INTERVENTION_ID|NCT_ID|INTERVENTION_TYPE|INTERVENTION_NAME|DESCRIPTION
103|NCT00695422|Other|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
104|NCT00695422|Other|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
1|NCT00695604|Drug|Placebo|Placebo via MDI.
2|NCT00695604|Drug|Fluticasone|Fluticasone MDI.
3|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
4|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
5|NCT00005780|Drug|EPOCH-R|EPOCH-R for 6 cycles
6|NCT00695630|Drug|Flumazenil|2 mL, 0.2 mg SM
7|NCT00695630|Drug|Placebo|2 mL sterile saline SM
8|NCT00695643|Drug|Mesalazine|3 g per day
9|NCT00695643|Drug|Placebo|0 g per day
10|NCT00695669|Biological|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
11|NCT00695682|Drug|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
12|NCT00695708|Behavioral|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
13|NCT00695708|Behavioral|Cogpack|Computer-aided cognitive program for cognitive abilities
14|NCT00695747|Procedure|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
15|NCT00695786|Drug|Lenalidomide|20 mg by mouth (PO) daily on days 1 - 21 followed by 7 days rest (28 day cycle). Following cycle 3, if patients fail to show a response (partial or complete) the dose will be increased to 25mg/day.
Schedule B: Lenalidomide will be administered orally at 20 mg total daily dose on days 2 to 22 of a 28 day cycle in patients with follicular lymphoma. Following cycle 3, if patients fail to show a response (partial or complete) the dose will be increased to 25mg/day. Patients with a diagnosis of small lymphocytic lymphoma (SLL) will begin at a dose of 10 mg total daily on days 2 to 22 of a 28 day cycle. This dose will be escalated by 5mg every 28 days up to 20mg if no toxicity is encountered. If no response is observed by cycle 3, the dose will be increased to 25 mg.
16|NCT00000679|Drug|Zidovudine|
17|NCT00005780|Biological|GM-CSF|GM-CSF monthly with the vaccine for 5 doses
41|NCT00005776|Drug|Placebo|100% Oxygen
42|NCT00695032|Other|laboratory biomarker analysis|
43|NCT00695045|Drug|intra thecal morphine|100 mcg intrathecal morphine given once .
44|NCT00695045|Drug|intra thecal morphine|200 mcg intrathecal morphine given once
45|NCT00695045|Drug|intra thecal morphine|300 mcg intrathecal morphine given once
46|NCT00695058|Device|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.
In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).
A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.
In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw.
47|NCT00695071|Drug|Itraconazole|Oral
48|NCT00695084|Behavioral|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
49|NCT00695097|Drug|Rituximab|Rituximab infusion on Day 1 and Day 15
50|NCT00695097|Drug|No Rituximab|No Rituximab
51|NCT00695110|Drug|Testosterone undecanoate (TU)|300 mg T equivalents BID for 7 days
52|NCT00005777|Procedure|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (>52 mm Hg)
53|NCT00695110|Drug|TU + testosterone enanthate (TE)|400 mg T equivalents BID for 7 days
54|NCT00695110|Drug|Testosterone undecanoate (TU)|200 mg T equivalents BID for 8 days; pharmacokinetics determined when oral TU administered with and without food.
55|NCT00695110|Drug|TU + testosterone enanthate (TE)|300 mg T equivalents BID for 7 days
56|NCT00695136|Drug|Donepezil hydrochloride|
57|NCT00695136|Behavioral|Increase REM sleep percentage|
58|NCT00695149|Procedure|Transplantation of bone marrow stromal cell|
59|NCT00695162|Other|quiet|no noise
60|NCT00695162|Other|non-speech noise|noise without speech
18|NCT00695786|Drug|Rituximab|375 mg/m^2 by vein over 4-8 Hours on day 1 of cycles 1-12 in schedule A, and day 1, 8,15, and 22 of cycle 1 and on day 1 of every subsequent cycle in schedule B.
19|NCT00695825|Dietary Supplement|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
20|NCT00695825|Dietary Supplement|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
21|NCT00695851|Drug|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
22|NCT00695851|Drug|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
23|NCT00695864|Drug|Ondansetron and Placebo crossover|
24|NCT00695877|Biological|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
25|NCT00695903|Drug|daptomycin|daptomycin 10 mg/kg IV every 24 hours
26|NCT00000102|Drug|Nifedipine|
27|NCT00000110|Drug|dietary fat|
28|NCT00000176|Drug|Estrogen|
29|NCT00000678|Drug|Zalcitabine|
30|NCT00005776|Drug|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
31|NCT00694967|Drug|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
32|NCT00694980|Drug|placebo|Intravenous and subcutaneous escalating doses
33|NCT00694980|Drug|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
34|NCT00694993|Drug|GSK1004723|
35|NCT00695006|Other|Sham Traction|Traction <5lbs
36|NCT00695006|Other|Traction|Standard supine intermittent traction
37|NCT00695019|Drug|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
38|NCT00695019|Drug|placebo lozenges|200 mg matching placebo lozenges
39|NCT00695032|Drug|cisplatin|
40|NCT00695032|Drug|ifosfamide|
65|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
66|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
67|NCT00695214|Drug|Propofol sedation|Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
68|NCT00695227|Drug|Proton Pump Inhibitor|Screened patients with extraesophageal reflux symptoms will be followed prospectively in order to gauge response to acid suppressing medication treatment. Non-responders will be tested with pharyngeal pH monitoring.
69|NCT00695240|Device|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
70|NCT00695253|Device|Endoluminal treatment of abdominal aortic aneurysms using the Medtronic/Talent Stent Graft|Stent-graft for AAA
71|NCT00695279|Procedure|Venipuncture|Blood draw
72|NCT00695292|Drug|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
73|NCT00695292|Drug|Carboplatin|carboplatin AUC=4 on Day 1
74|NCT00005777|Drug|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
75|NCT00695292|Drug|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
76|NCT00695305|Drug|rilapladib|250 mg oral dose once daily
77|NCT00695305|Drug|placebo|placebo
78|NCT00695305|Other|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
79|NCT00695318|Drug|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
80|NCT00695318|Drug|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
81|NCT00695331|Drug|Misoprostol|Titrated Misoprostol Solution
82|NCT00695331|Drug|Oxytocin|Titrated Intravenous Oxytocin
83|NCT00695344|Drug|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
84|NCT00695344|Drug|azathioprine or mycophenolate mofetil|2 times per day during 2 years
85|NCT00005777|Drug|Placebo|The infants in the placebo groups received equal volumes of saline.
86|NCT00695370|Drug|Pegfilgrastim (drug)|
87|NCT00695383|Behavioral|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
88|NCT00695383|Behavioral|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
89|NCT00695396|Drug|Placebo|Matching volume 2 mLfor 48 weeks
90|NCT00695396|Drug|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
91|NCT00695396|Drug|Placebo|Matching volume 1 mL for 48 weeks
92|NCT00695396|Drug|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
93|NCT00695409|Biological|rituximab|Given IV
94|NCT00695409|Drug|carmustine|Given IV
95|NCT00695409|Drug|cytarabine|Given IV
96|NCT00005778|Drug|High-dose immunoablative therapy|High dose cyclophosphamide for 4 days.
NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years.
97|NCT00695409|Drug|etoposide|Given IV
98|NCT00695409|Drug|melphalan|Given IV
99|NCT00695409|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
100|NCT00695409|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
101|NCT00695409|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
102|NCT00695422|Genetic|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
189|NCT00696150|Procedure|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
190|NCT00696150|Procedure|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
191|NCT00696150|Procedure|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
192|NCT00696163|Drug|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
193|NCT00696176|Drug|STAT 3 DECOY|single administration to a head and neck tumor
194|NCT00696202|Drug|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
195|NCT00696215|Drug|placebo|Placebo 1 mg once a day
196|NCT00696215|Drug|rasagiline|1mg
197|NCT00696228|Dietary Supplement|Placebo|Placebo
198|NCT00005785|Drug|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
199|NCT00696228|Dietary Supplement|MUFA|MUFA
200|NCT00696228|Dietary Supplement|PUFA|PUFA
201|NCT00696228|Dietary Supplement|SFA|SFA
202|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
203|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
204|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
205|NCT00696241|Drug|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
206|NCT00696241|Drug|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
207|NCT00696254|Behavioral|Nerve excitability measurement|
208|NCT00696280|Behavioral|Functional Living Index - Emesis|
61|NCT00695162|Other|speech noise|noise with speech present
62|NCT00695188|Drug|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
63|NCT00005777|Procedure|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target <48 mm Hg)
64|NCT00695188|Drug|methotrexate|25 mg oral administration
105|NCT00695422|Procedure|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
106|NCT00695435|Drug|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
107|NCT00005779|Drug|Interleukin-12|
108|NCT00695435|Drug|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
109|NCT00695435|Drug|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
110|NCT00695448|Drug|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
111|NCT00695461|Dietary Supplement|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
112|NCT00695461|Dietary Supplement|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
113|NCT00695487|Drug|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
114|NCT00695500|Drug|Varenicline|
115|NCT00695500|Drug|Varenicline (Chantix)|
116|NCT00695513|Dietary Supplement|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
117|NCT00695526|Dietary Supplement|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
118|NCT00005779|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
119|NCT00695552|Behavioral|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
120|NCT00695552|Behavioral|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
121|NCT00695565|Drug|placebo|TID x 12 weeks
122|NCT00695565|Drug|topical clonidine (ARC-4558)|TID x 12 weeks
123|NCT00695578|Drug|Biafine|ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
124|NCT00695591|Other|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
223|NCT00696410|Drug|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels ~10-12.
224|NCT00696423|Biological|Infanrix™|Intramuscular injection, one dose
225|NCT00696423|Biological|Hiberix™|Intramuscular injection, one dose
226|NCT00696436|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.
227|NCT00696436|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.
228|NCT00696436|Drug|Valsartan|Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.
229|NCT00696436|Drug|Olmesartan|Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.
230|NCT00696436|Drug|Placebo|Matching placebo, orally, once daily for up to six weeks.
231|NCT00005787|Biological|epoetin alfa|
232|NCT00696449|Drug|Adapalene|Subjects will treat the face once daily in the evening.
This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
233|NCT00696449|Drug|Adapalene|Subjects will treat the face once daily in the evening
This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
234|NCT00696449|Drug|Adapalene|Subjects will treat the face once daily in the evening
n this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
235|NCT00696449|Drug|Adapalene|Subjects will treat the face once daily in the evening
This group is considered to be the "standard of care" arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits.
236|NCT00696462|Device|forced-air warming|forced-air warming device
237|NCT00696475|Drug|Diazoxide choline|
238|NCT00696475|Drug|Diazoxide choline|
239|NCT00696475|Drug|Diazoxide choline|
240|NCT00696475|Drug|Placebo|
241|NCT00696488|Drug|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas.
242|NCT00005787|Biological|filgrastim|
243|NCT00696514|Dietary Supplement|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
244|NCT00696514|Dietary Supplement|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
245|NCT00696540|Drug|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
246|NCT00696540|Drug|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
247|NCT00696553|Other|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
248|NCT00696553|Behavioral|Nutrition plus Exercise|Nutrition plus Exercise
249|NCT00696566|Drug|Clopidogrel and Rifampicin|Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days
Rifampicin: 300 mg b.d. for up to 28 days
250|NCT00696579|Drug|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
251|NCT00696579|Drug|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
252|NCT00696592|Drug|Bevacizumab (Avastin), Verteporfin (Visudyne)|
253|NCT00000679|Drug|Zalcitabine|
254|NCT00005787|Biological|recombinant flt3 ligand|
255|NCT00696618|Drug|Fleets enema|hyper-osmolar preparation
256|NCT00696618|Drug|tap water enema|hypo-osmolar preparation
257|NCT00696618|Drug|Normosol-R enema|iso-osmolar preparation
258|NCT00696631|Drug|Dronedarone (SR33589)|oral administration
259|NCT00696631|Drug|Placebo|oral administration
260|NCT00696644|Drug|Teriparatide|20 mcg daily subcutaneous for 18 months.
261|NCT00696657|Drug|semaglutide|0.1 mg, once weekly, s.c. injection
262|NCT00696657|Drug|semaglutide|0.2 mg, once weekly, s.c. injection
263|NCT00696657|Drug|semaglutide|0.4 mg, once weekly, s.c. injection
264|NCT00696657|Drug|semaglutide|0.8 mg, once weekly, s.c. injection
265|NCT00005787|Biological|recombinant interleukin-3|
125|NCT00696852|Behavioral|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
126|NCT00696865|Drug|AZD2624|oral suspension, 3 doses
127|NCT00696865|Drug|Placebo|
128|NCT00696878|Drug|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
129|NCT00696878|Biological|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
130|NCT00696878|Biological|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
131|NCT00696878|Biological|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
132|NCT00696878|Drug|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
133|NCT00005790|Procedure|biopsy|
134|NCT00696891|Biological|HBV-MPL vaccine|3-dose intramuscular injection
135|NCT00696891|Biological|Engerix™-B|3-dose intramuscular injection
136|NCT00696904|Drug|ABT-333|Capsule, see arms for intervention description
137|NCT00696904|Drug|Placebo|Capsule, see arms for intervention description
138|NCT00696917|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
139|NCT00696917|Biological|Engerix™-B|3-dose intramuscular injection
140|NCT00696930|Drug|90Y-SMT487|
141|NCT00696943|Drug|([18F]-ML-10)|[18F]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of [18F]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
142|NCT00696956|Device|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
143|NCT00696956|Device|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
144|NCT00005790|Procedure|magnetic resonance imaging|
145|NCT00696969|Drug|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
146|NCT00696969|Drug|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
147|NCT00696969|Drug|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
148|NCT00696969|Drug|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
149|NCT00696982|Drug|sitagliptin|sitagliptin 100 mg once daily for 3 months
150|NCT00696982|Drug|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
151|NCT00696995|Drug|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
152|NCT00695903|Drug|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
153|NCT00695916|Procedure|Breast MRI|
154|NCT00005780|Drug|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
155|NCT00695929|Drug|Levosimendan|Intravenous injection
156|NCT00695929|Drug|Milrinone|Intravenous injection
157|NCT00695955|Drug|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
158|NCT00695955|Drug|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
159|NCT00695981|Procedure|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
160|NCT00695981|Procedure|Conservative treatment|Physiotherapy according to a standardized protocol
161|NCT00695994|Drug|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
162|NCT00695994|Drug|gemcitabine and carboplatin|Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.
Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.
Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.
Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
163|NCT00696007|Drug|Gemcitabine and cisplatin|Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.
Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.
Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²
164|NCT00696007|Other|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
165|NCT00005782|Drug|Granulocyte colony-stimulating factor|
166|NCT00696020|Drug|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
167|NCT00696020|Drug|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
168|NCT00696020|Device|Respimat® Inhaler|
169|NCT00696033|Drug|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
170|NCT00696033|Drug|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
171|NCT00696033|Drug|placebo|lorazépam placebo or Diazépam placebo
172|NCT00696046|Procedure|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical & steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
173|NCT00696059|Drug|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
174|NCT00696072|Drug|Dasatinib + Letrozole|Tablets, Oral, once daily, up to 2 years
Dasatinib 100 mg + Letrozole 2.5 mg
175|NCT00696072|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
176|NCT00005782|Procedure|Leukapheresis|
177|NCT00696085|Behavioral|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
178|NCT00696098|Other|sodium butyrate|1 enema (60 ml) once daily containing 100mM
179|NCT00696098|Other|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
180|NCT00696111|Drug|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
181|NCT00696111|Drug|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
182|NCT00696111|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
183|NCT00696124|Genetic|VM202|2mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
184|NCT00696124|Genetic|VM202|4mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
185|NCT00696124|Genetic|VM202|8mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
186|NCT00696124|Genetic|VM202|16mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
187|NCT00005783|Drug|Recombinant-methionyl human stem cell factor|
188|NCT00696137|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
285|NCT00696735|Procedure|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
286|NCT00696735|Procedure|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
287|NCT00005787|Procedure|in vitro-treated peripheral blood stem cell transplantation|
288|NCT00696748|Drug|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
289|NCT00696748|Drug|Placebo|Placebo 4 mL intramuscular
290|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
291|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
292|NCT00696761|Drug|alfuzosin|10mg, once daily, 12 months
293|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
294|NCT00696774|Drug|Duloxetine|Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.
Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.
295|NCT00696787|Drug|Desvenlafaxine Sustained Release (DVS SR)|
296|NCT00696787|Drug|Lyrica® (Pregabalin)|
297|NCT00696787|Drug|Placebo|
298|NCT00005788|Biological|aldesleukin|
299|NCT00696800|Drug|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
300|NCT00696800|Biological|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
301|NCT00696800|Drug|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
302|NCT00696800|Drug|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
303|NCT00696800|Biological|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
325|NCT00697242|Biological|Engerix™-B|Intramuscular injection, 3 doses
326|NCT00697242|Biological|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
327|NCT00697255|Drug|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
328|NCT00697255|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
329|NCT00697255|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
330|NCT00697255|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
331|NCT00697281|Drug|OC000459|Tablets twice daily for 8 days
Dose level 1
332|NCT00697281|Drug|OC000459|Tablets twice daily for 8 days
Dose level 2
333|NCT00697281|Drug|OC000459|Tablets twice daily for 8 days
Dose level 3
334|NCT00697281|Drug|OC000459|Tablets twice daily for 8 days
Dose level 4
335|NCT00005792|Drug|etoposide phosphate|Etoposide phosphate 1363 mg/m2/day IV over 4 hours (total dose 2726 mg/m2, or 2400 mg/m2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
336|NCT00697281|Drug|Placebo|Tablets twice daily for 8 days
Dose level 5
337|NCT00697294|Dietary Supplement|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
338|NCT00697320|Drug|activated recombinant human factor VII|A NON INTERVENTIONAL OBSERVATIONAL STUDY:
Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation
339|NCT00697333|Procedure|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
340|NCT00697346|Drug|MLN8237|MLN8237 administered twice daily (BID) on Days 1-7 of each cycle. The planned rest period is 14 days in length.
Number of Cycles: until progression or unacceptable toxicity, up to 12 months unless clinical benefit supports continued therapy.
341|NCT00697359|Device|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
342|NCT00697372|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
304|NCT00696800|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
305|NCT00696800|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
306|NCT00696800|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
307|NCT00696826|Drug|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
308|NCT00696839|Behavioral|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
309|NCT00005790|Other|laboratory biomarker analysis|
310|NCT00696852|Behavioral|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
311|NCT00696852|Behavioral|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
312|NCT00000680|Drug|Zidovudine|
313|NCT00005791|Drug|fluorouracil|
314|NCT00697190|Device|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
315|NCT00697203|Drug|Placebo|po daily for 12 weeks
316|NCT00697203|Drug|Pravastatin|40mg po daily for 12 weeks
317|NCT00697203|Drug|dalceptrapib|300mg po daily for 12 weeks
318|NCT00697203|Drug|dalceptrapib|600mg po daily for 12 weeks
319|NCT00697203|Drug|dalceptrapib|900mg po daily for 12 weeks
320|NCT00697216|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
321|NCT00697216|Biological|Engerix™-B|3-dose intramuscular injection
322|NCT00697229|Biological|Engerix™-B|Intramuscular injection, 1 or 3 doses
323|NCT00697229|Biological|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
324|NCT00005791|Drug|irinotecan hydrochloride|
209|NCT00005786|Drug|arsenic trioxide|Given IV
210|NCT00696293|Drug|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
211|NCT00696293|Other|Duloxetine + Problem Solving Therapy for Depression and Pain (PST-DP).|Delivered over the course of 8-10 sessions.
212|NCT00696319|Other|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
213|NCT00696319|Other|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
214|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
215|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
216|NCT00696332|Other|placebo|capsules, placebo, 3 times a day, for 52 weeks
217|NCT00696358|Radiation|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
218|NCT00696358|Radiation|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
219|NCT00696384|Drug|Azilsartan medoxomil|All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and <130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.
Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit.
220|NCT00005786|Other|laboratory biomarker analysis|Correlative studies
221|NCT00696384|Drug|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
222|NCT00696384|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
367|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
368|NCT00005792|Procedure|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
369|NCT00697580|Behavioral|Control|delayed intervention - they receive intervention classes (ST + N) at the end of the study that is not compared to the other groups.
370|NCT00697580|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
371|NCT00697580|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
372|NCT00697580|Behavioral|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
373|NCT00697593|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
374|NCT00697606|Device|Seprafilm®|Seprafilm® placed at time of primary cesarean
375|NCT00697606|Other|Control|no Seprafilm® used at primary cesarean
376|NCT00697619|Drug|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
377|NCT00697632|Drug|MGCD265|Oral daily administration without interruption
378|NCT00697996|Drug|Rituximab for transplant rejection|
379|NCT00698009|Drug|Fludarabine|25 mg/m^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
380|NCT00697645|Device|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
381|NCT00005793|Drug|Cytarabine|
382|NCT00697645|Device|Brainsway Deep TMS|Deep TMS applied over the motor strip
383|NCT00697658|Drug|Paliperidone ER|6 mg tablet once daily, variable treatment length.
384|NCT00697671|Other|NK Cell Infusion|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
385|NCT00697671|Biological|Immunotherapy|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
386|NCT00697671|Device|Miltenyi Biotec CliniMACS device|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
387|NCT00697671|Drug|Interleukin-2 (IL-2)|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
388|NCT00697671|Drug|Clofarabine|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
389|NCT00697671|Drug|Cyclophosphamide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
390|NCT00697671|Drug|Etoposide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
391|NCT00697684|Drug|Antithymocyte Globulin|
392|NCT00005793|Drug|Daunorubicin|
393|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
394|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
395|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
396|NCT00697697|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
266|NCT00696657|Drug|semaglutide|0.8 mg with titration, once weekly, s.c. injection
267|NCT00696657|Drug|semaglutide|1.6 mg with titration, once weekly, s.c. injection
268|NCT00696657|Drug|placebo|0.1 mg, once weekly, s.c. injection
269|NCT00696657|Drug|placebo|0.2 mg, once weekly, s.c. injection
270|NCT00696657|Drug|placebo|0.4 mg, once weekly, s.c. injection
271|NCT00696657|Drug|placebo|0.8 mg with titration, once weekly, s.c. injection
272|NCT00696657|Drug|placebo|0.8 mg with titration, once weekly, s.c. injection
273|NCT00696657|Drug|placebo|1.6 mg, once weekly, s.c. injection
274|NCT00696657|Drug|liraglutide|1.2 mg with titration, once daily, s.c. injection
275|NCT00696657|Drug|liraglutide|1.8 mg with titration, once daily, s.c. injection
276|NCT00005787|Biological|sargramostim|
277|NCT00696683|Other|None, this is an observational study|
278|NCT00696696|Drug|Gemcitabine|1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
279|NCT00696696|Drug|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
280|NCT00696696|Drug|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
281|NCT00696709|Biological|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered ~30 days apart
282|NCT00696709|Biological|Comparator: Placebo|Placebo; 4-dose regimen administered ~30 days apart.
283|NCT00696722|Drug|placebo + atazanavir|Placebo treatment first, atazanavir treatment second
4 day treatment
284|NCT00696722|Drug|atazanavir + placebo|Atazanavir treatment first, placebo treatment second
4 day treatment
468|NCT00697164|Drug|Placebo|Saline Admission, day 1, day 2 3 days
469|NCT00697164|Drug|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
470|NCT00697190|Device|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
471|NCT00699114|Drug|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
472|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
473|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
474|NCT00699127|Behavioral|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
475|NCT00699140|Biological|IGIV3I Grifols|Immune Globulin Intravenous (Human)
476|NCT00005799|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
477|NCT00699153|Drug|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
478|NCT00699153|Drug|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
479|NCT00699166|Drug|DNK333|25 mg and 100 mg oral doses, each taken twice daily
480|NCT00699179|Drug|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
481|NCT00699192|Drug|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
482|NCT00699192|Drug|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
483|NCT00699192|Drug|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
484|NCT00699192|Drug|Placebo|1 capsule placebo to match valsartan orally once daily
485|NCT00699218|Device|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
486|NCT00699231|Biological|HBV-MPL vaccine 208129|IM injection
487|NCT00005799|Procedure|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
488|NCT00699231|Biological|Engerix™-B|IM injection
343|NCT00697372|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
344|NCT00697385|Drug|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
345|NCT00697398|Other|Transcranial stimulation|Stimulation to white
346|NCT00005792|Drug|melphalan|Melphalan 50 mg/m2/day IV over 30 minutes (total dose 150 mg/m2), followed immediately by topotecan. Days -7, -6, -5
347|NCT00697398|Other|Transcranial stimulation|Repetitive transcranial magnetic stimulation (rTMS)
348|NCT00697424|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
349|NCT00697437|Drug|Docetaxel|70mg q3wx 1 dose
350|NCT00697437|Drug|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
351|NCT00697450|Drug|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
352|NCT00697463|Drug|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily for 18 months
353|NCT00697476|Drug|topotecan, vorinostat|Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.
Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal.
354|NCT00697489|Procedure|correction of POP plus preventive continence procedure|
355|NCT00697489|Procedure|POP surgery followed by eventual incontinence procedure|
356|NCT00697502|Drug|Capecitabine|Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.
Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period.
357|NCT00005792|Drug|topotecan|Topotecan 3.3 mg/m2/day (starting total dose = 10 mg/m2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
358|NCT00697515|Drug|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
359|NCT00697515|Drug|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
360|NCT00697541|Drug|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
361|NCT00697541|Drug|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
362|NCT00697541|Drug|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
363|NCT00697541|Drug|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
364|NCT00697554|Biological|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
365|NCT00697554|Biological|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
366|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
397|NCT00697697|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
398|NCT00697710|Drug|50 mg S-777469|S-777469, 50 mg BID
399|NCT00697710|Drug|200 mg S-777469|S-777469, 200 mg BID
400|NCT00697710|Drug|800 mg S-777469|S-777469, 800 mg BID
401|NCT00697710|Drug|Placebo|Matching Placebo
402|NCT00697723|Procedure|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
403|NCT00005793|Drug|Etoposide|
404|NCT00697736|Procedure|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
405|NCT00697749|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
406|NCT00697749|Biological|Engerix™-B|3-dose intramuscular injection
407|NCT00697762|Drug|RWJ-333369|200 mg tablet twice daily for 12 weeks
408|NCT00697762|Drug|RWJ-333369|100 mg tablet twice daily for 12 weeks
409|NCT00697762|Drug|Placebo|Placebo tablet twice daily for 12 weeks
410|NCT00697775|Biological|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
411|NCT00697775|Biological|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
412|NCT00697775|Biological|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
413|NCT00697788|Drug|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
414|NCT00005793|Drug|Topotecan|
415|NCT00697801|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
416|NCT00697801|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
417|NCT00697801|Drug|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
418|NCT00697814|Drug|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
419|NCT00697827|Device|Interspinous Spacer device|Device: In-Space
420|NCT00697827|Device|Interspinous Process Distraction Device|Device: X STOP
527|NCT00698230|Drug|INCB013739|INCB013739 15 mg QD tablet
528|NCT00698230|Drug|INCB013739|INCB013739 50 mg QD tablet
529|NCT00698230|Drug|INCB013739|INCB013739 100 mg QD tablet
530|NCT00005796|Drug|procarbazine hydrochloride|chemotherapy is administered every 21 days.
531|NCT00698230|Drug|INCB013739|INCB013739 200 mg QD
532|NCT00698230|Drug|Placebo comparator matching INCB013739|Orally once daily tablet
533|NCT00698243|Drug|OSI-027|Administered orally
534|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
535|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
536|NCT00698269|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
537|NCT00698269|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
538|NCT00698269|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
539|NCT00698282|Drug|AZD1981|Oral tablet, 250 mg single dose
540|NCT00698282|Drug|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
541|NCT00005796|Drug|vincristine sulfate|chemotherapy is administered every 21 days
542|NCT00698282|Drug|Placebo|
543|NCT00698321|Behavioral|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
544|NCT00698321|Behavioral|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
545|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
546|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
547|NCT00698347|Device|M2a-Magnum™ Hip System|
548|NCT00698386|Dietary Supplement|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
549|NCT00698386|Dietary Supplement|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
550|NCT00698412|Device|Cane|This group use the cane every day since the baseline
551|NCT00698425|Other|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
552|NCT00005796|Procedure|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
553|NCT00698425|Drug|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
554|NCT00698438|Device|Ex-PRESS implantation|I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.
X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.
XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.
XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.
XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture.
555|NCT00698438|Procedure|Trabeculectomy|standard trabeculectomy
556|NCT00698451|Drug|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
557|NCT00698464|Drug|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
558|NCT00698490|Biological|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
559|NCT00698490|Biological|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
560|NCT00698516|Drug|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
561|NCT00698529|Behavioral|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
562|NCT00698529|Behavioral|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
563|NCT00005797|Drug|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
421|NCT00697840|Biological|Engerix™-B|Intramuscular injection, 2 doses
422|NCT00697840|Biological|HBV-MPL 208129|Intramuscular injection, 2 doses
423|NCT00697840|Biological|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
424|NCT00697853|Biological|Engerix™-B|3-dose intramuscular injection
425|NCT00000680|Drug|Aldesleukin|
426|NCT00005794|Drug|perifosine|
427|NCT00697853|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
428|NCT00697866|Biological|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
429|NCT00697866|Biological|Engerix™-B|3-dose intramuscular injection
430|NCT00697879|Drug|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
431|NCT00697892|Drug|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
432|NCT00697892|Drug|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
433|NCT00697892|Drug|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
434|NCT00697905|Drug|Gemcitabine|Intravenous administration on days 1, 8 of a 21-day cycle
435|NCT00697905|Drug|Carboplatin|Intravenous following Gemcitabine infusion on day 1
436|NCT00697905|Drug|Cisplatin|Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle
437|NCT00005795|Drug|arsenic trioxide|
438|NCT00697905|Drug|5-fluorouracil (5-FU)|Intravenous infusion on day 2 to day 5
439|NCT00697918|Drug|RWJ-333369|100 mg to 400 mg twice daily
440|NCT00697931|Biological|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
441|NCT00697931|Biological|Engerix™-B|Intramuscular injection, 3 doses
442|NCT00697944|Drug|Amphotericine in liposome (Ambisome®)|2 IV infusions separated by one week 10 mg/kg per injection
443|NCT00697957|Behavioral|Exercise|Progressive impact exercise
444|NCT00697970|Biological|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
445|NCT00697970|Biological|Engerix™-B|Intramuscular injection, 3 doses
446|NCT00697021|Drug|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
447|NCT00697021|Drug|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
448|NCT00697034|Drug|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
449|NCT00005790|Radiation|gadopentetate dimeglumine|
450|NCT00697047|Behavioral|Usual care plus automated mailing|Part 2 - patients with positive stool test or flexible sigmoidoscopy are randomized to receive usual care or nurse care management (registered nurse)
451|NCT00697047|Behavioral|Usual care, automated mailing plus phone assistance by a medical assistant|Part 2 - patients with positive stool test or flexible sigmoidoscopy are randomized to receive usual care or nurse care management (registered nurse)
452|NCT00697047|Behavioral|Usual care, automated mailing, phone assistance by a medical assistant, who refers care to a registered nurse who provides care management for screening|Part 2 - patients with positive stool test or flexible sigmoidoscopy are randomized to receive usual care or nurse care management (registered nurse)
453|NCT00697060|Drug|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
454|NCT00697073|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
455|NCT00697086|Drug|Dronedarone (SR33589)|
456|NCT00697086|Drug|Placebo|
457|NCT00697099|Drug|Semuloparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
458|NCT00697099|Drug|Enoxaparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
459|NCT00697099|Drug|Placebo|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component
Subcutaneous injection
460|NCT00005791|Drug|cisplatin|
461|NCT00697112|Drug|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
462|NCT00697125|Biological|Engerix™-B|Intramuscular injection, 3 doses
463|NCT00697125|Biological|HBV-MPL vaccine (208129)|
464|NCT00697125|Biological|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
465|NCT00697138|Drug|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
466|NCT00697151|Drug|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
467|NCT00697151|Drug|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
707|NCT00699881|Drug|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
708|NCT00699894|Drug|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
709|NCT00699894|Drug|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
710|NCT00699907|Drug|flutamide|Given orally
711|NCT00699920|Drug|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
712|NCT00699920|Drug|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
713|NCT00699933|Other|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
714|NCT00005800|Drug|Docetaxel|
564|NCT00698529|Behavioral|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
565|NCT00698555|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
566|NCT00698555|Biological|Engerix™-B|3-dose intramuscular injection
567|NCT00698568|Biological|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
568|NCT00698568|Biological|Placebo|Intramuscular injection, 3 doses
569|NCT00698581|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
570|NCT00698581|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
571|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
572|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
573|NCT00698594|Biological|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
574|NCT00005797|Drug|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
593|NCT00698724|Drug|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
594|NCT00698724|Drug|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
595|NCT00698763|Drug|Levosimendan|from 0.125 mg to 2 mg in escalating doses
596|NCT00698763|Drug|Placebo|Placebo capsules are identical in appearance to active capsules
597|NCT00005797|Radiation|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
598|NCT00698776|Drug|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
599|NCT00698776|Biological|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
600|NCT00698789|Drug|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
601|NCT00698789|Drug|INCB019602|20 mg in AM with placebo administration in PM
602|NCT00698789|Drug|INCB019602|5 mg in PM with placebo administration in AM
603|NCT00698789|Drug|INCB019602|20 mg in PM with placebo administration in AM
604|NCT00698789|Drug|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
605|NCT00698789|Drug|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
606|NCT00698789|Drug|Metformin|Stable dose metformin monotherapy
607|NCT00698802|Drug|EX1000|Treat-to-target titration scheme, s.c. injection
608|NCT00005798|Drug|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
609|NCT00698802|Drug|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
610|NCT00698815|Drug|pemetrexed disodium|Given IV
611|NCT00698815|Drug|sunitinib malate|Given PO
612|NCT00698815|Other|laboratory biomarker analysis|Correlative studies
613|NCT00698828|Drug|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
575|NCT00698607|Device|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
576|NCT00698607|Device|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
577|NCT00698607|Drug|6-month clopidogrel therapy|Use clopidogrel for 6 months
578|NCT00698607|Drug|12-month clopidogrel therapy|Use clopidogrel for 12 months
579|NCT00698646|Drug|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
580|NCT00698646|Drug|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
581|NCT00698646|Drug|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
582|NCT00698672|Device|charnley OGEE|charnley OGEE
583|NCT00698672|Device|Spectron Reflection CoCr|Spectron Reflection CoCr
584|NCT00698672|Device|Spectron XLPE CoCr|Spectron XLPE CoCr
585|NCT00000681|Drug|Bleomycin sulfate|
586|NCT00005797|Drug|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
587|NCT00698672|Device|Spectron Reflection Oxinium|Spectron Reflection Oxinium
588|NCT00698672|Device|Spectron XLPE CoCR|Spectron XLPE CoCR
589|NCT00698685|Drug|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
590|NCT00698685|Biological|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
591|NCT00698685|Procedure|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
592|NCT00698711|Biological|MUC-2-KLH|The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.
After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient.
489|NCT00699244|Device|ultrasound|ultrasound guided placement
490|NCT00699283|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
491|NCT00699283|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
492|NCT00699296|Drug|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
493|NCT00699322|Drug|Sitagliptin|100mg P.O. per day for 1month
494|NCT00699322|Drug|Glimepiride|2mg P.O. per day for 1 month
495|NCT00699335|Drug|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
496|NCT00699348|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|i.v. every month (starting dose based on previous ESA therapy).
497|NCT00005796|Procedure|filgrastim|GCSF is given after chemo administration
498|NCT00698009|Drug|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
499|NCT00698009|Biological|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
500|NCT00698009|Drug|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
501|NCT00698009|Drug|Interleukin-2|Received under skin three times weekly for 9 total doses following NK Cell Infusion:
For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses.
502|NCT00698022|Drug|risperidone|daily risperidone plus mifepristone for 28 days
503|NCT00698022|Drug|risperidone matched placebo|risperidone-matched placebo plus mifepristone daily for 28 days
504|NCT00698022|Drug|risperidone-matched placebo|daily risperidone-matched placebo plus mifepristone for 28 days
505|NCT00698022|Drug|Mifepristone-matched placebo|daily mifepristone-matched placebo for 28 days
506|NCT00698035|Drug|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
507|NCT00698035|Drug|Estring|2mg ring inserted vaginally once every 12 weeks
508|NCT00005796|Biological|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
509|NCT00698061|Biological|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
510|NCT00698061|Biological|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
511|NCT00698074|Device|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
512|NCT00698087|Biological|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
513|NCT00698087|Biological|Engerix™-B|Intramuscular injection, 2 or 3 doses
514|NCT00698100|Biological|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
515|NCT00698100|Biological|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
516|NCT00698113|Procedure|Massage|Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.
Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol.
517|NCT00698113|Other|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
518|NCT00698126|Drug|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
519|NCT00005796|Drug|lomustine|chemotherapy is administered every 21 days
520|NCT00698126|Drug|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
521|NCT00698139|Device|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
522|NCT00698178|Other|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
523|NCT00698191|Biological|Allogeneic MSC (AlloMSC)|Intervention:
Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.
Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight
524|NCT00698204|Drug|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
525|NCT00698204|Drug|placebo|Subject was asked to take placebo each day that radiation therapy was given.
526|NCT00698230|Drug|INCB013739|INCB013739 5 mg QD tablet
671|NCT00699556|Drug|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
672|NCT00699569|Dietary Supplement|hyperimmune colostrum|hyperimmune colostrum
673|NCT00699569|Dietary Supplement|Placebo|
674|NCT00699582|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
675|NCT00699582|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
676|NCT00699582|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
677|NCT00699608|Drug|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
678|NCT00699621|Biological|platelets|Four units of fresh platelets will be infused immediately
679|NCT00699634|Drug|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
680|NCT00699660|Behavioral|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
681|NCT00005799|Other|pharmacological study|Correlative studies
682|NCT00699660|Behavioral|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
683|NCT00699686|Drug|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
684|NCT00699686|Drug|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
685|NCT00699712|Drug|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
686|NCT00699738|Behavioral|Breastfeeding|Breastfeeding
687|NCT00699738|Behavioral|Bottlefeeding|Bottlefeeding
688|NCT00699751|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
689|NCT00699751|Drug|Placebo|Isotonic saline 6 IV administrations separated by 4 weeks intervals.
690|NCT00699751|Drug|Best standard of care (BSoC)|Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
691|NCT00699764|Biological|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
692|NCT00005799|Other|laboratory biomarker analysis|Correlative studies
693|NCT00699764|Biological|Placebo injection|Intramuscular injection, 3 doses
694|NCT00699777|Drug|Risedronate|1 risedronate 150 mg tablet administered orally
695|NCT00699777|Drug|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
696|NCT00699790|Drug|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
697|NCT00699790|Drug|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
698|NCT00699803|Drug|T-PRED|sterile ophthalmic solution at the first time point
699|NCT00699803|Drug|T-PRED|sterile ophthalmic solution at the second time point
700|NCT00699803|Drug|Pred Forte|sterile ophthalmic solution at the first time point
701|NCT00699803|Drug|Pred Forte|sterile ophthalmic solution at the second time point
702|NCT00699816|Biological|Immuncell-LC|adjuvant adoptive immune therapy using a CIK cell agent
703|NCT00005800|Biological|Filgrastim|
704|NCT00699842|Drug|Lenalidomide|Dose Level Lenalidomide Schedule
15mg/day for d1-21 out of 28 days
20mg/day for d1-21 out of 28 days
25mg/day for d1-21 out of 28 days
705|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
706|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
750|NCT00700102|Drug|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
751|NCT00700115|Drug|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
752|NCT00700115|Drug|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
753|NCT00700128|Drug|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
754|NCT00700128|Drug|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
755|NCT00700128|Drug|placebo|placebo
756|NCT00700154|Procedure|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
757|NCT00700167|Biological|dendritic cell vaccine|The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional "booster" doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.
758|NCT00000681|Drug|Doxorubicin hydrochloride|
759|NCT00005801|Procedure|peripheral blood stem cell transplantation|
760|NCT00700180|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
761|NCT00700180|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
762|NCT00700180|Drug|Carboplatin-based chemotherapy|As prescribed
763|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
764|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
765|NCT00700206|Drug|Ezatiostat Hydrochloride|Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.
Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle.
766|NCT00700245|Behavioral|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
614|NCT00698828|Drug|SUN11031|Twice daily subcutaneous injections of SUN11031 for 12 weeks.
615|NCT00698841|Drug|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m^2 over 60 minutes.
616|NCT00698854|Device|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
617|NCT00698854|Device|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
618|NCT00698880|Procedure|Right hepatic vein embolization|Embolization of the right hepatic vein
619|NCT00005798|Drug|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
620|NCT00698893|Biological|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
621|NCT00698906|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
622|NCT00698906|Biological|Engerix™-B|3-dose intramuscular injection
623|NCT00698919|Other|Observational study|This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.
The new techniques used (DNA detection) will done later on and thus won't modify their decision.
624|NCT00698932|Drug|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
625|NCT00698932|Drug|Placebo|oral tablet, once daily for 24 weeks
626|NCT00698945|Drug|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
627|NCT00698945|Drug|Alphagan|Alphagan: two drops a day for 28 days
628|NCT00698958|Procedure|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
629|NCT00698958|Procedure|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
630|NCT00005798|Drug|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
631|NCT00698984|Dietary Supplement|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
632|NCT00698984|Dietary Supplement|Placebo|2 capsules per day over a period of 6 months
633|NCT00698997|Behavioral|Early Start Denver Model|Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.
Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week.
634|NCT00698997|Behavioral|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
635|NCT00699010|Drug|Niacin|Niacin 240 mg every 48 hours
636|NCT00699010|Drug|Oxycodone HCL plus Niacin|Oxycodone HCL 40 mg plus Niacin 240 mg every 48 hours
637|NCT00699010|Drug|Placebo|Placebo every 48 hours
638|NCT00699010|Drug|Oxycodone HCL plus Niacin|Oxycodone HCl 40 mg plus Niacin 240 mg every 48 hours
639|NCT00699010|Drug|Oxycodone HCl|Oxycodone HCl 40 mg every 48 hours
640|NCT00699023|Drug|ezetimibe tablets|ezetimibe tablets 10 mg/die
641|NCT00005799|Drug|fludarabine phosphate|Given IV
642|NCT00699023|Drug|simvastatin tablets|simvastatin tablets 20 mg/die
643|NCT00699023|Drug|placebo|placebo
644|NCT00699036|Drug|avandia|4 mg twice daily
645|NCT00699036|Drug|metformin|500 mg twice daily for 48 weeks
646|NCT00699036|Drug|losartan|losartan 50 mg once daily
647|NCT00699049|Drug|Alpha blocker|oral
648|NCT00699049|Drug|placebo|oral
649|NCT00699049|Drug|solifenacin|oral
650|NCT00699062|Drug|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
651|NCT00699062|Drug|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
652|NCT00005799|Radiation|total-body irradiation|Undergo low-dose TBI
653|NCT00699101|Device|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
654|NCT00699114|Drug|Placebo|Lactose as powder in gelatine capsules, single dose
655|NCT00699114|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
656|NCT00699114|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
657|NCT00699114|Drug|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
658|NCT00699504|Drug|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
659|NCT00005799|Drug|cyclosporine|Given PO
660|NCT00699504|Drug|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
661|NCT00699504|Drug|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
662|NCT00699504|Drug|placebo|placebo IV and oral
663|NCT00699517|Drug|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
664|NCT00699517|Drug|Placebo|I.V. infusion followed by administration of cisplatin
665|NCT00699530|Other|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
666|NCT00699543|Device|Coroflex Please stent implantation|Use Coroflex Please stent in the treatment of coronary stenosis
667|NCT00699543|Device|Taxus stent implantation|Use Taxus stent in the treatment of coronary stenosis
668|NCT00699556|Drug|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
669|NCT00699556|Drug|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
670|NCT00005799|Drug|mycophenolate mofetil|Given PO
715|NCT00699946|Drug|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
716|NCT00699946|Drug|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
717|NCT00699972|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
718|NCT00699972|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
719|NCT00699972|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
720|NCT00699998|Drug|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
721|NCT00699998|Drug|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
722|NCT00699998|Drug|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
723|NCT00700011|Drug|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
724|NCT00700011|Drug|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
725|NCT00005800|Drug|Doxorubicin|
726|NCT00700024|Drug|Testim|50 mg/dose7day
727|NCT00700024|Behavioral|Strength training|three times a week
728|NCT00700024|Drug|placebo|placebo
729|NCT00700037|Drug|high-dose atorvastatin|20mg/day
730|NCT00700037|Drug|low-dose atorvastatin|5mg/day
731|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 1 (females with cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, she will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
732|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 2 (females without cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, she will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
733|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 3 (males with cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, he will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
831|NCT00701805|Drug|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
832|NCT00701831|Drug|Insulin glargine|The dose is titrated according to patient needs
833|NCT00701844|Behavioral|Writing A (Experimental informative writing)|Experimental informative writing
834|NCT00701844|Behavioral|Writing B (Experimental noninformative writing)|Experimental noninformative writing
835|NCT00701844|Behavioral|Writing C (Control informative writing)|Control informative writing
836|NCT00701844|Behavioral|Writing D (Control noninformative writing)|Control noninformative writing
837|NCT00701857|Drug|cisplatin|
838|NCT00701857|Drug|pemetrexed disodium|
839|NCT00005803|Drug|Mycophenolate Mofetil|Given PO
840|NCT00701857|Radiation|radiation therapy|
841|NCT00701870|Drug|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
842|NCT00701883|Drug|Placebo|2 capsules, once a day for 8 weeks
843|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
844|NCT00701883|Drug|MBX-8025|2 capsule, once daily for 8 weeks
845|NCT00700388|Device|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
846|NCT00700388|Procedure|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
847|NCT00700401|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
848|NCT00700401|Drug|ribavirin [Copegus]|800mg po daily for 24 weeks
849|NCT00700427|Drug|atomoxetine hydrochloride|Oral 40-100 mg/day
850|NCT00700427|Drug|Placebo|Oral delivery of matching placebo
851|NCT00700440|Drug|C225 (cetuximab)|one week before and then weekly during radiotherapy
852|NCT00005802|Biological|therapeutic allogeneic lymphocytes|
853|NCT00700453|Behavioral|Control group with no video game play|Subjects will abstain from all video game play during study participation.
854|NCT00700453|Behavioral|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
855|NCT00700453|Behavioral|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
856|NCT00700453|Behavioral|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
857|NCT00700466|Drug|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
858|NCT00700479|Drug|aldosterone|4 hour infusion
859|NCT00700479|Dietary Supplement|low or high sodium diet|
860|NCT00700479|Drug|placebo|placebo
861|NCT00700492|Drug|progesterone|vaginal capsules 3X200mg daily
862|NCT00700505|Device|FlowPants(R) Garment|The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.
The garment is activated and begins to heat up 5-15 minutes prior to voiding.
863|NCT00005802|Drug|cytarabine|
864|NCT00700518|Drug|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
865|NCT00700518|Drug|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
866|NCT00700518|Drug|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
867|NCT00700518|Drug|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
868|NCT00700518|Drug|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
869|NCT00700531|Device|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
870|NCT00700531|Procedure|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
871|NCT00700544|Drug|chemotherapy treatment (see arm) + norethandrolone|oral form
Dosage:
10 mg in patients with a weight < 60 kgs 20 mg in patients with a weight > 60 kgs frequency: every day Duration: 2 years
872|NCT00700544|Drug|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
873|NCT00700557|Dietary Supplement|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
874|NCT00005802|Drug|etoposide|
875|NCT00700557|Dietary Supplement|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
734|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 4 (males without cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, he will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
735|NCT00700063|Drug|PEP005 Topical Gel|0.005%, two days treatment
736|NCT00005800|Procedure|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
737|NCT00700063|Drug|PEP005 Topical Gel|0.01%, two days treatment
738|NCT00700063|Drug|PEP005 Topical Gel|0.015%, two days treatment
739|NCT00700063|Drug|Vehicle gel|two days treatment
740|NCT00700063|Drug|PEP005 Topical Gel|0.005%, three days treatment
741|NCT00700063|Drug|PEP005 Topical Gel|0.01%, three days treatment
742|NCT00700063|Drug|PEP005 Topical Gel|0.015%, three days treatment
743|NCT00700063|Drug|Vehicle gel|three days treatment
744|NCT00700076|Drug|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
745|NCT00700076|Drug|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
746|NCT00700089|Behavioral|Assertive intervention|8-20 assertive contacts after suicide attempt
747|NCT00005801|Biological|therapeutic allogeneic lymphocytes|
748|NCT00700089|Other|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
749|NCT00700102|Drug|Chemotherapy|As prescribed
1002|NCT00701428|Drug|Losartan|Losartan 50 mg daily during 6 + 6 weeks
1003|NCT00701428|Other|CPAP|CPAP during the second 6 week-period
1004|NCT00701454|Other|No intervention|No intervention
1005|NCT00701480|Other|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
1006|NCT00701480|Other|marketed skin cleanser|face washing 2-3 times/day
1007|NCT00005803|Drug|Etoposide|Given IV
1008|NCT00701493|Drug|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
1009|NCT00701506|Device|Patterned Electrical Neuromuscular Stimulation|20-minute session, to each affected knee, 3 times per week for 12 weeks.
PENS for 20 minutes:
Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).
Minimal twitch for 5 minutes.
Moderate to strong, but well-tolerated twitch contractions for 15 minutes.
Electrodes placed on quadriceps and hamstrings
1010|NCT00701506|Device|Placebo PENS|20-minute session, to each affected knee, 3 times per week for 12 weeks.
Placebo PENS for 20 minutes:
Electrodes placed on quadriceps and hamstrings.
1011|NCT00701532|Drug|Modafinil and PET (brain imaging)|duration 90 days
1012|NCT00701532|Drug|placebo|duration 90 days
1013|NCT00701558|Drug|erlotinib [Tarceva]|150mg po daily
1014|NCT00701558|Drug|gemcitabine|1000mg/m2 i.v. weekly for 3 weeks of each 4 week cycle
1015|NCT00701571|Procedure|Virtual Reality distraction|Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is "Snow World". In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities.
1016|NCT00701597|Drug|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
1017|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
1018|NCT00005803|Drug|Fludarabine Phosphate|Given IV
1019|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
1020|NCT00701623|Drug|folder water|patients will receive the application of folder water directly on the injured area
881|NCT00700596|Drug|Placebo|Control or Placebo SA (30 % ethanolic solution)
882|NCT00700609|Behavioral|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
883|NCT00700622|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
884|NCT00700622|Drug|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
885|NCT00005802|Drug|fludarabine phosphate|
886|NCT00700622|Drug|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
887|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
888|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
889|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
890|NCT00700648|Drug|insulin aspart|Intravenous NovoRapid dose & frequency as decided by treating physician
891|NCT00700661|Drug|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
892|NCT00700661|Drug|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
893|NCT00700687|Drug|PA32540|aspirin/omeprazole
894|NCT00700687|Drug|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
895|NCT00700687|Drug|aspirin and [NSAID]|aspirin and [NSAID]
896|NCT00005802|Drug|methotrexate|
897|NCT00700700|Device|Active Cardiac Resynchronization Therapy (CRT)|Initiation of active biventricular pacing/cardiac resynchronization therapy
Devices by Medtronic:
Insync Sentry 7298 & 7299
Concerto C174 ASK (Most frequently implanted)
Insync III 8042 (PM)
Devices by Guidant/Boston Scientific:
Contak Renewal 4 H190 & H199
Contak Renewal 3 H127
Devices by ELA/Sorin:
1. Ovatio CRT 6750
898|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
899|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
900|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
901|NCT00700739|Device|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
1021|NCT00701636|Drug|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9%NS and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
1022|NCT00701649|Biological|CYT006-AngQb|s.c.
1023|NCT00701649|Biological|Placebo|s.c.
1024|NCT00701662|Biological|Vivaglobin|
1025|NCT00701675|Drug|sertraline 50 mg daily|50 mg daily
1026|NCT00701675|Drug|sertraline 100 mg daily|100 mg daily
1027|NCT00701675|Drug|Placebo 50 or 100 mg|matching placebo
1028|NCT00701688|Drug|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
1029|NCT00000681|Drug|Sargramostim|
1030|NCT00005803|Other|Laboratory Biomarker Analysis|Correlative studies
1031|NCT00701701|Biological|Myozyme (alglucosidase alfa)|Myozyme: Intravenous (IV) infusion of 20 mg/kg every other week (qow); Cyclophosphamide: 250 mg/m2 IV every 4 wks after Myozyme infusion for 6 months
1032|NCT00005803|Biological|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
1033|NCT00702117|Drug|ajmaline|1 mg/kg iv in 10 minutes
1034|NCT00702117|Drug|procainamide|10 mg/kg iv in 10 minutes
1035|NCT00702130|Drug|Pravastatin|pravastatin 40mg per os once daily
1036|NCT00702143|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
1037|NCT00702156|Drug|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
876|NCT00700570|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
877|NCT00700570|Drug|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
878|NCT00700570|Drug|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
879|NCT00700583|Drug|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
880|NCT00700596|Drug|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
767|NCT00700245|Behavioral|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
768|NCT00700245|Behavioral|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
769|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
770|NCT00005801|Radiation|radiation therapy|
771|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
772|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
773|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
774|NCT00700258|Drug|Axitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
775|NCT00700271|Drug|Amlodipine|5 mg or 10 mg tablets.
776|NCT00700271|Drug|Valsartan|160 mg capsules.
777|NCT00700284|Drug|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
778|NCT00700284|Drug|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
779|NCT00700297|Drug|Colchicine|100 mg Colchicine per day for 4 months
780|NCT00700297|Drug|Placebo|One tablet placebo per day for 4 months
781|NCT00005802|Biological|aldesleukin|
782|NCT00700310|Drug|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
783|NCT00700310|Drug|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
784|NCT00700310|Drug|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
785|NCT00700310|Drug|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
786|NCT00700323|Dietary Supplement|PS-Omega3 conjugate supplementation|
787|NCT00700323|Dietary Supplement|placebo|
788|NCT00700336|Drug|pemetrexed, cisplatin and CBP501|CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.
Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.
Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.
789|NCT00700336|Drug|pemetrexed and cisplatin|Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.
Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.
790|NCT00700349|Other|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
791|NCT00700362|Procedure|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
792|NCT00005802|Biological|filgrastim|
793|NCT00700362|Procedure|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
794|NCT00700375|Drug|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
795|NCT00700375|Drug|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
796|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg I.V.
797|NCT00005799|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
798|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
799|NCT00699374|Drug|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
800|NCT00699374|Drug|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
801|NCT00699387|Drug|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
802|NCT00699413|Drug|Super CitriMax and ChromeMate (in overweight adolescents)|After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.
Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal.
803|NCT00699426|Drug|nexium|40 mg once daily is tested together with Yoghurt
804|NCT00699426|Drug|nexium|nexium and placebo are tested
805|NCT00699426|Dietary Supplement|Yoghurt|Yoghurt
806|NCT00699426|Drug|placebo+placebo|placebo and placebo are tested.
807|NCT00699439|Other|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
808|NCT00000681|Drug|Vincristine sulfate|
809|NCT00005799|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
810|NCT00699452|Drug|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
811|NCT00699452|Drug|placebo|placebo
812|NCT00699465|Drug|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
813|NCT00699465|Drug|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
814|NCT00699478|Drug|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
815|NCT00699491|Biological|cixutumumab|Given IV
816|NCT00699491|Drug|temsirolimus|Given IV
817|NCT00699491|Other|laboratory biomarker analysis|Correlative studies
818|NCT00699504|Drug|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
819|NCT00701701|Biological|Myozyme (alglucosidase alfa)|Myozyme: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m2 IV weekly beginning the day after MZ infusion for 4 weeks (an optional additional 2nd cycle may be administered at the discretion of the investigator); Methotrexate: 15mg/m2 subcutaneous every other week on the day after Myozyme infusion for 6 months
820|NCT00701714|Drug|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
821|NCT00701714|Drug|ERYPO|Solution for injection (s.c.)
822|NCT00701727|Drug|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
823|NCT00701727|Drug|Placebo|1 tablet, once a day, for 7 weeks
824|NCT00701740|Drug|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
825|NCT00701740|Drug|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
826|NCT00701766|Drug|BI 2536|
827|NCT00701779|Drug|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
828|NCT00005803|Drug|Melphalan|Given IV
829|NCT00701792|Procedure|liver transplantation|liver transplantation
830|NCT00701792|Other|standard care for liver disease|standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving "standard medical therapy".
992|NCT00701337|Drug|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
993|NCT00701363|Drug|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
994|NCT00701376|Other|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
995|NCT00701389|Drug|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
996|NCT00005803|Drug|Cytarabine|Given IV
997|NCT00701389|Drug|sumatriptan|single oral dose of 100 mg sumatriptan
998|NCT00701389|Drug|sumatriptan placebo|single oral dose
999|NCT00701389|Drug|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
1000|NCT00701415|Biological|agalsidase beta|1.0 mg/kg/4 weeks
1001|NCT00701415|Biological|agalsidase beta|0.5 mg/kg/2 weeks
1183|NCT00702078|Behavioral|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
1184|NCT00702078|Behavioral|usual care|follow-up according to todays best practice
1185|NCT00702091|Drug|Ramipril|10 mg capsule
1186|NCT00702104|Other|survey administration|
1187|NCT00702117|Drug|flecainide|2 mg/kg iv in 10 minutes
1188|NCT00005814|Drug|cisplatin|
1189|NCT00703781|Drug|bromfenac ophthalmic solution|sterile ophthalmic solution
1190|NCT00703781|Drug|placebo|sterile ophthalmic solution
1191|NCT00703794|Device|The AXIUM Progressive Coil System|Embolization of aneurysm
1192|NCT00703807|Drug|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
1193|NCT00703807|Drug|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
1194|NCT00703820|Drug|Cytarabine|See Detailed Description
1195|NCT00703820|Drug|Daunorubicin|See Detailed Description
1059|NCT00702273|Drug|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
1060|NCT00702273|Drug|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1061|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
1062|NCT00702273|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
1063|NCT00702273|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
1064|NCT00702273|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
1065|NCT00005804|Procedure|allogeneic bone marrow transplantation|
902|NCT00700739|Device|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
903|NCT00700752|Device|senofilcon A|silicone hydrogel contact lens
904|NCT00700752|Device|balafilcon A|silicone hydrogel contact lens
905|NCT00700765|Drug|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
906|NCT00700778|Biological|recombinant human chorionic gonadotropin|
907|NCT00005802|Drug|mitoxantrone hydrochloride|
908|NCT00700778|Genetic|microarray analysis|
909|NCT00700778|Other|immunohistochemistry staining method|
910|NCT00700778|Other|laboratory biomarker analysis|
911|NCT00700778|Procedure|needle biopsy|
912|NCT00700791|Dietary Supplement|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
913|NCT00700791|Device|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
914|NCT00700791|Other|Placebo|Oral Placebo
915|NCT00700791|Other|Placebo Cream|Topical Placebo Cream
916|NCT00700804|Behavioral|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
917|NCT00700804|Behavioral|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
918|NCT00000681|Drug|Zidovudine|
919|NCT00005802|Drug|therapeutic hydrocortisone|
920|NCT00700817|Drug|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
921|NCT00700817|Drug|sitagliptin|Tablets, 100 mg daily
922|NCT00700817|Drug|metformin|Tablets, minimum 1500 mg daily
923|NCT00700817|Drug|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
924|NCT00700830|Drug|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
925|NCT00700856|Drug|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
926|NCT00700856|Drug|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
927|NCT00700869|Procedure|mechanical ventilation|mechanical ventilation
928|NCT00700882|Drug|dasatinib|
929|NCT00700882|Other|laboratory biomarker analysis|
930|NCT00005802|Radiation|radiation therapy|
931|NCT00700895|Drug|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
932|NCT00700908|Behavioral|automated telephone intervention vs. usual care|
933|NCT00700921|Drug|Lovastatin|40mg po once daily
934|NCT00700921|Drug|Placebo|One capsule, once daily
935|NCT00700947|Drug|Beta-blocker therapy (TOPROL-XL® )|Patients who have been surgically treated for mitral regurgitation that start Beta-Blocker therapy.
936|NCT00700960|Drug|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
937|NCT00700973|Behavioral|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
938|NCT00700973|Other|Usual care|Substance use disorder usual care
939|NCT00700986|Drug|AZD9056|Oral tablet, 800mg, one single administration
940|NCT00700986|Drug|Placebo|Single dose
941|NCT00005803|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
942|NCT00700999|Drug|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
943|NCT00701012|Procedure|preservation of nerve fibers around IMA|low ligation
944|NCT00701012|Procedure|resection of nerve fibers around IMA|high ligation
945|NCT00701038|Device|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
946|NCT00701051|Behavioral|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
947|NCT00701051|Behavioral|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
948|NCT00701064|Other|Bright Light Exposure|Administered via bright light box
949|NCT00701064|Other|Negative Ion Generator|Administered via Negative Ion Generatore
950|NCT00701077|Drug|3,4-Di-amino-Pyridine|a single 20 mg dosing
951|NCT00701077|Drug|placebo|placebo
952|NCT00005803|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
953|NCT00701090|Drug|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
954|NCT00701090|Drug|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
955|NCT00701090|Drug|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
956|NCT00701103|Drug|Comparator: MK-0646|MK-0646 by intravenous infusion
957|NCT00701129|Biological|Alglucosidase Alfa|Administered as IV infusion.
958|NCT00701129|Drug|Methotrexate|Administered subcutaneously.
959|NCT00701129|Drug|Rituximab|Administered as IV infusion.
960|NCT00701142|Biological|Haemocomplettan® P|Single intravenous infusion
961|NCT00701142|Biological|Saline solution|Single intravenous infusion
962|NCT00701155|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
963|NCT00005803|Drug|Carmustine|Given IV
964|NCT00701168|Device|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
965|NCT00701181|Procedure|Laser Treatment|Necessity of laser treatment is assessed every three months.
966|NCT00701181|Drug|PF-04523655 high|3 mg intravitreal injection
967|NCT00701181|Drug|PF-04523655 middle|1 mg intravitreal injection
968|NCT00701181|Drug|PF-04523655 low|0.4 mg intravitreal injection
969|NCT00701194|Behavioral|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
970|NCT00701207|Drug|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
971|NCT00701220|Drug|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
972|NCT00701233|Drug|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
973|NCT00701233|Drug|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
974|NCT00005803|Drug|Cyclophosphamide|Given IV
975|NCT00701246|Drug|ferrous sulfate|
976|NCT00701246|Drug|folic acid|
977|NCT00701246|Drug|placebo (folic acid)|
978|NCT00701259|Drug|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
979|NCT00701259|Drug|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
980|NCT00701259|Drug|placebo|
981|NCT00701285|Drug|pitavastatin|pitavastatin 4mg once daily
982|NCT00701285|Drug|pravastatin|pravastatin 10mg once daily
983|NCT00701298|Biological|peginterferon alfa-2b|Given SC
984|NCT00701298|Drug|decitabine|Given IV
985|NCT00005803|Drug|Cyclosporine|Given PO
986|NCT00701298|Other|laboratory biomarker analysis|Correlative studies
987|NCT00701311|Drug|CC-10004|CC-10004 20 mg per day
988|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
989|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 1)
990|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 15)
991|NCT00701337|Drug|oestradiol|oestradiol 2 mg oral route 30 days
1038|NCT00702156|Drug|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
1039|NCT00702182|Drug|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
1040|NCT00702182|Drug|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
1041|NCT00702182|Drug|Erlotinib|Daily Oral Erlotinib 100 mg
1042|NCT00702195|Drug|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
1043|NCT00005803|Radiation|Total-Body Irradiation|Undergo radiotherapy
1044|NCT00702195|Drug|Placebo|single dose of placebo (administered under protocol 38805)
1045|NCT00702195|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
1046|NCT00702208|Device|Delphi Screener|Self-sampling device for cervical vaginal lavage
1047|NCT00702221|Biological|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
1048|NCT00702221|Biological|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
1049|NCT00702234|Biological|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1050|NCT00702234|Biological|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1051|NCT00702234|Biological|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1052|NCT00702234|Biological|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1053|NCT00702234|Drug|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1054|NCT00005804|Drug|cyclophosphamide|
1055|NCT00702247|Procedure|Hematopoietic Stem Cell Transplantation|
1056|NCT00702260|Drug|Ramipril|10 mg capsule
1057|NCT00702273|Drug|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
1058|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1151|NCT00702702|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
1152|NCT00702702|Drug|Placebo|Placebo, 2 capsules daily for 3 months
1153|NCT00702715|Drug|sugammadex|Each subject will receive an
intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After
this dose, maintenance doses of 0.1 - 0.2 mg.kg-1
rocuronium may be given. In case of maintenance dosing, the target depth of
neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC.
1154|NCT00702728|Drug|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
1155|NCT00702728|Drug|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
1156|NCT00005808|Drug|photodynamic therapy|Undergo laser therapy
1157|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
1158|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
1159|NCT00702741|Drug|Placebo|Intra-articular injection of Hyaluronan
1160|NCT00702754|Biological|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
1161|NCT00701883|Drug|Atorvastatin|2 capsules, once daily for 8 weeks
1162|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
1163|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
1164|NCT00701896|Drug|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
1165|NCT00701896|Drug|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
1166|NCT00005803|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
1167|NCT00701896|Other|Biological Control|No treatment intervention only information and procedures.
1168|NCT00701896|Behavioral|Motivational Interview|60 minute one-on-one Interview
1169|NCT00701909|Drug|morphine plus saline|During the first wound care procedure, some patients will receive morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS), according to randomization, while other patients will receive morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg
1170|NCT00701909|Drug|morphine plus ketamine|Patients who received morphine 0.1 mg/kg (maximum dose of 8 mg)plus saline during the first wound care procedure will now receive ketamine 0.25 mg/kg IV plus morphine 0.05 mg/kg
1171|NCT00701935|Drug|placebo|subcutaneous injection, twice a day
1172|NCT00701935|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
1173|NCT00701961|Drug|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
1174|NCT00701974|Biological|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
1175|NCT00701974|Biological|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
1176|NCT00701987|Drug|ALS-357|Topical application of ALS-357
1177|NCT00005803|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
1178|NCT00702026|Dietary Supplement|multispecies probiotic (Ecologic 801)|once daily, 5 gram [10e9 cfu/gram]
1179|NCT00702026|Dietary Supplement|Placebo|once daily, 5 gram [10e9 cfu/gram]
1180|NCT00702039|Other|No Music|No music will be played in patients in arm 2 of the study.
1181|NCT00702039|Other|Music Therapy|Classical music being played during intravitreal injection.
1182|NCT00702052|Drug|RAD001|
1132|NCT00702598|Behavioral|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
1133|NCT00702598|Behavioral|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
1134|NCT00005807|Drug|ixabepilone|
1135|NCT00702611|Device|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
1136|NCT00702624|Drug|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
1137|NCT00702624|Biological|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
1138|NCT00702624|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
1139|NCT00702624|Biological|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
1140|NCT00702624|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
1141|NCT00702624|Drug|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
1142|NCT00702624|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
1143|NCT00702624|Biological|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
1144|NCT00702637|Drug|Modafinil|
1145|NCT00005808|Drug|motexafin lutetium|Given IV
1146|NCT00702650|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
1147|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
1148|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
1316|NCT00703326|Biological|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
1317|NCT00703326|Drug|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
1318|NCT00703326|Other|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
1319|NCT00703339|Drug|Treprostinil sodium for inhalation|Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose
Dose:
Cohort 1: dosed at 3 breaths (18 mcg)
Cohort 2: dosed at 6 breaths (36 mcg)
Cohort 3: dosed at 9 breaths (54 mcg)
Cohort 4: dosed at 12 breaths (72 mcg)
The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events.
1320|NCT00005811|Other|laboratory biomarker analysis|Correlative studies
1321|NCT00703352|Drug|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
1322|NCT00703365|Drug|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
1323|NCT00703378|Drug|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
1324|NCT00703391|Drug|AZD9668|30mg oral tablets twice daily (bid) for 14 days
1325|NCT00703391|Drug|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
1326|NCT00703417|Device|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
1327|NCT00703417|Device|Computed Tomography|CT scan of the lower back and hip
1328|NCT00703417|Device|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
1329|NCT00703430|Drug|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
1330|NCT00703456|Behavioral|Balance Training|balance training three days per week for 4 weeks during single limb standing
1331|NCT00005812|Drug|temozolomide|
1332|NCT00703469|Drug|MDX1106-02|Single dose
1333|NCT00703469|Drug|Placebo|Placebo single dose
1334|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
1149|NCT00702689|Drug|Gleevec, STI571(Imatinib Mesylate)|Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)
1150|NCT00702702|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
1300|NCT00703222|Biological|SJNB-JF-IL2 and SJNB-JF-Lptn cells and SKNLP Unmodified Neuroblastoma Cell Lines|*SJNB-JF-IL2 and SJNB-JF-Lptn cells are each dosed at 1x10e7 cells/m2/vaccination. This will be given in conjunction with an escalating dose of SKNLP vaccine.
Dose Level 1: 1x10e6 cells/m2/vaccination dose of SKNLP Unmodified Neuroblastoma Cell Line Vaccine Component
Dose Level 2: 1x10e7 cells/m2/vaccination dose of SKNLP Unmodified Neuroblastoma Cell Line Vaccine Component
1301|NCT00703235|Drug|Bevacizumab|
1302|NCT00703248|Procedure|Osteopathic Manipulative Treatments|opening the thoracic inlet
pectoral traction for 1 minute bilaterally
rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine ]
thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally
abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally.
1303|NCT00703261|Drug|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
1304|NCT00703261|Drug|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
1305|NCT00703274|Behavioral|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
1306|NCT00703287|Other|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
1307|NCT00703287|Other|Physiotherapy|Generic physiotherapy
1308|NCT00703300|Drug|bortezomib|Given IV
1309|NCT00005811|Drug|topotecan hydrochloride|Given IT
1310|NCT00703300|Drug|decitabine|Given IV
1311|NCT00703300|Other|pharmacological study|Correlative studies
1312|NCT00703300|Other|laboratory biomarker analysis|Optional correlative studies
1313|NCT00703313|Drug|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
1314|NCT00703313|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
1315|NCT00703313|Drug|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
1066|NCT00702299|Drug|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
1067|NCT00702299|Drug|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
1068|NCT00702299|Drug|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
1069|NCT00702299|Other|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
1070|NCT00702312|Behavioral|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
1071|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
1072|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
1073|NCT00702325|Drug|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
1074|NCT00702325|Drug|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
1075|NCT00702338|Drug|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
1076|NCT00005804|Radiation|radiation therapy|
1077|NCT00702338|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
1078|NCT00702338|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
1079|NCT00702338|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
1080|NCT00702351|Drug|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
1081|NCT00702364|Drug|atomoxetine|
1082|NCT00702364|Drug|placebo|
1083|NCT00702377|Other|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
1084|NCT00702377|Other|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
1085|NCT00702403|Drug|nilotinib|Given PO
1086|NCT00702403|Drug|imatinib mesylate|Given PO
1087|NCT00000176|Drug|Estrogen and Progesterone|
1088|NCT00000682|Drug|Zidovudine|
1089|NCT00005805|Dietary Supplement|St. John's wort|
1090|NCT00702403|Other|pharmacological study|Correlative studies
1091|NCT00702416|Procedure|Ultrasound-guided continuous interscalene brachial plexus block|With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.
A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.
At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots.
1092|NCT00702416|Procedure|Continuous interscalene brachial plexus block using electrical nerve stimulation|With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.
A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.
An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought
Injection of the local anesthetic will start with a visible motor response at a current <0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA.
1093|NCT00702416|Drug|Ropivacaine|Block induction [1% (wt/vol) solution]:
20 ml (200 mg)
Postoperative analgesia [0.2% (wt/vol) solution]:
Background infusion: 4 ml/h (8 mg/h)
Incremental on-demand dose: 2 ml (4 mg)
Lockout time: 15 min
1094|NCT00702416|Drug|Paracetamol|1 g iv q8h
1095|NCT00702416|Drug|Morphine|5 mg im prn q1h (in the postoperative period)
1096|NCT00702767|Drug|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
1097|NCT00702416|Drug|Fentanyl|50 µg iv prn (in the intraoperative period)
1098|NCT00702416|Procedure|General anesthesia|Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.
The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well.
1099|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
1100|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
1101|NCT00005806|Drug|carboplatin|
1102|NCT00702442|Drug|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
1103|NCT00702442|Drug|Saline solution|Saline solution administrated i.v 30 min prior surgery
1104|NCT00702455|Behavioral|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
1105|NCT00702455|Behavioral|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
1106|NCT00702468|Drug|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
1107|NCT00702468|Drug|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
1108|NCT00702481|Drug|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
1109|NCT00702481|Drug|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
1110|NCT00702481|Radiation|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
1111|NCT00702494|Biological|TB-403|Multiple IV
1112|NCT00005806|Drug|gefitinib|
1113|NCT00702507|Drug|0.25 % Miconazole Nitrate Ointment|Topical Application
1114|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
1115|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
1116|NCT00702520|Drug|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
1117|NCT00702520|Biological|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
1118|NCT00702520|Biological|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
1119|NCT00702546|Drug|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
1120|NCT00702546|Biological|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
1121|NCT00702546|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
1122|NCT00702546|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
1123|NCT00005806|Drug|paclitaxel|
1124|NCT00702546|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
1125|NCT00702546|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
1126|NCT00702546|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
1127|NCT00702546|Biological|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
1128|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which <2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
1129|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
1130|NCT00702585|Drug|Org 36286|Org 36286 single-dose subcutaneous injection
1131|NCT00702585|Drug|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
1470|NCT00704665|Drug|Relaxin|Placebo
1471|NCT00704678|Drug|SBR759|1g tid
1472|NCT00704678|Drug|Sevelamer HCl|1.6 g tid
1473|NCT00005819|Drug|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
1474|NCT00704678|Drug|Sevelamer HCl|1.5 g tid
1475|NCT00704678|Drug|Sevelamer HCl|0.8 g tid
1476|NCT00704691|Drug|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
1477|NCT00704704|Drug|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
1478|NCT00704717|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
1479|NCT00704717|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
1480|NCT00704730|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
1481|NCT00704730|Drug|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
1482|NCT00704743|Device|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
1483|NCT00704743|Device|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
1484|NCT00005819|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
1485|NCT00704743|Device|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
1486|NCT00704756|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
1487|NCT00704756|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg : 800 mg, 65 - 85 kg : 1000 mg, >85 kg : 1200 mg) orally for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
1488|NCT00704769|Drug|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
1489|NCT00704782|Drug|dimebon|
1335|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
1336|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
1337|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
1338|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
1339|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
1340|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
1196|NCT00703820|Drug|Etoposide|See Detailed Description
1197|NCT00703820|Drug|Clofarabine|See Detailed Description
1198|NCT00703833|Drug|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
1199|NCT00005814|Radiation|radiation therapy|
1200|NCT00703833|Drug|Placebo (unspecified)|matching placebo
1201|NCT00703846|Drug|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
1202|NCT00703859|Drug|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
1203|NCT00703872|Drug|Oral HDV-Interferon + ribavarin|Naive pateints
1204|NCT00703872|Drug|Injectable HDV-Interferon + ribavarin|Nonresponders
1205|NCT00703885|Drug|0.25 mg alprazolam|0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
1206|NCT00703885|Drug|1.0 mg alprazolam|1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
1207|NCT00703885|Drug|placebo|Placebo (liquid) to be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
1208|NCT00703898|Drug|nevirapine|200 mg/day twice a day
1209|NCT00703911|Drug|activated recombinant human factor VII|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
1210|NCT00005815|Drug|temozolomide|
1211|NCT00703924|Drug|WR 279,396|A topical cream containing 15% paromomycin
1212|NCT00703924|Drug|Placebo|Topical cream vehicle
1213|NCT00703937|Drug|Ferric Carboxymaltose (FCM)|
1214|NCT00703937|Drug|Standard Medical Care (SMC) for the treatment of IDA|
1215|NCT00702780|Drug|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
1216|NCT00702780|Drug|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
1217|NCT00702793|Drug|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
1218|NCT00702806|Drug|Org 36286|Intra-abdominal injection of Org 36286
1219|NCT00702806|Drug|Puregon®|Subcutaneous Puregon® 150 IU
1220|NCT00005808|Procedure|loop electrosurgical excision procedure|Undergo LEEP
1221|NCT00702806|Drug|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
1222|NCT00702806|Drug|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
1223|NCT00702819|Drug|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
1224|NCT00702832|Behavioral|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
1225|NCT00702832|Other|standard treatment|treatment as usual
1226|NCT00702845|Drug|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
1227|NCT00702845|Drug|recFSH (follitropin beta)|150 IU recFSH SC injection
1228|NCT00702845|Drug|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
1229|NCT00702845|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
1230|NCT00702845|Biological|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
1231|NCT00005808|Other|laboratory biomarker analysis|Correlative studies
1232|NCT00702845|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
1233|NCT00702845|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
1234|NCT00702845|Biological|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
1235|NCT00702858|Drug|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
1236|NCT00702858|Drug|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
1237|NCT00702871|Drug|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
1238|NCT00702871|Drug|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
1239|NCT00702884|Drug|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
1240|NCT00702910|Drug|Placebo|comparator
1241|NCT00702910|Drug|GW642444|investigational drug or placebo
1242|NCT00005809|Procedure|computed tomography|
1243|NCT00702923|Drug|Bicalutamide and CP-675,206 (Tremelimumab)|Dose level -1 :
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
1244|NCT00702923|Drug|Bicalutamide, CP-675,206 (tremelimumab)|Dose level 1:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
1245|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|Dose level 2:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
1246|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|Dose level 3:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
1247|NCT00702923|Drug|Bicalutamide, CP-675,206|Final Dose Level:
Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112
At month 9, if evidence of PSA progression:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29
1248|NCT00702936|Drug|TELMISARTAN|80 mg daily
1249|NCT00702936|Drug|RAMIPRIL|5 mg daily
1250|NCT00702949|Drug|pregabalin|Given orally
1251|NCT00702949|Other|placebo|Given orally
1252|NCT00702962|Drug|Vorinostat, Carboplatin, Etoposide|Sequential cohorts of 3-6 patients will be entered to the following dose levels: Level 1 - Days 1-14: Vorinostat 200 mg po QD; Day 3: Carboplatin 6 AUC; Days 1,2,3: Etoposide 100 mg/m2. Level 2 - Days 1-14: Vorinostat 300 mg po QD; Day 3: Carboplatin 6 AUC; Days 1,2,3: Etoposide 100 mg/m2; Level 3: Days 1-14: Vorinostat 400 mg po QD; Day 3: Carboplatin 6 AUC; Days 1,2,3: Etoposide 100 mg/m2. Treatment cycles will be repeated every 3 weeks. A maximum of 4 cycles will be administered to each patient.
1253|NCT00000682|Drug|Zalcitabine|
1254|NCT00005809|Procedure|diagnostic colonoscopy|
1255|NCT00702962|Other|Vorinostat, Carboplatin, Etoposide|Once the recommended phase II dose has been established and additional 15 patients will be enrolled. Days 1-4 Vorinostat recommended phase II dose po QD;Day 3 Carboplatin 6 AUC; Days 1,2,3 Etoposide 100 mg/m2. Treatment cycles will be repeated every 3 weeks. A maximum of 4 cycles will be administered to each patient. An additional 35 patients on the phase II portion of the trial will be required to achieve the outlined objectives.
1256|NCT00702975|Drug|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
1257|NCT00702988|Drug|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
1258|NCT00702988|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
1259|NCT00703001|Behavioral|Educational Intervention|students in this arm will receive several oral health educational modules in class
1260|NCT00703001|Behavioral|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
1261|NCT00703014|Drug|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
1262|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1263|NCT00703014|Drug|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
1264|NCT00703014|Drug|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1265|NCT00005810|Biological|filgrastim|
1266|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
1267|NCT00703014|Drug|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
1268|NCT00703014|Biological|hCG|In the Base Trial P05787, when 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
1269|NCT00703014|Biological|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
1270|NCT00703053|Biological|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
1271|NCT00703053|Biological|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
1272|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
1273|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
1274|NCT00703066|Biological|Rabies vaccine|3 doses of Rabies vaccine
1275|NCT00703079|Drug|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
1276|NCT00005810|Drug|carboplatin|
1277|NCT00703079|Procedure|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
1278|NCT00703092|Drug|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
1279|NCT00703105|Biological|Ontak DC|Administration of a single dose of Ontak at 18 µg/kg followed in 96 hours by DC vaccination with 1 x 10(6th) tumor lysate and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals (6 weeks)
1280|NCT00703105|Biological|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
1281|NCT00703105|Drug|Ontak|administration of Ontak 18 µg/kg without vaccination
1282|NCT00703118|Drug|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
1283|NCT00703118|Drug|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
1284|NCT00703118|Drug|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
1285|NCT00703118|Drug|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
1286|NCT00703131|Device|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
1287|NCT00005810|Drug|docetaxel|
1288|NCT00703144|Drug|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
1289|NCT00703144|Procedure|Pharmacokinetic|
1290|NCT00703157|Procedure|Catheter Ablation|Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
1291|NCT00703157|Procedure|Surgical Ablation|patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
1292|NCT00703170|Drug|Temsirolimus|
1293|NCT00703170|Drug|Pegylated liposomal doxorubicin|
1294|NCT00703183|Drug|ACU-4429|administered as a single dose, orally
1295|NCT00703183|Drug|matching placebo|administered as a single dose, orally
1296|NCT00703196|Dietary Supplement|folic acid|Given orally once daily
1297|NCT00703196|Other|placebo|Given orally once daily
1298|NCT00005810|Drug|estramustine phosphate sodium|
1299|NCT00703209|Procedure|Nerve Decompression|Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is "blinded" to which leg received the decompression.
1341|NCT00703495|Device|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
1342|NCT00005813|Biological|bispecific antibody MDX447|
1343|NCT00703508|Drug|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
1344|NCT00703521|Biological|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
1345|NCT00703534|Drug|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
1346|NCT00703534|Drug|Placebo|capsule. administered as a single dose twice daily for 4 weeks
1347|NCT00703534|Drug|Gelusil®|Chewable tablets taken as needed
1348|NCT00703547|Drug|GSK586529|
1349|NCT00703573|Drug|S-777469 400 mg|S-777469 400 mg BID
1350|NCT00703573|Drug|S-777469 800 mg|S-777469 800 mg BID
1351|NCT00703573|Drug|Placebo|Placebo BID
1352|NCT00703586|Drug|Maraviroc|ARM A:
Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:
150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
600 mg orally BID when coadministered with efavirenz or nevirapine
ARM B:
Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:
Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.
Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.
Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.
1353|NCT00005813|Biological|lymphokine-activated killer cells|
1354|NCT00703599|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
1355|NCT00703612|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
1356|NCT00703625|Drug|Temsirolimus|
1357|NCT00703625|Drug|Docetaxel|
1358|NCT00703638|Drug|cisplatin|Cisplatin administered intravenously, 75 mg/m^2 over 1-2 hours on day 1 of a 21 day cycle
1359|NCT00703638|Drug|pemetrexed disodium|Pemetrexed 500 mg/m^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
1360|NCT00703638|Drug|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
1361|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
1466|NCT00704639|Drug|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
1467|NCT00704639|Drug|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
1468|NCT00704639|Radiation|Radiotherapy|The radiotherapy schedule will be the "infield boost" (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended).
1469|NCT00704665|Drug|Relaxin|10 ug/kg/day or 25 ug/kg/day
1421|NCT00704353|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
1422|NCT00704353|Drug|Standard Medical Care (SMC)|Per product label
1423|NCT00704366|Drug|AZD0530|oral, tablet, once daily, dose will be variable
1424|NCT00704379|Drug|Placebo|an inactive substance
1425|NCT00704379|Drug|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
1426|NCT00704392|Drug|XL647|Tablets supplied at 50-mg strength administered orally daily
1427|NCT00704392|Drug|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
1428|NCT00000683|Biological|gp160 Vaccine (MicroGeneSys)|
1429|NCT00005818|Drug|irinotecan hydrochloride|Given IV
1430|NCT00704405|Drug|Vaniprevir|Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
1431|NCT00704405|Drug|Pegylated Interferon (Peg-IFN)|Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
1432|NCT00704405|Drug|Ribavirin (RBV)|Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing <=75 kg and 1200 mg for participants weighing >75 kg.
1433|NCT00704405|Drug|Placebo (PBO)|Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
1434|NCT00704418|Drug|Bromfenac|sterile ophthalmic solution
1435|NCT00704418|Drug|Placebo|sterile ophthalmic solution
1436|NCT00704431|Drug|SB-480848 (darapladib)|160 mg darapladib
1437|NCT00704444|Drug|Ezetimibe|Ezetimibe, 10-mg tablets
1438|NCT00704444|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
1439|NCT00704470|Other|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
1460|NCT00704561|Device|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
1461|NCT00704561|Device|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
1462|NCT00005819|Drug|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
1463|NCT00704574|Drug|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
1464|NCT00704600|Drug|nelfinavir|Phase I:
take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days
day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
day 0: PET-CT
Phase II:
take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days
day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
day 7 biopsy
day 7, 21 and week 15 :PET-CT + perfusion CT
1465|NCT00704626|Other|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
1600|NCT00705198|Radiation|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
1601|NCT00705211|Drug|Ezetimibe|Ezetimibe, 10-mg tablets,
1602|NCT00705211|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
1603|NCT00705224|Biological|Pegylated Interferon|Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.
The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous
injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.
The Sponsor did not provide formal drug supply.
1604|NCT00705224|Drug|Ribavirin|Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.
The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the
morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.
The Sponsor did not provide formal drug supply.
1605|NCT00705237|Procedure|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
1606|NCT00705250|Drug|bendamustine hcl|Patients will receive bendamustine 120mg/m2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is > 1000/ul and the platelet count is > 75,000/ul.
1607|NCT00705263|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1440|NCT00005818|Drug|semaxanib|Given IV
1441|NCT00704470|Other|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
1442|NCT00704483|Drug|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
1443|NCT00704483|Drug|Sevelamer HCl|0.8 g tid
1444|NCT00704483|Drug|SBR759|1.5 g tid
1445|NCT00704483|Drug|Sevelamer HCl|1.6 g tid
1446|NCT00704496|Drug|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
1447|NCT00704496|Drug|Placebo|
1448|NCT00704509|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
1449|NCT00704509|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
1450|NCT00704509|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
1451|NCT00005818|Other|laboratory biomarker analysis|Correlative studies
1452|NCT00704522|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1453|NCT00704522|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1454|NCT00704522|Behavioral|Patient assistance program|Assistance programs will be classified as follows:
Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)
Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).
In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only.
1455|NCT00704535|Drug|Ezetimibe|1 tablet of 10 mg once daily
1456|NCT00704548|Drug|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
1457|NCT00704548|Drug|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
1458|NCT00704561|Device|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
1459|NCT00704561|Device|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
1490|NCT00704795|Other|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
1491|NCT00704795|Other|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
1492|NCT00704808|Procedure|Primary surgical treatment|Primary surgery for tumor resection.
1493|NCT00704808|Radiation|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
1494|NCT00704808|Drug|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
1495|NCT00005820|Drug|nitrocamptothecin|
1496|NCT00704821|Drug|PTC299|PTC299 orally administered 2 or 3 times per day.
1497|NCT00704834|Procedure|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
1498|NCT00704847|Drug|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
1499|NCT00704847|Drug|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
1500|NCT00704860|Other|Open label pharmacotherapy|Dosage and drug types change based on patients need and response.
doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,
1501|NCT00704886|Other|video|video of dementia
1502|NCT00704899|Procedure|Physiotherapy|Structured exercise regimen
1503|NCT00704899|Drug|Amitryptiline|Amitryptiline 25mg once daily
1504|NCT00704912|Drug|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
1505|NCT00704912|Drug|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
1506|NCT00005821|Drug|patent blue V dye|
1362|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
1363|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
1364|NCT00000683|Biological|HIVAC-1e|
1365|NCT00005813|Procedure|conventional surgery|
1366|NCT00703664|Drug|Bortezomib|Given IV
1367|NCT00703664|Other|Laboratory Biomarker Analysis|Correlative studies
1368|NCT00703664|Drug|Vorinostat|Given PO
1369|NCT00703677|Drug|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
1370|NCT00703690|Drug|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
1371|NCT00703690|Drug|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
1372|NCT00703690|Drug|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
1373|NCT00703703|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
1374|NCT00703703|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
1375|NCT00703703|Drug|Placebo|Placebo tablet once daily
1376|NCT00005814|Biological|cetuximab|
1377|NCT00703729|Device|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
1378|NCT00703729|Other|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
1379|NCT00703742|Drug|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
1380|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
1381|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
1382|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
1383|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
1384|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
1385|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
1386|NCT00703755|Drug|Placebo|Placebo
1387|NCT00704080|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
1388|NCT00704080|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
1389|NCT00704093|Device|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
1390|NCT00704106|Drug|Entecavir|0.5 or 1 mg dose qd
1391|NCT00704119|Drug|RhuDex®|Treatment A.1: 31.65 mg RhuDex® once N=12
Treatment A.2: 63.33 mg RhuDex® once N=12
Treatment A.3: 126.63 mg RhuDex® once N=12
Treatment A.4: 253.26 mg RhuDex® once N=12
Treatment B.1: 31.65 mg RhuDex® once N=12
Treatment B.2: selected dose of RhuDex® once N=12
Treatment C: selected dose of RhuDex® once N=12
Treatment D: selected dose of RhuDex® twice daily for 6 days N=12
1392|NCT00704132|Drug|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
1393|NCT00704132|Drug|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
1394|NCT00704145|Device|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
1395|NCT00005816|Procedure|conventional surgery|
1396|NCT00704158|Drug|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
1397|NCT00704171|Procedure|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
1398|NCT00704171|Device|PleuraSeal Lung Sealant System|
1399|NCT00704184|Drug|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
1400|NCT00704184|Drug|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
1401|NCT00704184|Drug|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
1402|NCT00704184|Drug|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
1403|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
1404|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
1405|NCT00704223|Drug|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
1406|NCT00005817|Drug|becatecarin|Given IV
1407|NCT00704236|Drug|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
1408|NCT00704236|Drug|Placebo|
1409|NCT00704249|Drug|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
1410|NCT00704249|Drug|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
1411|NCT00704262|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
1412|NCT00704275|Drug|0.05% cyclosporin eye drop|bid dosage for 4 months
1413|NCT00704288|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
1414|NCT00704301|Drug|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
1415|NCT00704301|Drug|Placebo|Placebo, 2 times a day
1416|NCT00704314|Drug|Simvastatin|80 mg Simvastatin daily for 8 weeks
1417|NCT00005817|Other|laboratory biomarker analysis|Correlative studies
1418|NCT00704314|Drug|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
1419|NCT00704340|Device|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
1420|NCT00704340|Other|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
1635|NCT00705419|Drug|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
1636|NCT00705419|Drug|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
1637|NCT00705432|Biological|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
1638|NCT00705432|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
1639|NCT00705432|Drug|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
1640|NCT00705432|Drug|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
1641|NCT00005822|Procedure|conventional surgery|Patients undergo a modified radical mastectomy.
1642|NCT00705445|Dietary Supplement|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
1643|NCT00705445|Dietary Supplement|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
1644|NCT00705445|Other|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
1645|NCT00705458|Procedure|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
1646|NCT00705458|Procedure|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
1647|NCT00705471|Biological|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
1648|NCT00705484|Biological|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
1649|NCT00705484|Drug|Standard Therapy|The standard therapy group will consist of subjects receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy subject will be left to the discretion of the treating physician and may change during the course of a subject's participation in the registry.
1650|NCT00705484|Biological|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
1608|NCT00005821|Radiation|Technetium Tc 99m human serum albumin colloid|
1609|NCT00705263|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1610|NCT00705276|Drug|Lactic acid (Dermacyd Femina Delicata)|
1611|NCT00705289|Biological|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
1612|NCT00705302|Behavioral|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
1613|NCT00705302|Behavioral|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
1614|NCT00705315|Drug|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
1615|NCT00705315|Drug|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
1616|NCT00705315|Drug|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
1617|NCT00705328|Behavioral|Control Model (EXIST)|conventional low-income assistance with self-directed use of existing government and community services.
1618|NCT00705328|Behavioral|Primary Health Care Model|Primary health care service delivery
1619|NCT00005822|Drug|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
1620|NCT00705328|Behavioral|Recreation Coordination Model (REC)|Recreation coordination service delivery
1621|NCT00705328|Behavioral|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of EXIST plus PRMHLTH plus REC.
1622|NCT00705341|Drug|fluticasone|Inhaled corticosteroid approved for treatment of asthma
1623|NCT00705354|Drug|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
1624|NCT00705354|Procedure|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
1625|NCT00705367|Drug|Placebo|Infusion, Intravenous, single dose, Day 1
1626|NCT00705367|Drug|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
1627|NCT00705367|Drug|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
1628|NCT00705380|Behavioral|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
1629|NCT00705380|Behavioral|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
1630|NCT00005822|Drug|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
1631|NCT00705406|Drug|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
1632|NCT00705406|Drug|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
1507|NCT00704912|Drug|Combination of treatments|Medications will be administered as described for the other 2 arms.
1508|NCT00704925|Drug|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
1509|NCT00704938|Biological|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
1510|NCT00704938|Biological|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10^8 cells to 5 x 10^10 cells.
1511|NCT00704938|Biological|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
1512|NCT00704938|Biological|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
1513|NCT00704938|Drug|cyclophosphamide|60mg/kg/day (Days-7,-6)
1514|NCT00704938|Drug|fludarabine phosphate|25mg/m^2 (Days -5, -4, -3, -2, and -1)
1515|NCT00704951|Drug|Posaconazole or alternative fungal treatment|Dosage of Posaconazole:
Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)
1516|NCT00704964|Biological|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
1517|NCT00005821|Procedure|conventional surgery|
1518|NCT00704964|Drug|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
1519|NCT00704977|Procedure|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|The eye operated is disinfected and covered according routine protocol.
Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.
Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.
Wound closure by by technique described in each arm.
Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.
Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.
Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs.
1520|NCT00704990|Dietary Supplement|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
1521|NCT00705003|Drug|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
1522|NCT00705003|Drug|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
1523|NCT00703950|Procedure|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
1524|NCT00703950|Procedure|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
1525|NCT00703963|Device|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
1526|NCT00703963|Other|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
1527|NCT00703976|Drug|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
1528|NCT00703976|Drug|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
1529|NCT00005815|Drug|thalidomide|
1530|NCT00703976|Drug|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
1531|NCT00703976|Radiation|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
1532|NCT00703989|Dietary Supplement|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
1533|NCT00704002|Procedure|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
1534|NCT00704002|Procedure|conservative treatment|conservative treatment with 2-finger splint for one week
1535|NCT00704015|Behavioral|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
1536|NCT00704028|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
1537|NCT00704028|Drug|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
1538|NCT00704041|Biological|MAGE-A3 HPV-16 vaccine|500, 1000, 1500 micrograms 4 times, biweekly
1539|NCT00704054|Drug|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
1540|NCT00005816|Biological|therapeutic autologous dendritic cells|
1541|NCT00704067|Behavioral|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
1542|NCT00704067|Behavioral|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
1543|NCT00705887|Behavioral|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
1544|NCT00705900|Drug|LCD|2 applications / day for 12 weeks
1545|NCT00705900|Drug|calcipotriol|2 applications / day for 12 weeks
1546|NCT00705913|Device|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
1547|NCT00705913|Device|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
1548|NCT00705926|Drug|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
1549|NCT00705926|Other|No treatment|Participants in this group will not receive treatment at this stage of their infection.
1550|NCT00705939|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
1551|NCT00005823|Drug|mitoxantrone hydrochloride|
1552|NCT00705952|Other|Lifestyle intervention|Diet, exercise and behavioural change intervention.
1553|NCT00705965|Behavioral|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
1554|NCT00705965|Behavioral|Information session|One information session about living with heart disease.
1555|NCT00705965|Other|Usual cardiological care|Usual cardiological care
1556|NCT00705978|Drug|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
1557|NCT00705978|Drug|Placebo|placebo
1558|NCT00705991|Procedure|ROTEM|
1559|NCT00706004|Drug|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
1560|NCT00706017|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1561|NCT00706030|Drug|neratinib|Neratinib 240mg daily
1562|NCT00005823|Drug|thioguanine|
1563|NCT00706030|Drug|vinorelbine|vinorelbine 25 mg/m2 on day 1 and day 8 of a 21 days cycle.
1564|NCT00706069|Drug|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
1565|NCT00706069|Drug|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
1566|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m^2 for normal hepatic function.
1567|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m^2 for mild hepatic impairment (Child-Pugh A)
1568|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m^2 for moderate hepatic impairment (Child-Pugh B)
1569|NCT00705003|Drug|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
1570|NCT00705016|Drug|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
1571|NCT00705016|Drug|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
1572|NCT00705016|Drug|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m^2) as infusion (initial starting dose of 400 mg/m^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
1573|NCT00705016|Drug|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
1574|NCT00005821|Procedure|lymphangiography|
1575|NCT00705016|Drug|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
1576|NCT00705042|Drug|Etanercept|
1577|NCT00705081|Drug|ezetimibe|10 mg once daily
1578|NCT00705081|Drug|statin|
1579|NCT00705107|Biological|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
1580|NCT00705107|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
1581|NCT00705120|Other|Bone Marrow Cell Transplantation|
1582|NCT00705120|Radiation|Irradiation, Total Body|
1583|NCT00705120|Drug|Cyclophosphamide|
1584|NCT00705120|Drug|Cyclosporin|
1585|NCT00000684|Drug|Dextran sulfate|
1586|NCT00005821|Procedure|radionuclide imaging|
1587|NCT00705120|Procedure|Mesenchymal Stem Cell Transplantation|
1588|NCT00705120|Drug|Busulfan|
1589|NCT00705133|Drug|treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min per day initially as tolerated and then increased by 0.5ng/kg/min every 2 days as an outpatient. The maximum dose at 3 months will be 40ng/kg/min
1590|NCT00705146|Device|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
1591|NCT00705146|Device|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
1592|NCT00705159|Drug|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
1593|NCT00705159|Drug|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
1594|NCT00705159|Drug|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
1595|NCT00705159|Drug|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
1596|NCT00705172|Drug|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
1597|NCT00005821|Procedure|sentinel lymph node biopsy|
1598|NCT00705198|Drug|Temozolomide (for newly diagnosed malignant glioma)|Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.
Temozolomide is administered as 20 mg and 100 mg capsules.
1599|NCT00705198|Drug|Temozolomide (for relapsed malignant glioma)|Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.
Temozolomide is administered as 20 mg and 100 mg capsules.
1633|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
1634|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
1687|NCT00705679|Drug|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
1688|NCT00705679|Drug|Tenofovir placebo|placebo gel
1689|NCT00705692|Drug|Levamisole|
1690|NCT00705692|Drug|Placebo|
1691|NCT00705705|Behavioral|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
1692|NCT00705705|Behavioral|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
1693|NCT00705718|Device|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
1694|NCT00705744|Drug|Lactic acid (Dermacyd Femina)|
1695|NCT00705757|Drug|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
1696|NCT00000685|Drug|Zidovudine|
1697|NCT00005823|Drug|etoposide|
1698|NCT00705757|Drug|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
1699|NCT00705757|Drug|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
1700|NCT00705770|Drug|Anecortave Acetate|Low dose
Sustained release depot suspension
1701|NCT00705770|Drug|Anecortave Acetate|Middle dose
Sustained release depot suspension
1702|NCT00705770|Drug|Anecortave Acetate|High dose
Sustained release depot suspension
1703|NCT00705770|Drug|Placebo|Placebo treatment with vehicle
1704|NCT00705783|Drug|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
1705|NCT00705783|Drug|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
1706|NCT00705796|Drug|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
1707|NCT00705796|Drug|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
1724|NCT00706303|Behavioral|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
1725|NCT00706316|Biological|EBV-Specific CTLs and CD45 Mab|One time infusion (IV) at one of the following dose levels:
Dose level I: 5 x 107 cells/m2
Dose level II: 1 x 108 cells/m2
Dose level III: 2 x 108 cells/m2
1726|NCT00706329|Device|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
1727|NCT00706342|Drug|Fostamatinib Disodium / R935788|R935788 tablets
1728|NCT00706355|Drug|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
1729|NCT00706368|Device|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
1730|NCT00706381|Drug|Sincalide|
1731|NCT00706381|Drug|Ursodiol Acid|
1732|NCT00706381|Procedure|High Fat/Low Fat Diet|
1733|NCT00706394|Device|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
1734|NCT00005824|Drug|busulfan|
1735|NCT00706407|Device|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
1736|NCT00706420|Procedure|Islet Transplantation + Immunosuppression|Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
1737|NCT00706420|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
1738|NCT00706433|Drug|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
1739|NCT00706433|Other|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
1708|NCT00005823|Drug|hydroxyurea|
1709|NCT00705822|Drug|Docetaxel + Estramustine + Hydrocortisone|Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.
Combination of these 3 drugs every 3 weeks
1710|NCT00705822|Drug|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
1711|NCT00705835|Biological|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
1712|NCT00705861|Drug|Placebo|Placebo as a substitute of SK3530 100mg
1713|NCT00705861|Drug|SK3530|SK3530 100mg
1714|NCT00705874|Drug|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
1715|NCT00705874|Drug|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
1716|NCT00705874|Drug|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1717|NCT00705874|Drug|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1718|NCT00705874|Drug|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1719|NCT00005823|Drug|idarubicin|
1720|NCT00705874|Drug|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1721|NCT00705874|Drug|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
1722|NCT00706290|Behavioral|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
1723|NCT00005824|Biological|filgrastim|
1752|NCT00706576|Drug|[Met5]-enkephalin (Infusion of opioid growth factor )|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
1753|NCT00706589|Drug|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
1754|NCT00706589|Drug|placebo|Initial dose: 2mg, Maximum dose:20mg
1755|NCT00706615|Biological|Ad-sig-hMUC-1/ecdCD40L vaccine|
1756|NCT00000686|Drug|Stavudine|
1757|NCT00005824|Procedure|peripheral blood stem cell transplantation|
1758|NCT00706628|Drug|BIBF 1120|
1759|NCT00706628|Drug|BIBW 2992|
1760|NCT00706628|Drug|Sequential BIBF 1120 + BIBW 2992|
1761|NCT00706641|Drug|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
1762|NCT00706641|Procedure|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
1763|NCT00706654|Drug|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
1764|NCT00706654|Drug|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
1765|NCT00706654|Drug|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
1766|NCT00706654|Drug|Placebo depot|Placebo depot was supplied in lyophilized vials.
1767|NCT00706654|Drug|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
1768|NCT00005825|Drug|cisplatin|
1769|NCT00706667|Drug|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
1770|NCT00706680|Drug|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
1771|NCT00706693|Dietary Supplement|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
1772|NCT00706693|Dietary Supplement|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
1773|NCT00706693|Dietary Supplement|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
1774|NCT00706706|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
1775|NCT00706719|Drug|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
1776|NCT00706719|Drug|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
1777|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
1778|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
1779|NCT00005825|Drug|mitomycin C|
1780|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
1781|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
1782|NCT00706745|Dietary Supplement|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
1783|NCT00706745|Dietary Supplement|placebo|identical placebo capsules.
1784|NCT00706758|Behavioral|IBS school|Structured patient group education
1785|NCT00706758|Behavioral|IBS-guidebook|Written information - IBS-guidebook
1786|NCT00706771|Drug|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
1787|NCT00706771|Drug|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
1788|NCT00706784|Drug|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
1789|NCT00706797|Drug|etanercept (EnbrelTM)|
1790|NCT00005825|Drug|tretinoin|
1791|NCT00706797|Drug|methotrexate|
1651|NCT00705497|Procedure|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
1652|NCT00005822|Radiation|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
1653|NCT00705510|Drug|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
1654|NCT00705523|Drug|varenicline|1.0 mg BID for 12 weeks
1655|NCT00705523|Drug|placebo|BID 12 weeks
1656|NCT00705536|Drug|Humalog|
1657|NCT00705536|Drug|Humulin-R|
1658|NCT00705536|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
1659|NCT00705549|Drug|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
1660|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
1661|NCT00705549|Drug|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
1662|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
1663|NCT00005822|Drug|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
1664|NCT00705549|Drug|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
1665|NCT00705549|Drug|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
1666|NCT00705562|Other|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
1667|NCT00705575|Drug|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
1668|NCT00705575|Drug|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
1669|NCT00705588|Drug|Tadalafil|Orally, titrated to maximum 20mg od
1670|NCT00705588|Drug|Vardenafil|Orally, titrated to 10 mg bid
1671|NCT00705601|Procedure|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
1672|NCT00705614|Biological|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
1673|NCT00705627|Drug|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
1674|NCT00005823|Drug|cytarabine|
1675|NCT00705640|Biological|incomplete Freund's adjuvant|Given subcutaneously and intradermally
1676|NCT00705640|Biological|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
1677|NCT00705640|Biological|tetanus toxoid helper peptide|Given subcutaneously and intradermally
1678|NCT00705640|Procedure|biopsy|Patients undergo surgical biopsy at replicate vaccine site
1679|NCT00705653|Drug|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
1680|NCT00705666|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
1681|NCT00705666|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
1682|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
1683|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
1684|NCT00705679|Drug|Tenofovir disoproxil fumarate|300 mg tablet
1685|NCT00005823|Drug|daunorubicin hydrochloride|
1686|NCT00705679|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet
1872|NCT00706264|Device|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
1873|NCT00706277|Drug|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
1874|NCT00706277|Drug|propofol|propofol 2mg
1875|NCT00706277|Drug|remifentanil|remifentanil 0,25mcg/kg/hour
1876|NCT00706277|Drug|fentanyl|fentanyl 100mcg
1877|NCT00706277|Drug|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
1878|NCT00708227|Drug|Ipratropium bromide|Fluticasone propionate MDI(dose to be determined by patient's current treatment) for 2 weeks, followed by Advair(R)Diskus (same dose of fluticasone propionate) for 2 weeks; Ipratropium bromide MDI used for prn symptom relief
1879|NCT00708240|Drug|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
1880|NCT00708253|Device|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
1881|NCT00708253|Device|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
1882|NCT00708266|Device|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
1883|NCT00708266|Dietary Supplement|Intralipid 20%|Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the "treatment" study visits.
1884|NCT00708266|Other|0.9% Saline Solution|0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the "control" study visits.
1885|NCT00708279|Procedure|Osteopathic manipulation|Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
1886|NCT00005834|Drug|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
1887|NCT00708292|Drug|AUY922|
1888|NCT00708292|Drug|Bortezomib|
1889|NCT00708292|Drug|Dexamethasone|
1740|NCT00706446|Drug|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
1741|NCT00706446|Drug|salmeterol or formoterol|salmeterol diskus 1 puff twice a day or formoterol inhaler 2 puffs twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
1742|NCT00706459|Device|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
1743|NCT00706485|Device|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
1744|NCT00706498|Drug|BI 2536|
1745|NCT00005824|Drug|cyclophosphamide|
1746|NCT00706511|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
1747|NCT00706537|Drug|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
1748|NCT00706537|Drug|Placebo|Placebo as two tablets once daily for three weeks
1749|NCT00706550|Biological|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
1750|NCT00706550|Biological|Placebo|Placebo
1751|NCT00706563|Biological|Fluarix™|Single intramuscular dose on Day 0
1890|NCT00708305|Drug|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
1891|NCT00708305|Drug|Placebo|Fluoride free toothpaste (0ppmF)
1892|NCT00708318|Drug|i.v. fentanyl and AeroLEF|Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).
Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN.
1893|NCT00708331|Device|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
1894|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
1895|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
1896|NCT00708357|Drug|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
1897|NCT00005834|Drug|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
1898|NCT00707161|Procedure|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
1899|NCT00707174|Drug|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
1900|NCT00707174|Drug|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
1901|NCT00005830|Drug|Doxorubicin Hydrochloride|Given IV
1902|NCT00707187|Drug|Cialis|35 pills of study medication (20 mg)
1903|NCT00707213|Procedure|Imaging study (FDG-PET/CT scan)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar ([18F]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
1904|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
1905|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
1906|NCT00707239|Drug|imipenem/cilastatin|Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
1907|NCT00707252|Drug|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
1908|NCT00707252|Drug|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
1909|NCT00707265|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.
The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used.
1910|NCT00707265|Device|Autograft/CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
1911|NCT00707278|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
1912|NCT00000687|Drug|Interferon alfa-2a|
1913|NCT00005830|Drug|Cisplatin|Given IV
1914|NCT00707278|Drug|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
1915|NCT00707278|Drug|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
1916|NCT00707304|Drug|Talactoferrin|Oral, 1.5 grams twice per day
1917|NCT00707304|Drug|Placebo|Oral, twice per day
1918|NCT00707330|Drug|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
1919|NCT00707343|Radiation|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-[F-18]fluorothymidine, [F-18]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
1792|NCT00706810|Drug|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
1793|NCT00706810|Drug|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
1794|NCT00706823|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
1795|NCT00706823|Device|Laryngeal Mask Airway-Unique|supra-glottic airway device
1796|NCT00706836|Drug|pregabalin|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
1797|NCT00706836|Drug|pregabalin|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
1798|NCT00706836|Drug|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
1799|NCT00706849|Drug|mipomersen sodium|200 mg /mL
1800|NCT00706849|Drug|placebo|1 mL matching placebo
1801|NCT00005825|Drug|vinorelbine tartrate|
1802|NCT00706862|Drug|Talactoferrin|Oral, 1.5 grams twice per day
1803|NCT00706862|Drug|Placebo|Oral, twice per day
1804|NCT00706875|Behavioral|questionnaire|A patient questionnaire, which includes validated instruments. Data collection methods are as follows:
In person at the medical appointment
Over the telephone
Mailed with self-addressed return envelope and prepaid postage
E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage
1805|NCT00706875|Behavioral|questionnaire|A patient questionnaire, which includes validated instruments. Data collection methods are as follows:
In person at the medical appointment
Over the telephone
Mailed with self-addressed return envelope and prepaid postage
E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage
1806|NCT00706888|Dietary Supplement|Vitamins B6, B9 and B12 and polyphenols|
1807|NCT00706888|Dietary Supplement|placebo|
1808|NCT00706901|Behavioral|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller & Rollnick 2013) and based on a manualized protocol (Martino & Santa Ana 2013; Santa Ana & Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
1809|NCT00706901|Behavioral|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
1810|NCT00706901|Behavioral|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
1811|NCT00706914|Drug|Aclidinium Bromide and Formoterol Fumarate fixed-dose combination (FDC)|Aclidinium bromide and formoterol fumarate FDC once daily for 4 weeks;
1812|NCT00005826|Drug|rubitecan|
1813|NCT00706914|Drug|Aclidinium Bromide and Formoterol Fumarate fixed-dose combination (FDC)|Aclidinium bromide and formoterol fumarate FDC every morning and formoterol fumarate every evening for 4 weeks;
1814|NCT00706914|Drug|Formoterol Fumarate|Formoterol fumarate twice daily for 4 weeks
1815|NCT00706927|Drug|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
1816|NCT00706927|Drug|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
1817|NCT00706953|Drug|bortezomib; pegylated liposomal doxorubicin|1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
1818|NCT00706966|Drug|dutasteride|6 months of dutasteride 3.5 mg daily
1819|NCT00706979|Other|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
1820|NCT00706979|Behavioral|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
1821|NCT00706992|Biological|ALVAC-MART-1 vaccine|Given subcutaneously
1822|NCT00706992|Biological|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
1823|NCT00005827|Dietary Supplement|genistein|
1824|NCT00706992|Biological|Aldesleukin|Given subcutaneously
1825|NCT00706992|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
1826|NCT00706992|Biological|incomplete Freund's adjuvant|Given subcutaneously
1827|NCT00707018|Device|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
1828|NCT00707018|Device|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
1829|NCT00707031|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1830|NCT00707031|Device|Pen auto-injector|
1831|NCT00707031|Drug|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
1832|NCT00707031|Device|Prefilled pen injector|
1833|NCT00707031|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
1834|NCT00005828|Dietary Supplement|green tea extract|
1835|NCT00707044|Procedure|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
1836|NCT00707044|Procedure|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
1837|NCT00707057|Drug|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
1838|NCT00707057|Drug|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
1839|NCT00707070|Drug|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
1840|NCT00707070|Drug|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
1841|NCT00707083|Drug|dexamethasone|Given oral
1842|NCT00707083|Drug|mercaptopurine|Given orally
1843|NCT00707083|Drug|methotrexate|Given orally
1844|NCT00707083|Drug|vincristine sulfate|Given IV
1845|NCT00005829|Drug|gemcitabine hydrochloride|
1846|NCT00707122|Other|Albumin and Crystalloids|From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:
1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:
if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;
if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;
if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted.
1847|NCT00707122|Other|Crystalloids|Volume replacement will be performed in both the treated and the control group according to the "early-goal directed therapy".
control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed.
1848|NCT00707135|Drug|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
1849|NCT00707148|Drug|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
1850|NCT00707148|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
1851|NCT00707161|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
1852|NCT00707161|Drug|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
1853|NCT00706108|Behavioral|Observational study|Observational (descriptive) study of technical and non-technical performance
1854|NCT00706121|Drug|Vitamin E|400 IU daily by mouth for 7 - 12 years
1855|NCT00706121|Drug|Selenium|200 mcg daily for 7 - 12 years
1856|NCT00706121|Drug|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
1857|NCT00005823|Drug|tretinoin|
1858|NCT00706121|Drug|selenium placebo|1 pill by mouth daily for 7 - 12 years
1859|NCT00706134|Drug|Placebo|Placebo tablet taken once daily in the morning with a light meal.
1860|NCT00706134|Drug|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
1861|NCT00706134|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
1862|NCT00706134|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
1863|NCT00706147|Drug|Arimoclomol|Drug: Placebo capsules given three times per day
Drug: Arimoclomol capsules given three times per day
1864|NCT00706173|Drug|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
1865|NCT00706173|Drug|Placebo|Placebo "10-20 mg" PO daily for 4 weeks.
1866|NCT00706186|Drug|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
1867|NCT00706199|Procedure|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
1868|NCT00005823|Drug|valspodar|
1869|NCT00706225|Drug|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
1870|NCT00706238|Biological|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration
1871|NCT00706251|Device|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
1951|NCT00707577|Behavioral|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
1952|NCT00707590|Drug|BMS-767778 or Placebo|
1953|NCT00707616|Other|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
1954|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)] given one month apart
1955|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)] given one month apart
1956|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)] given one month apart
1957|NCT00005831|Drug|carboplatin|Given IV
1958|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg)] given one month apart
1959|NCT00707655|Drug|Zalutumumab|Eight weekly infusions
1960|NCT00707681|Drug|MS-20|4 ml/vial
1961|NCT00707681|Drug|Placebo|4ml/vial
1962|NCT00707707|Drug|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
1963|NCT00707707|Drug|Paclitaxel|Intravenous infusion over 1 hour
1964|NCT00707720|Device|TERIS procedure|The implantation of the restrictive implant
1965|NCT00707746|Drug|mipomersen|
1966|NCT00707746|Drug|placebo|
1967|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.
1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses
2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses
3°day: Prednisone 2 mg/kg/d in 2 doses
4ºday: Prednisone 1 mg/kg/d in 2 doses
5ºday: Prednisone 0.5 mg/kg/d in 2 doses
6ºday: Prednisone 0.25 mg/kg/d in 2 doses
7ºday: Stop Prednisone
1968|NCT00005831|Drug|gemcitabine hydrochloride|Given IV
1969|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day
10°days after Tx: 2 mg/kg/d
Day 11 - 20: 1 mg/kg/d
Day 21 - 30: 0.5 mg/kg/d
Day 31 - 60: 0.3 mg/k/d
Week 8 - 12: 0.25 mg/k/d
Week 12 - 16: 0.20 mg/k/d
Week 16 - 20: 0.15 mg/k/d
Month 6 - 12: 0.10 - 0.12 mg/k/d
1991|NCT00707889|Drug|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
1992|NCT00707889|Drug|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
1993|NCT00707889|Drug|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
1994|NCT00707902|Drug|chlorhexidine/lidocaine|
1995|NCT00707902|Drug|echinacea/sage|
1996|NCT00707915|Drug|Drug: Benzodiazepine (listed out below)|The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.
All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks.
1997|NCT00707928|Drug|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
1998|NCT00707928|Other|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
1999|NCT00707941|Drug|Oseltamivir|Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)
Patients≥12 years: 75 mg capsules as follows:
1 cap (75 mg) PO BID X 5 days
≥ 40 75 mg PO BID 6.25
2000|NCT00707941|Drug|Placebo|Children < 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)
Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days
≥ 40 75 mg PO BID 6.25
2001|NCT00005833|Drug|R115777|300mg P.O. BID.
2002|NCT00707954|Drug|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
2003|NCT00707954|Drug|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
2004|NCT00707967|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
2005|NCT00707967|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
2006|NCT00707967|Biological|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
2007|NCT00707980|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
2008|NCT00707993|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
1970|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
1971|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
1972|NCT00707785|Dietary Supplement|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
1973|NCT00707798|Biological|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
1974|NCT00707798|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
1975|NCT00707824|Drug|nalbuphine|nalbuphine 5 mg epidural
1976|NCT00707824|Drug|nalbuphine|nalbuphine 10 mg epidural
1977|NCT00707824|Other|NSS|NSS
1978|NCT00707837|Other|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
1979|NCT00005831|Other|laboratory biomarker analysis|Correlative studies
1980|NCT00707837|Other|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
1981|NCT00707850|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
1982|NCT00707863|Drug|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
1983|NCT00707863|Drug|Escitalopram|10 mg of Escitalopram by mouth per day for 8 weeks
1984|NCT00707876|Drug|ferumoxytol|Dose 1 versus non-contrast MRA
1985|NCT00707876|Drug|ferumoxytol|Dose 2 versus non-contrast MRA
1986|NCT00707876|Drug|ferumoxytol|Dose 3 versus non-contrast MRA
1987|NCT00707889|Drug|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
1988|NCT00707889|Drug|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
1989|NCT00707889|Drug|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
1990|NCT00005832|Drug|R115777|300mg/dose BID, PO, Days 1-21, q 28days
1920|NCT00707356|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kgand6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
1921|NCT00707369|Drug|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
1922|NCT00707369|Drug|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
1923|NCT00707382|Genetic|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation "normal", "slow" or "fast" metabolizer of CYP2D6 or "normal" or "slow" metabolizer of CYP2C19. Different treatment options for the different genotypes are described.
1924|NCT00005830|Radiation|Radiation Therapy|Undergo radiation therapy
1925|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
1926|NCT00707382|Other|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
1927|NCT00707408|Drug|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
1928|NCT00707421|Drug|ketorolac acetate|
1929|NCT00707421|Drug|fluorometholone|
1930|NCT00707421|Drug|artificial lacrimal tears|
1931|NCT00707434|Device|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
1932|NCT00707447|Behavioral|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
1933|NCT00707447|Behavioral|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
1934|NCT00707460|Behavioral|Dietary Intervention (Macronutrient composition)|The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.
All groups are exposed to nutrition education on serving size and portion size.
2036|NCT00708162|Drug|Background regimen|Background Regimen is administered according to prescribing information, and contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either atazanavir, darunavir, fosamprenavir, lopinavir (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
2037|NCT00708175|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
2038|NCT00708175|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
2039|NCT00708188|Device|Multidetector raw CT|Multidetector raw CT
2040|NCT00708201|Drug|Alvimopan|
2041|NCT00708201|Drug|Placebo|
2042|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
2043|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
2044|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
2045|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
2046|NCT00005834|Drug|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
2047|NCT00708227|Drug|fluticasone|Fluticasone propionate MDI(dose to be determined by patient's current treatment) for 2 weeks, followed by Advair(R)Diskus (same dose of fluticasone propionate) for 2 weeks; Ipratropium bromide MDI used for prn symptom relief
2048|NCT00708227|Drug|Salmeterol|Fluticasone propionate MDI(dose to be determined by patient's current treatment) for 2 weeks, followed by Advair(R)Diskus (same dose of fluticasone propionate) for 2 weeks; Ipratropium bromide MDI used for prn symptom relief
2049|NCT00708526|Other|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
2050|NCT00708526|Device|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
2051|NCT00005835|Drug|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
2052|NCT00708539|Drug|progesterone|90 mg, vaginal, once daily
2053|NCT00708539|Drug|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
2054|NCT00708552|Drug|SB-742457|investigational drug
2055|NCT00708552|Drug|Donepezil|comparator
2056|NCT00708552|Drug|Placebo|comparator
2057|NCT00708565|Drug|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
2058|NCT00708578|Drug|Glimepiride|Once a day before breakfast
2059|NCT00708578|Drug|Metformin|After breakfast and supper
2060|NCT00708578|Drug|Insulin Glargine|Injection in the morning
2061|NCT00708591|Drug|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
2062|NCT00005835|Procedure|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
2063|NCT00708591|Drug|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
2064|NCT00708604|Procedure|Islet Transplantation|Islet Transplantation
2065|NCT00708604|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
2066|NCT00708630|Behavioral|Extended information on side effects|More detailed information on possible side effects of vaccine
2067|NCT00708643|Device|Habitual Silicone Hydrogel Contact Lens|contact lens
2068|NCT00708643|Device|narafilcon A|contact lens
2069|NCT00708656|Drug|mesalazine (Asacol®)|800 mg tablets
2070|NCT00708669|Device|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
2071|NCT00708669|Device|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
2072|NCT00708682|Biological|13-valent pneumococcal conjugate vaccine|
2073|NCT00005835|Other|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC >/= 1500 mm3 for three consecutive days.
2074|NCT00708695|Behavioral|Nurse Home Visitation|Visits from nurses from mid-pregnancy to child age 2 years.
1935|NCT00005831|Biological|trastuzumab|Given IV
1936|NCT00707473|Drug|Docetaxel|75 mg/m^2 IV on day 1 of each cycle.
1937|NCT00707473|Drug|5-Fluorouracil|750 mg/m^2 continuous infusion on days 1 through 4 of each cycle.
1938|NCT00707473|Drug|Cisplatin|75 mg/m^2 IV over 30-120 minutes on day 1 of each cycle.
1939|NCT00707486|Device|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
1940|NCT00707486|Device|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
1941|NCT00707499|Drug|BMS747158|Single dose administration.
1942|NCT00707512|Drug|natalizumab|Administered as specified in the TOUCH Prescribing Program
1943|NCT00707525|Procedure|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
1944|NCT00707538|Drug|BMS747158|2 IV injection of ~11 mCi (total) F-18 labeled compound
1945|NCT00707551|Drug|Ketoconazole|Tablet, administered as repeated doses.
1946|NCT00005831|Drug|paclitaxel|Given IV
1947|NCT00707551|Drug|Verapamil|Extended Release tablet, administered as repeated doses.
1948|NCT00707551|Drug|AZD1305|Extended Release tablet, administered as a single dose.
1949|NCT00707564|Device|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
1950|NCT00707564|Device|Gauze with pressure|Gauze with pressure
2133|NCT00709150|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
2134|NCT00709150|Behavioral|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
2135|NCT00709163|Drug|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
2136|NCT00709163|Drug|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
2137|NCT00709176|Behavioral|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
2138|NCT00709176|Behavioral|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
2139|NCT00709189|Drug|Norgestimate/Ehinyl Estradiol; Folic acid.|
2140|NCT00005838|Drug|vinorelbine tartrate|Given IV
2141|NCT00709202|Drug|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID.
2142|NCT00709215|Drug|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
2143|NCT00709228|Drug|PegIntron|1.5 ug/kg/week
2144|NCT00709228|Drug|Rebetol|800-1200 mg/day
2145|NCT00709254|Drug|i.v. fentanyl|single dose, 200 ug
2146|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
2147|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
2148|NCT00709267|Drug|Folic acid|
2009|NCT00707993|Drug|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
2010|NCT00708006|Drug|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
2011|NCT00708019|Behavioral|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls [total time 12.3 hours]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls [8.0 hours]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
2012|NCT00005834|Biological|filgrastim|Arms 1 and 2: 300 mcg (pts </= 60 kg) or 480 mcg (pts > 60 kg), SC beginning day 5
2013|NCT00708032|Device|spectacles|habitual spectacles
2014|NCT00708032|Device|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
2015|NCT00708045|Procedure|Imaging assessments|FDG-PET scans, functional MRI (fMRI) scans, Neuropsychological Testing
2016|NCT00708071|Biological|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
2017|NCT00708084|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
2018|NCT00708084|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
2019|NCT00708097|Drug|NaF|Fluoride
2020|NCT00708097|Drug|Placebo|Placebo
2021|NCT00708097|Drug|NaMFP|Fluoride
2022|NCT00708110|Drug|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
2023|NCT00000687|Drug|Zidovudine|
2024|NCT00005834|Drug|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
2025|NCT00708110|Drug|Placebo|Placebo is a tablet with no drug in it.
2026|NCT00708123|Drug|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
2027|NCT00708123|Drug|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
2028|NCT00708136|Behavioral|water based training program to improve balance|
2029|NCT00708149|Drug|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
2030|NCT00708149|Drug|placebo|takepron placebo
2031|NCT00708162|Drug|Elvitegravir|Elvitegravir 85 mg or 150 mg tablet administered orally once daily with food; dose level is dependent on which ritonavir-boosted protease inhibitor (PI/r) is administered as part of the background regimen.
2032|NCT00708162|Drug|Raltegravir|Raltegravir 400 mg tablet administered orally twice daily according to prescribing information
2033|NCT00708162|Drug|Placebo to match elvitegravir|Placebo to match elvitegravir administered orally once daily
2034|NCT00708162|Drug|Placebo to match raltegravir|Placebo to match raltegravir administered orally twice daily.
2035|NCT00005834|Drug|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
2164|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
2165|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
2166|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
2167|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
2168|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
2169|NCT00709384|Procedure|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
2170|NCT00709397|Other|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
2171|NCT00708370|Other|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
2172|NCT00708370|Other|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
2173|NCT00708383|Other|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
2174|NCT00708383|Other|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
2175|NCT00708396|Drug|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
2176|NCT00708409|Procedure|Cardiac valve surgery|Different autograft implantation techniques.
2177|NCT00708422|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
2178|NCT00708422|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
2179|NCT00708435|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
2180|NCT00708435|Biological|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
2181|NCT00005835|Drug|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
2182|NCT00708448|Radiation|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
2183|NCT00708461|Behavioral|weight gain prevention|Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.
Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.
Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.
Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices.
2184|NCT00708474|Device|OsseoFit™ Porous Tissue Matrix™|Bone void filler
2185|NCT00708487|Other|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
2186|NCT00708500|Drug|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
2187|NCT00708500|Biological|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
2188|NCT00708500|Drug|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
2189|NCT00708500|Drug|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
2190|NCT00710684|Drug|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
2191|NCT00710684|Drug|Placebo|Placebo added to existing donepezil
2192|NCT00710684|Drug|donepezil 5-10mg|existing donepezil treatment
2193|NCT00710697|Drug|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
2194|NCT00710710|Drug|BI 2536|
2195|NCT00710723|Procedure|vitrification|Vitrification using Hemi-straw carrier system.
2196|NCT00005845|Drug|tipifarnib|Given PO
2197|NCT00710736|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
2198|NCT00710736|Drug|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
2199|NCT00710749|Device|Disposable device|Disposable urine flow meter
2200|NCT00710749|Device|Digital device|Digital urine flowmeter
2201|NCT00710749|Device|Clinic flow measurement|Clinic gold standard flow measurement
2202|NCT00710762|Drug|BIBF1120|
2075|NCT00708708|Drug|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
2076|NCT00708721|Drug|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
2077|NCT00708734|Behavioral|functional exercise training|twice weekly group sessions for 5 weeks
2078|NCT00708747|Drug|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
2079|NCT00708747|Drug|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
2080|NCT00708760|Behavioral|paper based training|read selected material, test skills learned in simulator lab
2081|NCT00708760|Behavioral|web based training|read and view selected web based material, test skills learned in simulator lab
2082|NCT00708773|Drug|Irinotecan|90 minute IV infusion once every 3 weeks.
Dose will be based on sex and genotype determination.
2083|NCT00708786|Device|ICD|Ventricular arrhythmia treatment
2084|NCT00005836|Drug|oxaliplatin|
2085|NCT00708786|Device|CRT-D|Ventricular arrhythmia treatment
2086|NCT00708799|Other|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
2087|NCT00708812|Drug|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
2088|NCT00708812|Drug|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
2089|NCT00708851|Other|LCD Solution with NB-UVB Phototherapy|LCD Solution: 2 applications / day
NB-UVB Phototherapy: 3 light sessions / week
2090|NCT00708851|Device|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
2091|NCT00708877|Procedure|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
2092|NCT00708890|Behavioral|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
2093|NCT00708903|Drug|neratinib|HKI-272
2094|NCT00708903|Other|Placebo|Placebo
2095|NCT00000688|Drug|Ganciclovir|
2096|NCT00005837|Drug|oxaliplatin|
2097|NCT00708903|Drug|Moxifloxacin|
2098|NCT00708916|Drug|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
2099|NCT00708929|Procedure|Squatting|Squatting for 6 minutes
2100|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
2101|NCT00708942|Drug|Placebo|Placebo suppository, for 3-7 hours application
2102|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
2103|NCT00708942|Drug|Placebo|Placebo ointment for 5 hours application
2104|NCT00708968|Behavioral|FOCUS Program|Supportive, educative sessions with patients and spouses.
2105|NCT00708981|Other|Multifactorial Intervention|Study group will receive multifactorial intervention for advanced diabetic nephropathy:
Elements of multifactorial intervention:
BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.
Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.
Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.
Patient enhanced self-management provided by combined diabetes-renal education curriculum.
Behavior and social intervention
Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators.
2106|NCT00708994|Drug|THC|Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes.
Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes.
2107|NCT00005838|Drug|shark cartilage extract AE-941|Given orally
2108|NCT00708994|Drug|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
2109|NCT00709007|Behavioral|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
2110|NCT00709007|Behavioral|SAT|Participants take their HIV medications by themselves.
2111|NCT00709020|Drug|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
2112|NCT00709020|Other|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
2113|NCT00709020|Other|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
2114|NCT00709020|Other|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
2115|NCT00709020|Other|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
2116|NCT00709020|Other|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
2117|NCT00709020|Other|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
2118|NCT00005838|Other|placebo|Given orally
2119|NCT00709033|Genetic|autologous or syngeneic PBTLs and EBV-CTLs|Three dose levels are being evaluated namely:
GROUP 1
PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2
GROUP 2
PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2
GROUP 3
PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2
2120|NCT00709046|Drug|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
2121|NCT00709046|Drug|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
2122|NCT00709059|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
2123|NCT00709059|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg: 800 mg; 65 - 85 kg: 1000 mg; >85 kg: 1200 mg) orally for 48 weeks
2124|NCT00709072|Behavioral|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
2125|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
2126|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
2127|NCT00709111|Drug|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
2128|NCT00709124|Device|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
2129|NCT00005838|Drug|cisplatin|Given IV
2130|NCT00709124|Device|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
2131|NCT00709137|Drug|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
2132|NCT00709137|Drug|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
4896|NCT00723099|Other|Laboratory Biomarker Analysis|Correlative studies
4897|NCT00723099|Drug|Mycophenolate Mofetil|Given IV or PO
4898|NCT00723099|Radiation|Total-Body Irradiation|Undergo TBI
4899|NCT00723099|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
4900|NCT00715351|Drug|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
3628|NCT00725504|Drug|Intravenous lidocaine|Intravenous lidocaine administered during fMRI scan at a maximum dose of 3mcg/ml
3629|NCT00005945|Drug|dexamethasone|Given PO
3630|NCT00725517|Drug|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
3631|NCT00725530|Device|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
3632|NCT00725530|Device|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
3633|NCT00725543|Biological|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
3634|NCT00725556|Other|Speech Therapy|Speech Therapy
3635|NCT00725569|Drug|Bellis perennis and Staphysagria (C6)|homeopathic remedy
3636|NCT00725569|Drug|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
3637|NCT00725569|Drug|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
3638|NCT00725582|Drug|IMA-026|
3639|NCT00725582|Other|Placebo|
3640|NCT00005945|Drug|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
3641|NCT00725608|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
3642|NCT00725621|Biological|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
3179|NCT00727311|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
3180|NCT00727311|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
3181|NCT00727324|Drug|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
3182|NCT00727337|Behavioral|LACE-computer|Computerized Auditory Training
3183|NCT00005949|Other|laboratory biomarker analysis|Correlative studies
3184|NCT00727337|Behavioral|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
3185|NCT00727337|Behavioral|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
3186|NCT00727337|Behavioral|Lace-DVD|DVD based Auditory Training
3187|NCT00727350|Radiation|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
3188|NCT00727363|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
3189|NCT00727363|Dietary Supplement|Placebo|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
3190|NCT00727389|Behavioral|Physiotherapy|Exercise two days a week for six month
3191|NCT00727415|Drug|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
3192|NCT00727415|Drug|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
3501|NCT00730340|Procedure|Tonsillectomy with open fossa|SOP for a tonsillectomy.
3502|NCT00730353|Drug|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
3503|NCT00730353|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
3504|NCT00730366|Drug|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
2403|NCT00711243|Drug|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
2404|NCT00711243|Drug|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
2405|NCT00711256|Other|sunscreen MATAS sunlotion SPF 8|
2406|NCT00711256|Radiation|UVB light|duration 4 times 1 minute radiation on the trunk.
2407|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
2408|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
2409|NCT00711269|Drug|Placebo|
2410|NCT00711269|Drug|Risperidone|
2710|NCT00712816|Other|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
2711|NCT00712829|Drug|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
2712|NCT00712829|Drug|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
2713|NCT00712842|Other|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
2714|NCT00005852|Drug|methylprednisolone|
2715|NCT00712855|Biological|mapatumumab|3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
2716|NCT00712855|Drug|sorafenib|400 mg orally, twice a day continuously in each cycle
2717|NCT00712868|Drug|Lactic acid|Once a day
2718|NCT00712881|Drug|MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles|MYOCET® (60 mg/m2) and cyclophosphamide (600 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (6 mg/kg) once every 3 weeks for 4 cycles (MCH→TH).
2719|NCT00712881|Drug|Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles|Free doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) once every 3 weeks for 4 cycles (AC→TH).
2720|NCT00712894|Drug|Diltiazem|Intracoronary Infusion 400-2000ug
2721|NCT00712894|Drug|Verapamil|Intracoronary Infusion 200-1000ug
2722|NCT00712894|Drug|Nitroglycerin|Intracoronary Infusion 200-1000ug
3104|NCT00729690|Drug|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
3105|NCT00729690|Drug|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
3106|NCT00729703|Device|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
3107|NCT00729703|Device|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
3108|NCT00729716|Biological|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
3109|NCT00005962|Drug|liposomal daunorubicin citrate|
3110|NCT00729716|Procedure|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
3420|NCT00732303|Radiation|Radiation Therapy|Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.
The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks.
3421|NCT00732316|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
3422|NCT00732316|Procedure|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
3423|NCT00732329|Behavioral|Occupational Therapy|optimized home Based Occupational Therapy including:
diagnostic assessment
patient-centered definition of targets involving the care giver
occupational therapy
3424|NCT00732342|Behavioral|Contingency Management|Prizes given for targeted behavior of abstinence
3425|NCT00732355|Device|Syph-Check POC|Rapid membrane test for syphilis antibodies
3426|NCT00732368|Drug|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
3427|NCT00732381|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
3428|NCT00005976|Drug|pyrazoloacridine|
2474|NCT00711776|Drug|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
2475|NCT00711776|Drug|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
2476|NCT00711789|Drug|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
2477|NCT00711789|Drug|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
2478|NCT00711802|Drug|Daptomycin|
2479|NCT00711802|Drug|Standard of Care (SOC)|
2480|NCT00005849|Drug|paclitaxel|
2481|NCT00711828|Drug|Bortezomib|Given IV
2482|NCT00711828|Biological|Rituximab|Given IV
2483|NCT00711828|Drug|Cyclophosphamide|Given PO
2484|NCT00711828|Drug|Dexamethasone|Given PO
2485|NCT00711828|Other|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
2486|NCT00711828|Other|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
2487|NCT00711841|Drug|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
2791|NCT00724048|Drug|ACR16 45 mg|ACR16 capsules: 45mg twice daily
2792|NCT00724048|Other|Placebo|Placebo capsules
2793|NCT00724061|Biological|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
2794|NCT00724061|Other|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
3505|NCT00005965|Drug|bryostatin 1|
3506|NCT00730366|Drug|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
3507|NCT00730379|Drug|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
3508|NCT00732537|Drug|inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If >5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If > 5% drop in oxygen saturation or >5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A "Masking Shield" covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
3509|NCT00732537|Drug|Oxygen (>90% by hood) - standard therapy|Oxygen (>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the "Low NO Pressure" alarm. A "Masking Shield" covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
3510|NCT00732550|Procedure|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
3511|NCT00732550|Procedure|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
3512|NCT00732563|Drug|chemotherapy|Given IV and Orally
3513|NCT00005977|Drug|cytarabine|Given IV
3514|NCT00732563|Procedure|lymphadenectomy|Removal of lymph nodes
3515|NCT00732563|Procedure|neoadjuvant therapy|Tumor reduction
3516|NCT00732563|Procedure|quality-of-life assessment|Correlative Study
3517|NCT00732563|Procedure|therapeutic conventional surgery|Treatment for cancer
3518|NCT00732563|Procedure|thoracic surgical procedure|removal of tissue
2552|NCT00713011|Drug|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
2723|NCT00712907|Dietary Supplement|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
2724|NCT00712907|Dietary Supplement|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
2725|NCT00005852|Procedure|allogeneic bone marrow transplantation|
2726|NCT00712907|Other|100% O2 (AGA) two times for 12 min|Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.
Dosage reference: Strenn K 1997
2727|NCT00712920|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
2728|NCT00712920|Drug|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
2729|NCT00712920|Drug|Placebo|Placebo
2730|NCT00712933|Drug|belimumab|Recombinant, fully human, monoclonal antibody
Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.
3036|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
3037|NCT00729690|Drug|Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
3038|NCT00732017|Device|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
3039|NCT00732017|Other|standard physical therapy treatment|Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.
Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.
Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions.
3040|NCT00732030|Device|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
3041|NCT00732043|Dietary Supplement|pomegranate extract|8 oz per day, 48 months
3042|NCT00732043|Dietary Supplement|pomegranate juice|8 oz per day, 48 months
3429|NCT00732381|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
3430|NCT00732394|Other|MSDR|The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.
MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated.
3431|NCT00732407|Drug|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
3432|NCT00732407|Drug|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
3433|NCT00732420|Drug|topotecan|Topoisomerase I inhibition.
3434|NCT00725114|Biological|Tetrodotoxin|30 µg twice daily for 4 days
3435|NCT00725114|Biological|Placebo|2 mL subcutaneous injection twice daily for 4 days
3436|NCT00725127|Drug|aspirin|100 mg/day upon awakening for five years
3437|NCT00725127|Drug|aspirin|100 mg/day at bedtime for five years
3438|NCT00725153|Device|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
2466|NCT00711646|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
2467|NCT00711646|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
2468|NCT00711685|Procedure|coronary artery bypass grafting via midline sternotomy|
2469|NCT00005849|Drug|bryostatin 1|
2470|NCT00711698|Procedure|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
2471|NCT00711698|Drug|NAIBOD|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
2472|NCT00711711|Other|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
2473|NCT00711711|Other|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
2795|NCT00724061|Other|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
2796|NCT00724074|Device|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
2797|NCT00724074|Device|Usual Care|Usual Care
2798|NCT00724087|Other|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
2799|NCT00005941|Drug|mycophenolate mofetil|
2800|NCT00726622|Procedure|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
2801|NCT00726622|Procedure|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
2802|NCT00005947|Biological|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
2803|NCT00726635|Behavioral|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
2804|NCT00726635|Other|Control group|A one hour conversation with a nurse
2805|NCT00726635|Other|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
2806|NCT00726648|Drug|CDP323|50mg capsules, 100mg bid for 4 weeks
2807|NCT00726648|Drug|CDP323|250mg capsules, 500mg bid for 4 weeks
2808|NCT00726648|Drug|CDP323|250mg capsules, 1000mg bid for 4 weeks
3111|NCT00729729|Drug|PCA|Placebo tablet, once
3112|NCT00729729|Drug|PCA|PO, 700mg, once
3113|NCT00729729|Drug|PCA|PO, 1000mg, once
3114|NCT00729742|Drug|Comparator: erlotinib + dalotuzumab|Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.
Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.
Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib.
2553|NCT00005853|Biological|anti-thymocyte globulin|
2554|NCT00713037|Procedure|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
2555|NCT00713050|Behavioral|Imitate Therapy|Imitation-based computer therapy
2556|NCT00713063|Behavioral|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
2557|NCT00713063|Behavioral|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
2558|NCT00713076|Other|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
2559|NCT00713115|Procedure|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
2560|NCT00713154|Drug|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
2561|NCT00713154|Drug|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
2562|NCT00713167|Drug|Grape Seed Extract (Vitagrape)|Drug {Each Containing: Grape Seed Extract100 mg +...}
1 capsule twice daily for 2 months
2563|NCT00713167|Drug|Placebo of Grape Seed Extract|Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}
1 capsule twice daily for 2 months
2564|NCT00005853|Biological|etanercept|
2565|NCT00713180|Procedure|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
2566|NCT00713193|Drug|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
2567|NCT00713193|Drug|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
2568|NCT00713206|Device|Dental Implant (Osseotite)|Root form titanium dental implant
2569|NCT00713219|Radiation|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
2570|NCT00713258|Drug|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
3043|NCT00732043|Dietary Supplement|placebo|8 oz per day, 48 months
3044|NCT00732056|Drug|GRN163L|25% dose escalation infused over 2 hours weekly
3045|NCT00732069|Drug|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
3046|NCT00732069|Drug|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
3047|NCT00732069|Drug|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
3048|NCT00005975|Drug|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
3049|NCT00732082|Drug|Gemcitabine|
3361|NCT00725062|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
3362|NCT00725075|Drug|Org 25935|After screening, eligible subjects will be maintained on a stable dose of
Second Generation Antipsychotic (SGA) and will be randomized to
double-blind add-on treatment, i.e., twice daily (morning and evening) oral
administration of 4-8 mg Org 25935. This phase will last 84 (81-87) days for all subjects.
3363|NCT00725075|Drug|Placebo|Placebo
3364|NCT00725075|Drug|Org 25935|After screening, eligible subjects will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and will be randomized to double-blind add-on treatment, i.e., twice daily (morning and evening) oral administration of 12-16 mg Org 25935. This phase will last 84 (81-87) days for all subjects.
3365|NCT00725088|Behavioral|Exercise training|Exercise training
3366|NCT00725101|Drug|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
3367|NCT00005944|Procedure|laparoscopic surgery|
3368|NCT00727636|Biological|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
3369|NCT00727649|Drug|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
4832|NCT00717730|Dietary Supplement|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
4833|NCT00717756|Drug|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
4834|NCT00717769|Drug|SUN13834|Daily oral doses, low dose, for 28 days of SUN13834
3865|NCT00730886|Procedure|Myomectomy|Invasive surgical procedure for fibroid removal
3866|NCT00730912|Drug|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
3867|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
3868|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
3869|NCT00730925|Drug|BIBW2992|tablet BIBW high dose
3870|NCT00730925|Drug|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
3871|NCT00730938|Drug|cefuroxime|intracameral cefuroxime 0.1 ml
3872|NCT00730938|Drug|Saline placebo|0.1 ml of Ringers lactate
3873|NCT00005970|Drug|Aromatase Inhibition Therapy|Given orally
3874|NCT00730951|Dietary Supplement|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
3875|NCT00730951|Dietary Supplement|Corn Starch|500mg Capsulated Corn Starch
3876|NCT00730964|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.
The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .
The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study.
3877|NCT00730977|Drug|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
3878|NCT00730990|Other|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
3879|NCT00730990|Other|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
3880|NCT00730990|Other|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
3115|NCT00729742|Drug|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
3116|NCT00729755|Dietary Supplement|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
3117|NCT00729755|Dietary Supplement|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
3118|NCT00729768|Drug|basiliximab|2 intravenous doses
3119|NCT00729768|Drug|efalizumab|Subcutaneous repeating dose
3120|NCT00005962|Drug|topotecan hydrochloride|
3121|NCT00729768|Drug|mycophenolate mofetil|Oral repeating dose
3122|NCT00729768|Drug|corticosteroids|Repeating doses
3123|NCT00729768|Drug|cyclosporine|Oral repeating dose
3124|NCT00729781|Device|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
3125|NCT00729794|Drug|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|Combination Treatment
Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR
3126|NCT00732147|Drug|Placebo|120 micrograms given subcutaneously before each meal x 3.
3127|NCT00732160|Drug|Comparison of the effect of aldosterone versus vehicle infusion|36 subjects will receive a calculated diet then a dose of aldosterone or placebo. Blood levels of insulin secretion will be measured.
3128|NCT00005975|Drug|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
3129|NCT00732160|Drug|Comparison of the effect of aldosterone versus vehicle infusion|24 subjects will be given a controlled diet for 9 days then a dose of aldosterone. Blood will be collected and measured for levels of insulin sensitivity.
3130|NCT00732173|Behavioral|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
3131|NCT00732173|Behavioral|exercise intervention|Undergo SUCCEED lifestyle intervention
3439|NCT00725153|Device|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
3440|NCT00725166|Other|Skeletal muscle aging|W1 - Blood test
Maximal voluntary contraction of quadriceps
Hydrostatic weighing
W2 - Maximal metabolic test using a cycloergometer
W3 - Muscular biopsy
3643|NCT00725634|Biological|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
3644|NCT00725634|Biological|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
3645|NCT00725686|Drug|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
3646|NCT00725712|Drug|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
3647|NCT00725725|Behavioral|Cognitive-behavioral therapy|Five weekly sessions of cognitive-behavioral therapy, lasting 60 to 90-min each
3648|NCT00725725|Drug|Org 25935|4 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
2651|NCT00712569|Behavioral|audio recordings , questionnaires|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.
However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not.
2652|NCT00712569|Behavioral|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
2653|NCT00712582|Drug|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
2654|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
2655|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.
Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital.
2656|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
2657|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
3370|NCT00727649|Drug|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
3371|NCT00727662|Other|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
3372|NCT00727662|Other|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
3373|NCT00727675|Behavioral|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
3374|NCT00005952|Biological|filgrastim|
3375|NCT00727701|Behavioral|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
3376|NCT00727727|Drug|Piribedil|
3377|NCT00727740|Drug|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
3378|NCT00727740|Drug|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
2411|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
2412|NCT00005847|Drug|mitoxantrone hydrochloride|
2413|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
2414|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
2415|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
2416|NCT00711308|Drug|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
2417|NCT00711308|Drug|acenocoumarol|acenocoumarol for 6 months
2418|NCT00711347|Device|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
3881|NCT00723502|Drug|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
3882|NCT00723502|Drug|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
3883|NCT00005940|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
3884|NCT00723515|Drug|sodium fluoride|sodium fluoride 5%
4161|NCT00723944|Device|Osseotite Certain Prevail|Root form titanium dental implant
4162|NCT00723944|Device|Osseotite Certain|Dental implant without the lateralized design
4163|NCT00723957|Drug|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m^2
4164|NCT00723957|Drug|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m^2
4165|NCT00723957|Drug|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
4166|NCT00723970|Drug|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
4167|NCT00723983|Drug|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
4168|NCT00723983|Drug|NP101 Study Patch|NP101 study patch 4 hour application
4169|NCT00723996|Behavioral|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
4170|NCT00005941|Drug|cyclosporine|
4171|NCT00724009|Drug|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
4172|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
4173|NCT00719342|Other|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
4174|NCT00005889|Drug|lipids|
4175|NCT00719355|Behavioral|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
3441|NCT00725192|Behavioral|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
3442|NCT00725192|Behavioral|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
3443|NCT00725205|Biological|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms [mcg]/killogram [kg]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
3444|NCT00000697|Drug|Foscarnet sodium|
3445|NCT00005945|Drug|cyclophosphamide|Given IV
3446|NCT00725205|Drug|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
3447|NCT00725218|Drug|Saline|Saline 5 ml injection 10 min prior to propofol administration.
3448|NCT00725218|Drug|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
3449|NCT00725231|Biological|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
3450|NCT00725231|Drug|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
3451|NCT00725244|Device|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
3452|NCT00725244|Device|Argon Plasma Coagulation|Argon plasma coagulation was delivered using a "spray-painting" technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort.
3453|NCT00725257|Other|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
3454|NCT00725257|Other|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
3455|NCT00725270|Drug|Mifepristone|
3456|NCT00727831|Radiation|radiation therapy|
2488|NCT00711841|Drug|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
2658|NCT00005852|Biological|anti-thymocyte globulin|
2659|NCT00712608|Other|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
2660|NCT00712608|Other|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
2661|NCT00712608|Other|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
2662|NCT00712621|Behavioral|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
2663|NCT00712621|Behavioral|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
2664|NCT00712634|Biological|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
2973|NCT00724308|Other|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
2974|NCT00724308|Other|Telephone Care Coordination with state Quitline|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state "Quitline"; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
2975|NCT00005942|Drug|liposomal daunorubicin citrate|Given IV
2976|NCT00724321|Drug|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
2977|NCT00724334|Drug|SAR302503 (TG101348)|orally administered, once a day
2978|NCT00724347|Behavioral|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
2979|NCT00724360|Drug|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
2980|NCT00724373|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
2981|NCT00724373|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
2982|NCT00724386|Drug|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
2419|NCT00711347|Device|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
2420|NCT00711360|Device|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
2421|NCT00711373|Procedure|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
2422|NCT00711386|Drug|GSK706769|GSK706769 or placebo
2423|NCT00000689|Drug|Doxorubicin hydrochloride|
2424|NCT00005847|Drug|paclitaxel|
2425|NCT00711399|Device|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
2426|NCT00711412|Drug|Capecitabine - Induction Therapy|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
2427|NCT00711412|Drug|Oxaliplatin - Induction Therapy|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
2428|NCT00711412|Drug|Capcitabine - Combination Therapy|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
2429|NCT00711412|Drug|Oxaliplatin - Combination Therapy|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
2430|NCT00711412|Radiation|Radiation - Combination Therapy|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
2731|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
2732|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
2733|NCT00712985|Drug|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
2734|NCT00729079|Behavioral|DPP|The primary outcome measure is weight loss with a goal of 7% of initial weight.
Secondary outcomes are adherence to behavior changes:
Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
Fat intake less than 25% and saturated fat less than 10%
Fiber intake of at least 25 grams per day
Fasting blood sugar < 100 mg/dL
Absence of tobacco use
2735|NCT00729118|Drug|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
2736|NCT00729118|Drug|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
4176|NCT00719355|Behavioral|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
4177|NCT00719381|Drug|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
4178|NCT00719394|Drug|GSI 136|
4179|NCT00719394|Drug|placebo|
4180|NCT00719407|Drug|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
4181|NCT00719420|Drug|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
4182|NCT00719420|Drug|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
4462|NCT00717171|Device|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
4463|NCT00717171|Device|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
4464|NCT00717184|Drug|Interleukin, NK cells|
4465|NCT00717197|Drug|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
4466|NCT00717210|Drug|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
4467|NCT00717210|Radiation|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
4468|NCT00719849|Radiation|total body irradiation|200 cGy Day -1
4469|NCT00719862|Drug|Placebo nasal spray|Placebo
4470|NCT00719862|Drug|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
4471|NCT00719875|Drug|Vorinostat|BID days -7, 1-7 and 15-21, 200 mg
4472|NCT00719888|Drug|Cyclophosphamide|Given IV
4473|NCT00719888|Drug|Cyclosporine|Given IV and PO
4474|NCT00719888|Procedure|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
2489|NCT00711841|Drug|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
2490|NCT00711854|Drug|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
2491|NCT00005850|Drug|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
2492|NCT00711854|Drug|Linezolid|Linezolid (600 mg IV or PO twice daily)
2493|NCT00711854|Drug|Rifampicin|Rifampicin (600 mg IV or PO once daily)
2494|NCT00711867|Device|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
2495|NCT00711867|Device|Bair Hugger|Arizant Bair Hugger temperature management system.
2496|NCT00711880|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
2497|NCT00711880|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
2498|NCT00711893|Device|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
2499|NCT00711906|Drug|Cotrimoxazole|Cotrimoxazole
2500|NCT00711906|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
2501|NCT00711919|Drug|Pitavastatin|comparison of different target levels of lipid lowering using Pitavastatin
Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months.
2502|NCT00005850|Drug|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
2503|NCT00711919|Drug|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
2504|NCT00711958|Drug|HX 575 solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
2505|NCT00711958|Drug|ERYPO®, Janssen-Cilag, Germany. Solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
2506|NCT00711971|Drug|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
2507|NCT00711971|Drug|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
2508|NCT00711971|Drug|placebo|control arm
2983|NCT00724386|Drug|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
2984|NCT00724386|Drug|Filgrastim|daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).
For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject
2985|NCT00724386|Radiation|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
2986|NCT00000179|Drug|Trazodone|
2987|NCT00000696|Drug|Zidovudine|
2988|NCT00005942|Drug|semaxanib|Given IV
2989|NCT00724399|Behavioral|Survey on womens health Issues.|Cardiovascular health.
2990|NCT00726934|Other|Neutropenic Diet|The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:
Avoid raw vegetables and fruit (Oranges and bananas are okay.)
Avoid take-out foods and fast foods and fountain drinks.
Avoid aged cheese (blue, Roquefort, Brie).
Cook all produce to well done. Eggs must be hard-boiled.
Avoid deli meats.
No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.
No well water
No yogurt
2991|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Acute DVT
3299|NCT00729937|Other|Placebo|Placebo tablet administered orally.
3300|NCT00729937|Drug|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
3301|NCT00729950|Biological|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
3302|NCT00729963|Drug|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
3303|NCT00729963|Device|CPAP|
3304|NCT00729976|Drug|Ibuprofen suppository|5-10mg/Kg of ibuprofen
3305|NCT00729976|Drug|Ibuprofen Suspension|5-10mg/Kg
3306|NCT00729989|Procedure|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
3307|NCT00730002|Procedure|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
2737|NCT00729131|Drug|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
2738|NCT00729157|Radiation|Fludeoxyglucose F-18|Correlative studies
2739|NCT00729157|Other|Laboratory Biomarker Analysis|Correlative studies
2740|NCT00005960|Drug|docetaxel|
2741|NCT00729157|Other|Pharmacological Study|Correlative studies
2742|NCT00729157|Procedure|Positron Emission Tomography|Correlative studies
2743|NCT00729157|Biological|Ziv-Aflibercept|Given IV
2744|NCT00729170|Dietary Supplement|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
2745|NCT00729183|Drug|Odanacatib|Odanacatib 50 mg tablets once weekly, Vitamin D3 tablets 5600 IU once weekly and Calcium supplements 1200 mg daily. Treatment period of 24 months.
2746|NCT00729183|Drug|Placebo|Placebo tablets once weekly, Vitamin D3 tablets 5600 IU once weekly and Calcium Supplements 1200 mg once daily. Treatment period of 24 months.
2747|NCT00729196|Behavioral|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
2748|NCT00729209|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
2749|NCT00729209|Drug|Placebo; oral|matching placebo
2750|NCT00729222|Drug|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
2751|NCT00005960|Drug|doxorubicin hydrochloride|
2752|NCT00729222|Drug|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
3050|NCT00732082|Biological|LAG-3|
3051|NCT00732095|Behavioral|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
3052|NCT00732108|Drug|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
3053|NCT00732108|Drug|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
3054|NCT00732121|Drug|Sitagliptin|100 mg daily for 4 weeks
3055|NCT00732121|Drug|Placebo|Placebo
4475|NCT00719888|Drug|Fludarabine Phosphate|Given IV
4476|NCT00719888|Other|Laboratory Biomarker Analysis|Correlative studies
4477|NCT00719888|Drug|Mycophenolate Mofetil|Given IV and PO
4478|NCT00005893|Drug|busulfan|
4479|NCT00719888|Radiation|Total-Body Irradiation|Undergo TBI
4480|NCT00719888|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
4481|NCT00719901|Drug|obatoclax mesylate|Given IV
4482|NCT00719901|Drug|bortezomib|Given IV
4483|NCT00719901|Other|laboratory biomarker analysis|Correlative studies
4484|NCT00719914|Drug|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
4485|NCT00719914|Drug|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
4835|NCT00717769|Drug|Placebo|Daily oral doses, placebo, for 28 days of SUN13834
4836|NCT00717782|Procedure|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
4837|NCT00717782|Procedure|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
4838|NCT00717795|Behavioral|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
4839|NCT00005879|Drug|Placebo|matched tablet dialy
4840|NCT00717795|Behavioral|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
4841|NCT00717808|Drug|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
4842|NCT00717808|Drug|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
4843|NCT00717821|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120 micrograms or 200 micrograms iv or sc (starting dose)
4844|NCT00717821|Drug|Epoetin beta or darbepoetin alfa|As prescribed
2509|NCT00711984|Device|Herkulink renal artery Stent|renal artery stent
2809|NCT00726648|Drug|CDP323|250mg capsules, 1000mg daily for 4 weeks
2810|NCT00726648|Drug|Placebo|placebo capsules for 4 weeks
2811|NCT00726687|Drug|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
2812|NCT00726687|Drug|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
2813|NCT00005947|Biological|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
2814|NCT00726700|Biological|pegfilgrastim|Given subcutaneously
2815|NCT00726700|Biological|rituximab|Given IV
2816|NCT00726700|Drug|cyclophosphamide|Given IV
2817|NCT00726700|Drug|doxorubicin hydrochloride|Given IV
2818|NCT00726700|Drug|prednisone|Given orally
2819|NCT00726700|Drug|vincristine sulfate|Given IV
2820|NCT00726713|Other|Metanx (a medical food)|Metanx one tablet twice a day
2821|NCT00726713|Other|Metanx placebo|Metanx placebo one tablet twice a day
2822|NCT00726726|Drug|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
2823|NCT00726726|Drug|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
2824|NCT00005948|Biological|aldesleukin|
2825|NCT00729287|Other|placebo|Given orally
2826|NCT00729300|Drug|placebo|placebo daily
2827|NCT00729300|Drug|disulfiram|250mg daily
2828|NCT00005960|Procedure|pain therapy|
2829|NCT00729313|Drug|Lanreotide microparticles|
2830|NCT00729313|Drug|Placebo|
3308|NCT00005964|Drug|cyclophosphamide|
3309|NCT00730002|Procedure|Magnetic resonance imaging|MR spectroscopy
3310|NCT00730002|Procedure|MRA|MRA of the brain
3311|NCT00730002|Procedure|MRA|
3312|NCT00730002|Procedure|diffusion Imaging|MRA of the Brain
3313|NCT00730002|Procedure|perfusion imaging.|MRA of the brain
3314|NCT00730015|Drug|Matching Placebo|Oral, once daily
3315|NCT00730015|Drug|Linaclotide|Oral, once daily
3316|NCT00730028|Drug|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child > 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child < 40 kg dose). Study drug will be administered for 10 days.
3317|NCT00730028|Other|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
3318|NCT00730028|Drug|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
3319|NCT00005964|Drug|doxorubicin hydrochloride|
3649|NCT00725725|Drug|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
3650|NCT00725725|Drug|Placebo|Placebo is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
3651|NCT00005945|Drug|mercaptopurine|Given PO
3652|NCT00728182|Drug|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
3653|NCT00728182|Drug|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
3654|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
3655|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
3656|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
3056|NCT00732147|Drug|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
3057|NCT00724412|Other|Systane|Dry Eye relief eye drops
3058|NCT00724412|Other|Optive|Dry Eye relief eye drops
3059|NCT00724425|Drug|IPI-493|Capsules, Multiple Schedules
3060|NCT00724451|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
3061|NCT00724451|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
3062|NCT00724451|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
3063|NCT00724464|Biological|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
3064|NCT00724464|Drug|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
3065|NCT00724477|Drug|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
3066|NCT00005942|Other|laboratory biomarker analysis|Correlative studies
3067|NCT00724490|Procedure|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
3068|NCT00724503|Drug|Systemic chemotherapy (FOLFOX)|Oxaliplatin 85 mg/m2, IV infusion, q two weeks
Leucovorin 200 mg/m2, IV infusion, q two weeks
5-Fluorouracil 400 mg/m2, IV bolus, q two weeks
5-Fluorouracil 2.4 g/m2, IV infusion, q two weeks
3069|NCT00724503|Device|SIR-Spheres yttrium-90 microspheres|SIR-Spheres microspheres implanted once on the 3rd or 4th day of the first week of the first chemotherapy cycle
3070|NCT00724503|Drug|Systemic chemotherapy (FOLFOX)|Oxaliplatin 60 mg/m2,IV infusion, q two weeks for first 3 cycles
Oxaliplatin 85 mg/m2, IV infusion, q two weeks from cycle 4 onwards
Leucovorin 200 mg/m2, IV infusion, q two weeks
5-Fluorouracil 400 mg/m2, IV bolus, q two weeks
5-Fluorouracil 2.4 g/m2, IV infusion, q two weeks
3379|NCT00727753|Drug|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
3380|NCT00727753|Drug|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
3381|NCT00727753|Other|No treatment|No treatment
3382|NCT00727766|Drug|Clofarabine|
4845|NCT00717834|Biological|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
4846|NCT00720304|Other|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
4847|NCT00720304|Other|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
4848|NCT00720304|Procedure|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
4849|NCT00720304|Radiation|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
4850|NCT00720304|Radiation|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
4851|NCT00005898|Drug|filgrastim|
3885|NCT00723515|Drug|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
3886|NCT00723528|Drug|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
3887|NCT00723528|Drug|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
3888|NCT00723528|Drug|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
3889|NCT00723528|Drug|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
3890|NCT00723528|Drug|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
3891|NCT00723528|Drug|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
2831|NCT00729326|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
2832|NCT00729326|Drug|sitagliptin|oral administration (100mg), once a day in the morning
2833|NCT00729326|Drug|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
3132|NCT00732173|Other|counseling intervention|Undergo SUCCEED lifestyle intervention
3133|NCT00732173|Other|educational intervention|Receive information
3134|NCT00732173|Other|survey administration|Undergo SUCCEED lifestyle intervention
3135|NCT00732186|Biological|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
3136|NCT00732199|Other|hyperventilation and episodic hypoxia|noninvasive hyperventilation to determine apneic threshold; episodic hypoxia to determine long term facilitation
3137|NCT00732212|Device|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
3138|NCT00732212|Other|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage & visual cues for risk stratification and completion of endoscopic treatment.
3139|NCT00000179|Drug|Haloperidol|
3140|NCT00000703|Drug|Doxorubicin hydrochloride|
3141|NCT00005975|Drug|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
3142|NCT00732225|Device|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
3143|NCT00732225|Device|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
3144|NCT00732225|Device|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
3145|NCT00732225|Device|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
3146|NCT00732225|Device|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
3147|NCT00732238|Other|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
3657|NCT00728195|Drug|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
3658|NCT00728195|Drug|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
3659|NCT00728208|Drug|GSK372475|1.5mg for 28 days
3660|NCT00005957|Radiation|radiation therapy|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
3661|NCT00728221|Dietary Supplement|Korean Red Ginseng|Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: whole root in capsules (3g)
3662|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax ginseng)|Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total ginsenoside fraction in capsules
3663|NCT00728221|Dietary Supplement|Cornstarch|Placebo
3664|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax Ginseng)|Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total polysaccharide fraction (panaxans) in capsules
3665|NCT00728234|Device|aEEG recording|weekly recordings with aEEG
3666|NCT00728247|Procedure|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
3667|NCT00728260|Biological|None administered in this study|N/A in this study
2665|NCT00712647|Drug|Beta Carotene and Retinol|Pilot participants (ppts):
Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol
Vanguard & Efficacy ppts:
Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol
2666|NCT00712647|Other|Placebo|Two placebos, one each/day
2667|NCT00712660|Drug|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
2668|NCT00712660|Other|no intervention|Treatment as usual
2669|NCT00005852|Biological|filgrastim|
2670|NCT00712673|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
2671|NCT00712673|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
2672|NCT00712673|Device|Pen auto-injector|
3383|NCT00727779|Behavioral|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
3384|NCT00727792|Procedure|MRI -Clinical|MRI done is standard of care
3385|NCT00005952|Drug|temozolomide|
3386|NCT00727792|Procedure|MRI-Research|MRI includes extra sequences
3387|NCT00727818|Device|guided bone regeneration|
3388|NCT00727831|Drug|glucarpidase|
3389|NCT00727831|Drug|leucovorin calcium|
3390|NCT00727831|Drug|methotrexate|
3391|NCT00727831|Other|laboratory biomarker analysis|
3392|NCT00727831|Procedure|quality-of-life assessment|
3393|NCT00730041|Device|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
3394|NCT00730041|Device|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
3395|NCT00730054|Drug|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
3396|NCT00730067|Drug|sildenafil|Sildenafil 50 mg three times daily
3397|NCT00730067|Drug|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
3398|NCT00730080|Drug|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
3399|NCT00730093|Dietary Supplement|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
2431|NCT00711425|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
3892|NCT00723528|Drug|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
3893|NCT00723541|Procedure|Computer aided analysis of breast lesions|Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
3894|NCT00005940|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
3895|NCT00723554|Drug|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
3896|NCT00723554|Drug|Iloprost PD-15|Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.
Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
3897|NCT00723580|Drug|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
3898|NCT00723606|Drug|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
3899|NCT00726102|Other|Meat|2 0z of locally available meat per day
3900|NCT00726102|Other|Cereal|Daily provision of cereal to infants from 6-18 mos
3901|NCT00726102|Other|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
4183|NCT00719433|Device|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
4184|NCT00719433|Other|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
4185|NCT00005889|Drug|urea|
4186|NCT00719459|Drug|Iron Sucrose|Venofer 20 mg/mL
4187|NCT00719459|Drug|Iron Sucrose|Iron sucrose 20 mg/mL
4188|NCT00719472|Drug|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
3148|NCT00732238|Other|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
3149|NCT00724594|Drug|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
3150|NCT00724594|Drug|Control|Saline was given in the same volume, at the same timing as NAC infusions
3457|NCT00727844|Drug|Immediate Start Linezolid|
3458|NCT00727844|Drug|Delayed Start Linezolid|
3459|NCT00000699|Drug|Ribavirin|
3460|NCT00005952|Procedure|peripheral blood stem cell transplantation|
3461|NCT00727857|Drug|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
3462|NCT00727857|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
3463|NCT00727857|Drug|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
3464|NCT00727870|Device|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
3465|NCT00727870|Device|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
3466|NCT00727870|Device|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
3467|NCT00727896|Behavioral|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
3468|NCT00727896|Drug|Diabetes Treatment|Life style modification and drug therapy
3469|NCT00727909|Device|Hearing Aid Treatments|Hearing aid treatments:
Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)
3470|NCT00727922|Drug|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
3471|NCT00005954|Drug|temozolomide|
3472|NCT00727935|Drug|Lidocaïne|
3473|NCT00727935|Drug|Ropivacaïne|
2673|NCT00712673|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
2674|NCT00712686|Drug|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
2675|NCT00712686|Drug|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
2676|NCT00712699|Drug|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
2677|NCT00712699|Drug|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
2678|NCT00712712|Drug|acetaminophen|
2679|NCT00712712|Drug|morphine sulfate|
2680|NCT00005852|Biological|muromonab-CD3|
2681|NCT00712712|Other|questionnaire administration|
2682|NCT00712712|Procedure|quality-of-life assessment|
2683|NCT00712712|Procedure|radiofrequency ablation|
2684|NCT00712725|Drug|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
2685|NCT00712725|Drug|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
2686|NCT00712725|Drug|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
2687|NCT00712725|Drug|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
2992|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Chronic DVT
2993|NCT00726960|Drug|aprepitant|Oral, 125 mg once daily for one week
2994|NCT00726960|Drug|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
2995|NCT00726973|Drug|Ranibizumab|Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness >100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
2432|NCT00711438|Behavioral|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
2433|NCT00711438|Behavioral|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
2434|NCT00711451|Behavioral|Manual removal|Manual removal of placenta during cesarean delivery
2435|NCT00005847|Drug|vinorelbine ditartrate|
2436|NCT00711451|Procedure|Expressed removal|Surgeon will perform an expressed delivery of the placenta
2437|NCT00711464|Drug|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
2438|NCT00711477|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
2439|NCT00711477|Drug|Placebo|
2440|NCT00711477|Other|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
2441|NCT00711490|Drug|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
2442|NCT00711503|Drug|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
2443|NCT00711503|Drug|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
2444|NCT00711516|Drug|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
2445|NCT00711516|Drug|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
2446|NCT00005848|Drug|chemotherapy|
2447|NCT00711529|Behavioral|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
2753|NCT00729235|Device|Ovatio CRT 6750|Slow VT zone programmed as a "Monitoring" zone (Monitoring arm)
4189|NCT00719472|Drug|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
4190|NCT00719472|Drug|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
4191|NCT00719472|Drug|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
4192|NCT00719485|Other|Educational program|Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
4193|NCT00719498|Drug|Epo-alpha|
4194|NCT00719511|Drug|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
4195|NCT00719511|Drug|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
4196|NCT00721539|Device|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
4197|NCT00721539|Procedure|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
4198|NCT00721552|Drug|Sitagliptin 100 mg|28 days administration of 100 mg daily
4199|NCT00721552|Drug|Prednisolone 30 mg|14 days administration of 30 mg daily
4200|NCT00721552|Drug|Sitagliptin-placebo|28 days administration once daily
4201|NCT00721552|Drug|Prednisolone-placebo|14 days administration once daily
4486|NCT00719914|Drug|normal saline|Intra-coronary injection, weight based, of normal saline.
4487|NCT00719927|Behavioral|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
4488|NCT00719940|Behavioral|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
4489|NCT00005893|Drug|cyclophosphamide|
4490|NCT00719940|Other|Waiting group|No intervention
3474|NCT00727935|Drug|Placebo|
3475|NCT00727948|Drug|Aspirin|325 mg tablets, once daily for 45 days
3476|NCT00727961|Drug|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
3477|NCT00727987|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
3478|NCT00727987|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
2510|NCT00711984|Other|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
2511|NCT00711997|Biological|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
2512|NCT00712010|Other|Whey protein native|Whey protein native against the 6 other arms
2513|NCT00005850|Drug|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
2514|NCT00712010|Other|Whey protein microgels|Whey protein microgels versus the six other arms
2515|NCT00712010|Other|Hydrolyzed whey protein|versus the six other arms
2516|NCT00712010|Other|Casein native|versus the six other arms
2517|NCT00712010|Other|Hydrolyzed casein|versus the six other arms
2518|NCT00712010|Other|Total milk protein native|versus the six other arms
2519|NCT00712010|Other|Hydrolyzed milk protein|versus the six other arms
2520|NCT00712023|Device|warming device (a reusable, custom-made forced- air warming mattress)|2=forced-air warming mattress
1=circulating-water mattress
2521|NCT00712036|Behavioral|Interim|Methadone maintenance with emergency counseling only for up to 4 months
2522|NCT00712036|Behavioral|Comprehensive|Methadone treatment with counseling as usual
2523|NCT00712036|Behavioral|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
2524|NCT00005851|Drug|fludarabine phosphate|Given IV
2525|NCT00712049|Drug|simvastatin|simvastatin 40 mg
2996|NCT00726973|Drug|Ranibizumab monotherapy|3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
2997|NCT00726986|Drug|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
2998|NCT00726986|Drug|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
2999|NCT00726986|Drug|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
3000|NCT00000699|Drug|Inosine pranobex|
3001|NCT00005948|Drug|busulfan|
3002|NCT00726999|Drug|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
3003|NCT00726999|Drug|Placebo|
3004|NCT00726999|Drug|Morphine|Administered as needed
3005|NCT00727012|Device|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
3006|NCT00727025|Device|wound closure device (Steri-Strip™)|wound closure with steri-strip S
3007|NCT00727038|Drug|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
3008|NCT00727064|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
3009|NCT00727064|Drug|Venlafaxine Extended Release (VEN ER)|
3010|NCT00727077|Biological|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
3011|NCT00727077|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
3012|NCT00005948|Procedure|peripheral blood stem cell transplantation|
3320|NCT00732615|Drug|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
3321|NCT00732628|Device|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
3322|NCT00732641|Drug|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
2754|NCT00729235|Device|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
2755|NCT00729261|Procedure|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
2756|NCT00729261|Procedure|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
2757|NCT00729274|Drug|normal saline solution|Two 4ml nebulizations with 30 minute interval
2758|NCT00729287|Dietary Supplement|selenium|Given orally
2759|NCT00731523|Drug|fingolimod (FTY720)|
2760|NCT00731536|Other|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
2761|NCT00731549|Drug|Aripiprazole IM Depot|300mg or 400mg
2762|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
2763|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
2764|NCT00731575|Drug|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
2765|NCT00731588|Biological|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns ~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
2766|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
2767|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
2768|NCT00731601|Drug|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
2769|NCT00005972|Drug|gemcitabine hydrochloride|
2770|NCT00731601|Drug|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
4491|NCT00719953|Dietary Supplement|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
4492|NCT00719966|Drug|anastrozole|Patients receive aromatase inhibition therapy.
4493|NCT00719966|Drug|exemestane|Patients receive aromatase inhibition therapy.
4494|NCT00719966|Drug|letrozole|Patients receive aromatase inhibition therapy.
4495|NCT00719966|Procedure|assessment of therapy complications|Endothelial function is measured
4496|NCT00722072|Drug|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
4497|NCT00722072|Drug|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
4498|NCT00722098|Biological|DC Vaccine & Cyclophosphamide|Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.
Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7.
4499|NCT00005922|Drug|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
4500|NCT00722098|Biological|DC Vaccine & Placebo|Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.
Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7.
4501|NCT00722111|Device|lingual press|lingual press (high-intensity, oral, non-swallowing)
4852|NCT00720330|Drug|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
4853|NCT00720330|Drug|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
4854|NCT00720330|Other|placebo|placebo
4855|NCT00720343|Drug|Choline|Oral Choline 20 grams before surgery
2526|NCT00710853|Other|Hatha yoga|One hour weekly class for 8 week duration
2527|NCT00710866|Biological|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
2528|NCT00710879|Device|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
2529|NCT00005845|Other|pharmacological study|Correlative studies
2530|NCT00710892|Biological|Allodepleted T Cells|Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.
Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity.
2834|NCT00729326|Drug|placebo|oral administration (100mg), once a day in the morning
2835|NCT00729339|Drug|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
2836|NCT00729339|Drug|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
2837|NCT00729365|Drug|Ramipril|ACE inhibitor known as Ramipril
Subjects with nighttime blood pressure that does not drop during the night ("non-dippers") maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the "Non-Dippers" groups II and III will be randomized to receive either drug or placebo.
2838|NCT00729365|Drug|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
2839|NCT00000701|Drug|Zidovudine|
2840|NCT00005961|Drug|O6-benzylguanine|
2841|NCT00729365|Drug|Placebo|Subjects with nighttime blood pressure that does not drop during the night ("non-dippers") maybe randomized into the control group and given Placebo.
2842|NCT00729378|Other|skeletal loading|impact activities, 3 times per week, increasing (up to 40) of jumps and height (from 6 inches to 18 inches per repetition) over the initial 2 months. New activities will be introduced approximately every 2-3 months and continually stress the skeleton over 2 years.
2843|NCT00729391|Behavioral|Woman-Focused Intervention (Women's CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
2844|NCT00729391|Behavioral|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
2845|NCT00729391|Behavioral|VCT Only|Participants in this group will receive VCT only.
3323|NCT00732654|Drug|Milk Protein Extract Immunotherapy|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
3324|NCT00005977|Drug|doxorubicin hydrochloride|Given IV
3325|NCT00732654|Drug|Milk Protein Extract Immunotherapy|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
3326|NCT00732654|Drug|Milk Powder Immunotherapy|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
3327|NCT00732654|Drug|Milk Powder Immunotherapy|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
3328|NCT00732680|Drug|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
3329|NCT00732693|Drug|Ethinylestradiol / Norethisterone|Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 "pill free" days
3330|NCT00732693|Drug|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
3331|NCT00732706|Procedure|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
3332|NCT00732706|Procedure|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
3333|NCT00732719|Device|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
3334|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3335|NCT00005977|Drug|etoposide|Given IV
3336|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3337|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3338|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3339|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3340|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
2365|NCT00710580|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
2366|NCT00710593|Biological|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
2771|NCT00731614|Behavioral|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
3071|NCT00724516|Device|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
3072|NCT00724529|Biological|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
3073|NCT00724542|Drug|Voglibose tablets|0.2mg Tid
3074|NCT00724568|Drug|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
3075|NCT00724568|Drug|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
3076|NCT00724568|Drug|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
3077|NCT00005943|Biological|aldesleukin|
3078|NCT00724568|Drug|Doxil|Patients will be treated with Doxil on day 4.
3079|NCT00724581|Drug|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
3080|NCT00727090|Drug|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
3081|NCT00727103|Drug|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
3082|NCT00727103|Drug|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
3083|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
3084|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
3085|NCT00727129|Drug|Divigel|
4856|NCT00720343|Drug|Placebo|Gelatin Capsule
4857|NCT00720356|Drug|bevacizumab|10mg/kg administered intravenously every 2 weeks
4858|NCT00720356|Drug|erlotinib hydrochloride|150 mg/daily orally
4859|NCT00720369|Drug|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
4860|NCT00720382|Drug|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
4861|NCT00720382|Drug|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
4862|NCT00005898|Drug|fludarabine|
4863|NCT00720408|Drug|Prograf-XL|oral
4864|NCT00720408|Drug|Prograf|oral
4865|NCT00720408|Drug|MMF|oral
4866|NCT00720421|Drug|AZD7325|AZD7325 10 mg oral 2 capsules
4867|NCT00720421|Drug|AZD7325|AZD7325 1 mg oral 2 capsules
4868|NCT00720421|Drug|AZD7325|AZD7325 Placebo oral 2 capsules
4869|NCT00720421|Drug|Lorazepam|Lorazepam 1 mg oral 2 tablets
4870|NCT00720421|Drug|Lorazepam|Lorazepam Placebo oral 2 tablets
4871|NCT00722917|Drug|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
4872|NCT00722930|Drug|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
4873|NCT00722943|Other|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
4874|NCT00722943|Other|no intervention|The infant will not be touched by the therapist.
4875|NCT00722956|Drug|AZD5672|100 mg once daily, 10 days
4876|NCT00722956|Drug|atorvastatin|one single dose of 40 mg on day 10
3902|NCT00726115|Drug|SAM-531|
3903|NCT00726115|Drug|placebo|
3904|NCT00726128|Device|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF
2846|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
2847|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
2848|NCT00729430|Drug|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
2849|NCT00729430|Drug|Placebo|Placebo tablets taken orally once per day for 6 months
2850|NCT00005972|Drug|irinotecan hydrochloride|
2851|NCT00731679|Drug|Placebo|
2852|NCT00731692|Drug|FTY720|
2853|NCT00731692|Drug|Placebo|Capsules
3151|NCT00724620|Biological|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
3152|NCT00724620|Drug|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
3153|NCT00724633|Other|Lowering the dialysate sodium|Please see above
3154|NCT00724646|Other|Survey|3 individual surveys
3155|NCT00724646|Other|Focus group|Focus group discussions facilitated by a psychologist
3156|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
3157|NCT00005943|Biological|staphylococcal enterotoxin B|
3158|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
3159|NCT00724672|Drug|etanercept|etanercept 50 mg subcutaneously once weekly
3160|NCT00724672|Drug|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
3161|NCT00724672|Drug|adalimumab|adalimumab 40 mg subcutaneously biweekly
3162|NCT00724685|Drug|Naropeine (Ropivacaine)|
2367|NCT00710606|Drug|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
2368|NCT00710606|Drug|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
2369|NCT00710619|Drug|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
2370|NCT00710619|Drug|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
2371|NCT00710632|Other|laboratory biomarker analysis|
2372|NCT00710632|Other|physiologic testing|
2373|NCT00710632|Other|questionnaire administration|
2374|NCT00005844|Drug|oxaliplatin|
2375|NCT00710632|Procedure|management of therapy complications|
2376|NCT00710645|Device|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
2377|NCT00710658|Behavioral|WebChoice|Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
Patients in the control group received usual care
2378|NCT00710684|Drug|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
2379|NCT00005847|Biological|recombinant interferon alfa|
2380|NCT00711100|Other|General Snus|
2381|NCT00711113|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
2382|NCT00711126|Drug|GW642444|2.5mcg IV
2383|NCT00711126|Drug|GW642444|5mcg IV
2384|NCT00711126|Drug|GW642444|10mcg IV
2385|NCT00711126|Drug|GW642444|100mcg inhaled
2386|NCT00711126|Drug|GW642444|20mcg IV
3086|NCT00727142|Procedure|Surgical treatment|Insertion of a functioning shunt
3087|NCT00727155|Behavioral|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
3088|NCT00727181|Device|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
3400|NCT00730119|Device|Measuring vital signs using the GE Monitor|Measuring vital signs (NIBP, SpO2, Temperature, Respiration, and ECG)
3401|NCT00730132|Drug|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
3402|NCT00730132|Drug|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
3403|NCT00005964|Drug|etoposide|
3404|NCT00730145|Drug|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
3405|NCT00730158|Drug|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, beginning at a dose of 1,800 mg twice a day, and escalating to 2,400 mg twice a day in dose level 2-4.
3406|NCT00730158|Drug|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, beginning at a dose of 180 mg/m², and escalating to 215 mg/m²in dose level 3 and 250 mg/m² in dose level 4.
3407|NCT00730158|Drug|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
3408|NCT00730171|Drug|Linaclotide|Oral, once daily
3409|NCT00730184|Dietary Supplement|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
3410|NCT00730184|Dietary Supplement|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
3411|NCT00730197|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
3412|NCT00730197|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
3413|NCT00730210|Drug|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
3414|NCT00732251|Drug|Allopurinol|Allopurinol: 300-600 mg/day over a 4 week period
3415|NCT00732277|Drug|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
3905|NCT00726141|Behavioral|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
3906|NCT00726154|Behavioral|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
3907|NCT00000698|Drug|Ganciclovir|
3908|NCT00005945|Radiation|radiation therapy|Undergo radiation therapy
3909|NCT00726154|Behavioral|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
3910|NCT00726167|Device|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
3911|NCT00726180|Drug|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
3912|NCT00726193|Device|OsteoGen|OsteoGen Implatable stimulator
3913|NCT00726206|Other|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
3914|NCT00726219|Other|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
3915|NCT00726232|Drug|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
3916|NCT00726245|Biological|PRGF|3-6mg IM (to area of muscle tear)
3917|NCT00726245|Biological|Placebo|3cc IM of physiological saline
3918|NCT00726258|Drug|ketamine|ketamine with various concentrations
3919|NCT00005946|Biological|filgrastim|
3163|NCT00724685|Drug|Placebo|saline
3164|NCT00724698|Drug|Desloratadine|Desloratadine 5 mg once daily
3165|NCT00724711|Drug|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
3166|NCT00724711|Drug|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
3167|NCT00724724|Drug|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
3168|NCT00005944|Drug|chemotherapy|
3169|NCT00724724|Drug|Aspirin|Aspirin 100mg Qd for 1 year
3170|NCT00724737|Procedure|Presurgical MRI|MRI of the Brain
3171|NCT00724750|Device|Gauze suction (G-SUC)|Negative pressure wound therapy
3172|NCT00724750|Device|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
3173|NCT00724763|Device|acupuncture|to Liv 3 and PE 9.
3479|NCT00727987|Drug|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
3480|NCT00728000|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
3481|NCT00728000|Drug|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
3482|NCT00005955|Drug|temozolomide|
3483|NCT00005964|Drug|prednisone|
3484|NCT00730210|Drug|b:placebo|100 microgram placebo subcutaneous a day for 6 months
3485|NCT00730223|Drug|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
3486|NCT00730236|Drug|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
3487|NCT00730249|Drug|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
3488|NCT00730249|Drug|Placebo|twice daily according to an individual titration schedule
3489|NCT00730262|Drug|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
2688|NCT00712725|Drug|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
2689|NCT00712725|Drug|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
2690|NCT00712725|Drug|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
2691|NCT00000689|Drug|Methotrexate|
2692|NCT00005852|Drug|cyclophosphamide|
2693|NCT00712738|Drug|Nifedipine|
2694|NCT00712738|Procedure|Phlebotomy|
2695|NCT00712738|Procedure|Urinalysis|
2696|NCT00712738|Procedure|Echocardiogram|
2697|NCT00712738|Procedure|Electrocardiogram|
2698|NCT00712751|Behavioral|questionnaires|Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, "usual care" will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline.
2699|NCT00712751|Behavioral|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
2700|NCT00712764|Drug|Adenosine|
2701|NCT00712764|Drug|Placebo|
2702|NCT00712777|Drug|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
2703|NCT00005852|Drug|cyclosporine|
2704|NCT00712790|Drug|Sorafenib|Tablet, 400mg orally, twice daily
2705|NCT00712790|Radiation|SIR-Spheres|one time treatment and capped at 3.0 Gbq
2706|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^3 dose of rDEN3-3'D4delta30 vaccine.
2707|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^5 dose of rDEN3-3'D4delta30 vaccine.
3416|NCT00732290|Drug|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
3417|NCT00005976|Drug|carboplatin|
3418|NCT00732290|Drug|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
3419|NCT00732303|Drug|Pemetrexed|Pemetrexed (Alimta) 500mg/m2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
2448|NCT00711529|Drug|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
2449|NCT00711542|Biological|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
2450|NCT00711542|Biological|placebo medium|intracoronary infusion of placebo medium
2451|NCT00712049|Drug|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
2452|NCT00711555|Drug|aprepitant, ondansetron, dexamethasone|On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.
FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.
FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting.
2453|NCT00711568|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
2454|NCT00711568|Procedure|Sham rTMS|20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
2455|NCT00711568|Device|Repetitive Transcranial Magnetic Stimulator|Repetitive Transcranial Magnetic Stimulator
2456|NCT00711581|Device|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
2457|NCT00711594|Drug|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
2458|NCT00005848|Drug|tipifarnib|
2459|NCT00711594|Drug|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
2460|NCT00711594|Drug|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
4202|NCT00721565|Behavioral|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
4203|NCT00721578|Drug|voriconazole|Patients must have received (in the Intensive Care Unit [ICU] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
4204|NCT00721604|Drug|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
4205|NCT00721617|Other|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
4206|NCT00005918|Drug|Efavirenz|
4207|NCT00721617|Other|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
4208|NCT00721617|Other|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
4209|NCT00721630|Drug|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
4210|NCT00721643|Dietary Supplement|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
4211|NCT00721643|Dietary Supplement|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
4212|NCT00721656|Drug|Placebo|
4213|NCT00721656|Drug|KLS-0611|
4214|NCT00721669|Drug|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
4215|NCT00721695|Drug|OMS302|OMS302 Irrigation Solution
4216|NCT00721695|Drug|OMS302-PE|OMS302-PE HCI Irrigation Solution
4217|NCT00005918|Drug|Lamivudine|
4218|NCT00714181|Drug|hydroxychloroquine|
4219|NCT00714181|Drug|temozolomide|
3490|NCT00730275|Drug|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
3491|NCT00730275|Drug|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
3492|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
3493|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
3494|NCT00005964|Drug|vincristine sulfate|
3495|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
3496|NCT00730301|Procedure|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
3497|NCT00730314|Procedure|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
3498|NCT00730327|Device|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
3499|NCT00730327|Other|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
3500|NCT00730340|Procedure|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
2531|NCT00710905|Device|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
2532|NCT00710931|Device|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
2533|NCT00710944|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
2534|NCT00710970|Drug|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
2535|NCT00710983|Biological|Oral polio vaccine|
2536|NCT00711009|Drug|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
2537|NCT00711009|Drug|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
2538|NCT00711009|Drug|raltegravir (RAL)|RAL 400 mg BID
2708|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^1 dose of rDEN3-3'D4delta30 vaccine.
2709|NCT00712816|Device|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
3013|NCT00729586|Other|Laboratory Biomarker Analysis|Correlative studies
3014|NCT00729586|Drug|Megestrol Acetate|Given PO
3015|NCT00729586|Drug|Tamoxifen Citrate|Given PO
3016|NCT00729586|Drug|Temsirolimus|Given IV
3017|NCT00729599|Drug|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
3018|NCT00729612|Drug|carboplatin|
3019|NCT00729612|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
3020|NCT00729612|Genetic|protein expression analysis|
3021|NCT00005962|Drug|cytarabine|
3022|NCT00729612|Other|immunoenzyme technique|
3023|NCT00729612|Other|immunohistochemistry staining method|
3024|NCT00729612|Other|laboratory biomarker analysis|
3025|NCT00729625|Device|robotic device|The device has a small "air muscle" that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand.
3026|NCT00729638|Drug|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
3027|NCT00729638|Drug|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
3028|NCT00729651|Drug|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
3029|NCT00729651|Drug|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
3030|NCT00729651|Dietary Supplement|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
3031|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
2461|NCT00711594|Drug|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
2462|NCT00711607|Drug|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
2463|NCT00711620|Drug|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
2464|NCT00711633|Dietary Supplement|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
2465|NCT00711633|Dietary Supplement|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
2772|NCT00731614|Behavioral|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
2773|NCT00731614|Behavioral|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
2774|NCT00731627|Drug|placebo|one tablet a day for up to 21 days
2775|NCT00731627|Drug|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
2776|NCT00731640|Device|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
2777|NCT00731653|Drug|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
2778|NCT00731666|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
2779|NCT00731679|Drug|Rifaximin|
2780|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
2781|NCT00724022|Drug|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
2782|NCT00724035|Drug|Midazolam|Procedural sedation before the execution of the block.
0.03 mg/kg iv bolus
2783|NCT00724035|Drug|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
2784|NCT00724035|Drug|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
2785|NCT00724035|Procedure|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
4220|NCT00714181|Genetic|TdT-mediated dUTP nick end labeling assay|
4221|NCT00714181|Genetic|western blotting|
4222|NCT00714181|Other|electron microscopy|
4502|NCT00722111|Behavioral|effortful swallowing|effortful swallowing (high-intensity swallowing)
4503|NCT00722111|Behavioral|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
4504|NCT00722111|Behavioral|non-oral sham (control) exercise|non-oral sham (control) exercise
4505|NCT00722124|Drug|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
4506|NCT00722124|Drug|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
4507|NCT00722124|Other|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
4508|NCT00722137|Drug|Rituximab 375 mg/m^2|Intravenous rituximab 375 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles.
4509|NCT00722137|Drug|Cyclophosphamide 750 mg/m^2|Intravenous cyclophosphamide 750 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles
4510|NCT00005922|Other|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
4511|NCT00722137|Drug|Doxorubicin 50 mg/m^2|Intravenous doxorubicin 50 mg/m^2 on Day 1of a 21 day (3 week) cycle for 6 cycles
4512|NCT00722137|Drug|VELCADE 1.3 mg/m^2|Intravenous VELCADE 1.3 mg/m^2 on Days 1,4,8, and 11of a 21 day (3 week) cycle for 6 cycles
4513|NCT00722137|Drug|Prednisone 100 mg/m^2|Oral prednisone 100 mg/m^2 on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
4514|NCT00722137|Drug|Vincristine 1.4 mg/m^2|Intravenous vincristine 1.4 mg/m^2 on Day 1of a 21 day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
4515|NCT00722150|Drug|Artesunate|2 mg/kg/day x 7 days
4516|NCT00714558|Drug|Fentanyl citrate; Naltrexone; Naloxone|
4517|NCT00714571|Behavioral|explicit memory training|Participants receive training in various cognitive rehabilitation techniques designed to facilitate learning and memory.
4518|NCT00005862|Drug|semaxanib|
4519|NCT00714571|Behavioral|implicit memory training|Participants receive training in various cognitive rehabilitation techniques designed to facilitate learning and memory.
2539|NCT00711022|Device|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
2540|NCT00005846|Drug|tipifarnib|
2541|NCT00711035|Biological|Trivirus Specific CTLs|Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
2542|NCT00711048|Drug|AZD1386|oral, single dose
2543|NCT00711048|Drug|Placebo|Oral solution, single dose
2544|NCT00711074|Drug|AZD5672|single dose 200mg aqueous solution
2545|NCT00711087|Drug|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
2546|NCT00711087|Other|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
2547|NCT00711100|Other|Camel Snus|Subjects will sample each product for 1/2 day and choose one product to use for smoking cessation.
2548|NCT00711100|Other|Marlboro Snus|
2549|NCT00711100|Other|Stonewall|
2550|NCT00711100|Other|Ariva|
2551|NCT00713011|Drug|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
2854|NCT00731705|Procedure|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
2855|NCT00731718|Device|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
2856|NCT00731731|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
2857|NCT00731731|Drug|temozolomide|Given PO
2858|NCT00731731|Drug|vorinostat|Given PO
2859|NCT00731731|Procedure|cognitive assessment|Ancillary studies
2860|NCT00731731|Other|laboratory biomarker analysis|Correlative studies
2861|NCT00005973|Drug|BMS-214662|Given IV
3032|NCT00005962|Drug|gemtuzumab ozogamicin|
3033|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
3034|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
3035|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
3341|NCT00732732|Dietary Supplement|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
3342|NCT00732732|Other|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
3343|NCT00732745|Drug|docetaxel|Given IV
3344|NCT00732745|Drug|oxaliplatin|Given IV
3345|NCT00005944|Drug|mitomycin C|
3346|NCT00724958|Biological|Infliximab|Not specified in the protocol.
3347|NCT00724971|Drug|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
3348|NCT00724971|Drug|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
3349|NCT00724984|Drug|PCI-24781|Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart ("BID"), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).
Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I.
3350|NCT00724997|Biological|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
3351|NCT00725010|Drug|Temozolomide|Temozolomide will be administered orally at 75 mg/m^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m^2 to 200 mg/m^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
3352|NCT00725010|Radiation|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
3353|NCT00725023|Device|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
3354|NCT00725023|Device|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
2786|NCT00724035|Procedure|Axillary brachial plexus nerve block|Blocks will be performed under high-resolution real-time ultrasound guidance.
Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.
A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose.
2787|NCT00724035|Procedure|Infraclavicular brachial plexus block|Blocks will be performed under high-resolution real-time ultrasound guidance.
Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.
The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks.
2788|NCT00005941|Drug|fludarabine phosphate|
2789|NCT00724048|Drug|ACR16 10 mg|ACR16 capsules: 10mg twice daily
2790|NCT00724048|Drug|ACR16 22.5 mg|ACR16 capsules: 22.5mg twice daily
3089|NCT00727194|Drug|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 my IV every two weeks for 7 doses
3090|NCT00005949|Biological|aldesleukin|Given SC
3091|NCT00727194|Drug|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
3092|NCT00727207|Drug|everolimus|
3093|NCT00727233|Drug|Nexavar (BAY 43-9006) (Sorafenib)|
3094|NCT00727233|Drug|Toxicity, Pharmacokinetics|
3095|NCT00727233|Drug|Pharmacodynamics|
3096|NCT00727233|Drug|Radiographic Evaluation|
3097|NCT00727233|Drug|QOL assessment, Neuropsychological|
3098|NCT00727233|Drug|Bony Toxicity|
3099|NCT00727246|Drug|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
3100|NCT00727246|Drug|Placebo|Treatment with placebo for 6 weeks
3101|NCT00005949|Biological|gp100:209-217(210M) peptide vaccine|Given SC
3102|NCT00727259|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
3103|NCT00727259|Drug|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
4520|NCT00714584|Drug|Naltrexone HCl.|
4521|NCT00714597|Drug|Semuloparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
4522|NCT00714597|Drug|Enoxaparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
4877|NCT00722969|Drug|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
4878|NCT00722995|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
4879|NCT00000695|Drug|Zidovudine|
4880|NCT00005937|Drug|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
4881|NCT00722995|Procedure|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
4882|NCT00723008|Device|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
4883|NCT00723021|Drug|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
4884|NCT00723021|Drug|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
4885|NCT00723021|Drug|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
4886|NCT00723021|Drug|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
4887|NCT00723021|Drug|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
4888|NCT00723047|Procedure|Fibrin glue injection in fistula|
4889|NCT00723060|Drug|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
4890|NCT00723086|Drug|docetaxel (XRP6976)|combined treatment with prednisolone
4891|NCT00005938|Drug|exatecan mesylate|
4892|NCT00723099|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
4893|NCT00723099|Drug|Cyclophosphamide|Given IV
4894|NCT00723099|Drug|Cyclosporine|Given IV
4895|NCT00723099|Drug|Fludarabine Phosphate|Given IV
2862|NCT00731744|Procedure|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
2863|NCT00731757|Drug|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
2864|NCT00731770|Drug|fluticasone/salmeterol 250/50|250/50 1 puff bid
2865|NCT00731770|Drug|placebo|placebo diskus 1 puff bid
2866|NCT00731783|Drug|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
2867|NCT00731783|Drug|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
2868|NCT00731783|Behavioral|Hygiene protocol|Follow key hygiene tips indefinitely. Tips are:
Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.
Use liquid(pour or pump) soaps instead of bar soaps.
Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.
Do not share personal care items such as razors and brushes.
Wash all sheets and towels in hot water. Wash sheets every week.
Use towels and wash cloths only once before washing and do not share.
2869|NCT00731796|Device|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
2870|NCT00731809|Radiation|FDG PET CT|FDG PET CT
2871|NCT00731822|Drug|GW685698/GW642444|GW685698/GW642444
2872|NCT00005973|Other|laboratory biomarker analysis|Correlative studies
2873|NCT00731835|Procedure|Endovascular Revascularization|angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or
stent placement
atherectomy
2874|NCT00731848|Dietary Supplement|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
3174|NCT00724763|Device|sham needle treatment|needle not in meridian area
3175|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
3176|NCT00727272|Drug|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
3177|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
3178|NCT00727298|Biological|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
3355|NCT00725036|Drug|inhaled human insulin|
3356|NCT00005944|Procedure|conventional surgery|
3357|NCT00725036|Drug|insulin aspart|
3358|NCT00725036|Drug|insulin NPH|
3359|NCT00725049|Device|Dental Implant (Nanotite)|Root form titanium dental implant
3360|NCT00725062|Biological|CD4+CD25+ regulatory T cells|Cohort 1 will receive 3 x 10^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10^7 CD4+CD25 cells/kg
2387|NCT00711126|Drug|GW642444|500mcg oral
2388|NCT00711152|Other|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
2389|NCT00711152|Other|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
2390|NCT00005847|Drug|estramustine phosphate sodium|
2391|NCT00711165|Drug|Placebo|2 puffs, qd
2392|NCT00711165|Drug|Mometasone Furoate|400 mcg, qd for 8 weeks
2393|NCT00711178|Procedure|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
2394|NCT00711191|Biological|monoclonal antibody|CP-870,893 intravenous administration [IV] on day 3 of 4-week cycles
2395|NCT00711191|Drug|chemotherapy|gemcitabine 1000 mg/m^2 intravenous administration [IV] q week [wk]x3 of 4-week cycles
2396|NCT00711204|Drug|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
2397|NCT00711217|Other|Medical Food|twice daily
2398|NCT00711217|Other|Drink mix calorically similar to experimental product|twice daily
2399|NCT00711230|Biological|DermaVir|
2400|NCT00711230|Biological|Placebo|glucose/dextrose
2401|NCT00005847|Drug|isotretinoin|
2402|NCT00711243|Drug|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
4741|NCT00717587|Other|immunohistochemistry staining method|
4742|NCT00717587|Other|iodine I-124 girentuximab|
4743|NCT00005877|Drug|rubitecan|
4744|NCT00717587|Other|laboratory biomarker analysis|
4745|NCT00717587|Other|pharmacological study|
4746|NCT00717587|Procedure|adjuvant therapy|
4747|NCT00717587|Procedure|neoadjuvant therapy|
4748|NCT00717587|Procedure|therapeutic conventional surgery|
4749|NCT00717600|Dietary Supplement|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
4750|NCT00717626|Drug|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is < 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
4751|NCT00717639|Procedure|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
4752|NCT00717652|Drug|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
4753|NCT00717652|Drug|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
4754|NCT00005878|Drug|celecoxib|
4755|NCT00717665|Device|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
4756|NCT00717665|Other|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
3784|NCT00730769|Drug|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
3785|NCT00730782|Biological|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
3786|NCT00730795|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
3787|NCT00730808|Dietary Supplement|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
4441|NCT00714532|Behavioral|Enhanced Expert System|The intervention consists of 3 components:
Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention
telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials
a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction
4442|NCT00714545|Radiation|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
4443|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
4444|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
4445|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
4446|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
4447|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
4448|NCT00717080|Procedure|IOL surgery|IOL surgery using capsular tension ring (AURORING)
4449|NCT00005871|Drug|fluorouracil|
4450|NCT00717080|Procedure|IOL surgery|IOL surgery without CTR
4451|NCT00717093|Drug|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
4452|NCT00717093|Drug|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
4453|NCT00717132|Behavioral|Behavior Modification|Individual child and parent behavioral treatment
4454|NCT00717132|Behavioral|Behavior Modification|Family-based behavioral treatment
4455|NCT00717145|Drug|risedronate|one risedronate 20 mg DR tablet
4456|NCT00717145|Drug|risedronate|One risedronate 20 mg DR tablet
4457|NCT00717145|Drug|risedronate|One risedronate 35 mg DR tablet
4458|NCT00717145|Drug|risedronate|One risedronate 35 mg IR tablet
4459|NCT00717158|Behavioral|Usual medical care|
4460|NCT00005871|Drug|rubitecan|
4545|NCT00717262|Drug|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
4546|NCT00005872|Drug|rubitecan|
4547|NCT00717262|Drug|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
4548|NCT00717275|Drug|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
4549|NCT00717288|Drug|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
4550|NCT00717288|Drug|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
4551|NCT00717288|Drug|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
4552|NCT00717314|Drug|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
4553|NCT00717314|Drug|CNI (50%)|50% reduction from BL
4554|NCT00717314|Drug|CNI (≥75%)|≥75% reduction from BL
4555|NCT00717327|Other|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
4556|NCT00717340|Drug|tivozanib (AV-951) + paclitaxel|Tivozanib (AV-951):
Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.
Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.
Paclitaxel: Phase 1b study and Phase 2a study:
All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks).
4557|NCT00005873|Drug|rubitecan|
4558|NCT00717366|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Intermediate starting dose iv weekly, based on previous weekly epoetin dose
4559|NCT00717366|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|High or low dose iv weekly, based on previous weekly epoetin dose
4560|NCT00717379|Drug|Tacrolimus|oral
4561|NCT00717379|Drug|Mycophenolate Mofetil|oral
4562|NCT00717379|Drug|Methylprednisolone or equivalent|oral
4563|NCT00717379|Drug|Prednisone|oral
4564|NCT00717405|Drug|Standard chemotherapy|As prescribed
3724|NCT00723320|Drug|Atorvastatin|atorvastatin 10mg/d
3725|NCT00723320|Behavioral|Aggressive lifestyle intervention|aggressive lifestyle intervention
3726|NCT00725738|Genetic|Stem Cell Transplantation|1-2 million of CD34 cells injected through the infarct related artery by PTCA "over-the-wire" catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes.
3727|NCT00725751|Biological|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
3728|NCT00725751|Drug|Ribavirin|Ribavirin administered according to European labeling.
3729|NCT00725764|Drug|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
3730|NCT00725777|Drug|artemether-lumefantrine|Standard artemether-lumefantrine treatment
4002|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
4003|NCT00726427|Drug|AZD1656|Dose escalation to achieve maximum tolerated dose
4004|NCT00726427|Drug|AZD1656|Oral single dose
4005|NCT00726440|Device|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
4006|NCT00726440|Device|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
4007|NCT00726440|Device|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
4008|NCT00726453|Device|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
4009|NCT00726466|Drug|Efalizumab, Ranibizumab|
4010|NCT00726479|Drug|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
4011|NCT00005946|Drug|cyclophosphamide|
4012|NCT00726492|Other|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
4013|NCT00726492|Other|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
4014|NCT00726505|Drug|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
4015|NCT00728715|Drug|A|medium dose of budesonide-formoterol
3788|NCT00730821|Drug|BIBW 2992|
3789|NCT00723333|Procedure|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
3790|NCT00723346|Biological|GRASPA|50 UI/Kg
3791|NCT00723346|Biological|GRASPA|100 UI/Kg
3792|NCT00723346|Biological|GRASPA|150 UI/Kg
3793|NCT00723346|Drug|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
3794|NCT00723359|Drug|BT062|biologic
3795|NCT00005940|Drug|busulfan|Given PO
3796|NCT00723385|Dietary Supplement|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
3797|NCT00723385|Other|Placebo|Administration of placebo for 12 weeks with repeated D measurements
3798|NCT00723398|Dietary Supplement|Lovaza|dietary supplement
3799|NCT00723398|Drug|Raloxifene|60 mg orally every day for two years
3800|NCT00723398|Drug|Raloxifene 30 mg|30 mg orally daily for two years
3801|NCT00723398|Drug|Lovaza plus Raloxifene|Lovaza 4 gm daily plus Raloxifene 30 mg daily for two years
3802|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
3803|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
3804|NCT00723411|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
3805|NCT00723424|Drug|AZD5672|50 mg, for 13 days
3806|NCT00005940|Drug|cyclophosphamide|Given IV
4087|NCT00726531|Behavioral|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
4461|NCT00717158|Behavioral|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
4815|NCT00715273|Drug|Placebo Colesevelam|Placebo colesevelam each day
4816|NCT00715286|Other|timing of surgery|Surgery is followed by chemotherapy
4817|NCT00715286|Other|timing of surgery|Chemotherapy is followed by surgery
4818|NCT00715299|Behavioral|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
4819|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
4820|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
4821|NCT00715325|Device|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
4822|NCT00715351|Drug|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
4823|NCT00005865|Drug|vinorelbine tartrate|
4824|NCT00717691|Other|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
4825|NCT00717704|Drug|ixabepilone|by vein once every 3 weeks
4826|NCT00717704|Drug|Dasatinib|by mouth once daily
4827|NCT00717717|Behavioral|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
4828|NCT00005879|Drug|arzoxifene|one tablet daily
4829|NCT00717730|Dietary Supplement|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
4830|NCT00717730|Dietary Supplement|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
4831|NCT00717730|Dietary Supplement|Placebo|Placebo with no active ingredients
4565|NCT00717405|Drug|bevacizumab [Avastin]|15mg/kg iv 3 weekly in cycles 1-8
4587|NCT00720109|Drug|Cytarabine|Given IT or IV
4588|NCT00720109|Drug|Dasatinib|Given PO
4589|NCT00720109|Drug|Daunorubicin Hydrochloride|Given IV
4590|NCT00720109|Drug|Dexamethasone|Given IV or PO
4591|NCT00720109|Drug|Etoposide|Given IV
4592|NCT00720109|Biological|Filgrastim|Given IV or SC
4593|NCT00722150|Drug|Artesunate|4 mg/kg/day x 7 days
4594|NCT00722150|Drug|Artesunate|6 mg/kg/day x 7 days
4595|NCT00722163|Other|Cognitive Behavioural Therapy|
4596|NCT00722163|Other|befriending|
4597|NCT00722176|Drug|BL-1020|10 mg
4598|NCT00000695|Drug|Interferon beta-1b|
4599|NCT00005925|Drug|Muscimol|
4600|NCT00722176|Drug|BL-1020 10-30 mg|BL-1020 10-30 mg
4601|NCT00722176|Drug|risperidone|risperidone
4602|NCT00722202|Drug|ERB-257|
4603|NCT00722202|Other|placebo|
4604|NCT00722215|Drug|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
4605|NCT00722215|Drug|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
4606|NCT00722215|Drug|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
4607|NCT00722228|Biological|Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated|
4608|NCT00722280|Procedure|Hand Transplantation|This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the "Pittsburgh Protocol" has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the "Pittsburgh Protocol" to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants.
4016|NCT00728715|Drug|B|High Dose Inhaled Budesonide
4017|NCT00728728|Drug|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
4018|NCT00005959|Drug|doxorubicin hydrochloride|
4019|NCT00728728|Dietary Supplement|Placebo|Placebo
4020|NCT00728754|Device|Dental implant Osseotite Prevail|Root form titanium dental implant
4021|NCT00728754|Device|Dental implant Osseotite|root form titanium dental implant
4022|NCT00728767|Other|Brief intervention|The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.
The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.
The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.
Employees had been instructed to ask these questions during the intervention: "What are you already doing to restrain your drinking?" And "What can you do more?"
4291|NCT00719680|Biological|IgPro20|
4292|NCT00719693|Drug|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
4293|NCT00719693|Drug|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
4294|NCT00719706|Drug|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
4295|NCT00719706|Drug|Placebo|Placebo
4296|NCT00721695|Drug|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
4297|NCT00721708|Dietary Supplement|pure carnosine|one time dose of pure carnosine (450 mg)
4298|NCT00721708|Other|Beef|one time dose, 150 g of beef
4299|NCT00721708|Other|Chicken|One time dose, 150g of chicken breast
4300|NCT00721708|Other|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
4301|NCT00721721|Behavioral|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
4302|NCT00721721|Behavioral|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
4303|NCT00721721|Dietary Supplement|Potassium Supplementation|60 mmol potassium supplement
4088|NCT00726531|Behavioral|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
4089|NCT00726531|Other|Treatment As Usual|Treatment as usual by the general practitioner
4090|NCT00726544|Drug|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
4091|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
4092|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
4093|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
4094|NCT00005946|Drug|etoposide|
4095|NCT00726557|Biological|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
4096|NCT00726557|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
4097|NCT00726570|Device|Sequential compression device therapy|Pneumatic stockings will be applied to patients.
Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery.
4098|NCT00726570|Drug|Dalteparin|2500 UI qd if ≤ 50 kg body weight
5000 UI qd if > 50 kg
4099|NCT00726570|Procedure|TEG|A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.
TEG analyses will be run at:
Patient admission (before SCD start)
40-60 min after admission
Morning after surgery
4100|NCT00726583|Drug|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
4380|NCT00719784|Device|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
2149|NCT00709280|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
2150|NCT00709280|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
2151|NCT00005838|Drug|carboplatin|Given IV
2152|NCT00709293|Drug|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
2153|NCT00709293|Drug|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
2154|NCT00709306|Device|UV-Detect Instant Photos|UV-Detect Instant Photos
2155|NCT00709306|Behavioral|Motivational Interviewing|Motivational Interviewing
2156|NCT00709306|Behavioral|Education|Education
2157|NCT00709332|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
2158|NCT00709345|Behavioral|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
2159|NCT00709345|Behavioral|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
2160|NCT00709358|Other|Detection of microbial DNA in blood by SeptiFast®|The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.
Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours.
2161|NCT00709358|Other|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
2162|NCT00005838|Drug|paclitaxel|Given IV
2163|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
4609|NCT00722293|Drug|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
4610|NCT00005926|Drug|Gemcitabine|
4917|NCT00715520|Drug|Sinemet, ritalin, amphetamine, and placebo|Each subject will take a single dose of the following during Transcranial Magnetic Stimulation sessions:
Ritalin: 40 mg dose taken 2 hours prior to the baseline measurement. Sinemet: 25/100 mg dose taken 1 hour prior to the baseline measurement. Amphetamine: 10 mg dose taken 2 hours prior to the baseline measurement. Placebo: 1 pill taken 2 hours prior to the baseline measurement.
4918|NCT00717860|Drug|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
4919|NCT00717860|Drug|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
4920|NCT00717873|Device|Airway clearance|Provided by the Vest Airway clearance system
4921|NCT00717873|Device|Airway clearance|Airway clearance provided by manual CPT
4922|NCT00005880|Drug|budesonide|
4923|NCT00717886|Radiation|isosulfan blue dye|At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies "day of" mapping for patient convenience.
4924|NCT00717899|Device|Spirometry (Pony spirometer)|Spirometry at rest
4925|NCT00717912|Other|experimental sweetener syrup 1|3 glucose and insulin responses with experimental sweetener syrup 1 : 50 grams of digestible carbohydrate plus fiber
4926|NCT00717912|Other|classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate
4927|NCT00717912|Other|experimental sweetener syrup 2|1 glucose and insulin responses with experimental sweetener syrup 2 : 50 grams of digestible carbohydrate plus fiber
4928|NCT00717925|Drug|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
4929|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
4304|NCT00721734|Drug|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
4305|NCT00721747|Drug|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
4306|NCT00005918|Drug|Stavudine|
4307|NCT00721760|Drug|Enoxaparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
4308|NCT00721760|Drug|Semuloparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
4309|NCT00721760|Drug|Placebo|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component
Subcutaneous injection
4310|NCT00721773|Drug|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
4311|NCT00721773|Drug|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
4312|NCT00721773|Drug|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
4670|NCT00720109|Drug|Vincristine Sulfate|Given IV
4671|NCT00720122|Drug|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
4672|NCT00720135|Biological|DI-Leu16-IL2 immunocytokine|Given IV
4673|NCT00720135|Biological|rituximab|Given IV
4674|NCT00720135|Other|flow cytometry|Correlative studies
4675|NCT00720135|Other|immunohistochemistry staining method|Correlative studies
4676|NCT00720135|Other|pharmacological study|Correlative studies
4677|NCT00720135|Other|laboratory biomarker analysis|Correlative studies
4678|NCT00720135|Other|enzyme-linked immunosorbent assay|Correlative studies
4679|NCT00720135|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
4680|NCT00005898|Drug|anti-thymocyte globulin|
4381|NCT00719797|Biological|bevacizumab|Given IV
4382|NCT00719797|Drug|fluorouracil|Given IV
4383|NCT00719797|Drug|irinotecan hydrochloride|Given IV
4384|NCT00719797|Drug|leucovorin calcium|Given IV
4385|NCT00719797|Drug|oxaliplatin|Given IV
4386|NCT00719810|Drug|delafloxacin|300 mg intravenous every 12 hours
4387|NCT00005892|Procedure|Allogeneic Bone Marrow Transplantation|
4388|NCT00719810|Drug|delafloxacin|450 mg intravenous every 12 hours
4389|NCT00719810|Drug|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
4390|NCT00719823|Drug|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
4391|NCT00719836|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
4392|NCT00719849|Biological|anti-thymocyte globulin|30mg/Kg Days -6 to -4
4393|NCT00719849|Drug|cyclophosphamide|50 mg/Kg Day -6
4394|NCT00719849|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
4395|NCT00719849|Drug|fludarabine phosphate|40mg/m2 Days -6 to -2
4396|NCT00719849|Drug|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
4397|NCT00719849|Procedure|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
4398|NCT00005893|Drug|anti-thymocyte globulin|
4399|NCT00721877|Other|pharmacological study|Correlative studies
4400|NCT00721877|Other|laboratory biomarker analysis|Correlative studies
4401|NCT00721890|Dietary Supplement|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
2203|NCT00710775|Procedure|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
2204|NCT00710788|Drug|sevelamer phosphate-binders|1600 mg/day for 2 years
2205|NCT00710788|Drug|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
2206|NCT00710814|Drug|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
2207|NCT00005845|Other|laboratory biomarker analysis|Correlative studies
2208|NCT00710814|Other|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
2209|NCT00710827|Drug|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
2210|NCT00710827|Drug|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
2211|NCT00710840|Procedure|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
2212|NCT00710840|Procedure|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
2213|NCT00710853|Other|YiRen Qi gong|One hour weekly class for 8 week duration
2214|NCT00710853|Other|Tai Chi|One hour weekly class for 8 week duration
2215|NCT00709410|Biological|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
2216|NCT00709423|Drug|Moxaverine|
2217|NCT00005838|Radiation|radiation therapy|Undergo radiotherapy
2218|NCT00709423|Drug|Moxaverin 150mg|intravenous administration
2219|NCT00709423|Drug|NaCl|intravenous administration
4930|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
4931|NCT00717951|Drug|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
4932|NCT00717977|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
3941|NCT00728689|Drug|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
3942|NCT00728715|Drug|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
3943|NCT00728715|Drug|High dose of budesonide|1600 mcg/d of budesonide
3944|NCT00730990|Other|PET Scan with PF-03654746|Part 2 of the study will have 3 possible interventions:
1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg).
3945|NCT00731003|Drug|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
3946|NCT00731003|Other|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
3947|NCT00005970|Drug|Cyclophosphamide|Given IV
3948|NCT00731003|Other|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
3949|NCT00731003|Drug|Placebo capsule|Placebo for 5-HTP
3950|NCT00731016|Drug|Zoledronic acid, pravastatin|Pravastatin : 10 mg daily
Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :
injection 1, S1: 0.0125 mg/kg of zoledronic acid
injection 2, S6: 0.025 mg/kg of zoledronic acid
injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid
3951|NCT00731029|Biological|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
3952|NCT00731029|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
3953|NCT00731042|Drug|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
3954|NCT00731042|Drug|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
4681|NCT00720148|Drug|Sunitinib and Bortezomib|50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops
4682|NCT00720161|Drug|Metformin|daily 850 mg
4683|NCT00720161|Drug|placebo|placebo
4684|NCT00720174|Biological|Cixutumumab|Given IV
4685|NCT00720174|Drug|Doxorubicin Hydrochloride|Given IV
4686|NCT00720174|Other|Laboratory Biomarker Analysis|Correlative studies
4687|NCT00720200|Behavioral|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
4688|NCT00720200|Behavioral|Usual Care|Family Members receiving usual care/clinical interaction
4689|NCT00720226|Drug|Losartan|Losartan 100 mg daily
4690|NCT00722345|Behavioral|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current & past activities; 2) reviewing the pros & cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
4691|NCT00722358|Drug|BMS-650032|Capsule, Oral, Q12h, 3/5 days
Panel 1: 200 mg
Panel 2: 400 mg
Panel 3: 600 mg
4692|NCT00722358|Drug|Placebo|Capsule, Oral, Q 12h, 3/5 days
Panel 1: matching placebo
Panel 2: matching placebo
Panel 3: matching placebo
3731|NCT00725790|Drug|Vardenafil|10 mg vardenafil on demand treatment for first 4 weeks.
A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.
A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.
3732|NCT00725790|Drug|Placebo|10 mg placebo on demand treatment for first 4 weeks.
A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.
A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.
3733|NCT00725803|Drug|GS-9450|GS-9450 capsules administered orally once daily
3734|NCT00725803|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
3735|NCT00725829|Drug|simvastatin|Simvastatin 40mg/d
4757|NCT00717678|Drug|Prograf-XL|oral
4758|NCT00717678|Drug|Prograf|oral
4759|NCT00717678|Drug|MMF|oral
4760|NCT00717691|Device|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
4761|NCT00720226|Drug|Placebo|Placebo pill daily
4762|NCT00000694|Drug|Interferon alfa-2b|
4763|NCT00005898|Drug|cyclophosphamide|
4764|NCT00720239|Other|Taliderm wound healing dressing|Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:
Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.
Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
4765|NCT00720252|Device|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
4766|NCT00720265|Drug|Prograf|oral
4767|NCT00720265|Drug|MR4|oral
4768|NCT00720278|Drug|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
4769|NCT00720278|Drug|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
4770|NCT00720278|Drug|Placebo|0 mcg Placebo daily
4771|NCT00720291|Drug|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
4772|NCT00720291|Drug|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
4773|NCT00720304|Drug|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
4774|NCT00005898|Drug|cyclosporine|
4775|NCT00720304|Drug|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
2220|NCT00709436|Drug|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
2329|NCT00005841|Biological|tyrosinase peptide|
2330|NCT00710242|Drug|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
2331|NCT00710255|Procedure|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
2332|NCT00710268|Drug|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
2333|NCT00710268|Drug|Bevacizumab|IV administration10 mg/kg every 14 days
2334|NCT00710281|Radiation|Additional scan time on standard MR angiography|Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography
Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements
Arms:
2335|NCT00710294|Device|CVRx Rheos Baroreflex Hypertension Therapy System|The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.
Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator.
2336|NCT00710307|Procedure|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
2337|NCT00710307|Genetic|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
2338|NCT00710320|Procedure|Covered and uncovered anesthesia induction|We hypothesize that the core temperatures of:
the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.
both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group.
2339|NCT00710333|Drug|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
2340|NCT00005842|Biological|trastuzumab|
2341|NCT00710333|Drug|placebo|placebo
2342|NCT00710359|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
2343|NCT00710372|Biological|CYT006-AngQb|s.c. injection
2344|NCT00710385|Drug|heroin, naloxone, buprenorphine, buprenorphine/naloxone|Dosage form: intravenous Dosage: heroin (25 mg), naloxone (0.5-4 mg), buprenorphine (2-16 mg), buprenorphine/naloxone (2/0.5-16/4 mg)
3955|NCT00731055|Drug|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
3956|NCT00731068|Biological|PRGF|injection of 6cc into injured area of tendon
3957|NCT00731068|Biological|placebo|injection of 6 cc of saline into injured area
3958|NCT00005970|Drug|Doxorubicin Hydrochloride|Given IV
3959|NCT00731094|Behavioral|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
4566|NCT00717405|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
4567|NCT00719979|Behavioral|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
4568|NCT00719979|Behavioral|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
4569|NCT00719979|Behavioral|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
4570|NCT00719992|Procedure|coronary angiography|effect of level of HS-CRP
4571|NCT00005893|Procedure|Bone marrow transplantation|
4572|NCT00720005|Device|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
4573|NCT00720018|Drug|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
4574|NCT00720031|Biological|autologous Melan-A/MART-1 specific CTL clones|By using patients' blood, several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient, 3 to 6 months after collecting blood sample. During this production period of the T cell clone, the patient will be treated with deticene at the dose of 250mg/m2/j by IV for 4 days each month.
After each T cell clone infusion (J1), the patient will receive IFN-α at the dose of 9 M/U 3 times a week for 4 weeks and Interleukin-2 at the dose of 9 M/U from Day 1 to day 5 and from Day 8 to Day 12.
4575|NCT00720057|Drug|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
4576|NCT00720057|Drug|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
4577|NCT00720070|Procedure|positron emission tomography/computed tomography|Patients undergo PET/CT scan
3736|NCT00005945|Drug|methotrexate|Given PO and IT
3737|NCT00725829|Drug|ezetimibe|ezetimibe 10mg/d
3738|NCT00725829|Drug|placebo|placebo
3739|NCT00725842|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
3740|NCT00725842|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
3741|NCT00725855|Drug|MEM 3454|1 mg dose
3742|NCT00725855|Drug|MEM 3454|5 mg dose
3743|NCT00725855|Drug|MEM 3454|15 mg dose
3744|NCT00725855|Drug|MEM 3454|50 mg dose
3745|NCT00725855|Drug|Placebo for MEM 3454|Placebo dose
3746|NCT00725868|Other|Data private hospitals, angioplasty, sampling of blood|Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency
coronary angioplasty
Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made
3747|NCT00005945|Drug|pegaspargase|Given IM
3748|NCT00725881|Drug|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
3749|NCT00725881|Drug|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
4023|NCT00728767|Other|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
4024|NCT00728780|Drug|ABT-143|once
4025|NCT00728780|Drug|ABT-335 and rosuvastatin|once
4026|NCT00728793|Drug|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
4027|NCT00728819|Device|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
4028|NCT00728819|Device|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
4776|NCT00720304|Genetic|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
3807|NCT00723424|Drug|Digoxin|0.5mg dose
3808|NCT00723437|Drug|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
3809|NCT00723450|Drug|lamictal|Flexible Dosing
3810|NCT00723463|Procedure|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
3811|NCT00723476|Behavioral|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
3812|NCT00723476|Behavioral|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
3813|NCT00723489|Biological|Live Yellow Fever Vaccine (YFV-17D)|
3814|NCT00723489|Drug|YFV-17D Placebo|
3815|NCT00725894|Device|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
3816|NCT00725907|Biological|PGRF|injection of 6cc into injured area
3817|NCT00725907|Biological|placebo saline|injection of 6cc into injured area
3818|NCT00725920|Drug|Topiramate|patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
3819|NCT00725920|Drug|placebo control group|initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
3820|NCT00725933|Drug|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
3821|NCT00725946|Procedure|124I PET/CT|
3822|NCT00725959|Behavioral|Online social networking HIV prevention|messages about HIV posted in online social networking sites
3823|NCT00005945|Drug|thioguanine|Given PO
2345|NCT00710398|Behavioral|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
2346|NCT00710398|Behavioral|Dietary - Caloric Restriction|Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.
Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake.
2347|NCT00710424|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
2348|NCT00710424|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
2349|NCT00710437|Drug|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
2350|NCT00710463|Device|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
2351|NCT00005842|Drug|tipifarnib|
2352|NCT00710476|Procedure|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
2353|NCT00710502|Procedure|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
2354|NCT00710502|Procedure|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
2355|NCT00710515|Drug|AZD6244|75mg
2356|NCT00710528|Drug|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
2357|NCT00710541|Device|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
2358|NCT00710554|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
2359|NCT00710554|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
4578|NCT00720070|Procedure|therapeutic conventional surgery|Patients undergo neck dissection
4579|NCT00720083|Drug|cisplatin|Given IV
4580|NCT00720083|Drug|vandetanib|Given orally
4581|NCT00720083|Radiation|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
4582|NCT00005896|Drug|filgrastim|
4583|NCT00720096|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
4584|NCT00720096|Drug|Topotecan|Topotecan (daily x 5 days of a 21 day cycle)
Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)
4585|NCT00720109|Drug|Asparaginase|Given IT
4586|NCT00720109|Drug|Cyclophosphamide|Given IV
4611|NCT00722293|Drug|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
4612|NCT00722293|Drug|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
4613|NCT00722306|Drug|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
4614|NCT00722332|Biological|HepaGam B|Hepatitis B Immunoglobulin
4615|NCT00722345|Behavioral|review of "Canada's Physical Activity Guide for Youth"|The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's "Canada's Physical Activity Guide for Youth" was used for the exercise booklet
4616|NCT00714779|Behavioral|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
4617|NCT00714818|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
4618|NCT00714818|Behavioral|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
4619|NCT00714831|Behavioral|Physical activity intervention|3-months physical activity intervention
4029|NCT00005959|Drug|prednisone|
4030|NCT00728832|Drug|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
4031|NCT00728845|Biological|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
4032|NCT00728845|Drug|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
4033|NCT00728845|Drug|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
4034|NCT00728845|Drug|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
4035|NCT00728871|Procedure|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
4036|NCT00728897|Drug|GSK598809|
4037|NCT00728910|Drug|Atorvastatin|10 mg QD for 4 weeks
4038|NCT00728910|Drug|ABT335|135 mg QD added to atorvastatin for 8 weeks
4039|NCT00731159|Biological|sperm capacitation|sperm capacitation measured at Bar Ilan University
4040|NCT00731159|Other|biologic|sperm synthesis of G-actine to F-actine
4041|NCT00005970|Other|Laboratory Biomarker Analysis|Correlative studies
4042|NCT00731159|Other|sperm capacitation|sperm synthesis of G-actine to F-actine
4043|NCT00731172|Drug|glatiramer acetate|20 mg daily subcutaneous injection through week 12
4044|NCT00731172|Drug|placebo|subcutaneous daiky injection through week 12
4045|NCT00731185|Drug|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
4313|NCT00721773|Drug|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
4314|NCT00721786|Behavioral|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
4315|NCT00721799|Drug|F-18 Fluorothymidine|FLT PET scan [0.04 to 0.08 mCi/kg (maximum of 5 mCi +/- 10%)]
4316|NCT00721812|Drug|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
4317|NCT00005920|Drug|L-743,872|
3824|NCT00725972|Other|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
3825|NCT00725972|Procedure|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
3826|NCT00725985|Drug|Cladribine|Cladribine tablets will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the initial treatment period (ITP) of 96 weeks or until CDMS conversion, whichever occur first
4101|NCT00726596|Drug|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
4102|NCT00726609|Drug|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
4103|NCT00728910|Drug|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
4104|NCT00005959|Drug|vincristine sulfate|
4105|NCT00728923|Drug|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
4106|NCT00728936|Drug|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
4107|NCT00728936|Drug|placebo|saline placebo
4108|NCT00728949|Biological|IMC-A12 (cixutumumab)|10 mg/kg I.V.
4109|NCT00728949|Drug|tamoxifen|Daily 20 mg, oral
4110|NCT00728949|Biological|Anastrozole|Daily 1 mg, oral
4111|NCT00728949|Biological|Letrozole|Daily 2.5 mg, oral
4112|NCT00728949|Drug|Exemestane|Daily 25 mg, oral
4113|NCT00728949|Drug|Fulvestrant|Monthly 250 mg, intramuscularly
4114|NCT00728988|Drug|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
4115|NCT00005960|Biological|filgrastim|
4116|NCT00728988|Drug|Atorvastatin|40mg daily after PCI for 30 days.
4117|NCT00729001|Biological|Human Rotavirus Vaccine - two different formulations|Two oral doses
2360|NCT00710567|Device|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanated in using open heart surgery
2361|NCT00710580|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
2362|NCT00000689|Drug|Vincristine sulfate|
2363|NCT00005843|Drug|tipifarnib|
2364|NCT00710580|Biological|etanercept|SQ injection 50 mg BIW
2221|NCT00709436|Drug|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
2222|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
2223|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
2224|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
2225|NCT00709462|Biological|CDX1307|
2226|NCT00709475|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
2227|NCT00709488|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
2228|NCT00005839|Drug|capecitabine|
2229|NCT00709488|Procedure|Placement of device in prostate urethra|Placement of device in prostate urethra
2230|NCT00709488|Device|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
2231|NCT00709501|Behavioral|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
2232|NCT00709501|Behavioral|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
2233|NCT00709514|Drug|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
2234|NCT00709514|Drug|Placebo|Placebo
2235|NCT00709527|Drug|ARC1905|intravitreal injection
4620|NCT00714831|Behavioral|Health educational program|Health education sessions and stretching sessions
4621|NCT00714857|Drug|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
4622|NCT00714870|Behavioral|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
4623|NCT00714883|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
4624|NCT00005863|Drug|daunorubicin hydrochloride|
4625|NCT00714896|Behavioral|Stepped-Care|stage-based expert system written intervention at baseline and 3 months
in-person stage appropriate counseling at baseline and 3 months
telephone counseling sessions at weeks 2,4 and 8,
as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study
optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges
3668|NCT00728273|Dietary Supplement|worm treatment and multiple micronutrient fortified biscuits|A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).
The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin.
3669|NCT00728299|Drug|PomWonderful Juice|8 oz per day each day for 78 weeks
3670|NCT00728299|Drug|Placebo juice|8 oz per day for 78 weeks
3671|NCT00005958|Biological|filgrastim|
3672|NCT00728312|Drug|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
3673|NCT00728312|Drug|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
3674|NCT00730561|Biological|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
3675|NCT00730574|Dietary Supplement|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
3676|NCT00730600|Procedure|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
4318|NCT00721825|Drug|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
4319|NCT00721825|Drug|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
4320|NCT00721877|Drug|resveratrol|Given orally
4321|NCT00714246|Drug|Docetaxel, Carboplatin, Bortezomib|Patients will be enrolled to Phase 1 at the following dose levels: Level 1 - Carboplatin (day 1) 5 AUC mg/ml/min), Docetaxel (day 1) 60 mg/m2, Bortezomib (day 1,4,8,11) 0.7 mg/m2. Level 2A - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 60 mg/m2, Bortezomib (day 1,4,8,11) 0.7 mg/m2. Level 2B - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 60 mg/m2, Bortezomib (day 1,4,8,11) 1.0 mg/m2. Level 3 - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 75 mg/m2, Bortezomib (day 1,4,8,11) 0.7 mg/m2. Level 4 - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 75 mg/m2, Bortezomib (day 1,4,8,11) 1.0 mg/m2. Level 5 - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 75 mg/m2, Bortezomib (day 1,4,8,11) 1.3 mg/m2
4322|NCT00714259|Drug|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
4323|NCT00714259|Radiation|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
4324|NCT00714259|Other|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.
4325|NCT00714285|Biological|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
4326|NCT00714285|Biological|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
4327|NCT00714298|Other|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
4328|NCT00005860|Drug|leucovorin calcium|
4329|NCT00714311|Behavioral|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
4330|NCT00714311|Behavioral|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
4693|NCT00722371|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
4694|NCT00722371|Drug|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
4695|NCT00005926|Drug|Herceptin|
4118|NCT00729001|Biological|Prevnar|Three-dose intramuscular injection (US subjects only)
4119|NCT00729001|Biological|IPOL|Two-dose intramuscular injection (US subjects only)
4120|NCT00729001|Biological|Infanrix|Three-dose intramuscular injection (US subjects only)
4121|NCT00729001|Biological|OmniHIB|Three-dose intramuscular injection (US subjects only)
4122|NCT00729001|Biological|Pentacel|Three-dose intramuscular injection (Canada only)
4123|NCT00729001|Biological|Placebo|2 oral doses
4124|NCT00729027|Drug|AVE5530|one tablet in the evening with dinner
in addition to statin treatment (HMG-CoA Reductase Inhibitors)
4402|NCT00721903|Procedure|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will match the age ranges of the patients with symptoms, initially 30 to 70 years of age.
4403|NCT00721903|Procedure|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
4404|NCT00721916|Drug|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
4405|NCT00721916|Drug|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
4406|NCT00005921|Drug|L-743,872|
4407|NCT00721929|Procedure|MRI|Magnetic Resonance Imaging
4408|NCT00721955|Drug|loxapine|Staccato loxapine 5 mg
4409|NCT00721955|Drug|loxapine|Staccato loxapine 10 mg
4410|NCT00721955|Drug|placebo|Staccato Placebo
4411|NCT00721968|Device|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
4412|NCT00721968|Procedure|cataract surgery alone|Cataract surgery alone
4413|NCT00721994|Device|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
4414|NCT00722007|Device|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
4415|NCT00722020|Device|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
2236|NCT00709540|Biological|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
2237|NCT00709553|Drug|midazolam|
2238|NCT00709553|Drug|ZD4054|ZD4054 10 mg od
2239|NCT00005839|Drug|oxaliplatin|
2240|NCT00709566|Behavioral|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
2241|NCT00709566|Behavioral|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
2242|NCT00709579|Drug|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
2243|NCT00709579|Drug|Placebo|placebo
2244|NCT00709592|Biological|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
2245|NCT00709605|Drug|VRC-HIVADV014-00-VP|
2246|NCT00709618|Drug|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
2247|NCT00709644|Drug|Norgestimate; Ethinyl Estradiol; Folic acid.|
2248|NCT00709657|Drug|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
2249|NCT00709670|Procedure|MSCT and stress echocardiography|tests MSCT and stress echocardiography
2250|NCT00000177|Drug|Estrogen|
2251|NCT00000689|Drug|Bleomycin sulfate|
2252|NCT00005840|Drug|Paclitaxel|Given IV
2253|NCT00709683|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
2254|NCT00709696|Drug|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
2255|NCT00709696|Drug|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
2256|NCT00709709|Procedure|multislice coronary scan|multislice coronary scan
3677|NCT00730613|Biological|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
3678|NCT00730613|Genetic|gene expression analysis|At the time of excess pathology samples documenting response/relapse
3679|NCT00005966|Drug|thalidomide|
3680|NCT00730613|Other|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
3681|NCT00730626|Dietary Supplement|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
3682|NCT00730626|Dietary Supplement|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
3683|NCT00730626|Dietary Supplement|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
3684|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
3685|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
3686|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
3960|NCT00731107|Procedure|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
3961|NCT00731107|Procedure|laparoscopic surgery|Veress Needle laparoscopic entry
3962|NCT00731120|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
3963|NCT00731120|Drug|Placebo|Vortioxetine placebo-matching capsules
3964|NCT00731133|Drug|Disulfiram|250 mg/day
3965|NCT00731146|Other|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
3966|NCT00731146|Other|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
3967|NCT00723606|Drug|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
4696|NCT00722371|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
4697|NCT00722371|Drug|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
4698|NCT00722371|Drug|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
4699|NCT00722384|Drug|bevasiranib|
4700|NCT00722384|Drug|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
4701|NCT00722410|Dietary Supplement|VSL#3|A probiotic preparation.
4702|NCT00722410|Drug|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
4703|NCT00722423|Behavioral|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
4704|NCT00722423|Behavioral|Usual Care Model|
4705|NCT00722436|Drug|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
4706|NCT00005926|Procedure|Radiation therapy|
4707|NCT00722436|Drug|saline|Placebo
4708|NCT00722462|Procedure|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
4709|NCT00722462|Procedure|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
4710|NCT00714961|Drug|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
4711|NCT00714961|Drug|Placebo|plus acetylsalicylic acid (ASA)
4712|NCT00714974|Device|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
4416|NCT00722033|Drug|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
4417|NCT00005922|Behavioral|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
4418|NCT00722046|Biological|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
4419|NCT00722046|Biological|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
4420|NCT00722046|Biological|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
4421|NCT00722046|Drug|Placebo|Placebo every 60 days (10 doses total)
4422|NCT00722046|Biological|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
4423|NCT00722046|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
4424|NCT00722059|Procedure|Breast Tomosynthesis|3D breast imaging
4777|NCT00720304|Genetic|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
4778|NCT00720304|Other|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
4779|NCT00720304|Other|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
4780|NCT00722566|Drug|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
4781|NCT00722579|Device|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
4782|NCT00722592|Drug|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
4783|NCT00722592|Drug|pegylated liposomal doxorubicin (PLD)|50 mg/m^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
4784|NCT00722592|Other|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
2257|NCT00709722|Drug|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
2258|NCT00709735|Drug|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
2259|NCT00709748|Device|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
2260|NCT00709748|Device|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
2261|NCT00709761|Drug|Lapatinib/nab-Paclitaxel|This is an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Sixty subjects will be enrolled in the study. Subjects will receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
2262|NCT00709774|Device|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
2263|NCT00005840|Drug|Cisplatin|Given IV
2264|NCT00709787|Other|Usual Care|Normal care for hypertensive patients with risk factors for CHD
2265|NCT00709800|Biological|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
2266|NCT00709800|Biological|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
2267|NCT00709800|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
2268|NCT00709800|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
2269|NCT00709800|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
2270|NCT00709813|Behavioral|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
2271|NCT00709826|Drug|gemcitabine|Gemcitabine: per package insert.
2272|NCT00709826|Drug|placebo|placebo: 100 mg tablets, 400 mg/day
2273|NCT00709826|Drug|Erlotinib|Erlotinib - per package insert.
2274|NCT00005840|Radiation|Radiation Therapy|Undergo whole abdominal radiation therapy
2275|NCT00709826|Drug|apricoxib|apricoxib: 100mg tablets, given orally
3968|NCT00723632|Biological|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
3969|NCT00723632|Drug|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants <65 kg, 1000 mg/day for participants >65 to <85 kg, and 1200 mg/day for participants >=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
3970|NCT00723658|Biological|rituximab|
3971|NCT00723658|Drug|bortezomib|
3972|NCT00723658|Drug|carmustine|
3973|NCT00005940|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
3974|NCT00723658|Drug|cisplatin|
3975|NCT00723658|Drug|cyclophosphamide|
3976|NCT00723658|Drug|cytarabine|
3977|NCT00723658|Drug|dexamethasone|
3978|NCT00723658|Drug|doxorubicin hydrochloride|
3979|NCT00723658|Drug|etoposide|
3980|NCT00723658|Drug|melphalan|
3981|NCT00723658|Drug|thalidomide|
3982|NCT00723658|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
4244|NCT00716768|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
4245|NCT00716768|Procedure|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
4246|NCT00716794|Drug|HE3235|HE3235 will be administered orally in 28 day cycles.
4247|NCT00000690|Drug|Dextran sulfate|
4248|NCT00005869|Drug|rubitecan|
4249|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
4250|NCT00716807|Drug|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
3750|NCT00728325|Behavioral|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
3751|NCT00728325|Behavioral|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
3752|NCT00728338|Dietary Supplement|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
3753|NCT00728338|Dietary Supplement|Olive oil|7.5 g olive oil/day
3754|NCT00728351|Drug|vildagliptin + metformin|
3755|NCT00728351|Drug|metformin|1000 bid metformin
3756|NCT00728377|Behavioral|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
3757|NCT00728377|Behavioral|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
3758|NCT00005958|Drug|docetaxel|
3759|NCT00728390|Drug|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
3760|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
3761|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
3762|NCT00728403|Dietary Supplement|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
4785|NCT00722605|Procedure|cone-beam CT|You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.
During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.
For all scans, an external monitor will be used to record your breathing.
If needed, you will be repositioned by adjusting the radiation machine's treatment couch position.
4786|NCT00005934|Drug|5-Azacytidine|
4787|NCT00722618|Behavioral|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
4788|NCT00722618|Other|Written materials|2 written materials available on public website
4789|NCT00722631|Drug|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
4790|NCT00722631|Drug|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
4791|NCT00722644|Behavioral|Cognitive Behavioral Stress Management|
4792|NCT00722670|Behavioral|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
3827|NCT00725985|Drug|Cladribine|Cladribine tablets will be administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occur first
3828|NCT00725985|Drug|Placebo|Placebo matched to cladribine tablets will be administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occur first
3829|NCT00725985|Drug|Rebif® new formulation (RNF)|Participants who will convert to CDMS during ITP will enter in open-label maintenance period (OLMP) and receive RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who will convert to CDMS during long-term follow-up (LTFU) period, will also receive RNF subcutaneously at a dose of 44 mcg three times a week
3830|NCT00726011|Biological|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
3831|NCT00726037|Drug|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
3832|NCT00726063|Device|Nanotite dental implant|Nanotite root form titanium dental implant
3833|NCT00726063|Device|Osseotite dental implant|Osseotite Root form titanium dental implant
3834|NCT00005945|Drug|vincristine sulfate|Given IV
3835|NCT00726076|Behavioral|WebEase|Computer-based epilepsy self-management program
The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment
2276|NCT00709839|Drug|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
2277|NCT00709839|Drug|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
2278|NCT00709852|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
2279|NCT00709852|Drug|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
2280|NCT00709865|Drug|tonapofylline|IV
2281|NCT00709865|Drug|Placebo|IV
2282|NCT00709878|Procedure|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
2283|NCT00709891|Device|cobas® 4800 HPV Test|
2284|NCT00709904|Drug|Open-label Semuloparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection once daily with an initial dose given 8 hours after surgery
2285|NCT00005841|Biological|MART-1 antigen|
2286|NCT00709904|Drug|Placebo (for Semuloparin sodium)|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component
Subcutaneous injection once daily
2287|NCT00709904|Drug|Semuloparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection once daily
2288|NCT00709917|Drug|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
2289|NCT00709930|Device|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
2290|NCT00709930|Device|Placebo magnetic field generator|Placebo device with no magnetic fields
2291|NCT00709956|Drug|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
2292|NCT00709956|Drug|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
2293|NCT00709969|Drug|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - < 10kg (BWG 1) = 6 doses of 1 tablet / 10 - < 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
2294|NCT00709982|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
2295|NCT00709995|Drug|Enzastaurin|Administered orally
4251|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
4252|NCT00716807|Drug|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
4253|NCT00716820|Drug|SUNITINIB MALATE|SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.
The dosage may be decreased according to the patient's clinical condition."
4254|NCT00716833|Drug|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
4255|NCT00716833|Drug|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
4256|NCT00716846|Drug|simvastatin|10mg, 2 weeks
4257|NCT00716846|Drug|atorvastatin|10mg
4258|NCT00716846|Drug|pitavastatin|2mg
4259|NCT00005870|Drug|fluorouracil|
4260|NCT00716859|Drug|Timolol|Timolol 0.5% dosed twice-daily
4261|NCT00716859|Drug|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
4262|NCT00716872|Behavioral|Sleep Healthy Using the Internet (SHUTi)|SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive "Cores" of information. As they progress through the program, users receive tailored instructions for how to improve their sleep.
4263|NCT00716872|Behavioral|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
4264|NCT00716911|Drug|ganciclovir|
4626|NCT00714896|Behavioral|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
4627|NCT00714922|Procedure|PRK|Laser refractive surgery
4628|NCT00714922|Procedure|SBK|Laser refractive surgery
4629|NCT00714935|Behavioral|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
3763|NCT00728416|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
4046|NCT00731185|Drug|Placebo|
4047|NCT00731198|Drug|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
4048|NCT00731198|Drug|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
4049|NCT00731211|Drug|Pazopanib|800 mg of pazopanib orally each day continuously
4050|NCT00731224|Drug|Rivastigmine transdermal patch|
4051|NCT00731250|Drug|SB-705498|400mg oral SB-705498
4052|NCT00005970|Drug|Paclitaxel|Given IV
4053|NCT00731250|Drug|Placebo|SB-705498 placebo
4054|NCT00731250|Other|0.5-5-50ug Caspaicin|3 doses capsaicin challenge
4055|NCT00731250|Other|50ug caspaicin|SD 50ug capsacin
4056|NCT00731263|Drug|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
4057|NCT00731276|Drug|irinotecan hydrochloride|
4058|NCT00731276|Other|pharmacogenomic studies|
4059|NCT00731276|Other|pharmacological study|
4060|NCT00731289|Drug|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
4061|NCT00731289|Drug|triamcinolone|one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
antiinflammatory intervention
4062|NCT00731302|Drug|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
4063|NCT00005970|Drug|Tamoxifen Citrate|Given orally
4064|NCT00731315|Other|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
4065|NCT00731315|Other|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
3836|NCT00726076|Behavioral|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
3837|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
3838|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
3839|NCT00005958|Drug|gemcitabine hydrochloride|
3840|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
3841|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
3842|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
3843|NCT00728455|Drug|placebo|Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
3844|NCT00728455|Drug|placebo|Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
4125|NCT00729027|Drug|AVE5530|one tablet in the evening with dinner
in addition to statin treatment (HMG-CoA Reductase Inhibitors)
4126|NCT00005960|Drug|cyclophosphamide|
4127|NCT00729027|Drug|placebo|one tablet in the evening with dinner
in addition to statin treatment (HMG-CoA Reductase Inhibitors)
4128|NCT00729040|Behavioral|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
4129|NCT00729053|Drug|IMO-2055|immunostimulatory oligonucleotide
4130|NCT00729079|Behavioral|DPP|The primary outcome measure is weight loss with a goal of 7% of initial weight.
Secondary outcomes are adherence to behavior changes:
Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
Fat intake less than 25% and saturated fat less than 10%
Fiber intake of at least 25 grams per day
Fasting blood sugar < 100 mg/dL
Absence of tobacco use
4131|NCT00731341|Procedure|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
2296|NCT00005841|Biological|gp100 antigen|
2297|NCT00709995|Drug|Sunitinib|Administered orally
2298|NCT00709995|Drug|Placebo|Administered orally
2299|NCT00710008|Other|exercise training|3 bouts of exercise at 90%RCP during one week
2300|NCT00710021|Drug|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
2301|NCT00710021|Drug|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
2302|NCT00710034|Other|Oral tobacco|Snus
2303|NCT00710034|Drug|Nicotine Gum|4 mg Nicotine gum
2304|NCT00710047|Drug|ZD4054|one single 10mg dose
2305|NCT00710060|Behavioral|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
2306|NCT00710060|Behavioral|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
2307|NCT00005841|Biological|incomplete Freund's adjuvant|
2308|NCT00710073|Device|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
2309|NCT00710086|Drug|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
2310|NCT00710086|Drug|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
2311|NCT00710099|Drug|sildenafil|systemic absorption of sildenafil
2312|NCT00710099|Drug|nitroprussiate iontophoresis|nitroprussiate iontophoresis
2313|NCT00710112|Genetic|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
2314|NCT00710125|Drug|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
4630|NCT00714935|Behavioral|Coronary Artery Disease Decision Aid|Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: "Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke"
The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing.
4631|NCT00714948|Drug|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) > 2.1), after consultation with the Principal Investigator.
4632|NCT00717418|Drug|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
4633|NCT00005874|Drug|rubitecan|
4634|NCT00717431|Procedure|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
4635|NCT00717444|Behavioral|contingency management|contingency management for abstinence plus 12-step facilitation therapy
prizes awarded for target behaviors
4636|NCT00717444|Behavioral|contingency management|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
prizes awarded for target behaviors
4637|NCT00717457|Drug|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
4638|NCT00717457|Drug|taspoglutide|10mg once weekly
4639|NCT00717457|Drug|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
4640|NCT00717470|Drug|Prograf®|oral
4641|NCT00717470|Drug|Advagraf®|oral
4642|NCT00717470|Drug|Mycophenolate Mofetil|oral
4643|NCT00717470|Drug|Simulect|oral
4644|NCT00000178|Drug|Prednisone|
4645|NCT00000691|Drug|Foscarnet sodium|
4646|NCT00005875|Drug|rubitecan|
3687|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
3688|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
4066|NCT00731328|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
4067|NCT00723710|Biological|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
4331|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
4332|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
4333|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
4334|NCT00714350|Behavioral|New ICU Display Visualization|
4335|NCT00714363|Procedure|LASIK|Refractive surgery
4336|NCT00714363|Procedure|SBK|Refractive surgery
4337|NCT00714376|Drug|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
4338|NCT00714415|Drug|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
4339|NCT00005860|Drug|oxaliplatin|
4340|NCT00714441|Behavioral|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
4341|NCT00716911|Other|flow cytometry|
4342|NCT00716911|Other|immunologic technique|
4343|NCT00716911|Procedure|allogeneic bone marrow transplantation|
4344|NCT00716911|Procedure|allogeneic hematopoietic stem cell transplantation|
4345|NCT00005870|Drug|gemcitabine hydrochloride|
4346|NCT00716911|Procedure|assessment of therapy complications|
4347|NCT00716911|Procedure|peripheral blood stem cell transplantation|
4348|NCT00716924|Drug|Clopidogrel|300 mg
4132|NCT00731354|Device|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
4133|NCT00731354|Device|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
4134|NCT00731367|Device|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
4135|NCT00731367|Device|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
4136|NCT00731380|Drug|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
4137|NCT00731393|Biological|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
4138|NCT00000703|Drug|Vincristine sulfate|
4139|NCT00005970|Biological|Trastuzumab|Given IV
4140|NCT00731393|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
4425|NCT00714441|Behavioral|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
4426|NCT00714441|Behavioral|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
4427|NCT00714454|Other|APS Topical Lotion|
4428|NCT00714454|Other|Placebo|
2315|NCT00710138|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
2316|NCT00710164|Drug|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
2317|NCT00710164|Drug|Placebo|14 days of Placebo
2318|NCT00005841|Biological|progenipoietin|
2319|NCT00710190|Device|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
2320|NCT00710203|Device|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
2321|NCT00710203|Procedure|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
2322|NCT00710203|Procedure|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
2323|NCT00710203|Other|No treatment|A fourth lesion will not be treated and will serve as a control.
2324|NCT00710216|Drug|Lamivudine|100 mg/day
2325|NCT00710216|Drug|Telbivudine|600 mg/day
2326|NCT00710229|Drug|Ranibizumab|intravitreal injection
2327|NCT00710229|Drug|Bevacizumab|intravitreal injection
2328|NCT00710242|Drug|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
4223|NCT00714181|Other|high performance liquid chromatography|
4224|NCT00714181|Other|immunoenzyme technique|
4225|NCT00714181|Other|immunohistochemistry staining method|
4226|NCT00714181|Other|laboratory biomarker analysis|
4227|NCT00005859|Drug|tipifarnib|
4228|NCT00714181|Other|mass spectrometry|
4229|NCT00714181|Other|pharmacological study|
4230|NCT00714194|Procedure|Normal continuous sedation|Normal continuous sedation.
3689|NCT00730652|Biological|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
3690|NCT00000703|Drug|Bleomycin sulfate|
3691|NCT00005967|Drug|tipifarnib|
3692|NCT00730665|Drug|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
3693|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
3694|NCT00730665|Drug|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
3695|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
3696|NCT00730665|Drug|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
3697|NCT00723125|Drug|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
3698|NCT00723125|Drug|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
3699|NCT00005939|Radiation|brachytherapy|
3700|NCT00723125|Drug|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
3701|NCT00723151|Behavioral|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
3702|NCT00723164|Drug|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
3703|NCT00723164|Drug|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
3704|NCT00723177|Drug|AV411|Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks
3705|NCT00723190|Drug|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
3706|NCT00723203|Drug|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
3983|NCT00723658|Procedure|peripheral blood stem cell transplantation|
4349|NCT00716924|Drug|Clopidogrel|600 mg
4350|NCT00716937|Procedure|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
4351|NCT00716937|Procedure|laying open|laying open the site of excision of sinus or cyst without any flap
4352|NCT00716950|Drug|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
4353|NCT00716950|Drug|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
4713|NCT00005863|Drug|etoposide|
4714|NCT00715000|Procedure|Oral rehydration therapy|oral rehydration solution
4715|NCT00715000|Procedure|classical hydration via intravenous infusion|intravenous infusion
4716|NCT00715013|Drug|Patupilone|Patupilone
4717|NCT00715026|Device|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
4718|NCT00715039|Drug|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
4719|NCT00715039|Drug|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
4720|NCT00715039|Drug|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
4721|NCT00715052|Procedure|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
4722|NCT00715065|Procedure|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting ~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
4723|NCT00715078|Biological|Sipuleucel-T|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with prostate antigen PA2024.
4724|NCT00005863|Drug|fludarabine phosphate|
4725|NCT00715091|Drug|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
4726|NCT00715091|Drug|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
4727|NCT00715104|Biological|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
4429|NCT00714467|Behavioral|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
4430|NCT00714467|Behavioral|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
4431|NCT00714480|Drug|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
4432|NCT00714480|Drug|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
4433|NCT00714480|Drug|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
4434|NCT00005861|Drug|pegylated liposomal doxorubicin hydrochloride|
4435|NCT00714493|Biological|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
4436|NCT00714506|Behavioral|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
4437|NCT00714506|Other|Physical activity control|physical activity plus successful aging health education
4438|NCT00714519|Drug|Xenaderm® Ointment|Topical, BID or as needed
4439|NCT00714519|Drug|Placebo Comparator|Topical, BID or as needed
4440|NCT00714532|Behavioral|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
4793|NCT00722670|Behavioral|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
4794|NCT00722683|Procedure|Ultrasound Imaging with Contrast to Map Vascular Flow|An ultrasound contrast agent, Definity, will be started through the IV line already in place. The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times.
4795|NCT00722696|Other|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
4796|NCT00722709|Drug|Ropivacaine|In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.
At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
4797|NCT00005935|Drug|Mycophenolate mofetil|
4231|NCT00714194|Other|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
4232|NCT00714207|Behavioral|NOT program|Students in this arm of the study received the reformatted NOT intervention
4233|NCT00714207|Behavioral|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
4234|NCT00714207|Behavioral|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
4235|NCT00714207|Behavioral|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
4236|NCT00714233|Drug|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
4237|NCT00714233|Drug|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
4238|NCT00000689|Drug|Leucovorin calcium|
4239|NCT00005860|Drug|floxuridine|
4240|NCT00714233|Behavioral|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
4241|NCT00714233|Drug|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
4242|NCT00714246|Drug|Docetaxel, Carboplatin, Bortezomib|Phase II recommended dose is the highest dose level at which less than 2 patients (out of 6) experience dose limiting toxicity. A maximum of 4 cycles (1 cycle = 21 days) of chemotherapy will be administered to patients. Patients who demonstrate an ongoing response at the end of the 4th cycle of chemotherapy, may receive 2 more cycles of treatment.
4243|NCT00716755|Drug|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, [11C]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
4523|NCT00714623|Device|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
4524|NCT00714649|Drug|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
4525|NCT00714662|Device|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
4526|NCT00714675|Dietary Supplement|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
3984|NCT00000696|Drug|Interferon alfa-2a|
3985|NCT00005940|Drug|cyclosporine|Given IV or PO
3986|NCT00723671|Procedure|MRI|
3987|NCT00723684|Other|Placebo EEG Neurofeedback|The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).
In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects.
3988|NCT00723684|Other|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
3989|NCT00723697|Drug|buprenorphine|0.4, 2, or 8 mg sublingual tablets
3990|NCT00726258|Drug|placebo|physiological serum
3991|NCT00726271|Dietary Supplement|light olive oil, fish oil capsules, flax seed oil capsules|fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
3992|NCT00726310|Device|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
3993|NCT00726323|Drug|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
3994|NCT00726336|Drug|GSK1349572 and tenofovir|
3995|NCT00726349|Other|No intervention|Observational study.
3996|NCT00726375|Drug|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
3997|NCT00726388|Drug|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
3998|NCT00726401|Drug|COLD-fX|200mg BID for 4 weeks
3999|NCT00726401|Drug|Placebo|200mg BID for 4 weeks
4000|NCT00005946|Biological|therapeutic allogeneic lymphocytes|
4728|NCT00715104|Biological|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
4729|NCT00715117|Drug|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
4730|NCT00715117|Other|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
4731|NCT00715130|Behavioral|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
3764|NCT00728416|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
3765|NCT00728429|Behavioral|exercise intervention|24 week program of exercise
3766|NCT00728442|Device|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
3767|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
3768|NCT00730665|Drug|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
3769|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
3770|NCT00730665|Other|Placebo|Capsule, Placebo, every 12 hours (twice a day)
3771|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
3772|NCT00005968|Drug|irofulven|
3773|NCT00730691|Drug|Placebo|Placebo-matching capsules
3774|NCT00730691|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
3775|NCT00730691|Drug|Duloxetine|Overencapsulated duloxetine capsules
4798|NCT00715169|Drug|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
4799|NCT00715169|Other|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
4800|NCT00000689|Drug|Sargramostim|
4801|NCT00005863|Drug|tretinoin|
4802|NCT00715182|Drug|TKI258|
4803|NCT00715195|Behavioral|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
4804|NCT00715208|Drug|rituximab|
4805|NCT00715208|Drug|cyclophosphamide|
4806|NCT00715208|Drug|doxorubicin|
4807|NCT00715208|Drug|VELCADE|
4808|NCT00715208|Drug|prednisone|
4809|NCT00715234|Other|Reminder/recall notices for vaccines|Receive a generic letter reminding them to make an appointment to get vaccines.
Receive a computer-generated telephone message at 1 week post initial letter.
Receive a computer-generated telephone message at 2 months post initial letter.
Receive a letter at 3 months post initial letter.
4810|NCT00715273|Drug|Atorvastatin|10 to 80 mg of atorvastatin each day
4811|NCT00715273|Drug|Niacin|2000 mg of niacin each day
4812|NCT00005864|Drug|chloroquinoxaline sulfonamide|
4813|NCT00715273|Drug|Colesevelam|3.8 g of colesevelam each day
4814|NCT00715273|Drug|Placebo Niacin|Placebo niacin each day
3845|NCT00728455|Drug|placebo|Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
3846|NCT00728455|Drug|placebo|Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
3847|NCT00728455|Drug|placebo|Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
3848|NCT00728468|Drug|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days.
Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
4527|NCT00714675|Dietary Supplement|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
4528|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
4529|NCT00005863|Biological|filgrastim|
4530|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
4531|NCT00714688|Drug|Placebo|2xplacebo once daily for 13 weeks
4532|NCT00714714|Drug|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
4533|NCT00714714|Drug|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
4534|NCT00714727|Procedure|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
4535|NCT00714740|Drug|acetazolamide|acetazolamide 2 times 250mg per day
4536|NCT00714753|Radiation|brachytherapy|
4537|NCT00714753|Radiation|hypofractionated radiation therapy|
4538|NCT00714753|Radiation|image-guided radiation therapy|
4539|NCT00714753|Radiation|intensity-modulated radiation therapy|
4540|NCT00005863|Drug|cytarabine|
4541|NCT00714766|Procedure|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
4542|NCT00714779|Drug|Fluoxetine|20-40 mg / day orally
4543|NCT00717236|Drug|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
4901|NCT00715364|Drug|NTx™-265: rhCG, then rEPO|rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then
rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
4902|NCT00715364|Drug|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then
Saline IV, on Day 7, 8, and 9 of study participation
4903|NCT00715377|Drug|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
4001|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
4265|NCT00716911|Genetic|polymerase chain reaction|
4266|NCT00005890|Drug|corticotropin|
4267|NCT00719511|Drug|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
4268|NCT00719511|Drug|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
4269|NCT00719524|Drug|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
4270|NCT00719537|Drug|Aspirin and progesterone|aspirin 81 mg once a day oral progesterone 200mg twice daily
4271|NCT00719537|Drug|Aspirin and placebo|Aspirin 81mg once daily and placebo
4272|NCT00719550|Drug|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
4273|NCT00719550|Drug|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
4274|NCT00719550|Drug|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
4275|NCT00719550|Drug|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
4276|NCT00719550|Drug|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
4277|NCT00005891|Drug|cyclophosphamide|
4278|NCT00719563|Drug|American ginseng|Given orally
4279|NCT00719563|Other|placebo|Given orally
4280|NCT00719576|Biological|Matrix-Induced Autologous Chondrocyte Implant (MACI)|Implantation
4281|NCT00719576|Procedure|Microfracture|Microfracture
4282|NCT00719602|Drug|Lamivudine|Taken orally twice daily
4283|NCT00719602|Drug|Lopinavir/Ritonavir|Taken orally twice daily
4284|NCT00719602|Drug|Nevirapine|Taken orally twice daily
4285|NCT00719602|Drug|Zidovudine|Taken orally twice daily
4286|NCT00719641|Procedure|Colonoscopy|
3776|NCT00730717|Drug|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
3777|NCT00730717|Drug|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
3778|NCT00730730|Device|Complete SE Iliac Stent|Iliac stenting
3779|NCT00730730|Device|Complete SE Iliac Stent|Self-expanding stent
3780|NCT00730743|Procedure|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
3781|NCT00730756|Drug|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
3782|NCT00730756|Other|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
3783|NCT00005969|Drug|Chemotherapy|
4068|NCT00723723|Drug|Statin|Statin
4069|NCT00723736|Drug|Desloratadine|2.5 ml (1.25 mg) once daily
4070|NCT00723749|Drug|Buprenorphine/Naloxone|Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine & 0.5 mg naloxone and 8 mg buprenorphine & 2 mg naloxone.
The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity.
4071|NCT00723762|Procedure|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
4072|NCT00723775|Drug|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
4073|NCT00005940|Drug|methotrexate|Given IV
4074|NCT00723788|Device|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
4075|NCT00723801|Drug|Atenolol|Atenolol 50mg PO QD
4076|NCT00723801|Drug|Losartan|Losartan 100mg PO QD
4077|NCT00723827|Drug|Temozolomide|Administration of temozolomide based on the product labeling.
4078|NCT00723827|Radiation|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
4079|NCT00723840|Other|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
3849|NCT00728481|Drug|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
3850|NCT00005959|Biological|filgrastim|
3851|NCT00728481|Drug|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
3852|NCT00728494|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
3853|NCT00728494|Drug|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
3854|NCT00728494|Behavioral|Patient Assistance Program|The patient assistance program includes the following:
Training by physicians or specialized nurses.
Informational materials based on the "To beat HCV" program.
Management of specific side effects.
3855|NCT00728507|Drug|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects <= 45kg and 450mg for those >45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
3856|NCT00728507|Drug|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
3857|NCT00730821|Drug|BIBF 1120|
3858|NCT00730834|Device|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
3859|NCT00730847|Biological|Cervarix|Subjects received three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
3860|NCT00730860|Procedure|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
3861|NCT00730860|Procedure|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
3862|NCT00005969|Drug|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
3863|NCT00730873|Device|Continuous positive airway pressure|
3864|NCT00730886|Device|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
4141|NCT00731419|Device|SEMS|Comparing plastic and metal stents
4142|NCT00731432|Drug|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
4143|NCT00731432|Drug|Placebo Patch|Identical in shape and texture to treatment patch
4904|NCT00715403|Drug|BIBF 1120|
4905|NCT00715416|Device|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
4906|NCT00715416|Procedure|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
4907|NCT00715429|Drug|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
4908|NCT00715429|Drug|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
4909|NCT00715442|Drug|Sunitinib|50 mg by mouth daily for 28 consecutive days
4910|NCT00005866|Drug|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
4911|NCT00715442|Procedure|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
4912|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
4913|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
4914|NCT00715455|Drug|Unfractionated Heparin|Heparin will be administered per standard of care at sites
4915|NCT00715494|Behavioral|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
4916|NCT00715507|Device|medication monitor|the medication monitor will aid in expertise and decision-making.
3920|NCT00728520|Drug|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
3921|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
3922|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
4287|NCT00719641|Procedure|Colon Cancer Screening|
4288|NCT00005891|Procedure|Allogeneic Bone Marrow Transplantation|
4289|NCT00719641|Device|Segmental Stiffening Wire|
4290|NCT00719667|Other|coronary artery bypass grafting|on pump off pump
4647|NCT00717470|Drug|methylprednisolone / prednisone|oral
4648|NCT00717496|Other|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
4649|NCT00717522|Drug|Pomalidomide|
4650|NCT00717535|Other|cryopreservation|
4651|NCT00717535|Other|questionnaire administration|
4652|NCT00717535|Other|study of socioeconomic and demographic variables|
4653|NCT00717548|Behavioral|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
4654|NCT00717561|Drug|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
4655|NCT00717561|Drug|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
4656|NCT00717574|Drug|nitrous oxide|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
4657|NCT00005876|Drug|rubitecan|
4658|NCT00005896|Genetic|Autologous stem cells transduced with FACC retroviral vector|
4659|NCT00720109|Drug|Hydrocortisone Sodium Succinate|Given IT
4660|NCT00720109|Drug|Ifosfamide|Given IV
4661|NCT00720109|Other|Laboratory Biomarker Analysis|Correlative studies
4662|NCT00720109|Drug|Leucovorin Calcium|Given IV or PO
4080|NCT00723853|Behavioral|Reach-Out Program, nutritional and exercise program|This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.
During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise.
4081|NCT00723853|Behavioral|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
4082|NCT00723866|Other|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
4083|NCT00723866|Other|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
4084|NCT00005940|Other|laboratory biomarker analysis|Correlative studies
4085|NCT00723879|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
4086|NCT00723879|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
4354|NCT00716963|Drug|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
4355|NCT00716963|Drug|budesonide 400 mcg|budesonide 400 mcg
4356|NCT00005870|Drug|mitomycin C|
4357|NCT00716963|Other|Placebo|Placebo
4358|NCT00716976|Drug|sodium thiosulfate|Given IV
4359|NCT00716976|Procedure|examination|Patients undergo audiological assessments periodically
4360|NCT00716989|Biological|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
4361|NCT00717054|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
4362|NCT00717054|Drug|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
4363|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
4364|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
4144|NCT00731445|Drug|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
4145|NCT00731458|Device|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
4146|NCT00731471|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
4147|NCT00731497|Device|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
4148|NCT00731510|Dietary Supplement|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
4149|NCT00731510|Dietary Supplement|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
4150|NCT00005971|Drug|alvocidib|
4151|NCT00723879|Behavioral|Patient assistance program|Patient assistance programs will be classified as follows:
medications, including psychiatric medications (antidepressants);
other interventions, including nurse telephone calls and nurse support in the office: and
educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment.
4152|NCT00723892|Biological|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg^kg^week
4153|NCT00723892|Drug|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg^day
4154|NCT00723892|Behavioral|Psychotherapy support program|Each site has implemented a psychotherapy support program.
4155|NCT00723918|Drug|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
4156|NCT00723918|Drug|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
4157|NCT00723918|Drug|SAB placebo|an inactive substance
4158|NCT00723918|Drug|Methadone placebo|Methadone placebo
4159|NCT00005941|Biological|therapeutic allogeneic lymphocytes|
4160|NCT00723931|Biological|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
3923|NCT00728546|Drug|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
3924|NCT00000700|Drug|Zidovudine|
3925|NCT00005959|Biological|rituximab|
3926|NCT00728559|Drug|bupivacain 0.5%|trocar site injection
3927|NCT00728572|Procedure|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
3928|NCT00728572|Other|Surface EMG|Surface EMG only, no intervention
3929|NCT00728572|Procedure|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
3930|NCT00728585|Biological|palifermin|Given IV
3931|NCT00728585|Other|placebo|Given IV
3932|NCT00728611|Biological|PRGF|intra auricular injection 6mg
3933|NCT00728611|Drug|hyaluronic acid|20 mg / 2 ml
3934|NCT00728611|Drug|placebo|physiological water 3cc + lidocain 3cc
3935|NCT00728637|Behavioral|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
3936|NCT00005959|Drug|cyclophosphamide|
3937|NCT00728637|Behavioral|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
3938|NCT00728663|Biological|cetuximab|Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8
--- for max. 24 weeks or until progression or unacceptable toxicity ---
3939|NCT00728663|Drug|docetaxel|75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle
--- for max. 24 weeks or until progression or unacceptable toxicity ---
3940|NCT00728689|Drug|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
4544|NCT00717236|Other|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
4663|NCT00720109|Drug|Mercaptopurine|Given PO
4664|NCT00720109|Drug|Methotrexate|Given IT, PO, or IV
4665|NCT00720109|Drug|Methylprednisolone|Given IV
4666|NCT00720109|Drug|Pegaspargase|Given IM
4667|NCT00720109|Drug|Prednisone|Given PO or IV
4668|NCT00720109|Radiation|Radiation Therapy|Some patients undergo cranial RT
4669|NCT00005896|Procedure|Autologous Stem Cell Transplantation|
3707|NCT00723203|Genetic|gene expression analysis|Day 1 and day 28 samples
3708|NCT00723203|Genetic|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
3709|NCT00723203|Other|laboratory biomarker analysis|Day 1 and day 28 samples
3710|NCT00005939|Radiation|phosphorus P32|
3711|NCT00723216|Drug|enoxaparin|20 mg twice a day
3712|NCT00723216|Other|Physical prophylaxis|
3713|NCT00723229|Drug|acyclovir|Acyclovir 400 mg PO BID for 28 days
3714|NCT00723242|Drug|Viraferon-peg and Rebetol|
3715|NCT00723255|Biological|bevacizumab|Given IV
3716|NCT00723255|Drug|temsirolimus|Given IV
3717|NCT00723268|Drug|Prednisolone|5MG Prednisolone per day for 3 months
3718|NCT00723268|Drug|Colchicine|0.5 MG Colchicine per day for 3 months
3719|NCT00723294|Procedure|cryosurgery|
3720|NCT00723294|Procedure|therapeutic conventional surgery|
3721|NCT00005940|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
3722|NCT00723307|Drug|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
3723|NCT00723307|Drug|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
4365|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
4366|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
4367|NCT00005870|Drug|rubitecan|
4368|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
4369|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
4370|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
4371|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
4372|NCT00719732|Device|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
4373|NCT00719745|Drug|Prograf|oral
4374|NCT00719745|Drug|MR4|oral
4375|NCT00000693|Drug|Acyclovir|
4376|NCT00005892|Drug|cyclophosphamide|
4377|NCT00719758|Drug|TRK-100STP (BERASUS LA)|oral
4378|NCT00719758|Drug|AST-120 (Kremezin®)|oral
4379|NCT00719771|Device|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
4732|NCT00715143|Device|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
4733|NCT00717574|Device|BIS Monitor|BIS Monitor electrodes placed on forehead
4734|NCT00717574|Device|Entropy Monitor|Entropy monitor electrodes placed to forehead
4735|NCT00717587|Drug|motexafin gadolinium|
4736|NCT00717587|Drug|sunitinib malate|
4737|NCT00717587|Genetic|comparative genomic hybridization|
4738|NCT00717587|Genetic|gene expression analysis|
4739|NCT00717587|Genetic|mutation analysis|
4740|NCT00717587|Genetic|polymorphism analysis|
6776|NCT00766220|Drug|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
6777|NCT00766220|Drug|Cetuximab|400 mg/m2 by vein over 2 hours once a week.
Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions.
6778|NCT00766220|Drug|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
6779|NCT00766233|Other|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
6780|NCT00000725|Drug|Interferon alfa-2a|
6781|NCT00006164|Drug|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
6782|NCT00766246|Drug|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
7042|NCT00764192|Procedure|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
7043|NCT00006146|Biological|Approved influenza virus vaccine.|
7044|NCT00764218|Device|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
7045|NCT00764218|Other|No positive airway pressure treatment|No treatment
7046|NCT00764231|Behavioral|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
7047|NCT00766519|Other|volume optimization|Fluid management:
basal fluid administration = 5 ml/kg/h lactated Ringer's solution
+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery
hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is > 10%
7048|NCT00766519|Other|standard volume administration|Fluid management:
basal fluid administration = 5 ml/kg/h lactated Ringer's solution
hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV
7049|NCT00766532|Drug|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
7050|NCT00766545|Drug|cilostazol|oral tablet 100 mg, twice daily, over 1 year
7051|NCT00766545|Drug|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
7052|NCT00766584|Other|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
6027|NCT00764907|Drug|prednisone|Given intrathecally during reinduction
6028|NCT00764907|Drug|thioguanine|Given orally during reinduction
6029|NCT00764907|Drug|vincristine sulfate|Given IV during reinduction
6030|NCT00764907|Drug|vindesine|Given IV during reinduction
6031|NCT00764920|Device|non-invasive imaging modalities for assessment of skin|skin imaging
6032|NCT00764933|Behavioral|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
6033|NCT00764933|Other|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
6034|NCT00764946|Drug|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
6035|NCT00006154|Drug|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
6036|NCT00764959|Device|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
6037|NCT00767117|Drug|Etravirine; Lopinavir; Ritonavir|
6038|NCT00767156|Other|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
6039|NCT00767156|Other|Base cream|The subjects use the base cream on the face, twice per day
5060|NCT00722722|Drug|Bortezomib|A minimum of four, four-dose cycles (16 doses) and up to eight, four-dose cycles(32 doses) of Velcade(TM) as an intravenous infusion (IV) (through a vein).
5061|NCT00722735|Drug|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
5062|NCT00722735|Drug|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
5063|NCT00722761|Drug|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
5064|NCT00722761|Drug|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
5065|NCT00722774|Biological|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
5549|NCT00716469|Drug|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
5550|NCT00716495|Biological|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
5551|NCT00716508|Procedure|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
5552|NCT00716508|Procedure|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
5553|NCT00716521|Drug|placebo|single oral dose placebo
5554|NCT00005868|Drug|cisplatin|
5555|NCT00719095|Drug|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
5556|NCT00719095|Behavioral|Behavioral therapy|
5557|NCT00719108|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
5558|NCT00719108|Biological|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
5559|NCT00719121|Drug|Talarozole|Topical Application (20 mg)
5880|NCT00769470|Drug|docetaxel|Given IV
5881|NCT00769470|Drug|lapatinib ditosylate|Given orally
5882|NCT00769483|Drug|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
5883|NCT00769483|Drug|Gemcitabine|1000 mg/m^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
5884|NCT00769483|Drug|Erlotinib|100 mg by mouth daily.
5885|NCT00769496|Drug|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
5955|NCT00767065|Radiation|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate <70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
4979|NCT00722540|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
4980|NCT00722540|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
4981|NCT00722540|Drug|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
4982|NCT00722540|Drug|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
4983|NCT00005931|Drug|SU5416|
4984|NCT00722553|Drug|Pralatrexate Injection|Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).
Initial dose: 190 mg/m2
Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.
Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
4985|NCT00722553|Dietary Supplement|Vitamin B12|1 mg intramuscular injection
Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
4986|NCT00722553|Dietary Supplement|Folic Acid|1-1.25 mg orally
Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate.
4987|NCT00722566|Drug|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
4988|NCT00715520|Device|Transcranial magnetic stimulation (TMS)|Subjects will be scheduled for six different sessions using TMS. Applications will include five different stimulation settings and one at no stimulation setting.
4989|NCT00715520|Other|Combined drug treatment and TMS|Data analysis from the healthy adult subjects participating in Specific Aims 1 and 2 will provide the drug/TMS settings to be used in Specific Aim 3 (Stroke subjects)
4990|NCT00715546|Procedure|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
4991|NCT00005866|Drug|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
5316|NCT00720967|Procedure|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs < 75 kg, and 4 hours if > 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
5317|NCT00721006|Biological|MESENDO|40 subcutaneous injections of biological product
5318|NCT00721006|Biological|Placebo|40 subcutaneous injections of placebo
5319|NCT00005908|Drug|Doxorubicin hydrochloride|60 mg/m^2 will be administered as a slow intravenous push on day 1
5320|NCT00721019|Other|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
5321|NCT00721019|Other|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
5322|NCT00721032|Procedure|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
5323|NCT00721032|Drug|Increased dose of amiodarone|Increase the dose of amiodarone according to the following scheme:
current dose -> new dose 100 QD -> 200 QD; 200 QD -> 400 QD; 300 QD -> 600 QD; 400 QD -> 600 QD
5631|NCT00714168|Behavioral|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
5632|NCT00005858|Biological|LMB-9 immunotoxin|
5633|NCT00714168|Behavioral|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
5634|NCT00716521|Drug|zolpidem|single oral dose, 5 mg zolpidem
5635|NCT00716521|Drug|zolpidem|single oral dose, 10 mg zolpidem
5636|NCT00716534|Drug|ABT-869|12.5 mg ABT-869
5637|NCT00716534|Drug|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
5638|NCT00716534|Drug|ABT-869|7.5 mg ABT-869
5639|NCT00716534|Drug|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
5640|NCT00716534|Drug|Paclitaxel|Paclitaxel (200 mg/m2)
5066|NCT00722800|Drug|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
5067|NCT00722800|Drug|Placebo|1 tablet daily for 24 weeks
5068|NCT00722813|Other|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
5069|NCT00005935|Drug|Cyclosporine|
5070|NCT00722839|Biological|PADRE-CMV fusion peptide vaccine|Given subcutaneously
5071|NCT00722839|Biological|tetanus-CMV fusion peptide vaccine|Given subcutaneously
5072|NCT00722839|Drug|agatolimod sodium|Given subcutaneously
5073|NCT00722852|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
5074|NCT00722852|Drug|Placebo|100 mg (b.i.d.)
5075|NCT00722865|Drug|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
5076|NCT00722891|Device|Balafilcon A Lenses with ReNu Multiplus|Balafilcon A lenses using ReNu Multiplus lens solution for 28 days
5077|NCT00722891|Device|Balafilcon A Lenses with Optifree RepleniSH|Balafilcon A lenses using Optifree RepleniSH lens solution for 28 days
5078|NCT00722917|Drug|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
5079|NCT00722917|Drug|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
5080|NCT00005937|Drug|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
5081|NCT00722917|Drug|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
5387|NCT00005889|Drug|alanine|
5388|NCT00718835|Behavioral|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
5389|NCT00718848|Procedure|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
5886|NCT00769509|Other|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
5887|NCT00769509|Other|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
5888|NCT00006195|Drug|olanzapine|
5889|NCT00769522|Biological|rituximab|Given IV
5890|NCT00769522|Drug|bendamustine hydrochloride|Given IV
5891|NCT00769522|Drug|cyclophosphamide|Given IV
5892|NCT00769522|Drug|fludarabine phosphate|Given IV
5893|NCT00769535|Genetic|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
5894|NCT00769548|Drug|flutamide|Drug used for TAS.
5895|NCT00769548|Drug|goserelin acetate|Drug used for TAS.
5896|NCT00769548|Radiation|low-LET photon therapy|radiation therapy
5897|NCT00769561|Behavioral|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
5898|NCT00769561|Device|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
5899|NCT00006196|Drug|Vitamin D|
5900|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
6226|NCT00765297|Device|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
6227|NCT00765310|Dietary Supplement|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
6228|NCT00765310|Dietary Supplement|Placebo|two capsules once daily in morning on empty stomach
6229|NCT00006181|Behavioral|Team-based intervention|
4992|NCT00715559|Drug|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
4993|NCT00715572|Drug|thyroxine|monotherapy with thyroxine
4994|NCT00715572|Drug|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
4995|NCT00715585|Behavioral|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
4996|NCT00715585|Behavioral|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
4997|NCT00715585|Behavioral|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
5307|NCT00718718|Drug|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
5308|NCT00718731|Drug|GSI-136|
5309|NCT00718731|Other|Placebo|
5310|NCT00718744|Other|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
5311|NCT00005888|Behavioral|Preterm Formula supplement|
5312|NCT00718757|Drug|Dexamethasone|5 doses given on Days 6-10
5313|NCT00718757|Drug|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
5314|NCT00720967|Procedure|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
5315|NCT00720967|Procedure|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP >75 mmHg, CVP > 12 mmHg, Htc > 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at ~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
5641|NCT00716547|Drug|ketoprofen in Diractin®|50 mg (b.i.d.)
5642|NCT00716547|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
5643|NCT00716547|Drug|Placebo|b.i.d.
5644|NCT00005868|Drug|docetaxel|
5645|NCT00716547|Drug|celecoxib|100 mg (b.i.d.)
5646|NCT00716573|Drug|everolimus|0,75 mg bid, 24 months
5647|NCT00716586|Drug|dorzolamide|2% dorzolamide- 1 Gtt TID
5648|NCT00716599|Device|training in use of rapid diagnostic tests (RDTs) for malaria|training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
5649|NCT00716612|Drug|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
5650|NCT00716612|Drug|Placebo control|po Placebo QD
5651|NCT00716625|Drug|sunitinib malate|SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.
The dosage may be decreased according to the patient's clinical condition."
5652|NCT00716638|Behavioral|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
5956|NCT00767065|Other|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
5957|NCT00006172|Device|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
5958|NCT00767091|Drug|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
5959|NCT00767091|Drug|placebo|transdermal patch of placebo
5960|NCT00767104|Device|silk-like fabric standard pillowcase|study pillowcases are fabricated from a light-weight plain-weave fabric woven of 100 percent synthetic yarns. The fabric is comprised of approximately 50% polyester and 50% nylon. The yarns in the fabric are formed from continuous-filament fibers, with no fibers projecting beyond the planar surface of the fabric. The antimicrobial technology used in the fabric is incorporated into the fibers during the finishing process and does not migrate out of the fabric or cause adverse reactions with skin contact. PAtient will sleep on this pillowcase every night for 12 weeks.
5961|NCT00767104|Device|pillowcase made of 100% cotton|pillowcase made of 100% cotton, sleep on this pillowcase every night for 12 weeks
5962|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
5390|NCT00718848|Procedure|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
5391|NCT00718861|Drug|Placebo|
5392|NCT00718861|Drug|Zoledronic acid|
5393|NCT00718874|Other|Dietary|modification of macronutrient content
5394|NCT00718887|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
5395|NCT00718887|Drug|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
5396|NCT00718913|Drug|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
5397|NCT00718913|Drug|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
5398|NCT00005889|Drug|amino acids|
5399|NCT00718913|Drug|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
5400|NCT00718913|Radiation|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
5401|NCT00721071|Drug|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
5402|NCT00721097|Other|spirometry, and blood taken|each month during one year
5403|NCT00721110|Drug|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
5404|NCT00721110|Drug|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
5717|NCT00771459|Drug|Isotonic NaCl|Local infiltration analgesia
5718|NCT00771472|Drug|vorinostat|Parts I & II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
5719|NCT00771485|Drug|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
6230|NCT00767520|Drug|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
6231|NCT00767520|Drug|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
6232|NCT00767546|Drug|Botulinum toxin|60- 100 units Local injection to the rash area
6233|NCT00767559|Drug|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
6234|NCT00767559|Drug|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
6235|NCT00767559|Drug|warfarin|Fixed Low Dose warfarin
1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery.
6236|NCT00767572|Drug|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
6237|NCT00767572|Drug|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
6238|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
6239|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
6240|NCT00006181|Behavioral|One-on-one intervention|
6241|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
6242|NCT00767624|Drug|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
6243|NCT00767624|Behavioral|Desensitization Therapy for Insomnia|
6244|NCT00767624|Behavioral|Cognitive Behavioral Therapy for Insomnia|
6245|NCT00767637|Drug|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
6246|NCT00767663|Drug|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
6247|NCT00767663|Drug|placebo|placebo twice daily, minimal three days pretreatment
5241|NCT00713492|Drug|Alcohol|
5242|NCT00713492|Procedure|Self-Administration|
6718|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
6719|NCT00768573|Drug|sildenafil|Oral suspension of sildenafil.
6720|NCT00768599|Drug|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
6721|NCT00768599|Drug|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
6722|NCT00768599|Drug|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
6723|NCT00768612|Drug|SCA-136 50mg/day|
6724|NCT00768612|Drug|SCA-136 150 mg/day|
6725|NCT00768612|Drug|SCA-136 300mg/day|
6726|NCT00768612|Drug|Risperidone 4mg/day|
6975|NCT00768911|Drug|CT-322|Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week
Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week
6976|NCT00768911|Drug|Temozolomide|75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)
150 mg/M2/day X 5 days; adjuvant cycle #1
200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met
6977|NCT00768911|Procedure|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
6978|NCT00006185|Drug|Avandia administration for 6-12 weeks|
6979|NCT00768937|Drug|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
6980|NCT00768937|Procedure|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
6981|NCT00768950|Procedure|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
6982|NCT00768950|Procedure|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
6983|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
6984|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
6985|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
5963|NCT00769587|Drug|thalidomide|
5964|NCT00769600|Drug|Itraconazole|Itraconazole 200 mg once daily
5965|NCT00769613|Biological|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
5966|NCT00769613|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
5967|NCT00769613|Biological|therapeutic allogeneic lymphocytes|
5968|NCT00769613|Genetic|polymerase chain reaction|
5969|NCT00769613|Other|flow cytometry|
5970|NCT00769613|Other|immunological diagnostic method|
5971|NCT00006198|Drug|thalidomide|
5972|NCT00769613|Other|laboratory biomarker analysis|
5973|NCT00769626|Other|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
5974|NCT00769626|Other|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
4998|NCT00715611|Procedure|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
4999|NCT00715611|Drug|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes.
5000|NCT00715611|Radiation|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
5001|NCT00715624|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
5002|NCT00005866|Drug|cyclosporine|both arms per published schedule
5003|NCT00715624|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
5004|NCT00715624|Drug|Basal Insulin|Dose to be kept stable.
7053|NCT00766597|Drug|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
7054|NCT00766623|Dietary Supplement|high fat meal|milkshake containing 95g fat
7055|NCT00766623|Dietary Supplement|control meal|milkshake comparable with a normal breakfast
7056|NCT00006168|Drug|Methotrexate|
7057|NCT00766636|Drug|Gemcitabine|Arm A:
1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.
Arm B:
400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.
7058|NCT00766636|Radiation|Radiation Therapy|1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.
7059|NCT00766636|Drug|Erlotinib|100 mg daily by mouth on days 1-42.
7060|NCT00766636|Procedure|Surgery|Surgical removal of the pancreas and duodenum
7061|NCT00766649|Drug|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
7426|NCT00736463|Drug|Simvastatin|One arm of randomized crossover
7427|NCT00736463|Drug|Atorvastatin 80 mg|Second arm of randomized crossover
7428|NCT00736476|Biological|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
7429|NCT00736476|Biological|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
7430|NCT00005987|Procedure|radiation therapy|
7431|NCT00736489|Drug|AZD3199|Dry powder for inhalation, single dose
7432|NCT00736489|Drug|Formoterol|Dry powder for inhalation, single dose
7433|NCT00736489|Drug|Placebo|Dry powder for inhalation, single dose
7434|NCT00736515|Drug|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
7435|NCT00736515|Drug|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
7436|NCT00736528|Drug|PF-04447943|05 mg BID for 14 days
7437|NCT00736528|Drug|PF-04447943|15 mg BID for 14 days
5243|NCT00713505|Other|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
5244|NCT00713505|Procedure|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
5245|NCT00713518|Drug|0.5 mg ranibizumab|
5246|NCT00713518|Drug|3 mg PF-04523655|
5247|NCT00713518|Drug|1 mg PF-04523655|
5248|NCT00005854|Procedure|allogeneic bone marrow transplantation|
5249|NCT00713544|Drug|AZD5672|20 mg oral, once daily
5250|NCT00713544|Drug|Etanercept|50 mg, subcutaneous injection, weekly
5251|NCT00713544|Drug|Placebo|placebo, oral, once daily
5252|NCT00713544|Drug|AZD5672|50 mg oral, once daily
5253|NCT00713544|Drug|AZD5672|100 mg oral, once daily
5254|NCT00713544|Drug|AZD5672|150 mg oral, once daily
5255|NCT00713557|Device|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
5256|NCT00713557|Drug|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
5257|NCT00713583|Drug|levodopa|800/200 mg/d levodopa carbidopa
5258|NCT00713583|Drug|Placebo|Placebo
5259|NCT00000689|Drug|Cytarabine|
5260|NCT00005854|Procedure|in vitro-treated bone marrow transplantation|
5261|NCT00713596|Drug|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
5262|NCT00713596|Procedure|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
5263|NCT00713596|Procedure|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
5264|NCT00715858|Drug|rifampin|capsule, 300 mg, od, 12 months
6986|NCT00768989|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
6987|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
6988|NCT00768989|Drug|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
6989|NCT00006186|Procedure|Autologous fresh whole blood|
6990|NCT00768989|Drug|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
6991|NCT00769002|Biological|FluShield, FluMist|Flu vaccine
6992|NCT00769015|Behavioral|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
6993|NCT00771004|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
6994|NCT00006211|Drug|Capravirine|
6995|NCT00771004|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
7361|NCT00739336|Behavioral|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
7362|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
7363|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
7364|NCT00739349|Drug|NOVA22007|Vehicle
7365|NCT00739362|Behavioral|Behavioral Weight Loss Treatment|
7366|NCT00741585|Drug|Any antihypertensive medication alone or in combination|All drugs on awakening
7367|NCT00741585|Drug|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
7368|NCT00741585|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
7369|NCT00741598|Drug|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
7370|NCT00741598|Drug|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
7371|NCT00006012|Drug|topotecan hydrochloride|
5005|NCT00715624|Drug|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
5006|NCT00715624|Device|Pen auto-injector|
5007|NCT00715637|Drug|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
5008|NCT00715637|Drug|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
5009|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
5010|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
5011|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
5012|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
5013|NCT00718081|Drug|Oral sufentanil|Oral dosage of sufentanil
5014|NCT00718081|Drug|Placebo|Oral dosage of placebo
5015|NCT00718094|Drug|Polyphenon E®|Oral capsules
5016|NCT00005882|Drug|eflornithine plus sulindac|Patients will be randomized to 36 months of treatment with either DFMO+sulindac or placebo.
5324|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
5325|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
5326|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
5327|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
5328|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
5329|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
5330|NCT00005908|Drug|Tamoxifen Citrate|20 mg/day orally for five years
7438|NCT00736528|Drug|PF-04447943|45mg BID for 14 days
7439|NCT00736528|Drug|Placebo|Placebo for 14 days
7440|NCT00736541|Drug|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
7441|NCT00005988|Drug|cyclophosphamide|
7442|NCT00736580|Other|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
7443|NCT00736580|Other|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
7444|NCT00739362|Procedure|Transcranial Direct Current Stimulation (TDCS)|
7445|NCT00739362|Device|Transcranial Direct Current Stimulation (TDCS)|
7446|NCT00739362|Behavioral|Appetite Control|
7447|NCT00739362|Procedure|Appetite Control|
7448|NCT00005999|Drug|arsenic trioxide|
7449|NCT00739362|Device|Weight Control|
7450|NCT00739362|Behavioral|Weight Loss|
6483|NCT00772590|Other|raltegravir placebo|One tablet, twice daily
6484|NCT00772590|Other|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
6485|NCT00000728|Drug|Zidovudine|
6486|NCT00006222|Drug|cilengitide|
6487|NCT00772590|Drug|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
6488|NCT00772603|Drug|Placebo|Non-active tablet identical to study drug tablets
6489|NCT00772603|Drug|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
6490|NCT00772603|Drug|1200mg SPN-804|two active tablets and two non-active tablets, all identical
6491|NCT00772616|Drug|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
6492|NCT00772616|Drug|Sufentanil|dosage according to usual criteria
5265|NCT00715858|Drug|placebo|placebo matched to rifampin; placebo matched to doxycycline
5560|NCT00719121|Drug|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
5561|NCT00719134|Drug|Maxalt|anti-migraine drug
5562|NCT00005889|Drug|glutamine|
5563|NCT00719134|Drug|placebo pill|placebo pills
5564|NCT00719134|Drug|placebo pills|placebo pills
5565|NCT00719147|Procedure|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
5566|NCT00719147|Other|Functional Status and Symptom Questionnaire|Questionnaire
5567|NCT00719160|Drug|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
5568|NCT00719160|Drug|Placebo|Placebo 20 mg twice a day for 9 days
5569|NCT00719173|Drug|aprepitant|Given orally
5570|NCT00719173|Drug|cyclophosphamide|Given IV
5571|NCT00719173|Other|placebo|Given orally
5572|NCT00719186|Drug|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
5573|NCT00005889|Drug|glycerol|
5574|NCT00719186|Drug|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
5575|NCT00719199|Drug|IMO-2055|SC weekly injections
5576|NCT00719199|Drug|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
5577|NCT00719199|Drug|FOLFIRI|Given day 1 of each cycle
5578|NCT00719212|Biological|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
5579|NCT00719225|Drug|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
5580|NCT00719238|Behavioral|Nutrition plus education|Nutritional instruction in small groups plus education
5581|NCT00719238|Behavioral|Education only|Educational video and pamphlets
7372|NCT00741611|Device|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
7373|NCT00741611|Drug|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
7374|NCT00741624|Other|Bandage|one application for one week
7375|NCT00741637|Biological|CholeraGarde®|Live attenuated oral Cholera vaccine
Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials
7376|NCT00741637|Biological|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
7377|NCT00741650|Behavioral|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
7378|NCT00741650|Behavioral|Information, peer advisor and fast referral|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.
In addition,
7379|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
6427|NCT00765648|Drug|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
6428|NCT00765661|Drug|Tacrolimus (Tacro™)|The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
Other Names:
Tacrolimus modified-release
6429|NCT00767962|Other|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
6430|NCT00767962|Other|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
6431|NCT00767975|Drug|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
6432|NCT00767975|Drug|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
6433|NCT00006184|Drug|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
5331|NCT00721058|Other|CT-scan|A pre-operative CT-scan will be made
5332|NCT00713596|Procedure|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
5333|NCT00713596|Other|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
5334|NCT00713609|Drug|Benzoyl peroxide/clindamycin gel + tazarotene cream|clindamycin phosphate, benzoyl peroxide,and/or tazarotene cream applied topically once a day for 12 weeks
5335|NCT00713609|Drug|Benzoyl peroxide/clindamycin gel + vehicle cream|clindamycin phosphate, benzoyl peroxide, vehicle cream applied topically once a day for 12 weeks
5336|NCT00713609|Drug|Benzoyl peroxide gel + tazarotene cream|benzoyl peroxide, tazarotene cream applied topically once a day for 12 weeks
5337|NCT00713609|Drug|Clindamycin gel + tazarotene cream|clindamycin gel and tazarotene cream applied topically once a day for 12 weeks
5338|NCT00713609|Drug|Vehicle gel+ tazarotene cream|Vehicle gel and tazarotene cream applied topically once a day for 12 weeks
5339|NCT00005854|Radiation|radiation therapy|
5340|NCT00713609|Drug|Vehicle gel + vehicle cream|Vehicle gel and vehicle cream applied topically once a day for 12 weeks
5341|NCT00713622|Drug|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
5342|NCT00713622|Drug|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
5343|NCT00713648|Drug|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
5344|NCT00713661|Drug|TachoSil®|Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.
Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy.
5653|NCT00716638|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
5654|NCT00716651|Drug|mepolizumab|750 mg mepolizumab iv q4wk until week 32
5655|NCT00005869|Drug|gemcitabine hydrochloride|
5656|NCT00716664|Other|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
5657|NCT00716664|Other|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
6493|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
6494|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
6495|NCT00772655|Drug|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 [if platelets are below 150000/µl only 11 MBq/kg are administered).
6496|NCT00772655|Drug|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
6497|NCT00006223|Biological|recombinant flt3 ligand|
6498|NCT00772668|Drug|Rituximab|375 mg/m2 IV infusion at 50 mg/hr on Day 1 of every 21 days cycle for 8 cycles
6499|NCT00765661|Drug|Prograf|Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
Other name: tacrolimus
6500|NCT00765674|Drug|Aliskiren|150 and 300 mg tablets
6501|NCT00765674|Drug|Amlodipine|5 and 10 mg capsules
6502|NCT00765674|Drug|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
6503|NCT00765674|Drug|Placebo|tablet
6783|NCT00766246|Drug|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
6784|NCT00766246|Drug|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
6785|NCT00766272|Device|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
6786|NCT00766285|Biological|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
6787|NCT00766285|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
5582|NCT00721409|Drug|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
5583|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
5584|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
5901|NCT00771706|Drug|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
5902|NCT00771706|Drug|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
5903|NCT00771719|Drug|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
5904|NCT00771732|Device|light therapy|6 minute light therapy
5905|NCT00771732|Device|light therapy|combination of wavelengths
5906|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
5907|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
5908|NCT00771758|Drug|oxycodone IR|maximum daily dose 450 mg
5909|NCT00006214|Other|placebo|
5910|NCT00771758|Drug|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
5911|NCT00771758|Drug|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
5912|NCT00771771|Other|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
5913|NCT00771771|Other|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
5914|NCT00771797|Dietary Supplement|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
5915|NCT00771797|Dietary Supplement|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
5916|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 100 ug/kg
5917|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 300 ug/kg
5918|NCT00771810|Drug|Placebo|Once daily subcutaneous injection of placebo
6434|NCT00767988|Dietary Supplement|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
6435|NCT00767988|Other|Placebo|Capsule once daily at approximately the same time each day for 6 months.
6436|NCT00768040|Drug|Aliskiren|300 mg once daily
6437|NCT00768040|Drug|Placebo|Matching placebo once daily
6438|NCT00768053|Drug|Etanercept|Etanercept 50 mg once a week
6439|NCT00768066|Biological|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
6440|NCT00768066|Biological|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
6441|NCT00768066|Biological|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
6442|NCT00768079|Biological|MEDI-563|0.3 mg/kg IV MEDI-563 on Study Day 0
6443|NCT00768079|Biological|MEDI-563|1.0 mg/kg IV MEDI-563 on Study Day 0
6727|NCT00000726|Drug|Foscarnet sodium|
6728|NCT00006184|Drug|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m^2 day continuous intravenous days 1-3
6729|NCT00768638|Drug|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
6730|NCT00770640|Drug|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
6731|NCT00770653|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
6732|NCT00006207|Drug|PRO 2000|
6733|NCT00770653|Drug|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
6734|NCT00770666|Drug|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
5658|NCT00716690|Procedure|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
5659|NCT00716703|Other|CT Scan using IV contrast alone|CT scan using IV contrast alone
5660|NCT00716716|Drug|rFIXFc|As specified in the treatment arm
5661|NCT00716742|Drug|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
5662|NCT00719251|Device|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
5663|NCT00719251|Device|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
5664|NCT00005889|Drug|insulin|
5665|NCT00719251|Other|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
5666|NCT00719264|Drug|RAD001(everolimus)|10 mg qd
5667|NCT00719264|Drug|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
5668|NCT00719264|Drug|bevacizumab|10 mg/kg every 2 weeks
5669|NCT00719277|Device|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
5670|NCT00719290|Procedure|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
5975|NCT00769652|Behavioral|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
5976|NCT00769652|Behavioral|Standard Care|Standard nutritional care includes the National Cancer Institute's booklet "Eating Hints for cancer patients: before, during & after treatment".
5977|NCT00769665|Other|Systane Ultra|Re-wetting ocular eye drop
6788|NCT00766298|Behavioral|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
6789|NCT00766298|Behavioral|Weight Loss|The reduction of kcal/day through implementation of low fat diet
6790|NCT00766298|Behavioral|Exercise and weight loss|Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.
Weight Loss: Reduction of kcal/day through implementation of a low fat diet.
6791|NCT00768638|Drug|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
6792|NCT00768651|Drug|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
6793|NCT00768651|Drug|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
6794|NCT00768664|Drug|PF-00299804|45 mg by continuous oral dosing
6795|NCT00768677|Drug|topiramate|
6796|NCT00768690|Drug|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
6797|NCT00768690|Drug|ketoconazole|Tablet, see arms for intervention description
6798|NCT00768690|Drug|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
6799|NCT00768703|Device|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
6800|NCT00006184|Drug|Methotrexate|Transplant: 5 mg/m^2 intravenous on days +1, +3, +6, +11
6801|NCT00768716|Drug|Acetaminophen|2 x 500 mg oral once
7062|NCT00766662|Drug|Sulfadoxine pyrimethamine|
7063|NCT00766675|Drug|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
7064|NCT00766675|Drug|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
7065|NCT00766688|Drug|AVE5530|one tablet in the evening with dinner
in addition to high doses of statin treatment
5919|NCT00771823|Drug|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
5920|NCT00006215|Biological|filgrastim|
5921|NCT00771823|Drug|Maraviroc|Placebo twice daily for the first 14 days of the study.
Maraviroc 300 mg twice daily for the last 14 days of the study.
5922|NCT00771849|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
5923|NCT00771849|Biological|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
4933|NCT00005881|Other|Quality of Life Forms|Completion of the instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
4934|NCT00717990|Drug|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
4935|NCT00717990|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
4936|NCT00717990|Drug|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
4937|NCT00720434|Drug|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
4938|NCT00720434|Drug|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
4939|NCT00005898|Drug|methylprednisolone|
4940|NCT00720434|Drug|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
4941|NCT00720434|Drug|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
4942|NCT00720447|Biological|alemtuzumab|
4943|NCT00720447|Biological|donor lymphocytes|
4944|NCT00720447|Drug|carmustine|
4945|NCT00720447|Drug|cytarabine|
4946|NCT00720447|Drug|etoposide|
4947|NCT00720447|Drug|melphalan|
4948|NCT00720447|Procedure|allogeneic bone marrow transplantation|
6735|NCT00770666|Drug|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
6736|NCT00770679|Drug|lipitor|80 mg everyday (QD) for 3 weeks
6737|NCT00770692|Drug|Eszopiclone 1 mg- Elderly|Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
6738|NCT00770692|Drug|Eszopiclone 2 mg- Elderly|Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
6739|NCT00770692|Drug|Eszopiclone 3 mg- Non-elderly|Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
6740|NCT00770692|Drug|Eszopiclone 2 mg- Non-elderly|Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
6741|NCT00770705|Drug|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
6742|NCT00770705|Other|Standard surgical approach|Historical controls
6743|NCT00006208|Drug|Efavirenz|
6996|NCT00771017|Biological|GVAX prostate cancer vaccine|Given intradermally
6997|NCT00771017|Drug|bicalutamide|Given orally
6998|NCT00771017|Drug|goserelin|Given intramuscularly
6999|NCT00771017|Drug|leuprolide acetate|Given intramuscularly
7000|NCT00771030|Drug|AMG 827|Five treatment dose levels plus placebo
7001|NCT00771043|Drug|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
7002|NCT00771056|Drug|Hydroxychloroquine|400mg by mouth daily x 1 year
7003|NCT00771095|Behavioral|podcasting|
7004|NCT00771108|Behavioral|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
7005|NCT00006211|Drug|Nelfinavir mesylate|
5978|NCT00769665|Other|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
5979|NCT00769678|Device|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
5980|NCT00769704|Biological|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
5981|NCT00769704|Biological|GM-CSF|125 µg/m² subcutaneous injection
5982|NCT00006198|Procedure|chemoembolization with doxorubicin/collagen|
5983|NCT00769717|Behavioral|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
5984|NCT00771875|Drug|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
5985|NCT00771875|Drug|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
5986|NCT00771875|Drug|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
5987|NCT00771875|Drug|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
5988|NCT00771875|Drug|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
5989|NCT00000727|Drug|Zidovudine|
5990|NCT00006215|Drug|docetaxel|
5991|NCT00771888|Drug|lanreotide|lanreotide
5992|NCT00771901|Drug|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
5993|NCT00771901|Other|placebo|7 pills daily for 4 weeks
5017|NCT00718120|Biological|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
5018|NCT00718133|Device|Spirometry (Pony spirometer)|Spirometry at rest
7066|NCT00766688|Drug|Placebo|one tablet in the evening with dinner
in addition to high doses of statin treatment
7067|NCT00006169|Behavioral|Behavioral Treatment|
7068|NCT00766701|Procedure|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
7069|NCT00766714|Device|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
7070|NCT00766714|Device|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
7071|NCT00769015|Behavioral|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
7072|NCT00769028|Drug|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
7073|NCT00769028|Drug|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
7074|NCT00769041|Drug|moxifloxacin|400mg
7075|NCT00769041|Drug|avanafil|100mg single dose
7076|NCT00769041|Drug|avanafil|800mg single dose
7077|NCT00769041|Drug|sugar pill|single dose
7078|NCT00006187|Drug|Investigational drug|
7079|NCT00769054|Drug|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
7080|NCT00769054|Drug|Isotonic NaCl|Local Infiltration with NaCl
7081|NCT00769067|Drug|Erlotinib|Continuous oral dosing at 150 mg daily.
7082|NCT00769067|Drug|PF-00299804|Continuous oral dosing at 45mg daily
7083|NCT00769093|Drug|Ferumoxytol|2 mg/kg
7084|NCT00769106|Biological|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
7085|NCT00769119|Drug|AZD9668|2 x 30 mg, oral tablet, twice daily for 28 days
7451|NCT00739375|Procedure|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
7452|NCT00739388|Drug|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
4949|NCT00720447|Procedure|peripheral blood stem cell transplantation|
4950|NCT00005901|Drug|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
4951|NCT00720473|Drug|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
4952|NCT00720486|Behavioral|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
4953|NCT00720486|Behavioral|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
4954|NCT00720499|Drug|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
5266|NCT00715871|Drug|Nicotine|Subjects received an amount of "liquid nicotine cigarettes" (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of "liquid nicotine cigarettes" received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study.
5267|NCT00715871|Device|Smoke-Break nicotine delivery device|The Smoke-Break nicotine delivery device is a "liquid nicotine cigarette" designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive.
5268|NCT00715884|Device|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
5269|NCT00715884|Device|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
5270|NCT00715897|Procedure|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
5271|NCT00715910|Biological|Nimenrix|One dose, as intramuscular injection
5272|NCT00715910|Procedure|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
5273|NCT00715923|Other|Modified consent form|modified consent form used
5274|NCT00000689|Drug|Dexamethasone|
5275|NCT00005867|Drug|CHOP regimen|
5276|NCT00715923|Other|Standard consent form|standard consent form used
5277|NCT00715936|Behavioral|Health Education|Health Education on Hygiene, Primary Health Care.
7006|NCT00771121|Drug|urea/lactic acid|new emulsion type
7007|NCT00771121|Drug|Placebo|only emulsion base
7008|NCT00771134|Drug|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
7009|NCT00771134|Drug|Placebo|B.I.D. for 8 weeks
7010|NCT00771134|Drug|Quetiapine|300mg/day for 8 weeks
7011|NCT00771147|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
7012|NCT00771160|Drug|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
7013|NCT00771173|Drug|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
7014|NCT00771173|Other|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
7015|NCT00771199|Drug|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
7016|NCT00000727|Drug|Sulfadoxine/Pyrimethamine|
7017|NCT00006212|Drug|cisplatin|
7018|NCT00771212|Other|Observational pain control study|Observational pain control study
7019|NCT00771225|Procedure|fascial repair|surgery to treat genital prolapse with fascia repair
7020|NCT00771225|Procedure|mesh repair|surgery to genital prolapse with mesh
7380|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
7381|NCT00741676|Procedure|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
7382|NCT00006012|Radiation|radiation therapy|
5019|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
5020|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
5021|NCT00718159|Drug|LY573636-sodium|Individualized dose is dependent on patient's height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for AML and Day 1 of a 28-day cycle for ET for at least one cycle. A patient may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
5022|NCT00718172|Procedure|Liver Biopsy|
5023|NCT00718172|Drug|Peginterferon & amp; Ribavirin for Hepatitis C|
5024|NCT00718172|Drug|Pre-treatment Ribavirin|
5025|NCT00718185|Procedure|Obtain blood specimens|Obtain blood samples at multiple timepoints.
5026|NCT00718224|Drug|Semuloparin sodium|0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe
Subcutaneous injection
5027|NCT00005883|Drug|phenethyl isothiocyanate|
5028|NCT00718224|Drug|Enoxaparin|0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe
Subcutaneous injection
5029|NCT00718224|Drug|Placebo|0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component
Subcutaneous injection
5030|NCT00718237|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
5031|NCT00718237|Biological|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
5032|NCT00718250|Biological|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
5033|NCT00720564|Drug|arsenic trioxide|
5034|NCT00720564|Drug|temozolomide|
5035|NCT00720564|Procedure|adjuvant therapy|
5036|NCT00720564|Radiation|intensity-modulated radiation therapy|
5037|NCT00720564|Radiation|radiation therapy|
5038|NCT00720577|Drug|Simvastatin|40 Mg. tablet, 1 tablet daily
5039|NCT00720577|Drug|Losartan|50 mg., tablets, 1 tablet once daily
5040|NCT00005905|Drug|hu Leptin (A-100)|
7453|NCT00739401|Device|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
7454|NCT00739414|Drug|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
7455|NCT00739440|Biological|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
7456|NCT00739453|Drug|OSI-906|administered orally
7457|NCT00739453|Drug|erlotinib|administered orally
7458|NCT00739466|Drug|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
7459|NCT00000180|Drug|AIT-082|
7460|NCT00000706|Drug|Quinine sulfate|
7461|NCT00006000|Drug|cisplatin|
7462|NCT00739466|Drug|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
7463|NCT00739466|Drug|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
7464|NCT00739479|Dietary Supplement|Weight Loss|Participants will reduce their total dietary intake by ~800 kcal/day. ~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of ~700 kcal/day.
7465|NCT00739492|Behavioral|financial incentives|financial incentives based on attaining weight loss goals
7466|NCT00739505|Biological|Asfotase Alfa|The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:
Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC.
7467|NCT00739505|Biological|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
7468|NCT00739518|Procedure|MRI|Neurological MRI with new technology evaluation
7469|NCT00739531|Device|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
7470|NCT00741702|Other|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP >=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP>=13/80 mm Hg, increase verapamil to 240 mg/d
5278|NCT00715936|Behavioral|Early Child Development|Responsive parenting education, responsive feeding, psychosocial stimulation activities.
5279|NCT00715936|Behavioral|Enhanced Nutrition Education|Nutrition messages for pregnant women, newborns and infants and delivery of Sprinkles for Infants 6-24months
5280|NCT00715949|Other|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
5281|NCT00715962|Behavioral|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
5282|NCT00715962|Other|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
5283|NCT00715962|Other|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
5284|NCT00715975|Drug|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
5585|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
5586|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
5587|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
5588|NCT00005916|Drug|rV-PSA|
5589|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
5590|NCT00721435|Procedure|Tomosynthesis and ultrasound imaging|3D and ultrasound imaging for breast abnormalities and masses
5591|NCT00721448|Drug|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
5592|NCT00721448|Drug|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
5593|NCT00721461|Biological|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
5594|NCT00721474|Drug|Bosutinib|Bosutinib fasting
5595|NCT00721474|Drug|Bosutinib|Bosutinib fed
5596|NCT00721487|Drug|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
7383|NCT00741676|Procedure|open distal gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
7384|NCT00741689|Drug|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
7385|NCT00734214|Drug|0.45%NaCl|Intravenous Fluid
Hypotonic Parenteral Fluid
7386|NCT00734227|Procedure|Emergency portacaval shunt|
7387|NCT00005982|Other|pharmacological study|Correlative studies
7388|NCT00734227|Other|Emergency TIPS|
7389|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, single dose
7390|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
7391|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, single dose
7392|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
7393|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
7394|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, single dose
7395|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, single dose
7396|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, single dose
7397|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, single-dose
7398|NCT00000703|Drug|Methotrexate|
7399|NCT00005983|Radiation|radiation therapy|
7400|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
6444|NCT00006184|Drug|Bortezomib|Induction chemotherapy: 1.3 mg/m^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
6445|NCT00768079|Other|Placebo|Placebo on Study Day 0 (3mL vials filled with 1.2 mL solution of 10mM histidine, 300 mM glycine, 0.02% polysorbate 20, pH 6.0.)
6446|NCT00768105|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
5345|NCT00713674|Other|Theraworx|Theraworx swab intranasal BID for 5 days
5346|NCT00713674|Drug|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
5347|NCT00713687|Drug|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|Photodynamic therapy (PDT) after successful drainage:
Photosan® 2 mg/kg i.v. 48 hrs before laser activation
9 cycles of GemOx chemotherapy (start 4 weeks after PDT):
Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy
Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy
iteration every 14 days
afterwards 4 weeks intermission
Iteration of 1. and 2. in case of good compatibility
5348|NCT00713700|Device|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
5349|NCT00713713|Procedure|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
5350|NCT00005855|Drug|carmustine|
5351|NCT00713726|Drug|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
5352|NCT00713726|Drug|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
5353|NCT00715988|Drug|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution)
5354|NCT00715988|Drug|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
5355|NCT00716001|Drug|N-acetylcysteine|
5356|NCT00716014|Drug|TD101|TD101 is injection into a callus on the bottom of one of the patient's feet
5357|NCT00716014|Drug|Normal saline (placebo)|A normal saline solution (placebo) is injected into one of the patient's feet.
5358|NCT00716027|Behavioral|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
5359|NCT00716027|Behavioral|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
5360|NCT00716040|Behavioral|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
5361|NCT00716040|Other|Usual care|The control group will be submitted to the usual care of the health service
6504|NCT00765674|Drug|Placebo|capsules
6505|NCT00006160|Behavioral|home based worker|
6506|NCT00765687|Drug|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
6507|NCT00765700|Drug|Topical Ketoprofen 10% Cream|Topical Administration
6508|NCT00765700|Drug|Topical Placebo Cream|Topical Administration
6509|NCT00765713|Device|Nasal continuous positive airway pressure|Nocturnal
6510|NCT00765726|Biological|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
6511|NCT00765726|Procedure|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
6512|NCT00765739|Other|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
6513|NCT00765739|Other|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
6514|NCT00765765|Drug|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
6515|NCT00765765|Drug|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
6516|NCT00006161|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
6517|NCT00765791|Procedure|Selective Neck Dissection Including Level IIB|Level IIB is dissected
6518|NCT00765791|Procedure|Selective Neck Dissection Excluding Level IIB|Level IIB is not dissected
6519|NCT00765804|Drug|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
6520|NCT00765804|Drug|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
6521|NCT00765817|Drug|placebo|subcutaneous injection, twice a day
6522|NCT00765817|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
6523|NCT00765830|Drug|vildagliptin|50mg qd
6524|NCT00765830|Drug|Placebo|qd
5597|NCT00721500|Device|etafilcon A|contact lens
5598|NCT00721500|Device|narafilcon A|contact lens
5599|NCT00000694|Drug|Sargramostim|
5600|NCT00005916|Drug|rF-PSA|
5601|NCT00721513|Biological|cetuximab|
5602|NCT00721513|Drug|cisplatin|
5603|NCT00721513|Drug|docetaxel|
5604|NCT00721513|Drug|fluorouracil|
5605|NCT00721513|Procedure|computed tomography|
5606|NCT00721513|Procedure|positron emission tomography|
5607|NCT00721513|Procedure|quality-of-life assessment|
5608|NCT00721513|Radiation|3-dimensional conformal radiation therapy|
5609|NCT00721513|Radiation|intensity-modulated radiation therapy|
5610|NCT00721526|Drug|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
5924|NCT00771862|Procedure|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
5925|NCT00771875|Drug|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
5926|NCT00000724|Drug|Trimetrexate glucuronate|
5927|NCT00006154|Drug|Ritonavir|100 mg liquid capsules equaling 400 mg daily
5928|NCT00764725|Biological|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
5929|NCT00764738|Device|OCT, Multifocal ERG, Microperimetry|OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.
Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.
Multifocal ERG done at the same monthly visits as the microperimetry.
5930|NCT00764751|Drug|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
5931|NCT00764751|Drug|Dovonex® cream|Twice daily application
6447|NCT00768105|Drug|Placebo|Dosing to match AZD1656
6448|NCT00768118|Dietary Supplement|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
6449|NCT00768118|Genetic|electrophoretic mobility shift assay|
6450|NCT00768118|Other|laboratory biomarker analysis|
6451|NCT00768131|Drug|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
6452|NCT00770328|Drug|Pentoxifylline|400mg PO TID x 8 weeks
6453|NCT00770328|Drug|Placebo|PO TID x 8 weeks
6454|NCT00770341|Drug|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
6455|NCT00770341|Drug|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
6456|NCT00006205|Drug|ondansetron + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d)
6457|NCT00770341|Drug|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
6458|NCT00770354|Drug|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
6459|NCT00770354|Drug|Letrozole|Daily 2.5 mg oral letrozole tablet
6460|NCT00770367|Drug|Pioglitazone then Placebo|Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
6461|NCT00770367|Drug|Placebo then Pioglitazone|Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
6462|NCT00770380|Behavioral|behavior relapse prevention counseling|two one-hour sessions
6463|NCT00770380|Other|hypnosis|two one-hour sessions
6744|NCT00770718|Drug|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
5362|NCT00716053|Drug|BLVR|BLVR 20 mL
5363|NCT00005867|Drug|doxorubicin hydrochloride|
5671|NCT00719290|Procedure|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
5672|NCT00719303|Behavioral|Behavioral Dietary Intervention|Receive dietary intervention
5673|NCT00719303|Behavioral|Compliance Monitoring|Complete daily fat gram and step diaries
5674|NCT00719303|Other|Counseling|Undergo face-to-face and telephone counseling
5675|NCT00005889|Drug|leucine|
5676|NCT00719303|Other|Educational Intervention|Receive educational materials
5677|NCT00719303|Behavioral|Exercise Intervention|Undergo physical activity intervention
5678|NCT00719303|Other|Laboratory Biomarker Analysis|Correlative studies
5679|NCT00719303|Other|Quality-of-Life Assessment|Ancillary studies
5680|NCT00719303|Other|Questionnaire Administration|Ancillary studies
5681|NCT00719316|Drug|Aliskiren|Aliskiren 300mg per day for 6 weeks
5682|NCT00719329|Drug|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
5683|NCT00719329|Behavioral|Dry Cord Care|Educational messages regarding clean cord care
5684|NCT00719342|Drug|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
5685|NCT00769210|Drug|Simvastatin|Simvastatin 40 mg tablet
5686|NCT00769223|Other|medical chart review|
5687|NCT00769223|Other|questionnaire administration|
5688|NCT00769223|Procedure|quality-of-life assessment|
5689|NCT00769223|Radiation|brachytherapy|
5690|NCT00769223|Radiation|radiation therapy|
5691|NCT00769236|Other|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
6525|NCT00768131|Drug|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
6526|NCT00768131|Drug|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
6527|NCT00768144|Drug|Sunitinib|
6802|NCT00768729|Drug|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
6803|NCT00768729|Drug|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
6804|NCT00768742|Device|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
6805|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po
6806|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
6807|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
6808|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
6809|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
6810|NCT00768768|Other|Electrokinetic Transungual System (ETS) - Terbinafine Gel|Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min
6811|NCT00006184|Biological|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m^2 subcutaneously every day, days 1-4
6812|NCT00770718|Biological|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
6813|NCT00770731|Drug|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
6814|NCT00770731|Drug|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
6815|NCT00770731|Drug|Velcade (Bortezomib)|Starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
5932|NCT00764751|Drug|Cream vehicle|Twice daily application
5933|NCT00764764|Procedure|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
5934|NCT00764764|Procedure|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
5935|NCT00764777|Device|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
5936|NCT00764790|Biological|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
5937|NCT00764790|Biological|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
5938|NCT00006154|Drug|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
5939|NCT00764803|Device|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
5940|NCT00764803|Device|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
5941|NCT00764816|Other|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
5942|NCT00764816|Other|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
5943|NCT00764842|Device|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
4955|NCT00720499|Device|Respimat® Inhaler|
4956|NCT00720512|Biological|bevacizumab|Given IV
4957|NCT00720512|Drug|fluorouracil|Given IV
4958|NCT00720512|Drug|irinotecan hydrochloride|Given IV
4959|NCT00720512|Drug|leucovorin calcium|Given IV
4960|NCT00720512|Drug|oxaliplatin|Given IV
4961|NCT00005903|Drug|GDNF & Synchro Med Infusion System|
4962|NCT00720538|Drug|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
4963|NCT00720538|Drug|placebo|placebo capsules
6745|NCT00770718|Drug|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
6746|NCT00763568|Biological|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
6747|NCT00763594|Behavioral|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
6748|NCT00006136|Drug|epoetin alfa|
6749|NCT00763594|Behavioral|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
6750|NCT00763607|Genetic|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
6751|NCT00763620|Device|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
6752|NCT00763633|Drug|vitamin B6|high dose of vitamin B6
6753|NCT00763633|Drug|vitamin B6|low vitamin B6
6754|NCT00763646|Drug|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
6755|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
6756|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
6757|NCT00763659|Dietary Supplement|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
6758|NCT00763672|Other|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
6759|NCT00006137|Drug|enalapril|
6760|NCT00763672|Other|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
7021|NCT00771238|Device|P500 Mattress|Study mattress
5692|NCT00769236|Other|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
5693|NCT00769236|Other|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
5694|NCT00769249|Other|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
5994|NCT00771901|Drug|sodium phenylbutyrate|20g/day for four weeks.
5995|NCT00771914|Drug|Aspirin|Aspirin 81mg tablet
5996|NCT00771914|Drug|Lovaza|Lovaza 4 grams
5997|NCT00771914|Drug|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
5998|NCT00771914|Other|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
5999|NCT00771927|Drug|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
6000|NCT00771940|Drug|Ghrelin|Solvent, cont. infusion
6001|NCT00006215|Drug|vinorelbine tartrate|
6002|NCT00771953|Drug|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
6003|NCT00771953|Drug|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
6004|NCT00771953|Drug|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
6005|NCT00771966|Procedure|Standard therapy|Standard therapy
6006|NCT00771966|Procedure|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
6007|NCT00771979|Drug|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
6008|NCT00771979|Drug|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
6009|NCT00771992|Procedure|Bronchoscopy|Bronchoscopy with segmental allergen challenge
6010|NCT00772005|Drug|armodafinil|150 mg/day armodafinil
6816|NCT00770744|Drug|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
6817|NCT00770744|Drug|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
6818|NCT00770757|Drug|CC-4047|
6819|NCT00770770|Drug|Fluocinolone Acetonide|0.2 µg/day
6820|NCT00006208|Drug|Emtricitabine|
7086|NCT00769119|Drug|Placebo|2 x Matched placebo, oral tablet, twice daily for 28 days
7087|NCT00769132|Drug|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
7088|NCT00769132|Drug|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
7089|NCT00006190|Drug|Nelfinavir mesylate|
7090|NCT00769132|Drug|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
7091|NCT00769132|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
7092|NCT00769145|Drug|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
7093|NCT00769158|Drug|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
7094|NCT00769158|Other|Placebo|Placebo Comparator
7095|NCT00769171|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
7096|NCT00769171|Drug|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
7097|NCT00769184|Drug|Corticosteroid|One side of body:
clobetasol: 2 applications / day along with LCD application 2 applications/day
7098|NCT00769184|Other|Placebo|One side of body:
Placebo Solution: 2 applications / day along with clobetasol 2 applications/day
7099|NCT00769184|Drug|LCD|One side of body:
LCD Solution: 2 applications / day along with clobetasol 2 applications/day
7100|NCT00006190|Drug|Stavudine|
7101|NCT00771251|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
4964|NCT00720551|Other|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
4965|NCT00722475|Drug|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
4966|NCT00722475|Drug|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
4967|NCT00722488|Drug|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
4968|NCT00722501|Drug|ERB-257|
4969|NCT00722501|Other|placebo|
4970|NCT00722514|Behavioral|patient education|complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally
Patient education 6 x 90 Minutes
4971|NCT00722514|Behavioral|Standard Care|complex individual antiinflammatory rehabilitation program during inpatient
complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally
further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)
4972|NCT00005928|Drug|Ramipril|
4973|NCT00722540|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
4974|NCT00722540|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
4975|NCT00722540|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
4976|NCT00722540|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
4977|NCT00722540|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
4978|NCT00722540|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
5285|NCT00715975|Drug|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
5286|NCT00005867|Drug|cyclophosphamide|
5287|NCT00718588|Drug|MTRX1011A|Subcutaneous and intravenous single and repeating dose
5288|NCT00718601|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
5289|NCT00005887|Radiation|radiation therapy|
7022|NCT00771251|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
7023|NCT00764010|Dietary Supplement|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
7024|NCT00764010|Dietary Supplement|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
7025|NCT00764036|Drug|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
7026|NCT00764049|Device|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
7027|NCT00764062|Drug|Amoxicillin|Amoxicillin :drug
7028|NCT00764075|Device|Beutel TM|application of BeutelTM
7029|NCT00764075|Other|standard|standard procedure will be applied but no Beutel TM software
7030|NCT00764075|Device|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
7031|NCT00764101|Behavioral|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
7032|NCT00006145|Drug|Valganciclovir|
7033|NCT00764114|Drug|antibiotic|6 or 12 weeks
7034|NCT00764140|Biological|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
7035|NCT00764153|Procedure|Bipolar hemiarthroplasty|Lateral approach. FWB.
7036|NCT00764153|Procedure|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
7037|NCT00764166|Drug|Docetaxel + hormonal treatment (LH-RH agonist)|Docetaxel will be administered:
To D1 of every cycle in the dose of 70 mg/m²,
Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).
Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally
7038|NCT00764166|Drug|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
7039|NCT00764179|Other|milk enriched in proteins (2.15 g/100ml)|Neonates will drink the hyperproteinic milk until they reach the 25th of "Sempé and Pedron" curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)
7040|NCT00764179|Other|milk with normal protein concentration (1.45g/100ml)|Neonates will drink the normoproteinic milk until they reach the 25th of "Sempé and Pedron" curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)
6011|NCT00764881|Drug|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
6012|NCT00764881|Drug|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
6013|NCT00006154|Drug|Efavirenz|200 mg capsules equaling 600 mg daily
6014|NCT00764894|Device|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
6015|NCT00764907|Drug|asparaginase|Given IV during reinduction
6016|NCT00764907|Drug|cyclophosphamide|Given IV during reinduction
5041|NCT00720577|Drug|Pioglitazone|30 mg, tablet, 1 tablet once daily
5042|NCT00720590|Drug|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
5043|NCT00720590|Drug|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
5044|NCT00720590|Drug|Placebo|Daily dose of placebo for 4 weeks
5045|NCT00720603|Drug|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
5046|NCT00720616|Drug|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
5047|NCT00720629|Drug|Visilizumab|3 mg/m^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
5048|NCT00720629|Drug|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
5049|NCT00720629|Drug|Methotrexate|15 mg/m^2 intravenously (IV) on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
5050|NCT00720629|Drug|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
5051|NCT00005906|Drug|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
5052|NCT00720629|Drug|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
7102|NCT00771264|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
7103|NCT00771277|Behavioral|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
7104|NCT00771290|Procedure|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
7105|NCT00771303|Other|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
7106|NCT00006212|Drug|vinblastine sulfate|
7107|NCT00771316|Drug|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
7471|NCT00741715|Drug|AVE5530|oral administration once daily in the evening with dinner
7472|NCT00741715|Drug|atorvastatin|oral administration once daily in the evening with dinner
7473|NCT00741715|Drug|placebo|oral administration once daily in the evening with dinner
7474|NCT00741728|Other|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
7475|NCT00741741|Drug|TMC278|
7476|NCT00741754|Other|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
7477|NCT00741767|Drug|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
7478|NCT00006013|Drug|semaxanib|
7479|NCT00741780|Drug|Placebo|
7480|NCT00741780|Drug|plerixafor|
7481|NCT00741780|Drug|granulocyte colony-stimulating factor (G-CSF)|
7482|NCT00741806|Biological|GHB04L1|single dose intranasal administration of GHB04L1
7483|NCT00741806|Other|Placebo|SPGN buffer
7484|NCT00741819|Drug|Inhaled treprostinil|
5290|NCT00718614|Procedure|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
5291|NCT00718627|Biological|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
5292|NCT00718640|Drug|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
5293|NCT00718640|Drug|Bortezomib|Bortezomib 1.3 milligram per meter^2 (mg/m^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
5294|NCT00718653|Dietary Supplement|Lutein|Lutein (12 mg/d)
5295|NCT00718653|Dietary Supplement|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
5296|NCT00718666|Biological|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
5297|NCT00718679|Drug|IVN201|Intralymphativ injection of the study drug
5298|NCT00718679|Drug|Placebo|
5299|NCT00718692|Biological|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
5300|NCT00005888|Behavioral|Fortified Pasteurized Donor Human Milk supplement|
5301|NCT00718705|Drug|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
5302|NCT00718705|Drug|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
5303|NCT00718718|Drug|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
5304|NCT00718718|Drug|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
5305|NCT00718718|Drug|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
5306|NCT00718718|Drug|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
5611|NCT00005916|Drug|rV-B7.1|
5612|NCT00714012|Other|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
5613|NCT00714025|Drug|RAD001|RAD001 10mg, daily, PO
7041|NCT00764192|Procedure|blood sample|blood sample before and after a single HD
7401|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
7402|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
7403|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
7404|NCT00734240|Drug|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
7405|NCT00734240|Drug|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
7406|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
7407|NCT00734253|Drug|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
7408|NCT00734253|Drug|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
7409|NCT00734253|Drug|Placebo|Placebo capsules taken twice a day for 1-year
7410|NCT00005983|Procedure|surgery|surgery
7411|NCT00734279|Drug|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
7412|NCT00734279|Drug|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
7413|NCT00734279|Drug|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
7414|NCT00736450|Biological|oblimersen sodium|Given IV
7415|NCT00736450|Biological|rituximab|Given IV
7416|NCT00736450|Drug|cyclophosphamide|Given IV
7417|NCT00736450|Drug|doxorubicin hydrochloride|Given IV
7418|NCT00736450|Drug|vincristine sulfate|Given IV
7419|NCT00005987|Procedure|peripheral blood stem cell transplantation|
7420|NCT00736450|Drug|prednisone|Given orally
7421|NCT00736450|Procedure|biopsy|Correlative studies
5053|NCT00720629|Drug|Methotrexate|15 mg/m^2 IV on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
5054|NCT00720655|Other|Dietary intervention|Fatty fish at least 4 meals per week.
5055|NCT00720655|Other|Dietary intervention|Lean fish at least 4 meals per week.
5056|NCT00720655|Other|Dietary intervention|Control diet with lean meat and chicken.
5057|NCT00720668|Procedure|radiofrequency ablation|radiofrequency ablation for HCC
5058|NCT00720707|Procedure|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
5059|NCT00722709|Drug|0.9% Saline|In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.
At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
5364|NCT00716066|Biological|anti-thymocyte globulin|Given IV
5365|NCT00716066|Drug|carmustine|Given IV
5366|NCT00716066|Drug|cytarabine|Given IV
5367|NCT00716066|Drug|etoposide|Given IV
5368|NCT00716066|Drug|melphalan|Given IV
5369|NCT00716066|Drug|prednisone|Given PO
5370|NCT00716066|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous or syngeneic peripheral blood stem cell transplantation
5371|NCT00716066|Procedure|peripheral blood stem cell transplantation|Undergo autologous or syngeneic peripheral blood stem cell transplantation
5372|NCT00716066|Procedure|syngeneic bone marrow transplantation|Undergo syngeneic bone marrow transplantation
5373|NCT00716066|Other|laboratory biomarker analysis|Correlative studies
5374|NCT00005867|Drug|etoposide|
5375|NCT00716079|Other|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
5376|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
5377|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
7485|NCT00741832|Device|Conical Positive Expiratory Pressure Device (C-PEP)|Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.
The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.
Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device.
7486|NCT00741832|Other|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
7487|NCT00741845|Drug|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
7488|NCT00741858|Procedure|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
7489|NCT00006014|Drug|semaxanib|
7490|NCT00741858|Procedure|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
7491|NCT00741871|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
6207|NCT00765167|Drug|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
6208|NCT00765167|Drug|Fluoride|Brush half mouth daily for four days
6209|NCT00765180|Device|TRE vs. NBI|TRE NBI
6210|NCT00765193|Other|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
6211|NCT00765206|Drug|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
6212|NCT00765206|Drug|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
6213|NCT00006156|Other|Control|No injection of FSH
6214|NCT00765219|Behavioral|CBT|10-12 weekly sessions of CBT in person or over the telephone.
6215|NCT00765219|Other|Usual Care|Treatment as usual provided by participants' physician(s)
6216|NCT00765232|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
5614|NCT00714051|Behavioral|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
5615|NCT00714051|Behavioral|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
5616|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
5617|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
5618|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
5619|NCT00714090|Other|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
active rTMS : 5 sessions per week for 2 to 6 weeks
5620|NCT00714090|Other|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
5621|NCT00005857|Drug|docetaxel|
5622|NCT00714090|Other|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
5623|NCT00714103|Drug|8-Chloro-Adenosine|45 mg/m^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
5624|NCT00714116|Drug|SBI-087|Single IV or SC dose of SBI-087
5625|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
5626|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
5627|NCT00714142|Drug|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
5628|NCT00714142|Drug|15O-water|10-20 mCi, IV
5629|NCT00714142|Procedure|Positron Emission Tomography|PET Scan
5630|NCT00714155|Other|Questionnaires, Physical Examination|Questionnaires, Physical Examination
7422|NCT00736450|Genetic|microarray analysis|Correlative studies
7423|NCT00736450|Other|immunohistochemistry staining method|Correlative studies
7424|NCT00736450|Genetic|gene expression analysis|Correlative studies
7425|NCT00736450|Genetic|cytogenetic analysis|Correlative studies
6464|NCT00770393|Procedure|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
6465|NCT00770393|Procedure|Conventionnal chemotherapy|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion.
6466|NCT00770406|Drug|botulinum toxin type A|100 or 200 units intravesically
6467|NCT00006205|Drug|topiramate + cognitive behavioral therapy|topiramate (up to 300 mg/day)
6468|NCT00770419|Other|medical chart review|
6469|NCT00770419|Other|questionnaire administration|
6470|NCT00770419|Procedure|psychosocial assessment and care|
6471|NCT00770432|Drug|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
6472|NCT00770432|Other|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
6473|NCT00772538|Drug|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
6474|NCT00006221|Drug|ixabepilone|
6475|NCT00772538|Drug|placebo|Matching placebo
6476|NCT00772551|Drug|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
5378|NCT00716092|Drug|Sitagliptin|100 mg once daily for 28 days
5379|NCT00718757|Drug|Vincristine|1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8
* Patients < 1 year of age or < 10kg in weight: Vincristine 0.05 mg/kg
5380|NCT00718770|Drug|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
5381|NCT00718783|Other|Tissue samples taken from retinoblastoma|Tissue banking
5382|NCT00718783|Other|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
5383|NCT00718796|Other|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
5384|NCT00718796|Other|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
5385|NCT00718809|Drug|saracatinib|Given orally
5386|NCT00718822|Other|oxygen concentration in the culture atmosphere|
5695|NCT00006190|Drug|Lamivudine|
5696|NCT00769249|Other|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
5697|NCT00769249|Procedure|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
5698|NCT00769262|Other|Conservative weaning protocol|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
5699|NCT00769262|Other|Aggressive weaning protocol|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
5700|NCT00769288|Drug|2'-F-ara-deoxyuridine|Given IV
5701|NCT00769288|Other|positron emission tomography|Correlative studies
5702|NCT00769288|Other|laboratory biomarker analysis|Correlative studies
5703|NCT00769288|Other|pharmacological study|Correlative studies
6217|NCT00765232|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
6218|NCT00765245|Drug|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
6219|NCT00765245|Drug|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
6220|NCT00765245|Drug|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
6221|NCT00765271|Drug|Abacavir|Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study
Group 2 will be instructed to take
• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study
6222|NCT00765271|Drug|Darunavir/ritonavir|Group 1 will be instructed to take
• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)
6223|NCT00765271|Drug|Raltegravir|Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)
Group 2 will be instructed to take
• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)
6224|NCT00006156|Drug|Drug: FSH|FSH Stimulation Test
6225|NCT00765297|Device|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
5222|NCT00720850|Drug|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
5223|NCT00720876|Biological|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
5224|NCT00720876|Drug|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
5225|NCT00720902|Procedure|Blood draws|Subjects will have serum cardiovascular markers assessed
5226|NCT00720902|Drug|Growth hormone releasing hormone (GHRH) and arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
5227|NCT00720902|Procedure|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
5228|NCT00720902|Procedure|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
5229|NCT00720902|Procedure|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
5944|NCT00764855|Procedure|Automatic administration of propofol and opiates during routine clinical practice|The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.
The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.
The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device.
5945|NCT00764868|Drug|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
5946|NCT00764881|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
5947|NCT00767026|Behavioral|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
5948|NCT00767026|Behavioral|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
5949|NCT00767039|Drug|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
5950|NCT00767039|Drug|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
5951|NCT00767052|Drug|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
5952|NCT00767052|Drug|Placebo|Placebo tablet matching to the active in multiple dose part.
5953|NCT00767052|Drug|AZD1236|75mg single dose will be administered in relative bioavailability part.
5954|NCT00767052|Drug|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
6477|NCT00772551|Drug|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
6478|NCT00772564|Drug|Atorvastatin|Oral Atorvastatin
6479|NCT00772577|Drug|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
6480|NCT00772577|Drug|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
6481|NCT00772590|Drug|Raltegravir|Tablets, 400mg, twice daily
6482|NCT00772590|Drug|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
6761|NCT00763685|Drug|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
6762|NCT00763698|Device|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
6763|NCT00763711|Device|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
6764|NCT00763737|Procedure|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-32+6 weeks and removal at 34-35 wks
6765|NCT00763737|Procedure|expectant management during pregnancy|observation
6766|NCT00763750|Drug|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
6767|NCT00763763|Drug|Imatinib mesylate|imatinib 600 mg/day for 2 years
6768|NCT00763763|Drug|Interferon|45 micrograms per week during 2 years
6769|NCT00763763|Drug|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
6770|NCT00766155|Drug|oxaliplatin|Given IV
6771|NCT00766168|Other|HDS HI 1.54; pahrifocon A|Contact Lens
6772|NCT00766168|Device|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
6773|NCT00766181|Behavioral|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
6774|NCT00766207|Other|Clinical decision support|multi-faceted decision support
6775|NCT00766207|Other|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
5704|NCT00769288|Other|pharmacogenomic studies|Correlative studies
5705|NCT00769314|Drug|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
5706|NCT00000727|Drug|Pentamidine isethionate|
5707|NCT00006190|Drug|Efavirenz|
5708|NCT00769314|Drug|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
5709|NCT00769327|Drug|imatinib mesylate|
5710|NCT00769327|Drug|nilotinib|
5711|NCT00771420|Other|Placebo|Active: Placebo 5:1 for arms 2-6
5712|NCT00006212|Radiation|radiation therapy|
5713|NCT00771433|Biological|filgrastim|Given subcutaneously
5714|NCT00771446|Biological|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
5715|NCT00771446|Other|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
5716|NCT00771459|Drug|Ropivacaine 0.5 %|Local infiltration analgesia
6017|NCT00764907|Drug|cytarabine|Given IV during reinduction
6018|NCT00764907|Drug|daunorubicin hydrochloride|Given IV during reinduction
6019|NCT00764907|Drug|dexamethasone|Given IV or orally during reinduction
6020|NCT00764907|Drug|doxorubicin hydrochloride|Given IV during reinduction
6021|NCT00764907|Drug|etoposide|Given IV during reinduction
6022|NCT00764907|Drug|ifosfamide|Given IV during reinduction
6023|NCT00764907|Drug|leucovorin calcium|Given IV during reinduction
6024|NCT00006154|Drug|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
6025|NCT00764907|Drug|mercaptopurine|Given orally during reinduction
6026|NCT00764907|Drug|methotrexate|Given orally during reinduction
5230|NCT00720915|Other|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
5231|NCT00720915|Other|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
5232|NCT00005908|Drug|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m^2 intravenous day 1
5233|NCT00720928|Drug|flucinolone acetonide|Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
5234|NCT00720941|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
5235|NCT00720941|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
5236|NCT00720954|Procedure|Ct-guided pleural needle biopsy|Biopsy of pleura
5237|NCT00720954|Procedure|Thoracoscopy|Biopsy of pleura
5238|NCT00713440|Other|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.
Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.
Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days
5239|NCT00713479|Drug|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
5240|NCT00713479|Drug|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
5544|NCT00716417|Drug|BIBW 2992|low to high dose, daily
5545|NCT00716430|Behavioral|Quality Improvement Programme|Quality Improvement training programme
5546|NCT00716443|Drug|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
5547|NCT00716443|Drug|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
5548|NCT00716456|Drug|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
6629|NCT00768391|Biological|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
6630|NCT00768404|Drug|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
6631|NCT00768417|Behavioral|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
6632|NCT00768417|Behavioral|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
6633|NCT00768417|Behavioral|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
6634|NCT00768430|Drug|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
6635|NCT00768430|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
6636|NCT00770510|Drug|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
6637|NCT00770510|Drug|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
6638|NCT00000727|Drug|Sulfamethoxazole/Trimethoprim|
6639|NCT00006206|Drug|naltrexone (Revia)|
6640|NCT00770510|Drug|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
6641|NCT00770510|Drug|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
6642|NCT00770536|Drug|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
6643|NCT00770536|Drug|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
6892|NCT00768794|Dietary Supplement|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
7358|NCT00739297|Drug|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
7359|NCT00005998|Procedure|radiation therapy|
7360|NCT00739310|Device|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
6407|NCT00772265|Biological|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
6408|NCT00772278|Procedure|carotid artery stenting|carotid artery angiography, angioplasty and stenting
6409|NCT00772278|Procedure|carotid endarterectomy|open surgery including endarterectomy
6410|NCT00772291|Drug|pregabalin|pregabalin 150-600mg/day during 8 weeks
6411|NCT00765531|Genetic|Pediatric Urologic DNA and History Repository|All Stone Forming Patients and their families will undergo one of three groups of testing:
Testing 1 - This testing form involves using a specimen from the Pediatric Urologic Blood, Tissue, Urine, Serum, and DNA Repository.
Testing 2 - Involves complete in-patient evaluation at UT Southwestern GCRC for patients with hypercalciuria and their families.
Testing 3 - Involves simple out-patient evaluation for patients with hypercalciuria and their family members.
6412|NCT00765544|Device|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
6413|NCT00006158|Drug|Testosterone|
6414|NCT00765544|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
6415|NCT00765557|Drug|Miralax|Every subject will be given one bottle of the laxative/placebo, and depending on the patient's weight, will be instructed to take 1-3 tsps (.75 gm/kg) of the medication daily.
6416|NCT00765570|Radiation|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
6417|NCT00765570|Radiation|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
6418|NCT00765570|Radiation|Standard radiation|15 Standard radiation treatments
6419|NCT00765570|Radiation|Standard radiation|standard radiation treatment
6420|NCT00765583|Drug|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
6421|NCT00765596|Other|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
2951|NCT00731926|Dietary Supplement|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
3256|NCT00724867|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days
3257|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
3258|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
3259|NCT00005944|Drug|leucovorin calcium|
3260|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
3261|NCT00724893|Biological|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
3262|NCT00724893|Drug|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
3263|NCT00724906|Drug|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
3264|NCT00724932|Drug|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
3265|NCT00724932|Drug|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
3266|NCT00724932|Drug|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
3267|NCT00724932|Drug|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
3268|NCT00724945|Device|balafilcon A|multifocal contact lens
3269|NCT00724945|Device|senofilcon A|multifocal contact lens
3270|NCT00727441|Drug|cyclophosphamide|Given IV
3271|NCT00727454|Device|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
3272|NCT00727454|Device|No treatment|No treatment
3273|NCT00727467|Device|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
7163|NCT00005998|Drug|filgrastim|
7164|NCT00738855|Other|Nothing per os|A nasogastric tube
7165|NCT00738868|Biological|cetuximab|
7166|NCT00738868|Radiation|stereotactic body radiation therapy|
7167|NCT00738881|Drug|Erlotinib Hydrochloride|Given PO
7168|NCT00738881|Drug|Pemetrexed Disodium|Given IV
7169|NCT00738894|Device|GORE® HELEX® Septal Occluder / GORE® Septal Occluder|PFO closure with GORE® HELEX® Septal Occluder / GORE® Septal Occluder
7170|NCT00738894|Other|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
7171|NCT00738920|Behavioral|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
7172|NCT00738920|Behavioral|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
7173|NCT00738920|Behavioral|Behavioral Education and Supportive Therapy|This 4 session treatment emphasizes support, information giving about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
7195|NCT00006012|Drug|cisplatin|
7196|NCT00741403|Drug|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
7197|NCT00741429|Drug|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
7198|NCT00741429|Drug|Comparator|Subjects previously treated with other anti-diabetic medications
7199|NCT00733889|Drug|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|Neoadjuvant chemotherapy plus cetuximab:
3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.
Radio-chemotherapy plus cetuximab:
The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).
Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36
7200|NCT00733902|Biological|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
7201|NCT00733902|Biological|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
6893|NCT00768807|Device|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
6894|NCT00006184|Biological|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) > 1000/ul x 2 days
6895|NCT00770861|Drug|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
6896|NCT00770861|Drug|Placebo|Matching placebo tablets, oral administration
6897|NCT00006208|Drug|Didanosine|
6898|NCT00770874|Drug|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
6899|NCT00770874|Drug|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
6900|NCT00770887|Procedure|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
6901|NCT00770900|Drug|montelukast sodium|Asthmatic children and teenagers took montelukast daily for 12 weeks.
Children aged 2-5 years took 4mg tablet of montelukast
Children aged 6-15 years took 5mg tablet of montelukast
Children >15 years took 10mg tablet of montelukast
6902|NCT00770900|Drug|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
6903|NCT00770913|Drug|E3810|20 mg taken orally, once a day for 8 weeks.
6904|NCT00770913|Drug|E3810|10 mg, taken orally, twice a day for 8 weeks.
6905|NCT00770913|Drug|E3810|20 mg taken orally, twice a day for 8 weeks.
6906|NCT00770926|Behavioral|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
6907|NCT00770939|Device|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
6908|NCT00006209|Drug|Tucaresol|
6909|NCT00770952|Drug|Pioglitazone and Glimepiride|Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:
Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:
Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks.
6422|NCT00765635|Drug|drops intilation (Taponoto ® )|four drops, unique doses
6423|NCT00765635|Drug|drops intilation (Otocerum®)|four drops, unique doses
6424|NCT00006159|Behavioral|lifestyle (exercise, diet, and family and community support)|
6425|NCT00765635|Drug|drops intilation (Placebo)|Placebo
6426|NCT00765648|Drug|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
6704|NCT00768456|Drug|Isotonic NaCl|Local Infiltration with NaCl
6705|NCT00006184|Drug|Fludarabine phosphate|Induction chemotherapy: 25 mg/m^2 day intravenous days 1-3 Transplant: 30 mg/m^2 day x 4 days (days -6, -5, -4, -3 )
6706|NCT00768469|Drug|HKI-272 + Paclitaxel|HKI-272: 240 mg, continuous daily OD Paclitaxel: 80 mg/m2 IV, day 1, 8, 15 of 28 day cycle
6707|NCT00768482|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
6708|NCT00768482|Drug|Sublingual Buprenorphine|16 mg/day, QD
6709|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
6710|NCT00768508|Drug|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
6711|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
6712|NCT00768508|Other|Placebo + Cognitive Behavioral Therapy|Placebo comparator
6713|NCT00768521|Drug|tolterodine tartrate|Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days
Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days
Part IIb: single dose tolterodine tartrate 4 mg capsule
6714|NCT00768521|Drug|Comparator: Placebo to tolterodine tartrate|Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days
Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days
Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule
6715|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
6716|NCT00006184|Drug|Prednisone|60 mg/m^2 day 1-4
6717|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
3274|NCT00727480|Procedure|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
3275|NCT00727493|Drug|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
3276|NCT00727493|Drug|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
3582|NCT00730405|Drug|Placebo 400 mg|Placebo for 36 weeks
3583|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
3584|NCT00005965|Drug|cisplatin|
3585|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
3586|NCT00730431|Drug|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
3587|NCT00730431|Drug|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
3588|NCT00730444|Drug|Iobenguane I 123 Injection|1-10 mCi administered intravenously
3589|NCT00730457|Biological|VAX125|Single intramuscular dose
3590|NCT00730470|Drug|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
3591|NCT00730483|Drug|PVA microporous hydrospheres/doxorubicin hydrochloride|
3592|NCT00730496|Procedure|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
3593|NCT00730509|Dietary Supplement|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
3594|NCT00730522|Drug|CPP-109 vigabatrin|tablets, bid for 12 weeks
3595|NCT00005966|Biological|recombinant interferon alfa|
3596|NCT00730522|Drug|Matching Placebo|tablets, bid, 12 weeks
3597|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
3598|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
7202|NCT00733902|Biological|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
7203|NCT00733902|Biological|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
7204|NCT00733915|Device|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
7205|NCT00733928|Device|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
7206|NCT00733928|Device|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
7207|NCT00733941|Behavioral|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
7208|NCT00005980|Drug|pegylated liposomal doxorubicin hydrochloride|
7209|NCT00733941|Behavioral|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
7210|NCT00733954|Drug|clobetasol propionate spray|Apply twice daily
7211|NCT00733954|Drug|clobetasol propionate ointment|Apply twice daily
7212|NCT00733967|Drug|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
7213|NCT00733967|Drug|Placebo|Matching oral placebo capsules as control.
7214|NCT00733980|Drug|GSK561679|GSK561679
7215|NCT00733980|Other|Placebo|Placebo
6248|NCT00767676|Device|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
6249|NCT00767689|Drug|vitamin b6|vitamin b6 100 mg po daily
6250|NCT00767689|Drug|placebo|placebo is given in the placebo arm
6251|NCT00006182|Procedure|Blood Transfusion|
6252|NCT00767715|Drug|olanzapine|physician determined dose, oral, daily, 5 months
6253|NCT00767715|Drug|haloperidol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
6254|NCT00767715|Drug|zuclopentixol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
6255|NCT00770042|Drug|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
6910|NCT00770952|Drug|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:
Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:
Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks.
7276|NCT00006012|Drug|etoposide|
7277|NCT00741468|Drug|CYP2D6 probe|Dextromethorphan (30 mg)
7278|NCT00741468|Drug|CYP3A4 probe|Midazolam (2mg)
7279|NCT00741481|Procedure|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
7280|NCT00741494|Device|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
7281|NCT00741507|Behavioral|Alcohol drinking|Never drinking of alcohol
7282|NCT00741507|Behavioral|Alcohol drinking|Mild drinking of alcohol assessed by "alcohol use disorders identification test (AUDIT)"
7283|NCT00741507|Behavioral|Alcohol drinking|Moderate drinking of alcohol assessed by "alcohol use disorders identification test (AUDIT)"
7284|NCT00741507|Behavioral|Alcohol drinking|Severe over drinking of alcohol assessed by "alcohol use disorders identification test (AUDIT)"
7285|NCT00741507|Behavioral|Alcohol drinking|Alcohol-dependent assessed by "alcohol use disorders identification test (AUDIT)"
7286|NCT00741520|Device|CPAP|Control - no treatment
7287|NCT00000707|Drug|Pentamidine isethionate|
7288|NCT00006012|Drug|paclitaxel|
7289|NCT00741520|Device|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
7290|NCT00741546|Procedure|Cardiac Surgery|Cardiac Surgery
7291|NCT00741559|Device|magnetoencephalography|MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
7292|NCT00741559|Device|Positron emission tomography (PET)|An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
7293|NCT00741559|Device|Magnetic resonance imaging|MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
2875|NCT00724087|Other|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
2876|NCT00724100|Drug|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
2877|NCT00724113|Procedure|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
2878|NCT00724113|Procedure|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
2879|NCT00724126|Drug|Rifaximin|
2880|NCT00724126|Drug|Placebo|
2881|NCT00724139|Device|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
2882|NCT00724152|Behavioral|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
2883|NCT00724152|Behavioral|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
2884|NCT00724165|Behavioral|Intervention|Culturally-modified, individually tailored physical activity print materials
2885|NCT00005941|Procedure|peripheral blood stem cell transplantation|
2886|NCT00724165|Behavioral|Control|Bilingual health education booklets
2887|NCT00724178|Dietary Supplement|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
2888|NCT00724191|Procedure|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
2889|NCT00724204|Dietary Supplement|follow on formula without probiotics|A follow on formula without probiotics
2890|NCT00724204|Dietary Supplement|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
2891|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
2892|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
3599|NCT00730535|Drug|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
3600|NCT00730548|Behavioral|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
3601|NCT00732745|Drug|vandetanib|Given orally
3602|NCT00005977|Drug|ifosfamide|Given IV
3603|NCT00732745|Other|placebo|Given orally
3604|NCT00732758|Dietary Supplement|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
2631|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
2632|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
2633|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
2634|NCT00712465|Drug|AZD1305|Extended Release tablet, repeated administration
2635|NCT00712465|Drug|Digoxin|Tablet, repeated administration
2636|NCT00005851|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
2637|NCT00712478|Drug|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
2638|NCT00712491|Drug|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
2639|NCT00712491|Drug|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
2640|NCT00712504|Drug|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
2641|NCT00712504|Drug|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
2642|NCT00712517|Drug|propofol|propofol anesthesia 3-5mg/kg
2643|NCT00712517|Drug|sevoflurane|sevoflurane anesthesia
6256|NCT00770042|Drug|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
6257|NCT00006200|Drug|dacarbazine|
6258|NCT00770042|Drug|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
6259|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 8
6260|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 6
6261|NCT00770042|Drug|Avanafil|Avanafil 200mg Days 1 and 6
6262|NCT00770055|Other|medical chart review|
6263|NCT00770055|Other|questionnaire administration|
6264|NCT00770055|Other|survey administration|
6265|NCT00770055|Procedure|psychosocial assessment and care|
6266|NCT00770081|Drug|vildagliptin|50mg qd
6267|NCT00770081|Drug|sitagliptin|25mg qd
6268|NCT00006202|Drug|Lutein|
6269|NCT00770094|Device|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
6270|NCT00770094|Device|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
6271|NCT00770094|Device|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
6272|NCT00770107|Drug|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
6573|NCT00770497|Drug|Ramipril|Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:
Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.
6574|NCT00770510|Drug|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
6575|NCT00772902|Drug|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
7294|NCT00734058|Device|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
7295|NCT00734071|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
7296|NCT00734071|Drug|Placebo|Vortioxetine placebo-matching capsules
7297|NCT00734084|Device|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
6343|NCT00006183|Procedure|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
6344|NCT00767767|Drug|Midazolam|IV Midazolam infusion for 2 hours.
6345|NCT00767767|Drug|Dexmedetomidine|IV Dexmedetomidine Infusion for 2 hours.
6346|NCT00767780|Device|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
6347|NCT00767793|Drug|Placebo|One drop in each eye every 12 hours for seven days
6348|NCT00767793|Drug|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
6349|NCT00767793|Drug|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
6350|NCT00767793|Drug|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
6351|NCT00767806|Drug|Duloxetine|60 mg orally once daily for 12 weeks
6352|NCT00767806|Drug|Placebo|Placebo once daily orally for 12 weeks
6353|NCT00767819|Drug|Everolimus/RAD001|10 mg orally
6354|NCT00006183|Procedure|Thoracic Surgery|
6355|NCT00767845|Other|questionnaire administration|
6356|NCT00767845|Other|survey administration|
6357|NCT00767845|Procedure|psychosocial assessment and care|
6358|NCT00767871|Drug|Lexapro|12 week treatment with lexapro
2893|NCT00724230|Drug|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
Subcutaneous injection once weekly for 24 weeks.
3193|NCT00727415|Drug|Lenalidomide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose.
3194|NCT00005950|Drug|nelarabine|Given IV
3195|NCT00727428|Biological|FluLaval® TF|One IM injection.
3196|NCT00727441|Biological|GVAX pancreatic cancer vaccine|Given intradermally
3197|NCT00729794|Drug|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
3198|NCT00729807|Drug|pentamidine|
3199|NCT00729807|Genetic|gene expression analysis|
3200|NCT00729807|Genetic|polymerase chain reaction|
3201|NCT00729807|Genetic|western blotting|
3202|NCT00005963|Drug|carboplatin|
3203|NCT00729807|Other|bioluminescence|
3204|NCT00729807|Other|immunoenzyme technique|
3205|NCT00729807|Other|immunohistochemistry staining method|
3206|NCT00729807|Other|laboratory biomarker analysis|
3207|NCT00729833|Drug|CP-751,871|CP-751,871 IV, every 3 weeks
3208|NCT00729833|Drug|Sunitinib|Sunitinib - daily dosing
3209|NCT00729846|Drug|Bevacizumab and verteporfin photodynamic therapy|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence [300mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
3210|NCT00729846|Drug|Bevacizumab and visudyne photodynamic therapy|Patients will receive combination verteporfin photodynamic therapy with stand fluence [600mW/cm2] followed by intravitreal bevacizumab (1.25 mg) on the same day after photodynamic therapy.
3211|NCT00729859|Drug|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
2644|NCT00712530|Biological|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
2645|NCT00712530|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
2646|NCT00712543|Drug|lactulose (Kristalose®)|Crystals to be dissolved in water and taken as prescribed.
2647|NCT00005851|Other|laboratory biomarker analysis|Correlative studies
2648|NCT00712543|Drug|liquid lactulose|Liquid to be taken as prescribed.
2649|NCT00712556|Radiation|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
2650|NCT00712569|Behavioral|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
2952|NCT00731926|Other|placebo|twice a day for 1 month
2953|NCT00731939|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
2954|NCT00005974|Drug|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
2955|NCT00731952|Drug|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
2956|NCT00731965|Biological|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
2957|NCT00731978|Procedure|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
2958|NCT00731991|Other|ART|ART to the levator scapulae.
2959|NCT00731991|Other|PNF|PNF to the levator scapulae.
2960|NCT00731991|Other|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
2961|NCT00732004|Device|Silicone Hydrogel Contact Lenses|
2962|NCT00732004|Device|1x PMBH preserved MPS|
6576|NCT00772902|Drug|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
6577|NCT00772915|Drug|dexamethasone|Dose: -40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression.
If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.
If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly.
6578|NCT00772915|Drug|lenalidomide|25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.
Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described).
6579|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
6580|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
6581|NCT00006225|Biological|recombinant flt3 ligand|
6582|NCT00772941|Drug|Varenicline|Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.
Frequency and duration are according to Package Insert as follows.
"The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
6583|NCT00772954|Biological|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
6584|NCT00772954|Biological|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
6585|NCT00772954|Biological|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
6586|NCT00772967|Drug|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
6587|NCT00772967|Drug|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
6846|NCT00763815|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
6847|NCT00763815|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
6848|NCT00763815|Device|Pen auto-injector|
6359|NCT00767897|Drug|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
6360|NCT00767949|Biological|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
6361|NCT00770159|Drug|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
6362|NCT00770172|Biological|filgrastim|Given subcutaneously
6363|NCT00770185|Drug|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
6364|NCT00770185|Genetic|gene expression analysis|
6644|NCT00770536|Drug|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
6645|NCT00770536|Drug|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
6646|NCT00770562|Drug|rituximab|
6647|NCT00770562|Drug|Dexamethasone|
6648|NCT00770575|Drug|Pioglitazone and atorvastatin|Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:
Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
6649|NCT00770575|Drug|Atorvastatin|Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to
Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
6650|NCT00006206|Drug|acamprosate (Campral)|
6651|NCT00770588|Drug|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
6652|NCT00770588|Drug|Placebo|To match Gefitinib
6653|NCT00770601|Drug|Canakinumab|
6654|NCT00770614|Drug|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
6655|NCT00770614|Drug|Isotonic saline|0.9% sodium chloride
6656|NCT00770614|Drug|Placebo|Placebo
3212|NCT00729859|Drug|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
3213|NCT00005963|Drug|docetaxel|
3214|NCT00729859|Drug|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
3519|NCT00732563|Radiation|fludeoxyglucose F 18|given IV
3520|NCT00732563|Radiation|radiation therapy|undergoing radiotherapy
3521|NCT00732576|Dietary Supplement|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
3522|NCT00732576|Dietary Supplement|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
3523|NCT00732576|Dietary Supplement|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
3524|NCT00005977|Drug|dexamethasone|Given IV
3525|NCT00732589|Drug|1% xylocaine|10 cc. of 1%xylocaine, once a week
3526|NCT00732589|Other|ultrasound|ultrasound at shoulder area about 10 mins.
3527|NCT00732602|Other|GIP-infusion|
3528|NCT00732602|Other|Sodium-chloride|
3529|NCT00732602|Other|GLP-2 infusion|
3530|NCT00732615|Drug|Placebo|Placebo for subcutaneous injection
3531|NCT00005945|Drug|cytarabine|Given IT
3532|NCT00725283|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular administration
3533|NCT00725296|Biological|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
3534|NCT00725322|Drug|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
3535|NCT00725322|Drug|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
3536|NCT00725335|Procedure|curative resection without Pringle|Radical excision of liver cancer without the procedure of pringle manoeuvre
2963|NCT00732004|Device|1x Polyquad/Aldox MPS|
2964|NCT00732017|Device|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
2965|NCT00005975|Drug|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
2966|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
2967|NCT00724269|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
2968|NCT00724269|Device|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
2969|NCT00724282|Drug|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
2970|NCT00724282|Drug|Placebo|Placebo by mouth daily at bedtime for 9 days
2971|NCT00724295|Drug|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
2972|NCT00724295|Drug|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
3277|NCT00727506|Drug|BIBW 2992|BIBW 2992 once daily
3278|NCT00005951|Drug|irinotecan hydrochloride|
3279|NCT00727506|Drug|TMZ|TMZ 21/28
3280|NCT00727506|Drug|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
3281|NCT00727519|Dietary Supplement|Pomegranate juice|
3282|NCT00727519|Dietary Supplement|Placebo|
3283|NCT00727532|Drug|sorafenib tosylate|400mg by mouth twice daily for 28 consecutive days
3284|NCT00727532|Procedure|diffusion-weighted magnetic resonance imaging|At baseline and just prior to surgery after sorafenib treatment
3285|NCT00727545|Other|iron bisglycine chelate|
3286|NCT00727545|Other|placebo|
3287|NCT00727558|Device|nelfilcon A|spherical soft contact lens
6849|NCT00763815|Drug|Pioglitazone|Dose to be kept stable.
6850|NCT00763815|Drug|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
6851|NCT00006143|Drug|Somatropin|
6852|NCT00763828|Device|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
6853|NCT00763841|Device|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
6854|NCT00763841|Device|Sham|
6855|NCT00763867|Drug|Placebo|
6856|NCT00763867|Drug|Sildenafil|
6857|NCT00763880|Drug|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
6858|NCT00763880|Drug|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
6859|NCT00763893|Drug|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
6860|NCT00763893|Drug|Losartan|50 mg/day if < weight 50 kg 100 mg/day if weight > 50 kg
6861|NCT00763906|Device|norepinephrine infused at the clinician's discretion|
6862|NCT00006144|Drug|Lopinavir/Ritonavir|
6863|NCT00763906|Device|norepinephrine infused under computerized fuzzy logic control|
6864|NCT00763919|Behavioral|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
6865|NCT00766311|Other|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
7216|NCT00733993|Drug|Caffeine|300 mg for 7 days; then 600 mg for 7 days; then 900 mg for 7 days; followed by a 3 day taper. all dosing three times per day
6657|NCT00770627|Dietary Supplement|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
6658|NCT00770640|Drug|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
6659|NCT00753597|Drug|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
6660|NCT00753623|Drug|Ramelteon|ramelteon (8 mg)
6661|NCT00753623|Drug|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
6662|NCT00006083|Drug|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
6663|NCT00753636|Drug|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
6664|NCT00753649|Biological|Infanrix™ hexa|Intramuscular, three doses
6665|NCT00753662|Device|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
6911|NCT00770965|Biological|AIN457|
6912|NCT00770965|Biological|Placebo|
6913|NCT00770978|Drug|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
6914|NCT00770978|Drug|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
6915|NCT00770991|Drug|Black raspberry (BRB) Slurry|20 grams BRB Slurry
6916|NCT00770991|Drug|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
6917|NCT00770991|Drug|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
6918|NCT00763919|Behavioral|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
6919|NCT00763919|Behavioral|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
6920|NCT00763919|Behavioral|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
6921|NCT00763932|Biological|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
3537|NCT00725335|Procedure|curative resection with Pringle manoeuvre|curative resection liver cancer under pringle manoeuvre
3538|NCT00725348|Drug|Talarozole|1.0 mg oral dose per day
3539|NCT00725361|Drug|Ambrisentan|
3540|NCT00725374|Drug|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
3541|NCT00725374|Drug|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
3542|NCT00005945|Drug|daunorubicin hydrochloride|Given IV
2571|NCT00713258|Drug|Alendronate|70 mg alendronate weekly
2572|NCT00712062|Drug|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
2573|NCT00712075|Behavioral|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
2574|NCT00712075|Behavioral|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
2575|NCT00712075|Behavioral|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
2576|NCT00712088|Behavioral|Project ICARE|Group-level intervention (Project ICARE)
2577|NCT00712088|Behavioral|HCT|Offer of HIV counseling and testing
2578|NCT00712101|Drug|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
2579|NCT00712101|Drug|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
2580|NCT00000689|Drug|Cyclophosphamide|
2581|NCT00005851|Radiation|total-body irradiation|Undergo TBI
2582|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
2583|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
3288|NCT00727558|Device|narafilcon A|spherical soft contact lens
3289|NCT00005951|Drug|temozolomide|
3290|NCT00727571|Other|Observations|This is a non-interventional, observational study; no investigational product is being used
3291|NCT00727584|Radiation|radiation therapy|Patients undergo external beam radiotherapy
3292|NCT00727597|Drug|Efavirenz 600mg|QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
The intervention may be switched for the following reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)
3293|NCT00727597|Drug|Boosted Lexiva|Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
The intervention may be switched for the following reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)
3294|NCT00729924|Drug|Raltegravir|400mg orally every 12 hours for 7 days
3295|NCT00729937|Drug|Cephalexin|500 mg, four times per day.
3296|NCT00000702|Drug|Zidovudine|
3297|NCT00005964|Biological|filgrastim|
3298|NCT00729937|Drug|Clindamycin|300 mg, four times per day.
3605|NCT00732758|Dietary Supplement|Placebo Tablet|Placebo Tablet once daily for 6 months
3606|NCT00732771|Drug|LCI699|
3607|NCT00732784|Drug|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
3608|NCT00732784|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
3609|NCT00732797|Behavioral|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
3610|NCT00732797|Behavioral|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
3611|NCT00732810|Drug|SCH 727965|SCH 727965 50 mg/m^2 IV on Day 1 of each 21 day cycle until disease progression.
7217|NCT00733993|Drug|Placebo|3 times per day
7218|NCT00734019|Device|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
7219|NCT00005981|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
7220|NCT00734032|Drug|SB480848 40mg EC Tablet|1 tablet once a day
7221|NCT00734032|Drug|SB480848 80mg EC Tablet|1 tablet once a day
7222|NCT00734032|Drug|SB480848 160mg EC Tablet|1 tablet once a day
7223|NCT00734032|Drug|SB480848 Placebo Tablet|1 tablet once a day
7224|NCT00736112|Procedure|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
7225|NCT00736125|Device|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
7226|NCT00005987|Drug|mitoxantrone hydrochloride|
7227|NCT00736125|Device|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
7228|NCT00736138|Procedure|training and pellots|training and pellots
7229|NCT00736151|Drug|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
7230|NCT00736164|Dietary Supplement|selenomethionine|Given orally
7231|NCT00736164|Other|placebo|Given orally
7232|NCT00736177|Procedure|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
7233|NCT00736177|Procedure|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
7234|NCT00736190|Drug|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
7235|NCT00736216|Other|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases [STDs], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
6922|NCT00763945|Other|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
6923|NCT00763958|Drug|Placebo|Placebo to match buprenorphine administered for 3 months
6924|NCT00763958|Drug|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
6925|NCT00763971|Drug|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
6926|NCT00000723|Drug|Dexamethasone|
6927|NCT00006144|Drug|Emtricitabine|
6928|NCT00763971|Drug|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
6929|NCT00763971|Drug|Placebo|Placebo capsule once per day (Overencapsulated)
6930|NCT00763984|Behavioral|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
7298|NCT00734097|Drug|Esomeprazole 40 mg|Once a day
7299|NCT00734097|Procedure|Physical Exam|every visit
7300|NCT00005981|Drug|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
7301|NCT00734097|Other|Quality of Life Questionnaires|every visit
7302|NCT00734097|Procedure|pregnancy test, if applicable|as needed
7303|NCT00734110|Device|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
7304|NCT00734123|Drug|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
7305|NCT00734123|Drug|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
7306|NCT00734123|Drug|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
7307|NCT00734123|Drug|Rimonabant|In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.
Drugs will be prescribed as the standard clinical care
7308|NCT00734136|Procedure|Blood Draws and a hepatectomy specimen|Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).
Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.
Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)
2584|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
2585|NCT00712127|Other|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
2586|NCT00712127|Other|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
2587|NCT00712140|Biological|trastuzumab|Given IV
2588|NCT00712140|Drug|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
2589|NCT00712166|Drug|AZLI 75 mg three times daily (TID)|
2590|NCT00712166|Drug|Placebo three times daily (TID)|
2591|NCT00712192|Procedure|coronary artery bypass grafting|patient with coroary artery diseases underwent coronary artery bypass grafting surgery
2894|NCT00724230|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
2895|NCT00724243|Drug|Infliximab|Infliximab given in accordance with the local summary of product characteristics
2896|NCT00005941|Radiation|radiation therapy|
2897|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
2898|NCT00726726|Drug|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
2899|NCT00726739|Biological|aldesleukin|IL-2 Alone - administer 10 x 10^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
2900|NCT00726739|Biological|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI [1 x 10^7, 5-μm silica spheres]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
2901|NCT00726752|Drug|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
2902|NCT00726791|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
2903|NCT00726804|Drug|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
3612|NCT00732810|Drug|Capecitabine|Capecitabine 1250 mg/m^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
3613|NCT00000703|Drug|Cyclophosphamide|
3614|NCT00005977|Drug|leucovorin calcium|Given IV
3615|NCT00732810|Drug|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
3616|NCT00732823|Device|Placebo - No device worn|
3617|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3618|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3619|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
3620|NCT00732836|Drug|HAI Abraxane|Escalating doses (beginning dose 180 mg/m^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
3621|NCT00732836|Procedure|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
3622|NCT00732836|Drug|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
3623|NCT00732849|Drug|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
3624|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
3625|NCT00005977|Drug|methotrexate|Given IV
3626|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
3627|NCT00732875|Biological|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
6821|NCT00770770|Drug|Fluocinolone Acetonide|0.5 µg/day
6822|NCT00770783|Device|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
6823|NCT00770783|Device|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
6824|NCT00770796|Drug|Atorvastatin|80 mg die
6825|NCT00770796|Drug|Placebo|
6826|NCT00770809|Drug|Lapatinib Ditosylate|Given PO
7236|NCT00736229|Drug|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
6273|NCT00770107|Drug|Placebo|Placebo, once daily, for a duration of 4 weeks
6274|NCT00770120|Drug|everolimus|
6275|NCT00770133|Drug|Ketotifen/naphazoline|One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
6276|NCT00770133|Drug|Naphazoline|One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
6277|NCT00770133|Drug|Ketotifen|One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
6278|NCT00770133|Drug|Vehicle|One drop of vehicle ophthalmic solution at visit 3 and visit 4.
6279|NCT00006203|Drug|naltrexone (Revia)|
6280|NCT00770146|Drug|Mipomersen sodium|200 mg/mL
6281|NCT00770146|Drug|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
6282|NCT00770159|Drug|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
6283|NCT00772668|Drug|Bortezomib|1.6 mg/m2 IV push over 3-5 seconds on Days 1 and 8 of every 21 days cycle for 8 cycles
6284|NCT00772668|Drug|Cyclophosphamide|750 mg/m2 IVPB over 30 minuntes on Day 1 of every 21 day cycle for 8 cycles
6285|NCT00772668|Drug|Prednisone|100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles
6286|NCT00772681|Drug|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
6287|NCT00772694|Drug|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
6288|NCT00772707|Device|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI‐FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
6289|NCT00772707|Device|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
6290|NCT00772720|Drug|raltegravir|raltegravir 400 mg BID for 7 days
6291|NCT00772720|Drug|Placebo|Placebo BID for 7 days
6292|NCT00006224|Drug|gemcitabine hydrochloride|
7309|NCT00734136|Procedure|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
7310|NCT00734149|Drug|Bortezomib|
7311|NCT00005982|Drug|nelarabine|Given IV
7312|NCT00734149|Drug|Melphalan|
7313|NCT00734149|Drug|Prednisone|
7314|NCT00734162|Drug|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet, once daily (QD)
7315|NCT00734162|Drug|Placebo|Placebo to match TDF QD
7316|NCT00734175|Biological|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
7317|NCT00734188|Drug|PTI-6D2|monoclonal antibody
7318|NCT00734201|Drug|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
7319|NCT00734214|Drug|0.9% NaCl|Intravenous Fluid
Isotonic Parenteral Fluid
6365|NCT00770185|Other|immunohistochemistry staining method|
6366|NCT00770185|Other|laboratory biomarker analysis|
6367|NCT00770211|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
6368|NCT00006204|Drug|naltrexone (Revia)|
6369|NCT00770211|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
6370|NCT00770224|Biological|rituximab|
6371|NCT00770224|Biological|tositumomab|
6372|NCT00770224|Drug|cyclophosphamide|
6373|NCT00770224|Drug|doxorubicin|
6374|NCT00770224|Drug|prednisone|
6375|NCT00770224|Drug|vincristine|
6376|NCT00770224|Radiation|tositumomab|
2904|NCT00726817|Drug|Butyrate|
2905|NCT00726830|Drug|methadone hydrochloride|Given orally
2906|NCT00726830|Drug|morphine sulfate|Given orally
2907|NCT00726830|Drug|oxycodone hydrochloride|Given orally
2908|NCT00005948|Biological|recombinant interferon alfa|
2909|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
2910|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
2911|NCT00726856|Drug|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
2912|NCT00726869|Drug|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8.
3215|NCT00729872|Biological|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
3216|NCT00729872|Other|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
3217|NCT00729885|Device|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
3218|NCT00729885|Device|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
3219|NCT00729898|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
3220|NCT00729911|Procedure|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
3221|NCT00729911|Drug|Amiodarone|Taken orally on a daily basis.
3222|NCT00732420|Drug|pazopanib|Tyrosine kinase inhibitor
3223|NCT00732433|Procedure|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
6827|NCT00770809|Biological|Trastuzumab|Given IV
6828|NCT00770809|Drug|Paclitaxel|Given IV
6829|NCT00770809|Other|Laboratory Biomarker Analysis|Correlative studies
6830|NCT00770822|Device|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
6831|NCT00006208|Drug|Stavudine|
6832|NCT00770822|Device|Brachytherapy|Standard of care
6833|NCT00770835|Drug|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
6834|NCT00770835|Drug|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
6835|NCT00770848|Drug|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
6836|NCT00770848|Drug|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
6837|NCT00770848|Drug|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
6838|NCT00770848|Drug|Placebo|Placebo
6839|NCT00770848|Drug|Prednisone|5 mg orally BID
6840|NCT00006142|Behavioral|phenylalanine restricted diet|
6841|NCT00763763|Drug|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
6842|NCT00763776|Device|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
6843|NCT00763776|Device|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
6844|NCT00763789|Other|local anaesthesia and remifentanil sedation|
6845|NCT00763789|Other|total intravenous anaesthesia|
7108|NCT00771316|Drug|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
7109|NCT00771329|Drug|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
7110|NCT00771329|Other|Placebo (sterile normal saline)|Single IV dose of Placebo
6293|NCT00772759|Drug|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
6294|NCT00772759|Drug|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
6295|NCT00772772|Drug|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
6588|NCT00772967|Drug|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
6589|NCT00772980|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
6590|NCT00772980|Drug|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
6591|NCT00773019|Device|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
6592|NCT00765843|Device|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
6593|NCT00765856|Drug|Oxymorphone IR - Opioid|Opana IR 5mg tablet
6594|NCT00006161|Procedure|Distal Splenorenal Shunt|
6595|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
6596|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
6597|NCT00765869|Other|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
6598|NCT00765882|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
6599|NCT00765882|Drug|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
6600|NCT00765882|Drug|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
6601|NCT00765895|Drug|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
6377|NCT00770237|Behavioral|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
6378|NCT00770237|Behavioral|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
6379|NCT00006204|Drug|fluoxetine (Prozac)|
6380|NCT00770263|Drug|Erlotinib|
6381|NCT00770263|Drug|Temsirolimus|
6382|NCT00770289|Other|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
6383|NCT00770302|Drug|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
6384|NCT00770315|Biological|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
6385|NCT00770315|Biological|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
6666|NCT00753662|Device|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
6667|NCT00753662|Device|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
6668|NCT00753675|Drug|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
6669|NCT00753675|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
6670|NCT00753675|Drug|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
6671|NCT00753675|Drug|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
6672|NCT00753688|Drug|PAZOPANIB|800 mg once daily orally
6673|NCT00006083|Other|placebo|placebo injected subcutaneously daily
6674|NCT00753688|Drug|Placebo|matching placebo 800 mg once daily orally
3224|NCT00732446|Drug|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
3225|NCT00732446|Drug|Moxifloxacin|moxifloxacin 0,5% qid and
3226|NCT00732446|Drug|Dexamethasone|dexamethasone 0,1% qid
3227|NCT00005977|Biological|filgrastim|Given IV
3228|NCT00732459|Device|Electro-acupuncture preconditioning|electro-acupuncture
3229|NCT00732472|Drug|GSK573719|7 day repeat dose
3230|NCT00732485|Drug|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
3231|NCT00732485|Drug|placebo|Placebo, sugar pill, from admission to 6 months post burn
3232|NCT00732498|Drug|methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
3233|NCT00732498|Drug|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
3234|NCT00732498|Drug|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
3543|NCT00725400|Other|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
3544|NCT00725400|Procedure|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
3545|NCT00725413|Drug|etonogestrel implant (Implanon)|subdermal etonogestrel implant
3546|NCT00725426|Drug|Bosutinib|
3547|NCT00725439|Drug|Talarozole|Oral Dose 1.0 mg once daily
3548|NCT00725452|Biological|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
3549|NCT00725478|Drug|Piribedil|
7111|NCT00771342|Drug|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
7112|NCT00771342|Drug|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
7113|NCT00771368|Drug|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
7114|NCT00771381|Drug|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
7115|NCT00771381|Drug|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
7116|NCT00771394|Drug|Tamsulosin hydrochloride|oral
7117|NCT00006212|Radiation|phosphorus P32|
7118|NCT00771394|Drug|Solifenacin succinate|oral
7119|NCT00771407|Device|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
7120|NCT00771407|Other|Standard ostomy creation|Ostomy will be created as routinely performed
7121|NCT00771420|Drug|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
7122|NCT00771420|Drug|CAM-3001|Dosed at 0.1mg/kg.
7123|NCT00771420|Drug|CAM-3001|Dosed at 0.3mg/kg
7124|NCT00771420|Drug|CAM-3001|Dosed at 1.0 mg/kg.
7125|NCT00771420|Drug|CAM-3001|Dosed at 3.0 mg/kg.
7126|NCT00771420|Drug|CAM-3001|Dosed at 10 mg/kg.
7127|NCT00764231|Behavioral|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
7128|NCT00764244|Procedure|Vitrectomy|Vitrectomy
7129|NCT00764244|Drug|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
7130|NCT00764244|Procedure|Laser photocoagulation|Laser photocoagulation
7492|NCT00741884|Drug|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
6602|NCT00765895|Drug|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
6603|NCT00765908|Device|Angioplasty balloon|90 second balloon inflation x 2
6604|NCT00765908|Device|Angioplasty balloon|30 seconds or less balloon inflations x 2
6605|NCT00006162|Behavioral|exercise and diet|
6606|NCT00765921|Drug|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
6607|NCT00765934|Drug|Rapydan|lidocaine / tetracaine 70/70 mg patch
6866|NCT00006165|Behavioral|'Ohana (Family) Support Lifestyle Intervention|
6867|NCT00766311|Other|Knee extension strength|Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is "broken."
6868|NCT00766311|Other|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
6869|NCT00766311|Other|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
6870|NCT00766311|Other|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
6871|NCT00766311|Other|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
6872|NCT00766311|Other|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
6873|NCT00766324|Drug|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
6874|NCT00766324|Drug|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
6875|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
6675|NCT00753714|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
6676|NCT00753714|Drug|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
6677|NCT00753714|Drug|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
6678|NCT00753727|Drug|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
6679|NCT00753727|Radiation|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
6680|NCT00006163|Behavioral|Personalized Self-management|
6681|NCT00766012|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
6682|NCT00766012|Drug|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
6931|NCT00763984|Behavioral|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
6932|NCT00763997|Drug|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
6933|NCT00763997|Drug|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
6934|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
6935|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
6936|NCT00763997|Drug|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
3550|NCT00725491|Drug|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
3551|NCT00725491|Drug|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 <= 50 pg/ml (<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
3552|NCT00728000|Drug|Erlotinib|100mg/day PO on days 1-14 and 15-28
3553|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
3554|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
3555|NCT00728052|Drug|GSK598809, placebo|treatment drug
3556|NCT00728065|Dietary Supplement|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
3557|NCT00728065|Dietary Supplement|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
3558|NCT00728065|Dietary Supplement|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
3559|NCT00728065|Dietary Supplement|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
2592|NCT00005851|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
2593|NCT00712205|Drug|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
2594|NCT00712205|Drug|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
2595|NCT00712218|Procedure|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
2596|NCT00712218|Procedure|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions [24, ].
2597|NCT00712244|Device|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
7493|NCT00741884|Drug|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
7494|NCT00734279|Drug|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
7495|NCT00734292|Drug|fluticasone propionate, formoterol fumarate|● Period 1 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)
● Period 2 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
● Period 3 Treatment Regimen C: placebo
SKP placebo; (two actuations)
7496|NCT00734292|Other|fluticasone propionate, formoterol fumarate|● Period 1 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
● Period 2 Treatment Regimen C: placebo
SKP placebo; (two actuations)
● Period 3 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)
7497|NCT00734292|Other|fluticasone propionate, formoterol fumarate|● Period 1 Treatment Regimen C: placebo
SKP placebo; (two actuations)
● Period 2 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)
● Period 3 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
7498|NCT00734305|Drug|MM-121|Dose escalation Frequency - once weekly
7499|NCT00734318|Drug|Flutiform 250/10 micrograms|
7500|NCT00734318|Drug|Flutiform 50/5 micrograms|
7501|NCT00005984|Drug|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
7502|NCT00734318|Drug|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
7503|NCT00734318|Drug|Flixotide pMDI 250 micrograms|
7504|NCT00734344|Drug|Raltegravir, tenofovir, emtricitibine|Raltegravir 400 mg. BID combined with tenofovir 300 mg and emtricitibine 200 mg once daily
7505|NCT00734344|Drug|Efavirenz plus tenofovir with emtricitibine|efavirenz 600 mg once daily combined with tenofovir 300mg and emtricitibine 200mg once daily
7506|NCT00734357|Procedure|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
7507|NCT00734370|Behavioral|Virtual Reality Exposure Therapy for agoraphobic participants|This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
Psycho-education, breathing training and cognitive restructuring
Virtual reality Exposure to agoraphobic situations and interoceptive exposure
Relapse prevention
6876|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
6877|NCT00006166|Procedure|Transjugular intrahepatic portasystemic shunts (TIPS)|
6878|NCT00766337|Drug|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
6879|NCT00766350|Drug|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
6880|NCT00766350|Drug|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
6881|NCT00766363|Drug|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
6882|NCT00766363|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
7237|NCT00005987|Drug|recombinant interferon alfa|
7238|NCT00736242|Biological|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
7239|NCT00736242|Drug|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
7240|NCT00736255|Drug|Lis-dexamphetamine (LDX; Vyvanse) and Transdermal Nicotine Patch|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week. All subjects will continue to receive transdermal nicotine patch during these weeks. The dose will be tapered down from 21 mg to 14mg after week 1,then to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
7241|NCT00736255|Drug|Placebo and transdermal nicotine patch|Subjects on this arm will receive matching placebo and NRT.
7242|NCT00736268|Behavioral|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
7243|NCT00738933|Dietary Supplement|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
7244|NCT00738933|Dietary Supplement|placebo|Margarine product without plant stanol or sterol esters
7245|NCT00738946|Drug|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
6937|NCT00763997|Other|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
6938|NCT00006144|Drug|Stavudine|
6939|NCT00764010|Dietary Supplement|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
6940|NCT00766363|Drug|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
6941|NCT00766363|Drug|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
6942|NCT00766363|Drug|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
6943|NCT00766376|Device|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
6944|NCT00006166|Procedure|Total paracentecis (TP)|
6945|NCT00766402|Drug|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
6946|NCT00766402|Drug|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
6947|NCT00766415|Drug|AZD1981|Oral tablet, twice daily, 4 weeks treatment
6948|NCT00766415|Drug|Placebo|Placebo
6949|NCT00766441|Drug|Sitagliptin|tablet, 100mg, once daily, 4 weeks
6950|NCT00766441|Drug|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
7320|NCT00736268|Other|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
7321|NCT00736281|Other|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
7322|NCT00736294|Drug|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
2598|NCT00712244|Device|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
2599|NCT00712244|Device|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
2600|NCT00712244|Device|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
2601|NCT00712257|Device|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
2602|NCT00712270|Drug|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
2603|NCT00005851|Drug|cyclosporine|Given PO or IV
2604|NCT00712270|Drug|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
2605|NCT00712283|Drug|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
2606|NCT00712296|Drug|ASHMI|6 capsules orally twice a day
2607|NCT00712296|Drug|ASHMI|2 capsules orally twice a day
2608|NCT00712296|Drug|Placebo|Placebo 6 capsules twice a day
2913|NCT00726882|Procedure|Blood sample collection only|Approximately monthly collection of blood samples.
2914|NCT00726882|Drug|ABT-333|Previous treatment in prior ABT-333 studies.
2915|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
2916|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
2917|NCT00726908|Dietary Supplement|Low carbohydrate|43% CHO
2918|NCT00726934|Other|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
2919|NCT00005948|Biological|sargramostim|
7508|NCT00734370|Behavioral|Standard exposure in vivo for agoraphobic participants|This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
Psycho-education, breathing training and cognitive restructuring
Standard exposure in vivo to agoraphobic situations and interoceptive exposure
Relapse prevention (according to the protocol of Craske & Barlow)
6528|NCT00006184|Drug|Cyclophosphamide|Induction chemotherapy: 600 mg/m^2 day 4 Transplant: 1200 mg/m^2 intravenous x 4 days (days -6, -5, -4, -3)
6529|NCT00768157|Drug|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
6530|NCT00768157|Procedure|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
6531|NCT00768170|Drug|MK0633|MK0633 (50 mg) Oral, single dose
6532|NCT00768183|Other|KADIAN + Ethanol|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
6533|NCT00768183|Other|KADIAN + Water|Capsules 100mg + 240 mL in 4 shots of 60 mL
6534|NCT00768183|Other|morphine sulfate IR oral solution + water|Solution 20mg/5mL, 235 mL of water in 1 shot of 55 mL (+ 5mL IR morphine) + 3 shots of 60 mL of water
6535|NCT00768209|Drug|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
6536|NCT00768222|Device|silk suture|skin closure
6537|NCT00768222|Device|VICRYL* Plus suture|skin closure
6538|NCT00768235|Other|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
6539|NCT00006184|Drug|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
6540|NCT00768248|Drug|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
6541|NCT00768248|Drug|normal saline (placebo)|the basal rate will be set at 7 mL/h
6542|NCT00768261|Drug|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
6543|NCT00768261|Drug|Memantine (Namenda®)|Initial dose of 10mg/day and increased to full dose of 20mg/day if no serious side-effects
6544|NCT00768261|Drug|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
7246|NCT00738959|Drug|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
7247|NCT00738972|Drug|valsartan|80 mg valsartan. Duration: 12 months. Tablets
7248|NCT00738972|Drug|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
7249|NCT00738972|Drug|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
7250|NCT00738972|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
7251|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
7252|NCT00005998|Drug|retrovirus vector LN|
7253|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
7254|NCT00738998|Behavioral|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
6296|NCT00772785|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
6297|NCT00772798|Drug|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
6298|NCT00772811|Drug|Flu-Mel|Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.
Melphalan will be administered following the completion of Fludarabine infusion at day -2.
6299|NCT00772824|Dietary Supplement|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
6300|NCT00772824|Dietary Supplement|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
6301|NCT00772837|Drug|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
6302|NCT00772837|Drug|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
6303|NCT00006225|Biological|filgrastim|
6304|NCT00772863|Drug|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
6305|NCT00772876|Drug|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
6306|NCT00772889|Biological|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
7323|NCT00736294|Drug|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
7324|NCT00736307|Procedure|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
7325|NCT00000703|Drug|Zidovudine|
7326|NCT00005987|Drug|sargramostim|
7327|NCT00736320|Drug|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
7328|NCT00736320|Radiation|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
7329|NCT00736333|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m^2, given for up to 6 cycles
7330|NCT00736346|Behavioral|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
7331|NCT00736346|Behavioral|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
7332|NCT00736346|Drug|paroxetine|40 mg die, for 6 months
7333|NCT00736372|Drug|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
7334|NCT00736385|Drug|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
7335|NCT00736385|Drug|Placebo|placebo 2000 mg daily for 12 months
7336|NCT00736398|Procedure|Spinal fusion|Spinal fusion
7337|NCT00005987|Procedure|bone marrow ablation with stem cell support|
7338|NCT00736411|Procedure|acupuncture|16 treatments over 8 weeks
7339|NCT00736411|Procedure|IVF|one 4 week IVF cycle
6386|NCT00772148|Drug|LCP -Tacro|LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.
Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)
6387|NCT00772148|Drug|Prograf|Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.
Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)
6388|NCT00772161|Drug|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
2920|NCT00729443|Drug|AZD3241|single oral dose
2921|NCT00005961|Drug|carmustine|
2922|NCT00729443|Drug|Placebo|
2923|NCT00729456|Other|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
2924|NCT00729469|Drug|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12)
2925|NCT00729469|Drug|Placebo|
2926|NCT00729469|Drug|Non-hormonal vaginal lubricant|Vaginal lubricant should be used as needed
2927|NCT00729482|Drug|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
2928|NCT00729495|Drug|celecoxib|dose form
2929|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
2930|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
2931|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
2932|NCT00005962|Biological|sargramostim|
2933|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
2934|NCT00729508|Biological|Cat-PAD|Placebo
3235|NCT00732498|Drug|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
3236|NCT00732498|Drug|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
3237|NCT00732498|Drug|In Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
3238|NCT00005977|Drug|cyclophosphamide|Given IV
3239|NCT00732498|Drug|Y Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from >/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
3240|NCT00732511|Drug|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
6545|NCT00768274|Drug|RVX000222 (common name RVX-208)|RVX000222 or placebo twice daily (b.i.d.) for 28 days
6546|NCT00768287|Biological|IB1001 (On-Demand)|use as needed
6547|NCT00768287|Biological|IB1001 (Prophylaxis)|use on a prophylaxis basis
6548|NCT00768300|Drug|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
7131|NCT00764257|Device|PREVELLE Shape|
7132|NCT00764257|Device|Restylane|
7133|NCT00764270|Dietary Supplement|Crossover of R-alpha lipoic acid and placebo|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of placebo or 300 mg R-alpha-lipoic acid for 12 weeks
7134|NCT00006151|Behavioral|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
7135|NCT00764283|Device|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
7136|NCT00764283|Device|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
7137|NCT00764283|Device|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
7138|NCT00764296|Other|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
7139|NCT00764296|Other|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
7140|NCT00764309|Drug|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
7141|NCT00764322|Drug|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
7142|NCT00764322|Genetic|gene expression analysis|Genetic analysis of blood sample.
7143|NCT00764322|Other|pharmacogenomic studies|Genetic analysis of blood sample.
7144|NCT00764322|Other|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
7145|NCT00006152|Drug|Ritonavir|
7146|NCT00764322|Procedure|quality-of-life assessment|Self administration of a multiquestion questionnaire called the FACT-B. Given pre-study, at 4 months and at 8-10 months.
7147|NCT00764348|Other|no treatment|
6307|NCT00772889|Biological|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
6308|NCT00765323|Drug|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
6309|NCT00765323|Drug|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range ~10-40 mg every 28 days)
6310|NCT00765336|Drug|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
6311|NCT00765336|Drug|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
6312|NCT00765362|Device|Encore Mobile-Bearing Knee|Used for primary total knee replacement
6313|NCT00765375|Drug|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
6314|NCT00006157|Drug|Desipramine|
6315|NCT00765375|Drug|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
6316|NCT00765388|Device|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
6317|NCT00765388|Device|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
6608|NCT00765947|Drug|Aliskiren|Aliskiren 150 or 300 mg
6609|NCT00765947|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
6610|NCT00765947|Drug|Amlodipine|Amlodipine 5 or 10 mg
6611|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
6612|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
6613|NCT00765986|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
6614|NCT00765986|Other|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
6615|NCT00765999|Drug|Linaclotide 300 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
6616|NCT00006184|Drug|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m^2 day continuous intravenous (CIV) days 1-3
6389|NCT00772174|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
6390|NCT00772174|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
6391|NCT00772187|Drug|morphine|Single dose: 0.1-0.5 mg
6392|NCT00772187|Drug|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
6393|NCT00772187|Drug|general anesthesia (fentanyl)|general anesthesia alone
6394|NCT00772200|Procedure|psychosocial assessment and care|Complete COG Standard Neuropsychological and Behavioral Battery testing
6395|NCT00006219|Drug|clarithromycin|
6396|NCT00772200|Procedure|cognitive assessment|Complete COG Standard Neuropsychological and Behavioral Battery testing
6397|NCT00772200|Other|quality-of-life assessment|Ancillary studies
6398|NCT00772200|Other|questionnaire administration|Ancillary studies
6399|NCT00772213|Procedure|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
6400|NCT00772226|Device|music pillow|according to randomisation patients will receive with/without music.
6401|NCT00772226|Device|pillow without music|According to randomisation patients will receive a pillow with/without music
6402|NCT00772239|Device|Rotation thromboelastometry (ROTEM)|Coagulation measurement
6403|NCT00772239|Procedure|Standard coagulation managment procedure|Standard coagulation managment procedure
6404|NCT00772252|Other|liver support treatment|plasma exchange for liver support treatment
6405|NCT00772265|Biological|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
6406|NCT00006219|Drug|prasterone|
6683|NCT00766025|Drug|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
6684|NCT00766038|Drug|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
6685|NCT00766038|Drug|Placebo|SC injection daily
3241|NCT00732511|Drug|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
3242|NCT00732524|Drug|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
3243|NCT00732524|Drug|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
3244|NCT00724776|Biological|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
3245|NCT00724789|Drug|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
3246|NCT00724789|Drug|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
3247|NCT00724802|Dietary Supplement|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
3248|NCT00005944|Drug|fluorouracil|
3249|NCT00724802|Drug|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
3250|NCT00724815|Drug|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
3251|NCT00724815|Drug|Placebo|NP101 Placebo iontophoretic transdermal patch
3252|NCT00724841|Drug|GMX1777|GMX1777 at various doses in combination with temozolomide
3253|NCT00724854|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
3254|NCT00724854|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
3255|NCT00724867|Biological|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV over one hour every 28 days
3560|NCT00728065|Dietary Supplement|Rice milk|Rice milk containing 50g of available carbohydrates
3561|NCT00728065|Dietary Supplement|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
3562|NCT00005956|Biological|HER-2/neu intracellular domain protein|
3563|NCT00728065|Dietary Supplement|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
3564|NCT00728065|Dietary Supplement|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
7148|NCT00764361|Drug|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
7149|NCT00764361|Drug|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
7150|NCT00764374|Drug|YM443|oral
7151|NCT00764387|Drug|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
7152|NCT00764387|Drug|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
7153|NCT00738790|Radiation|Short course of radiotherapy|5 x 5 Gy plus boost 4 Gy
7174|NCT00005998|Drug|mitoxantrone hydrochloride|
7175|NCT00738933|Dietary Supplement|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
7176|NCT00741312|Behavioral|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
7177|NCT00741325|Drug|granulocyte colony-stimulating factor (G-CSF)|
7178|NCT00741325|Drug|plerixafor|
7179|NCT00741325|Drug|Placebo|
7180|NCT00741338|Biological|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
7181|NCT00741338|Drug|Cyclosporine A (CsA)|Orally three times daily.
7182|NCT00741338|Drug|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
7183|NCT00741351|Drug|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
7184|NCT00006012|Drug|amifostine trihydrate|
7185|NCT00741351|Drug|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
7186|NCT00741351|Drug|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
7187|NCT00741364|Dietary Supplement|vitamin D3 (cholecalciferol)|liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
6617|NCT00768313|Device|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
6618|NCT00768313|Device|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
6619|NCT00768326|Drug|Zicronapine|Study Part A:
3mg; orally, film-coated tablets, once daily, 8 weeks
6620|NCT00768326|Drug|Zicronapine|Study Part B:
5mg; orally, film-coated tablets, once daily, 8 weeks
6621|NCT00768326|Drug|Zicronapine|Study Part C:
7mg; orally, film-coated tablets, once daily, 8 weeks
6622|NCT00768326|Drug|Zicronapine|Study Part D:
2 x 5mg; orally, film-coated tablets, once daily, 8 weeks
6623|NCT00768326|Drug|Zicronapine|Study Part E:
2 x 7mg; orally, film-coated tablets, once daily, 8 weeks
6624|NCT00768326|Drug|Placebo|Study Part A, B, C, D and E:
Placebo; orally, film-coated tablets, once daily, 8 weeks
6625|NCT00768339|Drug|AEG35156 antisense IV infusion|AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.
Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.
Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion
6626|NCT00768352|Other|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
6883|NCT00766363|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
6884|NCT00768768|Other|ETS-Terbinafine Gel|Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min
6885|NCT00768768|Other|ETS-Terbinafine Gel|Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min
6886|NCT00768768|Other|ETS-Terbinafine Gel|Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min
6686|NCT00766051|Other|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
6687|NCT00766064|Drug|Paliperidone|Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:
Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily*, Week 6: fixed dose,
*Criteria to increase the dose from 3 mg to 6 mg daily are 1] absence of any side effects, 2] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline.
6688|NCT00766090|Drug|GW685698X|Inhaled Corticosteroid
6689|NCT00766103|Other|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
6690|NCT00766116|Drug|5-Azacitidine|A = given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit
6691|NCT00006163|Behavioral|Community Resources|
6692|NCT00766116|Drug|Gemtuzumab ozogamicin|M = Mylotarg given 2 times over 2 weeks
6693|NCT00766129|Device|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
6694|NCT00766129|Device|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
6695|NCT00766142|Biological|cetuximab|
6696|NCT00766142|Drug|fluorouracil|
6697|NCT00766142|Drug|leucovorin calcium|
6698|NCT00766142|Drug|oxaliplatin|
6699|NCT00766142|Procedure|adjuvant therapy|
6700|NCT00766142|Procedure|therapeutic conventional surgery|
6701|NCT00766155|Drug|capecitabine|Given orally
6702|NCT00006164|Drug|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight <75 kg, >75 kg) daily in two divided doses for 24 weeks
6703|NCT00768456|Drug|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
6951|NCT00766454|Genetic|DNA analysis|
3565|NCT00728078|Drug|thalidomide|thalidomide 50mg tid for 6 months
3566|NCT00728091|Drug|satavaptan (SR121463)|tablets
3567|NCT00728091|Drug|satavaptan (SR121463)|tablets
3568|NCT00728091|Drug|placebo|tablets
3569|NCT00728117|Other|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
3570|NCT00728117|Other|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
3571|NCT00728130|Procedure|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
3572|NCT00728143|Dietary Supplement|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
3573|NCT00005956|Biological|therapeutic autologous dendritic cells|
3574|NCT00728156|Drug|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
3575|NCT00728156|Drug|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
3576|NCT00730392|Drug|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
3577|NCT00730392|Drug|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
3578|NCT00730405|Drug|Albaconazole 100mg|Albaconazole for 36 weeks
3579|NCT00730405|Drug|Albaconazole 200mg|Albaconazole for 36 weeks
3580|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 36 weeks
3581|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
2609|NCT00712309|Device|Lifestent|Stent for endovascular treatment of popliteal artery lesions
2610|NCT00712309|Device|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
2611|NCT00712322|Drug|Darifenacin|(0.030 mg/kg/day)
2612|NCT00712322|Drug|Darifenacin|(0.0625 mg/kg/day)
7188|NCT00741377|Drug|BHQ880|
7189|NCT00741377|Drug|Zoledronic acid|
7190|NCT00741390|Device|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
7191|NCT00741390|Device|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
7192|NCT00741390|Device|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
7193|NCT00741390|Device|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
7194|NCT00741390|Device|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
7509|NCT00734383|Drug|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
7510|NCT00734383|Drug|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
7511|NCT00734396|Procedure|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
7512|NCT00736593|Drug|Nexagon™ or Nexagon™ vehicle|
7513|NCT00736606|Drug|simvastatin|One single dose of 40mg
7514|NCT00736606|Drug|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
7515|NCT00736619|Other|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.
The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored.
7516|NCT00736632|Drug|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
7517|NCT00736632|Drug|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
7518|NCT00736645|Dietary Supplement|selenomethionine|Given orally
6887|NCT00768768|Other|ETS-Terbinafine Gel|Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min
6888|NCT00768781|Behavioral|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
6889|NCT00768781|Behavioral|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
6890|NCT00768781|Behavioral|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
6891|NCT00768794|Dietary Supplement|Acidophilus|Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
7255|NCT00738998|Other|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
7256|NCT00739011|Device|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
7257|NCT00739024|Drug|Ramelteon|8 mg tablet, oral, once daily
7258|NCT00739024|Drug|Placebo|Placebo tablet, oral, once daily
7259|NCT00739037|Drug|Placebo|
7260|NCT00739037|Drug|PAZ-417|
7261|NCT00739050|Drug|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
7262|NCT00739050|Drug|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
6952|NCT00766454|Genetic|mutation analysis|
6953|NCT00766454|Genetic|polymorphism analysis|
6954|NCT00766454|Other|laboratory biomarker analysis|
6955|NCT00006167|Drug|oxandrolone|
6956|NCT00766454|Other|medical chart review|
6957|NCT00766454|Other|questionnaire administration|
6958|NCT00766454|Procedure|evaluation of cancer risk factors|
6959|NCT00766467|Drug|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
6960|NCT00766467|Other|Placebo|Placebo taken once a day in the morning
6961|NCT00766480|Drug|cisplatin|Given IV
6962|NCT00766480|Drug|fluorouracil|Given IV
6963|NCT00766480|Radiation|radiation therapy|Patients undergo radiotherapy
6964|NCT00766493|Device|GORE® Embolic Filter|Embolic protection during carotid stenting
6965|NCT00766506|Device|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
6966|NCT00006167|Behavioral|Progressive Resistance Training|
6967|NCT00766506|Device|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
6968|NCT00768820|Drug|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
6969|NCT00768846|Device|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
6970|NCT00768846|Device|Xience V Stent|Everolimus-eluting Xience V Stent
6971|NCT00768859|Drug|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
6972|NCT00768885|Device|PureVision 1|Currently marketed PureVision soft contact lens.
6973|NCT00768885|Device|PureVision 2|Alternate design soft contact lens.
2613|NCT00712322|Drug|Darifenacin|(0.125 mg/kg/day)
2614|NCT00005851|Drug|mycophenolate mofetil|Given PO or IV
2615|NCT00712322|Drug|Darifenacin|(0.250 mg/kg/day)
2616|NCT00712335|Drug|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
2617|NCT00712335|Drug|Montelukast|PO 10 mg QHS for 3 weeks
2618|NCT00712335|Drug|Salmeterol|DPI 50mg BID for 3 weeks
2619|NCT00712348|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
2620|NCT00712361|Device|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
2621|NCT00712374|Drug|sulfadoxine-pyrimethamine plus amodiaquine|SP+AQ on three occasions during the malaria transmission season
Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine
2622|NCT00712387|Behavioral|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
2623|NCT00712400|Drug|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
2624|NCT00712400|Drug|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
2625|NCT00005851|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
2626|NCT00712413|Drug|OBMT|Omeprazole 20 mg bid, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
2627|NCT00712426|Drug|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
2628|NCT00712426|Drug|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
2629|NCT00712439|Drug|Gabapentin Extended Release tablets|
2630|NCT00712439|Drug|Placebo|
7519|NCT00736645|Drug|finasteride|Given orally
7520|NCT00005988|Drug|cyclosporine|
7521|NCT00736645|Other|placebo|Given orally
7522|NCT00736658|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
7523|NCT00736658|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
7524|NCT00736684|Device|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
7525|NCT00736684|Device|Gamma Nail 3TM (Gamma3)|intramedullary nailing
7526|NCT00736697|Drug|moxidectin|
6549|NCT00768300|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
6550|NCT00770445|Drug|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
6551|NCT00770445|Drug|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
6552|NCT00770445|Drug|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
6553|NCT00770471|Drug|temozolomide|
6554|NCT00770471|Drug|veliparib|
6555|NCT00006205|Drug|Placebo + cognitive behavioral therapy|placebo
6556|NCT00770471|Genetic|DNA methylation analysis|
6557|NCT00770471|Genetic|gene expression analysis|
6558|NCT00770471|Genetic|mutation analysis|
6559|NCT00770471|Genetic|proteomic profiling|
6560|NCT00770471|Other|high performance liquid chromatography|
6561|NCT00770471|Other|immunoenzyme technique|
6562|NCT00770471|Other|laboratory biomarker analysis|
6563|NCT00770471|Other|mass spectrometry|
7263|NCT00005998|Procedure|in vitro-treated peripheral blood stem cell transplantation|
7264|NCT00739063|Drug|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
7265|NCT00739076|Behavioral|Virtual Reality|Using Virtual Reality for pain control
7266|NCT00739102|Device|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
7267|NCT00739115|Other|Heliox gas|Heliox gas used in conjunction with nasal CPAP
7268|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
7269|NCT00741442|Drug|RDEA806|Uricosuric agent for the treatment of gout
7270|NCT00741442|Drug|Placebo|Matching Placebo.
7271|NCT00741455|Procedure|Chemotherapy followed by Stem Cell Transplantation|Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be > 5 x 106 CD34+cells/kg of recipient.
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.
7272|NCT00741468|Drug|Proellex|2, 25 mg Proellex capsules administered daily
7273|NCT00741468|Drug|CYP1A2 probe|Caffeine (200 mg)
7274|NCT00741468|Drug|CYP2C9 probe|Tolbutamide (250 mg)
7275|NCT00741468|Drug|CYP2C19 probe|Omeprazole (20 mg)
6318|NCT00765414|Biological|Myozyme|30 mg/kg qow f and 40 mg/kg qow
6319|NCT00765427|Drug|QLT091001|7-day repeated dose
6320|NCT00765440|Dietary Supplement|therapeutic nutritional supplementation|Given orally
6321|NCT00765440|Other|placebo|Given orally
6322|NCT00765453|Other|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
6323|NCT00765453|Other|Placebo infusion|Placebo infusion
6974|NCT00768898|Other|2.5/5.0/10.0 ÂµL lissamine green|vital stain solution
7340|NCT00736424|Device|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
7341|NCT00736437|Drug|ME-609|Cream applied topically 6 times daily over the UVR exposed area
7342|NCT00736437|Drug|Vehicle|Treatment applied 6 times daily over the UVR exposed area
7343|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
7344|NCT00739141|Other|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
7345|NCT00739180|Other|Control|Standard care control (no exercise)
7346|NCT00739180|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
7347|NCT00739180|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
7348|NCT00005998|Procedure|peripheral blood stem cell transplantation|
7349|NCT00739193|Drug|amiodarone|
7350|NCT00739206|Drug|SAR97276A|Dose based on body weight
7351|NCT00739219|Device|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
7352|NCT00739232|Drug|HSD-016|
7353|NCT00739232|Other|placebo|
7354|NCT00739271|Other|Early feeding|
7355|NCT00739271|Other|late feeding after bowel sounds return|Traditional method
7356|NCT00739284|Device|nephrostomy tube and ureteral stent|
7357|NCT00739297|Drug|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
2935|NCT00729521|Other|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
2936|NCT00729521|Other|Standard Program|a "Standard Program" group receiving modest funding to implement an "evidence-based" fall prevention program in their local community;
2937|NCT00729547|Behavioral|Neurofeedback|enhance relative activity level of left frontal activity
2938|NCT00729547|Behavioral|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
2939|NCT00729560|Drug|Flutamide|250 mg twice daily for 4 weeks
2940|NCT00729560|Drug|Placebo|Placebo twice daily for 4 weeks
2941|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
2942|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
2943|NCT00005962|Drug|cyclophosphamide|
2944|NCT00729573|Drug|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
2945|NCT00729573|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
2946|NCT00731861|Drug|Paclitaxel plus PTK787|Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.
In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY.
2947|NCT00731874|Drug|Tacrolimus|Dosed to achieve target trough concentrations.
2948|NCT00731887|Procedure|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
2949|NCT00731913|Other|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
2950|NCT00731926|Dietary Supplement|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
6564|NCT00770471|Other|pharmacogenomic studies|
6565|NCT00770471|Other|pharmacological study|
6566|NCT00006205|Drug|ondansetron + topiramate + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
6567|NCT00770471|Procedure|adjuvant therapy|
6568|NCT00770471|Radiation|radiation therapy|
6569|NCT00770484|Drug|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
6570|NCT00770484|Drug|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
6571|NCT00770497|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:
Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks.
6572|NCT00770497|Drug|Pioglitazone and ramipril|Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:
Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.
7154|NCT00738790|Radiation|Radiochemotherapy|28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
7155|NCT00738803|Procedure|Total hip replacement|Total hip replacement typically preformed for hip arthritis
7156|NCT00738816|Other|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
7157|NCT00738829|Drug|Lenalidomide|Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.
During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage.
7158|NCT00738829|Drug|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
7159|NCT00738829|Biological|Rituximab|Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.
Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage.
7160|NCT00738842|Drug|AZD6140|Oral tablets taken bid for 5 days
7161|NCT00738842|Drug|Placebo to match AZD6140|Oral tablets taken bid for 5 days
7162|NCT00738855|Other|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
6324|NCT00765466|Drug|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
6325|NCT00000724|Drug|Leucovorin calcium|
6326|NCT00006157|Behavioral|Cognitive Behavioral Treatment|
6327|NCT00765479|Dietary Supplement|soy protein isolate|Given orally
6328|NCT00765479|Other|placebo|Given orally
6329|NCT00765492|Drug|AZD8529|oral
6330|NCT00765492|Drug|Placebo|oral
6331|NCT00765505|Behavioral|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
6332|NCT00765505|Behavioral|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
6333|NCT00765518|Biological|Cardiac Repair Cells (CRCs)|CRCs will be administered via direct injection into the heart muscle.
6334|NCT00765531|Radiation|Radiological testing|Bone mineral density
6335|NCT00767728|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
6336|NCT00767728|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
6337|NCT00767741|Device|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
6338|NCT00767754|Drug|Paxil CR|12 week treatment of Paxil(20-40mg)
6339|NCT00767767|Drug|Propofol|IV Propofol infusion for 2 hours.
6340|NCT00767767|Drug|Placebo|IV Saline infusion for 2 hours.
6341|NCT00767767|Drug|Thiopental|IV Thiopental infusion for 2 hours.
6342|NCT00000725|Drug|Interferon alfa-n1|
6627|NCT00006184|Drug|Etoposide|Induction chemotherapy: 50 mg/m^2 day continuous intravenous days 1-3
6628|NCT00768378|Device|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
9592|NCT00006101|Drug|eflornithine|
9593|NCT00756223|Drug|Arm B|Dose escalation Arm B (3 weeks)
9594|NCT00756236|Drug|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
9595|NCT00756236|Drug|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
9941|NCT00756730|Drug|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
9942|NCT00756743|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
9943|NCT00756743|Drug|Placebo|Placebo capsules q12 hours for 10 days
9944|NCT00756756|Drug|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
9945|NCT00756756|Drug|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
9946|NCT00756782|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
9947|NCT00756782|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
9948|NCT00756795|Behavioral|Intervention group|5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.
Structured Interview will be conducted at baseline and post-intervention.
Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.
All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis.
9949|NCT00006104|Drug|docetaxel|
9950|NCT00756847|Drug|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
9951|NCT00756847|Drug|paclitaxel|Intravenous injection dosed once every three weeks
9952|NCT00756847|Drug|carboplatin|Intravenous injection dosed once every three weeks
9953|NCT00756860|Drug|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
9954|NCT00756860|Drug|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
9955|NCT00756873|Drug|Administration of placebo|Placebo qd orally day 0-14
7903|NCT00740116|Drug|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to scin incision at surgery
7904|NCT00740116|Drug|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before scin incision at surgery.
7905|NCT00000706|Drug|Probenecid|
7906|NCT00006004|Drug|gemcitabine hydrochloride|
7907|NCT00740129|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
7908|NCT00740142|Drug|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
7909|NCT00740142|Drug|placebo and lactulose|placebo 3 times a day for 7 days
7910|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
7911|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
7912|NCT00740155|Biological|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
7913|NCT00740155|Biological|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
7914|NCT00740155|Biological|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
7915|NCT00740168|Drug|bevacizumab treatment|single infusion 10 mg/kg
7916|NCT00740181|Drug|chemotherapy|
7917|NCT00006004|Drug|paclitaxel|
7918|NCT00740194|Drug|Aromatase inhibition|Letrozole
7919|NCT00740194|Drug|Estradiol|Dermestril
8231|NCT00733135|Device|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
8232|NCT00735397|Drug|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
8233|NCT00735410|Biological|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
8234|NCT00735423|Device|No intervention|IDE used for outcome measurement not intervention
10010|NCT00754429|Drug|losartan|losartan 50mg qd for 30 weeks.
10011|NCT00754429|Drug|amlodipine|amlodipine 5 mg q.d for 30 weeks.
10012|NCT00754442|Drug|Teriparatide|Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both "patients" and "controls"
10013|NCT00754455|Biological|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
10014|NCT00754455|Biological|Placebo|Placebo as a single injection of 0.5 mL.
10015|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
10016|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
10017|NCT00754481|Other|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) will be maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who are hypothermic (temperature < 35 ºC) when randomized to the normothermia group will be rewarmed slowly using the servo-controlled mattress. Patients who are hyperthermic following randomization to the normothermia group will be actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers will be administered as needed intravenously in both groups of patients to prevent shivering.
10018|NCT00006087|Procedure|study of high risk factors|
9063|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
9064|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
9065|NCT00760552|Other|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
9066|NCT00760552|Other|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, & possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
9067|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
9068|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
7829|NCT00742079|Behavioral|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
7830|NCT00742092|Drug|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
7831|NCT00742092|Drug|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
7832|NCT00742105|Drug|BGT226|
7833|NCT00742118|Procedure|Colic biopsies|colic biopsies and analysis
7834|NCT00742131|Drug|GSK1363089 (formerly XL880)|Experimental drug
7835|NCT00742144|Drug|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
7836|NCT00742157|Drug|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
8151|NCT00735345|Drug|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
8152|NCT00735345|Drug|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
8153|NCT00735345|Drug|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
8154|NCT00735345|Biological|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
8155|NCT00735345|Radiation|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
8156|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
8157|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
8158|NCT00735371|Drug|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
8159|NCT00005986|Drug|cyclophosphamide|
8160|NCT00735371|Drug|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
8485|NCT00741117|Procedure|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
8486|NCT00006011|Biological|Pegfilgrastim|Given SC
8487|NCT00741117|Procedure|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
8488|NCT00733499|Device|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
8489|NCT00733499|Device|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
8490|NCT00733512|Device|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
8491|NCT00000703|Drug|Allopurinol|
8492|NCT00005978|Radiation|radiation therapy|
8493|NCT00733525|Behavioral|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
8494|NCT00733525|Drug|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
8495|NCT00733525|Behavioral|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
8496|NCT00733538|Drug|zometa|patients receiving treatment during their follow-up
7527|NCT00736710|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
7528|NCT00736710|Procedure|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
7529|NCT00736736|Other|Additional Hip Muscle Strengthening to Leg Press Exercise|
7530|NCT00736736|Other|Leg Press Exercise|
7531|NCT00005988|Drug|leucovorin calcium|
8235|NCT00735436|Drug|Gliadel/Avastin/CPT-11|
8236|NCT00735449|Drug|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
8237|NCT00735449|Drug|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
8238|NCT00735449|Drug|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
8239|NCT00005986|Drug|filgrastim|
8240|NCT00735462|Drug|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
8241|NCT00735462|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
8242|NCT00735462|Drug|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
8243|NCT00735475|Biological|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
8244|NCT00735475|Biological|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
8245|NCT00735488|Other|Observational|Summary of data
8246|NCT00735501|Drug|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
8247|NCT00735514|Behavioral|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
8248|NCT00735514|Other|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
8249|NCT00735514|Procedure|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
8556|NCT00738621|Drug|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
8557|NCT00741117|Procedure|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
9069|NCT00762736|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
9070|NCT00762749|Drug|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
9071|NCT00762762|Drug|Triclosan and fluoride|Brush twice daily
9072|NCT00006126|Radiation|radiation therapy|
9073|NCT00762762|Drug|Fluoride|swished twice daily
9074|NCT00762775|Dietary Supplement|Calcium and vitamin D supplementation|Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
9075|NCT00762788|Device|senofilcon A|1 week extended wear contact lens
9076|NCT00762788|Device|lotrafilcon A|1 week extended wear contact lens
9077|NCT00762788|Device|lotrafilcon B|1 week extended wear contact lens
9078|NCT00762788|Device|balafilcon A|1 week extended wear contact lens
9079|NCT00762788|Device|comfilcon A|1 week extended wear contact lens
9080|NCT00762788|Device|etafilcon A|1 week extended wear contact lens
9363|NCT00763256|Drug|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
9364|NCT00763256|Drug|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
9365|NCT00000723|Drug|Zidovudine|
9366|NCT00006133|Drug|ethinyl estradiol|
9367|NCT00763269|Drug|Triclosan, Silicon dioxide, fluoride|Brush twice daily
9368|NCT00763269|Drug|Triclosan, fluoride|Brush twice daily
9369|NCT00763282|Behavioral|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
9370|NCT00763282|Behavioral|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
8161|NCT00735371|Drug|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
8162|NCT00735371|Drug|Placebo|Placebo will be identical to test product.
8163|NCT00737724|Drug|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
8164|NCT00737737|Drug|MS Contin|
8165|NCT00737737|Drug|Placebo|
8166|NCT00737750|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
8167|NCT00737750|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
8168|NCT00737750|Behavioral|Control|Voluntary quadriceps muscle contractions.
8169|NCT00737763|Drug|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
8170|NCT00737763|Drug|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
8477|NCT00741039|Biological|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
8478|NCT00741052|Drug|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
8479|NCT00741052|Drug|Azithromycin|1 gm Azithromycin single dose
8480|NCT00741065|Procedure|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
8481|NCT00741078|Drug|statin, amlodipine|
8482|NCT00741091|Device|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
8483|NCT00741091|Device|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
8484|NCT00741104|Drug|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
7532|NCT00736749|Other|Questionnaire Administration|Complete patient response form and Health Status Update Form
7533|NCT00739544|Other|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
7534|NCT00739570|Device|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
7535|NCT00006000|Drug|irinotecan hydrochloride|
7536|NCT00739583|Drug|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
7537|NCT00739583|Drug|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
7538|NCT00739596|Drug|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
7539|NCT00739596|Drug|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
7540|NCT00739609|Drug|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
7541|NCT00739622|Drug|TMC278|
7542|NCT00739635|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
7543|NCT00739635|Drug|Placebo|Double-blind treatment period of 17 weeks placebo
7544|NCT00739648|Drug|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
7837|NCT00742170|Device|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
7838|NCT00006015|Drug|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 & 15 of each cycle
7839|NCT00742183|Device|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
7840|NCT00742183|Device|Silvadene|Silvadene - dressing changes every day, more frequently if needed
7841|NCT00742209|Drug|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
7842|NCT00742209|Drug|Placebo|Placebo-control
8558|NCT00741143|Other|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
8559|NCT00741156|Drug|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
8560|NCT00741169|Drug|TMC435350|200 mg taken by mouth once daily for 7 days
8561|NCT00741169|Drug|Rifampin|600 mg taken by mouth once daily for 7 days
8562|NCT00741169|Drug|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
8563|NCT00741182|Drug|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
8564|NCT00741195|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
8565|NCT00741195|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
8566|NCT00006011|Drug|Paclitaxel|Given IV
8567|NCT00741208|Dietary Supplement|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
8568|NCT00741221|Drug|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
8569|NCT00741221|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
8570|NCT00741234|Drug|SB939|SB939 taken orally in a 4-week cycle.
8571|NCT00741234|Drug|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
8572|NCT00741247|Procedure|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
8573|NCT00741260|Drug|Neratinib|Neratinib 240mg, continuous daily
8574|NCT00741260|Drug|capecitabine|1500mg/m² of Capecitabine, on days 1-14 of each 21 day cycle.
8575|NCT00741273|Drug|Proellex|Proellex 25 mg capsule, single dose
8576|NCT00741286|Drug|Aspirin|Asprin (100mg) plus placebo
8577|NCT00006012|Biological|filgrastim|
7606|NCT00736775|Drug|placebo|Intravenous single and multiple doses
9371|NCT00763282|Behavioral|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
9372|NCT00763295|Other|T-Spot.TB test|diagnostic test
9373|NCT00755807|Drug|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
9374|NCT00755807|Drug|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams [mg] QD for 12 weeks).
9375|NCT00755820|Behavioral|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
9376|NCT00755820|Behavioral|Exposure Therapy + Placebo|Exposure therapy with placebo medication
9377|NCT00755820|Behavioral|Supportive Psychotherapy|Supportive psychotherapy
9378|NCT00755833|Drug|biphasic insulin aspart 50|Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
9379|NCT00755846|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
9380|NCT00006099|Procedure|immunoscintigraphy|
9381|NCT00755846|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
9661|NCT00006085|Drug|CP-609,754|
9662|NCT00753857|Other|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
9663|NCT00753857|Other|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
9664|NCT00753870|Biological|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
9665|NCT00753883|Drug|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
9666|NCT00753883|Drug|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
9667|NCT00753896|Drug|exenatide|subcutaneous injection, 2.0mcg, once weekly
9668|NCT00753909|Drug|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
9669|NCT00753909|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
9532|NCT00761163|Other|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
9533|NCT00000722|Drug|Pentamidine isethionate|
9887|NCT00759265|Other|resistance training|During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).
During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home.
9888|NCT00759278|Procedure|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
9889|NCT00759291|Drug|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
9890|NCT00759291|Drug|matching placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
9891|NCT00759317|Drug|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
9892|NCT00759330|Drug|Flurbiprofen Tape|Two 31.5 mg Flurbiprofen Tape for 24 hour continuous administration for 7 day treatment phase
9893|NCT00759330|Drug|Flurbiprofen Placebo Tape|Two Flurbiprofen Placebo Tapes for 12 hour continuous administration for 7 day treatment phase
9894|NCT00759330|Drug|Flurbiprofen Placebo Tape|Two Flurbiprofen Placebo Tape for 24 hour continuous administration for 7 day treatment phase
9895|NCT00006113|Biological|recombinant interleukin-4|
9896|NCT00759330|Drug|Flurbiprofen Tape|Two 31.5 mg Flurbiprofen Tapes for 12 hour continuous administration for 7 day treatment phase
9897|NCT00761631|Biological|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
9898|NCT00761644|Drug|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.
7843|NCT00742222|Radiation|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
7844|NCT00742222|Radiation|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
7845|NCT00742235|Drug|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
7846|NCT00742248|Drug|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
7847|NCT00742248|Drug|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
7848|NCT00742248|Drug|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
7849|NCT00006016|Drug|thalidomide|Given orally
7850|NCT00734812|Procedure|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
7851|NCT00734812|Procedure|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
7852|NCT00734825|Other|Omnipaque|oral contrast for CT scan
7853|NCT00005985|Drug|cyclophosphamide|
7854|NCT00734838|Device|High Resolution Microendoscope|
7855|NCT00734838|Device|Bench-top optical spectrometer|
7856|NCT00734851|Drug|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
7857|NCT00734851|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
7858|NCT00734851|Radiation|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
8171|NCT00737776|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
8172|NCT00000704|Drug|Zalcitabine|
8173|NCT00005993|Drug|recombinant human stem cell factor|
8174|NCT00737789|Drug|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
8175|NCT00737789|Drug|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
9956|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
9957|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
9958|NCT00756886|Drug|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
9959|NCT00756886|Drug|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
9960|NCT00006105|Drug|amifostine trihydrate|
8989|NCT00006094|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
8990|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
8991|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
8992|NCT00755287|Drug|insulin glargine|starting dose 10 IU daily
8993|NCT00755287|Drug|metformin|As prescribed
8994|NCT00755287|Drug|taspoglutide|10 mg once weekly
8995|NCT00755287|Drug|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
8996|NCT00755300|Procedure|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
8997|NCT00755313|Biological|trastuzumab|
8998|NCT00755313|Drug|aromatase inhibition therapy|
8999|NCT00755313|Drug|carboplatin|
9000|NCT00006095|Drug|irinotecan hydrochloride|
9001|NCT00755313|Drug|cyclophosphamide|
9002|NCT00755313|Drug|docetaxel|
9003|NCT00755313|Drug|doxorubicin hydrochloride|
9004|NCT00755313|Other|metabolic assessment|
9005|NCT00755313|Other|questionnaire administration|
9006|NCT00755313|Other|study of socioeconomic and demographic variables|
9670|NCT00753909|Drug|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
9671|NCT00756236|Drug|Placebo|Placebo group:
60 ml syringes of 0.9% NaCl, 5 ml syringes of 0.9% NaCl
9672|NCT00756249|Drug|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
9673|NCT00756249|Drug|Placebo|Vials with solution for IV infusion
9674|NCT00756262|Biological|Lactobacillus GG or Culturelle|Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10^10 bacteria
9675|NCT00756275|Drug|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
9676|NCT00756275|Drug|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
9677|NCT00756275|Behavioral|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
9678|NCT00006101|Drug|Placebo|
9679|NCT00756275|Drug|Placebo patch|Commercially available matched placebo patches will be used for 12 weeks.
9680|NCT00756275|Drug|Placebo|The placebos use identical opaque capsules to the varenicline condition, containing inert filler. Participant takes 1 placebo capsule per day for the first 3 days and 2 per day for 4 days and 12 weeks.
10019|NCT00754481|Other|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) will be cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe will be placed in the esophagus and its position confirmed using a chest radiograph. Patients will be placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reaches 34.0ºC, the ice and second cooling blanket will be removed and esophageal temperature will be maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO will be cooled using the extracorporeal circuit cooling-device. Rewarming will be done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC is reached. Thereafter temperature will be recorded but not controlled by surface cooling.
10020|NCT00754494|Drug|erlotinib hydrochloride|Given PO
10021|NCT00754494|Other|placebo|Given PO
10022|NCT00754494|Other|laboratory biomarker analysis|Correlative studies
9899|NCT00761644|Drug|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
9900|NCT00761644|Drug|Temsirolimus|Days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
9901|NCT00761657|Drug|FG-4592|FG-4592 1.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
9902|NCT00761657|Drug|FG-4592|FG-4592 1.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
9903|NCT00761657|Drug|FG-4592|FG-4592 2.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
9904|NCT00006123|Drug|carboplatin|
8928|NCT00757549|Genetic|TdT-mediated dUTP nick end labeling assay|
8929|NCT00757549|Other|3'-deoxy-3'-[18F]fluorothymidine|
8930|NCT00757549|Other|immunohistochemistry staining method|
8931|NCT00757549|Other|laboratory biomarker analysis|
8932|NCT00757549|Radiation|fludeoxyglucose F 18|
8933|NCT00757549|Radiation|radiation therapy|
8934|NCT00006107|Procedure|conventional surgery|
8935|NCT00757562|Drug|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects >=2 to <6 years, 2.5 mg (5 mL) for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
8936|NCT00757562|Drug|Placebo|placebo syrup: 2.5 mL for subjects >=2 to <6 years, 5 mL for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
8937|NCT00757588|Drug|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
8938|NCT00757588|Drug|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
8939|NCT00757601|Drug|MK1006|MK1006 capsules: 1 mg, 10 mg, and 20 mg.
Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose
8940|NCT00757601|Drug|Placebo|Placebo capsule to match MK1006 1, 10, and 20 mg.
Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose
8176|NCT00737815|Dietary Supplement|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
8177|NCT00737815|Other|Placebo|Inactive placebo pill
8178|NCT00737828|Other|Perioperative care pathway guided by CPX results|AT > 11ml/min/kg no myocardial ischaemia or Ve/VO2 <35 - Level 1 Ward Care
AT > 11ml/min/kg with myocardial ischaemia or Ve/VO2 >35 - Level 2/3 (ITU) Critical Care Unit
AT <11mls/min/kg - Level 2/3 Critical Care Unit
AT <8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure
8179|NCT00737841|Drug|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
8180|NCT00737841|Drug|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
8181|NCT00737854|Procedure|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
8182|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
8183|NCT00737867|Drug|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
8184|NCT00005993|Procedure|peripheral blood stem cell transplantation|
8185|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
8186|NCT00740597|Procedure|neoadjuvant therapy|
8187|NCT00740597|Procedure|therapeutic conventional surgery|
8188|NCT00740597|Radiation|intensity-modulated radiation therapy|
8189|NCT00740610|Drug|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
8190|NCT00740610|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
8191|NCT00740623|Drug|Carisbamate|800 mg/day for 14 weeks
8497|NCT00733551|Drug|GSK962040 oral tablets (1, 5, 10, 25 mg)|Active GSK962040. Planned and actual doses per cohort as follows:
Cohort 1 planned dose = 10 mg; actual dose = 10 mg Cohort 2 planned dose = 30 mg; actual dose = 20 mg Cohort 3 planned dose = 100 mg; actual dose = 50 mg Cohorts 4 and 5 planned doses to be determined.
8498|NCT00733564|Drug|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
9007|NCT00755313|Procedure|cognitive assessment|
9008|NCT00755313|Procedure|positron emission tomography|
9009|NCT00755313|Radiation|fludeoxyglucose F 18|
9010|NCT00755326|Drug|HLXL|Three daily dosages will be investigated. The lowest dosage condition will be 6 capsules (2,400 mg) daily, followed by an escalation to the 10 capsule condition (4,000 mg), and then to the 14 capsule (5,600 mg) condition. Participants will be treated for 6 weeks
9011|NCT00006095|Drug|vincristine sulfate|
9012|NCT00755352|Drug|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
9013|NCT00755352|Drug|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
9299|NCT00755768|Behavioral|additional review by dietician|
9300|NCT00755781|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
9301|NCT00755794|Drug|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
9302|NCT00758173|Other|laboratory biomarker analysis|
9303|NCT00758173|Other|questionnaire administration|
9304|NCT00758186|Procedure|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
9305|NCT00758186|Procedure|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
9306|NCT00758199|Drug|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
9307|NCT00758199|Drug|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
9308|NCT00758199|Drug|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
9309|NCT00006110|Procedure|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
10023|NCT00754507|Drug|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
10024|NCT00754507|Drug|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
10025|NCT00756912|Drug|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
10026|NCT00756925|Drug|Acthrel|1 ug/kg, i.v., 1 minute
10027|NCT00756938|Drug|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
10028|NCT00756951|Drug|Placebo|Placebo
10029|NCT00756951|Drug|SCV-07|0.02 mg/kg
10030|NCT00756951|Drug|SCV-07|0.10 mg/kg
10031|NCT00756964|Drug|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
10032|NCT00756964|Drug|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
10033|NCT00756977|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
10034|NCT00756977|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
10035|NCT00006105|Drug|cisplatin|
10036|NCT00756990|Drug|Depot Naltrexone|228mg of injectable naltrexone
10037|NCT00757003|Device|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the aneurysm in the thoracic aorta
10038|NCT00757016|Drug|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
9081|NCT00762814|Device|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
9082|NCT00762827|Drug|Salsalate|4 grams daily for 28 days
8941|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
8942|NCT00760214|Drug|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
8943|NCT00760227|Other|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
8944|NCT00006115|Drug|fluorouracil|
8945|NCT00760227|Other|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
8946|NCT00760227|Other|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
9243|NCT00760773|Drug|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
9244|NCT00760773|Drug|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
9245|NCT00760786|Drug|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
9246|NCT00760786|Drug|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
9247|NCT00760786|Drug|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
9248|NCT00760786|Drug|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
9249|NCT00760799|Procedure|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
9250|NCT00760812|Behavioral|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
8499|NCT00733564|Drug|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
8500|NCT00733564|Drug|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
8501|NCT00733577|Drug|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
8502|NCT00733603|Other|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
8503|NCT00005979|Drug|FOLFIRI regimen|
8504|NCT00733603|Other|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
8505|NCT00733616|Drug|DOX: Docetaxel, oxaliplatin, Capecitabine|Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1
Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1
Capecitabine 625 mg/m2, bid, oral, continuous
6 cycles, every 3 weeks
Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)
8506|NCT00733642|Biological|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
8507|NCT00733642|Biological|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
8508|NCT00733642|Biological|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
8509|NCT00733642|Biological|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
8510|NCT00733668|Drug|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
8511|NCT00733681|Device|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
8512|NCT00733694|Device|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
8513|NCT00735813|Device|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
8514|NCT00735826|Drug|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
8515|NCT00735839|Biological|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
8516|NCT00735839|Biological|Placebo|Saline placebo (0.5 ml) single injection on Day 1
7545|NCT00739648|Drug|Placebo|same frequency as study drug using the same method of delivery
9310|NCT00758212|Biological|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
9311|NCT00758225|Drug|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients > 45 kg: 900 mg/day (2 tablets 3 times a day)
9312|NCT00758238|Other|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
9313|NCT00758264|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
9314|NCT00758264|Biological|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
9315|NCT00758277|Drug|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
9316|NCT00758277|Drug|Placebo|Sugar Pill
9596|NCT00758615|Behavioral|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
9597|NCT00758628|Drug|Bromefenac|Bromfenac BID 3 months
9598|NCT00758628|Drug|Blink|Blink BID for 3 months
9599|NCT00758641|Device|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
9600|NCT00758641|Drug|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
9601|NCT00758667|Drug|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
9602|NCT00758680|Drug|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
9603|NCT00758680|Drug|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
9604|NCT00758693|Drug|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
9605|NCT00006112|Drug|fluorouracil|
9606|NCT00758693|Drug|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
9607|NCT00758706|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
9083|NCT00006127|Drug|amifostine|
9084|NCT00762827|Drug|Placebo|Matching Placebo
9085|NCT00762840|Device|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
9086|NCT00762840|Procedure|Conventional endodontic procedure|Standard root canal treatment
9087|NCT00762853|Drug|Fluoride|Brush half mouth once with assigned study treatment
9088|NCT00762853|Drug|Fluoride and triclosan|Brush half mouth once with assigned study treatment
9089|NCT00762892|Drug|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
9090|NCT00762892|Drug|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
9091|NCT00755391|Behavioral|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
9092|NCT00755404|Drug|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
9093|NCT00755404|Drug|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
9094|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
9095|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
9096|NCT00006096|Drug|cisplatin|
9097|NCT00755417|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
9098|NCT00755443|Device|Drug eluting stent|Drug eluting stent implantation
9099|NCT00755443|Device|Bare metal stent|
9382|NCT00755846|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
9383|NCT00755846|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
9384|NCT00755846|Drug|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
9251|NCT00760812|Behavioral|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
9252|NCT00006117|Drug|oxaliplatin|
9253|NCT00760825|Biological|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
9254|NCT00760838|Drug|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
9255|NCT00763308|Behavioral|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
9256|NCT00763321|Drug|ABT-712|ABT-712 extended-release tablet
9257|NCT00763321|Drug|Placebo|Placebo tablet
9258|NCT00763347|Drug|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
9259|NCT00006133|Drug|medroxyprogesterone|
9534|NCT00006120|Drug|paclitaxel|
9535|NCT00761163|Other|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
9536|NCT00761163|Other|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
9537|NCT00761176|Device|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
9538|NCT00761189|Drug|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
9539|NCT00761202|Drug|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
9540|NCT00761202|Drug|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
9541|NCT00761215|Drug|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
9542|NCT00761215|Drug|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
7546|NCT00006000|Drug|semaxanib|
7547|NCT00739661|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
7548|NCT00739661|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
7549|NCT00739674|Drug|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:
Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:
Losartan 50 mg
Losartan 100 mg
Losartan 100 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 25 mg
Losartan 100 mg/HCTZ 25 mg + CCB
Patients with severe hypertension:
Losartan 50 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 25 mg
Losartan 100 mg/HCTZ 25 mg + CCB
Losartan 100 mg/HCTZ 25 mg + increasing CCB
7550|NCT00739674|Behavioral|Low Salt Diet|Low-salt intake diet (Dietary Approaches to Stop Hypertension [DASH]) including:
Healthy diet
Reduction in sodium intake to less than 2300 mmol/day
Low alcohol consumption (less than 2 standard drinks/day)
7551|NCT00739687|Drug|ALT-711|200 mg tablet BID for 9 months.
7552|NCT00739687|Drug|Placebo|200 mg tablet BID for 9 months.
7553|NCT00739713|Dietary Supplement|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
7554|NCT00739713|Dietary Supplement|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
7555|NCT00739739|Drug|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
7556|NCT00741884|Drug|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
7557|NCT00741884|Drug|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
7558|NCT00741884|Drug|Placebo|Placebo BID for 7 weeks
7559|NCT00741897|Drug|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
7560|NCT00741910|Drug|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
7561|NCT00741923|Other|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
7562|NCT00006015|Biological|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, & 22)
7563|NCT00741936|Drug|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
7564|NCT00741936|Drug|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
9608|NCT00758706|Drug|Placebo|Dosing to match AZD1236
9609|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
9610|NCT00758732|Drug|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
9611|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
9612|NCT00758732|Drug|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
9613|NCT00758745|Device|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
9614|NCT00758745|Device|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
9615|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
9616|NCT00000720|Drug|Globulin, Immune|
9617|NCT00006112|Drug|leucovorin calcium|
9618|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
9961|NCT00759356|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
9962|NCT00759356|Drug|KADIAN|2 x 100 mg, single-dose capsule
9963|NCT00759369|Other|Water prescription|Water prescription in 12 to 16 equally divided doses
9964|NCT00759395|Drug|AZD2327|Tablet, Oral, Daily
9965|NCT00759395|Drug|Placebo|Tablet, Oral, Daily
9966|NCT00759408|Drug|BQ-123|6-120 µg/min
9967|NCT00759421|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
9968|NCT00759421|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
9969|NCT00759434|Procedure|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
9970|NCT00006113|Biological|sargramostim|
9385|NCT00755846|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
9386|NCT00755859|Drug|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
9387|NCT00755859|Drug|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
9388|NCT00755872|Drug|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
9389|NCT00755872|Drug|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
9390|NCT00755872|Drug|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
9391|NCT00006099|Radiation|indium In 111 monoclonal antibody Hu3S193|
9392|NCT00755872|Drug|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
9393|NCT00755885|Drug|abiraterone acetate|
9394|NCT00755885|Other|laboratory biomarker analysis|
9395|NCT00755885|Other|pharmacogenomic studies|
9396|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
9397|NCT00758316|Other|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
9398|NCT00758316|Procedure|Thoracoscopy|Talc poudrage
9399|NCT00758329|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
9400|NCT00758342|Drug|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
9401|NCT00758342|Drug|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
9402|NCT00758368|Drug|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
9681|NCT00756288|Procedure|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
9543|NCT00761215|Drug|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
9544|NCT00761228|Drug|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
9545|NCT00006121|Drug|oxaliplatin|
9546|NCT00761228|Drug|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
9547|NCT00763451|Device|Pen auto-injector|
9548|NCT00006135|Drug|acyclovir|
9549|NCT00763451|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
9550|NCT00763464|Procedure|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
9551|NCT00763464|Procedure|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
9552|NCT00763477|Biological|ghrelin|subcutaneous injection
9553|NCT00763490|Procedure|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
9554|NCT00763490|Drug|Flu/Bu4 conditioning regimen|Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2
Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2
9905|NCT00761657|Drug|FG-4592|FG-4592 2.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
9906|NCT00761657|Drug|FG-4592|FG-4592 3.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
9907|NCT00761657|Drug|FG-4592|Placebo Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
9908|NCT00761657|Drug|FG-4592|FG-4592 0.7 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
9909|NCT00761670|Drug|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
9910|NCT00761696|Drug|IPI-926|Oral daily dosing
9911|NCT00761709|Drug|AL-39256 Ophthalmic Suspension, 1%|
9912|NCT00761709|Drug|Latanoprost Ophthalmic Solution, 0.005%|
9913|NCT00761709|Drug|Vehicle|Inactive ingredients used as a placebo comparator
7565|NCT00741949|Drug|Propofol|Sedation in TCI with propofol
7859|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
7860|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
7861|NCT00734877|Drug|M-VTD-PACE|2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
7862|NCT00734877|Drug|TT3-LITE Regimen (L-TT3)|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
7863|NCT00734890|Biological|bevacizumab|
7864|NCT00000703|Drug|Cytarabine|
7865|NCT00005985|Drug|cytarabine|
7866|NCT00734890|Drug|vandetanib|
7867|NCT00734890|Other|laboratory biomarker analysis|
7868|NCT00734890|Other|pharmacological study|
7869|NCT00734903|Behavioral|A Woman's Path to Recovery (WPR)|A Woman's Path to Recovery (WPR) is an evidence-based gender-specific treatment model for women with substance use disorder. It is a 12-session model that is conducted once per week in individual modality, with eight core sessions and four session topics that participants can select from a larger menu.
7870|NCT00734903|Behavioral|Twelve-Step Facilitation (TSF)|Twelve-Step Facilitation (TSF) consists of a brief, structured, and manual-driven approach to facilitating early recovery from alcohol abuse/alcoholism and other drug abuse/addiction. It is intended to be implemented on an individual basis in 12 to 15 sessions and is based in behavioral, spiritual, and cognitive principles that form the core of 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA).
7871|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
7872|NCT00737230|Other|questionnaire administration|
7873|NCT00005990|Drug|topotecan hydrochloride|
7874|NCT00737230|Procedure|assessment of therapy complications|
7875|NCT00737230|Procedure|gastrointestinal complications management/prevention|
9971|NCT00759434|Procedure|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
9972|NCT00759460|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
9973|NCT00759460|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
9974|NCT00759473|Drug|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
9975|NCT00759512|Other|Therapeutic Touch|
9976|NCT00759525|Drug|Glycyrrhetic Acid|130 mg daily for fourteen days
9977|NCT00759525|Drug|Placebo|Placebo daily for fourteen days
9978|NCT00759551|Drug|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
9979|NCT00759551|Drug|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
9980|NCT00759551|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
9981|NCT00006113|Biological|therapeutic autologous dendritic cells|
9982|NCT00759551|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
9014|NCT00755378|Drug|AZD8529|Oral
9015|NCT00755378|Drug|Placebo|Oral
9016|NCT00755391|Behavioral|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
9017|NCT00757614|Genetic|DNA analysis|
9018|NCT00757614|Genetic|polymorphism analysis|
9019|NCT00757614|Other|laboratory biomarker analysis|
9020|NCT00757614|Other|questionnaire administration|
9021|NCT00006107|Radiation|radiation therapy|
9022|NCT00757627|Drug|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
9682|NCT00756288|Procedure|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
9683|NCT00756301|Other|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
9684|NCT00756314|Behavioral|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
9685|NCT00756340|Drug|Bevacizumab|Bevacizumab IV every 2 weeks
Dose Level 0- 8 mg/kg
Dose Level 1 (starting dose)- 10 mg/kg
Dose Level 2- 10 mg/kg
9686|NCT00756340|Drug|Everolimus|Everolimus
Dose Level 0- 4 mg/m2
Dose level 1 (starting dose)- 4 mg/m2
Dose Level 2- 5 mg/m2
9687|NCT00756366|Other|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
9688|NCT00756366|Other|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
9689|NCT00006102|Drug|becatecarin|
9690|NCT00756366|Other|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
9691|NCT00758836|Drug|ibuprofen|
9692|NCT00758836|Drug|acetominophen|
9693|NCT00758836|Drug|telcagepant|
9694|NCT00758849|Drug|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
9695|NCT00006112|Drug|mitomycin C|
9696|NCT00758849|Drug|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
9697|NCT00758862|Drug|2% TD1414 Cream|Application 3 times daily for 7 days
9698|NCT00758888|Procedure|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
9699|NCT00758888|Procedure|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
9700|NCT00758888|Other|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
9701|NCT00758901|Device|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
9914|NCT00761722|Drug|azacitidine|Arm 1:
Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.
Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.
Arm 2:
All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle.
9915|NCT00006123|Drug|carmustine|
9916|NCT00761735|Biological|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
9917|NCT00761735|Drug|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
9918|NCT00754247|Drug|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
9919|NCT00006087|Procedure|comparison of screening methods|
9920|NCT00754260|Behavioral|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
9921|NCT00754273|Other|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
9922|NCT00754286|Other|Aromatherapy Scented Wand|The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a "wand" dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
8947|NCT00760266|Drug|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
8948|NCT00760266|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
8949|NCT00760279|Drug|Azithromycin|
8950|NCT00760305|Behavioral|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
8951|NCT00760318|Drug|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
8952|NCT00760344|Drug|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
7876|NCT00737230|Procedure|management of therapy complications|
7877|NCT00737230|Procedure|quality-of-life assessment|
7878|NCT00737243|Drug|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
8192|NCT00740623|Drug|placebo|placebo for 14 weeks
8193|NCT00740623|Drug|Carisbamate|1,200 mg/day for 14 weeks
8194|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
8195|NCT00006008|Drug|arsenic trioxide|
8196|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
8197|NCT00740649|Drug|HSD-016|
8198|NCT00740649|Drug|placebo|
8199|NCT00740662|Procedure|Distal gastric bypass|Distal gastric bypass
8200|NCT00740675|Other|Outpatient Medication Reconciliation|The post-discharge medication reconciliation module has the following features:
Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.
Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).
Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists).
8201|NCT00740688|Procedure|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
8202|NCT00740688|Procedure|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
8203|NCT00740701|Device|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
8204|NCT00740714|Drug|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
8205|NCT00740714|Drug|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
8206|NCT00006009|Biological|visilizumab|
8207|NCT00740727|Drug|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
9023|NCT00757640|Procedure|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
9024|NCT00757666|Device|Rate adaptive pacemaker|Accelerometer sensor
9025|NCT00757666|Device|Rate adaptive pacemaker|Minute ventilation sensor
9026|NCT00757679|Drug|Milnacipran|capsules
9027|NCT00757679|Drug|Placebo|capsules
9028|NCT00757692|Drug|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
9029|NCT00757692|Drug|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
9030|NCT00757705|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
9031|NCT00757718|Device|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
9032|NCT00006108|Biological|trastuzumab|
9033|NCT00757718|Device|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
9034|NCT00757731|Drug|milnacipran|hard capsule
9035|NCT00757731|Drug|Placebo|hard capsule
9036|NCT00757744|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
9037|NCT00757744|Behavioral|Drug counseling|individual drug counseling
9317|NCT00758290|Drug|Triclosan/Fluoride|Brush twice daily for 3 weeks
9318|NCT00758290|Drug|Fluoride/triclosan|Brush daily for 3 weeks
9319|NCT00758303|Drug|Low Dose TRIA-662|One Capsule 3 times a day
9320|NCT00006110|Radiation|Radiation Therapy|All patients undergoing breast-conserving surgery will undergo adjuvant (after surgery) whole breast radiation therapy. If the patient undergoes mastectomy, postmastectomy radiotherapy to the chest wall, supraclavicular region and axilla will be administered at the discretion of the treating radiation oncologist
9321|NCT00758303|Drug|High Dose TRIA-662|3 Capsules 3 times daily
10039|NCT00757016|Drug|Saline solution|Saline solution
10040|NCT00757029|Genetic|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
10041|NCT00757042|Drug|AMG 157|Part A (healthy subjects): 6 subcutaneous (SC) cohorts and 2 intravenous (IV) cohorts receiving a single dose of either AMG 157 (dose escalating by cohort) or placebo. Part B (subjects with moderate to severe atopic dermatitis):two cohorts receiving a single dose (SC or IV; dose to be determined) of AMG 157 or placebo.
10042|NCT00757055|Drug|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate < 60 bpm.
10043|NCT00757055|Drug|Placebo|No active treatment given
10044|NCT00757068|Behavioral|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
10045|NCT00757068|Behavioral|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
10046|NCT00006105|Drug|gemcitabine hydrochloride|
10047|NCT00757081|Drug|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
10048|NCT00757107|Device|Taperloc Microplasty|primary total hip arthroplasty
10049|NCT00759564|Drug|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
10050|NCT00759577|Drug|Solifenacin|5mg and 10 mg, oral once daily
10051|NCT00759590|Procedure|CT scan and Pressure volume curve|CT scan
10052|NCT00759603|Drug|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
10053|NCT00759603|Drug|Rituximab|Dose of 375 mg/m^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
10054|NCT00759616|Device|Oxford Partial Knee|Oxford Partial Knee
10055|NCT00000720|Drug|Zidovudine|
10056|NCT00006113|Biological|therapeutic tumor infiltrating lymphocytes|
8953|NCT00760344|Drug|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
8954|NCT00760344|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
8955|NCT00006115|Drug|irinotecan hydrochloride|
8956|NCT00760344|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
8957|NCT00760344|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
8958|NCT00760344|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
8959|NCT00760370|Drug|Zoledronic Acid|4 mg intravenous (iv), one treatment
8960|NCT00760383|Dietary Supplement|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
8961|NCT00760383|Dietary Supplement|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
8962|NCT00762606|Procedure|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
8963|NCT00762606|Procedure|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
8964|NCT00762619|Drug|Fluoride|Brush twice daily
8965|NCT00762619|Drug|Triclosan, fluoride|Brush twice daily
8966|NCT00762632|Drug|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
9260|NCT00763347|Drug|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
9261|NCT00763347|Drug|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
9262|NCT00763347|Drug|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
9263|NCT00763347|Drug|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
9264|NCT00763347|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
8208|NCT00740727|Procedure|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
8209|NCT00740753|Device|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
8210|NCT00733018|Behavioral|"Western" versus "balanced" macro nutrient diet composition|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
8211|NCT00733031|Drug|AZD6918|liquid suspension, daily, oral dose
8517|NCT00735852|Drug|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
8518|NCT00735865|Procedure|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin & tarsal/inferior fornix conjunctiva obtained & plated according to protocol
8519|NCT00005987|Drug|cyclophosphamide|
8520|NCT00735865|Procedure|Punctal Plug, Punctal thermocauterization|Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.
This group ONLY, cultures will be obtained of the lid margin & conjunctiva/inferior fornix of BOTH eyes
8521|NCT00735865|Procedure|Silicone plug or thermodynamic hydrophobic acrylic plug|Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.
In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes
8522|NCT00735865|Other|Previous subjects with Punctal occlusion|Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.
Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol.
8523|NCT00735878|Drug|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
8524|NCT00735891|Drug|First-Line Treatment|Docetaxel 75 mg/m2, Carboplatin AUC=6,Bevacizumab 15 mg/kg administered in 21-day cycles on day 1 of each cycle.
8525|NCT00735891|Drug|Maintenance|Bevacizumab 15 mg/kg maintenance in 21 day cycles for up to 18 cycles.
8526|NCT00735891|Drug|Second-Line Treatment|Arm A: Pemetrexed 500 mg/m2 plus Bevacizumab 15 mg/kg administered in 21 day cycles on Day 1 of each cycle. Arm B: Pemetrexed 500 mg/m2 administered in 21 day cycles on Day 1 of each cycle.
8527|NCT00735904|Drug|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
9322|NCT00758303|Drug|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
9323|NCT00760838|Drug|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
9324|NCT00760851|Other|probiotic strain Bb-12|10^9 CFU Bb-12 per 4 oz yogurt
9325|NCT00760851|Other|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
9326|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
9327|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
9328|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
9329|NCT00760864|Drug|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
9330|NCT00760877|Drug|Nilotinib|
9331|NCT00006118|Drug|cisplatin|
9332|NCT00760877|Drug|Imatinib|400 mg QD or 600 mg QD
9333|NCT00760890|Dietary Supplement|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
9334|NCT00760890|Dietary Supplement|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
9335|NCT00760903|Other|Conventional MRI of the brain|
9336|NCT00760903|Other|MR spectroscopy (MRS)|
9337|NCT00760903|Other|MR Diffusion Tensor Imaging (DTI)|
9338|NCT00760916|Drug|UT-15C 1 mg|UT-15C 1 mg
9339|NCT00760916|Drug|UT-15C 0.25 mg|UT-15C 0.25 mg
9340|NCT00760916|Drug|UT-15C 5 mg|UT-15C 5 mg
9619|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
9620|NCT00758784|Drug|Refresh Tears|sterile ophthalmic solution
9621|NCT00758797|Other|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
8781|NCT00762359|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
8782|NCT00762359|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
8783|NCT00762372|Drug|desflurane|volatile liquid for inhalation
8784|NCT00762372|Drug|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
8785|NCT00762372|Drug|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
8786|NCT00006125|Drug|topotecan hydrochloride|
8787|NCT00762385|Device|galyfilcon A|galyfilcon A
8788|NCT00762385|Device|comfilcon A|comfilcon A
8789|NCT00762398|Device|Masimo hemoglobin-meter|Placing a probe on the finger
8790|NCT00762398|Biological|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
8791|NCT00762411|Drug|LY450139|Administered orally once daily.
8792|NCT00762411|Drug|Placebo|Administered orally once daily.
8793|NCT00762424|Drug|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
8794|NCT00762424|Drug|placebo|cornstarch
8795|NCT00754975|Device|JACTAX LD DES|Drug Eluting Stent
8796|NCT00754975|Device|TAXUS™ Libertè™ DES|Drug Eluting Stent
8797|NCT00754988|Drug|taspoglutide|10mg sc once weekly
8798|NCT00754988|Drug|taspoglutide|20mg sc once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
8799|NCT00006092|Drug|Arsenic Trioxide|
8800|NCT00754988|Drug|sitagliptin|100mg po once daily
8801|NCT00754988|Drug|placebo|sc once weekly
8802|NCT00754988|Drug|metformin|As prescribed
8803|NCT00754988|Drug|placebo|po once daily
9265|NCT00763360|Device|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
9266|NCT00763360|Drug|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
9267|NCT00763360|Drug|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
9268|NCT00763373|Other|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
9269|NCT00763386|Device|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
9270|NCT00006133|Drug|norethindrone|
9271|NCT00763386|Device|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
9272|NCT00763399|Dietary Supplement|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10^8CFU/day
9273|NCT00763412|Drug|placebo|CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
9274|NCT00763412|Drug|repaglinide|CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
9275|NCT00763425|Procedure|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
9276|NCT00763425|Procedure|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
9277|NCT00763438|Drug|Sertindole|Flexible dose
9278|NCT00763451|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
9279|NCT00763451|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
9555|NCT00763490|Radiation|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
9556|NCT00763490|Drug|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
8528|NCT00735904|Drug|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
8529|NCT00735904|Drug|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
8530|NCT00005987|Drug|dexamethasone|
8531|NCT00735917|Drug|saracatinib|Given PO
8532|NCT00005998|Drug|carmustine|
8533|NCT00738452|Procedure|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
7566|NCT00741949|Drug|Placebo|Isotonic saline solution infusion
7567|NCT00741962|Dietary Supplement|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
7568|NCT00741962|Dietary Supplement|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
7569|NCT00741975|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
7570|NCT00741975|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
7571|NCT00741988|Drug|Ixabepilone|ixabepilone 30 mg/m2
7572|NCT00741988|Drug|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
7573|NCT00006015|Drug|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
7574|NCT00741988|Drug|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
7575|NCT00742001|Biological|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
7576|NCT00742014|Drug|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
7577|NCT00742027|Drug|Panobinostat|Oral 40 mg/dose, three times per week, every week dosing on a 21-day cycle
7578|NCT00742040|Drug|Captopril|A rapid 3-day up-titration protocol
7579|NCT00742040|Drug|Captopril|A slower 9-day up-titration protocol
7580|NCT00742053|Device|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
9622|NCT00758823|Device|Paranix|pediculicide product
9623|NCT00758836|Drug|placebo|
9624|NCT00761241|Drug|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
9625|NCT00761241|Biological|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
9626|NCT00761241|Radiation|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
9627|NCT00761241|Procedure|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
9628|NCT00761254|Drug|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
9629|NCT00761267|Drug|Anidulafungin|Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).
Maximum treatment duration with anidulafungin is 35 days.
9630|NCT00761267|Drug|Fluconazole|Subjects may be switched to oral fluconazole [6-12 mg/kg/day (not to exceed 800mg/day] provided they meet specified criteria:
received minimum IV anidulafungin treatment of 10 days, and
study specific clinical improvement criteria are met. Maximum total treatment duration is 49 days.
9631|NCT00761280|Drug|trabedersen|
9632|NCT00761280|Drug|temozolomide|
9633|NCT00006122|Drug|cytarabine|
9634|NCT00761280|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
9635|NCT00761280|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
9636|NCT00761280|Drug|carmustine|
9637|NCT00761280|Drug|lomustine|
9638|NCT00761306|Drug|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
9983|NCT00759551|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
8804|NCT00755001|Device|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
8805|NCT00755001|Device|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
7796|NCT00737165|Behavioral|Suicide prevention program as usual|Usual suicide prevention program
7797|NCT00737178|Device|CuT380A|Comparison of different timing of IUD insertion
7798|NCT00737191|Drug|olanzapine|Given orally
7799|NCT00737191|Other|placebo|Given orally
7800|NCT00737204|Drug|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
7801|NCT00737204|Drug|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
7802|NCT00737217|Behavioral|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
7803|NCT00737230|Other|educational intervention|
7804|NCT00739973|Drug|Amlodipine 5 mg capsule|
7805|NCT00739973|Drug|Amlodipine 10 mg capsule|
7806|NCT00739973|Drug|Aliskiren/amlodipine 150/5 mg tablet|
7807|NCT00739973|Drug|Aliskiren/amlodipine 150/10 mg tablet|
7808|NCT00739973|Drug|Aliskiren/amlodipine 300/5 mg tablet|
7809|NCT00739973|Drug|Aliskiren/amlodipine 300/10 mg tablet|
7810|NCT00739986|Drug|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
7811|NCT00739986|Drug|Semapimod|Semapimod 60 mg IV x 3 days
7812|NCT00739986|Drug|Placebo|placebo IV x 3 days
7813|NCT00739999|Drug|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
7814|NCT00006004|Drug|carboplatin|
7815|NCT00739999|Drug|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
9557|NCT00763490|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) < 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.
MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued.
9558|NCT00763503|Drug|CD 2027|3µg/g Oily Spray
9559|NCT00006136|Drug|arginine butyrate|
9560|NCT00763516|Radiation|Proton radiation and chemotherapy|Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only
Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks
Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation
Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses
9561|NCT00763529|Drug|Mometasone|Mometasone furoate cream 0.1% applied once daily
9562|NCT00763529|Drug|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
9563|NCT00763542|Behavioral|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
9564|NCT00763542|Behavioral|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
9565|NCT00763555|Drug|CD 2027|3 µg/g Oily Spray, twice a day for 8 weeks
9566|NCT00763555|Drug|Vehicle (placebo)|placebo spray, twice a day for 8 weeks
9567|NCT00763568|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
9568|NCT00756041|Drug|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
9569|NCT00756067|Biological|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
9570|NCT00006100|Drug|fludarabine phosphate|
9571|NCT00756067|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
9572|NCT00756080|Drug|citrulline|0.06 G/kg three times/day during 7 days
9923|NCT00754286|Other|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
7581|NCT00742066|Drug|Irbesartan|Single dose 600mg orally
7582|NCT00742066|Drug|Felodipine|single dose 10mg Felodipine ER
7583|NCT00005984|Drug|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
7584|NCT00734409|Device|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
7585|NCT00734422|Behavioral|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
7586|NCT00734435|Drug|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
7587|NCT00734435|Drug|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
7879|NCT00737243|Drug|Carboplatin|AUC 6.0 IV Day 1
7880|NCT00737243|Drug|Bevacizumab|15 mg/kg IV infusion Day 1
7881|NCT00737243|Drug|Erlotinib|150 mg PO
7882|NCT00737243|Other|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
7883|NCT00737256|Drug|Aripiprazole|15-30 mg
7884|NCT00005991|Drug|gemcitabine hydrochloride|
7885|NCT00737256|Drug|Perphenazine|8-16 mg
7886|NCT00737282|Drug|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
7887|NCT00737282|Drug|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
7888|NCT00737295|Procedure|CCK Injection and Ultrasound|All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:
If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.
An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder.
7889|NCT00737308|Other|ceramic crown|Zirconia
9984|NCT00759551|Drug|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
9985|NCT00759551|Drug|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
9986|NCT00761748|Device|Convatec Uro 2-piece|Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.
The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look.
9987|NCT00761748|Device|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
9988|NCT00761761|Drug|Sensoril|Sensoril® (or placebo) will be administered using random assignment at a dose of 250mg/day, increasing to a dose of 500mg/day by the second week. The dose of 500mg (or 250mg if tolerability is an issue) will be continued for a total of 8 weeks.
9989|NCT00761774|Drug|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
9990|NCT00761800|Drug|Lactic acid|
9991|NCT00761813|Device|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
9992|NCT00761813|Device|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
9993|NCT00761826|Device|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
9994|NCT00000723|Drug|Methotrexate|
9995|NCT00006123|Drug|cisplatin|
9996|NCT00761839|Behavioral|After-care summary|The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated "after-care summary" will be discussed with the patient and used to set self-management goals.
9997|NCT00761839|Behavioral|Control group|Patients in the control group will receive usual counseling for self-management.
7816|NCT00740012|Other|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
7817|NCT00740012|Other|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
7818|NCT00740012|Other|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
7819|NCT00740012|Other|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
8131|NCT00732966|Drug|valsartan|valsartan 160 mg once daily
8132|NCT00732979|Procedure|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
8133|NCT00732979|Procedure|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
8134|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
8135|NCT00005978|Biological|filgrastim|
8136|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
8137|NCT00733005|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
8138|NCT00733005|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
8139|NCT00735254|Device|Affirm Laser (non-ablative laser )|
8140|NCT00735254|Device|combined PDL and Affirm Lasers|
8141|NCT00735254|Device|Placebo|
8142|NCT00735267|Drug|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
8143|NCT00735280|Drug|unfractionated heparin|bolus of 100 U/kg of unfractionated heparin
8144|NCT00735293|Device|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
8145|NCT00735306|Drug|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
9924|NCT00754312|Drug|SNDX-275|
9925|NCT00754325|Drug|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
9926|NCT00754325|Drug|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
9927|NCT00754338|Drug|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
9928|NCT00754338|Drug|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
9929|NCT00754338|Drug|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
9930|NCT00000717|Drug|Primaquine|
9931|NCT00006087|Procedure|computed tomography|
9932|NCT00754351|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
9933|NCT00754351|Drug|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
9934|NCT00754351|Drug|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
9935|NCT00754364|Drug|Pemetrexed/Carboplatin|Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.
Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day.
9936|NCT00754364|Drug|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
9937|NCT00754377|Other|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
9938|NCT00754390|Dietary Supplement|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
9939|NCT00756717|Drug|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
9940|NCT00756730|Drug|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
8967|NCT00762632|Drug|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
7890|NCT00737321|Procedure|samples collection will be done.|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
7891|NCT00737334|Device|EEGo, BIS, FORE-SIGHT cerebral oximeter|The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.
All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed.
7892|NCT00737347|Behavioral|Lifestyle modification|lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
7893|NCT00737360|Drug|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
7894|NCT00737373|Drug|Docetaxel|50mg/m2 qd15
7895|NCT00740038|Behavioral|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
7896|NCT00740051|Drug|Linagliptin|5mg once daily
8212|NCT00733031|Drug|gemcitabine|intravenous, doses are on an intermittent schedule
8213|NCT00733031|Drug|pemetrexed|intravenous, dose administered every 21-days
8214|NCT00733044|Behavioral|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
8215|NCT00733044|Other|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
8216|NCT00733057|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
8217|NCT00005978|Drug|carboplatin|
8218|NCT00733057|Drug|Placebo (200 mg/day)|
8219|NCT00733070|Device|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
9038|NCT00757757|Drug|MCS110|Anti-M-CSF antibody
9039|NCT00757770|Biological|Rotarix|Two oral doses.
9040|NCT00757770|Biological|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
9041|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
9042|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
9043|NCT00006108|Drug|capecitabine|
9044|NCT00757783|Drug|darunavir|800 mg tablet once daily for 48 weeks
9045|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
9046|NCT00760396|Drug|VGX-1027|Subjects will
9047|NCT00760422|Device|NIR|Thermometer
9048|NCT00760435|Drug|Infliximab|5 mg/kg IV over 2 hours once
9049|NCT00760435|Drug|Placebo|Placebo (same volume as active drug)
9050|NCT00006115|Drug|leucovorin calcium|
9051|NCT00760448|Drug|insulin detemir|
9052|NCT00760448|Drug|insulin NPH|
9053|NCT00760461|Drug|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
9054|NCT00760474|Drug|Pregabalin, then placebo|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
9055|NCT00760474|Drug|Placebo, then pregabalin|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
9056|NCT00760487|Device|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
9057|NCT00760500|Other|Nasopharyngeal Swab|Nasopharyngeal Swab
9058|NCT00760513|Drug|OMACOR|4 grammes daily, oral capsule
9059|NCT00760526|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
9060|NCT00760526|Device|Home blood glucose monitor|Home monitoring 3 or more times a day
8146|NCT00735306|Drug|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
8147|NCT00735306|Radiation|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
8148|NCT00005986|Drug|busulfan|
8149|NCT00735319|Device|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
8150|NCT00735332|Drug|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
8459|NCT00738387|Drug|Placebo|Placebo i.v. on day 1 of each 21 day cycle
8460|NCT00738387|Drug|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
8461|NCT00738400|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
8462|NCT00738400|Drug|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
8463|NCT00738413|Drug|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
8464|NCT00738413|Drug|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
8465|NCT00738426|Device|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
8466|NCT00738426|Device|Sham device|non-therapeutic light energy output
8467|NCT00738452|Other|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
8468|NCT00738452|Other|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
8469|NCT00741013|Drug|placebo pill and placebo IV|Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
8470|NCT00741013|Drug|Lovastatin pill and placebo IV|lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
8471|NCT00741013|Drug|placebo pill and recombinant human activated protein C IV|placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
8968|NCT00762645|Drug|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
8969|NCT00762645|Drug|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
8970|NCT00762658|Drug|AN2728 Ointment, 5%|
8971|NCT00006126|Drug|fludarabine phosphate|
8972|NCT00762658|Drug|AN2728 Ointment, 2%|
8973|NCT00762658|Drug|AN2728 Ointment, 0.5%|
8974|NCT00762658|Drug|AN2728 Ointment Vehicle|
8975|NCT00762658|Drug|Betnesol®-V Creme, 0.1%|
8976|NCT00762658|Drug|Protopic® Ointment, 0.1 %|
8977|NCT00762671|Drug|Ebselen|150 mg BID for 2 weeks
8978|NCT00762671|Drug|Placebo|Placebo 1 po BID for 2 weeks
8979|NCT00762684|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
8980|NCT00762684|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
8981|NCT00762710|Drug|Prazosin medication|Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg
8982|NCT00006126|Procedure|peripheral blood stem cell transplantation|
8983|NCT00762710|Drug|Placebo medication|Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg
8984|NCT00762723|Device|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
8985|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
8986|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
8987|NCT00762736|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
8220|NCT00733083|Drug|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
8221|NCT00733083|Drug|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
8222|NCT00733083|Drug|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
8223|NCT00733083|Drug|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
8224|NCT00733096|Drug|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
8225|NCT00733096|Drug|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
8226|NCT00733096|Drug|normal saline|Two transforaminal epidural saline injections, two weeks apart
8227|NCT00733109|Procedure|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
8228|NCT00005978|Drug|etoposide|
8229|NCT00733109|Other|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
8230|NCT00733122|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
8534|NCT00738452|Procedure|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
8535|NCT00738452|Radiation|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
8536|NCT00738452|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
8537|NCT00738478|Device|nasogastric tube|insertion of nasogastric tube for 2 days after operation
8538|NCT00738478|Device|without nasogastric tube|without nasogastric tube after operation
8539|NCT00738517|Device|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
8540|NCT00738530|Drug|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks
8541|NCT00738530|Drug|interferon alfa 2a [Roferon]|9 MIU SC 3x/week
8542|NCT00738530|Drug|placebo|iv every 2 weeks
9061|NCT00000721|Drug|CD4 Antigens|
9062|NCT00006115|Drug|oxaliplatin|
9341|NCT00760916|Drug|Placebo|Placebo
9342|NCT00006118|Drug|gemcitabine hydrochloride|
9343|NCT00760929|Drug|Placebo|iv 9mg/kg weekly
9344|NCT00760929|Drug|Placebo|iv 16mg/kg every 3 weeks
9345|NCT00760929|Drug|RG1507|iv 9mg/kg weekly
9346|NCT00760929|Drug|RG1507|iv 16mg/kg every 3 weeks
9347|NCT00760929|Drug|erlotinib [Tarceva]|150mg oral daily
9348|NCT00760942|Dietary Supplement|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
9349|NCT00760942|Dietary Supplement|Similac human milk fortifier|Powdered human milk fortifier.
9350|NCT00760955|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
9351|NCT00760955|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
9352|NCT00760955|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
9353|NCT00763191|Other|UPDRS test|
9354|NCT00006133|Drug|estradiol|
9355|NCT00763191|Other|CRST test|
9356|NCT00763204|Drug|AN2728 Cream, 2%|
9357|NCT00763204|Drug|AN2728 Cream, 1%|
9358|NCT00763204|Drug|AN2728 Cream, 0.3%|
9359|NCT00763204|Drug|AN2728 Cream Vehicle|
9360|NCT00763204|Drug|Betnesol®-V Creme, 0.1%|
8472|NCT00741013|Biological|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
8473|NCT00741026|Drug|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
8474|NCT00741026|Drug|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
8475|NCT00006011|Biological|Filgrastim|Given SC
8476|NCT00741039|Biological|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients >65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
8806|NCT00755014|Other|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
8807|NCT00755027|Drug|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
8808|NCT00755040|Drug|cyclosporine ophthalmic emulsion|Given as eye drops
8809|NCT00755040|Other|placebo|Given as eye drops
8810|NCT00006093|Drug|cilengitide|
8811|NCT00755053|Drug|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
8812|NCT00755053|Drug|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
8813|NCT00755066|Drug|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
8814|NCT00755066|Drug|Placebo|Placebo intranasal spray
8815|NCT00755079|Drug|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
8816|NCT00755079|Drug|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
8817|NCT00755092|Behavioral|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
8818|NCT00755092|Behavioral|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
8819|NCT00755118|Drug|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
8988|NCT00755261|Drug|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
9280|NCT00755664|Dietary Supplement|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
9281|NCT00755677|Other|Pulses|subjects consume 1 pulse food daily for eight weeks
9282|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
9283|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
9284|NCT00755690|Behavioral|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
9285|NCT00755703|Biological|Pandemic Influenza Vaccine|Undetermined
9286|NCT00006099|Other|immunohistochemistry staining method|
9287|NCT00755703|Biological|Placebo|
9288|NCT00755716|Drug|Placebo (sugar pill)|patients receive
9289|NCT00755716|Drug|topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
9290|NCT00755716|Drug|nicotine patch|subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day for a total time of 10 weeks. On the quit date (after 2 weeks of medication use), subjects also use 21mg patch for 8 weeks.
9291|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
9292|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
9293|NCT00755742|Other|Lifestyle intervention|The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):
i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.
ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).
iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided.
9294|NCT00755755|Drug|PGL4001 (ulipristal) and iron|tablets
9295|NCT00755755|Drug|PGL4001 matching placebo and iron|tablets
8543|NCT00005998|Drug|cyclophosphamide|
8544|NCT00738543|Other|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
8545|NCT00738556|Device|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
8546|NCT00738569|Drug|Raltegravir|Raltegravir 400 mg PO BID for 12 months
8547|NCT00738582|Drug|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
8548|NCT00738582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
8549|NCT00738582|Drug|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
8550|NCT00738595|Drug|EVT 302|EVT 302 5 mg once daily
8551|NCT00738595|Drug|Placebo|Placebo to match EVT 302, 5 mg
8552|NCT00738595|Drug|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
8553|NCT00738595|Drug|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
8554|NCT00000705|Drug|Zidovudine|
8555|NCT00005998|Drug|cytarabine|
7588|NCT00734448|Dietary Supplement|myo-inositol|2 g twice a day until delivery
7589|NCT00734461|Drug|oxycodone and naltrexone|tablets containing 20 mg or 40 mg oxycodone
/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone
7590|NCT00734474|Drug|LY2189265|
7591|NCT00734474|Drug|Sitagliptin|
7592|NCT00734474|Drug|Placebo solution|
7593|NCT00734474|Drug|Placebo tablet|
7594|NCT00005984|Drug|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
7595|NCT00734474|Drug|Metformin|
9361|NCT00763230|Device|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
9362|NCT00763243|Other|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
9639|NCT00761319|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
9640|NCT00761319|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
9641|NCT00761332|Drug|teriparatide|treatment will be prescribed according to usual standard of care
9642|NCT00761332|Drug|antiresorptives|treatment will be prescribed according to usual standard of care
9643|NCT00761345|Drug|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
9644|NCT00006122|Drug|etoposide|
9645|NCT00761345|Drug|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
9646|NCT00753740|Drug|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
9647|NCT00753740|Drug|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
9648|NCT00753740|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
9649|NCT00753766|Other|Multifactorial Intervention|
9650|NCT00006084|Biological|lintuzumab|
9651|NCT00753779|Drug|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
9652|NCT00753779|Drug|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
8820|NCT00755118|Drug|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
8821|NCT00000188|Drug|Selegiline|
8822|NCT00000717|Drug|Clindamycin|
8823|NCT00006094|Drug|oxaliplatin|Given IV
8824|NCT00757263|Genetic|polymorphism analysis|
8825|NCT00757263|Other|laboratory biomarker analysis|
8826|NCT00757263|Other|questionnaire administration|
8827|NCT00757289|Biological|PRP Injection|PRP Injection
8828|NCT00757289|Biological|Corticosteroid Injection|Corticosteroid Injection
7820|NCT00740012|Other|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
7821|NCT00740012|Other|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
7822|NCT00740038|Behavioral|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, & provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
7823|NCT00740038|Behavioral|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
7824|NCT00740038|Behavioral|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
7825|NCT00006004|Drug|cisplatin|
7826|NCT00742066|Drug|Placebo|Single dose tablet orally
7827|NCT00006015|Drug|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
7828|NCT00742079|Drug|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
9296|NCT00755755|Drug|PGL4001 (ulipristal) and iron|Tablets
9297|NCT00000718|Drug|Zidovudine|
9298|NCT00006099|Procedure|biopsy|
9573|NCT00756080|Drug|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
9574|NCT00756093|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
9575|NCT00756093|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
9576|NCT00756093|Other|Blink Tears|Blink Tears one drop each eye one time
9577|NCT00756093|Other|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
9578|NCT00756106|Drug|temozolomide|chemotherapy
9579|NCT00756106|Other|imaging biomarker analysis|MRI
9580|NCT00756145|Procedure|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
9581|NCT00006100|Procedure|peripheral blood stem cell transplantation|
9582|NCT00756145|Procedure|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
9583|NCT00756145|Procedure|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
9584|NCT00756171|Drug|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
9585|NCT00756171|Drug|placebo|2 times 3 625mg tablets daily
9586|NCT00756184|Device|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
9587|NCT00756184|Device|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
9588|NCT00756197|Device|Cryo Spray Ablation Group 1|Cryo Spray Ablation
9589|NCT00756197|Device|Cryo Spray Ablation Group 2|cryo spray ablation
9590|NCT00756210|Other|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
9591|NCT00756223|Drug|Arm A|Dose escalation Arm A (4 weeks)
7596|NCT00734500|Drug|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
7597|NCT00734513|Behavioral|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
7598|NCT00734513|Behavioral|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
7599|NCT00734526|Drug|Temozolomide|Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.
Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle.
7600|NCT00734526|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
7601|NCT00734526|Drug|Sorafenib|Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.
Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
7602|NCT00734539|Drug|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
7603|NCT00736749|Procedure|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
7604|NCT00736762|Other|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
7605|NCT00736775|Drug|anti-Abeta|Intravenous single and multiple doses
7897|NCT00740051|Drug|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
7898|NCT00740051|Drug|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
7899|NCT00740064|Drug|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
7900|NCT00740077|Other|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
7901|NCT00740090|Drug|AMA1-C1/Alhydrogel plus CPG 7909|
7902|NCT00740103|Drug|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
9653|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
9654|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
9655|NCT00753792|Drug|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
9656|NCT00753805|Dietary Supplement|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
9657|NCT00753818|Other|DHA and ARA|various levels of DHA and ARA
9658|NCT00753818|Other|Control|
9659|NCT00753831|Procedure|Aurosling|Silicon rod to be used in frontalis suspension surgery
9660|NCT00753844|Biological|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
9998|NCT00761852|Drug|Ruboxistaurin|32 mg daily for 2 weeks
9999|NCT00761852|Drug|Placebo|1 tab po QD for 2 weeks
10000|NCT00761865|Device|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
10001|NCT00761878|Procedure|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
10002|NCT00761891|Drug|Enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
10003|NCT00761891|Drug|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
10004|NCT00754390|Dietary Supplement|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
10005|NCT00754390|Dietary Supplement|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
10006|NCT00754390|Dietary Supplement|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
10007|NCT00006087|Procedure|radiography|
10008|NCT00754403|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
10009|NCT00754403|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
9433|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
9434|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
9435|NCT00006119|Drug|hydroxyurea|
9436|NCT00761007|Drug|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
9437|NCT00761020|Other|Mefloquine and Control Cohort|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
9438|NCT00761033|Behavioral|music|
9439|NCT00761059|Drug|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
9440|NCT00761059|Drug|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
9441|NCT00761085|Drug|Morphine|Standard of care for pain management of acute episode of pain
9442|NCT00761085|Drug|Methadone|Methadone given to compare to standard of care for pain management
9443|NCT00761085|Drug|Methadone|Patients are randomized to either receive standard of care or methadone for pain management of acute episode of pain.
9444|NCT00761098|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
9445|NCT00761098|Drug|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
9446|NCT00006120|Drug|docetaxel|
9447|NCT00761111|Behavioral|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
9448|NCT00763048|Drug|Fluoride, triclosan|Brush twice daily
9803|NCT00759161|Drug|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
9804|NCT00759174|Drug|No intervention|No intervention occurs in this observational study.
9805|NCT00759187|Drug|Fluoride|Brush twice daily
9806|NCT00759187|Drug|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
9807|NCT00006113|Biological|recombinant CD40-ligand|
8927|NCT00757549|Drug|cisplatin|
9225|NCT00758069|Drug|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
9226|NCT00758069|Drug|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
9227|NCT00758069|Drug|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
9228|NCT00758082|Device|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
9229|NCT00758082|Device|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
9230|NCT00758121|Device|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
9231|NCT00758134|Drug|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
9232|NCT00006110|Drug|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
9233|NCT00758147|Device|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
9234|NCT00758160|Drug|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
9235|NCT00758173|Genetic|polymorphism analysis|
9236|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
9237|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
9238|NCT00760747|Drug|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
9239|NCT00760760|Drug|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
9240|NCT00760760|Drug|control|equivalent amount of fat as butter
9241|NCT00006117|Drug|gemcitabine hydrochloride|
9242|NCT00760773|Drug|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
5797|NCT00769392|Drug|Lidocaine|A subconjunctival injection of Lidocaine 2%
5798|NCT00769405|Drug|fluorouracil|Given IV
5799|NCT00769405|Drug|leucovorin calcium|Given IV
6107|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
6108|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
6109|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
6110|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
6111|NCT00772122|Drug|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
6112|NCT00772122|Drug|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
6113|NCT00006218|Drug|triapine|
6114|NCT00772135|Drug|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
6115|NCT00764972|Drug|Sorafenib and Vinorelbine|vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);
sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.
6116|NCT00764998|Biological|Fluviral|
6117|NCT00765011|Drug|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
6118|NCT00765011|Procedure|H&N surgery|Rescue surgery
6119|NCT00765024|Drug|Ivermectin|single dose of 200 mcg/kg
6120|NCT00765024|Drug|ivermectin|two single dose of 200mcg/kg in 2 weeks
6121|NCT00765024|Drug|Albendazole|Albendazole 7 days
6122|NCT00765037|Device|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
6123|NCT00765050|Biological|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
5539|NCT00716391|Other|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
5540|NCT00716391|Other|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
5541|NCT00716404|Device|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
5542|NCT00716417|Drug|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
5543|NCT00005867|Drug|vincristine sulfate|
5858|NCT00766896|Drug|Aspirin (platelet sensitive versus platelet hyperreactivity)|The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a "simple" preparation (no buffer, no extended release).
5859|NCT00766909|Drug|cyclosporine|For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.
For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days.
5860|NCT00766909|Drug|tacrolimus|For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.
For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days.
5861|NCT00766909|Other|Capsules and isotonic saline|For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.
For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days.
5862|NCT00000725|Drug|Zidovudine|
5863|NCT00006172|Device|Bright light box|60-min light therapy shortly after awakening
5864|NCT00766948|Other|There is no intervention, this is a biorepository.|There are no interventions in this study.
5865|NCT00766961|Procedure|Trans-catheter arterial embolization|Trans-catheter arterial embolization
5866|NCT00766961|Procedure|Surgery|Surgery
5867|NCT00766974|Device|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
5868|NCT00766974|Device|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
9808|NCT00761527|Drug|Desloratadine Syrup|Desloratadine (Aerius) Syrup;
Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:
Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg [milligrams] of desloratadine)
Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)
Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)
9809|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
9810|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
9811|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
9812|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
9813|NCT00006122|Drug|mitoxantrone hydrochloride|
9814|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
9815|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
9816|NCT00761553|Other|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
9817|NCT00761553|Dietary Supplement|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
9818|NCT00761566|Other|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
9819|NCT00761566|Other|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
9820|NCT00761579|Drug|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
8846|NCT00760006|Drug|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
8847|NCT00760006|Other|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
9513|NCT00758563|Drug|Triclosan/Fluoride|Brush twice daily
9514|NCT00758576|Device|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
9515|NCT00758589|Drug|AZD1981|Oral tablet, 50 mg twice daily
9516|NCT00758589|Drug|AZD1981|Oral tablet, 400 mg twice daily
9517|NCT00758589|Drug|AZD1981|Oral tablet, 1000 mg twice daily
9518|NCT00758589|Drug|Placebo|
9519|NCT00758602|Drug|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
9520|NCT00758602|Drug|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
9521|NCT00758602|Drug|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
9522|NCT00006112|Drug|chemotherapy|
9523|NCT00758602|Drug|corticosteroids|According to center's practice
9524|NCT00761124|Behavioral|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
9525|NCT00761124|Behavioral|Printed Material|General prostate cancer pamphlet
9526|NCT00761137|Drug|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
9527|NCT00761137|Drug|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
9528|NCT00761137|Drug|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
9529|NCT00761137|Drug|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
9530|NCT00761150|Drug|ABT-712|ABT-712 extended-release tablet
9531|NCT00761150|Drug|Placebo|Placebo tablet
6124|NCT00006154|Drug|Aldesleukin|Subcutaneous injection equaling 15 x 10^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
6125|NCT00765063|Drug|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
6126|NCT00765076|Biological|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
6127|NCT00765076|Biological|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
6128|NCT00765089|Procedure|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
5145|NCT00720798|Drug|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
5146|NCT00000694|Drug|Zidovudine|
5147|NCT00005908|Drug|Anastrozole|1 mg orally daily for five years
5148|NCT00720798|Drug|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
5149|NCT00720798|Drug|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
5150|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
5151|NCT00720811|Drug|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
5152|NCT00720811|Drug|paracetamol|paracetamol 500mg tablet <36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
5153|NCT00713271|Drug|AZD3199|Low dose
Dry powder for inhalation, o.d., 1+12 days
5154|NCT00713271|Drug|Placebo|
5155|NCT00713271|Drug|AZD3199|intermediate dose
Dry powder for inhalation, o.d., 1+12 days
5156|NCT00005854|Drug|cyclophosphamide|
5157|NCT00713271|Drug|AZD3199|high dose
Dry powder for inhalation, o.d., 1+12 days
5158|NCT00713284|Drug|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
5159|NCT00713297|Behavioral|satisfaction questionnaire|Satisfaction questionnaire
5869|NCT00767000|Drug|MK-0941|MK-0941 tablets three times daily
5870|NCT00767000|Drug|Comparator: Placebo|Matching placebo to MK-0941 three times daily
5871|NCT00767000|Biological|Lantus|Lantus injection once daily
5872|NCT00767000|Drug|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
5873|NCT00767013|Other|DSCT, TTE|One assessment each
5874|NCT00006172|Device|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
5875|NCT00769431|Other|study of socioeconomic and demographic variables|
5876|NCT00769457|Device|Access Arm|Active OptiVol-System with CareAlert via CareLink
5877|NCT00006195|Drug|risperidone|
5878|NCT00769470|Biological|trastuzumab|Given IV
5879|NCT00769470|Drug|carboplatin|Given IV
6184|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
6185|NCT00772343|Biological|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
6186|NCT00006220|Drug|arsenic trioxide|
6187|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
6188|NCT00772356|Device|Accu-Chek Spirit Insulin Pump|
6189|NCT00772356|Device|Comparator insulin pump|
6190|NCT00772382|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
6191|NCT00772395|Drug|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
6192|NCT00772395|Drug|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
6193|NCT00772421|Device|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
6194|NCT00772447|Drug|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
8848|NCT00760019|Drug|salsalate|1.5 grams orally 3 times daily
8849|NCT00006115|Drug|FOLFIRI regimen|
8850|NCT00760019|Drug|placebo|matching placebo
8851|NCT00760032|Drug|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
8852|NCT00760032|Drug|Placebo|Placebo capsules, one capsule per day during four weeks.
8853|NCT00760045|Drug|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
8854|NCT00760045|Drug|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
8855|NCT00760058|Device|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
8856|NCT00760058|Device|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
8857|NCT00760058|Device|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
8858|NCT00760084|Drug|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
8859|NCT00760097|Device|Transcranial direct stimulation|sessions of 20 minutes each
8860|NCT00006115|Drug|FOLFOX regimen|
8861|NCT00760110|Device|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
8862|NCT00760123|Other|Early Physical Therapy and Educational strategy|Experimental group:
physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.
Other: control group: only the educational strategy
8863|NCT00760136|Procedure|Computed Tomography|CT imaging of bilateral knee
8864|NCT00760149|Drug|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
9162|NCT00760695|Drug|dronabinol|tablets, twice daily, for 4 weeks
9163|NCT00760695|Drug|placebo|tablets, twice daily, for 4 weeks
5720|NCT00771485|Drug|Marketed Bowel Cleanser|Marketed bowel cleanser
5721|NCT00771498|Drug|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
5722|NCT00771511|Drug|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
5723|NCT00006213|Drug|BMS-214662|Given IV
5724|NCT00771511|Drug|Placebo|Only lidocaine gel will be appled to the cervix
5725|NCT00771524|Drug|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
5726|NCT00771537|Behavioral|Message Sidedness|There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
5727|NCT00771563|Drug|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
5728|NCT00771563|Drug|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
5729|NCT00771589|Device|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
5730|NCT00771602|Drug|Rituximab|375 mg/m^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
5731|NCT00771602|Drug|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
5732|NCT00771615|Biological|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
5733|NCT00764400|Behavioral|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
5734|NCT00764413|Drug|methylprednisolone|1 gram intravenous a day for 3 days
5735|NCT00764413|Drug|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
5160|NCT00713310|Drug|Asacol 400 mg|High dose:
17-<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM
5161|NCT00713310|Drug|Asacol 400 mg|Low dose:
17-<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM
5162|NCT00713323|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
5163|NCT00713336|Drug|ZD4054|ZD4054 10mg Tablet
5164|NCT00713336|Drug|Moxifloxacin|400 mg capsule
5165|NCT00713336|Drug|ZD4054 Placebo|3 tablets
5166|NCT00713336|Drug|Moxifloxacin placebo|1 capsule
5457|NCT00716339|Behavioral|motivation|
5458|NCT00716352|Behavioral|Educational intervention programme|
5459|NCT00716365|Device|HemCon bandage|5 cm X 5 cm
5460|NCT00716378|Behavioral|Teen Passenger Presence|
5461|NCT00718913|Drug|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
5462|NCT00718939|Device|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
5463|NCT00718952|Drug|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
5464|NCT00718952|Drug|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
5465|NCT00718952|Drug|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
5466|NCT00718965|Drug|AVE5530|one tablet in the evening with dinner
5467|NCT00718965|Drug|Placebo|one tablet in the evening with dinner
5468|NCT00718978|Procedure|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
6195|NCT00772447|Drug|Vancomycin|Vancomycin - 1g per 12 hrs, for 7-14 days
Or switch to
Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:
- 1 g every 6 hours or 2 g every 8 hours
6196|NCT00772460|Device|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
6197|NCT00006220|Drug|tretinoin|
6198|NCT00772473|Other|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
6199|NCT00772486|Biological|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
6200|NCT00772499|Drug|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
6201|NCT00772499|Drug|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
6202|NCT00772512|Drug|PF-04802540|5 mg capsule, single dose
6203|NCT00772512|Drug|PF-04802540|15 mg capsule, single dose
6204|NCT00772512|Drug|Placebo|Placebo capsule, single dose
6205|NCT00772525|Drug|Nerispirdine|form: tablet
Route: oral
6206|NCT00772525|Drug|Placebo|form: tablet
Route: oral
9403|NCT00758381|Drug|Sorafenib 400 mg po bid, continuously|NEXAVAR*112CPR RIV 200MG
Titolare AIC:
BAYER SpA
Numero di AIC dell'IMP:
037154010
9404|NCT00758381|Drug|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
9405|NCT00006111|Drug|cisplatin|
9406|NCT00758394|Drug|Fluoride|Brush two times a day for 4 days.
9407|NCT00758394|Drug|Triclosan/Fluoride|Brush two times daily for 4 days
9408|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
9409|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
9410|NCT00758407|Drug|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
9411|NCT00758407|Drug|Placebo|dosage according to an individual titration schedule
9164|NCT00760721|Behavioral|Educational Small Group Session|1 hour small group health-related discussion
9165|NCT00762905|Device|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
9166|NCT00762905|Device|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
9167|NCT00762918|Dietary Supplement|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
9168|NCT00006129|Drug|testosterone|
9169|NCT00762931|Device|Neurostimulation|An electrical neurostimulation signal will be applied to the neck.
9170|NCT00762931|Device|Neurostimulation|Subcutaneous lead placement for vagal nerve stimulation
9171|NCT00762957|Drug|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
9172|NCT00762957|Drug|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
9173|NCT00762957|Drug|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
9174|NCT00762970|Device|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
9175|NCT00762970|Device|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
9176|NCT00762970|Device|Control Lens|Spectacle Lenses.
9177|NCT00762983|Drug|loratadine|Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.
Claritin Dry Syrup 1%: For pediatric patients aged 3 to < 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.
The observation period will not be specified.
9178|NCT00762996|Device|etafilcon A|contact lens
9179|NCT00006130|Procedure|Core decompression|
9180|NCT00762996|Device|omafilcon A|contact lens
6040|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
6041|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
6042|NCT00767169|Device|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
6043|NCT00006174|Drug|Letrozole|
6044|NCT00767182|Other|blood sample|biological markers evaluated : D-Dimer, sEPCR
6045|NCT00767208|Other|oral glucose load|oral ingestion of 13C labeled glucose
6046|NCT00767221|Drug|Budesonide|8 mg PL-56 once daily for six months
6047|NCT00767234|Procedure|Observation|Standard of Care
6048|NCT00767260|Drug|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
6049|NCT00767260|Drug|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
6050|NCT00767260|Device|HOT|Hyperbaric Oxygen Therapy
6051|NCT00767260|Drug|SMT|hypoglycemic drugs or exogenous insulin
6052|NCT00767273|Procedure|PET Scan|
6053|NCT00767273|Drug|FLT|
6054|NCT00006178|Drug|Sirolimus|
6055|NCT00767273|Drug|FDG|
6056|NCT00767286|Drug|flutamide|
6057|NCT00767286|Drug|goserelin acetate|
6058|NCT00767286|Radiation|low-LET cobalt-60 gamma ray therapy|
6059|NCT00767286|Radiation|low-LET photon therapy|
6060|NCT00767299|Drug|arzoxifene|20 mg, QD, PO,24 weeks
6061|NCT00767299|Drug|Placebo|QD, PO, 24 weeks
6062|NCT00767325|Drug|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
5469|NCT00005889|Drug|glucagon|
5470|NCT00718991|Device|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
5471|NCT00719004|Procedure|Ultrasound of the foot|One ultrasound scan of the each foot
5472|NCT00719017|Procedure|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
5473|NCT00719017|Radiation|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
5474|NCT00719017|Procedure|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
5475|NCT00719030|Dietary Supplement|Pomegranate pill|Pomegranate extract pill
5476|NCT00719030|Dietary Supplement|Pomegranate pill placebo|Pomegranate pill placebo
5477|NCT00719043|Biological|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
5800|NCT00769405|Drug|oxaliplatin|Given during surgery
5801|NCT00769405|Procedure|hyperthermia treatment|Given intraperitoneally during surgery
5802|NCT00769418|Drug|odanacatib|Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.
Panel A: odanacatib tablets 2.5 mg qd for 14 days.
Panel B: odanacatib tablets 5 mg qd for 14 days.
Panel C: odanacatib tablets 10 mg qd for 14 days.
Panel D: odanacatib tablets 25 mg qd for 14 days.
Panel E: odanacatib tablets 0.5 mg qd for 21 days.
Panel F: odanacatib tablets 2.5 mg qd for 21 days.
Panel G: odanacatib tablets 10 mg qd for 21 days.
5803|NCT00769418|Drug|Comparator: Placebo|Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.
Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.
Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.
Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.
Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.
Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.
Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.
Panel G: placebo to odanacatib tablets 10 mg qd for 21 days.
5804|NCT00769431|Other|educational intervention|
5805|NCT00771628|Device|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
5806|NCT00006213|Other|pharmacological study|Correlative studies
5807|NCT00771628|Device|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
5808|NCT00771641|Procedure|conventional surgery|
9412|NCT00758420|Drug|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
9413|NCT00758420|Drug|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
9414|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
9415|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
9416|NCT00006111|Drug|fluorouracil|
9417|NCT00758433|Drug|Placebo patch|Placebo patch q.d. 24 hours for 7 days
9418|NCT00758446|Drug|BLX-028914|50 mg capsules, p.o, daily, 14 days
9419|NCT00758446|Drug|BLX-028914|15 mg capsules, p.o, daily, 14 days
9420|NCT00758446|Drug|placebo|capsules, p.o, daily, 14 days
9421|NCT00758459|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
9422|NCT00758459|Drug|Placebo|Dosing to match AZD1236
9423|NCT00758472|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
9424|NCT00006118|Drug|paclitaxel|
9425|NCT00760955|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
9426|NCT00760968|Drug|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
9427|NCT00760968|Drug|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
9702|NCT00758914|Dietary Supplement|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
9703|NCT00758927|Drug|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
9704|NCT00758927|Drug|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
9705|NCT00758940|Device|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
9706|NCT00006113|Biological|MART-1 antigen|
9707|NCT00758953|Drug|Danazol Once Weekly|semi-solid
9449|NCT00763061|Drug|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo & 9 PM
9450|NCT00763061|Drug|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM & 9 PM
9451|NCT00006131|Drug|Valacyclovir|
9452|NCT00763074|Behavioral|Standard life style modification for type 2 diabetes|Two session of education for exercise and diet.
----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30~35kcal/day
9453|NCT00763074|Behavioral|Diet restriction|Education for diet and exercise every 2 weeks
----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day
9454|NCT00763074|Behavioral|Exercise|Education for diet and exercise every 2 weeks
----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day
9455|NCT00763074|Behavioral|Diet and exercise|Education for diet and exercise every 2 weeks
----------- Exercise education like as exercise group and diet education like as diet group
9456|NCT00763087|Behavioral|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
9457|NCT00763087|Behavioral|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
9458|NCT00763087|Behavioral|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
9459|NCT00763113|Device|Vanguard PS Knee|Vanguard PS Knee
9460|NCT00763113|Device|Vanguard CR Knee|Vanguard CR Knee
9461|NCT00763126|Behavioral|stress level|Stress levels
9462|NCT00006132|Drug|acyclovir|
9463|NCT00763139|Drug|Pioglitazone|45 mg by mouth once a day for 8 weeks
9464|NCT00763139|Drug|Placebo|By mouth once a day for 8 weeks
9465|NCT00763152|Other|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
9466|NCT00763165|Drug|Triclosan|Brush twice daily
6063|NCT00767325|Drug|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
6064|NCT00767338|Behavioral|Timed intercourse|Timed intercourse
5082|NCT00722917|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
5083|NCT00715650|Behavioral|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
5084|NCT00715650|Behavioral|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
5085|NCT00715663|Drug|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
5086|NCT00715676|Drug|Placebo|oral, once daily
5087|NCT00005866|Drug|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
5088|NCT00715676|Drug|DP001|oral, once daily
5089|NCT00715689|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
5090|NCT00715689|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
5091|NCT00715689|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
5092|NCT00715689|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
5093|NCT00715689|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
5094|NCT00715689|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
5095|NCT00715689|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
5096|NCT00715689|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
5097|NCT00715702|Drug|AZD5672|100 mg oral single dose
5098|NCT00005866|Procedure|allogeneic bone marrow transplantation|day 0
5809|NCT00771641|Radiation|low-LET cobalt-60 gamma ray therapy|
5810|NCT00771641|Radiation|low-LET electron therapy|
5811|NCT00771641|Radiation|low-LET photon therapy|
5812|NCT00771641|Radiation|radiation therapy|
5813|NCT00771654|Drug|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
5814|NCT00771654|Other|Placebo|daily for one year
5815|NCT00771667|Drug|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
5816|NCT00771667|Drug|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
5817|NCT00006213|Other|laboratory biomarker analysis|Correlative studies
5818|NCT00771667|Drug|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
5819|NCT00771667|Drug|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
5820|NCT00771667|Drug|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
6129|NCT00765102|Drug|Bortezomib|Bortezomib was administered at a dose of 1.0 mg/m^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.
Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.
6130|NCT00765102|Drug|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m^2.
6131|NCT00765115|Drug|LY450139|
6132|NCT00765115|Drug|placebo|
6133|NCT00765128|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
6134|NCT00765128|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
6135|NCT00006155|Drug|SU5416 and carboplatin|
6136|NCT00765154|Drug|darunavir|two 400mg tablets (800mg) once daily
6137|NCT00765154|Drug|ritonavir|one 100mg capsule once daily
9708|NCT00758953|Drug|Danazol Twice Weekly|semi-solid
9709|NCT00758953|Drug|Placebo Once Weekly|semi-solid
9710|NCT00758953|Drug|Placebo Twice Weekly|semi-solid
9711|NCT00758966|Drug|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
9712|NCT00758966|Drug|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
9713|NCT00758966|Drug|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
9714|NCT00759005|Drug|propranolol and cortisol|
9715|NCT00759018|Biological|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
9716|NCT00761345|Radiation|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
9717|NCT00761358|Drug|Z-338|Oral
9718|NCT00761358|Drug|Placebo|Oral
9719|NCT00761371|Drug|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
9720|NCT00761384|Drug|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
9721|NCT00761397|Behavioral|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
9722|NCT00761397|Behavioral|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
10057|NCT00759629|Other|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
9467|NCT00763165|Drug|Fluoride|Brush twice daily
9468|NCT00763165|Drug|Fluoride|Brush twice daily
9821|NCT00761592|Biological|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
9822|NCT00761592|Biological|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
9823|NCT00761605|Drug|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
9824|NCT00006123|Biological|trastuzumab|
9825|NCT00761618|Procedure|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
9826|NCT00761618|Procedure|IPC Placement|IPC placed in chest cavity to drain excess fluid
9827|NCT00761618|Radiation|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
9828|NCT00754065|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
9829|NCT00754065|Drug|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
9830|NCT00006087|Procedure|annual screening|
9831|NCT00754078|Radiation|Tomotherapy|30 fractions of tomotherapy treatment
9832|NCT00754104|Drug|ABT-869|0.25 mg/kg. daily.
9833|NCT00754104|Drug|Tarceva|150mg, daily.
9834|NCT00754130|Drug|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
9835|NCT00754130|Drug|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
9836|NCT00754143|Drug|FG-3019|Placebo every 2 weeks IV for all infusions
9837|NCT00754143|Drug|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
9838|NCT00754143|Drug|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
5099|NCT00715715|Drug|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
5100|NCT00715741|Other|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
5101|NCT00715741|Other|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
5102|NCT00715741|Other|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 >0.9 with 3-5 cm water PEEP
5405|NCT00721110|Drug|Lidocaine and Ketamine|At general anesthetic induction intravenous lidocaine (1.5 mg/kg) will be given. Upon induction of anesthesia, lidocaine 2 mg/kg/hour, to a maximum of 200 mg/hour, will be infused. The lidocaine infusion will be reduced to 1.3 mg/kg/hour up to 133 mg/hour at skin closure and discontinued 24 hours postoperatively. Upon induction of anesthesia, a bolus of ketamine (0.25mg/kg) will be given followed by an infusion of ketamine (0.25mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
5406|NCT00721110|Other|placebo|Placebo boluses and infusions will be substituted for the lidocaine and ketamine not given
5407|NCT00721123|Drug|Tocilizumab|Tocilizumab (myeloma receptor antibody [MRA]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
5408|NCT00721136|Drug|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
5409|NCT00721136|Drug|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
5410|NCT00005908|Drug|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m^2 orally twice daily day 2-15
5411|NCT00721136|Drug|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
5412|NCT00721149|Device|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
5413|NCT00721162|Biological|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
5414|NCT00721175|Device|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
5415|NCT00721175|Device|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
5416|NCT00721188|Drug|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
6138|NCT00765167|Drug|Fluoride|Brush half mouth twice daily for four days
6139|NCT00765167|Drug|Triclosan|Brush half mouth daily for four days
6140|NCT00767338|Procedure|Intrauterine insemination|Intrauterine insemination
6141|NCT00767364|Biological|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
6142|NCT00767377|Drug|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
6143|NCT00767390|Device|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
6144|NCT00767403|Behavioral|Internet Intervention + Stepped Care|Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly "follow-ups," where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones.
5167|NCT00005854|Drug|cyclosporine|
5168|NCT00713336|Drug|ZD4054 Placebo|2 tablets
5169|NCT00713336|Drug|ZD4054|30mg tablet
5170|NCT00713336|Drug|ZD4054|10mg tablet
5171|NCT00713349|Drug|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
5172|NCT00713349|Other|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
5173|NCT00713362|Procedure|Video-assisted thoracoscopic surgery|VATS for bullectomy and mechanical pleurodesis
5174|NCT00713362|Procedure|chest tube drainage|Chest tube drainage for pneumothroax
5175|NCT00713401|Drug|Tecadenoson|Tecadenoson administered intravenously (i.v.)
5176|NCT00713401|Drug|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
5177|NCT00713427|Device|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
10058|NCT00759629|Other|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
10059|NCT00759642|Drug|lapatinib|lapatinib 1500 mg PO daily
10060|NCT00759655|Biological|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
10061|NCT00759668|Device|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
10062|NCT00759668|Device|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
10063|NCT00759681|Device|ArterX Surgical Sealant|Apply at the suture site.
10064|NCT00759681|Device|Gelfoam and Thrombin|Apply at the suture site.
10065|NCT00759707|Drug|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein [arterial] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
10066|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
10067|NCT00006113|Biological|tyrosinase peptide|
10068|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
10069|NCT00759720|Drug|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
10070|NCT00761904|Behavioral|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
10071|NCT00761917|Device|Tear Film Analyzer|tear film images
10072|NCT00006123|Drug|cyclophosphamide|
10073|NCT00761930|Drug|Fluoride|Brush twice daily
10074|NCT00761930|Drug|Triclosan and fluoride|Brush twice daily
10075|NCT00761930|Drug|Herbal Ingredient and fluoride|Brush twice daily
9100|NCT00755456|Drug|PD solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
9839|NCT00754156|Device|ABRA Abdominal Closure System|ABRA Abdominal Closure System
9840|NCT00754156|Device|V.A.C. Therapy|V.A.C. Therapy Alone
9841|NCT00006087|Procedure|bronchoscopic and lung imaging studies|
9842|NCT00754156|Device|KCI ABThera|KCI ABThera
9843|NCT00754182|Device|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
8865|NCT00760175|Biological|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
8866|NCT00760188|Device|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
8867|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
8868|NCT00762437|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
8869|NCT00762450|Drug|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
8870|NCT00006126|Drug|busulfan|
8871|NCT00762450|Drug|fluoride|Rinse 3 times daily with assigned toothpaste slurry
8872|NCT00762450|Drug|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
8873|NCT00762463|Drug|Celecoxib|capsule, 200 mg QD, 6-12 weeks
8874|NCT00762463|Drug|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
8875|NCT00762476|Drug|3804-250A|topical product
apply 2 pumps
apply at least every 4 hours or after hand washing
8876|NCT00762476|Drug|3804-291|topical
apply 2 pumps
apply at least every 4 hours or after hand washing
8877|NCT00762489|Other|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
8878|NCT00762502|Device|senofilcon A toric contact lens|soft contact lens
8879|NCT00762502|Device|balafilcon A toric contact lens|soft contact lens
8880|NCT00762515|Drug|Fluoride|Brush teeth two times daily for 6 weeks
5417|NCT00721201|Drug|Mifepristone|Use of mifepristone 200mg bd for 8 weeks
5418|NCT00721214|Drug|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
5419|NCT00721227|Procedure|Reduction Gastroplasty|Subjects will undergo reduction gastroplasty by gastric plication
Subjects are followed for 12 months to evaluate outcomes and potential complications.
5420|NCT00713739|Drug|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
5736|NCT00006152|Drug|Abacavir sulfate|
5737|NCT00764426|Drug|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
5738|NCT00764426|Drug|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
5739|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
5740|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
5741|NCT00764465|Drug|Maraviroc|300 mg BID
5742|NCT00764465|Drug|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
5743|NCT00764465|Drug|Ritonavir|100 mg BID, 100 mg QD
5744|NCT00764478|Drug|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
5745|NCT00764478|Drug|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
5746|NCT00764478|Drug|Placebo|placebo sublingual tablet, administered BID for 21 days
5747|NCT00006152|Drug|Amprenavir|
5748|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
5749|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
5750|NCT00764517|Drug|Cladribine|Given IV
5751|NCT00764517|Other|Laboratory Biomarker Analysis|Correlative studies
5178|NCT00005854|Drug|methotrexate|
5179|NCT00715767|Behavioral|Assessment|Cognitive Assessment:
Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:
Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).
Survey Instrument for Barriers to Acute Medicine Education:
A survey tool will be used to identify barriers to acute medicine education implementation and efficacy.
5180|NCT00715780|Drug|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
5181|NCT00715780|Drug|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
5182|NCT00715780|Drug|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
5183|NCT00715780|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
5184|NCT00005866|Radiation|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
5185|NCT00715780|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
5186|NCT00715780|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
5478|NCT00719043|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
5479|NCT00719043|Biological|Placebo|Administered as an intramuscular (IM) injection
5480|NCT00000693|Drug|Zidovudine|
5481|NCT00005889|Drug|glucose|
5482|NCT00719056|Drug|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
5483|NCT00719056|Drug|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
5484|NCT00719069|Drug|PSI-697|
5485|NCT00721240|Drug|montelukast|5mg montelukast once daily for 12 weeks
5486|NCT00005908|Drug|Capecitabine - Dose A|capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
9101|NCT00755456|Drug|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
9102|NCT00755469|Procedure|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
9103|NCT00755482|Drug|Aquamin F|
9104|NCT00755482|Drug|Placebo (maltodextran)|
9105|NCT00755495|Drug|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
9106|NCT00755495|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
9107|NCT00006096|Radiation|radiation therapy|
9108|NCT00755495|Drug|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
9109|NCT00755495|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
9110|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
9111|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
9112|NCT00755508|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
9113|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
9114|NCT00757783|Drug|atazanavir|300 mg capsule once daily for 48 weeks
9115|NCT00757809|Drug|neratinib|HKI-272
9116|NCT00757822|Drug|Dronabinol|Dronabinol will be administered perioperatively.
9117|NCT00757822|Drug|Ondansetron|Ondansetron will be administered perioperatively in those patients not receiving Dronabinol.
9118|NCT00757835|Drug|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
9119|NCT00757835|Drug|latanoprost/timolol fixed combination drops|once in the evening
8881|NCT00006126|Drug|cyclophosphamide|
8882|NCT00762515|Drug|Triclosan|Brush two times daily for 6 weeks
8883|NCT00762515|Drug|Fluoride|Brush two times daily for 6 weeks
8884|NCT00762528|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
8885|NCT00762528|Drug|Sodium monofluorophosphate toothpaste|Twice daily usage
8886|NCT00762541|Device|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
8887|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section.
9181|NCT00763009|Drug|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
9182|NCT00763022|Drug|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
9183|NCT00763022|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
9184|NCT00763022|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
9185|NCT00763035|Drug|Regadenoson, Dobutamine|Cross-over design in which each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit and dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
9186|NCT00763048|Drug|Fluoride|Brush twice daily for 6 weeks
9187|NCT00755508|Drug|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
9188|NCT00755508|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
9189|NCT00755521|Drug|etoricoxib|Treating Fibromyalgia with etoricoxib
etoricoxib - 90mg
9190|NCT00755534|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
9191|NCT00755534|Drug|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
9192|NCT00006097|Drug|CC-1088|
9193|NCT00755534|Drug|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
9194|NCT00755534|Drug|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
5752|NCT00764517|Biological|Rituximab|Given IV
5753|NCT00764517|Drug|Vorinostat|Given PO
5754|NCT00764530|Device|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
5755|NCT00764530|Device|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
5756|NCT00764543|Device|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
5757|NCT00764556|Drug|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
5758|NCT00006153|Biological|HIV-1 Immunogen|
5759|NCT00764569|Device|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
6065|NCT00006178|Drug|Thymoglobulin|
6066|NCT00767338|Procedure|Microsurgical varicocelectomy|Microsurgical varicocelectomy
6067|NCT00769717|Behavioral|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
6068|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
6069|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
6070|NCT00769782|Procedure|therapeutic conventional surgery|
6071|NCT00769795|Drug|IMC-A12 in combination with androgen deprivation therapy|All participants will begin bicalutamide 50 mg p.o. daily, one week prior to goserelin administration. On study day 1 the patients will be administered a single dose of goserelin 10.8 mg s.q. and continue on bicalutamide 50 mg daily for the duration of the trial. Total treatment length is 13 weeks. IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
6072|NCT00769821|Other|questionnaire administration|
6073|NCT00769821|Procedure|assessment of therapy complications|
6074|NCT00769821|Procedure|bioimpedance spectroscopy|
5487|NCT00721253|Device|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
5488|NCT00721253|Device|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
5489|NCT00721253|Device|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
5490|NCT00721266|Drug|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
5491|NCT00721279|Drug|Sifrol® (pramipexole dihydrochloride)|
5492|NCT00721305|Drug|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
5493|NCT00721305|Other|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
5494|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
5495|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
5496|NCT00721331|Drug|nortriptyline HCl|Topical
5497|NCT00005910|Procedure|Intraoperative ultrasound|
5498|NCT00721331|Drug|mometasone furoate|Topical
5499|NCT00721331|Drug|Active ingredient free vehicle cream of CRx-197|Topical
5500|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
5821|NCT00771667|Drug|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
5822|NCT00771667|Drug|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
5823|NCT00771667|Drug|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
5824|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
5825|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
9120|NCT00757848|Drug|AZD9668|60 mg, oral tablet, twice daily for 28 days
9723|NCT00761397|Other|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
9724|NCT00761397|Other|Questionnaire|Day 1 of study, 10 weeks after starting study, & 12 months after starting study
9725|NCT00006122|Drug|gemtuzumab ozogamicin|
9726|NCT00761410|Device|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
9727|NCT00761423|Biological|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
9728|NCT00761423|Biological|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
9729|NCT00761436|Biological|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
9730|NCT00761449|Drug|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
9731|NCT00761462|Drug|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
9732|NCT00761462|Drug|Non-quinolone antibiotic|Common used dose and route
9733|NCT00761475|Procedure|mesh supported closure|onlay mesh supported closure midline laparotomy
9734|NCT00761475|Procedure|primary closure|primary closure of the midline
9735|NCT00761475|Procedure|mesh supported closure|sublay mesh supported closure midline laparotomy
9736|NCT00006122|Drug|idarubicin|
9737|NCT00761488|Device|AcrySof® Toric IOL|Implanted into the study eye
9738|NCT00761501|Drug|PN400|Oral
9739|NCT00761501|Drug|Naproxen (Proxen S)|Oral
9740|NCT00761501|Drug|Naproxen (Naprosyn E)|Oral
9741|NCT00761514|Drug|Humira (adalimumab)|40 mg eow
9195|NCT00755547|Other|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
9196|NCT00755560|Drug|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
9197|NCT00755560|Drug|Placebo|Placebo BID for 15 days
9198|NCT00755573|Drug|Pregabalin|Pregabalin 300 mg - 600 mg BID
9199|NCT00755573|Drug|placebo|Regime as described for pregabalin
9200|NCT00755586|Procedure|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 * 10e8 cells in the m. biceps brachii.
9469|NCT00763178|Drug|Duloxetine|Dosage given according to the following schedule:
Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose
9470|NCT00763191|Other|examination of ocular movements|
9471|NCT00763191|Other|MATTIS test|
9472|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
9473|NCT00755911|Biological|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
9474|NCT00755911|Device|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
9475|NCT00755924|Dietary Supplement|Vinegar|Apple cider vinegar 2 TBlsp/day
9476|NCT00755924|Other|Placebo|Water placebo colored with balsamic vinegar
9477|NCT00006100|Biological|aldesleukin|
9478|NCT00755937|Other|Data collection post infusion|
9479|NCT00755950|Dietary Supplement|Silymarin|280 mg three times daily for four weeks
9480|NCT00755950|Dietary Supplement|Silymarin|420 mg three times daily for four weeks
6075|NCT00769821|Procedure|quality-of-life assessment|
6076|NCT00006199|Drug|R115777 (farnesyl transferase inhibitor)|
6077|NCT00769847|Procedure|Endoscopic strip craniectomy|Surgery
6078|NCT00769860|Drug|Arimoclomol|Arimoclomol 100 mg TID for 4 months
6079|NCT00769860|Other|Placebo|Placebo for 4 months
6080|NCT00769873|Drug|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days
6081|NCT00769886|Drug|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
6082|NCT00769886|Drug|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
6083|NCT00769886|Drug|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
6084|NCT00769886|Drug|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
5103|NCT00715741|Other|FiO2 >0.9 without PEEP|FiO2 >0.9 without PEEP
5104|NCT00718250|Biological|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
5105|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
5106|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
5107|NCT00718263|Drug|Nilotinib|
5108|NCT00718263|Drug|Imatinib|
5109|NCT00000692|Drug|Butyldeoxynojirimycin|
5110|NCT00005884|Drug|eflornithine|
5111|NCT00718276|Drug|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
5112|NCT00718276|Dietary Supplement|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
5113|NCT00718289|Other|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
5114|NCT00718289|Other|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
5826|NCT00771680|Drug|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
5827|NCT00771680|Drug|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
5828|NCT00006214|Drug|flutamide|
5829|NCT00771680|Drug|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
5830|NCT00771693|Drug|Insulin aspart (Novorapid®)|a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
5831|NCT00764582|Drug|1.5% levofloxacin ophthalmic solution|Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.
Group 1: 30 minutes prior to surgery
Group 2: 1 hour prior to surgery
Group 3: 2 hours prior to surgery
Group 4: 4 hours prior to surgery
5832|NCT00764582|Drug|0.5% moxifloxacin ophthalmic solution|Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.
Group 5: 30 minutes prior to surgery
Group 6: 1 hour prior to surgery
Group 7: 2 hours prior to surgery
Group 8: 4 hours prior to surgery
5833|NCT00764595|Drug|imatinib mesylate|
5834|NCT00764621|Procedure|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
5835|NCT00764621|Procedure|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
5836|NCT00764621|Procedure|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
5837|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
5838|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
5839|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
6145|NCT00767403|Behavioral|Internet Intervention|As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly "follow-ups," where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses.
6146|NCT00767403|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
9742|NCT00753922|Device|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
9743|NCT00006086|Drug|BMS-188797|
9764|NCT00756392|Procedure|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
9765|NCT00756405|Behavioral|Antioxidants from supplements vs foods|
9766|NCT00756418|Drug|montelukast|montelukast 5 mg QD 4-weeks.
9767|NCT00756418|Drug|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
9768|NCT00756431|Device|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
9769|NCT00756431|Device|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
9770|NCT00756444|Drug|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
9771|NCT00756444|Drug|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
9772|NCT00000718|Drug|Zalcitabine|
9773|NCT00006103|Drug|fluorouracil|
9774|NCT00756444|Drug|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
9775|NCT00756457|Device|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
9776|NCT00756457|Other|Strengthening exercises|Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a "warm up."
9481|NCT00755950|Other|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
9482|NCT00755963|Drug|estradiol valerate|Progynova® 21; 2mg/d
9483|NCT00755963|Drug|micronized progesterone|Utrogestan®; 200mg/d
9484|NCT00755963|Drug|placebo|maltodextrin
9485|NCT00755976|Drug|epirubicin hydrochloride|
9486|NCT00755976|Drug|sulindac|
9487|NCT00755976|Other|immunologic technique|
9488|NCT00006100|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
9489|NCT00755989|Drug|morphine topical gel|morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay
9490|NCT00755989|Drug|placebo|topical gel without morphine
9491|NCT00756002|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
9492|NCT00756002|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
9844|NCT00754182|Device|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
9845|NCT00754195|Other|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
9846|NCT00754208|Drug|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
9847|NCT00754221|Drug|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
9848|NCT00754234|Behavioral|My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7|Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
9849|NCT00754247|Drug|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
9850|NCT00754247|Drug|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
5115|NCT00718302|Device|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
5116|NCT00718302|Device|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
5117|NCT00718315|Drug|erlotinib [Tarceva]|150mg po daily
5118|NCT00718315|Drug|fusidic acid [Verutex]|topical, daily for 30 days.
5119|NCT00718315|Drug|erythromycin [Eritex]|topical, daily for 30 days.
5120|NCT00718315|Drug|Fisiogel|topical, daily for 30 days
5121|NCT00005886|Drug|arzoxifene hydrochloride|
5122|NCT00718328|Drug|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
5123|NCT00718328|Drug|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
5124|NCT00718341|Drug|AF056|
5125|NCT00718341|Drug|Placebo|
5126|NCT00718354|Drug|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
5127|NCT00718354|Drug|Standard Chemotherapy|Investigator's discretion
5421|NCT00713739|Drug|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
5422|NCT00713739|Drug|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
5423|NCT00713739|Drug|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
5424|NCT00713765|Drug|AZD3480|18 total doses of 40 mg, on days 1-18
5425|NCT00713765|Drug|Donepezil|One single dose of mg on day 5
6147|NCT00767416|Biological|MEDI-559|Cohort 1 (5 to <24 months): N=80 MEDI-559 at 10^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
6148|NCT00767416|Other|Placebo|Cohort 1 (5 to < 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
6149|NCT00006180|Drug|Alendronate|
6150|NCT00767429|Device|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
6151|NCT00767455|Device|HP828-101|21 day patches
6152|NCT00767468|Drug|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
6153|NCT00767481|Drug|Travoprost/Brinzolamide|Eye drop suspension, once daily
6154|NCT00767481|Drug|Cosopt|Eye drop solution, one drop BID
6155|NCT00767494|Drug|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
6156|NCT00767494|Drug|Azopt|Eye Drop Suspension, 1 drop BID
6157|NCT00767494|Drug|Travatan|Eye Drop Solution, 1 drop BID
6158|NCT00767507|Drug|cangrelor|
6159|NCT00767507|Other|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
6160|NCT00769925|Behavioral|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
6161|NCT00769925|Behavioral|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
6162|NCT00769938|Device|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
6163|NCT00769951|Other|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
5187|NCT00715793|Drug|Decitabine|In Part I patients will be treated on a standard "3+3" phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle.
9777|NCT00756457|Other|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
9778|NCT00756470|Drug|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
9779|NCT00756470|Drug|Paclitaxel|80 mg/m^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
9780|NCT00756470|Drug|5-Fluorouracil (5-FU)|500 mg/m^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
9781|NCT00756470|Drug|Epirubicin|75 mg/m^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
9782|NCT00756470|Drug|Cyclophosphamide|500 mg/m^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
10076|NCT00761956|Device|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
10077|NCT00761956|Device|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
10078|NCT00761969|Other|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
10079|NCT00761982|Procedure|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
10080|NCT00761995|Drug|Azopt|topical eye drop dosed 1 drop 3 times daily
10081|NCT00761995|Drug|Cosopt|topical eye drop dosed 1 drop 2 times daily
10082|NCT00762021|Device|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
10083|NCT00006123|Drug|thiotepa|
10084|NCT00762021|Device|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
10085|NCT00762034|Drug|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
10086|NCT00762034|Drug|Pemetrexed|Maintenance therapy 500 mg/m^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
10087|NCT00762034|Drug|Paclitaxel|Induction therapy 200 mg/m^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
9851|NCT00006103|Drug|irinotecan hydrochloride|
9852|NCT00756522|Other|There is no intervention. Study is observational.|There is no intervention. Study is observational.
9853|NCT00756535|Procedure|Exercise training|Group-based exercise training 5 days a week during hospitalization
9854|NCT00756535|Procedure|usual treatment and rehabilitation|usual treatment and rehabilitation
9855|NCT00756548|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
9856|NCT00756548|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
9857|NCT00756574|Device|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
9858|NCT00756574|Device|N95 mask|N95 mask worn for patients with febrile respiratory illness
9859|NCT00756587|Device|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
9860|NCT00756587|Device|Bottle Feeding|receiving all feeding by bottle
9861|NCT00756600|Drug|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
9862|NCT00006103|Drug|leucovorin calcium|
9863|NCT00756600|Drug|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
8888|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
8889|NCT00762554|Drug|Fentanyl|Epidural fentanyl infusion started after epidural lidocaine or spinal bupivacaine used for the cesarean section.
8890|NCT00762567|Drug|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
8891|NCT00762593|Device|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
8892|NCT00000189|Drug|Gepirone|
8893|NCT00000723|Drug|Leucovorin calcium|
8894|NCT00006126|Drug|etoposide|
8895|NCT00762593|Device|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
5426|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
5427|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
5428|NCT00005855|Drug|efaproxiral|
5429|NCT00713778|Procedure|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
5430|NCT00713791|Drug|ZD4054|Treatment period 1: 10mg oral solution
5431|NCT00713791|Drug|ZD4054|Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
5432|NCT00713791|Drug|ZD4054|Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
5433|NCT00713791|Drug|ZD4054|Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
5434|NCT00713804|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
5435|NCT00713804|Behavioral|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
5436|NCT00713817|Drug|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
5760|NCT00766740|Device|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
5761|NCT00766740|Device|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
5762|NCT00766753|Biological|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
5763|NCT00766753|Biological|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
5188|NCT00715793|Drug|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
5189|NCT00715793|Procedure|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
5190|NCT00715806|Device|Open MRI scanner.|Imaging in an Open MRI scanner.
5191|NCT00715806|Device|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
5192|NCT00715832|Biological|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
5193|NCT00715845|Procedure|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
5194|NCT00715858|Drug|doxycycline|capsule, 100 mg, b.i.d., 12 months
5195|NCT00005867|Biological|bleomycin sulfate|
5196|NCT00005886|Drug|tamoxifen citrate|
5197|NCT00718432|Behavioral|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
5198|NCT00718432|Behavioral|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
5199|NCT00718432|Behavioral|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
5200|NCT00718471|Drug|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
5501|NCT00721344|Drug|Moxifloxacin|Tablets 400mg
10088|NCT00762034|Drug|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
10089|NCT00762034|Biological|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
10090|NCT00762034|Biological|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
10091|NCT00762047|Device|Durasphere FI|Durasphere Injection
10092|NCT00762047|Device|Sham|Sham injection with anesthesia
10093|NCT00762060|Device|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
10094|NCT00006123|Procedure|peripheral blood stem cell transplantation|
10095|NCT00762060|Drug|Patient controlled analgesia|IV opioids delivered via PCA
10096|NCT00762073|Drug|budesonide|oral suspension
10097|NCT00754533|Other|Continuous versus interval training|Influence of different exercise training programs
9121|NCT00006108|Drug|paclitaxel|
9122|NCT00757848|Drug|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
9123|NCT00757874|Drug|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
9124|NCT00757874|Drug|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
9125|NCT00757887|Biological|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
9126|NCT00757900|Biological|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
9127|NCT00757913|Dietary Supplement|n-3 enriched nutrition|
9128|NCT00757926|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
9129|NCT00757926|Other|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
9130|NCT00757939|Other|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
9131|NCT00757939|Other|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
8896|NCT00755118|Drug|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
8897|NCT00755118|Drug|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
8898|NCT00755118|Drug|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
8899|NCT00755118|Drug|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
8900|NCT00755131|Other|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
8901|NCT00755157|Drug|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
8902|NCT00755157|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
8903|NCT00755170|Drug|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
8904|NCT00755170|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
8905|NCT00755183|Drug|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
8906|NCT00006094|Drug|fluorouracil|Given IV
9201|NCT00755586|Procedure|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 * 10e8 cells in the m. biceps brachii.
9202|NCT00755586|Procedure|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
9203|NCT00006098|Drug|bortezomib|
9204|NCT00755599|Procedure|no-stirrup vaginal examination|Vaginal speculum examination done with feet on table extender.
9205|NCT00755599|Procedure|Vaginal speculum examination done with stirrups.|Speculum examination done with feet in stirrups.
9206|NCT00755638|Biological|ACE-031|single subcutaneous dose of ACE-031
5764|NCT00766753|Biological|The second booster vaccine phase:|At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued up to five years from the initial vaccine (the first vaccine for the patient on Week 1). DC vaccines in this phase will be administered every 6 months+/- 2 weeks.
2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays
5765|NCT00766766|Behavioral|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
5766|NCT00766766|Behavioral|Telephone Coaching Sessions|Telephone Coaching Sessions
5767|NCT00006170|Drug|Bupropion|
5768|NCT00766766|Behavioral|Physician Feedback Letter|Physician Feedback Letter
5769|NCT00766779|Procedure|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
5770|NCT00766779|Drug|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
5771|NCT00766792|Procedure|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
5772|NCT00766792|Procedure|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
5773|NCT00766805|Drug|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
5774|NCT00766805|Other|EVL alone|
5775|NCT00766818|Drug|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
6085|NCT00769899|Drug|AZD7325|Capsule for oral, single dose
6086|NCT00769899|Drug|Placebo|Placebo capsule for oral, single dose
6087|NCT00006199|Drug|Topotecan|
6088|NCT00769912|Drug|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
6089|NCT00769912|Drug|Placebo (air)|Placebo administration during the intervention
6090|NCT00772005|Drug|placebo|placebo
5502|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
5503|NCT00721344|Drug|Placebo|Placebo cartridges
5504|NCT00721357|Behavioral|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
5505|NCT00721357|Other|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
5506|NCT00721370|Device|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
5507|NCT00721383|Behavioral|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
5508|NCT00005912|Drug|Voriconazole|
5509|NCT00721383|Behavioral|CSBI|Caregiver skill-building
5510|NCT00721396|Biological|rMenB+OMV NZ|
5511|NCT00721396|Biological|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
5512|NCT00721396|Biological|Pneumococcal vaccine|
5513|NCT00713817|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
5514|NCT00713830|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
5515|NCT00005856|Drug|oxaliplatin|Given IV
5516|NCT00713830|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
5517|NCT00713830|Device|Pen auto-injector|
5518|NCT00713830|Drug|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
5519|NCT00713830|Drug|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day [except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea]) up to the end of treatment.
5520|NCT00713843|Other|Manual Therapy Utrecht|Manual Therapy (6 weeks).
5521|NCT00713843|Other|Physical Therapy|Physical Therapy (six weeks).
5522|NCT00713856|Procedure|Custom PRK with iris registration|PRK
5523|NCT00713856|Procedure|Conventional PRK|PRK
9132|NCT00006110|Biological|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
9133|NCT00757952|Other|Fourier transform ion cyclotron resonance mass spectrometry|
9134|NCT00757952|Other|chromatography|
9135|NCT00757952|Other|diagnostic laboratory biomarker analysis|
9136|NCT00757952|Other|questionnaire administration|
9137|NCT00757965|Genetic|polymorphism analysis|
9138|NCT00757965|Other|laboratory biomarker analysis|
9139|NCT00757965|Other|questionnaire administration|
9140|NCT00757978|Drug|memantine|memantine 10mg twice a day
9141|NCT00757978|Drug|placebo|1 capsule of placebo twice a day
9744|NCT00753935|Drug|aspirin|enteric-coated aspirin 81mg daily for 2 weeks
9745|NCT00753935|Drug|aspirin|chewable aspirin 81mg daily for 2 weeks
9746|NCT00753948|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
9747|NCT00753961|Other|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
9748|NCT00753961|Other|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
9749|NCT00753974|Procedure|Obtaining tissue samples for testing|Obtaining tissue samples from heart surgery patients for studying cardiac tissue and the genetic trends associated with heart failure
9750|NCT00753987|Drug|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
9751|NCT00754000|Other|Observation|AE monitoring and EPIC QOL survey
9752|NCT00754013|Drug|Aricept (Donepezil hydrochloride)|All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.
All doses will be administered orally.
9753|NCT00754013|Drug|Placebo|All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.
All doses will be administered orally.
9754|NCT00006086|Drug|carboplatin|
9755|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
9207|NCT00755651|Procedure|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
9208|NCT00757991|Genetic|polymorphism analysis|
9209|NCT00006110|Drug|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
9210|NCT00757991|Other|laboratory biomarker analysis|
9211|NCT00757991|Other|questionnaire administration|
9212|NCT00758004|Drug|Atorvastatin|A single dose of 80 mg atrovastatin tablet
9213|NCT00758004|Drug|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
9214|NCT00758017|Other|Acupuncture 1|Application of individualised acupuncture
9215|NCT00758017|Other|Acupuncture 2|Application of standardised acupuncture
9216|NCT00758030|Drug|Paliperidone ER OROS|
9217|NCT00758043|Drug|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
9218|NCT00758043|Drug|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
9219|NCT00758043|Biological|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
9220|NCT00000719|Drug|Zalcitabine|
9221|NCT00006110|Drug|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
9222|NCT00758056|Genetic|polymorphism analysis|
9223|NCT00758056|Other|laboratory biomarker analysis|
9224|NCT00758056|Other|questionnaire administration|
9493|NCT00756015|Other|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
9494|NCT00756015|Other|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
6091|NCT00006216|Biological|PA-1-STK ovarian carcinoma vaccine|
6092|NCT00772005|Drug|armodafinil|200 mg/day armodafinil
6093|NCT00772005|Drug|armodafinil|250 mg/day armodafinil
6094|NCT00772031|Drug|propranolol LA|Propranolol LA up to 240 mg/day
6095|NCT00772031|Drug|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
6096|NCT00772031|Drug|placebo|an inactive substance
6097|NCT00772044|Device|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
6098|NCT00772044|Device|Sham Device|Sham device will be applied
6099|NCT00772057|Drug|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
6100|NCT00772057|Drug|Placebo|Placebo tablets given two times daily.
6101|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
6102|NCT00006216|Drug|ganciclovir|
6103|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
6104|NCT00772083|Behavioral|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
6105|NCT00772083|Behavioral|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
6106|NCT00772096|Drug|n-3 fatty acids|
5128|NCT00718380|Drug|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
5129|NCT00718406|Drug|Metoprolol|
5130|NCT00718406|Drug|metoprolol plus morphine|
5524|NCT00713895|Behavioral|stage-based expert system|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
5840|NCT00006154|Drug|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
5841|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
5842|NCT00764647|Behavioral|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
5843|NCT00764660|Drug|Org 25935|12 mg BID, administered in tablets containing 4 mg of active substance in the morning and in the evening;
treatment duration: 12 weeks
5844|NCT00764660|Drug|Placebo|Placebo
5845|NCT00764673|Device|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
5846|NCT00764686|Other|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
5847|NCT00764686|Other|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
5848|NCT00764699|Drug|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
5849|NCT00764712|Drug|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
5850|NCT00764725|Drug|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
5851|NCT00006170|Drug|Placebo|A matched placebo pill
5852|NCT00766857|Drug|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
5853|NCT00766857|Drug|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
5854|NCT00766870|Drug|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
5855|NCT00766870|Drug|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
9756|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
9757|NCT00754039|Drug|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
9758|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
9759|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
9760|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All subjects will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur at 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
9761|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All subjects will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
9762|NCT00754052|Drug|Placebo|All subjects will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
9763|NCT00756379|Other|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
9783|NCT00756509|Drug|Nilotinib|800 mg/d orally
9784|NCT00759031|Drug|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
9785|NCT00006113|Biological|aldesleukin|
9786|NCT00759031|Drug|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
9787|NCT00759057|Device|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
9788|NCT00759070|Drug|Tenofovir + emtricitabine + efavirenz|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)
+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily
9789|NCT00759070|Drug|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
9790|NCT00759083|Drug|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
9791|NCT00759096|Device|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
9792|NCT00759109|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
9495|NCT00756028|Drug|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
9496|NCT00756028|Drug|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
9497|NCT00758485|Drug|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
9498|NCT00758485|Drug|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
9499|NCT00758498|Drug|armodafinil|50 mg/day orally, once daily in the morning for 3 days
9500|NCT00006111|Procedure|conventional surgery|
9501|NCT00758498|Drug|armodafinil|150 mg/day orally, once daily in the morning for 3 days
9502|NCT00758498|Drug|placebo|placebo tablets, once daily in the morning for 3 days
9503|NCT00758511|Procedure|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
9504|NCT00758511|Procedure|facilitated tucking|facilitated tucking before, during and after heel stick
9505|NCT00758511|Procedure|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
9506|NCT00758524|Drug|LCI699|
9507|NCT00758524|Drug|Eplerenone|
9508|NCT00758524|Drug|Placebo|Placebo
9509|NCT00758550|Device|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
9510|NCT00758550|Device|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
9511|NCT00006111|Radiation|radiation therapy|
9512|NCT00758563|Drug|Fluoride|Brush twice daily
9864|NCT00756626|Behavioral|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
9865|NCT00756639|Radiation|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
5131|NCT00718419|Drug|Enzastaurin|Enzastaurin: Cycle 1 Day 1 only: 3, 125-mg tablets three times on Day 1 (Day 1 total dose = 1125 mg) Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally BID (500 mg total per day) Cycle length (all cycles): 28 Days Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression.
5132|NCT00720707|Procedure|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
5133|NCT00720720|Dietary Supplement|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
5134|NCT00720720|Dietary Supplement|placebo margarine|
5135|NCT00005908|Drug|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m^2 intravenous day 1
5136|NCT00720733|Behavioral|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
5137|NCT00720733|Behavioral|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning & Purpose.
5138|NCT00720759|Drug|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
5139|NCT00720759|Behavioral|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
5140|NCT00720759|Drug|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
5141|NCT00720759|Behavioral|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
5142|NCT00720772|Drug|25% intravenous (IV) sodium thiosulfate|50 ml IV drip twice/week post hemodialysis
5143|NCT00720785|Drug|NK cells +CliniMACs CD3 and CD56 systems|
5144|NCT00720798|Drug|Tocilizumab|For participants weighing > 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
5437|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
5438|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
5439|NCT00716092|Drug|Linagliptin|5mg once daily for 28 days
5856|NCT00766870|Drug|Placebo|Per oral doses, twice daily as capsules during 10 weeks
5857|NCT00766883|Behavioral|Problem Solving Education|
6164|NCT00769951|Other|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
6165|NCT00769951|Procedure|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
6166|NCT00769951|Procedure|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
6167|NCT00769951|Procedure|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
6168|NCT00000111|Procedure|Oral mucosal graft|
6169|NCT00000190|Procedure|Parotid Gland|
6170|NCT00000727|Drug|Pyrimethamine|
6171|NCT00006200|Drug|thalidomide|
6172|NCT00769964|Drug|VA111913 TS / placebo|
6173|NCT00769990|Dietary Supplement|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
6174|NCT00769990|Radiation|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
6175|NCT00770003|Drug|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
6176|NCT00770003|Drug|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
6177|NCT00770016|Drug|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
6178|NCT00770029|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
6179|NCT00770029|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
9793|NCT00759109|Other|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
9794|NCT00759122|Drug|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
9795|NCT00759122|Drug|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
9796|NCT00006113|Biological|gp100 antigen|
9797|NCT00759135|Drug|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
9798|NCT00759135|Drug|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
9799|NCT00759135|Drug|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
9800|NCT00759148|Drug|Moxifloxacin eye drops|eyedrops; 1 drop in each eye, twice daily for 3 days
9801|NCT00759148|Drug|Moxifloxacin AF Ophthalmic Solution Vehicle (placebo)|Eyedrops; 1 drop in each eye, twice daily for 3 days
9802|NCT00759161|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
8829|NCT00757302|Device|SLN procedure (CarolIReS camera)|Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).
Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).
8830|NCT00000719|Drug|Zidovudine|
8831|NCT00006106|Drug|fluorouracil|
8832|NCT00757315|Device|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
8833|NCT00757315|Drug|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
8834|NCT00757341|Drug|SKI-606|
8835|NCT00757354|Procedure|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
9866|NCT00756639|Other|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
9867|NCT00756652|Device|Mentor Silicone Gel-Filled Breast Implants|
9868|NCT00756652|Device|Saline Breast Implants|
9869|NCT00756678|Drug|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days`
9870|NCT00756678|Drug|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
9871|NCT00756691|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
9872|NCT00756704|Behavioral|Smoking cessation guideline implementation|a tutorial on brief cessation counseling for ED nurses and physicians
use of an ED algorithm that includes recommended tobacco counseling items
fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy
group feedback to ED staff
9873|NCT00006104|Biological|trastuzumab|
9874|NCT00759187|Drug|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
9875|NCT00759200|Drug|alb-interferon alfa 2b|900 mcg every 4 weeks
9876|NCT00759200|Drug|alb-interferon alfa 2b|1200 mcg every 4 weeks
9877|NCT00759200|Drug|alb-interferon alfa 2b|1500 mcg every 4 weeks
9878|NCT00759200|Drug|alb-interferon alfa 2b|1800 mcg every 4 weeks
9879|NCT00759200|Drug|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
9880|NCT00759226|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
9881|NCT00759226|Drug|Cisplatin|Cisplatin 30 mg/m2 (90 min)
9882|NCT00759226|Drug|5-FU|5-FU 750 mg/m2 (24h CI)
9883|NCT00759226|Drug|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
9884|NCT00006113|Biological|recombinant interferon gamma|
9885|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
9886|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
8907|NCT00755183|Drug|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
5440|NCT00716105|Other|Standard infant formula|From 3 to 12 months of age. As per standard requirement
5441|NCT00716105|Other|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
5442|NCT00716144|Drug|Talarozole|Oral Capsule Once Daily
5443|NCT00005867|Drug|mitoxantrone hydrochloride|
5444|NCT00716170|Biological|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|Day A: Oral glucose tolerance test (50g glucose)
Day B: Isoglycemic intravenous (iv) glucose infusion
Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)
Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)
Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)
Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E.
5445|NCT00716183|Biological|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
5446|NCT00716183|Biological|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
5447|NCT00716183|Biological|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
5448|NCT00716183|Drug|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
5449|NCT00716248|Drug|bucillamine|bucillamine 100 mg, twice a day
5450|NCT00716248|Drug|methotrexate|methotrexate 6 mg or more per week
5451|NCT00716261|Device|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
5452|NCT00716274|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 32 weeks
5453|NCT00716274|Drug|Placebo|oral, daily, for 32 weeks
5454|NCT00005867|Drug|prednisolone|
5455|NCT00716326|Device|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
5456|NCT00716326|Device|Cefar Primo Pro TENS device|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.
Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold.
6180|NCT00772291|Drug|placebo|placebo drug during 8 weeks
6181|NCT00772304|Drug|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
6182|NCT00772317|Device|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
6183|NCT00772343|Biological|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
5201|NCT00718471|Drug|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
5202|NCT00718484|Drug|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
5203|NCT00718484|Drug|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
5204|NCT00718510|Drug|L-Arginine|3 grams, twice daily, oral administration
5205|NCT00718523|Drug|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
5206|NCT00718523|Drug|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
5207|NCT00005887|Drug|efaproxiral|
5208|NCT00718536|Drug|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
5209|NCT00718549|Drug|cladribine|0.12mg/kg iv on days 2-4 of each cycle (induction phase)
5210|NCT00718549|Drug|cyclophosphamide|250mg/m2 iv on days 2-4 (induction phase)
5211|NCT00718549|Drug|rituximab [MabThera/Rituxan]|375mg/m2 on day 1 of cycle 1 (induction phase)
5212|NCT00718549|Drug|rituximab [MabThera/Rituxan]|500mg/m2 iv on day 1 of cycles 2-6 (induction phase)
5213|NCT00718549|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 12 weeks (maintenance phase)
5214|NCT00718562|Drug|AMN107|
5215|NCT00718575|Procedure|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
5216|NCT00720811|Device|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
8836|NCT00757367|Drug|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
8837|NCT00757380|Procedure|Trypan Blue|Membranepeeling with TB
8838|NCT00757380|Procedure|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
8839|NCT00757393|Dietary Supplement|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
8840|NCT00757393|Drug|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
8841|NCT00757419|Drug|AZD3355|capsules, oral, single or twice daily dose
8842|NCT00006106|Drug|ONYX-015|
8843|NCT00757419|Drug|Placebo|To match dosing of AZD3355
8844|NCT00757458|Drug|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
8845|NCT00757458|Other|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
9142|NCT00760552|Other|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
9143|NCT00760565|Drug|RO4905417|3mg/kg iv every 28 days for 3 infusions
9144|NCT00760565|Drug|RO4905417|20mg/kg iv every 28 days for 3 infusions
9145|NCT00760565|Drug|RO4905417|7mg/kg iv every 28 days for 3 infusions
9146|NCT00760565|Drug|placebo|3mg/kg iv every 28 days for 3 infusions
9147|NCT00760565|Drug|placebo|7mg/kg iv every 28 days for 3 infusions
9148|NCT00006116|Drug|cisplatin|
8908|NCT00755196|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
8909|NCT00755196|Drug|AN2728|AN2728 Ointment Vehicle, twice daily for 12 weeks
8910|NCT00755209|Drug|tranexamic acid|Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
8911|NCT00755222|Biological|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
8912|NCT00755222|Biological|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
8913|NCT00755235|Other|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
8914|NCT00755248|Procedure|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
8915|NCT00755261|Drug|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
8916|NCT00757458|Other|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
8917|NCT00757458|Other|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
8918|NCT00757471|Procedure|Brillant Blue|Membrane Peeling with Brillant Blue
8919|NCT00757471|Procedure|Indocyanine Green|Membrane Peeling with indocyanine Green
8920|NCT00757497|Behavioral|Electrical Polarization|
8921|NCT00757523|Drug|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
8922|NCT00757523|Drug|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
8923|NCT00006107|Drug|docetaxel|
8924|NCT00757536|Procedure|Encircling Band|ppVE and encircling band
8925|NCT00757536|Procedure|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
8926|NCT00757549|Biological|cetuximab|
5776|NCT00766831|Drug|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram [mg] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
5777|NCT00766844|Device|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
5778|NCT00769327|Genetic|cytogenetic analysis|
5779|NCT00769327|Genetic|fluorescence in situ hybridization|
5780|NCT00769327|Genetic|microarray analysis|
5781|NCT00769327|Genetic|mutation analysis|
5782|NCT00769327|Genetic|polymerase chain reaction|
5783|NCT00769327|Genetic|polymorphism analysis|
5784|NCT00769327|Other|laboratory biomarker analysis|
5785|NCT00006193|Behavioral|diet|
5786|NCT00769353|Behavioral|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
5787|NCT00769353|Behavioral|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
5788|NCT00769366|Behavioral|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
5789|NCT00769366|Drug|Medical therapy|Optimal medical therapy after Acute myocardial infarction
5790|NCT00769379|Other|Laboratory Biomarker Analysis|Correlative studies
5791|NCT00769379|Biological|Trastuzumab|Given IV
5792|NCT00769379|Radiation|Whole Breast Irradiation|Undergo standard whole breast irradiation
5793|NCT00769392|Drug|Proparacaine|Drops of Proparacaine on the eye, administered as described in the package insert
5794|NCT00769392|Drug|Tetracaine|Drops of Tetracaine on the eye, administered as described in the package insert
5795|NCT00769392|Drug|Lidocaine|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
5796|NCT00006194|Behavioral|Exercise|
5217|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
5218|NCT00720824|Behavioral|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
5219|NCT00720824|Behavioral|Office routine|Standard vaccine administration
5220|NCT00720837|Procedure|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
5221|NCT00005908|Drug|cyclophosphamide|600 mg/m^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
5525|NCT00713895|Behavioral|Standard self-help|standard smoking cessation self-help manual
5526|NCT00005856|Other|pharmacological study|Correlative studies
5527|NCT00713921|Drug|Detrol LA|Oral Detrol LA, 4mg daily for sim months
5528|NCT00713934|Biological|CD133|portal vein infusion of CD133+ cells
5529|NCT00713934|Biological|BM-MNC|portal vein infusion of BM-MNC
5530|NCT00713947|Drug|during one week for the active treatments|during one week for the active treatments placebo during 25 weeks
5531|NCT00713947|Drug|Pantoprazole|6 months at 20 mg
5532|NCT00713947|Drug|Placebo Formula 515|26 weeks, one tablet per day
5533|NCT00713986|Procedure|Water 2mL PO 2 minutes prior to intra-muscular injection|Sterile Water 2mL PO - single dose
5534|NCT00713986|Procedure|skin-to-skin contact|neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.
5535|NCT00713986|Procedure|Glucose 25% 2 mL PO 2 minutes prior to injection|Glucose 25% 2mL PO - single dose
5536|NCT00713986|Procedure|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.|neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
5537|NCT00005857|Biological|trastuzumab|
5538|NCT00713999|Drug|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
9149|NCT00760565|Drug|placebo|20mg/kg iv every 28 days for 3 infusions
9150|NCT00760578|Drug|Placebo|Once daily, oral
9151|NCT00760578|Drug|Pioglitazone|Once daily, oral
9152|NCT00760578|Drug|MSDC-0160 90 mg|Once daily, oral
9153|NCT00760578|Drug|MSDC-0160 220 mg|Once daily, oral
9154|NCT00760604|Procedure|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
9155|NCT00760617|Biological|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
9156|NCT00760617|Biological|Fluarix|Intramuscular (IM) administration, 1 dose
9157|NCT00760630|Device|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
9158|NCT00760669|Drug|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
9159|NCT00006116|Drug|gemcitabine hydrochloride|
9160|NCT00760669|Drug|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
9161|NCT00760682|Procedure|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
9428|NCT00760981|Drug|Imatinib|
9429|NCT00760994|Behavioral|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert & Forsyth, 2005; Hayes, Strosahl, & Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, & Barlow, 2004).
9430|NCT00760994|Behavioral|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
9431|NCT00760994|Other|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
9432|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
11784|NCT00787761|Biological|anti-thymocyte globulin|Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains > 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.
Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.
Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration.
11785|NCT00789971|Drug|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
11786|NCT00000740|Drug|Sitamaquine|
11787|NCT00006360|Radiation|radiation therapy|
11788|NCT00789971|Drug|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
11789|NCT00789984|Device|noncontact specular microscopy|
11790|NCT00789997|Drug|Etanercept + Levofloxacin + placebo prednisone capsules|Levofloxacin 750 mg daily for 10 days + etanercept 50 mg subcutaneous given on the day of randomization and one week later + placebo prednisone capsule, 1 daily for 10 days.
11791|NCT00789997|Drug|Prednisone + Levofloxacin + placebo Etanercept subcutaneous injections|Levofloxacin 750 mg daily for 10 days + prednisone 40 mg daily for 10 days + placebo subcutaneous injections given on day of randomization and one week later.
11792|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
11793|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
11794|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
11795|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
11796|NCT00790023|Drug|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
11797|NCT00790023|Drug|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
11798|NCT00006361|Drug|semaxanib|
11799|NCT00790023|Drug|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
11800|NCT00790036|Drug|RAD001|RAD001 10 mg (two 5 mg tablets), daily for 12 months
11801|NCT00790036|Drug|Placebo|Placebo
11065|NCT00751218|Drug|placebo|placebo, once daily for 28 days
11066|NCT00751218|Drug|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
11067|NCT00742820|Drug|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
11068|NCT00742820|Drug|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
11069|NCT00742820|Dietary Supplement|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
11070|NCT00742833|Drug|KUC-7483|
11071|NCT00742833|Drug|Placebo|
11072|NCT00006020|Drug|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
11073|NCT00742846|Drug|Lidocaine + Kenalog|5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint
Intra-articular injection with local anesthetic and steroid
11074|NCT00742846|Drug|Lidocaine + Kenalog|5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space
Local anesthetic and steroid in to the subacromial space
11075|NCT00742846|Drug|Lidocaine|5ml 1% Lidocaine alone into the shoulder joint.
intra-articular local anesthetic injection
11076|NCT00742846|Drug|Lidocaine|5ml 1% Lidocaine alone into the subacromial space.
subacromial local anesthetic injection
11077|NCT00742859|Drug|betrixaban|blinded and randomly assigned: 40 mg, 60mg or 80mg doses, orally, once daily for at least 3 months
11078|NCT00742859|Drug|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
11079|NCT00742872|Drug|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
11080|NCT00742872|Drug|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
11081|NCT00742885|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
10121|NCT00754754|Device|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
10122|NCT00754767|Drug|L-carnitine L-tartrate|Given orally
11863|NCT00787761|Drug|cyclophosphamide|Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.
The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.
Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.
Each dose will be infused over 1-2 hr (depending on the total volume).
11864|NCT00787761|Drug|fludarabine phosphate|Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.
Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.
Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.
Fludarabine will be administered as an IV infusion over 30 minutes.
12145|NCT00785772|Drug|Gabapentin|100-200mg once a day
12146|NCT00785772|Drug|Gabapentin|200-500mg once a day
12147|NCT00785772|Drug|Gabapentin|400-1000mg (200-500 mg twice a day)
12148|NCT00785785|Drug|Nilotinib (AMN107)|
12149|NCT00785785|Drug|imatinib (STI571)|
12150|NCT00785798|Drug|Vorinostat|200mg to 400 mg twice daily on days 1-7
12151|NCT00785798|Drug|Pegylated Liposomal Doxorubicin (PLD)|IV 30mg/m2 on day 3 of a 21-day cycle
12152|NCT00785811|Drug|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
12153|NCT00785811|Drug|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
12154|NCT00788125|Drug|dasatinib|
12155|NCT00788125|Drug|etoposide phosphate|
12156|NCT00788125|Drug|ifosfamide|
12157|NCT00788125|Genetic|microarray analysis|
12158|NCT00788125|Genetic|western blotting|
12159|NCT00788125|Other|immunohistochemistry staining method|
12160|NCT00788125|Other|laboratory biomarker analysis|
12161|NCT00788125|Procedure|therapeutic conventional surgery|
12591|NCT00783679|Device|NICO device|Measurement of cardiac output and simultaneous blood sampling.
The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy.
12592|NCT00783692|Drug|vedolizumab|Vedolizumab for intravenous infusion
12593|NCT00783692|Other|Placebo|Placebo intravenous infusion
12594|NCT00783705|Other|placebo|Given orally
12595|NCT00783705|Drug|inositol|Given orally
12596|NCT00783718|Drug|vedolizumab|Vedolizumab for intravenous infusion
12597|NCT00783718|Other|Placebo|Placebo intravenous infusion
12598|NCT00000734|Drug|Zidovudine|
12599|NCT00006280|Drug|Tobramycin for Inhalation|
12600|NCT00783731|Drug|Low dose midazolam|
12601|NCT00783744|Drug|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
12602|NCT00783744|Drug|Glimepiride|Glimepiride 3 or 4 mg
12603|NCT00783744|Drug|Metformin|At least 850 mg od
11639|NCT00789815|Drug|Clinical-judged midazolam administration|Induction:
Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S* 2~3.
Maintenance:
Midazolam: 2 mg/ 2min prn to keep OAA/S* 2~3 or if intolerance of procedure. Alfentanil as study arm.
*Observer's assessment of alertness/sedation (OAA/S):
Class 5: Responds readily to name spoken in normal tone.
Class 4: Lethargic response to name called in normal tone.
Class 3: Responds only to name called loudly.
Class 2: Responds only to shaking.
Class 1: No response to shaking.
11640|NCT00006359|Radiation|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
11641|NCT00792220|Procedure|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
11642|NCT00792233|Other|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
11643|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
11931|NCT00785408|Drug|AC2307|subcutaneous, twice daily, middle dose
11932|NCT00785408|Drug|placebo|subcutaneous, twice daily, middle dose
11933|NCT00000192|Drug|Lamotrigine|
11934|NCT00000736|Drug|Zidovudine|
11935|NCT00006327|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
11936|NCT00785408|Drug|AC2307|subcutaneous, twice daily, high dose
11937|NCT00785408|Drug|placebo|subcutaneous, twice daily, high dose
11938|NCT00785421|Drug|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
11939|NCT00785421|Drug|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
11940|NCT00785421|Drug|only chemotherapy|observation, no treatment with LMWH
11941|NCT00785434|Drug|escitalopram|Dose ranging up to 50mg
11942|NCT00785447|Other|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
11943|NCT00785460|Drug|Benfotiamine|
11944|NCT00785473|Dietary Supplement|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
12240|NCT00785863|Other|Placebo|Placebo IV before placebo infusion
12241|NCT00785863|Drug|Remifentanil|placebo IV and remifentanil infusion
12242|NCT00785863|Drug|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
12243|NCT00785863|Drug|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
12244|NCT00785876|Other|LRAR Implementation|Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.
Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals.
10123|NCT00006089|Other|laboratory biomarker analysis|Correlative studies
10124|NCT00749489|Procedure|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
10125|NCT00749502|Drug|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
10126|NCT00749515|Drug|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and TIBC by atomic absorption.
10127|NCT00749515|Drug|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
10128|NCT00749515|Radiation|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
10129|NCT00006050|Drug|leucovorin calcium|
10130|NCT00749554|Device|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
10131|NCT00749554|Device|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
10132|NCT00749567|Drug|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
10133|NCT00749567|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
10134|NCT00749580|Drug|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA <75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
10135|NCT00749606|Behavioral|Individual telephone intervention|Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the "coach" will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff.
10429|NCT00752570|Drug|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
12162|NCT00788125|Radiation|radiation therapy|
12163|NCT00006350|Biological|daclizumab|
12164|NCT00788138|Dietary Supplement|Vitamin D3|250,000 IU of vitamin D3
12165|NCT00788138|Dietary Supplement|Placebo|Matching Placebo
12166|NCT00788151|Biological|Chimeric dengue serotype 1, 2, 3, and 4|0.5 mL, SC
12167|NCT00788151|Biological|Pneumococcal polysaccharide vaccine|0.5 mL, SC
12168|NCT00788164|Biological|TA-HPV|Given intramuscularly
12169|NCT00788164|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
12170|NCT00788164|Drug|imiquimod|Given topically
12171|NCT00788177|Drug|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
12521|NCT00786370|Drug|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
12522|NCT00786370|Drug|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
12523|NCT00786370|Drug|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
12524|NCT00006340|Drug|arginine butyrate|
12525|NCT00786383|Biological|IMC-1121B|Cohort 1
6 mg/kg I.V., once every other week for 4 weeks
12526|NCT00786383|Biological|1121B|Cohort 2
8mg/kg I.V., once every other week for 4 weeks
12527|NCT00786383|Biological|1121B|Cohort 3
10 mg/kg I.V., once every other week for 4 weeks
12528|NCT00786383|Biological|1121B|Cohort 4
15 mg/kg I.V., once every 3 weeks for 6 weeks
12529|NCT00786383|Biological|1121B|Cohort 5
20 mg/kg I.V., once every 3 weeks for 6 weeks
12530|NCT00786396|Behavioral|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
12531|NCT00786409|Biological|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
11644|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
11645|NCT00006370|Radiation|yttrium Y 90-edotreotide|
11646|NCT00792285|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
11647|NCT00792298|Drug|Suvorexant|oral tablet taken before bedtime
11648|NCT00792298|Drug|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
11649|NCT00792311|Procedure|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
11650|NCT00792324|Drug|Etravirine|Four 100mg tablets daily for 12-24 weeks
11651|NCT00792324|Drug|Efavirenz|One 600mg tablet daily
11652|NCT00792337|Drug|simvastatin|10 mg per oral once daily for 8 weeks
11653|NCT00792337|Drug|B1-6-12|1 table per day for 8 weeks
11654|NCT00792350|Drug|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
11655|NCT00792363|Drug|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
11656|NCT00006371|Drug|aminoglutethimide|
11922|NCT00006326|Drug|Delavirdine mesylate|
11923|NCT00785356|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
11924|NCT00785356|Drug|Placebo|Placebo, 2 capsules daily for 3 months
11925|NCT00785369|Device|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
11926|NCT00785382|Drug|Placebo|Lactulose Placebo
11927|NCT00785382|Drug|Pregabalin 150 mg|150 mg Q12H x 2 doses
11928|NCT00785395|Drug|Oxytocin infusion|Up-down dosing determination
11929|NCT00785408|Drug|AC2307|subcutaneous, twice daily, low dose
11930|NCT00785408|Drug|placebo|subcutaneous, twice daily, low dose
12245|NCT00785889|Procedure|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
12246|NCT00785902|Device|AtriCure Bipolar System|
12247|NCT00785915|Drug|AZD6765|single administration and once daily for 5 days
12248|NCT00785915|Drug|Placebo|single administration and once daily for 5 days
12249|NCT00006337|Drug|IV Levodopa|
12250|NCT00785928|Biological|LY2127399|subcutaneously q 4 weeks
12251|NCT00785928|Drug|Placebo|subcutaneously q 4 wks
12252|NCT00785941|Biological|IMC-A12|Cohort 1
6 mg/kg I.V., once every other week for 4 weeks
12253|NCT00785941|Biological|IMC-A12|Cohort 2
10 mg/kg I.V., once every other week for 4 weeks
12254|NCT00785941|Biological|IMC-A12|Cohort 3
15 mg/kg I.V., once every other week for 4 weeks
12255|NCT00785941|Biological|IMC-A12|Cohort 4
21 mg/kg I.V., once every other week for 4 weeks
12256|NCT00785941|Biological|IMC-A12|Cohort 5
27 mg/kg I.V., once every other week for 4 weeks
12257|NCT00785954|Drug|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
12258|NCT00785967|Biological|Various vaccines|VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
12259|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
12260|NCT00006339|Drug|Indinavir sulfate|
12261|NCT00785980|Drug|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
12604|NCT00783744|Drug|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
12605|NCT00783757|Device|Near-Infrared Tomographic Optical Breast Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
12606|NCT00783796|Device|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
12607|NCT00783822|Other|RGCT|rapid genetic counseling and testing
10430|NCT00752570|Drug|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
10431|NCT00752570|Drug|FOLFIRI|Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.
FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.
FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.
10432|NCT00744185|Drug|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
10433|NCT00006029|Drug|vinorelbine tartrate|
10434|NCT00744185|Drug|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
10435|NCT00744198|Procedure|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
10436|NCT00744198|Procedure|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
10437|NCT00744198|Procedure|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
10438|NCT00744224|Drug|Placebo|Single dose of placebo with saline infusion
10439|NCT00744224|Drug|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
10440|NCT00744224|Drug|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
10441|NCT00744237|Drug|Nebivolol|Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration
Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration
Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration
Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration
10442|NCT00744237|Drug|Metoprolol ER|Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration
Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration
Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration
Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration
10443|NCT00744237|Drug|HCTZ|HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration
HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration
10444|NCT00006030|Drug|tamoxifen citrate|
10445|NCT00744250|Drug|Pancrelipase|PANCRECARB MS-16
10446|NCT00744263|Biological|VACCINE: placebo|0.5 mL, single intra-muscular injection
12532|NCT00786422|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
12533|NCT00786448|Drug|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
12534|NCT00786461|Procedure|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
12535|NCT00006340|Drug|ganciclovir|
12536|NCT00786461|Procedure|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
12537|NCT00786474|Drug|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
12538|NCT00786474|Drug|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
12539|NCT00786487|Drug|20% lipid infusion|1.5 ml/min for 6 hours
12540|NCT00788710|Drug|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
11573|NCT00746499|Drug|Raltegravir|400mg raltegravir BID x 7 days
11574|NCT00746512|Drug|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
11575|NCT00746512|Drug|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
11576|NCT00746512|Drug|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
11577|NCT00746512|Drug|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
11578|NCT00746525|Other|Surface functional electrical stimulation (FES) assisted movement training|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
11579|NCT00746525|Other|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
11580|NCT00746525|Other|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
11581|NCT00746538|Device|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
11457|NCT00751881|Drug|Teriflunomide|Film-coated tablet
Oral administration
11458|NCT00751894|Drug|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
11459|NCT00743366|Drug|Quetiapine|0, 200 mg/day
11732|NCT00792467|Drug|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
11733|NCT00006371|Drug|ketoconazole|
11734|NCT00792480|Behavioral|Dietary and lifestyle counseling|The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.
At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise.
11735|NCT00792493|Drug|ORM-12741|Alternating panel multiple dose escalation
11736|NCT00792506|Drug|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to end of treatment. The patient had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
11737|NCT00792519|Behavioral|HIV support group|group support
11738|NCT00792519|Behavioral|CBT|group cognitive behavioral treatment
11739|NCT00792532|Procedure|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
11740|NCT00792532|Device|DBS electrodes|Deep brain stimulation (DBS) electrodes
11741|NCT00792558|Drug|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
11742|NCT00792571|Drug|Beraprost Sodium Modified Release|
11743|NCT00792584|Drug|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
11744|NCT00006371|Drug|therapeutic hydrocortisone|
11745|NCT00792584|Drug|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
11746|NCT00792610|Biological|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
12608|NCT00783835|Drug|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
12609|NCT00783861|Drug|Lactic Acid|Lactic Acid (Dermacyd Femina)
12610|NCT00006286|Drug|Fluoxetine|
12611|NCT00783887|Other|Blood sample|Blood sample of 5 ml
12612|NCT00783900|Other|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
12613|NCT00783913|Other|Visumotor Upper Extremity Training|Control
12614|NCT00783913|Other|Anodal/Sham tDCS|Condition
12615|NCT00786487|Drug|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
12616|NCT00786500|Dietary Supplement|Gynostemma pentaphyllum tea|3 grams twice daily, orally
12617|NCT00786500|Dietary Supplement|Placebo tea|3 grams twice daily, orally
12618|NCT00786513|Other|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
12619|NCT00786513|Other|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
12620|NCT00786539|Device|Diffuse Optical Spectroscopy|mitochondria
12621|NCT00006341|Other|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
12622|NCT00786552|Drug|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
12623|NCT00786565|Device|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
11349|NCT00751751|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
11350|NCT00006056|Drug|filgrastim|
11351|NCT00751751|Drug|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
11802|NCT00790049|Drug|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
11803|NCT00790049|Drug|Placebo; oral|matching placebo
12083|NCT00790426|Drug|TKI258|
12084|NCT00790439|Drug|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
12085|NCT00790439|Drug|Heparin|Anticoagulant
12086|NCT00790439|Drug|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
12087|NCT00790439|Drug|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
12088|NCT00790439|Drug|Tacrolimus|Calcineurin inhibitor
12089|NCT00790439|Drug|Cyclosporine|Calcineurin inhibitor, immunosuppressant
12090|NCT00006363|Drug|busulfan|Given orally
12091|NCT00790439|Drug|Daclizumab|Monoclonal IL-2 receptor blocker
12092|NCT00790439|Drug|Basiliximab|Monoclonal IL-2 receptor blocker
12093|NCT00790439|Biological|Allogeneic Pancreatic Islet Cells|
12094|NCT00790452|Drug|Aspirin|325 mg daily by mouth
12095|NCT00790452|Drug|Placebo|Tablet daily by mouth
12096|NCT00790465|Dietary Supplement|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
12097|NCT00790465|Dietary Supplement|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
12098|NCT00790478|Dietary Supplement|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
12099|NCT00790478|Other|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
12100|NCT00790491|Behavioral|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
12101|NCT00006363|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
11582|NCT00006038|Procedure|conventional surgery|
11583|NCT00746551|Drug|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
11584|NCT00746551|Drug|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
11585|NCT00746564|Device|SJM Confirm|All patients in this study will receive the SJM Confirm device.
11586|NCT00746577|Other|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
11587|NCT00746590|Drug|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
11588|NCT00746603|Drug|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
11589|NCT00749307|Dietary Supplement|Docosahexaenoic acid (DHA)|
11590|NCT00749307|Dietary Supplement|Placebo|
11865|NCT00006347|Radiation|yttrium Y 90 monoclonal antibody MN-14|
11866|NCT00787761|Drug|methotrexate|Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.
Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.
Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.
Administer via slow IV push.
11867|NCT00787761|Drug|tacrolimus|Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).
Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.
Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F).
11868|NCT00787761|Procedure|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem & Seattle, RICT has been used to treat hematologic & solid malignancies with related & unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute & chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
11747|NCT00792623|Biological|VarilrixTM|Subcutaneous injection, 2 doses
11748|NCT00792636|Drug|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
11749|NCT00792636|Drug|sumatriptan tablet|sumatriptan 85mg
11750|NCT00784979|Drug|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
12014|NCT00792948|Drug|Vincristine Sulfate|Given IV
12015|NCT00792961|Device|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
12016|NCT00792974|Behavioral|A brief psycho-educational intervention|A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.
This study is an open pilot study ("feasibility study") to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment.
12017|NCT00793000|Drug|PF-04287881|75 mg oral dose (prepared solution) given once
12018|NCT00793000|Drug|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
12019|NCT00793000|Drug|PF-04287881|150 mg oral dose (prepared solution) given once
12020|NCT00793000|Drug|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
12021|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
12022|NCT00006373|Procedure|autologous bone marrow transplantation|
12023|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
12024|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
12025|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
12026|NCT00793000|Drug|PF-04287881|1000 mg oral dose (prepared solution) given once
12027|NCT00785486|Drug|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
12028|NCT00785486|Drug|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
12029|NCT00785499|Behavioral|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
11352|NCT00751764|Drug|Moxidectin|
11353|NCT00751777|Biological|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
11354|NCT00743197|Drug|Lovaza|Lovaza 1 gram daily
11355|NCT00743197|Behavioral|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
11356|NCT00006024|Drug|lomustine|
11357|NCT00743210|Drug|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
11358|NCT00743210|Drug|Placebo|Placebo, 3 grams once per day for 3 weeks.
11359|NCT00743223|Other|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
11360|NCT00743236|Procedure|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
11361|NCT00743236|Procedure|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
11362|NCT00743249|Device|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
11363|NCT00743249|Device|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
11364|NCT00743262|Device|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
11365|NCT00743275|Biological|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
11366|NCT00743288|Drug|Melphalan|Same as above
11367|NCT00006024|Drug|temozolomide|
11368|NCT00743288|Drug|Panobinostat|
11369|NCT00743301|Other|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
11370|NCT00743314|Other|screening questionnaire administration|
10369|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
12102|NCT00790517|Behavioral|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
12103|NCT00790530|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
12104|NCT00790530|Other|Usual Care|Usual Care
12454|NCT00788645|Behavioral|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
12455|NCT00788658|Behavioral|Diet modifications|Diet consultation
12456|NCT00788658|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
12457|NCT00788671|Device|Levonorgestrel IUD|Intrauterine placement during surgery
12458|NCT00788684|Drug|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
12459|NCT00006352|Biological|monoclonal antibody BEC2|
12460|NCT00788684|Drug|rituximab|IV infusion once weekly for four doses
12461|NCT00788697|Drug|SonoVue®|SonoVue® (2.4 mL)
12462|NCT00788697|Procedure|Unenhanced Ultrasound(US)|Gray scale and Doppler (color or power imaging) ultrasound
12463|NCT00788710|Drug|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
12464|NCT00790985|Dietary Supplement|flavocoxid|medical food
12465|NCT00790985|Drug|Naproxen|antiinflammatory drug
12466|NCT00790998|Drug|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
12467|NCT00790998|Drug|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
12468|NCT00006364|Other|laboratory biomarker analysis|Correlative studies
12469|NCT00791011|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
12470|NCT00791011|Other|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
12471|NCT00791011|Other|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
11869|NCT00787774|Drug|resume raltegravir|resume raltegravir after 16 weeks of stopping
11870|NCT00787787|Drug|sunitinib malate|Given PO
11871|NCT00787787|Drug|capecitabine|Given PO
11872|NCT00787800|Device|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
11873|NCT00790114|Drug|Caffeine|single dose, twice during treatment
11874|NCT00790127|Drug|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
11875|NCT00790127|Drug|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
11876|NCT00790140|Dietary Supplement|Prosure|This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
11877|NCT00790140|Dietary Supplement|Ensure Plus|This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
11878|NCT00790153|Drug|Insulin|Insulin infusion given during 3 hours at one occasion.
11879|NCT00790153|Drug|AZD1656|Single dose oral suspension given at one occasion.
12172|NCT00788190|Procedure|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
12173|NCT00788190|Other|Conservative Management|Conservative management of Distal Radius Fractures
12174|NCT00006350|Biological|therapeutic allogeneic lymphocytes|
12175|NCT00788216|Other|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
12176|NCT00788229|Drug|AT01|eye drop for 12 weeks
12177|NCT00788229|Drug|AT02|eye drop for 12 weeks
12178|NCT00788229|Drug|AT03|eye drop for 12 weeks
12179|NCT00788229|Drug|AT04|eye drop for 12 weeks
12030|NCT00785512|Drug|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
12031|NCT00785512|Drug|Placebo|Matching placebo tablets, oral administration
12032|NCT00785525|Drug|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
12033|NCT00785538|Biological|IMC-A12|Cohort 1
3 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period.
12034|NCT00785538|Biological|IMC-A12|Cohort 2
6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period.
12398|NCT00790972|Drug|Placebo|two sprays in each nostril three times daily for one week
12399|NCT00793247|Drug|PLA-PRU-PRU-PLA|
12400|NCT00793247|Drug|PRU-PLA-PLA-PRU|
12401|NCT00793260|Behavioral|Enhanced Support|The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.
The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.
The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness.
12402|NCT00793260|Behavioral|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
12403|NCT00793273|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
12404|NCT00793286|Procedure|Mesh fixation by staples|Mesh fixation by staples
12405|NCT00793286|Procedure|Mesh fixation by glue|Mesh fixation by glue
12406|NCT00793299|Behavioral|Video Illness Narrative|video
12407|NCT00793325|Drug|Somatropin|Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.
Frequency and duration are according to Package Insert as follows. " Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
12408|NCT00006374|Drug|paclitaxel|
12409|NCT00793338|Drug|Sildenafil|Sildenafil 20mg three times a day for 3 months.
10370|NCT00746863|Drug|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
10371|NCT00746876|Device|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
10372|NCT00746876|Device|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
10373|NCT00006040|Procedure|peripheral blood stem cell transplantation|
10374|NCT00746889|Drug|triamcinolone acetonide|single intraarticular injection of 40 mg of triamcinolone acetonide
10375|NCT00746889|Drug|saline|Single intraarticular injection of 1 ml of 0.9% saline
10376|NCT00746902|Device|nCPAP|Active nCPAP
10377|NCT00746915|Device|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
10378|NCT00746928|Other|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
10379|NCT00746941|Drug|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
10380|NCT00746954|Drug|Acetazolamide|Cabonic Anhydrase inhibitor
10381|NCT00746954|Drug|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
10382|NCT00746967|Drug|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
10383|NCT00746980|Drug|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
10384|NCT00006040|Radiation|yttrium Y 90 monoclonal antibody M195|
10385|NCT00746993|Other|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
10386|NCT00747006|Drug|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
10387|NCT00749892|Drug|Erlotinib Hydrochloride|150 mg (pill) by mouth daily for 3 to 5 weeks prior to surgery
12472|NCT00791024|Drug|CRC-Pharma 001|50 mg
12473|NCT00791024|Drug|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
12474|NCT00791037|Biological|HER-2/neu peptide vaccine|Given ID
12475|NCT00791037|Procedure|leukapheresis|Undergo leukapheresis
12476|NCT00791037|Biological|ex vivo-expanded HER2-specific T cells|Given IV
12477|NCT00791037|Drug|cyclophosphamide|Given IV
12478|NCT00791037|Biological|sargramostim|Given ID
11519|NCT00749190|Drug|sitagliptin|
11520|NCT00749203|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
11521|NCT00749203|Drug|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
11522|NCT00749216|Drug|Solanezumab|
11523|NCT00749229|Device|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
11524|NCT00749242|Other|orthopedic brace|antalgic drugs and orthopedic brace
11525|NCT00749242|Device|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
11526|NCT00749268|Device|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
11527|NCT00006050|Drug|FOLFOX regimen|
11528|NCT00749268|Device|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
11529|NCT00751907|Drug|atorvastatin|40mg daily for 4 months
11530|NCT00751907|Drug|Placebo|Matching placebo daily for 4 months
11531|NCT00006060|Drug|standard gadolinium contrast|
11532|NCT00751920|Procedure|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
12180|NCT00788242|Drug|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over two 60 min periods: before aortic cross-clamping and after aortic unclamping
12181|NCT00788242|Drug|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over two 60 min periods: before aortic cross-clamping and after aortic unclamping
12182|NCT00788255|Procedure|thromboelastography|
12183|NCT00788281|Procedure|laparoscopic surgery|surgery would be performed by laparoscope
12184|NCT00788281|Procedure|open surgery|surgery would be performed by traditional surgery.
12185|NCT00790556|Drug|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
12186|NCT00790569|Drug|nicotine|Given transdermally and orally
12187|NCT00790569|Drug|varenicline|Given orally
12188|NCT00790569|Other|placebo|Given orally
12189|NCT00790582|Drug|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
12190|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
12191|NCT00000741|Drug|Methylprednisolone|
12192|NCT00006363|Procedure|peripheral blood stem cell transplantation|Undergo autologous PBSCT
12193|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
12194|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
12195|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
12541|NCT00788710|Drug|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
12542|NCT00788723|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
12543|NCT00788749|Drug|Prednisolone|tablets 25 mg/day
12544|NCT00788749|Drug|Placebo|tablets once daily
12410|NCT00793351|Procedure|Reduced-intensity allogeneic hematopoietic stem cell transplantation|Treatment Scheme
Enrollment - Pre-RIST treatment - RIST
4 cycles of conventional chemotherapy will be given prior to RIST.
Surgery will be done whenever possible prior to RIST.
Local radiotherapy will be applied whenever possible prior to RIST.
topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.
Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT.
12411|NCT00793364|Dietary Supplement|Stanol ester spread|Stanol ester spread 20 g every day
12412|NCT00793364|Dietary Supplement|Placebo spread|Placebo spread 20 g every day
12413|NCT00793364|Dietary Supplement|Mediterranean Diet|Mediterranean Diet every day
12414|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
11460|NCT00743379|Drug|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
11461|NCT00743405|Drug|GSK1034702|Oral or liquid
11462|NCT00743405|Drug|Placebo|To match GSK1034702
11463|NCT00743418|Device|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
11464|NCT00743431|Drug|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
11465|NCT00743444|Drug|AZD3355|65 mg capsules, oral, 3 single doses
11466|NCT00743444|Drug|Placebo|capsules, oral, 3 single doses
11467|NCT00006025|Drug|temozolomide|
11468|NCT00743457|Device|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
11469|NCT00743470|Drug|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
11470|NCT00743470|Drug|rifabutin|rifabutin capsule; see arms for intervention description
11471|NCT00743483|Drug|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
11472|NCT00743496|Biological|Anti-GD2 antibody|Anti-GD2 antibody
10388|NCT00749905|Other|low fiber diet|Low fiber diet for 5 days prior to colon capsule
10698|NCT00753246|Drug|nimotuzumab|monoclonal antibody
10699|NCT00753259|Other|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
10700|NCT00753259|Other|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
10701|NCT00753272|Biological|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
10702|NCT00753272|Biological|Fluarix TM|IM administration, two times one annual dose
10703|NCT00753285|Device|Renal Denervation|
10704|NCT00753298|Device|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
10705|NCT00753298|Device|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
10706|NCT00753311|Drug|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
10707|NCT00753324|Drug|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
10708|NCT00006081|Drug|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
10709|NCT00753337|Device|Assurant® Cobalt Iliac Stent System|Iliac Stenting
10710|NCT00753350|Device|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
10711|NCT00753363|Other|Weight Loss|6 months of weight loss
10712|NCT00753363|Other|Aerobic Exercise Training|6 months of aerobic exercise training
10713|NCT00753389|Other|None (anesthesia)|anesthesia
10714|NCT00753402|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
11533|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral + oats|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
11534|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
11535|NCT00751933|Dietary Supplement|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
11536|NCT00751933|Other|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
11804|NCT00790062|Drug|Oxytocin|See arms
11805|NCT00790075|Drug|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was >30 minutes.
11806|NCT00790101|Drug|Risedronate|
11807|NCT00790101|Drug|Raloxifene|
11808|NCT00790101|Other|Placebo|
11809|NCT00006362|Drug|bortezomib|
11810|NCT00790114|Drug|AZD7325|Oral, day 1-12
11811|NCT00790114|Drug|Midazolam|single dose, twice during treatment
11812|NCT00792636|Drug|naproxen sodium tablet|Naproxen sodium 500mg
11813|NCT00792662|Drug|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
11814|NCT00792662|Drug|Placebo|Standard inactive pill.
11815|NCT00792675|Other|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
11816|NCT00792688|Drug|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
11817|NCT00006372|Drug|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
11818|NCT00792688|Drug|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
11819|NCT00792688|Drug|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
12545|NCT00788749|Other|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
12546|NCT00006353|Drug|temozolomide|
12547|NCT00788749|Other|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
12548|NCT00788775|Drug|Nilotinib|400mg by mouth twice a day
12549|NCT00788788|Drug|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
12550|NCT00788801|Drug|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
12551|NCT00788814|Behavioral|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
12552|NCT00788827|Biological|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
12553|NCT00788840|Drug|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
12554|NCT00788840|Drug|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
12555|NCT00788853|Other|No treatment given|No treatment is given
12556|NCT00788866|Dietary Supplement|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
12557|NCT00006353|Radiation|radiation therapy|
12558|NCT00788866|Dietary Supplement|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
12559|NCT00788879|Behavioral|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
11591|NCT00749320|Other|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
11592|NCT00749333|Drug|AZD8566|solution. Specific dose will be selected by the safety review committee
11593|NCT00749333|Drug|Placebo|Single 10ml oral solution.
11594|NCT00749346|Device|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
11595|NCT00749359|Drug|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
11473|NCT00743509|Drug|Cyclophosphamide and Sirolimus|The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.
Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously
11474|NCT00743522|Device|ICD/ CRT-D|Cardiac device
11475|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TOT|Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.
Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle
11476|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TVT|Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.
Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle.
11477|NCT00743548|Device|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
11478|NCT00006026|Drug|rubitecan|
11751|NCT00784992|Procedure|Endonasal dacryocystorhinostomy|The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.
Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted.
11752|NCT00006324|Drug|Medroxyprogesterone acetate|
11753|NCT00785018|Drug|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
11754|NCT00785018|Drug|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
11755|NCT00785031|Other|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
11756|NCT00785083|Drug|FTY720|
11757|NCT00785083|Drug|Placebo|
11758|NCT00785096|Other|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
11759|NCT00785109|Dietary Supplement|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
10715|NCT00753402|Biological|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes/Epinephrine 30mcg/kg/min
10716|NCT00744562|Drug|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
10717|NCT00744614|Procedure|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
11024|NCT00748189|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
11025|NCT00748189|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
11026|NCT00748202|Drug|C1-Esterase Inhibitor|1000 I.E.
11027|NCT00748215|Drug|calcium aluminosilicate anti-diarrheal|Given orally
11028|NCT00748215|Other|placebo|Given orally
11029|NCT00748228|Dietary Supplement|dietary sodium|10 mEq/day
11030|NCT00006045|Drug|cytarabine|
11031|NCT00748228|Dietary Supplement|dietary sodium|300 mEq/day
11032|NCT00748228|Dietary Supplement|dietary sodium|150 mEq/day dietary sodium
11033|NCT00748241|Device|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
11034|NCT00748254|Procedure|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on all finger joints of the hand with the scanning methods described above.
11035|NCT00748254|Procedure|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on all finger joints of the hand with the scanning methods described above.
11036|NCT00748267|Other|questionnaire administration|
11037|NCT00748267|Procedure|hypnotherapy|
11038|NCT00748267|Procedure|therapeutic conventional surgery|
11039|NCT00748280|Procedure|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
11820|NCT00792701|Drug|cisplatin|Given IV
11821|NCT00792701|Drug|gemcitabine hydrochloride|Given IV
11822|NCT00792701|Other|active surveillance|Patients undergo active monitoring
11823|NCT00792714|Drug|Mannitol|400mg twice daily for 7 days
11824|NCT00792727|Drug|ketoprofen Patch|2 topical patches applied once daily for 28 days
11825|NCT00792727|Other|Placebo Patch|2 topical placebo patches applied once daily for 28 days
11826|NCT00792740|Drug|ITF2357|ITF2357 will be supplied as hard gelatin capsules for oral administration at the dose strength of 50 mg.
11827|NCT00792740|Drug|Placebo capsules|Placebo will be supplied as matching capsules for oral administration with the same outer appearance
12105|NCT00790556|Drug|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
12106|NCT00793104|Procedure|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
12107|NCT00793117|Procedure|packing|packing in middle meatus for duration of 5 day
12108|NCT00793130|Dietary Supplement|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
12109|NCT00793156|Drug|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
12110|NCT00793156|Drug|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
12111|NCT00793156|Other|Placebo|Placebo daily dose
12112|NCT00793169|Procedure|Blood Draw|Serum levels were measured
12113|NCT00006374|Drug|cisplatin|
12114|NCT00793182|Drug|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
12115|NCT00793182|Drug|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
11596|NCT00749372|Other|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
11597|NCT00749385|Drug|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
11598|NCT00006050|Drug|fluorouracil|
11599|NCT00749385|Drug|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
11600|NCT00749385|Drug|EC naproxen|Enteric-coated naproxen tablet (500mg)
11601|NCT00749385|Drug|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
11602|NCT00749398|Biological|Infliximab|According to local country regulations.
11603|NCT00749411|Drug|Placebo|matching placebo
11604|NCT00749411|Drug|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
11605|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
11606|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
11607|NCT00749437|Radiation|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
11608|NCT00749450|Drug|capecitabine|Given orally
11609|NCT00006050|Drug|isolated perfusion|
11610|NCT00749450|Drug|fluorouracil|Given IV
11611|NCT00749450|Drug|oxaliplatin|Given IV
11612|NCT00749463|Drug|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
11613|NCT00749463|Drug|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
11880|NCT00790166|Device|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
11881|NCT00006363|Drug|cytarabine|Given IV
11882|NCT00790166|Device|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
11760|NCT00785122|Drug|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
11761|NCT00785122|Drug|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
11762|NCT00785135|Device|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
11763|NCT00006325|Drug|Peginterferon alfa-2b|
11764|NCT00785135|Device|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
11765|NCT00785148|Drug|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
11766|NCT00785161|Device|Penumbra System|Mechanical Thrombectomy in acute stroke
11767|NCT00785174|Device|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
12035|NCT00785538|Biological|IMC-A12|Cohort 3
10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period.
12036|NCT00006330|Drug|Digoxin|
12037|NCT00785538|Biological|IMC-A12|Cohort 4
15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period.
12038|NCT00785538|Biological|IMC-A12|Cohort 5
21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period.
12039|NCT00785538|Biological|IMC-A12|Cohort 6
27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period.
12040|NCT00785551|Drug|quinine sulfate|2 x 324mg given in one dose to healthy subjects
12041|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
12042|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
12043|NCT00785577|Drug|Placebo|LY545694 placebo BID po for 5 weeks
Pregabalin placebo capsules TID po for 6 weeks
12044|NCT00785577|Drug|Pregabalin|Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6
LY545694 placebo BID po for 5 weeks
12045|NCT00785577|Drug|LY545694 21 mg|LY545694 21 mg BID po for 1 week
Pregabalin placebo TID po for 6 weeks
11040|NCT00748280|Procedure|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
11041|NCT00006045|Drug|etoposide|
11042|NCT00748293|Other|Low-residue diet|Commercialized (not yet marketed)low-residue diet
11043|NCT00748306|Drug|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
11371|NCT00743314|Procedure|computed tomography|
11372|NCT00743314|Procedure|lymphoscintigraphy|
11373|NCT00743314|Procedure|single photon emission computed tomography|
11374|NCT00743314|Radiation|intensity-modulated radiation therapy|
11375|NCT00743314|Radiation|technetium Tc 99m sulfur colloid|
11376|NCT00743327|Drug|Pioglitazone|45mg capsule, once daily for 1 year
11377|NCT00743340|Drug|Emtricitabine|Emtricitabine (FTC) administered based on body weight at a dose of 6 mg/kg once daily, with a maximum dose of 200 mg once daily with the capsule formulation (for children weighing ≥ 33 kg) or a maximum dose of up to 240 mg once daily with the oral solution formulation.
11378|NCT00006025|Drug|irinotecan hydrochloride|
11379|NCT00743353|Drug|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
11380|NCT00743366|Drug|Marijuana|0,6.9% THC
11381|NCT00746109|Procedure|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
11382|NCT00746122|Procedure|Open repair|Immediate open surgery
11383|NCT00746122|Procedure|EVAR|Endovascular Aneurysm Repair
11384|NCT00746135|Device|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
11385|NCT00746148|Other|Reflexology|10 weekly sessions of 45 minutes each
11386|NCT00746161|Procedure|Reconstruction after total gastrectomy|Roux-en-Y
11387|NCT00746161|Procedure|Reconstruction after total gastrectomy|double tract reconstruction
12116|NCT00793195|Drug|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
12117|NCT00793195|Drug|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
12118|NCT00793208|Biological|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.
Subjects will have immunizations administered at 4 different sites for each vaccination as follows:
Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site.
12119|NCT00793221|Device|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
12120|NCT00793221|Device|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
12479|NCT00006365|Radiation|brachytherapy|
12480|NCT00791037|Other|laboratory biomarker analysis|Correlative study
12481|NCT00791050|Device|Allon Thermowrap. MTRE Advanced Technologies Ltd.|Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to "monitoring" and set again to 37 °C from rewarming during CPB to end of surgery.
12482|NCT00791063|Other|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
12483|NCT00791076|Drug|Placebo|2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.
12484|NCT00791076|Drug|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.
12485|NCT00791089|Drug|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
12486|NCT00791089|Drug|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
11883|NCT00790166|Device|CPAP + No added humidity|ambient humidity
11884|NCT00790179|Procedure|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.
Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.
11885|NCT00790192|Drug|Lurasidone|Lurasidone 80 mg tablets
11886|NCT00790192|Drug|Lurasidone|Lurasidone 4 40 mg tablets
11887|NCT00790192|Drug|Quetiapine XR|Quetiapine XR 600mg
11888|NCT00790192|Drug|Placebo|Matching Placebo to Lurasidone or Quetiapine
11889|NCT00790205|Drug|Sitagliptin phosphate|sitagliptin phosphate, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily
11890|NCT00790205|Drug|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin phosphate tablet, orally, once daily
11891|NCT00790218|Drug|CF102|CF102 capsules twice daily by mouth
11892|NCT00006363|Drug|daunorubicin hydrochloride|Given IV
11893|NCT00790231|Device|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
11894|NCT00790244|Drug|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
11895|NCT00790244|Drug|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
11896|NCT00790244|Drug|doxorubicin, ifosfamide|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.
(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
11897|NCT00790244|Drug|doxorubicin, ifosfamide|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.
(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
11898|NCT00792805|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
11899|NCT00792818|Drug|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
11900|NCT00006372|Drug|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
11901|NCT00792818|Drug|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
12196|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
12046|NCT00785577|Drug|LY545694 49 mg|LY545694 escalated to 49 mg BID po for 1 week during Week 2.
Pregabalin placebo TID po for 6 weeks.
12047|NCT00006330|Drug|Hawthorn|
12048|NCT00785577|Drug|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks
Pregabalin placebo TID po for 6 weeks
12049|NCT00785590|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
12050|NCT00785603|Drug|Paroxetine|tablets of 20 mg paroxetine
12051|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
12052|NCT00787956|Behavioral|Internet Chronic Disease Self-Management Program (ICDSMP)|
12053|NCT00787969|Biological|rituximab|Give IV
12054|NCT00787969|Drug|cladribine|Give IV
12055|NCT00787969|Drug|temsirolimus|Give IV
12056|NCT00006349|Dietary Supplement|vitamin E|
12057|NCT00787969|Biological|Filgrastim|Give SC
12058|NCT00787969|Biological|Pegfilgrastim|
12415|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
12416|NCT00793403|Other|As per routinary clinical care|As per routine clinical care
12417|NCT00793416|Device|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
12418|NCT00793429|Drug|Prucalopride|
12419|NCT00786188|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
12420|NCT00786188|Drug|Sugar pill|Subjects will receive a sugar pill.
12421|NCT00786201|Drug|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
12422|NCT00786201|Drug|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
12423|NCT00786201|Drug|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
11388|NCT00746174|Drug|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
11389|NCT00746174|Drug|Placebo|Placebo 1 tablet PO daily for 16 weeks
11390|NCT00006038|Drug|cisplatin|
11391|NCT00746187|Device|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
11392|NCT00746187|Device|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
11393|NCT00746200|Procedure|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
11394|NCT00746200|Procedure|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
10389|NCT00749905|Other|regular diet|Regular diet until 1 day before colon capsule
10390|NCT00749918|Dietary Supplement|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
10391|NCT00749931|Device|MarginProbe|Device use to assess margin status of the excised specimen surface.
10392|NCT00749931|Procedure|Lumpectomy|Standard of care lumpectomy procedure
10393|NCT00749944|Drug|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
10394|NCT00749944|Drug|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
10395|NCT00749957|Biological|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
10396|NCT00006053|Drug|imatinib mesylate|
10397|NCT00749983|Dietary Supplement|Creatine supplementation|
10398|NCT00749983|Dietary Supplement|Dextrose supplementation|
10399|NCT00749996|Device|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
10400|NCT00749996|Procedure|Herniectomy|Herniectomy is defined as the "removal of the extruded/protruded/sequestrated disc material". This is done by probing the annulus and disc space and removing all mobile disc fragments.
10401|NCT00750009|Other|educational intervention|Patients receive a tailored intervention or generic information
12487|NCT00791089|Other|placebo|Control group will receive placebo before & after ablation.
12488|NCT00791102|Drug|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
12489|NCT00791102|Drug|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
12490|NCT00006365|Radiation|iodine I 125|
12491|NCT00793572|Drug|Cyclosporine|Given PO
12492|NCT00793572|Drug|Fludarabine Phosphate|Given IV
12493|NCT00793572|Other|Laboratory Biomarker Analysis|Correlative studies
12494|NCT00793572|Drug|Melphalan|Given IV
12495|NCT00793572|Drug|Mycophenolate Mofetil|Given PO
12496|NCT00793572|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
12497|NCT00793572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
12498|NCT00793572|Procedure|Syngeneic Bone Marrow Transplantation|Undergo transplantation
12499|NCT00793572|Radiation|Total-Body Irradiation|Undergo radiotherapy
12500|NCT00000743|Drug|Alvircept sudotox|
12501|NCT00006376|Drug|tipifarnib|
11537|NCT00751946|Behavioral|Trauma Adaptive Recovery Group Education and Therapy|Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.
TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis & Steele, 2005), summarized by an acronym "FREEDOM". TARGET also uses creative arts activities: personalized "lifelines" via collage, drawing, poetry, and writing.
11538|NCT00751946|Behavioral|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, & Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
11539|NCT00751959|Drug|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
12197|NCT00790608|Drug|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
12198|NCT00790647|Biological|filgrastim|16 mcg/kg daily beginning 3 days before SCC through day before final SCC
12199|NCT00790647|Drug|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
12200|NCT00790647|Drug|melphalan|100 mg/m2/dose D -2, D -1
12201|NCT00790647|Procedure|Stem Cell Infusion|infusion of previously collected autologous stem cells
12202|NCT00790660|Drug|ASP1941|Oral
12203|NCT00006363|Biological|aldesleukin|Given SC
12204|NCT00790660|Drug|Placebo|Oral
12205|NCT00790673|Drug|CF 102|Oral capsules
12206|NCT00790673|Drug|Placebo|Matching placebo capsules
12207|NCT00790686|Procedure|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
12208|NCT00790699|Device|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
12209|NCT00790699|Other|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
12210|NCT00790725|Other|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
12211|NCT00790725|Other|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
12212|NCT00790738|Drug|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
12213|NCT00006374|Drug|topotecan hydrochloride|
12214|NCT00793429|Other|Placebo|
12215|NCT00793455|Behavioral|Educational outreach|Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
12216|NCT00793468|Drug|GSK598809|GSK598809 once daily for 12 weeks
12217|NCT00793468|Drug|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
12424|NCT00786201|Drug|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
12425|NCT00786214|Other|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
12426|NCT00786214|Other|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
12427|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
12428|NCT00006339|Drug|Stavudine|
12429|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
12430|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
12431|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
12432|NCT00786266|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
12433|NCT00786266|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
12434|NCT00786279|Other|ethanol|15 gm ethanol daily for 6 months
12435|NCT00786279|Other|Ethanol-free beverage|0 grams ethanol daily for 6 months.
12436|NCT00786292|Other|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
12437|NCT00786305|Drug|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
11479|NCT00743548|Device|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
11480|NCT00743561|Device|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
11481|NCT00746317|Drug|GC33|IV administration at 4 escalating dose levels.
11482|NCT00746330|Drug|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
11483|NCT00746330|Drug|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
11484|NCT00746330|Drug|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
10402|NCT00750022|Behavioral|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
10403|NCT00750022|Behavioral|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
10404|NCT00750035|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
10405|NCT00750035|Procedure|Subtotal abdominal hysterectomy|
10406|NCT00750048|Drug|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
10407|NCT00006054|Drug|anti-thymocyte globulin|
10408|NCT00750061|Drug|Lithium Carbonate|The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.
The course of medication is 6 weeks.
10409|NCT00750061|Drug|Placebo|Matching placebo
10718|NCT00744627|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
10719|NCT00744627|Drug|Placebo|Vortioxetine placebo-matching capsules
10720|NCT00744640|Drug|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
10721|NCT00744653|Procedure|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
10722|NCT00744666|Drug|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
10723|NCT00744679|Drug|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
10724|NCT00744692|Biological|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
10725|NCT00006032|Drug|ifosfamide|
10726|NCT00744692|Drug|Reduced Intensity Conditioning|
10727|NCT00744718|Drug|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
10728|NCT00744718|Drug|Carboplatin|Carboplatin AUC 5 every 5 weeks
11540|NCT00751959|Drug|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
11541|NCT00751972|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
11542|NCT00000715|Drug|Pentamidine isethionate|
11543|NCT00006061|Drug|phosphatidylcholine|
11544|NCT00751985|Other|Personalised normative feedback (PNF)|The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.
The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.
Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help.
11545|NCT00743561|Device|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
11546|NCT00743574|Dietary Supplement|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
11547|NCT00743574|Drug|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
11548|NCT00743574|Dietary Supplement|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
11549|NCT00743574|Dietary Supplement|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
11550|NCT00743587|Drug|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
11551|NCT00743587|Drug|Oxycodone|Oral, 1 x 20mg controlled-release tablets
11552|NCT00743587|Drug|Tramadol|Oral, 2 x 50mg immediate release capsules
11828|NCT00006372|Drug|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
11829|NCT00792753|Device|Medtronic Endeavor Coronary Stent System|coronary stent implantation
11830|NCT00792753|Device|DESyne BD Novolimus Stent System|coronary stent implantation
11831|NCT00792753|Device|DESyne Novolimus Stent System|coronary stent implantation
11832|NCT00792766|Drug|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
12218|NCT00793468|Drug|Placebo|Placebo once daily for 12 weeks
12560|NCT00788879|Behavioral|TSSC Randomized Behavioral Intervention for weight loss|We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).
Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes.
12561|NCT00791115|Procedure|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
12562|NCT00791141|Drug|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
12563|NCT00791154|Drug|AMG 479|AMG 479 is administered to subjects
12564|NCT00791154|Drug|Etoposide|Etoposide is administered to subjects
12565|NCT00791154|Drug|Placebo|Placebo is administered with Carboplatin and Etoposide
12566|NCT00791154|Drug|AMG 102|AMG 102 is administered to subjects
12567|NCT00791154|Drug|Carboplatin|Carboplatin is administered to some subjects in combination
12568|NCT00791154|Drug|Cisplatin|Cisplatin is administered to some subjects in combination
12569|NCT00791167|Drug|Paliperidone ER|
12570|NCT00791193|Drug|Paliperidone ER|
12571|NCT00006365|Radiation|radiation therapy|
12572|NCT00791206|Procedure|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
12573|NCT00791206|Procedure|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
12574|NCT00791219|Drug|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
12575|NCT00791219|Drug|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
11485|NCT00746330|Drug|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
11486|NCT00000711|Drug|Zidovudine|
11487|NCT00006038|Drug|floxuridine|
11488|NCT00746330|Drug|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
11489|NCT00746343|Behavioral|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
11490|NCT00746343|Behavioral|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
11491|NCT00746356|Device|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
11492|NCT00746356|Device|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
11493|NCT00746369|Behavioral|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
11494|NCT00746382|Drug|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
11495|NCT00746382|Drug|Placebo cream|Placebo cream
11496|NCT00746395|Drug|Lubiprostone|24 mcg oral administration
11497|NCT00746395|Drug|Placebo|Oral administration
11498|NCT00006038|Drug|fluorouracil|
11768|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
11769|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
11770|NCT00787605|Drug|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
11771|NCT00787618|Drug|50 mg Proellex|Single dose
11772|NCT00787644|Drug|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
11773|NCT00787644|Drug|Placebo|Matching placebo (inert tablet)
10729|NCT00744731|Drug|placebo|placebo for 1 week
10730|NCT00744731|Drug|carisbamate|400 mg/day to 1,200 mg per day
10731|NCT00744744|Other|informational intervention|Patient educational information
10732|NCT00744744|Other|questionnaire administration|Survey
10733|NCT00744744|Procedure|management of therapy complications|Survey
10734|NCT00744744|Procedure|psychosocial assessment and care|Survey
10735|NCT00744744|Procedure|quality-of-life assessment|Survey
10736|NCT00006032|Drug|topotecan hydrochloride|
10737|NCT00744757|Drug|Decitabine|Decitabine 20 mg per m^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
10738|NCT00744770|Drug|TMC278|
10739|NCT00744796|Procedure|DSEAK|Endothelial Keratoplasty
10740|NCT00744809|Drug|TMC278; Moxifloxacin; Efavirenz|
10741|NCT00744835|Procedure|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
11044|NCT00751101|Drug|nicotine|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
11045|NCT00751114|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
11046|NCT00751114|Drug|Sitagliptin|Oral administration. 100 mg film-coated tablets.
11047|NCT00751114|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
11048|NCT00751127|Drug|PhXA41|One drop in the affected eye once daily for six months.
11049|NCT00751127|Drug|timolol|One drop in the affected eye twice daily for six months.
11050|NCT00006055|Drug|methylprednisolone|
11051|NCT00751140|Procedure|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
11052|NCT00751153|Drug|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
11833|NCT00792779|Drug|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
11834|NCT00792792|Device|Modulated Imaging|Modulated Imaging Spectroscopy
11835|NCT00792805|Drug|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
11836|NCT00792805|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
11837|NCT00785187|Device|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
11838|NCT00785200|Other|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
11839|NCT00785200|Other|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
11840|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
11841|NCT00006326|Drug|Indinavir sulfate|
11842|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
11843|NCT00785213|Drug|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
11844|NCT00785226|Drug|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
11845|NCT00785226|Drug|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
11846|NCT00785252|Device|Powered Intraosseous device (EZIO)|EZIO
11847|NCT00785252|Device|standard central line|placement of a central line
11848|NCT00785265|Behavioral|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
12121|NCT00793234|Drug|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
12122|NCT00793234|Drug|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
12123|NCT00793247|Drug|PRU-PLA-PRU-PLA|
12576|NCT00791219|Drug|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
12577|NCT00791232|Drug|extended-release (ER) OROS paliperidone|
12578|NCT00791245|Biological|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
11614|NCT00749476|Biological|Factor IX recovery|
11615|NCT00789724|Drug|Anakinra|100 mg daily subcutaneous injection for 14 days
11616|NCT00789724|Drug|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
11617|NCT00789737|Drug|Welchol|Welchol 625mg tablets
11618|NCT00006359|Drug|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
11619|NCT00789737|Drug|Placebo|placebo
11620|NCT00789750|Drug|Welchol|Welchol 625 mg Tablets
11621|NCT00789750|Drug|placebo|placebo tablets
11622|NCT00789750|Drug|Pioglitazone|patients will be on stable pioglitazone 30mg or 45 mg
11623|NCT00789763|Drug|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
11624|NCT00789763|Radiation|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
11625|NCT00789763|Drug|Sorafenib|200-800 mg/day p.o. during 5 weeks
11626|NCT00789776|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
11627|NCT00789776|Drug|Cyclophosphamide|Given IV
11628|NCT00789776|Drug|Fludarabine Phosphate|Given IV
11629|NCT00006359|Radiation|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
11630|NCT00789776|Other|Laboratory Biomarker Analysis|Correlative studies
11631|NCT00789776|Drug|Mycophenolate Mofetil|Given PO
11632|NCT00789776|Biological|Natural Killer Cell Therapy|Given IV
11633|NCT00789776|Drug|Tacrolimus|Given IV or PO
11774|NCT00787657|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
11775|NCT00787670|Other|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
11776|NCT00787670|Procedure|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
11777|NCT00006347|Radiation|indium In 111 monoclonal antibody MN-14|
11778|NCT00787670|Other|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
11779|NCT00787683|Device|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
11780|NCT00787696|Behavioral|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
11781|NCT00787709|Behavioral|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
11782|NCT00787722|Procedure|Hematopoietic stem cell transplantation|Mobilization
G-CSF- guidelines, 5-10 mcg/kg/day will be started day +5 and continued until the absolute neutrophil counts reaches at least 1,000
Cytoxan dose of 2gm/m will be infused over two hours.
Mesna, given the dose of 2.0 gm/m, infusion to be given over 24 hours.
Transplant Conditioning Regimen
Cyclophosphamide 50 mg/kg/day will be given IV over 2 hours in 500 cc of normal saline.
r ATG 0.5 mg/kg given on day -5, then 1.0 mg/kg given on day -4, then 1.5 mg/kg given on days -3 through -1.
Rituxan ( Rituximab ) - The dose of 500 mg of Rituximab will be given on days -6 and on day + 1.
G-CSF - guidelines, 5-10 mcg/kg/day will be started day + 5 and continued until the absolute neutrophil counts reaches at least 1,000/μl.
11783|NCT00787735|Behavioral|Counseling compliance|Rates of attendance to call counseling session over specific time points
12059|NCT00787982|Device|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
12060|NCT00788008|Drug|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
12061|NCT00788034|Drug|Lu AA21004|5 or 10 mg/day
12062|NCT00788034|Drug|Placebo|Once daily
12063|NCT00788047|Drug|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
11053|NCT00751166|Drug|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
11054|NCT00751166|Drug|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
11055|NCT00751166|Drug|placebo|placebo once daily for 28 days
11056|NCT00751179|Drug|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
11057|NCT00751179|Drug|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
11058|NCT00751179|Drug|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
11059|NCT00751192|Device|HIV-testing motivational videos|
11060|NCT00751192|Device|Standard public health text|
11061|NCT00006055|Drug|prednisone|
11062|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
10098|NCT00754546|Drug|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
10099|NCT00754546|Drug|Placebo: Normal Saline|Normal saline was nebulized.
10100|NCT00754546|Other|Treadmill Exercise|
10101|NCT00006088|Drug|vinorelbine tartrate|
10102|NCT00754546|Other|Cycle Exercise|
10103|NCT00754559|Drug|Tocilizumab|8mg/kg iv every 4 weeks
10104|NCT00754572|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
10105|NCT00754572|Drug|methotrexate|10-25mg oral or parenteral weekly.
10106|NCT00754585|Device|Logic Back Grahl Duo Back Model DB11‐01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
10107|NCT00754624|Drug|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
12124|NCT00006374|Drug|etoposide|
12125|NCT00793247|Drug|PLA-PRU-PLA-PRU|
12126|NCT00785603|Drug|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
12127|NCT00785603|Drug|Tramadol|Capsules of 50 mg tramadol
12128|NCT00785616|Other|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
12129|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
12130|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
12131|NCT00785629|Drug|Calcium acetate|
12132|NCT00785629|Drug|Lanthanum Carbonate|
12133|NCT00006331|Procedure|renal transplant|
12134|NCT00785629|Drug|Sevelamer Carbonate|
12135|NCT00785629|Drug|Placebo|
12136|NCT00785642|Drug|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
12137|NCT00785655|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
12138|NCT00785668|Drug|AER 001|10 mg dry powder administered using a handheld device
12139|NCT00785681|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
12140|NCT00785694|Drug|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
12141|NCT00785720|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
12142|NCT00785746|Other|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
12143|NCT00785759|Drug|AH110690 (18F) Injection|All subjects will receive an I.V. dose of [18F]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of [18F]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
12144|NCT00006332|Drug|Tetrathiomolybdate|
11634|NCT00789776|Radiation|Total-Body Irradiation|Undergo total-body irradiation
11635|NCT00789802|Drug|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
11636|NCT00789802|Drug|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
11637|NCT00789802|Drug|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
11638|NCT00789815|Device|Bispectral index guide propofol infusion|Induction:
Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.
Maintenance:
Propofol infusion (3~12 mg/kg/hour) to maintain BIS around 65~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough.
11902|NCT00792831|Drug|ITF2357|Histone-Deacetylase Inhibitor
11903|NCT00792844|Dietary Supplement|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
11904|NCT00792844|Dietary Supplement|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
11905|NCT00792857|Drug|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
11906|NCT00792857|Drug|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
11907|NCT00792870|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
11908|NCT00792896|Behavioral|family conference|family conference
11909|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
11910|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
11911|NCT00006373|Drug|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
11912|NCT00792922|Drug|Azithromycin|Comparison of community coverage rate
11913|NCT00792922|Drug|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is >5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
11914|NCT00792935|Drug|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
12064|NCT00788047|Drug|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
12065|NCT00788060|Drug|Everolimus (RAD001)|5mg per day, continuously
12066|NCT00788060|Drug|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
12067|NCT00006349|Drug|donepezil hydrochloride|
12068|NCT00788073|Drug|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
12069|NCT00788073|Drug|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
12070|NCT00788099|Drug|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
12071|NCT00788099|Drug|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
12072|NCT00788112|Drug|vorinostat|
12073|NCT00788112|Genetic|protein expression analysis|
12074|NCT00788112|Other|immunohistochemistry staining method|
12075|NCT00788112|Other|laboratory biomarker analysis|
12076|NCT00788112|Procedure|neoadjuvant therapy|
12077|NCT00788112|Procedure|therapeutic conventional surgery|
12078|NCT00006349|Other|placebo|
12079|NCT00788125|Drug|carboplatin|
12080|NCT00790413|Procedure|Donor Lymphocyte Infusion|
12081|NCT00790413|Drug|Rituximab|
12082|NCT00790413|Procedure|Co-transplantation of mesenchymal stem cells|
12438|NCT00786305|Drug|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
12439|NCT00006339|Drug|Didanosine|
12440|NCT00786318|Drug|ziprasidone|ziprasidone 20mg IM
10108|NCT00754650|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
10109|NCT00754663|Behavioral|exercise training|walking training at least 3 times a week
10110|NCT00754689|Drug|rimonabant (SR141716)|oral administration
10111|NCT00754689|Drug|metformin|oral administration
10112|NCT00006089|Biological|trastuzumab|Given IV
10113|NCT00754689|Drug|placebo|oral administration
10114|NCT00754702|Drug|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
10115|NCT00754702|Drug|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
10116|NCT00754715|Drug|AZD2516|Solution administered once orally
10117|NCT00754715|Drug|Placebo|Solution administered only once
10118|NCT00754728|Device|JACTAX DES|Drug Eluting Stent
10119|NCT00754741|Behavioral|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
10120|NCT00754741|Behavioral|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
10410|NCT00750100|Drug|human chorionic gonadotropin|hCG 200IU in the late follicular phase
10411|NCT00750100|Drug|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
10412|NCT00752440|Other|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
10413|NCT00752453|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
10414|NCT00752453|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
10415|NCT00752453|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
10416|NCT00752466|Drug|Topiramate; flunarizine|
12502|NCT00793585|Drug|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level < 6mg/dl , the dosage changed to 200mg/d.
12503|NCT00793585|Other|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
12504|NCT00793598|Drug|Placebo|Placebo Cohort 3A placebo once weekly for a total of 5 doses Cohort 4A placebo twice weekly for a total of nine doses Cohort 4B placebo once or twice weekly Cohort 4C placebo once or twice weekly
12505|NCT00793598|Drug|CMX001|Cohort 3A 40mg CMX001 once weekly for a total of 5 doses Cohort 4A 100mg CMX001 twice weekly for a total of nine doses Cohort 4B 200mg CMX001 once or twice weekly Cohort 4C 300mg CMX001 once or twice weekly
12506|NCT00793611|Behavioral|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
12507|NCT00793611|Other|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
12508|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
12509|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
12510|NCT00793624|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
12511|NCT00793624|Drug|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
12512|NCT00006377|Drug|carboplatin|
12513|NCT00793624|Drug|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
12514|NCT00793650|Drug|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
12515|NCT00793650|Drug|Melphalan|All patients received melphalan (100 mg/m^2/day × 2; days
−3 and −2), for a total dose of 200 mg/m^2.
12516|NCT00793650|Procedure|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
12517|NCT00793663|Drug|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
12518|NCT00786344|Behavioral|Lifestyle Redesign|For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.
Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects.
11915|NCT00792935|Drug|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
11916|NCT00792935|Drug|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin [(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)], the participant should remain on the same metformin dose throughout the study.
11917|NCT00792948|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
11918|NCT00792948|Drug|Cyclophosphamide|Given IV
11919|NCT00792948|Drug|Cytarabine|Given IT
11920|NCT00792948|Drug|Dasatinib|Given PO
11921|NCT00785356|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
12219|NCT00793481|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
12220|NCT00793494|Other|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
12221|NCT00793494|Other|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
12222|NCT00793507|Other|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
12223|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
12224|NCT00006375|Drug|LY293111|
12225|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
12226|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
12227|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
12228|NCT00793546|Drug|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
12229|NCT00793546|Drug|exemestane|25 mg tablet once daily
12441|NCT00786318|Drug|Standard therapy|Haldol 5mg/ Ativan 2mg IM
12442|NCT00786331|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
12443|NCT00786331|Drug|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
12444|NCT00788593|Drug|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
12445|NCT00788593|Drug|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
12446|NCT00788606|Drug|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
12447|NCT00788619|Procedure|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
12448|NCT00006352|Biological|BCG vaccine|
12449|NCT00788619|Procedure|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
12450|NCT00788632|Behavioral|Patient educational DVD and brochure|Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and "closing the loop" between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored "story-telling", and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a "booster".
12451|NCT00788632|Behavioral|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
12452|NCT00788632|Behavioral|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
12453|NCT00788645|Behavioral|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
11499|NCT00746408|Other|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
10417|NCT00752479|Biological|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|Cell therapy
Mesenchymal cells infusion.
Induction therapy:
Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).
Maintenance therapy:
Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).
10418|NCT00752479|Drug|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|Routine immunosuppressive therapy
Induction therapy:
Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).
Maintenance therapy:
Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).
10419|NCT00752492|Other|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
10420|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
10421|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
10422|NCT00006066|Drug|Aldesleukin|
10423|NCT00752518|Drug|bortezomib|
10424|NCT00752531|Behavioral|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
10425|NCT00752544|Drug|TMC435350|
10426|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
10427|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
10428|NCT00752557|Drug|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
10742|NCT00744848|Drug|Bupivacaine HCl|100 mg Bupivacaine HCl
10743|NCT00744848|Drug|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
10744|NCT00747526|Drug|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
10745|NCT00747539|Drug|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
12519|NCT00786357|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
12520|NCT00786357|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
11553|NCT00006027|Drug|cisplatin|
11554|NCT00743587|Drug|Naproxen|Oral, 1 x 500mg enteric-coated
11555|NCT00743600|Other|ultrasound|ultrasound of painful shoulder
11556|NCT00743600|Other|ultrasound|healthy volunteers have US of asymptomatic shoulder
11557|NCT00743613|Behavioral|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
11558|NCT00743613|Procedure|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
11559|NCT00743626|Other|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
11560|NCT00743639|Procedure|intramyocardial bone marrow stem cells implantation|Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.
Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10[7] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days.
11561|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
11562|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
11563|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
11564|NCT00006027|Drug|paclitaxel|
11565|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
11566|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
11567|NCT00743678|Drug|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
11568|NCT00746447|Drug|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
12230|NCT00793546|Drug|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
12231|NCT00793559|Drug|terlipressin|1 mg of terlipressin one time only
12232|NCT00793559|Drug|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
12233|NCT00793572|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
12234|NCT00793572|Drug|Bortezomib|Given SC
12235|NCT00006376|Drug|chemotherapy|
12236|NCT00793572|Drug|Cyclosporine|Given IV
12237|NCT00785837|Other|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
12238|NCT00006337|Drug|KW-6002|
12239|NCT00785850|Drug|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
12579|NCT00791258|Drug|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
12580|NCT00791258|Drug|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
12581|NCT00791271|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
12582|NCT00000742|Drug|Atevirdine mesylate|
12583|NCT00006366|Drug|fluorouracil|
12584|NCT00791271|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
12585|NCT00791284|Drug|Intermediate release (IR) Paliperidone|
12586|NCT00791297|Drug|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
12587|NCT00006279|Drug|Nevirapine|
12588|NCT00783640|Drug|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
12589|NCT00783653|Drug|Sunitinib|25 mg or 37,5 mg daily dose until DLT
12590|NCT00783666|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
11500|NCT00746421|Drug|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
11501|NCT00746421|Drug|Placebo|200mg, 300mg or 400mg
11502|NCT00746434|Drug|Roflumilast cream|Roflumilast cream 0.5%
11503|NCT00746434|Drug|Placebo cream|Placebo cream
11504|NCT00746447|Drug|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
11505|NCT00746447|Drug|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
11506|NCT00749086|Device|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
11507|NCT00749086|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
11508|NCT00749099|Drug|pancrelipase|The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal.
Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
11509|NCT00749099|Drug|placebo|5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.
Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
11510|NCT00749112|Drug|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
11511|NCT00749125|Drug|Escalitopram|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
11512|NCT00749138|Drug|tamoxifen|giving drug tamoxifen
11513|NCT00749151|Behavioral|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
11514|NCT00749164|Procedure|MSC transplantation|1-2X10^6 MSC per kg
11515|NCT00749177|Other|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
11516|NCT00006049|Drug|paclitaxel|
11517|NCT00749190|Drug|BI 10773|
11518|NCT00749190|Drug|placebo|
10746|NCT00747565|Device|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
10747|NCT00006042|Drug|mycophenolate mofetil|
10748|NCT00747565|Device|CeeOn 911A monofocal IOL|Monofocal Control IOL
10749|NCT00747604|Biological|mecasermin [rDNA origin] injection|As prescribed by the physician.
10750|NCT00747617|Drug|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
10751|NCT00747630|Other|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
10752|NCT00747643|Drug|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
10753|NCT00747643|Drug|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
10754|NCT00747669|Drug|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
10755|NCT00747695|Drug|Rabeprazole sodium|
10756|NCT00747708|Drug|Granulocyte-colony stimulating factor|5 days subcutaneous injection
10757|NCT00747708|Procedure|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
10758|NCT00006042|Drug|tacrolimus|
10759|NCT00747708|Procedure|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
10760|NCT00747721|Drug|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
10761|NCT00747734|Drug|MNRP1685A|Escalating intravenous dose
10762|NCT00747747|Biological|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
11063|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
11064|NCT00751218|Drug|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
11569|NCT00746460|Behavioral|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
11570|NCT00746486|Drug|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
11571|NCT00006038|Drug|leucovorin calcium|
11572|NCT00746486|Drug|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
11849|NCT00785265|Behavioral|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
11850|NCT00785291|Drug|Paclitaxel|Given IV
11851|NCT00785291|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
11852|NCT00006326|Drug|Ritonavir|
11853|NCT00785291|Drug|Ixabepilone|Given IV
11854|NCT00785291|Biological|Bevacizumab|Given IV
11855|NCT00785291|Other|Questionnaire Administration|Ancillary studies
11856|NCT00785291|Other|Laboratory Biomarker Analysis|Correlative studies
11857|NCT00785317|Drug|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
11858|NCT00785330|Drug|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
11859|NCT00785330|Drug|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
11860|NCT00785343|Device|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
11861|NCT00785343|Procedure|Conventional Therapy|Occupational therapy that is the current standard of care
11862|NCT00787761|Drug|busulfan|Commercially available in 60 mg/10 mL ampuls.
Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.
Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.
IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses.
12630|NCT00786643|Drug|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
12631|NCT00786669|Drug|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
12632|NCT00006342|Genetic|chromosomal translocation analysis|
12633|NCT00786669|Drug|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
12634|NCT00788892|Drug|CPX-351|CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5 as a 90 minute infusion
12635|NCT00788892|Drug|Cytarabine + Daunorubicin - 7 and 3|Cytarabine at a dose of 100mg/m2/day for 7 days plus daunorubicin at dose of 60mg/m2 for 3 days
12636|NCT00788905|Device|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
12637|NCT00788918|Drug|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
12638|NCT00788931|Drug|IV LBH589|
12639|NCT00788931|Drug|Oral LBH589|
12640|NCT00788931|Drug|trastuzumab|
12641|NCT00006354|Dietary Supplement|mistletoe extract|
12642|NCT00788931|Drug|paclitaxel|
12643|NCT00788944|Procedure|blood draw|Test Article was not provided to subjects for this study.
11657|NCT00792363|Drug|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
11658|NCT00792376|Drug|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
11659|NCT00792376|Drug|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
11660|NCT00792389|Other|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
11661|NCT00792389|Other|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
11662|NCT00792428|Device|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
11663|NCT00792428|Device|Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
12384|NCT00790881|Drug|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
12385|NCT00790894|Drug|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
12386|NCT00790894|Drug|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
12387|NCT00790907|Drug|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein [GP] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) [maximum two additional bolus doses]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
12388|NCT00790907|Drug|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
12389|NCT00790907|Drug|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
12390|NCT00790920|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
12391|NCT00790920|Drug|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
12392|NCT00006364|Other|pharmacological study|Correlative studies
12393|NCT00790933|Drug|vedolizumab|Enrolled patients will receive vedolizumab (MLN0002) every 4 weeks, starting at Week 0, for up to a maximum of 7 years. The dosing period will be followed by a 16-week post-treatment observation and safety assessment period.Patients will also receive safety phone calls at 6-month intervals for 2 years following receipt of the last dose.
12394|NCT00790946|Drug|Valsartan|Valsartan 80 to 160 mg
12395|NCT00790959|Behavioral|SASA!|A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours
The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention.
12396|NCT00790959|Other|Control|Control communities will receive the full SASA! intervention after completion of the SASA! Study.
For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers.
12397|NCT00790972|Drug|Sinofresh|two sprays in each nostril three times daily for one week
7682|NCT00734578|Drug|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
7683|NCT00734591|Drug|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
7684|NCT00734591|Other|Randomized diabetes therapy|Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.
Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
7685|NCT00734604|Drug|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
7686|NCT00734604|Drug|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
7687|NCT00734604|Drug|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
7982|NCT00737464|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks
7983|NCT00737477|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|s.c. every month (starting dose based on previous ESA therapy).
7984|NCT00737490|Other|"Sequential Arm" (Promote , model # 2207-36 or Atlas HF , model # V-343)|Echocardiographically guided optimized device programming: specifically sequential BiV pacing. "Sequential Arm"
Using one of the FDA approved St. Jude devices, depending on MD preference.
7985|NCT00737490|Other|"Simultaneous Arm" (Promote , model # 2207-36 or Atlas HF , model # V-343)|simultaneous BiV pacing.
Using one of the FDA approved St. Jude devices, depending on MD preference.
7986|NCT00737503|Biological|Rotavirus Vaccine (ROTARIX)|Rotavirus Vaccine two doses four weeks apart
7987|NCT00737516|Biological|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
7988|NCT00737529|Drug|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
7989|NCT00737542|Drug|lidocaine|
7990|NCT00737542|Drug|NACL 0.9%|
7991|NCT00737555|Drug|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
7992|NCT00005992|Biological|therapeutic autologous dendritic cells|
7993|NCT00737568|Drug|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
7994|NCT00740207|Drug|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
8714|NCT00754884|Drug|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
8715|NCT00754910|Drug|porfimer sodium|Given IV
8716|NCT00754910|Procedure|bronchoscopy|Patients undergo bronchoscopy
8717|NCT00006091|Drug|arsenic trioxide|
8718|NCT00754923|Drug|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
8719|NCT00754936|Drug|Escitalopram|20 mg by mouth daily
8720|NCT00754949|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
7742|NCT00006018|Drug|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
7743|NCT00742547|Other|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
7744|NCT00742560|Biological|elotuzumab (HuLuc63)|Humanized Anti-CS1 Monoclonal IgG1 Antibody
7745|NCT00742560|Drug|lenalidomide|25 mg PO days 1 though 21 of each 28 day cycle
7746|NCT00742560|Drug|dexamethasone|40 mg PO days 8 and 22; 28 mg PO and 8 mg IV days 1 and 15 of each 28 day cycle.
7747|NCT00742573|Drug|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
7748|NCT00742573|Behavioral|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
7749|NCT00742599|Drug|NPO-11|20 ml NPO-11
7750|NCT00742599|Drug|Placebo|20 ml NPO-11(Placebo)
7751|NCT00742612|Drug|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
11664|NCT00784810|Drug|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
11665|NCT00784810|Drug|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
11666|NCT00784823|Drug|Bortezomib|Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line
Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1
Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen
11667|NCT00784823|Drug|Melphalan|Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour
Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration
The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period
Melphalan will be given as a single dose (not split over 2 or more days)
Dosing will be based body surface area calculated using actual body weight
11668|NCT00784836|Drug|BG9418 (interferon beta 1-a)|
11669|NCT00784849|Drug|Methylene blue|1 mC1
11670|NCT00006320|Procedure|determine blood levels of anti-HIV drugs|
11671|NCT00784862|Drug|Anastrozole|1mg, orally, once daily
11672|NCT00784862|Drug|Tamoxifen|20mg, orally, once daily
11673|NCT00784875|Drug|LY2624803|1 mg, oral capsule, once nightly before bedtime
11674|NCT00784875|Drug|LY2624803|3 mg, oral capsule, once nightly before bedtime
11675|NCT00784875|Drug|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
11676|NCT00784875|Drug|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
11677|NCT00784888|Other|Aromatase inhibitors|non-interventional study
12284|NCT00788398|Procedure|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
12285|NCT00006350|Procedure|peripheral blood stem cell transplantation|
12286|NCT00788398|Procedure|Low Pressure Irrigation|Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.
Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i.
11437|NCT00751803|Drug|BI 44370 TA Medium Dose|
11438|NCT00751816|Drug|systemic chemotherapy|Not specified
11439|NCT00006056|Drug|methotrexate|
11440|NCT00751816|Other|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
11441|NCT00751816|Procedure|adjuvant therapy|not specified
11442|NCT00751816|Procedure|management of therapy complications|not specified
11443|NCT00751816|Procedure|musculoskeletal complications management/prevention|Not specified
11444|NCT00751816|Procedure|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
11445|NCT00751816|Radiation|radiation therapy|not specified
11446|NCT00751829|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
11447|NCT00751829|Drug|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
11448|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
11449|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
11450|NCT00006056|Procedure|allogeneic hematopoietic stem cell transplantation|
11451|NCT00751842|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
11452|NCT00751855|Behavioral|Prolonged Exposure therapy|10 weekly sessions
11453|NCT00751855|Drug|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
11454|NCT00751855|Drug|placebo|placebo
11455|NCT00751868|Drug|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
11456|NCT00751881|Drug|Placebo (for teriflunomide)|Film-coated tablet
Oral administration
7995|NCT00740246|Drug|VIT-45|
7996|NCT00740259|Drug|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
7997|NCT00740272|Procedure|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
7998|NCT00740272|Procedure|Pacemaker implantation|regular pacemaker implantation
7999|NCT00740285|Drug|Lidocaine 2% without vessel constrictor|first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours
next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
8000|NCT00740285|Other|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
8001|NCT00006005|Drug|thalidomide|
8002|NCT00740298|Other|sucrose|sweet taste
8315|NCT00733252|Procedure|diagnostic bronchoscopy|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
8316|NCT00733252|Procedure|histopathologic examination|All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
8317|NCT00733252|Procedure|optical coherence tomography|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
8318|NCT00733265|Drug|AZD6140|single oral dose
8319|NCT00733278|Device|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
8320|NCT00733291|Device|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
8321|NCT00005978|Procedure|autologous bone marrow transplantation|
8322|NCT00733291|Device|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
8323|NCT00733291|Device|FID 107027 solution|Commercially marketed solution for contact lens disinfection
8324|NCT00733304|Drug|Pazopanib|eyedrops
8325|NCT00733317|Drug|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
8326|NCT00733317|Drug|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
7752|NCT00742612|Drug|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
7753|NCT00006018|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
7754|NCT00742625|Drug|daunorubicin hydrochloride|Given IV
7755|NCT00742625|Drug|cytarabine|Given IV
7756|NCT00742625|Drug|bortezomib|Given IV
7757|NCT00742638|Drug|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
7758|NCT00742638|Drug|Sodium valproate|Sodium valproate tablet 200 mg
7759|NCT00734682|Drug|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m^2 (wild type) or 60 mg/m^2 IV q3 weeks.
7760|NCT00734695|Dietary Supplement|vitamin c|Subconjunctival daily or bid
8065|NCT00737568|Drug|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
8066|NCT00737568|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
8067|NCT00737568|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
8068|NCT00737594|Drug|Placebo|0 mcg capsules three times daily (TID)
8069|NCT00737594|Drug|Cobiprostone|12 mcg cobiprostone (capsules) three times daily (TID)
8070|NCT00737594|Drug|Cobiprostone|18 mcg cobiprostone (capsules) three times daily (TID)
8071|NCT00737620|Procedure|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
8072|NCT00737633|Drug|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
8073|NCT00737646|Behavioral|Usual care|No intervention will be conducted in this arm of the study.
8074|NCT00005993|Drug|aldesleukin|
12287|NCT00788398|Procedure|High Pressure|Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.
Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i.
12288|NCT00790738|Drug|placebo|placebo
12289|NCT00006363|Other|clinical observation|Undergo clinical observation
12290|NCT00790751|Drug|placebo|30 minutes orally prior to initiation of sexual activity
12291|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
12292|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
12293|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
12294|NCT00790764|Biological|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
12295|NCT00790764|Other|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
12296|NCT00790777|Drug|Paliperidone ER|
12297|NCT00790790|Drug|Placebo|LY545694 placebo BID po for 5 weeks
12298|NCT00790790|Drug|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
12299|NCT00790790|Drug|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
12300|NCT00006363|Other|pharmacological study|Correlative studies
12301|NCT00790803|Drug|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
12302|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
12303|NCT00790816|Drug|Lapatinib|Lapatinib monotherapy
12322|NCT00793013|Device|Volume-Cycled Assist-Control (AC) mode|Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40%
Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min
Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2
Inspiratory to Expiratory ratio set at 1:1 to 1:3
If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased
Mgmt of PEEP will be conducted as per the ARDSnet Protocol
Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%
Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol
7607|NCT00736788|Drug|AZD1704|single dose oral suspension, 4 different dose levels
7608|NCT00736788|Drug|Placebo|single dose oral suspension
7609|NCT00736801|Drug|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
7610|NCT00736814|Drug|carboplatin|Given intravenously
7611|NCT00736814|Drug|docetaxel|Given intravenously
7612|NCT00005988|Drug|methotrexate|
7613|NCT00736814|Drug|gemcitabine hydrochloride|Given intravenously
7614|NCT00736814|Drug|vinorelbine tartrate|Given intravenously
7615|NCT00736840|Device|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
7616|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
7617|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
7618|NCT00736853|Drug|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
7619|NCT00736866|Drug|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
7620|NCT00736866|Drug|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
7621|NCT00736879|Drug|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
7622|NCT00736879|Drug|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
7623|NCT00005988|Drug|methylprednisolone|
7624|NCT00736905|Drug|TMC278|
7625|NCT00736918|Behavioral|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
7626|NCT00736918|Other|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
8327|NCT00735514|Procedure|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
8328|NCT00735527|Drug|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
8329|NCT00735527|Drug|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
8330|NCT00735540|Other|Observational|Data summary only
8331|NCT00735553|Drug|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
8332|NCT00735553|Drug|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
8333|NCT00735553|Drug|Placebo|Two placebo capsules orally daily for up to four months
8334|NCT00735592|Other|Observational|Retrospective data obtained from electronic files
8335|NCT00735605|Other|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
8336|NCT00000703|Drug|Leucovorin calcium|
8645|NCT00738712|Procedure|MRI Magnetic Resonance Imaging|MRI
8646|NCT00738738|Drug|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
8647|NCT00738751|Drug|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
8648|NCT00738751|Drug|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
8649|NCT00738764|Biological|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
8650|NCT00738777|Drug|Anastrozole|1 mg,QD,PO
8651|NCT00738777|Drug|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
8075|NCT00737646|Behavioral|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
8076|NCT00737646|Behavioral|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
8077|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg*h\L) measured on Days 7,14,Months 1,3,6 and 12.
8078|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
8079|NCT00737672|Device|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
8080|NCT00737672|Procedure|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
8081|NCT00737685|Drug|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 & -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 & -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 & -1)
8082|NCT00737698|Other|Exercise|Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
8083|NCT00737698|Other|Repetitive magnetic stimulation|Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
8394|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
8395|NCT00733343|Device|Europe: AutoSet CS 2 (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
8396|NCT00733356|Drug|Vyvanse|Subject's will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subject's will take their prescribed dose once a day in the morning with breakfast.
8397|NCT00733369|Device|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
8398|NCT00005978|Procedure|peripheral blood stem cell transplantation|
8399|NCT00733369|Device|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
8400|NCT00733382|Drug|dexamethazone|injection form, 8 miligram, injected once
12323|NCT00793013|Device|Airway Pressure Release Ventilation (APRV) mode|Ventilation uses Drager Model X1
Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels
Time periods for the high & low pressure levels can be set independently
Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume
Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min
Spontaneous frequency will be targeted for 6 to 18 breaths/per min
If spontaneous breathing is achieved,level of sedation will be decreased
If spontaneous respirations are >20 breaths/min, sedation will be increased
If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased
12324|NCT00793026|Drug|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
12325|NCT00793052|Drug|Etodalac, Etoricoxib and Dexamethasone|Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.
Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.
Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction.
12326|NCT00793065|Other|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
12327|NCT00006374|Biological|filgrastim|
12328|NCT00793065|Other|Medical Home redesign|Implementation of NCQA Level II Medical Home
12329|NCT00793091|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
12330|NCT00793091|Drug|Placebo|4 drops applied daily for 120 days
12331|NCT00785993|Other|Vitrification of oocytes for IVF treatment|
12332|NCT00785993|Other|Protocolary IVF treatment with fresh donor oocytes|
12333|NCT00786006|Drug|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
12334|NCT00786006|Drug|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
12335|NCT00786019|Behavioral|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
12336|NCT00786019|Drug|Ascorbic Acid (Vitamin C)|During one exercise study visit, 0.06 g Vit C per kg fat-free mass per 100 ml of normal saline administered; Subjects will receive a bolus of 100mL Vit C solution given at 5ml/min over 20minutes followed by a "drip-infusion" given at 1.7ml/min.
12644|NCT00788957|Drug|Panitumumab|Panitumumab for intravenous infusion
12645|NCT00788957|Drug|Ganitumab|Ganitumab for intravenous infusion
12646|NCT00788957|Drug|Rilotumumab|Rilotumumab for intravenous infusion
7627|NCT00736931|Drug|Brivaracetam|Brivaracetam 10 mg tablets
7920|NCT00740207|Drug|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
7921|NCT00742404|Genetic|protein analysis|
7922|NCT00742404|Other|immunologic technique|
7923|NCT00742417|Biological|Albutein 5%|18 Plasma Exchanges using
Albutein 5% (estimated 3000mL per plasma exchange) or
Sham Procedure
three weeks of intensive treatment with two plasma exchanges per week
six weeks of maintenance treatment with one weekly plasma exchange
three months of maintenance treatment with one plasma exchange every two weeks
7924|NCT00006016|Other|laboratory biomarker analysis|Correlative studies
7925|NCT00742430|Procedure|PCI|percutaneous coronary intervention in stable coronary artery disease
7926|NCT00742443|Drug|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
7927|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
7928|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
7929|NCT00742456|Dietary Supplement|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
7930|NCT00742456|Dietary Supplement|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
7931|NCT00742469|Drug|Rifaximin|
7932|NCT00742469|Drug|Placebo|
7933|NCT00742482|Drug|HL 10|Freeze dried HL 10
7934|NCT00742495|Drug|Forodesine|PK study
7935|NCT00006017|Drug|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
7936|NCT00742508|Drug|SK&F-105517-D 10 mg capsule|1 capsule once a day
7937|NCT00742508|Drug|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
8652|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
8653|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
8654|NCT00005998|Drug|etoposide|
8655|NCT00759733|Procedure|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
8656|NCT00759733|Procedure|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
8657|NCT00759746|Behavioral|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
8658|NCT00759746|Behavioral|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
7688|NCT00005984|Procedure|radiation therapy|total body irradiation twice a day on days -4 through -1
7689|NCT00734617|Drug|Nicotine Patch|Groups 1 & 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day
Groups 2 & 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day
7690|NCT00734630|Drug|nebivolol|Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily
Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
7691|NCT00734630|Drug|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
7692|NCT00734656|Drug|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
7693|NCT00734656|Drug|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
7694|NCT00734656|Drug|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
7695|NCT00734656|Drug|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
7696|NCT00734669|Drug|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
8401|NCT00733395|Dietary Supplement|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
8402|NCT00733395|Dietary Supplement|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
8403|NCT00733408|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
8404|NCT00733408|Biological|bevacizumab|Given IV
8405|NCT00733408|Drug|erlotinib hydrochloride|Given PO
8406|NCT00733408|Other|laboratory biomarker analysis|Correlative studies
8407|NCT00733421|Drug|etoricoxib|90 mg once daily
8408|NCT00733421|Drug|tramadol|100 mg twice daily
8409|NCT00005978|Radiation|iobenguane I 131|
8410|NCT00733434|Drug|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
8411|NCT00733434|Other|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
8412|NCT00733447|Device|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
8413|NCT00733460|Drug|BFPET|
8414|NCT00733473|Drug|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
8721|NCT00754949|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
8722|NCT00754949|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
8723|NCT00754962|Drug|protriptyline|10 mg tablet
8724|NCT00757107|Device|Taperloc standard|primary total hip arthroplasty
8725|NCT00757133|Procedure|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
12647|NCT00788957|Drug|Placebo|Placebo intravenous infusion
12648|NCT00788970|Behavioral|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
12649|NCT00788996|Behavioral|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
12650|NCT00789035|Drug|BI 10773|
12651|NCT00789035|Drug|placebo|
12652|NCT00006355|Drug|pyrazoloacridine|
12653|NCT00789035|Drug|metformin|
12654|NCT00789048|Other|radiograph|One radiograph with the patient lying on his contralateral side
12655|NCT00789061|Drug|Proton pump inhibitor|One dosage/day/year
12656|NCT00789074|Drug|Varenicline|Varenicline 1mg twice daily
12657|NCT00789074|Drug|Placebo|Placebo 1mg BD
12658|NCT00789087|Procedure|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
12659|NCT00789087|Procedure|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
12660|NCT00789113|Drug|Extended Release Lamotrigine|
12661|NCT00789126|Drug|VX-509|
12662|NCT00789139|Device|ICM Implantation|Sub cutaneous implantation of the ICM
12663|NCT00006355|Procedure|adjuvant therapy|
12664|NCT00789152|Drug|desloratadine|desloratadine 5 mg daily x 8 days
12665|NCT00791310|Drug|Flucis|FDG injected i.v
12666|NCT00791323|Drug|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
12667|NCT00791323|Drug|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
12668|NCT00791336|Drug|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
12669|NCT00791349|Drug|Immediate release (IR) Paliperidone|
7938|NCT00742508|Drug|SK&F-105517-D 20 mg capsule|1 capsule once a day
7939|NCT00742508|Drug|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
7940|NCT00742508|Drug|Carvedilol-IR 10 mg tablet|1 tablet twice a day
8250|NCT00005986|Drug|recombinant interferon alfa|
8251|NCT00735514|Procedure|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
8252|NCT00737867|Drug|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert`s formula)
8253|NCT00737880|Other|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
8254|NCT00737893|Drug|Placebo|Saline injection subcutaneously given pre-op day, day of surgery, day after surgery.
8255|NCT00737893|Drug|EPO|Erythropoietin 20,000 units subcutaneously given pre-op day, day of surgery, day after surgery.
8256|NCT00737906|Procedure|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
8257|NCT00737919|Dietary Supplement|Plant Stanol|Plant stanols in margarines daily 2 grams
8258|NCT00737919|Dietary Supplement|Plant Sterol|Plant sterols in margarines daily 2 grams
8259|NCT00737932|Drug|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
8260|NCT00737932|Other|placebo|Matching placebo for 8 weeks of treatment
8261|NCT00005994|Drug|ondansetron|
8262|NCT00737971|Drug|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
8263|NCT00737971|Drug|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
8264|NCT00737971|Drug|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
8265|NCT00737984|Procedure|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
8266|NCT00737997|Drug|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
7697|NCT00736931|Drug|lorazepam|lorazepam 2 mg over encapsulated tablets
7698|NCT00736931|Other|placebo|placebo capsules
7699|NCT00736944|Drug|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
7700|NCT00736944|Drug|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
7701|NCT00736944|Drug|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
7702|NCT00005988|Procedure|in vitro-treated bone marrow transplantation|
7703|NCT00736944|Drug|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
7704|NCT00736944|Drug|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
7705|NCT00736944|Radiation|Radiation (Post induction)|Monday-Friday, weeks 1-7
7706|NCT00736944|Drug|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
7707|NCT00736944|Drug|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
8003|NCT00740298|Other|warmth|warmth
8004|NCT00740311|Device|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
8005|NCT00740324|Drug|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
8006|NCT00740324|Drug|NPO-11|NPO-11 after administration of NPO-11
8007|NCT00740324|Drug|NPO-11|1 mg glucagons after administration of NPO-11
8008|NCT00740350|Procedure|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
8009|NCT00740363|Drug|sitagliptin|Once daily sitagliptin. If GFR>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
8010|NCT00740363|Drug|placebo|No active sitagliptin treatment for 4 weeks
8011|NCT00740376|Device|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
8012|NCT00006006|Biological|recombinant interferon alfa|
8726|NCT00757133|Procedure|Laparotomy closure with mesh augmentation|Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a "Stoppa repair for incisional hernias"
8727|NCT00757159|Device|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
8728|NCT00757159|Device|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
8729|NCT00757172|Biological|panitumumab|
8730|NCT00757172|Drug|cisplatin|
8731|NCT00757172|Drug|docetaxel|
8732|NCT00006105|Procedure|adjuvant therapy|
8733|NCT00757172|Procedure|neoadjuvant therapy|
8734|NCT00757172|Procedure|therapeutic conventional surgery|
8735|NCT00757172|Radiation|radiation therapy|
8736|NCT00757185|Drug|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
8737|NCT00757185|Drug|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
8738|NCT00757198|Drug|remifentanil|remifentanil infusion
8739|NCT00757198|Drug|remifentanil|remifentanil infusion
8740|NCT00757211|Genetic|polymorphism analysis|
8741|NCT00757211|Other|laboratory biomarker analysis|
8742|NCT00757211|Other|questionnaire administration|
7761|NCT00005985|Biological|filgrastim|
7762|NCT00734695|Dietary Supplement|vitamin c|topical and systemic
7763|NCT00734695|Dietary Supplement|vitamin c|topical systemic
7764|NCT00734708|Drug|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
11678|NCT00784914|Drug|temsirolimus|Receive temsirolimus IV
11679|NCT00784914|Other|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
11680|NCT00784914|Other|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
11681|NCT00006324|Drug|Ethinyl estradiol/levonorgestrel|
11682|NCT00784927|Biological|rituximab|
11683|NCT00784927|Drug|cyclophosphamide|
11684|NCT00784927|Drug|dexamethasone|
11685|NCT00784927|Drug|lenalidomide|
11686|NCT00784940|Drug|Anastrozole|1mg, orally, once daily
11687|NCT00784940|Drug|Tamoxifen|20mg, orally, once daily
11688|NCT00784966|Drug|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
11689|NCT00784966|Drug|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
11690|NCT00787462|Drug|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
11691|NCT00787475|Other|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
11692|NCT00787488|Device|Hyperthermia|Every 3 weeks
11693|NCT00787501|Drug|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI < 2) and tolerability is adequate. Nonresponse at week 10 (CGI < 2) will be cause for medication switch or augmentation.
8267|NCT00737997|Other|Saline|10 ml saline alone
8268|NCT00738010|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
8269|NCT00738010|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
8270|NCT00738010|Behavioral|Control|Voluntary quadriceps muscle contractions.
8271|NCT00738023|Drug|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
8578|NCT00741286|Drug|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
8579|NCT00741312|Behavioral|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises.
8580|NCT00733707|Behavioral|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
8581|NCT00005979|Drug|fluorouracil|
8582|NCT00733720|Drug|Suboxone|4/1mg, 8/2mg 16/4mg
8583|NCT00733733|Drug|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
8584|NCT00733746|Drug|erlotinib hydrochloride|oral administration
8585|NCT00733746|Drug|gemcitabine hydrochloride|Intravenous administration
8586|NCT00733746|Procedure|therapeutic conventional surgery|
8587|NCT00733772|Dietary Supplement|flaxseed|30 grams/day of flaxseed for 12 weeks
8588|NCT00733772|Behavioral|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
8589|NCT00733785|Drug|Rosiglitazone XR|Rosiglitazone extended release formulation
8590|NCT00733798|Drug|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
8013|NCT00740376|Device|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
8014|NCT00740389|Drug|TMC125|
8015|NCT00740415|Biological|rituximab|Rituximab, 375 mg/m2 Intraveinous
8016|NCT00740415|Drug|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
8017|NCT00740415|Drug|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
8018|NCT00742664|Behavioral|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
8019|NCT00742664|Behavioral|Wait-list control|The subject will not receive active treatment during this interval.
8020|NCT00742677|Procedure|nutritional support|Given orally
8021|NCT00742690|Drug|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
8337|NCT00005986|Procedure|in vitro-treated peripheral blood stem cell transplantation|
8338|NCT00735605|Procedure|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
8339|NCT00735605|Other|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
8340|NCT00735618|Other|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
8341|NCT00735631|Device|SISO model-based predictive closed-loop system|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
8342|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
8343|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
7765|NCT00734708|Drug|Placebo|Control
7766|NCT00734721|Behavioral|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
7767|NCT00734734|Biological|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
7768|NCT00734747|Device|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
7769|NCT00734760|Behavioral|education|face-to-face education and counseling intervention
7770|NCT00734773|Biological|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
7771|NCT00734773|Drug|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
7772|NCT00005985|Drug|carmustine|
7773|NCT00734773|Drug|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
7774|NCT00734773|Drug|Motexafin gadolinium|Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).
For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.
During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter.
7775|NCT00734773|Drug|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
7776|NCT00734773|Drug|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
7777|NCT00734773|Radiation|Radiation therapy|Given at weeks 11 through 16.
7778|NCT00734786|Other|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
8084|NCT00737711|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
8085|NCT00005993|Drug|filgrastim|
8086|NCT00737724|Drug|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
8087|NCT00740415|Drug|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
11694|NCT00787501|Behavioral|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
11695|NCT00006346|Procedure|psychosocial assessment and care|
12304|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
12305|NCT00790829|Drug|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
12306|NCT00790842|Drug|Group A=30-60 CrCl (mL/min)|Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.
12307|NCT00790842|Drug|Group B=CrCL<30 mL/min not on dialysis|Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.
12308|NCT00790842|Drug|Group C=CrCL<30 mL/min and on dialysis|Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.
Dialysis includes hemodialysis or peritoneal dialysis. When lenalidomide and/or dexamethasone treatment occurs on a dialysis day, lenalidomide and/or dexamethasone must be taken after dialysis.
12309|NCT00790855|Drug|Bendamustine|Starting dose of 50 mg/m^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
12310|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
12311|NCT00793000|Drug|PF-04287881|1250 mg oral dose (prepared solution) given once
12312|NCT00793000|Drug|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
12313|NCT00793000|Drug|PF-04287881|1500 mg oral dose (prepared solution) given once
12314|NCT00793000|Drug|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
12315|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
12316|NCT00006373|Drug|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
12317|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
8591|NCT00733811|Drug|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
8592|NCT00005979|Drug|irinotecan hydrochloride|
8593|NCT00733811|Drug|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
8594|NCT00733824|Drug|AMD3100|
8595|NCT00733824|Drug|G-CSF|
8596|NCT00733824|Procedure|Apheresis|
8597|NCT00733837|Other|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
7628|NCT00736931|Drug|levetiracetam|500mg tablets
7629|NCT00739739|Drug|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
7630|NCT00006001|Drug|semaxanib|
7631|NCT00739739|Drug|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
7632|NCT00739752|Behavioral|Message Framing|Subjects receive 1 of 3 possible Framing Messages about HBV Vaccination: 1. Non-Framed (information only); 2. Loss-Framed (emphasizing risks on non-vaccination); and 3. Gain-Framed (emphasizing benefits of vaccination)
7633|NCT00739752|Behavioral|Intention|Subjects randomized to 1 of 2 intention conditions: 1. Not Asked Intention Question and 2. Asked Intention Question. The intention question asks subjects if they intend to accept free HBV vaccine, if offered.
7634|NCT00739752|Behavioral|Recommendation|Subjects randomized to 1 of 2 Recommendation Conditions: 1. Health care provider offers free HBV vaccine and 2. Health care provider recommends HBV vaccine
7635|NCT00739765|Behavioral|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
7636|NCT00739765|Behavioral|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
7637|NCT00739765|Behavioral|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
7638|NCT00739778|Other|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
7639|NCT00739778|Other|food vehicle blank|water blank
7640|NCT00739778|Other|food - sweetener, positive control|4.7% sucrose in water
8344|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
8345|NCT00735644|Biological|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
8346|NCT00735644|Biological|Hepatitis A vaccine|0.5 mL, Intramuscular
8347|NCT00735657|Device|needle|Peribulbar blockade with standard (25 mm) needle
8348|NCT00005986|Procedure|peripheral blood stem cell transplantation|
8349|NCT00735657|Device|needle|Peribulbar blockade with short (12.5 mm) needle
8350|NCT00735657|Procedure|Pars Plana Vitrectomy|Peribulbar block
8351|NCT00738075|Device|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
8352|NCT00738088|Drug|gliclazide|Gliclazide 80mg bd for 6 weeks
8353|NCT00738101|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
8354|NCT00738127|Procedure|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
8355|NCT00738140|Behavioral|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
8659|NCT00759746|Behavioral|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
8660|NCT00759759|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
8661|NCT00759759|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
8662|NCT00759772|Drug|Teriparatide|Teriparatide 20 mcg sc daily for 6 months
8663|NCT00006113|Radiation|Candida albicans skin test reagent|
8664|NCT00759772|Drug|Placebo|Placebo 20 mcg sc daily for 6 months
8088|NCT00740428|Procedure|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
8089|NCT00740441|Drug|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
8090|NCT00740454|Other|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
8091|NCT00740467|Biological|anti-thymocyte globulin|
8092|NCT00006006|Drug|thalidomide|
8093|NCT00740467|Drug|busulfan|
8094|NCT00740467|Drug|cyclophosphamide|
8095|NCT00740467|Drug|cyclosporine|
8096|NCT00740467|Drug|fludarabine phosphate|
8097|NCT00740467|Drug|mycophenolate mofetil|
8098|NCT00740467|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
8099|NCT00740493|Drug|warfarin|18 months of warfarin therapy
8100|NCT00740493|Drug|placebo of warfarin|18 months of placebo of warfarin therapy
8101|NCT00740506|Behavioral|Frequency of Intercourse|
8102|NCT00740519|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
8103|NCT00006007|Drug|gemcitabine hydrochloride|
8104|NCT00740532|Genetic|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
8105|NCT00740545|Drug|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
8106|NCT00740545|Drug|placebo|Women inject ourselves every days with placebo
8107|NCT00740558|Procedure|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
8415|NCT00733473|Drug|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
8416|NCT00733486|Device|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
12318|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
12319|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
12320|NCT00793000|Drug|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
12321|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
12337|NCT00786032|Device|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
12338|NCT00786045|Other|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
12339|NCT00006339|Drug|Ritonavir|
12340|NCT00786058|Drug|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
12341|NCT00786097|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
12342|NCT00786110|Drug|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
12343|NCT00786110|Drug|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
12344|NCT00786123|Dietary Supplement|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
12345|NCT00786123|Dietary Supplement|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
12346|NCT00786136|Drug|rosuvastatin|rosuvastatin
12347|NCT00786149|Other|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
12348|NCT00786149|Other|Varenicline without counseling|Brief advice, one time during initial session
12349|NCT00786162|Other|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
12350|NCT00000737|Drug|Dronabinol|
12351|NCT00006339|Drug|Hydroxyurea|
7641|NCT00006002|Drug|dexamethasone|
7642|NCT00739778|Other|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
7643|NCT00739791|Behavioral|exercise intervention|
7644|NCT00739791|Genetic|gene expression analysis|
7645|NCT00739791|Genetic|polymerase chain reaction|
7646|NCT00739791|Genetic|proteomic profiling|
7647|NCT00739791|Genetic|reverse transcriptase-polymerase chain reaction|
7648|NCT00739791|Other|laboratory biomarker analysis|
7649|NCT00739791|Other|medical chart review|
7650|NCT00739791|Other|questionnaire administration|
7941|NCT00742521|Procedure|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
7942|NCT00742521|Procedure|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
7943|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
7944|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
7945|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
7946|NCT00734916|Dietary Supplement|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
7947|NCT00734929|Drug|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
7948|NCT00734929|Drug|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
7949|NCT00005985|Drug|dexamethasone|
7950|NCT00734942|Other|support service|professional partners for communication
befriending with other families concerned
information and education (about illness, symptoms, first aid, caring)
free-time activities and time out
homework assistance
administrative advise
support for everyday life
7951|NCT00734955|Device|49-channel optical spectrometer|
8665|NCT00759785|Drug|Comparator: Dalotuzumab (MK0646)|Single dose of Dalotuzumab 20 mg/kg infused over 60 - 120 minutes.
8666|NCT00759798|Drug|Fludarabine|25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
8667|NCT00759798|Drug|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
8668|NCT00759798|Drug|Rituximab|375 mg/m2 given intravenously on Day 1 of Course 1
All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)
8669|NCT00759811|Drug|Methotrexate|Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
8670|NCT00759811|Drug|Placebo|Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
8671|NCT00762073|Drug|placebo|oral suspension matching budesonide
8672|NCT00762086|Device|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
8673|NCT00762086|Other|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
8674|NCT00762099|Drug|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
8675|NCT00762099|Drug|Placebo|Placebo/sugar tabs will look identical to active drug.
8676|NCT00762112|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
7708|NCT00736957|Drug|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
7709|NCT00736970|Drug|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
7710|NCT00736970|Drug|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
7711|NCT00736983|Drug|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
7712|NCT00736983|Drug|ciprofloxacin|12 weeks; daily 2 x 500mg
8417|NCT00735670|Drug|Venlafaxine HCI|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
8418|NCT00735670|Other|Placebo|Subjects will receive a placebo instead of drug for 6 months during the duration of treatment
8419|NCT00735683|Drug|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
8420|NCT00735683|Drug|Placebo|includes diet, physical activity, and lifestyle modification
8421|NCT00735696|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
8422|NCT00735696|Drug|Paclitaxel|200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
8423|NCT00735696|Drug|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
8424|NCT00735709|Drug|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
8425|NCT00005986|Procedure|radiation therapy|
8426|NCT00735709|Drug|Placebo|Vortioxetine placebo-matching capsules
8427|NCT00735722|Device|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
8428|NCT00735722|Drug|Best Medical Therapy|Best Medical Therapy according to local guidelines
8429|NCT00735735|Other|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
8430|NCT00735748|Drug|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
8431|NCT00735748|Drug|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
8432|NCT00735761|Drug|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
8433|NCT00735761|Drug|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
8434|NCT00735774|Drug|11C-ORM-13070|Single dose of i.v. solution
8743|NCT00006106|Drug|cisplatin|
12352|NCT00786162|Other|BP cuff at workplace|Provided BP cuff for communal use at the worksite
12353|NCT00788424|Drug|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
12354|NCT00788463|Drug|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
12355|NCT00788463|Drug|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
12356|NCT00788476|Other|Survey|Survey packets to adult (>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their "primary caregivers" i.e. guardians of survivors who are currently under age 18.
11395|NCT00746226|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10^9 CFU of a combination of L. acidophilus and B. lactis
11396|NCT00746226|Biological|Placebo|Microcrystalline cellulose
As capsule which could be opened
11397|NCT00746239|Drug|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
11398|NCT00746239|Drug|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
11399|NCT00746252|Drug|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
11400|NCT00746252|Drug|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
11401|NCT00006038|Drug|docetaxel|
11402|NCT00746265|Behavioral|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
11403|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
11404|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
11405|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
11406|NCT00746291|Other|6 min walk test, Step climbing|walking for 6 minute and climbing steps
11407|NCT00748891|Drug|Recentin (Cediranib)|30mg once daily, oral dose
11408|NCT00748904|Drug|Rifaximin|400 mg orally
7952|NCT00734968|Drug|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
7953|NCT00734968|Other|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
7954|NCT00734994|Device|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
7955|NCT00734994|Drug|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
7956|NCT00735007|Drug|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
7957|NCT00735020|Biological|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
7958|NCT00735020|Biological|Influenza Vaccine|1 dose of Influenza Vaccine
7959|NCT00735033|Other|Physiotherapy with Swiss Ball|
7960|NCT00005985|Drug|etoposide|
7961|NCT00735046|Behavioral|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
8272|NCT00005995|Drug|shark cartilage extract AE-941|
8273|NCT00738023|Drug|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
8274|NCT00738023|Drug|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
8275|NCT00738049|Drug|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
8276|NCT00738062|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
8277|NCT00738062|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
8278|NCT00740766|Behavioral|Food diary and behavioral model|The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.
The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.
All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study.
7713|NCT00000703|Drug|Dexamethasone|
7714|NCT00005988|Radiation|radiation therapy|
7715|NCT00736996|Drug|Pioglitazone|30 - 45mg tablet daily for 6 months
7716|NCT00736996|Drug|Placebo|Matching tablet daily for 6 months
7717|NCT00736996|Behavioral|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
7718|NCT00737035|Behavioral|Interactive Healthcare Communication Application|The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an "Ask an Expert" system staffed by researchers; and (6) personal stories of others dealing with IPH.
7719|NCT00737035|Behavioral|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
7720|NCT00737048|Drug|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
7721|NCT00737048|Drug|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
7722|NCT00739830|Drug|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
7723|NCT00739830|Drug|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
7724|NCT00739830|Drug|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
7725|NCT00739856|Procedure|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
8022|NCT00742690|Drug|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
8023|NCT00006019|Drug|azacitidine|
8024|NCT00742703|Other|Mineralized water|
8025|NCT00742703|Other|Low mineralized water|
8026|NCT00742716|Drug|CTA018 Injection|Comparison of different dosages of drug
8744|NCT00757224|Behavioral|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
8745|NCT00757237|Drug|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
8746|NCT00757237|Drug|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
8747|NCT00757250|Drug|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
8748|NCT00759824|Drug|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
8749|NCT00759837|Drug|Bosutinib|
8750|NCT00759850|Device|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
8751|NCT00006114|Drug|mitoxantrone hydrochloride|
8752|NCT00759863|Behavioral|Lifezig|Personalized Reminiscence Video
8753|NCT00759876|Drug|Ataluren|Oral powder in a sachet taken 3 times per day with dosing based on subject body weight. Doses are 20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner.
8754|NCT00759902|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
8755|NCT00759902|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
8756|NCT00759915|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
8757|NCT00759915|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
8758|NCT00759928|Drug|Erlotinib|150 mg once daily by mouth
8759|NCT00759928|Drug|Sorafenib|400 mg twice daily by mouth
8760|NCT00759941|Drug|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
11409|NCT00006048|Drug|gemcitabine hydrochloride|
11410|NCT00748904|Drug|Lactulose|20 grams titrate to 2-3 bowel movements in one day
11411|NCT00748930|Other|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
11412|NCT00748943|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
11413|NCT00748956|Drug|Low dose NPY|50nmol, administered intranasally
11414|NCT00748956|Drug|High dose NPY|100nmol administered intranasally
11415|NCT00748956|Drug|Placebo|placebo comparator (0nmol)) administered intranasally
11696|NCT00787527|Drug|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
11697|NCT00787527|Drug|Cyclophosphamide|750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
11698|NCT00787527|Drug|Doxorubicin|50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
11699|NCT00787527|Drug|Vincristine|1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
11700|NCT00787527|Drug|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
11701|NCT00787553|Drug|cefazolin|2.0 g, IV, 2 hours before surgery
11702|NCT00787553|Drug|tinidazole|2.0 g orally, 12 hours before surgery
11703|NCT00787553|Drug|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
11704|NCT00787566|Drug|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
11705|NCT00787579|Device|Bifocal spectacles|+1.50D bifocal spectacles
11706|NCT00006346|Procedure|quality-of-life assessment|
11707|NCT00787579|Device|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
11708|NCT00787605|Drug|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
8279|NCT00740779|Drug|Silodosin 8 mg|Silodosin 8 mg daily
8280|NCT00740779|Drug|Placebo|Placebo
8281|NCT00740779|Drug|Silodosin 4 mg|Silodosin 4 mg daily
8282|NCT00740792|Drug|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
8283|NCT00740792|Drug|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
8284|NCT00740792|Drug|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
8285|NCT00006010|Drug|docetaxel|
8286|NCT00740792|Drug|placebo|placebo one spray per nostril BID
8287|NCT00740805|Drug|Cyclophosphamide|Given IV
8288|NCT00740805|Drug|Doxorubicin Hydrochloride|Given IV
8289|NCT00740805|Other|Laboratory Biomarker Analysis|Correlative studies
8290|NCT00740805|Other|Pharmacological Study|Correlative studies
8291|NCT00740805|Drug|Veliparib|Given PO
8292|NCT00740818|Other|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
8598|NCT00733850|Drug|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
8599|NCT00733850|Drug|Gemcitabine|Intravenous repeating dose
8600|NCT00733863|Biological|Placebo|
8601|NCT00733863|Biological|CAD106|
8602|NCT00733876|Biological|Multipotent Stromal Cells|Post-operative administration of MSC
8603|NCT00005979|Drug|leucovorin calcium|
8604|NCT00733876|Biological|Administration of MSC|Dose escalation protocol
8605|NCT00735917|Other|pharmacogenomic studies|Optional correlative studies
8606|NCT00735917|Other|pharmacological study|Optional correlative studies
8027|NCT00742729|Behavioral|Arm 1|Educational small group session with free FOBT kit
8028|NCT00742729|Behavioral|Arm 2|Educational small group session with no FOBT kit
8029|NCT00742729|Behavioral|Arm 3|Educational small group session, exercise
8030|NCT00742742|Behavioral|healthy life style education|healthy life style education
8031|NCT00742755|Behavioral|Prospective intervention|Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
8032|NCT00742755|Other|Retrospective observation|Usual care
8033|NCT00742768|Dietary Supplement|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
8034|NCT00006019|Drug|sodium phenylbutyrate|
8035|NCT00742768|Dietary Supplement|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
8036|NCT00742781|Dietary Supplement|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
8037|NCT00742794|Other|Observation|Observation of sting frequency
8038|NCT00742807|Drug|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
8039|NCT00742807|Drug|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
8040|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for three days
8041|NCT00005985|Drug|mitoxantrone hydrochloride|
8042|NCT00735085|Drug|Placebo|SLV334 Placebo arm
8043|NCT00735098|Other|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
8044|NCT00735098|Other|strength training exercise|strength training exercise, 3 times per week for 8 weeks
8356|NCT00005996|Drug|cisplatin|
8357|NCT00738153|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
8358|NCT00738166|Other|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
8359|NCT00738166|Other|Diet (organic or conventional)|organic or conventional diet
8761|NCT00759941|Drug|Placebo eye drops|One drop three times a day in both eyes for 3 months
7779|NCT00734799|Behavioral|Sleep Intervention for PTSD (SIP).|Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's "rescripting" of reoccurring nightmares to decrease their associated affective distress.
7780|NCT00737048|Drug|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
7781|NCT00737048|Drug|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
7782|NCT00737061|Device|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
7783|NCT00005989|Drug|tipifarnib|
7784|NCT00737087|Device|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
7785|NCT00737100|Drug|Placebo Respimat|patient to receive placebo matching active drug once daily
7786|NCT00737100|Drug|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
7787|NCT00737100|Drug|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
7788|NCT00737113|Drug|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of ~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
7789|NCT00737126|Drug|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
7790|NCT00737126|Drug|Placebo|Administration of an oral placebo pill
7791|NCT00737139|Procedure|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
7792|NCT00737139|Procedure|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
7793|NCT00737152|Other|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
7794|NCT00005990|Drug|tipifarnib|
11709|NCT00787605|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
11710|NCT00789828|Drug|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
11711|NCT00789828|Drug|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
11712|NCT00789841|Device|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
11713|NCT00789854|Drug|Quetiapine XR|300 mg once daily (od)
11714|NCT00789854|Drug|Lithium carbonate|900 mg once daily (od)
11715|NCT00789854|Drug|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
11716|NCT00789867|Drug|pGM169/GL67A|Plasmid expressing the human CFTR gene complexed with cationic lipid 67 and helper lipids: 10 ml nebulised and 1 ml nasal administration (n=3) and 20 ml nebulised and 2 ml nasal (n=24)
11964|NCT00787917|Drug|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
11965|NCT00787917|Drug|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
11966|NCT00787917|Drug|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
11967|NCT00787930|Drug|Valproic Acid|Tablets, 250mg-3000mg
11968|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
11969|NCT00790257|Device|Encapsulated human islets in a "Monolayer Cellular Device"|The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based "Monolayer Cellular Device".
One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation.
11970|NCT00790270|Drug|Cyclobenzaprine|5 mg orally every 8 hours as needed
11971|NCT00790270|Drug|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
11972|NCT00790270|Drug|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
11973|NCT00790283|Device|PTCA with stent implantation|Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.
Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure.
11974|NCT00006363|Drug|etoposide|Given IV
8607|NCT00735917|Procedure|positron emission tomography|Optional correlative studies
8608|NCT00735917|Radiation|fludeoxyglucose F 18|Optional correlative studies
8609|NCT00735917|Other|laboratory biomarker analysis|Optional correlative studies
8610|NCT00735930|Drug|Alvocidib Hydrochloride|Given IV
8611|NCT00735930|Drug|Lenalidomide|Given PO
8612|NCT00735930|Other|Pharmacological Study|Correlative studies
8613|NCT00735930|Other|Laboratory Biomarker Analysis|Correlative studies
8614|NCT00005987|Drug|etoposide|
8615|NCT00735943|Other|No intervention|No intervention
8616|NCT00735956|Behavioral|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
8617|NCT00735969|Drug|Peginterferon|
8618|NCT00735969|Drug|Ribavirin|
8619|NCT00735995|Behavioral|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
8620|NCT00735995|Behavioral|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
8621|NCT00736008|Other|Observational|Data summary only
8622|NCT00736021|Drug|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
8623|NCT00736034|Dietary Supplement|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
7651|NCT00739791|Procedure|psychosocial assessment and care|
7652|NCT00006002|Drug|semaxanib|
7653|NCT00739791|Procedure|quality-of-life assessment|
7654|NCT00739791|Procedure|support group therapy|
7655|NCT00739791|Procedure|therapeutic dietary intervention|
8360|NCT00738179|Device|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
8361|NCT00738179|Other|Standard care|Standard care of cardiovascular risk factors
8362|NCT00738192|Drug|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
8363|NCT00738192|Drug|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
8364|NCT00738192|Drug|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
8365|NCT00738218|Other|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
8366|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
8367|NCT00005996|Drug|gemcitabine hydrochloride|
8368|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
8369|NCT00738257|Drug|Pamidronate|
8370|NCT00738296|Drug|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
8371|NCT00738296|Drug|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
8372|NCT00740870|Device|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
8373|NCT00740883|Drug|warfarin|18 months of warfarin therapy, once daily
8374|NCT00740883|Drug|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
8375|NCT00740896|Behavioral|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
8677|NCT00762125|Behavioral|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
8678|NCT00762125|Behavioral|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
7795|NCT00737165|Behavioral|Multimodal suicide prevention program|A community intervention of multimodal suicide prevention program includes following components:
Building support networks for suicide prevention and mental health promotion in public health system
Primary prevention of suicide and suicide related behaviors
Secondary prevention of suicide and suicide related behaviors
Tertiary prevention; after care for suicide survivors
Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders
Suicide prevention targeting for people with work-related problems
8108|NCT00740558|Procedure|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
8109|NCT00740571|Drug|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
8110|NCT00740571|Drug|pregabalin|Strategy in which patient starts with pregabalin
8111|NCT00740584|Drug|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
8112|NCT00740597|Genetic|gene expression analysis|
8113|NCT00740597|Genetic|polymerase chain reaction|
8114|NCT00006007|Drug|pemetrexed disodium|
8115|NCT00740597|Genetic|western blotting|
8116|NCT00732888|Drug|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
8117|NCT00732888|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
8118|NCT00732901|Drug|Escitalopram|20 mg daily for 5 weeks
8119|NCT00732901|Drug|Mirtazapine|45mg daily for 5 weeks
8120|NCT00732901|Drug|Placebo|daily for 5 weeks
8121|NCT00732914|Drug|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
8122|NCT00732914|Drug|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
8123|NCT00732927|Drug|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
8124|NCT00005977|Drug|vincristine sulfate|Given IV
8125|NCT00732927|Drug|aspirin|tablets, 100 mg for 3 months
8126|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
11975|NCT00790296|Drug|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
11976|NCT00790296|Drug|Placebo|Saline
11977|NCT00790309|Procedure|Weight loss surgery|Weight loss surgery
11978|NCT00790309|Procedure|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
11979|NCT00790322|Drug|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
11980|NCT00790322|Other|Placebo|Solution for oral use
11981|NCT00790335|Drug|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
11982|NCT00790374|Drug|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
11983|NCT00790374|Drug|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
11984|NCT00790374|Drug|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
11985|NCT00006363|Drug|valspodar|Given IV
11986|NCT00790387|Drug|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
12357|NCT00788502|Behavioral|Healing Touch|
12358|NCT00788502|Behavioral|Desensitization Therapy|
12359|NCT00788502|Behavioral|Standard Care|
12360|NCT00788515|Drug|Volinanserin (M100907)|2 mg tablets QD
12361|NCT00006351|Drug|gemcitabine hydrochloride|
12362|NCT00788515|Drug|Lormetazepam|1 mg tablets (overencapsulated) QD
12363|NCT00788528|Drug|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
12364|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
12365|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
12366|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
12367|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
7656|NCT00742261|Drug|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
7657|NCT00742274|Device|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
7658|NCT00742274|Other|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
7659|NCT00742287|Dietary Supplement|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
7660|NCT00742287|Dietary Supplement|Placebo|placebo
7661|NCT00742300|Procedure|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
7662|NCT00742313|Biological|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
7663|NCT00742326|Drug|Pioglitazone|45 mg/daily
7664|NCT00742339|Drug|Terlipressin plus albumin|The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
7665|NCT00742339|Drug|Midodrine plus octreotide plus human albumin|Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
7666|NCT00000708|Drug|Flucytosine|
7962|NCT00735046|Other|Control|Patients and proxies who are assigned to treatment as usual
7963|NCT00735059|Device|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, > 3 hours
8679|NCT00006124|Drug|celecoxib|Given orally
8680|NCT00762125|Behavioral|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
8681|NCT00762138|Device|AutoloGel System|The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:
Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease
8682|NCT00762151|Other|Negative Control (Regular Toothpaste)|Regular Toothpaste
8683|NCT00762151|Other|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
8684|NCT00762151|Drug|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
8685|NCT00762164|Drug|Vytorin|Vytorin 10/80 split into 4
8686|NCT00762164|Drug|Simvastatin|Simvastatin 20 milligrams
8687|NCT00762177|Drug|Fluoride|Brush twice a day for 14 days
8688|NCT00762177|Drug|Fluoride, Triclosan|Brush twice daily for 14 days
8689|NCT00762177|Drug|Stannous Fluoride|Brush twice daily for 14 days
8690|NCT00006124|Drug|placebo|Given orally
8691|NCT00762190|Drug|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
8692|NCT00762190|Drug|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
8693|NCT00762216|Device|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
8694|NCT00762229|Drug|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
8695|NCT00762229|Drug|Ezetimibe 5 mg|Ezetimibe 5 mg daily for 4 weeks, "formulated" as a 10 mg tablet split in half
8696|NCT00754767|Other|placebo|Given orally
8697|NCT00754780|Drug|Pirfenidone|Capsule 800 mg TID, oral
8127|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
8128|NCT00732953|Device|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
8129|NCT00732953|Device|Genous stent implantation|Genous stent implantation
8130|NCT00732966|Drug|losartan|with losartan 50 mg once daily for one month
8435|NCT00735787|Biological|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
8436|NCT00005987|Drug|carmustine|
8437|NCT00735787|Biological|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
8438|NCT00735800|Behavioral|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
8439|NCT00735800|Behavioral|Telephone Support|Supportive telephone counseling about caregiving
8440|NCT00735813|Device|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
8441|NCT00738296|Drug|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
8442|NCT00738322|Drug|AZD1305|Solution for iv infusion, single dose
8443|NCT00738322|Drug|Placebo|NaCl solution for iv infusion, single dose
8444|NCT00738335|Drug|erlotinib hydrochloride|
8445|NCT00738335|Other|immunoenzyme technique|
8446|NCT00738335|Other|laboratory biomarker analysis|
8447|NCT00005996|Drug|semaxanib|
8448|NCT00738335|Other|liquid chromatography|
8449|NCT00738335|Other|mass spectrometry|
8450|NCT00738335|Other|pharmacological study|
8451|NCT00738335|Radiation|stereotactic radiosurgery|
8452|NCT00738348|Drug|sivelstat|sivelstat sodiumhydrate
12368|NCT00788541|Other|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
12369|NCT00788554|Procedure|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
12370|NCT00788554|Procedure|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
12371|NCT00788567|Drug|mycophenolate mofetil|1
12372|NCT00000738|Drug|Zidovudine|
12373|NCT00006351|Drug|lonafarnib|
12374|NCT00788580|Drug|pazopanib hydrochloride|
12375|NCT00788580|Drug|temsirolimus|
12376|NCT00788580|Procedure|immunoenzyme technique|
12377|NCT00788580|Procedure|laboratory biomarker analysis|
12378|NCT00788580|Procedure|pharmacological study|
12379|NCT00788593|Drug|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
12380|NCT00790868|Drug|d-cycloserine|50mg
12381|NCT00006364|Drug|omacetaxine mepesuccinate|Given IV or SC
11416|NCT00748969|Drug|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
11417|NCT00748982|Drug|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
11418|NCT00748982|Drug|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
11419|NCT00749021|Drug|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
11420|NCT00006049|Drug|carboplatin|
11421|NCT00749021|Drug|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
11422|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
7964|NCT00735059|Device|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, > 3 hours
7965|NCT00735072|Drug|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
7966|NCT00735072|Drug|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
7967|NCT00735085|Drug|SLV334|1000mg SLV334 as a single dose
7968|NCT00735085|Drug|SLV334|1000mg SLV334 b.i.d. for one day
7969|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for one day
7970|NCT00005991|Drug|pegylated liposomal doxorubicin hydrochloride|
7971|NCT00737373|Drug|5-Fluorouracil|2600mg/m2 qd15
7972|NCT00737373|Drug|Oxaliplatin|85mg/m2 qd15
7973|NCT00737373|Drug|folinic acid|200mg/m2 qd15
7974|NCT00737399|Behavioral|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
7975|NCT00737412|Other|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
7976|NCT00737412|Other|Placebo|Matching capsules devoid of microorganisms
7977|NCT00737425|Device|PainShield|
7978|NCT00737425|Device|Sham PainShield|
7979|NCT00737438|Drug|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.
Patients with a good metabolic response (eg. > 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).
Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
7980|NCT00737451|Behavioral|blood sampling|blood sampling 10ml from the study subjects
7981|NCT00005992|Biological|PSA prostate cancer vaccine|
7726|NCT00739882|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
7727|NCT00739882|Drug|Placebo|Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
7728|NCT00739895|Procedure|Cardiac magnetic Resonance study|follow-up studies
7729|NCT00006003|Drug|semaxanib|Given IV
7730|NCT00739895|Procedure|Blood testing|Blood sample tested for myocardial biomarkers
7731|NCT00739908|Drug|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
7732|NCT00739908|Drug|Placebo|Six capsules administered three times a day for six weeks.
7733|NCT00739921|Procedure|Nasal swab under endoscopic guidance|After the application of pontocaine and neosynephrine spray, the following will be done:
A small sponge applicator will be used to swab the inside of your mouth for saliva collection
A blood sample (6cc - one tube) will be collected
A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)
Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you
You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well
The samples will be refrigerated and analyzed using PCR to detect and speciate fungus.
7734|NCT00739934|Drug|voriconazole (Vfend)|Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h
Notes:
If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.
Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.
(IV = Intravenous; POS = Powder for oral suspension)
7735|NCT00739947|Other|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
7736|NCT00739960|Drug|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
7737|NCT00739973|Drug|Placebo|
7738|NCT00739973|Drug|Aliskiren 150 mg tablet|
7739|NCT00739973|Drug|Aliskiren 300 mg tablet|
7740|NCT00006003|Other|laboratory biomarker analysis|Correlative studies
8453|NCT00738348|Drug|glucose|glucose
8454|NCT00738361|Drug|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
8455|NCT00738374|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
8456|NCT00738374|Drug|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
8457|NCT00738387|Drug|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
8458|NCT00005997|Drug|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
8762|NCT00006114|Drug|vinorelbine tartrate|
8763|NCT00759941|Drug|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
8764|NCT00759954|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
8765|NCT00759954|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
8766|NCT00759967|Procedure|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
8767|NCT00759967|Procedure|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
8768|NCT00759993|Drug|chromium piccolinate|1000mg tab
8769|NCT00759993|Drug|placebo for chromium piccolinate|
8770|NCT00762242|Procedure|blood sampling and brachial artery ultrasound|Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)
Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.
Following completion of blood sampling, an additional "resting" image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation.
8771|NCT00762255|Drug|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
8772|NCT00762255|Drug|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
8773|NCT00762255|Drug|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
11423|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
11424|NCT00749034|Biological|VPM1002|live vaccine
11425|NCT00749034|Biological|BCG|commercially available live vaccine BCG
11426|NCT00749047|Drug|Pioglitazone|15-45 mg/day
11427|NCT00749060|Other|conventional treatment|with our without brace
11428|NCT00749060|Procedure|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
11429|NCT00749060|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
11430|NCT00749073|Device|Minimally Invasive Lumbar Decompression (MILD™)|The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
11431|NCT00006049|Drug|gefitinib|
11432|NCT00751777|Biological|Placebo|Travelers' Diarrhea Vaccine System
11433|NCT00751790|Drug|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
11434|NCT00751803|Drug|BI 44370 TA Low Dose|
11435|NCT00751803|Drug|Eletriptan|
11436|NCT00751803|Drug|Placebo|
11717|NCT00789880|Drug|Vitamin D3|Administration of oral vitamin D3 at 4000IU
11718|NCT00789880|Drug|Placebo|Administration of oral Vitamin D3 placebo
11719|NCT00789893|Device|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis & assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st & 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, & the 2nd will be one month ± 2 weeks from last day of radiation.
11720|NCT00006360|Drug|radioprotection|
8293|NCT00740818|Procedure|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
8294|NCT00740818|Procedure|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
8295|NCT00740831|Drug|PGL4001|tablets
8296|NCT00000706|Drug|Zidovudine|
8297|NCT00006010|Drug|gemcitabine hydrochloride|
8298|NCT00740831|Drug|leuprorelin|solution for injection
8299|NCT00740844|Device|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
8300|NCT00740857|Drug|placebo|2 placebo gels capsules delivered as a single dose.
8301|NCT00740857|Drug|ibuprofen Formulation 1|2 marketed ibuprofen gels
8302|NCT00740857|Drug|ibuprofen Formulation 2|2 marketed ibuprofen gels
8303|NCT00733148|Drug|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
8304|NCT00733161|Other|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
8305|NCT00733161|Other|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
8306|NCT00733174|Drug|Rosiglitazone|tablet
8307|NCT00733174|Drug|Placebo|
8308|NCT00733187|Drug|ABT-869|0.25 mg/kg
8309|NCT00733200|Procedure|Minor or Major Liver Resection|
8310|NCT00005978|Drug|melphalan|
8311|NCT00733226|Drug|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
8312|NCT00733226|Drug|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
7741|NCT00742534|Drug|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
8045|NCT00735098|Other|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
8046|NCT00735098|Other|Control group|8 week control group
8047|NCT00735111|Other|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
8048|NCT00735124|Drug|Gabapentin|1200 mg single dose gabapentin
8049|NCT00735124|Other|Sham or placebo|Injection of placebo/sham
8050|NCT00735137|Device|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
8051|NCT00735150|Behavioral|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
8052|NCT00005985|Procedure|peripheral blood stem cell transplantation|
8053|NCT00735163|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
8054|NCT00735176|Procedure|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
8055|NCT00735176|Procedure|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
8056|NCT00735189|Other|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
8057|NCT00735189|Other|usual care|patient receives usual anticoagulation care from their regular primary care physician
8058|NCT00735228|Device|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
8059|NCT00735241|Device|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
8060|NCT00735241|Drug|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
8774|NCT00762268|Drug|SAMe|SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day "rest-period", before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.
8775|NCT00006125|Drug|doxorubicin hydrochloride|
8776|NCT00762268|Drug|Placebo|
8777|NCT00762281|Device|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
8778|NCT00762307|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
8779|NCT00762320|Drug|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
8780|NCT00762346|Drug|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
11945|NCT00785473|Dietary Supplement|calcium carbonate|calcium carbonate 500 mg daily for 2 years
11946|NCT00006329|Procedure|Minimally invasive radioguided parathyroidectomy|
11947|NCT00785486|Drug|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
11948|NCT00787800|Device|Single Chamber ICD|Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.
VT/VF detection and therapies with discrimination criteria for single chamber device.
11949|NCT00787813|Drug|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
11950|NCT00787813|Drug|Placebo|
11951|NCT00006348|Drug|ondansetron|
11952|NCT00787826|Biological|Live Francisella Tularensis Vaccine|Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive "take" reaction and a MA titer of ≥ 1:20.
11953|NCT00787839|Other|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
11954|NCT00787839|Other|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
11721|NCT00789919|Procedure|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
11722|NCT00789932|Behavioral|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
11723|NCT00789932|Behavioral|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
11724|NCT00789945|Other|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
11725|NCT00789945|Other|Study Arm B|Study Arm B will include participants with type 1 diabetes which will utilize "Timing" to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor.
11726|NCT00789958|Drug|capecitabine|Adjuvant chemotherapy: 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle
Chemoradiotherapy: 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT
11727|NCT00789958|Drug|gemcitabine hydrochloride|1000 mg/m^2, IV, Days 1 & 8 of each cycle
11728|NCT00789958|Radiation|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
11729|NCT00789958|Radiation|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
11730|NCT00792441|Device|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
11731|NCT00792454|Behavioral|exercise training|Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.
Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.
Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet.
11987|NCT00790387|Drug|Tirofiban|
11988|NCT00790387|Drug|unfractionated heparin|
11989|NCT00790400|Drug|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
11990|NCT00790400|Drug|Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
11991|NCT00790413|Drug|iodine I 131 metaiodobenzylguanidine|
8313|NCT00733239|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
8314|NCT00733252|Procedure|bronchoscopic and lung imaging studies|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
8624|NCT00736047|Biological|NIC002|
8625|NCT00005987|Drug|filgrastim|
8626|NCT00736047|Biological|Placebo|
8627|NCT00736060|Other|Observational|Summary of clinical and laboratory data
8628|NCT00736073|Drug|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
8629|NCT00736073|Drug|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
8630|NCT00736086|Device|Vessel Closure (StarClose™)|
8631|NCT00736099|Drug|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
8632|NCT00736099|Drug|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
8633|NCT00736112|Other|Food Allergy Diagnosis|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
8634|NCT00738621|Drug|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
8635|NCT00738634|Behavioral|Self-motivated physical activity|Components:
Physical activity education in the form of a brief booklet (double sided A4 page).
Physical activity motivation tips (one sided A4 page).
Pedometer
Monitoring chart
Online presentation of common obstacles and ways to overcome these obstacles
8636|NCT00738634|Behavioral|Nutrition|Components:
Nutrition education booklet (Double-sided A4 page)
Nutrition motivation tips (single-sided A4 page)
Nutrition monitoring chart
Online presentation of common obstacles and ways to overcome these obstacles
8637|NCT00738634|Behavioral|Physical activity researcher contact|Behavioral: Self-motivated physical activity
Components:
Physical activity education in the form of a brief booklet (double sided A4 page).
Physical activity motivation tips (one sided A4 page).
Pedometer
Monitoring chart
Online presentation of common obstacles and ways to overcome these obstacles
8638|NCT00738647|Procedure|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
8061|NCT00735241|Drug|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
8062|NCT00735241|Drug|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
8063|NCT00005985|Radiation|radiation therapy|
8064|NCT00735254|Device|pulsed dye laser (the VBEAM)|
8376|NCT00740896|Behavioral|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
8377|NCT00006011|Drug|Doxorubicin Hydrochloride|Given IV
8378|NCT00740909|Behavioral|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
8379|NCT00740922|Drug|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
8380|NCT00740935|Biological|Rotateq vaccine|Vaccination against rotavirus
Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose.
8381|NCT00740948|Drug|Rituximab (mabthera) Injection|2 * 1g of Rituximab at the 1st day and at the 14th day.
8382|NCT00740948|Drug|Placebo: NaCl 0.9% or Glucose 5%|2* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
8383|NCT00740961|Behavioral|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
8384|NCT00740961|Drug|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
8385|NCT00740961|Other|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
8386|NCT00740961|Other|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
8387|NCT00740961|Other|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
8388|NCT00006011|Drug|Cisplatin|Given IV
8389|NCT00740961|Procedure|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
11955|NCT00787852|Drug|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43
Dasatinib is to be taken 1x daily
50 mg daily 100 mg daily
70 mg daily 100 mg daily
100 mg daily 100 mg daily
Maintenance x 2 years*
11956|NCT00787852|Drug|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36
Dasatinib is to be taken 1x daily
50 mg daily 100 mg daily
70 mg daily 100 mg daily
100 mg daily 100 mg daily Maintenance x 2 years*
11957|NCT00787878|Drug|somatropin|SGA previously treated with Norditropin®
11958|NCT00787878|Drug|No treatment given|Untreated SGA
11959|NCT00787878|Drug|No treatment given|AGA (Average gestational age)
11960|NCT00787891|Drug|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
11961|NCT00787891|Drug|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
11962|NCT00000738|Drug|Nimodipine|
11963|NCT00006348|Other|placebo|
12262|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
12263|NCT00006350|Drug|mycophenolate mofetil|
12264|NCT00788294|Biological|tanezumab|Drug solution given intravenously only once at dose of 10 mg
12265|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
12266|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
12267|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
12268|NCT00788307|Biological|Ad5-CMV-NIS|
12269|NCT00788307|Drug|liothyronine sodium|
12270|NCT00788307|Genetic|reverse transcriptase-polymerase chain reaction|
12271|NCT00788307|Other|laboratory biomarker analysis|
12272|NCT00788307|Radiation|iodine I 131|
11992|NCT00790413|Drug|Fludarabine|
11993|NCT00790413|Drug|Thiotepa|
11994|NCT00790413|Procedure|T-cell depletion|
11995|NCT00790413|Procedure|Haploidentical stem cell transplantation|
11996|NCT00006363|Biological|filgrastim|Given SC
11997|NCT00792948|Drug|Dexamethasone|Given IV or PO
11998|NCT00006373|Drug|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
11999|NCT00792948|Drug|Doxorubicin Hydrochloride|Given IV
12000|NCT00792948|Drug|Etoposide|Given IV
12001|NCT00792948|Biological|Filgrastim|Given SC
12002|NCT00792948|Other|Laboratory Biomarker Analysis|Correlative studies
12003|NCT00792948|Drug|Leucovorin Calcium|Given IV
12004|NCT00792948|Drug|Methotrexate|Given IV or IT
12005|NCT00792948|Drug|Methylprednisolone|Given IV
12006|NCT00792948|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
12007|NCT00792948|Drug|Prednisone|Given PO
12008|NCT00792948|Drug|Sirolimus|Given PO
12009|NCT00000193|Drug|Gamma hydroxybutyric|
12010|NCT00000742|Drug|Didanosine|
12011|NCT00006373|Drug|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
12012|NCT00792948|Drug|Tacrolimus|Given IV
12013|NCT00792948|Radiation|Total-Body Irradiation|Undergo TBI
12382|NCT00790868|Drug|placebo|50mg
12383|NCT00790881|Drug|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
8639|NCT00738660|Drug|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
8640|NCT00738673|Drug|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
8641|NCT00738686|Device|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
8642|NCT00738699|Drug|MORAb-003 (farletuzumab)|2.5mg/kg IV day 1 weeks 1-12 (cycle 1); day 1 weeks 1-3 with week 4 as rest week for subsequent cycles
8643|NCT00005998|Drug|dexamethasone|
8644|NCT00738699|Drug|0.9% Saline|2.5mg/kg IV day 1 weeks 1-12 (cycle 1); day 1 weeks 1-3 with week 4 as rest week for subsequent cycles
7667|NCT00006016|Drug|doxorubicin hydrochloride|Given transarterially (chemoembolization)
7668|NCT00742365|Device|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
7669|NCT00742365|Device|Red light placebo|One hour of exposure to red light.
7670|NCT00742391|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
7671|NCT00742391|Drug|Vehicle gel|two day treatment
7672|NCT00742404|Drug|bortezomib|
7673|NCT00742404|Drug|dexamethasone|
7674|NCT00742404|Drug|pegylated liposomal doxorubicin hydrochloride|
7675|NCT00734539|Drug|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
7676|NCT00734552|Dietary Supplement|α-Keto Acid with low protein diet|Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.
Low Protein Diet: Diet contain protein 0.8g/kg/d.
7677|NCT00005984|Procedure|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
7678|NCT00734552|Dietary Supplement|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
7679|NCT00734565|Biological|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
7680|NCT00734578|Drug|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
7681|NCT00734578|Drug|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
8390|NCT00740961|Procedure|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
8391|NCT00740987|Device|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
8392|NCT00741000|Procedure|Cervical Stairstep|Cervical low force mobilization procedure.
8393|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
8698|NCT00754793|Drug|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
8699|NCT00754793|Drug|placebo|inactive comparator; titrated as per protocol over 12 weeks
8700|NCT00754819|Drug|Colchicine|1mg once daily
8701|NCT00754819|Drug|Placebo|1 capsule daily
8702|NCT00754832|Drug|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
8703|NCT00754832|Drug|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
8704|NCT00754845|Drug|letrozole|Given orally
8705|NCT00754845|Other|placebo|Given orally
8706|NCT00006090|Drug|arsenic trioxide|
8707|NCT00754858|Drug|belotecan hydrochloride|
8708|NCT00754858|Drug|cisplatin|
8709|NCT00754871|Drug|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
8710|NCT00754871|Drug|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
8711|NCT00754871|Drug|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
8712|NCT00754871|Drug|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
8713|NCT00754884|Drug|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
12273|NCT00788320|Drug|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
12274|NCT00006350|Drug|tacrolimus|
12275|NCT00788320|Drug|Placebo|Placebo three times a week for 8 weeks
12276|NCT00788333|Drug|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
12277|NCT00788333|Drug|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
12278|NCT00788346|Behavioral|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
12279|NCT00788346|Behavioral|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
12280|NCT00788372|Drug|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
12281|NCT00788385|Device|ShuntCheck test|
12282|NCT00788398|Procedure|Saline Solution|Irrigation with Saline
12283|NCT00788398|Procedure|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
12624|NCT00786565|Device|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
12625|NCT00786630|Behavioral|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
12626|NCT00786630|Behavioral|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
12627|NCT00786643|Drug|5-Fluorouracil|5-FU bolus was administered at 400mg/m^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
12628|NCT00786643|Drug|Leucovorin (LV)|Leucovorin 200mg/m^2 was administered over 2 hours on day 1 and day 2 of each cycle.
12629|NCT00786643|Drug|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
14595|NCT00808808|Other|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
14596|NCT00808808|Biological|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
14597|NCT00808834|Device|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
14598|NCT00006487|Drug|etoposide|During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion
During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion.
14599|NCT00810927|Procedure|Measurement of intraocular pressure|
14600|NCT00810940|Drug|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP < 20 mmHg, then IV 100 ml same schedule for 24 hours
14601|NCT00810940|Drug|mannitol|mannitol plus standard treatment
14602|NCT00810953|Drug|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
14603|NCT00810966|Drug|cyclophosphamide|
14604|NCT00810966|Drug|veliparib|
14605|NCT00810966|Other|immunologic technique|
14606|NCT00006591|Drug|Amprenavir|
14607|NCT00810966|Other|laboratory biomarker analysis|
14960|NCT00807157|Dietary Supplement|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
14961|NCT00807170|Drug|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
14962|NCT00809250|Biological|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
14963|NCT00000753|Drug|Zalcitabine|
14964|NCT00006493|Drug|Rosiglitazone|
14965|NCT00809263|Drug|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
14966|NCT00809276|Drug|Busulfan, Fludarabine, Cytoxan|Busulfan once a day for 4 days
Fludarabine once a day for 4 days
Bone marrow transplant
Cytoxan two doses
14967|NCT00809289|Drug|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
13940|NCT00781066|Procedure|No controlled cord traction|Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).
No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).
After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity.
13941|NCT00781079|Behavioral|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
13942|NCT00781092|Other|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
13943|NCT00781092|Other|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
13944|NCT00781105|Drug|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
12960|NCT00791999|Drug|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
12961|NCT00791999|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
12962|NCT00791999|Drug|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
12963|NCT00791999|Drug|Placebo of CDP870|given every 2 weeks until Week22 (SC)
12964|NCT00792012|Radiation|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
12965|NCT00792012|Drug|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
12966|NCT00792025|Drug|sunitinib malate|
12967|NCT00006367|Procedure|peripheral blood stem cell transplantation|
12968|NCT00792051|Biological|Inactivated influenza vaccine|0.5ml intramuscular single dose
12969|NCT00792051|Biological|Saline|0.5ml intramuscular, one dose
12970|NCT00792077|Drug|Lenalidomide|5 mg daily for 56 days.
12971|NCT00792090|Other|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
12972|NCT00792090|Other|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
12973|NCT00792103|Drug|NP101|NP101 study patch 4 hour application
15027|NCT00006479|Drug|fluorouracil|
15028|NCT00807170|Drug|ZD6474|200 mg as a once daily oral dose, 21 days
15029|NCT00807170|Drug|ZD6474|300 mg as a once daily oral dose, 21 days
15030|NCT00807183|Other|woodstove|installation of new EPA-certified woodstove
15031|NCT00807183|Other|inactive air filter|air filter units without filter in place
15032|NCT00807183|Other|Active air filter|air filter units correctly operating
15033|NCT00807196|Drug|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
15034|NCT00807196|Drug|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
15035|NCT00807196|Drug|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
15036|NCT00807196|Drug|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
15037|NCT00807196|Other|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
15038|NCT00000195|Drug|Naltrexone|
15039|NCT00000752|Drug|Beclomethasone dipropionate|
15040|NCT00006479|Drug|leucovorin calcium|
14085|NCT00775931|Drug|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
14086|NCT00775931|Radiation|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
14087|NCT00775931|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
14088|NCT00775931|Drug|Busulfan|patients<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
14089|NCT00775931|Drug|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
14090|NCT00775931|Procedure|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
14455|NCT00776607|Drug|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
14456|NCT00776620|Drug|Glimepiride 1mg Tablets|
14457|NCT00776633|Drug|6 weeks|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
14458|NCT00006241|Procedure|in vitro-treated peripheral blood stem cell transplantation|
14459|NCT00776633|Drug|6 months|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
14460|NCT00776646|Drug|hydrochlorothiazide 50 mg tablet|
14461|NCT00776659|Other|Aromasin|Non-Interventional study design.
14462|NCT00776672|Drug|Fosinopril 40mg Tablets|
14463|NCT00776685|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
14464|NCT00776698|Drug|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
14465|NCT00776698|Drug|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
14466|NCT00776698|Drug|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
14467|NCT00779129|Drug|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
14468|NCT00779129|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
14469|NCT00779142|Drug|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
14470|NCT00779155|Device|The Resonator|active magnetic field therapy
14471|NCT00779155|Device|The Resonator control|inactive magnetic field therapy with placebo fields
14751|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
14752|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
15104|NCT00805129|Drug|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
15105|NCT00805142|Drug|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
15106|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
15107|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
15108|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
15109|NCT00805168|Drug|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
15110|NCT00000752|Drug|Pseudoephedrine hydrochloride|
15111|NCT00006468|Drug|leucovorin calcium|
15112|NCT00805168|Drug|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
15113|NCT00805194|Drug|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
15114|NCT00805194|Drug|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
15115|NCT00805207|Drug|Progesterone|Micronized progesterone, 100 mg/d vaginally, 14 days followed by 14 days of placebo. Repeat this cycle 3 times.
15116|NCT00805207|Drug|testosterone|Testosterone gel 1250 ug/d, 21 days
15117|NCT00805207|Drug|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily, 21 days
15118|NCT00805207|Device|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks
15119|NCT00805207|Drug|Estrogens|Estrogen treatment (100 ug Estradiol daily) administered 14 days followed by 14 days without treatment. Repeat this cycle 3 times.
12974|NCT00792116|Behavioral|Gum Chewing|
12975|NCT00792129|Device|The Atavi System|The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.
The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used.
12976|NCT00792142|Drug|bortezomib|Given IV
12977|NCT00792142|Drug|dexamethasone|Given orally
12978|NCT00006368|Radiation|yttrium Y 90-edotreotide|
12979|NCT00792142|Drug|melphalan|Given IV
12980|NCT00792142|Drug|thalidomide|Given orally
12981|NCT00792142|Genetic|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
12982|NCT00792142|Genetic|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
13281|NCT00779649|Other|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.
Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed
13282|NCT00779675|Biological|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
13283|NCT00779688|Device|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
13284|NCT00779701|Drug|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
13285|NCT00779714|Drug|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
13286|NCT00006252|Drug|G-CSF|5 ug/kg/day subQ injection until ANC > 1000/uL for 3 days beginning Day 5
13287|NCT00779714|Drug|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
13288|NCT00779714|Drug|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
14091|NCT00778388|Biological|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
14092|NCT00778388|Drug|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
14093|NCT00778401|Drug|Gabapentin tablets 800 mg|
14094|NCT00778414|Drug|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
14095|NCT00778427|Drug|metformin hydrochloride 1000 mg tablets|
14096|NCT00778453|Other|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
14097|NCT00778453|Other|Hospital-based BIT|bilateral symmetric, repetitive arm training
14098|NCT00778453|Other|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
14099|NCT00778453|Other|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
14100|NCT00006249|Procedure|adjuvant therapy|
14101|NCT00778453|Other|Home-based BAT|bilateral symmetric, repetitive arm training
14102|NCT00778453|Other|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
14390|NCT00779051|Drug|Zolpidem 10mg tablets|
14391|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
14392|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
14393|NCT00779090|Procedure|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
14394|NCT00000731|Drug|Zidovudine|
14395|NCT00006251|Drug|cyclosporine|Given PO
14396|NCT00779103|Drug|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
14732|NCT00804622|Drug|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
14733|NCT00804622|Drug|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
14734|NCT00804648|Drug|Timolol Maleate in Sorbate|0.5%
14735|NCT00006465|Drug|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
14736|NCT00804648|Drug|Timolol hemihydrate|0.5%
14737|NCT00804648|Drug|Timolol maleate gel forming solution|0.5%
14738|NCT00804661|Device|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
14739|NCT00804674|Drug|bupivacain|
14740|NCT00804674|Drug|placebo|
14741|NCT00804687|Other|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
14742|NCT00804687|Drug|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
14743|NCT00804687|Drug|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
14744|NCT00804700|Behavioral|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
14745|NCT00804713|Drug|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
14746|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
14747|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
14748|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
14749|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
14750|NCT00006477|Dietary Supplement|mistletoe extract|
15120|NCT00805220|Other|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
15121|NCT00805233|Drug|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
15122|NCT00006468|Drug|oxaliplatin|
14166|NCT00775957|Procedure|FLT-PET scan|imaging scan
14167|NCT00775957|Procedure|FDG-PET scan|imaging scan
14168|NCT00775970|Behavioral|walking activity|
14169|NCT00775983|Device|laminaria|place device in cervix for dilation
14170|NCT00775983|Device|Dilapan-S|Place in cervix for dilation.
14171|NCT00775996|Drug|Clorazepate Dipotassium 15mg Tablets|
14172|NCT00776009|Drug|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
14173|NCT00776009|Drug|Placebo|Placebo Comparator
14174|NCT00776022|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
14175|NCT00006239|Drug|sodium phenylbutyrate|
14176|NCT00776035|Procedure|PET (positron Emission Tomography)|this is a diagnostic scan that requires the injection of radioactive tracers into an IV placed in the arm.
14177|NCT00776035|Procedure|Echocardiogram|an ultrasound of the heart
14178|NCT00776035|Procedure|VO2 peak test|walking on a treadmill during which you will breath in and out through a tube
14179|NCT00776035|Procedure|Body composition Study|a scan of your entire body measuring Body Mass Index, fat percentage etc...
14180|NCT00776035|Radiation|15O water|radioactive tracer used to study blood flow during the PET scan
14181|NCT00776035|Radiation|11C Acetate|radioactive tracer that helps study heart metabolism
14182|NCT00776035|Radiation|11C Palmitate|radioactive tracer used to study fatty acid usage in the heart
14183|NCT00776035|Radiation|11C Glucose|radioactive tracer usde to study glucose usage in the heart
13289|NCT00779727|Procedure|Placement of drainages|
13290|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
13291|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
13292|NCT00779753|Dietary Supplement|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
13293|NCT00779766|Biological|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
13294|NCT00779766|Biological|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
13295|NCT00779779|Biological|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
13596|NCT00783263|Drug|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
13597|NCT00774852|Drug|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
13598|NCT00774852|Drug|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
13599|NCT00774865|Procedure|MIBI and CTA|Rest and Stress MIBI and CT Angiography
13600|NCT00774878|Drug|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
13601|NCT00774878|Drug|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
13602|NCT00774904|Drug|Losartan|Angiotensin II Type 1 Receptor Blockers
13603|NCT00774917|Device|Numen|Numen Co-Cr coronary stent implant
13604|NCT00006233|Drug|fludarabine phosphate|
13605|NCT00774930|Drug|Somatuline Depot (lanreotide)|subcutaneous injection, 120 mg, q28d
13606|NCT00774930|Drug|placebo|inactive substance
14397|NCT00779116|Drug|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
14398|NCT00779116|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
14399|NCT00781820|Drug|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
14400|NCT00781833|Device|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
14401|NCT00781846|Drug|ridaforolimus|oral tablets, daily for 5 days/week
14402|NCT00781846|Drug|bevacizumab|IV infusion
14403|NCT00006260|Drug|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
14404|NCT00781859|Drug|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
14405|NCT00781859|Drug|Placebo|Placebo intravitreal injection
14406|NCT00781872|Biological|injection of autologous stem cells|60 milion cells intrathecally and 20 milion intravenously
14407|NCT00781885|Drug|Beraprost sodium modified release|Tablets 60mcg
14408|NCT00781898|Drug|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
14409|NCT00781898|Other|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
14410|NCT00781911|Biological|IMC-A12 (cixutumumab)|Patients will receive intravenous (I.V.) IMC-A12 (cixutumumab) 10 mg/kg over 1 hour every 2 weeks. ). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
14411|NCT00781911|Drug|depot octreotide|Patients must be receiving depot octreotide at the time of enrolling into the study.Patients on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
14674|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
14675|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
14676|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
14677|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
14859|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
14860|NCT00809133|Drug|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
14861|NCT00006489|Drug|Naltrexone|Daily dosing 100 mg for 24 weeks
14862|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
14863|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
14864|NCT00809146|Drug|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
14865|NCT00809146|Drug|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
14866|NCT00809159|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
14867|NCT00809159|Drug|Placebo|Placebo to AIN457
14868|NCT00809172|Drug|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
14892|NCT00811408|Radiation|brachytherapy|
14893|NCT00811408|Radiation|radiation therapy|
14894|NCT00811421|Drug|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
14895|NCT00811421|Drug|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
14896|NCT00006630|Drug|Vaccinia Immune Globulin (Human)|
14897|NCT00811421|Drug|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
14898|NCT00811421|Drug|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
14899|NCT00811421|Drug|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
14900|NCT00811434|Drug|Lactulose|1.5cc/kg/day po for three months
14901|NCT00811434|Drug|placebo|1.5 ml sugar water/kg day for three months
14902|NCT00811447|Drug|5-fluorouracil|600 mg/m²/day intravenous
14184|NCT00776074|Drug|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
14185|NCT00776074|Drug|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
14186|NCT00006239|Drug|tretinoin|
14187|NCT00776087|Device|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
14188|NCT00776087|Device|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
14189|NCT00778557|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
14472|NCT00779168|Drug|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
14473|NCT00779168|Other|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
14474|NCT00006251|Drug|mycophenolate mofetil|Given PO
14475|NCT00779168|Other|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
14476|NCT00779168|Other|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
14477|NCT00779168|Other|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
14478|NCT00779168|Other|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
14479|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a high total daily dose
14480|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
14481|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a low total daily dose
14482|NCT00779181|Drug|Placebo|Placebo taken three times a day
14483|NCT00779194|Drug|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
14968|NCT00809289|Drug|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
14969|NCT00809289|Drug|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
14970|NCT00809302|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
14971|NCT00809315|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
14972|NCT00809315|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
14973|NCT00809328|Drug|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
14974|NCT00809341|Drug|R-CHOP, R-CHOEP, R-EPOCH|Based on the PET-CT scan results patients will complete standard chemotherapy consisting of R-CHOP (or equivalent anthracycline-containing regimen (e.g. R-CHOEP, R-EPOCH)
14975|NCT00006495|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
14976|NCT00809341|Drug|R-ICE, Cyclophosphamide|Two cycles of R-ICE, followed by high dose cyclophosphamide and Rituximab
14977|NCT00809354|Drug|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
14978|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
14979|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
14980|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
14028|NCT00781196|Drug|placebo|capsule, once a day
14029|NCT00781209|Procedure|Irradiation plus Stereotactic Radiosurgery|Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.
Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:
Maximum Tumor Diameter:<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy.
14030|NCT00781248|Device|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
14031|NCT00781261|Drug|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
14032|NCT00781261|Drug|Placebo|Subjects in the control group will receive a placebo drug for a similar period
14033|NCT00781274|Drug|MP-424|750 mg every 8 hours for 12 weeks
14678|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
14679|NCT00808834|Device|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
14680|NCT00808860|Dietary Supplement|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
14681|NCT00808860|Dietary Supplement|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
14682|NCT00808873|Other|socio-educational intervention|brief mental health education and 6 follow-up visits
14683|NCT00808899|Drug|Temsirolimus|Temsirolimus
14684|NCT00808899|Drug|Irinotecan|Irinotecan
14685|NCT00808899|Procedure|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
14686|NCT00808899|Drug|Cyclophosphamide|Cyclophosphamide
14687|NCT00808899|Drug|Doxorubicin|Doxorubicin
14688|NCT00808899|Drug|Etoposide|Etoposide
14689|NCT00006487|Drug|tirapazamine|During induction:
Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion
Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion
During consolidation:
330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion.
14690|NCT00808899|Drug|Cisplatin|Cisplatin
14691|NCT00808899|Drug|Topotecan|Topotecan
14692|NCT00808899|Procedure|PBSC|Peripheral Blood Stem Cell Harvest
14693|NCT00808899|Radiation|Radiation Therapy|Radiation Therapy
14694|NCT00808899|Drug|13-cis-retinoic acid|13-cis-retinoic acid
14695|NCT00808912|Drug|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
14696|NCT00808912|Other|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
15041|NCT00807209|Drug|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
15042|NCT00807209|Drug|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
14903|NCT00811447|Drug|Cisplatin|60 mg/m² or 75 mg/m² intravenous
14904|NCT00811447|Drug|Docetaxel|60 mg/m² intravenous
14905|NCT00811460|Drug|Placebo|sc for 4 days
14906|NCT00811460|Drug|taspoglutide|300micrograms/day sc for 2 days
14907|NCT00006656|Drug|carmustine in ethanol|
14908|NCT00811460|Drug|taspoglutide|800 micrograms/day sc for 2 days
14909|NCT00811473|Drug|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
14910|NCT00811473|Drug|Placebo|Oral treatment once daily in the evening
14911|NCT00804843|Drug|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
14912|NCT00804843|Drug|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
14913|NCT00006466|Drug|beta alethine|
14914|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
13966|NCT00783562|Other|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
13967|NCT00783562|Other|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
13968|NCT00783588|Biological|ISF35|Subjects participating in this study will receive up to two doses of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
13969|NCT00783601|Drug|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
13970|NCT00783601|Drug|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
13971|NCT00783601|Drug|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
14484|NCT00779207|Behavioral|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
14485|NCT00006251|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
14486|NCT00779207|Behavioral|weight loss|10 percent weight loss through diet and behavioral modification
14487|NCT00779220|Drug|placebo|Intravenous repeating dose
14488|NCT00779220|Drug|methotrexate|Oral repeating dose
14489|NCT00779220|Drug|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
14753|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
14754|NCT00806858|Device|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
14755|NCT00806871|Drug|Methylprednisolone 40 mg|Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use
1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline
14756|NCT00806871|Drug|Methylprednisolone 80 mg|Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.
2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine
14757|NCT00806871|Drug|Sodium chloride|Saline solution 0,9%, injection in the carpal tunnel, one time use
1 ml 10 mg Lidocaine + 2 ml saline
14758|NCT00806884|Other|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
14759|NCT00806884|Other|Control group measurements|None other than control group measurements
14760|NCT00806897|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
14761|NCT00006478|Biological|autologous tumor cell vaccine|
14762|NCT00806910|Drug|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
14763|NCT00806910|Other|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
14764|NCT00806923|Drug|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
14765|NCT00806923|Drug|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
14034|NCT00781274|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
14035|NCT00006258|Drug|methotrexate|
14036|NCT00781274|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
14037|NCT00781287|Drug|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
14038|NCT00781287|Drug|Raltegravir|400 mg BID PO
14039|NCT00781300|Drug|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
14040|NCT00781300|Drug|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
14041|NCT00781326|Drug|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
14042|NCT00781326|Drug|Placebo|Placebo will be given in doses matching those of nimodipine.
14043|NCT00781339|Drug|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
14044|NCT00781352|Drug|nitrous oxide|65% nitrous oxide administered during surgery
14045|NCT00781352|Drug|nitrogen|Nitrogen administration during surgery
14046|NCT00006258|Drug|vincristine sulfate|
14331|NCT00773565|Dietary Supplement|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
14332|NCT00773578|Device|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
14333|NCT00773578|Device|Measurement of biomarkers of nasal inflammation|Nasal lavage
14334|NCT00773591|Drug|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
15043|NCT00807209|Drug|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
15044|NCT00807209|Drug|Fentanyl via PCA|Fentanyl via PCA
15045|NCT00807209|Drug|Bupivacaine via epidural|Bupivacaine via epidural
15046|NCT00807222|Drug|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
15047|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
15048|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
15049|NCT00807248|Drug|Escitalopram placebo|Once daily before bedtime for 8 weeks
15050|NCT00807248|Drug|Gaboxadol placebo|Once daily before bedtime for 8 weeks
15051|NCT00006479|Drug|oxaliplatin|
15052|NCT00807248|Drug|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
15053|NCT00807248|Drug|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
15054|NCT00809380|Behavioral|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
15055|NCT00006495|Biological|HIV-1 Immunogen|
15056|NCT00809380|Behavioral|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
15057|NCT00809393|Drug|tranexamic acid|10 mg/kg
15058|NCT00809393|Drug|tranexamic acid|30 mg/kg
15059|NCT00809419|Device|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
14103|NCT00778466|Drug|metformin hydrochloride 1000 mg tablets|
14104|NCT00778479|Device|Sepraspray|Max. 10g of Sepraspray
13972|NCT00783601|Drug|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
13973|NCT00783614|Drug|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
13974|NCT00783614|Drug|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
13975|NCT00783627|Procedure|Angiography|Angiography done at the J1 visit
13976|NCT00775632|Drug|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
13977|NCT00775645|Dietary Supplement|acetyl-L-carnitine hydrochloride|Given orally
13978|NCT00775645|Other|placebo|Given orally
13979|NCT00775658|Drug|olopatadine 0.2% opthalmic solution|
13980|NCT00006237|Biological|filgrastim|Given subcutaneously
13981|NCT00775658|Drug|placebo, normal saline opthalmic solution|
13982|NCT00775671|Drug|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
13983|NCT00775671|Drug|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
13984|NCT00775671|Drug|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
14272|NCT00776217|Drug|loratadine 10 mg orally disintegrating tablets|
14273|NCT00776230|Biological|IC51|6 mcg im. at day 0 and day 28
14274|NCT00776256|Dietary Supplement|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
14275|NCT00776269|Procedure|argon laser and radiofrequency|
14276|NCT00776282|Drug|loratadine 10 mg orally disintegrating|
14277|NCT00776295|Biological|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes|Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
14766|NCT00806923|Drug|Placebo|iv on day 1 of each 3 week cycle until disease progression
14767|NCT00806923|Drug|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
14768|NCT00806923|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
14769|NCT00808977|Drug|Mesalazine|Mesalazine 2400 mg daily
14770|NCT00808977|Drug|Placebo|Placebo matching active and experimental treatments
14771|NCT00808990|Dietary Supplement|probiotics: BioFemale by SOLGAR Israel, SupHerb)|Use instructions: before breakfast 2 pills followed by cold drink or food.
Probiotics: Each pill contains 10x10^9 of the following bacteria:
Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus, Lactobacillus casei, Streptococcus thermophilus. All participants will receive either probiotics or placebo pills blindly for six months.
All participants will receive either probiotics or placebo pills blindly for six months.
15123|NCT00805233|Drug|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
15124|NCT00805259|Behavioral|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
15125|NCT00807248|Drug|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
15126|NCT00807261|Drug|Gemcitabine and Docetaxel|Drug and schedule
Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)
Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days
Dose modification
Treatment should be delayed if the ANC<1,500/ mm3, or if the platelet count <75,000/mm3 on the first day of the next cycle.
Gemcitabine & docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.
Patients with response or no change will receive 2 additional cycles.
15127|NCT00807287|Procedure|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
15128|NCT00807287|Procedure|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
15129|NCT00807300|Radiation|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
15130|NCT00807300|Procedure|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
15131|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
14335|NCT00773604|Device|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
14336|NCT00773617|Behavioral|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
14337|NCT00773617|Behavioral|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
14338|NCT00773630|Drug|Cilostazol|100 mg Cilostazol
14339|NCT00773643|Other|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
14340|NCT00773656|Other|Whole blood sample|70 ml per patient for collection of biological sample
14341|NCT00006228|Biological|aldesleukin|Given SC
14342|NCT00773682|Other|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
14343|NCT00773695|Drug|Placebo|iv every 3 weeks
14344|NCT00773695|Drug|Standard chemotherapy or endocrine therapy|As prescribed
14345|NCT00773695|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
14346|NCT00773708|Drug|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
14347|NCT00773734|Drug|Apremilast 10mg|
14348|NCT00773734|Drug|Apremilast 20mg|
14349|NCT00773734|Drug|Apremilast 30 mg|
14350|NCT00773734|Drug|Placebo|
14351|NCT00773734|Drug|Apremilast 30mg|
14608|NCT00810966|Other|liquid chromatography|
14609|NCT00810966|Other|mass spectrometry|
14610|NCT00810966|Other|pharmacological study|
14611|NCT00810979|Drug|SLx-4090|tablet
14612|NCT00810979|Drug|SLx-4090|tablet
14105|NCT00778505|Drug|Propofol|closed-loop administration using bispectral index as the controller
14106|NCT00778505|Drug|remifentanil|closed-loop administration using bispectral index as the controller
14107|NCT00778505|Drug|Propofol|manual administration according bispectral index values
14108|NCT00778505|Drug|Remifentanil|manual administration according bispectral index values
14109|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
14110|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
14111|NCT00006250|Drug|chlorambucil|
14112|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
14113|NCT00778531|Device|ArteFill injectable implant|Treatment will be according to the approved labeling for ArteFill for the correction of nasolabial folds. The nasolabial fold is the line or fold that extends from approximately the inferior aspect of the ala of the nose to the commissure of the mouth on the right and left side of the face.
14114|NCT00778544|Drug|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
14115|NCT00781391|Drug|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
14116|NCT00781391|Drug|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
14117|NCT00781391|Drug|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
14118|NCT00781391|Drug|placebo warfarin|placebo warfarin
14119|NCT00781391|Drug|placebo edoxaban|placebo edoxaban
14120|NCT00781404|Drug|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
14121|NCT00781417|Dietary Supplement|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
14122|NCT00006258|Procedure|adjuvant therapy|
14123|NCT00781417|Other|Placebo|Matching Placebo
14124|NCT00781430|Drug|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
14125|NCT00781443|Drug|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
14278|NCT00006240|Drug|dexamethasone|
14279|NCT00776321|Drug|Eprotirome|
14280|NCT00776321|Drug|Placebo|
14281|NCT00776334|Drug|Fosinopril 40mg Tablets|
14282|NCT00776347|Drug|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
14283|NCT00776347|Drug|Donepezil|
14284|NCT00776360|Drug|oxytocin|80mIE/min as continuous infusion for 70 minutes
14285|NCT00778830|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
14286|NCT00778830|Drug|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
14287|NCT00778830|Drug|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
14288|NCT00778843|Dietary Supplement|Viusid|Viusid, three oral sachets daily during 24 weeks
14289|NCT00006250|Drug|mitoxantrone hydrochloride|
14290|NCT00778843|Other|Placebo|Placebo three oral sachets daily during 24 weeks
14291|NCT00778856|Procedure|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
14292|NCT00778869|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
14549|NCT00776841|Drug|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
14550|NCT00006241|Radiation|radiation therapy|
14551|NCT00776841|Drug|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
14552|NCT00776841|Drug|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
14553|NCT00776854|Device|Noveon laser|870 and 930nm wavelengths
15132|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
15133|NCT00006479|Procedure|adjuvant therapy|
15134|NCT00807326|Drug|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
15135|NCT00807339|Radiation|Stereotactic radiation|Dose escalation three consecutive treatments
15136|NCT00807339|Device|CyberKnife Robotic Radiosurgery System|
15137|NCT00807365|Drug|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, & 5:00 AM for 6 months.
15138|NCT00807378|Other|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
15139|NCT00807391|Procedure|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
14190|NCT00778583|Drug|Nitrofurantoin 100 mg capsules|
14191|NCT00778596|Drug|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
14192|NCT00778596|Drug|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
14193|NCT00778609|Drug|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
14194|NCT00778609|Drug|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
14195|NCT00778622|Drug|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
14196|NCT00006250|Drug|dexamethasone|
14197|NCT00778648|Dietary Supplement|Juice Plus|Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).
Subjects will take four capsules of Juice Plus+® daily.
14198|NCT00778648|Dietary Supplement|Placebo|Four capsules of placebo daily.
14199|NCT00778661|Drug|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
14200|NCT00778674|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
14613|NCT00810979|Other|Placebo|matching tablet
14614|NCT00810979|Drug|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
14615|NCT00810992|Behavioral|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
14616|NCT00810992|Behavioral|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
14617|NCT00006604|Drug|ATV|Participants will receive varying doses of ATV, depending on their age and weight. The medication will be administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants are in.
14618|NCT00811005|Radiation|8-methoxypsoralen or 5- methoxypsoralen|Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.
Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.
14619|NCT00811005|Radiation|8-methoxypsoralen or 5methoxypsoralen|PUVA treatment:
Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.
Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.
14620|NCT00811018|Drug|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
14621|NCT00811031|Drug|Taxotere|75 mg/m^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
14622|NCT00811031|Drug|Prednisone|5 mg twice a day by mouth.
14623|NCT00811057|Drug|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
14624|NCT00804323|Procedure|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
14625|NCT00804336|Drug|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
14626|NCT00006463|Drug|ECTEINASCIDIN 743|
14627|NCT00804336|Drug|RAD001|Given orally once a day
14981|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
14982|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
14126|NCT00781443|Drug|placebo|Repeating subcutaneous injection
14412|NCT00781924|Procedure|biopsy|ultrasound guided biopsy of tumors.
14413|NCT00781937|Drug|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
14414|NCT00006261|Biological|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
14415|NCT00781937|Drug|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
14416|NCT00781950|Dietary Supplement|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
14417|NCT00781950|Dietary Supplement|Placebo|Wheat and Mixed Dietary Oils
14418|NCT00781963|Behavioral|CBTI|Individual format
14419|NCT00781963|Behavioral|CBTI|Group format
14420|NCT00781963|Behavioral|Sleep education|Group format
14421|NCT00781976|Drug|AZD7295|700mg per day maximum
14422|NCT00781976|Drug|Placebo|matched placebo
14423|NCT00773734|Drug|Apremilast 20mg|
14424|NCT00773747|Drug|vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.
14425|NCT00773747|Drug|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
14426|NCT00773747|Drug|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.
14427|NCT00773760|Other|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
14428|NCT00773773|Other|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
14554|NCT00776867|Drug|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
14555|NCT00776880|Other|ASA scale|ASA scale evaluation before operation
14556|NCT00776880|Other|PPS scale|PPS scale evaluation before operation
14557|NCT00779220|Drug|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
14558|NCT00779220|Drug|ocrelizumab 500mg|Intravenous repeating dose (500mg)
14559|NCT00779233|Drug|Zidovudine tablets 300 mg|
14560|NCT00779246|Other|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
14561|NCT00779246|Drug|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
14562|NCT00779246|Other|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
14563|NCT00006251|Biological|donor lymphocytes|Undergo DLI
14564|NCT00779259|Drug|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
14565|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
14566|NCT00779259|Drug|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
14915|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
14916|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
14917|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
14918|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
14201|NCT00778700|Drug|INCB018424 Phosphate Cream|0.5, 1.0 and 1.5% phosphate cream
14202|NCT00778700|Drug|Placebo Cream|Cream with no active drug
14203|NCT00778713|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
14204|NCT00778726|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
14205|NCT00778739|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
14206|NCT00778752|Drug|Revlimid (Lenalidomide)|3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.
If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.
If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials.
14207|NCT00006250|Drug|fludarabine phosphate|
14208|NCT00778765|Drug|400 mg Gabapentin Capsules|
14209|NCT00778778|Drug|cefprozil 500mg tablets|
14210|NCT00778791|Drug|metformin HC1 750 mg extended-release tablets|
14490|NCT00782002|Biological|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
14491|NCT00782015|Dietary Supplement|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
14492|NCT00006261|Drug|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
14493|NCT00782028|Other|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
14494|NCT00782028|Other|Standard Care|
14495|NCT00782041|Drug|Oxaliplatin|85 mg/m²
14983|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
14984|NCT00809367|Other|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
14985|NCT00811486|Drug|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
14986|NCT00811499|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
14987|NCT00811499|Drug|Placebo; oral|matching placebo
14988|NCT00811499|Drug|Placebo; oral|multiple dose, single schedule
14989|NCT00811525|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.
With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style.
14990|NCT00811538|Procedure|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
14991|NCT00811538|Procedure|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
14992|NCT00006656|Procedure|conventional surgery|
14993|NCT00811551|Device|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
14994|NCT00811564|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
14995|NCT00811564|Drug|latanoprost 0.005%|1 drop of study medication taken once daily
14996|NCT00811577|Drug|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
14997|NCT00811577|Drug|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
14429|NCT00773786|Drug|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
14430|NCT00773786|Drug|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
14431|NCT00773812|Drug|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
14697|NCT00808925|Other|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
14698|NCT00808938|Device|MST|Magnetic Seizure Therapy
14699|NCT00808951|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
14700|NCT00006487|Radiation|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
14701|NCT00808951|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
14702|NCT00808964|Drug|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
14703|NCT00808977|Drug|Dersalazine sodium|Dersalazine sodium 2400 mg daily
14704|NCT00811057|Drug|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
14705|NCT00811057|Drug|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
14706|NCT00811070|Drug|SKI-606 (Bosutinib)|Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.
SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing.
14707|NCT00811083|Drug|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
14708|NCT00006604|Drug|Ritonavir|Administered as 100 mg capsules or oral solution.
14709|NCT00811096|Drug|Tinidazole|2gms, p.o. q.d. for 5 days
14710|NCT00811096|Drug|chloroquine|
14919|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
14920|NCT00804869|Device|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
14921|NCT00804869|Device|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
14922|NCT00804895|Drug|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
14923|NCT00804895|Drug|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
14924|NCT00006467|Drug|ISIS 2503|
14925|NCT00804895|Drug|Verapamil|standard prophylactic treatment
14926|NCT00804908|Drug|temozolomide|150 mg/m2 temozolomide daily for 5 days every 28 days
14927|NCT00804908|Drug|ABT-888|Either 20 mg or 40 mg BID for 7 days every 28 days
14928|NCT00804908|Other|Placebo|Placebo BID for 7 days every 28 days
14929|NCT00804921|Drug|bevacizumab|
14930|NCT00804921|Procedure|anterior chamber paracentesis|
14931|NCT00804921|Drug|acetazolamide|
14932|NCT00804921|Drug|brimonidine|
14933|NCT00804934|Drug|Lucentis|0.5mg Lucentis every four months
14934|NCT00804947|Drug|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
14935|NCT00006467|Drug|gemcitabine hydrochloride|
14936|NCT00807053|Drug|Placebo|Placebo
14937|NCT00807066|Drug|Gefitinib|Gefitinib 250 mg/day
14938|NCT00807066|Drug|Platinum|Platinum based chemotherapy with cycles every 21 days
13985|NCT00775684|Drug|Exenatide|Exenatide (Byetta®)—5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
13986|NCT00775684|Drug|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
14496|NCT00782041|Drug|5-FluoroUracil|2,000 mg/m²
14497|NCT00782041|Drug|Folinic acid|20 mg/m²
14498|NCT00782054|Other|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
14499|NCT00782054|Other|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
14500|NCT00782067|Drug|Midostaurin|
14501|NCT00782080|Drug|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
14502|NCT00782080|Drug|Placebo|Placebo
14503|NCT00006261|Drug|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
14504|NCT00782093|Drug|volociximab|volociximab intravitreal injection
14505|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
14506|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|IV infusion of IGIV, 10% to determine pharmacokinetics
Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
14507|NCT00782145|Other|educational intervention|
14772|NCT00809016|Radiation|3-dimensional conformal radiation therapy|
14773|NCT00809016|Radiation|fludeoxyglucose F 18|
14774|NCT00809016|Radiation|intensity-modulated radiation therapy|
14775|NCT00809029|Other|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
14776|NCT00006488|Drug|recombinant-methionyl human glial cell line-derived neurotrophic factor|
14777|NCT00809042|Drug|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
14778|NCT00809042|Drug|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
14047|NCT00781365|Other|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
14048|NCT00781378|Drug|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
14049|NCT00781378|Drug|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
14050|NCT00006225|Biological|recombinant human thrombopoietin|
14051|NCT00773032|Drug|Sodium Oxybate|2.5g Sodium Oxybate administered during nap
14052|NCT00773032|Drug|Zolpidem|5mg Zolpidem administered during nap
14053|NCT00773032|Drug|placebo|Placebo administered during nap
14054|NCT00773045|Other|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
14055|NCT00773058|Drug|hydrocortisone|hydrocortisone 100mg q8h
14056|NCT00773058|Drug|placebo|normal saline 100ml q8h
14057|NCT00773071|Device|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
14058|NCT00773084|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
14059|NCT00773097|Biological|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
14060|NCT00773110|Drug|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
14061|NCT00006225|Biological|recombinant interleukin-3|
14062|NCT00773110|Drug|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
14711|NCT00811109|Device|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
14712|NCT00811109|Device|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
14713|NCT00811109|Device|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
15060|NCT00809432|Device|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
15061|NCT00809432|Other|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
15062|NCT00809445|Behavioral|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
15063|NCT00809445|Behavioral|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
15064|NCT00809445|Behavioral|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
15065|NCT00809458|Drug|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
15066|NCT00006501|Procedure|ECG|A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
15067|NCT00809471|Drug|placebo|30 minutes orally prior to initiation of sexual activity
15068|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
15069|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
15070|NCT00809497|Drug|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
15071|NCT00809510|Drug|ABT-089|20 mg ABT-089 taken once-daily for 6 months
15072|NCT00809523|Device|Negative Ion Generator|Equivalent exposure to inactivated Negative Ion Generator
15073|NCT00809523|Device|Light-emitting Photodiode light treatment device|Light-emitting Photodiode light treatment device, used for 30 min before 8 am
13987|NCT00775684|Drug|Glimepiride|Glimepiride (Amaryl®)—0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
13988|NCT00775697|Drug|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
13989|NCT00775697|Drug|Montelukast|montelukast 4 mg day for 4 weeks
13990|NCT00775710|Device|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
13991|NCT00006237|Biological|interferon alfa|Given IV and subcutaneously
13992|NCT00775736|Drug|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
13993|NCT00775736|Drug|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
13994|NCT00775736|Drug|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
13995|NCT00775749|Drug|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
13996|NCT00775749|Drug|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
13997|NCT00775762|Drug|aspirin|Aspirin (75-100 mg)die for three months
13998|NCT00775762|Drug|clopidogrel|Clopidogrel (75mg) die for three months
13999|NCT00775762|Drug|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
14000|NCT00775788|Procedure|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
14001|NCT00775801|Device|FLD|Artificial lumbar disc
14002|NCT00000730|Drug|Leucovorin calcium|
14003|NCT00006248|Drug|fluorouracil|
14004|NCT00778193|Drug|Aspirin|1 tablet 81mg QD for 8 days
14005|NCT00778193|Drug|Celecoxib|1 capsule 200mg QD for 8 days
14006|NCT00778193|Drug|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
14007|NCT00778193|Drug|Placebo|1 capsule BID for 8 days
14779|NCT00809042|Drug|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
14780|NCT00809042|Drug|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
14781|NCT00809055|Drug|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
14782|NCT00809068|Drug|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
14783|NCT00809068|Drug|tibolone|tibolone 2.5 mg daily 23 weeks
14784|NCT00809081|Procedure|Enteral Feeding and Total Parental Support|Enteral Feeding : 20ml/hr on POD1
Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)
14785|NCT00809094|Drug|N-acetylcysteine (NAC)|
14786|NCT00809094|Drug|Placebo|
14787|NCT00006489|Behavioral|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
14788|NCT00809107|Drug|HCG|5000IU
14789|NCT00809120|Device|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
14790|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
14791|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
14792|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
15140|NCT00807404|Procedure|histopathologic examination|
15141|NCT00807404|Procedure|optical coherence tomography|
15142|NCT00807430|Device|Grindcare (Active)|Active treatment
15143|NCT00807430|Device|Grindcare (Placebo - the device is not activated)|Placebo treatment
15144|NCT00006479|Procedure|conventional surgery|
15145|NCT00807443|Drug|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp & Dohme. A dose of 400 mg will be administered every 12 hours
14063|NCT00773136|Drug|Bimatoprost Suspension|see prior
14352|NCT00006228|Other|laboratory biomarker analysis|Correlative studies
14353|NCT00776360|Drug|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
14354|NCT00776373|Drug|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
14355|NCT00776399|Device|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
14356|NCT00776425|Drug|epoetin beta [NeoRecormon]|150 IU/kg three times per week
14357|NCT00006240|Drug|oral sodium phenylbutyrate|
14358|NCT00776425|Drug|epoetin beta [NeoRecormon]|30,000 IU once weekly
14359|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
14360|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
14361|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
14362|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
14363|NCT00776464|Device|Noveon laser|Two wavelenghts of light
14364|NCT00776477|Drug|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
14365|NCT00776477|Drug|aspirin|aspirin 100mg daily
14366|NCT00776490|Drug|Glimepiride 1mg Tablets|
14367|NCT00776503|Drug|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
14368|NCT00006241|Biological|filgrastim|
14369|NCT00776516|Drug|mirabegron|oral
14370|NCT00776516|Drug|rifampin|oral
14371|NCT00776529|Other|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
14372|NCT00776529|Other|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
15074|NCT00809536|Drug|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
15075|NCT00811629|Other|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
15076|NCT00811642|Drug|Posaconazole|400mg BID oral suspension for 12 weeks
15077|NCT00006669|Biological|rituximab|
15078|NCT00811655|Procedure|therapeutic conventional surgery|Surgery of a single brain metastasis.
15079|NCT00811655|Radiation|stereotactic radiosurgery|Pre-operative single fraction SRS
14127|NCT00781456|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
14128|NCT00781456|Drug|Placebo|1 tablet daily to match experimental arm
14129|NCT00781482|Drug|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
14130|NCT00781495|Device|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
14131|NCT00781508|Drug|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
14132|NCT00781508|Other|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
14133|NCT00006258|Radiation|radiation therapy|
14134|NCT00781521|Drug|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
14135|NCT00781534|Dietary Supplement|Ginseng, ginsenoside Re or placebo|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
14136|NCT00781534|Dietary Supplement|Ginseng|
14137|NCT00781534|Dietary Supplement|ginsenoside RE|active metabolite of ginseng
14138|NCT00781534|Dietary Supplement|Placebo (sugar pill)|
14139|NCT00781547|Drug|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
14293|NCT00778882|Drug|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
14294|NCT00778895|Biological|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
14295|NCT00778895|Biological|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
14296|NCT00778908|Radiation|Late-course accelerated hyperfractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease
IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately.
14297|NCT00778908|Drug|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
14298|NCT00778908|Radiation|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
14299|NCT00778921|Drug|Amlodipine 10 mg|Amlodipine 10 mg
14300|NCT00006251|Radiation|total-body irradiation|Undergo TBI
14301|NCT00778921|Drug|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
14302|NCT00778921|Drug|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
14303|NCT00778934|Other|Intimate Health Gel|Intimate Health Gel
14304|NCT00778947|Procedure|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
14305|NCT00781664|Drug|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
14306|NCT00781664|Drug|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
14307|NCT00781664|Drug|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
14308|NCT00781664|Drug|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
14309|NCT00006260|Drug|etoposide|etoposide IV over 60-90 minutes on days 1-3.
14310|NCT00781664|Other|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
15146|NCT00809536|Drug|Metformin|Single, oral, 500 mg of metformin immediate release
15147|NCT00809536|Drug|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
15148|NCT00006505|Procedure|Islets|
15149|NCT00809536|Drug|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
15150|NCT00809549|Drug|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
15151|NCT00809562|Drug|RO4917523|orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
15152|NCT00809562|Drug|Placebo|po daily for 10 days
15153|NCT00809575|Other|questionnaire administration|
15154|NCT00809575|Other|fatigue assessment and management|
15155|NCT00809575|Other|observation|
15156|NCT00809575|Other|quality-of-life assessment|
15157|NCT00809588|Biological|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
15158|NCT00809601|Device|Insertion of a specific type of ventilation tube through the tympanic membrane|The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.
The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.
The first combination will test:
"Shepard tube" (double flanged, Fluoroplastic) vs "Donaldson tube" (double flanged, silicone)
The second combination will test:
"Straight tube" (single flanged, Fluoroplastic) vs "Armstrong" (single flanged, silicone)
The third combination will test:
"Armstrong" (single flanged, silicone) vs "Donaldson tube" (double flanged, silicone)
The fourth combination will test:
"Straight tube" (single flanged, Fluoroplastic) vs "Shepard tube" (double flanged, Fluoroplastic)
15159|NCT00006507|Behavioral|Occupational Therapy|
15160|NCT00809614|Biological|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
14211|NCT00778804|Behavioral|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
14212|NCT00778817|Biological|IMC-A12|Given IV
14213|NCT00778817|Drug|mitotane|Given orally
14214|NCT00781586|Dietary Supplement|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
14373|NCT00776542|Drug|Minocycline 100mg Tablets|
14628|NCT00804349|Device|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
14629|NCT00804375|Drug|2PX|cutaneous solution to be applied twice daily for 84 days
14630|NCT00804375|Drug|Placebo|cutaneous solution to be applied twice daily for 84 days
14631|NCT00804388|Procedure|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
14632|NCT00804401|Drug|Naproxen Tablets, 500 mg|
14633|NCT00804414|Drug|SBG|Solution for topical use
14634|NCT00804414|Drug|Placebo Comparator|Solutin for topical use
14635|NCT00804427|Behavioral|Dietary Supplement: Fish Oil|
14636|NCT00804440|Drug|Ibuprofen Tablets, 800 mg|
14637|NCT00000751|Drug|Zidovudine|
14638|NCT00006464|Drug|7-hydroxystaurosporine|
14639|NCT00804453|Device|Cartridge blood set|Once a week
14640|NCT00804453|Device|Standard blood line|Once a week
14641|NCT00804466|Device|CareHPV|Low-cost HPV DNA Screening test
14642|NCT00804479|Other|No intervention.|
14643|NCT00804492|Behavioral|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
14644|NCT00804505|Device|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
14645|NCT00804505|Device|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
14646|NCT00804518|Other|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at ~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
14647|NCT00804531|Drug|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
14140|NCT00781573|Drug|Clopidogrel|Clopidogrel, 75 mg QD, for one year
14141|NCT00773188|Drug|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
14142|NCT00773201|Drug|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
14143|NCT00006225|Procedure|in vitro-treated peripheral blood stem cell transplantation|
14144|NCT00773214|Behavioral|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
14145|NCT00773227|Procedure|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
14146|NCT00773240|Drug|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
14147|NCT00773240|Drug|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
14432|NCT00773812|Drug|placebo|One pill is taken once daily.
14433|NCT00006228|Other|pharmacological study|Correlative studies
14434|NCT00773838|Drug|vorinostat (HDAC inhibitor)|Four 100 mg vorinostat capsules once daily by mouth on days 1-14 of each 21 day treatment cycle. Up to 18 months of treatment.
14435|NCT00773838|Drug|bortezomib|bortezomib 1.3 mg/m2 by IV on days 1, 4, 8, and 11 of each 21-day treatment cycle. Total treatment is up to 18 months.
14436|NCT00773838|Drug|dexamethasone|Five 4 mg Dexamethasone tablets by mouth on days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if disease progression is observed after 2 treatment cycles if no change to disease is observed after 4 treatment cycles .
14437|NCT00773851|Procedure|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
14438|NCT00773851|Procedure|mesh fixation by staples|mesh fixation by staples
14439|NCT00773890|Drug|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
14440|NCT00773890|Drug|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
14441|NCT00773916|Drug|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
14442|NCT00773929|Drug|TAK-593|Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.
Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety
14311|NCT00781690|Device|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
14567|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
14568|NCT00779285|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
14569|NCT00779311|Drug|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
14570|NCT00779311|Drug|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
14571|NCT00779311|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
14572|NCT00779324|Drug|Amantadine Hydrochloride|100 mg every morning and noon
14573|NCT00779324|Drug|Placebo|one placebo tablet every morning and 12 Noon
14574|NCT00006251|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
14575|NCT00779337|Biological|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
14576|NCT00779350|Drug|sertraline 100 mg tablets|
14577|NCT00808678|Drug|rosuvastatin|once, see arm description for more detail
14578|NCT00808691|Other|Critical care|Standard care for each group of patients
14579|NCT00808704|Drug|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
14580|NCT00808717|Drug|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
14581|NCT00808730|Procedure|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
14582|NCT00808743|Drug|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
14583|NCT00808743|Drug|Ursodeoxycholic acid|Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:
below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses
14215|NCT00781586|Drug|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
14216|NCT00781586|Drug|Placebo|Placebo 1 tablet at 1st visit
14217|NCT00006259|Radiation|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
14218|NCT00781599|Drug|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
14219|NCT00781599|Behavioral|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
14220|NCT00781599|Behavioral|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
14221|NCT00781612|Drug|docetaxel|Intravenous repeating dose
14222|NCT00781612|Drug|paclitaxel|Intravenous repeating dose
14223|NCT00781612|Drug|pertuzumab [Perjeta]|Intravenous repeating dose
14224|NCT00781612|Drug|trastuzumab [Herceptin]|Intravenous repeating dose
14225|NCT00781612|Drug|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
14226|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
14227|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
14228|NCT00000732|Drug|Zidovudine|
14229|NCT00006260|Drug|cisplatin|cisplatin IV over 30 minutes on days 1-3.
14230|NCT00781625|Dietary Supplement|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
14508|NCT00782145|Other|informational intervention|
14509|NCT00782145|Other|internet-based intervention|
14648|NCT00804531|Drug|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
14649|NCT00006464|Drug|cisplatin|
14650|NCT00804544|Device|SPECT/CT|SPECT/Low-Dose MultiSclice CT
14998|NCT00811590|Drug|Everolimus|Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.
Everolimus is being investigated as an anticancer agent based on its potential to act
directly on the tumor cells by inhibiting tumor cell growth and proliferation
indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells.
14999|NCT00811603|Drug|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
15000|NCT00811616|Device|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
15001|NCT00804960|Drug|Letrozole|1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
15002|NCT00804960|Drug|Std IVF Protocol|2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
15003|NCT00804973|Drug|LY2590443|200mg as 4-50 mg capsules, oral, once
15004|NCT00804973|Drug|Placebo injection|saline solution, injection, once
15005|NCT00804973|Drug|Sumatriptan|6mg injection (0.5mL of 12mg/mL solution), once
15006|NCT00804973|Drug|Placebo capsule|4 capsules, once
15007|NCT00804986|Drug|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
15008|NCT00804986|Drug|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
15009|NCT00804999|Drug|Clear Care|neutralized Clear Care
15010|NCT00804999|Drug|ReNu MultiPlus MPS|overnight soak in solution
15011|NCT00006468|Drug|FOLFOX regimen|
15012|NCT00804999|Drug|OPTI-FREE RepleniSH MPDS|overnight soak in solution
14443|NCT00773942|Behavioral|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
14444|NCT00006229|Drug|carboplatin|
14445|NCT00776568|Drug|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
14446|NCT00776581|Procedure|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
14447|NCT00006241|Drug|chemotherapy|
14448|NCT00776581|Procedure|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
14449|NCT00776581|Procedure|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
14450|NCT00776581|Procedure|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
14451|NCT00776594|Drug|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
14452|NCT00776594|Drug|bicalutamide|50mg orally daily for 6 months
14453|NCT00776594|Drug|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
14714|NCT00811122|Radiation|11C-PIB PET Scan|Each of the 30 participants will receive an 11C-PIB PET scan of the brain. A subset (6 participants) will receive a whole body 11C-PIB PET scan to determine relative biodistribution of 11C-PIB.
14715|NCT00811122|Radiation|FDG-PET Scan|Each of the 30 participants will receive an FDG-PET scan of the brain. To minimize radiation exposure, FDG-PET scans will not be repeated if available from a previous clinical study.
14716|NCT00811135|Drug|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
14717|NCT00811135|Drug|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
14718|NCT00811135|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
14719|NCT00006617|Drug|Abacavir sulfate|
14720|NCT00811148|Procedure|Tissue Bank|Collection of clinical data and tumor tissue.
14721|NCT00811161|Device|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
14722|NCT00811174|Drug|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
14584|NCT00808743|Drug|Placebo|Placebo: orally, 6 months, dosage based on body weight:
below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses
14585|NCT00808756|Dietary Supplement|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
14586|NCT00808756|Other|Standard infant formula.|Standard infant formula.
14939|NCT00807079|Drug|carboplatin|
14940|NCT00807079|Drug|topotecan hydrochloride|
14941|NCT00006478|Procedure|adjuvant therapy|
14942|NCT00807092|Drug|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
14943|NCT00807092|Drug|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
14944|NCT00807092|Drug|metformin|Metformin dose must remain the same as that used prior to the trial.
14945|NCT00807105|Device|H-coil dTMS|treatment with deep TMS stimulation.
14946|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
14947|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
14948|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
14949|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
14950|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
14951|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
14952|NCT00006479|Drug|FOLFOX regimen|
14953|NCT00807131|Behavioral|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
14954|NCT00807131|Behavioral|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
14955|NCT00807131|Behavioral|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
14510|NCT00782145|Other|questionnaire administration|
14511|NCT00782145|Other|study of socioeconomic and demographic variables|
14512|NCT00773942|Behavioral|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
14513|NCT00773955|Drug|R-(-)-gossypol acetic acid|Given orally
14514|NCT00773955|Other|pharmacological study|Correlative studies
14515|NCT00773955|Other|laboratory biomarker analysis|Correlative studies
14516|NCT00773968|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection
14517|NCT00773981|Procedure|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
14518|NCT00773994|Other|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
14519|NCT00774007|Drug|mesalazine|
14520|NCT00774007|Drug|placebo|
14521|NCT00774020|Drug|Zoledronic acid|5mg, i.v. single dose
14522|NCT00006229|Drug|paclitaxel|
14523|NCT00774033|Device|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
14524|NCT00774033|Procedure|classic skin grafts|classic skin grafts used for the treatment of acute burn
14525|NCT00774046|Drug|Ara-C|Induction: 3000mg/m2 IV infusion for day 1 and day 5
Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)
14526|NCT00774046|Drug|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
14527|NCT00774046|Drug|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
14528|NCT00774059|Device|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
14529|NCT00774072|Drug|Tobramycin (Gernebcin®)|1 ml / day in each nostril
15013|NCT00805012|Drug|docetaxel+CDDP|docetaxel+CDDP
15014|NCT00805012|Drug|docetaxel+S-1|docetaxel+S-1
15015|NCT00805025|Drug|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
15016|NCT00805038|Behavioral|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
14064|NCT00773149|Drug|Alemtuzumab (CAMPATH 1H) associated to G-CSF|All patients receive Alemtuzumab in 3 successive phases:
Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.
Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.
Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months.
14065|NCT00773162|Drug|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
14066|NCT00773162|Drug|Sugar Pill|Sugar pill to match seroquel
14067|NCT00773175|Drug|recombinant human hyaluronidase|150 Units in 1 mL
14068|NCT00773188|Drug|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
14069|NCT00773188|Drug|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
14070|NCT00006237|Drug|cisplatin|Given IV
14071|NCT00775801|Device|Control|Artificial lumbar disc
14072|NCT00775814|Drug|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
14073|NCT00775814|Drug|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
14074|NCT00775827|Drug|fenofibrate 160 mg tablets|
14075|NCT00775840|Drug|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
14076|NCT00775840|Drug|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
14077|NCT00775866|Procedure|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
14078|NCT00775879|Drug|Induction with Sevoflurane|
14723|NCT00811187|Drug|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
14724|NCT00811187|Drug|Normal Saline|5cc Normal Saline injection in each paracervical region
14725|NCT00811200|Drug|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
14726|NCT00811200|Drug|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
14727|NCT00804570|Drug|placebo|QD, PO, 16 weeks
14728|NCT00804596|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
14729|NCT00804609|Drug|DepoDur following epidural lidocaine|All participant underwent cesarean delivery. An epidural "top-up" anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.
Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration.
14730|NCT00804609|Drug|DepoDur following spinal anesthetic|Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.
Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug.
14731|NCT00804622|Drug|telbivudine|daily oral administration,600mg,over 12 weeks
15080|NCT00811668|Device|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
15081|NCT00811668|Device|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
15082|NCT00811681|Drug|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
15083|NCT00811681|Drug|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
15084|NCT00811694|Other|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
15085|NCT00811720|Drug|Placebo|as-needed use, tablets, orally, 6 months
15086|NCT00811720|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
14956|NCT00807131|Behavioral|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
14957|NCT00807144|Drug|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
14958|NCT00807144|Drug|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
14959|NCT00807157|Dietary Supplement|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
14008|NCT00778206|Drug|Kuvan|After the baby is born, follow-up assessments will be requested for six months. If Kuvan is taken by the mother during and/or after pregnancy, blood samples will be requested from the mother and the baby.
If the mother is lactating and taking Kuvan, breast milk samples will be requested.
14009|NCT00778219|Device|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
14010|NCT00778232|Drug|Gabapentin tablets 800 mg|
14011|NCT00778245|Drug|cefprozil 500mg tablets|
14012|NCT00778258|Biological|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
14013|NCT00778258|Biological|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
14014|NCT00006248|Drug|paclitaxel|
14015|NCT00778271|Drug|Gabapentin 400mg capsules|
14016|NCT00778284|Drug|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
14017|NCT00778297|Biological|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
14018|NCT00778297|Biological|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
14019|NCT00778310|Drug|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
14020|NCT00778310|Drug|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
14793|NCT00811200|Other|sham|at baseline one sham-injection
14794|NCT00811213|Device|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
14795|NCT00811213|Device|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
14796|NCT00006617|Drug|Amprenavir|
14797|NCT00811226|Drug|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
14798|NCT00811239|Drug|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
14799|NCT00811239|Other|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
14800|NCT00811252|Drug|Placebo|capsules; daily; orally
14801|NCT00811252|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
14802|NCT00811252|Drug|Duloxetine|encapsulated tablets; daily; orally
14803|NCT00811265|Device|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
14804|NCT00811291|Dietary Supplement|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
14805|NCT00811291|Dietary Supplement|calcium|according to protocol
14806|NCT00811317|Device|Closed-loop device|Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
14807|NCT00000754|Drug|Zidovudine|
14808|NCT00006617|Drug|Lamivudine|
14809|NCT00811317|Device|Open-loop continuous sub-cutaneous infusion of insulin|Subject will regulate sub-cutaneous insulin infusion according to their usual practice and with their own insulin pump using information from self-monitoring blood glucose measurements
14810|NCT00811330|Drug|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
14811|NCT00811343|Biological|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
14079|NCT00775892|Device|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
14080|NCT00775905|Drug|amlodipine 10 mg tablet|
14081|NCT00000730|Drug|Methylprednisolone|
14082|NCT00006237|Drug|dacarbazine|Given IV
14083|NCT00775918|Drug|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
14084|NCT00775931|Procedure|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
14374|NCT00776555|Drug|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
14375|NCT00776555|Drug|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
14376|NCT00776568|Procedure|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
14377|NCT00778947|Procedure|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
14378|NCT00778960|Behavioral|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
14379|NCT00778960|Behavioral|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
14380|NCT00778960|Behavioral|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
14381|NCT00778960|Behavioral|Sitting Quietly|The SQ control group's "intervention" will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily.
15087|NCT00811733|Biological|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
15088|NCT00006669|Biological|sargramostim|
15089|NCT00811746|Drug|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
15090|NCT00811746|Drug|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
15091|NCT00811746|Other|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
15092|NCT00811759|Drug|sorafenib tosylate|
15093|NCT00811759|Drug|temozolomide|
15094|NCT00811759|Genetic|gene expression analysis|
15095|NCT00811759|Genetic|mutation analysis|
15096|NCT00811759|Other|laboratory biomarker analysis|
15097|NCT00811759|Other|pharmacological study|
15098|NCT00811759|Procedure|biopsy|
15099|NCT00006669|Drug|EPOCH regimen|
15100|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
15101|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
15102|NCT00811785|Drug|Copper Histidine|A physiologically acceptable form of the trace metal copper.
15103|NCT00805116|Dietary Supplement|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
14148|NCT00773253|Drug|Botulinum toxin A|All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
14149|NCT00773279|Device|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
14150|NCT00773279|Device|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
14151|NCT00773292|Drug|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
14021|NCT00778323|Procedure|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
14022|NCT00778349|Drug|Metformin solution 100 mg/mL|
14023|NCT00778375|Drug|Clofarabine|20 mg/m^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
14024|NCT00778375|Drug|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
14025|NCT00006249|Biological|pegylated interferon alfa|
14026|NCT00778375|Drug|Decitabine|20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
14027|NCT00781196|Drug|folic acid|capsule 0.5 mg once a day
14312|NCT00781703|Other|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
14313|NCT00781716|Device|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
14314|NCT00781729|Behavioral|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
14315|NCT00781729|Behavioral|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
14316|NCT00781742|Drug|AZD6765|IV once per dosing day, multiple times during the treatment period
14317|NCT00781742|Drug|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
14318|NCT00781755|Drug|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
14319|NCT00781755|Behavioral|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
14320|NCT00006260|Drug|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
14321|NCT00781768|Drug|Standard PO ondansetron + dexamethasone|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
14812|NCT00811356|Drug|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
15161|NCT00809614|Biological|Placebo|Matching placebo to AIN457
15162|NCT00809627|Drug|Caffeine|Caffeine 500 mg IV
15163|NCT00809627|Drug|saline|Normal saline
15164|NCT00809640|Behavioral|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
15165|NCT00809653|Device|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
15166|NCT00809653|Device|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
15167|NCT00809666|Device|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
15168|NCT00809679|Drug|T-62 Dose 1|Capsule dosage form 100 mg bid
15169|NCT00809679|Drug|T-62 Dose 2|Capsule dosage form 200 mg bid
15170|NCT00812019|Biological|FCC H5N1 7,5 µg + 25% MF59|2 doses of Cell Culture-Derived H5N1 7,5 µg Subunit Influenza Vaccine containing 25% of MF59
15171|NCT00812019|Biological|FCC H5N1 15 µg + 25% MF59|2 doses of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59
15172|NCT00812019|Biological|FCC H5N1 3,75 µg + 50% MF59|2 doses of Cell Culture-Derived H5N1 3,75 µg Subunit Influenza Vaccine containing 50% of MF59
15173|NCT00812019|Biological|FCC H5N1 7,5 µg + 50% MF59|2 doses of Cell Culture-Derived H5N1 7,5 µg Subunit Influenza Vaccine containing 50% of MF59
15174|NCT00812019|Biological|FCC H5N1 15 µg + 50% MF59|2 doses of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59
15175|NCT00812019|Biological|FCC H5N1 3,75 µg + 100% MF59|2 doses of Cell Culture-Derived H5N1 3,75 µg Subunit Influenza Vaccine containing 100% of MF59
15176|NCT00812019|Biological|FCC H5N1 7,5 µg + 100% MF59|2 doses of Cell Culture-Derived H5N1 7,5 µg Subunit Influenza Vaccine containing 100% of MF59
15177|NCT00812019|Biological|FCC H5N1 15 µg + 100% MF59|2 doses of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59
15178|NCT00006682|Drug|docetaxel|
14382|NCT00778973|Drug|sertraline 100 mg tablets|
14383|NCT00006251|Drug|fludarabine phosphate|Given IV
14384|NCT00778986|Device|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
14385|NCT00778999|Drug|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
14386|NCT00779012|Biological|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
14387|NCT00779025|Device|PD-F-5254|Female Personal Lubricant (MINE)
14388|NCT00779025|Device|10855-096|Male Personal Lubricant (YOURS)
14389|NCT00779038|Drug|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
14651|NCT00804570|Drug|LY2196044|250 mg (titrate via 1 week at 50 mg and 1 week at 125 mg), QD, PO, 16 weeks
14652|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
14653|NCT00806741|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
14654|NCT00806741|Drug|Phenylephrine|1μg/kg/min, infusion period 20 minutes
14655|NCT00806741|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
14656|NCT00806741|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
14657|NCT00806741|Device|Goldmann applanation tonometer|intraocular pressure measurements
14658|NCT00806741|Other|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
14659|NCT00806754|Drug|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
14660|NCT00806754|Drug|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
14661|NCT00006476|Drug|suramin|
14662|NCT00806767|Biological|therapeutic immune globulin|
14663|NCT00806767|Drug|busulfan|
14152|NCT00773318|Procedure|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
14153|NCT00773331|Drug|epoetin beta|As prescribed
14154|NCT00006226|Drug|thalidomide|Given PO
14155|NCT00773331|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
14156|NCT00773344|Drug|Tanespimycin|Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT
This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)
14157|NCT00773357|Drug|guanfacine|3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
14158|NCT00773357|Drug|placebo|placebo
14159|NCT00773357|Drug|Carvedilol|50 mg/day titrated to stead state. The starting dose is 12.5 mg/day for day 1, followed by 25 mg/day for days 2-3, followed by 50 mg from days 4 to the end of the study.
14160|NCT00773370|Behavioral|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
14161|NCT00773370|Behavioral|Sittercize|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
14162|NCT00775944|Behavioral|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
14163|NCT00775944|Behavioral|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
14164|NCT00006237|Drug|vinblastine|Given IV
14165|NCT00775944|Drug|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
14454|NCT00776607|Drug|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
14322|NCT00781768|Drug|aprepitant (MK-869) + PO ondansetron + dexamethasone|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
14323|NCT00781781|Drug|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
14324|NCT00781794|Drug|NSA-789 at 2 different doses|
14325|NCT00781807|Other|multi-module rehabilitation program|The multi-module rehabilitation program includes:
Nutrition management
Home-based ergometer training program
Psychosocial support
14326|NCT00781820|Drug|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
14327|NCT00773539|Procedure|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
14328|NCT00773552|Drug|solifenacin succinate|5mg PO Qday x 90 days
14329|NCT00773552|Drug|placebo|1 tab PO Qday x 90 days
14330|NCT00006228|Biological|trastuzumab|Given IV
14587|NCT00006487|Drug|cisplatin|During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion
During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion.
14588|NCT00808769|Drug|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
14589|NCT00808769|Drug|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
14590|NCT00808782|Device|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
14591|NCT00808782|Device|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
14592|NCT00808795|Drug|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
14593|NCT00808795|Drug|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
14594|NCT00808808|Biological|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
15179|NCT00812032|Drug|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
15180|NCT00812032|Drug|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
15181|NCT00812045|Drug|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
15182|NCT00812045|Drug|Placebo|
13926|NCT00778128|Drug|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
13927|NCT00778141|Drug|metformin HC1 750 mg extended-release tablets|
13928|NCT00778167|Biological|cixutumumab|Given IV
13929|NCT00778167|Drug|erlotinib hydrochloride|Given PO
13930|NCT00778167|Other|laboratory biomarker analysis|Correlative studies
13931|NCT00778180|Drug|furosemide 80 mg tablets|
13932|NCT00778193|Drug|Naproxen|1 tablet 500mg BID for 8 days
13933|NCT00780988|Procedure|Autologous hematopoietic and immune cell rescue (transplantation)|
13934|NCT00781001|Drug|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
13935|NCT00781027|Procedure|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
13936|NCT00781040|Other|Severe sepsis vs. non-severe sepsis|To compare these two groups
13937|NCT00781053|Drug|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
13938|NCT00006258|Drug|cyclophosphamide|
13939|NCT00781066|Procedure|Controlled cord traction|Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.
Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.
Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).
With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.
If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:
Gently hold the cord and wait until the uterus is well contracted again;
With the next contraction, repeat CCT with counter-pressure.
14664|NCT00806767|Drug|fludarabine phosphate|
14665|NCT00806767|Procedure|allogeneic hematopoietic stem cell transplantation|
14666|NCT00806780|Procedure|on table cholangiography|x-ray imaging of common bile duct
14667|NCT00806806|Drug|SKY0402|Local administration of SKY0402 followed by noxious stimulus
14668|NCT00806806|Drug|Placebo|Local administration of Placebo followed by noxious stimuli
14669|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
14670|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
14671|NCT00806819|Drug|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
14672|NCT00006476|Procedure|conventional surgery|
14673|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
15017|NCT00805038|Behavioral|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
15018|NCT00805064|Drug|triamcinolone and bevacizumab|
15019|NCT00805077|Procedure|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
15020|NCT00805077|Other|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
15021|NCT00805090|Drug|Sporanox|200 mg
15022|NCT00006468|Drug|fluorouracil|
15023|NCT00805090|Drug|Diclofenac Sodium|37.5 mg
15024|NCT00805103|Radiation|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
15025|NCT00805116|Dietary Supplement|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
15026|NCT00807170|Radiation|Whole Brain Radiotherapy (WBRT)|
10328|NCT00752375|Drug|placebo|Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age
Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age
Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy.
10329|NCT00752401|Drug|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels >2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
10330|NCT00752401|Drug|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
10331|NCT00752414|Drug|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
10332|NCT00752414|Drug|Placebo|same frequency as MP-376
10333|NCT00752427|Drug|Paliperidone ER OROS®|
10334|NCT00006066|Drug|Bacteriophage phi X 174|
10335|NCT00743964|Drug|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
10336|NCT00743977|Drug|Phenazopyridine HCl|100mg tablet in fasting state
10337|NCT00743990|Other|Ointment containing camphor, eucalyptus oil, and menthol|One time use
10338|NCT00743990|Other|Petroleum jelly|One time use
10339|NCT00744016|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
10340|NCT00744016|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
10341|NCT00744029|Behavioral|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
10342|NCT00744042|Biological|asfotase alfa|
10343|NCT00006029|Drug|gemcitabine hydrochloride|
10344|NCT00744055|Drug|Prazosin|prazosin (16mg/day) 2 times a day
10345|NCT00744055|Drug|Placebo|Placebo
10659|NCT00747383|Drug|Sitagliptin|100mg oral tablet.
15216|NCT00807456|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
15217|NCT00807495|Drug|MLN8237|MLN8237 will be administered orally at a dose of 50 mg twice daily for seven consecutive days followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable treatment-related toxicity
15218|NCT00807508|Dietary Supplement|placebo|wheat meal capsules with each main meal
15219|NCT00807508|Dietary Supplement|leucine|daily leucine capsules with each main meal
15220|NCT00807521|Drug|Dexamethasone|Single high dose bolus of dexamethasone before surgery
15221|NCT00807521|Drug|Placebo|Placebo for dexamethasone
15222|NCT00807534|Drug|ipratropium bromide|ipratropium bromide nebulization
14251|NCT00006227|Drug|Paclitaxel|Given IV
14252|NCT00773500|Other|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
14253|NCT00773513|Drug|ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)|As prescribed
14254|NCT00773513|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg iv every 2 weeks in patients not already receiving ESAs
14255|NCT00773513|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose 120, 200 or 360 micrograms monthly in patients receiving maintenance ESA therapy.
14256|NCT00773526|Drug|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
14257|NCT00773539|Procedure|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
14258|NCT00773539|Procedure|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
14259|NCT00776100|Other|clinical observation|Patients undergo observation for 6 weeks.
14260|NCT00776100|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
14261|NCT00776113|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
14262|NCT00776126|Device|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
14263|NCT00776139|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
10839|NCT00747877|Drug|cyclophosphamide|Given orally
10840|NCT00747877|Drug|melphalan|Given IV
10841|NCT00747877|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
10842|NCT00747890|Procedure|Modified tonsillectomy|Tonsillectomy
Uvulectomy
Soft palatal resection
Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance
10843|NCT00747890|Other|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
11142|NCT00751244|Behavioral|Present Centered Therapy (PCT) - psychotherapy|Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the "traumagenic dynamics" of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework.
11143|NCT00751244|Other|No-treatment "waitlist" group|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
11144|NCT00000714|Drug|Leucovorin calcium|
11145|NCT00006055|Procedure|Autologous Peripheral Blood Stem Cell Transplantation|
11146|NCT00751257|Drug|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
11147|NCT00751257|Drug|Placebo|Identically appearing placebo capsules, packaged in an N-acetylcysteine "slurry" so that placebo has similar odor as active NAC capsules
11148|NCT00751270|Biological|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
11149|NCT00751270|Drug|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
11150|NCT00751283|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
11151|NCT00751296|Drug|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
11152|NCT00751309|Other|Non-interventional|Post-transplantation observational study
11153|NCT00751322|Other|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
10584|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
10585|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
10586|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
10587|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
10588|NCT00750308|Drug|Ramipril|Ramipril 10 mg per day for three weeks
10589|NCT00750308|Drug|Tadalafil|tadalafil 10 mg every other day for three weeks
10590|NCT00750308|Drug|placebo|placebo matching ramipril
10591|NCT00750308|Drug|placebo|placebo matching tadalafil
10592|NCT00750321|Device|Inactive Placebo|
10593|NCT00750321|Device|Transient Placebo|
10594|NCT00006054|Drug|etoposide|
10595|NCT00750321|Device|Active TENS|
10596|NCT00750334|Drug|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
10597|NCT00750334|Drug|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
10598|NCT00750347|Drug|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
10908|NCT00745017|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
10909|NCT00745017|Drug|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
10910|NCT00745030|Drug|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
10911|NCT00745030|Drug|Placebo|Placebo 8 mg tablets
10912|NCT00006033|Biological|interleukin-2 gene|
10660|NCT00747396|Other|Foster Care Placement|A group of children living in institutions for children in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and received training in Romanian. Prior to placement, foster parents visited their children to begin developing a relationship with the child. Once hired, foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occuring weekly for several months after initial placement of the child, then biweekly and later monthly. Foster parents also had the opportunity to participate in a support group organized by project social workers. Project social workers received weekly consultation from US staff experienced in dealing with young children in foster care.
10661|NCT00747409|Drug|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
10662|NCT00747409|Drug|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
10663|NCT00006042|Drug|fludarabine phosphate|
10664|NCT00747422|Device|Ulthera™ System|ultrasound treatment
10665|NCT00747461|Device|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
10666|NCT00747474|Drug|Lipotecan|Lipotecan IV day 1, 8, 15
10667|NCT00747487|Drug|Idebenone|Idebenone 900 mg/day
10668|NCT00747487|Drug|Placebo|Placebo
10669|NCT00747513|Behavioral|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
10670|NCT00747526|Drug|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
10671|NCT00000714|Drug|Trimetrexate glucuronate|
10672|NCT00006054|Drug|methotrexate|
10673|NCT00750412|Behavioral|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
10674|NCT00750425|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
10675|NCT00750438|Dietary Supplement|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
10676|NCT00750438|Dietary Supplement|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
14264|NCT00776165|Biological|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
14265|NCT00776165|Biological|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
14266|NCT00776191|Drug|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
14267|NCT00006240|Biological|sargramostim|
14268|NCT00776191|Drug|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
14269|NCT00776204|Device|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
14270|NCT00776204|Device|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
14271|NCT00776204|Device|Taxus Libertè|Taxus Libertè stent placed in coronary artery
14848|NCT00807014|Drug|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
14849|NCT00807027|Drug|Activated T lymphocyte(Immuncell-LC)|Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention
Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)
14850|NCT00006478|Biological|sargramostim|
14851|NCT00807040|Procedure|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
14852|NCT00807040|Procedure|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
14853|NCT00807053|Drug|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
14854|NCT00807053|Drug|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
14855|NCT00807053|Drug|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
14856|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
14857|NCT00809133|Drug|BIBW2992|MTD dose of part A
14858|NCT00809133|Drug|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
11154|NCT00751322|Other|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
11155|NCT00751335|Device|Heated breathing tube (CPAP with ThermoSmart)|heated humidification with a heated breathing tube.
11156|NCT00006056|Drug|anti-thymocyte globulin|
11157|NCT00751335|Device|Non heated breathing tube (CPAP with conventional humidification)|Heated humidification without a heated breathing tube
11158|NCT00751348|Biological|PriorixTM|Subcutaneous administration in left upper arm
11159|NCT00742924|Drug|ifosfamide|Given IV
11160|NCT00742924|Drug|leucovorin calcium|Given IV or orally
11161|NCT00742924|Drug|methotrexate|Given IV
10188|NCT00746655|Procedure|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
10189|NCT00746668|Behavioral|Module 1: Visual Awareness and Eccentric Viewing|In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.
This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice.
10190|NCT00746668|Behavioral|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
10191|NCT00746668|Behavioral|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation [RSVP]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
10192|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
10193|NCT00746681|Drug|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
10194|NCT00746681|Drug|Placebo|Placebo, Oral, twice daily for 4 weeks
10195|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
10913|NCT00745043|Drug|bronchodilator response|
10914|NCT00745069|Drug|tapentadol HCl|
10915|NCT00745095|Drug|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
10916|NCT00745108|Drug|tibolone|oral 1.25 mg tablet, once daily, for 2 years
10917|NCT00745108|Drug|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
10918|NCT00745108|Drug|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
10919|NCT00745121|Device|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
10920|NCT00745134|Drug|Curcumin|4 gm tablets by mouth twice a day
10921|NCT00745134|Drug|Placebo|Tablets by mouth twice a day
10922|NCT00745134|Radiation|Radiotherapy|45 Gy once a day, for 5 days in a row for 5-6 weeks (up to 28 treatments in all)
10923|NCT00006033|Drug|methotrexate|
10924|NCT00745134|Drug|Capecitabine|825 mg/m^2 by mouth twice a day only on days of radiation (Monday through Friday).
10925|NCT00745147|Drug|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
10926|NCT00745147|Drug|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
10927|NCT00745160|Other|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
11226|NCT00748618|Dietary Supplement|vitamin D3|50,000 I.U./wk of vitamin D3 orally for 6 months
11227|NCT00748631|Device|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
10677|NCT00750438|Dietary Supplement|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
10981|NCT00753467|Drug|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
10982|NCT00753480|Drug|D4064A|
10983|NCT00753493|Drug|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
10984|NCT00753506|Dietary Supplement|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
10985|NCT00753506|Dietary Supplement|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
10986|NCT00000716|Drug|Zidovudine|
10987|NCT00006082|Drug|rubitecan|
10988|NCT00753519|Device|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
10989|NCT00753519|Device|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
10990|NCT00753532|Dietary Supplement|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort received either 200 mg softgels of Palm Vitamin E (tocotrienols) or placebo taken orally twice a day.
10991|NCT00753545|Drug|AZD2281|Oral 400mg bid
10992|NCT00753545|Drug|matching placebo|matching placebo bid
10993|NCT00753558|Drug|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel.
Arm #2: Oral placebo solutions, placebo buccal gel.
10994|NCT00753571|Drug|Cistanche Total Glycosides|Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd*9months Arms: 1 Drug: blank capsules 6 capsules po Qd*9months
Arms: 2
10995|NCT00745199|Drug|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
10996|NCT00745225|Drug|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
10997|NCT00006034|Biological|keyhole limpet hemocyanin|Given intradermally and IV
10998|NCT00745225|Drug|placebo comparator|1 capsule daily, 96 weeks.
10999|NCT00745238|Other|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
10447|NCT00744263|Biological|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
10763|NCT00747747|Device|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
10764|NCT00747773|Device|CryoSpray Ablation System|CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications" (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold
10765|NCT00747799|Drug|Sorafenib plus Cisplatin and 5-fluorouracil|Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
Sorafenib 400 mg bid per daily . Every 21-day cycles.
Cisplatin 80 mg/m2 day d1, every 21 days cycle.
5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles
10766|NCT00750646|Device|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
10767|NCT00750659|Drug|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
10768|NCT00006054|Drug|prednisone|
10769|NCT00750685|Device|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
10770|NCT00750698|Drug|SNDX-275|SNDX-275 (10 mg fixed dose PO Q2W) on days 1 and 15 of a 28-day cycle for up to 6 cycles
10771|NCT00750698|Drug|erlotinib|erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
10772|NCT00750711|Procedure|Radiofrequency ablation for atrial flutter by catheters|
10773|NCT00750724|Drug|25 mg sodium hyaluronate "GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
10774|NCT00750724|Drug|normal saline,2 ml., intraarticular weekly for 5 weeks|
10775|NCT00750737|Drug|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
10776|NCT00750737|Drug|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
10196|NCT00746681|Drug|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
10197|NCT00746707|Device|1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate|adhesive of perineal tears
10198|NCT00006040|Biological|filgrastim|
10199|NCT00749632|Drug|oxybutynin|middle dose oxybutynin administered daily
10200|NCT00749632|Drug|oxybutynin|high dose oxybutynin administered daily
10201|NCT00749645|Drug|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
10202|NCT00749645|Drug|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
10203|NCT00749658|Drug|Bupropion SR|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
10204|NCT00749658|Drug|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
10508|NCT00752622|Biological|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
10509|NCT00752622|Biological|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
10510|NCT00752635|Drug|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
10511|NCT00752648|Drug|TMC435350|
10512|NCT00752661|Drug|Tramadol Hydrochloride; JNS013|
10513|NCT00752674|Other|Neuromuscular balance|
10514|NCT00006070|Drug|etanercept (Enbrel)|
10515|NCT00752687|Drug|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
10516|NCT00752687|Drug|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
10517|NCT00752700|Other|Conventional resistance training|Conventional resistance training program (CRT)
10518|NCT00752700|Other|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
10519|NCT00752713|Procedure|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
11228|NCT00748644|Drug|Rituximab|rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.
All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
11229|NCT00748644|Drug|Azathioprine|azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.
All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
11230|NCT00751348|Biological|VarilrixTM|Subcutaneous administration in right upper arm
11231|NCT00751348|Biological|GSK Biologicals' vaccine 208136|Subcutaneous injection in left upper arm
11232|NCT00751361|Device|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
11233|NCT00751374|Drug|gentamicin|topical gentamicin cream on daily basis
11234|NCT00751374|Drug|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
11235|NCT00751400|Drug|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
11236|NCT00751413|Drug|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
11237|NCT00751465|Behavioral|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
11238|NCT00006056|Drug|busulfan|
11239|NCT00751465|Behavioral|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
11240|NCT00751478|Drug|ALO-01|ALO-01 capsules
11241|NCT00751478|Drug|MSIR|immediate release morphine sulfate
11242|NCT00751478|Drug|Placebo|Placebo
11243|NCT00751491|Drug|Adenosin|Intracoronary Adenosin 50 microg;
11244|NCT00751491|Other|placebo|no intervention
11245|NCT00751491|Drug|Clopidogrel|Clopidogrel 300/600 mg
10269|NCT00743951|Behavioral|2 Usual care|Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.
ii) Referral to the surgeon with a standardized report of their clinical findings.
11000|NCT00745251|Drug|VI-0521|15 mg Phentermine and 92 mg Topiramate
11001|NCT00745251|Drug|placebo|placebo
11002|NCT00745264|Drug|Diractin|100 mg Ketoprofen to 2 joints
11003|NCT00745264|Drug|Diractin|400 mg ketoprofen to 4 joints
11304|NCT00748696|Other|resistance training|3 sessions of resistance training per week
11305|NCT00006048|Drug|cisplatin|
11306|NCT00748696|Other|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
11307|NCT00748709|Drug|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
11308|NCT00748722|Device|CT Angiography|Injection of contrast material (iodine)
11309|NCT00748735|Procedure|Implantation of a cardiac resynchronization therapy device|
11310|NCT00748735|Procedure|Echocardiography (myocardial deformation imaging)|
11311|NCT00748748|Biological|Culturelle|10^10 Lactobacillus rhamnosus GG per capsule
11312|NCT00748761|Behavioral|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
11313|NCT00748761|Behavioral|Waitlist|Contact waitlist weekly for 12 weeks
11314|NCT00748774|Behavioral|Questionnaire|Two questionnaires taking about 10 minutes to complete.
11315|NCT00748787|Drug|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
11316|NCT00000712|Drug|Acyclovir|
11317|NCT00006048|Drug|gefitinib|
11318|NCT00748787|Drug|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
11319|NCT00748800|Behavioral|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
11320|NCT00748800|Behavioral|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
11321|NCT00748813|Biological|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
10777|NCT00750750|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
10778|NCT00750750|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
10779|NCT00006054|Procedure|Allogeneic Bone Marrow Transplantation|
11082|NCT00742898|Other|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
11083|NCT00006021|Dietary Supplement|ascorbic acid|
11084|NCT00742911|Drug|Disulfiram|Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.
Patients must not consume beverages containing alcohol while taking disulfiram.
11085|NCT00742911|Drug|Copper Gluconate|Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.
Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.
Patients will receive 2 mg, 4mg, 6mg or 8mg daily
11086|NCT00742924|Drug|cisplatin|Given IV
11087|NCT00742924|Drug|dexrazoxane hydrochloride|Given IV
11088|NCT00742924|Drug|doxorubicin hydrochloride|Given IV
11089|NCT00742924|Drug|etoposide|Given IV
11090|NCT00006035|Biological|bleomycin sulfate|
11091|NCT00745407|Drug|fenofibrate|
11092|NCT00745420|Biological|Hematopoietic Stem Cell Transplantation|The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.
Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively
Fludarabine: 30 mg/m^2/day IV on Days -8 through -4
Melphalan: 140 mg/m^2 IV on Day -3
Rest on Days -2 and -1
Transplant occurs on Day 0
GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD
11093|NCT00745433|Drug|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
11094|NCT00745433|Drug|metformin|Start dose and frequency at the discretion of the physician following clinical practice
11095|NCT00745446|Procedure|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
10520|NCT00752726|Drug|Orlistat|Weight loss treatment
10521|NCT00752726|Drug|Placebo|Inactive
10522|NCT00752739|Dietary Supplement|selenium|Given orally
10523|NCT00752739|Other|placebo|Given orally
10524|NCT00752778|Other|pet-scan FDG-F18|
10525|NCT00000715|Drug|Sulfamethoxazole-Trimethoprim|
10526|NCT00006072|Drug|Rituxan|
10527|NCT00752791|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
10528|NCT00744328|Drug|Sertraline|Sertraline dose will range from 50 - 200 mg/day
10529|NCT00006030|Procedure|conventional surgery|
10530|NCT00744328|Other|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
10531|NCT00744341|Drug|SLV320|1.25mg i.v. bid
10844|NCT00747903|Drug|aminolevulinic acid hydrochloride|
10845|NCT00747916|Device|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
10846|NCT00747929|Drug|Placebo|Total of 54 weeks, four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet
10847|NCT00747929|Drug|S-2367 800 mg|Total of 54 weeks, two 400 mg S-2367 tablets and two placebo tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet
10848|NCT00747929|Drug|S-2367 1600 mg|Total of 54 weeks, four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet
10849|NCT00006042|Radiation|radiation therapy|
10850|NCT00747942|Behavioral|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
10851|NCT00747968|Drug|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol*kg-1*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
10270|NCT00743964|Drug|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
10271|NCT00746707|Procedure|3. traditional suturing with vicryl rapid 2X0|suturing of perineal tears grade one with vicryl rapid 2X0
10272|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
10273|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
10274|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
10275|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
10276|NCT00746733|Drug|Lisdexamfetamine Dimesylate|50mg capsule
10277|NCT00746733|Drug|Adderall XR (mixed salts amphetamine)|20mg capsule
10278|NCT00746746|Biological|HyperAcute vaccine|1.8 mL weekly
10279|NCT00746746|Drug|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
10280|NCT00746759|Device|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
10281|NCT00006040|Drug|etoposide|
10282|NCT00746772|Drug|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
10283|NCT00746772|Drug|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
10284|NCT00746785|Drug|2.5 mg Olanzapine|2.5 mg
10285|NCT00746785|Drug|5mg Olanzapine|5 mg
10286|NCT00746785|Drug|placebo|placebo
10287|NCT00746798|Biological|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
11322|NCT00748826|Biological|Infliximab|Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of
Infliximab therapy with additional infusions of 5 mg/kg at week 2
11323|NCT00748852|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
11324|NCT00748865|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
11325|NCT00748865|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
10346|NCT00744068|Behavioral|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
10347|NCT00744081|Drug|Glivec|
10348|NCT00744081|Drug|Mitoxantrone|
10349|NCT00744081|Drug|Topotecan|
10350|NCT00744081|Drug|AraC|
10351|NCT00744094|Dietary Supplement|protein drink|250 ml protein hydrolysate solution
10352|NCT00744094|Behavioral|Resistance training|12 weeks resistance training, 3 days per week
10353|NCT00744107|Device|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
10354|NCT00006029|Drug|pegylated liposomal doxorubicin hydrochloride|
10355|NCT00744133|Biological|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
10356|NCT00744146|Biological|Protexia|Single 50 mg IM dose
10357|NCT00744146|Biological|Protexia|Single 100 mg dose
10358|NCT00744146|Biological|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
10359|NCT00744146|Biological|Protexia|Single 500 mg dose, IM
10360|NCT00744146|Biological|Protexia|Single 750 mg dose, IM
10361|NCT00744172|Procedure|laparoscopy|laparoscopic hysterectomy
11096|NCT00745459|Drug|NPO-11|20 mL NPO-11
11097|NCT00745485|Drug|zoledronic acid|
11098|NCT00745498|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
11099|NCT00745511|Drug|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
11100|NCT00745511|Drug|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
11101|NCT00006035|Drug|electroporation therapy|
10136|NCT00749606|Behavioral|Group telephone intervention|Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the "coach" will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff.
10137|NCT00749619|Other|Catheter Lock Solution Taurolidine and Citrate|
10138|NCT00749619|Other|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
10139|NCT00749619|Other|Catheter Lock Solution : Heparin|
10140|NCT00006050|Drug|oxaliplatin|
10141|NCT00749632|Drug|oxybutynin|low dose oxybutynin administered daily
10142|NCT00751985|Other|Self-help material|The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.
The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.
Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help.
10143|NCT00751985|Other|Control|The participant is being informed about their allocation to the control group.
10144|NCT00751998|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
10145|NCT00752011|Drug|TAS-106|Starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
10146|NCT00752011|Drug|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
10852|NCT00747981|Procedure|Thoracic CT Scan|Perform a CT Scan and an endoscopy
10853|NCT00748007|Drug|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
10854|NCT00748020|Procedure|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
10855|NCT00748020|Procedure|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
10856|NCT00748046|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
10857|NCT00748059|Procedure|Standing or upright tilt|stand upright or tilt table test
10858|NCT00748059|Procedure|Microneurography|Recording from sympathetic nerve
10859|NCT00006055|Drug|anti-thymocyte globulin|
10860|NCT00750815|Drug|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
10861|NCT00750815|Drug|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
10862|NCT00750841|Drug|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
10863|NCT00750854|Dietary Supplement|NEM Formulation X|see Treatment Arms
11162|NCT00742924|Drug|zoledronic acid|Given IV
11163|NCT00006021|Drug|arsenic trioxide|
11164|NCT00742924|Procedure|adjuvant therapy|
11165|NCT00742924|Procedure|neoadjuvant therapy|
11166|NCT00742924|Procedure|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
11167|NCT00742924|Biological|filgrastim|Given SC
11168|NCT00742924|Drug|Mesna|Given IV
11169|NCT00742937|Dietary Supplement|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
11170|NCT00742937|Dietary Supplement|Placebo|second capsule with vitamin E, eight days after delivery.
10599|NCT00750360|Biological|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
10600|NCT00750373|Procedure|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
10601|NCT00750386|Drug|Paclitaxel|175 mg/m2, I.V, every 2 weeks
10602|NCT00750386|Drug|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
10603|NCT00750399|Drug|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
10604|NCT00750399|Drug|ranibizumab|intravitreal ranibizumab 0.5 mg
10605|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
10606|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
10607|NCT00752986|Drug|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
10608|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
10609|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
10610|NCT00752999|Drug|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
10611|NCT00752999|Drug|Placebo|Placebo tablet, oral, twice-a-day
10612|NCT00006077|Drug|Levodopa and Domperidone|
10613|NCT00753012|Drug|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
10614|NCT00753025|Procedure|Bone marrow aspiration, injection of cells|Bone marrow is aspirated at patients in all arms.
Arm "TNC" receives injection of total nucleated cells into ischemic muscle
10615|NCT00753025|Procedure|Bone marrow aspiration , injection of isolated CD 133+ cells|arm "CD133" receives injection of isolated CD 133+ cells
10616|NCT00753025|Procedure|Bone marrow aspiration, injection of saline|arm "placebo" receives injection of saline
10362|NCT00744172|Procedure|vaginal|vaginal hysterectomy
10363|NCT00744172|Procedure|abdominal|abdominal hysterectomy
10364|NCT00746824|Drug|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
10365|NCT00746837|Drug|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
10366|NCT00746837|Drug|AZD5672|50 mg od, 12 days
10367|NCT00746837|Drug|AZD5672|150mg od, 12 days
10368|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
10678|NCT00750451|Drug|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
10679|NCT00750451|Drug|crinone 8% gel|routine luteal phase support with progesterone gel
10680|NCT00750477|Dietary Supplement|NEM|see Treatment Arms
10681|NCT00750477|Dietary Supplement|Placebo|Placebo comparator containing inactives
10682|NCT00750503|Behavioral|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
10683|NCT00006054|Drug|methylprednisolone|
10684|NCT00750529|Drug|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
10685|NCT00750555|Drug|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
10686|NCT00750581|Drug|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
10687|NCT00750620|Drug|YM178|oral
10688|NCT00750633|Drug|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
10147|NCT00752024|Device|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.
To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
10148|NCT00752024|Drug|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
10149|NCT00752037|Drug|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
10150|NCT00752050|Drug|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
10151|NCT00006062|Drug|oxaliplatin|
10448|NCT00744276|Drug|danazol|danazol applied topically once per day for 4 treatment cycles
10449|NCT00744276|Drug|Placebo|placebo topically applied once daily for 4 treatment cycles
10450|NCT00744289|Other|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
10451|NCT00744302|Drug|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
10452|NCT00744315|Procedure|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
10453|NCT00744328|Drug|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
10454|NCT00747006|Drug|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
10455|NCT00747019|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.
11171|NCT00742950|Procedure|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
11172|NCT00742950|Procedure|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
11173|NCT00742950|Procedure|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
11174|NCT00000708|Drug|Fluconazole|
11175|NCT00006022|Biological|aldesleukin|
11176|NCT00742963|Drug|TH-302|TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.
Dose escalation dose levels:
Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2
11177|NCT00742976|Drug|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
11178|NCT00742976|Drug|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
11179|NCT00742989|Other|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
11180|NCT00742989|Other|Sham OLT|Therapeutic massage performed
11181|NCT00743002|Drug|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
11182|NCT00743002|Drug|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
11183|NCT00743015|Drug|BI 44370 TA tablet|
10205|NCT00749671|Device|Bispectral index monitoring using Aspect Monitor|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
10206|NCT00749671|Other|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
10207|NCT00749684|Biological|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
10208|NCT00000713|Drug|Ampligen|
10209|NCT00006051|Drug|cisplatin|
10210|NCT00749697|Other|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
10617|NCT00753038|Biological|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
10928|NCT00745173|Drug|Premarin|
10929|NCT00745186|Drug|Glucagen|0.2 mg or 1 mg Glucagen single injection
10930|NCT00745186|Drug|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
10931|NCT00745199|Drug|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
10932|NCT00748059|Procedure|QSweat|quantitative sweat testing
10933|NCT00000712|Drug|Zidovudine|
10934|NCT00006043|Drug|temozolomide|
10935|NCT00748059|Device|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
10936|NCT00748059|Drug|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|IV Pharmacological Testing
phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect
10937|NCT00748059|Drug|clonidine,yohimbine,metoclopramide,alpha-methyldopa|Oral Pharmacological Testing
clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo
10938|NCT00748059|Procedure|BodPod|Determination of body composition
10939|NCT00748059|Procedure|Eye exam|Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:
0.5% proparacaine (Alcaine, Allergan, Inc)
Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)
0.5%, 1% tropicamide (Mydriacyl, Alcon)
Over-the-counter preservative-free artificial tears
0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)
1% cyclopentolate hydrochloride (Alcon)
10940|NCT00748059|Procedure|Sleep study|Recording of sleep pattern overnight
10941|NCT00748059|Procedure|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
10942|NCT00748059|Procedure|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
10943|NCT00748059|Procedure|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
10944|NCT00748059|Procedure|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
10945|NCT00006044|Drug|therapeutic testosterone|
10946|NCT00748072|Drug|DDAVP|0.3 mcg/kg subcutaneous
10689|NCT00750633|Drug|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
10690|NCT00750633|Drug|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
10691|NCT00750633|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
10692|NCT00753207|Other|immunohistochemistry staining method|
10693|NCT00753207|Other|liquid chromatography|
10694|NCT00753207|Other|mass spectrometry|
10695|NCT00753220|Biological|VDC2008|Intratumoral injection of VDC2008 post-cryotherapy.
Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8 cells
10696|NCT00753220|Drug|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
10697|NCT00006080|Drug|fenretinide|
11004|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
11005|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
11006|NCT00745277|Drug|Carbidopa-Levodopa|For the first four weeks, the patient will receive carbidopa 75mg daily plus placebo, plus levodopa at level the patient was taking prior to start of study.
For the last 4 weeks, the patient will receive carbidopa 450mg daily plus previous dose of levodopa
11007|NCT00745277|Drug|Carbidopa- Levodopa|For the first four weeks, the patient will receive carbidopa 450mg daily plus levodopa at level the patient was taking prior to start of study.
For the last 4 weeks, the patient will receive carbidopa 75mg daily plus placebo, plus previous dose of levodopa
11008|NCT00000710|Drug|Didanosine|
11009|NCT00006034|Drug|doxorubicin hydrochloride|Given IV
11010|NCT00745290|Drug|Bupivacaine HCl|200 mg bupivacaine HCl
11011|NCT00745290|Drug|SKY0402|600 mg SKY0402 (study drug).
11012|NCT00745303|Procedure|Tai Chi Cuan|Tai Chi Cuan training for 3 months
11013|NCT00745316|Drug|Tonapofylline|Oral Tonapofylline - 2 capsules bid
11014|NCT00745316|Drug|Placebo|Oral placebo - 2 capsules bid
11015|NCT00745329|Other|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
10456|NCT00747019|Behavioral|Physical Exercise (PE)|The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
10457|NCT00747032|Drug|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
10458|NCT00747032|Drug|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
10459|NCT00747045|Other|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
10460|NCT00747058|Drug|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
10461|NCT00747058|Drug|Placebo|Placebo
10462|NCT00000187|Drug|Ritanserin|
10463|NCT00000711|Drug|Sargramostim|
10464|NCT00006041|Biological|MUC1-KLH conjugate vaccine|
10465|NCT00747071|Drug|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
10780|NCT00750750|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
10781|NCT00750750|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
10782|NCT00750763|Drug|Colonlytely|Bowel preparation
10783|NCT00750763|Drug|Picolax/Picoprep|Bowel preparation
10784|NCT00750763|Drug|Fleet|Bowel preparation
10785|NCT00750789|Dietary Supplement|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
10786|NCT00750802|Drug|AZD6280|10mg Capsule, oral, single-dose
10787|NCT00750802|Drug|AZD6280|40mg Capsule, oral, single-dose
10788|NCT00750802|Drug|Lorazepam|2mg tablet, oral single-dose
10789|NCT00750802|Drug|Placebo|
10790|NCT00752804|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
10211|NCT00749710|Procedure|clopidogrel|ORIF - surgical treatment
10212|NCT00749710|Procedure|no antiaggregant therapy|ORIF - surgical treatment
10213|NCT00749723|Drug|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
10214|NCT00749723|Drug|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
10215|NCT00749723|Drug|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
10216|NCT00749723|Drug|thiotepa, carboplatin, etoposide|HD-chemotherapy prior to stem cell transplantation
10217|NCT00749723|Drug|temozolomide, thiotepa|HD-chemotherapy prior to autologous stem cell transplantation
10218|NCT00749723|Procedure|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
10219|NCT00749723|Drug|etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (>3m to <3y 0.7 mg; >3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
10220|NCT00006051|Drug|fluorouracil|
10221|NCT00749723|Drug|trofosfamide/etoposide|maintenance therapy: trofosfamide/etoposide: 25 and 100 mg/m²/d for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
10222|NCT00749736|Dietary Supplement|cholecalciferol|4000 IU of cholecalciferol per day
15 patients will be enrolled in each arm.
10223|NCT00749736|Dietary Supplement|doxercalciferol|1 mcg of doxercalciferol per day
10224|NCT00752115|Drug|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
10225|NCT00752115|Drug|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
10226|NCT00006063|Drug|pancrelipase with bicarbonate|
10532|NCT00744341|Drug|SLV320|3.75mg i.v. bid
10533|NCT00744341|Drug|SLV320|7.5mg i.v. bid
10534|NCT00744341|Drug|SLV320|15.0mg i.v. bid
10535|NCT00744341|Drug|Placebo|
10536|NCT00744354|Drug|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
10947|NCT00748072|Drug|saline solution|saline solution 1 ml subcutaneous
10948|NCT00748085|Device|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
10949|NCT00748098|Drug|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
11246|NCT00751504|Drug|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
11247|NCT00751517|Drug|Methotrexate|
11248|NCT00751517|Drug|Cyclophosphamide|
11249|NCT00006056|Drug|cyclophosphamide|
11250|NCT00751530|Drug|raltegravir|New combination ART incorporating raltegravir with other ARVs.
11251|NCT00751543|Radiation|CT, radiation therapy|Computed tomography (CT) is the mainstay for evaluating lung cancer. The advance of multi-row detector CT (MDCT) provides volumetric acquisition within a breath hold, and enables detailed evaluation of tissue and organ perfusion with excellent resolution
11252|NCT00751556|Drug|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
11253|NCT00751556|Drug|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
11254|NCT00751569|Other|blood donation|obtaining cord blood
11255|NCT00751582|Dietary Supplement|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
11256|NCT00751582|Behavioral|Nutrition education|Nutrition education for children for three months
11257|NCT00751582|Other|Control Group|No Nutrition Education
11258|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
11259|NCT00006022|Drug|bryostatin 1|
11260|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
11261|NCT00743041|Behavioral|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
11262|NCT00743067|Drug|GSK1363089 (formerly XL880)|Experimental Drug
11016|NCT00745342|Behavioral|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
11017|NCT00745355|Behavioral|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
11018|NCT00745368|Drug|Raltegravir|400 mg tablets twice daily during duration of trial
11019|NCT00745381|Other|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
11020|NCT00748150|Biological|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
11021|NCT00748163|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
11022|NCT00748163|Drug|sunitinib malate|
11023|NCT00748176|Procedure|spinal anesthesia|spinal anesthesia with bupivacaine
11326|NCT00751595|Biological|Tat protein|Biologically active recombinant Tat protein
11327|NCT00751608|Drug|APL180|
11328|NCT00006056|Drug|cyclosporine|
11329|NCT00751608|Drug|APL180|
11330|NCT00751608|Drug|Placebo|
11331|NCT00751621|Biological|IgPro20|
11332|NCT00751634|Device|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
11333|NCT00751647|Other|Physical Therapy|Treatment
11334|NCT00751660|Other|laboratory biomarker analysis|
11335|NCT00751660|Other|screening questionnaire administration|
11336|NCT00751660|Procedure|bronchoscopic and lung imaging studies|
11337|NCT00751660|Procedure|computed tomography|
10791|NCT00752804|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
10792|NCT00752804|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
10793|NCT00752817|Other|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
10794|NCT00752817|Other|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
10795|NCT00752830|Drug|AZD0328|Oral capsule, single dose
10796|NCT00752843|Drug|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
10797|NCT00752856|Drug|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
10798|NCT00752856|Drug|Atripla|Atripla 1 tab once a day
10799|NCT00006075|Drug|Chlorhexidine gluconate|
10800|NCT00752869|Drug|dutasteride|0.5mg by mouth one time per day for 1 year
10801|NCT00752869|Drug|placebo|one tablet per day for 1 year
10802|NCT00752882|Drug|ceftazidime|
10803|NCT00752895|Dietary Supplement|American ginseng|Given orally
11102|NCT00745537|Other|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
11103|NCT00745550|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
11104|NCT00745563|Device|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
11105|NCT00745576|Drug|SAM-531|
11106|NCT00745589|Drug|sevelamer hydrochloride|First-line high dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
11107|NCT00745602|Procedure|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
11108|NCT00745615|Drug|laquinimod|0.6 mg, oral, once daily
10537|NCT00744354|Drug|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
10538|NCT00744354|Drug|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
10539|NCT00744367|Drug|metformin|>1500 mg/day or MTD
10540|NCT00006030|Radiation|radiation therapy|
10541|NCT00744367|Drug|pioglitazone|>= 30 mg/day
10542|NCT00744367|Drug|placebo|sc once weekly
10543|NCT00744367|Drug|taspoglutide|10 mg sc once weekly;
10544|NCT00744367|Drug|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
10545|NCT00744380|Drug|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
10546|NCT00744380|Drug|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
10547|NCT00744393|Drug|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
10548|NCT00744393|Drug|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
10549|NCT00744406|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
10550|NCT00744406|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
10551|NCT00000709|Drug|Zidovudine|
10552|NCT00006031|Procedure|Needle localized breast biopsy with specimen x-ray|
10553|NCT00747188|Behavioral|PBL|
10864|NCT00750854|Dietary Supplement|NEM Formulation Y|see Treatment Arms
10865|NCT00750867|Drug|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
11263|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).
Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation.
10288|NCT00746798|Biological|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
10289|NCT00746798|Biological|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
10290|NCT00746798|Biological|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
10291|NCT00746811|Drug|P-OM3|4 grams/day - 4 one gram capsules
10292|NCT00006040|Procedure|autologous bone marrow transplantation|
10293|NCT00746811|Drug|Placebo|4 grams/day - 4 one gram capsules
10294|NCT00749736|Dietary Supplement|placebo|placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.
15 patients will be enrolled in each arm.
10295|NCT00749749|Device|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
10296|NCT00749749|Device|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
10297|NCT00749775|Drug|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
10298|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
10299|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
10300|NCT00749788|Drug|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
10301|NCT00006051|Radiation|radiation therapy|
10302|NCT00749801|Drug|Nattokinase|2 capsules in the morning and before bed-time daily
10303|NCT00749814|Dietary Supplement|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
10304|NCT00749814|Other|Placebo tablets|Placebo
11338|NCT00751660|Procedure|endoscopic biopsy|
11339|NCT00006056|Drug|etoposide|
11340|NCT00751660|Procedure|quality-of-life assessment|
11341|NCT00751686|Procedure|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
11342|NCT00751686|Other|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
11343|NCT00751699|Drug|Asacol|Asacol tablets, 6 tablets per day at 7 am for 7 days
11344|NCT00751699|Drug|Asacol|Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
11345|NCT00751699|Drug|Lialda|Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
11346|NCT00751712|Device|Sensor|Control
11347|NCT00751712|Device|Testing of Two Sensors|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. Because the electrode stickers need to make direct contact with the skin, a small amount of hair at the base of the skull will need to be shaved. . In this study, the stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours.
11348|NCT00751738|Drug|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
14530|NCT00774085|Other|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
14531|NCT00774098|Drug|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
14532|NCT00774098|Drug|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
14533|NCT00006229|Drug|rebimastat|
14534|NCT00774098|Dietary Supplement|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
14535|NCT00774098|Drug|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
14536|NCT00776711|Drug|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
14537|NCT00776711|Drug|VRC-AViDNA036-00-VP|
11109|NCT00745667|Procedure|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
11110|NCT00745667|Procedure|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
11111|NCT00745693|Drug|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
11112|NCT00006036|Drug|cisplatin|
11113|NCT00748306|Drug|Placebo|Matching Intervention Drug
11114|NCT00748319|Other|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
11115|NCT00748332|Dietary Supplement|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
11116|NCT00748332|Dietary Supplement|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
11117|NCT00748345|Drug|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
11118|NCT00748358|Drug|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
11119|NCT00748371|Drug|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
11120|NCT00748371|Drug|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
11121|NCT00006045|Drug|mitoxantrone hydrochloride|
11122|NCT00748371|Drug|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
10152|NCT00752050|Drug|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
10153|NCT00752063|Drug|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
10154|NCT00752076|Other|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
10155|NCT00752089|Drug|Fluoride|
10156|NCT00752102|Drug|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
10866|NCT00750880|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
10867|NCT00750893|Biological|Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe)|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine.
10868|NCT00750919|Drug|esmirtazapine|
10869|NCT00750945|Other|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
10870|NCT00006055|Drug|cyclophosphamide|
10871|NCT00750945|Other|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
10872|NCT00750945|Other|Home program|Home walking program 6 days/wk x 4 weeks
10873|NCT00750958|Procedure|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
10874|NCT00750971|Procedure|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
10875|NCT00750984|Procedure|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
10876|NCT00750984|Procedure|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
10877|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
10878|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
10879|NCT00751023|Drug|Modafinil|400 mg daily for four weeks
10880|NCT00751023|Drug|Placebo|Placebo 2 tablets daily for 4 weeks
10881|NCT00006055|Drug|cyclosporine|
10882|NCT00753064|Drug|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
10883|NCT00753090|Device|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
10884|NCT00753090|Device|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
10305|NCT00749827|Drug|Bicarbonate Hydration|Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.
Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
10306|NCT00749827|Drug|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
10307|NCT00749840|Behavioral|Questionnaire|Questionnaire taking 60-90 minutes.
10618|NCT00753038|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
10619|NCT00753038|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
10620|NCT00753051|Drug|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
10621|NCT00753051|Drug|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
10622|NCT00753064|Drug|Antiscorpion venom serum(AScVS).|AScVS therapy group
If the score is 5 and if the patient belongs to pediatric group(>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.
According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:
Vials of AScVS Composite score Child Adult 5-10 2 4 > 10-15 3 6 >15- 21 4 8
10623|NCT00006078|Dietary Supplement|lycopene|
10624|NCT00753064|Drug|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
10625|NCT00744406|Drug|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
10626|NCT00744419|Drug|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose [0.4 mg/kg (< 44 wks PMA) or 0.8 mg/kg (44 wks to < 1 yr)] and the last 6 subjects in each age group will receive high dose [0.8 mg/kg(< 44 wks PMA) or 1.6 mg/kg(44 wks to < 1 yr)]
10627|NCT00744445|Drug|r-HuEPO|r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
10628|NCT00744458|Other|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
10629|NCT00744458|Other|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
14538|NCT00000730|Drug|Pentamidine isethionate|
14539|NCT00006241|Procedure|peripheral blood stem cell transplantation|
14540|NCT00776724|Drug|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
14541|NCT00776724|Drug|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.
Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.
Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.
Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.
Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.
Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.
Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.
Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8.
14542|NCT00776750|Biological|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
14543|NCT00776763|Drug|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
14544|NCT00776789|Other|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
14545|NCT00776789|Other|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
14546|NCT00776802|Drug|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
14547|NCT00776802|Drug|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
14548|NCT00776828|Drug|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
14813|NCT00811369|Drug|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
14814|NCT00811369|Drug|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
14815|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
14816|NCT00006465|Drug|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
14817|NCT00804713|Drug|TST|Administer TB Skin test (TST)
10157|NCT00752102|Drug|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
10158|NCT00752115|Drug|sildenafil|50mg, day1,8 and 15 in each cycle
10159|NCT00752115|Drug|placebo|1 tab, day 1,8 and 15 in each cycle.
10160|NCT00743691|Other|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
10161|NCT00743704|Other|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
10162|NCT00743717|Device|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
10163|NCT00743717|Device|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
10164|NCT00743730|Other|Pain and standard side effect management for PNCA with basal method.|Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.
Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure.
10165|NCT00743730|Other|Pain and standard side effect management with PNCA without basal|Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.
Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure.
10166|NCT00743730|Other|Pain and standard side effect management with IV on an as needed basis method.|Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.
Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol.
10167|NCT00000708|Drug|Amphotericin B|
10168|NCT00006027|Procedure|adjuvant therapy|
10466|NCT00747084|Procedure|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
10467|NCT00747097|Drug|gemcitabine + cetuximab|gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
10468|NCT00747110|Drug|budesonide|3x 3mg budesonide capsules once daily
10469|NCT00747110|Drug|mesalazine|3x 1000mg mesalazine onc daily
10470|NCT00747123|Biological|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
11184|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
11185|NCT00745693|Drug|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
11186|NCT00745706|Device|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
11187|NCT00745719|Procedure|parathyroidectomy|total parathyroidectomy with forearm autografting
11188|NCT00745732|Drug|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
11189|NCT00745732|Radiation|Radiation Therapy|Phase I: 45 Gy at 3 Gy per fractions once a day.
Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.
11190|NCT00745745|Device|Device Implantation|ICD lead implantation
11191|NCT00745771|Drug|Diractin|
11192|NCT00745771|Drug|Diractin|
11193|NCT00745784|Behavioral|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
11194|NCT00745797|Radiation|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
11195|NCT00006036|Drug|lurtotecan liposome|
11196|NCT00745810|Other|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
11197|NCT00745823|Drug|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
11198|NCT00745823|Drug|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
11199|NCT00745823|Drug|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
11200|NCT00745836|Drug|statin|
11201|NCT00745849|Drug|esomeprazole|40mg by mouth twice daily
11202|NCT00745849|Drug|placebo|
10630|NCT00744458|Other|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
10631|NCT00744471|Biological|tanezumab|Tanezumab 10 mg IV every 8 weeks
10632|NCT00744471|Biological|tanezumab|Tanezumab 5mg IV every 8 weeks
10633|NCT00744471|Biological|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
10634|NCT00744471|Biological|Placebo|Placebo to match tanezumab IV every 8 weeks
10635|NCT00006031|Procedure|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
10636|NCT00744484|Behavioral|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
10950|NCT00748098|Drug|Placebo|Placebo
10951|NCT00748111|Other|Blood sample|Blood sample and thrombus sample
10952|NCT00748124|Device|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
10953|NCT00748124|Procedure|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
10954|NCT00748137|Device|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
10955|NCT00748137|Other|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
10956|NCT00006045|Biological|lintuzumab|
10957|NCT00751036|Drug|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
10958|NCT00751036|Drug|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
10959|NCT00751049|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
10960|NCT00751049|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
10961|NCT00751062|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
14818|NCT00804713|Other|QFT|Perform QFT TB test
14819|NCT00804713|Other|T-spot|Perform T-Spot TB test
14820|NCT00804726|Device|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
14821|NCT00804739|Other|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
14822|NCT00804752|Drug|Adding vitamin D|Adding 1000IU/Vitamin D daily
14823|NCT00804752|Drug|Vitamin D|Addition of 1000IU/day Vitamin D
14824|NCT00804765|Other|Therapeutic education|Intensive training individual and collective teaching
14825|NCT00804765|Other|Follow-up|classical follow-up with two individual consultations
14826|NCT00804791|Other|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
14827|NCT00006465|Drug|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
14828|NCT00804791|Other|Unisol 4 Saline Solution|saline solution for irrigating the cornea
14829|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
14830|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
14831|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
15183|NCT00812058|Drug|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
15184|NCT00812058|Drug|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
15185|NCT00812071|Biological|RiVax|vaccine
10471|NCT00747123|Biological|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
10472|NCT00747149|Drug|Rosuvastatin|Oral
10473|NCT00747162|Device|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
10474|NCT00747162|Device|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
10475|NCT00006041|Biological|MUC1-KLH vaccine/QS21|
10476|NCT00747175|Drug|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
10477|NCT00747175|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
10478|NCT00750113|Drug|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
10479|NCT00750113|Drug|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
10480|NCT00750113|Drug|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
10481|NCT00750126|Drug|Fludarabine, Busulfan, Thymoglobulin|study :
acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation
the effectiveness of the protocol on tumor response
overall survival
10482|NCT00750139|Drug|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
10483|NCT00750139|Drug|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
10484|NCT00006054|Drug|busulfan|
10485|NCT00750139|Drug|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
10486|NCT00750139|Drug|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
10487|NCT00750152|Drug|NAFT-500|topical cream application up to 4 weeks
10488|NCT00750152|Drug|Placebo|placebo cream applied for up to 4 weeks
10804|NCT00752895|Dietary Supplement|Placebo|Given orally
10805|NCT00752921|Drug|etoricoxib|120 mg
10806|NCT00752921|Drug|placebo|placebo
11203|NCT00745862|Behavioral|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
10227|NCT00752128|Device|Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation
10228|NCT00752141|Drug|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
10229|NCT00752141|Drug|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
10230|NCT00752141|Other|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
10231|NCT00752154|Drug|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
10232|NCT00752180|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
10233|NCT00752180|Biological|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
10234|NCT00752193|Other|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
10235|NCT00752193|Other|Placebo|Placebo in combination with antibiotic therapy
10236|NCT00752206|Drug|Saracatinib|Oral Agent
10237|NCT00006066|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
10238|NCT00752206|Drug|Placebo|Oral Agent
10239|NCT00752219|Drug|ceftazidime/NXL104 + metronidazole|IV TID
10240|NCT00752219|Drug|meropenem|IV TID
10241|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
10242|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
10243|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
10244|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
10962|NCT00751062|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
10963|NCT00751075|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
10964|NCT00751075|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
10965|NCT00751075|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
10966|NCT00751075|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
10967|NCT00006055|Drug|filgrastim|
11264|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).
Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation.
11265|NCT00743093|Drug|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
11266|NCT00743093|Drug|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
11267|NCT00743106|Drug|Fenoldopam|Fenoldopam (0.1 ~g/kg/min)started during surgery and lasting for a total of 24 hours
11268|NCT00743106|Drug|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
11269|NCT00743119|Drug|Oral THC|0, 10, and 20 mg
11270|NCT00006023|Drug|capecitabine|
11271|NCT00743119|Drug|Marijuana|0%, 1.98% and 3.56%
11272|NCT00743145|Drug|Naltrexone|12 mg/70kg
11273|NCT00743145|Drug|Smoked marijuana|0,2,4, or 6 puffs of 6.2% THC
11274|NCT00743184|Drug|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
11275|NCT00743184|Drug|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution
15186|NCT00812097|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The thicker consistency provides a higher resistance to flow. The gel is made from the same materials as Mentor's standard silicone gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant. These marks help the physician orient the implant and ensure proper placement during implantation. CPG is available in sizes 120 cc-775 cc and 5 styles with various projection and height options.
15187|NCT00812110|Drug|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
15188|NCT00812123|Drug|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
15189|NCT00006682|Drug|vinorelbine ditartrate|
15190|NCT00812123|Drug|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
15191|NCT00812123|Drug|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
15192|NCT00812123|Drug|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
15193|NCT00805272|Other|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
15194|NCT00805285|Drug|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
15195|NCT00805298|Drug|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
15196|NCT00805298|Drug|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
15197|NCT00805298|Drug|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
15198|NCT00805298|Drug|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
15199|NCT00805311|Procedure|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
15200|NCT00805311|Drug|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
15201|NCT00006469|Drug|carboplatin|
10807|NCT00752934|Drug|oral baclofen + placebo|Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.
For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.
For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.
Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur.
10808|NCT00752934|Drug|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
10809|NCT00752947|Drug|moxifloxacin|Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
10810|NCT00006077|Drug|NS2330|
10811|NCT00752947|Drug|levofloxacin|Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
10812|NCT00752947|Drug|metronidazole|metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
10813|NCT00752973|Drug|MALG (malathion) Treatment|MALG applied for 30 minutes
10814|NCT00744861|Device|Low Intensity Pulsed Ultrasound|
10815|NCT00744861|Device|Sham|
10816|NCT00744874|Procedure|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
10817|NCT00006032|Procedure|peripheral blood stem cell transplantation|
10818|NCT00744887|Drug|Darunavir|
10819|NCT00744900|Drug|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
10820|NCT00744913|Drug|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
10821|NCT00744913|Other|Counselling|Women in this arm of the study will receive standard counseling only.
10822|NCT00744926|Drug|placebo|sc, once weekly
10245|NCT00752232|Other|PBS|IM injection, Day 1, month 3, 6, 9, 12
10246|NCT00752245|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
10247|NCT00752245|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
10248|NCT00006066|Biological|Diphtheria and Tetanus Toxoids Adsorbed|
10249|NCT00752245|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
10554|NCT00747201|Behavioral|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
10555|NCT00747201|Behavioral|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
10556|NCT00747214|Drug|CRx-102|
10557|NCT00747214|Drug|Placebo|
10558|NCT00747214|Drug|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
10559|NCT00747227|Device|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
10560|NCT00747227|Device|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
10561|NCT00006041|Biological|QS21|
10562|NCT00747253|Device|AutoLITT system|laser treatment with the AutoLITT system
10563|NCT00747279|Other|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
10564|NCT00747279|Drug|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
10565|NCT00747292|Procedure|epidural|Patients in this limb receive epidural analgesia
10566|NCT00747292|Procedure|PCA|Patients in this limb receive a PCA for their pain control
10567|NCT00747292|Procedure|Spinal|Patients in limb will receive spinal analgesia
10568|NCT00747305|Drug|sunitinib malate|
11276|NCT00743197|Drug|Aspirin|Aspirin 81 mg daily
11277|NCT00743197|Drug|Lisinopril|Lisinopril 10 mg every night
11278|NCT00743197|Drug|Simvastatin|Simvastatin 20 mg every night
11279|NCT00745901|Drug|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
11280|NCT00745914|Drug|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
11281|NCT00745914|Drug|Placebo comparator|Placebo comparator
11282|NCT00745927|Other|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
11283|NCT00745940|Behavioral|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
11284|NCT00745953|Drug|Valsartan|Valsartan 320mg PO daily for 8 months
10308|NCT00749853|Drug|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
10309|NCT00749853|Drug|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
10310|NCT00749866|Drug|Gentamicin|Nebulised 80mg twice daily
10311|NCT00749866|Drug|Saline|Nebulised 4mls 0.9% Saline twice daily
10312|NCT00006052|Drug|imatinib mesylate|
10313|NCT00749879|Drug|Proellex®|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
10314|NCT00752258|Drug|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
10315|NCT00752284|Procedure|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
14231|NCT00781638|Device|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
14232|NCT00781664|Other|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
14233|NCT00781664|Drug|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
14234|NCT00781664|Drug|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
14235|NCT00781664|Other|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
14236|NCT00773383|Drug|RG1507|iv 9mg/kg weekly
14237|NCT00773383|Drug|erlotinib [Tarceva]|150mg oral daily
14238|NCT00773422|Drug|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
14239|NCT00006226|Other|laboratory biomarker analysis|Correlative studies
14240|NCT00773422|Drug|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
14241|NCT00773422|Drug|placebo|placebo
14242|NCT00773435|Biological|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
14243|NCT00773435|Other|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
14244|NCT00773448|Device|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
14245|NCT00773448|Other|Limited Malignancy Screening|1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)
In women, a pap smear/pelvic examination (if > 18 and < 70 years old and not performed during the past year),a mammogram (> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (>40 years old) will be performed if not conducted in the past year.
14246|NCT00773461|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
14247|NCT00773461|Drug|Placebo|iv every 4 weeks for 24 weeks
14248|NCT00773474|Drug|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
11123|NCT00748397|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
11124|NCT00748410|Drug|SB-656933|7 days repeat dose
11125|NCT00748423|Drug|Nitric Oxide|NO in inhalation for 3 days
11126|NCT00748423|Drug|Placebo|Placebo in inhalation for 3 days
11127|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
11128|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
11129|NCT00748436|Drug|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
11130|NCT00748449|Procedure|Colonoscopy|1 Colonoscopy
11131|NCT00748449|Procedure|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
11132|NCT00006046|Biological|monoclonal antibody Hu3S193|
11133|NCT00748462|Device|Fractional CO2 Laser|the treatment settings:
Pulse duration : 5 to 7ms depending on skin reaction
Spot Density: 49 MTZ/cm2 (Low density)
Power: 15 W = (75 - 105) mJ/MTZ
11134|NCT00748475|Behavioral|Neurofeedback|
11135|NCT00748488|Other|Physical therapy aimed to move safely|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.
Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes
11136|NCT00748488|Other|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
11137|NCT00748501|Drug|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
11138|NCT00748527|Drug|carboplatin|Given IV
11139|NCT00751231|Drug|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
11140|NCT00751231|Drug|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
11141|NCT00751244|Behavioral|Trauma Affect Regulation: Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic ("FREEDOM"), e.g., Focusing ("F"), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized "lifelines" via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize "life story" narrative reconstruction with no exposure therapy.
10569|NCT00747305|Genetic|gene expression analysis|
10570|NCT00747305|Genetic|reverse transcriptase-polymerase chain reaction|
10571|NCT00747305|Genetic|western blotting|
10572|NCT00006042|Biological|filgrastim|
10573|NCT00747305|Other|immunohistochemistry staining method|
10574|NCT00747305|Other|laboratory biomarker analysis|
10575|NCT00747305|Procedure|adjuvant therapy|
10576|NCT00747305|Procedure|neoadjuvant therapy|
10885|NCT00753103|Biological|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
10886|NCT00753103|Drug|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
10887|NCT00753103|Drug|Prednisolone|Daily oral 1mg/kg tapered over 12 months
10888|NCT00753103|Drug|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
10889|NCT00753103|Procedure|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine > 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
10890|NCT00753103|Drug|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
10891|NCT00006079|Drug|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
10892|NCT00753103|Drug|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
10893|NCT00753116|Device|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
10894|NCT00753129|Procedure|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
10895|NCT00753142|Drug|Intralipid 20%|48hr infusion with intralipid at 40ml/hr
10896|NCT00753142|Drug|Glucose infusion|Glucose infusion for 20 hours at 200 mg/m2/min
10897|NCT00753155|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
10316|NCT00752284|Procedure|Total Excision|Total excision of lower third molar
10317|NCT00752297|Drug|Preservative-free Saline|Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
10318|NCT00752297|Drug|Mentor Purified Toxin|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
10319|NCT00752310|Drug|Darunavir|
10320|NCT00752323|Drug|aminolevulinic acid|Given orally
10321|NCT00752336|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
10322|NCT00752349|Procedure|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
10323|NCT00006066|Biological|Tetanus and Diphtheria Toxoids Adsorbed|
10324|NCT00752362|Device|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
10325|NCT00752362|Device|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
10637|NCT00744484|Behavioral|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
10638|NCT00744497|Drug|Placebo|
10639|NCT00744497|Drug|Dasatinib|
10640|NCT00744497|Drug|Docetaxel|
10641|NCT00744497|Drug|Prednisone|
10642|NCT00744510|Other|Reflexology|10 weekly sessions of 45 minutes each
10643|NCT00744523|Device|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
10644|NCT00744536|Drug|Lenalidomide and melphalan|Lenalidomide 10 mg po daily for 21d/28 Melphalan 2 mg po daily for 21d/28
10645|NCT00744549|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
14249|NCT00773487|Other|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
14250|NCT00000728|Drug|Aldesleukin|
14832|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
14833|NCT00804817|Behavioral|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
14834|NCT00804817|Behavioral|SCION-HSCT program|Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.
The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects.
14835|NCT00804830|Drug|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
14836|NCT00806936|Drug|human insulin|Any kind of human insulin administered at the discretion of the physician
14837|NCT00806936|Drug|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
14838|NCT00806962|Drug|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
14839|NCT00006478|Biological|keyhole limpet hemocyanin|
14840|NCT00806962|Device|placebo|intranasal, puff of air, 2 doses, 21 days apart
14841|NCT00806962|Biological|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
14842|NCT00806962|Biological|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
14843|NCT00806975|Device|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
14844|NCT00806988|Procedure|Mitral Valve Repair|Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:
All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.
The heart will be arrested with cardioplegia.
A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings.
10169|NCT00743743|Dietary Supplement|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
10170|NCT00743743|Dietary Supplement|placebo|1 capsule of placebo daily for 52 weeks
10171|NCT00743756|Dietary Supplement|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
10172|NCT00743756|Dietary Supplement|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
10173|NCT00743756|Behavioral|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
10174|NCT00743769|Drug|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
10175|NCT00743769|Other|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
10176|NCT00743782|Drug|Synthetic Human Parathyroid Hormone 1-34|
10177|NCT00743795|Drug|placebo|oral BID
10178|NCT00743795|Drug|GS-9190|40 mg oral BID
10179|NCT00006027|Radiation|radiation therapy|
10180|NCT00743795|Drug|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
10181|NCT00743795|Drug|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
10182|NCT00743808|Other|quality improvement|3-phase quality improvement intervention
10183|NCT00746616|Device|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
10184|NCT00746629|Behavioral|FOCUS|Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are "prescribed" or "self-directed". Children and parents will be weighed at each clinic visit.
10185|NCT00746642|Device|Mellitor device for glucose measurement|Glucose measurement using "Mellitor" device
10186|NCT00746655|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
10898|NCT00753168|Drug|OT-730 ophthalmic solution|one eye drop twice daily
10899|NCT00753168|Drug|timolol maleate ophthalmic solution|one eye drop twice daily
10900|NCT00753168|Drug|OT-730 placebo|one eye drop twice daily
10901|NCT00753181|Other|Nutritional Formula|nutritional shake daily
10902|NCT00006079|Other|Placebo|Patients receive oral placebo daily for 28 days.
10903|NCT00753181|Other|Usual diet|usual dietary habits
10904|NCT00753181|Other|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
10905|NCT00753207|Drug|epirubicin hydrochloride|
10906|NCT00753207|Drug|lapatinib ditosylate|
10907|NCT00753207|Other|biomarker analysis|
11204|NCT00745875|Drug|ZD4054|10mg oral tablet, once daily
11205|NCT00745875|Drug|Pemetrexed|500mg2/m IV infusion
11206|NCT00006037|Drug|fluorouracil|
11207|NCT00745875|Drug|Placebo|10mg oral tablet, once daily
11208|NCT00745888|Other|Chemiluminescence Analyzer|measure reactive oxygen species
11209|NCT00748527|Drug|decitabine|Given IV
11210|NCT00748540|Device|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
11211|NCT00748553|Drug|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
11212|NCT00748553|Drug|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
11213|NCT00006047|Drug|Oral Etoposide|
11214|NCT00748566|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
11215|NCT00748579|Drug|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
11216|NCT00748579|Drug|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
10646|NCT00006032|Drug|etoposide|
10647|NCT00744549|Drug|Placebo|Twice a day with meals.
10648|NCT00747331|Drug|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
10649|NCT00747331|Drug|Placebo|Intravenous infusion (saline)
Infused at the same rate (ml/h) as the experimental drug
10650|NCT00747344|Drug|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
10651|NCT00747344|Drug|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
10652|NCT00006042|Drug|cyclophosphamide|
10653|NCT00747344|Drug|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
10654|NCT00747344|Drug|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
10655|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
10656|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
10657|NCT00747370|Procedure|movement of midurethra, bladder neck, cervix and rectum|
10658|NCT00747383|Drug|Glimepiride|3mg oral tablet.
10968|NCT00751088|Procedure|MiniArc positioning|Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower "frenulum" attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure.
10969|NCT00751088|Procedure|TVT secur system positioning|Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower "frenulum" attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure.
10970|NCT00751088|Procedure|Ajust positioning|Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower "frenulum" attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure.
14845|NCT00806988|Procedure|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
14846|NCT00807001|Drug|IDX184|oral dose, active or placebo
14847|NCT00807014|Drug|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
14869|NCT00809172|Drug|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
14870|NCT00809185|Drug|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
14871|NCT00809185|Other|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
14872|NCT00006489|Drug|Placebo|Pill Placebo daily dosing 24 weeks
14873|NCT00809185|Procedure|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
14874|NCT00809198|Other|Sodium Hyaluronate|
14875|NCT00809198|Other|Carboxymethylcellulose sodium|
14876|NCT00809211|Drug|nilotinib|
14877|NCT00809211|Genetic|cytogenetic analysis|
14878|NCT00809211|Genetic|mutation analysis|
14879|NCT00809211|Genetic|polymerase chain reaction|
14880|NCT00809211|Other|pharmacological study|
14881|NCT00809237|Drug|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
14882|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
14883|NCT00811395|Drug|Teriflunomide|Film-coated tablet
Oral administration
14884|NCT00811395|Drug|Placebo (for teriflunomide)|Film-coated tablet
Oral administration
14885|NCT00006617|Drug|Zidovudine|
10187|NCT00006039|Biological|pegylated interferon alfa|
10489|NCT00750165|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
10490|NCT00750178|Drug|vorinostat (MK0683 )|Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28
Total treatment period is 28 days
10491|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
10492|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
10493|NCT00750204|Device|APRV|APRV Protocol
Set FiO2 at 0.1 higher than the setting on conventional MV currently used
Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).
Respiratory rate (RR) to equal 60-65% of RR on conventional MV.
Phigh = the inspiratory plateau pressure. Maximum Phigh = 30 cm H20.
Plow = 5 cm H2O. Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of PBW.
If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease Phigh in increments of 2-4 cm H20 to achieve desired release volumes (minimum Phigh = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV.
10494|NCT00750204|Device|Conventional MV|Low tidal-volume mechanical ventilation
10495|NCT00006054|Drug|cyclophosphamide|
10496|NCT00750217|Drug|Buprenorphine patch and sublingual tablets|Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.
Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake.
10497|NCT00750230|Dietary Supplement|NEM|see Treatment Arm
10498|NCT00750243|Drug|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
10499|NCT00750243|Drug|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
10500|NCT00750256|Drug|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
10501|NCT00750269|Radiation|stereotactic body radiation therapy (SBRT)|
10502|NCT00752583|Procedure|Peritoneal dialysis|Blood, urine and dialysate sampling
10503|NCT00006068|Procedure|Pancreatic Islet Transplantation|
10504|NCT00752583|Procedure|Haemodialysis|Blood, urine and dialysate sampling
10505|NCT00752596|Drug|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
11217|NCT00748592|Drug|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
11218|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
11219|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
11220|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
11221|NCT00748605|Drug|Placebo|Total of 60 weeks of double-blind dosing, four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet) and RCD (reduced calorie diet)
11222|NCT00748605|Drug|Placebo plus S-2367|Total of 6 weeks of double-blind dosing, with four placebo tablets (total dose = 0 mg/day S-2367) during LCD and 54 weeks of four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD
11223|NCT00748605|Drug|S-2367|Total of 60 weeks of double-blind dosing, four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD
11224|NCT00006047|Drug|Oral 9-Nitrocamptothecin|
11225|NCT00748618|Dietary Supplement|vitamin D3|10,000 I.U./wk of vitamin D3 orally for 6 months
10250|NCT00743834|Drug|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
10251|NCT00743834|Behavioral|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
10252|NCT00743847|Drug|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
10253|NCT00743847|Drug|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
10254|NCT00743847|Drug|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
10255|NCT00743860|Drug|darapladib|experimental drug
10256|NCT00743873|Biological|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
10257|NCT00006028|Drug|cisplatin|
10971|NCT00751088|Procedure|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
10972|NCT00753415|Biological|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10^9 vector genomes/mL) or a HD (1 x 10^11 vector genomes/mL).
10973|NCT00753415|Biological|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
10974|NCT00753428|Other|Community-based Survey|Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.
Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults.
10975|NCT00006081|Drug|Paclitaxel (Taxol)|80 mg/m^2 one-hour infusion weekly x 3 every 4 weeks
10976|NCT00753441|Procedure|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
10977|NCT00753441|Procedure|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
10978|NCT00753454|Drug|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 & Week 4, followed by 200 mg every 2 weeks).
10979|NCT00753467|Drug|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
10980|NCT00753467|Drug|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
11285|NCT00745953|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
11286|NCT00745992|Other|Blood drawn (lab data)|Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated
Check genetic polymorphism of liver enzyme 3-5 days after start of drug
11287|NCT00006037|Drug|irinotecan hydrochloride|
11288|NCT00746005|Dietary Supplement|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
11289|NCT00746005|Dietary Supplement|placebo, sunflower oil|3 g of sunflower oil
14886|NCT00811395|Drug|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
14887|NCT00811395|Drug|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
14888|NCT00811408|Drug|carboplatin|
14889|NCT00811408|Drug|cidofovir|
14890|NCT00811408|Genetic|protein expression analysis|
14891|NCT00811408|Other|laboratory biomarker analysis|
15202|NCT00805324|Drug|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
15203|NCT00805337|Device|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
15204|NCT00805350|Drug|Eplivanserin|one 5 mg tablet once a day
15205|NCT00805350|Drug|Placebo|Placebo of Eplivanserin one tablet once a day
15206|NCT00805376|Drug|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
15207|NCT00805376|Procedure|Tumor Removal|Surgical Tumor Resection
15208|NCT00805389|Biological|Engerix-B™|2 doses intramuscular injections
15209|NCT00805389|Biological|Fendrix™|2 doses intramuscular injections
15210|NCT00805389|Biological|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
15211|NCT00805389|Biological|HBsAg (Booster injection)|Single dose intramuscular injection
15212|NCT00006469|Drug|paclitaxel|
15213|NCT00805402|Other|flow cytometry|flow cytometry
15214|NCT00805415|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
15215|NCT00805415|Drug|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
10506|NCT00752609|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
10507|NCT00752622|Biological|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
10823|NCT00744926|Drug|taspoglutide|10mg sc, once weekly
10824|NCT00744926|Drug|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
10825|NCT00744939|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
10826|NCT00744965|Drug|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
10827|NCT00744965|Drug|Placebo|Sham dose adjustments of the placebo will be made.
10828|NCT00006033|Biological|gene therapy|
10829|NCT00744978|Drug|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
10830|NCT00744978|Drug|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
10831|NCT00744991|Drug|Enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
10832|NCT00745004|Drug|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
10833|NCT00745004|Drug|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
10834|NCT00745017|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
10835|NCT00747812|Device|Precision|Implantable Neurostimulator
10836|NCT00747825|Drug|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
10837|NCT00747838|Procedure|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
10838|NCT00006042|Procedure|allogeneic bone marrow transplantation|
10258|NCT00743873|Drug|placebo|injection of 6 cc of saline into injured area
10259|NCT00743886|Biological|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
10260|NCT00743886|Drug|saline|injection of 6 cc of saline into injured area
10261|NCT00743899|Procedure|The aggressive group|Stents were implanted in lesions with diameter stenosis >50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis >50% and RD ≥2.0 mm and <2.25 mm.
10262|NCT00743899|Procedure|The conservative group|Stenting was performed only in lesions with diameter stenosis >70% and reference diameter (RD) ≥2.25 mm
10263|NCT00743912|Drug|rifaximin|550 mg TID
10264|NCT00743925|Drug|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
10265|NCT00743938|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
10266|NCT00743938|Drug|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
10267|NCT00743951|Behavioral|1 Patient decision aid|Patients will receive:
i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.
iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.
iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference).
10268|NCT00006028|Drug|gemcitabine hydrochloride|
10577|NCT00747305|Procedure|therapeutic conventional surgery|
10578|NCT00747318|Drug|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
10579|NCT00750282|Drug|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
10580|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
10581|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
10582|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
10583|NCT00006054|Drug|cyclosporine|
11290|NCT00746018|Device|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
11291|NCT00746031|Drug|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
11292|NCT00746031|Drug|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
11293|NCT00746057|Biological|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
11294|NCT00746070|Other|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
11295|NCT00746083|Behavioral|Challenge!|Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a "personal trainer" (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer.
11296|NCT00746096|Drug|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
11297|NCT00746096|Drug|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
11298|NCT00006037|Drug|oglufanide disodium|
11299|NCT00746109|Procedure|Wound packing|1/4" non-iodoform packing loosely placed inside abscess cavity.
11300|NCT00748657|Biological|bevacizumab|Given IV
11301|NCT00748670|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
11302|NCT00748683|Other|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
11303|NCT00748696|Dietary Supplement|Fortimel Extra®|260kcal and 20g protein per day
10326|NCT00752362|Device|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
10327|NCT00752375|Drug|Trimethoprim Sulfamethoxazole|Children >3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.
Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.
Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year.
16525|NCT00800267|Drug|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
16526|NCT00006441|Drug|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
16527|NCT00800267|Drug|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
16528|NCT00802776|Procedure|Femtosecond laser assisted keratoplasty|
16529|NCT00802776|Procedure|PKP|
16530|NCT00802802|Drug|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
16531|NCT00006455|Drug|etoposide|
16532|NCT00802802|Drug|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
16533|NCT00802815|Drug|Etanercept|50 milligrams subcutaneously every week
16534|NCT00802828|Drug|Famotidine Tablets, 40 mg|
16535|NCT00802841|Drug|nilotinib|Supplied as 200 mg tablets
16536|NCT00802841|Drug|imatinib|Supplied as 100 mg and 400 mg tablets
16537|NCT00802867|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
16538|NCT00802880|Drug|Dacarbazine|
16539|NCT00802893|Drug|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
16540|NCT00802893|Other|Placebo|placebo given BID for entire length of study
16541|NCT00802906|Device|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
16542|NCT00006455|Drug|ifosfamide|
16543|NCT00802906|Drug|bevacizumab|1.5 mg initial intravitreal injection
16826|NCT00803101|Biological|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
16827|NCT00803114|Drug|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
17311|NCT00798863|Procedure|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
17312|NCT00798876|Dietary Supplement|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
17313|NCT00798876|Dietary Supplement|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
17314|NCT00006417|Procedure|Stem cell transplantation|
17315|NCT00798876|Dietary Supplement|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
17316|NCT00798876|Dietary Supplement|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
17317|NCT00798876|Other|Medical Examination|Subjects will have a routine medical exam.
17669|NCT00822523|Drug|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
17670|NCT00822523|Drug|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
17671|NCT00822523|Drug|Saline|Single Dose, Intramuscular into right EDB muscle
17672|NCT00822536|Drug|Aspirin and Clopidogrel|Aspirin <= 325 mg/j Clopidogrel = 75 mg /j
17673|NCT00822536|Drug|Aspirin|Aspirin : <= 325 mg/j
17674|NCT00007852|Procedure|autologous hematopoietic stem cell transplantation|Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
17675|NCT00822549|Drug|intravenous morphine titration|intravenous morphine titration
17676|NCT00822562|Other|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
17677|NCT00822562|Procedure|surgery|only surgery
17678|NCT00822575|Device|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
17679|NCT00822588|Device|Sangvia® System|Sangvia® Intra- and Post-op System
16606|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
16607|NCT00800280|Drug|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
16886|NCT00800865|Other|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
16887|NCT00800917|Drug|Temsirolimus|25 mg weekly IV
16888|NCT00800917|Drug|Bevacizumab|10 mg/kg every 2 weeks
16889|NCT00800930|Biological|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
16890|NCT00000748|Drug|Sulfamethoxazole-Trimethoprim|
16891|NCT00006446|Procedure|Training in parenting skills and communication|
16892|NCT00800930|Biological|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
16893|NCT00800943|Biological|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
16894|NCT00800956|Drug|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi [14C]-esreboxetine
16895|NCT00800969|Procedure|FDG-PET-CT|Radiologic standard procedure
16896|NCT00800982|Procedure|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
16897|NCT00800982|Drug|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
16898|NCT00803309|Drug|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
16899|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
16900|NCT00803309|Drug|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
17238|NCT00798850|Procedure|Supervised Exercise Programme (SEP)|SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.
Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).
Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)
Station 2-Exercise bicycles
Station 3-Knee extensions with weights(2kg beanbag)
Station 4-Heel raises
Station 5-Knee bends(Alternating legs after 10 bends)
Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.
This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants.
17584|NCT00822419|Drug|ketamine|ketamine 5%
17585|NCT00822419|Drug|non-drug cream|will be put on the skin
17586|NCT00822458|Drug|vismodegib|Given orally
17587|NCT00822458|Other|laboratory biomarker analysis|
17588|NCT00822458|Other|pharmacological study|
17589|NCT00822471|Behavioral|Diabetes Self-Management Education|DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the "ABCs of diabetes" and training in how to talk to your doctor.
17590|NCT00824486|Behavioral|Injury prevention education (safe home)|using safe home model
17591|NCT00824499|Other|Complex regional intervention|Components of the complex intervention:
Introduction of a program coordinator
Introduction of a self-management education program
Bottom up development of a interdisciplinary care protocol
Support program for the intiation of insulin therapy in primary care
Regional audit
17592|NCT00824512|Drug|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
17593|NCT00824512|Drug|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
17594|NCT00824538|Drug|sunitinib malate|
17595|NCT00824538|Other|flow cytometry|
17596|NCT00007982|Biological|filgrastim|
17597|NCT00824538|Other|immunohistochemistry staining method|
17598|NCT00824538|Other|laboratory biomarker analysis|
17599|NCT00824551|Procedure|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
17600|NCT00824551|Other|Standard care|Patient will undergo standard care
16673|NCT00798070|Drug|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
16674|NCT00798070|Drug|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
16675|NCT00798083|Drug|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
16676|NCT00798096|Drug|Fostamatinib Disodium|200 mg PO BID
16677|NCT00798109|Behavioral|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
16678|NCT00000746|Biological|Env 2-3|
16679|NCT00006399|Drug|Donepezil|
16680|NCT00798109|Behavioral|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
16681|NCT00798122|Procedure|Intravascular ultrasound|intravascular ultrasound
16957|NCT00798538|Other|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
16958|NCT00798538|Other|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
16959|NCT00800995|Dietary Supplement|SOD|
16960|NCT00800995|Dietary Supplement|Sham|
16961|NCT00801008|Behavioral|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
16962|NCT00801021|Drug|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
16963|NCT00006447|Procedure|Social Support|
16964|NCT00801034|Drug|Calcium|tablets, 1 tablet 2 times per day in 28 days
16965|NCT00801034|Drug|Potassium|Tablets, 5 tablets 2 times per day for 28 days
16966|NCT00801047|Drug|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
16967|NCT00801047|Drug|Remifentanil|40-50 mic per 1-2 min via PCA
17680|NCT00822601|Device|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
17681|NCT00822601|Device|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
17682|NCT00822614|Drug|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
17683|NCT00822614|Drug|Opioid|Current optimized BTP treatment
17684|NCT00822627|Drug|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
17685|NCT00007865|Biological|rituximab|
17686|NCT00822627|Behavioral|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
17687|NCT00007982|Drug|cisplatin|
17688|NCT00824681|Behavioral|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
17689|NCT00824681|Other|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
17690|NCT00824694|Other|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
16739|NCT00795678|Drug|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
16740|NCT00006385|Biological|sargramostim|
16741|NCT00795678|Drug|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
16742|NCT00795678|Drug|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
16743|NCT00795691|Behavioral|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
16744|NCT00795691|Behavioral|low-fat diet|low-fat diet in patients with type 2 diabetes
16901|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
16902|NCT00803335|Drug|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
16903|NCT00006457|Drug|oltipraz|
17169|NCT00801385|Drug|erlotinib hydrochloride|
17170|NCT00801385|Drug|sorafenib tosylate|
17171|NCT00801385|Genetic|DNA analysis|
17172|NCT00801385|Genetic|mutation analysis|
17173|NCT00801385|Genetic|polymerase chain reaction|
17174|NCT00801385|Genetic|protein analysis|
17175|NCT00801385|Genetic|protein expression analysis|
17176|NCT00006450|Drug|Phenylbutyrate|
17177|NCT00801385|Other|immunohistochemistry staining method|
17178|NCT00801385|Other|laboratory biomarker analysis|
17179|NCT00801398|Drug|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
17180|NCT00801411|Drug|cyclophosphamide|Given IV
17181|NCT00801411|Drug|docetaxel|Given IV
17182|NCT00801411|Drug|doxorubicin hydrochloride|Given IV
17183|NCT00793988|Procedure|Vibration-assisted anaesthesia|All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.
The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site.
17184|NCT00793988|Procedure|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
17185|NCT00794001|Behavioral|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
17601|NCT00824564|Drug|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
17602|NCT00824564|Procedure|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
17603|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
17604|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
17605|NCT00824616|Drug|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
17606|NCT00824616|Drug|Placebo|Placebo tablets, taken 3 times daily.
17607|NCT00007982|Drug|carmustine|
16666|NCT00795678|Drug|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
16667|NCT00795678|Drug|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
16668|NCT00798031|Device|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
16669|NCT00798031|Device|Placement of dental implant|Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.
A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis.
16670|NCT00798031|Device|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
16671|NCT00798044|Behavioral|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
16672|NCT00798044|Behavioral|Patient Feedback|Weekly feedback reports provided to counselors
16968|NCT00801060|Drug|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
16969|NCT00801060|Drug|FCR|Dosage, schedule, and duration in the protocol
16970|NCT00801073|Procedure|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
16971|NCT00801086|Drug|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
16972|NCT00801086|Drug|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
16973|NCT00801099|Drug|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
16974|NCT00006448|Behavioral|cognitive therapy|
16975|NCT00801125|Drug|TYSABRI (natalizumab)|
16976|NCT00801138|Drug|Ropivacaine|
16977|NCT00801138|Drug|Bupivacaine|
16978|NCT00801138|Drug|Dexamethasone|steroid
16979|NCT00801138|Drug|Placebo|saline
17239|NCT00801424|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
17240|NCT00801437|Drug|Xalacom|Xalacom 1 drop into the affected eye daily
17241|NCT00801450|Drug|Triamcinolone acetonide|4 mg
17242|NCT00801450|Drug|Triamcinolone acetonide|40 mg
17243|NCT00006451|Drug|anti-thymocyte globulin|
17244|NCT00801463|Drug|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
17245|NCT00801476|Procedure|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
17246|NCT00801489|Drug|Fludarabine|30 mg/m^2 intravenously days 1, 2, 3, 4, and 5 (infusion time approximately 30 minutes). Post-Remission Therapy will consist of 3 days rather than 5 days.
16745|NCT00795704|Drug|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
16746|NCT00795704|Drug|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
16747|NCT00795717|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
16748|NCT00795717|Drug|Placebo|2 capsules given twice daily
16749|NCT00795730|Drug|NSA-789|
16750|NCT00795730|Other|placebo|
16751|NCT00006385|Biological|tyrosinase peptide|
16752|NCT00795756|Drug|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
16753|NCT00795756|Drug|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
16754|NCT00795769|Drug|ondansetron|Given IV
16755|NCT00795769|Other|survey administration|Correlative studies
16756|NCT00798161|Drug|metformin|metformin 1000 mg tablet, twice daily
16757|NCT00006399|Drug|Estrogen|
16758|NCT00798161|Drug|matching placebo|matching placebo
16759|NCT00798174|Device|Azygos vein coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
17045|NCT00006409|Behavioral|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
17046|NCT00798590|Drug|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
17047|NCT00798590|Drug|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
17048|NCT00798603|Biological|bevacizumab|
17049|NCT00798603|Drug|carboplatin|
17186|NCT00794014|Procedure|Conservative strategy|Main vessel stenting was performed.
Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow <3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) >75% in LM subgroup.
Side branch stenting was performed if TIMI flow <3 in the Side branch after ballooning in non-LM subgroup, and DS >50% or dissection in the Side branch after ballooning in LM subgroup.
17187|NCT00794014|Procedure|Aggressive strategy|Main vessel was performed.
Side branch ballooning and kissing ballooning were done if DS >75% in the side branch after main vessel stenting in non-LM subgroup, and DS >50% in LM subgroup.
Side branch stenting was performed if DS >50% in the side branch after ballooning in non-LM subgroup, and DS >30% or dissection in the side branch after ballooning in LM subgroup.
17525|NCT00827099|Drug|fludarabine phosphate|fludarabine phosphate
17526|NCT00827099|Drug|Melphalan|melphalan
17527|NCT00827099|Drug|mycophenolate mofetil|mycophenolate mofetil
17528|NCT00008021|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
17529|NCT00827099|Drug|tacrolimus|tacrolimus
17530|NCT00827099|Procedure|umbilical cord blood transplantation|umbilical cord blood transplantation
17531|NCT00827112|Drug|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
17532|NCT00827112|Drug|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
17533|NCT00827125|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
17534|NCT00827138|Drug|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
17535|NCT00827151|Drug|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
17536|NCT00827164|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
17537|NCT00827164|Behavioral|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
13580|NCT00783198|Biological|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
13581|NCT00783198|Biological|Placebo|matching placebo sublingual tablets administered once daily
13582|NCT00783211|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
13583|NCT00006268|Drug|isolated perfusion|
13584|NCT00783211|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
13585|NCT00783211|Drug|placebo|placebo, once daily for 15 days
13586|NCT00783224|Drug|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
13587|NCT00783224|Drug|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
13588|NCT00783224|Drug|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
13589|NCT00783224|Drug|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
13590|NCT00783237|Drug|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
13591|NCT00783237|Drug|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
13592|NCT00783250|Drug|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
13593|NCT00783250|Drug|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
13594|NCT00006268|Procedure|conventional surgery|
13595|NCT00783263|Drug|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
13903|NCT00775632|Drug|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
13904|NCT00778011|Drug|Ondansetron|4 mg
13905|NCT00778011|Drug|Metoclopramide|10 mg IV
13906|NCT00778024|Drug|fluoxetine HCL 40 mg capsules|
13907|NCT00778037|Drug|Cyclobenzaprine hydrochloride 10 mg tablet|
17247|NCT00801489|Drug|Cytarabine|2 g/m^2 intravenously over 4 hours daily days 1, 2, 3, 4, and 5; each infusion begins 3.5 hours after completion of that day's fludarabine infusion - Post-Remission Therapy will consist of 3 days rather than 5 days.
17248|NCT00801489|Drug|G-CSF (Filgrastim, Neupogen)|5 mcg/kg body weight (rounded off to the nearest number) starting day-1 till recovery of absolute neutrophil count (ANC) to 1.0 x 109/L or above. (G-CSF will be started on day 2 for patients with presenting WBC count > 10 x 109/L. Post-Remission Therapy will consist of 4 days rather than 5 days.
17249|NCT00801489|Drug|Idarubicin|6 mg/m2 by vein over 30 minutes to be given immediately after fludarabine administration on Days 3 and 4. Idarubicin will be administered as in induction cycle, in one post-remission cycle (from cycle 3-6). Idarubicin will be given immediately after fludarabine administration on Days 2 and 3.
17250|NCT00801502|Dietary Supplement|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
17251|NCT00801502|Other|Control|No change to habitual diet from week 20 of pregnancy until giving birth
17252|NCT00801515|Drug|Maraviroc|150 mg twice per day
17253|NCT00801528|Drug|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
17254|NCT00000749|Biological|rgp120/HIV-1 SF-2|
17255|NCT00006451|Drug|cyclophosphamide|
17256|NCT00801567|Device|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
17257|NCT00801580|Drug|doxorubicin liposomal|Cyclophosphamide
Mesna
Methotrexate
Doxorubicin liposomal
Vincristine
Dexamethasone
Rituximab
Cytarabine
17608|NCT00824616|Drug|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
17609|NCT00824629|Procedure|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
17610|NCT00824629|Procedure|Direct embryo transfer procedure|Direct embryo transfer procedure
17611|NCT00824642|Device|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
17612|NCT00824642|Device|placebo|placebo TENS applied prior to exercise
17613|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
17614|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
17615|NCT00824668|Drug|biphasic insulin aspart 30|
16828|NCT00803114|Drug|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
16829|NCT00803127|Device|vs-sense|detection swab
16830|NCT00795769|Procedure|management of therapy complications|Ondansetron IV
16831|NCT00795782|Procedure|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
16832|NCT00795795|Procedure|Preimplantation Genetic Screening|Preimplantation Genetic Screening
16833|NCT00795795|Procedure|IVF without PGS|IVF without PGS
16834|NCT00795808|Drug|Metformin|500mg tds for 6 months
16835|NCT00795808|Drug|Placebo|One tablet tds for 6 months
16836|NCT00000745|Biological|Hepatitis B Vaccine (Recombinant)|
16837|NCT00006386|Drug|carmustine|
16838|NCT00795808|Drug|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
16839|NCT00795808|Drug|Metformin|500mg tds for 6 months
16840|NCT00795808|Drug|Clomiphene|Ovulatory dose for 6 months
16841|NCT00795821|Drug|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
16842|NCT00795821|Drug|Placebo|Dose: 3 tablets QD for 62 weeks
16843|NCT00795834|Dietary Supplement|High polyphenol beverage|Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0
250ml twice daily for 1 month (56 doses)
16844|NCT00795834|Dietary Supplement|Placebo Beverage|Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0
250ml twice daily for 1 month (56 doses)
16845|NCT00795847|Drug|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
16846|NCT00795860|Other|Weight loss|Subjects are randomized to one of two weight loss programs (see arms 1 and 2)until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
17108|NCT00793975|Biological|1121B|Cohort 3
6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
17538|NCT00827177|Drug|Treatment with ARQ 197 in combination with sorafenib|Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.
If < 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid).
17539|NCT00008034|Drug|capecitabine|
17540|NCT00827190|Drug|ILS-920|
17541|NCT00829582|Drug|ETI-204, "Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
16608|NCT00800293|Drug|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
16609|NCT00800306|Drug|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
16610|NCT00800306|Drug|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
16611|NCT00800319|Drug|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
16612|NCT00800319|Drug|Placebo|Volume matched placebo; oral solution; single dose
16613|NCT00006441|Drug|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
16614|NCT00800332|Drug|CYT003-QbG10|subcutaneous injection
16615|NCT00800332|Drug|Placebo|subcutaneous injection
16616|NCT00800345|Drug|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
16617|NCT00800345|Drug|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
16618|NCT00800358|Drug|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
16619|NCT00800358|Drug|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
16620|NCT00800371|Procedure|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
16621|NCT00800384|Device|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
13908|NCT00778050|Drug|Amoxicillin 600mg|
13909|NCT00778063|Drug|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
13910|NCT00778063|Drug|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
13911|NCT00006247|Drug|semaxanib|
13912|NCT00778076|Device|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
13913|NCT00778076|Device|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
13914|NCT00778089|Device|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
13915|NCT00778102|Drug|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
13916|NCT00778102|Drug|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
13917|NCT00778102|Drug|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
13918|NCT00778102|Drug|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
13919|NCT00778102|Drug|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
13920|NCT00778102|Drug|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
13921|NCT00778102|Drug|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
13922|NCT00006248|Drug|cisplatin|
13923|NCT00778102|Drug|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
13924|NCT00778115|Drug|Loperamide HCl 2 mg and simethicone 125 mg tablets|
13925|NCT00778128|Drug|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
17086|NCT00801268|Drug|tripterygium wilfordii|TW，60mg/d
17087|NCT00801268|Drug|Emodin|100mg/d
17088|NCT00801281|Drug|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
17089|NCT00801281|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
17616|NCT00824668|Drug|insulin glargine|
17617|NCT00824668|Drug|insulin glulisine|
17618|NCT00827203|Drug|Elesclomol Sodium|Chemotherapy agent
17619|NCT00827216|Drug|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
17620|NCT00827216|Drug|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
17621|NCT00827229|Device|Labor Monitor|
17622|NCT00827242|Drug|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
17623|NCT00827242|Drug|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
17624|NCT00827255|Drug|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
17625|NCT00827268|Behavioral|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
17626|NCT00827268|Radiation|Functional Magnetic Resonance Imaging (fMRI)|fMRI during reading pseudowords and during repeating pseudowords, as well as finger tapping (non-language task).
16682|NCT00798122|Procedure|MRI|cardiac MRI
16683|NCT00798135|Drug|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
16684|NCT00798148|Drug|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
16685|NCT00798161|Drug|BI 1356|BI 1356 high dose tablet, once daily
16686|NCT00798161|Drug|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
16687|NCT00798161|Drug|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
17109|NCT00793975|Biological|1121B|Cohort 4
8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
17110|NCT00793975|Biological|1121B|Cohort 5
10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
17111|NCT00006378|Radiation|radiation therapy|
17112|NCT00793975|Biological|1121B|Cohort 6
13 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
17113|NCT00793975|Biological|1121B|Cohort 7
16 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
17114|NCT00796237|Other|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
17115|NCT00796250|Biological|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
17116|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
17117|NCT00796250|Drug|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
17118|NCT00796250|Drug|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
17119|NCT00006388|Radiation|radiation therapy|
17120|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
17121|NCT00796250|Biological|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
17122|NCT00796263|Drug|HAART|Tenofovir/emtricitabine (TDF/FTC) fixed dose combination 300/200 mg orally once daily
Efavirenz (EFV) 600 mg orally once daily
17123|NCT00796263|Drug|Mega-HAART|Tenofovir/emtricitabine (TDF/FTC) fixed dose combination 300/200 mg orally once daily
Efavirenz (EFV) 600 mg orally once daily
Maraviroc (MVC) 600 mg orally twice daily
Raltegravir (RAL) 400 mg orally twice daily
17124|NCT00796276|Drug|IR OROS paliperidone and ER OROS paliperidone|
16622|NCT00800410|Behavioral|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
16623|NCT00800423|Drug|Brimonidine Tartrate 0.2%|Brimonidine Tartrate 0.2% drops
1 drop twice a day for 1 month in the operated eye
16624|NCT00006443|Drug|Indinavir sulfate|
16625|NCT00800423|Drug|Timolol maleate 0.5%|timolol maleate 0.5% drops
1 drop twice a day for 1 month in the operated eye
16626|NCT00800436|Drug|trastuzumab [Herceptin]|6mg/kg iv (healthy males)
16627|NCT00800436|Drug|trastuzumab [Herceptin]|6mg/kg iv (female patients)
16628|NCT00800436|Drug|trastuzumab [Herceptin]|6mg/kg sc (healthy males)
16629|NCT00800436|Drug|trastuzumab [Herceptin]|10mg/kg sc (healthy males)
16904|NCT00803335|Drug|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
16905|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
16906|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
16907|NCT00803348|Drug|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
16908|NCT00803361|Drug|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
16909|NCT00803361|Drug|Placebo|placebo capsules, oral, once a day for 15 weeks
16910|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
16911|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
16912|NCT00803374|Drug|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
16913|NCT00803374|Drug|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
16914|NCT00006458|Radiation|indium In 111 monoclonal antibody MN-14|
17090|NCT00801281|Drug|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
17091|NCT00793832|Behavioral|supervised exercise|supervised exercise
17092|NCT00793832|Behavioral|Diet advice|Diet Advice
17093|NCT00793845|Procedure|tandem high-dose chemotherapy|Conventional chemotherapy (6 cycles) -> surgery -> conventional chemotherapy (3 cycles) -> first HDCT/ASCR -> second HDCT/ASCR -> Local RT + Retinoic acid + IL-2
First HDCT/ASCR: CEC regimen
Second HDCT/ASCR:
TM-TBI (in case of stage 4 neuroblastoma) or TM regimen (in case of stage 3 neuroblastoma)
17094|NCT00793858|Drug|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
17095|NCT00793871|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
17096|NCT00793897|Drug|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
17097|NCT00793897|Drug|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
17098|NCT00793897|Drug|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
17099|NCT00793910|Drug|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
17100|NCT00006378|Drug|paclitaxel|
17101|NCT00793910|Drug|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
17102|NCT00793923|Drug|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
17103|NCT00793923|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
17104|NCT00793962|Radiation|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
17105|NCT00793962|Radiation|conventional fractionation radiotherapy|50Gy/25/f/5w
17106|NCT00793975|Biological|IMC-1121B|Cohort 1
2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
17107|NCT00793975|Biological|1121B|Cohort 2
4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
17362|NCT00794339|Other|laboratory biomarker analysis|
17363|NCT00794339|Radiation|copper Cu 64-ATSM|
16688|NCT00798161|Drug|Metformin|Metformin 500 mg tablet, twice daily
16689|NCT00800436|Drug|trastuzumab [Herceptin]|<12mg/kg sc (female patients)
16690|NCT00800462|Drug|Oxybutynin Cl|15 mg qd for 3 months
16691|NCT00800462|Drug|Trospium Cl|20mg bid for 3 months
16692|NCT00800462|Drug|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
16693|NCT00800475|Drug|Gemfibrozil Tablets|
16694|NCT00006443|Drug|Nelfinavir mesylate|
16695|NCT00800501|Drug|sNN0029|Continuous ICV infusion at one of three dose levels
16696|NCT00800501|Drug|Placebo|Continuous ICV infusion
16697|NCT00800514|Drug|amantadine|amantadine twice daily
16698|NCT00800514|Drug|amantadine|amantadine 100 mg twice daily
16699|NCT00800527|Drug|Gabapentin|Gabapentin 800 mg one a day up to 30 day
16700|NCT00800527|Drug|Diclofenac|Diclofenac 75 mg one a day up to 30 day
16701|NCT00800540|Drug|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
16702|NCT00800540|Drug|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
16703|NCT00800553|Drug|donepezil|5mg o.m. p.o. for approx. 2 weeks
16704|NCT00800566|Drug|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
16705|NCT00006443|Drug|Lamivudine|
16706|NCT00800579|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
16980|NCT00801151|Drug|Zolinza (vorinostat), vinorelbine|Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).
Patients may receive a maximum of 6 cycles of study medication.
16981|NCT00801164|Drug|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
16982|NCT00801164|Drug|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
17125|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
17468|NCT00794612|Drug|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
17469|NCT00794625|Drug|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
17470|NCT00794625|Drug|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
17471|NCT00794625|Drug|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
17472|NCT00794625|Drug|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
17473|NCT00794625|Behavioral|Behavioral family counseling|Weekly behavioral counseling with a therapist
17474|NCT00006381|Biological|trastuzumab|
17475|NCT00794638|Drug|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
17476|NCT00794638|Drug|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
17477|NCT00794664|Drug|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
17478|NCT00796770|Biological|Dendritic Cell Vaccine|Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.
At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:
two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks
an opportunistic infection
a CDC class C-defining event (defined in appendix 2)
a serious non-AIDS defining event.
Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48.
17479|NCT00796783|Drug|Cushing's syndrome confirmation|
17480|NCT00796796|Drug|Temsirolimus|
17481|NCT00796796|Radiation|Radiation therapy|
17482|NCT00796822|Drug|Pentoxifylline|400 mg three times a day for 8 weeks
17483|NCT00796822|Drug|Placebo|One pill three times a day for 8 weeks
17484|NCT00006390|Radiation|radiation therapy|
16915|NCT00803374|Drug|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
16916|NCT00803374|Drug|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
16917|NCT00803387|Drug|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
16918|NCT00803400|Drug|Alprazolam|The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.
Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.
16919|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
16920|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
16921|NCT00795951|Biological|T.R.U.E. Test|48 hour application of 28 allergens and negative control
17188|NCT00794027|Behavioral|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
17189|NCT00794027|Behavioral|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
17190|NCT00794040|Drug|Citalopram|
17191|NCT00006379|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
17192|NCT00794040|Drug|Methylphenidate|
17193|NCT00794053|Procedure|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
17194|NCT00794066|Procedure|measuring the ankle brachial index|Assessment of the ankle brachial index using the "boso-ABI-system 100" (www.boso.de).
17195|NCT00794079|Dietary Supplement|omega-3 fatty acids|4 grams per day for 8 weeks
17196|NCT00794079|Dietary Supplement|corn oil|4 grams per day for 8 weeks
17197|NCT00794092|Drug|Sinerem administration|Single dose
17364|NCT00794339|Radiation|fludeoxyglucose F 18|
17365|NCT00794339|Radiation|radiation therapy|
17366|NCT00794365|Drug|Varenicline|There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:
Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily
Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water.
17367|NCT00794378|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
17368|NCT00794378|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
17369|NCT00006379|Procedure|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
17370|NCT00794391|Behavioral|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
17371|NCT00794391|Behavioral|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
17372|NCT00794417|Biological|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
17373|NCT00794417|Biological|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
17374|NCT00794417|Biological|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
17375|NCT00794430|Drug|V3381|100 mg capsules, titrated to a maximum of 200 mg bid for 13 weeks
17376|NCT00794430|Drug|Placebo|Capsule, bid, for 13 weeks
17377|NCT00794443|Drug|YM529 / ONO-5920|Oral
17378|NCT00794456|Drug|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
17379|NCT00794456|Drug|Valeriana|1 tablet PO twice a day
17380|NCT00006380|Biological|monoclonal antibody muJ591|
17381|NCT00794469|Other|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
17382|NCT00794482|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
16983|NCT00801177|Biological|IMC-11F8|Cohort 1
100 mg I.V.
16984|NCT00801177|Biological|IMC-11F8|Cohort 2
200 mg I.V.
16985|NCT00006448|Procedure|Physical Therapy|
16986|NCT00801177|Biological|IMC-11F8|Cohort 3
400 mg I.V.
16987|NCT00801177|Biological|IMC-11F8 I.V.|Cohort 4
600 mg I.V.
16988|NCT00793663|Drug|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
16989|NCT00793663|Drug|Dexamethasone|Intravenous use, 4 mg, single shot
16990|NCT00793663|Drug|NaCl|Intravenous use; single shot
16991|NCT00793663|Drug|Ondansetron|Intravenous use; 4 mg; single shot
16992|NCT00793663|Drug|NaCl|Intravenous use; single shot
16993|NCT00006377|Drug|doxorubicin hydrochloride|
16994|NCT00793676|Other|spirometry|
16995|NCT00793676|Other|blood test|
16996|NCT00793702|Biological|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
16997|NCT00793715|Procedure|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
16998|NCT00793715|Procedure|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
16999|NCT00793728|Procedure|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
17000|NCT00793741|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
17001|NCT00793754|Drug|Aspirin|100 mg / day for 8 weeks
17002|NCT00793754|Drug|Atorvastatin|40 mg / day for 8 weeks
17258|NCT00801593|Procedure|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
17259|NCT00801606|Drug|Zinc|Zinc 20 mg/day
17485|NCT00796835|Drug|ER OROS Paliperidone|
17486|NCT00796848|Device|Navigator Continuous Glucose Monitor|
17487|NCT00796861|Drug|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
16544|NCT00802919|Drug|Varenicline|Varenicline 1-2 mg/day
16545|NCT00802919|Drug|Placebo for varenicline|Placebo
16546|NCT00802932|Device|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
16547|NCT00802932|Device|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
16548|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
16549|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
16550|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
16551|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
16552|NCT00802971|Dietary Supplement|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
16553|NCT00000751|Drug|Anti-HIV Immune Serum Globulin (Human)|
16554|NCT00006455|Drug|leucovorin calcium|
16555|NCT00802984|Device|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
16556|NCT00795418|Biological|Placebo|Placebo comparator
16557|NCT00795418|Biological|CAD106|
16558|NCT00795444|Drug|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
16559|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
17198|NCT00794118|Other|As per clinical practice|As per clinical practice
17199|NCT00794131|Biological|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
17200|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
17201|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
17202|NCT00796302|Drug|Methylphenidate HCl|For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.
Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.
One pill is taken once daily.
17203|NCT00796302|Drug|Risperidone|For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.
For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day.
17204|NCT00796302|Behavioral|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
17542|NCT00829582|Other|placebo|single intravenous infusion
17543|NCT00829595|Biological|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
17544|NCT00829608|Biological|Human Papillomavirus Quadrivalent Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
17545|NCT00829621|Other|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
17546|NCT00829621|Other|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
17547|NCT00829634|Drug|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
17548|NCT00829634|Drug|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
17549|NCT00000770|Drug|Zidovudine|
17550|NCT00008151|Drug|mycophenolate mofetil|
17735|NCT00008047|Drug|hydroxyurea|
17736|NCT00827463|Biological|dosage of the NFS and iron|a blood test will be made.
17737|NCT00827476|Procedure|ovarian transplantation|ovarian xenotransplantation or in vitro culture
17738|NCT00829933|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
17739|NCT00829933|Drug|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
17740|NCT00829946|Behavioral|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of ~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
17741|NCT00008164|Procedure|umbilical cord blood transplantation|
17742|NCT00829959|Behavioral|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
17743|NCT00829985|Biological|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
17744|NCT00829985|Biological|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
17745|NCT00829998|Drug|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
17746|NCT00829998|Drug|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
17747|NCT00830011|Behavioral|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
17748|NCT00830011|Other|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
17749|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
17750|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
17751|NCT00830037|Drug|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
17752|NCT00008177|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
17260|NCT00801606|Drug|Micronutrient without zinc|Multimineral 2 RDA
17261|NCT00801606|Drug|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
17262|NCT00006379|Biological|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
17263|NCT00794157|Drug|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
17264|NCT00794157|Drug|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
17265|NCT00794157|Drug|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
17266|NCT00794170|Behavioral|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
17267|NCT00794183|Device|CRT device settings|Comparision of A-V delay settings
17268|NCT00794196|Behavioral|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
17269|NCT00794209|Drug|i.v fentanyl, AeroLEF|i.v fentanyl
5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)
5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)
5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)
3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device.
17270|NCT00794222|Device|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
17271|NCT00794235|Drug|Sorafenib (Nexavar), Dacarbazine (DTIC)|Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.
DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42.
17272|NCT00794248|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
17273|NCT00006379|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
17274|NCT00794248|Drug|fexofenadine|Allegra 180 mg daily x 7 days
17275|NCT00794261|Drug|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
17276|NCT00794261|Drug|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
17627|NCT00008034|Drug|cyclophosphamide|
16560|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
16561|NCT00795470|Drug|Antimicrobial|Appropriate antimicrobial based on urine culture results
16562|NCT00795470|Device|Catheter change|Change urine catheter
16563|NCT00795483|Drug|Zoledronic acid|Zoledronic Acid 5mg/year
16564|NCT00006385|Biological|gp100 antigen|
16847|NCT00795886|Drug|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
16848|NCT00006386|Radiation|radiation therapy|
16849|NCT00795899|Drug|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d
Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d
16850|NCT00795912|Drug|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
16851|NCT00795925|Drug|propiverine hydrochloride|coated tablets containing 5 mg
consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d.
16852|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
16853|NCT00798291|Other|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
16854|NCT00798291|Other|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
16855|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
16856|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
16857|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
16858|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
16859|NCT00006400|Drug|Placebo|Participants will receive placebo.
17551|NCT00829647|Drug|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
17552|NCT00829660|Drug|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
17553|NCT00829660|Drug|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
17554|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
17555|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
17556|NCT00829686|Drug|Septra|(800/125) PO BID X 7 days
17557|NCT00829699|Procedure|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
17558|NCT00829699|Procedure|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
17559|NCT00829699|Procedure|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
17560|NCT00829699|Procedure|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
17561|NCT00008151|Procedure|allogeneic bone marrow transplantation|
17562|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
16630|NCT00803140|Procedure|Cautery vs Active Control Arm (Scalpel)|Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a "cut" setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.
A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.
The closure will be standardized.
16631|NCT00803153|Procedure|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
16632|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
16633|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
16634|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
17753|NCT00830037|Drug|Ferrous Sulfate|Oral ferrous gluconate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
17754|NCT00830050|Drug|Naproxen|500 mg BID 7 days
16783|NCT00798291|Other|Ad lib diet and An 777|one packet with water two times a day
16784|NCT00800657|Procedure|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
16785|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
16786|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
16787|NCT00800683|Drug|BI 1356|BI 1356 dosed once daily
16788|NCT00800683|Drug|placebo|placebo matching BI 1356 taken once daily
16789|NCT00800696|Procedure|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
16790|NCT00800709|Drug|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
16791|NCT00800722|Drug|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
16792|NCT00006445|Procedure|Ultrasound|
16793|NCT00800735|Drug|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
16794|NCT00800735|Drug|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing < 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
16795|NCT00800748|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 2, 3, 4, 5, 6 and to particpants with HIV co-infection, or for 24 weeks to participants with genotype 2, and 3.
16796|NCT00800748|Drug|Ribavirin|Ribavirin will be administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800mg po daily for 24 weeks to participants with genotype 2, and 3.
16797|NCT00800761|Drug|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
16798|NCT00800761|Drug|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
17628|NCT00827281|Drug|D-cycloserine|Single dosage prior to sessions 3, 4 & 5
17629|NCT00827281|Drug|Placebo|Single dosage prior to sessions 3, 4 & 5
17630|NCT00827294|Behavioral|Mirror Therapy|The study is designed as a single group trial comparing pre- and post-treatment measures. Up to 40 subjects will be enrolled. Each subject will receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20-30 minutes daily. Prior to beginning treatment, subjects will complete standard questionnaires designed to measure phantom pain level, function, depressive symptoms, pain-related anxiety, catastrophizing, and sleep quality. Subjects will also be asked about current use of pain medications and demographic data will be collected. Subjects will complete the same questionnaires 1 month, 2 months, 3 months, and 6 months after beginning treatment. Subjects will also be asked to keep a daily diary to record the frequency of their home treatment sessions. Study staff will check in with the study subjects weekly for the first month after beginning treatment, and monthly thereafter.
17631|NCT00827307|Drug|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
17632|NCT00827307|Drug|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
17633|NCT00827320|Drug|Levetiracetam|1000 mg tablet
17634|NCT00827333|Other|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
17635|NCT00827333|Other|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
17636|NCT00829725|Device|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four "TeleScrews" which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented
17637|NCT00829738|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
17638|NCT00829751|Device|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
17639|NCT00829751|Device|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
17640|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
17641|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
17642|NCT00829777|Drug|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:
Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo.
17643|NCT00008151|Procedure|peripheral blood stem cell transplantation|
16860|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
16861|NCT00798317|Drug|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
16862|NCT00798317|Drug|Placebo|Intravitreal injection placebo.
16863|NCT00798343|Biological|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
16864|NCT00798343|Biological|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
16865|NCT00798356|Other|Yoga training|Yoga training for 12 weeks
16866|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
17126|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
17127|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
17128|NCT00796289|Drug|clomiphene citrate|Oral, 50 mg daily for 5 days
17129|NCT00796289|Drug|placebo clomiphene citrate|oral, taken for 5 days
17130|NCT00006389|Drug|bryostatin 1|Given IV
17131|NCT00796289|Drug|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
17132|NCT00798681|Dietary Supplement|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
17133|NCT00798681|Other|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
17134|NCT00798681|Other|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
17135|NCT00798694|Drug|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
17136|NCT00000746|Biological|HIVAC-1e|
17137|NCT00006412|Drug|Pravastatin sodium|
17138|NCT00798694|Drug|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
16635|NCT00006455|Drug|vinblastine sulfate|
16636|NCT00803179|Drug|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
16637|NCT00803192|Drug|Famotidine Tablets, 40 mg|
16638|NCT00803205|Drug|Ataluren (PTC124)|10-, 10-, 20-mg/kg TID at morning, midday, and evening doses
16639|NCT00803205|Drug|Placebo|Placebo
16640|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
16641|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
16642|NCT00803244|Biological|300 IR grass pollen tablet|one tablet per day during 5 months
16643|NCT00803244|Biological|Placebo tablet|one tablet per day during 5 months
16644|NCT00803257|Other|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
16645|NCT00803270|Drug|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
16646|NCT00006456|Radiation|stereotactic radiosurgery|
16647|NCT00803270|Procedure|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
16648|NCT00803283|Drug|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
16922|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
16923|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
16924|NCT00795977|Biological|dendritic cells, OK-432|Single Group Assignment
16925|NCT00006386|Radiation|stereotactic radiosurgery|
16926|NCT00796003|Drug|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
16799|NCT00800774|Procedure|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
16800|NCT00800787|Biological|Nabi-HB|Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.
Dosage will be according to each patients body weight, as follow:
< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly
16801|NCT00800800|Drug|Rosuvastatin|40 mg, oral, single dose
17383|NCT00794495|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
17384|NCT00796627|Genetic|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
17385|NCT00796640|Drug|ER Paliperidone|
17386|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
17387|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
17388|NCT00796653|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
17389|NCT00796653|Drug|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
17390|NCT00006390|Drug|cyclophosphamide|
17391|NCT00796666|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
17392|NCT00796666|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
17393|NCT00796679|Drug|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH <500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
17394|NCT00796692|Drug|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
17395|NCT00796692|Drug|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
17396|NCT00796705|Drug|Adalimumab|40 mg injection of adalimumab administered subcutaneously
17397|NCT00796705|Drug|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
16707|NCT00800579|Drug|Placebo|Inhaled volume-matched placebo in sterile saline
16708|NCT00800592|Drug|sildenafil|10 mg sildenafil bolus
16709|NCT00800605|Biological|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
16710|NCT00800605|Biological|Placebo: Phosphate-buffered saline|Single intramuscular injection
16711|NCT00800618|Drug|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
16712|NCT00800618|Drug|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
16713|NCT00800618|Drug|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
16714|NCT00800618|Drug|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
16715|NCT00800618|Drug|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
16716|NCT00006443|Drug|Stavudine|
16717|NCT00800644|Procedure|CT or MRI + Blood Test|During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
Blood (about 1 tablespoon) will be drawn to test for bone turnover.
16718|NCT00800657|Procedure|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
16719|NCT00802646|Drug|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
16720|NCT00802659|Radiation|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
16721|NCT00802672|Drug|Ciclopirox Olamine Cream|topical cream
16722|NCT00802672|Drug|Loprox Cream 0.77%|topical cream
16723|NCT00802672|Drug|Placebo|topical cream
16724|NCT00802685|Drug|Early ibuprofen|IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to "early treatment" receive blinded ibuprofen. Infants randomized to "late treatment" receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen.
17139|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
17140|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
17141|NCT00798707|Drug|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
17142|NCT00798720|Drug|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
17143|NCT00798720|Drug|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
17144|NCT00798746|Behavioral|Telephone Questionnaire|Ten questions regarding symptoms of reflux
17145|NCT00798759|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
17146|NCT00798759|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
17488|NCT00796874|Other|active surveillance|Correlative Study
17489|NCT00796874|Other|imaging biomarker analysis|Correlative Study
17490|NCT00796874|Procedure|biopsy|Tissue Removal
17491|NCT00796874|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
17492|NCT00796874|Procedure|magnetic resonance imaging|Radiolical Medical Imaging
17493|NCT00796874|Procedure|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
17494|NCT00796887|Drug|Extended-Release Niacin|500mg tablet once daily
17495|NCT00006391|Drug|oxaliplatin|
17496|NCT00796887|Drug|Extended-Release Niacin|1000mg tablet once daily
17497|NCT00796887|Drug|Placebo|Placebo tablet once daily
17498|NCT00796900|Drug|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
16927|NCT00796003|Drug|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
16928|NCT00796029|Drug|14C-paliperidone|
16929|NCT00796042|Other|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
16930|NCT00796042|Other|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
16931|NCT00796055|Drug|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
16932|NCT00796068|Drug|Cyclosporine|Given IV or PO
16933|NCT00796068|Drug|Fludarabine Phosphate|Given IV
16934|NCT00796068|Other|Laboratory Biomarker Analysis|Correlative studies
16935|NCT00796068|Drug|Mycophenolate Mofetil|Given IV
16936|NCT00006387|Biological|QS21|
16937|NCT00796068|Radiation|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
16938|NCT00796068|Drug|Treosulfan|Given IV
17205|NCT00796302|Drug|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
17206|NCT00796315|Drug|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
17207|NCT00796328|Drug|Phenylephrine infusion|Up-down, biased coin design
17208|NCT00796341|Procedure|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
17398|NCT00796705|Drug|Etanercept|50 mg dimeric fusion protein administered subcutaneously
17399|NCT00796718|Radiation|Standard radiotherapy|As prescribed
17400|NCT00796718|Drug|capecitabine [Xeloda]|825mg/m2 po bid for 5 weeks
17401|NCT00006390|Procedure|peripheral blood stem cell transplantation|
17402|NCT00796731|Drug|SAR3419|administered by intravenous infusion
17403|NCT00796744|Drug|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
17426|NCT00799110|Drug|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
17427|NCT00799136|Drug|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
17428|NCT00799149|Drug|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
17429|NCT00801710|Device|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|Revascularization of coronary artery chronic total occlusion.
Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant
17430|NCT00006451|Drug|methylprednisolone|
17431|NCT00801723|Drug|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
17432|NCT00801723|Drug|Placebo Tablet|Placebo Tablet once daily.
17433|NCT00801736|Drug|Cisplatin, Paclitaxel|Cisplatin 75mg/m2, Day 1
Paclitaxel 175mg/m2, Day 1
17434|NCT00801749|Behavioral|sleep|
17435|NCT00801762|Device|Fibered confocal microscope|
17436|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
17437|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
17438|NCT00801801|Drug|Taxotere and Nexavar|Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
17003|NCT00793754|Drug|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
17004|NCT00006377|Drug|paclitaxel|
17005|NCT00793767|Drug|erythropoietin|bolus of 400 IU/kg
17006|NCT00793767|Drug|placebo (saline)|i.v
17007|NCT00793780|Drug|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
17008|NCT00793780|Other|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
17009|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
17010|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
17011|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
17012|NCT00793793|Drug|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
17013|NCT00793793|Drug|Placebo|
17014|NCT00793806|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
17015|NCT00006378|Drug|carboplatin|
17016|NCT00793819|Drug|silodosin|α1-adrenergic antagonist
17017|NCT00796068|Procedure|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
17018|NCT00796081|Drug|ER OROS paliperidone, paliperidone ER|
17019|NCT00796094|Other|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
17020|NCT00796107|Drug|RG1507|16mg/kg iv every 3 weeks
17021|NCT00796107|Drug|letrozole|2.5mg po daily
17022|NCT00796120|Drug|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
17023|NCT00796120|Drug|Doxorubicin|Doxorubicin 60 or 75 mg/m^2 will be given intravenously every 3 weeks until disease progression.
17024|NCT00796120|Drug|Ifosfamide|Ifosfamide 6 to 9 g/m^2 will be given intravenously every 3 weeks until disease progression.
17499|NCT00796900|Drug|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
17500|NCT00796913|Other|Stop medication|Stop medication Stop medication + se supplement
17501|NCT00796926|Drug|Systane Ultra eyedrops|Four times a day
17502|NCT00799162|Other|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
17503|NCT00799175|Drug|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
17504|NCT00006427|Drug|Amitriptyline|
17505|NCT00799175|Drug|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
16565|NCT00795483|Behavioral|Lifestyle modifications|Lifestyle modifications
16566|NCT00795483|Drug|Zoledronic acid|Zoledronic acid (5mg/2years)
16567|NCT00795496|Procedure|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
16568|NCT00795496|Procedure|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
16569|NCT00795496|Procedure|Serum IgE blood testing|One blood test to measure total serum IgE
16570|NCT00795496|Procedure|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
16571|NCT00795509|Drug|Tolterodine tartrate|Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
16572|NCT00795522|Drug|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
17209|NCT00796354|Drug|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
17210|NCT00796354|Drug|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
17211|NCT00006389|Drug|cisplatin|Given IV
17212|NCT00796367|Drug|VI-0521|7.5 mg phentermine and 46 mg topiramate
17213|NCT00796367|Drug|Placebo|placebo
17214|NCT00796367|Drug|VI-0521|15 mg phentermine and 92 mg topiramate
17215|NCT00796380|Drug|Xingnaojing|injection
17216|NCT00796393|Dietary Supplement|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
17217|NCT00796393|Dietary Supplement|Starch of potato|1 pill per day for 12 weeks
17218|NCT00796419|Drug|5% human albumin|Intravenous administration of 250mL 5% human albumin every 8 hours for 5 days
17219|NCT00796419|Drug|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
17220|NCT00796432|Drug|OROS paliperidone|
17221|NCT00796445|Drug|GSK 2132231A|IM solution, a course of 13 injections will be administered over 27 months
17222|NCT00006389|Other|laboratory biomarker analysis|Correlative studies
17223|NCT00796445|Drug|Placebo|IM solution, a course of 13 injections will be administered over 27 months
17224|NCT00796458|Drug|docetaxel|Given IV
17225|NCT00798785|Drug|ATG-basilixumab-MMF-TAC|First transplantation:
ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Second transplantation:
Basilixumab:
the day before the second transplantation followed by 4days after transplantation.
Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.
17563|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
17564|NCT00829725|Device|screws-internal fixation|3-4-screws-internal fixation
17565|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
17566|NCT00822328|Dietary Supplement|Yakult®300|Yakult®300 was given 100 ml once per day for four weeks.
Fermented or unfermented milk per 100 ml bottle per day for four week.
17439|NCT00801814|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
17440|NCT00801814|Dietary Supplement|PolyGlycopleX (PG)|5.0 grams of PGX
17441|NCT00006451|Procedure|allogeneic bone marrow transplantation|
17442|NCT00801814|Dietary Supplement|PolyGlycopleX|7.5 grams of PGX
17443|NCT00801814|Dietary Supplement|Control|0g of PGX
17444|NCT00801814|Dietary Supplement|Second Control|0g of PGX
17445|NCT00801827|Drug|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
17446|NCT00801853|Drug|Aerovant|Aerovant 1mg bid (dry powder)
17755|NCT00830050|Drug|Placebo|BID 7 days
17756|NCT00830063|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
17757|NCT00830063|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
17758|NCT00830063|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
17759|NCT00830063|Other|placebo|placebo to match tanezumab and naproxen dosing
17760|NCT00830076|Drug|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
17761|NCT00822640|Device|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
17762|NCT00822653|Device|Effects of Plantar Stimulation|Plantar stimulation:
Use of a low-intensity mechanical stimulus to the plantar surface (sole) so as to trigger a reflex response causing soleus muscle contraction, and thereby an increase in calf muscle pump activity. The plantar stimulation device (VStim; Juvent Medical Inc., Somerset, NJ) delivers a 50 micrometer displacement to the plantar surface of the foot at 45 Hz. This device has been shown to significantly increase lower limb blood and lymphatic flow when patients use the device while in a seated or supine position.
17763|NCT00822666|Drug|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
17764|NCT00822679|Drug|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
17765|NCT00822679|Other|Placebo|Subjects are given placebo for 3 consecutive nights
17766|NCT00822692|Drug|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
17025|NCT00006387|Biological|ras peptide cancer vaccine|
17277|NCT00794274|Drug|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
17278|NCT00794287|Other|Taking blood samples|No intervention is done. Only blood samples are taken.
17279|NCT00794300|Device|second magnetic resonance imaging scan|
17280|NCT00794313|Drug|Amantadine 300 mg|Amantadine, 300 mg, capsule, three times a day, two weeks
17281|NCT00794313|Drug|Topiramate|Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
17282|NCT00794313|Drug|Sugar Pill|sugar pill, capsule, three times a day, 2 weeks
17283|NCT00794326|Drug|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
17284|NCT00000743|Drug|Zidovudine|
17285|NCT00796458|Drug|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
17286|NCT00796471|Drug|Paliperidone ER|
17287|NCT00796484|Drug|XL888|Administered orally
17288|NCT00796497|Drug|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
17289|NCT00796510|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
17290|NCT00796510|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
17291|NCT00796523|Behavioral|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
17292|NCT00796523|Behavioral|control videotape|a videotape with general newborn care instructions
17293|NCT00000745|Biological|gp160 Vaccine (MicroGeneSys)|
17294|NCT00006390|Biological|alemtuzumab|
17295|NCT00796536|Behavioral|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
16573|NCT00795548|Drug|5-Azacitidine|5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.
DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given.
16574|NCT00795561|Procedure|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
16575|NCT00006385|Biological|incomplete Freund's adjuvant|
16576|NCT00795561|Procedure|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
16577|NCT00797849|Device|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
16578|NCT00797849|Device|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
16579|NCT00797862|Drug|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
16580|NCT00797862|Drug|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
16581|NCT00006397|Drug|Stavudine|
16582|NCT00797862|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
16583|NCT00797875|Procedure|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
16584|NCT00797875|Procedure|passive stretching|passive stretching x 5 repetitions continue 3 days
16867|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
16868|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
16869|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
16870|NCT00006401|Drug|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
16871|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
16872|NCT00798369|Drug|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
17567|NCT00822328|Dietary Supplement|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
17568|NCT00000764|Drug|Interferon alfa-2a|
17569|NCT00007852|Drug|cytarabine|100 mg/m2 on days -5 through -2
17570|NCT00822341|Drug|TG-0054|0.1, 0.2, 0.4, 0.8, 1.6, and 3.2 mg/kg of TG-0054/placebo via 15 min IV infusion
17571|NCT00822354|Drug|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
17572|NCT00822367|Dietary Supplement|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
17573|NCT00822380|Dietary Supplement|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
17574|NCT00822380|Dietary Supplement|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
17575|NCT00822380|Dietary Supplement|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
17576|NCT00822380|Dietary Supplement|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
17577|NCT00822380|Dietary Supplement|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
17578|NCT00822393|Drug|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
17579|NCT00822393|Drug|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
17580|NCT00007852|Drug|etoposide|100mg/M2 BID on days -5 through -2
17581|NCT00822406|Drug|homeopathic medicine|individualized homeopathic medicine
17582|NCT00822406|Drug|placebo|placebo - 6 months
17583|NCT00822419|Drug|lidocaine|lidocaine cream 5%
16649|NCT00803283|Drug|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
16650|NCT00803296|Other|Oral glucose tolerance test (OGTT)|
17767|NCT00822692|Drug|placebo|matched placebo 2 pills PO BID x 7 days
17768|NCT00822705|Drug|Placebo tablet|Control arm
17769|NCT00822731|Drug|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
17770|NCT00007865|Drug|carboplatin|
17771|NCT00822744|Drug|SSR411298|Form: capsule
Route: oral administration with food
17772|NCT00822744|Drug|Escitalopram|Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)
Route: oral administration with food
17773|NCT00822744|Drug|Placebo (for SSR411298)|Form: capsule
Route: oral administration with food
17774|NCT00822757|Biological|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
17775|NCT00822757|Biological|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
16802|NCT00800800|Drug|Placebo|oral, single dose
16803|NCT00006445|Procedure|Serum screen|
16804|NCT00802997|Device|Sinergy|radiofrequency denervation
16805|NCT00802997|Device|Placebo sham|sham procedure
16806|NCT00803010|Drug|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
16807|NCT00803010|Drug|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
16808|NCT00803010|Drug|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
16809|NCT00803023|Drug|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
16810|NCT00803023|Drug|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
16811|NCT00803023|Drug|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
16812|NCT00803023|Drug|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
16813|NCT00006455|Drug|methotrexate|
17296|NCT00796536|Behavioral|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
17297|NCT00796549|Drug|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
17644|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5mL oral dose
17645|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
17646|NCT00829803|Device|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
17647|NCT00829816|Drug|Dimebon|
17648|NCT00829816|Drug|Placebo|
17649|NCT00829829|Drug|rilonacept|Placebo loading dose followed by placebo SC injections (2 mL) once a week for 16 weeks
17650|NCT00829829|Drug|rilonacept|rilonacept 160 mg SC loading dose followed by rilonacept 80 mg/2 mL SC injections once a week for 16 weeks
17651|NCT00829829|Drug|rilonacept|rilonacept 320 mg SC loading dose followed by rilonacept 160 mg/2 mL SC injections once a week for 16 weeks
17652|NCT00829842|Other|oral hygiene|oral hygiene with 0.12% chlorexidine
17653|NCT00829842|Other|placebo|oral hygiene placebo
17654|NCT00008151|Radiation|radiation therapy|
17655|NCT00829868|Drug|Zaleplon 10 mg Capsules|1 x 10 mg
17656|NCT00829868|Drug|SONATA® 10 mg capsules|1 x 10 mg
17657|NCT00829881|Drug|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
17658|NCT00829881|Drug|Placebo Capsule|A single placebo capsule
17659|NCT00829894|Drug|Risperidone|1 mg Tablet
17660|NCT00829894|Drug|Risperidone|1 mg Tablet
17661|NCT00829907|Drug|ORM-12741|Single dose as a capsule, oral administration
17662|NCT00822484|Biological|ILV-095|
17663|NCT00007852|Drug|melphalan|140 mg/m2 IV on day -1
16873|NCT00798382|Other|soy protein formula|ad lib for 0-35 days of age
16874|NCT00798382|Other|Commercially available soy formula|ad lib for 0-35 days of age
16875|NCT00798382|Other|Soy formula experimental #2|ad lib for 0-35 days of age
16876|NCT00798395|Drug|Org 50081|1.5 mg on day 1-7
16877|NCT00798395|Drug|Org 50081|4.5 mg on Day 1-7
16878|NCT00798395|Drug|Placebo|Once daily on Day 1-7
16879|NCT00798395|Drug|zopiclone|Single dose of 7.5 mg
16880|NCT00800813|Behavioral|Penile Exam, Peyronie's Plaque and Erectile function assessment|At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.
After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level.
16881|NCT00800826|Drug|dexmedetomidine|
16882|NCT00800839|Drug|Busulfan|Starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
16883|NCT00800839|Drug|Fludarabine|Dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
16884|NCT00800839|Drug|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
16885|NCT00800865|Other|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
17147|NCT00798772|Dietary Supplement|Micronutrients and antioxidants|8 capsules twice daily for two years
17148|NCT00006412|Drug|Fenofibrate|
17149|NCT00798772|Dietary Supplement|Multivitamins and minerals|8 capsules twice daily for two years
17150|NCT00798785|Drug|ATG-MMF-TAC|ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver.
16651|NCT00803296|Other|Isoglycemic intravenous glucose infusion|
16652|NCT00795574|Drug|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
16653|NCT00795574|Drug|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
16654|NCT00795587|Drug|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
16655|NCT00795600|Drug|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
16656|NCT00795600|Drug|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
16657|NCT00795613|Drug|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
16658|NCT00795613|Drug|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
16659|NCT00795626|Behavioral|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
16660|NCT00795639|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
16661|NCT00006385|Biological|recombinant interferon alfa|
16662|NCT00795639|Drug|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
16663|NCT00795652|Behavioral|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
16664|NCT00795665|Drug|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
16665|NCT00795665|Drug|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
16814|NCT00803049|Drug|teriflunomide (HMR1726)|Tablet, oral administration once daily.
16815|NCT00803062|Biological|Bevacizumab|Given IV
16816|NCT00803062|Drug|Cisplatin|Given IV
16817|NCT00803062|Other|Laboratory Biomarker Analysis|Correlative studies
16818|NCT00803062|Drug|Paclitaxel|Given IV
16819|NCT00803062|Other|Quality-of-Life Assessment|Ancillary studies
16820|NCT00803062|Other|Questionnaire Administration|Ancillary studies
16821|NCT00803062|Drug|Topotecan Hydrochloride|Given IV
16822|NCT00803075|Device|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
16823|NCT00803088|Device|The Alair System|Treatment of airways with the Alair System
16824|NCT00006455|Drug|therapeutic hydrocortisone|
16825|NCT00803101|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
17404|NCT00796757|Drug|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
17405|NCT00796757|Drug|interferon alfa-2a|3 MIU sc t.i.w.
17406|NCT00798967|Drug|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
17407|NCT00798967|Drug|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
17408|NCT00798980|Drug|Mirena (BAY86-5028)|Nulliparous Women
17409|NCT00006422|Procedure|current standard of care treatments|
17410|NCT00798993|Other|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
17411|NCT00798993|Drug|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
17412|NCT00798993|Other|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
17413|NCT00799006|Drug|Placebo|Subjects will be given placebo or PF-04620110
17664|NCT00822484|Other|Placebo|
17665|NCT00822497|Behavioral|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
17666|NCT00822497|Behavioral|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
17667|NCT00822510|Behavioral|Telephone Interpersonal Counselling Intervention|Telephone delivered 8 week education and support intervention
17668|NCT00822510|Behavioral|Telephone delivered education only|Telephone delivered education for 8 weeks
16725|NCT00802685|Other|Late ibuprofen expectant group (placebo)|Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to "late ibuprofen expectant group" will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV.
16726|NCT00802698|Device|Transcorneal electric stimulation|central artery occlusion
16727|NCT00802698|Device|Transcorneal stimulation|new waveform
16728|NCT00006455|Drug|doxorubicin hydrochloride|
16729|NCT00802698|Device|transcorneal electric stimulation|Novel waveform central artery occlusion
16730|NCT00802711|Radiation|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
16731|NCT00802711|Radiation|brachytherapy|Given twice a day for 10 fractions
16732|NCT00802724|Behavioral|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
16733|NCT00802724|Behavioral|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
16734|NCT00802737|Drug|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
17151|NCT00798785|Drug|ATG-Rituximab-MMF-TAC|ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.
17152|NCT00801281|Drug|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
17153|NCT00801281|Drug|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
17154|NCT00006449|Behavioral|broad spectrum treatment|
17155|NCT00801281|Drug|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
17156|NCT00801294|Drug|BIBF 1120 and BIBW 2992|
17157|NCT00801307|Device|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
17158|NCT00801320|Procedure|Tumor collection|Tumor collected at the time of planned surgery
17159|NCT00801346|Other|laboratory biomarker analysis|
17160|NCT00801346|Other|metabolic assessment|
17161|NCT00801346|Other|questionnaire administration|
17162|NCT00801346|Procedure|assessment of therapy complications|
17163|NCT00801346|Procedure|fatigue assessment and management|
17164|NCT00801346|Procedure|quality-of-life assessment|
17165|NCT00006449|Behavioral|motivational enhancement therapy|
17166|NCT00801359|Procedure|Phacoemulsification|
17167|NCT00801359|Drug|BSSPlus solution|
17168|NCT00801359|Drug|Lactated Ringer's solution|
17506|NCT00799188|Drug|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
17507|NCT00799201|Drug|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
16939|NCT00798408|Dietary Supplement|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
16940|NCT00006401|Other|Placebo|Inhaled Nitrogen
16941|NCT00798408|Dietary Supplement|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
16942|NCT00798434|Drug|Placebo|placebo administered orally in the morning or evening.
16943|NCT00798434|Drug|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
16944|NCT00798447|Drug|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
16945|NCT00798447|Drug|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
16946|NCT00798460|Drug|adefovir|adefovir 10mg
16947|NCT00798460|Drug|clevudine|clevudine 30mg
16948|NCT00798460|Drug|lamivudine|lamivudine 100mg
16949|NCT00798473|Drug|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
16950|NCT00798473|Other|IV saline infusion|
16951|NCT00006405|Behavioral|Exercise|
16952|NCT00798486|Device|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
16953|NCT00798499|Other|Laboratory variables|1 visit
16954|NCT00798512|Device|Carotid artery stenting|The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.
For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal).
16955|NCT00798525|Drug|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of > 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
17414|NCT00799006|Drug|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
17415|NCT00799032|Device|PCI|coronary stent implantation
17416|NCT00799045|Drug|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
17417|NCT00799058|Drug|dapivirine|dapivirine gel 4789, 0.05%, 2.5g applied once daily
17418|NCT00799058|Drug|dapivirine|dapivirine gel 4759, 0.05%, 2.5g applied once daily
17419|NCT00799058|Drug|placebo|HEC-based universal placebo gel, 2.5g applied once daily
17420|NCT00006426|Procedure|Achilles tendon-lengthening surgery|
17421|NCT00799071|Drug|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
17422|NCT00799084|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
17423|NCT00799084|Behavioral|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
17424|NCT00799110|Drug|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
17425|NCT00799110|Biological|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
17447|NCT00801853|Drug|Aerovant|Aerovant 3mg bid (dry powder)
17448|NCT00801853|Drug|Aerovant|Aerovant 10mg bid (dry powder)
17449|NCT00801853|Other|placebo|placebo control (dry powder)
17450|NCT00801866|Drug|Bevacizumab|Intravitreal administration
17451|NCT00801866|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation
17452|NCT00006451|Procedure|in vitro-treated bone marrow transplantation|
17453|NCT00801879|Drug|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
17454|NCT00801879|Drug|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
16735|NCT00802763|Device|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
16736|NCT00795678|Drug|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
16737|NCT00795678|Drug|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
16738|NCT00795678|Drug|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
17026|NCT00796133|Drug|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
17027|NCT00796159|Drug|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
17028|NCT00796172|Behavioral|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
17029|NCT00796172|Behavioral|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
17030|NCT00796185|Drug|Paliperidone ER|
17031|NCT00796198|Drug|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
17032|NCT00796198|Drug|Xalatan|Xalatan ophthalmic solution one drop at 10pm
17033|NCT00796211|Drug|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
17034|NCT00796211|Drug|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
17035|NCT00796211|Drug|Nortriptyline|0.1% nortriptyline HCl topical cream
17036|NCT00006388|Drug|tamoxifen citrate|
17037|NCT00796211|Drug|Calcipotriol|0.005% calcipotriol topical cream
17038|NCT00796211|Other|Placebo|Vehicle of CRx-197 topical cream (placebo)
17508|NCT00799214|Drug|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
17509|NCT00799214|Drug|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
17510|NCT00799214|Drug|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
17511|NCT00799227|Drug|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
17512|NCT00799240|Drug|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
17513|NCT00799240|Drug|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
17514|NCT00799266|Drug|Zoledronic acid|
17515|NCT00006428|Drug|Amitriptyline|
17516|NCT00799266|Drug|Placebo|
17517|NCT00799279|Behavioral|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
17518|NCT00799279|Behavioral|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
17519|NCT00799292|Drug|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
17520|NCT00799292|Other|No injection|Patients did not receive an injection of medication at cervix prior to beginning of procedure
17521|NCT00827047|Procedure|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
17522|NCT00827073|Drug|tetracaine 0.5%|betadine 5%
17523|NCT00827073|Drug|Lidocaine 2% Jelly|Betadine 5%
17524|NCT00827099|Biological|anti-thymocyte globulin|anti-thymocyte globulin
16956|NCT00798525|Drug|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine < 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
17226|NCT00798785|Procedure|omentum|Two clinical implants: first in omentum followed by a clinical implant in the liver:
In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels >= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum.
17227|NCT00798798|Device|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
17228|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery -> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
17229|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
17230|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
17231|NCT00798824|Procedure|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
17232|NCT00006413|Procedure|Stem cell transplantation|
17233|NCT00798824|Procedure|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
17234|NCT00798824|Device|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
17235|NCT00798824|Device|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
17236|NCT00798837|Radiation|Intraprostatic maximal simultaneous boost|Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.
Doses of radiotherapy are as follows:
The prescription dose will be 73.7 Gy in 28 fractions
A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints.
17237|NCT00798850|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull & East Yorshire Yospitals NHS Trust.
17455|NCT00801892|Device|Continuous Positive Airway Pressure (CPAP)|Worn over nose to splint open the airway and prevent the subject from holding their breath (apneas).
17456|NCT00794495|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
17457|NCT00794508|Biological|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
17458|NCT00794547|Drug|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
17459|NCT00794547|Drug|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
17460|NCT00794560|Behavioral|patient education|Possible, individualized interventions:
Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material
Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)
Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom
First self-injection under control of a specially trained pharmacist
17461|NCT00794573|Drug|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
17462|NCT00794573|Other|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
17463|NCT00006380|Radiation|iodine I 131 monoclonal antibody muJ591|
17464|NCT00794586|Drug|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
17465|NCT00794586|Drug|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
17466|NCT00794599|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
17467|NCT00794599|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
16520|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
16521|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
16522|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
16523|NCT00800254|Device|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
16524|NCT00800254|Other|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
17039|NCT00796224|Drug|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
17040|NCT00796224|Drug|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
17041|NCT00796237|Device|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
17042|NCT00798551|Behavioral|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
17043|NCT00798577|Drug|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
17044|NCT00798577|Drug|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
17298|NCT00796562|Drug|Drug: busulfan, Cyclophosphamide, Total Body Irradiation|Arm A:
Patient will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis(in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed. Patient will then receive Cy by IV once a day for 2 days.
Arm B:
Patients will start on Cy IV once a day for 2 days followed by TBI once a day for 4 days.
Transplant:
Bone Marrow Transplant will follow busulfan/Cy or Cy/TBI preparative regimen.
17299|NCT00796575|Drug|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
17300|NCT00796575|Drug|placebo tablets|placebo tablets matching active
17301|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
17302|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
17303|NCT00796588|Other|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
17304|NCT00796601|Drug|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
17305|NCT00006390|Biological|filgrastim|
17306|NCT00796601|Drug|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
17307|NCT00796614|Drug|tamsulosin hydrochloride|Oral
17308|NCT00796614|Drug|Placebo|Oral
17309|NCT00796627|Genetic|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
17310|NCT00798850|Procedure|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
16585|NCT00797888|Behavioral|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
16586|NCT00797901|Other|Collaborative Care|
16587|NCT00797927|Drug|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
16588|NCT00797927|Other|no intervention|keep the original conventional antipsychotic agent for 28 days
16589|NCT00797940|Drug|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
16590|NCT00797953|Drug|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
16591|NCT00797966|Drug|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
16592|NCT00006397|Drug|Didanosine|
16593|NCT00797966|Drug|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
16594|NCT00797966|Drug|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
16595|NCT00797979|Device|Skull Grip bone fixation|Skull Grip bone fixation
16596|NCT00797979|Device|sutures|Standard skull bon flap fixation, sutures
16597|NCT00797992|Drug|Injection|Intravitreal injection of 1.25 mg bevacizumab
16598|NCT00798005|Drug|XRP0038 (NV1FGF)|
16599|NCT00798018|Drug|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
16600|NCT00798018|Drug|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
16601|NCT00798018|Drug|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
16602|NCT00798018|Drug|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
16603|NCT00006398|Drug|Timolol Maleate|
16604|NCT00800267|Drug|timolol 0.5%|one drop in the morning and evening
16605|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
13200|NCT00779571|Behavioral|Crispbread|8 week low calorie diet
13201|NCT00779584|Drug|SCH 900776|SCH 900776 will be administered to sequential escalating dose cohorts as an intravenous infusion over at least 30 minutes. Doses of SCH 900776 will either be doubled or increased by 40%, depending on the toxicities observed and the specific dose level, and by 20% increments above 200 mg. SCH 900776 will be given as monotherapy on Cycle 0 Day 1 for participants in the dose escalation portion, and starting with Cycle 1 in combination with gemcitabine on Days 1 and 8 of a 21 day treatment cycle for all participants
13498|NCT00782977|Other|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
13499|NCT00782990|Procedure|Surgical treatment: TVT|
13500|NCT00782990|Procedure|Surgical treatment: colposuspension|
13501|NCT00783003|Drug|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
13502|NCT00783003|Drug|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
13503|NCT00783003|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
13504|NCT00783003|Drug|Placebo|Matching placebo.
13505|NCT00783016|Drug|Morphine|
13506|NCT00783042|Drug|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
13507|NCT00783042|Drug|Placebo|Tablet, oral, once daily for 1 month (double blind)
13508|NCT00774761|Drug|fluticasone propionate|inhalation suspension
13509|NCT00774761|Drug|formoterol fumarate|inhalation solution
13510|NCT00774774|Device|control|Non sterile surgical mask,high filtration "AEROKYN",type 2 with eardrop
13511|NCT00774774|Device|Face mask|Non sterile surgical mask, high filtration "AEROKYN", type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor
Masks will not be worn:
during the night,
when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended
13512|NCT00774787|Drug|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
13513|NCT00774787|Drug|Untreated|No treatment of control side
13514|NCT00774800|Drug|Humalog|
12948|NCT00789503|Dietary Supplement|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
12949|NCT00789529|Device|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
12950|NCT00789529|Device|ReNu MultiPlus®|soft contact lens disinfecting solution
12951|NCT00789542|Device|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
12952|NCT00789542|Other|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
12953|NCT00789555|Drug|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
12954|NCT00006358|Drug|temozolomide|
12955|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
12956|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
12957|NCT00789568|Drug|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
12958|NCT00789568|Drug|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
12959|NCT00791986|Device|ULB , LB|ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.
LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.
13263|NCT00777127|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
13264|NCT00777127|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
13265|NCT00777140|Drug|Deferoxamine|Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.
Bolus + 72h perfusion of saline solution for the placebo group.
13266|NCT00777153|Drug|Cediranib|30 mg/day, oral, until progression
13267|NCT00777153|Drug|Cediranib|20 mg/day, oral, until progression
13268|NCT00006243|Biological|tyrosinase peptide|Given SC
12720|NCT00786695|Drug|esomeprazole|esomeprazole (40 mg o d) for 14 days
12721|NCT00786695|Drug|Placebo|Identical looking Placebo, same regimen, for 14 days
12722|NCT00786721|Device|Diffuse Optical Spectroscopy|muscle properties scanning
12723|NCT00786734|Drug|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
12724|NCT00006342|Genetic|gene rearrangement analysis|
12725|NCT00786734|Drug|Pitavastatin|4mg daily for 28 days after PCI
12726|NCT00786747|Behavioral|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
12727|NCT00786747|Behavioral|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
12728|NCT00786760|Other|Cohort: 3000 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
12729|NCT00786760|Other|Pilot study: 150 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
12730|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|Omega-3's are administered in the form of an orange pudding made by Coromega
1 mg of omega-3 fatty acid 2 times per day
12731|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids in orange pudding form
1 packet two times per day
13040|NCT00789646|Procedure|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
13041|NCT00789659|Other|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
13042|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
13043|NCT00006359|Drug|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
13044|NCT00789672|Device|patching|2 hours daily patching
13045|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
13046|NCT00789685|Drug|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
13738|NCT00780598|Drug|Tosedostat|In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:
120 mg for 6 months once daily, OR
240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months
In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A.
13739|NCT00780624|Device|NIPPV|Ventilator is Bird VIP.
13740|NCT00780624|Device|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
13741|NCT00780624|Device|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
13742|NCT00780637|Drug|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
13743|NCT00780650|Drug|Atomoxetine|80 mg oral dose, once per day for 6 weeks
13744|NCT00780650|Drug|Placebo|80 mg dose once per day for 6 weeks
13745|NCT00006257|Drug|paclitaxel|
13746|NCT00780663|Drug|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
13747|NCT00780676|Drug|Dasatinib|100 mg tablet by mouth daily
13748|NCT00780676|Drug|AZD6244|75 mg by mouth twice daily.
13749|NCT00780702|Drug|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
13750|NCT00780702|Drug|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
13751|NCT00780715|Drug|Gliclazide MR|30mg daily increased to 60mg if HbA1c > 7% at 3 months
13752|NCT00780715|Drug|Sitagliptin|Sitagliptin 100mg daily for 6 months
13753|NCT00780715|Drug|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c >7% at 3 months. 6 months duration
13754|NCT00780715|Drug|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
13755|NCT00780728|Drug|Sildenafil|
13756|NCT00000732|Drug|Sulfamethoxazole-Trimethoprim|
13757|NCT00006257|Drug|semaxanib|
13515|NCT00774800|Drug|Humulin-R|
13516|NCT00006233|Biological|therapeutic allogeneic lymphocytes|
13517|NCT00774800|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
13518|NCT00774800|Other|Liquid meal|
13519|NCT00774813|Device|Nexalin 1.3mA Device|3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of placebo antidepressant
13520|NCT00774813|Device|Nexalin 15mA device|3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of a placebo antidepressant
13824|NCT00777959|Drug|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
13825|NCT00777959|Drug|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
13826|NCT00777972|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
13827|NCT00777985|Drug|bosentan|62.5 mg b.i.d for 4 weeks
13828|NCT00777985|Device|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
13829|NCT00006246|Drug|busulfan|
13830|NCT00777998|Procedure|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|*Multiple myeloma
-> Induction Therapy (max. 8 cycles)
-> Registration of patient, stem cell mobilization, start of donor search
-> Melphalan (200mg/qm) plus autologous PBSCT
-> 2 months later: Melphalan plus allogeneic PBSCT
-> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)
-> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10^6 (MRD) or 5 x 10^5 (MUD) CD3+ cells per kg BW)
-> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)
-> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)
-> Further DLI depending on MRD-measurement
13831|NCT00777998|Procedure|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|*Multiple myeloma
-> Induction Therapy (max. 8 cycles)
-> Registration of patient, stem cell mobilization, start of donor search
-> Melphalan (200mg/qm) plus autologous PBSCT
-> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT
-> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)
13832|NCT00778011|Drug|Ondansetron|dosage
13269|NCT00777153|Drug|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
13270|NCT00777153|Drug|Placebo Cediranib|Oral, until progression
13271|NCT00777166|Drug|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
13272|NCT00777166|Drug|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
13273|NCT00777179|Drug|Vandetanib|Tablet, oral, daily
13274|NCT00777179|Drug|Placebo|Placebo
13275|NCT00777192|Behavioral|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
13276|NCT00777205|Behavioral|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
13277|NCT00777205|Behavioral|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
13278|NCT00777218|Drug|propranolol|standard pediatric doses, based on body weight
13279|NCT00006243|Biological|MART-1:27-35 peptide vaccine|Given SC
13280|NCT00779649|Other|MoviPrep Kit|Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.
Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption.
13575|NCT00783172|Drug|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
13576|NCT00783172|Biological|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
13577|NCT00783185|Behavioral|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
13578|NCT00783185|Behavioral|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
13579|NCT00783198|Biological|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
13047|NCT00789698|Drug|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
13048|NCT00789698|Drug|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
13049|NCT00789711|Drug|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
13050|NCT00789711|Drug|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
13051|NCT00792142|Other|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
13052|NCT00792142|Procedure|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
13053|NCT00792142|Procedure|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
13054|NCT00792168|Drug|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
13055|NCT00792168|Other|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
13056|NCT00000742|Drug|Zidovudine|
13355|NCT00777309|Drug|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
13356|NCT00777309|Drug|Placebo|The placebo is provided as a capsule
13357|NCT00777322|Procedure|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15−30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross−linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
13358|NCT00777335|Drug|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
12797|NCT00784225|Drug|vitamin E|400 IU daily by mouth for 7-12 years
12798|NCT00784225|Drug|vitamin E placebo|daily for 7-12 years
12799|NCT00784225|Drug|selenium placebo|daily for 7-12 years
12800|NCT00784238|Drug|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
12801|NCT00784277|Drug|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
12802|NCT00006291|Drug|Aldesleukin|
12803|NCT00784277|Drug|oxycodone IR|10mg for 14 days
12804|NCT00784277|Drug|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
12805|NCT00784277|Drug|Tapentadol IR (CG5503)|50mg for 14 days
12806|NCT00784277|Drug|Tapentadol IR (CG5503)|75mg for 14 days
12807|NCT00784277|Drug|placebo|1 capsule for 14 days
12808|NCT00784277|Drug|placebo|Tablets and capsules 2 x a day for 28 days
12809|NCT00784290|Drug|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
12810|NCT00784303|Drug|E7080|E7080 given orally continuously at 24 mg, once a day.
12811|NCT00784316|Drug|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
12812|NCT00784329|Device|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
12813|NCT00006292|Drug|Infliximab|
12814|NCT00784355|Procedure|Laparoscopic cholecystectomy|Surgery
12815|NCT00786877|Other|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
12816|NCT00786877|Other|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
12817|NCT00786890|Other|observational, no intervention needed|observational, no intervention needed
13833|NCT00780767|Device|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
13834|NCT00780780|Drug|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
13835|NCT00780780|Drug|triamcinolone intravitreal injection|triamcinolone intravitreal injection
13836|NCT00780793|Drug|progressive spacing of TNF-blocker injections|Experimental arm
Progressive spacing of TNF-blocker injections according to the following algorithm :
if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1
if DAS28 > 2.6 and DAS28 change ≤ 0.6: continue at step N
if DAS28 > 2.6 and DAS28 change > 0.6 : return to step N-1 (relapse as defined by the European expert consensus).
Step 0 (inclusion) :
Adalimumab 40 mg / 14 days
Etanercept 50 mg / 7 days
Step 1 :
Adalimumab 40 mg / 21 days
Etanercept 50 mg / 10 days
Step 2 :
Adalimumab 40 mg / 28 days
Etanercept 50 mg / 14 days
Step 3 :
Adalimumab 40 mg / 42 days
Etanercept 50 mg / 21 days
Step 4 :
TNF-blocker stop
13837|NCT00780793|Drug|DMARD maintenance|DMARD maintenance
13838|NCT00780806|Biological|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
12878|NCT00791934|Device|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
12879|NCT00791947|Drug|CHOEP + G-CSF followed by BEAM|CHOEP:
Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5
BEAM:
Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6
12880|NCT00791960|Drug|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
12881|NCT00791960|Other|Placebo|single dose, 10 mL normal saline, IV
12882|NCT00006367|Drug|idarubicin|
12883|NCT00791973|Drug|fluticasone furoate|2 puffs in each nostril once daily for 1 week
12884|NCT00791973|Drug|Placebo|2 puffs in each nostril once daily for 1 week
12885|NCT00784368|Drug|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
12886|NCT00784368|Drug|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
13607|NCT00774943|Drug|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
13608|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
13609|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
13610|NCT00774969|Drug|Metronidazole|Metronidazole 10% ointment three times a day 7 days
13611|NCT00774982|Drug|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
13612|NCT00774982|Drug|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
13613|NCT00774995|Biological|EngerixTM-B|Intramuscular injection, one dose.
13614|NCT00775008|Behavioral|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
13615|NCT00006233|Drug|mycophenolate mofetil|
13616|NCT00775021|Device|etafilcon A|Contact Lens
13617|NCT00775021|Device|nelfilcon A|Contact Lens
13618|NCT00775034|Drug|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
13619|NCT00775034|Procedure|Drainage|Mesh repair for open incisional hernia repair with drainage
13945|NCT00781118|Device|AngelMed Guardian System|An implantable heart monitoring device that detects and alerts subjects to rapidly progressive ST shifts that might be indicative of thrombotic coronary occlusions. Components include Programmable monitoring device (IMD), Right Ventricle Lead, Lead Adapter, External Alarm Device (EXD) and a programmer.
13946|NCT00781131|Drug|Pregabalin|pregabalin 75 or 150 mg
13947|NCT00781131|Drug|Placebo|lactulose placebo
13948|NCT00781157|Drug|Phenylephrine bolus|The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the "data analysis" section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose.
13949|NCT00006258|Drug|etoposide|
13950|NCT00781170|Procedure|allogeneic hematopoietic SCT|
13359|NCT00777335|Drug|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
13360|NCT00777348|Drug|Combination DSCG and Reproterol|1:
13361|NCT00777361|Drug|AZD3480|Iv single dose, 4-hour infusion of 25 mg
13362|NCT00777361|Drug|AZD3480|Oral solution single dose of 50 mg
13363|NCT00777374|Drug|Patch|epicutaneous application of allergen patch
13364|NCT00779792|Drug|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
13365|NCT00000731|Drug|Acetaminophen|
13366|NCT00006252|Biological|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
13367|NCT00779792|Drug|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
13368|NCT00779792|Drug|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
13369|NCT00779792|Drug|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
13370|NCT00779792|Drug|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
13371|NCT00779805|Drug|Pseudoephedrine hydrochloride 120 mg ER tablets|
13372|NCT00779818|Device|Electrical acupuncture|Treatment by electrical acupuncture
13373|NCT00779818|Device|Laser|Treatment by laser
13374|NCT00779831|Drug|120 mg Pseudoephedrine hydrochloride extended release tablets|
13375|NCT00779844|Procedure|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
13676|NCT00783484|Drug|PF-03716539|PF-03716539 10 mg oral solution, single dose
13677|NCT00783484|Drug|PF-03716539|PF-03716539 25 mg oral solution, single dose
13678|NCT00783484|Drug|PF-03716539|PF-03716539 3 mg oral solution, single dose
13679|NCT00783484|Other|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
13680|NCT00783484|Drug|PF-03716539|PF-03716539 100 mg oral solution, single dose
12818|NCT00786916|Drug|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
13120|NCT00782145|Procedure|standard follow-up care|
13121|NCT00782171|Device|SLActive dental implant|Immediate restoration or early restoration (4 weeks)
13122|NCT00782184|Drug|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
13123|NCT00782184|Drug|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
13124|NCT00782184|Drug|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
13125|NCT00782197|Device|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
13126|NCT00782197|Device|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
13127|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
13128|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
13129|NCT00006261|Drug|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
13130|NCT00782210|Drug|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
13131|NCT00782236|Device|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
13132|NCT00782249|Device|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
13133|NCT00782249|Device|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
13134|NCT00782249|Device|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
13135|NCT00782262|Dietary Supplement|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
12887|NCT00784381|Device|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
12888|NCT00784394|Drug|diindolylmethane|Given PO
12889|NCT00784394|Other|placebo|Given PO
12890|NCT00784394|Other|pharmacological study|Correlative studies
12891|NCT00784394|Other|laboratory biomarker analysis|Correlative studies
12892|NCT00784394|Other|quality-of-life assessment|Ancillary studies
12893|NCT00784407|Device|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
12894|NCT00006299|Drug|Celebrex|
12895|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
12896|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
12897|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
12898|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
13202|NCT00779584|Drug|Gemcitabine|Depending on the part of the dose escalation portion of the trial, the participant will receive 800 mg/m2, 1000 mg/m2 or based upon safety, 1250 mg/m2. Starting with Cycle 1, gemcitabine will be administered intravenously over at least 30 minutes on Days 1 and 8 of a 21-day treatment cycle.
13203|NCT00779597|Behavioral|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
13204|NCT00006252|Biological|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
13205|NCT00779610|Procedure|Vibration with flexion|Vibration with forearm flexion (active contraction)
13206|NCT00779610|Procedure|Vibration without flexion|Vibration without forearm flexion (passive)
13207|NCT00779636|Drug|Desloratadine|Desloratadine 10 mg daily x 28 days
13208|NCT00779636|Drug|Placebo|Placebo daily x 28 days
13951|NCT00781183|Other|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
13952|NCT00783484|Drug|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
13953|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
13954|NCT00006275|Drug|calcitriol|
13955|NCT00783510|Biological|adalimumab|As prescribed by treating physician
13956|NCT00783510|Drug|Methotrexate|As prescribed by treating physician
13957|NCT00783523|Drug|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
13958|NCT00783536|Drug|Etanercept + Methotrexate|
13959|NCT00783536|Drug|DMARDS|
13960|NCT00783549|Drug|an undetermined dose of GSK1292263|GSK investigational product or placebo
13961|NCT00783549|Drug|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
13962|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
13963|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposures.
13964|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
13965|NCT00006276|Drug|Micellar Paclitaxel|
12983|NCT00792142|Other|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
12984|NCT00784511|Other|microcrystalline cellulose|1/d
12985|NCT00784524|Biological|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
12986|NCT00784524|Biological|aldesleukin|Subcutaneous aldesleukin (10 x 10^6 International Units) will be given on day 7 and day 8 after each LMI injection.
12987|NCT00784537|Drug|ABVD|ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
Randomization to Arm A (Observation)
13681|NCT00783484|Drug|PF-03716539|PF-03716539 200 mg oral solution, single dose
13682|NCT00783484|Drug|PF-03716539|PF-03716539 50 mg oral solution, single dose
13683|NCT00006270|Drug|metyrapone|
13684|NCT00783484|Other|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
13685|NCT00783484|Drug|Midazolam|Midazolam 1 mg IV, single dose
13686|NCT00783484|Drug|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
13687|NCT00783484|Drug|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
13688|NCT00783484|Drug|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
13689|NCT00783484|Drug|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
13690|NCT00783484|Drug|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
13691|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
13692|NCT00775099|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
13693|NCT00775099|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
13694|NCT00000730|Drug|Trimetrexate glucuronate|
13695|NCT00006233|Procedure|peripheral blood stem cell transplantation|
13696|NCT00775112|Device|pillow|use of pillow for lumbar punctures
13697|NCT00775125|Drug|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
13698|NCT00775138|Drug|Arikace 280 mg|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
12732|NCT00786812|Drug|Nilotinib|
12733|NCT00786825|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
12734|NCT00786838|Drug|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
13136|NCT00782275|Drug|avastin|Given intravenously on days 1 and 15
13137|NCT00782275|Drug|temsirolimus|Given intravenously on days 1, 8, 15, and 22
13138|NCT00782288|Drug|digitoxin|0.05mg tabs, once daily for 28 days
13139|NCT00782288|Drug|digitoxin|0.1mg pills, once daily for 28 days.
13435|NCT00777374|Drug|Placebo patch|epicutanoeus application of a placebo patch
13436|NCT00777387|Procedure|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
13437|NCT00777387|Procedure|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
13438|NCT00777400|Drug|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
13439|NCT00777413|Drug|Minocycline 100mg Tablets|
13440|NCT00777439|Drug|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
13441|NCT00777478|Drug|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
13442|NCT00777491|Drug|cisplatin|Given IV
13443|NCT00777491|Drug|fluorouracil|Given IV
13444|NCT00777491|Drug|gemcitabine hydrochloride|Given IV
13445|NCT00006243|Biological|sargramostim|Given SC
13446|NCT00777491|Radiation|radiation therapy|Given once or twice daily
13447|NCT00777504|Drug|usage oral angiogenesis inhibitor|see under 'study arms'
13448|NCT00777504|Drug|stop oral angiogenesis inhibitor|see under 'study arms'
13449|NCT00777517|Drug|Lipitor|A single dose of 10 mg Lipitor tablet
13450|NCT00777517|Drug|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
13451|NCT00777530|Drug|Bosutinib (SKI-606)|
13209|NCT00006261|Procedure|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
13210|NCT00782288|Other|placebo|pill taken once daily for 28 days
13211|NCT00782301|Drug|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
13212|NCT00782301|Drug|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
13213|NCT00782327|Drug|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
13214|NCT00782327|Drug|Placebo|Daily placebo capsule
13215|NCT00782340|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
13216|NCT00782340|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
13217|NCT00782353|Drug|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
13218|NCT00782353|Drug|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
13219|NCT00782353|Drug|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
13220|NCT00000733|Drug|Ribavirin|
13221|NCT00006262|Drug|becatecarin|
13222|NCT00782366|Genetic|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
13521|NCT00774813|Drug|placebo device and Citalopram|3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of a a SSRI (Citalopram or similar)
13522|NCT00774826|Drug|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
13523|NCT00774826|Drug|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
13524|NCT00774826|Drug|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
12988|NCT00784537|Drug|ABVD and Radiotherapy|ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk).
12989|NCT00784550|Drug|Tiotropium Bromide|Long-acting muscarinic antagonist
12990|NCT00006305|Procedure|Coronary Artery Bypass|Coronary Artery Bypass
12991|NCT00784550|Drug|FLuticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
12992|NCT00784563|Behavioral|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age[Goldberg, Elliot, and Kuehl1988] and reduced by 20% in participants who used beta-blockers.[Wonisch et al. 2003] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
12993|NCT00784563|Behavioral|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking [Wisloff et al. 2007].
12994|NCT00784589|Drug|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
12995|NCT00784589|Drug|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
12996|NCT00784615|Procedure|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
12997|NCT00784654|Drug|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
12998|NCT00784654|Drug|Placebo|Placebo capsule once per day (double-blind period)
13296|NCT00782418|Drug|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
13297|NCT00782418|Drug|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
13298|NCT00782431|Biological|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
13299|NCT00782431|Biological|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
12735|NCT00006342|Genetic|mutation analysis|
12736|NCT00786838|Drug|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
12737|NCT00786851|Drug|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
12738|NCT00786864|Other|exercise programme|Specific low back pain exercise programme for children
12739|NCT00789152|Drug|levocetirizine|levocetirizine 5 mg daily x 8 days
12740|NCT00789165|Drug|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
12741|NCT00789165|Drug|no therapy|No therapy; this is not a placebo-controlled trial
12742|NCT00789191|Drug|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
12743|NCT00789191|Drug|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
12744|NCT00789191|Drug|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
12745|NCT00789191|Drug|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
12746|NCT00789204|Other|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
12747|NCT00789204|Other|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
12748|NCT00006355|Radiation|radiation therapy|
12749|NCT00789217|Procedure|Immediate skin test|Intradermal test with immediate reading
12750|NCT00789230|Procedure|primary suture closure|primary suture closure of hernia
12751|NCT00789230|Procedure|mesh enforced closure|mesh enforced closure of hernia
13057|NCT00006369|Drug|ERA-923|
13058|NCT00792181|Drug|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
13452|NCT00777543|Other|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
13453|NCT00777543|Dietary Supplement|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
13454|NCT00777543|Dietary Supplement|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
13455|NCT00777556|Drug|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
13456|NCT00000191|Drug|Carbamazepine|
13758|NCT00780741|Procedure|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
13759|NCT00780741|Procedure|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
13760|NCT00780754|Drug|dutasteride|0.5mg
13761|NCT00780754|Procedure|prostate biopsy|prostate biopsy
13762|NCT00006265|Biological|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, & IV); & D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) & D 14 (Cohort II)
13763|NCT00783055|Other|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
13764|NCT00783068|Drug|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
13765|NCT00783068|Drug|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
13766|NCT00783068|Drug|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
13767|NCT00783081|Drug|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
13768|NCT00783081|Drug|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
13769|NCT00783081|Drug|Placebo|Placebo BID for 26 weeks.
13525|NCT00774839|Behavioral|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
13526|NCT00774852|Drug|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
13527|NCT00006233|Drug|cyclosporine|
13528|NCT00774852|Drug|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
13529|NCT00774852|Drug|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
13530|NCT00774852|Drug|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
13531|NCT00777569|Drug|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
13532|NCT00777569|Drug|Nicotine Lozenge|4 mg nicotine lozenge
13533|NCT00777582|Drug|AZD2281|Oral single dose formulation
13534|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
13535|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
13536|NCT00777595|Drug|Placebo|Inhaled solution, single dose of placebo
13537|NCT00777595|Drug|Moxifloxacin|Tablet, oral, 400mg, single dose
13538|NCT00777608|Drug|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
13539|NCT00777608|Drug|Donepezil 5 - 10 mg|Donepezil 1 capsule (5 mg) orally, once daily for 14 days.
Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
13540|NCT00006244|Drug|melphalan|Given IV
13541|NCT00777608|Drug|Comparator: Placebo 5-10 mg|Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.
Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
13839|NCT00006258|Biological|filgrastim|
13840|NCT00780806|Procedure|Blood draw|Blood draw
13841|NCT00780819|Device|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
13300|NCT00782444|Procedure|Computer navigated knee replacement|Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
13301|NCT00782444|Procedure|Conventional knee replacement|Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
13302|NCT00782457|Procedure|RECTAL CANCER RESECTION|
13303|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
13304|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
13305|NCT00006263|Drug|carboplatin|
13306|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
13307|NCT00782483|Device|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
13308|NCT00782483|Device|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
13309|NCT00782483|Device|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
13310|NCT00782496|Device|Education + new meter|Diabetes education and a new meter with basic features
13311|NCT00782496|Device|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
13312|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
13313|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
13314|NCT00782509|Drug|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
13315|NCT00782522|Procedure|Eccentric training program|Eccentric training program
13316|NCT00006263|Drug|temozolomide|
13620|NCT00775047|Other|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
13621|NCT00775047|Other|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
13622|NCT00775073|Drug|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
13059|NCT00792181|Other|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
13060|NCT00792194|Other|Exercise training|Subjects will be randomised in two groups:
a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
a training group, where subjects are asked to exercise three times a week, whenever they want during the day.
13061|NCT00792207|Other|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
13062|NCT00792207|Other|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
13063|NCT00792220|Procedure|MSU|In the "Mobile Stroke Unit" procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland.
13064|NCT00784680|Drug|Tamoxifen|20mg, orally, once daily
13065|NCT00784693|Biological|Tanezumab|15 mg IV single dose
13066|NCT00784693|Drug|Placebo|Placebo IV single dose
13067|NCT00784706|Other|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
13068|NCT00784706|Other|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
13069|NCT00784706|Other|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
13070|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
13071|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
13072|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
13770|NCT00783094|Drug|Tadalafil 2.5 mg|oral, daily
13771|NCT00783094|Drug|Tadalafil 5 mg|oral, daily
13772|NCT00783094|Drug|Placebo|oral, daily
13773|NCT00006267|Drug|rubitecan|
13774|NCT00783107|Drug|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
13775|NCT00783107|Drug|Placebo|
13776|NCT00783120|Other|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
13777|NCT00783120|Other|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
12819|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
12820|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
12821|NCT00786929|Procedure|Catheter drainage|
12822|NCT00006343|Biological|recombinant interferon alfa|
12823|NCT00786929|Drug|Conservative treatment|
12824|NCT00786942|Procedure|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
12825|NCT00786942|Procedure|higi tibial osteotomy|the gap of the tibia is unfilled
12826|NCT00786968|Drug|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
12827|NCT00786981|Other|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
12828|NCT00786981|Other|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
12829|NCT00786994|Drug|Oleogel-S10 100 mg/g|topical use once or twice daily
13842|NCT00780832|Behavioral|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
13843|NCT00780832|Drug|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
13844|NCT00780858|Drug|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
13845|NCT00780884|Device|acupuncture|16 sessions of acupuncture treatment, twice a week.
13846|NCT00780910|Drug|MP-424|750 mg every 8 hours for 12 weeks
13847|NCT00780910|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
13848|NCT00780910|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
13849|NCT00780923|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
13850|NCT00006258|Drug|cisplatin|
13851|NCT00780936|Procedure|femoral nerve block|
13852|NCT00780949|Other|intestinal biopsies|intestinal biopsies during routine endoscopy
13853|NCT00780962|Drug|N-Acetycysteine (NAC)|Experimental: 3 g NAC IV in 500 cc Normal Saline (NS) before CT, followed by 200 mg NAC/hour in NS at 67 cc/hour for up to 24 hours after CT.
Placebo: 500 cc NS before CT, followed by NS at 67 cc/hour after CT
13854|NCT00780975|Drug|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
13855|NCT00780988|Biological|Autologous tumor cell + CpG vaccine|
13856|NCT00783263|Drug|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
13857|NCT00783263|Drug|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
13858|NCT00783276|Drug|SYN115|100 mg single dose
13859|NCT00783276|Drug|PLACEBO|PLACEBO
13860|NCT00783289|Biological|MEDI-563|25,50-mg MEDI-563 injections
13861|NCT00783289|Other|Placebo|Placebo SC injections
12899|NCT00784433|Dietary Supplement|alcohol|150 cc
13623|NCT00775086|Drug|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
13624|NCT00777699|Drug|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
13625|NCT00777712|Other|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
13626|NCT00777725|Device|FibroScan|Liver scan, similar to an ultrasound.
13627|NCT00777738|Drug|BORTEZOMIB|Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).
For responding patients : up to 6 cycles
For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days
13628|NCT00777764|Drug|Cohort I|In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.
For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.
Dilutions of omalizumab and its excipients were in SWFI.
13629|NCT00777764|Drug|Cohort 2|In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.
For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.
Dilutions of omalizumab and its excipients were made in saline.
13630|NCT00777777|Device|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
13631|NCT00006244|Biological|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
13632|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
13633|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
13634|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
12670|NCT00791362|Other|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
13376|NCT00779844|Procedure|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
13377|NCT00006253|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
13378|NCT00779857|Device|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
13379|NCT00779870|Other|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
13380|NCT00779883|Biological|ISF35|Subjects participating in this study will receive a single dose of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells.
13381|NCT00779896|Drug|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
13382|NCT00779909|Drug|vitamin D3|oral supplementation once per day for 12 weeks
13383|NCT00779922|Drug|lenalidomide|
13384|NCT00779935|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
13385|NCT00779961|Procedure|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
13386|NCT00779961|Procedure|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
13387|NCT00779974|Other|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
13388|NCT00006253|Behavioral|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
13389|NCT00782548|Drug|morphine sulfate sustained-release capsules|Capsules, 30 mg
13390|NCT00782561|Drug|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
13391|NCT00782574|Drug|AZD2281|Capsule Oral bid
13392|NCT00782574|Drug|Cisplatin|IV every 3 weeks
13393|NCT00782587|Drug|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
13394|NCT00782600|Drug|suspension IR|50 mg IR suspension once daily for one day
13395|NCT00006264|Biological|aldesleukin|
12830|NCT00786994|Drug|Placebo (petroleum jelly)|topical use once or twice daily
12831|NCT00787007|Drug|S-equol|capsule, oral, single dose
12832|NCT00787007|Drug|Placebo|capsule, oral, single dose
12833|NCT00000737|Drug|Megestrol acetate|
12834|NCT00006343|Drug|cytarabine|
12835|NCT00787033|Drug|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
12836|NCT00787059|Drug|Ad5.hAC6|Intracoronary delivery of Ad5.hAC6 or sucrose solution (placebo) in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10^9 vp to 10^12 vp in 5 dose groups
12837|NCT00789282|Other|reflects current patterns of care|Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.
Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice.
13140|NCT00774111|Drug|GSK1349572|GSK1349572 50 mg in combination with Etravirine
13141|NCT00774124|Other|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
13142|NCT00774124|Other|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
13143|NCT00774150|Behavioral|Cognitive Behavioral Therapy|16 sessions of CBT
13144|NCT00774150|Behavioral|Client Centered Therapy|16 sessions of CCT
13145|NCT00774163|Biological|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
13146|NCT00774163|Other|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
13147|NCT00774189|Drug|clarithromycin 250 mg tablets|
13148|NCT00006230|Drug|rubitecan|
13149|NCT00774202|Drug|Rituxan and Cyclophosphamide, Vincristine and Prednisone|
13150|NCT00774202|Drug|Higher Dose of Rituximab|
13151|NCT00774228|Device|I-ZIP Ocular Bandage|
12900|NCT00784446|Drug|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|Dose level I:
Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg
Repeat on day 22.
Dose level II:
Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg
Repeat on day 22.
12901|NCT00784459|Drug|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
12902|NCT00784459|Drug|Placebo|Treatment with Placebo, IV
12903|NCT00784472|Drug|oxycodone|intravenous according to patients weight, pn.
12904|NCT00784472|Drug|morphine|intravenous administration according to patients weight, pn.
12905|NCT00006305|Procedure|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
12906|NCT00784485|Drug|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
12907|NCT00784498|Drug|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
12908|NCT00784498|Drug|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
12909|NCT00784511|Dietary Supplement|cholecalciferol|4000 IU/d
12910|NCT00787059|Drug|Sucrose (3%)|
12911|NCT00787072|Drug|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
12912|NCT00787072|Drug|Placebo|Oral suspension
12913|NCT00787098|Other|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
12914|NCT00787111|Drug|Fluoxetine (prozac)|Formulation: ODT
12915|NCT00787137|Drug|PG102|A single intravenous infusion
12916|NCT00787137|Drug|Placebo comparator|Phosphate-buffered saline
12671|NCT00791375|Behavioral|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
12672|NCT00006366|Drug|irinotecan hydrochloride|
12673|NCT00791388|Drug|Placebo|oral capsule, 2x/day for 14 days
12674|NCT00791388|Drug|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
12675|NCT00791388|Drug|PG-760564|oral capsule, 100mg, 2x/day for 14 days
12676|NCT00791388|Drug|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
12677|NCT00791388|Drug|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
12678|NCT00791401|Drug|ER OROS Paliperidone|
12679|NCT00791427|Drug|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
12680|NCT00791440|Behavioral|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
12681|NCT00791440|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
12682|NCT00791453|Behavioral|Education|Patients will receive literacy appropriate health information.
12683|NCT00006366|Procedure|conventional surgery|
12684|NCT00791466|Dietary Supplement|Placebo|Daily placebo supplementation from enrolment <14 wk of gestation until delivery
12685|NCT00791466|Dietary Supplement|Iodine|Daily supplementation with 200 µg iodine from enrolment <14 wk of gestation until delivery
12686|NCT00791479|Drug|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
12687|NCT00791479|Drug|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
12688|NCT00791492|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
12689|NCT00791505|Drug|ciprofloxacin|1500 mg a day for 10 days
12690|NCT00791505|Drug|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
12999|NCT00784667|Drug|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
13000|NCT00784667|Drug|Erlotinib|100mg orally daily continuously
13396|NCT00782600|Drug|CR 1|50 mg shorter release CR once daily for one day
13397|NCT00782600|Drug|CR 2|50 mg medium release CR once daily for one day
13699|NCT00775138|Drug|Arikace 560 mg|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
13700|NCT00775138|Drug|Matching Placebo|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
13701|NCT00775151|Drug|amlodipine 10 mg tablet|
13702|NCT00775164|Drug|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
13703|NCT00775164|Drug|Metformin|Metformin XR; 1000 mg once daily
13704|NCT00775177|Drug|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
13705|NCT00775190|Drug|ortho tricyclen|brand name oral contraceptive
13706|NCT00006233|Radiation|radiation therapy|
13707|NCT00775190|Drug|Trinessa|generic oral contraceptive
13708|NCT00775203|Drug|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
13709|NCT00775203|Drug|Placebo|
13710|NCT00775216|Behavioral|Behavioral counseling plus "telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
13711|NCT00775229|Drug|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
13712|NCT00775229|Drug|Placebo|pill, by mouth, daily
13713|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
13714|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
13715|NCT00775255|Drug|clarithromycin 250 mg/5 mL powder for oral suspension|
13152|NCT00774228|Device|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
13153|NCT00774241|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
13154|NCT00774241|Drug|docetaxel|75mg/m2 every 3 weeks for 18 weeks
13155|NCT00774267|Drug|BZA 20 mg/CE 0.45 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
13156|NCT00774267|Drug|BZA 20 mg/CE 0.625 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
13157|NCT00774267|Drug|Raloxifene 60 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
13158|NCT00774267|Drug|Placebo|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
13159|NCT00006231|Procedure|quality-of-life assessment|
13160|NCT00774280|Drug|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
13457|NCT00000730|Drug|Sulfamethoxazole-Trimethoprim|
13458|NCT00006243|Other|laboratory biomarker analysis|Correlative studies
13459|NCT00777569|Drug|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
13460|NCT00779987|Drug|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
13461|NCT00779987|Drug|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
13462|NCT00780000|Drug|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
13463|NCT00780013|Drug|metformin hydrochloride liquid 500 mg per 5 mL|
13464|NCT00780026|Procedure|insulin|bolus or infusion 80 to 110 mg/dl
13465|NCT00780039|Drug|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
12917|NCT00787150|Drug|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
12918|NCT00006343|Drug|imatinib mesylate|
13223|NCT00782379|Drug|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
13224|NCT00782379|Drug|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
13225|NCT00782379|Drug|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
13226|NCT00782379|Drug|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
13227|NCT00782379|Drug|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
13228|NCT00782379|Procedure|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
13229|NCT00782379|Procedure|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
13230|NCT00782405|Drug|quetiapine|XR, 150-300mg
13231|NCT00782405|Drug|mirtazapine|30-45 mg
13232|NCT00006263|Biological|filgrastim|
13233|NCT00782418|Drug|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
13234|NCT00774306|Drug|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
13235|NCT00774306|Drug|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
13236|NCT00774319|Radiation|conventional radiotherapy with 'high' dose cisplatin|radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.
100 mg/m2 cisplatin iv on day 1, 22 and 43
13237|NCT00774319|Radiation|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
13238|NCT00774332|Drug|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
13239|NCT00774345|Drug|Lenalidomide|Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
13001|NCT00000735|Drug|Ampligen|
13002|NCT00006305|Drug|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
13003|NCT00784680|Drug|Anastrozole|1mg, orally, once daily
13004|NCT00787254|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
13005|NCT00787254|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
13006|NCT00787267|Drug|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
13007|NCT00787280|Behavioral|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
13008|NCT00787280|Behavioral|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
13009|NCT00006345|Biological|denileukin diftitox|
13010|NCT00787293|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
13011|NCT00787306|Behavioral|Active risk factor surveillance|Cardiovascualr risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
13012|NCT00787319|Other|no intervention|Outpatients with age-related macular degeneration (AMD)
13013|NCT00787332|Drug|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
13014|NCT00787345|Other|simulation based training|simulation based training in aseptic techniques that included specified AT categories
13015|NCT00787358|Drug|ZT-031|80 ul subcutaneous injection per day
13016|NCT00787358|Other|placebo|80 ul daily subcutaneous injection of vehicle only
13017|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
13018|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
13019|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
13020|NCT00006345|Drug|dexamethasone|
13317|NCT00782522|Procedure|Traditional training program|Traditional training program
13716|NCT00775268|Procedure|Biopsy|Biopsy taken
13717|NCT00777829|Drug|Low-dose sodium oxybate|Participants will receive one dose of 2.5 g before each nap.
13718|NCT00777829|Drug|High-dose sodium oxybate|Participants will receive one dose of 3 g before each nap.
13719|NCT00777829|Drug|Low-dose zolpidem|Participants will receive one dose of 5 mg before each nap.
12752|NCT00789243|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
12753|NCT00789256|Drug|Melphalan|Melphalan: 2mg orally, once daily
12754|NCT00789256|Drug|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
12755|NCT00789256|Drug|Melphalan and bortezomib|
12756|NCT00789269|Drug|rhubarb|14 days of rhubarb
12757|NCT00789269|Drug|placebo|14 days of placebo
12758|NCT00789282|Other|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
12759|NCT00006356|Drug|carboplatin|
12760|NCT00789282|Other|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
12761|NCT00791518|Drug|No intervention|No intervention
12762|NCT00791531|Drug|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
12763|NCT00791544|Drug|AVE1642|intravenous infusion
12764|NCT00006366|Radiation|radiation therapy|
12765|NCT00791544|Drug|sorafenib|oral intake
12766|NCT00791544|Drug|erlotinib|oral intake
12767|NCT00791557|Drug|Infliximab|IV drug given at weeks 1,2,14,22
12768|NCT00791570|Biological|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
13466|NCT00780039|Drug|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
13467|NCT00780052|Drug|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
13468|NCT00780078|Procedure|extubation|extubation failure in patients intubated orotracheally
13469|NCT00780091|Other|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
13470|NCT00006254|Biological|salmonella VNP20009|
13471|NCT00780091|Other|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
13472|NCT00780104|Drug|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
13473|NCT00780104|Drug|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
13474|NCT00780130|Other|No Intervention|male & female college students ages 20 to 50, asymptomatic normals
13475|NCT00780143|Drug|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
13476|NCT00780169|Drug|sorafenib + FOLFIRI|escalating doses of sorafenib and irinotecan
sorafenib starting dose 400 mg/day
irinotecan starting dose 80 mg/m2 on day 1
13778|NCT00783133|Drug|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
13779|NCT00783133|Drug|fexofenadine|Allegra 180 mg daily x 7 days
13780|NCT00783146|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
13781|NCT00783146|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
13782|NCT00783146|Drug|placebo|placebo, once daily for 15 days
13783|NCT00783159|Procedure|Power Training|Power training, Vitamin D substitution
13784|NCT00000734|Drug|Sulfamethoxazole-Trimethoprim|
13785|NCT00006268|Biological|cintredekin besudotox|
13240|NCT00000729|Drug|Foscarnet sodium|
13241|NCT00006231|Procedure|standard follow-up care|
13242|NCT00774345|Drug|Placebo|Placebo capsules given orally on days 1 - 28 of a 28 day cycle
13542|NCT00777608|Drug|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
13543|NCT00777621|Other|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
13544|NCT00777621|Other|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
13545|NCT00777621|Other|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
13546|NCT00777634|Other|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
13547|NCT00777647|Other|Sugar-sweetened soft drink|One litre a day for six months.
13548|NCT00777647|Other|Aspartame-sweetened soft drink|One litre a day for six months.
13549|NCT00777647|Other|Semi-skimmed milk|One litre a day for six months
13550|NCT00777647|Other|Water|One litre a day for six months.
13551|NCT00006244|Biological|recombinant interferon alfa|Given SC
13552|NCT00777673|Drug|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|Eligible patients will receive:
nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.
Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.
Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.
After completion of the above regimen, patients will receive:
Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.
Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.
Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.
Patients will then proceed with:
- Surgery including axillary staging
A minimum of 4 weeks post operatively, patient will receive:
- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses.
13553|NCT00777686|Procedure|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
13554|NCT00777699|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
13555|NCT00780208|Drug|Daytrana (methylphenidate transdermal system)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
13318|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
13319|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
13320|NCT00782535|Drug|Placebo|Inhaled solution, single dose of placebo
13321|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
13322|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
13323|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
13324|NCT00774397|Drug|Placebo|Placebo
13325|NCT00774423|Drug|Riluzole|50 mg per day during 24 months
13326|NCT00774436|Procedure|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
13327|NCT00006232|Drug|dexamethasone|
13328|NCT00774462|Drug|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
13329|NCT00774475|Drug|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
13330|NCT00774475|Drug|doubled therapy|clopidogrel 150 mg/day
13331|NCT00774488|Other|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
13332|NCT00774501|Procedure|image guidance with general anesthesia and suspended ventilation during treatment delivery|All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.
Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.
The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery.
13333|NCT00774514|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
12769|NCT00791596|Other|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
12770|NCT00791622|Drug|Paliperidone ER|
12771|NCT00791635|Behavioral|Questionnaires|11 Questionnaires
12772|NCT00791648|Drug|atorvastatin|Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.
12773|NCT00791648|Drug|placebo|Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.
13073|NCT00006305|Drug|Insulin, sulfonylurea|Insulin, sulfonylurea
13074|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
13075|NCT00784719|Drug|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
13076|NCT00784719|Drug|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
13077|NCT00784732|Drug|QAV680|
13078|NCT00784732|Drug|QAV680|
13079|NCT00784732|Drug|Mometasone Furoate|
13080|NCT00784745|Drug|Dexamethasone|2mg morning and night for 5 days.
13081|NCT00784758|Device|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
13082|NCT00784758|Device|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
13083|NCT00784771|Behavioral|Hypnotherapeutic Olfactory Conditioning (HOC)|
13084|NCT00006305|Drug|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
13085|NCT00784784|Biological|Fluviral|One dose
13086|NCT00784784|Drug|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
13087|NCT00784797|Drug|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
13088|NCT00784797|Drug|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
13786|NCT00006234|Procedure|peripheral blood stem cell transplantation|
13787|NCT00775268|Radiation|Fluordeoxyglucose F 18|Undergo scans
13788|NCT00775268|Other|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
13789|NCT00775268|Procedure|computed tomography|Undergo scans
13790|NCT00775268|Procedure|fine-needle aspiration|sample collected
13791|NCT00775294|Drug|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
13792|NCT00775307|Drug|PAZOPANIB|400 mg/day (24 weeks)
13793|NCT00775307|Drug|Placebo|Placebo 400 mg/day (24 weeks)
13794|NCT00775320|Procedure|FLT-PET scan|Imaging test
13795|NCT00775333|Procedure|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
13796|NCT00775359|Drug|Fenofibrate 160 mg tablets|
13797|NCT00006234|Radiation|holmium Ho 166 DOTMP|
13798|NCT00775372|Drug|Clarithromycin 250mg/5mL|
13799|NCT00775385|Drug|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
13800|NCT00775385|Drug|Customized Treatment|Mutated EGFR : Erlotinib 150mg/day (1 year)
Wild-type EGFR or "undetermined" depends on ERCC1 status :
ERCC1 high : no treatment
ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)
13801|NCT00775411|Drug|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
13802|NCT00775411|Biological|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
12838|NCT00789295|Other|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
12839|NCT00789308|Drug|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
12840|NCT00789308|Drug|Heparin|Anticoagulation
12841|NCT00789308|Drug|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
13556|NCT00780234|Procedure|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
13557|NCT00780234|Procedure|quantitative high resolution CT scan|High resolution CT scan of the chest
13862|NCT00783315|Behavioral|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
13863|NCT00783315|Behavioral|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
13864|NCT00006269|Drug|irinotecan hydrochloride|
13865|NCT00783315|Behavioral|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
13866|NCT00783328|Drug|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
13867|NCT00783341|Drug|GAP-134|
13868|NCT00783341|Drug|placebo|
13869|NCT00783354|Drug|desloratadine|Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (Placebo) in case of symptoms for 2 months.
13870|NCT00783354|Drug|desloratadine|Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (desloratadine 5 mg) in case of symptoms for 2 months.
13871|NCT00783367|Drug|lenalidomide-low dose dexamethasone plus rituximab|Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study; Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study; rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
13872|NCT00783367|Drug|Lenalidomide + Rituximab|
13873|NCT00783380|Biological|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
13874|NCT00783380|Biological|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
13875|NCT00006269|Drug|octreotide acetate|
13876|NCT00783393|Drug|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
13877|NCT00783406|Drug|PF-00610355|dry powder inhaler, 1472 mcg, single dose
13334|NCT00774527|Drug|Cyclophosphamide-fludarabine-anti thymocyte globulin|Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.
Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).
Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.
13635|NCT00777803|Drug|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
13636|NCT00777803|Drug|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
13637|NCT00777816|Drug|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
13638|NCT00777816|Drug|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
13639|NCT00780351|Device|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
13640|NCT00780377|Drug|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
13641|NCT00006256|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
13642|NCT00780390|Device|Spinal Cord Stimulator|SCS before and after implant
13643|NCT00780390|Other|CRPS patients under treatment other than spinal cord stimulator|RSD CRPS Not currently using a spinal cord stimulator
13644|NCT00780403|Drug|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
13645|NCT00780403|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
13646|NCT00780416|Drug|MP-424|750 mg every 8 hours for 12 weeks
13647|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
13648|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
13649|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
13089|NCT00779363|Device|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
13090|NCT00779376|Drug|Zidovudine 300mg tablets|
13091|NCT00779389|Drug|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
13092|NCT00779389|Drug|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
13093|NCT00779389|Drug|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
13094|NCT00779389|Drug|Placebo|Placebo for 14-21 days.
13095|NCT00779389|Drug|Erlotinib|Erlotinib 150 mg for 14-21 days.
13398|NCT00782600|Drug|CR 3|longer release SR formulation once daily for one day
13399|NCT00782613|Drug|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
13400|NCT00782613|Drug|Placebo|Placebo in a cream formulation
13401|NCT00782626|Drug|everolimus|
13402|NCT00782639|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
13403|NCT00782639|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
13404|NCT00782652|Drug|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
13405|NCT00782652|Drug|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
13406|NCT00006264|Drug|ganciclovir|
13407|NCT00782665|Procedure|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
13408|NCT00782691|Other|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
13409|NCT00782717|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
13410|NCT00782717|Other|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
12842|NCT00789308|Drug|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
12843|NCT00789308|Drug|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
12844|NCT00789308|Drug|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
12845|NCT00789308|Drug|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
12846|NCT00000739|Drug|Dapsone|
12847|NCT00006356|Drug|cisplatin|
12848|NCT00789308|Drug|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
12849|NCT00789308|Drug|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
12850|NCT00789321|Drug|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
12851|NCT00789321|Drug|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
12852|NCT00789360|Drug|Placebo -- Active|Placebo followed by Active (Staccato Loxapine, 10 mg x 2)
12853|NCT00789360|Drug|Active -- Placebo|Active (Staccato Loxapine, 10 mg x 2) followed by Placebo
12854|NCT00789373|Drug|Pemetrexed|Induction therapy: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
12855|NCT00789373|Drug|Cisplatin|Induction therapy: Cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles
12856|NCT00789373|Drug|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
12857|NCT00789373|Drug|Pemetrexed|Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
12858|NCT00006356|Procedure|conventional surgery|
13161|NCT00774293|Drug|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
13162|NCT00774293|Drug|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
13163|NCT00774306|Drug|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
13164|NCT00776906|Device|Advance® 18PTX® Balloon Catheter|
13165|NCT00776906|Device|Advance® 18LP Balloon Catheter|
13878|NCT00783406|Drug|PF-00610355|dry powder inhaler, 736 mcg, single dose
13879|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
13880|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
13881|NCT00775463|Drug|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
12919|NCT00787150|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
12920|NCT00787150|Drug|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
12921|NCT00787163|Procedure|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
12922|NCT00787176|Procedure|Lactated Ringers bolus of 1000 ml|Lactated Ringers bolus of 1000 ml initiated at patient positioning for epidural placement
12923|NCT00787176|Procedure|No additional fluid|Regular maintenance infusion of Lactated Ringers @ 125 ml/hr; no additional fluids
12924|NCT00787176|Procedure|Routine oxytocin|per regular oxytocin protocols
12925|NCT00787176|Procedure|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes after initiation of labor analgesia
12926|NCT00787189|Device|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
12927|NCT00787189|Device|Placebo Laser|inactive low level laser light therapy with no therapeutic output
12928|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
12929|NCT00006344|Radiation|radiation therapy|
12930|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
12931|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
12932|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
12933|NCT00787202|Other|placebo|Administration via oral route twice daily for the duration of treatment
12934|NCT00787215|Other|observational: no treatment involved|observational: no treatment involved
13650|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
13651|NCT00780442|Drug|d-cycloserine|50 mg DCS or placebo
13652|NCT00006256|Procedure|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
13653|NCT00780455|Drug|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
12691|NCT00783926|Biological|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
12692|NCT00783939|Drug|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
12693|NCT00783952|Device|'Cerebral/Somatic Tissue Oximeter' device|Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.
Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy.
12694|NCT00783965|Drug|tazarotene|Applied to the skin
12695|NCT00783965|Other|placebo|Applied to the skin
12696|NCT00783978|Other|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
12697|NCT00006286|Behavioral|Psychotherapy|
12698|NCT00784004|Other|Breathing Patterns|All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:
Breathing in through the nose only and out through the mouth only
Breathing in through the mouth only and out through the nose only
Breathing in and out through the nose only
Breathing in and out through the mouth only
12699|NCT00784017|Drug|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
12700|NCT00784017|Drug|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
12701|NCT00784030|Other|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
12702|NCT00784043|Device|Cochlear Implant|Bilateral Implantation in children
12703|NCT00784056|Drug|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
12704|NCT00784069|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
13411|NCT00782717|Drug|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
13412|NCT00782756|Other|radiotherapy (RT) in combination with temozolomide and bevacizumab|Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.
Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.
Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly.
13413|NCT00782769|Drug|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
13414|NCT00774592|Behavioral|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
13415|NCT00774592|Behavioral|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
13416|NCT00774592|Behavioral|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
13720|NCT00006244|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
13721|NCT00777829|Drug|High-dose zolpidem|Participants will receive one dose of 10 mg before each nap.
13722|NCT00777829|Drug|Placebo|Participants will receive a dose of placebo before each nap.
13723|NCT00777842|Device|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
13724|NCT00777855|Drug|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
13725|NCT00777855|Drug|warfarin|warfarin 7.5mg po x 1
13726|NCT00777868|Drug|Low Strength IDP-108|Topical application once a day for 9 months
13727|NCT00777868|Drug|High Strength IDP-108|Topical application once a day for 9 months
13728|NCT00777868|Drug|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
13729|NCT00777868|Drug|Vehicle|Topical application once a day for 9 months
13730|NCT00777881|Drug|Lenalidomide|• Lenalidomide (25 mg daily) is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
13731|NCT00006245|Drug|alvocidib|
13166|NCT00776919|Drug|clindamycin / benzoyl peroxide gel|Once a day application to the face
13167|NCT00776919|Drug|clindamycin gel|Once a day application to the face
13168|NCT00006242|Drug|BMS-214662|Given IV
13169|NCT00776919|Drug|BPO gel|Once a day application to the face
13170|NCT00776919|Drug|vehicle gel|Once a day application to the face
13171|NCT00776958|Other|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
13172|NCT00776971|Other|Sugar-sweetened soft drink|500mL as a preload drink
13173|NCT00776971|Other|Aspartame-sweetened soft drink|500mL as a preload drink
13174|NCT00776971|Other|Semi-skimmed milk|500mL as a preload drink
13175|NCT00776971|Other|Water|500mL as a preload drink
13176|NCT00776984|Drug|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
13177|NCT00776984|Drug|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
13178|NCT00776997|Device|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
13179|NCT00006242|Other|laboratory biomarker analysis|Correlative studies
13180|NCT00777010|Other|Carbohydrate restricted, ketogenic diet|Carbohydrate restricted diet compared to a healthy, higher carbohydrate diet
13181|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
13182|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
13477|NCT00780182|Drug|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
13478|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
13479|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
12935|NCT00789386|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
12936|NCT00789399|Drug|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
12937|NCT00789399|Other|Placebo|subcutaneous equivolume isotonic saline
12938|NCT00789425|Dietary Supplement|Standardized Extract of Olive Polyphenols|Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.
A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
12939|NCT00789425|Dietary Supplement|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
13243|NCT00774358|Drug|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
13244|NCT00774371|Behavioral|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
13245|NCT00774384|Biological|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
13246|NCT00774397|Drug|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
13247|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
13248|NCT00774397|Drug|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
13249|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
13250|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
13251|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
13252|NCT00006231|Radiation|radiation therapy|
13253|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
13254|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
13255|NCT00774397|Drug|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
12705|NCT00784082|Drug|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
12706|NCT00784095|Other|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
12707|NCT00784095|Other|Attention Control|Subjects will listen to a non-guided relaxation CD.
12708|NCT00006289|Drug|Neurotropin|Double Blind study
12709|NCT00784108|Device|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
12710|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
13021|NCT00787384|Drug|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
13022|NCT00787397|Behavioral|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
13023|NCT00787410|Drug|ZD1839|250mg tablet, once daily, orally administered
13024|NCT00787436|Drug|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
13025|NCT00787462|Drug|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
13026|NCT00789581|Drug|Doxorubicin|Doxorubicin 60 mg/m2
13027|NCT00789581|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2
13028|NCT00789581|Drug|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
13029|NCT00789581|Drug|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
13030|NCT00789594|Behavioral|laboratory monitoring alerts|laboratory monitoring alerts
13031|NCT00789594|Behavioral|Result management module|Result management module
13032|NCT00006358|Drug|thalidomide|
13732|NCT00777881|Drug|Dexamethasone|• Dexamethasone (40 mg daily) is also taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
13733|NCT00777894|Radiation|3-dimensional conformal radiation therapy|Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.
Phase I: Dose finding according to the following escalation table:
Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)
(3 patients) 27 x 2 Gy = 54 Gy
(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy
(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy
Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed.
13734|NCT00777894|Radiation|intensity-modulated radiation therapy|Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.
Phase I: Dose finding according to the following escalation table:
Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)
(3 patients) 27 x 2 Gy = 54 Gy
(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy
(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy
Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed.
13735|NCT00777894|Radiation|stereotactic body radiation therapy|Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.
Phase I: Dose finding according to the following escalation table:
Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)
(3 patients) 27 x 2 Gy = 54 Gy
(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy
(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy
Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed.
12774|NCT00791661|Drug|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
12775|NCT00006367|Biological|filgrastim|
12776|NCT00791661|Drug|Placebo|Matching placebo to MK-1006 in a single oral dose
12777|NCT00791700|Drug|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
12778|NCT00791713|Drug|Paliperidone ER|
12779|NCT00791739|Drug|trazodone, pregabalin|phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability
phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability
12780|NCT00791752|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
12781|NCT00791752|Drug|Placebo|Placebo
12782|NCT00791765|Biological|Etanercept|Etanercept for subcutaneous injection.
13480|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
13481|NCT00006255|Procedure|radiofrequency ablation|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
13482|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
13483|NCT00782769|Drug|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
13484|NCT00782795|Drug|Pioglitazone|Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.
13485|NCT00782821|Drug|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
13486|NCT00006264|Drug|zidovudine|
13487|NCT00782821|Drug|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
13488|NCT00782821|Drug|Rituxan|Given via IV per group assignment.
13489|NCT00782834|Drug|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
13490|NCT00782847|Behavioral|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
13491|NCT00782925|Other|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
13492|NCT00782925|Other|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
13493|NCT00782925|Other|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
13494|NCT00782951|Drug|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
13495|NCT00782951|Drug|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
13496|NCT00782951|Drug|Placebo|single IV dose of placebo after dental impaction surgery
13497|NCT00006265|Drug|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
13256|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
13257|NCT00006242|Other|pharmacological study|Correlative studies
13258|NCT00777088|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
13259|NCT00777101|Drug|Neratinib|Tablets, 240mg once per day until disease progression or unacceptable toxicity
13260|NCT00777101|Drug|Lapatinib|Tablets 1250mg once per day until disease progression or unacceptable toxicity.
13261|NCT00777101|Drug|Capecitabine|Tablets 2000mg/m2 given in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
13262|NCT00777114|Drug|bortezomib, tositumomab|0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,
0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,
0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,
0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and
1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab.
13558|NCT00780234|Drug|PIOGLITAZONE VS. PLACEBO 30 mg|Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-
activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare.
13559|NCT00780260|Behavioral|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
13560|NCT00780273|Device|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
13561|NCT00780273|Device|Biomet 3i Prevail Implants|
13562|NCT00780299|Device|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
13563|NCT00780299|Procedure|CVVH|hemofiltration intermittent dialysis
13564|NCT00006255|Procedure|thermal ablation therapy|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
13565|NCT00780312|Other|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
13033|NCT00789607|Device|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
13034|NCT00789607|Device|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
13035|NCT00789620|Drug|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
13036|NCT00789620|Drug|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
13037|NCT00789633|Drug|masitinib (AB1010)|9 mg/kg/day
13038|NCT00789633|Drug|placebo|matching placebo
13039|NCT00789646|Procedure|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
13335|NCT00774540|Drug|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
13336|NCT00774540|Drug|Placebo|Saline
13337|NCT00774553|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
13338|NCT00006232|Drug|doxorubicin hydrochloride|
13339|NCT00774553|Drug|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
13340|NCT00774566|Procedure|PV-Isolation RF|Radiofrequency
13341|NCT00774566|Procedure|PV-Isolation Cryo|Cryo-Balloon
13342|NCT00774592|Behavioral|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
13343|NCT00777218|Drug|zonisamide|standard pediatric dosages, based on body weight
13344|NCT00777218|Drug|topiramate|standard pediatric dosages, based on body weight
13345|NCT00777231|Device|Enriched Hematopoetic Stem Cell Transplant|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points
13346|NCT00777244|Drug|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
12783|NCT00791765|Biological|Placebo|Placebo for subcutaneous injection.
12784|NCT00791778|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
12785|NCT00791778|Drug|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
12786|NCT00006367|Drug|busulfan|
12787|NCT00784147|Drug|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
12788|NCT00784160|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
12789|NCT00784186|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
12790|NCT00784186|Drug|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
12791|NCT00006291|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
12792|NCT00784186|Drug|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
12793|NCT00784212|Drug|BGG492|
12794|NCT00784212|Drug|BGG492|
12795|NCT00784212|Drug|Placebo|
12796|NCT00784225|Drug|selenium|200 mcg daily for 7-12 years
13096|NCT00779402|Other|Placebo|Non autologous PAP loaded dendritic cells
13097|NCT00006251|Other|laboratory biomarker analysis|Correlative studies
13098|NCT00779402|Biological|Provenge|Biologic: Immunotherapy with PAP loaded dendritic cells.
13099|NCT00779428|Drug|Tanespimycin|Solution, IV
This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)
13100|NCT00779441|Drug|Zolpidem 10mg tablets|
13101|NCT00779454|Drug|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
13102|NCT00779454|Drug|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
13803|NCT00775424|Biological|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
13804|NCT00775424|Biological|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
13805|NCT00775424|Biological|PLACEBO|PLACEBO
13806|NCT00775424|Biological|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
13807|NCT00775437|Drug|Adalimumab|Adalimumab solution for injection for subcutaneous use.
13808|NCT00006235|Drug|carboplatin|
13809|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
13810|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
13811|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
13812|NCT00777907|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
13813|NCT00777907|Device|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
13814|NCT00777920|Drug|Ambrisentan|Ambrisentan tablet administered orally once daily
13815|NCT00777933|Drug|tacrolimus|
13816|NCT00777933|Drug|cyclosporine|
13817|NCT00777946|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
13818|NCT00006245|Drug|paclitaxel|
13819|NCT00777946|Drug|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
13820|NCT00777946|Drug|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
13821|NCT00777946|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
13822|NCT00777946|Drug|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
13566|NCT00780325|Drug|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
13567|NCT00780325|Drug|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
13568|NCT00780325|Drug|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
13569|NCT00780325|Drug|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
13570|NCT00780325|Drug|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
13571|NCT00780325|Drug|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
13572|NCT00780338|Other|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
13573|NCT00783159|Procedure|Strength Training|Strength training, Vitamin D substitution
13574|NCT00783159|Other|Control|Vitamin D substitution, Lifestyle consultation
13882|NCT00775463|Drug|placebo|
13883|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, 1.2 g twice daily
13884|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, 2.4 g twice daily
13885|NCT00775476|Drug|Placebo|2.4 g of placebo (sugar) twice daily
13886|NCT00006235|Drug|pegylated liposomal doxorubicin hydrochloride|
13887|NCT00775489|Drug|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
13888|NCT00775489|Drug|Saline|control group will receive normal saline inhaler
13889|NCT00775502|Drug|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
13890|NCT00775515|Procedure|laparoscopic prostatectomy|laparoscopic prostatectomy
13891|NCT00775528|Drug|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
13892|NCT00775541|Dietary Supplement|Vitamin C|One IV infusion of 2 gm vitamin C
13347|NCT00777257|Biological|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
13348|NCT00777257|Biological|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
13349|NCT00777257|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
13350|NCT00777270|Procedure|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
13351|NCT00777270|Procedure|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
13352|NCT00777296|Drug|Arikace™|All patients participating in the extension period of the study will receive 560 mg once daily dose of Arikace™ administered for six cycles over eighteen months. Each cycle comprising of 28 days of treatment followed by 56 days off treatment. Safety, tolerability, serum PK, quantitative microbiology, spirometry and clinical data will be obtained during this period.
13353|NCT00006243|Biological|gp100 antigen|Given SC
13354|NCT00777309|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
13654|NCT00780455|Drug|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
13655|NCT00780468|Behavioral|Existing diet plan|
13656|NCT00780468|Behavioral|New diet plan|
13657|NCT00780481|Drug|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
13658|NCT00780494|Drug|bevacizumab|IV 15 mg/kg
13659|NCT00780494|Drug|carboplatin|AUC 6, Intravenously Day 1 every 21 days
13660|NCT00780494|Drug|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
13661|NCT00780520|Dietary Supplement|alanine-glutamine infusion|
13662|NCT00780559|Behavioral|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
13663|NCT00006256|Radiation|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
13664|NCT00780559|Behavioral|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
13103|NCT00779467|Drug|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
13104|NCT00779467|Drug|Bupivacaine|
13105|NCT00779467|Drug|fentanyl|fentanyl 2 mcg/ml
13106|NCT00779480|Drug|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
13107|NCT00779493|Dietary Supplement|curcumin|curcumin 900mg twice daily by mouth
13108|NCT00006252|Drug|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
13109|NCT00779493|Dietary Supplement|placebo|placebo capsule to simulate 900mg curcumin capsule
13110|NCT00779506|Drug|Quetiapine Fumarate XR|oral, once daily, flexible dose
13111|NCT00779519|Drug|TTP435|
13112|NCT00779519|Drug|Placebo|
13113|NCT00779532|Drug|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
13114|NCT00779532|Drug|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
13115|NCT00779532|Drug|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
13116|NCT00782145|Other|survey administration|
13117|NCT00782145|Procedure|psychosocial assessment and care|
13118|NCT00006261|Drug|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
13119|NCT00782145|Procedure|quality-of-life assessment|
13417|NCT00774592|Behavioral|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
13418|NCT00774592|Behavioral|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
13419|NCT00774605|Drug|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
13420|NCT00006232|Drug|idarubicin|
13421|NCT00774605|Drug|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
13823|NCT00777959|Drug|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
12859|NCT00789373|Other|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
12860|NCT00789386|Drug|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
12861|NCT00791791|Procedure|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
12862|NCT00791804|Drug|AeroLEF|Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)
for nebulized administration as required by the patient.
Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl.
12863|NCT00791817|Drug|PG-760564|200 mg capsule, single dose,fasted when dosed, duration is 4 days
12864|NCT00791817|Drug|PG-760564|200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
12865|NCT00791830|Drug|Irbesartan|Tablets, 300 mg * 1 daily, 1 year
12866|NCT00791830|Drug|Placebo matching irbesartan 150 mg|Tablets, 300 mg * 1 daily, 1 year
12867|NCT00791843|Drug|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
12868|NCT00791856|Drug|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
12869|NCT00791856|Drug|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
12870|NCT00791882|Behavioral|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
12871|NCT00006367|Drug|cytarabine|
12872|NCT00791895|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme
12873|NCT00791908|Procedure|Electrodessication|Treatment applied to a third of the torso at each study visit.
12874|NCT00791908|Procedure|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
12875|NCT00791908|Procedure|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
13893|NCT00775554|Other|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
13894|NCT00775554|Other|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
13895|NCT00775567|Dietary Supplement|Fructose powder|30g in 250ml water twice a day
13896|NCT00775580|Drug|Atenolol 100mg Tablets|
13897|NCT00006237|Biological|interleukin-2|Given IV
13898|NCT00775593|Drug|clofarabine|Patients will receive one course of low-dose Clofarabine in combination with Temsirolimus (CloTor regimen) for remission induction.
Induction therapy
- Clofarabine 20 mg/m2/day, administered by iv infusion over 1 hour on days 1 through 5
13899|NCT00775593|Drug|temsirolimus|Those who achieve morphologic CR and morphologic CRi will receive maintenance treatment with Temsirolimus monthly for 12 months, or until relapse.
Those who achieve a PR will receive one additional course of CloTor and, if a CR/CRi is obtained, maintenance treatment with Temsirolimus as above.
Induction therapy:
- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1, 8 and 15.
Maintenance therapy:
- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1 and 8 of each month for 12 months, or until relapse.
13900|NCT00775606|Drug|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
13901|NCT00775606|Drug|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
13902|NCT00775619|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
12940|NCT00789451|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
12941|NCT00789464|Dietary Supplement|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
12942|NCT00789464|Drug|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
12943|NCT00006357|Drug|imatinib mesylate|
12944|NCT00789477|Procedure|Laser Photocoagulation|laser every 16 weeks as needed
12945|NCT00789477|Drug|Intravitreal Aflibercept Injection|
12946|NCT00789490|Dietary Supplement|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
12947|NCT00789490|Dietary Supplement|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
13665|NCT00783406|Drug|PF-00610355|dry powder inhaler, 368 mcg, single dose
13666|NCT00783406|Drug|Placebo|Placebo
13667|NCT00783432|Drug|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
13668|NCT00783432|Drug|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
13669|NCT00783445|Behavioral|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
13670|NCT00783445|Behavioral|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
13671|NCT00783458|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
13672|NCT00006270|Drug|cosyntropin|
13673|NCT00783458|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
13674|NCT00783471|Drug|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
13675|NCT00783471|Drug|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
12711|NCT00784121|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
12712|NCT00784134|Drug|Cathflo Activase|1.0 mg of Cathflo Activase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
12713|NCT00784134|Other|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
12714|NCT00784147|Drug|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
12715|NCT00786669|Drug|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
12716|NCT00786669|Drug|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
12717|NCT00786669|Drug|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
12718|NCT00786682|Drug|docetaxel|
12719|NCT00786682|Drug|hydroxychloroquine|
13422|NCT00774618|Device|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
13423|NCT00774631|Procedure|Mild induced hypothermia (32-34°C)|Mild Induced hypothermia:
Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 [6, 48]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods.
13424|NCT00774631|Procedure|local recommendations and guidelines|Investigational procedure:
This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.
Controls will receive standard care and will be also be deeply sedated for 48 hours.
13425|NCT00774644|Drug|Clarithromycin 500mg|
13426|NCT00774683|Drug|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
13427|NCT00774696|Drug|clarithromycin 500mg tablets|
13428|NCT00774722|Drug|Metronidazole|10% ointment, three times daily for 14 days
13429|NCT00774735|Drug|GSK1349572|30 mg given in combination with lopinavir/ritonavir
13430|NCT00774735|Drug|GSK1349572|30 mg in combination with darunavir/ritonavir
13431|NCT00006232|Drug|vincristine sulfate|
13432|NCT00774748|Device|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
13433|NCT00774761|Drug|fluticasone propionate/formoterol fumarate|inhalation suspension
13434|NCT00006243|Biological|incomplete Freund's adjuvant|Given SC
13736|NCT00780572|Behavioral|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
13737|NCT00780585|Drug|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
12876|NCT00791921|Drug|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
12877|NCT00791921|Drug|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
13183|NCT00777023|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
13184|NCT00777036|Drug|Dasatinib|
13185|NCT00777049|Drug|Panobinostat - LBH589|hard gelatine capsule - 5mg and 20mg
13186|NCT00777062|Drug|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
13187|NCT00777062|Drug|Placebo|Placebo injection at the start of weeks 2 and 6.
13188|NCT00777075|Drug|L-arginine|
13189|NCT00777075|Drug|Placebo|
13190|NCT00779532|Drug|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
13191|NCT00779545|Drug|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
13192|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
13193|NCT00006252|Drug|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
13194|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
13195|NCT00779545|Drug|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
13196|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
13197|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
13198|NCT00779558|Drug|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
13199|NCT00779558|Drug|Placebo infusion|Infusion of normal saline
16465|NCT00795353|Drug|Amevive exposure|Commercial alefacept prescribed by Physician
16466|NCT00795366|Drug|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
16467|NCT00795366|Drug|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
16468|NCT00795379|Behavioral|Interoceptive Exposure|Exposure to internal stimuli.
16469|NCT00795392|Other|ASA scale|ASA scale evaluation before operation
16470|NCT00795392|Other|Full-scale psychological assessment|Full-scale psychological evaluation before operation
16471|NCT00006385|Biological|MART-1 antigen|
16472|NCT00795405|Behavioral|Exposure to sporting events|Exposure to sporting events
16473|NCT00795405|Behavioral|No exposure to sporting events|No exposure to sporting events
16474|NCT00797667|Drug|140 mg telcagepant placebo|
19658|NCT00818831|Drug|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
19659|NCT00818844|Drug|Nepafenac 0.1%|NSAID
19660|NCT00007332|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
19661|NCT00818844|Other|BSS|BSS
19662|NCT00818857|Behavioral|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
19663|NCT00818857|Behavioral|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
19664|NCT00818870|Drug|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
19665|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
19666|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
19667|NCT00818883|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.
For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment.
19260|NCT00815685|Drug|Eicosapentaenoic Acid|Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
19261|NCT00815698|Procedure|suture|suture for mesh fixation
19262|NCT00815698|Procedure|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
19263|NCT00815724|Behavioral|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
19264|NCT00006929|Drug|suramin|Given IV
19265|NCT00815737|Drug|rhubarb|14 days of rhubarb
19266|NCT00815737|Drug|Placebo|14 days of Placebo
19267|NCT00815750|Other|Information Gathering|An information gathering phase leading to development of a new decision aid.
19268|NCT00815750|Other|Decision Aid|To test the newly developed decision aid.
19269|NCT00815763|Drug|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
19270|NCT00815763|Drug|placebo|infusion placebo once a day and continued for 14 day
19271|NCT00815776|Device|Clayton Intra-aural Device (CID)|The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the "CID").
19272|NCT00815776|Device|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
19273|NCT00815776|Other|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
19563|NCT00818636|Behavioral|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
19687|NCT00820820|Biological|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
19688|NCT00820820|Biological|placebo|Vehicle (water for injection), 0.5 ml, once
19689|NCT00820833|Other|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
19690|NCT00820833|Other|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
19691|NCT00007748|Behavioral|Cognitive behavioral therapy|
19692|NCT00820846|Biological|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
19693|NCT00820846|Biological|Placebo|1 mL of sodium chloride for injection
19694|NCT00820846|Biological|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
19695|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
19696|NCT00814229|Biological|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
19697|NCT00814229|Biological|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
19698|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
20009|NCT00819481|Device|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
20010|NCT00812500|Other|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
20011|NCT00006695|Procedure|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
20012|NCT00812500|Other|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
20013|NCT00812500|Other|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
20014|NCT00812513|Drug|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
20015|NCT00812526|Procedure|Suction cup application|
19190|NCT00815646|Drug|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
19191|NCT00815659|Drug|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
19192|NCT00815672|Behavioral|Exercise|Progressive walking and resistance exercise treatment
19193|NCT00817986|Drug|Arbaclofen placarbil, 30 mg BID|After the screening/randomization visit, eligible subjects will be randomized to study treatment (arbaclofen placarbil or placebo) for 14 days with taper period
19194|NCT00817986|Drug|Arbaclofen placarbil, 40 mg BID|After the screening/randomization visit, eligible subjects will be randomized to study treatment (arbaclofen placarbil or placebo) for 14 days with taper period
19195|NCT00817999|Dietary Supplement|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
19196|NCT00817999|Drug|Clopidogrel 75 mg/day|
19197|NCT00817999|Drug|Clopidogrel 300 mg|
19198|NCT00818025|Behavioral|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
19199|NCT00818038|Drug|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
19200|NCT00818051|Radiation|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
19201|NCT00007202|Drug|Stavudine|
19481|NCT00818584|Drug|Micafungin|IV Administration
19482|NCT00818597|Device|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
19483|NCT00007280|Device|Bioengineered skin|
19484|NCT00818610|Drug|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
19485|NCT00818610|Drug|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
19486|NCT00818623|Drug|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
19487|NCT00818623|Drug|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
19488|NCT00818623|Drug|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
19758|NCT00821015|Device|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
19759|NCT00821028|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
19760|NCT00007774|Drug|Haloperidol|
19761|NCT00821041|Behavioral|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
19762|NCT00821054|Drug|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
19763|NCT00821067|Dietary Supplement|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
19764|NCT00821067|Dietary Supplement|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
19765|NCT00821080|Drug|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
19766|NCT00821080|Drug|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
19767|NCT00821093|Drug|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
19768|NCT00821093|Drug|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
19769|NCT00821093|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
19770|NCT00821093|Drug|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
20085|NCT00819572|Drug|Placebo|
20086|NCT00819585|Drug|Canakinumab 25 mg|25 mg subcutaneous injection once on day 1.
20087|NCT00819585|Drug|Canakinumab 50 mg|50 mg subcutaneous injection once on day 1.
20088|NCT00819585|Drug|Canakinumab 100 mg|100 mg subcutaneous injection once on day 1.
20089|NCT00819585|Drug|Canakinumab 200 mg|200 mg subcutaneous injection once on day 1.
19564|NCT00818649|Drug|bortezomib|1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
19565|NCT00818649|Drug|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
19566|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
19567|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
19568|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
19569|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
19570|NCT00818675|Drug|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
19571|NCT00818675|Drug|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
19572|NCT00818675|Drug|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
19573|NCT00007306|Drug|Parathyroid hormone ointment|
19574|NCT00818688|Procedure|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
19575|NCT00818701|Drug|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
19576|NCT00818701|Drug|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
19577|NCT00818714|Radiation|SBRT|SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)
Dose Escalation Schema:
Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort
Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3
Continue +1 Gy x 3 until reach MTD
19578|NCT00818740|Drug|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
19579|NCT00818753|Drug|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
19580|NCT00818753|Drug|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
19581|NCT00818753|Drug|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
20016|NCT00812526|Procedure|Squatting|
20017|NCT00812539|Other|Subject/Provider Portal "Diabetes Connected Health" tool - Deluxe|Subjects enrolled into the "Deluxe"intervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal ("Diabetes Connected Health" tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading.
20018|NCT00812539|Other|Subject only Portal "Diabetes Connected Health Tool" Basic|Patients enrolled in the Diabetes Connect "Basic" intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the "Diabetes Connected Health" tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system.
20019|NCT00812565|Drug|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
20020|NCT00812565|Biological|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
20021|NCT00812578|Drug|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
20022|NCT00000755|Biological|rgp120/HIV-1MN|
20023|NCT00006695|Radiation|tositumomab and iodine I 131 tositumomab|Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the "dosimetric dose" and the "therapeutic dose". The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject
19121|NCT00817986|Drug|Arbaclofen placarbil, 20 mg BID|After the screening/randomization visit, eligible subjects will be randomized to study treatment (arbaclofen placarbil or placebo) for 14 days with taper period
19122|NCT00817986|Drug|Placebo|After the screening/randomization visit, eligible subjects will be randomized to study treatment (arbaclofen placarbil or placebo) for 14 days with taper period
19123|NCT00820118|Drug|Structured treatment interruption|The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir
Usual dosage recommended :
atazanavir : 300 mg/d
ritonavir : 100 mg/d
abacavir 600 mg and lamivudine 300 mg : once a day
tenofovir 245 mg and emtricitabine 200 mg : once a day
19124|NCT00820131|Procedure|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
19125|NCT00820131|Procedure|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
19126|NCT00820144|Biological|CTB by nasal way|
19489|NCT00818623|Drug|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
19490|NCT00818623|Drug|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
19491|NCT00818623|Drug|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
19492|NCT00818623|Drug|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
19493|NCT00820859|Behavioral|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
19494|NCT00820859|Behavioral|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
19495|NCT00820872|Biological|trastuzumab|
19496|NCT00820872|Drug|carboplatin|
19497|NCT00820872|Drug|docetaxel|
19498|NCT00820872|Drug|lapatinib ditosylate|
19499|NCT00820885|Drug|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
19500|NCT00007761|Behavioral|Bipolar Disorder Program|
19501|NCT00820885|Drug|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
19502|NCT00820885|Drug|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
19503|NCT00820898|Drug|Gemcitabine Hydrochloride|Given IV
19504|NCT00820911|Drug|cyclosporine (reduced exposure) / everolimus|twice daily
19751|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
19752|NCT00819013|Biological|Saline placebo|0.5 mL, Intramuscular
19753|NCT00819039|Drug|Aprepitant|Aprepitant administered orally or intraveously.
19754|NCT00819039|Drug|Ondansetron|Ondansetron administered intravenously.
19755|NCT00819052|Drug|Nevirapine XR|Nevirapine XR
19756|NCT00007423|Biological|ALVAC-HIV MN120TMG (vCP205)|
19757|NCT00819052|Drug|Nevirapine XR|Nevirapine extended release
20090|NCT00819585|Drug|Canakinumab 300 mg|300 mg subcutaneous injection once on day 1.
20091|NCT00819585|Drug|Canakinumab repeated every 4 week (q4wk)|50 mg subcutaneous injection (s.c) once on day 1 and day 29 followed by 25 mg s.c. once on Days 57, and 85.
20092|NCT00819585|Drug|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
20093|NCT00007527|Drug|naloxone|
20094|NCT00819585|Drug|Allopurinol|100- 300 mg orally once daily for 24 weeks.
20095|NCT00819585|Drug|Placebo Matching Canakinumab|Subcutaneous injection.
20096|NCT00819585|Drug|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
20097|NCT00819598|Procedure|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
20098|NCT00819598|Procedure|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
20099|NCT00819611|Behavioral|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
20100|NCT00819611|Behavioral|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
20101|NCT00812617|Dietary Supplement|Mineral water (Aso-gun, Kumamoto, Japan)|
20102|NCT00812630|Drug|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
20103|NCT00812643|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
20104|NCT00812669|Biological|pegfilgrastim|
20105|NCT00812669|Biological|rituximab|
20106|NCT00812669|Drug|cyclophosphamide|
20107|NCT00006708|Biological|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
20108|NCT00812669|Drug|fludarabine phosphate|
19202|NCT00818064|Drug|Anti-IL-20|Single s.c. injection (per dose cohort)
19203|NCT00818064|Drug|placebo|Single s.c. injection (per dose cohort)
19816|NCT00819065|Drug|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
19817|NCT00819078|Drug|Bupropion|300 mg/d
19818|NCT00819078|Drug|Placebo|no dosage
19819|NCT00819091|Drug|BI 1356|5mg orally (po) tablet qd
19820|NCT00819091|Drug|Placebo|Placebo matching BI 1356 5mg one tablet daily
19821|NCT00819104|Drug|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
19822|NCT00819104|Drug|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
19823|NCT00007423|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
19824|NCT00819104|Drug|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
19825|NCT00819104|Drug|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
19826|NCT00819104|Drug|Amlodipine 5mg|tablet,oral,OD,8 weeks
19827|NCT00819117|Device|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
19828|NCT00819156|Drug|degarelix|Degarelix was given as subcutaneous injections.
19829|NCT00819169|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
19830|NCT00819169|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
19831|NCT00819182|Behavioral|Paced respiration|Breathing exercise
19832|NCT00819182|Behavioral|Sham comparator: fast shallow breathing|sham breathing exercise
19833|NCT00819195|Drug|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
19834|NCT00007436|Drug|Tenofovir disoproxil fumarate|
19835|NCT00819208|Behavioral|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
19127|NCT00820144|Biological|absorption of CTB by oral way|absorption of CTB by oral way
19128|NCT00820144|Biological|absorption of dukoral by oral way|absorption of dukoral by oral way
19129|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
19130|NCT00007657|Procedure|Intensive medical therapy|
19131|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
19132|NCT00820157|Procedure|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
19133|NCT00820157|Procedure|TACE|TACE alone or TACE followed by downstage resection for MNHCC
19134|NCT00820170|Drug|Dasatinib and Paclitaxel|A treatment cycle will consist of 28 days, according to the following schedule:
Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel.
19135|NCT00820183|Other|Quality Improvement plan for Hypertension Control|Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:
Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation
19136|NCT00820196|Drug|Nexagon®|
19137|NCT00820196|Drug|Nexagon® vehicle|
19138|NCT00820222|Drug|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
19139|NCT00820222|Drug|lapatinib|oral medication; daily dose taken once a day
19417|NCT00820716|Other|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
19418|NCT00820742|Drug|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
19419|NCT00813839|Other|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
19420|NCT00813852|Behavioral|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
16404|NCT00799968|Drug|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
16405|NCT00800007|Drug|ANZ-521|3x10^7 cfu or 3x10^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
16406|NCT00800007|Drug|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
16407|NCT00800033|Behavioral|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
16408|NCT00800033|Dietary Supplement|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
15451|NCT00810082|Device|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
15452|NCT00006517|Device|dawn simulator|gradual rise in bedroom illumination prior to wake-up
15453|NCT00810082|Other|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
15454|NCT00810095|Device|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
15455|NCT00810108|Drug|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
15456|NCT00810121|Drug|ketoprofen 100 mg|100 mg b.i.d. for 5 days
15457|NCT00812123|Procedure|Protocol biopsies|protocol kidney biopsies at month one and three
15458|NCT00812136|Behavioral|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
15459|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
15460|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
15461|NCT00812175|Drug|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
15462|NCT00812188|Other|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
15463|NCT00812188|Other|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
15464|NCT00006695|Drug|carmustine|300 mg/m2 IV on Day -6
19204|NCT00818077|Other|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
19205|NCT00818090|Drug|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
19206|NCT00818103|Drug|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
19207|NCT00818103|Drug|β-interferon|β-interferon 50ug i.m. qod for 2 years
19208|NCT00818103|Drug|EPO|EPO 10000U i.h. bid for 5 days
19209|NCT00818116|Device|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
19210|NCT00818129|Drug|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
19211|NCT00818129|Drug|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
19212|NCT00007202|Drug|Didanosine|
19213|NCT00818142|Behavioral|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
19214|NCT00818155|Drug|desvenlafaxine succinate SR|desvenlafaxine succinate SR
19215|NCT00818155|Other|Placebo|
19216|NCT00818168|Biological|Infliximab|Dosage and infusion intervals were employed in
accordance to the Summary of Product Characteristics (SmPC)
19217|NCT00818181|Drug|Biological: AL0206st|
19218|NCT00818194|Drug|extended release tacrolimus|oral
19219|NCT00820248|Drug|cisplatin|Given IV
19220|NCT00820248|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
19221|NCT00820248|Radiation|accelerated radiation therapy|Patients undergo accelerated fractionation radiotherapy
19222|NCT00820248|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
19223|NCT00820261|Other|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
19668|NCT00818883|Drug|Azilsartan medoxomil and hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.
For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment.
19669|NCT00818909|Other|Systane|Systane prescription
19670|NCT00818935|Dietary Supplement|Low-Intermediate-Glycemic Index diets|
19671|NCT00007345|Drug|Romidepsin|
19672|NCT00818935|Dietary Supplement|High GI diet|
19673|NCT00820755|Drug|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram*hour/milliliter (mg*hr/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
19674|NCT00820755|Drug|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
19675|NCT00820755|Drug|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
19913|NCT00819247|Drug|Degarelix|Given as a subcutaneous injection.
19914|NCT00819260|Device|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
19915|NCT00819260|Device|Electrocautery|Electrocautery used to reduce breast on this side
19916|NCT00819286|Device|SternaLock Rigid Fixation System|patients will have their sternum closed by rigid fixation using SternaLock plates.
19917|NCT00819286|Device|Wire (control)|patients will have their sternum closed using stainless steel wires.
19918|NCT00819312|Drug|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
19919|NCT00007475|Procedure|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
19920|NCT00819325|Drug|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
19921|NCT00819325|Drug|oral hypoglycemic agents|sulfonylurea or metformin
19421|NCT00813865|Drug|AT2101|AT2101 oral capsules
19422|NCT00813878|Genetic|protein analysis|protein analysis
19423|NCT00813878|Genetic|protein expression analysis|protein expression analysis
19424|NCT00813878|Genetic|proteomic profiling|proteomic profiling
19425|NCT00813878|Other|diagnostic laboratory biomarker analysis|Performed one time on study
19426|NCT00813878|Other|immunohistochemistry staining method|Performed one time on study
19427|NCT00813878|Other|liquid chromatography|Performed on samples collected one time on study
19428|NCT00006734|Procedure|conventional surgery|
19429|NCT00813878|Other|mass spectrometry|Performed on samples collected one time on study
19430|NCT00813878|Procedure|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
19431|NCT00813878|Procedure|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
19432|NCT00813878|Procedure|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
19433|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
19434|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
19435|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
19436|NCT00813904|Biological|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
19437|NCT00813917|Drug|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
19438|NCT00813917|Drug|placebo|12 weeks of placebo (double blinded) by mouth twice per day
19699|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
19700|NCT00814229|Biological|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
19701|NCT00006747|Drug|Etoposide|200 mg/sq m IV days -5 thru -2
15465|NCT00812201|Device|No intervention is used. Collection of signals only.|Device received per standard of care.
15466|NCT00812214|Drug|eszopiclone|3 mg qhs
15467|NCT00812214|Drug|placebo|
15468|NCT00812227|Behavioral|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
15469|NCT00812240|Drug|masitinib (AB1010)|masitinib (AB1010) 7.5 mg/kg/day, per os
15470|NCT00812240|Drug|imatinib|imatinib 400 mg or 600 mg per day, per os
15471|NCT00812253|Drug|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
15472|NCT00812253|Drug|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
15772|NCT00806338|Drug|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
15773|NCT00806338|Drug|Placebo|
15774|NCT00806351|Drug|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
15775|NCT00806351|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
15776|NCT00806390|Drug|Metoprolol|Metroprolol tartrate titrated up
15777|NCT00806403|Drug|reteplase 10+10 U|comparison to primary PCI
15778|NCT00006473|Drug|oxaliplatin|Given IV
15779|NCT00808366|Drug|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
15780|NCT00808379|Drug|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
15781|NCT00808379|Radiation|Additional Radiation boost to the primary tumor volume|15-20Gy
15782|NCT00808392|Biological|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
15783|NCT00808392|Biological|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
19505|NCT00820911|Drug|AEB071 300 mg b.i.d. / everolimus|twice daily
19506|NCT00820911|Drug|AEB071 200 mg b.i.d. / everolimus|twice daily
19507|NCT00820924|Drug|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
19508|NCT00820937|Procedure|Single photon emission computed tomography and Magnetic Resonance Imaging|
19509|NCT00820950|Drug|INCB018424 phosphate cream|INCB018424 phosphate cream 0.5%, 1.0% and 1.5%
19510|NCT00820950|Drug|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
19511|NCT00000197|Drug|Propranolol|
19512|NCT00000763|Drug|TNP-470|
19513|NCT00007761|Behavioral|Usual (psychiatric) Care|
19514|NCT00820950|Drug|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
19515|NCT00820950|Drug|Placebo cream|Cream applied once or twice daily for 56 days
19516|NCT00820963|Drug|temozolomide|Given orally
19517|NCT00820963|Radiation|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
19518|NCT00820963|Radiation|radiation therapy|Patients undergo standard radiotherapy
19519|NCT00820976|Drug|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
19520|NCT00820989|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
19521|NCT00821002|Drug|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
19522|NCT00813943|Drug|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
19523|NCT00813943|Drug|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
19922|NCT00819338|Dietary Supplement|Efamax|5g daily as capsules for 3 months
19923|NCT00819351|Drug|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
19924|NCT00819351|Drug|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
19925|NCT00812318|Drug|GSK1265744 10 mg oral solution|GSK1265744
19926|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
19927|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
19928|NCT00812331|Drug|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
19929|NCT00006695|Drug|etoposide|100 mg/m2 BID on Days -5 through -2
19930|NCT00812344|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
19931|NCT00812344|Drug|Ketoconazole|tablets, orally, once daily for 3 days
19932|NCT00812344|Drug|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
19933|NCT00812370|Drug|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
19934|NCT00812383|Device|RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System|Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
20277|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
20278|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
20279|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
19702|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
19703|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
19704|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
19705|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
19706|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
19707|NCT00814242|Procedure|surgical resection|radical resection performed in patinets with HCC.
19708|NCT00814242|Procedure|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
19709|NCT00814255|Drug|Adalimumab|Adalimumab 24 mg/m2 (maximum dose 40 mg) sc q 14 days
19710|NCT00814255|Drug|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
19711|NCT00814255|Drug|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
19712|NCT00006760|Biological|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
19713|NCT00814268|Drug|Clopidogrel|75mg tablet, oral administration once daily
19714|NCT00814268|Drug|Clopidogrel placebo|Matching tablet, oral administration once daily
19715|NCT00814268|Drug|Aspirin|100mg tablet, oral administration once daily
19716|NCT00814281|Other|placebo|Placebo
19717|NCT00814281|Drug|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
19718|NCT00814294|Drug|placebo|placebo capsule,0 units, QID for 18 weeks
19719|NCT00814294|Drug|Oral HDV-I|Oral HDV-I Caps; 15 U; QID for 18 weeks.
20024|NCT00812591|Procedure|OGTT and CLAMP|Oral Glucose Tolerance Test (OGTT):
Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
Hyperinsulinemic euglycemic clamp (CLAMP):
Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe.
20025|NCT00812604|Drug|Ping On Ointment|Ping On Ointment
15784|NCT00808405|Drug|acyclovir|400mg taken orally three times daily for 5 days
15785|NCT00808405|Drug|matching placebo|matching placebo taken orally three times daily for 5 days.
15786|NCT00808418|Drug|Elesclomol Sodium|Chemotherapy agent
15787|NCT00006484|Drug|tirapazamine|
15788|NCT00808418|Drug|Docetaxel|Chemotherapy agent
15789|NCT00808431|Behavioral|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
15790|NCT00808444|Biological|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
15791|NCT00808444|Biological|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
15792|NCT00808444|Biological|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
15793|NCT00808444|Biological|Rotarix|Oral, 2 doses
16080|NCT00794794|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
16081|NCT00794794|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
16082|NCT00794807|Drug|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
16083|NCT00794820|Drug|Fludarabine Phosphate|25 mg/m^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
16084|NCT00794820|Drug|Cyclophosphamide|250 mg/m^2 by vein over 60 minutes daily for 3 days (days 2-4)
16085|NCT00794820|Drug|Rituximab|375 mg/m^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m^2 on days 2-3
16086|NCT00006382|Procedure|bronchoscopic and lung imaging studies|
16087|NCT00794846|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
16088|NCT00794846|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
16089|NCT00794859|Drug|Sorafenib|400mg twice daily
16090|NCT00794872|Other|blood sampling|
16091|NCT00794885|Drug|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
19524|NCT00813943|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
19525|NCT00813943|Radiation|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
19771|NCT00007774|Drug|Olanzapine|
19772|NCT00821106|Procedure|Right radial|diagnostic or interventional procedures performed through right transradial approach
19773|NCT00821106|Procedure|left radial|diagnostic or interventional procedures performed through left transradial approach
19774|NCT00821119|Device|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
19775|NCT00821132|Other|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
19776|NCT00821145|Procedure|conventional surgery|AAA patients operated using a conventional incision
19777|NCT00821145|Procedure|laparoscopic AAA resection|laparoscopic AAA resection
19778|NCT00821145|Procedure|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
19779|NCT00821158|Drug|Antioxidant|Antioxidant iv bolus
19780|NCT00814294|Drug|Oral HDV-Insulin|Oral HDV-I; Caps; 5 U; QID for 18 weeks.
19781|NCT00814307|Drug|CP-690,550|5mg CP-690,550 BID PO for 6 months
19782|NCT00814307|Drug|CP-690,550|10 mg CP-690,550 BID PO for 6 months
19783|NCT00006760|Drug|ifosfamide|V over 24 hours on days 1-4
19784|NCT00814307|Drug|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
19785|NCT00814307|Drug|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
19786|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous [SC] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.
Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).
20280|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
20281|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
20282|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
20283|NCT00819819|Dietary Supplement|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
20284|NCT00819819|Dietary Supplement|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
20285|NCT00819832|Procedure|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
20286|NCT00819832|Procedure|Vertebroplasty|Medical cement will be injected into broken back bone.
20287|NCT00812955|Drug|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
20288|NCT00812968|Drug|Lenalidomide|Capsules for oral administration
20289|NCT00812981|Biological|GSK1562902A|Formulation 1
20290|NCT00812981|Biological|GSK1562902A|Formulation 2
19356|NCT00815893|Drug|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
19357|NCT00815893|Drug|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
19358|NCT00006929|Drug|paclitaxel|Given IV
19359|NCT00815893|Drug|propofol 1%|Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.
The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion.
19360|NCT00815906|Drug|SBI-087|IV, Single dose
19361|NCT00815906|Drug|SBI-087|IV, Single dose
20026|NCT00812604|Drug|Vaseline|Placebo
20027|NCT00812617|Dietary Supplement|Mineral water (Hita, Oita, Japan)|
20028|NCT00814580|Drug|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
20029|NCT00814593|Biological|lymphokine-activated killer cells|Instilled into the tumor bed cavity
20030|NCT00814593|Drug|polifeprosan 20 with carmustine implant|Intracranial placement
20031|NCT00814606|Drug|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
20032|NCT00814606|Drug|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
20033|NCT00814606|Drug|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
20034|NCT00814619|Biological|panitumumab|Given IV
20035|NCT00814619|Drug|capecitabine|Given orally
20036|NCT00006786|Drug|leucovorin calcium|
20037|NCT00814619|Procedure|therapeutic conventional surgery|Patients undergo surgical resection
20038|NCT00814619|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
20039|NCT00814632|Drug|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
20040|NCT00814645|Drug|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
20041|NCT00814645|Drug|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
20042|NCT00814658|Drug|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
20043|NCT00814658|Drug|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
20044|NCT00814658|Drug|Placebo|Matching placebo three times a day (tid).
19140|NCT00820222|Drug|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
16092|NCT00796926|Drug|Refresh eye drops|Four times a day
16093|NCT00796939|Device|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
16094|NCT00796939|Device|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
16095|NCT00796952|Behavioral|focused attention sessions|Patient management by the attending Radiation oncologist "as usual". Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period.
16096|NCT00006391|Drug|topotecan hydrochloride|
16097|NCT00796952|Behavioral|Valchuff|Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver ("valchuff") and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment.
16098|NCT00796952|Behavioral|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
16099|NCT00796965|Drug|AZD7268|Solution/Capsule, Oral, once daily
16100|NCT00796965|Drug|Placebo|
16409|NCT00800059|Radiation|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
16410|NCT00800072|Device|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
16411|NCT00800085|Drug|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
16412|NCT00800098|Drug|herbal topical cream|
16413|NCT00006438|Device|Shoes with Rocker Soles|
16414|NCT00800111|Procedure|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
16415|NCT00800124|Procedure|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
19787|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|Comprises all other subjects.
Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.
Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).
19788|NCT00814333|Drug|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
19789|NCT00814333|Drug|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
19790|NCT00814346|Drug|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
19791|NCT00814346|Drug|Placebo|Placebo 1 tablet BID
20109|NCT00812669|Genetic|cytogenetic analysis|
20110|NCT00812669|Genetic|fluorescence in situ hybridization|
20111|NCT00812669|Genetic|gene expression analysis|
20112|NCT00812669|Genetic|mutation analysis|
20113|NCT00812669|Genetic|protein expression analysis|
20114|NCT00812669|Other|flow cytometry|
20115|NCT00812669|Other|laboratory biomarker analysis|
20116|NCT00812682|Drug|Symbicort|
20117|NCT00812695|Device|CPAP|Gold standard treatment for Obstructive sleep apnea
20118|NCT00006708|Biological|rituximab|
20119|NCT00812708|Device|Surgery|Surgical implantation of Morcher iris device(s)
20120|NCT00812721|Other|Preservative Free Saline|One drop will be instilled into each eye once
20121|NCT00812721|Other|Optive|One drop will be instilled into each eye once
20122|NCT00812721|Other|Refresh Moderate/Severe|One drop will be instilled into each eye once
20123|NCT00812721|Other|Systane|One drop will be instilled into each eye once
20124|NCT00812721|Other|Systane Ultra|One drop will be instilled into each eye once
20125|NCT00812734|Procedure|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
19362|NCT00815906|Drug|SBI-087|SC, Single dose
19363|NCT00815906|Drug|SBI-087|SC, Single dose
19364|NCT00815919|Drug|bortezomib|Given intravenously at a dose of 1.3 mg/m^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
19365|NCT00815919|Drug|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
19366|NCT00815932|Device|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
19367|NCT00815945|Drug|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
19368|NCT00815945|Drug|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
19369|NCT00000760|Drug|Ro 24-7429|
19370|NCT00006929|Other|pharmacological study|Correlative studies
19371|NCT00815958|Procedure|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
19372|NCT00818337|Drug|Aspirin|Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
19373|NCT00818350|Drug|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
19374|NCT00818363|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER™-Bupivacaine/Once
19375|NCT00818363|Drug|SABER™-Placebo|Injectable Solution; 5.0 mL SABER™-Placebo/Once
19935|NCT00812396|Drug|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
19936|NCT00812396|Drug|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
19937|NCT00812396|Drug|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
19141|NCT00007657|Procedure|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
19142|NCT00820235|Device|OsseoSpeed™|OsseoSpeed™ implant
19143|NCT00820235|Device|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
19144|NCT00820235|Device|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
19145|NCT00820248|Biological|panitumumab|Given IV
19146|NCT00813436|Drug|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
19147|NCT00813436|Drug|Placebo|saline liquid, intranasally administered
19148|NCT00813449|Drug|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
19149|NCT00813449|Drug|dacarbazine plus placebo (control group)|dacarbazine plus placebo
19150|NCT00813475|Drug|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
19151|NCT00813475|Drug|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
19152|NCT00006734|Drug|cyclophosphamide|Given IV
19153|NCT00813488|Drug|Fentanyl Buccal Tablet|FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.
The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).
For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician.
19154|NCT00813488|Drug|Immediate release oxycodone|Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.
The maximum single dose would be 60 mg (4 capsules).
19155|NCT00813501|Biological|immunosuppressive therapy|
19156|NCT00813501|Other|immunological diagnostic method|
19157|NCT00813501|Procedure|allogeneic hematopoietic stem cell transplantation|
19158|NCT00813514|Genetic|VEGF genotyping|blood sample for gene analysis
19159|NCT00813527|Drug|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
19160|NCT00813527|Drug|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
16416|NCT00800137|Drug|low molecular weight heparin or unfractionated heparin|For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.
Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.
Last dose given in the morning(ie. > 24 hours)of the day prior to the procedure.
Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.
Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery.
16417|NCT00800137|Drug|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be < 3.0
16418|NCT00800150|Drug|fludarabine phosphate|
16419|NCT00800150|Drug|melphalan|
16420|NCT00802477|Procedure|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
16421|NCT00006455|Drug|cyclophosphamide|
16422|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
16423|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
16424|NCT00802503|Dietary Supplement|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line.
16425|NCT00802516|Dietary Supplement|stanol ester|enriched margarine
16426|NCT00802516|Dietary Supplement|sterol ester|enriched margarine
16427|NCT00802516|Dietary Supplement|No intervention|placebo margarine
15473|NCT00812266|Drug|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
15474|NCT00812266|Drug|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
15475|NCT00006695|Drug|cytarabine|100 mg/m2 BID on Days -5 through -2
15476|NCT00812279|Other|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
15477|NCT00812279|Other|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
20126|NCT00812747|Other|observation|
20127|NCT00812760|Drug|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
20128|NCT00812773|Drug|GSK2190915|Investigational Product
20129|NCT00006708|Drug|carboplatin|
20130|NCT00812786|Drug|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
20131|NCT00812799|Drug|Oralgen|19.000 BU daily
20132|NCT00814710|Biological|Tritanrix-HepB|Intramuscular injection, 3 doses
20133|NCT00814723|Drug|fluvastatin|80 mg MR, 12 weeks
20134|NCT00814723|Drug|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
19224|NCT00820274|Procedure|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
19225|NCT00000762|Biological|gp160 Vaccine (MicroGeneSys)|
19226|NCT00007670|Drug|Carbamazepine|
19227|NCT00820287|Procedure|Biopsy of testicular tumor|testicular biopsies performed through open surgery
19228|NCT00820300|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
19229|NCT00820313|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.
Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.
Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).
Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program.
19230|NCT00820326|Drug|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
19231|NCT00820326|Drug|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
19232|NCT00820339|Procedure|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
19233|NCT00820339|Procedure|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
19938|NCT00812409|Dietary Supplement|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
19939|NCT00812409|Other|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
19940|NCT00006695|Drug|melphalan|140 mg/m2 IV on Day -1
19941|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
19942|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
19943|NCT00812422|Drug|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
19944|NCT00812435|Drug|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
19945|NCT00812448|Dietary Supplement|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
19946|NCT00812461|Drug|Placebo|as-needed use, tablets, orally, 6 months
19947|NCT00812461|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
19948|NCT00812487|Drug|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
19949|NCT00812487|Drug|Subcutaneous insulin|4 injections of insulin/day
19950|NCT00814489|Biological|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
19951|NCT00814489|Biological|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
19952|NCT00814502|Drug|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects will be randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
19953|NCT00814502|Drug|Zolpidem CR placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects will be randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
19954|NCT00006786|Drug|fluorouracil|
19974|NCT00816595|Drug|pentostatin|Given IV
19975|NCT00816621|Behavioral|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
19439|NCT00000196|Drug|Naltrexone|
19440|NCT00000756|Drug|Lymphocytes, Activated|
19441|NCT00006734|Procedure|neoadjuvant therapy|
19442|NCT00813930|Behavioral|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
19443|NCT00815958|Procedure|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
19444|NCT00815984|Procedure|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
19445|NCT00815997|Device|TRI using a 4-Fr guiding catheter|TRI will be performed using a 4-Fr guiding catheter.
19446|NCT00816010|Behavioral|telephone contact|for lifestyle and compliance counseling
19447|NCT00816023|Drug|ecallantide|infusion administered IV over the duration of the surgical procedure
19448|NCT00816023|Drug|placebo|solution for IV infusion over the duration of the surgical
>> procedure
19449|NCT00816036|Behavioral|Smoking Cessation Guideline Implementation|1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized "quick orders" for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit.
19450|NCT00816049|Drug|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
19451|NCT00816049|Drug|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
19452|NCT00006929|Other|laboratory biomarker analysis|Correlative studies
19453|NCT00816062|Device|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
19454|NCT00816075|Drug|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
19455|NCT00816101|Other|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
15478|NCT00812279|Other|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
15479|NCT00812292|Drug|TMC278|
15480|NCT00812305|Drug|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
15481|NCT00812305|Drug|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
15482|NCT00805766|Drug|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
15483|NCT00805779|Device|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
15484|NCT00805792|Drug|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
15485|NCT00805805|Drug|Tetrathiomolybdate|120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
15486|NCT00006470|Biological|monoclonal antibody 3H1 anti-idiotype vaccine|
15487|NCT00805805|Other|Placebo|Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
15488|NCT00805818|Drug|NNZ-2566|Solution for intravenous infusion.
20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours.
15794|NCT00808470|Dietary Supplement|Micronutrient Supplement, capsule form|18 mg beta-carotene 500 mg vitamin C (delivered as 500 mg ascorbic acid) 270 mg vitamin E (delivered as 305 mg alpha-tocopherol acetate) 315 mg magnesium (delivered as 1949 mg magnesium citrate)
All substances will be given to subjects orally in capsule form. The total daily dose will be divided into two equal half-doses, and the half doses will be consumed for two consecutive days (cross-over studies).
15795|NCT00808470|Other|Placebo, capsule form|Inert
Inert placebo control will be given to subjects orally in capsule form; capsules appear identical to active agent capsules with respect to both shape and color. Capsules will be consumed as two equal "half-doses," on a time-schedule that is identical to active agent treatments. Half doses will be consumed for two consecutive days (cross-over studies).
19234|NCT00820352|Drug|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
19235|NCT00820352|Drug|placebo|placebo twice a day for 12 weeks
19236|NCT00820365|Drug|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
19237|NCT00007670|Drug|Gabapentin|
19238|NCT00820378|Other|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
19239|NCT00820391|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
19240|NCT00820391|Behavioral|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
19241|NCT00820404|Drug|BLI-489|
19526|NCT00813956|Drug|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
19527|NCT00813969|Biological|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
19528|NCT00813982|Device|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
19529|NCT00813982|Device|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
19530|NCT00813995|Drug|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
19531|NCT00006734|Radiation|brachytherapy|
19532|NCT00813995|Drug|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
19533|NCT00814008|Drug|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
19534|NCT00814008|Drug|Glucose|Glucose:
Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose
19535|NCT00814021|Drug|sunitinib malate|
19536|NCT00814047|Drug|Yohimbine hydrochloride|
19976|NCT00816621|Behavioral|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
19977|NCT00816634|Drug|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.
Chemotherapy regimen (XP):
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks
Chemotherapy regimen (XT):
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks
19978|NCT00816647|Procedure|Patellofemoral stabilizing surgery|Comparison of surgical techniques
19979|NCT00816660|Biological|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
19980|NCT00816660|Biological|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
19981|NCT00816673|Drug|placebo Circadin|Placebo tabs of Prolonged release melatonin
19982|NCT00816673|Drug|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
19983|NCT00006994|Dietary Supplement|glutamine|20 cc three times daily for 60 days
19984|NCT00816686|Biological|AGS-16M18|IV Infusion
19985|NCT00816699|Other|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
19986|NCT00816712|Drug|Comparator: Testosterone 300 mg, intramuscular injection|Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 & 7 - Testosterone 300 mg, Intramuscular injection.
19987|NCT00816712|Drug|Comparator: Testosterone 100 mg, Intramuscular injection|Day 1 & 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 & 7 - Testosterone 100 mg, Intramuscular injection.
19988|NCT00816712|Drug|Comparator: Placebo given by Intramuscular Injection|Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 & 7 - Placebo given as intramuscular injection.
19989|NCT00816725|Behavioral|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
19990|NCT00819364|Behavioral|BCRI intervention program|Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.
Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions.
20291|NCT00006721|Biological|rituximab|Given IV
19456|NCT00816101|Other|Mepilex® Border Lite|Self-adherent foam dressing
19457|NCT00816101|Device|Adhesive Bandage|Adhesive bandage
19720|NCT00816335|Procedure|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
19721|NCT00816348|Drug|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
19722|NCT00816361|Drug|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
19723|NCT00816374|Other|Reading materials and discussions|We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:
The American Cancer Society
The American Academy of Dermatology
The Skin Cancer Foundation
The pamphlets contain information about ways to reduce risk for skin cancer including:
Sun protection practices
Risk factors for melanoma
Information about what melanoma looks like
How to do skin self-examinations
There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets.
19724|NCT00816374|Other|Reading materials and discussions|We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:
Melanoma and skin cancer protection guidelines
The benefits of skin screening practices
Ways to protect yourself from the sun
In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets.
19725|NCT00816374|Other|Questionnaires|Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:
knowledge of melanoma
current and past skin cancer screening practices
current and past sun protection practices
attitudes about skin cancer and sun protection
feelings about relative's melanoma diagnosis and treatment
19726|NCT00816387|Procedure|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
19727|NCT00816387|Procedure|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
19728|NCT00006968|Drug|cyclosporine|
19729|NCT00816400|Drug|MEDI-575|Administered at a dose determined by the subjects enrollment cohort as a 60 or 90 min. IV infusion as part of a 21 day treatment cycle.
19730|NCT00816413|Drug|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
15796|NCT00808470|Drug|Dietary supplement consisting of beta-carotene, vitamins C and E, magnesium|6 mint-flavored tablets per day, taken once daily
total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene.
15797|NCT00808470|Other|Placebo Control|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
15798|NCT00006485|Drug|alvocidib|
15799|NCT00808483|Other|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
15800|NCT00810524|Drug|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
15801|NCT00810524|Drug|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
15802|NCT00810550|Procedure|Carotid ultrasound|Measurement of intima-media thickness
15803|NCT00810563|Drug|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
15804|NCT00810563|Drug|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
15805|NCT00810576|Drug|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
15806|NCT00810576|Drug|Bortezomib|Dose of 1.3 mg/m^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
15807|NCT00810589|Drug|Levemir|0,4 IE per kg bodyweight
15808|NCT00810589|Drug|Humalog NPL Insulin|0,4 IE per kg bodyweight
15809|NCT00006578|Drug|Ritonavir|
15810|NCT00810602|Procedure|reduced intensity, related donor stem cell transplant|Fludarabine /Busulfan(FluBu2)regimen
Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant.
15811|NCT00810602|Drug|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
16101|NCT00796978|Biological|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
16102|NCT00796978|Other|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
19537|NCT00814060|Drug|neratinib|HKI-272
19538|NCT00814073|Drug|masitinib (AB1010)|masitinib (AB1010) 6 mg/kg/day per os
19539|NCT00814073|Drug|placebo|matching placebo
19540|NCT00814086|Drug|Paclitaxel|Given IV or intraperitoneally
19541|NCT00814086|Drug|Cisplatin|Given intraperitoneally
19542|NCT00006734|Radiation|radiation therapy|
19543|NCT00816166|Device|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
19544|NCT00816166|Drug|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
19545|NCT00816179|Procedure|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
19792|NCT00814359|Drug|Combination of Magic Mouthwash Plus Sucralfate|Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.
The concentration of the sucralfate suspension will be 1g/5ml.
Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
19793|NCT00814359|Drug|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
19794|NCT00006760|Drug|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
19795|NCT00814372|Drug|MBX-102|capsule
19796|NCT00814372|Drug|Placebo|matching placebo
19797|NCT00814372|Drug|Actos|over-encapsulated to match MBX-102 and placebo
19798|NCT00814372|Drug|Metformin|greater than or equal to 1500 mg/kg day
19799|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
19800|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
20292|NCT00812994|Drug|Escitalopram|SSRI antidepressant
20293|NCT00812994|Drug|Placebo|
20294|NCT00813007|Behavioral|Questionnaires|5 Questionnaires at differing times before and after surgery.
20295|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
20296|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
20297|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
20298|NCT00813033|Other|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
20299|NCT00813046|Biological|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
20300|NCT00813059|Drug|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
20301|NCT00813072|Drug|PEP02|120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
20302|NCT00006721|Drug|cyclophosphamide|Given IV
20303|NCT00813072|Drug|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
20304|NCT00813072|Drug|docetaxel|75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
20305|NCT00813085|Other|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
20306|NCT00813098|Drug|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
20307|NCT00813098|Drug|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
20308|NCT00813098|Drug|Placebo|Matching placebo dosing with daily oral intake
20309|NCT00813111|Drug|SKY0402|600mg SKY0402 instilled into breast pocket during surgery
20310|NCT00813111|Drug|Bupivacaine HCl|200mg Bupivacaine HCl instilled into breast pocket during surgery
20311|NCT00813124|Drug|Fludarabine|40 mg/m^2 by vein over 60 minutes on Day -5 through Day -2.
19731|NCT00816413|Drug|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
19732|NCT00816413|Drug|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
20045|NCT00814671|Drug|Rifapentine|rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
20046|NCT00814671|Drug|Rifapentine|rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
20047|NCT00006799|Drug|megestrol acetate|
20048|NCT00814671|Drug|Rifampin|rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
20049|NCT00814697|Device|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
20050|NCT00814710|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
20051|NCT00814710|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
20052|NCT00814710|Biological|Hiberix|Intramuscular injection, 3 doses
20053|NCT00816751|Procedure|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
20054|NCT00816751|Procedure|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
20055|NCT00816751|Drug|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
20056|NCT00816764|Biological|AGS-8M4|IV Infusion
20057|NCT00006994|Radiation|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
20058|NCT00816777|Procedure|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
20059|NCT00816777|Drug|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
16103|NCT00796978|Procedure|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
16104|NCT00796978|Procedure|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
16105|NCT00796991|Drug|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
16106|NCT00796991|Drug|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
16107|NCT00006392|Drug|Vitamin E|400 IU daily by mouth for 7-12 years
16108|NCT00796991|Drug|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
16109|NCT00796991|Drug|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
16110|NCT00797017|Drug|fentanyl|Infection, starting with 12mcg/h (flexible dose)
16111|NCT00797017|Drug|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
16112|NCT00797017|Drug|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
16113|NCT00797017|Drug|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
16114|NCT00799461|Procedure|fatigue assessment and management|Assessing and managing fatigue
16115|NCT00799461|Other|counseling intervention|Counseling provided via telephone
16116|NCT00006431|Biological|DC RCC-RNA|
16117|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
16118|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
16119|NCT00799500|Other|Screening|Weekly vaginal pH
16120|NCT00799513|Drug|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
16121|NCT00799526|Procedure|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
16428|NCT00802529|Drug|Methylprednisolone|2 transtympanic injections at interval of two weeks.
19801|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
19802|NCT00816413|Genetic|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
19803|NCT00816413|Other|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
19804|NCT00816413|Other|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
19805|NCT00816413|Other|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
19806|NCT00006968|Drug|pentostatin|
20135|NCT00814736|Drug|UK369,003|oral tablet, once a day
20136|NCT00814736|Drug|sildenafil|single oral dose on day 14 or day 17
20137|NCT00006799|Procedure|quality-of-life assessment|
20138|NCT00814736|Drug|sildenafil matching placebo|single oral dose on day 14 or day 17
20139|NCT00814749|Procedure|midureteral sling|midureteral sling
20140|NCT00814749|Other|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
20141|NCT00814762|Biological|HIV Vaccine 732461|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
20142|NCT00814762|Biological|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
20143|NCT00814775|Device|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
20144|NCT00814775|Device|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
20145|NCT00814788|Drug|bicalutamide|Bicalutamide 50 mg oral daily
20146|NCT00814788|Drug|Everolimus|RAD001 10 mg oral capsule daily - continuously. Patients will be on this study continuously until disease progression, development of side effects, or patient request
20312|NCT00813124|Drug|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
19376|NCT00818376|Other|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
19377|NCT00818389|Drug|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
19378|NCT00007267|Behavioral|Cognitive behavioral therapy|
19379|NCT00818389|Drug|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
19380|NCT00818389|Drug|placebo|an inactive substance
19381|NCT00818415|Drug|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
19382|NCT00818415|Drug|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
19383|NCT00818428|Behavioral|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
19384|NCT00818428|Behavioral|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
19385|NCT00818428|Behavioral|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
19386|NCT00818428|Behavioral|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
19387|NCT00818441|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
19388|NCT00818441|Drug|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
19389|NCT00007267|Behavioral|Disease/health education|
19390|NCT00818454|Drug|Combivent CFC MDI|
20060|NCT00816790|Drug|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR < 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
20061|NCT00816790|Drug|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
20062|NCT00816803|Procedure|Autologous bone marrow transplant|
20063|NCT00816803|Procedure|Physical therapy|
19161|NCT00813540|Behavioral|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
19162|NCT00813540|Other|Usual Care|Usual Care
19163|NCT00006734|Drug|doxorubicin hydrochloride|Given IV
19164|NCT00813553|Dietary Supplement|placebo|daily
19165|NCT00813553|Dietary Supplement|beta-alanine|daily
19166|NCT00813553|Dietary Supplement|beta-alanine|daily
19167|NCT00813566|Radiation|Multi-tracer PET exams of 18F-FDG, 18F-FLT, 11C-ACE, and 15O-H2O|Baseline: prior to surgery or immediately after surgery and prior to any tumor-directed therapy;
After the initial (~6-8 weeks) chemoradiotherapy;
At the time of MRI-documented recurrence within 2 years (patients with a known primary brain tumor who have previously undergone treatment and have recurred will be eligible for study). The PET scanning will be implemented in two phases: Phase A (separate single-tracer scans with each tracer) will be completed with imaging over two consecutive days and Phase B (where two or more tracers will be imaged in a single scan using rapid multi-tracer PET techniques under development) in one or two imaging sessions according to the best method validated from the Phase A results. The exact order and timing of the multi-tracer exams will vary.
19168|NCT00815451|Dietary Supplement|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
19169|NCT00815451|Dietary Supplement|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
19170|NCT00815464|Device|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
19171|NCT00815477|Behavioral|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
19172|NCT00815477|Behavioral|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
19173|NCT00815490|Device|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
19174|NCT00815503|Drug|Ropivacaine|Approved by the Danish Medicines Agency
16429|NCT00802529|Drug|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
16430|NCT00802555|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
16431|NCT00802568|Biological|anti-thymocyte globulin|
16432|NCT00006455|Drug|cytarabine|
16433|NCT00802568|Drug|busulfan|
16434|NCT00802568|Drug|fludarabine phosphate|
16435|NCT00802568|Procedure|allogeneic bone marrow transplantation|
16436|NCT00802568|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
16437|NCT00802581|Procedure|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
16438|NCT00802581|Procedure|Non-circumferential spread of local anesthetic|The anesthetist will perform a "single shot" injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve.
16439|NCT00802594|Drug|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
16440|NCT00802620|Procedure|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
16441|NCT00802633|Device|Stapling device during radical cystectomy|Hemostasis
16442|NCT00802633|Device|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
16443|NCT00006455|Drug|dexamethasone|
16444|NCT00802646|Drug|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
16445|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
16446|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
16447|NCT00795236|Drug|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
16448|NCT00795249|Behavioral|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
20147|NCT00814801|Drug|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
20148|NCT00006812|Drug|capecitabine|
20149|NCT00814801|Drug|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
20150|NCT00814801|Drug|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
20151|NCT00814840|Device|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
20152|NCT00814840|Device|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
20153|NCT00814853|Device|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
20154|NCT00814866|Drug|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
20155|NCT00814879|Drug|Raltegravir|400 mg BID
19242|NCT00813592|Drug|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
19243|NCT00813605|Other|FOLFIRI|Day 1 of each Cycle
Combination Therapy of:
irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion
19244|NCT00813605|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
19245|NCT00813605|Other|Placebo|Inactive dummy agent (to maintain blind)
19246|NCT00813605|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
19247|NCT00813618|Drug|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
19248|NCT00006734|Drug|etoposide|Given IV
19391|NCT00818454|Drug|Albuterol HFA MDI|
19392|NCT00818454|Drug|Respimat Combivent|
19393|NCT00007683|Drug|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
19955|NCT00814515|Drug|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
19956|NCT00814515|Drug|NOVA22007|Vehicle
19957|NCT00814528|Drug|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
19958|NCT00814528|Drug|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
19959|NCT00814541|Drug|Bortezomib|
19960|NCT00814541|Drug|Doxorubicin|
19961|NCT00814541|Drug|Dexamethasone|
19962|NCT00814554|Behavioral|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
19963|NCT00814554|Behavioral|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
19964|NCT00814554|Other|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
19965|NCT00006786|Drug|irinotecan hydrochloride|
19966|NCT00814567|Radiation|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
19967|NCT00814580|Drug|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
19175|NCT00006916|Device|Ommaya reservoir|
19176|NCT00815503|Drug|Placebo|Saline
19177|NCT00815516|Drug|micafungin|Administered by intravenous infusion
19178|NCT00815516|Drug|amphotericin B deoxycholate|Administered by intravenous infusion
19179|NCT00815529|Device|Acupuncture, Pak-sham needle|25*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
19180|NCT00815542|Device|double balloon catheter|cervical ripening using double balloon catheter
19458|NCT00816114|Other|Chart Review|Investigator review of MDACC CML patient charts.
19459|NCT00816127|Drug|Desmopressin|intranasal desmopressin (300μg)
19460|NCT00816127|Biological|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
19461|NCT00816140|Drug|Cravit based triple therapy|Levofloxacin based triple therapy
LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days
19462|NCT00816140|Drug|Klaricid based triple therapy|Clarithromycin based triple therapy
CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days
19463|NCT00006942|Drug|bryostatin 1|Given IV
19464|NCT00816153|Other|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
19465|NCT00818467|Other|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
19466|NCT00818467|Other|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
19467|NCT00818480|Drug|YM155|continuous infusion
19468|NCT00818493|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
19469|NCT00818493|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
19470|NCT00818493|Drug|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
19471|NCT00818519|Drug|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
19472|NCT00007267|Behavioral|Self-help cognitive behavioral intervention facilitated by a psychologist|
16449|NCT00006384|Biological|recombinant interferon alfa|
15489|NCT00805831|Device|HDH|sutureless vascular anastomosis
15490|NCT00805857|Drug|Tipranavir|
15491|NCT00805870|Drug|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
15492|NCT00805870|Drug|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
15493|NCT00805883|Procedure|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
15494|NCT00805896|Drug|Songyou|4g/pack
15495|NCT00805896|Drug|placebo|4g/pack
15496|NCT00805909|Drug|NI-0401|5 daily infusions with escalating doses of NI-0401
15497|NCT00006470|Radiation|radiation therapy|
15498|NCT00805922|Other|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
15499|NCT00805935|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
15500|NCT00805935|Drug|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
15501|NCT00805935|Drug|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
15502|NCT00805935|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
15503|NCT00807859|Drug|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
15504|NCT00807859|Drug|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
15505|NCT00807859|Drug|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
15506|NCT00807859|Drug|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
15507|NCT00807872|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
19249|NCT00813618|Drug|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
19250|NCT00813618|Drug|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
19251|NCT00813631|Other|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
19252|NCT00813657|Behavioral|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, ~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (~8 minutes), followed by toning and very light resistance exercises (~20 minutes) and a light intensity cool-down (~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
19253|NCT00813670|Drug|XPF-001|Single oral dose, or 6 days of repeated oral doses.
19254|NCT00813683|Other|Acupuncture stimulation|Acupuncture by stimulation of "67 Bladder" point
19255|NCT00813683|Other|Acupuncture stimulation|Acupuncture stimulation of "45 Stomach" point (sham)
19256|NCT00813696|Drug|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
19257|NCT00813696|Drug|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
19546|NCT00816192|Procedure|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
19547|NCT00816205|Drug|Coated Nifedipine Suppositories|Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:
The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.
The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine.
19548|NCT00816218|Drug|Pioglitazone|pioglitazone, 45 mg daily
19549|NCT00816231|Behavioral|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
19968|NCT00816595|Biological|bevacizumab|Given IV
19969|NCT00816595|Biological|pegfilgrastim|Given subcutaneously
19970|NCT00816595|Biological|rituximab|Given IV
19971|NCT00000760|Drug|Zidovudine|
19972|NCT00006981|Biological|SS1(dsFv)-PE38 immunotoxin|
19973|NCT00816595|Drug|cyclophosphamide|Given IV
19991|NCT00819364|Behavioral|Standard community care|Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.
Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.
Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year.
19992|NCT00819377|Drug|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
19993|NCT00819377|Drug|Normal saline|5 ml normal saline by inhalation over 15 min
19994|NCT00819390|Drug|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
19995|NCT00007475|Drug|Cyclophosphamide|For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
19996|NCT00819390|Drug|Placebo|Taken orally, once daily for 12 weeks.
19997|NCT00819403|Drug|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
19998|NCT00819403|Drug|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
19999|NCT00819416|Drug|5% albumin|5% albumin for the first 7 days of care in the ICU
20000|NCT00819416|Drug|Normal Saline|Normal Saline for the first 7 days of care in the ICU
20001|NCT00819429|Dietary Supplement|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
20002|NCT00819429|Behavioral|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
19473|NCT00818519|Drug|Placebo|Inert tablet
19474|NCT00818545|Drug|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
19475|NCT00818545|Drug|placebo|
19476|NCT00818558|Biological|ISET Methode|Sampling of blood - ISET Methode
19477|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
19478|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
19479|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
19480|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
19733|NCT00816413|Genetic|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
19734|NCT00816413|Genetic|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
19735|NCT00818948|Drug|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
19736|NCT00818961|Biological|alemtuzumab|43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
19737|NCT00818961|Biological|graft-versus-tumor induction therapy|curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
19738|NCT00818961|Biological|rituximab|in patients with Cd20+ malignancies: rituximab 375 mg/m*2 day -13. rituximab 1000 mg/m*2 on days, -6, +1, +8.
19739|NCT00818961|Drug|busulfan|For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
19740|NCT00818961|Drug|cyclophosphamide|750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
19741|NCT00818961|Drug|fludarabine phosphate|For patients with CLL, NHL & HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
15508|NCT00807885|Drug|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
15509|NCT00807911|Drug|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
15510|NCT00807911|Drug|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
15812|NCT00810602|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
15813|NCT00810602|Drug|vorinostat|Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.
Dose escalation/ de-escalation
Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher [probably or definitely related to the drug] then vorinostat dose will be escalated to 200 mg PO BID.
If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.
If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study.
15814|NCT00810615|Other|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
15815|NCT00810628|Behavioral|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
15816|NCT00810641|Procedure|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
15817|NCT00810641|Procedure|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
15818|NCT00810641|Procedure|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
15819|NCT00810654|Dietary Supplement|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
15820|NCT00006461|Drug|cisplatin|Given IV
15821|NCT00803751|Device|Use of the Macintosh laryngoscope|Intubation using the traditional Macintosh laryngoscope
15822|NCT00803764|Drug|Naproxen Tablets, 500 mg|
15823|NCT00803777|Device|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
19550|NCT00816231|Other|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
19551|NCT00816231|Other|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
19552|NCT00006942|Drug|cisplatin|Given IV
19553|NCT00816244|Drug|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
19554|NCT00816270|Procedure|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
19555|NCT00816283|Drug|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
19556|NCT00816283|Drug|vorinostat|100 mg orally 2 times per day
19557|NCT00816283|Genetic|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
19558|NCT00816283|Genetic|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
19559|NCT00816283|Genetic|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
19560|NCT00816283|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
19561|NCT00818623|Drug|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
19562|NCT00007293|Device|UV-B Lightsource and Fiber Optic Comb|
19807|NCT00816413|Other|reduced-intensity transplant conditioning procedure|Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .
Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .
Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.
Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.
Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4).
19808|NCT00816413|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
19809|NCT00816413|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
20003|NCT00819429|Other|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
20004|NCT00819442|Procedure|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
20005|NCT00819455|Behavioral|Experimental|Active Life style modification-motivation by I.T technology
20006|NCT00007501|Biological|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
20007|NCT00819455|Behavioral|Control arm (usual care/standard care arm)|Life style modification only once
20008|NCT00819468|Drug|teduglutide|20 mg dose of lypholized powder mixed with sterile water and injected subcutaneously into the abdomen.
19100|NCT00817804|Device|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
19101|NCT00817817|Device|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
19102|NCT00817817|Device|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
19103|NCT00817830|Drug|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
19104|NCT00817843|Drug|Simvastatin|6 weeks of treatment with simvastatin 80 mg
19105|NCT00817843|Drug|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
19106|NCT00817869|Other|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
19107|NCT00817882|Other|individually targeted vocational rehabilitation|individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.
Maximum of 25 participants with low back pain
19108|NCT00817882|Other|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
19109|NCT00007189|Drug|Celecoxib (Celebrex)|
19110|NCT00817895|Drug|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
19111|NCT00817895|Drug|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
19742|NCT00818961|Drug|methotrexate|5 mg/m2 administered on days +1, +3 and +6
19743|NCT00818961|Drug|tacrolimus|0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
19744|NCT00000762|Biological|rgp120/HIV-1MN|
19745|NCT00007358|Drug|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
19746|NCT00818961|Procedure|allogeneic bone marrow transplantation|Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
19747|NCT00818987|Other|Open reduction internal fixation; reduction and immobilization|
19748|NCT00819000|Drug|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
19749|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
19750|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
20064|NCT00816816|Drug|docetaxel, cisplatin, fluorouracil|neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.
concurrent chemotherapy:cisplatin 40 mg/m2 weekly.
20065|NCT00816829|Drug|Placebo|Fenofibrate-matching placebo tablet
20066|NCT00816829|Drug|Fenofibrate|145 mg NanoCrystal tablet
20067|NCT00816855|Drug|docetaxel, cisplatin, fluorouracil|neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.
concurrent chemotherapy:cisplatin 40 mg/m2 weekly
20068|NCT00006994|Drug|l-glutamine placebo|20 cc three times daily for 60 days
20069|NCT00816868|Drug|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
20070|NCT00816881|Device|flutter mucus clearance device|five minutes every session, four sessions per day
20071|NCT00816894|Drug|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
20072|NCT00816894|Drug|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
20073|NCT00816907|Drug|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
15824|NCT00803790|Drug|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
15825|NCT00803790|Drug|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
15826|NCT00803790|Dietary Supplement|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
15827|NCT00803803|Drug|Pilocarpine Concentration|Varying concentration 0.5 to 8%
15828|NCT00803803|Drug|Pilocarpine Frequency|1 to 4 times daily
16122|NCT00799526|Procedure|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
16123|NCT00799539|Drug|bortezomib|From cycles 1-4, 1.3mg/m^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
16124|NCT00799539|Drug|bortezomib|From cycles 5-9, 1.3mg/m^2 on days 1, 8, 22, and 29 of each 6-week cycle
16125|NCT00799539|Drug|melphalan|9 mg/m^2 once daily on days 1-4 of each 6-week cycle
16126|NCT00799539|Drug|prednisone|60 mg/m^2 once daily on days 1-4 of each 6-week cycle
16127|NCT00006432|Procedure|very low fat diet|
16128|NCT00799552|Drug|RX-10045|RX-10045 eye drop
16129|NCT00799552|Drug|Placebo|Placebo eye drop
16130|NCT00799565|Genetic|catch of blood|4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.
This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects
16131|NCT00799578|Drug|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
16132|NCT00799591|Other|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
16133|NCT00799604|Drug|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
16134|NCT00799617|Drug|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
16135|NCT00799617|Drug|Placebo|Testosterone levels will be measured at regular intervals.
19810|NCT00816413|Radiation|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
19811|NCT00816426|Drug|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
19812|NCT00816426|Drug|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
19813|NCT00816426|Drug|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
19814|NCT00819052|Drug|Nevirapine IR|Nevirapine Immediate Release
19815|NCT00819065|Drug|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
20156|NCT00814879|Drug|Atazanavir|300 mg BID
20157|NCT00816920|Other|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
20158|NCT00816933|Procedure|appendectomy|appendectomy according to the number of trocar
20159|NCT00816946|Behavioral|Routine advice|Routine advice to mother and/or other key care provider by the local Lady Health Workers (LHWs)during her routine community visits.
19112|NCT00817895|Procedure|TACE|All patients will accept TACE one month after tumor was resected.
19113|NCT00817934|Drug|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
19114|NCT00817947|Device|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
19115|NCT00817960|Drug|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
19116|NCT00817973|Dietary Supplement|Casein|
19117|NCT00817973|Dietary Supplement|Whey|
19118|NCT00817973|Dietary Supplement|Cod|
19119|NCT00817973|Dietary Supplement|Gluten|
19120|NCT00007202|Drug|Atazanavir|
19394|NCT00820573|Drug|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
19395|NCT00820573|Drug|Placebo|Placebo 6 weeks
19396|NCT00820586|Procedure|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
19397|NCT00820599|Device|Sapien XT™ transcatheter heart valve and its transfemoral delivery system|Transfemoral placement of a transcatheter aortic heart valve
SAPIEN XT™ study valve and its transfemoral delivery components
19398|NCT00820612|Drug|Indomethacin|100 mg PR once at the time of ERCP
19399|NCT00820612|Other|Placebo suppositories|2 placebo suppositories at the time of ERCP
19400|NCT00820625|Procedure|pulmonary vein isolation|common pulmonary vein isolation procedure
19401|NCT00820625|Procedure|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
19402|NCT00820638|Device|myomo e100|use of the myomo e100 in home
19403|NCT00820651|Dietary Supplement|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
19404|NCT00007683|Drug|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
19405|NCT00820651|Other|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with <10% of saturated fatty acids and protein 14%, and exercise)
20074|NCT00816907|Drug|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
20075|NCT00819494|Procedure|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
20076|NCT00819507|Drug|Fluocinonide|Fluocinonide 0.1% cream topical daily for two weeks
20077|NCT00819520|Drug|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
20078|NCT00819520|Drug|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
20079|NCT00819533|Device|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
20080|NCT00819546|Drug|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
20081|NCT00819546|Drug|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
20082|NCT00007501|Biological|Placebo|Placebo vaccine
20083|NCT00819559|Radiation|PCRT|Preoperative chemoradiotherapy
20084|NCT00819572|Biological|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
19181|NCT00815542|Drug|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
19182|NCT00815555|Other|There is no intervention - this is an observational study|
19183|NCT00815568|Drug|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)
19184|NCT00815581|Device|photorefraction,cycloautorefraction,cycloretinoscopy|
19185|NCT00815594|Drug|bevacizumab|0.05ml, 1.25mg
19186|NCT00006916|Radiation|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
19187|NCT00815607|Drug|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
19188|NCT00815607|Biological|INXN-3001|Intratumoral injection
19189|NCT00815633|Drug|Alefacept|15mg intramuscular injection weekly for 12 weeks
16136|NCT00799630|Dietary Supplement|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
16137|NCT00799643|Drug|Salsalate|Salsalate 3.5 g/d orally, divided dosing
16138|NCT00801957|Biological|AC VAX|im injection
16139|NCT00801970|Behavioral|Psychological Treatment|15 weekly therapy sessions.
16140|NCT00801970|Behavioral|Group Therapy|3 months of weekly group therapy sessions.
16141|NCT00801983|Device|Alternative Keyboard|Subjects use either a typical or alternative keyboard
16142|NCT00802009|Drug|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
16450|NCT00795262|Drug|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
16451|NCT00795262|Drug|accupril, placebo|accupril 40 mg
16452|NCT00795262|Drug|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
16453|NCT00795275|Drug|Januvia (sitagliptin phosphate)|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
16454|NCT00795288|Drug|Simvastatin, 80 mg/day for 21 days|Active treatment group
16455|NCT00795288|Drug|placebo|Control group
16456|NCT00795301|Drug|Capecitabine, Cetuximab, Oxaliplatin|
16457|NCT00795314|Drug|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
16458|NCT00795314|Drug|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
16459|NCT00795327|Device|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
16460|NCT00006384|Drug|semaxanib|
16461|NCT00795340|Drug|carboplatin|Given IV
16462|NCT00795340|Drug|cediranib maleate|Given orally
16463|NCT00795340|Drug|paclitaxel|Given IV
16464|NCT00795340|Other|placebo|Given orally
20160|NCT00816946|Behavioral|Enhanced education|Enhanced Nutritional education/counseling to mothers on the following topics:
During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI & protection against ARI
20161|NCT00007007|Procedure|management of therapy complications|
20162|NCT00816959|Drug|R-mabHDI and ABVD|The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.
Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
20163|NCT00816959|Drug|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
20164|NCT00816972|Drug|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
20165|NCT00816972|Drug|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
20166|NCT00816972|Drug|Placebo for Desloratadine 2.5 mg|Placebo BID
20167|NCT00816972|Drug|Placebo for Oxybutynin 2.5 mg|Placebo BID
20168|NCT00816985|Procedure|Liposuction|We plan to show the efficacy of liposuction as a treatment for lymphedema. Durability will be tested for equivalence, by comparing the 3-month and 12-month arm volumes.
20169|NCT00816998|Procedure|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
20170|NCT00816998|Procedure|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
20171|NCT00817011|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
20172|NCT00007007|Procedure|quality-of-life assessment|
20173|NCT00817011|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
20174|NCT00817024|Drug|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
19258|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
19259|NCT00006734|Drug|ifosfamide|Given IV
19406|NCT00820664|Drug|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
19407|NCT00820664|Drug|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
19408|NCT00820664|Drug|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
19409|NCT00820677|Behavioral|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
19410|NCT00820690|Drug|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
19411|NCT00820690|Drug|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
19412|NCT00820690|Drug|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
19413|NCT00820690|Procedure|Surgery|The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.
The oncoplastic surgery rate will be reported
19414|NCT00820703|Drug|Nexagon®|
19415|NCT00007735|Drug|Doxycycline (200mg/day) or Placebo|
19416|NCT00820703|Drug|Nexagon® vehicle|
19676|NCT00820768|Drug|ABI-010|17-AAG and ABI-007
19677|NCT00820781|Procedure|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
19678|NCT00820781|Procedure|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
19679|NCT00820794|Drug|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
19680|NCT00007748|Behavioral|Aerobic exercise|
19681|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
19682|NCT00820794|Drug|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
19683|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
19684|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
19685|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
19686|NCT00820807|Other|Placebo|oral consumption in beverage
16316|NCT00799864|Drug|Rilpivirine|Patients will receive rilpivirine tablet 25 milligram or adjusted dose orally once daily for 240 weeks.
16317|NCT00799864|Drug|Zidovudine|Type=exact, form=tablet, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
16318|NCT00799864|Drug|Abacavir|Type=exact, form=tablet, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
16319|NCT00799864|Drug|Tenofovir disoproxil fumarate|Type=exact, form=tablet, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
16320|NCT00799864|Drug|Lamivudine|Type=exact, form=tablet, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
16321|NCT00799864|Drug|Emtricitabine|Type=exact, form=tablet, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
16322|NCT00006436|Biological|filgrastim|Figrastim day 6 until ANC reaches 5000 after the nadir, every cycle
16323|NCT00799890|Drug|Sunphenon EGCG|200-800mg (1-4 capsules)
16324|NCT00799890|Drug|Placebo|1-4 capsules
16325|NCT00799903|Drug|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
16326|NCT00799903|Drug|Placebo|Placebo administered in addition to standard therapy
16327|NCT00799916|Drug|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
15373|NCT00811850|Drug|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
15374|NCT00811876|Other|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
15375|NCT00811889|Other|Placebo|Placebo
15376|NCT00811889|Drug|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
15377|NCT00811902|Drug|Nerispirdine|tablet, oral administration
15378|NCT00811902|Drug|placebo|tablet, oral administration
15379|NCT00811915|Drug|Sirolimus|Sirolimus introduction and tacrolimus withdrawal
Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml
15380|NCT00811928|Drug|Posaconazole|40 mg/mL; 200 mg (5 mL) TID
Treatment was continued with each cycle of chemotherapy until:
The onset of a proven or probable diagnosis of invasive fungal infection (IFI)
3 chemotherapy cycles or
Total treatment duration up to 12 weeks (84 days)
16060|NCT00801931|Drug|Busulfan, Cyclosphosphamide, Rabbit ATG,|Patients with Selected Hemoglobinopathies and non-malignant diseaseswill begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
16061|NCT00801944|Drug|Solifenacin succinate|oral
16062|NCT00801944|Drug|Placebo|oral
16063|NCT00801957|Drug|tacrolimus ointment 0.03%|topical application
16064|NCT00801957|Drug|hydrocortisone acetate ointment 1%|topical application
16065|NCT00801957|Drug|hydrocortisone butyrate ointment 0.1%|topical application
16066|NCT00801957|Biological|Meningitec|im injection
16067|NCT00006452|Drug|motexafin gadolinium|
16068|NCT00794664|Drug|Placebo|1 mL weekly subcutaneous injections for 26 weeks
16069|NCT00794677|Drug|ezetimibe|Blinded study medication (ezetimibe 10 mg or matching placebo in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
16070|NCT00794690|Drug|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
16071|NCT00794703|Drug|micafungin (Mycamine)|Intravenous
16072|NCT00794703|Drug|itraconazole|oral
16073|NCT00794716|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
16074|NCT00794755|Dietary Supplement|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
16075|NCT00006381|Drug|celecoxib|
16076|NCT00794755|Dietary Supplement|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
16077|NCT00794768|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
16078|NCT00794768|Drug|fexofenadine|Allegra 180 mg daily x 7 days
15856|NCT00006474|Drug|O6-benzylguanine|
15857|NCT00806494|Drug|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
15858|NCT00806507|Procedure|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
15859|NCT00806507|Procedure|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
15860|NCT00806533|Drug|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
15861|NCT00806546|Drug|NP101|NP101 study patch four hour application
15862|NCT00806559|Other|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
15863|NCT00806559|Other|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
15864|NCT00806572|Drug|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
15865|NCT00806585|Drug|MK-0736|
15866|NCT00806585|Drug|Comparator: Placebo|
15867|NCT00006474|Drug|temozolomide|
15868|NCT00806585|Drug|Comparator: HCTZ|
15869|NCT00806598|Drug|Thymoglobulin|3.5 or 2.5 mg/kg/day IV for 5 days
Aplastic anemia patients receive 3.5 mg/kg/day for 5 days
MDS patients <55 years receive 3.5 mg/kg/day for 5 days
MDS patients >55 years receive 2.5 mg/kg/day for 5 days
15870|NCT00806598|Drug|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
15871|NCT00806598|Drug|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
16167|NCT00794885|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
16168|NCT00794898|Biological|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
16169|NCT00794911|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
16170|NCT00794911|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
15309|NCT00805532|Other|Usual VA Treatment for PTSD|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
15310|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
15616|NCT00808171|Drug|EMLA|Lidocaine-prilocain cream
15617|NCT00808184|Drug|CPT-11, Raltegravir (Isentress®), Midazolam|
15618|NCT00808197|Procedure|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
15619|NCT00808210|Drug|infliximab|Intravenous repeating dose
15620|NCT00808210|Drug|methotrexate|Oral or parenteral repeating dose
15621|NCT00808210|Drug|methylprednisolone|Intravenous repeating dose
15622|NCT00808210|Drug|ocrelizumab|Intravenous repeating dose
15623|NCT00808210|Drug|sham|Intravenous repeating dose
15624|NCT00808223|Biological|alefacept|IM injection
15625|NCT00006483|Biological|sargramostim|
15626|NCT00808236|Device|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
15627|NCT00810277|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
15628|NCT00810290|Behavioral|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
15629|NCT00810303|Drug|Ezetrol (ezetimibe) multiple dose|administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
15630|NCT00006517|Device|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
15631|NCT00810303|Drug|Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)
15381|NCT00811928|Drug|Fluconazole|50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);
400 mg QD
Treatment was continued with each cycle of chemotherapy until:
The onset of a proven or probable diagnosis of invasive fungal infection (IFI)
3 chemotherapy cycles or
Total treatment duration up to 12 weeks (84 days)
15382|NCT00811941|Drug|Placebo|as-needed use, tablets, orally, 52 weeks
15383|NCT00006669|Drug|doxorubicin hydrochloride|
15384|NCT00811941|Drug|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
15385|NCT00811954|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
15386|NCT00811954|Drug|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
15387|NCT00811954|Drug|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
15388|NCT00811954|Drug|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
15389|NCT00811954|Drug|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
15390|NCT00805636|Drug|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|[18F]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for [18F]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of [18F]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
15391|NCT00805636|Radiation|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
15696|NCT00808275|Dietary Supplement|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
15697|NCT00808288|Drug|PF-00610355|oral, inhaled, dry powder, 600ug, OD
15698|NCT00808288|Drug|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
15699|NCT00006484|Drug|carboplatin|
15700|NCT00808288|Drug|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
15701|NCT00808288|Drug|Placebo|oral, inhaled, dry powder, placebo, OD
15702|NCT00808288|Drug|Salmeterol|salmeterol, 50ug, BID
15703|NCT00808301|Other|Gluten-free products|Gluten-free bakery products containing oatmeal.
16079|NCT00794781|Drug|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
16387|NCT00797589|Drug|HES|20ml/kg as prime fluid
16388|NCT00797589|Drug|Ringer lactate|
16389|NCT00797615|Behavioral|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
16390|NCT00797615|Behavioral|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
16391|NCT00797628|Behavioral|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
16392|NCT00797628|Behavioral|Smoking Coach|Control Patients will be referred by paper prescription to the control- "Smoking Coach" website.
16393|NCT00006396|Drug|Zidovudine|
16394|NCT00797654|Behavioral|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
16395|NCT00797654|Behavioral|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
16396|NCT00797667|Drug|Telcagepant 140 mg|
16397|NCT00797667|Drug|Telcagepant 280 mg|
16398|NCT00799929|Other|in vitro fertilization (IVF/ICSI)|
16399|NCT00799942|Drug|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
16400|NCT00799955|Procedure|Placebo block|100 micrograms of spinal morphine
16401|NCT00799955|Procedure|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
16402|NCT00006436|Drug|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
16403|NCT00799968|Drug|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
16171|NCT00794924|Dietary Supplement|VSL#3|one sachet per day, for 45 consecutive days
16172|NCT00006382|Procedure|comparison of screening methods|
16173|NCT00794924|Dietary Supplement|placebo|one sachet per day, for 45 consecutive days
16174|NCT00794950|Drug|Sunitinib|Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.
Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy.
16175|NCT00794963|Drug|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
16176|NCT00794963|Other|As selected by community physician|As selected by community physician
16177|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (low dose)|
16178|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (high dose)|
16179|NCT00794976|Drug|Dexamethasone Passive Patch|
16180|NCT00794976|Drug|Placebo Patch|
16181|NCT00794989|Dietary Supplement|Ground Flaxseed|Given orally
16182|NCT00794989|Other|No Intervention|Participants randomized to Arm 2 do not receive any intervention
16183|NCT00006382|Procedure|computed tomography|
16184|NCT00795002|Drug|alvocidib|Given IV
16185|NCT00795002|Drug|mitoxantrone hydrochloride|Given IV
16186|NCT00795002|Drug|cytarabine|Given IV
16187|NCT00795002|Other|pharmacological study|Correlative studies
15223|NCT00807534|Drug|placebo|placebo nebulization
15224|NCT00807534|Behavioral|constant rate step test|nebulization of 500ug
15225|NCT00006479|Procedure|neoadjuvant therapy|
15632|NCT00810303|Drug|Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
15633|NCT00810303|Drug|Sustiva (efavirenz) single dose|administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
15634|NCT00810316|Drug|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
15635|NCT00810316|Drug|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
15925|NCT00804089|Procedure|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
15926|NCT00804102|Device|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
15927|NCT00804102|Device|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
15928|NCT00804115|Drug|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
15929|NCT00006461|Procedure|therapeutic conventional surgery|Undergo surgery
15930|NCT00804128|Procedure|contrast-enhanced magnetic resonance imaging|
15931|NCT00804141|Drug|N-methylnaltrexone bromide (MOA-728)|48 week treatment with 12 mg MOA-728 administered subcutaneously at least once per week with a maximum frequency of once daily.
15932|NCT00804154|Drug|(Resiniferatoxin)(RTX)|
15933|NCT00804154|Drug|Intrathecal Resiniferatoxin|
15934|NCT00806598|Drug|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
15935|NCT00806611|Procedure|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
15936|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
15937|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
15938|NCT00806624|Drug|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
15704|NCT00808314|Drug|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
15705|NCT00808314|Drug|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
15706|NCT00808327|Drug|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
15707|NCT00808327|Drug|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
15708|NCT00808340|Device|balafilcon A|multifocal contact lens
15709|NCT00808340|Device|senofilcon A production|multifocal contact lens
15710|NCT00006484|Drug|paclitaxel|
15711|NCT00808340|Device|senofilcon A test|multifocal contact lens
15712|NCT00808366|Drug|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
15713|NCT00810381|Drug|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
15714|NCT00810394|Drug|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
15999|NCT00804193|Drug|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
16000|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
16001|NCT00804206|Drug|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
16002|NCT00804206|Drug|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
16003|NCT00006461|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
17050|NCT00798603|Drug|pemetrexed disodium|
17051|NCT00798616|Drug|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
17052|NCT00798616|Drug|placebo|oral or IV placebo
17053|NCT00798629|Biological|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
17054|NCT00798642|Behavioral|Hypnotherapy|8 weeks of gut-directed hypnotherapy
17055|NCT00798642|Behavioral|Standard care|8 weeks of standard of care
17056|NCT00006411|Other|corneas assigned by donor age group|A web-based computer program was used to select a cornea from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors >=66 and <66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
17057|NCT00798642|Behavioral|Mind Body Therapy|8 weeks of mind-body therapy
17058|NCT00798655|Drug|Panitumumab|Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.
The panitumumab dose will be calculated based on the subject's actual weekly body weight
17059|NCT00798655|Drug|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
17060|NCT00798655|Radiation|Radiation Therapy|Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.
Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day.
17061|NCT00798668|Dietary Supplement|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
17062|NCT00798668|Dietary Supplement|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
17318|NCT00798876|Other|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
17319|NCT00798876|Other|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
17320|NCT00798876|Procedure|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
17321|NCT00798889|Drug|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
15226|NCT00807534|Behavioral|constant rate shuttle walk test|nebulization of 500ug
15227|NCT00807547|Biological|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
15228|NCT00807560|Behavioral|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
15229|NCT00807560|Behavioral|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
15230|NCT00807573|Drug|Paclitaxel|Day 1: Paclitaxel (90 mg/m^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m^2 over 60 minutes)
15231|NCT00807573|Drug|Pemetrexed|Day 1: Pemetrexed (500 mg/m^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
15232|NCT00807573|Drug|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
15233|NCT00807586|Drug|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
15234|NCT00807586|Drug|Placebo|Normal saline (1.6 cc)
15235|NCT00807599|Procedure|Stem cell transplant x 1 or x 2|After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.
On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.
15236|NCT00006480|Biological|aldesleukin|
15237|NCT00807599|Drug|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
15238|NCT00807612|Biological|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
15239|NCT00006508|Procedure|Controlled hypoglycemia using insulin|
15240|NCT00809679|Other|Placebo|Capsule dosage form placebo bid
15241|NCT00809692|Procedure|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
15242|NCT00809692|Procedure|new technique for histamine response|laser Dopper technique and genotyping
15939|NCT00806637|Procedure|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
15940|NCT00006474|Procedure|conventional surgery|
15941|NCT00806637|Procedure|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
15942|NCT00806650|Genetic|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
16253|NCT00802204|Behavioral|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study.
16254|NCT00802204|Other|Caloric Restriction|Obese participants will go a shortterm very low calorie diet
16255|NCT00802217|Drug|Civamide|5 mg liquid filled softgel capsules
16256|NCT00802217|Drug|Civamide|5 mg x 2 liquid softgel capsules
16257|NCT00802230|Drug|Terbutaline Infusion|
16258|NCT00802243|Drug|leflunomide|
16259|NCT00006454|Drug|carboplatin|
16260|NCT00802256|Procedure|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
16261|NCT00802269|Procedure|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
16262|NCT00802282|Drug|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
16263|NCT00802282|Behavioral|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
16264|NCT00802282|Behavioral|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
16265|NCT00802295|Drug|Gonadotrophins|Administration of standard ovarian stimulation protocol
16266|NCT00802295|Drug|Low dosis Gonadotrophin|
16004|NCT00804219|Biological|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
16005|NCT00804232|Behavioral|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
16006|NCT00804245|Procedure|needle biopsy|Biopsy of positive findings found on CT scan
16007|NCT00804245|Drug|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
16008|NCT00804258|Drug|intraperitoneal chemotherapy|
16009|NCT00804258|Other|educational intervention|
16010|NCT00804258|Other|medical chart review|
16011|NCT00804258|Other|questionnaire administration|
16012|NCT00804258|Procedure|assessment of therapy complications|
16013|NCT00804258|Procedure|end-of-life treatment/management|
16014|NCT00006462|Drug|gemcitabine hydrochloride|
16015|NCT00804258|Procedure|psychosocial assessment and care|
16016|NCT00804258|Procedure|quality-of-life assessment|
16017|NCT00804271|Drug|memantine|memantine tablets, OD, 12 weeks
16018|NCT00804284|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
16019|NCT00804284|Biological|Other DTap Vaccines|0.5 mL, Intramuscular
16020|NCT00804297|Drug|Octreotide (drug)|
16021|NCT00804310|Drug|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
16328|NCT00799916|Drug|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
17322|NCT00798902|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
17323|NCT00798902|Other|Iliac crest autograft|autograft
17324|NCT00798915|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
17325|NCT00006418|Procedure|DNA collection|
17326|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
17327|NCT00798915|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
17328|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
17329|NCT00798941|Behavioral|mouth care|mouth spray, mouth swab, moisturizer
17330|NCT00798941|Behavioral|pain intervention|music and massage
17331|NCT00798954|Device|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
17332|NCT00798954|Device|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
17333|NCT00801606|Drug|Placebo|Placebo
17334|NCT00801632|Procedure|Kidney Transplantation|Surgical transplantation of donor kidney
17335|NCT00801632|Procedure|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
17336|NCT00801632|Biological|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
17337|NCT00006451|Drug|cyclosporine|
17338|NCT00801632|Drug|cyclophosphamide|60 mg/kg infusion on days -5, -4
17339|NCT00801632|Biological|rituximab|375 mg/m^2 infusion on days -7, -2, 5, and 12
17691|NCT00824694|Other|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
17692|NCT00824694|Other|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
17693|NCT00824707|Drug|Entecavir|Entecavir 0.5mg per day
15555|NCT00803400|Drug|Alprazolam + Aerobic exercise|The patients assigned to exercise have to pass an ergometric test to determine the functional capacity expressed in Metabolic Equivalents of Task (METs), and their maximum heart rates to standardize the future exercise indication.
Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.
At the same time they have to follow a protocolized aerobic exercise plan for this study 3 times a week for 12 weeks.
The type of selected exercise consists of a rapid walk (both in not inclined treadmill or natural courses) for 30 minutes divided in stages.
After each stage the patient has to control his own heart frequency that has to be maintained between 50 and 75% of their maximum not to turn to an anaerobic condition, according to the American Cardiological Association.
15556|NCT00803413|Behavioral|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
15557|NCT00803413|Behavioral|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
15558|NCT00803413|Behavioral|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
15559|NCT00803413|Behavioral|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
15560|NCT00803426|Procedure|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
15561|NCT00006458|Radiation|yttrium Y 90 monoclonal antibody MN-14|
15562|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
15563|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
15564|NCT00803452|Drug|doxycycline|Oral doxycycline 100mg bid
15565|NCT00803452|Drug|essential fatty acid|Oral essential fatty acid 1000mg per day
15566|NCT00803452|Drug|azithromycin|topical 1% azithromycin daily to eye
15567|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
15568|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
15569|NCT00803478|Procedure|LASIK|
16267|NCT00802308|Drug|Morphine sulphate|Extended release tablet combined with alcohol or water
16268|NCT00802321|Drug|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
16269|NCT00795028|Other|Standard Care for people after hip fracture|
16270|NCT00795028|Other|Standard Care + exercise intervention|
16271|NCT00795054|Other|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
16272|NCT00006382|Procedure|radiography|
16273|NCT00795080|Procedure|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
16274|NCT00795106|Drug|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
15311|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
15312|NCT00805558|Drug|moxifloxacin|400 mg moxifloxacin once daily for 7 days
15313|NCT00805558|Drug|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
15314|NCT00006469|Procedure|neoadjuvant therapy|
15315|NCT00805584|Drug|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
15316|NCT00805597|Radiation|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
15317|NCT00805597|Radiation|no radiation|no radiotherapy
15318|NCT00805610|Biological|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
15319|NCT00805623|Dietary Supplement|sucrose|1 cc of sucrose 33.5% with or without pacifier
15320|NCT00807612|Biological|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
16329|NCT00802334|Drug|generic lopinavir/ritonavir|Screening visit
• Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available
Baseline visit
• (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician
Week 4
Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)
Clinical, safety and laboratory assessment
Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment
16330|NCT00006454|Drug|paclitaxel|
16331|NCT00802347|Drug|I5NP|Single IV injection of I5NP
Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg
Part B: 10.0 mg/kg
16332|NCT00802347|Drug|Saline|Single IV injection of saline
Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg
Part B: 10.0 mg/kg
16333|NCT00802360|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
16334|NCT00802360|Drug|Progestrone vaginal insert|100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
16335|NCT00802360|Drug|follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
16336|NCT00802360|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
16337|NCT00802360|Drug|Ganirelix|Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
16338|NCT00802373|Drug|Solifenacin succinate|oral
16339|NCT00802373|Drug|Tolterodine|Oral
16340|NCT00802399|Procedure|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
16341|NCT00006454|Drug|topotecan hydrochloride|
16342|NCT00802412|Drug|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
16343|NCT00802412|Drug|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
16344|NCT00802425|Drug|AM-111|single intratympanic injection
16345|NCT00802425|Drug|placebo|single intratympanic injection
17694|NCT00824707|Drug|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
17695|NCT00824720|Drug|High Dose Device|inserted for 14 days
17696|NCT00824720|Drug|Low Dose Device|inserted for 14 days
17697|NCT00824720|Device|Placebo Device|inserted for 14 days
17698|NCT00007982|Drug|cyclophosphamide|
17699|NCT00824733|Drug|Trastuzumab|IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
17700|NCT00824733|Drug|PF03512676|Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
17701|NCT00824733|Other|Correlative Studies|Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
17702|NCT00824746|Drug|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
17703|NCT00824759|Other|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
17704|NCT00824785|Drug|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
17705|NCT00824785|Drug|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
17706|NCT00824811|Drug|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
17707|NCT00824811|Drug|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
17708|NCT00824811|Drug|Fluorometholone Eye Drops (FML Forte®)|Week 1: One drop four times a day to both eyes.
Week 2: One drop three times a day to both eyes.
Week 3: One drop twice a day to both eyes.
Week 4: One drop once a day to both eyes.
Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®.
17709|NCT00007982|Drug|etoposide|
17710|NCT00827333|Procedure|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
16760|NCT00798187|Behavioral|Group Meetings|10 weekly group meetings lasting 2 hours.
16761|NCT00798187|Behavioral|Questionnaire|Surveys
15570|NCT00803491|Other|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
15571|NCT00803491|Other|Traditional rheumatology care.|Individually base.
15872|NCT00808496|Other|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).
MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported.
15873|NCT00808496|Other|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.
Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported.
15874|NCT00808496|Other|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
15875|NCT00808509|Biological|adalimumab|40 mg every other week via subcutaneous injection
15876|NCT00808509|Drug|methotrexate|At least 10 mg/week administered orally or subcutaneously
15877|NCT00808522|Drug|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
15878|NCT00808535|Procedure|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
15879|NCT00808548|Other|counseling, emotional support|
15880|NCT00808548|Other|emotional support|emotional support during the interview
15881|NCT00006485|Drug|irinotecan hydrochloride|
15882|NCT00808548|Other|emotional support|emotional supporting during the interview
15883|NCT00808561|Other|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
15884|NCT00808561|Other|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
15885|NCT00808574|Behavioral|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
15321|NCT00807612|Drug|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
15322|NCT00807612|Biological|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
15323|NCT00807612|Drug|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
15324|NCT00807625|Drug|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
15325|NCT00807625|Device|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
15326|NCT00807651|Procedure|Immunosuppression and autologous stem cell transplantation|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation.
15327|NCT00807664|Device|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
15328|NCT00006480|Biological|therapeutic autologous lymphocytes|
15329|NCT00807664|Device|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
15330|NCT00807677|Drug|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
15331|NCT00807690|Drug|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
15636|NCT00810316|Drug|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
15637|NCT00810342|Behavioral|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
15638|NCT00810342|Behavioral|physical activity standard|standard print and website information on how to become more active
15639|NCT00810355|Behavioral|Support Group|General support and problem solving for work activity
15640|NCT00810355|Behavioral|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
15641|NCT00006519|Drug|Capravirine|
15642|NCT00810355|Behavioral|Cognitive Remediation|Computerized training to enhance cognitive functioning.
15643|NCT00810368|Drug|Carnosine|500mg Carnosine x2 daily
16346|NCT00802438|Biological|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
15392|NCT00805636|Procedure|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of [18F]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
15393|NCT00805649|Procedure|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
15394|NCT00805649|Procedure|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
15395|NCT00006469|Radiation|radiation therapy|
15396|NCT00805649|Drug|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
15397|NCT00805649|Drug|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
15398|NCT00805649|Procedure|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
15399|NCT00805649|Drug|triamcincolone|intravitreal injection of 8 mg triamcincolone
15400|NCT00805662|Drug|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
15401|NCT00805675|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
15402|NCT00805675|Drug|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
15403|NCT00805675|Drug|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
15404|NCT00805688|Behavioral|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
15405|NCT00805688|Procedure|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
15406|NCT00006470|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
15407|NCT00805688|Device|Pedometer|Worn daily to measure physical activity.
15408|NCT00805701|Drug|avodart|0.5 avodart once daily for 13 weeks
15409|NCT00805701|Drug|Placebo|placebo
15410|NCT00805740|Drug|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
16762|NCT00798200|Other|Exercise program|All exercise programs will include endurance and strength exercises.
16763|NCT00798213|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
16764|NCT00798213|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
16765|NCT00798226|Dietary Supplement|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 og gestation to 1 week after delivery
16766|NCT00798226|Dietary Supplement|olive oil|Oral intake of 4 capsules (1 g) daily from 26 weeks of gestation to 1 week after delivery
16767|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
16768|NCT00006399|Drug|Progesterone|
16769|NCT00798239|Other|Iliac crest autograft|autograft
16770|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
16771|NCT00798252|Drug|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
16772|NCT00798252|Drug|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
16773|NCT00798252|Drug|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
16774|NCT00798252|Drug|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
16775|NCT00798252|Drug|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
16776|NCT00798252|Drug|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
16777|NCT00798265|Biological|Gardisil|.5 mL dose injected IM at 0 2 and 6 months
16778|NCT00798265|Behavioral|Survey|Administration of on-line risk behavior and knowledge survey
16779|NCT00006400|Drug|Hydroxyurea|Participants will receive hydroxyurea.
16780|NCT00798278|Drug|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
16781|NCT00798278|Procedure|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
16782|NCT00798291|Other|Ad lib diet and Control placebo|one packet with water two times a day
15886|NCT00808600|Behavioral|resource-activating behavioural training programme|Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.
Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report.
16188|NCT00795002|Other|laboratory biomarker analysis|Correlative studies
16189|NCT00795015|Drug|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
16190|NCT00795015|Drug|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
16191|NCT00797017|Drug|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
16192|NCT00797017|Drug|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
16193|NCT00797017|Drug|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
16194|NCT00797030|Drug|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
16195|NCT00006392|Drug|Selenium|200 mcg daily for 7-12 years
16196|NCT00797030|Drug|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
16197|NCT00797056|Drug|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
16198|NCT00797056|Drug|Placebo|Saline SQ daily for 10 days
16199|NCT00797056|Drug|Aspirin|Aspirin 75 mg/day for 14 days
16200|NCT00797056|Drug|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
16201|NCT00797069|Other|standard nutritional product (medical food)|once during crossover
16202|NCT00797069|Other|nutritional product for diabetes (medical food)|once during crossover
16203|NCT00797069|Other|diabetes specific experimental nutritional product (medical food)|once during crossover
16204|NCT00797082|Device|MRI|MRI = Myocardial Perfusion Stress
15644|NCT00810368|Drug|Placebo|Microcrystalline cellulose placebo tablets x2 daily
15645|NCT00810381|Drug|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
15646|NCT00810381|Drug|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
15647|NCT00810381|Drug|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
15648|NCT00803530|Drug|ATO + Ascorbic acid|ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.
The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution.
15649|NCT00803543|Drug|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
15650|NCT00803543|Drug|Placebo|Dosage: Two tablets once a day for 24 weeks
15651|NCT00803556|Drug|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
15652|NCT00803556|Drug|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
15653|NCT00803556|Drug|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
15654|NCT00803569|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|
15655|NCT00803569|Biological|sargramostim|
15656|NCT00803582|Procedure|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
15657|NCT00006459|Drug|paclitaxel|
15943|NCT00806650|Genetic|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
15944|NCT00806650|Other|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
15945|NCT00806650|Other|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
15946|NCT00806650|Other|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
15947|NCT00806663|Drug|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
15411|NCT00805740|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
15412|NCT00805753|Drug|ACTH|comparison of different dosages of drug
15715|NCT00810407|Drug|rifabutin|Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " 1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.
2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily".
15716|NCT00810433|Procedure|GO-LIF - Guided Oblique Lumbar Interbody Fusion|All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.
Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.
Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused.
15717|NCT00006565|Device|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
15718|NCT00810446|Drug|rifabutin|Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " 1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.
2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.
3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.".
15719|NCT00810472|Other|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
15720|NCT00810472|Procedure|Penetrating keratoplasty|Corneal transplantation.
15721|NCT00810485|Drug|ADX10059|oral administration
15722|NCT00810485|Drug|ADX10059|oral administration
15723|NCT00810485|Drug|ADX10059|oral administration
15724|NCT00810485|Drug|ADX10059 Matching Placebo|oral administration
15725|NCT00810511|Device|Lotrafilcon A contact lens|Silicone hydrogel contact lens
15726|NCT00810511|Device|Comfilcon A contact lens|Silicone hydrogel contact lens
17063|NCT00801177|Biological|IMC-11F8|Cohort 5
800 mg I.V.
17064|NCT00801177|Biological|IMC-11F8|Cohort 6
1000 mg I.V.
17065|NCT00801177|Biological|IMC-11F8|Cohort 1
100 mg I.V.
17066|NCT00801177|Biological|IMC-11F8|Cohort 2
200 mg I.V.
17067|NCT00801177|Biological|IMC-11F8|Cohort 3
400 mg I.V.
17068|NCT00801177|Biological|IMC-11F8|Cohort 4
600 mg I.V.
17069|NCT00801177|Biological|IMC-11F8|Cohort 5
800 mg I.V.
17070|NCT00801177|Biological|IMC-11F8|Cohort 6
1000 mg I.V.
17071|NCT00006448|Drug|Methadone|
17072|NCT00801190|Other|HES (130/0.4)|33 ml/kg i.v. during surgery
17073|NCT00801190|Other|Ringer's Lactate|33 ml/kg i.v.
17074|NCT00801203|Drug|IRCT|Up to two administrations of the IRCT during a single cough testing session
17075|NCT00801216|Drug|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
17076|NCT00801229|Drug|Vyvanse|Vyvanse 30, 50, or 70 mg daily
17077|NCT00801229|Drug|Placebo|Placebo 30, 50, 70 mg daily
17078|NCT00801242|Drug|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
17079|NCT00801255|Drug|RO5024048|500mg po bid/100mg po q8h for 7 days
17080|NCT00801255|Drug|danoprevir|500mg po bid/100mg po q8h for 14 days
17081|NCT00801255|Drug|danoprevir|1000mg po bid/100mg po q8h for 14 days\n500mg po bid/200mg po q8h for 14 days
17082|NCT00006449|Drug|naltrexone (Revia)|
17083|NCT00801255|Drug|danoprevir|1000mg po bid/200mg po q8h for 14 days
16205|NCT00797082|Device|MPS|MPS = Myocardial Perfusion Scintigraphy
16206|NCT00006392|Other|Vitamin E placebo|daily for 7-12 years
16207|NCT00797108|Drug|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
16208|NCT00797108|Drug|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
16209|NCT00797108|Drug|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
15243|NCT00809705|Drug|Placebo|sc once weekly for 12 weeks
15244|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
15245|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 12 weeks
15246|NCT00809718|Drug|Raltegravir and rifapentine|Period 1- Raltegravir 400 mg q12h by mouth for 4 days
Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days
Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days
15247|NCT00809744|Drug|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
15248|NCT00809757|Drug|Levalbuterol|90 ug Levalbuterol (2 actuations)
15249|NCT00809757|Drug|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
15250|NCT00006508|Procedure|formula meal|
15251|NCT00809757|Drug|Placebo|Placebo (2 actuations)
15252|NCT00809770|Behavioral|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
15253|NCT00809770|Behavioral|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
15254|NCT00809783|Biological|tanezumab|Tanezumab 10 mg
15255|NCT00809783|Biological|tanezumab|Tanezumab 5 mg
15256|NCT00809783|Biological|tanezumab|Tanezumab 2.5 mg
15257|NCT00809796|Drug|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
15948|NCT00806676|Drug|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
15949|NCT00806689|Procedure|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
15950|NCT00806689|Device|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
15951|NCT00000752|Drug|Cefuroxime axetil|
15952|NCT00006475|Drug|imatinib mesylate|
15953|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
15954|NCT00808600|Behavioral|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
15955|NCT00808600|Behavioral|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
15956|NCT00808613|Device|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
15957|NCT00808613|Device|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
15958|NCT00000753|Drug|Zidovudine|
16275|NCT00795106|Drug|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
16276|NCT00795119|Device|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
15727|NCT00810524|Drug|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
15728|NCT00006565|Device|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
15729|NCT00810524|Drug|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
16022|NCT00804310|Drug|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
16023|NCT00799331|Drug|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
16024|NCT00799331|Drug|placebo|Oral suspension.
16025|NCT00799344|Device|Catania Stent|coronary stent implantation
16026|NCT00799370|Procedure|Early weight bearing|Weight bearing performed immediately after surgery
16027|NCT00799370|Procedure|Delayed weight bearing|Weight bearing performed 2 months after surgery
16028|NCT00006429|Procedure|body weight-supported treadmill training|
16029|NCT00799383|Drug|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
I labelled the intervention type as "drug", even though "dietary supplement" would be more appropriate as the system sent the following error message:
ERROR: An IND/IDE study must have at least one intervention of type: Drug, Device, Biological/Vaccine, Radiation or Genetic.
16030|NCT00799396|Drug|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
16031|NCT00799396|Drug|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
16032|NCT00799409|Drug|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
16033|NCT00799409|Drug|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
16034|NCT00799422|Device|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
16035|NCT00799422|Device|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
16036|NCT00799422|Device|Clear Care|Commercially marketed contact lens solution for contact lens care
16037|NCT00799422|Device|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
17084|NCT00801255|Drug|danoprevir|1000mg/600mg po twice daily for 14 days
17085|NCT00801255|Drug|danoprevir|1000mg/900mg po twice daily for 14 days
17340|NCT00801632|Drug|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
17341|NCT00801632|Drug|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
17342|NCT00801632|Radiation|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
17343|NCT00801645|Behavioral|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
17344|NCT00801658|Device|selective Laser Trabeculoplasty (SLT)|
17345|NCT00801671|Procedure|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
17346|NCT00801684|Drug|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
17347|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
17348|NCT00006451|Drug|methotrexate|
17349|NCT00801684|Drug|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
17350|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
17351|NCT00801684|Drug|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
17352|NCT00801697|Biological|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
17353|NCT00801697|Biological|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
17354|NCT00801697|Biological|rAd35|VRC-HIVADV027-00-VP 1 x 10^10 PU administered as 1 mL
17355|NCT00801697|Biological|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
17356|NCT00801697|Biological|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
17357|NCT00801697|Biological|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
15258|NCT00809809|Drug|Zicam (Ionic zinc)|33mmol/l of ionic zinc
15259|NCT00809809|Drug|placebo|placebo swab
15260|NCT00809822|Drug|NPB-01|Intravenous immunoglobulin
15261|NCT00006509|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
15262|NCT00809822|Drug|Placebo|Physiological saline
15263|NCT00809835|Drug|Galantamine|Daily 8 mg galantamine capsule
15264|NCT00809835|Behavioral|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
15265|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
15572|NCT00006459|Drug|gemcitabine hydrochloride|
15573|NCT00803504|Procedure|ocular blood flow measurement|
15574|NCT00805935|Drug|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
15575|NCT00805948|Device|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aneurysms using the Talent Thoracic Stent Graft System.
15576|NCT00805961|Radiation|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
15577|NCT00805961|Drug|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
15578|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
15579|NCT00000752|Drug|Guaifenesin|
15580|NCT00006471|Drug|Fenretinide|1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
15581|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
15582|NCT00805961|Drug|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
15583|NCT00805974|Biological|Biological examinations (blood and urinary).|
16277|NCT00795132|Drug|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
16278|NCT00795132|Drug|Anti-Thymocyte Globulin|Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of
1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion.
16279|NCT00795132|Drug|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
16280|NCT00795132|Drug|Cyclosporine|Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G
1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference.
16281|NCT00000746|Biological|rgp120/HIV-1 SF-2|
16282|NCT00006392|Other|selenium placebo|daily for 7-12 years
16283|NCT00797251|Procedure|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
16284|NCT00797264|Drug|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
16285|NCT00797264|Drug|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
15332|NCT00807703|Procedure|Select Stim|Select Stim: see summary
15333|NCT00807716|Other|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
16038|NCT00799435|Drug|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
16039|NCT00000746|Biological|gp160 Vaccine (MicroGeneSys)|
16040|NCT00006430|Biological|Autologous dendritic cells transfected with amplified tumor RNA|
16041|NCT00799448|Drug|repaglinide|
16042|NCT00799448|Drug|biphasic human insulin 30|
16043|NCT00799448|Drug|insulin NPH|
16347|NCT00802451|Drug|Mesalamine|
16348|NCT00802464|Biological|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
16349|NCT00802464|Biological|Placebo|2 vaccinations at Months 0 and 2 with placebo
16350|NCT00802477|Procedure|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
16351|NCT00795132|Drug|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
16352|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
16353|NCT00000744|Drug|Fluconazole|
16354|NCT00006382|Procedure|study of high risk factors|
16355|NCT00795145|Drug|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
16356|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
16357|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
16358|NCT00795145|Drug|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
16359|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
16360|NCT00795145|Drug|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
17358|NCT00006379|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
17359|NCT00794339|Drug|parenteral chemotherapy|
17360|NCT00794339|Other|imaging biomarker analysis|
17361|NCT00794339|Other|immunohistochemistry staining method|
17711|NCT00827333|Procedure|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
17712|NCT00008034|Drug|epirubicin hydrochloride|
17713|NCT00827333|Procedure|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
17714|NCT00827346|Drug|Clopidogrel|600 mg now
17715|NCT00827346|Drug|Clopidogrel|600 mg now and 600 mg in 3 hours
17716|NCT00827346|Drug|Clopidogrel|900 mg now
17717|NCT00827346|Drug|Clopidogrel|600 mg now and 300 mg in 3 hours
17718|NCT00827359|Drug|Everolimus|Tablet form taken orally once a day
17719|NCT00827372|Drug|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
17720|NCT00827398|Biological|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
17721|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
17722|NCT00827411|Device|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
17723|NCT00008047|Drug|fluorouracil|
17724|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
17725|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
17726|NCT00827411|Drug|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
17727|NCT00827424|Behavioral|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
17728|NCT00827437|Other|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
15584|NCT00806026|Drug|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
15585|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
15586|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
15587|NCT00806026|Drug|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
15588|NCT00806026|Drug|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
15589|NCT00806026|Drug|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
15590|NCT00806039|Other|Early Renal Involvement|Renal Consultation
15591|NCT00006472|Drug|carboplatin|
15592|NCT00806065|Drug|ENMD-2076|Oral capsules, once daily in 28-day cycles
15593|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
15887|NCT00808600|Behavioral|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
15888|NCT00000754|Drug|Interferon alfa-2a|
15889|NCT00006578|Drug|Abacavir sulfate|
15890|NCT00810654|Dietary Supplement|Placebo|Placebo
15891|NCT00810667|Drug|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
15892|NCT00810667|Drug|Placebo|twice daily oral dose
15893|NCT00810680|Drug|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
15894|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
15895|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
15334|NCT00807716|Other|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
15335|NCT00807729|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
15336|NCT00807729|Procedure|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
15337|NCT00807742|Drug|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, then 14mg patch for 2 weeks and 7mg patch for 2 weeks. This is supplemental intervention provided to all.
15338|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
15339|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
15340|NCT00809848|Drug|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
15341|NCT00809848|Drug|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
15342|NCT00809861|Procedure|volar locking plating|open reduction and internal fixation
15343|NCT00809861|Procedure|external immobilisation|closed reduction and external fixation
15344|NCT00006509|Biological|gp160 MN/LAI-2|
15345|NCT00809874|Dietary Supplement|Casein|
15346|NCT00809874|Dietary Supplement|Whey Isolate|
15347|NCT00809874|Dietary Supplement|Whey Hydrolysate|
15348|NCT00809874|Dietary Supplement|Alphalact-Albumin|
15349|NCT00809887|Drug|Micafungin lock therapy|
16361|NCT00795158|Drug|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
16362|NCT00795171|Drug|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
16363|NCT00795171|Drug|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
16364|NCT00795171|Drug|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
16365|NCT00006383|Drug|liposomal vincristine sulfate|
16366|NCT00795184|Device|Probe-based confocal laser endomicroscopy|All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.
Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.
Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.
After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.
15413|NCT00807742|Behavioral|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
15414|NCT00006480|Drug|chemotherapy|
15415|NCT00807755|Drug|carboplatin|IV (in the vein) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.
15416|NCT00807755|Drug|etoposide|80mg/m2, IV (in the vein) on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
15417|NCT00807755|Drug|everolimus|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
15418|NCT00807755|Other|Correlative studies|Pharmacokinetics: blood collected Cycle 1, Days 1, 15; Cycle 2, Day 1. Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1.
15419|NCT00807768|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
15420|NCT00807768|Drug|Carboplatin|Given IV
15421|NCT00807768|Radiation|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
15422|NCT00807768|Radiation|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
15423|NCT00807768|Other|Laboratory Biomarker Analysis|Correlative studies
15424|NCT00807768|Drug|Paclitaxel|Given IV
17729|NCT00827450|Dietary Supplement|Ctl|Control, isocaloric diet; no coffee
17730|NCT00827450|Dietary Supplement|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
17731|NCT00827450|Dietary Supplement|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
17732|NCT00827450|Dietary Supplement|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
17733|NCT00827450|Dietary Supplement|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
17734|NCT00000768|Drug|Ganciclovir|
16475|NCT00797667|Drug|280 mg telcagepant placebo|
16476|NCT00797680|Other|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
16477|NCT00797680|Other|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
16478|NCT00797693|Drug|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
16479|NCT00797706|Drug|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
16480|NCT00006397|Drug|Indinavir sulfate|
16481|NCT00797719|Other|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
16482|NCT00797732|Device|Acupuncture|active acupuncture (n=21) or sham acupuncture (n=21), once every 2 weeks for 24 weeks.
16483|NCT00797745|Biological|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
16484|NCT00797745|Drug|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
16485|NCT00797745|Drug|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
16486|NCT00797745|Drug|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
16487|NCT00797758|Other|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
16488|NCT00797771|Device|"Adi" Insulin pump|insulin delivery will be defined by the physician
15896|NCT00810693|Drug|Placebo|Matching Placebo tid orally for 12 weeks
15897|NCT00810706|Drug|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
15898|NCT00810719|Drug|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
15899|NCT00810719|Drug|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
15900|NCT00006578|Drug|Amprenavir|
15901|NCT00810732|Drug|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
15902|NCT00810732|Drug|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
15903|NCT00810732|Drug|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
15904|NCT00810745|Procedure|starr|stapled transanal rectal resection
15905|NCT00810758|Drug|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
15906|NCT00810758|Drug|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
15907|NCT00810758|Drug|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
16210|NCT00797121|Procedure|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
16211|NCT00797160|Drug|propofol|2mg/Kg IV in bolus before tracheal intubation
16212|NCT00797186|Other|Intensive risk factor management|Aggressive medical and lifestyle therapy.
16213|NCT00797212|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
16214|NCT00797225|Drug|NBI-56418 sodium|NBI-56418 sodium, 150 mg or 250 mg
16215|NCT00797225|Drug|Leuprorelin|Leuprorelin 3.75 mg
16216|NCT00797225|Drug|placebo|Placebo tablet, placebo injection
16217|NCT00006433|Drug|Doxil|
16218|NCT00799643|Drug|Salsalate Placebo|
15658|NCT00803582|Procedure|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
15659|NCT00803595|Drug|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
15660|NCT00803595|Drug|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
15661|NCT00803595|Drug|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
15662|NCT00803608|Device|TrueContour® Insole|Novel designed insole
15663|NCT00803608|Device|Current standard of care insole|Current Medicare approved A5513 insole
15664|NCT00803621|Other|Toxoplasma PCR assay|Toxoplasma PCR assay
15665|NCT00803634|Drug|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
15666|NCT00803634|Drug|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
15667|NCT00806117|Other|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135~175mg/m2 over 3 hours Cisplatin 60~75mg/m2
15668|NCT00806143|Device|repetitive transcranial stimulation (rTMS)|Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.
In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days.
15669|NCT00806143|Device|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
15670|NCT00006472|Drug|fluorouracil|
15671|NCT00806156|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
15425|NCT00006480|Drug|ganciclovir|
15426|NCT00807768|Other|Quality-of-Life Assessment|Ancillary studies
15427|NCT00807768|Other|Questionnaire Administration|Ancillary studies
15428|NCT00807781|Biological|Mammaglobin-A DNA vaccine|
15429|NCT00807794|Drug|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
15430|NCT00807794|Drug|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
15431|NCT00807794|Drug|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
15432|NCT00807794|Drug|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
15433|NCT00807794|Drug|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
15434|NCT00807807|Dietary Supplement|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
15730|NCT00803647|Biological|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
15731|NCT00000751|Drug|Globulin, Immune|
15732|NCT00006460|Drug|hyperbaric oxygen|
15733|NCT00803647|Drug|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
15734|NCT00803647|Drug|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
15735|NCT00803647|Drug|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
15736|NCT00803673|Drug|1000mcg|1000mcg '719
15737|NCT00803673|Drug|100mcg|100mcg '719
15738|NCT00803673|Drug|500mcg|500mcg '719
15739|NCT00803673|Drug|Placebo|Placebo '719
16489|NCT00797784|Drug|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
16490|NCT00797797|Drug|No Treatment Added|No added treatment
16491|NCT00006397|Drug|Ritonavir|
16492|NCT00797797|Drug|Milnacipran Added|Milnacipran 100 mg/d added
16493|NCT00797810|Drug|Rituximab|
16494|NCT00797823|Drug|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
16495|NCT00797823|Drug|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
16496|NCT00797823|Drug|Placebo|Saline solution 0.9%
15511|NCT00000753|Drug|Atevirdine mesylate|
15512|NCT00006481|Procedure|quality-of-life assessment|
15513|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
15514|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
15515|NCT00807937|Drug|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
15516|NCT00807937|Drug|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
15517|NCT00807950|Drug|Simvastatin|
15518|NCT00807963|Drug|rHuPH20|recombinant human hyaluronidase PH20
15519|NCT00807989|Drug|Carbamazepine|
15520|NCT00807989|Drug|Lamotrigine/Valproate|
15521|NCT00808002|Drug|Raltegravir|Raltegravir 400 mg every 12 hours
15522|NCT00808002|Drug|Maraviroc|Maraviroc 300 mg every 12 hours
15523|NCT00006481|Radiation|radiation therapy|
15524|NCT00808002|Drug|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
15525|NCT00808015|Drug|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
16219|NCT00799656|Drug|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
16220|NCT00799656|Drug|placebo|oral administration once daily for 28 days
16221|NCT00799669|Behavioral|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
16222|NCT00799669|Other|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
16223|NCT00799669|Other|preventive intervention|
16224|NCT00799669|Other|questionnaire administration|
16225|NCT00799682|Drug|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
16226|NCT00799682|Drug|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
16227|NCT00799695|Behavioral|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
16228|NCT00006433|Procedure|heat treatment|
16229|NCT00799708|Drug|Comparator: placebo|placebo capsule once daily for 7 days.
16230|NCT00799708|Drug|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
16231|NCT00799734|Drug|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
16232|NCT00799747|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
15266|NCT00811967|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
15267|NCT00811967|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
15268|NCT00811980|Drug|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
15269|NCT00811993|Drug|RG1507|Starting dose of >=3mg/kg iv escalating to a maximum dose of <=16mg/kg iv, depending on dosing schedule in each combination treatment arm
15270|NCT00000754|Drug|Zalcitabine|
15271|NCT00006669|Drug|etoposide|
15672|NCT00806156|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
15673|NCT00806169|Drug|triamcinolone and bevacizumab|
15959|NCT00006486|Drug|carboxyamidotriazole|Given orally
15960|NCT00808626|Drug|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
15961|NCT00808639|Drug|Methotrexate|intravenously 30mg/m2 over 30 minutes
15962|NCT00808639|Drug|Doxorubicin|intravenously 30mg/ms over 15 minutes
15963|NCT00808639|Drug|vinblastine|intravenously 3mg/m2 over 30 minutes
15964|NCT00808639|Drug|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
15965|NCT00808639|Drug|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
15966|NCT00808652|Other|Measurement of flow mediated dilation of brachial artery.|Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.
Study Phases:
Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.
NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter.
15967|NCT00808665|Drug|Intravenous infusion of Dexmedetomidine or 0.9% Saline|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
15968|NCT00808678|Drug|ABT-143|once, see arm description for more information
15969|NCT00808678|Drug|ABT-335|once, see arm description for more information
15970|NCT00006486|Other|placebo|Given orally
15971|NCT00006578|Drug|Lamivudine|
15972|NCT00810797|Drug|exemestane|Given orally
15973|NCT00810797|Other|laboratory biomarker analysis|One year after completion of study treatment
15974|NCT00810797|Procedure|quality-of-life assessment|One year after completion of study treatment
15740|NCT00803686|Drug|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
15741|NCT00803686|Drug|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
15742|NCT00803686|Drug|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
15743|NCT00006460|Radiation|radiation therapy|
15744|NCT00803686|Drug|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
15745|NCT00803699|Dietary Supplement|placebo|daily placebo capsules for 12 months
15746|NCT00803699|Dietary Supplement|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
15747|NCT00803712|Drug|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
15748|NCT00803712|Drug|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
15749|NCT00803725|Drug|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
15750|NCT00803725|Drug|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
16044|NCT00799461|Other|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
16045|NCT00799461|Other|questionnaire administration|Completion of questions in an online format
16046|NCT00799461|Procedure|psychosocial assessment and care|Assessment and care of psychosocial aspects
16047|NCT00799461|Procedure|assessment of therapy complications|Evaluation of complications of treatment
16048|NCT00799461|Procedure|management of therapy complications|Managing therapy complications
16049|NCT00801892|Device|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Worn over nose to splint open the airway and prevent the subject from holding their breath (apneas).
16050|NCT00801905|Drug|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
15526|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
15527|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
15528|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
15529|NCT00808028|Other|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
15530|NCT00810121|Drug|ketoprofen|150 mg b.i.d. for 5 days
15531|NCT00810134|Procedure|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
15532|NCT00810134|Procedure|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
15533|NCT00810147|Drug|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
15534|NCT00810147|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
15535|NCT00810147|Drug|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
15829|NCT00803816|Drug|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
15830|NCT00803829|Other|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
15831|NCT00006461|Drug|cyclophosphamide|Given IV
15832|NCT00803842|Drug|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
15833|NCT00803855|Drug|AZD1446|oral, single dose
15834|NCT00803868|Drug|varenicline|up to 1mg po bid for 9 weeks
15835|NCT00803868|Drug|placebo|placebo matching study drug up to 1mg po bid
15836|NCT00803881|Other|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
15837|NCT00803894|Drug|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
15838|NCT00803894|Drug|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
15272|NCT00811993|Drug|RO1507|27mg/kg iv, monotherapy
15273|NCT00811993|Drug|bevacizumab [Avastin]|as prescribed
15274|NCT00811993|Drug|capecitabine [Xeloda]|as prescribed
15275|NCT00811993|Drug|carboplatin|as prescribed
15276|NCT00811993|Drug|cetuximab|as prescribed
15277|NCT00811993|Drug|docetaxel|as prescribed
15278|NCT00811993|Drug|erlotinib [Tarceva]|as prescribed
15279|NCT00811993|Drug|etoposide|as prescribed
15280|NCT00811993|Drug|gemcitabine|as prescribed
15281|NCT00811993|Drug|irinotecan|as prescribed
15282|NCT00006669|Drug|prednisone|
15283|NCT00811993|Drug|mFOLFOX6|as prescribed
15284|NCT00811993|Drug|paclitaxel|as prescribed
15285|NCT00811993|Drug|pemetrexel|as prescribed
15286|NCT00811993|Drug|sorafenib|as prescribed
15287|NCT00811993|Drug|temozolomide|as prescribed
15288|NCT00811993|Drug|trastuzumab [Herceptin]|as prescribed
15289|NCT00812006|Drug|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
15290|NCT00812006|Drug|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
15594|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
15595|NCT00806104|Dietary Supplement|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
15596|NCT00806104|Dietary Supplement|Maltodextrins|Dietary supplementation for 4 weeks
15597|NCT00806117|Radiation|Radiotherapy (RT)|External irradiation 50Gy/5 weeks
Lateral: 2 cm lateral to the bony margin of the pelvis
Superior: Between L5 and S1
Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)
15975|NCT00810797|Other|immunohistochemistry staining method|Correlative studies
15976|NCT00810810|Biological|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
15977|NCT00810810|Biological|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
16286|NCT00797264|Drug|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
16287|NCT00797277|Drug|IM olanzapine|10mg olanzapine IM
16288|NCT00797277|Drug|IM haloperidol plus lorazepam|IM 5 mg haloperidol plus IM 2 mg lorazepam
16289|NCT00797303|Drug|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
16290|NCT00797316|Drug|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
16291|NCT00797316|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
16292|NCT00797329|Other|chart review|cholesterol
cognitive profiles
violent behavior
16293|NCT00006394|Drug|growth hormone|
16294|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
16295|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
16296|NCT00797342|Drug|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
16297|NCT00797368|Other|Manual Therapy and Exercise|Manual Therapy and Exercise
16298|NCT00797368|Other|Home exercises|Home exercises
16299|NCT00797394|Dietary Supplement|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
16300|NCT00797394|Dietary Supplement|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
16301|NCT00797407|Dietary Supplement|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
16302|NCT00797420|Drug|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
16051|NCT00801905|Other|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
16052|NCT00801918|Drug|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
16053|NCT00801918|Drug|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
16054|NCT00801931|Drug|TBI, Thiotepa, Cyclophosphamide, ATG|APatients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
16055|NCT00801931|Drug|Busulfan, Melphalan, Rabbit ATG|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
16056|NCT00006451|Procedure|radiation therapy|
16057|NCT00801931|Drug|Busulfan, Fludarabine, Alemtuzumab|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
16058|NCT00801931|Drug|Busulfan, Fludarabine, Rabbit ATG|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
16059|NCT00801931|Drug|Fludarabine, Cyclophosphamide, ATG|Patients with Fanconi's Anemia will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and anti-thymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
16367|NCT00795184|Device|Narrow Band Imaging (NBI)|All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.
Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.
Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.
After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.
16368|NCT00795210|Drug|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
16369|NCT00795210|Drug|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
16370|NCT00795223|Drug|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
15839|NCT00803894|Drug|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
15840|NCT00803907|Drug|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
15841|NCT00803933|Drug|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
15842|NCT00006461|Drug|vincristine sulfate|Given IV
15843|NCT00803933|Drug|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
15844|NCT00803946|Drug|Ibuprofen Tablets, 800 mg|
15845|NCT00803959|Other|Office evaluation|Office evaluation
15846|NCT00806403|Procedure|primary PCI|comparison to thrombolysis
15847|NCT00806416|Drug|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
15848|NCT00806416|Drug|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
15849|NCT00806416|Dietary Supplement|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
16143|NCT00802009|Drug|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
16144|NCT00802022|Device|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
16145|NCT00802035|Drug|Baclofen IR|30 mg; single dose
16146|NCT00802035|Drug|Baclofen ER|30 mg; single dose
16147|NCT00802048|Drug|Local anesthetic (Ropivacaine)|Local anesthetic infusion
16148|NCT00006452|Radiation|radiation therapy|
16149|NCT00802048|Drug|Saline|Saline serum infusion
16150|NCT00802061|Behavioral|Sleeping position in glaucoma patient|
16151|NCT00802074|Drug|Raltegravir|400mg BID
16152|NCT00802074|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
15598|NCT00806117|Other|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
15599|NCT00808041|Device|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
15600|NCT00808054|Drug|EMLA|0.5g topical EMLA
15601|NCT00808067|Drug|dabigatran dose 1|dabigatran high dose twice daily
15602|NCT00808067|Drug|dabigatran dose 2|dabigatran low dose twice daily
15603|NCT00006482|Drug|cisplatin|
15604|NCT00808080|Biological|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
15605|NCT00808093|Drug|GSK256073|GSK256073 100 mg study drug
15606|NCT00808119|Drug|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
15607|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
15608|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
15609|NCT00808132|Drug|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
15610|NCT00808132|Drug|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
15611|NCT00808132|Drug|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
15612|NCT00808145|Drug|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
15613|NCT00808171|Drug|Livopan|Inhalation of oxygen and nitrous oxide 50%
15614|NCT00006482|Drug|gemcitabine hydrochloride|
15615|NCT00808171|Drug|Livopan|equimolar mixture of N2O/O2
15908|NCT00810771|Behavioral|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
16303|NCT00797420|Drug|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
16304|NCT00006395|Drug|St. John's Wort|
16305|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
16306|NCT00799812|Drug|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
15350|NCT00809900|Dietary Supplement|Experimental|Administration of of 480 mL cranberry juice
15351|NCT00809913|Drug|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
15352|NCT00809926|Drug|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
15353|NCT00809926|Drug|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
15354|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
15355|NCT00000753|Drug|Didanosine|
15356|NCT00006516|Behavioral|Infant stimulation|
15357|NCT00809939|Drug|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
15358|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
15359|NCT00809939|Drug|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
15360|NCT00809952|Procedure|recombinant FSH|
15361|NCT00809965|Drug|Rivaroxaban 2.5 mg|One tablet twice daily
15362|NCT00809965|Drug|Rivaroxaban 5 mg|One tablet twice daily
15363|NCT00809965|Drug|Placebo|One placebo tablet twice daily
15364|NCT00809965|Drug|Standard of care|
15365|NCT00811798|Biological|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
16371|NCT00795223|Drug|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
16372|NCT00797459|Device|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
16373|NCT00797472|Drug|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
16374|NCT00797472|Drug|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
16375|NCT00797485|Biological|bevacizumab|Given IV
16376|NCT00797485|Drug|capecitabine|Given orally
16377|NCT00797485|Drug|fluorouracil|Given IV
16378|NCT00797485|Drug|irinotecan hydrochloride|Given IV
16379|NCT00797485|Drug|leucovorin calcium|Given IV
16380|NCT00797498|Other|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
16381|NCT00797511|Biological|TdcP-IPV vaccine|0.5 mL, Intramuscular
16382|NCT00006396|Drug|Nevirapine|
16383|NCT00797537|Procedure|Echography|Echography
16384|NCT00797550|Procedure|Bone Repair Cells (BRCs) with allogeneic, demineralized bone matrix|BRCs will be administered during spine fusion surgery
16385|NCT00797550|Procedure|Spine fusion with autologous bone graft|
16386|NCT00797563|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
15435|NCT00807807|Drug|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
15436|NCT00006481|Drug|Biafine cream|
15437|NCT00807846|Drug|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
15438|NCT00807846|Drug|Naproxen|Naproxen 7.5 mg/kg PO BID [maximum of 500 mg BID] for 6 weeks
16153|NCT00802074|Drug|Ritonavir|100 mg BID or QD
16154|NCT00802087|Drug|hydrocodone|Extended Release tablet
16155|NCT00802087|Drug|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
16156|NCT00802100|Drug|Olanzapine|Daily tablets of 10 to 30 mg
16157|NCT00802100|Drug|Perphenazine|Daily tablets of 8 to 24 mg
16158|NCT00802100|Drug|Aripiprazole|Daily tablets of 10 to 30 mg
16159|NCT00006453|Drug|carboplatin|
16160|NCT00802100|Drug|Metformin|Daily tablets of 850 to 2550 mg
16161|NCT00802100|Drug|Simvastatin|Daily tablets of 20 to 40 mg
16162|NCT00802100|Drug|Benztropine|Daily tablets of 1 to 2 mg
16163|NCT00802113|Drug|Fludarabine and Busulfan|Fludarabine 30 mg/m2 x 5 days Busulfan 3.2 mg/kg/day x 2 days GVHD Prophylaxis with MMF and FK506
16164|NCT00802113|Drug|Fludarabine, Busulfan and ATG|Fludarabine 30 mg/m2 x 5 days Busulfan 3.2 mg/kg/day x 2 days Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days GVHD Prophylaxis with MMF and FK506
16165|NCT00802126|Drug|Combination therapy "IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
16166|NCT00802139|Drug|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
16497|NCT00797836|Procedure|Quantiferon Gold|Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response
Health Personnel Hospitals, General Occupational Diseases/*epidemiology/*statistics & numerical data Occupational Exposure/*statistics & numerical data
Tuberculosis/*diagnosis/*epidemiology/prevention & control Immunologic Tests/methods/*standards Disease Transmission, Horizontal/*statistics & numerical data Patient Isolation
Tuberculin Test/standards/*methods Immunoassay/methods/*standards T-Lymphocytes/immunology Interferon Type II/*blood/*analysis
*Reagent Kits, Diagnostic
Mass Screening/*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/*methods
16498|NCT00800150|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
16499|NCT00800150|Radiation|intensity-modulated radiation therapy|
16500|NCT00800150|Radiation|tomotherapy|
16501|NCT00800150|Radiation|total marrow irradiation|
16502|NCT00000194|Drug|Cycloserine|
16503|NCT00000747|Drug|Nevirapine|
15909|NCT00810771|Behavioral|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
15910|NCT00810784|Behavioral|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
15911|NCT00803959|Other|UDS|Urodynamics
15912|NCT00803972|Drug|rHuPH20|recombinant human hyaluronidase PH20
15913|NCT00803985|Procedure|Retro-muscular versus on lay mesh|Operation for primary inguinal hernias i men
15914|NCT00804011|Other|ATC|Automatic tube compensation
15915|NCT00804011|Other|PSV|Pressure support ventilation
15916|NCT00804024|Device|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
15917|NCT00804037|Procedure|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
15918|NCT00006461|Drug|etoposide|Given PO
15919|NCT00804050|Drug|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
15920|NCT00804050|Drug|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
15921|NCT00804063|Procedure|drawing blood sample|fasting blood sample
15922|NCT00804076|Biological|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
15923|NCT00804089|Procedure|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
15924|NCT00804089|Procedure|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
16233|NCT00799747|Drug|Placebo|placebo
15366|NCT00811811|Behavioral|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
15367|NCT00811811|Behavioral|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
15368|NCT00811824|Behavioral|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
15369|NCT00811837|Drug|Midazolam|Intravenous infusion
15370|NCT00811837|Drug|Remifentanil|Intravenous infusion
15371|NCT00811850|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
15372|NCT00006669|Drug|cyclophosphamide|
15674|NCT00806195|Biological|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
15675|NCT00806195|Biological|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
15676|NCT00806195|Biological|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
15677|NCT00806195|Biological|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
15678|NCT00806195|Biological|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
15679|NCT00806195|Biological|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
15680|NCT00806195|Biological|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
15681|NCT00006472|Drug|paclitaxel|
15682|NCT00806195|Biological|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
15683|NCT00806208|Drug|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
15684|NCT00806208|Drug|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
15685|NCT00806208|Drug|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
15686|NCT00806208|Drug|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
15439|NCT00809991|Radiation|hypofractionation|This will be a Phase II study evaluating the effectiveness and toxicity of a regimen of 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens of 2.5 Gy, 2.7 Gy, and 3.0 Gy daily fractions. The total dose is calculated to be iso-effective for late effects to a conventionally fractionated total dose of 81 Gy, which has been shown to be effective and safe in a large prospective Phase II study. If the alpha/beta ratio for prostate is between 1.5-3.0, then this regimen should be at least as effective or more effective for tumor control than 81 Gy given in conventional fractions.
15440|NCT00810004|Drug|Ferinject|Intravenous infusion of iron
15441|NCT00006517|Device|bright light box|10,000 lux bright light therapy
15442|NCT00810017|Drug|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
15443|NCT00810017|Drug|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
15444|NCT00810030|Drug|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
15445|NCT00810030|Drug|Iron Sucrose|VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:
• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.
The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.
The individual iron deficit will be calculated using the modified formula of Ganzoni.
If the patient's body mass index is >25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height [m] x height [m].
The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.
Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit.
15446|NCT00810043|Device|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
15447|NCT00810056|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
15448|NCT00810056|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
15449|NCT00810069|Drug|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
15450|NCT00810069|Drug|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
15751|NCT00803738|Drug|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
15752|NCT00803738|Drug|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
15753|NCT00803751|Device|Use of Truview EVO2 laryngoscope|will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
16504|NCT00006439|Behavioral|Counseling in the home|
16505|NCT00800150|Radiation|total nodal irradiation|
16506|NCT00800163|Other|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
16507|NCT00800176|Drug|Placebo|po daily for 12 weeks
16508|NCT00800176|Drug|RO4998452|2.5mg po daily for 12 weeks
16509|NCT00800176|Drug|RO4998452|5mg po daily for 12 weeks
16510|NCT00800176|Drug|RO4998452|10mg po daily for 12 weeks
16511|NCT00800176|Drug|RO4998452|20mg po daily for 12 weeks
16512|NCT00800176|Drug|RO4998452|40mg po daily for 12 weeks
16513|NCT00800189|Radiation|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
16514|NCT00800202|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
16515|NCT00006441|Drug|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
16516|NCT00800202|Drug|carboplatin|AUC6 iv every 3 weeks for 6 cycles
16517|NCT00800202|Drug|erlotinib [Tarceva]|150mg/day po
16518|NCT00800202|Drug|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
16519|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
15536|NCT00006517|Device|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
15537|NCT00810147|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
15538|NCT00810147|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
15539|NCT00810160|Dietary Supplement|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
15540|NCT00810160|Dietary Supplement|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
16234|NCT00799760|Drug|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
16235|NCT00799760|Drug|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
16236|NCT00799760|Drug|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
16237|NCT00799773|Drug|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
16238|NCT00799773|Procedure|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
16239|NCT00006434|Biological|tumor-pulsed dendritic cells|
16240|NCT00799773|Drug|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
16241|NCT00799786|Behavioral|Building Better Caregivers Online Workshop|
16242|NCT00799799|Biological|NK cells|NK cells infusion after immunosuppressive chemotherapy
16243|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
16244|NCT00802139|Drug|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
16245|NCT00802152|Device|In-home "smart" diagnostic devices|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
16246|NCT00802165|Device|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
16247|NCT00000750|Drug|Zidovudine|
16248|NCT00006453|Drug|gemcitabine hydrochloride|
16249|NCT00802165|Device|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
16250|NCT00802204|Radiation|PET scan|Subjects will undergo a PET scan of the brain using the radioligand,fallypride [18F]. Obese subjects who complete caloric restriction will have repeat scan after diet.
16251|NCT00802204|Procedure|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period
15687|NCT00806208|Other|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
15688|NCT00806221|Drug|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
15689|NCT00806234|Drug|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
15690|NCT00808236|Other|Control|Advanced cardiac life support according to American Heart Association & European Resuscitation Council 2005 Guidelines
15691|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
15692|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
15693|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
15694|NCT00808249|Drug|Placebo|2 tablets taken twice a day for 28 days
15695|NCT00808262|Biological|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
15978|NCT00810810|Biological|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
15979|NCT00810836|Drug|BG00012|oral
15980|NCT00810836|Drug|BG00012|Oral
15981|NCT00810836|Drug|placebo|oral placebo
15982|NCT00006578|Drug|Filgrastim|
15983|NCT00810849|Drug|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
15984|NCT00810849|Biological|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
15985|NCT00810862|Drug|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
15986|NCT00810862|Other|placebo base cream|apply to affected study area twice daily for 21 days
15987|NCT00810888|Drug|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
15988|NCT00810888|Drug|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
15754|NCT00806234|Drug|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
15755|NCT00806234|Drug|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
15756|NCT00006472|Procedure|conventional surgery|
15757|NCT00806247|Drug|tapentadol HCl|
15758|NCT00806260|Drug|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
15759|NCT00806260|Drug|Placebo|Placebo daily for 4 weeks
15760|NCT00806260|Other|Alcohol|
15761|NCT00806260|Other|alcohol placebo|fruit juice
15762|NCT00806273|Device|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
15763|NCT00806273|Device|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
15764|NCT00806286|Drug|CS7017 tablets|CS7017 tablets, strength 0.25mg, two tablets, two times daily for twenty-five to thirty months
15765|NCT00806286|Drug|Paclitaxel|IV, 200mg/m2, once every three weeks for up to 18 weeks
15766|NCT00806286|Drug|Carboplatin|IV, AUC of 6, once every three weeks for up to 18 weeks
15767|NCT00006472|Radiation|radiation therapy|
15768|NCT00806286|Drug|Placebo Tablets|Placebo tablets matching CS-7017 tablets
15769|NCT00806299|Drug|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
15770|NCT00806299|Drug|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
15771|NCT00806299|Drug|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
15541|NCT00810160|Dietary Supplement|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
15542|NCT00810160|Dietary Supplement|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
15543|NCT00810173|Behavioral|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
15544|NCT00810199|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
15545|NCT00810199|Drug|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
15546|NCT00810199|Drug|placebo|Placebo matching methotrexate capsule taken orally once a week.
15547|NCT00006517|Device|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
15548|NCT00810212|Procedure|PLF with autograft|6 subjects
15549|NCT00810212|Genetic|PLF with NeoFuse|6 subjects low dose
15550|NCT00810212|Genetic|PLF with NeoFuse|6 subjects medium dose
15551|NCT00810212|Genetic|PLF with NeoFuse|6 subjects high dose
15552|NCT00810238|Biological|C-Cure|Intraventricular injection
15553|NCT00810251|Device|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
15554|NCT00810264|Device|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
15850|NCT00806429|Procedure|transvaginal appendectomy|patient undergoes transvaginal appendectomy
15851|NCT00806442|Dietary Supplement|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
15852|NCT00806442|Dietary Supplement|Corn Oil|9 g/day of corn oil
15853|NCT00806468|Drug|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
15854|NCT00806481|Drug|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
15855|NCT00806481|Drug|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
16252|NCT00802204|Procedure|MRI|An MRI of the brain and abdomen will be performed prior to PET scan
15291|NCT00812019|Biological|FCC H5N1 3,75 µg|2 doses of Cell Culture-Derived H5N1 3,75 µg Subunit Influenza Vaccine
15292|NCT00812019|Biological|FCC H5N1 7,5 µg|2 doses of Cell Culture-Derived H5N1 7,5 µg Subunit Influenza Vaccine
15293|NCT00006669|Drug|vincristine sulfate|
15294|NCT00812019|Biological|FCC H5N1 15 µg|2 doses of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine
15295|NCT00812019|Biological|FCC H5N1 3,75 µg + 25% MF59|2 doses of Cell Culture-Derived H5N1 3,75 µg Subunit Influenza Vaccine containing 25% of MF59
15296|NCT00805441|Drug|LY686017|50 mg daily by oral route for 12 weeks
15297|NCT00805441|Drug|Placebo|Daily by oral route for 12 weeks
15298|NCT00805454|Drug|OPC-34712|Single oral dose, 0.5 to 25 mg
15299|NCT00805467|Drug|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
15300|NCT00805480|Drug|AIN457|AIN457 was administered intravenously.
15301|NCT00805480|Drug|Placebo|Matching placebo to AIN457 was administered intravenously.
15302|NCT00805493|Drug|Riluzole|
15303|NCT00006469|Procedure|conventional surgery|
15304|NCT00805519|Drug|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
15305|NCT00805519|Drug|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
15306|NCT00805519|Drug|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
15307|NCT00805519|Drug|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
15308|NCT00805532|Behavioral|Behavioral Activation treatment|Behavioral Activation (BA)- modified to be delivered in 6-8, 60 minute sessions in a primary care setting. BA has also been modified to better address PTSD concerns
15989|NCT00810901|Behavioral|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
15990|NCT00810901|Behavioral|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
15991|NCT00810914|Drug|bupivicaine epidural|bupivicaine continuous epidural infusion
15992|NCT00810914|Drug|bupivicaine epidural infusion patient epidural|bupivicaine
15993|NCT00006591|Drug|Ritonavir|
15994|NCT00810914|Drug|bupivicaine|patient controlled anesthesia only
15995|NCT00810927|Procedure|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
15996|NCT00810927|Procedure|Laser Doppler flowmetry|Measurement of choroidal blood flow
15997|NCT00804180|Behavioral|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
15998|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension|topical suspension
16307|NCT00799812|Other|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
16308|NCT00799812|Other|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
16309|NCT00799825|Biological|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
16310|NCT00799838|Drug|Ketoprofen|Formulation: oral solution 20mg/mL
Route of administration: oral
Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d
16311|NCT00006436|Biological|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
16312|NCT00799838|Drug|Placebo (for Ketoprofen)|Formulation: oral solution
Route of administration: oral
Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d
16313|NCT00799838|Drug|Amoxicillin|Formulation: suspension 125mg/5 mL
Route of administration: oral
Dose regimen: 20-40mg/Kg/day administered t.i.d
16314|NCT00799851|Device|Variceal band ligation|
16315|NCT00799851|Drug|cyanoacrylate injection|cyanoacrylate injection
18347|NCT00823654|Other|Blood draw and questionnaires|Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent
↓ Register patients at Memorial Sloan-Kettering Cancer Center
↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)
↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires
18348|NCT00823667|Other|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
18349|NCT00823667|Other|medical chart review|Occurs at 1 year post study enrollment
18350|NCT00823667|Other|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
18666|NCT00826566|Dietary Supplement|Caffeine|2 times 250 mg caffeine per day
18667|NCT00008125|Drug|carboplatin|
18668|NCT00828971|Drug|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
18669|NCT00828984|Drug|macrogol 3350-based oral osmotic laxative|Given PO
18670|NCT00828984|Other|Placebo|Given PO
18671|NCT00828984|Other|Laboratory Biomarker Analysis|Correlative studies
18672|NCT00828997|Biological|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
18673|NCT00829010|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
18674|NCT00829010|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
18675|NCT00829010|Biological|measles|Intramuscular injection, 2 doses
18676|NCT00829010|Biological|Rotarix|Oral, 2 doses
18677|NCT00829010|Biological|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
18678|NCT00008125|Drug|docetaxel|
18679|NCT00829023|Other|chlorhexidine gluconate and isopropyl alcohol, iodophor and isopropyl alcohol, povidone-iodine scrub and paint|surgical skin preparation solutions
18680|NCT00829036|Device|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
18681|NCT00829049|Drug|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
22257|NCT00841178|Procedure|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
22258|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
22259|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
22260|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
22261|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
22262|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
22263|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
22264|NCT00832780|Radiation|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
22265|NCT00832806|Behavioral|Extended IVR (integrated voice response technology)|See detailed description
22266|NCT00008281|Drug|leucovorin calcium|
22267|NCT00832806|Drug|Varenicline (Champix)|See detailed description
22268|NCT00832806|Behavioral|IVR treatment|See detailed description
22269|NCT00832819|Drug|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
22270|NCT00832819|Drug|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
22271|NCT00832819|Drug|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
22272|NCT00832819|Drug|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
22273|NCT00832832|Other|Eyelid closure|Eyelid will be closed after eye drop instillation
22776|NCT00839345|Drug|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
22777|NCT00839358|Drug|albumin|albumine 40 g every 15 days
22778|NCT00839358|Drug|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
22779|NCT00839358|Drug|Placebo|saline solution
22780|NCT00839371|Drug|Propofol|i.v. propofol titration until adequate depth of sedation
22781|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
22782|NCT00000771|Drug|Paromomycin sulfate|
22783|NCT00008203|Biological|aldesleukin|
21819|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
21820|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
21821|NCT00842712|Drug|Chemotherapy|Cis 80 mg/m^2 intravenous infusion on Day 1 + Vin 25 mg/m^2 or Cis 75 mg/m^2 intravenous infusion on Day 1 + Gem 1250 mg/m^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
21822|NCT00842738|Behavioral|Mindfulness meditation|Mindfulness meditation
21823|NCT00842738|Other|No meditation|Health care services as usual
21824|NCT00009841|Biological|growth factor antagonist therapy|
21825|NCT00842738|Other|Controls|No intervention
21826|NCT00842751|Drug|First Intervention (7 days)|Acyline 300mcg/kg subcutaneous (days 1, 15 & 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
21827|NCT00842751|Other|First Washout (7 days)|Washout of 7 days between each of the 3 treatment arms
21828|NCT00842751|Drug|Second Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
22183|NCT00832637|Drug|Gemcitabine|1000 mg/m2 on Days 1, 15 every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine HCl (expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
22184|NCT00832650|Drug|fesoterodine fumarate|8 mg OD for 14 days
22185|NCT00832650|Drug|placebo|OD for 14 days
22186|NCT00832650|Drug|solifenacin|10 mg OD for 14 days
22187|NCT00832663|Drug|NSAID|Effect of NSAID ingestion on muscle regeneration
22188|NCT00832663|Drug|placebo|receive placebo
22189|NCT00832689|Drug|Irinotecan and Gemcitabine|
22190|NCT00008281|Drug|fluorouracil|
22191|NCT00832702|Procedure|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
22192|NCT00832715|Procedure|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
22193|NCT00832728|Other|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
22194|NCT00832728|Device|ELAD®|ELAD therapy
22195|NCT00832754|Device|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
22539|NCT00841295|Drug|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
22540|NCT00841308|Other|Decision to start and titrate drug treatment based only on home blood pressure monitoring|Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure ("Usual care" arm) versus based on home blood pressure monitoring only ("Home blood pressure monitoring" arm).
22541|NCT00841321|Drug|Ginkgo biloba|120 mg orally twice a day for 12 weeks
22542|NCT00841321|Drug|Placebo|One capsule orally twice a day for 12 weeks
22543|NCT00841334|Behavioral|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
22544|NCT00009763|Drug|cyclosporine|
21606|NCT00847522|Drug|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
21607|NCT00847535|Biological|autologous muscle cell injection|Injection of autologous muscle cells
21608|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
21609|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
21610|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
21611|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
21612|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
21613|NCT00010361|Drug|mycophenolate mofetil|
21614|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
21615|NCT00849680|Biological|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
21616|NCT00849693|Drug|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
21617|NCT00849693|Drug|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
21618|NCT00849693|Drug|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
21619|NCT00849693|Drug|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
21620|NCT00849706|Other|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
21903|NCT00832195|Device|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
21904|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
21905|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
22612|NCT00841555|Radiation|radiation therapy|Radiation therapy will be started up to 8 weeks after surgery/biopsy. Patients will receive focal radiation therapy to an area including the Gross Target Volume (GTV) defined as the contrast enhancing area and/or the surgical cavity plus the surrounding edema + 2 cm margin. GTV will be determined with a contrast enhanced pre RT MRI/CT scan of the brain.
22613|NCT00841555|Radiation|stereotactic radiotherapy|Patients will receive intensity modulated conformal stereotactic radiotherapy at a dose of 3.5 Gy/fraction over 3 consecutive weeks in 5 fractions/ week, using the Peacock system with the Talon immobilization/localization device. Patients will be seen by one of the radiation oncology co-investigators prior to talon anchor placement.
22614|NCT00841568|Drug|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
22615|NCT00841581|Drug|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
22616|NCT00841594|Drug|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
22617|NCT00841594|Drug|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
22618|NCT00009763|Radiation|yttrium Y 90 monoclonal antibody m170|
22619|NCT00841607|Procedure|pancreaticojejunostomy vs pancreaticogastrostomy|
22620|NCT00841620|Procedure|Haemorrhoidectomy a.m. Milligan|Surgery
22621|NCT00841620|Procedure|Stapled anopexy|Surgery
22622|NCT00841633|Drug|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
22623|NCT00841646|Biological|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
22624|NCT00841659|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
22625|NCT00841659|Drug|Paxil®|40 mg Film-Coated Tablet
22626|NCT00841672|Drug|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
21829|NCT00842751|Drug|Third Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
21830|NCT00842751|Other|Second wash-out period|Washout of 7 days between each of the 3 treatment arms
21831|NCT00842764|Device|eyelid|eyelid
21832|NCT00842777|Behavioral|Parent manualized group treatment|Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.
Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.
Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment
21833|NCT00837655|Drug|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of <1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of <1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
21834|NCT00837655|Drug|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration <1.8 mmol/l.
21835|NCT00837707|Drug|aripiprazole|Flexible dose: 5-30 mg/day
22439|NCT00841711|Behavioral|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
22440|NCT00841711|Drug|Buprenorphine|All participants that have a history of opiate dependency and need treatment with opiate substitution therapy will be offered Buprenorphine as an option for their substance use. For those who need additional or more structured treatment will be referred to methadone maintenance program.
22441|NCT00841711|Behavioral|Money Management|All participants will be offered money management as a component for further assistance to this population who need financial management services in order to stabilize them and help with the transition back into the community upon release from incarceration.
22442|NCT00841724|Drug|Fludarabine, Busulfan, Thymoglobuline|
22443|NCT00009776|Drug|cyclosporine|
22444|NCT00841737|Other|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
22445|NCT00841737|Other|Control Group|In the control group the depression is treated as usual with the conventional treatment.
22545|NCT00841334|Behavioral|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
22546|NCT00833300|Drug|Olanzapine|2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Discontinue current drug therapy and select one of:
Quetiapine up to 100 mg/day
Risperidone up to 6 mg/day
Loxapine up to 50 mg/day
Methotrimeprazine up to 75 mg/day
Reassess in 24 hours.
Delirium absent - Continue for 24 hours then discontinue.
Delirium present - Treatment at discretion of attending physician.
22547|NCT00008294|Drug|leucovorin calcium|
22548|NCT00833313|Other|Atrial biopsy|Biopsy of right atrial free wall
22549|NCT00833326|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
22550|NCT00833326|Drug|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
22551|NCT00833326|Drug|Prophylactic growth factors; subcutaneous|standard of care
22552|NCT00833339|Drug|mifepristone|600 mg/day x 1 week
22553|NCT00833339|Drug|placebo|placebo
22554|NCT00833352|Device|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
22555|NCT00833365|Drug|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
22556|NCT00833365|Drug|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
22557|NCT00833378|Drug|Eltrombopag|Eltrombopag 100 mg single oral dose
22558|NCT00008294|Drug|oxaliplatin|
22559|NCT00833378|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
21603|NCT00847496|Device|AWBAT|One-time application of dressing over partial-thickness burns
21604|NCT00847496|Device|Biobrane|One-time application over partial-thickness burns
21605|NCT00847509|Drug|[F-18]FLT|The individual doses of [F-18]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
21906|NCT00832221|Drug|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
21907|NCT00834886|Other|Bright light|Bright light therapy 10.000 lux by Miljølys AS
21908|NCT00834886|Other|Placebo red light|Red light 400 lux as placebo light
21909|NCT00834886|Other|Placebo capsule|Capsules containing 3 mng rice flour, once every night
21910|NCT00834899|Drug|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
21911|NCT00834899|Drug|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
21912|NCT00834912|Drug|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
21913|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
21914|NCT00008385|Other|placebo|Given orally
21915|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
21916|NCT00834925|Drug|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
21917|NCT00834938|Other|No intervention|No intervention
21918|NCT00834951|Radiation|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
21919|NCT00834964|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
21920|NCT00834964|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
21921|NCT00834977|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
21922|NCT00834977|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
21923|NCT00834990|Drug|divalproex sodium|delayed-release 500 mg tablet
22196|NCT00832754|Other|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
22627|NCT00833482|Drug|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
21685|NCT00847574|Behavioral|Moderate-fat|35% of calories from fat
21686|NCT00847574|Behavioral|Lower-fat|20% of calories from fat
21687|NCT00847587|Drug|Etonogestrel contraceptive implant|Implant insertion postpartum prior to hospital discharge
21688|NCT00847587|Drug|Etonogestrel contraceptive implant|Standard insertion at 4-8 weeks postpartum
21689|NCT00847600|Dietary Supplement|Pregnenolone|50 mg, caps.
21690|NCT00847600|Dietary Supplement|Placebo|caps
21691|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
21692|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
21693|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
21694|NCT00010166|Drug|gemcitabine hydrochloride|
21695|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
21696|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
21697|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
21698|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
21699|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
21700|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
21701|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
22446|NCT00841750|Procedure|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
22447|NCT00841750|Procedure|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
22448|NCT00841763|Biological|Placebo|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle.
22449|NCT00841763|Biological|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
22450|NCT00833118|Procedure|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
22451|NCT00833131|Radiation|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
22452|NCT00833131|Radiation|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
22453|NCT00833157|Drug|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg * 3 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks.
22454|NCT00833157|Drug|ibuprofen|Subjects are administered 600 mg * 2 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks
22472|NCT00835861|Drug|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values <90 and one hour post prandial values <130.
22473|NCT00835874|Drug|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
22474|NCT00835887|Dietary Supplement|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
22475|NCT00835900|Drug|varenicline|variable dosing schedule
22476|NCT00835900|Drug|placebo|placebo
22477|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
22478|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
22479|NCT00835939|Drug|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
18289|NCT00828321|Drug|Ramipril 10 mg capsule|1 x 10 mg
18290|NCT00828321|Drug|Altace® 10 mg capsule|1 x 10 mg
18607|NCT00821678|Other|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
18608|NCT00821691|Drug|Amantadin|Amantadin caps
18609|NCT00821691|Drug|Placebo|Placebo caps
18610|NCT00821717|Drug|Ferinject ® (Ferric carboxymaltose)|Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.
After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
18611|NCT00821717|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
18612|NCT00821743|Device|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
18613|NCT00821756|Behavioral|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
18614|NCT00000764|Drug|Isotretinoin|
18615|NCT00007813|Drug|cyclophosphamide|
18616|NCT00821782|Drug|Levofloxacin; Azithromycin|
18617|NCT00821795|Drug|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
18618|NCT00821795|Drug|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
18619|NCT00823875|Drug|Cilostazol + Probucol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
18620|NCT00823875|Drug|control group|routine treatment
22197|NCT00832767|Procedure|SILS™ port laparoscopic cholecystectomy|This interventional arm will have a single incision laparoscopic cholecystectomy procedure.
22198|NCT00832767|Procedure|Four Port Laparoscopic Cholecystectomy|This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
22199|NCT00835367|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
22200|NCT00835380|Biological|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
22201|NCT00835393|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
22202|NCT00835393|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
22203|NCT00835406|Drug|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
22204|NCT00835406|Drug|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
22205|NCT00835419|Drug|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
22206|NCT00835432|Device|Ossix|Test group
22207|NCT00835432|Device|Biogide|controls
22208|NCT00008437|Device|high-intensity focused ultrasound ablation|
22209|NCT00835458|Procedure|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
22210|NCT00835471|Drug|erlotinib plus docetaxel or pemetrexed|non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.
squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.
22211|NCT00835471|Drug|erlotinib|erlotinib 150 mg/day continuously until disease progression
22212|NCT00835484|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
22213|NCT00835484|Drug|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
22214|NCT00835497|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
22215|NCT00835497|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
18682|NCT00829049|Drug|Adapalene|1 pea-size amount, QD x 16 weeks
18683|NCT00829062|Device|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
18684|NCT00829075|Drug|r-FSH|
18685|NCT00829075|Drug|HP-hMG|
18686|NCT00829075|Drug|r-FSH plus HP-hMG|
18687|NCT00829088|Drug|AZD2066|1 dose oral solution
18995|NCT00822263|Drug|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
18996|NCT00822263|Drug|Placebo|Control for study
18997|NCT00822302|Drug|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
18998|NCT00822302|Drug|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
18999|NCT00822315|Drug|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
19000|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
19001|NCT00817583|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
19002|NCT00817596|Device|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
19003|NCT00817609|Drug|Angongniuhuang Pill|7 days of Angongniuhuang Pill
19004|NCT00817609|Drug|placebo|7 days of placebo
19005|NCT00007085|Device|Tomography, X-ray Computed|
19006|NCT00817622|Dietary Supplement|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
19007|NCT00817635|Drug|LCI699|
19008|NCT00817635|Drug|Placebo|
22480|NCT00835939|Drug|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
22481|NCT00835939|Procedure|sclerotherapy|
22482|NCT00008463|Drug|Ribavirin|
22483|NCT00835952|Drug|ATX-101|ATX-101 single doses
22484|NCT00835965|Drug|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
22485|NCT00835965|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
22486|NCT00835965|Drug|Placebo Dexamethasone|
22487|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
22488|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
22489|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label)
22490|NCT00835991|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
22491|NCT00835991|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
22492|NCT00836004|Drug|Clindamycin 300 mg capsule|1 x 300 mg
22493|NCT00008463|Drug|Interferon alfa-2a|
22494|NCT00836004|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
22784|NCT00830999|Behavioral|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
22785|NCT00830999|Behavioral|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
22786|NCT00830999|Behavioral|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
22787|NCT00830999|Behavioral|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
22788|NCT00830999|Behavioral|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
18621|NCT00007904|Radiation|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
18622|NCT00823888|Device|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
18623|NCT00823901|Drug|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
18937|NCT00826930|Drug|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
18938|NCT00826943|Drug|Cetirizine|Cetirizine 10 mg tab daily x 7 days
18939|NCT00826943|Drug|Levocetirizine|5 mg tab daily x 7 days
18940|NCT00008021|Procedure|peripheral blood stem cell transplantation|
18941|NCT00826943|Drug|Placebo|Placebo tablet daily x 7 days
18942|NCT00826956|Procedure|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
18943|NCT00826969|Drug|Ciclesonide|320µg Ciclesonide versus Placebo
18944|NCT00826969|Drug|Placebo|Placebo
18945|NCT00826995|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
18946|NCT00827008|Drug|Neramexane mesylate|Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
18947|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
18948|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
18949|NCT00827034|Drug|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
18950|NCT00827034|Drug|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
18951|NCT00008021|Radiation|indium In 111 monoclonal antibody Lym-1|
18952|NCT00827034|Drug|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
22560|NCT00833378|Drug|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
22561|NCT00833391|Drug|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
22562|NCT00833404|Drug|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
22563|NCT00833417|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
22564|NCT00833443|Drug|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
22565|NCT00833469|Drug|Escitalopram|Once daily by mouth
22566|NCT00833482|Drug|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
22567|NCT00836030|Other|No treatment given|No treatment given
22568|NCT00836043|Drug|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
22569|NCT00836056|Drug|Clindamycin 300 mg capsule|1 x 300 mg
22570|NCT00836056|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
22571|NCT00836069|Drug|PD 0332334|Experimental study drug for generalized anxiety disorder, oral tablet, twice daily
22572|NCT00836069|Drug|Paroxetine|FDA Approved medication for generalized anxiety disorder, oral tablet
22573|NCT00836069|Other|Placebo|inactive substance, oral tablet, once per day
22574|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
22575|NCT00008463|Drug|Peginterferon alfa-2a|
22576|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
22577|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
19009|NCT00817635|Drug|Eplerenone|
19010|NCT00817648|Drug|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
19011|NCT00817648|Drug|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
19012|NCT00817661|Dietary Supplement|Vitamin A|10000 IU Vitamin A or placebo per week
19013|NCT00817661|Dietary Supplement|Placebo|10000 IU Vitamin A or placebo per week
19014|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
19015|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
19016|NCT00007163|Drug|J695|
19017|NCT00817700|Other|Sleep restriction|Sleep restriction.
18015|NCT00830310|Behavioral|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
18016|NCT00830310|Behavioral|Improved communication/rapport with provider module|Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of "1" or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance "appearing medicated" or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module.
18017|NCT00830310|Behavioral|Medication routines management module|Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of "1" or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI.
18018|NCT00830323|Drug|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
18019|NCT00830323|Drug|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
18020|NCT00830323|Drug|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
18021|NCT00830336|Drug|Azithromycin|Oral Suspension
18022|NCT00830336|Drug|Zithromax®|Oral Suspension
18023|NCT00000770|Drug|Didanosine|
18024|NCT00008177|Drug|cyclosporine|Given orally or IV
18025|NCT00830349|Drug|Risperidone|1 mg Tablet
22789|NCT00831012|Biological|rDEN3delta30/31‐7164|A live attenuated, recombinant DEN3 candidate vaccine virus
22790|NCT00831025|Biological|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
22791|NCT00831025|Biological|Placebo|Placebo for subcutaneous monthly administration
22792|NCT00831038|Procedure|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
22793|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
22794|NCT00008203|Biological|recombinant interferon gamma|
22795|NCT00831051|Drug|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
22796|NCT00831051|Drug|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
22797|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
22798|NCT00831051|Drug|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
22799|NCT00831051|Drug|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
22800|NCT00831064|Procedure|colonoscopy bowel prep (PEG, bisacodyl, NaP, PSMC and Mg-citrate)|colonoscopy bowel prep
22801|NCT00831077|Drug|ORM-14540|i.v.
22802|NCT00831077|Drug|ORM-12741|i.v.
22803|NCT00831103|Drug|EPB-348|Treated over seven days
22804|NCT00831103|Drug|Valacyclovir|Treated over seven days
22805|NCT00008203|Drug|carboplatin|
21836|NCT00008866|Drug|Hydroxyurea|
21837|NCT00837733|Procedure|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
21838|NCT00837733|Procedure|Endometrial Biopsy|Biopsy catheter
21839|NCT00837746|Drug|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
21840|NCT00837759|Drug|Insulin|
21841|NCT00837759|Drug|Lansoprazole|
18953|NCT00827047|Procedure|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
18954|NCT00827047|Procedure|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
17962|NCT00823004|Drug|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
17963|NCT00823004|Drug|GnRH agonist (buserelin)|50 µg SC twice daily
17964|NCT00823004|Drug|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
17965|NCT00823004|Drug|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
17966|NCT00823017|Other|Patient-preferred music|Music of patients' preference
17967|NCT00823017|Other|Relaxation Music|Relaxation music compiled from results of first three stages of study
17968|NCT00823017|Other|Standard Care Environment|Control, no interventions
17969|NCT00823030|Procedure|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
17970|NCT00825136|Behavioral|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
17971|NCT00825149|Drug|CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone)|As prescribed, for 8x3week cycles
17972|NCT00825149|Drug|FC(fludarabine,cyclophosphamide)|As prescribed, for 6x4week cycles
17973|NCT00825149|Drug|RO5072759|1000 mg iv on days 1 and 8 of first cycle, and on day 1 of each subsequent cycle
17974|NCT00825149|Drug|RO5072759|1600mg iv on days 1 and 8 of first cycle, followed by 800mg iv on day 1 of each subsequent cycle
17975|NCT00825149|Drug|RO5072759|400mg iv on days 1 and 8 of first cycle, and on day 1 of each subsequent cycle
17976|NCT00007982|Procedure|peripheral blood stem cell transplantation|
22578|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
21621|NCT00849719|Drug|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
21622|NCT00849719|Drug|PCA MO only|When visual analog scale [VAS] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
21623|NCT00849732|Biological|V520|Intentionally Blank
21624|NCT00010374|Device|intramuscular diaphragm electrodes|Conditioning of the diaphragm
21625|NCT00849732|Biological|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^9 vp/d given at Day 1, Week 4, and Week 26
21626|NCT00849732|Biological|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^10 vp/d given at Day 1, Week 4, and Week 26
21627|NCT00849732|Biological|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
21628|NCT00842439|Dietary Supplement|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
21629|NCT00842452|Drug|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
21630|NCT00842452|Other|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
21631|NCT00842465|Biological|blood collection for hormonal status analysis|for hormonal status analysis
21632|NCT00842465|Procedure|breast Biopsy or surgery|breast Biopsy or surgery
21633|NCT00009815|Drug|tegafur-uracil|
21634|NCT00842465|Genetic|blood collection|blood collection for prlR gene sequencing
21635|NCT00842465|Other|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
21636|NCT00842478|Procedure|Toothbrushing|
18026|NCT00830349|Drug|Risperidone|1 mg Tablets
18027|NCT00830362|Drug|Propranolol|40 mg administered once
18028|NCT00830362|Drug|Placebo|administered once
18029|NCT00830375|Drug|Memantine|10-30mg, by mouth, daily
18030|NCT00830388|Drug|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
18031|NCT00830401|Procedure|Treatment of predefined abnormality by hysteroscopic surgery|Polyp resection with Hysteroscopic scissors or Versapoint
Resection of myoma with Resectoscope Storz or Versapoint
Septum resection with Resectoscope Storz or Versapoint
Resection of adhesions with Hysteroscopic scissors or Versapoint
18032|NCT00830401|Drug|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
18033|NCT00823030|Drug|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
18034|NCT00007878|Other|pharmacological study|Correlative studies
18035|NCT00823030|Other|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
18351|NCT00825786|Drug|Mepivacaine and ropivacaine|One syringe will contain mepivacaine (15 ml) and the other will contain ropivacaine (15 ml).
18352|NCT00825812|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
18353|NCT00825812|Drug|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
18354|NCT00825825|Drug|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
18355|NCT00825825|Drug|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
18356|NCT00825825|Drug|Placebo|Two weeks of placebo taken orally.
18357|NCT00825838|Dietary Supplement|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
18358|NCT00825838|Dietary Supplement|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
18359|NCT00007995|Procedure|peripheral blood stem cell transplantation|
21842|NCT00837759|Drug|Sitagliptin|
21843|NCT00837759|Biological|Diamyd|
21844|NCT00837759|Drug|GAD65 (Diamyd)|
21845|NCT00837772|Device|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
21846|NCT00837772|Device|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
21847|NCT00008866|Drug|Didanosine|
21848|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally three times a day
21849|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally twice a day
21850|NCT00837798|Device|CRM Device|Pacemaker, ICD, or CRT device
21851|NCT00837811|Biological|LY2127399|60 mg (with potential for dose escalation to 120 mg) subcutaneously every 4 weeks for 48 weeks
21852|NCT00837824|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
21853|NCT00837824|Biological|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
21854|NCT00837837|Drug|Chlorpheniramine|
21855|NCT00837850|Device|Bone cement 1|Bone cement SmartSet® HV
21856|NCT00837850|Device|Bone cement 2|Bone cement Palacos R
21857|NCT00837863|Drug|Somatropin|ALTU-238 0.3 mg/kg daily
21858|NCT00009009|Drug|immunosuppressive regimen designed to complement HAART|
21859|NCT00837863|Drug|Somatropin|ALTU-238 0.6 mg/kg daily
21860|NCT00837863|Drug|Somatropin|ALTU-238 0.9 mg/kg daily
21861|NCT00840385|Drug|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
22455|NCT00833157|Drug|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (*3 weekly) with both legs for 12 weeks
22456|NCT00833183|Drug|MAL|80 mg/g cream one administration with incubation for 90 minutes
17977|NCT00825149|Drug|RO5072759|Patients with complete response or partial response after completion of 1st line RO5072759 + chemotherapy may receive mainentance treatment with RO5072759 every 3 month for 2 years or until disease progression, whichever comes first
17978|NCT00825149|Drug|bendamustine|As prescribed, for 6x4 weekly cycles
17979|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
17980|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
17981|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
17982|NCT00825175|Behavioral|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
18291|NCT00828347|Drug|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
18292|NCT00828347|Drug|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
18293|NCT00828373|Drug|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
18294|NCT00828373|Drug|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
18295|NCT00828386|Procedure|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
18296|NCT00008086|Dietary Supplement|calcitriol|
18297|NCT00828399|Dietary Supplement|Glutamine|Oral glutamine 30g/day
18298|NCT00828399|Dietary Supplement|Whole protein|Oral whole protein 30 g/day
18299|NCT00828412|Device|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
18300|NCT00828412|Drug|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
18301|NCT00828438|Drug|Lorcaserin 10mg|
18302|NCT00828451|Biological|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
21637|NCT00842491|Drug|endostar, cisplatin, capecitabine|Product 1: endostar
Dosing schedule: 15mg daily dose, d1-14
Mode of administration: intravenously
21638|NCT00842491|Drug|capecitabine|Product 2: capecitabine
Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Mode of administration: orally
21639|NCT00842491|Drug|cisplatin|Product 3: cisplatin
Dosing schedule: 80mg/m2, day 1 of every 3 weeks
Mode of administration: intravenously
21924|NCT00834990|Drug|Depakote®|delayed-release 500 mg tablet
21925|NCT00008398|Biological|sargramostim|
21926|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
21927|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
21928|NCT00835016|Behavioral|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
21929|NCT00835029|Drug|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
21930|NCT00837863|Drug|Somatropin|Nutropin AQ 0.043 mg/kg daily
21931|NCT00837876|Drug|Sorafenib|400 mg taken by mouth 1 time per day.
21932|NCT00837876|Drug|Erlotinb|150 mg taken by mouth 1 time per day.
21933|NCT00837889|Drug|diuretics, inotropica|
21934|NCT00837902|Drug|Atenolol (β-blocker)|25 mg tablet
21935|NCT00837915|Drug|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
21936|NCT00837928|Drug|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
21937|NCT00837928|Other|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
21938|NCT00009048|Drug|EMD 128130|
21939|NCT00837928|Procedure|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
21940|NCT00837928|Radiation|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
18360|NCT00825851|Drug|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
18361|NCT00825851|Drug|Placebo patch|
18362|NCT00825851|Behavioral|Smoking cessation|
18363|NCT00825851|Behavioral|Continuous smoking|subjects smoke 20 cigarettes per day
18364|NCT00825864|Drug|diclofenac drops|one drop 4 times a day for 3 months
18365|NCT00825864|Drug|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
18366|NCT00825903|Behavioral|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
18367|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
18368|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
18369|NCT00825916|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
18370|NCT00008008|Biological|filgrastim|
18688|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
18689|NCT00008125|Drug|gemcitabine hydrochloride|
18690|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
18691|NCT00829127|Drug|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
18692|NCT00829127|Drug|Placebo|Oral suspension
18693|NCT00821808|Device|Compression Device|The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:
Immediately following device application
1 hour
4 hours
8 hours
18694|NCT00821808|Device|Profore®|Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:
Immediately following device application
1 hour
4 hours
8 hours
22457|NCT00833209|Procedure|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
22458|NCT00833209|Procedure|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
22459|NCT00833209|Procedure|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
22460|NCT00008294|Drug|fluorouracil|
22461|NCT00833235|Other|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
22462|NCT00833248|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
22463|NCT00833248|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
22464|NCT00833248|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
22465|NCT00833261|Drug|cetuximab|cetuximab
22466|NCT00833261|Drug|cisplatin|cisplatin
22467|NCT00833261|Radiation|intensity-modulated radiation therapy|IMRT
22468|NCT00833274|Behavioral|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
22469|NCT00833300|Drug|Haloperidol|2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Discontinue current drug therapy and select one of:
Quetiapine up to 100 mg/day
Risperidone up to 6 mg/day
Loxapine up to 50 mg/day
Methotrimeprazine up to 75 mg/day
Reassess in 24 hours.
Delirium absent - Continue for 24 hours then discontinue.
Delirium present - Treatment at discretion of attending physician.
22470|NCT00835861|Drug|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
22471|NCT00008450|Other|laboratory biomarker analysis|Correlative studies
22495|NCT00836017|Other|No Intervention|No intervention was administered as part of the study.
18303|NCT00828464|Drug|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
18304|NCT00830414|Drug|medroxyprogesterone acetate|IM Injection
18305|NCT00830414|Drug|medroxyprogesterone acetate|IM injection
18306|NCT00008177|Drug|mycophenolate mofetil|Given orally or IV
18307|NCT00830427|Drug|PF-00610355|100 mcg, QD, dry powder inhaler
18308|NCT00830427|Drug|PF - 00610355|600 mcg, QD, dry powder inhaler
18309|NCT00830427|Other|Placebo|QD, dry powder inhaler
18310|NCT00830427|Drug|PF - 00610355|300 mcg, QD, dry powder inhaler
18311|NCT00830440|Device|GI Sleeve™ (EndoBarrier)|Monthly visits
18624|NCT00823901|Drug|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
18625|NCT00823940|Drug|Glucagon|0.5mg IV bolus
18626|NCT00823940|Drug|GSK1362885|5 - 100mg of GSK1362885 or placebo
18627|NCT00823940|Drug|GSK1362885|100 - 600mg or placebo
18628|NCT00823940|Drug|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
18629|NCT00823953|Drug|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
18630|NCT00823953|Other|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
18631|NCT00823966|Drug|Rescriptor|RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
18632|NCT00007917|Drug|alvocidib|
18633|NCT00823979|Drug|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
18634|NCT00823979|Drug|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
21941|NCT00837941|Drug|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
21942|NCT00837941|Drug|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
21943|NCT00837941|Drug|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
22216|NCT00835510|Drug|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
22217|NCT00835510|Drug|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
22218|NCT00835510|Drug|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
22219|NCT00008450|Drug|cyclosporine|Given PO or IV
22220|NCT00835536|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
22221|NCT00835536|Drug|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
22222|NCT00835549|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
22223|NCT00835549|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
22224|NCT00838292|Dietary Supplement|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
22225|NCT00000776|Drug|Flucytosine|
22226|NCT00009061|Drug|GW433908|
22227|NCT00838292|Other|nutrition counseling|
22228|NCT00838305|Drug|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
22229|NCT00838305|Drug|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
22230|NCT00838318|Behavioral|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
22231|NCT00838331|Biological|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
18695|NCT00821821|Drug|MCI-186|Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion
Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion
18696|NCT00821821|Drug|Placebo|Cohort1:circa 1000mg / 72-hour infusion matching placebo
Cohort2:circa 2000mg / 72-hour infusion matching placebo
18697|NCT00821834|Drug|clopidogrel (SR25990)|Form: tablets
Route: oral
18698|NCT00821834|Drug|ticlopidine|Form: tablets
Route: oral
18699|NCT00821834|Drug|Placebo|Form: tablets
Route: oral
18700|NCT00007813|Drug|etoposide|
18701|NCT00821847|Other|DEXA scan|DEXA scan
18702|NCT00821860|Other|talc|Talc pleurodesis
18703|NCT00821860|Procedure|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
18704|NCT00821860|Procedure|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
18705|NCT00821873|Other|CR Plug|CR Plug will be placed in the harvest site
18706|NCT00821886|Drug|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
18707|NCT00821886|Drug|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
18708|NCT00821886|Drug|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
19018|NCT00817713|Drug|Praziquantel, Ivermectin, Albendazole|Standard HIV care plus triple anthelminthic treatment
Praziquantel 2400mg single dose
Ivermectin 12 mg, single dose
Albendazole 400mg, 2 doses in 1 day
All drugs given at baseline, after 6 months and after 12 months.
19019|NCT00817739|Drug|Leuprorelin|Leuprorelin injection
19020|NCT00817739|Drug|Flutamide|Flutamide tablets
19021|NCT00817752|Dietary Supplement|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
19022|NCT00817765|Drug|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
19023|NCT00817765|Drug|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
22496|NCT00838799|Drug|pregabalin|100 mg, TID, capsules, 14 weeks.
22497|NCT00838799|Drug|placebo|TID, capsules, 14 weeks.
22498|NCT00838812|Drug|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
22499|NCT00838825|Other|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
22500|NCT00009217|Drug|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
22501|NCT00838838|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 18yrs in medical practices fulfilling all criteria for documentation.
22502|NCT00838851|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
22503|NCT00838864|Drug|ceftrioxone|500 mg iv q12h for 3 days
22504|NCT00838864|Drug|ceftrioxone|500 mg q12h for 7 days
22505|NCT00838877|Drug|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
22506|NCT00838877|Drug|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
22507|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
22508|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
22509|NCT00838903|Biological|albiglutide|albiglutide
22510|NCT00838903|Drug|sitagliptin|sitagliptin
22511|NCT00009217|Drug|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
22512|NCT00838903|Drug|glimepiride|Glimepiride
22513|NCT00838903|Drug|metformin|Metformin
22514|NCT00838903|Biological|placebo albiglutide|placebo to match albiglutide
22515|NCT00838903|Drug|placebo sitagliptin|placebo to match sitagliptin
22516|NCT00838903|Drug|placebo glimepiride|placebo to match glimepiride
18635|NCT00823979|Drug|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
18636|NCT00823992|Drug|placebo|sc once weekly
18637|NCT00823992|Drug|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
18638|NCT00824005|Biological|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
18639|NCT00824005|Biological|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
18640|NCT00824044|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
18641|NCT00824044|Drug|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
18642|NCT00826397|Procedure|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
18643|NCT00826397|Procedure|sham acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
18955|NCT00829400|Behavioral|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
18956|NCT00829413|Drug|SonoVue®|SonoVue (2.4 mL)
18957|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
18958|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
18959|NCT00829439|Drug|Levodopa/Carbidopa (4:1)|Dosages are based on levodopa.
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
18960|NCT00829452|Drug|Ramipril 10 mg capsule|1 x 10 mg
18961|NCT00829452|Drug|Altace® 10 mg capsule|1 x 10 mg
18962|NCT00829465|Drug|Licartin|Licartin
18963|NCT00829465|Procedure|Transcatheter arterial chemoembolization|TACE
18964|NCT00008151|Drug|gemtuzumab ozogamicin|
22232|NCT00838331|Biological|Aged blood|In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (< 7 days) and impaired (> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly "repairing" NO bioavailability in previous aims, some patients may also receive impaired and repaired (> 28 days; washed or rejuvenated) RBC transfusions.
22233|NCT00838344|Other|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
22579|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
22580|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
22581|NCT00836095|Device|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
22582|NCT00836095|Device|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
22583|NCT00836108|Behavioral|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
22584|NCT00836121|Procedure|right thoracotomy|complete surgical resection
22585|NCT00836134|Procedure|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
22586|NCT00008476|Drug|Capsaicin|
22587|NCT00836134|Procedure|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
22588|NCT00836147|Drug|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
22589|NCT00836147|Drug|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
22590|NCT00838942|Behavioral|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
22591|NCT00009230|Drug|Celecoxib|
19024|NCT00817765|Drug|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
19025|NCT00817778|Drug|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
19026|NCT00817778|Drug|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
19027|NCT00007189|Drug|Naproxen Sodium (Aleve)|
19028|NCT00820001|Behavioral|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
19029|NCT00820001|Behavioral|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
19030|NCT00820001|Other|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
19031|NCT00820001|Other|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
19032|NCT00820014|Drug|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
19033|NCT00820027|Drug|Etoricoxib 90 mg|One 90 mg tablet once daily
19034|NCT00820027|Drug|Etoricoxib 120 mg|Two 60 mg tablets once daily
18036|NCT00823043|Drug|timolol hemihydrate|timolol hemihydrate 0.5% solution
18037|NCT00823043|Drug|timolol maleate|timolol maleate in sorbate
18038|NCT00823056|Dietary Supplement|probiotics|placebo
18039|NCT00823056|Dietary Supplement|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
18040|NCT00823069|Device|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
22517|NCT00838916|Biological|albiglutide|albiglutide weekly injection
21566|NCT00844896|Behavioral|DEF-only|The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.
In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise.
21567|NCT00844896|Behavioral|DEF + COPE|All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.
For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks.
21568|NCT00844909|Drug|CNTO 136|
21569|NCT00844922|Drug|SCH 900636|Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the "usual treatment" for psychotic major depression.
21570|NCT00009984|Drug|fludarabine phosphate|Given IV
21571|NCT00844922|Drug|Placebo|Placebo
21572|NCT00844961|Behavioral|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
21573|NCT00844974|Other|Prevalence|Mood and cognitive assessments
21574|NCT00845000|Drug|Treatment A|One dose of 10 mg Preladenant, Levodopa infusion (IV), and 25-mg oral Carbidopa administered three times daily (TID)
21575|NCT00845000|Drug|Treatment B|One dose of 100 mg Preladenant, Levodopa infusion (IV), and 25-mg oral Carbidopa administered three times daily (TID)
21576|NCT00845000|Drug|Treatment C|One dose of placebo matching Preladenant, Levodopa infusion (IV), and 25-mg oral Carbidopa administered three times daily (TID)
21577|NCT00845026|Drug|LY2140023|80mg, oral tablets,twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40mg or a maximum of 160mg.
21578|NCT00845026|Drug|aripiprazole|10mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20mg, 2-10mg oral tablets,once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 30mg (3-10mg oral tablets).
21579|NCT00845026|Drug|olanzapine|10mg dose (2-5mg oral tablets) once every evening, for 3 days. Followed by an increase to 15mg (3-5mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 20mg (4-5mg oral tablets).
18965|NCT00829478|Behavioral|Decision Aid for Atrial Fibrillation|Single contact educational session
18966|NCT00829478|Other|Usual Care|Usual Care
18967|NCT00829491|Behavioral|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
18968|NCT00829504|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
18969|NCT00829504|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg
18970|NCT00829517|Other|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
18971|NCT00829517|Other|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
18972|NCT00829530|Drug|Ramipril 10 mg capsule|1 x 10 mg
18973|NCT00829530|Drug|Altace® 10 mg capsule|1 x 10 mg
18974|NCT00829543|Procedure|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
18975|NCT00008151|Drug|methotrexate|
18976|NCT00829556|Device|Integuseal|
17983|NCT00825175|Device|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
17984|NCT00825188|Drug|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
17985|NCT00825188|Drug|eplerenone|Eplerenone 25-50mg daily x 8 weeks
17986|NCT00825188|Drug|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
17987|NCT00007995|Biological|filgrastim|
17988|NCT00825188|Drug|amlodipine|amlodipine 5-10mg daily for 8 weeks
17989|NCT00825201|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
22592|NCT00838955|Drug|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
22593|NCT00838968|Drug|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
22594|NCT00838981|Drug|Modafinil|Modafinil will be phase in from 200mg to 400mg
22595|NCT00838981|Drug|Sugar Pill|placebo, sugar pill will mirror active drug
22596|NCT00838994|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
22597|NCT00839007|Drug|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
21640|NCT00842504|Drug|Micafungin|3 mg/kg IV once over 1 hour
21641|NCT00842517|Behavioral|Contingency Management|
21642|NCT00842530|Biological|Chimeric tetravalent dengue (serotype 1, 2, 3, 4)|0.5 mL, Subcutaneous
21643|NCT00842530|Biological|Inactivated Rabies virus vaccine|0.5 mL, Subcutaneous
21644|NCT00009828|Drug|leucovorin calcium|
21645|NCT00842543|Dietary Supplement|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
21646|NCT00842543|Dietary Supplement|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
21647|NCT00842556|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
21648|NCT00842556|Drug|Glimepiride|Tablets, Oral, 4 mg, Single Dose
21649|NCT00842556|Drug|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
21650|NCT00842582|Drug|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
21651|NCT00842582|Drug|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
21652|NCT00842582|Drug|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
21653|NCT00842595|Drug|rituximab|6 courses every 28 days
21654|NCT00842595|Drug|vinorelbine|6 courses every 28 days
18041|NCT00823082|Drug|Antithrombin III|Single dose of antithrombin III sufficient to achieve a level of 120%
18042|NCT00823095|Drug|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
18043|NCT00823108|Drug|GIK|12 hour infusion of GIK solution
18044|NCT00823121|Procedure|freezing embryos by vitrification|vitrification by Cryotop method
18045|NCT00007878|Other|laboratory biomarker analysis|Correlative studies
18046|NCT00823121|Procedure|fresh embryo transfers|fresh embryo transfers
18047|NCT00823121|Drug|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
18048|NCT00823121|Drug|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
18049|NCT00823121|Drug|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
18050|NCT00823134|Device|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
18051|NCT00823147|Behavioral|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
18052|NCT00823160|Procedure|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
18053|NCT00823160|Procedure|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
18054|NCT00823173|Biological|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
18055|NCT00823186|Drug|Phyxol(Paclitaxel)|Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10
-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine
18056|NCT00007891|Biological|filgrastim|
18057|NCT00823199|Drug|Allopurinal|300mg once daily by mouth for four weeks
18371|NCT00825942|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
18372|NCT00825955|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
18373|NCT00825955|Drug|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
21580|NCT00845026|Drug|risperidone|2mg dose, 2-1mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4mg (4-1mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2mg/day or a maximum of 6mg/day (6-1mg tablets).
21581|NCT00009984|Drug|thalidomide|Given orally
21862|NCT00840398|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
21863|NCT00840398|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
21864|NCT00840411|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
21865|NCT00840411|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
21866|NCT00840450|Drug|Gleevec/Paclitaxel|One treatment cycle:
Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.
Paclitaxel: 80 mg/m^2/week intravenously, 3 weeks on, one week off, every 28 days.
After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression.
21867|NCT00840463|Drug|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
21868|NCT00840463|Other|Placebo|Sugar pill
21869|NCT00009737|Drug|5-FU|425mg/m2 iv daily from day 1 to day 5 every 28 days.
21870|NCT00840476|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
21871|NCT00840476|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
21872|NCT00840489|Drug|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
21873|NCT00840489|Drug|Colchicine|Colchicine 0.5 mg bd for 24 weeks
21874|NCT00840528|Other|ozone|0.4 ppm ozone for 2 hours
21875|NCT00840554|Other|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
21876|NCT00840554|Other|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
21877|NCT00840567|Procedure|Skin biopsy|
21878|NCT00840567|Procedure|Blood draw & sample|
21879|NCT00840580|Drug|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
17990|NCT00825201|Other|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
17991|NCT00825201|Other|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
17992|NCT00825201|Other|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
17993|NCT00825201|Other|laboratory biomarker analysis|Correlative studies
17994|NCT00825214|Device|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
17995|NCT00827866|Other|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
17996|NCT00827866|Other|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
17997|NCT00827879|Behavioral|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
17998|NCT00008060|Drug|FOLFOX regimen|
17999|NCT00827879|Behavioral|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
18000|NCT00827892|Drug|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
18001|NCT00827892|Drug|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
18312|NCT00830440|Other|Diet + Lifestyle Counseling|Monthly Visits
18313|NCT00830453|Procedure|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
18314|NCT00830466|Drug|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
18315|NCT00830479|Procedure|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
18316|NCT00830479|Procedure|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
18317|NCT00008177|Other|laboratory biomarker analysis|Correlative studies
21655|NCT00845065|Drug|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
21656|NCT00845065|Other|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
21657|NCT00845065|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
21658|NCT00845065|Drug|Ribavirin|Ribavirin 200-mg capsules, weight-based dosing
<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)
>=75 kg, 1200 mg/day PO, divided BID
for 48 weeks
21659|NCT00845091|Behavioral|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
21660|NCT00845091|Behavioral|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
21661|NCT00845104|Drug|fludarabine phosphate|Given IV
21662|NCT00009997|Biological|trastuzumab|
21663|NCT00845104|Biological|rituximab|Given IV
21944|NCT00837954|Device|Lyostypt® AND Surgicel®|The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.
21945|NCT00837954|Device|Lyostypt®|The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.
21946|NCT00837954|Procedure|Surgicel®|The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.
21947|NCT00837967|Drug|Symbicort Turbuhaler|160/4.5μg for 3 days
21948|NCT00837967|Drug|Terbutaline Turbuhaler|0.4 mg for 3 days
21949|NCT00009048|Drug|IV Levodopa|
21950|NCT00838006|Device|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
21951|NCT00838006|Device|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
18374|NCT00828477|Drug|Xibrom|Xibrom: two times a day for seven days in the first eye.
18375|NCT00828477|Drug|Nevanac|Nevanac: three times a day for seven days in the second eye.
18376|NCT00828490|Behavioral|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
18377|NCT00008086|Drug|carboplatin|
18378|NCT00828490|Behavioral|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
18379|NCT00828490|Behavioral|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
18380|NCT00828503|Drug|Certican (everolimus) + valganciclovir|Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)
MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
18381|NCT00828503|Drug|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
18382|NCT00828516|Other|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
18383|NCT00828529|Drug|TMC207|
18384|NCT00828542|Drug|etonogestrel-releasing implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
18385|NCT00828542|Drug|depot medroxyprogesterone|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
18386|NCT00828555|Other|Vaccination Program|Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis
18387|NCT00828568|Drug|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
18388|NCT00008099|Biological|MUC1 antigen/SB AS-2|
18389|NCT00828568|Drug|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
18709|NCT00821899|Biological|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
21880|NCT00009737|Drug|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
21881|NCT00840580|Drug|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
21882|NCT00840593|Procedure|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
22154|NCT00840931|Drug|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
22155|NCT00840931|Biological|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
22156|NCT00009750|Drug|paclitaxel|
22157|NCT00840944|Drug|somatropin|somatropin 0.050 mg/kg/day
22158|NCT00840944|Drug|triptorelin|triptorelin 3.75 mg each month
22159|NCT00840957|Biological|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
22160|NCT00840983|Procedure|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
22161|NCT00840996|Drug|Lidocaine|General Anesthesia plus perioperative intravenous lidocaine infusion and post operative patient controlled analgesia
22162|NCT00840996|Drug|placebo|General Anesthesia and postoperative Patient Controlled Analgesia and placebo IV infusion
22163|NCT00841022|Other|Information with comics|Information of children with comic leaflet
22164|NCT00841035|Drug|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
22165|NCT00841048|Drug|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
22166|NCT00841048|Drug|Placebo|
22167|NCT00009750|Procedure|peripheral blood stem cell transplantation|
22168|NCT00841061|Dietary Supplement|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
22169|NCT00841061|Dietary Supplement|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
18318|NCT00830492|Drug|clomiphene citrate|100 mg from cycle day 3 through 7
18319|NCT00830492|Procedure|Ultrasound|cycle day 8
18320|NCT00830492|Drug|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
18321|NCT00830492|Drug|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
18322|NCT00830492|Drug|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
18323|NCT00830492|Drug|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
18324|NCT00830505|Drug|fluticasone/ salmeterol|2 puffs twice a day for 2 weeks
18325|NCT00830505|Drug|fluticasone|2 puffs twice a day for 2 weeks
18326|NCT00830518|Drug|MLN8237|MLN8237 will be administered orally (PO) at a dose of 50 mg twice daily (BID) for seven consecutive days followed by a 14-day rest period, in 21-day cycles. Dose reductions will be implemented in the setting of drug-related toxicities.
The first dose of MLN8237 on Cycle 1, Day 1 will be administered in the study clinic. Patients will continue to receive repeated cycles of MLN8237 treatment for up to 12 months, or until there is evidence of disease progression or unacceptable treatment-related toxicity. Treatment with MLN8237 may be continued beyond 12 months if it is determined that a patient would clearly derive benefit from continued therapy.
18327|NCT00830531|Drug|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
18328|NCT00008190|Biological|aldesleukin|
18329|NCT00830635|Other|survey administration|
18330|NCT00823563|Procedure|Intravascular ultrasound (IVUS)|
18331|NCT00007904|Biological|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC > 10,000/uL x1 day after the nadir cycles 1-3.
18332|NCT00823563|Procedure|Coronary pressure/flow wire testing|
18644|NCT00826410|Device|Redon drain|subcutaneous suction drain after laparotomy for two days
18645|NCT00826449|Drug|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
18646|NCT00826449|Drug|Erlotinib|150 mg by mouth daily every 21 day cycle.
18647|NCT00826462|Drug|triamcinolone|Injection with triamcinolone 10 mg at start and at 3 weeks
21952|NCT00838006|Device|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
21953|NCT00840593|Procedure|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
21954|NCT00840606|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
21955|NCT00840606|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
21956|NCT00840632|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
21957|NCT00840632|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
21958|NCT00840645|Drug|YM178|Oral
21959|NCT00840658|Behavioral|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
22234|NCT00838357|Drug|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
22235|NCT00838370|Drug|Capecitabine, 5-fluorouracil|Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD*2A. Patients heterozygous or homozygous mutant for DPYD*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.
In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients.
22236|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
22237|NCT00009178|Drug|Fluoxetine|
22238|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
22239|NCT00838383|Drug|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
22240|NCT00838396|Drug|XP19986 CR|On study Day 1, patients received a single dose of XP19986 10, 20, 40 or 60 mg or placebo. On study Day 5, after completion of the minimum 3-day washout period, patients crossed over to the other treatment and received a single dose of XP19986 CR or matching Placebo. XP19986 CR was administered as a single dose of 10, 20, 40, or 60 mg.
22241|NCT00841113|Drug|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
18710|NCT00821912|Drug|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
18711|NCT00007813|Procedure|autologous bone marrow transplantation|
18712|NCT00821912|Drug|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
18713|NCT00821925|Procedure|bone densitometry|All patients do a bone densitometry after the inclusion.
18714|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
18715|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
18716|NCT00821951|Drug|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
18717|NCT00824044|Device|Quantitative electroencephalogram (QEEG)|The QEEG will be administered 5 times during the study (week 0, 1, 2, 8 and endpoint) allowing us to assess whether there are any correlations between QEEG patterns and changes in clinical functioning.
18718|NCT00007917|Drug|gemcitabine hydrochloride|
18719|NCT00824057|Drug|AZD6280|oral
18720|NCT00824057|Drug|Midazolam|oral
18721|NCT00824057|Drug|Caffeine|oral
18722|NCT00824070|Drug|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
18723|NCT00824070|Drug|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
18724|NCT00824070|Drug|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
18725|NCT00824096|Procedure|Bronchoscopy|The patients in our ICU intubated for > 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3~4 days even with CLV ＜24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
18726|NCT00824109|Device|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
22170|NCT00841074|Drug|chlorhexidine|0.12% chlorhexidine mouthwash spray, ~1.3 ml, twice a day.
22171|NCT00841074|Drug|Placebo mouthwash|Placebo mouthwash spray application of ~1.3 ml twice a day.
22172|NCT00841087|Drug|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
22173|NCT00841087|Drug|insulin detemir|Injection subcutaneously at bedtime
22174|NCT00841087|Drug|insulin aspart|Injection subcutaneously immediately before each meal.
22175|NCT00841100|Drug|Kuvan|20mg/kg/d, once daily
22518|NCT00838916|Drug|insulin glargine|insulin glargine
22519|NCT00838929|Drug|Vorinostat|All doses given for 3 weeks
Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd
22520|NCT00838929|Radiation|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
22521|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
22522|NCT00009763|Biological|filgrastim|
22523|NCT00841204|Drug|sulindac|Given orally
22524|NCT00841204|Other|placebo|Inactive agent
22525|NCT00841204|Other|laboratory biomarker analysis|Correlative studies
22526|NCT00841217|Drug|GW501516|2.5mg/day
22527|NCT00841217|Drug|placebo pill|
22528|NCT00841230|Drug|Deanxit|Deanxit 1x/day
22529|NCT00841230|Drug|Lactose placebo|Lactose used as placebo
22530|NCT00841243|Dietary Supplement|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
22531|NCT00841256|Biological|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
18648|NCT00826462|Drug|Placebo|Injection with sodium chloride at start and at 3 weeks
18649|NCT00826462|Drug|Lidocaine|10 mg of lidocaine at start and at 3 weeks
18650|NCT00826462|Other|Physiotherapy|12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises
18651|NCT00826462|Drug|Naproxen|Naproxen 500 mg bid for 14 days
18652|NCT00008008|Procedure|peripheral blood stem cell transplantation|
18653|NCT00826475|Behavioral|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
18654|NCT00826475|Behavioral|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
18655|NCT00826488|Device|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
18656|NCT00826501|Procedure|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
18657|NCT00826501|Procedure|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
18658|NCT00826514|Drug|Tanezumab|Intravenous, 20 mg, single dose.
18659|NCT00826514|Drug|Placebo|Intravenous placebo, single dose
18660|NCT00826527|Drug|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
18661|NCT00826540|Drug|sorafenib tosylate|Given orally
18662|NCT00826540|Biological|bevacizumab|Given IV
18663|NCT00008021|Biological|filgrastim|
18664|NCT00826553|Drug|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
18665|NCT00826553|Drug|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
22242|NCT00841113|Drug|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
22243|NCT00009750|Radiation|indium In 111 monoclonal antibody m170|
22244|NCT00841126|Drug|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
22245|NCT00841126|Drug|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
22246|NCT00841126|Drug|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
22247|NCT00841139|Drug|Perhexiline|100mg o bd
22248|NCT00841139|Drug|Placebo|1 tablet bd
22249|NCT00841152|Device|Bioactive glass|Surgical implantation
22250|NCT00841152|Device|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
22251|NCT00841152|Procedure|Autograft|Surgical transplantation from iliac crest
22252|NCT00841152|Procedure|Allograft (frozen femoral head)|Surgical transplantation
22253|NCT00841165|Device|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
22598|NCT00839020|Procedure|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
22599|NCT00839020|Procedure|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
22600|NCT00839033|Device|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
22601|NCT00839033|Device|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
22602|NCT00009542|Drug|kava (Piper methysticum)|
18727|NCT00824135|Drug|Clofarabine|One dose intravenously every 24 hrs for five days total.
Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous
19035|NCT00820027|Drug|Ibuprofen 600 mg|One tablet three times daily
19036|NCT00007631|Other|Placebo|Patients receive placebo for same amount of time
19037|NCT00820027|Drug|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
19038|NCT00820027|Drug|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
19039|NCT00820027|Drug|Matching Placebo for Ibuprofen|One tablet three times daily
19040|NCT00820053|Drug|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
19041|NCT00820079|Drug|ADX10059|oral administration
19042|NCT00820079|Drug|ADX10059 Matching Placebo|oral administration
19043|NCT00820092|Drug|Xerecept 1.0|24 hour infusion
19044|NCT00820092|Drug|Xerecept 2.0|24 hour infusion
19045|NCT00820092|Drug|Xerecept 3.0|24 hour infusion
19046|NCT00820105|Drug|ADX10059|oral administration
19047|NCT00007644|Procedure|Radical prostatectomy|Surgical removal of the prostate
19048|NCT00820105|Drug|ADX10059|Oral administration
19049|NCT00820105|Drug|ADX10059|Oral administration
19050|NCT00820105|Drug|ADX10059 Matching Placebo|Oral administration
19051|NCT00813293|Drug|Sorafenib|Short course of sorafenib given orally twice a day prior to RFA
19052|NCT00813293|Procedure|Radiofrequency Ablation|Radiofrequency ablation to tumor. Repeat sessions allowed for full tumor treatment.
19053|NCT00813306|Drug|AZD2066|13 mg oral solution, 1 single dose
19054|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
19055|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
22532|NCT00841256|Drug|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
22533|NCT00009763|Biological|monoclonal antibody m170|
22534|NCT00841269|Drug|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
22535|NCT00841282|Procedure|Colonoscopy for colorectal cancer screening|
22536|NCT00841282|Procedure|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
22537|NCT00841282|Procedure|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
22538|NCT00841295|Drug|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
21582|NCT00845039|Biological|Cetuximab|Cetuximab 500 mg/m2 every 14 days until disease progression or patient intolerance
21583|NCT00845039|Drug|Irinotecan|180 mg/m2 every 14 days until disease progression or patient intolerance
21584|NCT00845039|Biological|IMC-A12 (cixutumumab)|IMC-A12 10mg/kg every 14 days until disease progression or patient intolerance
21585|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
21586|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
21587|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
21588|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
21589|NCT00010140|Procedure|adjuvant therapy|
21590|NCT00847379|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner) for up to 96 weeks.
21591|NCT00847392|Procedure|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
21592|NCT00847405|Drug|Sumatriptan Succinate|100 mg Tablets
21593|NCT00847405|Drug|Imitrex®|100 mg Tablet
21594|NCT00847418|Drug|esketamine hydrochloride|
18977|NCT00829569|Dietary Supplement|Intralipid +/- Omegaven|Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.
Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.
Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil).
18978|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
18979|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
18980|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
18981|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
18982|NCT00007852|Biological|rituximab|Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
18983|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
18984|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
18985|NCT00822198|Device|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
18986|NCT00822211|Drug|Vildagliptin 50 mg bid|
18987|NCT00822211|Drug|Vildagliptin 50 mg qd|
18988|NCT00822211|Drug|Placebo|
18989|NCT00822224|Drug|MEOPA|inhalation of MEOPA during the painful care
18990|NCT00822237|Biological|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
18991|NCT00822237|Biological|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
18992|NCT00822237|Biological|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection ~6 weeks apart
22603|NCT00839046|Behavioral|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
22604|NCT00839046|Device|Provision of Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
22605|NCT00839046|Device|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
22606|NCT00839059|Drug|lenalidomide|Dose escalation:
Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.
Duration of the first cycle: 56days, each following cycle will last 28 days
22607|NCT00009763|Procedure|peripheral blood stem cell transplantation|
22608|NCT00841529|Device|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
22609|NCT00841542|Drug|Amlodipine Besylate|10 mg Tablet
22610|NCT00841542|Drug|Norvasc®|10 mg Tablet
22611|NCT00841555|Drug|temozolomide|Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.
Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment
21664|NCT00845104|Biological|bevacizumab|Given IV
21665|NCT00845104|Other|laboratory biomarker analysis|Correlative studies
21666|NCT00845104|Other|flow cytometry|Correlative studies
21667|NCT00845104|Genetic|polymerase chain reaction|Correlative studies
21668|NCT00845104|Genetic|fluorescence in situ hybridization|Correlative studies
21669|NCT00845117|Procedure|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
19056|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
19057|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
19058|NCT00813319|Behavioral|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
22133|NCT00838175|Procedure|suture mediated closure|Suture mediated closure of femoral venous access
22134|NCT00838188|Other|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
22135|NCT00838201|Drug|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
22136|NCT00838214|Drug|budesonide|3mg capsule, 3x per day for 6 months
22137|NCT00838214|Drug|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
22138|NCT00838227|Drug|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
22139|NCT00838240|Drug|clofarabine|Given IV
22140|NCT00838240|Drug|cytarabine|Given IV
22141|NCT00009061|Drug|Lamivudine|
22142|NCT00838240|Drug|idarubicin|Given IV
22143|NCT00838253|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
22144|NCT00838253|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
22145|NCT00838253|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
22146|NCT00838253|Drug|Placebo|Placebo continuous i.v. infusion for 24 hours
22147|NCT00838266|Drug|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
22148|NCT00838266|Other|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
22149|NCT00838279|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
21595|NCT00847444|Drug|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
21596|NCT00847444|Behavioral|Lifestyle-based Intervention|All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:
Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention.
21597|NCT00847457|Behavioral|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
21598|NCT00847457|Behavioral|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
21599|NCT00847483|Drug|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
21600|NCT00010153|Drug|fulvestrant|
21601|NCT00847483|Drug|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
21602|NCT00847483|Drug|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
21883|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
21884|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
21885|NCT00832078|Device|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
21886|NCT00832078|Device|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
21887|NCT00832091|Drug|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
21888|NCT00832091|Drug|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
21889|NCT00832117|Drug|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
21890|NCT00008242|Drug|doxorubicin hydrochloride|
21891|NCT00832117|Drug|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
18993|NCT00007852|Drug|carmustine|BCNU 300 mg/M2 IV day -6
18994|NCT00822250|Other|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
18002|NCT00827905|Device|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
18003|NCT00827918|Drug|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
18004|NCT00827918|Drug|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
18005|NCT00827918|Drug|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
18006|NCT00827931|Drug|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
18007|NCT00827931|Procedure|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
18008|NCT00827944|Device|Parietex Progrip|Surgical technique:
Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation.
18009|NCT00008060|Drug|fluorouracil|
18010|NCT00827944|Device|Low weight polypropylene mesh|Surgical technique:
Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures
18011|NCT00827957|Device|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
18012|NCT00827957|Device|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
18013|NCT00830297|Drug|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
21670|NCT00845130|Biological|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
21671|NCT00845156|Dietary Supplement|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
21672|NCT00845169|Procedure|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
21673|NCT00009997|Drug|cyclophosphamide|
21674|NCT00845182|Drug|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
21675|NCT00845182|Drug|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
21676|NCT00845182|Drug|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
21677|NCT00845195|Drug|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
21678|NCT00845195|Drug|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
21679|NCT00845208|Behavioral|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
21680|NCT00847548|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
21681|NCT00847548|Behavioral|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
21682|NCT00847561|Behavioral|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
21683|NCT00010153|Procedure|conventional surgery|
21684|NCT00847561|Behavioral|Information Monitoring|Packet providing information on strategies for coping with anxiety
21960|NCT00840658|Behavioral|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
21961|NCT00009737|Drug|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
21962|NCT00840658|Behavioral|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
22150|NCT00838279|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
22151|NCT00840892|Other|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
22152|NCT00840918|Drug|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
22153|NCT00840918|Other|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
22422|NCT00838760|Drug|TMC558445; TMC310911; Darunavir; Placebo|
22423|NCT00009204|Drug|Perphenazine [Trilafon]|
22424|NCT00838773|Behavioral|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
22425|NCT00838773|Behavioral|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
22426|NCT00838773|Behavioral|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
22427|NCT00838799|Drug|RGH-896|45 mg TID, capsules, 14 weeks.
22428|NCT00838799|Drug|RGH-896|30 mg TID, capsules, 14 weeks.
22429|NCT00838799|Drug|RGH-896|15 mg TID, capsules, 14 weeks.
22430|NCT00841672|Drug|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
22431|NCT00841685|Device|Goldlock|Insertion of Goldlock marker
22432|NCT00009776|Biological|monoclonal antibody Lym-1|
21892|NCT00832117|Drug|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
21893|NCT00832117|Drug|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
21894|NCT00832130|Device|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
21895|NCT00832130|Device|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
21896|NCT00832143|Behavioral|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
21897|NCT00832156|Biological|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
21898|NCT00832169|Drug|AZD1386|1 dose of oral solution
21899|NCT00832182|Drug|insulin aspart|
21900|NCT00832182|Drug|insulin NPH|
21901|NCT00008242|Drug|thalidomide|
21902|NCT00832195|Device|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
22176|NCT00832598|Radiation|[18F]FACBC PET and [18F]FLT PET imaging|[18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
22177|NCT00832611|Device|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
22178|NCT00000772|Drug|Didanosine|
22179|NCT00008281|Drug|FOLFOX regimen|
22180|NCT00832624|Drug|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
22181|NCT00832637|Drug|Cisplatin|Cisplatin 40 mg/ m2 on day 1 and day 15 in patients treated with Gem + Cis, with Cisplatin to be given following Gemcitabine. Cisplatin administration should be given along with hydration with NS at 250 mL/ hour for at least 4 hours pre-and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
22182|NCT00832637|Drug|Erlotinib|100 mg orally daily.
18014|NCT00830310|Behavioral|Psychoeducation module|Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of "1" or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item).
18333|NCT00823563|Procedure|Coronary pressure/flow testing: Acetycholine challenge|
18334|NCT00823563|Procedure|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
18335|NCT00823563|Procedure|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
18336|NCT00823576|Drug|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
18337|NCT00823589|Other|Blood test and clinical test|Blood test and clinical test
18338|NCT00823602|Drug|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
18339|NCT00823602|Drug|suprefact|GnRH agonist, standard protocol
18340|NCT00823615|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
18341|NCT00823615|Device|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
18342|NCT00007904|Drug|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
18343|NCT00823628|Drug|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
18344|NCT00823628|Drug|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
18345|NCT00823641|Drug|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
18346|NCT00823654|Other|Blood draw and questionnaires|At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment
↓
Tests in the middle of chemotherapy (if applicable):
Blood draw and collection of monthly menstrual calendars ↓
Tests when chemotherapy is over (if applicable):
Blood draw and collection of monthly menstrual calendars
↓
Tests every 4 months for about 1 year:
Blood draw, collection of monthly menstrual calendars, and questionnaire ↓
Tests every 6 months for about 1 year:
Blood draw, collection of monthly menstrual calendars, and questionnaire
↓
Yearly follow-up for about 2 years:
Blood draw collection of monthly menstrual calendars, and questionnaire
21963|NCT00840671|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
21964|NCT00840671|Drug|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
21965|NCT00840684|Drug|amsacrine|
21966|NCT00840684|Drug|busulfan|
21967|NCT00840684|Drug|cytarabine|
21968|NCT00840684|Drug|daunorubicin hydrochloride|
21969|NCT00840684|Drug|laromustine|
21970|NCT00840684|Drug|melphalan|
21971|NCT00840684|Drug|mitoxantrone hydrochloride|
21972|NCT00009750|Biological|filgrastim|
21973|NCT00840684|Procedure|allogeneic hematopoietic stem cell transplantation|
21974|NCT00840684|Procedure|autologous hematopoietic stem cell transplantation|
21975|NCT00840697|Behavioral|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
21976|NCT00832221|Drug|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
21977|NCT00832221|Drug|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
21978|NCT00832234|Drug|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
21979|NCT00832247|Genetic|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
22254|NCT00009750|Radiation|yttrium Y 90 monoclonal antibody m170|
22255|NCT00841165|Device|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
22256|NCT00841178|Procedure|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
22433|NCT00841685|Device|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
22434|NCT00841685|Device|Visicoil larger size|Insertion of Visicoil, larger size, marker
22435|NCT00841685|Device|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
22436|NCT00841685|Device|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
22437|NCT00841698|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
22438|NCT00841698|Drug|Paxil®|40 mg Film-Coated Tablet
22761|NCT00839280|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
22762|NCT00009581|Drug|Acetylcholine|
22763|NCT00839280|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
22764|NCT00839293|Drug|ABT-335|Once, see arm description for more information
22765|NCT00839306|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
22766|NCT00839306|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
22767|NCT00839319|Drug|Acyline|300 ug/kg subcutaneous injections on Day 1.
22768|NCT00839319|Other|placebo hCG (no active ingredient)|placebo hCG
22769|NCT00839319|Drug|hCG (human chorionic gonadotropin)|15 IU subcutaneous injection every other day for 10 days (5 doses)
22770|NCT00839319|Drug|hCG (human chorionic gonadotropin)|60 IU subcutaneous injection
22771|NCT00839319|Drug|hCG (human chorionic gonadotropin)|125 IU subcutaneous injection
22772|NCT00839319|Drug|Testosterone gel|75 mg testosterone gel applied transdermally for 10 days
22773|NCT00009594|Procedure|Naturopathic Medicine|
22774|NCT00839332|Drug|LY2603618|70-300 mg/m2 intravenous administered once per week for 3 weeks followed by 1 week of rest, repeating every 28 days for a minimum of 2 cycles and until disease progression
22775|NCT00839332|Drug|Gemcitabine|1000 mg/m2 intravenous administered once per week for 3 weeks followed by 1 week of rest, repeating every 28 days for a minimum of 2 cycles continuing until disease progression
18189|NCT00828178|Device|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
18190|NCT00828178|Drug|Fish oil|3 capsules qd for 12weeks
18191|NCT00828191|Drug|Progesterone|25 mg, once a day, SC
18192|NCT00828191|Drug|Progesterone|100 mg, twice a day, vaginally
18193|NCT00828204|Device|single-use autoinjector with a prefilled liquid Avonex syringe|
18194|NCT00000198|Drug|Piracetam|
18195|NCT00000769|Drug|Interleukin-4|
18196|NCT00008073|Drug|doxorubicin hydrochloride|
18197|NCT00828204|Device|Avonex prefilled syringe via manual IM injection|
18198|NCT00828204|Drug|BG9418 (interferon beta-1a)|
18199|NCT00828217|Other|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
18200|NCT00828230|Drug|budesonide|One application of 2mg budesonide once daily for 8 weeks
18201|NCT00828230|Drug|Placebo foam|One application of placebo foam once daily for 8 weeks
18202|NCT00828243|Drug|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids (palmitate and acetate) and of surfactant-associated proteins (leucine) to infants with neonatal respiratory distress syndrome. We measure with mass spectrometry incorporation of stable isotopically labeled precursors into tracheal aspirates to estimate surfactant phospholipid and protein kinetics.
18521|NCT00821626|Device|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
18522|NCT00821626|Other|Control|No rapid flu test
18523|NCT00821639|Behavioral|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
18524|NCT00823784|Procedure|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
18525|NCT00823784|Procedure|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
18526|NCT00823797|Drug|bendamustine hydrochloride|Given IV
18527|NCT00823797|Other|quality-of-life assessment|Ancillary studies
17944|NCT00830284|Procedure|Recruitment maneuver|Three types of maneuvers will be performed.
6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.
6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.
PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher.
17945|NCT00830297|Drug|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
17946|NCT00008177|Drug|fludarabine phosphate|Given IV
17947|NCT00822900|Drug|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
17948|NCT00007878|Drug|fluorouracil|Given IV
17949|NCT00822900|Drug|Placebo|Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour "loading dose" of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours.
17950|NCT00822913|Drug|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
17951|NCT00822926|Drug|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
17952|NCT00822926|Drug|Saline|Subcutaneous injection of saline into scar tissue
17953|NCT00822965|Other|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
17954|NCT00822965|Other|Phone Interviews|2 follow-up phone interviews.
17955|NCT00822965|Behavioral|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
17956|NCT00822978|Drug|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
17957|NCT00822991|Device|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
17958|NCT00822991|Device|B-mode US|screening by conventional B-mode US every 3-5 months
17959|NCT00000765|Drug|Zidovudine|
17960|NCT00007878|Drug|leucovorin calcium|Given IV
19336|NCT00813735|Drug|Escitalopram|Escitalopram 10mg or 20mg
19337|NCT00813748|Drug|Xolair|
19338|NCT00006734|Drug|vincristine sulfate|Given IV
19339|NCT00813761|Device|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
19340|NCT00813761|Device|Proclear contact lens|control contact lens to be worn for entire length of study.
19341|NCT00813761|Device|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
19342|NCT00813761|Device|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
19343|NCT00813774|Biological|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
19344|NCT00813774|Biological|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
19345|NCT00813774|Biological|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
19346|NCT00813800|Drug|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
19347|NCT00813813|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
19348|NCT00813826|Drug|SLC022|SLC022 150 mg capsule, 900mg daily dose
19349|NCT00006734|Procedure|adjuvant therapy|
19350|NCT00813826|Drug|Placebo|Placebo capsule, TID
19351|NCT00815854|Dietary Supplement|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
19352|NCT00815854|Dietary Supplement|folic acid|subjects may receive folic acid 5mg daily for 4 months
19353|NCT00815854|Other|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
19354|NCT00815867|Drug|epoetin beta (NeoRecormon ®)|comparison of administration of high dosage of epoetin vs no administration of epoetin
30000 UI: 4 injections
18453|NCT00826059|Device|The Ischemic Stroke System|SPG stimulation and standard of care
18454|NCT00826059|Device|Sham control|Sham stimulation and standard of care
18767|NCT00829179|Drug|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
18768|NCT00829192|Drug|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
18769|NCT00829192|Drug|Placebo|Placebo subcutaneous implant administered every 60 days
18770|NCT00829205|Biological|filgrastim|
18771|NCT00829205|Biological|rituximab|
18772|NCT00829205|Dietary Supplement|Se-methyl-seleno-L-cysteine|
18773|NCT00829205|Drug|carboplatin|
18774|NCT00829205|Drug|etoposide|
18775|NCT00829205|Drug|ifosfamide|
18776|NCT00829205|Other|laboratory biomarker analysis|
18777|NCT00008138|Drug|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
18778|NCT00829205|Other|pharmacological study|
18779|NCT00829218|Other|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
18780|NCT00829218|Other|Placebo diet|Juice with nothing added.
18781|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
18782|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
18783|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
18784|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
18785|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
18528|NCT00823810|Other|PET/CT|18F-FDG PET/CT
18529|NCT00823823|Other|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
18530|NCT00823823|Other|Circumferential cast|Circumferential cast will be applied following closed reduction
18531|NCT00823836|Drug|ropinirole PR/XR|Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.
The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).
Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.
Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.
Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
18532|NCT00823836|Drug|ropinirole IR|Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.
The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).
Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.
Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.
Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
18533|NCT00007904|Procedure|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
18534|NCT00823849|Drug|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
18535|NCT00823849|Drug|Probucol|250 mg Bid, PO after breakfast and dinner.
18536|NCT00823849|Drug|Cilostazol+Probucol|TBD
18851|NCT00826826|Drug|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
18852|NCT00826839|Drug|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
18853|NCT00826839|Drug|E2 patch/antagonist|Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.
Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses.
18854|NCT00826852|Drug|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
18855|NCT00826865|Drug|Levetiracetam|750 mg tablet
17961|NCT00823004|Drug|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
18270|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
18271|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
18272|NCT00825734|Drug|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
18273|NCT00825734|Drug|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m^2)
18274|NCT00825747|Device|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
18275|NCT00825760|Drug|Topical PPA904 gel and light|
18276|NCT00825760|Drug|Topical placebo gel plus light|
18277|NCT00000767|Biological|Smallpox Vaccine|
18278|NCT00007995|Procedure|bone marrow ablation with stem cell support|
18279|NCT00825773|Device|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
18280|NCT00825786|Drug|Ropivacaine|mepivacaine (15 ml) and ropivacaine (15 ml).
18281|NCT00828256|Procedure|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
18282|NCT00828269|Procedure|Comparator: Fine needle aspiration biopsy|Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.
Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit
18283|NCT00828282|Drug|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
18284|NCT00828295|Drug|palonosetron|palonosetron IV 1 mcg/kg
18285|NCT00008073|Drug|octreotide acetate|
18286|NCT00828295|Drug|palonosetron|palonosetron 3mcg/kg IV
18287|NCT00828308|Drug|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
18288|NCT00828308|Procedure|Prostatectomy|
19355|NCT00815880|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
19643|NCT00816335|Drug|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
19644|NCT00816335|Procedure|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
19645|NCT00006968|Biological|filgrastim|
19646|NCT00816335|Drug|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
19647|NCT00816335|Procedure|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
19648|NCT00818766|Drug|Placebo|Subjects will receive IV placebo for 48 hours post-operatively, or until all chest tubes are removed -- whichever comes first.
19649|NCT00007332|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
19650|NCT00818779|Drug|Aliskiren|150 - 300 mg once daily for 6 weeks
19651|NCT00818779|Drug|Amlodipine|5-10 mg once daily for 6 weeks
19652|NCT00818792|Device|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
19653|NCT00818805|Drug|Olopatadine 0.1%|one drop in one eye
19654|NCT00818805|Drug|Tranilast 0.5%|one drop in one eye
18786|NCT00829257|Drug|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
18787|NCT00821951|Radiation|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
18788|NCT00821964|Drug|imiquimod|Given topically
18789|NCT00821964|Drug|Abraxane|Given IV
17798|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
17799|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
17800|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
17801|NCT00824902|Procedure|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
17802|NCT00824928|Procedure|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
17803|NCT00824954|Procedure|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
17804|NCT00824967|Other|Training and valuation of the treating personnel|Training and valuation of the treating personnel
17805|NCT00824980|Drug|IP10.C8|IP10.C8 Gel 1%
17806|NCT00824993|Drug|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
17807|NCT00007982|Procedure|adjuvant therapy|
17808|NCT00824993|Drug|Vitamin Supplements|Calcium 500 mg by mouth everyday for 12 months
Vitamin D 400 units by mouth 2 times a day for 12 months
17809|NCT00825006|Device|Triple site pacing mode|The experimental "Triple site pacing mode" includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.
Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months.
17810|NCT00827489|Drug|HTC-867|
17811|NCT00827489|Other|Placebo|
17812|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
17813|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
18856|NCT00826878|Drug|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.
Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated.
18857|NCT00829257|Drug|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
18858|NCT00008138|Procedure|debulking surgery|exploratory laparotomy, interval cytoreduction (to < 1 cm residual)
18859|NCT00829257|Drug|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
18860|NCT00829283|Behavioral|Behavioral Weight Loss|weekly individual sessions for 6 months
18861|NCT00829283|Behavioral|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
18862|NCT00829283|Drug|Placebo|One pill daily
18863|NCT00829283|Drug|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
18864|NCT00829296|Drug|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
18865|NCT00829296|Drug|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
18866|NCT00829309|Drug|Pravastatin|80 mg Tablet
18867|NCT00829309|Drug|Pravastatin|80 mg Tablets
18868|NCT00829322|Drug|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
18869|NCT00008151|Drug|cyclosporine|
18870|NCT00829322|Drug|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
17877|NCT00825019|Drug|placebo|oral administration in 12h intervals
17878|NCT00825019|Drug|paroxetine|oral administration of 20 mg/day
17879|NCT00825032|Procedure|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
17880|NCT00825032|Procedure|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
20175|NCT00817024|Drug|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
20176|NCT00817024|Drug|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
20177|NCT00817037|Drug|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
20178|NCT00817037|Drug|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
20179|NCT00819624|Other|Interactive Voice Response System (IVRS)|Telephone based system
20180|NCT00819624|Other|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
20181|NCT00819637|Drug|arformoterol (RR formoterol)|Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.
Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
20182|NCT00000762|Biological|rgp120/HIV-1 SF-2|
20183|NCT00007527|Drug|buprenorphine|
20184|NCT00819637|Drug|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
20185|NCT00819637|Drug|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
20186|NCT00819650|Drug|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na[131I],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
20187|NCT00819676|Other|analysis of exhaled breath by biosensors|
20188|NCT00819676|Other|measurement of exhaled nitric oxide|
20189|NCT00819702|Other|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
20190|NCT00819728|Drug|Docetaxel|35mg/m2 IV each week for 4 weeks
20191|NCT00819728|Drug|Irinotecan|50mg/m2 IV each week for 4 weeks
20192|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
20193|NCT00819741|Drug|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
19655|NCT00818805|Drug|Placebo (Olopatadine)|one drop in contralateral eye
19656|NCT00818805|Drug|Placebo (Tranilast)|one drop in contralateral eye
19657|NCT00818818|Drug|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
19892|NCT00816556|Drug|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
19893|NCT00816556|Drug|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
19894|NCT00816556|Drug|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
19895|NCT00816569|Device|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
19896|NCT00816582|Procedure|Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline|A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
19897|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - Baseline|A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
19898|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up|A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
19899|NCT00819208|Other|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
19900|NCT00819208|Other|educational intervention|Once at the beginning of the program
19901|NCT00819208|Other|laboratory biomarker analysis|Every 12 months
19902|NCT00819208|Other|questionnaire administration|Every 6 months
19903|NCT00819208|Other|study of socioeconomic and demographic variables|Every 6 months
19904|NCT00819208|Procedure|fatigue assessment and management|Every 6 months
19905|NCT00819208|Procedure|quality-of-life assessment|Every 6 months
19906|NCT00819208|Other|Educational Intervention|For Arm 2 just once at beginning of program.
19907|NCT00819208|Other|Fitness testing|Objective fitness testing for both arms
17814|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
17815|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
17816|NCT00827528|Procedure|Traditional correction of anterior vaginal wall prolapse|Traditional repair.
Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery.
17817|NCT00827528|Procedure|Biologic Graft (SIS)|Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery.
17818|NCT00008047|Drug|paclitaxel|
18119|NCT00830726|Procedure|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
18120|NCT00830726|Procedure|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
18121|NCT00830726|Procedure|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
18122|NCT00830765|Drug|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
18123|NCT00008190|Drug|etoposide|
18124|NCT00830765|Drug|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
18125|NCT00830778|Procedure|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
18126|NCT00830778|Procedure|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
18127|NCT00830791|Drug|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
18128|NCT00830791|Drug|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
18129|NCT00830804|Drug|Raltegravir|400 mg tablet taken orally twice daily
18130|NCT00823212|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).
18131|NCT00823212|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
17881|NCT00825045|Drug|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
17882|NCT00825058|Drug|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
17883|NCT00825058|Drug|placebo|oral administration 12 hours intervals
17884|NCT00000767|Biological|TBC-3B Vaccine|
17885|NCT00007982|Procedure|autologous bone marrow transplantation|
17886|NCT00825058|Drug|paroxetine|oral 20 mg/day
17887|NCT00825071|Drug|Dexamethasone|8 mg, Intravenous
17888|NCT00825071|Drug|Ondansetron|4 mg, intravenously
17889|NCT00825071|Drug|normal saline|2 ml, intravenously
17890|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
17891|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
17892|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
17893|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
17894|NCT00825097|Procedure|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
17895|NCT00825097|Drug|Botulinum toxin injection|Botulinum toxin type A
17896|NCT00007982|Procedure|bone marrow ablation with stem cell support|
17897|NCT00825123|Drug|Ivabradine|Ivabradine 10 mg once
17898|NCT00825123|Drug|Metoprolol|Metoprolol 50 mg once
18203|NCT00830531|Drug|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
18204|NCT00830544|Drug|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
20194|NCT00007592|Drug|Chlorthalidone|
20195|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
19274|NCT00815789|Behavioral|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
19275|NCT00006929|Drug|carboplatin|Given IV
19276|NCT00815815|Behavioral|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
19277|NCT00815828|Other|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
19278|NCT00815841|Drug|METHYLPHENIDATE|15-20mg during one of the two sessions
19279|NCT00818194|Drug|cyclosporine A microemulsion|oral
19280|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
19281|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
19282|NCT00818220|Procedure|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
19283|NCT00007241|Device|Isometric exercise|
19284|NCT00818220|Other|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
19285|NCT00818233|Device|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
19286|NCT00818246|Device|Sham light|
19287|NCT00818246|Device|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
19288|NCT00818259|Drug|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
19289|NCT00818259|Drug|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial, IV
19908|NCT00007449|Drug|DPC 083|
19909|NCT00819221|Drug|AZD2281|capsules, oral, bd, 2 months
19910|NCT00819221|Drug|liposomal doxorubicin|once every 4 weeks at 40mg/m2
19911|NCT00819234|Drug|Placebo|placebo pramlintide and placebo metreleptin twice daily
19912|NCT00819234|Drug|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
20259|NCT00817089|Drug|placebo|placebo pills
20260|NCT00817089|Other|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice
20261|NCT00817102|Procedure|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
20262|NCT00817115|Device|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
20263|NCT00817128|Procedure|PEPT|Pain Exposure Physical Therapy
20264|NCT00817128|Procedure|CBO standard|Standard therapy as defined in CBO guideline 2006
20265|NCT00817141|Other|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
20266|NCT00007033|Drug|magnesium gluconate|
20267|NCT00817154|Behavioral|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
20268|NCT00817167|Device|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
20269|NCT00817167|Device|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
20270|NCT00817180|Other|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
20271|NCT00817180|Other|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
20272|NCT00817193|Behavioral|Physical Activity|Physical Activity program
18132|NCT00823212|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
18133|NCT00823225|Procedure|standard therapy|wound debridement, moist wound dressing
18134|NCT00823225|Drug|Urokinase|Daily infusion up to 21 applications, dose dependent on fibrinogen level:
> 2,5g/l 1 000 000 IU, < 2,5g/l 500 000 IU
18135|NCT00823238|Drug|ceftazidime and tobramycin|
18136|NCT00823238|Drug|inhaled tobramycin|
18137|NCT00823264|Drug|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
18138|NCT00007891|Procedure|autologous bone marrow transplantation|
18455|NCT00826085|Drug|ThermoDox in combination with Microwave Hyperthermia (heat)|ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.
Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.
All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals.
18456|NCT00008008|Biological|sargramostim|
18457|NCT00826098|Biological|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
18458|NCT00826111|Drug|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
18459|NCT00826111|Drug|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
18460|NCT00826124|Procedure|Epidural steroid injection|Injection based solely on history and physical exam
18461|NCT00826124|Procedure|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
18462|NCT00826124|Procedure|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
18463|NCT00826137|Dietary Supplement|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
18464|NCT00826137|Dietary Supplement|Placebo|Placebo is base powder of product with no oligosaccharides.
18205|NCT00830544|Drug|Chemotherapy|Neoadjuvant chemotherapy
18206|NCT00830544|Drug|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
18207|NCT00830557|Other|medical chart review|baseline, 12 month and 36 months
18208|NCT00830557|Other|survey administration|baseline, 6 month, 12 month
18209|NCT00830557|Other|biospecimen collection|baseline
18210|NCT00830570|Other|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
18211|NCT00830583|Procedure|blood test|There is only a blood test at the beginning.
18212|NCT00830596|Other|1|High velocity, low amplitude lumbo-pelvic manipulation
18213|NCT00008190|Biological|filgrastim|
18214|NCT00830596|Other|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
18215|NCT00830596|Other|light effleurage followed by SMT|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
18216|NCT00830609|Drug|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
18217|NCT00830609|Drug|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks
18218|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 24 weeks
18219|NCT00830609|Drug|ribavirin|ribavirin 800 mg/day for 24 weeks
18220|NCT00830609|Drug|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
18221|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
18222|NCT00830622|Other|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
18223|NCT00830635|Other|educational intervention|
18537|NCT00823849|Other|Control Group|Routine treatment
18538|NCT00823862|Drug|SD-101|Intramuscular (IM)
19290|NCT00818259|Drug|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
19291|NCT00818259|Drug|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
19292|NCT00818259|Drug|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
19582|NCT00818766|Drug|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours, or until all chest tubes have been removed -- whichever comes first. Subjects under 80kg will receive 1 gram of cefazolin and subjects who are 80kg or more will receive 2 grams of cefazolin. Subjects who are penicillin-allergic will receive 1 gram of vancomycin every 12 hours for 48 hours, or until all chest tubes are removed -- whichever comes first.
19583|NCT00821158|Other|Placebo|Placebo tablet and iv
19584|NCT00821158|Drug|Anti-inflammatory drug|Anti-inflammatory tablet
19585|NCT00007787|Biological|Cyclosporine|
19586|NCT00821184|Drug|Vesicare (solifenacin)|5mg po qd
19587|NCT00821184|Behavioral|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
19588|NCT00821197|Procedure|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
19589|NCT00821197|Procedure|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
19590|NCT00821210|Device|Sham CPAP|CPAP with pressure of 3cm H2O
19591|NCT00821210|Device|CPAP of optimal pressure|CPAP of optimal pressure
19592|NCT00821223|Procedure|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
19593|NCT00821223|Procedure|manual small incision surgery|
19594|NCT00821223|Procedure|phacoemulsification|cataract surgery
19595|NCT00821236|Device|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
19596|NCT00007787|Biological|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
19597|NCT00821236|Device|AMO/VISX CustomVue™|Excimer Laser
19598|NCT00821236|Device|LADARVision 4000 excimer laser|Excimer Laser
20273|NCT00817193|Behavioral|Wellness|Wellness program
20274|NCT00819780|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
20275|NCT00819793|Device|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
20276|NCT00007592|Drug|Furosemide|
19059|NCT00006721|Radiation|tositumomab and iodine I 131 tositumomab|Given IV
19060|NCT00813332|Drug|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
19061|NCT00813332|Drug|Placebo plus Docetaxel|Placebo plus Docetaxel
19062|NCT00813345|Other|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
19063|NCT00813345|Other|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
19064|NCT00813358|Device|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
19065|NCT00813371|Device|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
19066|NCT00813371|Device|ARDSnet protocol|ARDSnet protocol
19067|NCT00813384|Drug|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c‑Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
19068|NCT00813397|Device|Sepraspray|Max. 10g of Sepraspray
19069|NCT00813410|Procedure|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
19070|NCT00006734|Biological|filgrastim|Given IV
19071|NCT00813423|Drug|Hydroxychloroquine|Given PO
19072|NCT00813423|Other|Laboratory Biomarker Analysis|Correlative studies
18465|NCT00826150|Biological|BC-819|Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
18466|NCT00826163|Drug|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
18467|NCT00008008|Drug|cyclophosphamide|
18468|NCT00826176|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
18469|NCT00826202|Drug|D-serine|60 mg/kg/day
18470|NCT00826202|Other|Placebo|Inert Placebo
18471|NCT00828646|Drug|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
18472|NCT00828646|Drug|Placebo|Capsules, Oral, once daily, 14 days
18473|NCT00008112|Drug|cisplatin|
18474|NCT00828659|Drug|Placebo|
18790|NCT00821964|Other|laboratory biomarker analysis|Correlative studies
18791|NCT00821964|Genetic|RNA analysis|Correlative studies
18792|NCT00007813|Procedure|peripheral blood stem cell transplantation|
18793|NCT00821964|Other|immunoenzyme technique|Correlative studies
18794|NCT00821977|Drug|Vildagliptin|
18795|NCT00821977|Drug|Vildagliptin|
18796|NCT00821977|Drug|Placebo|
18797|NCT00821990|Drug|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
18798|NCT00821990|Other|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
18799|NCT00822003|Drug|Oral GLP-1|GLP-1 tablet (2mg)
18800|NCT00822003|Drug|Placebo|Control tablet
18539|NCT00823862|Drug|ribavirin|oral, 2 times per day, for 2 months
18540|NCT00823875|Drug|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
18541|NCT00823875|Drug|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
18542|NCT00826215|Device|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
18543|NCT00826215|Device|Sham laser acupuncture|Sham laser acupuncture
18544|NCT00826228|Drug|teriparatide|teriparatide 20ug daily sc for 6 months
18545|NCT00826228|Other|weight-bearing|device assisted walking
18546|NCT00826241|Drug|Temozolomide|Starting dose 125 mg/m2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle.
18547|NCT00826241|Drug|Lapatinib|Starting dose 1250 mg daily by mouth.
18548|NCT00826254|Drug|Vitamin K|180 micrograms vitamin K daily
18549|NCT00008008|Drug|thiotepa|
18550|NCT00826254|Drug|Vitamin K|2 capsules daily 180 micrograms vitamin K daily or placebo
1 year
18551|NCT00826267|Drug|lapatinib|lapatinib tablets 1500 mg daily
18552|NCT00826267|Drug|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
18553|NCT00826267|Drug|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
18554|NCT00826280|Drug|regadenoson|IV
18555|NCT00826280|Drug|overencapsulated caffeine|oral
18556|NCT00826280|Radiation|technetium|IV
18557|NCT00826280|Drug|placebo|oral
18558|NCT00826293|Procedure|Stabilization belt|Patients receive true stabilization.
18559|NCT00826293|Procedure|Stabilization belt|Patients receive sham stabilization.
18560|NCT00008008|Procedure|autologous bone marrow transplantation|
19599|NCT00821249|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
19600|NCT00821249|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
19601|NCT00821249|Drug|Dexamethasone, steroid; oral|Part 3: standard of care.
19602|NCT00821262|Drug|sevoflurane|
19603|NCT00821262|Drug|propofol|
19836|NCT00821288|Behavioral|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
19837|NCT00007787|Drug|Tacrolimus|
19838|NCT00821301|Drug|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
19839|NCT00821327|Drug|Gemcitabine, Cisplatin, Sunitinib|Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.
2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.
3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity.
19840|NCT00821340|Genetic|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
19841|NCT00821353|Procedure|RF catheter ablation|RF catheter ablation
19842|NCT00821353|Drug|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
19843|NCT00821366|Behavioral|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
19844|NCT00821366|Dietary Supplement|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
19845|NCT00821366|Drug|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
19846|NCT00821392|Drug|Febuxostat|
19847|NCT00821418|Device|PulseHaler treatment|treatment is for two weeks, 3 times per day
19073|NCT00813423|Other|Pharmacological Study|Correlative studies
19074|NCT00813423|Drug|Sunitinib Malate|Given PO
19075|NCT00815295|Drug|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
19076|NCT00815308|Drug|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8)
19077|NCT00815308|Drug|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m^2,(Day1 in every week for Weeks 2-8)
19078|NCT00815308|Drug|Cisplatin|Cisplatin,injection,loading dose 20 mg/m^2,(Day1 in every week for Weeks 2-8)
19079|NCT00815308|Radiation|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
18058|NCT00823212|Device|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
18059|NCT00825214|Device|Inactivated zapperclick device|placebo
18060|NCT00825227|Drug|Armodafinil 150 mg/day|150 mg/day armodafinil
concurrent with one cycle of taxane chemotherapy alone or in combination with other agents
patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents
18061|NCT00825227|Drug|Placebo,|placebo
concurrent with one cycle of taxane chemotherapy alone or in combination with other agents
patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents
18062|NCT00007995|Biological|recombinant interferon alfa|
18063|NCT00825240|Behavioral|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
18064|NCT00825253|Drug|biphasic insulin aspart 30|
18065|NCT00825253|Drug|biphasic human insulin 30|
18066|NCT00825266|Drug|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
18067|NCT00825266|Drug|Pioglitigone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
18068|NCT00825279|Device|Bare Metal Stent|Stainless steel stent
18069|NCT00825279|Device|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
18801|NCT00822029|Drug|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
18802|NCT00822029|Other|PLACEBO|patient receiving one tablet (oral use) placebo by week
18803|NCT00007826|Biological|BCG vaccine|
18804|NCT00822042|Other|Samples and procedures|Scanner, histomorphometry : at the inclusion and M3 visits
whole blood samples, cytoponction : at the inclusion and M3 visits
18805|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
18806|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
18807|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
18808|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
18809|NCT00822068|Device|anodal tDCS|anodal transcranial direct current stimulation
18810|NCT00822068|Device|cathodal tDCS|cathodal transcranial direct current stimulation
18811|NCT00822068|Device|sham stimulation|sham stimulation
18812|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
18813|NCT00822081|Drug|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
17819|NCT00827541|Drug|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
17820|NCT00827554|Drug|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
17821|NCT00827554|Procedure|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
17822|NCT00827567|Drug|RAD 001|RAD 001-10 mg by mouth once everyday
17823|NCT00827580|Drug|Eniluracil|
17824|NCT00827580|Drug|Capecitabine|
17825|NCT00827593|Behavioral|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
17826|NCT00827593|Behavioral|Weight Watchers|Participants will receive 12 months of Weight Watchers
18561|NCT00826306|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
18871|NCT00829335|Procedure|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
18872|NCT00829348|Other|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
18873|NCT00829348|Behavioral|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
18874|NCT00829361|Other|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
18875|NCT00829374|Drug|Dimebon|5 mg orally three times daily
18876|NCT00829374|Drug|Dimebon|20 mg orally three times daily
18877|NCT00829374|Drug|Placebo comparator|Placebo orally three times daily
18878|NCT00829387|Behavioral|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
18879|NCT00829387|Behavioral|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
18880|NCT00008151|Drug|fludarabine phosphate|
18881|NCT00829400|Behavioral|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
18882|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
18883|NCT00822081|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
18884|NCT00822094|Drug|CPX-351|100u/m2 will be administered on study days 1, 3 and 5 as a 90 minute infusion
18885|NCT00822094|Drug|Intensive Salvage Therapy|Investigators choice of an Intensive Salvage Therapy as used for remission induction
18886|NCT00822107|Drug|Hydrochlorothiazide|50 mg one time
18887|NCT00822120|Biological|bleomycin sulfate|
19848|NCT00007800|Behavioral|Behavioral Group Weight Loss Intervention|
19849|NCT00821418|Device|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
19850|NCT00821431|Device|Compression Device|Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:
Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.
Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day.
19851|NCT00821431|Device|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
20196|NCT00819754|Drug|IXO regimen + bevacizumab|Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose
Phase II study - assesses efficacy and safety of IXO with bevacizumab
20197|NCT00819767|Drug|Aliskiren|Aliskiren was supplied in 150 mg tablets.
20198|NCT00819767|Drug|Valsartan|Valsartan was supplied in 160 mg capsules.
20199|NCT00819767|Drug|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
20200|NCT00819767|Drug|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
20201|NCT00819780|Drug|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
20202|NCT00819780|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
20203|NCT00812799|Other|placebo control|placebo control
20204|NCT00812812|Drug|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
20205|NCT00812812|Drug|paroxetine 20mg tablet|1 tablet once a day
20206|NCT00812812|Drug|matched placebo to paroxetine 10mg|2 tablets once a day
20207|NCT00812812|Drug|matched placebo to paroxetine 20mg|1 tablet once a day
20208|NCT00812825|Drug|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
20209|NCT00812825|Drug|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
18070|NCT00825292|Procedure|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
18071|NCT00825292|Procedure|colon polyp removal|identify and remove polyp
18072|NCT00825292|Procedure|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
18073|NCT00007995|Biological|sargramostim|
18074|NCT00825305|Biological|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
18075|NCT00825305|Biological|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
18076|NCT00825318|Procedure|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
18077|NCT00825344|Drug|Etanercept|50 mg subcutaenous preoperatively
18078|NCT00825344|Drug|Saline|Given subcutaneously preoperatively
18390|NCT00828568|Drug|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
18391|NCT00828581|Drug|lorcaserin|
18392|NCT00828594|Drug|RAD001|
18393|NCT00828594|Drug|RAD001, sorafenib|
18394|NCT00828620|Other|Imaging study|PET-CT
18395|NCT00828646|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
18396|NCT00828646|Drug|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
18397|NCT00830804|Drug|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
18398|NCT00830830|Drug|Hyalgan (sodium hyaluronate)|
18399|NCT00830843|Drug|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
18400|NCT00830843|Drug|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
18401|NCT00008190|Drug|melphalan|
18402|NCT00830856|Drug|Fluconazole|Fluconazole 800mg po qday
17827|NCT00827593|Behavioral|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
17828|NCT00827606|Drug|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
17829|NCT00008047|Procedure|conventional surgery|
17830|NCT00827619|Device|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
17831|NCT00827632|Drug|Low dose formulation|Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.
Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.
17832|NCT00827632|Drug|High dose formulation|Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.
Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.
17833|NCT00830076|Drug|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
17834|NCT00830076|Drug|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
17835|NCT00008177|Radiation|total-body irradiation|Undergo total-body irradiation
17836|NCT00830076|Drug|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
17837|NCT00830089|Drug|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
18139|NCT00823277|Other|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after ~ 1 Year.
18140|NCT00823290|Drug|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
18141|NCT00823303|Drug|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
18142|NCT00823303|Drug|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
18143|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
18144|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
18888|NCT00822120|Biological|filgrastim|
18889|NCT00822120|Drug|ABVD regimen|
18890|NCT00822120|Drug|BEACOPP regimen|
18891|NCT00822120|Drug|cyclophosphamide|
18892|NCT00007826|Drug|alum adjuvant|
17899|NCT00825123|Drug|Placebo|Lactose powder
17900|NCT00825136|Behavioral|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
17901|NCT00827658|Procedure|Local Block|total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)
17902|NCT00827671|Drug|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
17903|NCT00827671|Radiation|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
17904|NCT00827684|Drug|Irinotecan|
17905|NCT00827684|Drug|Temsirolimus|
17906|NCT00827697|Other|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
17907|NCT00827710|Behavioral|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
17908|NCT00008047|Radiation|radiation therapy|
17909|NCT00827710|Behavioral|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
17910|NCT00827736|Procedure|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
17911|NCT00827736|Drug|ISDN ointment|application of ISDN 1% ointment 6 times a day
17912|NCT00827736|Drug|Placebo|Injection of placebo into internal anal sphincter (ISDN ointment arm)
Applied to the anoderm six times a day (Botox injection arm)
17913|NCT00827749|Device|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
17914|NCT00827762|Drug|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
17915|NCT00827775|Drug|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
20210|NCT00812825|Drug|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
20211|NCT00006708|Drug|etoposide|
20212|NCT00812825|Drug|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
20213|NCT00812825|Drug|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
20214|NCT00812838|Drug|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
20215|NCT00812838|Other|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
20216|NCT00812851|Drug|Dronabinol|
19293|NCT00818272|Biological|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
19294|NCT00000761|Drug|Interferon gamma-1b|
19295|NCT00007254|Drug|Pain relief for pressure ulcers|
19296|NCT00818285|Device|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
19297|NCT00818298|Drug|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
19298|NCT00818311|Device|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
19299|NCT00818324|Drug|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
19300|NCT00820404|Drug|Placebo|
19301|NCT00820417|Drug|Cetuximab/Gefitinib combination and/or monotherapy|
19302|NCT00820430|Other|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
18403|NCT00830856|Drug|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
18404|NCT00830856|Drug|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
18405|NCT00830869|Drug|IXAZOMIB|All patients will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.
The first stage of the study will be initiated at a starting dose of 0.125 mg/m2
Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
18406|NCT00830882|Drug|levosalbutamol|2 puffs four times a day for 2 weeks
18407|NCT00830882|Drug|racemic salbutamol|2 puffs four times a day for 2 weeks
18408|NCT00830882|Drug|placebo|2 puffs four times a day for 2 weeks
18409|NCT00830895|Drug|RAD001|RAD001 10mg/day
18410|NCT00830908|Device|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
18411|NCT00830921|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
18412|NCT00008190|Procedure|peripheral blood stem cell transplantation|
18728|NCT00824135|Procedure|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
18729|NCT00007930|Procedure|conventional surgery|
18730|NCT00824135|Other|OKT3|Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total
Muromonab-CD3
18731|NCT00824135|Drug|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
18732|NCT00824135|Drug|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
18733|NCT00824135|Drug|Mycophenolate mofetil|Mycophenolate mofetil 600 mg/m2 intravenous two times a day
(continue for approximately 2 months or as clinically indicated)
18734|NCT00824135|Drug|Rituximab|375 mg/m2 intravenous for 1 dose total
18735|NCT00824135|Other|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
18736|NCT00824148|Device|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
18737|NCT00824148|Other|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
18145|NCT00823329|Device|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
18146|NCT00823342|Drug|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
18147|NCT00823342|Drug|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
18148|NCT00823342|Drug|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
18149|NCT00007891|Procedure|peripheral blood stem cell transplantation|
18150|NCT00823355|Drug|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
18151|NCT00823355|Drug|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
18152|NCT00823355|Drug|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
18153|NCT00823355|Drug|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
18154|NCT00825435|Procedure|Coronary CT Angiogram|Coronary CT Angiogram
18155|NCT00825448|Procedure|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
18156|NCT00825474|Other|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
18157|NCT00825487|Drug|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher (cohort 8 and above).
18158|NCT00825500|Drug|High dose|Staccato Loxapine 2.5 mg
18159|NCT00825500|Drug|Low dose|Staccato Loxapine 1.25 mg
18475|NCT00828659|Drug|Active Comparator #1|
18476|NCT00828659|Drug|Active Comparator #2|
18477|NCT00828659|Drug|Active Comparator #3|
18478|NCT00828659|Drug|Lorcaserin Dose #1|
18479|NCT00828659|Drug|Lorcaserin Dose #2|
17916|NCT00827788|Drug|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
17917|NCT00827788|Drug|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
17918|NCT00827801|Behavioral|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 & 8.
17919|NCT00008060|Drug|FOLFIRI regimen|
17920|NCT00827814|Drug|Dutasteride|Dutasteride 0.5 mg od.
17921|NCT00827827|Other|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
18224|NCT00008190|Drug|busulfan|
18225|NCT00830635|Other|informational intervention|
18226|NCT00830635|Other|internet-based intervention|
18227|NCT00830635|Other|questionnaire administration|
18228|NCT00830635|Other|study of socioeconomic and demographic variables|
18229|NCT00823368|Drug|STX209|
18230|NCT00823381|Dietary Supplement|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
18231|NCT00823381|Other|placebo|one placebo pill taken once a day with breakfast
18232|NCT00823381|Behavioral|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
18233|NCT00823394|Behavioral|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
18234|NCT00823394|Other|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
18235|NCT00007891|Radiation|indium In 111 monoclonal antibody BrE-3|
18236|NCT00823394|Behavioral|Self-help Materials|Information on how to lower risk for developing cancer.
18237|NCT00823407|Drug|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
18238|NCT00823407|Drug|Placebo|Subjects will receive a single oral dose of placebo
18239|NCT00823420|Procedure|prematuration culture|The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a "prolonged" IVM (PMC)) in comparison to "conventional" IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos.
19303|NCT00820443|Device|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
19304|NCT00820456|Other|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
19305|NCT00820469|Drug|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
19306|NCT00007670|Drug|Lamotrigine|
19307|NCT00820469|Drug|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
19308|NCT00820482|Drug|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
19309|NCT00820482|Drug|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
19310|NCT00820495|Behavioral|Web + Phone|Web + Phone
19311|NCT00820495|Behavioral|Web Only|Web Only
19312|NCT00820495|Behavioral|Phone Only|Phone Only
19604|NCT00821275|Procedure|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
19605|NCT00821288|Behavioral|Survivorship Intervention|Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals "Survivorship Prescription" including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker).
19606|NCT00814099|Behavioral|Team approach to sedation management|The team approach to sedation management includes the following:
Team education and consensus on the use of sedatives
Team identification of the patient's trajectory of illness and daily prescription of a sedation goal
A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines
Team feedback on sedation management performance
19607|NCT00814099|Behavioral|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
19608|NCT00814125|Drug|Anastrozole (Arimidex)|1mg, orally, once daily
19609|NCT00814125|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
19610|NCT00814125|Drug|Nolvadex placebo|
19611|NCT00814125|Drug|Arimidex placebo|
18738|NCT00824161|Drug|TAS-109|14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.
Number of cycles: until unacceptable toxicity or disease progression requires discontinuation.
18739|NCT00826566|Dietary Supplement|placebo|2 times 250 mg per day
18740|NCT00826579|Procedure|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
18741|NCT00826579|Procedure|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
18742|NCT00826592|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
18743|NCT00826618|Drug|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
18744|NCT00826631|Procedure|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
18745|NCT00826644|Drug|Belotecan/Cisplatin|Belotecan : 0.5mg/㎡/day for Day 1 to 4, Cisplatin : 60mg/㎡/day for Day 1.
18746|NCT00000768|Drug|Glutamic acid hydrochloride|
18747|NCT00008021|Biological|monoclonal antibody Lym-1|
19080|NCT00815321|Biological|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
19081|NCT00815334|Procedure|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
19082|NCT00815347|Drug|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
19083|NCT00815347|Drug|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
19084|NCT00006903|Drug|fulvestrant|
19085|NCT00815360|Drug|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
18480|NCT00828659|Drug|Lorcaserin Dose #3|
18481|NCT00828672|Drug|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
18482|NCT00828672|Drug|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
18483|NCT00828672|Drug|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
18484|NCT00008112|Procedure|hyperthermia treatment|
18485|NCT00828672|Radiation|radiotherapy|Total dose 45Gy
18486|NCT00828685|Procedure|CRPP|Closed reduction, percutaneous pinning
18487|NCT00828685|Procedure|ORIF|Open reduction, internal fixation
18488|NCT00828698|Other|No intervention|
18489|NCT00828711|Drug|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
18490|NCT00828711|Drug|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
18491|NCT00828711|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
18492|NCT00828724|Drug|Lorcaserin 10mg|
18493|NCT00828737|Drug|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
18494|NCT00828750|Drug|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
18495|NCT00008112|Radiation|brachytherapy|
18496|NCT00828763|Drug|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
18497|NCT00828776|Biological|Heparin sodic - Cristália|5000UI/mL
18814|NCT00007826|Biological|monoclonal antibody 105AD7 anti-idiotype vaccine|
18815|NCT00824174|Behavioral|Questionnaire|1 questionnaire, about 15-20 minutes.
18816|NCT00007930|Procedure|laparoscopic surgery|
18240|NCT00823433|Drug|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
18241|NCT00823446|Device|Revera Wound Care|Revalesio Part Number MDW0060
18242|NCT00823446|Device|Normal Saline|Sodium Chloride for Irrigation
18243|NCT00823459|Drug|RAD001|RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.
18244|NCT00823472|Drug|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
18245|NCT00823485|Procedure|fibrinolysis in situ|intraventricular injection of actilyse
18246|NCT00007891|Radiation|yttrium Y 90 monoclonal antibody BrE-3|
18562|NCT00826332|Procedure|transabdominal ultrasound|transabdominal ultrasound
18563|NCT00826332|Procedure|transvaginal ultrasound|transvaginal ultrasound
18564|NCT00826345|Other|Acupuncture / Moxibustion|Acupuncture/Moxibustion points will be administered per point prescription.
- Active
18565|NCT00826345|Other|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
18566|NCT00826358|Drug|ABT-143|Once, please see Arm Description for more details.
18567|NCT00826358|Drug|ABT-335|Once, see Arm Description for more detail
18568|NCT00826358|Drug|rosuvastatin|once, see Arm Description for more detail
18569|NCT00826371|Drug|ranibizumab 0.5 mg|
18570|NCT00826384|Procedure|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
18571|NCT00008008|Procedure|bone marrow ablation with stem cell support|
18572|NCT00828789|Drug|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
18573|NCT00828802|Drug|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
18574|NCT00828815|Drug|TMC125|
18575|NCT00828828|Biological|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
19612|NCT00814138|Drug|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
19613|NCT00814138|Other|Placebo|Weekly
19614|NCT00814151|Other|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|In vitro diagnostic: The MicroPhage "Intervention" was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The "Intervention" results were not made available to the patient or their physician.
19615|NCT00814164|Drug|clofarabine|IV
19616|NCT00006747|Drug|ara-C|200 mg/sq m /day IV days -5 thru -2
19617|NCT00814164|Drug|daunorubicin hydrochloride|IV
19618|NCT00814164|Genetic|cytogenetic analysis|Correlative study
19619|NCT00814164|Genetic|protein expression analysis|Correlative Study
19620|NCT00814164|Other|immunologic technique|Correlative Study
19621|NCT00814164|Other|pharmacological study|Correlative Study
19622|NCT00814177|Drug|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
19852|NCT00821444|Drug|ziprasidone|40 mg capsule, single dose x 3
19853|NCT00821444|Drug|B16 Fasted|40 mg tablet, single dose X 3
19854|NCT00821444|Drug|B16 Fed|40 mg tablet, single dose X 3
19855|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
19856|NCT00814385|Biological|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
19857|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
19858|NCT00006773|Drug|bortezomib|Given IV
19859|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
19860|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
19086|NCT00815360|Procedure|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
19087|NCT00815360|Drug|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
19088|NCT00815360|Procedure|macular laser|macular laser to areas of retinal thickening or leakage
19089|NCT00815373|Drug|Dorzolamide+Timolol Maleate0.5%|Cosopt* b. i. d.
19090|NCT00815373|Drug|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom* QHS
19091|NCT00815386|Device|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
19092|NCT00815399|Drug|Pioglitazone|15-45 mg/die
19093|NCT00815399|Drug|Metformin|500-2000 mg/die
19094|NCT00815412|Behavioral|Counseling in use of health care|
19095|NCT00006916|Biological|bleomycin|
19096|NCT00815412|Behavioral|Counseling in diet, exercise|
19097|NCT00815412|Other|Control|
19098|NCT00815438|Procedure|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
19099|NCT00817791|Device|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
18079|NCT00825370|Drug|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
18080|NCT00825370|Drug|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
18081|NCT00825383|Other|High Fiber and Moderate Fiber Diets|Dietary
18082|NCT00825396|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
18083|NCT00825422|Drug|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
18084|NCT00007995|Drug|busulfan|
18085|NCT00827970|Behavioral|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
18086|NCT00827983|Drug|Progesterone|25 mg, s.c., once à day
18817|NCT00824187|Drug|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
18818|NCT00824187|Drug|Placebo|Inert tablet
18819|NCT00824200|Behavioral|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema.
18820|NCT00824200|Drug|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
18821|NCT00824200|Drug|placebo|tamsulosin placebo
18822|NCT00824200|Behavioral|placebo|placebo behavioral intervention
18823|NCT00824226|Dietary Supplement|magnesium|magnesium 350 mg tablets once a day for 3 weeks
18824|NCT00824239|Procedure|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
18825|NCT00824239|Procedure|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
18826|NCT00824252|Behavioral|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
18827|NCT00007943|Drug|gemcitabine hydrochloride|
18828|NCT00824265|Drug|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
18829|NCT00824265|Drug|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
18830|NCT00824291|Drug|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
18831|NCT00824291|Genetic|Genotyping|CYP2D6 genotyping at randomization
18832|NCT00824317|Drug|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
18833|NCT00824317|Drug|Placebo|
18834|NCT00824330|Behavioral|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
18576|NCT00828841|Drug|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
18577|NCT00828841|Drug|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
18578|NCT00828841|Drug|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
18579|NCT00008112|Radiation|radiation therapy|
18580|NCT00828841|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
18581|NCT00828841|Drug|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
18582|NCT00828854|Drug|entinostat (SNDX-275)|5 mg PO every week
18583|NCT00828867|Drug|100 mg GSK investigational drug|
18584|NCT00828867|Drug|200 mg GSK investigational drug|
18585|NCT00828867|Drug|400 mg GSK investigational drug|
18586|NCT00828867|Drug|800 mg GSK investigational drug|
18893|NCT00822120|Drug|dacarbazine|
18894|NCT00822120|Drug|doxorubicin hydrochloride|
18895|NCT00822120|Drug|etoposide|
18896|NCT00822120|Drug|prednisone|
18897|NCT00822120|Drug|procarbazine hydrochloride|
18898|NCT00822120|Drug|vinblastine sulfate|
18899|NCT00822120|Drug|vincristine sulfate|
18900|NCT00822133|Drug|lidocaine|lidocaine 5%
18901|NCT00822133|Drug|ketamine|ketamine cream
18902|NCT00822133|Drug|non-active drug cream|will be put on the skin
18903|NCT00007839|Drug|beta alethine|
18904|NCT00822146|Device|CRT|classified
19861|NCT00814385|Biological|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
19862|NCT00814398|Procedure|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
19863|NCT00814398|Procedure|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
19864|NCT00814411|Behavioral|group family planning counseling|group family planning counseling for gynecological patients with unmet need
19865|NCT00814411|Behavioral|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
19866|NCT00814424|Device|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
19867|NCT00814424|Device|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
19868|NCT00814450|Device|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
19869|NCT00000757|Biological|gp160 Vaccine (MicroGeneSys)|
19870|NCT00006786|Biological|bevacizumab|
19871|NCT00814463|Behavioral|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
19872|NCT00814463|Behavioral|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
19873|NCT00814463|Procedure|MRI|MRI done every 3 months for the length of the study.
20217|NCT00812864|Drug|Capecitabine|Pharmacokinetic of its metabolites.
Capecitabine, 1250 mg/m2 twice a day
20218|NCT00812877|Drug|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
20219|NCT00812877|Drug|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
20220|NCT00812890|Device|semi-quantitative pregnancy test|
20221|NCT00812903|Behavioral|Exercise|Training exercises chosen with background in knowledge of intelligent training
20222|NCT00006708|Drug|ifosfamide|
20223|NCT00812916|Procedure|RF ablation, using specialized CFAE software|RF ablation
20224|NCT00812929|Drug|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
18087|NCT00827983|Drug|Progesterone|90 mg, vaginally, once à day
18088|NCT00827996|Drug|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
18089|NCT00828009|Biological|bevacizumab|
18090|NCT00828009|Biological|emepepimut-S|
18091|NCT00828009|Drug|carboplatin|
18092|NCT00008060|Drug|irinotecan hydrochloride|
18093|NCT00828009|Drug|cyclophosphamide|
18094|NCT00828009|Drug|paclitaxel|
18095|NCT00828009|Radiation|radiation therapy|
18096|NCT00828022|Biological|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
18097|NCT00828035|Procedure|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
18098|NCT00828061|Drug|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
18099|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
18100|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
18101|NCT00828074|Drug|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
18413|NCT00830934|Procedure|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
18414|NCT00830934|Procedure|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
18415|NCT00830947|Device|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
18416|NCT00830947|Device|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
18417|NCT00830960|Drug|Prasugrel|Oral, daily, 90 days
17838|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)
Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI
Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
17839|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)
Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)
Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
17840|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)
Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
17841|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)
Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
17842|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)
Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)
Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)
17843|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI
Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)
Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)
17844|NCT00830115|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
17845|NCT00830128|Drug|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
17846|NCT00008177|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
17847|NCT00830154|Drug|pagoclone|0.30 mg BID, 0.60 mg BID
17848|NCT00830154|Other|placebo|placebo
17849|NCT00822796|Device|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
17850|NCT00822809|Drug|Catumaxomab|Catumaxomab will be infused 4 times within 11 days as follows:
10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10
18905|NCT00822159|Device|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
18906|NCT00822172|Dietary Supplement|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
18907|NCT00822172|Drug|cilostazol|Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.
Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.
18908|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
18909|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
18910|NCT00824356|Drug|GSK1004723 (1000mg)|Intranasal antihistamine.
18911|NCT00824369|Drug|No drug will be administered|No drug will be administered.
18912|NCT00824382|Drug|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
18913|NCT00824382|Drug|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
18914|NCT00824382|Drug|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
18915|NCT00824382|Drug|Placebo|2 puffs delivered by the RespimatÂ® inhaler
18916|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
17922|NCT00827827|Other|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
17923|NCT00827840|Drug|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
17924|NCT00827840|Drug|Risperidone|1 to 6 mg of risperidone once or twice a day
17925|NCT00827853|Procedure|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
17926|NCT00827853|Procedure|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
17927|NCT00830167|Drug|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
17928|NCT00830167|Drug|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
20225|NCT00812929|Drug|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
20226|NCT00812942|Procedure|colonoscopy|colonoscopy screening
20227|NCT00812942|Procedure|faecal test|faecal occult blood test for screening
20228|NCT00812955|Drug|ABT-143|Once daily for 8 weeks
20229|NCT00814879|Other|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
20230|NCT00814892|Biological|allogeneic tumor cell vaccine|Given intradermally
20231|NCT00006825|Biological|trastuzumab|
20232|NCT00814892|Biological|therapeutic autologous dendritic cells|Given intradermally
20233|NCT00814905|Drug|saline|A saline infusion after delivery (one dose)
20234|NCT00814905|Drug|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
20235|NCT00814905|Drug|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
20236|NCT00814905|Drug|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
20237|NCT00814918|Drug|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
19313|NCT00820495|Behavioral|Usual Care|Usual Care
19314|NCT00820508|Drug|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
19315|NCT00820521|Drug|active|
19316|NCT00820521|Drug|placebo|
19317|NCT00007683|Drug|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
19318|NCT00820534|Drug|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
19319|NCT00820534|Drug|Placebo|Placebo every 2 hous during waking hours for 96 hours
18418|NCT00830960|Drug|Clopidogrel|Oral, daily, 90 days
18419|NCT00830973|Other|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
18420|NCT00830973|Other|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
18421|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
18422|NCT00823667|Procedure|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
18423|NCT00823667|Procedure|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
18424|NCT00000766|Drug|Foscarnet sodium|
18425|NCT00007904|Drug|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
18426|NCT00823667|Procedure|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
18427|NCT00823680|Drug|Placebo|po bid for 4 weeks
18428|NCT00823680|Drug|RO5027838|200mg po qd for 4 weeks
18429|NCT00823680|Drug|RO5027838|50mg po bid for 4 weeks
18430|NCT00823680|Drug|RO5093151|400mg po bid for 4 weeks
18431|NCT00823680|Drug|RO5093151|10mg po bid for 4 weeks
18432|NCT00823693|Drug|Bimosiamose Cream|
18433|NCT00823693|Drug|Placebo Cream|
18748|NCT00826644|Drug|Etoposide/Cisplatin|Etoposide : 100mg/㎡/day for Day 1 to 3, Cisplatin : 60mg/㎡/day for Day 1. Repeat next cycle at Day 22.
18749|NCT00826657|Dietary Supplement|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
18750|NCT00826657|Dietary Supplement|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
18751|NCT00826670|Drug|Decolonization|Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days
plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days
17851|NCT00822809|Drug|Prednisolone|25 mg premedication
17852|NCT00822822|Behavioral|First Questionnaire|Complete questionnaire before completing health history
18160|NCT00825500|Drug|Placebo|Staccato Placebo
18161|NCT00825513|Device|Akreos Toric IOL|Lens implant following cataract surgery
18162|NCT00825513|Device|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
18163|NCT00825526|Behavioral|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
18164|NCT00007995|Drug|cyclophosphamide|
18165|NCT00825539|Drug|AQW051|
18166|NCT00825539|Drug|Placebo|
18167|NCT00825552|Drug|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
18168|NCT00825565|Drug|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
18169|NCT00825578|Device|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
18170|NCT00825591|Dietary Supplement|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
18171|NCT00825591|Dietary Supplement|Placebo Comparator|Oral administration before bed. 6 week duration.
18172|NCT00825604|Procedure|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
18173|NCT00825617|Drug|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
18174|NCT00825630|Drug|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
18175|NCT00007995|Drug|melphalan|
17929|NCT00830180|Biological|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
17930|NCT00830193|Drug|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
17931|NCT00830193|Drug|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
17932|NCT00830206|Other|Azithromycin|Oral Suspension
17933|NCT00830206|Drug|Zithromax®|Oral Suspension
17934|NCT00830219|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
17935|NCT00008177|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
17936|NCT00830219|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
17937|NCT00830232|Device|closed-cell stent|Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.
Carotid stenting was used on standard fashion using filters as embolic protection device.
17938|NCT00830232|Device|Open-cell stent|Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.
Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device.
17939|NCT00830245|Drug|Erlotinib|Erlotinib 150mg/day
17940|NCT00830258|Drug|Pravastatin sodium 80 mg tablets|1 x 80 mg
17941|NCT00830258|Drug|Pravachol® 80 mg tablets|1 x 80 mg
17942|NCT00830271|Device|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
18247|NCT00823485|Procedure|drainage|drainage
18248|NCT00823498|Behavioral|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
18249|NCT00823498|Behavioral|Interview|Interview with a member of study staff at housing development site.
18250|NCT00823498|Other|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
18251|NCT00823524|Biological|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
19320|NCT00820547|Biological|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
19321|NCT00820547|Drug|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
19322|NCT00820547|Drug|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
19323|NCT00820547|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
19324|NCT00820547|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
19325|NCT00820560|Drug|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
19326|NCT00820573|Drug|Sitagliptin|tablet, 100 mg/day, 6 weeks
19327|NCT00820573|Drug|Metformin|tablet, 1000 mg/ bid, 6 weeks
19328|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
19329|NCT00813709|Drug|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
19330|NCT00813709|Drug|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
19331|NCT00813722|Behavioral|phone call|patients received or not phone calls to give orientation abou treatment
19332|NCT00813722|Drug|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
19333|NCT00813722|Drug|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
19334|NCT00813735|Drug|Eszopiclone|Eszopiclone 2mg daily at bedtime
19335|NCT00813735|Drug|Placebo|Placebo daily at bedtime
19623|NCT00814177|Drug|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
19624|NCT00814190|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
19625|NCT00814216|Drug|QAV680|
19626|NCT00814216|Drug|Matching placebo for QAV680|
18752|NCT00826670|Drug|Placebo (Decolonization)|Placebo
18753|NCT00826683|Biological|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
18754|NCT00826709|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
18755|NCT00826722|Drug|Levetiracetam|1000 mg tablet
18756|NCT00826735|Behavioral|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
18757|NCT00826748|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
18758|NCT00008021|Drug|cyclosporine|
18759|NCT00829140|Drug|Placebo|
18760|NCT00829140|Drug|Lorcaserin 10mg BID|
18761|NCT00829153|Device|U Clip|Interuppted nitional clips
18762|NCT00829153|Procedure|Conventional prolene anastomosis|Continuous prolene anastomosis
18763|NCT00829166|Drug|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
18764|NCT00829166|Drug|Lapatinib|Lapatinib was available as film-coated tablets.
18765|NCT00829166|Drug|Capecitabine|Capecitabine was available as film-coated tablets.
18766|NCT00008138|Drug|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
17776|NCT00822770|Drug|Plerixafor|Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I
17777|NCT00822770|Drug|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
17778|NCT00822770|Drug|Fludarabine|Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
17779|NCT00822770|Drug|Busulfan|Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
18176|NCT00828100|Device|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
18177|NCT00828113|Drug|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
18178|NCT00828113|Drug|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
18498|NCT00828776|Biological|heparin - Liquemine (Roche)|5000UI/mL
18499|NCT00821457|Drug|Juvista|250ng
18500|NCT00821457|Drug|Placebo|Powder for solution for injection
18501|NCT00821457|Drug|Juvista|500ng
18502|NCT00821470|Procedure|core decompression|core decompression procedure only
18503|NCT00007800|Behavioral|Motivational Interviewing|
18504|NCT00821470|Procedure|Bone marrow implantation into the necrotic lesion|
18505|NCT00821483|Drug|Frovatriptan|2.5mg, qd
18506|NCT00821496|Drug|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
18507|NCT00821509|Behavioral|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
18508|NCT00821509|Behavioral|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
18509|NCT00821522|Procedure|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
18510|NCT00821535|Drug|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
18511|NCT00821548|Procedure|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
18512|NCT00821561|Drug|Nexagon®|
18513|NCT00821561|Drug|Nexagon® vehicle|
18514|NCT00007813|Biological|filgrastim|
18515|NCT00821574|Drug|Fluvastatin|Fluvastatin: daily 80 mg, oral
18252|NCT00823537|Procedure|therapeutic electrical stimulation|
18253|NCT00823550|Drug|Entecavir|entecavir 0.5 mg QD
18254|NCT00823550|Drug|Lamivudine|lamivudine 100 mg QD
18255|NCT00823563|Procedure|30 cc blood draw|
18256|NCT00825630|Drug|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
18257|NCT00825630|Drug|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
18258|NCT00825630|Drug|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
18259|NCT00825643|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
18260|NCT00825656|Drug|Sinol or Sinol-M nasal spray|One spray in each nostril up to a maximum of 12 times / day on an "as needed" basis
18261|NCT00825669|Drug|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
18262|NCT00825669|Procedure|Laser ablation|Laser ablation is given to the PVTT.
18263|NCT00825682|Other|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.
18264|NCT00825695|Dietary Supplement|cocoa|two servings of cocoa daily for one month
18265|NCT00825708|Device|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
18266|NCT00007995|Procedure|autologous bone marrow transplantation|
18267|NCT00825708|Device|shamTMS|sham TMS session
18268|NCT00825721|Drug|LiquiTears|4 drops applied daily for 360 days
18269|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
18587|NCT00828867|Drug|2000 mg GSK investigational drug|
18588|NCT00828867|Drug|1500 mg GSK investigational drug|
18589|NCT00828867|Drug|800mg fed GSK investigational drug|
18590|NCT00008125|Biological|filgrastim|
19627|NCT00006747|Drug|melphalan|140 mg/sq m IV on day -1
19628|NCT00814216|Drug|Fluticasone Propionate|
19629|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
19630|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
19631|NCT00814229|Biological|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
19632|NCT00816283|Other|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
19633|NCT00816283|Other|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
19634|NCT00006942|Other|laboratory biomarker analysis|Correlative studies
19635|NCT00816296|Other|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
19636|NCT00816296|Other|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
19637|NCT00816296|Other|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
19638|NCT00816296|Other|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
19639|NCT00816309|Device|Acapella Physiotherapy|twice daily- around 20 minutes
19640|NCT00816322|Dietary Supplement|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
19641|NCT00816322|Dietary Supplement|Placebo|high oleic oil
19642|NCT00816335|Procedure|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
19874|NCT00814463|Radiation|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
19875|NCT00814476|Other|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
17780|NCT00822770|Procedure|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
17781|NCT00007865|Drug|etoposide|
17782|NCT00822770|Drug|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
17783|NCT00822783|Drug|Omalizumab|
17784|NCT00822783|Drug|Placebo|
17785|NCT00822796|Device|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
17786|NCT00824824|Drug|Cosopt|2.0% dorzolamide-0.5% timolol BID OU 6 weeks
17787|NCT00824824|Drug|Combigan|0.2% brimonidine-0.5% timolol BID OU 6 weeks
17788|NCT00824837|Other|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
17789|NCT00824837|Other|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
17790|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
17791|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
17792|NCT00824863|Drug|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
17793|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
17794|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
17795|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
17796|NCT00007982|Drug|thiotepa|
17797|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
18102|NCT00828074|Drug|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
18103|NCT00008060|Drug|leucovorin calcium|
18516|NCT00821574|Drug|Valsartan|Valsartan: daily 160 mg, oral
18517|NCT00821574|Drug|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
18518|NCT00821587|Drug|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
18519|NCT00821587|Drug|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
18520|NCT00821600|Drug|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
18835|NCT00824343|Drug|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
18836|NCT00824356|Drug|GSK1004723 (200mg)|Intranasal antihistamine.
18837|NCT00824356|Other|Placebo|Equivalent to GSK1004723 in presentation etc.
18838|NCT00000766|Drug|Ganciclovir|
18839|NCT00007956|Biological|monoclonal antibody mono-dgA-RFB4|
18840|NCT00826761|Dietary Supplement|probiotic|One capsule per meal test (high dose or low dose)
18841|NCT00826761|Dietary Supplement|placebo|1 capsuel every morning
18842|NCT00826774|Behavioral|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
18843|NCT00826774|Behavioral|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
18844|NCT00826774|Behavioral|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
18845|NCT00826787|Drug|Levetiracetam|750 mg tablet
18591|NCT00828867|Drug|3000mg GSK investigational drug|
18592|NCT00828867|Drug|4000mg GSK investigational drug|
18593|NCT00828880|Device|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
18594|NCT00828893|Device|navigation station|navigation station for gestures (carried out under CT) guidance
18595|NCT00828906|Drug|DuoTrav|DuoTrav Eye Drops
18596|NCT00828919|Drug|axitinib|BID oral tablets. dose of AG 013736 will be the same as they were taking in the previous trial
18597|NCT00828932|Drug|Lorcaserin|
18598|NCT00828945|Device|Lipid Self Test|Self test for lipid levels, twice during study period
18599|NCT00828958|Drug|Risperidone long-acting injectable|
18600|NCT00828971|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
18601|NCT00000770|Drug|Nevirapine|
18602|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
18603|NCT00007813|Drug|carboplatin|
18604|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
18605|NCT00821665|Dietary Supplement|Sucrose consumption|Sucrose
18606|NCT00821665|Dietary Supplement|water consumption|water
18917|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
18918|NCT00824408|Drug|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
18919|NCT00824421|Drug|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
18920|NCT00007969|Biological|Detox-B adjuvant|
19876|NCT00814476|Other|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
19877|NCT00816426|Drug|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
19878|NCT00816426|Drug|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
19879|NCT00816465|Dietary Supplement|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
19880|NCT00006968|Procedure|allogeneic bone marrow transplantation|
19881|NCT00816465|Other|Placebo|PO Placebo pill
19882|NCT00816478|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
19883|NCT00816491|Device|conventional white light colonoscopy|conventional white light colonoscopy
19884|NCT00816491|Device|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
19885|NCT00816504|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
19886|NCT00816517|Biological|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
19887|NCT00816530|Device|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density > 50% is confirmed by routine digital screening mammography, ABUS will be performed.
19888|NCT00816543|Drug|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
19889|NCT00816543|Drug|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
19890|NCT00816543|Drug|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
19891|NCT00006968|Procedure|peripheral blood stem cell transplantation|
20238|NCT00814918|Drug|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
18104|NCT00828087|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
18105|NCT00828087|Device|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
18106|NCT00828100|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
18107|NCT00830635|Procedure|psychosocial assessment and care|
18108|NCT00830635|Procedure|quality-of-life assessment|
18109|NCT00830648|Biological|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
18110|NCT00830661|Procedure|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
18111|NCT00830661|Procedure|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
18112|NCT00008190|Drug|cyclophosphamide|
18113|NCT00830674|Drug|Placebo|single dose IV or SC administration
18114|NCT00830674|Drug|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
18115|NCT00830687|Device|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
18116|NCT00830700|Other|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
18117|NCT00830713|Procedure|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
18118|NCT00830726|Drug|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
18846|NCT00826800|Drug|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
18847|NCT00826813|Device|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
18848|NCT00826826|Procedure|Catheter ablation|(Pulmonary vein isolation)
18849|NCT00826826|Drug|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
18850|NCT00008021|Drug|paclitaxel|
17853|NCT00822822|Behavioral|Health History|Complete electronic health history
17854|NCT00822822|Behavioral|Second Questionnaire|Complete questionnaire after completing electronic health history
17855|NCT00007865|Drug|ifosfamide|
17856|NCT00822835|Biological|ILV-095|
17857|NCT00822835|Biological|Placebo|
17858|NCT00822848|Drug|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
17859|NCT00822848|Drug|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
17860|NCT00822848|Drug|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
17861|NCT00822848|Other|immunoenzyme technique|
17862|NCT00822848|Other|immunohistochemistry staining method|
17863|NCT00822848|Other|laboratory biomarker analysis|
17864|NCT00822848|Procedure|adjuvant therapy|Preoperative administration has been the preference at our institution.
17865|NCT00822848|Procedure|neoadjuvant therapy|
18921|NCT00824421|Drug|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
18922|NCT00824421|Drug|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
18923|NCT00824434|Device|PROMUS Element™|Drug eluting coronary stent system
18924|NCT00824447|Drug|Oralgen|allergen solution sublingually
18925|NCT00824447|Other|placebo|placebo control
18926|NCT00824460|Drug|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
18927|NCT00824460|Drug|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
18928|NCT00824460|Drug|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
18929|NCT00824460|Drug|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
18930|NCT00824460|Drug|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
18931|NCT00007969|Drug|verteporfin|
18932|NCT00824460|Drug|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
18933|NCT00824473|Drug|Placebo|Placebo
18934|NCT00824473|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
18935|NCT00824486|Behavioral|Injury prevention education (TIPP)|using TIPP materials
18936|NCT00826891|Drug|Cisplatin Combined With Topotecan|Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).
Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.
Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2
Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2
17943|NCT00830271|Device|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
20239|NCT00814931|Drug|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
20240|NCT00814931|Drug|Placebo|matching oral liquid suspension placebo twice a day for 8 days
20241|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
20242|NCT00006825|Drug|pegylated liposomal doxorubicin hydrochloride|
20243|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
20244|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
20245|NCT00814944|Drug|Sirolimus|Subconjunctival injection of placebo in each eye.
20246|NCT00814957|Drug|GSK618334|D3 receptor antagonist
20247|NCT00814970|Device|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
20248|NCT00814983|Procedure|Naive T-cell Depleted Stem Cell Transplant|The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- "flow-through"fraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant.
20249|NCT00814983|Procedure|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
20250|NCT00814983|Device|Isolex device from Baxter|
20251|NCT00817037|Drug|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
20252|NCT00817050|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
20253|NCT00817050|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
20254|NCT00817063|Drug|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
20255|NCT00007020|Drug|Cholic Acids|10-15 mg/kg body weight/day taken orally.
20256|NCT00817063|Drug|Placebo|Patients receive matching placebo for up to 24 weeks
20257|NCT00817076|Drug|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
20258|NCT00817089|Drug|naltrexone|phase 1: 30 or 50 mg of naltrexone prior to challenge session; phase 2: 50mg/day for 12 weeks
18434|NCT00823719|Drug|ofatumumab + ICE|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg
ICE regimen:
ifosfamide + mesna - 5 grams (g)/meters squared (m^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m^2 on days 1, 2 and 3 of dosing cycle.
18435|NCT00823719|Drug|ofatumumab + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.
DHAP regimen:
dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m^2 q12 hrs (2 doses) on day 2 of dosing cycle.
18436|NCT00007904|Drug|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
18437|NCT00823732|Other|educational intervention|Undergo individualized interdisciplinary palliative care intervention
18438|NCT00823732|Other|medical chart review|Ancillary studies
18439|NCT00823732|Other|questionnaire administration|Ancillary studies
18440|NCT00823732|Procedure|end-of-life treatment/management|Undergo end-of-life treatment/management
18441|NCT00823732|Procedure|psychosocial assessment and care|Undergo psychosocial assessment and care
18442|NCT00823732|Procedure|quality-of-life assessment|Ancillary studies
18443|NCT00823732|Procedure|management of therapy complications|Undergo management of therapy complications
18444|NCT00823732|Procedure|assessment of therapy complications|Undergo assessment of therapy complications
18445|NCT00823745|Drug|[14C]-PF-00868554|solution, single dose
18446|NCT00823758|Behavioral|Focus Groups|6 to 8 participants per group.
18447|NCT00007904|Drug|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
18448|NCT00823758|Behavioral|Personal Interviews|Conducted by phone and audiotaped.
18449|NCT00825981|Other|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
18450|NCT00825994|Drug|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), PO [by mouth], qd [every day]
18451|NCT00826020|Drug|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
18452|NCT00826046|Drug|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
17866|NCT00007878|Drug|bortezomib|Given IV
17867|NCT00822848|Procedure|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
17868|NCT00822848|Radiation|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. *Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
17869|NCT00822861|Drug|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
17870|NCT00822861|Drug|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
17871|NCT00822861|Drug|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
17872|NCT00822861|Drug|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
17873|NCT00822874|Procedure|prematuration culture|The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a "prolonged" IVM (PMC)) in comparison to "conventional" IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos.
17874|NCT00822887|Drug|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
17875|NCT00822887|Radiation|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
17876|NCT00825019|Drug|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
18179|NCT00828113|Behavioral|Individual smoking cessation counseling|Brief (<10 minutes) smoking cessation counseling delivered at clinic visits
18180|NCT00828126|Procedure|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
18181|NCT00828139|Biological|ziv-aflibercept|Given IV
18182|NCT00828139|Drug|topotecan hydrochloride|Given IV
18183|NCT00008060|Drug|oxaliplatin|
18184|NCT00828152|Behavioral|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
18185|NCT00828152|Behavioral|On line discussion group|Placebo. On line discussion group.
18186|NCT00828165|Drug|ARRY-300, MEK inhibitor; oral|single dose, escalating
18187|NCT00828165|Drug|Placebo|matching placebo
18188|NCT00828178|Drug|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
21427|NCT00847197|Drug|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
20483|NCT00850265|Device|Volumatic spacer|A spacer is a plastic device to inhaler medication
20484|NCT00850278|Other|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
20485|NCT00842777|Behavioral|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
20486|NCT00842803|Drug|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
20487|NCT00009841|Drug|DC-cholesterol liposome|
20488|NCT00842816|Drug|ST101|10 mg; administered once/day
20489|NCT00842816|Drug|ST101|60 mg; administered once/day
20490|NCT00842816|Drug|ST101|120 mg; administered once/day
20491|NCT00842816|Drug|Placebo|placebo tablets to match ST101 tablets
20492|NCT00842829|Drug|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
20493|NCT00842842|Procedure|tack fixation of mesh|tack fixation of mesh
20494|NCT00842842|Procedure|glue fixation of mesh|glue fixation of mesh
20495|NCT00842881|Device|Healingstone navel belt|6~8hours/day for 3months
20496|NCT00842894|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
20497|NCT00842894|Drug|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
20498|NCT00009854|Drug|carmustine in ethanol|
20499|NCT00842907|Drug|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
20500|NCT00842907|Drug|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
24195|NCT00868725|Other|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
24196|NCT00868738|Dietary Supplement|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
24197|NCT00870922|Procedure|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
24469|NCT00862225|Drug|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
24470|NCT00862238|Behavioral|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
24471|NCT00862238|Other|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, & C
24472|NCT00862251|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
24473|NCT00862251|Drug|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
24474|NCT00862251|Drug|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
24475|NCT00862251|Drug|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
24476|NCT00862264|Drug|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
24477|NCT00862277|Biological|Menactra®|0.5 mL, Intramuscular (from a previous study)
24478|NCT00862277|Biological|Menomune®|0.5 mL, Intramuscular (from a previous study)
24479|NCT00012103|Procedure|bronchoscopy|
24480|NCT00862303|Biological|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
24481|NCT00862303|Drug|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
24482|NCT00862316|Device|Oxford Unicompartmental Knee|Knee Arthroplasty
24483|NCT00862329|Dietary Supplement|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
24484|NCT00862329|Dietary Supplement|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
20561|NCT00850408|Procedure|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
20861|NCT00843713|Drug|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
20862|NCT00843713|Drug|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
20863|NCT00843726|Radiation|stereotactic body radiation therapy|Patients undergo 1 or 3 high-dose fractions
20864|NCT00843739|Device|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
20865|NCT00843739|Device|sham EMST|Four week sham device training program
20866|NCT00843765|Other|acupuncture, massage and basic TCM treatment|During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.
After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes.
20867|NCT00009893|Drug|gemcitabine hydrochloride|
20868|NCT00846170|Drug|co-biotic|give probiotic 2 t/day
20869|NCT00846170|Drug|placebo 2T/day|cross over of patients from study arm to placebo arm
20870|NCT00846183|Procedure|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
20871|NCT00010036|Radiation|radiation therapy|
20872|NCT00846196|Drug|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
20873|NCT00846196|Drug|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
20874|NCT00846209|Other|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
20875|NCT00846222|Procedure|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
20876|NCT00846235|Other|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
24393|NCT00864422|Behavioral|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
24394|NCT00864435|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
24395|NCT00864435|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
24396|NCT00864448|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
24397|NCT00864448|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
24398|NCT00864474|Drug|CELSENTRI® Tablets|CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food".
24399|NCT00864487|Drug|Neratinib|HKI-272
24400|NCT00864500|Drug|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
24401|NCT00012246|Biological|sargramostim|
24402|NCT00864500|Drug|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
24403|NCT00864513|Drug|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
24404|NCT00864526|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
24405|NCT00864526|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
24406|NCT00864539|Dietary Supplement|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
24407|NCT00864539|Dietary Supplement|plain milk|daily intake of 200 ml plain milk
24408|NCT00864539|Dietary Supplement|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
24409|NCT00864539|Dietary Supplement|plain orange juice|daily intake of 250 ml plain orange juice
24973|NCT00860795|Drug|placebo|placebo 25 ml daily in 2 divided doses for 10 days
24995|NCT00853073|Drug|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
25017|NCT00855738|Drug|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|Gabapentin: up to 3.600 mg/d
Lamotrigine: up to 400 mg/d
Levetiracetam: up to 3.000 mg/d
Pregabalin: up to 600 mg/d
Oxcarbazepine: up to 2.400 mg/d
Tiagabine: up to 30 mg/d
Topiramate: up to 400 mg/d
Zonisamide: up to 500 mg/d
25018|NCT00855764|Drug|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
25019|NCT00855777|Drug|etoricoxib|etoricoxib 120 mg/day for 3 days
25020|NCT00011193|Behavioral|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
25021|NCT00855777|Drug|ibuprofen|ibuprofen 1,800 mg/day for 3 days
25022|NCT00855790|Other|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
25023|NCT00855803|Radiation|radiation|Given in 1 or 5 fractions
25024|NCT00855816|Behavioral|Breathing training|relaxation training
25025|NCT00011921|Drug|etoposide|
25026|NCT00858351|Behavioral|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
25027|NCT00858364|Drug|darbepoetin alfa 500 mcg Q3W|darbepoetin alfa 500 mcg (Q3W)
25028|NCT00858364|Drug|placebo|Placebo
25029|NCT00858377|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
25030|NCT00858377|Drug|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
25031|NCT00858390|Dietary Supplement|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
25032|NCT00858403|Drug|Dasatinib|Take tablets of Dasatinib by mouth once a day.
25033|NCT00858416|Device|"Kineticure System" followed by sham|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
24485|NCT00864591|Procedure|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
24749|NCT00862745|Drug|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
24750|NCT00012155|Biological|NV1020|
24751|NCT00862745|Drug|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
24752|NCT00862758|Drug|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
24753|NCT00862784|Biological|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
24754|NCT00862784|Drug|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
24755|NCT00862784|Drug|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
24756|NCT00862784|Drug|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
24757|NCT00857779|Biological|subcutaneous immunotherapy|7 injections
24758|NCT00857792|Drug|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
24759|NCT00857805|Procedure|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
24760|NCT00857805|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
24761|NCT00011895|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
24762|NCT00857818|Drug|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
24763|NCT00857818|Drug|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
20877|NCT00846248|Dietary Supplement|Chromium|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
20878|NCT00846248|Dietary Supplement|placebo|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
21172|NCT00848939|Drug|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
21173|NCT00848952|Other|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
21174|NCT00848965|Drug|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
21175|NCT00848965|Drug|Placebo|Placebo comparator
21176|NCT00848978|Behavioral|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity ~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
21177|NCT00848991|Drug|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
21178|NCT00848991|Drug|Propofol|evaulation of propofol for emergence from anesthesia
21179|NCT00851188|Behavioral|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
21180|NCT00010517|Procedure|Acupuncture|
21181|NCT00851188|Other|Waiting list|Waiting list
21182|NCT00851201|Behavioral|lifestyle intervention|Study will compare a minimal intervention control (standard intervention) to a comprehensive lifestyle intervention.
21183|NCT00851214|Device|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
21184|NCT00851227|Drug|conivaptan hydrochloride|intravenous
21185|NCT00851240|Drug|BTT-1023|intravenous
24974|NCT00860808|Drug|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
24975|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
24976|NCT00853008|Drug|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
24977|NCT00853008|Drug|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
24978|NCT00853008|Drug|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
24979|NCT00853008|Drug|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
24980|NCT00853021|Biological|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
24981|NCT00010829|Behavioral|Macrobiotic dietary intervention|
24982|NCT00853021|Biological|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
24983|NCT00853034|Dietary Supplement|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
intake period: 2 weeks, 1.25 or 2.50g every morning and evening
24984|NCT00853034|Dietary Supplement|AXOS|arabinoxylan-oligosaccharides (AXOS)
intake period: 2 weeks, 1.25 or 2.50g every morning and evening
24985|NCT00853047|Drug|Low Dose Part 1|A low dose of LX1606; daily oral intake for 28 days
24986|NCT00853047|Drug|Mid-Low Dose Part 1|A mid-low dose of LX1606; daily oral intake for 28 days
24987|NCT00853047|Drug|Mid-High Dose Part 1|A mid-high dose of LX1606; daily oral intake for 28 days
24988|NCT00853047|Drug|High Dose Part 1|A high dose of LX1606; daily oral intake for 28 days
24989|NCT00853047|Drug|Part 2 Expanded Cohort|A dose of LX1606 to an expanded cohort based upon Part 1; daily oral intake for 28 days
24990|NCT00853047|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days
24991|NCT00853047|Drug|Open Label Dose Extension|Patients can enter an eight-week extension period at current dose based upon qualification.
24992|NCT00010842|Drug|Ginkgo biloba|
24993|NCT00853047|Drug|Open Label Extension 2|Patients can enter a 24-week extension period at current dose after the 8-week open-label extension period.
24994|NCT00853047|Drug|Open Label Extension 3|Patients can enter a 48-week extension period at current dose after the 8-week open-label extension period and the 24-week open-label extension period.
25034|NCT00858416|Device|sham followed by "Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
25035|NCT00858429|Drug|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
25036|NCT00000791|Drug|Glycovir|
25037|NCT00011921|Drug|etoposide phosphate|
24118|NCT00870662|Device|AFS System|AFS System with patient specific flow rate
24119|NCT00870688|Drug|sodium valproate|valproate sustained release minitablets, once daily.
24120|NCT00870701|Radiation|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
24121|NCT00870701|Other|absence of radiotherapy|absence of radiotherapy
24122|NCT00870714|Drug|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
24123|NCT00870714|Drug|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
24124|NCT00870727|Drug|aripiprazole|Minimum dose of 2mg per day to a maximum of 20 mg per day over the first 4 weeks of treatment.
24125|NCT00870740|Biological|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process (DAC HYP) subcutaneous (SC) injection
24126|NCT00870740|Drug|Placebo|Placebo SC injection
24127|NCT00870753|Behavioral|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
24128|NCT00013039|Behavioral|Computer reminders|
24129|NCT00870766|Procedure|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
24130|NCT00870779|Drug|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
24131|NCT00864097|Other|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
24132|NCT00864110|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
24133|NCT00864110|Radiation|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
24764|NCT00857831|Dietary Supplement|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
24765|NCT00857857|Drug|GW870086X|Investigational product
24766|NCT00857857|Drug|FP|Positive control
24767|NCT00857857|Drug|Placebo|Placebo control
25094|NCT00855829|Device|Miniature Actilady device not active|Devices: Targeted pressure waves are created by two kind of methods ActiLady).
The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an "off the shelf" pressure waves generator and controller.
Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves.
25095|NCT00855842|Device|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
25096|NCT00855855|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
25097|NCT00855868|Drug|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
25098|NCT00855868|Drug|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose [11C]-PIB
25099|NCT00011258|Drug|Paraoxonase|
25100|NCT00855881|Drug|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
25101|NCT00855894|Drug|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
25102|NCT00855894|Drug|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
25103|NCT00855907|Other|clinical evaluation|Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.
Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.
25104|NCT00855920|Drug|rilonacept|rilonacept 320 mg SC injection at baseline
25105|NCT00855920|Drug|indomethacin|oral indomethacin for 12 days (50mg TID for 3 days, then 25mg TID x 9 days)
25106|NCT00855920|Other|placebo|oral placebo TID x 12 days
25107|NCT00855920|Other|placebo|placebo one time dose
25108|NCT00855933|Device|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (~13% dry weight CPC)
25109|NCT00855959|Drug|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
21186|NCT00851240|Drug|Placebo|Intravenous
21187|NCT00851253|Radiation|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
21188|NCT00851266|Biological|V512|Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:
1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;
21495|NCT00844818|Behavioral|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
21496|NCT00844831|Drug|Lubiprostone|24 mcg bid for 28 days
21497|NCT00844844|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
21498|NCT00009971|Drug|fenretinide|
21499|NCT00844857|Drug|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
21500|NCT00844857|Drug|Placebo|Orally, once daily in the evening for 8 weeks.
21501|NCT00844870|Behavioral|stabilization training|training of arm function with the trunk stabilized
21502|NCT00844870|Behavioral|auditory training group|response to an auditory signal
21503|NCT00844883|Drug|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
21504|NCT00844883|Procedure|LC Bead-TACE|LC Beads loaded with doxorubicin
Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period
21505|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
21506|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
21507|NCT00847223|Drug|ZARNESTRA (Tipifarnib)|
21508|NCT00847249|Drug|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
21509|NCT00847249|Drug|Placebo|Each subject will receive a single-dose.
21369|NCT00841945|Drug|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
20426|NCT00817427|Other|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
20427|NCT00000760|Drug|Didanosine|
20428|NCT00007072|Drug|azacitidine|
20429|NCT00817427|Other|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
20430|NCT00817440|Other|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
20431|NCT00817440|Other|Fasting|3 days of fasting and then the same as arm 1
20432|NCT00817466|Drug|Racemic adrenaline|For inhalation.
Dosing (as in previous study):
1) 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3
Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number.
20433|NCT00817466|Drug|Isotonic saline|2ml NaCl 9mg/ml.
20434|NCT00817479|Drug|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
20435|NCT00817479|Drug|Placebo|Placebo saline
20436|NCT00817505|Drug|AZD1656|Single dose oral tablet
20437|NCT00817505|Drug|AZD1656|Single dose oral suspension
20438|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
20439|NCT00007072|Drug|phenylbutyrate|
20440|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
20441|NCT00817531|Drug|Dasatinib|pill form, 100 mg daily
20442|NCT00817544|Drug|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
20443|NCT00817557|Drug|Loteprednol|Anti-inflammatory
20444|NCT00817557|Other|Rewetter|
20445|NCT00817583|Drug|docetaxel, cisplatin, fluorouracil|neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.
concurrent chemotherapy:cisplatin 40 mg/m2 weekly
24134|NCT00864110|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
24135|NCT00012220|Drug|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 & 15 of ea cycle
24136|NCT00864123|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
24410|NCT00864539|Dietary Supplement|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
24411|NCT00864539|Dietary Supplement|Placebo|daily placebo
24412|NCT00012259|Drug|troxacitabine|
24413|NCT00864552|Drug|Kogenate (BAY14-2222)|Patients with severe haemophilia A (<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
24414|NCT00864565|Drug|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
24415|NCT00864565|Drug|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
24416|NCT00866619|Biological|Meningococcal C Conjugate Vaccine|Children enrolled to receive a comparator booster dose (i.e. those enrolled to R3C [children] or C3C [children]) will get 1 dose of Meningococcal C Conjugate Vaccine at the booster dose visit.
Infants enrolled to receive a comparator booster dose (i.e. those enrolled to R3C [infants] or C3C [infants]) will get 1 dose of Meningococcal C Conjugate Vaccine at the booster dose visit.
In addition, infants enrolled to receive a primary course comprising 3 doses of comparator vaccine (i.e. those enrolled to C3C [infants]) will get 3 doses of Meningococcal C Conjugate Vaccine.
Subjects will receive either Meningitec (Wyeth), NeisVac-C (Baxter) or Menjugate (Novartis). Note: where a subject is enrolled to receive 3 doses, each of the 3 doses will be from the same manufacturer
24417|NCT00866619|Biological|Cell-culture rabies vaccine|Children enrolled to receive a primary course comprising 3 doses of comparator vaccine (i.e. those enrolled to C3C [children]) will get 3 doses of cell-culture rabies vaccine. Subjects will receive either Human Diploid Cell Rabies Vaccine (Sanofi Pasteur) or Purified Chick Embryo Cell Culture Vaccine (i.e. Rabipur, or equivalent) (Novartis). Note: each of the 3 doses will be from the same manufacturer
24418|NCT00866619|Biological|TritanrixHepB/Hib|Diptheria, Tetanus, whole-cell Pertussis, Hemophilus influenzae (type B) Hepatitis B vaccine (0.5 mL dose).
All infants enrolled to the trial will receive 3 doses of TritanrixHebB/Hib, a standard EPI-compatible vaccine, commonly administered to infants in sub-Saharan Africa.
24419|NCT00866619|Biological|Polio Sabin Oral Polio Vaccine (GSK)|All infants enrolled to the trial will receive 3 doses of Polio Sabin Oral Polio Vaccine, a standard EPI-compatible vaccine, commonly administered to infants in sub-Saharan Africa
24420|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
24421|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
20501|NCT00842920|Drug|Simvastatin|60 mg once daily
20502|NCT00842920|Drug|Placebo|one tablet once daily
20503|NCT00842933|Drug|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
20803|NCT00848237|Device|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
20804|NCT00848250|Drug|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
20805|NCT00848250|Other|No ACE inhibitor|Patients randomized to this arm will discontinue their ACE inhibitor at least 48 hours prior to surgery
20806|NCT00848263|Procedure|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
20807|NCT00848263|Procedure|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
20808|NCT00848289|Other|Specimens, personal and follow-up telephone interviews|Specimens, personal and follow-up telephone interviews
20809|NCT00848302|Drug|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
20810|NCT00010231|Dietary Supplement|calcitriol|
20811|NCT00848315|Behavioral|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
20812|NCT00848328|Biological|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
20813|NCT00848328|Drug|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
20814|NCT00848341|Device|GUIDANT ICD SYSTEM|
20815|NCT00848354|Biological|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
20816|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
20817|NCT00848354|Drug|Phase 2: Optional ETN, SSZ, HCQ, MTX|Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.
Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.
Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.
Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128.
21510|NCT00847262|Drug|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
21511|NCT00847262|Drug|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
21512|NCT00847275|Other|Exclusive nephrology follow-up|250 patients will be included and randomized in the "exclusive nephrology follow-up" arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring.
20562|NCT00850421|Drug|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
20563|NCT00850447|Other|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
20564|NCT00850447|Other|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
20565|NCT00850460|Drug|Statins|Subjects will be randomized to continue their statin (whichever type they were on when they enrolled into the study) or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician.
20566|NCT00850460|Drug|Lactose placebo pills|Placebo pills will consist of lactose
20567|NCT00850473|Radiation|Positron Emission Tomography|image scan. approximately 1 hour
20568|NCT00850473|Radiation|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose|maximum of 10mCi of 18F-FDG will be injected for imaging purposes
20569|NCT00842946|Behavioral|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
20570|NCT00842959|Device|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
20571|NCT00842959|Device|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
20572|NCT00000778|Drug|Pyridoxine hydrochloride|
20573|NCT00009854|Procedure|conventional surgery|
20446|NCT00847756|Procedure|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
20447|NCT00847769|Other|High velocity, low amplitude stretch|This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
20749|NCT00850746|Drug|Placebo|Oral
20750|NCT00850746|Drug|Moxifloxacin|Oral
20751|NCT00850759|Device|virtual pedestrian environment|a computer-driven virtual pedestrian environment
20752|NCT00850759|Device|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
20753|NCT00850759|Behavioral|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
20754|NCT00850772|Dietary Supplement|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
20755|NCT00850785|Biological|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
20756|NCT00850798|Drug|Intensive glycemic control|Intensive glycemic control
20757|NCT00850798|Drug|Conservative glycemic control|OADs and insulin
20758|NCT00010465|Drug|Botanicals|
20759|NCT00850811|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
20760|NCT00850824|Behavioral|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
20761|NCT00850837|Drug|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
20762|NCT00850837|Drug|HEC gel|5 g application of hydroxyethylcellulose gel
20763|NCT00843388|Drug|placebo tablet|placebo tablet 25 mg OD
20764|NCT00843427|Behavioral|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
24422|NCT00866645|Drug|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
24423|NCT00866645|Drug|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
24424|NCT00012389|Drug|oxaliplatin|
24425|NCT00866658|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
24426|NCT00866658|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
24687|NCT00866944|Drug|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
24688|NCT00866944|Drug|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
24689|NCT00012467|Drug|Amphotericin B|
24690|NCT00866944|Drug|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
24691|NCT00866957|Procedure|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
24692|NCT00866970|Biological|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
24693|NCT00866970|Biological|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
24694|NCT00866970|Biological|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
24695|NCT00866970|Biological|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
24696|NCT00866983|Drug|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
24697|NCT00866996|Drug|Methylphenidate extended-release; Atomoxetine|
24698|NCT00867009|Drug|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
24699|NCT00867009|Drug|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
24700|NCT00012467|Drug|Interferon gamma-1b|
20818|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
20819|NCT00848354|Drug|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
21112|NCT00851513|Drug|Lidocaine|local anesthetics
21113|NCT00010621|Procedure|Acupuncture|
21114|NCT00851513|Drug|Depmedrol|local steroids
21115|NCT00009932|Drug|cisplatin|
21116|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
21117|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
21118|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
21119|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
21120|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
21121|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
21122|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
21123|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
21124|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
21125|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
21126|NCT00009932|Drug|fenretinide|
21127|NCT00844207|Drug|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
21128|NCT00844207|Drug|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
21129|NCT00844220|Procedure|CT/MR|CT/MRI-directed clinical management strategy
20574|NCT00842985|Drug|Dronabinol + Modafinil|Dronabinol (15mg)+ Modafinil (400mg)
20575|NCT00842985|Drug|Dronabinol + Placebo|Dronabinol (15mg) + Placebo Modafinil
20576|NCT00842985|Drug|Placebo + Modafinil|Placebo Dronabinol + Modafinil (400mg)
20577|NCT00842985|Drug|Placebo + Placebo|Placebo Dronabinol + Placebo Modafinil
20578|NCT00842998|Drug|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
20579|NCT00843011|Drug|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
20879|NCT00846261|Device|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
20880|NCT00846274|Biological|SK Antithrombin III|
20881|NCT00846287|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
20882|NCT00010049|Drug|imatinib mesylate|
20883|NCT00846287|Drug|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
20884|NCT00846287|Drug|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
20885|NCT00846300|Behavioral|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
20886|NCT00846313|Other|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
20887|NCT00846326|Drug|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
20888|NCT00846326|Drug|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
20889|NCT00846339|Drug|Bupropion|bupropion
20890|NCT00848393|Drug|Fentanyl|patients will receive a total of 10mcg/kg of fentanyl. half the dose will be given at induction and the second half before incision.
20891|NCT00848393|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr.in addition this group will receive a total of 10 mcg/kg fentanyl. Half the dose will be given at induction and the second half before incision.
20765|NCT00843440|Drug|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
20766|NCT00843453|Other|blood collection|blood collection
20767|NCT00843453|Drug|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
21054|NCT00846508|Drug|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
21055|NCT00846521|Drug|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
21056|NCT00846547|Drug|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
21057|NCT00846573|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
21058|NCT00846586|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
21059|NCT00846586|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
21060|NCT00846586|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
21061|NCT00846599|Other|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
21062|NCT00846599|Other|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
21063|NCT00846612|Drug|Doxil|1 cycle: 3 weeks; 30 mg/m^2, IV, every cycle
21064|NCT00010075|Drug|leucovorin calcium|
21065|NCT00846612|Drug|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
21066|NCT00846625|Drug|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
21067|NCT00846625|Drug|ranibizumab|Intravitreal injection, 0.5 mg
21068|NCT00848744|Drug|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
24701|NCT00867009|Drug|Cetuximab|Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles
Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation
24702|NCT00867035|Drug|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
24703|NCT00867035|Drug|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
24704|NCT00867048|Drug|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
24705|NCT00867061|Drug|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
24706|NCT00867087|Drug|inotuzumab ozogamicin (CMC-544)|1.8 mg/m2 every 21 days by intravenous infusion, 3 to 6 doses
25038|NCT00858429|Radiation|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
25039|NCT00858442|Procedure|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width & length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width & length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
25040|NCT00858455|Drug|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
25041|NCT00858455|Drug|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
25042|NCT00858455|Drug|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
25043|NCT00858455|Drug|GSK1349572|A single dose of GSK1349572
25044|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
25045|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
25046|NCT00858481|Drug|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
25047|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
21130|NCT00844220|Procedure|Catheterization|Standard clinical management directed by conventional coronary angiography
21131|NCT00844233|Device|Irinotecan Bead|Irinotecan eluting bead
21132|NCT00844246|Other|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
21428|NCT00000779|Biological|rgp120/HIV-1MN|
21429|NCT00010140|Drug|epirubicin hydrochloride|
21430|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
21431|NCT00849316|Drug|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
21432|NCT00849329|Drug|lapatinib|1250mg lapatinib
21433|NCT00849329|Drug|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
21434|NCT00849342|Drug|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
21435|NCT00849355|Drug|RCOMP-14 + rituximab|Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.
Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d.
21436|NCT00849368|Drug|Azathioprine / Allopurinol|Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.
Azathioprine: Imurek (R) 50 mg and 25 mg tablets
Allopurinol: Mephanol (R) 100 mg tablets
21437|NCT00849381|Biological|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
21438|NCT00000781|Drug|Nevirapine|
21439|NCT00010348|Drug|Mycophenolate mofetil|Beginning within 6 hours of transplantation, oral mycophenolate mofetil every 12 hours until Day 27.
21440|NCT00849446|Device|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
21441|NCT00849459|Biological|adenovirus-mediated human interleukin-12|
21442|NCT00849459|Other|enzyme-linked immunosorbent assay|
21443|NCT00849459|Other|fluorescence activated cell sorting|
20892|NCT00848419|Drug|Epidural administration of bolus|
20893|NCT00848432|Drug|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
20894|NCT00848445|Device|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
20895|NCT00848445|Device|Atrial pacing preference turned on or off|programing changes in the device
20896|NCT00848458|Other|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
20897|NCT00848458|Other|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
20898|NCT00848471|Device|Quark RMR|Quark RMR calorimeter (Cosmed)
21189|NCT00851266|Biological|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
21190|NCT00851279|Device|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
21191|NCT00010530|Procedure|Meditation|
21192|NCT00851292|Device|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
21193|NCT00851305|Device|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
21194|NCT00851305|Device|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
21195|NCT00851318|Drug|Certolizumab pegol|Subcutaneous (SC) injection
21196|NCT00851318|Drug|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
21197|NCT00851331|Genetic|genome analyzes (genetic defects and pathophysiological mechanisms )|
21198|NCT00851344|Drug|GSK835726 (100mg)|GSK835726 (100mg) tablet
21199|NCT00851344|Drug|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
21200|NCT00851344|Drug|GSK835726 (10mg)|GSK835726 (10mg) tablet
21201|NCT00851344|Drug|GSK835726 (50mg)|GSK835726 (50mg) tablet
21069|NCT00848744|Drug|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
21070|NCT00010270|Biological|LMB-9 immunotoxin|
21071|NCT00848757|Behavioral|Intensive Lifestyle Intervention|Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP "Lifestyle Balance" program, but modified for a group format and to be more culturally and linguistically appropriate for this population.
21370|NCT00841945|Drug|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
21371|NCT00841945|Drug|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
21372|NCT00841945|Drug|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
21373|NCT00841945|Procedure|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
21374|NCT00841958|Procedure|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
21375|NCT00841971|Drug|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
21376|NCT00841971|Drug|Fluconazole|400 mg IV for 21 days
21377|NCT00842023|Drug|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
21378|NCT00009789|Radiation|accelerated conformational radiotherapy|
21379|NCT00842023|Drug|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
21380|NCT00842036|Behavioral|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
21381|NCT00842036|Behavioral|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
21382|NCT00842036|Behavioral|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
25048|NCT00860834|Behavioral|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
25049|NCT00860834|Behavioral|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
25050|NCT00860847|Dietary Supplement|Aged garlic extract and Coenzyme Q10|AGE (1200 mg) and CoQ10 (120 mg)
25051|NCT00860860|Drug|TF2|TF2: 75-300 mg
25052|NCT00860860|Drug|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
25053|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
25054|NCT00012051|Biological|filgrastim|
25055|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
25056|NCT00860873|Dietary Supplement|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
24137|NCT00864123|Drug|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
24138|NCT00864123|Drug|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
24139|NCT00864136|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
24140|NCT00864136|Drug|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
24141|NCT00864136|Drug|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
24142|NCT00864149|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
24143|NCT00864149|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
24144|NCT00864162|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
24145|NCT00864162|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
21444|NCT00849459|Other|immunohistochemistry staining method|
21445|NCT00849459|Other|laboratory biomarker analysis|
21446|NCT00849472|Drug|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
21447|NCT00849472|Drug|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
21448|NCT00849472|Procedure|surgery|neoadjuvant surgery for breast cancer
21449|NCT00849472|Drug|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
20504|NCT00842933|Drug|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
20505|NCT00842946|Behavioral|Exposure w/ Acceptance-Based Rationale|Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. "Willingness" to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions.
20506|NCT00845481|Drug|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
20507|NCT00845481|Drug|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
20508|NCT00845481|Drug|Dermovat ointment|Once daily application 6 days a week for 3 weeks
20509|NCT00009997|Drug|tamoxifen citrate|
20510|NCT00845481|Drug|Elocon ointment|Once daily application 6 days a week for 3 weeks
20511|NCT00845481|Drug|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
20512|NCT00845494|Behavioral|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
20513|NCT00845507|Drug|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
20514|NCT00845533|Drug|Dihydroartemisinin-Piperaquine|
20515|NCT00845546|Drug|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
21202|NCT00010608|Behavioral|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
21203|NCT00844272|Behavioral|Psychoeducation|Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.
The group leaders are trained in performance of the psycho-education.
21204|NCT00844285|Drug|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
21205|NCT00844298|Drug|Nilotinib+mVPD|Induction:
Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)
Vincristine 2 mg iv push (d1, 8, 15, 22)
Prednisolone 60 mg/m2/day po (d1-28)
Nilotinib 400mg bid/d (d8-)
Consolidation A (cycle1)
Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)
Vincristine 2 mg iv (d1, 8)
Prednisolone 60 mg/m2/day po (d1-14)
Nilotinib 400mg bid/d
Consolidation B (cycles 2&4)
Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)
Etoposide 150 mg/m2/day iv over 3 hours (d1-4)
Nilotinib 400mg bid/d
Consolidation C (cycles 3&5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)
Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,
Nilotinib 400mg bid/d
Maintenance
◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)
Consider alloHCT
21206|NCT00009932|Drug|paclitaxel|
21513|NCT00847275|Other|Geriatric follow-up|250 patients will be included and randomized in "geriatric follow-up" arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the "geriatric follow-up" arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status.
21514|NCT00847288|Other|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
21515|NCT00010140|Drug|tamoxifen citrate|
21516|NCT00847288|Other|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
21517|NCT00847314|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 35yrs in medical practices fulfilling all criteria for documentation.
21518|NCT00847327|Behavioral|Parental Support|The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
21519|NCT00847327|Behavioral|Diabetes Education|The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
21383|NCT00844545|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
21384|NCT00844558|Other|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
21385|NCT00844558|Other|Power Training|Power exercise training with an exercise specialist 2/week for 3 months, followed by by training with the exercise specialist 1/week and training at home 1/week for 3 months
21386|NCT00844558|Other|Control|There is no intervention associated with this arm of the study
20448|NCT00847769|Other|Slow, mobilization stretch|This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
20449|NCT00847769|Other|Passive Positioning|This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
20450|NCT00847782|Procedure|Blood draw|1 day
20451|NCT00847795|Drug|Avotermin|Intradermal administration
20452|NCT00847795|Drug|Placebo|Placebo
20453|NCT00847808|Drug|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
20454|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
20455|NCT00010192|Biological|rituximab|Given IV
20456|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
20457|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
24146|NCT00012220|Drug|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 & 8 of ea treatment cycle
24147|NCT00864175|Drug|INCB007839 and trastuzumab|100 mg BID
24148|NCT00864175|Drug|INCB007839 and trastuzumab|200 mg BID
24149|NCT00864175|Drug|INCB007839 and trastuzumab|300 mg BID
24150|NCT00864175|Drug|INCB007839 and Docetaxel|300 mg BID
24151|NCT00864188|Dietary Supplement|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
24152|NCT00864188|Dietary Supplement|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
24153|NCT00866268|Device|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
24154|NCT00866281|Drug|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
24155|NCT00866294|Drug|paroxetine IR 10mg tablet|1 or 2 tablets once a day
24427|NCT00866658|Device|Pen auto-injector|
24428|NCT00866658|Drug|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
24429|NCT00866658|Drug|Basal Insulin|To be continued at a stable dose.
24430|NCT00866671|Drug|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
24431|NCT00866684|Drug|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
24432|NCT00866684|Drug|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
24433|NCT00866684|Drug|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
24434|NCT00866684|Drug|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
24435|NCT00012441|Procedure|hemodialysis|
24436|NCT00866684|Drug|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
20516|NCT00845559|Drug|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
20517|NCT00845572|Behavioral|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
20518|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
20519|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
20520|NCT00009997|Procedure|conventional surgery|
20521|NCT00845598|Drug|Azelastine , fluticasone|Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination
1 squirt in each nostril twice daily
20522|NCT00845598|Drug|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
20820|NCT00848367|Behavioral|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
20821|NCT00010231|Drug|dexamethasone|
20822|NCT00848393|Drug|Fentanyl|25 mcg/kg in two divided doses. half the dose will be given at induction and the second half will be given prior to incision.
20823|NCT00850850|Drug|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
20824|NCT00850850|Drug|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
20825|NCT00850889|Device|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
20826|NCT00850889|Device|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
20827|NCT00850902|Other|High Humidity (HH)|High Humidity Level
20828|NCT00850902|Other|Moderate Humidity|Moderate Humidity Level
20829|NCT00010478|Procedure|Acupuncture|
21520|NCT00847340|Procedure|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
21521|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression.
21522|NCT00849537|Drug|Triamcinolone|Injection of intravitreal Triamcinolone
21523|NCT00849550|Drug|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
21524|NCT00849563|Other|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
21525|NCT00849576|Drug|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
21526|NCT00849576|Drug|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
21527|NCT00849576|Drug|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
24668|NCT00864916|Drug|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
24669|NCT00864916|Drug|Placebo|Participants will receive placebo three times per day for 48 weeks.
24670|NCT00864942|Drug|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
24671|NCT00864942|Drug|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
24672|NCT00864942|Drug|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
24673|NCT00012298|Biological|filgrastim|Given subcutaneously
24674|NCT00864942|Drug|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
20458|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
20459|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
20460|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
20461|NCT00850096|Drug|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
20768|NCT00843466|Other|mild, moisturizing hand cleanser|Hand cleanser ingredient list:
Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water
20769|NCT00009880|Drug|paclitaxel|
20770|NCT00843492|Drug|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg [0.5mL] (1.5 mg [0.3mL] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
20771|NCT00843492|Drug|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
20772|NCT00843505|Behavioral|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
20773|NCT00843505|Behavioral|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
20774|NCT00843518|Drug|LY451395|3 mg BID oral 12 weeks. May be reduced to 1 mg if unable to tolerate
20775|NCT00843518|Drug|Placebo|BID oral 12 weeks
20776|NCT00843531|Drug|RAD001|5 mg/day PO (oral)
20777|NCT00843531|Drug|erlotinib|100 mg/day (oral)
24437|NCT00869063|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
24438|NCT00869076|Other|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
24439|NCT00869076|Other|Usual care|Patient was managed by their primary care physician as usual
24440|NCT00869089|Drug|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
24441|NCT00012740|Behavioral|Casefinding and Referral System|
24442|NCT00869102|Drug|GLP-1|intravenous, 124,5 pmol/kg body weight
24443|NCT00869115|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
24444|NCT00869115|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
24445|NCT00869115|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
24446|NCT00869115|Drug|Istaroxime|Placebo continuous i.v. infusion for 24 hours
24447|NCT00869128|Drug|Circadin|2 mg prolonged-release melatonin
24448|NCT00869128|Drug|Placebo|
24449|NCT00869141|Drug|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
24707|NCT00867087|Drug|rituximab|375 mg/m2 two days before cycle 1 by intravenous infusion; 375 mg/m2 every 21 days by intravenous infusion, 3 to 6 doses
24708|NCT00867100|Drug|AMG 827|This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
24709|NCT00000796|Drug|Aminosalicylic acid|
24710|NCT00012818|Behavioral|relaxation technique|
24711|NCT00869466|Other|educational intervention|
24712|NCT00869466|Other|laboratory biomarker analysis|
24713|NCT00869466|Other|questionnaire administration|
24714|NCT00869466|Procedure|quality-of-life assessment|
24715|NCT00869466|Procedure|support group therapy|
20830|NCT00850915|Other|community IPT|In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.
In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.
All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB.
20831|NCT00850941|Behavioral|Questionnaire|Information collection.
20832|NCT00850954|Behavioral|Printed Materials|Pamphlets:
Specific materials for non-smokers and motivated/not motivated smokers.
20833|NCT00850954|Behavioral|Fotonovelas|Illustrated storybooks.
20834|NCT00850993|Drug|stannsoporfin|single IM injection of 1.5, 3.0, or 4.5 mg/kg
20835|NCT00850993|Other|Saline|Normal saline (0.9%) solution
20836|NCT00851006|Drug|Creatine Monohydrate|Creapure brand of creatine monohydrate
20837|NCT00851019|Behavioral|DDR|Ad libitum attendance to engage in "Dance Dance Revolution" (DDR) Exergaming, for a 3-month period
20838|NCT00851019|Behavioral|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
21133|NCT00844246|Other|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
21134|NCT00846638|Behavioral|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
21135|NCT00846638|Behavioral|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
21136|NCT00846651|Other|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
21137|NCT00846651|Other|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
21138|NCT00846651|Drug|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
21139|NCT00846664|Procedure|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
24675|NCT00864955|Radiation|UVA and UVB irradiation|4 cutaneous biopsies for Ex-vivo irradiation
Determination of the minimal erythemic dose of UVA and UVB for each volunteer
24676|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
24677|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
24678|NCT00864981|Drug|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
24679|NCT00864981|Drug|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
24680|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
24681|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
24682|NCT00865020|Drug|Aliskiren|Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
24683|NCT00865020|Drug|Telmisartan|Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
24684|NCT00012311|Biological|filgrastim|
24685|NCT00865020|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
24686|NCT00866918|Drug|methotrexate|Given orally
24942|NCT00858234|Drug|bortezomib|bortezomib (1.3 mg/m2 ) intravenous push on Day 1, 4, 8 and 11 of a 21 day cycle
24943|NCT00858247|Dietary Supplement|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
24944|NCT00858260|Genetic|blood sample|Searching for Klotho variants in DNA
24945|NCT00858273|Dietary Supplement|Antioxidant supplement|1 capsule daily with dinner
24946|NCT00858273|Other|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
24947|NCT00011921|Drug|epirubicin hydrochloride|
24948|NCT00858273|Drug|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
20778|NCT00843544|Behavioral|Integrative Medicine|Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:
Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.
Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice
Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date.
20779|NCT00843570|Drug|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
20780|NCT00009880|Radiation|radiation therapy|
20781|NCT00843596|Procedure|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
20782|NCT00845988|Drug|aripiprazole|dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
20783|NCT00846001|Procedure|Coronary artery bypass grafting|Standard coronary surgry according guidelines
20784|NCT00010036|Drug|carboplatin|
21072|NCT00848770|Drug|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).
NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.
NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
21073|NCT00848770|Drug|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
21074|NCT00848770|Drug|manipulation of SAP|Esmolol or NPS or NOR
21075|NCT00848783|Drug|Irinotecan|
21076|NCT00848783|Drug|Cisplatin|
21077|NCT00848783|Procedure|Surgery|
21078|NCT00848783|Drug|Floxuridine|
21079|NCT00848783|Drug|Capecitabine|
21080|NCT00848796|Drug|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
21081|NCT00010283|Drug|beclomethasone dipropionate|
24716|NCT00869492|Drug|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
24717|NCT00869492|Drug|nadifloxacine|Nadifloxacine 1% cream twice dailly
24718|NCT00869518|Drug|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
24719|NCT00869518|Drug|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
24720|NCT00869531|Other|wholegrain|wholegrain wheat vs. refined wheat products
24721|NCT00012818|Behavioral|educational program|
24722|NCT00869531|Other|refined wheat|refined wheat products
24723|NCT00869557|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
24724|NCT00869557|Drug|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
24725|NCT00869570|Drug|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
24726|NCT00869570|Drug|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
24727|NCT00869570|Radiation|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
24728|NCT00869583|Behavioral|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents [METS]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
25057|NCT00860873|Dietary Supplement|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
25058|NCT00860899|Drug|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine [Catapres®, Boehringer Ingelheim, Germany], 7 mL of 0.25% levobupivacaine [Chirocaine®, Abbott S.p.A., Italy] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
25059|NCT00860912|Procedure|Veritas Collagen Matrix|surgical/reinforcing material
25060|NCT00860925|Drug|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
21140|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
21141|NCT00010075|Drug|mitoxantrone hydrochloride|
21142|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
21143|NCT00846690|Drug|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
21144|NCT00846690|Drug|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
21145|NCT00846703|Drug|6-mercaptopurine, Methotrexate|6-mercaptopurine p.o. qd
Methotrexate p.o. qw
21146|NCT00846703|Drug|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w
(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d
Go to (1) and (2)
21147|NCT00846716|Drug|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
21148|NCT00846716|Drug|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
21149|NCT00846729|Procedure|CT angiogram of the remaining kidney.|
21150|NCT00846729|Procedure|Kidney Function study using Iothalamate & PAH as clearance markers|
21450|NCT00010348|Procedure|Total body irradiation and stem cell or bone marrow transplantation|Assuming donor is available, total body irradiation followed by allogeneic peripheral blood stem cell or bone marrow transplantation on Day 0.
21451|NCT00849485|Drug|Levetiracetam|750 mg Tablet
21452|NCT00849485|Drug|Keppra®|750 mg Tablet
21453|NCT00849511|Drug|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
21454|NCT00849524|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
21455|NCT00842049|Device|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
21456|NCT00842049|Other|No lumbar drain|No lumbar drain
21457|NCT00842062|Device|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
21458|NCT00842075|Drug|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
24949|NCT00858286|Other|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
24950|NCT00858299|Drug|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
24951|NCT00858312|Other|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
24952|NCT00858312|Other|Low Dairy|less than 1 serving of dairy foods per day.
24953|NCT00858325|Drug|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
24954|NCT00858338|Procedure|Potentially curative surgery|Surgery:
Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.
Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy.
24955|NCT00858338|Drug|Floxuridine (IP)|Adjuvant IP Chemotherapy:
week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy.
24956|NCT00858338|Procedure|Adjuvant Chemoradiation therapy|Adjuvant Chemoradiation therapy:
week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days.
24957|NCT00858351|Behavioral|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
25294|NCT00856297|Biological|MenACWY-CRM conjugate vaccine|
25295|NCT00856297|Biological|Licensed comparator|
25296|NCT00856310|Biological|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
25297|NCT00856323|Drug|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
25298|NCT00856323|Behavioral|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
25299|NCT00858780|Drug|Etanercept|50 mg etanercept once weekly + methotrexate
25300|NCT00858780|Drug|Etanercept|25mg etanercept once weekly + methotrexate
25301|NCT00858780|Drug|Placebo|Placebo comparator once weekly + methotrexate
21082|NCT00848809|Procedure|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
21083|NCT00848809|Procedure|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
21084|NCT00848835|Device|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
21085|NCT00848848|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
21086|NCT00848848|Biological|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
21087|NCT00848848|Biological|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
21088|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
21089|NCT00848848|Biological|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
21090|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
21091|NCT00848848|Biological|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
21092|NCT00851344|Other|Placebo|Placebo to match active
21387|NCT00844571|Other|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
21388|NCT00009958|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
21389|NCT00844584|Procedure|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
21390|NCT00844597|Drug|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
21391|NCT00844623|Genetic|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
21392|NCT00844636|Device|Sharp needle|
21393|NCT00844636|Device|Blunt needles|
21394|NCT00844649|Drug|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m^2 administered by intravenous infusion
21395|NCT00844649|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
25061|NCT00860925|Drug|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
25062|NCT00860925|Drug|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
25063|NCT00860925|Drug|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
25064|NCT00860938|Drug|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
25065|NCT00012051|Biological|rituximab|
25066|NCT00860951|Device|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
25067|NCT00860964|Drug|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
25068|NCT00860964|Drug|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
25069|NCT00010842|Drug|Alpha-lipoic acid|
25070|NCT00853112|Drug|PF-00489791|tablet form, 10 mg, single dose (Day 1)
25071|NCT00853112|Drug|PF-00489791|tablet form, 20 mg, single dose (Day 1)
25072|NCT00853112|Drug|placebo|tablet form, single dose (Day 1)
25073|NCT00853112|Drug|sildenafil|tablet form, 20 mg, single dose (Day 1)
25074|NCT00853125|Biological|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
25075|NCT00853125|Drug|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
24156|NCT00866294|Drug|paroxetine IR 20mg tablet|1 tablet once a day
24157|NCT00866294|Drug|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
24158|NCT00012363|Drug|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 & 8, q 21days
24159|NCT00866294|Drug|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
21459|NCT00842088|Drug|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
21460|NCT00842088|Drug|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
21461|NCT00009802|Dietary Supplement|calcitriol|
21462|NCT00842101|Device|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
21463|NCT00842114|Biological|R+CVP+IFN|Immunochemotherapy
21464|NCT00842127|Drug|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
21465|NCT00842140|Drug|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
21466|NCT00842140|Drug|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
21467|NCT00842140|Drug|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
21468|NCT00842153|Drug|Clobetasol propionate foam|Topical Clobetasol propionate foam
21469|NCT00842153|Drug|Vehicle foam|Vehicle foam does not include the active drug.
21470|NCT00842166|Other|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
21471|NCT00842192|Drug|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
20523|NCT00845611|Biological|peptide vaccine|peptides emulsified with Montanide ISA51
20524|NCT00845637|Drug|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
20525|NCT00845637|Drug|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
20526|NCT00845650|Biological|Anthrax Immune Globulin Intravenous (AIGIV)|Three cohorts evaluating three dosage levels of AIGIV containing 3.5, 7.0, or 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
20527|NCT00845650|Biological|Gamunex|Three cohorts evaluating three dosage levels containing Gamunex 90, 180, or 360 mg/kg total IgG as a single intravenous infusion.
20528|NCT00845663|Drug|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
25302|NCT00858793|Procedure|PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)|Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
25303|NCT00858806|Drug|Imatinib|Intermittent Imatinib administration.
1 week on / 1 week off for the 1st month(weeks 1-4)
2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)
1 month on / 1 month off from the 4th month thereafter (weeks 13 on)
25304|NCT00011921|Procedure|peripheral blood stem cell transplantation|
25305|NCT00858832|Drug|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
25306|NCT00858845|Drug|Clonidine Patch|A clonidine patch (0.1 mg/week) will be worn for 3 months.
25307|NCT00858858|Drug|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
25308|NCT00858871|Drug|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
25309|NCT00858871|Drug|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
25310|NCT00858871|Drug|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
25311|NCT00858871|Drug|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
25312|NCT00858884|Other|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
25313|NCT00858897|Other|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-[3,3-2H2]cysteine
24370|NCT00862030|Procedure|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
24371|NCT00862043|Drug|Sildenafil Citrate|40 mg t.i.d.
24372|NCT00862043|Drug|Placebo|Placebo t.i.d.
24373|NCT00862056|Procedure|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
24374|NCT00012103|Other|screening questionnaire administration|
24375|NCT00862082|Drug|PR104 550 mg/m^2 + sorafenib|550 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
21396|NCT00844662|Drug|Fermagate|Film coated tablet 500mg
21397|NCT00844662|Drug|Sevelamer hydrochloride|Tablet 800mg
21398|NCT00844675|Drug|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
21399|NCT00009958|Biological|sargramostim|Given SC
21400|NCT00844675|Drug|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
21401|NCT00844688|Drug|sorafenib|Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:
Progression of disease.
The patient is unlikely to benefit from further treatment as
Judged by the Investigator.
Intolerable toxicity of the drugs.
Withdrawal of consent for any reason.
21402|NCT00844688|Drug|Gemcitabine|Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 & 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:
Progression of disease. The patient is unlikely to benefit from further treatment as
Judged by the Investigator.
Intolerable toxicity of the drugs. Withdrawal of consent for any reason.
21403|NCT00844714|Drug|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
21404|NCT00847145|Biological|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
21405|NCT00847145|Biological|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
20462|NCT00010400|Drug|Cyclophosphamide|
20463|NCT00850122|Drug|cefazolin|Cefazolin dosing - administered for 48 hours Dosage
≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8
20464|NCT00850135|Device|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
20465|NCT00850148|Procedure|Anwar|Anwar surgical method
20466|NCT00850148|Procedure|Melles|Melles surgical method
20467|NCT00850161|Drug|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
20468|NCT00850161|Drug|Nasulin™|100 IU(2 puffs in each nostril)
20469|NCT00850174|Drug|Oxcarbazepine|600 mg Tablet
24160|NCT00866294|Drug|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
24161|NCT00866294|Drug|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
24162|NCT00866307|Drug|pegaspargase|Given IV
24163|NCT00866307|Drug|cytarabine|Given IT and IV or SC
24164|NCT00866307|Drug|vincristine sulfate|Given IV
24165|NCT00866307|Drug|doxorubicin hydrochloride|Given IV
24166|NCT00866307|Drug|cyclophosphamide|Given IV
24167|NCT00866307|Drug|prednisone|Given IV or PO
24168|NCT00866307|Drug|dexamethasone|Given IV
24169|NCT00012376|Drug|bryostatin 1|Given IV
24170|NCT00866307|Drug|methotrexate|Given IT and PO
24171|NCT00866307|Drug|daunorubicin hydrochloride|Given IV
24172|NCT00866307|Drug|mercaptopurine|Given PO
24173|NCT00866307|Drug|thioguanine|Given PO
24174|NCT00866307|Radiation|prophylactic cranial irradiation|Undergo radiation
24175|NCT00866307|Other|laboratory biomarker analysis|Correlative studies
24176|NCT00866320|Drug|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
24177|NCT00866333|Drug|entinostat (SNDX-275)|entinostat, oral, once weekly for 3 weeks followed by a 1-week break in a 4-week cycle
24178|NCT00866346|Biological|PR1-primed lymphocyte (PR1-CTL) Infusion|Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.
Starting infusion dose 1 x 106 nucleated cells/kg.
24179|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
24180|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
24450|NCT00869154|Behavioral|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
20529|NCT00847821|Drug|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
20530|NCT00847821|Drug|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
20531|NCT00847834|Drug|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
20532|NCT00847834|Drug|Irbesartan 150mg|Once a day
20533|NCT00847847|Procedure|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
20534|NCT00000779|Biological|rgp120/HIV-1 SF-2|
20535|NCT00010192|Biological|aldesleukin|Given SC
20536|NCT00847860|Drug|Cilostazol|Cilostazol 100 mg bid for 12 months
20537|NCT00847860|Drug|Aspirin|Aspirin 100 mg qd for 12 months
20538|NCT00847873|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
20539|NCT00847873|Behavioral|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
20540|NCT00847886|Drug|LX3305|Daily oral intake of LX3305 for 14 days.
20541|NCT00847886|Drug|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
20542|NCT00847886|Drug|Methotrexate|Once weekly stable-dose methotrexate.
20839|NCT00851032|Other|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer patients' stored tissue bank samples.
20840|NCT00010491|Procedure|Acupuncture|
20841|NCT00851045|Drug|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
20842|NCT00851045|Drug|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
20843|NCT00851045|Drug|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
24376|NCT00862082|Drug|PR104 770 mg/m^2 + sorafenib|770 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
24377|NCT00862095|Drug|Placebo|Every month for 3 months
24378|NCT00862095|Drug|Propranolol|target does 80 mg per day for 3 months
24379|NCT00862095|Drug|Amitriptyline|Target does of 50 mg per day for 3 months
24380|NCT00862095|Drug|Topiramate|Target dose 100 mg a day for 3 months
24381|NCT00862108|Drug|Methylphenidate|mg/kg dose: 0.7~1.2mg/kg PO daily morning intake 8 weeks
24382|NCT00862121|Drug|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
24383|NCT00862121|Drug|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
24384|NCT00862134|Drug|PR104|770 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
24385|NCT00012103|Other|sputum cytology|
24386|NCT00862134|Drug|docetaxel|75 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
24387|NCT00862134|Drug|docetaxel|60 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
24388|NCT00862134|Drug|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
24389|NCT00862147|Behavioral|ICDP|Parent training group
24390|NCT00862147|Behavioral|Treatment as usual|Parent and/or child focused interventions
24391|NCT00862160|Device|ROCsafeTM|using minimized perfusion circuit while CABG
24958|NCT00860691|Other|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
24959|NCT00860704|Other|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
20470|NCT00850174|Drug|Trileptal®|600 mg Tablet
20471|NCT00850187|Biological|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
20472|NCT00850200|Radiation|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
20473|NCT00000781|Drug|Zidovudine|
20474|NCT00010400|Drug|filgrastim|
20475|NCT00850200|Radiation|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
20476|NCT00850200|Radiation|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
20477|NCT00850213|Device|Endeavor Resolute Stent|Single implantation
20478|NCT00850226|Behavioral|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
20479|NCT00850226|Behavioral|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
20480|NCT00850239|Drug|dutogliptin|400 mg
20481|NCT00850239|Drug|placebo|
20482|NCT00850252|Device|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
20785|NCT00846001|Device|Epicardial implantation of cardiac resynchronization therapy device|During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
20786|NCT00846014|Drug|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
20787|NCT00846027|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
20788|NCT00846027|Drug|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
24451|NCT00869154|Behavioral|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
24452|NCT00012753|Procedure|Automated telephone health status assessments with nurse follow-up.|
24453|NCT00869167|Drug|Ramelteon|melatonin agonist
24454|NCT00869180|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
24455|NCT00869180|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
24456|NCT00869193|Dietary Supplement|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
24457|NCT00869193|Dietary Supplement|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
24458|NCT00869206|Drug|zoledronic acid|Given IV
24459|NCT00869219|Drug|Nevanac|1 drop of NEVANAC at random eye
24460|NCT00869219|Drug|Acular LS|One drop of Acular LS
24461|NCT00869232|Drug|Velcade|1.0mg/m2 days 1, 5, 8, & 11
24462|NCT00869245|Other|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
24463|NCT00012766|Behavioral|Integrated team care|
24464|NCT00862212|Behavioral|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
24465|NCT00862225|Drug|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
24466|NCT00862225|Drug|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
24467|NCT00000793|Drug|Amitriptyline hydrochloride|
24468|NCT00012103|Procedure|bronchoscopic and lung imaging studies|
20844|NCT00851045|Drug|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
20845|NCT00851045|Drug|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
20846|NCT00851045|Drug|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
20847|NCT00843609|Device|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
20848|NCT00843622|Drug|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
20849|NCT00843622|Other|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
20850|NCT00843635|Drug|Tadalafil|Given orally
20851|NCT00843635|Other|Placebo|Given orally
20852|NCT00843661|Drug|ezetimibe|10 mg ezetimibe/day
20853|NCT00843661|Drug|fenofibrate|200 mg fenofibrate/day
20854|NCT00843661|Drug|pravastatin|40 mg pravastatin/day
20855|NCT00843674|Behavioral|Interpersonal Psychotherapy|
20856|NCT00009893|Drug|fluorouracil|
20857|NCT00843674|Behavioral|Treatment as usual|
20858|NCT00843687|Drug|Risperidone long-acting injectable|
20859|NCT00843700|Behavioral|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
20860|NCT00843700|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
21151|NCT00846742|Drug|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
21152|NCT00010088|Drug|fluorouracil|
24960|NCT00012025|Drug|fulvestrant|
24961|NCT00860704|Other|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
24962|NCT00860717|Procedure|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
24963|NCT00860717|Radiation|Low level laser therapy (LLLT)|The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.
Wound beds were irradiated using a scanning technique with no direct contact.
24964|NCT00860730|Device|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
24965|NCT00860743|Drug|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
24966|NCT00860756|Other|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
24967|NCT00860769|Behavioral|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
24968|NCT00860769|Behavioral|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
24969|NCT00860782|Behavioral|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
24970|NCT00860795|Biological|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
24971|NCT00000793|Drug|Mexiletine hydrochloride|
24972|NCT00012038|Drug|irofulven|
24996|NCT00853073|Other|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
24997|NCT00853086|Drug|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
24998|NCT00853099|Biological|adalimumab|
24999|NCT00853099|Drug|placebo|
20789|NCT00846027|Drug|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
20790|NCT00846053|Procedure|[18F]FDG PET/CT|FDA-approved Investigational New Drug (IND) to use [18F]FDG in CF patients under the age of 18 years (PI: Robert Mach, MD, IND # 76079). Imaging data will be acquired with a Siemens Biograph 40PET/CT Tomograph. Research participants will be positioned supine in the scanner and a scout CT topograph obtained.
20791|NCT00846066|Other|Hands on training|Hands on training by a pediatric dentist on preventive oral health
20792|NCT00846066|Other|Web based training|Web based training alone
20793|NCT00846079|Device|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
20794|NCT00846092|Device|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
20795|NCT00010036|Drug|irinotecan hydrochloride|
20796|NCT00846092|Device|Near-infrared light (NIR)|Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.
Treatments involve application of the LED-generated light for 80 seconds, twice daily.
20797|NCT00846105|Other|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
20798|NCT00846118|Drug|Pitavastatin|1-4mg/day
20799|NCT00846131|Drug|Sorafenib|Randomized to Y-90 ± Sorafenib
20800|NCT00846131|Drug|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
20801|NCT00846144|Dietary Supplement|copper sulfate|copper sulfate 3mg/d for a period of 6 months
20802|NCT00846157|Biological|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
21093|NCT00851357|Drug|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
24729|NCT00869596|Drug|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
24730|NCT00869596|Drug|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
24731|NCT00869596|Drug|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
24732|NCT00012844|Device|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
24733|NCT00869596|Drug|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
24734|NCT00862641|Drug|Placebo|IV
24735|NCT00862654|Drug|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
24736|NCT00862654|Drug|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
24737|NCT00862654|Drug|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
24738|NCT00862654|Drug|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
24739|NCT00012142|Drug|temsirolimus|
24740|NCT00862667|Drug|Treatment A|PF-00241939 300ug using Inhaler A
24741|NCT00862667|Drug|Treatment B|PF-00241939 300ug using Inhaler B
24742|NCT00862667|Drug|Treatment C|PF-00241939 300ug using Inhaler C
24743|NCT00862680|Procedure|PET/CT Scan|Routine PET/CT scan with small plastic box (weighing less than 1 oz) placed on abdominal area to track breathing motion.
24744|NCT00862693|Drug|Calcitriol|0.5ug/Biw
24745|NCT00862706|Drug|Telbivudine/LDT600A|Oral once daily
24746|NCT00862719|Drug|Sitagliptin|600 mg/day PO starting on Day -1 for a total of 4 doses.
600 mg/bid PO starting on Day -1 for a total of 8 doses.
600 mg/tid PO starting on Day -1 for a total of 12 doses.
24747|NCT00862732|Behavioral|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
21153|NCT00846742|Radiation|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
21154|NCT00846755|Drug|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
21155|NCT00846768|Drug|BI 1744 CL|
21156|NCT00846781|Drug|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
21157|NCT00846833|Biological|Haploidentical NK cell|Collection of PBMCs by leukapheresis
CD3+ depletion of apheresis product using CliniMACS®
21158|NCT00010309|Biological|MART-1 antigen|
21159|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
21160|NCT00848848|Biological|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
21161|NCT00848848|Biological|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
21162|NCT00848861|Drug|propofol (sedation for outpatient colonoscopy)|
21163|NCT00848861|Drug|midazolam plus meperidine (sedation for outpatient colonoscopy)|
21164|NCT00848874|Behavioral|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
21165|NCT00848887|Biological|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
21166|NCT00848900|Behavioral|Outdoor activity|Adding 1 hour outdoor time into school curricula
21167|NCT00848913|Other|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
21168|NCT00848913|Other|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
21169|NCT00010309|Biological|gp100 antigen|
21170|NCT00848926|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
21171|NCT00848939|Drug|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
21472|NCT00009802|Drug|paclitaxel|
25000|NCT00853112|Drug|PF-00489791|tablet form, 1 mg, single dose (Day 1)
25001|NCT00853112|Drug|PF-00489791|tablet form, 2 mg, single dose (Day 1)
25002|NCT00853112|Drug|PF-00489791|tablet form, 4 mg, single dose (Day 1)
25003|NCT00855660|Drug|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
25004|NCT00855660|Drug|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
25005|NCT00855673|Device|Intermittent Mechanical Compression|FM220 device
25006|NCT00855673|Drug|Control|Standard medical treatment
25007|NCT00855686|Drug|Memantine|20mg once daily oral dose
25008|NCT00855686|Drug|Placebo|Daily oral dose
25009|NCT00011141|Drug|Oral lactobacillus administration|
25010|NCT00855699|Drug|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
25011|NCT00855712|Device|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
25012|NCT00855712|Device|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
25013|NCT00855725|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
25014|NCT00855725|Other|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
25015|NCT00855725|Other|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
25016|NCT00855725|Other|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
25314|NCT00858897|Drug|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
25315|NCT00011921|Radiation|radiation therapy|
21094|NCT00851357|Behavioral|Telephone Counseling|Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.
Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling.
21095|NCT00851357|Drug|Placebo|Placebo nicotine patch
21096|NCT00851357|Other|Self-Help Materials|Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.
Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day.
21097|NCT00851370|Drug|Omalizumab (Xolair)|Bi-weekly
21098|NCT00851370|Drug|Placebo|Bi-Weekly
21099|NCT00851383|Biological|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
21100|NCT00851383|Biological|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
21101|NCT00851409|Drug|Recombinant Human C1 Inhibitor|50 IU/kg "rhC1INH", "IV" injection over 4 to 5 minutes, once weekly over an 8-week treatment period.
21102|NCT00010608|Behavioral|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
21103|NCT00851435|Biological|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
21104|NCT00851448|Dietary Supplement|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
21105|NCT00851461|Drug|Goserelin|Goserelin 10.8 mg SC every 3 months
21106|NCT00851461|Procedure|Electrophysiologic study|Nerve conduction study Electromyogram
21107|NCT00851461|Procedure|tissue biopsy|skin and muscle biopsy before and after treatment every year
21108|NCT00851487|Drug|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
21109|NCT00851487|Drug|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
21110|NCT00851500|Drug|K-604|K-604 is given for 26 weeks
21111|NCT00851500|Other|Placebo|placebo tablets are given for 26 weeks
21406|NCT00010127|Biological|therapeutic autologous dendritic cells|
24748|NCT00862732|Other|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
25076|NCT00853138|Behavioral|cognitive-behavioral therapy|In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.
The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.
Assignments are incorporated into each module for the participant to work on during the treatment week.
25077|NCT00853151|Drug|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
25078|NCT00853151|Drug|TT223|subcutaneous injection once a day for 4 weeks
25079|NCT00853151|Drug|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
25080|NCT00000782|Biological|gp160 Vaccine (MicroGeneSys)|
25081|NCT00010842|Drug|Vitamin E/Selenium|
25082|NCT00853151|Drug|Placebo for TT223|subcutaneous injection once a day for 4 weeks
25083|NCT00853164|Behavioral|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
25084|NCT00853164|Behavioral|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
25085|NCT00853164|Behavioral|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
25086|NCT00853177|Procedure|MEOPA inhalation|N2O of 50% and 50% O2
25087|NCT00853177|Procedure|xylocaine|Ampoule-bottle of 20 ml
25088|NCT00853190|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
25089|NCT00853190|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
25090|NCT00853203|Behavioral|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
25091|NCT00853203|Behavioral|Questionnaires|Written survey taking about 1 hour.
25092|NCT00010842|Drug|Essential fatty acids|
21473|NCT00842205|Drug|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
21474|NCT00842205|Drug|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
21475|NCT00842231|Other|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
21476|NCT00842244|Drug|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
21477|NCT00842244|Drug|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
21478|NCT00842244|Drug|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m^2 on day 1.
21479|NCT00842257|Drug|panitumumab|Given by a central line infusion on days 1 and 15 of each 4-week cycle.
21480|NCT00844727|Drug|Rofecoxib|
21481|NCT00844727|Drug|placebo|placebo pills
21482|NCT00844740|Drug|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
21483|NCT00844753|Drug|atomoxetine|atomoxetine
21484|NCT00844753|Drug|Placebo|Placebo + parent management treatment
21485|NCT00844753|Behavioral|Parent Management Training|
21486|NCT00000779|Biological|Aluminum hydroxide|
21487|NCT00009958|Other|laboratory biomarker analysis|Correlative studies
21488|NCT00844779|Procedure|Bariatric surgery|Gastric bypass.
21489|NCT00844779|Procedure|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
21490|NCT00844792|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
21491|NCT00844792|Drug|Placebo|Twice a day with meals.
21492|NCT00844805|Drug|Infliximab|
21493|NCT00844805|Drug|Placebo|
25316|NCT00858910|Other|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
25317|NCT00858910|Other|Control intervention|The control intervention encloses relaxation and breathing exercises, and information about:
the disease (stroke),
therapy options,
self-help groups and their offers for support,
helping aids for independent living at home.
25318|NCT00858923|Device|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
25319|NCT00858936|Drug|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
25320|NCT00858936|Drug|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
25321|NCT00858962|Drug|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
25322|NCT00012051|Procedure|bone marrow ablation with stem cell support|
25323|NCT00861614|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
25324|NCT00861627|Biological|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
25325|NCT00861627|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
25326|NCT00861627|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
25327|NCT00861640|Drug|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
25328|NCT00861640|Drug|Oral Rabeprazole|Oral Rabeprazole 1 bid
25329|NCT00861666|Behavioral|Forgiveness-Based Writing|Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.
Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.
Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task.
24392|NCT00862186|Behavioral|'Fatigue Facts & Fixes'|'Fatigue Facts & Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: "Why am I so tired?" (description of cancer-related fatigue); "What causes fatigue?" (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and "What can help me to not be so tired?" (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource.
21407|NCT00847145|Biological|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
21408|NCT00847145|Biological|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
21409|NCT00847145|Biological|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
21410|NCT00847145|Biological|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
21411|NCT00847145|Biological|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
21412|NCT00847158|Procedure|phacoemulsification alone|phacoemulsification alone
21413|NCT00847158|Device|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
21414|NCT00847171|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:
12 intradermal injections of a divided total dose of 5 x108 cells.
21415|NCT00847171|Biological|trastuzumab|Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.
Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg
21416|NCT00847171|Drug|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
21417|NCT00010140|Drug|docetaxel|
21418|NCT00847171|Other|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
21419|NCT00847171|Other|immunoenzyme technique|
21420|NCT00847171|Other|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
21421|NCT00847171|Other|laboratory biomarker analysis|
21422|NCT00847171|Other|pharmacological study|
21423|NCT00847171|Procedure|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
21424|NCT00847184|Device|Intubation|Intubation using the standard MacIntosh blade
21425|NCT00847184|Device|Airtraq|Intubation with the use of the Airtraq technique
21426|NCT00847197|Drug|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
25093|NCT00855829|Device|Miniature Actilady device active|Devices: Targeted pressure waves are created by two kind of methods ActiLady).
The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an "off the shelf" pressure waves generator and controller.
Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves.
24181|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
24182|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
24183|NCT00868634|Drug|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
24184|NCT00868647|Procedure|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
24185|NCT00868660|Drug|ZP1848|sc. bolus
24186|NCT00868673|Dietary Supplement|low fructose|patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of "healthy" fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
24187|NCT00012662|Behavioral|Diabetes Self Management Education|
24188|NCT00868673|Dietary Supplement|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
24189|NCT00868686|Device|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
24190|NCT00868686|Device|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
24191|NCT00868686|Device|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
24192|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
24193|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-7
24194|NCT00868699|Drug|Placebo|Placebo Comparator
21494|NCT00844805|Drug|Naproxen|
20543|NCT00847899|Drug|AR9281|AR9281 taken in BID dosing regimen for 28 days
20544|NCT00847899|Drug|AR9281|AR9281 taken in TID dosing regimen for 28 days
20545|NCT00847899|Drug|Placebo|Placebo taken in BID dosing regimen for 28 days
20546|NCT00010192|Other|laboratory biomarker analysis|Correlative studies
20547|NCT00847899|Drug|Placebo|Placebo taken in TID dosing regimen for 28 days
20548|NCT00847912|Drug|5-fluorouracil|Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate "cool-down" treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the "cool-down" routine will be followed, but 5-FU will be stopped.
20549|NCT00010413|Drug|cyclophosphamide|
20550|NCT00850304|Drug|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
20551|NCT00850304|Drug|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
20552|NCT00850317|Device|Miltenyi CliniMACs device|CD34 selection
20553|NCT00850330|Other|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
20554|NCT00850343|Drug|Certolizumab pegol|Subcutaneous (SC) injection
20555|NCT00850369|Other|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
20556|NCT00850382|Drug|Dasatinib|Induction cycle(s):
Dasatinib 100 mg QD on days 8-21.
Consolidation Cycles 1, 2, 3, 4:
Patients will receive dasatinib 100 mg QD on days 6-28.
Maintenance therapy:
Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse).
20557|NCT00850382|Drug|daunorubicin|Induction cycle(s):
Daunorubicin 60 mg/m2/day administered on days 1 through 3
20558|NCT00850382|Drug|Cytarabine|Induction cycle(s):
Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).
Consolidation cycles 1, 2, 3, 4:
Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours.
20559|NCT00850395|Drug|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
20560|NCT00010413|Drug|filgrastim|
21275|NCT00851708|Drug|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
21276|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
21277|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
21278|NCT00010634|Drug|Connective Tissue Nutrient Formula|
21279|NCT00851734|Drug|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
21280|NCT00851747|Drug|Subcutaneous Phosphatidylcholine and Deoxycholate Injections|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
21281|NCT00851747|Drug|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
21282|NCT00851760|Procedure|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
21283|NCT00851760|Procedure|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
21284|NCT00851773|Drug|semaglutide|0.1 mg once weekly, s.c. injection
21285|NCT00851773|Drug|semaglutide|0.2 mg once weekly, s.c. injection
21286|NCT00851773|Drug|semaglutide|0.4 mg once weekly, s.c. injection
21287|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
21288|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
21289|NCT00000201|Drug|Selegiline|
21290|NCT00000781|Drug|Didanosine|
21291|NCT00010634|Drug|Adaptogenic herbs|
20347|NCT00817323|Procedure|Dietary amino-acid depletion|See detailed description
20348|NCT00817336|Drug|D Serine|60 mg/kg/day
20349|NCT00007059|Drug|mycophenolate mofetil|
20350|NCT00817336|Drug|Placebo|oral
21035|NCT00009919|Drug|semaxanib|Given IV
21036|NCT00844103|Drug|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
21037|NCT00844103|Drug|Placebo|10ml oral solution administered once a day over 10 days.
21038|NCT00844116|Device|spirometry|Conventional and telematic spirometry
21039|NCT00844142|Drug|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
21040|NCT00844142|Drug|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
21041|NCT00844155|Drug|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
21042|NCT00844168|Drug|sorafenib tosylate|Given orally
21043|NCT00844168|Other|laboratory biomarker analysis|Correlative studies
21044|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
21045|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
21046|NCT00846456|Biological|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
21047|NCT00846469|Procedure|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
21048|NCT00846469|Other|Control section|Normal emergency room treatment for symptoms of chest pain.
21049|NCT00846482|Drug|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
21050|NCT00846495|Drug|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
21051|NCT00846495|Drug|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
21052|NCT00000779|Biological|rgp120/HIV-1IIIB|
21053|NCT00010075|Drug|fluorouracil|
22062|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
22063|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
22064|NCT00840827|Drug|lenalidomide|Lenalidomide 10mg po daily
22065|NCT00840827|Drug|cyclosporine A|CSA 250mg orally twice daily
22066|NCT00840840|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
22340|NCT00838578|Drug|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
22341|NCT00841347|Behavioral|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
22342|NCT00841347|Behavioral|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
22343|NCT00841360|Other|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
22344|NCT00841360|Other|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
22345|NCT00841373|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
22346|NCT00841373|Procedure|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
22347|NCT00841386|Drug|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
22348|NCT00841386|Drug|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
22349|NCT00841399|Biological|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
22350|NCT00009763|Drug|paclitaxel|
22351|NCT00841412|Behavioral|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
21538|NCT00849654|Drug|PCI-32765|In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.
In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days.
21539|NCT00010361|Drug|fludarabine|
21540|NCT00849667|Drug|MORAb-003 (farletuzumab)|MORAb-003 1.25 mg/kg infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
21541|NCT00849667|Drug|MORAb-003 (farletuzumab)|MORAb-003 2.5mg/kg infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
21542|NCT00849667|Drug|0.9% Saline|0.9% infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
21543|NCT00849680|Other|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
21544|NCT00849680|Biological|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
21545|NCT00842270|Drug|AB1010|3 mg/kg/day
21546|NCT00842270|Drug|AB1010|4,5 mg/kg/day
21547|NCT00842270|Drug|AB1010|6 mg/kg/day
21548|NCT00000778|Drug|Isoniazid|
21549|NCT00009815|Drug|etoposide|
20580|NCT00843024|Drug|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
20581|NCT00843024|Drug|Placebo|Placebo to match
20582|NCT00843037|Drug|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
20583|NCT00843050|Drug|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
20584|NCT00009867|Drug|arsenic trioxide|Given IV
20585|NCT00843063|Drug|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
20586|NCT00843089|Other|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
20587|NCT00843115|Other|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
20351|NCT00817362|Drug|IPI-504|IPI-504 IV infusion 300 mg/m2
20352|NCT00817362|Drug|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
20353|NCT00817375|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
20354|NCT00007605|Drug|Amiodarone|Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
20355|NCT00819832|Device|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
20356|NCT00819845|Drug|carvedilol|carvedilol vs ramipril
20357|NCT00819845|Drug|ramipril|carvedilol vs ramipril
20358|NCT00819858|Dietary Supplement|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
20359|NCT00819884|Drug|AZD1656|Oral suspension
20360|NCT00819910|Drug|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
20361|NCT00819910|Drug|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
20362|NCT00819910|Drug|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
20363|NCT00819910|Drug|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
20364|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
20365|NCT00007605|Drug|Sotalol|Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
20366|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
20367|NCT00819936|Procedure|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
20368|NCT00819936|Procedure|backward walking|physiotherapy with use a backward walking type of physiotherapy
20665|NCT00850616|Biological|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
20666|NCT00843154|Drug|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
21352|NCT00849212|Drug|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
21353|NCT00849238|Drug|mycophenolate mofetil|
21354|NCT00849251|Drug|cyclophosphamide|Given IV or PO
21355|NCT00849251|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
21356|NCT00849251|Drug|bortezomib|Given IV
21357|NCT00849251|Drug|dexamethasone|Given IV or PO
21358|NCT00849264|Drug|chemotherapy with endostar|15mg/d×14d
21359|NCT00849264|Drug|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
21360|NCT00849264|Drug|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
21361|NCT00849277|Drug|Lactobacillus casei Shirota|
21362|NCT00010348|Drug|Cyclosporine|Oral or IV cyclosporine 2 to 3 times daily on Days -1 to 50
21363|NCT00849290|Biological|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
21364|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
21365|NCT00841919|Drug|NPH insulin and regular insulin|The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the "Inpatient Diabetes Advisory Group" and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.
21366|NCT00841919|Drug|lispro insulin|Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of "insulin pen/syringe on the food tray") by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the "Inpatient Diabetes Advisory Group" and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.
21367|NCT00009776|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
21368|NCT00841932|Procedure|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
22352|NCT00841412|Behavioral|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
22353|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
22354|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
22355|NCT00841451|Drug|Lovaza (Fish Oils)|Double blinded placebo controlled
22356|NCT00841477|Biological|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
22357|NCT00841477|Behavioral|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
22678|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
22679|NCT00839163|Drug|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
22680|NCT00839176|Drug|RX-10100|Extended-release tablet, 5~15mg, twice day (morning & evening) at least 30 min before meal, 8 weeks
22681|NCT00009581|Drug|L-NMMA|
22682|NCT00839189|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
22683|NCT00839202|Device|FVIII immuno-assay|
22684|NCT00839228|Drug|Perhexiline|100mg o bd for 3 months
22685|NCT00841763|Biological|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
22686|NCT00841763|Biological|Adjuvanted trivalent influenza vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
22687|NCT00841776|Drug|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
22688|NCT00841776|Drug|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
22689|NCT00009776|Drug|paclitaxel|
22690|NCT00841789|Drug|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
20588|NCT00843128|Device|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
20589|NCT00843128|Device|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
20590|NCT00843141|Behavioral|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
20591|NCT00843141|Behavioral|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
20592|NCT00843154|Drug|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
20593|NCT00845663|Drug|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
20594|NCT00845676|Drug|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
20595|NCT00000779|Biological|MF59|
20596|NCT00010010|Drug|exemestane|
20597|NCT00845689|Drug|placebo|NaCl 0,9 %
20598|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0, 2 %
20599|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0,2 %
20600|NCT00845689|Procedure|Liver resection|Liver resection with Pringle maneuver
20601|NCT00845702|Drug|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
20899|NCT00010244|Radiation|radiation therapy|
20900|NCT00848471|Device|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
20901|NCT00848484|Drug|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
20902|NCT00848484|Drug|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
20903|NCT00848497|Drug|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
20667|NCT00843167|Dietary Supplement|broccoli sprout extract|Given orally
20668|NCT00009880|Biological|filgrastim|
20669|NCT00843167|Other|placebo|Given orally
20670|NCT00843180|Other|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
20671|NCT00843193|Drug|Active GSK679586|Drug: GSK679586
20672|NCT00843193|Drug|Placebo|Placebo treatment
20673|NCT00843219|Procedure|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
20674|NCT00843245|Other|No intervention|No intervention
20675|NCT00843258|Device|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
20676|NCT00843284|Drug|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
20677|NCT00843297|Device|Coolgard|invasive Cooling via femoral ICY-catheter
20678|NCT00843297|Device|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
20679|NCT00009880|Drug|cisplatin|
20680|NCT00843297|Other|Conventional treatment|Intensive care-treatment without cooling
20681|NCT00843310|Drug|Lenalidomide (Revlimid)|
20682|NCT00843310|Drug|Melphalan|
20683|NCT00843310|Drug|Dexamethasone|
20684|NCT00843323|Other|Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device
20685|NCT00843336|Behavioral|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
20686|NCT00843336|Behavioral|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
20687|NCT00843349|Drug|Lanthanum Carbonate|Phosphorus binder
20688|NCT00843349|Other|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
21702|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
21703|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
21980|NCT00832273|Device|ELAD®|liver assist system
21981|NCT00008255|Drug|INS316|
21982|NCT00832286|Drug|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
21983|NCT00832299|Drug|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
21984|NCT00832299|Procedure|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
21985|NCT00832312|Other|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
21986|NCT00832312|Other|placebo (saline)|Injection of 1cc of saline into the knee joint
21987|NCT00832325|Behavioral|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
21988|NCT00832325|Behavioral|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
21989|NCT00832325|Behavioral|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
21990|NCT00832338|Drug|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
21991|NCT00832338|Drug|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
21992|NCT00008255|Other|sputum cytology|
21993|NCT00832351|Procedure|Mobilisation|Mobilisation
21994|NCT00832364|Drug|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
21995|NCT00832364|Drug|Placebo|Placebo capsules
21996|NCT00832364|Biological|Etanercept|Injectable Biologic
22691|NCT00841789|Drug|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
22692|NCT00841802|Drug|Prednisone|Prednisone 30mg once daily x 5 days
22693|NCT00841815|Drug|Amlodipine Besylate|10 mg Tablet
22694|NCT00841815|Drug|Norvasc®|10 mg Tablet
22695|NCT00841828|Drug|Epirubicin, Cyclophosphamide, Taxotere, Herceptín, Lapatinib|- EC (each 21 days for 4 cycles) -> T + lapatinib (each 21 days for 4 cycles) vs
EC (each 21 days for 4 cycles) -> T + herceptin (each 21 days for 4 cycles)
22696|NCT00841841|Drug|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
22697|NCT00841854|Drug|pantoprazole|pantoprazole 40mg bid
22698|NCT00841854|Drug|bismuth|bismuth 300mg qid
22699|NCT00841854|Drug|metronidazole|metronidazole 500mg tid
21757|NCT00009997|Drug|paclitaxel|
21758|NCT00845364|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
21759|NCT00845377|Behavioral|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
21760|NCT00845429|Biological|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
21761|NCT00845429|Biological|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
21762|NCT00845429|Biological|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
21763|NCT00845442|Device|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
21764|NCT00845481|Drug|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
21765|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
21766|NCT00010166|Procedure|adjuvant therapy|
21767|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
20904|NCT00848497|Other|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
20905|NCT00848497|Drug|Viagra®|Viagra 25mg was the dose given to the patient which he started.
20906|NCT00848510|Biological|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease [SD], complete response [CR], or partial response [PR]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
20907|NCT00848523|Drug|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
20908|NCT00848536|Drug|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
20909|NCT00848536|Drug|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
20910|NCT00851045|Drug|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
20911|NCT00851058|Behavioral|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
20912|NCT00851058|Behavioral|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
20913|NCT00851058|Behavioral|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
20914|NCT00000781|Drug|Zalcitabine|
20915|NCT00010491|Procedure|Moxibustion|
20916|NCT00851058|Behavioral|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
20917|NCT00851071|Behavioral|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
21207|NCT00844311|Drug|rFSH|150 iu/day of rFSH
21208|NCT00844311|Drug|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
21209|NCT00844311|Drug|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
21210|NCT00844311|Drug|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
21211|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
20974|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
20975|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
20976|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
20977|NCT00010257|Drug|carboplatin|Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
20978|NCT00848549|Drug|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
20979|NCT00848549|Drug|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
20980|NCT00848562|Drug|Nicorandil|Oral administration of nicorandil (15 mg/day)
20981|NCT00848575|Device|Flexible Endoscope|
20982|NCT00848601|Drug|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
20983|NCT00848627|Other|Specimen and questionnaires only|Specimen and questionnaires only
20984|NCT00848640|Drug|Sorafenib|400 mg twice daily
20985|NCT00848653|Device|CRT device|market approved CRT device
20986|NCT00848666|Drug|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
20987|NCT00848679|Drug|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
20988|NCT00000779|Biological|Env 2-3|
20989|NCT00010257|Drug|paclitaxel|225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
20990|NCT00848679|Drug|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
20991|NCT00848692|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
21997|NCT00832377|Drug|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
21998|NCT00835029|Drug|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
21999|NCT00835042|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
22000|NCT00835042|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
22274|NCT00832832|Other|No intervention will be assigned|No intervention will be assigned to this arm
22275|NCT00832845|Behavioral|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 24 weeks.
22276|NCT00832845|Behavioral|Treatment as usual (TAU)|Patients will receive their regular treatment for 24 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians. However, in addition to the standard of care, subjects receiving TAU will have 24 weekly 60-minute non-structured meetings, including half-hour lunch break, to control for non-specific factors associated with group therapy.
22277|NCT00008281|Drug|oxaliplatin|
22278|NCT00832871|Drug|Mifepristone|Mifepristone 200 mg will be administered orally
22279|NCT00832884|Drug|Lacosamide|0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes
22280|NCT00832884|Drug|Lacosamide|1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes
22281|NCT00832884|Drug|Lacosamide|2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes
22282|NCT00832884|Drug|Lacosamide|2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes
22283|NCT00832884|Drug|Lacosamide|0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes
22284|NCT00832884|Drug|Lacosamide|1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes
22285|NCT00832884|Drug|Lacosamide|2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes
22286|NCT00832884|Drug|Lacosamide|2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes
22287|NCT00832897|Procedure|Corneal collagen crosslinking|The patients will be submitted to corneal collagen crosslinking, that consists:
Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop.
22288|NCT00835562|Procedure|Non-surgical management|Non-surgical management (physiotherapy and self-training)
21768|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
21769|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
21770|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
21771|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
21772|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
21773|NCT00847639|Drug|lenalidomide|Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.
Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.
The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
21774|NCT00847665|Other|repositioning|Turning every 4 or 2 hours
21775|NCT00847678|Biological|Efungumab (Mycograb)|
21776|NCT00847678|Biological|placebo|
21777|NCT00010166|Radiation|radiation therapy|
22067|NCT00840840|Drug|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
22068|NCT00009750|Drug|cyclosporine|
22069|NCT00840853|Genetic|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
22070|NCT00840866|Drug|cefprozil|500 mg Tablet
22071|NCT00840866|Drug|Cefzil®|500 mg Tablet
22072|NCT00840879|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
22073|NCT00840879|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
22074|NCT00832390|Drug|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
22075|NCT00832403|Other|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
22076|NCT00832416|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
22077|NCT00832416|Drug|Placebo|One Placebo tablet daily.
21212|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
21213|NCT00844337|Drug|Gentamicin & Amoxicillin x 7days|Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.
The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day.
21214|NCT00844337|Drug|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
21215|NCT00844337|Drug|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
21216|NCT00844350|Drug|letrozole , oxytocin,hCG,clomiphene citrate|
21217|NCT00009945|Drug|clodronate|1600 mg PO daily
21218|NCT00844363|Procedure|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
21219|NCT00844376|Drug|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
21220|NCT00844376|Drug|Lipitor|A single dose of 80 mg Lipitor tablet
21221|NCT00844389|Device|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
21222|NCT00844389|Device|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
21223|NCT00846846|Device|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
21224|NCT00846859|Drug|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
21225|NCT00846859|Drug|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
21226|NCT00846872|Drug|GHRP-3|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
21550|NCT00842270|Drug|placebo|matching placebo to AB1010 dosages
21551|NCT00842283|Other|skin tissue sample|skin tissue sample
21552|NCT00842296|Device|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
20992|NCT00848692|Drug|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
20993|NCT00848705|Behavioral|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
21292|NCT00851773|Drug|placebo|0.1 mg once weekly, s.c. injection
21293|NCT00851773|Drug|placebo|0.2 mg once weekly, s.c. injection
21294|NCT00851773|Drug|placebo|0.4 mg once weekly, s.c. injection
21295|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
21296|NCT00844402|Drug|Atorvastatin|oral, 10 mg, daily, 48 weeks
21297|NCT00844415|Drug|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
21298|NCT00844428|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
21299|NCT00844441|Other|medical chart review|
21300|NCT00844441|Other|questionnaire administration|
21301|NCT00009945|Drug|placebo|2 pills PO daily
21302|NCT00844441|Procedure|quality-of-life assessment|
21303|NCT00844454|Procedure|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
21304|NCT00844454|Procedure|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
21305|NCT00844467|Biological|serotypes and resistance|screening patients with invasive pneumococci
21306|NCT00844480|Drug|zoledronic acid|zoledronic acid, 5mg, iv
21307|NCT00844480|Drug|placebo|iv
21308|NCT00844493|Biological|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
21309|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
21310|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
22289|NCT00835562|Procedure|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
22290|NCT00835562|Procedure|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
22291|NCT00835575|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
22292|NCT00835575|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
22293|NCT00835588|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
22294|NCT00008450|Drug|mycophenolate mofetil|Given PO or IV
22295|NCT00835588|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
22628|NCT00833482|Drug|Ritonavir|Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.
Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.
22629|NCT00000773|Drug|Atovaquone|
22630|NCT00008307|Biological|anti-thymocyte globulin|
22631|NCT00833495|Drug|Prednisolone Acetate 0.12% (Pred Mild®)|Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
22632|NCT00833495|Drug|FOV1101-00|This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
22633|NCT00833495|Drug|Prednisolone Acetate 1% (Pred Forte®)|PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
22634|NCT00833495|Drug|Placebo|The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
22635|NCT00833508|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
22636|NCT00833521|Drug|Zolpidem 10 mg tablets|1 x 10 mg
22078|NCT00832429|Procedure|Lymphatic Mapping|SPECT/CT scan following Tc99m-Sulfur colloid injection into eyelid tumor(s) making lymph nodes visible on imaging scan.
22079|NCT00008268|Biological|filgrastim|
22080|NCT00832429|Procedure|SLN Mapping/Biopsy|SLN mapping and biopsy done in OR under general anesthesia. Injection of Tc99m-Sulfur colloid again around eyelid tumor(s) or removed tumor site(s). Lymph nodes visible from injection removed and tested for signs of metastatic disease.
22081|NCT00832442|Drug|Beta blocker|as determined by individual study
22082|NCT00832442|Other|Placebo|in addition to usual care
22083|NCT00832455|Drug|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
22084|NCT00832468|Other|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
22085|NCT00832468|Other|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
22086|NCT00832481|Drug|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
22087|NCT00832481|Drug|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
22088|NCT00832494|Drug|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
22358|NCT00841503|Other|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
22359|NCT00841516|Other|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
22360|NCT00841516|Biological|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
22361|NCT00000777|Biological|gp160 Vaccine (MicroGeneSys)|
22362|NCT00008294|Drug|FOLFOX regimen|
22363|NCT00832923|Behavioral|PEPAC|The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an "asthma care toolkit" to improve communication around asthma care with the child's primary care provider.
22364|NCT00832962|Genetic|Genotyping|Whole blood sample
22365|NCT00832962|Other|Usual prophylaxis|Prophylactic anti-RhD
21553|NCT00842309|Drug|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
21554|NCT00842309|Drug|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
21555|NCT00842322|Behavioral|high fluid intake|fluid intake of 4 litres per day
21556|NCT00842322|Behavioral|normal fluid intake|Fluid intake of 2 litres per day
21557|NCT00842335|Drug|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
21558|NCT00842348|Drug|lanreotide (Autogel formulation)|Autogel 120mg
21559|NCT00842361|Drug|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
21560|NCT00009815|Drug|leucovorin calcium|
21561|NCT00842361|Drug|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
21562|NCT00842400|Drug|Metformin, VI-0521, Sitagliptan, Probenecid|This trial is an open-label, non-randomized, one-sequence crossover study.
metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34
sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39
VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)
2 g (four 500 mg) probenecid tablets on Day 29.
21563|NCT00842426|Behavioral|Self-management program (SM)|Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.
During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management.
21564|NCT00842426|Behavioral|Care management program (CM)|In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.
During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support.
21565|NCT00842439|Behavioral|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
20602|NCT00845702|Other|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
20603|NCT00845715|Other|Early motion|Early referral to physical therapy for range of motion (2 days post)
21311|NCT00844493|Biological|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
21312|NCT00009958|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
21313|NCT00844506|Drug|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
20369|NCT00819949|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
20370|NCT00819962|Drug|Bupivacaine|Local anesthetic
20371|NCT00819962|Other|TAP|
20372|NCT00819975|Dietary Supplement|Casein|
20373|NCT00819975|Dietary Supplement|Whey Isolate|
20374|NCT00819975|Dietary Supplement|Whey Hydrolysate|
20375|NCT00819975|Dietary Supplement|Alphalact-Albumin|
20376|NCT00007631|Drug|Tretinoin 0.1% cream or placebo|
20377|NCT00819988|Drug|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
20378|NCT00819988|Other|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
20379|NCT00813124|Drug|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
20380|NCT00813124|Drug|Azacitidine|Start cycles of 32 mg/m^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
20381|NCT00813124|Procedure|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
20382|NCT00813137|Drug|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1~7, D15~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
22637|NCT00833521|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
22638|NCT00833534|Biological|rituximab|Given IV
22639|NCT00833534|Drug|lenalidomide|Given orally
22640|NCT00833547|Drug|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
22641|NCT00008307|Drug|cyclosporine|
22642|NCT00833547|Drug|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
22643|NCT00833560|Drug|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
22644|NCT00833560|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
21704|NCT00849745|Procedure|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
21705|NCT00849797|Drug|Oxcarbazepine|600 mg Tablet
21706|NCT00849797|Drug|Trileptal®|600 mg Tablet
21707|NCT00849810|Drug|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
21708|NCT00849810|Drug|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
21709|NCT00849823|Behavioral|Male Sexual Health Program|An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size "fits all" condoms) and a brief (nurse-delivered) counseling message to practice safer sex.
21710|NCT00849823|Behavioral|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
21711|NCT00010374|Device|Intramuscular diaphragm electrodes|to test the safety, efficacy and clinical utility of diaphragm pacing using IM electrodes placed through a laparoscopic approach to achieve artificial ventilation in spinal cord injured patients who have an internal cardiac pacemaker and require full-time ventilator support.
22366|NCT00832988|Other|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
22367|NCT00833001|Device|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
22368|NCT00833014|Device|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
22369|NCT00833027|Drug|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
22370|NCT00833040|Drug|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
22371|NCT00833053|Drug|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
22372|NCT00833053|Drug|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
22373|NCT00008294|Drug|dexamethasone|
22374|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
22375|NCT00833066|Biological|Placebo|placebo entero-coated capsules
22376|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
22377|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
22700|NCT00009776|Radiation|indium In 111 monoclonal antibody Lym-1|
22701|NCT00841854|Drug|tetracycline|tetracycline 500mg qid
22702|NCT00841867|Procedure|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
22703|NCT00841880|Drug|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
22704|NCT00841880|Drug|Ramipril|10 mg once a day
22705|NCT00841880|Drug|Ramipril|5mg once a day
22706|NCT00841893|Dietary Supplement|Mustard (dijon)|The specific spice added to a brunch meal
22707|NCT00841893|Dietary Supplement|Placebo|Placebo added to a brunch meal
20604|NCT00845715|Other|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
20605|NCT00845728|Drug|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
20606|NCT00845728|Drug|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
20607|NCT00010010|Drug|goserelin acetate|
20608|NCT00845754|Drug|ketorolac|15mg IV every6 hours for 4doses
20609|NCT00845754|Drug|saline|15mg IV every 6hrs for 4 doses
20610|NCT00845767|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a "nitric oxide clamp". Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min).
20611|NCT00845780|Drug|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
20612|NCT00845793|Behavioral|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
20613|NCT00845806|Other|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
20614|NCT00845819|Drug|rhEGF + povidone iodine, chlorhexidine, & nystatin|Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) & nystatin (5,000IU/mL) three times a day.
Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.
For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva.
20615|NCT00847912|Drug|Placebo, vehicle control|Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate "cool-down" treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the "cool-down" routine will be followed, but vehicle control cream will be stopped.
20616|NCT00847925|Drug|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
20617|NCT00847938|Drug|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
20618|NCT00847938|Drug|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
20619|NCT00847938|Drug|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
20383|NCT00813150|Drug|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
20384|NCT00813150|Drug|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
20385|NCT00813150|Drug|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
20386|NCT00813163|Drug|PEP02|120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
20387|NCT00813176|Device|Double Lumen Endotracheal Tube|
20388|NCT00813176|Device|Arndt Bronchial Blocker|
20689|NCT00843349|Drug|LC Placebo|Placebo for Lanthanum Carbonate
20690|NCT00009880|Drug|fluorouracil|
20691|NCT00843349|Other|Ad Libitum Diet|Patients continued to eat their usual diet.
20692|NCT00843362|Drug|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
20693|NCT00843362|Drug|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
20694|NCT00843388|Drug|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
20695|NCT00845819|Drug|Placebo + povidone iodine, chlorhexidine, & nystatin|Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.
Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.
For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva.
20696|NCT00845832|Drug|Placebo|iv on days 1 and 15 (Parts 1 and 2)
20697|NCT00845832|Drug|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
20698|NCT00010023|Drug|capecitabine|
20699|NCT00845832|Drug|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
20700|NCT00845845|Drug|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
20701|NCT00845845|Drug|Placebo|Daily placebo with dietary counseling for 24 weeks.
20702|NCT00845858|Drug|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
21712|NCT00849862|Drug|Levetiracetam|750 mg Tablet
21713|NCT00849862|Drug|Keppra®|750 mg Tablet
21714|NCT00849875|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
21715|NCT00849875|Drug|Dacarbazine|Intravenous administration Chemotherapy
21716|NCT00849888|Biological|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects >4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg & serum free (SF) in other. After first 2 subjects >10% naïve T cells, 3rd receives only SF thymus. After 3rd subject >10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant & thymus biopsy. Followed by immune evaluations.
21717|NCT00849888|Other|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg & serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, >10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject >10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy & skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
22001|NCT00835068|Other|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
22002|NCT00835081|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
22003|NCT00835081|Drug|DURICEF® capsules 500 mg|1 x 500 mg
22004|NCT00000774|Biological|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
22005|NCT00008398|Procedure|quality-of-life assessment|
22006|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
22007|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
22008|NCT00835107|Drug|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
22009|NCT00835107|Drug|placebo|placebo comparator, oral capsules, BID, for one month
22010|NCT00835120|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
22011|NCT00835133|Other|biologic sample preservation procedure|one blood sample or saliva sample collection
22708|NCT00841919|Drug|Glargine insulin|The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the "Inpatient Diabetes Advisory Group" and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.
22709|NCT00833560|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
22710|NCT00833586|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
22711|NCT00833586|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
22712|NCT00833599|Drug|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
22713|NCT00833612|Device|Counterpulsation with IAB|IABC pre-reperfusion PCI
22714|NCT00833625|Procedure|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
22715|NCT00833625|Other|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
22716|NCT00008307|Drug|fludarabine phosphate|
22717|NCT00833638|Drug|Placebo|One tablet orally daily
22718|NCT00833638|Drug|Tadalafil|Orally once daily
22719|NCT00833664|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
22720|NCT00833664|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
22721|NCT00833677|Behavioral|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
21778|NCT00847678|Biological|Amphotericin B|
21779|NCT00847678|Biological|5 flucytosine|
21780|NCT00847704|Device|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
21781|NCT00847704|Device|Assisted movement and enhanced sensation|Thirty treatment sessions on the AMES device, each session 30 minutes of cyclic rotation of the ankle with tendon vibration. Testing before, during, and after treatments to evaluate response to treatments.
21782|NCT00847717|Procedure|Selective neck dissection|Level IIb preserving neck dissection
20918|NCT00851084|Drug|aflibercept|administration: IV infusion
20919|NCT00851084|Drug|oxaliplatin|administration: IV infusion
20920|NCT00851084|Drug|5-FU|administration: IV infusion
20921|NCT00851084|Drug|Folinic Acid|administration: IV infusion
20922|NCT00851110|Procedure|stem cell reinfusion|hematopoietic stem cell reinfusion
20923|NCT00851110|Drug|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
20924|NCT00851123|Behavioral|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
20925|NCT00851123|Behavioral|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
20926|NCT00010504|Procedure|Acupuncture|
20927|NCT00851136|Drug|bevacizumab|Intravenous repeating dose
20928|NCT00851136|Drug|FOLFOX|Intravenous repeating dose
20929|NCT00851136|Drug|PRO95780|Intravenous repeating dose
20930|NCT00851149|Device|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
20931|NCT00851162|Biological|Trinity multipotent stem cells|Enough to fill voids which vary in size
20932|NCT00851162|Biological|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
20933|NCT00851175|Drug|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
20934|NCT00851175|Drug|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
20935|NCT00851188|Behavioral|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
20936|NCT00843765|Other|rehabilitation and WM basic treatment|there two steps:
during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education
After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet
20703|NCT00845858|Drug|Placebo|30 minutes before meals and at bedtime
20704|NCT00845871|Drug|deferasirox:|deferasirox 20mg/kg/day unless on a higher dose at time of study entry. Crushed or dissolved tablets taken once daily with either breakfast,dinner or no meal for 4 months.
20705|NCT00845884|Drug|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.
Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.
Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.
Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days.
20706|NCT00845897|Drug|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
20707|NCT00845897|Drug|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
20708|NCT00845910|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
20709|NCT00010023|Drug|cisplatin|
20994|NCT00848718|Drug|MK-2206 combined with carboplatin + paclitaxel|MK-2206 given by mouth on days 1, 3, 5, and 7 of the 21 day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 given by mouth on Day 1 of the 21 day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg). On Day 1 of each 21 Day cycle, carboplatin + paclitaxel is given intravenously.
20995|NCT00848718|Drug|MK-2206 combined with docetaxel|MK-2206 given by mouth on days 1, 3, 5, and 7 of the 21 day cycle (either 45 mg or 60 mg) (this dosing schedule is no longer enrolling). MK-2206 given by mouth on Day 1 of the 21 day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg). On day 1 of each 21 day cycle, docetaxel is given intravenously. In this treatment arm, an oral corticosteroid is to be taken by mouth every day.
20996|NCT00848718|Drug|MK-2206 combined with erlotinib|MK-2206 given by mouth every other day (30 mg, 45 mg or 60 mg) OR MK-2206 given by mouth on Days 1, 8, and 15 of the 21 day cycle (90 mg, 135 mg, or 200 mg). In addition, erlotinib is given daily by mouth in a continuous 21 day cycle for the duration of the study.
20997|NCT00848731|Drug|nitric oxide|nitric oxide gas is delivered by facemask
20998|NCT00851513|Other|physiological serum|important volumes of physiological serum
20999|NCT00851539|Behavioral|Video|Behavioral Intervention Video
21000|NCT00851552|Biological|rituximab|Given IV
21001|NCT00851552|Drug|bortezomib|Given IV
21002|NCT00851552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
21003|NCT00851552|Genetic|gene expression analysis|Correlative Study
21004|NCT00851552|Genetic|polymerase chain reaction|Correlative Study
21005|NCT00851552|Genetic|polymorphism analysis|Correlative Study
22012|NCT00835133|Other|medical chart review|confirmation of cancer diagnosis
22013|NCT00835133|Other|survey administration|at baseline enrollment and 12 months post-enrollment
22014|NCT00835146|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
22015|NCT00835146|Drug|COPEGUS™|1 x 200 mg, single-dose fasting
22016|NCT00008398|Radiation|radiation therapy|
22017|NCT00835159|Drug|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
22018|NCT00835159|Other|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
22019|NCT00835172|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
22020|NCT00835172|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
22021|NCT00835185|Biological|IMC-11F8 (necitumumab)|IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
22022|NCT00835185|Drug|Oxaliplatin|Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
22023|NCT00835185|Drug|Folinic acid (FA)|FA 400 mg/m² IV infusion bolus injection
22296|NCT00835614|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
22297|NCT00835614|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
22298|NCT00835627|Drug|sertraline|flexible dose sertraline
22299|NCT00835627|Behavioral|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
22300|NCT00835627|Other|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
22301|NCT00835627|Other|Standard Care|community care, treatment as usual: routine follow up with existing providers
22302|NCT00835640|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
22303|NCT00835640|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
22304|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
21783|NCT00847717|Procedure|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
21784|NCT00847730|Device|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an enviroment that promotes wound healing in chronic and acute wounds
21785|NCT00847743|Dietary Supplement|Tart Cherry Juice|8 fl.oz. twice per day
21786|NCT00847756|Other|questionnaire|Identification of risk factors
21787|NCT00847756|Procedure|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
21788|NCT00010179|Drug|lurtotecan liposome|
21789|NCT00847756|Procedure|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
21790|NCT00849901|Drug|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
21791|NCT00849940|Device|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
21792|NCT00010387|Drug|cyclophosphamide|
21793|NCT00849966|Drug|Celebrex suspension|Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.
All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
21794|NCT00849966|Drug|Placebo|Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.
All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
21795|NCT00849979|Behavioral|Questionnaire|Day 1 MDASI-GI Questionnaire
21796|NCT00849979|Other|Interview|Open-ended, audiotaped interviews
21797|NCT00849992|Drug|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
22089|NCT00832507|Drug|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
22090|NCT00008268|Drug|melphalan|
22091|NCT00832507|Drug|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
20937|NCT00843778|Biological|Certolizumab Pegol|200 mg every two weeks
Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 [NCT00674362], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks.
21227|NCT00846872|Drug|GHRP-3|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
21228|NCT00010088|Drug|gemcitabine hydrochloride|
21229|NCT00846872|Drug|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
21230|NCT00846885|Drug|Sumatriptan Succinate|100 mg Tablet
21231|NCT00846885|Drug|Imitrex®|100 mg Tablet
21232|NCT00846898|Dietary Supplement|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
21233|NCT00846911|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
21234|NCT00846924|Device|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
21235|NCT00846924|Device|24-hour Holter|Repeat standard 24-hour Holter Monitor
21236|NCT00846937|Dietary Supplement|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
21237|NCT00846950|Drug|dexchlorpheniramine, lorazepam|
21238|NCT00846963|Drug|Ursodiol|Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (>33mmol/L) to the resolution of cholestasis (conjugated bilirubin <34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.
If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given.
21239|NCT00010088|Drug|leucovorin calcium|
21240|NCT00846963|Drug|placebo|Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
21241|NCT00846976|Drug|Bicalutamide|200mg daily
21242|NCT00846989|Drug|RKI983A|RKI983 0.05 % twice daily
21243|NCT00846989|Drug|RKI983A|RKI983 0.1 % twice daily
21006|NCT00851552|Genetic|proteomic profiling|Correlative Study
21007|NCT00010621|Procedure|chiropractic therapy|
21008|NCT00851552|Other|flow cytometry|Correlative Study
21009|NCT00851552|Other|laboratory biomarker analysis|Correlative Study
21010|NCT00851565|Procedure|Measurement of serum infliximab and anti-infliximab antibodies|In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:
Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.
Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.
High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.
High s-infliximab in the presence of anti-infliximab Ab: Same as number 3.
21011|NCT00851565|Procedure|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
21012|NCT00851578|Device|WATCHMAN|WATCHMAN LAA Closure Device
21013|NCT00851591|Drug|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
21314|NCT00844506|Drug|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
21315|NCT00844519|Drug|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
21316|NCT00844519|Drug|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
21317|NCT00844532|Device|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
21318|NCT00847002|Device|Standard Wound Care|Standard wound care treatment will include gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
21319|NCT00847002|Device|Flexitouch System with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis. They will be instructed to remove the FarrowWrap during the time they are using Flexitouch. The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
22305|NCT00008450|Radiation|total-body irradiation|Undergo TBI
22306|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
22307|NCT00835666|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
22308|NCT00835666|Drug|PROSCAR®|1 x 5 mg, single dose fasting
22309|NCT00835679|Biological|cetuximab|Given IV
22310|NCT00835679|Drug|dasatinib|Given orally
22311|NCT00835679|Procedure|therapeutic conventional surgery|Undergo surgery
22312|NCT00835679|Other|laboratory biomarker analysis|Correlative studies
22313|NCT00835692|Drug|Clarithromycin|500 mg Tablet
22314|NCT00835692|Drug|Biaxin®|500 mg Tablet
22315|NCT00835705|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
22316|NCT00008450|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
22317|NCT00838396|Drug|Placebo for XP19986 CR|On study Day 1, patients received a single dose of XP19986 10, 20, 40 or 60 mg or placebo. On study Day 5, after completion of the minimum 3-day washout period, patients crossed over to the other treatment and received a single dose of XP19986 CR or matching Placebo. XP19986 CR was administered as a single dose of 10, 20, 40, or 60 mg.
22318|NCT00838435|Drug|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
22645|NCT00836173|Drug|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
22646|NCT00836173|Drug|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
22647|NCT00836186|Radiation|radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600cGy. Treatments will be given Monday through Friday.
22648|NCT00836199|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
22649|NCT00836199|Biological|Placebo vaccine|Placebo vaccine given 6 times over 6 months
22092|NCT00832520|Drug|Remeron (mirtazapine)|Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance < 50% or a bilirubin or transaminases > twice the upper limit of normal will take a 7.5 mg dose.
Drug Administration: Drug will be administered orally, every day for a period of 8 weeks
Dose modifications: None
22093|NCT00832546|Drug|Placebo|
22094|NCT00832546|Drug|Oral NGX426 (Powder in solution)|
22095|NCT00832559|Biological|Coxsackievirus A21|1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
22096|NCT00832572|Drug|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
22097|NCT00832572|Drug|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
22098|NCT00832585|Drug|Alefacept|Alefacept 15mg IM every week for 12 weeks
22099|NCT00835198|Drug|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
22100|NCT00835198|Drug|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
22101|NCT00008411|Drug|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
22102|NCT00835211|Drug|Desmopressin Acetate 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
22103|NCT00835211|Drug|DDAVP® 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
22104|NCT00835224|Drug|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
22105|NCT00835224|Drug|Midodrine|To treat low blood pressure.
22106|NCT00835224|Drug|Placebo|A pill with an inactive substance that looks like the study drug.
22107|NCT00835237|Biological|Boostrix®|Intramuscular, single dose.
22108|NCT00835237|Biological|Decavac™|Intramuscular, single dose.
22109|NCT00835250|Procedure|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
22110|NCT00835250|Procedure|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
22378|NCT00833079|Drug|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
21244|NCT00846989|Drug|Latanoprost|Latanoprost 0.005 % once a day
21245|NCT00849004|Other|silicone gel|silicone gel
21246|NCT00010322|Drug|atamestane|
21247|NCT00849004|Other|silicone sheet|silicone sheet
21248|NCT00849004|Other|paper tape|paper tape
20313|NCT00006721|Drug|doxorubicin hydrochloride|Given IV
20314|NCT00815009|Behavioral|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
20315|NCT00815009|Behavioral|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
20316|NCT00006864|Biological|aldesleukin|
20317|NCT00815009|Behavioral|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
20318|NCT00815022|Drug|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
20319|NCT00815035|Drug|Peanut|Peanut flour will be given in increasing amounts.
20320|NCT00815035|Drug|Oat Flour|The doses of oat flour will be increases every 2 weeks until a maintenance dose is achieved.
20321|NCT00815048|Drug|Atropine/Remifentanil|Atropine 20mcg/kg
Remifentanil 3mcg/kg
20322|NCT00815048|Drug|Fentanyl/Atropine/Succinylcholine|Atropine 20mcg/kg
Fentanyl 2mcg/kg
Succinylcholine 2mg/kg
20323|NCT00815087|Device|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
20324|NCT00815087|Behavioral|Exercise home program|Daily exercise training
20325|NCT00815100|Drug|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
20326|NCT00815100|Drug|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
21320|NCT00847015|Drug|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
21321|NCT00847015|Drug|Gemcitabine|Gemcitabine 1,000 mg/m^2
21322|NCT00847015|Drug|cisplatin|cisplatin 35 mg/m^2 will be administered intravenously on days 1 and 8.
21323|NCT00010088|Procedure|conventional surgery|
21324|NCT00847028|Other|glucose 10%|2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
21325|NCT00847028|Other|20% glucose|2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
21326|NCT00847028|Other|glucose 30%|2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
21327|NCT00847028|Other|sterile water|2 minutes prior to the venipuncture, sterile water was administered orally
21328|NCT00847054|Drug|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
21329|NCT00847067|Procedure|Paravertebral block|3ml 1% Ropivacaine at each level T1 - T5
21330|NCT00847067|Procedure|Sham injections|Sham injections with Normal Saline
21331|NCT00847080|Drug|Sitagliptin phosphate|Sitagliptin phosphate 100 mg per day per 2 weeks
20389|NCT00006721|Drug|prednisone|Given orally
20390|NCT00813189|Device|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
20391|NCT00813202|Drug|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
20392|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on saturated fat.
20393|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
20394|NCT00813228|Drug|Sitagliptin (Januvia)|
20395|NCT00813241|Drug|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
20396|NCT00813241|Drug|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
20397|NCT00813241|Drug|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
22650|NCT00836212|Drug|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
22651|NCT00836212|Drug|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
22652|NCT00008489|Drug|Didanosine|
22653|NCT00836225|Drug|ISIS 388626|4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg
Placebo: 0.9% sterile saline
22654|NCT00836238|Behavioral|Interview|Physical Function and Symptom Assessment Interviews
22655|NCT00836238|Other|Physical Function Tests|3 physical function tests.
22656|NCT00836251|Dietary Supplement|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
22657|NCT00836277|Drug|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
22658|NCT00836277|Drug|Irinotecan|125mg/m2 IV Day 1 and Day 8
22659|NCT00836290|Behavioral|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
22660|NCT00836290|Behavioral|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
21718|NCT00849901|Drug|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
21719|NCT00849901|Drug|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
21720|NCT00009828|Drug|paclitaxel|
21721|NCT00842595|Drug|ifosfamide|6 courses every 28 days
21722|NCT00842595|Drug|Mitoxantrone|6 courses every 28 days
21723|NCT00842595|Drug|Prednisone|6 courses every 28 days
21724|NCT00842608|Behavioral|Reduced exposure to anticholinergics|Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.
Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can & cannot receive Haldol
22379|NCT00833079|Drug|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
22380|NCT00833079|Drug|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
22381|NCT00833092|Dietary Supplement|Sugar Pill|Sugar pill supplementation for 9 weeks
22382|NCT00833092|Dietary Supplement|magnesium|300 milligrams daily for 8 weeks
22383|NCT00833105|Device|AMES treatment|The AMES device rotates the fingers-thumb and the wrist over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the hand. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
22384|NCT00008294|Drug|floxuridine|
22385|NCT00835705|Drug|Augmentin®|400 mg-57 mg chewable tablet
22386|NCT00835718|Drug|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
22387|NCT00835718|Drug|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
22388|NCT00835718|Drug|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
22389|NCT00835718|Drug|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
22390|NCT00835731|Drug|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D&E
22391|NCT00835731|Device|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D&E
22392|NCT00835744|Drug|clomiphene citrate|ovulation induction
22393|NCT00835744|Drug|gonadotropins|ovulation induction
22394|NCT00835770|Drug|dimethyl fumarate|BG00012 capsules
22395|NCT00000199|Drug|Piracetam|
22396|NCT00000774|Biological|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
22397|NCT00008450|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
22398|NCT00835770|Drug|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
20327|NCT00000758|Drug|Fluorouracil|
20328|NCT00006877|Drug|temozolomide|
20329|NCT00815126|Procedure|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
20330|NCT00815152|Behavioral|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
20331|NCT00815152|Behavioral|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
20620|NCT00847951|Procedure|3D Ultrasound Imaging|3D renal ultrasound to check kidney perfusion in pre-mature and/or very low birth weight babies.
20621|NCT00847964|Device|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
20622|NCT00847977|Drug|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
20623|NCT00010192|Other|pharmacological study|Correlative studies
20624|NCT00847977|Drug|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
20625|NCT00847990|Other|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
20626|NCT00848003|Drug|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
20627|NCT00848003|Drug|Placebo|Strawberry flavored yogurt
20628|NCT00848016|Drug|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
20629|NCT00848029|Biological|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
20630|NCT00848042|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
20631|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
20632|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
20633|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
20634|NCT00010205|Drug|benzoylphenylurea|Given orally
20398|NCT00813241|Drug|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
20399|NCT00813254|Behavioral|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
20400|NCT00000755|Drug|Zidovudine|
20401|NCT00006721|Drug|vincristine sulfate|Given IV
20402|NCT00813267|Biological|mesenchymal stem cell infusion|
20403|NCT00813267|Biological|bone marrow mononuclear cell infusion|
20404|NCT00815191|Device|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
20405|NCT00815204|Procedure|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
20406|NCT00815204|Procedure|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
20407|NCT00815217|Procedure|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
20408|NCT00006890|Drug|prednisone|Prednisone 50mg on alternate days
20710|NCT00845910|Drug|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
20711|NCT00845910|Drug|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
20712|NCT00845923|Drug|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
20713|NCT00845936|Drug|Metformin|Metformin 850 mg bid
20714|NCT00845962|Drug|chloroprocaine|spinal administration of chloroprocaine 2%, 40 mg (2 mL)
20715|NCT00845962|Drug|bupivacaine|spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
20716|NCT00845975|Device|Erchonia Hearing Lasers #1 & #2|Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.
Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site.
21725|NCT00842608|Procedure|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
21726|NCT00842608|Drug|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
21727|NCT00842608|Procedure|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
21728|NCT00842621|Procedure|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
21729|NCT00842621|Other|Laboratory Studies|Blood for:
Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,
Serum for:
Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha
Plasma for:
Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1
Urine for:
Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin
21730|NCT00842634|Biological|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
21731|NCT00009828|Drug|tegafur-uracil|
21732|NCT00842634|Other|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
21733|NCT00842660|Drug|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
21734|NCT00842673|Drug|ST101|30 mg; administered once/day
21735|NCT00842673|Drug|ST101|90 mg; administered once/day
21736|NCT00842673|Drug|ST101|180 mg; administered once/day
22024|NCT00835185|Drug|5-FU|5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
22025|NCT00838019|Procedure|Intrabone administration of umbilical cord blood|Single administration
22026|NCT00838032|Drug|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
22027|NCT00838032|Drug|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
22399|NCT00835796|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
22722|NCT00833690|Drug|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
22723|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
22724|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
22725|NCT00833703|Drug|Clopidogrel|Form: reconstituted solution using Clopidogrel powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight
22726|NCT00833703|Drug|placebo|Form: reconstituted solution using matching placebo powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight
22727|NCT00008307|Drug|melphalan|
22728|NCT00833716|Drug|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
22729|NCT00833729|Drug|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
22730|NCT00833742|Behavioral|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
22731|NCT00833755|Drug|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
22732|NCT00833768|Drug|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
22733|NCT00008515|Drug|Fluocinolone|
22734|NCT00836329|Behavioral|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
22735|NCT00836329|Behavioral|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
22736|NCT00836355|Drug|Enoxaparin|2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
22737|NCT00836355|Drug|Minocycline|200 mg orally once daily for 5 days
20635|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
20636|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
20637|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
20638|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
20639|NCT00850473|Radiation|Computed Tomography|image scan
20640|NCT00850473|Drug|CT Contrast Dye|used for obtaining images. weight based dose
20641|NCT00010426|Drug|cysteamine hydrochloride|
20938|NCT00843791|Drug|placebo|treatment with placebo for 3 months
20939|NCT00843791|Drug|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
20940|NCT00843817|Drug|Pulmozyme|Pulmozyme® 2.5mg by inhalation
20941|NCT00843830|Radiation|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
20942|NCT00843830|Biological|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
20943|NCT00843843|Device|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
20944|NCT00843856|Drug|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
20945|NCT00843856|Drug|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
20946|NCT00009893|Drug|leucovorin calcium|
20947|NCT00843882|Biological|Epoetin Alfa|Given SC
20948|NCT00843882|Other|Laboratory Biomarker Analysis|Correlative studies
20949|NCT00843882|Drug|Lenalidomide|Given PO
20950|NCT00843895|Biological|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
20951|NCT00843908|Device|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
20717|NCT00845975|Device|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
20718|NCT00848055|Drug|AbGn168 subcutaneous injection|single dose subcutaneous injection
20719|NCT00848068|Other|FID 114657|artificial tears
20720|NCT00848068|Other|OPTIVE Lubricant Eye Drops|artificial tears
20721|NCT00848081|Drug|Tadalafil|5 mg taken by mouth once daily for 12 weeks
20722|NCT00848081|Drug|Placebo|By mouth once daily for 12 weeks
20723|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
20724|NCT00010205|Other|pharmacological study|Correlative studies
20725|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
20726|NCT00848107|Drug|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
20727|NCT00848120|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
20728|NCT00848133|Procedure|mini-midvastus surgical approach for total knee arthroplasty|
20729|NCT00848133|Procedure|mini-subvastus surgical approach for total knee arthroplasty|
21014|NCT00851591|Drug|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
21015|NCT00851617|Device|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
21016|NCT00851630|Drug|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
21017|NCT00851643|Biological|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
21018|NCT00010621|Procedure|bodywork therapy|
21019|NCT00851643|Biological|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
22028|NCT00838045|Device|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch & Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
22029|NCT00838058|Drug|CE-224,535|one 250mg tablet, once in the morning in fasted state
22030|NCT00838058|Drug|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
22031|NCT00838058|Drug|CE-224,535|4x250mg tablets, once in the morning, in fasted state
22032|NCT00009061|Drug|Ritonavir|
22033|NCT00838058|Drug|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
22034|NCT00838058|Drug|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
22035|NCT00838058|Drug|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
22036|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
22037|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
22038|NCT00838071|Drug|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
22039|NCT00838084|Drug|LY2811376|Oral capsules
22040|NCT00838084|Drug|Placebo|Oral capsules
22041|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
22042|NCT00838110|Drug|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
22043|NCT00009061|Drug|Abacavir sulfate|
22044|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
22045|NCT00838110|Drug|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
22319|NCT00838448|Behavioral|Exercise|Exercise performed on a treadmill for 20-30 minutes
22320|NCT00838461|Drug|HSD-016|
22321|NCT00838461|Drug|placebo|
22322|NCT00838474|Other|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
22738|NCT00836368|Dietary Supplement|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
22739|NCT00836381|Drug|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
22740|NCT00836381|Drug|Placebo|Identical Placebo once daily
21798|NCT00849992|Procedure|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
21799|NCT00850005|Biological|Intravenous immunoglobulin|2 g/kg divided over five days
21800|NCT00850005|Biological|Normal Saline|Same volume as experimental arm
21801|NCT00850018|Procedure|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
21802|NCT00850018|Behavioral|Usual care|Participants will receive usual care for the treatment of SCD.
21803|NCT00010387|Drug|filgrastim|
21804|NCT00850031|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
21805|NCT00850044|Drug|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
21806|NCT00850044|Drug|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
21807|NCT00850044|Drug|placebo for ABT-450|capsules, QD, one dose
21808|NCT00850044|Drug|Placebo for ritonavir|capsules, QD, one dose
21809|NCT00850057|Biological|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
21810|NCT00850070|Drug|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
21811|NCT00850070|Drug|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
21812|NCT00850096|Other|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
21813|NCT00009841|Biological|EGFR antisense DNA|
21814|NCT00842712|Drug|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m^2 as intravenous infusion on Day 1.
20952|NCT00843908|Device|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
20953|NCT00843921|Drug|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
20954|NCT00843934|Drug|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
20955|NCT00843934|Drug|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
20956|NCT00843947|Procedure|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
20957|NCT00000113|Device|Progressive Addition Lenses|
21249|NCT00849017|Biological|albiglutide|albiglutide weekly injection
21250|NCT00849017|Biological|albiglutide uptitration|albiglutide uptitration at week 12
21251|NCT00849017|Biological|placebo|matching albiglutide placebo weekly injection
21252|NCT00849030|Drug|Anastozole (Arimidex)|1mg, orally, once daily
21253|NCT00849030|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
21254|NCT00849030|Drug|Anastozole (Arimidex) placebo|1mg, orally, once daily
21255|NCT00849030|Drug|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
21256|NCT00849056|Biological|albiglutide|albiglutide weekly subcutaneous injection
21257|NCT00010322|Drug|toremifene|
21258|NCT00849056|Drug|placebo|placebo weekly subcutaneous injection
21259|NCT00849069|Biological|GSK2231395A|3 doses intramuscular injections
21260|NCT00849069|Biological|TwinrixTM|3 doses intramuscular injections
21261|NCT00849082|Drug|cyproterone acetate|
21262|NCT00849082|Drug|goserelin acetate|
21263|NCT00849082|Radiation|radiation therapy|
21020|NCT00851643|Biological|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
21021|NCT00851643|Biological|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
21022|NCT00000200|Drug|Methadone|normal maintenance dose
21023|NCT00000778|Drug|Levofloxacin|
21024|NCT00009906|Drug|Imatinib Mesylate|Given orally
21025|NCT00843960|Behavioral|behavioral adaptation and symptom management|behavioral adaptation and symptom management
21026|NCT00843973|Other|cell viability and osteogenic potential analysis|Samples from both the ICBG and the RIA groups will be analyzed with flow cytometry, cell culture, transmission electron microscopy, and functional assay for viability and osteogenic differentiation
21027|NCT00843986|Drug|conivaptan|Premix bag
21028|NCT00843986|Drug|placebo|Premix bag
21029|NCT00844012|Drug|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
21030|NCT00844012|Drug|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
21031|NCT00844025|Behavioral|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
21032|NCT00844051|Biological|School-based influenza vaccination program|School-based influenza vaccination program
21033|NCT00844064|Drug|AP 12009|Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.
Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles
21332|NCT00847080|Drug|Placebo|Placebo 1 tablet per day per 2 weeks
21333|NCT00847093|Drug|LMX4|One inch every six hours
21334|NCT00010088|Radiation|radiation therapy|
21335|NCT00847093|Drug|LMX4 Placebo|One inch every six hours
21336|NCT00847106|Drug|Daclizumab|
21337|NCT00847106|Biological|Dendritic cells|
22323|NCT00838487|Other|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
22324|NCT00009178|Behavioral|Guided Self-Help|
22325|NCT00838487|Other|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
22326|NCT00838500|Drug|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
22327|NCT00838500|Drug|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
22328|NCT00838513|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
22329|NCT00838526|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
22330|NCT00838526|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
22331|NCT00838539|Drug|Neratinib|neratinib 40mg tablets will be taken orally in doses of either 120mg, 160mg, 200mg OR 240mg daily dose, for as long tolerated and the disease under study does not worsen.
22332|NCT00838539|Drug|Temsirolimus|Temsirolimus will be administered intravenously once a week, at either 15mg, 25mg, 50, or 75mg, for as long as tolerated and the disease under study does not worsen.
22333|NCT00838565|Drug|Placebo|intravenous infusion on three consecutive months
22334|NCT00838565|Drug|dose level 1|intravenous infusion on three consecutive months
22335|NCT00009191|Drug|Sertraline [Zoloft]|
22336|NCT00838565|Drug|dose level 2|intravenous infusion on three consecutive months
22337|NCT00838565|Drug|dose level 3|intravenous infusion on three consecutive months
22338|NCT00838565|Drug|dose level 4|intravenous infusion on 3 consecutive months
22339|NCT00838578|Biological|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
21815|NCT00842712|Drug|Cisplatin|Cis will be administered at a dose of 80 mg/m^2 as intravenous infusion on Day 1.
21816|NCT00842712|Drug|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m^2 as intravenous infusion on Days 1 and 8.
21817|NCT00842712|Drug|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m^2 as intravenous infusion on Days 1 and 8.
21818|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
22111|NCT00835263|Drug|Lamotrigine|200 mg Tablet
22112|NCT00008411|Drug|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
22113|NCT00835263|Drug|Lamictal®|200 mg Tablet
22114|NCT00835276|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
22115|NCT00835276|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
22116|NCT00835289|Dietary Supplement|n-3 polyunsaturated fatty acids|Omax3[TM] (Cenestra Health [TM]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
22117|NCT00835289|Other|Placebo|3 capsules of matching corn oil placebo
22118|NCT00835302|Procedure|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
22119|NCT00835328|Drug|exendin-(9-39)|exendin-(9-39) 1000-30000pmol/kg/min (0.2-6mg/kg/hr) Intravenous infusion over 9 hours
22120|NCT00835328|Other|placebo|normal saline Intravenous infusion over 9 hours
22121|NCT00835354|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
22122|NCT00835354|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
22123|NCT00008424|Drug|irinotecan hydrochloride|
22124|NCT00835367|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
22125|NCT00838149|Dietary Supplement|Whey protein|Whey protein group:
Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
21264|NCT00849095|Drug|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
21265|NCT00849095|Drug|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
21266|NCT00849095|Drug|placebo|bid inhaled placebo
21267|NCT00849095|Drug|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
21268|NCT00010335|Procedure|Stem Cell Transplantation|Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
21269|NCT00849108|Drug|BMS747158|dosages at rest and at stress were not to exceed a total of 14 mCi.
Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.
Cohort 2: Patients to recieve IV bolus injections of BMS747158:
For the Pharmacologic (Adenosine) Stress:
Doses at rest were to range between 2.9 and 3.4 mCi.
Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.
For the Exercise Stress:
Doses at rest were to range between 1.7 and 2.0 mCi.
Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.
21270|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
20332|NCT00815178|Behavioral|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
20333|NCT00815178|Behavioral|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
20334|NCT00815191|Device|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
20335|NCT00817206|Drug|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
20336|NCT00817206|Drug|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
20337|NCT00817219|Drug|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
20338|NCT00007033|Drug|magnesium sulfate|
20339|NCT00817232|Device|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
21338|NCT00847119|Biological|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
21339|NCT00847119|Drug|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
21340|NCT00847119|Radiation|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
21341|NCT00847132|Behavioral|Collaborative care vs. usual care|depression education, treatment recommendations, coordination of care
21342|NCT00847145|Biological|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
21343|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
21344|NCT00849134|Drug|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
21345|NCT00849147|Biological|Haploidentical Bone Marrow Transplantation|The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.
Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2
Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5
Total body irradiation (TBI): 200 centigray (cGy) on Day -1
Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor.
21346|NCT00849147|Biological|GVHD prophylaxis|The GVHD prophylaxis regimen will consist of the following:
Cy: 50 mg/kg IV on Days 3 and 4
Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL
Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID
Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm^3 for 3 consecutive days
21347|NCT00849160|Drug|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
21348|NCT00849186|Drug|sunitinib malate|oral
21349|NCT00849186|Procedure|neoadjuvant therapy|IV
21350|NCT00849186|Procedure|therapeutic conventional surgery|Surgery
21351|NCT00010335|Device|CD34 selection|CD34+ cells are separated from the rest of the peripheral blood stem cells.
20409|NCT00815217|Other|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
20410|NCT00815243|Procedure|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
20411|NCT00815243|Procedure|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
22661|NCT00836303|Behavioral|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
22662|NCT00836316|Drug|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
22663|NCT00839072|Drug|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
22664|NCT00839072|Drug|Trazodone HCl|300 mg extended-release caplet, single dose
22665|NCT00839085|Drug|GSE|grape seed extract (100 mg/6h), PO
22666|NCT00839085|Drug|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
22667|NCT00839098|Other|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
22668|NCT00839098|Other|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction & Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
22669|NCT00000776|Drug|Fluconazole|
22670|NCT00009555|Drug|Testosterone|
22671|NCT00839111|Drug|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
22672|NCT00839111|Drug|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
22673|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
22674|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
22675|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
22676|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
22126|NCT00838162|Drug|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
22127|NCT00838162|Drug|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
22128|NCT00838162|Drug|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
22129|NCT00838162|Drug|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
22130|NCT00009061|Drug|Nelfinavir mesylate|
22131|NCT00838162|Drug|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
22132|NCT00838162|Drug|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
22400|NCT00835796|Drug|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
22401|NCT00835822|Drug|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
22402|NCT00835822|Drug|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
22403|NCT00835835|Other|Body-weight supported treadmill training +/- Lokomat assistance|walking
22404|NCT00835835|Other|Usual Care - no active intervention|No treatment used for comparison
22405|NCT00835848|Drug|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
22406|NCT00835848|Drug|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
22407|NCT00838591|Drug|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
22408|NCT00838591|Drug|Placebo|
22409|NCT00838630|Drug|Cilostazol 100 mg tablets|1 x 100 mg
22410|NCT00838630|Drug|Pletal® 100 mg tablets|1 x 100 mg
22411|NCT00838656|Drug|carboplatin|Given IV in one of two schedules
22412|NCT00009204|Drug|Citalopram [Celexa]|
20340|NCT00817245|Drug|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
20341|NCT00817258|Drug|cisplatin|Cisplatin 40mg/m2,weekly
20342|NCT00817258|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
20343|NCT00817271|Drug|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
20344|NCT00817271|Drug|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
20345|NCT00817284|Drug|bevacizumab and Irinotecan and radiotherapy|Bevacizumab 10 mg/kg is administered on days 1 and 15.
Irinotecan:
Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).
Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.
During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.
Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.
20346|NCT00817284|Drug|Bevacizumab and Temozolomide and radiotherapy|Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.
Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.
After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.
Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.
20642|NCT00850486|Device|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
20643|NCT00850499|Drug|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
20644|NCT00850499|Drug|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
20645|NCT00850499|Drug|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
20646|NCT00850512|Drug|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
20647|NCT00850512|Drug|Zevalin|12-week safety period for Zevalin
20648|NCT00850538|Radiation|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
20649|NCT00850538|Procedure|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
20650|NCT00850551|Other|Early Intervention|Twice a week home spirometry and symptom assessment
20412|NCT00815256|Procedure|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
20413|NCT00815269|Drug|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
20414|NCT00815269|Drug|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
20415|NCT00815269|Drug|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
20416|NCT00815269|Drug|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
20417|NCT00815269|Drug|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
20418|NCT00815282|Drug|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
20419|NCT00006890|Drug|thalidomide|THALIDOMIDE 200 mg qhs
20420|NCT00815295|Drug|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
20421|NCT00817375|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
20422|NCT00817388|Other|No intervention|No intervention
20423|NCT00817401|Device|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
20424|NCT00817414|Drug|Placebo|
20425|NCT00817414|Drug|LCI699|
20730|NCT00848146|Procedure|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
22677|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
21737|NCT00842673|Drug|Placebo|placebo to match ST101 tablets
21738|NCT00842686|Drug|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
21739|NCT00842712|Drug|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
21740|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
21741|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) as intravenous infusion over 2 hours on Day 1.
21742|NCT00845221|Drug|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
21743|NCT00845234|Behavioral|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
21744|NCT00845247|Other|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
21745|NCT00845260|Behavioral|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
21746|NCT00009997|Drug|doxorubicin hydrochloride|
21747|NCT00845260|Behavioral|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
21748|NCT00845273|Drug|Pegaptanib sodium|Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.
Frequency and duration are according to Package Insert as follows. "Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )".
21749|NCT00845286|Behavioral|Munich Marathon|42,195 km marathon run
21750|NCT00845299|Drug|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
21751|NCT00845299|Drug|artificial tears preserved with Benzalkonium Chloride|
21752|NCT00845325|Behavioral|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
21753|NCT00845325|Behavioral|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
22413|NCT00838656|Drug|gemcitabine hydrochloride|Given IV in one of two schedules
22414|NCT00838656|Drug|paclitaxel|Given IV in one of two schedules
22415|NCT00838669|Drug|Extended release OROS paliperidone|
22416|NCT00838682|Drug|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
22417|NCT00838682|Drug|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
22418|NCT00838695|Drug|phenylephrine and nitroglycerin|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
22419|NCT00838708|Drug|SRD174 Cream|topical SRD174 Cream
22420|NCT00838708|Other|vehicle cream|topical vehicle cream
22421|NCT00838721|Other|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
22741|NCT00836394|Device|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
22742|NCT00836407|Drug|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
22743|NCT00836407|Biological|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
22744|NCT00008528|Drug|Enfuvirtide|
22745|NCT00836420|Procedure|no intervention|the value of the clinical use of microdialysis monitoring of the brain
22746|NCT00836433|Behavioral|CONNECT educational intervention|The CONNECT educational intervention is a training program for staff to improve communication with a more dense network of co-workers, in order to improve resident problem-solving. Includes in class sessions, group and individual mapping exercises, self-monitoring of interactions, and individual staff coaching.
22747|NCT00836433|Behavioral|FALLS educational intervention|FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions
22748|NCT00836446|Other|physical activity|physical activity routines 5 times a weeks for 12 weeks.
22749|NCT00836459|Behavioral|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
22750|NCT00836459|Behavioral|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
20651|NCT00850564|Drug|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
20652|NCT00010439|Drug|Alendronate|Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
20653|NCT00850577|Drug|Paclitaxel|Solution, IV, 200 mg/m2, Q21days, 6 cycles
20654|NCT00850577|Drug|Carboplatin|Solution, IV, AUC=6, Q21days, 6 cycles
20655|NCT00850577|Drug|CT-322|Solution, IV, 2 mg/kg, Q7days, Until PD
20656|NCT00850577|Drug|Bevacizumab|Solution, IV, 15 mg/kg, Q21days, Until PD
20657|NCT00850577|Drug|Bevacizumab placebo (ie saline solution)|Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
20658|NCT00850590|Drug|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
20659|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
20660|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
20661|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
20662|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
20663|NCT00010452|Drug|picibanil|Up to .2 mg per injection, given intralesionally every 6-8 weeks
20664|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
20958|NCT00846352|Procedure|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
20959|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
20960|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
20961|NCT00010062|Drug|fluorouracil|
20731|NCT00848172|Drug|Octanoic Acid|4mg/kg
20732|NCT00848172|Drug|Placebo|identical capsules
20733|NCT00848211|Other|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
20734|NCT00848211|Biological|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
20735|NCT00010218|Drug|karenitecin|
20736|NCT00848211|Biological|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
20737|NCT00848211|Biological|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
20738|NCT00848224|Behavioral|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
20739|NCT00850616|Biological|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
20740|NCT00850629|Behavioral|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
20741|NCT00850629|Behavioral|placebo|no intervention, only follow up
20742|NCT00850642|Drug|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
20743|NCT00850642|Drug|Placebo|Placebo :
2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)
20744|NCT00850668|Biological|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
20745|NCT00850681|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
20746|NCT00850720|Other|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
20747|NCT00010465|Procedure|Craniosacral Osteopathic Manipulative Treatment|
20748|NCT00850746|Drug|YM443|Oral
21034|NCT00844090|Drug|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
21754|NCT00845338|Drug|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
21755|NCT00845351|Drug|Bexarotene|bexarotene at 300 mg/m2/day
21756|NCT00845364|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
22046|NCT00838136|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
22047|NCT00838136|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
22048|NCT00838149|Dietary Supplement|Glutamine|Glutamine group :
Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
22049|NCT00840697|Behavioral|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
22050|NCT00840697|Behavioral|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
22051|NCT00840736|Procedure|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
22052|NCT00840736|Procedure|vertical banded gastroplasty|vertical banded gastroplasty
22053|NCT00840749|Radiation|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
22054|NCT00840749|Procedure|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
22055|NCT00840762|Other|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
22056|NCT00000776|Drug|Dexamethasone|
22057|NCT00009750|Biological|monoclonal antibody m170|
22058|NCT00840762|Other|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
22059|NCT00840775|Device|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
22060|NCT00840788|Procedure|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
22061|NCT00840788|Procedure|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
22751|NCT00836472|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
22752|NCT00836472|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
22753|NCT00836485|Drug|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
22754|NCT00836485|Drug|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
22755|NCT00839228|Drug|Placebo|Placebo one tablet bd for 3 months
22756|NCT00839241|Device|Bellovac ABT|Bellovac ABT (autologous blood)
22757|NCT00839241|Procedure|Allogenic Blood Transfusion|Transfusion of allogenic ("bank") blood.
22758|NCT00839254|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
22759|NCT00839254|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children < 12 months of age at the time of first study vaccination.
22760|NCT00839254|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children >= 12 months of age at the time of first study vaccination.
21528|NCT00010361|Drug|cyclosporine|
21529|NCT00849576|Drug|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
21530|NCT00849589|Behavioral|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
21531|NCT00849589|Behavioral|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
21532|NCT00849602|Drug|Placebo|Placebo bid for three days
21533|NCT00849602|Drug|Chloroquine|Chloroquine bid for three days
21534|NCT00849615|Drug|Docetaxel|50mg/m2 qd15
21535|NCT00849615|Drug|5-Fluorouracil|2600mg/m2 qd15
21536|NCT00849615|Drug|Oxaliplatin|85mg/m2 qd15
21537|NCT00849615|Drug|folinic acid|200mg/m2 qd15
20962|NCT00846365|Drug|Olmesartan medoxomil-hydrochlorothiazide|Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.
20963|NCT00846378|Procedure|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
20964|NCT00846378|Procedure|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
20965|NCT00846391|Drug|MK8245 5 mg (twice a day) b.i.d.|All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.
Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening.
20966|NCT00846391|Drug|MK8245 50 mg b.i.d.|All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.
Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening.
20967|NCT00846391|Drug|Placebo|All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.
Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening.
20968|NCT00846430|Drug|Peg-Interferon alpha-2b|age and weight dependant
20969|NCT00846430|Drug|Celecoxib (Celebrex)|age and weight dependant
20970|NCT00846430|Drug|Temozolomide (temodar)|age and weight dependant
20971|NCT00846430|Drug|Vincristine Sulfate (Oncovin)|age and weight dependant
20972|NCT00010062|Radiation|radiation therapy|
20973|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
21271|NCT00851643|Biological|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
21272|NCT00851669|Behavioral|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
21273|NCT00851669|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
21274|NCT00851682|Device|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
23608|NCT00865423|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
23609|NCT00865436|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
23610|NCT00865436|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
23611|NCT00865449|Drug|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
23915|NCT00868309|Biological|Antivenin Crotalinae (pit viper) equine immune F(ab)2|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
23916|NCT00868309|Biological|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
23917|NCT00868335|Device|Activ C disc prosthesis|cervical disc prosthesis
23918|NCT00868335|Procedure|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
23919|NCT00870792|Behavioral|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
23920|NCT00870805|Procedure|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
23921|NCT00870805|Procedure|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
23922|NCT00870805|Procedure|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
23923|NCT00870805|Procedure|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
23924|NCT00870818|Drug|Teplizumab|No additional drug or placebo will be administered in this study. Blood will be drawn every 6 months after the last visit of the Protege Study for 3 years. Blood will be collected for chemistry, hematology, thyroid function, immunology, serology, autoantibodies, and metabolic function.
23925|NCT00870831|Other|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
23926|NCT00870844|Drug|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
23927|NCT00013052|Behavioral|Peer led classes. Led by trained veterans with a chronic disease.|
23928|NCT00870844|Drug|Placebo|Vials with solution for IV infusion
27577|NCT00923351|Biological|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
27578|NCT00923351|Drug|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
27579|NCT00018356|Drug|testosterone|
27580|NCT00923351|Biological|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
27581|NCT00923364|Drug|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
27582|NCT00923364|Drug|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
27583|NCT00923364|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
27584|NCT00923364|Procedure|Allogeneic HSC|stem cell transplant
27585|NCT00923364|Drug|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
27586|NCT00923390|Genetic|2G-1 TCR Retroviral Vector-Transduced lyn|
27587|NCT00923390|Drug|Aldesleukin|
27588|NCT00923390|Drug|Cyclophosphamide|
27589|NCT00923390|Drug|Fludarabine|
27590|NCT00018382|Drug|rosiglitazone|
27591|NCT00923390|Drug|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
27592|NCT00923403|Dietary Supplement|plant sterol enriched soymilk|plant sterol enriched soymilk
27593|NCT00923403|Dietary Supplement|control dairy milk|control dairy milk
27594|NCT00923429|Procedure|Stay-active care|No other treatment than the stay-active care
27595|NCT00923429|Procedure|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
27596|NCT00923429|Procedure|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
23991|NCT00866060|Drug|Placebo memantine|Placebo memantine
23992|NCT00866073|Drug|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
23993|NCT00868348|Drug|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
23994|NCT00868348|Drug|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
23995|NCT00868361|Drug|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
23996|NCT00868374|Drug|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
23997|NCT00868374|Drug|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
23998|NCT00868387|Other|energy-restricted, carbohydrate-restricted diet|carbohydrate content of the diet < 40% Frequency: daily Duration: 12 months
23999|NCT00012584|Drug|fluvoxamine|
23015|NCT00834249|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
23016|NCT00834249|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
23017|NCT00834262|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
23018|NCT00834262|Drug|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
23019|NCT00834262|Drug|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
23020|NCT00834275|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
23021|NCT00834275|Drug|DURICEF® capsules 500 mg|1 x 500 mg
23022|NCT00834288|Drug|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
23023|NCT00834288|Drug|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
23024|NCT00836875|Drug|Voriconazole|All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.
Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.
Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension.
23429|NCT00865072|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
23430|NCT00865072|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
23431|NCT00000794|Drug|Pyrimethamine|
23432|NCT00012311|Drug|CMF regimen|
23433|NCT00865085|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
23434|NCT00865085|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
23435|NCT00865098|Drug|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
23436|NCT00865111|Drug|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
23437|NCT00865111|Drug|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
23438|NCT00865124|Drug|Spironolactone|25 mg daily
23439|NCT00865124|Drug|hydrochlorothiazide + potassium|12.5 mg hydrochlorothiazide daily plus 10mEq potassium
23440|NCT00865124|Other|placebo|placebo capsule
23441|NCT00865137|Drug|Tacrolimus, modified release|Oral
23442|NCT00865176|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
23443|NCT00012311|Drug|carboplatin|
23739|NCT00870116|Radiation|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
23740|NCT00870129|Procedure|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
24067|NCT00866086|Other|questionnaire administration|
24068|NCT00866086|Procedure|computed tomography|
24069|NCT00866086|Radiation|radiation therapy treatment planning/simulation|
24070|NCT00866099|Other|Educational Dementia training|Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified.
24071|NCT00866112|Other|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
24072|NCT00012350|Drug|FTI|
24073|NCT00866112|Other|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
24074|NCT00866138|Drug|masitinib (AB1010)|masitinib 9 mg/kg/day per os
24075|NCT00866164|Device|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
24076|NCT00866177|Other|Laboratory Biomarker Analysis|Correlative studies
24077|NCT00866177|Drug|Selumetinib|Given orally
24078|NCT00866190|Drug|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
24079|NCT00866190|Drug|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
24080|NCT00866203|Drug|HDS vs ProMECE/CytaBOM|
24081|NCT00866216|Drug|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
24082|NCT00866216|Drug|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
24083|NCT00012363|Drug|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 & 8, q 21 days
24084|NCT00866229|Drug|Rosuvastatin|10 mg per day for 12 weeks
27209|NCT00910598|Drug|glatiramer acetate|20 mg daily s.c. for 1 year
27597|NCT00923429|Procedure|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
26674|NCT00928915|Drug|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
26675|NCT00000834|Drug|Lamivudine|
26676|NCT00019097|Drug|autologous tumor cell vaccine|
26677|NCT00928928|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
26678|NCT00928928|Procedure|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
26679|NCT00921687|Behavioral|Multifactorial intervention|Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
26680|NCT00921700|Drug|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
26681|NCT00921700|Drug|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
26682|NCT00921700|Drug|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
26683|NCT00921700|Drug|Placebo|Single oral dose of lactose as placebo in gelatine capsules
26684|NCT00921713|Other|Oncology Nurse Care Management|
26685|NCT00921713|Other|Patient-centered materials|
26686|NCT00018200|Drug|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
26687|NCT00921726|Drug|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
26688|NCT00921726|Drug|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
26689|NCT00921739|Radiation|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
26690|NCT00921765|Drug|Saline|Saline single bolus dose followed by saline single bolus dose iv
26691|NCT00921765|Drug|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
26692|NCT00921765|Drug|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
23025|NCT00836888|Biological|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
23026|NCT00836901|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
23027|NCT00836901|Drug|Augmentin®|400 mg-57 mg chewable tablet
23028|NCT00836914|Drug|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
23029|NCT00836914|Drug|Placebo|Placebo capsules administered orally BID for 7 days
23030|NCT00836927|Drug|ridaforolimus|Oral or IV deforolimus, as described in the parent protocol. If the parent protocol involves a combination of deforolimus with one or several other drugs, the additional drug(s) may be continued as described in the parent protocol.
23031|NCT00008736|Drug|metoclopramide|
23032|NCT00836940|Drug|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
23033|NCT00836953|Biological|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
23034|NCT00837018|Other|physical exercise program|45 min, 3times a week
23355|NCT00867152|Drug|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
23356|NCT00867152|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
23357|NCT00012519|Drug|indinavir sulfate|
23358|NCT00867152|Drug|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
23359|NCT00867165|Drug|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
23360|NCT00867165|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
23361|NCT00867178|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
23362|NCT00867178|Drug|Carboplatin|Given IV
23363|NCT00867178|Drug|Cisplatin|Given IV
23364|NCT00867178|Drug|Cyclophosphamide|Given IV
23365|NCT00867178|Drug|Etoposide Phosphate|Given IV
23741|NCT00870142|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
23742|NCT00870142|Drug|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
23743|NCT00870155|Drug|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
23744|NCT00870168|Drug|chemotherapy|
23745|NCT00870168|Genetic|gene expression analysis|
23746|NCT00870168|Other|laboratory biomarker analysis|
23747|NCT00012948|Procedure|Telephone Care|
23748|NCT00870168|Procedure|breast biopsy|
23749|NCT00870181|Biological|ADV-TK/GCV|gene therapy
23750|NCT00870181|Procedure|Surgery|
23751|NCT00870181|Drug|systemic chemotherapy|
23752|NCT00870194|Drug|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
23753|NCT00870194|Drug|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
23754|NCT00870207|Behavioral|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
23755|NCT00870220|Drug|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
24063|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
24064|NCT00864097|Biological|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
24065|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
24066|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
27210|NCT00910611|Device|Buzzy|"Buzzy", the vibrating cold pack, is pressed by parent or nurse immediately prior to immunizations. The vibration is activated and the device remains in place throughout the procedure, moving locations to complete the 4 shots.
27211|NCT00910624|Drug|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
27212|NCT00910624|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
27213|NCT00017225|Procedure|conventional surgery|
27214|NCT00910624|Drug|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
27215|NCT00910637|Drug|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 13 cycles
27216|NCT00910650|Biological|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
27217|NCT00910650|Drug|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
27218|NCT00910663|Drug|Mycophenolate Mofetil|250 mg Capsule
27219|NCT00910663|Drug|CellCept®|250 mg Capsule
27220|NCT00910676|Drug|Diprosone|Start of treatment: as soon as the EGF-R inhibitors treatment begins
Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening
Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.
Period of treatment: 8 weeks
27221|NCT00910689|Drug|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
27222|NCT00910689|Drug|Placebo control|Placebo
27223|NCT00910689|Behavioral|Behavioral Migraine Management (BMM)|Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with "basic" migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback ("hand warming") training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed
27224|NCT00017225|Procedure|peripheral blood stem cell transplantation|
26693|NCT00921765|Drug|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
26694|NCT00921778|Device|Lapcone|Use of Lapcone during LSH
26695|NCT00921778|Procedure|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
26696|NCT00921791|Device|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
26973|NCT00922389|Procedure|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
26974|NCT00922389|Drug|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
26975|NCT00922389|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
26976|NCT00922402|Procedure|Intensive insulin infusion|The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.
In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase.
26977|NCT00922441|Drug|Fimasartan 60 mg group|Fimasartan 60 mg
26978|NCT00924664|Biological|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
26979|NCT00924664|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
26980|NCT00924677|Procedure|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
26981|NCT00924677|Procedure|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
26982|NCT00924690|Other|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
26983|NCT00924690|Other|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
26984|NCT00924703|Drug|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
26985|NCT00018668|Drug|Risperidone|
23366|NCT00867178|Drug|Isotretinoin|Given PO
23367|NCT00867178|Other|Laboratory Biomarker Analysis|Correlative studies
23368|NCT00012519|Drug|ritonavir|
23369|NCT00867178|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
23370|NCT00867178|Drug|Thiotepa|Given IV
23371|NCT00869609|Behavioral|GLB Traditional Maintenance|Group Lifestyle Balance (GLB)-Carb-focused Maintenance: Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
23372|NCT00869609|Behavioral|GLB-Carb-focused Maintenance|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
23373|NCT00869622|Drug|Risedronate|35 mgs/week + calcium and vit d
23374|NCT00869622|Drug|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
23375|NCT00869635|Drug|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
23676|NCT00863304|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
23677|NCT00863304|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
23678|NCT00863304|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
23679|NCT00863304|Other|placebo|placebo to match tanezumab and naproxen dosing
23680|NCT00863317|Drug|montelukast sodium|4mg granules daily for 14 days
23681|NCT00863317|Other|sucrose|table sugar as placebo daily for 14 days
23682|NCT00863330|Biological|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
23683|NCT00863343|Biological|Public Health Notification|For any H5 positive results, notification of the result to the site's local public health authorities.
23684|NCT00863356|Device|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
23556|NCT00869856|Drug|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
23557|NCT00869869|Drug|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
23558|NCT00869869|Drug|placebo|placebo
23559|NCT00869882|Procedure|Circumferential arthrodesis|Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.
The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.
In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.
The end of the procedure is the same as for GPLI.
23857|NCT00863603|Other|oxygen|5 Liter/minute by nasal cannula for 6 wks
23858|NCT00863616|Device|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
23859|NCT00863629|Drug|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
23860|NCT00863642|Procedure|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
23861|NCT00863642|Procedure|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
23862|NCT00863655|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
23863|NCT00000794|Drug|Clarithromycin|
23864|NCT00012207|Biological|aldesleukin|
23865|NCT00863655|Drug|Exemestane|Exemestane 25 mg orally daily.
23866|NCT00863655|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
27225|NCT00922753|Other|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
27475|NCT00920660|Drug|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
27476|NCT00920673|Procedure|MRI|MRI during 35 to 65 minutes
27477|NCT00920686|Drug|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
27478|NCT00920686|Drug|placebo|administered as 3 placebo hard gelatin capsules
27479|NCT00920686|Drug|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
27480|NCT00920699|Drug|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
27481|NCT00920712|Drug|Weiqi decotion|Decoction ,two times a day
27482|NCT00920725|Drug|Insulin (Aspart Insulin [Novolog], Regular Insulin)|Aspart Insulin 0.2units/sq q 2 hours
Regular Insulin 0.1units/kg/hr intravenous
Aspart Insulin 0.1 units/kg/hr intravenous
27483|NCT00923195|Drug|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
27484|NCT00923195|Genetic|Anti-gp 100:154 TCR PBL|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14
27485|NCT00018343|Drug|estrogen|
27486|NCT00923195|Genetic|Anti-MART-1 F5 TCR PBL|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14
27487|NCT00923234|Drug|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
27488|NCT00923234|Drug|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
27489|NCT00923247|Drug|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & amp; 11 every 28 days in adults
27490|NCT00923247|Drug|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & amp; 11 every 28 days in adults
23929|NCT00870870|Drug|Gemcitabine|1000 mg/m2 on Days 1 and 8 of each cycle
(First 6 cycles [18 weeks])
23930|NCT00870870|Drug|Cisplatin|75 mg/m2 , day 1 of each cycle
(First 6 cycles [18 weeks])
23931|NCT00870870|Biological|IMC-A12 (cixutumumab)|6 mg/kg I.V. infusion, administered once per week (on Days 1, 8, and 15 of each cycle)
(First 6 cycles [18 weeks])
23932|NCT00870870|Biological|Cetuximab|400 mg/m2 I.V. infusion, administered on Day 1 of Cycle 1, 250 mg/m2 once per week thereafter
(First 6 cycles [18 weeks])
23933|NCT00870870|Biological|IMC-A12 (cixutumumab)|10 mg/kg I.V. infusion, administered once every 2 weeks
[Maintenance period]
23934|NCT00870870|Biological|Cetuximab|500 mg/m2 I.V. infusion, administered once every 2 weeks
[Maintenance period]
22955|NCT00839566|Other|Rate Control|Rate control by drug
22956|NCT00839579|Other|1x4 min interval|Aerobic interval training
22957|NCT00839592|Other|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
22958|NCT00839605|Drug|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
22959|NCT00839631|Drug|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
22960|NCT00839644|Device|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
22961|NCT00839644|Device|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
22962|NCT00839644|Other|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
22963|NCT00009646|Drug|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
22964|NCT00839657|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
23685|NCT00863369|Biological|rituximab|Given IV
23686|NCT00012181|Other|pharmacological study|Correlative studies
23687|NCT00863369|Drug|bortezomib|Given IV
23688|NCT00863369|Drug|gemcitabine hydrochloride|Given IV
23689|NCT00863369|Other|questionnaire administration|Ancillary studies
23690|NCT00863382|Device|Standard Event Monitor|Standard Event Monitor
23691|NCT00863382|Device|Sleuth Monitor|Implantable Sleuth Recorder
23692|NCT00865475|Drug|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
23693|NCT00012311|Drug|etoposide|
23694|NCT00865475|Drug|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
23695|NCT00865488|Biological|ADHEXIL|Adhesions prevention
23696|NCT00865501|Drug|spironolactone|25mg per oral once daily
23697|NCT00865501|Drug|placebo|placebo
23698|NCT00865514|Drug|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
24000|NCT00868387|Other|energy-restricted, fat-restricted diet|carbohydrate content of diet > 55% Frequency: daily Duration: 12 months
24001|NCT00868400|Dietary Supplement|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
24002|NCT00868400|Dietary Supplement|flavored water|will be given in doses equal to those of high-carbohydrate beverage
24003|NCT00868413|Drug|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
24004|NCT00868413|Drug|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
24005|NCT00868413|Drug|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
23867|NCT00863668|Drug|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
23868|NCT00863668|Drug|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
23869|NCT00863668|Procedure|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
23870|NCT00863668|Procedure|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
23871|NCT00863681|Drug|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
23872|NCT00863707|Drug|Regadenoson|IV
23873|NCT00863707|Drug|Placebo|IV
23874|NCT00865722|Procedure|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
23875|NCT00865748|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
22893|NCT00831181|Procedure|therapeutic surgical procedure|
22894|NCT00831194|Behavioral|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
22895|NCT00831233|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
22896|NCT00831233|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
22897|NCT00831233|Drug|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
22898|NCT00831246|Other|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
22899|NCT00831246|Other|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
22900|NCT00008203|Drug|cyclosporine|
22901|NCT00831272|Drug|naltrexone|50mg/day
22902|NCT00831272|Drug|Placebo|Placebo
27491|NCT00923260|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
27840|NCT00874536|Dietary Supplement|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
27841|NCT00874536|Dietary Supplement|Placebo|
27842|NCT00013663|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
27843|NCT00874549|Biological|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
27844|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
27845|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
27846|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
27847|NCT00874562|Drug|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
27848|NCT00874562|Drug|Rapamycin|Taken orally mixed with water or orange juice
27849|NCT00874575|Dietary Supplement|Placebo|
27850|NCT00874575|Dietary Supplement|Vitamin D|
27851|NCT00874575|Dietary Supplement|Beta-hydroxy-Beta-methylbutyrate|
27852|NCT00874575|Drug|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
27853|NCT00013663|Drug|Aldesleukin|
27854|NCT00877227|Drug|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
27855|NCT00877240|Behavioral|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
27856|NCT00877253|Drug|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
22965|NCT00839657|Behavioral|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
22966|NCT00839670|Other|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
22967|NCT00839670|Other|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
22968|NCT00839683|Drug|simvastatin|Tablets, Oral, 20 mg, Single Dose
22969|NCT00839683|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
22970|NCT00839683|Drug|simvastatin|Oral, 40 mg, Single Dose
22971|NCT00839683|Drug|valsartan|Tablets, Oral, 320 mg, Single Dose
22972|NCT00839709|Procedure|blood sampling|peripheral blood draw
23292|NCT00832039|Procedure|Procalcitonin guided therapy|Causal therapy of sepsis is guided by applying the following algorithm:
Day 4: PCT drop from baseline >=50%: no change in causal therapy; PCT drop from baseline <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.
Day 7, 10, 14: PCT <=1.0 ng/ml: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement >=50%: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.
23293|NCT00008242|Drug|dexamethasone|
23294|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
23295|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
23296|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
23297|NCT00834678|Drug|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
23298|NCT00008359|Drug|liposomal amphotericin B|
23299|NCT00834704|Drug|PEGPH20|PEGylated recombinant human hyaluronidase
23300|NCT00834717|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
23301|NCT00834717|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
23302|NCT00834730|Drug|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
24006|NCT00868426|Drug|Budesonide/Formoterol Batch 1|Single, inhaled dose
24007|NCT00868426|Drug|Budesonide/Formoterol Batch 2|Single, inhaled dose
24008|NCT00868426|Drug|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
24009|NCT00868439|Drug|patiromer|Active investigational drug
24010|NCT00012597|Procedure|Web-based telemedicine system for assessment of status of pressure ulcers|
24011|NCT00868439|Drug|placebo|placebo
24012|NCT00868452|Drug|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
24013|NCT00868452|Drug|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
24014|NCT00868465|Drug|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania
24015|NCT00868465|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
24016|NCT00870272|Drug|Misoprostol|400mcg misoprostol taken sublingually or buccally
24017|NCT00870285|Radiation|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
24018|NCT00870298|Drug|Trimethoprim/Sulfamethoxazole and Warfarin|
24019|NCT00870311|Drug|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
23035|NCT00837031|Drug|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
23036|NCT00837031|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
23037|NCT00837044|Drug|Treximet|Treximet
23038|NCT00837044|Drug|Migraine rescue medication of choice|Migraine rescue medication of choice
22903|NCT00831285|Dietary Supplement|food product|food product given at one of six visits
22904|NCT00831298|Other|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
22905|NCT00831311|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
22906|NCT00833898|Behavioral|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development & application of various stress-mgmt techniques such as effective problem-solving, identifying & challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support & goal setting.
22907|NCT00833911|Drug|Tramadol Once A Day|
22908|NCT00833924|Device|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
22909|NCT00833937|Drug|Zolpidem 10 mg tablets|1 x 10 mg
22910|NCT00833937|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
22911|NCT00833950|Device|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
23231|NCT00837304|Procedure|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
23232|NCT00837317|Dietary Supplement|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
23233|NCT00837330|Drug|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
23234|NCT00837343|Drug|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
23235|NCT00837356|Drug|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
23236|NCT00837356|Drug|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
23237|NCT00008853|Biological|GBS III-TT-SSI|
23238|NCT00837369|Drug|Regadenoson|400ug IV bolus injection, single dosage
27857|NCT00014079|Genetic|microsatellite instability analysis|
27858|NCT00877253|Drug|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
27859|NCT00877253|Drug|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
26917|NCT00927238|Device|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
26918|NCT00927238|Other|Lumbar fusion surgery|Lumbar fusion surgery
26919|NCT00927251|Device|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
26920|NCT00927264|Behavioral|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate families to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Families will receive 2 home visits & 2 telephone session, both with a health counselor. Families will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
26921|NCT00927264|Behavioral|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
26922|NCT00927277|Device|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
26923|NCT00927277|Device|Erchonia(R) LipoLASER PL|
26924|NCT00018954|Drug|doxorubicin hydrochloride|
26925|NCT00927290|Drug|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
26926|NCT00927290|Drug|Placebo|Placebo 45 mg QD (30 mg QD the first month)
26927|NCT00927303|Device|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
26928|NCT00927303|Device|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
26929|NCT00927316|Biological|E. coli 83972|Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).
Placebo arm: Identical procedure but with saline, 30 ml.
26930|NCT00927329|Biological|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
23303|NCT00834743|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
23304|NCT00834743|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
23305|NCT00834756|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
23306|NCT00834756|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
23307|NCT00834782|Procedure|IOP measurement|Measuring IOP
23308|NCT00834795|Drug|Carvedilol 25 mg tablets|1 x 25 mg
23309|NCT00008372|Drug|chloroquinoxaline sulfonamide|
23310|NCT00834795|Drug|COREG® 25 mg tablets|1 x 25 mg
23311|NCT00834808|Drug|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
23312|NCT00834821|Behavioral|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
23612|NCT00865449|Drug|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
23613|NCT00865462|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
23614|NCT00865462|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
23615|NCT00867542|Other|no intervention|no intervention
23616|NCT00867555|Dietary Supplement|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
23617|NCT00867568|Drug|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
23618|NCT00867594|Drug|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
23619|NCT00867607|Drug|MRX-6|b.i.d treatment for 21 days
23620|NCT00867607|Drug|Steroid|b.i.d. 21 days
23621|NCT00867659|Drug|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
23039|NCT00837057|Procedure|crrt|early CRRT (35 ml/kg/h)& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
23040|NCT00837070|Procedure|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
23041|NCT00837096|Device|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
23042|NCT00008775|Device|Pressure support ventilation|
23043|NCT00837096|Device|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
23044|NCT00837109|Behavioral|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
23045|NCT00839722|Procedure|embolization|fertility after embolization
23046|NCT00009646|Drug|Indomethacin|0.1 mg per kilogram of body weight
23047|NCT00839761|Dietary Supplement|iron fortified rice|
23048|NCT00839761|Dietary Supplement|iron drops|
23049|NCT00839774|Other|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
23050|NCT00839774|Other|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
23051|NCT00839774|Other|White wheat flour|White wheat flour will be administered at 50 g/day
23052|NCT00839787|Drug|Morphine Sulfate|Morphine Sulfate group: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
23053|NCT00839800|Drug|Symbicort Turbuhaler|160/4.5 µg
23054|NCT00839800|Drug|Terbutaline Turbuhaler|0.4 mg
23055|NCT00839813|Behavioral|Yoga|10 weeks of a trauma-sensitive yoga class
23376|NCT00869635|Procedure|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
23377|NCT00869635|Procedure|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
23378|NCT00869648|Procedure|Extension|After anaesthesia induction the head is placed in extension
23379|NCT00869648|Procedure|Neutral head position|After anaesthesia induction the head is placed in neutral position
23239|NCT00837382|Behavioral|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
23240|NCT00837382|Behavioral|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
23241|NCT00837434|Drug|Etanercept|50 mg dose of etanercept by subcutaneous injection
23242|NCT00837434|Drug|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
23243|NCT00837447|Device|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
23244|NCT00837447|Device|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
23245|NCT00837460|Other|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
23246|NCT00837473|Device|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
23247|NCT00837486|Device|Reclaim™ DBS System|
23248|NCT00008853|Biological|GBS III-TT-MPHL|
23249|NCT00009685|Drug|VRC4302|
23250|NCT00840216|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
23560|NCT00869882|Procedure|Posterolateral fusion with instrumentation|Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.
Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:
Central stenosis: decompression is performed including medial facectomy, laminectomy;
Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;
Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.
Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.
Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.
Bone autograft is placed into this bed.
23561|NCT00869895|Drug|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
23562|NCT00012896|Behavioral|Telephone Care + Educational (AV Materials)|
23563|NCT00869908|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
23564|NCT00869908|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
26931|NCT00927342|Other|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
26932|NCT00927342|Other|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
26933|NCT00927355|Drug|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
26934|NCT00928941|Behavioral|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
27492|NCT00923260|Procedure|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
27493|NCT00923273|Drug|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
27494|NCT00923273|Drug|Pemetrexed|
27495|NCT00923273|Drug|Sirolimus|
27496|NCT00018356|Procedure|exercise|
27497|NCT00923273|Dietary Supplement|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
27498|NCT00923273|Dietary Supplement|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
27499|NCT00923273|Drug|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
27500|NCT00923299|Biological|cetuximab|
27501|NCT00923299|Biological|trastuzumab|
27502|NCT00923312|Biological|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
27503|NCT00925652|Drug|Methotrexate|One pill orally twice a day on days 1 and 2 of each week for approximately 6 months.
27504|NCT00925652|Behavioral|Diet Intervention|Series of 13 telephone calls over the course of one-year with a dedicated and trained counselor
27505|NCT00925652|Behavioral|Diet and Exercise Intervention|Counseling targeted toward increasing physical activity and a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
23622|NCT00867672|Drug|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
23623|NCT00012558|Drug|lamotrigine|
23624|NCT00867672|Drug|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
23625|NCT00867672|Drug|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
23626|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
23627|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
23628|NCT00867698|Drug|AST-120|AST-120
23629|NCT00867724|Device|aeroscopy (aer-o-scope)|screening of the colon for crc using the aer-o-scope
23630|NCT00867737|Drug|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
23631|NCT00867737|Drug|Symbicort 160/4.5 pMDI|Symbicort 160/4.5 pMDI
Two puffs from MDI twice daily for 4 weeks
23632|NCT00867750|Device|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
23633|NCT00867750|Drug|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
23634|NCT00012558|Drug|risperidone|
23935|NCT00870870|Drug|Carboplatin|AUC = 5, day 1 of each cycle
(First 6 cycles [18 weeks])
*Carboplatin will be replaced by Cisplatin
23936|NCT00870883|Drug|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
23937|NCT00870896|Drug|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
23938|NCT00000796|Drug|Ethambutol hydrochloride|
23939|NCT00013078|Procedure|Physical restoration intervention|
23940|NCT00870909|Procedure|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
23941|NCT00870909|Procedure|sham tDCS|sham condition as delivered by the stimulator
23380|NCT00012844|Procedure|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
23381|NCT00869648|Procedure|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
23382|NCT00869661|Drug|Copegus|1000/1200mg po daily for 24 or 48 weeks
23383|NCT00869661|Drug|Copegus|1000/1200mg po daily for 48 weeks
23384|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
23385|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 48 weeks
23386|NCT00869661|Drug|RO5024048|1000mg bid for 24 weeks
23387|NCT00869661|Drug|RO5024048|500mg bid for 12 weeks
23388|NCT00869661|Drug|RO5024048|1000mg bid for 8 weeks
23389|NCT00869661|Drug|RO5024048|1000mg bid for 12 weeks
23390|NCT00869674|Procedure|GeneSearch™ Breast Lymph Node (BLN) Assay|Each of the sentinal lymph node will be divided in half according to cutting scheme.
Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing.
23391|NCT00012857|Drug|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
23392|NCT00869687|Device|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
23393|NCT00869700|Drug|Artemether/Lumefantrine|80mg artemether/480mg lumefantrine
Trade name: Coartem
Indication: for management of non-severe malaria
23394|NCT00862784|Drug|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
23395|NCT00862797|Other|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
23396|NCT00862810|Biological|Received HPV vaccine first|
23397|NCT00862810|Biological|Received concomitant vaccines first|
23398|NCT00012168|Drug|isosulfan blue|
23699|NCT00865514|Genetic|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
23565|NCT00869908|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
23566|NCT00869934|Other|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
23567|NCT00869934|Other|Behavior Therapy|Sleep restriction and stimulus control
23568|NCT00869934|Other|Cognitive Therapy|Cognitive restructuring therapy
23569|NCT00869947|Device|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
23570|NCT00869947|Other|No device|
23571|NCT00869960|Drug|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
23572|NCT00863057|Drug|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
23573|NCT00863083|Behavioral|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
23574|NCT00863096|Biological|Gardasil|HPV vaccine
23876|NCT00865748|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
23877|NCT00865761|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
23878|NCT00865761|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under fasting conditions
23879|NCT00865774|Behavioral|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
23880|NCT00865774|Behavioral|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
23881|NCT00000794|Drug|Leucovorin calcium|
23882|NCT00012311|Procedure|peripheral blood stem cell transplantation|
27506|NCT00018811|Behavioral|Surface EMG biofeedback|
27507|NCT00925665|Device|Glidescope|Patients are to be intubated using the Glidescope technique
27508|NCT00925665|Device|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
27509|NCT00925678|Drug|DSP-3025|
27510|NCT00925678|Drug|Placebo|
27511|NCT00925691|Device|RV lead|The RV lead is implanted at the apex or at the interventricular septum
27512|NCT00925704|Drug|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
27513|NCT00925704|Drug|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
27534|NCT00928083|Drug|OZ439 200mg API capsules|
27535|NCT00928083|Drug|OZ439 400mg aqueous dispersion|
27536|NCT00928083|Drug|OZ439 800mg aqueous dispersion|
27537|NCT00928083|Drug|OZ439 100mg API capsules|OZ439 100mg (2x50mg API capsules)
27538|NCT00928083|Drug|OZ439 400mg API capsules|OZ439 400mg (2x200mg API capsules)
27539|NCT00019032|Biological|monoclonal antibody Mik-beta-1|
27540|NCT00928083|Drug|OZ439 1600mg aqueous dispersion|
27541|NCT00928083|Drug|OZ439 800mg API capsules|OZ439 800mg (4x200 API capsules)
27542|NCT00928083|Drug|OZ439 1200mg API capsules|OZ439 1200mg (6x200mg API capsules)
27543|NCT00928083|Drug|Placebo|
27544|NCT00928083|Drug|OZ439 200mg aqueous dispersion|
27545|NCT00928109|Behavioral|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
27546|NCT00928109|Behavioral|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
27547|NCT00928122|Device|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
23942|NCT00863733|Drug|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
23943|NCT00012207|Biological|therapeutic autologous lymphocytes|
23944|NCT00863746|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
23945|NCT00863746|Drug|Placebo|Placebo - 2 tablets twice daily (BID)
23946|NCT00863759|Procedure|implantation of intraocular lens (IOL)|implantation of intraocular lens during cataract surgery.
Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.
Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye.
23947|NCT00863772|Biological|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
23948|NCT00863772|Biological|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
23949|NCT00863772|Other|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
23950|NCT00863785|Drug|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
23951|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
23952|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
23953|NCT00863798|Drug|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
23954|NCT00012207|Drug|cyclophosphamide|
23955|NCT00863837|Drug|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
22973|NCT00831311|Biological|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
22974|NCT00831324|Drug|everolimus|
22975|NCT00831324|Other|immunohistochemistry staining method|
22976|NCT00831324|Other|laboratory biomarker analysis|
22977|NCT00831337|Dietary Supplement|VSL3|2 times daily 450 billion live bacteria (in each saschet)
22978|NCT00008203|Drug|thiotepa|
22979|NCT00831337|Dietary Supplement|Lactobacillus plantarum 299v|20 billion bacteria (2 capsules daily) given daily to patients as a food supplement
23700|NCT00865514|Other|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
23701|NCT00865514|Other|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
23702|NCT00865527|Other|Fecal occult blood test|
23703|NCT00865527|Procedure|Virtual colonoscopy|
23704|NCT00012311|Drug|fluorouracil|
23705|NCT00865527|Procedure|Optical colonoscopy|
23706|NCT00865540|Drug|prednisolone acetate 1%|1 drop every 8h two days before surgery
23707|NCT00865540|Drug|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
23708|NCT00865540|Drug|nepafenac 0.1%|1 drop every 8h two days before surgery
23709|NCT00865540|Drug|methylcellulose 0.5%|1 drop every 8h two days before surgery
23710|NCT00865553|Behavioral|computer-assisted smoking cessation intervention|
23711|NCT00865553|Other|cancer prevention|
23712|NCT00865553|Other|educational intervention|
23713|NCT00865553|Other|survey administration|
23714|NCT00865566|Biological|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
23715|NCT00012311|Drug|ifosfamide|
23716|NCT00865566|Biological|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
23717|NCT00867802|Behavioral|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
23718|NCT00867815|Drug|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
23883|NCT00865813|Procedure|Punch Biopsy|Instillation of anesthetic eye drops.
Asepsis
Placement of surgical cloths and drapes
Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.
Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions
Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade
23884|NCT00865826|Other|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
23885|NCT00865839|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
23886|NCT00865839|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
23887|NCT00865852|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
23888|NCT00865852|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
23889|NCT00865865|Procedure|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
23890|NCT00865865|Procedure|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
23891|NCT00865878|Drug|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
23892|NCT00865878|Other|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
23893|NCT00012324|Drug|doxorubicin hydrochloride|
22912|NCT00008307|Procedure|allogeneic bone marrow transplantation|
22913|NCT00833976|Drug|Lovaza|4 grams per day
22914|NCT00833989|Drug|GSK249320|I.V. infusion
22915|NCT00833989|Drug|PLACEBO|Placebo
22916|NCT00834002|Biological|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
22917|NCT00834015|Other|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
22918|NCT00834041|Drug|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
27548|NCT00928122|Device|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
27549|NCT00928122|Device|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
27550|NCT00019058|Drug|chemotherapy|
27551|NCT00928122|Device|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
27552|NCT00920738|Other|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
27553|NCT00920738|Other|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
27554|NCT00018148|Drug|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
27860|NCT00877266|Procedure|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
27861|NCT00877279|Device|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
27862|NCT00877279|Device|Belotero Soft|Dermal Filler
27863|NCT00877305|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
27864|NCT00877305|Other|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
27865|NCT00877318|Device|SCAD information system|Cardiac rehabilitation at home by telemedicine
27866|NCT00877331|Behavioral|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
27867|NCT00877344|Device|LNG-IUC or Copper T380|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
22980|NCT00831350|Drug|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
22981|NCT00831363|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
22982|NCT00831363|Procedure|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
22983|NCT00831376|Drug|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
22984|NCT00831376|Drug|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
22985|NCT00831376|Drug|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
22986|NCT00831389|Device|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
22987|NCT00831402|Dietary Supplement|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
22988|NCT00831402|Dietary Supplement|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
22989|NCT00008203|Procedure|autologous bone marrow transplantation|
22990|NCT00831415|Drug|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
22991|NCT00831428|Other|no intervention|this is a screening study, not an interventional study
22992|NCT00831441|Drug|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
22993|NCT00831441|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
22994|NCT00831467|Biological|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
23313|NCT00834821|Behavioral|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
23314|NCT00834834|Drug|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
23315|NCT00834834|Behavioral|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
23316|NCT00834834|Drug|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
23719|NCT00867828|Dietary Supplement|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
24020|NCT00870324|Device|OptiSense Lead|The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and "narrow-spaced" compared to the Tendril lead.
24021|NCT00870324|Device|Tendril Lead|The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is "wide spaced" compared to the OptiSense lead.
24022|NCT00870337|Drug|everolimus|
24023|NCT00870350|Biological|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
24024|NCT00870350|Biological|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
24025|NCT00870363|Drug|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
24026|NCT00012974|Procedure|Provider education, computer reminders, nurse case management|
24027|NCT00870363|Drug|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
24028|NCT00870363|Drug|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
24029|NCT00870376|Other|biomarkers|To define a biomarker or combination of overactive bladder syndrome
24030|NCT00870402|Drug|Spironolactone|25 mg per day for 9 months
24031|NCT00870402|Drug|Placebo|Placebo 1 tablet per day for nine months
24032|NCT00870415|Procedure|quality-of-life assessment|
24033|NCT00870415|Procedure|therapeutic conventional surgery|
24034|NCT00870441|Drug|ASP2151|Oral
24035|NCT00870441|Drug|Valacyclovir|Oral
24036|NCT00870441|Drug|Placebo|Oral
24037|NCT00012987|Behavioral|Quality Improvement|
22919|NCT00834054|Procedure|Double-lung transplantation|Double-lung transplanted patients
22920|NCT00834067|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
22921|NCT00834067|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
22922|NCT00834080|Drug|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
22923|NCT00008307|Procedure|peripheral blood stem cell transplantation|
22924|NCT00834093|Biological|Epstein-Barr Virus Specific Immunotherapy|Two infusions given fourteen days apart, with a possible third infusion given 8 weeks later.
22925|NCT00834106|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
22926|NCT00834106|Biological|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
22927|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
22928|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
22929|NCT00834132|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
22930|NCT00836680|Device|Colorectal Stent|Diagnosis of an internal rectal prolapse:
The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.
An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch.
22931|NCT00836693|Drug|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
22932|NCT00836693|Drug|placebo|tablet administered orally once a day for 12 weeks.
23251|NCT00840216|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
23252|NCT00840229|Drug|Triamcinolone hexacetonide|20 mg
23253|NCT00840229|Drug|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
23254|NCT00840242|Drug|Nicotine gum|8-12 pieces per day, maximum 24 daily
23255|NCT00840242|Drug|Placebo gum|8-12 pieces per day, maximum 24 daily
23256|NCT00840242|Drug|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
27868|NCT00014092|Biological|aldesleukin|
27869|NCT00877344|Device|LNG-IUC or Copper T380|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
27870|NCT00877357|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
27871|NCT00879658|Drug|BAF312|
27872|NCT00879658|Drug|Placebo|
27873|NCT00879671|Dietary Supplement|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
27874|NCT00879671|Dietary Supplement|placebo|Placebo capsules identical in taste and appearance
27875|NCT00879684|Biological|CVX-060|Weekly, intravenous dose
27876|NCT00879697|Behavioral|Walking Training Program|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 s of each exercise bout.
26935|NCT00928941|Behavioral|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
26936|NCT00928954|Drug|gabapentin|increasing to 1200 mg/day
26937|NCT00928954|Drug|memantine|increasing to 40 mg/day
26938|NCT00928967|Drug|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
26939|NCT00928980|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
26940|NCT00928980|Drug|Optimal Medical Care|Therapeutic dose of antidepressant medication
26941|NCT00929006|Drug|Micronized progesterone suspension|micronized progesterone 0.8 mg/kg at 0700, 1500 2300 and 0700
26942|NCT00019097|Drug|keyhole limpet hemocyanin|
26943|NCT00929006|Drug|Placebo|Placebo
26944|NCT00929019|Biological|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
23317|NCT00834847|Drug|pravastatin|40 mg tablet
23318|NCT00834847|Drug|Pravachol®|40 mg Tablet
23319|NCT00834860|Drug|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
23320|NCT00008385|Dietary Supplement|selenium|Given orally
23321|NCT00834873|Drug|Carvedilol 25 mg tablets|1 x 25 mg
23322|NCT00834873|Drug|COREG® 25 mg tablets|1 x 25 mg
23323|NCT00834886|Dietary Supplement|Melatonin|Capsules, 3 mg, once every night
23324|NCT00837499|Behavioral|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
23325|NCT00837512|Device|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
23326|NCT00837512|Device|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
23327|NCT00837525|Procedure|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
23328|NCT00837551|Drug|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
23329|NCT00837564|Other|CBASP psychotherapy|specific psychotherapy for chronic depression
23330|NCT00837564|Drug|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
23331|NCT00837577|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
23332|NCT00837577|Drug|Sitagliptin|Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).
Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20.
23333|NCT00837577|Drug|Voglibose|All participants received a stable dose of voglibose, in
accordance with the package insert, throughout the study.
23635|NCT00867763|Procedure|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
23636|NCT00867763|Procedure|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
24038|NCT00870454|Drug|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
24039|NCT00870454|Drug|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
24040|NCT00863928|Drug|Belladonna and Opium Suppositories|Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain
23056|NCT00839826|Drug|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
23057|NCT00009646|Drug|Placebo|0.1 mg per kilogram of body weight
23058|NCT00839826|Drug|Enoxaparin|40 mg bid
23059|NCT00839839|Procedure|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
23060|NCT00839852|Drug|Cariprazine|Patients who meet eligibility criteria will receive open-label cariprazine.
23061|NCT00839865|Drug|herb ointment|a kind of ointment made from herb
23062|NCT00839878|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
23063|NCT00839891|Drug|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
23064|NCT00839904|Behavioral|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
23065|NCT00839917|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
23066|NCT00839917|Biological|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
23067|NCT00839930|Drug|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
23068|NCT00000776|Drug|Amphotericin B|
23069|NCT00009659|Drug|CDB 2914|
23070|NCT00839930|Drug|Pletal®|1 x 50 mg, single-dose tablet
23071|NCT00839943|Other|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
23072|NCT00839956|Drug|Bortezomib|Given IV
23073|NCT00839956|Drug|Vorinostat|Given PO
23257|NCT00840242|Drug|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
23258|NCT00840255|Behavioral|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
23259|NCT00840255|Other|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
23260|NCT00009698|Biological|aldesleukin|Given SQ and IV
23261|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
23262|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
23263|NCT00840281|Drug|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
23264|NCT00840281|Drug|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
23265|NCT00840294|Drug|Ciprofloxacin|
23266|NCT00840320|Drug|1278863|15mg, 25mg, 50mg, 150mg
23267|NCT00840320|Drug|Placebo|matching placebo
23268|NCT00840333|Drug|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
23269|NCT00840346|Drug|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
23270|NCT00840359|Procedure|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
23271|NCT00009711|Procedure|management of therapy complications|
23575|NCT00863109|Biological|Peginterferon alfa-2b (PEG)|Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
23576|NCT00863109|Drug|Ribavirin (RBV)|Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
23577|NCT00863122|Drug|lapatinib|1500 mg lapatinib by mouth per day for 10 days
26945|NCT00929032|Radiation|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
26946|NCT00929045|Drug|Growth Hormone Replacement|
26947|NCT00929058|Drug|Bevacizumab|Intra-arterial infusion during 6 minutes
26948|NCT00929071|Device|Evolence|Injectable collagen
26949|NCT00929071|Device|Lidocaine|admix anesthetic
26950|NCT00929071|Drug|topical anesthetic|
26951|NCT00929084|Other|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
26952|NCT00929097|Other|Implementation aids|Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids
Clinicians receive the guidelines and a risk communication tool, as well as education
26953|NCT00019097|Drug|melphalan|
26954|NCT00929097|Other|Control|Dissemination of guidelines
26955|NCT00929110|Drug|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
27514|NCT00925704|Drug|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
27515|NCT00925730|Drug|Pimecrolimus|
27516|NCT00925743|Drug|cabazitaxel (XRP6258)|administered by IV infusion
in addition to cisplatin treatment
27517|NCT00018824|Drug|NALTREXONE|
27518|NCT00925756|Drug|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment
27519|NCT00925769|Drug|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
27520|NCT00925769|Drug|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
27521|NCT00925769|Drug|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
27522|NCT00925782|Drug|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
23637|NCT00867776|Behavioral|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
23638|NCT00867789|Drug|Trimethoprim-sulfamethoxazole|10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
23639|NCT00867789|Drug|Sugar pill|10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
23640|NCT00869960|Drug|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
23641|NCT00012909|Behavioral|Hormone Replacement Therapy Decision-Aid|
23642|NCT00869960|Drug|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
23643|NCT00869960|Drug|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
23644|NCT00869973|Drug|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
23645|NCT00869973|Drug|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
23646|NCT00869986|Drug|dirucotide|500mg, intravenous, every 6 months for 15 months
23647|NCT00869986|Drug|placebo|intravenous, once every six months for 15 months
23648|NCT00869999|Drug|Everolimus|Taken orally once daily in the morning
23649|NCT00869999|Drug|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
23650|NCT00870012|Drug|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
23651|NCT00870012|Other|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
23652|NCT00012922|Behavioral|Low Literacy Intervention for Colorectal Cancer Screening|
23653|NCT00870025|Biological|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
23654|NCT00870025|Biological|placebo|diluent, every 5 days, s.c., 4 doses
23956|NCT00863837|Drug|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
23074|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
23075|NCT00008203|Procedure|peripheral blood stem cell transplantation|
23076|NCT00831506|Drug|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
23077|NCT00831532|Drug|Dimebon|Dimebon 5mg in healthy controls
23078|NCT00831532|Drug|Dimebon|Dimebon 5mg in mild hepatic impairment patients
23079|NCT00831532|Drug|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
23399|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
23400|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
23401|NCT00862836|Drug|Vandetanib|100mg doses orally, once daily
23402|NCT00862849|Drug|Insulin Lispro|
23403|NCT00862849|Drug|Regular Human Insulin|
23404|NCT00862849|Drug|rHuPH20|
23405|NCT00862875|Drug|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
23406|NCT00862888|Drug|PF-00446687|Single 200mg dose as an oral solution
23407|NCT00862888|Drug|Placebo|Placebo for oral solution
23408|NCT00862888|Drug|Placebo|Placebo for tablet
23409|NCT00012168|Genetic|polymerase chain reaction|
23410|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
23411|NCT00862888|Drug|PF-00446687|Single 125 mg dose as an oral solution
23412|NCT00862888|Drug|PF-00446687|Single 175 mg dose as an oral solution
23413|NCT00862888|Drug|PF-00446687|Single 20 mg dose as an oral solution
23414|NCT00862888|Drug|Placebo|Placebo for oral solution
23415|NCT00862888|Drug|Placebo|Placebo for tablet
23578|NCT00863135|Device|CPAP|continuous positive airways pressure
23579|NCT00863135|Device|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
23580|NCT00012168|Procedure|sentinel lymph node biopsy|
23581|NCT00863148|Drug|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
23582|NCT00863161|Drug|AZD3355|capsule, oral, single dose
23583|NCT00863174|Drug|SPARC147709|SPARC147709 injection
23584|NCT00863174|Drug|Reference147709|Reference147709 injection
23585|NCT00863187|Biological|rituximab|b cell depletion
23586|NCT00863200|Behavioral|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
23587|NCT00863200|Behavioral|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
23588|NCT00863213|Procedure|Atrial fibrillation ablation|Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.
It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested.
23589|NCT00863213|Drug|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
23590|NCT00863226|Device|Resonator Device|Application of Magnetic Fields Using the Resonator Device
23591|NCT00012168|Radiation|technetium Tc 99m sulfur colloid|
23592|NCT00863239|Drug|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight < 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight > 85 kg: 1200 mg/day.
23894|NCT00865891|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
23895|NCT00868127|Drug|Lapaquistat acetate|Participants from 01-04-TL-475-008 Monotherapy Study:
Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks.
27523|NCT00925782|Drug|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
27524|NCT00925795|Other|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
27525|NCT00925795|Other|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
27526|NCT00925808|Behavioral|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
27527|NCT00925821|Procedure|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
27528|NCT00019019|Drug|paclitaxel|
27529|NCT00928057|Device|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
27530|NCT00928057|Device|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
27531|NCT00928070|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg
27532|NCT00928070|Drug|Placebo|Placebo sham 4 mg and 8 mg
27533|NCT00928083|Drug|OZ439 50mg API capsules|
27555|NCT00920751|Procedure|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
27556|NCT00920751|Procedure|Air insufflation|Conventional air insufflation colonoscopy
27557|NCT00920764|Drug|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
27558|NCT00920764|Drug|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
27559|NCT00920764|Drug|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
27560|NCT00920764|Drug|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
27561|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 16 weeks
27562|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 8 weeks
23957|NCT00863850|Drug|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled [14C] bendamustine will be given on day 1 of cycle 1 only.
23958|NCT00863863|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
23959|NCT00863863|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
23960|NCT00863889|Drug|Depomedrol injection|1 cc of Depomedrol 80
23961|NCT00863889|Drug|Lidocaine, Marcaine|4 cc of each local anesthetic
23962|NCT00863902|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
23963|NCT00863902|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
23964|NCT00863915|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
23965|NCT00012207|Drug|prednisone|
23966|NCT00863915|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
23967|NCT00865891|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
23968|NCT00865904|Drug|VX-809|Capsules
23969|NCT00865904|Drug|Placebo|Placebo matched to VX-809 capsules.
23970|NCT00865917|Drug|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
23971|NCT00865917|Drug|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
23972|NCT00865917|Drug|Placebo|matching appearance
23973|NCT00865943|Drug|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
23974|NCT00865943|Drug|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
23975|NCT00865956|Behavioral|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
23976|NCT00012324|Drug|nolatrexed dihydrochloride|
23416|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
23417|NCT00862901|Device|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
23418|NCT00862927|Other|Breath Sample|Breathe into machine measuring carbon monoxide.
23419|NCT00862927|Other|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
23420|NCT00000794|Drug|Sulfadiazine|
23421|NCT00012168|Other|immunohistochemistry staining method|
23422|NCT00865020|Drug|Placebo to Telmisartan|Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
23720|NCT00867828|Dietary Supplement|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
23721|NCT00867828|Dietary Supplement|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
23722|NCT00012558|Drug|inositol|
23723|NCT00867841|Procedure|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
23724|NCT00867854|Other|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
23725|NCT00867867|Drug|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
23726|NCT00867867|Drug|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
23727|NCT00867867|Drug|Placebo|9.3 mg once per day, 6 days per week, for 9 months
23728|NCT00867880|Drug|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
23729|NCT00867906|Biological|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
23730|NCT00867906|Biological|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
23896|NCT00868127|Drug|Lapaquistat acetate and additional lipid-lowering therapy|Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:
Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.
Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks.
23897|NCT00868140|Drug|pioglitazone|pioglitazone 45 mg
23898|NCT00868140|Drug|Placebo|placebo daily
23899|NCT00868153|Drug|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
23900|NCT00868166|Drug|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
23901|NCT00868166|Drug|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
23902|NCT00868179|Drug|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
23903|NCT00012558|Behavioral|Interpersonal and Social Rhythms Therapy|
23904|NCT00868192|Drug|Pemetrexed|
23905|NCT00868192|Drug|Bevacizumab|
23906|NCT00868205|Dietary Supplement|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
23907|NCT00868218|Biological|Influenza vaccine|Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14
23908|NCT00868231|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
23909|NCT00868231|Drug|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
23910|NCT00868231|Drug|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
23911|NCT00868283|Drug|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
23912|NCT00868283|Drug|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
23913|NCT00868296|Drug|pantoprazole|
23914|NCT00012584|Drug|methylphenidate|
27563|NCT00920777|Behavioral|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
27564|NCT00920790|Biological|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
27565|NCT00018148|Drug|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
27566|NCT00920803|Drug|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
27567|NCT00920803|Drug|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
27568|NCT00920816|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
27569|NCT00920816|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
27570|NCT00920829|Drug|Drug|Naltrexone 25 or 50 mg per tiration schedule
27571|NCT00920829|Drug|Placebo|placebo
27572|NCT00920855|Drug|bendamustine|Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.
Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle.
27573|NCT00920855|Drug|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
27574|NCT00920868|Drug|dasatinib|dasatinib at 50 mg PO BID)
27575|NCT00923338|Device|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
26654|NCT00926861|Device|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
26655|NCT00926887|Device|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
26656|NCT00928824|Dietary Supplement|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
26657|NCT00928837|Other|Flavocoxid (Medical Food)|Limbrel 250 mg
26658|NCT00928837|Drug|Naproxen|500 mg
23977|NCT00865956|Other|Case management|Nurse case manager assigned to participant
22995|NCT00831480|Drug|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
22996|NCT00831493|Radiation|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
22997|NCT00831493|Drug|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
22998|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
22999|NCT00834132|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
23000|NCT00834145|Device|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
23001|NCT00834158|Procedure|TACE|1 time
23002|NCT00834158|Procedure|PVE|1 time
23003|NCT00008307|Procedure|syngeneic bone marrow transplantation|
23004|NCT00834171|Drug|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
23005|NCT00834171|Drug|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
23006|NCT00834184|Drug|nikkomycin Z|Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.
250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.
23007|NCT00834197|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
23008|NCT00834197|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
23009|NCT00834210|Drug|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
23010|NCT00834210|Drug|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
23011|NCT00834223|Device|Aquashunt|A shunt which is implanted into the suprachoroidal space.
23731|NCT00867919|Behavioral|Behavioral Family Treatment|11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:
parent-adolescent conflict
adolescent development
support and closeness
behavioral activation
response to adolescent negative affect
relapse prevention
suicide prevention, if necessary
23732|NCT00867919|Other|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
23733|NCT00000796|Drug|Ethionamide|
23734|NCT00012558|Drug|tranylcypromine|
23735|NCT00867932|Drug|Eculizumab|Eculizumab as an IV infusion.
Depending on the age of the patient, induction and maintenance doses vary as follows:
Cohort 1 (ages 2-7 years): Induction: 300mg/week x 4 weeks, then 450mg/week x 1 week; Cohort 1: Maintenance: 450mg every 2 weeks for 12 weeks, and a 8 week follow up period
Cohort 2: (ages 8 to 11 years)Induction: 300mg/week X 4 weeks then 600 mg/week x 1 week; Cohort 2: Maintenance: 600mg every 2 weeks for 12 weeks and a 8 week follow up period
Cohort 3: (ages 12 to 17 years) Induction: 600 mg/week x 4 weeks then 900mg/wee x 1 week; Cohort 3: maintenance: 900 mg every 2 weeks for 12 weeks and a 8 week follow up period.
23736|NCT00867958|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
23737|NCT00867971|Other|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
23738|NCT00870116|Radiation|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
24041|NCT00863941|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
24042|NCT00863941|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
24043|NCT00863954|Device|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
24044|NCT00863980|Drug|Micardis (Telmisartan)|40-80 mg/day oral administration
24045|NCT00863980|Drug|Blopress (Candesartan)|8-12 mg/day oral administration
24046|NCT00864006|Drug|Divalproex Sodium|
24047|NCT00864006|Drug|Depakote DR Tablets|
24048|NCT00864019|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
24049|NCT00012207|Drug|vincristine sulfate|
24050|NCT00864019|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
24051|NCT00864032|Drug|Sorafenib|400mg twice daily
22933|NCT00836706|Drug|clarithromycin|500 mg Tablet
22934|NCT00836706|Drug|BIAXIN®|500 mg Tablet
22935|NCT00836719|Drug|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
22936|NCT00008554|Drug|GW433908|
22937|NCT00836732|Procedure|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
22938|NCT00836745|Other|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
22939|NCT00836758|Device|REMstar Auto with A-Flex|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated.
22940|NCT00836771|Dietary Supplement|Infant Formula|
22941|NCT00836784|Other|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
22942|NCT00836784|Other|New tooth brush|The tooth brush which will be use in this study is "Jordan". A new Jordan toothbrush will be give to all children, and in "new tooth brush" group they will use these toothbrushes.
22943|NCT00836810|Drug|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
22944|NCT00836810|Drug|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
22945|NCT00836823|Drug|Alfuzosin|Alfuzosin 10mg once daily for 12 months
22946|NCT00836836|Other|Modified Atkins diet|Modified Atkins Diet administration
Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)
Fats (e.g. cream, butter, oils, ghee) encouraged.
Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.
Clear carbohydrate-fluids not restricted.
Calcium and multivitamin supplementation will be provided.
22947|NCT00008697|Drug|arsenic trioxide|
22948|NCT00836849|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
22949|NCT00836849|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
22950|NCT00836862|Other|Biologic specimens|Banking of serum, DNA and tissue
22951|NCT00839540|Drug|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
22952|NCT00009620|Drug|Saline|Infusion of normal sal
26659|NCT00928837|Other|Placebo|Placebo
26660|NCT00928837|Other|Limbrel|Medical food product
26661|NCT00928837|Drug|Naproxen|antiinflammatory
26662|NCT00928850|Procedure|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|Cancer cells can spill during surgery and this can cause cancer to return ("recur"). Some surgeons believe that "irrigating" could help stop spilling of cancer cells. "Irrigating" means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
26663|NCT00928850|Procedure|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches ("sutures") to the connective tissue ("fascia") could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
26664|NCT00019084|Biological|therapeutic tumor infiltrating lymphocytes|
26665|NCT00928850|Procedure|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
26666|NCT00928850|Procedure|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
26667|NCT00928863|Other|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
26668|NCT00928876|Drug|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
26669|NCT00928876|Drug|Placebo|placebo s/c daily for four weeks
26670|NCT00928889|Drug|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
26671|NCT00928889|Drug|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
26672|NCT00928902|Drug|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
26673|NCT00928902|Biological|melanoma vaccine|six melanoma vaccines given over a 6-week period
26956|NCT00929110|Drug|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
26957|NCT00929110|Drug|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
26958|NCT00929123|Procedure|neural mobilization|manual therapy technique known to directly stress the median nerve
23012|NCT00834236|Other|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
23013|NCT00834236|Other|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
23014|NCT00008320|Drug|ceramide|
23334|NCT00000775|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
23335|NCT00008866|Biological|Tetanus Toxoid Vaccine|
23336|NCT00837590|Drug|salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
23337|NCT00837590|Drug|metformin|metformin po 1000mg bid
23338|NCT00837590|Drug|lisinopril|lisinopril po 20mg qd
23339|NCT00837603|Behavioral|Training|Controlled home ergometer training
23340|NCT00837616|Drug|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
23341|NCT00837616|Drug|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
23342|NCT00837642|Dietary Supplement|Vitamin C and E|
23343|NCT00867113|Drug|imatinib mesylate|imatinib mesylate 400 mg once per day by mouth for 5 years.
23344|NCT00867126|Drug|pioglitazone hydrochloride|
23345|NCT00000796|Drug|Cycloserine|
23346|NCT00012506|Drug|TNFR:Fc|
23347|NCT00867126|Other|laboratory biomarker analysis|
23348|NCT00867126|Other|questionnaire administration|
23349|NCT00867126|Procedure|quality-of-life assessment|
23350|NCT00867139|Drug|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
24052|NCT00864045|Drug|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
24053|NCT00864045|Drug|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
24054|NCT00864058|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
24055|NCT00864058|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
24056|NCT00864071|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
24057|NCT00864071|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
24058|NCT00864084|Other|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
24059|NCT00864097|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
24060|NCT00012207|Procedure|adjuvant therapy|
24061|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
24062|NCT00864097|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
23080|NCT00831532|Drug|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
23081|NCT00831545|Drug|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
23082|NCT00831597|Drug|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
23083|NCT00831597|Drug|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
23084|NCT00831610|Procedure|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
23085|NCT00831610|Procedure|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
23086|NCT00008216|Procedure|Peripheral Blood Stem Cell Transplantation|
23087|NCT00831623|Radiation|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
22953|NCT00839553|Procedure|Intrapleural Minocycline application|
22954|NCT00839566|Procedure|Ablation|AV-node ablation
23272|NCT00840359|Procedure|Cryotherapy|Cryotherapy for 2 times 20 sec
23273|NCT00840372|Procedure|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
23274|NCT00831883|Behavioral|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
23275|NCT00831896|Biological|TAK-701|Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks
Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy.
23276|NCT00831922|Drug|masitinib (AB1010)|3 mg/kg/day
23277|NCT00831922|Drug|masitinib (AB1010)|6 mg/kg/day
23278|NCT00831948|Genetic|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
23279|NCT00831961|Procedure|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
23280|NCT00831974|Drug|masitinib (AB1010)|3 mg/kg/day
23281|NCT00831974|Drug|masitinib (AB1010)|6 mg/kg/day
23282|NCT00008229|Radiation|holmium Ho 166 DOTMP|
23283|NCT00831987|Biological|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
23284|NCT00831987|Biological|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
23285|NCT00832000|Drug|Mexiletine|200 mg three times a day; in pill form
23286|NCT00832000|Drug|Placebo|Placebo three times a day; in pill form
23287|NCT00832013|Drug|Propofol|See detailed description
23288|NCT00832013|Drug|Propofol|See detailed description
23289|NCT00832026|Device|Trans Nasal Insuflation (TNI) [nasal canula]|Trans Nasal Insuflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.
By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing.
26959|NCT00922285|Procedure|stress management therapy|6 weekly 60 minute sessions
26960|NCT00922311|Drug|Aliskiren|Titrate from 150 mg daily to 300 mg daily
26961|NCT00922324|Drug|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
26962|NCT00922337|Device|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
26963|NCT00922350|Other|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
26964|NCT00922350|Other|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
26965|NCT00922350|Other|HELIOX+POSTURE|Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece "Y" with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th .
26966|NCT00922350|Other|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
26967|NCT00922363|Biological|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
26968|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
26969|NCT00018265|Behavioral|Task specific endurance training|
26970|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
26971|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
26972|NCT00922376|Device|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
27226|NCT00922753|Other|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
27227|NCT00018291|Drug|Risperidone|
23351|NCT00867139|Drug|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
23352|NCT00867139|Other|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
23353|NCT00867152|Drug|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
23354|NCT00867152|Drug|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
23655|NCT00870038|Device|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
23656|NCT00870038|Device|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
23657|NCT00870038|Device|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
23658|NCT00870051|Device|Endurant Stent Graft|Endurant Stent Graft implantation
23659|NCT00870064|Procedure|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
23660|NCT00870064|Procedure|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
23661|NCT00870077|Dietary Supplement|ProWHEY 94 CFM, SponserR|3 times 20g per day
23662|NCT00870103|Drug|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
23663|NCT00000796|Drug|Streptomycin sulfate|
23664|NCT00012935|Behavioral|Help with decision making on prostate cancer treatment|
23665|NCT00870116|Radiation|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
23666|NCT00863239|Drug|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
23667|NCT00863239|Drug|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
23668|NCT00863252|Drug|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
23669|NCT00863252|Drug|angiotensin blockade|Continuation of angiotensin blockade
23088|NCT00831623|Radiation|Proton|As above
23089|NCT00831636|Drug|CP-4055|D1-5 and D8(+2)-12(+2) q4w
23090|NCT00831636|Drug|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
23091|NCT00831649|Drug|TYSABRI (natalizumab)|
23092|NCT00831662|Drug|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
23093|NCT00831662|Drug|Placebo|One to two drops in each eye QID for 6 weeks
23094|NCT00831675|Biological|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
23095|NCT00831675|Biological|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
23096|NCT00831688|Device|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
23097|NCT00008229|Biological|filgrastim|
23098|NCT00831688|Device|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
23099|NCT00831701|Drug|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
23100|NCT00834301|Dietary Supplement|Oral Multivitamin|Oral Multivitamin
23101|NCT00000774|Biological|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
23423|NCT00865033|Drug|Metformin HCL Tablets, 1000 mg Sandoz|
23424|NCT00865033|Drug|Glucophage 1000 mg|
23425|NCT00865046|Other|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
23426|NCT00865046|Other|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
23427|NCT00865059|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
23428|NCT00865059|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
23290|NCT00832039|Drug|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
23291|NCT00832039|Drug|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
23593|NCT00865306|Behavioral|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|This is a cognitive-behavioral intervention modeled loosely after Kendall's "Coping Cat," which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments.
23594|NCT00012311|Drug|docetaxel|
23595|NCT00865319|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
23596|NCT00865319|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
23597|NCT00865345|Device|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
23598|NCT00865358|Behavioral|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
23599|NCT00865371|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
23600|NCT00865371|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
23601|NCT00865384|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
23602|NCT00865384|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
23603|NCT00865397|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
23604|NCT00865410|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
23605|NCT00012311|Drug|doxorubicin hydrochloride|
23606|NCT00865410|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
23607|NCT00865423|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
27228|NCT00922766|Drug|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).
27229|NCT00922779|Drug|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
27230|NCT00922779|Drug|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
27231|NCT00922792|Drug|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
27232|NCT00922792|Drug|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
27233|NCT00922805|Dietary Supplement|guar gum|guar gum (20 g/l of formula) for one week
27234|NCT00922844|Drug|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
27235|NCT00922857|Procedure|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
27236|NCT00922870|Device|Cascade|Cascade treatment over 48h
27237|NCT00922870|Other|Standard treatment|Standard therapy
27238|NCT00018291|Drug|Gabapentin|
27239|NCT00922883|Drug|Eltrombopag (Promacta)|
27240|NCT00922883|Drug|Eltrombopag|
27241|NCT00922896|Drug|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|Erlotinib 100 mg po q d daily AND
Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8
Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8
Every 3 weeks
27242|NCT00922909|Behavioral|Simon task|Reaction time task
27243|NCT00922935|Device|Cresco|Cresco components loading 10 days post surgery
27244|NCT00922935|Device|Cresco|Cresco loading at 6-8 weeks post surgery
27245|NCT00922935|Device|Straumann components|Straumann components loading 6-8 weeks post surgery
27246|NCT00922948|Procedure|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
27576|NCT00923351|Drug|Tumor Purged/CD25 Depleted Lymphocytes|
23670|NCT00863265|Drug|Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols|Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.
23671|NCT00863278|Procedure|pulsed dye laser treatment|On one side of the face according to Arm placement.
23672|NCT00863278|Drug|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
23673|NCT00863291|Drug|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
23674|NCT00863291|Drug|placebo|Placebo in a manner similar to the active comparator
23675|NCT00012181|Drug|alvocidib|Given IV
23978|NCT00865969|Drug|PXD101|Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of every 3-week cycle
23979|NCT00865982|Drug|Docetaxel, Cisplatin, Capecitabine|3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks
followed by resection
and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks.
23980|NCT00865995|Procedure|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
23981|NCT00866008|Drug|Ovarian stimulation|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment
Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
23982|NCT00866021|Drug|Lopinavir/ritonavir|NRTI sparing-regimen
23983|NCT00866021|Drug|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
23984|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
23985|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
23986|NCT00866047|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
23987|NCT00012337|Drug|gefitinib|
23988|NCT00866060|Drug|Memantine|20mg memantine
23989|NCT00866060|Drug|Donepezil|10mg donepezil
23990|NCT00866060|Drug|Placebo donepezil|Placebo donepezil
23471|NCT00869726|Drug|dirucotide|500mg, intravenous, dosed once every six months for 18 months
23472|NCT00869726|Drug|Placebo|intravenous, once every six months for 18 months
23473|NCT00869739|Behavioral|telephone-based intervention|
23474|NCT00869739|Other|educational intervention|
23475|NCT00869739|Other|partner-assisted coping skills training|
23476|NCT00869739|Other|questionnaire administration|
23477|NCT00869739|Procedure|psychosocial assessment and care|
23478|NCT00012870|Behavioral|Behavioral Management|
23479|NCT00869739|Procedure|quality-of-life assessment|
23480|NCT00869752|Biological|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
23481|NCT00869752|Drug|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
23482|NCT00869752|Drug|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
23483|NCT00869765|Drug|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
23484|NCT00869765|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
23485|NCT00869778|Biological|The therapeutic (synthesized peptide) HBV vaccine (εPA-44)|The therapeutic (synthesized peptide) HBV vaccine (εPA-44)
23486|NCT00869778|Biological|Placebo|Placebo
23780|NCT00863551|Drug|Trospium Chloride|Extended release, 60 mg, oral daily
23781|NCT00863564|Dietary Supplement|Caseine|
23782|NCT00863564|Dietary Supplement|Cod|
23783|NCT00863564|Dietary Supplement|Gluten|
23784|NCT00863564|Dietary Supplement|Whey Isolate|
22888|NCT00831181|Drug|oxaliplatin|
22889|NCT00008203|Drug|cyclophosphamide|
22890|NCT00831181|Procedure|adjuvant therapy|
22891|NCT00831181|Procedure|neoadjuvant therapy|
22892|NCT00831181|Procedure|quality-of-life assessment|
23209|NCT00834574|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
23210|NCT00834587|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
23211|NCT00834587|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
23212|NCT00834600|Drug|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
23213|NCT00834600|Drug|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
23214|NCT00834613|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
23215|NCT00834613|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
23216|NCT00008359|Drug|caspofungin acetate|
23217|NCT00834626|Procedure|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
23218|NCT00834639|Drug|divalproex sodium|delayed-release 500 mg tablet
23219|NCT00834639|Drug|Depakote®|delayed-release 500 mg tablet
23220|NCT00834652|Drug|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
23221|NCT00834652|Drug|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
23222|NCT00834665|Biological|Telomerase (hTERT vaccine + pneumococcal conjugate vaccine (PCV))|One vaccination prior to autologous transplant and 3 vaccination after autologous transplant.
23223|NCT00834665|Biological|PCV vaccine|Receipt of PCV vaccine and GM-CSF injections prior to autologous transplant and post transplant
23224|NCT00834678|Drug|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
24262|NCT00868790|Drug|Comparator: Placebo to MK3577|Placebo to MK3577 tablets twice daily for 4 weeks
24263|NCT00868790|Drug|MK3577|MK3577 tablets totaling 10 mg once daily in the morning for 4 weeks.
24264|NCT00868790|Drug|Comparator: metformin|Metformin tablets 1000 mg twice daily for 4 weeks.
24265|NCT00868790|Drug|MK3577|MK3577 tablets totaling 6 mg once daily in the evening for 4 weeks.
24266|NCT00868790|Drug|MK3577|MK3577 tablets totaling 25 mg twice daily for 4 weeks.
24267|NCT00868816|Drug|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
24268|NCT00868816|Drug|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
24269|NCT00868829|Device|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
24270|NCT00012688|Procedure|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
24544|NCT00869336|Drug|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
24545|NCT00869336|Drug|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
24546|NCT00869336|Drug|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
24547|NCT00869336|Drug|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
24548|NCT00862329|Dietary Supplement|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
24549|NCT00862329|Dietary Supplement|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
24550|NCT00862342|Drug|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
24551|NCT00862355|Drug|SPARC147609|IV infusion
24552|NCT00862355|Drug|Reference147609|IV infusion
24553|NCT00012103|Procedure|computed tomography|
24554|NCT00862368|Behavioral|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
25241|NCT00861393|Behavioral|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
25242|NCT00861406|Drug|Pegylated Interferon-Alfa 2b (PEG Intron)|Group 1:
6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.
Group 2:
6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.
Group 3:
6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks.
25243|NCT00012051|Drug|ifosfamide|
25244|NCT00861406|Drug|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
25245|NCT00861419|Drug|Sorafenib|Sorafenib 400 mg PO (BID)
25246|NCT00861419|Drug|AMG 706|AMG 706 125 mg PO (QD)
25247|NCT00861419|Drug|AMG 706|AMG 706 75 mg PO (QD)
25248|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of RCC and will be administered to all subjects.
25249|NCT00853372|Drug|AMG386|10 mg/kg IV QW AMG 386 will be administered until a subject develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
24335|NCT00866515|Drug|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
24336|NCT00000203|Drug|Buprenorphine|
24337|NCT00000795|Biological|HIV-1 Peptide Immunogen, Multivalent|
24338|NCT00012376|Other|pharmacological study|Correlative studies
24339|NCT00866528|Drug|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
24340|NCT00866528|Drug|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
24341|NCT00866541|Device|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
24342|NCT00866554|Drug|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
24343|NCT00866554|Drug|administration of Bicalutamide, Dutasteride and Tamoxifen|Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.
Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride
Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered.
24344|NCT00866580|Biological|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
23785|NCT00863577|Drug|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
23786|NCT00012194|Other|laboratory biomarker analysis|Correlative studies
23787|NCT00863590|Drug|odanacatib|[Intervention Name: odanacatib (Panel A)] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
23788|NCT00865566|Biological|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
23789|NCT00865566|Biological|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
23790|NCT00865579|Drug|Safinamide|The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).
Trial Medication is to be taken once daily, in the morning.
23791|NCT00865592|Drug|dutogliptin|dutogliptin 400 mg, once daily tablet
23792|NCT00865605|Drug|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
23793|NCT00865605|Drug|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
23794|NCT00865618|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
23795|NCT00865618|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
23796|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
23797|NCT00012311|Drug|methotrexate|
23798|NCT00865631|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
23799|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
23800|NCT00865644|Drug|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
23801|NCT00865657|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
22806|NCT00831116|Device|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
22807|NCT00833768|Drug|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
23225|NCT00834678|Drug|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
23226|NCT00008827|Behavioral|Behavioral weight loss|
23227|NCT00837265|Drug|Pegfilgrastim|6mg
23228|NCT00837291|Drug|CF101|CF101 tablets 1 mg BID
23229|NCT00837291|Drug|Placebo|Placebo tablets BID
23230|NCT00837304|Device|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
23544|NCT00867490|Drug|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
23545|NCT00867490|Drug|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
23546|NCT00867490|Drug|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
23547|NCT00867503|Drug|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
23548|NCT00867516|Biological|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
23549|NCT00867516|Biological|Infusion without ALD518`|250 cc Normal saline IV over one hour Weeks 1 and 8.
23550|NCT00867529|Biological|rituximab|Given IV
23551|NCT00867529|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
23552|NCT00867529|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
23553|NCT00012558|Drug|paroxetine|
23554|NCT00867529|Other|pharmacological study|Correlative studies
23555|NCT00867529|Other|laboratory biomarker analysis|Correlative studies
24555|NCT00862368|Behavioral|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
24556|NCT00862368|Behavioral|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
24557|NCT00862381|Drug|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
24558|NCT00862381|Drug|Placebo|NaCl 0.9%
24559|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
24560|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
24561|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
24562|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
24826|NCT00855283|Drug|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
24827|NCT00855309|Drug|acyclovir sodium|Given IV
24828|NCT00855322|Other|Gym exercise group intervention|Gym based circuit class
24829|NCT00011089|Drug|Tenofovir disoproxil fumarate|
24830|NCT00855322|Other|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
24831|NCT00855322|Other|Control group|No intervention
24832|NCT00855335|Drug|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
24833|NCT00855335|Drug|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
24834|NCT00855335|Drug|Etravirine|Two 200 mg tablets twice daily up to 12 weeks postpartum.
24835|NCT00855335|Drug|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
24345|NCT00866580|Biological|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
24346|NCT00866580|Biological|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
24347|NCT00866593|Drug|Generic Escitalopram|10mg/d or 20mg/d
24348|NCT00866593|Drug|Innovator Escitalopram|10mg/d or 20mg/d
24349|NCT00012389|Drug|irinotecan hydrochloride|
24350|NCT00866606|Biological|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
24351|NCT00866619|Biological|Malaria Vaccine 257049|Vaccine, 0.5mL per dose
24352|NCT00012714|Behavioral|Case management services|
24353|NCT00868933|Other|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
24354|NCT00868933|Other|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
24626|NCT00869401|Other|placebo|Given orally
24627|NCT00869401|Radiation|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
24628|NCT00869414|Drug|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
24629|NCT00869414|Drug|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
24630|NCT00869414|Drug|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
24631|NCT00869427|Drug|vitamin C|vitamin C 1g bid for 1 year
24632|NCT00012805|Procedure|Telephone Monitoring|
24633|NCT00869440|Drug|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
24634|NCT00869440|Drug|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
24635|NCT00869453|Other|test meal|Mixed meal containing bread, butter, beef
24636|NCT00869453|Other|glucose|administration of a glucose meal
22808|NCT00833781|Biological|mRNA-transfected autologous dendritic cells|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
22809|NCT00833781|Biological|autologous dendritic cells with no mRNA transfection|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
22810|NCT00833794|Drug|Tramadol Once a day|
22811|NCT00833794|Drug|Placebo|
22812|NCT00008307|Drug|methylprednisolone|
22813|NCT00833807|Drug|Nab-Paclitaxel (Abraxane)|Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.
Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days.
22814|NCT00833820|Procedure|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
22815|NCT00833820|Procedure|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
22816|NCT00833833|Drug|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
22817|NCT00833833|Drug|Dexamethasone|oral dexamethasone
22818|NCT00833833|Drug|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
22819|NCT00833859|Drug|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
22820|NCT00833859|Radiation|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
22821|NCT00833872|Drug|LEO 22811|First-in-man
22822|NCT00833872|Drug|placebo solution|
22823|NCT00008307|Drug|mycophenolate mofetil|
22824|NCT00833885|Device|Masks|Wearing of surgical masks
22825|NCT00833885|Device|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
22826|NCT00833885|Other|Control|General information about virus transmission in households and basic means to prevent it
25110|NCT00011297|Drug|gabapentin (Neurontin)|
25111|NCT00855959|Drug|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
25112|NCT00855972|Drug|Low Dose Naltrexone|
25113|NCT00855985|Procedure|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
25114|NCT00856024|Biological|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
24198|NCT00870935|Procedure|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
24199|NCT00870935|Procedure|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
24200|NCT00870948|Drug|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
24201|NCT00870961|Dietary Supplement|cholecalciferol|Given orally
24202|NCT00870961|Other|placebo|Given orally
24203|NCT00870974|Drug|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]F-PEB
24204|NCT00870987|Biological|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
24205|NCT00013091|Behavioral|Self-management therapy; Psychoeducational group therapy|
24206|NCT00870987|Biological|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
24207|NCT00871000|Biological|Boostrix Polio™ 711866|Single dose, intramuscular administration.
24208|NCT00871000|Biological|Priorix Tetra TM 208136|Single dose, subcutaneously.
24209|NCT00871000|Biological|Tetravac TM|Single dose, intramuscular administration.
24210|NCT00871013|Drug|Velcade, Revlimid, Dexamethasone, Melphalan, Cisplatin, Thalidomide|First Transplant Bortezomib (Velcade) By vein Day -5 and Day -2
First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4
Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4
Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2
Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days
Years 2 & 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days
24211|NCT00871026|Procedure|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
24836|NCT00855335|Drug|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
24837|NCT00855348|Other|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
24838|NCT00855361|Drug|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
24839|NCT00855387|Other|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
24840|NCT00011102|Behavioral|Weight Gain Prevention for Women Project|
24841|NCT00855400|Procedure|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
24842|NCT00855400|Procedure|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
24843|NCT00855413|Drug|Darunavir/Ritonavir and Etravirine|DRV/r will be administered 800 mg/100 mg orally once daily.
ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen.
24844|NCT00855439|Drug|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
25178|NCT00853307|Drug|MLN8237|MLN8237 will be given by mouth in a dosage of 50 mg twice a day for 7 Days (Days 1-7) of each 21-day treatment cycle.
25179|NCT00853320|Drug|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
25180|NCT00853320|Drug|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
25181|NCT00853333|Drug|dexmedetomidine|
25182|NCT00010868|Drug|Omega-3 Fatty Acids|
25183|NCT00853333|Drug|midazolam|
25184|NCT00853333|Drug|propofol|
25185|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
25186|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
24637|NCT00869453|Other|fat|administration of a lipid meal
24638|NCT00869453|Other|protein|administration of a protein meal
24639|NCT00869453|Other|control|no meal
24640|NCT00869466|Behavioral|behavioral dietary intervention|
24641|NCT00869466|Behavioral|exercise intervention|
24642|NCT00869466|Other|counseling intervention|
24643|NCT00862459|Drug|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
24644|NCT00862459|Drug|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
24645|NCT00862459|Drug|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
24646|NCT00862472|Drug|DuoTrav APS|DuoTrav APS QD AM
24647|NCT00862472|Drug|DuoTrav|DuoTrav QD AM
24648|NCT00012116|Drug|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
24903|NCT00852995|Biological|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
24904|NCT00852995|Biological|Placebo (Vehicle)|Placebo (Vehicle) consisting of:
Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution
24905|NCT00853008|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
24906|NCT00853008|Drug|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
24907|NCT00853008|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
24908|NCT00010829|Behavioral|American Heart Association Step 2 diet + 10 g/day flax seed|
24909|NCT00853008|Drug|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
24910|NCT00853008|Drug|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
23142|NCT00837239|Drug|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
23143|NCT00837239|Drug|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
23144|NCT00837239|Drug|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
23145|NCT00837252|Drug|Finasteride|Participants received 5mg of oral finasteride daily for three months.
23146|NCT00837265|Biological|Neugranin|Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor)at two dose levels or comparator (pegfilgrastim 6 mg) administered approximately 24 hours following chemotherapy for 4 treatment cycles
23147|NCT00839969|Procedure|Cystoscopy|Saline cystoscopy under general anaesthesia
23148|NCT00839969|Procedure|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
23149|NCT00839982|Drug|clofarabine|Given PO
23150|NCT00839982|Drug|cytarabine|Given SC
23151|NCT00840008|Other|Educational intervention|As per detailed protocol.
23152|NCT00840034|Drug|LY2216684|Starting dose is 6 mg, then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered PO QD for up to 12 weeks
23153|NCT00009672|Drug|Nortriptyline|
23154|NCT00840034|Drug|Placebo|3 tablets PO QD for up to 12 weeks
23155|NCT00840047|Drug|Methionine|Intravenous injection
23156|NCT00840060|Behavioral|AMALS|Addressing multiple aspects of language simultaneously
23157|NCT00840060|Behavioral|DTA|Discrete Trial Approach
23158|NCT00840073|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
23159|NCT00840073|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
23160|NCT00840086|Drug|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
23161|NCT00840099|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
23162|NCT00840099|Drug|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
24212|NCT00871026|Procedure|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
24213|NCT00871039|Drug|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
24214|NCT00871039|Drug|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
24215|NCT00871052|Drug|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
24216|NCT00013117|Behavioral|Telephone specialist consultation|
24217|NCT00871065|Drug|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
24218|NCT00871078|Device|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
24486|NCT00864591|Procedure|Stress Adenosine CMR|CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.
Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography.
24487|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
24488|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
24489|NCT00864617|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
24490|NCT00864617|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
24491|NCT00864630|Behavioral|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
24492|NCT00012298|Biological|rituximab|Given IV
24493|NCT00864643|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
24494|NCT00864643|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
24495|NCT00864669|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
25187|NCT00856024|Drug|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
25188|NCT00856037|Drug|Doxorubicin Hydrochloride|Given IV
25189|NCT00856037|Other|Laboratory Biomarker Analysis|Correlative studies
25190|NCT00856037|Other|Quality-of-Life Assessment|Ancillary studies
25191|NCT00856037|Drug|Topotecan Hydrochloride|Given PO
25192|NCT00856050|Drug|letrozole|Taken orally once a day continuously
25193|NCT00011297|Drug|lorazepam (Ativan)|
25194|NCT00856063|Drug|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
25195|NCT00856089|Drug|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
25196|NCT00856102|Behavioral|Exercise|Home-base walking program
25197|NCT00856102|Behavioral|Control|Usual care
25198|NCT00856115|Other|medical chart review|Patient charts are reviewed to obtain medical data.
24271|NCT00868855|Drug|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
24272|NCT00868894|Drug|DE-104 medium concentration|Topical ocular application
24273|NCT00868894|Drug|DE-104 high concentration|Topical ocular application
24274|NCT00868894|Drug|Placebo|Topical ocular application
24275|NCT00868894|Drug|0.005% latanoprost|Topical ocular application
24276|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
24277|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
24278|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
24911|NCT00853008|Drug|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
24912|NCT00853008|Drug|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
24913|NCT00853008|Drug|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
24914|NCT00855452|Procedure|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
24915|NCT00855465|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
24916|NCT00855465|Drug|Placebo|Matching Placebo tid orally for 16 weeks
24917|NCT00855478|Device|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
24918|NCT00855491|Procedure|Phaco|AcrySof Single-Piece IOL
24919|NCT00000788|Drug|Fluconazole|
24920|NCT00011115|Behavioral|Weight loss motivations|
24921|NCT00855517|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
24922|NCT00855530|Drug|amibegron (SR58611A)|oral administration of 300 mg twice daily
25250|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of RCC and will be administered to all subjects.
25251|NCT00853372|Drug|AMG 386|15 mg/kg IV QW AMG 386 will be administered until a subject develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
25252|NCT00853385|Drug|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
25253|NCT00853385|Drug|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
25254|NCT00010881|Drug|antioxidants|
25255|NCT00853385|Other|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
25256|NCT00853385|Other|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
25257|NCT00853385|Biological|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
23163|NCT00840112|Dietary Supplement|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
23164|NCT00009672|Drug|Morphine|
23487|NCT00869791|Drug|IPX066|IPX066
23488|NCT00869791|Drug|CD-LD|CD-LD
23489|NCT00012883|Behavioral|Homewalking exercise program|
23490|NCT00869804|Behavioral|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
23491|NCT00869804|Behavioral|Attention control|
23492|NCT00869830|Other|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
23493|NCT00869843|Procedure|RF Ablation|
23494|NCT00862927|Behavioral|Questionnaire|6 surveys, taking approximately 30 minutes total.
23495|NCT00862927|Behavioral|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
23496|NCT00862940|Drug|Memantine|10 mg tablets twice daily
23497|NCT00862940|Drug|Placebo|Tablets twice daily
23498|NCT00862953|Dietary Supplement|Normal protein energy-restricted|Normal protein diet energy restricted
23499|NCT00862953|Dietary Supplement|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
23500|NCT00862966|Other|citrate|comparison of different catheter lock solutions
23501|NCT00862966|Other|heparin|comparison of different lock solutions
23502|NCT00862979|Drug|Sandimmun Optoral / Tac + RAD001|RAD001 / CNI group
23503|NCT00862979|Drug|MPA + RAD001|RAD001 / MPA group
23504|NCT00012168|Procedure|lymphangiography|
23505|NCT00862992|Drug|Cariprazine low dose|
23506|NCT00862992|Drug|Cariprazine medium dose|
24496|NCT00864669|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
24497|NCT00864682|Drug|Saline|3.3 mL normal saline
24498|NCT00864682|Drug|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
24499|NCT00864682|Drug|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
24500|NCT00864695|Other|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
24501|NCT00864708|Device|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
24502|NCT00864721|Drug|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
24503|NCT00866697|Drug|Pazopanib|Pazopanib 800 mg daily for 104 weeks (24 months)
24768|NCT00857870|Drug|Metformin|Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.
Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.
After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose.
24769|NCT00857870|Drug|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
24770|NCT00857883|Drug|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
24771|NCT00857896|Drug|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
24772|NCT00011895|Drug|Efavirenz|
24773|NCT00857909|Drug|Amiloride|1 tablet twice a day
24774|NCT00857909|Drug|Spironolactone|1 tablet twice a day
24775|NCT00857909|Drug|Placebo|Placebo
24776|NCT00857909|Drug|Placebo and spironolactone|5mg twice daily
24777|NCT00857909|Drug|Spironolactone|25mg twice daily
24279|NCT00868920|Other|patient control of pump|Patient controls sedation pump during colonoscopy.
24280|NCT00868920|Other|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
24281|NCT00861861|Drug|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
24282|NCT00861861|Drug|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
24283|NCT00861874|Drug|Decitabine|20 mg/m2 IV, Days 1-5
24284|NCT00861874|Drug|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
24285|NCT00861887|Drug|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
24286|NCT00861887|Drug|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
24287|NCT00861913|Other|Laboratory Biomarker Analysis|Correlative studies
24288|NCT00861913|Drug|Pazopanib Hydrochloride|Given orally
24289|NCT00861913|Other|Pharmacological Study|Correlative studies
24290|NCT00012090|Drug|goserelin acetate|
24291|NCT00861926|Drug|Ventolin|Ventolin : salbutamol sulfate 100µg
24292|NCT00861926|Drug|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
24293|NCT00861939|Drug|Bupropion HCI 300 mg Extended-Release Tablets EON|
24563|NCT00862420|Drug|clopidogrel (SR25990)|oral administration (tablets)
24564|NCT00012103|Procedure|study of high risk factors|
24565|NCT00862420|Drug|ticlopidine|oral administration (tablets)
24566|NCT00862433|Dietary Supplement|Vitamin E|
24567|NCT00862433|Dietary Supplement|Vitamin C|
24568|NCT00862446|Drug|Omegaven|1 gram/kg/day daily until on feeds
24569|NCT00862459|Drug|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
24570|NCT00012298|Biological|yttrium Y 90 ibritumomab tiuxetan|Given IV
25258|NCT00853398|Procedure|surgical technique|
25259|NCT00853411|Drug|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
25260|NCT00853424|Procedure|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
25261|NCT00853424|Other|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
25262|NCT00853450|Drug|AZD6482|Single intravenous infusion during a maximum of 5 hours
25263|NCT00853450|Drug|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
25264|NCT00853450|Drug|ASA|75 mg orally once daily during 7 days in each treatment arm
25265|NCT00010881|Behavioral|stress reduction|
25266|NCT00853463|Behavioral|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
25267|NCT00853489|Device|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
25268|NCT00853489|Procedure|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
25269|NCT00853502|Drug|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
24355|NCT00868946|Drug|Virazole (Ribavirin)|Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.
Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
24356|NCT00868959|Drug|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
24357|NCT00868972|Procedure|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
24358|NCT00868972|Device|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
24359|NCT00868985|Drug|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
23507|NCT00862992|Drug|Cariprazine high dose|
23508|NCT00863005|Drug|K201|Cream
23509|NCT00863005|Drug|K201|
23510|NCT00863031|Behavioral|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
23511|NCT00863031|Behavioral|Video-viewing|Three sessions of viewing health educational videos.
23802|NCT00865657|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under non-fasting conditions
23803|NCT00865670|Drug|Azithromycin Monohydrate 600 mg Tablets|
23804|NCT00865670|Drug|Zithromax (azithromycin dihydrate) 600 mg Tablets|
23805|NCT00865683|Dietary Supplement|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
23806|NCT00865683|Dietary Supplement|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
23807|NCT00865696|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
23808|NCT00012311|Drug|thiotepa|
23809|NCT00865696|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
23810|NCT00865709|Drug|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
23811|NCT00865709|Drug|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
23812|NCT00867984|Other|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
23813|NCT00867984|Other|Usual Care|AV optimization (VTI) only
23814|NCT00867997|Other|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
23815|NCT00867997|Other|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
23816|NCT00867997|Other|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
24778|NCT00857922|Other|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
24779|NCT00857935|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
24780|NCT00857935|Drug|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
24781|NCT00860418|Behavioral|Standard asthma education|Standard asthma education during 2 home visits.
24782|NCT00860431|Drug|AST-120|6g/day (3 times a day)
24783|NCT00860444|Behavioral|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
24784|NCT00860444|Behavioral|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
24785|NCT00860457|Drug|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
24786|NCT00860457|Drug|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
24787|NCT00860457|Drug|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
25115|NCT00858481|Drug|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
25116|NCT00011921|Drug|ifosfamide|
25117|NCT00858481|Drug|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
25118|NCT00858481|Drug|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
25119|NCT00858494|Drug|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
25120|NCT00858507|Behavioral|Personal Health Assessment/brief intervention|RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
25121|NCT00858507|Behavioral|Social work administered outreach|Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
25122|NCT00858533|Behavioral|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
24571|NCT00864734|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
24572|NCT00864734|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
24573|NCT00864747|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
24574|NCT00864747|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
24575|NCT00864760|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
24576|NCT00864760|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
24577|NCT00864773|Procedure|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
24578|NCT00864786|Drug|PF03635659|Inhaled doses of 200 mcgQD
24579|NCT00864786|Drug|PF03635659|Inhaled doses of 600 mcg QD
24580|NCT00864786|Drug|PF03635659|Inhaled doses of 1000 mcg QD
24581|NCT00012298|Biological|indium In 111 ibritumomab tiuxetan|Given IV
24582|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
24583|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
24584|NCT00864799|Drug|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
24845|NCT00855439|Drug|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
24846|NCT00857948|Drug|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
24847|NCT00857948|Drug|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
24848|NCT00011908|Drug|hLL2 (Epratuzumab)|
24849|NCT00857961|Drug|Testosterone MD-Lotion|Administered Topically
24360|NCT00868985|Drug|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
24361|NCT00868998|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
24362|NCT00869011|Other|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
24363|NCT00012727|Procedure|Matching Symptom Severity to Service Intensity|
24364|NCT00869024|Biological|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
24365|NCT00869037|Drug|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
24366|NCT00869037|Drug|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
24367|NCT00869050|Drug|Capecitabine|Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles
After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle.
24368|NCT00869050|Drug|Temozolomide|Temozolomide 150-200 mg/m2/day (PO divided BID).
Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles
After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle.
24369|NCT00869063|Drug|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
24649|NCT00862498|Other|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
24650|NCT00862511|Device|Total Knee Arthroplasty (TKA)|Implantation of a TKA, either specially coated or normal
24651|NCT00862524|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
24652|NCT00862524|Drug|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
24653|NCT00862537|Device|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
23817|NCT00868010|Drug|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
23818|NCT00868010|Drug|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
23819|NCT00012558|Behavioral|Cognitive Behavioral Therapy|
23820|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
23821|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
23822|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
22827|NCT00833898|Device|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
22828|NCT00008554|Drug|Abacavir sulfate|
22829|NCT00836485|Drug|Olopatadine 0.2%|1 gtt/eye on two separate occasions
22830|NCT00836485|Drug|Artificial tears|1 gtt/eye on two separate occasions
22831|NCT00836498|Biological|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
22832|NCT00836498|Biological|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
22833|NCT00836498|Biological|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
22834|NCT00836524|Procedure|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
22835|NCT00836537|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
22836|NCT00836537|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
22837|NCT00836550|Behavioral|Video|The participants saw a 6 minute video
22838|NCT00836550|Behavioral|in-person HIV pre-test counseling|
25123|NCT00858546|Device|Repetitive transcranial stimulation|Repetitive transcranial stimulation
25124|NCT00858559|Device|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
25125|NCT00858559|Device|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
25126|NCT00858572|Drug|STA-9090 (ganetespib)|Chemotherapy agent
25127|NCT00011921|Drug|paclitaxel|
25128|NCT00858611|Drug|VRC-FLUDNA047-00-VP|
25129|NCT00858611|Drug|Flulaval (Registered) Seasonal Influenza Vaccine|
25130|NCT00858624|Drug|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
25131|NCT00858637|Drug|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
25132|NCT00858637|Drug|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
25133|NCT00858637|Drug|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
25134|NCT00858637|Drug|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
24219|NCT00871078|Device|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
24220|NCT00871091|Procedure|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
24221|NCT00864188|Dietary Supplement|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
24222|NCT00864188|Dietary Supplement|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
24223|NCT00864201|Drug|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
24224|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
24850|NCT00857974|Other|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
24851|NCT00857987|Drug|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
24852|NCT00857987|Other|Placebo|Vehicle
24853|NCT00858000|Other|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
24854|NCT00858013|Drug|Nateglinide|Nateglinide 90~120mg three times a day
24855|NCT00858013|Drug|Glimepiride|Glimepiride 1~2mg once a day
24856|NCT00858026|Other|Breastmilk|Exclusively breastfed babies
24857|NCT00858026|Other|Standard milk|Weaning babies fed with the standard formula
24858|NCT00858026|Other|Fermented milk|Weaning babies fed with the fermented formula
24859|NCT00011921|Biological|filgrastim|
24860|NCT00858052|Device|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
24861|NCT00858065|Behavioral|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
24862|NCT00858065|Behavioral|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
24863|NCT00858104|Procedure|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
24864|NCT00858117|Biological|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
24865|NCT00858117|Biological|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
25199|NCT00856115|Other|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
25200|NCT00856115|Other|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
24654|NCT00862550|Other|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
24655|NCT00862563|Drug|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
24656|NCT00862563|Drug|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
24657|NCT00862563|Drug|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
24658|NCT00862563|Drug|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
24659|NCT00012129|Drug|liposomal annamycin|
24660|NCT00862589|Other|GLP-1 infusion|physiological effect of GLP-1
24661|NCT00862602|Behavioral|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet & nutrition and prevention.
24662|NCT00862615|Other|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.
Isotopes are :
(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)
24663|NCT00862628|Drug|Rebamipide|100mg tid, 4 or 8 weeks
24664|NCT00862641|Drug|Regadenoson|IV
24665|NCT00864890|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
24666|NCT00864890|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
24667|NCT00864916|Drug|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
24923|NCT00855556|Genetic|blood draw|The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:
Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.
Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.
No fasting, activity or medication restrictions are required prior to or following blood collection.
Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection.
22839|NCT00000774|Biological|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
22840|NCT00008554|Drug|Nelfinavir mesylate|
22841|NCT00836576|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
22842|NCT00836576|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
22843|NCT00836589|Device|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
22844|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
22845|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
22846|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, <= 4 mg, Once daily, 7 days
22847|NCT00836602|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
23165|NCT00840125|Drug|erlotinib|150mg tablet daily
23166|NCT00840125|Drug|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
23167|NCT00840138|Procedure|Surgical reconstruction|Hepaticojejunostomy
End-to-end anastomosis
Duct suture over T-tube
23168|NCT00840151|Behavioral|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
23169|NCT00840177|Drug|cytarabine|
23170|NCT00840177|Drug|idarubicin|
23171|NCT00840177|Drug|pravastatin sodium|
23172|NCT00840190|Drug|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
23173|NCT00840203|Drug|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
23174|NCT00840203|Drug|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
23175|NCT00831701|Drug|Placebo|One placebo pill per day for 21 days or until stone expulsion
23176|NCT00831714|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
24225|NCT00012220|Drug|gemcitabine hydrochloride|Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, & 15 of ea cycle
cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle
docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 & 8 of ea cycle
24226|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
24227|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
24228|NCT00864214|Drug|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
24229|NCT00864227|Biological|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.
Fludarabine: 40 mg/m^2 intravenously (IV) on Days -6, -5, -4, -3, and -2
Cyclophosphamide: 50 mg/kg IV on Day -6
Total body irradiation: 200 centigray (cGy) on Day -1
24230|NCT00864227|Biological|GVHD prophylaxis|GVHD prophylaxis regimen will consist of:
Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL
MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later
Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.
Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm^3 for three consecutive measurements, each on different days.
24231|NCT00864240|Drug|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
24232|NCT00864253|Drug|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
24233|NCT00864253|Drug|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
24234|NCT00864266|Drug|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
24504|NCT00866697|Drug|Placebo|Matching placebo 800 mg daily, for 104 weeks (24 months).
24505|NCT00866710|Other|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
24506|NCT00866723|Drug|bevacizumab|
24507|NCT00866736|Drug|dasatinib|100mg QD
24508|NCT00866749|Drug|Daunorubicin|Starting Dose 25 mg/m^2 by vein weekly
24509|NCT00866749|Drug|Vincristine|Starting Dose 2 mg by vein weekly
25201|NCT00856115|Other|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
25202|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
25203|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
25204|NCT00011362|Drug|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
25205|NCT00856154|Biological|Peptides on autologous Dendritic Cells|10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.
Gag150 RLLNAWVKV
Gag433 FLGKIWPV
Env 67 NIWATHACV
Pol606 KLGKAGYVV
Vpu66 ALVEMGHHV
Vif101 GLADQLIHL
Vif23 SLVKHHMYV
Gag298 KRWIILGLNKIVRMY
gp41 VWGIKQLQARVLAVERYLKD
Padre AKXVAAWTLKAAA
25206|NCT00856167|Drug|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
25207|NCT00856167|Behavioral|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
25208|NCT00858663|Radiation|intensity modulated radiation therapy|All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.
Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.
Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan.
25209|NCT00858663|Drug|RAD001 (everolimus) + Cisplatin|All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.
Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.
Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan.
25210|NCT00011921|Procedure|autologous bone marrow transplantation|
25211|NCT00858676|Drug|acarbose|50mg acarbose 3 times a day PO. duration: one year
24294|NCT00861939|Drug|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
24295|NCT00861952|Other|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
24296|NCT00861952|Other|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
24924|NCT00855569|Device|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
24925|NCT00855582|Drug|Tadalafil|tablet once daily by mouth for 12 weeks.
24926|NCT00855582|Drug|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
24927|NCT00855595|Drug|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
24928|NCT00855595|Drug|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
24929|NCT00855595|Drug|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
24930|NCT00855608|Drug|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
24931|NCT00011128|Behavioral|Antiretroviral Treatment Interruption|
24932|NCT00855621|Procedure|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
24933|NCT00855634|Procedure|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
24934|NCT00855634|Procedure|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
24935|NCT00855647|Procedure|Hypo-fractionated Radiotherapy|
24936|NCT00011921|Drug|carboplatin|
24937|NCT00858182|Drug|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
24938|NCT00858195|Drug|Indomethacin 75mg Extended-Release Capsules, Sandoz|
24939|NCT00858195|Drug|Indocin 75mg SR Capsules|
24940|NCT00858208|Drug|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
24941|NCT00858234|Drug|vorinostat|MK0683 (400 mg) Oral, once daily treated for Day 1 through 14 of a 21 day cycle
25270|NCT00853502|Other|Bone monitoring|bone mineral density and bone microarchitecture will be monitored over time without hormonal intervention
25271|NCT00856180|Drug|Avastin|Standard dose given intravenously every three weeks
23177|NCT00831714|Drug|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
23178|NCT00831727|Behavioral|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
23179|NCT00831727|Behavioral|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
23180|NCT00831740|Other|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
23181|NCT00831740|Other|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
23182|NCT00831753|Biological|DTaP IPV HB PRP~T vaccine|0.5 mL, Intramuscular
23183|NCT00000772|Drug|Ribavirin|
23184|NCT00008229|Drug|melphalan|
23512|NCT00863044|Procedure|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
23513|NCT00863044|Procedure|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
23514|NCT00863057|Drug|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
23515|NCT00012168|Procedure|radionuclide imaging|
23516|NCT00863057|Drug|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
23517|NCT00863057|Drug|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
23518|NCT00865189|Drug|bevacizumab [Avastin]|4 x 2 week cycles of 5mg/kg iv + 5-FU + radiotherapy
24510|NCT00866749|Drug|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
24511|NCT00866749|Drug|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
24512|NCT00012454|Drug|E-Selectin nasal spray|
24513|NCT00866749|Drug|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
24514|NCT00866749|Drug|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
24515|NCT00866749|Drug|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
24516|NCT00866749|Drug|Methotrexate|Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
24517|NCT00866749|Drug|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
24518|NCT00866749|Drug|Thioguanine|60 mg/m2 by mouth daily for two weeks
24519|NCT00866762|Drug|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
24520|NCT00866775|Drug|Eslicarbazepine acetate|1600 mg QD
24521|NCT00866775|Drug|Eslicarbazepine acetate|1200 mg QD
24522|NCT00866788|Drug|omalizumab|Administered by subcutaneous injection
24523|NCT00012467|Drug|Itraconazole|
24524|NCT00866788|Drug|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
24525|NCT00866788|Drug|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
24526|NCT00866788|Drug|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
24788|NCT00860470|Dietary Supplement|Iron (27 mg) - folic acid (600 ug)|Supplement serves as the "Control" (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.
24789|NCT00860470|Dietary Supplement|Multiple micronutrient|Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).
Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.
24297|NCT00861965|Biological|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
24298|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
24299|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
24300|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
24301|NCT00012103|Other|bronchoalveolar lavage|
24302|NCT00861978|Drug|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
24303|NCT00861978|Drug|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
24304|NCT00861991|Behavioral|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
24305|NCT00862004|Procedure|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
24306|NCT00862017|Dietary Supplement|MSg supplementation|
24307|NCT00862017|Dietary Supplement|NaCl supplementation|
24308|NCT00864305|Drug|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
24309|NCT00864318|Drug|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
24310|NCT00864318|Drug|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
24311|NCT00864318|Drug|Carboplatine|From cycle 3 to cycle 5 :
Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient
24312|NCT00864318|Drug|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
24313|NCT00864318|Procedure|cytapheresis + transfusion of autologous peripheral blood stem cells|Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.
At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end
24314|NCT00864331|Radiation|radiation|39 Gy in 13 daily fractions of 3 Gy
24585|NCT00864812|Drug|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
25272|NCT00856180|Drug|cyclophosphamide|Taken orally once a day
25273|NCT00856193|Drug|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
25274|NCT00856193|Drug|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
25275|NCT00856206|Biological|Rilonacept|160mg once a week
25276|NCT00856206|Other|Placebo|Placebo once a week
25277|NCT00856219|Dietary Supplement|Enteral Continuous|Continuous Tube Feeding for 72 hours
25278|NCT00011362|Drug|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was >=2.4 on treatment day 14, or an additional two weeks of saline
25279|NCT00856219|Dietary Supplement|Enteral Intermittent|Intermittent Tube Feedings
25280|NCT00856219|Dietary Supplement|Parenteral Continuous|Parenteral Continuously for 72 hours
25281|NCT00856232|Biological|Medical Air|Compressed medical air
25282|NCT00856232|Biological|Oxygen|Medical Oxygen
25283|NCT00856245|Drug|Rituximab|375 MG/M2 given IV weekly x 4-8 doses.
25284|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
25285|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
25286|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
25287|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
25288|NCT00856271|Drug|olmesartan medoxomil|oral tablets, once daily for 8 weeks
25289|NCT00011375|Drug|Rolipram|
25290|NCT00856271|Drug|losartan potassium|capsules, once daily for 8 weeks
25291|NCT00856284|Drug|Alogliptin|Alogliptin tablets
25292|NCT00856284|Drug|Metformin|Metformin tablets
25293|NCT00856284|Drug|Glipizide|Glipizide tablets
23519|NCT00865202|Drug|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
23520|NCT00865202|Drug|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
23521|NCT00865215|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
23522|NCT00865215|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
23523|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
23524|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
23525|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
23526|NCT00012311|Drug|cyclophosphamide|
23527|NCT00865228|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
23528|NCT00865241|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
23823|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
23824|NCT00868023|Drug|Placebo|Placebo
23825|NCT00868036|Procedure|Patch Testing|Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.
Results will be graded and interpreted at a "delayed read," 3-4 days after allergens are placed with patch testing.
23826|NCT00868062|Other|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
23827|NCT00868075|Procedure|Chest physiotherapy|Twice daily for 8 weeks
23828|NCT00868075|Procedure|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
24790|NCT00012012|Drug|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
24791|NCT00860483|Other|observational|PET Scan
24792|NCT00860496|Drug|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
24793|NCT00860496|Drug|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
24794|NCT00860509|Other|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
24795|NCT00860522|Drug|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
24796|NCT00860522|Drug|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
24797|NCT00860535|Other|Comparator: Biomarker evaluation|Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a ~3.5 month period.
Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day [qd]), dasatinib (recommended dose 70 mg twice a day [bid]), or nilotinib (recommended dose 400 mg bid).
Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I.
24798|NCT00860548|Drug|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
24799|NCT00860574|Drug|treosulfan|Given IV
24800|NCT00860574|Drug|fludarabine phosphate|Given IV
24801|NCT00852683|Drug|Placebo|75 mg twice a day
24802|NCT00852696|Drug|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
24803|NCT00852696|Other|Placebo|Take orally once daily for 9 weeks.
24804|NCT00852709|Drug|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
24805|NCT00852709|Drug|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
25135|NCT00858650|Other|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
25136|NCT00860977|Drug|valacyclovir|oral valacyclovir 500mg twice daily
24586|NCT00864812|Drug|tiotropium|COPD patients treated with tiotropium
24587|NCT00864825|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
24588|NCT00864838|Drug|Acetazolamide|250 mg 1 hour before intravitreal injection
24589|NCT00864838|Drug|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
24590|NCT00864838|Procedure|Anterior chamber paracentesis|Immediately after bevacizumab injection
24591|NCT00864851|Biological|Replagal|Intravenous (IV) infusion for 12 months
24592|NCT00012298|Biological|oprelvekin|Given subcutaneously
24593|NCT00864864|Drug|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
24594|NCT00864877|Device|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
24595|NCT00866853|Drug|TMC435|
24596|NCT00866866|Drug|N-Acetyl Cysteine|600 mg PO BID
24597|NCT00866866|Drug|Placebo|1 tab PO BID
24598|NCT00866879|Drug|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
24599|NCT00012467|Drug|Flucytosine|
24600|NCT00866879|Other|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
24601|NCT00866879|Procedure|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
24602|NCT00866879|Procedure|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
24603|NCT00866879|Procedure|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
24085|NCT00866229|Drug|Simvastatin|20 mg per day
24086|NCT00866242|Biological|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
24087|NCT00866255|Device|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
24088|NCT00866268|Device|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
24089|NCT00868478|Drug|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
24090|NCT00868491|Drug|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
24091|NCT00868491|Radiation|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
24092|NCT00868491|Drug|cetuximab, cisplatin|cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20
cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)
24093|NCT00868504|Other|no intervention|no intervention
24094|NCT00012610|Procedure|Telepsychiatry|
24095|NCT00868517|Other|True group auricular acupuncture|Received true group auricular acupuncture
24096|NCT00868517|Other|Sham group auricular acupuncture|Received sham auricular acupuncture.
24097|NCT00868517|Other|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
24098|NCT00868530|Biological|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
23829|NCT00868088|Procedure|PDT prior to Mohs surgery|Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.
7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.
3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.
6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.
Photographs may be taken at each subject visit.
23830|NCT00012558|Behavioral|Family-focused Therapy|
23831|NCT00868101|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
23832|NCT00868114|Biological|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
23833|NCT00870454|Drug|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
23834|NCT00870454|Drug|Placebo|Placebo capsules twice daily
23835|NCT00870467|Biological|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
23836|NCT00870467|Drug|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
23837|NCT00870467|Biological|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
23838|NCT00870467|Biological|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
23839|NCT00870480|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
22848|NCT00836628|Drug|Busulfan|
22849|NCT00836641|Biological|prevenar|7-valent pneumococcal conjugate vaccine
22850|NCT00836641|Biological|pneumovax|23 valent pneumococcal polysaccharide vaccine
22851|NCT00008554|Drug|Lamivudine|
22852|NCT00836654|Biological|Catumaxomab (Removab)|Puncture free survival
22853|NCT00836654|Procedure|paracentesis|
22854|NCT00836667|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
25137|NCT00860977|Drug|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
25138|NCT00860990|Other|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
25139|NCT00861003|Device|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
25140|NCT00861016|Drug|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
25141|NCT00861029|Drug|Pazopanib|Subjects treated with pazopanib
25142|NCT00861029|Other|Placebo for pazopanib|Control for comparison with pazopanib
25143|NCT00012051|Drug|carmustine|
25144|NCT00861029|Drug|Moxifloxacin|Comparator for pazopanib
25145|NCT00861029|Other|Placebo for moxifloxacin|Placebo for moxifloxacin
25146|NCT00861042|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
25147|NCT00861068|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
25148|NCT00861068|Other|Placebo|Placebo tablets two times a day for 10 weeks
25149|NCT00861081|Behavioral|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
25150|NCT00861081|Behavioral|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
25151|NCT00861094|Drug|cisplatin|
25152|NCT00861094|Drug|5-FU|
25153|NCT00861094|Drug|oxaliplatin|
25154|NCT00012051|Drug|cisplatin|
25155|NCT00861094|Radiation|radiation therapy|
24604|NCT00866879|Other|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
24866|NCT00858130|Device|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
24867|NCT00858143|Other|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
24868|NCT00858156|Drug|BG9928|Oral 75 mg single dose
24869|NCT00858182|Drug|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
24870|NCT00012012|Radiation|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
24871|NCT00860574|Radiation|total-body irradiation|Low dose starting at 2Gy
24872|NCT00860574|Procedure|peripheral blood stem cell transplantation|Given IV per institutional standard practice
24873|NCT00860574|Drug|tacrolimus|Given IV or PO
24874|NCT00860574|Procedure|allogeneic bone marrow transplantation|Given IV per institutional standard practice
24875|NCT00860574|Procedure|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
24876|NCT00860574|Drug|methotrexate|Given IV
24877|NCT00860600|Drug|PG2|500mg/vial, iv infusion, 3 ~ 5 times/week, 2.5 ~ 3.5 hr/time
24878|NCT00860613|Other|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
24879|NCT00860626|Drug|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
24880|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
24099|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
23102|NCT00008333|Drug|vinorelbine tartrate|
23103|NCT00834314|Procedure|Vacuum-Pack-technique for temporary abdominal closure|Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: "Temporary Closure of Open Abdominal Wounds - the Vacuum Pack" (see citations).
23104|NCT00834314|Procedure|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
23105|NCT00834327|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
23106|NCT00834340|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose fasting
23107|NCT00834340|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose fasting
23108|NCT00834353|Drug|ATT|
23109|NCT00834366|Drug|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
23110|NCT00834379|Drug|pravastatin sodium|40 mg Tablet
23111|NCT00834379|Drug|Pravachol®|40 mg tablet
23112|NCT00834392|Behavioral|Exercise|Walking exercise
23113|NCT00008346|Procedure|breast imaging study|
23114|NCT00834405|Drug|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
23115|NCT00834405|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
23116|NCT00834418|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
23117|NCT00834418|Drug|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
23118|NCT00834431|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
23119|NCT00834431|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
22855|NCT00836667|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
22856|NCT00839371|Drug|Midazolam|i.v. midazolam titration until adequate depth of sedation
22857|NCT00839384|Device|Advisa IPG|Implantable Pulse Generator will be implanted
22858|NCT00839397|Drug|Paroxetine|Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response ("1. Very much improved" or "2. Much improved" based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.
Dosage adjustment will be made at the discretion of the PI or Sub-PI
22859|NCT00009594|Procedure|Traditional Chinese Medicine|
22860|NCT00839423|Drug|Placebo|capsules, daily, orally
22861|NCT00839423|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
22862|NCT00839423|Drug|Venlafaxine XL|capsules, daily, orally
22863|NCT00839436|Drug|CYT107|
22864|NCT00839449|Drug|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
22865|NCT00839462|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
22866|NCT00839462|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
22867|NCT00839488|Drug|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
22868|NCT00839488|Drug|famotidine 20 mg iv|famotidine 20 mg q12h
23185|NCT00831753|Biological|DTaP-HB-IPV and Haemophilus influenzae type b|0.5 mL, Intramuscular
23186|NCT00831766|Drug|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
23187|NCT00831766|Drug|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
23188|NCT00831766|Drug|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
23189|NCT00831779|Drug|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
24235|NCT00864279|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
24236|NCT00012220|Drug|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 & 8 of ea cycle
24237|NCT00864279|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
24238|NCT00864305|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
24239|NCT00864305|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
24240|NCT00866359|Drug|Apremilast (CC-10004)|Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-85: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.
Extension Phase All subjects will be given active drug Days 86-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.
Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)
24241|NCT00012376|Biological|sargramostim|Given subcutaneously
24242|NCT00866359|Drug|Placebo|Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.
Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.
Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)
24243|NCT00866385|Drug|AZD8566|Single 6 mg oral solution dose
24244|NCT00866385|Drug|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
24245|NCT00866411|Procedure|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
24246|NCT00866411|Procedure|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
24247|NCT00866424|Procedure|Hyperbaric oxygen, Mock hyperbaric chamber|Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.
Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.
Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars.
24248|NCT00866437|Drug|Skin test panel|Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L
Estradiol 1mmol/L
Estrone 3mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)
24249|NCT00866437|Drug|Skin test panel|Hormones:
Progesterone 1mmol/L
Estradiol 1 mmol/L
Estrone 3 mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)
24881|NCT00012012|Radiation|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
24882|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
25212|NCT00858689|Drug|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
25213|NCT00858702|Drug|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
25214|NCT00858702|Drug|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
25215|NCT00858715|Drug|aspirin|100 mg aspirin
25216|NCT00858715|Drug|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
25217|NCT00858728|Behavioral|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
25218|NCT00858728|Behavioral|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
25219|NCT00858741|Radiation|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
25220|NCT00858741|Radiation|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
25221|NCT00011921|Procedure|bone marrow ablation with stem cell support|
25222|NCT00858754|Drug|methylnaltrexone|
25223|NCT00858754|Drug|placebo|
25224|NCT00858767|Dietary Supplement|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
25225|NCT00858767|Dietary Supplement|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
25226|NCT00858767|Dietary Supplement|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
25227|NCT00861315|Drug|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
25228|NCT00861315|Drug|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
23120|NCT00834444|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
23121|NCT00834444|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
23122|NCT00834457|Drug|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
23123|NCT00834457|Drug|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
23124|NCT00008346|Procedure|comparison of screening methods|
23444|NCT00865176|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
23445|NCT00865189|Drug|bevacizumab [Avastin]|6x2 week cycles of 5mg/kg iv + FOLFOX, followed by 4x2 week cycles of 5mg/kg iv + 5-FU + radiotherapy
23446|NCT00867178|Drug|Vincristine Sulfate|Given IV
23447|NCT00867178|Drug|Vorinostat|Given PO
23448|NCT00867191|Drug|Placebo|Placebo, 1 tablet daily, per os., 15 days
23449|NCT00867191|Drug|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
23450|NCT00867204|Procedure|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
23451|NCT00867217|Drug|High Dose Vitamin D3|Drug: High Dose Vitamin D3 High Dose Vitamin D3 (3 capsules of 10,000 IU or placebo) weekly for 24 weeks Arms: Vitamin D
23452|NCT00867217|Drug|Placebo|Drug: Placebo Placebo comparator Arms: Placebo
23453|NCT00867230|Drug|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
23454|NCT00012558|Drug|lithium|
23455|NCT00867282|Drug|Treatment A|PF-00241939 750ug using inhaler A
23456|NCT00867282|Drug|Treatment B|PF-00241939 750ug using inhaler B
23457|NCT00867295|Drug|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
23458|NCT00867295|Drug|placebo|placebo
23459|NCT00867308|Drug|Lenalidomide|Lenalidomide 50 mg PO daily on days 1 - 28 out of a 42 day cycle for 4 cycles.
23460|NCT00867321|Biological|bevacizumab|Given IV
23190|NCT00831779|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
23191|NCT00831792|Drug|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
23192|NCT00831831|Behavioral|Safety planning|See detailed description
23193|NCT00831844|Biological|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
23194|NCT00831844|Other|laboratory biomarker analysis|Correlative studies
23195|NCT00008229|Procedure|peripheral blood stem cell transplantation|
23196|NCT00831857|Other|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
23197|NCT00831883|Behavioral|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
23198|NCT00834496|Procedure|Liver biopsy|percutaneous liver biopsy
23199|NCT00834509|Device|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
23200|NCT00834522|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
23201|NCT00834522|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
23202|NCT00834535|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
23203|NCT00834535|Drug|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
23204|NCT00834548|Procedure|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
23205|NCT00008346|Procedure|radiomammography|
23206|NCT00834561|Drug|Lamotrigine|200 mg Tablet
23207|NCT00834561|Drug|Lamictal®|200 mg Tablet
23208|NCT00834574|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
23529|NCT00865241|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
23530|NCT00865254|Behavioral|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
24250|NCT00866450|Dietary Supplement|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
24527|NCT00866814|Device|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
24528|NCT00866827|Other|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
24529|NCT00866840|Drug|riluzole|100 mg orally twice daily
24530|NCT00869245|Other|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
24531|NCT00869258|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
24532|NCT00869258|Radiation|Radiation therapy with gemcitabine|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
24533|NCT00869271|Procedure|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg
folfox4
Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
24534|NCT00869271|Procedure|Folfox4|folfox4
Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle
24535|NCT00869284|Drug|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
24536|NCT00869284|Procedure|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.
The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8.
24537|NCT00869297|Other|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
24538|NCT00869297|Other|Control|Fluids titrated at discretion of anesthesiologist.
24539|NCT00869310|Drug|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
24540|NCT00012779|Behavioral|Health Education Program|
25229|NCT00861315|Drug|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
25230|NCT00861328|Drug|ON 01910.Na and irinotecan|ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.
The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent.
24315|NCT00000794|Drug|Atovaquone|
24316|NCT00012246|Biological|carcinoembryonic antigen peptide 1-6D|
24317|NCT00864331|Other|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
24318|NCT00864331|Drug|Chemotherapy|Chemotherapy given alone
24319|NCT00864331|Other|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
24320|NCT00864344|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
24321|NCT00864344|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
24322|NCT00864357|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
24323|NCT00864357|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
24324|NCT00864383|Drug|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|Moxifloxacin 400 mg Rifampicin < 45 kg 450 mg > 45 kg 600 mg Isoniazid 300 mg Pyrazinamide < 40 kg 25 mg/kg rounded to nearest 500 mg* 40-55 kg 1000 mg > 55 kg - 75 kg 1500 mg > 75 kg 2000 mg Ethambutol < 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg > 55 kg - 75 kg 1200 mg > 75 kg 1600 mg *For pyrazinamide dosing in patients < 40 kg, 1000 mg used instead of 500 mg
All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.
24325|NCT00864396|Drug|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
24326|NCT00864409|Drug|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
24327|NCT00012246|Biological|incomplete Freund's adjuvant|
24328|NCT00864409|Drug|saline.9%|Wound infiltration with 170 mL sterile saline
24329|NCT00864422|Behavioral|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
23461|NCT00867321|Drug|sorafenib tosylate|Given orally
23462|NCT00867334|Drug|Imatinib mesylate followed by a combination of imatinib mesylate & panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
23463|NCT00867334|Drug|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
23464|NCT00867347|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
23465|NCT00012558|Drug|valproate|
23756|NCT00870233|Behavioral|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
23757|NCT00870259|Dietary Supplement|Optifast VLCD|Meal replacement, three times daily for 8 weeks
23758|NCT00012974|Behavioral|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
23759|NCT00863395|Procedure|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
23760|NCT00863434|Drug|clofarabine|Given IV
23761|NCT00863434|Drug|cytarabine|Given IV
23762|NCT00863434|Biological|filgrastim|Given SC
23763|NCT00863460|Radiation|cranial radiotherapy|40 Gy
23764|NCT00012194|Drug|7-hydroxystaurosporine|Given IV
23765|NCT00863460|Drug|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
23766|NCT00863460|Drug|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58&59 and days79&80
23767|NCT00863473|Procedure|Surgical treatment with LCP|
23768|NCT00863499|Drug|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
23531|NCT00865254|Behavioral|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
23532|NCT00865254|Behavioral|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
23533|NCT00865267|Drug|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
23534|NCT00865280|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
23535|NCT00865280|Drug|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
23536|NCT00867425|Behavioral|Virtual Lifestyle Management|The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.
Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the "Keeping Track" functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity).
23537|NCT00867438|Procedure|Sigmoidoscopy|
23538|NCT00867451|Behavioral|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
23539|NCT00867451|Drug|Melatonin|Body Weight <40mg will be given 3mg at bedtime for two weeks Body Weight >40mg will be given 6 mg at bedtime for two weeks
23540|NCT00867477|Procedure|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
23541|NCT00867477|Behavioral|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
23542|NCT00012558|Drug|bupropion|
23543|NCT00867477|Procedure|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
23840|NCT00870480|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
24541|NCT00869310|Drug|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
24542|NCT00869323|Biological|rituximab|375 mg/m^2 intravenously on Days 1,8, 15 and 22
24543|NCT00869323|Drug|bortezomib|1.3 mg/m^2 intravenous bolus days 1, 8, 15 and 22
24806|NCT00852722|Other|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
24807|NCT00852735|Dietary Supplement|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
24808|NCT00010803|Drug|Placebo|One pill twice daily
24809|NCT00852761|Drug|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
24810|NCT00852761|Drug|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
24811|NCT00852787|Drug|Digoxin immune fab|Intravenously one time
24812|NCT00852787|Drug|Placebo|Intravenously one time
24813|NCT00852800|Drug|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
24814|NCT00852800|Drug|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
24815|NCT00852813|Dietary Supplement|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
24816|NCT00852826|Procedure|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
24817|NCT00852826|Procedure|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
24818|NCT00852839|Drug|Placebo|The placebo formulation will be identical to the oromucosal formulation of 552-02 except for 552-02 content.
24819|NCT00010816|Drug|Herbal remedies|
24820|NCT00852839|Drug|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives. The placebo formulation will be identical except for 552-02 content.
24330|NCT00866476|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
24331|NCT00866489|Procedure|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
24332|NCT00866502|Drug|sNN0031|Continuous ICV infusion for two weeks
24333|NCT00866502|Drug|Placebo|Continous ICV infusion
24334|NCT00866515|Drug|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
24605|NCT00866879|Procedure|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
24606|NCT00866892|Procedure|Irrigation|irrigation
24607|NCT00866892|Procedure|No irrigation|no irrigation
24608|NCT00866905|Drug|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
24609|NCT00866905|Drug|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
24610|NCT00012467|Drug|Fluconazole|
24611|NCT00866918|Drug|arsenic trioxide|Given IV
24612|NCT00866918|Drug|mitoxantrone hydrochloride|Given IV
24613|NCT00866918|Other|diagnostic laboratory biomarker analysis|Correlative studies
24614|NCT00866918|Drug|idarubicin|Given IV
24615|NCT00866918|Drug|tretinoin|Given orally
24616|NCT00866918|Drug|cytarabine|Given IT or IV
24617|NCT00866918|Drug|mercaptopurine tablet|Given orally
24618|NCT00869349|Behavioral|IFS|The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.
Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline.
23769|NCT00863499|Drug|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
23770|NCT00863512|Drug|cisplatin|Given IV
23771|NCT00863512|Drug|docetaxel|Given IV
23772|NCT00863512|Drug|gemcitabine hydrochloride|Given IV
23773|NCT00863512|Drug|pemetrexed disodium|Given IV
23774|NCT00863512|Drug|vinorelbine tartrate|Given IV
23775|NCT00012194|Drug|cisplatin|Given IV
23776|NCT00863512|Procedure|standard follow-up care|Standard care
23777|NCT00863525|Drug|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
23778|NCT00863525|Drug|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
23779|NCT00863538|Drug|KPS-0373|
24100|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
24101|NCT00868569|Procedure|TACE + folfox 4|tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml
folfox4
24102|NCT00868569|Procedure|TAC + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg
folfox4
24103|NCT00868582|Other|PET scanning in cancer|Collection of institutional practice PET imaging data
24104|NCT00868595|Biological|BPX-101|Vaccine
24105|NCT00012636|Procedure|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
24106|NCT00868595|Drug|AP1903|Activating agent, infusion
24107|NCT00868608|Drug|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
23841|NCT00013000|Behavioral|Test strategy for implementation guideline|
23842|NCT00870493|Drug|Aliskiren|Aliskiren 300 mg daily oral
23843|NCT00870493|Drug|Placebo|starch tablet, 300 mg/day
23844|NCT00870506|Behavioral|video|5-minute video compared (intervention) to no video and no other intervention (control)
23845|NCT00870519|Drug|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
23846|NCT00870519|Drug|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
23847|NCT00870532|Drug|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
23848|NCT00870532|Drug|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
23849|NCT00870545|Behavioral|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
23850|NCT00870558|Drug|ethiodized oil|Given as an intra-arterial infusion
23851|NCT00870558|Radiation|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
23852|NCT00013013|Procedure|Systems Support|
23853|NCT00870571|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
23854|NCT00863590|Drug|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
23855|NCT00863590|Drug|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
24821|NCT00852852|Behavioral|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
24822|NCT00852865|Drug|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4*109 CFU
24823|NCT00855283|Drug|IN NEO|40 mg Neostigmine via intranasal administration
24824|NCT00855283|Drug|IN NEO|60 mg Neostigmine via intranasal administration
24825|NCT00855283|Drug|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
25156|NCT00861094|Drug|Folinic Acid|
25157|NCT00861107|Biological|AlloStim-7|intradermal injection once a week for 3 weeks
25158|NCT00861107|Procedure|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
25159|NCT00861107|Biological|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
25160|NCT00861107|Biological|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10^8 cell dose and if no toxicity dose escalates to 10^9 cell dose.
25161|NCT00853203|Other|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
25162|NCT00853203|Behavioral|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
25163|NCT00853203|Behavioral|Written Materials|Written educational materials plus community resource information.
25164|NCT00853216|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
25165|NCT00853216|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
25166|NCT00853229|Drug|pregabalin|pregabalin 150mg twice daily for 4 weeks
25167|NCT00853242|Drug|Placebo|
25168|NCT00853242|Drug|Genz-644470|
25169|NCT00853242|Drug|Sevelamer carbonate|
25170|NCT00853255|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
24619|NCT00869349|Other|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
24620|NCT00869362|Other|Diabetes management team|MD evaluation followed by NP education and and medication titration
24621|NCT00012792|Behavioral|Exercise Training|
24622|NCT00869375|Device|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
24623|NCT00869388|Biological|rBBX-01|
24624|NCT00869401|Drug|dasatinib|Given orally
24625|NCT00869401|Drug|temozolomide|Given orally
24883|NCT00860639|Drug|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
24884|NCT00860652|Radiation|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
24885|NCT00860652|Radiation|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
24886|NCT00860678|Other|Physical activity|
24887|NCT00860678|Other|no Intervention|
24888|NCT00860691|Procedure|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
24889|NCT00860691|Procedure|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
24890|NCT00852865|Drug|Placebo|1 capsule per day
24891|NCT00852878|Behavioral|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
24892|NCT00852878|Behavioral|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
24893|NCT00852917|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
24894|NCT00852917|Drug|Placebo|One Placebo tablet daily.
24895|NCT00852930|Procedure|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
24108|NCT00870571|Drug|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
24109|NCT00870584|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
24110|NCT00870584|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
24111|NCT00870597|Procedure|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
24112|NCT00870597|Procedure|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
24113|NCT00870610|Procedure|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
24114|NCT00870636|Drug|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
24115|NCT00870649|Biological|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
24116|NCT00870649|Biological|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
24117|NCT00013026|Behavioral|CHF Self-management Education (Web-based Education)|
23125|NCT00834470|Drug|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
23126|NCT00834483|Device|Knotless suture for wound closure|Angiotech Quill SRS
23127|NCT00834483|Device|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
23128|NCT00837109|Behavioral|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
23129|NCT00837135|Other|Screening|A. SCREENING
Consent
Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)
Physical Exam, History, Blood Tests
Skin Test (for allergy to saccaromyces cerevisiae) yeast.
Collection of Blood for research
B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)
C. ENROLLMENT INTO ACTIVE PART OF STUDY
Consent
Chemotherapy
GI-4000 Vaccine #1 + Prevnar + Activated T Cells
GI-4000 Vaccine #2
Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B.
23130|NCT00837135|Biological|GI-4000 Vaccine|Chemotherapy and Radiation
GI-4000 Vaccine #3
GI-4000 Vaccine #4
23131|NCT00837135|Biological|GI-4000 Vaccine + Activated T Cells|Apheresis #2
Chemoradiation
Activated T Cells + GI-4000 Vaccine #3
GI-4000 Vaccine #4
23856|NCT00863590|Drug|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
22869|NCT00839501|Dietary Supplement|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
22870|NCT00009620|Drug|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
22871|NCT00839501|Drug|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
22872|NCT00839527|Drug|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
22873|NCT00839527|Biological|albiglutide|albiglutide weekly subcutaneous injection
22874|NCT00839527|Drug|metformin|metformin
22875|NCT00839527|Drug|glimepiride|glimepiride
22876|NCT00839527|Drug|pioglitazone|pioglitazone
22877|NCT00839527|Drug|placebo to match pioglitazone|pioglitazone matching placebo
22878|NCT00839540|Drug|micafungin|100 mg qd by slow IV infusion for 24 h
22879|NCT00839540|Drug|Micafungin|200 mg qd by slow IV infusion for 24 h
22880|NCT00831129|Drug|40 mg simvastatin|dosage is once daily
22881|NCT00831129|Drug|Rosiglitazone|Subjects will either receive Simvastatin 40mg once daily plus Rosiglitazone at 4mg once daily or Simvastatin 40mg once daily plus placebo 1 tab daily
22882|NCT00831129|Other|Placebo|Subjects will either receive Simvastatin 40mg once daily plus Rosiglitazone at 4mg once daily or Simvastatin 40mg once daily plus placebo 1 tab daily
22883|NCT00831155|Drug|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
22884|NCT00831168|Behavioral|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
22885|NCT00831181|Drug|FOLFOX regimen|
22886|NCT00831181|Drug|fluorouracil|
22887|NCT00831181|Drug|leucovorin calcium|
25171|NCT00010855|Behavioral|Self-hypnotic relaxation|
25172|NCT00853268|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
25173|NCT00853268|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
25174|NCT00853281|Other|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
25175|NCT00853281|Other|Standard vector control measures|Insectice-treated net
25176|NCT00853294|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
25177|NCT00853294|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
24251|NCT00866450|Dietary Supplement|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
24252|NCT00012376|Other|laboratory biomarker analysis|Correlative studies
24253|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
24254|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
24255|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
24256|NCT00866476|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
24257|NCT00868751|Biological|tocilizumab|Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.
Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16.
24258|NCT00000796|Drug|Capreomycin sulfate|
24259|NCT00012688|Drug|Doxycycline HCI 10mg po for 2 weeks|
24260|NCT00868764|Drug|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
24261|NCT00868777|Procedure|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
24896|NCT00852930|Procedure|laser alone|The intervention is therapist administered laser
24897|NCT00010829|Behavioral|American Heart Association Step 1 diet|
24898|NCT00852930|Procedure|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
24899|NCT00852956|Drug|Betahistine|The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:
Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)
On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:
Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00
24900|NCT00852969|Drug|Niacin|1000 mg tablets once per day
24901|NCT00852969|Drug|Active Placebo|100 mg Niacin tablets once per day
24902|NCT00852982|Behavioral|Exercise|Nordic walking, with walking poles, five hours per week during four months
25231|NCT00861328|Drug|ON 01910.Na and oxaliplatin|ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.
The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent.
25232|NCT00012051|Drug|etoposide|
25233|NCT00861341|Drug|Aspirin|81 mg
25234|NCT00861341|Drug|Pioglitazone|30mg Pioglitazone x1
25235|NCT00861354|Device|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
25236|NCT00861367|Drug|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
25237|NCT00861380|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
25238|NCT00861380|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.
Control 3+1 and Control 2+1 groups, only for children < 12 months of age at the time of first study vaccination.
25239|NCT00861380|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children >= 12 months of age at the time of first study vaccination.
25240|NCT00861393|Behavioral|CBT|12 Session CBT group
23132|NCT00837135|Biological|Surgical Evaluation after Vaccine #4|SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.
B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR.
23133|NCT00837148|Drug|Sorafenib and Dacarbazine|Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.
All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance.
23134|NCT00837161|Device|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
23135|NCT00837174|Drug|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
23136|NCT00008801|Drug|hOKT3gamma1 (Ala-ala)|
23137|NCT00837187|Drug|Intravenous dexmedetomidine|100 ug
23138|NCT00837187|Drug|Intranasal dexmedetomidine|100 ug
23139|NCT00837200|Drug|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
23140|NCT00837213|Drug|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
23141|NCT00837213|Drug|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
23466|NCT00867347|Radiation|radiation therapy|Patients undergo radiotherapy
23467|NCT00867360|Drug|Mifepristone (RU-486)|
23468|NCT00867373|Behavioral|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
23469|NCT00867399|Drug|ABT-126|See arm for details
23470|NCT00869713|Biological|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 & 14, & once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer <1:40. Initial non-responders: Individual who has a PRNT80 titer <1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 <1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of <1:40.
25424|NCT00861172|Procedure|3T MR scanner|The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.
We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.
The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection.
25425|NCT00861185|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
25426|NCT00861185|Drug|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
25427|NCT00861198|Other|ERCP as per medical indication|ERCP as per medical indication
25428|NCT00861211|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
25429|NCT00861211|Drug|Placebo|Placebo comparator
25430|NCT00861224|Other|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
25431|NCT00861237|Drug|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
25432|NCT00861237|Drug|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
25433|NCT00861250|Drug|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
25434|NCT00012051|Drug|dexamethasone|
25435|NCT00861263|Device|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
25753|NCT00854308|Drug|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
25754|NCT00854308|Drug|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
25755|NCT00854308|Drug|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
25756|NCT00854321|Drug|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
25757|NCT00854321|Drug|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
25758|NCT00010985|Procedure|massage|
30559|NCT00016302|Drug|doxorubicin hydrochloride|Given IV
30560|NCT00898924|Genetic|molecular diagnostic method|
30561|NCT00898924|Genetic|mutation analysis|
30562|NCT00898937|Genetic|microarray analysis|tumor specimen will be assessed by microarray analysis
30563|NCT00898937|Procedure|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
30564|NCT00898950|Drug|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
29469|NCT00895531|Procedure|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
29470|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
29471|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
29472|NCT00897494|Other|mass spectrometry|Venous blood collection
29473|NCT00897494|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
29474|NCT00897507|Genetic|polymorphism analysis|
29475|NCT00897520|Biological|recombinant interferon alfa|
29476|NCT00897520|Genetic|proteomic profiling|
29477|NCT00897520|Other|immunoenzyme technique|
29478|NCT00897520|Other|laboratory biomarker analysis|
29479|NCT00016198|Drug|leucovorin calcium|
29480|NCT00897533|Genetic|gene mapping|
29481|NCT00897533|Genetic|polymorphism analysis|
29482|NCT00897533|Other|diagnostic laboratory biomarker analysis|
29483|NCT00897533|Other|immunohistochemistry staining method|
25817|NCT00852033|Other|Assessment only|No intervention, assessment only.
25818|NCT00852046|Drug|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
25819|NCT00852059|Drug|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
25820|NCT00852059|Drug|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
25821|NCT00852072|Procedure|Mechanical Lithotripsy|Ability to clear the CBD of all stones using mechanical lithotripsy within 20 minutes following sphincterotomy.
25822|NCT00854360|Drug|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
25823|NCT00854360|Drug|Placebo|HFA Vehicle Aerosol
25824|NCT00854373|Drug|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
25825|NCT00854373|Other|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
25826|NCT00854386|Drug|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
25827|NCT00854386|Drug|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
25828|NCT00854399|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
25829|NCT00854412|Other|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
26136|NCT00857571|Drug|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
26137|NCT00857571|Drug|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
26138|NCT00857571|Drug|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
26139|NCT00857571|Drug|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
26140|NCT00857571|Drug|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
26141|NCT00857571|Drug|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
26142|NCT00857571|Drug|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
26143|NCT00857571|Drug|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
26535|NCT00924014|Drug|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
26536|NCT00926562|Drug|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
26537|NCT00926575|Drug|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
26538|NCT00926575|Drug|Placebo|Two tablets QID for 50 days
26539|NCT00926588|Drug|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
26540|NCT00926614|Drug|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
26541|NCT00926614|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
26542|NCT00018902|Drug|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
26543|NCT00926627|Drug|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)
26544|NCT00926627|Drug|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
26545|NCT00926640|Drug|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
26546|NCT00926640|Drug|Cisplatin|6 cycles at 60mg/m2 IV on day 2
26547|NCT00926640|Drug|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
26548|NCT00926653|Drug|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
26549|NCT00926666|Drug|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
26550|NCT00926692|Other|Blood draw|Subject will have blood draw.
25555|NCT00853918|Other|$50 check|$50 check incentive mailed with survey
25556|NCT00856622|Drug|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
25557|NCT00856635|Drug|Glatiramer Acetate|20 mg injected daily subcutaneously
25558|NCT00856635|Drug|placebo|injected daily subcutaneously
25559|NCT00856648|Device|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
25898|NCT00859989|Other|questionnaire administration|
25899|NCT00852072|Procedure|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones within 20 minutes in one ERCP session using balloon sphincteroplasty.
25900|NCT00852085|Behavioral|Enhanced community service|Two educational sessions and volunteering at a local community service site
25901|NCT00852085|Behavioral|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
25902|NCT00852098|Procedure|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
25903|NCT00010712|Drug|Black Cohosh|
25904|NCT00852098|Procedure|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
25905|NCT00852124|Biological|VSL#3|VSL#3 2 times daily
25906|NCT00852124|Biological|VSL#3 or placebo|1 packet 2 x daily of placebo
25907|NCT00852137|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
25908|NCT00852137|Drug|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
25909|NCT00852163|Drug|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
25910|NCT00852189|Drug|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
25911|NCT00852189|Drug|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
25912|NCT00852189|Drug|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
25913|NCT00852202|Drug|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
25914|NCT00010725|Drug|MAK|
25915|NCT00852202|Drug|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
25916|NCT00852202|Drug|placebo|placebo capsules, oral administration, once daily dosing
25917|NCT00852215|Device|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
29484|NCT00897546|Other|laboratory biomarker analysis|
29485|NCT00897559|Genetic|gene expression analysis|
29486|NCT00897559|Genetic|mutation analysis|
29487|NCT00897559|Genetic|polymorphism analysis|
29488|NCT00897559|Genetic|protein analysis|
29489|NCT00897559|Other|flow cytometry|
29490|NCT00016198|Drug|oxaliplatin|
29491|NCT00897559|Other|laboratory biomarker analysis|
29492|NCT00897611|Procedure|DNA methylation analysis|
30163|NCT00900380|Other|flow cytometry|
30164|NCT00016406|Drug|paclitaxel|
30165|NCT00900380|Other|immunological diagnostic method|
30166|NCT00900380|Other|laboratory biomarker analysis|
30167|NCT00900406|Genetic|gene expression analysis|blood collection
30168|NCT00900406|Genetic|microarray analysis|Blood collection
30169|NCT00900406|Genetic|polymorphism analysis|Blood collection
30170|NCT00900406|Genetic|proteomic profiling|Blood collection
30171|NCT00900406|Other|flow cytometry|Blood collection
30172|NCT00900406|Other|immunologic technique|Blood collection
30173|NCT00900406|Other|laboratory biomarker analysis|Blood collection
30174|NCT00900406|Procedure|biopsy|Blood collection
30175|NCT00016406|Procedure|surgery|
30176|NCT00900419|Other|immunohistochemistry staining method|Laboratory test
30177|NCT00900419|Other|laboratory biomarker analysis|Laboratory Test
30178|NCT00900419|Other|sputum cytology|Laboratory Test
26144|NCT00857571|Drug|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
26145|NCT00857571|Drug|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
26146|NCT00000790|Drug|Thalidomide|
26147|NCT00011804|Drug|Topiramate|
26148|NCT00857584|Drug|Extended release quetiapine (quetiapine XR)|Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.
Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study.
26149|NCT00857584|Drug|Sertraline|Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.
Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study.
26150|NCT00857584|Drug|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
26151|NCT00860275|Drug|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
26152|NCT00011999|Procedure|conventional surgery|
26153|NCT00860275|Drug|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
26154|NCT00860275|Drug|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
26155|NCT00860288|Drug|Vildagliptin|
26156|NCT00860288|Drug|Metformin|
26157|NCT00860288|Drug|Placebo|
26158|NCT00860288|Drug|Sitagliptin|
26463|NCT00928616|Dietary Supplement|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
26464|NCT00928616|Dietary Supplement|margarine (placebo)|non-sterol ester supplemented margarine
26465|NCT00928629|Procedure|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
26466|NCT00019084|Biological|aldesleukin|
26467|NCT00928642|Drug|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
26468|NCT00928642|Drug|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
25560|NCT00856661|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
25561|NCT00011544|Procedure|Performance Measure|
25562|NCT00856661|Drug|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
25563|NCT00856674|Biological|OPL-CCL2-LPM|CCL2-LPM
intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg
2 doses one week apart
25564|NCT00856687|Drug|PF-03893787|Oral, two doses 12 hours apart
25565|NCT00856687|Drug|Placebo|Oral, two doses 12 hours apart
25566|NCT00856687|Drug|Montelukast|Oral, two doses 12 hours apart
25567|NCT00856700|Drug|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
25568|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
25569|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
25570|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
25571|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
25572|NCT00011557|Device|Assistance in Voiding|
25573|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
25574|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
25575|NCT00856726|Drug|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
25576|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
25577|NCT00856752|Drug|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
25578|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
25895|NCT00859989|Other|educational intervention|
25896|NCT00859989|Other|immunoenzyme technique|
25897|NCT00859989|Other|laboratory biomarker analysis|
26223|NCT00011076|Drug|Pirfenidone|
26224|NCT00855257|Drug|Placebo|
26225|NCT00855270|Drug|Placebo|IV saline will be used as placebo for control
26226|NCT00855270|Drug|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
26227|NCT00855283|Drug|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
26228|NCT00857597|Procedure|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
26229|NCT00857597|Drug|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
26230|NCT00857623|Drug|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
26231|NCT00857623|Drug|Placebo|Capsule, once daily
26232|NCT00857636|Behavioral|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
26233|NCT00857649|Drug|Memantine|20 mg Oral Tablets Once Daily
26234|NCT00857649|Drug|Placebo|Oral Tablets Once Daily
26235|NCT00011830|Drug|G-CSF|
26236|NCT00857662|Device|Onyx|Embolization
26237|NCT00857662|Device|TRUFILL|Embolization
26238|NCT00857675|Drug|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
26239|NCT00857675|Drug|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
26240|NCT00857675|Drug|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
26241|NCT00857688|Drug|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
26242|NCT00857688|Other|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
30179|NCT00900419|Procedure|biopsy|Laboratory Test
30180|NCT00900432|Other|immunoenzyme technique|
30181|NCT00900432|Other|laboratory biomarker analysis|
30182|NCT00900445|Drug|daunorubicin hydrochloride|Given IV
30183|NCT00894023|Drug|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
30184|NCT00894023|Drug|IV abciximab|IV abciximab + infusion
30185|NCT00894049|Drug|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
30186|NCT00894062|Device|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
30187|NCT00015925|Drug|entinostat|
30188|NCT00894062|Device|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
30189|NCT00894075|Biological|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
30208|NCT00896389|Procedure|Salt loading|We will perform salt loading intervention, a routinely prescribed diagnostic test to determine if patients have hypoaldosteronism, on 120 subjects. After overnight fasting, subjects will arrive at the Amish Research clinics. After taking height, weight, BP, and body temperature (intervention will not proceed if fever is detected), the patient will be in supine position, have IV line inserted and fitted for an automatic BP monitor. BP will be taken every 5 minutes until the last 3 SBP (systolic blood pressure) readings are within 3 mmHg. Once the BP has "equilibrated" 2 L of 0.9% NaCl (sodium chloride) saline will be intravenously infused over 4 hours. BP will be taken every 15 minutes during this procedure and for 2 hours after the intervention. Blood and urine samples will be collected from all subjects pre- and post-infusion.
30209|NCT00896389|Drug|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects.The subjects will arrive to the ARC after overnight fasting (day 1), have their height, weight, and BP measured. Subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. The subjects will return to ARC on day 8 and have height, weight, and BP measured again. Blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will come back to the ARC and repeat the 7-day diuretics intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
30210|NCT00016094|Biological|bevacizumab|Given IV
30211|NCT00896402|Drug|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
30212|NCT00896402|Drug|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
30213|NCT00896428|Drug|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
26469|NCT00928655|Drug|acetazolamide|acetazolamide 250mg 1/0/2
26470|NCT00928655|Procedure|nocturnal continuous positive airway pressure|continuous positive airway pressure
26471|NCT00928655|Drug|placebo|placebo capsules
26472|NCT00928668|Drug|Placebo|Placebo device for comparison
26473|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
26474|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
26475|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
26476|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
26477|NCT00019084|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
26478|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
26479|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
26480|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
26481|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
26482|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
26483|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
26484|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
26485|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
26486|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
26487|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
25494|NCT00859196|Drug|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
25495|NCT00859222|Drug|LBH589|Taken orally three times per week
25496|NCT00859222|Drug|bevacizumab|Given as an infusion intravenously on days 1 and 15 of each 28-day cycle
25362|NCT00853645|Device|Subcutaneous Implantable Defibrillator (S-ICD) System|
25363|NCT00853658|Drug|Enalapril monotherapy|Enalapril monotherapy -10 mg
25364|NCT00853658|Drug|Aliskiren monotherapy|Aliskiren monotherapy-150 mg titrated to 300 mg
25365|NCT00853658|Drug|Aliskiren / Enalapril combination therapy|Aliskiren / Enalapril combination therapy- 150 mg/10 mg titrated to 300 mg/ 10 mg
25366|NCT00853671|Radiation|Cardiac CT|Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; IV contrast- total dose of 150cc; CT radiation - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)
25367|NCT00853684|Drug|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
25368|NCT00853684|Drug|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
25369|NCT00856336|Drug|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
25370|NCT00000789|Drug|Stavudine|
25371|NCT00011414|Drug|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
25372|NCT00856349|Behavioral|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
25686|NCT00011960|Radiation|radiation therapy|
25687|NCT00859547|Biological|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
25688|NCT00859573|Drug|Modafinil|400 mg/day
25689|NCT00859573|Drug|Placebo|inactive substance
25690|NCT00859586|Device|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
25691|NCT00859599|Device|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
25692|NCT00859599|Device|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
26243|NCT00857701|Device|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
26551|NCT00926705|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
26552|NCT00926705|Drug|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
26553|NCT00018902|Drug|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
26554|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
26555|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
26556|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
26557|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
26558|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
26559|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
26560|NCT00926731|Drug|AZD1152|Variable dose via a 7-day continuous infusion
26561|NCT00926731|Drug|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
26562|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
26563|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
26564|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
26565|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
26566|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
26567|NCT00928694|Drug|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
26568|NCT00928694|Drug|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
26569|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
25759|NCT00856934|Other|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
25760|NCT00856947|Dietary Supplement|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
25761|NCT00856947|Other|Placebo tablet|2 tablets containing no active substance
25762|NCT00856960|Drug|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
25763|NCT00856960|Drug|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
25764|NCT00856960|Drug|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
25765|NCT00856960|Drug|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
25766|NCT00856960|Drug|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
25767|NCT00000789|Drug|Zidovudine|
25768|NCT00011596|Procedure|Gait Training|
25769|NCT00856973|Drug|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
25770|NCT00856973|Drug|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
25771|NCT00856973|Drug|Placebo|1 tablet per day for 12 weeks
25772|NCT00856986|Drug|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
25773|NCT00856986|Drug|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
25774|NCT00856986|Drug|metformin|Metformin tablets, at least 1500 mg/day
26078|NCT00860262|Drug|telmisartan|telmisartan 80mg for the 8w, no titration required
26079|NCT00860262|Drug|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
26080|NCT00860275|Drug|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
26081|NCT00860275|Drug|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
25497|NCT00859235|Drug|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
25498|NCT00859235|Other|Plain water|Mouth wash prior to procedure
25499|NCT00000202|Drug|Buprenorphine|
25500|NCT00000791|Drug|Zidovudine|
25501|NCT00011960|Drug|cisplatin|
25502|NCT00859261|Procedure|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
25503|NCT00859261|Procedure|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
25504|NCT00859274|Drug|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
25505|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
25506|NCT00861419|Drug|AMG 386|AMG 386 10 mg/kg IV (QW)
25507|NCT00861419|Drug|Sunitinib|Sunitinib 50 mg PO (QD)
25508|NCT00861419|Drug|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
25509|NCT00861419|Drug|AMG 386|AMG 386 3 mg/kg IV (QW)
25510|NCT00861432|Other|additive homeopathic treatment|These patients receive homeopathic treatment
25511|NCT00861432|Other|No additive homeopathic treatment|These patients do not receive homeopathic treatment
25512|NCT00012051|Drug|melphalan|
25513|NCT00861445|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
25830|NCT00854425|Drug|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
25831|NCT00854438|Other|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
25693|NCT00859625|Procedure|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
25694|NCT00859638|Behavioral|Physiotherapy|group self-management classes
25695|NCT00859638|Behavioral|Occupational Therapy|group self-management classes
25696|NCT00859638|Behavioral|Capacity Building|workshops and case reviews with primary health care team members
25697|NCT00011973|Drug|fenretinide|
25698|NCT00859651|Drug|cholecalciferol (capsules+placebo)|20,000 IU (2 active capsules + 1 matching placebo) PO qweek for 1 year.
25699|NCT00859651|Drug|cholecalciferol (capsules)|30,000 IU (3 active capsules) PO qweek for 1 year.
25700|NCT00859664|Other|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
25701|NCT00859703|Drug|Risedronate|35mg oral risedronate once per week for 24 months
25702|NCT00859703|Drug|Placebo|Placebo 35 mg once a week for 24 months
25703|NCT00859716|Biological|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
25704|NCT00859716|Biological|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
25705|NCT00859729|Biological|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
25706|NCT00859729|Device|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
25707|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
26014|NCT00011024|Procedure|Osteopathic Manipulation|
26015|NCT00854737|Drug|placebo|sugar pill
26016|NCT00854750|Drug|ACTHAR|SQ weekly injections
26017|NCT00854750|Drug|ACTHAR|SQ weekly injections
26018|NCT00854750|Drug|ACTHAR|SQ weekly injections
26019|NCT00854750|Drug|ACTHAR|SQ weekly injection
26020|NCT00854763|Drug|olmesartan|olmesartan
26021|NCT00854776|Drug|lansoprazole|30 mg once daily
26570|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
26571|NCT00928720|Device|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
26572|NCT00019084|Biological|sargramostim|
25579|NCT00856765|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
25580|NCT00856765|Device|Bare metal stent|Bare metal stent
25581|NCT00856765|Device|Drug eluting stent|Paclitaxel eluting stent
25582|NCT00856778|Device|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
25583|NCT00011570|Device|Bladder & Bowel Control|
25584|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
25585|NCT00859313|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
25586|NCT00859339|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
25587|NCT00859339|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
25588|NCT00859339|Drug|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
25589|NCT00859339|Procedure|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
25590|NCT00011960|Drug|paclitaxel|
25591|NCT00859352|Drug|AZD1981|oral tablets during 14 consecutive days.
25592|NCT00859352|Drug|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
25593|NCT00859365|Procedure|Real Acupuncture|Real acupuncture treatment in real acupuncture points
25594|NCT00859365|Procedure|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
25595|NCT00859365|Procedure|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
26082|NCT00852384|Procedure|NIPPV and IRM|non invasive positive pressure support ventilation (NIPPV group)
alveolar recruitment maneuver (IRM group)
26083|NCT00852397|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
26084|NCT00852397|Drug|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
26085|NCT00852397|Other|Placebo|Placebo tablet for 24 weeks
26086|NCT00852410|Drug|1% lidocaine with 1:100,000 adrenaline|high dose
26087|NCT00010751|Procedure|Reiki|
26088|NCT00852410|Drug|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
26089|NCT00852423|Drug|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
26090|NCT00852423|Drug|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
26091|NCT00852423|Drug|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
26092|NCT00852423|Drug|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
26093|NCT00852436|Drug|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
26401|NCT00921232|Behavioral|Questionnaires|During a consultation:
3 questionnaires (HADS, FRI, CRA)
and a form for the sociodemographic data
26402|NCT00921245|Drug|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
26403|NCT00921258|Procedure|prostate biopsy|patient of control group will have :
1 prostate biopsy 3 months after diagnostic biopsy
1 prostate biopsy each year during 2 years
1 prostate biopsy each 2 years during 8 years
25832|NCT00010998|Procedure|Yoga|
25833|NCT00854451|Drug|omeprazole plus amoxicillin|
25834|NCT00854451|Drug|omeprazole plus amoxicillin|
25835|NCT00854451|Drug|omeprazole plus amoxicillin|
25836|NCT00854451|Drug|omeprazole plus amoxicillin|
25837|NCT00854477|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
25838|NCT00854503|Drug|Simvastatin|20 mg/day in one oral administration
25839|NCT00854503|Drug|Rosuvastatin|20 mg/day in one oral administration.
25840|NCT00854516|Procedure|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|Procedure Schedule: The total duration for study participation will be 14 days (8 visits).
Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days.
25841|NCT00854529|Drug|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
25842|NCT00854542|Behavioral|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
25843|NCT00011011|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
25844|NCT00854555|Other|Locomotor training with robot|60 days locomotor training during 6 months periode in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
25845|NCT00854555|Other|Locomotor training with manual assistance|60 days training during 6 months periode on in-patiest setting. Training 2 times per day total 120 minutes. Control group recieves conventional training/treatment.
25846|NCT00857051|Other|Film|A DVD addressing common stressors in the early postpartum.
25847|NCT00857077|Drug|Sulfadoxine-pyrimethamine|
25848|NCT00857077|Drug|Placebo|
25849|NCT00857090|Drug|OMS201|Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery
Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery
25850|NCT00857090|Drug|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
26022|NCT00854776|Drug|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
26023|NCT00854789|Biological|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
26024|NCT00854802|Drug|Debio 025|Debio 025 supplied in soft gel capsules
26025|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10^ 7 TCID50 administered intramuscularly
26026|NCT00854802|Drug|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
26027|NCT00854802|Drug|Ribavirin|Ribavirin supplied in tablets
26028|NCT00854802|Drug|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
26029|NCT00854815|Procedure|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
26030|NCT00854815|Procedure|No Irrigation|Suction only using suction/irrigator
26031|NCT00854828|Procedure|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
26032|NCT00854828|Other|Non operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
26033|NCT00854841|Drug|Dasatinib and Imatinib|Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.
Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted.
26034|NCT00857389|Drug|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
26035|NCT00857389|Drug|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
26339|NCT00923676|Drug|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
26340|NCT00926224|Device|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
26341|NCT00926237|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) - ACTIVE|Active rTMS will be targeted according to the following decision tree: 1) to auditory cortex in the superior temporal gyrus opposite the ear with loudest tinnitus; 2) to the same region in the left temporal lobe. Active stimulation will be delivered at 110% of motor threshold (MT) at a frequency of 1 or 10 Hz for a total of 1800 magnetic pulses per session (and a total of 4 sessions per week of active rTMS therapy).
25596|NCT00859378|Device|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith & Nephew)
25597|NCT00859378|Device|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
25598|NCT00859404|Drug|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
25599|NCT00859417|Procedure|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
25600|NCT00859417|Device|Perigee® prosthesis|Surgical method with Perigee® prosthesis
25601|NCT00011960|Procedure|adjuvant therapy|
25918|NCT00852215|Device|Vision stent|Stenting with VISION coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
25919|NCT00852228|Drug|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
25920|NCT00852228|Drug|HAI chronomodulated chemotherapy|Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00
Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.
5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.
Treatments will be repeated every 2 weeks.
25921|NCT00852228|Drug|HAI conventional chemotherapy|Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then
Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then
5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.
Treatments will be repeated every 2 weeks.
25922|NCT00854568|Drug|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
25923|NCT00854568|Drug|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
25924|NCT00854581|Biological|PEG-interferon alfa-2b|PEG-IFN-alfa2b 1.5 ug/kg SQ weekly.
25925|NCT00854581|Biological|Interferon alfa-2b|Days 3 - 14: Interferon Alpha-2b 5 10 million units IV twice daily.
25926|NCT00854581|Drug|Valproic Acid|Patients will be started on one capsule (250 mg) with water twice daily.
25927|NCT00854581|Drug|Zidovudine|Days 1-2: (0-48 hours) Zidovudine (AZT) 1.5 grams intravenously (IV) twice daily. Days 3-14: Zidovudine (AZT) 1.5 grams IV twice daily and Interferon Alpha-2b 5 10 million units IV twice daily. Subsequent doses dependent on patient response.
25928|NCT00854581|Genetic|Molecular Evaluation/Analysis of Malignant Clones of ATLL|Blood Sample - Baseline/Pre-Treatment, months 3 and 6, End of Month 12, Disease Progession
26404|NCT00921271|Device|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
26405|NCT00921284|Drug|NaCl 9/00|Same volume as in the dexmedetomidine group
26406|NCT00018174|Drug|Placebo|
26407|NCT00921284|Drug|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
26408|NCT00921297|Procedure|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
26409|NCT00921310|Drug|Pemetrexed|
26410|NCT00921310|Drug|Temsirolimus|
26411|NCT00921323|Behavioral|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
26412|NCT00923702|Biological|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants will be randomly allocated in equal numbers to receive either two or three doses of the vaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18. Girls in the two-dose group will receive the vaccine at Day 1 and Day 180, girls in the three-dose group will receive the vaccine at Day 1, Day 60, and Day 180.
26413|NCT00923715|Drug|Insulin|Dose will be as per usual home regimen.
26414|NCT00923715|Drug|Insulin and Exenatide|Exenatide 1.25 up to 2.5 mcg will be given before breakfast and before supper
26415|NCT00923715|Drug|Insulin and Pramlintide|Pramlintide 15 to 45 mcg will be given before breakfast and supper
26416|NCT00018447|Drug|MFPSR-fluoride|
26417|NCT00923728|Drug|AVN944|
26418|NCT00923741|Drug|Talactoferrin|
26419|NCT00923741|Procedure|Apheresis|
26420|NCT00923793|Device|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
26421|NCT00923793|Device|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
26422|NCT00923806|Biological|PG13-CEA_TCR (Anti-CEA TCR PBL)|
25436|NCT00861276|Drug|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
26159|NCT00860301|Other|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
26160|NCT00860314|Procedure|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
26161|NCT00860314|Procedure|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
26162|NCT00860340|Drug|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
26163|NCT00011999|Radiation|radiation therapy|
26164|NCT00860353|Drug|AZD2551|Single dose of oral solution.
26165|NCT00860353|Drug|Placebo|Single dose of oral solution
26166|NCT00860366|Drug|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
26167|NCT00860366|Other|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
26168|NCT00860379|Drug|Selenium1|2 ug/kg
26169|NCT00860379|Drug|Selenium2|4 ug/kg
26170|NCT00860379|Drug|Placebo|IV saline as placebo
26171|NCT00860392|Drug|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
26172|NCT00860405|Drug|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
26173|NCT00860405|Drug|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
26174|NCT00012012|Drug|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
26175|NCT00860418|Behavioral|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
26176|NCT00852475|Dietary Supplement|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA diet and exercise
26342|NCT00926237|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) - SHAM|Sham rTMS will be targeted using a commercially available sham coil and delivered to the same site within the temporal lobe as active rTMS and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
26343|NCT00926250|Dietary Supplement|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
26344|NCT00926250|Dietary Supplement|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
26345|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
26346|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
26347|NCT00926263|Biological|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
26348|NCT00926276|Procedure|Fundoplication|Fundoplication
26349|NCT00018850|Drug|haloperidol|
26350|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
26351|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
26352|NCT00926289|Drug|Hydrochlorothiazide|Hydrochlorothiazide25mg
26353|NCT00926302|Drug|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
26354|NCT00926302|Drug|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
26355|NCT00926315|Drug|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
26356|NCT00926315|Drug|Calcitriol|calcitriol 0.25 mcg PO bid
26357|NCT00926328|Drug|Triclosan, fluoride|Six Month study, brush twice daily
26358|NCT00926328|Drug|Fluoride|twice daily usage
25373|NCT00856362|Drug|Moxidectin|
25374|NCT00856362|Drug|Midazolam|
25375|NCT00856375|Drug|NKTR-102|IV every 3 weeks
25376|NCT00856375|Drug|irinotecan|IV every 3 weeks
25929|NCT00854581|Genetic|NF-kB Inhibition|Blood Sample - Baseline/Pre-Treatment, Induction,
25930|NCT00011024|Procedure|Self Hypnosis|
25931|NCT00854594|Behavioral|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
25932|NCT00854607|Other|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
25933|NCT00854620|Drug|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
25934|NCT00854633|Drug|Talactoferrin|Enteral, 150 mg/kg twice per day
25935|NCT00854633|Drug|Placebo|Oral, twice per day
26244|NCT00857714|Drug|lapatinib|1500 mg lapatinib for 14-21 days
26245|NCT00857727|Drug|Dexmedetomidine|Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
26246|NCT00011830|Procedure|Apheresis|
26247|NCT00857727|Drug|Saline|Given by a continuous infusion
26248|NCT00857740|Behavioral|Education|Education about the neurophysiology of pain
26249|NCT00857753|Drug|Fentanyl patch 25 ug/nr Sandoz|
26250|NCT00857753|Drug|Duragesic|
26251|NCT00857766|Drug|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
26252|NCT00857766|Other|Placebo|COPD subjects-Placebo DISKUS
26253|NCT00925990|Drug|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
26254|NCT00925990|Drug|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
26255|NCT00018850|Drug|ondansetron|
26256|NCT00925990|Drug|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
25437|NCT00861276|Drug|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
25438|NCT00861302|Behavioral|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
25439|NCT00861315|Drug|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
25440|NCT00853697|Other|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.
Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study).
25441|NCT00853710|Other|PSA assay|rapid prostate specific antigen assay.
25442|NCT00010933|Drug|chamomile tea|
25443|NCT00853723|Drug|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
25444|NCT00853723|Drug|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
25445|NCT00853723|Drug|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
25446|NCT00853736|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
25447|NCT00853736|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
25448|NCT00853749|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
25449|NCT00853749|Procedure|Blood draw|Collection of 10 mL of blood
25450|NCT00853762|Drug|Atacicept|During Part A subjects will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) i.e. 25mg once a week (QW) subcutaneously (SC), 75mg QW SC or 150mg QW SC. Subjects randomized to placebo in ATAMS will receive atacicept 150mg QW SC without loading dose. Once the results of ATAMS are available and the atacicept dose with the best benefit/risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). The study treatment period will be up to five years starting from first administration of the first dose of atacicept from the core study (28063 - ATAMS).
25451|NCT00853762|Drug|Atacicept|Best benefit / risk ratio treatment of Atacicept dose that has been identified
25452|NCT00853775|Other|No intervention, observational study|
26177|NCT00852488|Procedure|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
26488|NCT00019084|Biological|ras peptide cancer vaccine|
26489|NCT00921336|Drug|KW-2450|Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
26490|NCT00921349|Procedure|Ligation of varices|all varices are ligated until obliteration
26491|NCT00921349|Drug|Nadolol|Nadolol (beta-blocker)
26492|NCT00921375|Drug|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
26493|NCT00921388|Other|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
26494|NCT00000829|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
26495|NCT00018187|Drug|Bupropion|
26496|NCT00921388|Behavioral|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
26497|NCT00921401|Behavioral|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
26498|NCT00921414|Drug|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
26499|NCT00921414|Other|Watch and wait|No treatment patient follow-up every 2 months during 3 years
26500|NCT00921427|Behavioral|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
26501|NCT00921427|Device|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
26502|NCT00921492|Device|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
26503|NCT00921492|Other|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
26504|NCT00921505|Drug|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
25377|NCT00856388|Drug|fludarabine phosphate|Given IV
25378|NCT00856388|Drug|melphalan|Given IV
25379|NCT00856388|Radiation|total-body irradiation|Undergo total-body irradiation
25380|NCT00856388|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
25381|NCT00856388|Biological|anti-thymocyte globulin|Given IV
25382|NCT00011479|Drug|Abacavir sulfate|
25383|NCT00856401|Drug|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
25384|NCT00856414|Biological|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
25385|NCT00856427|Radiation|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
25386|NCT00856427|Procedure|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
25387|NCT00856440|Drug|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
25388|NCT00856440|Drug|Colyte|Lavage preparation for colonoscopy
25389|NCT00856440|Drug|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
25390|NCT00856453|Behavioral|Home yoga practice|training for and tracking of patient's practice of yoga at home
25391|NCT00856453|Procedure|yoga classes|organized out of home classes for yoga
25392|NCT00856479|Device|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse" is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. "Infuse" may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention.
25393|NCT00011505|Drug|G-CSF|
25394|NCT00856479|Procedure|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
25395|NCT00858975|Procedure|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
25396|NCT00858988|Drug|Rifaximin|
25708|NCT00851786|Biological|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
26257|NCT00926003|Behavioral|Computerized cognitive rehabilitation therapy (CCRT)|8 weeks of 3 times weekly intervention for 45 min per session with Captain's Log program
26258|NCT00926003|Behavioral|control group|no computer training
26259|NCT00926016|Drug|Pioglitazone (Actos)|pioglitazone 45 mg a day
26260|NCT00926029|Drug|Fluoride|Brush twice daily
26261|NCT00926029|Drug|Triclosan, fluoride|Brush twice daily
26262|NCT00926029|Other|Metal salt|Brush twice daily
26263|NCT00926055|Drug|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
26264|NCT00926055|Drug|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
26265|NCT00926068|Drug|HO/03/03 10µg|
26266|NCT00018850|Behavioral|neuropsychological testing|
26267|NCT00926068|Drug|Placebo|
26573|NCT00928720|Device|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
26574|NCT00928733|Device|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
26575|NCT00928746|Device|Ipratropium bromide|
26576|NCT00928772|Device|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
26577|NCT00928772|Drug|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
26578|NCT00928772|Other|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
26579|NCT00928785|Biological|REPEVAX|1 dose of 0.5 mL at Day 0
26580|NCT00928785|Biological|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
26581|NCT00928798|Drug|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
26582|NCT00928798|Drug|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
25453|NCT00010933|Procedure|Relaxation/Guided Imagery|
25775|NCT00856999|Drug|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
25776|NCT00857025|Biological|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
25777|NCT00857025|Other|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
25778|NCT00857025|Other|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
25779|NCT00011609|Device|Robotic Arm|
25780|NCT00857025|Other|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
25781|NCT00857038|Drug|Doxycycline|Doxycycline tablets, 100mg daily
25782|NCT00857038|Drug|Placebo|Placebo tablets 100mg
25783|NCT00857051|Other|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
25784|NCT00859742|Procedure|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
25785|NCT00011986|Drug|ABI-007/carboplatin/trastuzumab|Given IV
25786|NCT00859755|Drug|ARRY-403, glucokinase activator; oral|single dose, escalating
25787|NCT00859755|Drug|Placebo; oral|matching placebo
25788|NCT00859768|Other|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
25789|NCT00859781|Drug|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
25790|NCT00859781|Drug|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
25791|NCT00859781|Drug|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
26505|NCT00921505|Drug|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
26506|NCT00018187|Drug|Mecamylamine|
26507|NCT00921505|Drug|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
25514|NCT00861445|Other|Placebo|Placebo tablets two times a day for 10 weeks
25515|NCT00861458|Drug|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
25516|NCT00861471|Drug|Docetaxel|One treatment cycle is defined as 21 days.
Docetaxel: 70 mg/m^2 (60 mg/m^2 was tested in Phase I as well), Intravenous, every 21 days.
25517|NCT00861471|Drug|Imatinib Mesylate|One treatment cycle is defined as 21 days.
Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days.
25518|NCT00861484|Drug|GSK958108|Coated Tablets 1 mg
25519|NCT00861484|Drug|Placebo|Coated tablets
25520|NCT00861497|Drug|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
25521|NCT00861510|Drug|ON01910 Na|
25522|NCT00861523|Drug|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
25523|NCT00000793|Drug|Benztropine mesylate|
25524|NCT00012051|Drug|methotrexate|
25525|NCT00861536|Drug|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
25526|NCT00861536|Drug|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
25527|NCT00861549|Drug|Phencynonate hydrochloride|2mg/tablet
25528|NCT00861562|Drug|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
25529|NCT00861562|Drug|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
25530|NCT00861588|Drug|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
25531|NCT00861588|Drug|placebo|starch placebo
25532|NCT00861601|Drug|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
25533|NCT00861601|Drug|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
25709|NCT00851786|Biological|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
25710|NCT00851799|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
Other Name: TDF/FTC
25711|NCT00851799|Drug|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
Other Name: RTV
25712|NCT00851799|Drug|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
Other Name: ATV
25713|NCT00010634|Drug|glutamine|
25714|NCT00851799|Drug|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
Other Name: RAL
25715|NCT00851799|Drug|Darunavir|100 mg taken orally once daily. A protease inhibitor (PI).
Other Name: RTV
25716|NCT00851812|Behavioral|Exercise|Standard care monitoring
25717|NCT00851812|Behavioral|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
25718|NCT00851838|Drug|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
25719|NCT00851864|Drug|Tinzaparin|LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.
Treatment will be done for the duration of the pregnancy.
25720|NCT00851877|Biological|cetuximab|cetuximab infusion
25721|NCT00851877|Drug|cisplatin|cisplatin
25722|NCT00851877|Drug|paclitaxel albumin-stabilized nanoparticle formulation|paclitaxel albumin-stabilized nanoparticle formulation
25723|NCT00851877|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiation therapy
25724|NCT00010647|Procedure|Acupuncture|
25725|NCT00851877|Radiation|intensity-modulated radiation therapy|intensity-modulated radiation therapy
25726|NCT00851890|Drug|ABT-333|50 mg capsules
25727|NCT00851890|Other|Placebo for ABT-333|Capsule
25728|NCT00851890|Drug|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
25729|NCT00851890|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
26583|NCT00019084|Biological|therapeutic autologous lymphocytes|
26584|NCT00928811|Drug|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
26585|NCT00928811|Drug|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
26586|NCT00921518|Drug|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
26587|NCT00921531|Drug|Thalidomide|Thalidomide is used for adjuvant therapy for TACE
Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day.
26588|NCT00921531|Drug|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
26589|NCT00921544|Other|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
26590|NCT00921544|Other|Sterile water|Sterile water administered 2 mins prior to eye exam
26591|NCT00921557|Drug|Alendronate|Oral tablet taken once weekly. Dosage is dependent on body weight
26592|NCT00921557|Drug|Alendronate placebo|Oral tablet taken once weekly
25602|NCT00859430|Drug|Levetiracetam|1000 mg Tablet
25603|NCT00859430|Drug|Keppra®|1000 mg Tablet
25604|NCT00859456|Drug|Sunitinib|Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.
25605|NCT00859469|Drug|Oxaliplatin/Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes followed by oxaliplatin 100 mg/m2 IV infusion for 2 hours repeated for 14 days up to 6 cycles
25606|NCT00859495|Drug|Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)|Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.
25607|NCT00859508|Device|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
25608|NCT00012051|Radiation|radiation therapy|
25609|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
25792|NCT00859781|Drug|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
25793|NCT00859794|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognitive functions.
25794|NCT00859794|Other|Releasing Data|Subjects in the study will be asked to release data about their surgery, and electrostimulation to the research team for analysis.
26094|NCT00852436|Drug|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
26095|NCT00852449|Other|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation > 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity < 13% and no further increases in SV
26096|NCT00852462|Behavioral|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
26097|NCT00852475|Dietary Supplement|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA diet and exercise program
26098|NCT00000782|Biological|gp160 Vaccine (Immuno-AG)|
26099|NCT00010764|Procedure|Acupuncture|
26100|NCT00854854|Biological|TKCell|TKCell 150ml IV for 7times after each FOLFOX-4 regimen :
From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8
26101|NCT00854867|Drug|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
26102|NCT00011037|Biological|MN rgp120/HIV-1|0.6 mg administered intramuscularly
26103|NCT00854867|Drug|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
26104|NCT00854880|Drug|PDC339|
26105|NCT00854880|Drug|Placebo|
26106|NCT00854893|Device|transcranial direct current stimulation|1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
26107|NCT00854919|Drug|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
25534|NCT00861614|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
25535|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
25536|NCT00853840|Drug|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
25851|NCT00857103|Behavioral|CHOICE|Use of Choice support system as preparation for patient consultations
25852|NCT00011622|Device|Continuous ambulatory subcutaneous glucose monitor|
25853|NCT00857116|Drug|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
25854|NCT00857116|Drug|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
25855|NCT00857129|Procedure|Normal Unit|low-risk patients randomised to Normal Unit
25856|NCT00857129|Procedure|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
25857|NCT00857142|Drug|oxymorphone hydrochloride|
25858|NCT00857142|Drug|Opana|
25859|NCT00857155|Other|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
25860|NCT00857168|Drug|Testosterone MD-Lotion|
25861|NCT00857194|Procedure|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
25862|NCT00857194|Procedure|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
25863|NCT00011635|Drug|Silymarin (milk thistle)|
25864|NCT00857207|Behavioral|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
25865|NCT00857220|Drug|eszopiclone|One 2 mg tablet per day for 12 months
25866|NCT00857220|Drug|eszopiclone|one 3mg tablet per day for 12 months
25730|NCT00851903|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
26036|NCT00857389|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
26037|NCT00011752|Drug|FCWAY|
26038|NCT00857389|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
26039|NCT00857389|Drug|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
26040|NCT00857389|Drug|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
26041|NCT00857402|Dietary Supplement|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
26042|NCT00857402|Dietary Supplement|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
26043|NCT00857415|Drug|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
26044|NCT00857428|Drug|oxymorphone|Tablets
26045|NCT00857428|Drug|Oxymorphone|40 mg tablets
26046|NCT00857441|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
26047|NCT00857441|Device|Liberté|Bare metal stent
26048|NCT00011765|Drug|Fluoxetine|
26049|NCT00857441|Device|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
26050|NCT00857441|Device|Taxus|Paclitaxel eluting stent
26051|NCT00857454|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
26052|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
26053|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
26054|NCT00857480|Drug|NRL972|Single intravenous administration of 2 mg NRL972
25610|NCT00861744|Biological|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
25611|NCT00861744|Biological|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
25612|NCT00861744|Biological|Varivax®|Subcutaneous injection, one dose
25613|NCT00861744|Biological|Havrix®|Intramuscular injection, one dose
25614|NCT00861744|Biological|Prevnar®|Intramuscular injection, one dose
25615|NCT00861757|Drug|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
25616|NCT00861757|Drug|Placebo|PO, QD (30 min after meal) for 12 weeks
25617|NCT00861757|Drug|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
25618|NCT00861770|Other|Ultrafiltration|Ultrafiltration based on standard of care.
25619|NCT00012064|Biological|therapeutic autologous dendritic cells|Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
25620|NCT00861770|Other|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
25621|NCT00861783|Drug|irinotecan and ON 01910.Na|ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.
Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling.
25936|NCT00854646|Drug|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
25937|NCT00854659|Drug|ABT-102|BID tablets, 7 days of treatment
25938|NCT00854659|Drug|Placebo|BID tablets, 7 days of treatment
25939|NCT00854685|Drug|ART621|3.0mg/kg s.c. - weekly
25940|NCT00854685|Drug|ART621|3.0mg/kg s.c. - fortnightly
25941|NCT00000788|Drug|Methadone hydrochloride|
25942|NCT00011024|Procedure|Acupuncture|
25943|NCT00854685|Drug|ART621|1.5mg/kg s.c. - weekly
26108|NCT00854919|Behavioral|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
26109|NCT00854932|Other|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
26110|NCT00854945|Drug|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
26111|NCT00854971|Biological|TKCell|Biological/Vaccine: TKCell
26423|NCT00923806|Drug|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
26424|NCT00923819|Procedure|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from other hospitals in Norway. The procedure will take place at the Hospital of Vestfold.
26425|NCT00923819|Behavioral|Standard conservative treatment|The participants are included for 2 years follow-up with visits to a multidisciplinary team every 3rd month, either at the Morbid Obesity Center or a similar center in Norway.
26426|NCT00923845|Drug|Pentostatin|Pentostatin: 2- 4mg/m^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
26427|NCT00018460|Drug|Vitamin B|
26428|NCT00923845|Drug|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
26429|NCT00923845|Drug|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
26430|NCT00923845|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
26431|NCT00923845|Procedure|Th2 rapa cells|Th2 rapa cell Transplantation
26432|NCT00923845|Procedure|Donor Lymphocyte Harvest|Apheresis
26433|NCT00923845|Procedure|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
26434|NCT00923845|Procedure|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
26435|NCT00923845|Procedure|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
26436|NCT00923871|Procedure|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
26437|NCT00926367|Drug|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
25867|NCT00857233|Drug|Memantine|20 mg oral tablets once daily
25868|NCT00857246|Drug|Cetuximab|
25869|NCT00857246|Drug|Irinotecan|
25870|NCT00857246|Drug|Cisplatin|
25871|NCT00857246|Procedure|Surgery|
25872|NCT00857246|Drug|5-FU|
26178|NCT00852501|Other|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
26179|NCT00852514|Device|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
26180|NCT00852540|Drug|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
26181|NCT00852540|Drug|Linezolid|Adult and adolescent (=>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects <5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
26182|NCT00852566|Drug|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
26183|NCT00852566|Drug|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
26184|NCT00852579|Drug|Azithromycin|Daily dose 250mg
26185|NCT00852579|Drug|Placebo|Placebo
26186|NCT00010777|Procedure|Multiple Component Mind/Body therapy|
26187|NCT00852592|Device|active light therapy unit|dosage - 15-60minutes NOON-2PM daily
26188|NCT00852592|Device|Inactive light therapy unit|dosage: 15-60minutes NOON-2PM daily
26189|NCT00852605|Other|Intermittent Non-Invasive Ventilation|
26190|NCT00852631|Drug|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
26191|NCT00852644|Procedure|computed tomography|Standard CT scans
26055|NCT00857480|Drug|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
26056|NCT00857480|Drug|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
26057|NCT00857493|Biological|IMVAMUNE|Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
26359|NCT00926341|Drug|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
26360|NCT00000832|Biological|MF59|
26361|NCT00018863|Drug|Methylphenidate|
26362|NCT00926341|Drug|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
26363|NCT00926354|Drug|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
26364|NCT00928343|Drug|Placebo|Matching subcutaneous or oral placebo
26365|NCT00928356|Procedure|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
26366|NCT00928356|Procedure|Off Pump CABG|Standard of Care Off Pump CABG
26367|NCT00928395|Device|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
26368|NCT00928408|Drug|Cinacalcet|
26369|NCT00928421|Drug|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
26370|NCT00928434|Drug|Degarelix|
26371|NCT00019071|Drug|cladribine|
26372|NCT00928434|Drug|Degarelix|
26373|NCT00928434|Drug|Lupron (Leuprolide)|
26374|NCT00928447|Drug|rHuPH20|ID syringe push bolus injection of either rHuPH20 or placebo control. Each injection will be administered once daily for 5 days.
26375|NCT00928460|Procedure|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
25944|NCT00854685|Drug|ART621|1.5mg/kg s.c. - fortnightly
25945|NCT00854685|Drug|Placebo|Placebo s.c. - weekly
25946|NCT00854685|Drug|Placebo|Placebo s.c. - fortnightly
25947|NCT00854698|Other|exercise training|subjects are asked to exercise 20 or 30 minutes.
25948|NCT00857246|Radiation|Radiation|
25949|NCT00011661|Behavioral|Education on behaviors to reduce lead exposure|
25950|NCT00857259|Drug|Everolimus|5 mg oral tablet
25951|NCT00857259|Drug|Ranibizumab|0.5 mg administered by intravitreal injection
25952|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
25953|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
25954|NCT00857285|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
25955|NCT00857285|Drug|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
25956|NCT00857298|Behavioral|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be ~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
25957|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
25958|NCT00857311|Biological|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
26268|NCT00926081|Behavioral|Supervised exercise training|A standardized supervised exercise training program
26269|NCT00926107|Drug|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
26270|NCT00926120|Dietary Supplement|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
26271|NCT00926133|Other|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
26272|NCT00926146|Behavioral|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
26438|NCT00926367|Drug|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
26439|NCT00926380|Drug|denosumab|denosumab: 60 mg SC every 6 months
26440|NCT00926380|Drug|teriparatide|teriparatide: 20 mcg SC QD
26441|NCT00926393|Drug|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
26442|NCT00926393|Drug|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
25454|NCT00853801|Behavioral|Lifestyle intervention and provider feedback|Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.
Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months.
25455|NCT00853814|Behavioral|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
25456|NCT00853827|Drug|Placebo|Placebo
25457|NCT00853827|Drug|Aliskiren|300 mg
25458|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
25459|NCT00853840|Drug|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
25460|NCT00856492|Biological|bevacizumab|Given IV
25461|NCT00856492|Biological|pegfilgrastim|Given subcutaneously
25462|NCT00856492|Drug|cyclophosphamide|Given IV
25463|NCT00856492|Drug|doxorubicin hydrochloride|Given IV
25464|NCT00856492|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
25465|NCT00856505|Drug|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
25466|NCT00856518|Device|Expiratory Muscle Strength Trainer|Pressure threshold device targeted at increase muscle force generation of expiratory and submental muscles.
26192|NCT00852644|Radiation|fludeoxyglucose F 18|standard doses with CT scans
26193|NCT00852644|Radiation|hypofractionated radiation therapy|4 doses over 2 weeks
26194|NCT00852644|Radiation|stereotactic radiosurgery|CyberKnife radiosurgery
26195|NCT00852657|Procedure|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
26196|NCT00852657|Procedure|Physiotherapy|According to a rehabilitation program which was established prior to study start.
26197|NCT00010803|Drug|Ginkgo biloba|120mg twice a day
26198|NCT00852670|Drug|ACT-128800|ACT-128800 administered orally once daily
26508|NCT00921505|Drug|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
26509|NCT00921518|Drug|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
26510|NCT00923897|Radiation|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
26511|NCT00000831|Drug|Stavudine|
26512|NCT00018512|Procedure|Implant-supported denture|
26513|NCT00923910|Drug|WT1 Peptide-Pulsed Dendritic Cells|
26514|NCT00923910|Drug|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
26515|NCT00923910|Drug|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
26516|NCT00923910|Drug|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
26517|NCT00923910|Drug|WT1 Peptides|dendritic cell vaccine
26518|NCT00923910|Drug|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
26519|NCT00923910|Drug|Diphenhydramine|Pre-medication
26520|NCT00923910|Drug|Acetaminophen|Pre-medication
26521|NCT00923923|Behavioral|stress|compare levels of stress
26376|NCT00928473|Behavioral|Weightloss treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
26377|NCT00928486|Drug|CC-5013 (lenalidomide)|initial dose 25mg for one cycle (days 1 - 21)
26378|NCT00928486|Drug|dexamethasone|40 mg once daily on days 1 -4 , 9 - 12 and 17 - 20 of each cycle
26379|NCT00928499|Device|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
26380|NCT00928512|Drug|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
25397|NCT00859001|Drug|FM+R|Fludarabine-Mitoxantrone-Rituximab
25398|NCT00859001|Drug|Zevalin (Ibritumomab Tiuxetan)|
25399|NCT00011934|Biological|recombinant interferon alfa|
25400|NCT00859014|Biological|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
25401|NCT00859027|Drug|risedronate|35 mg/week by mouth
25402|NCT00859027|Drug|placebo|One tablet by mouth every week as directed
25403|NCT00859040|Drug|SOM230C|Injection in the buttocks every 28 days
25404|NCT00859053|Drug|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
25405|NCT00859079|Drug|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
25406|NCT00859079|Drug|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
25407|NCT00859092|Dietary Supplement|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
25408|NCT00859105|Drug|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
25409|NCT00859105|Drug|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
25410|NCT00011934|Biological|sargramostim|
25411|NCT00859105|Drug|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
26273|NCT00926146|Behavioral|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
26274|NCT00926185|Drug|Lifitegrast|Ophthalmic Solution
26275|NCT00926185|Drug|Placebo|Ophthalmic Solution
26276|NCT00926211|Device|ARTAS™ System|Hair harvest using a computer-assisted system
26277|NCT00018850|Drug|nicotine|
26278|NCT00926211|Procedure|Manual Hair Harvest|Hair harvesting via the manual technique
26279|NCT00928226|Device|Linear accelerator|Standard of care
26280|NCT00928239|Procedure|laparoscopic sacropexy with mid vaginal attachment|supracervical hysterectomy for uterine prolapse
exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior
dissection up to ventrolateral part of the levator ani muscle
Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder
Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment
suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump
placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex
suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2
26281|NCT00928239|Procedure|laparoscopic sacropexy with caudal vaginal attachment|supracervical hysterectomy for uterine prolapse
exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior
dissection up to ventrolateral part of the levator ani muscle
Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder
Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment
suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump
placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex
suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2
26282|NCT00928252|Drug|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
26593|NCT00018187|Drug|Nicotine Patch|
26594|NCT00921557|Dietary Supplement|Calcium carbonate/vitamin D|Tablet taken once or twice daily. Dosage is dependent on participant's measured vitamin D levels
26595|NCT00921570|Drug|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
26596|NCT00921570|Drug|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
26597|NCT00921583|Device|Long-term examination|Follow-up dental implants 20 year in function
25467|NCT00856518|Device|sham device|Looks just like the EMST device but does not provide a load on the target muscle group
25468|NCT00856544|Drug|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
25469|NCT00011505|Procedure|Leukapheresis|
25470|NCT00856544|Drug|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
25471|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
25472|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
25473|NCT00856557|Behavioral|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
25474|NCT00856570|Drug|warfarin|Oral
25795|NCT00859794|Other|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsych evaluations for analysis.
25796|NCT00011986|Drug|gemcitabine hydrochloride|Given IV
25797|NCT00859794|Other|Additional electrode implantation|Subjects normally will have anywhere from 100-200 electrodes implanted as part of their surgery. As part of the study, we would implant 1-2 electrodes that are able to record from smaller, more specific parts of the brain to better understand how your brain is wired.
25798|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
25799|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
25800|NCT00859833|Drug|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
25801|NCT00859833|Drug|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
25802|NCT00859846|Procedure|Arterial line placement|The following measures will be collected and compared.
Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.
number of attempts, defined as forward advancements of needle, required to cannulate the artery.
number of separate skin punctures.
number of arteries into which entry is attempted.
25803|NCT00851929|Drug|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
25804|NCT00010686|Drug|Dietary Phytoestrogens|
25805|NCT00851942|Drug|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
26522|NCT00923936|Drug|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m2 and bevacizumab every 3 weeks for six cycles.
26523|NCT00018525|Procedure|Lung Volume Reduction Surgery|
26524|NCT00923936|Drug|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
26525|NCT00923949|Drug|Pioglitazone|45 mg tablet daily by mouth for six weeks
26526|NCT00923962|Drug|Glucagon like peptide-1|0,1 pmol/kg/min
26527|NCT00923962|Drug|Adenosine|20-40 microgram/minute
26528|NCT00923975|Device|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
25537|NCT00853853|Device|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
25538|NCT00853853|Procedure|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
25539|NCT00000787|Behavioral|Pre- and post-test counseling|
25540|NCT00010946|Procedure|Acupuncture|
25541|NCT00853866|Drug|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
25542|NCT00853866|Drug|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
25543|NCT00853866|Device|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
25544|NCT00853866|Device|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
25545|NCT00853879|Dietary Supplement|Folic Acid, Vitamin B6, Vitamin B12|Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as "triple therapy with folate."
25546|NCT00853879|Dietary Supplement|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
25412|NCT00859105|Drug|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
25413|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
25414|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
25415|NCT00859131|Drug|Rabbit Antithymocyte globulin|1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
25416|NCT00859131|Drug|Daclizumab|1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
25417|NCT00859144|Behavioral|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
25731|NCT00851903|Drug|Sitagliptin|Oral administration. 100mg film-coated tablets.
25732|NCT00851903|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
25733|NCT00851916|Radiation|CyberKnife Radiosurgery|CyberKnife Radiosurgery
25734|NCT00854113|Drug|Placebo|Placebo to match EGT0001474
25735|NCT00854126|Drug|GDC-0980|Escalating repeating dose
25736|NCT00010985|Procedure|Acupuncture|
25737|NCT00854139|Drug|Cyclophosphamide, anti-thymocyte globulin|Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5
Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications
25738|NCT00854139|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
25739|NCT00854139|Radiation|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
25740|NCT00854139|Procedure|Bone marrow transplant from a related donor|• Donor bone marrow (> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is > 60 seconds, the protamine treatment shall be repeated
25741|NCT00854152|Drug|GDC-0980|Escalating repeating dose
26598|NCT00921596|Procedure|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
26599|NCT00921609|Other|OGTT|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
26600|NCT00921622|Dietary Supplement|Vitamin D|1000 IU twice daily for up to 10 days
26601|NCT00921622|Dietary Supplement|Vitamin C|500 mg twice daily for up to 10 days
26602|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
26603|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
26604|NCT00018200|Drug|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
26605|NCT00921661|Drug|AVE0005 (aflibercept)|IV infusion
26606|NCT00921674|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
26607|NCT00921687|Behavioral|Education only|The education will consist of a lecture and distribution of a CKD reference card.
26608|NCT00924014|Drug|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
26609|NCT00924014|Drug|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
26610|NCT00924027|Radiation|Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
26611|NCT00924040|Drug|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
29830|NCT00897988|Genetic|gene expression analysis|
29831|NCT00897988|Genetic|mutation analysis|
29832|NCT00897988|Genetic|polyacrylamide gel electrophoresis|
25806|NCT00851968|Procedure|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
25807|NCT00851968|Procedure|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
25808|NCT00851968|Procedure|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
25809|NCT00851981|Other|Placebo|TID
25810|NCT00851981|Dietary Supplement|SAMe|300 mg TID
25811|NCT00852007|Biological|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
26112|NCT00854984|Behavioral|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
26113|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
26114|NCT00855010|Drug|pioglitazone|pioglitazone 45 mg daily
26115|NCT00855010|Drug|placebo|one daily
26116|NCT00855036|Other|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
26117|NCT00855049|Drug|Acetaminophen|Intranasal acetaminophen administration
26118|NCT00855049|Drug|Acetaminophen|Oral acetaminophen administration
26119|NCT00855062|Drug|minocycline|100 mg capsule every 12 hours by mouth
26120|NCT00855062|Drug|minocycline placebo capsule|1 capsule every 12 hours by mouth
26121|NCT00855075|Device|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
26122|NCT00855088|Drug|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
26123|NCT00855088|Drug|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
26124|NCT00011778|Drug|bortezomib|
25547|NCT00853879|Dietary Supplement|B6, B12, Placebo|Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as "triple therapy with placebo"
25548|NCT00853892|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
25549|NCT00853892|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
25550|NCT00853905|Drug|Triesence|At the end of standard glaucoma surgery after the anterior chamber is reformed with balanced salt solution or viscoelastic to adequate intraocular pressure; 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound
25551|NCT00010959|Drug|Cimicifuga racemosa|
25552|NCT00853905|Drug|balanced salt solution BSS|standard technique for glaucoma surgery . At the end of the case anterior chamber will be reformed with balanced salt solution to adequate intraocular pressure.
25553|NCT00853918|Other|$20 cash|$20 cash incentive mailed with survey
25554|NCT00853918|Other|$50 cash|$50 cash incentive mailed with survey
25873|NCT00859859|Device|Vagus Nerve Stimulation|Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.
Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed.
25874|NCT00859872|Drug|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
25875|NCT00859872|Drug|haloperidol|haloperidol IM injection (5-20mg/d)
25876|NCT00859885|Drug|Antithrombotic treatment|antiplatelets, anticoagulants
25877|NCT00011986|Drug|17-N-allylamino-17-demethoxygeldanamycin/paclitaxel|Given IV
25878|NCT00859885|Device|percutaneous device closure of PFO|umbrella device for PFO closure
25879|NCT00859898|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
25880|NCT00859898|Drug|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
25881|NCT00859898|Drug|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
25882|NCT00859898|Drug|dapagliflozin matching Placebo|
25883|NCT00859898|Drug|metformin HCl Modified Release matching Placebo|
25742|NCT00854178|Drug|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
25743|NCT00854191|Device|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
25744|NCT00854204|Drug|TMC114; TMC41629|
25745|NCT00854217|Procedure|acute normovolemic hemodilution|
25746|NCT00854230|Drug|Naltrexone|Naltrexone dose 25-100mg
25747|NCT00010985|Procedure|Chiropractic|
25748|NCT00854256|Procedure|Canaloplasty|Canaloplasty surgery
25749|NCT00854256|Procedure|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
25750|NCT00854269|Procedure|surgery|cervical biopsy or specimen of hysterectomy
25751|NCT00854282|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
25752|NCT00854295|Device|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
26058|NCT00857493|Biological|IMVAMUNE|One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
26059|NCT00860145|Procedure|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
26060|NCT00860158|Drug|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
26061|NCT00011999|Drug|cisplatin|
26062|NCT00860158|Drug|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
26063|NCT00860158|Procedure|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
26064|NCT00860171|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
26065|NCT00860171|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV
26066|NCT00860171|Other|Laboratory Biomarker Analysis|Correlative studies
29833|NCT00897988|Genetic|polymerase chain reaction|
29834|NCT00897988|Genetic|protein expression analysis|
29835|NCT00897988|Genetic|reverse transcriptase-polymerase chain reaction|
29836|NCT00897988|Other|flow cytometry|
29837|NCT00897988|Other|immunoenzyme technique|
29838|NCT00897988|Other|immunologic technique|
29839|NCT00897988|Other|laboratory biomarker analysis|
29840|NCT00016276|Drug|cyclophosphamide|Given IV
29841|NCT00897988|Other|pharmacological study|
29842|NCT00898014|Genetic|fluorescence in situ hybridization|
29843|NCT00898014|Other|immunologic technique|
29844|NCT00898014|Other|laboratory biomarker analysis|
29845|NCT00898027|Other|laboratory biomarker analysis|laboratory biomarker analysis
29846|NCT00898040|Genetic|polymorphism analysis|
29847|NCT00898053|Other|laboratory biomarker analysis|Correlative studies
29848|NCT00898066|Genetic|cytogenetic analysis|marrow and peripheral blood
29849|NCT00900237|Drug|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
29850|NCT00900250|Other|Cytology Specimen Collection Procedure|Correlative studies
29851|NCT00900263|Genetic|cytogenetic analysis|
29852|NCT00016406|Biological|filgrastim|
29853|NCT00900263|Genetic|microarray analysis|
29854|NCT00900263|Other|biologic sample preservation procedure|
29855|NCT00900263|Other|laboratory biomarker analysis|
29856|NCT00900276|Other|immunologic technique|
26125|NCT00857506|Drug|florbetapir F 18|370 Mega Becquerel (10 mCi)
26126|NCT00857519|Drug|Melphalan, Carboplatin|intra-arterial chemotherapy
26127|NCT00857532|Drug|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
26128|NCT00857545|Other|Laboratory Biomarker Analysis|Correlative studies
26129|NCT00857545|Biological|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
26130|NCT00857545|Biological|Saponin-based Immunoadjuvant OBI-821|Given SC
26131|NCT00857558|Drug|saxagliptin|orally administration at 1 mg once a day for 12 weeks
26132|NCT00857558|Drug|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
26133|NCT00857558|Drug|saxagliptin|orally administration at 5 mg once a day for 12 weeks
26134|NCT00857558|Drug|placebo|orally administration once a day for 12 weeks
26135|NCT00011778|Radiation|radiation therapy|
26443|NCT00926406|Drug|lead chelation therapy|Patients with lead poisoning (BLL> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL < 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
26444|NCT00926419|Biological|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
26445|NCT00018876|Procedure|Lumbar nerve root decompression|
26446|NCT00926419|Biological|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
26447|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
26448|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
26449|NCT00926471|Behavioral|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
26450|NCT00926497|Other|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
26451|NCT00926510|Behavioral|Language toolkit|Simple toolkit of interactive things to stimulate language.
25884|NCT00859911|Dietary Supplement|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
25885|NCT00859937|Drug|dasatinib|Given orally
25886|NCT00859937|Other|laboratory biomarker analysis|Correlative studies
25887|NCT00859950|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
25888|NCT00011986|Drug|pegylated liposomal doxorubicin hydrochloride|
25889|NCT00859976|Device|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
25890|NCT00859976|Device|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
25891|NCT00859989|Behavioral|behavioral dietary intervention|
25892|NCT00859989|Behavioral|exercise intervention|
25893|NCT00859989|Behavioral|telephone-based intervention|
25894|NCT00859989|Other|counseling intervention|
26199|NCT00852670|Drug|Placebo|Matching placebo capsules administered orally once daily
26200|NCT00852683|Drug|Pregabalin|75 mg twice a day
26201|NCT00011037|Biological|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
26202|NCT00855088|Drug|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
26203|NCT00855101|Drug|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
26204|NCT00855114|Drug|everolimus|5 mg/day x 7 days by mouth
26205|NCT00855114|Procedure|therapeutic conventional surgery|Definitive excision of breast cancer tissue
26206|NCT00855140|Other|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
26207|NCT00855153|Other|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
26067|NCT00860197|Dietary Supplement|Fully torrefied coffee|Fully torrefied coffee
26068|NCT00860197|Dietary Supplement|Partially torrefied coffee|Partially torrefied coffee
26069|NCT00860210|Device|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
26070|NCT00860223|Drug|Digoxin|
26071|NCT00860223|Drug|Neratinib|HKI-272
26072|NCT00011999|Drug|paclitaxel|
26073|NCT00860236|Other|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
26074|NCT00860236|Behavioral|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
26075|NCT00860249|Behavioral|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
26076|NCT00860249|Behavioral|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
26077|NCT00860262|Drug|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
26381|NCT00928512|Drug|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
26382|NCT00019071|Radiation|radiation therapy|
26383|NCT00928525|Drug|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
26384|NCT00928538|Other|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
26385|NCT00928551|Drug|vabicaserin|
26386|NCT00928564|Drug|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
26387|NCT00928564|Drug|Placebo|5ml of saline at each block site.
26388|NCT00921102|Drug|Isotonic saline solution|0.9% NaCl solution
0.1 ml, intrathecally in group Control and IV Atropine
0.1 ml, intravenously in group Control and Intrathecal Atropine
30135|NCT00898378|Other|gas chromatography|gas chromatography
30136|NCT00898378|Other|laboratory biomarker analysis|laboratory biomarker analysis
30137|NCT00898378|Other|liquid chromatography|liquid chromatography
30138|NCT00898378|Other|mass spectrometry|mass spectrometry
30139|NCT00898378|Other|questionnaire administration|questionnaire administration
30140|NCT00898391|Other|laboratory biomarker analysis|Correlative studies
30141|NCT00898391|Genetic|polymerase chain reaction|Correlative studies
30142|NCT00898391|Genetic|polyacrylamide gel electrophoresis|Correlative studies
30143|NCT00898391|Genetic|DNA analysis|Correlative studies
30144|NCT00016302|Drug|prednisone|Given orally
30145|NCT00898404|Other|laboratory biomarker analysis|Correlative studies
30146|NCT00898417|Biological|bevacizumab|
30147|NCT00898417|Drug|carboplatin|
30148|NCT00898417|Drug|paclitaxel|
30149|NCT00900341|Genetic|gene expression analysis|
30150|NCT00900341|Genetic|protein expression analysis|
30151|NCT00900341|Genetic|reverse transcriptase-polymerase chain reaction|
30152|NCT00000814|Drug|Nevirapine|
30153|NCT00016406|Drug|doxorubicin|
30154|NCT00900341|Genetic|western blotting|
30155|NCT00900341|Other|immunohistochemistry staining method|
30156|NCT00900341|Other|laboratory biomarker analysis|
30157|NCT00900354|Genetic|molecular genetic technique|
30158|NCT00900354|Other|mass spectrometry|
30159|NCT00900354|Other|pharmacological study|
26452|NCT00926510|Behavioral|Safety counseling|Smoke detector and general safety counseling
26453|NCT00926523|Other|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
26454|NCT00926523|Other|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
26455|NCT00926523|Other|Spirometry|To assess subjects lung function
26456|NCT00018876|Procedure|Preoperative low-dose external beam radiation|
26457|NCT00926523|Other|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
26458|NCT00926536|Device|C-arm CT in imaging guidance of TACE|Standard of care
26459|NCT00926549|Device|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
26460|NCT00926562|Drug|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
26461|NCT00928590|Drug|Travoprost/Timolol Maleate Fixed Combination solution|
26462|NCT00928603|Procedure|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
25475|NCT00856570|Drug|YM178|Oral
25476|NCT00856583|Drug|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
25477|NCT00856583|Drug|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
25478|NCT00856596|Drug|Sertaconazole nitrate cream 2%|Once a day topical cream
25479|NCT00856609|Drug|Byetta (exenatide)|Exenatide is an injectable medication
25480|NCT00011531|Procedure|Prevention of Pressure Ulcers|
25481|NCT00856609|Behavioral|Weight loss|Because response to weight loss
25482|NCT00856609|Other|Metabolic Chamber|The subject stays in the small room
26208|NCT00855153|Drug|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
26209|NCT00855166|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
26210|NCT00855166|Drug|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
26211|NCT00855166|Drug|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
26212|NCT00011063|Drug|Ginkgo Biloba|
26213|NCT00855166|Drug|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
26214|NCT00855179|Drug|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
26215|NCT00855179|Drug|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
26216|NCT00855192|Behavioral|mindful meditation|interpersonal and psycho-educational
26217|NCT00855192|Behavioral|interpersonal therapy|psycho-educational
26218|NCT00855205|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
26219|NCT00855218|Drug|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. [twice daily], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
26220|NCT00855218|Drug|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
26221|NCT00855244|Other|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
26222|NCT00855257|Drug|Acid Nicotinique|
26529|NCT00923988|Other|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
26530|NCT00924001|Drug|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10^9 and 1 x 10^11 lymphocytes) after expansion in interleukin-2 and OKT-3
26531|NCT00924001|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
26532|NCT00924001|Drug|Fludarabine|25 mg/m^2/day intravenously x 5 days
26533|NCT00924001|Drug|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
26534|NCT00018538|Drug|calcifidiol|
26389|NCT00921102|Drug|Atropine|100 µg of a 1 mg/ml preservative-free solution
intrathecally in group Intrathecal Atropine
intravenously in group IV Atropine
26390|NCT00921115|Drug|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
26391|NCT00921115|Drug|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
26392|NCT00921128|Drug|Muscimol|
26393|NCT00921154|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
26394|NCT00921167|Drug|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks
26395|NCT00018174|Behavioral|Behavioral group smoking cessation treatment|
26396|NCT00921180|Drug|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
26397|NCT00921180|Drug|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
26398|NCT00921193|Device|Radiation Therapy Positioning System (RTPS)|
26399|NCT00921206|Biological|VAX102|1 ug i.m. compared to 2 ug s.c.
26400|NCT00921219|Drug|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
25418|NCT00859144|Behavioral|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
25419|NCT00861120|Drug|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
25420|NCT00861120|Drug|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
25421|NCT00861133|Device|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
25422|NCT00861146|Behavioral|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
25423|NCT00012051|Drug|cytarabine|
30160|NCT00900367|Other|high performance liquid chromatography|
30161|NCT00900367|Other|laboratory biomarker analysis|
30162|NCT00900367|Procedure|spectroscopy|
30538|NCT00896857|Other|immunohistochemistry staining method|
30539|NCT00896857|Other|laboratory biomarker analysis|
30540|NCT00896857|Procedure|breast duct lavage|
30541|NCT00896883|Device|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
30542|NCT00898794|Other|laboratory biomarker analysis|
30543|NCT00898794|Other|platelet aggregation test|
30544|NCT00898807|Drug|citalopram|target dose 30mg daily for 9 weeks
30545|NCT00898807|Drug|placebo|daily for 9 weeks
30546|NCT00898820|Genetic|gene expression analysis|
30547|NCT00898820|Genetic|polymorphism analysis|
30548|NCT00016302|Drug|dexamethasone|Given orally
30549|NCT00898820|Genetic|protein expression analysis|
30550|NCT00898833|Other|laboratory biomarker analysis|
30551|NCT00898846|Drug|tegafur-uracil|
30552|NCT00898846|Genetic|polymerase chain reaction|
30553|NCT00898846|Genetic|reverse transcriptase-polymerase chain reaction|
30554|NCT00898846|Other|diagnostic laboratory biomarker analysis|
30555|NCT00898872|Other|cryopreservation|
30556|NCT00898885|Procedure|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
30557|NCT00898898|Other|diagnostic laboratory biomarker analysis|Correlative studies
30558|NCT00898911|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
25483|NCT00856609|Drug|Placebo|
25484|NCT00856622|Drug|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
25485|NCT00856622|Drug|timolol 0.5% ophthalmic solution|one drop in the morning and evening
25486|NCT00859144|Behavioral|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
25487|NCT00859157|Procedure|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
25488|NCT00011934|Procedure|autologous bone marrow transplantation|
25489|NCT00859170|Device|Accordion device|an antiretropulsion device
25490|NCT00859183|Drug|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
25491|NCT00859183|Drug|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
25492|NCT00859183|Drug|Placebo|Placebo oral
25493|NCT00859196|Drug|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
25812|NCT00852020|Dietary Supplement|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
25813|NCT00852033|Behavioral|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
25814|NCT00852033|Behavioral|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
25815|NCT00010699|Drug|Vitamin E|
25816|NCT00852033|Behavioral|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
27819|NCT00872014|Drug|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort & 10mg/kg cohort
26898|NCT00924573|Drug|placebo|oral administration
26899|NCT00924573|Drug|Glimepiride (HOE490)|oral administration
26900|NCT00924586|Drug|ONO-1101|Placebo for one minute IV
26901|NCT00924586|Drug|ONO-1101|0.125 mg/kg for one minute IV
26902|NCT00924599|Behavioral|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
26903|NCT00924599|Behavioral|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
26904|NCT00924612|Drug|Oral testosterone undecanoate (containing 300 mg of T)|Single dose administered orally, 30 minutes after the initiation of protocol-defined breakfast or while fasting, in each of the 5 arms.
26905|NCT00924625|Other|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
26906|NCT00000211|Drug|Buprenorphine|
26907|NCT00000831|Drug|Zidovudine|
26908|NCT00018655|Behavioral|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
26909|NCT00924625|Other|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
26910|NCT00924638|Device|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
26911|NCT00924651|Behavioral|exercise|home based walking and progressive resistance training exercise
26912|NCT00927199|Dietary Supplement|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
26913|NCT00018954|Drug|daunorubicin hydrochloride|
26005|NCT00852371|Drug|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
26006|NCT00852371|Drug|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
26007|NCT00852371|Drug|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
26008|NCT00852371|Drug|placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
26009|NCT00854698|Other|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
26010|NCT00854711|Procedure|inhaled nitric oxide|80 PPM
26011|NCT00854724|Drug|Puerarin, Placebo|400 mg, three times a day for 7 days
26012|NCT00854737|Dietary Supplement|cytidine|cytidine (2g po daily for 4 months)
26013|NCT00854737|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
26322|NCT00018421|Procedure|Treadmill Exercise|
26323|NCT00923494|Drug|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
26324|NCT00923520|Drug|dimethane sulfonate (DMS612, NSC 281612)|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 until MTD is reached
26325|NCT00923533|Drug|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
26326|NCT00923533|Drug|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
26327|NCT00923559|Other|Treatment as Usual at Child Health Centre|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment may be initiated by the health visitor or the mother. This will be registered at the end-point interview.
26328|NCT00923559|Other|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief whatsoever that the infant understands verbal communication. Rather, the analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
26329|NCT00923572|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
27317|NCT00922974|Radiation|radiosurgery|Patients undergo 1 high-dose image-guided radiosurgery treatment.
27318|NCT00922974|Radiation|stereotactic body radiation therapy|Patients undergo 1 high-dose image-guided SBRT treatment.
27319|NCT00922987|Drug|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
27320|NCT00923000|Drug|Nalbuphine|Nalbuphine 10mg with oral administration
27321|NCT00923000|Drug|Morphine|Morphine 10mg with oral administration
27322|NCT00923000|Drug|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
27323|NCT00923000|Drug|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
27324|NCT00018317|Behavioral|resistance training|
27325|NCT00923000|Drug|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
27659|NCT00920959|Drug|FSC 100/50mcg|Once-daily dosing
27660|NCT00920959|Drug|Placebo|Once-daily dosing
27661|NCT00920972|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
GVHD Prophylaxis:
Starting day -3: Tacrolimus or cyclosporine... Days +1, +3, +6: Methotrexate
27662|NCT00920972|Drug|Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Options:
Regimen 1= Starting day -3: Tacrolimus or cyclosporine... Days +1, +3, +6: Methotrexate.... Starting on day +7: Prednisone...
OR Regimen 2 = Starting day -3: tacrolimus or cyclosporine Starting day -3: mycophenolate mofetil
27663|NCT00876941|Behavioral|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
27664|NCT00876954|Procedure|Normothermia|Warming without increase in core temperature
27665|NCT00876954|Procedure|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
27117|NCT00929591|Radiation|low-LET electron therapy|
27118|NCT00929591|Radiation|low-LET photon therapy|
27119|NCT00929591|Radiation|radiation therapy|
27120|NCT00929604|Other|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
27121|NCT00929617|Behavioral|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
27122|NCT00929617|Other|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
27123|NCT00929630|Procedure|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
27124|NCT00929630|Procedure|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
27125|NCT00929630|Procedure|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
27126|NCT00000834|Drug|Methotrexate|
27127|NCT00019175|Biological|aldesleukin|
27128|NCT00929630|Procedure|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
27129|NCT00929643|Other|no intervention|success of the initial empiric treatment
27130|NCT00929656|Procedure|Unimanual UE training + rTMS|rTMS application to lesioned hemisphere followed by unimanual (paretic) UE exercise (100 repetitions) for 16 sessions (4 sessions/week for 4 weeks)
27382|NCT00920543|Drug|FP 500mcg|Twice daily dosing
27383|NCT00920543|Drug|FP 250mcg|Twice daily dosing
27384|NCT00920543|Drug|FSC 100/50mcg|Twice daily dosing
27385|NCT00920543|Drug|FSC 250/50mcg|Twice daily dosing
27386|NCT00920543|Drug|FSC 500/50mcg|Twice daily dosing
27387|NCT00018135|Drug|calcium acetate|
26914|NCT00927212|Drug|AS101 ointment|Twice daily topical application
26915|NCT00927225|Drug|ropivacaine 0.2%, 50 mL|
26916|NCT00927225|Drug|normal saline|
27190|NCT00927641|Drug|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
27191|NCT00927641|Other|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
27192|NCT00927654|Drug|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
27193|NCT00927654|Drug|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
27194|NCT00018954|Drug|vincristine sulfate|
27195|NCT00927667|Procedure|No Drug|Patients have received primary FVIII prophylaxis (started < 2 years of age)
27196|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - < 6 years of age)
27197|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - < 12 years of age)
27198|NCT00927667|Procedure|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
27199|NCT00927667|Procedure|No Drug|Patients have received on-demand therapy
27200|NCT00927693|Other|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
27201|NCT00927706|Device|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
27202|NCT00927719|Biological|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
27203|NCT00927732|Drug|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
27204|NCT00927732|Drug|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
27205|NCT00018954|Procedure|conventional surgery|
26330|NCT00923598|Drug|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
26331|NCT00923611|Drug|Fimasartan|
26332|NCT00923624|Other|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
26333|NCT00018447|Drug|PTH 1-34|
26334|NCT00923624|Behavioral|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
26335|NCT00923637|Drug|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
26336|NCT00923663|Drug|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
26337|NCT00923676|Drug|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
26338|NCT00923676|Drug|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
25352|NCT00853554|Drug|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
25353|NCT00853567|Drug|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
25354|NCT00853567|Other|placebo|Placebo
25355|NCT00853580|Drug|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
25356|NCT00853580|Device|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
25357|NCT00853593|Device|Pacing Lead|implant and follow-up of study device
25358|NCT00853606|Drug|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
25359|NCT00853619|Other|Service based decision support intervention|Delivering CDS via services
25360|NCT00010920|Drug|Ginkgo Biloba Extract|
25361|NCT00853632|Device|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
27666|NCT00876967|Device|metallic single use blade|metallic single use blade
27667|NCT00014066|Drug|hematoporphyrin derivative|
27668|NCT00876967|Device|plastic single use blade|plastic single use blade
27669|NCT00876967|Device|metallic reusable blade|metallic reusable blade
27670|NCT00876980|Device|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
27671|NCT00876993|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
27672|NCT00876993|Drug|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
27673|NCT00876993|Drug|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
27674|NCT00877006|Drug|bendamustine|
27675|NCT00877006|Drug|rituximab|
27676|NCT00877006|Drug|vincristine|
26761|NCT00929175|Device|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
26762|NCT00929188|Drug|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
26763|NCT00929188|Drug|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
26764|NCT00929201|Drug|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
26765|NCT00929201|Drug|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
26766|NCT00929201|Drug|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
26767|NCT00929214|Drug|Standard Therapy|Chemotherapy and/or Endocrine Therapy:
For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist.
27388|NCT00920556|Drug|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
27389|NCT00920556|Drug|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
27390|NCT00920569|Device|Ultrasound dilution measurements|Measurement of cardiac output in venoarterial extracorporeal membrane oxygenation patients, recirculation in venovenous extracorporeal membrane oxygenation patients and oxygenator blood volume in venoarterial and venovenous extracorporeal membrane oxygenation patients.
27391|NCT00920582|Drug|Teplizumab (MGA031)|IV dosing daily for 14 days times 2 courses
27392|NCT00920582|Drug|Placebo|IV dosing daily for 14 days times 2 courses
27393|NCT00920595|Drug|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
27394|NCT00920608|Drug|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
27395|NCT00920608|Drug|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
27396|NCT00920621|Dietary Supplement|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
27397|NCT00920621|Dietary Supplement|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
27398|NCT00000829|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
27399|NCT00018135|Drug|aluminum hydroxide|
27400|NCT00920634|Drug|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
27401|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
27402|NCT00000831|Drug|Lamivudine|
27743|NCT00874315|Drug|cyclosporine|1.5 mg/kg/dose every 12 hours.
27744|NCT00874315|Drug|fludarabine phosphate|30 mg/m2/day for 5 days.
27745|NCT00874315|Drug|mycophenolate mofetil|15 mg/kg/dose every 8 hours
27206|NCT00910546|Device|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
27207|NCT00910572|Device|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
27208|NCT00910585|Behavioral|Coaching, providing social support|Active telephone and in person coaching
27459|NCT00928018|Drug|Sirolimus|Taken orally for at least 12 months
27460|NCT00928018|Drug|Methotrexate|Given intravenously on the first, third and sixth day after transplant
27461|NCT00928018|Drug|Tacrolimus|Taken orally or given intravenously for at least 6 months
27462|NCT00928018|Drug|Cyclosporine|Taken orally or given intravenously for at least 6 months
27463|NCT00928018|Drug|MMF|Taken orally for about 2 months
27464|NCT00928057|Device|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
27465|NCT00920647|Other|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
27466|NCT00920647|Drug|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
27467|NCT00920647|Drug|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
27468|NCT00920647|Drug|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
27469|NCT00920660|Drug|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
26986|NCT00924729|Drug|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
26987|NCT00924729|Drug|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
26988|NCT00924742|Drug|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
26989|NCT00924755|Device|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
26990|NCT00924768|Biological|20K EU CCRE|Inhalation of CCRE
27247|NCT00922948|Procedure|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
27248|NCT00922961|Biological|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
27249|NCT00018317|Behavioral|low protein diet|
27250|NCT00925145|Procedure|Single Incision Laparoscopic Appendectomy|
27251|NCT00925158|Procedure|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
27252|NCT00925171|Behavioral|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
27253|NCT00925197|Other|INR self-testing program|
27254|NCT00925210|Procedure|Sequential pEBUS - ENB|Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.
If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected.
27255|NCT00925262|Behavioral|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
27256|NCT00018746|Device|repetitive transcranial magnetic stimulation|
27257|NCT00925262|Behavioral|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
26768|NCT00019110|Biological|human papillomavirus 16 E7 peptide|
26769|NCT00929214|Procedure|Local Therapy|Surgery and/or Radiation Therapy
With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks.
26770|NCT00929240|Drug|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
26771|NCT00929240|Drug|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
26772|NCT00929253|Drug|Suboxone|Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks
26773|NCT00929253|Behavioral|CRA|Computer-delivered Community Reinforcement Approach
26774|NCT00929253|Behavioral|Therapy|Therapist-delivered therapy
26775|NCT00929253|Behavioral|CM|Contingency management (vouchers) for providing a drug negative urine sample.
26776|NCT00921804|Drug|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
26777|NCT00921830|Drug|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
26778|NCT00921843|Drug|Methadone|Subjects will receive methadone as their intraoperative opioid.
27053|NCT00922480|Drug|Fimasartan|Fimasartan 60 ~ 120mg/po take one tablets once a day
27054|NCT00922480|Drug|Losartan (Control)|Losartan 50 mg ~ 100 mg/po, take one tablets once a day
27055|NCT00922493|Other|inspiratory muscle training|Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming "hard" due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.
An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º.
27056|NCT00922506|Drug|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
27057|NCT00922519|Other|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 4 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
27058|NCT00018278|Drug|Aricept|
27746|NCT00013611|Drug|Proleukin|Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
27747|NCT00874315|Drug|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
27748|NCT00874315|Procedure|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
27749|NCT00874328|Drug|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
27750|NCT00874328|Drug|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
27751|NCT00874328|Drug|TS-1 (S-1)|TS-1 po D1~D14 q 3 weeks until maximum 6 cycles
27752|NCT00874341|Other|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
27753|NCT00874354|Procedure|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
27754|NCT00874380|Other|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
27755|NCT00874393|Drug|Dopamine|Dopamine
27756|NCT00874393|Drug|Hydrocortisone|Hydrocortisone
27757|NCT00000796|Drug|Levofloxacin|
27758|NCT00013624|Drug|IV Levodopa|
27759|NCT00874393|Drug|Infusion Placebo|Dextrose (D5W)
27760|NCT00874393|Drug|Syringe Placebo|Normal saline
27761|NCT00874406|Drug|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
27762|NCT00874406|Drug|folfox4|folfox4 will be done within 28 days after liver resection
27763|NCT00874419|Drug|erlotinib|erlotinib 150 mg oral, once a day
27764|NCT00874419|Drug|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
26838|NCT00927173|Device|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
27470|NCT00920660|Drug|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
27471|NCT00920660|Drug|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
27472|NCT00920660|Drug|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
27473|NCT00920660|Drug|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
27474|NCT00018135|Drug|Sevelamer|
27820|NCT00872027|Drug|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
27821|NCT00872027|Drug|Placebo|Placebo pills for 8 weeks
27822|NCT00872040|Other|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
27823|NCT00872053|Device|Anklebot|The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training "games," the Anklebot can assist ankle movement throughout 3 planes.
27824|NCT00872053|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
27825|NCT00872066|Device|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
27826|NCT00872066|Device|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
27827|NCT00874432|Drug|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
27828|NCT00874432|Drug|lisinopril|1 x 40 mg per day
27829|NCT00874445|Device|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
27830|NCT00874458|Procedure|magnetic resonance imaging|
27831|NCT00013650|Drug|Cyclophosphamate|
27832|NCT00874458|Procedure|radiomammography|
27258|NCT00925262|Behavioral|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
27259|NCT00925275|Drug|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
27260|NCT00925288|Biological|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
27261|NCT00925301|Drug|migalastat hydrochloride|oral capsule every other day
27262|NCT00925301|Drug|Placebo|oral capsule every other day
27263|NCT00925314|Biological|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
27264|NCT00925327|Other|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
27598|NCT00923481|Drug|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
27599|NCT00923494|Drug|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
27600|NCT00018824|Drug|Placebo|
27601|NCT00925821|Drug|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
27602|NCT00925834|Behavioral|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
27603|NCT00925847|Drug|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
27604|NCT00925860|Procedure|non positive pressure mechanical ventilatory support|
27605|NCT00925873|Drug|Active comparator (no fludarabine)|Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).
The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm
Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)
27606|NCT00925873|Drug|Experimental (fludarabine)|The same regimen with addition of fludarabine in every treatment sequence
Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.
Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.
Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2.
27607|NCT00925886|Procedure|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
27059|NCT00922532|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
27060|NCT00922532|Drug|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
27061|NCT00922545|Other|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
27062|NCT00922558|Other|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
27063|NCT00922571|Procedure|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
27064|NCT00922571|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
27065|NCT00922584|Drug|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
27066|NCT00922597|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
27067|NCT00924833|Drug|placebo|placebo tablet BID
27068|NCT00924833|Drug|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
27069|NCT00924833|Drug|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
27070|NCT00924846|Procedure|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
27326|NCT00923013|Drug|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
27327|NCT00923013|Drug|Rituximab|Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
27328|NCT00923078|Behavioral|Brain Fitness|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Our laboratory procedures include review of progress with the participant at the end of each session, intended to encourage motivation. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory.
27329|NCT00923078|Behavioral|Cortex with Insight|The program entails five computer-based exercises designed with the same features of Brain Fitness, which train: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view.
26839|NCT00927186|Drug|Teriparatide|20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.
After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.
26840|NCT00927186|Drug|Zoledronic Acid|5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.
After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.
26841|NCT00927199|Dietary Supplement|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
26842|NCT00927199|Dietary Supplement|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
26843|NCT00929409|Drug|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
26844|NCT00929409|Drug|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
26845|NCT00019136|Biological|MOv-gamma chimeric receptor gene|
26846|NCT00929461|Drug|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
26847|NCT00929474|Device|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
26848|NCT00929474|Device|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
26849|NCT00929487|Device|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
26850|NCT00929487|Other|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
26851|NCT00929487|Device|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
27833|NCT00874458|Procedure|ultrasound imaging|
27834|NCT00874484|Drug|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
27835|NCT00874497|Drug|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
27836|NCT00874497|Drug|placebo|Placebo for 104 weeks (2 years)
27837|NCT00874510|Behavioral|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
27838|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
27839|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
26612|NCT00924053|Drug|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
26613|NCT00924053|Drug|Placebo|Placebo capsules to match EGT0001474
26614|NCT00924066|Drug|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m^2 for a total of 30mg/m^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
26615|NCT00924079|Drug|nalbuphine|oral dosage form, 66 mg, single dose
26616|NCT00924092|Biological|GI-6207 [Recombinant Saccharomyces Cerevisia|
26617|NCT00018551|Drug|Folic Acid|
26618|NCT00924092|Drug|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
26619|NCT00924105|Drug|CYT013-IL1bQb|s.c. injection
26620|NCT00924105|Drug|Placebo|s.c. injection
26621|NCT00924118|Drug|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
26622|NCT00924157|Dietary Supplement|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
26623|NCT00924157|Other|Placebo|Matching placebo capsules
27608|NCT00925899|Drug|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
27609|NCT00925899|Drug|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
27610|NCT00925912|Procedure|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
27611|NCT00018837|Behavioral|Community Re-Entry Program: What is Schizophrenia|
27612|NCT00925912|Procedure|Perianal block|0.25% bupivacaine injected at perianal region
27613|NCT00925925|Other|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
27614|NCT00925938|Drug|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
26697|NCT00018200|Drug|Benztropine|Daily dose 0.125 to 0.5mg
26698|NCT00921791|Device|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
26699|NCT00921791|Behavioral|Pharmaceutical care|consultations with the pharmacists
26700|NCT00921791|Other|Usual care|Consultation with the physician.
26701|NCT00921804|Drug|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
26702|NCT00921804|Drug|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
26703|NCT00921804|Drug|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
26704|NCT00924209|Procedure|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
26705|NCT00924209|Drug|Etoposide|100 mg/m^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
26706|NCT00924222|Drug|Sevoflurane|Sedation with sevoflurane
26707|NCT00924222|Drug|Propofol|Sedation on intensive care unit with propofol
26708|NCT00924248|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
27330|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
27331|NCT00923091|Drug|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
27332|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
27333|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
27334|NCT00925392|Drug|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
27335|NCT00925405|Procedure|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
27336|NCT00925405|Procedure|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
27337|NCT00925418|Procedure|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
27338|NCT00925431|Behavioral|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
27339|NCT00925431|Behavioral|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
27340|NCT00925444|Device|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
27341|NCT00018759|Behavioral|ongoing psychological screening|
27342|NCT00925444|Device|Stapling|Stapling alon or associated with sealants
27343|NCT00925457|Other|No Intervention|Neither current domperidone nor current PPI
27677|NCT00877006|Drug|prednisone|
27678|NCT00014066|Radiation|brachytherapy|
27679|NCT00877006|Drug|cyclophosphamide|
27680|NCT00877006|Drug|doxorubicin|
27681|NCT00877019|Device|Sonicare elite medium brush head|
27682|NCT00877019|Device|Sonicare elite mini brushhead|
27683|NCT00877019|Device|GABA Elmex sensitive extra soft toothbrush|
27131|NCT00929656|Procedure|Unimanual UE training + sham rTMS|sham rTMS application to lesioned hemisphere followed by unimanual (paretic) UE exercise (100 repetitions) for 16 sessions (4 sessions/week for 4 weeks)
27132|NCT00929669|Drug|pasireotide LAR|pasireotide LAR 80 mg IM once a month
27133|NCT00929682|Drug|Randomization between two referenced treatments|Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.
Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.
27134|NCT00929695|Drug|prednisone|immunosuppressive drug
27135|NCT00929695|Drug|methylprednisolone|immunosuppressive drug
27136|NCT00929695|Other|questionnaire administration|Ancillary studies
27137|NCT00929708|Drug|AZD3199|Dry powder for inhalation, o.d., 4 weeks
27138|NCT00019175|Biological|fowlpox virus vaccine vector|
27139|NCT00922610|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
27140|NCT00922623|Device|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
27141|NCT00018278|Drug|Exelon|
27142|NCT00922636|Drug|LY2216684|Taken in tablet form QD po.
27143|NCT00922636|Drug|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
27144|NCT00922636|Drug|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
27145|NCT00922636|Drug|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
27146|NCT00922649|Drug|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on >2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
27147|NCT00922675|Procedure|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
27148|NCT00922675|Procedure|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
27149|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
26624|NCT00924170|Drug|LMB-2|Begin with 30 mcg/Kg IV on days 3, 5 and 7. Escalate to 40 mcg/Kg if DLT in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
26625|NCT00924170|Drug|Fludarabine|Days 1-3:
Patients 1-7, 10-14, and & gt; 18:25mg/m2/day Patients 8 9:30 mg/m2/day Patients 15 17:20 mg/m2/day
26626|NCT00924170|Drug|Cyclophosphamide|Days 1-3:
Patients 1-7, 10 -14, and & gt; 18:250 mg/m2/day Patients 8 9:300 mg/m2/day Patients 15-17:200 mg/m2/day
26627|NCT00924183|Other|Treatment-as-usual|
26628|NCT00018564|Drug|treatments for essential tremor|
26629|NCT00924209|Drug|Gemcitabine|1250 mg/m^2 dose for two doses on days 1 and 8
26630|NCT00924209|Drug|Cisplatin|80 mg/m^2 on day 1
26631|NCT00924209|Drug|Bevacizumab|7.5 mg/m^2 on day 1 every 21 days for first two cycles only
26632|NCT00926744|Behavioral|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
26633|NCT00926757|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
25622|NCT00861783|Drug|oxaliplatin and ON 01910.Na|ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.
Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling.
25623|NCT00861796|Drug|CYR-101|Experimental arm
25624|NCT00861796|Drug|Placebo|Placebo comparator
25625|NCT00861809|Drug|GSK962040 25 mg|25 mg
25626|NCT00861809|Drug|Placebo|placebo comparator
25627|NCT00861809|Drug|GSK962040 50 mg|50 mg
25628|NCT00861809|Drug|GSK962040 1250 mg|125 mg
25629|NCT00861822|Other|Advanced red blood cell transfusion|Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).
In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate
25630|NCT00012090|Drug|bicalutamide|
25631|NCT00861835|Other|ROSE|rapid on-site evaluation by cytopathology
26709|NCT00924261|Other|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
26710|NCT00924261|Other|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
26711|NCT00018603|Drug|guanfacine|
26712|NCT00924274|Dietary Supplement|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
26713|NCT00924274|Dietary Supplement|sunflower oil|sunflower oil
26714|NCT00924287|Drug|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
26715|NCT00924287|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
26716|NCT00924287|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
26717|NCT00924287|Drug|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
26718|NCT00924313|Drug|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
26991|NCT00924781|Drug|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
26992|NCT00924781|Drug|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
26993|NCT00924781|Drug|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
26994|NCT00924794|Procedure|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
26995|NCT00924807|Drug|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
26996|NCT00018668|Drug|Olanzapine|
26997|NCT00924820|Drug|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
26998|NCT00927368|Procedure|stimulation needle and stimulating catheter|ultrasound guided femoral nerve catheter using a stimulation needle and stimulating catheter
27684|NCT00877019|Device|ADA reference toothbrush|
27685|NCT00877032|Biological|RN6G|intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
27686|NCT00877032|Biological|Placebo|intravenous, single dose with experimental dose.
27687|NCT00877058|Behavioral|preventive home visit|
27688|NCT00877058|Behavioral|senior meetings|
27689|NCT00014079|Genetic|DNA stability analysis|
27690|NCT00879307|Drug|quetiapine|Use of quetiapine for 16 weeks in acute mania and depression
27691|NCT00879333|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
27692|NCT00879333|Drug|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
27693|NCT00879333|Drug|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
27694|NCT00879346|Drug|AZD8931|160mg oral single dose (4 x 40mg tablets)
27695|NCT00014222|Drug|doxorubicin hydrochloride|60 mg/m2
27696|NCT00879359|Drug|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
27697|NCT00879372|Drug|tianeptine|tianeptine 12,5mg TID
27698|NCT00879372|Drug|Placebo|Placebo 12.5 mg TID
27699|NCT00879385|Drug|Dacogen™ (decitabine)|Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).
Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs
26779|NCT00921856|Other|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
26780|NCT00018213|Drug|Naltrexone Hydrochloride|
26781|NCT00921869|Drug|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
27150|NCT00922688|Drug|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
27403|NCT00018317|Behavioral|combination of diet control and exercise|
27404|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
27405|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
27406|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
27407|NCT00923117|Drug|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
27408|NCT00923130|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
27409|NCT00923130|Drug|Ixabepilone|Ixabepilone will be given on a days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m2/day on five successive days.
27410|NCT00923156|Drug|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
27411|NCT00923156|Drug|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
27412|NCT00923156|Drug|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
27413|NCT00923156|Drug|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
27414|NCT00018330|Behavioral|Weight Loss|
27415|NCT00923169|Drug|Anti-Transforming Growth Factor-beta (GC 1008)|
27416|NCT00923182|Drug|alemtuzumab|
27417|NCT00923195|Drug|MART-1: 26-35(27L) Peptide|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
27418|NCT00923195|Drug|Montanide ISA 51 VG|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
25632|NCT00853918|Other|$100 check|$100 check incentive mailed with survey
25633|NCT00853931|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
25634|NCT00853944|Drug|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
25635|NCT00853957|Drug|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
25636|NCT00853957|Drug|Amlodipine|Amlodipine 5 mg titrated to 10mg
25637|NCT00853970|Drug|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
25638|NCT00010959|Drug|Trifolium pratense|
25639|NCT00853970|Drug|Placebo Comparator|sterile ophthalmic solution
25640|NCT00853983|Drug|[14C] AZD0530|Solution, Oral, once
25641|NCT00853996|Drug|acolbifene hydrochloride|Given orally
25642|NCT00853996|Other|questionnaire administration|Ancillary studies
25643|NCT00853996|Other|laboratory biomarker analysis|Correlative studies
25644|NCT00854009|Drug|BLI-489|
25959|NCT00857311|Biological|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
25960|NCT00011713|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
25961|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
25962|NCT00857324|Drug|Vorinostat|Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:
Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses
In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.
Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
26999|NCT00018954|Drug|etoposide|
27000|NCT00927368|Procedure|nerve catheter with stimulating needle|Ultrasound guided femoral nerve catheter using a stimulation needle, but non-stimulating catheter
27001|NCT00927368|Procedure|guided femoral nerve block without stimulation|ultrasound guided femoral nerve block without stimulation.
27002|NCT00927394|Drug|Aliskiren|Aliskiren 150 mg tablet
27003|NCT00927394|Drug|Valsartan|Valsartan 160 mg capsules
27004|NCT00927394|Drug|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
27005|NCT00927394|Drug|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
27006|NCT00927407|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
27007|NCT00927407|Drug|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
27008|NCT00927433|Behavioral|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
27009|NCT00927446|Procedure|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
27010|NCT00018954|Drug|ifosfamide|
27265|NCT00925340|Behavioral|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
27266|NCT00925340|Behavioral|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
27267|NCT00018759|Drug|paroxetine|
27268|NCT00925353|Drug|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
27269|NCT00925366|Other|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
27270|NCT00925392|Drug|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
27271|NCT00927745|Device|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
27272|NCT00927745|Device|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
26782|NCT00921882|Procedure|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
26783|NCT00921895|Device|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
26784|NCT00921908|Other|2 mBq radioactive technetium diluted in 20 mL saline|
26785|NCT00921921|Drug|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
26786|NCT00921921|Drug|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
26787|NCT00921947|Biological|VAX102|Universal M2e influenza vaccine
26788|NCT00921960|Other|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
26789|NCT00921973|Biological|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
26790|NCT00921973|Biological|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
26791|NCT00018213|Drug|Transdermal Nicotine|
26792|NCT00922012|Device|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
26793|NCT00922038|Behavioral|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
26794|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|
26795|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
26796|NCT00922064|Procedure|ECT|ECT series consisting of 6 to 14 ECTs
26797|NCT00922077|Behavioral|standard physical therapy program with emphasis on dynamic balance exercises|
26798|NCT00922103|Procedure|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
26799|NCT00922103|Procedure|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
27071|NCT00924859|Other|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
27419|NCT00923195|Drug|gp100:154-162 Peptide|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
27420|NCT00923195|Procedure|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
27421|NCT00923195|Drug|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
27765|NCT00877071|Drug|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
27766|NCT00877084|Other|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
27767|NCT00877084|Other|Usual care|usual care according to clinical pathway for COPD, No training
27768|NCT00877097|Drug|Klodronate and Kliogest|
27769|NCT00877097|Procedure|Placebo+ Kliogest|
27770|NCT00877097|Drug|Bonefos|
27771|NCT00877110|Drug|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
27772|NCT00877123|Drug|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
27773|NCT00877123|Drug|Placebo|similar placebo once a month for three consecutive months
27774|NCT00877136|Device|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
27775|NCT00014079|Genetic|loss of heterozygosity analysis|
27776|NCT00877149|Drug|telbivudine/LDT600|
25963|NCT00857376|Dietary Supplement|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
25964|NCT00857389|Drug|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
25965|NCT00857389|Drug|Clofarabine|40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
25966|NCT00857389|Drug|Busulfan|Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.
High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3.
25967|NCT00857389|Procedure|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
25968|NCT00011986|Drug|liposomal topotecan hydrochloride|Given IV
25969|NCT00859989|Other|study of socioeconomic and demographic variables|
25970|NCT00859989|Procedure|evaluation of cancer risk factors|
25971|NCT00859989|Procedure|support group therapy|
25972|NCT00860015|Drug|Alimta/Gemcitabine|500 mg/m2 Alimta via IV for 10 minutes, followed by 1000 mg/m2 Gemcitabine via IV for 90 minutes for 14 days. This cycle is repeated for 4 cycles
25973|NCT00860028|Drug|Varenicline|
25974|NCT00860041|Behavioral|pain questionnaires|
25975|NCT00860054|Dietary Supplement|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
25976|NCT00860067|Biological|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
26283|NCT00928265|Device|Endovascular treatment of intracranial aneurysm.|Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.
Accomplishes this by providing coil support at the neck of the aneurysm
26284|NCT00928278|Drug|Treatment A|Inhaled, 300/150, single dose
26285|NCT00928278|Drug|Treatment B|Inhaled, 300/150, single dose
26286|NCT00000833|Drug|Didanosine|
26287|NCT00019058|Radiation|radiation therapy|
26288|NCT00928278|Drug|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
27273|NCT00927758|Drug|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
27274|NCT00927771|Drug|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
27275|NCT00927771|Drug|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
27276|NCT00927784|Biological|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
27277|NCT00927784|Drug|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
27278|NCT00927797|Drug|Cyclophosphamide, Pentostatin, Rituximab|
27279|NCT00927810|Drug|Canakinumab|
27280|NCT00927823|Drug|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
27281|NCT00000833|Drug|Ribavirin|
27282|NCT00018954|Radiation|radiation therapy|
27283|NCT00927836|Biological|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
27284|NCT00927836|Drug|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
27285|NCT00927849|Procedure|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
27286|NCT00927849|Drug|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
27615|NCT00925938|Drug|placebo|placebo
27616|NCT00925951|Device|Wet Cupping|Wet cupping (Seongho trade & company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
27617|NCT00925951|Drug|Acetaminophen|Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
27618|NCT00925977|Drug|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
27619|NCT00925977|Drug|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
27620|NCT00928122|Device|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
27072|NCT00924872|Other|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
27073|NCT00924885|Device|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
27074|NCT00924885|Device|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
27075|NCT00924898|Drug|Atripla|Once daily HAART with FTC/TDF (FDC, Truvada) + EFV administered as a single dose pill called Atripla
27076|NCT00018668|Drug|Quetiapine|
27077|NCT00924911|Drug|GSK1322322|Four different formulations of 1000mg of GSK1322322
27078|NCT00924911|Drug|GSK1322322|GSK1322322 1000mg
27079|NCT00924924|Behavioral|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
27080|NCT00924937|Behavioral|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; <10% SAT).
27081|NCT00924937|Behavioral|Low Fat Diet|Low fat diet: <30% fat (12% MUFA; 6-8%PUFA; <10% SAT)
27082|NCT00924950|Drug|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
27083|NCT00924950|Drug|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
27084|NCT00924963|Device|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
27085|NCT00924963|Device|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
27086|NCT00924963|Drug|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
27087|NCT00018694|Drug|Chenodeoxycholic Acid|
27088|NCT00924976|Behavioral|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
27089|NCT00924989|Drug|OSI-906|Administered orally
27090|NCT00924989|Other|Placebo|Matching placebo administered orally
27091|NCT00925002|Drug|Tafamidis|20 mg oral Fx-1006A daily
27777|NCT00877162|Behavioral|Controlled crying and routines|Behavioural (teaching and support)
27778|NCT00877175|Drug|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
27779|NCT00877188|Other|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
27780|NCT00877201|Drug|CDR2|
27781|NCT00877214|Drug|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
26852|NCT00929500|Behavioral|MAST program|MAST program: twice a week for 4 months
26853|NCT00929526|Procedure|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
26854|NCT00929526|Procedure|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
26855|NCT00929539|Drug|JTT-130|Tablets
26856|NCT00019136|Biological|aldesleukin|
26857|NCT00929539|Drug|JTT-130 Placebo|Tablets
26858|NCT00929552|Dietary Supplement|Dietary oils (fish, vegetable oil)|6g pr day.
26859|NCT00929578|Drug|Fluphenazine|Intralesional injection of Fluphenazine
26860|NCT00929578|Drug|Placebo|Intralesional injection of placebo
26861|NCT00929591|Drug|cyclophosphamide|
26862|NCT00929591|Drug|doxorubicin hydrochloride|
26863|NCT00929591|Drug|endocrine therapy|
26864|NCT00929591|Drug|endocrine-modulating drug therapy|
26865|NCT00922116|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
26866|NCT00922129|Drug|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
26867|NCT00018226|Behavioral|Case Management|
26289|NCT00928278|Drug|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
26290|NCT00928291|Other|procalcitonin|plasma PCT measurement
26291|NCT00928291|Drug|antibiotic therapy|antibiotic therapy use
26292|NCT00928304|Drug|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
26293|NCT00928317|Drug|ART621|3.0mg/kg s.c.
26294|NCT00928317|Drug|ART621|1.5mg/kg s.c.
26295|NCT00928317|Drug|ART621|0.75mg/kg s.c.
26296|NCT00928317|Drug|Placebo|Placebo s.c.
26297|NCT00928330|Drug|GDC-0941|Oral repeating dose
26298|NCT00019071|Drug|chemotherapy|
26299|NCT00928330|Drug|Trastuzumab|Intravenous repeating dose
26300|NCT00928330|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
26301|NCT00928343|Drug|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
26302|NCT00920972|Drug|Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IVor SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Regimen:
Children < 6 years of age, BM recipients:
Regimen 1 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Starting day +7: prednisone...
Children >/=6 years, BM recipients:
Regimen 3 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Days -1, +5, +14, +28: abatacept...
UCB recipients:
Regimen 1 (described above) OR Regimen 2 = Starting day -3: tacro or CsA... Starting day -3: MMF
26634|NCT00018902|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
26635|NCT00926757|Drug|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
26636|NCT00926783|Procedure|CFAE ablation|CFAE ablation (targeted vs. generalized)
26637|NCT00926796|Drug|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
26638|NCT00926796|Drug|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients >45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
27621|NCT00928135|Drug|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
27622|NCT00928135|Drug|Saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
27623|NCT00928148|Drug|SPD465|50 or 75 mg once daily for 7 days
27624|NCT00928148|Drug|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
27625|NCT00928148|Drug|Placebo|Once daily for 7 days
27626|NCT00928161|Drug|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
27627|NCT00928174|Drug|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
27628|NCT00928187|Drug|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
27629|NCT00019058|Drug|hydroxyurea|
27630|NCT00928187|Drug|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight < 60 kg, 400 mg if weight > 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
27631|NCT00928187|Drug|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
27632|NCT00928200|Drug|Erwinase|The dose of Erwinase will be assigned at study entry. Erwinase will be administered as a 2-hour intravenous infusion. A total of 10 doses will be given on a Monday-Wednesday-Friday schedule.
27633|NCT00928200|Drug|Vincristine|1.5 mg/m2/dose IV push on days 1, 8, 15 and 22
27634|NCT00928200|Drug|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14
27635|NCT00928200|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
26719|NCT00924326|Drug|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
26720|NCT00924326|Drug|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 500mg/m2 IV will be infused over 60 minutes followed by fludarabine.
26721|NCT00924326|Biological|Anti-CD19-CAR PBL|On day 0, cells will infused intravenously (IV) on the patient care unit over 20 - 30 minutes (2-4 days after the last dose of fludarabine).
26722|NCT00018616|Behavioral|MEMS caps|
27092|NCT00925015|Drug|dalotuzumab (MK0646)|Arm 1: Dalotuzumab (10 mg/kg) intravenously administered on Day 22 and 36 Arm 2: Dalotuzumab (initial infusion 15 mg/kg, subsequent infusions 7.5 mg/kg) intravenous administered on Day 8, 22 and 36 Arm 3: Dalotuzumab (10 mg/kg) intravenously administered on Day 1, 22 and 29
27344|NCT00925457|Drug|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
27345|NCT00925457|Drug|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
27346|NCT00925483|Procedure|dialysis|different dialysis schedules for each arm
27347|NCT00925509|Procedure|Therapeutic assessment -Radio-surgical guidance.|The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.
Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.
Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.
A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement.
27348|NCT00925522|Device|Therapy Cool Path Duo Cardiac Ablation System|Consists of the following three system components:
A flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.
The 1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode.
The Cool Point ™ Irrigation Pump and Cool Point™ Tubing Set is an external volumetric pump that is intended for use in administration of general I.V. fluids to patient's vascular system through the catheter in the hospital environment.
27349|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
27350|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
27351|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
27352|NCT00000831|Drug|Didanosine|
27353|NCT00018785|Procedure|donor bone marrow infusion|
27354|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
27355|NCT00927862|Other|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients >=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
27356|NCT00927875|Drug|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
26868|NCT00922129|Drug|Cyclosporin (Neoral) or Tacrolimus (Prograf)|Cyclosporin: 3-4 mg/kg, BID, PO, 24 months
Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months
26869|NCT00922155|Device|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
26870|NCT00922181|Device|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
26871|NCT00922181|Device|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
26872|NCT00922194|Drug|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
26873|NCT00922207|Drug|Adefovir|From week -4 to week 2
26874|NCT00922207|Drug|Entecavir|From week -4 to week 2
26875|NCT00922207|Drug|Placebo|From week -4 to week 2
27151|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
27152|NCT00018278|Drug|Nicoderm Patch|
27153|NCT00922701|Drug|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
27154|NCT00922714|Drug|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
27155|NCT00922714|Drug|saline (placebo)|NaCl 0.9 g/L
27156|NCT00922727|Biological|L. reuteri|The oil drops contains 10^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10^8 CFU/ 5 drops and less than 8 x 10^8 CFU/ 5 drops.
27157|NCT00922727|Biological|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops.
27158|NCT00922740|Drug|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
27159|NCT00922740|Drug|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
27160|NCT00922753|Other|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
27161|NCT00925015|Drug|Comparator: cetuximab|cetuximab (initial intravenous infusion 400 mg/m2, subsequent intravenous infusions 250 mg/m2, once weekly)
26639|NCT00926796|Drug|Gemifloxacin|One 320 mg tablet administered orally.
26640|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
26641|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
26642|NCT00926835|Drug|paroxetine|6 weeks, 20-50mg/day
26643|NCT00926835|Drug|Escitalopram|10-20mg/day for 6 weeks
26644|NCT00926835|Drug|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
26645|NCT00018902|Drug|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
26646|NCT00926835|Drug|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
26647|NCT00926835|Drug|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
26648|NCT00926835|Drug|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
26649|NCT00926835|Drug|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
26650|NCT00926835|Drug|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
26651|NCT00926835|Drug|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
26652|NCT00926848|Behavioral|Partners Together in Health (PaTH) Intervention|Both partners actively participate in comprehensive CR and the usual care group where only the patient participates in CR and the partner is invited to attend the educational sessions with the patient. The CR activities that patients in both groups and partners in the intervention group will be provided with will be the same and are based on the clinical practice guidelines of the core components of CR. These components are: prescribed exercise, education about cardiac risk factor modification, and counseling about self-efficacy strategies that may be effective in assisting with initial lifestyle changes and in preventing and managing relapse. All patients and partners in CR will be provided with a comprehensive, individualized, multidisciplinary risk factor modification program focused on all of the person's risk factors for coronary heart disease.
26653|NCT00926861|Device|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
25645|NCT00854009|Drug|Placebo|
25646|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
25647|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
25648|NCT00854061|Drug|T-Pred|sterile ophthalmic solution
26723|NCT00924339|Dietary Supplement|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
26724|NCT00924339|Dietary Supplement|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
26725|NCT00924352|Drug|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level − 1;100 mg QD,Dose Level − 2;70 mg QD.
26726|NCT00924352|Drug|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level − 1;12 mg/m2,Dose Level − 2;12 mg/m2.
26727|NCT00924391|Dietary Supplement|phytosterol enhanced soy based beverage|
26728|NCT00924391|Dietary Supplement|1% milk|
26729|NCT00018941|Biological|aldesleukin|
26730|NCT00926887|Device|Placebo Laser|Inactive light
26731|NCT00926900|Drug|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
26732|NCT00926900|Drug|Placebo|Placebo
26733|NCT00926926|Drug|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
26734|NCT00926926|Drug|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
26735|NCT00926939|Behavioral|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
26736|NCT00926939|Behavioral|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
26737|NCT00926952|Drug|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
26738|NCT00926952|Device|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
26739|NCT00926965|Drug|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
26740|NCT00018954|Drug|asparaginase|
27011|NCT00927459|Drug|PRO-040201|Single dose IV infusion
27012|NCT00927459|Drug|Placebo|placebo
27357|NCT00927875|Drug|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
27358|NCT00018967|Drug|glucarpidase|
27359|NCT00927875|Drug|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, & 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
27360|NCT00927888|Drug|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
27700|NCT00879385|Drug|Vectibix® (panitumumab)|Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.
DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.
Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr
27701|NCT00879398|Drug|Toviaz treatment|4 mg starting then can be followed by 8 mg
27702|NCT00879411|Drug|Micardis|
27703|NCT00879424|Dietary Supplement|cholecalciferol (vitamin D)|1000 IU once daily x 1 month
Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.
27704|NCT00879424|Dietary Supplement|Placebo|1000 IU once daily x 1 month
Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.
27705|NCT00879437|Drug|Valproic acid|Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.
Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml
27706|NCT00014222|Drug|epirubicin hydrochloride|60 mg/m2
27707|NCT00879437|Drug|Bevacizumab|All patients will receive bevacizumab (10mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
27708|NCT00879437|Radiation|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. the total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
27709|NCT00871910|Drug|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
27710|NCT00871910|Drug|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
27711|NCT00871910|Drug|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
27162|NCT00925015|Drug|Comparator: irinotecan|irinotecan intravenous infusion (150 mg/m2, every other week) for 42 days
27163|NCT00925028|Drug|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
27164|NCT00925028|Drug|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
27165|NCT00925054|Drug|rAvPAL-PEG|In Part 1, the planned starting dose levels are those tested in PAL-001 (0.001, 0.003, 0.01, 0.03, and 0.1 mg/kg), provided no dose-limiting toxicity was observed in PAL-001. After each subject completes Part 1, the subject's rAvPAL-PEG dosing will continue in Part 2. In Part 2, each subject's dose will be adjusted to attain a target blood Phe concentration with target levels between 120-600 micromol/L and a minimum blood Phe concentration decrease of 30% from baseline.
27166|NCT00018733|Drug|paroxetine|
27422|NCT00923195|Drug|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
27423|NCT00925548|Biological|Tecemotide (L-BLP25) and Hormonal Treatment|Investigational Arm:
Pretreatment (Single Dose) 300 mg/m^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).
Primary treatment phase:
Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* (Week 1 to 8).
Maintenance treatment phase:
Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).
*calculated as mass of lipopeptide (antigen)
27424|NCT00925548|Biological|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|Control Arm:
Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.
Primary treatment phase:
Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).
Maintenance treatment phase:
Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).
27425|NCT00925548|Drug|cyclophosphamide|300 mg/m^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
27426|NCT00925548|Drug|sodium chloride (NaCl)|NaCl 9 g/L infusion
27427|NCT00925574|Drug|CNTO 1959; Placebo|
27428|NCT00925587|Drug|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
27429|NCT00925600|Biological|Denosumab|Denosumab 60 mg is administered subcutaneously on Day 1 and Month 6.
27430|NCT00925600|Biological|Placebo|Placebo administered subcutaneously on Day 1 and Month 6.
25649|NCT00010972|Procedure|Acupuncture|
25650|NCT00854061|Drug|Pred Forte|sterile ophthalmic solution
25651|NCT00854074|Device|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
25652|NCT00854087|Drug|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
25653|NCT00854087|Drug|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
25654|NCT00854100|Drug|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
25655|NCT00854100|Drug|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
25656|NCT00854100|Drug|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
25657|NCT00854113|Drug|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
25658|NCT00856791|Drug|ON 01910.Na|
25659|NCT00856804|Drug|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
25660|NCT00856817|Drug|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
25661|NCT00856817|Drug|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
25662|NCT00856830|Drug|Bendamustine, Irinotecan, Etoposide/Carboplatin (Novel drug combination)|Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.
All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.
At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks.
25663|NCT00856843|Drug|BLI800|Solution for oral administration prior to colonoscopy
25977|NCT00860067|Biological|FluMist/B/Yamagata|0.2 mL dose at Day 0
25978|NCT00860067|Biological|FluMist/B/Victoria|0.2 mL dose at Day 0
25979|NCT00000792|Drug|Hypericin|
27013|NCT00927472|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
27014|NCT00927472|Drug|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
27015|NCT00927485|Drug|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
27016|NCT00927485|Other|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
27017|NCT00927485|Other|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
27018|NCT00927485|Other|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
27019|NCT00927485|Other|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
27020|NCT00927498|Drug|conventional chemotherapy (AraC + Daunorubicin),|Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.
Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
27021|NCT00018954|Drug|mercaptopurine|
27022|NCT00929266|Biological|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
27023|NCT00929279|Drug|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
27024|NCT00929279|Drug|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
27025|NCT00019110|Biological|synthetic human papillomavirus 16 E6 peptide|
27026|NCT00929292|Other|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
27027|NCT00929292|Other|Modilac 1|Infant formula used for non breastfed children
27028|NCT00929305|Device|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
27029|NCT00929305|Device|Placebo laser|Inactive laser light
27030|NCT00929318|Procedure|blood sampling|
27712|NCT00871910|Drug|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
27713|NCT00871910|Drug|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
27714|NCT00871910|Drug|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
27715|NCT00871910|Drug|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
27716|NCT00013299|Device|Prevention of Diabetic Ulcers|
26800|NCT00924404|Drug|Xylitol|5% solution for sinus rinse
26801|NCT00924404|Drug|Saline|saline for sinus rinse
26802|NCT00924417|Behavioral|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
26803|NCT00924417|Behavioral|Distraction|Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction "toys/tools" to assist with peripheral intravenous line placement.
26804|NCT00018642|Drug|quetiapine|
26805|NCT00924430|Drug|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
26806|NCT00924430|Drug|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
26807|NCT00924443|Drug|clofarabine|
26808|NCT00924456|Behavioral|Transcendental Meditation program|a natural effortless mental technique
26809|NCT00924469|Drug|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
26810|NCT00924469|Drug|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
26811|NCT00924469|Drug|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
26812|NCT00924482|Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
27431|NCT00925613|Device|LMA Proseal|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube.
27432|NCT00018811|Behavioral|Relaxation training & thermal biofeedback|
27433|NCT00925613|Device|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
27434|NCT00925626|Procedure|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
27435|NCT00925626|Procedure|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
27436|NCT00925639|Drug|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
27782|NCT00877214|Drug|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
27783|NCT00879450|Other|Booklet|booklet given to parents for home exercises
27784|NCT00879463|Procedure|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
27785|NCT00879463|Procedure|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
27786|NCT00879476|Drug|Ramipril 10mg capsules|
27787|NCT00879489|Biological|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
27788|NCT00879528|Other|Patients with negative PET after salvage therapy|All patients included in the study will treat with a salvage scheme according to each center.
After the end of salvage therapy, consolidation depends on the outcome of PET:
PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells.
25980|NCT00011986|Procedure|conventional surgery|Undergo surgery
25981|NCT00860080|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
25982|NCT00860080|Drug|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
25983|NCT00860093|Other|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
25984|NCT00860093|Drug|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
25985|NCT00860106|Other|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
25986|NCT00860119|Drug|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
25987|NCT00860119|Drug|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
25988|NCT00860145|Procedure|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
25989|NCT00852241|Drug|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
25990|NCT00852267|Other|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
25991|NCT00852267|Other|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
25992|NCT00010725|Drug|Vitamin Supplements|
25993|NCT00852267|Other|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
25994|NCT00852280|Device|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
27031|NCT00929318|Procedure|blood sampling|
27287|NCT00927849|Drug|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
27288|NCT00927862|Genetic|IWPC adapted genotype-guided dosing algorithm for warfarin|Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)
Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group.
27289|NCT00927862|Genetic|Modified IWPC genetic-guided warfarin dosing algorithm|Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.
Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group.
27290|NCT00920296|Drug|GSK1265744|GSK drug
27291|NCT00018096|Biological|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
27292|NCT00920309|Drug|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
27293|NCT00920309|Other|Standard of Care-Placebo|
27294|NCT00920322|Device|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
27295|NCT00920322|Device|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
27296|NCT00920335|Other|tumoral sample|Ependymoma tumoral sample
27297|NCT00920361|Drug|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
27298|NCT00920374|Biological|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
27299|NCT00920387|Drug|Experimental 200 mcg Lysergic acid diethylamide|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
27300|NCT00920387|Drug|Active Comparator 20 mcg lysergic acid diethylamide|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
27301|NCT00920387|Behavioral|Psychotherapy|Psychotherapy provided by a male and a female psychotherapist
26813|NCT00924495|Device|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
26814|NCT00924508|Device|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
26815|NCT00018642|Drug|haloperidol decanoate|
26816|NCT00924508|Drug|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
26817|NCT00924521|Dietary Supplement|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
27093|NCT00927498|Drug|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.
Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.
27094|NCT00927511|Drug|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
27095|NCT00927524|Drug|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
27096|NCT00927524|Drug|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
27097|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
27098|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
27099|NCT00927550|Drug|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
27100|NCT00927550|Drug|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
27101|NCT00927563|Drug|Tolcapone|pill, 100-300mg/day for 8 weeks
27789|NCT00879528|Other|Patients with positive PET after salvage therapy|All patients included in the study will treat with a salvage scheme according to each center.
After the end of salvage therapy, consolidation depends on the outcome of PET
PET positive, the consolidation therapy consists of 2 phases:
phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells
phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.
If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells.
27790|NCT00879541|Biological|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
27791|NCT00014222|Drug|fluorouracil|500mg/m2
27792|NCT00879541|Biological|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
27793|NCT00879541|Biological|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
27794|NCT00879554|Biological|CVX-045|Weekly, intravenous dose
27795|NCT00879593|Device|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
27796|NCT00879606|Drug|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
27797|NCT00879606|Drug|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
27798|NCT00879619|Drug|sunitinib malate|Given PO
27799|NCT00879619|Drug|docetaxel|Given IV
26876|NCT00922207|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
26877|NCT00922220|Other|stationary bike|Participants rode a stationary bike for five minutes
26878|NCT00018239|Procedure|Exercise|
26879|NCT00922220|Other|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
26880|NCT00922220|Other|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
26881|NCT00922233|Drug|levonorgestrel|oral contraceptive pills
26882|NCT00922246|Device|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
26303|NCT00920972|Drug|Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Regimen:
Children < 6 years of age, BM recipients:
Regimen 1 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Starting day +7: prednisone...
Children >/=6 years, BM recipients:
Regimen 3 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Days -1, +5, +14, +28: abatacept...
UCB recipients:
Regimen 1 (described above) OR Regimen 2 = Starting day -3: tacro or CsA... Starting day -3: MMF
26304|NCT00920985|Drug|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
26305|NCT00920985|Drug|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
26306|NCT00018161|Behavioral|Cigarette brand switching|
26307|NCT00920998|Drug|Z-338|oral
26308|NCT00921024|Drug|CXA-101|intravenous
26309|NCT00921024|Drug|Ceftazidime|intravenous
26310|NCT00921037|Procedure|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
26311|NCT00921050|Drug|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
26312|NCT00921050|Drug|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
26313|NCT00921063|Drug|PD 0332334|250 mg capsule, BID for 4 weeks
26314|NCT00921063|Drug|PD 0332334|100 mg capsule, BID for 4 weeks
26315|NCT00921063|Drug|placebo|0 mg capsule, BID for 4 weeks
26316|NCT00921063|Drug|Alprazolam extended release|1 mg capsule, BID for 4 weeks
26317|NCT00018174|Drug|Fluoxetine|
26318|NCT00921076|Behavioral|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
26319|NCT00921102|Drug|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
27302|NCT00018109|Drug|glutamine|
27303|NCT00920413|Dietary Supplement|Vitamin C|vitamin C 500mg orally once a day
27636|NCT00928200|Drug|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
27637|NCT00928200|Drug|Methotrexate|Given Intrathecally to all patients with CNS negative disease at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
27638|NCT00928200|Drug|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS positive at study entry. Doses determined by age.
27639|NCT00928213|Drug|Progesterone|40 units daily admission
27640|NCT00019058|Drug|pentoxifylline|
27641|NCT00928213|Drug|Low molecular weight Heparin|40-80 mg/day
27642|NCT00928213|Drug|No Drug|no treatment
27643|NCT00928226|Procedure|Fractionated Stereotactic Radiosurgery|Standard of care
27644|NCT00920868|Drug|bevacizumab|7.5 mg/kg IV day 1
27645|NCT00018161|Drug|Mecamylamine|
27646|NCT00920868|Drug|Oxaliplatin|130 mg/m2 IV day 1
27647|NCT00920868|Drug|Capecitabine|850 mg/m2 PO BID on days 1-14
27648|NCT00920881|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
27649|NCT00920894|Dietary Supplement|plant stanol ester|the effect of plant stanol esters on plasma lipids
27650|NCT00920907|Biological|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
27651|NCT00920920|Radiation|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
27652|NCT00920933|Biological|AIN457|
27653|NCT00920933|Other|Placebo|
27102|NCT00927576|Behavioral|Digit span testing|Testing of short-term verbal memory with digit span
27103|NCT00018954|Drug|methotrexate|
27104|NCT00927576|Behavioral|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
27105|NCT00927576|Behavioral|Finger tapping|Testing motor speed with a finger tapping test.
27106|NCT00927576|Behavioral|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
27107|NCT00927576|Behavioral|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
27108|NCT00927576|Behavioral|Verbal fluency|Evaluating how many words are produced in 90s.
27109|NCT00927576|Behavioral|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
27361|NCT00927901|Drug|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
27362|NCT00927901|Drug|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
27363|NCT00927901|Drug|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
27364|NCT00927901|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
27365|NCT00927914|Drug|Ranirestat|Ranirestat 40 mg tablets
27366|NCT00927914|Drug|Placebo|Placebo tablets
27367|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
27368|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
27369|NCT00019006|Drug|Detox-B adjuvant|
27370|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
27371|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
27372|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
26883|NCT00922259|Biological|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
26884|NCT00922272|Drug|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
26885|NCT00922272|Drug|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
26886|NCT00922285|Other|psychosocial support for caregiver|6 weekly 60 minute sessions
26887|NCT00922285|Other|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
26888|NCT00922285|Procedure|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
26889|NCT00000829|Biological|Placebo|Administered at 0, 2, 4, and 15 months of age
26890|NCT00018252|Behavioral|exercise|
26891|NCT00924534|Drug|SLV337|SLV337 1400 mg/day
26892|NCT00924547|Dietary Supplement|Docosahexanoic Acid Supplement|The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.
These dosages will be divided BID-TID and will be given for 4 weeks.
26893|NCT00924547|Dietary Supplement|Placebo|Placebo identical to active treatment.
26894|NCT00924560|Drug|91-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.
Take 1 tablet daily
26895|NCT00018655|Behavioral|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
26896|NCT00924560|Drug|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
26897|NCT00924573|Drug|Metformin|oral administration
27167|NCT00925067|Procedure|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
27168|NCT00925067|Device|lightweight TiMesh|
27169|NCT00925067|Device|lightweight VyproII|
27170|NCT00925067|Device|Heavyweight Marlex|
27171|NCT00925080|Device|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
26320|NCT00921102|Drug|Morphine|200 µg of a 200 µg/ml solution, intrathecally
26321|NCT00923494|Drug|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
25330|NCT00861679|Procedure|Transplantation with Stem Cells from Umbilical Cord|According to results from published experiences in children following suggestions are given:
Number of Cells:
Number of nucleated cells infused exceed 2,5x10*7/kg recipient BW or
Number of nucleated cells collected exceed 3x10*7/kg BW
Number of CD34+ cells infused exceed 2x10*5/kg Recipient BW
GVHD-prophylaxis:
• MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)
• UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.
HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group "MD". Less than 6/6 HLA matches allocate the patient to the "MMD" group.
If many choices available ABO- major incompatibility should be avoided.
25331|NCT00861692|Drug|argatroban|
25332|NCT00861705|Biological|Bevacizumab|Given IV
25333|NCT00012051|Procedure|peripheral blood stem cell transplantation|
25334|NCT00861705|Drug|Carboplatin|Given IV
25335|NCT00861705|Drug|Cyclophosphamide|Given IV
25336|NCT00861705|Drug|Doxorubicin Hydrochloride|Given IV
25337|NCT00861705|Other|Laboratory Biomarker Analysis|Correlative studies
25338|NCT00861705|Drug|Paclitaxel|Given IV
25339|NCT00861718|Drug|AZD7268|Capsule, Oral, QD
25340|NCT00861718|Drug|AZD7268|Capsule, Oral, BID
25341|NCT00861718|Drug|Placebo|Capsule, Oral BID
25342|NCT00861731|Drug|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
25343|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
25344|NCT00853515|Other|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
25345|NCT00853528|Other|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
25346|NCT00853528|Procedure|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
27654|NCT00920933|Drug|prednisolone|
27655|NCT00920946|Drug|Dimebon|20 mg Dimebon orally TID
27656|NCT00018161|Drug|Nicotine Patch|
27657|NCT00920946|Other|Placebo|Orally TID
27658|NCT00920959|Drug|FP 100mcg|Once-daily dosing
26741|NCT00926965|Drug|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
26742|NCT00926965|Drug|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
26743|NCT00926978|Radiation|Radioactive Iodine 124|After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131.
26744|NCT00926991|Other|No intervention|No intervention; observation only
26745|NCT00927004|Drug|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
26746|NCT00927004|Drug|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
26747|NCT00927017|Other|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
26748|NCT00927017|Other|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
26749|NCT00927030|Drug|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
26750|NCT00927030|Drug|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
26751|NCT00018954|Drug|cyclophosphamide|
26752|NCT00929123|Procedure|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
26753|NCT00929123|Other|healthy controls|People without carpal tunnel syndrome for comparison
26754|NCT00929136|Biological|USP endotoxin|Continuous intra-arterial infusion
27373|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
27374|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
27375|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
27376|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
27377|NCT00920504|Other|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
27378|NCT00920517|Biological|rDEN2/4delta30(ME) vaccine|10^3 PFU dose
27379|NCT00920517|Biological|Placebo|placebo for rDEN2/4delta30(ME) vaccine
27380|NCT00920543|Drug|Placebo|Twice daily dosing
27381|NCT00920543|Drug|FP 100mcg|Twice daily dosing
27717|NCT00871923|Drug|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
27718|NCT00871923|Radiation|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
27719|NCT00871936|Drug|SLx-4090|SLx-4090
27720|NCT00871936|Other|Placebo|matching tablets
27721|NCT00871936|Drug|Metformin|
27722|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
27723|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
27724|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
27725|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
27726|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
27727|NCT00013312|Procedure|Determine colonic tone|
27728|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
27172|NCT00925093|Drug|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
27173|NCT00925093|Drug|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
27174|NCT00925093|Drug|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
27175|NCT00925106|Drug|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
27176|NCT00925106|Drug|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
27177|NCT00018733|Drug|Desipramine|
27178|NCT00925106|Drug|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
27179|NCT00925106|Drug|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
27180|NCT00925119|Drug|Atenolol|12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
27181|NCT00925132|Drug|Temozolomide, Decitabine, Panobinostat|Temozolomide - given each cycle.
Decitabine - 6 cohorts with dose escalation.
Panobinostat - 6 cohorts with dose escalation.
27182|NCT00927589|Drug|carboplatin|Intravenous repeating dose
27183|NCT00018954|Drug|prednisone|
27184|NCT00927589|Drug|docetaxel|Intravenous repeating dose
27185|NCT00927589|Drug|trastuzumab|Intravenous repeating dose
27186|NCT00927602|Drug|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
27187|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intracoronary)
27188|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intravenous)
27189|NCT00927628|Procedure|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
27437|NCT00925639|Drug|Placebo|Starch pill
27438|NCT00925652|Drug|Bevacizumab|Given intravenously once every 3 weeks for approximately 6 months, then every 6 weeks for additional 1.5 years.
27439|NCT00925652|Drug|Cyclophosphamide|Taken orally once a day for approximately 6 months.
25347|NCT00853528|Procedure|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
25348|NCT00853528|Radiation|hypofractionated radiation therapy|two to three consecutive daily sessions within one week
25349|NCT00010907|Drug|NPI-028|
25350|NCT00853528|Radiation|stereotactic radiosurgery|two to three consecutive daily sessions within one week
25351|NCT00853554|Drug|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
25664|NCT00856843|Drug|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
25665|NCT00856856|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
25666|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
25667|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
25668|NCT00011583|Device|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
25669|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
25670|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
25671|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
25672|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
25673|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
25674|NCT00856882|Dietary Supplement|soy protein|
25675|NCT00856882|Dietary Supplement|isoflavones|
25676|NCT00856882|Dietary Supplement|milk protein|
25677|NCT00856908|Drug|AZD1656|Tolerable dose given twice daily
25678|NCT00856908|Drug|Placebo|Tolerable dose given twice daily
25679|NCT00011583|Device|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
26755|NCT00929162|Drug|ZD4054 Zibotentan|10 mg oral tablets once daily
26756|NCT00929162|Drug|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
26757|NCT00019097|Drug|sargramostim|
26758|NCT00929162|Drug|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
26759|NCT00929162|Drug|Placebo|matching placebo for ZD4054 10 mg
26760|NCT00929175|Device|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
27032|NCT00929331|Biological|Fluviral®|Intramuscular injection, one dose
27033|NCT00929344|Drug|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
27034|NCT00929344|Drug|Duloxetine|Duloxetine, 40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
27035|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
27036|NCT00019123|Drug|thalidomide|
27037|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
27038|NCT00929344|Drug|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
27039|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
27040|NCT00929357|Drug|DMARDs or Biologics|
27041|NCT00929370|Drug|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
27042|NCT00929383|Device|Wingspan Stent System with Gateway PTA Balloon Catheter|The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.
The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion.
27043|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
27044|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
27045|NCT00922441|Drug|Fimasartan 120 mg group|Fimasartan 120 mg
27729|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
27730|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
27731|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
27732|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
27733|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
27734|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
27735|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
27736|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
27737|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
27738|NCT00013325|Procedure|Cardiac Disease|
27739|NCT00874302|Drug|Proellex|One 25mg capsule taken orally once every day.
27740|NCT00874302|Drug|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
27741|NCT00874315|Other|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
27742|NCT00874315|Drug|busulfan|0.8 mg/kg/dose for total of 8 doses.
26818|NCT00924521|Dietary Supplement|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
26819|NCT00924534|Drug|Placebo|Placebo
26820|NCT00924534|Drug|SLV337|SLV337 400 mg/day
26821|NCT00924534|Drug|SLV337|SLV337 800 mg/day
26822|NCT00927043|Other|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
26823|NCT00927056|Procedure|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
26824|NCT00927069|Drug|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
26825|NCT00927069|Drug|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
27440|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
27441|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
27442|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
27443|NCT00019006|Drug|ras peptide cancer vaccine|
27444|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
27445|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
27446|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
27447|NCT00927940|Device|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
27448|NCT00927953|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
27449|NCT00927953|Biological|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
27450|NCT00927966|Drug|RAD001|Taken orally once a day.
27451|NCT00927966|Drug|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
27452|NCT00927979|Drug|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
27453|NCT00927979|Drug|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
27454|NCT00019019|Drug|carboxyamidotriazole|
27455|NCT00927979|Drug|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
27456|NCT00927992|Other|Epidemiological Non interventional|Epidemiological Non interventional
27457|NCT00928005|Behavioral|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
27458|NCT00928005|Behavioral|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
27800|NCT00879619|Drug|prednisone|Given PO
25680|NCT00856934|Biological|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
25681|NCT00856934|Biological|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
25682|NCT00859508|Device|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
25683|NCT00859521|Drug|Levetiracetam|1000 mg Tablet
25684|NCT00859521|Drug|Keppra®|1000 mg Tablet
25685|NCT00859534|Drug|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
25995|NCT00852293|Other|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
25996|NCT00852306|Procedure|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
25997|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
25998|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
25999|NCT00852332|Dietary Supplement|phytochemical|
26000|NCT00852332|Drug|docetaxel|
26001|NCT00852332|Procedure|complementary or alternative medicine procedure|
26002|NCT00852345|Drug|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
26003|NCT00010738|Procedure|Meditation|
26004|NCT00852358|Drug|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
27046|NCT00922441|Drug|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
27047|NCT00018265|Behavioral|Tai Chi|
27048|NCT00922454|Procedure|Endovascular Repair of the abdominal aorta|Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.
EVAR, CTA imaging, 1, 6 12 months post treatment.
27049|NCT00922454|Device|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
27050|NCT00922454|Device|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
27051|NCT00922467|Drug|NaCl 9/00|Same volume as in the esmolol group
27052|NCT00922467|Drug|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
27304|NCT00920413|Dietary Supplement|placebo|
27305|NCT00920426|Drug|GSK1265744|Active drug
27306|NCT00920426|Drug|Placebo|Placebo to match GSK1265744
27307|NCT00920439|Biological|PoliorixTM|Single dose, intramuscular administration.
27308|NCT00920465|Drug|mifegyne and cytotec|One day dosage versus two days dosage
27309|NCT00920478|Other|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
27310|NCT00920478|Other|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
27311|NCT00920491|Biological|biomarker-enhanced disposition decision with proADM|To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
27312|NCT00920504|Behavioral|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
27313|NCT00018109|Drug|creatine monohydrate|
27314|NCT00922961|Procedure|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
27315|NCT00922974|Radiation|external beam radiation therapy|Patients undergo 1 standard-dose external beam radiotherapy treatment.
27316|NCT00922974|Radiation|image-guided radiation therapy|Patients undergo 1 high-dose image-guided radiosurgery treatment.
26826|NCT00927082|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
26827|NCT00927095|Drug|low dose oral contraceptive (20 ug ethinyl estradiol + 3 mg drospirenone)|daily for three months
26828|NCT00927095|Drug|20 ug ethinyl estradiol + 3 mg drospirenone|daily for 21 days each month
26829|NCT00927095|Drug|placebo|daily
26830|NCT00927108|Other|Progenitor Stem Cell Culture|
26831|NCT00927121|Device|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.
Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.
The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system
26832|NCT00000832|Biological|rgp120/HIV-1 SF-2|
26833|NCT00018954|Drug|cytarabine|
26834|NCT00927134|Genetic|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
26835|NCT00927147|Radiation|BNCT|Boronophenylalanine infusion followed by neutron irradiation
26836|NCT00927147|Drug|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
26837|NCT00927173|Device|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
27110|NCT00927576|Behavioral|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
27111|NCT00927576|Behavioral|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
27112|NCT00927576|Behavioral|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
27113|NCT00929591|Drug|fluorouracil|
27114|NCT00929591|Drug|tamoxifen citrate|
27115|NCT00019136|Biological|therapeutic allogeneic lymphocytes|
27116|NCT00929591|Radiation|brachytherapy|
27801|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
27802|NCT00014222|Drug|paclitaxel|175 mg/m2
27803|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
27804|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
27805|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
27806|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
27807|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
27808|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
27809|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
27810|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
27811|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
27812|NCT00871962|Other|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
27813|NCT00871975|Device|TETRA - NIRS|The Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome from the detrusor muscle from the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified the correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures and uroflow procedures.
27814|NCT00872001|Drug|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
27815|NCT00872001|Drug|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
27816|NCT00013338|Procedure|Ambulation Training|
27817|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
27818|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
28548|NCT00880958|Dietary Supplement|Placebo|
28549|NCT00880971|Radiation|3D conform radiotherapy|3D conform radiotherapy, 2 Gy per fraction, total 25 fractions (50Gy).
28550|NCT00880984|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
28551|NCT00014313|Drug|cisplatin|
28552|NCT00873275|Drug|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
28553|NCT00873275|Drug|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
28554|NCT00873275|Drug|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
28555|NCT00873275|Drug|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
28556|NCT00873275|Genetic|RNA analysis|Analysis on discard tissues
28557|NCT00873275|Genetic|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
28558|NCT00873275|Genetic|polymerase chain reaction|Analysis on discard tissues
28559|NCT00873275|Genetic|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
28560|NCT00873275|Other|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
28561|NCT00013520|Drug|Atazanavir|
28562|NCT00873275|Other|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
28563|NCT00873275|Other|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
28564|NCT00873275|Procedure|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
28565|NCT00873288|Other|informational intervention|
28566|NCT00873288|Other|questionnaire administration|
28127|NCT00877721|Device|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
28128|NCT00877734|Drug|baclofen|10 mg Baclofen administered tid for 11 weeks
28129|NCT00877734|Drug|placebo|Placebo administered tid for 11 weeks
28130|NCT00877734|Behavioral|BRENDA counseling|
28131|NCT00877760|Drug|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
28132|NCT00014105|Drug|temozolomide|
28133|NCT00877760|Drug|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
28134|NCT00877773|Drug|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
28135|NCT00877786|Behavioral|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
28136|NCT00877799|Drug|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
28137|NCT00877799|Drug|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
28138|NCT00877799|Drug|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
28456|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
28457|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
28458|NCT00880490|Drug|Inhaled placebo|single dose, inhaled
28459|NCT00880490|Drug|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
28460|NCT00880529|Device|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
28461|NCT00014274|Drug|gemcitabine hydrochloride|
28462|NCT00880529|Drug|IV opioid administration|Patient controlled analgesia with IV narcotics
28463|NCT00880542|Drug|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
28464|NCT00880542|Drug|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
28628|NCT00013130|Behavioral|Provision of health status information to patients provider|
28945|NCT00873886|Drug|Oseltamivir (Tamiflu)|The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.
A) Subject will take 75 mg of oseltamivir pill by mouth
B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected.
28946|NCT00873886|Procedure|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
28947|NCT00873899|Device|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
28948|NCT00873912|Biological|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
28949|NCT00013533|Procedure|Stem cell transplantation|& gt; 3 x 106/kg CD34+ stem cells by IV infusion
28950|NCT00873912|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
28951|NCT00873925|Biological|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
28952|NCT00873925|Dietary Supplement|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
28953|NCT00876473|Procedure|CPAP system|Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange
CPAP systems:
Continuous high-flow CPAP with fixed value PEEP valve
Continuous high-flow CPAP with Boussignac valve
Demand flow CPAP supplied by ventilator
28954|NCT00876486|Drug|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
28955|NCT00876486|Drug|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
28956|NCT00876499|Behavioral|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
28049|NCT00877695|Behavioral|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
28371|NCT00880217|Drug|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
28372|NCT00880217|Drug|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
28373|NCT00872989|Drug|docetaxel|Given IV
28374|NCT00872989|Drug|vandetanib|Given orally
28375|NCT00873002|Drug|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
28376|NCT00873002|Drug|sorafenib tosylate|400 mg PO BID
28377|NCT00873015|Drug|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
28378|NCT00873015|Drug|Saline|14 day continuous infusion of a vehicle control infusion
28379|NCT00873028|Other|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
28380|NCT00873041|Drug|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
28381|NCT00873041|Drug|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
28382|NCT00873067|Procedure|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
28383|NCT00013481|Procedure|Stroke Rehabilitation|
28384|NCT00873067|Procedure|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
28385|NCT00873093|Drug|asparaginase|Given IM
28386|NCT00873093|Drug|doxorubicin hydrochloride|Given IV
28387|NCT00873093|Drug|therapeutic hydrocortisone|Given IT
28704|NCT00878618|Drug|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
28705|NCT00878631|Drug|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
28706|NCT00878631|Drug|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
28707|NCT00878644|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
29012|NCT00871728|Drug|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
29013|NCT00871741|Biological|GSK2202083A vaccine|Intramuscular, three doses
29014|NCT00871741|Biological|Infanrix hexa|Intramuscular, three doses
29015|NCT00871741|Biological|Menjugate|Intramuscular, two doses
29016|NCT00873925|Dietary Supplement|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
29017|NCT00873951|Other|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
29018|NCT00873951|Dietary Supplement|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
29019|NCT00873951|Dietary Supplement|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
29020|NCT00873951|Dietary Supplement|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
29021|NCT00873977|Device|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
29022|NCT00873990|Other|Total etch bonding agent (5th generation)|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.
Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
29023|NCT00013546|Drug|TMTDS|
28465|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
28466|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
28467|NCT00880581|Drug|PF-3512676|18 mg injection
28468|NCT00880581|Radiation|Local radiotherapy|2 x 2 Gy
28469|NCT00880594|Drug|Desipramine|Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of "Adequate relief". Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum.
28470|NCT00873106|Device|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
28471|NCT00873119|Drug|belinostat, carboplatin, paclitaxel|
28472|NCT00873119|Drug|carboplatin, paclitaxel|
28473|NCT00873145|Procedure|HMRS|Modular prosthetic replacement of the humerus and elbow.
28474|NCT00873158|Device|Dynasplint|Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or "Experimental" group will add this therapy to their standard of care regimen
28475|NCT00013507|Procedure|Falls|
28770|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
28771|NCT00876200|Drug|Minoxidil|Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
28772|NCT00876200|Drug|Placebo|Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
28773|NCT00876226|Drug|Citalopram|Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.
Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose.
28774|NCT00876252|Biological|IC43|
28775|NCT00014001|Drug|quetiapine|
28776|NCT00876252|Drug|Placebo|NaCl
28957|NCT00876525|Device|Freedom SOLO|The Freedom SOLO heart valve prosthesis is a stentless bioprosthesis manufactured with bovine pericardium.
28958|NCT00876538|Drug|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
28959|NCT00014001|Drug|fluphenazine decanoate|
27972|NCT00879879|Drug|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
27973|NCT00879892|Drug|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
27974|NCT00879892|Other|Hypothermia|24 hour, target core temperature 33
27975|NCT00879905|Drug|HSP990|
27976|NCT00879918|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
27977|NCT00014235|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
27978|NCT00879931|Drug|Methylprednisolone|Methylprednisolone
27979|NCT00879931|Drug|Placebo|Placebo (NaCl 0.9%)
27980|NCT00879944|Other|Blood pressure|Blood pressure will be measured once while patient is seated
27981|NCT00879944|Other|Height|Height will be measured in centimeters at the time of enrollment
27982|NCT00879944|Other|Weight|Weight will be measured in kilograms at enrollment
27983|NCT00879944|Other|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
27984|NCT00879944|Other|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
27985|NCT00872274|Drug|sumatriptan 100mg|
27986|NCT00872287|Procedure|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
27987|NCT00872287|Procedure|SILS|Single transumbilical incision laparoscopic cholecystectomy
27988|NCT00013377|Procedure|Low vision|
27989|NCT00872300|Drug|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
27990|NCT00872326|Procedure|Autologous Bone Marrow Mononuclear Cells|Infusion > 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
28388|NCT00873093|Drug|liposomal vincristine sulfate|Given IV
28389|NCT00873093|Drug|cytarabine|Given IT or IV
28390|NCT00873093|Drug|prednisone|Given PO or IV
28391|NCT00873093|Drug|bortezomib|Given IV
28392|NCT00873093|Drug|pegaspargase|Given IM
28691|NCT00876161|Drug|Lactose|
28692|NCT00876174|Procedure|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
28693|NCT00876174|Procedure|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
28694|NCT00876187|Biological|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
28695|NCT00878566|Other|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
28696|NCT00878566|Other|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
28697|NCT00878579|Device|PDS System|Percutaneous Dynamic Stabilization System
28698|NCT00014183|Drug|gefitinib|
28699|NCT00878579|Device|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
28700|NCT00878592|Behavioral|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
28701|NCT00878605|Drug|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
28702|NCT00878605|Drug|Placebo|Placebo control
28703|NCT00878618|Drug|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
29024|NCT00873990|Other|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
29025|NCT00874003|Drug|mirtazapine|oral tablet, 30 mg daily
29026|NCT00874003|Drug|placebo|oral tablet, 1 daily
29027|NCT00874016|Device|Airtraq|Intubation using Airtraq
29028|NCT00874016|Device|Direct Laryngoscopy|Intubation using direct laryngoscopy
29029|NCT00874029|Device|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
28050|NCT00879957|Drug|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
28051|NCT00879957|Drug|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
28052|NCT00879970|Dietary Supplement|vitamin D|vitamin D factor intervention
28053|NCT00014235|Drug|cyclosporine|Given PO or IV
28054|NCT00879970|Drug|pioglitazone|thiazolidinedione factor intervention
28055|NCT00879970|Drug|rosiglitazone|thiazolidinedione factor intervention
28056|NCT00879970|Drug|placebo|thiazolidinedione factor intervention
28057|NCT00879970|Dietary Supplement|placebo|Vitamin D factor intervention
28058|NCT00879983|Drug|azithromycin (Zithromax)|a single dose of azithromycin ER 2g
3-day regimen of azithromycin tablet 500mg
28059|NCT00879983|Drug|azithromycin (Zithromax)|3-day regimen of azithromycin tablet 500mg
a single dose of azithromycin ER 2g
28060|NCT00879996|Drug|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
28061|NCT00879996|Drug|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
28062|NCT00880009|Drug|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
28063|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
28777|NCT00876265|Device|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
28778|NCT00876265|Device|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
28779|NCT00876278|Device|*AT.Smart 46LC|Primary implantation of *AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
28780|NCT00876291|Dietary Supplement|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
28781|NCT00876291|Dietary Supplement|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
28782|NCT00876304|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
28783|NCT00878670|Drug|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
28784|NCT00878683|Device|silicone catheter boot|silicone device using Dermabond
28785|NCT00878696|Procedure|TMS transcranial magnetic stimulation|200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).
The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.
Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz.
28786|NCT00878709|Drug|neratinib|240 mg orally daily for 1 year
29091|NCT00871806|Drug|ODT #2 without water|40 mg tablet given once to each subject
29092|NCT00871806|Drug|ODT #1 with water|40 mg tablet given once to each subject
29093|NCT00013273|Procedure|Physical Conditioning|
29094|NCT00871806|Drug|ODT #2 with water|40 mg tablet given once to each subject
29095|NCT00871819|Device|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
29096|NCT00871845|Drug|Orlistat|Orlistat 60 mg capsules, three times daily, before meals) will be prescribed for a time frame starting 3 to 6 weeks prior to and during the 48 weeks of the standard anti-HCV therapy.
27991|NCT00872352|Procedure|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
27992|NCT00872365|Behavioral|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
27993|NCT00872365|Dietary Supplement|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
28309|NCT00875355|Radiation|radiation therapy|Patients undergo radiotherapy
28310|NCT00875368|Drug|maraviroc|maraviroc dose dependent on co-medication
28311|NCT00875368|Drug|Placebo|Placebo drug
28312|NCT00875394|Drug|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
28313|NCT00875394|Drug|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
28314|NCT00875394|Drug|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
28315|NCT00013871|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
28316|NCT00875394|Drug|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
28317|NCT00875407|Other|Scintigraphy in 123I-IBZM|
28318|NCT00875420|Drug|RAD1901|10 mg Oral once a day for 28 days.
28319|NCT00875420|Drug|RAD1901|25 mg Oral once a day for 28 days
28320|NCT00875420|Drug|RAD1901|50 mg Oral once a day for 28 days.
28321|NCT00875420|Drug|RAD1901|100 mg Oral once a day for 28 days
28322|NCT00875420|Drug|Placebo|Placebo Oral once a day for 28 days
28323|NCT00875433|Drug|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
28324|NCT00875446|Drug|PLACEBO|Placebo
28325|NCT00875446|Drug|GSK1223249|I.V Infusion
28326|NCT00013871|Biological|Hepatitis B Vaccine (Recombinant)|
28327|NCT00875459|Drug|VIAject™|Subcutaneous injection 25 IU/mL
28492|NCT00875706|Behavioral|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
28493|NCT00875719|Device|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
28494|NCT00875719|Device|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
28495|NCT00013897|Drug|Lamivudine/Zidovudine|
28496|NCT00875732|Device|Bi Ventricular Pacing|
28497|NCT00875732|Device|Right Ventricular Pacing|
28498|NCT00875745|Drug|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
28499|NCT00875758|Procedure|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
28500|NCT00875758|Procedure|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
28501|NCT00875771|Drug|Capecitabine+Irinotecan+Bevacizumab|Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks
Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks
Bevacizumab: 5 mg/kg day 1, every 2 Weeks
Treatment will be given until disease progression or unacceptable toxicity.
28502|NCT00875784|Drug|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
28503|NCT00875784|Drug|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
28504|NCT00875784|Drug|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
28505|NCT00875784|Drug|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
28506|NCT00013897|Drug|Efavirenz|
28809|NCT00871377|Drug|Placebo|corn oil (n-6 fatty acids)
28810|NCT00871377|Drug|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
28064|NCT00014235|Drug|mycophenolate mofetil|Given IV or PO
28065|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
28066|NCT00880022|Device|Flexitouch System|pneumatic compression ( 10 to 30 treatments depending on group assignment)
28067|NCT00880035|Device|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
28068|NCT00880048|Drug|orvepitant|neurokinin-1 antagonist
28069|NCT00880048|Other|Placebo|Placebo to match orvepitant 30 mg and 60 mg
28070|NCT00880061|Drug|IL13-PE38QQR|
28071|NCT00880074|Radiation|PET Scan|3 Positron Emission Tomography (PET) scans performed 60-90 minutes after intravenous injection of FLT: 1) within 2 weeks before day 1 of chemotherapy treatment; 2) day 6-7 of chemotherapy treatment; and,3) at end of chemotherapy treatment, day 19-20.
28072|NCT00880074|Drug|FLT|FLT solution is administered through a peripheral intravenous catheter approximately 60 minutes before the PET scan.
28393|NCT00873093|Drug|methotrexate|Given IT or IV
28394|NCT00013494|Procedure|Stroke Rehabilitation|
28395|NCT00873093|Drug|etoposide phosphate|Given IV
28396|NCT00873093|Drug|cyclophosphamide|Given IV
28397|NCT00873093|Biological|filgrastim|Given IV or SC
28398|NCT00873093|Drug|leucovorin calcium|Given PO or IV
28399|NCT00873093|Other|laboratory biomarker analysis|Correlative studies
28400|NCT00875485|Biological|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
28401|NCT00875498|Procedure|active iTBS|Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.
80% MT, 20 sessions of 6 minutes, 2 per day
28402|NCT00875498|Procedure|sham iTBS|iTBS placebo (placebo coil)
28403|NCT00875524|Biological|Chimeric dengue serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
28404|NCT00875524|Biological|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
28882|NCT00876447|Biological|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
28883|NCT00876447|Biological|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
28884|NCT00876460|Drug|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
28885|NCT00014001|Drug|clozapine|
28886|NCT00876460|Drug|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
28887|NCT00876460|Drug|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
28888|NCT00876460|Drug|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
28889|NCT00876460|Drug|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
28890|NCT00878852|Behavioral|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
28891|NCT00878865|Drug|Alprazolam|1 mg tablet one oral dose
28892|NCT00878865|Drug|Alprazolam|1 mg tablet
28893|NCT00878878|Drug|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.
Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.
28894|NCT00878878|Drug|Dextrose|Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.
Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.
28895|NCT00878891|Device|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
28896|NCT00878904|Drug|epirubicin hydrochloride|
28897|NCT00014209|Drug|cisplatin|
28898|NCT00878904|Drug|panobinostat|
28899|NCT00878904|Genetic|gene expression analysis|
28900|NCT00878904|Genetic|protein expression analysis|
28328|NCT00875485|Procedure|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
28329|NCT00877994|Behavioral|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
28330|NCT00014118|Radiation|radiation therapy|
28331|NCT00877994|Behavioral|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
28629|NCT00871117|Biological|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
28630|NCT00871130|Procedure|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
28631|NCT00871143|Behavioral|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
28632|NCT00871143|Behavioral|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
28633|NCT00871156|Drug|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
28634|NCT00871156|Drug|Placebo|Placebo
28635|NCT00871169|Drug|Irinotecan, oxaliplatin, and cetuximab|Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).
The treatment interval (one cycle) is every 14 days.
28636|NCT00871182|Drug|Inhaled PT001|single dose, inhaled
28637|NCT00871182|Drug|Inhaled Placebo|single dose, inhaled
28638|NCT00871182|Drug|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
28639|NCT00013143|Behavioral|Patient risk profiling (potential ADEs) w/provider feedback|
28811|NCT00871377|Drug|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
28812|NCT00013182|Behavioral|social activity|
28813|NCT00871403|Drug|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m^2 once every 3 weeks, then pazopanib 800 mg once daily
28814|NCT00871403|Drug|pemetrexed and cisplatin|pemetrexed IV 500 mg/m^2 and cisplatin IV 75 mg/m^2 once every 3 weeks
28815|NCT00871416|Device|NovoFine® needle 6 mm|
28816|NCT00871416|Device|NovoFine® needle 12 mm|
28817|NCT00871429|Other|Lindi skin care products|Subjects will then be instructed to apply all three products daily for 1 month.
The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C).
28818|NCT00871442|Other|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
28819|NCT00871442|Other|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
28820|NCT00871442|Drug|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
28821|NCT00871455|Drug|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
28822|NCT00871468|Procedure|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
28823|NCT00013195|Behavioral|Telephone Care|
28824|NCT00871468|Procedure|anterior-inferior plate|ORIF clavicle with anterior inferior plate
28825|NCT00871481|Biological|ipilimumab|Given IV
28826|NCT00871481|Drug|cyclophosphamide|Given IV
28827|NCT00871481|Procedure|biopsy|Optional correlative studies
28828|NCT00871481|Biological|aldesleukin|Given SC
28829|NCT00871481|Other|immunohistochemistry staining method|Correlative studies
28830|NCT00871481|Genetic|polymerase chain reaction|Correlative studies
28831|NCT00871481|Other|immunoenzyme technique|Correlative studies
28832|NCT00871481|Biological|therapeutic allogeneic cytotoxic T lymphocytes|Given IV
28405|NCT00875537|Other|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
28406|NCT00875537|Other|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
28407|NCT00875550|Drug|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
28408|NCT00013884|Drug|T-20|
28409|NCT00875550|Drug|Midazolam|Rescue medication for sedation according to UMSS scores
28410|NCT00875550|Drug|Fentanyl|Rescue medication for pain based on UMSS scores
28411|NCT00875550|Drug|Morphine|Rescue medication for pain based on UMSS scores.
28412|NCT00875563|Device|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
28413|NCT00875602|Device|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
28414|NCT00875615|Drug|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
28708|NCT00878644|Other|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
28709|NCT00014196|Drug|cisplatin|
28710|NCT00878657|Drug|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
28711|NCT00878657|Radiation|intensity-modulated radiation therapy|Dose escalation levels (cohorts) for this study:
Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy
28712|NCT00871247|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
28713|NCT00871247|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
28714|NCT00871260|Drug|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
28901|NCT00878904|Genetic|western blotting|
28902|NCT00878904|Other|immunologic technique|
28903|NCT00878904|Other|laboratory biomarker analysis|
27912|NCT00872248|Procedure|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
27913|NCT00872248|Procedure|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
27914|NCT00874588|Biological|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
27915|NCT00874601|Drug|Diovan® (valsartan)|The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded.
27916|NCT00874614|Radiation|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
27917|NCT00874627|Other|Milk|sublingual administration of milk
27918|NCT00874627|Other|Milk|placebo
27919|NCT00874640|Biological|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
27920|NCT00874653|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
27921|NCT00874666|Other|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
27922|NCT00874666|Dietary Supplement|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
27923|NCT00874679|Drug|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
27924|NCT00013689|Drug|Fansidar (pyrimethamine and sulfadoxine)|
27925|NCT00874692|Other|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
28640|NCT00871208|Drug|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
28641|NCT00871208|Drug|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
28642|NCT00871234|Drug|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
28643|NCT00873366|Drug|dextromethorphan hydrobromide|
28644|NCT00873366|Drug|tamoxifen citrate|
28645|NCT00873366|Other|high performance liquid chromatography|
28646|NCT00873366|Other|laboratory biomarker analysis|
28647|NCT00873366|Other|pharmacogenomic studies|
28960|NCT00876538|Drug|Placebo Control|Placebo Control 2 capsules once day with the noon meal
28961|NCT00876551|Procedure|Endoscopic vacuum assisted closure|Endoscopic debridement of wound using a regular biopsy forceps.
Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)
Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson & Johnson, St-Stevens-Woluwe, Belgium).
Trimming of the sponge to the specific wound size.
Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)
Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).
Sponge exchange twice a week until wound grounds are clean and closed
28962|NCT00876564|Other|Trauma patients|
28963|NCT00876577|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
28964|NCT00876603|Procedure|ACDF|Anterior cervical decompression and fusion
28965|NCT00876603|Procedure|Cervical laminoplasty|Cervical laminoplasty
28966|NCT00876616|Drug|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
28967|NCT00876616|Drug|Cyclophosphamide|CTX 0.75g/m2 BSA
28968|NCT00876629|Device|Pneumatic Driver|Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.
The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed.
28969|NCT00876642|Drug|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
28970|NCT00014014|Drug|Lamivudine/Zidovudine|
29146|NCT00876941|Behavioral|Enhanced Brief Intervention|Intervention: Less structured, motivational interview.
Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.
Counselor: Master's level/Doctoral student.
Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.
Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.
Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.
Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings.
29147|NCT00897117|Genetic|protein expression analysis|Blood and lung tissue collection
29148|NCT00897117|Other|biologic sample preservation procedure|Blood and lung tissue collection
29149|NCT00897117|Other|laboratory biomarker analysis|Blood and lung tissue collection
29150|NCT00897117|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
29151|NCT00897130|Drug|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
29152|NCT00897143|Genetic|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
29153|NCT00016159|Drug|idarubicin|
29154|NCT00897143|Genetic|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
29155|NCT00897143|Other|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
29156|NCT00897143|Other|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
29157|NCT00897169|Other|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
29158|NCT00897169|Other|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
29159|NCT00897182|Genetic|microarray analysis|
29160|NCT00897182|Genetic|polymerase chain reaction|
29161|NCT00897208|Other|high performance liquid chromatography|
29162|NCT00897208|Other|laboratory biomarker analysis|
29163|NCT00897208|Other|mass spectrometry|
29164|NCT00016159|Drug|tretinoin|
28715|NCT00871273|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
28716|NCT00871286|Procedure|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
28717|NCT00871286|Procedure|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
28718|NCT00871299|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual ("automatic") dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression.
28719|NCT00013156|Procedure|Effectiveness of Lung Reduction Therapy|
28720|NCT00871299|Behavioral|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
28721|NCT00871312|Device|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
28722|NCT00871312|Device|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
28723|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
29030|NCT00874042|Drug|Treatment with ARQ 197 in combination with gemcitabine|Enrollment of an initial cohort of 3 or 6 patients will follow the traditional "3 + 3" dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest.
29031|NCT00874068|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
29032|NCT00874068|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
29033|NCT00874094|Biological|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
29034|NCT00013572|Biological|ALVAC-HIV MN120TMG (vCP205)|
29035|NCT00874107|Biological|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
29036|NCT00876694|Drug|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
29037|NCT00876694|Drug|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
27926|NCT00874718|Behavioral|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
27927|NCT00874718|Behavioral|General education|Non-specific educational program for general health.
27928|NCT00874731|Drug|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
28248|NCT00877968|Dietary Supplement|Whole pea flour biscotti|Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 86 g Available CHO: 51.7 g
28249|NCT00877968|Dietary Supplement|Whole wheat pasta|Dose was portioned so that subjects received 50 g available carbohydrate
Portion (Dry): 70 g Available CHO: 51.1 g
28250|NCT00877968|Dietary Supplement|Whole pea pasta|Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum
Portion (Dry pasta) : 90 g Available CHO: 53.1 g
28251|NCT00877968|Dietary Supplement|White bread|Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 100 g Available CHO: 50 g
28252|NCT00877968|Dietary Supplement|Boiled yellow peas|Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 100 g (dry) --> 250 g cooked Available CHO: 52.8 g
28253|NCT00877981|Procedure|Minimal invasive Parathyroid surgery|
28254|NCT00880607|Drug|DepoDur™|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
28255|NCT00880620|Drug|placebo|placebo
28256|NCT00014274|Drug|methotrexate|
28257|NCT00880620|Drug|IPX066|dose level 1
28258|NCT00880620|Drug|IPX066|dose level 2
28259|NCT00880620|Drug|IPX066|dose level 3
28260|NCT00880646|Dietary Supplement|Oolong tea containing L-arabinose and indigestible dextrin|
28261|NCT00880646|Dietary Supplement|Oolong tea (Placebo)|
28262|NCT00880659|Behavioral|Soap|Promotion of handwashing with soap
28263|NCT00880672|Drug|dutasteride|5mg, oral, daily, 2-4 weeks
28264|NCT00880685|Drug|Memantine|10-30mg, daily for 8 weeks
28971|NCT00876655|Drug|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
28972|NCT00876655|Drug|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
28973|NCT00876681|Procedure|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
28974|NCT00878995|Drug|Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone|Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone
28975|NCT00878995|Drug|Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate|Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate
28976|NCT00879008|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
27994|NCT00872365|Other|Activities of daily living + placebo|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.
Placebo Comparator: Equivalent to placebo (maltodextrin).
27995|NCT00872378|Drug|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
27996|NCT00872378|Drug|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
27997|NCT00872391|Radiation|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
27998|NCT00872404|Drug|CP-751,871|20mg/kg/3 weeks
27999|NCT00013390|Procedure|Tinnitus Masking|Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or "covering up" (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle).
28000|NCT00872417|Drug|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
28001|NCT00872417|Drug|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
28002|NCT00872430|Other|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
29165|NCT00897208|Other|medical chart review|
29166|NCT00897208|Procedure|evaluation of cancer risk factors|
28182|NCT00872625|Radiation|stereotactic radiosurgery|
28183|NCT00872638|Procedure|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
28184|NCT00872638|Procedure|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
28185|NCT00872651|Drug|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
28186|NCT00872651|Drug|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
28187|NCT00872664|Dietary Supplement|carotenoids|beta-carotene, lycopene, lutein
28188|NCT00872677|Behavioral|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
28189|NCT00872677|Other|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
28190|NCT00872716|Drug|Quetiapine XR|100 mg single-dose Quetiapine XR
28191|NCT00872716|Other|Placebo|Placebo
28192|NCT00013429|Procedure|Visual|
28193|NCT00872729|Drug|Cystagon®|Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.
Duration of Treatment and Dose: Reference Period up to four doses Q6H.
28194|NCT00872729|Drug|RP103|Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.
Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.
28195|NCT00872742|Behavioral|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
28196|NCT00872742|Behavioral|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
28197|NCT00872755|Procedure|Nissen|Laparoscopic Nissen Fundoplication
28198|NCT00872755|Procedure|Gastropexy|posterior gastropexy
28199|NCT00872781|Drug|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
28200|NCT00872794|Device|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
29038|NCT00876707|Device|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
29039|NCT00876707|Device|ReSTOR implant|Implant of multifocal IOL ReSTOR
29040|NCT00876707|Device|ReZoom implant|Implant of multifocal IOL ReZoom
29041|NCT00876720|Device|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
29042|NCT00876720|Device|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
29043|NCT00000798|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
29044|NCT00014027|Drug|Docosahexaenoic acid (DHA)|
29045|NCT00876746|Procedure|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
29046|NCT00876759|Radiation|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
29047|NCT00876759|Radiation|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
29048|NCT00876772|Drug|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
28073|NCT00880087|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
28074|NCT00880087|Procedure|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
28075|NCT00872469|Drug|Tranexamic acid|1-2 grams by intravenous injection
28076|NCT00872469|Drug|Placebo [Saline]|Matched to active comparator
28077|NCT00872482|Drug|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
28078|NCT00872521|Drug|PAD induction|Open Label Treatment:
Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 & 11), Doxorubicin 20 mg/m2 i.v. (D1 & 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 & 12)
28265|NCT00880698|Biological|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IUs per aggregate dose
28266|NCT00880698|Biological|Placebo|2 mL solution
28267|NCT00014274|Drug|vinblastine sulfate|
28268|NCT00880724|Device|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
28269|NCT00880750|Drug|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
28567|NCT00873301|Procedure|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
28568|NCT00873314|Behavioral|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
28569|NCT00873314|Behavioral|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
28570|NCT00873327|Drug|piperacillin-tazobactam|6 doses intravenously at the following doses:
Infants <32 weeks gestation at birth < 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6
Infants ≥32 weeks gestation at birth < 14 days PNA 100 mg/kg Q6
≥ 14 days PNA 100 mg/kg Q6
28571|NCT00873340|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
28572|NCT00013520|Drug|Lamivudine/Zidovudine|
28573|NCT00873353|Drug|capecitabine + erlotinib|6 cycles (3 weeks each one) of :
capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
erlotinib (Tarceva®) 150mg/day, oral. Days: every days
28574|NCT00875797|Dietary Supplement|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
28575|NCT00875797|Dietary Supplement|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
28576|NCT00875836|Drug|Buspirone|Flexible dose, up to 60 mg daily
28577|NCT00875836|Drug|Placebo|Flexible dose, up to 60 mg daily
28578|NCT00875849|Biological|cetuximab|
28579|NCT00875849|Drug|cisplatin|
28580|NCT00875849|Radiation|radiation therapy|
28003|NCT00872430|Other|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
28004|NCT00872443|Other|Data collection|Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.
Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI.
28005|NCT00013702|Drug|Adefovir|
28006|NCT00874770|Drug|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
28007|NCT00874770|Drug|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
28008|NCT00874770|Drug|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
28009|NCT00874770|Drug|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
28010|NCT00874796|Drug|GS-9450|Taken as one capsule by mouth once daily
28011|NCT00874796|Drug|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
28332|NCT00878007|Drug|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
28333|NCT00878007|Behavioral|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness & vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
28334|NCT00878007|Other|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
28335|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose, 1 day
28336|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
28337|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
28338|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
28339|NCT00878046|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
28340|NCT00878072|Drug|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
28201|NCT00872807|Behavioral|Lifestyle counseling in groups|The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.
They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
28202|NCT00872807|Behavioral|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
28507|NCT00878254|Drug|Leucovorin|Leucovorin 100 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 10 mg/m2 IV every 6 hours until methotrexate level is below 0.05 nM. Day 10, Cycles 1 and 3.
28508|NCT00878254|Drug|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Days 1 - 5 Cycles 2 and 4
28509|NCT00878254|Drug|Methotrexate|Methotrexate 1,200 mg/m2 in 250 mL D5W IV over 1 hour followed by Methotrexate 3,000 mg/m2 in 1,000 mL D5W by continuous infusion over 23 hours (130 mg/m2 every hour for 23 hours). Day 10 Cycles 1 and 3
28510|NCT00878254|Drug|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg) days 1 and 8 for Cycles 1 and 3
28511|NCT00014170|Other|pharmacological study|Correlative studies
28512|NCT00878267|Behavioral|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
28513|NCT00878293|Drug|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
28514|NCT00878293|Drug|MS Continus®|60 mg, capsule, once daily
28515|NCT00878293|Drug|Placebo|liquid formulation and capsule, once daily
28516|NCT00878306|Drug|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
28517|NCT00878306|Drug|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
28518|NCT00878306|Drug|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
28519|NCT00878306|Drug|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
28520|NCT00878319|Procedure|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using a 3.5 mm or 4.5 mm dynamic compression plate (DCP) or 4.5 mm broad DCP.
28521|NCT00878319|Other|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
28522|NCT00014170|Other|laboratory biomarker analysis|Correlative studies
28079|NCT00872534|Drug|acetylsalicylic acid|325mg once a day for 7 days
28080|NCT00013390|Procedure|Tinnitus Retraining Therapy|Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at "retraining" brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus "signal" to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted.
28081|NCT00872547|Device|DePuy ASR™ Hip System|Resurfacing system
28082|NCT00872547|Device|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
28083|NCT00872560|Device|NovoFine® needle 6 mm|
28084|NCT00872560|Device|NovoFine® needle 8 mm|
28085|NCT00872573|Device|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
28086|NCT00872586|Drug|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
28087|NCT00872586|Drug|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
28088|NCT00872599|Drug|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
28089|NCT00872599|Drug|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
28415|NCT00875615|Drug|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
28416|NCT00875615|Drug|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
28417|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
28418|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
28419|NCT00013897|Drug|Atazanavir|
28420|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
28581|NCT00875862|Procedure|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
28582|NCT00875875|Drug|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
28583|NCT00875888|Device|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
28584|NCT00013910|Drug|NNC 90-1170|
28585|NCT00875901|Radiation|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
28904|NCT00878904|Other|pharmacological study|
28905|NCT00878917|Drug|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
28906|NCT00878943|Drug|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
28907|NCT00878956|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
28908|NCT00000800|Drug|Methadone hydrochloride|
28909|NCT00014209|Drug|dexamethasone|
28910|NCT00878956|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
28911|NCT00878969|Drug|valsartan (ARB)|
28912|NCT00878969|Drug|ramipril (ACE inhibitor)|
28913|NCT00878969|Drug|Placebo|
28914|NCT00871494|Drug|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
28915|NCT00013208|Behavioral|Case Management|
28916|NCT00871507|Drug|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
28341|NCT00014131|Biological|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
28342|NCT00878085|Device|Robot Therapy Device|3x a week for 4 weeks
28343|NCT00878085|Behavioral|Occupational Therapy|3x a week for 4 weeks
28344|NCT00878111|Drug|NGR-hTNF|First cohort: iv q3W 60 mcg/sqm over 120 min*
Second cohort: iv q3W 80 mcg/sqm over 120 min*
Third cohort: iv q3W 100 mcg/sqm over 120 min*
Fourth cohort: iv q3W 125 mcg/sqm over 120 min*
Fifth cohort: iv q3W 150 mcg/sqm over 120 min*
Sixth cohort: iv q3W 175 mcg/sqm over 120 min*
Seventh cohort: iv q3W 200 mcg/sqm over 120 min*
Eighth cohort: iv q3W 225 mcg/sqm over 120 min*
Ninth cohort: iv q3w 250 mcg/sqm over 120 min*
Tenth cohort: iv q3w 275 mcg/sqm over 120 min*
Eleventh cohort: iv q3w 300 mcg/sqm over 120 min*
Twelfth cohort: iv q3w 325 mcg/sqm over 120 min*
* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period.
28345|NCT00878124|Dietary Supplement|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
28346|NCT00878124|Other|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
28347|NCT00014235|Other|laboratory biomarker analysis|Correlative studies
28348|NCT00880100|Drug|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
28648|NCT00873366|Other|pharmacological study|
28649|NCT00873366|Procedure|fluorescence imaging|
28650|NCT00873379|Dietary Supplement|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
28651|NCT00873379|Dietary Supplement|placebo|half a white placebo tablet
28652|NCT00013520|Drug|Abacavir sulfate|
28653|NCT00873392|Drug|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
28654|NCT00873392|Other|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
28655|NCT00873405|Procedure|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
28523|NCT00878345|Drug|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
28524|NCT00878345|Drug|pentobarbital sedation protocol|Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.
May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation.
28525|NCT00878358|Other|Hydrotherapy|
28526|NCT00878358|Other|Physiotherapy|
28833|NCT00873665|Other|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
28834|NCT00873678|Biological|Whole blood sample|Whole blood sample (10 ml)
28835|NCT00873691|Device|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
28836|NCT00873704|Other|supplemental postoperative oxygen|
28837|NCT00013520|Drug|Stavudine|
28838|NCT00873717|Other|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
28839|NCT00873717|Other|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
28840|NCT00873717|Other|Dentary + Nutrition|trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
associated with control of the administration of dietary prescriptions, incitement to eat.
28841|NCT00873730|Drug|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
28842|NCT00873730|Drug|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
28843|NCT00873756|Drug|FOLFOX regimen|Intravenous repeating dose
28844|NCT00873756|Drug|bevacizumab|Intravenous repeating dose
28845|NCT00873756|Drug|dulanermin|Intravenous repeating dose
28846|NCT00873769|Drug|Staccato Loxapine|inhalation
28847|NCT00873782|Other|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
28421|NCT00875641|Procedure|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
28422|NCT00875654|Genetic|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume<100ml) less than 6 weeks after stroke
28423|NCT00878137|Device|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
28424|NCT00878150|Behavioral|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
28425|NCT00878150|Behavioral|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
28426|NCT00878163|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
28427|NCT00878163|Drug|Erlotinib Hydrochloride|Given PO
28428|NCT00014144|Drug|gefitinib|
28429|NCT00878163|Drug|Gemcitabine Hydrochloride|Given IV
28430|NCT00878163|Drug|Vismodegib|Given PO
28431|NCT00878176|Procedure|First stage tined lead procedure|bilateral first stage tined lead placement
28432|NCT00878189|Drug|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
28433|NCT00878202|Device|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
28434|NCT00878215|Procedure|Phase 1-4,To localize anatomical points on the liver surface|The objectives of phase 1 are complete. Phases 2 and 3 will enroll concurrently. If the objectives of any phase are not met, then the study will be discontinued and postponed and the experimental protocol will be revised.
28724|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
28725|NCT00871325|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
28726|NCT00871338|Biological|GSK2197870A|3 doses given at 2, 3 and 4 months of age
28727|NCT00871338|Biological|Prevenar™|3 co-administered doses, intramuscular into right thigh
28728|NCT00871338|Biological|Menitorix™|1 booster dose at 12 months of age
28917|NCT00871507|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
28918|NCT00871507|Drug|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
28919|NCT00871507|Drug|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
28920|NCT00871520|Other|no specific interventions|There are no specific interventions in this observational study
28921|NCT00871533|Drug|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
28922|NCT00871533|Drug|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
28923|NCT00871533|Drug|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
27929|NCT00874731|Drug|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
27930|NCT00874731|Drug|Placebo|A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
27931|NCT00874744|Drug|Bevacizumab|1.25mg bevacizumab (0.05ml)
27932|NCT00874744|Drug|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
27933|NCT00874770|Drug|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
27934|NCT00874770|Drug|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
27935|NCT00877370|Drug|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
27936|NCT00877383|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
27937|NCT00877383|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
27938|NCT00877383|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
28656|NCT00873405|Procedure|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
28657|NCT00873418|Behavioral|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
28658|NCT00873431|Biological|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
28659|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
28660|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
28661|NCT00873457|Drug|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
28662|NCT00873470|Procedure|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
28663|NCT00013520|Drug|Efavirenz|
28664|NCT00873483|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 3 cycles
28665|NCT00873496|Drug|Hydroxychloroquine|
28666|NCT00873509|Drug|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
28667|NCT00873509|Drug|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
28977|NCT00879021|Drug|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
28978|NCT00879021|Drug|matching placebo|150 mg by mouth ,twice a day for 49 weeks
28979|NCT00879034|Drug|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
28980|NCT00014209|Drug|gemcitabine hydrochloride|
28981|NCT00879034|Drug|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
28982|NCT00879034|Drug|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
28848|NCT00013520|Drug|Zidovudine|
28849|NCT00873795|Drug|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
28850|NCT00873808|Drug|clodronate disodium|
28851|NCT00873808|Drug|demeclocycline hydrochloride|
28852|NCT00873808|Drug|ibandronate sodium|
28853|NCT00873808|Drug|tetracycline hydrochloride|
28854|NCT00873808|Drug|zoledronic acid|
28855|NCT00873808|Other|laboratory biomarker analysis|
27877|NCT00879697|Behavioral|Strength Training Program|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
27878|NCT00014235|Drug|fludarabine phosphate|Given IV
27879|NCT00879710|Drug|simvastatin|Subjects will be started on eithersimvastatin or ezetimibe(we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
27880|NCT00879723|Dietary Supplement|Vitamin and Mineral supplementation|IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.
Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg.
27881|NCT00879736|Behavioral|THT PACE Training|Patient training
27882|NCT00879736|Behavioral|THT PACE Training|Patient training
27883|NCT00879736|Other|placebo|
27884|NCT00879749|Biological|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
27885|NCT00879749|Biological|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
27886|NCT00879749|Biological|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
27887|NCT00879749|Biological|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
28729|NCT00871338|Biological|Pediacel™|3 doses given at 2, 3 and 4 months of age
28730|NCT00013169|Behavioral|Strong Patient Focus|
28731|NCT00871338|Biological|Menjugate™|2 doses given at 3 and 4 months of age
28732|NCT00871351|Drug|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
28733|NCT00871351|Drug|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
28734|NCT00871351|Drug|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
28735|NCT00873509|Drug|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
28736|NCT00873535|Drug|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
28737|NCT00873535|Drug|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
28738|NCT00873548|Device|PFNA-Asia|The operation is performed under regional or general anesthesia and involves the following main steps:
Positioning of the patient
Definition of the CCD-angle
Fracture reduction
Determination of the nail diameter
Incision
Insertion of the device
28739|NCT00873561|Drug|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
28740|NCT00873574|Biological|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
28741|NCT00013520|Drug|Nevirapine|
28742|NCT00873587|Procedure|Chest tube pull on inspiration|Pull chest tube on Inspiration
28743|NCT00873587|Procedure|Expiration|Pull chest tube on Expiration
28744|NCT00873600|Drug|chemotherapy|
28745|NCT00873600|Other|medical chart review|
29049|NCT00876785|Other|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
29050|NCT00876785|Other|wheat bread based breakfast|Reference wheat bread breakfast
27939|NCT00877396|Biological|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
27940|NCT00877396|Biological|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
27941|NCT00877409|Drug|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
27942|NCT00877409|Drug|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
27943|NCT00014092|Biological|recombinant interferon alfa|
27944|NCT00877422|Dietary Supplement|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
27945|NCT00877435|Behavioral|Cognitive behavioral therapy (CBT)|
27946|NCT00877448|Biological|Adjuvanted Multimeric-001 250 Mcg|
27947|NCT00877448|Biological|Multimeric-001 250 Mcg|
27948|NCT00877448|Biological|Phosphate Buffered saline|
28270|NCT00880750|Drug|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
28271|NCT00880763|Drug|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
28272|NCT00880763|Drug|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
28273|NCT00880763|Drug|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
28274|NCT00880763|Drug|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
28275|NCT00880789|Biological|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
28276|NCT00880815|Drug|Bendamustine|Starting dose of 70 mg/m^2 by vein over 1 hour on Day -5 through Day -3.
28277|NCT00880815|Drug|Rituximab|Dose of 375 mg/m^2 by vein over 5-7 hours on Day -13 and 1000 mg/m^2 on Day -6, Day +1 and Day +8 (1 time each week for four weeks).
28983|NCT00879047|Drug|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
28984|NCT00879047|Drug|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
28985|NCT00879060|Drug|spironolactone|spironolactone 50mg daily
28986|NCT00879073|Drug|Bendamustine|Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
28987|NCT00879086|Drug|eribulin mesylate|E7389 (eribulin mesylate) given at a dose of 1.4 mg/m^2 as a 2 - 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.
The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.
28988|NCT00879086|Drug|ixabepilone|Ixabepilone given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.
The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.
28989|NCT00879099|Drug|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
28990|NCT00879099|Drug|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
28991|NCT00014222|Biological|epoetin alfa|40,000 IU
28992|NCT00879099|Drug|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
28993|NCT00879099|Drug|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
28994|NCT00879112|Drug|MB07811|Oral
28012|NCT00874809|Device|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
28013|NCT00874835|Device|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
28014|NCT00874848|Biological|Imprime PGG® Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
28015|NCT00874848|Biological|Cetuximab|initial loading dose of 400 mg/m2 over 120 min and subsequent doses at 250 mg/m2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
28016|NCT00013741|Behavioral|Tailored Education Messages|
28017|NCT00874848|Drug|Paclitaxel|200 mg/m2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
27888|NCT00879749|Biological|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
27889|NCT00000800|Drug|Zidovudine|
27890|NCT00014235|Radiation|total-body irradiation|Undergo TBI
27891|NCT00879749|Other|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
27892|NCT00879762|Biological|IMVAMUNE® High Dose|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10^8 TCID50 (5×10^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
27893|NCT00879762|Drug|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
27894|NCT00000796|Drug|Isoniazid|
27895|NCT00013351|Procedure|Prevention of Falls|
28203|NCT00875173|Drug|Selenium|selenium as a drug according to Brazilian regulation laws
28204|NCT00875173|Drug|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
28205|NCT00875186|Other|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
28206|NCT00875186|Other|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
28207|NCT00875199|Behavioral|contingency management|Prize-based contingency management for weight loss
28208|NCT00000796|Drug|Rifampin|
28209|NCT00013871|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
28210|NCT00875199|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
28211|NCT00875212|Drug|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
28212|NCT00875212|Drug|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
28213|NCT00875212|Drug|fluoride|use of a dentifrice containing fluoride (1500ppm) only
28214|NCT00875212|Drug|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
28215|NCT00875225|Behavioral|DVD|Control group will receive usual care DVD from health professionals
29051|NCT00876798|Drug|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
29052|NCT00876798|Drug|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
29053|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
29054|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
29055|NCT00014027|Drug|Eicosapentaenoic acid|
29056|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
29057|NCT00876824|Drug|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
29058|NCT00879112|Drug|Placebo|Oral
29059|NCT00879138|Drug|VA106483|
29060|NCT00879151|Behavioral|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
29061|NCT00879151|Behavioral|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
29062|NCT00879151|Behavioral|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
29063|NCT00879164|Drug|bupivacaine hydrochloride|
29064|NCT00879164|Other|questionnaire administration|
29065|NCT00014222|Biological|filgrastim|5 mg/kg/d - days 2-13
29066|NCT00879177|Drug|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
29067|NCT00879177|Behavioral|behavioral therapy|confirmed negative smoking status at different time points
28278|NCT00013442|Procedure|Auditory Evoked Response|
28279|NCT00872820|Behavioral|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
28280|NCT00872820|Behavioral|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
28281|NCT00872846|Device|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
28282|NCT00872859|Procedure|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
28283|NCT00872872|Drug|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
28284|NCT00872885|Drug|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
28285|NCT00872885|Drug|Morphine|60 mg
28286|NCT00872885|Drug|Placebo|single dosage
28287|NCT00872898|Drug|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
28288|NCT00872898|Drug|Placebo|Placebo capsules, once daily, oral administration.
28586|NCT00875901|Radiation|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
28587|NCT00875914|Procedure|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
28588|NCT00875927|Other|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
28589|NCT00875927|Other|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
28590|NCT00875927|Other|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
28591|NCT00875927|Other|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
28592|NCT00875927|Other|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
28593|NCT00875940|Other|Diagnostic imaging procedures.|
28018|NCT00874848|Drug|Carboplatin|dose equal to an AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
28019|NCT00874861|Biological|Peptide vaccine + Poly-ICLC|Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.
Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical & Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine.
28020|NCT00874874|Drug|sorafenib tosylate|
28021|NCT00874887|Drug|moxifloxacin 0.5% HCI ophthalmic solution|1 drop in study eye three times a day for 14 days
28022|NCT00874887|Drug|gatifloxacin ophthalmic solution 0.3%|1 drop in study eye four times a day for 14 days
28023|NCT00874900|Other|Educational game|"Quest for the Code" is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department.
28024|NCT00874900|Other|Educational game + motivational interview|"Quest for the Code" is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
28025|NCT00874900|Other|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
28026|NCT00877513|Behavioral|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
28027|NCT00877526|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
28028|NCT00877539|Drug|PF-03526299|Inhaled, two doses 4 hours apart
28349|NCT00880113|Procedure|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
28350|NCT00880126|Behavioral|Community Development Teams|CDTs bring together counties who are implementing a new practice
28351|NCT00880139|Procedure|Blood sampling|Determination of cytokine plasma levels (ELISA)
28352|NCT00880139|Procedure|Noninvasive measurement of systemic hemodynamics|performed once
28353|NCT00880139|Procedure|Visual acuity assessment|ETDRS charts
28216|NCT00875225|Behavioral|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
28217|NCT00875238|Biological|trastuzumab|
28218|NCT00875238|Drug|doxorubicin hydrochloride|
28219|NCT00875238|Genetic|polymorphism analysis|
28220|NCT00013871|Biological|Measles-Mumps-Rubella Vaccine (Live)|
28221|NCT00875238|Other|laboratory biomarker analysis|
28222|NCT00875238|Other|questionnaire administration|
28223|NCT00875238|Procedure|assessment of therapy complications|
28224|NCT00875238|Procedure|magnetic resonance imaging|
28225|NCT00875251|Device|Measurements of body composition|Measurements of body composition using 3 different devices: Measurements of body composition using DXA using iDXA- General Electric, Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) and the Hydra multi-frequency equipment (Xitron technologies), air-displacement plethysmography in the PEA POD System (Life Measurement).
28527|NCT00878371|Procedure|Repair of descending thoracic aneurysm and morphine|Elective surgical patients undergoing repair of a descending thoracic aortic aneurysm, requiring insertion of a cerebral spinal fluid (CSF) drain and receiving Morphine as their primary analgesic agent can be enrolled
28528|NCT00878371|Procedure|all patients went repair of thier TAA|patient stratified into three groups
patients undergoing insertion of aortic stent
patients undergoing thoracotomy
patients undergoing thoracotomy and CPB
2. TAA repair endovascular
28529|NCT00014287|Drug|gemcitabine hydrochloride|
28530|NCT00880815|Drug|Fludarabine|30 mg/m^2 on Day -5 to Day -3.
28531|NCT00880815|Procedure|Stem Cell Transplant (SCT)|Infusion of donor blood stem cells by vein over 30-45 minutes on Day 0.
28532|NCT00880828|Other|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
28533|NCT00880828|Other|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
28534|NCT00880828|Drug|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
28535|NCT00880841|Drug|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
28090|NCT00872612|Procedure|EUS-FNA/EBUS-TBNA + BAL|EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.
EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.
BAL = bronchoalveolar lavage
28091|NCT00013403|Procedure|Blindness|
28092|NCT00872612|Procedure|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
28093|NCT00872625|Drug|cyclophosphamide|
28094|NCT00872625|Drug|docetaxel|
28095|NCT00872625|Drug|epirubicin hydrochloride|
28096|NCT00872625|Drug|fluorouracil|
28097|NCT00872625|Procedure|neoadjuvant therapy|
28098|NCT00874913|Device|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
28099|NCT00013767|Behavioral|Individual and Community education|
28100|NCT00874926|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
28101|NCT00874939|Drug|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
28102|NCT00874939|Drug|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
28103|NCT00874939|Drug|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
28104|NCT00874939|Drug|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
28105|NCT00874939|Drug|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
28106|NCT00874965|Device|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
28107|NCT00874965|Device|Sham stimulation|30 min; 5 times / week
28108|NCT00874978|Drug|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
28109|NCT00875004|Biological|epoetin beta|
28110|NCT00013793|Behavioral|Motivational enhancement and ultrasound|
28111|NCT00875004|Drug|systemic chemotherapy|
28594|NCT00875953|Procedure|standard neck dissection|standard surgical technique
28595|NCT00000796|Drug|Clofazimine|
28596|NCT00013923|Drug|Nutritional Supplement|
28597|NCT00875953|Procedure|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
28598|NCT00875966|Drug|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
28599|NCT00878384|Drug|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of <80bpm and <110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
28600|NCT00878384|Procedure|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
28601|NCT00878397|Device|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
28602|NCT00878423|Drug|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
28603|NCT00014170|Other|questionnaire administration|Ancillary studies
28604|NCT00878423|Drug|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
28605|NCT00878436|Drug|Panobinostat|
28924|NCT00871533|Drug|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
28925|NCT00871546|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
28926|NCT00000796|Drug|Amikacin sulfate|
28927|NCT00013221|Behavioral|Exercise|
28928|NCT00871546|Drug|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
28929|NCT00871546|Biological|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
28930|NCT00871559|Drug|REGN421(SAR153192)|
28354|NCT00880139|Device|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
28355|NCT00880139|Procedure|Ophthalmic examination and fundus photography|7 + 1 standard fields
28356|NCT00880139|Device|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
28357|NCT00880139|Device|High resolution optical coherence tomography (OCT)|performed once
28358|NCT00014248|Drug|adenosine triphosphate|
28359|NCT00880152|Behavioral|Mindfulness-based stress reduction|An 8-week course in mindfulness training
28360|NCT00880165|Device|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
28361|NCT00880178|Drug|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
28362|NCT00880191|Drug|dexamethasone|Given orally
28363|NCT00880191|Drug|gabapentin|Given orally
28364|NCT00880191|Other|placebo|Given orally
28365|NCT00880204|Behavioral|ESS-EMCH training|The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of "Advanced Pediatric Life Support (APLS)" and "Management of Obstetric Emergencies and Trauma (MOET)".
28366|NCT00880217|Drug|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
28367|NCT00880217|Drug|Placebo|Placebo capsule once daily for 42 days
28368|NCT00880217|Drug|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
28369|NCT00014248|Procedure|quality-of-life assessment|
28370|NCT00880217|Drug|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
28668|NCT00875966|Drug|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
28669|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
28670|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
28536|NCT00880854|Drug|BCG and CP-675,206|Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15
Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15
Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15
Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15
28537|NCT00880867|Drug|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
28538|NCT00880880|Other|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
28539|NCT00880893|Biological|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
28540|NCT00014300|Drug|glufosfamide|
28541|NCT00880893|Biological|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
28542|NCT00880906|Procedure|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
28543|NCT00880906|Drug|Steroid and Proton Pump Inhibitor Therapy|
28544|NCT00880919|Drug|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
28545|NCT00880919|Drug|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
28856|NCT00873808|Procedure|adjuvant therapy|
28857|NCT00873808|Procedure|computed tomography|
28858|NCT00873808|Procedure|dual x-ray absorptiometry|
28859|NCT00013520|Drug|Didanosine|
28860|NCT00876304|Drug|Placebo|Placebo capsules every 12 hours for 10 days
28861|NCT00876317|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
28862|NCT00876317|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
28863|NCT00014001|Drug|risperidone|
28864|NCT00876330|Other|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
28112|NCT00875004|Procedure|quality-of-life assessment|
28113|NCT00875017|Drug|Lanthanum Carbonate|1 x 1000mg tablet
28114|NCT00875017|Drug|Sevelamer|3 x 800mg tablets
28435|NCT00878228|Drug|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
28436|NCT00878228|Drug|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
28437|NCT00878241|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
28438|NCT00878254|Biological|G-CSF|G-CSF 480 mcg SQ starting on day 13 (Cycle 1, 3) and day 7 (Cycle 2, 4)
28439|NCT00000799|Drug|Probenecid|
28440|NCT00014170|Drug|gefitinib|Given orally
28441|NCT00878254|Drug|Rituximab|375 mg/m2 IV according to standard protocol; Day 1 for 4 Cycles
28442|NCT00878254|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV on Day 1 and 200 mg/m2 IV on Days 2 - 5 for Cycle 1, 3
28443|NCT00878254|Drug|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, days 1 and 2, Cycles 2 and 4
28444|NCT00878254|Drug|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus Day 1 , Cycles 1 and 3
28445|NCT00878254|Drug|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Days 1 - 5, Cycles 2 and 4
28446|NCT00878254|Drug|Ifosfamide|Ifosfamide 1.5 grams/m2 IV QD x 5 days, Days 1 - 5, Cycles 2 and 4
28447|NCT00880412|Drug|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
28448|NCT00880412|Drug|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
28449|NCT00000801|Drug|Filgrastim|
28450|NCT00014274|Drug|carboplatin|
28451|NCT00880464|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
28931|NCT00871572|Drug|LY2409021|4 capsules by mouth taken once daily for 12 weeks
28932|NCT00871572|Drug|Placebo|4 capsules by mouth once daily for 12 weeks
28933|NCT00871598|Drug|BTT1023|intravenous, three infusions over three weeks
28934|NCT00871598|Drug|Placebo|intravenous, three infusions over three weeks
28935|NCT00871598|Drug|BTT1023|Test challenge
28936|NCT00871624|Drug|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
28937|NCT00871624|Drug|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
28938|NCT00013234|Procedure|Teledermatology|
28939|NCT00873821|Drug|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
28940|NCT00873821|Drug|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
28941|NCT00873834|Drug|fluoxetine|Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.
A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized
28942|NCT00873834|Drug|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
28943|NCT00873860|Drug|CAT-354|SC CAT-354 once every 2 weeks
28944|NCT00873860|Other|Placebo|Placebo contains the same excipients, in the same concentration only lacking CAT-354.
27949|NCT00877448|Biological|Adjuvanted PBS|
27950|NCT00877448|Biological|Adjuvanted Multimeric-001 500 Mcg|
27951|NCT00877448|Biological|Multimeric-001 500 Mcg|
27952|NCT00877448|Biological|Multimeric-001 125 Mcg|
27953|NCT00877474|Drug|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
27954|NCT00000799|Drug|Cidofovir|
28671|NCT00875979|Drug|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
28672|NCT00875992|Device|ETN with ASLS|Angle stable locking of ETN using ASLS
28673|NCT00875992|Device|ETN locked with conventional locking bolts|Conventional surgical procedure
28674|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
28675|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
28676|NCT00013962|Drug|Vitamin D|
28677|NCT00876018|Other|Nutritional supplement|Fortified nutritional powder
28678|NCT00876018|Other|Placebo|Un-fortified nutritional powder
28679|NCT00876031|Drug|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
28680|NCT00876044|Drug|aflibercept (AVE0005)|Intravenous route
28681|NCT00876044|Drug|placebo|Intravenous route
28682|NCT00876057|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy
28683|NCT00876057|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
28684|NCT00876083|Drug|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
28685|NCT00876096|Other|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
28686|NCT00876109|Drug|GDC-0941|Escalating oral dose
28687|NCT00014001|Drug|perphenazine|
28688|NCT00876122|Drug|GDC-0941|Escalating oral dose
28689|NCT00876135|Drug|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
28690|NCT00876161|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
28995|NCT00871650|Other|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
28865|NCT00876330|Other|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
28866|NCT00876330|Other|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
28867|NCT00876330|Other|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
28868|NCT00876343|Drug|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
28869|NCT00876343|Drug|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
28870|NCT00876343|Drug|Placebo|administered orally once daily, 6 weeks
28871|NCT00876356|Dietary Supplement|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
28872|NCT00876356|Dietary Supplement|Olive oil|Olive oil 4.5g/day x 12 weeks
28873|NCT00876395|Drug|Everolimus|
28874|NCT00014001|Drug|ziprasidone|
28875|NCT00876395|Drug|Placebo|
28876|NCT00876421|Drug|Placebo|Placebo / 12 weeks
28877|NCT00876421|Drug|Tolterodine|4mg / 12 weeks
28878|NCT00876421|Drug|ONO-8539|low dose / 12 weeks
28879|NCT00876421|Drug|ONO-8539|medium dose / 12 weeks
28880|NCT00876421|Drug|ONO-8539|higher dose / 12 weeks
28881|NCT00876434|Drug|Sirolimus|
27896|NCT00872079|Device|Genomics|Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
27897|NCT00872092|Other|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
27898|NCT00872105|Procedure|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
28452|NCT00880477|Biological|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
28453|NCT00880477|Biological|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
28454|NCT00880477|Biological|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
28455|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
28746|NCT00873600|Other|questionnaire administration|
28747|NCT00873600|Procedure|adjuvant therapy|
28748|NCT00873600|Procedure|assessment of therapy complications|
28749|NCT00873600|Procedure|cognitive assessment|
28750|NCT00873600|Procedure|psychosocial assessment and care|
28751|NCT00873600|Procedure|quality-of-life assessment|
28752|NCT00000204|Drug|Buprenorphine|
28753|NCT00000796|Drug|Pyridoxine hydrochloride|
28754|NCT00013520|Drug|Lamivudine|
28755|NCT00873613|Procedure|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
28756|NCT00873626|Drug|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
28757|NCT00873639|Drug|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
28758|NCT00873639|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
28759|NCT00873652|Biological|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
28760|NCT00873665|Other|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
28761|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
28762|NCT00876187|Biological|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
27955|NCT00014092|Biological|sargramostim|
27956|NCT00877487|Drug|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
27957|NCT00877487|Drug|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
27958|NCT00877500|Drug|Ixabepilone|40 mg/m^2 by vein over 3 hours on Day 1 of each 21-day study cycle for up to 6 cycles.
27959|NCT00879762|Biological|IMVAMUNE® Standard Dose|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10^8 tissue culture infectious dose 50 [TCID50] per 0.5 mL dose)
27960|NCT00879775|Drug|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
27961|NCT00879775|Drug|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
27962|NCT00879788|Drug|Ramipril 10mg capsules|
27963|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
27964|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
27965|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
27966|NCT00014235|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
27967|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
27968|NCT00879827|Biological|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
27969|NCT00879827|Biological|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
27970|NCT00879853|Behavioral|Interpersonal Therapy|
27971|NCT00879866|Biological|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
28289|NCT00013455|Device|Hearing|
28290|NCT00872911|Dietary Supplement|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
28291|NCT00872911|Drug|Exercise|progressive exercise training
28996|NCT00871650|Other|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
28997|NCT00871650|Other|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
28998|NCT00871663|Drug|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
28999|NCT00871676|Behavioral|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
29000|NCT00871676|Behavioral|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
29001|NCT00871689|Biological|aldesleukin|IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
29002|NCT00871689|Drug|cyclophosphamide|60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
29003|NCT00871689|Drug|fludarabine phosphate|25 mg/m^2 intravenously (IV) over 1 hour on days -7 through -5.
29004|NCT00871689|Procedure|umbilical cord blood transplantation|On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
29005|NCT00013247|Behavioral|Prostate Cancer Screening Education|
29006|NCT00871689|Radiation|total-body irradiation|administered on days -5 through -2; 330 cGy daily
29007|NCT00871702|Genetic|CD34-TK75 transduced donor lymphocytes|
29008|NCT00871702|Radiation|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
29009|NCT00871715|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
29010|NCT00871715|Behavioral|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
29011|NCT00871715|Behavioral|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
28029|NCT00877539|Drug|Placebo|Inhaled, two doses 4 hours apart
27899|NCT00872105|Procedure|Operative Treatment|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:
Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)
27900|NCT00872118|Behavioral|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
27901|NCT00872118|Behavioral|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
27902|NCT00872131|Drug|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
27903|NCT00872144|Drug|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
27904|NCT00872157|Drug|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
27905|NCT00872170|Drug|Sildenafil|Participants will receive sildenafil for 12 weeks with the following therapy:
50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg
27906|NCT00013364|Behavioral|Talker variability|
27907|NCT00872196|Drug|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
27908|NCT00872209|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
27909|NCT00872209|Drug|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
27910|NCT00872222|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
27911|NCT00872235|Drug|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
28226|NCT00875264|Drug|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
28227|NCT00875277|Drug|LEO 29102 cream and combination products|Once daily application 6 days a week for 4 weeks
28228|NCT00875290|Device|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
28763|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
28764|NCT00014001|Drug|olanzapine|
28765|NCT00876187|Biological|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
28766|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
28767|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
28768|NCT00876187|Drug|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
28769|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
29068|NCT00879190|Drug|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
29069|NCT00879190|Drug|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
29070|NCT00879216|Drug|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
29071|NCT00879216|Drug|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
29072|NCT00879229|Drug|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
29073|NCT00879229|Drug|Placebo|Placebo to match ambrisentan administered orally once daily.
29074|NCT00879242|Drug|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
29075|NCT00879255|Behavioral|Cognitive Processing Therapy Group Videoteleconference|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.
29076|NCT00014222|Drug|cyclophosphamide|75, 600 and 830 mg/m2
29077|NCT00879255|Behavioral|Cognitive Processing Therapy Group In-Person|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
29078|NCT00879268|Device|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
29079|NCT00879281|Behavioral|Action plan|Individualized "written" Action Plan to enhance self-management and early detection of an exacerbation.
29080|NCT00879294|Device|Motion sickness wristband|No drugs are involved.
28292|NCT00872924|Drug|sumatriptan 100mg|
28293|NCT00872950|Drug|3,4-DIAMINOPYRIDINE|Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
28294|NCT00872950|Drug|3,4-Diaminopyridine|
28295|NCT00872963|Biological|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
28296|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
28297|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles
Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles
28298|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
28299|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles
Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles
28300|NCT00000796|Drug|Pyrazinamide|
28301|NCT00013468|Procedure|Tinnitus|
28302|NCT00875303|Behavioral|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
28303|NCT00875303|Behavioral|Control|Routine primary care.
28304|NCT00013871|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
28305|NCT00875316|Drug|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
28306|NCT00875342|Drug|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
28307|NCT00875342|Other|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
28308|NCT00875355|Drug|temozolomide|Given orally
28606|NCT00878436|Drug|Bicalutamide|
28030|NCT00877539|Drug|Fluticasone propionate|Inhaled
28031|NCT00877578|Dietary Supplement|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
28032|NCT00877578|Dietary Supplement|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
28033|NCT00014092|Drug|temozolomide|
28034|NCT00877591|Drug|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
28035|NCT00877591|Drug|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
28036|NCT00877591|Drug|Rifampin|600 mg once daily for 15 days total
28037|NCT00877591|Drug|Rifabutin|300 mg once daily for 15 days total
28038|NCT00877591|Drug|Buprenorphine|FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days
DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days
RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days
RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days
28039|NCT00877604|Drug|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
28040|NCT00877604|Drug|Placebo|identical placebo by oral route at the same dosing schedule
28041|NCT00877617|Behavioral|QOL Questionnaire|Mailed survey.
28042|NCT00877643|Other|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
28043|NCT00877643|Other|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
28044|NCT00014105|Drug|carboplatin|
28045|NCT00877656|Biological|HuMax-CD4|Active treatment
28046|NCT00877669|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
28047|NCT00877669|Procedure|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
28048|NCT00877682|Procedure|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
28229|NCT00877864|Behavioral|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
28230|NCT00877864|Behavioral|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
28231|NCT00877864|Behavioral|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
28232|NCT00877864|Behavioral|Control|No exercise program provided by the study
28233|NCT00014118|Drug|paclitaxel|
28234|NCT00877877|Procedure|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
28235|NCT00877890|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
28236|NCT00877890|Drug|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
28237|NCT00877903|Drug|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
28238|NCT00877903|Drug|Placebo|Intravenous infusion of excipients of Prochymal®
28239|NCT00877929|Drug|Telmisartan 80|Telmisartan 80 mg
28240|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
28241|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
28242|NCT00877955|Drug|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
28243|NCT00877955|Drug|alprazolam sublingual tablet test|0.5 mg tablet, single dose
28244|NCT00014118|Procedure|conventional surgery|
28245|NCT00877968|Dietary Supplement|Whole wheat banana bread|Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 62.8 g Available CHO: 51.7 g
28246|NCT00877968|Dietary Supplement|Whole pea flour banana bread|Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 67.8 g Available CHO: 52.0 g
28247|NCT00877968|Dietary Supplement|Whole wheat biscotti|Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 79.8 g Available CHO: 53.1 g
28546|NCT00880932|Behavioral|Electronic Alert|
28547|NCT00880958|Dietary Supplement|Mixture of various probiotics and fermentation products|
29081|NCT00879294|Dietary Supplement|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
29082|NCT00013260|Procedure|Integrated model of primary care|
29083|NCT00871767|Drug|AZD5672|40 mg tablet (Test formulation)
29084|NCT00871767|Drug|AZD5672|40 mg tablet (Reference formulation)
29085|NCT00871767|Drug|AZD5672|100 mg tablet (Test formulation)
29086|NCT00871767|Drug|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
29087|NCT00871780|Drug|BG00002 (natalizumab)|
29088|NCT00871793|Other|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
29089|NCT00871806|Drug|Commercial tablet with water|40 mg tablet, given once to each subject
29090|NCT00871806|Drug|ODT #1 without water|40 mg tablet given once to each subject
28115|NCT00875030|Drug|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
28116|NCT00875030|Drug|Arsuamoon|single dose 50 mg arsuamoon tablet
28117|NCT00875056|Drug|vorinostat|MK0683 (200 mg capsule) Oral, twice daily (400 mg/day) for Day 1 through 14 of a 21 day cycle
28118|NCT00875069|Other|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
28119|NCT00875082|Drug|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
28120|NCT00875082|Drug|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
28121|NCT00013806|Drug|131I-MIBG|
28122|NCT00875108|Drug|VIAject™|Subcutaneous injection 25 IU/mL
28123|NCT00875134|Other|Verbal prompt|Patient hears a voice recording
28124|NCT00875134|Other|Skin Stimulus|Patient receives either a skin stimulus
28125|NCT00875147|Drug|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
28126|NCT00875160|Drug|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
28607|NCT00878449|Drug|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
28608|NCT00878449|Drug|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
28609|NCT00878462|Drug|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
28610|NCT00878462|Drug|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
28611|NCT00878462|Drug|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
28612|NCT00878501|Drug|AZD1386|oral, during 4 weeks
28613|NCT00878501|Drug|AZD1386|oral, during 4 weeks
28614|NCT00014170|Procedure|quality-of-life assessment|Ancillary studies
28615|NCT00878501|Drug|Placebo|Oral, during 4 weeks
28616|NCT00878514|Drug|Alprazolam|Alprazolam 1 mg tablet
28617|NCT00878514|Drug|Xanax|Xanax 1 mg tablet
28618|NCT00878527|Device|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
28619|NCT00878540|Drug|mirtazapine|30 mg mirtazapine once daily for 7 days
28620|NCT00878553|Drug|placebo|tablet at bedtime
28621|NCT00878553|Drug|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
28622|NCT00871091|Procedure|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
28623|NCT00871091|Procedure|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
28624|NCT00871104|Drug|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
28625|NCT00871104|Drug|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
28626|NCT00871117|Biological|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
28627|NCT00871117|Biological|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
29752|NCT00899964|Behavioral|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
29753|NCT00899977|Drug|Placebo|Matching placebo
29754|NCT00016367|Biological|Trastuzumab|Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.
Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15.
29755|NCT00899977|Drug|TC-5214|
29756|NCT00899990|Other|laboratory biomarker analysis|Correlative studies
29757|NCT00900003|Genetic|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
29758|NCT00900003|Other|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
29759|NCT00900016|Genetic|protein expression analysis|
30039|NCT00900042|Other|flow cytometry|
30040|NCT00900042|Other|laboratory biomarker analysis|
30041|NCT00900055|Genetic|microarray analysis|
30042|NCT00900055|Genetic|polyacrylamide gel electrophoresis|
30043|NCT00900055|Genetic|polymerase chain reaction|
30044|NCT00900055|Genetic|protein expression analysis|
30045|NCT00900055|Genetic|reverse transcriptase-polymerase chain reaction|
30046|NCT00016367|Drug|Gemcitabine Hydrochloride|Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.
Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.
30047|NCT00900055|Genetic|western blotting|
30048|NCT00900055|Other|chromatography|
30049|NCT00900055|Other|high performance liquid chromatography|
30050|NCT00900055|Other|immunoenzyme technique|
30051|NCT00900068|Other|immunoenzyme technique|
29135|NCT00876863|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 X 10^11 vg
29136|NCT00876863|Procedure|Placebo Surgery|Placebo Surgery
29137|NCT00876876|Drug|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
29138|NCT00876889|Drug|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
29139|NCT00876902|Drug|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
29140|NCT00014040|Drug|Nitric Oxide and INOpulse Delivery System|
29141|NCT00876902|Drug|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
29142|NCT00876915|Drug|dalteparin injection|Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
29143|NCT00876928|Drug|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
29144|NCT00876928|Drug|placebo|medium chain triglyceride given once per week
29145|NCT00876941|Behavioral|Standard Brief Intervention|Intervention: Structured, brief negotiated interview.
Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.
Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.
Contacts, Duration: One, 10-15 minutes.
Communication content delivered to primary care physician: Results of screening and BI.
Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor.
28159|NCT00880295|Procedure|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
28160|NCT00880295|Procedure|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
28161|NCT00880308|Drug|LDE225|
28162|NCT00880321|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
29227|NCT00892606|Drug|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
29228|NCT00892619|Procedure|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
29229|NCT00892619|Procedure|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
29230|NCT00892632|Procedure|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
29231|NCT00892658|Drug|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
29232|NCT00892671|Other|Simulation|simulation of airway management and vascular access
29233|NCT00895063|Behavioral|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
29234|NCT00895076|Drug|dexamethasone|iontophoretic patch and injection
29235|NCT00895089|Drug|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
29236|NCT00895089|Drug|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
29237|NCT00895102|Drug|ABT-333 Tablet|See Arm Description for more information.
29238|NCT00016016|Drug|mitoxantrone hydrochloride|Given IV
29567|NCT00895583|Drug|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
29568|NCT00895583|Drug|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
29569|NCT00895583|Drug|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
29570|NCT00895596|Drug|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
29975|NCT00015899|Drug|lonafarnib|
30356|NCT00891644|Other|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
30357|NCT00891657|Device|SprayShield™|Anti-adhesion barrier
30358|NCT00891670|Drug|cilostazol|100mg twice daily for at least 1 month
30359|NCT00891670|Drug|clopidogrel|75mg once daily (triple group arm)
150mg once daily (high maintenance dose group arm)
30360|NCT00891670|Drug|aspirin|aspirin 100mg
30361|NCT00891683|Drug|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
30362|NCT00015652|Drug|Aldesleukin|
30363|NCT00891696|Drug|Rapamycin|Single 16-mg oral dose
30364|NCT00891696|Other|Amino acid supplementation|Nutritional drink containing essential amino acids
30365|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
30366|NCT00891696|Drug|Sodium nitroprusside|Variable rate for 3 hours
30367|NCT00891696|Device|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
30368|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
30369|NCT00891709|Drug|LEO 29102|First-in-man. Healthy volunteers
30370|NCT00891722|Other|biologic sample preservation procedure|
30371|NCT00891722|Other|laboratory biomarker analysis|
30372|NCT00891722|Other|questionnaire administration|
30373|NCT00015652|Drug|Peginterferon alfa-2b|
30374|NCT00891735|Drug|Ranibizumab|Sterile solution for intravitreal injection.
30052|NCT00900068|Other|laboratory biomarker analysis|
30053|NCT00900068|Other|medical chart review|
30054|NCT00900081|Other|immunohistochemistry staining method|
30055|NCT00900081|Other|laboratory biomarker analysis|
30056|NCT00900081|Other|medical chart review|
30057|NCT00016380|Drug|dexamethasone|
30058|NCT00900094|Genetic|fluorescence in situ hybridization|
30059|NCT00900094|Genetic|polymerase chain reaction|
30060|NCT00900094|Genetic|protein expression analysis|
30061|NCT00900094|Other|immunohistochemistry staining method|
30062|NCT00900094|Other|laboratory biomarker analysis|
30063|NCT00900094|Other|mass spectrometry|
30064|NCT00900107|Behavioral|exercise training over 4 hours|Cycling over a period of 4 hours at 70% of max.
30065|NCT00900133|Other|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
30449|NCT00898703|Other|laboratory biomarker analysis|
30450|NCT00898716|Drug|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
30451|NCT00898742|Genetic|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
30452|NCT00898742|Genetic|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
30453|NCT00898742|Other|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
30454|NCT00898755|Genetic|DNA analysis|
30455|NCT00898755|Genetic|reverse transcriptase-polymerase chain reaction|
30456|NCT00898755|Other|biologic sample preservation procedure|
28163|NCT00880321|Drug|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
28164|NCT00880321|Drug|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
28165|NCT00880334|Drug|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
28166|NCT00880334|Drug|vandetanib|taken orally once a day, every day
28167|NCT00880334|Drug|Placebo|Taken orally once a day every day
28168|NCT00014261|Drug|temozolomide|
28169|NCT00880347|Device|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
28170|NCT00880360|Drug|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
28171|NCT00880373|Drug|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
28172|NCT00880373|Drug|Placebo|Matching placebo three times daily for 4 days
28173|NCT00880373|Drug|Diamorphine or Morphine|Diamorphine or Morphine by PCA
28174|NCT00880386|Drug|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
28175|NCT00880399|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
28176|NCT00880399|Other|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
28177|NCT00872625|Procedure|therapeutic conventional surgery|
28178|NCT00872625|Radiation|hypofractionated radiation therapy|
28179|NCT00872625|Radiation|image-guided radiation therapy|
28180|NCT00872625|Radiation|radiation therapy|
28181|NCT00013416|Procedure|Hearing|
28490|NCT00875680|Device|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
28491|NCT00875693|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
29571|NCT00016029|Procedure|computed tomography colonography|
29572|NCT00895609|Drug|Sugammadex, Neostigmine, Saline|Single intravenous injection of either:
Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)
29573|NCT00895622|Other|clinical observation|Patients undergo observation.
29574|NCT00895622|Radiation|3-dimensional conformal radiation therapy|Patients undergo 3-dimensional conformal radiation therapy once daily 5 days a week for 6 weeks
29575|NCT00895622|Radiation|intensity-modulated radiation therapy (IMRT)|Patients undergo IMRT once daily 5 days a week for 6 weeks
29576|NCT00895635|Behavioral|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
29577|NCT00895635|Behavioral|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
29578|NCT00895635|Behavioral|Usual Care|Usual care for PAD
29579|NCT00895648|Drug|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
29580|NCT00895648|Drug|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
29581|NCT00895661|Drug|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
29582|NCT00016029|Procedure|diagnostic colonoscopy|
29583|NCT00895674|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
29584|NCT00895687|Drug|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
29585|NCT00895687|Drug|Bortezomib|Beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
29891|NCT00895999|Behavioral|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
29892|NCT00896012|Procedure|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
29893|NCT00016042|Drug|fluorouracil|
30375|NCT00891748|Genetic|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
30376|NCT00891761|Drug|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
29311|NCT00899470|Drug|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
29312|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
29313|NCT00899470|Drug|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
29314|NCT00899483|Drug|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
29315|NCT00892684|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
29316|NCT00892684|Dietary Supplement|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
29317|NCT00892697|Drug|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
29318|NCT00892697|Drug|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
29319|NCT00015847|Biological|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
29320|NCT00892697|Drug|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
29321|NCT00892710|Drug|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
29322|NCT00892710|Drug|Bevacizumab|15 mg/kg IV every 21 days
29323|NCT00892710|Drug|Carboplatin|AUC=5 IV every 21 days
29324|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
29325|NCT00892723|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
30457|NCT00898755|Other|flow cytometry|
30458|NCT00016302|Drug|leucovorin calcium|Given IV or orally
30459|NCT00898755|Other|laboratory biomarker analysis|
30460|NCT00898768|Procedure|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
30461|NCT00898794|Biological|bevacizumab|
30462|NCT00898794|Other|coagulation study|
30463|NCT00891761|Drug|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
30464|NCT00891761|Drug|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
30465|NCT00891761|Drug|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
30466|NCT00891761|Drug|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
30467|NCT00891774|Device|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
30468|NCT00891787|Dietary Supplement|Probiotic Supplement|
30469|NCT00891800|Device|Brachytherapy|SIR-Sphere contains radiation of Y-90.
29404|NCT00899522|Procedure|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
29405|NCT00899535|Genetic|DNA analysis|
29406|NCT00899535|Genetic|RNA analysis|
29407|NCT00899535|Genetic|microarray analysis|
29408|NCT00899535|Genetic|mutation analysis|
29409|NCT00899535|Genetic|polymorphism analysis|
29410|NCT00016328|Other|laboratory biomarker analysis|Correlative studies
29411|NCT00899548|Genetic|DNA methylation analysis|laboratory analysis
30214|NCT00896428|Drug|Placebo.|1 tablet morning and evening for 12 months
30215|NCT00896441|Drug|Citalopram|Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.
Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.
Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.
Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.
Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.
Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI.
30216|NCT00896454|Drug|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
30217|NCT00896467|Other|questionnaire administration|
30218|NCT00896467|Procedure|psychosocial assessment and care|
30219|NCT00896467|Procedure|quality-of-life assessment|
30220|NCT00896480|Biological|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
30221|NCT00016094|Other|laboratory biomarker analysis|Correlative studies
30222|NCT00896493|Drug|anti-thymocyte globulin|1.5 mg/kg x 5 days, IV
30223|NCT00898417|Genetic|proteomic profiling|
30565|NCT00898950|Drug|Aspirin|300mgs/day orally for 2 weeks
30566|NCT00898950|Drug|Aspirin|aspirin 900mgs QID orally for 2 weeks
30567|NCT00898950|Other|placebo tablet|placebo tablet with lactose and excipients.
30568|NCT00898963|Genetic|gene expression analysis|
30569|NCT00898963|Genetic|microarray analysis|
30570|NCT00000813|Biological|ALVAC-HIV gp160MN (vCP125)|
30571|NCT00016302|Drug|thioguanine|Given orally
30572|NCT00898963|Genetic|polymorphism analysis|
30573|NCT00898963|Other|diagnostic laboratory biomarker analysis|
30574|NCT00898963|Other|immunohistochemistry staining method|
30575|NCT00891930|Drug|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
29894|NCT00896012|Drug|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
29895|NCT00896012|Drug|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
29896|NCT00896025|Drug|N-acetylcysteine|Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.
NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.
i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour
ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours
iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours
iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours
v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours
29897|NCT00896038|Drug|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
29898|NCT00896038|Drug|Placebo|Non-active placebo
29899|NCT00896051|Drug|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
29900|NCT00896051|Drug|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
29901|NCT00896051|Drug|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
29902|NCT00896051|Drug|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
29903|NCT00896051|Drug|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
30284|NCT00894270|Procedure|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
30285|NCT00894270|Device|Novofine needle|Novofine 5mm needle
30286|NCT00894283|Drug|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
29326|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
29327|NCT00892736|Other|Laboratory Biomarker Analysis|Correlative studies
29328|NCT00892736|Other|Pharmacological Study|Correlative studies
29329|NCT00892736|Drug|Veliparib|Given PO
29666|NCT00893295|Other|medical chart review|
29667|NCT00893295|Other|screening questionnaire administration|
29668|NCT00893295|Other|study of socioeconomic and demographic variables|
29669|NCT00893295|Procedure|barium enema injection|
29670|NCT00015873|Drug|mercaptopurine|
29671|NCT00893295|Procedure|colon imaging study|
29672|NCT00893295|Procedure|screening colonoscopy|
29673|NCT00893295|Procedure|sigmoidoscopy|
29674|NCT00893321|Procedure|Inferior Oblique Muscle Recession and Myectomy|
29675|NCT00893347|Behavioral|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
29676|NCT00893347|Behavioral|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
29677|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
29678|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
29679|NCT00893373|Drug|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
29680|NCT00893373|Drug|placebo|Standard AML chemotherapy plus placebo
29681|NCT00895700|Behavioral|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
29682|NCT00895713|Drug|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
29412|NCT00899548|Genetic|microarray analysis|laboratory analysis
29413|NCT00899548|Genetic|polymerase chain reaction|laboratory analysis
29414|NCT00899548|Other|laboratory biomarker analysis|laboratory analysis
29415|NCT00899574|Drug|Imiquimod|Each treatment cycle consists of 8 weeks.
Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.
Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease.
29416|NCT00899587|Drug|enalapril|enalapril 5 mg every night
29417|NCT00899587|Other|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
29418|NCT00899587|Drug|placebo|
29419|NCT00899600|Drug|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
29420|NCT00899600|Other|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
29421|NCT00016328|Other|pharmacological study|Correlative studies
29422|NCT00899613|Other|laboratory biomarker analysis|
29423|NCT00899613|Procedure|study of high risk factors|
29424|NCT00899626|Genetic|protein analysis|
29425|NCT00899626|Genetic|proteomic profiling|
29426|NCT00899626|Other|biologic sample preservation procedure|
29760|NCT00900016|Genetic|western blotting|
29761|NCT00900016|Other|immunohistochemistry staining method|
29762|NCT00900016|Other|immunologic technique|
29763|NCT00900016|Other|laboratory biomarker analysis|
29764|NCT00900042|Genetic|DNA ploidy analysis|
29765|NCT00015873|Drug|methotrexate|
29766|NCT00893386|Procedure|LV Lead Extraction|Removal of a LV lead using any tools & techniques.
30576|NCT00891943|Other|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
30577|NCT00891982|Drug|CTGel/ BPO Wash|Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days
Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.
30578|NCT00891982|Drug|Soap Free Cleanser and CTGel|Soap Free Cleanser will be used once daily in the morning for 28 days
Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days.
30579|NCT00891995|Device|Closed loop therapy followed by use of insulin pump/CGM|Closed loop therapy for up to 4 to 6 days followed by 2 years of intense management using an insulin pump and continuous glucose monitor.
30580|NCT00891995|Device|Home glucose monitoring|Standard diabetes management using a home glucose meter.
30581|NCT00892008|Drug|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
30582|NCT00015691|Drug|Rosiglitazone maleate|
30583|NCT00892021|Drug|NSA-789|
30584|NCT00892021|Drug|Placebo|
30585|NCT00892047|Drug|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
30586|NCT00892047|Drug|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
30587|NCT00892073|Drug|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
29493|NCT00897611|Procedure|polymerase chain reaction|
29494|NCT00897611|Procedure|computed tomography|
29495|NCT00897611|Procedure|magnetic resonance imaging|
29496|NCT00897624|Genetic|gene expression analysis|
29497|NCT00897624|Genetic|reverse transcriptase-polymerase chain reaction|
29498|NCT00897624|Other|laboratory biomarker analysis|
29499|NCT00897637|Other|laboratory biomarker analysis|Correlative studies
29500|NCT00897650|Genetic|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
29501|NCT00016211|Radiation|radiation therapy|
30287|NCT00894283|Drug|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
30288|NCT00015938|Drug|vinorelbine|
30289|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
30290|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
30291|NCT00894322|Other|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
30292|NCT00894361|Procedure|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
30293|NCT00896493|Drug|cyclosporine|5 mg/kg PO or IV
30294|NCT00896519|Biological|rituximab|
30295|NCT00896519|Biological|sargramostim|
30296|NCT00896519|Drug|cyclophosphamide|
30297|NCT00896519|Drug|doxorubicin hydrochloride|
30298|NCT00896519|Drug|prednisone|
30299|NCT00896519|Drug|vincristine sulfate|
30300|NCT00896519|Genetic|gene expression analysis|
30301|NCT00896519|Genetic|gene rearrangement analysis|
30302|NCT00016107|Drug|estramustine phosphate sodium|Given orally
30303|NCT00896519|Genetic|polymerase chain reaction|
30304|NCT00896519|Other|R-CHOP regimen|
30305|NCT00896519|Other|laboratory biomarker analysis|
30306|NCT00896532|Drug|Active Comparator Alendronate|70mg PO every week (QW)
30307|NCT00896532|Drug|Placebo|SC Q3M
30308|NCT00896532|Drug|AMG 785|140mg SC QM
29239|NCT00895102|Drug|Placebo|See Arm Description for more information.
29240|NCT00895102|Drug|ABT-333 Capsule|See arm description for more information
29683|NCT00895726|Drug|APD209|Oral tablets twice per day for 56 days
29684|NCT00895739|Biological|alemtuzumab|
29685|NCT00895739|Drug|cyclosporine|
29686|NCT00895752|Drug|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
29687|NCT00895778|Other|Neuromuscular blockade with rocuronium and reversal with sugammadex|
29688|NCT00016029|Procedure|screening colonoscopy|
29689|NCT00895791|Device|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
29976|NCT00893737|Drug|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
29977|NCT00893750|Behavioral|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
29978|NCT00893750|Behavioral|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
29979|NCT00893750|Behavioral|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
29980|NCT00893763|Procedure|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
29981|NCT00893763|Procedure|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
29982|NCT00893776|Other|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
29983|NCT00893789|Drug|Armodafinil|Armodafinil 50 mg/day
29984|NCT00893789|Drug|Armodafinil|Armodafinil 150 mg/day
29985|NCT00893789|Drug|Armodafinil|Armodafinil 250 mg/day
29986|NCT00015912|Biological|recombinant interferon alfa|Given IV
29987|NCT00893789|Other|Placebo|Placebo
29988|NCT00016055|Biological|lymphokine-activated killer cells|
29989|NCT00896051|Drug|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
29767|NCT00893399|Drug|Gemtuzumab Ozogamicin (Mylotarg)|Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (> 60 yrs) patients.
Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (> 60 yrs) patients.
Consolidation 2, 3: no GO
29768|NCT00893399|Drug|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
29769|NCT00893412|Drug|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
29770|NCT00893412|Procedure|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
29771|NCT00893412|Drug|Placebo|
29772|NCT00893425|Drug|ramipril|
29773|NCT00893438|Behavioral|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
29774|NCT00893438|Other|Usual care|Usual care treatment for adolescents with CFS
29775|NCT00893451|Drug|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
29776|NCT00015873|Drug|prednisolone|
29777|NCT00893451|Drug|Placebo|Placebo orally twice daily
29778|NCT00893464|Drug|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
29779|NCT00893477|Biological|rituximab|
29780|NCT00893477|Biological|sargramostim|
29781|NCT00893477|Genetic|gene expression analysis|
29782|NCT00893477|Genetic|gene rearrangement analysis|
29783|NCT00893477|Genetic|polymerase chain reaction|
30066|NCT00900133|Other|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
30067|NCT00893802|Other|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
29502|NCT00897650|Genetic|Protein expression analysis|Lung tumor tissue will be collected.
29503|NCT00897650|Procedure|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
29504|NCT00897650|Procedure|Blood sample|Patients will be asked for a venous blood sample
29505|NCT00899626|Other|laboratory biomarker analysis|
29506|NCT00899626|Other|medical chart review|
29507|NCT00899626|Procedure|diagnostic colonoscopy|
29508|NCT00899626|Procedure|diagnostic endoscopic procedure|
29509|NCT00899626|Procedure|diagnostic endoscopic surgery|
29510|NCT00016341|Biological|filgrastim|
29511|NCT00899626|Procedure|diagnostic surgical procedure|
29512|NCT00899626|Procedure|endoscopic surgery|
29513|NCT00899626|Procedure|screening colonoscopy|
29514|NCT00899652|Genetic|Southern blotting|
29515|NCT00899652|Genetic|chromosomal translocation analysis|
29516|NCT00899652|Genetic|cytogenetic analysis|
29517|NCT00899652|Genetic|gene rearrangement analysis|
29518|NCT00899652|Genetic|mutation analysis|
29519|NCT00899665|Genetic|fluorescence in situ hybridization|
30190|NCT00894088|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
30191|NCT00894101|Drug|[F-18] FLT|10 mCi [F-18] FLT and 10 mCi [F-18] FDG will be used for PET imaging.
30192|NCT00894114|Biological|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
30193|NCT00894114|Biological|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
30194|NCT00894127|Device|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
29241|NCT00895115|Dietary Supplement|vitamin E|Given once daily
29242|NCT00895115|Procedure|sham intervention|No supplementation
29243|NCT00895128|Drug|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
29244|NCT00895128|Drug|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
29245|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
29246|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
29247|NCT00895154|Behavioral|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
29248|NCT00895154|Behavioral|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
29249|NCT00016016|Drug|alvocidib|Given IV
29250|NCT00895167|Dietary Supplement|curcumin|one oral dose of 12 caplets = 12 g curcumin
29251|NCT00895180|Biological|anti-PDGFR alpha monoclonal antibody IMC-3G3|Given IV
29252|NCT00895180|Biological|ramucirumab|Given IV
29253|NCT00895193|Other|Apple pectin|Apple pectin 2000mg
29254|NCT00895193|Drug|Aspirin 325 mg|Aspirin 325 mg
29255|NCT00895193|Other|Placebo|Placebo
29256|NCT00895206|Drug|individual adapted immunosuppression|individual adapted immunosuppression
29257|NCT00895206|Drug|golden standard therapy|golden standard therapy
29258|NCT00895219|Other|Breathing re-training|Breathing re-training
29259|NCT00897260|Drug|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.
DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x
Fludarabine dose adjustment:
70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.
UCB Infusion
29260|NCT00016172|Drug|pegylated liposomal doxorubicin hydrochloride|
29990|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
29991|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
29992|NCT00896077|Drug|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
29993|NCT00896129|Other|HRQOL Survey Packet|Questionnaires
29994|NCT00896155|Drug|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
29995|NCT00896155|Radiation|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
29996|NCT00896168|Drug|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
30377|NCT00894361|Procedure|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
30378|NCT00894374|Drug|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
30379|NCT00894374|Drug|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
30380|NCT00894387|Drug|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
30381|NCT00894387|Drug|Placebo|Placebo
30382|NCT00894400|Procedure|catheter ablation|catheter ablation using radiofrequency energy
30383|NCT00015951|Biological|bevacizumab|
30384|NCT00894413|Drug|Tadalafil|20 mg once daily for 10 - 14 days
30385|NCT00894413|Other|Placebo Pill|Placebo
30386|NCT00894439|Drug|BLI-489/Piperacillin|
30387|NCT00894439|Drug|BLI-489|
30388|NCT00894439|Drug|Piperacillin|
30389|NCT00894465|Drug|midazolam|Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
30390|NCT00894465|Drug|placebo|Children are randomized to receive a placebo prior to undergoing VCUG
30068|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
30069|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
30070|NCT00893841|Drug|placebo|placebo
30071|NCT00893841|Drug|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
30072|NCT00893854|Drug|Diclophenac|
30073|NCT00893854|Drug|Triamcinolone|
30074|NCT00893867|Drug|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
30075|NCT00893867|Drug|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
30076|NCT00015912|Drug|thalidomide|Given orally
30077|NCT00893880|Drug|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
30078|NCT00893906|Biological|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
30079|NCT00893906|Biological|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
30080|NCT00893919|Drug|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
30081|NCT00893945|Drug|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
30082|NCT00893945|Drug|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
30083|NCT00893945|Drug|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
30084|NCT00893958|Drug|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
30085|NCT00893971|Drug|PT001|Inhaled PT001, single dose
30086|NCT00893971|Drug|PT005|Inhaled PT005, single dose
30087|NCT00015912|Other|laboratory biomarker analysis|Correlative studies
30088|NCT00893971|Drug|PT003|Inhaled PT003, single dose
30470|NCT00015665|Drug|Voriconazole|
30195|NCT00894140|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
30196|NCT00894153|Drug|chemotherapy plus p53|chemotherapy plus p53
30197|NCT00894153|Drug|chemotherapy|chemotherapy
30198|NCT00015938|Biological|filgrastim|
30199|NCT00894153|Radiation|radiotherapy|radiotherapy
30200|NCT00894166|Drug|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
30201|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
30202|NCT00894166|Drug|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
30203|NCT00894166|Drug|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
30204|NCT00896363|Drug|GSK163090 Placebo Tablets|Developed for the treatment of Major Depressive Disorder
30205|NCT00896376|Biological|trastuzumab|
30206|NCT00896376|Other|laboratory biomarker analysis|
30207|NCT00896376|Other|pharmacological study|
30224|NCT00898417|Other|laboratory biomarker analysis|
30225|NCT00898417|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
30226|NCT00898430|Genetic|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
30227|NCT00898430|Genetic|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
30228|NCT00898430|Genetic|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
29586|NCT00897663|Genetic|gene expression analysis|
29587|NCT00897663|Genetic|microarray analysis|
29588|NCT00897663|Genetic|protein expression analysis|
29589|NCT00897663|Other|diagnostic laboratory biomarker analysis|
29590|NCT00897663|Other|immunohistochemistry staining method|
29591|NCT00897676|Drug|Exendin-(9-39)|100-500pmol/kg/min
29592|NCT00897676|Drug|placebo|placebo (0.9% NaCl)
29593|NCT00016224|Drug|thalidomide|
29594|NCT00897702|Other|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
29595|NCT00897702|Other|immunoenzyme technique|
29596|NCT00897702|Procedure|biopsy|
29597|NCT00897702|Procedure|histopathologic examination|
29598|NCT00897715|Drug|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
29599|NCT00897715|Drug|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
29600|NCT00897728|Other|laboratory biomarker analysis|
29601|NCT00897741|Genetic|microarray analysis|
29602|NCT00897741|Other|laboratory biomarker analysis|
29603|NCT00897754|Genetic|gene expression analysis|
29604|NCT00016237|Biological|tucotuzumab celmoleukin|
29605|NCT00897754|Genetic|protein expression analysis|
29606|NCT00897754|Genetic|reverse transcriptase-polymerase chain reaction|
29607|NCT00897754|Other|immunoenzyme technique|
29608|NCT00897754|Other|immunohistochemistry staining method|
29609|NCT00897754|Other|immunologic technique|
30391|NCT00894478|Procedure|Diffusion Tensor Imaging (DTI)|MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.
DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)
Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan
30392|NCT00894478|Procedure|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
30393|NCT00894504|Drug|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
30394|NCT00000809|Biological|MN rsgp120/HIV-1|
30395|NCT00015951|Drug|cytarabine|
30396|NCT00894504|Drug|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
30397|NCT00894504|Drug|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
30398|NCT00894517|Biological|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
29330|NCT00015847|Drug|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
29331|NCT00892749|Drug|ASP1585|oral
29332|NCT00892762|Drug|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
29333|NCT00892762|Drug|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
29334|NCT00892775|Biological|Priorix-Tetra TM (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
29335|NCT00892775|Biological|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
29336|NCT00892788|Behavioral|contingency management|Prize-based contingency management for weight loss
29337|NCT00892788|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
29338|NCT00895219|Other|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
29339|NCT00000810|Drug|Delavirdine mesylate|
30471|NCT00891800|Device|SIR-Sphere|Brachytherapy Radiation seeds
30472|NCT00891813|Drug|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
30473|NCT00891826|Dietary Supplement|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
30474|NCT00891826|Dietary Supplement|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
30475|NCT00891839|Drug|Bendamustine|Bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
30476|NCT00891839|Drug|Rituximab|Patients receive 375 mg/m^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
30477|NCT00891878|Drug|capecitabine|Given orally
30478|NCT00891878|Drug|sunitinib malate|Given orally
30479|NCT00891904|Biological|cetuximab|Given IV
30480|NCT00891904|Radiation|stereotactic body radiation therapy|Undergoing Radiotherapy
30481|NCT00015691|Drug|Metformin hydrochloride|
30482|NCT00891917|Drug|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
30483|NCT00891930|Biological|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
30484|NCT00891930|Biological|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
30485|NCT00894543|Other|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
30486|NCT00894556|Drug|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
30487|NCT00894556|Drug|Comparator: Placebo|Placebo to Rizatriptan
30488|NCT00015951|Drug|mitoxantrone hydrochloride|
30229|NCT00000812|Drug|Thalidomide|
30230|NCT00016302|Drug|vincristine sulfate|Given IV
30231|NCT00898443|Other|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
30232|NCT00898443|Other|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
30233|NCT00898456|Genetic|gene expression analysis|
30234|NCT00898456|Genetic|molecular genetic technique|
30235|NCT00898456|Genetic|polymorphism analysis|
30236|NCT00898456|Genetic|protein expression analysis|
30237|NCT00898456|Other|diagnostic laboratory biomarker analysis|
30238|NCT00898469|Genetic|polymorphism analysis|
30239|NCT00898482|Other|This is a non-intervention study for all groups.|This is a non-intervention study.
30240|NCT00898482|Other|study of socioeconomic and demographic variables|Non-intervention study.
30241|NCT00016302|Drug|daunorubicin hydrochloride|Given IV
30242|NCT00898495|Genetic|loss of heterozygosity analysis|
30243|NCT00898495|Genetic|polymerase chain reaction|
30244|NCT00898495|Genetic|polymorphism analysis|
30245|NCT00898508|Genetic|gene expression analysis|
30246|NCT00898508|Genetic|mutation analysis|
30247|NCT00898508|Genetic|proteomic profiling|
30248|NCT00898508|Genetic|reverse transcriptase-polymerase chain reaction|
29167|NCT00897221|Drug|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
29168|NCT00897221|Drug|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
29169|NCT00897234|Other|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
29610|NCT00897767|Other|biologic sample preservation procedure|
29611|NCT00897780|Behavioral|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
29904|NCT00898066|Genetic|fluorescence in situ hybridization|marrow and peripheral blood
29905|NCT00898079|Other|cytology specimen collection procedure|Correlative studies
29906|NCT00016276|Drug|paclitaxel|Given IV
29907|NCT00898092|Genetic|microarray analysis|
29908|NCT00898092|Genetic|molecular genetic technique|
29909|NCT00898092|Genetic|mutation analysis|
29910|NCT00898092|Genetic|polymerase chain reaction|
29911|NCT00898092|Genetic|reverse transcriptase-polymerase chain reaction|
29912|NCT00898092|Other|diagnostic laboratory biomarker analysis|
29913|NCT00898118|Genetic|polymerase chain reaction|
29914|NCT00898118|Other|flow cytometry|
29915|NCT00898118|Other|laboratory biomarker analysis|
29916|NCT00898118|Procedure|allogeneic hematopoietic stem cell transplantation|
29917|NCT00016276|Biological|trastuzumab|Given IV
29918|NCT00898144|Other|Papanicolaou test|
29919|NCT00898144|Other|laboratory biomarker analysis|
29920|NCT00898157|Other|laboratory biomarker analysis|
29921|NCT00898170|Procedure|myoma removal|surgical removal of myoma by hysterectomy
29922|NCT00898183|Genetic|gene expression analysis|
29923|NCT00898183|Genetic|polymorphism analysis|
29924|NCT00898209|Genetic|protein expression analysis|Blood and exhaled breath condensate will be collected.
29925|NCT00898209|Genetic|proteomic profiling|Blood and exhaled breath condensate will be collected.
29340|NCT00016016|Other|pharmacological study|Correlative studies
29341|NCT00895232|Drug|Cohort I|
29342|NCT00895232|Drug|Cohort II|
29343|NCT00895232|Drug|Cohort III|
29344|NCT00895245|Drug|fosaprepitant dimeglumine|Given IV
29345|NCT00895245|Drug|cisplatin|Given IV
29346|NCT00895245|Drug|palonosetron hydrochloride|Given IV
29347|NCT00895245|Drug|dexamethasone|Given IV and orally
29348|NCT00895245|Other|questionnaire administration|Ancillary studies
29349|NCT00895245|Procedure|quality-of-life assessment|Ancillary studies
29350|NCT00895245|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
29351|NCT00016016|Other|laboratory procedure|Correlative studies
29352|NCT00895245|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
29353|NCT00895258|Behavioral|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
29690|NCT00895791|Device|culotte stenting (Xience V)|implantation of stent
29691|NCT00895804|Drug|MDMA|capsule, 1.6 mg/kg body weight, single dose
29692|NCT00895804|Drug|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
29693|NCT00895817|Drug|Swallowed fluticasone|440 µg twice daily for 8 weeks
29694|NCT00895817|Drug|Esomeprazole|40 mg once daily for 8 weeks
29695|NCT00895830|Drug|APD405|IV
29696|NCT00895830|Drug|Placebo|IV
29697|NCT00895843|Drug|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
29698|NCT00895843|Drug|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
29699|NCT00016042|Biological|lymphokine-activated killer cells|
30489|NCT00894556|Drug|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
29427|NCT00892801|Drug|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
29428|NCT00892801|Radiation|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
29429|NCT00892814|Radiation|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
29430|NCT00015860|Drug|daunorubicin hydrochloride|
29431|NCT00892814|Radiation|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
29432|NCT00892827|Drug|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
29433|NCT00892840|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
29434|NCT00892840|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
29435|NCT00892853|Procedure|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
29436|NCT00892866|Other|Cytology Specimen Collection Procedure|Correlative studies
29437|NCT00892866|Other|Laboratory Biomarker Analysis|Correlative studies
29438|NCT00892879|Device|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
29439|NCT00892892|Drug|Rilmenidine|1 mg Rilmenidine per day versus
29440|NCT00892892|Drug|Nitrendipine|20 mg Nitrendipine per day
29441|NCT00000809|Biological|Aluminum hydroxide|
29442|NCT00015860|Drug|imatinib mesylate|
29443|NCT00892918|Drug|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
29444|NCT00892931|Drug|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
29445|NCT00892944|Drug|AZD2516|Fractionated single oral dose
29170|NCT00897247|Genetic|microarray analysis|
29171|NCT00897247|Genetic|protein expression analysis|
29172|NCT00897247|Genetic|proteomic profiling|
29173|NCT00897247|Other|laboratory biomarker analysis|
29174|NCT00899210|Other|laboratory biomarker analysis|
29175|NCT00899210|Procedure|cryosurgery|
29176|NCT00899210|Procedure|radiofrequency ablation|
29177|NCT00016302|Other|laboratory biomarker analysis|Correlative studies
29178|NCT00899210|Procedure|therapeutic conventional surgery|
29179|NCT00899223|Other|biologic sample preservation procedure|
29180|NCT00899262|Other|immunohistochemistry staining method|
29181|NCT00899262|Other|laboratory biomarker analysis|
29182|NCT00899262|Other|sputum cytology|
29183|NCT00899262|Procedure|Fourier transform infrared spectroscopy|
29184|NCT00899262|Procedure|diagnostic bronchoscopy|
29185|NCT00899275|Other|biologic sample preservation procedure|
29186|NCT00899288|Procedure|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
29187|NCT00899301|Other|biologic sample preservation procedure|Tissue, urine and blood collection.
29188|NCT00016315|Drug|carboplatin|
29189|NCT00899327|Genetic|DNA methylation analysis|
29190|NCT00899327|Genetic|RNA analysis|
29191|NCT00899327|Genetic|cytogenetic analysis|
29192|NCT00899327|Genetic|gene expression analysis|
29193|NCT00899327|Genetic|mutation analysis|
29520|NCT00899665|Genetic|microarray analysis|
29926|NCT00898209|Other|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
29927|NCT00898209|Other|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
29928|NCT00016276|Procedure|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
29929|NCT00898209|Other|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
30309|NCT00896532|Drug|AMG 785|140mg SC Q3M
30310|NCT00896532|Drug|AMG 785|210mg SC Q3M
30311|NCT00896532|Drug|Placebo|SC QM
30312|NCT00896532|Drug|Active comparator teriparatide|20µg SC every day (QD)
30313|NCT00000207|Drug|Buprenorphine|
30314|NCT00000810|Drug|Didanosine|
30315|NCT00016107|Drug|docetaxel|Given IV
30316|NCT00896532|Drug|AMG 785|210mg SC QM
30317|NCT00896532|Drug|AMG 785|70mg SC QM
30318|NCT00896532|Drug|Denosumab|60 mg SC Q6M
30319|NCT00896532|Drug|AMG 785|210mg SC QM
30320|NCT00896532|Drug|Zoledronic acid|5 mg IV
30321|NCT00896532|Drug|Placebo|
30322|NCT00896545|Behavioral|5-keys counseling|5-session small group intervention
30323|NCT00896545|Behavioral|Lifestyle counseling|5-session small group behavioral intervention
30324|NCT00896558|Drug|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
30325|NCT00896558|Drug|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
30326|NCT00016107|Biological|bevacizumab|Given IV
30327|NCT00898508|Other|mass spectrometry|
30328|NCT00898508|Other|medical chart review|
29700|NCT00895843|Drug|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
29701|NCT00895856|Other|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
29702|NCT00895882|Drug|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
29703|NCT00895882|Drug|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
29704|NCT00895882|Drug|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
29705|NCT00895882|Drug|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
29706|NCT00895882|Drug|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
29707|NCT00897819|Genetic|loss of heterozygosity analysis|
29708|NCT00897819|Genetic|microsatellite instability analysis|
29709|NCT00897819|Other|laboratory biomarker analysis|
29710|NCT00897832|Other|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
29997|NCT00896168|Drug|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
29998|NCT00896181|Drug|docetaxel|Given IV
29999|NCT00016055|Drug|temozolomide|
30000|NCT00896181|Drug|cisplatin|Given IV
30001|NCT00896181|Drug|carboplatin|Given IV
30002|NCT00896181|Drug|fluorouracil|Given IV
30003|NCT00896181|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
30004|NCT00896181|Radiation|intensity-modulated radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
29446|NCT00892957|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
29447|NCT00892957|Other|Surgical gauze pads|Manual compression with surgical gauze pads
29448|NCT00892970|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
29784|NCT00893477|Genetic|polymorphism analysis|
29785|NCT00893477|Other|laboratory biomarker analysis|
29786|NCT00893490|Device|Ahmed Glaucoma Valve (AGV)|AGV implantation
29787|NCT00015873|Drug|vincristine sulfate|
29788|NCT00893490|Drug|Mitomycin C (MMC)|3 minute MMC application
29789|NCT00893490|Procedure|amniotic membrane coverage|single layer coverage of amniotic membrane
29790|NCT00893503|Procedure|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
29791|NCT00893516|Biological|CHOP + CD4|
29792|NCT00893516|Drug|CHOP|
29793|NCT00895895|Drug|Placebo|Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
29794|NCT00895895|Drug|SAM-531 1.5 mg|Capsules SAM-531 1.5 mg, once a day during 52 weeks.
29795|NCT00895895|Drug|SAM-531 3.0 mg|Capsules SAM-531 3.0 mg, once a day during 52 weeks.
29796|NCT00016042|Biological|recombinant interferon alfa|
29797|NCT00895895|Drug|SAM-531 5.0 mg|Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
29798|NCT00895895|Drug|Donepezil|Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
29799|NCT00895908|Behavioral|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
29800|NCT00895908|Behavioral|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
29801|NCT00895921|Drug|Olanzapine|Single intramuscular 10-mg dose
29521|NCT00016341|Drug|cisplatin|
29522|NCT00899665|Genetic|molecular diagnostic method|
29523|NCT00899665|Other|immunohistochemistry staining method|
29524|NCT00899665|Other|laboratory biomarker analysis|
29525|NCT00899665|Procedure|biopsy|
29526|NCT00899665|Procedure|immunoscintigraphy|
29527|NCT00899678|Drug|Certolizumab Pegol|400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
29528|NCT00899678|Drug|Certolizumab Pegol|200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
29529|NCT00899691|Genetic|protein expression analysis|
29530|NCT00899704|Genetic|microarray analysis|
29531|NCT00899704|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
29532|NCT00016341|Drug|doxorubicin hydrochloride|
29533|NCT00899704|Other|diagnostic laboratory biomarker analysis|
29534|NCT00899717|Procedure|Occlusal adjustment|modification of occlusal surfaces
29535|NCT00899717|Procedure|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
29536|NCT00892983|Behavioral|Sleep|Standard well child care plus 5 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), sleep problem prevention starting at 3 weeks and then sleep problem intervention starting at 6 months or if problems emerge upto 2 years of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called "parental presence", and if this does not fit family a technique called "camping out" and finally, if neither of the first two fit family, controlled crying.
29537|NCT00892996|Drug|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
29538|NCT00015860|Drug|prednisone|
29539|NCT00892996|Drug|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
29540|NCT00893009|Drug|Theophylline|100 mg twice a day
30329|NCT00898508|Procedure|quality-of-life assessment|
30330|NCT00898521|Drug|DGD|DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.
Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).
Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.
The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.
DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.
DGD should not be applied more than twice to the same burn wound area.
30331|NCT00898534|Device|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
30332|NCT00898547|Other|immunoenzyme technique|
29261|NCT00897260|Radiation|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
29262|NCT00897260|Procedure|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
29263|NCT00897273|Genetic|comparative genomic hybridization|
29264|NCT00897273|Genetic|gene expression analysis|
29265|NCT00897273|Other|study of socioeconomic and demographic variables|
29266|NCT00897273|Procedure|evaluation of cancer risk factors|
29267|NCT00897273|Procedure|study of high risk factors|
29268|NCT00897299|Genetic|microarray analysis|
29269|NCT00897299|Genetic|protein expression analysis|
29270|NCT00897299|Other|immunohistochemistry staining method|
29271|NCT00016172|Drug|picoplatin|
29272|NCT00897299|Other|laboratory biomarker analysis|
29273|NCT00897312|Biological|infliximab|Not specified
29274|NCT00897312|Biological|pegylated interferon alfa|not specified
29275|NCT00897312|Biological|ticilimumab|not specified
29276|NCT00897312|Drug|ribavirin|not specified
30005|NCT00896194|Behavioral|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
30006|NCT00896194|Behavioral|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
30007|NCT00896207|Drug|Akt inhibitor SR13668|Given orally as a single dose
30008|NCT00896233|Procedure|MRE|Part 1: Participants will have a screening visit, followed ~1 month later by two imaging visits over ~14 days. Each imaging visit will consist of two liver MRE scans.
Part 2: Participants will have a screening visit, followed ~1
month later by one imaging visit. The imaging visit will consist
of two liver MRE scans.
30009|NCT00896246|Drug|Klean-Prep®|Four litres of solution administered orally as a divided dose.
30010|NCT00016068|Drug|ganciclovir|
30011|NCT00896246|Drug|Moviprep®|Two litres of solution administered orally as a divided dose
30012|NCT00898235|Other|biologic sample preservation procedure|preserve biologic samples
30013|NCT00898235|Other|laboratory biomarker analysis|analyze laboratory biomarkers
30014|NCT00898235|Procedure|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
30015|NCT00898235|Procedure|quality-of-life assessment|assess quality of life at each follow-up for life
30016|NCT00016276|Radiation|radiation therapy|Undergo radiation therapy
30017|NCT00898261|Genetic|microarray analysis|
30018|NCT00898261|Genetic|reverse transcriptase-polymerase chain reaction|
30019|NCT00898261|Other|flow cytometry|
30399|NCT00894517|Drug|Placebo (saline)|Saline injected into the prostate on Day 1.
30400|NCT00894530|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
30401|NCT00894530|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
30402|NCT00894543|Drug|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
29802|NCT00895921|Drug|Aripiprazole|Single intramuscular 9.75-mg dose
29803|NCT00895934|Drug|vorinostat|Given orally
29804|NCT00895934|Drug|gemtuzumab ozogamicin|Given intravenously (IV)
29805|NCT00895934|Drug|azacitidine|Given IV or subcutaneously (SC)
29806|NCT00895947|Drug|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
29807|NCT00000810|Drug|Zidovudine|
29808|NCT00016042|Biological|sargramostim|
30089|NCT00893971|Drug|PT001 + PT005|Inhaled PT001 + PT005, single dose
30090|NCT00893984|Drug|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
30091|NCT00893997|Biological|PR-1 vaccine|0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
30092|NCT00894010|Drug|carbamazepine 400mg|
30093|NCT00894010|Drug|levetiracetam 1000mg|
30094|NCT00896259|Other|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
30095|NCT00896285|Other|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
30096|NCT00896285|Other|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
30097|NCT00896285|Other|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
30098|NCT00896285|Other|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
30099|NCT00896298|Drug|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
30100|NCT00896298|Drug|Placebo|Sugar pill
30101|NCT00896311|Drug|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
29541|NCT00893009|Drug|Placebo|Placebo
29857|NCT00900276|Other|laboratory biomarker analysis|
29858|NCT00900276|Other|mass spectrometry|
29859|NCT00900289|Genetic|DNA methylation analysis|
29860|NCT00900289|Genetic|microarray analysis|
29861|NCT00900289|Genetic|polymerase chain reaction|
29862|NCT00900289|Other|immunohistochemistry staining method|
29863|NCT00016406|Drug|cyclophosphamide|
29864|NCT00900289|Other|laboratory biomarker analysis|
29865|NCT00900302|Genetic|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
29866|NCT00900302|Other|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
29867|NCT00900302|Other|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
29868|NCT00900302|Procedure|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
29869|NCT00900328|Other|laboratory biomarker analysis|Correlative Studies
29870|NCT00900341|Genetic|DNA analysis|
29871|NCT00893529|Dietary Supplement|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
29277|NCT00897312|Other|high performance liquid chromatography|not specified
29278|NCT00897312|Other|laboratory biomarker analysis|not specified
29279|NCT00897325|Other|biologic sample preservation procedure|
29280|NCT00897338|Other|flow cytometry|laboratory analysis
29281|NCT00897338|Other|fluorescence activated cell sorting|laboratory analysis
29282|NCT00016185|Drug|alvocidib|
29283|NCT00897338|Other|immunohistochemistry staining method|laboratory analysis
29284|NCT00897338|Other|immunologic technique|laboratory analysis
29285|NCT00897338|Other|biomarker analysis|laboratory analysis
29286|NCT00897351|Genetic|mutation analysis|
29287|NCT00897351|Genetic|polymorphism analysis|
29612|NCT00897793|Procedure|venipuncture|Venipuncture for blood samples. Samples will be tested for TGF-beta.
29613|NCT00897793|Radiation|radiation therapy|Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
29614|NCT00897806|Genetic|Microarray analysis|
29615|NCT00016250|Drug|MKC-1|
29616|NCT00897806|Other|Laboratory biomarker analysis|
29617|NCT00897819|Genetic|DNA methylation analysis|
29618|NCT00899743|Genetic|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
29619|NCT00899743|Genetic|western blotting|western blotting
29620|NCT00899743|Other|immunologic technique|immunologic technique
29621|NCT00899743|Other|laboratory biomarker analysis|laboratory biomarker analysis
29622|NCT00899756|Genetic|molecular diagnostic method|
29623|NCT00899756|Genetic|mutation analysis|
29624|NCT00899769|Genetic|protein expression analysis|
30403|NCT00896571|Drug|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
30404|NCT00896597|Drug|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
30405|NCT00896623|Genetic|mutation analysis|
30406|NCT00896623|Genetic|polymorphism analysis|
30407|NCT00896623|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
30408|NCT00896636|Procedure|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
30409|NCT00896636|Other|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
30410|NCT00896649|Other|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with PEM experience.
30411|NCT00896649|Procedure|digital mammography|standard screening mammogram
30412|NCT00896649|Procedure|positron emission mammography|one-time PEM to compare recall rates with that of standard mammogram
30413|NCT00016107|Other|laboratory biomarker analysis|Correlative studies
30414|NCT00896662|Other|immunologic technique|immunologic technique
30415|NCT00896662|Other|laboratory biomarker analysis|laboratory biomarker analysis
30416|NCT00896662|Other|pharmacological study|pharmacological study
30417|NCT00896675|Other|proteomic profiles|blood samples analysis
30418|NCT00896675|Other|proteomic profiles|blood samples analysis
30419|NCT00896688|Procedure|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
30420|NCT00896701|Other|flow cytometry|
30421|NCT00896701|Other|immunologic technique|
29354|NCT00895258|Behavioral|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
29355|NCT00895284|Procedure|Robotic hysterectomy|Robotic hysterectomy.
30102|NCT00896311|Drug|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
30103|NCT00016068|Drug|valganciclovir|
30104|NCT00896324|Behavioral|Cognitive Rehabilitation|Cognitive rehabilitation exercises: 30 minutes per day, 5 days per week for 6 weeks.
30105|NCT00896324|Behavioral|Neurofeedback Training (randomized)|Neurofeedback training: 2-3, 30 min training sessions.
30106|NCT00896324|Behavioral|Neuropsychological testing and MRI assessments|Neurofeedback training: 2-3, 30 min training sessions.
30107|NCT00896337|Device|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
30108|NCT00896337|Drug|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
30109|NCT00896337|Drug|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
30490|NCT00894569|Drug|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
30491|NCT00894569|Drug|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
30492|NCT00894582|Procedure|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
30493|NCT00894595|Behavioral|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
30494|NCT00894608|Drug|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
30495|NCT00894608|Drug|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
30496|NCT00894621|Drug|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
30497|NCT00894621|Drug|Placebo|
30498|NCT00894634|Drug|Brompheniramine maleate|
30499|NCT00015964|Drug|ZD1839|
29872|NCT00893529|Dietary Supplement|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
29873|NCT00893542|Drug|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
29874|NCT00893555|Drug|voriconazole|TDM (through level of 2-5mg/L).
30249|NCT00898508|Other|fluorescent antibody technique|
30250|NCT00898508|Other|immunohistochemistry staining method|
30251|NCT00898508|Other|laboratory biomarker analysis|
30252|NCT00016302|Drug|asparaginase|Given IM
30253|NCT00898508|Other|liquid chromatography|
30254|NCT00891527|Drug|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.
Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated.
30255|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.5%
30256|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.2%
30257|NCT00015626|Drug|rosiglitazone|
30258|NCT00891540|Drug|placebo|Isotonic NaCl
30259|NCT00891553|Procedure|DXA|CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
30260|NCT00891566|Procedure|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
30261|NCT00891579|Drug|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
30262|NCT00891579|Drug|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
30263|NCT00891592|Biological|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.
Table 6: Dose escalation (Dose level CD3+ cell dose)
1xE5 cells/kg
2xE6 cells/kg
3xE7 cells/kg
4xE8 cells/kg
29625|NCT00016341|Drug|megestrol acetate|
29626|NCT00899769|Genetic|proteomic profiling|
29627|NCT00899769|Other|immunoenzyme technique|
29628|NCT00899769|Other|laboratory biomarker analysis|
29629|NCT00899769|Other|liquid chromatography|
29630|NCT00899769|Other|mass spectrometry|
29631|NCT00899782|Other|cytology specimen collection procedure|correlative studies
29632|NCT00899795|Genetic|cytogenetic analysis|
29633|NCT00899795|Genetic|fluorescence in situ hybridization|
29634|NCT00899795|Other|flow cytometry|
29635|NCT00899795|Procedure|biopsy|
29636|NCT00016341|Drug|paclitaxel|
29637|NCT00899821|Biological|aldesleukin|
29638|NCT00899821|Biological|recombinant interleukin-12|
29639|NCT00899821|Biological|sargramostim|
29930|NCT00898209|Other|questionnaire administration|Questionnaire will be completed.
29931|NCT00898222|Drug|aspirin|81 mg orally daily for two weeks
29932|NCT00898235|Genetic|clonality analysis|analyze clonality
29933|NCT00898235|Genetic|polymerase chain reaction|analyze polymerase chain reaction
29934|NCT00898235|Genetic|protein analysis|analyze protein
29935|NCT00900146|Drug|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
29936|NCT00016380|Drug|ondansetron|
29937|NCT00900146|Drug|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
29356|NCT00895284|Procedure|Standard Hysterectomy|Standard hysterectomy.
29357|NCT00895297|Drug|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
29358|NCT00895310|Drug|Ketoconazole|Ketoconazole is taken three times a day by mouth.
29359|NCT00895323|Other|enzyme-linked immunosorbent assay|
29360|NCT00895323|Other|pharmacological study|
29361|NCT00895323|Procedure|whole-body scintigraphy|
29362|NCT00016029|Other|screening questionnaire administration|
29363|NCT00895323|Radiation|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
29364|NCT00895336|Biological|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
29365|NCT00895349|Procedure|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
29366|NCT00895349|Procedure|CT Abdomen and Pelvis scan|Pre-treatment scan
29367|NCT00897351|Genetic|protein expression analysis|
29368|NCT00897351|Other|immunohistochemistry staining method|
29369|NCT00897351|Other|laboratory biomarker analysis|
29370|NCT00897364|Other|laboratory biomarker analysis|
29371|NCT00897377|Radiation|Radiation therapy|
29372|NCT00016185|Drug|docetaxel|
29373|NCT00897377|Drug|Temozolomide|
29374|NCT00897390|Drug|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
29375|NCT00897390|Drug|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
29376|NCT00897390|Drug|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
29377|NCT00897403|Other|biologic sample preservation procedure|
29378|NCT00897403|Procedure|diagnostic colonoscopy|
30500|NCT00894647|Drug|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
30501|NCT00894647|Drug|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
30502|NCT00894660|Drug|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
30503|NCT00894660|Drug|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
30504|NCT00894673|Biological|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
30505|NCT00894673|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
30506|NCT00894686|Biological|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
30507|NCT00894699|Drug|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
30508|NCT00894699|Drug|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
30509|NCT00894712|Other|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
30510|NCT00896766|Genetic|polymorphism analysis|
29449|NCT00892970|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
29450|NCT00892983|Behavioral|FAB|Standard well child care plus 8 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, 3-4, 6, 12, 15, 18, and 21 months post-partum.
29451|NCT00895362|Drug|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
29452|NCT00895362|Drug|Cetuximab|Loading dose of 200 mg/m^2 (maintenance 125 mg/m^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
29453|NCT00895388|Behavioral|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
29454|NCT00895401|Dietary Supplement|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
29455|NCT00895401|Other|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
29456|NCT00895414|Drug|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
30264|NCT00891592|Other|Observation Arm|Single infusion of Cord Blood Cells
30265|NCT00891605|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
30266|NCT00891605|Drug|paclitaxel|175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.
Note - The dose and schedule is subject to change based on the toxicities observed.
30267|NCT00891618|Other|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
29194|NCT00899327|Genetic|polymerase chain reaction|
29195|NCT00899327|Genetic|protein expression analysis|
29196|NCT00899327|Other|laboratory biomarker analysis|
29197|NCT00899340|Genetic|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
29198|NCT00899340|Genetic|microarray analysis|microarray analysis
29199|NCT00016315|Drug|gemcitabine hydrochloride|
29200|NCT00899340|Genetic|protein expression analysis|protein expression analysis
29201|NCT00899340|Other|immunohistochemistry staining method|immunohistochemistry staining method
29202|NCT00899340|Other|laboratory biomarker analysis|laboratory biomarker analysis
29203|NCT00899353|Dietary Supplement|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
29204|NCT00899366|Genetic|microarray analysis|
29205|NCT00899366|Genetic|mutation analysis|
29206|NCT00892515|Other|gas chromatography|
29207|NCT00892515|Other|immunoenzyme technique|
29208|NCT00892515|Other|immunologic technique|
29209|NCT00892515|Other|laboratory biomarker analysis|
29210|NCT00892515|Other|mass spectrometry|
29211|NCT00892515|Other|physiologic testing|
29938|NCT00900146|Drug|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
29939|NCT00900159|Drug|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
29940|NCT00900159|Drug|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
29941|NCT00900172|Biological|bevacizumab|
29942|NCT00900172|Drug|carboplatin|
29943|NCT00900172|Drug|paclitaxel|
29944|NCT00900172|Genetic|gene expression analysis|
29945|NCT00900172|Genetic|polymerase chain reaction|
29946|NCT00900172|Genetic|polymorphism analysis|
29947|NCT00016380|Procedure|quality-of-life assessment|
29948|NCT00900172|Other|laboratory biomarker analysis|
29949|NCT00900185|Genetic|mutation analysis|
29950|NCT00900185|Genetic|polymerase chain reaction|
29951|NCT00900185|Genetic|polymorphism analysis|
29952|NCT00900198|Procedure|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
29953|NCT00900211|Genetic|microarray analysis|
29954|NCT00900211|Genetic|molecular diagnostic method|
30333|NCT00898547|Other|laboratory biomarker analysis|
30334|NCT00898560|Drug|eslicarbazepine acetate and Microginon®|eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.
Microginon®: single oral dose on day 14 of treatment period
30335|NCT00898560|Drug|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
30336|NCT00016302|Drug|methotrexate|Given IT and orally
30337|NCT00898573|Drug|lapatinib ditosylate|
30338|NCT00898573|Genetic|fluorescence in situ hybridization|
29711|NCT00897845|Genetic|RNA analysis|
29712|NCT00897845|Genetic|microarray analysis|
29713|NCT00897845|Other|immunohistochemistry staining method|
29714|NCT00897845|Other|laboratory biomarker analysis|
29715|NCT00016263|Biological|oblimersen sodium|
29716|NCT00897871|Drug|carboplatin|
29717|NCT00897871|Drug|cyclophosphamide|
29718|NCT00897871|Drug|etoposide phosphate|
29719|NCT00897871|Genetic|gene expression analysis|
29720|NCT00897871|Genetic|polymorphism analysis|
29721|NCT00897871|Other|pharmacological study|
29722|NCT00897884|Drug|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
29723|NCT00897897|Device|Philips MRI-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
29724|NCT00897910|Other|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
29725|NCT00897910|Other|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
29726|NCT00016263|Drug|dacarbazine|
29727|NCT00897910|Other|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
29728|NCT00897923|Procedure|radionuclide imaging|
29729|NCT00897923|Radiation|indium In 111-labeled autologous peripheral blood mononuclear cells|
29730|NCT00897923|Radiation|indium In 111-labeled autologous polymorphonuclear leukocytes|
29731|NCT00897936|Genetic|DNA methylation analysis|
29732|NCT00897936|Genetic|comparative genomic hybridization|
29733|NCT00897936|Genetic|fluorescence in situ hybridization|
29457|NCT00016029|Procedure|barium enema injection|
29458|NCT00895414|Drug|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
29459|NCT00895453|Drug|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
29460|NCT00895453|Drug|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
29461|NCT00895453|Drug|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
29462|NCT00895466|Biological|PEP-223/CoVaccine HT|
29463|NCT00895479|Procedure|Graft placement surgery plus Trinam therapy|Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.
Control arm: graft placement surgery
29464|NCT00895505|Drug|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
29465|NCT00895505|Drug|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
29466|NCT00895518|Behavioral|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
29467|NCT00895531|Drug|Depodur|7.5 mg Depodur via the epidural catheter
29468|NCT00016029|Procedure|computed tomography|
29809|NCT00895947|Other|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
29810|NCT00895960|Drug|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
29811|NCT00895960|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
29812|NCT00895960|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
29813|NCT00895973|Other|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
29814|NCT00895986|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
29212|NCT00892515|Other|questionnaire administration|
29213|NCT00892515|Other|survey administration|
29214|NCT00892515|Procedure|dual x-ray absorptometry|
29215|NCT00015834|Drug|imatinib mesylate|Given PO
29216|NCT00892515|Procedure|magnetic resonance imaging|
29217|NCT00892515|Procedure|study of high risk factors|
29218|NCT00892541|Drug|ER OROS paliperidone|
29219|NCT00892554|Dietary Supplement|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
29542|NCT00893048|Drug|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
29543|NCT00893061|Drug|anastrozole|Given orally
29544|NCT00893061|Drug|exemestane|Given orally
29545|NCT00893061|Drug|letrozole|Given orally
29546|NCT00893061|Drug|tamoxifen citrate|Given orally
29547|NCT00893074|Drug|bupropion, diazepam, dronabinol, ramelteon (Investigational Drug)|multiple doses of an investigational drug administered three times per day, double blind during brief periods of marijuana abstinence
29548|NCT00893087|Device|Triggering mode of the ventilator|10 min of each triggering mode
29549|NCT00015860|Drug|vincristine sulfate|
29550|NCT00893087|Device|Triggering method of the ventilator|Flow triggering
29551|NCT00893087|Device|Triggering method of the ventilator|Pressure triggering
29552|NCT00893087|Device|Triggering method of the ventilator|NAVA triggering
29553|NCT00893100|Drug|Diltiazem|2%,3 times daily
29554|NCT00893113|Drug|Alfuzosin|10 mg once daily
29555|NCT00893113|Drug|Alfuzosin|10 mg once daily
29556|NCT00893126|Procedure|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
29557|NCT00893139|Drug|AL-38583 ophthalmic solution 0.05%|
30339|NCT00898573|Genetic|gene expression analysis|
30340|NCT00898573|Genetic|mutation analysis|
30341|NCT00898573|Genetic|polymerase chain reaction|
30342|NCT00898573|Genetic|reverse transcriptase-polymerase chain reaction|
30343|NCT00898573|Other|cell sorting|
30344|NCT00898573|Other|immunohistochemistry staining method|
30345|NCT00898573|Other|laboratory biomarker analysis|
30346|NCT00898599|Dietary Supplement|Prebiotic|Inulin type fructooligosaccharides
30347|NCT00016302|Drug|cyclophosphamide|Given IV
30348|NCT00898599|Dietary Supplement|Placebo|Maltodextrin as placebo
30349|NCT00898638|Other|biologic sample preservation procedure|
30350|NCT00898638|Other|medical chart review|
30351|NCT00898664|Genetic|cytogenetic analysis|not specified
30352|NCT00898664|Genetic|gene expression analysis|Not specified
30353|NCT00898664|Genetic|mutation analysis|Not specified
30354|NCT00898664|Genetic|polymerase chain reaction|not specified
30355|NCT00891644|Other|Snowball sampling|Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.
When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.
Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care.
29288|NCT00899366|Other|immunologic technique|
29289|NCT00899379|Drug|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
29290|NCT00899379|Drug|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
29291|NCT00899392|Other|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
29292|NCT00016315|Drug|paclitaxel|
29734|NCT00897936|Genetic|microarray analysis|
29735|NCT00897936|Genetic|polymerase chain reaction|
30020|NCT00898274|Other|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
30021|NCT00898274|Other|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
30022|NCT00898287|Drug|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
30023|NCT00898287|Drug|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
30024|NCT00898300|Other|biologic sample preservation procedure|
30025|NCT00898300|Procedure|biopsy|
30026|NCT00898313|Genetic|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
30027|NCT00016276|Drug|tamoxifen citrate|Given orally
30028|NCT00898313|Genetic|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
30029|NCT00898313|Genetic|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
30030|NCT00898313|Other|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
30031|NCT00898313|Procedure|nasal brushing|Using a brush, superficial cells are removed from the nose.
30032|NCT00898313|Procedure|Blood draw|Venous blood will be collected
30033|NCT00898313|Procedure|Urine collection|Subjects will be asked to provide a urine specimen.
30034|NCT00898313|Procedure|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
29815|NCT00895986|Behavioral|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
29816|NCT00897936|Other|diagnostic laboratory biomarker analysis|
29817|NCT00016276|Drug|dexrazoxane hydrochloride|Given IV
29818|NCT00897936|Other|immunologic technique|
29819|NCT00897949|Drug|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
29820|NCT00897949|Drug|Comparator: placebo|Placebo to rizatriptan
29821|NCT00897962|Other|Healthy Controls|One blood draw (2 teaspoons)
29822|NCT00897962|Other|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
29823|NCT00897962|Other|Non-cancer medical illness|One blood draw (2 teaspoons)
29824|NCT00897975|Dietary Supplement|red yeast rice|600 mg 3 capsules bid
29825|NCT00897975|Drug|phytosterol|phytosterol 450 mg 2 tabs bid with food
29826|NCT00897975|Behavioral|therapeutic lifestyle program|TLC - 12 weeks
29827|NCT00897975|Drug|placebo|placebo
29828|NCT00000811|Drug|Sulfamethoxazole-Trimethoprim|
29829|NCT00016276|Drug|doxorubicin hydrochloride|Given IV
30110|NCT00896350|Drug|chemotherapy|
30111|NCT00896350|Other|diagnostic laboratory biomarker analysis|
30112|NCT00896350|Other|tissue oxygen measurement|
30113|NCT00896350|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
30114|NCT00016081|Drug|ribavirin|
30115|NCT00896350|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
30116|NCT00896350|Procedure|magnetic resonance spectroscopic imaging|
30117|NCT00896350|Radiation|radiation therapy|
29558|NCT00893139|Drug|AL-38583 ophthalmic solution 0.10%|
29559|NCT00893139|Drug|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
29560|NCT00015873|Drug|asparaginase|
29561|NCT00893165|Behavioral|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
29562|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
29563|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
29564|NCT00895557|Drug|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
29565|NCT00895570|Drug|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
29566|NCT00895570|Drug|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
29875|NCT00893555|Drug|voriconazole (dosing according to the SPC)|No serum concentrations are determined
29876|NCT00015886|Drug|docetaxel|75 milligrams per meter squared intraveneously
29877|NCT00893568|Other|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
29878|NCT00893581|Drug|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
29879|NCT00893581|Drug|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
29880|NCT00893581|Other|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
29881|NCT00893594|Drug|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
29882|NCT00893594|Drug|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
29293|NCT00899418|Genetic|gene expression analysis|
29294|NCT00899418|Genetic|polymerase chain reaction|
29295|NCT00899418|Genetic|polymorphism analysis|
29296|NCT00899418|Other|immunohistochemistry staining method|
29297|NCT00899431|Drug|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
29298|NCT00899431|Drug|Fludarabine|30 mg/m^2 intravenously daily on days -5, -4, -3.
29299|NCT00899431|Drug|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8.
29300|NCT00899431|Drug|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
29301|NCT00899431|Procedure|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
29302|NCT00899431|Drug|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
29303|NCT00000813|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
29304|NCT00016315|Radiation|radiation therapy|
29305|NCT00899431|Drug|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
29306|NCT00899457|Genetic|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
29307|NCT00899457|Other|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
29308|NCT00899457|Other|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
29309|NCT00899457|Procedure|bronchoscopy|Collection of breath condensate.
29310|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
29640|NCT00899821|Other|immunologic technique|
29641|NCT00899821|Procedure|biopsy|
29642|NCT00899847|Procedure|Autologous/Allogeneic HCT|Undergo autologous hematopoietic SCT
29643|NCT00899847|Drug|cyclophosphamide|Given IV
30035|NCT00016367|Drug|Cisplatin|Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.
Regimen B: Cisplatin IV over 2 hours on day 1.
30036|NCT00900042|Genetic|DNA stability analysis|
30037|NCT00900042|Genetic|chromosomal translocation analysis|
30038|NCT00900042|Genetic|cytogenetic analysis|
30422|NCT00896701|Other|laboratory biomarker analysis|
30423|NCT00896714|Device|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
30424|NCT00016133|Biological|BCG vaccine|
30425|NCT00896727|Genetic|gene expression analysis|
30426|NCT00896727|Genetic|protein expression analysis|
30427|NCT00896727|Other|fluorescent antibody technique|
30428|NCT00896727|Other|laboratory biomarker analysis|
30429|NCT00896740|Genetic|microarray analysis|
30430|NCT00896740|Procedure|biopsy|
30431|NCT00896766|Genetic|loss of heterozygosity analysis|
30432|NCT00896766|Genetic|microarray analysis|
30433|NCT00898664|Other|immunohistochemistry staining method|not specified
30434|NCT00898664|Other|laboratory biomarker analysis|not specified
30435|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
30436|NCT00016302|Drug|cytarabine|Given IV or SC
30437|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
30438|NCT00898677|Drug|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
30439|NCT00898677|Drug|Comparator: Placebo|placebo to rizatriptan
30440|NCT00898690|Genetic|cytogenetic analysis|
30441|NCT00898690|Genetic|gene expression analysis|
30118|NCT00896363|Drug|GSK163090 Tablets|Developed for the treatment of Major Depressive Disorder
30119|NCT00898313|Procedure|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
30120|NCT00898313|Procedure|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
30121|NCT00898313|Procedure|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
30122|NCT00016276|Other|laboratory biomarker analysis|Correlative studies
30123|NCT00898326|Other|laboratory biomarker analysis|
30124|NCT00898326|Procedure|biopsy|
30125|NCT00898352|Procedure|regional lymph node dissection|
30126|NCT00898352|Radiation|radiation therapy|
30127|NCT00898365|Other|laboratory biomarker analysis|Correlative studies
30128|NCT00898365|Other|cytology specimen collection procedure|Correlative studies
30129|NCT00898378|Genetic|gene expression analysis|gene expression analysis
30130|NCT00898378|Genetic|polymerase chain reaction|polymerase chain reaction
30131|NCT00898378|Genetic|polymorphism analysis|polymorphism analysis
30132|NCT00898378|Genetic|protein expression analysis|protein expression analysis
30133|NCT00016289|Biological|recombinant interleukin-12|Given intraperitoneally
30134|NCT00898378|Genetic|proteomic profiling|proteomic profiling
30511|NCT00896766|Genetic|tumor replication error analysis|
30512|NCT00016133|Biological|autologous tumor cell vaccine|
30513|NCT00896779|Drug|ranibizumab|Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months
Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months
30514|NCT00896792|Other|counseling intervention|
30515|NCT00896792|Other|questionnaire administration|
29883|NCT00893607|Drug|NRL001|10mg NRL001 was administered as a slow release suppository
29884|NCT00893620|Device|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
29885|NCT00893646|Behavioral|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
29886|NCT00893659|Dietary Supplement|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
29887|NCT00000809|Biological|QS-21|
29888|NCT00015886|Drug|fluorouracil|350 milligrams intraveneously
29889|NCT00893659|Dietary Supplement|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
29890|NCT00895999|Behavioral|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
30268|NCT00015652|Drug|Ribavirin|
30269|NCT00891631|Behavioral|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
30270|NCT00891631|Behavioral|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
30271|NCT00891644|Other|Case Management|Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.
Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts.
30272|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
29644|NCT00899847|Biological|filgrastim|Given SC
29645|NCT00899847|Drug|melphalan|Given IV
29646|NCT00899847|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic SCT
29647|NCT00016341|Drug|tamoxifen citrate|
29648|NCT00899847|Radiation|total nodal irradiation|Undergo TLI
29649|NCT00899847|Biological|anti-thymocyte globulin|Given IV
29650|NCT00899847|Drug|cyclosporine|Given PO
29651|NCT00899847|Drug|mycophenolate mofetil|Given PO
29652|NCT00893230|Dietary Supplement|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
29653|NCT00893230|Dietary Supplement|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
29654|NCT00893256|Drug|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
29655|NCT00893256|Drug|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
29656|NCT00893256|Drug|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
29657|NCT00893256|Drug|Placebo|Placebo: once daily
29658|NCT00893269|Drug|eszopiclone|Oral capsule at dose recommended for adults
29659|NCT00015873|Drug|cytarabine|
29660|NCT00893269|Drug|Placebo|Participants receive placebo prior to sleep
29661|NCT00893269|Drug|ramelteon|ramelteon
29662|NCT00893269|Drug|zolpidem|zolpidem
29663|NCT00893282|Device|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
29664|NCT00893282|Device|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
29665|NCT00893295|Other|informational intervention|
29955|NCT00900211|Other|biologic sample preservation procedure|
29956|NCT00900224|Genetic|DNA analysis|
30442|NCT00898690|Genetic|microarray analysis|
30443|NCT00898690|Genetic|mutation analysis|
30444|NCT00898690|Genetic|reverse transcriptase-polymerase chain reaction|
30445|NCT00898690|Other|immunohistochemistry staining method|
30446|NCT00898703|Other|flow cytometry|
30447|NCT00016302|Drug|mercaptopurine|Given orally
30448|NCT00898703|Other|immunoenzyme technique|
29379|NCT00897416|Other|laboratory biomarker analysis|
29380|NCT00897429|Procedure|laboratory biomarker analysis|Correlative studies
29381|NCT00897442|Other|biologic sample preservation procedure|
29382|NCT00897455|Genetic|DNA analysis|
29383|NCT00016198|Drug|FOLFOX regimen|
29384|NCT00897455|Genetic|mutation analysis|
29385|NCT00897455|Genetic|polymorphism analysis|
29386|NCT00897455|Other|laboratory biomarker analysis|
29387|NCT00897455|Procedure|evaluation of cancer risk factors|
29388|NCT00897468|Other|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
29389|NCT00897468|Other|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
29390|NCT00897481|Genetic|gene expression analysis|
29391|NCT00897481|Genetic|mutation analysis|
29392|NCT00897481|Other|diagnostic laboratory biomarker analysis|
29393|NCT00897481|Other|immunohistochemistry staining method|
29394|NCT00000811|Drug|Atovaquone|
29395|NCT00016198|Drug|fluorouracil|
30516|NCT00896792|Other|survey administration|
30517|NCT00896792|Procedure|end-of-life treatment/management|
30518|NCT00896792|Procedure|psychosocial assessment and care|
30519|NCT00896818|Genetic|DNA analysis|
30520|NCT00896818|Genetic|genetic linkage analysis|
30521|NCT00896818|Genetic|loss of heterozygosity analysis|
30522|NCT00896818|Genetic|polymorphism analysis|
30523|NCT00016133|Drug|fluorouracil|
30524|NCT00896818|Other|laboratory biomarker analysis|
30525|NCT00896818|Other|medical chart review|
30526|NCT00896818|Other|questionnaire administration|
30527|NCT00896831|Drug|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
30528|NCT00896831|Drug|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
30529|NCT00896844|Behavioral|emotional disclosure|writing about emotional events from the past
30530|NCT00896844|Behavioral|placebo writing|writing about how they spent their time the previous day
30531|NCT00896857|Genetic|RNA analysis|
30532|NCT00896857|Genetic|polymerase chain reaction|
30533|NCT00896857|Genetic|protein expression analysis|
30534|NCT00016133|Drug|leucovorin calcium|
30535|NCT00896857|Genetic|reverse transcriptase-polymerase chain reaction|
30536|NCT00896857|Genetic|western blotting|
30537|NCT00896857|Other|immunoenzyme technique|
29133|NCT00876850|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
29134|NCT00876850|Drug|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
30273|NCT00894166|Drug|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
30274|NCT00894166|Drug|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
30275|NCT00894192|Device|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
30276|NCT00894192|Device|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
30277|NCT00015938|Drug|docetaxel|
30278|NCT00894205|Behavioral|strengthening exercise program|A low intensity strengthening exercise program based on the Tufts University "Strong Bones" program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks.
30279|NCT00894218|Procedure|Arthroplasty|Hip or knee arthroplasty
30280|NCT00894231|Drug|levocetirizine (Xyzal)|5mg po QD
30281|NCT00894231|Drug|placebo|sugar tablet
30282|NCT00894244|Device|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
30283|NCT00894270|Procedure|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
29220|NCT00892554|Dietary Supplement|Corn/soy oil|Capsules taken once daily
29221|NCT00892567|Biological|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
29222|NCT00892580|Drug|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
29223|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
29224|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
29225|NCT00892606|Drug|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
29226|NCT00015834|Drug|cytarabine|Given IV
29957|NCT00900224|Genetic|DNA methylation analysis|
29958|NCT00016393|Drug|ixabepilone|
29959|NCT00900224|Genetic|gene expression analysis|
29960|NCT00900224|Genetic|mutation analysis|
29961|NCT00900224|Genetic|polymerase chain reaction|
29962|NCT00900224|Genetic|reverse transcriptase-polymerase chain reaction|
29963|NCT00900224|Other|high performance liquid chromatography|
29964|NCT00900224|Other|laboratory biomarker analysis|
29965|NCT00900237|Drug|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
29966|NCT00893685|Device|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
29967|NCT00893698|Procedure|bilateral allotransplantation|bilateral allotransplantation of upper limbs
29968|NCT00893711|Other|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
29969|NCT00893711|Other|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
29970|NCT00893711|Dietary Supplement|L.reuteri + Vit D|
29971|NCT00893711|Dietary Supplement|Vit D placebo|
29972|NCT00893724|Drug|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
29973|NCT00893724|Dietary Supplement|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine [SR] - 1[500mg] tablet bid Tocopherols [200IU], Tocotrienol [10mg], CoQ10 [50mg] - combination capsule bid Sustained Release Niacinamide - 1 [750mg] tablet bid Vitamin C - 1 [1000mg] sustained release tablet bid N-acetyl Cysteine - 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
29974|NCT00893724|Drug|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine [SR] - 1 [500mg] tablet bid Tocopherol [200IU], Tocotrienol [10mg], CoQ10 [50mg] combination capsule bid Sustained Release Niacinamide 1 [750mg] tablet bid Vitamin C 1 [1000mg] sustained release tablet bid N-acetyl Cysteine 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 [50mg] tablet qd
29396|NCT00897481|Procedure|sentinel lymph node biopsy|
29397|NCT00897494|Genetic|protein expression analysis|Venous blood collection
29398|NCT00897494|Other|laboratory biomarker analysis|Venous blood collection
29399|NCT00016328|Drug|temsirolimus|Given IV
29400|NCT00899496|Other|immunological diagnostic method|
29401|NCT00899496|Other|physiologic testing|
29402|NCT00899509|Other|laboratory biomarker analysis|correlative studies
29403|NCT00899522|Other|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
29736|NCT00899847|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic SCT
29737|NCT00899847|Other|laboratory biomarker analysis|Correlative studies
29738|NCT00899873|Genetic|cytogenetic analysis|
29739|NCT00899873|Other|flow cytometry|
29740|NCT00899873|Other|fluorescence activated cell sorting|
29741|NCT00899873|Other|immunoenzyme technique|
29742|NCT00000813|Biological|rgp120/HIV-1 SF-2|
29743|NCT00016354|Drug|benzoylphenylurea|
29744|NCT00899873|Other|laboratory biomarker analysis|
29745|NCT00899899|Genetic|microarray analysis|
29746|NCT00899899|Genetic|reverse transcriptase-polymerase chain reaction|
29747|NCT00899899|Other|laboratory biomarker analysis|
29748|NCT00899912|Genetic|microarray analysis|
29749|NCT00899912|Other|diagnostic laboratory biomarker analysis|
29750|NCT00899951|Drug|fentanyl citrate|
29751|NCT00899951|Other|pharmacological study|
31883|NCT00883883|Drug|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
31884|NCT00883896|Other|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
31885|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
31886|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
31887|NCT00883896|Other|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
31888|NCT00883896|Drug|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
31889|NCT00883909|Drug|dutasteride|A follow-up study in adult male subjects who have received investigational product
31890|NCT00883935|Drug|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
31891|NCT00883935|Drug|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
31892|NCT00014508|Drug|melphalan|
30916|NCT00887315|Drug|Docetaxel and cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
30917|NCT00887315|Radiation|Docetaxel and cisplatin Plus Hypofractionated Radiotherapy|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
30918|NCT00887328|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
30919|NCT00014755|Drug|prednisone|
30920|NCT00887328|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
30921|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
30922|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
30923|NCT00887354|Drug|Teriparatide|Administered subcutaneously
30924|NCT00887354|Drug|Risedronate|Administered orally
30925|NCT00887354|Drug|Placebo|Weekly: Administered orally
Daily: Administered subcutaneously
30926|NCT00887354|Dietary Supplement|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
31455|NCT00885690|Drug|Olanzapine|Olanzapine 10-20 mg
31760|NCT00014937|Drug|stavudine|
31761|NCT00888758|Device|everolimus|200 patients with STEMI will be treated with PROMUS DES.
31762|NCT00888784|Procedure|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
31763|NCT00880997|Drug|Doxazosin|The target dose of 8 mg will probably not be attained by some patients over a 8 week induction period (starting at week 1 of the overall 17 week study). We will try to increase the subjects' dose up to a minimum of 4 mg and optimum of 8 mg daily as once daily dosing. The starting dose will be 1 mg once daily at week 1, then 2 mg once daily at week 2, with 1mg/week induction rate for 8 weeks. They will be maintained on 4mg-8mg daily dosing until week 13. The subjects will be undergo the discontinuation from the study medication during weeks 14 -17.
31764|NCT00880997|Drug|Placebo|Placebo daily dosing
31765|NCT00881010|Behavioral|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
31766|NCT00881010|Behavioral|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
31767|NCT00881023|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
31768|NCT00881023|Device|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
31769|NCT00881049|Drug|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
31770|NCT00881062|Drug|Proellex|A single oral dose administered after at least a 10 hour fast
31771|NCT00881075|Drug|SeeMore(TM)|single dose intravenous injectable
31772|NCT00881088|Drug|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
31773|NCT00014313|Drug|etoposide|
31774|NCT00881088|Drug|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
31775|NCT00881101|Drug|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
31776|NCT00881114|Drug|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
30991|NCT00884871|Procedure|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
30992|NCT00884884|Drug|Double Placebo|1 capsule daily
30993|NCT00884884|Drug|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
30994|NCT00884884|Drug|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
30995|NCT00014573|Biological|filgrastim|
30996|NCT00884884|Drug|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
30997|NCT00884884|Drug|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
30998|NCT00884884|Drug|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
30999|NCT00884884|Drug|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
31000|NCT00884884|Drug|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
31001|NCT00884884|Drug|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
31002|NCT00884884|Drug|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
31302|NCT00887861|Drug|Investigational new drug, company code: BGG492|
31303|NCT00887861|Drug|Placebo|
31304|NCT00887874|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
31305|NCT00887900|Procedure|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
31306|NCT00890526|Other|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
31307|NCT00890526|Other|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
31686|NCT00891033|Drug|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
31687|NCT00891046|Drug|Canakinumab|Canakinumab
31688|NCT00891072|Drug|R-(-)-gossypol acetic acid|Given orally
31689|NCT00891072|Drug|paclitaxel|Given IV
31690|NCT00891072|Drug|carboplatin|Given IV
31691|NCT00891072|Other|pharmacological study|Correlative studies
31692|NCT00015548|Drug|Citalopram|
31693|NCT00891098|Behavioral|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
31694|NCT00891098|Behavioral|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
31695|NCT00891111|Behavioral|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
31696|NCT00891111|Behavioral|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
31697|NCT00883506|Drug|Lisinopril 40 mg Tablet under fasting conditions.|
31698|NCT00883506|Drug|Lisinopril 40 mg Tablet under fed conditions.|
31699|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
31700|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
31701|NCT00883532|Drug|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 < 30% or is extubated
31702|NCT00883532|Drug|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
30728|NCT00894985|Biological|heparin sodium - blausiegel|heparin sodium 5.000UI
30729|NCT00894985|Biological|heparin sodium - APP|heparin sodium 5.000 USP - APP
30730|NCT00894998|Biological|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
30731|NCT00894998|Biological|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
31067|NCT00882388|Drug|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
31068|NCT00882388|Drug|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
31069|NCT00882401|Drug|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
31070|NCT00882401|Drug|Placebo|Matching placebo at same dose schedule as ergocalciferol
31071|NCT00882414|Drug|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
31072|NCT00882414|Drug|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
31073|NCT00882427|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
31074|NCT00882440|Drug|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
31075|NCT00882440|Drug|Placebo|Placebo capsule to losartan
31076|NCT00882440|Drug|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
31077|NCT00014443|Drug|thalidomide|
31078|NCT00884949|Drug|BMN 110|Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:
Weeks 1-12: 0.1 mg/kg/week
Weeks 13-24: 1.0 mg/kg/week
Weeks 25-36: 2.0 mg/kg/week
Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week.
31079|NCT00884962|Device|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
31080|NCT00884988|Drug|Lymphomyosot|20 drops X3/day, until discharge
31081|NCT00884988|Drug|Placebo remedy|20 drops X3/day, until discharge
31082|NCT00885001|Procedure|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
31083|NCT00885014|Behavioral|CBT|Telephone cognitive-behavioral therapy
31084|NCT00885014|Behavioral|EAP|Employees Assistance Program
31085|NCT00885053|Dietary Supplement|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
31777|NCT00881114|Drug|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
31778|NCT00881127|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
30822|NCT00015821|Other|laboratory biomarker analysis|Correlative studies
30823|NCT00892515|Other|counseling intervention|
30824|NCT00887159|Drug|etoposide|Given IV
30825|NCT00887172|Drug|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
30826|NCT00887172|Drug|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
30827|NCT00887172|Drug|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
30828|NCT00887185|Other|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
30829|NCT00014755|Drug|cyclophosphamide|
30830|NCT00887198|Drug|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
30831|NCT00887198|Drug|Placebo|4 placebo tablets per day taken orally.
30832|NCT00887198|Drug|Prednisone|5 mg tablet orally twice daily.
30833|NCT00887211|Device|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
30834|NCT00887211|Device|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
31308|NCT00890539|Drug|Methacholine challenge|Clinical and research test used in asthma
31309|NCT00890552|Drug|Lenalidomide|
31310|NCT00890552|Drug|Melphalan|
31311|NCT00015275|Behavioral|Cocaine-Related Disorders|
31312|NCT00890552|Drug|Dexamethasone|
31313|NCT00890565|Drug|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
31314|NCT00890578|Procedure|adhesive to suture|surgical closure
31315|NCT00890591|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
31316|NCT00890604|Drug|Acetaminophen|APAP 650mg q4h prn; RTC dosing
31317|NCT00890604|Other|Usual Care|Care per attending physician discretion for fever management
31318|NCT00890604|Drug|Ibuprofen|Ibuprofen 600mg q6h
31319|NCT00890604|Other|Physical Cooling Measures|Fan, Ice Packs
31320|NCT00890604|Device|Cooling Blanket|Water Circulating Cooling Blanket
31321|NCT00890604|Device|Hydrogel Cooling Pads|Application to torso and extremities
31618|NCT00883480|Drug|Docetaxel-Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
31619|NCT00883480|Drug|Gemcitabine-Cisplatin|Cisplatin 75 mg/ day 1 x 4 cycles
Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles
31620|NCT00883480|Drug|Erlotinib|Erlotinib 150 mg/day x 21 days
31621|NCT00883493|Drug|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
31622|NCT00883493|Drug|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
31623|NCT00014495|Drug|cytarabine|
31624|NCT00883506|Drug|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
30732|NCT00895011|Drug|Placebo|One dose 30 minutes prior to initiation of sexual activity
30733|NCT00016016|Drug|cytarabine|Given IV
30734|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
30735|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
30736|NCT00895024|Behavioral|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
30737|NCT00895037|Drug|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
30738|NCT00895050|Other|Review of clinical records|
30739|NCT00897026|Drug|paclitaxel|
30740|NCT00897026|Genetic|fluorescence in situ hybridization|
30741|NCT00897026|Other|immunohistochemistry staining method|
30742|NCT00897039|Other|flow cytometry|
30743|NCT00000811|Drug|Azithromycin|
30744|NCT00016159|Biological|filgrastim|
30745|NCT00897039|Other|immunohistochemistry staining method|
30746|NCT00897052|Genetic|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
30747|NCT00897052|Other|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
30748|NCT00897065|Genetic|microarray analysis|
30749|NCT00897065|Genetic|polymerase chain reaction|
30750|NCT00897065|Genetic|protein expression analysis|
30751|NCT00897065|Other|diagnostic laboratory biomarker analysis|
30752|NCT00897065|Other|fluorescent antibody technique|
31066|NCT00014430|Drug|vinorelbine ditartrate|Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
31380|NCT00887952|Procedure|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
31381|NCT00887952|Procedure|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
31382|NCT00887965|Drug|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
31383|NCT00887978|Drug|UT-15C SR|treprostinil diolamine sustained release tablets
31384|NCT00887978|Drug|Placebo|
31385|NCT00888004|Drug|AFQ056|
31386|NCT00888004|Drug|Placebo|
31387|NCT00888030|Other|there are no interventions currently listed for this study|
31388|NCT00014911|Drug|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
31389|NCT00888043|Drug|CNTO 95 and avastin|STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab
2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks
1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks
3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks
3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab
20 Recommended Phase II Dose Recommended Phase II Dose
31390|NCT00888056|Procedure|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
31391|NCT00015457|Drug|Amlodipine plus Botulinum toxin|
31392|NCT00890786|Drug|Temozolomide|High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.
High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5.
30835|NCT00887224|Drug|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
30836|NCT00887224|Drug|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
30837|NCT00887224|Drug|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
30838|NCT00887237|Device|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
31149|NCT00890331|Behavioral|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
31150|NCT00890370|Procedure|Airway clearance technique|
31151|NCT00890383|Drug|tetrastarch (Voluven)|Goals directed volume therapy for severe trauma resuscitation
31152|NCT00882453|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
31153|NCT00882466|Drug|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
31154|NCT00882492|Biological|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
31155|NCT00882492|Biological|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
31156|NCT00882505|Dietary Supplement|vitamin D|Subject will receive vitamin d supplements
31157|NCT00882505|Other|Placebo|Subject will receive a placebo.
31158|NCT00882518|Drug|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|200 mg or 300 mg, oral, single dose
31159|NCT00882518|Drug|Chlorpromazine|50 mg, oral, double dose
31160|NCT00882531|Drug|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
31161|NCT00882531|Drug|placebo|
31162|NCT00014443|Drug|topotecan hydrochloride|
31163|NCT00882557|Drug|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
31164|NCT00882557|Drug|daptomycin|6 mg/kg administered after a hemodialysis session
31165|NCT00882570|Drug|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
31625|NCT00885885|Drug|Panitumumab+FOLFIRI|Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.
A cycle of panitumumab is defined as 14 days.
FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:
Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle
Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing
A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1
5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle.
31626|NCT00885898|Procedure|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
31627|NCT00885898|Procedure|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
31628|NCT00885924|Drug|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
31629|NCT00885924|Drug|Placebo|NaCl 0.9%
31630|NCT00885937|Drug|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
31631|NCT00885937|Drug|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
31632|NCT00885937|Device|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
31633|NCT00885963|Drug|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
31634|NCT00885989|Drug|SLV338|5 - 1000 mg IV
31635|NCT00000802|Drug|Dapsone|
31636|NCT00014612|Procedure|axillary lymph node dissection|
31637|NCT00885989|Drug|Placebo|Placebo
31638|NCT00886002|Drug|Fentanyl; Buprenorphine; Naloxone|
30658|NCT00898976|Other|laboratory biomarker analysis|
30659|NCT00899002|Genetic|comparative genomic hybridization|Not specified
30660|NCT00899002|Genetic|molecular genetic technique|Not specified
30661|NCT00899002|Genetic|mutation analysis|Not specified
30662|NCT00899002|Genetic|polymerase chain reaction|Not noted
30663|NCT00016302|Radiation|radiation therapy|Undergo cranial irradiation
32117|NCT00881673|Drug|AL38583 Ophthalmic Solution|Topical ophthalmic
32118|NCT00881673|Drug|Maxidex|Topical ophthalmic
32119|NCT00881673|Drug|Vehicle|AL38583 Vehicle
32120|NCT00881686|Drug|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
32121|NCT00881699|Behavioral|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
32407|NCT00017862|Drug|SCH55700|
32408|NCT00918957|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
32409|NCT00918957|Drug|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
32410|NCT00918983|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
32411|NCT00918983|Drug|Placebo|Single intraprostatic injection of placebo
32412|NCT00918996|Procedure|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
32413|NCT00919009|Procedure|TACE (Transcatheter Arterial Chemoembolization )|TACE will be performed according to National Cancer Center protocol:
Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions
32414|NCT00919022|Drug|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
32415|NCT00911547|Drug|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
32416|NCT00911547|Drug|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
32417|NCT00911547|Drug|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
31703|NCT00883545|Other|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
31704|NCT00883545|Other|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
31705|NCT00883558|Drug|Insulin Lispro|
31706|NCT00014495|Radiation|bismuth Bi213 monoclonal antibody M195|
31707|NCT00883558|Drug|regular human insulin|
31708|NCT00883558|Drug|recombinant human hyaluronidase PH20|
31709|NCT00883558|Drug|Insulin glargine|
31710|NCT00883571|Procedure|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
31711|NCT00883571|Procedure|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
31712|NCT00883571|Procedure|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
31713|NCT00883584|Drug|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
31714|NCT00883584|Drug|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
31715|NCT00883623|Drug|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
31716|NCT00883636|Other|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
31717|NCT00000801|Drug|Cytarabine|
31718|NCT00014508|Biological|sargramostim|
31719|NCT00883636|Other|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
30927|NCT00887354|Dietary Supplement|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
30928|NCT00887367|Drug|GSK598809|Two 175 mg doses of GSK598809 will be given.
30929|NCT00887367|Other|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
30930|NCT00014755|Procedure|peripheral blood stem cell transplantation|
30931|NCT00889863|Drug|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
30932|NCT00000805|Drug|Ganciclovir|
30933|NCT00015106|Drug|Lamotrigine|
30934|NCT00889863|Drug|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
30935|NCT00889876|Drug|Metformin group|2000 mg/day for one year
30936|NCT00889876|Behavioral|Exercise|3 times/week with a personal coach for one year. Endurance training.
31240|NCT00882661|Device|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
31241|NCT00882674|Drug|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
31242|NCT00882687|Drug|Lifitegrast|Ophthalmic Solution
31243|NCT00882687|Other|Placebo|Ophthalmic Solution
31244|NCT00882700|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
31245|NCT00014456|Drug|docetaxel|
31246|NCT00882700|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
31247|NCT00882713|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120 or 200 micrograms, based on previous ESA therapy)
31248|NCT00882726|Drug|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
31249|NCT00882726|Drug|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
30664|NCT00899002|Genetic|proteomic profiling|not specified
30665|NCT00899002|Other|immunohistochemistry staining method|not noted
30666|NCT00899002|Other|laboratory biomarker analysis|not noted
30667|NCT00899002|Other|mass spectrometry|not noted
30668|NCT00899002|Other|medical chart review|not noted
30669|NCT00899015|Other|pharmacological study|
30670|NCT00899028|Genetic|comparative genomic hybridization|
30671|NCT00899028|Genetic|fluorescence in situ hybridization|
30672|NCT00899028|Genetic|gene expression analysis|
30673|NCT00899028|Genetic|microarray analysis|
30674|NCT00016302|Drug|nelarabine|Given IV
30675|NCT00899028|Genetic|protein expression analysis|
30676|NCT00899028|Other|immunohistochemistry staining method|
30677|NCT00899028|Other|laboratory biomarker analysis|
30678|NCT00899028|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
30679|NCT00899028|Other|medical chart review|
30680|NCT00899028|Procedure|diagnostic bronchoscopy|
30681|NCT00899041|Procedure|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
30682|NCT00899054|Drug|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
31003|NCT00884897|Drug|Oxytocin|Oxytocin given as 20 IU BID
31004|NCT00884897|Drug|Placebo|Placebo given as 20 IU BID
31005|NCT00884910|Device|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
31006|NCT00014573|Biological|sargramostim|
32418|NCT00911560|Biological|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Patients receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, and 52. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), and continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic and bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood and bone marrow. The treatment schedule may require minor adjustment as clinically indicated or due to unforeseen circumstance (e.g., due to PDH closure for holidays or due to inclement weather).
32419|NCT00911573|Drug|Tigecycline|50 mg IV every 12 hours up to 14 days
32420|NCT00911573|Drug|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
32421|NCT00911586|Drug|Testosterone undecanoate|Oral testosterone undecanoate, twice daily for one month.
32422|NCT00911599|Device|A Class BFH|A Class BFH versus Metal on Poly
32423|NCT00911599|Device|Metal on Polyethylene|A Class BFH versus Metal on Poly
32674|NCT00919503|Drug|Mycophenolate Mofetil|Given IV or PO
32675|NCT00919503|Procedure|Peripheral Blood Stem Cell Transplantation|Infused IV
32676|NCT00919503|Drug|Tacrolimus|Given IV or PO
32677|NCT00919503|Radiation|Total-Body Irradiation|Undergo total body irradiation
32678|NCT00919503|Drug|Treosulfan|Given IV
32679|NCT00919503|Procedure|Umbilical Cord Blood Transplantation|Single or double unit umbilical cord blood transplant, infused IV
32680|NCT00919516|Procedure|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
32681|NCT00919542|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
32682|NCT00017992|Drug|Stavudine|
32683|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
32684|NCT00911963|Biological|peginterferon alfa-2a|subcutaneous injection, 180 μg, once weekly, 48 weeks
32685|NCT00911963|Drug|ribavirin|tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
31720|NCT00886080|Procedure|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
30753|NCT00897065|Other|immunohistochemistry staining method|
30754|NCT00897065|Other|immunologic technique|
30755|NCT00016159|Biological|lintuzumab|
30756|NCT00897078|Other|laboratory biomarker analysis|Not specified
30757|NCT00897078|Other|medical chart review|not specified
30758|NCT00897078|Other|metabolic assessment|not specified
30759|NCT00897078|Other|questionnaire administration|will be obtained at a single clinic visit
30760|NCT00897078|Procedure|assessment of therapy complications|not specified
30761|NCT00897091|Genetic|comparative genomic hybridization|
30762|NCT00897091|Genetic|microarray analysis|
30763|NCT00897091|Genetic|reverse transcriptase-polymerase chain reaction|
30764|NCT00897091|Other|diagnostic laboratory biomarker analysis|
30765|NCT00897104|Drug|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
30766|NCT00016159|Drug|arsenic trioxide|
30767|NCT00897104|Drug|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
30768|NCT00897104|Drug|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
30769|NCT00897117|Genetic|gene expression analysis|Blood and lung tissue collection
30770|NCT00897117|Genetic|microarray analysis|Blood and lung tissue collection
30771|NCT00899080|Genetic|reverse transcriptase-polymerase chain reaction|
30772|NCT00899080|Other|immunoenzyme technique|
30773|NCT00899080|Other|laboratory biomarker analysis|
30774|NCT00899080|Other|platelet aggregation test|
31250|NCT00882726|Drug|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
31251|NCT00882726|Drug|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
31252|NCT00882739|Drug|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
31253|NCT00882739|Drug|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
31254|NCT00882739|Drug|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
31255|NCT00882752|Procedure|molecular analysis|bowel disease
31256|NCT00014456|Drug|gemcitabine hydrochloride|
31257|NCT00882765|Dietary Supplement|genistein|Given orally
31258|NCT00882778|Drug|activated recombinant human factor VII|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
31259|NCT00885287|Drug|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
31260|NCT00885300|Drug|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
31261|NCT00885300|Drug|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
31553|NCT00888329|Drug|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
31554|NCT00888329|Drug|Placebo|Placebo
31555|NCT00888342|Drug|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 < 90%. If SpO2 < 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
31556|NCT00888342|Drug|zopiclone|5 mg sedative given approximately 1 hour before sleep
31557|NCT00014911|Drug|Trimethoprim|An antibacterial used to prevent opportunistic infections
31558|NCT00888342|Other|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
31559|NCT00888355|Drug|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
31560|NCT00888355|Drug|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
31007|NCT00887380|Drug|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
31008|NCT00887380|Radiation|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
31009|NCT00887380|Drug|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
31010|NCT00887393|Other|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (< 15% of total kcaloric intake)
31011|NCT00887393|Other|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
31012|NCT00887406|Drug|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
31013|NCT00887406|Drug|GSK961081 200mcg SD|single dose via nebuliser
31014|NCT00887406|Drug|GSK961081 300mcg SD|single dose via nebuliser
31015|NCT00887406|Drug|Placebo SD|single dose via nebuliser
31016|NCT00887406|Drug|GSK961081 300mcg RD|repeat dose vai nebuliser
31017|NCT00000803|Drug|Zidovudine|
31018|NCT00014755|Procedure|irradiation|
31019|NCT00887406|Drug|Placebo RD|repeat dose via nebuliser
31020|NCT00887406|Drug|GSK961081 100mcg RD|repeat dose via nebuliser
31021|NCT00887406|Drug|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
31022|NCT00887406|Drug|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
31023|NCT00887406|Drug|GSK961081 3mcg SD|single dose delivered via nebulsier
31024|NCT00887419|Behavioral|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
31322|NCT00015288|Drug|Buprenorphine/naloxone|
31323|NCT00890617|Procedure|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
32686|NCT00911976|Device|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
32687|NCT00911989|Device|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
32688|NCT00912002|Drug|MK-0941|A single dose of 40 mg of [14C]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
32689|NCT00912015|Drug|Tramadol OAD|
32690|NCT00912015|Drug|Tramadol OAD|
32691|NCT00017303|Drug|oglufanide disodium|
32692|NCT00912015|Drug|Tramadol OAD|
32693|NCT00912015|Drug|Tramadol OAD 100mg|
32694|NCT00912028|Device|senofilcon A|contact lens
32695|NCT00912028|Device|lotrafilcon B|contact lens
32696|NCT00912028|Device|balafilcon A|contact lens
32697|NCT00912028|Device|methafilcon A|contact lens
32698|NCT00912028|Device|vifilcon A|contact lens
33029|NCT00919945|Other|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
33030|NCT00919958|Biological|PLX-PAD IM injection|Single treatment; multiple injections
33031|NCT00919984|Drug|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
33032|NCT00919997|Genetic|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
33033|NCT00919997|Genetic|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
33034|NCT00000827|Drug|Anti-HIV Immune Serum Globulin (Human)|
33035|NCT00018031|Drug|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
33036|NCT00919997|Other|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
33037|NCT00919997|Other|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
30775|NCT00899093|Other|Cytology Specimen Collection Procedure|Correlative studies
30776|NCT00899093|Other|Laboratory Biomarker Analysis|Correlative studies
30777|NCT00899119|Procedure|leukapheresis|
31086|NCT00885053|Dietary Supplement|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
31087|NCT00885066|Drug|capecitabine|
31088|NCT00014573|Biological|therapeutic autologous lymphocytes|
31089|NCT00885066|Drug|erlotinib hydrochloride|
31090|NCT00885066|Drug|gemcitabine hydrochloride|
31091|NCT00885079|Drug|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
31092|NCT00885079|Drug|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
31093|NCT00885092|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
31094|NCT00885092|Device|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
31095|NCT00885092|Device|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
31096|NCT00885092|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
31097|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
31098|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
31099|NCT00014573|Drug|carmustine|
31100|NCT00885118|Drug|Placebo (middle dose)|Placebo tablets once a day
31101|NCT00885118|Drug|Placebo|Placebo tablets once a day
31102|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
31103|NCT00885118|Drug|BI 10773|BI 10773 high dose tablets once a day
31104|NCT00887445|Drug|SLV341|5 - 1000mg once daily
31561|NCT00888368|Procedure|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
31562|NCT00888368|Procedure|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
31563|NCT00888381|Biological|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
31564|NCT00888394|Procedure|chiropody|basic procedure of chiropody in podiatry
31565|NCT00888394|Procedure|basic orthesis|individual basic orthesis of foot
31566|NCT00888394|Procedure|advantage orthesis|advantage orthesis of foot with special material and design
31567|NCT00888394|Procedure|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
31568|NCT00014911|Drug|Pentamidine|An antiprotozoal used to prevent disease
31569|NCT00888407|Behavioral|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
31570|NCT00888407|Behavioral|Nutrition - Small group educational session|Small group session with diet & nutrition focused, topic related resources provided.
31571|NCT00888420|Other|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
31572|NCT00888433|Device|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
31573|NCT00888446|Biological|tgAAC09|
31574|NCT00888446|Biological|tgAAC09|
31575|NCT00888446|Biological|tgAAC09|
31576|NCT00888446|Other|Formulation buffer|Sterile isotonic buffered salt solution
30588|NCT00892073|Drug|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
30589|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given weekly
30590|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given monthly
30591|NCT00892099|Other|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
30592|NCT00892112|Drug|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
31324|NCT00890617|Drug|Prednisone|Prednisone taken:
20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure
31325|NCT00890630|Procedure|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
31326|NCT00890630|Drug|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
31327|NCT00890643|Drug|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
31328|NCT00890643|Drug|placebo|placebo
31329|NCT00882804|Drug|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in ~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
31330|NCT00882804|Drug|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
31331|NCT00882817|Other|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
31332|NCT00882830|Procedure|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
31333|NCT00882856|Drug|Bisoprolol|Bisoprolol "Vitabalnas" 10 mg once daily
31334|NCT00882856|Drug|Placebo|placebo
31335|NCT00882869|Drug|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
31336|NCT00882869|Drug|Sorafenib|Sorafenib will be administered at 400 mg BID every day
31337|NCT00000801|Drug|Cyclophosphamide|
31338|NCT00014469|Drug|busulfan|
31339|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
31340|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
31341|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
31342|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
31343|NCT00882895|Procedure|Stem cell infusion|
33038|NCT00919997|Other|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
33039|NCT00919997|Procedure|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
33040|NCT00920010|Other|biologic sample preservation procedure|
33041|NCT00920023|Drug|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Three MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
33042|NCT00920036|Device|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
33043|NCT00920049|Behavioral|Persuasion|
33044|NCT00920062|Device|Ultrasound dilution recirculation measurements|Ultrasound dilution recirculation measurements will be made in patients receiving venovenous extracorporeal membrane oxygenation as treatment.
33045|NCT00912574|Drug|Saline|For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
33046|NCT00912587|Drug|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
33047|NCT00912600|Other|Intensive Care Unit admission|Intensive Care Unit admission
33048|NCT00912613|Other|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
32122|NCT00881699|Behavioral|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
32123|NCT00881712|Radiation|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
32124|NCT00881712|Radiation|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
32125|NCT00881712|Radiation|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
32126|NCT00881725|Drug|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
32127|NCT00014352|Drug|ketoconazole|
31105|NCT00887445|Drug|placebo|
31106|NCT00887458|Drug|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
31107|NCT00887458|Drug|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
31108|NCT00887471|Procedure|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
31393|NCT00890786|Drug|Bevacizumab|High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.
High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.
Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.
Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days).
31394|NCT00890786|Drug|Irinotecan|High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.
Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days).
31395|NCT00890799|Device|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
31396|NCT00890799|Procedure|surgery|Patient in this group received open surgical repair of pmVSD.
31397|NCT00890825|Drug|AZD6244|oral capsules, 75mg twice daily
31398|NCT00890825|Drug|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
31399|NCT00890825|Drug|Placebo|placebo
31400|NCT00890838|Dietary Supplement|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
31401|NCT00890851|Procedure|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
31402|NCT00015548|Drug|Olanzapine|
31403|NCT00890864|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
31404|NCT00890877|Drug|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
31405|NCT00890890|Drug|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
31406|NCT00890890|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
31407|NCT00890916|Device|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
30593|NCT00015704|Drug|Aldesleukin|
30594|NCT00892112|Drug|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
30595|NCT00892125|Drug|paliperidone ER; Carbamazepine|
30596|NCT00892138|Behavioral|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
30597|NCT00892151|Device|GLUCOFACTS® Deluxe|Diabetes Data Management Software
30598|NCT00892164|Device|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
30599|NCT00892164|Device|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
30600|NCT00015977|Biological|PSA prostate cancer vaccine|
30601|NCT00894712|Device|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
30602|NCT00894725|Procedure|laparoscopic left colonic resection|laparoscopic colonic resection
30603|NCT00894725|Procedure|open left colonic resection|conventional open colonic resection
30604|NCT00894738|Procedure|Testing (MRS, US, DEXA)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
30605|NCT00894751|Drug|dexmedetomidine|dexmedetomidine general anesthesia for MRI
30606|NCT00894751|Drug|propofol|propofol general anesthesia for MRI
30607|NCT00894777|Other|Clinical record review|
30608|NCT00894790|Drug|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
30609|NCT00894790|Drug|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
30937|NCT00889889|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
30938|NCT00889889|Biological|Placebo|Placebo
30939|NCT00889915|Drug|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
30940|NCT00889915|Drug|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
31344|NCT00882895|Procedure|TLI|
31639|NCT00886015|Device|TT Clamp|trichiasis surgery performed with TT clamp
31640|NCT00886015|Procedure|Standard BTRP Technique|bilamellar tarsal rotation procedure in trichiasis surgery
31641|NCT00886028|Drug|Liposomal doxorubicin|Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.
Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
31642|NCT00886028|Drug|Cisplatin|Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
31643|NCT00886041|Procedure|laparoscopy|subjected to laparoscopy
31644|NCT00886041|Other|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
31645|NCT00886067|Drug|AZD1446|Solution, oral, single dose
31646|NCT00886067|Radiation|2-[18F]-F-A85380|iv, single dose
31647|NCT00014612|Procedure|lymphoscintigraphy|
31648|NCT00888459|Drug|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
31649|NCT00888459|Drug|placebo NRT|Placebo nicotine lozenges
31650|NCT00014937|Drug|lopinavir/ritonavir|
31651|NCT00888472|Procedure|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
31652|NCT00888485|Behavioral|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
31653|NCT00888498|Other|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
31654|NCT00888498|Other|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
32128|NCT00881738|Drug|Clarithromycin 250 mg Tablets (Geneva, USA)|
32129|NCT00881738|Drug|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
32130|NCT00881751|Biological|bevacizumab|Given IV
32131|NCT00881751|Drug|erlotinib hydrochloride|Given orally
32132|NCT00881751|Drug|sorafenib tosylate|Given orally
32133|NCT00881764|Procedure|Inguinal hernia surgery|Non-experimental procedure
32134|NCT00881764|Procedure|General anesthesia|Non-experimental procedure/treatment
32135|NCT00881777|Procedure|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
32136|NCT00884286|Drug|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
32137|NCT00884299|Dietary Supplement|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
32138|NCT00884312|Drug|Carfilzomib|IV push on Days 1, 2, 15, and 16 of a 28 day cycle (e.g., every other week)
32139|NCT00884325|Drug|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
32140|NCT00884325|Drug|placebo|One tablet taken orally at night for 28 days
32424|NCT00911612|Drug|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
32425|NCT00017290|Biological|keyhole limpet hemocyanin|
32426|NCT00911612|Drug|Placebo|Inert capsule matching the study drug, given twice daily
32427|NCT00911625|Drug|Glargine & glulisine|insulin dose will be 0.6 units/kg. Half of this will be given as glargine once daily. The other half will be given as glulisine, divided equally between breakfast, lunch, and dinner
32428|NCT00911625|Drug|Glargine & glulisine|total daily insulin dose will be 0.3 units/kg. Half of this will be given as glargine in the morning. The other half will be given as glulisine, divided equally between breakfast, lunch, and dinner
31408|NCT00890929|Drug|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
31409|NCT00890929|Drug|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
31410|NCT00890942|Drug|naloxone|naloxone 0.4mg.(1 ml) intramuscular
31411|NCT00890942|Drug|normal saline|normal saline 1 ml IM
31412|NCT00890955|Drug|Amrubicin|Dose Level -1: 20mg/m2
Dose Level 1: 25mg/m2
Dose Level 2: 30mg/m2
Dose Level 3: 35mg/m2
Dose Level 4: 40mg/m2
Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle.
31413|NCT00015548|Drug|Quetiapine|
31721|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
31722|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
31723|NCT00886106|Drug|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
31724|NCT00886106|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
31725|NCT00886119|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
31726|NCT00886119|Device|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
31727|NCT00886132|Drug|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
31728|NCT00886145|Device|Mechanical Stimulation with the Vibration Plate|All subjects will undergo mechanical intervention in the seated position 5 sessions a week, with each session lasting up to 20 minutes in duration for 6 months. Subject participation will involve seven visits to the laboratory. The baseline (BL) visit, subjects will receive instruction on the use of and receive the equipment needed for vibration plate therapy at home. Training sessions will be recorded directly on the vibrating plate and compliance will be assessed during the monthly visits.
Testing will be performed at BL, 1, 3 and 6 months will involve the following: Dual energy X-ray absorptiometry (DXA), Blood Samples, 24 hour Urine and Vitamin D and Calcium Administration. Peripheral Quantitative Computed Tomography (pQCT) will be assessed only at BL and 6 months.
31729|NCT00886171|Behavioral|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
31730|NCT00014612|Procedure|therapeutic conventional surgery|
31731|NCT00886171|Behavioral|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
30941|NCT00889915|Drug|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
30942|NCT00889915|Drug|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
30943|NCT00889928|Device|NOTES GEN 1 Toolbox|Articulating Hook Knife
Articulating Snare
Articulating Needle Knife
Articulating Graspers
Articulating Biopsy Forceps
Steerable Flex Trocar with Rotary Access Needle
Flexible Bipolar Hemostasis Forceps
Flexible Maryland Dissector
30944|NCT00015132|Drug|Sertraline|
30945|NCT00889941|Procedure|LASIK|laser-assisted in situ keratomileusis
30946|NCT00889954|Genetic|TGFBeta resistant HER2/EBV-CTLs|Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).
Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals.
30947|NCT00889967|Drug|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
30948|NCT00889967|Drug|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
30949|NCT00889967|Drug|Placebo|Placebo once daily by inhalation for 28 days
30950|NCT00889980|Other|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
30951|NCT00889993|Dietary Supplement|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
30952|NCT00890006|Procedure|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
30953|NCT00890019|Biological|AdCh63 ME-TRAP|A:Intradermal injection 1x10^8 vp at day 0
A:Intradermal injection 1x10^9 vp at day 0
A:Intradermal injection 1x10^10 vp at day 0
A:Intradermal injection 5x10^10 vp at day 0
5:Intramuscular injection 1x10^10 vp at day 0
6A:Intramuscular injection 5x10^10 vp at day 0
7A: Intramuscular injection 2x10^11 vp at day 0
30954|NCT00882154|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
30955|NCT00882154|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
30956|NCT00882167|Other|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
31262|NCT00885313|Drug|DHA250|DHA 250 mg/kg/d
31263|NCT00885313|Drug|DHA500|DHA 500 mg/kg/d
31264|NCT00885313|Drug|PLACEBO|placebo
31655|NCT00888498|Other|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
31656|NCT00888511|Drug|Tarceva|Tarceva 150 mg/day
30683|NCT00899054|Radiation|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
30684|NCT00899080|Genetic|gene expression analysis|
30685|NCT00016302|Drug|pegaspargase|Given IM
30686|NCT00892177|Biological|bevacizumab|Given intravenously
30687|NCT00892177|Drug|dasatinib|Given orally
30688|NCT00892177|Other|placebo|Given orally
30689|NCT00892190|Drug|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
30690|NCT00000808|Drug|Nevirapine|
30691|NCT00015769|Drug|levetiracetam|
30692|NCT00892190|Drug|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
30693|NCT00892203|Drug|BGG492|
30694|NCT00892203|Drug|Sumatriptan|
30695|NCT00892203|Drug|Placebo|
30696|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
30697|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
30698|NCT00892229|Drug|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
30699|NCT00892229|Drug|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
30700|NCT00892242|Drug|Zoledronic acid|
32429|NCT00911638|Behavioral|Patient decision aid|Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.
iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.
iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference).
32430|NCT00911638|Behavioral|Usual care|Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.
ii) Referral onward to surgeon with a standardized report of clinical findings only
32431|NCT00911651|Drug|Salbutamol|400 µg inhalation once
32432|NCT00911651|Drug|ipratropium bromide|80 µg inhalation once
32433|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
32434|NCT00911664|Drug|No supplementation|Control
32435|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
32436|NCT00914095|Drug|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
32437|NCT00914095|Drug|placebo|tablets of placebo 3 times a day
32438|NCT00914108|Behavioral|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
32439|NCT00914121|Drug|SKI-606|
32440|NCT00914121|Drug|Placebo|
32441|NCT00914121|Drug|Moxifloxacin|
32699|NCT00912041|Device|Placement of the BrainGate2 sensor into the motor cortex|The 4x4 mm BrainGate2 sensor is placed into the motor cortex, connected to a percutaneous pedestal. Neural recordings are made at least weekly for a year or more.
32700|NCT00912054|Drug|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
32701|NCT00912054|Drug|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
32702|NCT00017303|Drug|paclitaxel|
31732|NCT00886184|Procedure|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
31733|NCT00886184|Procedure|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
31734|NCT00886210|Procedure|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
31735|NCT00886210|Procedure|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
31736|NCT00886223|Procedure|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
31737|NCT00888628|Biological|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
30778|NCT00899132|Genetic|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
30779|NCT00899132|Genetic|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
30780|NCT00899132|Other|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
30781|NCT00016302|Radiation|radiation therapy|Undergo craniocervical radiotherapy
30782|NCT00899145|Other|Laboratory Biomarker Analysis|Correlative studies
30783|NCT00899158|Other|immunologic technique|
30784|NCT00899158|Other|laboratory biomarker analysis|
30785|NCT00899158|Procedure|biopsy|
30786|NCT00899171|Genetic|DNA analysis|
30787|NCT00899171|Genetic|DNA methylation analysis|
30788|NCT00899171|Genetic|RNA analysis|
30789|NCT00899171|Genetic|gene expression analysis|
31265|NCT00014573|Drug|paclitaxel|
31266|NCT00885313|Behavioral|Lifestyle intervention|lifestyle intervention [including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity], for 12 months.
31267|NCT00885326|Drug|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
31268|NCT00885326|Drug|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
31269|NCT00885326|Drug|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
31270|NCT00885352|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
31271|NCT00885352|Drug|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
31272|NCT00885352|Drug|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
31273|NCT00885352|Drug|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
31274|NCT00885352|Drug|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
31275|NCT00885365|Drug|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
31276|NCT00014573|Procedure|autologous bone marrow transplantation|
31277|NCT00885365|Drug|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
31278|NCT00885378|Drug|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
31279|NCT00885378|Drug|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
31577|NCT00890656|Drug|Cyclophosphamide (CTX)|300 mg/m^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
30701|NCT00892255|Device|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
30702|NCT00015795|Device|airway interruption test|
30703|NCT00892268|Procedure|acupuncture therapy|Undergo acupuncture
30704|NCT00892268|Procedure|pain therapy|Receive standard care
30705|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
30706|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
31025|NCT00887419|Behavioral|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
31026|NCT00887432|Dietary Supplement|Cholecalciferol|Given PO
31027|NCT00887432|Other|Laboratory Biomarker Analysis|Correlative studies
31028|NCT00887432|Other|Patient Observation|
31029|NCT00014768|Drug|glucose|
31030|NCT00887432|Drug|Placebo Administration|Given PO
31031|NCT00887432|Other|Quality-of-Life Assessment|Ancillary studies
31032|NCT00887432|Other|Questionnaire Administration|Ancillary studies
31033|NCT00890019|Biological|AdCh63 ME-TRAP; MVA ME-TRAP|B: AdCh63 ME-TRAP intradermally at dose of 1x10^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
B: AdCh63 ME-TRAP intradermally at dose of 1x10^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
B: AdCh63 ME-TRAP intradermally at dose of 1x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
B: AdCh63 ME-TRAP intradermally at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
31034|NCT00015171|Drug|Buprenorphine/naloxone|
31035|NCT00890032|Biological|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10^6, 5x10^6, and 2x10^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
31036|NCT00890045|Device|HeRO Vascular Access Device|HeRO Vascular Access Device
31037|NCT00890045|Device|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
32703|NCT00912080|Genetic|genomic signature|genomic signature analysis
32704|NCT00912093|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
32705|NCT00912093|Drug|Placebo|Single subcutaneous injection of matching placebo
32706|NCT00912106|Other|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
32707|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
32708|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
32709|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
32710|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
32711|NCT00000824|Drug|Lymphocytes, Activated|
32712|NCT00017394|Other|laboratory biomarker analysis|Correlative studies
32713|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
32714|NCT00914589|Drug|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
32715|NCT00914602|Drug|XP21279|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
32716|NCT00914602|Drug|Sinemet®|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
32717|NCT00914602|Drug|Lodosyn®|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
33049|NCT00912626|Behavioral|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
33050|NCT00912639|Drug|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
30790|NCT00899171|Genetic|reverse transcriptase-polymerase chain reaction|
30791|NCT00899171|Other|laboratory biomarker analysis|
30792|NCT00016302|Other|pharmacological study|Correlative studies
30793|NCT00899184|Genetic|polymorphism analysis|
30794|NCT00899184|Other|laboratory biomarker analysis|
30795|NCT00899197|Drug|tamoxifen citrate|
30796|NCT00899197|Genetic|gene expression analysis|
30797|NCT00899197|Genetic|protein expression analysis|
30798|NCT00899197|Other|immunoenzyme technique|
30799|NCT00899197|Other|laboratory biomarker analysis|
30800|NCT00015808|Drug|Idebenone|
30801|NCT00892385|Genetic|DNA analysis|Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects. Samples are analyzed for DNA strand break determination by comet assay.
31109|NCT00887484|Drug|Clindoxyl gel|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply clindoxyl gel to the entire face for an additional 6 weeks.
31110|NCT00887484|Drug|Epiduo Gel|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply clindoxyl gel to the entire face for an additional 6 weeks.
31111|NCT00014768|Drug|insulin|
31112|NCT00887497|Procedure|Angioembolization|Angioembolization
31113|NCT00887510|Drug|Hydrochlorothiazide|25 mg tablet once daily for 6 weeks
Other Names:
HCTZ
31114|NCT00887510|Drug|Trandolapril|4 mg tablet once daily for 6 weeks
31115|NCT00887523|Behavioral|radiation in prone position|radiation in prone position
31116|NCT00887523|Behavioral|radiation in supine position|radiation in supine position
31117|NCT00887536|Drug|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
31118|NCT00887536|Drug|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
31578|NCT00890656|Drug|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
31579|NCT00890656|Drug|Doxorubicin|50 mg/m^2 by vein (IV) over 24 hours
31580|NCT00890656|Drug|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
31581|NCT00000806|Drug|Telinavir|
31582|NCT00015301|Drug|Methylphenidate|
31583|NCT00890656|Drug|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
31584|NCT00890656|Drug|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
31585|NCT00890656|Drug|Ara-C|3 gm/m^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
31586|NCT00890656|Drug|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
31587|NCT00890669|Other|Treadmill walking training with additional body load|The training program was divided into three phases (A1-B-A2):
treadmill training with additional body load (A1),
control condition (conventional physical therapy group) (B). and
treadmill training with additional body load again (A2).
Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle.
31588|NCT00890682|Drug|SKY0402|Local infiltration of 8cc SKY0402
31589|NCT00890682|Drug|Placebo|Local infiltration of 8cc Placebo
31590|NCT00890695|Dietary Supplement|Ready to Use Supplementary Food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
31591|NCT00890708|Drug|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
31592|NCT00890721|Drug|SKY0402|During the operation, 30cc of SKY0402 are injected into the wound.
31593|NCT00015340|Drug|Buprenorphine/naloxone|
31594|NCT00890721|Drug|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
31595|NCT00890734|Drug|CYT003-QbG10|subcutaneous injection
31596|NCT00890734|Drug|Placebo|subcutaneous injection
31597|NCT00890747|Drug|sunitinib malate|Given PO
31598|NCT00890747|Other|pharmacological study|Correlative studies
31038|NCT00890071|Other|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
31039|NCT00890084|Drug|Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)|Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
31040|NCT00890097|Drug|AL-8309B Ophthalmic Solution|
31041|NCT00890097|Drug|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
31042|NCT00890110|Biological|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
31043|NCT00890123|Dietary Supplement|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
31044|NCT00890149|Drug|Ondansetron + BASICS Plus|Ondansetron (4ug/kg bid), Brief Alcohol Screening and Intervention for College Students
31345|NCT00882895|Drug|Anti-thymocyte globulin|
31346|NCT00882895|Drug|Solumedrol|
31347|NCT00882895|Drug|Tacrolimus|
31348|NCT00882895|Drug|Mycophenolate mofetil|
31349|NCT00014469|Drug|melphalan|
31350|NCT00882908|Drug|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
31351|NCT00882908|Drug|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
31352|NCT00882908|Drug|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
31353|NCT00882908|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
31354|NCT00882921|Biological|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
31355|NCT00882934|Other|Induction to efficient treatment|Informative letters.
31356|NCT00882934|Other|Doubt to the efficacy of treatment|Informative letters.
31357|NCT00885404|Drug|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
33051|NCT00912652|Behavioral|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
33052|NCT00017355|Biological|filgrastim|
33053|NCT00912652|Behavioral|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
33054|NCT00912665|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
33055|NCT00912665|Device|Goldmann applanation tonometer|intraocular pressure measurements
33056|NCT00912665|Other|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
33057|NCT00912665|Device|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
33058|NCT00912678|Drug|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
33059|NCT00912678|Drug|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
33060|NCT00912691|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
33061|NCT00912743|Drug|olaparib|400 mg po bid continuously
33062|NCT00912756|Drug|cilostazol|200 mg/day BID
33063|NCT00017355|Biological|therapeutic autologous dendritic cells|
33064|NCT00912782|Drug|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
33065|NCT00912782|Drug|Placebo|Placebo one time per week for 3 weeks
33066|NCT00912795|Behavioral|SMS Turkey|6-week smoking cessation program delivered via text messaging
33067|NCT00912808|Drug|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
33068|NCT00912808|Drug|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
33069|NCT00915187|Drug|CCS/C|Adjuvant to influenza vaccine
33070|NCT00017459|Drug|vinorelbine tartrate|
33071|NCT00915187|Biological|Influenza Vaccine|Influenza vaccine
31850|NCT00881192|Procedure|IABP|preoperative IABP placement
31119|NCT00887536|Drug|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
31120|NCT00887536|Drug|cyclophosphamide|Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles
31121|NCT00887536|Drug|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles [filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.]
31122|NCT00014768|Drug|leucine|
31123|NCT00887549|Drug|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
31124|NCT00887549|Drug|cisplatin|Induction Therapy: 75 mg/m^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
31125|NCT00887562|Drug|Idebenone|900 mg/day for 1 month
31126|NCT00887562|Drug|Idebenone|2250 mg/day for one month
31127|NCT00887562|Other|Placebo|Placebo - No idebenone
31128|NCT00887575|Drug|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
31414|NCT00882934|Other|Induction to ineffective treatment|Informative letters
31415|NCT00882947|Drug|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
31416|NCT00882960|Drug|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
31417|NCT00014469|Drug|methotrexate|
31418|NCT00882960|Drug|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
31419|NCT00882973|Drug|Genexol-PM and gemcitabine|
31420|NCT00882999|Drug|LY2127399|Injection: 6 doses, one every 4 weeks or every 12 weeks for 24 weeks.
31421|NCT00882999|Drug|Placebo|Injection: Every 4 weeks in the placebo arm for 24 weeks. Every 4 weeks in the LY arms for 24 weeks (except week 12 and week 24).
31422|NCT00883012|Biological|Trivalent sub-unit influenza vaccine|Composition per 0.5 ml dose:
Active substance:
Split Influenza virus*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms**, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms**, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms** Two doses, one month apart
31599|NCT00890747|Other|laboratory biomarker analysis|Correlative studies
30610|NCT00894803|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
30611|NCT00015977|Biological|recombinant interleukin-12|
30612|NCT00894803|Drug|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
30613|NCT00894816|Dietary Supplement|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
30614|NCT00894816|Dietary Supplement|Placebo|Infant cereals without any addition
30615|NCT00894829|Biological|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
30616|NCT00894829|Biological|heparin sodium - APP|Heparin sodium APP 5.000 USP
30617|NCT00894842|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
30618|NCT00894842|Drug|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
30619|NCT00894855|Behavioral|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
30620|NCT00894855|Behavioral|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
30621|NCT00894855|Other|dermatologist skin exam|Full body skin exam.
30622|NCT00015990|Drug|thalidomide|Given orally
30623|NCT00894868|Drug|vildagliptin|
30624|NCT00896896|Other|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
30625|NCT00896896|Other|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
30626|NCT00896909|Genetic|gene expression analysis|
31358|NCT00885417|Drug|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
31359|NCT00885430|Drug|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
31360|NCT00885443|Drug|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
31361|NCT00885443|Drug|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
31362|NCT00885456|Behavioral|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
31363|NCT00885456|Behavioral|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
31364|NCT00014573|Procedure|conventional surgery|
31657|NCT00888511|Radiation|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
31658|NCT00888524|Procedure|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
31659|NCT00888524|Procedure|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
31660|NCT00888537|Other|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
31661|NCT00014937|Drug|lamivudine/zidovudine|
31662|NCT00888537|Other|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
31663|NCT00888550|Procedure|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
31664|NCT00888550|Procedure|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
31665|NCT00888602|Dietary Supplement|3.4 g psyllium|3.4 g psyllium served with meal
31666|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium served with a meal
31667|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium
31851|NCT00881205|Drug|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
31852|NCT00881205|Drug|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
31853|NCT00881218|Drug|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
31854|NCT00014339|Drug|Wobe-Mugos E|
31855|NCT00881231|Drug|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
31856|NCT00881231|Drug|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
31857|NCT00881244|Drug|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
31858|NCT00881257|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
31859|NCT00881270|Drug|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
31860|NCT00881296|Drug|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
31861|NCT00881296|Drug|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
31862|NCT00881309|Drug|Tripterygium|TW 90mg/d
31863|NCT00881322|Dietary Supplement|BC-130 (Gas Defense)|Product Dosing:
Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)
Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish.
31864|NCT00881322|Dietary Supplement|Placebo|Product Dosing:
Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)
Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule
31865|NCT00000205|Drug|Buprenorphine|
31866|NCT00000801|Drug|Vincristine sulfate|
31867|NCT00014339|Drug|melphalan|
31868|NCT00881335|Device|flutter mucus clearance device|five minutes every sessions, three sessions per day
31869|NCT00883779|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
31423|NCT00883012|Biological|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
31424|NCT00883038|Other|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
31425|NCT00883038|Other|low-fat vegetarian diet|The low-fat vegetarian diet (~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
31426|NCT00883051|Drug|COL-144|Oral application of one dose of either COL-144 50 mg, COL-144 100 mg, COL-144 200 mg, COL-144 400 mg or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
31427|NCT00883051|Drug|Placebo|Placebo
31428|NCT00014469|Drug|tacrolimus|
31429|NCT00883064|Drug|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
31430|NCT00883064|Drug|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
31431|NCT00883090|Biological|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
31432|NCT00883103|Drug|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
31433|NCT00883103|Drug|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
31738|NCT00014937|Drug|efavirenz|
31739|NCT00888628|Drug|Etanercept|Given as induction for islet cell transplant
31740|NCT00888641|Procedure|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
31741|NCT00888654|Drug|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
31742|NCT00888654|Procedure|Radical Prosatectomy|
31743|NCT00888667|Other|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
31744|NCT00888680|Drug|BGC20-1531|BGC20-1531 administered orally
31745|NCT00888680|Drug|Lactose|Placebo administered orally
31746|NCT00888693|Drug|ABT-288|See Arm Description for details.
30627|NCT00016133|Procedure|adjuvant therapy|
30628|NCT00896909|Genetic|mutation analysis|
30629|NCT00896909|Genetic|polymerase chain reaction|
30630|NCT00896909|Other|diagnostic laboratory biomarker analysis|
30957|NCT00882180|Drug|ALN-VSP02|IV infusion administered every two weeks
30958|NCT00882193|Drug|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
30959|NCT00014391|Drug|ribavirin|
30960|NCT00882193|Drug|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
30961|NCT00882193|Drug|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight < or > 75mg in 2 divided doses
30962|NCT00882206|Drug|cytarabine|At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
30963|NCT00882206|Drug|decitabine|Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
30964|NCT00882206|Drug|doxorubicin hydrochloride|Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
30965|NCT00882206|Drug|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age <18 years and 400 mg orally every day for >18 years on Days 5-33.
30966|NCT00882206|Drug|methotrexate|**Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
30967|NCT00882206|Drug|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
30968|NCT00882206|Drug|prednisone|40mg/m2/day divided BID (days 5 - 33)
30969|NCT00882206|Drug|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
30970|NCT00014404|Drug|celecoxib|
30971|NCT00882206|Drug|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
30972|NCT00882219|Device|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
30973|NCT00882232|Device|Cross-linked hyaluronan gel|Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3" to 2/3" at the start of radiotherapy.
31668|NCT00888602|Other|Meal|meal
31669|NCT00888615|Drug|Elesclomol Sodium|Given IV
31670|NCT00888615|Drug|Paclitaxel|Given IV
31671|NCT00890955|Drug|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
31672|NCT00890968|Drug|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
31673|NCT00890968|Drug|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
31674|NCT00890981|Procedure|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
31675|NCT00890981|Procedure|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
31676|NCT00890981|Biological|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
31677|NCT00890981|Drug|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
31678|NCT00891007|Biological|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
31679|NCT00891007|Biological|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
30707|NCT00892307|Radiation|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
30708|NCT00892320|Drug|ER OROS paliperidone|
30709|NCT00892346|Procedure|Single ASCT with Thalidomide maintenance|Single ASCT with Thalidomide maintenance:
Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)
Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)
30710|NCT00892359|Drug|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
30711|NCT00892385|Drug|methoxyamine|Methoxyamine IV over 1 hour every 28 days. Methoxyamine IV administration will follow, within 5 minutes, initial administration of TMZ on day 1.
30712|NCT00892385|Drug|temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
30713|NCT00894868|Drug|placebo of vildagliptin|
30714|NCT00894881|Procedure|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
31870|NCT00014508|Drug|cyclosporine|
30896|NCT00884767|Drug|FOLFOX regimen|
30897|NCT00884767|Drug|fluorouracil|
30898|NCT00884767|Drug|leucovorin calcium|
30899|NCT00884767|Drug|oxaliplatin|
30900|NCT00884767|Genetic|gene expression analysis|
30901|NCT00884767|Genetic|protein expression analysis|
30902|NCT00884767|Genetic|proteomic profiling|
30903|NCT00884767|Other|laboratory biomarker analysis|
30904|NCT00014573|Biological|aldesleukin|
30905|NCT00884767|Other|pharmacogenomic studies|
30906|NCT00884793|Drug|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
30907|NCT00884793|Drug|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
30908|NCT00884793|Drug|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
30909|NCT00884806|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
30910|NCT00884806|Device|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
30911|NCT00884806|Device|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
30912|NCT00887263|Drug|Budesonide|3 mg TID
30913|NCT00887263|Drug|Placebo|0 mg TID
30914|NCT00887276|Drug|Moxifloxacin|intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)
20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes
20 ml physiologic saline solution (placebo) (over 30 min)
20 ml physiologic saline solution (placebo) (over 30 min)
following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):
1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo
2 capsules Placebo
2 capsules Placebo
Total time of the therapy:at least 7 days, but at most 10 days
31747|NCT00888693|Drug|Placebo|See Arm Description for details.
31748|NCT00888706|Behavioral|Control Condition|The group participated in the usual nursing home activities and routines.
31749|NCT00014937|Drug|lamivudine|
31750|NCT00888706|Behavioral|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
31751|NCT00888706|Behavioral|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
31752|NCT00888706|Behavioral|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
31753|NCT00888719|Drug|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
31754|NCT00888719|Drug|placebo|Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.
Twice a day, 1 tablet at a time for 12 weeks
31755|NCT00888719|Drug|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
31756|NCT00888732|Drug|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
31757|NCT00888745|Drug|placebo|Intravenous and subcutaneous ascending dose
31758|NCT00888745|Drug|PRO283698|Intravenous and subcutaneous ascending dose
31759|NCT00888758|Device|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
30802|NCT00892385|Other|laboratory biomarker analysis|Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects. Samples are analyzed for apurinic/apyrimidinic sites.
30803|NCT00892385|Other|pharmacological study|Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects. Samples are analyzed for methoxyamine and temozolomide pharmacokinetics.
30804|NCT00892398|Drug|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
30805|NCT00892398|Procedure|standard care|standard post-operative care after trabeculectomy with mitomycin C
30974|NCT00882245|Other|Vehicle ointment|Topical vehicle cream
30975|NCT00882245|Drug|Ointment|SRD441 Ointment
30976|NCT00882258|Drug|12.5 mg Proellex|12.5 mg Proellex administered orally daily
30977|NCT00882258|Drug|25 mg Proellex|25 mg Proellex administered orally daily
30978|NCT00882258|Drug|Placebo|Administered orally daily
30979|NCT00882271|Other|Acupuncture|Ten Acupuncture treatments within six weeks
31280|NCT00887757|Drug|ABT-263|150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.
325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.
This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
31281|NCT00887757|Drug|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
31282|NCT00887770|Drug|AZD5672|12 x 50mg tablet, oral, single dose
31283|NCT00887770|Drug|Moxifloxacin|1 x 400mg capsule, oral, single dose
31284|NCT00887770|Drug|placebo|12 x matched to AZD5672 50 mg tablet
31285|NCT00014911|Procedure|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
31286|NCT00887770|Drug|AZD5672|3 x 50mg tablet, oral. single dose
31287|NCT00887770|Drug|placebo|9 x matched to AZD5672 50mg tablet
31288|NCT00887770|Drug|placebo|1 x matched to Moxifloxacin capsule
31289|NCT00887783|Drug|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
31290|NCT00887783|Radiation|irradiation-66 Gy|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
31291|NCT00887783|Radiation|irradiation-60 Gy|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
31292|NCT00887809|Drug|gemcitabine|
31293|NCT00887809|Drug|docetaxel|
31294|NCT00887809|Drug|bevacizumab|
31295|NCT00887822|Drug|Placebo|iv every 3 weeks until disease progression
30715|NCT00894894|Drug|MP-470|escalating daily doses of amuvatinib
30716|NCT00894894|Drug|amuvatinib (MP-470)|escalating doses of daily amuvatinib
30717|NCT00894907|Other|PiCCO-parameter-guided volume resuscitation|Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:
ITBI: 850-1000 ml/sqm, if ELWI <=12*ml/kg; ITBI 750-850 ml/sqm, if ELWI >12*ml/kg and/or PaO2:FiO2 <200 (*ELWI<=12ml/kg, if MAP>65mmHg without catecholamines; ELWI<=14ml/kg, if catecholamines required for MAP>65mmHg); SVV<10% (only in controlled ventilation and sinus rhythm); MAP>65mmHg (MAP: Mean Arterial Pressure); IAPP >60mmHg (IAPP: Intra-abdominal Perfusion Pressure)
30718|NCT00894907|Other|Control-group|Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
Main haemodynamic goals: CVP 8-12 mmHg; MAP >65mmHg;IAPP >60mmHg
30719|NCT00894920|Dietary Supplement|biotin|capsule approximately 30 mcg daily 21 days
30720|NCT00894920|Dietary Supplement|biotin|capsule 300 mcg daily 21 days
30721|NCT00894933|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
30722|NCT00015990|Other|laboratory biomarker analysis|Correlative studies
30723|NCT00894946|Procedure|Lipiodol + IVF|IVF preceded by lipiodol
30724|NCT00894946|Procedure|IVF|IVF alone
30725|NCT00894959|Biological|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
30726|NCT00894959|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
30727|NCT00894972|Other|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
31045|NCT00015210|Drug|Nefazodone|
31046|NCT00890149|Drug|Placebo + BASICS Plus|Placebo bid, Brief Alcohol Screening and Intervention for College Students
31047|NCT00890162|Drug|Epinephrine|
31048|NCT00890162|Procedure|Bone Marrow Apsiration|
31049|NCT00890162|Drug|Omalizumab (Xolair)|
31050|NCT00890175|Drug|Staccato Loxapine|2 doses 10 hours apart
31051|NCT00890175|Drug|Staccato Placebo|2 doses 10 hours apart
31052|NCT00890188|Drug|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
30915|NCT00887276|Drug|Ampicillin;Amoxicillin|intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)
following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):
2 capsules Amoxicillin (0,5 g)
2 capsules Amoxicillin (0,5 g)
2 capsules Amoxicillin (0,5 g)
Total time of the therapy: at least 7 days, but at most 10 days
31226|NCT00890461|Radiation|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
31227|NCT00890474|Procedure|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
31228|NCT00890487|Other|hyaluronic acid pill|pill, 220 mg, once a day, three months
31229|NCT00890500|Drug|Fludarabine|30mg/m2/day IV x 6 days
31230|NCT00890500|Drug|Melphalan|100 mg/m2/day IV x 1 day
31231|NCT00015249|Drug|Amantadine|
31232|NCT00890500|Drug|Antithymocyte Globulin|1mg/kg/day x 4 days
31233|NCT00890500|Drug|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
31234|NCT00890500|Drug|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
31235|NCT00890526|Other|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from ~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
31236|NCT00890526|Other|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
30806|NCT00892424|Drug|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
30807|NCT00892437|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
30808|NCT00892437|Drug|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
30809|NCT00892437|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
30810|NCT00892437|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
30811|NCT00015821|Drug|thalidomide|Given PO
30812|NCT00892437|Drug|COBI placebo|Placebo to match COBI administered orally once daily
30813|NCT00892437|Drug|RTV placebo|Placebo to match RTV administered orally once daily
30814|NCT00892450|Drug|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
30815|NCT00892463|Drug|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
30816|NCT00892476|Dietary Supplement|Calcium Supplementation|Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:
Amount of feeding Actual Weight < 1000 g Actual Weight < 1000 g
25 ml ¼ tsp 1/8 tsp
50 ml ½ tsp ¼ tsp
100 ml 1 tsp ½ tsp
200 ml 2 tsp 1 tsp
30817|NCT00892476|Other|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
30818|NCT00892489|Drug|ER OROS Paliperidone|
30819|NCT00892502|Drug|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
30820|NCT00892502|Drug|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
30821|NCT00892515|Behavioral|exercise intervention|
31129|NCT00890214|Drug|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
31130|NCT00015210|Behavioral|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
31296|NCT00014911|Drug|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
31297|NCT00887822|Drug|bevacizumab [Avastin]|7.5mg/kg every 3 weeks until disease progression
31298|NCT00887822|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle until disease progression
31299|NCT00887822|Drug|cisplatin|80mg/m2 iv every 3 weeks for a maximum of 6 cycles, or until disease progression
31300|NCT00887835|Device|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
31301|NCT00887848|Other|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
31600|NCT00890760|Biological|AdCh63 ME-TRAP|5 x 10*10 vp IM
31601|NCT00890760|Biological|MVA ME-TRAP|2 x 10*8 pfu ID
31602|NCT00890760|Other|Sporozoite challenge|Infected mosquito bite
31603|NCT00890760|Biological|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10*10 vp MVA ME-TRAP 2 x 10*8 pfu
31604|NCT00883311|Device|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
31605|NCT00883337|Drug|interferon β-1a|Sterile preservative-free solution packaged in graduated pre-filled syringes
Subcutaneous injection
Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®
31606|NCT00883337|Drug|teriflunomide|Film-coated tablet
Oral administration
31607|NCT00883350|Behavioral|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
31608|NCT00883363|Procedure|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
31609|NCT00883389|Device|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
31610|NCT00883402|Procedure|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
31053|NCT00890201|Procedure|Gallbladder bile sampling and intraoperative cholangiography|Interventions were exactly similar for both groups, and that is how it was intended to be:
Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.
Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished
31054|NCT00890214|Drug|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
31055|NCT00014430|Biological|trastuzumab|Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably.
31056|NCT00882310|Drug|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
31057|NCT00882310|Drug|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
31058|NCT00882310|Drug|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
31059|NCT00882323|Drug|Cyclophosphamide, Fludarabine, Thymoglobulin|cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)
fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)
thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)
31060|NCT00882362|Drug|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
31061|NCT00882375|Drug|Nicotine|Nicotine administered using novel NRT user instructions
31062|NCT00882375|Drug|Placebo|Placebo administered using novel NRT user instructions
31063|NCT00882388|Drug|aspirin|aspirin 100 mg qd for 7 days
31064|NCT00882388|Drug|celecoxib|celecoxib 200 mg bid * 7 days
31065|NCT00882388|Drug|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
31365|NCT00885482|Drug|Lamiduvine (Epivir)|Epivir 300 mg
31366|NCT00885482|Drug|Atazanavir (Reyataz)|Reyataz 300 mg
31367|NCT00885482|Drug|Ritonavir (Norvir)|Norvir 100 mg
31368|NCT00885495|Drug|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
31369|NCT00885495|Drug|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
31237|NCT00882635|Drug|enoxaparin|Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.
Maintenance dose adjustment for renal insufficiency - creatinine clearance < 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency
31238|NCT00882635|Drug|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
31239|NCT00882661|Device|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
31537|NCT00885768|Procedure|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
31538|NCT00885781|Drug|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
31539|NCT00014586|Procedure|orchiectomy|
31540|NCT00885794|Drug|Ranibizumab|3 intravitreal injection every 5 weeks
31541|NCT00885820|Drug|Tacrolimus|Oral
31542|NCT00885820|Drug|MMF|Oral
31543|NCT00885820|Drug|Corticosteroids (Prednisone)|Oral
31544|NCT00885833|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
31545|NCT00885846|Other|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
31546|NCT00885846|Other|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
31547|NCT00885859|Device|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
31548|NCT00885872|Drug|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
31131|NCT00890227|Procedure|Traditional technique|All level open instrumented posterior spinal fusions
31132|NCT00890227|Procedure|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
31133|NCT00890240|Drug|JNJ-31001074|
31134|NCT00890253|Drug|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
31135|NCT00890253|Drug|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
31136|NCT00890253|Drug|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
31137|NCT00890253|Drug|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
31138|NCT00890266|Procedure|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
31139|NCT00890279|Drug|Cilnidipine|Cilnidipine up to 20 mg
31140|NCT00890279|Drug|Imidapril|Imidapril up to 10 mg per day
31141|NCT00015223|Drug|Methylphenidate|
31142|NCT00890292|Drug|JNJ-31001074|
31143|NCT00890305|Drug|CT-011|
31144|NCT00890305|Drug|FOLFOX|FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.
mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours).
31145|NCT00890318|Drug|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
31146|NCT00890318|Other|ketoconazole|Tablet, see Arm Description for intervention information.
31147|NCT00890318|Drug|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
31148|NCT00890331|Behavioral|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
31434|NCT00883116|Drug|Ixabepilone|
31611|NCT00883415|Drug|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
31612|NCT00014495|Biological|filgrastim|
31613|NCT00883428|Other|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
31614|NCT00883441|Other|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
31615|NCT00883467|Procedure|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
31616|NCT00883467|Procedure|no preconditioning|no preconditioning
31617|NCT00883480|Drug|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
30631|NCT00896922|Genetic|microarray analysis|
30632|NCT00896922|Other|immunohistochemistry staining method|
30633|NCT00896922|Other|laboratory biomarker analysis|
30634|NCT00896935|Other|biologic sample preservation procedure|biologic sample preservation procedure
30635|NCT00896948|Genetic|Southern blotting|
30636|NCT00896948|Genetic|TdT-mediated dUTP nick end labeling assay|
30637|NCT00896948|Genetic|gene expression analysis|
30638|NCT00016146|Biological|GPI-0100|
30639|NCT00896948|Genetic|protein expression analysis|
30640|NCT00896948|Other|flow cytometry|
30641|NCT00896948|Other|fluorescent antibody technique|
30642|NCT00896948|Other|immunoenzyme technique|
30643|NCT00896948|Other|immunohistochemistry staining method|
30644|NCT00896948|Other|immunologic technique|
30645|NCT00896961|Drug|EF5|
30646|NCT00896961|Other|diagnostic laboratory biomarker analysis|
31370|NCT00885508|Drug|Lenalidomide|Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.
Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy
Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse
In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J
31371|NCT00885521|Other|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
31372|NCT00885534|Drug|Cisplatin, Vinblastine, Temozolomide|Patients will receive CVT chemotherapy which consists of the following:
Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1.
31373|NCT00885547|Drug|tripterygium wilfordii (TW)|90 mg/d for 6 months
31374|NCT00885573|Device|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
31375|NCT00014573|Procedure|peripheral blood stem cell transplantation|
31376|NCT00887900|Procedure|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
31377|NCT00014911|Drug|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
31378|NCT00887913|Device|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
31379|NCT00887926|Biological|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all patients in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Patients who experience a dose limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Patients may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
31680|NCT00891007|Biological|Rouvax|Standard measles vaccine, approved in South Africa
31681|NCT00015548|Drug|Risperidone|
31682|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous every 4 weeks for 24 weeks
31683|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|4 mg/kg every 4 weeks for 24 weeks
31684|NCT00891020|Drug|Nonbiologic DMARDs of investigator's choice|Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
31685|NCT00891033|Drug|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
31549|NCT00885885|Drug|Panitumumab+FOLFOX-4|Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.
A cycle of panitumumab is defined as 14 days.
FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:
Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle
Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2
A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2
5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2
31550|NCT00014599|Drug|paclitaxel|
31551|NCT00888316|Procedure|magnetic resonance imaging|MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.
The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC.
31552|NCT00888316|Procedure|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
31871|NCT00883779|Drug|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
31872|NCT00883792|Procedure|Colonoscopy|Once-only colonoscopy screening
31873|NCT00883805|Biological|Blood draw|Subjects will give blood for analysis of metal ion concentrations
31874|NCT00883805|Radiation|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
31875|NCT00883818|Drug|azithromycin, doxycycline|azithromycin 1g once for women with positive cultures at baseline
doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g
31876|NCT00883831|Procedure|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
31877|NCT00883844|Drug|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
31878|NCT00883844|Drug|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
31879|NCT00883870|Drug|mesenchymal stem cells|Intramuscular injection
31880|NCT00883870|Drug|Plasmalyte A|Intramuscular injection
31881|NCT00014508|Drug|fludarabine phosphate|
31882|NCT00883883|Drug|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
31435|NCT00883116|Drug|Doxorubicin|
31436|NCT00883116|Drug|Paclitaxel|
31437|NCT00883129|Drug|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
31438|NCT00885586|Device|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
31439|NCT00885586|Drug|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
31440|NCT00885586|Procedure|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
31441|NCT00885599|Drug|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
31442|NCT00885599|Drug|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
31443|NCT00885599|Drug|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
31444|NCT00885599|Drug|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
31445|NCT00885625|Biological|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
31446|NCT00885638|Drug|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
31447|NCT00885638|Drug|placebo|A placebo tablet is given before ingestion of macronutrients
31448|NCT00014586|Drug|bicalutamide|
31449|NCT00885651|Drug|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
31450|NCT00885651|Drug|Placebo|
31451|NCT00885664|Drug|Truvada (tenofovir/emitricitabine)|Tenofovir/emitricitabine fixed dose combination once daily
31452|NCT00885664|Drug|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
31453|NCT00885677|Device|Medtronic CareLink® Network|Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.
31454|NCT00885690|Drug|Sertindole|Sertindole 16-24 mg once daily
30647|NCT00896961|Other|pharmacological study|
30648|NCT00896974|Other|Laboratory Biomarker Analysis|Correlative studies
30649|NCT00016146|Biological|MUC-2-Globo H-KLH conjugate vaccine|
30650|NCT00896974|Other|Pharmacological Study|Correlative studies
30651|NCT00896974|Drug|Retinoid 9cUAB30|Given orally
30652|NCT00896987|Drug|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
30653|NCT00896987|Drug|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg~600 mg) and maintenance for 40 weeks (600 mg)
30654|NCT00897026|Drug|cyclophosphamide|
30655|NCT00897026|Drug|doxorubicin hydrochloride|
30656|NCT00898963|Other|immunologic technique|
30657|NCT00898976|Other|immunohistochemistry staining method|
30980|NCT00882297|Procedure|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
30981|NCT00884806|Device|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
30982|NCT00884806|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
30983|NCT00884819|Drug|Fenofibrate|fenofibrate 200 mg daily for 6-months
30984|NCT00014573|Biological|autologous tumor cell vaccine|
30985|NCT00884819|Other|Placebo|Placebo match for 6 months
30986|NCT00884832|Drug|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
30987|NCT00884832|Drug|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
30988|NCT00884845|Drug|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
30989|NCT00884845|Drug|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
30990|NCT00884858|Drug|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
32956|NCT00919711|Drug|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
32957|NCT00919737|Drug|NPC-08|Polifeprosan 20 with Carmustine 3.85%
32025|NCT00881504|Drug|"Bevacizumab" in combination with "modified FOLFOX6".|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay > 4 weeks
32026|NCT00014352|Drug|docetaxel|
32027|NCT00881517|Drug|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
32028|NCT00881517|Drug|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
32029|NCT00881530|Drug|BI 10773|BI 10773 high dose once daily
32030|NCT00881530|Drug|Metformin|open label comparator
32031|NCT00881530|Drug|BI 10773|BI 10773 low dose once daily
32032|NCT00881530|Drug|Sitagliptin|open label comparator
32033|NCT00881543|Drug|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
32034|NCT00881556|Drug|Reduced Intensity Transplant conditioning|Palifermin (Kepivance®) 60 mcg/kg/day for 6 days
Fludarabine 30 mg/m2 IV x 1 for 6 days
Busulfan 4 mg/kg/day IV divided BID for 4 days
Lorazepam 0.02-0.05 mg/kg for 5 days
Alemtuzumab 20 mg/m2 IV for 5 days
Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days
32035|NCT00881569|Drug|CS-7017|CS-7017 tablets twice daily at strength 0.25mg
32036|NCT00881582|Drug|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 & 4: 48 weeks; genotypes 2 & 3: 24 weeks)
32037|NCT00014352|Drug|doxorubicin hydrochloride|
32038|NCT00881595|Drug|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
32039|NCT00881595|Radiation|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
32040|NCT00881595|Procedure|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
32669|NCT00919503|Drug|Cyclosporine|Given IV or PO
32670|NCT00919503|Drug|Fludarabine Phosphate|Given IV
32671|NCT00017992|Drug|Emtricitabine|
32672|NCT00919503|Other|Laboratory Biomarker Analysis|Correlative studies
32673|NCT00919503|Drug|Methotrexate|Given IV
33012|NCT00917553|Drug|Placebo|Cellulose Placebo Capsule
33013|NCT00917566|Device|Airtraq|intubation with airtraq
33014|NCT00917566|Device|Macintoch|use Macintoch laryngoscope for intubation
33015|NCT00000826|Drug|Sulfamethoxazole-Trimethoprim|
33016|NCT00017680|Drug|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
33017|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
33018|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
33019|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
33020|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
33021|NCT00917605|Other|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
33022|NCT00917618|Other|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
33023|NCT00018031|Drug|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
33024|NCT00919919|Drug|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
33025|NCT00919919|Drug|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
32764|NCT00919841|Other|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
32765|NCT00018018|Drug|CD34+ cells transduced with ADA retrovir|
32766|NCT00919854|Drug|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
32767|NCT00919854|Drug|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
32768|NCT00919867|Drug|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
32769|NCT00919867|Drug|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
32770|NCT00919867|Drug|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
32771|NCT00919880|Drug|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
32772|NCT00919880|Drug|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
32773|NCT00919893|Drug|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
32774|NCT00919893|Drug|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
32775|NCT00919906|Device|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
32795|NCT00912275|Drug|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
32796|NCT00912288|Drug|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
32797|NCT00912288|Drug|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
32252|NCT00014547|Drug|BBR 3464|
32253|NCT00884598|Drug|cilengitide|
32254|NCT00884598|Other|pharmacological study|
32255|NCT00884598|Radiation|radiation therapy|
32256|NCT00884611|Device|Medtronic Real Time Continuous Glucose monitor|insulin pump delivery will be suspend when hypoglcyemia is predicted based on Medtronic real time continuous glucose monitor. Algorithym resides on a bedside computer
32257|NCT00884650|Drug|oral analgesic|per clinical standard of care
32258|NCT00884650|Drug|intravenous analgesic per pump|per clinical standard of care
32259|NCT00884663|Drug|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
32260|NCT00884663|Drug|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
32261|NCT00884663|Drug|placebo|placebo tablets and capsules
32262|NCT00884676|Drug|Ixabepilone|Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:
Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)
Schedule B: Day 1 of each 3-week cycle.
32263|NCT00014560|Biological|bispecific antibody 4G7xH22|
32264|NCT00884676|Drug|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
32265|NCT00887003|Drug|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
32266|NCT00887003|Drug|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
32267|NCT00887003|Drug|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
32268|NCT00887003|Drug|Depo-Medrol|80mg Depo-Medrol
32269|NCT00887029|Drug|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
32270|NCT00887029|Drug|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
32271|NCT00887042|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, & -6)
32272|NCT00887055|Device|CRT device|
32041|NCT00881608|Drug|Placebo|Placebo, 1 capsule daily for five days
32042|NCT00881608|Drug|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
32043|NCT00881621|Drug|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
32044|NCT00881634|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
32332|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
32333|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
32334|NCT00911443|Biological|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
32335|NCT00911443|Drug|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
32336|NCT00911456|Procedure|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
32337|NCT00911456|Procedure|Ultrasound Guided Imaging|Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.
About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals.
32338|NCT00017277|Radiation|radiation therapy|
32339|NCT00911456|Procedure|3 DUS|3 DUS
32340|NCT00911469|Drug|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
32341|NCT00911469|Drug|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
32342|NCT00911495|Drug|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
32343|NCT00911508|Device|Left atrial ablation|St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path
Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF
Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System
Bard: Stinger
Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath
33026|NCT00919932|Behavioral|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
33027|NCT00919932|Device|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
33028|NCT00919945|Other|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
32102|NCT00889343|Drug|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
32103|NCT00889343|Drug|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
32104|NCT00889356|Drug|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
32105|NCT00889356|Drug|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
32106|NCT00889369|Drug|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
32107|NCT00889382|Drug|OSI-906|Administered orally
32108|NCT00015028|Drug|Buprenorphine/naloxone|
32109|NCT00889382|Drug|Paclitaxel|Administered intravenously
32110|NCT00889395|Behavioral|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
32111|NCT00889408|Biological|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
32112|NCT00889421|Drug|Apremilast|oral dose of 30 mg BID for 6 months
32113|NCT00889434|Dietary Supplement|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
32114|NCT00881647|Other|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
32115|NCT00881660|Device|Goldballoon Detachable Balloon and delivery microcatheter|Between 22+0/7 - 29+ 6/7 weeks gestation, placement of the Goldvalve detachable balloon. At 34 weeks gestation (or a maximum of 10 weeks if placed prior to 24 weeks gestational age), removal of the balloon.
32116|NCT00014352|Drug|estramustine phosphate sodium|
32798|NCT00017407|Drug|carboplatin|
32799|NCT00914719|Behavioral|sexual risk reduction + alcohol risk reduction component|
32800|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
32801|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose [2x10^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose] by intradermal (ID) route on Days 0 and 28.
32802|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
32803|NCT00914745|Drug|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
32804|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
32805|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
32806|NCT00914797|Drug|inhaled and oral terbutaline|Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.
Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.
Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954.
32807|NCT00914810|Dietary Supplement|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
32808|NCT00914810|Dietary Supplement|Placebo|Placebo (sugar pill) daily for 6 weeks
32809|NCT00017407|Drug|paclitaxel|
32810|NCT00914823|Drug|kisspeptin 112-121|one or more intravenous doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
32811|NCT00914823|Drug|GnRH|One or more intravenous doses of GnRH
32812|NCT00914836|Drug|Betamethasone Sodium Phosphate|1cc:2cc
32813|NCT00914836|Drug|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
32814|NCT00914836|Drug|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
32815|NCT00914849|Drug|AMD3100|
32816|NCT00914849|Procedure|Leukopheresis|
31893|NCT00883935|Drug|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
31894|NCT00883935|Drug|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
32273|NCT00887068|Drug|Azacitidine|32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
32521|NCT00911807|Drug|Donepezil + placebo|Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
32522|NCT00911820|Drug|Bevacizumab|Given intravenously on day one of every 3 week cycle
32523|NCT00911820|Drug|Cisplatin|Given intravenously on days 1 and 8 of each three week cycle
32524|NCT00911820|Drug|Irinotecan|Given intravenously on days 1 and 8 of every three week cycle
32525|NCT00911820|Device|Docetaxel|Given intravenously on days 1 and 8 of every three week cycle.
32526|NCT00017290|Drug|prednisone|
32527|NCT00911846|Other|interview|interview using questionnaires
32528|NCT00914251|Drug|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
32529|NCT00914251|Drug|Placebo|Administration of oral Placebo, 500 mg/daily
32530|NCT00914264|Device|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 & 12 months
32531|NCT00914277|Drug|SAR407899|Oral administration
32532|NCT00914277|Drug|Placebo|Oral administration
32533|NCT00914277|Drug|Sildenafil|Oral administration
32534|NCT00914290|Drug|IPX056|Encapsulated IPX056
32535|NCT00017381|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
32536|NCT00914290|Drug|Baclofen|Encapsulated baclofen capsule
32537|NCT00914303|Drug|AZD3241|Oral Tablet, Repeated Administration
32538|NCT00914303|Drug|Placebo Tablet|Oral Tablet. Repeated Administration
32539|NCT00914316|Drug|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
32540|NCT00914316|Drug|Placebo|twice daily
32541|NCT00914329|Drug|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
32344|NCT00911508|Drug|Rate or Rhythm Control Therapy|Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg
Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg
32345|NCT00911521|Drug|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
32346|NCT00911534|Drug|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
32347|NCT00911534|Drug|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
32596|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
32597|NCT00911859|Drug|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
32598|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
32599|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
32600|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
32601|NCT00017290|Drug|vincristine sulfate|
32602|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
32603|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
32604|NCT00911872|Device|collagen (EVOLENCE)|injectable collagen
32605|NCT00911885|Behavioral|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
32606|NCT00911898|Drug|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
32607|NCT00911911|Procedure|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
32608|NCT00911911|Procedure|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
32609|NCT00911911|Procedure|SURGERY|Surgery after neoadjuvant chemotherapy
29097|NCT00871845|Behavioral|Dietary and Lifestyle modification educational sessions|6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
29098|NCT00871858|Drug|anastrozole|Given orally
29099|NCT00871858|Drug|fulvestrant|Given intramuscularly
29100|NCT00871871|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
29101|NCT00871871|Drug|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
29102|NCT00871871|Drug|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
29103|NCT00871871|Drug|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
29104|NCT00013286|Device|Prevention Diabetic Foot Ulcer|
29105|NCT00871884|Behavioral|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
29106|NCT00871884|Behavioral|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
29107|NCT00871884|Behavioral|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
29108|NCT00874107|Biological|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
29109|NCT00874107|Drug|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
29110|NCT00874107|Drug|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
29111|NCT00874120|Drug|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
28139|NCT00877799|Drug|Placebo|Matched placebo administered the day after surgery (Day 1)
28140|NCT00877799|Drug|Placebo|Matched placebo administered immediately after surgery (Day 0)
28141|NCT00877812|Dietary Supplement|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
31895|NCT00886366|Drug|AZD6714|Oral single doses d and g suspension
31896|NCT00886379|Dietary Supplement|Mongolian milk without vitamin D|710ml per day for 49 days
31897|NCT00886379|Dietary Supplement|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
31898|NCT00014638|Drug|letrozole|
31899|NCT00886379|Dietary Supplement|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
31900|NCT00886379|Dietary Supplement|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
31901|NCT00886379|Dietary Supplement|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
31902|NCT00886379|Dietary Supplement|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
31903|NCT00886405|Drug|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
31904|NCT00886418|Drug|muscle relaxant|muscle relaxant administration throughout anesthesia
31905|NCT00886418|Drug|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
31906|NCT00886431|Other|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
31907|NCT00886444|Drug|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
31908|NCT00886457|Drug|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
31909|NCT00014651|Drug|vapreotide|
31910|NCT00886470|Biological|ACCS (Amnion-derived Cytokine Suspension)|ACCS is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
31911|NCT00886483|Device|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
31912|NCT00886483|Device|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
32542|NCT00914329|Drug|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
32543|NCT00914329|Drug|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
32881|NCT00912379|Biological|hemoglobin determination|laboratory and non invasive hemoglobin determinations
32882|NCT00912392|Drug|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
32883|NCT00912392|Drug|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
32884|NCT00912405|Device|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
32885|NCT00912418|Biological|autologous tumor cells plus GM-CSF-in Adjuvant|Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.
Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods.
32886|NCT00017329|Drug|bortezomib|
32887|NCT00912431|Drug|ABT-126|ABT-126 administered on Day 1 of Period 1
32888|NCT00912431|Drug|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
32889|NCT00912444|Drug|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
32890|NCT00912444|Drug|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
32891|NCT00912457|Drug|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
32892|NCT00912457|Drug|placebo|placebo 1 p/day for 28 days
32893|NCT00912470|Procedure|ocular blood flow measurement|Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye
Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)
Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms
32894|NCT00912483|Biological|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
32895|NCT00914888|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|Subject with cIAI:
Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.
In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given.
32610|NCT00911924|Device|iStent|Glaukos iStent, medication
32611|NCT00911937|Drug|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
32612|NCT00017303|Drug|carboplatin|
32613|NCT00911937|Drug|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
32614|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 4 doses once daily or twice daily, 3 days
32615|NCT00914420|Device|Intrepide Trapidil eluting stent|The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.
The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia.
32958|NCT00919750|Other|cytology specimen collection procedure|Correlative studies
32959|NCT00018005|Other|attention control|18 educational mailings follow by a a telephone call.
32960|NCT00919763|Drug|CD 2027|Topical Ointment; two applications daily, once in the morning and once in the evening for 4 weeks
32961|NCT00919763|Drug|CD 2027 Vehicle|Topical Ointment, two applications daily, once in the morning and once in the evening for 4 weeks
32962|NCT00912483|Biological|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
32963|NCT00912496|Biological|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
32964|NCT00017342|Drug|bryostatin 1|
32965|NCT00912496|Biological|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal [0.01%(w/v)] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
32966|NCT00912496|Drug|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
32967|NCT00912509|Drug|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
32968|NCT00912509|Device|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
32969|NCT00912522|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
32970|NCT00912535|Drug|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
28142|NCT00877812|Dietary Supplement|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
28143|NCT00014118|Drug|carboplatin|
28144|NCT00877825|Procedure|dairy food control diet and high- and low- isoflavone soyfood diets|
28145|NCT00877838|Drug|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
28146|NCT00877838|Drug|Placebo|Gelatin capsules resembling the ones containing the active substance
28147|NCT00877851|Behavioral|CD-ROM|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the CD−ROM and some instructions on how to navigate around the different sections of the CD−ROM. As a minimum level of use, participants will be asked to use the self−monitoring and goal setting aspects of the CD−ROM on at least a weekly basis.
28148|NCT00877864|Behavioral|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
28149|NCT00877864|Behavioral|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
28150|NCT00880230|Device|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
28151|NCT00880243|Drug|GM-CSF|Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.
Randomiization 2: Consolidation high dose AraC versus consolidation EMA
28152|NCT00880256|Behavioral|mindfulness-based stress reduction|An 8-week course in mindfulness training
28153|NCT00880269|Drug|Panobinostat/LBH589|
28154|NCT00880282|Biological|cixutumumab|Given IV
28155|NCT00880282|Drug|temsirolimus|Given IV
28156|NCT00880282|Other|pharmacological study|Correlative studies
28157|NCT00014261|Biological|PEG-interferon alfa-2b|
28158|NCT00880282|Other|laboratory biomarker analysis|Correlative studies
28476|NCT00873184|Behavioral|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
32185|NCT00887003|Drug|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
32186|NCT00889434|Dietary Supplement|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
32187|NCT00889434|Dietary Supplement|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
32188|NCT00889460|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
32189|NCT00889460|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
32190|NCT00889473|Drug|Larazotide acetate (AT1001)|One capsule TID given with gluten or gluten placebo
32191|NCT00015041|Drug|Buprenorphine|
32192|NCT00889473|Drug|Placebo|One capsule TID given with gluten or gluten placebo
32193|NCT00889486|Drug|TZP-102|
32194|NCT00889486|Drug|Placebo|
32195|NCT00889499|Drug|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
32196|NCT00889499|Drug|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
32197|NCT00889499|Drug|Placebo|NHCL 0,9%
32198|NCT00889512|Drug|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
32199|NCT00889512|Drug|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
32200|NCT00889525|Drug|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
32201|NCT00889538|Drug|placebo|50 mL of 1/2 normal saline IV
32202|NCT00015054|Drug|Methylphenidate|
32203|NCT00889538|Drug|glutathione|glutathione 600 mg IV
32204|NCT00889538|Drug|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
32205|NCT00889564|Device|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
32896|NCT00914888|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|Subject with CAP:
IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
31971|NCT00884026|Device|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
31972|NCT00884026|Device|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
31973|NCT00014508|Procedure|peripheral blood stem cell transplantation|
31974|NCT00884039|Drug|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
31975|NCT00884039|Drug|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
31976|NCT00884052|Drug|levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
31977|NCT00884052|Drug|levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
31978|NCT00884065|Other|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
31979|NCT00884065|Other|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
31980|NCT00886548|Procedure|Ultrasound performed|Nurse-driven ultrasound performed
31981|NCT00886561|Behavioral|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
31982|NCT00886574|Drug|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
31983|NCT00014651|Procedure|conventional surgery|
31984|NCT00886574|Drug|Aspirin|100 mg once a day
32971|NCT00912535|Drug|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
32972|NCT00912548|Drug|goserelin|Zoladex™ administration:
Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.
Sequence of administration Zoladex depot:
The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).
Dosage:
Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .
Storage instructions for Zoladex™ Zoladex™ is kept a room temperature.
32973|NCT00912548|Drug|tamoxifen|Dose and period of Tamoxifen therapy:
Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.
Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light.
32974|NCT00912561|Behavioral|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
32975|NCT00017342|Drug|cytarabine|
32045|NCT00881634|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
32046|NCT00884078|Other|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
32047|NCT00884104|Drug|Solifenacin|Oral
32048|NCT00884117|Procedure|Virology testing|Virology testing (nasal/throat swabs) will be taken at baseline, and on days 3 and 6
32049|NCT00884130|Procedure|laparoscopic colorectal resection|
32050|NCT00014521|Drug|karenitecin|
32051|NCT00884130|Procedure|open colorectal resection|
32052|NCT00884169|Drug|M518101|Proper quantity twice a day
32053|NCT00884169|Drug|placebo|Proper quantity twice a day
32054|NCT00884182|Biological|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
32055|NCT00884195|Behavioral|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
32056|NCT00884195|Behavioral|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
28477|NCT00873197|Drug|granisetron|Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).
Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only.
28478|NCT00873210|Drug|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
28479|NCT00873223|Drug|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
28480|NCT00873223|Drug|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
28481|NCT00873236|Biological|bevacizumab|Given IV
28482|NCT00873236|Biological|recombinant interferon alpha-2a|Given SC
28483|NCT00873262|Drug|Skin test panel and desensitization kit|Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L
Controls:
Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)
Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:
Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml
Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml
Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
28484|NCT00873262|Drug|Skin test panel and solvent|Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L
Controls:
Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)
Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:
Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml
Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml
Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
28485|NCT00873275|Biological|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
28486|NCT00013520|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
28487|NCT00873275|Drug|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
28488|NCT00875667|Drug|Lenalidomide|For patients with a creatinine clearance of ≥60 mL/min: 25mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.
For patients who have a moderate renal insufficiency (creatinine clearance is ≥30 mL/min but <60mL/min: 10mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.
28489|NCT00875667|Drug|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
28787|NCT00878709|Other|placebo|orally daily for 1 year
32206|NCT00889590|Drug|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
32463|NCT00916409|Device|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
32464|NCT00916409|Drug|Temozolomide|maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.
Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.
32465|NCT00916422|Biological|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
32466|NCT00916422|Biological|Placebo|Subcutaneous monthly treatment
32467|NCT00916448|Drug|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
32468|NCT00916448|Drug|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
32469|NCT00916461|Drug|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
32470|NCT00916461|Drug|Placebo|Placebo + treatment as usual.
32471|NCT00916474|Drug|telaprevir|
32472|NCT00017628|Drug|methylprednisolone|
32473|NCT00916487|Dietary Supplement|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
32474|NCT00916500|Drug|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
32475|NCT00916526|Procedure|bronchial provocation test with mannitol|Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.
Apply nose clip and subject should be directed to breathe through the mouth
Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)
The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration
At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip
At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)
Insert 5 mg capsule into inhalation device, and proceed as above
Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered.
32476|NCT00916552|Drug|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
31985|NCT00886587|Device|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
31986|NCT00886587|Device|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
31987|NCT00886600|Drug|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
31988|NCT00886600|Drug|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
32274|NCT00014742|Drug|collagenase|
32275|NCT00887081|Drug|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
32276|NCT00887094|Behavioral|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
32277|NCT00887094|Behavioral|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
32278|NCT00887107|Drug|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
32279|NCT00887120|Drug|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|BW 6-7.9 kg: 1.5 mL oral q 12 hr
BW 8.0-16.9 kg: 2.0 ml oral q 12 hr
BW 17.0-19.9 kg: 2.5 ml oral q 12 hr
BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr
BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr
BW 30.0-34.9 kg: 4.0 ml oral q 12 hr
BW > 35 kg: 5.0 ml oral q 12 hr
Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
32280|NCT00887120|Drug|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|BW 6-7.9 kg: 1.0 mL oral q 12 hr
BW 8.0-16.9 kg: 1.5 ml oral q 12 hr
BW 17.0-19.9 kg: 1.8 ml oral q 12 hr
BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr
BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr
BW 30.0-34.9 kg: 3.0 ml oral q 12 hr
BW > 35 kg: 3.5 ml oral q 12 h
Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
32281|NCT00887146|Drug|concomitant temozolomide (TMZ)|75 mg/m^2, orally daily
32282|NCT00887146|Radiation|radiotherapy|
32283|NCT00887146|Drug|procarbazine|Days 8-21: 60 mg/m^2 orally
32284|NCT00887146|Drug|adjuvant temozolomide (TMZ)|150 or 200 mg/m^2 orally
32285|NCT00014755|Drug|anti-thymocyte globulin|
32286|NCT00887146|Drug|CCNU|Day 1: 110 mg/m^2 orally
32287|NCT00887146|Drug|vincristine|Days 8 and 29: 1.4 mg/m^2 IV
32288|NCT00887159|Biological|cixutumumab|Given IV
32057|NCT00884221|Drug|Highly purified menotrophin|The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.
NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
32058|NCT00884221|Drug|Recombinant FSH|The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.
NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
32059|NCT00884234|Other|Vehicle Control|Two sequential doses of RT001 or Vehicle Control at Baseline (Day 0) and Week 2
32060|NCT00884234|Drug|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 or Vehicle Control at Baseline (Day 0) and Week 2
32061|NCT00014534|Biological|filgrastim|6 mg sub Q
32062|NCT00884260|Drug|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
32348|NCT00911547|Drug|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
32349|NCT00000822|Drug|Stavudine|
32350|NCT00017290|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
32351|NCT00913965|Drug|Atenolol Tablets 100 mg (Cord Laboratories)|
32352|NCT00913965|Drug|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
32353|NCT00017368|Procedure|peripheral blood stem cell transplantation|
32354|NCT00913978|Other|Warming pre operatively|The first group will have the warming devices started in the pre operative area. You will receive warm blankets and a full body warm air blanket called the Bair Paws. This device is non experimental and is FDA approved and used within the hospital to keep patients warm. You will have an intravenous catheter (IV is a small plastic flexible hollow tubing) placed by the pre operative care staff. You will then receive warmed IV solution (salt water).
32355|NCT00913978|Other|Warming in OR|The second group will receive the warming devices and warmed IV fluids once they are in the operating room.
32356|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
32357|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
32358|NCT00914004|Drug|Desipramine HCl 50 mg Tablets Cord Laboratories|
28788|NCT00878722|Drug|PXD101|
28789|NCT00878722|Drug|idarubicin|
28790|NCT00878735|Behavioral|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
28791|NCT00014196|Drug|docetaxel|
28792|NCT00878748|Drug|Effexor XR|
28793|NCT00878748|Other|Effexor XR discontinue|
28794|NCT00878761|Biological|STX-100|SC, single dose followed by multiple dose
28795|NCT00878774|Biological|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
28796|NCT00878774|Biological|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
28797|NCT00878787|Device|Transcranial magnetic stimulation|
28798|NCT00878800|Drug|PXD101|Administered in combination with doxorubicin (BelDox)
28799|NCT00878800|Drug|Doxorubicin|Administered in combination with PXD101 (BelDox)
28800|NCT00878813|Procedure|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
28801|NCT00878813|Procedure|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
28802|NCT00014196|Radiation|radiation therapy|
28803|NCT00878826|Drug|Enoxaparin|Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.
Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation.
28804|NCT00878839|Device|Toric|AcrySof Toric IOL
28805|NCT00878852|Behavioral|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
28806|NCT00871351|Drug|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
28807|NCT00871364|Drug|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
32477|NCT00916578|Radiation|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
32478|NCT00916578|Drug|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
32817|NCT00914862|Drug|Ramelteon|Ramelteon tablets, orally for one day only.
32818|NCT00914888|Drug|Tigecycline|Subject with cIAI:
Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
32819|NCT00914888|Drug|Tigecycline|Subject with CAP:
IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
32820|NCT00017433|Drug|arsenic trioxide|
32821|NCT00917085|Behavioral|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
32822|NCT00917098|Behavioral|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
32823|NCT00917098|Behavioral|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
32824|NCT00017654|Drug|anti-thymocyte globulin|
32825|NCT00917111|Drug|Nasal CO2|Four times a day for 14 days
32826|NCT00917111|Drug|Inactive Placebo Gas|Placebo
32827|NCT00917124|Device|INVOS|Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.
None of the interventions are outside the range of good clinical practice.
32828|NCT00917137|Procedure|TBNA + transbronchial lung biopsy + bronchial washing|
32829|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
32289|NCT00887159|Drug|vismodegib|Given PO
32290|NCT00887159|Drug|cisplatin|Given IV
32291|NCT00916123|Drug|Prednisone|10 mg per day starting on cycle 1, day 1
32292|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
32293|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
32294|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
32544|NCT00914355|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
32545|NCT00914368|Drug|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
32546|NCT00017381|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
32547|NCT00914381|Behavioral|Behavioral therapy|
32548|NCT00914394|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
32549|NCT00914394|Drug|Phenylephrine|1µg/kg/min, infusion period 20 minutes
32550|NCT00914394|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
32551|NCT00914394|Device|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
32552|NCT00914394|Device|Goldmann applanation tonometer|intraocular pressure measurements
32553|NCT00914394|Device|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
32554|NCT00914407|Drug|Oxygen|100% Oxygen inhalation for 30 minutes
32555|NCT00916604|Drug|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
32556|NCT00916604|Drug|Placebo|Placebo oral suspension, 8 days treatment
32359|NCT00914004|Drug|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
32360|NCT00914017|Drug|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
32361|NCT00914017|Drug|Placebo|sugar pill daily for 1 year
32362|NCT00914030|Other|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
32363|NCT00914043|Genetic|gene expression analysis|
32364|NCT00017368|Radiation|radiation therapy|
32365|NCT00914043|Genetic|microarray analysis|
32366|NCT00914043|Genetic|polymerase chain reaction|
32367|NCT00914043|Genetic|polymorphism analysis|
32368|NCT00914043|Genetic|reverse transcriptase-polymerase chain reaction|
32369|NCT00914043|Other|biologic sample preservation procedure|
32370|NCT00914043|Other|enzyme-linked immunosorbent assay|
32616|NCT00914420|Device|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
32617|NCT00017394|Biological|bevacizumab|Given IV
32618|NCT00914433|Drug|TPI 1100|1 dose only increasing dose
32619|NCT00914446|Procedure|hepatic biopsies|hepatic biopsies
32620|NCT00914459|Biological|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
32621|NCT00914459|Procedure|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
32622|NCT00914472|Biological|heparin sodium - APP|Heparin 5000 IU / mL
32623|NCT00914472|Biological|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
32624|NCT00914485|Behavioral|Provider Communication Skills Training|Consists of 4 separate 1-hour sessions, 1 per "best act," in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity.
32625|NCT00914498|Drug|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
28808|NCT00871364|Drug|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
29112|NCT00874120|Drug|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
29113|NCT00874133|Procedure|Acupuncture|Acupuncture treatment for 12 weeks.
29114|NCT00874133|Drug|Motilium|20 mg motilium thrice daily
29115|NCT00874146|Genetic|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
29116|NCT00874159|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
29117|NCT00013585|Drug|Selegiline hydrochloride|
29118|NCT00874172|Drug|Rapid optimized analgesic strategy|Oral treatment :
1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus
29119|NCT00874172|Drug|current analgesic strategy|paracetamol 1 g per os nasal oxygen therapy
1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration
29120|NCT00874198|Procedure|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system [pressure settings: 30 - 200 mmH20]
29121|NCT00874211|Procedure|assessment of therapy complications|By dental and medical assessments.
29122|NCT00874224|Procedure|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
29123|NCT00874224|Procedure|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
29124|NCT00874237|Drug|1 (Staccato Loxapine)|Staccato Loxapine
29125|NCT00874237|Drug|2 (Moxifloxacin)|Oral moxifloxacin
29126|NCT00874237|Drug|3 (Placebo)|Placebo
29127|NCT00874250|Device|GORE CTAG Device|Endovascular aortic stent-graft
29128|NCT00013598|Drug|Pioglitazone|
29129|NCT00874276|Drug|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
32830|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
32831|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
32832|NCT00917150|Drug|placebo|oral administration of placebo, once daily for 24months
31913|NCT00886496|Biological|recombinant human mannose-binding lectin|
31914|NCT00886509|Biological|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
31915|NCT00886509|Other|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
31916|NCT00886522|Procedure|Intrabone cord blood infusion|Myeloablative conditioning regimen (MAC):
i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg
Reduced intensity conditioning regimen (RIC):
Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg
GVHD prophylaxis:
Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27
31917|NCT00888914|Drug|RT001|RT001
31918|NCT00888914|Drug|RT001|RT001
31919|NCT00000206|Drug|Buprenorphine|
31920|NCT00000804|Drug|Indinavir sulfate|
31921|NCT00014937|Drug|didanosine|
31922|NCT00888914|Drug|RT001|RT001
31923|NCT00888914|Drug|RT001|RT001
31924|NCT00888914|Other|Vehicle Comparator|Vehicle Comparator
31925|NCT00888927|Biological|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
31926|NCT00888940|Drug|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
31927|NCT00888940|Drug|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
31928|NCT00888953|Other|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
32557|NCT00916617|Drug|bapineuzumab|5 mg/week subcutaneous bapineuzumab
32558|NCT00916630|Drug|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
32559|NCT00000114|Drug|Vitamin E|
32560|NCT00000210|Drug|Buprenorphine|
32561|NCT00000826|Drug|Rifabutin|
32562|NCT00017628|Procedure|Autologous Stem Cell Transplantation|
32563|NCT00916643|Device|HELP Secura (apheresis treatment)|Process is described in Arm (above).
32564|NCT00916656|Biological|Fibrinogen Concentrate, Human (FCH)|Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.
If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually.
32897|NCT00914901|Drug|inhaled salmeterol|Inhalation of 100 micrograms salmeterol in one dose.
32898|NCT00914914|Drug|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
32899|NCT00914927|Drug|E5501|E5501 First Dose 80 mg followed by 10 mg a day for up to 6 additional days
32900|NCT00914927|Drug|E5501|E5501 First Dose 80mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
32901|NCT00914927|Drug|Placebo|Placebo or inactive substance once a day for up to 7 days
32902|NCT00914940|Drug|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
32903|NCT00914940|Drug|Tacrolimus|Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.
For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.
In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules.
32904|NCT00914940|Drug|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
32905|NCT00017446|Drug|CP4071|
32906|NCT00914940|Radiation|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
32626|NCT00914511|Drug|avanafil 200mg|single dose tablet of 200mg avanafil
32627|NCT00914511|Drug|avanafil 200mg|single tablet dose of 200mg avanafil
32628|NCT00017394|Drug|vinorelbine tartrate|Given IV
32629|NCT00914524|Drug|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
32630|NCT00914550|Other|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
32631|NCT00914563|Device|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
32632|NCT00914563|Other|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
32633|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
32634|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
32635|NCT00914576|Drug|Placebo|2 capsules/day for 14 days
32636|NCT00914576|Drug|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
32976|NCT00912574|Drug|GM-CSF-in-adjuvant|For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
32977|NCT00912574|Drug|Montanide ISA-51|For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
32978|NCT00912574|Biological|GM-CSF and Montanide ISA-51|For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
29130|NCT00874276|Genetic|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
29131|NCT00874289|Other|NGAL kit|Kit to test NGAL levels in heart failure patients
29132|NCT00876824|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
32442|NCT00914134|Drug|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
32443|NCT00914147|Procedure|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
32444|NCT00017381|Drug|cyclophosphamide|Given IV
32445|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
32446|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
32447|NCT00914160|Drug|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
32448|NCT00914173|Device|Scanlaf Circulator and water bath|Cold Pressor Test
32449|NCT00914173|Device|Medoc TSA 2000|Thermal stimuli pain
32450|NCT00914186|Drug|TS022|Lotion
32451|NCT00914186|Drug|Vehicle|Lotion
32452|NCT00914199|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
32453|NCT00914212|Drug|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
32454|NCT00914212|Drug|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
32455|NCT00017381|Biological|filgrastim|Given SC
32456|NCT00914225|Other|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
32457|NCT00914238|Behavioral|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
31929|NCT00888953|Other|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
31930|NCT00888979|Drug|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
31931|NCT00888992|Behavioral|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
31932|NCT00014950|Procedure|CF newborn screening|
32207|NCT00889603|Drug|Aricept® Evess|5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.
Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing).
32208|NCT00889616|Drug|BSAM2/Alhydrogel + CPG 7909|
32209|NCT00889629|Drug|Doxercalciferol|1 mcg qd then uptitrated as specified in protocol
32210|NCT00889629|Drug|placebo|placebo of doxercalciferol
32211|NCT00889642|Device|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
32212|NCT00889642|Device|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
32213|NCT00881777|Procedure|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
32214|NCT00881790|Other|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
32215|NCT00014352|Drug|warfarin|
32216|NCT00881816|Drug|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
32217|NCT00881829|Device|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
32218|NCT00881842|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
32219|NCT00881855|Drug|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
32220|NCT00881855|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
32907|NCT00914940|Other|Magnetic Affinity Cell Sorting|Device
32908|NCT00914940|Procedure|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
32909|NCT00914940|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
32910|NCT00914940|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
32911|NCT00914953|Drug|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
32912|NCT00914966|Biological|C1 inhibitor (human) [C1 INH]|
32913|NCT00914979|Device|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
32914|NCT00917241|Drug|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
32915|NCT00917241|Drug|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
32916|NCT00917254|Drug|YM150|oral
31989|NCT00886600|Drug|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
31990|NCT00886613|Biological|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
31991|NCT00886613|Biological|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
31992|NCT00886613|Biological|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
31993|NCT00886613|Other|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
31994|NCT00014664|Biological|apolizumab|
31995|NCT00886613|Other|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
31996|NCT00886626|Drug|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
31997|NCT00886639|Other|6MWT with oxygen|2 liter per minute as continuous-flow
32979|NCT00914992|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
32980|NCT00914992|Other|Squatting|Squatting
32981|NCT00017459|Drug|cisplatin|
32982|NCT00915005|Radiation|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
32983|NCT00915005|Radiation|Proton Therapy|Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.
Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.
Each daily treatment should take about 20-30 minutes to complete.
32984|NCT00915005|Drug|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
32985|NCT00915005|Drug|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
32986|NCT00915018|Drug|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
32987|NCT00915018|Drug|Trastuzumab|Trastuzumab - 4mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
32988|NCT00915018|Drug|Paclitaxel|Paclitaxel - 80mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
32989|NCT00915031|Device|UroCool|Hypothermia Endorectal Device
32990|NCT00915057|Drug|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
32991|NCT00915070|Drug|BQ-123|60 mcg/min, infusion period: 60 min
32063|NCT00884273|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
32064|NCT00884273|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
32065|NCT00884273|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
32066|NCT00886678|Radiation|thoracic radiation|66 Gy over 33 fractions
32067|NCT00014677|Biological|interleukin-4 PE38KDEL cytotoxin|
32458|NCT00914238|Behavioral|OPUS 5 years|
32459|NCT00916383|Drug|350 mg Donepezil Transdermal Patch System (DTP-System)|DTP-System (active and placebo) will be applied once every 7 days for 21 days
32460|NCT00916396|Drug|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
32461|NCT00017628|Drug|filgrastim|
32462|NCT00916396|Drug|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
32718|NCT00914615|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
32719|NCT00914628|Genetic|HSV-Tk|Infusion of genetically modified lymphocytes 1x10^7 c/kg: first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
32720|NCT00914628|Other|T cell repletion strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10^4/Kg)
32721|NCT00914641|Drug|Apixaban IR|immediate release tablet, 10 mg, single dose
32722|NCT00914641|Drug|Apixaban MR1|modified release tablet 1, 10 mg, single dose
32723|NCT00017407|Biological|ISIS 3521|
32724|NCT00914641|Drug|Apixaban MR2|modified release tablet 2, 10 mg, single dose
32725|NCT00914641|Drug|Apixaban MR3|modified release tablet 3, 10 mg, single dose
32726|NCT00914654|Drug|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
32727|NCT00914667|Drug|warfarin|Single Dose Warfarin 25 mg on Day 1
32728|NCT00914667|Drug|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
32729|NCT00914680|Procedure|magnetic seizure therapy|antidepressant treatment with MST
32730|NCT00914693|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
32731|NCT00914706|Other|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
32732|NCT00914719|Behavioral|Information only|
32221|NCT00881868|Drug|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
32222|NCT00881868|Drug|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
32223|NCT00881894|Drug|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm^2 patch applied for 24 hours
32224|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
32225|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
32226|NCT00014365|Drug|MKC-1|
32227|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
32479|NCT00919035|Drug|torisel|Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
32480|NCT00919061|Drug|Gemcitabine|Gemcitabine: 800 mg/m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
32481|NCT00919061|Drug|Cisplatin|20 mg /m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
32482|NCT00017927|Drug|Pegvisomant|
32483|NCT00919061|Drug|Sorafenib|400 mg PO once a day continuously.
32484|NCT00919074|Procedure|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
32485|NCT00919074|Procedure|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
32486|NCT00919087|Device|Avivo System|Non invasive external monitoring deive
32487|NCT00919100|Device|Buzzy|"Buzzy" is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front.
32488|NCT00919100|Other|vapocoolant|venipuncture with vapocoolant spray offered
32489|NCT00919113|Drug|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
32490|NCT00919113|Drug|Placebo|The identical buffer used in Uracyst for the same administration
32491|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
31998|NCT00886639|Other|6MWT with medical air|2 liters as continuous-flow
31999|NCT00886652|Other|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
32000|NCT00886665|Drug|placebo|placebo, 4 g, powder, oral, 3 times a day
32001|NCT00886665|Drug|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
32002|NCT00886678|Drug|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
32003|NCT00886678|Drug|carboplatin|AUC=5,IV,q 21 days x 2 cycles
32004|NCT00889031|Other|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
32005|NCT00889044|Drug|clopidogrel by chewing|600 mg clopidogrel by chewing
32006|NCT00889044|Drug|Placebo|Placebo p.o
32007|NCT00889057|Drug|sorafenib|400 mg bid until progression or inacceptable toxicity
32008|NCT00889096|Drug|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
32295|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
32296|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
32297|NCT00916136|Procedure|Femoral Traction|Temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
32298|NCT00916149|Drug|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
32299|NCT00916149|Drug|Lamotrigine|The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:
The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study.
32068|NCT00886691|Biological|bevacizumab|Given IV
32069|NCT00886691|Drug|everolimus|Given orally
32070|NCT00886691|Other|placebo|Given orally
32071|NCT00886704|Dietary Supplement|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..
Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.
Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
32072|NCT00886704|Dietary Supplement|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
32073|NCT00886717|Drug|carboplatin|
32074|NCT00886717|Drug|paclitaxel-loaded polymeric micelle|
32075|NCT00886730|Behavioral|Simple Card|Participants will receive a simple 3"x5" card with the name of the website and the following description. "www.psychobabble.com (or new name). A website to help individuals with depression recover."
32076|NCT00886730|Behavioral|Patient Centered Brochure|Participants will receive an 8"x11" handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email.
32077|NCT00886730|Behavioral|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
32078|NCT00000803|Drug|Delavirdine mesylate|
32079|NCT00014677|Procedure|conventional surgery|
32371|NCT00914043|Other|laboratory biomarker analysis|
32372|NCT00914043|Procedure|fatigue assessment and management|
32373|NCT00914056|Drug|lactulose|withdrawal of lactulose
32374|NCT00914069|Device|RIVS vascular access|Access to peripheral vasculature
32375|NCT00017381|Biological|rituximab|Given IV
32376|NCT00914069|Device|Conventional vascular access|Vascular access using conventional venous access device
32733|NCT00914719|Behavioral|Sexual risk reduction intervention|
32734|NCT00916916|Other|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
32735|NCT00916929|Device|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
32736|NCT00916942|Drug|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
32737|NCT00916942|Drug|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
32738|NCT00017641|Drug|filgrastim|
32739|NCT00916955|Other|Observation|Observe development of syndrome over time
33072|NCT00915200|Dietary Supplement|N-acetylcysteine|600 mg orally twice daily for three months
33073|NCT00915200|Dietary Supplement|silibin|480 mg orally twice daily for three months
33074|NCT00915200|Dietary Supplement|high-dose silibin|960 mg orally twice daily for three months
33075|NCT00915200|Dietary Supplement|N-acetylcysteine placebo|excipient orally twice daily for three months
33076|NCT00915200|Dietary Supplement|silibin placebo|excipient orally twice daily for three months
33077|NCT00915226|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
33078|NCT00915226|Procedure|Squatting|Squatting
33079|NCT00915239|Drug|Pantoprazole|40 mg pantoprazole once daily for 28 days
33080|NCT00915239|Drug|Placebo|identical placebo once daily for 28 days
33081|NCT00017472|Biological|apolizumab|Given IV
33082|NCT00915252|Drug|azacitidine|Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:
During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).
During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy.
33083|NCT00915252|Drug|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|Induction therapy:
Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7
Consolidation therapy:
AraC 1g/m² twice a day on day 1,3,5
33084|NCT00915265|Other|Multilobed catheter (group CPA)|- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
32492|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
32493|NCT00000826|Drug|Fluconazole|
32494|NCT00017940|Genetic|Human Nerve Growth Factor|
32495|NCT00919126|Drug|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
32496|NCT00919139|Other|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
32497|NCT00919178|Biological|DEN4 Vaccine Candidate|DEN4 Vaccine Candidate
Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL.
32498|NCT00919178|Biological|DEN4 Vaccine Placebo|DEN4 Vaccine Placebo
Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL.
32499|NCT00919191|Drug|Tretinoin gel|Tretinoin gel 0.04% used once daily in a split-face model
32500|NCT00919191|Drug|Adapalene and Benzoyl peroxide|Adapalene .1% and Benzoyl peroxide 2.5%
32833|NCT00917163|Device|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
32834|NCT00917163|Device|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
32835|NCT00017654|Drug|cyclophosphamide|
32836|NCT00917176|Device|Occipital nerve stimulation|
32837|NCT00917189|Behavioral|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
32838|NCT00917202|Drug|Methylenblue|
32839|NCT00917215|Device|Disposable stainless steel acupuncture (0.2mmx4mm)|For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.
For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks.
32840|NCT00917228|Device|recordings with device equipped|
32841|NCT00917228|Device|Control|Recording without device equipped
32842|NCT00920075|Drug|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
32300|NCT00916175|Dietary Supplement|placebo1 and placebo2|30ml liquid resembling aloe vera juice plus 200ml liquid resembling chayamansa infusion
32301|NCT00017602|Biological|oblimersen sodium|
32302|NCT00916175|Dietary Supplement|Placebo 2 and CC|Cnidoscolus Chayamansa infusion
32303|NCT00916175|Dietary Supplement|Aloe Vera and placebo 1|aloe vera juice and placebo 1
32304|NCT00916175|Dietary Supplement|Aloe Vera and Cnidoscolus Chayamansa|aloe vera juice plus Cnidoscolus chayamansa infusion
32305|NCT00916188|Dietary Supplement|Black Tea Extract|Amount/dose depends on Arm assignment.
32306|NCT00916201|Drug|URB597|10 mg / d for 5 days, orally
32307|NCT00916201|Drug|intranasal Insulin|160 IU / d for 5 days, intranasal
32308|NCT00916201|Drug|Cannabidiol CR|320 mg / d for 5 days, orally
32309|NCT00916214|Other|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
32310|NCT00916227|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
32311|NCT00918762|Procedure|video-assisted surgery|
32312|NCT00918775|Other|Evaluation|Evaluation during and after surgery: vital signs, performance status, physical exam, chest x-ray, CT and MRI plus health questions.
32313|NCT00918788|Other|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
32565|NCT00916656|Biological|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
32566|NCT00916669|Drug|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
32567|NCT00916669|Drug|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
32568|NCT00916669|Drug|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
32569|NCT00916695|Device|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.
Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique.
32377|NCT00914082|Behavioral|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
32378|NCT00916240|Behavioral|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
32379|NCT00017602|Drug|dexamethasone|
32380|NCT00916240|Behavioral|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
32381|NCT00916253|Drug|Modafinil|Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):
during 3 days at home
during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil).
32382|NCT00916253|Drug|Placebo|Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):
during 3 days at home
during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo.
32383|NCT00916266|Procedure|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
32384|NCT00916279|Device|Lutonix Paclitaxel-Coated Balloon|PTCA
32385|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
32386|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
32387|NCT00916305|Other|Modified Audio video|The active intervention will be an audio video with 3 parts: 1) unaltered music. 2) the same music, but after modification to mimic noise induced hearing loss after one night at a loud club 3) hearing loss after repeated exposure to loud music 4) noise-induced tinnitus
32388|NCT00916305|Other|Audio video|The active intervention will be an audio video with 3 parts: 1) unaltered music. 2) the same music, but after modification to mimic noise induced hearing loss after one night at a loud club 3) hearing loss after repeated exposure to loud music 4) noise-induced tinnitus
32637|NCT00914576|Drug|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
32638|NCT00916721|Drug|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
33085|NCT00915265|Other|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
33086|NCT00915278|Drug|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
33087|NCT00915291|Other|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
33088|NCT00915304|Behavioral|The EBMeDS reminders|Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.
Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months.
33089|NCT00915330|Procedure|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
33090|NCT00915330|Procedure|TBNA|transbronchial needle aspiration
32141|NCT00884338|Other|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
32142|NCT00014534|Drug|cisplatin|60 mg/sq m IV
32143|NCT00884338|Other|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
32144|NCT00884364|Other|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
32145|NCT00884364|Behavioral|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
32146|NCT00884377|Drug|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
32147|NCT00884377|Device|ThermoMed|ThermoMed heat treatment device, one treatment
32148|NCT00884390|Drug|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
32149|NCT00884390|Procedure|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
32150|NCT00884416|Drug|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
32151|NCT00884429|Procedure|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
32843|NCT00018070|Procedure|Angiography|
32844|NCT00920088|Drug|darunavir/ritonavir|DRV/RTV 600/100mg
32845|NCT00920088|Drug|lopinavir/ritonavir|LPV/RTV 400/100mg
32846|NCT00920088|Drug|Midazolam|Midazolam 3mg
32847|NCT00920088|Drug|Dextromethorphan|Dextromethorphan 30mg
32848|NCT00920088|Drug|Flurbiprofen|Flurbiprofen 50mg
32849|NCT00920088|Drug|GSK2248761|NNRTI under investigation
32850|NCT00920101|Drug|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
32851|NCT00920101|Behavioral|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
32852|NCT00920114|Biological|blood sample|
32853|NCT00920127|Dietary Supplement|AKL1|Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.
The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm.
31933|NCT00888992|Behavioral|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
31934|NCT00889005|Other|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
31935|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
31936|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
31937|NCT00881348|Drug|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
31938|NCT00881361|Drug|systemic chemotherapy|
32570|NCT00916708|Procedure|Intensive/Low-Risk Treatment (IA G1; IA G2)|- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months
- Since the third to the fifth year of FU: clinical visit* every 6 months; Pap test every 12 months
* clinical visit with gynecological exploration
32571|NCT00916708|Procedure|Intensive/High-Risk Treatment (≥ IA G3)|- First 3 years of FU since the end of primary treatment: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months
- In the fourth and fifth years of FU: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months
* clinical visit with gynecological exploration
32572|NCT00916708|Procedure|Minimalist/Low-Risk Treatment (IA G1; IA G2)|- First 5 years of FU since the end of primary treatment: clinical visit* every 6 months.
* clinical visit with gynecological exploration
32573|NCT00017641|Drug|anti-thymocyte globulin|
32574|NCT00916708|Procedure|Minimalist/High-Risk Treatment (≥ IA G3)|- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; chest, abdomen, pelvis CT every 12 months
- Since the third to the fifth year of surveillance: clinical visit* every 6 months.
* clinical visit with gynecological exploration
32575|NCT00919243|Drug|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
32576|NCT00017953|Behavioral|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
32577|NCT00919269|Other|biologic sample preservation procedure|
32578|NCT00919269|Other|laboratory biomarker analysis|Correlative studies
32579|NCT00919282|Drug|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
32580|NCT00919295|Drug|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
32917|NCT00917254|Drug|Placebo|oral
32918|NCT00017654|Drug|cyclosporine|
32919|NCT00917254|Drug|Enoxaparin|injection
32920|NCT00917267|Drug|exenatide once weekly|2.0mg subcutaneous injection, once a week
32921|NCT00917267|Drug|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
32922|NCT00917293|Drug|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
32639|NCT00916721|Drug|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
32640|NCT00916734|Procedure|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
32641|NCT00916734|Procedure|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
32642|NCT00916747|Drug|Lonafarnib, Zoledronic Acid, and Pravastatin|Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.
Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.
Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily.
32643|NCT00916760|Biological|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
32644|NCT00916760|Biological|Placebo|Subcutaneous monthly treatment
32645|NCT00916773|Device|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
32646|NCT00916799|Device|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
32647|NCT00017641|Drug|cyclophosphamide|
32648|NCT00916825|Behavioral|rehabilitation programme "getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
32649|NCT00916877|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
32650|NCT00916890|Drug|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
32992|NCT00017459|Drug|tirapazamine|
32993|NCT00915070|Drug|Physiological saline solution|infusion period 60 minutes
32994|NCT00915070|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
32995|NCT00915070|Device|Goldmann Applanation Tonometer|intraocular pressure measurements
32152|NCT00884429|Procedure|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
32153|NCT00014534|Drug|doxorubicin hydrochloride|50 mg/ sq m IV
32154|NCT00884429|Procedure|3-Airway suction|Airway suction
32155|NCT00884442|Drug|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
32156|NCT00884442|Drug|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
32157|NCT00884481|Other|Natalizumab|Participants treated with Tysabri
32158|NCT00884494|Drug|Ghrelin infusion to assess effects on insulin sensitivity|
32159|NCT00884507|Drug|Placebo|po daily for 24 weeks
32160|NCT00886821|Biological|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
32161|NCT00886834|Drug|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
32162|NCT00014690|Drug|plevitrexed|
32740|NCT00916968|Device|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
32741|NCT00916968|Device|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
32742|NCT00916981|Procedure|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
32743|NCT00916994|Device|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
32744|NCT00917020|Drug|Nasal CO2|As-Needed during the 14 day Treatment Period
32745|NCT00917020|Drug|Inactive Placebo Gas|Placebo
32746|NCT00917033|Device|GlideScope|Orotracheal intubation
32747|NCT00917033|Device|Macintosh direct laryngoscope|Orotracheal intubation
32748|NCT00917046|Behavioral|Aerobic Interval Training|3 weekly sessions of aerobic interval training in 12 weeks
32749|NCT00017641|Procedure|CD34+ Peripheral Blood Stem Cell Reinfusion|
32750|NCT00917046|Behavioral|Moderate continues training|3 weekly sessions of moderate continues training for 12 weeks
31939|NCT00881361|Procedure|axillary lymph node dissection|
31940|NCT00881361|Procedure|neoadjuvant therapy|
31941|NCT00881361|Procedure|sentinel lymph node biopsy|
31942|NCT00881361|Procedure|therapeutic conventional surgery|
31943|NCT00881361|Procedure|ultrasound imaging|
31944|NCT00881374|Drug|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
31945|NCT00881387|Biological|rituximab|Given IV
31946|NCT00014339|Drug|prednisone|
31947|NCT00881387|Drug|gemcitabine hydrochloride|Given IV
31948|NCT00881387|Drug|vinorelbine ditartrate|Given IV
31949|NCT00881400|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
31950|NCT00881400|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
31951|NCT00881413|Drug|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
31952|NCT00881413|Drug|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
32228|NCT00881920|Biological|Kappa CD28 T cells|Patients with B-CLL will receive 12.5 mg/kg of Cyclophosphamide as a single i.v. infusion. In contrast patients with lymphoma will receive cyclophosphamide only if the count of CD3+ lymphocytes in the peripheral blood is >500 ul.
Group 1: Day 0 2x10^7 cells/m^2 CAR-Kappa
Group 2: Day 0 1x10^8 cells/m^2 CAR-Kappa
Group 3: Day 0 2x10^8 cells/m^2 CAR-Kappa
32229|NCT00881933|Other|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, & -2) (if body weight < 10 kg or if age < 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, & -8) total body irradiation (3G on days -1)
32230|NCT00881946|Drug|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
32231|NCT00881959|Device|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
32232|NCT00881972|Behavioral|Exercise|walking/running/cycling
32233|NCT00881985|Device|continuous positive airway pressure|Use CPAP whenever sleep
32923|NCT00917293|Drug|Placebo|Placebo 2 pills, po bid for 12 weeks.
32924|NCT00917306|Drug|PEP005 Gel|0.05% two day treatment
32925|NCT00917319|Other|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
32926|NCT00917332|Behavioral|relaxation (breathing and muscles) and guided imagery ("safe place")|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
32927|NCT00917345|Drug|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
32928|NCT00917358|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
32929|NCT00017654|Drug|methylprednisolone|
32930|NCT00917384|Biological|IMC-1121B (ramucirumab)|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
32931|NCT00917384|Drug|Placebo|Placebo comparator for IMC-1121B (ramucirumab) 8 mg/kg as intravenous infusion every 2 weeks
32932|NCT00917384|Other|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
32933|NCT00917397|Drug|Sertraline|varies
32934|NCT00917397|Behavioral|trauma-focused cognitive behavioural therapy|once a week
32935|NCT00917410|Behavioral|SMS support|The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.
Remember to take your preventive asthma medication (sent at 8.00 am).
Were you awakened during the night due to your asthma? Answer YES or NO.
How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.
What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study).
32936|NCT00917436|Drug|Thiocolchicoside|
32937|NCT00917449|Drug|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
32009|NCT00889096|Drug|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
32010|NCT00014989|Drug|magnesium sulfate|
32011|NCT00889109|Other|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
32996|NCT00915070|Other|squatting|subjects will perform squatting for 6 minutes while blood flow measurements
32997|NCT00915083|Drug|Amrubicin|40mg/m^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
32998|NCT00915122|Radiation|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
32999|NCT00915135|Drug|Ramelteon and Placebo (25 possible combinations total)|Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:
Ramelteon 4 mg, tablets, orally over two nights
Ramelteon 8 mg, tablets, orally over two nights
Ramelteon 16 mg, tablets, orally over two nights
Ramelteon 32 mg, tablets, orally over two nights
Ramelteon placebo-matching tablets, orally over two nights
33000|NCT00915148|Other|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
33001|NCT00915174|Drug|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
33002|NCT00917449|Drug|Placebo|Oral Placebo BID for 18 months
33003|NCT00917462|Drug|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
33004|NCT00017654|Procedure|Allogeneic Bone Marrow Transplantation|
33005|NCT00917462|Procedure|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
33006|NCT00917488|Other|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
33007|NCT00917501|Drug|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
33008|NCT00917501|Drug|Placebo|Placebo given twice a day which will be compared to Omega 3
33009|NCT00917501|Procedure|Healthy Controls MRI|Healthy controls used from previous study that will be compared to the MRI of those on Omega 3.
33010|NCT00917527|Drug|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
33011|NCT00917553|Drug|doxycycline monohydrate|50 mg
32080|NCT00886743|Drug|oprelvekin|injection, 50 mg/kg, once daily
32081|NCT00886756|Drug|AZD8529|Oral
32751|NCT00917046|Behavioral|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
32752|NCT00917059|Drug|Escitalopram|Fixed dose of 10 mg per day
32753|NCT00917059|Drug|Bupropion XL|Fixed dose of 150 mg per day
32754|NCT00917072|Behavioral|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
32755|NCT00917072|Behavioral|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
32756|NCT00917072|Behavioral|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
32757|NCT00919776|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
32758|NCT00919776|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
32759|NCT00919802|Drug|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
32776|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
32777|NCT00912145|Drug|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
32778|NCT00912158|Other|standard therapy (ST)|standard medical therapy
32779|NCT00017303|Procedure|conventional surgery|
32780|NCT00912158|Device|CPAP|Non-invasive mechanical ventilation (CPAP)
32781|NCT00912158|Device|BIPAP|Non-invasive mechanical ventilation (BIPAP)
32782|NCT00912171|Drug|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
32783|NCT00912171|Drug|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
32784|NCT00912184|Device|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
32234|NCT00881998|Procedure|Minimally Invasive Total Hip Arthroplasty|
32235|NCT00881998|Procedure|Conventional Total Hip Arthroplasty|
32236|NCT00884507|Drug|RO5313534|1mg po daily for 24 weeks
32237|NCT00884507|Drug|RO5313534|5mg po daily for 24 weeks
32238|NCT00884507|Drug|RO5313534|15mg po daily for 24 weeks
32239|NCT00884520|Drug|[F-18] VM4-037|The individual doses of [F-18]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.
The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
32240|NCT00000801|Drug|Dexamethasone|
32241|NCT00014534|Drug|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
32242|NCT00884533|Drug|Rosi XR|Rosi XR
32243|NCT00884533|Other|Placebo|Placebo
32244|NCT00884533|Drug|Moxifloxacin|400mg single dose
32245|NCT00884546|Drug|BMS-833923|Capsule, Oral, Once daily, 6 months
32246|NCT00884546|Drug|Lenalidomide|Capsule, Oral, Once daily, 6 months
32247|NCT00884546|Drug|Dexamethasone|Capsule, Oral, Once a week, 6 months
32248|NCT00884546|Drug|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
32249|NCT00884559|Other|instruction|Debriefing
32250|NCT00884585|Drug|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
32501|NCT00919204|Drug|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
32502|NCT00919230|Drug|Ferrous sulphate tablets|200mg twice daily for four weeks
32503|NCT00919243|Drug|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
32504|NCT00017290|Biological|sargramostim|
32505|NCT00911716|Biological|bevacizumab|
32506|NCT00911716|Drug|cyclophosphamide|
32012|NCT00889122|Behavioral|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
32013|NCT00889135|Drug|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
32014|NCT00889148|Drug|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
32015|NCT00889148|Other|Placebo|Half the patients will be randomized to placebo
32016|NCT00889161|Drug|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
32017|NCT00889187|Radiation|Accelerated Short Course Radiation|Beginning on a weekday for 7 to 12 days
32018|NCT00889187|Drug|Capecitabine|Twice a day for 10 consecutive weekdays while receiving radiation therapy
32019|NCT00889200|Drug|eszopiclone|6 weeks standard oral therapy
32020|NCT00889213|Procedure|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
32021|NCT00015002|Drug|Betamethasone|coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the "Course"). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first.
32022|NCT00889213|Procedure|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
32023|NCT00881491|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
32024|NCT00881491|Drug|Mineral Trioxide Aggregate|standard material providing an apical barrier
32314|NCT00918788|Other|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
32315|NCT00918788|Other|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC).
32082|NCT00886756|Drug|Placebo|Oral
32083|NCT00886769|Drug|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
32084|NCT00886769|Drug|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
32085|NCT00886782|Drug|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
32086|NCT00886795|Drug|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
32087|NCT00886808|Drug|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
32088|NCT00889226|Drug|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
32089|NCT00889226|Drug|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
32090|NCT00889239|Other|lithia-disilicate-based crown|all-ceramic crown
32091|NCT00889252|Device|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
32092|NCT00889252|Device|contact lens|Placebo contact lens
32093|NCT00889265|Device|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
32094|NCT00889304|Device|Position HTO system|open wedge high tibial osteotomy
32095|NCT00889317|Device|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
32096|NCT00889330|Drug|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
32097|NCT00015015|Drug|Dichloroacetate|
32098|NCT00889330|Drug|Placebo|Vehicle without active, one drop in each eye at each of two visits.
32099|NCT00889343|Drug|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
32100|NCT00889343|Drug|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
32101|NCT00889343|Drug|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
32785|NCT00912184|Device|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
32786|NCT00912197|Dietary Supplement|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
32787|NCT00912197|Dietary Supplement|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
32788|NCT00912210|Dietary Supplement|Whey protein isolate|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
32789|NCT00912210|Dietary Supplement|Maltodextrin powder supplement|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
32790|NCT00000822|Drug|Didanosine|
32791|NCT00017316|Drug|semaxanib|
32792|NCT00912223|Biological|Hematopoietic Stem Cell Transplant|NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
The conditioning regimen will consist of the following:
Rituxan 375 mg/m^2 on Day -13
Rituxan 1000 mg/m^2 on Days -6, +1, and +8
Fludarabine 30 mg/m^2 on Days -5 to -3
Cyclophosphamide 750 mg/m^2 on Days -5, -4, -3
Day 0 will be the day of the transplant.
The GVHD prophylaxis will consist of the following:
Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.
Methotrexate 5 mg/m^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11.
32793|NCT00912249|Behavioral|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
32794|NCT00912262|Drug|Capsaicin Topical Liquid|
33091|NCT00917618|Other|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
33092|NCT00917631|Procedure|Co-bedding (caring for twins in the same incubator)|Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.
Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.
Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes).
33093|NCT00917631|Other|Standard care - No intervention|For infants who are randomized to receive standard care, the twin pair will remain in separate incubators as per current NICU policy. The infant will be nested in boundaries consistent with neonatal care practices. The heelstick may occur at any time following randomization (within 10 days) to maintain consistency between groups.
33094|NCT00917644|Drug|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
33095|NCT00017680|Procedure|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
32507|NCT00911716|Drug|docetaxel|
32508|NCT00911716|Procedure|adjuvant therapy|
32509|NCT00911742|Drug|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
32510|NCT00911742|Drug|Zytram|1 Zytram 200 mg tablet as a single dose
32511|NCT00911755|Procedure|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
32512|NCT00911755|Procedure|Endotracheal Intubation|
32513|NCT00911768|Dietary Supplement|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
32514|NCT00911768|Dietary Supplement|Corn-starch powder with ginseng flavor|There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.
The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).
Main contents: corn-starch with Panax ginseng flavor
32515|NCT00017290|Drug|cyclophosphamide|
32516|NCT00911781|Other|No intervention|We are only asking for photographs from parents.
32517|NCT00911794|Other|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
32518|NCT00911794|Other|Neutral (Sham) Writing|Patients write about neutral subjects
32519|NCT00911807|Drug|Cerebrolysin + donepezil|Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
32520|NCT00911807|Drug|Cerebrolysin + placebo|Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Placebo for donepezil was given PO once daily during the whole study duration (28 weeks).
32854|NCT00018070|Procedure|Laser Treatment|
32855|NCT00920140|Drug|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
32856|NCT00920140|Drug|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
32857|NCT00920153|Biological|bleomycin sulfate|Given IV
32858|NCT00920153|Drug|ABVD regimen|Given IV
32316|NCT00918788|Other|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
32317|NCT00918788|Procedure|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
32318|NCT00017810|Behavioral|Dietary intervention|
32319|NCT00918788|Procedure|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
32320|NCT00918788|Procedure|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
32321|NCT00918814|Drug|LIPO-102|Subcutaneous Injection
32322|NCT00918814|Drug|Placebo|Placebo
32323|NCT00918840|Biological|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
32324|NCT00918840|Biological|Placebo|Dextrose/glucose solution
32325|NCT00918840|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
32326|NCT00918853|Procedure|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
32327|NCT00918866|Drug|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
32328|NCT00918879|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
32329|NCT00017823|Procedure|Acupressure|
32330|NCT00918879|Drug|Placebo|Oral tablet, once daily for 24 weeks
32331|NCT00918892|Genetic|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
32581|NCT00919295|Drug|placebo|placebo
32389|NCT00916318|Behavioral|Obesity-Children|(A) internet based information and communication tool "Sundabarn.se"(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group.
32390|NCT00017628|Drug|cyclophosphamide|
32391|NCT00916331|Procedure|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
32392|NCT00916331|Procedure|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
32393|NCT00916344|Device|EVIA Pacemaker|patient has standard indication for pacemaker therapy
32394|NCT00916357|Drug|Humalog|
32395|NCT00916357|Drug|Humulin-R|
32396|NCT00916357|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
32397|NCT00916370|Device|Core size Xience Prime|Core size includes a range of stent sizes.
32398|NCT00916370|Device|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
32399|NCT00918892|Other|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
32400|NCT00918892|Other|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
32401|NCT00918905|Device|Telemonitor|Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.
During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day.
32402|NCT00918918|Dietary Supplement|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
32403|NCT00918918|Dietary Supplement|Orange juice|200 mL orange juice
32404|NCT00918931|Drug|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
32405|NCT00918944|Other|Control|The asthma disease management toolkit available to all practices in the EHR will consist of four elements:
A data entry tool for capturing asthma control data
Standardized documentation templates to facilitate severity classification
Order sets to facilitate ordering controller medications
An asthma care plan that can be supplied to families
33096|NCT00917644|Genetic|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
33097|NCT00917657|Procedure|Photorefractive keratectomy|
33098|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
33099|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
33100|NCT00917709|Other|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with [123I]-iodobenzovesamicol
33101|NCT00917709|Other|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
33102|NCT00917709|Behavioral|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
33103|NCT00917735|Drug|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
33104|NCT00917735|Other|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
33105|NCT00917748|Drug|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
33106|NCT00017693|Biological|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
33107|NCT00917748|Drug|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
32163|NCT00886834|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
32164|NCT00886847|Procedure|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
32165|NCT00886860|Drug|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
32166|NCT00886860|Drug|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
32167|NCT00886873|Drug|Mifepristone|
32168|NCT00886886|Drug|MDMA|125 mg, single dose
32169|NCT00886886|Drug|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
32859|NCT00920153|Drug|carmustine|Given IV
32860|NCT00920153|Drug|cisplatin|Given IV
32861|NCT00920153|Drug|cytarabine|Given IV
32862|NCT00920153|Drug|dacarbazine|Given IV
32863|NCT00920153|Drug|dexamethasone|Given orally
32864|NCT00920153|Drug|doxorubicin hydrochloride|Given IV
32865|NCT00018083|Drug|rifabutin|
32866|NCT00920153|Drug|etoposide|Given IV
32867|NCT00920153|Drug|gemcitabine hydrochloride|Given IV
32868|NCT00920153|Drug|ifosfamide|Given IV
32869|NCT00920153|Drug|melphalan|Given IV
32870|NCT00920153|Drug|methylprednisolone|Given IV
32871|NCT00912301|Drug|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
32872|NCT00912301|Other|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
32873|NCT00912314|Procedure|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
32874|NCT00912327|Biological|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
32875|NCT00017316|Drug|thalidomide|
32876|NCT00912340|Drug|Everolimus|
32877|NCT00912340|Biological|Trastuzumab|
32878|NCT00912353|Drug|AZD7268|Single Oral
32879|NCT00912353|Drug|Placebo|Single Oral
32880|NCT00912366|Procedure|Lobectomy|Assessment of VATS versus open surgery.
31953|NCT00881426|Drug|Cefprozil 500 mg Tablets (Sandoz GmbH)|
31954|NCT00881426|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
32582|NCT00919308|Other|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
32583|NCT00919321|Biological|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
32584|NCT00919334|Device|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
32585|NCT00919347|Other|ANSAR ANX 3.0 Software|Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:
RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;
LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;
SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.
The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):
Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa < 0.1 bpm2.
Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa < 0.5 bpm2 or 0.1 < RFa < 0.5 bpm2.
Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing.
32586|NCT00919360|Procedure|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
32587|NCT00017953|Behavioral|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
32588|NCT00919360|Procedure|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
32589|NCT00919360|Procedure|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
32590|NCT00919360|Procedure|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
32591|NCT00919373|Procedure|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
32592|NCT00911859|Drug|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
32593|NCT00911859|Drug|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
32594|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
32595|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
32406|NCT00918944|Other|Intervention|Three alerts and two reminders will be programmed:
Alert providers to enter asthma severity classification if none is on file
Alert providers to prescribe controller medications for persistent asthma if none on file
Alert providers to complete an asthma care plan if none on file
Remind providers to review the asthma care plan if it is already on file by providing a link to the form
Remind providers that educational content is available on-line by providing a web link
32651|NCT00916890|Drug|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
32652|NCT00916890|Drug|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
32653|NCT00916890|Drug|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
32654|NCT00919373|Procedure|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
32655|NCT00919373|Procedure|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
32656|NCT00919399|Drug|Exemestane|25mg a day during 4 months
32657|NCT00919399|Drug|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
32658|NCT00919425|Other|biologic sample preservation procedure|
32659|NCT00919438|Device|AVIVO™ Mobile Patient Management System|Non Invasive monitoring device
32660|NCT00017992|Drug|Lopinavir/Ritonavir|
32661|NCT00919451|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
32662|NCT00919464|Device|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
32663|NCT00919464|Device|Compartmental fracture pressure monitoring|
32664|NCT00919464|Device|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
32665|NCT00919490|Drug|ABT-333|Tablet, see arms for interventional description
32666|NCT00919490|Drug|Placebo|Tablet, see arms for interventional description.
32667|NCT00919503|Procedure|Allogeneic Bone Marrow Transplantation|Infused IV
32668|NCT00919503|Biological|Anti-Thymocyte Globulin|Given IV
32170|NCT00886886|Drug|Placebo|capsules identical to MDMA or Reboxetine
32171|NCT00886899|Device|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
32172|NCT00886912|Other|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
32173|NCT00014690|Drug|topotecan hydrochloride|
32174|NCT00886912|Other|normoxia|training under normoxic conditions
32175|NCT00886925|Drug|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
32176|NCT00886925|Drug|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
32177|NCT00886938|Device|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
32178|NCT00886951|Drug|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
32179|NCT00886964|Biological|Intradermal HBV 1 course|Dosage: 2 microgram (mcg), 0.1 ml per dose
Location: left deltoid area x 1 injection
Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months
32180|NCT00886964|Biological|Intramuscular HBV I course|Dosage: 2 microgram (mcg), 0.1 ml per dose
Location: left deltoid area x 1 injection
Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months
32181|NCT00886977|Drug|YAM80|Oral administration, 2 to 6 mg, once a day.
32182|NCT00886990|Drug|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
32183|NCT00886990|Drug|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
32184|NCT00014729|Drug|isotretinoin|
32760|NCT00919802|Other|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
32761|NCT00919815|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
32762|NCT00919815|Drug|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
32763|NCT00919828|Device|Avivo System|Non invasive external monitoring device
31955|NCT00881439|Drug|Aliskiren|Oral, 300 mg, once daily, 6 months
31956|NCT00881439|Drug|Placebo|Matching Placebo once daily, 6 months
31957|NCT00014339|Procedure|quality-of-life assessment|
31958|NCT00881452|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
31959|NCT00881452|Drug|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
31960|NCT00881465|Behavioral|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
31961|NCT00881465|Behavioral|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
31962|NCT00881478|Other|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
31963|NCT00881478|Other|Nutrition counseling|Nutrition counseling with registered dietician
31964|NCT00881491|Drug|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
31965|NCT00883948|Behavioral|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
31966|NCT00883948|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
31967|NCT00883961|Other|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
31968|NCT00883974|Behavioral|Sensitivity Training|The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, "shut-down" mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; "kangaroo care" (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping.
31969|NCT00884000|Drug|Genotropin|
31970|NCT00884000|Drug|Zomacton|
32251|NCT00884585|Drug|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
32938|NCT00919542|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
32939|NCT00919555|Drug|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
32940|NCT00919555|Drug|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
32941|NCT00919555|Drug|Placebo|Placebo
32942|NCT00919594|Behavioral|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
32943|NCT00919594|Behavioral|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
32944|NCT00919607|Drug|quetiapine fumarate extended-release|200mg,oral,single dose
32945|NCT00919607|Drug|quetiapine fumarate extended-release|300mg,oral,single dose
32946|NCT00919620|Behavioral|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
32947|NCT00919633|Drug|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
32948|NCT00018005|Behavioral|Self-Management|18 in-person group sessions providing self-management training.
32949|NCT00919633|Drug|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
32950|NCT00919633|Drug|ribavirin, USP|All patients will receive oral ribavirin
32951|NCT00919633|Device|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
32952|NCT00919659|Dietary Supplement|parenteral nutrition|25kcal/kg bw with parenteral nutrition
32953|NCT00919672|Device|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
32954|NCT00919685|Biological|blood sample|from rest of blood sample collected for other measurements
32955|NCT00919711|Drug|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
35267|NCT00947492|Biological|Venous blood sample|Venous blood sample twice a year during 3 years
35268|NCT00947505|Device|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
35269|NCT00947505|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
35270|NCT00947518|Drug|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
35271|NCT00947518|Drug|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
35272|NCT00947531|Drug|Cerebrolysin|
35273|NCT00947531|Drug|0.9% Saline Solution|
35274|NCT00947544|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
35275|NCT00947544|Drug|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
35625|NCT00945802|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
35626|NCT00945802|Drug|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
35627|NCT00945815|Biological|epratuzumab|
35628|NCT00020605|Drug|naloxone hydrochloride|
35629|NCT00945815|Drug|clofarabine|
35630|NCT00945815|Drug|cytarabine|
35631|NCT00945815|Other|laboratory biomarker analysis|
35632|NCT00945828|Behavioral|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
35633|NCT00948155|Drug|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
35634|NCT00948168|Drug|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
35635|NCT00948194|Drug|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
33284|NCT00915603|Drug|Everolimus|Everolimus 10mg PO daily continuously for all 28 days of a cycle
33285|NCT00915603|Drug|Bevacizumab|Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
33286|NCT00915603|Drug|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
33609|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> C -> B. Each of these treatments will be separated by a 7 day washout period.
33610|NCT00918632|Drug|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> C -> A. Each of these treatments will be separated by a 7 day washout period.
33611|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> A -> C. Each of these treatments will be separated by a 7 day washout period.
33612|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> A -> B. Each of these treatments will be separated by a 7 day washout period.
33613|NCT00017758|Drug|Nelfinavir mesylate|
33614|NCT00911157|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
33615|NCT00911157|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
33616|NCT00911170|Drug|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
33617|NCT00911170|Drug|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
33618|NCT00911170|Biological|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
33619|NCT00911170|Drug|Standard Chemotherapy|Each participant received one of the following chemotherapy regimens at the discretion of treating physician:
FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil.
33620|NCT00911183|Biological|filgrastim|Given subcutaneously
33621|NCT00911183|Biological|pegfilgrastim|Given subcutaneously
33622|NCT00911183|Biological|rituximab|Given IV
34106|NCT00904176|Drug|Digoxin|Tablets, Oral, 0.25, Single Dose
34107|NCT00016913|Drug|carboplatin|AUC=6 week one of each 4 week cycle
34108|NCT00904189|Radiation|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
34109|NCT00904202|Drug|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
34110|NCT00000818|Drug|Zidovudine|
34111|NCT00017095|Other|laboratory biomarker analysis|
34112|NCT00907036|Drug|fludarabine phosphate|
34113|NCT00907036|Drug|melphalan|
34114|NCT00907036|Procedure|allogeneic hematopoietic stem cell transplantation|
34115|NCT00907062|Dietary Supplement|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
34116|NCT00907075|Behavioral|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
34117|NCT00907075|Behavioral|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
34118|NCT00907088|Other|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
33108|NCT00917748|Drug|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
33109|NCT00917761|Drug|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
33110|NCT00917761|Drug|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
33111|NCT00920153|Drug|mitoguazone|Given IV
33112|NCT00920153|Drug|vincristine sulfate|Given IV
33113|NCT00920153|Drug|vindesine|Given IV
33114|NCT00920153|Drug|vinorelbine tartrate|Given IV
33528|NCT00911079|Radiation|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
33529|NCT00911092|Procedure|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
33530|NCT00911092|Radiation|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
33531|NCT00911092|Drug|Chemotherapy (Fluorouracil and Cisplatin)|At weeks 1, 5, 8 and 11
Day 1 to day 4: Fluorouracil 1 gr/m²/day
Day 1 or 2: Cisplatin 75 mg/m²
33532|NCT00911118|Radiation|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if < 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
33533|NCT00911131|Device|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
33534|NCT00911131|Procedure|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
33535|NCT00911131|Device|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
33536|NCT00911144|Biological|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
33537|NCT00911144|Biological|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
33538|NCT00017251|Drug|etoposide|Given IV
33539|NCT00911144|Biological|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
33540|NCT00017368|Drug|isotretinoin|
33541|NCT00913627|Drug|ibuprofen|
33542|NCT00913627|Drug|naproxen|
33859|NCT00909064|Drug|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
33860|NCT00909077|Drug|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
34187|NCT00904202|Drug|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
34188|NCT00904202|Drug|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
34189|NCT00904202|Drug|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
34190|NCT00904202|Drug|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
34191|NCT00904202|Drug|Gabapentin 1800 mg/day + Lidoderm patch|
34192|NCT00904215|Drug|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
34193|NCT00904228|Other|Plastic Lined Stockinette hat|hat made of unbleached 100% cotton stockinette that is lined with plastic (standard food sandwich bag)
34194|NCT00904241|Other|laboratory biomarker analysis|Correlative studies
34195|NCT00016913|Drug|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
34196|NCT00904241|Other|cytology specimen collection procedure|Correlative studies
34197|NCT00904254|Radiation|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
34198|NCT00904280|Drug|Oxymorphone ER|Open label
34199|NCT00904293|Other|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
34200|NCT00904293|Other|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
34201|NCT00904306|Dietary Supplement|Sugar Pill|placebo oral tablet taken once per day
34202|NCT00904306|Dietary Supplement|chromium picolinate|1000 ug/day chromium picolinate for 6 months
34203|NCT00904306|Dietary Supplement|chromium picolinate|600 ug/day chromium picolinate
34204|NCT00904319|Other|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
33623|NCT00017251|Other|pharmacological study|Correlative studies
33624|NCT00911183|Drug|cyclophosphamide|Given IV
33625|NCT00911183|Drug|liposome-encapsulated doxorubicin citrate|Given IV
33626|NCT00911183|Drug|prednisone|Given orally
33627|NCT00911183|Drug|vincristine sulfate|Given IV
33628|NCT00911196|Other|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
33938|NCT00906724|Procedure|Aerobic exercise|A graded exercise stress test (GXT) will be done under cardiologist supervision.
Subjects will undergo three month of supervised aerobic exercise.
33939|NCT00906737|Device|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
33940|NCT00906737|Other|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
33941|NCT00017095|Drug|fluorouracil|
33942|NCT00906750|Biological|FluMist|FluMist is a live attenuated intranasal influenza vaccine
33943|NCT00906750|Biological|Inactivated influenza vaccine|Inactivated influenza vaccine
33944|NCT00906763|Dietary Supplement|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
33945|NCT00906776|Device|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
33946|NCT00906776|Device|Autogenous bone|Autogenous bone application during periodontal surgery
33947|NCT00906789|Behavioral|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
33948|NCT00906802|Procedure|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
33949|NCT00906828|Drug|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
33950|NCT00909259|Device|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
33115|NCT00920153|Procedure|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
33116|NCT00018083|Drug|isoniazid|
33117|NCT00920153|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
33118|NCT00920166|Dietary Supplement|Pétunia 1|Infant formula used for non breastfed children
33119|NCT00920166|Dietary Supplement|Regular formula|Infant formula used for non breastfed children
33120|NCT00920192|Drug|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
33121|NCT00920205|Drug|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
33122|NCT00920218|Biological|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
33123|NCT00920218|Biological|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
33124|NCT00920231|Device|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
33125|NCT00920231|Device|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
33126|NCT00920244|Procedure|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
33127|NCT00018083|Drug|efavirenz|
33128|NCT00920244|Drug|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
33129|NCT00920244|Drug|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency < 60 beat/min.
33460|NCT00913549|Drug|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
33461|NCT00017368|Drug|ifosfamide|
33462|NCT00913562|Drug|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
33463|NCT00913562|Drug|Placebo|one tablet a day for 12 weeks
33464|NCT00913575|Other|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
33861|NCT00017173|Drug|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
33862|NCT00909077|Drug|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
33863|NCT00909090|Dietary Supplement|lutein and zeaxanthin supplements|12 mg taken daily for one year
33864|NCT00909090|Drug|Placebo|Placebo
33865|NCT00909116|Procedure|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
33866|NCT00909129|Drug|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
33867|NCT00909129|Drug|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
33868|NCT00909142|Drug|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
33869|NCT00909155|Drug|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
33870|NCT00909155|Drug|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
33871|NCT00909168|Drug|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5
ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5
IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5
GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6
33872|NCT00017173|Procedure|conventional surgery|conventional surgery
33873|NCT00909181|Drug|Oxybutynin|Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.
Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
33874|NCT00909181|Drug|Placebo|Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.
Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
33875|NCT00909194|Behavioral|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
33876|NCT00909207|Behavioral|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
34185|NCT00901979|Drug|LCQ908A|
34186|NCT00901979|Drug|LCQ908A|
33195|NCT00917826|Drug|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
33196|NCT00917826|Drug|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
33197|NCT00917839|Drug|lamotrigine|100 mg, once daily, 12 months
33198|NCT00917852|Device|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
33199|NCT00917865|Drug|anti [18F]FACBC|Anti[18F]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
33200|NCT00917878|Dietary Supplement|Milk|500 mL low-fat milk added to high-fat meal
33201|NCT00917878|Dietary Supplement|Protein|Milk protein in 500 mL water added to high-fat meal
33202|NCT00917878|Dietary Supplement|Calcium|Milk calcium in 500 mL water added to high-fat meal
33203|NCT00917878|Dietary Supplement|Control|Lactose in 500 mL water added to high-fat meal
33204|NCT00917891|Drug|dapivirine|dosage form: vaginal gel
dosage: 1.25mg dapivirine/day
frequency: once daily
duration: 6 weeks
33205|NCT00017706|Behavioral|physician-delivered weight control|
33206|NCT00917891|Drug|placebo|dosage form: vaginal gel
frequency: once daily
duration: 6 weeks
33207|NCT00917904|Drug|dapivirine|dosage form: vaginal gel
dosage: 1.25mg dapivirine/day
frequency: once daily
duration: 6 weeks
33208|NCT00917904|Drug|placebo|dosage form: vaginal gel
frequency: once daily
duration: 6 weeks
33209|NCT00917917|Behavioral|Type of physical activity (resistance, endurance)|To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.
Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities.
33210|NCT00917917|Behavioral|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
33211|NCT00917930|Behavioral|physical training|intensive cardiac rehabilitation program
33212|NCT00900445|Drug|prednisolone|Given orally
33213|NCT00900445|Drug|prednisone|Given orally
33214|NCT00900445|Drug|vincristine sulfate|Given IV
33215|NCT00016419|Biological|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
33951|NCT00909272|Procedure|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
33952|NCT00909272|Procedure|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
33953|NCT00909285|Device|TMS stimulation|TMS stimulation and cognitive training
33954|NCT00017173|Radiation|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
33955|NCT00909285|Device|Sham comparator|Sham comparator
34265|NCT00902044|Drug|Fludarabine|Fludarabine will be administered for 5 days prior to the T cells
The dose:
>10 kg: 25 mg/m2/day;
<10 kg: 1 mg/kg/day IV over 30 minutes
34266|NCT00902044|Drug|Cyclophosphamide|Cyclophosphamide will be administered for 2 days and then fludarabine will be given for the next 5 days and then the T cells will be administered
Cyclophosphamide Dose:
30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)
Fludarabine Dose:
>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes
34267|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
34268|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 3mcg
34269|NCT00016601|Drug|Nevirapine|
34270|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 15mcg
34271|NCT00902057|Drug|placebo|saline subcutaneous
34272|NCT00902070|Drug|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
34273|NCT00902083|Drug|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
34274|NCT00902083|Procedure|surgery|remove tumor surgery
34275|NCT00902083|Drug|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
34276|NCT00902083|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
33465|NCT00913575|Behavioral|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
33466|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
33467|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
33468|NCT00913588|Drug|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
33469|NCT00913601|Device|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
33470|NCT00913614|Drug|Eplivanserin (SR46349)|Oral administration
33471|NCT00913627|Drug|ibuprofen|
33472|NCT00915811|Drug|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
33473|NCT00915811|Drug|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
33474|NCT00915811|Procedure|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
33475|NCT00017550|Biological|anti-thymocyte globulin|
33476|NCT00915824|Other|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
33477|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
33478|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
33479|NCT00915850|Drug|DCF|docetaxel, Cisplatin and 5-FU
33480|NCT00915863|Procedure|Billroth-II-type reconstruction|surgical procedure
33481|NCT00915863|Procedure|Isolated Roux-en-Y type reconstruction|surgical procedure
33798|NCT00901368|Drug|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
33799|NCT00901368|Drug|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
33800|NCT00901381|Drug|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
35212|NCT00903435|Other|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
35213|NCT00903448|Drug|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
35214|NCT00906022|Device|Astron Pulsar Stent|Stenting with Astron Pulsar
35215|NCT00906022|Device|PTA alone|Balloon angioplasty alone
35216|NCT00906035|Drug|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
35217|NCT00906035|Drug|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
35218|NCT00906035|Drug|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
35562|NCT00941304|Drug|Placebo Capsule|Single-dose of oral placebo capsule
35563|NCT00941317|Device|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
35564|NCT00941330|Drug|Exemestane|25 mg daily by mouth for 6 to 12 months.
35565|NCT00941330|Drug|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
35566|NCT00941330|Drug|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
35567|NCT00020176|Drug|cyclophosphamide|
35568|NCT00941343|Drug|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
35569|NCT00941356|Dietary Supplement|Bio-K+ CL1285|2 capsules per day before breakfast
35570|NCT00941356|Dietary Supplement|Placebo|2 capsules per day before breakfast
35571|NCT00941369|Drug|Insulin Glargine (HOE901)/NPH Insulin|Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time
Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician
The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.
The dose adjustments will be based on the results of self-monitoring.
35572|NCT00941382|Drug|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
33216|NCT00900445|Other|pharmacological study|Correlative studies
33217|NCT00900458|Behavioral|Aerobic Exercise training|aerobic exercise training (cycling)
33543|NCT00913627|Drug|Placebo|
33544|NCT00913653|Drug|LCZ696|
33545|NCT00913666|Drug|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
33546|NCT00913679|Procedure|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
33547|NCT00913692|Drug|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
33548|NCT00913692|Drug|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
33549|NCT00913705|Drug|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
33550|NCT00913705|Drug|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
33551|NCT00017368|Drug|melphalan|
33552|NCT00913705|Procedure|Surgery|Surgery
33553|NCT00913718|Drug|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
33554|NCT00913718|Drug|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
33555|NCT00913744|Drug|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
33556|NCT00913744|Drug|Sham injection|Sham injection
33557|NCT00913770|Behavioral|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
33558|NCT00913770|Drug|Buprenorphine Initiation|
33559|NCT00913783|Drug|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
33560|NCT00913783|Drug|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
35636|NCT00020761|Drug|irinotecan hydrochloride|The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.
Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.
35637|NCT00948207|Behavioral|My Living Story|Components include:
1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);
2) Edited transcript is delivered in a word format on...;
3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.
4) miStory, a life review education website and portal to websites for: cancer information, databases to "do your own research," social support, interactive planning tools, and a page to add their own weblinks.
35638|NCT00948207|Behavioral|My Own Resources|miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for "do your own research," social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks.
35639|NCT00948220|Drug|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
35640|NCT00948233|Behavioral|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
35641|NCT00948233|Behavioral|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
35642|NCT00948233|Behavioral|Surveys|Computer surveys taken at 4 points throughout the study.
35643|NCT00948246|Device|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
34686|NCT00908050|Drug|Botulinum toxin type A|week 1: the patient will undergo the following: a. physical examination; b. sleep questionnaire c. bruxism questionnaire to establish a clinical diagnosis of bruxism; d. headache questionnaire; e. Clinical Global Improvement scale; f. masseter muscle measurement; g. anxiety questionnaire; h. demographic questionnaire;
week 2: The patient undergoes a polysomnogram (sleep study). The patient will spend one night (10:30pm-8:00am or until spontaneous awakening) in a sleep lab. During the sleep study, the following parameters will be recorded: electroencephalogram, electro-oculogram, upper airway resistance, heart rate, muscle activity; upper airway resistance,masseter muscles bilaterally. All recordings are performed using surface electrodes (self-adhesive to the skin), none of them invasive.
Study visit 3 (week 3): Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
34687|NCT00908063|Drug|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
34688|NCT00908063|Drug|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
34689|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
34690|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
33801|NCT00901394|Drug|B-vitamins|IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.
IV folic acid, 5 mg, single administration over 30 min.
Both diluted in 250 ml normal saline.
33802|NCT00901394|Drug|Nitrous oxide (NO)|60% nitrous oxide anesthesia
33803|NCT00901394|Drug|Placebo|Placebo: only 250 ml normal saline, no B-vitamins
33804|NCT00901394|Drug|Placebo nitrous oxide|NO nitrous oxide (60% air and oxygen mix).
33805|NCT00016523|Drug|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
33806|NCT00901407|Drug|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
33807|NCT00901407|Drug|placebo|placebo: 1-2 tablets bid; 10 weeks
33808|NCT00901407|Drug|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
33809|NCT00901420|Procedure|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
33810|NCT00901420|Behavioral|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
33811|NCT00903448|Drug|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
33812|NCT00903461|Biological|EGFR Antisense DNA|Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule
EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment.
33813|NCT00903474|Other|questionnaire administration|
33814|NCT00903474|Other|study of socioeconomic and demographic variables|
33815|NCT00016887|Drug|cytarabine|
33816|NCT00903474|Procedure|CAM exercise therapy|
33817|NCT00903474|Procedure|psychosocial assessment and care|
33818|NCT00903474|Procedure|quality-of-life assessment|
34119|NCT00907088|Other|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
35573|NCT00941382|Drug|Sibutramine|15 mg per day for 180 days
35574|NCT00941382|Drug|Metformin|Metformin 850 mg per day for 180 days
35575|NCT00941395|Behavioral|Survey|Completion of 3 surveys on the internet over the 3 months between the 1-week visit and the 3-month visit. The surveys should take about 20 minutes to complete.
35576|NCT00941395|Behavioral|Counseling|In-person end of study visit at 6 months.
35577|NCT00941395|Behavioral|Survey|3 Internet-based surveys over 3 months, each taking approximately 20 minutes.
35578|NCT00020176|Drug|cyclosporine|
35579|NCT00941395|Behavioral|Counseling|Individual in-person study visits at 1 week, 3 months, and 6 months.
35580|NCT00941408|Procedure|Diagnostic tumor core biopsy|
35581|NCT00941421|Device|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
35582|NCT00941434|Dietary Supplement|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
34628|NCT00902512|Drug|Treatment B|Sildenafil 100 mg CT administered with water single dose
34629|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
34630|NCT00902512|Drug|Treatment C|Sildenafil 100 mg CT administered without water single dose
34631|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
34632|NCT00902525|Drug|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
34633|NCT00016718|Drug|Efavirenz|Antiretroviral
34634|NCT00902538|Drug|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
34635|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
34636|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
34637|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
33561|NCT00913796|Drug|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
33562|NCT00017368|Drug|thiotepa|
33563|NCT00913796|Drug|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
33564|NCT00913809|Drug|Desipramine HCL 100 mg Tablets Cord Laboratories|
33877|NCT00909220|Behavioral|Behavioral Activation|16 weekly study visits aimed at identifying avoidance patterns used in social or physical situations that contribute to depression and replacing them with reinforcing experiences using directive behavioral strategies
33878|NCT00909233|Drug|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
33879|NCT00901433|Device|Personal WheezoMeter|pulmonary sounds analyzer
33880|NCT00901446|Device|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
33881|NCT00901459|Device|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
33882|NCT00901459|Device|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
33883|NCT00901459|Device|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
33884|NCT00016523|Drug|Placebo|Started at 5 ppm and could be increased to 10 ppm
33885|NCT00901485|Device|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
33886|NCT00901485|Device|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
33887|NCT00901498|Drug|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
33888|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
33889|NCT00901498|Drug|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
33890|NCT00901498|Drug|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
34691|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
34692|NCT00891241|Drug|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
34693|NCT00891254|Device|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
34694|NCT00891267|Drug|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
34695|NCT00891267|Drug|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
34696|NCT00891267|Drug|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
34697|NCT00891280|Drug|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
34698|NCT00891293|Drug|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
34699|NCT00015626|Procedure|skin biopsy|
34700|NCT00891306|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
34701|NCT00891306|Drug|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
34702|NCT00891306|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
35001|NCT00900835|Procedure|fatigue assessment and management|
35002|NCT00900835|Procedure|quality-of-life assessment|
35003|NCT00900835|Procedure|standard follow-up care|
35004|NCT00900874|Drug|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
35005|NCT00900874|Drug|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
35006|NCT00900887|Drug|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
35007|NCT00903032|Behavioral|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
34120|NCT00907101|Drug|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
34121|NCT00907114|Drug|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
34122|NCT00017095|Procedure|biopsy|
34123|NCT00907114|Drug|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
34124|NCT00907127|Behavioral|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
34125|NCT00907140|Procedure|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
34126|NCT00907153|Dietary Supplement|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
34127|NCT00907153|Drug|Placebo|Placebo by mouth once daily for 12 weeks
34128|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
34129|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
34130|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
34131|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
34132|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
34133|NCT00017095|Procedure|conventional surgery|
34134|NCT00909545|Drug|Placebo|4 Placebo to Match (PTM) tablets once daily
34135|NCT00909558|Biological|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.
The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks.
34136|NCT00909571|Drug|FK506E (modified release tacrolimus)|oral
34137|NCT00909571|Drug|Prograf (tacrolimus)|injection
34138|NCT00909584|Drug|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
34638|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
34639|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
34640|NCT00902564|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
34641|NCT00902577|Drug|18F-Fluoromisonidazole|Undergo FMISO PET scans
34642|NCT00902577|Procedure|Magnetic Resonance Imaging|Undergo MRI
34643|NCT00902577|Procedure|Positron Emission Tomography|Undergo FMISO PET scan
34644|NCT00016718|Drug|Emtricitabine|Antiretroviral
34645|NCT00902590|Other|saliva sample and questionaire|Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have previously completed athe "the "Urothelial Baseline Questionnaire," in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire.
34646|NCT00902590|Other|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
34647|NCT00902603|Drug|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
34935|NCT00905463|Procedure|Lung transplantation|Lung transplantation
34936|NCT00905489|Drug|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
34937|NCT00905489|Drug|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
34938|NCT00017004|Drug|Cisplatin|Given IV
34939|NCT00905502|Drug|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
34940|NCT00905502|Drug|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
34941|NCT00905515|Drug|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
34942|NCT00905515|Drug|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
34943|NCT00905528|Drug|Telmisartan 80 mg/d|
34944|NCT00905528|Drug|Ramipril 10 mg/d|
33891|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
33892|NCT00901511|Drug|GM-CSF [Leukine (Sargramostim)]|Acute treatment: the PAP subjects will receive inhaled rGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg/24 hours. The acute treatment will be accomplished in 12 weeks, for 7 consecutive days every second week (thus, 6 weeks on and 6 weeks off). For those PAP patients receiving the GM-CSF for the first time (1st and 2nd level treated groups), the treatment will be performed by 1 week run-in, after discharge from the ICU, in the Respiratory Disease Department (during this period PAP patients usually receive e.v. corticosteroids, and oral antibiotics). After the run-in period, the patient is discharged and inhalation treatment will continue at home.
Maintenance treatment: 17 weeks after the WLL (4 weeks after the completion of the acute treatment), the PAP patient will start the maintenance treatment. He/she will receive inhaled GM-CSF at the dose of 250 mcg/daily for 2 consecutive days every 14 days (2 days on and 12 days off) for a period of 6 month
33893|NCT00901511|Procedure|WLL|Whole lung lavage
34205|NCT00904345|Drug|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
34206|NCT00016913|Drug|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
34207|NCT00904345|Radiation|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
34208|NCT00907179|Drug|LBH 589|LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).
Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2
Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2
Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2
Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2
34209|NCT00907179|Drug|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
34210|NCT00907192|Behavioral|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
34211|NCT00907192|Behavioral|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
34212|NCT00907205|Drug|SF1126|Dose Escalating with 3+ patients in each cohort
34213|NCT00907218|Drug|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
34214|NCT00907257|Drug|benzoyl peroxide wash|5% benzoyl peroxide wash
34215|NCT00907257|Drug|Tretinoin gel|0.04% tretinoin gel
35008|NCT00016874|Drug|cisplatin|
35009|NCT00903032|Behavioral|Usual care|Usual care following ACS hospital discharge.
35010|NCT00903045|Drug|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
35011|NCT00903045|Drug|Placebo|Identical placebo twice a day
35012|NCT00903071|Behavioral|Real PPL|See above arm description
35013|NCT00903071|Behavioral|Sim PPL|See above arm description
35014|NCT00903084|Drug|Tenofovir Disoproxil Fumarate|300-mg tablet
35015|NCT00903110|Drug|Increlex®|Increlex® (mecasermin [rDNA origin] injection), 10 mg/ml solution for injection, 20-120mcg/kg BID or 0,02 to 0,12 mg/kg BID, as prescribed by physician
35016|NCT00903136|Other|questionnaire administration|
35017|NCT00903136|Procedure|comparison of screening methods|
35018|NCT00903136|Procedure|diagnostic endoscopic procedure|
35019|NCT00016874|Drug|paclitaxel|
35020|NCT00903136|Procedure|esophagogastroduodenoscopy|
35021|NCT00903136|Procedure|tethered capsule endoscopy|
35022|NCT00903162|Drug|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
35023|NCT00903162|Drug|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
35024|NCT00903162|Drug|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
35276|NCT00947557|Drug|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
35277|NCT00000849|Drug|Aldesleukin|
35278|NCT00020722|Procedure|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
35279|NCT00947557|Drug|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
35280|NCT00947570|Behavioral|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
34139|NCT00017212|Drug|exatecan mesylate|
33130|NCT00920244|Drug|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
33131|NCT00920244|Device|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
33132|NCT00920257|Drug|GSK2141795|GSK2141795 is an oral AKT inhibitor.
33133|NCT00920270|Drug|nebulized colistin|nebulized colistin 75 mg every 12 hours
33134|NCT00920270|Drug|antibiotics|conventional parenteral antibiotics
33135|NCT00920283|Device|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
33136|NCT00920283|Device|Driver Cobalt Alloy Coronary Stent|
33137|NCT00912821|Drug|6 L dialysate|6 L peritoneal dialysis solution
33138|NCT00912821|Drug|8 L dialysate|8 L peritoneal dialysis solution
33139|NCT00912860|Drug|Interferon beta-1a|serum free Avonex given IM once a week
33140|NCT00912873|Drug|ropivicaine (Psoas compartment block)|Patients will be randomized to one of two groups: ropivicaine 0.1% infusion or ropivicaine 0.4% infusion. The infusion rate will be set at 12mL/hour and 3mL/hour respectively and the outcome measures will be assessed by physical therapy using the described methods.
33141|NCT00912899|Drug|Noscapine HCl|Escalating doses given twice per day
33142|NCT00017368|Biological|filgrastim|
33143|NCT00912912|Drug|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
33144|NCT00912925|Biological|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
33145|NCT00912925|Biological|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
33146|NCT00912938|Drug|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
33147|NCT00912964|Drug|Mirabegron|Mirabegron tablets
33148|NCT00912964|Drug|Placebo|Matching mirabegron placebo tablets.
34945|NCT00905541|Drug|simvastatin|40 mg/day
34946|NCT00905541|Drug|simvastatin|80 mg simvastatin acute-on-chronic
34947|NCT00905554|Procedure|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
34948|NCT00905554|Procedure|air insufflation|air insufflation during the insertion phase of colonoscopy
34949|NCT00017004|Radiation|Internal Radiation Therapy|Undergo radiation
34950|NCT00905567|Drug|Topiramate 2 x 25 mg tablet|
34951|NCT00905567|Drug|Topamax® Tablet 2 x 25 mg|
34952|NCT00905580|Drug|Pregabalin|Pregabalin 150 mg orally
34953|NCT00905580|Drug|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
34954|NCT00905593|Drug|Nilotinib|
34955|NCT00905606|Drug|Topiramate Tablets|
34956|NCT00905606|Drug|Topamax® Tablets|
34957|NCT00905632|Drug|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
34958|NCT00905632|Drug|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
34959|NCT00908375|Drug|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
35219|NCT00906048|Drug|Levofloxacin (HR355) and Rifampicin Therapy|Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day
Weight < 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin
35220|NCT00906061|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
35221|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review.
35222|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review
35223|NCT00000817|Procedure|Point acupuncture|Standardized or alternate acupuncture procedure
35224|NCT00017069|Drug|arsenic trioxide|
35225|NCT00906087|Drug|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
34216|NCT00907270|Dietary Supplement|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
34217|NCT00907283|Drug|Deferiprone|15 mg/Kg/twice for 1 year
34218|NCT00017095|Procedure|neoadjuvant therapy|
34219|NCT00907296|Drug|AMG 785 210mg|210mg AMG 785, subcutaneous (under the skin) injection
34220|NCT00907296|Drug|AMG 785 70mg|70mg AMG 785, subcutaneous (under the skin) injection
34221|NCT00907296|Drug|AMG 785 140 mg|140mg AMG 785, subcutaneous (under the skin) injection
34222|NCT00907296|Drug|Placebo|Placebo, subcutaneous (under the skin) injection
34223|NCT00907309|Behavioral|iMET|Participants will receive the iMET intervention
33218|NCT00900471|Other|biologic sample preservation procedure|
33219|NCT00900471|Other|medical chart review|
33220|NCT00900484|Other|biologic sample preservation procedure|
33221|NCT00900484|Other|immunohistochemistry staining method|
33222|NCT00900484|Other|laboratory biomarker analysis|
33223|NCT00900497|Biological|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
33224|NCT00900510|Procedure|Incision and drainage|
33225|NCT00900510|Drug|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
33226|NCT00016419|Drug|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
33227|NCT00900510|Drug|Placebo|
33228|NCT00900523|Genetic|protein expression analysis|protein expression analysis
33229|NCT00900523|Other|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
33230|NCT00900536|Genetic|mutation analysis|
33231|NCT00900536|Genetic|polymorphism analysis|
33232|NCT00900536|Genetic|protein expression analysis|
35281|NCT00940849|Dietary Supplement|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
35282|NCT00940849|Dietary Supplement|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
35283|NCT00940862|Biological|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
35284|NCT00940862|Device|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
35285|NCT00940862|Other|Topical treatment|This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:
Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids.
35286|NCT00940875|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
35287|NCT00940875|Drug|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
35288|NCT00940875|Drug|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
35289|NCT00020098|Procedure|evaluation of cancer risk factors|
35290|NCT00940888|Device|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
35291|NCT00940901|Drug|sildenafil|sildenafil/placebo 50 mg tablet daily for 8 weeks and then sildenafil 50 mg tablet daily for 8 weeks.
35292|NCT00940901|Other|placebo|placebo 50 mg tablets daily for 8 weeks.
35293|NCT00940914|Drug|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
35294|NCT00940927|Drug|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
35295|NCT00940940|Biological|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
35296|NCT00940940|Biological|Placebo vaccine|0.65 mL subcutaneous
35644|NCT00948259|Drug|NP031112|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
35645|NCT00948259|Drug|Placebo|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
35646|NCT00948272|Biological|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
33149|NCT00912990|Drug|Cisatracurium|
33150|NCT00912990|Drug|Normal saline|
33151|NCT00913003|Drug|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
33482|NCT00915876|Drug|Paricalcitol|paricalcitol 1 mg QD x 8 weeks
33483|NCT00915876|Drug|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
33484|NCT00915889|Behavioral|telephone-based intervention|Either 6 or 8 telephone educational sessions
33485|NCT00915889|Other|counseling intervention|counseling and communications studies
33486|NCT00017563|Drug|docetaxel|35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
33487|NCT00915889|Other|questionnaire administration|Ancillary studies
33488|NCT00915889|Other|study of socioeconomic and demographic variables|Ancillary Studies
33489|NCT00915889|Procedure|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
33490|NCT00915902|Drug|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
33491|NCT00915902|Drug|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
33492|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
33493|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
33494|NCT00915928|Drug|Perindopril|2,5 mg daily for 3 months
33495|NCT00915928|Drug|Placebo|
33496|NCT00918320|Drug|Temozolomide/Hycamtin (Topotecan)|Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg
Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg
Patients receive during 5 days (Day 1 to Day 5):
Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes
33497|NCT00918333|Drug|panobinostat|Given PO
33498|NCT00918333|Drug|everolimus|Given PO
35226|NCT00906113|Drug|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
35227|NCT00906113|Drug|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
35228|NCT00906126|Drug|Misoprostol|Oral misoprostol
35229|NCT00906139|Drug|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
35230|NCT00906139|Drug|Midazolam|Midazolam dose: 0.1 mg/kg
35231|NCT00906139|Drug|Fentanyl|Fentanyl dose: 0.05 mg
35232|NCT00906165|Device|Straumann® Bone Level SLActive Implant (4.1mm diameter)|Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
35233|NCT00906178|Behavioral|CybereSenga|Internet-based HIV prevention program
35234|NCT00906191|Drug|SAM-531|
35235|NCT00017069|Drug|dexamethasone|
35236|NCT00906204|Biological|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
35237|NCT00906204|Biological|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
35238|NCT00945191|Drug|carboplatin|carboplatin (target area under the concentration versus time curve of 6.0 using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
35583|NCT00943566|Drug|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
35584|NCT00943566|Drug|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
35585|NCT00943579|Drug|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
35586|NCT00943592|Drug|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
35587|NCT00943592|Drug|Melphalan|Doses ranging from 100 to 140 mg/m2
35588|NCT00943592|Drug|Campath|20mg/d x5
33233|NCT00900536|Other|immunohistochemistry staining method|
33234|NCT00900536|Other|laboratory biomarker analysis|
33235|NCT00900549|Device|CRT on|12 months
33236|NCT00900549|Device|CRT off|12-month
33237|NCT00016432|Drug|exemestane|25 mg for 5 years
33238|NCT00900562|Drug|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
33239|NCT00900575|Device|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
33240|NCT00900575|Device|Portable Optical Spectrometer|This device is a portable optical spectrometer
33241|NCT00900575|Device|Transvaginal colposcope|
33242|NCT00900588|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
33565|NCT00913809|Drug|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
33566|NCT00913822|Drug|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
33567|NCT00915954|Other|oral glucose tolerance test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
33568|NCT00017563|Drug|mitoxantrone hydrochloride|Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
33569|NCT00915954|Other|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
33570|NCT00915967|Drug|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
33571|NCT00915967|Drug|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
33572|NCT00915980|Procedure|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
33573|NCT00915993|Drug|sunitinib malate|
33574|NCT00915993|Genetic|mutation analysis|
33575|NCT00915993|Other|immunohistochemistry staining method|
35647|NCT00020761|Drug|paclitaxel|The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.
Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.
35648|NCT00948272|Biological|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
35649|NCT00948285|Procedure|MRI|magnetic resonance imaging (MRI)
35650|NCT00948298|Drug|vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
35651|NCT00948298|Drug|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
35652|NCT00948324|Drug|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
35653|NCT00941447|Behavioral|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
35654|NCT00941447|Behavioral|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
35655|NCT00941447|Behavioral|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
35656|NCT00941460|Drug|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
35657|NCT00941460|Drug|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
35658|NCT00941473|Drug|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
35659|NCT00000844|Drug|Interferon alfa-n1|
35660|NCT00020176|Drug|fludarabine phosphate|
35661|NCT00941486|Drug|FST-100 (0.1% dexamethasone) Ophthalmic Suspension|A regimen of 2 drops 4 times a day while awake for 5 days.
35662|NCT00941486|Drug|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
35663|NCT00941499|Drug|HAI Oxaliplatin|140 mg/m^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
35664|NCT00941499|Drug|5-FU|900-1750 mg/m^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
34408|NCT00907595|Drug|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
33499|NCT00918333|Other|laboratory biomarker analysis|Correlative studies
33500|NCT00918333|Other|pharmacological study|Correlative studies
33501|NCT00918346|Drug|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
33502|NCT00918385|Drug|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
33503|NCT00918385|Drug|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
33819|NCT00903474|Procedure|stress management therapy|
33820|NCT00903500|Behavioral|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
33821|NCT00903500|Behavioral|Usual care|Usual care
33822|NCT00903539|Device|SecurAcath Securement System|Subcutaneous catheter securement system
33823|NCT00903552|Biological|Influenza VLP Vaccine|
33824|NCT00903552|Biological|Placebo|phosphate-buffered saline (PBS)
33825|NCT00903591|Other|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
33826|NCT00016887|Drug|dexamethasone|
33827|NCT00903604|Drug|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
33828|NCT00903604|Drug|Placebo|Three 10-minutes infusions of isotonic saline solution
33829|NCT00903617|Drug|GSK256073|5 mg for 8 weeks
33830|NCT00903617|Drug|GSK256073|50 mg for 8 weeks
33831|NCT00903617|Drug|GSK256073|150 mg for 8 weeks
33832|NCT00903617|Drug|Placebo|placebo for 8 weeks
35589|NCT00943592|Procedure|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
35590|NCT00943605|Device|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
35591|NCT00000846|Biological|HIV-1 Peptide Immunogen, Multivalent|
35592|NCT00020449|Biological|recombinant interleukin-12|
35593|NCT00943605|Device|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
35594|NCT00943618|Drug|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
35595|NCT00943618|Drug|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
35596|NCT00943618|Other|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
35597|NCT00943618|Behavioral|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
35598|NCT00943631|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
35599|NCT00943644|Device|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
35600|NCT00943644|Device|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
35601|NCT00943657|Biological|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
35602|NCT00943670|Biological|pertuzumab|Intravenous repeating dose
34648|NCT00902616|Dietary Supplement|L-arginine|3gm TDS for three months
34649|NCT00904982|Device|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
34650|NCT00904995|Drug|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
34651|NCT00016965|Drug|ixabepilone|
34652|NCT00904995|Drug|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
33576|NCT00915993|Other|laboratory biomarker analysis|
33577|NCT00915993|Other|pharmacological study|
33578|NCT00915993|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
33579|NCT00000826|Drug|Clarithromycin|
33580|NCT00017563|Procedure|conventional surgery|Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
33581|NCT00916006|Drug|PEP005 Gel|0.015%, three day treatment
33582|NCT00916006|Drug|Vehicle gel|Vehicle gel, three day treatment
33583|NCT00916019|Other|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
33584|NCT00916032|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
33585|NCT00916045|Drug|Thiotepa|
33586|NCT00916045|Drug|Fludarabine|
33587|NCT00916045|Drug|Intravenous busulphan|
33894|NCT00901524|Drug|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
33895|NCT00016536|Drug|Naphthalene 2-sulfonate polymer|
33896|NCT00901537|Drug|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
33897|NCT00901550|Drug|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
33898|NCT00901550|Drug|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
33899|NCT00903617|Drug|GSK256073|optional dose based on data from Part A
33900|NCT00903630|Drug|Lenalidomide|Administered by mouth at the assigned dose; beginning at 10 mg and schedule of each 28 day cycle
33901|NCT00000816|Drug|Sulfamethoxazole-Trimethoprim|
33902|NCT00016887|Drug|etoposide|
34409|NCT00907608|Drug|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
34410|NCT00907621|Procedure|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
34411|NCT00907660|Behavioral|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
34412|NCT00907660|Dietary Supplement|Portion-Controlled Foods|Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. "Full dose" patients are provided with both meals by the study; "half dose" patients are provided with one out of two meals by the study.
34413|NCT00907673|Device|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
34414|NCT00907699|Genetic|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
34415|NCT00017121|Biological|sargramostim|
34416|NCT00907699|Genetic|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
34417|NCT00017225|Drug|carboplatin|
34418|NCT00909753|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
34419|NCT00909766|Drug|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
34420|NCT00909766|Drug|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
34421|NCT00909766|Drug|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
34422|NCT00909766|Drug|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
34423|NCT00909766|Drug|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
34424|NCT00909766|Drug|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
34425|NCT00909766|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
34426|NCT00909779|Drug|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
34427|NCT00909779|Drug|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
33833|NCT00903617|Drug|Niaspan|1500 mg for 8 weeks
33834|NCT00903617|Drug|GSK256073|x mg for 8 weeks based from data from Part A
33835|NCT00906373|Biological|IMC-A12 (cixutumumab)|intravenous infusions 20 mg/kg on day 1 of each 3 week cycle
33836|NCT00906373|Drug|sorafenib|400 mg twice per day orally
33837|NCT00906386|Drug|Varenicline|oral, 1 mg twice daily, 12 weeks
33838|NCT00906386|Drug|placebo|oral, 1 mg twice daily, 12 weeks
33839|NCT00906399|Drug|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
34140|NCT00909597|Drug|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
34141|NCT00909597|Drug|taspoglutide|10mg sc once weekly
34142|NCT00909597|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
34143|NCT00909610|Drug|Ursodiol|Ursodiol Tablets, 500 mg
34144|NCT00909610|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
34145|NCT00909636|Drug|ABT-333|See arm description for more information
34146|NCT00909636|Drug|Placebo|See arm description for more information
34147|NCT00909649|Procedure|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
34148|NCT00909662|Procedure|assessment of therapy complications|Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen
Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS
Borg 15-Category Scale
34149|NCT00909662|Procedure|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
34150|NCT00017225|Biological|filgrastim|
34151|NCT00909662|Procedure|fatigue assessment and management|Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen
Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS
Borg 15-Category Scale
34152|NCT00909688|Drug|BLI-489|
34153|NCT00909688|Drug|placebo|
34653|NCT00905008|Procedure|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis <30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
34654|NCT00905008|Device|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
34655|NCT00905021|Drug|Exemestane|Exemestane 25 mg by mouth every day.
34656|NCT00905021|Drug|Sutent|Sunitinib 37.5 mg by mouth every day.
34657|NCT00905034|Drug|Methotrexate|200 mg/m^2 by vein on days 1 and 15.
34658|NCT00905034|Drug|Vincristine|1.4 mg/m^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
34659|NCT00905034|Drug|PEG-l-asparaginase|2500 International units/m^2 by vein on days 2 and 16
34660|NCT00905034|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
34661|NCT00905034|Drug|Rituximab|Rituximab 375 mg/m^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
34662|NCT00016978|Drug|FOLFOX regimen|
34663|NCT00905047|Drug|XELODA|XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.
Cycle treatment duration : 21 days
34664|NCT00905047|Drug|TEGAFUR URACIL - FOLINIC ACID|Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.
Duration of treatment cycle : 35 days.
34665|NCT00905060|Biological|HSPPC-96|Patients will receive 4 weekly injections of HSPPC-96 followed by a 5th vaccine injection on the same day of the start of maintenance temozolomide administered 2 weeks (+ 4 days) following vaccine administration #4 on the same day of the start of maintenance temozolomide (Day 36). Monthly vaccine injections will then begin on day 21 (+/- 7 days) of the first 28 day temozolomide cycle (Day 56 of the study)3 weeks following vaccine administration #5 and will continue every 28 days until depletion of vaccine or progression.
Immune monitoring will be completed pre-operatively, intra-operatively, 48-hours post-surgery, prior to vaccine administration #1, at prior to vaccine administration #5 and at weeks 09, 13, 37 and 53.
The total volume of each vaccine or place provided is 0.47 mL. The total volume that should be administered is 0.4 mL (0.07 mL overage).
34960|NCT00908375|Drug|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
34961|NCT00908388|Device|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
34962|NCT00908401|Other|Breastmilk|Breastmilk: 0.2 ml
33903|NCT00903630|Drug|pegylated liposomal doxorubicin hydrochloride|Liposomal doxorubicin at a fixed dose of 40 mg/m^2 intravenously (IV) on day 1 of each 28 day cycle
33904|NCT00903643|Other|Physical examination|Physical examination and multiple questionnaires will be administered
33905|NCT00903656|Drug|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
33906|NCT00903682|Drug|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
33907|NCT00903682|Drug|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
33908|NCT00903695|Drug|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, & acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
33909|NCT00903695|Drug|placebo|placebo comparator
33910|NCT00903708|Drug|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
33911|NCT00903721|Drug|mometasone furoate|Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)
Duration: up to 6 months
33912|NCT00903734|Drug|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
33913|NCT00016887|Drug|melphalan|
33914|NCT00903747|Drug|prucalopride|2-10 mg prucalopride
33915|NCT00903747|Drug|moxifloxacin|400 mg moxifloxacin (Group 2a)
34224|NCT00907309|Behavioral|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
34225|NCT00907322|Drug|Dimebon|Oral tablet; 20 mg Dimebon, single dose
34226|NCT00907322|Drug|Dimebon|Oral tablet; 40 mg Dimebon, single dose
34227|NCT00907322|Drug|Dimebon|Oral tablet; 60 mg Dimebon, single dose
34228|NCT00907322|Drug|Dimebon|Oral tablet; placebo, single dose
34229|NCT00017095|Radiation|radiation therapy|
34230|NCT00907335|Drug|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
34231|NCT00907335|Drug|Vehicle control|Color-matched facial gel vehicle control used once daily
34428|NCT00017225|Drug|cisplatin|
33419|NCT00918281|Drug|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
33420|NCT00918294|Device|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
33421|NCT00918307|Drug|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
33422|NCT00017719|Drug|Zidovudine|
33423|NCT00918307|Drug|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
33424|NCT00910871|Drug|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
33425|NCT00910871|Drug|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
33426|NCT00910884|Other|laboratory biomarker analysis|No supplements are given
33427|NCT00910884|Procedure|therapeutic dietary intervention|Given orally daily for 12 months
33428|NCT00910897|Drug|Velcade-Dexamethasone|
33429|NCT00910897|Drug|Velcade-Thalidomide-Dexamethasone|
33430|NCT00910910|Drug|Lenalidomide|For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.
For patients with moderate renal impairment (defined as CrCl ≥ 30 to < 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.
33431|NCT00017238|Other|pharmacological study|Correlative studies
33432|NCT00910910|Drug|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
33433|NCT00910923|Drug|JNJ-38431055|
33434|NCT00910936|Behavioral|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
33435|NCT00910962|Drug|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
33436|NCT00910962|Drug|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
33437|NCT00910962|Drug|Placebo|Placebo
34154|NCT00909701|Dietary Supplement|PreOP Booster|1 serving of 400 ml per study arm
34155|NCT00909701|Dietary Supplement|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
34156|NCT00909714|Device|DC-Stimulator to apply tDCS or Sham tDCS|Anodal tDCS (20 minutes) or Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
34157|NCT00909727|Drug|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
34158|NCT00909727|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
34159|NCT00909740|Drug|MEGF0444A|Intravenous escalating dose
34160|NCT00909753|Drug|Ursodiol|Ursodiol Tablets, 500 mg
34161|NCT00901836|Radiation|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
34162|NCT00901836|Procedure|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
33152|NCT00913003|Drug|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
33153|NCT00017368|Biological|sargramostim|
33154|NCT00913029|Device|iStent|iStent
33155|NCT00913029|Drug|latanoprost/timolol|Combination latanoprost/timolol
33156|NCT00913042|Other|sample blood|Early culture
Bacterial DNA tests in blood
33157|NCT00913055|Drug|octreotide acetate|subcutaneous implant
33158|NCT00913068|Procedure|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
33159|NCT00913068|Procedure|standard post op pain control|opiates
33160|NCT00913081|Dietary Supplement|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
33161|NCT00913081|Dietary Supplement|Placebo|Placebo PO one time
33162|NCT00913107|Drug|Lamictal®|The regime of prescription for Lamictal® during the clinical trials was as follows:
50 mg twice daily for 10days, followed by,
100 mg twice daily for the next 10days, followed by,
100 mg thrice daily for the next10 days, followed by,
100 mg four times daily for the final 10 days.
33163|NCT00915343|Drug|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
34963|NCT00017160|Procedure|chemotherapy|
34964|NCT00908401|Other|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
34965|NCT00908414|Drug|TMC589337, TMC589354, TMC310911, placebo|
34966|NCT00908427|Procedure|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
34967|NCT00908427|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
34968|NCT00908440|Behavioral|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
34969|NCT00908453|Drug|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
34970|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
34971|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
34972|NCT00908479|Behavioral|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
34973|NCT00908479|Behavioral|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
34974|NCT00000820|Drug|Aldesleukin|
34975|NCT00017160|Procedure|colony-stimulating factor therapy|
34976|NCT00908492|Behavioral|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
34977|NCT00908492|Behavioral|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
34978|NCT00908505|Procedure|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
34979|NCT00908531|Drug|letrozole (Femara)|tablet 2.5 mg daily
34232|NCT00909857|Drug|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
34233|NCT00909857|Drug|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
34234|NCT00909857|Drug|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
34235|NCT00017225|Drug|dacarbazine|
34236|NCT00909870|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
34237|NCT00909870|Device|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
34238|NCT00909883|Drug|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
34239|NCT00909883|Drug|Placebo|Placebo injection
34240|NCT00909909|Radiation|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
34241|NCT00909909|Radiation|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
34242|NCT00909935|Drug|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
34243|NCT00909948|Other|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
34244|NCT00909948|Radiation|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
34245|NCT00909961|Drug|Zoledronic acid|
33243|NCT00913107|Drug|Tegretol®|The regime of prescription for Tegretol® during the clinical trials was as follows:
150 mg twice daily for 10days, followed by,
200 mg thrice daily for the next 10days, followed by,
300 mg thrice daily for the next 10 days, followed by,
300 mg four times daily for the final 10 days.
33244|NCT00017368|Drug|carboplatin|
33245|NCT00913120|Drug|YM150|oral
33246|NCT00913120|Drug|Placebo|oral
33247|NCT00913120|Drug|Enoxaparin|injection
33248|NCT00913133|Drug|Desirudin|Desirudin SC 15mg q12h
33438|NCT00910975|Drug|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
33439|NCT00910975|Drug|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
33440|NCT00910988|Drug|Olanzapine|
33759|NCT00906347|Drug|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
33760|NCT00906347|Drug|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
33761|NCT00906360|Drug|sunitinib malate|Given orally or by percutaneous gastrostomy tube
33762|NCT00017095|Biological|filgrastim|
33763|NCT00906360|Other|pharmacological study|Correlative studies
33764|NCT00906360|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
33765|NCT00906360|Biological|cetuximab|Given IV
33766|NCT00906373|Biological|IMC-A12 (cixutumumab)|intravenous infusions 10 mg/kg on day 1 of each 3 week cycle
33767|NCT00908856|Drug|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
33768|NCT00908869|Drug|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.
Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.
Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.
Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week .
33769|NCT00908882|Behavioral|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
33770|NCT00017160|Procedure|surgery|
33771|NCT00908895|Procedure|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
33772|NCT00908895|Procedure|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
33773|NCT00908908|Drug|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
33774|NCT00908921|Drug|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
33164|NCT00000825|Drug|Aldesleukin|
33165|NCT00017472|Other|laboratory biomarker analysis|Correlative studies
33166|NCT00915343|Drug|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
33167|NCT00915356|Drug|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
33168|NCT00915356|Drug|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
33169|NCT00915369|Drug|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
33170|NCT00915382|Drug|S-1 and cisplatin|S-1: 80 mg/m2/day po on Days 1-14
cisplatin: 60 mg/m2 iv on Day 1
33171|NCT00915382|Drug|S-1 and cisplatin|S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and
cisplatin: 60 mg/m2 iv on Day 1 or 8
33172|NCT00915408|Drug|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
33504|NCT00918398|Drug|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
33505|NCT00000826|Drug|Dapsone|
33506|NCT00017758|Drug|Pravastatin sodium|
33507|NCT00918398|Drug|AZD1981|514 mg oral solution, single dose
33508|NCT00918398|Drug|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
33509|NCT00918398|Drug|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
33510|NCT00918411|Drug|Ramosetron|oral
33511|NCT00918411|Drug|Placebo|oral
33512|NCT00918424|Drug|Oxcarbazepine|
33513|NCT00918450|Drug|ABT-263|Continuous dosing until disease progression using one of the following formulations:
25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed
33514|NCT00918463|Drug|dasatinib|100 mg daily dosing
35239|NCT00945204|Other|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
35240|NCT00945230|Procedure|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
35241|NCT00945243|Device|ACDF|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
35242|NCT00945256|Other|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
35243|NCT00945256|Drug|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
35244|NCT00945256|Dietary Supplement|Amino Acid Drink|7.5 gram Amino Acid drink
35245|NCT00945269|Biological|therapeutic autologous lymphocytes|Given IV
35246|NCT00945269|Biological|aldesleukin|Given SC
35247|NCT00945269|Biological|denileukin diftitox|Given IV
35248|NCT00020566|Drug|doxorubicin hydrochloride|Given IV
35249|NCT00945269|Procedure|biopsy|Optional correlative studies
35250|NCT00945269|Other|immunohistochemistry staining method|Correlative studies
35251|NCT00945269|Other|laboratory biomarker analysis|Correlative studies
35252|NCT00945269|Genetic|polymerase chain reaction|Correlative studies
35253|NCT00945282|Drug|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
35254|NCT00945282|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
35255|NCT00945282|Drug|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
35256|NCT00945282|Drug|Placebo|Placebo is a capsule with no drug in it.
33249|NCT00913159|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
33250|NCT00913172|Other|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
33251|NCT00913185|Drug|Acne Free, Proactiv|
33252|NCT00913198|Drug|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
33253|NCT00913211|Device|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
33254|NCT00913211|Procedure|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
33255|NCT00000823|Drug|Zidovudine|
33256|NCT00017368|Drug|cisplatin|
33257|NCT00913211|Procedure|rTMS and Tracking|Combination of rTMS and finger tracking
33258|NCT00913211|Device|Sham rTMS|Sham treatment of rTMS
33259|NCT00913224|Drug|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
33260|NCT00913224|Drug|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
33261|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
33262|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
33263|NCT00913250|Drug|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
33264|NCT00913250|Drug|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
33265|NCT00913263|Drug|2-hydroxyflutamide (2-HOF) [Liproca Depot]|Ready made paste including 600 mg 2-HOF for injection as a single dose
33588|NCT00916045|Drug|Thymoglobulin|
33589|NCT00916045|Drug|Ciclosporin|
33590|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
33591|NCT00017576|Dietary Supplement|calcitriol|
33592|NCT00916045|Drug|Fludarabine|
33593|NCT00916045|Drug|Cyclophosphamide|
33775|NCT00908934|Drug|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
33776|NCT00908934|Drug|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
33777|NCT00908934|Drug|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
33778|NCT00908934|Drug|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
33779|NCT00908947|Device|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
34080|NCT00901797|Procedure|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
34081|NCT00901797|Procedure|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
34082|NCT00901810|Device|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
34083|NCT00901810|Device|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
34084|NCT00016601|Drug|Indinavir sulfate|
34085|NCT00901823|Drug|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
34086|NCT00901823|Drug|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
34087|NCT00904033|Dietary Supplement|Multivitamin|One daily multivitamin
34088|NCT00904046|Drug|Pioglitazone|30 mg orally daily for 6 months
34089|NCT00904046|Drug|Placebo|Placebo taken orally once a day for 6 months.
34090|NCT00904059|Drug|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
34091|NCT00904059|Drug|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
34092|NCT00904059|Drug|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
33515|NCT00918476|Drug|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
33516|NCT00918489|Drug|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
33517|NCT00017758|Drug|Simvastatin|
33518|NCT00918502|Device|AVIVO system|Non invasive external monitoring device
33519|NCT00918515|Drug|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
33520|NCT00918528|Procedure|Internal urethrotomy|
33521|NCT00911053|Drug|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
33522|NCT00911053|Behavioral|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
33523|NCT00911053|Behavioral|Light|Subjects will be exposed to light.
33524|NCT00911066|Drug|MLN4924|MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:
Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)
Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)
Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)
Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)
Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)
33840|NCT00906399|Drug|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
33841|NCT00017095|Drug|cyclophosphamide|
33842|NCT00906425|Device|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
33843|NCT00906438|Dietary Supplement|2006-RD-05|300 mg daily, once a day for 28 consecutive days
33844|NCT00906438|Dietary Supplement|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
33845|NCT00906451|Drug|Simvastatin|Simvastatin
33846|NCT00906477|Procedure|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
33847|NCT00906490|Device|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
35257|NCT00945282|Drug|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
35603|NCT00020449|Drug|paclitaxel|
35604|NCT00943670|Biological|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
35605|NCT00943683|Drug|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
35606|NCT00943683|Drug|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
35607|NCT00945698|Dietary Supplement|Maize-soy flour|No food supplement during the primary trial period (6 to 18 months of age)
1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
35608|NCT00945724|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate|WEEKS 1-15 - 6 cycles of CHOP i.v. on days 1 to 5, to be repeated q 21 days cyclophosphamide 750 mg/m2 doxorubicin 50 mg/m2 vincristine 1.4 mg/m2 prednisone 40 mg/m2
Rituximab i.v. 375 mg/m2 on day 0 or day 1
Intrathecal chemotherapy: Depocyte®, 50 mg on day 0 of cycles 2, 3, 4, 5 of CHOP WEEKS 18-22
Methotrexate i.v. 1.5 g/m2 q 14 days x 2 FROM WEEKS 24
Scrotal prophylactic radiotherapy or involved field radiotherapy (but can be planned concomitantly to R-CHOP in patients with bilateral disease)
35609|NCT00945737|Dietary Supplement|Soy protein; 25 grams/day|Soy protein
35610|NCT00945737|Dietary Supplement|Control protein|Milk protein
35611|NCT00945750|Drug|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
35612|NCT00945750|Drug|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
35613|NCT00945763|Drug|N1539|30 mg
35614|NCT00945763|Drug|placebo|tablets
35615|NCT00945763|Drug|N1539|15 mg
35616|NCT00945763|Drug|N1539|60 mg
35617|NCT00020579|Drug|entinostat|
35618|NCT00945763|Drug|Motrin|400 mg
35619|NCT00945776|Behavioral|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
35620|NCT00945776|Behavioral|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
35621|NCT00945776|Behavioral|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
33594|NCT00916045|Radiation|Radiotherapy|
33595|NCT00918528|Drug|Mitomycin C - local injection|
33596|NCT00918554|Drug|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
33597|NCT00918554|Drug|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
33598|NCT00918567|Drug|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
33599|NCT00918567|Behavioral|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
33600|NCT00918580|Biological|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
33601|NCT00918593|Drug|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
33602|NCT00017758|Drug|Atorvastatin calcium|
33603|NCT00918593|Radiation|Radiotherapy|Radiotherapy according to hospital procedures.
33604|NCT00918593|Drug|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
33605|NCT00918606|Drug|LIPO-102|LIPO-102
33606|NCT00918619|Device|Sangustop|Application of Sangustop haemostatic agent on resection area
33607|NCT00918619|Drug|Tachosil|Application of Tachosil fibrin sealant on resection area
33608|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> B -> C. Each of these treatments will be separated by a 7 day washout period.
33916|NCT00903747|Drug|placebo|placebo (Group 2b)
33917|NCT00903760|Drug|Decitabine|Decitabine 20 mg/m^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
34093|NCT00904059|Drug|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
34094|NCT00904085|Drug|Oxymorphone IR|5 mg
34095|NCT00904098|Drug|Frovatriptan|This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:
A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)
An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period.
34096|NCT00016900|Drug|liposomal paclitaxel|
34429|NCT00909792|Device|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
34430|NCT00909792|Device|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
34431|NCT00909805|Device|cutaneous suture (Surjet)|cutaneous surjet suture
34432|NCT00909805|Device|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
34433|NCT00909818|Radiation|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
34434|NCT00909818|Radiation|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
34435|NCT00909831|Drug|hydroxychloroquine|
34436|NCT00909831|Drug|temsirolimus|
34437|NCT00909831|Other|electron microscopy|
34438|NCT00909831|Other|high performance liquid chromatography|
34439|NCT00017225|Drug|cyclophosphamide|
34440|NCT00909831|Other|immunologic technique|
34441|NCT00909831|Other|laboratory biomarker analysis|
34442|NCT00909831|Other|mass spectrometry|
34443|NCT00909831|Other|pharmacological study|
34444|NCT00909831|Procedure|autophagy inhibition therapy|
34445|NCT00909844|Drug|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
33848|NCT00906503|Drug|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
33849|NCT00906503|Procedure|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
33850|NCT00906503|Radiation|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
33851|NCT00906516|Drug|Neuradiab in combination with Bevacizumab (Avastin)|Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.
Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient.
33852|NCT00017095|Drug|docetaxel|
33853|NCT00906529|Drug|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
33854|NCT00906555|Procedure|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
33855|NCT00906581|Behavioral|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
33856|NCT00906594|Drug|latanoprost|
33857|NCT00906620|Other|QPR: question, persuade and refer (SEYLE)|The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), "key gatekeepers" are "people who regularly come into contact with individuals or families in distress" and gatekeeper training has been identified as one of a number of promising prevention strategies.
33858|NCT00909051|Drug|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
34163|NCT00901849|Drug|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
34164|NCT00901862|Device|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
34165|NCT00901862|Device|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
34166|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
34167|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|
34168|NCT00901888|Drug|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
35622|NCT00945789|Drug|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
35623|NCT00945789|Procedure|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
35624|NCT00945789|Biological|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
34666|NCT00905073|Drug|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
34667|NCT00905086|Other|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
34668|NCT00017147|Radiation|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
34669|NCT00907946|Procedure|NT 1 day before PCNL|A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:
Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.
If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol.
34670|NCT00907959|Drug|BZL101|Oral BZL101 20 grams/day (10 grams BID).
34671|NCT00907972|Dietary Supplement|Vitamin D3|Vitamin D3
34672|NCT00907972|Other|Placebo|Placebo
34673|NCT00907985|Drug|Placebo|Placebo for both Drug A and Drug B
34674|NCT00907985|Drug|Drug A (lamotrigine)|150mg/175mg
34675|NCT00907985|Drug|Drug B (vofopitant)|10mg
34676|NCT00907998|Drug|APL180|
34677|NCT00907998|Drug|APL180|
34678|NCT00907998|Drug|Placebo|
34679|NCT00017147|Drug|O6-Benzylguanine|120 mg/m^2 IV over 1 hour on day 1 of each cycle
34680|NCT00908011|Drug|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
33918|NCT00903760|Drug|Clofarabine|Clofarabine 10 mg/m^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
33919|NCT00903773|Drug|telaprevir|
33920|NCT00903786|Drug|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
33921|NCT00903799|Device|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
33922|NCT00903812|Other|No intervention|No intervention as observational study
33923|NCT00903825|Procedure|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
33924|NCT00016887|Procedure|bone marrow ablation with stem cell support|
33925|NCT00906646|Dietary Supplement|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
33926|NCT00906646|Dietary Supplement|Placebo|Placebo tablets
33927|NCT00906672|Device|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
33928|NCT00906672|Procedure|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
33929|NCT00906685|Drug|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
33930|NCT00017095|Drug|epirubicin hydrochloride|
33931|NCT00906685|Drug|Sham bevacizumab injection|Sham intravitreal injection
33932|NCT00906698|Drug|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
33933|NCT00906698|Drug|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
33934|NCT00906698|Drug|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
33935|NCT00906698|Drug|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
33936|NCT00906698|Drug|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
33937|NCT00906698|Drug|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
34446|NCT00909857|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
34447|NCT00902252|Device|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
34448|NCT00902252|Device|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
34449|NCT00902252|Device|Vitala™|After the successful completion of Stages 1 and 2, subjects will enter the "ramp up" schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215).
34450|NCT00902265|Drug|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
34451|NCT00902278|Biological|Fluvirin|one 0.5-mL dose via intramuscular injection
34452|NCT00902278|Biological|Flulaval|one 0.5-mL dose via intramuscular injection
33441|NCT00910988|Drug|Ziprasidone|
33442|NCT00017251|Biological|oblimersen sodium|Given IV
33443|NCT00911001|Behavioral|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
33444|NCT00911014|Other|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
33445|NCT00911027|Drug|Contrast-enhanced ultrasound guided biopsy|One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part
One to four bolus (each 2.4mL) of SonoVue per patient in the main part
33446|NCT00911027|Procedure|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
33447|NCT00913458|Drug|etanercept|
33448|NCT00913471|Other|blood samples|Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.
Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.
Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.
33449|NCT00913484|Drug|Disulfiram|Disulfiram 250 mg per day
33450|NCT00017368|Drug|etoposide phosphate|
34169|NCT00016601|Drug|Ritonavir|
34170|NCT00901888|Drug|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
34171|NCT00901901|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily + matching erlotinib placebo daily
34172|NCT00901901|Drug|Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva|Sorafenib 400 mg twice daily + erlotinib 150 mg daily
34173|NCT00901914|Biological|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
34174|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
34175|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
34176|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
34177|NCT00901927|Drug|Bendamustine|Starting dose 90 mg/m^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
34178|NCT00901927|Drug|Mitoxantrone|10 mg/m^2 by vein over 15 minutes on Day 2 of each cycle.
34179|NCT00901927|Drug|Rituximab|375 mg/m^2 by vein over several hours on Day 1 of each cycle.
34180|NCT00016601|Drug|Nelfinavir mesylate|
34181|NCT00901940|Biological|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
34182|NCT00901940|Biological|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
34183|NCT00901979|Drug|LCQ908A|
34184|NCT00901979|Drug|LCQ908A|
33173|NCT00915408|Drug|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
33174|NCT00915408|Drug|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
33175|NCT00915421|Procedure|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
33176|NCT00017472|Other|pharmacological study|Correlative studies
34681|NCT00908011|Drug|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
34682|NCT00908024|Drug|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
34683|NCT00908024|Drug|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
34684|NCT00908037|Drug|eltrombopag|thrombopoietin receptor agonist
34685|NCT00908037|Drug|Placebo|placebo for comparison
34980|NCT00908544|Other|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
34981|NCT00908544|Other|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
34982|NCT00900731|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
34983|NCT00900731|Drug|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
34984|NCT00900744|Drug|Tamoxifen|20 mg daily
34985|NCT00900757|Drug|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
34986|NCT00016458|Drug|anti-thymocyte globulin|
34987|NCT00900783|Drug|valacyclovir|1 gram, three times a day for seven days
34988|NCT00900783|Drug|FV-100|400 mg, once daily, for seven days
34989|NCT00900783|Drug|FV-100|200 mg, once daily, for seven days
34990|NCT00900783|Drug|Valacyclovir placebo|three times a day, for seven days
34991|NCT00900783|Drug|FV-100 placebo|once daily, for seven days
34992|NCT00900796|Other|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
34246|NCT00017225|Drug|doxorubicin hydrochloride|
34247|NCT00909974|Dietary Supplement|UNIMMAP - multiple micronutrients|Daily supplementation of one UNIMMAP tablet
multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
34248|NCT00909974|Dietary Supplement|Food supplement enriched with multiple micronutrients|One dose of 72g per day during whole pregnancy
Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
34249|NCT00909987|Drug|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
34250|NCT00909987|Drug|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
34251|NCT00909987|Drug|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
34252|NCT00909987|Radiation|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
34253|NCT00909987|Drug|Capecitabine during all Radiotherapy period|825 mg/m2 bid
34254|NCT00901979|Drug|LCQ908A|
34255|NCT00901979|Drug|Placebo|
34256|NCT00901979|Drug|Sitagliptin|
34257|NCT00901979|Drug|metformin|
34258|NCT00016601|Drug|Efavirenz|
34259|NCT00901992|Behavioral|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
34260|NCT00901992|Behavioral|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
34261|NCT00902018|Drug|Promacta (eltrombopag)|Subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times a week for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
34262|NCT00902031|Drug|Docusate Sodium, Sennoside|Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.
Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.
34263|NCT00902031|Drug|Sennoside + Placebo|Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.
Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days
33451|NCT00913484|Drug|Placebo|Placebo daily
33452|NCT00913497|Drug|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
33453|NCT00913497|Drug|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
33454|NCT00913510|Device|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
33455|NCT00913510|Drug|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
33456|NCT00913523|Device|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
33457|NCT00913523|Device|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
33458|NCT00913536|Other|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
33459|NCT00913549|Drug|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
33780|NCT00908960|Drug|Enoxaparin|Given subcutaneously daily for 2 months
33781|NCT00017173|Biological|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
33782|NCT00908986|Drug|Rituximab|375mg/m2 q week x 4; repeated in 6 months
33783|NCT00909012|Dietary Supplement|high oleic sunflower oil|placebo, which does not provide DHA
33784|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 35 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
33785|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
33786|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 140 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
33787|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 225 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
33788|NCT00909025|Drug|Claudiximab|Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.
After completion of study treatment, patients are followed for 4 weeks.
33177|NCT00915434|Drug|JNJ-31001074|
33178|NCT00915460|Drug|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
33179|NCT00915473|Drug|bupivicaine|2.5 mL 0.5% bupivicaine
33180|NCT00915473|Drug|normal saline|2.75 mL normal saline
33181|NCT00915473|Drug|methylprednisolone|0.5 mL 20 mg methylprednisolone
33182|NCT00915473|Drug|lidocaine|0.25 mL 1% lidocaine
33183|NCT00915486|Procedure|Good Standard of Care (GSoC)|Procedural treatment twice per week
33184|NCT00915486|Biological|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
33185|NCT00915486|Biological|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
33186|NCT00915499|Device|VPAP Adapt SV|Comparison of ASV and CPAP modes
33187|NCT00017485|Drug|HPPH|
33188|NCT00917761|Drug|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
33189|NCT00917774|Device|Standard LPS flex TKA|TKA by Standard LPS flex TKA
33190|NCT00917774|Device|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
33191|NCT00917813|Drug|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
33192|NCT00917813|Drug|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
33193|NCT00917826|Drug|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
33194|NCT00017693|Biological|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
33525|NCT00911066|Drug|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
33526|NCT00911079|Procedure|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
33527|NCT00017251|Drug|carboplatin|Given IV
34993|NCT00900809|Biological|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
34994|NCT00900822|Device|Straumann Bone Ceramic|Granules applied once during surgery
34995|NCT00900822|Device|BioOss|Granules that are applied once during surgery
34996|NCT00900835|Other|educational intervention|
34997|NCT00016458|Drug|cyclophosphamide|
34998|NCT00900835|Other|questionnaire administration|
34999|NCT00900835|Other|study of socioeconomic and demographic variables|
35000|NCT00900835|Procedure|assessment of therapy complications|
35258|NCT00945295|Drug|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
35259|NCT00020566|Drug|etoposide|Given IV
35260|NCT00947414|Device|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
35261|NCT00947427|Drug|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
35262|NCT00947440|Drug|ABT-072|See arm description for more information
35263|NCT00947453|Drug|montelukast|montelukast 10 mg once daily for 8 weeks
35264|NCT00947466|Drug|Buprenorphine|Transdermal patch
35265|NCT00947479|Other|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
35266|NCT00020722|Drug|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).
Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.
Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.
Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2.
34264|NCT00902044|Genetic|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels.
If the patient has stable disease or a reduction in the size of the tumor they can receive up to 6 additional doses of T cells.
33266|NCT00913263|Drug|2-Hydroxyflutamide|The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
33267|NCT00017368|Drug|cyclophosphamide|
33268|NCT00913276|Drug|Propofol|
33269|NCT00913276|Drug|Sevoflurane|
33270|NCT00913289|Biological|adipose tissue derived stromal cells|dosage
33271|NCT00915512|Drug|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
33272|NCT00915525|Biological|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
33273|NCT00915538|Drug|pMD Symbicort 160/4.5|The subjects will receive Symbicort pMDI 160/4.5 pMDI used in conventional fashion, and have pulmonary function measured over 12 hours. Secondly on another day, they will receive pMDI using a valved holding chamber
33274|NCT00915538|Drug|Symbicort|Symbicort 160/4.5 will be administered first first through a valved holding chamber, and on another day in the conventional fashion. Pulmonary functions will be measured ove r12 hours
33275|NCT00915551|Drug|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
33276|NCT00915551|Drug|Vehicle Gel|once daily for 3 consecutive days
33277|NCT00915564|Drug|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
33278|NCT00915564|Other|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily [extremes included]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
33279|NCT00915577|Drug|Interferon beta-1a|30mcg, IM once-a-week
33280|NCT00915577|Device|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
33281|NCT00017498|Drug|gemcitabine hydrochloride|
33282|NCT00915590|Drug|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
33283|NCT00915590|Drug|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
33789|NCT00901290|Drug|monophasic oral contraceptive|mg, oral dose
33790|NCT00901290|Drug|AZD7325|mg, oral dose
33791|NCT00901303|Drug|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
33792|NCT00901316|Procedure|Routine Measures Group|Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections.
33793|NCT00901316|Procedure|Bleach Bath Group|Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths.
33794|NCT00016497|Procedure|adenoidectomy|
33795|NCT00901329|Device|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
33796|NCT00901329|Device|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
33797|NCT00901342|Drug|Sipuleucel-T|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
34097|NCT00904098|Drug|Usual Care|Current treatment used to treat all migraine headaches
34098|NCT00904111|Drug|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
34099|NCT00904111|Drug|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
34100|NCT00904124|Dietary Supplement|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
34101|NCT00904137|Procedure|Cast|
34102|NCT00904137|Procedure|Splint|
34103|NCT00904137|Procedure|Tape|
34104|NCT00904176|Drug|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
34105|NCT00904176|Drug|Warfarin|Tablets, Oral, 25 mg, Single Dose
35132|NCT00903318|Behavioral|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
35133|NCT00905827|Behavioral|CAMS|Collaborative assessment management in suicidality
35134|NCT00905840|Device|Titanium Zircon implant|The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.
The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing.
35135|NCT00905840|Device|Titanium Grade IV implant|The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.
The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing.
35136|NCT00905853|Procedure|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
35137|NCT00905853|Drug|Aggressive Antiarrhythmic Therapy (Amiodarone)|Patients who have 'failed' antiarrhythmic therapy (except amiodarone) -Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.
Patients who 'failed' amiodarone (less than 300mg/day) - Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.
Patients who 'failed' amiodarone (greater or equal to 300mg/day) - Amiodarone at the current dose with the addition of mexiletine 400-800 mg/day
35138|NCT00905866|Other|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
35139|NCT00905879|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
35140|NCT00905892|Dietary Supplement|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
35141|NCT00905905|Drug|Simvastatin|Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
35142|NCT00017043|Drug|ixabepilone|
35143|NCT00905905|Drug|Ezetimibe-Simvastatin|Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
35144|NCT00905918|Dietary Supplement|vitamin E|Given orally
35145|NCT00905918|Other|laboratory biomarker analysis|All patients undergo biomarker analyses
35146|NCT00905931|Drug|Lycopene|30 mg oral, daily, for 21 days
35147|NCT00905931|Drug|placebo|starch
35148|NCT00905944|Other|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
34624|NCT00910533|Drug|ceftriaxone|ceftriaxone 2 g od i.v. for 14 days
34625|NCT00902486|Drug|Placebo|Placebo matching INCB028050 QD
34626|NCT00902512|Drug|Treatment A|Viagra® 100 mg tablet, administered with water single dose
34627|NCT00902512|Drug|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
34911|NCT00902941|Drug|Azilect 1mg|1 mg daily orally for 120 days
34912|NCT00902941|Drug|Placebo|1 mg daily orally for 120 days
34913|NCT00902954|Drug|anastrozole|anastrozole 1 mg qd
34914|NCT00902954|Drug|letrozole|letrozole 2.5 mg qd
34915|NCT00902954|Drug|exemestane|exemestane 25 mg qd
34916|NCT00902967|Drug|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
34917|NCT00902967|Drug|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
34918|NCT00000815|Biological|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
34919|NCT00016861|Drug|irinotecan hydrochloride|
34920|NCT00902980|Other|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
34921|NCT00902993|Drug|AZD1446|Solution, oral single and multiple dose
34922|NCT00902993|Drug|Placebo|Placebo
34923|NCT00903006|Drug|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
34924|NCT00903006|Drug|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
34925|NCT00903006|Drug|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
34926|NCT00903019|Behavioral|Tele-Problem-Solving Therapy|Six sessions of tele-PST
34927|NCT00903019|Behavioral|In-Person PST|Six sessions of in person PST
34928|NCT00903019|Behavioral|Attention control|Six weekly telephone calls
31533|NCT00885742|Biological|FXIII Concentrate (Human)|Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.
Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 [NCT00883090]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion.
31534|NCT00885755|Drug|Standard taxane therapy|As prescribed
31535|NCT00885755|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
31536|NCT00885755|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
31833|NCT00888836|Procedure|Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
31834|NCT00888836|Procedure|Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
31835|NCT00888836|Behavioral|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (<30% total fat and <10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
31836|NCT00014937|Drug|zidovudine|
31837|NCT00888849|Procedure|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
31838|NCT00888849|Procedure|Suturing|Suturing
31839|NCT00888862|Drug|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
31840|NCT00888875|Device|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
31841|NCT00888875|Device|ILMA|Insertion after Induction. Insertion of tracheal tube over device
31842|NCT00888888|Procedure|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
31843|NCT00888901|Drug|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
35406|NCT00943319|Drug|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
35407|NCT00943319|Procedure|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
35408|NCT00943332|Procedure|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
35409|NCT00943345|Drug|indometacin|capsule for oral consumption
at 22h00 evening before test day: 75 mg
at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).
35410|NCT00943358|Biological|MF59 H1N1 vaccine|3.75-7.5ug dose
35411|NCT00943358|Biological|Plain H1N1 vaccine|7.5-15ug
35412|NCT00943371|Drug|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
35413|NCT00943371|Drug|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
35414|NCT00943384|Device|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
35415|NCT00943397|Drug|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
35416|NCT00020410|Biological|filgrastim|
35417|NCT00943397|Drug|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
35418|NCT00943410|Radiation|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
34472|NCT00904722|Drug|Rituximab|Administered intravenously at the standard dose of 375 mg/m^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
34473|NCT00904735|Drug|hydroxyurea|Given orally
34474|NCT00904735|Drug|imatinib mesylate|Given orally
34475|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
34476|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
34477|NCT00904748|Drug|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
35484|NCT00941187|Other|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
35485|NCT00941200|Biological|Blood collection|
35486|NCT00941213|Device|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
35487|NCT00941213|Device|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
35488|NCT00941239|Drug|metformin ER|850mg daily for 30 days
35489|NCT00941239|Drug|metformin|850 mg daily for 30 days
35490|NCT00941252|Drug|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
35491|NCT00941265|Drug|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
35492|NCT00020176|Biological|therapeutic allogeneic lymphocytes|
35493|NCT00941265|Drug|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
35494|NCT00943410|Drug|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
35495|NCT00943423|Radiation|Involved Field Radiotherapy|IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
35496|NCT00943423|Other|No further treatment|
35497|NCT00943436|Other|Exercise Session|This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The "Exercise Session" will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum.
35498|NCT00943436|Other|Rest Session|This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The "Rest Session" will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum.
35499|NCT00943449|Drug|4SC-201|oral administration
35500|NCT00943449|Drug|Sorafenib|oral administration
34929|NCT00905424|Drug|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
34930|NCT00905424|Drug|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
34931|NCT00905437|Drug|Placebo|Placebo as an adjunct to standard of care
34932|NCT00905437|Drug|Pregabalin|75 mg BD for 14 days
34933|NCT00905450|Drug|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
34934|NCT00905450|Drug|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
35200|NCT00903370|Device|MVS + ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins.
For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
35201|NCT00903370|Procedure|MVS alone|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
35202|NCT00903383|Drug|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
35203|NCT00903383|Drug|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
35204|NCT00903383|Drug|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
35205|NCT00903383|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
35206|NCT00903396|Drug|palonosetron hydrochloride|Given IV
35207|NCT00016887|Drug|cyclophosphamide|
35208|NCT00903396|Other|placebo|Given IV
35209|NCT00903409|Drug|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) [formerly known as Omacor]
35210|NCT00903422|Drug|eltrombopag olamine|thrombopoietin receptor agonist
35211|NCT00903422|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
31844|NCT00888901|Drug|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
31845|NCT00881166|Drug|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
31846|NCT00881166|Drug|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
31847|NCT00881166|Drug|MP-470 + carboplatin/etoposide|Carboplatin IV infustion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100mg/m2 IV infustion over 2 hours on Days 1-3
31848|NCT00881179|Drug|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
31849|NCT00881179|Drug|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
35025|NCT00903175|Drug|RAD001|
35026|NCT00903175|Drug|sunitinib|
35027|NCT00903188|Drug|cyclosporine|Cyclosporine (Group 1):
basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4
Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.
C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml
Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.
Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.
Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop
35028|NCT00903188|Drug|Everolimus|Everolimus (Group 2):
Basiliximab dose: idem as in group 1
Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.
Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.
Enteric-coated mycophenolate (MPA) dosing idem as group 1.
Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.
Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60.
35029|NCT00903201|Drug|SB656933|20 mg
35030|NCT00016874|Drug|triapine|
35031|NCT00903201|Drug|SB656933|50mg
35032|NCT00905632|Drug|Placebo + SOC|Placebo tid +SOC
35033|NCT00017004|Biological|Epoetin Alfa|Given SC
35034|NCT00905632|Drug|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
35035|NCT00905645|Device|Silimed Gel-Filled Mammary Implant|
35036|NCT00905658|Dietary Supplement|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
35037|NCT00905658|Procedure|standard follow-up care|Patients undergo standard monitoring
34478|NCT00904761|Other|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
34479|NCT00904787|Drug|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
34480|NCT00016952|Drug|fluorouracil|
34481|NCT00904800|Drug|AZD0837|tablet, oral, once daily, 1+5 days
34482|NCT00904800|Drug|Placebo|Placebo
34483|NCT00904813|Radiation|Preoperative radiotherapy|5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
34484|NCT00904813|Radiation|Preoperative radiotherapy|5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
34485|NCT00904813|Radiation|Preoperative radiotherapy|2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
34486|NCT00904826|Drug|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.
The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months.
34487|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
34488|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
34489|NCT00904839|Drug|mFolfox|standard i.v chemotherapy
34490|NCT00904839|Drug|Bevacizumab|100 mg/Kg solution , IV infusion
34491|NCT00016952|Drug|irinotecan hydrochloride|
34492|NCT00904839|Drug|mFolfox 6|IV standard chemotherapy
34765|NCT00908102|Other|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
34766|NCT00908102|Other|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
34767|NCT00908115|Biological|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
34768|NCT00908128|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
35501|NCT00943462|Radiation|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2‑Gy fractions, for a total of 30 fractions
35502|NCT00020410|Procedure|peripheral blood stem cell transplantation|
34546|NCT00902395|Behavioral|Protective stabilization|Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
34547|NCT00902395|Drug|Midazolam, ketamine|Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
34548|NCT00902408|Dietary Supplement|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
34549|NCT00902421|Drug|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
34550|NCT00902421|Drug|Antimuscarinics|Antimuscarinics for 3 months
34551|NCT00902460|Drug|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
34552|NCT00902460|Drug|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
34553|NCT00902473|Drug|Topiramate|25mg tablets
34554|NCT00902486|Drug|INCB028050|4 mg capsules QD
34555|NCT00016718|Drug|Didanosine|Antiretroviral
34556|NCT00902486|Drug|INCB028050|7 mg capsules QD
34557|NCT00902486|Drug|INCB028050|10 mg capsule QD
34558|NCT00904839|Drug|bevacizumab|100 mg/4 ml solution
34559|NCT00904852|Drug|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
34560|NCT00904865|Procedure|SPA cholecystectomy|SPA cholecystectomy
34561|NCT00904865|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
34562|NCT00904891|Behavioral|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
34563|NCT00904891|Behavioral|Cognitive-behavioral bibliotherapy|Cognitive-behavioral bibliotherapy, delivered from the book "Feeling Good"
31166|NCT00882570|Drug|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
31167|NCT00882583|Drug|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
31168|NCT00882583|Drug|Dasatinib|Oral Dasatinib Days 8 through 64.
31169|NCT00882583|Drug|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
31170|NCT00882583|Radiation|Radiation Therapy|Standard Radiation Therapy.
31171|NCT00882596|Device|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
31456|NCT00885703|Drug|Fluconazole|Dosages will be 1200 mg, 1600 mg, or 2000 mg for Stage 1, Arm A. MTD determined in Stage 1 (1600 mg or 2000 mg) will be given to participants in Stage 2, Arm C. Participants in both stages of the study will receive lower doses of fluconazole (a minimum daily dose of 200 mg) in Steps 2, 3, and 4 than in Step 1.
31457|NCT00885703|Drug|Amphotericin B|Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
31458|NCT00885716|Behavioral|patient training in shared decision making|
31459|NCT00014586|Drug|goserelin acetate|
31460|NCT00885716|Behavioral|cognitive training|
31461|NCT00885729|Procedure|stem cells|Stem cells or chondrocytes under a commercial available membrane
31462|NCT00885729|Procedure|Chondrocytes|Implantation of chondrocytes
31463|NCT00888069|Drug|CTAP101 Capsules|Single dose oral administration
31464|NCT00888069|Drug|CTAP101 Injection|single IV injection
31465|NCT00888082|Drug|Goserelin acetate|3.6 mg depot injectable preparation
31466|NCT00888095|Procedure|deep brain stimulation|electrode implantation in either STN or cZI
31467|NCT00888108|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
31468|NCT00888108|Drug|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
31469|NCT00888134|Drug|Selumetinib|Given PO
35038|NCT00905671|Device|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
35039|NCT00905684|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
35040|NCT00905684|Drug|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
35041|NCT00905697|Procedure|Living donor lung transplantation|Living donor lung transplantation
35042|NCT00905710|Procedure|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
35043|NCT00905723|Drug|estradiol|1 mg daily for 6 months
35044|NCT00017017|Drug|paclitaxel poliglumex|
35045|NCT00905723|Drug|isoflavone|150 mg isoflavone daily for 6 months
35046|NCT00905723|Drug|Placebo|sugar pill daily for six months
35297|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
35298|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
35299|NCT00940953|Drug|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
35300|NCT00020111|Drug|arsenic trioxide|
35301|NCT00940966|Dietary Supplement|standard ADA diet|standard ADA diet
35302|NCT00940966|Dietary Supplement|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
35303|NCT00940966|Dietary Supplement|low glycemic diet|restricted ketogenic diet
35304|NCT00940979|Procedure|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
35305|NCT00940992|Drug|DER 45 EV|Topical application to face for 12 weeks
35306|NCT00943111|Drug|Eliglustat tartrate|Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. The dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than [<] 5 nanogram per milliliter [ng/mL] the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was greater than or equal to [>=] 5 ng/mL the same dose was continued. The pharmacokinetic (PK) assessment at Week 2 and Week 6 were used for dose adjustment after Week 4 and Week 8, respectively.
34769|NCT00908128|Drug|CellCept®|CellCept® Tablets, 500 mg
34770|NCT00908141|Biological|sargramostim|Given subcutaneously on varying schedule
34771|NCT00017160|Drug|filgrastim|
34772|NCT00908154|Drug|Placebo|Tablets to match GSK1014802
34773|NCT00908154|Drug|GSK1014802|Sodium channel blocker
34774|NCT00908167|Drug|Sorafenib|Please see detailed description.
34775|NCT00908167|Drug|Cytarabine|Please see Detailed Description.
34776|NCT00908167|Drug|Clofarabine|Please see Detailed Description.
34777|NCT00908180|Biological|alemtuzumab|
34778|NCT00908180|Biological|donor lymphocytes|
34779|NCT00908180|Drug|carmustine|
34780|NCT00908180|Drug|cyclosporine|
34781|NCT00908180|Drug|cytarabine|
34782|NCT00017160|Drug|ifosfamide|
34783|NCT00908180|Drug|etoposide|
34784|NCT00908180|Drug|melphalan|
34785|NCT00908180|Procedure|allogeneic hematopoietic stem cell transplantation|
34786|NCT00000807|Drug|Etoposide|
34787|NCT00015626|Behavioral|diet and exercise|
34788|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
34789|NCT00891397|Drug|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
35067|NCT00908622|Procedure|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
35068|NCT00908622|Procedure|Cardiac revascularization|Cardiac revascularization
34564|NCT00904904|Drug|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
34565|NCT00904904|Drug|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
34566|NCT00904917|Behavioral|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
34847|NCT00905372|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
34848|NCT00905372|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
34849|NCT00905385|Biological|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
34850|NCT00905398|Drug|Nilotinib|400mg, Oral, Bid, Daily for three years
34851|NCT00017004|Radiation|External Beam Radiation Therapy|Undergo radiation
34852|NCT00905411|Behavioral|PacDASH intervention|Effect of the PacDASH intervention on nutrition and physical activity behavior of children.
15 months study.
34853|NCT00908193|Device|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
34854|NCT00908193|Procedure|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
34855|NCT00908206|Drug|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
34856|NCT00908219|Drug|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
34857|NCT00908232|Drug|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
34858|NCT00908232|Drug|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
34859|NCT00908232|Drug|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
34860|NCT00017160|Procedure|biological response modifier therapy|
34861|NCT00908232|Drug|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
34862|NCT00908245|Procedure|Control|Surgery without preconditioning surgery
34863|NCT00908245|Procedure|Preconditioning ischemia|Surgery with a preconditioning ischemia
31470|NCT00888147|Dietary Supplement|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
31471|NCT00000803|Drug|Didanosine|
31472|NCT00014911|Drug|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
31473|NCT00888173|Drug|Brivanib Alaninate|Given PO
31474|NCT00888173|Other|Laboratory Biomarker Analysis|Correlative studies
31475|NCT00888186|Drug|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
31476|NCT00888199|Device|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
31477|NCT00888212|Procedure|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
31478|NCT00888225|Procedure|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
31779|NCT00881127|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
31780|NCT00881140|Drug|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
31781|NCT00881153|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
31782|NCT00881153|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
31783|NCT00881166|Drug|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
31784|NCT00014326|Radiation|radiation therapy|
31785|NCT00881166|Drug|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
31786|NCT00883636|Other|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
31787|NCT00883649|Dietary Supplement|Hydroeye|2 Capsules BID
31788|NCT00883649|Other|Inactive Capsule|2 Capsules BID
31789|NCT00883662|Drug|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
31790|NCT00883675|Drug|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
35307|NCT00943111|Drug|Imiglucerase|Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.
35308|NCT00943124|Drug|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
35309|NCT00943124|Drug|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
35310|NCT00943124|Drug|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
35311|NCT00020371|Drug|filgrastim|
35312|NCT00943137|Drug|5-Fluorouracil|Chemotherapy will be one of the following:
de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.
FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.
Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.
35313|NCT00943150|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
35314|NCT00943150|Procedure|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
35315|NCT00943176|Drug|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
35665|NCT00941499|Drug|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
35666|NCT00941499|Drug|Cetuximab|Loading dose of 250-500mg/m^2 and Maintenance dose of 125-250 mg/m^2 by vein on Day 1 of 21 day cycle.
35667|NCT00941499|Drug|Leucovorin|200 mg/m^2 by vein on Days 1 and 2 of each 21 day cycle.
35668|NCT00941499|Drug|5-FU|300-400 mg/m^2 bolus + 600-1000 mg/m^2 infusion over 22 hours on Days 1-2 of each cycle.
35669|NCT00941499|Drug|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
35670|NCT00941525|Drug|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
35671|NCT00020176|Procedure|peripheral blood stem cell transplantation|
35672|NCT00941551|Drug|levothyroxine|levothyroxine 75-125 ug/day
35673|NCT00941551|Drug|no levothyroxine|observation only without prophylactic levothyroxine
35674|NCT00941564|Other|Infant Formula milk based|Consume ad lib
35069|NCT00908648|Procedure|Narrow Band Imaging|Narrow Band Imaging
35070|NCT00908661|Device|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
35071|NCT00908674|Drug|Cyproterone acetate (Androcur)|The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).
Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.
Administration period: 12 months.
35072|NCT00017160|Procedure|cytokine therapy|
35073|NCT00908687|Biological|A/H5N1|A/H5N1 Low Dose
35074|NCT00908687|Biological|A/H5N1|A/H5N1 High Dose
35075|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
35076|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch High Dose
35077|NCT00908700|Procedure|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
35078|NCT00908700|Procedure|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
35079|NCT00908713|Drug|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
35080|NCT00908713|Drug|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
35081|NCT00908726|Drug|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
35082|NCT00900887|Drug|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
35083|NCT00000814|Drug|Zidovudine|
35084|NCT00016471|Procedure|Audiogram|
35085|NCT00900887|Drug|Polietilenglicol 400, propilenglicol|ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml
dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week
35086|NCT00900900|Dietary Supplement|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
35087|NCT00900900|Dietary Supplement|pregnenolone|one-time 400mg oral dose of pregnenolone
34864|NCT00908271|Drug|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
34865|NCT00908284|Behavioral|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
34866|NCT00908284|Behavioral|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
34867|NCT00908297|Dietary Supplement|Coenzyme Q10|By mouth (wafer) once daily for duration of study (8 weeks).
Dose escalation:
300 mg for two weeks
600 mg for two weeks
1200 mg for two weeks
1800 mg for final two weeks
35149|NCT00905957|Procedure|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
35150|NCT00905957|Procedure|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
35151|NCT00905983|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
35152|NCT00905996|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
35153|NCT00017056|Drug|ixabepilone|
35154|NCT00905996|Drug|Beta-blocker (propranolol)|
35155|NCT00908739|Genetic|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
35156|NCT00017160|Procedure|intraoperative radiotherapy|
35157|NCT00908739|Other|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
35158|NCT00908739|Other|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
35159|NCT00908752|Drug|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
35160|NCT00908752|Drug|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
35161|NCT00908765|Behavioral|Exercise|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
31791|NCT00883688|Drug|Bevacizumab|10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week "study cycle").
31792|NCT00883688|Drug|Lapatinib|Pills of 700 mg/m^2/dose given orally 2 times each day.
31793|NCT00883714|Other|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
31794|NCT00883714|Other|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
31795|NCT00014508|Drug|cyclophosphamide|
31796|NCT00883727|Drug|Stem cell|IV infusion of stem cells
31797|NCT00883727|Drug|Plasmalyte A|IV infusion
31798|NCT00883740|Drug|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
31799|NCT00883740|Drug|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
31800|NCT00883753|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
30839|NCT00887237|Device|Conventional cardiac resynchronization|Conventional cardiac resynchronization
30840|NCT00014755|Drug|filgrastim|
30841|NCT00887250|Drug|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
30842|NCT00887250|Drug|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
30843|NCT00887250|Drug|Comparator: Placebo|Placebo to Losartan
30844|NCT00015067|Drug|Methylphenidate|
30845|NCT00889655|Drug|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
30846|NCT00889655|Drug|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
30847|NCT00889668|Device|GlucoTrack|comparison of different glucose monitoring devices
35675|NCT00941564|Other|Infant formula milk based|consume ad lib
35676|NCT00941577|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
35677|NCT00941577|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
35678|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
35679|NCT00943696|Dietary Supplement|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
35680|NCT00943709|Biological|insulin glargine recombinant|Given subcutaneously
35681|NCT00943709|Drug|therapeutic insulin|Given subcutaneously
35682|NCT00943722|Biological|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
35683|NCT00943735|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
35684|NCT00943735|Behavioral|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
35685|NCT00943748|Drug|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
35686|NCT00020449|Drug|pegylated liposomal doxorubicin hydrochloride|
34703|NCT00891306|Drug|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
34704|NCT00891319|Device|Electrical stimulator|• 12-week intervention
Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)
Self-administered hand opening exercise performed twice a day, 5 days a week at home using the device.
34705|NCT00891332|Drug|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
34706|NCT00891345|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
34707|NCT00891358|Behavioral|Prevention Empowerment Intervention for Young Women|Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.
The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs.
35419|NCT00945425|Drug|Placebo|oral capsule, once or twice daily, 7 days
35420|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
35421|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
35422|NCT00945451|Drug|cisplatin|
35423|NCT00945451|Drug|docetaxel|
35424|NCT00945451|Procedure|quality-of-life assessment|
35425|NCT00945451|Radiation|radiation therapy|CyberKnife Radiation therapy
35426|NCT00945451|Radiation|stereotactic radiosurgery|
35427|NCT00945464|Other|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
35428|NCT00945477|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
35429|NCT00000847|Biological|rgp120/HIV-1 SF-2|
35430|NCT00020566|Drug|vincristine sulfate|Given IV
35431|NCT00945490|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
35432|NCT00945490|Drug|Placebo|Single intraprostatic injection of placebo
35433|NCT00945503|Drug|GSK1018921|GSK1018921 is a GT1 recepor antagonist
35434|NCT00945516|Device|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
35435|NCT00945516|Device|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
35436|NCT00945529|Drug|inhaled nitric oxide|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
35437|NCT00945542|Other|Massive transfusion protocol|Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.
Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians.
35162|NCT00908778|Drug|Vitreosolve|intravitreal injection
35163|NCT00908778|Drug|Vitreosolve|intravitreal injection
35164|NCT00908791|Drug|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
35165|NCT00908804|Procedure|open appendectomy|
35166|NCT00908804|Procedure|laparoscopic appendectomy|
35167|NCT00017160|Procedure|radiation therapy|
35168|NCT00908817|Drug|triamcinolone acetonide|paste applied over tracheal tube for lubrication
35503|NCT00943462|Drug|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
35504|NCT00943475|Procedure|circumcision|circumcision by plastbell
35505|NCT00943488|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
35506|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
35507|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
35508|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
35509|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
35510|NCT00943540|Drug|raltegravir QD|Raltegravir 800mg QD
35511|NCT00943540|Drug|atazanavir|atazanavir
35512|NCT00943540|Drug|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
35513|NCT00020410|Radiation|yttrium Y 90 monoclonal antibody B3|
35514|NCT00943553|Drug|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day)
30848|NCT00889681|Device|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
30849|NCT00889694|Drug|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
30850|NCT00889694|Drug|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
30851|NCT00889694|Drug|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
30852|NCT00889707|Drug|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
30853|NCT00889707|Drug|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
30854|NCT00889720|Drug|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
30855|NCT00015080|Drug|Naltrexone|
30856|NCT00889733|Drug|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
30857|NCT00889785|Behavioral|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
31172|NCT00882609|Device|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
31173|NCT00014456|Biological|filgrastim|
31174|NCT00882622|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
31175|NCT00882622|Procedure|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
31176|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
31177|NCT00885118|Drug|Placebo (high dose)|Placebo tablets once a day
34708|NCT00891371|Drug|lanreotide (Autogel formulation)|Autogel 120mg
34709|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
34710|NCT00902616|Dietary Supplement|Placebo Lactose powder|3gm TDS for 3 months
34711|NCT00902629|Procedure|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
34712|NCT00902642|Behavioral|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
34713|NCT00902655|Drug|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
34714|NCT00902668|Drug|lovastatin|
34715|NCT00902668|Other|questionnaire administration|
34716|NCT00016744|Drug|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
34717|NCT00902668|Procedure|adjuvant therapy|
34718|NCT00902668|Radiation|accelerated partial breast irradiation|
34719|NCT00902668|Radiation|external beam radiation therapy|
34720|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
34721|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
34722|NCT00902694|Behavioral|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
35316|NCT00943202|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
35317|NCT00943202|Biological|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - <36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
35318|NCT00943228|Drug|mycophenolate mofetil|High dose 4gms daily
35438|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
35439|NCT00945555|Drug|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
34493|NCT00907699|Genetic|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
34494|NCT00907699|Genetic|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
34495|NCT00907699|Genetic|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
34496|NCT00907699|Genetic|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
34497|NCT00907699|Genetic|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
34498|NCT00907699|Other|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
34499|NCT00907712|Other|cardiac echo examination|cardiac echo examination - before and after the surgery
34500|NCT00907725|Other|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
34501|NCT00907725|Other|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
35515|NCT00943553|Drug|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day only)
35516|NCT00945594|Device|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
35517|NCT00945607|Other|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
35518|NCT00945620|Drug|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
35519|NCT00945620|Drug|placebo|Placebo
35520|NCT00945646|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
35521|NCT00945646|Drug|Vehicle|Instill four times two times a day
35522|NCT00945659|Device|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
35523|NCT00945659|Other|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
34567|NCT00016952|Drug|leucovorin calcium|
34568|NCT00904917|Behavioral|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
34569|NCT00904930|Device|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
34570|NCT00904930|Device|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
34571|NCT00904943|Drug|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
34572|NCT00904943|Drug|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
34573|NCT00904969|Device|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
34574|NCT00904969|Device|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
31178|NCT00885118|Drug|BI 10773|BI 10773 low dose tablets once a day
31179|NCT00885118|Drug|Placebo (low dose)|Placebo tablets once a day
31180|NCT00885144|Dietary Supplement|Nutributter|Test dose of "standard" supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
31181|NCT00885144|Dietary Supplement|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
31182|NCT00000802|Drug|Atovaquone|
31183|NCT00014573|Drug|cisplatin|
31184|NCT00885144|Dietary Supplement|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
31185|NCT00885144|Dietary Supplement|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
31186|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
31187|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
31188|NCT00885170|Drug|odanacatib|odanacatib 50 mg tablets once weekly for 24 months
31189|NCT00885170|Drug|Comparator: Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
31190|NCT00885170|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
31479|NCT00888225|Procedure|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
31480|NCT00888238|Drug|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
31481|NCT00888238|Drug|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
31482|NCT00888251|Other|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
31483|NCT00014911|Drug|Ganciclovir|An antiviral used to kill viruses and stop viral replication
31484|NCT00888290|Drug|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
35319|NCT00943254|Other|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
35320|NCT00943254|Other|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
35321|NCT00943267|Drug|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
35322|NCT00020397|Biological|NY-ESO-1 peptide vaccine|
35323|NCT00943267|Drug|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
35324|NCT00945295|Other|Rehabilitation Therapy|Rehabilitation therapy
35325|NCT00945308|Drug|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
35326|NCT00945308|Drug|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
35327|NCT00945321|Drug|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
35328|NCT00945321|Drug|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
35329|NCT00945321|Drug|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
35330|NCT00945321|Drug|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
35331|NCT00945334|Drug|Neomycin|500 mg po bid for 14 days
35332|NCT00945334|Drug|Placebo|placebo for 14 days tid
35333|NCT00945334|Drug|Rifaximin|550 mg po tid
35334|NCT00020566|Drug|ifosfamide|Given IV
35335|NCT00945347|Drug|Miglustat|Nasal instillation of miglustat
35355|NCT00947674|Device|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
35356|NCT00947687|Drug|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
35357|NCT00947700|Behavioral|Assessment & Monitoring|Assessment & monitoring at 6, 12, 18 and 24 months.
34502|NCT00017134|Drug|fenretinide|
34503|NCT00907738|Drug|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
34504|NCT00907751|Drug|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
34505|NCT00907764|Drug|regadenoson|400 ug, IV
34790|NCT00891397|Other|Placebo|Sugar pill
34791|NCT00891423|Drug|Meropenem short infusion|
34792|NCT00891423|Drug|Meropenem extended infusion|
34793|NCT00891436|Drug|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
34794|NCT00891436|Drug|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
34795|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
34796|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
34797|NCT00891462|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
34798|NCT00015626|Drug|pioglitazone|
34799|NCT00891475|Procedure|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
34800|NCT00891475|Procedure|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
34801|NCT00891475|Drug|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
34802|NCT00891501|Procedure|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
34575|NCT00904982|Behavioral|Financial Incentive and Med-eMonitor|Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.
Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server.
34576|NCT00907790|Behavioral|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
34577|NCT00907803|Drug|ST-246 400 mg|Capsules, 400 mg daily for 14 days
34578|NCT00907803|Drug|ST-246 600 mg|Capsules, 600 mg daily for 14 days
34579|NCT00907803|Drug|Placebo|Capsules, once daily for 14 days
34580|NCT00000819|Drug|Prednisone|
34581|NCT00017134|Procedure|conventional surgery|
34582|NCT00907829|Drug|lidocaine|comparison of the effect of the drug to help improve finger function
34583|NCT00907829|Device|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
34584|NCT00907842|Device|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
34868|NCT00908310|Drug|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
34869|NCT00908323|Biological|JS7 DNA vaccine|
34870|NCT00908323|Biological|MVA/HIV62 vaccine|
34871|NCT00017160|Procedure|brachytherapy|
34872|NCT00908336|Drug|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
34873|NCT00908336|Drug|Erlotinib|150 mg/day po daily
34874|NCT00908349|Drug|Oxcarbazepine|Open Label Study
34875|NCT00908362|Drug|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
34876|NCT00908362|Drug|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
31485|NCT00888303|Drug|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
31486|NCT00888303|Drug|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
31487|NCT00888303|Procedure|Thyroidectomy, total or partial|Surgical standard intervention
31488|NCT00891137|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
31489|NCT00891150|Drug|Oxytocin|Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.
Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min).
31490|NCT00891163|Drug|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
31491|NCT00891163|Drug|Placebo Patch|placebo
31492|NCT00891176|Biological|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
31493|NCT00891176|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
31494|NCT00015600|Behavioral|Behavior modification through social marketing|
31495|NCT00891176|Biological|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
31496|NCT00891176|Biological|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
31801|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5
Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days
Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm
Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)
Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound
Day before HCG: stop rFSH
Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)
Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C
Day 7 after pick-up: ultrasound, patient evaluation.
Day 14 after pick-up: HCG in blood
Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive
(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)
35358|NCT00947700|Behavioral|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months; and 12 and 18 months based on symptom severity
35359|NCT00947713|Drug|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
35360|NCT00947713|Drug|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
35361|NCT00947726|Drug|CeraVe|Using OTC cream on foot twice daily for two weeks.
35362|NCT00947739|Drug|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
35363|NCT00947752|Drug|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
35364|NCT00947752|Drug|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
35365|NCT00020735|Drug|toremifene|
35366|NCT00947765|Biological|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
35367|NCT00947765|Drug|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
35368|NCT00947778|Other|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
35369|NCT00947778|Other|1 training session|20 sessions of 30 minutes by week during 24 semaines
35370|NCT00940992|Drug|Vehicle|Topical application to face for 12 weeks
35371|NCT00941005|Device|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
35372|NCT00941018|Drug|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
35373|NCT00941031|Drug|AIN457|
35374|NCT00941031|Drug|AIN457A|Induction with monthly injections - "Monthly": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9
34803|NCT00891501|Procedure|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
34804|NCT00891514|Behavioral|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
34805|NCT00891514|Behavioral|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
35088|NCT00900900|Drug|Placebo|one-time dose oral dose
35089|NCT00900913|Drug|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
35090|NCT00900939|Behavioral|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
35091|NCT00900939|Behavioral|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
35092|NCT00900952|Other|Clinical record review|
35093|NCT00900965|Device|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
35094|NCT00900965|Device|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
35095|NCT00016471|Procedure|Electroretinogram|
35096|NCT00900978|Biological|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
35097|NCT00900991|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
35098|NCT00901017|Device|Straumann BoneCeramic|Bone augmentation procedure performed with Bone Ceramic
35099|NCT00901017|Device|Bio-Oss|Bone Augmentation procedure performed with Bio Oss
35100|NCT00901030|Procedure|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
34877|NCT00908362|Drug|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
34878|NCT00900601|Procedure|Arthrodesis to the sacroiliac joint and symphysis|Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.
To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery.
34879|NCT00900614|Drug|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
34880|NCT00900627|Drug|AZD8931|Tablet Oral bid
34881|NCT00900627|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
34882|NCT00900627|Drug|Placebo|Oral bid (twice daily)
34883|NCT00016432|Drug|Placebo|Placebo
34884|NCT00900640|Procedure|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
34885|NCT00900653|Drug|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
34886|NCT00900666|Drug|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
34887|NCT00900666|Drug|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
35169|NCT00908817|Drug|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
35170|NCT00908830|Drug|mycophenolate mofetil|Patients will take thier own 500-mg tablets of mycophenolate mofetil
35171|NCT00908843|Other|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
35172|NCT00908843|Other|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
35173|NCT00908856|Biological|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
31802|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5
Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm
Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)
Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO
Day before HCG: stop rFSH + cetrorelix
Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)
Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C
Day 7 after pick-up: ultrasound, patient evaluation.
Day 14 after pick-up: HCG in blood
Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)
31803|NCT00883779|Drug|Placebo|po on days 15-28 of each 4 week cycle until disease progression
31804|NCT00883779|Drug|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
31805|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
31806|NCT00886236|Drug|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
31807|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
31808|NCT00886249|Device|Acrysof IQ|Intraocular lens
31809|NCT00014612|Radiation|radiation therapy|
31810|NCT00886249|Device|Acrysof Natural IOL|Intraocular Lens
31811|NCT00886262|Drug|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
31812|NCT00886262|Drug|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
31813|NCT00886275|Drug|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
30858|NCT00889785|Behavioral|Usual Care|Will receive usual care and monthly phone calls as an active control.
30859|NCT00889811|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
30860|NCT00889824|Device|balance prosthesis|vibrotactile stimulation
35687|NCT00943748|Drug|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
35688|NCT00943761|Drug|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
35689|NCT00943761|Drug|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
35690|NCT00943761|Drug|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
35691|NCT00943761|Drug|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (<75 kg or ≥75 kg, respectively), for 48 weeks
35692|NCT00943774|Other|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
35693|NCT00943787|Procedure|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
35694|NCT00943800|Drug|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
35695|NCT00943800|Procedure|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
35696|NCT00943800|Procedure|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
35697|NCT00020462|Biological|aldesleukin|
35698|NCT00945828|Behavioral|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
35699|NCT00945841|Biological|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
35101|NCT00901043|Dietary Supplement|Walnut supplementation|Eight weeks of walnut supplementation
35102|NCT00901043|Dietary Supplement|Ad lib diet|Eight weeks without walnut supplementation
35103|NCT00901056|Device|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
35104|NCT00901069|Drug|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2^ Azacitidine 50 mg/m2^ Azacitidine 75 mg/m2^ Azacitidine 100 mg/m2^
35105|NCT00903201|Drug|Placebo|placebo
35106|NCT00903214|Drug|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
35440|NCT00945568|Drug|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
35441|NCT00020566|Procedure|autologous hematopoietic stem cell transplantation|Given IV
35442|NCT00945581|Other|Experimental Nutritional Powder Formula|Powder twice a day
35443|NCT00945581|Other|Placebo comparator|Powder twice a day
35444|NCT00947791|Drug|Midazolam|participants in this group/condition receive a single IV infusion of ketamine, IV 0.5 mg/kg
35445|NCT00947791|Drug|midazolam|participants in this group/condition receive a single IV infusion of midazolam, 0.025 mg/kg
35446|NCT00947817|Other|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
35447|NCT00947843|Drug|aspirin + pregrel (Clopidogrel resinate)|
35448|NCT00947843|Drug|aspirin + placebo|
35449|NCT00947843|Drug|aspirin + plavix (Clopidogrel bisulfate)|
35450|NCT00020735|Procedure|conventional surgery|
35451|NCT00947856|Drug|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
35452|NCT00947882|Drug|Placebo|Mannitol 50 mg/mL solution
35453|NCT00947882|Drug|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
35454|NCT00947882|Drug|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
35174|NCT00908856|Biological|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
35175|NCT00901082|Behavioral|Relaxation and information session|Relaxation and information session before the medial branch block
35176|NCT00016497|Procedure|bilateral myringotomy|
35177|NCT00901095|Behavioral|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
35178|NCT00901108|Procedure|Trabectome-IOL|Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.
Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery.
35179|NCT00901108|Procedure|Trab-IOL|Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.
Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C.
35180|NCT00901121|Device|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
35181|NCT00901121|Device|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
35182|NCT00901147|Drug|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
35183|NCT00901160|Procedure|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
35184|NCT00901186|Drug|RFB002|0.5 mg
35185|NCT00901186|Procedure|Laser photocoagulation|
35524|NCT00020566|Procedure|conventional surgery|Given to patients deemed to require it
35525|NCT00945659|Behavioral|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
35526|NCT00945672|Biological|PF-04360365 10 mg/kg|10 mg/kg every 90 days (5 total doses)
35527|NCT00945672|Biological|PF-04360365 7.5 mg/kg|10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
30861|NCT00889837|Drug|Staccato Loxapine|2 doses 10 hours apart
30862|NCT00889837|Drug|Staccato Placebo|2 doses 10 hours apart
30863|NCT00889850|Drug|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
30864|NCT00889850|Drug|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
30865|NCT00882011|Other|Latest generation chemotherapies for T-LBL + transplant|Standard doses of one of the following chemotherapies:
Holzer
LSA2-L2 modified
Stanford regimen
Hyper CVAD
Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)
Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)
Autologous transplant or allogeneic transplant or mini-allogeneic transplant
30866|NCT00014378|Drug|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
30867|NCT00882024|Drug|Tranilast|150 mg tranilast tablets, bid, 12 weeks
30868|NCT00882024|Drug|Tranilast|75 mg tablets, bid, 12 weeks
30869|NCT00882024|Drug|Placebo|Placebo tablets, bid, 12 weeks
30870|NCT00882050|Drug|Exenatide|Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.
30871|NCT00882050|Drug|Exenatide|Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours
30872|NCT00882050|Drug|Placebo|Intravenous Placebo of normal saline solution to be infused at same rate as drug comparator
30873|NCT00882063|Drug|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
30874|NCT00882076|Drug|Etoposide, Mitoxantrone, Clofarabine|Cohort 1: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6)20 mg/m2. Cohort 2:Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6)25 mg/m2 Cohort 3: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6)30 mg/m2. Cohort 4: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (5 doses); Clofarabine (Days 2-6)30 mg/m2. In the event of excessive DLT in Cohort 1, a Cohort 0 will be explored: Cohort 0: Etoposide (Days 1-5) 100 mg/m2
31191|NCT00885170|Dietary Supplement|Calcium|Patients will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
31192|NCT00885183|Procedure|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
31193|NCT00885196|Drug|Placebo|
31194|NCT00014573|Drug|cyclophosphamide|
35700|NCT00945854|Other|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
34723|NCT00902694|Other|Control|group health classes quarterly with topics not related to weight
34724|NCT00902707|Drug|Mucinex 1200mg|Compared to Placebo
34725|NCT00902707|Drug|Placebo|Compare to active Mucinex
34726|NCT00902720|Other|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
34727|NCT00016744|Drug|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
34728|NCT00902733|Other|medical chart review|
34729|NCT00902733|Other|questionnaire administration|
34730|NCT00902733|Procedure|fatigue assessment and management|
34731|NCT00902733|Procedure|psychosocial assessment and care|
34732|NCT00902733|Procedure|quality-of-life assessment|
34733|NCT00902746|Drug|NPC-01|This study consist of the following steps.
Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.
Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):
After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point.
34734|NCT00905086|Procedure|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
34735|NCT00905086|Procedure|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
34736|NCT00905086|Procedure|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
34737|NCT00905112|Other|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
35455|NCT00947882|Drug|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
35456|NCT00947895|Drug|Methylprednisolone|IV 1000 mg daily for 3 days
35457|NCT00947895|Drug|ACTH|IM ACTH 80 mg/day for 5 days.
35458|NCT00947895|Other|IV placebo|IV placebo (saline) daily for 3 days.
35459|NCT00947895|Other|IM placebo|IM placebo (saline) daily for 5 days.
35460|NCT00947908|Biological|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
35461|NCT00020735|Procedure|neoadjuvant therapy|
35462|NCT00947921|Procedure|Plasty|Restrictive Annuloplasty
35463|NCT00947921|Procedure|Prosthesis|Valve replacement
34506|NCT00907777|Biological|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
34507|NCT00907777|Biological|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
34508|NCT00907790|Behavioral|Usual Care (Control Group)|
34509|NCT00909987|Procedure|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
34510|NCT00910000|Drug|Vorinostat|Taken orally once a day in the AM for the first two weeks of each three-week cycle. Dose will depend upon when participant enters into the clinical trial
34511|NCT00910000|Device|Carboplatin|Given intravenously on day 1 of every three week cycle
34512|NCT00000822|Drug|Ritonavir|
34513|NCT00017225|Drug|etoposide|
34514|NCT00910000|Drug|Gemcitabine|Given intravenously on day and day 8 of every three week cycle
34515|NCT00910013|Drug|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
34516|NCT00910026|Procedure|low tidal volume ventilation|6 ml/kg tidal volume ventilation
34517|NCT00910026|Procedure|high tidal volume ventilation|12 ml/kg tidal volume ventilation
35528|NCT00945672|Drug|placebo|placebo administered every 90 days or monthly to match experimental treatment arms.
35529|NCT00945685|Device|Endymion Imagine™ System for Skin Tightening|Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):
Pulse energy (J);
RF frequency (1MHz);
Pulse duration (30 sec);
Treatment hand piece (skin tightening);
35530|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 10gM|140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
35531|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 20gM|280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
35532|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 20gNoM|280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
35533|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 40gM|560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
35534|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 40gNoM|560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
35535|NCT00020566|Radiation|radiation therapy|Given to patients deemed to require it
35536|NCT00947973|Behavioral|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
35537|NCT00947986|Other|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
35538|NCT00948025|Device|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
35539|NCT00020748|Drug|epirubicin hydrochloride|
35540|NCT00948025|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve tissue scaffold at time of surgery.
35541|NCT00948038|Dietary Supplement|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
34585|NCT00907868|Radiation|partial breast irradiation|Patients undergo radiation tumor bed boost
34586|NCT00907868|Radiation|whole breast irradiation|Patients undergo whole breast irradiation
34587|NCT00907881|Drug|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
31195|NCT00885196|Drug|AEB071|
31196|NCT00885222|Device|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
31197|NCT00885274|Drug|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
31198|NCT00885274|Drug|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
31199|NCT00887575|Drug|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
31200|NCT00887575|Drug|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
31201|NCT00887588|Drug|LCZ696|50 mg, 100 mg and 200 mg tablets
31202|NCT00887588|Drug|Valsartan|40 mg, 80 mg and 160 mg tablets
31203|NCT00014794|Drug|15-O labeled water|
31204|NCT00887588|Drug|Placebo|matching placebo to LCZ696 and Valsartan
31205|NCT00887601|Drug|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
31206|NCT00887601|Drug|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
31207|NCT00887601|Drug|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
31208|NCT00887601|Drug|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
31497|NCT00891176|Biological|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
31498|NCT00891176|Biological|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
31499|NCT00891176|Biological|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
34738|NCT00905112|Other|Standard OB Care|Receive standard obstetrical care
34739|NCT00016978|Drug|fluorouracil|
34740|NCT00905125|Biological|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
34741|NCT00905125|Biological|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
35336|NCT00945347|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
35337|NCT00945360|Drug|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
35338|NCT00945373|Drug|calcium dobesilate|2.5% gel
35339|NCT00945373|Procedure|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
35340|NCT00945399|Procedure|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
35341|NCT00945399|Procedure|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
35342|NCT00945412|Device|Micropolysaccharide Hemospheres (Arista)|MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.
No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect.
35343|NCT00945412|Device|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
35344|NCT00945425|Drug|AZD7325|oral capsule, once or twice daily, 7 days
35345|NCT00020566|Drug|melphalan|Given orally and IV
35346|NCT00947583|Biological|Osteocel Plus|biologic
35347|NCT00947596|Drug|atropine sulfate|dry powder for inhalation
35348|NCT00947596|Drug|atropine sulfate|intramuscular injection
34518|NCT00910039|Drug|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
34519|NCT00910039|Other|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
34520|NCT00910052|Device|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
34521|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
34522|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
34523|NCT00910065|Drug|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
34524|NCT00017225|Drug|ifosfamide|
34525|NCT00910091|Drug|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
34806|NCT00902759|Other|Walking Program|"Brisk" walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program.
34807|NCT00902772|Drug|Lorazepam|mg, oral dose
34808|NCT00902772|Drug|AZD7325|mg, oral dose
34809|NCT00902772|Drug|Placebo|
34810|NCT00016744|Drug|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
34811|NCT00902785|Other|no drug|observational no drug
34812|NCT00902798|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
34588|NCT00907894|Drug|LDT600 (Telbivudine)|LDT600 (Telbivudine)
34589|NCT00907907|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
34590|NCT00907907|Drug|CellCept® Tablets|CellCept® Tablets, 500 mg
34591|NCT00907920|Other|laboratory biomarker analysis|Correlative studies
34592|NCT00017147|Drug|carmustine|40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.
200 mg/m^2 IV over 1 hour on day 2 of each cycle for the active comparator arm.
34593|NCT00907933|Drug|SB-705498|0.5mg intranasal SB-705498
34594|NCT00907933|Drug|SB-705498|1.5mg intranasal SB-705498
34595|NCT00907933|Drug|SB-705498|3mg intranasal SB-705498
34596|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498
34597|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498
34598|NCT00907933|Drug|Placebo|Placebo '498
34599|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498 for 14 days bid
34600|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498 14 days bid
34601|NCT00907933|Drug|Placebo|Placebo
34602|NCT00907946|Procedure|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
34603|NCT00910390|Procedure|Slow freezing method with propane diol|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
34604|NCT00910390|Procedure|Vitrification solution - Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
34605|NCT00910390|Procedure|Vitrification solution - vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
34606|NCT00910403|Procedure|LASIK|Excimer Laser Ablation using LASIK
34888|NCT00900679|Behavioral|telephone-based intervention|
31500|NCT00891176|Biological|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
31501|NCT00891176|Biological|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
31502|NCT00891202|Drug|Eliglustat tartrate|Eliglustat tartrate capsule as a single 50 milligram (mg) dose on Day 1 followed by eliglustat tartrate 50 mg capsule twice daily (BID) from Day 2 to Week 4, and then either eliglustat tartrate 50 mg capsule BID (in participants who had a Genz-99067 [active moiety of eliglustat tartrate in plasma] trough plasma concentration greater than or equal to [>=] 5 nanogram per milliliter [ng/mL]) or eliglustat tartrate 100 mg capsule BID (in participants who had a Genz-99067 trough plasma concentration less than [<] 5 ng/mL), up to Week 39. The pharmacokinetic (PK) assessment at Week 2 was used for dose adjustment after Week 4.
31503|NCT00891202|Drug|Placebo|Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39.
31504|NCT00891228|Drug|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
31505|NCT00015626|Drug|Metformin|
31506|NCT00883129|Drug|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
31507|NCT00014469|Procedure|allogeneic bone marrow transplantation|
31508|NCT00883129|Drug|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
31509|NCT00883155|Drug|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
31510|NCT00883155|Drug|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
31511|NCT00883168|Drug|Placebo|Placebo
31512|NCT00883168|Drug|azelastineHcl|azelastine hydrochloride 548 mg
31513|NCT00883168|Drug|fluticasone propionate|fluticasone propionate 200 mcg
31514|NCT00883168|Drug|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
31515|NCT00883194|Drug|PRF-108|Ropivacaine
31516|NCT00883194|Drug|Placebo|PRF-108 Placebo
31814|NCT00886275|Drug|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
31815|NCT00886275|Drug|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
35349|NCT00947622|Device|Transcranial direct current stimulation|Transcranial Direct current stimulation
35350|NCT00947635|Dietary Supplement|Dietary intervention - supplements|Supplement bar & spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
35351|NCT00947648|Other|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
35352|NCT00947648|Other|Cooked Foods|Diet containing only cooked foods.
35353|NCT00947661|Drug|Formulation 2:Latanoprost (without BAC)|Eye drops, once daily, 12 weeks
35354|NCT00020722|Procedure|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
35375|NCT00020124|Drug|doxorubicin hydrochloride|
35376|NCT00941031|Drug|AIN457A|Early loading induction - "Early": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5
35377|NCT00941031|Drug|Placebo|Placebo - "Placebo": Placebo administered at weeks 1, 2, 3, 5, 9
35378|NCT00941044|Device|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
35379|NCT00941057|Drug|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
35380|NCT00941057|Drug|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
35381|NCT00941057|Drug|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
35382|NCT00941070|Drug|triapine|Given IV
35383|NCT00941070|Drug|cisplatin|Given IV
35384|NCT00941070|Radiation|external beam radiation therapy|Undergo pelvic external beam radiation therapy
35385|NCT00941070|Procedure|quality-of-life assessment|Ancillary studies
35386|NCT00020150|Drug|O6-benzylguanine|
35387|NCT00941070|Other|questionnaire administration|Ancillary studies
35388|NCT00941070|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
35389|NCT00941070|Procedure|positron emission tomography|Undergo FDG-PET/CT
34813|NCT00902798|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
34814|NCT00902811|Drug|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
34815|NCT00902811|Drug|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
34816|NCT00902811|Drug|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
34817|NCT00902811|Drug|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group <6yrs of age, a subdivision according to weight is made
34818|NCT00902811|Drug|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
34819|NCT00902824|Biological|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10^7 pfu TBC-M4 (IM)
34820|NCT00902824|Biological|TBC-M4|Receive 5x10^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
34821|NCT00016835|Procedure|periodontal scaling and local antibiotic irrigation|
34822|NCT00902824|Other|Placebo|Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.
Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM.
35107|NCT00903214|Genetic|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
35108|NCT00903214|Procedure|axillary lymph node biopsy|
35109|NCT00903214|Procedure|digital image analysis|
35110|NCT00903214|Procedure|needle biopsy|
35111|NCT00903214|Procedure|sentinel lymph node biopsy|
35112|NCT00903214|Procedure|therapeutic conventional surgery|
35113|NCT00903227|Drug|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
35114|NCT00016887|Biological|filgrastim|
34889|NCT00900679|Other|counseling intervention|
34890|NCT00900679|Other|educational intervention|
34891|NCT00900679|Other|medical chart review|
34892|NCT00900679|Other|questionnaire administration|
34893|NCT00900679|Procedure|psychosocial assessment and care|
34894|NCT00016445|Drug|growth hormone|
34895|NCT00900679|Procedure|quality-of-life assessment|
34896|NCT00900692|Device|Dynasplint|Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or "Experimental" group will add this therapy to their standard of care regimen
34897|NCT00900718|Device|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
34898|NCT00900718|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
34899|NCT00900731|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
34900|NCT00900731|Drug|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
34901|NCT00902850|Device|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
34902|NCT00902850|Device|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
34903|NCT00902863|Behavioral|YOGA|Patients with chronic pain will undergo a six week course of YOGA
34904|NCT00902876|Device|Mucograft|Collagen Matrix for soft tissue regeneration
34905|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
34906|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
34907|NCT00016835|Procedure|systemic antibiotic (either doxycycline or metronidazole).|
34908|NCT00902915|Drug|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
34909|NCT00902928|Drug|YM150|oral
31816|NCT00886301|Procedure|liver biopsy|liver biopsy
31817|NCT00886314|Drug|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
31818|NCT00886314|Other|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
31819|NCT00886327|Procedure|Colonic capsule endoscopy|
31820|NCT00014625|Drug|indisulam|
31821|NCT00886340|Behavioral|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
31822|NCT00886340|Behavioral|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
31823|NCT00886353|Biological|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
31824|NCT00886353|Other|Placebo|Physiological saline administrated i.v.
31825|NCT00886366|Drug|AZD6714|Oral single doses a-h suspension
31826|NCT00886366|Drug|Placebo|Oral single doses suspension
31827|NCT00886366|Drug|AZD6714|Oral single doses a-d suspension
31828|NCT00888784|Drug|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
31829|NCT00888797|Drug|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
31830|NCT00888810|Drug|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
31831|NCT00888810|Drug|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
31832|NCT00888823|Radiation|Stereotactic Radiotherapy|Stereotactic Radiotherapy
35390|NCT00941070|Procedure|computed tomography|Undergo FDG-PET/CT
35391|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
35392|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
35393|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
35394|NCT00941096|Drug|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
35395|NCT00941109|Drug|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
35396|NCT00943267|Drug|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
35397|NCT00943267|Procedure|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
34453|NCT00902278|Biological|Fluzone|one 0.5-mL dose via intramuscular injection
34454|NCT00902278|Biological|Fluarix|one 0.5-mL dose via intramuscular injection
34455|NCT00902278|Biological|Afluria|one 0.5-mL dose via intramuscular injection
34456|NCT00902291|Biological|AGS-1C4D4|IV infusion
34457|NCT00016666|Drug|Propranolol|
34458|NCT00902291|Biological|Gemcitabine|IV infusion
34459|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
34460|NCT00902304|Drug|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
34461|NCT00902304|Drug|Usual care|As directed by investigator
34462|NCT00902304|Drug|Valsartan|Valsartan 160mg per day to 320mg per day orally
34463|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
34464|NCT00902317|Procedure|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
35115|NCT00903227|Drug|Placebo|1 puff of inhaled Placebo twice a day
35116|NCT00903227|Drug|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
35117|NCT00903227|Drug|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
35118|NCT00903227|Drug|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
35119|NCT00903253|Drug|LNK-754|
35120|NCT00903266|Behavioral|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
35121|NCT00903266|Behavioral|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
35122|NCT00903279|Drug|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
35123|NCT00903279|Drug|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
35124|NCT00903292|Drug|erlotinib (Tarceva)|chemotherapy with erlotinib
35125|NCT00016887|Biological|recombinant interferon alfa|
35126|NCT00903292|Drug|pemetrexed (Alimta)|Chemotherapy with pemetrexed
35127|NCT00903305|Other|medical chart review|
35128|NCT00903305|Other|questionnaire administration|
35129|NCT00903305|Procedure|fatigue assessment and management|
35130|NCT00903305|Procedure|psychosocial assessment and care|
35464|NCT00947934|Device|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
35465|NCT00947947|Behavioral|Tailored Information Program for Safer Sex|Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
35466|NCT00947960|Drug|Triheptanoin|1-2g/kg of body weight per day divided into 4 doses per day.
35467|NCT00947960|Dietary Supplement|Vegetable Oil|1-2g/kg of body weight per day divided into 4 doses.
34910|NCT00902928|Drug|enoxaparin|SC injection
35186|NCT00901199|Drug|Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)|All subjects will be given Exjade 7 days per week 20-30mg/kg and Deferoxamine 3-7 days per week 50mg/kg. Days per week are dependent on how much iron overload subject has.
35187|NCT00016497|Procedure|bilateral myringotomy and tubes|
35188|NCT00901212|Device|Device programming|6-month period
35189|NCT00901225|Drug|G-CSF plus Plerixafor|On Day 5 of G-CSF mobilization,
if the patient's peripheral CD34+ cell count is < 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.
if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is < 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected.
35190|NCT00901238|Procedure|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
35191|NCT00901277|Behavioral|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
35192|NCT00901277|Behavioral|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
35193|NCT00903331|Drug|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
35194|NCT00903331|Drug|Placebo|matching placebo, once daily
35195|NCT00903344|Drug|Vitamin D3|4000IU vitamin D3 tablet taken daily
35196|NCT00016887|Drug|carmustine|
35197|NCT00903344|Dietary Supplement|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
35198|NCT00903357|Drug|Montelukast first, then placebo|Patients in "Montelukast first, then placebo" will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in "Placebo first, then Montelukast" are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks.
35199|NCT00903357|Drug|Placebo first, then Montelukast|Patients in "Montelukast first, then placebo" will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in "Placebo first, then Montelukast" are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks.
30875|NCT00882076|Drug|Clofarabine, Etoposide, Mitoxantrone|Retreatment doses should be as follows: Cohort 1: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2 (2 doses); Clofarabine (Days 1-4)20 mg/m2. Cohort 2:Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2 (2 doses); Clofarabine (Days 1-4)25 mg/m2; Cohort 3: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2 (2 doses); Clofarabine (Days 1-4)30 mg/m2. Cohort 4: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-4) 8 mg/m2 (4 doses); Clofarabine (Days 1-4)30 mg/m2; Cohort 0: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2; Clofarabine (Days 1-4) 10 mg/m2.
30876|NCT00882089|Device|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
30877|NCT00000801|Drug|Doxorubicin hydrochloride|
30878|NCT00014391|Biological|palivizumab|
30879|NCT00882102|Drug|Decitabine|Decitabine 20 mg/m^2 IV over 1-1/2 hours daily for 5 days.
30880|NCT00882102|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m^2 IV on day 5.
30881|NCT00882115|Drug|Broccoli sprout extract|Broccoli sprout extract will be ingested by drinking a liquid formula in a volume equaling less than 1 cup at study Visits 6,7,8, and 9
30882|NCT00882141|Behavioral|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
30883|NCT00882141|Behavioral|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
30884|NCT00884715|Drug|Octreotide|short acting octreotide
30885|NCT00884741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimentional conformal radiation therapy
30886|NCT00884741|Biological|Bevacizumab|Given IV
30887|NCT00884741|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
30888|NCT00884741|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
30889|NCT00884741|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
30890|NCT00884741|Other|Laboratory Biomarker Analysis|Correlative studies
30891|NCT00884741|Other|Placebo|Given IV
30892|NCT00884741|Other|Quality-of-Life Assessment|Ancillary studies
30893|NCT00014560|Biological|sargramostim|
34465|NCT00902317|Procedure|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
34466|NCT00902317|Procedure|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
34467|NCT00902317|Device|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
34468|NCT00000815|Biological|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
34469|NCT00016679|Drug|1-Octanol|
34470|NCT00904709|Drug|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
34471|NCT00904722|Drug|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
34742|NCT00905138|Drug|GLPG0259|single ascending doses, oral solution
34743|NCT00905138|Drug|placebo|single dose, oral solution
34744|NCT00905138|Drug|GLPG0259|multiple dose, oral solution, 5 days
34745|NCT00905138|Drug|placebo|oral solution, 5 days
34746|NCT00905164|Drug|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
34747|NCT00905164|Drug|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
34748|NCT00905190|Drug|Ondansetron|24 mg one time
34749|NCT00905203|Other|exercise|exercise training
34750|NCT00016978|Drug|leucovorin calcium|
34751|NCT00905216|Drug|heparin sodium - Bergamo|5.000 UI/mL
34752|NCT00905216|Drug|heparin sodium - APP|5.000 USP
34753|NCT00905229|Drug|Phytonadione|2.5 mg po
34754|NCT00905229|Drug|Phytonadione|0.5 mg IV
35468|NCT00947973|Behavioral|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
35469|NCT00941109|Drug|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
35470|NCT00020150|Drug|temozolomide|
35471|NCT00941109|Drug|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
35472|NCT00941109|Drug|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
35473|NCT00941122|Device|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
35474|NCT00941135|Other|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks
Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43
35475|NCT00941148|Drug|Insulin Glargin|
35476|NCT00941148|Drug|NPH insulin|
35477|NCT00941148|Drug|Insulin detemir|
35478|NCT00941148|Drug|metformin|metformin (2000 mg/day)
35479|NCT00941161|Drug|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
35480|NCT00941161|Drug|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
35481|NCT00020176|Biological|filgrastim|
35482|NCT00941161|Drug|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
35483|NCT00941174|Drug|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
34526|NCT00910091|Drug|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
34527|NCT00910104|Drug|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
34528|NCT00910117|Drug|nimotuzumab|nimotuzumab 400 mg d1
34529|NCT00910117|Drug|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
35542|NCT00948038|Dietary Supplement|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
35543|NCT00948051|Dietary Supplement|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
35544|NCT00948051|Dietary Supplement|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
35545|NCT00948064|Drug|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
35546|NCT00948064|Drug|Azacitidine|75 mg/m^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
35547|NCT00948077|Drug|Rifater and EMB|The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.
The patients assigned randomly the Arm "Treatment A" on the fifth day will be switched to the Arm "Treatment B" on the sixth day. On the other hand, the patients assigned randomly the Arm "Treatment B" on the fifth day will be switched to the Arm "Treatment A" on the sixth day. The flow of intervention is drawn as below.
Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)
35548|NCT00948090|Drug|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
35549|NCT00948103|Drug|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
35550|NCT00020748|Drug|irinotecan hydrochloride|
35551|NCT00948103|Drug|Oxygen|oxygen
35552|NCT00948129|Behavioral|Smoking cessation training, support, and telephone follow-up|Brief coach advice to quit smoking, nicotine replacement therapy (NRT), and self-help written materials
35553|NCT00948129|Behavioral|Smoking cessation intervention|SC components plus a single motivational interviewing counseling session and a cell phone-delivered text/graphical messaging component
35554|NCT00948129|Behavioral|Weekly Telephone Coaching|SC and EC components plus a series of 11 cell phone-delivered proactive counseling sessions and a cell phone-delivered text/graphical messaging component
35555|NCT00948142|Drug|CEM-102|600 mg BID oral tablets for 10-14 days
35556|NCT00948142|Drug|Linezolid|600 mg BID oral tablets
35557|NCT00948142|Drug|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
35558|NCT00941278|Drug|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
35559|NCT00941304|Drug|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
30894|NCT00884741|Drug|Temozolomide|Given orally
30895|NCT00884754|Device|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
31209|NCT00887614|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
31210|NCT00887627|Drug|conivaptan hydrochloride|intravenous
31211|NCT00887640|Drug|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
31212|NCT00887640|Drug|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
31213|NCT00887653|Drug|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
31214|NCT00014807|Behavioral|Reducing Pesticide Exposure in Minority Families|
31215|NCT00887679|Drug|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
31216|NCT00887692|Behavioral|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
31217|NCT00887705|Behavioral|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
31218|NCT00887718|Biological|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
31219|NCT00887744|Device|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
31220|NCT00015236|Behavioral|Amantadine|
31221|NCT00890409|Device|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
34755|NCT00905242|Drug|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
34756|NCT00905255|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
34757|NCT00905255|Device|Pen auto-injector|
34758|NCT00905268|Drug|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
34759|NCT00908076|Drug|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
34760|NCT00017160|Drug|doxorubicin|
34761|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
34762|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
34763|NCT00908102|Other|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
34764|NCT00908102|Other|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
35047|NCT00905736|Procedure|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
35048|NCT00905736|Procedure|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
35049|NCT00905762|Drug|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
35050|NCT00905762|Drug|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
35051|NCT00905762|Drug|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
35052|NCT00905788|Procedure|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
35053|NCT00905801|Other|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
34530|NCT00910143|Procedure|conventional rectal surgery|type of rectal surgery before the introduction of TME
34531|NCT00910143|Procedure|total mesorectal excision|total mesorectal excision
34532|NCT00910156|Device|Airtraq laryngoscope|Airtraq intubation
34533|NCT00910156|Device|Glidescope laryngoscope|glidescope intubation
34534|NCT00902317|Procedure|Angioplasty/Stent (Guidant "Absolute" stent)|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
34535|NCT00902330|Procedure|energy-based therapy|Given once a day for 18 weeks
34536|NCT00902330|Procedure|sham intervention|Given once a day for 18 weeks
34537|NCT00902343|Procedure|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
34538|NCT00902343|Procedure|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
34539|NCT00902356|Drug|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
34540|NCT00902356|Drug|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
34541|NCT00902369|Drug|AK106-001616|Part1: Dose escalation Part2: Dose expansion
34542|NCT00902369|Drug|Placebo|
34543|NCT00902369|Drug|Active comparator|
34544|NCT00016692|Drug|Z-100|
34545|NCT00902395|Drug|Midazolam|Oral midazolam 1.0 mg/kg (maximum 20 mg)
34823|NCT00902837|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
34824|NCT00902837|Drug|oxycodone prolonged release tablet|
34825|NCT00902837|Drug|oxycodone naloxone tablet|
35560|NCT00941304|Drug|Buprenorphine|Single-dose of buprenorphine HCl buccal film
35561|NCT00941304|Drug|Placebo Film|Single-dose of placebo buccal film
34607|NCT00910416|Drug|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
34608|NCT00910416|Drug|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
34609|NCT00910416|Device|EEG monitoring|simultaneous monitoring with Bis and Neurosense
34610|NCT00017225|Drug|vindesine|
34611|NCT00910429|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
34612|NCT00910442|Dietary Supplement|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
34613|NCT00910455|Drug|SRX246|single oral dose of SRX246 capsule
34614|NCT00910455|Drug|Placebo|Single oral dose of placebo capsule
34615|NCT00910468|Procedure|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
34616|NCT00910481|Device|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
34617|NCT00910494|Radiation|Photon Radiosurgery System IORT|
34618|NCT00910494|Radiation|Photon Radiosurgery System IORT|
34619|NCT00910507|Behavioral|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
34620|NCT00910507|Behavioral|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
34621|NCT00017225|Procedure|autologous bone marrow transplantation|
34622|NCT00910520|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
34623|NCT00910520|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
31222|NCT00890422|Biological|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
31223|NCT00890435|Other|questionnaire administration|
31224|NCT00890435|Procedure|psychosocial assessment and care|
31225|NCT00890448|Other|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
31517|NCT00883194|Drug|Ropivacaine|Solution
31518|NCT00014482|Procedure|pain therapy|
31519|NCT00883194|Drug|PRF-110|
31520|NCT00883207|Behavioral|Psychotherapy|Narrative and dialogical approach for couples
31521|NCT00883220|Behavioral|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
31522|NCT00883233|Drug|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
31523|NCT00883233|Drug|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
31524|NCT00883233|Drug|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
31525|NCT00883233|Drug|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
31526|NCT00883246|Device|SilverHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
31527|NCT00883259|Drug|Metformin|850 mg twice daily
31528|NCT00883259|Other|Placebo|Microcristallyne cellulose 1 table twice daily
31529|NCT00014482|Procedure|psychosocial assessment and care|
31530|NCT00883272|Dietary Supplement|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
31531|NCT00883298|Drug|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 & 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 & 5 every 28-day cycle
31532|NCT00885729|Other|Rehabilitation program|Strength exercises, neuromuscular exercises
35054|NCT00905814|Drug|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
35055|NCT00017030|Drug|trabectedin|
35056|NCT00905814|Drug|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
35057|NCT00908557|Other|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
35058|NCT00908557|Other|Control|information based on the classic informed consent document
35059|NCT00908570|Drug|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
35060|NCT00908570|Drug|Placebo|Placebo cream
35061|NCT00017160|Procedure|conventional surgery|
35062|NCT00908583|Drug|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
35063|NCT00908583|Drug|Bortezomib|Patients will receive bortezomib as described in protocol
35064|NCT00908583|Drug|Rituximab|Patients will receive rituximab as described in protocol
35065|NCT00908583|Drug|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
35066|NCT00908596|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
35398|NCT00943267|Procedure|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
35399|NCT00943293|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
35400|NCT00943293|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
35401|NCT00943293|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
35402|NCT00943306|Drug|lomitapide|5-60 mg po every day
35403|NCT00943319|Drug|Busulfan|Daily intravenous dosing to target AVC
35404|NCT00943319|Drug|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
35405|NCT00020397|Biological|aldesleukin|
34826|NCT00905268|Drug|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
34827|NCT00905281|Other|Action Group|On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.
Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary.
34828|NCT00000817|Drug|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
34829|NCT00016978|Drug|oxaliplatin|
34830|NCT00905281|Other|Standard care|No specific intervention
34831|NCT00905294|Other|Blood draws|Observational: blood draws only
34832|NCT00905307|Drug|OPC-34712|oral, once daily
34833|NCT00905307|Drug|Placebo|Placebo
34834|NCT00905307|Drug|Aripiprazole|oral, once daily
34835|NCT00905320|Procedure|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
34836|NCT00905320|Procedure|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
34837|NCT00905333|Drug|Candesartan (test)|16 mg oral tablet, single dose
34838|NCT00905333|Drug|Felodipine (test)|5 mg oral extended release tablet, single dose
34839|NCT00905333|Drug|Candesartan Cilexetil|16 mg oral tablet, single dose
34840|NCT00016991|Drug|gefitinib|
34841|NCT00905333|Drug|Felodipine|5 mg oral extended release tablet, single dose
34842|NCT00905346|Drug|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
34843|NCT00905346|Drug|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
34844|NCT00905346|Other|Applesauce|Applesauce
34845|NCT00905359|Procedure|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
34846|NCT00905359|Procedure|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
35131|NCT00903305|Procedure|quality-of-life assessment|
37198|NCT00939419|Other|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
37199|NCT00939419|Other|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
37200|NCT00000213|Drug|Fluoxetine|
37201|NCT00000842|Drug|Nerve Growth Factor, Recombinant Human|
37202|NCT00019890|Drug|sargramostim|
37203|NCT00939419|Other|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
37204|NCT00939445|Procedure|Online HDF|Online HDF
37205|NCT00939445|Procedure|Short Daily Hemodialysis|Short Daily Hemodialysis
37206|NCT00939458|Drug|Lamotrigine|
37207|NCT00939471|Device|Relieva™ Balloon Sinuplasty™ System|Balloon dilation will be performed using endoscopic equipment with video documentation capability.
37208|NCT00931567|Biological|Autologous platelets gel|Application of autologous platelets gel (Platelet Rich Fibrin) after the " open palm " surgical treatment of Dupuytren's disease.
37209|NCT00931567|Device|Vaselitulle|application of standardized wound dressing after the " open palm " surgical treatment of Dupuytren's disease.
37210|NCT00931580|Dietary Supplement|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
37211|NCT00931593|Device|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|Visit V0 (day 0 - 2 to 14 days):
Subject selection
Obtaining of written informed consent
Visit V1 (day 0):
Fasting subject
Randomization to determine the examination order
Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)
Visit V2 (day 0 + 1 day): Phone contact
Visit V3 (day 0 + 2 to 7 days):
Same as V1
Visit V4 (V3 + 1 day): Phone contact and end of the study
37212|NCT00019383|Biological|aldesleukin|
37213|NCT00931606|Biological|Biological: ACE-011|up to 4 subcutaneous doses of ACE-011 given once every 28 days
36456|NCT00944853|Dietary Supplement|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
36457|NCT00944853|Dietary Supplement|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
36458|NCT00944892|Drug|REGN475|2 Administrations of REGN475 within 24 weeks.
36459|NCT00944892|Other|Placebo|Placebo to match REGN475 doses
36460|NCT00944905|Biological|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
36461|NCT00944918|Drug|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
36462|NCT00944918|Drug|anastrozole|Tablet, oral, once daily until disease progression.
36463|NCT00000847|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
36464|NCT00020527|Drug|caspofungin acetate|
36465|NCT00944918|Drug|exemestane|Tablet, oral, once daily until disease progression.
36466|NCT00944931|Device|DC Brain Polarization|
36467|NCT00944944|Behavioral|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
36468|NCT00947128|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
36764|NCT00933374|Drug|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
36765|NCT00933387|Drug|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
36766|NCT00933400|Procedure|CT Coronary Angiography|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
36767|NCT00019448|Drug|gp100 antigen|
37551|NCT00939848|Drug|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
37552|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
37553|NCT00939861|Procedure|laparoscopy|colorectal resection
37554|NCT00939861|Procedure|laparotomy|colorectal resection
37555|NCT00939874|Drug|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
37556|NCT00019955|Procedure|laparoscopic surgery|
37557|NCT00939887|Drug|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
37558|NCT00939900|Drug|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
37559|NCT00939913|Drug|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
37560|NCT00939913|Drug|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
37561|NCT00939926|Drug|Risperidone|
37562|NCT00939939|Drug|sitagliptin|sitagliptin 100 mg/d for 10 weeks
37563|NCT00939939|Drug|glimepiride|glimepiride 1 mg/d for 10 weeks
37564|NCT00939952|Drug|ertapenem|500 mg IV once
37565|NCT00939965|Drug|isotretinoin|
37566|NCT00939965|Genetic|DNA analysis|
37567|NCT00019955|Procedure|radiofrequency ablation|
37568|NCT00939965|Genetic|polymerase chain reaction|
37569|NCT00939965|Other|laboratory biomarker analysis|
37570|NCT00939965|Other|pharmacological study|
37571|NCT00939978|Drug|rhEPO|recombinant human erythropoietin(rhEPO)
36371|NCT00946998|Drug|placebo|Placebo tablet will be identical and matched to sertraline tablet.
36372|NCT00947011|Drug|Placebo|1 tablet 100 mg once a day
36373|NCT00947011|Drug|Januvia|1 tablet 100 mg once a day
36374|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
36375|NCT00947024|Drug|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
36376|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
36377|NCT00020709|Drug|cisplatin|Given IV
36378|NCT00947037|Drug|AP-CD/LD|
36379|NCT00947050|Other|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
36688|NCT00940823|Device|Baerveldt-350 Tube|Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
36689|NCT00940836|Drug|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
36690|NCT00000844|Drug|Interferon alfa-n3|
36691|NCT00020072|Other|laboratory biomarker analysis|
36692|NCT00940836|Drug|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
36693|NCT00940836|Drug|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
36694|NCT00935844|Drug|TAK-901|This study consists of three sequential parts.
Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.
Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.
Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2.
36695|NCT00935857|Device|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
36696|NCT00935857|Device|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
36697|NCT00935870|Device|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
35730|NCT00948662|Drug|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
35731|NCT00948662|Drug|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
35732|NCT00948662|Drug|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
35733|NCT00020787|Biological|G17DT Immunogen|Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
35734|NCT00948675|Drug|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
35735|NCT00948675|Drug|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 [maximum possible dose of 900 milligrams (mg)] intravenously infused over 30 minutes.
35736|NCT00948675|Drug|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
35737|NCT00948675|Biological|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
35738|NCT00948688|Radiation|Radiation therapy|Once per day, 5 days a week for 6 weeks
36035|NCT00942149|Drug|Daptomycin|single dose of 6 mg/kg of daptomycin
36036|NCT00942162|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
36037|NCT00944073|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
36038|NCT00944086|Other|Recruitment Manoeuvre|Recruitment Manoeuvre
36039|NCT00944099|Behavioral|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
36040|NCT00944112|Biological|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
36041|NCT00944112|Biological|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
36042|NCT00944125|Device|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
36043|NCT00944125|Device|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
36768|NCT00933400|Procedure|Traditional, Standard of Care|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
36769|NCT00933413|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
36770|NCT00933426|Drug|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
36771|NCT00933426|Drug|Paclitaxel|50 mg/m^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
36772|NCT00933439|Drug|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
36773|NCT00933452|Drug|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
36774|NCT00933452|Drug|duloxetine|15mg, oral administer
36775|NCT00933452|Drug|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
36776|NCT00933465|Drug|Imodium (Loperamide Hydrochloride) syrup|syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.
Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most.
36777|NCT00933465|Drug|Imodium (Loperamide hydrochloride) tablets|tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.
Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most
36778|NCT00000838|Drug|Stavudine|
36779|NCT00019448|Drug|interleukin-2|
36780|NCT00933478|Device|Clay|Small dime sized piece of clay.
35797|NCT00946127|Procedure|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
35798|NCT00946127|Procedure|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
35799|NCT00946140|Procedure|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
35800|NCT00946153|Drug|E7080|In the Dose-Escalation Component of the study, E7080 will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
37572|NCT00939991|Drug|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
37847|NCT00930033|Procedure|Nephrectomy|Current surgery
37848|NCT00019201|Other|sputum cytology|
37849|NCT00930033|Other|Sunitinib alone|Sunitinib alone without nephrectomy
37850|NCT00930046|Device|Wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
37851|NCT00930046|Device|wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
37852|NCT00930059|Drug|PF-04447943|tablets, 25 mg every 12 hours for 12 wks
37853|NCT00930059|Drug|Placebo|matching placebo tablets, every 12 hours for 12 wks
37854|NCT00930072|Drug|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
37855|NCT00930085|Other|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
37856|NCT00930098|Drug|clofarabine|
37857|NCT00930111|Other|2-week rotation|Attending physician is assigned to a 2-week rotation.
37858|NCT00930111|Other|4-week rotation|Attending physician is assigned to a 4-week rotation.
37859|NCT00019201|Procedure|bronchoscopic and lung imaging studies|
37860|NCT00930124|Procedure|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
37861|NCT00930124|Procedure|Distraction osteogenesis|
37862|NCT00930137|Other|isocaloric for week diet|Consumption of the 2 experimental diets
a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);
a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).
37863|NCT00930150|Behavioral|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
37864|NCT00930150|Behavioral|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
36698|NCT00935883|Drug|Eculizumab|Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).
Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.
Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.
36699|NCT00019604|Radiation|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
36700|NCT00935883|Drug|Saline|Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).
Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.
Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.
36701|NCT00935896|Procedure|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
35719|NCT00948519|Device|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
35720|NCT00948519|Device|Laser only|same only without ICG
35721|NCT00948532|Biological|biologic, Osteocel Plus|Osteocel® Plus
35722|NCT00020774|Procedure|conventional surgery|
35723|NCT00948545|Other|Observational study - there is no intervention|Observational study - there is no intervention
35724|NCT00948584|Other|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
35725|NCT00948610|Drug|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
35726|NCT00948623|Behavioral|physical activity counseling program|
35727|NCT00948623|Behavioral|sham counseling program|
35728|NCT00948649|Drug|Placebo|Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
35729|NCT00948649|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
36044|NCT00944138|Behavioral|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
36045|NCT00000847|Biological|ALVAC-HIV MN120TMG (vCP205)|
36046|NCT00020488|Drug|fluorouracil|
36047|NCT00944151|Procedure|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
36048|NCT00944164|Behavioral|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
36049|NCT00944164|Behavioral|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
36050|NCT00944177|Drug|Metformin HCl|
36051|NCT00944190|Behavioral|Self-management intervention|Brief counseling technique, self-management,
36052|NCT00944190|Behavioral|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
36053|NCT00944203|Drug|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
36054|NCT00944216|Drug|Salkera Emollient Foam|
36380|NCT00947063|Drug|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
36381|NCT00947063|Drug|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
36382|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
36383|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
36384|NCT00947089|Device|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
36385|NCT00947089|Device|iodoform gauze|one iodoform gauze
36386|NCT00947102|Other|Observation|
36387|NCT00947115|Procedure|Blood sampling|Blood samples will be collected at Years 5, 6, 7, 8, 9 and 10
36388|NCT00020709|Drug|docetaxel|Given IV
36389|NCT00947115|Procedure|Cervico-vaginal secretion (CVS) samples|CVS will be collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteer for this procedure.
35801|NCT00946166|Drug|simvastatin|40 mg daily in the evening for a maximum of 14 days
35802|NCT00946166|Drug|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
35803|NCT00946179|Biological|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
35804|NCT00020644|Drug|gemcitabine hydrochloride|
35805|NCT00946192|Drug|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
35806|NCT00948805|Drug|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
35807|NCT00948818|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
35808|NCT00948818|Drug|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
35809|NCT00948831|Biological|Osteocel Plus|biologic
35810|NCT00948844|Device|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
35811|NCT00948857|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
35812|NCT00020800|Biological|rituximab|
35813|NCT00948857|Dietary Supplement|Placebo|Blinded placebo
35814|NCT00948870|Drug|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
35815|NCT00948896|Drug|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
35816|NCT00948896|Drug|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
36117|NCT00942227|Other|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
36118|NCT00942227|Other|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
36119|NCT00942240|Drug|ACU-4429|administered orally once a day for 14 days
36120|NCT00942240|Drug|matching placebo tablet|administered orally once a day for 14 days
37865|NCT00930150|Behavioral|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
37866|NCT00930150|Behavioral|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
37867|NCT00930163|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
37868|NCT00930163|Drug|placebo|Subcutaneous repeating dose
38226|NCT00964366|Drug|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
38227|NCT00964366|Drug|Dapsone gel|Twice-daily applications of dapsone gel
38228|NCT00964379|Procedure|intraperitoneal or extraperitoneal colostomy|creation of colostomy
38229|NCT00964392|Procedure|Atrial Fibrillation ablation procedure|Radiofrequency ablation procedure
38230|NCT00964392|Device|NAVISTAR THERMOCOOL and NAVISTAR EZ STEER THERMOCOOL|The NAVISTAR THERMOCOOL and NAVISTAR EZ STEER THERMOCOOL catheters are diagnostic/ablation deflectable tip, luminal catheters designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency.
38231|NCT00964405|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist
38232|NCT00964405|Drug|Placebo|Matching placebo
38233|NCT00964418|Drug|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
38234|NCT00966914|Drug|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
38235|NCT00966914|Drug|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
38236|NCT00022581|Drug|thalidomide|Given orally
38237|NCT00966940|Drug|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
38238|NCT00966940|Drug|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
38239|NCT00966953|Drug|Fluoride|Brush twice daily
38240|NCT00966953|Drug|Triclosan/Fluoride toothpaste|Brush twice daily
38241|NCT00966953|Drug|Fluoride|Brush twice daily
37140|NCT00933985|Other|pharmacological study|Correlative studies
37141|NCT00933985|Other|laboratory biomarker analysis|Correlative studies
37142|NCT00933998|Other|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
37143|NCT00934011|Other|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
37144|NCT00934011|Other|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
37145|NCT00934024|Drug|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
37146|NCT00934037|Procedure|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
37147|NCT00934037|Other|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
37148|NCT00934050|Drug|ELND005 (scyllo-inositol)|Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks
After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
37149|NCT00019487|Biological|aldesleukin|
37150|NCT00934063|Drug|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
37151|NCT00934063|Other|No treatment given|Control group not receiving treatment
37152|NCT00934076|Drug|Tarceva plus AT-101|150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.
Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis.
37153|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
37154|NCT00934089|Drug|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
37155|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
37428|NCT00937053|Other|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
37429|NCT00019721|Biological|aldesleukin|
37430|NCT00937053|Other|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
37431|NCT00937053|Other|Platelet transfusion|Patients whose platelets fall below 10 x 10*9 will be transfused with platelets
36390|NCT00947128|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
36391|NCT00940329|Drug|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
36392|NCT00019994|Biological|aldesleukin|
36393|NCT00940329|Drug|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
36394|NCT00940342|Drug|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
36395|NCT00940342|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly for four weeks
36396|NCT00940355|Behavioral|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
36397|NCT00940368|Dietary Supplement|Provision of capsules containing ginger powder or placebo|The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.
For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.
For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram.
36398|NCT00940381|Drug|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
36399|NCT00940381|Drug|Cetuximab|Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
36400|NCT00940394|Behavioral|mutual support group|bi-weekly, 12-session, family-led mutual support group
36401|NCT00940394|Behavioral|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
36702|NCT00935896|Procedure|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
36703|NCT00935896|Other|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
36704|NCT00935922|Dietary Supplement|Flaxseed|Flaxseed omega-3 fatty acids and lignans
36705|NCT00935948|Drug|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
36706|NCT00935948|Drug|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
37214|NCT00931606|Drug|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
37492|NCT00932139|Procedure|Electro-acupuncture|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heartrate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
37493|NCT00932152|Drug|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
37494|NCT00932152|Drug|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
37495|NCT00932152|Drug|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
37496|NCT00932152|Drug|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
37497|NCT00932165|Drug|Exemestane|Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
37498|NCT00932178|Behavioral|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
37499|NCT00932191|Procedure|Standard phacoemulsification|Cataract nucleus removal using standard amounts of ultrasound energy
37500|NCT00019396|Drug|MART-1 antigen|
37501|NCT00932191|Procedure|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
37502|NCT00934544|Drug|INC424/INCB018424|Oral 5 mg tablets with packaged as 60-count in high-density polyethylene bottles.
37503|NCT00934544|Drug|Best Available Therapy (BAT)|Best available investigator-selected therapy (oral or parenteral therapies) was commercially available and was administered according to manufacturer's instructions and investigator discretion. Instructions for prescribing and taking these therapies were found in their respective package inserts.
37504|NCT00934557|Drug|ATG Fresenius|
37505|NCT00934557|Drug|ATG Fresenius|
37506|NCT00934557|Drug|ATG Fresenius|
37507|NCT00934557|Drug|ATG Fresenius|
37508|NCT00934557|Drug|ATG Fresenius|
37509|NCT00934557|Drug|ATG Fresenius|
38242|NCT00966953|Drug|Fluoride|Brush twice daily
38243|NCT00966953|Other|antibacterial plant extract|Brush twice daily
38244|NCT00966966|Drug|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
38245|NCT00966979|Device|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
38246|NCT00966992|Drug|Zoledronic acid|
38247|NCT00022581|Other|laboratory biomarker analysis|Correlative studies
36962|NCT00933777|Drug|Combination of sorafenib and everolimus|Combination of defined dose of sorafenib (2x400 mg) with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg)
36963|NCT00936364|Other|Modified fast|Minimal caloric intake on days -2 and -1
36964|NCT00936364|Other|Fasting|Day -1
36965|NCT00936364|Other|Fasting|Days -2 and -1
36966|NCT00936364|Other|Fasting|Days -3, -2, and -1
36967|NCT00936364|Other|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
36968|NCT00019669|Biological|gp100 antigen|
36969|NCT00936377|Drug|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
36970|NCT00936377|Other|Placebo|Normal saline for five days.
36971|NCT00936390|Drug|bicalutamide|Given orally
36972|NCT00936390|Drug|buserelin|Given subcutaneously or as an injection
36973|NCT00936390|Drug|flutamide|Given orally
36974|NCT00936390|Drug|goserelin acetate|Given subcutaneously or as an injection
36975|NCT00936390|Drug|leuprolide acetate|Given subcutaneously or as an injection
36976|NCT00936390|Drug|triptorelin|Given subcutaneously or as an injection
36977|NCT00936390|Radiation|3-dimensional conformal radiation therapy|Given as external-beam radiation therapy
37432|NCT00937079|Other|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
37433|NCT00937092|Drug|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
37434|NCT00937092|Drug|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
37435|NCT00937105|Device|lotrafilcon A contact lenses|FDA approved soft contact lenses
37436|NCT00937105|Device|Renu Multiplus|
37437|NCT00937105|Device|Clear Care|
37438|NCT00937131|Drug|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
37439|NCT00937144|Drug|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
37440|NCT00019721|Biological|gp100 antigen|
37441|NCT00937144|Drug|placebo|
37442|NCT00937157|Drug|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
37443|NCT00937170|Device|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
37444|NCT00937170|Device|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
37445|NCT00937170|Device|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
37446|NCT00937183|Biological|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
37447|NCT00937183|Biological|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
37448|NCT00937183|Biological|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
37715|NCT00937508|Drug|varenicline|varenicline (an approved medication for smoking cessation)
37716|NCT00937508|Drug|placebo|sugar pill without any active medication
37717|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation I
36707|NCT00935961|Drug|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
36708|NCT00938340|Dietary Supplement|Walnut "meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
36709|NCT00938340|Dietary Supplement|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
36710|NCT00938340|Dietary Supplement|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
36711|NCT00938353|Drug|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
36712|NCT00938353|Drug|Placebo solution for nebulisation 2 ml|single dose: 4 ml
36713|NCT00938366|Drug|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
36714|NCT00938366|Drug|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
36715|NCT00938379|Drug|20% deet insect repellent|skin-applied repellent lotion
36716|NCT00938379|Drug|placebo control|Identical base formulation of lotion but without any deet active
36717|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
36718|NCT00019812|Drug|paclitaxel|
36719|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
35739|NCT00948688|Drug|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
35740|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
35741|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
35742|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
35743|NCT00020189|Drug|acetylsalicylic acid|
35744|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
37510|NCT00019513|Drug|leucovorin calcium|
37511|NCT00934557|Drug|ATG Fresenius|
37512|NCT00934557|Drug|ATG Fresenius|
37782|NCT00932607|Drug|sublingual immunotherapy|Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.
Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.
Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy).
37783|NCT00932620|Drug|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
37784|NCT00932620|Drug|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
37785|NCT00932646|Drug|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
37786|NCT00019409|Drug|daunorubicin hydrochloride|
37787|NCT00932646|Drug|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
37788|NCT00932646|Drug|Placebo|Placebo Respimat once daily and placebo Foradil
37789|NCT00932646|Drug|Foradil|12 mcg twice daily and placebo Respimat
37790|NCT00932659|Device|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
37791|NCT00932672|Behavioral|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
37792|NCT00932685|Drug|Midazolam|Midazolam 0.5mg/kg
37793|NCT00934947|Drug|Propranolol|40 mg
37794|NCT00934947|Drug|Placebo|sugar pill
37795|NCT00934947|Drug|Propanolol|120 mg twice per day
37796|NCT00000838|Drug|Didanosine|
37797|NCT00019565|Radiation|fludeoxyglucose F 18|
37798|NCT00934973|Drug|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
37799|NCT00934973|Drug|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
36978|NCT00936390|Radiation|intensity-modulated radiation therapy|Given as external-beam radiation therapy
36979|NCT00019682|Biological|Aldesleukin|Given IV
36980|NCT00936403|Drug|NNC126-0083|One single dose administered in four dose levels in an escalating order
36981|NCT00936403|Drug|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
36982|NCT00936416|Procedure|Inulin and PAH clearance and MRI|GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;
The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes.
36983|NCT00936429|Biological|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
36984|NCT00936429|Biological|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
36985|NCT00936442|Drug|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
35980|NCT00946413|Behavioral|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
35981|NCT00946413|Behavioral|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
35982|NCT00946426|Other|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
35983|NCT00020657|Drug|ondansetron|
35984|NCT00946439|Device|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
35985|NCT00946465|Drug|Ramipril 10 Capsule (Sandoz)|
35986|NCT00946465|Drug|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
37718|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation II
37719|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation III
37720|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation IV
37721|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation V
37722|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation VI
37723|NCT00019747|Procedure|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
37724|NCT00937521|Biological|Control|Control
37725|NCT00937521|Biological|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
37726|NCT00937534|Drug|Fimasartan|Fimasartan 240mg/day
37727|NCT00937560|Drug|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
37728|NCT00937560|Drug|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
37729|NCT00937560|Drug|Carboplatin|Carboplatin was supplied locally in commercial batches.
37730|NCT00937599|Dietary Supplement|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
37731|NCT00937612|Radiation|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
37732|NCT00937625|Biological|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
37733|NCT00937638|Dietary Supplement|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
37734|NCT00019747|Other|Placebo|oral placebo once daily
37735|NCT00937638|Dietary Supplement|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
37736|NCT00937638|Dietary Supplement|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
35745|NCT00941603|Drug|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
35746|NCT00941616|Biological|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
35747|NCT00941616|Biological|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
35748|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
35749|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
35750|NCT00941642|Drug|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
35751|NCT00941642|Drug|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
35752|NCT00941655|Drug|Oxaliplatin|Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.
Systemic chemotherapy - Oxaliplatin 85 mg/m^2 over 120 minutes,
35753|NCT00941655|Drug|Irinotecan|Irinotecan 165 mg/m^2 IV over 90 minutes
35754|NCT00020189|Drug|alvocidib|
35755|NCT00941655|Drug|5-Fluorouracil|Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes.
systemic chemotherapy -3200 mg/m^2 continuous intravenous over 48 hours.
35756|NCT00941655|Drug|Leucovorin|surgery and heated intraperitoneal chemotherapy -20 mg/m^2 intravenous over 5 minutes.
systemic chemotherapy - 200 mg/m^2 intravenous over 120 minutes.
35757|NCT00941655|Procedure|Gastrectomy and/or metastasectomy|Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.
Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy.
35758|NCT00941668|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
36055|NCT00944229|Drug|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
36056|NCT00944229|Drug|Placebo|4 capsules of placebo every 24 hours
36057|NCT00020488|Drug|irinotecan hydrochloride|
36058|NCT00944242|Drug|Sertraline|
37800|NCT00934973|Drug|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
37801|NCT00934973|Behavioral|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
37802|NCT00934973|Behavioral|No website|No CBT website
37803|NCT00934973|Behavioral|CBT website with minimal support|
38160|NCT00933231|Drug|Corticosteroids|IV and Oral
38161|NCT00933231|Drug|Ramipril|Oral
38162|NCT00933231|Drug|Irbesartan|Oral
38163|NCT00019422|Drug|lobradimil|
38164|NCT00933244|Dietary Supplement|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
38165|NCT00933244|Dietary Supplement|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
38166|NCT00933244|Dietary Supplement|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
38167|NCT00933257|Drug|LACTIC ACID(ND)|Treatment duration 5 weeks
38168|NCT00933270|Device|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
38169|NCT00933283|Drug|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
38170|NCT00933283|Drug|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
38171|NCT00933309|Drug|Exemestane|25 mg tablets orally once a day
38172|NCT00933309|Drug|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
38173|NCT00933322|Dietary Supplement|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
38174|NCT00019435|Biological|LMB-9 immunotoxin|
38175|NCT00933322|Dietary Supplement|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
35987|NCT00946478|Drug|Pimecrolimus|20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.
Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit).
35988|NCT00946478|Other|Vehicle cream|20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.
Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit).
35989|NCT00946491|Drug|Haloperidol 10 mg Tablets (Cord Laboratories)|
35990|NCT00946491|Drug|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
35991|NCT00948688|Drug|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
35992|NCT00948701|Behavioral|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
35993|NCT00948714|Behavioral|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
35994|NCT00948714|Behavioral|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
36313|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
36314|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
36315|NCT00942448|Other|Placebo s.c.|1 single injection at day of dental surgical extraction
36316|NCT00942461|Procedure|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
36317|NCT00942461|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
36318|NCT00020332|Drug|docetaxel|
36319|NCT00942474|Device|Facilitate nerve stimulation lead placement with the nerve access tool|
36320|NCT00942487|Drug|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
36321|NCT00942487|Drug|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
38107|NCT00019604|Procedure|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
38108|NCT00935545|Biological|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
38109|NCT00935558|Biological|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
38110|NCT00935558|Drug|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
38111|NCT00935571|Drug|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
38112|NCT00935584|Behavioral|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
38113|NCT00935597|Biological|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
38114|NCT00935610|Dietary Supplement|Immunocal|20 grams per day of Immunocal for 135 days.
38115|NCT00935610|Dietary Supplement|Casein|20 grams per day for 135 days
38116|NCT00935623|Biological|Malaria Challenge|Malaria challenge
38117|NCT00938184|Drug|paroxetine CR|3-period crossover single dosing at the dose levels of 12.5, 25 and 50mg into healthy volunteers
38118|NCT00938197|Drug|Fimasartan|Fimasartan (1d~7d) Amlodipine (12d~14d) Fimasartan + Amlodipine(15d~21d)
38119|NCT00938197|Drug|Amlodipine|Amlodipine (1d~10d) Amlodipine (25d~27d) Fimasartan + Amlodipine(28d~34d)
38120|NCT00938210|Procedure|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
36059|NCT00944242|Drug|Sertraline Hydrochloride|
36060|NCT00946504|Drug|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
36061|NCT00946504|Drug|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
36062|NCT00946517|Other|Questionnaires|Parenting and behavioral questionnaires
36063|NCT00020657|Drug|prochlorperazine|
36064|NCT00946530|Device|Bright light|
36065|NCT00946543|Radiation|hypofractionated radiation therapy|
36066|NCT00946543|Radiation|intensity-modulated radiation therapy|
36067|NCT00946556|Drug|Valacyclovir|1g po od for 2 months
36068|NCT00946556|Drug|Placebo|Placebo po od for 2 months
36069|NCT00946569|Drug|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
36070|NCT00946569|Drug|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
36071|NCT00946582|Behavioral|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
36072|NCT00946595|Drug|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
36073|NCT00946595|Drug|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
36074|NCT00020657|Procedure|quality-of-life assessment|
36075|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
36076|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
36077|NCT00946608|Drug|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
36078|NCT00946621|Drug|Ramipril 10 mg Capsule (Sandoz)|
36402|NCT00940394|Other|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
36403|NCT00019994|Biological|gp100 antigen|
38176|NCT00933322|Dietary Supplement|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
38177|NCT00933335|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
38178|NCT00933348|Drug|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
38179|NCT00933348|Drug|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
37215|NCT00931632|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
37216|NCT00931632|Drug|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
37217|NCT00931645|Procedure|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
37218|NCT00931645|Procedure|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
37219|NCT00931645|Procedure|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) & cyclophosphamide (300 mg/sqm)
37220|NCT00931671|Other|Exercise training|aerobic exercise training
37221|NCT00931697|Drug|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
37222|NCT00931697|Drug|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
37223|NCT00019383|Biological|incomplete Freund's adjuvant|
37224|NCT00931697|Drug|Placebo|Over-encapsulated placebo to maintain blinding
37225|NCT00931710|Drug|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
37226|NCT00931710|Drug|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
37227|NCT00931723|Drug|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
36322|NCT00942500|Procedure|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade <2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
36323|NCT00942513|Other|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
36324|NCT00942513|Other|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
36325|NCT00942513|Other|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
36326|NCT00942513|Other|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
36327|NCT00942513|Other|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
36328|NCT00942513|Other|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
36329|NCT00020345|Drug|fluorouracil|
36330|NCT00942513|Other|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
36331|NCT00942526|Drug|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
36332|NCT00942526|Other|Water|perioperative gargling with water
36650|NCT00947336|Drug|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
36651|NCT00947336|Drug|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
36652|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
36653|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
36654|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
36655|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
36656|NCT00947349|Drug|BI 201335 NA low placebo|Placebo
36657|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
38121|NCT00938223|Biological|4-peptide and 12-peptide melanoma vaccines|Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.
Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.
Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN).
37156|NCT00934089|Drug|latanoprost|Topical ocular solution, once-daily for 14 days
37157|NCT00934102|Device|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
37158|NCT00934102|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
37159|NCT00934102|Device|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
37160|NCT00019487|Biological|gp209-2M antigen|
37161|NCT00934128|Device|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
37162|NCT00934128|Device|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
37163|NCT00936650|Drug|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
37164|NCT00936650|Drug|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
37165|NCT00936663|Drug|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
37166|NCT00936663|Drug|Placebo|Drug will be available as 100, 50, and 25 mg size with identical placebo.
37167|NCT00936676|Drug|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
37168|NCT00936689|Procedure|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
37169|NCT00936689|Procedure|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
36404|NCT00940407|Device|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
36405|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
36406|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
36407|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
36408|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
36409|NCT00940433|Procedure|open properitoneal hernia repair|suprapubic retro-inguinal approach
36410|NCT00940433|Procedure|Lechtestien hernia repair|onlay mesh repair
36411|NCT00940433|Procedure|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
36412|NCT00940433|Procedure|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
36413|NCT00940446|Device|Insorb staples|absorbable staples required for wound closure
36414|NCT00019994|Biological|incomplete Freund's adjuvant|
36415|NCT00940446|Device|metal staples (Ethicon metal stapler)|wound closure with metal staples
36416|NCT00942565|Drug|acetaminophen|
36417|NCT00942578|Drug|Bevacizumab|15 mg/kg cycle 1 day 1, repeated every 21 days
36418|NCT00942578|Drug|Lenalidomide|Once daily days 1-14 of every 21
36419|NCT00942578|Drug|Docetaxel|75 mg/m2 IV over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
36420|NCT00942578|Drug|Prednisone|10 mg orally every day
36421|NCT00020345|Drug|gemcitabine|
36422|NCT00942591|Drug|Interferon beta 1b|
36423|NCT00942591|Drug|Atorvastatin|
36424|NCT00942604|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
36425|NCT00942604|Drug|Vehicle gel|two day treatment
36426|NCT00942617|Drug|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
37228|NCT00931723|Drug|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
37229|NCT00934141|Other|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives—to help agencies learn and gather support from each other and from outside experts.
37230|NCT00934141|Other|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
37513|NCT00934570|Drug|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
37514|NCT00934570|Drug|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
37515|NCT00934570|Behavioral|Placebo Standard exercise|Standard exercise
37516|NCT00934570|Behavioral|Intensive exercise|Placebo Intensive exercise
37517|NCT00934583|Behavioral|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
37518|NCT00934596|Procedure|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV & Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
37519|NCT00934596|Drug|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
37520|NCT00934609|Behavioral|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
37521|NCT00019539|Drug|bevacizumab|
37522|NCT00934622|Device|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
37523|NCT00934635|Drug|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 2 hours
36658|NCT00020722|Biological|therapeutic autologous lymphocytes|Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.
The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion.
36659|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
36660|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
36661|NCT00947349|Drug|BI 201335 NA low|BI 201335 NA
36662|NCT00947349|Drug|BI 201335 NA high placebo|placebo
36663|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
36664|NCT00947349|Drug|Placebo|
36665|NCT00947362|Other|Electro-thermo-coagulation|
36666|NCT00947362|Drug|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
36667|NCT00947362|Drug|saline|physiological saline
36668|NCT00947375|Drug|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
36669|NCT00020722|Drug|Ifosfamide, carboplatin, and etoposide (ICE) regimen|Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.
Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.
Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.
VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2
36670|NCT00947375|Drug|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
36986|NCT00936442|Other|Educational materials|Reception of educational material on regular basis.
36987|NCT00936468|Biological|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
36988|NCT00936494|Procedure|Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
36989|NCT00936507|Other|Energy Density/Portion Size|
36990|NCT00938782|Device|Sedline|
37170|NCT00936702|Drug|carboplatin|Given IV
37171|NCT00936702|Drug|everolimus|Given PO
37172|NCT00019682|Other|Questionnaire Administration|Ancillary studies
37173|NCT00936702|Drug|paclitaxel|Given IV
37174|NCT00936715|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
37175|NCT00936728|Other|therapeutic nutritional supplementation|Given orally
37449|NCT00937196|Drug|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
37450|NCT00937196|Drug|Histaminum hydrochloricum globuli|
37451|NCT00000841|Drug|Lamivudine|
37452|NCT00019721|Biological|incomplete Freund's adjuvant|
37453|NCT00937222|Dietary Supplement|Peanuts and peanut butter|Peanuts and peanut butter
37454|NCT00939484|Other|Pharmacological Study|Correlative studies
37455|NCT00939484|Drug|Vismodegib|Given PO
37456|NCT00939497|Drug|Risperidone|
37457|NCT00939510|Biological|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
37458|NCT00939510|Drug|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
37459|NCT00019916|Biological|aldesleukin|
37460|NCT00939510|Other|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
37461|NCT00939523|Drug|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
37462|NCT00939536|Drug|Zolpidem Tartrate Tablets 10 mg|
37463|NCT00939549|Drug|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
36720|NCT00938405|Drug|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
36721|NCT00938405|Drug|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
36722|NCT00938418|Radiation|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
36723|NCT00938431|Drug|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
36724|NCT00938457|Radiation|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
36725|NCT00938457|Procedure|implanted fiducial-based imaging|radiation therapy treatment planning
36726|NCT00938457|Procedure|cone-beam computed tomography|radiation therapy treatment planning
36727|NCT00938470|Drug|capecitabine|Given PO
36728|NCT00938470|Drug|docetaxel|Given IV
36729|NCT00019825|Drug|decitabine|
36730|NCT00938470|Drug|fluorouracil|Given IV
36731|NCT00938470|Drug|oxaliplatin|Given IV
36732|NCT00938470|Radiation|radiation therapy|Undergo radiation therapy
36733|NCT00938470|Procedure|therapeutic conventional surgery|Undergo surgery
36734|NCT00938483|Other|Nutramigen Lipil (Infant formula)|
36735|NCT00938509|Drug|ibuprofen suppositories|5-10 mg/kg/day-suppositories
36736|NCT00930670|Drug|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
36737|NCT00930670|Drug|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
36738|NCT00930670|Drug|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
36739|NCT00930683|Drug|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
36740|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
36741|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
37524|NCT00934635|Drug|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 2 hours
37525|NCT00937235|Drug|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
37526|NCT00937235|Behavioral|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
37527|NCT00937235|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
37528|NCT00937248|Device|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
37529|NCT00937248|Device|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
37804|NCT00934986|Other|Surface expression of functional biomarkers of the NK cell|An extra blood sample of 40 ml is required :
Stage A patient who does not require a treatment: one sample the day of enrollment.
Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment.
37805|NCT00934999|Procedure|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
37806|NCT00934999|Procedure|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
37807|NCT00935012|Drug|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
37808|NCT00019578|Procedure|Sterotactic radiosurgery|
37809|NCT00935025|Drug|AZD1305|single and multiple oral doses, extended-release capsule
37810|NCT00935025|Drug|Placebo|single and multiple oral doses, capsule
37811|NCT00935051|Other|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
37812|NCT00935064|Drug|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
37813|NCT00935064|Other|Placebo|Placebo orally one tablet once a day for 6 weeks.
37814|NCT00935077|Other|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
37815|NCT00935077|Other|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
36991|NCT00938795|Other|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
36992|NCT00938795|Other|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
36993|NCT00938808|Dietary Supplement|day formula diet|The Cambridge Programme. Formula diet
36994|NCT00938821|Procedure|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
36995|NCT00938834|Other|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
36996|NCT00938847|Device|PCI|Stent implantation after acute myocardial infarction
36997|NCT00938860|Drug|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
36998|NCT00938860|Drug|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
36999|NCT00938873|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
37000|NCT00019864|Drug|doxorubicin hydrochloride|
37001|NCT00938886|Drug|Naltrexone|Daily 50 mg naltrexone
37002|NCT00938886|Drug|Placebo|Matched naltrexone placebo
37003|NCT00938899|Drug|TMC435350; Placebo|
37004|NCT00938912|Drug|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
37005|NCT00938912|Drug|Lacosamide|Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 60 0mg (300 mg bid).
The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day.
35995|NCT00020787|Drug|cisplatin|dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
35996|NCT00948714|Other|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
37464|NCT00939562|Drug|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
37465|NCT00939562|Drug|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
37466|NCT00939588|Drug|Aliskiren/ Valsartan|
37467|NCT00939588|Drug|Telmisartan/ Ramipril|
37468|NCT00939601|Behavioral|Motivational Enhancement Therapy|
37469|NCT00939601|Behavioral|Educational Counseling|
37470|NCT00019916|Biological|p53 peptide vaccine|
37471|NCT00939614|Drug|Lamotrigine|
37472|NCT00939627|Biological|cetuximab|Given IV
37737|NCT00937651|Drug|Placebo|Placebo
37738|NCT00937651|Drug|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
37739|NCT00937651|Drug|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
37740|NCT00937651|Drug|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
37741|NCT00929851|Drug|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
37742|NCT00929851|Drug|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
37743|NCT00929864|Drug|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
37744|NCT00929864|Drug|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
37745|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
37746|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
37747|NCT00929877|Drug|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
37748|NCT00019201|Other|cytology specimen collection procedure|
37749|NCT00929890|Behavioral|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
36742|NCT00930683|Drug|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
36743|NCT00930683|Drug|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
36744|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
35759|NCT00941668|Drug|sodium monofluorophosphate toothpaste|Twice daily usage
35760|NCT00941681|Drug|CK-1827452|50 mg MR CK-1827452 BID for 10 days
35761|NCT00941681|Drug|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
35762|NCT00941681|Drug|CK-1827452|100 mg MR CK-1827452 BID for 10 days
35763|NCT00941694|Behavioral|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
35764|NCT00943800|Drug|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
35765|NCT00943800|Drug|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
35766|NCT00943813|Behavioral|video-recording and completing a survey|Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, "I disagree completely " to 5, "I agree completely ".
35767|NCT00943826|Drug|bevacizumab [Avastin®]|10 mg/kg intravenously every 2 weeks in the Concurrent and Maintenance Phases. 15 mg/kg intravenously every 3 weeks in the Monotherapy Phase.
35768|NCT00943826|Drug|Placebo|Intravenously every 2 weeks in the Concurrent and Maintenance Phases and every 3 weeks in the Monotherapy Phase.
35769|NCT00943826|Drug|temozolomide|75 mg/m2 once daily for 6 weeks, followed by 150-200 mg/m2 once daily on days 1-5 of each 6 x 4 week cycle.
35770|NCT00943826|Radiation|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks
35771|NCT00943839|Drug|sunitinib malate|
35772|NCT00943839|Other|laboratory biomarker analysis|
35773|NCT00943839|Other|pharmacological study|
35774|NCT00020462|Biological|autologous tumor cell vaccine|
35775|NCT00943852|Drug|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
37816|NCT00935077|Other|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
37817|NCT00935090|Device|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
37818|NCT00935103|Behavioral|Psychoeducation|
37819|NCT00937664|Drug|AZD7762|solution, intravenous, weekly
37820|NCT00937664|Drug|gemcitabine|intravenous, weekly
37821|NCT00937677|Drug|Tysabri|Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.
Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.
TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial.
37822|NCT00937703|Device|placebo|paper support for glycaemia face to face visit at T4mounths
38180|NCT00935649|Device|PinPointe FootLaser|Medical laser
38181|NCT00019604|Procedure|radionuclide imaging|Imaging following injection of a radioactive material.
38182|NCT00935662|Drug|AZD8329|Oral solution, single ascending doses
38183|NCT00935662|Drug|Placebo|Oral solution, placebo
38184|NCT00935675|Drug|Escitalopram|Escitalopram 10 mg once a day
38185|NCT00935688|Other|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
38186|NCT00935701|Device|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
38187|NCT00935714|Other|Exercise|
38188|NCT00935714|Other|Exercise|
38189|NCT00935727|Other|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
38190|NCT00935753|Drug|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
35997|NCT00948727|Behavioral|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
35998|NCT00948727|Drug|Cyclosporine (CsA)|Cyclosporine (CsA)
35999|NCT00948740|Drug|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
36000|NCT00948753|Drug|Maraviroc|Maraviroc 300 mg bid (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stell-cell infusion.
36001|NCT00948766|Drug|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm^2 patch which released 4.6 mg/24 h. Patches were changed daily.
36002|NCT00948766|Drug|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm^2 patch which released 9.5 mg/24 h. Patches were changed daily.
36003|NCT00948766|Drug|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm^2 patch which released 13.3 mg/24 h. Patches were changed daily.
36004|NCT00948766|Drug|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
36005|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
36006|NCT00020787|Drug|fluorouracil|Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
36007|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
36008|NCT00948792|Procedure|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
36009|NCT00948792|Procedure|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
36010|NCT00948805|Drug|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
36011|NCT00941954|Behavioral|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
36012|NCT00941967|Drug|gemcitabine hydrochloride|Given IV
37750|NCT00929890|Behavioral|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
37751|NCT00929903|Drug|pazopanib hydrochloride|Given orally
37752|NCT00929903|Other|pharmacological study|Correlative studies
37753|NCT00929929|Dietary Supplement|L-leucine.|10 g of leucine per day, during 12 weeks.
37754|NCT00929929|Dietary Supplement|Maltodextrin.|10 g of maltodextrin per day, during 12 weeks.
37755|NCT00929929|Behavioral|Exercise program.|Progressive resistance exercise program 4 days a week, during 12 weeks.
37756|NCT00929942|Device|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|Intervention "SX-ELLA Stent Degradable DV Bronchial (DV Stent)" will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.
37757|NCT00929955|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
37758|NCT00929955|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
38122|NCT00938236|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
38123|NCT00938249|Dietary Supplement|Monascus Garlic Fermented Extract|
38124|NCT00938249|Dietary Supplement|Placebo|
38125|NCT00019786|Procedure|conventional surgery|
38126|NCT00938262|Drug|Fimasartan, Ketoconazole, Rifampicin|Fimasartan (1 day)
Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)
Rifampicin (9 days) Rifampicin + Fimasartan (1 day)
38127|NCT00938275|Drug|0.5g SRT2104|SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.
Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment.
38128|NCT00938288|Drug|KW-3357|50IU/mL, IV single dose
38129|NCT00938301|Drug|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
38130|NCT00938301|Drug|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
35776|NCT00943852|Drug|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
35777|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
35778|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
35779|NCT00943852|Drug|Comparator: Placebo|Single dose placebo only in one of five treatment periods
36079|NCT00946621|Drug|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
36080|NCT00946634|Drug|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
36081|NCT00946634|Drug|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
36082|NCT00946634|Drug|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
36083|NCT00946647|Drug|Panobinostat (LBH589) and 5-Azacytidine|Each dose of panobinostat should be taken with 240 mL of water. Patients should be instructed to swallow the capsules whole and not chew them.
If the patient forgets to take his/her dose during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next scheduled treatment day. The patient should then continue treatment with the original dosing schedule.
The days when panobinostat and 5-Aza are scheduled together (Day 3 and Day 5 of a treatment cycle), panobinostat should be administered approximately 30 min prior to 5-Aza.
36084|NCT00948961|Biological|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
36085|NCT00948974|Behavioral|Cognitive Therapy|Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., "if I attempt to initiate a conversation I'll humiliate myself"), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005).
36086|NCT00948974|Behavioral|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, & Emmelkamp, 2009).
38191|NCT00935766|Drug|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
38192|NCT00000839|Drug|Didanosine|
38193|NCT00019604|Procedure|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
38194|NCT00935766|Drug|Placebo|
38195|NCT00935792|Drug|alemtuzumab|Given subcutaneously
38196|NCT00935792|Drug|everolimus|Given orally
38197|NCT00935805|Drug|Metformin|850 mg TID
38198|NCT00935805|Drug|Glybenclamide|10 mg BID
38199|NCT00935805|Drug|NPH insulin|Variable SC dose
38200|NCT00935805|Drug|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
38201|NCT00935805|Drug|Propranolol|40 mg BID
38202|NCT00935805|Drug|Captopril|50 mg TID
38203|NCT00935805|Drug|Amlodipine|10 mg QD
37231|NCT00934141|Other|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
37232|NCT00934141|Other|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
37233|NCT00934154|Drug|Thalidomide|100 mg/day continuously for 12 months
37234|NCT00934154|Drug|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
37235|NCT00934167|Biological|heparin sodium - Hipolabor|5.000 UI/0,25mL
37236|NCT00934167|Biological|Heparin sodium - APP|5.000 USP/mL
37237|NCT00019487|Biological|incomplete Freund's adjuvant|
36333|NCT00942539|Drug|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
36334|NCT00942565|Drug|tramadol/acetaminophen|
36335|NCT00944645|Drug|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
36336|NCT00020501|Drug|irinotecan hydrochloride|
36337|NCT00944645|Drug|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
36338|NCT00944658|Drug|Apremilast|As per protocol
36339|NCT00944658|Drug|Placebo (sugar pill)|As per protocol
36340|NCT00944671|Drug|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
36341|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
36342|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
36343|NCT00944684|Drug|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
36344|NCT00944684|Drug|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight <65kg) or 1,200mg (body weight equal or >65kg)
36345|NCT00944697|Drug|Oxycodone Naloxone|Oxycodone Naloxone tablets
36346|NCT00944697|Drug|Placebo tablets|Placebo Oxycodone Naloxone tablets
36347|NCT00020501|Drug|leucovorin calcium|
36348|NCT00944710|Drug|Atropine|Weekend atropine 1%
36349|NCT00944710|Device|Plano lens|plano lens over the sound eye
36350|NCT00944710|Drug|Atropine|Weekend atropine 1%
36351|NCT00944723|Dietary Supplement|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
36352|NCT00944723|Dietary Supplement|Zinc supplement|Liquid supplement with zinc
36353|NCT00944723|Dietary Supplement|Non-fortified bread|Daily consumption of non-fortified bread
38131|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
38132|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
38133|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
38134|NCT00938314|Drug|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
38135|NCT00938327|Biological|Rotarix™|Two doses of oral vaccine.
38136|NCT00019812|Biological|trastuzumab|
38137|NCT00930514|Drug|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m^2) administered every 2 or 3 months.
38138|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 375 mg/m^2 administered every 2 or 3 months.
38139|NCT00930527|Dietary Supplement|Omega-3 Fatty Acid|4g per day for 3 weeks
38140|NCT00930553|Biological|alemtuzumab|12 mg per day administered through IV, once a day for 3 consecutive days (patients may receive additional cycles of alemtuzumab upon documented evidence of resumed disease activity, but not within same 12-month period)
37176|NCT00936728|Dietary Supplement|white wine|Given orally
37177|NCT00936728|Other|questionnaire administration|Ancillary studies
37178|NCT00936741|Drug|mifepristone|Mifepristone 300 mg to 1200 mg once daily
37179|NCT00936754|Dietary Supplement|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
37180|NCT00936754|Dietary Supplement|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
37181|NCT00936767|Drug|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
37182|NCT00936767|Drug|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
37183|NCT00019682|Other|Laboratory Biomarker Analysis|Correlative studies
37184|NCT00936780|Device|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
36087|NCT00948987|Drug|Aspirin|325 mg enteric coated single dose p.o.
36088|NCT00020826|Other|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
36089|NCT00949000|Device|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
36090|NCT00949013|Other|immunohistochemistry staining method|
36091|NCT00949013|Other|laboratory biomarker analysis|
36092|NCT00949026|Drug|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
36427|NCT00942643|Device|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
36428|NCT00942656|Other|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
36429|NCT00942656|Other|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
36430|NCT00942656|Other|VA|base diet plus 3.0% energy added from vaccenic acid
36431|NCT00942656|Other|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
36432|NCT00020358|Biological|aldesleukin|
36433|NCT00942669|Device|SleepStrip OTC(TM)|self contained SAS screening device
36434|NCT00942682|Drug|Sorafenib|Taken orally twice daily
36435|NCT00942682|Drug|RAD001|Taken orally once daily in the morning
36436|NCT00942695|Other|1.5PD|average American diet plus 1.5 oz per day pistachios
36437|NCT00942695|Other|3.0PD|average American diet plus 3.0 oz per day pistachios
36438|NCT00942695|Other|control|average American diet without pistachios
36439|NCT00942708|Drug|Fluoxetine|Total dose How to take:
Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID
36440|NCT00942721|Behavioral|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
36441|NCT00942734|Drug|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
37238|NCT00934180|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
37239|NCT00934180|Drug|Zofran®|1 x 8 mg ODT
37240|NCT00934193|Drug|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
37241|NCT00934193|Drug|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
37242|NCT00934206|Behavioral|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
37243|NCT00934219|Drug|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
37244|NCT00934232|Drug|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
37245|NCT00936793|Drug|Ritonavir|
37246|NCT00936793|Drug|Beclomethasone Dipropionate HFA|
37247|NCT00936819|Biological|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
37530|NCT00937261|Drug|Risperidone|2mg - 8mg per day, for the duration of participation in the study
37531|NCT00937261|Drug|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
37532|NCT00937274|Other|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
37533|NCT00937274|Other|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
37534|NCT00019734|Biological|aldesleukin|
37535|NCT00937274|Other|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
37536|NCT00937287|Other|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
37537|NCT00937300|Biological|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
36354|NCT00944723|Dietary Supplement|Placebo supplement|Daily intake of placebo supplement
36355|NCT00944736|Dietary Supplement|VSL#3|1 packet BID
36356|NCT00944736|Dietary Supplement|Placebo|1 inactive packet BID
36671|NCT00947388|Drug|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
36672|NCT00947388|Biological|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
36673|NCT00947414|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
36674|NCT00940732|Other|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
36675|NCT00940745|Device|Stereotactic Aspiration and Thrombolysis|Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.
To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
36676|NCT00940745|Drug|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
36677|NCT00940758|Drug|PEP02|Dose escalation: 50-100 mg/m2 biweekly
36678|NCT00940771|Drug|Boosted Atazanavir|Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.
36679|NCT00020046|Drug|thalidomide|
36680|NCT00940784|Drug|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
36681|NCT00940784|Drug|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
36682|NCT00940784|Drug|Aspirin|81-100 mg qd
36683|NCT00940797|Drug|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
36684|NCT00940797|Drug|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
37185|NCT00936793|Drug|Darunavir|
37186|NCT00939328|Drug|bendamustine hydrochloride|
37187|NCT00939341|Drug|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
37188|NCT00939367|Drug|Zolpidem Tartrate Tablets 10 mg|
37189|NCT00019890|Drug|dendritic cell-gp100-MART-1 antigen vaccine|
37190|NCT00939367|Drug|'Sanofi-Synthelabo's Ambien® 10 mg Tablets|
37191|NCT00939380|Behavioral|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
37192|NCT00939380|Other|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
37193|NCT00939380|Other|DVD and pamphlet|Participants receive a "Discovery to Recovery" DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet "Top Tips for Parent Caregivers During the BMT Process" published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD.
37194|NCT00939380|Other|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
37195|NCT00939393|Device|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
37196|NCT00939393|Device|Balloon Sinuplasty|Balloon dilatation of sinuses
37473|NCT00939627|Other|placebo|Given orally
37474|NCT00939627|Drug|sorafenib tosylate|Given orally
37475|NCT00939627|Other|laboratory biomarker analysis|Correlative studies
37476|NCT00939627|Procedure|quality-of-life assessment|Ancillary studies
37477|NCT00939640|Behavioral|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
37478|NCT00939653|Drug|clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
37479|NCT00939653|Drug|etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
36442|NCT00942734|Drug|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
36443|NCT00000846|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
36444|NCT00020358|Biological|gp100 antigen|
36445|NCT00944775|Behavioral|Exercise training|10-month exercise training program during hemodialysis sessions
36446|NCT00944788|Other|qi-gong|Physical activity similar to tai-chi
36447|NCT00944801|Drug|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
36448|NCT00944814|Dietary Supplement|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
36745|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
36746|NCT00019227|Radiation|yttrium Y 90 daclizumab|
36747|NCT00930683|Drug|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
36748|NCT00930683|Drug|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
36749|NCT00930696|Procedure|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
36750|NCT00930696|Procedure|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
36751|NCT00930709|Drug|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
36752|NCT00930709|Behavioral|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
36753|NCT00930722|Drug|quinapril|per label as non interventional study
36754|NCT00930748|Device|MR imaging with endorectal coil|MR imaging with endorectal coil
36755|NCT00930748|Device|MRI with endo-rectal coil|MRI with endo-rectal coil
36756|NCT00930761|Behavioral|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
36757|NCT00019240|Drug|cidofovir|
37538|NCT00937313|Other|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
37539|NCT00937326|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
37540|NCT00937326|Drug|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
37541|NCT00937339|Device|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
37542|NCT00937339|Device|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
37543|NCT00937352|Drug|Bapineuzumab|0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.
1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.
37544|NCT00937365|Behavioral|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
37545|NCT00019734|Biological|fowlpox virus vaccine vector|
37546|NCT00937365|Procedure|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
37547|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
37548|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
37549|NCT00939848|Drug|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
37823|NCT00019760|Drug|floxuridine|
37824|NCT00937703|Device|IVS|patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.
Face to face visit at T4mounths plus telephone visits each 2 weeks.
37825|NCT00937703|Device|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
37826|NCT00937742|Dietary Supplement|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
37827|NCT00937768|Drug|Goserelin Acetate|Given SC
37828|NCT00937768|Other|Laboratory Biomarker Analysis|Correlative studies
37829|NCT00937768|Drug|Leuprolide Acetate|Given IM
36685|NCT00940810|Procedure|Plasma Disc Decompression/Nucleoplasty|Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.
Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires.
36686|NCT00940810|Procedure|Conservative Care (physiotherapy)|Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.
Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires.
36687|NCT00940823|Device|Ahmed FP7 Valve|Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
35701|NCT00945854|Other|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
35702|NCT00945880|Drug|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
35703|NCT00945893|Biological|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
35704|NCT00020618|Drug|morphine sulfate|
35705|NCT00945893|Other|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
35706|NCT00945906|Biological|FXIII Concentrate (Human) (FXIII)|Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.
Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion.
35707|NCT00945919|Drug|Oxymorphone ER|Rapid Opioid rotation/titration
35708|NCT00945932|Drug|GW870086X|Investigational product
35709|NCT00945932|Drug|Placebo|Placebo control
35710|NCT00945945|Drug|Duloxetine (DLX)|dose daily by mouth
35711|NCT00945945|Drug|Placebo (PLA)|Placebo Comparator daily by mouth
35712|NCT00945958|Drug|Latanoprost|Latanoprost eye drops, one drop in affected eye, once daily, 24 weeks
35713|NCT00945971|Other|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
37480|NCT00939653|Drug|cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
37481|NCT00932048|Drug|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
37482|NCT00932061|Other|Traditional Acupuncture|Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.
Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria.
37483|NCT00932061|Other|Sham Treatment|Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.
Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria.
37484|NCT00932074|Drug|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
37485|NCT00932087|Procedure|Blood sample|Blood sample for lipidomic study
37486|NCT00932100|Drug|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
37487|NCT00932100|Drug|Heparin|IV dose per standard of care at the local institution
37488|NCT00932113|Drug|Methotrexate|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
37489|NCT00019396|Drug|gp100 antigen|
37490|NCT00932113|Drug|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
37491|NCT00932126|Drug|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
37759|NCT00019201|Other|immunohistochemistry staining method|
37760|NCT00929955|Drug|Placebo|Placebo added to TAU
37761|NCT00929968|Biological|Placebo|
37762|NCT00929968|Biological|VAK694|
37763|NCT00929968|Drug|Fluticasone|
37764|NCT00929981|Drug|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
37765|NCT00929994|Behavioral|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
36758|NCT00930774|Device|FM system|Frequency modulation assistive device
36759|NCT00930774|Behavioral|Auditory training|Participation in computerized auditory training program for eight weeks
36760|NCT00930787|Device|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
36761|NCT00930787|Device|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
36762|NCT00933361|Drug|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
36763|NCT00933374|Drug|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
35780|NCT00943865|Behavioral|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
35781|NCT00943865|Behavioral|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
35782|NCT00943865|Behavioral|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
35783|NCT00943865|Behavioral|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
35784|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
35785|NCT00946010|Biological|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
37830|NCT00937768|Other|Quality-of-Life Assessment|Ancillary studies
37831|NCT00937781|Genetic|RNA analysis|
37832|NCT00937781|Genetic|gene expression analysis|
37833|NCT00937781|Genetic|microarray analysis|
37834|NCT00019760|Drug|leucovorin calcium|
37835|NCT00937781|Genetic|polymerase chain reaction|
37836|NCT00937781|Other|immunohistochemistry staining method|
37837|NCT00937781|Other|laboratory biomarker analysis|
37838|NCT00937794|Behavioral|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
37839|NCT00937794|Other|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
37840|NCT00937807|Drug|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
37841|NCT00937807|Drug|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
37842|NCT00937820|Drug|YM150|oral
37843|NCT00937833|Procedure|Prostatectomy|
37844|NCT00937833|Device|Surgisis Male Sling|
37845|NCT00019760|Drug|melphalan|
37846|NCT00930020|Drug|Matched placebo|matched placebo (cornstarch) once a day for 5 days
38204|NCT00019604|Radiation|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
38205|NCT00935818|Drug|Varenicline|varenicline - 1 mg bid for 12 weeks
38206|NCT00935818|Drug|placebo|placebo for 12 weeks
38207|NCT00935818|Drug|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
38208|NCT00935831|Drug|1278863|50mg, 150mg
38209|NCT00935831|Drug|Placebo|matching placebo
35714|NCT00945984|Procedure|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
35715|NCT00020618|Procedure|quality-of-life assessment|
35716|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
35717|NCT00948506|Drug|3% topical cidofovir|3% topical cidofovir
35718|NCT00948506|Drug|Placebo|topical placebo
36013|NCT00941967|Drug|oxaliplatin|Given IV
36014|NCT00941967|Drug|sorafenib tosylate|Given orally.
36015|NCT00941980|Biological|Osteocel Plus|biologic
36016|NCT00941993|Device|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
36017|NCT00942006|Drug|doxycycline|100 mg bid, 14 days
36018|NCT00020254|Biological|recombinant vaccinia-B7.1 vaccine|
36019|NCT00942006|Drug|ceftriaxone|2g x 1 iv, 14 days
36020|NCT00942045|Biological|Biologic - Osteocel Plus|Osteocel Plus
36021|NCT00942058|Other|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
36022|NCT00942071|Biological|MVA-NP+M1|1. Intradermal injection at 5 x 10^7 pfu at day 0
36023|NCT00942071|Biological|MVA-NP+M1|2.Intramuscular injection at 5 x 10^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10^8 pfu/ml at day 0
36024|NCT00942071|Biological|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
36025|NCT00942084|Drug|Acyclovir|Protocol V2 & up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).
Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).
36026|NCT00942097|Drug|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
36027|NCT00942097|Drug|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
36028|NCT00942110|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
37766|NCT00930007|Other|Blood sampling|Blood sampling for later hormone measurements
37767|NCT00930020|Drug|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
37768|NCT00932516|Behavioral|Calorie Restricted Diet|
37769|NCT00932529|Drug|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
37770|NCT00932529|Drug|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
37771|NCT00932529|Drug|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
37772|NCT00932529|Drug|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
37773|NCT00932542|Drug|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
37774|NCT00932542|Drug|placebo|placebo
37775|NCT00019409|Drug|cytarabine|
37776|NCT00932542|Drug|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
37777|NCT00932555|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
37778|NCT00932581|Other|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
37779|NCT00932581|Other|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
37780|NCT00932594|Procedure|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
37781|NCT00932594|Other|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
38141|NCT00930553|Biological|alemtuzumab|12 mg per day administered through IV, once a day for 5 consecutive days during the first cycle and 12 mg per day administered through IV, once a day for 3 consecutive days during the second cycle, 12 months later. Patients may qualify for as-needed retreatment (12 mg per day administered through IV, once a day for 3 consecutive days) after their second fixed annual cycle.
38142|NCT00930566|Drug|methoxsalen|UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.
In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :
Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.
After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient.
35786|NCT00946023|Drug|Bone marrow transplantation|Nonmyeloablative conditioning regimen: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1-2 hours on days -6 and -5. Patients undergo total body irradiation on day -1.
Allogeneic bone marrow transplantation: Patients undergo donor bone marrow infusion on day 0.
Post-transplantation therapy: Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 30, rituximab IV is administered once per week for 8 weeks.
Graft-vs-host disease prophylaxis: Beginning on day 5, patients receive oral mycophenolate mofetil until day 35 and tacrolimus (IV then changing to orally) until day 180.
35787|NCT00946036|Drug|Sertraline Hydrochloride|
35788|NCT00946049|Device|Vicryl Plus|
35789|NCT00946049|Device|Vicryl|
35790|NCT00946062|Other|orientation and mobility training|orientation and mobility training
35791|NCT00946088|Drug|Progesterone|Progesterone 400 mg per vagina qhs. vs polyethylene glycol 400 distearate & hydrogenated vegetable oil.
35792|NCT00946101|Biological|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
35793|NCT00020631|Drug|pirfenidone|
35794|NCT00946101|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
35795|NCT00946114|Drug|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
35796|NCT00946114|Drug|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
36093|NCT00949039|Drug|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
36094|NCT00949039|Radiation|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
36095|NCT00949039|Procedure|Surgery|
36096|NCT00949052|Genetic|DNA analysis|
36097|NCT00949052|Genetic|polymorphism analysis|
36098|NCT00949052|Other|laboratory biomarker analysis|
36099|NCT00020839|Drug|temozolomide|
36100|NCT00949052|Other|medical chart review|
36101|NCT00949052|Other|questionnaire administration|
36102|NCT00949052|Procedure|assessment of therapy complications|
36103|NCT00949052|Procedure|evaluation of cancer risk factors|
38210|NCT00964262|Drug|Placebo|Plcacebo of each doasage, single subcutanoeus injection
38211|NCT00964275|Procedure|diagnostic procedure|Standard diagnostic procedures followed
38212|NCT00964275|Radiation|fludeoxyglucose F 18|PET with flueoxyglucose F 18
38213|NCT00964288|Drug|GSK1014802 low dose|oral tablet
38214|NCT00022308|Drug|irinotecan hydrochloride|
38215|NCT00964288|Drug|Lidocaine|positive control
38216|NCT00964288|Drug|GSK1014802 high dose|oral tablet
38217|NCT00964288|Drug|Placebo|To match GSK drug and positive control
38218|NCT00964301|Other|Telemedicine Education|Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.
Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.
School Nurse Asthma Education. School nurses will participate in 2 sessions.
Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention.
38219|NCT00964301|Other|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
38220|NCT00964314|Other|music|Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
Experimental Group two: Listening western music based on conventional therapy in China.
Control Group: no music therapy will be done.
38221|NCT00964327|Drug|TMC114|
38222|NCT00964340|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
38223|NCT00964340|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
38224|NCT00964353|Drug|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
38225|NCT00022308|Radiation|radiation therapy|
37248|NCT00936819|Biological|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
37249|NCT00936819|Biological|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
37250|NCT00936832|Drug|FOLFIRI regimen|
36029|NCT00000845|Biological|P3C541b Lipopeptide|
36030|NCT00020254|Biological|sargramostim|
36031|NCT00942136|Drug|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
36032|NCT00942136|Drug|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
36033|NCT00942136|Drug|Placebo|Placebo Suspension as a single dose.
36034|NCT00942136|Drug|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
36357|NCT00944749|Drug|h-ATG (ATGAM )|
36358|NCT00020501|Drug|melphalan|
36359|NCT00944749|Drug|Cyclosporine (Gengraf )|
36360|NCT00944762|Behavioral|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
36361|NCT00944762|Behavioral|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
36362|NCT00946946|Drug|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
36363|NCT00946946|Drug|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
36364|NCT00946959|Procedure|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
36365|NCT00000848|Drug|Saquinavir|
36366|NCT00020696|Drug|tirapazamine|
36367|NCT00946972|Drug|JNJ-38431055; Placebo|
36368|NCT00946985|Drug|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
36369|NCT00946985|Drug|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
36370|NCT00946998|Drug|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
38143|NCT00930566|Procedure|Extracoporal Photopheresis (ECP)|In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.
After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient.
38144|NCT00930579|Drug|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
38145|NCT00930605|Drug|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
38146|NCT00019214|Biological|gp100 antigen|
38147|NCT00930605|Drug|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
38148|NCT00930618|Drug|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
38149|NCT00930618|Drug|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
38150|NCT00930631|Drug|[3H] BMS747158|Single bolus intravenous injection of [3H] BMS747158
38151|NCT00930644|Drug|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
38152|NCT00930670|Drug|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
38153|NCT00930670|Drug|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
38154|NCT00930670|Drug|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
38155|NCT00930670|Drug|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
38156|NCT00930670|Drug|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
38157|NCT00019227|Drug|pentetic acid calcium|
38158|NCT00933231|Biological|Simulect|IV
38159|NCT00933231|Drug|Cellcept|Oral
37197|NCT00939406|Device|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
36104|NCT00949065|Biological|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
36105|NCT00949078|Drug|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
36106|NCT00942175|Drug|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
36107|NCT00942175|Drug|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
36108|NCT00942175|Drug|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
36109|NCT00942175|Drug|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
36110|NCT00020254|Drug|nilutamide|
36111|NCT00942175|Drug|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
36112|NCT00942188|Drug|LY2189102|2 subcutaneous injections weekly for 12 weeks.
36113|NCT00942188|Drug|Placebo|2 subcutaneous injections weekly for 12 weeks.
36114|NCT00942201|Drug|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
36115|NCT00942201|Drug|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
36116|NCT00942214|Drug|Natalizumab|300mg, IV, every 4 weeks
36449|NCT00944814|Dietary Supplement|LNS without zinc|LNS containing no zinc
36450|NCT00944827|Dietary Supplement|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
36451|NCT00944827|Dietary Supplement|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
36452|NCT00020501|Procedure|hyperthermia treatment|
36453|NCT00944840|Drug|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
36454|NCT00944840|Drug|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
36455|NCT00944853|Dietary Supplement|Liquid zinc supplement|Liquid zinc supplement containing 5 mg zinc as zinc sulfate
37251|NCT00936832|Drug|fluorouracil|
37252|NCT00936832|Drug|irinotecan hydrochloride|
37253|NCT00019695|Drug|alendronate sodium|
37254|NCT00936832|Drug|leucovorin calcium|
37255|NCT00936832|Drug|sunitinib malate|
37256|NCT00936832|Other|laboratory biomarker analysis|
37257|NCT00936832|Other|pharmacogenomic studies|
37258|NCT00936832|Other|pharmacological study|
37259|NCT00936858|Drug|RAD001|Taken orally once a day in the morning
37260|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose
37261|NCT00936871|Drug|Placebo|Placebo single dose
37262|NCT00936871|Drug|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
37263|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
37264|NCT00019695|Drug|ketoconazole|
37265|NCT00936871|Drug|Placebo|Placebo single dose
37266|NCT00936871|Drug|Moxifloxacin|Moxifloxacin 400 mg single dose
37267|NCT00936884|Drug|MOA728|0.6 ml (12 mg), qod if weight=>62kg;
0.4ml (8 mg), qod if weight between 38 and <62;
0.0075ml/kg (0.15mg/kg), qod if weight between 27 and <38kg; study duration: 2 weeks
37268|NCT00936884|Drug|MOA728|0.6 ml, qod if weight=>62kg;
0.4ml, qod if weight between 38 and <62;
0.0075ml/kg, qod if weight between 27 and <38kg; study duration: 2 weeks
37269|NCT00936897|Drug|Ibandronate|Ibandronate 150mg PO QM (tablet)
37270|NCT00936897|Drug|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
37271|NCT00936910|Drug|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both IV systemic and antifungal lock therapy. Systemic therapy will be Ambisome administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing up to 2.3 ml of concentrated Ambisome (2 mg/ml) into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days.
37550|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
38024|NCT00935402|Behavioral|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
38025|NCT00935415|Drug|Montelukast|Montelukast 5 mg
38026|NCT00935415|Drug|Placebo|capsules of matching placebo
38027|NCT00935441|Behavioral|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
38028|NCT00935441|Behavioral|usual case management|telephone contact with a case manager
38029|NCT00935454|Procedure|Hepatocyte matrix implantation|First operation:
Removal of liver tissue and biopsy of pancreas
Second operation:
Implantation of hepatocyte matrix implant into small bowel mesentery
37042|NCT00933868|Drug|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
37043|NCT00933868|Drug|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
37044|NCT00933881|Other|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
37045|NCT00933894|Drug|Telaprevir; Escitalopram|
37046|NCT00933907|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks
37047|NCT00933920|Drug|Aliskiren|
37048|NCT00019474|Drug|fluorouracil|
37049|NCT00933920|Drug|Aliskiren|
37050|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
37051|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
37052|NCT00933946|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
37053|NCT00933959|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
37054|NCT00933959|Behavioral|Sleep Hygiene|Treatment as usual
37702|NCT00934856|Drug|docetaxel|multiple doses
37703|NCT00934856|Drug|pertuzumab|multiple doses
37704|NCT00934856|Drug|trastuzumab emtansine|multiple doses
37705|NCT00934882|Drug|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
37706|NCT00934895|Drug|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
37707|NCT00019565|Procedure|positron emission tomography|
37708|NCT00934895|Drug|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
37709|NCT00934908|Dietary Supplement|Green Tea|Green tea capsules taken twice a day.
37710|NCT00934908|Other|Placebo|Non-active "sugar pill".
37711|NCT00934921|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
37712|NCT00934921|Drug|Zofran®|1 x 8 mg ODT
37713|NCT00934934|Other|Normal Saline|Normal Saline
37714|NCT00934934|Drug|anidulafungin|TBA
38085|NCT00933166|Device|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
38086|NCT00933179|Drug|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
38087|NCT00933179|Drug|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
38088|NCT00933192|Device|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
38089|NCT00019422|Drug|carboplatin|
38090|NCT00933205|Drug|Tipranavir|
38091|NCT00933218|Dietary Supplement|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
33362|NCT00913380|Radiation|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
33363|NCT00913393|Drug|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
33364|NCT00913393|Drug|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
33365|NCT00913393|Drug|Placebo|Placebo IV every 2 weeks for 22 weeks
33366|NCT00017368|Drug|etoposide|
33367|NCT00913406|Other|Lutein fortification|
33368|NCT00913406|Other|Standard formula|
33369|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
33370|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
33371|NCT00913432|Drug|masitinib|3 mg/kg/day oral route
33372|NCT00913432|Drug|masitinib|masitinib 6 mg/kg/day oral route
33373|NCT00913445|Procedure|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
33374|NCT00915655|Drug|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
33375|NCT00915655|Drug|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
33698|NCT00918658|Other|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
33699|NCT00918658|Other|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
33700|NCT00918658|Other|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
33701|NCT00918671|Other|No new specific intervention|No new specific intervention
33702|NCT00918684|Drug|Escitalopram|10mg tab daily
33703|NCT00918697|Procedure|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
37275|NCT00939653|Drug|cytarabine|Given intrathecally on day 1 at the dose defined by age below. 30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients >3 years of age
37276|NCT00939666|Procedure|Omission of surgery or transanal endoscopic microsurgery, combined with intensive follow-up|Omission of surgery or transanal endoscopic microsurgery
37277|NCT00939679|Procedure|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
37278|NCT00939679|Dietary Supplement|low calorie diet (1,000 kcal/day)|Patients will consume a daily diet composed of:
4 powder diet portions (Cambridge Diets, UK)
plain yogurt (100-125g)
skim milk (1L)
a limited variety of vegetables
The diet will be consumed by both groups for a 10 week period.
37279|NCT00939692|Drug|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
37280|NCT00939705|Drug|topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
37281|NCT00939718|Dietary Supplement|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
37282|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
37283|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
37284|NCT00019929|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
37285|NCT00939757|Drug|mirabegron|oral tablet
37286|NCT00939770|Drug|crizotinib|
37287|NCT00939770|Other|pharmacogenomic studies|
37288|NCT00939770|Other|pharmacological study|
37289|NCT00939783|Drug|Dimebon|Tablet for oral administration
37290|NCT00939796|Device|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
37291|NCT00939809|Biological|Urokinase-Derived Peptide A6|Given SC
37891|NCT00932828|Drug|High Dose Peanut Protein|Peanut flour will be given in gradually increasing doses.
37055|NCT00933972|Drug|RO4998452|20mg po single dose
37056|NCT00933985|Drug|dexrazoxane hydrochloride|Given IV
37057|NCT00019682|Biological|gp100 Antigen|Given SC
37058|NCT00936520|Drug|SAR 1118 0.1%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
37059|NCT00936520|Drug|SAR 1118 1.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
37060|NCT00936520|Drug|SAR 1118 5.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
37061|NCT00936533|Drug|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
37350|NCT00936975|Radiation|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
37351|NCT00019721|Biological|MART-1 antigen|
37352|NCT00936988|Drug|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
37353|NCT00937001|Procedure|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
37354|NCT00937014|Other|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
37355|NCT00937014|Other|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
37356|NCT00937027|Drug|Aminopterin|oral tablets, 1.0 mg dose, once weekly, two weeks
37357|NCT00937040|Drug|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
37358|NCT00937040|Drug|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
37359|NCT00937040|Drug|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
38092|NCT00933218|Dietary Supplement|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
38093|NCT00933231|Drug|Advagraf|Standard dose, Oral
38094|NCT00933231|Drug|Advagraf|Low dose, Oral
38095|NCT00935467|Drug|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
38096|NCT00019604|Procedure|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
38097|NCT00935480|Drug|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
38098|NCT00935480|Drug|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
38099|NCT00935493|Drug|Guanfacine|Guanfacine 0.1 mg po qhs
38100|NCT00935493|Drug|Guanfacine|Guanfacine 0.5 mg po qhs
38101|NCT00935493|Drug|Placebo|Placebo po qhs
38102|NCT00935506|Drug|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
38103|NCT00935506|Drug|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
38104|NCT00935519|Device|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 5 years follow-up.
38105|NCT00935532|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
38106|NCT00935532|Drug|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
37133|NCT00931541|Drug|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
37134|NCT00931541|Drug|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
37135|NCT00931554|Procedure|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
37136|NCT00933985|Drug|doxorubicin hydrochloride|Given IV
37137|NCT00933985|Drug|obatoclax mesylate|Given IV
37138|NCT00019474|Drug|hydroxyurea|
37139|NCT00933985|Drug|liposomal vincristine sulfate|Given IV
33704|NCT00918697|Procedure|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
33705|NCT00918723|Drug|Fludarabine Phosphate|Given IV
33706|NCT00017758|Drug|Efavirenz|
33707|NCT00918723|Drug|Cyclophosphamide|Given IV
33708|NCT00918723|Biological|Rituximab|Given IV
33709|NCT00918723|Drug|Vorinostat|Given PO
33710|NCT00918736|Drug|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
33711|NCT00918749|Drug|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
33712|NCT00918749|Drug|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
33713|NCT00918749|Drug|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
33714|NCT00918762|Procedure|assessment of therapy complications|
33715|NCT00918762|Procedure|diagnostic endoscopic surgery|
33716|NCT00918762|Procedure|quality-of-life assessment|
33717|NCT00017784|Drug|Valganciclovir|
33718|NCT00918762|Procedure|therapeutic conventional surgery|
33719|NCT00918762|Procedure|therapeutic endoscopic surgery|
34018|NCT00906828|Drug|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
34019|NCT00906828|Drug|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
34020|NCT00017095|Genetic|microarray analysis|
34021|NCT00906841|Drug|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
34022|NCT00906867|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
37892|NCT00932841|Other|Placebo|One packet PO daily x 8 weeks.
37893|NCT00932841|Drug|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
37894|NCT00932841|Drug|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
37895|NCT00932854|Procedure|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
37896|NCT00932867|Drug|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
37897|NCT00019591|Biological|aldesleukin|
37898|NCT00935116|Drug|etoricoxib|G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.
G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery
37899|NCT00935129|Device|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
37900|NCT00935129|Device|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
37901|NCT00935142|Drug|[18F]VM4-037|Bolus IV injection of [18F]VM4-037
37902|NCT00935155|Procedure|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
37903|NCT00935155|Procedure|exercises|Coordination, mobilizing, endurance, strength
37904|NCT00935168|Drug|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
37905|NCT00935168|Drug|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
37906|NCT00935181|Behavioral|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
37907|NCT00935194|Drug|oseltamivir|75mg,bid,for 5 days
37908|NCT00019591|Biological|ras peptide cancer vaccine|
37909|NCT00935194|Other|blank|no antiviral therapy
37910|NCT00935194|Drug|chinese medicinal herbs|200ml,p.o,qid,for 5 days
37911|NCT00935194|Drug|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
37912|NCT00935207|Other|Pediatric Pain Diary|Pain diary designed for pediatric patients
37360|NCT00937040|Drug|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
37361|NCT00939120|Drug|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
37362|NCT00939120|Drug|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
37363|NCT00939133|Drug|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
37364|NCT00939133|Drug|vehicle gel|Placebo
37365|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
37366|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
37367|NCT00019864|Procedure|conventional surgery|
37368|NCT00939159|Drug|LBH589|20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
37369|NCT00939172|Drug|TTP607|3.3 mg/m^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
37634|NCT00937469|Behavioral|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
37635|NCT00937469|Other|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
37636|NCT00937482|Drug|cediranib maleate|Given orally
37637|NCT00937482|Radiation|whole-brain radiation therapy|Undergo whole-brain radiotherapy
37638|NCT00937495|Drug|vorinostat|400 mg given PO
37639|NCT00019747|Drug|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
37640|NCT00937495|Drug|bortezomib|1.3 mg/m^2 given IV
37641|NCT00937508|Behavioral|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
34277|NCT00904397|Drug|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
34278|NCT00904397|Drug|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
34279|NCT00904410|Other|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
34280|NCT00904423|Drug|Vitamin D|up to 2400 mg; oral tablet
34281|NCT00904436|Drug|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
34282|NCT00904449|Drug|Oxymorphone ER|10mg, 20mg, and 40mg PO
34283|NCT00904462|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
34284|NCT00904462|Drug|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
33287|NCT00915603|Drug|Placebo|Placebo PO daily continuously for all 28 days of a cycle
33288|NCT00915603|Drug|Bevacizumab|Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
33289|NCT00915603|Drug|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
33290|NCT00915616|Drug|Melatonin|
33291|NCT00915629|Dietary Supplement|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
33292|NCT00017511|Drug|cevimeline hydrochloride|
33293|NCT00915655|Drug|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
33294|NCT00915655|Drug|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
33295|NCT00917943|Behavioral|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
33296|NCT00917982|Other|vision therapy|
34023|NCT00906867|Procedure|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
34024|NCT00906880|Drug|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
34025|NCT00906893|Procedure|18F]-FMISO PET-CT|pretherapy([18F]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe [18F]-FMISO uptake will be used.
34026|NCT00906906|Device|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
34027|NCT00906919|Behavioral|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
34028|NCT00906919|Behavioral|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
34029|NCT00906945|Drug|G-CSF|
34030|NCT00906945|Drug|Plerixafor|
34031|NCT00017095|Other|immunohistochemistry staining method|
34032|NCT00906945|Drug|Mitoxantrone|
34033|NCT00906945|Drug|Etoposide|
34034|NCT00906945|Drug|Cytarabine|
34035|NCT00906971|Other|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
34036|NCT00906984|Device|TheraSphere|Given IV
34352|NCT00910377|Behavioral|counseling sessions|The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
34353|NCT00902109|Device|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
34354|NCT00902109|Device|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
37913|NCT00935220|Drug|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
37940|NCT00937937|Drug|dinaciclib|Given IV
37941|NCT00937950|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years.
37942|NCT00937963|Dietary Supplement|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
37943|NCT00937976|Procedure|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
37944|NCT00937989|Other|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
37945|NCT00937989|Other|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
37946|NCT00937989|Other|medical chart review|Baseline, 3, 6 and 9 months after starting the study
37947|NCT00937989|Other|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
37948|NCT00019773|Drug|oxaliplatin|
37949|NCT00937989|Other|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
37950|NCT00937989|Procedure|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
37951|NCT00938015|Other|Questionnaire|This is a non-interventional study
37952|NCT00938015|Other|Questionnaire|This is a non-interventional study
37953|NCT00930189|Drug|intravitreal injection of triamcinolone|
37954|NCT00930189|Procedure|photodynamic therapy|
37955|NCT00930202|Drug|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
37956|NCT00930215|Drug|D961H|Oral gelatin capsule
37957|NCT00930215|Drug|D961H|Oral HPMC capsule
37958|NCT00930228|Drug|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
37642|NCT00929708|Drug|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
37643|NCT00929708|Drug|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
37644|NCT00929721|Procedure|Blood draw|culture for Streptococcus pneumoniae Frequency-1
37645|NCT00929721|Procedure|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
37646|NCT00929721|Procedure|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
37647|NCT00929721|Procedure|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
37648|NCT00929721|Procedure|sputum|culture for Streptococcus pneumoniae Frequency-1
37649|NCT00929734|Drug|Rosuvastatin|10mg tablets, once daily in three months
37650|NCT00929734|Drug|Placebo|1 tablet, once daily in three months
37651|NCT00929747|Device|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
37652|NCT00019175|Biological|gp100 antigen|
37653|NCT00929747|Procedure|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
38030|NCT00938041|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
38031|NCT00938067|Behavioral|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
38032|NCT00938080|Biological|AG013|Mouth rinse once a day for 14 days
38033|NCT00938080|Biological|AG013|Mouth rinse three times a day for 14 days
38034|NCT00938080|Biological|AG013|Mouth rinse six times a day for 14 days
38035|NCT00938080|Other|Placebo|Mouth rinse once a day for 14 days
38036|NCT00019786|Drug|isolated perfusion|
38037|NCT00938080|Other|Placebo|Mouth rinse three times a day for 14 days
33297|NCT00917995|Device|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
33298|NCT00918008|Genetic|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
33299|NCT00017719|Drug|Lamivudine|
33300|NCT00918021|Drug|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
33301|NCT00918021|Drug|placebo|placebo
33302|NCT00918034|Drug|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
33303|NCT00918034|Device|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
33304|NCT00918034|Procedure|Placement|Placement of device in prostate urethra
33305|NCT00918047|Drug|Oxcarbazepine|Open Label study
33306|NCT00918060|Drug|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
33307|NCT00918086|Dietary Supplement|Vitamin D pill|Oral tablet taken for 16 weeks
33629|NCT00911209|Behavioral|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
33630|NCT00911222|Other|non-interventional|non-interventional
33631|NCT00911235|Drug|Fesoterodine|Single 8 mg oral dose of fesoterodine
33632|NCT00911235|Drug|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
33633|NCT00911248|Drug|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
33634|NCT00017251|Other|laboratory biomarker analysis|Correlative studies
33635|NCT00911261|Drug|Oxymorphone Extended Release|Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets
Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets
Treatment will consist of up to 12 months of dosing with Oxymorphone ER.
33636|NCT00911274|Drug|Mycophenolate Mofetil|250 mg Capsule
33637|NCT00911274|Drug|CellCept®|250 mg Capsule
34355|NCT00902109|Device|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
34356|NCT00016601|Drug|Medroxyprogesterone acetate|
34357|NCT00902122|Drug|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
34358|NCT00902122|Procedure|surgery|removal of thyroid tumor
34359|NCT00902122|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
34360|NCT00902122|Radiation|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
34361|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
34362|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
34363|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
34364|NCT00902148|Device|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
34365|NCT00902161|Drug|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
34366|NCT00902161|Drug|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
34367|NCT00016653|Drug|Creatine Monohydrate|
34368|NCT00902161|Drug|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
34369|NCT00902174|Drug|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
34370|NCT00902174|Drug|Placebo|Placebo to imatinib 100 mg film coated tablets
34371|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
34372|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
34373|NCT00902200|Drug|AR-12286|See arms
33376|NCT00915655|Drug|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
33377|NCT00915668|Drug|JNJ-31001074|
37959|NCT00930228|Drug|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
37960|NCT00930241|Drug|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
37961|NCT00930241|Drug|Prograf®|Prograf® (two daily doses of Tacrolimus)
37962|NCT00019201|Procedure|comparison of screening methods|
38273|NCT00022009|Drug|gemcitabine hydrochloride|
38274|NCT00959972|Drug|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
38275|NCT00959985|Device|Compression Sleeve|Worn for a minimum of 12 hours per day
38276|NCT00959985|Device|Short-Stretch Compression Bandage|Worn overnight at least 5 nights of the week
38277|NCT00959998|Other|Self-administered Acupressure|
38278|NCT00960011|Device|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
38279|NCT00960011|Device|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
38280|NCT00960024|Behavioral|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
38281|NCT00960024|Behavioral|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
38282|NCT00960037|Dietary Supplement|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
38283|NCT00960037|Dietary Supplement|Placebo equivalent|One capsule daily for 8 weeks
38284|NCT00022022|Drug|docetaxel|
38285|NCT00960050|Genetic|polymorphism analysis|
38286|NCT00960050|Other|laboratory biomarker analysis|
38287|NCT00960050|Other|medical chart review|
38288|NCT00960050|Procedure|assessment of therapy complications|
38038|NCT00938080|Other|Placebo|Mouth rinse six times a day for 14 days
38039|NCT00938093|Behavioral|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
38040|NCT00938093|Behavioral|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
38041|NCT00938106|Radiation|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
38042|NCT00938132|Drug|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
38043|NCT00938145|Procedure|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
38044|NCT00938145|Drug|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
38045|NCT00938145|Procedure|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
38046|NCT00938158|Biological|albiglutide|single dose of subcutaneously injected albiglutide
38047|NCT00019786|Drug|melphalan|
37062|NCT00936533|Drug|Placebo|Placebo preparation without active compound, administered as the active drug.
37063|NCT00936546|Drug|Rituximab|Mabthera, Rituximab 1000 mg I.V.
37064|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
37065|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
37066|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
37067|NCT00936572|Procedure|Probiotics (La1, BB536)|
37068|NCT00000841|Drug|Indinavir sulfate|
37069|NCT00019682|Drug|Montanide ISA 51 VG|Given SC
37070|NCT00936572|Biological|probiotics (La1, BB536)|
37071|NCT00936572|Biological|placebo|Maltodoxtrin
33638|NCT00911287|Drug|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
33639|NCT00913822|Drug|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
33640|NCT00913835|Biological|IMC-3G3|20 mg/kg every 2 weeks (14 days) Treatment will continue until there is evidence of Progressive Disease (PD) or development of unacceptable toxicity
33641|NCT00913835|Drug|liposomal doxorubicin|40 mg/m2 every 4 weeks (28 days). Treatment will continue until there is evidence of Progressive Disease (PD) or development of unacceptable toxicity
33642|NCT00913848|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
33643|NCT00913848|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
33644|NCT00913861|Behavioral|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
33645|NCT00017368|Drug|vincristine sulfate|
33646|NCT00913861|Drug|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
33647|NCT00913861|Behavioral|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
33648|NCT00913874|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
33649|NCT00913874|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
33956|NCT00909285|Behavioral|Cognitive training|TMS stimulation and cognitive training
33957|NCT00909298|Drug|TTP889|300 mg
33958|NCT00909298|Drug|Placebo|Placebo
33959|NCT00909311|Drug|ABT-450|capsules, QD, 1 dose in each cross-over period
33960|NCT00909311|Drug|ritonavir|capsule, QD, 1 dose in each cross-over period
33961|NCT00909324|Drug|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
33962|NCT00909324|Drug|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
33963|NCT00909337|Drug|Bosentan|2x62.5mg for 4 weeks, then 2x125mg
33378|NCT00915681|Drug|Silibinin|20 mg/kg/day IV
33379|NCT00915694|Drug|nelfinavir mesylate|
33380|NCT00915694|Drug|temozolomide|
33381|NCT00915694|Procedure|adjuvant therapy|
33382|NCT00017524|Drug|pelitrexol|
33383|NCT00915694|Radiation|radiation therapy|
33384|NCT00915707|Other|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
33385|NCT00915707|Other|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
33386|NCT00915707|Other|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
33387|NCT00915733|Drug|cilostazol|100 mg twice daily for at least 1 month
33388|NCT00915733|Drug|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
33389|NCT00915733|Genetic|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19*2 (rs4244285, c. 681G>A, p.P227P), and CYP2C19*3 (rs4986893, c. 636G>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
33390|NCT00915733|Drug|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
33391|NCT00915746|Drug|JNJ-31001074; ketoconazole|
33392|NCT00915759|Device|ProKera|ProKera placed in non-dominant eye after PRK
33393|NCT00017537|Biological|MVF-HER-2(628-647)-CRL 1005 vaccine|
33394|NCT00915759|Device|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after PRK
33395|NCT00915772|Drug|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
33396|NCT00915772|Drug|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
33397|NCT00915772|Drug|Metformin|Metformin 1000 mg tablet bid
33398|NCT00915785|Drug|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
33720|NCT00918762|Procedure|transoral robotic surgery|
38289|NCT00962039|Drug|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
38290|NCT00962065|Drug|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
38291|NCT00962065|Drug|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
38292|NCT00962065|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days
38293|NCT00962078|Other|continuous endurance training|at 60 percent of peak Watt
38294|NCT00962078|Other|interval training|at 100 percent of peak Watt
37292|NCT00939809|Other|Laboratory Biomarker Analysis|Correlative studies
37293|NCT00939822|Drug|Simvastatin|40 mg Simvastatin/day
37294|NCT00939822|Drug|Placebo|Matching Placebo
37295|NCT00019929|Procedure|adjuvant therapy|
37296|NCT00939835|Drug|Citalopram Hydrobromide|
37297|NCT00931723|Drug|Placebo|Oral treatment twice daily.
37298|NCT00931736|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
37299|NCT00931736|Drug|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
37300|NCT00931749|Device|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
37301|NCT00931749|Device|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
37302|NCT00019383|Biological|sargramostim|
37303|NCT00931762|Drug|Panobinostat|Panobinostat will be administered orally once a day on Monday, Wednesday and Friday at a fixed dose of 40 mg. A cycle is defined as 28 days of treatment.
37304|NCT00931775|Drug|Pindolol|Pill orally administered. 15 mg/day t.i.d.
37072|NCT00936585|Other|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
37073|NCT00936598|Drug|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women = or > 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
37074|NCT00936598|Drug|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
37075|NCT00936611|Drug|LBH589|Orally on Mondays, Wednesdays and Fridays
37076|NCT00936624|Drug|SOTB07|SOTB07 100mg
37077|NCT00936624|Drug|SOTB07|SOTB07 200mg
37078|NCT00936624|Drug|placebo|placebo
37079|NCT00936624|Drug|montelukast|montelukast 10mg po, bid, 12week
37080|NCT00019682|Other|Quality-of-Life Assessment|Ancillary studies
37081|NCT00936637|Other|Extensively hydrolyzed infant formula|
37082|NCT00938977|Device|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
37083|NCT00938990|Drug|Etomidate|
37084|NCT00938990|Drug|Midazolam|
37085|NCT00939003|Biological|Adalimumab|40 mg every other week up to Week 12
37086|NCT00939003|Biological|Placebo|Placebo every other week up to Week 12
37370|NCT00939185|Drug|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
37371|NCT00939198|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
37372|NCT00939211|Drug|AZD9164|Solution for inhalation through nebulization, single dose
37373|NCT00939211|Drug|Tiotropium|Dry powder for inhalation, single dose
37374|NCT00939211|Drug|Placebo|Placebo
37375|NCT00939224|Device|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
33964|NCT00909363|Drug|Promacta (eltrombopag)|Patients will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP.
33965|NCT00000209|Drug|Buprenorphine|
33966|NCT00000821|Drug|Aldesleukin|
33967|NCT00017186|Drug|epirubicin hydrochloride|
33968|NCT00909363|Drug|Eltrombopag/promacta|Patients will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP.
33969|NCT00909389|Drug|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
33970|NCT00909402|Drug|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
33971|NCT00901563|Drug|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
33972|NCT00901563|Other|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
33973|NCT00901576|Drug|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
33974|NCT00901576|Drug|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
33975|NCT00901576|Drug|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
33976|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
34285|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
34286|NCT00016913|Radiation|radiation therapy|77.4 Gy in 1.8 Gy fractions
34287|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
34288|NCT00904488|Drug|Intravenous Bolus Furosemide and Oral Metolazone|Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide
34289|NCT00904488|Drug|Intravenous Continuous Infusion Furosemide|Transition from intravenous bolus to continuous infusion furosemide
33721|NCT00911300|Drug|fondaparinux|Comparison of different drugs
33722|NCT00911300|Drug|unfractionated heparin|Comparison of different drugs
33723|NCT00911300|Drug|Vitamin-K-Antagonist|Comparison of different drugs
33724|NCT00911313|Drug|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
33725|NCT00911313|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
33726|NCT00911313|Drug|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
33727|NCT00017264|Drug|atrasentan hydrochloride|
33728|NCT00911326|Drug|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
33729|NCT00911339|Drug|Atorvastatin|Atorvastatin 10 mg associated with stent genous
33730|NCT00911339|Drug|Atorvastatin|Atorvastatin 80 mg associated with stent genous
33731|NCT00911352|Device|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for > 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
33732|NCT00911365|Biological|autologous mesenchymal stem cells|4*107 stem cell (100ml) Intra arterial infusion/ one time, then 4*107 stem cell(100ml)Intravenous infusion 3 times/monthly
-> Total four times
33733|NCT00911365|Biological|normal saline|saline
33734|NCT00911378|Procedure|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
33735|NCT00911378|Procedure|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
33736|NCT00911391|Device|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
33737|NCT00911391|Procedure|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
33738|NCT00017277|Biological|epoetin alfa|
37305|NCT00931788|Drug|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
37306|NCT00931788|Other|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
37307|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
37308|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
37309|NCT00931801|Drug|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
37310|NCT00931814|Other|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
37311|NCT00931827|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
37312|NCT00931827|Drug|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
37914|NCT00935233|Genetic|DNA analysis|
37915|NCT00935233|Genetic|polymorphism analysis|
37916|NCT00935233|Genetic|protein analysis|
37917|NCT00935233|Other|laboratory biomarker analysis|
37918|NCT00935233|Other|questionnaire administration|
37919|NCT00019591|Procedure|adjuvant therapy|
37920|NCT00935233|Other|survey administration|
37921|NCT00935246|Drug|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
37922|NCT00935259|Drug|Simvastatin|40 mg once daily for 2 weeks
37923|NCT00935259|Drug|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
37924|NCT00935272|Device|Restylane®|Restylane® injections in the lips
37925|NCT00935272|Device|Non-Treatment|Non- Treatment
37926|NCT00937846|Drug|GSK1034702|Single oral 5 mg dose in liquid formulation
37927|NCT00937859|Drug|SER120|SER120
37376|NCT00939237|Drug|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
37377|NCT00939237|Drug|Placebo|
37378|NCT00019864|Procedure|neoadjuvant therapy|
37379|NCT00939250|Behavioral|Diabetes and depression intervention|Disease self management for diabetes and depression
37380|NCT00939250|Behavioral|Diabetes intervention|Disease self management for diabetes
37381|NCT00939263|Other|assessment of disease activity using the EEsAI|disease activity index
37382|NCT00939276|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
37383|NCT00939276|Drug|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
37384|NCT00939289|Device|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
37385|NCT00939328|Biological|rituximab|
37386|NCT00931879|Drug|omega-3-acie ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients.
37387|NCT00931892|Dietary Supplement|Gluten|3g
37388|NCT00931892|Dietary Supplement|Gluten|10g
37389|NCT00931905|Drug|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
37654|NCT00929760|Behavioral|specialised renal care|Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.
Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG.
37655|NCT00929773|Device|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
37656|NCT00929773|Device|Placebo laser|Inactive laser light.
34290|NCT00904501|Procedure|Bone marrow harvest|Implantation of placebo
34291|NCT00904501|Procedure|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
34292|NCT00904514|Genetic|gene expression analysis|
34293|NCT00904514|Genetic|microarray analysis|
34294|NCT00904514|Genetic|mutation analysis|
34295|NCT00904514|Genetic|polymerase chain reaction|
34296|NCT00904514|Other|flow cytometry|
34297|NCT00000817|Drug|Amitriptyline hydrochloride|75 mg oral tablet taken daily
34298|NCT00016913|Drug|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
34299|NCT00904514|Other|immunoenzyme technique|
34300|NCT00904514|Other|laboratory biomarker analysis|
34301|NCT00904527|Behavioral|relaxation (Schultz)|Patients have relaxation consultations during 2 months
34302|NCT00907348|Drug|LR-CHOP21|FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14
SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14
THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14
FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days
34303|NCT00907361|Device|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
34304|NCT00907374|Drug|benazepril|benazepril 10 mg orally once daily
34305|NCT00907374|Drug|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
33308|NCT00918086|Dietary Supplement|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
33309|NCT00918099|Procedure|Avaulta mesh|Insertion of a mesh vs conventional repair
33310|NCT00017719|Drug|Lamivudine/Zidovudine|
33311|NCT00918099|Procedure|Anterior repair|Conventional repair
33739|NCT00911404|Behavioral|Low CHO|Diet with 40% total calories from carbohydrates. In the "Low-CHO" arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat.
34037|NCT00906997|Procedure|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
34038|NCT00906997|Procedure|Colonoscopy|Every 10 years, with sedation.
34039|NCT00907036|Biological|alemtuzumab|
34040|NCT00907036|Biological|donor lymphocytes|
34041|NCT00907036|Drug|cyclosporine|
34042|NCT00909402|Drug|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
34043|NCT00909402|Drug|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
34044|NCT00909428|Drug|Solifenacin 10mg|Daily for one month
34045|NCT00909441|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
34046|NCT00909454|Dietary Supplement|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
34047|NCT00909454|Dietary Supplement|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
34048|NCT00909467|Other|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
34049|NCT00017186|Drug|gemcitabine hydrochloride|
34050|NCT00909480|Drug|insulin detemir|Treat-to-target (individually adjusted dose) titration according to titration algorithm.
S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued
34051|NCT00909480|Drug|insulin glargine|Treat-to-target (individually adjusted dose) titration according to titration algorithm.
S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued
34052|NCT00909493|Other|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
34053|NCT00909506|Drug|Placebo|Control: Receive placebo pill once every evening on 1~2 weeks.
Receive placebo pill in every morning and evening on 3~24 weeks (twice a day).
37928|NCT00937859|Drug|Placebo|Placebo
37929|NCT00937872|Drug|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
37930|NCT00937872|Drug|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
37931|NCT00937885|Behavioral|Implementation of reminiscence|
37932|NCT00937898|Dietary Supplement|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
37933|NCT00937898|Dietary Supplement|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
37934|NCT00937911|Drug|YM150|oral
37935|NCT00937924|Drug|Saline|Saline solution injections
37936|NCT00000841|Drug|Stavudine|
37937|NCT00019773|Drug|capecitabine|
37938|NCT00937924|Drug|Diphenhydramine|Diphenhydramine injections
37939|NCT00937924|Drug|Promethazine|Promethazine
37963|NCT00930254|Procedure|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
37964|NCT00930293|Behavioral|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
37965|NCT00930293|Behavioral|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
37966|NCT00930293|Drug|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
37967|NCT00930306|Drug|AZD2066|12 doses, Given as capsule, 2 mg & 8 mg
37968|NCT00930306|Drug|Caffeine|2 doses, Given as Tablet, 2x50 mg
37969|NCT00930306|Drug|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
37970|NCT00930306|Drug|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
37971|NCT00930306|Drug|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
37657|NCT00929799|Drug|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
37658|NCT00929812|Drug|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
37659|NCT00929812|Drug|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
37660|NCT00929825|Device|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
37661|NCT00929825|Procedure|TENS|transcutaneous electrical stimulation
37662|NCT00929838|Behavioral|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
37663|NCT00019188|Drug|interleukin-12|
37664|NCT00929838|Behavioral|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
37665|NCT00929838|Behavioral|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
37666|NCT00929838|Behavioral|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
37667|NCT00932347|Drug|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
37668|NCT00932360|Device|Transient Placebo TENS (Rehabilicare Maxima TENS)|Transient placebo TENS will be applied for one arm of the study
37669|NCT00932360|Device|Active TENS (Rehabilicare Maxima TENS)|Active high frequency TENS will be use for Active TENS
37670|NCT00932360|Device|No TENS (Rehabilicare Maxima TENS)|No TENS will have a TENS unit in place but not turned on to blind the investigator and subject
37671|NCT00932373|Drug|trastuzumab-MCC-DM1|Intravenous escalating dose
37672|NCT00932386|Drug|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
37673|NCT00932386|Drug|normal saline|0.9% normal saline infusing
38048|NCT00938171|Procedure|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
38049|NCT00938171|Procedure|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
33312|NCT00918138|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
33313|NCT00918138|Drug|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
33314|NCT00918138|Drug|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
33315|NCT00918138|Drug|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
33316|NCT00918138|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
33317|NCT00918151|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study
33318|NCT00918164|Drug|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
33319|NCT00918177|Drug|AP09004|
33320|NCT00918177|Drug|Carbidopa/Levodopa, immediate release|
33321|NCT00017719|Drug|Nelfinavir mesylate|
33322|NCT00910689|Drug|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
33323|NCT00910702|Device|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
33324|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 10 days
33325|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 15 days
33326|NCT00910715|Drug|placebo|control subjects without a history of Lyme borreliosis
33327|NCT00910728|Drug|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
33328|NCT00910741|Drug|Nanoplatin (NC-6004) and Gemcitabine|
33329|NCT00910754|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
33330|NCT00910754|Drug|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
33650|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
33651|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
34054|NCT00909506|Drug|Metformin|Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1~2 weeks.
Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3~24 weeks.
34055|NCT00909506|Drug|Metformin|Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1~2 weeks. (Dose-escalate)
Receive oral metformin 500 mg in every morning and evening on 3~24 weeks (metformin 500 mg * twice a day = 1000 mg per day).
34056|NCT00909519|Drug|naproxcinod|naproxcinod 750 mg bid
34374|NCT00902200|Drug|AR-12286 vehicle|See arms
34375|NCT00902213|Behavioral|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
34376|NCT00902213|Behavioral|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
34377|NCT00902226|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
34378|NCT00016653|Drug|Glutamine|
34379|NCT00904540|Drug|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (<6 weeks) LBP, subacute (6 weeks to <3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (>12 months LBP)
34380|NCT00904553|Radiation|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
34381|NCT00904592|Drug|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
34382|NCT00904592|Drug|Placebo Comparator|Control group: Basic therapy ＆ placebo
Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.
placebo,Usage: 4.5g，po，tid
34383|NCT00904605|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
34384|NCT00904605|Drug|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
34385|NCT00904618|Procedure|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
34386|NCT00016926|Drug|capecitabine|
37972|NCT00930319|Other|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
37973|NCT00000834|Drug|Zidovudine|
37974|NCT00019201|Procedure|endoscopic biopsy|
37975|NCT00930332|Drug|methadone hydrochloride|Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)
Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
OR
Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
37976|NCT00930332|Other|questionnaire administration|within 48 hours of registration
37977|NCT00930332|Procedure|management of therapy complications|if required
37978|NCT00932880|Drug|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
37979|NCT00932880|Drug|Norvasc|10 mg dose (Pfizer, USA)
37980|NCT00019409|Drug|prednisone|
37981|NCT00932893|Drug|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
37982|NCT00932893|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
37983|NCT00932893|Drug|Docetaxel|Docetaxel, 75 mg/m^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
37984|NCT00932906|Other|Different self-training methods|Self training with MiniAnne Training Kit
37985|NCT00932906|Other|Standard training|Instructor-based training meeting ERC directions
37006|NCT00938925|Procedure|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
37007|NCT00938925|Procedure|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
37008|NCT00938938|Other|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
37009|NCT00938951|Other|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
37010|NCT00938964|Drug|Lidocaine|Lidocaine versus placebo infusion for 48 hours
37011|NCT00019864|Drug|leucovorin calcium|
38050|NCT00930345|Drug|Sunitinib (SUTENT)|Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).
Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.
At the end of the treatment period patients will be treated at the discretion of the Investigator.
38051|NCT00930358|Drug|MEOPA|anaesthetic gaz inhalation
38052|NCT00930358|Drug|general anaesthesia|Anaesthetic intravenous route
38053|NCT00930371|Other|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
38054|NCT00930371|Other|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
38055|NCT00930410|Procedure|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
38056|NCT00930436|Drug|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
38057|NCT00019214|Biological|MART-1 antigen|
38058|NCT00930449|Other|Cogmed Working Memory Training Program.|This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.
Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day.
38059|NCT00930449|Other|Academy of Math|This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.
Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide.
38060|NCT00930449|Other|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
38061|NCT00930462|Device|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
38062|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
38063|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
37087|NCT00939003|Biological|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
33652|NCT00913887|Drug|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
33653|NCT00913900|Biological|autologous CD133+ cells|Intramuscular injection
33654|NCT00913913|Biological|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
33655|NCT00913913|Drug|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
33656|NCT00000823|Drug|Didanosine|
33657|NCT00017368|Procedure|conventional surgery|
33658|NCT00913913|Biological|IL-2|IL-2 18 MiU/m2 CI 5 days
33659|NCT00913913|Biological|IFN|IFN 6 MiU subc TIW
33660|NCT00913926|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
33661|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
33662|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
33663|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
33664|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
33665|NCT00913952|Drug|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
33666|NCT00916045|Drug|Thymoglobulin|
33667|NCT00916045|Drug|Ciclosporin|
33668|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
33669|NCT00916045|Drug|Fludarabine|
33670|NCT00916045|Drug|Melphalan|
33671|NCT00916045|Drug|Thymoglobulin|
33672|NCT00916045|Drug|Ciclosporin|
33673|NCT00017576|Drug|carboplatin|
33674|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
34387|NCT00904618|Procedure|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
34388|NCT00904618|Drug|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
33399|NCT00915798|Behavioral|Cigarette smoking versus withdrawal in smokers|Each participant will undergo an fMRI scan during an experimental task consisting of mathematical problems and unpleasant and neutral pictures. Smokers will undergo two fMRI scans during similar experimental tasks under the following two conditions: (1) after smoking a cigarette and (2) after overnight abstinence (withdrawal).
33400|NCT00915811|Drug|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
33401|NCT00918190|Drug|Placebo|Saline
33402|NCT00918190|Drug|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
33403|NCT00918190|Drug|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
33404|NCT00918203|Biological|IMC-3G3|15 mg/kg of IMC-3G3 on Days 1, 8, and 15 of each 21-day cycle, administered as an I.V. infusion at 25mg/min, with a minimum infusion time of 30 minutes.
33405|NCT00918203|Drug|Paclitaxel|200 mg/m2 is then administered I.V. over 3 hours
33406|NCT00918203|Drug|carboplatin|AUC=6 administered I.V. over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of paclitaxel/carboplatin are reached the patient may continue on IMC-3G3 maintenance for up to 12 months.
33407|NCT00918216|Genetic|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
33408|NCT00918216|Other|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
33409|NCT00918216|Other|medical chart review|Patients' medical charts are reviewed to obtain clinical information
33410|NCT00918216|Procedure|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
33411|NCT00017719|Drug|Nevirapine|
33412|NCT00918216|Procedure|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
37012|NCT00938964|Drug|Placebo|Lidocaine versus placebo infusion for 48 hours
37013|NCT00938977|Device|CPAP|Before and after effect of treatment with CPAP
37014|NCT00931216|Procedure|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
37015|NCT00931229|Drug|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
37016|NCT00931242|Drug|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
37017|NCT00931255|Drug|Tacrolimus (FK506, Prograf)|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
37018|NCT00931255|Drug|Sirolimus (Rapamune, Rapamycin)|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
37019|NCT00931268|Device|Macrolane VRF 30|One administration
37020|NCT00931281|Drug|ABT-450|capsules, QD or BID, 14 days, ascending doses
37021|NCT00931281|Drug|ritonavir|capsules, QD or BID, 14 days, ascending doses
37022|NCT00931281|Drug|Placebo for ABT-450|capsule, QD or BID, 14 days
37023|NCT00931281|Drug|Placebo for ritonavir|capsule, QD or BID, 14 days
37024|NCT00019344|Drug|alvocidib|
37313|NCT00019383|Biological|tyrosinase peptide|
37314|NCT00931840|Drug|EZN-2208, Cetuximab and Irinotecan|Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.
Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).
37315|NCT00931853|Drug|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
37316|NCT00931866|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
37088|NCT00939016|Other|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
37089|NCT00939029|Drug|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
37090|NCT00019864|Drug|methotrexate|
37091|NCT00939029|Drug|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
37092|NCT00939042|Procedure|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
37093|NCT00939042|Procedure|BMNC therapy|Injection of BMNC after common PCI
37094|NCT00939055|Device|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
37095|NCT00939055|Procedure|Sham procedure|False procedure
37096|NCT00939068|Drug|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
37097|NCT00939068|Biological|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
37098|NCT00939081|Behavioral|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
37099|NCT00939081|Behavioral|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
37100|NCT00939094|Drug|AZD2066|Capsule, once daily
37101|NCT00019864|Procedure|adjuvant therapy|
37102|NCT00939094|Drug|Placebo|Capsule, once daily
37103|NCT00939107|Procedure|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
37104|NCT00939107|Procedure|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
37105|NCT00939120|Drug|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
33675|NCT00916058|Drug|Bendamustine|30 mg/m2 given on day 2 of melphalan
33977|NCT00901589|Dietary Supplement|thistle oil|four capsules a day
33978|NCT00016536|Drug|Carbopol polymer|
33979|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
33980|NCT00901589|Dietary Supplement|Thistle oil|Four capsules daily
33981|NCT00901615|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
33982|NCT00901628|Drug|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
33983|NCT00901628|Drug|morphine sulfate|10mg intraoperative periarticular injection
33984|NCT00901628|Drug|ketorolac|30 mg intraoperative periarticular injection
33985|NCT00901628|Drug|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
33986|NCT00901628|Drug|cefuroxime|750mg intraoperative periarticular injection
33987|NCT00901641|Device|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
33988|NCT00901654|Biological|ACE527 vaccine|First cohort: Two doses, each of 3x10^9 cfu of each strain (9x10^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).
Second cohort: Two doses, each of 3x10^10 cfu of each strain (9x10^10 cfu total per dose) administered on Days 0 and Day 21
33989|NCT00016549|Biological|Bevacizumab|
33990|NCT00901654|Biological|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
33991|NCT00901693|Drug|AL-46383A Ophthalmic Solution|
33992|NCT00901693|Drug|AL-46383A Ophthalmic Solution Vehicle|
33993|NCT00901706|Other|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
33994|NCT00901706|Other|APS usual care|APS usual care consists of social, medical, and legal assistance.
33995|NCT00903825|Procedure|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
33413|NCT00918216|Procedure|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
33414|NCT00918229|Device|BioProtect biodegradable balloon implant|biodegradable balloon implant to extend the distance between prostate and anterior rectal wall
33415|NCT00918229|Procedure|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
33416|NCT00918255|Biological|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
33417|NCT00918255|Drug|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
33418|NCT00918268|Biological|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
33740|NCT00911404|Dietary Supplement|High CHO diet|Diet with 55% total calories from carbohydrates.
33741|NCT00911417|Device|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
33742|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
33743|NCT00906243|Biological|CV9103|CV9103 encodes for 4 prostate specific antigens.
33744|NCT00906256|Drug|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
33745|NCT00906256|Drug|Placebo|Placebo
33746|NCT00906269|Drug|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
33747|NCT00906269|Drug|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
33748|NCT00906282|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week (21-day) treatment cycle for a total of 4 cycles (12 weeks).
33749|NCT00906282|Drug|Carboplatin|AUC=6 IV on Day 1 of every 3-week (21-day) treatment cycle for a total of 4 cycles (12 weeks).
33750|NCT00906295|Other|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
37317|NCT00931866|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
37318|NCT00934245|Biological|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
37319|NCT00934245|Biological|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
37320|NCT00934258|Drug|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
37321|NCT00000838|Drug|Zidovudine|
37322|NCT00019500|Drug|raloxifene|
37323|NCT00934258|Genetic|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
37324|NCT00934271|Radiation|fractionated stereotactic radiotherapy|Audit of outcome
37325|NCT00934284|Other|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
37326|NCT00934284|Other|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
37327|NCT00934323|Drug|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
37328|NCT00934323|Drug|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
37591|NCT00932334|Behavioral|Usual Care|Participants receive their usual care
37592|NCT00932347|Drug|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
37593|NCT00019396|Drug|tyrosinase peptide|
37594|NCT00934635|Other|PET Scan|PET Scan
37106|NCT00931372|Drug|Placebo|Subcutaneous injection
37390|NCT00931905|Other|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
37391|NCT00931918|Drug|Vc-RCHOP|bortezomib administered intravenously on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab intravenously, cyclophosphamide intravenously, doxorubicin intravenously and vincristine intravenously on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
37392|NCT00000212|Drug|Desipramine|
37393|NCT00000837|Biological|Varicella Virus Vaccine (Live)|
37394|NCT00019383|Biological|tyrosinase-related protein-1|
37395|NCT00931918|Drug|RCHOP|RCHOP administered as follows: rituximab intravenously, cyclophosphamide intravenously, doxorubicin intravenously and vincristine intravenously on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
37396|NCT00931931|Biological|HSV1716|
37397|NCT00931944|Drug|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
37398|NCT00931957|Drug|Etanercept, Methotrexate, Prednisolone|In: Arm A, Etanercept-MTX-Prednisolone:
Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.
In Arm B:
Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.
37399|NCT00931996|Drug|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
37400|NCT00932022|Drug|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
37401|NCT00932022|Other|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
37402|NCT00932035|Procedure|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
37403|NCT00932035|Drug|isosulfan blue based lymphatic mapping|
37404|NCT00932035|Procedure|axillary lymph node dissection|Undergo standard axillary lymph node dissection
37405|NCT00019396|Drug|flt3 ligand|
37406|NCT00932035|Procedure|quality-of-life assessment|Ancillary studies
37407|NCT00932035|Other|Questionnaire administration|Ancillary studies
33996|NCT00903838|Drug|pardoprunox|1.5 to 12 mg/day
33997|NCT00903838|Drug|pramipexole|0.75-4.5 mg/day
34306|NCT00907387|Drug|RT001|Dose A RT001
34307|NCT00907387|Drug|RT001|Dose B RT001
34308|NCT00907387|Other|Placebo|Dose C Placebo
34309|NCT00907400|Drug|PN400|oral tablet
34310|NCT00017108|Drug|chlorambucil|
34311|NCT00907400|Drug|Naproxen|oral tablet
34312|NCT00907413|Procedure|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
34313|NCT00907413|Procedure|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
34314|NCT00907426|Drug|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
34315|NCT00907426|Drug|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
34316|NCT00907452|Drug|melphalan-prednisone-thalidomide|
34317|NCT00907452|Drug|lenalidomide-dexamethasone|
34318|NCT00907478|Biological|romiplostim|Romiplostim administered by subcutaneous injection
34319|NCT00907491|Device|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
34320|NCT00907504|Drug|CP-751,871|CP-751,871 20mg/kg every 3 weeks
34321|NCT00017108|Drug|cyclophosphamide|
34322|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
34323|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
34324|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
34325|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
33751|NCT00017082|Drug|oxaliplatin|
33752|NCT00906295|Other|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
33753|NCT00906308|Drug|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
33754|NCT00906308|Drug|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
33755|NCT00906308|Drug|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
33756|NCT00906321|Behavioral|Web-Based Decision Support|
33757|NCT00906334|Drug|ON 01910.Na|The original dosing regimen was 800 mg/m^2 ON 01910.Na.
33758|NCT00906334|Drug|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
34057|NCT00909519|Drug|Naproxen|Naproxen 500 mg bid
34058|NCT00909519|Drug|placebo|placebo
34059|NCT00909519|Drug|furosemide|furosemide
34060|NCT00017199|Drug|bortezomib|
34061|NCT00909532|Drug|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
34062|NCT00909532|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
34063|NCT00909545|Drug|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
34064|NCT00909545|Drug|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
34065|NCT00909545|Drug|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
34066|NCT00901719|Drug|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
34067|NCT00901719|Drug|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
34068|NCT00901719|Drug|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
34069|NCT00901719|Drug|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
37595|NCT00934635|Drug|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 24 hours
37596|NCT00934635|Drug|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 2 hours
37597|NCT00934635|Drug|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 2 hours
37598|NCT00934635|Drug|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 24 hours
37599|NCT00934635|Drug|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 24 hours
37600|NCT00934635|Drug|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 24 hours
37601|NCT00019539|Drug|thalidomide|
37602|NCT00934648|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
37603|NCT00934648|Drug|methotrexate|10-25mg weekly
37604|NCT00934661|Drug|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
37605|NCT00934661|Drug|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
37606|NCT00934674|Drug|SKI-606 (Bosutinib)|Arm 1 - Commercial Tablet manufactured by Excella
Arm 2 - Clinical Tablet manufactured by Wyeth Montreal
37607|NCT00934687|Drug|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
37608|NCT00934687|Other|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
37609|NCT00934700|Other|Xenon gas|30% Xenon gas inhaled for 24 hours
37610|NCT00934713|Drug|montelukast|montelukast 4mg once per day for 8 weeks period
37611|NCT00934739|Drug|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
37612|NCT00019552|Drug|irofulven|
37613|NCT00934739|Drug|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
37986|NCT00932919|Behavioral|Thought field therapy|5 sessions with Thought field therapy
37408|NCT00934414|Drug|Technosphere Insulin Inhalation Powder|30U
37409|NCT00934427|Drug|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
37674|NCT00932412|Drug|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
37675|NCT00932412|Drug|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
37676|NCT00932425|Device|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
37677|NCT00019409|Drug|asparaginase|
37678|NCT00932438|Device|LC bead loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan in combination with Fluorouracil, Oxaliplatin, Leucovorin and Avastin alternating on a 2 weekly schedule
37679|NCT00932438|Drug|FOLFOX6 and Avastin|Fluorouracil, Oxaliplatin, Leucovorin and Avastin given biweekly
37680|NCT00932451|Drug|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
37681|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose under fasted conditions
37682|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
37683|NCT00932477|Drug|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
37684|NCT00932477|Drug|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
37685|NCT00932477|Drug|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
37686|NCT00932490|Behavioral|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
37687|NCT00932503|Device|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
37688|NCT00019409|Drug|cyclophosphamide|
37689|NCT00932516|Behavioral|South Beach Diet™ with South Beach Diet™ Products|
34326|NCT00910156|Device|Macintosh laryngoscope|Macintosh intubation
34327|NCT00017225|Drug|melphalan|
34328|NCT00910169|Other|inpatient treatment|Hospitalisation modalities are described but are naturalistic
34329|NCT00910182|Procedure|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
33331|NCT00910767|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
33332|NCT00017225|Radiation|radiation therapy|
33333|NCT00910767|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
33334|NCT00910780|Drug|Aripiprazole|via oral tablets, everyday
33335|NCT00910780|Drug|Zyprexa|via oral tablets, taken once daily
33336|NCT00910780|Drug|Risperdal|via oral tablets, taken once daily
33337|NCT00910793|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
33338|NCT00910806|Drug|TMC207; nevirapine|
33339|NCT00910819|Other|non-interventional|
33340|NCT00910832|Drug|Eductyl suppository|one suppository every morning during 21 days
33341|NCT00910832|Drug|Placebo suppository|placebo suppository every morning during 21 days
33342|NCT00910845|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
33343|NCT00000822|Biological|gp160 Vaccine (Immuno-AG)|
33344|NCT00017238|Drug|KRN5500|Given IV
33345|NCT00910845|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
33346|NCT00910858|Drug|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
33347|NCT00910858|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
33348|NCT00913302|Behavioral|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
34070|NCT00901732|Device|Caphosol|Oral Mouth Rinse
34071|NCT00000208|Drug|Buprenorphine|
34072|NCT00000814|Drug|Didanosine|
34073|NCT00016588|Drug|Tenofovir disoproxil fumarate|
34074|NCT00901745|Drug|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
34075|NCT00901745|Drug|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
34076|NCT00901758|Drug|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
34077|NCT00901758|Drug|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
34078|NCT00901771|Device|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
34079|NCT00901784|Drug|Topiramate|25mg Tablets
34389|NCT00904631|Device|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
34390|NCT00904644|Drug|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
34391|NCT00904657|Drug|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
34392|NCT00904670|Drug|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
34393|NCT00904670|Drug|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
34394|NCT00904670|Drug|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
34395|NCT00904683|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
34396|NCT00904683|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
34397|NCT00016939|Drug|alvocidib|
37987|NCT00932919|Behavioral|Cognitive therapy|12 sessions of Cognitive therapy
37988|NCT00932919|Behavioral|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
37989|NCT00932945|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
37990|NCT00932971|Drug|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
37991|NCT00019409|Drug|therapeutic hydrocortisone|
37992|NCT00932971|Drug|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
37993|NCT00932984|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
37994|NCT00932997|Behavioral|telephone-based intervention|Participants receive a "Survivorship Kit" and telephone sessions based upon responses to initial survey
37995|NCT00932997|Other|counseling intervention|Participants receive a "Survivorship Kit" and telephone sessions based upon responses to initial survey
37996|NCT00932997|Other|educational intervention|Participants receive a "Survivorship Kit" alone or in combination with telephone sessions based upon responses to initial survey
37997|NCT00932997|Other|questionnaire administration|Baseline and 9 months after enrollment and intervention
37998|NCT00932997|Procedure|psychosocial assessment and care|Participants receive a "Survivorship Kit" alone or in combination with telephone sessions based upon responses to initial survey
37999|NCT00932997|Procedure|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
38000|NCT00933023|Drug|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
38001|NCT00933023|Drug|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
38002|NCT00019409|Drug|vincristine sulfate|
38003|NCT00933036|Device|Crosstrees Pod system for PVA|Minimally invasive spine surgery
38004|NCT00933049|Drug|Amoxicillin|Oral amoxicillin (25mg/kg/dose)for 5 days
38005|NCT00935298|Drug|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*1 type and CYP3A5*1/*3 type administer 0.15mg/kg/d，CYP3A5*3/*3 type administer 0.08mg/kg/d).
38006|NCT00935311|Drug|ABT-712 Extended-release|ABT-712 extended-release tablet
37690|NCT00932516|Behavioral|South Beach Diet™|
37691|NCT00932516|Behavioral|Calorie restricted diet with South Beach Diet™ Products|
37692|NCT00934791|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
37693|NCT00934791|Drug|Prednisone|Prednisone tapered to 5 mg/day by day 92
37694|NCT00934804|Device|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
38064|NCT00930488|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
38065|NCT00930501|Biological|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
38066|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
38067|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 800 mg/m^2 dose level, administered every 2 or 3 months.
38068|NCT00019214|Biological|aldesleukin|
38069|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 625 mg/m^2 administered every 2 or 3 months.
38070|NCT00933049|Drug|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
38071|NCT00933049|Drug|Amoxicillin placebo|
38072|NCT00933049|Drug|Cotrimoxazole placebo|
38073|NCT00933062|Drug|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
38074|NCT00933062|Drug|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
38075|NCT00933075|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
38076|NCT00933088|Other|questionnaires|The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.
Mothers will be asked to complete data form.
33349|NCT00913315|Drug|tolterodine|4 mg of tolterodine ER
33350|NCT00913315|Drug|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
33351|NCT00913315|Drug|placebo|placebo once a day for 8 weeks
33352|NCT00913328|Drug|Montelukast (Singulair)|10 mg tablet once daily
33353|NCT00913328|Drug|Placebo|Oral placebo once daily
33354|NCT00913341|Drug|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
33676|NCT00916058|Drug|Melphalan|70 mg/m2 given 2 and 3 days prior to autologous cell transplant
33677|NCT00916058|Drug|Bendamustine|60 mg/m2 given on the 2nd day of melphalan
33678|NCT00916058|Drug|Bendamustine|90 mg/m2 given on the 2nd day of melphalan
33679|NCT00916058|Drug|Bendamustine|60 mg/m2 given on the 1st and 2nd day of melphalan
33680|NCT00916058|Drug|Bendamustine|90 mg/m2 given on the 1st day of melphalan and 60 mg/m2 given on the 2nd day of melphalan
33681|NCT00916084|Device|Fixed Tongue Appliance|A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
33682|NCT00916084|Device|Fixed Face Mask|An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
33683|NCT00916097|Drug|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
33684|NCT00017589|Biological|oblimersen sodium|
33685|NCT00916110|Drug|ATN-103|1.5 mg solution, single subcutaneous injection
33686|NCT00916110|Drug|ATN-103|4 mg solution, single subcutaneous injection
33687|NCT00916110|Drug|ATN-103|10 mg solution, single subcutaneous injection
33688|NCT00916110|Drug|ATN-103|25 mg solution, single subcutaneous injection
33689|NCT00916110|Drug|ATN-103|25 mg solution, single intravenous injection
33690|NCT00916110|Drug|ATN-103|50 mg solution, single subcutaneous injection
34398|NCT00907517|Drug|SCH 900776|SCH 900776 will be administered to sequential dose cohorts as a 15 minute infusion on Days 2 and 3 and again on Days 11 and 12 in combination with cytarabine. The SCH 900776 starting dose in the Dose-Escalation Part will be 10 mg/m2, and the dose will be doubled with each sequential cohort until 40 mg/m2 is reached, at which point all subsequent dose escalations will occur in 40% increments. If one DLT occurs in Cycle 1 of any dose level, dose escalation will change from dose doubling to 40% increments for the subsequent dose levels.
34399|NCT00907517|Drug|Cytarabine|Cytarabine will be administered as continuous intravenous infusion (CIV) at a total dose of 2.0 g/m² over 72 hours (667 mg/m2/24 h) on Days 1-3 and 10-12
34400|NCT00907530|Drug|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
34401|NCT00907530|Drug|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
34402|NCT00907543|Other|Preoperative treatment of chemotherapy and radiation|Cisplatin + 5FU with concurrent radiation followed by surgery
34403|NCT00907543|Other|Postoperative treatment of chemotherapy and radiation|Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
34404|NCT00017108|Drug|fludarabine phosphate|
34405|NCT00907569|Radiation|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
34406|NCT00907582|Procedure|autologous hematopoietic cell transplantation|Autologous hematopoietic cell transplantation and condition with the following:
idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3.
34407|NCT00907595|Drug|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
37573|NCT00932204|Device|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).
The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).
For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
37574|NCT00932217|Drug|filgrastim|subcutaneous filgrastim administration
37575|NCT00932217|Drug|lenograstim|subcutaneous lenograstim administration
37576|NCT00932230|Other|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
37577|NCT00932256|Drug|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
37578|NCT00932282|Drug|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
38007|NCT00935311|Drug|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
37025|NCT00931294|Behavioral|Choir singing|Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material "To Live with IBS" for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
37026|NCT00931294|Behavioral|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
37027|NCT00931307|Device|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
37028|NCT00931333|Procedure|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
37029|NCT00931346|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
37030|NCT00931346|Drug|Placebo|Placebo
37031|NCT00931359|Device|DTS-G2 System|Treatment with microwave energy
37032|NCT00931359|Device|DTS System (Sham treatment)|Sham treatment - no energy is delivered
37033|NCT00931372|Drug|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
37034|NCT00933790|Drug|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
37035|NCT00933816|Drug|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
37036|NCT00933829|Procedure|Absorbable Suture Arm|use of irradiated polyglactin 910
37037|NCT00019474|Biological|recombinant interferon alfa|
37038|NCT00933829|Device|Non-absorbable suture (Prolene)|suture
37039|NCT00933829|Procedure|suture|non-absorable sutures and absorable sutures
37040|NCT00933842|Drug|LACTIC ACID(ND)|Treatment duration: 5 weeks
38077|NCT00933114|Procedure|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
38078|NCT00019409|Radiation|radiation therapy|
38079|NCT00933127|Genetic|DNA analysis|
38080|NCT00933127|Genetic|polymerase chain reaction|
38081|NCT00933127|Genetic|polymorphism analysis|
38082|NCT00933127|Other|laboratory biomarker analysis|
38083|NCT00933153|Dietary Supplement|Ensure Plus|Ensure plus supplement with meals
38084|NCT00933153|Dietary Supplement|Meals on Wheels|Two Meals on Wheels twice daily
37107|NCT00019357|Biological|aldesleukin|
37108|NCT00931385|Drug|BI 1744|BI1744 Respimat Med Dose Once Daily
37109|NCT00931385|Drug|bi1744|1744 low dose
37110|NCT00931385|Drug|Placebo|Placebo Respimat and Foradil Placebo
37111|NCT00931385|Drug|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
37112|NCT00931398|Drug|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
37113|NCT00931398|Drug|Placebo|Matched placebo for all Concerta doses.
37114|NCT00931411|Other|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
37115|NCT00931411|Other|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
37116|NCT00931424|Procedure|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
37117|NCT00931437|Dietary Supplement|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
37118|NCT00019357|Biological|therapeutic autologous lymphocytes|
37119|NCT00931450|Drug|exemestane|Given orally
37120|NCT00931450|Drug|sunitinib malate|Given orally
37121|NCT00931450|Other|placebo|Given orally
33691|NCT00916110|Drug|ATN-103|100 mg solution, single subcutaneous injection
33692|NCT00916110|Drug|ATN-103|200 mg solution, single subcutaneous injection
33693|NCT00916110|Drug|ATN-103|200 mg solution, single intravenous injection
33694|NCT00916123|Drug|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
33695|NCT00017589|Drug|gemtuzumab ozogamicin|
33696|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> B -> A. Each of these treatments will be separated by a 7 day washout period.
33697|NCT00918645|Drug|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
33998|NCT00903851|Drug|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
33999|NCT00903877|Drug|T3|Patients receive T3 in a dose of 25mcg and 50mcg
34000|NCT00903877|Drug|Placebo|Patients receive a sugar pill
34001|NCT00903890|Other|Survey|Survey asking questions regarding the subjects cardiac and general health.
34002|NCT00903929|Drug|Eltrombopag|dose escalation
34003|NCT00903942|Radiation|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
34004|NCT00903942|Drug|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
34005|NCT00016887|Procedure|peripheral blood stem cell transplantation|
34006|NCT00903955|Other|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
34007|NCT00903968|Drug|Plerixafor (AMD3100)|Given subcutaneously on days 1 through 6.
34008|NCT00903968|Drug|bortezomib|Given intravenously on days 3, 6, 10 and 13 (90 minutes after AMD3100)
34009|NCT00903981|Drug|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
37579|NCT00932282|Drug|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
37580|NCT00932295|Other|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
37581|NCT00932295|Other|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
37582|NCT00019396|Drug|Montanide ISA-51|
37583|NCT00932295|Other|CROWN SEVEN|10 puffs from a so-called "electronic cigarette" named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)
37584|NCT00932295|Other|NJOY|10 puffs from a so-called "electronic cigarette" named NJOY(16 mg cartridge; 30 second inter puff interval)
37585|NCT00932308|Dietary Supplement|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
37586|NCT00932308|Dietary Supplement|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
37587|NCT00932321|Drug|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
37588|NCT00932321|Drug|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
37589|NCT00932334|Behavioral|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
37590|NCT00932334|Behavioral|TALK Standard|Participants receive and educational video and booklet about living kidney donation
37869|NCT00930176|Biological|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
37870|NCT00019201|Procedure|bronchoscopy|
37871|NCT00930189|Drug|intravitreal injection of ranibizumab|
37872|NCT00932685|Device|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
37873|NCT00932698|Drug|Oral IXAZOMIB|Phase 1: Patients will be administered IXAZOMIB orally on Days 1, 4, 8, and 11 during a 21-day treatment cycle. Doses will increase until a maximum tolerated dose (MTD) is established.
37874|NCT00932711|Behavioral|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
37041|NCT00933855|Behavioral|Questionnaires and training workshop|We will recruit a minimum of 1 and maximum of 12 patients for each workshop.
The workshop will follow the approximate time table below:
10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment
37329|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
37330|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
37331|NCT00934362|Drug|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
37332|NCT00934362|Drug|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
37333|NCT00019500|Procedure|evaluation of cancer risk factors|
37334|NCT00934375|Drug|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
37335|NCT00934375|Drug|placebo|
37336|NCT00934388|Procedure|Pre peritoneal mesh placement|
37337|NCT00934388|Procedure|Laparoscopy|
37338|NCT00936936|Drug|Gemcitabine|1800 mg/m^2 IV over 3 hours on Days -5 to Day -2.
37339|NCT00936936|Drug|Docetaxel|Docetaxel 300 mg/m^2 IV over 2 hours on Day -5.
37340|NCT00019708|Drug|tanespimycin|Given IV
37341|NCT00936936|Drug|Melphalan|50 mg/m^2 IV over 15 minutes on Days -4 to Day -2.
37342|NCT00936936|Drug|Carboplatin|Cycle 1: 333 mg/m^2 IV over 2 hours on Days -4 to -2.
Cycle #2: 300 mg/m^2 IV over 2 hours on Days -6 to -3.
37343|NCT00936936|Drug|Mesna|3,000 mg/m^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
37344|NCT00936936|Drug|Ifosfamide|3,000 mg/m^2 IV over 6 hours on Days -6 to -3
37345|NCT00936936|Drug|Etoposide|200 mg/m^2 IV over 3 hours, every 12 hours on Days -6 to -4.
37346|NCT00936936|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
37122|NCT00931463|Drug|raltegravir|400 mg raltegravir tablet taken every 12 hours
37123|NCT00931463|Drug|2N(t)RTI|2N(t)RTIs as prescribed
37124|NCT00931463|Drug|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
37125|NCT00931476|Drug|somatropin|
37126|NCT00931476|Drug|placebo|
37127|NCT00931489|Drug|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
37128|NCT00931515|Device|NuBac|NuBac device implanted at the L4/5 level.
37129|NCT00019357|Biological|therapeutic tumor infiltrating lymphocytes|
37130|NCT00931515|Device|Prodisc-L|Prodisc-L implanted at the L4/5 level.
37131|NCT00931528|Drug|tadalafil|Given orally
37132|NCT00931528|Other|placebo|Given orally
37410|NCT00934427|Drug|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
37411|NCT00934440|Drug|Bevacizumab|Phase 1: 10 MG/KG IV on day one every two weeks over 90 minutes. Second treatment will be over 60 minutes and third and subsequent doses will take approximately 30 minutes (minimum of two cycles).
37412|NCT00934440|Drug|Azacitidine|Dose escalation. Dose level 1: 35 mg/m2/day for 7 days. Dose level 2: 55 mg/m2/day for 7 days. Dose level 3: 75 mg/m2/day for 7 days.
mg/m2/day = dose based on height and weight
37413|NCT00934453|Biological|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
37414|NCT00019513|Drug|fluorouracil|
37415|NCT00934453|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
37416|NCT00934466|Drug|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
37417|NCT00934466|Drug|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
37418|NCT00934466|Drug|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
37419|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
34010|NCT00903981|Drug|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
34011|NCT00903981|Drug|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
34012|NCT00903994|Drug|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
34013|NCT00904007|Other|Interactive Spaced Education (ISE) --- online education|ISE is a novel educational methodology based on the "spacing effect", the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions.
34014|NCT00904020|Drug|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
34015|NCT00904033|Drug|calcitriol|Will receive pill once a week
34016|NCT00016887|Radiation|radiation therapy|
34017|NCT00904033|Behavioral|Exercise|Progressive walking and resistance band training
34330|NCT00910195|Device|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
34331|NCT00910195|Device|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
34332|NCT00910208|Device|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
34333|NCT00910208|Drug|morphine|Intravenous morphine
34334|NCT00910221|Drug|Atorvastatin|Atorvastatin tablet
34335|NCT00910221|Drug|Placebo|Placebo tablet
34336|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
34337|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
34338|NCT00017225|Drug|tretinoin|
34339|NCT00910234|Drug|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
34340|NCT00910247|Drug|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
37875|NCT00932724|Drug|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
37876|NCT00000838|Drug|Lamivudine|
37877|NCT00019409|Drug|mercaptopurine|
37878|NCT00932724|Drug|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
37879|NCT00932737|Drug|Placebo|1-5 tablets per episode
37880|NCT00932737|Drug|Placebo|1-5 tablets per episode
37881|NCT00932737|Drug|HBB 20 mg|Active drug, one to five tablets per episode
37882|NCT00932750|Dietary Supplement|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
37883|NCT00932750|Dietary Supplement|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
37884|NCT00932763|Drug|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
37885|NCT00932763|Drug|Norvasc|10 mg dose (Pfizer, USA)
37886|NCT00932776|Device|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
37887|NCT00932776|Device|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
37888|NCT00019409|Drug|methotrexate|
37889|NCT00932802|Drug|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
37890|NCT00932828|Drug|Low Dose Peanut Protein|Peanut flour mixed with placebo will be given in gradually increasing doses.
38248|NCT00967005|Drug|N Acetyl Cysteine|N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
38249|NCT00967005|Other|Sugar Pill|placebo control
38250|NCT00967018|Drug|Degarelix|
38251|NCT00967031|Drug|capecitabine|
38252|NCT00967031|Drug|lapatinib ditosylate|
38253|NCT00967031|Other|circulating tumor cell analysis|
37347|NCT00936949|Procedure|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
37348|NCT00936949|Procedure|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
37349|NCT00936962|Biological|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
37614|NCT00934752|Device|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
37615|NCT00934765|Behavioral|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
37616|NCT00934778|Procedure|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
37617|NCT00934791|Drug|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
37618|NCT00934791|Drug|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
37619|NCT00937365|Procedure|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
37620|NCT00937378|Drug|SER120|Nasal Spray, once a day
37621|NCT00937378|Drug|Placebo|Nasal Spray
37622|NCT00937391|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
37623|NCT00937404|Biological|Poliorix™|Three dose, intramuscular administration
37624|NCT00937417|Drug|docetaxel|
37625|NCT00937417|Drug|vandetanib|
37626|NCT00937417|Genetic|proteomic profiling|
37627|NCT00937417|Other|laboratory biomarker analysis|
37628|NCT00019734|Biological|vaccinia-tyrosinase vaccine|
37629|NCT00937417|Other|pharmacological study|
37420|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
37421|NCT00934479|Drug|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
37422|NCT00934492|Drug|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
37423|NCT00934492|Drug|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
37424|NCT00934518|Radiation|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
37425|NCT00019513|Drug|gemcitabine hydrochloride|
37426|NCT00934518|Drug|Cetuximab|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation
37427|NCT00934531|Drug|Donepezil|Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.
Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.
Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline.
37695|NCT00934817|Drug|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
37696|NCT00019565|Procedure|magnetic resonance imaging|
37697|NCT00934817|Drug|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
37698|NCT00934830|Drug|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
37699|NCT00934830|Other|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
37700|NCT00934843|Drug|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
37701|NCT00934843|Drug|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
34341|NCT00910260|Procedure|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
34342|NCT00910273|Drug|etanercept|etanercept 50 mg/week
34343|NCT00910286|Other|Pulmonary Ventilator|The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
34344|NCT00910299|Drug|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
34345|NCT00910299|Drug|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
34346|NCT00910312|Device|Ice-Sense|Ice-Sense Cryoprobe
34347|NCT00910325|Procedure|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
34348|NCT00910338|Device|PFMT with Extracorporeal Biofeedback|Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks
Twice a week for the first 4 weeks
Once a week for the next 8 weeks
34349|NCT00017225|Drug|vincristine sulfate|
34350|NCT00910351|Drug|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
34351|NCT00910364|Other|Exercise|Exercise
33355|NCT00017368|Drug|doxorubicin hydrochloride|
33356|NCT00913341|Drug|Alprazolam Tablets, 1 mg (The Upjohn Company)|
33357|NCT00913354|Device|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
33358|NCT00913354|Device|Placebo acupuncture (Strietberger®)|The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger.
33359|NCT00913367|Drug|glimepiride + insulin glargine (Amaryl + Lantus)|Amaryl® 4 mg at breakfast + Lantus® at dinner
The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
33360|NCT00913367|Drug|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner
The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
33361|NCT00913380|Radiation|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
38254|NCT00967031|Other|laboratory biomarker analysis|
38255|NCT00967044|Drug|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
38256|NCT00967044|Drug|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
38257|NCT00967057|Drug|asparaginase|Given intramuscularly
38258|NCT00022594|Drug|liposomal lurtotecan|
38259|NCT00967057|Drug|dexamethasone|Given orally
38260|NCT00967057|Drug|idarubicin|Given IV
38261|NCT00967057|Drug|methotrexate|Given intrathecally
38262|NCT00967057|Drug|mitoxantrone hydrochloride|Given IV
38263|NCT00959946|Drug|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
38264|NCT00959959|Drug|TOK-001|2 capsules (325 mg each), once per day
38265|NCT00959959|Drug|TOK-001|4 capsules (325 mg each), once per day
38266|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), once per day
38267|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day
38268|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day with supplement
38269|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
38270|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), once per day
38271|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
38272|NCT00959972|Drug|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
37272|NCT00936923|Drug|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
37273|NCT00019916|Procedure|in vitro-treated peripheral blood stem cell transplantation|
37274|NCT00939653|Drug|filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000 x 2 days.
37630|NCT00937430|Other|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
37631|NCT00937443|Other|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
37632|NCT00937443|Biological|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
37633|NCT00937456|Procedure|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
38008|NCT00935311|Drug|Placebo|Placebo tablet
38009|NCT00019604|Procedure|computed tomography|Scan to assess the effects of ablation.
38010|NCT00935337|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
38011|NCT00935337|Behavioral|Sleep Hygiene|treatment as usual
38012|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
38013|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|5.0 grams of PGX
38014|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|0 grams of PGX
38015|NCT00935363|Drug|glyburide|single oral dose
38016|NCT00935363|Drug|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
38017|NCT00935363|Drug|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
38018|NCT00935363|Drug|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
38019|NCT00935376|Behavioral|Sleep Education Program|Treatment as usual.
38020|NCT00019604|Procedure|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
38021|NCT00935376|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
38022|NCT00935376|Behavioral|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
38023|NCT00935389|Drug|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
40298|NCT00953342|Behavioral|Usual care|Standard medical care
40299|NCT00953355|Drug|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
40300|NCT00953355|Drug|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
40301|NCT00021229|Drug|imatinib mesylate|Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)
Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)
Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)
Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses.
40302|NCT00953368|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
40303|NCT00953381|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40304|NCT00953381|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40305|NCT00953381|Drug|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40306|NCT00953381|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
40307|NCT00953394|Drug|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
40308|NCT00953407|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
40654|NCT00951496|Drug|Paclitaxel|Given IP
40655|NCT00951496|Other|Quality-of-Life Assessment|Ancillary studies
40656|NCT00951509|Other|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
40657|NCT00951522|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
40658|NCT00951522|Drug|Placebo|Inhaled placebo in sterile saline
40659|NCT00951535|Other|questionnaire administration|
40660|NCT00951535|Procedure|quality-of-life assessment|
38347|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
38348|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
38652|NCT00962598|Dietary Supplement|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
38653|NCT00962611|Drug|Copanlisib (BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
38654|NCT00962624|Drug|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
38655|NCT00962637|Drug|Androxal|12.5 mg once daily
38656|NCT00962637|Drug|Androxal|25 mg once daily
38657|NCT00962637|Drug|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
38658|NCT00962637|Drug|Placebo|1 capsule daily
38659|NCT00962650|Device|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
38660|NCT00022178|Drug|vincristine sulfate|
38661|NCT00962663|Drug|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
38662|NCT00962663|Drug|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
38663|NCT00962663|Drug|Placebo|Subjects randomized to receive placebo will receive placebo to ICA
-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4.
38664|NCT00962702|Device|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
38665|NCT00962715|Biological|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
40724|NCT00949273|Procedure|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
40725|NCT00949299|Drug|buprenorphine|intradermal injection
40726|NCT00020852|Procedure|cryosurgery|
40727|NCT00949312|Genetic|RNA marker analysis of lymph node and primary tumors|
40728|NCT00949312|Genetic|microarray profiling of primary tumors|
40729|NCT00949312|Genetic|reverse transcriptase-polymerase chain reaction of lymph node specimens|
40730|NCT00949312|Other|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
40731|NCT00949312|Procedure|regional lymph node dissection|
40732|NCT00949312|Other|lymph node staining for H&E and pancytokeratin IHC|
40733|NCT00949325|Drug|temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)|Patients will be treated with temsirolimus weekly by iv and with liposomal doxorubicin (standard dose) by iv once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until maximally tolerated dose (MTD) is reached. Once MTD (standard dose) is achieved, dosing will be with standard doses for each drug, but dosing will be modified based on toxicity.
40734|NCT00949338|Procedure|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
40735|NCT00949351|Drug|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
40736|NCT00949364|Drug|Pomalidomide|Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.
If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.
If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles).
40737|NCT00020865|Drug|cefepime hydrochloride|
40738|NCT00949377|Drug|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
39786|NCT00957801|Drug|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
39787|NCT00957814|Behavioral|Nutritional education|Systematic nutritional orientation program
39788|NCT00957827|Drug|keflex|keflex 500 mg BID 5 days
38574|NCT00962520|Drug|erlotinib|Erlotinib 100 mg PO QD x 4 months
38575|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
38576|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
38577|NCT00962572|Behavioral|Patient management|Aggressive patient management will be implemented by a corps of "patient manager" volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged.
38578|NCT00962585|Drug|Placebo|
38579|NCT00022178|Drug|fluorouracil|
38580|NCT00962585|Drug|S-equol|Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:
S-equol 10 mg BID (20 mg total daily dose)
S-equol 50 mg BID (100 mg total daily dose)
S-equol 150 mg BID (300 mg total daily dose)
38581|NCT00962598|Drug|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
38582|NCT00964834|Drug|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
38583|NCT00964834|Drug|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
38584|NCT00964834|Drug|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
38585|NCT00964847|Behavioral|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
38586|NCT00964847|Behavioral|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
38587|NCT00964860|Device|Glide dental floss|Glide waxed dental floss
38588|NCT00964873|Drug|STA-9090 (ganetespib)|Chemotherapy agent
38892|NCT00967655|Drug|capecitabine|
38911|NCT00960804|Biological|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
39213|NCT00963599|Drug|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
39214|NCT00963599|Drug|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
39215|NCT00963599|Drug|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
39216|NCT00963599|Drug|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
39217|NCT00000865|Drug|Stavudine|
39218|NCT00022230|Biological|sargramostim|
39219|NCT00963612|Procedure|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
39220|NCT00963625|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
39221|NCT00963625|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
39222|NCT00963638|Dietary Supplement|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
39223|NCT00963638|Dietary Supplement|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
39224|NCT00963651|Device|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
39225|NCT00963664|Drug|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
39226|NCT00963664|Drug|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
39227|NCT00963677|Procedure|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
39228|NCT00963690|Device|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
39229|NCT00022230|Biological|therapeutic autologous lymphocytes|
39230|NCT00963690|Procedure|Standard compression|Use standard compression to achieve hemostasis
38666|NCT00962715|Drug|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
38667|NCT00962715|Drug|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
38668|NCT00962728|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
38669|NCT00962728|Device|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
38670|NCT00962741|Drug|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
38975|NCT00965705|Behavioral|Therapy|Individual Therapy and Group Therapy
38976|NCT00965718|Biological|activated T lymphocyte|intravenous dripping of 200 ml (109~2 1010 lymphocytes/60 kg adult) for 1 hour.
38977|NCT00965731|Drug|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
38978|NCT00967863|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
38979|NCT00967863|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
38980|NCT00967889|Genetic|gene expression analysis|
38981|NCT00967889|Genetic|protein analysis|
38982|NCT00022698|Drug|capecitabine|
38983|NCT00967889|Other|biologic sample preservation procedure|
38984|NCT00967889|Other|laboratory biomarker analysis|
38985|NCT00967902|Device|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
38986|NCT00967915|Procedure|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
38987|NCT00967915|Other|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
38988|NCT00967928|Drug|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
39789|NCT00957827|Drug|placebo|placebo BID for five days
39790|NCT00957840|Procedure|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
39791|NCT00021528|Drug|sertraline|
39792|NCT00957853|Drug|Cetuximab|First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
39793|NCT00957853|Drug|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
39794|NCT00957853|Procedure|Surgical tumor resection|Surgical tumor resection on Day 10.
39795|NCT00957866|Drug|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
39796|NCT00957879|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
39797|NCT00957879|Dietary Supplement|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
39798|NCT00957905|Drug|Alvocidib Hydrochloride|Given IV
39799|NCT00957905|Drug|Fluorouracil|Given IV
39800|NCT00957905|Drug|Leucovorin Calcium|Given IV
39801|NCT00957905|Drug|Oxaliplatin|Given IV
39802|NCT00021528|Drug|tranylcypromine|
39803|NCT00957918|Drug|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
39804|NCT00957918|Other|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
39805|NCT00950209|Dietary Supplement|infusion of Endolipide and heparin|an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
39806|NCT00950209|Other|hyperglycaemic hyperinsulinic clamp|a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
39807|NCT00950222|Drug|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
40100|NCT00950612|Biological|Placebo|Intramuscular injection, 2 doses
38893|NCT00967655|Drug|irinotecan hydrochloride|
38894|NCT00967655|Procedure|neoadjuvant therapy|
38895|NCT00967655|Procedure|therapeutic conventional surgery|
38896|NCT00967655|Radiation|radiation therapy|
38897|NCT00967668|Behavioral|Small change approach to improve physical activity and diet|The "Aspire to Lifelong Health" (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle.
38898|NCT00967668|Behavioral|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
38899|NCT00967681|Dietary Supplement|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
38900|NCT00022672|Drug|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
38901|NCT00967681|Dietary Supplement|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
38902|NCT00967694|Drug|Nitrous oxide|Nitrous oxide sedation by inhalation
38903|NCT00967707|Drug|gabapentin and venlafaxine|Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).
Week 7-12: Venlafaxine 75 mg once daily is added.
38904|NCT00960752|Drug|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
38905|NCT00960752|Drug|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
38906|NCT00960778|Drug|nicotine patch (Nicoderm CQ, Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
38907|NCT00022126|Drug|cyclosporine|
38908|NCT00960778|Other|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
38909|NCT00960791|Device|AZD1656|Oral single dose
38910|NCT00960804|Biological|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
39231|NCT00963703|Drug|Rituximab|Rituximab 1000 mg Intravenously day 1 and day 15
39232|NCT00966069|Other|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
39233|NCT00966082|Procedure|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
39564|NCT00959790|Dietary Supplement|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
39565|NCT00959803|Drug|PF-04447943|3 mg solution, oral single dose.
39566|NCT00959803|Drug|PF-04447943|10 mg solution, oral single dose.
39567|NCT00021866|Behavioral|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
39568|NCT00959803|Drug|PF-04447943|25 mg solution, oral single dose.
39569|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^9 PFU
39570|NCT00022139|Drug|paclitaxel|
39571|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^8 PFU
39572|NCT00961896|Drug|Vehicle|Placebo cream
39573|NCT00961896|Drug|LDE225 0.25%|
39574|NCT00961896|Drug|LDE225 0.75%|
39575|NCT00961909|Drug|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
39576|NCT00961909|Drug|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
39577|NCT00961909|Drug|metformin|stable dose
39578|NCT00961909|Drug|placebo|sc once weekly for 4 weeks
39579|NCT00961922|Other|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
39580|NCT00961922|Other|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
39581|NCT00022139|Procedure|conventional surgery|
39582|NCT00961961|Drug|Lithium / Fluoxetine|Individualized Daily Dosage
38989|NCT00967928|Drug|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
38990|NCT00967928|Radiation|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
38991|NCT00967941|Drug|Ancef (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
38992|NCT00967941|Drug|Vancomycin and Cefazolin (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
38993|NCT00000217|Drug|Carbamazepine|
38994|NCT00000868|Biological|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
38995|NCT00022698|Drug|irinotecan hydrochloride|
39290|NCT00961493|Behavioral|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
39291|NCT00961493|Behavioral|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
39292|NCT00022126|Drug|vincristine sulfate|
39293|NCT00961506|Procedure|LESS cholecystectomy|LESS cholecystectomy
39294|NCT00961506|Procedure|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
39295|NCT00961532|Drug|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
39296|NCT00961558|Procedure|Varicocelectomy|Varicocelectomy
39297|NCT00961571|Drug|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
39298|NCT00961597|Procedure|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
39299|NCT00963716|Device|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
39300|NCT00963716|Device|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
39301|NCT00963729|Drug|cyclophosphamide|Given IV
40101|NCT00950625|Drug|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
40102|NCT00950625|Drug|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
40103|NCT00950638|Drug|ARC1905|intravitreal injection
40104|NCT00950651|Drug|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
40105|NCT00950651|Drug|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
40106|NCT00950664|Drug|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
40107|NCT00950664|Drug|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
40108|NCT00950677|Drug|Byetta (exenatide)|exenatide 5 mcg subcutaneously
40109|NCT00950677|Drug|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
40110|NCT00020943|Drug|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 & 2
40111|NCT00950690|Drug|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
40112|NCT00950716|Behavioral|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
40113|NCT00950716|Behavioral|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
40114|NCT00950729|Procedure|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
40115|NCT00950729|Procedure|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
40116|NCT00952939|Other|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
40117|NCT00952952|Drug|Mesalamine|
40236|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
40237|NCT00956059|Drug|prednisone, FK506, MMF|1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
40238|NCT00956059|Drug|prednisone|In the initial 16~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
40239|NCT00956072|Drug|imatinib mesylate|Patients receive imatinib mesylate
40240|NCT00021398|Procedure|conventional surgery|
40241|NCT00956072|Procedure|therapeutic conventional surgery|Patients undergo surgery
40242|NCT00956085|Drug|Memantine|Memantine titrated in 5mg increments weekly to target dose of 10mg po bid; total study duration is 12 weeks
40243|NCT00956098|Drug|oltipraz|60mg bid 90mg qd
40244|NCT00956098|Drug|placebo|
40245|NCT00958776|Drug|Peramivir+SOC|Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
40246|NCT00958776|Drug|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
40247|NCT00958789|Device|Triathlon TS Knee System|Total knee replacement for revision cases
40248|NCT00000861|Drug|Indinavir sulfate|
40249|NCT00021671|Drug|Ampicillin sodium|
40250|NCT00958802|Other|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
40251|NCT00958802|Other|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
40598|NCT00953901|Drug|Fresh Frozen Plasma Transfusion|
40599|NCT00953914|Drug|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
40600|NCT00953914|Drug|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
39583|NCT00961961|Drug|Lithium / Placebo|Individualized Daily Dosage
39584|NCT00961974|Behavioral|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
39585|NCT00961974|Behavioral|Psychoeducational Intervention|A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing "diabetes burnout".
38589|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
38590|NCT00000865|Drug|Didanosine|
38591|NCT00022386|Procedure|quality-of-life assessment|
38592|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
38593|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
38594|NCT00964886|Drug|benztropine mesylate 0.125 mg daily|benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
38595|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
38596|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
38597|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
38598|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
38599|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
38600|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
38601|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
38602|NCT00022399|Drug|celecoxib|
38603|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
38604|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
38605|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
40661|NCT00951535|Radiation|image-guided radiation therapy|
40662|NCT00021060|Drug|paclitaxel|Given IV
40663|NCT00951535|Radiation|intensity-modulated radiation therapy|
40664|NCT00951535|Radiation|radiation therapy treatment planning/simulation|
40665|NCT00951548|Dietary Supplement|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
40666|NCT00951548|Dietary Supplement|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
40667|NCT00951561|Device|Vipon|The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
40668|NCT00951561|Drug|Ibuprofen|400 mg daily
40669|NCT00953927|Biological|Candida Skin Test Antigen|1 test, administered once as a placebo control.
40670|NCT00953940|Drug|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
40671|NCT00953953|Device|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
40672|NCT00953966|Other|Genetically modified potatoes|Starch from genetically modified potatoes
40673|NCT00021281|Drug|fluorouracil|
40674|NCT00953979|Drug|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
40675|NCT00954005|Drug|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
40676|NCT00954044|Behavioral|Randomized Exercise Intervention|The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.
Couples will participate in 2 exercise sessions a week for 6 months.
39719|NCT00950157|Other|Presentation of information on approval based on a surrogate outcome and levels of caution|Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question") statements: no open question statement, non-directive open question statement or directive open question statement.
39720|NCT00950170|Procedure|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
39721|NCT00950183|Device|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
40369|NCT00951067|Device|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
40370|NCT00021008|Drug|picoplatin|
40371|NCT00951080|Device|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
40372|NCT00951080|Device|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
40373|NCT00951093|Procedure|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
40374|NCT00951106|Drug|Pyrimethamine/sulfdoxine (Fansidar)|
40375|NCT00951119|Device|Resperate|device-guided breathing exercises
40376|NCT00951119|Device|Resperate|breathing device without slowing of breathing frequency
40377|NCT00951132|Drug|rosuvastatin|10mg tablets, once daily in three months
40378|NCT00951132|Drug|Placebo|tablet, once daily, three months
40379|NCT00953407|Device|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
40380|NCT00021229|Radiation|local irradiation therapy|Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.
Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.
40381|NCT00953407|Device|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
40382|NCT00953420|Drug|Docetaxel|60 mg/m2 IV on Day 1
40383|NCT00953420|Drug|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
40384|NCT00953420|Drug|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
40385|NCT00953420|Biological|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
40386|NCT00953433|Device|Endoflex tube|Size decided upon gender.
40387|NCT00953433|Device|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
40601|NCT00953927|Biological|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10^8 pfu.
40602|NCT00956475|Procedure|psychosocial assessment and care|questionnaire via telephone
40603|NCT00956475|Procedure|quality-of-life assessment|questionnaire via telephone
40604|NCT00956488|Behavioral|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
40605|NCT00021463|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
40606|NCT00956514|Device|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
40607|NCT00956527|Behavioral|Modified traditional martial arts training|Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in "at risk" youth) and how these issues relate to martial arts concepts.
40608|NCT00956540|Procedure|Deflating tracheal cuff|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
40609|NCT00956540|Procedure|Deflating tracheal cuff 2|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
40610|NCT00956553|Biological|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
40611|NCT00956553|Biological|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
40612|NCT00956566|Behavioral|dietary intervention|dietary counseling, group teaching
40613|NCT00956592|Device|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
40614|NCT00956592|Device|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
39660|NCT00955032|Device|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
38606|NCT00967434|Drug|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
38607|NCT00967434|Drug|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
38608|NCT00967460|Behavioral|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
38609|NCT00967473|Device|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
38610|NCT00022646|Drug|pemetrexed disodium|
38611|NCT00967486|Procedure|Carotid endarterectomy with routine shount|
38912|NCT00960804|Other|Placebo|IV, q 8 weeks, for up to 80 weeks
38913|NCT00960817|Drug|Statin, aspirin|
38914|NCT00960817|Drug|Dipyridamole|
38915|NCT00960830|Drug|mirtazapine|mirtazapine 15 mg daily tablets
38916|NCT00960830|Drug|mirtazapine|15 mg daily
38917|NCT00960843|Device|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
38918|NCT00022126|Drug|cytarabine|
38919|NCT00960843|Other|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
38920|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
38921|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
38922|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
38923|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
38924|NCT00960869|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
38925|NCT00960869|Drug|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
38926|NCT00960882|Drug|DMMET-01|1050.6 mg daily for 30 days
39722|NCT00950183|Other|Ice|postoperative cold therapy
39723|NCT00950196|Drug|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
39724|NCT00950209|Dietary Supplement|saline infusion|In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the "basal" production and clearance rates of the TRL-apoB48
39725|NCT00950209|Other|euglycaemic hyperinsulinic clamp|an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
39726|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
39727|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
39728|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
39729|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
39730|NCT00952276|Biological|Normal saline solution|0.5 mL, Intramuscular on Day 0
39731|NCT00952289|Drug|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
39732|NCT00952289|Drug|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
39733|NCT00952302|Drug|Iron sucrose|Single intravenous infusion of iron 200 mg
39734|NCT00952302|Drug|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
39735|NCT00952302|Procedure|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
39736|NCT00021112|Procedure|conventional surgery|
39737|NCT00952302|Drug|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
39738|NCT00952302|Drug|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
39739|NCT00952315|Device|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
40031|NCT00952900|Behavioral|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
40032|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
40388|NCT00953446|Procedure|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
40389|NCT00953459|Drug|sunitinib malate|
40739|NCT00949377|Drug|Placebo|Normal saline
40740|NCT00949390|Behavioral|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
40741|NCT00951574|Drug|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
40742|NCT00951574|Drug|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
40743|NCT00951587|Device|PillCam™ (Capsule Endoscopy)|Medical Device
40744|NCT00951600|Drug|oxcarbazepine 300 mg/5mL oral suspension|
40745|NCT00021060|Drug|carboplatin|Given IV
40746|NCT00951613|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
40747|NCT00951626|Behavioral|exercise intervention|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge.
40748|NCT00951626|Behavioral|telephone-based intervention|Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
40749|NCT00951626|Dietary Supplement|dietary intervention|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge.
40750|NCT00951626|Other|educational intervention|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge.
40751|NCT00951626|Other|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
40752|NCT00951626|Procedure|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
39661|NCT00955032|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
39662|NCT00955045|Drug|istradefylline|
39663|NCT00955058|Drug|OCP|Daily For 3 months
39664|NCT00955071|Other|Exercise: LVLI|low volume, low intensity
39665|NCT00955071|Other|Exercise: HVLI|high volume, low intensity
39666|NCT00955071|Other|Exercise: LVHI|low volume, high intensity
39667|NCT00955084|Drug|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
39668|NCT00000856|Drug|Ganciclovir|
39669|NCT00021333|Biological|filgrastim|
39670|NCT00955097|Drug|Definity®|Definity® injections given both pre-ablation and post-ablation
39671|NCT00955110|Drug|Oxymorphone ER|15mg or 30mg
39672|NCT00955110|Drug|Oxycodone CR|30mg or 60mg
39673|NCT00955110|Drug|Placebo|The placebo was a sugar pill.
39674|NCT00955110|Drug|Hydromorphone|8 mg
39675|NCT00955136|Device|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
39676|NCT00955149|Drug|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
39677|NCT00955162|Drug|Buprenorphine (Subutex)|Sublingual tablet
39678|NCT00955162|Drug|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
39679|NCT00955175|Radiation|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
39680|NCT00021333|Drug|cisplatin|
38927|NCT00960908|Device|Endeavor Resolute stents|2nd generation ZES
38928|NCT00960908|Device|Endeavor Sprint stent|1st generation ZES
38929|NCT00022126|Drug|daunorubicin hydrochloride|
38930|NCT00960921|Drug|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
38931|NCT00963066|Device|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
38932|NCT00022204|Drug|pentoxifylline|
38933|NCT00963079|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
39234|NCT00022490|Drug|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
39235|NCT00966082|Procedure|Endoscopic band ligation and propranolol|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
Active Comparator: EBL+Propranolol Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
39236|NCT00966108|Device|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
39237|NCT00966121|Procedure|endoscopic band ligation|Perform EBL within 7 days after randomization
Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).
Acid suppression using proton pump inhibitor until eradicated.
After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).
39238|NCT00966121|Procedure|EBL+Propranolol|Start with 20 mg b.i.d
Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min
After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
39239|NCT00966134|Other|exposure to high altitude|
39240|NCT00966147|Other|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
39241|NCT00966160|Drug|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
39242|NCT00966160|Drug|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
40033|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
40034|NCT00952913|Drug|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
40035|NCT00952939|Genetic|fluorescence in situ hybridization|At time of surgery
40036|NCT00952939|Other|laboratory biomarker analysis|At time of surgery
40037|NCT00952939|Procedure|fine-needle aspiration|At time of surgery
40038|NCT00952939|Procedure|therapeutic conventional surgery|At time of surgery
40039|NCT00021164|Biological|incomplete Freund's adjuvant|
40040|NCT00955643|Other|oxygen|
40041|NCT00955643|Other|other|
40042|NCT00955669|Biological|Symptoms and Objective Examination|5.0*108~5.0*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
40043|NCT00955682|Biological|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
40044|NCT00955682|Biological|Meningitec™|One intramuscular dose (Booster)
40045|NCT00955695|Drug|erlotinib hydrochloride|
40046|NCT00955695|Drug|gefitinib|
40047|NCT00955695|Other|questionnaire administration|
40048|NCT00021372|Drug|paclitaxel|
40049|NCT00955695|Procedure|quality-of-life assessment|
40050|NCT00955695|Radiation|whole-brain radiation therapy|
40051|NCT00955708|Device|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
40052|NCT00955721|Drug|Gemcitabine|Phase I: 1000 or 750 mg/m2, IV, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
Phase II: Recommended Phase II Dose determined from Phase I, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
40053|NCT00955721|Drug|Oxaliplatin|Phase I: 100 or 75 mg/m2, IV, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
Phase II: Recommended Phase II Dose determined from Phase I, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
40309|NCT00953407|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
40753|NCT00951626|Procedure|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
40754|NCT00951626|Procedure|assessment of therapy complications|Collected throughout the 12 month study period
40755|NCT00951626|Procedure|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
40756|NCT00021060|Biological|bevacizumab|Given IV
39808|NCT00020943|Biological|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 & 12 Tx 3, and weekly for 2 doses Tx 5
39809|NCT00950235|Behavioral|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
39810|NCT00950235|Other|Usual Care|Standard nutrition counseling from Health Plan
39811|NCT00950248|Drug|Idebenone|
39812|NCT00950261|Radiation|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
39813|NCT00950274|Drug|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
39814|NCT00950274|Drug|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
39815|NCT00950287|Device|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
39816|NCT00950300|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
39817|NCT00950300|Drug|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
39818|NCT00950300|Drug|Docetaxel|Participants will receive docetaxel, 75 mg/m^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
39819|NCT00020943|Drug|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
39820|NCT00950300|Drug|Epirubicin|Participants will receive epirubicin, 75 mg/m^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
39821|NCT00950300|Drug|Herceptin IV|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
39968|NCT00958139|Other|Placebo|water sprayed on clothing one time
39969|NCT00958152|Drug|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
39970|NCT00958152|Drug|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
39971|NCT00958152|Drug|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
39972|NCT00958152|Drug|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
39973|NCT00000859|Drug|Nelfinavir mesylate|
39974|NCT00021528|Drug|T3 (Triiodothyronine)|
39975|NCT00958165|Device|CardioFocus EAS-AC|PVI for PAF
39976|NCT00958178|Drug|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
39977|NCT00958191|Device|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
39978|NCT00958204|Procedure|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
39979|NCT00958204|Procedure|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
39980|NCT00958204|Drug|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
39981|NCT00958204|Drug|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
39982|NCT00958217|Behavioral|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
39983|NCT00958217|Behavioral|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
39984|NCT00958230|Device|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
39985|NCT00021541|Drug|tipifarnib|Given orally, 200 mg/m^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
39986|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
39987|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
39243|NCT00966173|Device|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
39244|NCT00966186|Procedure|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
39245|NCT00022516|Drug|Cyclophosphamide|50 mg/day orally continuously for 1 year
39246|NCT00966199|Drug|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
39247|NCT00966212|Behavioral|parent education|Especially for Daughters audio-cd parent education
39248|NCT00966225|Dietary Supplement|LIP-01|comparison of different dosages of natural health product
39249|NCT00966238|Biological|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
39250|NCT00966251|Drug|CT-011|CT-011
39251|NCT00966264|Drug|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
38295|NCT00962091|Drug|MLN8237|Prior to initiation of Part A, an accelerated dose escalation cohort will be evaluated. The first cohort will be administered a single 15-mg dose of the oral solution administered on Day 1 of Cycle 1. Once the safety and tolerability of study drug is established in this cohort, Part A will commence as described below.
Part A: patients will receive either a single 25 mg dose of MLN8237 (oral solution) or a 50 mg powder in capsule (PIC) dose of MLN8237 on Day 1 of Cycle 1, followed by administration of a single dose of the respective alternate formulation on Day 1 of Cycle 2. Dosing at 50 mg twice a day of the PIC formulation for 7 days (Days 3-9) will then be resumed after the single-dose administration of the oral solution or PIC for both Cycle 1 and Cycle 2 followed by a 14 day rest period. Beginning with Cycle 3, MLN8237 will be administered at 50 mg PIC twice a day for 7 days followed by a 14 day rest period in 21-day cycles.
38296|NCT00962091|Drug|MLN8237|Patients will receive a single dose of MLN8237 (oral solution) with or without a standard high fat breakfast on Day 1 of Cycle 1, followed by administration under the respective alternate food intake condition (fasted to fed, or fed to fasted; N = 7 per sequence) on Day 1 in Cycle 2. The dose of MLN8237 (oral solution) to be administered in this food effect assessment will be determined from the relative bioavailability estimate in Part A. Dosing at X mg twice/day MLN8237 (oral solution) for 7 days will be resumed after the single dose administration of the oral solution for both Cycle 1 and Cycle 2 followed by a 14-day rest period. Beginning with Cycle 3, MLN8237 will be administered at the 50 mg twice/day PIC formulation with 7 days of dosing followed by a 14 day rest period in 21-day cycles.
38297|NCT00962091|Drug|MLN8237|Patients will receive a single 50-mg dose of MLN8237 enteric-coated tablet (ECT) with or without a standard high fat breakfast on Day 1 of Cycle 1, followed by administration under the respective alternate food intake condition (fasted to fed, or fed to fasted; N = 7 per sequence) on Day 1 in Cycle 2.
Dosing at 40 mg twice/day MLN8237 ECT for 7 days will be resumed after the single dose administration of ECT for Cycle 1, followed by a 14-day rest period. In Cycle 2, MLN8237 ECT will be administered as a single dose of 50 mg on Day 1, followed by either 40 or 50 mg twice/day for Day 3 through the morning dose of Day 9 and followed by a 14-day rest period. Beginning with Cycle 3, MLN8237 ECT will be administered twice a day for 7 days followed by a 14 day rest period in 21-day cycles.
38298|NCT00962104|Drug|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
40310|NCT00953407|Device|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
40311|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
40312|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
40313|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
40314|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
40315|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
40316|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
40317|NCT00021398|Radiation|radiation therapy|
40318|NCT00956111|Biological|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
40319|NCT00956137|Procedure|Ultrasound guidance|ultrasound imaging
40320|NCT00956137|Procedure|Manual palpation|Manual Palpation of vertebra
40321|NCT00956150|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
40322|NCT00956150|Drug|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
40323|NCT00956150|Drug|Placebo|Placebo TID PO x 10 days
40324|NCT00956163|Procedure|magnetic resonance imaging|Undergo whole-body MRI
40325|NCT00956163|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
40326|NCT00956163|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
40327|NCT00956163|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
40328|NCT00021424|Biological|recombinant fowlpox-TRICOM vaccine|
39822|NCT00950300|Drug|Herceptin SC|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
39823|NCT00950313|Other|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
39824|NCT00950313|Other|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
39825|NCT00950326|Procedure|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
40118|NCT00952978|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40119|NCT00952978|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
40120|NCT00952991|Drug|LAF237 = vildagliptin|
40121|NCT00953004|Dietary Supplement|fiber drink and fiber bread|fiber drink or fiber bread three times daily
40122|NCT00953017|Drug|Miralax (PEG 3350)|Miralax 255gm bottle
40123|NCT00953017|Drug|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
40124|NCT00953017|Drug|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
40125|NCT00953017|Drug|Golytely (polyethylene glycol)|Golytely 1 gallon
40126|NCT00021164|Biological|telomerase: 540-548 peptide vaccine|
40127|NCT00953030|Behavioral|COACH|
40128|NCT00953030|Behavioral|RealAge|
40129|NCT00953043|Drug|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
40130|NCT00953043|Drug|Placebo|Placebo medication given for three days
40131|NCT00953043|Other|Bowel preparation|Polyethylene glycol-based bowel preparation
40132|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.
The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.
40133|NCT00953056|Biological|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
39988|NCT00958243|Biological|Placebo|Placebo
39989|NCT00958256|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
40252|NCT00958828|Device|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
40253|NCT00958828|Device|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
40254|NCT00958841|Drug|Pasireotide LAR|60 mg
40255|NCT00958854|Drug|cyclophosphamide|
40256|NCT00958854|Drug|fludarabine phosphate|
40257|NCT00958854|Drug|thalidomide|
40258|NCT00958854|Other|laboratory biomarker analysis|
40259|NCT00958867|Behavioral|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
40260|NCT00021671|Drug|Metronidazole|
40261|NCT00958867|Behavioral|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
40262|NCT00958867|Behavioral|Exercise training (S & R; control)|Six-month, twice-weekly stretch & relax (S & R; control) program
40263|NCT00958880|Behavioral|Group Cognitive Behavioral Therapy|5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations
One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy.
40264|NCT00958880|Drug|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
40265|NCT00958880|Drug|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
40266|NCT00958893|Drug|25 mg Proellex|one 25 mg capsules
40267|NCT00958906|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
40268|NCT00958919|Drug|naloxone|10 mg naloxone in 25 ml total volume
40269|NCT00958919|Drug|normal saline|25 ml
40270|NCT00950885|Biological|Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
38299|NCT00022152|Drug|vinorelbine tartrate|
38300|NCT00962104|Drug|Placebo|Taken by mouth, once daily for 10 weeks.
38301|NCT00962130|Device|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
38302|NCT00962143|Device|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
38303|NCT00962143|Procedure|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
38304|NCT00962156|Drug|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
38305|NCT00962156|Drug|Ringers acetate|Infusion for volume expansion in the ICU
38306|NCT00964418|Drug|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
38307|NCT00964431|Drug|Celecoxib 400 mg|Capsules 2 x 200 mg Single-Dose
38308|NCT00022321|Drug|gemtuzumab ozogamicin|
38309|NCT00964431|Drug|Placebo|Capsules 2 Single-Dose
38310|NCT00964431|Drug|Indomethacin Test (lower dose)|20-mg single dose
38311|NCT00964431|Drug|Indomethacin Test (upper dose)|40-mg single dose
38612|NCT00967486|Procedure|Carotid endarterectomy with selective shunt|
38613|NCT00967499|Drug|ondansetron|Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.
Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting.
38614|NCT00967499|Drug|palonosetron|Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.
Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery.
38615|NCT00967512|Drug|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
38616|NCT00967512|Drug|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
38617|NCT00967512|Drug|idarubicin, cytarabine|idarubicin, cytarabine
40329|NCT00956163|Radiation|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
40677|NCT00954044|Behavioral|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
40678|NCT00954057|Drug|LIPO-102|intraorbital injection
40679|NCT00954057|Drug|Placebo|intraorbital injection
40680|NCT00954070|Device|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
40681|NCT00954083|Behavioral|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
40682|NCT00954083|Behavioral|Routine care|Routine care
40683|NCT00954096|Drug|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
40684|NCT00021281|Drug|irinotecan hydrochloride|
40685|NCT00954109|Behavioral|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
40686|NCT00954122|Drug|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
40687|NCT00954135|Drug|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
40688|NCT00954135|Drug|letrozolo+sorafenib+cyclophosphamide|Letrozole (2,5 mg/daily) + "metronomic" cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months
40689|NCT00954148|Procedure|PET/CT|5 visits with PET/CT as only testing
40690|NCT00954148|Procedure|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
40691|NCT00954161|Other|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
40692|NCT00954161|Other|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
40693|NCT00956670|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
40694|NCT00956670|Procedure|Therapeutic Conventional Surgery|Undergo surgery
40695|NCT00956670|Procedure|Therapeutic Laparoscopic Surgery|Undergo surgery
40134|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.
40135|NCT00953056|Biological|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
40136|NCT00953095|Behavioral|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
40137|NCT00021216|Drug|bortezomib|Given IV
40390|NCT00953459|Other|laboratory biomarker analysis|
40391|NCT00000215|Drug|Pergolide|
40392|NCT00000855|Drug|Zidovudine|
40393|NCT00021242|Drug|docetaxel|Continuous IV infusion
40394|NCT00953459|Radiation|fludeoxyglucose F 18|
40395|NCT00953472|Drug|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
40396|NCT00953472|Other|no-added salt diet|instruction to reduce salt for one week prior to study
40397|NCT00953485|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
40398|NCT00953498|Drug|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
40399|NCT00953498|Drug|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
40400|NCT00953511|Genetic|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
40401|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
40402|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
40271|NCT00950885|Biological|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
40272|NCT00950885|Biological|Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
40615|NCT00956605|Behavioral|Computer attention training systems for children with ADHD|Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
40616|NCT00021463|Drug|Abacavir sulfate|
40617|NCT00956631|Procedure|Interlaminar Decompression|The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
40618|NCT00956644|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
40619|NCT00956644|Drug|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
40620|NCT00956657|Behavioral|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
40621|NCT00949091|Drug|TAK-875|Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:
TAK-875 25 mg tablets, orally
TAK-875 50 mg tablets, orally
TAK-875 100 mg tablets, orally
TAK-875 200 mg tablets, orally
TAK-875 400 mg tablets, orally
TAK-875 placebo-matching tablets, orally.
40622|NCT00949104|Drug|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
40623|NCT00949104|Drug|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
40624|NCT00949117|Dietary Supplement|Ensure|Given orally
40625|NCT00020839|Radiation|radiation therapy|
40626|NCT00949117|Dietary Supplement|PediaSure|Given orally
40627|NCT00949117|Drug|cyproheptadine hydrochloride|Given orally
40628|NCT00949130|Drug|NXL103|BID for 7-14 days
40629|NCT00949130|Drug|Linezolid|BID for 7-14 days
40630|NCT00949143|Other|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
40631|NCT00949143|Other|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
38618|NCT00967525|Procedure|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
38619|NCT00967538|Drug|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
38620|NCT00967551|Dietary Supplement|Micronutrient Sprinkles with zinc|Daily dose of 1 packet of sprinkles
38621|NCT00022659|Biological|bevacizumab|Given IV
38622|NCT00967551|Dietary Supplement|Micronutrient sprinkles without zinc|I packet of micronutrient sprinkles without zinc
38623|NCT00967564|Other|epidemiologic study|QoL assessment
38624|NCT00967577|Drug|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
38625|NCT00967590|Drug|RO5036505|380mg iv infusion once weekly for 8 weeks
38626|NCT00967590|Drug|placebo|iv infusion once weekly for 8 weeks
38627|NCT00967603|Drug|sunitinib|oral sunitinib 37.5 mg daily
38628|NCT00967616|Drug|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered PO BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
38629|NCT00960427|Genetic|RNA analysis|
38630|NCT00960427|Genetic|gene expression analysis|
38631|NCT00960427|Genetic|reverse transcriptase-polymerase chain reaction|
38632|NCT00960427|Other|immunohistochemistry staining method|
38934|NCT00963079|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
38935|NCT00963092|Genetic|DNA analysis|
38936|NCT00963092|Genetic|RNA analysis|
38937|NCT00963092|Genetic|microarray analysis|
38938|NCT00963092|Genetic|protein analysis|
38939|NCT00963092|Other|cytology specimen collection procedure|
38940|NCT00963092|Other|laboratory biomarker analysis|
40696|NCT00956670|Procedure|Study of High Risk Factors|Undergo lymphedema assessment
40697|NCT00956670|Other|Questionnaire Administration|Ancillary studies
40698|NCT00956670|Other|Quality-of-Life Assessment|Ancillary studies
40699|NCT00021463|Drug|Efavirenz|
39740|NCT00952315|Device|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
39741|NCT00952315|Device|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
39742|NCT00952328|Dietary Supplement|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
39743|NCT00952341|Drug|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
39744|NCT00952341|Drug|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
39745|NCT00952341|Drug|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
39746|NCT00952341|Drug|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
39747|NCT00021112|Radiation|radiation therapy|
39748|NCT00952341|Drug|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
39749|NCT00952367|Other|Nasopharyngeal swab|Nasopharyngeal swab
39750|NCT00952380|Drug|dalteparin|dalteparin subcutaneous injection
39751|NCT00952393|Drug|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
39752|NCT00955201|Behavioral|Exercise|Structured aerobic exercise (treadmill).
39753|NCT00955201|Behavioral|Exercise|Structured isokinetic strength exercise (dynameter).
39754|NCT00955214|Device|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
39755|NCT00955227|Dietary Supplement|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
39756|NCT00955227|Drug|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
40403|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
40404|NCT00021255|Drug|doxorubicine, cyclophosphamide, docetaxel|doxorubicine IV, cyclophosphamide IV, docetaxel IV
40405|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
40406|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
40407|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
40408|NCT00956215|Drug|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
40409|NCT00956215|Drug|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
40410|NCT00021450|Drug|bicalutamide|
40757|NCT00951626|Procedure|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
40758|NCT00951626|Procedure|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
40759|NCT00954174|Drug|Paclitaxel|Given IV
40760|NCT00954174|Drug|Carboplatin|Given IV
40761|NCT00021281|Drug|leucovorin calcium|
40762|NCT00954174|Drug|Ifosfamide|Given IV
40763|NCT00954174|Other|Quality-of-Life Assessment|Ancillary studies
40764|NCT00954187|Drug|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
40765|NCT00954187|Drug|pregabalin|50 mg PO TID
40766|NCT00954200|Drug|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
40767|NCT00954200|Drug|ibuprofen|10mg/kg syrup - single dose
40768|NCT00954213|Behavioral|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
40632|NCT00949156|Procedure|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
40633|NCT00949182|Drug|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
40634|NCT00949182|Other|laboratory biomarker analysis|
40635|NCT00949195|Other|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
39681|NCT00955188|Other|computer-assisted intervention|
39682|NCT00955188|Other|educational intervention|
39683|NCT00955188|Other|medical chart review|
39684|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally on Days 1-28 of a 28-day cycle. The starting dose will be 8 mg twice daily. The dose escalation will proceed until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
39685|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
39686|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
39687|NCT00957593|Drug|Oxytocin|Continuation of oxytocin once in active labor
39688|NCT00957593|Drug|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
39689|NCT00957606|Procedure|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
39690|NCT00957619|Drug|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
39691|NCT00957619|Drug|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
39692|NCT00021528|Drug|mirtazapine|
39693|NCT00957658|Device|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
39694|NCT00957671|Drug|Human Growth Hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
38941|NCT00963092|Other|questionnaire administration|
38942|NCT00963105|Drug|lenalidomide|Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:
Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily
Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily
Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity
38943|NCT00022204|Procedure|quality-of-life assessment|
38944|NCT00963118|Dietary Supplement|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
38945|NCT00963131|Drug|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
38946|NCT00963157|Drug|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
38947|NCT00963157|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
38948|NCT00963183|Drug|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
38949|NCT00963183|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
38950|NCT00963196|Dietary Supplement|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
38951|NCT00963196|Drug|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
38952|NCT00963209|Drug|tamoxifen citrate|
38953|NCT00963209|Other|laboratory biomarker analysis|
39252|NCT00959231|Radiation|total-body irradiation|
39253|NCT00959244|Other|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
39254|NCT00959244|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
39255|NCT00959244|Other|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
39256|NCT00021762|Procedure|Structured Treatment Interruption|
39757|NCT00955240|Biological|cetuximab|
39758|NCT00955240|Drug|cisplatin|
39759|NCT00021333|Drug|paclitaxel|
39760|NCT00955240|Drug|fluorouracil|
39761|NCT00955240|Other|laboratory biomarker analysis|
39762|NCT00955240|Radiation|radiation therapy|
39763|NCT00955253|Drug|Guanfacine|2mg oral guanfacine (encapsulated)
40054|NCT00955721|Drug|Sorafenib|Phase I: 200 mg, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
Phase II: Recommended Phase II Dose determined from Phase I, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
40055|NCT00955734|Other|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
40056|NCT00955734|Other|Immobilization|This set of patients will be casted for 6 weeks after surgery.
40057|NCT00955747|Drug|Tagatose|powder; 15 grams three times daily; one year
40058|NCT00955747|Drug|Sugar Substitute Splenda|1.5 g powder tid
40059|NCT00000857|Drug|Interleukin-12|
40060|NCT00021385|Drug|carboplatin|
40061|NCT00955760|Drug|Neramexane|Drug-Drug Interaction Study
40062|NCT00955773|Drug|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
40063|NCT00955786|Drug|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
40064|NCT00955799|Drug|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
40065|NCT00955799|Drug|Placebo|Double-blind treatment period of 29 weeks placebo
40066|NCT00955812|Drug|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
40067|NCT00958256|Drug|Cyclophosphamide|300 mg/m^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
40769|NCT00954226|Drug|Erlotinib|Standard Dose: 1 tablet of 150 mg erlotinib once a day, every day leading up to surgery.
Higher Dose: 200 mg or 300 mg in 2 tablets once a day, every day leading up to surgery.
Depending on your assigned dose level, the 2 tablets may contain the same drug amount or 2 different drug amounts.
40770|NCT00954252|Drug|CHF 5074|1x, oral capsule, single dose
40771|NCT00954252|Drug|placebo|placebo, oral capsule, single dose
40772|NCT00021281|Drug|semaxanib|
40773|NCT00954252|Drug|CHF 5074|2x, oral capsule, single dose
40774|NCT00954252|Drug|CHF 5074|4x, oral capsule, single dose
40775|NCT00954252|Drug|CHF 5074|8x, oral capsule, single dose
40776|NCT00954252|Drug|CHF 5074|16x, oral capsule, single dose
40777|NCT00954252|Drug|CHF 5074|24x, oral capsule, single dose
40778|NCT00954265|Drug|10000 IU urinary HCG|ovulation triggering
40779|NCT00954265|Drug|250 mcg recombinant HCG|ovulation triggering
40780|NCT00954278|Drug|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
39826|NCT00952406|Other|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
39827|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
39828|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
39829|NCT00952419|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
39830|NCT00952432|Drug|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
39831|NCT00952432|Procedure|Acupuncture|Acupuncture
39832|NCT00021125|Procedure|adjuvant therapy|
39833|NCT00952445|Drug|T0903131 Besylate|Once daily, oral
39834|NCT00952445|Drug|Placebo|Once daily, oral
39835|NCT00952458|Device|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
39695|NCT00957671|Drug|Placebo|Inert agent given in same manner as active drug for control purposes
39696|NCT00957684|Drug|eslicarbazepine acetate|once-daily oral tablet
39697|NCT00957684|Drug|placebo|once daily placebo comparator
39698|NCT00957710|Behavioral|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
39699|NCT00957723|Device|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
39990|NCT00958256|Drug|Rituximab|375 mg/m^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
39991|NCT00950456|Biological|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
39992|NCT00950482|Procedure|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
39993|NCT00950482|Other|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
39994|NCT00950482|Other|WC|Waiting Group
39995|NCT00950495|Device|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
39996|NCT00950495|Device|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
39997|NCT00020943|Drug|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1& 2
39998|NCT00950495|Device|placebo|as a placebo, a thin (< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
39999|NCT00950508|Procedure|High volume plasma exchange|3 high volume plasma exchanges over 3 days
40000|NCT00950508|Procedure|Standard medical treatment|Standard medical treatment
40001|NCT00950521|Procedure|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
40002|NCT00950521|Drug|convention therapy|antiplatelet
39257|NCT00959244|Other|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
39258|NCT00959283|Genetic|DNA analysis|
39259|NCT00959283|Genetic|RNA analysis|
39260|NCT00959283|Genetic|cytogenetic analysis|
39261|NCT00959283|Genetic|fluorescence in situ hybridization|
39262|NCT00959283|Genetic|gene expression analysis|
39263|NCT00959283|Genetic|microarray analysis|
39264|NCT00959283|Genetic|mutation analysis|
39265|NCT00959283|Genetic|polymerase chain reaction|
39266|NCT00959283|Genetic|polymorphism analysis|
39267|NCT00021788|Procedure|islet cell transplantation|
39268|NCT00959283|Other|flow cytometry|
39269|NCT00959283|Other|laboratory biomarker analysis|
39270|NCT00959283|Other|pharmacological study|
39271|NCT00959296|Device|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
38312|NCT00964444|Device|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
38313|NCT00964457|Drug|cetuximab|cetuximab 500mg per meter square every second week
38314|NCT00964470|Device|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
38315|NCT00964483|Behavioral|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
38316|NCT00964483|Behavioral|Delayed Intervention|The participants will receive a guide written by NHLBI entitled, "Your Guide to Lowering Blood Pressure."
40068|NCT00958256|Drug|Mesna|600 mg/m^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
40069|NCT00958256|Drug|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
40070|NCT00958269|Drug|dutogliptin|100 mg QD
40071|NCT00958269|Drug|dutogliptin|200 mg QD
40072|NCT00021541|Other|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
40073|NCT00958269|Drug|placebo|
40074|NCT00958269|Drug|sitagliptin|25 mg QD
40075|NCT00958269|Drug|sitagliptin|50 mg QD
40076|NCT00958282|Drug|lisdexamfetamine/Behavior Therapy|
40330|NCT00956163|Other|laboratory biomarker analysis|Correlative studies
40331|NCT00956176|Drug|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
40332|NCT00956189|Drug|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
40333|NCT00956189|Drug|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
40334|NCT00958399|Dietary Supplement|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
40335|NCT00021567|Drug|Interferon Gamma for Aerosol|
40336|NCT00958399|Dietary Supplement|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
40337|NCT00958399|Dietary Supplement|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
40338|NCT00958399|Dietary Supplement|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
40339|NCT00958412|Drug|Proellex®|one (1) 25 mg capsule daily
40340|NCT00958425|Device|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
39836|NCT00952471|Other|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
39837|NCT00952484|Biological|asfotase alfa|Either 2 mg/kg or 3 mg/kg subcutaneous injection three times per week for 6 months.
39838|NCT00952497|Drug|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
39839|NCT00952523|Drug|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
39840|NCT00952523|Drug|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
39841|NCT00952536|Dietary Supplement|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule
39842|NCT00952536|Dietary Supplement|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable & fruit & placebo capsule
39843|NCT00021125|Radiation|radiation therapy|
39844|NCT00952536|Dietary Supplement|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
39845|NCT00952549|Procedure|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
40138|NCT00955825|Biological|Grass pollen allergen extract|300IR sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
40139|NCT00955825|Drug|Placebo tablet|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
40140|NCT00955838|Other|Rehabilitation technique|12 therapy session
40141|NCT00955851|Other|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
40142|NCT00021385|Drug|squalamine lactate|
40143|NCT00955877|Drug|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
40144|NCT00955877|Drug|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
40003|NCT00950534|Drug|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
40004|NCT00950534|Drug|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
40005|NCT00950547|Device|CARDIOPAT|Cell Saver System at bedside for ICU stay
40006|NCT00950547|Device|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
40007|NCT00950586|Drug|GSK1043702|Oral dose in liquid or tablet formulation
40008|NCT00020943|Drug|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
40273|NCT00950898|Other|decaff|2 mugs of decaffeinated coffee
40274|NCT00020943|Procedure|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
40275|NCT00950898|Other|caffcoff|2 mugs of caffeinated coffee
40276|NCT00950898|Other|caffeine|2 mugs of hot water containing caffeine
40277|NCT00950898|Other|placebo|2 mugs of hot water
40278|NCT00950911|Drug|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
40279|NCT00950924|Device|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
40280|NCT00950924|Device|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
40281|NCT00950950|Drug|AMG 785|Subjects will be randomized to receive subcutaneous dose administrations of AMG 785 or placebo at a dose of 3 mg/kg every 4 weeks for 3 months.
40282|NCT00950950|Drug|Placebo|Subjects will be randomized to receive subcutaneous dose administrations of AMG 785 or placebo at a dose of 3 mg/kg every 4 weeks for 3 months.
40283|NCT00950963|Behavioral|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
40284|NCT00950963|Other|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
38317|NCT00964496|Drug|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
38318|NCT00964496|Drug|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
38319|NCT00022334|Biological|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
38320|NCT00964522|Other|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
38321|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
38322|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
38323|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
38324|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
38325|NCT00964548|Drug|Dantrolene|1.25 mg/kg IV once over 60 min
38326|NCT00964548|Drug|Dantrolene|2.5 mg/kg IV once over 60 min
38327|NCT00964561|Drug|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
38328|NCT00967057|Drug|pegaspargase|Given intramuscularly
38329|NCT00967057|Drug|vincristine sulfate|Given IV
38633|NCT00960427|Other|laboratory biomarker analysis|
38634|NCT00960427|Procedure|endoscopic biopsy|
38635|NCT00960427|Procedure|neoadjuvant therapy|
38636|NCT00960427|Procedure|sigmoidoscopy|
38637|NCT00960427|Radiation|radiation therapy|
40341|NCT00958425|Device|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
40342|NCT00958438|Drug|placebo|Placebo loading dose followed by placebo SC injections (2 mL) once a week for 16 weeks
40343|NCT00958438|Drug|rilonacept|rilonacept 160 mg SC loading dose followed by rilonacept 80 mg/2 mL SC injections once a week for 16 weeks
40344|NCT00958438|Drug|rilonacept|rilonacept 320 mg SC loading dose followed by rilonacept 160 mg/2 mL SC injections once a week for 16 weeks
40345|NCT00958451|Drug|Paricalcitol|Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;
Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.
40346|NCT00021580|Procedure|human cadaveric islet cell transplantation|
40347|NCT00958451|Drug|Ergocalciferol|If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.
If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.
If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.
40348|NCT00958464|Procedure|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- [Gd-DTPA2-] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
40700|NCT00956683|Procedure|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
40701|NCT00956683|Procedure|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
40702|NCT00956696|Drug|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
40703|NCT00956709|Drug|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
40704|NCT00956709|Drug|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
40705|NCT00956722|Drug|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
40706|NCT00956735|Other|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
40707|NCT00956748|Drug|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
40708|NCT00956748|Drug|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
40709|NCT00956761|Biological|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
40710|NCT00021463|Drug|Nevirapine|
40145|NCT00955877|Drug|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
40146|NCT00955890|Drug|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
40147|NCT00955890|Drug|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
40148|NCT00955903|Behavioral|Exercise Only|Participants will participate in supervised exercise sessions
40149|NCT00955903|Behavioral|Reduced Calorie Diet|Participants will follow a reduced calorie diet
40150|NCT00955903|Behavioral|Weight Maintenance Diet|Participants will follow a weight maintenance diet
40151|NCT00955916|Drug|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
40152|NCT00955916|Drug|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
40153|NCT00021398|Drug|fluorouracil|
40154|NCT00955929|Drug|Placebo QHS and sildenafil and questionnaires|Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
40411|NCT00956228|Radiation|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
40412|NCT00956241|Procedure|j-pouch coloanal anastomosis|
40413|NCT00956241|Procedure|side-to-end coloanal anastomosis|
40414|NCT00956254|Drug|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
40415|NCT00956267|Drug|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
40416|NCT00956267|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
40417|NCT00956293|Drug|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
40285|NCT00020969|Drug|arsenic trioxide|
40286|NCT00950976|Other|citrulline|TID for 5 days
40287|NCT00950976|Other|Lemonade|TID for 5 days
40288|NCT00950989|Drug|AMG 827 70 mg|70 mg AMG 827 SC + stable weekly dose of methotrexate
40289|NCT00950989|Drug|AMG 827 140 mg|140 mg AMG 827 SC + stable weekly dose of methotrexate
40290|NCT00950989|Drug|AMG 827 210 mg|210 mg AMG 827 SC + stable weekly dose of methotrexate
40291|NCT00950989|Drug|Placebo|Placebo SC + stable weekly dose of methotrexate
40292|NCT00951002|Procedure|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
40293|NCT00953303|Drug|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
40636|NCT00000850|Drug|Sargramostim|
40637|NCT00020852|Procedure|conventional surgery|
40638|NCT00949195|Other|Pulmonary pressure response during exercise|Semi-supine echocardiography test
40639|NCT00949221|Device|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;
group 2: intensive strategy using continuous glucose monitoring for 12 months;
group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
40640|NCT00949234|Drug|tenofovir + emtricitabine, lopinavir/ritonavir|The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above "standard" treatment, creating an "expanded" regimen:
Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily
40641|NCT00949247|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
40642|NCT00951457|Drug|Bendamustine|Dose escalation phase:
Days -3, -2, -1: 3 - 10 - 30 mg Alemtuzumab s.c.
Treatment phase:
Bendamustine 70 mg/m2 i.v. on d1 + d2 repeat every 28 days for 4 cycles
Alemtuzumab 30 mg s.c. 3x per week (days 1, 3, 5) continuously in parallel with chemotherapy cycles for a maximum of 16 weeks
40643|NCT00951470|Other|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
38638|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
38639|NCT00022087|Drug|zoledronic acid|4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
38640|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
38641|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
38642|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
38643|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
38644|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
38645|NCT00960453|Drug|Sitagliptin|Dosage form: 25mg, 50mg ,100mg
Amount: 25mg, 50mg, 100mg
Frequency and duration: once a day, for 4 days, including 5 days washout periods
38646|NCT00960466|Behavioral|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
38647|NCT00960466|Behavioral|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
38648|NCT00960479|Drug|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
38649|NCT00960479|Drug|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
38650|NCT00022113|Drug|cilengitide|Given IV
38651|NCT00960492|Drug|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
38954|NCT00965497|Drug|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
40711|NCT00956774|Procedure|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
40712|NCT00956774|Procedure|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
40713|NCT00956774|Procedure|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
40714|NCT00956787|Drug|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
40715|NCT00956800|Other|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
40716|NCT00956800|Other|Normal care|Control group will receive 5 routine office visits in one year
40717|NCT00956813|Dietary Supplement|flaxseed|Given orally
40718|NCT00956813|Other|placebo|Given orally
40719|NCT00956826|Device|Agit Vacuum|With an electrode and a regular vacuum device
40720|NCT00949247|Biological|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
39764|NCT00955253|Drug|Placebo|placebo
39765|NCT00955266|Drug|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
39766|NCT00955266|Drug|Placebo|Normal saline, 50cc delivered over 5 minutes
39767|NCT00955279|Drug|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
39768|NCT00955279|Drug|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
39769|NCT00955279|Drug|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
39770|NCT00021333|Radiation|radiation therapy|
39771|NCT00955292|Drug|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
39772|NCT00955305|Biological|Bevacizumab|Given IV
39773|NCT00955305|Drug|Carboplatin|Given IV
40418|NCT00956293|Drug|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
40419|NCT00956293|Drug|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
40420|NCT00956293|Drug|Cyclosporin A (CsA)|Dosage was based according to blood level
40421|NCT00021450|Drug|goserelin acetate|
40422|NCT00956293|Drug|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
40423|NCT00956306|Drug|Udenafil|100mg Single Oral Dose of Udenafil
40424|NCT00956319|Drug|Zolpidem MR|oral
40425|NCT00956319|Drug|Estazolam|oral
40426|NCT00956332|Biological|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
40427|NCT00956332|Biological|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
40428|NCT00956345|Drug|40K PEG-rFIX|Cohort to receive a single dose of 25U/kg 40K PEG-rFIX administered intravenously (into the vein)
40429|NCT00958685|Dietary Supplement|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
40430|NCT00958698|Other|communication intervention|
40431|NCT00958698|Other|educational intervention|
40781|NCT00954304|Drug|HM30181AK 1mg|HM30181AK 1mg tablet
40782|NCT00954304|Drug|HM30181AK 5mg|HM30181AK 5mg tablet
40783|NCT00000856|Drug|Foscarnet sodium|
40784|NCT00021294|Drug|eflornithine|
40785|NCT00954304|Drug|HM30181AK 15mg|HM30181AK 15mg tablet
40786|NCT00954304|Drug|HM30181AK 60mg|HM30181AK 60mg tablet
40787|NCT00954304|Drug|Loperamide 2mg|Loperamide 2mg capsule
40788|NCT00954317|Procedure|epidural placed low|epidural placed low
40644|NCT00951470|Other|Full CDT|Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.
During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
40645|NCT00951470|Other|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
40646|NCT00951483|Drug|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
40647|NCT00951496|Biological|Bevacizumab|Given IV
40648|NCT00951496|Drug|Carboplatin|Given IV
40649|NCT00951496|Drug|Carboplatin|Given IP
40650|NCT00951496|Drug|Cisplatin|Given IP
40651|NCT00021047|Drug|epirubicin hydrochloride|
40652|NCT00951496|Other|Laboratory Biomarker Analysis|Correlative studies
40653|NCT00951496|Drug|Paclitaxel|Given IV
39700|NCT00957736|Genetic|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
39701|NCT00957736|Other|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
39702|NCT00950053|Procedure|Achilles decompression & debridement|Surgical intervention
39703|NCT00950053|Procedure|Achilles decompression and debridement with FHL transfer|surgical intervention
39704|NCT00950066|Drug|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
39705|NCT00950066|Drug|Amlodipine|Oral administration of Amlodipine 5mg once a day
39706|NCT00950066|Drug|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
38955|NCT00965510|Behavioral|care coordination|patients receive care coordination to improve their type II diabetes
38956|NCT00965523|Drug|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
38957|NCT00022438|Biological|incomplete Freund's adjuvant|
38958|NCT00965549|Drug|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
38959|NCT00965549|Drug|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
38960|NCT00965549|Drug|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
38961|NCT00965562|Drug|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
38962|NCT00965562|Drug|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
38963|NCT00965562|Drug|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
38964|NCT00965575|Drug|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects.
38965|NCT00965588|Biological|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
38966|NCT00965601|Behavioral|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
38967|NCT00965614|Other|MCG|Cardiac Arrhythmia,Heart Disease
38968|NCT00022438|Biological|recombinant tyrosinase-related protein-2|
38969|NCT00965640|Drug|Botulinum Toxin - A injections|
38970|NCT00965653|Drug|folic acid|>/= 5 mg po weekly
38971|NCT00965653|Drug|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
38972|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
38973|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
38974|NCT00965666|Drug|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
39774|NCT00955305|Biological|Cixutumumab|Given IV
39775|NCT00955305|Drug|Paclitaxel|Given IV
39776|NCT00955318|Drug|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
39777|NCT00955344|Behavioral|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
39778|NCT00955344|Behavioral|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
39779|NCT00957749|Drug|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
39780|NCT00021528|Drug|nortriptyline|
39781|NCT00957762|Other|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
39782|NCT00957775|Behavioral|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
39783|NCT00957775|Behavioral|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
39784|NCT00957788|Drug|NST-001|Comparison of different dosages of drug.
39785|NCT00957801|Drug|Testosterone injection|150 mg single IM injection
40077|NCT00958282|Other|placebo|
40078|NCT00958308|Other|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
40079|NCT00958308|Other|Placebo|Placebo is devoid of microorganisms.
40080|NCT00958321|Procedure|computed tomography|
40081|NCT00958321|Radiation|3-dimensional conformal radiation therapy|
40082|NCT00958321|Radiation|fludeoxyglucose F 18|
40083|NCT00021554|Drug|Enfuvirtide|
40084|NCT00958321|Radiation|radiation therapy treatment planning/simulation|
40085|NCT00958334|Drug|Proellex®|25 mg daily (two 12.5 mg capsules)
40086|NCT00958334|Drug|Proellex®|12.5 mg daily
40789|NCT00954317|Procedure|high epidural|high epidural
40790|NCT00956839|Drug|Vitamin D3 (Cholecalciferol)|Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose
Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose
Arm 3 - Oral vitamin D3 500 Units/day for 6 months
40791|NCT00021476|Behavioral|Behavioral treatments|
40792|NCT00956865|Other|Voucher|Vouchers given to reimburse transportation
40793|NCT00956865|Other|Telephone Call|Telephone reminder calls
40794|NCT00956865|Other|Contact|Contact at senior center to encourage follow up
40795|NCT00956904|Device|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
40796|NCT00956917|Device|Akern USA EFG|Impedance measurement device
40797|NCT00956917|Device|RJL Impedance analyzer|Impedance analyzer
40798|NCT00956930|Radiation|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
40799|NCT00956930|Drug|Doxorubicin|75mg fixed dose
40800|NCT00956943|Drug|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
40801|NCT00956943|Drug|placebo|placebo patch
40802|NCT00021476|Behavioral|Physical therapy|
40803|NCT00956956|Drug|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
40804|NCT00956956|Drug|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
39540|NCT00022555|Drug|vincristine sulfate|Given IV
39541|NCT00959660|Behavioral|Exercise|walking, treadmill and bicycle exercise
39542|NCT00959660|Dietary Supplement|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
39543|NCT00959660|Behavioral|Diet and exercise|Combination of the exercise and diet group as previously described.
39707|NCT00020930|Biological|cetuximab|
39708|NCT00950066|Drug|Placebo|Oral administration of a placebo once a day
39709|NCT00950079|Drug|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
39710|NCT00950079|Drug|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
39711|NCT00950092|Device|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
39712|NCT00950105|Drug|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
39713|NCT00950131|Other|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
39714|NCT00950144|Other|medical chart review|
39715|NCT00950144|Other|questionnaire administration|
39716|NCT00950144|Other|study of socioeconomic and demographic variables|
39717|NCT00950144|Procedure|quality-of-life assessment|
39718|NCT00020943|Biological|filgrastim|5 ug/kg subQ daily day 4 until ANC >10,000 (or ANC> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
40009|NCT00950586|Drug|Dextromethorphan|30mg Oral dose
40010|NCT00950586|Drug|Placebo|To match GSK1034702
40011|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
40012|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
40013|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
40014|NCT00952770|Procedure|transradial coronary intervention|percutaneous coronary intervention with transradial approach
40015|NCT00952783|Drug|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
40016|NCT00952796|Drug|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
40017|NCT00021151|Biological|alemtuzumab|
39272|NCT00959309|Behavioral|Strategies to decrease screen time in children|15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.
Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
39273|NCT00959309|Behavioral|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
39274|NCT00959322|Device|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
39275|NCT00961415|Drug|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
39276|NCT00961415|Drug|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
39277|NCT00961441|Drug|Keppra XR|Keppra XR 500 mg tablets and Keppra XR 750 mg tablets
Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days
39278|NCT00961454|Device|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
39279|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
39280|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
39281|NCT00022126|Drug|thioguanine|
39282|NCT00961480|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
39283|NCT00961480|Drug|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
39284|NCT00961480|Drug|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
39285|NCT00961480|Drug|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
39286|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
39287|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
39288|NCT00961480|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
40087|NCT00958334|Drug|Placebo|Treatment with no active ingredients
40088|NCT00958347|Device|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
40089|NCT00958360|Other|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
40090|NCT00958360|Other|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
40091|NCT00958386|Drug|Panitumumab+irinotecan|Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.
Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.
Each treatment cycle will have a duration of 14 days.
40092|NCT00958399|Dietary Supplement|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
40093|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
40094|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
40095|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
40096|NCT00950599|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
40097|NCT00950612|Biological|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
40098|NCT00000851|Drug|Didanosine|
40099|NCT00020943|Drug|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels <0.05 uM, Tx 1 & 2
40349|NCT00958477|Biological|EMD 525797|EMD 525797 will be administered as an i.v. over 1 hour every two weeks for 6 weeks. Subjects with clinical benefit at end of week 6 will be offered continuation of treatment with EMD 525797 at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or in the opinion of the investigator, the subject is no longer benefiting from treatment.
Dose escalation carried out as follows:
Dose-level 1: 250 mg of EMD 525797 i.v. Dose-level 2: 500 mg dose of EMD 525797 i.v. Dose-level 3: 1000 mg dose of EMD 525797 i.v. Dose-level 4: 1500 mg dose of EMD 525797 i.v.
40350|NCT00958490|Other|Walking program|4 week physical activity walking program
40351|NCT00958503|Drug|Thiamphenicol|750 and 1500 mg/day;tablets
40352|NCT00958503|Drug|Placebo|Matched tablets without active ingredient
40353|NCT00958516|Drug|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
39544|NCT00959660|Other|Attention Control|control group- continue their previously randomized life style
39545|NCT00021853|Behavioral|constraint-induced movement therapy|
39546|NCT00959686|Drug|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
39547|NCT00959699|Drug|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
39548|NCT00959699|Drug|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
39549|NCT00959699|Drug|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
39550|NCT00959699|Drug|Boceprevir|Boceprevir (800 mg, orally, three times per day)
39551|NCT00959712|Behavioral|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
39552|NCT00959725|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
39553|NCT00959738|Procedure|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
39554|NCT00959738|Procedure|diverting loop ileostomy without rod|diverting loop ileostomy without rod
39555|NCT00959751|Drug|NXN-188|200 mg capsules, 600 mg, PRN
39556|NCT00021866|Behavioral|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
39557|NCT00959751|Drug|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
39558|NCT00959764|Drug|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
39559|NCT00959764|Drug|Intranasal Calcitonin|Intranasal Calcitonin Spray
39560|NCT00959764|Drug|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
39561|NCT00959777|Drug|DA-3031|
39562|NCT00959777|Drug|Filgrastim|
39563|NCT00959790|Dietary Supplement|Vegetables|200 or 50 grams of vegetables daily for four weeks
38572|NCT00962520|Radiation|Radiation Therapy|Radiotherapy 50.4 Gy delivered over 28 fractions (Mon-Fri)
38573|NCT00962520|Drug|gemcitabine|Gemcitabine 1000 mg/m2 D1,8, and 15 every 28 days x 4 cycles
40018|NCT00952796|Drug|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
40019|NCT00952822|Biological|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
40020|NCT00952835|Other|regular treatment|regular treatment
40021|NCT00952848|Other|questionnaire administration|Pain Rating Score
40022|NCT00952848|Other|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
40023|NCT00952848|Other|Quality of Life instrument|Uniscale 0-100 scale global quality of life
40024|NCT00952848|Device|MC5-A Scrambler device|Electrical stimulation for 60 minutes
40025|NCT00952861|Drug|Doxycycline|200 mg QD in 5 days
40026|NCT00952861|Drug|Placebo (matching)|Placebo QD i 5 days
40027|NCT00952887|Biological|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
40028|NCT00021164|Biological|aldesleukin|
40029|NCT00952887|Biological|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
40030|NCT00952900|Behavioral|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
40294|NCT00953303|Drug|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
40295|NCT00953316|Other|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
40296|NCT00953329|Drug|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
40297|NCT00953342|Behavioral|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
39289|NCT00961480|Drug|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
38330|NCT00967070|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
38331|NCT00967070|Drug|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
38332|NCT00967083|Behavioral|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
38333|NCT00967096|Drug|Rifaximin|Rifaximin for Bone marrow transplant patients
38334|NCT00022607|Biological|bevacizumab|
38335|NCT00967109|Other|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
38336|NCT00967109|Other|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
38337|NCT00967122|Procedure|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
38338|NCT00967135|Drug|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
38339|NCT00967135|Drug|Placebo|Matching oral placebo twice daily for 5 consecutive days.
38340|NCT00967148|Drug|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
38341|NCT00967161|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
38342|NCT00967161|Procedure|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
38343|NCT00967174|Drug|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
38344|NCT00967174|Drug|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
38345|NCT00022607|Drug|thalidomide|
38346|NCT00967174|Drug|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
40354|NCT00958529|Dietary Supplement|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
40355|NCT00959075|Dietary Supplement|Placebo|Sugar pill
40356|NCT00951015|Drug|GSK1349572|investigational HIV-1 integrase inhibitor
40357|NCT00951015|Drug|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
40358|NCT00951028|Behavioral|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
40359|NCT00020995|Procedure|therapeutic dietary intervention|
40360|NCT00951028|Behavioral|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
40361|NCT00951028|Behavioral|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
40362|NCT00951041|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
40363|NCT00951041|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
40364|NCT00951054|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
40365|NCT00951067|Other|Exercise, Elevation, and Compression Garment|Patients will be asked to daily:
exercise
elevate arm
wear an arm compression garment
40366|NCT00951067|Device|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
40367|NCT00951067|Device|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
40368|NCT00951067|Device|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
40721|NCT00949247|Drug|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
40722|NCT00949247|Drug|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
40723|NCT00949247|Other|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
39879|NCT00957996|Drug|Peramivir|300 mg twice daily
39880|NCT00957996|Drug|Peramivir|600 mg once daily
39881|NCT00021528|Drug|VenlafaxineXR|
39882|NCT00958009|Device|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
39883|NCT00958022|Drug|LBH589 and carboplatin with etoposide|LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.
Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin & mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit.
39884|NCT00958035|Drug|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
40472|NCT00951249|Behavioral|Peer health care system navigators|HIV/STI treatment and other medical and social services
40473|NCT00951249|Behavioral|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
40474|NCT00951262|Behavioral|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
40475|NCT00951275|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
40476|NCT00951275|Drug|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
40477|NCT00953524|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
40478|NCT00953537|Drug|capecitabine|
40479|NCT00953537|Other|laboratory biomarker analysis|
40480|NCT00953537|Other|pharmacological study|
40481|NCT00953550|Drug|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
40482|NCT00953550|Drug|Succinylcholine|1 mg/kg
40483|NCT00953563|Device|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
39649|NCT00959881|Drug|Begacestat|6 x 50-mg capsules, single dose
39650|NCT00959894|Drug|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
39651|NCT00959894|Drug|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
39652|NCT00959907|Drug|BOTULINUM TOXIN TYPE-A|On Visit 1 (Day 0):
Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.
Dysport®: 4 units will be injected in the left or right forehead side.
Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
39653|NCT00959920|Procedure|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
39654|NCT00959920|Procedure|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
39655|NCT00959933|Drug|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
39656|NCT00959933|Drug|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
39657|NCT00959946|Drug|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
39658|NCT00021996|Drug|valdecoxib|
39659|NCT00955006|Biological|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
39945|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
39946|NCT00955513|Drug|Placebo|Placebo
39947|NCT00955526|Drug|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
39948|NCT00955526|Drug|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
39949|NCT00955526|Drug|Placebo|Two placebo tablets once daily for 12 weeks
39950|NCT00955539|Device|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
39951|NCT00955539|Device|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
39952|NCT00021359|Drug|isotretinoin|
36521|NCT00942838|Radiation|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
36522|NCT00942851|Drug|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
36523|NCT00942851|Drug|placebo|topical treatment NOT containing AH-8
36524|NCT00942864|Drug|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
36525|NCT00942877|Drug|AZD2171|Cediranib (AZD2171), a VEGF/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with ASPS.
36526|NCT00944944|Behavioral|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
36527|NCT00944957|Drug|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
36528|NCT00944957|Drug|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
36529|NCT00944957|Drug|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
36530|NCT00944957|Drug|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
36531|NCT00944970|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
36532|NCT00944970|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
36533|NCT00020540|Biological|recombinant CD40-ligand|
36534|NCT00944996|Drug|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
36535|NCT00945009|Biological|Dactinomycin|Given IV
36536|NCT00945009|Drug|Doxorubicin Hydrochloride|Given IV
36537|NCT00945009|Drug|Vincristine Sulfate|Given IV
36538|NCT00945009|Drug|Carboplatin|Given IV
36539|NCT00945009|Drug|Cyclophosphamide|Given IV
35954|NCT00944021|Drug|PA-824|200 mg
35955|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
35956|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
35957|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
35958|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
35959|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
35960|NCT00020475|Drug|Montanide ISA-51|
35961|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
36271|NCT00946842|Drug|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
36272|NCT00946881|Drug|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
36273|NCT00946894|Procedure|Total thyroidectomy|Total thyroidectomy
36274|NCT00946894|Procedure|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
36275|NCT00946894|Procedure|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
36276|NCT00946907|Drug|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
36277|NCT00020696|Drug|cisplatin|
36278|NCT00946907|Drug|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
36279|NCT00946920|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
40484|NCT00953576|Drug|ketoconazole|Taken orally three times daily
40485|NCT00953576|Drug|hydrocortisone|Taken orally twice daily
40486|NCT00953576|Drug|dutasteride|Taken orally once a day
40487|NCT00021255|Drug|doxorubicine, cyclophosphamide, trastuzumab, docetaxel|doxorubicine IV, cyclophosphamide IV, trastuzumab IV, docetaxel IV
40488|NCT00953576|Drug|lapatinib|Starting week 5, taken orally once daily
40489|NCT00953589|Drug|ribavirin|Ribavirin - oral administration Subjects with body weight < 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight > 105 kg: 1400 mg/day
40490|NCT00953602|Other|Genetically modified potato|Genetically modified potato
40491|NCT00953615|Drug|Thalidomide|Titrate to 400 mg daily for 6 months
40492|NCT00953628|Drug|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
40493|NCT00953628|Drug|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
40513|NCT00956423|Behavioral|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
40514|NCT00956423|Behavioral|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
40515|NCT00956436|Drug|BIIB022|IV Q3W
40516|NCT00000859|Drug|Indinavir sulfate|
40517|NCT00021450|Radiation|radiation therapy|
40518|NCT00956436|Drug|Sorafenib|Standard dosing of Sorafenib
40519|NCT00956449|Biological|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
40520|NCT00956462|Drug|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
40521|NCT00956475|Behavioral|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
39953|NCT00955552|Drug|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
39954|NCT00955552|Drug|Condroflex (Zodiac)|oral capsule of glucosamine sulphate 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
39955|NCT00955565|Procedure|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
39956|NCT00955565|Procedure|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
39957|NCT00955578|Procedure|Punch Biopsy|5-6 punch biopsies of affected areas
39958|NCT00955591|Other|Papanicolaou test|
39959|NCT00955604|Drug|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
39960|NCT00955604|Drug|Group R Rasagiline|At least 2 months of rasagiline
39961|NCT00955604|Drug|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
39962|NCT00955617|Other|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
39963|NCT00021372|Drug|estramustine phosphate sodium|
39964|NCT00955630|Drug|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
39965|NCT00955630|Drug|ranibizumab|prn injections of ranibizumab throughout the study
39966|NCT00958126|Biological|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
39967|NCT00958139|Other|Permethrin|Permethrin 0.5% treatment of clothing one time
40231|NCT00956007|Biological|cetuximab|Given IV
40232|NCT00956007|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy.
40233|NCT00956020|Biological|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
40234|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
40235|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
36540|NCT00945009|Drug|Etoposide Phosphate|Given IV
36541|NCT00945009|Radiation|Radiation Therapy|Undergo radiation therapy
36843|NCT00019331|Biological|aldesleukin|
36844|NCT00930930|Other|placebo|Given orally
36845|NCT00930930|Procedure|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
36846|NCT00930943|Drug|Oxymorphone ER (Opana ER)|40 mg qd twice
36847|NCT00930956|Dietary Supplement|Resistant Starch|30 g of carbohydrate per Arm
36848|NCT00930969|Device|ICD|Subjects implanted with an ICD.
36849|NCT00930982|Drug|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
36850|NCT00930982|Drug|Placebo|Inhalation of matching placebo twice a day
36851|NCT00930995|Drug|Candesartan|16mg po daily
36852|NCT00930995|Drug|Placebo|once daily
36853|NCT00933504|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks.
36854|NCT00933517|Drug|vectibix|9mg/kg at D1 of each 21-days cycle
36855|NCT00933517|Drug|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
36856|NCT00933517|Drug|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
36857|NCT00933517|Drug|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
36858|NCT00933517|Drug|docetaxel|100 mg/m2 at D1 of each 21 days cycle
36859|NCT00933530|Drug|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
36280|NCT00946920|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
36281|NCT00946933|Dietary Supplement|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
36282|NCT00946933|Dietary Supplement|placebo|0.025 g/kg/day of NaCl (sodium chloride)
36283|NCT00946946|Drug|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
36284|NCT00946946|Drug|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
36285|NCT00940173|Device|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
36286|NCT00940173|Device|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
36287|NCT00940173|Device|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
36288|NCT00940173|Device|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
36289|NCT00000843|Drug|Adefovir dipivoxil|
36290|NCT00019968|Drug|tumor necrosis factor|
36606|NCT00942994|Drug|Aliskiren/Amlodipine|Amlodipine capsule (5 mg)
Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)
36607|NCT00942994|Drug|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)
HCTZ capsule (12.5 mg, 25mg)
36608|NCT00020358|Biological|tyrosinase peptide|
36609|NCT00943007|Device|Stealth Station|Neuronavigation based on preoperative MRI
36610|NCT00943007|Device|PoleStar N20|Intraoperative MRI guided surgery
36611|NCT00943020|Dietary Supplement|Nutricia PreOp nutritional supplement|nutritional supplement
36612|NCT00943020|Dietary Supplement|Lipid|Drink
36613|NCT00943020|Dietary Supplement|Glutamine|Drink
36614|NCT00943033|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
36615|NCT00943046|Device|Pacemaker lead|Implantation of the SIELLO pacemaker leads
40522|NCT00956475|Other|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
40523|NCT00956475|Procedure|assessment of therapy complications|questionnaire via telephone
40524|NCT00956475|Procedure|fatigue assessment and management|questionnaire via telephone
40525|NCT00958932|Behavioral|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
40526|NCT00021697|Drug|AVP-923|
40527|NCT00958932|Behavioral|Speech recognition|Automated, speech recognition telephone calls
40528|NCT00958958|Other|multifaceted strategy|There are multifaceted Interventions Including
Distribution of educational materials: distribution of published or printed recommendations for clinical care.
Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used
Reminders
Practical training
40529|NCT00958971|Drug|TKI258|
40530|NCT00958997|Drug|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
39586|NCT00961987|Other|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
39587|NCT00961987|Other|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
39588|NCT00962000|Other|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
39589|NCT00962000|Other|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
39590|NCT00962013|Device|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
39591|NCT00962026|Drug|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
39592|NCT00000865|Drug|Abacavir sulfate|
39593|NCT00022139|Radiation|radiation therapy|
36121|NCT00020267|Drug|interleukin-2|
36122|NCT00942253|Other|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
36123|NCT00942266|Drug|fluorouracil|Given IV
36124|NCT00942266|Drug|leucovorin calcium|Given IV
36125|NCT00942266|Drug|vorinostat|Given orally
36126|NCT00942266|Other|pharmacological study|Correlative study
36127|NCT00942292|Dietary Supplement|Lipidem- fish oil emulsion BBraun UK|
36128|NCT00942292|Procedure|Digital Contrast MRI scan|
36129|NCT00942305|Drug|CMX001|CMX001 200mg twice weekly for a total of up to 18 doses.
36130|NCT00942305|Drug|Placebo|Placebo tablets once weekly for a total of up to 11 doses.
36131|NCT00942318|Drug|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
36132|NCT00020267|Drug|MAGE-12 peptide vaccine|
36133|NCT00944268|Drug|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
36134|NCT00944281|Dietary Supplement|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
36135|NCT00944281|Dietary Supplement|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
36136|NCT00944281|Dietary Supplement|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
36137|NCT00944281|Dietary Supplement|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
36138|NCT00944294|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
36139|NCT00944294|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
36469|NCT00947141|Drug|ganciclovir (start when CMV PCR >200copies / ml x2)|Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
36860|NCT00933530|Drug|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
36861|NCT00933543|Drug|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
36862|NCT00019461|Drug|carboxyamidotriazole|
36863|NCT00933543|Drug|Vehicle cream (placebo)|Cream application followed by illumination with red light.
35882|NCT00946192|Dietary Supplement|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
35883|NCT00946205|Procedure|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
35884|NCT00946205|Procedure|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
35885|NCT00946257|Drug|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
35886|NCT00946270|Drug|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
35887|NCT00946270|Drug|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
35888|NCT00946283|Dietary Supplement|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
35889|NCT00946296|Drug|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
35890|NCT00000214|Drug|Buprenorphine|
35891|NCT00000848|Drug|Indinavir sulfate|
35892|NCT00020657|Drug|dolasetron mesylate|
35893|NCT00946309|Drug|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
35894|NCT00946309|Drug|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
36616|NCT00943059|Drug|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
36617|NCT00943059|Drug|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
36618|NCT00943072|Biological|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
36619|NCT00020371|Drug|BMS-247550|
36620|NCT00943072|Drug|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
36621|NCT00943085|Behavioral|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
36622|NCT00943085|Behavioral|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
36623|NCT00943098|Drug|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
36624|NCT00943098|Drug|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
36625|NCT00945061|Radiation|intracavitary balloon brachytherapy|Patients undergo brachytherapy
36626|NCT00945061|Radiation|intraoperative radiation therapy|Patients undergo radiotherapy
36627|NCT00020553|Procedure|psychosocial assessment and care|
36926|NCT00931034|Behavioral|South Beach Diet with South Beach Diet Products|
36927|NCT00931034|Behavioral|American Diabetes Association Diabetes Meal Plan|
36928|NCT00931060|Dietary Supplement|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
36929|NCT00931073|Drug|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
36930|NCT00931073|Drug|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
36931|NCT00931073|Drug|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
36932|NCT00931086|Drug|belimumab|IV 10mg/kg q28days
39594|NCT00964106|Drug|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
39595|NCT00964106|Drug|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
39596|NCT00964106|Drug|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
39597|NCT00964106|Drug|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
39598|NCT00964106|Drug|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
39599|NCT00964106|Drug|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
39600|NCT00022295|Drug|idronoxil|
39601|NCT00964106|Drug|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
39602|NCT00964106|Drug|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
39603|NCT00964132|Drug|NRX194204|Once Daily, Oral
39604|NCT00964158|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
39605|NCT00964171|Drug|efavirenz|
39606|NCT00964171|Procedure|quality-of-life assessment|
39607|NCT00964184|Drug|Metformin|
39608|NCT00964184|Behavioral|Lifestyle modification|
39885|NCT00958035|Drug|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
39886|NCT00958048|Device|non-invasive ventilation|CPAP, BiPAP
39887|NCT00958074|Drug|vorinostat|Given PO
39888|NCT00958074|Other|flow cytometry|correlative study
39889|NCT00958074|Other|laboratory biomarker analysis|correlative study
39890|NCT00958100|Drug|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
39891|NCT00958100|Drug|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
39892|NCT00021528|Behavioral|Cognitive Therapy|
36470|NCT00947141|Other|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
36471|NCT00947141|Drug|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
36472|NCT00947141|Other|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
36473|NCT00947154|Drug|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
36474|NCT00947167|Drug|pertuzumab|840 mg, 420 mg, iv
36475|NCT00947167|Drug|erlotinib|150 mg, PO
36476|NCT00020709|Drug|etoposide|Given IV
36477|NCT00947180|Behavioral|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
36478|NCT00947180|Other|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
36479|NCT00947180|Behavioral|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
36480|NCT00947193|Drug|Ataluren (PTC124)|Ataluren (PTC124) will be provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren (PTC124) will be taken 3 times per day, with dosing based on the patient's body weight. The dose level for ataluren (PTC124) will be 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days.
36481|NCT00947206|Behavioral|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
36482|NCT00947206|Behavioral|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
35895|NCT00946322|Behavioral|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
35896|NCT00946335|Drug|veliparib|Given PO
35897|NCT00946335|Drug|temozolomide|Given PO
35898|NCT00946335|Other|pharmacological study|Correlative studies
35899|NCT00946335|Other|laboratory biomarker analysis|Correlative studies
35900|NCT00946348|Drug|Dronabinol|Dronabinol 10 mg or 15 mg
35901|NCT00946348|Drug|Cannabis|Cannabis cigarette
35902|NCT00946361|Other|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
36207|NCT00019968|Drug|melphalan|
36208|NCT00940134|Biological|GLP-1|1.0 pmol/kg/min x 3 hours
36209|NCT00940134|Biological|saline infusion|saline infusion x 3 hours
36210|NCT00940160|Drug|QAX576|
36211|NCT00940160|Drug|QAX576|
36212|NCT00940160|Drug|QAX576|
36213|NCT00940160|Drug|Placebo|
36214|NCT00942331|Biological|Bevacizumab|Given IV
36215|NCT00942331|Drug|Cisplatin|Given IV
36216|NCT00942331|Drug|Gemcitabine Hydrochloride|Given IV
36217|NCT00942331|Other|Laboratory Biomarker Analysis|Correlative studies
36218|NCT00942331|Other|Placebo|Given IV
36219|NCT00942344|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
36220|NCT00942344|Drug|Amlodipine|amlodipine 5mg, 10mg
36221|NCT00942344|Drug|Losartan|Losartan 50mg, 100mg
36222|NCT00942357|Drug|Carboplatin|Given IV
36933|NCT00931112|Other|individualized exercise training|Lower extremities resistance exercise and bicycle training
36934|NCT00000836|Drug|Sevirumab|
36935|NCT00019331|Biological|sargramostim|
36936|NCT00931125|Drug|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
36937|NCT00931125|Procedure|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
36938|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
36939|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
36940|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
36941|NCT00931151|Dietary Supplement|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
36942|NCT00931164|Drug|Sodium Oxybate|dosage is by weight
36943|NCT00931177|Other|weight|weight and dehydration scores
36944|NCT00931177|Other|weight and dehydration score|weight and dehydration score
36945|NCT00931203|Drug|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
36946|NCT00019331|Drug|DetoxPC|
35962|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
35963|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
35964|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
35965|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
35966|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
35967|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
39893|NCT00958100|Drug|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
39894|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
39895|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
39896|NCT00950326|Procedure|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
39897|NCT00950326|Procedure|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
39898|NCT00950339|Drug|PPI Platelet Inhibitory|Each patient will undergo 3 phases of drug therapy:
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).
At the end of each phase- each patient will undergo the following evaluation:
Platelet reactivity
39899|NCT00950352|Drug|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
39900|NCT00020943|Drug|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 & 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
39901|NCT00950352|Drug|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
39902|NCT00950365|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on day 1 every 21 days
39903|NCT00950365|Drug|pemetrexed and erlotinib|pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and erlotinib 150 mg PO once daily on days 2-17 every 21 days
39904|NCT00950391|Drug|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
40168|NCT00958646|Other|Osteopathic Manipulation|Standardized rib raising protocol
40169|NCT00021658|Procedure|Pesticide application procedures|
40170|NCT00958646|Other|Placebo|Light touch control procedure
40171|NCT00958659|Other|laboratory biomarker analysis|Correlative studies
40172|NCT00958672|Other|Endoscopic capsule|Endoscopic capsule
40173|NCT00958685|Dietary Supplement|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
36781|NCT00935987|Drug|CYT387|For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.
Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.
For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups.
36782|NCT00936000|Dietary Supplement|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
36783|NCT00019630|Drug|doxorubicin HCl liposome|
36784|NCT00936013|Drug|oseltamivir|75mg p.o Bid for 5 days
36785|NCT00936013|Drug|oseltamivir and chinese medicinal herbs|oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
36786|NCT00936026|Drug|Neramexane|Drug-Drug Interaction Study
36787|NCT00936039|Behavioral|unloading|2 weeks of unloading of a single leg
36788|NCT00936052|Other|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
36789|NCT00936065|Drug|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
36790|NCT00936065|Drug|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
36791|NCT00936065|Drug|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
36792|NCT00936091|Drug|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
36793|NCT00936091|Drug|Placebo|125 children received placebo capsules
36794|NCT00019656|Drug|perifosine|
36795|NCT00936117|Drug|Posaconazole|200 mg (liquid) by mouth 3 times per day.
36796|NCT00936130|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
36797|NCT00936130|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
36223|NCT00942357|Drug|Cisplatin|Given IV
36224|NCT00020267|Drug|Montanide ISA-51|
36225|NCT00942357|Radiation|Internal Radiation Therapy|Undergo brachytherapy
36226|NCT00942357|Drug|Paclitaxel|Given IV
36227|NCT00942357|Other|Quality-of-Life Assessment|Ancillary studies
36228|NCT00942357|Radiation|Radiation Therapy|Undergo radiation therapy
36229|NCT00942370|Device|non invasive mechanomyographic device based on a 3 axes accelerometer|This biomedical research consists specifically in the simultaneous acquisition of:
EMG and MMG Signals of rectus abdominis of the abdomen,
Respiratory flow,
An electrocardiogram (ECG).
These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person.
36230|NCT00942383|Device|IOUS - Siemens Anteras|additional IOUS to acquire ultrasound elasticity imaging
36231|NCT00942396|Device|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
36542|NCT00945009|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
36543|NCT00945009|Procedure|Adjuvant Therapy|Undergo adjuvant therapy
36544|NCT00020540|Biological|recombinant flt3 ligand|
36545|NCT00945009|Procedure|Neoadjuvant Therapy|Undergo neoadjuvant therapy
36546|NCT00945022|Device|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
36547|NCT00945035|Drug|etoricoxib|Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
36548|NCT00945035|Drug|Comparator: etoricoxib|Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
36549|NCT00945048|Device|electrical velocimetry|determination of cardiac output by electrical velocimetry
36550|NCT00945048|Device|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
36551|NCT00945048|Device|spirometry|spirometry for testing the ventilatory function
36552|NCT00945048|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
36553|NCT00947232|Behavioral|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
35968|NCT00944047|Drug|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
35969|NCT00944047|Drug|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
35970|NCT00944047|Drug|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
35971|NCT00020488|Drug|FOLFIRI regimen|
35972|NCT00944047|Drug|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
35973|NCT00944060|Other|lifestyle intervention|
35974|NCT00946374|Drug|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( > 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
35975|NCT00946374|Other|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
35976|NCT00946387|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
35977|NCT00946387|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
35978|NCT00946400|Other|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
35979|NCT00946400|Other|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
36291|NCT00940212|Drug|AZD2423|oral, single administration
36292|NCT00940212|Drug|Placebo|oral administration and single dose
36293|NCT00940225|Drug|XL184|All subjects receive 100 mg XL184 (supplied at 19.7-, 50-, and 60-mg strength capsules) daily for 12 weeks. Subjects with a partial or complete response will continue daily XL184 administration until disease progression. Subjects with stable disease will be randomized to Arm 2 or 3.
36294|NCT00940225|Drug|Placebo|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 3 will receive capsules of placebo that are size- and color-matched to XL184 administered daily until disease progression. Subjects will be unblinded at disease progression and, if found to be receiving placebo, given the option to receive XL184.
36295|NCT00940225|Drug|XL184|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 2 will continue to receive XL184 (blinded) administered daily until disease progression.
36296|NCT00940225|Drug|XL184|All subjects receive open-label, 100 mg XL184 (supplied at 19.7-, 50-, and 60 mg strength capsules) daily until disease progression.
36297|NCT00940238|Drug|Citalopram Hydrobromide|
40174|NCT00950729|Procedure|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
40175|NCT00950742|Drug|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
40176|NCT00950742|Drug|BIBW 2992|Increased dose cohorts from low dose to MTD
40177|NCT00950755|Biological|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
40178|NCT00950768|Procedure|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
40179|NCT00020943|Drug|prednisone|100 mg/sq m PO Days 3-7, Tx 1 & 2
40180|NCT00950781|Procedure|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
40181|NCT00950794|Drug|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
40182|NCT00950794|Drug|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
40183|NCT00950807|Drug|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
40184|NCT00950807|Drug|Placebo|Inactive/ excipients only
40185|NCT00950807|Drug|GSK573179|GSK573179 investigational drug
40186|NCT00950820|Drug|Oxaliplatin, Capecitabine, Panitumumab|Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.
The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
40187|NCT00950820|Drug|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
40188|NCT00950833|Biological|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
40531|NCT00958997|Biological|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
40532|NCT00959010|Dietary Supplement|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
40533|NCT00959010|Dietary Supplement|Placebo|capsules containing middle chain triglycerides
36798|NCT00936130|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
36799|NCT00936130|Behavioral|Low Calorie Diet|Low Calorie Diet Program
35817|NCT00948896|Drug|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
35818|NCT00948909|Drug|Placebo|Placebo intervention
35819|NCT00948909|Drug|ABT-126|Experimental intervention
35820|NCT00948909|Drug|donepezil|Active comparator intervention
35821|NCT00948922|Drug|Bortezomib|Day -3 bortezomib (1.3 mg/m2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion)
35822|NCT00948922|Drug|Melphalan|Day -4 and Day -3 Melphalan 100 mg/m2/day IV over 30 minutes
35823|NCT00020800|Drug|fludarabine phosphate|
35824|NCT00948922|Procedure|Autologous Stem Cell Transplant|Day 0 Infusion of autologous stem cells
35825|NCT00948922|Drug|Bortezomib|Day -3 bortezomib (1.3 mg/m2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion)
35826|NCT00948922|Drug|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m2/day IV
35827|NCT00948922|Drug|Melphalan|Day -4, Day -3 Melphalan 70 mg/m2/day IV over 30 minutes
35828|NCT00948935|Drug|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
35829|NCT00948948|Device|Silicone Gel-Filled Mammary Prostheses|Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:
Gel-filled device which is available in smooth surface and textured surface (Siltex®)
Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version
Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only.
35830|NCT00941694|Behavioral|placebo group|3 phone calls not related to asthma self-management
35831|NCT00020189|Drug|clopidogrel bisulfate|
35832|NCT00941707|Drug|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
35833|NCT00941707|Drug|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
35834|NCT00941720|Drug|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
36554|NCT00947232|Behavioral|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
36555|NCT00020709|Drug|gefitinib|Given orally
36556|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
36557|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
36558|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
36559|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
36560|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
36561|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
36562|NCT00947245|Drug|Placebo|Capsules, Oral, Single Dose, One day
36563|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours, 14 days
36564|NCT00947245|Drug|Placebo|Capsules, Oral, Once Daily, 14 days
36565|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
36864|NCT00933543|Procedure|PDT|Photodynamic Therapy - Light dose 37 J/cm2
36865|NCT00933556|Dietary Supplement|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
36866|NCT00933556|Dietary Supplement|sugar pill (placebo)|placebo identical to the active product will be given
36867|NCT00933569|Drug|LACTIC ACID(ND)|treatment period: 21 consecutive days
36868|NCT00933582|Drug|JNJ-39439335; Placebo; Naproxen|
36869|NCT00933595|Behavioral|Smoking Cessation|The smoking cessation treatment will include 12 weeks of varenicline treatment and proactive telephone counseling.
36870|NCT00933608|Drug|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
36871|NCT00933608|Drug|Placebo|participants will be asked to take 2 tablets per day to match active drug
36872|NCT00933621|Procedure|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
36873|NCT00019461|Drug|chemotherapy|
36298|NCT00940251|Drug|Mersina|capsule, 3g/day, 3 months
36299|NCT00940264|Procedure|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
36300|NCT00940277|Behavioral|Group Counseling|Group counseling
36301|NCT00019994|Biological|MART-1 antigen|
36302|NCT00940290|Other|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
36303|NCT00940303|Drug|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
36304|NCT00940303|Drug|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
36305|NCT00940303|Drug|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
36306|NCT00940303|Drug|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
36307|NCT00940303|Drug|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
36308|NCT00940316|Biological|panitumumab|Given intravenously 6mg/kg every 2 weeks
36309|NCT00940316|Drug|erlotinib hydrochloride|Given orally 150mg daily
36310|NCT00940316|Drug|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
36311|NCT00942435|Procedure|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
36312|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
36628|NCT00945074|Other|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
36629|NCT00945074|Other|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
36630|NCT00945074|Other|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
36631|NCT00945087|Other|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
36632|NCT00945100|Device|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
36633|NCT00945100|Device|Eye Patch|2 hours patching daily
40534|NCT00959023|Other|laboratory biomarker analysis|
40535|NCT00959023|Other|medical chart review|
40536|NCT00959023|Other|questionnaire administration|
40537|NCT00021723|Biological|AN-1792 also known as AIP-001|
40538|NCT00959036|Drug|ATN-103|10 mg every 4 weeks until week 12
40539|NCT00959036|Drug|ATN-103|10 mg every 8 weeks until week 12
40540|NCT00959036|Drug|ATN-103|30 mg every 4 weeks until week 12
40541|NCT00959036|Drug|ATN-103|80 mg every 4 weeks until week 12
40542|NCT00959036|Drug|ATN-103|80 mg every 8 weeks until week 12
40543|NCT00959036|Drug|Placebo|Placebo every 4 weeks
40544|NCT00959036|Drug|Methotrexate|
40545|NCT00959049|Biological|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
40546|NCT00959049|Biological|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
40547|NCT00959062|Drug|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
40548|NCT00021736|Drug|EYE001 anti-VEGF aptamer|
40549|NCT00959062|Drug|placebo|Preparation visually identical to clonidine.
40550|NCT00959075|Dietary Supplement|Vitamin B1|100 mg Twice a day
40551|NCT00951288|Dietary Supplement|Saffron|Saffron 20 mg/day supplementation
40552|NCT00000852|Procedure|Allogeneic lymphocyte transfer|
40553|NCT00021034|Drug|taurolidine|
40554|NCT00951288|Dietary Supplement|Placebo|Placebo
40555|NCT00951301|Drug|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
35835|NCT00941720|Drug|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
35836|NCT00941720|Procedure|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
35837|NCT00941733|Device|IN.PACT Amphirion|Balloon Angioplasty
35838|NCT00941733|Device|Standard PTA|Balloon Angioplasty
36140|NCT00944307|Drug|raltegravir|raltegravir 400mg orally once
36141|NCT00020488|Drug|leucovorin calcium|
36142|NCT00944307|Drug|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
36143|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
36144|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
36145|NCT00944346|Drug|Metformin HCl|
36146|NCT00944359|Dietary Supplement|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
36147|NCT00944359|Dietary Supplement|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
36148|NCT00944359|Dietary Supplement|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
36149|NCT00944359|Other|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
36150|NCT00944372|Drug|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
36151|NCT00944385|Drug|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
36152|NCT00020501|Drug|FOLFIRI regimen|
36153|NCT00944398|Dietary Supplement|Zinc fortified food|Daily consumption
36154|NCT00944398|Dietary Supplement|Zinc supplement|Liquid supplement containing zinc sulfate
36155|NCT00944398|Other|Placebo supplement|Liquid placebo supplement
36156|NCT00944398|Dietary Supplement|Non-fortified food|Non-fortified complementary food.
36157|NCT00944424|Drug|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
36874|NCT00933634|Procedure|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
36875|NCT00933634|Drug|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
36876|NCT00936156|Drug|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
36877|NCT00936169|Procedure|IVUS optimised DES implantation|Ivus optimised stent implantation
36878|NCT00936169|Procedure|angiographically guided DES implantation|angiographically guided DES implantation
36879|NCT00936182|Drug|Fluconazole|Fluconazole daily for 30 days
36880|NCT00019669|Biological|aldesleukin|
36881|NCT00936195|Drug|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
36882|NCT00936195|Drug|Zidovudine-Lamivudine-Lopinavir/Ritonavir|Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day
Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day
36883|NCT00936221|Drug|AZD6244|oral capsules, 75mg twice daily
35903|NCT00020657|Drug|granisetron hydrochloride|
35904|NCT00946374|Drug|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
35905|NCT00948337|Behavioral|Brochure of Secondary Cancer Screening|One kind of printed educational material
35906|NCT00948350|Procedure|awake intubation|two anesthesia techniques
35907|NCT00948363|Other|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
35908|NCT00948363|Other|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
35909|NCT00948376|Genetic|IFT80 screening|Natural History
35910|NCT00020774|Drug|gemcitabine hydrochloride|
36634|NCT00945113|Behavioral|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
36635|NCT00945126|Other|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
36636|NCT00945139|Drug|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
36637|NCT00945139|Drug|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
36638|NCT00020566|Biological|dactinomycin|Given IV
36639|NCT00945152|Drug|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
36640|NCT00945152|Drug|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
36641|NCT00945165|Behavioral|Exercise intervention|various exercise characteristics
36642|NCT00945165|Behavioral|No exercise|No exercise control period
36643|NCT00945178|Drug|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
36644|NCT00945178|Drug|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
36645|NCT00945178|Drug|Naproxen|Tablet, single oral dose, 500mg
36646|NCT00945178|Drug|Placebo for Naproxen|Tablet, single oral dose
36647|NCT00945191|Drug|CS-1008|CS-1008 IV infusion up to 10 mg/kg once every 3 weeks (1 cycle) for 6 cycles
36648|NCT00945191|Drug|paclitaxel|paclitaxel 175 mg/m2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
36649|NCT00020566|Drug|busulfan|Given orally and IV
36947|NCT00933647|Dietary Supplement|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
36948|NCT00933647|Dietary Supplement|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
39609|NCT00964197|Device|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
39610|NCT00964210|Drug|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
39611|NCT00000865|Drug|Zidovudine|
39612|NCT00022308|Drug|cisplatin|
39613|NCT00964223|Drug|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
39614|NCT00964223|Drug|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
39615|NCT00964236|Drug|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
39616|NCT00964249|Drug|GW642444|Long acting Beta 2 agonist
39617|NCT00964249|Drug|Placebo|Matching placebo
39618|NCT00964262|Drug|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
39619|NCT00966823|Device|Fetal tracheal obstruction with detachable balloon (device)|Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.
Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation.
39620|NCT00966836|Drug|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
39621|NCT00966836|Drug|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
39622|NCT00966836|Drug|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
39623|NCT00966836|Drug|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
39905|NCT00950404|Drug|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
36158|NCT00944424|Drug|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
36159|NCT00944437|Device|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
36160|NCT00946647|Drug|5-Azacytidine|
36161|NCT00020670|Biological|autologous tumor cell vaccine|
36162|NCT00946673|Drug|Vorinostat|Orally up to 400 mg
36163|NCT00946673|Procedure|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
36483|NCT00947219|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
36484|NCT00947219|Device|Control device|Device is used 3 times a week on non-consecutive days
36485|NCT00940459|Device|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
36486|NCT00940459|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
36487|NCT00940459|Device|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
36488|NCT00940459|Device|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
36489|NCT00940459|Device|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
36490|NCT00940459|Device|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
36491|NCT00940472|Drug|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
36492|NCT00940472|Drug|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
36493|NCT00940485|Drug|entecavir|0.5mg po daily for 8 weeks
36494|NCT00020007|Drug|isolated perfusion|
36495|NCT00940485|Drug|entecavir|0.5mg po daily for 48 weeks
36496|NCT00940485|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
36497|NCT00940498|Drug|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
35911|NCT00948389|Drug|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
35912|NCT00948389|Drug|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
35913|NCT00948402|Drug|Metformin|metformin 1250 mg three times daily
35914|NCT00948402|Drug|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
35915|NCT00948415|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
35916|NCT00948428|Drug|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
35917|NCT00948428|Drug|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
35918|NCT00948428|Drug|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
35919|NCT00948441|Drug|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
35920|NCT00948441|Other|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
35921|NCT00000850|Drug|Indinavir sulfate|
35922|NCT00020774|Drug|lonafarnib|
36232|NCT00942409|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
36233|NCT00942422|Dietary Supplement|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
36234|NCT00942422|Genetic|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
36235|NCT00020332|Drug|alvocidib|
36949|NCT00933647|Dietary Supplement|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
36950|NCT00933660|Other|ERC-training by instructor|Standard way of training with an instructor
36951|NCT00933660|Other|Web-based training only|Experimental way of training with a web based training application
36952|NCT00933660|Other|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
36953|NCT00933673|Drug|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
36954|NCT00933686|Drug|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
36955|NCT00019474|Biological|filgrastim|
36956|NCT00933686|Drug|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
36957|NCT00933699|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
36958|NCT00933712|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
36959|NCT00933725|Other|TCM intervention|Drug: Particle of compound Chinese herbs(produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.
One tablet placebo of Tibolone (provided by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.
Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months.
36960|NCT00933725|Other|Western intervention|Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.
Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months.
36961|NCT00933751|Device|Central vein catheterization|Blood samplings from IVC catheter
40155|NCT00955929|Drug|Sildenafil and questionnaire|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
39906|NCT00950404|Drug|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
39907|NCT00950404|Drug|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
39908|NCT00950404|Drug|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
39909|NCT00950417|Drug|Nimotuzumab|
39910|NCT00950430|Drug|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
39911|NCT00020943|Drug|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
39912|NCT00950430|Drug|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
39913|NCT00950430|Drug|Tau (18-F-AV-1451)|PIB PET scan, Tau PET scan and/or FDG PET scan
Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan.
39914|NCT00950443|Device|Acoustic reflection method|Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.
39915|NCT00950443|Device|Acoustic method and breathing/endoscopic evaluation|Endoscopic evaluation done under general anaesthesia.
39916|NCT00952588|Drug|AZD1152|1200 mg, iv, 7 day infusion
39917|NCT00952588|Drug|LDAC|20 mg, sc, bd, 10 days
39918|NCT00952601|Dietary Supplement|Modified Atkins diet|Low carbohydrate diet
39919|NCT00952614|Device|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
39920|NCT00021138|Behavioral|smoking cessation intervention|
39921|NCT00952627|Dietary Supplement|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
39922|NCT00952627|Dietary Supplement|Placebo|
39923|NCT00952640|Dietary Supplement|vitamin A|high dose vitamin A, 200.000 IU
39924|NCT00952653|Drug|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
36498|NCT00940511|Behavioral|Coordinated care|
36499|NCT00940524|Drug|Dasatinib, Mitoxantrone, Cytarabine|INDUCTION- Dasatinib† (dose levels 1-3) *continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4
CONSOLIDATION A-Dasatinib† (dose levels 1-3) *continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29
36500|NCT00940550|Drug|Prolonged-release melatonin|2 mg tablet, once.
36501|NCT00940550|Drug|Temazepam|20 mg capsule, once
36502|NCT00940550|Drug|Zolpidem|10 mg capsule, once
36503|NCT00940550|Drug|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
36800|NCT00936143|Drug|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
36801|NCT00938522|Drug|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
36802|NCT00938522|Drug|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
36803|NCT00938535|Behavioral|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
36804|NCT00938548|Drug|Pregabalin|Pregabalin 75 mg orally
36805|NCT00019838|Drug|7-hydroxystaurosporine|
36806|NCT00938548|Drug|Vitamin Complex (placebo)|Vitamin Complex orally
36807|NCT00938561|Drug|Inulin|
36808|NCT00938574|Drug|Atu027|
36809|NCT00938587|Drug|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
36810|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
36811|NCT00938587|Drug|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
36236|NCT00942422|Genetic|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
36237|NCT00942422|Other|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
36238|NCT00942435|Drug|YM150|oral
36239|NCT00944437|Device|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
36240|NCT00944450|Drug|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
36241|NCT00944450|Drug|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets [monohydrate Final Market Image (FMI) form] in one of two treatment periods.
36242|NCT00020501|Drug|floxuridine|
36243|NCT00944463|Drug|Gemcitabine+simvastatin|Gemcitabine and simvastatin
36244|NCT00944463|Drug|Gemcitabine+Placebo|Gemcitabine plus Placebo
36245|NCT00944476|Procedure|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
36246|NCT00944502|Drug|Dexamethasone|Group A: Vitatonus DEXA injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group B: Vitatonus DEXA tablets:
1 tablet orally every 8 hours for 10 days.
Group C: Dexamethasone Injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group D: Dexamethasone tablets:
1 tablet orally every 8 hours for 10 days.
36247|NCT00944515|Drug|placebo|placebo tablet or syrup 3 days/week
36248|NCT00944515|Drug|azithromycin|azithromycin 3 days/week
36249|NCT00944528|Radiation|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
36566|NCT00020709|Radiation|radiation therapy|Undergo radiation therapy
36567|NCT00947258|Other|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
36568|NCT00947271|Behavioral|DVD 1|The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases [STDs]) and improve health
40156|NCT00958542|Procedure|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
40157|NCT00958568|Drug|Olanzapine and Fluoxetine combination (OFC)|Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.
Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.
Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks.
40158|NCT00021645|Drug|Vitamin E|
40159|NCT00958568|Drug|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
40160|NCT00958581|Drug|Tranexamic Acid|For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
40161|NCT00958581|Drug|Normal Saline|
40162|NCT00958581|Drug|Epsilon aminocaproic acid|For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
40163|NCT00958607|Behavioral|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care & by telephone during inpatient rehabilitation and community discharge. SSP provides support, information & guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
40164|NCT00958607|Behavioral|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
40165|NCT00958620|Procedure|Shock Wave Therapy|Extracorporal shock-wave therapy
40166|NCT00958633|Drug|Escitalopram|Escitalopram will be prescribed in the dose range 10-30 mg daily.
In patients randomized to the "8-week group", escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The tapering schedule for escitalopram is outlined in table 2.
The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points.
40167|NCT00958633|Drug|Wellbutrin XL|Bupropion XL will be prescribed in the dosage range 150-450 mg daily.
In patients randomized to the "8-week group", bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The tapering schedule for bupropion XL is outlined in table 2.
The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points.
40432|NCT00958698|Other|internet-based intervention|
40433|NCT00958698|Other|questionnaire administration|
39925|NCT00952653|Drug|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
40189|NCT00950846|Drug|Busulfan|Day -9, -8, -7 and -6
Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses.
40190|NCT00020943|Drug|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 & 2
40191|NCT00950846|Drug|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
40192|NCT00950846|Drug|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
40193|NCT00950846|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
40194|NCT00950859|Drug|GSK1349572 (Cohort I)|50 mg once daily
40195|NCT00950859|Drug|GSK1349572 (Cohort II)|50 mg twice daily
40196|NCT00950872|Device|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
40197|NCT00953108|Drug|quetiapine|300 mg per day
40198|NCT00953108|Drug|escitalopram|escitalopram 10 mg per day
40199|NCT00953121|Drug|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
40200|NCT00953134|Dietary Supplement|Ferrous fumarate (iron)|60 mg of ferrous fumarate
40201|NCT00953134|Dietary Supplement|folic acid|400 mcg folic acid
40202|NCT00953147|Drug|Ciclesonide HFA 80 mcg|Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
40203|NCT00953147|Drug|Ciclesonide HFA 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
40204|NCT00953147|Drug|Placebo|Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
40205|NCT00953160|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
40206|NCT00953173|Device|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
36812|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
36813|NCT00938587|Drug|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
36814|NCT00938587|Other|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
36815|NCT00938587|Other|Placebo|Placebo tablet every day for 14 days
36816|NCT00019838|Drug|fludarabine phosphate|
36817|NCT00938587|Other|Placebo for PF-04171327|Placebo tablet every day for 14 days
36818|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
36819|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
36820|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
36821|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
35839|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35840|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35841|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35842|NCT00020202|Drug|FR901228|
35843|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35844|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35845|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35846|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35847|NCT00941746|Biological|PG110|Single, slow intravenous infusion
35848|NCT00941746|Biological|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
35849|NCT00941772|Other|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
35850|NCT00941785|Drug|DHA-PQ|Three monthly administrations of Duocotexcin (DHA-PQ):
dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days
36569|NCT00947271|Behavioral|DVD 2|The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
36570|NCT00947284|Drug|nalbuphine plus naloxone|single dose administered intravenously
36571|NCT00947284|Drug|nalbuphine plus saline|single dose administered intravenously
36572|NCT00947284|Drug|naloxone plus saline|single dose administered intravenously
36573|NCT00947297|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
36574|NCT00947310|Device|Standard ICD programming|Standard ICD programming
36575|NCT00947310|Device|High rate cutoff|Programming of a high rate cutoff
36576|NCT00947310|Device|Long delay|Programming of a prolonged delay
36577|NCT00020709|Other|placebo|Given orally
36578|NCT00947323|Drug|Simvastatin|simvastatin 20 daily for six months.
36579|NCT00947323|Drug|Placebo|
36580|NCT00940602|Drug|Deferasirox|Deferasirox will be provided as 125 mg, 250 mg, and 500 mg dispersible tablets packaged in bulk high density polyethylene (HDPE) bottles with induction seals and child resistant closures.
36581|NCT00940602|Drug|Deferasirox placebo|Placebo will be formulated and packaged to be indistinguishable from the 125 mg, 250 mg, and 500 mg tablets of deferasirox.
36582|NCT00940615|Other|aerobic exercise|, participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
36583|NCT00940615|Other|stretching/toning|Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
36584|NCT00940628|Behavioral|Diet and Exercise|mildly hypocaloric diet and physical exercise
36585|NCT00940628|Drug|orlistat [Xenical]|120mg po tid
36586|NCT00020007|Procedure|hyperthermia treatment|
36884|NCT00936221|Drug|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
36885|NCT00936221|Drug|Placebo|Placebo
36886|NCT00936234|Drug|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
40434|NCT00958698|Other|study of socioeconomic and demographic variables|
40435|NCT00021671|Drug|Erythromycin|
40436|NCT00958698|Procedure|assessment of therapy complications|
40437|NCT00958698|Procedure|management of therapy complications|
40438|NCT00958698|Procedure|psychosocial assessment and care|
40439|NCT00958698|Procedure|quality-of-life assessment|
40440|NCT00958711|Device|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
40441|NCT00958711|Other|Saline and Gauze|gauze moistened with sterile saline
40442|NCT00958724|Drug|treatment with neratinib (HKI-272) + vinorelbine|HKI-272 : 240 mg, continuous daily OD Vinorelbine : 25 mg/m2, Day 1 and 8 of 21 day cycle
40443|NCT00958737|Drug|FOLFOX regimen|Given IV
40444|NCT00958737|Drug|fluorouracil|Given IV
40445|NCT00958737|Drug|leucovorin calcium|Given IV
40446|NCT00021671|Drug|Nevirapine|
40447|NCT00958737|Drug|oxaliplatin|Given IV
40448|NCT00958737|Drug|XELOX regimen|
40449|NCT00958737|Drug|Capecitabine|oral
40450|NCT00958750|Drug|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
40451|NCT00958763|Behavioral|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
40452|NCT00958763|Behavioral|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
40805|NCT00956969|Behavioral|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
40207|NCT00021216|Other|laboratory biomarker analysis|Correlative studies
40208|NCT00953186|Device|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
40209|NCT00953186|Device|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
40556|NCT00951301|Drug|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
40557|NCT00951340|Other|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
40558|NCT00951340|Behavioral|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
40559|NCT00951340|Behavioral|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
40560|NCT00951366|Other|Patient Registry|The BPD Patient Registry is used by both clinicians and researchers to better understand BPD and to improve care of individuals with BPD.
40561|NCT00951379|Drug|pioglitazone hydrochloride|Given PO
40562|NCT00951379|Other|placebo|Given PO
40563|NCT00951379|Other|laboratory biomarker analysis|Correlative studies
40564|NCT00021047|Drug|capecitabine|
40565|NCT00951392|Drug|euglycemic hyperinsulinemic clamp|Insulin perfusion at 1 mU.kg-1.min-1
Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l
Blood tests
40566|NCT00951392|Procedure|muscle biopsy|Gene expression in muscle tissue will be studied with two approaches :
Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)
Global transcriptome analysis by DNA Chip
40567|NCT00951392|Device|indirect calorimetry|energy expenditure measurement
40568|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
40569|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
40570|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
35851|NCT00941785|Drug|SP-AQ|Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:
One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg
35852|NCT00941798|Drug|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
35853|NCT00020254|Biological|aldesleukin|
35854|NCT00941798|Drug|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
35855|NCT00941811|Drug|Imiquimod|Local Imiquimod three times weekly for 16 weeks
35856|NCT00941824|Drug|mycophénolate acid|Day 0 to Day 7, 720 mg twice daily
Day 8 to Day 30, 540 mg twice daily
Day 30 to Day 90, 360 mg twice daily
35857|NCT00941837|Dietary Supplement|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
35858|NCT00943865|Behavioral|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
35859|NCT00020475|Drug|gp100 antigen|
35860|NCT00943878|Biological|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
36164|NCT00946686|Drug|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
36165|NCT00946686|Drug|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
36166|NCT00946699|Biological|MEDI-551|0.1 mg/kg
36167|NCT00946699|Biological|Placebo|0.3 mg/kg
36168|NCT00946699|Biological|MEDI-551|1.0 mg/kg
36169|NCT00946699|Biological|MEDI-551|3.0 mg/kg
36170|NCT00946699|Biological|MEDI-551|10.0 mg/kg
36171|NCT00946699|Other|Placebo|Placebo
36172|NCT00020683|Drug|incyclinide|High dose given orally
36173|NCT00946712|Biological|Bevacizumab|Given IV
36174|NCT00946712|Drug|Carboplatin|Given IV
36887|NCT00936247|Drug|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
36888|NCT00936247|Drug|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
36889|NCT00936260|Drug|alendronate|several duration of treatment
36890|NCT00936286|Device|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
36891|NCT00019669|Biological|fowlpox virus vaccine vector|
36892|NCT00936299|Drug|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
36893|NCT00936338|Behavioral|splint and joint mobilization self exercise|
36894|NCT00936351|Behavioral|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
36895|NCT00936351|Behavioral|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
36896|NCT00936364|Other|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
36897|NCT00938626|Procedure|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
36898|NCT00000841|Drug|Zidovudine|
36899|NCT00019864|Biological|filgrastim|
36900|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
36901|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
36902|NCT00938652|Drug|gemcitabine/carboplatin|Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)
Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)
36903|NCT00938652|Drug|Iniparib|Body weight adjusted dose
intravenous infusion (60 ± 10 minutes)
40806|NCT00956969|Behavioral|Relaxation Training|Teaches patients relaxation training
40807|NCT00956982|Drug|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing < 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
40808|NCT00957008|Behavioral|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
40809|NCT00957008|Other|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
40810|NCT00949442|Drug|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
40811|NCT00949442|Drug|Glimepiride|tablets of 1 and 2 mg
40812|NCT00949442|Drug|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
40813|NCT00949455|Drug|lapatinib ditosylate|Given orally
40814|NCT00949455|Other|Placebo|Given orally
40815|NCT00949481|Other|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
40816|NCT00949481|Other|Job aid|A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.
Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see "links" for more information on the checklist)
40817|NCT00020865|Drug|levofloxacin|
40818|NCT00949494|Device|Synvisc|intra-articular, 3 weekly injections
40819|NCT00949520|Other|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
40820|NCT00949520|Other|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
40571|NCT00951431|Drug|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
40572|NCT00951431|Drug|Placebo|Placebo in the form of study drug
40573|NCT00951444|Biological|dalotuzumab|Given IV
40574|NCT00951444|Drug|carboplatin|Given IV
40575|NCT00021047|Drug|carboplatin|
40576|NCT00951444|Drug|gemcitabine hydrochloride|Given IV
39624|NCT00966849|Other|Conditional Cash Transfer|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:
An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.
All children under 5 years in the household must be up-to-date with vaccinations.
All children under 5 years must attend a growth monitoring clinic twice per year.
All children 6-17 years in the household attended school at least 90% of days in the last month.
At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes.
39625|NCT00966849|Other|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
39626|NCT00966849|Other|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
39627|NCT00966849|Other|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
39628|NCT00966862|Other|Other: Dietary Fibers|
39629|NCT00022568|Biological|recombinant vaccinia-TRICOM vaccine|
39630|NCT00966875|Biological|LY2439821|subcutaneous
39631|NCT00966875|Drug|Placebo|subcutaneous
39632|NCT00966888|Procedure|standard follow-up care|No intervention
39633|NCT00966888|Radiation|radiation therapy|Chest wall radiotherapy
39634|NCT00966901|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
39635|NCT00966901|Drug|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
36175|NCT00946712|Biological|Cetuximab|Given IV
36176|NCT00946712|Other|Laboratory Biomarker Analysis|Correlative studies
36177|NCT00946712|Drug|Paclitaxel|Given IV
36178|NCT00946725|Drug|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
36179|NCT00946725|Drug|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
36180|NCT00946738|Other|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
36181|NCT00946738|Other|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
36182|NCT00946751|Drug|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
36183|NCT00020683|Drug|incyclinide|Low dose given orally
36184|NCT00946751|Drug|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
36185|NCT00946764|Drug|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
36186|NCT00946764|Drug|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
36187|NCT00946777|Other|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
36188|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
36189|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
36504|NCT00940563|Drug|Imatinib|
36505|NCT00020007|Drug|paclitaxel|
36506|NCT00940576|Dietary Supplement|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
36507|NCT00940576|Other|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
36508|NCT00940589|Drug|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
36509|NCT00940589|Drug|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
36510|NCT00942747|Drug|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
35923|NCT00948467|Drug|TAK-733|The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.
The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.
35924|NCT00948480|Biological|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
35925|NCT00948480|Drug|GM-CSF|500 mcg
35926|NCT00948493|Drug|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
35927|NCT00948506|Drug|1% topical cidofovir|1% topical cidofovir
35928|NCT00941850|Procedure|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
35929|NCT00941863|Drug|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
35930|NCT00941863|Drug|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
35931|NCT00941863|Drug|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
35932|NCT00941863|Drug|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
35933|NCT00941863|Drug|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
35934|NCT00020254|Biological|recombinant fowlpox-prostate specific antigen vaccine|
35935|NCT00941876|Behavioral|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
35936|NCT00941889|Drug|Saline|0.5 ml
35937|NCT00941889|Drug|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
35938|NCT00941915|Radiation|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
35939|NCT00941928|Drug|Epratuzumab|360 mg/m^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
35940|NCT00941928|Drug|Fludarabine|25 mg/m^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
40821|NCT00949533|Drug|oseltamivir [Tamiflu]|standard dose (30 - 75 mg orally bid) for 5 days
39846|NCT00952562|Dietary Supplement|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
39847|NCT00952562|Dietary Supplement|placebo|Empty capsules, 3 capsules per day for 16 weeks
39848|NCT00952575|Drug|polyclonal anti-D immunoglobulin|single injection of 300 µg
39849|NCT00952575|Drug|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
39850|NCT00955357|Drug|Lacosamide|Oral Lacosamide:
Subjects Titration Phase (6 Weeks):
Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid
Maintenance Phase (24 Weeks):
200 mg tablet bid OR 150 mg tablet bid
Taper Phase (1 - 3 Weeks):
50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week
39851|NCT00955383|Drug|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
39852|NCT00021346|Drug|carboplatin|
39853|NCT00955383|Drug|Placebo|Matching placebo
39854|NCT00955396|Drug|GSK1014802|Tablets
39855|NCT00955396|Drug|Placebo|Tablets
39856|NCT00955409|Drug|ACC-001+ QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
39857|NCT00955409|Drug|ACC-001|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
39858|NCT00955409|Drug|ACC-001 + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
39859|NCT00955435|Drug|bicalutamide|
39860|NCT00955435|Drug|releasing hormone agonist therapy|
39861|NCT00955435|Genetic|protein expression analysis|
39862|NCT00955435|Genetic|proteomic profiling|
39863|NCT00021346|Drug|gemcitabine hydrochloride|
39864|NCT00955435|Other|laboratory biomarker analysis|
39865|NCT00955435|Radiation|radiation therapy|
39866|NCT00955448|Device|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
39636|NCT00966901|Drug|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
39637|NCT00966901|Radiation|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
39638|NCT00959803|Drug|Placebo|Solution, oral single dose.
39639|NCT00959803|Drug|PF-04447943|25 mg solution, oral twice daily for 7 days.
39640|NCT00959803|Drug|Placebo|Solution, oral twice daily for 7 days.
39641|NCT00959816|Drug|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
39642|NCT00959829|Other|Music and message|Experimental group: music and message Control group: silence
39926|NCT00952666|Device|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
39927|NCT00952679|Device|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
39928|NCT00952692|Biological|dHER2 + AS15 ASCI|Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.
For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:
One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.
One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml.
39929|NCT00952692|Drug|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
39930|NCT00952705|Biological|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
39931|NCT00000854|Drug|Nandrolone decanoate|
39932|NCT00021138|Drug|nicotine|
39933|NCT00952705|Biological|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
39934|NCT00952705|Biological|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
39935|NCT00952718|Other|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
36511|NCT00942760|Device|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
36512|NCT00942773|Drug|Voriconazole|
36513|NCT00942799|Drug|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
36514|NCT00942799|Drug|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
36515|NCT00942812|Other|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
36516|NCT00942812|Other|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
36517|NCT00942825|Drug|CBP501 + Cisplatin + Pemetrexed|CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).
CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.
Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.
Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion.
36518|NCT00942825|Drug|Cisplatin + Pemetrexed|Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).
Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.
Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion.
36519|NCT00942838|Drug|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
36520|NCT00020358|Biological|incomplete Freund's adjuvant|
36822|NCT00938613|Drug|Placebo|nasal spray, one spray per nostril at time 0
36823|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
36824|NCT00938626|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
36825|NCT00938626|Procedure|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
35941|NCT00941928|Drug|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
35942|NCT00941928|Drug|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
36250|NCT00944541|Drug|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
36251|NCT00944554|Drug|Varenicline|Varenicline and placebo given twice a day or five weeks.
36252|NCT00944554|Drug|Placebo|Varenicline and placebo given twice a day or five weeks.
36253|NCT00020501|Drug|fluorouracil|
36254|NCT00944580|Biological|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
36255|NCT00944593|Dietary Supplement|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
36256|NCT00944593|Dietary Supplement|Normal Saline|200ml Normal Saline 0.9%
36257|NCT00944606|Dietary Supplement|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
36258|NCT00944606|Other|Placebo candy|candy gum drops
36259|NCT00944619|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
36260|NCT00944619|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
36261|NCT00944632|Drug|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
36262|NCT00944632|Drug|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
36263|NCT00946816|Behavioral|Nutritional Intervention|Nutritional Intervention
36264|NCT00946829|Drug|telmisartan|
36265|NCT00946842|Drug|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
36266|NCT00020683|Other|laboratory biomarker analysis|Correlative studies
36267|NCT00946842|Drug|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
39867|NCT00955448|Procedure|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
39868|NCT00955461|Procedure|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
39869|NCT00955461|Procedure|Fractionated Laser treatment|
40453|NCT00958763|Other|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
40454|NCT00951158|Dietary Supplement|Conjugated Linoleic Acid|This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.
CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression.
40455|NCT00951158|Drug|Conjugated Linoleic Acid|Phase I Dose Escalation Study
40456|NCT00021021|Biological|anti-FLT-1 ribozyme|
40457|NCT00951171|Procedure|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
40458|NCT00951171|Procedure|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
40459|NCT00951184|Behavioral|telephone-based intervention|
40460|NCT00951184|Other|screening questionnaire administration|
40461|NCT00951184|Other|study of socioeconomic and demographic variables|
40462|NCT00951184|Procedure|assessment of therapy complications|
40463|NCT00951184|Procedure|psychosocial assessment and care|
40464|NCT00951197|Other|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
40465|NCT00951210|Biological|PLX-PAD|IM injection
40466|NCT00951223|Drug|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
40467|NCT00021034|Drug|chemotherapy|
39936|NCT00952731|Drug|oral placebo|Oral placebo taken daily for 4-10 weeks.
39937|NCT00952731|Drug|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
39938|NCT00952731|Drug|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
39939|NCT00952731|Drug|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
39940|NCT00955487|Drug|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
39941|NCT00021359|Drug|dexamethasone|
39942|NCT00955500|Dietary Supplement|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
39943|NCT00955500|Dietary Supplement|Maltodextrin|30 grams of oral maltodextrin daily
39944|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
40210|NCT00953199|Drug|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
40211|NCT00953199|Drug|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
40212|NCT00953212|Drug|beta blockers|metoprolol 25mg by mouth every 6 hours
40213|NCT00953212|Drug|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
40214|NCT00953212|Drug|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
40215|NCT00953225|Drug|vitamin D3|4,000 IU daily for one year
40216|NCT00953225|Drug|Placebo daily for one year|Placebo
40217|NCT00953264|Behavioral|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
40218|NCT00021216|Other|pharmacological study|Correlative studies
40219|NCT00953277|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
40220|NCT00953290|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
36826|NCT00930800|Other|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
36827|NCT00930813|Device|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
36828|NCT00930813|Device|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
36829|NCT00930839|Drug|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
36830|NCT00930865|Drug|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
36831|NCT00930865|Drug|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
36832|NCT00019318|Drug|romidepsin|
36833|NCT00930878|Device|Cardiac Stenting|Drug Eluting stent
36834|NCT00930891|Drug|Standard Chemotherapy (PCDE or PE)|PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles
PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles
36835|NCT00930891|Drug|Experimental Treatment (PCDE or PE + bevacizumab)|PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression
PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression
36836|NCT00930891|Drug|Prerandomization Chemotherapy (PCDE or PE)|PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles
PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles
36837|NCT00930917|Device|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
36838|NCT00930917|Device|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
36839|NCT00930917|Other|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
36840|NCT00930930|Drug|cisplatin|Given IV
36841|NCT00930930|Drug|everolimus|Given orally
36842|NCT00930930|Drug|paclitaxel|Given IV
35861|NCT00943878|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
35862|NCT00943878|Drug|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
35863|NCT00943891|Procedure|Tumor biopsies|
36268|NCT00946842|Drug|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
36269|NCT00946842|Drug|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
36270|NCT00946842|Drug|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
36587|NCT00940641|Drug|AZD7325|IV Dose
36588|NCT00940641|Drug|AZD7325|oral dose
36589|NCT00940654|Other|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
36590|NCT00940667|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
36591|NCT00940667|Drug|Amlodipine|amlodipine 5mg q.d.
36592|NCT00940680|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
36593|NCT00940680|Drug|Losartan|losartan 100mg q.d.
36594|NCT00940693|Drug|duloxetine|60 mg capsule once per day for 6 weeks
36595|NCT00940693|Drug|placebo|one capsule of placebo taken one a day for 6 weeks
36596|NCT00940706|Device|TreadMill|Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes
TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session.
36597|NCT00020046|Drug|docetaxel|
36598|NCT00940706|Other|Physical activity in groups|Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.
Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time.
36599|NCT00940706|Behavioral|Monitoring physical activity|Activity monitoring with accelerometers
36600|NCT00940719|Dietary Supplement|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
36601|NCT00940732|Other|Destigmatisation and Mental Health Literacy|Written material delivered over 2 weeks via the Internet, including "mythbusters", debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information.
40468|NCT00951236|Drug|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
40469|NCT00951236|Drug|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
40470|NCT00951249|Behavioral|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
40471|NCT00951249|Behavioral|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
40494|NCT00953641|Drug|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
40495|NCT00953641|Drug|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
40496|NCT00953654|Other|Strength Training|6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
40497|NCT00953654|Other|Endurance Training|Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
40498|NCT00021255|Drug|trastuzumab, docetaxel, carboplatin|trastuzumab IV, docetaxel IV, carboplatin IV
40499|NCT00953667|Drug|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
40500|NCT00953680|Drug|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
40501|NCT00953680|Drug|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
40502|NCT00956345|Drug|40K PEG-rFIX|Cohort to receive a single dose of 50U/kg 40K PEG-rFIX administered intravenously (into the vein)
40503|NCT00956345|Drug|40K PEG-rFIX|Cohort to receive a single dose of 100U/kg 40K PEG-rFIX administered intravenously (into the vein)
40504|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
40505|NCT00021450|Procedure|adjuvant therapy|
40506|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
40507|NCT00956384|Procedure|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
40221|NCT00955929|Drug|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires|Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
40222|NCT00955942|Dietary Supplement|flaxseed|Given orally
40223|NCT00955942|Other|placebo|Given orally
40224|NCT00955955|Other|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
40225|NCT00955955|Other|Placebo|Inactive substance
40226|NCT00955968|Drug|Highly active antiretroviral therapy (HAART)|A combination of three or more HIV medications belonging to two or more drug classes
40227|NCT00955981|Drug|RDEA594|Uricosuric agent for the treatment of gout
40228|NCT00955981|Drug|Placebo|Matching placebo
40229|NCT00021398|Drug|leucovorin calcium|
40230|NCT00955994|Drug|asimadoline|
40577|NCT00953680|Drug|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
40578|NCT00953693|Procedure|Biopsy|Skin biopsy
40579|NCT00953706|Drug|Ivacaftor|Tablet
40580|NCT00953706|Drug|Placebo|Tablet
40581|NCT00953719|Device|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
40582|NCT00953719|Device|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
40583|NCT00953732|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
40584|NCT00021268|Drug|tocladesine|
40585|NCT00953745|Drug|escitalopram and adjunctive aripiprazole and placebo|escitalopram 20 mg per day plus placebo for 10 weeks followed by escitalopram 20mg and aripiprazole 10 mg for 6 weeks
40586|NCT00953758|Drug|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
35864|NCT00943904|Device|Interstim implant for SNS|stimulates third sacral nerve root
35865|NCT00943917|Other|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
35866|NCT00943917|Drug|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
35867|NCT00943917|Other|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
35868|NCT00943930|Drug|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
35869|NCT00943943|Drug|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
35870|NCT00020475|Drug|interleukin-2|
35871|NCT00943943|Drug|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
35872|NCT00943943|Drug|Sorafenib|First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).
Dose Level 0 = 400 mg orally twice daily.
35873|NCT00943956|Drug|bicalutamide|
35874|NCT00943956|Drug|everolimus|
35875|NCT00943956|Drug|leuprolide acetate|
35876|NCT00943956|Radiation|external beam radiation therapy|
35877|NCT00943969|Procedure|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
35878|NCT00943982|Drug|Interferon Gamma 1-b|
35879|NCT00943995|Drug|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
35880|NCT00944008|Drug|DepoCyte|
35881|NCT00946192|Drug|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
36190|NCT00946803|Behavioral|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
36602|NCT00940732|Other|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
36603|NCT00942890|Device|NMES (EMPI 300PV stimulator) plus standard of care|In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
36604|NCT00942903|Device|Provox Xtra HME|Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
36605|NCT00942968|Drug|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
36904|NCT00938665|Device|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
36905|NCT00938678|Drug|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
36906|NCT00938678|Drug|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
36907|NCT00938691|Procedure|Intradermal Suture|
36908|NCT00938691|Procedure|Intradermal Suture|
36909|NCT00938704|Drug|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
36910|NCT00019864|Drug|cisplatin|
36911|NCT00938704|Drug|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
36912|NCT00938717|Drug|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
36913|NCT00938730|Drug|YM150|oral
36914|NCT00938730|Drug|Warfarin|oral
36915|NCT00938743|Drug|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
36916|NCT00938756|Other|diagnostic laboratory biomarker analysis|
36917|NCT00938756|Other|immunoenzyme technique|
36918|NCT00938756|Procedure|magnetic resonance imaging|
40508|NCT00956384|Procedure|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
40509|NCT00956397|Drug|Rifaximin|rifaximin 550 mg TID PO x 10 days
40510|NCT00956397|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
40511|NCT00956397|Drug|Placebo|placebo TID x 10 days
40512|NCT00956410|Biological|CAD106|
40822|NCT00949533|Drug|oseltamivir [Tamiflu]|double dose (60 - 150 mg orally bid) for 5 days
40823|NCT00949546|Drug|etanercept|etanercept 50 mg sc twice weekly
40824|NCT00949559|Drug|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
40825|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
40826|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
40827|NCT00949585|Other|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
40828|NCT00020878|Drug|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
40829|NCT00949598|Drug|letrozole|Given orally
40830|NCT00949598|Drug|tamoxifen citrate|Given orally
40831|NCT00949611|Behavioral|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
40832|NCT00949611|Behavioral|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
40833|NCT00951626|Procedure|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
40587|NCT00953771|Drug|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
40588|NCT00953784|Procedure|standard operating management|As previously described
40589|NCT00953797|Device|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
40590|NCT00953810|Other|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
40591|NCT00953849|Drug|celecoxib|celecoxib (400 mg twice daily)
40592|NCT00953849|Drug|1,25-dihydroxyvitamin D3 + celecoxib|3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment) plus celecoxib (400 mg twice daily)
40593|NCT00953849|Drug|1,25-dihydroxyvitamin D3|3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment)
40594|NCT00953862|Drug|atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant for the final 6 weeks of the trial.
40595|NCT00021281|Drug|FOLFIRI regimen|
40596|NCT00953888|Drug|AZD5069|Single dose of oral solution.
40597|NCT00953888|Drug|Placebo|Single dose of oral solution.
39643|NCT00959842|Drug|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
39644|NCT00959855|Other|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
39645|NCT00959868|Drug|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
39646|NCT00959881|Drug|Donepezil plus placebo|5- and 10-mg tablets, single dose
39647|NCT00021983|Biological|BL22 immunotoxin|
39648|NCT00959881|Drug|Donepezil|5- and 10-mg tablets, single dose
36191|NCT00940004|Biological|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
36192|NCT00940017|Drug|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
36193|NCT00940030|Other|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
36194|NCT00940030|Other|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
36195|NCT00940056|Procedure|Endoscopic ablation of AF|The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .
After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care.
36196|NCT00019955|Procedure|thermal ablation therapy|
36197|NCT00940056|Drug|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
36198|NCT00940069|Drug|pemetrexed|'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.
'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.
36199|NCT00940095|Drug|Clazosentan|5 mg/h
36200|NCT00940095|Drug|Clazosentan|15 mg/h
36201|NCT00940095|Drug|Placebo|Matching Placebo
36202|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
36203|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
36204|NCT00940121|Drug|mirabegron|oral tablet
36205|NCT00940121|Drug|mirabegron|IV solution
36206|NCT00940134|Biological|PYY 3-36|0.8 pmol/kg/min x 3 hours
36919|NCT00938769|Other|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
2-hour in-person instruction of home care issues for caregivers of patients with cancer.
36920|NCT00938769|Other|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.
2-hour counseling session for cancer caregivers to locate community support resources
36921|NCT00019864|Drug|dexrazoxane hydrochloride|
36922|NCT00931008|Drug|SID530, Taxotere|75mg/m2
36923|NCT00019331|Biological|ras peptide cancer vaccine|
36924|NCT00931021|Drug|Varenicline (Chantix)|2 mg
36925|NCT00931021|Drug|Nicotine Patch|21 mg
35943|NCT00941928|Procedure|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
35944|NCT00941928|Drug|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
35945|NCT00020254|Biological|recombinant vaccinia prostate-specific antigen vaccine|
35946|NCT00941941|Procedure|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
35947|NCT00941941|Procedure|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
35948|NCT00941954|Behavioral|Structured Education|The intervention group will be offered a group−based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self−efficacy, barriers to physical activity and self−regulatory skills based on pedometer use. The programme will employ a person−centred approach to patient education that is based on self−management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5−10 participants by two trained educators and is 3.5 hours long. Brief follow−up counselling will be offered once every 6 months.
35949|NCT00020475|Drug|MART-1 antigen|
35950|NCT00944021|Drug|PA-824|50mg
35951|NCT00944021|Drug|PA-824|100mg
35952|NCT00944021|Drug|PA-824|150 mg
35953|NCT00944021|Drug|Rifafour e-275 mg|275 mg
40834|NCT00951639|Dietary Supplement|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
40835|NCT00951639|Procedure|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
40836|NCT00951639|Dietary Supplement|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
40837|NCT00951652|Behavioral|CBT|
40838|NCT00951652|Other|Interpersonal and emotional processing therapy|
40839|NCT00951652|Behavioral|supportive listening|
40840|NCT00951665|Drug|paclitaxel|Intravenous repeating dose
40841|NCT00021060|Other|laboratory biomarker analysis|Correlative studies
39870|NCT00955474|Drug|Quetiapine monotherapy|• Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
39871|NCT00955474|Drug|Quetiapine with SSRI|Quetiapine XR 100 mg/h.s. starting dose; increased by 100 mg q h.s. q day; target dose 300 mg/h.s. by day 3; continued on 300 mg/h.s. through week 3. Weeks 4-8: flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s.
Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.
Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.
Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m.
39872|NCT00955487|Drug|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
39873|NCT00957931|Procedure|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
39874|NCT00957931|Biological|Mesenchymal Stromal Cells|
39875|NCT00957944|Drug|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
39876|NCT00957970|Device|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
39877|NCT00957970|Device|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
39878|NCT00957983|Drug|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
43224|NCT00023244|Drug|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
43225|NCT00972543|Biological|Efalizumab (Raptiva)|Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.
Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
43226|NCT00972543|Biological|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
43227|NCT00974896|Drug|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
42268|NCT00023777|Biological|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
42269|NCT00977808|Device|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
42270|NCT00977808|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
42271|NCT00977821|Other|IVF|
42272|NCT00977821|Other|Oocyte Vitrification|
42273|NCT00977847|Other|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
42274|NCT00977860|Radiation|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
42275|NCT00977873|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
42276|NCT00977873|Dietary Supplement|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
42277|NCT00977886|Drug|Placebo|Oral, 10 days
42278|NCT00977886|Drug|ELB353|Oral, 10 days
42279|NCT00023777|Drug|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
42280|NCT00977899|Biological|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
42281|NCT00977912|Dietary Supplement|Probiotic supplementation|one capsule containing probiotics per day added to milk
41484|NCT00985959|Drug|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
41485|NCT00985959|Drug|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
41486|NCT00024271|Radiation|radiation therapy|
41487|NCT00985959|Drug|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
41488|NCT00985972|Behavioral|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
41489|NCT00985985|Drug|Nicotine|2 mg or 4 mg nicotine lozenge
41490|NCT00985985|Drug|Placebo|placebo lozenge
41491|NCT00985998|Drug|Nimotuzumab and chemotherapy|The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4~6cycles).
the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12~18 weeks).
41492|NCT00986011|Other|questionnaire administration|
41493|NCT00986011|Other|study of socioeconomic and demographic variables|
41494|NCT00986011|Other|survey administration|
41495|NCT00986011|Procedure|study of high risk factors|
41496|NCT00986024|Behavioral|aerobic exercise|carried out 3 times per week for 12 weeks
41497|NCT00024284|Drug|carboplatin|
41498|NCT00986024|Behavioral|strength training|carried out 3 times per week for 12 weeks
41499|NCT00986037|Drug|ABT-308|Single IV doses
41500|NCT00986037|Drug|ABT-308|Multiple SC doses x 3
41501|NCT00986037|Drug|Placebo|Single IV dose
41502|NCT00986037|Drug|Placebo|Multiple SC doses x 3
41503|NCT00986050|Drug|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
41504|NCT00986050|Device|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
41818|NCT00979667|Drug|Zanamivir|10 mg twice daily for 5 days
42349|NCT00984945|Biological|Placebo|0.5 mL, IM, two injections 21 days apart
42350|NCT00984958|Device|Bulkamid|injection of Bulkamid in the urethra
42351|NCT00024193|Procedure|peripheral blood stem cell transplantation|
42352|NCT00984958|Device|Bulkamid expectation|expectance
42353|NCT00984971|Drug|Tenofovir|Topical gel applied rectally
42354|NCT00984971|Drug|HEC Placebo|Placebo gel applied rectally
42355|NCT00984971|Drug|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
42356|NCT00984984|Drug|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
42641|NCT00985517|Procedure|Sham Surgery|Sham Surgery
42642|NCT00985530|Drug|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle
42643|NCT00985530|Drug|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
42644|NCT00985543|Drug|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
42645|NCT00000875|Drug|Lamivudine|
42646|NCT00024271|Biological|recombinant interferon gamma|
42647|NCT00985556|Drug|capecitabine|Given orally
42648|NCT00985556|Drug|oxaliplatin|Given IV
42649|NCT00985556|Drug|tegafur-gimeracil-oteracil potassium|Given orally
42650|NCT00978354|Drug|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
42651|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
42652|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
42995|NCT00023712|Other|pharmacological study|Correlative studies
42996|NCT00976859|Behavioral|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
42997|NCT00976859|Behavioral|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
42998|NCT00976872|Drug|omega-3|omega-3: 2 pills of Omega"950"®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA
42999|NCT00976872|Drug|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
43000|NCT00969735|Device|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
43001|NCT00022776|Procedure|Surgical decompression|Simple decompression not requiring fusion.
43002|NCT00969735|Device|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter > 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
43003|NCT00969761|Drug|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
43347|NCT00977028|Drug|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
43348|NCT00977028|Procedure|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
43349|NCT00977041|Behavioral|Neurofeedback|Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and "Do whatever is necessary to make and keep the bar wide." This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly.
42421|NCT00983034|Drug|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
42422|NCT00983047|Drug|Nimotuzumab and Docetaxel|The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.
Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity.
42423|NCT00983060|Drug|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
42424|NCT00983060|Drug|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
42425|NCT00983073|Drug|Tapentadol|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.
Maintenance Period: Participants continuing on the dose established in the previous period.
42426|NCT00983086|Drug|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
42427|NCT00983099|Drug|Neramexane|single and multiple dose, tablets, oral
42428|NCT00024115|Procedure|immunotoxin therapy|
42429|NCT00983112|Drug|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
42430|NCT00983112|Drug|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
42431|NCT00983125|Drug|Clonidine|Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.
To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour.
42432|NCT00983138|Drug|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
42433|NCT00985062|Procedure|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
42720|NCT00969176|Drug|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
42721|NCT00022737|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
41819|NCT00023920|Biological|bevacizumab|Given IV
41820|NCT00979667|Drug|Placebo of Oseltamivir|twice daily for 5 days
41821|NCT00979680|Radiation|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
41822|NCT00979680|Radiation|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
41823|NCT00982046|Device|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
41824|NCT00024050|Drug|cyclophosphamide|
41825|NCT00982046|Device|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
41826|NCT00982046|Device|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
41827|NCT00982046|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
41828|NCT00982059|Other|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
41829|NCT00982072|Drug|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
41830|NCT00982072|Drug|prednisolone|Prednisolone 1mg/kg maximum 60mg od
41831|NCT00982098|Procedure|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
41832|NCT00982111|Drug|pemetrexed|500 mg/m2 (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
41833|NCT00982111|Drug|cisplatin|75 mg/m2 (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
41834|NCT00982111|Biological|IMC-11F8|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V. infusion
41835|NCT00000219|Drug|Buprenorphine|
41836|NCT00000872|Drug|Zidovudine|
42653|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
42654|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
42655|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
42656|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
42657|NCT00023829|Radiation|radiation therapy|
42658|NCT00978380|Drug|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
42659|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
42933|NCT00969709|Drug|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
42934|NCT00969722|Biological|MAb-3F8|
42935|NCT00969722|Biological|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
42936|NCT00969722|Biological|13-cis-Retinoic Acid|
42937|NCT00972101|Drug|Fludarabine|40 mg/m^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
42938|NCT00972101|Drug|Rituximab|Regimen 1:
375 mg/m^2 may be given by vein over 4 - 6 hours on Day -9 if needed
Regimen 2:
375 mg/m^2 may be given by vein over 4 - 6 hours on Day -8 if needed
42939|NCT00972101|Drug|Etoposide|60 mg/m^2 by vein over 1-2 hours as a single dose on Day -3.
42940|NCT00972101|Drug|Anti-thymocyte globulin (ATG)|Regimen 1:
1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.
Regimen 2:
0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1.
42941|NCT00972101|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
42942|NCT00972101|Drug|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
42943|NCT00972101|Procedure|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
43350|NCT00977054|Drug|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
43351|NCT00977054|Drug|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
43352|NCT00977067|Drug|GDC-0152|Intravenous escalating dose
43353|NCT00023738|Biological|filgrastim|
43354|NCT00977080|Drug|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
43355|NCT00977080|Drug|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
43356|NCT00977093|Other|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
43357|NCT00977093|Other|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
43358|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
43359|NCT00977106|Drug|placebo|single iv infusion
43360|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
43361|NCT00977119|Other|Side-effect questionnaires|Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
43362|NCT00977626|Drug|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
43363|NCT00970489|Drug|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
43364|NCT00970489|Drug|Placebo|Olive Oil capsules
42417|NCT00024115|Procedure|biological response modifier therapy|
42418|NCT00983021|Drug|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
42419|NCT00983021|Drug|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
42420|NCT00983021|Drug|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
42722|NCT00969202|Radiation|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
42723|NCT00969215|Device|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
42724|NCT00969228|Biological|Rotarix ™|Two oral doses
42725|NCT00969228|Biological|Placebo|Two oral doses
42726|NCT00969254|Drug|Pílulas de Lussen|Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pílulas de Lussen®
** Drug B: placebo.
42727|NCT00969254|Drug|Pyridium®|Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pyridium®
** Drug B: placebo.
42728|NCT00969267|Other|ear-acupuncture A|with needle stimulation
42729|NCT00969267|Other|stimulation B|with bread stimulation on ear acupuncture point
42730|NCT00969267|Other|stimulation C|without needle stimulation
42731|NCT00969280|Device|Standardized Acupuncture|Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.
According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20*30mm (Dongbang Co., korea) acupuncture needle.
All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes.
42732|NCT00022737|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
42733|NCT00969280|Device|Non-acupuncture point shallow penetration acupuncture|Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.
Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes.
42734|NCT00969293|Drug|FOV2302 (Ecallantide)|Single intravitreal injection into the relevant eye.
Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.
Duration of Treatment: Single injection with 3 months follow-up.
42735|NCT00969306|Drug|Chloroquine, A-CQ 100|Administration:
Orally
Timing: Once daily
Tablets of 100 mg
During or after meals
In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.
Patients should always note date and time of intake on the chloroquine monitoring form.
42736|NCT00969319|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
42737|NCT00969332|Drug|Omegaven|0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday
43004|NCT00969761|Drug|BI 6727|low to high dose
41837|NCT00024050|Drug|cyclosporine|
40842|NCT00951665|Drug|pertuzumab [Perjeta]|Intravenous repeating dose
40843|NCT00951665|Drug|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
40844|NCT00951678|Other|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
40845|NCT00951691|Behavioral|Enhanced acute medical rehabilitation|Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, "Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial." J American Medical Director's Association, 2012 for details and outcome data.
40846|NCT00951691|Behavioral|Treatment as usual|Standard treatment with physical and occupational therapies
40847|NCT00951717|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
40848|NCT00951730|Other|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
40849|NCT00951743|Drug|Adaptavir (monomeric DAPTA)|Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.
Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.
Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day.
40850|NCT00951756|Other|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
40851|NCT00951782|Device|High frequency TMS|deep TMS HADD coil
40852|NCT00021073|Drug|alvocidib|Given IV
40853|NCT00951782|Device|Sham TMS|sham deep TMS HADD coil
40854|NCT00951782|Device|Low frequency TMS|Deep TMS - HADD coil
40855|NCT00954330|Procedure|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
40856|NCT00954330|Device|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
42944|NCT00972101|Drug|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is > 2.5 x 10e^9/L.
42945|NCT00972101|Procedure|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e^5 T cells/kg on Day 14+.
42946|NCT00972114|Procedure|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
42947|NCT00023231|Drug|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
42948|NCT00972114|Procedure|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
42949|NCT00972114|Procedure|CABG alone|Coronary artery bypass graft surgery alone
42950|NCT00972127|Drug|Neramexane|25 mg or 2x25mg tablets
42951|NCT00972140|Drug|Formoterol|Formoterol-HFA pMDI 12µg twice daily
42952|NCT00972140|Drug|Formoterol|Formoterol-DPI 12 µg twice daily
42953|NCT00972153|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
42954|NCT00972153|Device|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
43287|NCT00970398|Other|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
43288|NCT00970411|Drug|KRN951|Orally once daily administration
43289|NCT00970424|Drug|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
43290|NCT00970424|Drug|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
43291|NCT00970437|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
43292|NCT00970437|Behavioral|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
43293|NCT00022854|Procedure|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
43294|NCT00970450|Drug|Paracetamol|Paracetamol 1 g i.v. once
42204|NCT00980213|Drug|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
42205|NCT00980239|Drug|Irinotecan|Starting dose of 35 mg/m^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
42206|NCT00980239|Drug|Bevacizumab|10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
42207|NCT00980239|Drug|Oxaliplatin|Starting dose 60 mg/m^2 by vein over 2 hours on Days 1 and 15 of every cycle.
42208|NCT00023959|Radiation|radiation therapy|Undergo radiotherapy
42209|NCT00980239|Drug|Cetuximab|500 mg/m^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
42210|NCT00980252|Behavioral|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
42211|NCT00980278|Procedure|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
42212|NCT00980278|Biological|Aastrom BRCs|sinus augmentation, BRC application, dental implant
42213|NCT00980304|Drug|Rituximab|
42214|NCT00980317|Procedure|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
42215|NCT00980330|Drug|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
42216|NCT00980330|Drug|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
42217|NCT00982605|Procedure|EBUS_TBNA|EBUS during bronchoscopy
42218|NCT00982618|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
42219|NCT00024102|Drug|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 & 8 and 5-FU 600 mg/sq m IV push d 1 & 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
42220|NCT00982618|Procedure|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
42221|NCT00982618|Drug|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
43005|NCT00969787|Drug|DWP05195|tablets, oral administration, single and multiple administrations
43006|NCT00969800|Device|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
43007|NCT00969800|Device|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
43008|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
43009|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
43010|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
43011|NCT00969826|Drug|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
43012|NCT00022776|Procedure|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
43013|NCT00969839|Device|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
43014|NCT00969852|Drug|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
43015|NCT00969878|Drug|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
43016|NCT00969878|Other|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
43017|NCT00969891|Other|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
43018|NCT00969904|Drug|N-acetylcysteine|600 mg TID for 12 weeks
43019|NCT00972192|Behavioral|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
43020|NCT00972205|Drug|paclitaxel|Paclitaxel 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
43021|NCT00972205|Drug|CBT-1(Registered Trademark)|CBT-1 500 mg/m^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
43022|NCT00972205|Radiation|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
42282|NCT00977912|Dietary Supplement|Milk containing placebo|one capsule containing placebo per day added to milk
42283|NCT00977925|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
42284|NCT00977925|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
42285|NCT00977938|Drug|Placebo & Aspirin|
42286|NCT00977938|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|
42287|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
42583|NCT00980980|Drug|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
42584|NCT00981006|Procedure|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
42585|NCT00981032|Behavioral|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
42586|NCT00981032|Behavioral|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
42587|NCT00981045|Drug|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
42588|NCT00023998|Drug|cisplatin|Given IV
42589|NCT00981045|Drug|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
42590|NCT00981058|Biological|necitumumab|800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
42591|NCT00981058|Drug|gemcitabine|1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
42592|NCT00981058|Drug|cisplatin|75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.
43295|NCT00970450|Drug|Tropisetron|Tropisetron 5 mg i.v. once
43296|NCT00970450|Drug|Placebo|Saline
43297|NCT00972556|Drug|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
43298|NCT00972556|Drug|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
43299|NCT00972569|Drug|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
43300|NCT00972569|Drug|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
43301|NCT00972582|Dietary Supplement|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
43302|NCT00972595|Drug|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
43303|NCT00972595|Drug|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
43304|NCT00972608|Other|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
43305|NCT00023244|Drug|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
42357|NCT00984984|Drug|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
42358|NCT00984997|Procedure|Surgery|Segmentectomy or lobectomy with en bloc resection of the involved chest.
42359|NCT00984997|Radiation|Chest Irradiation|Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
42360|NCT00984997|Drug|Cisplatin|50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
42361|NCT00984997|Drug|Etoposide|given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
42362|NCT00024206|Drug|orantinib|Given orally
42222|NCT00982631|Drug|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
42521|NCT00983229|Procedure|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
42522|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
42523|NCT00983242|Drug|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
42524|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
42525|NCT00983255|Drug|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 & 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
42526|NCT00983255|Drug|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
42527|NCT00024128|Biological|therapeutic allogeneic lymphocytes|
42528|NCT00983268|Drug|capecitabine|1000 mg taken by mouth on the days of radiation only.
42529|NCT00983268|Drug|vorinostat|Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:
Vorinostat,at 100 mg
Vorinostat,at 200 mg
Vorinostat, at 300 mg
Vorinostat, at 400 mg
42530|NCT00983268|Radiation|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
42531|NCT00985218|Device|Culture dish|Standard IVF culture dish
42532|NCT00985231|Device|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
42533|NCT00985231|Device|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
42534|NCT00024232|Biological|monoclonal antibody huJ591|
42535|NCT00985244|Drug|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
42536|NCT00985244|Drug|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
43023|NCT00972218|Biological|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
43365|NCT00970502|Drug|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
43366|NCT00970515|Procedure|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
43367|NCT00970515|Procedure|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
43368|NCT00970528|Drug|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
43369|NCT00970528|Drug|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
43370|NCT00022854|Procedure|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
43371|NCT00970541|Dietary Supplement|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
43372|NCT00970541|Dietary Supplement|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
43373|NCT00970554|Other|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
43374|NCT00970554|Other|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
43375|NCT00970567|Behavioral|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
43376|NCT00970580|Drug|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
43377|NCT00970593|Drug|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
43378|NCT00970593|Drug|placebo comparator|Group 1 & 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
43379|NCT00970606|Drug|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
43380|NCT00970606|Drug|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
43381|NCT00022867|Drug|Nondigestible oligosaccharide (NDO)|
42593|NCT00981084|Drug|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
42594|NCT00981097|Genetic|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
42595|NCT00981097|Other|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
42596|NCT00981110|Device|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
42597|NCT00981110|Device|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
42598|NCT00981136|Procedure|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
42599|NCT00023998|Drug|methotrexate|Given IV
42867|NCT00974363|Procedure|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
42868|NCT00974376|Drug|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
42869|NCT00974376|Drug|Placebo|1200mg/day of placebo
42870|NCT00023426|Drug|rifapentine|
42871|NCT00974389|Biological|bevacizumab|
42872|NCT00974389|Drug|tegafur-gimeracil-oteracil potassium|
42873|NCT00974402|Behavioral|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
42874|NCT00974415|Procedure|CO2|CO2 treatment delivered to randomized flank at each study visit
42875|NCT00974415|Procedure|Sham|Sham treatment to other flank at each study visit
42876|NCT00974428|Dietary Supplement|Wobenzym® N|4 tablets TID, 6 weeks
42877|NCT00974428|Dietary Supplement|Placebo|4 tablets TID
42363|NCT00984997|Radiation|Prophylactic Cranial Irradiation|25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
42364|NCT00985023|Procedure|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
42365|NCT00985023|Procedure|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
42366|NCT00985036|Procedure|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
42367|NCT00977951|Drug|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
42368|NCT00023777|Drug|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
42369|NCT00977951|Drug|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
42370|NCT00977964|Other|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
42371|NCT00977964|Other|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
42372|NCT00977964|Other|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
42373|NCT00977964|Other|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
42374|NCT00977964|Other|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
42375|NCT00977964|Other|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
42376|NCT00977977|Drug|Rituximab Infusion|2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
42660|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
42661|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
42662|NCT00978393|Drug|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
42663|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
42537|NCT00985257|Device|DIDGET (Investigational Blood Glucose Monitoring System)|Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
42538|NCT00985270|Drug|Rifampicin|
42539|NCT00985270|Drug|Placebo|
42800|NCT00976469|Biological|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
42801|NCT00976495|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
42802|NCT00976495|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
42803|NCT00976495|Drug|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
42804|NCT00976508|Drug|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
42805|NCT00976508|Drug|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
42806|NCT00976521|Drug|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
42807|NCT00976521|Other|No local infusion|Intervention without local infusion
42808|NCT00976521|Procedure|Thrombus aspiration|Thrombus aspiration
42809|NCT00023686|Radiation|radiation|
42810|NCT00976534|Drug|AZD1386|90 mg, capsules, oral, during 3 weeks
42811|NCT00969345|Other|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
42812|NCT00969345|Other|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
42813|NCT00969371|Device|posterior chamber IOL implantation|
42814|NCT00969371|Device|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
42815|NCT00969384|Behavioral|Active awareness/Lifestyle counseling|Intervention (active awareness):
In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided.
42434|NCT00985062|Procedure|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
42435|NCT00985088|Biological|GSK2340274A|one or two intramuscular injections
42436|NCT00985088|Biological|GSK2340273A|one or two intramuscular injections
42437|NCT00985088|Biological|Saline placebo|One injection
42438|NCT00985114|Device|EndoBarrier|EndoBarrier implant
42439|NCT00024206|Other|laboratory biomarker analysis|Correlative studies
42440|NCT00985114|Behavioral|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
42441|NCT00985127|Drug|placebo|administered daily for 21 days
42442|NCT00985127|Drug|BCX4208|Administered daily for 21 days.
42443|NCT00985140|Device|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
42444|NCT00985153|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A Single 0.5 mL subcutaneous injection at Day 0
42445|NCT00985153|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 0
42446|NCT00985153|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 0
42447|NCT00985166|Biological|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
42448|NCT00985166|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
42449|NCT00985166|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
42450|NCT00024206|Other|pharmacological study|Correlative studies
42451|NCT00985166|Biological|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
42452|NCT00985179|Behavioral|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
42453|NCT00985192|Drug|everolimus|
42878|NCT00974441|Drug|Divalproex Sodium|500 mg Extended Release Tablet
42879|NCT00974441|Drug|Depakote®|500 mg Extended Release Tablet
42880|NCT00974454|Drug|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
42881|NCT00023439|Other|Nucleic Acid Amplification Methods for diagnosis|no intervention
42882|NCT00974454|Drug|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
42883|NCT00974467|Behavioral|After The Injury website|Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
42884|NCT00974467|Other|Control|Usual hospital care provided.
42885|NCT00974480|Other|Redermic|Cosmetic cream formulation 609637 43.
42886|NCT00974480|Drug|Tretinoin (Rejuva-A)|Tretinoin 0.025% cream.
42887|NCT00976534|Drug|Placebo|capsules, oral, during 3 weeks
42888|NCT00976560|Drug|GW856553|Wet granulated tablets, film coated white, 9mm round, biconvex, plain faced, containing 2.5 mg of GW856553
43228|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system
43229|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
43230|NCT00974922|Drug|aliskiren (Tekturna)|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
43231|NCT00974922|Dietary Supplement|cholecalciferol (Vitamin D3)|3,000 I.U. once daily for 6 weeks.
43232|NCT00023530|Drug|voriconazole|
43233|NCT00974922|Dietary Supplement|Placebo|Placebo
43234|NCT00974935|Drug|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
43235|NCT00974935|Biological|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
42664|NCT00978393|Drug|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
42665|NCT00978419|Drug|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
42666|NCT00978419|Drug|Placebo|Placebo administered every day for up to 28 days
42667|NCT00978432|Drug|RAD001|10 mg/day for Part 1 of the trial
42668|NCT00000872|Drug|Abacavir sulfate|
42669|NCT00023842|Biological|BCG vaccine|
42670|NCT00978432|Drug|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
42671|NCT00978432|Drug|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
42672|NCT00973986|Drug|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
42673|NCT00973999|Drug|Botulinum Toxin|Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.
Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle.
42674|NCT00974012|Drug|Divalproex Sodium|500 mg ER Tablet
42675|NCT00974012|Drug|Depakote®|500 mg ER Tablet
42676|NCT00974025|Drug|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
42677|NCT00974025|Drug|Placebo|Placebo will be administered twice daily for four weeks
42678|NCT00974038|Behavioral|psychotherapy|1) cognitive-behavioral therapy or 2) supportive psychotherapy
42679|NCT00974051|Drug|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
42680|NCT00974051|Other|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
42955|NCT00972179|Drug|AMG 157 Placebo|A total of 12 subjects will be receiving multiple doses of AMG 157 placebo. Each subject enrolled in cohorts 1-3 will receive three SC doses; each subject enrolled in cohort 4 will receive six SC doses; each subject enrolled in cohort 5 will receive 12 SC doses; and each subject enrolled in cohort 6 will receive three IV doses throughout the study period of 169 days.
42816|NCT00000868|Biological|MF59|
42817|NCT00022737|Procedure|umbilical cord blood transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
42818|NCT00969397|Drug|Topical Antiangiogenic|Topical Antiangiogenic
42819|NCT00969397|Device|Pulsed Dye Laser|Pulsed Dye Laser
42820|NCT00969410|Biological|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
42821|NCT00969423|Device|5mm videoscope|use of 5mm videoscope
42822|NCT00969423|Device|10mm videoscope|use of 10mm videoscope
43164|NCT00977158|Procedure|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
43165|NCT00977171|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
43166|NCT00977184|Procedure|50 HZ Repetitive TMS|
43167|NCT00977184|Procedure|Sham rTMS|
43168|NCT00977197|Drug|Pregabalin (Lyrica)|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
43169|NCT00977197|Drug|Placebo|A matching placebo will be administered twice a day
43170|NCT00977210|Drug|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
43171|NCT00977223|Drug|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
43172|NCT00023738|Drug|doxorubicin hydrochloride|
43173|NCT00977236|Device|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
43174|NCT00977236|Device|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
43175|NCT00977249|Behavioral|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
43176|NCT00977249|Drug|varenicline|
43177|NCT00977249|Drug|placebo|
42454|NCT00985192|Other|laboratory biomarker analysis|
42455|NCT00985205|Dietary Supplement|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs or TID if po.
42738|NCT00971789|Drug|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
42739|NCT00971789|Other|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
42740|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
42741|NCT00000870|Drug|Indinavir sulfate|
42742|NCT00023218|Drug|Efavirenz|
42743|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
42744|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
42745|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
42746|NCT00971815|Drug|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
42747|NCT00971815|Drug|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
42748|NCT00971841|Drug|Paclitaxel|
42749|NCT00971854|Procedure|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
42750|NCT00971867|Drug|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
42751|NCT00971880|Other|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
42752|NCT00971893|Drug|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
42753|NCT00023231|Drug|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
42754|NCT00971906|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant,or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups
42755|NCT00971919|Other|questionnaire administration|
43236|NCT00974948|Procedure|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
43237|NCT00974961|Drug|bupivacaine, levobupivacaine|intrathecal injection 15~20mg(for Levobupivacaine) or 10~15mg(for Bupivacaine) once
43238|NCT00974974|Drug|IPX066|extended-release carbidopa-levodopa capsules
43239|NCT00974974|Drug|IR CD-LD|immediate-release carbidopa-levodopa capsules
43240|NCT00974987|Radiation|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
43241|NCT00974987|Radiation|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
43242|NCT00974987|Drug|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
43243|NCT00023530|Procedure|bone marrow transplant|
43244|NCT00975000|Drug|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
43245|NCT00975000|Drug|Placebo|Administered orally following the same dosing regimen as the experimental arm.
43246|NCT00975026|Procedure|Massages ± Stretches|Chair Massage
42288|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
42289|NCT00980330|Drug|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
42290|NCT00980330|Drug|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
42291|NCT00023959|Biological|filgrastim|Given subcutaneously
42292|NCT00980343|Drug|vismodegib|Given orally
42293|NCT00980343|Procedure|therapeutic conventional surgery|Undergo surgery
42294|NCT00980343|Other|laboratory biomarker analysis|Correlative studies
42295|NCT00980356|Drug|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
42296|NCT00980382|Drug|S-1, Docetaxel|Phase I study
S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14
Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8
Phase II study
S-1 (80mg/m2/day) q 12 hours po Days 1-14
Docetaxel (35 mg/m2) iv : Days 1, 8
42956|NCT00972179|Drug|AMG 157|A total of 36 subjects will be receiving multiple doses of AMG 157 (dose escalating by cohort). Each subject enrolled in cohorts 1-3 will receive three SC doses; each subject enrolled in cohort 4 will receive six SC doses; each subject enrolled in cohort 5 will receive 12 SC doses; and each subject enrolled in cohort 6 will receive three IV doses throughout the study period of 169 days.
42957|NCT00972192|Behavioral|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
42958|NCT00023231|Drug|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
42959|NCT00974493|Drug|Antibiotics|The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.
42960|NCT00974506|Other|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
42961|NCT00974506|Other|Routine care therapy|Routine care therapy by general practitioner
42962|NCT00974519|Drug|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
42963|NCT00974519|Drug|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
42964|NCT00023452|Drug|RPT + INH once weekly for 3 months given by DOT|Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons > 50.0 kg. For persons < 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.
PLUS
Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if > 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2—11 years old.
Therapy will be given by Directly Observed Therapy (DOT).
42965|NCT00974519|Drug|Placebo|Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
42966|NCT00974532|Dietary Supplement|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
42967|NCT00974532|Dietary Supplement|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
42968|NCT00974558|Device|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
42969|NCT00974571|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
42970|NCT00974571|Drug|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
43178|NCT00977262|Other|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
43179|NCT00970099|Behavioral|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
43180|NCT00970099|Behavioral|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
43181|NCT00970112|Procedure|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
43182|NCT00970125|Behavioral|video|outline of the goals of care
43183|NCT00970138|Drug|apatinib tablet|A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
42223|NCT00982644|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
42224|NCT00982644|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
42225|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
42226|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
42227|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
42228|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
42229|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
42230|NCT00024102|Drug|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
42231|NCT00982657|Drug|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
42232|NCT00982696|Biological|Opioid Growth Factor|250ug per kilogram weekly IV infusions
42233|NCT00982709|Behavioral|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
42234|NCT00982722|Drug|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
42756|NCT00971919|Procedure|assessment of therapy complications|
42757|NCT00971919|Procedure|psychosocial assessment and care|
42758|NCT00971919|Procedure|quality-of-life assessment|
42759|NCT00971932|Drug|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
43024|NCT00972231|Other|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
43025|NCT00972244|Drug|Dapagliflozin|once daily, 12 weeks
43026|NCT00972244|Drug|Placebo|once daily, 12 weeks
43027|NCT00972257|Drug|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
43028|NCT00972257|Drug|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
43029|NCT00023231|Drug|Lipitor|Oral tablet taken daily
43030|NCT00972270|Device|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
43031|NCT00972270|Device|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
43032|NCT00972283|Drug|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
43033|NCT00972283|Drug|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
43034|NCT00972283|Drug|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
43035|NCT00972296|Device|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
43036|NCT00972309|Biological|TARP peptide vaccine|TARP peptides administered every 3 weeks for 5 vaccinations with a booster dose at weeks 48 and 96
43037|NCT00972309|Biological|TARP dendritic cell vaccine|TARP pulsed dendritic cells administered every 3 weeks for 5 vaccinations with a booster dose at weeks 48 and 96
43038|NCT00972322|Drug|MK-8245|MK-8245 50 mg twice daily for 28 days
43039|NCT00972322|Drug|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
42297|NCT00980395|Drug|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
42298|NCT00980395|Drug|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
42299|NCT00980395|Drug|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
42300|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
42301|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
42302|NCT00023959|Other|laboratory biomarker analysis|Correlative studies
42303|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
42304|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
42305|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
42306|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
42307|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
42308|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
42309|NCT00980421|Dietary Supplement|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
42310|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
42600|NCT00981136|Procedure|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
42601|NCT00983268|Procedure|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
42602|NCT00983281|Drug|Fluid resuscitation|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
42603|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
42604|NCT00983294|Drug|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
42605|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
43306|NCT00972621|Device|Vitrax II|Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
43307|NCT00972621|Device|Viscoat|Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
43308|NCT00972634|Other|computer-assisted intervention|symptom assessment
43309|NCT00972634|Other|questionnaire administration|Symptom assessment
43310|NCT00972634|Procedure|assessment of therapy complications|Symptom assessment
43311|NCT00972634|Procedure|quality-of-life assessment|Symptom assessment
43312|NCT00972647|Procedure|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
43313|NCT00972660|Biological|Mesenchymal stem cell (MSC)|Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
43314|NCT00972660|Drug|Prednisone and cyclosporine or primary therapies|Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus
Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)
43315|NCT00972673|Drug|Placebo|comparator
43316|NCT00023244|Drug|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
43317|NCT00975052|Drug|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
43318|NCT00975052|Drug|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
43319|NCT00975052|Drug|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
43320|NCT00975065|Drug|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
43321|NCT00975065|Drug|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
43322|NCT00023530|Drug|thalidomide|
42235|NCT00982722|Drug|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
42236|NCT00982748|Behavioral|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
42237|NCT00982774|Biological|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
42238|NCT00982787|Drug|Botanical extract from Passiflora incarnata|Dosage form: Liquid Passiflora extract
Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)
Frequency: Once/Twice a day
Duration: 11 week intervention period
42239|NCT00984750|Drug|acetyl-L-carnitine/statin (simvastatin)|acetyl-L-carnitine: 4 tablets of 500 mg a day
simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
42240|NCT00984750|Drug|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
42241|NCT00984763|Biological|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
42242|NCT00024193|Drug|melphalan|
42243|NCT00984776|Other|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
42540|NCT00985283|Behavioral|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
42541|NCT00985283|Behavioral|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
42542|NCT00985322|Drug|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
42543|NCT00985322|Drug|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
42544|NCT00985335|Other|Neem Based External Application Cream|Apply externally 3-4 times per day
42545|NCT00024245|Drug|pralatrexate|
42546|NCT00985348|Drug|Levetiracetam (Keppra)|Test Drug :
Levetiracetam dry syrup
Reference Drug :
500 mg oral tablets of Levetiracetam. Frequency: Single Dose
42547|NCT00985361|Dietary Supplement|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
42548|NCT00985361|Dietary Supplement|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
43040|NCT00023244|Drug|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
43041|NCT00972335|Drug|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
43042|NCT00972335|Drug|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
43043|NCT00974584|Drug|pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 of every 3-week cycle.
43044|NCT00974597|Device|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
43382|NCT00970619|Device|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
43383|NCT00972673|Drug|GW685698X|Inhaled steroid
43384|NCT00972686|Drug|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
43385|NCT00972699|Behavioral|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
43386|NCT00972712|Drug|Bortezomib and Tipifarnib|Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)
Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)
Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)
Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)
Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)
Schema B
Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)
Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)
43387|NCT00972725|Biological|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
43388|NCT00972725|Drug|Chloroquine|One dose of 300 mg
43389|NCT00972738|Drug|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
43390|NCT00972738|Drug|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
43391|NCT00972738|Drug|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
43392|NCT00972777|Drug|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
42606|NCT00983307|Other|Erlotinib plus hypofractionated radiotherapy|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
42607|NCT00983320|Drug|quetiapine|flexible dosage (50 to 300 mg)
42608|NCT00024128|Drug|cyclophosphamide|
42609|NCT00983320|Drug|placebo|placebo
42610|NCT00983333|Device|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
42611|NCT00983346|Drug|Bortezomib|Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.
Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle.
42612|NCT00983359|Radiation|stereotactic radiosurgery|
42613|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
42614|NCT00983372|Drug|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
42615|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
42616|NCT00983385|Drug|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.
42617|NCT00983385|Other|Observation period|Eligibilty assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
42889|NCT00976560|Drug|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
42890|NCT00976560|Other|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
42891|NCT00976573|Biological|bevacizumab|Given IV
42892|NCT00976573|Drug|carboplatin|Given IV
42893|NCT00976573|Drug|everolimus|Given orally
42894|NCT00976573|Drug|paclitaxel|Given IV
43323|NCT00975078|Procedure|adrenal insufficiency testing|On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.
All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.
Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.
On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol.
42377|NCT00977977|Drug|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
42378|NCT00978016|Drug|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
42379|NCT00023790|Drug|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
42380|NCT00978016|Drug|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
42381|NCT00978016|Drug|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
42382|NCT00978016|Drug|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
42383|NCT00978016|Drug|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
42384|NCT00978016|Drug|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
42385|NCT00978029|Drug|Placebo|Placebo sublingual tablet, once daily
42386|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
42387|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
42388|NCT00978042|Device|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
42389|NCT00980460|Other|Laboratory Biomarker Analysis|Correlative studies
42390|NCT00980460|Procedure|Liver Transplantation|Undergo liver transplant
42391|NCT00980460|Drug|Temsirolimus|Given IV
42549|NCT00985374|Drug|RAD001|5mg or 10mg po daily
42550|NCT00985374|Drug|RG1507|16mg/kg iv every 3 weeks
42551|NCT00985387|Drug|Solifenacin|oral
42552|NCT00985400|Behavioral|Exercise Program|Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day
42553|NCT00985400|Behavioral|Telephone-based intervention|Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.
42554|NCT00985400|Other|Counseling intervention|Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.
42555|NCT00023829|Drug|flutamide|
42556|NCT00978198|Drug|Placebo|oral
42557|NCT00978211|Drug|DOTA-TOC Treatment|Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of
renal toxicity
loss of patient transferability or
denial of further treatment.
42558|NCT00978224|Dietary Supplement|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
42559|NCT00978224|Dietary Supplement|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
42560|NCT00978237|Drug|EFV|one pill QD VO.
42561|NCT00978237|Drug|LPV/r|2 pills QD VO
42823|NCT00969436|Biological|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
42824|NCT00969436|Biological|Priorix™|Subcutaneous injection
42825|NCT00969436|Biological|Varilrix™|Subcutaneous injection
42826|NCT00969449|Drug|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
42827|NCT00969449|Drug|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
42828|NCT00022737|Radiation|radiation therapy|Undergo radiation therapy
42829|NCT00969462|Drug|Doxorubicin|measurements of serum Doxorubicin levels
42830|NCT00969475|Device|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
43393|NCT00023283|Drug|Buprenorphine|Experimental Standard Medical Management with once-weekly medication dispensing
Experimental Standard Medical Management with thrice-weekly medication dispensing
Experimental Enhanced Medical Management with thrice-weekly medication dispensing
43394|NCT00972777|Drug|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
43395|NCT00972790|Procedure|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
43396|NCT00972803|Drug|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
42130|NCT00982592|Drug|leucovorin calcium|Given IV
42131|NCT00982592|Drug|fluorouracil|Given IV
42132|NCT00982592|Other|placebo|Given PO
42133|NCT00982592|Drug|vismodegib|Given PO
42134|NCT00982592|Other|laboratory biomarker analysis|Correlative studies
42135|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
42136|NCT00984633|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
42137|NCT00984633|Drug|Propofol|4-10 mg/kg/hr maintenance anesthesia
42138|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42139|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42140|NCT00024193|Drug|doxorubicin hydrochloride|
42141|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42142|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42143|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42144|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42895|NCT00976599|Drug|CP-690,550 + methotrexate|CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
42896|NCT00000871|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
42897|NCT00023699|Drug|gefitinib|
42898|NCT00976599|Drug|Placebo + Methotrexate|Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
42899|NCT00976612|Drug|Nilotinib|Nilotinib 400mg bid daily
42900|NCT00976625|Procedure|Aortic Valve Replacement|Surgical valve replacement of the aorta
42901|NCT00976638|Other|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
42902|NCT00976638|Other|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
42903|NCT00976651|Drug|human menopausal gonadotropin|200 IU per day in the late follicular phase
42904|NCT00976664|Device|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
42905|NCT00976664|Device|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
42906|NCT00976677|Drug|erlotinib hydrochloride|Given PO
42907|NCT00976677|Drug|paclitaxel|Given IV
42908|NCT00023712|Drug|bortezomib|Given IV
42909|NCT00976677|Drug|carboplatin|Given IV
42910|NCT00976677|Biological|bevacizumab|Given IV
42911|NCT00976690|Drug|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
42912|NCT00976703|Other|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
43247|NCT00975039|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
43248|NCT00975052|Drug|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
42392|NCT00980460|Procedure|Therapeutic Conventional Surgery|Undergo surgery
42393|NCT00980460|Drug|Vincristine Sulfate|Given IV
42394|NCT00980473|Procedure|Argon Laser Iridoplasty|
42395|NCT00023972|Drug|gemcitabine hydrochloride|
42396|NCT00980473|Drug|Travatan/ Timolol/Azopt|
42397|NCT00980512|Behavioral|Parent Training|16 weeks of parent training led by trained group facilitator
42681|NCT00974051|Other|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
42682|NCT00023400|Drug|Nelfinavir|
42683|NCT00974077|Behavioral|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
42684|NCT00974077|Other|Waiting List Control|Patients receive MBCT with a delay of 6 months.
42685|NCT00974090|Drug|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
42686|NCT00974090|Drug|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
42687|NCT00974103|Other|exercise advise|Exercises
42688|NCT00974103|Other|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
42689|NCT00974116|Behavioral|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
42690|NCT00974116|Behavioral|Control Group|No intervention
42691|NCT00974142|Drug|Cyclosporine|The study population (n=30) will be divided into two patient cohorts intended to receive cyclosporine at an initial dosing of 3.0 mg/kg/day or placebo, in a randomized ratio of 1:1.
42692|NCT00974142|Drug|Placebo|The study population (n=30) will be divided into two patient cohorts intended to receive cyclosporine at an initial dosing of 3.0 mg/kg/day or placebo, in a randomized ratio of 1:1.
42693|NCT00023400|Drug|Rifabutin|
42694|NCT00974155|Drug|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
42831|NCT00969488|Other|High protein diet|INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.
The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats).
42832|NCT00969501|Drug|EUFLEXXA|2.5 mL of EUFLEXXA (per injection) x 3 injections
42833|NCT00969527|Dietary Supplement|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
42834|NCT00969527|Dietary Supplement|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
42835|NCT00969540|Device|Active Mattress Cover|Active Mattress Cover
42836|NCT00969540|Device|Placebo Mattress Cover|Placebo Mattress Cover
42837|NCT00971945|Drug|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
42838|NCT00971958|Procedure|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
42839|NCT00023231|Drug|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
42840|NCT00971958|Device|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
42841|NCT00971958|Device|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
42842|NCT00971958|Device|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
42843|NCT00971971|Procedure|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
42844|NCT00971971|Procedure|Standard SLED|
42845|NCT00971984|Other|Medical records summary|Summary of Medical files and laboratory results.
43184|NCT00022828|Device|3-D Laser Imaging Device|
43185|NCT00970177|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
43186|NCT00970203|Biological|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
43187|NCT00970203|Biological|DC1 vaccine|3-5 x 10e6 cells total
43188|NCT00970216|Drug|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
42145|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42146|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42147|NCT00984646|Drug|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
42148|NCT00984659|Drug|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
42149|NCT00984659|Drug|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
42150|NCT00984659|Drug|Placebo|Placebo DISKUS twice a day for 8 weeks
42151|NCT00024193|Drug|etoposide|
42152|NCT00984698|Behavioral|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
41137|NCT00021112|Drug|cisplatin|
41138|NCT00952198|Drug|ARRY-403, glucokinase activator; oral|multiple dose, escalating
41139|NCT00952198|Drug|Placebo; oral|matching placebo
41140|NCT00952211|Device|CPAP|CPAP at therapeutic pressure during nighttime
41141|NCT00952211|Device|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
41142|NCT00952224|Other|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
41143|NCT00952237|Drug|GM-CSF|GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.
G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis.
41144|NCT00952237|Drug|IL-2|IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.
Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).
Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above
41145|NCT00952250|Behavioral|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
41146|NCT00952250|Behavioral|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
43249|NCT00977392|Behavioral|compliance monitoring|
43250|NCT00977392|Other|cervical Papanicolaou test|
43251|NCT00977392|Other|educational intervention|
43252|NCT00977392|Other|screening questionnaire administration|
43253|NCT00977392|Other|survey administration|
43254|NCT00977392|Procedure|colposcopy|
43255|NCT00977405|Device|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
43256|NCT00977418|Behavioral|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
43257|NCT00977418|Other|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
43258|NCT00977431|Drug|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
43259|NCT00023738|Radiation|radiation therapy|
43260|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
43261|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
43262|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
43263|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
43264|NCT00977444|Drug|kondrium|intraarticular injections once month
43265|NCT00977444|Drug|kondrium f|intraarticular injections once month
43266|NCT00977444|Drug|methyl prednisolone (corticosteroid)|intraarticular injections once month
43267|NCT00977457|Genetic|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
43268|NCT00977457|Genetic|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
42311|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
42312|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
42695|NCT00976235|Device|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
42696|NCT00023673|Drug|carboplatin|
42697|NCT00976248|Drug|RAD001|Taken orally once a day
42698|NCT00976261|Drug|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
42699|NCT00976261|Drug|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
42700|NCT00976261|Other|Placebo|Comparator
42701|NCT00976274|Dietary Supplement|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
42702|NCT00976274|Dietary Supplement|starch|5 capsules three times everyday for 12 weeks
42971|NCT00974571|Drug|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
42972|NCT00974584|Drug|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\n\n\n\n\n\n
42973|NCT00974584|Drug|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
42974|NCT00974584|Drug|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter*minute (mg/mL*min).\n
42975|NCT00000870|Drug|Didanosine|
42976|NCT00023452|Drug|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
42977|NCT00974584|Drug|cisplatin|Cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of every 3-week cycle.\n
42978|NCT00974584|Drug|paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of every 3-week cycle.\n\n
42979|NCT00976716|Drug|Celecoxib|Day 1
The first dose: Celecoxib 400mg
The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed
Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)
- Celecoxib 200mg twice daily
42980|NCT00976729|Drug|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
42981|NCT00976729|Drug|NOX-E36|single SC doses, at safe and tolerable dose level
42982|NCT00976729|Drug|Placebo|
43189|NCT00970229|Drug|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not > 10% of 8 mCi limit)of [123I]MNI-420, followed by SPECT imaging.
43190|NCT00970255|Procedure|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
43191|NCT00970255|Procedure|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
43192|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
43193|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
43194|NCT00970281|Drug|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
43195|NCT00022841|Drug|Pamidronate|
43196|NCT00970281|Drug|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
43197|NCT00970294|Behavioral|Health Promotion Program|10 week health promotion program 3-4 times per week
43198|NCT00970307|Biological|GSK2202083A vaccine|Intramuscular, three doses
43199|NCT00970307|Biological|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
43200|NCT00970307|Biological|Infanrix hexa™|Intramuscular, three doses
43201|NCT00970307|Biological|Menjugate®|Intramuscular, two doses
43202|NCT00023244|Drug|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
43203|NCT00972413|Radiation|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
43204|NCT00972426|Drug|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
42244|NCT00984789|Drug|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
42245|NCT00984789|Drug|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
42246|NCT00984802|Drug|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
41147|NCT00952263|Biological|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
41148|NCT00021112|Drug|etoposide|
41149|NCT00954824|Biological|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
41150|NCT00954837|Procedure|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
41151|NCT00954876|Drug|capecitabine and cetuximab|Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks
Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks
41152|NCT00954889|Drug|tamsulosin|Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
41153|NCT00954889|Drug|placebo|(tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
41464|NCT00983853|Drug|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
41465|NCT00983866|Behavioral|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
41466|NCT00983892|Behavioral|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
41467|NCT00024154|Other|laboratory biomarker analysis|Correlative studies
41468|NCT00983905|Drug|Theophylline|single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
41469|NCT00983905|Drug|Colchicine|one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
41470|NCT00983918|Drug|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
41471|NCT00983918|Drug|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
42313|NCT00023972|Drug|exatecan mesylate|
42314|NCT00980460|Drug|Cisplatin|Given IV
42315|NCT00980460|Drug|Doxorubicin Hydrochloride|Given IV
42316|NCT00980460|Drug|Fluorouracil|Given IV
42317|NCT00980460|Drug|Irinotecan Hydrochloride|Given IV
42318|NCT00982800|Drug|Gabapentin|200mg 3x/day for 3 days (9 doses total)
42319|NCT00982800|Drug|Placebo Sugar Pill|
42320|NCT00024115|Drug|BL22 immunotoxin|
42321|NCT00982813|Other|Periodontal screening|Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.
Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction.
42322|NCT00982826|Drug|ABT-072|See Arms information for a detailed description.
42323|NCT00982826|Drug|Placebo|See Arms information for a detailed description.
42324|NCT00982839|Procedure|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
42325|NCT00982839|Procedure|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
42326|NCT00982865|Drug|MSC1936369B|MSC1936369B at escalating dose levels. Number of cycles: until progression or unacceptable toxicity develops
42327|NCT00982865|Drug|MSC1936369B|MSC1936369B at escalating doses levels. Number of cycles: until progression or unacceptable toxicity develops
42328|NCT00982865|Drug|MSC1936369B|MSC1936369B at escalating doses levels. Number of cycles: until progression or unacceptable toxicity develops
42329|NCT00982865|Drug|MSC1936369B|MSC1936369B at escalating doses levels. Number of cycles: until progression or unacceptable toxicity develops
42330|NCT00982878|Drug|Maraviroc|150mg twice daily
42331|NCT00000873|Drug|Infant Formula|
42332|NCT00024115|Procedure|antibody therapy|
42333|NCT00982891|Drug|Opioid (morphine sulphate) in low dose|individualized titration
42334|NCT00982904|Drug|Fexinidazole/Placebo|
42983|NCT00976742|Behavioral|Endurance exercise training|
42984|NCT00023712|Other|laboratory biomarker analysis|Correlative studies
42985|NCT00976755|Drug|everolimus|Everolimus:
10mg daily
42986|NCT00976768|Drug|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
42987|NCT00976794|Drug|lithium plus carbamazepine|Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.
Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability
42988|NCT00976794|Drug|lithium plus valproate|Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.
Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability.
43324|NCT00975078|Drug|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
43325|NCT00975091|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
43326|NCT00975091|Drug|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
43327|NCT00975104|Drug|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
43328|NCT00975104|Drug|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
43329|NCT00975104|Drug|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
43330|NCT00975104|Drug|Placebo|Placebo IV QW
43331|NCT00975117|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
43332|NCT00975117|Dietary Supplement|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
43333|NCT00023530|Drug|dexamethasone|
43334|NCT00975130|Biological|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
43335|NCT00975130|Biological|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
43336|NCT00975143|Drug|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
43337|NCT00975143|Drug|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
42247|NCT00984802|Drug|Placebo control|Vehicle solution for IV administration single dose.
42248|NCT00984815|Drug|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
42249|NCT00984828|Drug|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
42250|NCT00984841|Other|Tailored letter|
42251|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
42252|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
42253|NCT00000875|Drug|Lymphocytes, Activated|
42254|NCT00024193|Drug|vincristine sulfate|
42255|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
42256|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
42257|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
42258|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
42259|NCT00984854|Drug|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
42260|NCT00984867|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
42261|NCT00984867|Drug|Placebo|Matching placebo tablet
42262|NCT00984880|Drug|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
42263|NCT00984893|Drug|zoledronic acid|
42264|NCT00984893|Drug|Any oral bisphosphonates marketed in Canada|
42265|NCT00024193|Procedure|conventional surgery|
42266|NCT00977795|Drug|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
42267|NCT00000871|Biological|rgp120/HIV-1 SF-2|
41472|NCT00983918|Drug|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
41473|NCT00983918|Drug|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
41474|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
41475|NCT00983931|Drug|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
41476|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
41477|NCT00983944|Biological|bleomycin sulfate|Given IV
41478|NCT00024167|Drug|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
41479|NCT00985933|Drug|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
41480|NCT00985933|Drug|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
41481|NCT00985946|Drug|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
41796|NCT00986895|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
41797|NCT00023894|Drug|alvocidib|
41798|NCT00979550|Drug|non-medicated petroleum cream|.5 oz cream nightly to the affected area
41799|NCT00979563|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
41800|NCT00979576|Drug|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m2
41801|NCT00979576|Drug|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m2
41802|NCT00979576|Drug|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m2
41803|NCT00979576|Drug|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m2
41804|NCT00979576|Drug|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m2
42618|NCT00983385|Drug|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR Participants were not permitted to exceed 500 mg of Tapentadol per day.
42619|NCT00024128|Drug|cyclosporine|
42620|NCT00983398|Drug|Melphalan|intra-arterial
Dose Level / Dose
4 mg/m2 daily X 2 days (8 mg/m2/course)
6 mg/m2 daily X 2 days (12 mg/m2/course)
8 mg/m2 daily X 2 days (16 mg/m2/course)
10 mg/m2 daily X 2 days (20 mg/m2/course)
42621|NCT00983398|Drug|Carboplatin|intra-arterial 200mg/m2/day x 2 days
42622|NCT00985400|Other|Questionnaire administration|
42623|NCT00024245|Drug|probenecid|
42624|NCT00985400|Behavioral|Relaxation Program|Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
42625|NCT00985426|Biological|HEPLISAV|Intramuscular (IM) injections on Weeks 0, 4, and 24; placebo (saline) injection at Week 8
42626|NCT00985426|Biological|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
42627|NCT00985439|Drug|Diclofenac Test (lower dose)|18-mg Single dose
42628|NCT00985439|Drug|Diclofenac Test (upper dose)|35-mg Single dose
42629|NCT00985439|Drug|Celecoxib 400 mg|Capsules 2 x 200 mg Single-dose
42630|NCT00985439|Drug|Placebo|Capsules 2 Single-dose
42631|NCT00985452|Other|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
42632|NCT00985452|Other|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
42633|NCT00985465|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
42634|NCT00024258|Drug|arsenic trioxide|
42635|NCT00985478|Drug|SLV342|25 mg once daily - Maximal Tolerated Dose
42636|NCT00985478|Drug|placebo|matching placebo
42637|NCT00985491|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
42638|NCT00985504|Drug|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
43338|NCT00975156|Other|Physical Therapy|Conventional physical therapy
43339|NCT00975156|Device|Lokomat|Robotic-assisted walking device
43340|NCT00975182|Drug|GDC-0941|Oral repeating dose
43341|NCT00975182|Drug|erlotinib HCl|Oral repeating dose
43342|NCT00023725|Radiation|radiation therapy|
43343|NCT00977002|Other|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
43344|NCT00977002|Other|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
43345|NCT00977015|Drug|Treatment A|Inhaled, 750/150, single dose
43346|NCT00977015|Drug|Treatment B|Inhaled, 750/150, single dose
42398|NCT00980538|Drug|Etravirine|Dosed by weight up to a maximum dose of 200 mg bid until accessed by other means
42399|NCT00980551|Drug|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
42400|NCT00980551|Drug|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
42401|NCT00980551|Drug|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
42402|NCT00980551|Drug|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
42403|NCT00980577|Device|NUUS|Sonosite Micro Maxx
42404|NCT00980590|Device|Airway scope intubation tube|comparison of intubation speed
42405|NCT00980603|Drug|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
42406|NCT00000872|Drug|Lamivudine|
42407|NCT00023985|Biological|autologous tumor cell vaccine|
42408|NCT00980603|Drug|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
42562|NCT00978250|Drug|5-Fluoro-2-Deoxycytidine (FdCyd)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the AUC of the pare compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into DNA and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNM and in turn DNA methylation,can result in the re-expression of tumor suppressor genes.
42563|NCT00978250|Drug|Tetrahydrouridine (THU)|
42564|NCT00978263|Drug|metformin-based Oral Antidiabetic Drugs|
42565|NCT00978263|Drug|Glargine|
42566|NCT00023829|Drug|releasing hormone agonist therapy|
42567|NCT00978302|Drug|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
42568|NCT00978302|Drug|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
42569|NCT00978302|Drug|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
42570|NCT00978302|Drug|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
42571|NCT00978302|Drug|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
42572|NCT00978302|Drug|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
42573|NCT00978302|Drug|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
42574|NCT00978315|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
42575|NCT00978315|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
42576|NCT00978328|Drug|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
42577|NCT00023829|Procedure|adjuvant therapy|
42578|NCT00978341|Drug|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
42579|NCT00978341|Drug|Placebo for pregabalin|Placebo capsules BID for 7.5 days
42580|NCT00978354|Drug|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
42581|NCT00980954|Drug|paclitaxel|Given IV
41805|NCT00979589|Drug|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
41806|NCT00979589|Drug|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
41807|NCT00979602|Biological|GSK2340274A|One intramuscular injection
41808|NCT00023907|Drug|paclitaxel|
41809|NCT00979602|Biological|GSK2340273A|One intramuscular injection
41810|NCT00979615|Drug|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
41811|NCT00979615|Drug|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
41812|NCT00979628|Drug|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
41813|NCT00979628|Drug|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
41814|NCT00979628|Drug|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
41815|NCT00979641|Drug|bevacizumab plus docetaxel|i.v. bevacizumab 10 mg/kg and docetaxel 50 mg/square meter, q2w
41816|NCT00979654|Drug|Sifalimumab|IV-600 mg
41817|NCT00979667|Drug|Oseltamivir|75 mg twice daily for 5 days
42153|NCT00984698|Behavioral|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
42154|NCT00984724|Behavioral|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
42155|NCT00984724|Behavioral|Telephone Counseling|MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period
MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period
42156|NCT00984724|Behavioral|Quitline|Letter referring participants to a Quitline providing quit smoking services.
42157|NCT00984724|Behavioral|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
42158|NCT00984737|Drug|Insulin|Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.
Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection.
42639|NCT00985504|Drug|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
42640|NCT00985517|Biological|CERE-120: Adeno-Associated Virus Delivery of Neurturin|CERE-120 2.4 X 10^12 vg
42913|NCT00976703|Other|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
42914|NCT00969553|Drug|BI 6727|Dose level 1
42915|NCT00969566|Drug|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
42916|NCT00022750|Behavioral|Nurse Case Manager and Community Health Worker Team|
42917|NCT00969592|Drug|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
42918|NCT00969592|Drug|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
42919|NCT00969605|Procedure|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
42920|NCT00969618|Drug|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
42921|NCT00969631|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
42922|NCT00969631|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
42923|NCT00969644|Drug|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
42924|NCT00969644|Drug|Pegvisomant|s.c. injections once daily (10-15 mg/day)
42925|NCT00969683|Device|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
42926|NCT00969683|Device|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
42927|NCT00022763|Drug|Enfuvirtide|
42928|NCT00969696|Drug|Placebo|8Mg a day of a sugar pill
42929|NCT00969696|Drug|Galantamine|8mg of Galantamine
42409|NCT00980603|Drug|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
42410|NCT00980616|Drug|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
42411|NCT00980629|Drug|M516102|Twice a day
42412|NCT00980629|Drug|placebo|Twice a day
42413|NCT00980642|Device|Draeger double sensor|Draeger double sensor system on the forehead (central)
Draeger double sensor system on forehead (peripheral)
Skin temperature sensor system (calf)
Skin temperature sensor system (upper arm)
42414|NCT00980655|Biological|13vPnC|0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.
Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose.
42415|NCT00983008|Behavioral|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
42416|NCT00983021|Drug|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
42703|NCT00976287|Procedure|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
42704|NCT00976287|Procedure|Conserved Therapy|Conserved Therapy
42705|NCT00976300|Drug|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
42706|NCT00976300|Drug|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
42707|NCT00023673|Drug|paclitaxel|
42708|NCT00976313|Procedure|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
42582|NCT00980967|Other|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
42846|NCT00971997|Drug|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
42847|NCT00972023|Drug|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
42848|NCT00972023|Procedure|Surgical resection|Surgical procedure of the invasive breast cancer
42849|NCT00972036|Device|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
42850|NCT00023231|Drug|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
42851|NCT00972049|Drug|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
42852|NCT00972049|Drug|Placebo|Capsule administered once orally
42853|NCT00972062|Other|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
42854|NCT00972062|Other|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
42855|NCT00972075|Drug|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
42856|NCT00972075|Drug|placebo|one tablet per day 2 hours before going to bed
42857|NCT00972088|Device|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
42858|NCT00972101|Radiation|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
42859|NCT00972101|Drug|Melphalan|140 mg/m^2 by vein over 30 minutes as a single dose on Day -8
42860|NCT00972101|Drug|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
42861|NCT00023231|Drug|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
42862|NCT00974311|Drug|Placebo|Placebo comparator
42863|NCT00974324|Drug|endostar and CHOP|endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks
CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
42159|NCT00977626|Drug|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
42160|NCT00977639|Procedure|Pathwork TOO test|
42161|NCT00977652|Procedure|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
42162|NCT00977652|Procedure|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
42163|NCT00977665|Drug|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
42164|NCT00977665|Drug|placebo|placebo tablet for 48 weeks
42165|NCT00977678|Other|open access gastroscopy|access to gastroscopy without preceding appointment
42166|NCT00977678|Other|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
42167|NCT00977691|Procedure|PBMC Transplant|
42168|NCT00023764|Drug|bortezomib|Given IV
42169|NCT00977691|Drug|Alemtuzumab (Campath )|
42170|NCT00977691|Drug|Sirolimus (Rapamune )|
42171|NCT00977691|Drug|Cyclophosphamide (Cytoxan )|
42172|NCT00977691|Procedure|Low Dose Irradiation|
42173|NCT00977704|Device|Restylane and Perlane|
42174|NCT00977730|Dietary Supplement|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
42175|NCT00977730|Dietary Supplement|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
41154|NCT00021320|Procedure|neoadjuvant therapy|
41155|NCT00954902|Dietary Supplement|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
41156|NCT00954902|Behavioral|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
41157|NCT00954902|Other|Placebo antioxidant concentrate|Placebo capsules
42930|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
42931|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
42932|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
43269|NCT00977457|Genetic|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
43270|NCT00023751|Drug|fluorouracil|
43271|NCT00977457|Genetic|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
43272|NCT00977457|Genetic|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
43273|NCT00977457|Other|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
43274|NCT00977457|Procedure|therapeutic conventional surgery|
43275|NCT00977470|Drug|Erlotinib|Taken orally once daily
43276|NCT00977470|Drug|Hydroxychloroquine|Taken orally once daily after erlotinib
43277|NCT00970320|Other|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
43278|NCT00970333|Drug|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) of [18F]-FEPPA followed by serial PET imaging
43279|NCT00970346|Drug|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
43280|NCT00970359|Biological|AZD6244|Within 1 week of starting the study: Low iodine diet
The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process.
43281|NCT00000868|Biological|rgp120/HIV-1MN|
43282|NCT00022854|Procedure|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
42709|NCT00976313|Other|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
42710|NCT00976326|Drug|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
42711|NCT00976339|Drug|Cholecalciferol|Cholecalciferol (D3) 30,000 IU weekly for 1 year
42712|NCT00976339|Drug|Cholecalciferol|Cholecalciferol (D3) 20,000 IU weekly for 1 year
42713|NCT00976352|Drug|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
42714|NCT00976352|Other|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
42715|NCT00976365|Dietary Supplement|THL-P|20ml/bottle, TID, 24weeks
42716|NCT00969150|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
42717|NCT00969150|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
42718|NCT00969163|Drug|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
42719|NCT00969163|Drug|Comparator: placebo|transdermal placebo gel for 6 weeks
42989|NCT00976807|Other|Pulmonary Rehabilitation|Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.
Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.
Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.
Each session will also include an education session where relevant.
42990|NCT00976820|Biological|GSK2340274A|Two intramuscular injections
42991|NCT00976820|Biological|GSK2340273A|Two intramuscular injections
42992|NCT00976833|Other|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
42993|NCT00976833|Other|Usual Care|Usual Physical Therapy care
42994|NCT00976846|Device|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
42864|NCT00974350|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER™-Bupivacaine/Once
42865|NCT00974350|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER™-Bupivacaine/Once
42866|NCT00974350|Drug|SABER™-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER™-Placebo/Once
43205|NCT00972439|Drug|Oral Contraceptive: Ortho-Novum® 1/35|
43206|NCT00972439|Drug|Oral Contraceptive: Ovcon Fe®|
43207|NCT00972452|Behavioral|Exercise|short period of exercise training (5-10 days)
43208|NCT00972465|Drug|Nimotuzumab and chemotherapy|Experimental: Nimotuzumab and Irinotecan
the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)
the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)
43209|NCT00972478|Drug|Cyclophosphamide|Given IV
43210|NCT00972478|Drug|Doxorubicin Hydrochloride|Given IV
43211|NCT00972478|Other|Laboratory Biomarker Analysis|Correlative studies
43212|NCT00972478|Drug|Prednisone|Given IV
43213|NCT00023244|Drug|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
43214|NCT00972478|Biological|Rituximab|Given IV
43215|NCT00972478|Drug|Vincristine Sulfate|Given IV
43216|NCT00972478|Drug|Vorinostat|Given PO
43217|NCT00972491|Procedure|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
43218|NCT00972504|Drug|GSK835726 10mg|GSK835726 10mg tablet
43219|NCT00972504|Drug|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
43220|NCT00972504|Drug|Cetirizine 10mg|Cetirizine 10mg active comparator
43221|NCT00972504|Drug|placebo|placebo to match actives
43222|NCT00972517|Biological|GSK investigational vaccine GSK2340272A|Three intramuscular injections
43223|NCT00972530|Behavioral|immobilisation in a triangular sling|Intervention group: Immobilisation 48 hours in a triangular sling (mitella)
Control group: normal activity without restrictions
41158|NCT00954915|Biological|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
41159|NCT00954941|Drug|Ondansetron|8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
41160|NCT00954941|Drug|Aprepitant|125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
41161|NCT00954954|Device|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
41162|NCT00954954|Device|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
41163|NCT00954967|Behavioral|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
41164|NCT00954993|Drug|Vaniprevir|Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
41165|NCT00021320|Radiation|radiation therapy|
41166|NCT00955006|Biological|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
41167|NCT00983398|Drug|Sodium thiosulfate|20 gm/m2 at 4 hours post carboplatin
16 gm/m2 at 8 hours post carboplatin
41168|NCT00983398|Drug|Filgrastim|5 micrograms/kg/day subcutaneous (SC) beginning 24-48 hrs after chemotherapy
41169|NCT00983398|Drug|Pegfilgrastim|6 mg SC 24-48 hrs after chemotherapy
41170|NCT00983411|Other|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
41171|NCT00983424|Drug|Cyclosporins|dose escalation, administered orally twice a day
41172|NCT00983424|Drug|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
41482|NCT00985959|Drug|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
41483|NCT00985959|Drug|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
43283|NCT00970385|Drug|CHOP21|CHOP regimen:
cyclophosphamide 750 mg/m2 intravenously (IV) day 1
doxorubicin 50 mg/m2 IV day 1
vincristine 1,4 mg/m2 (maximum 2 mg) day 1
prednisone 100 mg/m2/D from D1 to D5.
43284|NCT00970385|Drug|VIP/ABVD|VIP regimen:
etoposide 100 mg/m2/D IV from D1 to D3
ifosfamide 1000 mg/m2/D from D1 to D5
cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5
ABVD regimen:
doxorubicin50 mg/m2/D on D1 and D14
bleomycin 10 mg/m2/D
vinblastine 10 mg/m2/D
dacarbazine 375 mg/m2/D
43285|NCT00970385|Radiation|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
43286|NCT00970398|Other|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
42335|NCT00982917|Behavioral|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
42336|NCT00982917|Behavioral|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
42337|NCT00982930|Drug|Tobramycin inhalation powder|Tobramycin inhaled powder
42338|NCT00982982|Drug|THC and Iomazenil|Iomazenil: 3.7 μg/kg intravenously over 10 minutes
Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". It is administered intravenously for 10 minutes.
42339|NCT00982982|Drug|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
42340|NCT00982995|Drug|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
42341|NCT00984906|Other|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
42342|NCT00984919|Other|high performance liquid chromatography|
42343|NCT00984919|Other|laboratory biomarker analysis|
42344|NCT00984919|Other|mass spectrometry|
42345|NCT00984932|Drug|Rosuvastatin|40 mg of rosuvastatin daily
42346|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
42347|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
42348|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
38888|NCT00967629|Drug|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
38889|NCT00022659|Other|laboratory biomarker analysis|Correlative studies
38890|NCT00967642|Drug|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
38891|NCT00967655|Biological|panitumumab|
39192|NCT00022126|Drug|methylprednisolone|
39193|NCT00961298|Drug|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
39194|NCT00961311|Procedure|Percutaneous Coronary Intervention|Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
39195|NCT00961311|Device|Sprinter Legend 1.25mm Balloon Catheter|Balloon Angioplasty
39196|NCT00961324|Drug|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
39197|NCT00961324|Drug|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
39198|NCT00961337|Biological|Trivalent inactivated influenza vaccine|one dose
39199|NCT00961350|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
39200|NCT00961350|Drug|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
39201|NCT00961363|Drug|Sitagliptin|sitagliptin 100 mg per day
39202|NCT00961363|Drug|Placebo|Placebo
39203|NCT00022126|Drug|pegaspargase|
39204|NCT00961376|Biological|PBMC re-infusion|Autologous PBMC re-infusion
42783|NCT00974298|Procedure|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
42784|NCT00974311|Drug|Enzalutamide|MDV3100, 160 mg orally per day
42785|NCT00976378|Drug|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
42786|NCT00976378|Drug|NOX-A12|single IV dose, at efficacious dose level
42787|NCT00023673|Radiation|three-dimensional conformal radiation therapy|
42788|NCT00976391|Biological|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
42789|NCT00976391|Drug|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
42790|NCT00976404|Biological|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
42791|NCT00976404|Drug|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
42792|NCT00976404|Drug|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
42793|NCT00976430|Procedure|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
42794|NCT00976443|Drug|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
42795|NCT00976443|Drug|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
42796|NCT00976456|Drug|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
42797|NCT00976456|Drug|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
42798|NCT00023686|Procedure|surgery|
42799|NCT00976469|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
43149|NCT00974818|Drug|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
38420|NCT00967226|Drug|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
38421|NCT00967226|Drug|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
38422|NCT00967239|Genetic|DNA analysis|
38423|NCT00967239|Genetic|polymorphism analysis|
38424|NCT00022620|Drug|paclitaxel|
38425|NCT00967239|Other|laboratory biomarker analysis|
38426|NCT00967239|Other|pharmacogenomic studies|
38427|NCT00967252|Drug|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
38428|NCT00967252|Drug|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
38429|NCT00967252|Drug|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
38733|NCT00960544|Drug|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
38734|NCT00960557|Drug|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
38735|NCT00960570|Drug|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
38736|NCT00960570|Drug|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
38737|NCT00960570|Drug|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
38738|NCT00960583|Other|Functional multidisciplinary rehabilitation|3-week outpatient multidisciplinary rehabilitation.
38739|NCT00960583|Other|Exercise program|24 group exercise sessions during 12 weeks
38740|NCT00960583|Other|Routine follow-up|Advice to stay active
38741|NCT00960596|Behavioral|Health promotion and health education for smoking habits|We provide the education to intervention group.
38742|NCT00000216|Drug|Buprenorphine|
38743|NCT00000864|Drug|Abacavir sulfate|
38744|NCT00022113|Other|laboratory biomarker analysis|Correlative studies
38745|NCT00960609|Procedure|Ultrasound guided liver resection|
39440|NCT00966628|Drug|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
39441|NCT00966641|Drug|Naproxen|Single orally administered dose of 500 mg naproxen
39442|NCT00966641|Drug|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
39443|NCT00959517|Drug|primaquine (PQ)|
39444|NCT00959530|Procedure|lingualized occlusion|occlusal surface arranged by lingualized occlusion
39445|NCT00959530|Procedure|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
39446|NCT00959543|Other|MRI|MRI and clinical investigation
39447|NCT00959556|Other|laboratory biomarker analysis|
39448|NCT00021814|Drug|Finasteride|
39449|NCT00959569|Drug|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
39450|NCT00959569|Drug|Placebo|normosaline (same ml of the study drug)
39451|NCT00959582|Procedure|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
39452|NCT00959595|Drug|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
38488|NCT00022373|Drug|iseganan HCl oral solution|
38489|NCT00964704|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
38490|NCT00964704|Drug|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
38491|NCT00964704|Drug|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
38492|NCT00964704|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
39205|NCT00961376|Biological|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
39206|NCT00961402|Behavioral|Exercise|6-month exercise intervention vs. wellness control
39207|NCT00961415|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
39208|NCT00963560|Device|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
39209|NCT00963560|Device|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
39210|NCT00963560|Device|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
39211|NCT00963573|Drug|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
39212|NCT00963573|Drug|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
39519|NCT00966654|Drug|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) saline or GLP-1 infused continuously over 72 hours.
39520|NCT00966680|Other|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
39521|NCT00966693|Drug|Lenalidomide|Starting dose:15 mg daily by mouth on Days 1-21 followed by 7-day rest every 28 day cycle for Cycles 1-8
39522|NCT00966693|Drug|Thalidomide|Starting dose:100 mg daily by mouth on Days 1-28 of Cycles 1-8
39523|NCT00966693|Drug|Dexamethasone|40 mg by mouth on Days 1-4, 9-12, and 17-20 of Cycles 1-2.
40 mg by mouth on Days 1, 8, 15, and 21 of Cycles 3-8.
39524|NCT00966706|Drug|capecitabine|Given systemically
39525|NCT00966706|Drug|cisplatin|Given systemically
39526|NCT00966706|Drug|docetaxel|Given systemically
39527|NCT00966706|Drug|epirubicin hydrochloride|Given systemically
39528|NCT00966706|Drug|gemcitabine hydrochloride|Given systemically
39529|NCT00022555|Drug|bryostatin 1|Given IV
39530|NCT00966719|Other|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
43150|NCT00974818|Biological|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
43151|NCT00974831|Other|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
43152|NCT00974831|Other|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
43153|NCT00023530|Drug|fluconazole|
43154|NCT00974857|Device|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
43155|NCT00974857|Other|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
43156|NCT00974870|Procedure|needling treatment|Needling treatment applied to half of the face at each study visit
43157|NCT00974883|Procedure|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
43158|NCT00974883|Procedure|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
43159|NCT00977119|Other|research blood samples|Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
43160|NCT00977132|Drug|Valproic aicd|Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme
day morning dose midday dose evening dose contents of 1 tablet
1+2 0 0 1 500 mg
3+4 ½ 0 1 500 mg
5+6 1 0 1 500 mg
7+8 1 ½ 1 500 mg
9+10 1 1 1 500 mg
11+12 1 1 1 500 mg
In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks.
43161|NCT00023738|Drug|dacarbazine|
43162|NCT00977132|Drug|Lenalidomide|5 mg/day, continuous therapy
Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.
Only one cycle of study drug (28 days) will be supplied to the patient every four weeks
43163|NCT00977145|Biological|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions.
42203|NCT00980200|Drug|Dose 1 BD|BD twice daily
38746|NCT00960622|Drug|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
38747|NCT00960622|Drug|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
38748|NCT00962780|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
38749|NCT00962780|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
38750|NCT00962780|Procedure|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
38751|NCT00962780|Procedure|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
38752|NCT00962806|Behavioral|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
38753|NCT00962806|Behavioral|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
38754|NCT00962819|Biological|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
39058|NCT00965770|Device|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
39059|NCT00965783|Other|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
39060|NCT00965783|Other|Extension|Bedtime is extended by 2 hours per night for 4 nights
39061|NCT00965796|Drug|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
39062|NCT00965809|Drug|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
39063|NCT00965809|Other|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
39064|NCT00022464|Drug|temsirolimus|
39065|NCT00965822|Other|North American ginseng|3 day, once daily, dosing
39066|NCT00965822|Other|Placebo|3 day, once daily dosing
39067|NCT00965848|Drug|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
38493|NCT00964717|Procedure|real chiropractic|real chiropractic manipulation
38494|NCT00964717|Procedure|Sham Chiropractic|Placebo stimulation using 'activator' thumper
38495|NCT00964730|Drug|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
38496|NCT00964730|Drug|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
38497|NCT00964730|Drug|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
38498|NCT00964743|Drug|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
38499|NCT00022373|Procedure|management of therapy complications|
38500|NCT00964743|Drug|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
38501|NCT00964756|Genetic|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
38502|NCT00964756|Drug|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
38503|NCT00964769|Biological|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
38504|NCT00964782|Drug|sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test
38505|NCT00964782|Other|placebo|Patient will receive a look-alike placebo
38506|NCT00964795|Drug|Intravitreal Aflibercept Injection 2mg|
38507|NCT00964808|Drug|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
38508|NCT00964808|Drug|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg * 2 pr. day until time to discharge from the Hospital or latest at day 12.
38509|NCT00964821|Biological|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
38510|NCT00022386|Biological|epoetin alfa|
38818|NCT00968201|Drug|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
38819|NCT00022737|Biological|filgrastim|Given SC
38820|NCT00960622|Drug|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
39531|NCT00966732|Behavioral|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
39532|NCT00966745|Drug|milrinone|
39533|NCT00966745|Drug|placebo|
39534|NCT00966758|Procedure|Computed Tomography|1 low dose CT scan is taken
39535|NCT00966758|Procedure|Single Photon Emission Computed Tomography|1 SPECT scan is taken
39536|NCT00966771|Drug|Copper T380 IUD|copper T 380 IUD
39537|NCT00966771|Drug|Oral levonorgestrel|1.5 mg
39538|NCT00966784|Other|Dietary Fibers|
39539|NCT00966810|Procedure|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect > 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
42760|NCT00971932|Drug|Cisplatin/Carboplatin|Subjects will receive 100 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 [AUC5]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
42761|NCT00971932|Drug|5-Fluorouracil|Subjects will receive 1000 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
42762|NCT00974155|Drug|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
42763|NCT00974168|Radiation|Cumulative BED ≤ 100|Radiation
42764|NCT00974168|Radiation|Cumulative BED ≤ 130 Gy2|Radiation
42765|NCT00974181|Device|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
42766|NCT00974181|Device|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
42767|NCT00974194|Procedure|Single Trocar CCK|CCK using Triport
39302|NCT00963729|Drug|docetaxel|Given IV
39303|NCT00963729|Drug|epirubicin hydrochloride|Given IV
39304|NCT00963729|Drug|fluorouracil|Given IV
39305|NCT00963729|Drug|letrozole|Given orally
39306|NCT00963742|Device|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
39307|NCT00022230|Drug|cyclophosphamide|
39308|NCT00963768|Drug|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
39309|NCT00963768|Drug|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
38349|NCT00967200|Other|laboratory biomarker analysis|laboratory biomarker analysis
38350|NCT00967200|Other|pharmacogenomic studies|pharmacogenomic studies
38351|NCT00960063|Drug|Temozolomide|
38352|NCT00960063|Drug|Vincristine|
38353|NCT00960063|Drug|Ifosfamide|
38354|NCT00960063|Drug|Irinotecan|
38355|NCT00960063|Biological|Robatumumab|
38356|NCT00960063|Drug|Doxorubicin|
38357|NCT00000863|Drug|Sitamaquine|
38358|NCT00022022|Procedure|quality-of-life assessment|
38359|NCT00960063|Drug|Cyclophosphamide|
38360|NCT00960063|Drug|Etoposide|
38361|NCT00960076|Drug|Saxagliptin|5mg oral tablet once daily
38362|NCT00960076|Drug|Metformin XR|500mg oral tablet once daily
38363|NCT00960076|Drug|Metformin XR|750mg, 2 tablets once daily
38364|NCT00960089|Device|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
39068|NCT00965861|Other|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
39069|NCT00965874|Drug|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
39070|NCT00965874|Drug|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
39071|NCT00965887|Drug|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
39072|NCT00965887|Drug|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
39073|NCT00965900|Procedure|Endoscopic band ligation|Perform EBL within 7 days after randomization
Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)
Acid suppression using proton pump inhibitor until eradicated.
After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).
39074|NCT00968214|Genetic|polymorphism analysis|
39075|NCT00968227|Biological|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
39076|NCT00968240|Drug|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.
Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier.
39368|NCT00961597|Procedure|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
39369|NCT00961610|Behavioral|Internet peer-support group|The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.
All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.
The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date.
39370|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
39371|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
39372|NCT00022126|Procedure|allogeneic bone marrow transplantation|
39373|NCT00961636|Drug|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
38821|NCT00960635|Drug|1,25-dihydroxy-vitamin D3 (calcitriol)|
38822|NCT00960635|Drug|placebo|pill without agent
38823|NCT00960648|Device|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
38824|NCT00960648|Device|Cypher|Retrospective historical controls that received sirolimus-eluting stent
38825|NCT00960661|Drug|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
38826|NCT00960661|Drug|insulin lispro|titrated based on pre-meal glucose level; three times a day
38827|NCT00022126|Drug|asparaginase|
38828|NCT00960661|Drug|Metformin|
38829|NCT00960661|Drug|Insulin/ Glargine|
38830|NCT00960674|Procedure|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
38831|NCT00960674|Behavioral|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
38832|NCT00960687|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
38833|NCT00960687|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
38834|NCT00960700|Device|Visual Acuity|Assessment of visual acuity
38835|NCT00960700|Device|Contrast sensitivity|Assessment of contrast sensitivity
38836|NCT00960700|Device|Reading Speed|Assessment of reading speed
38837|NCT00960700|Procedure|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
38838|NCT00022126|Drug|cyclophosphamide|
38839|NCT00960713|Drug|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
38840|NCT00960726|Drug|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
42768|NCT00974194|Procedure|Standard CCK|CCK using three or four ports
42769|NCT00974220|Drug|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
42770|NCT00974220|Drug|normal saline (placebo)|single dose, 0.9% saline solution
42771|NCT00023413|Drug|Rifabutin|
42772|NCT00974233|Drug|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
42773|NCT00974233|Drug|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
42774|NCT00974233|Drug|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
42775|NCT00974246|Drug|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
42776|NCT00974259|Device|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (> 20 mm Hg) or pBrO2 (< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
42777|NCT00974259|Device|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
42778|NCT00974272|Drug|Exenatide|Single subcutaneous injection (10 μg)
43045|NCT00974623|Device|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
43046|NCT00974636|Dietary Supplement|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
43047|NCT00974636|Dietary Supplement|Usual Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
43048|NCT00974649|Behavioral|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
43049|NCT00974662|Drug|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 & 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
43050|NCT00974675|Drug|CAT-354-0602|1, 5 and 10 mg/kg - Day 0,28, and 56
43051|NCT00023465|Procedure|FDG-PET|
38365|NCT00960102|Device|cochlear implant|Multichannel Nucleus cochlear implant
38366|NCT00960102|Device|hearing aid|Phonak Valeo hearing aid
38367|NCT00960115|Biological|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram [mcg]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
38368|NCT00960115|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg/m^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
38369|NCT00022035|Biological|trivalent influenza vaccine|
38370|NCT00960115|Biological|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
38371|NCT00960115|Other|Saline|A single dose of saline (sodium chloride, 9 grams per liter [g/L]) will be administered intravenously, 3 days prior to the start of placebo.
38372|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
38671|NCT00022191|Drug|cisplatin|
38672|NCT00962754|Procedure|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
38673|NCT00962767|Drug|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
38674|NCT00962767|Drug|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
38675|NCT00964912|Drug|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
38676|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
38677|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
38678|NCT00964938|Device|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
38679|NCT00964951|Biological|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
38680|NCT00964951|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
39374|NCT00961636|Drug|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
39375|NCT00961649|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
39376|NCT00961649|Drug|Brinzolamide ophthalmic suspension, 1%|
39377|NCT00961649|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
39378|NCT00961649|Other|Vehicle|Inactive ingredients used as placebo
39379|NCT00961662|Drug|D-Tagatose|powder to be dissolved in water prior to dosage.
39380|NCT00961675|Drug|FST201 (dexamethasone 0.1% with povidone-iodine 1%)|4gtt BID
39381|NCT00961675|Drug|Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )|4 gtt BID
39382|NCT00961714|Device|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
39383|NCT00022126|Radiation|radiation therapy|
39384|NCT00961727|Other|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; [1] an expert derived, multi-centre validated severity of illness score, [2] an inter-professionally developed documentation record into which the severity of illness score is embedded, [3] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and [4] an educator-developed education-implementation program.
39385|NCT00961740|Behavioral|Cognitive Behavioural Therapy|See summary
39386|NCT00961740|Other|Waitlist condition|See Summary
39387|NCT00961753|Drug|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
38430|NCT00967252|Drug|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
38431|NCT00967252|Other|Control|No statin being taken
38432|NCT00967265|Behavioral|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
38433|NCT00967265|Other|Usual care|Usual care
38434|NCT00967291|Drug|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
39132|NCT00963547|Drug|MK2206|Part 1: MK2206 tablets will be given starting at a dose of 45 mg every other day and escalated to 60 mg if tolerated OR starting at a dose of 135 mg weekly and escalated to 200 mg weekly if tolerated. Dose reduction to 30mg every other day or 90 mg weekly may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose of MK2206 for both the every other day and weekly dosing schedules in combination with trastuzumab. The Part 2 dosing level and schedule of MK2206 will be chosen from the maximum tolerated dose of either the every other day or weekly dosing schedules depending on the toxicity profile and preliminary efficacy.
39133|NCT00963547|Drug|Comparator: MK2206|Part 2: The maximum tolerated dose of MK2206 determined in Part 1 will be administered in combination with trastuzumab and lapatinib to determine the maximum tolerated dose of the three-drug combination.
39134|NCT00963547|Biological|Comparator: trastuzumab|Trastuzumab will be administered as a 90-minute intravenous infusion at a loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
39135|NCT00022230|Biological|filgrastim|
39136|NCT00963547|Drug|Comparator: lapatinib|Lapatinib tablets will be administered orally in doses of 500 mg, 750 mg, or 1000 mg.
39137|NCT00965900|Drug|Propranolol|start with 20 mg of propranolol b.i.d
Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min
After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
39138|NCT00022477|Drug|BMS-247550|
39139|NCT00965900|Procedure|endoscopic band ligation and propranolol|EBL
Perform EBL within 7 days after randomization
Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)
Acid suppression using proton pump inhibitor until eradicated.
After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).
Propranolol
start with 20 mg b.i.d
Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min
After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
39140|NCT00965913|Drug|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
39141|NCT00965913|Drug|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
39142|NCT00965913|Drug|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
39143|NCT00965926|Drug|YM178|oral
39144|NCT00965965|Behavioral|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
39145|NCT00965965|Behavioral|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
39146|NCT00965978|Drug|ONO-5920 / YM529|oral
43052|NCT00974675|Drug|Placebo|1,5, and 10 kg - Day 0, 28, and 56
43053|NCT00974688|Behavioral|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
43054|NCT00974688|Behavioral|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
43055|NCT00974701|Device|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
43056|NCT00974714|Drug|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
43057|NCT00974714|Other|placebo|oral placebo 2 g twice a day for 14 weeks
43058|NCT00974727|Other|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
43059|NCT00974740|Drug|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
43060|NCT00974740|Drug|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
43061|NCT00974753|Drug|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
43062|NCT00023465|Procedure|spirometry|
43397|NCT00972803|Drug|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
43398|NCT00972803|Drug|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
43399|NCT00972816|Biological|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
43400|NCT00972829|Drug|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
43401|NCT00972829|Drug|Ezetimibe|Ezetimibe 5 or 10 milligrams
43402|NCT00972842|Drug|Vorinostat, Lenalidomide|Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles
Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles
38681|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
38682|NCT00022399|Procedure|conventional surgery|
38683|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
38684|NCT00964964|Drug|placebo|Placebo injected s.c. (under the skin) four times weekly
38685|NCT00964977|Radiation|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
38686|NCT00964990|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
38687|NCT00964990|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
38688|NCT00965003|Procedure|MRI scan|Standard of Care
38689|NCT00965003|Device|Gadoversetamide|0.1 mmol/kg, IV
38690|NCT00965016|Procedure|hypothermia|Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
38691|NCT00965042|Drug|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
38996|NCT00967941|Drug|Daptomycin and Cefazolin (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
38997|NCT00967954|Drug|antiandrogen therapy|
38998|NCT00967954|Drug|releasing hormone agonist therapy|
38999|NCT00967954|Genetic|DNA analysis|
39000|NCT00967954|Genetic|RNA analysis|
39001|NCT00967954|Genetic|comparative genomic hybridization|
39002|NCT00967954|Genetic|gene expression analysis|
39003|NCT00967954|Other|laboratory biomarker analysis|
39004|NCT00967954|Procedure|diffusion-weighted magnetic resonance imaging|
39005|NCT00960921|Drug|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
38435|NCT00000867|Drug|Memantine|
38436|NCT00022633|Drug|gemcitabine hydrochloride|
38437|NCT00967291|Drug|mitomycin C|8 mg/mq on day 1 every 28 days
38438|NCT00967304|Other|Application of the"Men continue and HER DOO2" rule|Consecutive patients will have the"Men continue and HER DOO2" rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.
"Men continue and HER DOO2" rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years.
38439|NCT00967317|Drug|Auris-Sedina|Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.
The medication should be used for a maximum of 3 days when they should return to the doctor.
38440|NCT00967317|Drug|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
38441|NCT00960154|Procedure|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
38442|NCT00960167|Radiation|3DCRT or IMRT|All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;
Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:
Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)
38443|NCT00022048|Biological|bevacizumab|
38444|NCT00960180|Drug|MR1817|
38445|NCT00960180|Drug|Placebo|
38446|NCT00960193|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
38447|NCT00960193|Other|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
38755|NCT00000865|Drug|Lamivudine|
38756|NCT00022191|Drug|gemcitabine hydrochloride|
38757|NCT00962832|Drug|placebo|Part 1: Intravenous (IV) repeating dose; Part 2: Subcutaneous repeating dose
38758|NCT00962832|Drug|rontalizumab|Part 1: IV repeating dose; Part 2: Subcutaneous repeating dose; Part 3: Open-label extension IV repeating dose
39147|NCT00965991|Drug|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
39453|NCT00959595|Drug|EMLA cream|50g applied according to description of intervention
39454|NCT00959608|Behavioral|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
39455|NCT00959608|Behavioral|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
39456|NCT00959621|Drug|Aspirin|ASA 100 mg once daily per os
39457|NCT00959621|Drug|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
39458|NCT00959621|Drug|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
39459|NCT00021827|Drug|Parathyroid hormone-related protein or ''PTHrP''|
39460|NCT00959634|Drug|ABT-126|Dose administered twice daily on Study Days 1-10
39461|NCT00959634|Drug|Placebo|Dose administered twice daily on Study Days 1-10
39462|NCT00959647|Drug|Vismodegib|Vismodegib was supplied in capsules.
39463|NCT00959647|Drug|FOLFOX|FOLFOX (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and oxaliplatin [OX]) was supplied as solutions for intravenous administration.
39464|NCT00959647|Drug|FOLFIRI|FOLFIRI (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and irinotecan [IRI]) was supplied as solutions for intravenous administration.
39465|NCT00959647|Drug|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
39466|NCT00961779|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
39467|NCT00961779|Drug|Placebo|Normal saline infusion
39468|NCT00961792|Drug|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
39469|NCT00022139|Drug|carboplatin|
39470|NCT00961792|Drug|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
39471|NCT00961792|Drug|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
43403|NCT00975195|Drug|tiotropium inhalation|
43404|NCT00975195|Drug|salmeterol xinafoate|
43405|NCT00023543|Behavioral|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
43406|NCT00975195|Drug|fluticasone propionate|
43407|NCT00975195|Drug|placebo matched for fluticasone propionate|
43408|NCT00975221|Drug|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
43409|NCT00975221|Drug|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
43410|NCT00975234|Procedure|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
43411|NCT00975234|Procedure|Revascularisation|Revascularisation surgery
43412|NCT00975247|Other|Receiving an educational booklet|Patients who receive an educational booklet will be considered to be receiving an intervention
43413|NCT00975273|Behavioral|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
43414|NCT00975273|Behavioral|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
43415|NCT00975286|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
43416|NCT00000218|Drug|Carbamazepine|
43417|NCT00000870|Drug|Aldesleukin|
43418|NCT00023543|Behavioral|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
42456|NCT00985205|Dietary Supplement|Placebo|Maltodextrin mixed with water given via NG tube Q 4 hours or TID if po.
42457|NCT00985218|Device|SMART System|microfluidic embryo culture system
42458|NCT00978055|Drug|1: Liothyronine Sodium Tablets|Liothyronine Sodium Tablets, 50 mcg
2 x 50 mcg, single-dose, fasting
42459|NCT00023816|Drug|carbendazim|
39006|NCT00960934|Drug|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
39007|NCT00960934|Drug|Placebo|Dose-matched oral placebo to MK-5442
39008|NCT00960934|Dietary Supplement|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
39009|NCT00960934|Dietary Supplement|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
39010|NCT00960960|Drug|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg
39011|NCT00960960|Drug|GDC-0941|GDC-0491 will be administered PO at a dose of 260 mg.
39012|NCT00960960|Drug|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD.
39013|NCT00960960|Drug|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m^2.
39014|NCT00022126|Drug|dexamethasone|
39015|NCT00960960|Drug|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg.
39016|NCT00960973|Drug|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
39017|NCT00960973|Drug|Placebo|Placebo
39018|NCT00960986|Drug|Duloxetine hydrochloride|po, QD
39310|NCT00963781|Device|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
39311|NCT00963781|Drug|Reduced duration (6 months) DAPT|
39312|NCT00963794|Other|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
39313|NCT00963807|Drug|Cisplatin|Given IV
39314|NCT00963807|Procedure|Computed Tomography|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
38759|NCT00962845|Drug|hydroxychloroquine|200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
38760|NCT00962871|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
38761|NCT00962871|Drug|tenofovir|300mg po daily for 2 weeks
38762|NCT00962884|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
38763|NCT00962884|Device|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
38764|NCT00962897|Procedure|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
38765|NCT00962897|Procedure|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
38766|NCT00962910|Other|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
38767|NCT00022191|Drug|paclitaxel|
38768|NCT00962923|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
38769|NCT00962936|Drug|CT-011|CT-011
38770|NCT00962949|Drug|Angiotensin II|Angiotensin II infusion for 1 hour
38771|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
38772|NCT00965081|Drug|Placebo|QD po at the same time each day for 12 weeks
38773|NCT00965094|Drug|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
38774|NCT00965094|Drug|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
38775|NCT00965094|Drug|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg [day 0 (2 hrs prior to Tx) and day 4 post Tx] to be applied as 10 sec. bolus injection, i.v.
38776|NCT00965094|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
39077|NCT00968253|Drug|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
39472|NCT00961792|Drug|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
39473|NCT00961805|Behavioral|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
38511|NCT00964821|Other|immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
38512|NCT00964821|Other|laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
38513|NCT00967330|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
38514|NCT00967330|Drug|irinotecan|125mg/m2 iv every 2 weeks
38515|NCT00967330|Drug|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
38516|NCT00967343|Biological|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
38517|NCT00967356|Drug|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
38518|NCT00967356|Drug|Placebo|Oral suspension
38519|NCT00022633|Drug|paclitaxel|
38520|NCT00967369|Drug|Bortezomib|1.5 mg/m^2 by vein over 5 seconds on Days 1 and 4 of each cycle.
38521|NCT00967369|Drug|Ifosfamide|5 gm/m^2 by vein over 24 hours on Day 1 of each cycle. With Ifosfamide, receive Mesna 5 gm/m^2 by vein over 24 hours.
38522|NCT00967369|Drug|Carboplatin|Maximum of 800 mg by vein over 1 hour on Day 1 of each cycle.
38523|NCT00967369|Drug|Etoposide|100 mg/m^2 by vein over 2 hours each day on Days 1-3 of each cycle.
38524|NCT00967369|Drug|Neulasta (Pegfilgrastim)|6 mg through a needle under the skin on Day 5 (If you are in Group 1) or Day 4 (if you are in Group 2) of each cycle.
38525|NCT00967369|Drug|Mesna|2 gm/m2 by vein over 12 hours on Day 2 to start day after Ifosfamide + Mesna.
42460|NCT00978055|Drug|2: Cytomel® Tablets|Cytomel® Tablets, 50 mcg
2 x 50 mcg, single-dose, fasting
42461|NCT00978068|Drug|LPV/r + 2 NRTIs|Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
42462|NCT00978068|Drug|NVP or EFV + 2 NRTIs|Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children < 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be stavudine.
42463|NCT00978081|Drug|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
42464|NCT00978107|Biological|MVA-FCU1, flucytosine|TG4023: single IT injection; possibility to re-administer once,
Percutaneous IT injections, under radiological or ultrasound imaging guidance
Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),
MTD injected to up to 3 different lesions (Cohort #4)
5-FC (5-fluorocytosine)/flucytosine
Dose and dosing schedule:
Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L
Duration: 2 weeks.
Possible routes of administration:
PO: 500 mg tablets, qid
IV: 1% 250 mL vials, 45-minute infusions.
42465|NCT00978120|Biological|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
42466|NCT00978120|Biological|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
42467|NCT00978133|Procedure|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
42468|NCT00978133|Procedure|Skin closure with skin staples|Skin closure with skin staples
42469|NCT00978146|Drug|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
42470|NCT00023829|Drug|bicalutamide|
42471|NCT00978159|Drug|esomeprazole|esomeprazole 20 mg po for 4 weeks
42472|NCT00978159|Drug|Famotidine|Famotidine 40 mg po for 4 weeks
42473|NCT00978172|Drug|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
42474|NCT00978185|Other|medical chart review|
43063|NCT00974753|Other|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
43064|NCT00976898|Radiation|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
39315|NCT00963807|Drug|Dexamethasone|Given PO
39316|NCT00963807|Drug|Docetaxel|Given IV
39317|NCT00963807|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
39318|NCT00022230|Drug|doxorubicin hydrochloride|
39319|NCT00963807|Other|Fluorothymidine F-18|Undergo FLT PET/CT
39320|NCT00963807|Other|Laboratory Biomarker Analysis|Correlative studies
39321|NCT00963807|Procedure|Positron Emission Tomography|Undergo FDG PET/CT and FLT PET/CT
39322|NCT00963807|Procedure|Therapeutic Conventional Surgery|Undergo surgery
39323|NCT00966264|Procedure|Hysterectomy|operation
39324|NCT00966277|Drug|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
39325|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
39326|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
39327|NCT00022516|Drug|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
39328|NCT00966303|Other|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
39329|NCT00966316|Drug|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
38373|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
38374|NCT00960141|Drug|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
38375|NCT00960141|Drug|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
38376|NCT00960141|Drug|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
38377|NCT00960154|Device|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
39078|NCT00968253|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
39079|NCT00968253|Drug|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
39080|NCT00968253|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
39081|NCT00968253|Drug|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
39082|NCT00968253|Drug|Mesna|600 mg/m^2 IV continuous infusion daily for 24 hours days 1-3.
39083|NCT00968253|Drug|Methotrexate|200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 IV over 22 hours day 1.
39084|NCT00022737|Drug|asparaginase|Given IM
39085|NCT00968253|Drug|Ara-C (Cytarabine)|3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
39086|NCT00968253|Drug|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
39087|NCT00968253|Drug|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
39088|NCT00968266|Behavioral|Patient-centered group intervention|Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.
Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent.
39089|NCT00968292|Device|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
39090|NCT00968318|Procedure|Excision of strip of deep fascia|operative technique to excise deep fascia.
39091|NCT00968331|Drug|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
39388|NCT00961753|Drug|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
38526|NCT00967382|Drug|dalteparin sodium|Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;
dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)
Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum
38527|NCT00967395|Other|Healing|Healing in our study is given be a healer "no-touch", who just has to be present in the room.
38528|NCT00967395|Other|Sham healing|Sham Healing in our study is given be a student "no-touch", who just has to be present in the room.
38529|NCT00967408|Drug|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
38530|NCT00022646|Drug|gemcitabine hydrochloride|
38531|NCT00967408|Drug|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
38841|NCT00960739|Drug|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
38842|NCT00960739|Procedure|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
38843|NCT00960739|Radiation|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
38844|NCT00960739|Radiation|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
38845|NCT00960752|Drug|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
38846|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
38847|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
38848|NCT00962962|Behavioral|Exercise and Diet|Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week
Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight.
38849|NCT00962975|Drug|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
43065|NCT00976911|Drug|bevacizumab [Avastin]|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
43066|NCT00976911|Drug|liposomal doxorubicin|40mg/m2 iv every 4 weeks
43067|NCT00976911|Drug|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
43068|NCT00976911|Drug|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
43069|NCT00976924|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
43070|NCT00023725|Drug|semaxanib|
43071|NCT00976937|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
43072|NCT00976937|Drug|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
43073|NCT00976937|Device|Pen auto-injector|
43074|NCT00976937|Drug|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
43075|NCT00976937|Drug|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
43076|NCT00976937|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
43077|NCT00976950|Drug|Tipranavir|
43078|NCT00976950|Drug|ritonavir|low-dose
43079|NCT00976963|Drug|Fosfomycin|3g sachet single dose
43080|NCT00976963|Drug|TMP/SMX DS|160/800mg BID x 3 days
43081|NCT00023725|Procedure|conventional surgery|
43082|NCT00976976|Drug|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
43083|NCT00976989|Drug|FEC: 5-Fluorouracil/epirubicin/cyclophosphamide|500mg/m2 5-Fluorouracil iv + 100mg/m2 epirubicin iv + 600mg/m2 cyclophosphamide iv 3-weekly, cycles 1-3
43084|NCT00976989|Drug|carboplatin|AUC6 (Calvert's Formula) 3-weekly, cycles 1-6
43085|NCT00976989|Drug|docetaxel|75mg/m2 iv, escalated to 100mg/m2 iv 3-weekly, cycles 1-6
43086|NCT00976989|Drug|docetaxel|75mg/m2 iv, escalated to 100mg/m2 iv 3-weekly, cycles 4-6
38378|NCT00962169|Other|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
38379|NCT00962169|Other|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
38380|NCT00962182|Drug|STAN1|3-4 capsules/day at meals
38381|NCT00962182|Drug|Placebo enzyme|3-4 capsules/day at meals
38382|NCT00022165|Dietary Supplement|selenium|
38383|NCT00962182|Drug|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
38384|NCT00962195|Dietary Supplement|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
38385|NCT00962208|Device|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
38386|NCT00962208|Device|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
38387|NCT00962221|Procedure|laboratory analysis|laboratory analysis
38388|NCT00962234|Other|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
38389|NCT00962234|Biological|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
38692|NCT00965055|Drug|Ezetimibe|10 mg
38693|NCT00022399|Procedure|neoadjuvant therapy|
38694|NCT00965055|Drug|Atorvastatin|Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.
Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients
Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.
Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test
Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.
Visit 6: Final cholesterol panel and conclusion of study period
39389|NCT00961766|Drug|BG00010 (Neublastin)|Single dose, weight-based IV administration
39390|NCT00961766|Drug|Placebo|Single dose IV matched placebo
39391|NCT00963820|Drug|Ixazomib citrate|Ixazomib citrate capsules
39392|NCT00963833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
39393|NCT00963846|Drug|placebo|matching pill placebo
39394|NCT00963846|Drug|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
39395|NCT00963846|Drug|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
39396|NCT00963846|Drug|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
39397|NCT00022230|Drug|paclitaxel|
39398|NCT00963859|Procedure|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
39399|NCT00963872|Drug|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
39400|NCT00963872|Drug|fludarabine phosphate|40 mg/m^2 over 1 hour on Days -6 through -2.
39401|NCT00963872|Radiation|Total body irradiation|200 cGy on Day -1
39402|NCT00963872|Biological|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
39403|NCT00963872|Biological|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
39404|NCT00963885|Drug|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
39405|NCT00963885|Drug|Pegasys|180micrograms sc weekly for 24 or 48 weeks
39406|NCT00963885|Drug|Placebo|po for 12 weeks
39407|NCT00963885|Drug|Placebo|po for 24 weeks
39408|NCT00022243|Drug|batabulin sodium|
39409|NCT00963885|Drug|danoprevir|300mg po q8h for 12 weeks
38850|NCT00962988|Drug|Cost-Free Pharmacotherapy Group|Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.
Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.
For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.
For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months.
38851|NCT00962988|Other|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
38852|NCT00022204|Dietary Supplement|vitamin E|
38853|NCT00963001|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
38854|NCT00963001|Other|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
38855|NCT00963027|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
39148|NCT00965991|Drug|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
39149|NCT00022490|Drug|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
39150|NCT00966004|Drug|YM178|oral
39151|NCT00966004|Drug|Placebo|oral
39152|NCT00966004|Drug|tolterodine|oral
39153|NCT00966030|Drug|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
39154|NCT00966030|Drug|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
39155|NCT00966056|Drug|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
39156|NCT00966056|Device|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
39157|NCT00966069|Other|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
43107|NCT00022815|Device|Tissue ultrafiltration|
43108|NCT00970073|Biological|Thymoglobulin|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
43109|NCT00970073|Drug|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
43110|NCT00970073|Drug|tacrolimus|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
43111|NCT00970073|Drug|tacrolimus|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
43112|NCT00970086|Drug|Bupivacain/levobupivacaine|Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.
Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%.
43113|NCT00972348|Other|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
43114|NCT00972348|Other|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
43115|NCT00972374|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
43116|NCT00972374|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
43117|NCT00972374|Other|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
43118|NCT00972387|Dietary Supplement|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
43119|NCT00972387|Dietary Supplement|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
43120|NCT00972387|Dietary Supplement|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
43121|NCT00023244|Drug|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
38695|NCT00965068|Other|Cholesterol|
38696|NCT00965081|Drug|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
38697|NCT00967707|Drug|gabapentin and donepezil|Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).
Week 7-12: Donepezil 5 mg once daily is added.
38698|NCT00967733|Dietary Supplement|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
38699|NCT00967733|Dietary Supplement|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
38700|NCT00967733|Dietary Supplement|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
38701|NCT00967733|Dietary Supplement|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
38702|NCT00967746|Drug|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
38703|NCT00967746|Drug|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
38704|NCT00022672|Drug|anastrazole (Arimidex®)|1 mg tablet taken orally daily
38705|NCT00967746|Drug|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
38706|NCT00967746|Device|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
38707|NCT00967759|Drug|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
38708|NCT00967759|Drug|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
38709|NCT00967759|Drug|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
38710|NCT00967772|Drug|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
38711|NCT00967785|Drug|Mozobil (TM)|
39019|NCT00960999|Radiation|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
39410|NCT00963885|Drug|danoprevir|600mg po q12h for 12 weeks
39411|NCT00963885|Drug|danoprevir|900mg po q12h for 12 weeks
38448|NCT00960206|Device|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
38449|NCT00960206|Device|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
38450|NCT00960206|Device|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
38451|NCT00960219|Drug|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
38452|NCT00960219|Drug|placebo|1# BID, oral, for 6 weeks
38453|NCT00960232|Drug|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
38454|NCT00022074|Drug|gabapentin|
38455|NCT00960232|Drug|placebo|placebo
38456|NCT00960245|Drug|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
38457|NCT00960245|Drug|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
38458|NCT00960258|Drug|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
38459|NCT00960271|Procedure|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
38460|NCT00960284|Drug|capecitabine|Given orally
38461|NCT00960284|Drug|cisplatin|Given IV
38462|NCT00960284|Drug|epirubicin hydrochloride|Given IV
38463|NCT00960284|Drug|fluorouracil|Given IV
38464|NCT00960284|Drug|gemcitabine hydrochloride|Given IV
38465|NCT00022074|Procedure|quality-of-life assessment|
38466|NCT00960297|Drug|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
39158|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
39159|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
39160|NCT00959101|Drug|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
39161|NCT00959101|Drug|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
39162|NCT00959114|Biological|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
39163|NCT00959114|Biological|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
39164|NCT00959127|Drug|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
39165|NCT00021749|Drug|Oblimerson sodium, G3139|
39166|NCT00959140|Device|CD3+ T cell depletion|The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.
Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis.
39474|NCT00961805|Other|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
39475|NCT00961831|Drug|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
39476|NCT00961831|Drug|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
39477|NCT00961844|Biological|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
39478|NCT00961844|Drug|Temozolomide|
39479|NCT00961857|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
39480|NCT00022139|Drug|fluorouracil|
39481|NCT00961857|Drug|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
39482|NCT00961857|Drug|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
43122|NCT00972387|Dietary Supplement|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
43123|NCT00972400|Genetic|protein analysis|
43419|NCT00975286|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
43420|NCT00975286|Drug|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
43421|NCT00975286|Device|Pen auto-injector|Lantus® SoloStar® OptiClik®
43422|NCT00975286|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
43423|NCT00975286|Drug|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
43424|NCT00975299|Drug|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
43425|NCT00975299|Drug|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
43426|NCT00975312|Drug|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
43427|NCT00975312|Drug|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
43428|NCT00977262|Other|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
43429|NCT00977262|Other|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
43430|NCT00977275|Radiation|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
43431|NCT00977288|Drug|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
43432|NCT00000871|Biological|ALVAC-HIV MN120TMG (vCP205)|
43433|NCT00023738|Drug|ifosfamide|
43434|NCT00977288|Drug|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
43435|NCT00977288|Drug|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
43436|NCT00977301|Drug|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
39020|NCT00960999|Radiation|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
39021|NCT00961012|Procedure|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
39022|NCT00961025|Drug|DA-1229|single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg
multiple dose study : DA-1229 5,10,20,40mg
39023|NCT00961025|Drug|Placebo|placebo
39024|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
39025|NCT00022126|Drug|doxorubicin hydrochloride|
39026|NCT00022217|Drug|carboplatin|
39027|NCT00963209|Other|pharmacological study|
39028|NCT00963222|Drug|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
39029|NCT00963222|Drug|placebo|1 cap placebo/day for 3 month
39030|NCT00963235|Biological|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
39031|NCT00963235|Procedure|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
39032|NCT00963261|Behavioral|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
39033|NCT00963274|Drug|Bortezomib|Starting dose: 1.3 mg/sq m
39034|NCT00963274|Drug|Romidepsin|Starting dose: 8 mg/sq m
39035|NCT00963287|Drug|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
39036|NCT00963300|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
39037|NCT00022217|Drug|cisplatin-e therapeutic implant|
39330|NCT00966329|Drug|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
38467|NCT00962286|Drug|Furosemide|Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.
Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.
In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid.
38468|NCT00962299|Drug|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
38777|NCT00965094|Drug|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg [prednisone, or equivalent, was used throughout the study period.
38778|NCT00965107|Drug|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
38779|NCT00022412|Dietary Supplement|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
38780|NCT00965107|Drug|Propofol|Propofol given as a bolus dose of 1 mg/kg.
38781|NCT00965120|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
38782|NCT00965120|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
38783|NCT00965120|Drug|Placebo (saline)|Systemic infusion of placebo (saline).
38784|NCT00965133|Other|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
38785|NCT00965146|Device|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
38786|NCT00965172|Other|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
38787|NCT00965172|Other|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
38788|NCT00965185|Drug|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
38789|NCT00965185|Drug|Placebo|Placebo
38790|NCT00022412|Procedure|conventional surgery|Procedure: Prostatectomy for prostate cancer
38791|NCT00965211|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
39483|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
39484|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
39485|NCT00961857|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
39486|NCT00961870|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
39487|NCT00961883|Biological|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 ^7 PFU
39488|NCT00961883|Biological|Placebo|Sodium Chloride for injection, delivered intramuscularly
39489|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^10 PFU
39490|NCT00963924|Drug|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
39491|NCT00963924|Behavioral|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
39492|NCT00963937|Drug|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
39493|NCT00963937|Drug|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
39494|NCT00963937|Drug|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
38532|NCT00967408|Other|Rehabilitative treatment|Rehabilitative treatment
38533|NCT00967421|Drug|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
38534|NCT00967421|Drug|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
38535|NCT00967421|Other|Placebo drink|Placebo drink containing no alcohol + placebo pill
38536|NCT00967434|Drug|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
38537|NCT00960297|Drug|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
43437|NCT00977301|Drug|olanzapine|15 mg olanzapine single dose
43438|NCT00977301|Drug|olanzapine|10 mg olanzapine single dose
43439|NCT00977314|Device|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
43440|NCT00977314|Device|SoundBite|
43441|NCT00977314|Device|SoundBite Hearing System|
42475|NCT00978185|Other|questionnaire administration|
42476|NCT00978185|Procedure|acupressure therapy|
42477|NCT00978185|Procedure|quality-of-life assessment|
42478|NCT00978185|Procedure|sham intervention|
42479|NCT00978185|Procedure|standard follow-up care|
42480|NCT00978198|Drug|ASP1517|oral
42481|NCT00980655|Biological|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
42482|NCT00980681|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
42483|NCT00980694|Dietary Supplement|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
42484|NCT00023985|Biological|therapeutic autologous dendritic cells|
42485|NCT00980707|Drug|Inhaled corticosteroid (fluticasone)|inhaled fluticasone 220 ug/bid
42486|NCT00980733|Dietary Supplement|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
42487|NCT00980733|Dietary Supplement|Yoghurt|Plain yoghurt same as in intervention group without fortification
42488|NCT00980746|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
42489|NCT00980746|Drug|Placebo|oral route
42490|NCT00980759|Radiation|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
42491|NCT00980759|Radiation|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
39331|NCT00966329|Drug|control group|HAART regimen including 2 NRTI/NtRTIs plus one of the following :
1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)
or ATV/unboosted (in a regimen without tenofovir)
or 1 NNRTI (nevirapine or efavirenz).
39332|NCT00966342|Drug|Fluviral 2009/10|single dose given IM .05 mL
39333|NCT00966355|Drug|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
39334|NCT00966355|Drug|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
39335|NCT00966355|Drug|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
39336|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
39337|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
39338|NCT00022529|Drug|BMS-214662|Given IV
39339|NCT00966381|Other|Exercise and weight loss intervention|randomized control trial, stratified by parity
39340|NCT00966420|Device|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
39341|NCT00966433|Procedure|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
39342|NCT00966433|Procedure|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
39343|NCT00966433|Procedure|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
39344|NCT00966446|Drug|MRSA decolonization|Households will undergo decolonization for MRSA with mupirocin and chlorhexidine
39345|NCT00966459|Procedure|Computed Tomography|1 low-dose CT is taken
39346|NCT00966472|Drug|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
39347|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
39348|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
39349|NCT00959361|Behavioral|pharmaceutical care|consultation with the pharmacists and usual care
38792|NCT00965224|Biological|dendritic cell vaccination (active specific immunotherapy)|
38793|NCT00965237|Device|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
38794|NCT00965237|Device|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
38795|NCT00965237|Other|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
38796|NCT00967954|Procedure|magnetic resonance spectroscopic imaging|
38797|NCT00022711|Drug|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
39092|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
39093|NCT00961038|Drug|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
39094|NCT00961051|Device|Investigational MPS|Multi-purpose solution
39095|NCT00961051|Device|Opti-Free|Multi-purpose solution
39096|NCT00961064|Drug|Eltrombopag|
39097|NCT00961077|Drug|S-1 (TS-1) and Oxaliplatin (Oxalitin)|S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours
every 3 weeks
39098|NCT00961090|Drug|Aminolevulinic Acid|20 mg/kg mixed in water and taken orally prior to surgery
39099|NCT00961116|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
39100|NCT00961116|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
39101|NCT00961142|Drug|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
39102|NCT00022126|Drug|mercaptopurine|
39103|NCT00961155|Drug|cyklezonid|160 mcg once daily
39104|NCT00961155|Drug|montelukast sodium|5 or 10 mg according to age once daily
38538|NCT00960297|Drug|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
38539|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
38540|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
38541|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
38542|NCT00960323|Drug|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
38543|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
38544|NCT00960336|Drug|pegylated liposomal doxorubicin hydrochloride|
38545|NCT00960349|Drug|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
38546|NCT00022087|Dietary Supplement|calcium salts|1000 mg PO per day
38547|NCT00960349|Drug|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
38548|NCT00960349|Drug|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
38549|NCT00960349|Drug|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
38550|NCT00960349|Drug|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
38551|NCT00960362|Drug|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
38552|NCT00960362|Drug|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
38856|NCT00963027|Drug|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
38857|NCT00963040|Drug|Syntocinon (Oxytocin)|4 actuations in each nostril for a total dose of 32 IU
38858|NCT00963040|Drug|Sterile water|4 actuations in each nostril
38859|NCT00963053|Drug|VA111913 TS and placebo|VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
42492|NCT00980785|Drug|Ramipril|Ramipril 5 mg/day
42493|NCT00980785|Drug|Placebo|Matching Placebo
42494|NCT00980798|Drug|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
42495|NCT00023985|Procedure|conventional surgery|
42496|NCT00980798|Drug|Placebo|placebo tablet once daily for 16 weeks
42497|NCT00980824|Behavioral|Cognitive behavioural therapy|Six sessions brief CBT.
42498|NCT00980824|Other|Standard treatment|Referral to NHS services appropriate to patient's needs
42499|NCT00980850|Biological|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
43087|NCT00976989|Drug|pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly, cycles 1-6
43088|NCT00976989|Drug|pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly, cycles 4-6
43089|NCT00976989|Drug|trastuzumab|post surgery, 6mg/m2 iv 3-weekly, cycles 7-20
43090|NCT00976989|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly, cycles 1-6
43091|NCT00976989|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly, cycles 4-6
43092|NCT00969904|Drug|placebo|placebo tablet TID for 12 weeks
43093|NCT00969917|Drug|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
43094|NCT00969969|Device|Arthrodesis|arthrodesis using screws and/or a plate
43095|NCT00969969|Device|Cartiva|Cartiva Synthetic Cartilage Implant
43096|NCT00022802|Device|Image-guided surgical system|
43097|NCT00969982|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
43098|NCT00969982|Drug|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
43099|NCT00970008|Other|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
39350|NCT00021801|Procedure|Islet Cell Transplantation|
38390|NCT00962234|Procedure|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
38391|NCT00962247|Behavioral|Television reduction device|
38392|NCT00962260|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
38393|NCT00022178|Drug|cisplatin|
38394|NCT00962273|Behavioral|Interactive computerized learning resource|In a series of interactive scenarios, participants can "see" themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties.
38395|NCT00962273|Behavioral|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
38396|NCT00964561|Drug|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
38397|NCT00964561|Other|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
38398|NCT00022347|Drug|canfosfamide hydrochloride|
38399|NCT00964574|Drug|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:
APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet
Route of administration:
3-4 subcutaneous injections per day
38400|NCT00964574|Drug|INSULIN GLARGINE|Pharmaceutical form:
LANTUS 100U/ml solution for injection in cartridge
Route of administration:
Once daily subcutaneous injection in the evening
38401|NCT00964587|Behavioral|Education + Problem-Solving Training Self-Study|Education + Problem-Solving Training Self-Study
One session of Literacy-Adapted Diabetes and CVD Risk Education
Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant.
38402|NCT00964587|Behavioral|Education + Group Problem-Solving Training|Education + Group Problem-Solving Training
One session of the Literacy-Adapted Diabetes and CVD Risk Education
Group problem-solving training eight, 90-minute sessions
38403|NCT00964587|Behavioral|Education + Individual Problem-Solving Training|Education + Individual Problem-Solving Training
One session of the Literacy-Adapted Diabetes and CVD Risk Education
Individual problem-solving training (eight, 60-minute sessions)
38404|NCT00964587|Behavioral|Usual Care|Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1
Scripted set of instructions will be given along with a verbal description of the materials and the content provided.
39105|NCT00961155|Drug|placebo|fluticasone placebo twice daily, montelukast placebo once daily
39106|NCT00961155|Drug|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
39107|NCT00961168|Other|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
39108|NCT00961168|Other|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
39109|NCT00961181|Device|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
39110|NCT00961194|Drug|Ketamine|Initial dosage: 250 mg/5 ml
Three doses of ketamine will be tested:
0.35 mg/kg
0.7 mg/kg
1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).
The oral ketamine will be administered in form of syrup.
39111|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
39112|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
39412|NCT00963885|Drug|danoprevir|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
39413|NCT00963898|Device|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
39414|NCT00963911|Other|medical chart review|
39415|NCT00963911|Other|screening questionnaire administration|
39416|NCT00963911|Procedure|comparison of screening methods|
39417|NCT00963911|Procedure|quality-of-life assessment|
39418|NCT00963924|Drug|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
39419|NCT00022256|Drug|motexafin gadolinium|
39420|NCT00966485|Drug|80 mg ASA dosing|
39421|NCT00966485|Drug|500 mg ASA dosing|
39422|NCT00022529|Biological|trastuzumab|Given IV
39423|NCT00966498|Procedure|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
39424|NCT00966511|Procedure|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
38860|NCT00963066|Device|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
38861|NCT00963066|Device|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
38862|NCT00965250|Drug|IMC-12|20 mg/kg intravenously once every three weeks
38863|NCT00965263|Biological|TA-CD|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
38864|NCT00965289|Drug|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
38865|NCT00965302|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
38866|NCT00965302|Behavioral|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
38867|NCT00022425|Drug|perillyl alcohol|
38868|NCT00965315|Drug|Rosuvastatin,SFC fenofibrate|Rosuvastatin 10 mg once daily
Rosuvastatin 5 mg + SFC fenofibrate 160 mg
38869|NCT00965328|Procedure|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
38870|NCT00965328|Procedure|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
38871|NCT00965341|Drug|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
38872|NCT00965341|Drug|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
38873|NCT00965367|Device|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
38874|NCT00965393|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
38875|NCT00965393|Drug|Placebo|Systemic infusion of placebo (saline)
39167|NCT00959153|Device|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
39168|NCT00959192|Biological|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
39169|NCT00959192|Other|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
43100|NCT00970008|Other|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
43101|NCT00970008|Other|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
43102|NCT00970008|Other|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
43103|NCT00970021|Dietary Supplement|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
43104|NCT00970021|Dietary Supplement|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
43105|NCT00970060|Behavioral|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
43106|NCT00970073|Biological|Thymoglobulin|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
43124|NCT00972400|Other|laboratory biomarker analysis|
43125|NCT00972400|Other|mass spectrometry|
43126|NCT00972400|Other|questionnaire administration|
43127|NCT00972400|Procedure|assessment of therapy complications|
43128|NCT00972400|Procedure|cognitive assessment|
43129|NCT00972400|Procedure|quality-of-life assessment|
43130|NCT00972413|Radiation|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
43131|NCT00972413|Radiation|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
43132|NCT00000870|Drug|Lamivudine|
43133|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
43134|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
38405|NCT00964600|Procedure|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
38406|NCT00964626|Drug|cisplatin|
38407|NCT00964626|Drug|paclitaxel|
38712|NCT00967798|Drug|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
38713|NCT00967811|Drug|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
38714|NCT00967811|Drug|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
38715|NCT00022685|Biological|epratuzumab|
38716|NCT00967824|Other|informational intervention|
38717|NCT00967824|Other|questionnaire administration|
38718|NCT00967824|Other|survey administration|
38719|NCT00967837|Procedure|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
38720|NCT00967850|Drug|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
38721|NCT00967850|Drug|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
38722|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
38723|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
38724|NCT00960492|Radiation|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
38725|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
38726|NCT00960505|Other|Alternate day fasting|
38727|NCT00960505|Other|Calorie restriction|
38728|NCT00960505|Other|Control diet|
38729|NCT00960518|Drug|adefovir|adefovir at 10 mg daily for 48 weeks
39425|NCT00966524|Procedure|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
39426|NCT00966550|Other|Tomato|Tomato with high carb/fat meal
39427|NCT00966550|Other|Non-tomato|Non-tomato with high carb/fat meal
39428|NCT00966563|Drug|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
39429|NCT00966563|Drug|Placebo|
39430|NCT00966576|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
39431|NCT00966589|Procedure|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
39432|NCT00966602|Drug|VX-809|VX-809 capsule, once daily for 14 days
39433|NCT00022529|Other|pharmacological study|Correlative studies
39434|NCT00966602|Drug|VX-770|VX-770 tablet, once every 12 hours for 14 days
38469|NCT00962299|Drug|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
38470|NCT00962312|Drug|capecitabine|
38471|NCT00962312|Drug|lapatinib ditosylate|
38472|NCT00962325|Behavioral|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
38473|NCT00962338|Behavioral|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
38474|NCT00962351|Procedure|Total Hip Replacement|
38475|NCT00022178|Drug|cyclophosphamide|
38476|NCT00962364|Biological|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
38477|NCT00962377|Procedure|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
38478|NCT00962377|Procedure|AlloMap Molecular Testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
39170|NCT00959192|Other|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
39171|NCT00959205|Device|CARTO 3D|CARTO (3D Electroanatomic imaging)
39172|NCT00959205|Device|Angiography|Conventional fluoroscopically guided activation mapping
39173|NCT00959218|Drug|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
39174|NCT00959218|Drug|Placebo|oral solution
39175|NCT00959231|Drug|cyclophosphamide|
39176|NCT00021762|Biological|HIV-1 Immunogen|
39177|NCT00959231|Drug|cyclosporine|
39178|NCT00959231|Drug|fludarabine phosphate|
39179|NCT00959231|Drug|mycophenolate mofetil|
39180|NCT00959231|Other|laboratory biomarker analysis|
39181|NCT00959231|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
39182|NCT00959231|Procedure|umbilical cord blood transplantation|
39183|NCT00961220|Other|laboratory biomarker analysis|Correlative studies
39184|NCT00961233|Drug|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
39185|NCT00961233|Drug|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
39186|NCT00961246|Behavioral|general health information|participants received general health information
39187|NCT00961246|Behavioral|individually-tailored intervention|participants received individually-tailored intervention
39188|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
39189|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
39190|NCT00961259|Drug|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
39191|NCT00000864|Drug|Zidovudine|
39495|NCT00963950|Procedure|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
43135|NCT00974779|Device|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
43136|NCT00974779|Device|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
43137|NCT00974792|Biological|pegfilgrastim|
43138|NCT00974792|Biological|rituximab|
43139|NCT00974792|Drug|cyclophosphamide|
43140|NCT00974792|Drug|cytarabine|
43141|NCT00974792|Drug|doxorubicin hydrochloride|
43142|NCT00023465|Procedure|bronchoscopy with BAL|
43143|NCT00974792|Drug|etoposide phosphate|
43144|NCT00974792|Drug|ifosfamide|
43145|NCT00974792|Drug|leucovorin calcium|
43146|NCT00974792|Drug|methotrexate|
43147|NCT00974792|Drug|vincristine sulfate|
43148|NCT00974805|Drug|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
42176|NCT00977756|Drug|Raltegravir (RAL)|400 mg twice daily (BID)
42177|NCT00977756|Drug|Atazanavir (ATV)|300 mg daily
42178|NCT00977756|Drug|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
42179|NCT00023777|Biological|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
42180|NCT00977756|Drug|Tenofovir (TDF)|300 mg daily
42181|NCT00977756|Drug|Etravirine (ETV)|200 mg BID
42182|NCT00977756|Drug|Darunavir (DRV)|Dosing by weight
42183|NCT00977756|Drug|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
42184|NCT00977756|Drug|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
42185|NCT00977769|Drug|carbetocin 100 µg|Hemodynamic effect of
38730|NCT00960518|Procedure|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
38731|NCT00022113|Other|pharmacological study|Correlative studies
38732|NCT00960531|Drug|ACC-001+ QS21|IM injection, ACC-001(3mcg, or 10mcg, or 30mcg) + QS-21 50 mcg at Day 1 and weeks 26, 52, and 78
39038|NCT00963300|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
39039|NCT00963300|Procedure|magnetic resonance spectroscopic imaging|
39040|NCT00963300|Procedure|tissue-oxygen-level-dependent functional magnetic resonance imaging|
39041|NCT00963313|Drug|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
39042|NCT00963326|Other|laboratory biomarker analysis|
39043|NCT00963339|Device|Foresee Home|Home Monitoring
39044|NCT00963365|Drug|AZD6765|Single oral dose and single IV infusion of AZD6765
39045|NCT00963365|Drug|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
39046|NCT00963391|Other|ABHS use|Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.
Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
39047|NCT00963404|Radiation|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
39048|NCT00022217|Drug|paclitaxel|
39049|NCT00963417|Other|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
39050|NCT00963417|Procedure|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
39051|NCT00965731|Drug|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
39052|NCT00000866|Biological|MN rgp120/HIV-1|
38479|NCT00962390|Drug|S-equol|10mg S-equol 50mg S-equol, & 150mg S-equol
38480|NCT00962390|Drug|Placebo|Placebo
38481|NCT00962403|Behavioral|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
38482|NCT00962416|Device|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
38483|NCT00962416|Device|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
38484|NCT00962429|Drug|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
38485|NCT00962442|Drug|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
38486|NCT00022178|Drug|doxorubicin hydrochloride|
38487|NCT00964691|Drug|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
38798|NCT00967967|Drug|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
38799|NCT00967980|Procedure|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
38800|NCT00967993|Drug|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
38801|NCT00968006|Drug|Sitagliptin|100 mg once daily for 4 weeks
38802|NCT00968019|Device|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
38803|NCT00968032|Device|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
38804|NCT00968045|Drug|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
38805|NCT00968058|Procedure|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
39496|NCT00963950|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
39497|NCT00963963|Behavioral|Healthy Futures parent education|Multi-year audio CD parent education
39498|NCT00963976|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
39499|NCT00963989|Device|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
39500|NCT00022256|Radiation|radiation therapy|
39501|NCT00964002|Drug|efavirenz|
39502|NCT00964015|Drug|6% Hydroxyethyl Starch 130/0.4|
39503|NCT00964015|Drug|0.9% Normal Saline|
39504|NCT00964028|Biological|Infanrix™-IPV/Hib|Intramuscular, three doses
39505|NCT00964041|Drug|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
39506|NCT00964041|Drug|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
39507|NCT00964054|Other|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
39508|NCT00964054|Other|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
39509|NCT00964067|Other|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
39510|NCT00964080|Drug|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
39511|NCT00022282|Drug|shark cartilage extract AE-941|
39512|NCT00964093|Device|Silver Alginate|(Algidex ™)
39513|NCT00964106|Drug|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
39514|NCT00964106|Drug|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
39515|NCT00964106|Drug|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
39516|NCT00966654|Drug|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline or GLP-1 infused continuously over 72 hours.
42186|NCT00977769|Drug|oxytocin 5 u|Hemodynamic effect of
42187|NCT00977769|Drug|placebo (NaCl)|Hemodynamic effect of
42188|NCT00977782|Drug|Midostaurin (PKC412)|
42189|NCT00980135|Device|Sinecort cream|Application over 29 days
42190|NCT00980135|Drug|Hydrocortison cream|Application over 29 days
42191|NCT00980135|Other|Untreated skin|n.a
42192|NCT00980148|Drug|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
42193|NCT00980148|Drug|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
42194|NCT00980174|Drug|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
42195|NCT00980174|Other|Placebo|Placebo for denosumab (SC injection every 6 months)
42196|NCT00980187|Drug|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
42197|NCT00023959|Biological|bevacizumab|Given IV
42198|NCT00980187|Drug|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
42199|NCT00980200|Drug|Dose 4 QD|QD once daily
42200|NCT00980200|Drug|Dose 3 QD|QD once daily
42201|NCT00980200|Drug|placebo|placebo
42202|NCT00980200|Drug|Dose 2 QD|QD once daily
42500|NCT00980850|Biological|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
42501|NCT00980863|Behavioral|lifestyle intervention to increase physical activity|
42502|NCT00980876|Drug|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
42503|NCT00980876|Drug|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
42504|NCT00980889|Device|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
42505|NCT00980889|Device|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
39053|NCT00022451|Drug|tipifarnib|
39054|NCT00965731|Drug|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
39055|NCT00965744|Device|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
39056|NCT00965757|Drug|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
39057|NCT00965757|Drug|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
39351|NCT00959374|Device|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
39352|NCT00959374|Device|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
39353|NCT00959387|Drug|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
39354|NCT00959387|Radiation|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
39355|NCT00959400|Drug|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
39356|NCT00959426|Drug|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
39357|NCT00959426|Drug|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
39358|NCT00959439|Drug|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
39359|NCT00959439|Drug|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
39360|NCT00959452|Behavioral|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
39361|NCT00000862|Drug|Zidovudine|
38806|NCT00968071|Drug|Decitabine|20 mg/m^2 IV over an hour and half daily for 5 days.
38807|NCT00968071|Drug|Gemtuzumab Ozogamicin|3 mg/m^2 IV on day 5.
38808|NCT00022724|Drug|temsirolimus|
38809|NCT00968097|Drug|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
38810|NCT00968110|Drug|omalizumab|Dosing table established for omalizumab
38811|NCT00968149|Drug|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
38812|NCT00968149|Drug|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
38813|NCT00968162|Drug|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
38814|NCT00968175|Procedure|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
38815|NCT00968188|Behavioral|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
38816|NCT00968188|Behavioral|Information only|Medically fact based HIV information delivered online.
38817|NCT00968201|Drug|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
39113|NCT00022126|Drug|methotrexate|
39114|NCT00961220|Drug|O6-benzylguanine|Given IV. 120 mg/m2 over 1 hour
39115|NCT00961220|Drug|carmustine|Applied topically. BCNU will begin at a starting dose of 20 mg on Day 1. Beyond this first dose level, for each of the subsequent four patients enrolled, the BCNU dose will be escalated up to a limit of 40 mg total (given on day 1 only).
39116|NCT00963430|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
39117|NCT00963443|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
39118|NCT00963443|Drug|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
39119|NCT00963443|Drug|Placebo|Matching Placebo
39517|NCT00000866|Biological|TBC-3B Vaccine|
39518|NCT00022542|Drug|ixabepilone|Given IV
38553|NCT00960375|Behavioral|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
38554|NCT00960375|Behavioral|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
38555|NCT00960414|Behavioral|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detained nutritional education.
38556|NCT00960427|Drug|systemic chemotherapy|
38557|NCT00022087|Dietary Supplement|cholecalciferol|400 IU PO per day
38558|NCT00962442|Drug|placebo|Glucosé 5% perfusion for 14 days, intravenously
38559|NCT00962455|Other|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
38560|NCT00962455|Other|usual practice|Usual practice regarding spirometry execution in family practice
38561|NCT00962468|Other|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
38562|NCT00962481|Drug|Bimosiamose|
38563|NCT00962481|Drug|Placebo|
38564|NCT00962494|Behavioral|Cancer: Thriving and Surviving Online Workshop|
38565|NCT00962507|Drug|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
38566|NCT00962507|Drug|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
38567|NCT00962507|Other|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
38568|NCT00022178|Drug|epirubicin hydrochloride|
42506|NCT00023998|Drug|doxorubicin hydrochloride|Given IV
42507|NCT00980941|Dietary Supplement|soup with or without starch|
42508|NCT00980954|Drug|carboplatin|Given IV
42509|NCT00980954|Drug|cisplatin|Given IV
42510|NCT00983151|Drug|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
42511|NCT00983164|Dietary Supplement|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
42512|NCT00983177|Drug|Colchicine|0.5 mg twice daily for 4 months
42513|NCT00983177|Drug|lactose|lactose capsules twice daily
42514|NCT00983190|Device|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
42515|NCT00983203|Other|FID 114657 ORB Preserved Ocular Emulsion|1 drop OU
42516|NCT00024128|Biological|anti-thymocyte globulin|
42517|NCT00983203|Other|Soothe XP Lubricant Eye Drops|1 drop OU
42518|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
42519|NCT00983216|Drug|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
42520|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
42779|NCT00974272|Other|Normal Saline|Single subcutaneous injection
42780|NCT00974285|Drug|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
42781|NCT00974285|Drug|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
42782|NCT00023413|Drug|Efavirenz|
39362|NCT00021814|Drug|Doxazosin|
39363|NCT00959465|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
39364|NCT00959478|Behavioral|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
39365|NCT00959517|Drug|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
39366|NCT00959517|Drug|sulphadoxine-pyrimethamine (SP)|
39367|NCT00959517|Drug|Chloroquine (CQ)|
38408|NCT00964639|Drug|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
38409|NCT00022360|Drug|taurolidine|
38410|NCT00964639|Drug|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
38411|NCT00964652|Other|Treadmill walking training with additional body load|The training program was divided into three phases (A1-B-A2):
treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle.
38412|NCT00964665|Drug|albinterferon alfa-2b|
38413|NCT00964665|Drug|albinterferon alfa-2b|
38414|NCT00964665|Drug|albinterferon alfa-2b|
38415|NCT00964665|Drug|albinterferon alfa-2b|
38416|NCT00964665|Drug|Pegasys®|
38417|NCT00964678|Drug|Carvedilol|twice daily oral treatment in escalating dose
38418|NCT00964691|Drug|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
38419|NCT00967213|Drug|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
39120|NCT00963469|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
39121|NCT00963469|Drug|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
39122|NCT00963469|Drug|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
39123|NCT00963482|Behavioral|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra & Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
39124|NCT00022230|Biological|aldesleukin|
39125|NCT00963482|Behavioral|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
39126|NCT00963495|Drug|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
39127|NCT00963508|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
39128|NCT00963508|Drug|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
39129|NCT00963521|Biological|therapeutic autologous dendritic cells|
39130|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.
Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab.
39131|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
39435|NCT00966602|Drug|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
39436|NCT00966602|Drug|Placebo|Matching Placebo
39437|NCT00966615|Other|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
39438|NCT00966615|Other|glucose-based dialysis solution|2-L exchange; three times a day
39439|NCT00966628|Drug|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
38569|NCT00962507|Other|pharmacological study|Pre-study, day 1 and day 26
38570|NCT00962520|Drug|Erlotinib|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
38571|NCT00962520|Drug|capecitabine|Capecitabine 800 mg/m2 PO BID (1600 mg/m2 total) (5 days on/2 days off regimen)
38876|NCT00965393|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
38877|NCT00965406|Drug|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
38878|NCT00022438|Biological|aldesleukin|
38879|NCT00965419|Drug|LY2216684|0.1 mg/kg/day or patient specific known stable dose (rollover patients) up to 0.3 mg/kg/day, oral, daily for up to 5 years.
38880|NCT00965432|Drug|STX107|Single dose of an oral suspension
38881|NCT00965458|Biological|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
38882|NCT00965458|Drug|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
38883|NCT00965471|Drug|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
38884|NCT00965471|Drug|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
38885|NCT00965484|Device|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
38886|NCT00967616|Drug|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|FOLFIRI will be administered IV once every 2 weeks.
The FOLFIRI regimen consists of:
Irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes
Leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion
5-FU, 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion)
38887|NCT00967629|Drug|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
45069|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45070|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45071|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45072|NCT01001195|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45073|NCT00025441|Biological|dactinomycin|
45074|NCT01001208|Drug|Methotrexate|Methotrexate tablets over-encapsulated for blinding
45075|NCT01001208|Drug|Etanercept|1 mL for subcutaneous injection
45076|NCT01001208|Drug|Placebo|Matching placebo to methotrexate capsules
45077|NCT01001221|Drug|cabazitaxel|Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion
Route of administration: Intravenous infusion over 60 minutes
Dosage:
Study part 1: 15, 20 or 25 mg/m^2 according to pre-defined dose escalation schedule
Study part 2: MTD as determined in Study part 1
45078|NCT01001221|Drug|gemcitabine|Pharmaceutical form: According to United States Package Insert (USPI)
Route of administration: Intravenous infusion over 30 minutes
Dosage:
Study part 1: 700, 900 or 1000 mg/m^2 according to pre-defined dose escalation schedule
Study part 2: MTD as determined in Study part 1.
45079|NCT01001234|Drug|rizatriptan|For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).
Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet.
45346|NCT01001572|Drug|Placebo|1 capsule or tablet taken orally once daily
45347|NCT01001585|Drug|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
45348|NCT01001598|Drug|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
45349|NCT01001611|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
45350|NCT01001611|Drug|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
45351|NCT01001624|Other|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
44977|NCT00025428|Procedure|conventional surgery|
44978|NCT01001078|Device|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
44979|NCT01001078|Device|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
44980|NCT01001078|Device|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
44981|NCT01001091|Drug|AL-38583 ophthalmic solution|
44982|NCT01001091|Drug|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
44983|NCT00025545|Drug|methotrexate|
44984|NCT01003548|Device|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
44985|NCT01003548|Device|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
44986|NCT01003561|Procedure|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
44987|NCT01003574|Behavioral|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
44988|NCT01003574|Behavioral|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
44989|NCT01003587|Behavioral|District health information package|The intervention package consists of:
A report on disease burden, disease control priorities and health system performance in India
Condensed fact sheet based on the report
District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district
Customized speech for district level officials detailing key actions to reduce deaths
Reminder materials including poster version of the DRCs and video on key points and actionable messages
44990|NCT01003600|Behavioral|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
44991|NCT01003613|Drug|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
45286|NCT01004146|Procedure|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
45411|NCT00999336|Drug|Betrixaban|80 mg betrixaban qd for 8 days
45412|NCT00025389|Drug|carboplatin|
45413|NCT00999349|Drug|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
45414|NCT00999349|Drug|Placebo|
45415|NCT00999375|Behavioral|Education|
45416|NCT00999375|Behavioral|Problem Solving|
45417|NCT00999375|Behavioral|Social Learning|
45418|NCT00999375|Behavioral|Behavior Modification|
45419|NCT00999401|Drug|sapacitabine and seliciclib|sequential administration of sapacitabine and seliciclib
45420|NCT00999414|Drug|Carfilzomib|Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.
Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.
For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2.
45421|NCT00999427|Drug|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
45422|NCT00999440|Drug|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
45423|NCT00025389|Drug|paclitaxel|
45773|NCT00990236|Device|Thrombelastography (TEG®)|TEG 5000 Series Analyzer is an FDA approved device that measures blood clotting using whole blood. Blood will be collected from subjects and analyzed using the TEG. Subjects will not have direct contact with the TEG.
45774|NCT00990249|Drug|Busulfan|Test Dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
45775|NCT00990249|Drug|Clofarabine|40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3
45776|NCT00990249|Drug|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
44908|NCT01003496|Behavioral|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
44909|NCT01003509|Procedure|modified shouldice and double|one arm modified shouldice, other one is double repair
44910|NCT01003522|Other|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
44911|NCT01003522|Other|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
44912|NCT01003522|Procedure|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
44913|NCT01003522|Procedure|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
44914|NCT01003522|Other|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
44915|NCT01003522|Other|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
44916|NCT01003522|Other|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
44917|NCT01005459|Drug|Bupivacaine|Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
44918|NCT01005472|Drug|sunitinib malate|
45202|NCT00025298|Drug|amifostine trihydrate|
45203|NCT00996398|Other|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
45204|NCT00996411|Drug|Salvinorin A|This is an initial dose ranging study
45205|NCT00996424|Drug|Acetylcysteine|Inhalation with N-Acetylcysteine
45206|NCT00996424|Drug|normal saline|Inhalation with normal saline solution
45207|NCT00996437|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
45208|NCT00996437|Drug|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
45484|NCT00996879|Drug|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
45485|NCT00996879|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
45486|NCT00996892|Drug|GDC-0941|Repeating oral dose
45487|NCT00025324|Drug|carboplatin|
45488|NCT00996892|Drug|GDC-0973/XL518|Repeating oral dose
45489|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
45490|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
45491|NCT00996918|Drug|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
45492|NCT00996918|Drug|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
45493|NCT00996931|Drug|lenalidomide|2.5 mgs per day orally for 12 weeks
45494|NCT00996944|Drug|Ropinirole immediate release (IR)|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting "much improved" or "very much improved" in the CGI-I) without safety/tolerability problem.
45495|NCT00996944|Drug|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
45496|NCT00996957|Biological|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
45497|NCT00996983|Drug|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
45498|NCT00025324|Drug|cyclophosphamide|
45499|NCT00999505|Drug|Amantadine|Amantadine 200mg twice a day over 12 weeks
45500|NCT00999505|Drug|Placebo|Placebo capsules twice a day over 12 weeks
45854|NCT00988299|Other|exercise|exercise sessions at 45% and 60% of maximum effort
45855|NCT00988312|Biological|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
45287|NCT01004159|Drug|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
45288|NCT01004172|Drug|carboplatin|Given intravenously on Day 8 of cycle one and Day 1 of each subsequent cycle.
45289|NCT01004172|Drug|bevacizumab|Given intravenously on day 1 of each cycle
45290|NCT01004172|Drug|herceptin|given intravenously for patients with HER2-positive breast cancer only
45291|NCT01004185|Drug|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM & 2 Asacol 400mg PM; 33-<54kg = 5 Asacol 400 mg AM & 4 Asacol 400mg PM; 54-<90kg = 6 Asacol 400mg AM & PM
45292|NCT01004185|Drug|Asacol 400 mg|17-<33kg = 2 Asacol 400mg & 1 placebo AM, 1 Asacol 400mg & 1 placebo PM; 33-<54kg = 3 Asacol 400mg & 2 placebo AM, 2 Asacol 400mg & 2 placebo PM; 54-<90kg = 3 Asacol 400mg & 3 placebo AM & PM
45293|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
45294|NCT00025558|Procedure|peripheral blood stem cell transplantation|
45295|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
45296|NCT00996541|Behavioral|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
45297|NCT00996554|Procedure|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
45298|NCT00996554|Procedure|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
45299|NCT00996567|Drug|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
45300|NCT00996580|Drug|DR-103|One tablet daily.
Four 91-day cycles of the DR-103 regimen:
42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE.
45301|NCT00996593|Biological|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
45302|NCT00996606|Drug|DMARDs|stable dose as prescribed
45777|NCT00990249|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
45778|NCT00990262|Radiation|Cardiac Computed Tomography|Localization of the heart position in a projectional topographic scan of the chest.
Determination of contrast agent transit time: 10 ml contrast agent.
CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds.
45779|NCT00990275|Other|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
45780|NCT00990288|Drug|Hemostatic Matrix|
45781|NCT00990301|Drug|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
45782|NCT00025051|Procedure|cancer prevention intervention|
45783|NCT00990301|Drug|Uniretic® 15mg/25mg Tablets|reference drug
45784|NCT00990314|Drug|Beraprost Sodium Modified Release|
45785|NCT00990327|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
45786|NCT00990327|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
45787|NCT00992745|Drug|111-In capromab pendetide|Single 5 mCi intravenous injection
45788|NCT00025103|Drug|melphalan|
45789|NCT00992745|Drug|123-I-MIP-1072|Single 5 mCi intravenous injection
45790|NCT00992758|Biological|Iodine-131 Anti-B1 Antibody|Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.
Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached.
45791|NCT00992771|Drug|varenicline|up to 1mg BID for 8 weeks
45792|NCT00992771|Drug|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
44854|NCT01005342|Other|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
44855|NCT01005342|Other|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
44856|NCT01005342|Other|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
45209|NCT00996463|Procedure|Electro-thermo-coagulation|Electro-thermo-coagulation
45210|NCT00996463|Drug|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
45211|NCT00996463|Drug|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
45212|NCT00996476|Drug|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
45213|NCT00025298|Drug|carboplatin|
45214|NCT00996476|Drug|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
45215|NCT00996476|Drug|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
45216|NCT00996489|Device|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
45217|NCT00996502|Drug|Docetaxel|Phase I:
Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle
Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle
Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle
45218|NCT00996502|Drug|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
45219|NCT00996502|Drug|Erlotinib|200 mg of Erlotinib PO daily days 2-16
45220|NCT00996502|Drug|Prednisone|5 mg of Prednisone PO bid
45221|NCT00996515|Drug|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
45222|NCT00996515|Drug|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
45223|NCT00996528|Behavioral|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
45224|NCT00025298|Drug|cisplatin|
45481|NCT00996853|Other|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
45482|NCT00996866|Drug|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
45483|NCT00996866|Drug|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
45856|NCT00988325|Drug|Tamiflu|oral repeating dose
45857|NCT00988338|Biological|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
45858|NCT00990340|Device|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
45859|NCT00990340|Procedure|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
45860|NCT00990366|Device|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
45861|NCT00990392|Drug|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
45862|NCT00990392|Other|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
45863|NCT00990405|Drug|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
45864|NCT00025051|Procedure|chemoprevention of cancer|
45865|NCT00990418|Drug|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
45866|NCT00990431|Procedure|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
45867|NCT00990431|Procedure|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
45868|NCT00990444|Drug|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
45869|NCT00990457|Behavioral|Weight Loss Diets Plus Exercise|The weight loss diet will be either a low-carbohydrate diet or a low-fat, low-calorie diet. All participants will also be enrolled in a supervised exercise program.
The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
45870|NCT00990496|Drug|Fludarabine|30 mg/m2
45871|NCT00990496|Drug|Cyclophosphamide|600 mg/m2
45303|NCT00996606|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv infusion every 4 weeks for 48 weeks
45568|NCT01004536|Other|no treatment|left untreated during the study period
45569|NCT01004562|Other|informational intervention|
45570|NCT01004575|Device|Kaname cobalt-chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
45571|NCT00025597|Drug|doxorubicin hydrochloride|
45572|NCT01004588|Dietary Supplement|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
45573|NCT01004588|Dietary Supplement|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
45574|NCT01004601|Drug|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
45575|NCT01004601|Drug|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
45576|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
45577|NCT00996996|Biological|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).
Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass.
45578|NCT00997009|Drug|paclitaxel|175 mg/m2 IV day 1, every 21 days
45579|NCT00997009|Drug|carboplatin|AUC 5 IV day 1 every 21 days
45580|NCT00997009|Drug|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
45581|NCT00997022|Drug|Sorafenib|Dose escalation:
Dose level 1: 200mg of sorafenib daily
Dose level 2: 200mg of sorafenib BID (twice daily)
Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)
Dose level 4: 400mg BID (twice daily)
45582|NCT00997035|Drug|Voriconazole|1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing <40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.
44857|NCT01005342|Other|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
44858|NCT00025623|Procedure|conventional surgery|
44859|NCT01005342|Other|Control|No fiber was added to control meal (250 g black-currant beverage)
44860|NCT01005355|Biological|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
44861|NCT00998361|Procedure|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
44862|NCT00998400|Behavioral|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
44863|NCT00998413|Behavioral|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
44864|NCT00025363|Drug|ifosfamide|Given IV
44865|NCT00998426|Procedure|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
44866|NCT00998426|Biological|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
45143|NCT00025363|Other|pharmacogenomic studies|Correlative studies
45144|NCT00998946|Dietary Supplement|Folic Acid|1 mg orally
Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.
45145|NCT00998959|Behavioral|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
45000|NCT01003678|Drug|Clofarabine|Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.
Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug.
45001|NCT01005758|Drug|doxorubicin hydrochloride|
45002|NCT01005758|Drug|etoposide phosphate|
45003|NCT01005758|Drug|hydrocortisone sodium succinate|
45004|NCT01005758|Drug|imatinib mesylate|
45005|NCT00025636|Drug|etoposide|
45006|NCT01005758|Drug|mercaptopurine|
45007|NCT01005758|Drug|methotrexate|
45008|NCT01005758|Drug|methylprednisolone|
45009|NCT01005758|Drug|pegaspargase|
45010|NCT01005758|Drug|prednisolone|
45011|NCT01005758|Drug|prednisone|
45012|NCT01005758|Drug|vincristine sulfate|
45013|NCT01005758|Other|laboratory biomarker analysis|
45608|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
45609|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
45610|NCT00992524|Drug|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
45611|NCT00992524|Drug|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
45612|NCT00992537|Drug|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
45613|NCT00992537|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
45614|NCT00025103|Drug|cyclophosphamide|
45615|NCT00992537|Drug|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
44919|NCT01005472|Drug|temozolomide|
44920|NCT01005498|Dietary Supplement|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
44921|NCT01005498|Dietary Supplement|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
44922|NCT01005511|Device|Grindcare|Active treatment
44923|NCT01005511|Device|Grindcare - inactive|Placebo treatment
44924|NCT01005537|Biological|aldesleukin|Given IV and orally
44925|NCT00025636|Drug|cisplatin|
44926|NCT01005537|Biological|therapeutic autologous lymphocytes|Given IV
44927|NCT01005537|Drug|cyclophosphamide|Given IV
44928|NCT01005550|Drug|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
44929|NCT01005550|Drug|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
44930|NCT01005550|Drug|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
44931|NCT01005550|Drug|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
44932|NCT01005563|Other|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
44933|NCT01005563|Other|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
44934|NCT01005576|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
44935|NCT01005602|Other|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
44936|NCT00000885|Drug|Efavirenz|
44937|NCT00025636|Drug|cyclophosphamide|
44938|NCT01005602|Drug|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
45352|NCT01001624|Other|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
45353|NCT00025441|Drug|etoposide|
45354|NCT01001637|Dietary Supplement|Curcumin Formulation|2000mg or 3000mg daily BID
45355|NCT01001637|Dietary Supplement|Placebo|Placebo
45356|NCT01001650|Biological|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|Group 1: 4 doses of 7,500 PfSPZ/immunization,
Group 2: 4 doses of 30,000 PfSPZ/immunization,
Group 3: 4 doses of 135,000 PfSPZ/immunization, and
Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.
If > 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.
45357|NCT01001663|Device|FemoSeal®|Closure device for femoral artery access closure
45358|NCT01001663|Other|Manual compression|Conventional manual compression
45359|NCT01001676|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
45360|NCT01001676|Device|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
45361|NCT01001689|Behavioral|Nutritional counseling and twice weekly exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
45362|NCT01001702|Drug|Aripiprazole|Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
45363|NCT01001715|Drug|REGN475/SAR164877|Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes
45364|NCT01004198|Drug|Ringers Lactate solution|Ringers Lactate solution for Injection
45365|NCT01004211|Procedure|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
45715|NCT00992706|Drug|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
45716|NCT00992719|Biological|Inactivated H1N1 Vaccine|H1N1 vaccine [Influenza A (H1N1) 2009 Monovalent Vaccine] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
45717|NCT00992732|Drug|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
45146|NCT00998959|Behavioral|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
45147|NCT00998972|Drug|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
45148|NCT00998985|Drug|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
45149|NCT00998985|Drug|Placebo|Placebo tablet, orally, once a day for 7 days
45150|NCT00998998|Behavioral|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
45151|NCT00998998|Behavioral|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
45152|NCT00998998|Dietary Supplement|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
45153|NCT01001234|Drug|rizatriptan|For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder [moderate or severe pain 15 minutes after dose] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet.
45154|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
45155|NCT01001247|Drug|TMC278; Omeprazole|
45156|NCT00025441|Biological|filgrastim|
45157|NCT01001260|Drug|No ASA|Alternative antiplatelet therapy instead of aspirin
45158|NCT01001260|Drug|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
45159|NCT01001260|Drug|325 mg ASA|high dose of aspirin prior to PTCA
45160|NCT01001273|Other|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
45424|NCT00999453|Other|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
45425|NCT00999466|Drug|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
45616|NCT00992550|Drug|Cigarette|
45617|NCT00992550|Drug|Hookah|
45618|NCT00992563|Drug|AL-39324 ophthalmic suspension|
45619|NCT00992563|Drug|Ranibizumab 10 mg/mL|
45620|NCT00992576|Drug|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
45621|NCT00992576|Drug|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
45622|NCT00992589|Drug|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
45623|NCT00992589|Drug|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
45624|NCT00994773|Drug|Tenofovir|
45625|NCT00994773|Drug|Entecavir|Entecavir
45626|NCT00025233|Biological|bevacizumab|Given IV
45627|NCT00994786|Drug|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
45628|NCT00994786|Drug|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
45649|NCT00987974|Drug|placebo|placebo for 3 days.
45650|NCT00987974|Drug|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
45651|NCT00987974|Drug|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
45652|NCT00024466|Procedure|autologous hematopoietic stem cell transplantation|
45653|NCT00987974|Drug|placebo 7 days|placebo 7 days
45654|NCT00987987|Procedure|donor lymphocyte infusion|regulatory T cells depletion
45655|NCT00988000|Other|telephone consultation|alternative to face to face consultation for new referrals
45656|NCT00988013|Radiation|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
45225|NCT00999011|Procedure|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
45226|NCT00025363|Other|laboratory biomarker analysis|Correlative studies
45227|NCT00999011|Procedure|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
45228|NCT00999037|Drug|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
45229|NCT00999037|Other|Placebo|1 inert tablet tid x 12 weeks
45230|NCT00999050|Procedure|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
45231|NCT00999089|Procedure|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
45232|NCT00999089|Procedure|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
45233|NCT00999089|Procedure|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
45234|NCT00999102|Drug|Metoprolol|Comparison of Metoprolol and Nebivolol. Metoprolol succinate will be given at a dose of 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks. For nebivolol, dosage will be 5 mg and 10mg daily. Identical-appearing pills will be given, and the drugs will be given in randomized order without a placebo run-in.
45235|NCT00999102|Drug|Nebivolol|Comparison of Metoprolol and Nebivolol. Metoprolol succinate will be given at a dose of 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks. For nebivolol, dosage will be 5 mg and 10mg daily. Identical-appearing pills will be given, and the drugs will be given in randomized order without a placebo run-in.
45236|NCT00999115|Drug|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
45237|NCT00000882|Drug|Stavudine|
45238|NCT00025376|Drug|PS-341|
45239|NCT00999128|Drug|GDC-0941|Oral repeating dose
45240|NCT00999128|Drug|rabeprazole|Oral repeating dose
45718|NCT00992732|Drug|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
45719|NCT00992745|Drug|123-I-MIP-1072|Single 10 mCi intravenous injection
45720|NCT00994929|Biological|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
45721|NCT00994942|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
45722|NCT00994955|Device|selective retina therapy (SRT)|laser treatment
45723|NCT00025246|Drug|imatinib mesylate|Given orally
45724|NCT00994968|Drug|cyclophosphamide|
45725|NCT00994968|Drug|docetaxel|
45726|NCT00994968|Drug|doxorubicin hydrochloride|
45727|NCT00994968|Drug|tegafur-gimeracil-oteracil potassium|
45728|NCT00994968|Procedure|neoadjuvant therapy|
45729|NCT00994968|Procedure|therapeutic conventional surgery|
45730|NCT00994981|Drug|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
45731|NCT00994981|Drug|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
45732|NCT00994994|Drug|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
45733|NCT00995007|Drug|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
44790|NCT00000883|Drug|Azithromycin|
44791|NCT00025428|Drug|carboplatin|
44792|NCT01000636|Procedure|Metvix PDT|Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.
The target field will then be exposed to red light using Aktilite 128 lamp.
45426|NCT00999466|Drug|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
45427|NCT00999479|Drug|Norethindrone acetate and ethinyl estradiol tablets, USP|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.
Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc.
45428|NCT00999479|Drug|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
45429|NCT00999492|Device|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
45430|NCT00025441|Drug|ifosfamide|
45431|NCT01001715|Drug|Placebo (for REGN475/SAR164877)|Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes
45432|NCT01001728|Radiation|Imaging investigations (with radiation)|
45433|NCT01001741|Other|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
45434|NCT01001754|Drug|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
45435|NCT01001754|Drug|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
45436|NCT01001754|Drug|Ribavirin|Daily oral administration (400-600 mg BID)
45437|NCT01001767|Drug|Lovaza|Lovaza one gram twice a day for 24 weeks
45438|NCT01001767|Drug|Placebo|Placebo
45439|NCT01001780|Drug|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
45440|NCT01001793|Device|Levacor Ventricular Assist Device|Surgical procedure
45441|NCT00025441|Drug|vincristine sulfate|
45442|NCT01001806|Drug|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
45443|NCT01001806|Drug|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
45793|NCT00992784|Biological|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
45657|NCT00988013|Radiation|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
45658|NCT00988013|Radiation|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
45659|NCT00988013|Radiation|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
45660|NCT00988026|Drug|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
45661|NCT00988039|Drug|Aluvia + 2NRTIs|Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily
The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.
45662|NCT00988039|Drug|Aluvia + raltegravir|Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily
raltegravir (400mg) twice daily
45663|NCT00024466|Procedure|peripheral blood stem cell transplantation|
45664|NCT00988039|Drug|Aluvia monotherapy|Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily
raltegravir (400mg) twice daily for the first 12 weeks only
45665|NCT00988052|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
45666|NCT00988065|Drug|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
45667|NCT00988065|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
45668|NCT00988065|Drug|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
45669|NCT00988065|Drug|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
45670|NCT00988078|Drug|Placebo|Capsule (without biologic action) administered three times a day for six months
45671|NCT00988078|Drug|Metformin|Metformin 500mg three times a day for six months
45961|NCT00993018|Drug|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
45962|NCT00993018|Drug|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
45963|NCT00993031|Drug|Lopinavir/ritonavir|LPV 200mg/r 50mg
45964|NCT00993031|Drug|Efavirenz|600mg
45965|NCT00000879|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
45241|NCT00999141|Biological|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
45242|NCT00999167|Drug|HPN-100|Part B: 6 mL BID for 16 weeks.
45501|NCT00999518|Biological|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
45502|NCT00999518|Biological|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
45503|NCT00025389|Procedure|conventional surgery|
45504|NCT00999518|Biological|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
45505|NCT00999518|Biological|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
45506|NCT00999518|Other|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
45507|NCT00999531|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
45508|NCT00999531|Drug|Placebo|Inhaled Placebo, sterile saline
45509|NCT00999544|Drug|Aprepitant|Aprepitant (0, 40, 200 mg, p.o.) to be given in combination with a range of oxycodone doses (p.o. 20 and 40 mg, i.n. 15 and 30 mg) and double-dummy placebo with each aprepitant and oxycodone being tested once in each subject (a total of 15 conditions) in random order
45510|NCT00999544|Drug|Placebo|placebo condition
45511|NCT00999544|Drug|Oxycodone|Oxycodone was administered at 15 and 30 mg intranasally and at 20 and 40 mg orally once after each of the oral pretreatment conditions (placebo and active aprepitant)
45512|NCT00999557|Drug|bimatoprost ophthalmic solution|Applied topically
45513|NCT00999557|Drug|placebo|Applied topically
45514|NCT00025389|Procedure|neoadjuvant therapy|
45515|NCT00999570|Other|Specialty training for knee surgeons|
45516|NCT00999583|Drug|EPOETINE ALPHA|5 injections of 40000 UI of EPO
45517|NCT00999583|Other|Control arm|Usual take care of cardiac arrest
45518|NCT00999609|Biological|AAV2-hRPE65v2|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
45519|NCT00999622|Other|laboratory biomarker analysis|
45520|NCT00999622|Other|questionnaire administration|
44793|NCT01000649|Drug|FE 202158|
44794|NCT01000649|Drug|Sodium Chloride|
44795|NCT01000662|Radiation|Radiation Therapy|Arm 1= 15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
44796|NCT01000688|Drug|vildagliptin + acarbose|4 week treatment
44797|NCT01000688|Drug|acarbose + vildagliptin|4 week treatment
44798|NCT01000714|Drug|Psirelax|
44799|NCT01000727|Drug|Darapladib 160 mg|Lp-PLA2 inhibitor
44800|NCT01000727|Drug|Placebo|Placebo administered
44801|NCT01000727|Other|Standard Therapy|Guideline mandated therapy for individual's condition
44802|NCT00025428|Drug|cyclophosphamide|
44803|NCT01000740|Genetic|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
44804|NCT01000740|Genetic|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
44805|NCT01000753|Other|biologic sample preservation procedure|
44806|NCT01000753|Other|informational intervention|
44807|NCT01000779|Drug|Propranolol|upto 320mg/day maximum
44808|NCT01000779|Device|multi band ligator for esophageal varices|to obliterate esophageal varices
44809|NCT01000792|Drug|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
44810|NCT01000792|Drug|Levocetirizine|Levocetirizine
44811|NCT01000805|Drug|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
44812|NCT01000805|Drug|Placebo|Participants received placebo QD, po for 8 weeks.
45794|NCT00992784|Biological|FluarixTM|Single dose, intramuscular injection
45795|NCT00992797|Drug|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D < 100 nmol/L. If serum 25(OH)D > 100 placebo will be given. The cholecalciferol will be given in orange juice.
45796|NCT00992797|Other|Orange juice|Orange juice at randomization day and at week 5.
45797|NCT00992810|Procedure|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
45798|NCT00992810|Procedure|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
45799|NCT00025103|Drug|vincristine sulfate|
45800|NCT00992823|Drug|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
45801|NCT00992823|Biological|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
45802|NCT00992836|Biological|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
45803|NCT00992849|Drug|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
45804|NCT00992862|Drug|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
45805|NCT00992862|Drug|Univasc® 15mg Tablets|
45806|NCT00992875|Behavioral|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
45807|NCT00992888|Device|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
45808|NCT00992901|Drug|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
45809|NCT00992901|Drug|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
45810|NCT00025103|Procedure|autologous bone marrow transplantation|
45811|NCT00995046|Drug|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
45966|NCT00025103|Procedure|peripheral blood stem cell transplantation|
45967|NCT00993031|Drug|Zidovudine|Zidovudine 300 mg
45968|NCT00993031|Drug|Lamivudine|Lamivudine 150 mg
45969|NCT00993044|Drug|Irinotecan|Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2
45970|NCT00993044|Drug|Vincristine|Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2
45971|NCT00993044|Drug|Temozolomide|Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2
45972|NCT00993044|Drug|Bevacizumab|Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2
45973|NCT00993057|Drug|Insulin|Adjustable insulin infusion scale with loading doses
45014|NCT01005758|Radiation|radiation therapy|
45015|NCT01005771|Drug|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
45016|NCT00025636|Drug|melphalan|
45017|NCT01005771|Drug|Placebo|Matching placebo
45521|NCT00999635|Device|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
45522|NCT00999648|Other|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
45872|NCT00990496|Biological|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
45873|NCT00990509|Drug|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
45874|NCT00990509|Drug|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
45875|NCT00025051|Procedure|growth factor antagonist therapy|
45876|NCT00990509|Procedure|Brain MRI with and without contrast|All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)
45877|NCT00990522|Procedure|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
45878|NCT00992901|Drug|GLP-1 and GIP|A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
45879|NCT00992914|Procedure|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
45880|NCT00992914|Procedure|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
45881|NCT00992927|Procedure|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
45882|NCT00992927|Procedure|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
45883|NCT00992940|Procedure|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
45884|NCT00992940|Procedure|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
45885|NCT00992953|Behavioral|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
45886|NCT00992953|Behavioral|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
45080|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
45081|NCT01003691|Biological|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
45082|NCT01003691|Biological|Placebo|Intravenous, multiple dose with experimental dose
45083|NCT01003704|Procedure|Lower extremity amputation|
45084|NCT01003730|Other|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
45085|NCT00000222|Drug|Buprenorphine|
45086|NCT00000885|Drug|Indinavir sulfate|
45087|NCT00025545|Radiation|radiation therapy|
45088|NCT01003743|Device|endolumenal tissue approximation|
45089|NCT01003756|Other|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
45090|NCT01003769|Drug|Lenalidomide|Given PO
45091|NCT01003769|Drug|R-(-)-Gossypol Acetic Acid|Given PO
45092|NCT01003769|Other|Laboratory Biomarker Analysis|Correlative studies
45093|NCT01003808|Biological|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
45094|NCT01003834|Behavioral|Computerized brief intervention|Intervention based on Motivational Interviewing technique
45095|NCT01003834|Behavioral|Computerized health screening|Behavioral intervention
45096|NCT01003834|Behavioral|Computerized assessment|Behavioral intervention
45097|NCT01003834|Behavioral|Therapist-delivered motivational intervention|Behavioral intervention
45098|NCT00025558|Biological|filgrastim|
45099|NCT01003847|Drug|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
45100|NCT01003873|Biological|Evaluation of the endocannabinoid system|The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
45812|NCT00995046|Drug|FVIII|1 month period where thrombin generating capacity will be evaluated, followed by 6 months of "individually" tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
44867|NCT00998439|Device|SeQuent® Please|6 F, 7 F, or 8 F guiding catheters have to be used
after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))
additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour
Nitroglycerin (0.2 mg i.c.) prior to first contrast injection
ISR must be predilated with uncoated balloon
balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use
inflation time has to be ≥ 30 sec
select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %
each Paclitaxel-eluting balloon catheter is allowed for single use only
additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness
if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug
44868|NCT00998439|Device|SeQuent® II|6 F, 7 F, or 8 F guiding catheters have to be used
after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))
additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour
Nitroglycerin (0.2 mg i.c.) prior to first contrast injection
ISR must be predilated with uncoated balloon
balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use
inflation time has to be ≥ 30 sec
select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %
each Paclitaxel-eluting balloon catheter is allowed for single use only
additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness
if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug
44869|NCT00998452|Behavioral|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
44870|NCT00998465|Other|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
44871|NCT00998465|Other|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
44872|NCT00998465|Other|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
44873|NCT00998465|Radiation|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
44874|NCT01000818|Drug|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
44875|NCT01000831|Biological|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
44876|NCT01000857|Drug|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
44877|NCT01000870|Drug|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
44878|NCT01000883|Other|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
44879|NCT01000883|Other|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
45018|NCT01005784|Drug|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
45019|NCT01005784|Drug|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
45020|NCT01005797|Drug|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
45021|NCT01005810|Drug|N-Acetylcysteine|1200 mg twice daily for 8 weeks
45022|NCT01005810|Drug|placebo|2 capsules twice daily for 8 weeks
45023|NCT01005810|Behavioral|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
45024|NCT01005823|Drug|LEO 29102 cream|Twice daily application for 7 days
45025|NCT01005823|Drug|LEO 29102 placebo cream|LEO 29102 placebo cream
45026|NCT01005836|Behavioral|Cognitive behavioral therapy for youth anxiety|
45027|NCT00025636|Drug|methotrexate|
45028|NCT01005836|Other|Usual clinic care|
45029|NCT01005836|Behavioral|Cognitive behavioral treatment for youth depression|
45030|NCT01005849|Dietary Supplement|Protecflor|1 Capsule to be taken once a day during the entire study period
45031|NCT01005849|Dietary Supplement|Placebo|1 Capsule to be taken once a day during the entire study period
45032|NCT01005862|Biological|PF-04360365|10 mg/kg, single dose administered intravenously
45033|NCT00998608|Drug|risperidone|risperidone 4mg/d
45034|NCT00998621|Other|Adherence questionnaire|Adherence questionnaire
45035|NCT00998634|Drug|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
45036|NCT00998647|Device|modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus|usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
45037|NCT00998660|Device|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
45629|NCT00994799|Drug|ranibizumab|10mg/ml intravitreal injection
45887|NCT00992979|Procedure|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
45888|NCT00025103|Procedure|conventional surgery|
44939|NCT01005615|Device|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
44940|NCT01005615|Device|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
44941|NCT00998465|Radiation|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
44942|NCT00025363|Drug|etoposide|Given IV
44943|NCT00998465|Radiation|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
44944|NCT00998465|Other|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
44945|NCT00998465|Other|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
44946|NCT00998465|Dietary Supplement|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
44947|NCT00998478|Other|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
44948|NCT00998504|Dietary Supplement|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
44949|NCT00998504|Dietary Supplement|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
45101|NCT01003873|Procedure|Biopsy of visceral and peripheral adipose tissue|The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
45366|NCT01004211|Procedure|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
45367|NCT01004224|Drug|BGJ398|
45368|NCT01004237|Drug|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
45369|NCT01004250|Drug|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
45370|NCT01004250|Drug|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
45371|NCT01004250|Drug|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
45372|NCT01004263|Drug|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
45373|NCT00025571|Drug|HPPH|
45374|NCT01004276|Other|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
45375|NCT01004289|Procedure|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
45376|NCT01004289|Procedure|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
45377|NCT01004302|Procedure|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
45378|NCT01004315|Drug|KUC-7483|
45379|NCT01004315|Drug|Placebo|
45380|NCT01004315|Drug|Tolterodine|
45381|NCT01004328|Other|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
45382|NCT01004341|Behavioral|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
45383|NCT01004354|Drug|Ergocalciferols|2000 international units by mouth daily for 8 weeks.
44880|NCT01000883|Procedure|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
44881|NCT01000896|Drug|AZD0530|film coated tablet, PO, daily
44882|NCT00025428|Drug|etoposide|
45161|NCT01001286|Behavioral|Questscope Non-Formal Education|Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.
Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers ("facilitators").
45162|NCT01001299|Drug|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
45163|NCT01001299|Drug|RO5185426|960 mg orally twice daily
45164|NCT01001312|Other|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
45165|NCT01001312|Other|Clinical volume status assessment|Volume assessment based on history and physical examination
45166|NCT01001325|Biological|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
45167|NCT00000884|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
45168|NCT00025441|Drug|carboplatin|
45169|NCT01001325|Biological|Normal saline|0.5 mL intramuscular
45170|NCT01001338|Drug|RDEA594|Uricosuric agent for the treatment of gout.
45171|NCT01001338|Drug|Placebo|Matching Placebo
45172|NCT01001338|Drug|Allopurinol|Allopurinol
45173|NCT01001351|Drug|PRT-201|Applied topically during surgery.
45174|NCT01001351|Drug|Placebo|Applied topically during surgery
45175|NCT01001364|Drug|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
45176|NCT01001364|Drug|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
45177|NCT01003886|Drug|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
45178|NCT01003899|Drug|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
45630|NCT00994799|Radiation|macular grid-pattern laser|macular grid-pattern laser therapy
45631|NCT00994812|Drug|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
45632|NCT00994825|Drug|Levosimendan|
45633|NCT00994825|Drug|placebo|"Soluvit" ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%
45634|NCT00994838|Other|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
45635|NCT00994851|Drug|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
45636|NCT00994851|Drug|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
45637|NCT00025233|Other|laboratory biomarker analysis|Correlative studies
45638|NCT00994864|Drug|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
45639|NCT00994890|Biological|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
45640|NCT00994890|Biological|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
45641|NCT00994890|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
45642|NCT00994903|Drug|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
45643|NCT00994903|Drug|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
45644|NCT00994916|Drug|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
45645|NCT00987948|Drug|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
45646|NCT00987961|Behavioral|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
45647|NCT00987974|Drug|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
44950|NCT00998517|Dietary Supplement|Soy/peanut fortified spread|75kcal/kg/day
44951|NCT00998517|Dietary Supplement|Milk fortified corn/soy blend|75 kcal/kg/day
44952|NCT00998517|Dietary Supplement|Supplementary Plumpy®|75 kcal/kg/day
44953|NCT00025363|Drug|tirapazamine|Given IV
44954|NCT00998556|Drug|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
45243|NCT00999167|Drug|Placebo|Part B: same as experimental arm
45244|NCT00999180|Procedure|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
45245|NCT00999180|Procedure|Saline and Kinesiotherapy|Saline and Kinesiotherapy
45246|NCT01001377|Drug|Cetuximab|Administered by intravenous infusion
45247|NCT01001377|Drug|Panitumumab|Administered by intravenous infusion
45248|NCT00025441|Drug|cyclophosphamide|
45249|NCT01001390|Device|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
45250|NCT01001403|Drug|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
45251|NCT01001403|Drug|Normal saline|10 ml of normal saline
45252|NCT01001429|Drug|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
45253|NCT01001429|Drug|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
45254|NCT01001442|Drug|BT062|intravenous administration
45255|NCT01001468|Drug|VB-201|Single daily dose of oral VB-201 20 mg
45256|NCT01001468|Drug|VB-201|Single daily dose or oral VB-201 80 mg
45257|NCT01001468|Other|Placebo|Single daily dose of oral placebo
45258|NCT01001481|Other|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
45259|NCT00025441|Drug|doxorubicin hydrochloride|
45384|NCT00025584|Drug|bortezomib|Given IV
45385|NCT01004367|Other|Experimental|Environmental- and individual based components carried out in the school.
45386|NCT01004367|Other|No intervention|No intervention carried out in the school
45734|NCT00025246|Other|laboratory biomarker analysis|Correlative studies
45735|NCT00995007|Drug|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
45736|NCT00995020|Procedure|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
45737|NCT00995020|Procedure|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
45738|NCT00995033|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
45739|NCT00995033|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
45740|NCT00995033|Drug|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
45741|NCT00988091|Device|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
45742|NCT00988091|Device|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
45743|NCT00024492|Drug|Liposome Encapsulated Mitoxantrone (LEM)|
45744|NCT00988104|Behavioral|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
45745|NCT00988104|Behavioral|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
45746|NCT00988117|Drug|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
45747|NCT00988130|Other|laboratory biomarker analysis|
45748|NCT00988130|Other|questionnaire administration|
45179|NCT01003912|Biological|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
45180|NCT00025558|Drug|carboplatin|
45181|NCT01003925|Behavioral|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
45182|NCT01003925|Behavioral|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
45444|NCT01001806|Drug|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
45445|NCT01001832|Drug|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
45446|NCT01001832|Drug|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
45447|NCT01001845|Drug|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
45448|NCT01001845|Drug|vit E|200 mg twice daily for 3 weeks
45449|NCT01001845|Drug|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
45450|NCT01001858|Other|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
45451|NCT01001871|Dietary Supplement|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
45452|NCT00025441|Procedure|peripheral blood stem cell transplantation|
45453|NCT01001871|Dietary Supplement|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
45454|NCT01001884|Other|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
45455|NCT01001897|Drug|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
45456|NCT01004380|Drug|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
45648|NCT00987974|Drug|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
45672|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
45673|NCT00025051|Drug|celecoxib|
45674|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
45675|NCT00989963|Drug|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
45676|NCT00989976|Behavioral|normal sleep times|8.5 h bedtimes
45677|NCT00989976|Behavioral|bedtime restriction|4.5 h restricted bedtimes
45678|NCT00989989|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
45679|NCT00989989|Procedure|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
45680|NCT00989989|Drug|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
45681|NCT00989989|Procedure|Sham laser photocoagulation|Sham laser treatment administered at day 1.
45682|NCT00990015|Drug|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
45683|NCT00990015|Drug|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
45684|NCT00000878|Drug|Lamivudine|
45685|NCT00025051|Procedure|anti-cytokine therapy|
45686|NCT00990028|Drug|Rosuvastatin|20 mg oral, for 10 days
45687|NCT00990028|Drug|Placebo|20 mg vehicle
45688|NCT00990054|Drug|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
45689|NCT00990067|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
45690|NCT00990067|Drug|Duloxetine|120 mg two doses 12h and 2h before MDMA
45691|NCT00990067|Drug|Placebo|capsules identical to MDMA or duloxetine
45692|NCT00990080|Biological|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
45260|NCT01001494|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
45261|NCT01001494|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
45262|NCT01001494|Drug|Placebo|Placebo twice-daily by inhalation for 24 weeks
45263|NCT01001507|Procedure|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
45264|NCT01001520|Drug|Tolcapone|Participants will be asked to take study medication each day for both 11-day study medication periods.
The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.
45523|NCT00999648|Other|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
45524|NCT01001897|Drug|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
45525|NCT01001910|Drug|Carboplatin|Given IV
45526|NCT01001910|Other|Laboratory Biomarker Analysis|Correlative studies
45527|NCT01001910|Drug|Pemetrexed Disodium|Given IV
45528|NCT01001923|Drug|REGN475/SAR164877|Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes
45529|NCT01001923|Drug|Placebo (for REGN475/SAR164877)|Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes
45530|NCT01001936|Drug|SKI-606|
45531|NCT00025441|Radiation|radiation therapy|
45532|NCT01001949|Dietary Supplement|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
45533|NCT01001949|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
45534|NCT01001962|Drug|empagliflozin|ACTIVE TREATMENT FOR DIABETES
45535|NCT01001962|Drug|Metformin|ACTIVE TREATMENT FOR DIABETES
45536|NCT01001975|Drug|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
45749|NCT00988130|Procedure|assessment of therapy complications|
45750|NCT00988130|Procedure|high-intensity focused ultrasound ablation|
45751|NCT00988130|Procedure|quality-of-life assessment|
45752|NCT00988143|Biological|2009-2010 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
44813|NCT00025428|Drug|doxorubicin hydrochloride|
44814|NCT01000818|Drug|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
44815|NCT01000818|Drug|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
44816|NCT01003262|Other|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
44817|NCT01003275|Drug|Paricalcitol|Two 1 mcg soft gels by mouth daily for 8 weeks
44818|NCT01003275|Drug|Placebo|Two soft gels by mouth daily for 8 weeks
44819|NCT01003288|Biological|Pandemrix|Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)
* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)
44820|NCT01003301|Drug|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
44821|NCT01003301|Drug|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
44822|NCT01003314|Biological|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later
44823|NCT01003314|Biological|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
44824|NCT01003327|Device|I-gel|intubation with I-gel airway
44825|NCT00025519|Radiation|radiation therapy|
44826|NCT01003327|Device|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
45457|NCT01004393|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
45458|NCT01004406|Procedure|Percutaneous coronary intervention|Widening of coronary arteries using balloons or stents.
45459|NCT01004406|Procedure|Intravascular ultrasound with virtual histology|IVUS-VH allows for the identification of discrete plaque components using radiofrequency backscatter data. The technology can visualize the coronary artery wall and measure atherosclerosis volume.
45460|NCT01004406|Drug|Atorvastatin|80mg daily oral dose of Atorvastatin to lower LDL in blood.
45813|NCT00995059|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
45814|NCT00995059|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
45815|NCT00025259|Biological|bleomycin sulfate|Given IV or subcutaneously
45816|NCT00995059|Drug|bortezomib|Given IV
45817|NCT00995059|Drug|melphalan|Given IV
45818|NCT00995059|Drug|anti-thymocyte globulin|Given IV
45819|NCT00995059|Drug|sirolimus|Given orally
45820|NCT00995059|Drug|tacrolimus|Given oral or IV
45821|NCT00995059|Radiation|total-body irradiation|Undergo total-body irradiation
45822|NCT00995072|Drug|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
45823|NCT00995072|Drug|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
45824|NCT00995085|Drug|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
45825|NCT00995098|Dietary Supplement|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
45826|NCT00000881|Drug|Cidofovir|
45693|NCT00990093|Device|test intermittent catheter|CH 12 hydrophilic coated catheter
45694|NCT00990093|Device|Intermittent catheterization|CH 12 hydrophilic catheter
44749|NCT01005693|Procedure|cognitive assessment|
44750|NCT01005693|Procedure|examination|
44751|NCT01005693|Procedure|management of therapy complications|
44752|NCT01005706|Drug|rapamune, mycophenolate mofetil and steroid|At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.
Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.
44753|NCT01005706|Drug|tacrolimus, sirolimus and steroid|Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.
At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.
44754|NCT01005719|Drug|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
44755|NCT01005719|Drug|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
44756|NCT01005732|Device|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and <5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
44757|NCT01005745|Procedure|Surgery|Surgery to remove a tumor for growth of TIL
44758|NCT00025636|Drug|dexamethasone|
44759|NCT01005745|Drug|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
44760|NCT01005745|Other|Adoptive Cell Transfer|T-cell infusion
44761|NCT01005745|Drug|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
44762|NCT01005758|Drug|cyclophosphamide|
44763|NCT01005758|Drug|cytarabine|
44764|NCT01005758|Drug|dexamethasone|
44765|NCT00998218|Drug|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
45537|NCT01001975|Drug|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
45538|NCT01001975|Drug|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
45539|NCT01002014|Procedure|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
45540|NCT01002027|Behavioral|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
45541|NCT01002040|Biological|Arepanrix|Group A receives one dose of Arepanrix
45542|NCT00025454|Drug|tipifarnib|
45543|NCT01002040|Biological|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
45544|NCT01002053|Procedure|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
45889|NCT00992979|Procedure|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
45890|NCT00992992|Biological|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
45891|NCT00993005|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
45892|NCT00993005|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
45893|NCT00993018|Drug|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
45894|NCT00995137|Genetic|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
44827|NCT01003340|Behavioral|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
44828|NCT01003353|Behavioral|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
44829|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
44830|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
45102|NCT01003873|Biological|Evaluation of metabolic parameters|The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
45103|NCT01003873|Behavioral|Evolution of behavioral parameters|The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
45104|NCT01003873|Behavioral|Dietician consultation|The evaluation of the metabolic status will also be seen by a dietician.
45105|NCT01003873|Behavioral|Psychologist consultation|The behavioural evaluation will de done with a psychologist consultation
45106|NCT00996229|Dietary Supplement|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
45107|NCT00996229|Dietary Supplement|Placebo|Daily corn oil capsules for 6 months
45108|NCT00996229|Dietary Supplement|Resveratrol|daily resveratrol for 6 months
45109|NCT00996242|Drug|L-lysine|6 g/day for four weeks
45110|NCT00025285|Drug|irinotecan hydrochloride|
45111|NCT00996255|Drug|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
45112|NCT00996268|Drug|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
45113|NCT00996268|Drug|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
45114|NCT00996281|Drug|Azilsartan medoxomil and chlorthalidone|Combination tablet.
45115|NCT00996281|Drug|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
45827|NCT00025259|Biological|filgrastim|Given subcutaneously
45828|NCT00995098|Dietary Supplement|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
45829|NCT00995124|Drug|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
45830|NCT00995124|Drug|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
45831|NCT00995124|Drug|Moov Head Lice Solution|Single application for head lice with 10 min application time.
44883|NCT01000896|Drug|Carboplatin|intravenous, 3 weeks
44884|NCT01000896|Drug|paclitaxel|intravenous, 3 weeks
44885|NCT01000909|Procedure|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
44886|NCT01000922|Drug|Regular Human Insulin|Individual dose of RHI administered subcutaneously
44887|NCT01000922|Drug|Lispro|Individual dose of lispro administered subcutaneously
44888|NCT01000922|Drug|VIAject|Individual dose of VIAject administered subcutaneously
44889|NCT01000922|Drug|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
44890|NCT01000922|Drug|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
44891|NCT01000922|Drug|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
44892|NCT01000935|Other|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
44893|NCT00025428|Drug|vincristine sulfate|
44894|NCT01000935|Other|Platelet Rich plasma|The study group will have a surgical repair and will receive PRP treatment where the control group will undergo surgery without the PRP application.
44895|NCT01000948|Drug|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
44766|NCT00998218|Drug|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
44767|NCT00998231|Biological|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
44768|NCT00998244|Other|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
45038|NCT00025363|Biological|filgrastim|Given SC
45039|NCT00998673|Device|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
45040|NCT00998673|Device|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
45041|NCT00998686|Drug|dutogliptin|400 mg
45042|NCT00998686|Drug|sitagliptin|100 mg
45043|NCT00998699|Drug|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
45044|NCT00998699|Drug|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
45045|NCT00998738|Drug|Calcium Gluconate|Given IV
45046|NCT00998738|Drug|Magnesium Sulfate|Given IV
45047|NCT00998738|Other|Placebo|Given IV
45048|NCT00998738|Other|Quality-of-Life Assessment|Ancillary studies
45049|NCT00025363|Biological|sargramostim|Given SC
45050|NCT00998738|Other|Questionnaire Administration|Ancillary studies
45051|NCT00998738|Drug|Ixabepilone|Given IV
45052|NCT00998751|Drug|oral masitinib|7.5 mg/kg/day
45053|NCT00998764|Drug|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
45054|NCT00998777|Procedure|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
45895|NCT00995150|Drug|LNG20|levonorgestrel-releasing intrauterine system for contraception
45896|NCT00995150|Drug|Mirena|Mirena intrauterine system
45897|NCT00995189|Device|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
45898|NCT00995189|Device|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
45899|NCT00995189|Device|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
45900|NCT00025259|Drug|cisplatin|Given IV
45901|NCT00995202|Other|diagnostic laboratory biomarker analysis|
45902|NCT00995202|Procedure|computed tomography|
45903|NCT00995202|Procedure|diagnostic colonoscopy|
45904|NCT00995202|Procedure|standard follow-up care|
45905|NCT00995202|Procedure|ultrasound imaging|
44955|NCT00998569|Behavioral|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
44956|NCT00998569|Behavioral|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
44957|NCT00998582|Drug|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
44958|NCT00998595|Other|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
44959|NCT01000961|Drug|Cysteamine Bitartrate Delayed-release Capsules (RP103)|Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:
Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks
44960|NCT01000974|Biological|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
44961|NCT01000974|Biological|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
45116|NCT00996294|Procedure|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
45117|NCT00996307|Biological|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
45118|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
45119|NCT00996307|Biological|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
45120|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
45121|NCT00025285|Drug|thalidomide|
45122|NCT00996320|Other|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
45387|NCT00996697|Drug|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
45388|NCT00025298|Radiation|radiation therapy|
45389|NCT00996723|Drug|vandetanib and dasatinib|Two oral investigational agents (vandetanib [VEGFR2, RET, and EGFR inhibitor] and dasatinib [bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
45390|NCT00996736|Drug|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
45391|NCT00996736|Drug|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
45392|NCT00996749|Dietary Supplement|omega-3 fatty acid|Given PO
45393|NCT00996749|Other|bone scan|Correlative studies
45394|NCT00996749|Other|dual x-ray absorptometry|Correlative studies
45395|NCT00996749|Other|laboratory biomarker analysis|Correlative studies
45396|NCT00996749|Procedure|biopsy|Correlative studies
45397|NCT00996762|Drug|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
45398|NCT00996775|Behavioral|brief alcohol intervention|this intervention consists of brief assessment and feedback
45399|NCT00025311|Drug|topotecan hydrochloride|
44896|NCT01000961|Drug|Cystagon® (Cysteamine Bitartrate)|Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:
Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used
44897|NCT01003431|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
44898|NCT01003431|Biological|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
44899|NCT01003431|Biological|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
45183|NCT01003938|Drug|Topotecan|
45184|NCT01003938|Drug|Erlotinib|
45185|NCT01003951|Procedure|Acupuncture|Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.
Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol.
45186|NCT01003964|Drug|Irinotecan, Cisplatin, Gemcitabine, Pemetrexed, Docetaxel|GP:
Gemcitabine (1250 mg/m2) IV on day1, 8. Cisplatin (75 mg/m2) IV on day1 every 3 weeks
IP:
Irinotecan (65 mg/m2) IV on day 1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
2nd or 3rd: Pemetrexed (500 mg/m2) D1 with premedication every 3 weeks Docetaxel (75 mg/m2) D1 with premedication every 3 weeks
45187|NCT01003990|Drug|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
45188|NCT01003990|Drug|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
45189|NCT01003990|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
45190|NCT01004003|Drug|Sorafenib|
45191|NCT00025558|Drug|temozolomide|
45192|NCT01004003|Drug|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
45193|NCT01004016|Drug|KPS-0373|
45194|NCT01004016|Drug|Placebo|
45055|NCT00998790|Device|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
45056|NCT00998816|Drug|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
45057|NCT01001091|Drug|Dexamethasone ophthalmic suspension, 0.1%|
45058|NCT01001104|Drug|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
45059|NCT01001104|Drug|Placebo|Administered by SC injection, QW for 12 weeks.
45326|NCT00999219|Drug|Zolpidem|oral
45327|NCT00999232|Drug|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
45328|NCT00999232|Drug|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
45329|NCT00999245|Other|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
45330|NCT00999245|Other|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
45331|NCT00025389|Biological|bevacizumab|
45332|NCT00999258|Drug|sirolimus|The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.
The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care.
45333|NCT00999271|Other|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|two different dosages:
0.8 pmol/kg/min
1.5 pmol/kg/min for 300 minutes
45334|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
45335|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
45336|NCT00999284|Drug|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
45337|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
44962|NCT01000974|Biological|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
44963|NCT01000974|Biological|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
44964|NCT01000974|Biological|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
44965|NCT01000974|Biological|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
44966|NCT00025428|Procedure|adjuvant therapy|
44967|NCT01000974|Biological|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
44968|NCT01000974|Biological|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
44969|NCT01000987|Drug|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
44970|NCT01000987|Drug|placebo|placebo
44971|NCT01001000|Procedure|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
44972|NCT01001013|Drug|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
45265|NCT01001520|Drug|Placebo|Participants will be asked to take study medication each day for both 11-day study medication periods.
The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.
45266|NCT01001546|Behavioral|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
45267|NCT01001546|Behavioral|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
45268|NCT01001559|Drug|L-methylfolate|Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
45269|NCT01004055|Drug|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
45270|NCT01004055|Drug|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
45271|NCT01004068|Other|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
45400|NCT00996775|Behavioral|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
45401|NCT00996788|Drug|Rebamipide|Rebamipide 100 mg tid for 28 days
45402|NCT00996801|Drug|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
45403|NCT00996801|Drug|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
45404|NCT00996801|Drug|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
45405|NCT00996801|Drug|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
45406|NCT00996801|Drug|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
45407|NCT00996801|Drug|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
45753|NCT00988143|Biological|2008-2009 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
45754|NCT00024518|Drug|30,000 units hrINF-alpha|
45755|NCT00988143|Biological|Quadrivalent Influenza Virus Vaccine|0.5 mL, Intramuscular
45756|NCT00988156|Drug|Eslicarbazepine acetate (BIA 2-093)|Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.
The recommended target dose of double-blind study treatment will be 20mg/kg/day.
Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
45757|NCT00988156|Drug|Eslicarbazepine acetate|Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.
Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
45758|NCT00988169|Drug|oral erlotinib and pulsed doses of oral AT-101|Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
45759|NCT00988182|Other|dietary intervention|whey protein
45760|NCT00988182|Other|water control|
45761|NCT00988195|Biological|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
45195|NCT01004029|Drug|Hydroxyprogesterone Caproate Injection, 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
45196|NCT01004029|Drug|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
45197|NCT01004042|Drug|Botulinum Toxin Type A - BOTOX|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
45198|NCT01004055|Device|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
45199|NCT00996372|Drug|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
45200|NCT00996372|Drug|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
45201|NCT00996385|Drug|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
45461|NCT01004406|Device|LDL-apheresis|The device proposed for use in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. The Liposorber separates plasma from whole blood, then removes LDL from the plasma, recombines the plasma and blood cells, and returns the blood into the patient's body; the procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
45462|NCT01004419|Drug|ZD6474 (vandetanib)|vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
45463|NCT01004419|Drug|Faslodex (Fulvestrant)|Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
45464|NCT00025584|Other|laboratory biomarker analysis|Correlative studies
45465|NCT01004432|Drug|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
45466|NCT01004432|Drug|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
45467|NCT01004432|Drug|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
45468|NCT01004432|Drug|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
45469|NCT01004432|Drug|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
45470|NCT01004445|Drug|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
45338|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
45339|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
45340|NCT00999323|Device|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
45341|NCT01001559|Drug|Selective serotonin reuptake inhibitor (SSRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
45342|NCT00025441|Drug|epirubicin hydrochloride|
45343|NCT01001559|Drug|Serotonin and norepinephrine reuptake inhibitor (SNRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
45344|NCT01001572|Drug|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
45345|NCT01001572|Drug|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
45695|NCT00990106|Drug|prazosin hydrochloride|Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized "first dose" effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually.
45696|NCT00025051|Procedure|antiangiogenesis therapy|
45697|NCT00990106|Drug|placebo|placebo
45698|NCT00992589|Drug|Placebo|Matching placebo capsules once daily in the morning.
45699|NCT00025103|Drug|doxorubicin hydrochloride|
45700|NCT00992602|Drug|methotrexate|Given IV
45701|NCT00992602|Drug|liposomal cytarabine|Given IT or via LP
45702|NCT00992602|Other|quality-of-life assessment|Ancillary studies
45703|NCT00992602|Other|laboratory biomarker analysis|Correlative studies
45704|NCT00992615|Procedure|prostate biopsy|prostate cores - 12 or 20
45705|NCT00992628|Device|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
45706|NCT00992628|Device|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
45272|NCT00025558|Drug|thiotepa|
45273|NCT01004068|Drug|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
45274|NCT01004068|Behavioral|Structured exercise program plus hypocaloric diet|SET plus diet
45275|NCT01004081|Drug|BIIB021|BID orally for 28 days
45276|NCT01004081|Drug|BIIB021|TIW orally for 28 days
45277|NCT01004081|Drug|exemestane (Aromasin)|Daily in tablet form for 28 days
45278|NCT01004094|Behavioral|simple goal setting|This group will set goals only
45279|NCT01004094|Behavioral|goal setting plus action intentions|This group will set goals and form action intentions (plans)
45280|NCT01004094|Behavioral|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
45281|NCT01004094|Behavioral|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
45282|NCT01004107|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
45283|NCT00025558|Procedure|autologous bone marrow transplantation|
45284|NCT01004120|Dietary Supplement|Bimuno|5.5g daily intake
45285|NCT01004120|Dietary Supplement|Maltodextrin|5.5g daily intake
45545|NCT01002079|Drug|BMS-708163|Capsule, Oral, 125 mg, Once daily, 1 day
45546|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 7 days
45547|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 6 days
45548|NCT01002092|Drug|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
45549|NCT01002092|Drug|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
45550|NCT01004471|Device|Prototype nasal dilator|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11
45551|NCT01004484|Other|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving), once daily.
45762|NCT00990119|Device|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
45763|NCT00990132|Device|Non invasive ventilation|Nocturnal non-invasive ventilation
45764|NCT00990132|Device|LTOT|LTOT established as per national guidelines
45765|NCT00990145|Drug|EDP-322|
45766|NCT00990158|Drug|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
45767|NCT00990158|Drug|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
45768|NCT00990184|Drug|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
45769|NCT00990184|Other|placebo|tablet (s) orally given with evening meal
45770|NCT00990197|Drug|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
45771|NCT00025051|Procedure|biological therapy|
45772|NCT00990223|Drug|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
44831|NCT01003379|Drug|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
44832|NCT01003379|Drug|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
44833|NCT01003405|Drug|KUC-7483|
44834|NCT01003418|Biological|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
44835|NCT01003418|Biological|InfanrixTM-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
44836|NCT00025532|Other|iodine I 131 monoclonal antibody CC49-deltaCH2|
44837|NCT01003418|Biological|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
44838|NCT01005303|Drug|Placebo|1 Tablet Daily
44839|NCT01005303|Drug|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
44840|NCT01005316|Drug|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
45471|NCT01004445|Drug|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
45472|NCT01004445|Drug|Placebo|Two aerosol treatments per day (one treatment every 12hr)
45473|NCT01004458|Behavioral|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
45474|NCT01004458|Other|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
45475|NCT00000885|Drug|Abacavir sulfate|
45476|NCT00025597|Drug|carboplatin|
45477|NCT00996840|Drug|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
45478|NCT00996840|Drug|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
45479|NCT00996840|Drug|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
45480|NCT00996840|Other|Placebo|Placebo to match intervention
45832|NCT00988195|Drug|Doxorubicin|Weeks 13-24 (once every 3 weeks)
45833|NCT00988208|Drug|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
45834|NCT00988208|Drug|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
45835|NCT00000876|Drug|CD4-IgG2|
45836|NCT00024518|Drug|5,000 hrINF-alpha|
45837|NCT00988208|Drug|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
45838|NCT00988208|Drug|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
45839|NCT00988221|Drug|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
45840|NCT00988221|Drug|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
45841|NCT00988234|Procedure|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
45842|NCT00988234|Procedure|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
45707|NCT00992641|Other|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
45708|NCT00992641|Other|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
45709|NCT00992654|Drug|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
45710|NCT00025103|Drug|etoposide|
45711|NCT00992667|Drug|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
45712|NCT00992680|Device|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
45713|NCT00992693|Drug|Ribavirin (Virazole) Injection|The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.
1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60.
45714|NCT00992706|Drug|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
44769|NCT00000882|Drug|Lamivudine|
44770|NCT00025363|Drug|cyclophosphamide|Given IV
44771|NCT00998257|Drug|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
44772|NCT00998270|Procedure|Autologous bone marrow transplantation|Autologous transplantation:
Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day
G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days
Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days
44773|NCT00998270|Procedure|Allogeneic bone marrow transplantation|Allogeneic
Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days
Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days
44774|NCT00998283|Drug|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
44775|NCT00998283|Drug|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
44776|NCT00998283|Drug|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
44777|NCT00998283|Drug|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
44778|NCT00998283|Drug|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
45552|NCT01004484|Other|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
45553|NCT01004497|Drug|Dasatinib|After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
45554|NCT01004497|Drug|Cyclophosphamide|300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
45555|NCT01004497|Drug|Vincristine|1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 & 11
45556|NCT01004497|Drug|Daunorubicin|45 mg/m2/day, IV for 1 hour, days 4 & 11
45557|NCT01004497|Drug|Dexamethasone|40 mg/day, IV push, days 1-4 & days 11-14
45558|NCT01004497|Drug|Cytarabine|2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
45559|NCT01004497|Drug|Mitoxantrone|12 mg/m2/day, IV for 30 minutes, days 1-2
45560|NCT00025597|Drug|cyclophosphamide|
45561|NCT01004510|Drug|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
45562|NCT01004523|Genetic|fluorescence in situ hybridization|
45563|NCT01004523|Genetic|loss of heterozygosity analysis|
45564|NCT01004523|Genetic|polymerase chain reaction|
45565|NCT01004523|Other|flow cytometry|
45566|NCT01004523|Other|immunohistochemistry staining method|
45567|NCT01004536|Device|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
45906|NCT00995215|Procedure|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
45907|NCT00995215|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
45908|NCT00995241|Drug|Raltegravir|Raltegravir 800 mg / 24 hours.
44841|NCT01005316|Drug|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
44842|NCT01005316|Drug|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
44843|NCT01005316|Procedure|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
44844|NCT01005316|Procedure|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
44845|NCT01005316|Drug|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
44846|NCT01005316|Drug|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
44847|NCT00025623|Drug|vincristine sulfate|
44848|NCT01005329|Radiation|intensity-modulated radiation therapy|The vaginal planning target volume (PTV) and nodal PTV will receive 45 Gy in 25 fractions. Treatment will be delivered once daily, 5 fractions per week, over 5 weeks. Both target regions will be treated simultaneously with the same dose. Breaks in treatment should be minimized.
44849|NCT01005329|Drug|cisplatin|Given IV
44850|NCT01005329|Biological|bevacizumab|Given IV
44851|NCT01005329|Drug|carboplatin|Given IV
44852|NCT01005329|Drug|paclitaxel|Given IV
44853|NCT01005342|Other|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
45123|NCT00996333|Drug|Gemcitabine, Docetaxel, Capecitabine|1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11
This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles.
45124|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
45125|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
45126|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
45127|NCT00996359|Biological|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
45843|NCT00988234|Procedure|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
45844|NCT00988234|Procedure|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
45845|NCT00988247|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
45846|NCT00988247|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
45847|NCT00024518|Other|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
45848|NCT00988260|Drug|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
45849|NCT00988260|Drug|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
45850|NCT00988260|Drug|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
45851|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
45852|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
45853|NCT00988286|Procedure|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
44900|NCT01003444|Procedure|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
44901|NCT01003457|Other|ultrasonography|transvaginal ultrasonography of bladder wall thickness
44902|NCT01003470|Other|acupuncture|Xing Nao Kai Qiao Acupuncture
44903|NCT01003470|Behavioral|rehabilitation|Kinesitherapy
44904|NCT01003470|Other|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
44905|NCT01003483|Drug|orlistat|Tablet,120mg,three times a day,three months
44906|NCT00025545|Drug|cyclophosphamide|
44907|NCT01003496|Behavioral|Treatment as Usual (TAU)|Outpatient substance abuse treatment
44779|NCT00998283|Drug|Placebo|Subcutaneously administrate at 0 hour on Day 1
44780|NCT00998296|Drug|BIBW 2992|EGFR inhibitor
44781|NCT00025363|Drug|doxorubicin hydrochloride|Given IV
44782|NCT00998296|Drug|BIBF 1120|VEGF inhibitor
44783|NCT00998309|Drug|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
44784|NCT00998322|Biological|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
44785|NCT00998322|Drug|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
44786|NCT00998335|Drug|Long-acting bedtime insulin detemir (Levemir)|Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
44787|NCT00998335|Drug|Insulin detemir and pre-meal insulin aspart.|Insulin detemir at bedtime. Insulin aspart before breakfast, lunch and dinner.
44788|NCT00998348|Behavioral|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
44789|NCT01000623|Procedure|mind-body intervention procedure|Practice focused attention
45060|NCT01001117|Device|LensAR laser surgery|Use of laser for cataract surgery
45061|NCT01001117|Device|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
45062|NCT00025428|Procedure|neoadjuvant therapy|
45063|NCT01001130|Drug|fluticasone furoate group|patients who are administered fluticasone furoate at least once
45064|NCT01001143|Drug|Decitabine|
45065|NCT01001143|Drug|Bexarotene|
45066|NCT01001156|Other|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
45067|NCT01001169|Biological|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
45068|NCT01001182|Other|non interventional|non interventional
45909|NCT00995254|Behavioral|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
45910|NCT00995267|Behavioral|parent-child interaction/activities based on Adler's methods|Description of the Intervention:
5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories & pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.
Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations.
45911|NCT00025259|Drug|cyclophosphamide|Given IV
45912|NCT00995280|Device|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
45913|NCT00024531|Drug|Atorvastatin calcium|
45914|NCT00988351|Device|Continuous positive airway pressure|continuous positive airway pressure determined by polysomnography titration
45915|NCT00988351|Device|Auto-adjusting positive airway pressure treatment|Pressure range 4-18 centimeters of water (cm H2O)
45916|NCT00988364|Drug|Simvastatin|Simvastatin 20mg daily for 3 months.
45917|NCT00988364|Drug|Vytorin|Vytorin 20/10mg daily for 3 months.
45918|NCT00988364|Drug|Placebo|Placebo one tablet daily times 3 months.
45919|NCT00988364|Drug|Ezetimibe|Ezetimibe 10mg daily for 3 months.
45920|NCT00988377|Other|dietary intervention|whey protein 10-40 g
45921|NCT00988377|Other|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
44973|NCT01001026|Biological|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
44974|NCT01001026|Biological|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
44975|NCT01001052|Drug|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
44976|NCT01001065|Procedure|Vascular ultrasound|RI ist predictive for arteriosclerosis
45128|NCT00996359|Radiation|total-body irradiation|100 cGy TBI
45129|NCT00998829|Other|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
45130|NCT00998842|Device|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
45131|NCT00998842|Device|GE 5000 ECG Monitor System|Wired ECG system
45132|NCT00025363|Other|pharmacological study|Correlative studies
45133|NCT00998855|Behavioral|Exercise|12 wk aerobic or/ resistance exercise program
45134|NCT00998881|Drug|Teneligliptin 20 mg|
45135|NCT00998881|Drug|Placebo|
45136|NCT00998907|Device|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
45137|NCT00998907|Device|PDS II|polyglactin 910 suture material for abdominal wall closure
45138|NCT00998920|Drug|S-equol|oral, BID, 14 days
45139|NCT00998920|Drug|Placebo|oral, BID, 14 days
45140|NCT00998933|Drug|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
45141|NCT00998946|Drug|Pralatrexate Injection|Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).
Initial dose: 30 mg/m2
Dose reductions: to 20 mg/m2 weekly per protocol defined criteria.
Administered on days 1, 8 and 15 of a 4-week (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.
45142|NCT00998946|Dietary Supplement|Vitamin B12|1 mg intramuscular injection
Administered within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate.
45408|NCT00996814|Behavioral|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
45409|NCT00996840|Drug|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
45410|NCT00025324|Biological|filgrastim|
41727|NCT00981981|Dietary Supplement|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
41728|NCT00981981|Dietary Supplement|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
42044|NCT00984568|Drug|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
42045|NCT00984568|Drug|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
42046|NCT00984568|Drug|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
42047|NCT00984581|Drug|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
42048|NCT00984581|Drug|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
42049|NCT00984581|Drug|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
42050|NCT00984594|Other|Primary injury site|Autograft will be placed in the primary defect site.
42051|NCT00984594|Other|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
42052|NCT00984607|Procedure|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
42053|NCT00024193|Drug|cyclophosphamide|
42054|NCT00984620|Drug|BI 201335|BI 201335
42055|NCT00984620|Drug|BI 201335|BI 201335
42056|NCT00984620|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
42057|NCT00984620|Drug|Ribavirin (RBV)|Ribavirin (RBV)
42058|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
42059|NCT00986921|Drug|mifepristone 200 mg|mifepristone would be given the day before the procedure
42060|NCT00986921|Device|osmotic dilator insertion|osmotic dilators (3-6) would be inserted as usual the day before the procedure
45599|NCT00992446|Drug|Vorinostat|Given PO
45600|NCT00992459|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
45601|NCT00992459|Drug|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
45602|NCT00992472|Drug|Prochlorperazine suppositories, 25mg|
45603|NCT00025103|Drug|carboplatin|
45604|NCT00992472|Drug|Compazine® suppositories, 25mg|
45605|NCT00992485|Drug|ADIPOPLUS|autologous adipose-derived stem cell
45606|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
45607|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
45943|NCT00990574|Device|Spinal Anesthesia Group (SAG)|The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a "single shot" while still in the sitting position.
45944|NCT00990587|Drug|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
45945|NCT00990600|Other|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
45946|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
45947|NCT00025064|Biological|bleomycin sulfate|
45948|NCT00990613|Drug|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
45949|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
45950|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
45951|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
41255|NCT00981201|Drug|Placebo|Months 1-3:
By mouth twice daily.
41256|NCT00981201|Drug|Placebo|Months 4-6:
By mouth twice daily.
41257|NCT00981214|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
41258|NCT00981227|Drug|Eslicarbazepine acetate|Scored tablets
41569|NCT00983970|Behavioral|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
41570|NCT00983983|Dietary Supplement|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
41571|NCT00983983|Dietary Supplement|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
41572|NCT00983983|Dietary Supplement|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
41573|NCT00983996|Drug|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
41574|NCT00983996|Drug|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
41575|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
41576|NCT00984009|Other|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
41577|NCT00986063|Genetic|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
41578|NCT00986063|Other|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
41579|NCT00024284|Drug|irinotecan hydrochloride|
41580|NCT00986076|Drug|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
40996|NCT00957346|Drug|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
40997|NCT00957359|Drug|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
40998|NCT00957372|Drug|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
40999|NCT00957372|Drug|placebo (Part I)|once daily placebo comparator
41000|NCT00949728|Procedure|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
41001|NCT00949754|Drug|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
41002|NCT00949767|Drug|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
41003|NCT00949767|Drug|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
41004|NCT00020904|Drug|ixabepilone|
41005|NCT00949767|Drug|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
41006|NCT00949767|Drug|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
41007|NCT00949767|Drug|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
41008|NCT00949767|Drug|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
41318|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
41319|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
41320|NCT00978640|Other|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
41321|NCT00978640|Other|exercise|exercise 1 h 50% VO2max
41322|NCT00978653|Drug|allopurinol|150 mg once a day
41323|NCT00978679|Device|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
41324|NCT00023855|Drug|bortezomib|
41325|NCT00978679|Device|Spectacles|Daily use of single vision lenses to correct refractive errors
41326|NCT00978692|Device|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
42061|NCT00986947|Drug|IVIg and rituximab|A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.
If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA).
42062|NCT00024362|Drug|BBR 3464|
42063|NCT00986960|Drug|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
42064|NCT00986960|Drug|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
41073|NCT00954811|Drug|300IU rec-LH|luteal alternate doses
41074|NCT00954811|Drug|progesterone 600mg|luteal support
41075|NCT00957372|Drug|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
41076|NCT00957385|Drug|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
41077|NCT00021528|Drug|BuproprionSR|
41078|NCT00957411|Biological|cetuximab|Given IV
41079|NCT00957411|Drug|cisplatin|Given IV
41080|NCT00957424|Behavioral|telephone-based intervention|10-15 minute web-based survey on a computer
41081|NCT00957424|Drug|nicotine replacement therapy|One day supply
41082|NCT00957424|Other|informational intervention|
41083|NCT00957424|Other|internet-based intervention|
41084|NCT00957424|Other|questionnaire administration|Given out week 2, 4 and 6.
41085|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 1
41086|NCT00957437|Drug|AZD1305|ER formulation 1, bid for 5 days
41087|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 2
41088|NCT00021528|Drug|buspirone|
41089|NCT00957476|Dietary Supplement|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
45952|NCT00990639|Drug|candesartan for hepatic fibrosis|Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.
UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months
45953|NCT00990652|Drug|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
45954|NCT00990652|Drug|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
45955|NCT00990665|Device|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
45956|NCT00990678|Drug|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
45957|NCT00990678|Drug|Vitamin D|tablets, vitamin D3, 30 microgram daily
45958|NCT00025064|Drug|chlorambucil|
45959|NCT00990678|Drug|Calcium|tablets, 400 mg calcium, 3 times daily
45960|NCT00993018|Drug|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
44992|NCT01003613|Other|Beriplast P|0.1 ml to attach graft
44993|NCT01003626|Procedure|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
44994|NCT00025545|Procedure|peripheral blood stem cell transplantation|
44995|NCT01003626|Device|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
44996|NCT01003639|Drug|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
44997|NCT01003639|Drug|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
44998|NCT01003639|Behavioral|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
44999|NCT01003652|Procedure|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
41581|NCT00986076|Drug|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
41582|NCT00986102|Drug|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
41583|NCT00986115|Drug|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
41893|NCT00979732|Dietary Supplement|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
41894|NCT00023920|Drug|idarubicin|Given IV
41895|NCT00979732|Dietary Supplement|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
41896|NCT00979745|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
41897|NCT00979745|Drug|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
41898|NCT00979758|Drug|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
41899|NCT00979771|Drug|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
41900|NCT00979771|Drug|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
41901|NCT00979784|Behavioral|Better Weight|Standard cognitive behavioral treatment focused on dietary & exercise behavior
41902|NCT00979784|Behavioral|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
41903|NCT00979797|Other|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
41904|NCT00979810|Drug|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
41905|NCT00023920|Drug|cytarabine|Given SC
41906|NCT00979823|Other|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
41327|NCT00978692|Device|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
41328|NCT00978705|Drug|Autologous cultured keratinocyte cell|3x10^7 cell/ vial
41329|NCT00978718|Dietary Supplement|high-selenium baker's yeast|Given orally
41330|NCT00978718|Dietary Supplement|selenium|Given orally
41331|NCT00978718|Other|placebo|Given orally
41332|NCT00978731|Drug|Dasatinib|Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:
5 days on, 2 days off
6 days on, 1 day off
Continuous daily dosing
Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study
41333|NCT00978757|Drug|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
41334|NCT00978757|Other|Placebo|saline solution
41335|NCT00023855|Drug|doxorubicin hydrochloride|
41336|NCT00978770|Drug|systemic chemotherapy|
41337|NCT00978770|Procedure|diffusion-weighted magnetic resonance imaging|
41338|NCT00978770|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
41339|NCT00981305|Drug|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
41340|NCT00981305|Drug|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
41642|NCT00981903|Drug|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
41643|NCT00981929|Drug|Tramadol|50 mg single oral dose
41644|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
41645|NCT00984022|Device|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
41646|NCT00024167|Drug|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
41647|NCT00984022|Device|Type of dressing - Aquacel|Aquacel dressing
41090|NCT00957489|Other|Dynamax appliance|
41091|NCT00957489|Other|Twin-block appliance|
41092|NCT00957502|Device|ENTact™ Septal Stapler|1 year aged septal staples
41093|NCT00957502|Device|ENTact™ Septal Stapler|18 Month Aged Staples
41094|NCT00957528|Drug|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
41095|NCT00957528|Drug|Placebo|Weekly IM injections of sesame oil.
41096|NCT00957541|Device|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
41097|NCT00957554|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
41399|NCT00985920|Drug|tranexamic acid|Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).
The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
41400|NCT00985920|Drug|Placebo|Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).
The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
41401|NCT00978770|Procedure|magnetic resonance spectroscopic imaging|
41402|NCT00978770|Procedure|neoadjuvant therapy|
41403|NCT00978783|Device|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
41404|NCT00978783|Device|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
41405|NCT00978796|Drug|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
41406|NCT00978796|Drug|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
41407|NCT00978809|Other|Epley maneuver|
41408|NCT00023868|Drug|FOLFIRI regimen|
40857|NCT00954343|Procedure|Extracorporeal Shock Wave|
40858|NCT00954343|Procedure|Extracorporeal Shock Wave|
40859|NCT00954343|Procedure|Extracorporeal Shock Wave|
40860|NCT00021294|Drug|triamcinolone|
41173|NCT00983437|Drug|Armodafinil|
41174|NCT00983450|Other|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
41175|NCT00024128|Procedure|peripheral blood stem cell transplantation|
41176|NCT00983450|Other|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity [Celnik et al., 2008]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
41177|NCT00983476|Behavioral|in-person MOVE! SMI|Individual and group in-person sessions the deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
41178|NCT00983476|Behavioral|web-based MOVE! SMI|online sessions the deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
41179|NCT00983489|Behavioral|video demonstration|video will be shown to mothers
41180|NCT00983489|Behavioral|counselling|breast feeding counselling
41181|NCT00983515|Drug|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
41182|NCT00983515|Drug|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
41183|NCT00983515|Drug|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
41184|NCT00983528|Biological|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
41185|NCT00983528|Drug|Clofarabine|Dose Escalation
Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9
Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5
41907|NCT00982176|Other|Brain MRI and cerebral perfusion scintigraphy|A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).
MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide.
41908|NCT00982189|Drug|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
41909|NCT00982189|Drug|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
41910|NCT00982202|Drug|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for ~18months
41911|NCT00024050|Drug|methotrexate|
40924|NCT00949715|Device|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
40925|NCT00949715|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
40926|NCT00951808|Biological|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
40927|NCT00951808|Behavioral|Standard care|Participants will receive standard care for ACS while in the hospital.
40928|NCT00951821|Behavioral|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
40929|NCT00951821|Behavioral|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
40930|NCT00951834|Drug|Epigallocatechin-Gallate|Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:
Months 1-3: 200 mg EGCG/die (200-0-0 mg)
Months 4-6: 400 mg EGCG/die (200-0-200 mg)
Months 7-9: 600 mg EGCG/die (400-0-200 mg)
Months 10-18: 800 mg EGCG/die (400-0-400 mg)
40931|NCT00951834|Drug|Placebo|Placebo
40932|NCT00951847|Drug|oxcarbazepine 300 mg/5 mL oral suspension|
40933|NCT00951860|Other|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
40934|NCT00021073|Drug|leucovorin calcium|Given IV
41648|NCT00984035|Other|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
41649|NCT00984035|Other|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
41650|NCT00984035|Other|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
41651|NCT00984048|Other|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
41652|NCT00984061|Drug|colchicine|0.6mg tablet administered at 9am on Day 1
41653|NCT00984061|Drug|clarithromycin|250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
41654|NCT00984061|Drug|colchicine|0.6 mg tablet administered at 9am on Day 29
41655|NCT00984074|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
41656|NCT00984074|Procedure|diffusion tensor imaging|
41657|NCT00024167|Drug|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
41658|NCT00984074|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
41659|NCT00984074|Procedure|functional magnetic resonance imaging|
41660|NCT00984074|Radiation|intensity-modulated radiation therapy|
41661|NCT00984074|Radiation|radiation therapy treatment planning/simulation|
41662|NCT00984087|Device|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
41978|NCT00986609|Other|enzyme-linked immunosorbent assay|Correlative studies
41979|NCT00986609|Other|flow cytometry|Correlative studies
41980|NCT00024349|Drug|fluorouracil|
41981|NCT00986661|Drug|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
41982|NCT00986674|Biological|cixutumumab|Given IV
41409|NCT00978809|Other|Semont maneuver|
41410|NCT00978822|Drug|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
41411|NCT00978835|Behavioral|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
41412|NCT00978835|Behavioral|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
41413|NCT00978861|Drug|Hydrogen Peroxide|Whitening product syringe type
41414|NCT00978874|Radiation|fludeoxyglucose F 18|
41415|NCT00978874|Radiation|fluorine F 18 EF5|
41416|NCT00978887|Other|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
41729|NCT00981981|Dietary Supplement|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
41730|NCT00981981|Dietary Supplement|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
41731|NCT00981981|Dietary Supplement|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
41732|NCT00981994|Behavioral|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
41733|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
41734|NCT00982007|Drug|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
41735|NCT00024050|Drug|busulfan|
41736|NCT00982007|Drug|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
41737|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
41738|NCT00982020|Drug|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
41739|NCT00982020|Behavioral|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
41186|NCT00024128|Radiation|radiation therapy|
41187|NCT00983541|Drug|Fluorouracil (5-FU)|5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
41188|NCT00985608|Drug|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
41189|NCT00985608|Drug|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
41505|NCT00986050|Device|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
41506|NCT00979004|Drug|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
41507|NCT00979017|Drug|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
41508|NCT00979017|Drug|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
41509|NCT00023868|Drug|doxorubicin hydrochloride|
41510|NCT00979017|Drug|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
41511|NCT00979043|Behavioral|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
41512|NCT00979043|Behavioral|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
41513|NCT00979056|Drug|Rifaximin|400 mg per day, oral use, maximum duration 28 days
41514|NCT00979056|Drug|Lactose|Coated Tablet, Oral Use
41515|NCT00979069|Behavioral|Aerobic group|12 weeks of aerobic exercise 3 times a week
41516|NCT00979108|Other|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
41517|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
41518|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
40935|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
40936|NCT00951873|Drug|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
40937|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
40938|NCT00951899|Drug|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
40939|NCT00951899|Other|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
40940|NCT00951899|Behavioral|Diet|Subjects were instructed to follow a weight maintenance diet (~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
41259|NCT00981227|Drug|Placebo|oral route
41260|NCT00981240|Drug|SAR103168|Pharmaceutical form: Concentrate for solution for infusion
Route of administration: Intravenous infusion
41261|NCT00981253|Behavioral|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
41262|NCT00981253|Behavioral|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
41263|NCT00981266|Device|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
41264|NCT00023998|Biological|filgrastim|Given IV
41265|NCT00981292|Dietary Supplement|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
41266|NCT00981292|Dietary Supplement|Placebo|Pharmaceutical grade silica was utilized as placebo
41267|NCT00983541|Radiation|Brachytherapy or SBRT (Stereotactic body radiation therapy)|Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).
41983|NCT00979823|Other|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
41984|NCT00979836|Drug|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
41985|NCT00979849|Drug|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
41986|NCT00979849|Drug|Placebo|Solution for nebulisation, inhaled
41987|NCT00979862|Drug|Cediranib Maleate|Given PO
41988|NCT00979862|Drug|Cilengitide|Given IV
41989|NCT00979862|Other|Laboratory Biomarker Analysis|Correlative studies
41990|NCT00979875|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
41991|NCT00979875|Drug|Insulin lispro|
41992|NCT00023933|Drug|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
41993|NCT00979875|Drug|Insulin glulisine|
41994|NCT00979875|Drug|Insulin aspart|
41995|NCT00979888|Other|educational intervention|
41996|NCT00979888|Other|informational intervention|
41997|NCT00979888|Other|psychosocial support for caregiver|
41998|NCT00979888|Other|questionnaire administration|
41999|NCT00979888|Procedure|dyspnea management|
42000|NCT00979888|Procedure|management of therapy complications|
42001|NCT00979901|Drug|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
42002|NCT00979901|Drug|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
41009|NCT00949767|Drug|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
41010|NCT00949767|Drug|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
41740|NCT00982020|Behavioral|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
41741|NCT00982033|Drug|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
41742|NCT00982033|Drug|placebo|placebo qd for 24 weeks
41743|NCT00982046|Device|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
41744|NCT00982046|Device|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
41745|NCT00024167|Drug|Prednisone|5 mg orally 2 x daily, weeks 1-14
41746|NCT00984152|Drug|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
41747|NCT00984152|Drug|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
41748|NCT00984165|Procedure|Single fraction radiation|8-Gy fraction of radiation
41749|NCT00984165|Biological|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
41750|NCT00984165|Procedure|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
42065|NCT00986973|Drug|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
42066|NCT00986986|Drug|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
42067|NCT00986999|Drug|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
42068|NCT00987012|Dietary Supplement|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
42069|NCT00987012|Dietary Supplement|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
42070|NCT00987025|Behavioral|Telehealth|Use of telehealth blood pressure station every week
42071|NCT00987025|Behavioral|Educational materials|Control
42072|NCT00987038|Drug|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
41519|NCT00979121|Drug|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
41520|NCT00023868|Drug|fluorouracil|
41521|NCT00979121|Drug|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
41522|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
41523|NCT00979134|Drug|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
41524|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
41525|NCT00979147|Procedure|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
41838|NCT00982124|Drug|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
41839|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
41840|NCT00982137|Biological|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
41841|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
41842|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
41843|NCT00982150|Drug|Talampanel|50mg capsules tid
41844|NCT00984295|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
41845|NCT00984295|Biological|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
41846|NCT00984295|Biological|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
41847|NCT00984295|Biological|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
41848|NCT00984295|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
41849|NCT00984308|Procedure|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
41268|NCT00983541|Drug|Gemcitabine|Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.
Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.
Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.
Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC.
41269|NCT00983554|Drug|Anastrazole|Arimidex 1mg daily
41270|NCT00983554|Drug|Testosterone|Testim 10g daily
41271|NCT00983554|Drug|Dutasteride|Avodart 2.5mg daily
41272|NCT00983554|Drug|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
41273|NCT00983567|Other|teen web|Min web
41274|NCT00983580|Drug|Aspirin|Given PO
41275|NCT00983580|Drug|Eflornithine|Given PO
41276|NCT00024141|Drug|fluorouracil|
41277|NCT00983580|Other|Laboratory Biomarker Analysis|Correlative study
41278|NCT00983580|Other|Placebo|Given PO
41584|NCT00986115|Drug|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
41585|NCT00986128|Drug|topiramate|100 mg tablet twice daily for 3 weeks
41586|NCT00986128|Drug|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
41587|NCT00986141|Procedure|Surgery|Selective Laser Trabeculoplasty for glaucoma
41588|NCT00986141|Procedure|Selective Laser Trabeculoplasty|Glaucoma Treatment
41589|NCT00986154|Drug|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
41590|NCT00000875|Drug|Zidovudine|
41591|NCT00024297|Drug|warfarin|
41011|NCT00949780|Drug|Chloral Hydrate|
41012|NCT00949793|Device|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
41013|NCT00949806|Drug|BNT (intradermal injection)|Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.
Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient.
41014|NCT00949819|Other|Active surveillace|Serial, long term data collection
41015|NCT00020917|Biological|cetuximab|
41016|NCT00949832|Dietary Supplement|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
41017|NCT00949832|Dietary Supplement|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
41018|NCT00949832|Dietary Supplement|Vitamin D2|50,000 IU given orally once
41019|NCT00949832|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU given orally once
41020|NCT00949845|Drug|Endotoxin|
41021|NCT00949871|Other|communication analysis|
41022|NCT00949871|Other|questionnaire administration|
41023|NCT00949871|Procedure|psychosocial assessment and care|
41024|NCT00949871|Procedure|support group therapy|
41025|NCT00949884|Drug|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
41026|NCT00020917|Drug|fluorouracil|
41027|NCT00949884|Drug|Placebo|placebo oral tablets once daily for two weeks
41028|NCT00951925|Other|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
41029|NCT00951951|Procedure|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
41030|NCT00951951|Procedure|Posterior Approach|
41031|NCT00951964|Drug|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
42073|NCT00024375|Drug|DHA-paclitaxel|
42074|NCT00987038|Drug|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
42075|NCT00987051|Procedure|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
42076|NCT00987064|Device|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
42077|NCT00987064|Device|Placebo TLA|TLA treatment with disabled filtration function
42078|NCT00987077|Device|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
42079|NCT00987090|Biological|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
42080|NCT00979953|Drug|Oxycodone CR|
42081|NCT00979953|Drug|Placebo|
42082|NCT00023946|Other|laboratory biomarker analysis|Correlative studies
42083|NCT00979966|Drug|Temsirolimus|25 mg intravenously, once weekly infusion
42084|NCT00979966|Drug|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
41098|NCT00957554|Drug|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
41099|NCT00021528|Drug|Lithium|
41100|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The starting dose will be 8 mg twice daily. The dose escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
41101|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally on Days 1 to 21 of a 28-day cycle. The starting dose will be 8 mg twice daily. The dose escalation will proceed until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
41102|NCT00949884|Drug|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
41103|NCT00949897|Device|Biofoam|Device
41104|NCT00949897|Other|Iliac Crest Allograft with locked plate|
41850|NCT00984321|Behavioral|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
41851|NCT00984321|Behavioral|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
41852|NCT00984321|Behavioral|expressive writing (arm will not be include in the randomization)|intervention facilitate "reappraisal" through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions.
41853|NCT00984334|Drug|Naloxone SR 5 mg capsules|
40861|NCT00954343|Procedure|Extracorporeal Shock Wave|
40862|NCT00954356|Drug|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
40863|NCT00954356|Drug|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
40864|NCT00954369|Drug|[F-18]W372|The individual doses of [F-18]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.
The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
40865|NCT00954395|Other|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
40866|NCT00954421|Device|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
40867|NCT00954434|Dietary Supplement|red wine|intake of red wine on a daily basis
40868|NCT00954447|Drug|Placebo|Placebo, identical to Linagliptin tablet
40869|NCT00954447|Drug|Linagliptin|intended final marketed dose
40870|NCT00954460|Drug|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
40871|NCT00021307|Drug|carboplatin|
40872|NCT00954473|Other|laboratory biomarker analysis|Correlative studies
41592|NCT00986154|Drug|low molecular weight heparin/unfractionated heparin|LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.
Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment
41593|NCT00986154|Drug|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
41594|NCT00986167|Drug|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
41595|NCT00986180|Drug|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
41596|NCT00986180|Drug|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
41597|NCT00986193|Procedure|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
41598|NCT00986193|Procedure|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
41599|NCT00986206|Other|diagnostic laboratory biomarker analysis|
41600|NCT00979173|Drug|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
41601|NCT00000872|Drug|Nelfinavir mesylate|
41602|NCT00023868|Drug|irinotecan hydrochloride|
41603|NCT00979186|Device|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
41912|NCT00982202|Drug|Placebo|1 to 3 tablets daily for ~18 months
41913|NCT00982215|Drug|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
41914|NCT00982215|Drug|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
41915|NCT00982228|Drug|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
41916|NCT00982228|Drug|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
41917|NCT00982228|Drug|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
41032|NCT00951964|Drug|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
41341|NCT00981318|Drug|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
41342|NCT00981331|Procedure|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
41343|NCT00981344|Other|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
41344|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
41345|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
41346|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
41347|NCT00023998|Procedure|therapeutic conventional surgery|Undergo resection
41348|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
41349|NCT00981370|Drug|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
41350|NCT00981383|Dietary Supplement|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
41351|NCT00981383|Other|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
41352|NCT00981396|Behavioral|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
41353|NCT00981396|Behavioral|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
41354|NCT00981409|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
41355|NCT00981409|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
41356|NCT00981435|Drug|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
41357|NCT00981435|Drug|Diclofenac 0.1%|Diclofenac sodium 0.1% to lasered eye 4 times/day for 4.5 days
41358|NCT00023998|Radiation|radiation therapy|Undergo radiotherapy
41105|NCT00949910|Drug|erlotinib [Tarceva]|1
41106|NCT00949923|Dietary Supplement|tea capsule|3 tea capsules daily for 3 weeks
41107|NCT00949936|Device|CAdisc™-L (Total Disc Replacement)|
41108|NCT00949949|Drug|everolimus|Given PO
41109|NCT00949949|Drug|gemcitabine hydrochloride|Given IV
41110|NCT00949949|Drug|cisplatin|Given IV
41111|NCT00000851|Drug|Stavudine|
41112|NCT00020917|Drug|irinotecan hydrochloride|
41113|NCT00949962|Drug|antiandrogen therapy|Given systemically
41114|NCT00949962|Drug|leuprolide acetate|Given subcutaneously
41115|NCT00949962|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
41116|NCT00949975|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
41117|NCT00949975|Drug|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
41118|NCT00949975|Drug|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
41119|NCT00949975|Drug|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
41417|NCT00978887|Other|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
41418|NCT00978900|Dietary Supplement|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
41419|NCT00023868|Drug|cisplatin|
41420|NCT00978900|Dietary Supplement|Water|
41421|NCT00978913|Biological|DC vaccine|DC vaccination, one vaccine biweekly
41422|NCT00978939|Other|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
41423|NCT00978939|Other|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
41424|NCT00978952|Device|Large Diameter Advanta™ V12 Covered Stent|Stent placement
40873|NCT00954486|Drug|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
40874|NCT00954499|Behavioral|Tactile stimulation added to Standard care|Parent rubs the infant's skin near the injection site just before, during and after the injection.
Fast injection technique without aspiration.
Oral sucrose 2 minutes before first injection.
Parent holds infant close.
40875|NCT00954499|Behavioral|Standard care|Fast injection technique without aspiration.
Oral sucrose 2 minutes before first injection.
Parent holds infant close.
40876|NCT00954512|Drug|Carboplatin|
40877|NCT00954512|Drug|Epirubicin|
40878|NCT00954512|Biological|Trastuzumab|
40879|NCT00954512|Drug|Everolimus|
40880|NCT00954512|Drug|Gemcitabine|
40881|NCT00957008|Device|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
41190|NCT00985621|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
41191|NCT00985621|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
41192|NCT00985621|Drug|oxycodone|oxycodone CR, 10-40 mg q12h
41193|NCT00985621|Other|placebo|placebo
41194|NCT00985634|Device|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
41195|NCT00024271|Drug|cisplatin|
41196|NCT00985634|Device|Control|Vessel loops
41197|NCT00985647|Drug|Lamivudine (3TC)|3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.
3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days.
41198|NCT00985660|Drug|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
41199|NCT00985660|Drug|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
41200|NCT00985673|Biological|GSK2340274A|Two intramuscular injections
41918|NCT00982241|Dietary Supplement|water|drinking water / normal dietary fluids for oral intake
41919|NCT00982254|Drug|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
41920|NCT00982254|Drug|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
41921|NCT00982267|Drug|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
41922|NCT00024050|Procedure|allogeneic bone marrow transplantation|
41923|NCT00982280|Drug|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.
Maintenance Period: Participants continuing on the dose established in the previous period.
41924|NCT00982293|Device|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
41925|NCT00982293|Device|Resonator device - sham|Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be "on"
41926|NCT00982306|Behavioral|Brief intervention|20 minute one to one counseling session
41927|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
41928|NCT00024180|Drug|romidepsin|
41929|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
41930|NCT00984386|Drug|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
40941|NCT00951899|Drug|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
40942|NCT00951912|Dietary Supplement|Placebo|10g soy protein isolated per day
40943|NCT00951912|Dietary Supplement|Daidzein|50mg daidzein +10g soy protein isolated per day
40944|NCT00951912|Dietary Supplement|Genistein|50mg genistein +10g soy protein isolated per day
40945|NCT00000853|Biological|rgp120/HIV-1MN|
40946|NCT00021073|Drug|fluorouracil|Given IV
41359|NCT00981435|Drug|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
41360|NCT00981448|Dietary Supplement|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
41361|NCT00981461|Device|HairMax LaserComb|Device application 3 times week, for 26 weeks
41663|NCT00984100|Procedure|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
41664|NCT00984113|Drug|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
41665|NCT00984126|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
41666|NCT00984126|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
41667|NCT00984139|Biological|Engerix™-B Kinder|Intramuscular, one dose.
41668|NCT00986362|Drug|Placebo|Placebo intravitreal injection
41669|NCT00024310|Drug|paclitaxel|
41670|NCT00986375|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
41671|NCT00986375|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
41672|NCT00986401|Drug|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
41673|NCT00986401|Drug|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
41674|NCT00986414|Drug|AFQ056|
41675|NCT00986414|Drug|AFQ056|
41676|NCT00986414|Drug|AFQ056|
41677|NCT00986414|Drug|AFQ056|
41678|NCT00986414|Drug|AFQ056|
41679|NCT00986414|Drug|Placebo|
41680|NCT00024323|Drug|cisplatin|
41425|NCT00978965|Genetic|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
41426|NCT00978978|Drug|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'
Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists
41427|NCT00981474|Other|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised to level above an individuals autoregulatory limits
41428|NCT00981474|Other|Control group|Blood pressure management based on institutional standard of care.
41429|NCT00981487|Drug|Ondansetron|24 mg one time
41430|NCT00981487|Drug|Ondansetron|24 mg, on time in the am
41431|NCT00981500|Procedure|gastric bypass|Roux-en-Y gastric bypass
41432|NCT00981500|Procedure|gastric banding|laparoscopic adjustable gastric banding
41433|NCT00000872|Drug|Stavudine|
41434|NCT00023998|Drug|etoposide|Given IV
41435|NCT00981500|Procedure|sleeve gastrectomy|vertical sleeve gastrectomy
41436|NCT00981513|Biological|Trivalent live attenuated seasonal influenza vaccine|One dose
41437|NCT00981513|Biological|Monovalent live attenuated pandemic influenza vaccine|One dose
41438|NCT00981513|Biological|Saline|One dose
41439|NCT00981526|Drug|Telmisartan|Telmisartan (plus existing clozapine or olanzapine treatment) 40mg/day for the first 2 weeks.
Telmisartan (plus existing clozapine or olanzapine treatment) 80mg/day for the next 10 weeks.
41751|NCT00984178|Other|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
41752|NCT00984178|Other|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
41753|NCT00984191|Radiation|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
41754|NCT00984204|Device|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
41755|NCT00984217|Radiation|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
41756|NCT00024167|Drug|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
41201|NCT00985673|Biological|GSK2340273A|Two intramuscular injections
41202|NCT00985673|Biological|Seasonal trivalent influenza vaccine (TIV)|Single intramuscular injection
41203|NCT00985673|Biological|Saline placebo|Single intramuscular injection
41204|NCT00985686|Other|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
41205|NCT00985699|Genetic|polymorphism analysis|
41206|NCT00024271|Drug|doxorubicin hydrochloride|
41207|NCT00985699|Other|laboratory biomarker analysis|
41208|NCT00985699|Other|pharmacogenomic studies|
41209|NCT00985712|Drug|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
41210|NCT00985712|Drug|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
41211|NCT00985712|Device|HumaPen Memoir|subcutaneously, daily for 24 weeks
41526|NCT00979147|Procedure|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
41527|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
41528|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
41529|NCT00979160|Drug|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
41530|NCT00981617|Drug|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
41531|NCT00981617|Drug|Placebo|Matching placebo taken once daily for 12 weeks
41532|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
41533|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
41534|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
40947|NCT00954512|Biological|Robatumumab|In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
40948|NCT00021307|Drug|temozolomide|
40949|NCT00954512|Biological|Cetuximab|
40950|NCT00954512|Drug|Paclitaxel|
40951|NCT00954512|Drug|Cisplatin|
40952|NCT00954512|Drug|5-FU|
40953|NCT00954512|Drug|Erlotinib|
40954|NCT00954512|Drug|Irinotecan|
40955|NCT00954512|Drug|Folinic Acid|
40956|NCT00954525|Drug|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
40957|NCT00954525|Dietary Supplement|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
40958|NCT00954538|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
40959|NCT00021320|Drug|cisplatin|
40960|NCT00954564|Other|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
40961|NCT00954564|Other|medical chart review|Observational only
40962|NCT00954564|Other|questionnaire administration|Observational only
40963|NCT00954564|Procedure|assessment of therapy complications|Observational only
41279|NCT00983580|Other|Telephone-Based Intervention|Ancillary studies
41280|NCT00983593|Behavioral|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
41281|NCT00983619|Drug|MEDI-551|A humanized Immunoglobulin G (IgG)1 kappa monoclonal antibody (MAb) directed against human CD19.
41282|NCT00983619|Drug|Rituximab|Ritimab and MEDI-551
41681|NCT00986427|Drug|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
41682|NCT00986427|Drug|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
41683|NCT00986440|Drug|CS-7017|CS-7017
41684|NCT00986440|Drug|Placebo|Placebo
41685|NCT00986453|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
41686|NCT00986453|Procedure|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
42003|NCT00000872|Drug|Nevirapine|
42004|NCT00023946|Drug|ixabepilone|Given IV
42005|NCT00979901|Drug|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
42006|NCT00979901|Drug|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
42007|NCT00979914|Other|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
42008|NCT00979927|Drug|SPC3649|5 weekly doses
42009|NCT00979927|Drug|saline|5 weekly doses
42010|NCT00979940|Drug|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
42011|NCT00979953|Drug|ADL5859|
42012|NCT00979953|Drug|ADL5747|
42013|NCT00982319|Drug|Broccoli sprout extract (sulforaphane)|Women newly diagnosed with DCIS on core biopsy prior to definitive surgery will be randomized to either a prepartion of broccoli sprout extract and mango juice or a placebo preparation of mango juice alone. All women will be on a cruciferous free diet for the duration of the study (14 days) and complete a daily dietary check list. Twelve hour urine collections and blood samples will be collected at various time points during the study. Acceptability of the 14 day dose will be evaluated by monitoring indices of compliance, including urinary measurements of ITC excretion, the daily food check list and a questionnaire administered at the end of the study.
42014|NCT00982319|Dietary Supplement|Mango juice without extract|Mango juice without broccoli sprout extract
42015|NCT00982332|Drug|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
42016|NCT00982332|Drug|isotonic sodium chloride solution (placebo)|4 ml intramuscular
41757|NCT00984217|Drug|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
41758|NCT00984230|Other|BSF|feeding amount according to individual baby need
41759|NCT00984230|Other|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
41760|NCT00984230|Other|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
41761|NCT00984243|Procedure|PHOTODYNAMIC THERAPY (PDT)|Photodynamic Procedure:
Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.
It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.
Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens
Energy density:
Argon-dye laser: 200-300 Joules/cm^2 Excimer-dye laser: 100-200 Joules/cm^2
41762|NCT00984256|Drug|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
41763|NCT00984256|Other|Procedure - malaria challenge|2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
41764|NCT00984269|Procedure|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
41765|NCT00984282|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
41766|NCT00984282|Drug|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
41767|NCT00000875|Drug|Diphenhydramine hydrochloride|
41768|NCT00024167|Radiation|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
41769|NCT00986674|Drug|carboplatin|Given IV
41770|NCT00986674|Drug|paclitaxel|Given IV
41771|NCT00986674|Biological|cetuximab|Given IV
42085|NCT00979992|Other|Laboratory Biomarker Analysis|Correlative studies
42086|NCT00979992|Drug|Sunitinib Malate|Given PO
42087|NCT00980005|Biological|GSK investigational vaccine GSK1557482A|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
42088|NCT00980005|Biological|Fluzone®|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
41535|NCT00981630|Biological|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
41536|NCT00981643|Behavioral|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
41537|NCT00981656|Drug|cisplatin|Given IV
41538|NCT00981656|Drug|fluorouracil|Given IV
41539|NCT00981656|Drug|mitomycin C|Given IV
41540|NCT00023998|Other|laboratory biomarker analysis|Correlative studies
41541|NCT00981669|Biological|rotavirus vaccine|3 doses with 6 weeks interval
41542|NCT00981669|Biological|placebo|3 doses with 6 weeks interval
41543|NCT00981682|Drug|SER120|once a day treatment of nocturia
41544|NCT00981695|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
41545|NCT00981708|Drug|Lenalidomide, Dexamethasone and Cyclophosphamide|Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.
Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.
Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.
The cycle is to be repeated every 28 days (4 weeks)
41546|NCT00981721|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
41547|NCT00981734|Other|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
41548|NCT00981747|Drug|Sildenafil|Sildenafil 20mg three times per day for 3 months
41854|NCT00024167|Drug|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
41855|NCT00984334|Drug|Placebo|
41856|NCT00984334|Drug|Naloxone SR 10 mg capsules|
41857|NCT00984334|Drug|Naloxone SR 20mg capsules|
41858|NCT00984334|Drug|Naloxone SR 2.5 mg capsules|
41859|NCT00984347|Drug|Oxytocin|For low risk group (women at deliveries 1-5):
IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.
For high risk group (grandmultiparas [6th delivery and up] or women with a previous cesarean section)
IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol
41860|NCT00984347|Procedure|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
41283|NCT00983632|Procedure|Selective vagus nerve stimulation|Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.
For details see detailed study description
41284|NCT00983632|Device|selective vagus nerve stimulation|electrical vagus stimulation
41285|NCT00983645|Drug|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
41286|NCT00983645|Drug|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
41287|NCT00000875|Drug|Indinavir sulfate|
41288|NCT00024141|Drug|irinotecan hydrochloride|
41289|NCT00983658|Drug|huMAb OX40L|Intravenous repeating dose
41290|NCT00983658|Drug|placebo|Intravenous repeating dose
41291|NCT00985725|Drug|Matching placebo|oral, once daily
41292|NCT00985738|Drug|Dutasteride|Dutasteride (Avodart) 0.5 mg QD. Drug initiation 3 months before 3 D mapping biopsy.
41293|NCT00985738|Other|placebo|
41294|NCT00024271|Drug|gemcitabine hydrochloride|
41295|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
41296|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41297|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41298|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41299|NCT00985751|Biological|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41300|NCT00985764|Procedure|cesarean delivery|
41604|NCT00979199|Other|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
41605|NCT00979212|Biological|panitumumab|Given IV
42017|NCT00982345|Drug|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
42018|NCT00982358|Drug|Valsartan|
42019|NCT00024050|Procedure|peripheral blood stem cell transplantation|
42020|NCT00982358|Other|Placebo|
42021|NCT00982384|Other|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
42022|NCT00982384|Other|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
42023|NCT00982397|Device|Protecta Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D)|Secondary prevention subjects will have their device programmed to VF NID 18/24. VF NID (ventricular fibrillation number of intervals to detect) is a programmed parameter and indicates if 18 of the last 24 beat to beat intervals are shorter than the VF detection interval the device will detect ventricular fibrillation and initiate therapy to treat the rhythm.
41033|NCT00951990|Behavioral|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
41034|NCT00951990|Behavioral|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
41035|NCT00952003|Drug|Bevacvizumab, Irinotecan, Oxaliplatin, Docetaxel|Therapy regimen
Sequential chemoimmunotherapy:
Oxaliplatin: 85 mg/m2, q2w for 3 months (=3 cycles; Cycles 1-3)
Irinotecan: 125 mg/m2, q2w for 3 months (=3 cycles; Cycles 1-3)
Bevacizumab: 5 mg/kg, q2w for 3 months (=3 cycles; Cycles 1-3)
Docetaxel: 50 mg/m2, q2w for 3 months (=3 cycles; Cycles 4-6)
Bevacizumab: 5 mg/kg, q2w for 3 months (=3 cycles; Cycles 4-6)
Maintenance immunotherapy:
Bevacizumab: 5 mg/kg, q2w until progression
41036|NCT00952016|Drug|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
41037|NCT00952029|Biological|bevacizumab|
41038|NCT00021073|Drug|irinotecan hydrochloride|Given IV
41039|NCT00952029|Drug|FOLFIRI regimen|
41040|NCT00952029|Drug|fluorouracil|
41041|NCT00952029|Drug|irinotecan hydrochloride|
41042|NCT00952029|Drug|leucovorin calcium|
41043|NCT00952042|Other|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
42089|NCT00980018|Drug|Nilotinib|participants will take nilotinib 400mg twice daily by mouth every morning and every evening approximately 12 hours apart. Participants will take two 200mg capsules at each dosing. Nilotinib is taken on an empty stomach with 8 ounces of water. No food is to be eaten for 2 hours prior to the nilotinib dose or for one hour following the dose.
42090|NCT00980031|Drug|Eplerenone|25mg PO daily (QD)for 6 months
42091|NCT00980031|Drug|Lactose Tablet|Lactose tablet
42092|NCT00980044|Drug|Tramadol|Oral Medication
42093|NCT00023959|Drug|hydroxyurea|Given orally
42094|NCT00980044|Drug|Placebo|Oral Medication
42095|NCT00980057|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved Medtronic Vision 3D™ CRT-D implantable device (Consulta® CRT-D, Maximo II® CRT-D, or Concerto II® CRT-D)
42096|NCT00980057|Other|Adaptive CRT (aCRT) Pacing|Adaptive CRT pacing software adjusts how the device paces the heart based on the patient's current heart status
42097|NCT00980070|Device|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
42098|NCT00980070|Device|Lumbar Puncture Device|Lumbar Puncture positioner
42099|NCT00980070|Other|Standard of Care|Lumbar Puncture positioner
42100|NCT00980083|Drug|Saline|
42101|NCT00980083|Drug|Exendin(9-39)amide|
42102|NCT00980109|Drug|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
42103|NCT00980109|Drug|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
42104|NCT00023959|Drug|fluorouracil|Given IV
42105|NCT00980109|Drug|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
42106|NCT00980109|Drug|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
41120|NCT00949988|Drug|Dasatinib and Rituximab|In Phase I, subjects will be enrolled into a "3+3" dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional
41861|NCT00984360|Drug|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
41862|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
41863|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
41864|NCT00986206|Other|liquid chromatography|
41865|NCT00986206|Other|mass spectrometry|
41866|NCT00024310|Dietary Supplement|folic acid|
41867|NCT00986206|Procedure|screening method|
41868|NCT00986232|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
41869|NCT00986232|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
41870|NCT00986232|Biological|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
41871|NCT00986245|Drug|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
41872|NCT00986258|Drug|Tapentadol Prolonged Release|Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (twice daily). Opioid rotation to tapentadol was scheduled as follows:
if less than 100 mg morphine equivalent start with 50 mg tapentadol prolonged release;
if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol prolonged release;
if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol prolonged release.
Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks the doses of tapentadol prolonged release was kept stable (start of Maintenance phase). Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release once 500 mg tapentadol prolonged release dose was reached.
41873|NCT00986271|Procedure|EVLI was determinated by PiCCO plus system.|
40882|NCT00957021|Device|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
40883|NCT00957034|Drug|placebo|placebo patch
40884|NCT00021489|Drug|Abacavir sulfate|
40885|NCT00957034|Drug|testosterone|300 or 450 micrograms/day transdermal testosterone patch
40886|NCT00957047|Drug|eslicarbazepine acetate|oral tablets
40887|NCT00957047|Drug|placebo|once daily placebo comparator
40888|NCT00957047|Drug|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
41606|NCT00979212|Drug|carboplatin|Given IV
41607|NCT00979212|Drug|paclitaxel|Given IV
41608|NCT00979225|Other|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
41609|NCT00979225|Other|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
41610|NCT00979238|Genetic|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
41611|NCT00979251|Drug|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
41612|NCT00979251|Drug|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
41613|NCT00023868|Drug|leucovorin calcium|
41614|NCT00979264|Behavioral|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
41615|NCT00979303|Device|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
41616|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
41617|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
41618|NCT00979316|Drug|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
41619|NCT00979316|Drug|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
41620|NCT00979329|Other|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
41621|NCT00979342|Device|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
41622|NCT00981786|Drug|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
41044|NCT00952042|Other|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
41045|NCT00952068|Drug|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
41046|NCT00952081|Drug|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
41047|NCT00952094|Drug|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
41048|NCT00952107|Device|FLARE imaging system|Testing of operation of imaging system
41049|NCT00021099|Drug|ixabepilone|Given IV
41050|NCT00952120|Device|GSUC|Gauze-based wall suction negative pressure wound therapy
41051|NCT00952120|Device|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
41052|NCT00954655|Genetic|mutation analysis|
41053|NCT00954655|Genetic|polymorphism analysis|
41362|NCT00981461|Device|Control Device|Device application 3 times week, for 26 weeks
41363|NCT00983684|Device|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
41364|NCT00983684|Radiation|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
41365|NCT00983697|Other|laboratory biomarker analysis|
41366|NCT00983697|Procedure|quality-of-life assessment|
41367|NCT00983697|Procedure|therapeutic conventional surgery|
41368|NCT00983697|Radiation|fludeoxyglucose F 18|
41369|NCT00983710|Behavioral|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
41370|NCT00983710|Behavioral|Usual care|Booklet on coping with localized prostate cancer
41121|NCT00950001|Procedure|Stereotactic Radiosurgery (SRS)|1 day outpatient radiation procedure using stereotactic frame to target radiotherapy to surgical area found by MRI scan.
41122|NCT00950001|Procedure|MRI|Standard MRI scans of the brain after surgery, at 5-8 weeks after surgery, every 6-9 weeks for a year, and then every 3-4 months after that.
41123|NCT00020917|Drug|leucovorin calcium|
41124|NCT00950014|Other|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
41125|NCT00950027|Drug|povidone iodine|oropharyngeal decontamination every 4 hours
41126|NCT00950027|Drug|Placebo|oropharyngeal decontamination every 4 hours
41127|NCT00950040|Behavioral|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
41128|NCT00950040|Behavioral|General health education|The intervention will consist of information about several general health behaviors.
41129|NCT00952133|Drug|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
41130|NCT00952133|Drug|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
41131|NCT00952146|Procedure|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
41132|NCT00952159|Biological|Monitoring seric concentrations of O-demethyl-tramadol and tramadol|The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
41133|NCT00952172|Behavioral|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
41134|NCT00952185|Other|cytology specimen collection procedure|
41135|NCT00952185|Other|fluorescent antibody technique|
41136|NCT00952185|Procedure|assessment of therapy complications|
41440|NCT00981526|Drug|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
40889|NCT00957060|Drug|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
40890|NCT00957060|Drug|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
40891|NCT00957073|Device|Rheos Baroreflex Activation System|Implant procedure
40892|NCT00957086|Drug|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
40893|NCT00957086|Drug|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
40894|NCT00957112|Procedure|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
40895|NCT00021489|Drug|Mycophenolate mofetil|
40896|NCT00957112|Procedure|standard follow-up care|Patients receive standard care
40897|NCT00957125|Drug|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
40898|NCT00957125|Drug|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
40899|NCT00957125|Drug|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
40900|NCT00957151|Drug|Creon|
40901|NCT00957164|Behavioral|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
40902|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
41212|NCT00985712|Device|HumaPen Luxura|subcutaneously, daily for 24 weeks
41213|NCT00985725|Drug|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
41214|NCT00978445|Other|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
41215|NCT00978458|Drug|temozolomide|Given orally
41216|NCT00978458|Radiation|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
41931|NCT00984399|Drug|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
41932|NCT00984412|Procedure|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
41933|NCT00984425|Drug|Lapatinib and Sorafenib|Comparison of different dosages of two drug
41934|NCT00984438|Drug|BCNU Wafer|Implantable during surgical resection into the tumor bed
41935|NCT00984438|Drug|Irinotecan|IV every 2 weeks for up to one year
41936|NCT00984438|Drug|Bevacizumab|IV every 2 weeks for up to one year
41937|NCT00984451|Biological|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
41938|NCT00984464|Biological|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
41939|NCT00024193|Biological|filgrastim|
41940|NCT00984464|Drug|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
41941|NCT00984464|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
41942|NCT00984477|Drug|AZD5122|A single dose of oral suspension
41943|NCT00984477|Drug|Placebo|A single dose of oral suspension
41944|NCT00984477|Drug|AZD5122|A single intravenous infusion
41945|NCT00984490|Drug|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
41946|NCT00984490|Other|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
41947|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
41948|NCT00984503|Drug|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
41949|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
41950|NCT00024193|Drug|busulfan|
41371|NCT00024154|Biological|trastuzumab|Given IV
41372|NCT00983736|Drug|Tramadol Hydrochloride|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).
Subject will take the study drug for about 27 weeks.
41373|NCT00983736|Drug|Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).
Subject will take the study drug for about 27 weeks.
41374|NCT00983749|Device|External counterpulsation at a full pressure|A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
41375|NCT00983749|Device|External counterpulsation at sham-pressure|A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
41376|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
41377|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
41378|NCT00983788|Drug|Bezafibrate|3 x 200 mg/ day
41379|NCT00983788|Other|Placebo|Placebo
41687|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
41688|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
41689|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
41690|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
41691|NCT00024323|Drug|triapine|
41692|NCT00986479|Drug|AZD6765|Single IV infusion of 150 mg AZD6765.
41693|NCT00986479|Drug|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
41694|NCT00986505|Drug|Lidocaine|Intravenous lidocaine once a week
41441|NCT00981526|Drug|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
41442|NCT00981526|Drug|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
41443|NCT00981539|Procedure|enema|pre operative rectal enema
one adult bottle to be used rectally the night before surgery
41444|NCT00981552|Radiation|IMRT planning|
41445|NCT00023998|Drug|ifosfamide|Given IV
41446|NCT00981552|Radiation|4-Field Radiation Planning|
41447|NCT00981565|Procedure|open carpal tunnel release|surgery to release the carpal tunnel
41448|NCT00981565|Other|Night-cast|individual night time splinting
41449|NCT00981578|Device|ExAblate 2100|Conformal Bone System
41450|NCT00981591|Drug|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
41451|NCT00981591|Drug|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
41452|NCT00981604|Procedure|SILS|Single Incision Laparoscopic Cholecystectomy
41453|NCT00981604|Procedure|Standard Laparoscopic Cholecystectomy|4 port technique
41454|NCT00981617|Drug|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
41455|NCT00981617|Drug|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
41456|NCT00023998|Biological|trastuzumab|Given IV
41457|NCT00983814|Drug|Placebo|Placebo matched oral capsules taken TID from Baseline to end of Week 8
41458|NCT00983827|Device|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
41459|NCT00983840|Other|Family Eats|8-session web-based program on healthy eating for African American families
41460|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
41461|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
41462|NCT00983853|Biological|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
41217|NCT00978458|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
41218|NCT00978471|Drug|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
41219|NCT00978484|Behavioral|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
41220|NCT00978484|Behavioral|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
41221|NCT00978497|Drug|placebo|oral BID
41222|NCT00023842|Drug|mitomycin C|
41223|NCT00978497|Drug|ANA598|oral 200mg BID
41224|NCT00978497|Drug|ANA598|oral 400mg BID
41225|NCT00978523|Drug|AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)|Oral, dose-escalation
41226|NCT00978536|Other|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
41227|NCT00978549|Drug|docetaxel|
41228|NCT00978549|Drug|steroid therapy|
41229|NCT00978549|Other|questionnaire administration|
41230|NCT00978549|Procedure|nausea and vomiting therapy|
41231|NCT00978549|Procedure|pain therapy|
41232|NCT00978549|Procedure|quality-of-life assessment|
41233|NCT00023842|Procedure|adjuvant therapy|
41234|NCT00978549|Procedure|standard follow-up care|
41235|NCT00978549|Radiation|radiation therapy|
41236|NCT00978562|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
41549|NCT00981747|Drug|Losartan|Losartan 25mg two times a day for 3 months
41550|NCT00981747|Drug|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day.
41551|NCT00024011|Drug|bortezomib|Given IV
41951|NCT00984503|Drug|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
40964|NCT00954577|Behavioral|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
40965|NCT00954590|Drug|Dimebon (latrepirdine)|20 mg orally three times daily
40966|NCT00954590|Drug|Placebo|Placebo orally three times daily
40967|NCT00954603|Drug|quetiapine|25-100 mg
40968|NCT00954603|Drug|haloperidol|0.5-2 mg
40969|NCT00954629|Drug|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
40970|NCT00021320|Drug|fluorouracil|
40971|NCT00954629|Drug|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
40972|NCT00954642|Drug|bevacizumab|Intravenous repeating dose
40973|NCT00954642|Drug|MNRP1685A|Escalating intravenous dose
40974|NCT00954642|Drug|paclitaxel|Intravenous repeating dose
40975|NCT00957164|Behavioral|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
40976|NCT00957164|Behavioral|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
40977|NCT00957177|Drug|Pregabalin|300mg pregabalin orally 1 hour before operation
40978|NCT00957177|Drug|Placebo|Placebo
40979|NCT00021502|Drug|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
40980|NCT00957190|Drug|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
41695|NCT00986518|Biological|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
41696|NCT00979355|Device|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
41697|NCT00979368|Drug|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
41698|NCT00023868|Drug|mitomycin C|
41699|NCT00979368|Drug|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
41700|NCT00979368|Drug|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
41701|NCT00979368|Drug|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
41702|NCT00979368|Drug|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
41703|NCT00979368|Drug|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
41704|NCT00979381|Biological|influenza vaccine|influenza vaccination
41705|NCT00979407|Biological|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
41706|NCT00979407|Biological|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
41707|NCT00979433|Device|Bubble CPAP|Bubble CPAP will be delivered using Fischer & Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
42024|NCT00982397|Device|Protecta Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D)|Secondary prevention subjects will have their device programmed to VF NID 30/40. VF NID (ventricular fibrillation number of intervals to detect) is a programmed parameter and indicates if 30 of the last 40 beat to beat intervals are shorter than the VF detection interval the device will detect ventricular fibrillation and initiate therapy to treat the rhythm.
42025|NCT00982410|Behavioral|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
42026|NCT00982410|Behavioral|educational supportive group|A control condition providing social support and education about pain and/or drug use.
42027|NCT00982423|Drug|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
41463|NCT00983853|Drug|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
41772|NCT00986700|Dietary Supplement|late night meal|Three different kinds of late night meal each for 2 days.
41773|NCT00986713|Drug|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
41774|NCT00986752|Device|Stenting (Smart Stent)|Nitinol stent
41775|NCT00986752|Device|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
41776|NCT00986752|Procedure|Atherectomy (SilverHawk device)|Atherectomy
41777|NCT00024349|Drug|mitomycin C|
41778|NCT00986765|Drug|Lovenox® (enoxaparin)|Injectable solution 4000 UI
41779|NCT00986765|Drug|Aspegic ® (Aspirin)|100 mg/day
41780|NCT00986778|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
41781|NCT00986778|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
41782|NCT00986778|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
41783|NCT00986791|Other|Gold Standard Programme for Alcohol Cessation Intervention|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
41784|NCT00986804|Drug|Decitabine|
41785|NCT00986817|Drug|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
41786|NCT00986817|Drug|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
41787|NCT00986830|Device|FinESS Sinus Treatment|
41788|NCT00000875|Drug|Acetaminophen|
41789|NCT00024349|Radiation|radiation therapy|
41790|NCT00986843|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
41791|NCT00986856|Drug|Fucidin® cream|
41792|NCT00986869|Procedure|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
41552|NCT00981747|Drug|Placebo pill|Placebo pill three times per day for 3 months
41553|NCT00981760|Radiation|Total Body Irradiation|One low-dose total body irradiation 4-6 hours before the infusion of donor's stem cells.
41554|NCT00981760|Drug|Fludarabine|Given intravenously over 30 minutes for three days. Last dose given two days before TBI.
41555|NCT00981760|Procedure|Recipient Leukocyte Infusion|Infusion of participant's white blood cells given 5 weeks after the stem cell transplant if there is evidence of the stem cell graft having partially taken and no evidence of GVHD
41556|NCT00981773|Drug|Maraviroc|Maraviroc 150 mg bid
41557|NCT00981773|Drug|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
41558|NCT00983944|Biological|rituximab|Given IV
41559|NCT00983944|Drug|EPOCH regimen|Given IV or orally
41560|NCT00983944|Drug|cyclophosphamide|Given IV or orally
41561|NCT00983944|Drug|doxorubicin hydrochloride|Given IV or orally
41562|NCT00983944|Drug|etoposide|Given IV or orally
41563|NCT00983944|Drug|prednisone|Given IV or orally
41564|NCT00983944|Drug|vincristine sulfate|Given IV or orally
41565|NCT00983957|Drug|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
41566|NCT00983957|Drug|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
41567|NCT00983970|Behavioral|Interactive video game cycling|Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42" flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session.
41568|NCT00024167|Drug|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
41874|NCT00986284|Drug|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
41875|NCT00986297|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
40981|NCT00957203|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
40982|NCT00957216|Drug|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
40983|NCT00957216|Drug|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
40984|NCT00957229|Drug|GDC-0449|capsule, 150 mg, one pill daily, 18 months
41301|NCT00985777|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
41302|NCT00985790|Biological|Influenza vaccine GSK2321138A|Intramuscular injection
41303|NCT00985790|Biological|Fluarix™|Intramuscular injection
41304|NCT00985803|Other|Physical Activity: Cardio training (CT)|The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.
The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling.
41305|NCT00024271|Drug|mitomycin C|
41306|NCT00985803|Other|Physical Activity: Endurance exercise training (ET)|The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.
The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling.
41307|NCT00985816|Dietary Supplement|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
41308|NCT00985816|Dietary Supplement|Placebo|Placebo
41309|NCT00985829|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
41310|NCT00985842|Device|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
41311|NCT00985842|Device|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
41312|NCT00985842|Device|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
41313|NCT00023842|Procedure|conventional surgery|
42028|NCT00982436|Drug|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
42029|NCT00982436|Radiation|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
42030|NCT00024063|Drug|orantinib|
42031|NCT00982436|Drug|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
42032|NCT00982449|Other|FIAU-PET-CT scans|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
42033|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
42034|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
42035|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
42036|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
42037|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
42038|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
42039|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
42040|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
42041|NCT00984542|Drug|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
42042|NCT00024193|Drug|cisplatin|
42043|NCT00984568|Biological|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
41054|NCT00954655|Other|laboratory biomarker analysis|
41055|NCT00954668|Procedure|immediate angiography and revascularization|immediate angiography < 2 hours after randomization
41056|NCT00954668|Procedure|early invasive angiography|early invasive angiography 12-72 h after randomization
41057|NCT00954681|Drug|quetiapine|Quetiapine treatment from 25 mg daily to 300 mg twice daily
41793|NCT00986882|Drug|SAF312A|
41794|NCT00986882|Drug|Placebo|
41795|NCT00986882|Drug|Ibuprofen|
42107|NCT00982449|Other|FIAU-PET-CT scan|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
42108|NCT00982462|Dietary Supplement|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
42109|NCT00982462|Dietary Supplement|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
42110|NCT00982475|Procedure|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
42111|NCT00982488|Drug|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
42112|NCT00982488|Drug|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
42113|NCT00982501|Drug|WS® 1442 900 mg/d|
42114|NCT00982501|Drug|WS® 1442 1800 mg/d|
42115|NCT00024076|Procedure|radiofrequency ablation|
42116|NCT00982501|Behavioral|Nordic walking training 2 x 30 min/week|
42117|NCT00982501|Behavioral|Nordic walking training 4x45 min/week|
42118|NCT00982527|Drug|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
42119|NCT00982527|Drug|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
42120|NCT00982540|Drug|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
42121|NCT00982553|Drug|Ribavirin|800mg once daily
42122|NCT00982553|Drug|Raltegravir|400mg twice daily
42123|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
42124|NCT00982566|Drug|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
41876|NCT00986310|Drug|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
41877|NCT00024310|Drug|lometrexol|
41878|NCT00986310|Drug|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
41879|NCT00986323|Device|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
41880|NCT00986323|Device|Placebo TLA|Placebo TLA (without filtration and TLA function)
41881|NCT00986336|Drug|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
41882|NCT00986336|Drug|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
41883|NCT00986336|Drug|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
41884|NCT00986336|Drug|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
41885|NCT00986349|Device|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
41886|NCT00986362|Drug|Ocriplasmin|175µg ocriplasmin intravitreal injection
41887|NCT00979693|Drug|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
41888|NCT00979693|Drug|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
41889|NCT00979706|Drug|HAART|Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.
All patients will be followed-up during 1 year.
41890|NCT00979706|Drug|HAART + Immunotherapy|Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.
All patients will be followed-up during 1 year.
41891|NCT00979719|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
41892|NCT00979719|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
41314|NCT00978601|Procedure|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
41315|NCT00978614|Drug|Neramexane|Dosage form:
25 mg immediate release [IR] tablets (=15.9 mg neramexane free base)
37.5 mg IR tablets (=23.9 mg neramexane free base)
41316|NCT00978627|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
41317|NCT00978627|Drug|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
41623|NCT00981786|Drug|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
41624|NCT00981799|Drug|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
41625|NCT00981799|Drug|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
41626|NCT00024011|Other|laboratory biomarker analysis|Correlative studies
41627|NCT00981799|Drug|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
41628|NCT00981799|Drug|Methotrexate|Give between day 29 and 36 or when ANC>750 and PLTS>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.
Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but <2 years of age 10 mg for patients age greater than or equal to 2, but <3 years of age 12 mg for patients greater than or equal to 3, but < 9 years of age 15 mg for patients greater than or equal to >9 years of age
41629|NCT00981799|Drug|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000/mm3 for two consecutive days.
41630|NCT00981812|Procedure|PEM Breast Biopsy|Breast biopsy using PEM guidance and Stereo Navigator software
41631|NCT00981825|Drug|Fluoride|Whole mouth brushing for 7 days
41632|NCT00981825|Drug|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
41633|NCT00981838|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients > 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
41634|NCT00981851|Drug|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
41058|NCT00021320|Drug|paclitaxel|
41059|NCT00954694|Device|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
41060|NCT00954707|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
41061|NCT00954707|Drug|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
41062|NCT00954720|Other|No Intervention|There is no intervention on this trial
41063|NCT00954733|Other|Arterial blood draw|One arterial blood draw
41064|NCT00954759|Procedure|Chiropractic treatment|
41065|NCT00954759|Procedure|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
41066|NCT00954785|Device|Ankle brace|Sports Stirrup ankle brace (Aircast)
41067|NCT00954785|Drug|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
41068|NCT00954785|Drug|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
41069|NCT00021320|Procedure|conventional surgery|
41070|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
41071|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
41072|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
41380|NCT00983801|Drug|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
42125|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
42126|NCT00024089|Drug|gefitinib|
42127|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
42128|NCT00982579|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
42129|NCT00982592|Drug|oxaliplatin|Given IV
45304|NCT00996619|Procedure|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects "seen" by the endoscope
45305|NCT00996632|Procedure|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
45306|NCT00000882|Drug|Indinavir sulfate|
45307|NCT00025298|Drug|paclitaxel|
45308|NCT00996632|Procedure|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
45309|NCT00996645|Other|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
45310|NCT00996658|Drug|Placebo|Placebo matching linagliptin tablets once daily
45311|NCT00996658|Drug|Linagliptin|Linagliptin tablets once daily
45312|NCT00996671|Drug|Placebo|Placebo to be used as comparator for GSK2256098
45313|NCT00996671|Drug|GSK2256098|focal adhesion kinase inhibitor given as a single dose
45314|NCT00996684|Drug|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
45315|NCT00996684|Drug|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
45316|NCT00996697|Drug|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
45317|NCT00999193|Procedure|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
45318|NCT00999193|Procedure|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
40903|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
40904|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
40905|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
40906|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
40907|NCT00949624|Drug|Docetaxel|Intravenous 100 mg/m2 every three weeks
40908|NCT00020891|Procedure|computed tomography|
40909|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
40910|NCT00949624|Drug|AG-013736|Oral tablet 5 mg BID continuous
40911|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
40912|NCT00949637|Behavioral|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
40913|NCT00949637|Behavioral|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
40914|NCT00949650|Drug|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
40915|NCT00949650|Drug|BIBW 2992|BIBW 2992 once daily until progression
40916|NCT00949650|Drug|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
40917|NCT00949663|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
40918|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
40919|NCT00020891|Radiation|radiation therapy|
40920|NCT00949663|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
40921|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
41635|NCT00981851|Drug|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
41636|NCT00981864|Radiation|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
41637|NCT00024024|Drug|rebimastat|
41638|NCT00981877|Drug|GB (Florestor)|S. Boulardii preparation of 1 gram twice daily for 5 days
41639|NCT00981877|Drug|GRALB|mixed probiotic preparation 1 gram twice daily for 5 days.
41640|NCT00981877|Drug|GC (placebo)|Placebo 1 gram twice daily for 5 days.
41641|NCT00981890|Drug|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
41952|NCT00986531|Drug|AZD8529|2 capsules by mouth for 3 days
41953|NCT00986531|Drug|Placebo to match AZD8529|2 capsules by mouth for 3 days
41954|NCT00986544|Procedure|no drain|drain positioned on the skin
41955|NCT00986544|Procedure|drain positioned|drain positioned in the subhepatic space
41956|NCT00986544|Procedure|drain not positioned|Drain positioned in the abdominal wall
41957|NCT00986557|Biological|adoptive immunotherapy|
41958|NCT00024336|Drug|tamoxifen citrate|
41959|NCT00986557|Biological|alemtuzumab|
41960|NCT00986557|Biological|in vitro-treated peripheral blood lymphocyte therapy|
41961|NCT00986557|Drug|foscarnet sodium|
41962|NCT00986557|Drug|ganciclovir|
41963|NCT00986557|Genetic|polymerase chain reaction|
41964|NCT00986557|Procedure|allogeneic hematopoietic stem cell transplantation|
41965|NCT00986557|Procedure|infection prophylaxis and management|
41966|NCT00986557|Procedure|peripheral blood stem cell transplantation|
41381|NCT00983814|Drug|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID, provided as oral capsules taken TID from Baseline to end of Week 8
41382|NCT00024154|Drug|gefitinib|Given orally
41383|NCT00985842|Device|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
41384|NCT00985842|Device|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
41385|NCT00985855|Drug|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
41386|NCT00024271|Procedure|conventional surgery|
41387|NCT00985855|Drug|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
41388|NCT00985868|Drug|multikinase inhibitor AT9283|
41389|NCT00985868|Other|enzyme-linked immunosorbent assay|
41390|NCT00985868|Other|immunohistochemistry staining method|
41391|NCT00985868|Other|laboratory biomarker analysis|
41392|NCT00985868|Other|pharmacological study|
41393|NCT00985881|Device|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
41394|NCT00985881|Device|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
41395|NCT00985894|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
41396|NCT00985894|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
41397|NCT00024271|Procedure|hyperthermia treatment|
41398|NCT00985907|Drug|Doxil, melphalan, bortezomib|Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2
45319|NCT00999193|Other|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
45320|NCT00025376|Procedure|Tumor Biopsy|
45321|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45322|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
45323|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45324|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45325|NCT00999219|Drug|FK199B|oral
45585|NCT00997048|Procedure|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
45586|NCT00997061|Drug|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
45587|NCT00025324|Drug|etoposide|
45588|NCT00997074|Drug|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
45589|NCT00997087|Drug|Flumazenil|Sublingual daily
45590|NCT00997100|Drug|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
45591|NCT00997113|Drug|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
45592|NCT00997113|Drug|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
45593|NCT00997126|Drug|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
45594|NCT00997126|Drug|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
45595|NCT00997126|Drug|Nitrous Oxide|Nitrous oxide 30% inhaled, titrated to 70% prn sedation
45596|NCT00997139|Drug|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
45597|NCT00992446|Drug|Melphalan|Given IV
45598|NCT00992446|Drug|Rituximab|Given IV
40922|NCT00949689|Behavioral|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
40923|NCT00949702|Drug|vemurafenib|960 mg b.i.d. continuous oral dosing
41237|NCT00978562|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
41238|NCT00978562|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
41239|NCT00978562|Drug|Gadolinium|Given IV
41240|NCT00978575|Drug|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
41241|NCT00978575|Drug|Ferrosulfate|200mg daily for 12 weeks
41242|NCT00978575|Drug|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
41243|NCT00978588|Drug|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
41244|NCT00981149|Drug|duloxetine|Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
41245|NCT00981162|Drug|sorafenib tosylate|Given PO
41246|NCT00981162|Drug|everolimus|Given PO
41247|NCT00981162|Other|laboratory biomarker analysis|Correlative study
41248|NCT00981162|Other|pharmacogenomic studies|Correlative study
41249|NCT00981162|Other|pharmacological study|Correlative study
41250|NCT00981175|Biological|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
41251|NCT00981175|Biological|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
41252|NCT00981201|Drug|Celecoxib|Months 1-3:
As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
41253|NCT00023998|Drug|leucovorin calcium|Given IV or orally
41254|NCT00981201|Drug|Celecoxib|Months 4-6:
As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
41967|NCT00986557|Procedure|standard follow-up care|
41968|NCT00986557|Radiation|radiation therapy|
41969|NCT00024336|Radiation|radiation therapy|
41970|NCT00986570|Biological|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
41971|NCT00986583|Drug|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
41972|NCT00986596|Dietary Supplement|vitamin D3|4000 IU once daily by mouth for 4 months
41973|NCT00986596|Dietary Supplement|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
41974|NCT00986609|Biological|MUC-1 peptide vaccine|Given subcutaneously
41975|NCT00986609|Biological|poly ICLC|Given intramuscularly
41976|NCT00986609|Biological|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
41977|NCT00986609|Other|laboratory biomarker analysis|Correlative studies
40985|NCT00957242|Drug|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
40986|NCT00957242|Drug|placebo|Oral placebo (1mg or 2.5mg)
40987|NCT00957255|Device|OrthoADAPT|soft tissue augmentation device
40988|NCT00957255|Procedure|Standard of care|Standard of care rotator cuff repair
40989|NCT00957268|Drug|Alogliptin|Alogliptin tablets
40990|NCT00000859|Drug|Ritonavir|
40991|NCT00021528|Drug|citalopram|
40992|NCT00957320|Drug|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
40993|NCT00957320|Drug|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
40994|NCT00957333|Other|ketamine|N.A.
40995|NCT00957346|Drug|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
41708|NCT00979433|Device|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
41709|NCT00023881|Drug|bortezomib|
41710|NCT00979446|Behavioral|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
41711|NCT00979446|Behavioral|Self-directed|Received study materials but no phone coaching
41712|NCT00979459|Drug|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
41713|NCT00979459|Drug|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
41714|NCT00979472|Drug|Solifenacin|oral
41715|NCT00979511|Other|milk and exercise|milk fortified with 1000mg calcium or low-calcium milk
weight-bearing exercise or passive exercise
41716|NCT00979524|Behavioral|Comprehensive Mental Health Services and Supports|This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive "usual care" services delivered by the staff at the Westside YO Program and serve as this study's comparison group.
41717|NCT00979537|Drug|Nisoldipine Extended-release Tablets, 40 mg|
41718|NCT00979537|Drug|Sular Tablets, 40 mg|
41719|NCT00979550|Drug|Imiquimod (Aldara)|.5 oz cream nightly to the affected area
41720|NCT00981929|Drug|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
41721|NCT00981929|Drug|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
41722|NCT00981942|Drug|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
41723|NCT00981955|Dietary Supplement|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
41724|NCT00024037|Procedure|management of therapy complications|
41725|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
41726|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
48170|NCT01018030|Drug|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
48171|NCT01018043|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
48172|NCT01018056|Drug|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
48173|NCT01018056|Drug|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
48192|NCT01020357|Drug|Caffeine citrate injection|Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.
Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.
Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
48193|NCT01020357|Drug|placebo|normal saline
48194|NCT01020383|Drug|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
48195|NCT01020383|Drug|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
48196|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
48197|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
48198|NCT01020409|Procedure|cardiac surgery with CPB use|heart or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
48199|NCT01020422|Procedure|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
48200|NCT01020435|Other|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
48201|NCT01023191|Procedure|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
47473|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
47474|NCT01024660|Drug|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
47475|NCT01024660|Drug|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
47476|NCT01024660|Drug|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
47477|NCT01024686|Biological|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
47478|NCT00000892|Drug|Saquinavir|
47479|NCT00027820|Drug|Fludarabine Phosphate|Given IV
47757|NCT01024842|Other|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
47758|NCT01024855|Device|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
47759|NCT01024868|Drug|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
47760|NCT01024881|Procedure|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
47761|NCT01024881|Procedure|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
47762|NCT01024894|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
47763|NCT01024907|Radiation|proton beam radiation therapy|Undergo radiation
47764|NCT01024907|Procedure|quality-of-life assessment|Ancillary study
47765|NCT00027820|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
47766|NCT01024907|Other|questionnaire administration|Ancillary study
47767|NCT01024920|Drug|BIBF 1120|VEGF inhibitor
47768|NCT01024920|Drug|sunitinib|VEGF inhibitor
47769|NCT01025258|Behavioral|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
47770|NCT01017250|Radiation|Stereotactic Radiosurgery (SRS)|Tumor Volume < 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
48265|NCT01018173|Drug|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
48266|NCT01018186|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
48267|NCT01018186|Drug|Fluticasone propionate|Inhaled corticosteroid
48268|NCT01018199|Other|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
48269|NCT01018199|Other|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
48270|NCT01018212|Other|Cicatrix cream|We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.
The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application.
48271|NCT01018225|Drug|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
48272|NCT00000891|Drug|Lamivudine|
47307|NCT01016483|Drug|Gemcitabine|Gemcitabine: 1000 mg^m² (milligram per square meter) 30 minutes intravenous infusion on Days 1, 8, 15, 22, 29, 36 and 43 followed by 1 week rest (56-day cycle 1) then on Days 1, 8 and 15 of the following 28-day cycles.
47308|NCT01016483|Drug|Placebo|Placebo orally twice daily, continuously without a break for a 28-day cycle (BID continuous Regimen).
47309|NCT01016483|Drug|MSC1936369B (MEK Inhibitor)|MSC1936369B orally, 60 milligram (mg) twice daily, continuously without a break for a 28-day cycle (BID-continuous Regimen).
47310|NCT01016496|Other|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
47311|NCT00027014|Drug|oxycodone|
47312|NCT01016496|Other|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
47313|NCT01016509|Drug|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of <180 mg/dl.
47684|NCT01017107|Drug|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
47685|NCT01017120|Drug|Tazarotene Foam|Tazarotene foam once a day application to the face
47686|NCT01017120|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
47687|NCT01017133|Radiation|fludeoxyglucose F 18|Given IV
47688|NCT01017133|Radiation|Fluorine F 18 EF5|Given IV
47689|NCT01017133|Procedure|Positron emission tomography|Undergo scan
47690|NCT01017146|Drug|Tazarotene foam|Tazarotene foam once a day application to the face
47691|NCT01017146|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
47692|NCT01017159|Drug|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
47693|NCT00027066|Drug|Warfarin placebo|2mg scored placebo tablet
47694|NCT01017172|Other|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
47695|NCT01017185|Drug|HF10|
47696|NCT01017198|Drug|BIIB021 and Food|Assessing the effect of food use on BIIB021
47697|NCT01017198|Drug|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
47698|NCT01017211|Other|auricular acupuncture|Experimental group to receive ear needles in the Battlefield Acupuncture points.
Sham group to receive ear needles at points thought to be ineffective but standardized.
47699|NCT01017224|Other|18F-FAZA|PET scan
47960|NCT01017640|Other|Laboratory Biomarker Analysis|Correlative studies
47961|NCT01017640|Drug|Mitomycin|Given IV
47962|NCT00027209|Drug|prempro|
47963|NCT01017640|Drug|Veliparib|Given PO
47964|NCT01017653|Drug|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
48342|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
48343|NCT01015664|Drug|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
48344|NCT00026871|Procedure|Radiotherapy|
48345|NCT01015664|Drug|cisplatin|75 mg/m2 IV over 60 minutes on day 1
48346|NCT01015664|Drug|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
48347|NCT01015677|Drug|MK6913|Stage 1 and Stage 2: High-dose MK6913 once daily for 4 weeks.
48348|NCT01015677|Drug|Comparator: 17beta-estradiol|Stage 1 and Stage 2: 17beta-estradiol 1 mg daily for 4 weeks
48349|NCT01015677|Drug|Comparator: placebo|Stage 1 and Stage 2: placebo only once daily for 4 weeks
48350|NCT01015677|Drug|Comparator: MK6913|Stage 2 only: Low-dose MK6913 once daily for 4 weeks
48351|NCT01015703|Biological|CoVaccine HT|intramuscular injection, dose escalation
48352|NCT01015716|Behavioral|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
48353|NCT01018238|Drug|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
48354|NCT01018251|Other|3'-deoxy-3'-[18F]fluorothymidine|Given IV
48355|NCT01018251|Procedure|Positron Emission Tomography/computed tomography|
48356|NCT01018251|Radiation|FLT-PET/CT|
48357|NCT01018264|Drug|solifenacin succinate (VESIcare)|up to 10mg every day orally
48358|NCT01018264|Drug|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
48359|NCT01018277|Other|Mobilization (walking)|25 meters twice
48360|NCT01018303|Dietary Supplement|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
48361|NCT00027339|Drug|tenofovir disoproxil fumarate|
48362|NCT01018329|Procedure|Magnetic Resonance Imaging|
47387|NCT00027807|Biological|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
47771|NCT00027079|Drug|ondansetron (Zofran)|
47772|NCT01017250|Drug|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
47773|NCT01017263|Drug|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
47774|NCT01017276|Drug|ASP1585|oral
47775|NCT01017289|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
47776|NCT01017302|Drug|Placebo|Subcutenaous once weekly for 4 weeks
47777|NCT01017302|Drug|Placebo|Single subcutaneous dose in week 5
47778|NCT01017302|Drug|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
48043|NCT01015144|Drug|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
48044|NCT01015157|Procedure|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
48045|NCT00026637|Behavioral|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
48046|NCT01015170|Drug|bupropion HCl|150mg BID for up to 8 weeks + counseling
48047|NCT01015183|Drug|Zinc Sulfate|Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
48048|NCT01015183|Drug|Placebo|Placebo: as the same of intervention group
48049|NCT01015196|Drug|Zavedos|
48050|NCT01015196|Drug|Cerubidine|
48051|NCT01015209|Device|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
48052|NCT01015222|Drug|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
48053|NCT01015222|Drug|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
48054|NCT01015222|Drug|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
47314|NCT01016509|Drug|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of <200 mg/dl.
47315|NCT01018745|Drug|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
47316|NCT01018758|Drug|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
47317|NCT01018771|Procedure|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
47318|NCT01018771|Procedure|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
47319|NCT00027378|Drug|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
47320|NCT01018784|Drug|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
47321|NCT01018797|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
47622|NCT01019239|Procedure|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
47623|NCT01019252|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
47624|NCT01019265|Drug|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
47625|NCT01019278|Radiation|proton beam radiation therapy|Undergo external proton beam radiation
47626|NCT01019278|Radiation|radiation therapy treatment planning/simulation|
47627|NCT00027443|Drug|Cyclosporine|
47628|NCT01019278|Drug|cisplatin|Given IV
47629|NCT01019291|Other|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
47965|NCT01017653|Drug|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
47966|NCT01017666|Drug|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
47967|NCT01017666|Drug|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
47968|NCT01017679|Drug|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
47969|NCT01017692|Procedure|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
47970|NCT01017731|Biological|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
47971|NCT01017731|Drug|Moxifloxacin|Administered orally
47972|NCT01017731|Drug|Diphenhydramine|Administered IV
47973|NCT00027222|Procedure|retinal ablation|
47974|NCT01017744|Device|Anesthetic Conserving Device|Ventilation in PSV with the Anesthetic Conserving Device with remifentanil
Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane
47975|NCT01017757|Procedure|High-resolution CT scanning|High-resolution CT scanning
47976|NCT01017770|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
47977|NCT01017770|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
47978|NCT01017783|Behavioral|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
47979|NCT01017783|Behavioral|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
47980|NCT01017783|Behavioral|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
48339|NCT01015638|Drug|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
48340|NCT01015638|Drug|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
48341|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
47388|NCT01024621|Device|Standard endoscopy|Pentax EG-2931 gastroscope
47389|NCT01016522|Dietary Supplement|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
47390|NCT01016548|Biological|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
47391|NCT01016561|Radiation|intracavitary balloon brachytherapy|
47392|NCT01016561|Radiation|external beam radiation therapy|
47393|NCT01016561|Radiation|intensity-modulated radiation therapy|
47394|NCT01016561|Radiation|radiation therapy treatment planning/simulation|
47395|NCT01016561|Radiation|3-dimensional conformal radiation therapy|
47396|NCT00027014|Drug|fentanyl|
47397|NCT01016561|Drug|Cisplatin|
47398|NCT01016574|Device|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
47399|NCT01016600|Drug|Lenalidomide|
47400|NCT01016600|Drug|Azacitidine|
47401|NCT01016626|Drug|CKD-4101 tablet|CKD-4101 tablet 1000 mg
500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)
47402|NCT01016626|Drug|Mycophenolate Mofetil capsule|Mycophenolate Mofetil capsule 1000 mg
250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)
47403|NCT01016639|Other|oxaliplatin, capecitabine, radiotherapy|
47404|NCT01016652|Device|etafilcon A multifocal contact lens|low-add multifocal contact lens
47405|NCT01016652|Device|etafilcon A Contact Lens|standard sphere contact lens
47406|NCT01016665|Drug|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
47407|NCT00027027|Drug|rhuMAb 2C4|
47408|NCT01016678|Drug|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
47409|NCT01016691|Drug|High Dose Drug Device|device inserted for 4 days
48055|NCT01015235|Drug|Placebo|Subcutaneous infusion-once over 4 hours
48056|NCT01017822|Biological|conatumumab|
48057|NCT00027248|Drug|MBI 226|
48058|NCT01017822|Drug|capecitabine|
48059|NCT01017822|Drug|gemcitabine hydrochloride|
48060|NCT01017822|Radiation|3-dimensional conformal radiation therapy|
48061|NCT01017874|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
48062|NCT01017874|Drug|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
48063|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
48064|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
48428|NCT01023659|Drug|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
48429|NCT01023659|Behavioral|motivational emails|brief motivational emails, sent weekly for 12 weeks
48430|NCT01015716|Behavioral|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
48431|NCT01015729|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
48432|NCT00026897|Procedure|Gamma-camera imaging|
48433|NCT01015729|Drug|Esomeprazole|oral, single dose
48434|NCT01015729|Drug|ASA|Tablet, oral, single dose
48435|NCT01015742|Drug|Stem cell Transplantation|Busulfan: 3.2 mg/kg IV daily on days -7 to -4
Cyclophosphamide : 60 mg/m² daily on days -3 to -2
Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2
Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90
Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant.
48436|NCT01015755|Behavioral|combined therapy treatment|mouth care
48437|NCT01015768|Device|ReNu Multiplus multipurpose disinfecting solution|New lenses (PureVision) soaked 6 hours to overnight in ReNu Multiplus
48438|NCT01015768|Device|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
47630|NCT01019291|Other|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
47631|NCT01019317|Drug|Cytarabine|0.5 grams/m^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients > 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3).
47632|NCT01019317|Drug|Fludarabine|15 mg/m^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients > 65 years and 3 days in patients with PS > 3).
47633|NCT01019330|Other|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
47634|NCT01022099|Procedure|Implantation of a Total Knee Arthroplasty|In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.
The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.
The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides.
47635|NCT01022112|Drug|TA-7284-Low|TA-7284-Low
47636|NCT01022112|Drug|TA-7284-Low-middle|TA-7284-Low-middle
47637|NCT01022112|Drug|TA-7284-High-middle|TA-7284-High-middle
47638|NCT01022112|Drug|TA-7284-High|TA-7284-High
47639|NCT00027599|Biological|prostatic acid phosphatase-sargramostim fusion protein|
47899|NCT01019811|Procedure|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
47900|NCT00027521|Drug|electroporation therapy|
47901|NCT01019824|Drug|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
47902|NCT01019837|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
47903|NCT01019850|Drug|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
47904|NCT01019850|Radiation|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
43702|NCT00975689|Drug|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
43703|NCT00968435|Other|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
44000|NCT00971477|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
44001|NCT00971477|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
44002|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
44003|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
44004|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
44005|NCT00023192|Drug|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
44006|NCT00971503|Procedure|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
44007|NCT00971503|Other|Saline injection|Injection of saline solution for 5 days
44008|NCT00971516|Procedure|Implant placement|dental implant placement
44009|NCT00971516|Procedure|Implants surgery|dental implant surgery
44010|NCT00971542|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
44011|NCT00971581|Drug|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
44012|NCT00971594|Behavioral|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of ~0.2-0.4 kg/wk
44013|NCT00971594|Behavioral|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
47410|NCT01016691|Drug|Low Dose Drug Device|device inserted for 4 days
47411|NCT01016691|Drug|Placebo Device|device inserted for 4 days
47700|NCT01017237|Drug|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
47701|NCT01017237|Drug|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
47702|NCT01017237|Drug|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
47703|NCT01019330|Other|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
47704|NCT01019356|Drug|Rosiglitazone|4 mg twice daily for 8 weeks orally
47705|NCT01019356|Drug|Acarbose|100 mg three times daily for 8 weeks orally
47706|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
47707|NCT00027456|Drug|Leptin A-100|
47708|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
47709|NCT01019382|Drug|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
47710|NCT01019395|Drug|Daptomycin|Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;
Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;
Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
47711|NCT01019408|Drug|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
47712|NCT01019421|Drug|Lu AE58054|Add-on treatment to donepezil
47713|NCT01019421|Drug|Placebo|Add-on treatment to donepezil
47714|NCT01019434|Drug|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
47715|NCT01019434|Drug|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
47716|NCT01019447|Other|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
48202|NCT01023191|Procedure|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
48203|NCT01023204|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
48204|NCT01023217|Drug|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
48205|NCT01023217|Drug|Entecavir|Entecavir 1 mg/day orally
48206|NCT01023217|Drug|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
48207|NCT01023230|Drug|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
48208|NCT01023230|Drug|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
48209|NCT01023243|Other|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
48210|NCT00027690|Drug|Gefitinib|Given orally
48527|NCT01015924|Procedure|ESIN|Elastiv stable intramedullary nailing
48528|NCT01015937|Drug|Turmeric extract|turmeric 500 mg TID for 45 days
48529|NCT01015937|Drug|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
48530|NCT00000891|Drug|Ritonavir|
48531|NCT00026936|Procedure|Radiotherapy|
48532|NCT01015950|Dietary Supplement|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
48533|NCT01015950|Dietary Supplement|Local food supplement|Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder ("Mix Me") are provide, according to the national Mali CMAM protocol when special processed foods are not available.
48534|NCT01015950|Dietary Supplement|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
48535|NCT01015950|Dietary Supplement|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
48536|NCT01015963|Other|laboratory biomarker analysis|Perform DNA sample analysis
48537|NCT01015976|Procedure|bariatric surgery|Roux en Y bariatric surgery
48538|NCT01015976|Other|control|No surgery
47905|NCT01019850|Procedure|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
47906|NCT01019850|Drug|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
47907|NCT01019863|Drug|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
47908|NCT01019876|Drug|Fludarabine|Fludarabine/Busulfan/Alemtuzumab
47909|NCT01022541|Procedure|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
47910|NCT01022567|Procedure|Appendicectomy|Standard appendicectomy
47911|NCT01022567|Drug|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
47912|NCT01022580|Drug|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8.
47913|NCT01022606|Other|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
47914|NCT01022632|Dietary Supplement|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
47915|NCT01022632|Drug|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
47916|NCT01022632|Dietary Supplement|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
48273|NCT00027339|Drug|indinavir sulfate|
48274|NCT01018225|Drug|Placebo|Placebo pill, once a day, for six weeks
48275|NCT01018238|Drug|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
48276|NCT01020435|Other|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
48277|NCT00000891|Drug|Didanosine|
48278|NCT00027547|Drug|mycophenolate mofetil|
44014|NCT00971607|Drug|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
44015|NCT00971607|Drug|Oxygen (placebo)|Control will receive oxygen only.
44016|NCT00023205|Behavioral|11th grade reading level arthritis materials|
44017|NCT00971620|Biological|Botulinum toxin type A|Given as an intralesional injection.
44018|NCT00971620|Other|Placebo|Given as an intralesional injection
44019|NCT00971633|Drug|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
44020|NCT00971633|Drug|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
44333|NCT01002443|Drug|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
44334|NCT01002443|Drug|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
44335|NCT01002456|Other|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
44336|NCT01002456|Other|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
44337|NCT01002469|Other|sodium [1-13C] acetate|
44338|NCT00025480|Drug|tipifarnib|
44339|NCT01002482|Device|CGAO-based Glucose Control|Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.
CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a "human-in-the-loop" approach.
The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control.
44340|NCT01002482|Device|Standard-Care Glucose Control|Patients in the control group will receive conventional insulin therapy using the "usual care" protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl).
44341|NCT01002495|Genetic|VM202|Endocardial injections on Day 0.
44342|NCT01002508|Biological|Influenza vaccine|One dose of influenza vaccine
44343|NCT01002534|Drug|Vardenafil|Nasal instillation of Vardenafil
47717|NCT01019447|Other|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
47718|NCT00027469|Procedure|MRI|
47719|NCT01019460|Procedure|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
47720|NCT01019473|Drug|AFQ056|
47981|NCT01017796|Drug|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
47982|NCT01017809|Drug|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
47983|NCT01019876|Drug|Cyclophosphamide|Cyclophosphamide/Fludarabine/TMG
47984|NCT01019876|Drug|Cyclophosphamide 40|Cyclophosphamide/Fludarabine/ATG/TBI
47985|NCT00027534|Biological|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
47986|NCT01019876|Drug|Cyclophosphamide 30|Cyclophosphamide /Fludarabine/TMG
47987|NCT01019889|Drug|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
47988|NCT01019889|Drug|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
47989|NCT01019889|Drug|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
47990|NCT01019915|Device|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
47991|NCT01019928|Drug|AZD1386|95 mg, oral solution, single dose
47992|NCT01019928|Drug|Placebo to AZD1386|Placebo, oral solution, single dose
47993|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
47994|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
47995|NCT01019954|Drug|Levulan|
48539|NCT01015989|Other|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
48540|NCT01015989|Other|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
48541|NCT01016002|Drug|Temoporfin|Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.
Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan
48542|NCT00026962|Procedure|measuring estradiol and progesterone levels in saliva|
48543|NCT01016015|Biological|Cixutumumab|Given IV
48544|NCT01011387|Device|NPWT system|3 dressing changes/week for maximum 4 weeks.
48545|NCT01011413|Drug|Efavirenz|3 x EFV 200mg tablets once daily
48546|NCT01011413|Drug|Efavirenz|2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily
47563|NCT01022086|Procedure|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
47564|NCT01022086|Biological|Biomarker Testing|In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.
Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay.
47565|NCT01024933|Behavioral|Positive Affect/Self-Affirmation/Motivational Interviewing|The positive affect/self-affirmation intervention will receive small gifts one week prior to their scheduled follow up. Secondly, we will use a task that involves reminding people of their proud moments. The motivational interviewing intervention includes the following steps: 1) assess the patient's motivation and confidence in engaging in medication adherence; 2) elicit barriers and concerns about medication adherence; 3) summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior; 4) provide a menu of options to the patient based on the nature of barriers elicited from the patient; 5) assess the patient's values and goals, in order to help the patient link their current health behavior pattern to their core values and life goals; and finally, 6) each encounter will end with a global summary of what was discussed and a clarification of an agreed-upon action plan.
48279|NCT01020448|Drug|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
48280|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate venous blood sampling
48281|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
48282|NCT01020474|Drug|placebo|matching placebo capsules twice daily.
48283|NCT01020474|Drug|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
48284|NCT01020487|Drug|Zemplar (paricalcitol) Capsules|Group 1 - Paricalcitol capsules 1 - 3 mcg TIW (one to three Paricalcitol 1 mcg capsules TIW).
48285|NCT01020487|Drug|Placebo capsules|Group 2 - Placebo TIW (one to three placebo capsules TIW)
48286|NCT01020526|Drug|pregabalin|Oral capsule 75-450 mg/day
48287|NCT01020539|Drug|Fludarabine|Conditioning Regimen
48288|NCT01020539|Drug|Busulfan|Conditioning Regimen
48289|NCT00027547|Procedure|allogeneic bone marrow transplantation|
48290|NCT01020539|Drug|Graft-versus-host disease (GVHD) Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
48291|NCT01020539|Drug|Gemtuzumab Ozogamicin|Dose Escalation
48292|NCT01020539|Drug|Anti-Thymocyte Globulin|Unrelated Donors only
48293|NCT01020539|Drug|Isotretinoin|JMML patients only
48294|NCT01020552|Other|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
48295|NCT01020565|Drug|Entecavir|Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
47322|NCT01018810|Drug|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
47323|NCT01018810|Drug|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
47324|NCT01018810|Drug|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
47325|NCT01018810|Drug|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
44344|NCT01002534|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
44345|NCT01002547|Drug|placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
44346|NCT01002547|Drug|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
44347|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
44348|NCT01002547|Drug|placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
44349|NCT00025480|Radiation|radiation therapy|
44350|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
44661|NCT01005446|Device|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
44662|NCT01005459|Drug|Tetracaine|Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
44663|NCT00998049|Drug|filgrastim|Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
44664|NCT00998075|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
44665|NCT00998075|Drug|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
44666|NCT00998075|Drug|ASA|Tablet, oral, single dose
44667|NCT00998088|Other|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
44668|NCT00998088|Drug|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
44669|NCT00998088|Device|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
44670|NCT00025363|Drug|vincristine sulfate|Given IV
44671|NCT00998088|Device|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
44672|NCT00998088|Other|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
47996|NCT00027547|Biological|therapeutic allogeneic lymphocytes|
47997|NCT01019980|Drug|Diclofenac potassium|Diclofenac potassium
47998|NCT01019980|Drug|Acetaminophen|Acetaminophen
47999|NCT01019993|Procedure|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory [I: E] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio <0.3 and R.R 60 breaths/min.
48363|NCT01018329|Procedure|Diffusion Tensor Imaging|
48364|NCT01018329|Procedure|Magnetic Resonance Spectroscopic Imaging|
48365|NCT01018329|Procedure|Dynamic Contract-Enhanced magnetic resonance imaging|
48366|NCT01018329|Procedure|Diffusion-weighted magnetic resonance imaging|
48367|NCT01018342|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
48368|NCT01018342|Drug|Macrobid® Capsules 100 mg|
48369|NCT01018355|Device|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
48370|NCT01018368|Drug|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
48371|NCT01018368|Drug|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
48372|NCT00027339|Drug|ritonavir|
48373|NCT01018381|Procedure|PEIT|For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).
Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease.
48374|NCT01018381|Procedure|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
48375|NCT01018381|Procedure|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
47566|NCT01024933|Behavioral|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
47567|NCT01024946|Drug|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
47568|NCT01024959|Other|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
47569|NCT01024972|Drug|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
47570|NCT01024972|Drug|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
47571|NCT01024998|Biological|AAV2-sFLT01|2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
47572|NCT00027820|Drug|Cyclosporine|Given PO
47573|NCT01024998|Biological|AAV2-sFLT01|2 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
47574|NCT01024998|Biological|AAV2-sFLT01|6 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
47575|NCT01024998|Biological|AAV2-sFLT01|2 x 10^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
47576|NCT01025011|Device|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
48174|NCT01018056|Drug|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
48175|NCT01018069|Drug|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
48176|NCT01018095|Drug|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
48177|NCT01018108|Procedure|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
48178|NCT01018108|Procedure|Acupuncture Therapy|Undergo acupuncture
48179|NCT00027300|Drug|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
48180|NCT01018108|Other|Questionnaire Administration|Ancillary study
47326|NCT01018823|Drug|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
47327|NCT01018823|Drug|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
47328|NCT01018836|Drug|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
47329|NCT01018836|Radiation|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
47330|NCT00000891|Drug|Stavudine|
47331|NCT00027391|Drug|Albuterol|
47332|NCT01018849|Dietary Supplement|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
47333|NCT01018849|Dietary Supplement|Placebo|placebo by mouth every 2 months for 1 year
47334|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
47335|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
47336|NCT01018862|Drug|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
47337|NCT01018875|Drug|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
47338|NCT01018875|Drug|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
47339|NCT01021553|Drug|GSK557296|150 mg GSK557296
47340|NCT01021553|Drug|placebo|placebo
47341|NCT01021566|Device|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
47342|NCT01021566|Drug|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
47640|NCT01022112|Drug|Placebo|Placebo
47641|NCT01022125|Drug|TMC435|
47642|NCT01022138|Biological|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
44673|NCT00998088|Other|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
44674|NCT00998088|Device|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
44675|NCT00998101|Drug|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
44676|NCT00998101|Drug|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
44677|NCT00998101|Drug|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
44678|NCT00998114|Behavioral|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
44679|NCT00998153|Behavioral|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
44680|NCT00998166|Drug|Pemetrexed, Cisplatin, Bevacizumab|Pre-hydration for 1-1/2 hours at 250 ml/hour
Pemetrexed 500 mg/m2 IV over 10 minutes
Return to hydration for 30 minutes at 250 ml/hour
Cisplatin 75mg/m2 IV over 60-120 minutes
Bevacizumab 15mg/kg IV over 90 minutes
44681|NCT00025363|Drug|irinotecan hydrochloride|Given IV
44682|NCT00998179|Device|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
43704|NCT00968448|Behavioral|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
43705|NCT00968448|Behavioral|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
43706|NCT00968461|Drug|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
43707|NCT00022737|Drug|cytarabine|Given IT and IV
43708|NCT00968487|Biological|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
43709|NCT00968487|Other|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at −18 °C (−0.4 °F) (or colder) within 6 hours of collection.
48376|NCT01018381|Procedure|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
48377|NCT01018381|Dietary Supplement|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
48378|NCT01020630|Drug|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
48379|NCT01020643|Drug|controlled administration of propofol|comparison of propofol sedation
48380|NCT01020708|Drug|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
48381|NCT01020708|Drug|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
48382|NCT01020708|Drug|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
47412|NCT01016691|Drug|bimatoprost 0.03%|one drop in each eye on one day only
47413|NCT01016704|Behavioral|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
47414|NCT01016717|Drug|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
47415|NCT01016717|Drug|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
47416|NCT01016730|Drug|Bortezomib|Given IV
47417|NCT01016730|Other|Laboratory Biomarker Analysis|Correlative studies
47418|NCT01018875|Drug|placebo|Subjects will take 4 capsules once daily for 12 weeks.
47419|NCT01018888|Device|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
47420|NCT01018901|Other|Survey Administration|Patients complete survey
47421|NCT00027391|Drug|Oxandrolone|
47422|NCT01018914|Drug|Prograf|oral
47423|NCT01018914|Drug|Advagraf|oral
47424|NCT01018914|Drug|Myfortic|oral
48181|NCT01020253|Drug|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
48182|NCT01020266|Procedure|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
48183|NCT01020266|Procedure|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
48184|NCT01020279|Drug|Celecoxib, Ketoprofen|Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.
Celecoxib, 200 mg, one capsule b.i.d.
48185|NCT01020279|Drug|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
48186|NCT01020292|Drug|Nelfinavir|
48187|NCT01020305|Drug|Temsirolimus|Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)
IUPAC name: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
48188|NCT01020305|Drug|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
48189|NCT01020331|Drug|Memantine|
48190|NCT01020344|Procedure|Lung volume reduction surgery|Lung volume reduction surgery
48191|NCT00027547|Drug|methotrexate|
48211|NCT01023243|Other|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
48212|NCT01023256|Drug|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
48213|NCT01023256|Drug|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
48214|NCT01023256|Drug|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
48215|NCT01023269|Device|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
48216|NCT01023282|Drug|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
48217|NCT01023282|Drug|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
48218|NCT01023295|Drug|fosbretabulin|single dose, intravenous infusion
47643|NCT01022138|Drug|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
47644|NCT01022138|Other|Laboratory biomarker analysis|The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
47645|NCT01022151|Drug|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L [group P]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
47646|NCT01022151|Drug|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL [group A2]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
47647|NCT01022151|Drug|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL [group A3]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
47648|NCT01022151|Drug|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL [group A4]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
47649|NCT01022151|Drug|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL [group A5]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
47650|NCT00000892|Drug|Nelfinavir mesylate|
47651|NCT00027599|Biological|sipuleucel-T|
47652|NCT01022151|Drug|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL [group D]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
47653|NCT01022164|Procedure|fibrin glue|
47654|NCT01022177|Procedure|acupuncture|acupuncture of the eye in traditional chinese schematics
47655|NCT01025284|Drug|LY2523355|Administered intravenously
47656|NCT00027833|Biological|tetanus toxoid|
47657|NCT01025297|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
47658|NCT01025323|Behavioral|Lifestyle modification|DASH diet and exercise advice
47917|NCT00027612|Radiation|radiation therapy|
47918|NCT01022645|Device|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
43710|NCT00968500|Behavioral|Questionnaires/Interviews|Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.
The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer.
43711|NCT00968513|Behavioral|Brief Intervention|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
43712|NCT00968513|Behavioral|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
43713|NCT00968513|Behavioral|Usual Care|brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
43714|NCT00968526|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injections
43715|NCT00968526|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
43716|NCT00968539|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
43717|NCT00968539|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
43718|NCT00022737|Drug|daunorubicin hydrochloride|Given IV
43719|NCT00968552|Procedure|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
43720|NCT00022945|Drug|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)|
44021|NCT00971633|Drug|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
44022|NCT00973687|Drug|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
44023|NCT00973687|Drug|Dexamethasone|
44024|NCT00973700|Biological|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
44025|NCT00973700|Biological|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
44026|NCT00973713|Drug|RAD001|10mg/d
47425|NCT01018927|Device|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
47426|NCT01018953|Drug|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
47427|NCT01018966|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
47428|NCT01018979|Drug|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
47429|NCT01018979|Drug|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
47430|NCT01018992|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
47431|NCT01018992|Drug|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
47432|NCT00027404|Drug|Fluoxetine|
47433|NCT01019005|Device|Catheter|Catheter inserted into either perineural tibial nerve or wound
47434|NCT01019018|Device|subtenon block|subtenon block with stevens cannula
47721|NCT01019473|Drug|Placebo|
47722|NCT01019486|Drug|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
47723|NCT01019486|Drug|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
47724|NCT01019499|Other|berry products|effects of berry consumption on cardiovascular indicators
two portions daily
47725|NCT01019499|Other|control products|two portions daily
47726|NCT01019512|Other|questionnaire administration|Ancillary studies
47727|NCT01019512|Other|lymphedema management|
47728|NCT01022190|Drug|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
48219|NCT01023295|Drug|Saline|single dose, intravenous infusion
48220|NCT01023308|Drug|Panobinostat|
48221|NCT00027690|Other|Laboratory Biomarker Analysis|Correlative studies
48222|NCT01023308|Drug|Bortezomib|
48223|NCT01023321|Drug|GLPG0555|single ascending doses, oral solution
48224|NCT01023321|Drug|placebo|single dose, oral solution
48225|NCT01023321|Drug|GLPG0555|multiple dose, oral solution, 7 or 14 days
48226|NCT01023321|Drug|placebo|multiple dose, oral solution, 7 or 14 days
48227|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
48228|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
48229|NCT01015417|Other|No medication|no postoperative antibiotics
48230|NCT01015430|Drug|Placebo|Placebo daily po
48231|NCT01015430|Drug|Placebo|Placebo daily po
48232|NCT01015430|Drug|RO4917523|RO4917523 ascending doses daily po
48233|NCT01015430|Drug|RO4917523|RO4917523 fixed dose daily po
47272|NCT01021527|Other|Comparator: Treatment A|No Treatment
47273|NCT01021527|Drug|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
47274|NCT01021527|Drug|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
47275|NCT00027573|Drug|cyclophosphamide|
47276|NCT01021527|Procedure|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
47277|NCT01021540|Drug|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
47278|NCT01021553|Drug|GSK557296|50 mg GSK557296
47919|NCT01022645|Device|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
47920|NCT01022658|Drug|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
47921|NCT01022671|Drug|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
47922|NCT01022684|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
47923|NCT01022697|Other|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
47924|NCT01022736|Drug|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
47925|NCT01022749|Drug|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
47926|NCT01022749|Biological|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
47927|NCT01022762|Drug|repaglinide|Individually adjusted dose for 16 weeks
47928|NCT00027625|Drug|gefitinib|
47929|NCT01022762|Drug|gliclazide|Individually adjusted dose for 16 weeks
47930|NCT01022775|Procedure|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
47931|NCT01022775|Procedure|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
47932|NCT01022788|Behavioral|Home-based counselling|
47933|NCT01022801|Drug|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
47934|NCT01025466|Drug|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
47935|NCT01025492|Drug|Trilipix (fenofibric acid)|135 mg po daily
47936|NCT01025492|Drug|placebo|one tablet po daily
47937|NCT00027833|Drug|fluorouracil|
47938|NCT01025505|Drug|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
44027|NCT00973726|Other|Glucose test|Subjects ingest an oral glucose tolerance test.
44028|NCT00973739|Drug|Lapatinib|Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.
Children/adolescents (<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)
Adults (>=18 years of age): 1,500 mg PO (6 tablets once daily)
Duration: Up to 12 months, depending on treatment response.
44029|NCT00973752|Drug|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
44030|NCT00973752|Drug|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
44031|NCT00023374|Drug|Ethambutol|6mos REZ intermittent
44032|NCT00973752|Drug|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
44033|NCT00973752|Drug|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
44034|NCT00973752|Drug|Cytarabine|Intrathecally during Induction and CNS therapy
44035|NCT00973752|Drug|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
44036|NCT00973752|Drug|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
44037|NCT00973752|Drug|Clofarabine|Intravenously during Consolidation 1 Therapy
44038|NCT00973752|Drug|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
44039|NCT00973765|Drug|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
44040|NCT00973765|Drug|placebo|placebo 2 pills po BID x 7 days
44041|NCT00973778|Other|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
44042|NCT00023374|Drug|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
44351|NCT01002547|Drug|Vitamin E placebo|Placebo of vitamin E will be given to arm 3.
44352|NCT01002573|Drug|ibuprofen|Ibuprofen, 10 mg/kg
44353|NCT01002573|Drug|acetaminophen|Acetaminophen, 10mg/kg
44354|NCT01002586|Other|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
47729|NCT01022203|Behavioral|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
47730|NCT01022203|Other|PTSD Family Education|The PTSD Family Education intervention provides education for veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
47731|NCT01022216|Device|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
47732|NCT01022216|Device|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
47733|NCT01022229|Dietary Supplement|Compound Natural Health Product|15-35 mg zinc citrate
150-350 mg magnesium lactate
30-70 mg pyridoxine hydrochloride
150-350 mg calcium ascorbate
Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study
47734|NCT01022229|Dietary Supplement|Placebo|Placebo
47735|NCT00027599|Biological|therapeutic autologous dendritic cells|
47736|NCT01022242|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
47737|NCT01022242|Drug|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
47738|NCT01022255|Biological|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
47739|NCT01022294|Drug|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
48000|NCT01020006|Drug|PCI-27483|Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.
All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are >3.50,a reduced dosage will be calculated.
48001|NCT01020006|Drug|Gemcitabine|
48002|NCT01020019|Drug|Lofexidine and Dronabinol|Lofex: .6 mg/ TID Dronabinol: 20 mg/TID
48003|NCT01020019|Drug|Placebo|Placebo control
47279|NCT00027781|Drug|sabarubicin|
47280|NCT01024309|Procedure|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
47281|NCT01024322|Drug|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
47282|NCT01024322|Drug|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
47283|NCT01024322|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
47284|NCT01024335|Drug|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
47285|NCT01024335|Drug|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
47286|NCT01024348|Drug|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
47287|NCT01024348|Drug|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
47288|NCT01024361|Device|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
47289|NCT01024387|Drug|AMG 479|Given intravenously once every three weeks
47290|NCT00027794|Procedure|conventional surgery|
47291|NCT01024400|Biological|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
47292|NCT01024413|Drug|erlotinib|study arm.erlotinib 150 mg oral till disease progression
47293|NCT01024413|Drug|gefitinib|study arm.gefitinib 250 mg oral till disease progression
47577|NCT01025024|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
47578|NCT01025037|Device|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
47579|NCT01025050|Procedure|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
47580|NCT01025076|Device|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
48296|NCT01020578|Other|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
48297|NCT01020591|Other|Osteopathic evaluation|evaluation of movement and tissue mobility
48298|NCT01020591|Other|Osteopathic evaluation with treatment|osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
48299|NCT01020617|Dietary Supplement|Ls-33|10~10 CFU/day
48300|NCT00027547|Procedure|peripheral blood stem cell transplantation|
48301|NCT01020630|Drug|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
48302|NCT01023347|Drug|Paclitaxel (Genexol®)|
48303|NCT01023347|Drug|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
48304|NCT01023360|Drug|Clopidogrel and proton pump inhibitors|baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->
1 week washout --> aspirin 100mg PO QD for 1 week
48305|NCT00027703|Drug|gemcitabine hydrochloride|Given IV
48306|NCT01023373|Drug|Medical treatment|hypotensive drugs, statins and anti-platelets
48307|NCT01023373|Procedure|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
48308|NCT01023373|Device|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
48309|NCT01023373|Device|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
48310|NCT01023386|Drug|YM155|I.V.
48311|NCT01023399|Drug|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
48312|NCT01023412|Dietary Supplement|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
48313|NCT01023425|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
48314|NCT01023438|Other|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
44355|NCT01004861|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
44356|NCT01004874|Drug|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
44357|NCT01004874|Drug|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
44358|NCT01004874|Radiation|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
44359|NCT01004874|Drug|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
44360|NCT01004887|Genetic|DNA ploidy analysis|
44361|NCT01004887|Genetic|fluorescence in situ hybridization|
44362|NCT01004887|Genetic|microsatellite instability analysis|
44363|NCT01004887|Genetic|mutation analysis|
44364|NCT01004887|Genetic|polymerase chain reaction|
44365|NCT00025610|Drug|doxorubicin hydrochloride|
44366|NCT01004887|Other|diagnostic laboratory biomarker analysis|
44367|NCT01004887|Other|flow cytometry|
44368|NCT01004887|Other|immunohistochemistry staining method|
44369|NCT01004900|Procedure|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
44370|NCT01004900|Drug|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
44371|NCT01004926|Device|Echelon foot|One Echelon foot for each subject, for a period of a month.
44372|NCT01004939|Drug|fondaparinux|fondaparinux
44683|NCT00998179|Device|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
44684|NCT00998192|Biological|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
48004|NCT01022814|Device|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
48005|NCT01022827|Other|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes [about 6 minutes for each muscle and order was random] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
48006|NCT01022840|Drug|S-Ketamine|drug
48007|NCT01022840|Other|Placebo Comparison|saline control
48008|NCT01022853|Drug|BI 6727|intravenous each 21 days
48009|NCT00027625|Drug|temozolomide|
48010|NCT01022853|Drug|BIBF 1120|oral continuously
48011|NCT01022879|Procedure|vitrectomy|
48012|NCT01022905|Biological|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
48013|NCT01022918|Drug|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
48014|NCT01022918|Drug|Temodal/radiotherapy|
48015|NCT01022944|Procedure|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
48016|NCT01022944|Procedure|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
48017|NCT01022957|Genetic|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
48018|NCT01022970|Drug|QAX576 placebo|
48019|NCT01022970|Drug|QAX576|
48020|NCT00027638|Drug|thalidomide|
48383|NCT01020734|Biological|anti-thymocyte globulin|
48384|NCT01020734|Drug|busulfan|
48385|NCT01020734|Drug|cyclophosphamide|
48386|NCT01020734|Drug|cyclosporine|
48387|NCT00027547|Radiation|radiation therapy|
47581|NCT01025089|Drug|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
47582|NCT01025102|Drug|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
47583|NCT01016886|Drug|perindopril OR bisoprolol OR placebo|perindopril- oral daily titrated does from 2mg up to 8mg
bisoprolol- oral daily titrated dose from 2.5mg up to 10mg
47584|NCT01016899|Radiation|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
47585|NCT00027053|Drug|Placebo|
47586|NCT01016912|Drug|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
47587|NCT01016912|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
47588|NCT01016912|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
47589|NCT01016912|Drug|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
47590|NCT01016912|Drug|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
47591|NCT01016925|Procedure|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
47592|NCT01016951|Drug|AZD9164 Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.
The COPD patients will receive a dose of 1000 µg.
47593|NCT01016951|Drug|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
47594|NCT01016964|Device|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
47595|NCT01016964|Device|Sham Device|Sham Device
47596|NCT00027066|Drug|Active Aspirin|325mg tablet daily
47858|NCT01025219|Genetic|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
47859|NCT01025232|Drug|Ranibizumab|Intravitreal Injection of 2.0mg formulation
48315|NCT01023438|Other|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
48316|NCT00027703|Drug|cisplatin|Given IV
47343|NCT01021579|Drug|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
47344|NCT01021579|Drug|Metfomin plus Simvastatin|
47345|NCT01021592|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
47346|NCT00027573|Drug|fludarabine phosphate|
47347|NCT01021618|Drug|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
47348|NCT01021618|Other|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
47349|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
47350|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
47351|NCT01021644|Behavioral|aerobic exercise-training|3 times per week for 6 months
47352|NCT01021644|Behavioral|stretch exercise|3 times per week for 6 months
47353|NCT01021657|Procedure|trabeculectomies, non penetrating deep sclerectomies|
47354|NCT01021670|Drug|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
47355|NCT01021670|Other|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
47356|NCT01021683|Drug|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
47357|NCT00027573|Drug|methotrexate|
47358|NCT01021696|Drug|Paracetamol|Paracetamol Max. dose: 3g/d
47359|NCT01021696|Drug|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
44685|NCT00998192|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
44686|NCT00998192|Drug|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
44687|NCT00998205|Drug|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
44688|NCT01000480|Drug|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
44689|NCT01000480|Radiation|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
44690|NCT01000493|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
44691|NCT01000493|Other|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
44692|NCT01000506|Biological|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
44693|NCT01000506|Biological|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
44694|NCT00025415|Drug|imatinib mesylate|Given orally
44695|NCT01000506|Biological|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
44696|NCT01000506|Drug|Placebo saline|Placebo saline every four weeks by i.v.
44697|NCT01000519|Other|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
44698|NCT01000519|Other|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
44699|NCT01000532|Device|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
44700|NCT01000532|Device|Pacemaker therapy|Pacemaker therapy
44701|NCT01000532|Device|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
44702|NCT01000545|Drug|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
44703|NCT01000545|Drug|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
48388|NCT01020734|Drug|fludarabine phosphate|
48389|NCT01020734|Drug|methotrexate|
48390|NCT01020734|Procedure|allogeneic hematopoietic stem cell transplantation|
48391|NCT01020747|Drug|Avastin® (bevacizumab)|Bevacizumab injections (~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
48392|NCT01020747|Drug|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
48393|NCT01020760|Behavioral|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
48394|NCT01020773|Behavioral|spontaneous breathing trial|
48395|NCT01020786|Drug|Pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.
Maintenance Therapy: 500 mg/m^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity.
48396|NCT01020786|Drug|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
48397|NCT01020799|Drug|AZD7268|15 mg, oral, twice daily (BID)
48398|NCT00027560|Biological|alemtuzumab|Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.
Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours.
48399|NCT01020799|Drug|Escitalopram|20 mg, oral, once daily (QD)
48400|NCT01020799|Drug|Placebo capsules|Placebo capsules to match AZD7268
48401|NCT01020799|Drug|Placebo tablets|Placebo tablets to match encapsulated escitalopram
48402|NCT00027703|Biological|bevacizumab|Given IV
48403|NCT01023542|Drug|delayed, low-dose CNI|immunosuppression
48404|NCT01023542|Drug|BU-CNI|Immunosuppression
47435|NCT01019018|Device|subtenon block|subtenon block with Olive tip cannula cannula
47436|NCT01019044|Procedure|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
47860|NCT01025245|Drug|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ & Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
47861|NCT01025258|Behavioral|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
47862|NCT01025271|Drug|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
47863|NCT01017458|Drug|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
47864|NCT01017458|Drug|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
47865|NCT01017471|Procedure|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
47866|NCT01017484|Other|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
47867|NCT01017497|Radiation|Stereotactic Radiosurgery|PTV Diameter < 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
47868|NCT01017510|Device|Subcutaneous injection luer syringe|Right scalp: Luer syringe.
Left scalp: syringe without a needle.
All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.
The distance between injection locations will be 1 cm.
47869|NCT00000224|Drug|Buprenorphine|
47870|NCT00000891|Drug|Delavirdine mesylate|
47871|NCT00027131|Biological|Heat Shock Protein 70-peptide complexes (HSP70)|
47872|NCT01017510|Device|DERMOJET (a syringe without a needle)|Right scalp: Luer syringe.
Left scalp: syringe without a needle.
All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.
The distance between injection locations will be 1 cm.
47873|NCT01017523|Behavioral|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
47874|NCT01017523|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
47875|NCT01017536|Biological|AERAS-402|AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
47876|NCT01017536|Biological|Placebo|Placebo was the identical buffer solution in which AERAS-402 is formulated.
47360|NCT01021696|Drug|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
47361|NCT01021696|Drug|Pregabalin|25mgx1/d; max 300mg/d
47362|NCT01024452|Device|DAWN AC|computerized dosing management system for anticoagulation clinics
47363|NCT01024452|Device|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
47659|NCT01025323|Behavioral|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
47660|NCT01025336|Other|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
47661|NCT01025336|Other|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
47662|NCT01025349|Drug|Bevacizumab, docetaxel, cisplatin|Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.
docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.
cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks.
47663|NCT01025362|Behavioral|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
47664|NCT01025362|Behavioral|Standard care|Child Health Services offered standard care
47665|NCT01025375|Dietary Supplement|inulin|10gram/day inulin for 13-day treatment
47666|NCT01025375|Dietary Supplement|inulin|16gram/day inulin for 13-day treatment
47667|NCT00027833|Drug|FOLFIRI regimen|
47668|NCT01025375|Dietary Supplement|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
47669|NCT01025401|Device|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
47670|NCT01025414|Drug|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
47842|NCT01022541|Drug|Bevacizumab|Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.
The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes
Courses as per detailed description above.
47843|NCT00027820|Drug|Mycophenolate Mofetil|Given PO
47844|NCT01025115|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
47845|NCT01025115|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
47846|NCT01025128|Drug|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
47847|NCT01025141|Device|Skeletal anchorage (MINISCREW)|Skeletal anchorage
47848|NCT01025141|Device|dental anchorage|dental anchorage (reference)
47849|NCT01025154|Drug|Clofarabine|Induction Cycle: 20 mg/m^2 IV over approximately 1 hour daily for 5 days (days 1-5)
47850|NCT01025154|Drug|Idarubicin|Induction Cycle: 10 mg/m^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
47851|NCT01025154|Drug|Cytarabine|Induction Cycle: 1 g/m^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
47852|NCT01025167|Dietary Supplement|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
47853|NCT01025167|Dietary Supplement|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
47854|NCT00027833|Biological|ALVAC-CEA-B7.1 vaccine|
47855|NCT01025180|Other|Procalcitonin level|The duration of antibiotic treatment is based on PCT level:
< 0.25 ng/ml: antibiotic should be stopped
0.25 < PCT <0.5: antibiotic prescription is not recommended
> 0.5 ng/ml: antibiotic should be used
47856|NCT01025193|Drug|Belimumab|The subjects will be given this medication as an outpatient as an intravenous infusion through the arm. The medication will be given at the beginning of the study, two weeks later, and then every 4 weeks for up to one year pre-transplant.
47437|NCT01019057|Procedure|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
47438|NCT01019070|Drug|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
47439|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
47440|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
47441|NCT01019083|Other|Control|Control will be selected from the Arsenic non contaminated Area
47442|NCT01019083|Drug|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
47443|NCT00027417|Drug|Liothyronine sodium/triiodothyronine|
47444|NCT01021709|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 & 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
47445|NCT01021722|Procedure|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
47446|NCT01021735|Drug|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
47447|NCT01021735|Drug|Rituximab|1g x2 by IV infusion repeated every 5 months or more
47448|NCT01021748|Drug|MK-2206 plus AZD6244|MK-2206 (tablets) orally, in a once every-other-day (starting dose 45 mg) or once-weekly (starting dose 90 mg) schedule, and AZD6244 (capsules), orally, twice a day (starting dose 75 mg). Doses will be escalated to the MTD.
47449|NCT01021761|Drug|Ketorolac Tromethamine|ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
47450|NCT00027573|Drug|tacrolimus|
47451|NCT01021761|Drug|Bromfenac|Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
47452|NCT01021761|Drug|nepafenac|drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
47453|NCT01021774|Procedure|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
47454|NCT01021787|Drug|Titanium dioxide|Topical cream
47455|NCT01021800|Biological|MIS|Cell infusion
47740|NCT01022294|Drug|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
48234|NCT01015443|Biological|Tecemotide (L-BLP25)|All subjects randomized to the investigational arm will begin the following treatment regimen within three days of randomization: A single I.V. infusion of 300 mg/m2 of cyclophosphamide administered exactly three days prior to the first Tecemotide (L-BLP25) vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with 918 μg Tecemotide (L-BLP25) at weeks 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at six-week intervals, beginning at week 14 (maintenance phase) and continuing until disease progression is documented or the subject discontinues for any other reason.
48235|NCT01015443|Biological|Placebo|A single I.V. infusion of 0.9% sodium chloride will be administered to subjects randomized to the control arm exactly 3 days prior to treatment with placebo. Subjects will then receive eight consecutive weekly subcutaneous treatments with placebo at weeks 1, 2, 3, 4, 5, 6, 7, and 8 followed by maintenance treatment at 6 week intervals, beginning at week 14 and continuing until disease progression is documented.
48236|NCT00026845|Procedure|therapeutic conventional surgery|Patients undergo total mastectomy
48237|NCT01015456|Drug|mycophenolate sodium|per oral, twice daily, for 12 months
48238|NCT01015456|Drug|cyclophosphamide|intravenous, monthly, for 6 months
48239|NCT01015469|Procedure|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
48240|NCT01015469|Procedure|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
48241|NCT01015482|Drug|Remifentanil|Remifentanil Infusion
48242|NCT01015482|Drug|Midazolam|Midazolam Infusion
48243|NCT01015495|Drug|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
48244|NCT01015508|Other|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
48245|NCT01015508|Other|Weight maintenance|10 months
48246|NCT01015521|Drug|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
48247|NCT00026845|Radiation|radiation therapy|Patients undergo radiation therapy
48248|NCT01015534|Drug|Temozolomide|
48249|NCT01015534|Radiation|Whole brain irradiation|
48250|NCT01015547|Drug|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
48251|NCT01015547|Drug|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
47671|NCT01025414|Drug|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
47672|NCT01025427|Drug|Raltegravir, tenofovir/emtricitabine|Ten elite controllers and 10 untreated non-controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
47673|NCT01025453|Drug|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
47674|NCT01025466|Drug|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
47939|NCT01025505|Drug|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
47940|NCT01025518|Other|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
47941|NCT01025518|Dietary Supplement|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
47942|NCT01025518|Dietary Supplement|Placebo|Maltodextrine
47943|NCT01025544|Biological|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
47944|NCT01025544|Biological|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
47945|NCT01025557|Other|Dietary intervention|Dietary treatments with beverages
47946|NCT01025570|Drug|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
47947|NCT01025583|Dietary Supplement|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
47948|NCT00000225|Drug|Buprenorphine|
47949|NCT00000892|Drug|Delavirdine mesylate|
47950|NCT00027833|Drug|irinotecan hydrochloride|
47951|NCT01025583|Dietary Supplement|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
47857|NCT01025206|Biological|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
48131|NCT01023178|Drug|Progesterone, micronized|Given starting at 18 months
48132|NCT00000889|Drug|Aldesleukin|
48133|NCT00026819|Drug|Rofecoxib|
48134|NCT01015235|Drug|KAI-1678|Subcutaneous infusion-once over 4 hours
48135|NCT01015235|Drug|Ketorolac Tromethamine|Active comparator, IV infusion, once
48136|NCT01015248|Drug|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
48137|NCT01015261|Procedure|Bone Marrow Transplantation|Allogenic Bone Marrow Transplantation
48138|NCT01015261|Procedure|Chemotherapy|Cyclophosphamide 1200 mg/m2 D15
Daunorubicin 45 mg/m2 D15—D18
Vincristine 1 mg/m2 D15, D22
Dexamethasone 24 mg/d D12—D28
48139|NCT01015287|Drug|Placebo|Administered once orally
48140|NCT01015287|Drug|Prasugrel|Administered orally
48141|NCT01015300|Drug|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
48142|NCT01015313|Other|intensive sodium management|dietary sodium restriction
avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms
48143|NCT01015326|Other|Questionnaire|Administered questionnaire
48144|NCT00026845|Procedure|axillary lymph node dissection|Patients undergo axillary lymph node dissection
48145|NCT01015326|Other|Questionnaire|Administered questionnaire
48146|NCT01015339|Drug|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
48147|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
48148|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
48149|NCT01015339|Drug|cisplatin|80mg/m2, day 1 of every 3 weeks
48150|NCT01015352|Drug|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
48151|NCT01015352|Drug|Epoetin beta|Epoetin beta : 60000U weekly SQ injections
NeoRecormon®
47741|NCT01022320|Procedure|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
47742|NCT01022333|Dietary Supplement|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
47743|NCT01022346|Drug|Placebo|0.5 mL buffer solution sc on days 1, 8 and 15
47744|NCT01022346|Drug|RO5217790|sc in 0.5 mL buffer solution on days 1, 8 and 15
47745|NCT01022359|Device|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
47746|NCT00027599|Procedure|in vitro-treated peripheral blood stem cell transplantation|
47747|NCT01022359|Device|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
47748|NCT01022372|Procedure|Endometrial biopsy|For all the groups
47749|NCT01022385|Dietary Supplement|24-hour low-residual diet|
47750|NCT01024816|Behavioral|Restorative yoga|Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.
Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions
47751|NCT01024816|Behavioral|Stretching|Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.
Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions.
47752|NCT01024829|Radiation|Radiotherapy|Radiotherapy
47753|NCT01024842|Biological|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu at week 0, 4 and 12.
47754|NCT00027820|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
47755|NCT01024842|Other|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
47756|NCT01024842|Biological|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu at week 0, 4 and 12.
48252|NCT01018108|Other|Laboratory Biomarker Analysis|Correlative Study
47294|NCT01024426|Procedure|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
47295|NCT01024426|Other|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
47296|NCT01024439|Procedure|transumbilical single incision laparoscopic appendicectomy|Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.
Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done.
47297|NCT01024439|Procedure|conventional laparoscopic appendicectomy|Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.
Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings.
47298|NCT01016379|Other|laboratory biomarker analysis|
47299|NCT01016418|Dietary Supplement|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
47300|NCT00027014|Drug|St. John's Wort|
47301|NCT01016431|Other|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
47302|NCT01016431|Other|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
47303|NCT01016457|Device|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
47304|NCT01016470|Dietary Supplement|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
47305|NCT01016470|Dietary Supplement|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
47952|NCT01025596|Drug|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
47953|NCT01025622|Biological|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
47954|NCT01025635|Drug|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
47955|NCT01025635|Drug|Vehicle foam|Applied topically twice daily for 12 weeks
47956|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
47957|NCT01025648|Drug|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
47958|NCT01017627|Other|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
47959|NCT01017627|Other|No change from normal routine|Normal unit policy for labs and anemia treatment
48317|NCT01023464|Other|FID114657|artificial tears
48318|NCT01023464|Other|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
48319|NCT01023477|Drug|Chloroquine Standard Dose (500mg/week)|Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
48320|NCT01023477|Drug|Chloroquine Low Dose (250mg/week)|Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
48321|NCT01023477|Procedure|Breast Biopsy|Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
48322|NCT01023490|Drug|Vitamin D|34,5000 IU vitamin D per week
48323|NCT01023490|Drug|Placebo|Placebo
48324|NCT01023516|Drug|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
48325|NCT01023516|Drug|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
48326|NCT01023529|Radiation|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
48327|NCT01015547|Drug|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
48328|NCT01015560|Drug|anti-CCR2 monoclonal antibody MLN1202|
48152|NCT01015365|Procedure|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
48153|NCT01015378|Procedure|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
48154|NCT01015391|Drug|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
48509|NCT01023737|Drug|Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
48510|NCT01023750|Drug|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
48511|NCT01023763|Other|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
48512|NCT01023776|Biological|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
48513|NCT01023789|Device|ABSORB BVS|ABSORB Bioresorbable Vascular Scaffold (BVS) System implantation
48514|NCT01023815|Drug|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
48515|NCT01023815|Drug|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
48516|NCT00000892|Drug|Adefovir dipivoxil|
48517|NCT00027729|Biological|etaracizumab|
48518|NCT01023815|Drug|Prednison (continuous steroids)|continuous steroids
48519|NCT01023841|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
48520|NCT01023841|Drug|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
48521|NCT01015846|Other|Core stability exercise|Traditional core stability exercise
48021|NCT01022983|Drug|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
48022|NCT01022983|Drug|Placebo|ml/kg/hours - same infusion rate as active comparator
48023|NCT01022996|Drug|RAD001|
48024|NCT01022996|Drug|Everolimus (RAD001)|Everolimus 10 mg tablet given orally once daily.
48025|NCT01023009|Procedure|vitrectomy|
48026|NCT01023022|Other|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
48027|NCT01023035|Drug|Boceprevir|800 mg given three times a day (TID), orally (PO)
48028|NCT01023035|Drug|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
48029|NCT01023035|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
48030|NCT01023035|Drug|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
48031|NCT01015053|Procedure|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
48032|NCT01015066|Drug|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
48033|NCT01015066|Drug|Naltrexone|Oral tables, 50 mg/d, once a day for six months
48034|NCT00026637|Drug|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
48035|NCT01015105|Other|observation|observation
48036|NCT01015118|Drug|Placebo|comparator to BIBF 1120
48037|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
48038|NCT01015118|Drug|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
48039|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
48040|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
47306|NCT01016483|Drug|MSC1936369B (MEK Inhibitor)|Two different dosing regimens of MSC1936369B will be tested. QD-5 On/ 2 Off Regimen: MSC1936369B dose escalation treatment will be given orally once daily on Days 1 to 5 and then no medication on Days 6 and 7, that means 5 days on, 2 days off. Patients will continue on Days 8 to 12, 15 to 19 and 22 to 26, and so on up to Day 56 (first cycle) or Day 28 (all other cycles).
BID - Continuous Regimen: MSC1936369B dose escalation treatment will be given orally twice-per-day as continuous daily dosing from Days 1 to 28. There will be no treatment breaks, unless required due to toxicity or adverse events.
47597|NCT01016977|Drug|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
47598|NCT01016977|Drug|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
47599|NCT01016990|Drug|valproic acid|
47600|NCT01016990|Genetic|western blotting|
47601|NCT01016990|Other|laboratory biomarker analysis|
47602|NCT01016990|Other|pharmacological study|
47603|NCT01017003|Drug|colchicine tablets|0.6mg colchicine tablet
47604|NCT01017003|Drug|colchicine tablets|0.6mg q12 hours for 10 days
47605|NCT01017029|Drug|Everolimus|
47606|NCT01017029|Drug|Mycophenolate mofetil + Everolimus|
47607|NCT00027066|Drug|Active Warfarin|2mg scored tablet daily
47608|NCT01017042|Drug|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
47609|NCT01017055|Other|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
47610|NCT01017068|Drug|OME|4g/100ml) dose: п gutt tid x 1/52
47611|NCT01019187|Procedure|Management of therapy and complications|
47612|NCT01019187|Procedure|Sleep disorder therapy|
47613|NCT01019187|Drug|Armodafinil|Given orally
47614|NCT01019187|Procedure|Cognitive Assessment|
47615|NCT01019187|Procedure|Quality of Life Assessment|Quality of Life Assessment
47616|NCT00027443|Drug|Muromonab-CD3|
47617|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
48329|NCT01015560|Genetic|polymorphism analysis|
48330|NCT01015560|Other|laboratory biomarker analysis|
48331|NCT01015573|Device|magnetic sensor system to measure the movements of finger tapping|
48332|NCT01015586|Drug|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
48333|NCT00026858|Behavioral|collaboration|
48334|NCT01015586|Drug|Placebo|Placebo once daily for 12 weeks
48335|NCT01015599|Behavioral|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
48336|NCT01015612|Device|Medtronic CoreValve® System|The CoreValve® device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
48337|NCT01015625|Procedure|Surgery|lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
48338|NCT01015625|Procedure|Surgery on Demand|if necessary local therapy on demand
47364|NCT01024465|Device|ReShape Duo Balloon|ReShape Duo Balloon
47365|NCT00027807|Biological|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
47366|NCT01024491|Drug|paroxetine|daily dose of paroxetine 15mg for 12 weeks
47367|NCT01024491|Drug|paroxetine|active daily treatment with paroxetine 20 mg
47368|NCT01024491|Drug|placebo|active daily treatment with placebo
47369|NCT01024504|Drug|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
47370|NCT01024504|Drug|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
47371|NCT01024504|Drug|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
47372|NCT01024517|Drug|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
47373|NCT01024517|Drug|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
48522|NCT01015859|Device|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
48523|NCT01015872|Device|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
48524|NCT01015898|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
48525|NCT01015911|Drug|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
48526|NCT01015924|Procedure|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
47543|NCT01019187|Other|Placebo|Given orally
47544|NCT01019187|Procedure|Fatigue assessment and management|
47545|NCT01021930|Device|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
47546|NCT01021943|Drug|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
47547|NCT01021943|Drug|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
47548|NCT00027586|Drug|Imatinib mesylate (STI571)|400 mg twice a day orally
47549|NCT01021956|Drug|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two DLI.Second stage(dose confirmation)will be only initiated at a dose level which an effect has been seen at week 1 and there is no DLT at week 5.
47550|NCT01021969|Other|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
47551|NCT01021995|Drug|echinacea|drops, 0.9 ml, tid for 4 months
47552|NCT01021995|Drug|placebo|drops, 0.9 ml tid for 4 months
47553|NCT01022008|Device|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
47554|NCT01022021|Drug|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
47555|NCT01022021|Drug|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
47556|NCT01022034|Procedure|sacral rectopexy with sutures or meshes|
47557|NCT01022034|Procedure|full rectal mobilization from the sacrum without sacral rectopexy|
48041|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
48042|NCT01015131|Radiation|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
48405|NCT01023542|Drug|BU-Everolimus|Immunosuppression
48406|NCT01023555|Other|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
48407|NCT01023568|Device|Macintosh blade|Intubation with Macintosh blade laryngoscope
48408|NCT01023568|Device|Glidescope|Intubation with Glidescope laryngoscope.
48409|NCT01023568|Device|Truview PCD|Intubation with Truview PCD laryngoscope.
48410|NCT01023581|Drug|Alogliptin|Alogliptin tablets.
48411|NCT01023581|Drug|Metformin|Metformin capsules
48412|NCT01023581|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets.
48413|NCT00027703|Other|placebo|Given IV
48414|NCT01023581|Drug|Metformin Placebo|Metformin placebo-matching capsules.
48415|NCT01023594|Procedure|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
48416|NCT01023607|Drug|Atorvastatin|Atorvastatin 20mg/day
48417|NCT01023607|Drug|Atorvastatin|Atorvastatin, 60mg/day
48418|NCT01023607|Drug|Rosuvastatin|Rosuvastatin,10mg/day
48419|NCT01023620|Drug|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
48420|NCT01023620|Other|Observation|Participants will be observed for 16 weeks but will not receive drug
48421|NCT01023633|Drug|Oxaliplatin, LV, 5-FU|Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.
FOLFOX4 regimen:
OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W
48422|NCT01023646|Other|Carbohydrate + Protein|Light Tuna Packed in water.
47618|NCT01019187|Procedure|Fatifue assessment and management|
47619|NCT01019213|Other|Septal pacing|Septal lead activated
47620|NCT01019213|Other|His lead activated|His lead will be activated 80 ms before septal lead
47621|NCT01019239|Procedure|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
47877|NCT01017549|Radiation|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
47878|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
47879|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
47880|NCT01017575|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
47881|NCT01017575|Drug|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
47882|NCT00027144|Biological|Heat Shock Protein 70 HSP70|
47883|NCT01017575|Drug|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
47884|NCT01017588|Device|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
47885|NCT01017601|Biological|Seneca Valley virus-001|Given IV
47886|NCT01017601|Other|placebo|Given IV
47887|NCT01017614|Drug|Monofer|administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained
administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained
47888|NCT01017614|Drug|Iron Sulphate|200 mg daily
47889|NCT00027521|Biological|bleomycin sulfate|
47890|NCT01019707|Drug|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
47891|NCT01019733|Procedure|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
47892|NCT01019746|Drug|propofol|propofol administration
47374|NCT01024530|Biological|immune killer cells (IKC)|autologous immune killer cells
47375|NCT01024543|Drug|Angiotensin II|Angiotensin II
47376|NCT00027807|Biological|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
47377|NCT01024543|Drug|Phenylephrine|Phenylephrine
47378|NCT01024543|Drug|Placebo|
47379|NCT01024569|Behavioral|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
47380|NCT01024582|Procedure|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
47381|NCT01024582|Procedure|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
47382|NCT01024582|Radiation|accelerated partial breast irradiation|
47383|NCT01024582|Radiation|image-guided radiation therapy|
47384|NCT01024608|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
47385|NCT01024608|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
47386|NCT01024621|Device|Endomicroscope|Pentax EC3870K, Tokyo, Japan
47675|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
47676|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
47677|NCT01017068|Drug|OME|(4g/100ml) dose: п gutt tid x 1/52
47678|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
47679|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
47680|NCT01017081|Other|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
47681|NCT01017081|Other|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
47682|NCT00027066|Drug|Aspirin placebo|325mg aspirin placebo pill
47683|NCT01017094|Drug|silversulfadiazine|apply once a day
47558|NCT01022047|Drug|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
47559|NCT00027599|Biological|bevacizumab|
47560|NCT01022047|Drug|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
47561|NCT01022060|Dietary Supplement|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
47562|NCT01022060|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
48155|NCT00026845|Procedure|biopsy|Patients undergo excisional biopsy
48156|NCT01015391|Drug|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
48157|NCT01015404|Drug|Trafermin|Administered to the bone defect during flap operation
48158|NCT01015417|Drug|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
48159|NCT01017978|Procedure|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
48160|NCT01017991|Other|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
48161|NCT01017991|Other|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
48162|NCT01018004|Other|follow-up care|
48163|NCT01018004|Other|questionnaire administration|
48164|NCT01018004|Procedure|quality-of-life assessment|
48165|NCT01018017|Drug|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
48166|NCT01018017|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
48167|NCT01018030|Drug|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
48168|NCT00027300|Drug|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
48169|NCT01018030|Drug|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
48423|NCT01023646|Other|Carbohydrate + Fat|Butter
48424|NCT00027703|Other|laboratory biomarker analysis|Correlative studies
48425|NCT01023646|Other|Fiber|Unrefined Carbohydrate
48426|NCT01023646|Other|Carbohydrate load|Carbohydrate
48427|NCT01023659|Drug|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
47456|NCT01021813|Drug|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
47457|NCT01021813|Drug|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
47458|NCT01021839|Procedure|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
47459|NCT01021852|Drug|MK6096 2.5 mg and placebo|MK6096 2.5 mg or placebo taken before bedtime
47460|NCT01021852|Drug|Comparator: MK6096 5 mg and placebo|MK6096 5 mg or placebo taken before bedtime
47461|NCT00027573|Procedure|peripheral blood stem cell transplantation|
47462|NCT01021852|Drug|Comparator: MK6096 10 mg and placebo|MK6096 10 mg or placebo taken before bedtime
47463|NCT01021852|Drug|Comparator: MK6096 20 mg and placebo|MK6096 20 mg or placebo taken before bedtime
47464|NCT01021865|Drug|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|GLP-1 at a rate of 1.2 pmol/kg/min
Regadenoson as a stress agent 0.4mg IV given during MCE
Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump
47465|NCT01021878|Other|icodextrin|glucose sparing dialysis solution
47466|NCT01021878|Other|Dianeal|glucose based dialysis solution
47467|NCT01021891|Drug|Technosphere®/Insulin|
47468|NCT01021904|Biological|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
47469|NCT01024634|Behavioral|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
47470|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
47471|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
47472|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
47893|NCT01019759|Procedure|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
47894|NCT01019772|Biological|LBVH0101 (Hib vaccine)|
47895|NCT01019772|Biological|Hiberix™ Vaccine|
47896|NCT01019785|Dietary Supplement|Ergocalciferol|100 000 U drops is given once
47897|NCT01019785|Dietary Supplement|Ergocalciferol|500 U drops given once
47898|NCT01019798|Drug|sunitinib, docetaxel, cisplatin|Sunitinib given 10 days within 14 days of each cycle。
Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.
Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.
Overall 12 cycles (24 weeks)
48253|NCT01018121|Behavioral|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
48254|NCT01018121|Other|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
48255|NCT01018134|Drug|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
48256|NCT01018134|Drug|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
48257|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
48258|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
48259|NCT01018134|Drug|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
48260|NCT01018134|Drug|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
48261|NCT00027339|Drug|lopinavir/ritonavir|
48262|NCT01018147|Procedure|4-dimensional computed tomography|Undergo 4-D CT imaging
48263|NCT01018160|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
48264|NCT01018173|Drug|placebo|sc weekly
43620|NCT00968357|Drug|SCV-07|SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following "Lead-in Phase". Re-treatment with peg INF and RBV will be offered in the "Follow-up" to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the "end of treatment" visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy.
43621|NCT00022737|Drug|cyclophosphamide|Given IV
43622|NCT00968370|Other|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
43623|NCT00968370|Other|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
43624|NCT00968383|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
43625|NCT00968383|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
43626|NCT00968383|Drug|Statins|Participants will receive statins.
43627|NCT00968383|Drug|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
43628|NCT00968383|Procedure|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
43926|NCT00971386|Behavioral|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
43927|NCT00971399|Drug|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
43928|NCT00971399|Drug|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
43929|NCT00971425|Biological|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
43930|NCT00971425|Biological|Fluarix™|1 dose intramuscular injection
43931|NCT00971425|Biological|Placebo|1 dose intramuscular injection
43932|NCT00023166|Drug|PEG-paclitaxel|
43933|NCT00971438|Procedure|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
43934|NCT00971451|Other|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
44332|NCT00999986|Drug|cyclophosphamide|50 mg oral per day for 7 days
44642|NCT01005368|Genetic|mutation analysis|
44643|NCT01005368|Genetic|nucleic acid sequencing|
44644|NCT01005368|Genetic|polymerase chain reaction|
44645|NCT01005368|Genetic|western blotting|
44646|NCT01005368|Other|flow cytometry|
44647|NCT01005368|Other|laboratory biomarker analysis|
44648|NCT01005381|Dietary Supplement|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
44649|NCT00025636|Biological|filgrastim|
44650|NCT01005381|Dietary Supplement|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
44651|NCT01005381|Dietary Supplement|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
44652|NCT01005381|Dietary Supplement|Calcium Placebo|Placebo tablets identical to the large and small particle size calcium carbonate tablets.
Given twice daily.
44653|NCT01005394|Device|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
44654|NCT01005407|Biological|HEPLISAV|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
44655|NCT01005407|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
44656|NCT01005420|Dietary Supplement|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
44657|NCT01005420|Dietary Supplement|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
44658|NCT01005433|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
44421|NCT01002586|Other|Walking exercise program|walking exercise program
44422|NCT01002599|Device|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
44423|NCT01002599|Device|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
44424|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
44425|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
44426|NCT00025493|Drug|docetaxel|
44427|NCT01002638|Other|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
44428|NCT01002638|Procedure|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
44429|NCT01002651|Dietary Supplement|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
43465|NCT00022880|Drug|Iodine-131 Anti-B1 Antibody|
43466|NCT00970671|Other|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
43467|NCT00970671|Other|No treatment|No laser treatment
43468|NCT00970684|Biological|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
43469|NCT00970684|Drug|docetaxel|75 mg/m2 on day 1
43470|NCT00970684|Drug|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
43471|NCT00970697|Drug|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
43472|NCT00970697|Drug|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
43473|NCT00970710|Behavioral|VACOPP|Information about healthy diet and suitable physical activity during pregnancy of mothers to intervention group children and during childhood from 1 year of age to 5 years of age. Information is given by a health nutritionist,a physiotherapist and maternity clinic and child wellfare clinic nurses.
44169|NCT01004640|Genetic|Southern blotting|
44170|NCT01004640|Genetic|cytogenetic analysis|Correlative studies
44171|NCT01004640|Genetic|polymerase chain reaction|
44172|NCT01004653|Biological|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
44173|NCT01004692|Device|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
44174|NCT01004705|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
44175|NCT01004705|Drug|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
44176|NCT01004718|Radiation|Fludeoxyglucose F18|Undergo FDG PET/CT scans
44177|NCT01004718|Procedure|Computed Tomography|Undergo FDG PET/CT scans
44178|NCT01004718|Procedure|Positron emission tomography|Undergo FDG PET/CT scans
44179|NCT00025597|Drug|vincristine sulfate|
44180|NCT01004731|Drug|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
44181|NCT01004744|Drug|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
44182|NCT01004757|Other|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
44183|NCT01004757|Other|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
44184|NCT01004770|Drug|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
44491|NCT00997893|Drug|medroxyprogesterone acetate|At week 12 , after the participant completes her final assessments, women will begin taking MPA (10 mg/d for 10 days).
43935|NCT00973531|Device|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
43936|NCT00973544|Other|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
43937|NCT00973570|Behavioral|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
43938|NCT00973583|Dietary Supplement|vitamin D|vitamin D3 400 IU daily
43939|NCT00023374|Drug|Rifampin|6mos REZ intermittent
43940|NCT00973583|Dietary Supplement|placebo|placebo
43941|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.
Following induction treatment regimen (for maintenance treatment): No maintenance treatment.
43942|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.
Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab.
43943|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.
Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy.
44248|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
44249|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
44250|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
44251|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
44252|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
44253|NCT00025480|Drug|paclitaxel|
44254|NCT01002404|Procedure|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
44255|NCT01002417|Drug|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
44659|NCT01005433|Drug|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
44660|NCT00025636|Drug|carmustine|
43684|NCT00975572|Biological|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
43685|NCT00975572|Biological|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
43686|NCT00975585|Device|senofilcon A|soft contact lens, 2-week replacement indicated
43687|NCT00975585|Device|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
43688|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
43689|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
43690|NCT00975611|Drug|Placebo|tablets BID, for 4 weeks
43691|NCT00975637|Drug|AMG 827|70 mg SC
43692|NCT00975637|Drug|AMG 827|210 mg SC
43693|NCT00023634|Biological|GMCSF|arm 1: 100 mcg w/EGFRvIII
43694|NCT00975637|Drug|AMG 827|140 mg SC
43695|NCT00975637|Drug|AMG 827|280 mg SC
43696|NCT00975637|Drug|Placebo|Placebo SC
43697|NCT00975650|Drug|Nasobol® (Intra-nasal Testosterone)|BID administration
43698|NCT00975650|Drug|Androderm® (Positive Control)|QD administration
43699|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
43700|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
43701|NCT00975676|Other|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
43474|NCT00970723|Behavioral|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
43475|NCT00970723|Behavioral|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
43476|NCT00022893|Drug|Iodine-131 Anti-B1 Antibody|
43477|NCT00970723|Behavioral|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
43478|NCT00972855|Drug|Bicalutamide|50 mg Tablet
43479|NCT00023296|Drug|Nitric Oxide|
43480|NCT00972855|Drug|Casodex®|50 mg Tablet
43481|NCT00972868|Device|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
43482|NCT00972881|Biological|cetuximab|
43483|NCT00972881|Drug|capecitabine|
43780|NCT00975793|Other|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
43781|NCT00975806|Drug|Lenalidomide (CC-5013) in combination with sunitinib|Lenalidomide MTD mg daily for Days 1- 21 in combination with sunitinib 37.5 mg daily for Days 1-21 of a 21 day cycle until disease progression
43782|NCT00975806|Drug|Lenalidomide|
43783|NCT00975806|Drug|Sunitinib|
43784|NCT00975819|Drug|sirolimus|liquid dosing based on trough levels
43785|NCT00975845|Other|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
43786|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
43787|NCT00975858|Procedure|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
43788|NCT00968565|Drug|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
44492|NCT01000142|Procedure|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
44493|NCT00025402|Drug|hydroxyurea|
44494|NCT01000155|Drug|vorinostat|
44495|NCT01000168|Other|Treadmill therapy and conventional walking therapy.|The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.
The conventional group received traditional walking therapy for the same time period.
44496|NCT01000181|Other|PET-CT with CuATSM|PET-CT with CuATSM
44497|NCT01000194|Dietary Supplement|High fat meal|A high fat milkshake containing 55g of fat
44498|NCT01000207|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
44499|NCT01000220|Drug|Omeprazole|
44500|NCT01000220|Drug|Placebo|
44501|NCT01000233|Dietary Supplement|Phytine (phytate)|300 mg tid * 24 months
44502|NCT01000233|Dietary Supplement|Placebo|Phytine (Phytate)
44503|NCT01000246|Biological|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
44504|NCT00025402|Drug|idarubicin|
44505|NCT01000259|Other|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
44506|NCT01000285|Drug|Bortezomib|
44507|NCT01000285|Drug|Etoposide|
44508|NCT01000285|Drug|Vincristine|
44509|NCT01000285|Drug|Doxorubicin|
44510|NCT01000285|Drug|Prednisone|
44511|NCT01000285|Drug|Cyclophosphamide|
44512|NCT01000285|Drug|Raltegravir|
44513|NCT01000298|Drug|Placebo|liquid placebo medication given twice per day for 7 days
44256|NCT01002417|Drug|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
44257|NCT01002417|Drug|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
44258|NCT01002430|Biological|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
44259|NCT01004783|Genetic|gene expression analysis|
44260|NCT01004783|Genetic|loss of heterozygosity analysis|
44261|NCT01004783|Genetic|microarray analysis|
44262|NCT00025597|Procedure|conventional surgery|
44263|NCT01004783|Genetic|mutation analysis|
44264|NCT01004783|Genetic|polymerase chain reaction|
44265|NCT01004783|Genetic|reverse transcriptase-polymerase chain reaction|
44266|NCT01004783|Other|laboratory biomarker analysis|
44267|NCT01004796|Genetic|cytogenetic analysis|
44268|NCT01004796|Genetic|microarray analysis|
44269|NCT01004796|Genetic|mutation analysis|
44270|NCT01004796|Other|immunohistochemistry staining method|
44271|NCT01004796|Other|immunologic technique|
44581|NCT00997958|Drug|Mycophenolate mofetil|Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.
Each patient will be treated for eight weeks (56 days).
44582|NCT00997971|Other|Modilac Rose 1|Infant formula used for non-breastfed children
44583|NCT00997984|Drug|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
44584|NCT00997984|Drug|placebo|dosed in the AM or PM
44585|NCT00997984|Drug|extended-release guanfacine hydrochloride|Dosed in the PM
44586|NCT00997997|Drug|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
45583|NCT00997035|Drug|Placebo|1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.
45584|NCT00997048|Procedure|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
45922|NCT00988390|Behavioral|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
45923|NCT00988403|Dietary Supplement|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
45924|NCT00024544|Drug|anti-IL-4 monoclonal antibody (pascolizumab)|
45925|NCT00988403|Dietary Supplement|Fructan - 10|Subjects will consume 10 grams of fructan
45926|NCT00988403|Dietary Supplement|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
45927|NCT00988403|Dietary Supplement|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
45928|NCT00988416|Procedure|PET-CT|Pancreas Protocol PET-CT
45929|NCT00988429|Drug|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
45930|NCT00988429|Drug|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
45931|NCT00988429|Drug|Placebo|Placebo tablet given QD
45932|NCT00988442|Behavioral|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses may schedule more frequent calls at their discretion. Calls will provide information, motivational enhancement, problem-solving skills, and affective support.
45933|NCT00988442|Behavioral|Standard care|Care as usual for participants starting a new ART regimen; this may vary by study site.
45934|NCT00988455|Radiation|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
45935|NCT00024557|Drug|IL13-PE38QQR|
45936|NCT00988468|Procedure|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
45937|NCT00988468|Behavioral|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
45938|NCT00988468|Behavioral|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
43789|NCT00968578|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
43790|NCT00968578|Drug|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
43791|NCT00968591|Drug|Everolimus|
43792|NCT00968604|Genetic|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
43793|NCT00968617|Drug|MK2578|MK2578 1.0 mcg/kg/month
43794|NCT00968617|Drug|MK2578|MK2578 2.0 mcg/kg/month
43795|NCT00968617|Drug|MK2578|MK2578 3.6 mcg/kg/month
43796|NCT00968617|Drug|Comparator: darbepoetin alfa|darbepoetin alfa
43797|NCT00022737|Drug|dexamethasone|Given orally
43798|NCT00968630|Other|Laboratory Biomarker Analysis|Correlative studies
43799|NCT00968630|Procedure|Leukapheresis|Undergo leukapheresis
43800|NCT00968643|Radiation|radiation therapy|Given in multiple fractions or as a single fraction
43801|NCT00968656|Radiation|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
43802|NCT00968656|Other|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
44100|NCT00971685|Drug|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
44101|NCT00971711|Biological|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
44102|NCT00971724|Drug|Placebo|Oral administration, once daily, for 15 days
44103|NCT00971724|Drug|Prednisolone|Oral administration
44104|NCT00971737|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
44105|NCT00971737|Biological|trastuzumab|Given IV
44106|NCT00971737|Drug|cyclophosphamide|Given IV
44107|NCT00023218|Drug|Lopinavir/Ritonavir|
44108|NCT00971763|Biological|rituximab|
44514|NCT01000298|Drug|Amoxicillin|liquid amoxicillin given twice per day for 7 days
44515|NCT00025402|Procedure|allogeneic bone marrow transplantation|
43547|NCT00977600|Drug|Buphenyl|
43548|NCT00977613|Behavioral|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
43549|NCT00977626|Drug|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
43550|NCT00023751|Radiation|radiation therapy|
43551|NCT00970762|Drug|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
43552|NCT00970762|Drug|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
43553|NCT00970762|Drug|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
43554|NCT00970762|Drug|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
43555|NCT00970762|Drug|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
43556|NCT00970762|Drug|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
43557|NCT00970762|Drug|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
43558|NCT00970775|Drug|AZD2423|oral solution, single dose
43559|NCT00970775|Drug|Placebo|oral solution,single dose
43560|NCT00022906|Drug|Iodine-131 Anti-B1 Antibody|
43561|NCT00970788|Behavioral|Video intervention|Video of goals of care
43562|NCT00970814|Behavioral|BBCET|11 BBCET sessions
43563|NCT00970814|Behavioral|BBCET|11 BBCET Sessions
43564|NCT00970814|Drug|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
43565|NCT00970814|Drug|Sugar Pill|500mg - 2000mg Once per day 16 weeks
43566|NCT00970827|Procedure|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
44587|NCT00998010|Drug|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200cGy daily doses to a total dose of 6000 cGy.
44588|NCT00998023|Device|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
44589|NCT00025350|Drug|gefitinib|
44590|NCT00998023|Device|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
44591|NCT00998036|Drug|Temsirolimus, cisplatin, erlotinib|Cisplatin at 30mg/m2 and temosirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temosirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Cisplatin will be given first over a 30 minute infusion with prehydration and temsirolimus will be given second over a 30 minute infusion during posthydration. Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temosirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temosirolimus infusion.
Dose escalation will follow the standard 3 by 3 design with three set dosing levels.
Dose Level 1: Temosirolimus 15mg, Erlotinib 100mg
Dose Level 2: Temosirolimus 15mg, Erlotinib 150mg
Dose Level 3: Temosirolimus 25mg, Erlotinib 150mg
44592|NCT00998049|Drug|plerixafor|Plerixafor 160mg/kg/dose by IV on days 5-8
44593|NCT01000311|Biological|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
44594|NCT01000311|Biological|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
44595|NCT01000324|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
44596|NCT01000324|Biological|Engerix™-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
44597|NCT01000324|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
44598|NCT01000337|Drug|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
43629|NCT00968396|Procedure|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
43630|NCT00968396|Procedure|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
43631|NCT00968396|Drug|Melphalan|100 mg/m^2 IV over 30 minutes daily on Days -2 and -1
43632|NCT00022737|Drug|cyclosporine|Given IV
45939|NCT00990535|Drug|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
45940|NCT00990561|Drug|Ultravate ointment twice daily + LacHydrin lotion twice daily|Topical corticosteroid
45941|NCT00990561|Drug|Ultravate ointment once daily + LacHydrin lotion twice daily|Topical corticosteroid
45942|NCT00990574|Device|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
44704|NCT01000558|Other|biologic sample preservation procedure|
44705|NCT00025415|Other|pharmacological study|Correlative studies
44706|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
44707|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
44708|NCT01000597|Drug|fluticasone furoate|Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
44709|NCT01000610|Drug|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
44710|NCT01000610|Drug|methotrexate|10-25 mg weekly (oral or parenteral)
44711|NCT01000610|Drug|methylprednisolone|100 mg iv prior to each rituximab infusion
44712|NCT01000623|Drug|venlafaxine|Given orally
44713|NCT01000623|Drug|placebo|Given orally
44714|NCT01000623|Procedure|hypnotherapy|Practice hypnosis
44715|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
44716|NCT00025519|Drug|tacrolimus|
44717|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
44718|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
44719|NCT01003106|Drug|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
44109|NCT00971763|Drug|cyclophosphamide|
44110|NCT00971763|Drug|gemcitabine hydrochloride|
44111|NCT00971763|Drug|prednisolone|
44112|NCT00971763|Drug|vincristine sulfate|
44113|NCT00971776|Device|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
44114|NCT00971789|Radiation|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
44115|NCT00973804|Procedure|Double Cord Blood Transplantation|
44116|NCT00973817|Biological|ELAD plus standard of care treatment|Use of ELAD plus standard of care
44117|NCT00973817|Other|Standard of care|Standard of care in the treatment of AOCH will be administered
44118|NCT00973830|Other|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
44119|NCT00000870|Drug|Zidovudine|
44120|NCT00023387|Drug|Rifapentine|
44121|NCT00973856|Other|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
44122|NCT00973856|Other|Placebo Comparator|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
44430|NCT01002651|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
44431|NCT01002664|Drug|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
44432|NCT01002664|Drug|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
44433|NCT01002677|Behavioral|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
44434|NCT01002677|Behavioral|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
44435|NCT01002690|Drug|Etoricoxib|90 mg/day orally for 10-13 days
43567|NCT00970840|Dietary Supplement|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
43568|NCT00970853|Behavioral|MOM Program home visiting|Mixed professional home visiting program.
43569|NCT00970853|Other|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
43860|NCT00975897|Drug|irinotecan hydrochloride|
43861|NCT00975897|Drug|leucovorin calcium|
43862|NCT00975897|Drug|oxaliplatin|
43863|NCT00975897|Genetic|RNA analysis|
43864|NCT00975897|Genetic|cytogenetic analysis|
43865|NCT00000871|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
43866|NCT00023660|Drug|celecoxib|
43867|NCT00975897|Genetic|fluorescence in situ hybridization|
43868|NCT00975897|Genetic|gene expression analysis|
43869|NCT00975897|Genetic|mutation analysis|
43870|NCT00975897|Genetic|protein expression analysis|
43871|NCT00975897|Other|diagnostic laboratory biomarker analysis|
43872|NCT00975897|Other|immunohistochemistry staining method|
43873|NCT00975897|Other|questionnaire administration|
43874|NCT00975897|Procedure|cognitive assessment|
43875|NCT00975910|Drug|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
43876|NCT00975910|Drug|saline|Saline arm: infused at the same rate as lidocaine
43877|NCT00023660|Drug|cisplatin|
43633|NCT00968409|Radiation|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
43634|NCT00968409|Other|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
43635|NCT00968409|Other|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
43636|NCT00968409|Drug|F18-FFNP|injection of F18-FFNP
43637|NCT00968422|Drug|ABT-384|3 escalating doses will be administered daily for 21 days
43638|NCT00968422|Drug|Matching placebo to ABT-384|Doses will be administered daily for 21 days
43639|NCT00970866|Dietary Supplement|Lipid-based Nutrient Supplements (LNS) group|Pregnant women will receive 20 g of LNS-P&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.
The LNS products (LNS-P&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration.
43640|NCT00970879|Drug|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
43641|NCT00970879|Drug|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
43642|NCT00970892|Drug|Warfarin dose titration|Dosage
43643|NCT00970905|Drug|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
43644|NCT00970905|Drug|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
43645|NCT00970918|Procedure|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
43646|NCT00970918|Biological|Blood sample testing for hs-CRP|one time, blood sample taking
43944|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
44720|NCT01003106|Drug|Ranibizumab 2.0mg (monthly)|
44721|NCT01003106|Drug|Pro re nata (prn) ranibizumab|
44722|NCT01003106|Procedure|Pro re nata (prn) Laser photocoagulation|
44723|NCT01003119|Behavioral|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
44724|NCT01003132|Other|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
44725|NCT01003145|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
44726|NCT01003158|Drug|AZD8931|Tablet Oral bid
44727|NCT00025519|Drug|thalidomide|
43721|NCT00970996|Drug|Cisplatin|20 mg/m^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
43722|NCT00970996|Biological|Interleukin-2|9 MIU/m^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
43723|NCT00970996|Biological|Interferon alpha 2b|5 MIU/m^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
43724|NCT00971009|Behavioral|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
43725|NCT00971009|Behavioral|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
43726|NCT00971022|Behavioral|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
43727|NCT00971022|Behavioral|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
43728|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
43729|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
43730|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
43731|NCT00000869|Drug|Nevirapine|
43732|NCT00022958|Drug|Iodine-131 Anti-B1 Antibody|
43733|NCT00971035|Drug|placebo|Subcutaneous repeating dose
44436|NCT01002703|Drug|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
44437|NCT00025506|Other|Laboratory Biomarker Analysis|Correlative studies
44438|NCT01002716|Biological|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
44439|NCT01002729|Other|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI < 30 given Oseltamivir
44440|NCT01002729|Other|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI > 40 given Oseltamivir
44441|NCT01002742|Drug|Mycophenolate Mofetil|Oral dosing should be delivered in 250 mg units. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.
Patients who weight > 60 kg should receive MMF 1 gm PO/IV every 8 hours.
Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.
Patients who weight <40 kg should receive 20 mg/kg IV or PO every 8 hours.
44442|NCT01002742|Drug|Placebo|Oral dosing should be delivered in 250 mg units blinded placebo. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.
Patients who weight > 60 kg should receive placebo 1 gm PO/IV every 8 hours.
Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.
Patients who weight <40 kg should receive 20 mg/kg IV or PO every 8 hours.
44443|NCT01002755|Drug|Lenalidomide|10 mg daily, started on day 9 (day after second infusion of ofatumumab) and continued daily through 24 cycles (cycle = 28 day)
44444|NCT01004978|Other|Pharmacological Study|Correlative studies
44445|NCT01004978|Other|Placebo|Given PO
44446|NCT01004978|Drug|Sorafenib Tosylate|Given PO
44447|NCT01004991|Biological|rituximab|375 mg/m2 on Day 8 of each of 6 cycles
44448|NCT01004991|Drug|cyclophosphamide|750 mg/m2 on Day 8 of each of 6 cycles
44449|NCT01004991|Drug|vincristine|1.4 mg/m2 on Day 8 of each of 6 cycles
44450|NCT00000885|Drug|Nelfinavir mesylate|
43484|NCT00972881|Drug|irinotecan hydrochloride|
43485|NCT00972881|Procedure|neoadjuvant therapy|
43486|NCT00972881|Procedure|therapeutic conventional surgery|
43487|NCT00972881|Radiation|radiation therapy|
43488|NCT00972907|Drug|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
43878|NCT00975923|Behavioral|Collaborative Group|In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these "virtual" learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams.
43879|NCT00975923|Behavioral|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
43880|NCT00975936|Drug|Ketoconazole|200 mg Ketoconazole (Q12)
43881|NCT00975936|Drug|[14C]-GSK706769|50µg [14C]-GSK706769 containing 250 nCi
44185|NCT01004770|Drug|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
44186|NCT01004783|Genetic|DNA methylation analysis|
44187|NCT00997152|Drug|JTT-654|Tablets
44188|NCT00025324|Drug|thiotepa|
44189|NCT00997152|Drug|JTT-654 Placebo|Tablets
44190|NCT00997178|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
44191|NCT00997178|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
44192|NCT00997191|Procedure|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
44193|NCT00997191|Drug|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
44194|NCT00997191|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
44195|NCT00997204|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
44196|NCT00997217|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
43945|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
43946|NCT00973622|Device|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
43947|NCT00973635|Other|Web-based education|Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required "core articles" pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs.
43948|NCT00973661|Behavioral|Electronic tool set for counseling overweight patients|Physicians randomized to the "electronic tools" arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the "usual care" arm will not receive access to these tools, and will continue to provide their usual care for overweight patients.
43949|NCT00973674|Drug|Premarin IV|One time dose of Premarin IV
43950|NCT00023374|Drug|Pyrazinamide|6mos REZ intermittent
43951|NCT00973674|Drug|Placebo|One time dose of Placebo
43952|NCT00975962|Drug|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
43953|NCT00975962|Procedure|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
43954|NCT00975975|Drug|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
43955|NCT00975988|Drug|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
43956|NCT00976001|Other|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
43957|NCT00023660|Drug|fluorouracil|
43958|NCT00976001|Other|As the general practitioner wants to do|
43959|NCT00976027|Biological|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
43960|NCT00976027|Biological|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
43734|NCT00971048|Device|HP828-101|Topical test article applied once daily
43735|NCT00971048|Device|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
43736|NCT00971061|Device|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
43737|NCT00971061|Device|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
43738|NCT00971074|Drug|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
43739|NCT00971074|Other|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
43740|NCT00971087|Device|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are enrolled from either a screening population or a biopsy population. Both groups are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects recruited in the biopsy population will be imaged on the investigational device prior to their biopsy procedure.
44043|NCT00973791|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
44044|NCT00973791|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
44045|NCT00973804|Drug|EPOCH-F/R|
44046|NCT00973804|Drug|FLAG|
44047|NCT00973804|Drug|Transplant Preparative Regimen (Flu/Cy/Mes)|
44048|NCT00973804|Drug|GVHD Prophylaxis (tacrolimus and sirolimus)|
44049|NCT00976092|Drug|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
44050|NCT00976092|Drug|Heparin|i.v. bolus of 70-100 IU/kg body weight
44051|NCT00976105|Drug|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
44052|NCT00976105|Drug|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
44053|NCT00976118|Drug|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
44054|NCT00976118|Drug|placebo|matching placebo to masitinib
43489|NCT00972920|Procedure|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
43490|NCT00023296|Device|INO Pulse - NO Delivery System|
43491|NCT00972933|Drug|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
43492|NCT00972946|Biological|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
43493|NCT00972946|Drug|Administration of Endorem|single dose, intravenous
43494|NCT00972959|Drug|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
43495|NCT00972959|Drug|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
43496|NCT00972959|Drug|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
43497|NCT00972972|Dietary Supplement|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
43498|NCT00972972|Dietary Supplement|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
43499|NCT00972985|Drug|modafinil|oral tablet, 100 mg, single acute dose
43500|NCT00972985|Drug|methylphenidate|oral tablet, 20 mg, single acute dose
43501|NCT00023309|Drug|Lamivudine and adefovir|Lamivudine (100 mg/day) and adefovir (10 mg/day)
43502|NCT00972985|Drug|lorazepam|oral tablet, 1 mg, single, acute dose
43503|NCT00972985|Drug|placebo|oral tablet, single acute dose
43504|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
43505|NCT00023595|Procedure|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
43506|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
43803|NCT00968656|Other|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
44197|NCT00997243|Biological|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
44198|NCT00997243|Drug|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
44199|NCT00025324|Procedure|autologous bone marrow transplantation|
44200|NCT00997256|Drug|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
44201|NCT00997256|Drug|film-coated sugar-pill|3 x 2 tablets / day over 3 days
44202|NCT00997269|Dietary Supplement|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
44203|NCT00997269|Dietary Supplement|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
44204|NCT00997282|Drug|OPC-262 2.5 mg|orally administered once daily for 24 weeks
44205|NCT00997282|Drug|OPC-262 5 mg|orally administered once daily for 24 weeks
44516|NCT01000298|Drug|Cefdinir|liquid cefdinir given twice per day for 7 days
44517|NCT01000311|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
44518|NCT01000311|Biological|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
44519|NCT01000311|Biological|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
44520|NCT01002755|Drug|Ofatumumab|4 weekly IV infusions of 300 mg week 1, 1,000 mg week 2, 3 and 4, then monthly during months 2-6 and once every two months during months 7-24 (even months: 8,10,12 etc.).
44521|NCT01002768|Drug|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
44522|NCT01002768|Drug|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
44523|NCT01002781|Drug|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
44524|NCT00025506|Drug|Thalidomide|Given orally
44272|NCT01004796|Other|mass spectrometry|
44273|NCT00025610|Drug|carboplatin|
44274|NCT01004809|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
44275|NCT01004822|Drug|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44276|NCT01004822|Drug|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44277|NCT01004822|Drug|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44278|NCT01004822|Drug|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44279|NCT01004822|Drug|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44280|NCT01004822|Drug|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44281|NCT01004822|Drug|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44282|NCT01004822|Drug|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
44283|NCT01004848|Behavioral|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
44284|NCT00025610|Drug|cyclophosphamide|
44285|NCT00997334|Drug|erlotinib|Taken orally once daily
44286|NCT00997347|Drug|Mifepristone and misoprostol|200 mg oral mifepristone
800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone
44287|NCT00997360|Drug|PKI-179|
44288|NCT00997373|Drug|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
44055|NCT00976131|Drug|Coenzyme Q10|Dose Level 1:
300mg/d (2 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d placebo (2 capsules)taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 2:
600mg/d (4 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d placebo (4 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 3:
1200mg/d (8 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d placebo (8 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.
44056|NCT00976131|Other|Coenzyme Q10 Placebo|Dose Level 1:
300mg/d placebo (2 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d (2 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 2:
600mg/d placebo (4 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d (4 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 3:
1200mg/d placebo (8 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d (8 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.
44057|NCT00023660|Radiation|radiation therapy|
44058|NCT00976144|Drug|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
44059|NCT00976157|Procedure|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
44373|NCT01004952|Behavioral|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
44374|NCT01004965|Other|laboratory biomarker analysis|
44375|NCT01004978|Drug|Cisplatin|Undergo TACE
44376|NCT00025610|Drug|etoposide|
44377|NCT01004978|Drug|Doxorubicin Hydrochloride|Undergo TACE
44378|NCT01004978|Drug|Doxorubicin-Eluting Beads|Undergo TACE
44379|NCT01004978|Other|Laboratory Biomarker Analysis|Correlative studies
44380|NCT01004978|Drug|Mitomycin|Undergo TACE
43804|NCT00968656|Other|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
43805|NCT00968656|Drug|F-18-ISO|Patients receive F-18-ISO-1 i.v.
43806|NCT00968669|Biological|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
43807|NCT00968669|Biological|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
43808|NCT00000868|Biological|Aluminum hydroxide|
43809|NCT00022737|Drug|etoposide|Given IV
43810|NCT00968669|Biological|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
43811|NCT00968669|Other|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
43812|NCT00968682|Biological|trastuzumab|
43813|NCT00968682|Other|laboratory biomarker analysis|
43814|NCT00968682|Procedure|assessment of therapy complications|
43815|NCT00968695|Drug|Albumin|The pattern of administration of 20% human albumin is 1'5g/kg every week to infuse in 6 hours with a minimum of 90 g up to 150 g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
43816|NCT00971113|Dietary Supplement|sc-FOS and Sideritis euboea extract|dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days
placebo food: jelly with no sc-FOS and Sideritis euboea
43817|NCT00022971|Biological|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
43818|NCT00971126|Drug|sorafenib (Nexavar®), thalidomide (Thado®)|Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).
Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study.
43819|NCT00971139|Behavioral|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
43820|NCT00971152|Drug|menotropins for injection|comparison of different dosages
43821|NCT00971152|Drug|urofollitropin for injection|comparison of different dosages
43822|NCT00971165|Drug|losartan|Oral losartan up to 100 mg daily fo 18 months
44525|NCT01002794|Procedure|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital.
44526|NCT01002794|Other|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training.
44527|NCT01002807|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
44528|NCT01002807|Drug|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
44529|NCT01002807|Drug|Glucophage|Tablets, Oral, 1000 mg, Single Dose
44530|NCT01002820|Drug|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
44531|NCT01002833|Biological|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
44532|NCT01002846|Procedure|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
44533|NCT01002859|Drug|Sandimmum|Intravenous injection of cyclosporine
44534|NCT01002859|Drug|Placebo|Intravenous Injection of NaCl solution
44535|NCT00025519|Biological|therapeutic allogeneic lymphocytes|
43570|NCT00970866|Dietary Supplement|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
43571|NCT00022932|Drug|Iodine-131 Anti-B1 Antibody|
43572|NCT00970866|Dietary Supplement|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
43573|NCT00972998|Drug|Phenyephrine|Phenyephrine coated suppositories
43574|NCT00973011|Drug|FCFD4514S|Intravitreal escalating dose
43575|NCT00973024|Drug|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
43576|NCT00973024|Drug|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
44289|NCT00997386|Drug|busulfan, and melphalan, and alemtuzumab|intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).
intravenous melphalan 100 mg/m2 on day -3.
intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.
44290|NCT00997399|Drug|panobinostat (LBH589)|
44599|NCT00025402|Procedure|peripheral blood stem cell transplantation|
44600|NCT01000337|Drug|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
44601|NCT01000350|Drug|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
44602|NCT01000350|Other|Placebo|Placebo x1 lactose tablet
44603|NCT01000376|Drug|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m^2 alone on Day 1, then eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
44604|NCT01000376|Drug|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
44605|NCT01000389|Device|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
44606|NCT01000402|Drug|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
44607|NCT01000415|Other|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
44608|NCT01000441|Drug|infliximab, etanercept, adalimumab|
44609|NCT01000441|Drug|abatacept, rituximab or tocilizumab|
44610|NCT00025402|Radiation|radiation therapy|
44611|NCT01000467|Drug|probucol|group 3: 250 mg 1 tablet in the morning and evening
44612|NCT01000467|Drug|probucol|group 1: 250 mg
44613|NCT01000467|Drug|probucol|group 2: 250 mg 2 tablets at once in the morning
44614|NCT01000480|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
44381|NCT00997529|Drug|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 & 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 & 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction & immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression & do not have signs of GVHD, will receive a DLI
44382|NCT00997542|Drug|Allopurinol|
44383|NCT00997542|Drug|Placebo|
44384|NCT00997555|Procedure|bronchoscopy|Scheduled bronchoscopy.
44385|NCT00997568|Device|PET-511BTM|Transesophageal Transducer
44386|NCT00997581|Drug|apremilast|apremilast 20 mg taken twice daily by mouth
44387|NCT00997581|Drug|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
44388|NCT00997594|Procedure|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
44389|NCT00025324|Radiation|radiation therapy|
44390|NCT00997607|Biological|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
44391|NCT00997607|Biological|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
44392|NCT00997607|Other|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
44728|NCT01003158|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off
44729|NCT01003171|Drug|MCS-2 soft-gel capsule|MCS-2 30 mg/day
44730|NCT01003184|Drug|exenatide once weekly|subcutaneous injection, 2mg, once a week
44731|NCT01003184|Drug|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
44732|NCT01003210|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
43823|NCT00971165|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
44123|NCT00973869|Dietary Supplement|curcumin|
44124|NCT00973869|Other|high performance liquid chromatography|
44125|NCT00973869|Other|laboratory biomarker analysis|
44126|NCT00973869|Other|pharmacological study|
44127|NCT00973869|Procedure|diagnostic endoscopic procedure|
44128|NCT00973869|Procedure|therapeutic conventional surgery|
44129|NCT00973882|Drug|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
44130|NCT00973882|Drug|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
44131|NCT00023387|Drug|25-desacetyl Rifapentine|
44132|NCT00973895|Biological|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
44133|NCT00973908|Drug|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
44134|NCT00973908|Drug|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
44135|NCT00973934|Device|Magstim Theta|
44136|NCT00973934|Device|Thymatron System IV|
44137|NCT00973947|Other|questionnaire administration|
44138|NCT00973947|Radiation|3-dimensional conformal radiation therapy|
44139|NCT00973947|Radiation|radiation therapy treatment planning/simulation|
44140|NCT00973973|Drug|NBI-56418|150 mg immediate release (IR) taken daily, 24 week duration
44141|NCT00973973|Drug|Placebo|Matching placebo tablet taken daily, 8 week duration
44142|NCT00023387|Drug|Isoniazid|
44143|NCT01002105|Drug|Baclofen (as add-on to standard treatment of alcohol dependence)|Baclofen 30 mg per day for 12 weeks
44144|NCT01002118|Drug|Omega-3 Acid Ethyl Esters|1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks
43577|NCT00973024|Drug|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
43578|NCT00973024|Drug|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
43579|NCT00973024|Drug|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
43580|NCT00973037|Drug|Tamoxifen|Tamoxifen 20mg qd
43581|NCT00023309|Drug|Adefovir alone|Adefovir (10 mg/day)
43582|NCT00973050|Drug|Bicalutamide|50 mg Tablet
43583|NCT00973050|Drug|Casodex®|50 mg Tabelt
43584|NCT00973063|Behavioral|Routine sterile gloving|routinely new sterile gloving just before sampling
43585|NCT00973076|Drug|AZD8055|Tablets, orally administered, twice daily
43586|NCT00973089|Other|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
43587|NCT00973102|Drug|Premarin IV|One time dose of Premarin IV
43588|NCT00973102|Drug|Placebo|One time dose of placebo.
43589|NCT00973115|Drug|Simvastatin CR|
43882|NCT00975949|Other|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
43883|NCT00968708|Drug|Alogliptin|Alogliptin tablets
43884|NCT00968708|Drug|Placebo|Alogliptin placebo matching tablets
43885|NCT00968734|Dietary Supplement|colecalciferol|50.000UI single oral dose
43886|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
43887|NCT00022737|Drug|ifosfamide|Given IV
43888|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
44615|NCT01002924|Drug|EC145|EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
44616|NCT01002950|Drug|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
44617|NCT01002950|Drug|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
44618|NCT01002963|Drug|PF-04418948|solution, 30 mg, single
43647|NCT00970931|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
43648|NCT00022945|Drug|Iodine-131 Anti-B1 Antibody|
43649|NCT00970931|Drug|placebo|Oral placebo once a day, for 18 months
43650|NCT00970944|Drug|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
43651|NCT00970944|Drug|Placebo|Placebo administered twice daily.
43652|NCT00970957|Drug|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
43653|NCT00970957|Drug|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
43654|NCT00970970|Other|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
43655|NCT00970983|Procedure|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
43656|NCT00970983|Procedure|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
43657|NCT00970996|Drug|Temozolomide|250 mg/m^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
43658|NCT00970996|Drug|Abraxane|100 mg/m^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m^2 given on day 5 of each 21-day cycle.
43659|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
43660|NCT00973141|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
44733|NCT01003223|Other|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
44734|NCT01003236|Drug|placebo|140 mg placebo tablets, 3 times per day for 3 months
44735|NCT01003236|Drug|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
44736|NCT01003249|Drug|Baclofen|Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen).
44737|NCT01003249|Drug|Placebo Comparator: Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen).
44738|NCT00025519|Procedure|peripheral blood stem cell transplantation|
44739|NCT01003262|Other|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
44740|NCT01005628|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
44741|NCT01005641|Drug|exemestane|25 mg daily
44742|NCT01005641|Drug|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
44743|NCT01005667|Device|BirthTrack|Measurement of cervical dilation and head station
44744|NCT01005680|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
44745|NCT01005680|Drug|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
44746|NCT01005680|Drug|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
44747|NCT00025636|Drug|cytarabine|
44748|NCT01005693|Other|questionnaire administration|
43741|NCT00971100|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
43742|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
43743|NCT00973245|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
44145|NCT01002118|Drug|Placebo|4 capsules each day for 16 weeks
44146|NCT00000884|Biological|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
44147|NCT00025467|Drug|thalidomide|Given orally
44451|NCT00025610|Drug|vincristine sulfate|
44452|NCT01004991|Drug|doxorubicin|50 mg/m2 on Day 8 of each of 6 cycles
44453|NCT01004991|Drug|prednisone|100 mg PO days 8-12 of each of 6 cycles
44454|NCT01004991|Drug|azacytidine|﻿Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
44455|NCT01005004|Biological|HuCNS-SC cells|intracerebral transplantation
44456|NCT01005017|Procedure|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
44457|NCT01005030|Other|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
44458|NCT01005043|Radiation|heavy ion radiotherapy (C12)|Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:
Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.
44459|NCT01005056|Drug|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
44460|NCT01005069|Drug|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
44461|NCT01005069|Drug|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
44462|NCT00025623|Drug|carboplatin|
44463|NCT01005069|Drug|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
44464|NCT01005069|Drug|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
44465|NCT01005069|Drug|Placebo capsule|Placebo capsules once daily and lifestyle modification
44466|NCT01005082|Behavioral|Low salt diet|
44467|NCT01005082|Behavioral|Water therapy alone|
43889|NCT00968747|Behavioral|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
43890|NCT00968747|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
43891|NCT00968760|Procedure|Leukapheresis|Leukapheresis #1 - For Collecting T Cells
Leukapheresis #2 - For Collecting Stem Cells, month following #1
Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete.
43892|NCT00968760|Procedure|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
43893|NCT00968760|Procedure|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
43894|NCT00968760|Drug|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10^6 U/m^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
43895|NCT00968760|Drug|Carmustine|300 mg/m^2 IV over 1 hour on Day -6
43896|NCT00968760|Drug|Etoposide|200 mg/m^2 IV over 3 hours every 12 hours on Days -5 to -2
43897|NCT00968760|Drug|Cytarabine|200 mg/m^2 by vein over 1 hour every 12 hours on Days -5 to -2.
43898|NCT00022737|Drug|imatinib mesylate|Given orally
43899|NCT00968760|Drug|Melphalan|140 mg/m^2 IV over 30 minutes on Day -1
43900|NCT00968773|Device|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
43901|NCT00968773|Device|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
43902|NCT00968786|Device|Home monitoring|automated measuring devices for patients using at home
43903|NCT00968799|Procedure|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
43904|NCT00968799|Procedure|Cytoreduction|Surgical removal of tumor nodules
including resection of organs infested with tumor
44206|NCT00997282|Drug|Placebo|orally administered once daily for 24 weeks
44207|NCT00997308|Drug|AZD1446|Solution, oral, for 4 weeks
44208|NCT00997308|Drug|Placebo|
44209|NCT00997321|Drug|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
43661|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
43662|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
43663|NCT00973154|Drug|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
43664|NCT00973167|Device|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
43665|NCT00973180|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
43961|NCT00976040|Other|Early antiretroviral therapy|The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.
In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis.
43962|NCT00976053|Procedure|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
43963|NCT00976066|Drug|Part A Assessing GSK1521498|Each participant will receive up to three [11C]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.
Each subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan.
43964|NCT00976066|Drug|Part B Assessing GSK1521498|The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three [11C]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).
Each Part B subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
43965|NCT00976066|Drug|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three [11C]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
43966|NCT00976079|Device|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
43967|NCT00976079|Device|Placebo TENS|Placebo TENS use
43968|NCT00023660|Radiation|brachytherapy|
43969|NCT00976092|Drug|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
43744|NCT00973258|Dietary Supplement|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
43745|NCT00973258|Other|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
43746|NCT00973258|Other|Cognitive Training|The proposed cognitive training intervention program comprises:
Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.
Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.
Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors.
43747|NCT00973258|Other|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
43748|NCT00973258|Other|Placebo|Participants will receive their usual diet and placeboes.
43749|NCT00973271|Drug|290 mg DCCR|290 mg diazoxide choline
43750|NCT00973271|Drug|435 mg DCCR|435 mg diazoxide choline
43751|NCT00973271|Drug|135 mg fenofibric acid|135 mg fenofibric acid
43752|NCT00023348|Drug|Isoniazid|
43753|NCT00973271|Drug|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
43754|NCT00973271|Drug|atorvastatin|20 mg atorvastatin
43755|NCT00973284|Biological|Norwalk VLP vaccine|intranasal, two doses 21 days apart
43756|NCT00973284|Biological|mannitol and sucrose|two doses 21 days apart
43757|NCT00973297|Other|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
44060|NCT00976170|Drug|GC33(RO5137382)|IV administration at 6 escalating dose levels.
44061|NCT00976170|Drug|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
44468|NCT01005095|Dietary Supplement|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
44469|NCT01005095|Dietary Supplement|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
44470|NCT00997737|Device|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
43507|NCT00975338|Other|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
43508|NCT00975338|Other|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
43509|NCT00975351|Dietary Supplement|13C5-labelled 5-methyltetrahydrofolic acid|one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr "intervention".
43510|NCT00975377|Procedure|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
43511|NCT00975390|Dietary Supplement|Carbohydrate|1.2 g/kg/h
43512|NCT00975390|Dietary Supplement|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
43513|NCT00975390|Dietary Supplement|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
43514|NCT00975403|Device|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
43515|NCT00975403|Device|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
43516|NCT00023595|Drug|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
43517|NCT00975416|Behavioral|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
43518|NCT00975416|Drug|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
43519|NCT00975416|Drug|Placebo|Placebo given in the context of cognitive behavioral therapy
44210|NCT00025324|Procedure|bone marrow ablation with stem cell support|
44211|NCT00997321|Drug|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
44212|NCT00999674|Other|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
44213|NCT00025402|Biological|filgrastim|
44214|NCT00999687|Drug|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 12 weeks.
44215|NCT00999687|Other|Olive Oil|Patients were instructed to apply olive oil on one of two bilaterally symmetrical psoriatic finger nails which were different to the INOE side twice daily for first 12 weeks, after that, indigo naturalis oil extract was applied to replace olive oil for another 12 weeks.
44216|NCT00999700|Drug|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
44217|NCT00999700|Radiation|radiotherapy|Conformal radiotherapy or IMRT should be employed.
Standard radiotherapy:
Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.
44218|NCT00999700|Drug|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
44219|NCT00999700|Drug|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
44220|NCT00999700|Radiation|radiotherapy|Conformal radiotherapy or IMRT should be employed.
Standard radiotherapy:
Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.
44221|NCT00999713|Drug|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
44222|NCT00999713|Other|Air placebo|Endotracheal air administration
44223|NCT00999739|Biological|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
44224|NCT00025402|Biological|recombinant interferon alfa|
44225|NCT00999752|Drug|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure <140/90
44226|NCT00999752|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
43970|NCT00976092|Drug|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
43971|NCT00022737|Drug|leucovorin calcium|Given IV or orally
43972|NCT00968825|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
43973|NCT00968825|Drug|Placebo|Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
43974|NCT00968838|Procedure|White Blood Cell Transfusion|4 Transfusions, each taking approximately 1 hour:
Patients <50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.
Patients >50 years of age are randomized to receive either radiated or non radiated transfusions.
43975|NCT00968851|Drug|EVP-6124|Arms: 1
43976|NCT00968851|Drug|Placebo|Arm: 3
43977|NCT00968851|Drug|EVP-6124|Arms: 2
44291|NCT00997412|Drug|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
44292|NCT00997412|Drug|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
44293|NCT00997425|Device|Door cover/Floor cover|Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.
Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2" white duct tape placed at 2" intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door.
44294|NCT00000882|Drug|Delavirdine mesylate|
44295|NCT00025324|Procedure|conventional surgery|
44296|NCT00997438|Dietary Supplement|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
44297|NCT00997451|Behavioral|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
44298|NCT00997451|Behavioral|Symptom monitoring|Daily symptom via web diary
44299|NCT00997477|Drug|Foradil Combi (Formoterol-budesonide)|
44300|NCT00997490|Drug|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
44301|NCT00997490|Drug|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
44062|NCT00976183|Drug|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
44063|NCT00976183|Drug|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
44064|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
44065|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
44066|NCT00976222|Drug|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
44067|NCT00968994|Device|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
44068|NCT00968994|Device|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
44069|NCT00969007|Behavioral|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
44070|NCT00969020|Procedure|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
44071|NCT00969033|Drug|CS-1008|CS-1008
44072|NCT00969033|Drug|irinotecan|irinotecan
44073|NCT00969046|Drug|EPO906 (patupilone)|
44074|NCT00022737|Drug|pegaspargase|Given IM
44075|NCT00969059|Drug|GW856553|GW856553 7.5mg bid
44076|NCT00969059|Drug|PLACEBO|Placebo to match GW856553
44077|NCT00969072|Drug|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
44078|NCT00969072|Drug|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
43520|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
43521|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
43522|NCT00975442|Other|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
43523|NCT00975442|Device|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
43824|NCT00971178|Drug|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
43825|NCT00971178|Drug|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
43826|NCT00971178|Drug|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
43827|NCT00971191|Drug|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
43828|NCT00022971|Biological|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks Page 8 of 14
43829|NCT00971217|Other|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
43830|NCT00971217|Behavioral|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
43831|NCT00971230|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
43832|NCT00971230|Drug|Placebo|Placebo
43833|NCT00971243|Drug|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
43834|NCT00971243|Drug|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
44536|NCT01002872|Drug|Lanthanum Carbonate|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill TID Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus <3.5mg/dL Reduce to 1 pill BID. If Phosphorus >5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is <3.5mg/dL Reduce to 1 pill daily. If phosphorus >5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus <3.5mg/dL stop the drug If phosphorus is >5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
44537|NCT01002872|Drug|Fosrenol|Initial dose of drug will be 1500mg TID
44538|NCT01002872|Drug|placebo|Initial dose of placebo will be 1 pill three times a day
44539|NCT01002898|Drug|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
44540|NCT01002911|Drug|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
44541|NCT01002911|Drug|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
44542|NCT01005108|Drug|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
44543|NCT01005121|Drug|colchicine|2mg, per-os, once daily for six months
44544|NCT01005147|Drug|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
44545|NCT00025623|Drug|cyclophosphamide|
44546|NCT01005147|Other|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
44547|NCT01005160|Drug|Metformin|CKD-501 0.5mg, metformin 1000mg
44548|NCT01005160|Drug|CKD-501|CKD-501 0.5mg, metformin 1000mg
44549|NCT01005186|Behavioral|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
44550|NCT01005199|Drug|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
44551|NCT01005199|Drug|sorafenib tosylate|Sorafenib 2 x 400 mg daily
44552|NCT01005212|Drug|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
44553|NCT01005238|Drug|Lamivudine|
44554|NCT01005238|Drug|Telbivudine|
44302|NCT00997503|Device|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
44303|NCT00997503|Drug|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
44304|NCT00997503|Drug|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
44305|NCT00997503|Drug|aspirin|Oral, as prescribed by physician through end of study.
44306|NCT00025324|Procedure|peripheral blood stem cell transplantation|
44307|NCT00997516|Procedure|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
44308|NCT00997516|Procedure|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
44309|NCT00999817|Drug|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
44310|NCT00999830|Drug|IPH2101|One infusion of IPH2101 every 4 weeks
44311|NCT00999843|Drug|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
44619|NCT00000884|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
44620|NCT00025519|Drug|fludarabine phosphate|
44621|NCT01002963|Drug|PF-04418948|solution, 100 mg, single
44622|NCT01002963|Drug|PF-04418948|solution, 300 mg, single
44623|NCT01002963|Drug|PF-04418948|solution, 1000 mg, single
44624|NCT01002963|Drug|PF-04418948|solution, 3000 mg, single
44625|NCT01002963|Drug|PF-04418948|solution, 4500 mg, single
44626|NCT01002963|Drug|PF-04418948|solution, 6000 mg, single
44627|NCT01002989|Device|Doppler Ankle-Brachial Index measurement|Measurement of the Ankle-Brachial Index by Doppler.
44628|NCT01002989|Device|WatchBP Office Ankle-Brachial Index measurement.|Measurement of Ankle-Brachial Index by WatchBP Office device.
44393|NCT00997620|Drug|Fluticasone furoate Nasal Spray|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo
44394|NCT00997620|Drug|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo
44395|NCT00997659|Dietary Supplement|chromium picolinate|1000 mg per day
44396|NCT00997672|Drug|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
44397|NCT00997672|Drug|Placebo|
44398|NCT00997685|Drug|Capecitabine plus oxaliplatin|Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,
4 pre-operative cycles, 4 post-operative cycles
44399|NCT00997711|Device|Cypher|Sirolimus-eluting stents
44400|NCT00025337|Biological|bevacizumab|Given IV
44401|NCT00997724|Procedure|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
44402|NCT00999999|Procedure|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
44403|NCT01000012|Device|Becker 50 Expander/Breast implant|The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc.
44404|NCT01000012|Device|Becker 25 Expander/Breast implant|The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc.
44405|NCT01000025|Drug|PF-00299804|PF-804 45 mg PO, daily
44406|NCT01000025|Drug|Placebo|Placebo 45 mg PO, daily
44407|NCT01000038|Other|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
43835|NCT00971243|Drug|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
43836|NCT00971243|Drug|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
43837|NCT00971243|Drug|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
43838|NCT00023348|Drug|Rifabutin|
43839|NCT00973336|Drug|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
43840|NCT00973349|Biological|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
43841|NCT00973362|Device|APTIMA HPV Assay|The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer ("high-risk types"). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44).
43842|NCT00973388|Drug|Telaprevir; Moxifloxacin; Placebo|
44148|NCT01002131|Device|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
44149|NCT01002144|Other|blood sampling|
44150|NCT01002157|Dietary Supplement|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
44151|NCT01002157|Other|Placebo capsules|Capsules containing no Menaquinone-7
44152|NCT01002183|Drug|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
44153|NCT01002196|Behavioral|Stimulus fading procedures|Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety ("stimulus fading" and reward).
2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.
3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.
4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).
5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM
44154|NCT01002196|Behavioral|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
44155|NCT01002209|Procedure|Hyperbaric Oxygen treatment (HBO)|HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).
HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital.
44555|NCT01005251|Drug|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
44556|NCT00025623|Drug|doxorubicin hydrochloride|
43590|NCT00973128|Drug|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
43591|NCT00973128|Drug|Meglumine antimoniate|20mg/daily for 20 days
43592|NCT00000870|Drug|Stavudine|
43593|NCT00023322|Drug|Peginterferon Alpha-2a|Treatment
43594|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
43595|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
43596|NCT00975442|Device|Forearm band|All patients were instructed to use a forearm band during all daily activities.
43597|NCT00975468|Other|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
43598|NCT00975481|Drug|dimebon|Oral tablet; 20 mg dimebon, single dose
43599|NCT00023595|Procedure|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
43600|NCT00975481|Drug|dimebon|Oral tablet; 40 mg dimebon, single dose
43601|NCT00975481|Drug|dimebon|Oral tablet; 60 mg dimebon, single dose
43602|NCT00975481|Drug|placebo|Oral tablet or capsule; placebo, single dose
43603|NCT00975481|Drug|alprazolam|Oral capsule; 1 mg alprazolam, single dose
43604|NCT00975481|Drug|alprazolam|Oral capsule; 3 mg alprazolam, single dose
43605|NCT00975494|Drug|Sildenafil|
43606|NCT00975494|Drug|Placebo|
43607|NCT00975507|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
44629|NCT01003002|Drug|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
44630|NCT01003015|Drug|BAY73-4506|160 mg BAY73-4506
44631|NCT00025519|Drug|mycophenolate mofetil|
44632|NCT01003028|Drug|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
44633|NCT01003028|Drug|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
44634|NCT01003054|Drug|Busulfan|130 mg/m^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
44635|NCT01003054|Drug|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
44636|NCT01003054|Drug|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is >1500/mcl and platelets >50,000 /mcl, may be titrated to maintain ANC >1.0 and platelets >50,000 /mcl.
44637|NCT01003054|Procedure|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
44638|NCT01003067|Device|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
44639|NCT01003080|Device|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
44640|NCT01003080|Other|Standard of care treatment for hemostasis during a total knee arthroplasty.|The active comparator arm will receive the "standard-of-care" for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device.
44641|NCT01005368|Genetic|fluorescence in situ hybridization|
43666|NCT00973193|Drug|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
43667|NCT00023335|Drug|Rifapentine|
43668|NCT00973219|Drug|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
43669|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
43670|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
44408|NCT01000038|Other|Walking|Half hour daily, five days a week for 8 weeks
44409|NCT01000051|Drug|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
43442|NCT00977327|Device|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
43443|NCT00977327|Device|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
43444|NCT00023738|Drug|semaxanib|
43445|NCT00977340|Behavioral|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
43446|NCT00977340|Behavioral|confrontation|Confrontation
43447|NCT00977340|Behavioral|imagination|Imagination
43448|NCT00977353|Drug|citalopram|20-60 mg/day, oral, for 6 weeks
43449|NCT00977353|Drug|sarcosine|500-1500 mg/day, oral, for 6 weeks
43450|NCT00977366|Other|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
43451|NCT00977366|Other|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
43452|NCT00977379|Radiation|WBRT|3000 cGy in 10 single daily fractions over 12 to 14 days (300cGy/fraction)
43453|NCT00977379|Drug|capecitabine [Xeloda]|825 mg/sqm orally bid, days 1-14 of 1st 3-week cycle; 1000 mg/sqm orally bid, days 1-14 from cycle 2 onward
43454|NCT00977379|Drug|systemic therapy|at investigator's discretion from 4 weeks after 1st dose of WBRT onward
43455|NCT00023738|Procedure|conventional surgery|
43456|NCT00970632|Drug|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
43457|NCT00970632|Drug|Placebo tablet|Placebo tablet po QD for 12 weeks
43458|NCT00970632|Drug|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
43459|NCT00970632|Drug|Placebo capsule|Placebo capsule po QD for 12 weeks
43460|NCT00970645|Procedure|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
44156|NCT01002209|Procedure|Sham HBO|HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.
For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min "airbrakes" will also be included.
44157|NCT01002222|Drug|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
44158|NCT00025467|Other|laboratory biomarker analysis|Correlative studies
44159|NCT01002235|Genetic|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
44160|NCT01002248|Drug|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
44161|NCT01002248|Drug|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
44162|NCT01002248|Drug|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
44163|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
44164|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
44471|NCT00997750|Drug|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
44472|NCT00997763|Device|XIENCE V|everolimus-eluting stent
44473|NCT00997763|Device|CYPHER|sirolimus-eluting stent
44474|NCT00997776|Other|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
44475|NCT00997776|Other|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
44476|NCT00997789|Drug|Rebamide|Rebamipide 100 mg Tablet, three times a day
44477|NCT00997802|Device|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
44478|NCT00997815|Drug|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
44479|NCT00025337|Drug|oxaliplatin|Given IV
43608|NCT00975507|Biological|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
43609|NCT00975507|Biological|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
43610|NCT00023621|Drug|celecoxib|
43611|NCT00975507|Biological|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
43905|NCT00968799|Drug|Cisplatin|Cisplatin is applied as chemotherapy during surgery
43906|NCT00968812|Drug|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
43907|NCT00968812|Drug|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
43908|NCT00968812|Drug|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
43909|NCT00971269|Device|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
43910|NCT00023127|Procedure|Integrated Pest Management|
43911|NCT00971282|Drug|adapalen 0.1%|Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.
Visits will be conducted weekly for a maximum of 5 visits.
43912|NCT00971282|Other|Cetaphil®|Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.
Visits will be conducted weekly for a maximum of 5 visits.
43913|NCT00971295|Drug|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
43914|NCT00971295|Drug|Eslicarbazepine acetate|
43915|NCT00971308|Drug|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
43916|NCT00971308|Drug|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
43917|NCT00971308|Drug|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
43918|NCT00971308|Drug|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
43919|NCT00971308|Drug|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
43920|NCT00971321|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
43921|NCT00023153|Drug|Adefovir Dipivoxil|
43671|NCT00973232|Drug|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
43672|NCT00973232|Drug|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
43673|NCT00973232|Drug|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
43674|NCT00973232|Drug|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
43675|NCT00973232|Drug|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
43676|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
43677|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
43678|NCT00023335|Drug|Isoniazid|
43679|NCT00975572|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
43680|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
43681|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
43682|NCT00023634|Biological|KLH|100 mcg w/EGFRvIII
43683|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
43978|NCT00968864|Device|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
43979|NCT00968877|Drug|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
43980|NCT00968890|Biological|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
43461|NCT00970645|Procedure|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
43462|NCT00970658|Drug|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
43463|NCT00970658|Drug|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
43464|NCT00970671|Other|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
43758|NCT00973310|Other|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
43759|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
43760|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
43761|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
43762|NCT00973323|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
43763|NCT00975702|Procedure|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
43764|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
43765|NCT00975715|Drug|TRI476|TRI476 oral suspension doses, based on body weight twice daily
43766|NCT00975715|Drug|Placebo to TRI476|Placebo oral suspension, taken twice daily
43767|NCT00975715|Drug|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
43768|NCT00975728|Dietary Supplement|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
43769|NCT00975741|Device|OXIMAX|
43770|NCT00975741|Device|ASMANEX TWISTHALER|
43771|NCT00975754|Drug|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
43772|NCT00975754|Drug|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
43773|NCT00975754|Drug|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
44480|NCT00997815|Drug|Normal saline injection|Using normal saline 2.5 ml injected in control side
44481|NCT00997828|Device|everolimus-eluting stent|Xience V stent
44482|NCT00997828|Procedure|coronary artery bypass graft surgery|coronary artery bypass graft surgery
44483|NCT00997841|Procedure|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
44484|NCT00997854|Other|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
44485|NCT00997867|Procedure|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
44486|NCT00997880|Drug|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
44487|NCT00997880|Drug|Rosuvastatin calcium10mg|Rosuvastatin 10mg
44488|NCT00997893|Dietary Supplement|Phytoestrogen|Women in the phytoestrogen intervention group will take one active Novasoy® (55 mg) pill at breakfast and active Novasoy® (55 mg) pill at dinner, for a total daily dose of 110 mg Novasoy® and 0 mg estradiol.
44489|NCT00997893|Drug|Estradiol|Women in estradiol intervention group will take one active estradiol pill (1 mg) at breakfast and one placebo pill at dinner, for a total daily dose of 1 mg estradiol and 0 mg Novasoy®.
44490|NCT00025337|Drug|leucovorin calcium|Given IV
43524|NCT00977483|Drug|Thioctic Acid (alpha-lipocic acid)|600mg tablet once daily 4 years double-blind treatment period
43525|NCT00977483|Drug|Placebo|1 tablet once daily 4 years double-blind treatment period
43526|NCT00977496|Procedure|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
43527|NCT00977522|Drug|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
43528|NCT00023751|Drug|leucovorin calcium|
43529|NCT00977522|Drug|Placebo|Placebo tablet BID
43530|NCT00977548|Drug|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
43531|NCT00977561|Drug|figitumumab|Figitumumab (20 mg/kg)
43922|NCT00971347|Other|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
43923|NCT00971347|Behavioral|nutrition brochure|one-time at baseline visit
43924|NCT00971360|Other|conversion disorder|Proinflammatory cytokine levels in conversion disorder
43925|NCT00971373|Other|Vestagen scrubs|antimicrobial impregnated textile
44227|NCT00999765|Behavioral|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
44228|NCT00999778|Behavioral|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
44229|NCT00999778|Behavioral|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
44230|NCT00999791|Drug|Bevacizumab|
44231|NCT00999791|Drug|Diclofenac|
44232|NCT00999804|Drug|Herceptin / Lapatinib|biologic dosed mg per kg
44233|NCT00999804|Drug|Letrozole|2.5 mg
44234|NCT00999817|Drug|reference [dextromethorphan]|single 30 mg oral dose
44235|NCT00025402|Drug|busulfan|
44236|NCT01002248|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
44237|NCT01002274|Drug|MCS-2|2 soft-gel capsules Qd for 24 weeks
44238|NCT01002287|Device|SprayShield Adhesion Barrier System|Adhesion Barrier Device
44239|NCT01002287|Procedure|Good Surgical Technique Alone|Good Surgical Technique Alone
44240|NCT01002300|Drug|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
44241|NCT01002326|Behavioral|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
44242|NCT00025480|Drug|carboplatin|
43981|NCT00968890|Biological|Fluarix™|Intramuscular injection, 1 dose
43982|NCT00022737|Drug|mercaptopurine tablet|Given orally
43983|NCT00968890|Biological|Placebo|Intramuscular injection, 1 dose
43984|NCT00968903|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
43985|NCT00968916|Drug|ombrabulin (AVE8062)|Pharmaceutical form: injection solution
Route of administration: intravenous infusion
43986|NCT00968929|Drug|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
43987|NCT00968929|Drug|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
43988|NCT00968942|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
43989|NCT00968942|Drug|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
43990|NCT00968955|Drug|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
43991|NCT00968968|Drug|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib is a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
43992|NCT00968968|Biological|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab is a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
43993|NCT00022737|Drug|methotrexate|Given IT, IV, and orally
43994|NCT00968981|Drug|GDC-0449|Daily oral repeating dose
43995|NCT00968981|Drug|GDC-0449|Three times weekly oral repeating dose
43996|NCT00968981|Drug|GDC-0449|Once weekly oral repeating dose
43997|NCT00971451|Other|TENS|continuous use of TENS during the exercise session
43998|NCT00971464|Behavioral|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
43999|NCT00971464|Device|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
44312|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
43774|NCT00975754|Drug|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
43775|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
43776|NCT00975767|Drug|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
43777|NCT00975767|Drug|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
43778|NCT00975780|Other|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
43779|NCT00975780|Other|Usual oral care|Usual oral care and feeding positioning
44079|NCT00969072|Drug|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
44080|NCT00969085|Drug|Curcumin (Turmeric)|Chew then swallow 2 sticks per day for up to 6 months.
2 sticks = 1 packet of curcumin = 8 grams
44081|NCT00969085|Behavioral|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
44082|NCT00969085|Other|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
44083|NCT00969111|Radiation|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
44084|NCT00969111|Radiation|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
44085|NCT00022737|Drug|vincristine sulfate|Given IV
44086|NCT00969111|Radiation|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
44087|NCT00969111|Radiation|Proton to 66.6 CGE|Post-Op Non High Risk
44088|NCT00969124|Device|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
44089|NCT00969137|Drug|saline|intravenous saline
44090|NCT00969137|Drug|Nicotine|Intravenous nicotine
44091|NCT00971646|Other|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
44092|NCT00971646|Other|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
44093|NCT00971646|Other|EuroQol-5D|This questionnaire grades the health condition of the subject.
43532|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
43533|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
43534|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
43535|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
43536|NCT00977574|Biological|Bevacizumab|Given IV
43537|NCT00977574|Drug|Carboplatin|Given IV
43538|NCT00977574|Drug|Ixabepilone|Given IV
43539|NCT00023751|Procedure|conventional surgery|
43540|NCT00977574|Other|Laboratory Biomarker Analysis|Correlative studies
43541|NCT00977574|Drug|Paclitaxel|Given IV
43542|NCT00977574|Drug|Temsirolimus|Given IV
43543|NCT00977587|Drug|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
43544|NCT00977587|Drug|placebo|Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:
Calcium phosphate, Dibasic 472.0 mg
Maltodextrin DE14 112.1 mg
Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day
43545|NCT00977600|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
43546|NCT00977600|Drug|Ammonul|
43843|NCT00973401|Other|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
43844|NCT00973414|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
43845|NCT00973414|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
43846|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml Additional maintenance: 2 two-weekly injections 2.0* ml
*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
44243|NCT01002339|Drug|Tacrolimus with rapid steroid withdrawal|Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7
44244|NCT01002339|Drug|Tacrolimus with steroids minimization|Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months.
44245|NCT01002339|Drug|CsA with steroid minimization|CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2
44246|NCT01002365|Other|Oxygen delivery|
44247|NCT01002365|Other|Oxygen administration|
44557|NCT01005251|Drug|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
44558|NCT01005251|Drug|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
44559|NCT01005251|Drug|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
44560|NCT01005251|Drug|Placebo|oral,capsules, bid for 4 w
44561|NCT01005264|Device|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
44562|NCT01005264|Device|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
44563|NCT01005277|Genetic|gene expression analysis|
44564|NCT01005277|Genetic|microarray analysis|
44565|NCT01005277|Genetic|polymorphism analysis|
44566|NCT01005290|Drug|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
44567|NCT00025623|Drug|etoposide|
44568|NCT01005290|Drug|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
44569|NCT00997893|Other|Placebo|Women in this intervention group will take one placebo pill at breakfast and one placebo pill at dinner, for a total daily dose of 0 mg Novasoy® and 0 mg estradiol.
44570|NCT00997893|Other|Placebo|At week 12, after the participant completes her final assessments, women will begin taking placebo(10 days).
44313|NCT00999856|Device|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
44314|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
44315|NCT00999856|Device|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
44316|NCT00999856|Device|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
44317|NCT00999869|Drug|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
44318|NCT00999869|Drug|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
44319|NCT00000882|Drug|Zidovudine|
44320|NCT00025402|Drug|cyclophosphamide|
44321|NCT00999882|Drug|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
44322|NCT00999908|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
44323|NCT00999908|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
44324|NCT00999908|Drug|Placebo|Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
44325|NCT00999921|Drug|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
44326|NCT00999921|Drug|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
44327|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
44328|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
44329|NCT00999973|Drug|Mitomycin C 0.02%|
44330|NCT00999973|Drug|Placebo|
44331|NCT00025402|Drug|cytarabine|
44094|NCT00971646|Other|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
44095|NCT00971659|Drug|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
44096|NCT00023205|Behavioral|Interactive in-person arthritis education|
44097|NCT00971659|Drug|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
44098|NCT00971659|Drug|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
44099|NCT00971672|Other|Questionnaire filling and laboratory analysis|A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.
The laboratory analysis will include complete blood count and serum ferritin analysis.
44410|NCT01000051|Drug|Placebo|Once a day, orally for 8 weeks.
44411|NCT00025402|Drug|etoposide|
44412|NCT01000064|Drug|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks
44413|NCT01000064|Procedure|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
44414|NCT01000103|Device|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
44415|NCT01000103|Device|Sham rTMS|two TMS coils will be used: a passive one which is placed flat on top of the "actively" targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations
44416|NCT01000116|Procedure|Fibrin glue|Tissucol 2 ml
44417|NCT01000116|Procedure|Tacks|Protacks
44418|NCT01000129|Other|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
44419|NCT01000129|Other|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
44420|NCT01000142|Procedure|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
43847|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml.
Additional maintenance: 2 two-weekly injections 2.0* ml
*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
43848|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2*, 1.6* and 2.0*ml.
Additional maintenance: 2 two-weekly injections 2.0* ml
*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
43849|NCT00023361|Drug|Rifabutin|
43850|NCT00973479|Drug|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
43851|NCT00973479|Other|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
43852|NCT00973479|Drug|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
43853|NCT00973492|Other|functional insulinotherapy class|The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.
On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.
Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.
A one-day follow-up takes place 3 months later.
43854|NCT00973505|Drug|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
43855|NCT00973531|Device|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
43856|NCT00975884|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
43857|NCT00975897|Biological|bevacizumab|
43858|NCT00975897|Biological|cetuximab|
43859|NCT00975897|Drug|fluorouracil|
44165|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
44166|NCT01004627|Procedure|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
44167|NCT01004640|Genetic|DNA analysis|
44168|NCT00025597|Drug|etoposide|
44571|NCT00997906|Drug|carboplatin,|Given IV
44572|NCT00997906|Drug|cisplatin|Given IV
44573|NCT00997906|Drug|gemcitabine hydrochloride|Given IV
44574|NCT00997906|Drug|paclitaxel|Given IV
44575|NCT00997906|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
44576|NCT00997919|Drug|MABT5102A|single SC dose
44577|NCT00997919|Drug|MABT5102A|single IV dose
44578|NCT00025337|Drug|fluorouracil|Given IV
44579|NCT00997932|Device|Mirena Intrauterine Contraceptive System|Postpartum placement of the IUD
44580|NCT00997945|Drug|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
43612|NCT00975520|Other|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
43613|NCT00975520|Radiation|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
43614|NCT00975533|Device|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
43615|NCT00975533|Drug|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
43616|NCT00975546|Other|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
43617|NCT00975546|Procedure|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
43618|NCT00968344|Dietary Supplement|Leucine|3-4g Leucine added to daily meals
43619|NCT00968344|Dietary Supplement|Leucine|Powered amino acid
46858|NCT00992030|Radiation|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
46859|NCT00992043|Dietary Supplement|creatine|
46860|NCT00025077|Radiation|radiation therapy|
46861|NCT00992043|Other|Exercise training|
46862|NCT00992056|Drug|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
46863|NCT00992056|Drug|Metoprolol|Metoprolol 50 mg titrated to 100 mg
46864|NCT00992069|Drug|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
46865|NCT00992069|Drug|TMC207|Single oral dose of 400 mg in the morning
46866|NCT00992082|Drug|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
46867|NCT00992082|Drug|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
46868|NCT00992095|Drug|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
46869|NCT00992108|Drug|lidocaine|1cc 1%
46870|NCT00992108|Drug|chemodenercation|botulinum toxin
46871|NCT00025090|Drug|cisplatin|
46872|NCT00992121|Drug|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
46873|NCT00994448|Drug|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
46874|NCT00994448|Drug|Placebo tablets|One placebo tablet twice daily
46875|NCT00994461|Drug|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
47187|NCT00027768|Procedure|adjuvant therapy|
47188|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
50541|NCT01041066|Drug|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
50542|NCT01041092|Drug|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
50543|NCT01041144|Behavioral|lifestyle counseling|supporting diabetes patients using Internet communication
50544|NCT01041157|Other|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
50545|NCT01041170|Drug|THC|
50546|NCT00028873|Drug|docetaxel|
50547|NCT01041170|Drug|Rimonobant|
50548|NCT01041170|Drug|Rimonabant|
50549|NCT01041183|Drug|intravenous ramosetron|0.3 mg IV ramosetron (group I)
50550|NCT01041183|Drug|oral ramosetron|0.1 mg oral ramosetron (group II)
50551|NCT01041183|Drug|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
50883|NCT01039324|Other|Reports|Primary care event reports and patient letters
50884|NCT01039324|Other|Reports and Notices|Primary care event reports, patient letters and care manager notices
50885|NCT01039324|Other|Usual care|This is the study's control group
50886|NCT01039337|Other|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
50887|NCT00028769|Drug|leuprolide|
50888|NCT01039337|Other|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
50889|NCT01039337|Other|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
50890|NCT01039350|Drug|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
50106|NCT01042704|Other|Post-Treatment Follow Up|After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:
Physical exam
Performance status (check of ability to perform daily functions)
Recording of any new symptoms and any new medications being taken
Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)
Urine test (24hr urine)
Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).
A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse.
50107|NCT01042717|Drug|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
50108|NCT01042730|Drug|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
50109|NCT01042743|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
50110|NCT01042743|Procedure|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
50111|NCT01042769|Drug|Aleglitazar|aleglitazar 150 micrograms po daily
50112|NCT01042769|Drug|Placebo|placebo control po daily
50113|NCT01042782|Drug|RAD001 and MitomycinC|RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)
Mitomycin C 5 mg/m2 i.v. every 3 weeks
50114|NCT01042795|Drug|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
50115|NCT01042821|Procedure|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
50116|NCT00028938|Drug|carboplatin|
50117|NCT01042821|Procedure|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
50118|NCT01042834|Other|Air pollution study on healthy volunteers.|The subjects are examined three times:
First the volunteers get used to equipments.
Second and third the volunteers sleep in a pollution or purified air.
50119|NCT01045343|Other|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
50120|NCT01045343|Other|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
50704|NCT01039025|Drug|Melphalan|After stem cells are collected, Melphalan 70 mg/m^2/day intravenously given on Days 4 and 5.
50460|NCT01041027|Drug|Carboplatin|Given IV
50461|NCT00000898|Drug|Saquinavir|
50462|NCT00028860|Procedure|adjuvant therapy|
50804|NCT01039233|Drug|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
50805|NCT01041625|Drug|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
50806|NCT01041638|Biological|aldesleukin|Given IV - Doses and days vary by week of course:
Week 1 of Each Course: Dose: 3 Million International Units/m2/dose. Days: 0-3. Week 2 of Each Course: Dose: 4.5 Million International Units/m2/dose. Days: 7-10. Actual dosage is Body Surface Area calculated.
50807|NCT01041638|Biological|sargramostim|Given IV or SC
50808|NCT00028886|Drug|dexamethasone|
50809|NCT01041638|Biological|monoclonal antibody Ch14.18|Given IV
50810|NCT01041638|Drug|isotretinoin|Given orally
50811|NCT01041677|Drug|R256918|10 mg capsule twice daily
50812|NCT01041677|Drug|placebo|placebo capsule twice daily
50813|NCT01041677|Drug|R256918|15 mg capsule twice daily
50814|NCT01041690|Drug|Bevacizumab|
50815|NCT01041703|Drug|clofarabine|Given IV
50816|NCT01041703|Drug|cytarabine|Given IV
50817|NCT01041703|Drug|daunorubicin hydrochloride|Given IV
50818|NCT01041703|Drug|decitabine|Given IV
50819|NCT00028886|Drug|doxorubicin hydrochloride|
50820|NCT01041716|Other|None - Observational study|None - Observational study
50821|NCT01041729|Drug|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
50822|NCT01041729|Drug|Standard Medical Treatment|Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.
Standard Medical Treatment.
50823|NCT01041742|Procedure|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
49895|NCT01011127|Drug|pravastatin, rosuvastatin|
49896|NCT01011140|Behavioral|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
49897|NCT01011166|Drug|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
49898|NCT01011166|Drug|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
49899|NCT01011166|Biological|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
50180|NCT01040624|Radiation|< 15% risk of + LN|Total of 54 CGE over 30 treatments to prostate + SV, then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
50181|NCT01040624|Radiation|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
50182|NCT01040637|Drug|TD-1211|Dose level 1
50183|NCT01040637|Drug|TD-1211|Dose level 2
50184|NCT01040637|Drug|TD-1211|Dose level 3
50185|NCT01040637|Drug|TD-1211|Dose Level 4
50186|NCT01040637|Drug|TD-1211|Ascending doses
50187|NCT01040637|Drug|TD-1211|Ascending doses
50188|NCT01042860|Dietary Supplement|Lutein|Lutein supplement, 10 mg daily
50189|NCT01042860|Dietary Supplement|Placebo|Placebo
50190|NCT01042873|Drug|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
50191|NCT01042886|Behavioral|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
50192|NCT01042886|Behavioral|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
50891|NCT01039363|Drug|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|Salvage reinduction therapy:
Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)
Maintenance:
Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles
Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.
Gemtuzumab will be omitted in a consolidation schedule.
Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT.
50892|NCT01039376|Biological|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose will be 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years).
50893|NCT01039376|Other|Observation|Observation/Safety Evaluation
50894|NCT01039389|Drug|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
50895|NCT01039389|Drug|Placebo|bid placebo
50896|NCT01039428|Dietary Supplement|HS219|Chewing for 30 min three time a day far after meal
50897|NCT01041807|Drug|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
50898|NCT01041820|Behavioral|Exercise|Children will be exposed to a 10-week exercise intervention
50899|NCT01041833|Drug|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
50900|NCT01041833|Drug|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
49964|NCT01008969|Other|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
49965|NCT00000885|Drug|Zidovudine|
49966|NCT00026091|Other|laboratory biomarker analysis|Correlative studies
49967|NCT01008982|Drug|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
49968|NCT01008995|Drug|placebo|Subcutaneous injection at Week 0 and 4
49969|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
49970|NCT01008995|Drug|placebo|Subcutaneous injection at Week 12
49971|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
49972|NCT01009008|Device|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
50705|NCT00028769|Drug|estramustine|
50706|NCT01039025|Other|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
50707|NCT01039038|Radiation|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
50708|NCT01039051|Behavioral|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
50709|NCT01039077|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
50710|NCT01039090|Drug|Continuous Apomorphine infusion|Continuous Apomorphine infusion during 6 months
50711|NCT01039090|Drug|Usual dopaminergic per os treatment|No specific change in the dopaminergic per os treatment
50712|NCT01041430|Other|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
50713|NCT01041430|Other|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
50714|NCT01041443|Drug|5-fluoro-2-deoxycytidine|Given IV
50715|NCT01041443|Drug|tetrahydrouridine|Given IV
50716|NCT01041443|Other|laboratory biomarker analysis|Correlative studies
50717|NCT01041443|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
50718|NCT00028886|Biological|recombinant interferon alfa|
50719|NCT01041443|Genetic|DNA methylation analysis|Correlative studies
50720|NCT01041482|Drug|sorafenib|sorafenib 400mg twice daily
50721|NCT01041495|Drug|cyclobenzaprine ER (AMRIX)|active drug
50722|NCT01041495|Drug|placebo|matching placebo for AMRIX
50723|NCT01041508|Drug|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry.
50724|NCT01041508|Radiation|Total Body Irradiation|Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day "0" according to institutional guidelines.
50824|NCT01041755|Drug|L-ornithine-L-aspartate|a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
50825|NCT01041755|Drug|Lactose|a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
49876|NCT01008865|Procedure|T-Pouch orthotopic urinary diversion|
49877|NCT01008878|Behavioral|interdisciplinary intervention|
49878|NCT00026091|Drug|fenretinide|Given orally
49879|NCT01008891|Device|Augment™ Injectable|Beta-TCP/Bovine Collagen matrix + rhPDGF-BB
49880|NCT01008891|Procedure|Standard of care|Autologous Bone Graft
49881|NCT01008904|Drug|magnesium oxide|Given PO
49882|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
49883|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
49884|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
49885|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
49886|NCT01011062|Procedure|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
49887|NCT01011062|Drug|Losartan|Acute administration of losartan 200mg total prior to clamp
49888|NCT01011062|Drug|Saline|Infusion of Saline as a volume control intervention
49889|NCT00026208|Drug|VP-16|60 mg/m2 x 2; IV wk 3, 7 (d 15, 16, 43, 44)
49890|NCT01011075|Drug|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
49891|NCT01011075|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
49892|NCT01011088|Other|Not available|Not any artificial interventions were given
49893|NCT01011114|Drug|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
49894|NCT01011114|Drug|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
50193|NCT01042899|Behavioral|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
50194|NCT01042899|Behavioral|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
50195|NCT01042899|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
50196|NCT00028938|Drug|paclitaxel|
50463|NCT01041027|Radiation|Internal Radiation Therapy|Undergo HDR brachytherapy
50464|NCT01041027|Radiation|External Beam Radiation Therapy|Undergo EBRT
50465|NCT01041027|Other|Laboratory Biomarker Analysis|Correlative studies
50466|NCT01043367|Dietary Supplement|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
50467|NCT01043367|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
50468|NCT01043380|Drug|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
50469|NCT01043380|Drug|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
50470|NCT01043393|Drug|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
50471|NCT01043406|Device|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
50472|NCT01043419|Drug|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
49973|NCT01009021|Drug|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
49974|NCT01009034|Other|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
49975|NCT01009047|Drug|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
49976|NCT01009047|Drug|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
49977|NCT00026091|Other|pharmacological study|Correlative studies
49978|NCT01009060|Drug|GSK239512|Histamine H3 Antagonist
49979|NCT01009060|Drug|Placebo|Placebo to match GSK239512
49980|NCT01009073|Drug|ABT-263|ABT-263 is taken orally.
Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed.
49981|NCT01009073|Drug|erlotinib|150 mg of erlotinib is taken orally once daily.
49982|NCT01009073|Drug|irinotecan (3-week schedule)|180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.
Note - The dose and schedule is subject to change based on the toxicities observed.
49983|NCT01011218|Drug|Armodafinil|150 mg once a day
49984|NCT01011218|Behavioral|Brief Behavioral Intervention for Insomnia (BBT-I)|2 sessions in person and additional brief sessions over the phone
49985|NCT01011218|Drug|Placebo|Placebo pill
50258|NCT01040676|Behavioral|Automated Telephone Nutrition Support|See Intervention Group description.
50259|NCT01040689|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
50260|NCT01040689|Drug|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
50261|NCT01040689|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
50262|NCT01040689|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
50263|NCT01040689|Drug|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
50264|NCT01040702|Drug|methylphenidate|a single doses of 10-20 mg in each one of two visits
50742|NCT00028990|Drug|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
50743|NCT01043900|Procedure|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
50744|NCT01043913|Drug|Guarana extract|Guarana extract 50mg q12 hours for 21 days
50745|NCT01043926|Drug|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
50746|NCT01043939|Other|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
50747|NCT01043939|Other|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
50748|NCT01043952|Drug|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
50749|NCT01043952|Drug|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
50750|NCT01043952|Device|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
50751|NCT01043965|Drug|Metformin|Metformin 850mg
50752|NCT01043978|Behavioral|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
50753|NCT00029003|Drug|gefitinib|Given orally
50754|NCT01043991|Drug|Darbepoetin alfa|
50755|NCT00029380|Drug|Sangstat|
50756|NCT01046188|Other|Satisfaction questionnaire|Administered after the intervention and at study completion
50757|NCT01046188|Other|Web-based IVF teaching|Web-based IVF teaching
50758|NCT01046188|Other|Didactic lecture|Didactic lecture
50759|NCT01046214|Drug|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
46808|NCT00987532|Behavioral|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
46809|NCT00987532|Behavioral|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
46810|NCT00987545|Drug|QAX576|QAX576 injection
46811|NCT00987545|Drug|QAX576 placebo|Placebo to QAX576 injection
46812|NCT00987558|Drug|Eslicarbazepine acetate|
46813|NCT00987558|Drug|Simvastatin|
46814|NCT00987597|Behavioral|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
46815|NCT00987597|Behavioral|conventional follow-up|nicotinic substitutes
46816|NCT00987610|Device|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
46817|NCT00987623|Device|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
46818|NCT00000875|Drug|Aldesleukin|
47127|NCT01016080|Drug|glutathione|250 mg capsules, twice daily, orally
47128|NCT01016080|Drug|placebo|250 mg capsules, twice daily, orally
47129|NCT01016093|Drug|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
47130|NCT01016093|Drug|Placebo|Placebo
47131|NCT01016106|Genetic|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
47132|NCT01016119|Drug|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
47133|NCT00026988|Drug|Creatine|
47134|NCT01016119|Drug|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
50473|NCT01043445|Dietary Supplement|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
50474|NCT01043445|Dietary Supplement|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
50475|NCT00028964|Drug|doxorubicin hydrochloride|
50476|NCT01043445|Dietary Supplement|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
50477|NCT01043458|Drug|ABT-126|ABT-126 Low Dose & ABT-126 High Dose
50478|NCT01043458|Drug|Placebo for ABT-126|Matching Placebo for Arms 1 & 2
50479|NCT01043471|Other|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
50480|NCT01043471|Other|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
50481|NCT01043484|Drug|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
50482|NCT01043484|Drug|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
50483|NCT01043510|Drug|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
50826|NCT01041768|Procedure|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
50827|NCT01041781|Drug|carboplatin|Given IV
50828|NCT01041781|Drug|celecoxib|Given orally
50829|NCT01041781|Drug|gemcitabine hydrochloride|Given IV
50830|NCT00028886|Drug|melphalan|
50831|NCT01041781|Drug|pemetrexed disodium|Given IV
50832|NCT01041781|Other|placebo|Given orally
50833|NCT01043991|Drug|Placebo|
50834|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
50835|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
47189|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
47190|NCT01024179|Device|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
47191|NCT01024192|Drug|ZOLPIDEM SL800750|Pharmaceutical form: Zopidem 12.5 mg tablets
Route of administration: Oral
Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)
47192|NCT01024205|Drug|sunitinib malate|
47193|NCT01024205|Other|laboratory biomarker analysis|
47194|NCT01024205|Procedure|adjuvant therapy|
47195|NCT01024205|Procedure|neoadjuvant therapy|
47196|NCT01024205|Procedure|therapeutic conventional surgery|
47197|NCT01024218|Device|NovoFine® needle 8 mm|
47198|NCT00027768|Radiation|iodine I 131 ethiodized oil|
47199|NCT01024218|Device|autocover needle|
47200|NCT01024231|Drug|BMS-936558 (MDX1106-04)|
47201|NCT01024231|Drug|Ipilimumab|
47202|NCT01024244|Drug|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
47203|NCT01024244|Drug|LY2599506|Administered po for 12 weeks
47204|NCT01024257|Radiation|beta-irradiation|
47205|NCT01024257|Procedure|conjunctival autograft|
47206|NCT01024270|Drug|Misoprostol|
47207|NCT01024296|Device|Closing Port Site|
47208|NCT01024309|Procedure|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
47209|NCT01016158|Drug|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
47210|NCT01016184|Dietary Supplement|Vitamin D|Oral vitamin D 100,000 IU
47211|NCT01016184|Dietary Supplement|Placebo|Placebo
50760|NCT01046214|Drug|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
49819|NCT00026377|Drug|bicalutamide|50 mg daily for 1 month
49820|NCT01013467|Behavioral|"CoCo" colour coded blood pressure control|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
49821|NCT01013480|Drug|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
49822|NCT01013506|Drug|IGF-1R inhibitor OSI-906|Given orally
49823|NCT01013506|Drug|erlotinib hydrochloride|Given orally
49824|NCT01013506|Drug|goserelin|Given subcutaneously
49825|NCT01013506|Drug|letrozole|Given orally
49826|NCT01013532|Drug|Cilostazol|Cilostazol 100mg bid
49827|NCT01013532|Drug|Probucol|Probucol 250mg bid
49828|NCT01013532|Drug|Aspirin|Aspirin 100mg qd
49829|NCT01013532|Drug|placebo of cilostazol|same shape and size of active cilostazol
49830|NCT00026377|Drug|flutamide|250 mg 3 times daily for 1 month
49831|NCT01013532|Drug|placebo of aspirin|same size and shape of active aspirin 100mg
49832|NCT01013532|Device|ankle-brachial index (ABI)|measurement of ABI every years during follow up
49833|NCT01013532|Device|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
49834|NCT01013532|Device|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
49835|NCT01013532|Device|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
49836|NCT01013545|Behavioral|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
47135|NCT01016132|Device|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
47136|NCT01016145|Drug|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
47137|NCT01016145|Drug|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
47138|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
47139|NCT01018511|Drug|tamsulosin hydrochloride OCAS 0.4 mg|tablet
47140|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
47141|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
47142|NCT01018524|Procedure|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
47143|NCT01018550|Drug|AMG 853|AMG 853 5 mg (BID)
47144|NCT01018550|Drug|AMG 853|AMG 853 200 mg (QD)
47145|NCT00027365|Biological|NefTat|
47146|NCT01018550|Drug|AMG 853|AMG 853 25 mg (BID)
47147|NCT01018550|Drug|AMG 853|AMG 853 100 mg (BID)
47148|NCT01018550|Drug|Placebo|Placebo
47149|NCT01018563|Drug|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
46199|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort -1|Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
In this cohort, Hydralazine is administered at 10 mg/day.
46200|NCT00025272|Drug|topotecan hydrochloride|
46201|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 0|Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 25 mg/day in this cohort.
46202|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 1|Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 50 mg/day in this cohort.
50836|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
50837|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
50838|NCT01044017|Drug|Placebo|single oral dose
50839|NCT01044017|Drug|RO4998452|single oral doses
50840|NCT01044030|Drug|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
50841|NCT01044030|Drug|Placebo|7.5 mL by mouth three times daily
50842|NCT00029003|Other|laboratory biomarker analysis|Correlative studies
50843|NCT01044043|Procedure|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
50844|NCT01044056|Drug|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
50845|NCT01044056|Drug|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
50846|NCT01044056|Drug|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
49900|NCT00026221|Biological|Recombinant Interferon Alfa|Given SC
49901|NCT01011166|Drug|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
49902|NCT01011179|Behavioral|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
49903|NCT01011179|Behavioral|Self-Management|Adolescents' "own best efforts" at managing their JIA
49904|NCT01011205|Drug|Advagraf|Capsule
49905|NCT01011205|Drug|Mycophenolate Mofetil|Solution for infusion
49906|NCT01011205|Drug|Basiliximab|IV infusion
49907|NCT01011205|Drug|Corticosteroids|IV bolus
49908|NCT01013571|Drug|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
46253|NCT00993356|Procedure|Transsphenoidal surgery|
46254|NCT00025142|Drug|gefitinib|
46255|NCT00993369|Other|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
46256|NCT00993382|Drug|Celivarone (SSR149744)|50 or 100 mg capsules
oral administration with a meal
46257|NCT00993382|Drug|amiodarone|200 mg capsules
oral administration with a meal
46258|NCT00993382|Drug|placebo|Matching capsules
oral administration with a meal
46259|NCT00993395|Behavioral|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
46260|NCT00993408|Device|ACT-293987 (NS-304)|
46261|NCT00993421|Drug|LY377604|Given daily, orally for 24 weeks
46262|NCT00993421|Drug|Sibutramine|given daily, orally for 24 weeks
46263|NCT00993421|Drug|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
46264|NCT00993421|Drug|Placebo sibutramine|given daily, orally for 24 weeks
46265|NCT00025142|Drug|leucovorin calcium|
46266|NCT00993421|Drug|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
46267|NCT00993421|Drug|Placebo LY377604|given daily, orally for 24 weeks
46268|NCT00993434|Behavioral|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
46269|NCT00993434|Behavioral|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
46270|NCT00993447|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
46271|NCT00993447|Biological|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
46272|NCT00993473|Drug|Insulin glargine (HOE901)|100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U
Dose: titrated to achieve the following glycemic targets without hypoglycemia:
Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,
Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,
Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and
HbA1c <7.5%.
49837|NCT01013558|Drug|Remifentanil|0.15 microgram/kg/min continuous infusion.
49838|NCT01013558|Drug|saline|continuous infusion
49839|NCT01013571|Drug|insulin glargine|pre-filled disposable pen, in package of 5.
49840|NCT01006460|Drug|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
50121|NCT01045369|Drug|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
50122|NCT01045382|Biological|Mesenchymal stem cells|Mesenchymal stem cell injection
50123|NCT01045382|Other|Isotonic solution|Isotonic solution injection
50124|NCT01045395|Dietary Supplement|Corn starch|90mg/d
50125|NCT01045395|Dietary Supplement|Unique Marine Algae Concentrate (UMAC)|90mg/d
50126|NCT01045395|Dietary Supplement|Golden brown algae|90mg/d
50127|NCT00029237|Behavioral|Cognitive-behavioral relaxation (Positively Living)|
50128|NCT01045408|Dietary Supplement|Berry extract|Berry extract for weeks
50129|NCT01045421|Drug|MLN8237|Phase 1:
MLN8237 will be administered orally twice a day on a 7-day dosing schedule
Phase 2:
MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period.
50130|NCT01045434|Drug|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
50131|NCT01045447|Drug|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
50132|NCT01045447|Drug|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
50133|NCT01045460|Biological|aMILs|Activated marrow infiltrating lymphocytes
50134|NCT01045460|Biological|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine
50135|NCT01045486|Drug|ATP mixed probiotics|- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
50136|NCT01045486|Drug|Placebo|- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
46203|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 2|Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day.
46204|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 3|Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day.
46205|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 4|Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day.
46206|NCT00988715|Drug|Fludarabine Phosphate|Given IV
46207|NCT00988715|Other|Pharmacological Study|Correlative studies
46208|NCT00988715|Other|Laboratory Biomarker Analysis|Correlative studies
46209|NCT00988728|Drug|SCH 900435 (Org 25935)|Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.
Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day).
46210|NCT00988728|Drug|Placebo|Oral capsules and tablets containing excipients only.
Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.
46211|NCT00988728|Drug|Olanzapine|Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.
Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day).
46212|NCT00988741|Drug|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
46213|NCT00988741|Drug|Placebo|The placebo is provided in a capsule form.
46507|NCT00991393|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
46508|NCT00991406|Device|EMS 2000|Surface stimulation to contract the muscles in the lower extremity
46509|NCT00991419|Drug|[18F]AZD4694|[18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
49909|NCT00026377|Drug|goserelin acetate|3.6 mg once a month for 4 months
49910|NCT01013584|Dietary Supplement|cholecalciferol|daily dose
49911|NCT01013597|Drug|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
49912|NCT01013610|Drug|LNK-754|Escalating dose
49913|NCT01013610|Drug|Placebo|Escalating dose
49914|NCT01013623|Procedure|Surgery|surgical resection to remove all known disease
49915|NCT01013623|Procedure|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
49916|NCT01013623|Other|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
49917|NCT01013636|Procedure|Blood sampling|Anaplasma diagnosis test : serology and PCR
If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days
49918|NCT01013649|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
49919|NCT01013649|Drug|Capecitabine|Given PO
50197|NCT01042925|Drug|XL147 (SAR245408)|administered orally once daily as tablet(s)
50198|NCT01042925|Biological|trastuzumab|administered by IV once every 3 weeks
50199|NCT01042925|Drug|paclitaxel|administered by IV once every week
50200|NCT01042938|Drug|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
50201|NCT01042938|Drug|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
50202|NCT01042951|Biological|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
50203|NCT01042951|Other|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
46273|NCT00995475|Drug|Placebo|
46274|NCT00995488|Drug|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
46570|NCT00989222|Procedure|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
46571|NCT00989235|Drug|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
46572|NCT00989235|Drug|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
46573|NCT00989248|Other|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
46574|NCT00989261|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
46575|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
46576|NCT00025038|Drug|tipifarnib|Given orally
46577|NCT00989274|Biological|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
46578|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
46579|NCT00989287|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
46580|NCT00989300|Drug|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
46581|NCT00989300|Drug|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
46582|NCT00989300|Other|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
46583|NCT00989313|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
46584|NCT00989326|Other|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
50137|NCT01045499|Device|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
50138|NCT00029237|Behavioral|Spiritual growth group|
50139|NCT01045512|Drug|fluvastatin|40-80mg once daily
50140|NCT01045525|Procedure|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
50141|NCT01045525|Behavioral|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
50401|NCT01045928|Other|flow cytometry|Correlative study
50402|NCT01045928|Other|laboratory biomarker analysis|Correlative study
50403|NCT01045941|Drug|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
50404|NCT01045941|Procedure|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
50405|NCT01045954|Drug|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
50406|NCT01045967|Drug|Lansoprazole|30 mg delayed-release Capsule
50407|NCT01045967|Drug|Prevacid®|30 mg delayed-release Capsule
50408|NCT01045980|Drug|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
50409|NCT00029315|Drug|Recombinant Tissue Plasminogen Activator (rt-PA)|
50410|NCT01045980|Drug|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
50411|NCT01045980|Drug|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
50412|NCT01045980|Device|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
50413|NCT01045993|Device|Heat Device|8-Hour Heatwrap
50414|NCT01045993|Device|Sham Device|Inactive wrap worn for 8 hours
50415|NCT01045993|Drug|marketed analgesic|2 x 200 mg ibuprofen tablets
46510|NCT00991432|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
46511|NCT00991445|Procedure|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
46512|NCT00991445|Procedure|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
46513|NCT00025064|Radiation|radiation therapy|
46514|NCT00991458|Drug|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
46515|NCT00991458|Drug|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
46516|NCT00993746|Drug|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
46517|NCT00993759|Drug|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
46518|NCT00993785|Device|Costar Coronary Stent Delivery System|
46519|NCT00025168|Radiation|radiation therapy|
46520|NCT00993798|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
46521|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
46522|NCT00993798|Drug|Bupivacaine HCl Treatment 1c|20.0 ml
46523|NCT00993798|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
46524|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
46819|NCT00024440|Biological|oblimersen sodium|
46820|NCT00987623|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
50204|NCT01042964|Drug|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
50205|NCT01042977|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
50206|NCT01045551|Drug|Apremilast|20mg taken orally twice per day for 12 weeks
50207|NCT01045564|Biological|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
50208|NCT01045577|Drug|Masitinib|6 mg/kg/day
50209|NCT01045577|Drug|Masitinib|3 mg/kg/day
50210|NCT01045577|Drug|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
50211|NCT01045590|Drug|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
50212|NCT00029237|Behavioral|Focused Tai Chi|
50213|NCT01045590|Drug|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
50484|NCT01043510|Drug|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
50485|NCT01043523|Drug|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
50486|NCT00028964|Procedure|adjuvant therapy|
50487|NCT01043536|Radiation|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
50488|NCT01046032|Drug|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
46585|NCT00989339|Drug|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
46586|NCT00989352|Drug|Methotrexate|3g/m² i.v. max. 9 times
46587|NCT00025038|Drug|isotretinoin|Given orally
46588|NCT00989352|Drug|Lomustine|110 mg/m² p.o., max. 3 times
46589|NCT00989352|Drug|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
46876|NCT00994461|Drug|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
46877|NCT00994461|Drug|Placebo|Placebo tablet three times a day with meal for 2 weeks
46878|NCT00025207|Drug|gefitinib|Given orally
46879|NCT00994474|Procedure|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
46880|NCT00994474|Procedure|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
46881|NCT00994487|Other|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
46882|NCT00994487|Other|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
46883|NCT00994500|Drug|vorinostat|Given orally
46884|NCT00994500|Drug|bortezomib|Given IV
46885|NCT00994500|Other|pharmacological study|Correlative studies
46886|NCT00994500|Other|laboratory biomarker analysis|Correlative studies
46887|NCT00994513|Dietary Supplement|Alpha Lipoic Acid|1200 mg/day
46888|NCT00994513|Dietary Supplement|Placebo|1200 mg/day
46889|NCT00025207|Other|laboratory biomarker analysis|Correlative studies
46890|NCT00994526|Other|Ham|Ham : 180 g per day during 4 days
50416|NCT01045993|Drug|Placebo|2 x placebo tablets
50417|NCT01046006|Drug|Bortezomib, Rituximab, Dexamethasone|Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.
On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.
Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv
50418|NCT01038440|Dietary Supplement|Safflower Oil|One softgel consumed daily with food
50419|NCT00028743|Drug|topotecan hydrochloride|4 cycles
.75mg/m2 (30 mins) days 1-5 of 21 day cycle
50420|NCT01038440|Dietary Supplement|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
50421|NCT01038440|Dietary Supplement|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
50761|NCT01046227|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
50762|NCT01046240|Drug|Palonosetron|Palonosetron 3 mg administered SC or IV
50763|NCT01046253|Drug|Lansoprazole|30 mg Delayed-Release Capsules
50764|NCT01046253|Drug|Prevacid®|30 mg Delayed-Release Capsule
50765|NCT01046266|Drug|RO5083945|700mg iv weekly
50766|NCT00029380|Drug|Cyclophosphamide|
50767|NCT01046266|Drug|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
50768|NCT01046279|Drug|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
50769|NCT01046292|Drug|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
50770|NCT01046305|Behavioral|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
50771|NCT01046305|Behavioral|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
50772|NCT01046305|Behavioral|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
46821|NCT00987636|Drug|Zoledronic acid|intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.
Patients < 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.
Patients >= 18 years will receive a bodyweight-dependent dose:
Patients >40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h
46822|NCT00987636|Drug|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: <9 kg= 1mg/kg BW 9 - <16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW >23 - 34 kg= 0.95 mg/kg BW >34 kg = 0.8 mg/kg BW
46823|NCT00987636|Drug|Treosulfan|12 g/m² d-5 to d-3
46824|NCT00987662|Drug|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg.
46825|NCT00987662|Drug|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg
46826|NCT00987675|Other|pharmacological study|
46827|NCT00987675|Other|questionnaire administration|
46828|NCT00987675|Procedure|assessment of therapy complications|
46829|NCT00987675|Procedure|high-intensity focused ultrasound ablation|
46830|NCT00024440|Drug|cyclophosphamide|
46831|NCT00987675|Procedure|quality-of-life assessment|
46832|NCT00989586|Procedure|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
46833|NCT00989586|Procedure|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
46834|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
46835|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
46836|NCT00989586|Procedure|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
50489|NCT01046032|Drug|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
50490|NCT00029328|Drug|etanercept|
50491|NCT01046045|Drug|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
50492|NCT01046058|Drug|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
50493|NCT01046071|Procedure|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
50494|NCT01046071|Procedure|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
50495|NCT01046084|Drug|Lansoprazole|30 mg Delayed-Release Capsule
50496|NCT01046084|Drug|Prevacid®|30 mg Delayed-Release Capsule
50497|NCT01046097|Biological|Synflorix™|Intramuscular administration of 1, 2, 3 doses or a booster dose according to local prescribing information
50498|NCT01046110|Drug|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
50499|NCT01046110|Drug|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
50500|NCT01046123|Radiation|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
50501|NCT00029341|Behavioral|Treatment Interruption|
50502|NCT01046136|Drug|guaifenesin (Mucinex)|bid 7 days
50503|NCT01046136|Drug|placebo|bid 7 days
50847|NCT01044069|Biological|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed & frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, & transduced with the 19-28z chimeric receptor & expanded. All relapsed (either MRD+ or morphologic) & refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo & highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
50848|NCT01044082|Procedure|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
46891|NCT00994526|Other|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
46892|NCT00994526|Other|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
46893|NCT00994539|Drug|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
46894|NCT00994552|Other|Pressure support ventilation|Pressure support ventilation
46895|NCT00994552|Other|Pressure control ventilation|Pressure control ventilation
46896|NCT00994565|Behavioral|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
47212|NCT01016197|Procedure|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
47213|NCT01016210|Drug|Leuveris|IV
47214|NCT01016210|Drug|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
47215|NCT00027001|Behavioral|Aerobic and Resistance Exercises|
47216|NCT01016223|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
47217|NCT01016223|Drug|placebo|Matched placebo swallowed two puffs twice daily
47218|NCT01016249|Drug|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
47219|NCT01016249|Drug|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
47220|NCT01016249|Drug|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
47221|NCT01016262|Drug|MAX-002|MAX-002 1 g suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase. Completers at Study Week 6 will be offered to receive, on a voluntary basis, MAX-002 1 g suppositories once daily at bedtime for 8 weeks during the open-label phase.
47222|NCT01016262|Drug|Placebo|Placebo suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase.
47223|NCT01016262|Drug|Canasa®|Canasa® 1 g suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase.
47224|NCT01016275|Device|Misago (stent placement)|Misago iliac stent
50773|NCT01046318|Drug|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
50774|NCT01046357|Drug|AZD7687|Single oral dose
50775|NCT01046357|Drug|Placebo|Single oral dose
50776|NCT01046370|Behavioral|Amygdala Retraining Program|Mind-body intervention.
50777|NCT00029380|Drug|Busulfan|
50778|NCT01046383|Dietary Supplement|IMN1207|20 grams of IMN1207 per day for 40 weeks.
50779|NCT01046383|Dietary Supplement|Casein|20 grams of Casein per day for 40 weeks
50780|NCT01046396|Drug|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
50781|NCT01039103|Drug|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
50782|NCT01039103|Drug|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
49841|NCT01006460|Drug|Panax ginseng|3 capsules twice a day
49842|NCT01006460|Drug|Placebo - dark brown sugar|3 capsules twice a day
49843|NCT00025649|Drug|etoposide|
49844|NCT01006473|Other|Exercise training|
49845|NCT01006486|Other|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
49846|NCT01006486|Other|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
49847|NCT01006499|Drug|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
49848|NCT01006525|Drug|zolpidem|placebo or zolpidem (10mg)daily for one year
49849|NCT01006538|Device|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the CNV lesion. Each device is calibrated for a set duration.
49850|NCT01006538|Drug|Ranibizumab|intravitreal injection (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
47150|NCT01018576|Other|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
47151|NCT01018589|Other|Cicatrix cream|We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.
To the patient will be explained the technique of the application.
47152|NCT01018602|Drug|vildagliptin|100 mg per day over 24 months
47153|NCT01018602|Drug|inactive pill|1 pill per day over 24 months
47154|NCT01018615|Drug|silymarin|capsules, 280 mg or 700 mg, twice daily, 12 days
47155|NCT01018615|Dietary Supplement|green tea extract (EGCG)|capsules, 196.5 mg or 982.5 mg, twice daily, 12 days
47156|NCT00027365|Drug|AS02A Adjuvant|
47157|NCT01018628|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
47158|NCT01018628|Drug|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
47159|NCT01018641|Biological|SA3Ag vaccine|In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:
Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm
In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1.
47160|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
47161|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
47162|NCT01021202|Procedure|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
47163|NCT01021215|Drug|Zileuton|1200 mg twice daily given orally (PO) for 6 days
47164|NCT00027560|Procedure|peripheral blood stem cell transplantation|
47165|NCT01021215|Drug|Celecoxib|200 mg twice daily given orally for 6 days
47166|NCT01021215|Other|laboratory biomarker analysis|Correlative studies
47167|NCT01021241|Biological|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
50849|NCT01044082|Procedure|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
50850|NCT01044095|Biological|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
50851|NCT01044095|Biological|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
50852|NCT01044108|Drug|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
50853|NCT00000899|Drug|Stavudine|
50854|NCT00029029|Procedure|pain therapy|
50855|NCT01046669|Device|TORAYMYXIN PMX-20R (PMX cartridge)|Extracorporeal hemoperfusion device Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
50856|NCT01046682|Drug|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
50857|NCT01046695|Device|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
50858|NCT01046708|Drug|micronized progesterone|600mg in 3 separate doses per day
50859|NCT01046721|Drug|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
50860|NCT01046721|Drug|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
50861|NCT01046747|Procedure|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
49920|NCT00026377|Drug|leuprolide acetate|7.5 mg once a month for 4 months
49921|NCT01013649|Drug|Erlotinib Hydrochloride|Given PO
49922|NCT01013649|Drug|Fluorouracil|Given IV
49923|NCT01013649|Drug|Gemcitabine Hydrochloride|Given IV
47225|NCT01016301|Other|Pharmacist service|Medication Review, medication report
47226|NCT00027001|Behavioral|Qigong|
47227|NCT01016314|Device|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
47228|NCT01016314|Device|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
47229|NCT01016327|Drug|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
47230|NCT01016340|Drug|MCS|MCS-5 Softgel 5 mg
47231|NCT01016366|Drug|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
47232|NCT01016366|Drug|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
47233|NCT01016379|Genetic|DNA analysis|
50377|NCT01043224|Drug|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
50378|NCT01043263|Drug|EN3324 (axomadol)|twice daily dosing
50379|NCT00000899|Drug|Filgrastim|
50380|NCT00028964|Dietary Supplement|Chinese herbs|
50381|NCT01043263|Drug|Placebo|twice daily dosing
50382|NCT01043276|Drug|Treatment A|PF-00258210 220 µg using inhaler A
50383|NCT01043276|Drug|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
50384|NCT01043276|Drug|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
50385|NCT01043276|Drug|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
50386|NCT01043276|Drug|Treatment E|PF-00258210 220 µg using inhaler B
50387|NCT01043289|Other|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
50388|NCT01043341|Behavioral|educative folder|folder about HPV infection and vaccines
50389|NCT01043354|Behavioral|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
49851|NCT01006551|Drug|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
49852|NCT01006564|Other|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
49853|NCT01006564|Other|Other|Insertion of gold seeds into prostate for image registration.
49854|NCT00025649|Drug|melphalan|
49855|NCT01006577|Procedure|side-to-end anastomosis|Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
49856|NCT01006577|Procedure|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
50142|NCT01045538|Drug|Vorinostat, capecitabine, and cisplatin|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
50143|NCT01037881|Drug|LEO 29102|comparison of different dosages of drug
50144|NCT01037881|Drug|Elidel®|comparison
50145|NCT01037894|Procedure|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
50146|NCT01037894|Procedure|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
50147|NCT01037907|Drug|Pleneva TM BGC20-0134|Placebo or 5 g dose
50148|NCT00000896|Drug|Sargramostim|
50149|NCT00028730|Drug|thiotepa|
50150|NCT01037907|Drug|Placebo|Placebo or 5 g dose
47168|NCT01021267|Drug|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
47169|NCT01021293|Biological|Poliorix™|3 doses, intramuscular administration
46214|NCT00000114|Drug|Vitamin A|
46215|NCT00000220|Drug|Buprenorphine|
46216|NCT00000877|Drug|Indinavir sulfate|
46217|NCT00024648|Drug|LErafAON|
46218|NCT00988754|Behavioral|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
46219|NCT00988767|Biological|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
46220|NCT00988780|Drug|maraviroc|Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
46221|NCT00988780|Drug|Placebo|Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
46222|NCT00988793|Procedure|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
46223|NCT00988793|Procedure|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
46224|NCT00988806|Drug|Levosimendan|Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.
Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
46225|NCT00990951|Drug|Senna alexandrina and associations|Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
1 tablet PO twice a day
46226|NCT00990964|Device|Attain Success Lead|Attain Success Lead
46227|NCT00990977|Behavioral|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
49924|NCT01013649|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
49925|NCT01013649|Other|Laboratory Biomarker Analysis|Correlative studies
49926|NCT01013649|Other|Quality-of-Life Assessment|Ancillary studies
49927|NCT01013662|Procedure|glycemic control|exogenous insulin
49928|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
49929|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
49930|NCT01013688|Procedure|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
49931|NCT00026377|Drug|SU5416|IV infusion at assigned dose
49932|NCT01013701|Drug|fluticasone furoate|nasal steroid spray
49933|NCT01013701|Other|placebo|nasal steroid vehicle without drug
49934|NCT01006590|Drug|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
49935|NCT01006603|Drug|Saxagliptin|5 mg, oral tablet, once daily
49936|NCT01006603|Drug|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
49937|NCT01006616|Drug|Navarixin|Navarixin 10 mg and 30 mg capsules
49938|NCT01006616|Drug|Placebo|Placebo to navarixin capsules
49939|NCT01006616|Drug|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
49940|NCT01006629|Biological|palivizumab|palivizumab 15 mg/kg intramuscularly
49941|NCT00025649|Drug|vincristine sulfate|
49942|NCT01006655|Drug|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
49943|NCT01006655|Drug|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
49944|NCT01006668|Drug|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
50214|NCT01045629|Other|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
50390|NCT01043354|Behavioral|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
50391|NCT00028964|Drug|cyclophosphamide|
50392|NCT01043354|Behavioral|attention placebo intervention|6 monthly counseling sessions about general health topics
50393|NCT01045902|Drug|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
50394|NCT01045915|Biological|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
50395|NCT01045928|Drug|lenalidomide|Given orally
50396|NCT01045928|Biological|rituximab|Given IV
50397|NCT01045928|Genetic|polymerase chain reaction|Correlative study
50398|NCT00029289|Drug|Lutein (10 or 30 mg/day) capsules|
50399|NCT01045928|Genetic|nucleic acid sequencing|Correlative study
50400|NCT01045928|Genetic|polymorphism analysis|Correlative study
50668|NCT01043809|Behavioral|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
50669|NCT01043809|Behavioral|expanded school-based handwashing promotion|Procter & Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
50670|NCT01046396|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
50671|NCT01046409|Other|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
50672|NCT01046422|Drug|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
50673|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
50674|NCT01046422|Drug|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
50675|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
50676|NCT01046422|Drug|Placebo|Capsule, Oral, 0mg, Daily, 28 days
50677|NCT00029380|Drug|Mycophenolate Mofetil|
50151|NCT01037920|Behavioral|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
50152|NCT01037920|Behavioral|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
50153|NCT01037933|Other|Humor intervention|A 45-minute humorous DVD ("Bananas Bunch") using a portable DVD player.
50154|NCT01037933|Other|Non-humor intervention (distraction)|A 45-minute non-humorous DVD ("The A to Z of Steam Railways") using a portable DVD player
50155|NCT01037946|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
50156|NCT01037959|Drug|Norfloxacin|400 mg/day (per os) for 6 months
50157|NCT01037959|Drug|Placebo|1 pill/day (per os) for 6 months
50158|NCT01037972|Behavioral|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
50159|NCT01037972|Behavioral|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
50160|NCT00028730|Procedure|allogeneic bone marrow transplantation|
50161|NCT01037985|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
50162|NCT01037985|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
50163|NCT01037998|Drug|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
50164|NCT01038011|Drug|drug treatment|
50422|NCT01038453|Dietary Supplement|Cholecalciferol 35 µg per day|Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.
In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.
50423|NCT01038453|Other|placebo tablet|placebo 2 tablet, once a day,
50424|NCT01038453|Dietary Supplement|Cholecalciferol (Vitamin D3) 70 µg|Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.
In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.
50425|NCT01038479|Dietary Supplement|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
50426|NCT01038479|Behavioral|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
46228|NCT00025064|Drug|ifosfamide|
46229|NCT00990990|Drug|PNU-100480|100 mg BID for 14 days
46230|NCT00990990|Drug|Placebo|to match 100 mg BID for 14 days
46231|NCT00990990|Drug|PNU-100480|300 mg BID for 14 days
46232|NCT00990990|Drug|Placebo|to match 300 mg BID for 14 days
46525|NCT00993798|Drug|Bupivacaine HCl Treatment 2c|20.0 ml
46526|NCT00993811|Device|Shang Ring circumcision|novel device for adult male circumcision
46527|NCT00993824|Drug|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
46528|NCT00993824|Drug|placebo|
46529|NCT00993837|Procedure|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
46530|NCT00025181|Biological|MART-1 antigen|
46531|NCT00993850|Behavioral|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
46532|NCT00993850|Other|Bipolar education|Psychoeducation
46533|NCT00993863|Drug|Placebo|single dose
46534|NCT00993863|Drug|ADL5859 30 mg|single dose
46535|NCT00993863|Drug|ADL5859 100 mg|single dose
46536|NCT00993863|Drug|ADL5859 200 mg|single dose
46537|NCT00993863|Drug|ibuprofen 400 mg|single dose
46538|NCT00993876|Drug|citalopram|20 to 30 mg per day for 4 weeks
46539|NCT00993876|Drug|reboxetine|4 to 8 mg per day for 4 weeks
46540|NCT00993876|Behavioral|interpersonal psychotherapy|
46541|NCT00025181|Biological|gp100 antigen|
46542|NCT00993889|Behavioral|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
50215|NCT01045642|Drug|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
50216|NCT01045655|Behavioral|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
50217|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
50218|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
50219|NCT01045681|Drug|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
50220|NCT01045694|Drug|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
50221|NCT01045694|Drug|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
50222|NCT01045694|Drug|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
50223|NCT00029250|Drug|Garlic powder standardized to allicin|
50224|NCT01045707|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
50225|NCT01045707|Drug|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
50226|NCT01045720|Drug|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
50227|NCT01038063|Drug|Artemether-lumefantrine combination|
50228|NCT00028730|Radiation|radiation therapy|
50229|NCT01038076|Behavioral|MedCHEC tablet computer and Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
50230|NCT01038089|Dietary Supplement|Resveratrol|Resveratrol
50231|NCT01038102|Other|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
50232|NCT01038102|Other|SFA diet|Diet high in saturated fat (15E%)
50233|NCT01038115|Procedure|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
50234|NCT01038128|Drug|Memantine|Drug: Memantine, 10-40 mg daily
50678|NCT01046422|Drug|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
50679|NCT01046435|Procedure|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
50680|NCT01046435|Procedure|Two placebos|Two placebos 3 times a day for 7 days
50681|NCT01046461|Drug|Ramosetron, Aprepitant, Dexamethasone|Day 1:
Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy
Day 2 - 3:
Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning
Day 4 Dexamethasone 8 mg PO. in the morning
50682|NCT01046474|Behavioral|lifestyle|Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.
Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted.
50683|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|CYCLE 1 (42 days):
Day 1 to 14 Imatinib mesylate : 400 mg/day, per os
Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os
NEXT CYCLE (28 days):
Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os
50684|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|CYCLE 1 (42 days):
Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os
Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os
NEXT CYCLE (28 days):
Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os
51030|NCT01044342|Drug|donepezil|capsule, single oral dose
51031|NCT01044342|Drug|Placebo|capsule, single oral dose
51032|NCT01044355|Device|CPAP|6 weeks treatment with fixed CPAP
51033|NCT01044355|Device|APAP|6 weeks of treatment with auto-titrating positive airway pressure
51034|NCT01044368|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
51035|NCT01044381|Drug|Luliconazole Solution, 10%|28 days of daily application
51036|NCT01044394|Drug|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
51037|NCT01044407|Device|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
51038|NCT00029133|Procedure|mild intraoperative hypothermia (33 degrees Celsius)|
50427|NCT01038492|Behavioral|p16 Methylation and Lung Cancer Education|patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details
patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing
a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits
patients are called again at three months and asked about any changes in their attitudes or smoking habits.
50428|NCT01038505|Drug|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
50429|NCT01038531|Other|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
50430|NCT00028756|Drug|doxorubicin hydrochloride|Given IV
50431|NCT01038531|Other|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
50432|NCT01038544|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
50433|NCT01038544|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
50434|NCT01038557|Biological|Red Blood Cells|
50435|NCT01038570|Drug|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
50436|NCT01038570|Drug|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
50437|NCT01038583|Drug|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
50438|NCT01038583|Drug|Placebo|100 mg enteric-coated placebo
50439|NCT01038609|Drug|Hydrocodone/Acetaminophen Extended Release|
50440|NCT01038609|Drug|Acetaminophen|
50441|NCT00028756|Drug|gemcitabine hydrochloride|Given IV
50442|NCT01040871|Drug|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
50783|NCT01039116|Behavioral|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
50784|NCT01039116|Behavioral|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
50785|NCT00028769|Drug|etoposide|
46543|NCT00993889|Behavioral|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
46544|NCT00993889|Behavioral|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
46545|NCT00993902|Procedure|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
46546|NCT00987090|Radiation|MRI|intervention at the inclusion and 18 months after
46547|NCT00987090|Procedure|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
46548|NCT00987090|Biological|Apolipoprotein E genotyping|genotyping at the inclusion
46549|NCT00987090|Biological|Study of cerebrospinal fluid|intervention at the inclusion
46837|NCT00025038|Drug|cyclophosphamide|Given IV
46838|NCT00989586|Biological|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
46839|NCT00989599|Other|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
46840|NCT00989599|Other|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
46841|NCT00989612|Biological|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
46842|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
46843|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
46844|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
46845|NCT00989651|Biological|Bevacizumab|Given IV
46846|NCT00989651|Drug|Carboplatin|Given IV
46847|NCT00989651|Drug|Cisplatin|Given IP
46848|NCT00025038|Biological|anti-thymocyte globulin|Given IV
50235|NCT01038141|Procedure|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
50504|NCT01046149|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
50505|NCT01046149|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
50506|NCT01046162|Drug|Alprazolam|Single tablet
50507|NCT01046162|Drug|Alprazolam|Single tablet
50508|NCT01046175|Procedure|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
50509|NCT01046175|Procedure|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
50510|NCT01046188|Other|Knowledge Questionnaire|Administered before and after teaching intervention
50511|NCT01046188|Other|Perceived Stress Scale|Administered before and after teaching intervention
50512|NCT01038609|Drug|Morphine Extended Release|
50513|NCT01038609|Drug|Placebo|
50514|NCT01038622|Drug|L-arginine|5-day L-arginine treatment
50515|NCT01038622|Drug|placebo|5-day placebo treatment
50516|NCT01038635|Drug|5-Azacytidine|75 mg/m^2 IV daily x 5 days on days 1 to 5.
50517|NCT01038635|Drug|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
50518|NCT01038648|Drug|Sitagliptin|100mg/day
50519|NCT01038648|Other|life style modification at base line|Advice on physical activity, diet and drug adherence.
50520|NCT01038661|Drug|Docetaxel|Formulation: concentrated solution for intravenous infusion (IV)
Route(s) of administration: 1-hour IV
50521|NCT01038661|Drug|Cisplatin|Formulation: concentrated solution for intravenous infusion (IV)
Route(s) of administration: 1-3-hour IV
50522|NCT00028756|Drug|vinblastine sulfate|Given IV
50523|NCT01038661|Other|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief—but not chemotherapy — that is considered appropriate by the investigator
50524|NCT01038674|Drug|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
51039|NCT01044420|Drug|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
51040|NCT01044433|Drug|lapatinib ditosylate|Given orally
51041|NCT01044433|Drug|capecitabine|Given orally
51042|NCT01044446|Drug|Icodextrin|one exchange daily
51043|NCT01044446|Drug|glucose-based peritoneal dialysate|original exchange frequency
51044|NCT01044459|Drug|aclidinium bromide|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
51045|NCT01044459|Drug|aclidinium bromide|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
51046|NCT01044485|Drug|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
51047|NCT01036243|Dietary Supplement|reference formula|standard infant formula
51048|NCT01036282|Behavioral|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
51049|NCT01036282|Behavioral|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
51050|NCT01036308|Dietary Supplement|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
50085|NCT01040403|Drug|olodaterol (BI 1744) low|olodaterol (BI 1744) low
50086|NCT01040403|Drug|low tiotropium bromide|low tiotropium bromide
50087|NCT01040403|Drug|olodaterol (BI 1744) high|olodaterol (BI 1744) high
50088|NCT00028834|Biological|bevacizumab|Given IV
50089|NCT01040403|Drug|medium tiotropium bromide|medium tiotropium bromide
50090|NCT01040403|Drug|high tiotropium bromide|high tiotropium bromide
50091|NCT01040403|Drug|Placebo|Placebo
50092|NCT01040403|Device|Respimat|Respimat inhaler
50093|NCT01040429|Drug|Clonidine|Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients < 35 kg; 50 microgram (2 capsula) x 2/day for patients > 35 kg.
Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients < 35 kg; 25 microgram (2 capsula) x 2/day for patients > 35 kg.
50786|NCT01039129|Procedure|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
50787|NCT01039129|Procedure|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
50788|NCT01039129|Procedure|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
50789|NCT01039142|Drug|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
50790|NCT01039155|Drug|Azacitidine|Given IV
50791|NCT01039155|Other|Laboratory Biomarker Analysis|Correlative studies
50792|NCT01039155|Drug|Oxaliplatin|Given IV
50793|NCT01039155|Other|Pharmacological Study|Correlative studies
50794|NCT01039168|Behavioral|Workplace dialogue|
50795|NCT01039168|Other|Care as usual|
50796|NCT00028769|Drug|flutamide|
50797|NCT01039181|Drug|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
50798|NCT01039194|Drug|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
50799|NCT01039194|Drug|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
50800|NCT01039194|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
50801|NCT01039207|Other|Laboratory Biomarker Analysis|Correlative studies
50802|NCT01039207|Biological|Rilotumumab|Given IV
50803|NCT01039220|Biological|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
49857|NCT01006590|Drug|Saxagliptin|5 mg, oral tablet, once daily
49858|NCT01008774|Device|Paxman Cooling Machine|Scalp cooling procedures
46849|NCT00989651|Other|Laboratory Biomarker Analysis|Correlative studies
46850|NCT00989651|Drug|Paclitaxel|Given IV or IP
46851|NCT00991991|Genetic|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
46852|NCT00991991|Genetic|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
46853|NCT00991991|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
47170|NCT01021293|Biological|Oral Poliovirus vaccine|3 doses, oral administration
47171|NCT01021306|Device|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
47172|NCT01021306|Device|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
47173|NCT01021306|Other|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
47174|NCT01021306|Other|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
47175|NCT00000892|Drug|Ritonavir|
47176|NCT00027573|Biological|filgrastim|
47177|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
50525|NCT01038674|Drug|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
50526|NCT01038687|Drug|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
50527|NCT01038687|Drug|placebo|placebo
50862|NCT00029393|Drug|Immunosuppression|
50863|NCT01046760|Behavioral|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
50864|NCT01046773|Drug|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
50865|NCT01046773|Drug|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
50866|NCT01046786|Biological|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
50867|NCT01046786|Drug|Methylprednisolone|30 mg/kg methylprednisolone
50868|NCT01046786|Drug|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
50869|NCT01046799|Drug|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
50870|NCT01046812|Drug|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
50871|NCT01046825|Drug|COPAD|Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF
50872|NCT01046825|Drug|COP, COPD M3, CYM|GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab
50873|NCT00029458|Drug|Clozapine|
50874|NCT01039246|Procedure|Electrohydraulic lithotripsy|Fragmentation of biliary stones using elctrohydraulic lithotripsy
50875|NCT01039246|Procedure|Laser Lithotripsy|Fragmentation of biliary stones using laser lithotripsy
50876|NCT00028769|Drug|goserelin|
50877|NCT01039259|Device|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
50094|NCT01040429|Drug|Lactose capsula|Day 1-56 (week 1-8): 1 capsula x 2/day for patients < 35 kg; 2 capsula x 2/day for patients > 35 kg.
Day 57-63 (week 9): 1 capsula x 1/day for patients < 35 kg; 1 capsula x 2/day for patients > 35 kg
50095|NCT01040442|Other|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
50096|NCT01040455|Drug|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
50097|NCT01040455|Drug|placebo|placebo once daily for eight weeks
50098|NCT01040468|Procedure|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
50099|NCT00028834|Other|laboratory biomarker analysis|Correlative studies
50100|NCT01040468|Procedure|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
50101|NCT01042704|Drug|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
50102|NCT01042704|Other|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
50103|NCT01042704|Other|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
50685|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|CYCLE 1 (42 days):
Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os
Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os
NEXT CYCLE (28 days):
Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os
50686|NCT01046487|Procedure|Blood sampling|ONLY FOR CYCLE 1, at day 15 and day 28 :
11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)
50687|NCT01046500|Dietary Supplement|myo-inositol|2 grams twice a day
50688|NCT00000901|Drug|Lamivudine|
50689|NCT00029380|Drug|Cyclosporine|
50690|NCT01046500|Drug|Metformin|pill, 250 mg, twice a day
49859|NCT01008774|Device|Cold Caps|Scalp cooling procedures
49860|NCT01008787|Behavioral|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
49861|NCT01008787|Behavioral|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
49862|NCT01008787|Behavioral|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
49863|NCT01008787|Behavioral|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
49864|NCT01008800|Behavioral|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey & Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
49865|NCT01008800|Behavioral|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy & Grusec, 2001).
49866|NCT01008813|Biological|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (3,8 microgram) adjuvanted with AS 03A
49867|NCT00026078|Drug|ifosfamide|
49868|NCT01008813|Biological|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (15 microgram)
49869|NCT01008826|Dietary Supplement|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
49870|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
49871|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
49872|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
49873|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
49874|NCT01008852|Drug|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
49875|NCT01008865|Procedure|Studer Pouch orthotopic urinary diversion|
47178|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
47179|NCT01021358|Drug|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
47180|NCT01021358|Drug|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
47181|NCT01024075|Drug|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
47182|NCT01024075|Drug|Saline|8cc of Saline mixed with Sinufoam
47183|NCT01024101|Drug|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
47184|NCT01024127|Other|Laboratory Biomarker Analysis|Correlative studies
47185|NCT01024140|Drug|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
47186|NCT01024153|Behavioral|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
46233|NCT00990990|Drug|PNU-100480|600 mg BID for 14 days
46234|NCT00990990|Drug|Placebo|to match 600 mg BID for 14 days
46235|NCT00990990|Drug|PNU-100480|1200 mg QD for 14 days
46236|NCT00990990|Drug|Placebo|to match 1200 mg QD for 14 days
46237|NCT00990990|Drug|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
46238|NCT00990990|Drug|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
46239|NCT00025064|Drug|melphalan|
46240|NCT00990990|Drug|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
46241|NCT00990990|Drug|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
46242|NCT00990990|Drug|Linezolid|300 mg QD for 4 days (open label)
50878|NCT01039285|Drug|Curosurf|2.5 ml/kg instilled in the trachea
50879|NCT01039285|Other|Air|2.5ml/kg of Air will be instilled in the trachea
50880|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
50881|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
50882|NCT01039311|Device|Optical Coherence Tomography|Obtain OCT images.
49945|NCT01006668|Drug|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
49946|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate
Intra muscular
49947|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate
Intramuscular injection
49948|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
49949|NCT01006694|Other|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
49950|NCT01006694|Drug|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
49951|NCT01006707|Drug|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
49952|NCT00025649|Procedure|autologous bone marrow transplantation|
49953|NCT01006720|Drug|Sugammadex|Single intravenous injection of either:
Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)
49954|NCT01006720|Drug|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
49955|NCT01006720|Drug|Saline|Saline 0.9% (Saline)
49956|NCT01006733|Genetic|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
49957|NCT01006733|Drug|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
50691|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe
Pre-incision: SLN is not identified (No localization)
Inject blue dye into breast (nothing in arm)
i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)
50692|NCT01038921|Drug|Melatonin|8 mg dose of Melatonin
50693|NCT01038921|Drug|Placebo|Placebo
50694|NCT00028769|Drug|bicalutamide|
50695|NCT01038934|Procedure|samples collected by buccal cytobrush|
50696|NCT01038947|Biological|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
50697|NCT01038960|Behavioral|Exercise training|3 months supervised interval training
50698|NCT01038986|Biological|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
50699|NCT01038999|Biological|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
50700|NCT01039012|Other|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
50701|NCT01039012|Other|Standard Care|Participant follow the standard care recommended by their physician.
50702|NCT01039025|Drug|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m^2 intravenously given over 30 minutes on Days 1 - 5.
50703|NCT01039025|Drug|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m^2/day intravenously given over 2 hours on Days 1 - 3.
50725|NCT01041508|Other|Stem Cell Infusion|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
50726|NCT01041508|Drug|Cyclosporins|Cyclosporin (CSP) should be started on day -1 after completion of Clofarabine. CSP levels should be maintained between 300-400 ng/ml.
Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs). Age > 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)
50727|NCT01041508|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) will be at 15 mg/kg, based on adjusted body weight, every 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant.
50728|NCT01041521|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
50165|NCT01038024|Dietary Supplement|1 tablet composed of antioxidants and minerals|1 tablet daily
50166|NCT01038037|Drug|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
50167|NCT01038037|Drug|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
50168|NCT01038037|Drug|panitumumab|i.v. day 1: 9 mg/kg q3w
50169|NCT01038050|Drug|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
50170|NCT01040468|Behavioral|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
50171|NCT01040494|Drug|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
50172|NCT01040494|Drug|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
50173|NCT01040546|Behavioral|Individualized education|We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into "individualized health education group", "group weight control education" and "mail-delivered health education group".Obese subjects who were randomly allocated into "individualized health education group" received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months.
50174|NCT01040546|Behavioral|Grouped education|We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into "individualized health education group", "group weight control education" and "mail-delivered health education group".Obese subjects who were randomly allocated into "grouped health education group" attended 12 sessions of group intervention over 6 months.
50175|NCT01040559|Drug|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
50176|NCT01040585|Drug|Linezolid|Treatment for VAP as indication approved and as physician criterium.
50177|NCT01040598|Biological|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
50178|NCT01040611|Behavioral|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
46243|NCT00991003|Procedure|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
46244|NCT00991003|Procedure|Conventional Colonoscopy|
46245|NCT00991016|Drug|PF-04805712|ascending single and multiple doses starting at 30 mg
46246|NCT00991029|Drug|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
46247|NCT00991029|Drug|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
46248|NCT00991042|Other|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
46249|NCT00993317|Drug|Methotrexate|Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.
The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly.
46250|NCT00993343|Drug|Sirolimus/tacrolimus|Standard GVHD prophylaxis
46251|NCT00993343|Drug|cyclosporine/methotrexate|Standard GVHD prophylaxis
46252|NCT00993356|Drug|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
46550|NCT00024388|Drug|DHA-paclitaxel|
46551|NCT00987103|Drug|Tacrolimus|Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
46552|NCT00987116|Drug|Prednisone - Azathioprine|Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.
Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days.
46553|NCT00987142|Drug|CX501|Cultured chimeric skin
46554|NCT00987142|Device|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
46555|NCT00987155|Device|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
49958|NCT01008904|Other|questionnaire administration|Ancillary studies
49959|NCT01008904|Procedure|quality-of-life assessment|Ancillary studies
49960|NCT01008917|Drug|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
49961|NCT01008930|Procedure|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
49962|NCT01008943|Biological|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
49963|NCT01008956|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
50236|NCT01038154|Drug|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
50237|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
50238|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
50239|NCT00028743|Drug|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
50240|NCT01038167|Drug|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
50241|NCT01038167|Drug|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
50242|NCT01038167|Drug|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
50243|NCT01038167|Drug|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
50244|NCT01038193|Other|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
50245|NCT01038206|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
50246|NCT01038258|Procedure|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
50247|NCT01038271|Other|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
50248|NCT01038271|Other|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
50729|NCT00028886|Drug|cyclophosphamide|
50730|NCT01041534|Other|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
50731|NCT01041573|Biological|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
50732|NCT01041573|Biological|Havrix®720|0.5 ml im. at day 0 and month 7
50733|NCT01041573|Biological|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
50734|NCT01041586|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
50735|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
50736|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
50737|NCT01043835|Procedure|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
50738|NCT01043835|Procedure|Open gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
50739|NCT01043848|Procedure|external electric pudendal nerve stimulation|intervention timing: twice daily for 20 minutes during 3 consecutive months.
intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).
intervention device: contic+
stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable).
50740|NCT01043874|Drug|Nilotinib|400 mg BID
50741|NCT01043887|Drug|ridaforolimus|single oral dose administration 10 mg ridaforolimus
51051|NCT01036308|Dietary Supplement|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
51052|NCT01036321|Drug|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
51053|NCT01036321|Drug|Methyl cellulose blend|Placebo - Take 2 capsules daily
51054|NCT00028691|Radiation|radiation therapy|
50179|NCT00028847|Drug|cytarabine|
50443|NCT01040871|Drug|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
50444|NCT01040884|Other|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
50445|NCT01040897|Behavioral|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
50446|NCT01040897|Behavioral|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
50447|NCT01040910|Drug|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
50448|NCT01040910|Drug|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
50449|NCT01040923|Device|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
50450|NCT00028860|Drug|paclitaxel|
50451|NCT01040936|Drug|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
50452|NCT01040936|Drug|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
50453|NCT01040949|Behavioral|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
50454|NCT01040949|Behavioral|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
50455|NCT01040975|Behavioral|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
50456|NCT01041001|Biological|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
50457|NCT01041001|Procedure|Microfracture treatment|
50458|NCT01041014|Behavioral|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
50459|NCT01041027|Drug|Paclitaxel|Given IV
46556|NCT00987168|Drug|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
46557|NCT00987207|Drug|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
46558|NCT00987207|Other|No injection|No cyclosporine A is administered before aortic cross-declamping.
46559|NCT00987220|Drug|Placebo|Oral
46560|NCT00987220|Drug|donepezil (Aricept)|5mg oral
46561|NCT00024401|Drug|DHA-paclitaxel|
46562|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
46563|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
46564|NCT00987233|Drug|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
46565|NCT00987246|Drug|Placebo Gel|Topical
46566|NCT00987246|Drug|LAS41005|Topical
46567|NCT00987246|Drug|LAS106521|Topical
46568|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
46569|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
46854|NCT00991991|Other|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
46855|NCT00992004|Dietary Supplement|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
46856|NCT00992017|Biological|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
46857|NCT00992030|Drug|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
50249|NCT01038284|Behavioral|Patient education|Pharmaceutical care of patients with PAH
50250|NCT00028743|Drug|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
50251|NCT01038284|Other|Data collection|Clinical and biological data, treatment, medication errors and ADEs
50252|NCT01040637|Drug|TD-1211|Ascending doses
50253|NCT01040637|Drug|TD-1211|Ascending doses
50254|NCT00028847|Drug|imatinib mesylate|
50255|NCT01040637|Drug|TD-1211|Ascending doses
50256|NCT01040637|Drug|Placebo|Ascending doses
50257|NCT01040663|Other|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
50528|NCT01038713|Device|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
50529|NCT01038726|Other|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
50530|NCT01038726|Other|Cognitive Training|Based on cognitive training program Brain Fitness®
50531|NCT01038726|Other|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
50532|NCT01038726|Other|Educational Sessions|DVD-based educational programs on history, art, and literature
50533|NCT00000897|Drug|Zidovudine|
50534|NCT00028756|Drug|methotrexate|Given IV
50535|NCT01038739|Drug|Mesalazine|3 g per day
50536|NCT01038739|Drug|Mesalazine|1.5 g per day
50537|NCT01038739|Drug|Placebo|0 g per day
50538|NCT01038752|Drug|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
50539|NCT01041040|Drug|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
50540|NCT01041066|Drug|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
51055|NCT01036360|Other|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
51056|NCT01036399|Drug|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
51057|NCT01036412|Drug|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
51058|NCT01036412|Behavioral|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
51059|NCT01036438|Device|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
51060|NCT01036438|Device|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
51061|NCT01036490|Other|Structured Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
51062|NCT01036529|Device|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
51063|NCT01036529|Procedure|Back Surgery|Different types of back surgery may be performed
51064|NCT01036594|Drug|Ketoconazole, hydrocortisone|Ketoconazole 400mg po tid Hydrocortisone 20mg po qam and 10mg po qpm
51065|NCT00028704|Procedure|conventional surgery|
51066|NCT01036594|Drug|Ketoconazole, dexamethasone|Ketoconazole 400md po tid Dexamethasone 1mg po bid
51067|NCT01036633|Device|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
51068|NCT01039610|Drug|GSK945237|Dose detailed in Arm description
51069|NCT01039610|Drug|Placebo|matching placebo tablet
51070|NCT01039610|Drug|Linezolid|600 mg BID, 14 Days
50104|NCT01042704|Other|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
50105|NCT00028938|Biological|epoetin alfa|
46719|NCT00987415|Drug|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
46720|NCT00987415|Drug|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
46721|NCT00987428|Procedure|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
46722|NCT00987428|Procedure|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
46723|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
46724|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
46725|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
46726|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
46727|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
46728|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
46729|NCT00024427|Drug|triacetyluridine|6 grams (12 tablets)
46730|NCT00987454|Drug|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
46731|NCT00987454|Drug|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
46732|NCT00987467|Drug|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
46733|NCT00987467|Drug|Cyclosporin 0.05% ophthalmic|ophthalmic topical eye drop
46734|NCT00987480|Drug|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
46735|NCT00987480|Device|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
46736|NCT00987493|Biological|rituximab|day 1 at a fixed dose of 375mg/m2
46189|NCT00025272|Drug|etoposide|
46190|NCT00996008|Drug|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
46191|NCT00996021|Drug|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
46192|NCT00996021|Drug|Placebo Suspension|Placebo is a liquid with no drug in it.
46193|NCT00996021|Drug|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
46194|NCT00996034|Biological|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
46195|NCT00996034|Radiation|[123I]5-IA-85380|up to 10 mCi of [123I]5-IA-85380, I.V. on each of two SPECT Scan days
46196|NCT00996034|Drug|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
46197|NCT00996047|Genetic|cytogenetic analysis|
46198|NCT00996047|Genetic|fluorescence in situ hybridization|
46491|NCT00989170|Behavioral|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
46492|NCT00989183|Other|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
46493|NCT00989196|Biological|Human-cl rhFVIII|50 IU/kg for PK dose
46494|NCT00025025|Other|sample testing|
46495|NCT00989196|Biological|Kogenate FS|50 IU/kg for PK dose
46496|NCT00989209|Drug|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
46497|NCT00989209|Procedure|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
46498|NCT00989222|Procedure|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
46499|NCT00991341|Biological|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored >=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
47242|NCT01018641|Biological|SA3Ag with no booster in stage 2|In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:
Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm
In stage 2 the subject will receive no vaccine.
47243|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
47244|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
47245|NCT01018641|Procedure|Placebo with no booster in stage 2|In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.
In stage 2 the subject will receive no vaccine.
47246|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
47247|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
47248|NCT01018654|Behavioral|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
47249|NCT01018654|Behavioral|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
47250|NCT01018680|Drug|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
47251|NCT00027378|Drug|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
47252|NCT01018680|Drug|Placebo|Taken by mouth, once daily for 10 weeks
47253|NCT01018693|Drug|VAK694; Alutard Avanz SQ|
46275|NCT00995501|Drug|dexamethasone|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
46276|NCT00995501|Drug|glucose|The target range for blood glucose will be 80-110 mg/dl or Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
46277|NCT00995501|Device|BIS monitor|BIS of 55 (lighter anesthesia group)or to a target BIS of 35 (deeper anesthesia group)
46278|NCT00025259|Drug|doxorubicin hydrochloride|Given IV
46279|NCT00995540|Drug|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
46280|NCT00995540|Drug|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
46281|NCT00995540|Drug|Placebo|Placebo tid subcutaneous injection for 12 weeks
46956|NCT00992264|Behavioral|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
46957|NCT00992264|Behavioral|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
46958|NCT00992264|Behavioral|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
46959|NCT00992277|Procedure|Ablation and skin resurfacing|
46960|NCT00994578|Behavioral|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
46961|NCT00994578|Behavioral|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
46962|NCT00994578|Behavioral|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
46963|NCT00025220|Drug|Thalidomide|Given PO
46964|NCT00994591|Drug|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
46965|NCT00994604|Drug|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
46966|NCT00994617|Drug|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
46967|NCT00994617|Drug|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
46968|NCT00994643|Biological|Rituximab|Given IV
46969|NCT00994643|Biological|Interleukin-2|Given SC
46970|NCT00994656|Device|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
46021|NCT00988559|Biological|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
46022|NCT00988559|Procedure|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
46737|NCT00987493|Drug|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
46738|NCT00987493|Drug|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
47039|NCT00992303|Other|biologic sample preservation procedure|
47040|NCT00992303|Other|medical chart review|
47041|NCT00992303|Other|questionnaire administration|
47042|NCT00992316|Drug|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
47043|NCT00992329|Drug|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
47044|NCT00992342|Drug|PF-03893787|oral solution, 5 mg, QD for 14 days
47045|NCT00992342|Drug|PF-03893787|oral solution, 15 mg, QD for 14 days
47046|NCT00992342|Drug|PF-03893787|oral solution, 50 mg, QD for 14 days
47047|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1%|
47048|NCT00000879|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
47049|NCT00025090|Radiation|radiation therapy|
47050|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
47051|NCT00992368|Procedure|reduction mammaplasty|patients submitted to reduction mammaplasty
47052|NCT00992381|Drug|PN400|500mg Naproxen and 20mg esomeprazole
47053|NCT00992381|Drug|Naprosyn|500mg Naproxen
47054|NCT00992394|Drug|etanercept|etanercept 50 mg once weekly as requested.
47055|NCT00992394|Drug|etanercept|etanercept 25 mg or 50 mg as requested.
47056|NCT00992407|Drug|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
47057|NCT00992407|Drug|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
46500|NCT00991354|Biological|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
46501|NCT00991354|Biological|IL-12 DNA plasmids|Adjuvant for HIV vaccines
46502|NCT00025064|Procedure|peripheral blood stem cell transplantation|
46503|NCT00991367|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
46504|NCT00991367|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
46505|NCT00991380|Behavioral|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
46506|NCT00991380|Behavioral|Usual Care|Control
46797|NCT00994344|Drug|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
46798|NCT00994344|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
46799|NCT00994357|Device|Real-time CGM|See previous description.
46800|NCT00994357|Other|Standard care|See text.
46801|NCT00000880|Drug|Cyclosporine|
46802|NCT00025194|Drug|ixabepilone|
46803|NCT00994383|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
46804|NCT00994396|Dietary Supplement|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
46805|NCT00994396|Dietary Supplement|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
46806|NCT00994422|Drug|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
46807|NCT00994422|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
46282|NCT00995553|Behavioral|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
46283|NCT00995553|Behavioral|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
46284|NCT00995566|Drug|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
46285|NCT00995592|Behavioral|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
46286|NCT00995605|Drug|AMAP102|AMAP102 or Placebo
46287|NCT00995618|Drug|Tranilast|Tranilast tablets, 300 mg, QD
46288|NCT00995618|Drug|Febuxostat|Febuxostat Tablets, 40 mg, QD
46289|NCT00025259|Drug|etoposide|Given IV
46290|NCT00995618|Drug|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
46291|NCT00995631|Procedure|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
46292|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
46293|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
46294|NCT00995670|Drug|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
46590|NCT00989352|Drug|Rituximab|375 mg/m² i.v., max. 10 times
46591|NCT00989365|Other|Aerobic training|Treadmill training
46592|NCT00989378|Behavioral|baseline study|normal bedtimes
46593|NCT00991458|Drug|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
46594|NCT00991471|Behavioral|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
46595|NCT00991471|Behavioral|No MDRNSTAT|Standard management of nurse-only triage for assignment of CTAS
46023|NCT00988559|Drug|imiquimod|imiquimod applied to the cervix by the physician
46024|NCT00988572|Other|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
46025|NCT00988585|Dietary Supplement|EPA 600|EPA 600 mg/day for 6 weeks
46026|NCT00988585|Dietary Supplement|EPA 1800|1800 mg/day for 6 weeks
46027|NCT00988585|Dietary Supplement|Olive Oil|600 mg/day for 6 weeks
46028|NCT00990691|Drug|Administration of a high dose of desipramine|Administration of a daily dose of desipramine correlated with the patient's weight :
From 15 to 25 kg : 50 mg ;
From 26 to 35 kg : 75 mg ;
From 36 to 45 kg : 100 mg ;
> 46 kg : 150 mg.
46029|NCT00990691|Drug|Administration of a low dose of desipramine|Administration of a daily dose of desipramine correlated with the patient's weight :
From 15 to 25 kg : 25 mg ;
From 26 to 35 kg : 50 mg ;
From 36 to 45 kg : 75 mg ;
> 46 kg : 100 mg.
46030|NCT00990691|Drug|Administration of a placebo|Administration of a daily dose of placebo
46031|NCT00990704|Drug|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
46032|NCT00990704|Drug|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
46033|NCT00990717|Biological|NK-92 cells|Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:
Level I: 1x10^9 cells/m^2
Level II: 3x10^9 cells/m^2
Level III: 5x10^9 cells/m^2
46034|NCT00990743|Drug|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
46035|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
46036|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
46037|NCT00025064|Drug|cisplatin|
46038|NCT00990769|Other|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
46039|NCT00990782|Device|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
46354|NCT00993551|Procedure|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
47058|NCT00992433|Biological|Inactivated Influenza H1N1 vaccine|Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
47059|NCT00992446|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
47060|NCT00025103|Biological|dactinomycin|
47061|NCT00992446|Drug|Bortezomib|Given IV
47062|NCT00992446|Drug|Carmustine|Given IV
46107|NCT00988598|Drug|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
46108|NCT00988611|Other|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
46109|NCT00988624|Drug|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
46110|NCT00988624|Drug|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
46111|NCT00988624|Drug|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
46112|NCT00988624|Drug|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
46113|NCT00988624|Drug|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
46114|NCT00988637|Drug|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
46115|NCT00988637|Drug|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
46116|NCT00988650|Other|isocaloric diet|
46117|NCT00024570|Procedure|targeted fusion protein therapy|
46118|NCT00988650|Other|free living conditions|
46119|NCT00988663|Drug|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
46120|NCT00988663|Drug|Placebo|will give placebo that looks like memantine
46121|NCT00988689|Other|Dietary Intervention|soup with or without starch
48439|NCT01015781|Procedure|Progressive Tinnitus Management|The program follows a five-level "progressive intervention" model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support
48440|NCT01015781|Procedure|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
48441|NCT01015794|Drug|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
48442|NCT01015794|Drug|ephedrine hydrochloride|single dose of 1 mg/kg body weight
48443|NCT00026897|Procedure|Low-risk biopsy|
48444|NCT01015807|Drug|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
48445|NCT01015807|Drug|Clonidine Placebo|2 x 1mL 0.9% NaCl
48446|NCT01015807|Drug|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
48447|NCT01015807|Drug|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
48448|NCT01015820|Procedure|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
47480|NCT01024686|Biological|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
47481|NCT01024686|Biological|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
47482|NCT01024712|Drug|carboplatin|
47483|NCT01024712|Drug|gefitinib|
47484|NCT01024712|Drug|paclitaxel|
47485|NCT01024712|Procedure|quality-of-life assessment|
47486|NCT01024725|Other|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
47487|NCT01024738|Drug|Fluoride|Brush half mouth twice daily for four days.
47488|NCT01024738|Drug|Triclosan, fluoride|Brush twice daily
47489|NCT01024738|Drug|Chlorhexidine Gluconate|Rinse mouth twice a day
47490|NCT00027820|Radiation|Total-Body Irradiation|Undergo TBI
46596|NCT00991497|Device|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
46597|NCT00991510|Drug|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
46598|NCT00991510|Drug|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
46599|NCT00991523|Dietary Supplement|protein|protein
46600|NCT00991523|Dietary Supplement|placebo|placebo control
46601|NCT00000878|Drug|Zidovudine|
46602|NCT00025077|Biological|filgrastim|
46603|NCT00991549|Behavioral|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
46604|NCT00991562|Drug|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
46605|NCT00991588|Procedure|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
46606|NCT00991601|Procedure|FNAC (fine needle aspiration cytology)|UL guided biopsy
46607|NCT00991614|Device|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
46608|NCT00991627|Drug|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
46609|NCT00991627|Drug|Morphine|200 µg of a 100 µg/ml solution, intrathecally
46610|NCT00991627|Drug|Lactated Ringer's solution|25 ml/min intravenously
46897|NCT00987688|Other|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C 3 days. Rewarming will occur at a rate of 0.17C/hr and will be titrated to intracranial pressure (ICP) control.
46898|NCT00987688|Other|Normothermia|Standard management. Patients will be kept at normothermia (37C). If they develop a fever >38C they will be treated with paracetamol and surface temperature control equipment will be applied to maintain normothermia. Cooling to 35C is an option for refractory ICP.
46355|NCT00993577|Other|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
46356|NCT00025155|Drug|ixabepilone|Given IV
46357|NCT00993577|Device|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
46358|NCT00993577|Device|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
46359|NCT00993590|Behavioral|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
46360|NCT00993603|Behavioral|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
46361|NCT00993616|Drug|belinostat|Given IV
46362|NCT00993616|Drug|carboplatin|Given IV
46363|NCT00995839|Drug|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
46364|NCT00995852|Device|IBV Implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of "new" air during inspiration
46365|NCT00995852|Device|IBV Implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of "new" air during inspiration
46366|NCT00995865|Biological|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10^8 VE/0.5mL and Mid dose = 2.2 x 10^7 VE/0.5mL
46367|NCT00995865|Biological|Placebo|NaCl Injectable 0.9%
46122|NCT00988702|Behavioral|Dan Tian Breathing|Dan Tian Breathing for one month
46123|NCT00988702|Behavioral|Progressive muscle training|Progressive muscle training for one month
46124|NCT00988715|Biological|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
46125|NCT00988715|Drug|Cyclosporine|Given IV
46126|NCT00988715|Drug|Mycophenolate Mofetil|Given PO
46127|NCT00988715|Radiation|Total-Body Irradiation|Undergo total-body irradiation
46128|NCT00024570|Procedure|surgery|
46427|NCT00993629|Drug|pregnenolone|Administered adjunctively to "treatment as usual"
46428|NCT00993629|Drug|placebo|adjunctive placebo
46429|NCT00993642|Drug|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
46430|NCT00993655|Drug|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
46431|NCT00000879|Biological|ALVAC-HIV MN120TMG (vCP205)|
46432|NCT00025168|Drug|gemcitabine hydrochloride|
46433|NCT00993655|Drug|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
46434|NCT00993655|Drug|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
46435|NCT00993655|Procedure|quality-of-life assessment|day 1 cycle 2, day 1 cycle 3 and at 3, 6, 12 mo then annually until disease progression, death or initiation of second-line therapy
46436|NCT00993668|Other|Placebo|Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
46437|NCT00993668|Biological|Certolizumab pegol|Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
46438|NCT00993681|Biological|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
46439|NCT00993681|Biological|TD Vaccine System|placebo
46440|NCT00993694|Drug|chemotherapy|
47491|NCT01024751|Device|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
47492|NCT01024751|Device|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
47493|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
47494|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
47495|NCT01024790|Behavioral|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
47496|NCT01024803|Device|Device name: "Retina Implant model Alpha". Surgical implantation of medical device into eye|Surgical implantation of medical device named "Retina Implant" into eye to restore vision partially.
Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL.
47497|NCT00000891|Drug|Saquinavir|
47498|NCT00027040|Drug|Selegiline hydrochloride|
47499|NCT01016730|Other|Questionnaire Administration|Ancillary studies
47500|NCT01016743|Device|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
47779|NCT01017302|Drug|RO5095932|Single subcutenaous dose in week 5
47780|NCT01017315|Drug|Baby talcum|50 grams apply locally prior cast application
47781|NCT01017341|Device|PSU hip protector|hip protetor
47782|NCT00027079|Drug|naltrexone (ReVia)|
47783|NCT01017354|Drug|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
47784|NCT01017354|Dietary Supplement|ViDe3 (CH)|60000 vitamin D3 orally and once per month
47785|NCT01017354|Dietary Supplement|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
47786|NCT01017367|Drug|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
47787|NCT01017367|Drug|Placebo|Placebo
47788|NCT01017380|Drug|Celecoxib|celecoxib 400 mg 1 cap before surgery
46899|NCT00987701|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
46900|NCT00987701|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
46901|NCT00987714|Procedure|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
46902|NCT00987727|Drug|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
46903|NCT00987727|Drug|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
46904|NCT00987753|Drug|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
46905|NCT00987766|Drug|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
46906|NCT00024440|Drug|fludarabine phosphate|
46907|NCT00987766|Drug|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
46908|NCT00987766|Drug|oxaliplatin|Given through a vein in the arm 1 time every other week.
46909|NCT00987766|Other|laboratory biomarker analysis|Blood and tissue collection.
46910|NCT00987779|Drug|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
46911|NCT00987779|Drug|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
46912|NCT00987792|Drug|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
46913|NCT00987805|Dietary Supplement|Banhasasim-tang|Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
47254|NCT01018693|Drug|VAK694 placebo infusion; Alutard Avanz SQ|
47255|NCT01018693|Drug|VAK694 placebo infusion; Saline|
46668|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
46669|NCT00989391|Drug|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
46670|NCT00000877|Drug|Rifabutin|
46671|NCT00025038|Drug|fludarabine phosphate|Given IV
46672|NCT00989391|Drug|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
46673|NCT00989404|Drug|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
46674|NCT00989404|Drug|Zanamivir|Rotahaler placebo 10mg BID 5 days
46675|NCT00989404|Drug|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
46676|NCT00989417|Other|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
46677|NCT00989430|Behavioral|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
46678|NCT00989443|Drug|Cidofovir gel|topical gel applied once a week for 3 weeks
46679|NCT00991666|Procedure|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
46680|NCT00991692|Other|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
46681|NCT00991705|Drug|Atorvastatin|
46682|NCT00991705|Drug|Fimasartan|
46683|NCT00991718|Drug|GDC-0449|oral dosage administration, intravenous dosage administration
46441|NCT00993694|Drug|dapsone|
46442|NCT00993694|Other|medical chart review|
46443|NCT00025168|Drug|irinotecan hydrochloride|
46444|NCT00993694|Procedure|assessment of therapy complications|
46445|NCT00993707|Drug|CTX-100 (formerly ETX-100) (hyaluronic acid)|3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.
Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort.
46446|NCT00993720|Drug|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
46447|NCT00993720|Drug|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
46739|NCT00987506|Device|XIENCE V®|Participants with placement of a XIENCE V® EESS
46740|NCT00024440|Biological|filgrastim|
46741|NCT00989456|Behavioral|Self management education programme|The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.
After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh.
46742|NCT00989456|Behavioral|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
46743|NCT00989469|Drug|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
46744|NCT00025038|Drug|cytarabine|Given IV
46745|NCT00989482|Behavioral|Computer kiosk Education|computerized patient education; guidelines for physicians
46746|NCT00989495|Device|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
46747|NCT00989508|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
46748|NCT00989508|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
47789|NCT01017380|Drug|etoricoxib|120 mg 1 tab before surgery
47790|NCT01017393|Drug|Ketamine|
47791|NCT01017393|Drug|ketamine free|
47792|NCT01017406|Device|PSU heel cushion and plantar fascia specific stretching exercise|Wear heel cushion during daily activity
Plantar fascia stretching exercise 3 times per day
47793|NCT00027079|Behavioral|Cognitive Behavioral Therapy|
47794|NCT01017419|Behavioral|Counseling|Informational Counseling provided after hearing aid fitting
47795|NCT01017445|Other|Boonme stick exercise|individual exercise daily
47796|NCT01017458|Drug|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
47797|NCT01017458|Drug|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
47798|NCT01019538|Other|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
47799|NCT00000891|Drug|Zidovudine|
47800|NCT00027495|Dietary Supplement|curcumin|
47801|NCT01019551|Drug|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
47802|NCT01019551|Biological|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
48065|NCT01017887|Device|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
48066|NCT01017887|Device|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
48067|NCT01017900|Procedure|local excision|surgical excision by orthopaedic surgeon under local anesthesia
48068|NCT00027261|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
48069|NCT01017913|Other|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
48070|NCT01017913|Other|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
47256|NCT01018719|Device|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
47257|NCT01018732|Biological|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
47258|NCT01021371|Behavioral|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
47259|NCT01021384|Behavioral|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
47260|NCT01021397|Drug|rHPIV3cp45|10^5 TCID50 nasal drops
47261|NCT01021397|Drug|rHPIV3cp45 placebo|1X-L15 nasal drops
47262|NCT01021423|Drug|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
47263|NCT01021423|Other|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
47264|NCT00027573|Biological|therapeutic allogeneic lymphocytes|
47265|NCT01021436|Drug|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
47266|NCT01021462|Procedure|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
47267|NCT01021475|Procedure|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
47268|NCT01021475|Drug|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
47269|NCT01021488|Drug|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
47270|NCT01021488|Drug|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
47271|NCT01021501|Drug|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
46684|NCT00991718|Drug|GDC-0449|oral dosage administration
46971|NCT00994682|Drug|Pioglitazone|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of the study.
46972|NCT00994682|Drug|Placebo|An oral tablet identical to pioglitazone will be given once daily.
46973|NCT00994682|Drug|Pioglitazone|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of the study.
46974|NCT00025220|Other|Laboratory Biomarker Analysis|Correlative studies
46975|NCT00994682|Drug|Placebo|All subjects will take one placebo tablet per day that looks identical to pioglitazone but without active drug.
46976|NCT00994695|Biological|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
46977|NCT00994708|Drug|esomeprazole|
46978|NCT00994734|Drug|Mifepristone|home administration of mifepristone
46979|NCT00994747|Other|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
46980|NCT00994747|Other|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
46981|NCT00994760|Drug|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
46982|NCT00994773|Drug|Simvastatin|daily doses for 14 days
46983|NCT00987831|Other|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
46984|NCT00024453|Biological|teicoplanin|
46985|NCT00987831|Other|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
46986|NCT00987831|Drug|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
46987|NCT00987844|Drug|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
46988|NCT00987857|Other|questionnaire administration|
46749|NCT00989521|Drug|PUR003|PUR003 for inhalation
46750|NCT00989521|Drug|Placebo|Normal saline for inhalation
46751|NCT00989534|Behavioral|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
46752|NCT00989534|Behavioral|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
46753|NCT00989547|Other|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
46754|NCT00989560|Procedure|endoscopy|patients receive best treatment and care with an additional endoscopy
46755|NCT00025038|Radiation|radiation therapy|Undergo total body irradiation
46756|NCT00989573|Drug|Placebo|oral administration of placebo once-daily for 8 weeks
46757|NCT00989573|Drug|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
46758|NCT00989573|Drug|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
47063|NCT00992446|Drug|Cytarabine|Given IV
47064|NCT00992446|Drug|Etoposide|Given IV
47065|NCT01020955|Drug|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
47066|NCT01020955|Drug|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
47067|NCT01020968|Biological|Cardiac Repair Cells (CRCs)|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
47068|NCT01020994|Drug|LAS41003|Once daily, topically
47069|NCT01020994|Drug|LAS189962|Once daily, topically
47070|NCT00027560|Drug|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
47071|NCT01020994|Drug|LAS189961|Once daily, topically
47072|NCT01021007|Drug|Iodine|Rinse 2 times per day for 6 weeks
47073|NCT01021007|Other|water|Use 2 times per day for 6 weeks
48071|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
48072|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
48073|NCT01017939|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
48074|NCT01017939|Drug|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
48075|NCT01017939|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
48076|NCT01017939|Drug|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
48077|NCT01017952|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
48078|NCT01017952|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
48079|NCT00027287|Drug|Vitamin E|
48080|NCT01017965|Device|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
48081|NCT01020032|Other|Individual receptive music therapy by "U sequence" method|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
48082|NCT01020058|Procedure|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
48083|NCT01020071|Procedure|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
48084|NCT00027547|Drug|cyclosporine|
48085|NCT01020097|Drug|fluorine F18 EF5|Given IV
48449|NCT01015820|Device|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
48450|NCT01015833|Drug|Doxorubicin Hydrochloride|Given IV
48451|NCT01015833|Other|Laboratory Biomarker Analysis|Correlative studies
48452|NCT01015833|Other|Pharmacological Study|Correlative studies
48453|NCT01015833|Drug|Sorafenib Tosylate|Given PO
46295|NCT00995670|Drug|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
46296|NCT00995670|Drug|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
46297|NCT00988806|Drug|Placebo|Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.
Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
46298|NCT00988832|Biological|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
46299|NCT00988845|Dietary Supplement|Indole-3-carbinol|200 mg bid po X 8 weeks
46300|NCT00024661|Drug|LErafAON|
46301|NCT00988858|Drug|LY2603618|150 mg/m2 intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
46302|NCT00988858|Drug|Pemetrexed|500mg/m2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
46303|NCT00988871|Device|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
46304|NCT00988884|Biological|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
46305|NCT00988884|Biological|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
46306|NCT00988884|Biological|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
46307|NCT00988884|Biological|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
46308|NCT00988884|Biological|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
46309|NCT00988897|Drug|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
46310|NCT00988897|Drug|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
46311|NCT00024674|Drug|SS1(dsFv)-PE38|
46312|NCT00988897|Drug|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
46989|NCT00987857|Procedure|comparison of screening methods|
46990|NCT00987857|Procedure|diagnostic endoscopic procedure|
46991|NCT00987857|Procedure|endoscopic biopsy|
46040|NCT00990795|Drug|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
46041|NCT00990795|Drug|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
46042|NCT00990808|Drug|anacetrapib|[Intervention Name: MK0859] MK0859 100 mg tablet once daily for 8 weeks.
46043|NCT00990808|Drug|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
46044|NCT00990808|Drug|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
46045|NCT00990808|Drug|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
46046|NCT00990821|Drug|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
46047|NCT00990821|Drug|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
46048|NCT00025064|Drug|dacarbazine|
46049|NCT00990821|Drug|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
46050|NCT00993070|Drug|placebo|vehicle gel, applied 4 times per day for 8 weeks
46051|NCT00993083|Biological|MVA-NP+M1|Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
46052|NCT00025103|Radiation|radiation therapy|
46053|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
46054|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
46055|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
46056|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
47074|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
47075|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
47076|NCT01021020|Drug|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
47077|NCT01021046|Procedure|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
47078|NCT01021046|Procedure|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
47079|NCT01021059|Biological|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
47080|NCT01021072|Drug|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
47081|NCT00027560|Procedure|allogeneic bone marrow transplantation|
47082|NCT01021111|Device|Anterior Cruciate Ligament Measurement and Feedback System|
47083|NCT01021150|Drug|ombrabulin (AVE8062)|Pharmaceutical form:injection solution
Route of administration: intravenous infusion
47084|NCT01021150|Drug|cisplatin|Pharmaceutical form: injection solution
Route of administration: intravenous infusion
46129|NCT00988715|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
46130|NCT00988715|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
46131|NCT00990821|Drug|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
46132|NCT00990821|Drug|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
46133|NCT00990821|Drug|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
46134|NCT00990821|Drug|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
46135|NCT00990821|Drug|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
46136|NCT00990821|Drug|Placebo|Placebo matching MK-0517
46137|NCT00990821|Drug|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
46138|NCT00990821|Drug|125 mg Aprepitant|Aprepitant oral tablet, single dose
48454|NCT00026923|Procedure|Laparoscopic surgery|
48455|NCT01015846|Other|Exercise|Redcord (sling exercise) and traditional exercise
48456|NCT01018381|Drug|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
48457|NCT01018394|Drug|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
48458|NCT01018394|Drug|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
48459|NCT01018407|Behavioral|Discrete Trial Training|UCLA model, developed by Lovaas and colleagues (Smith, Groen & Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.
During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program.
48460|NCT01018407|Behavioral|Interpersonal Developmental Approach|Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).
Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities.
48461|NCT00027339|Drug|fosamprenavir|
48462|NCT01018420|Drug|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
48463|NCT01018420|Drug|Moxifloxacin|400 mg capsule at the 6 hour point
48464|NCT01018433|Behavioral|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
48465|NCT01018433|Other|Treatment as usual|Can include other psychotherapy and pharmacotherapy
48466|NCT01018446|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
47501|NCT01016769|Drug|Temsirolimus + Weekly Paclitaxel + Carboplatin|Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.
Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week.
47502|NCT01016782|Drug|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
46313|NCT00988897|Drug|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
46611|NCT00991627|Drug|Ephedrine, continuous infusion|37.5 mg/h intravenously
46612|NCT00991627|Drug|Ephedrine, bolus|6.25 mg IV bolus prn.
Hypotension defined according to study protocol for each arm.
46613|NCT00025077|Drug|carboplatin|
46614|NCT00991627|Drug|Atropine|0.1 mg/kg iv bolus prn
Bradycardia defined as 50% drop in heart rate from baseline values.
46615|NCT00991640|Behavioral|2-day preceptorship on obesity management|
46616|NCT00991653|Procedure|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
46617|NCT00993902|Procedure|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
46618|NCT00993915|Drug|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
46619|NCT00993928|Behavioral|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
46620|NCT00993941|Procedure|Autologous BMSCs transplantation|10 ml autologous BMSCs(7~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
46621|NCT00993941|Drug|Conserved therapy|Oral or intravenous administration
46622|NCT00993954|Procedure|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
46623|NCT00025181|Biological|incomplete Freund's adjuvant|
46624|NCT00993967|Drug|idebenone|Idebenone 1350 mg/d, patients < or equal 45 kg Idebenone 2250 mg/d, patients > 45 kg
46625|NCT00993980|Procedure|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
46626|NCT00993980|Procedure|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
46627|NCT00994006|Dietary Supplement|Magnesium oxide|520 mg of elemental magnesium q.d.
46628|NCT00994006|Dietary Supplement|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
46629|NCT00994032|Procedure|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
46057|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
46058|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
46059|NCT00993109|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
46060|NCT00993109|Drug|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
46368|NCT00995878|Procedure|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
46369|NCT00995878|Procedure|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
46370|NCT00995904|Drug|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
46371|NCT00995904|Drug|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
46372|NCT00000221|Drug|Buprenorphine|
46373|NCT00000881|Drug|Probenecid|
46374|NCT00025272|Drug|carboplatin|
46375|NCT00995904|Drug|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
46376|NCT00995917|Other|Vitamin K acupoint injection|Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
46377|NCT00995917|Other|Saline Injection|Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
46378|NCT00995930|Drug|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
46379|NCT00995930|Drug|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
46380|NCT00995969|Drug|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
46381|NCT00988949|Drug|PF-04455242|Single oral 18 mg dose of PF-04455242.
46139|NCT00990821|Drug|2 mg Midazolam|Midazolam oral tablet, single dose
46140|NCT00000878|Drug|Stavudine|
46141|NCT00025064|Drug|doxorubicin hydrochloride|
46142|NCT00990834|Drug|simvastatin|simvastatin 80 mg PO daily for one to eight months.
46143|NCT00990847|Drug|Procaterol, Salbultamol|
46144|NCT00990860|Drug|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
46145|NCT00990860|Procedure|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
46146|NCT00990873|Genetic|gene expression analysis|
46147|NCT00990873|Genetic|microarray analysis|
46148|NCT00990873|Genetic|reverse transcriptase-polymerase chain reaction|
46149|NCT00990873|Other|laboratory biomarker analysis|
46150|NCT00990886|Drug|Placebo|Once daily for 12 weeks
46151|NCT00990886|Drug|Oxybutynin chloride|15 mg once daily for 12 weeks
46152|NCT00025064|Drug|etoposide|
46153|NCT00990912|Drug|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
46448|NCT00993720|Other|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
46449|NCT00993733|Procedure|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
46450|NCT00993746|Drug|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
46451|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 5|Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day.
46452|NCT00996073|Biological|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
46453|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
47503|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
47504|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
47505|NCT01016795|Drug|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
47506|NCT01016808|Drug|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
47507|NCT01016808|Drug|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
47508|NCT01016808|Drug|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
47509|NCT00027053|Drug|Trazodone|50 to 150 mg qhs
47510|NCT01016821|Drug|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
47511|NCT01016834|Device|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
47512|NCT01016834|Drug|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
47513|NCT01016847|Drug|Montelukast|10 mg Q day
47514|NCT01016847|Other|Sugar pill|Sugar pill that looks like Montelukast that will be given Q day
47515|NCT01016860|Drug|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
47516|NCT01016860|Drug|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
47517|NCT01016873|Device|IRay|Low voltage stereotactic radiotherapy system
47518|NCT01019083|Drug|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
47519|NCT01019083|Other|Arsenic|Participant will be selected from the Arsenic Contaminated Area
47803|NCT01019564|Device|Complete Easy Rub Formula MPS|Multi-purpose solution
47804|NCT01019564|Device|Aquify MPS|Multi-purpose solution
46630|NCT00994032|Other|Medical treatment|standard antalgic medical treatment
46631|NCT00994045|Biological|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
46632|NCT00994045|Biological|Fresh Frozen Plasma|
46914|NCT00987805|Dietary Supplement|Corn-starch granules|This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
46915|NCT00987818|Other|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
46916|NCT00989651|Drug|Veliparib|Given PO
46917|NCT00989664|Biological|Tositumomab and Iodine I 131 Tositumomab|Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).
Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation.
46918|NCT00989690|Drug|docetaxel|
46919|NCT00989690|Drug|erlotinib hydrochloride|
46920|NCT00989690|Drug|pemetrexed disodium|
46921|NCT00989690|Genetic|fluorescence in situ hybridization|
46922|NCT00989690|Genetic|mutation analysis|
46923|NCT00989690|Genetic|proteomic profiling|
46924|NCT00025038|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
46925|NCT00989690|Other|immunohistochemistry staining method|
46926|NCT00989690|Other|laboratory biomarker analysis|
46927|NCT00989690|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
46928|NCT00989690|Procedure|breath test|
46929|NCT00989703|Drug|placebo|oral solution, daily for 14 days
46382|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
46383|NCT00988949|Other|Placebo|Oral placebo.
46384|NCT00024687|Drug|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
46385|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
46386|NCT00988949|Drug|PF-04455242|Single 30 mg oral dose of PF-04455242.
46387|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
46685|NCT00991731|Behavioral|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
46686|NCT00025077|Drug|cyclophosphamide|
46687|NCT00991731|Behavioral|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
46688|NCT00991744|Drug|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
46689|NCT00991744|Drug|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
46690|NCT00991757|Drug|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
46691|NCT00991770|Other|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
46692|NCT00991770|Other|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
46693|NCT00991783|Drug|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
46694|NCT00991796|Drug|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
46454|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
46455|NCT00996086|Device|CRT device implant|CRT device-recipients
46456|NCT00025272|Radiation|radiation therapy|
46457|NCT00996099|Device|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
46458|NCT00996099|Other|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
46459|NCT00996125|Biological|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
46460|NCT00996125|Other|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
46461|NCT00996138|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
46462|NCT00996151|Drug|Testosterone MD-Lotion|Single dose Testosterone MD-Lotion 2%
46463|NCT00996164|Drug|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
46464|NCT00996164|Drug|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
46465|NCT00996177|Drug|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
46466|NCT00996177|Drug|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
46467|NCT00025285|Drug|carboplatin|
46468|NCT00996190|Drug|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
46759|NCT00989586|Biological|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
46760|NCT00989586|Biological|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
47805|NCT01019577|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
47806|NCT01019590|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
47807|NCT01019590|Drug|Benicar HCT ® Tablets 40 mg/25 mg|
47808|NCT01019603|Drug|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
47809|NCT01019603|Drug|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
47810|NCT01019616|Drug|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
47811|NCT00027508|Drug|trabectedin|
47812|NCT01019642|Drug|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
47813|NCT01019642|Drug|placebo|no active principles given.
47814|NCT01019655|Drug|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
47815|NCT01019668|Drug|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
47816|NCT01019668|Drug|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
47817|NCT01019681|Biological|Cord blood stem cell injection|The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.
Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois).
47818|NCT01019694|Drug|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
47819|NCT01019694|Drug|Combivent Respimat 20/100 mcg|Open label randomized parallel
47820|NCT01019694|Drug|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
47821|NCT01019707|Drug|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
47822|NCT01022398|Drug|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
47823|NCT01022411|Dietary Supplement|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
46930|NCT00989703|Drug|GLPG0259|oral solution
46931|NCT00989703|Drug|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
46932|NCT00989716|Drug|Transdermal glyceryl trinitrate patch|5mg per day
46933|NCT00989716|Drug|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
46934|NCT00989729|Drug|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
46935|NCT00025038|Procedure|double-unit umbilical cord blood transplantation|
45974|NCT00993070|Drug|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
45975|NCT00995280|Device|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
45976|NCT00995293|Drug|DOCETAXEL|Intravenous
45977|NCT00995293|Drug|CISPLATIN|Intravenous
45978|NCT00995293|Drug|5-FLUOROURACIL|Intravenous
45979|NCT00995306|Drug|Civamide (Zucapsaicin)|Civamide Cream 0.075%, TID for 12 weeks
Civamide Cream 0.01%, TID for 12 weeks
45980|NCT00995332|Drug|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
45981|NCT00995345|Drug|KRP-104|Tablet
45982|NCT00995345|Drug|Placebo|Tablet
45983|NCT00995358|Biological|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
45984|NCT00025259|Drug|cytarabine|Given IV
45985|NCT00995371|Device|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
45986|NCT00995371|Drug|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
45987|NCT00995384|Procedure|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
45988|NCT00995397|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
46695|NCT00991796|Drug|Placebo|Placebo
46696|NCT00991796|Drug|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
46697|NCT00025077|Drug|thiotepa|
46698|NCT00991796|Drug|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
46699|NCT00991809|Drug|Alfentanil|15 mcg/kg IM
46700|NCT00991809|Drug|Diphenhydramine|25 mg IM
46701|NCT00994097|Drug|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
46702|NCT00994097|Drug|Gemcitabine|Gemcitabine: 1,250 mg/m2 intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
46992|NCT00987857|Procedure|endoscopic procedure|
46993|NCT00987857|Procedure|quality-of-life assessment|
46994|NCT00987857|Procedure|screening method|
46995|NCT00024466|Biological|autologous tumor cell vaccine|
46996|NCT00987870|Drug|BFH772|
46997|NCT00987870|Drug|Placebo|
46998|NCT00987870|Drug|BFH772|
46999|NCT00987870|Drug|Placebo|
47000|NCT00987870|Drug|calcipotriol/betamethasone|
47001|NCT00987896|Device|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
47002|NCT00987909|Biological|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
47003|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
47004|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
47005|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
46761|NCT00991822|Drug|Dorzolamide 2%|
46762|NCT00991822|Drug|Timolol 0.5%|
46763|NCT00991848|Drug|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
46764|NCT00991861|Drug|LAS41007 o.d.|Once daily, topical application
46765|NCT00991861|Drug|LAS41007 b.i.d.|Twice daily, topical application
46766|NCT00991861|Drug|LAS106521|Twice daily, topical application
46767|NCT00991887|Radiation|Radiation Therapy (XRT)|The dose will be 700 cGy in a single fraction, using AP-PA fields calculated to midplane. No Less than 6MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
46768|NCT00025077|Procedure|conventional surgery|
46769|NCT00991900|Device|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
46770|NCT00991926|Drug|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
46771|NCT00991926|Other|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
46772|NCT00991939|Drug|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients < 60 kg and 40 mg/day for patients > 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
46773|NCT00991939|Drug|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients > 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients < 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
46774|NCT00991952|Drug|alvocidib|Given IV
46775|NCT00991952|Drug|irinotecan hydrochloride|Given IV
46776|NCT00991952|Other|laboratory biomarker analysis|Correlative studies
47085|NCT01021163|Drug|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
47086|NCT01021176|Other|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
48086|NCT01020097|Procedure|immunohistochemistry staining method|Correlative study
48087|NCT01020097|Procedure|biopsy|Correlative study
48088|NCT01020097|Procedure|Positron Emission tomography|Undergo scan
48089|NCT01020123|Drug|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
48090|NCT01020123|Drug|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
48091|NCT01020123|Drug|Glipizide|Glipizide administered to 1 group of patients
48092|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
48093|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
48094|NCT01020149|Other|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
48095|NCT00027547|Drug|cytarabine|
48096|NCT01020162|Drug|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
48097|NCT01020162|Procedure|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
48098|NCT01020175|Procedure|Bone marrow transplantation|Patients received bone marrow transplantation
48099|NCT01020175|Procedure|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
48100|NCT01020214|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
48101|NCT01020214|Drug|Benicar HCT® Tablets 40 mg/25 mg|
48102|NCT01020227|Behavioral|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
48103|NCT01020240|Behavioral|Avolition|- avolition for cesarean discomforts
48104|NCT01020240|Behavioral|Orientation|avolition of cesarean discomfort
physiotherapy orientation
48105|NCT01020240|Behavioral|Guide|avolition of cesarean discomfort
physiotherapy orientation
guide orientation
48106|NCT00027547|Drug|fludarabine phosphate|
45989|NCT00995397|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
45990|NCT00995410|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
45991|NCT00995423|Device|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
45992|NCT00995423|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent
45993|NCT00995436|Device|Extraoral anchorage|Extra oral anchorage using headgear
45994|NCT00995436|Device|Intraoral skeletal anchorage - Temporary anchorage device|Intraoral skeletal anchorage using mini screws
45995|NCT00025259|Drug|dexamethasone|Given IV
45996|NCT00995436|Device|Intraoral dental anchorage|Intraoral dental anchorage by using Nance palatal arch on molars
45997|NCT00995449|Biological|KB003|KB003 IV x5 doses
46314|NCT00988910|Drug|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
46315|NCT00988910|Drug|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
46316|NCT00988923|Other|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
46317|NCT00988923|Other|No intervention|the intervention tool was switched in off, only bolus was activated
46318|NCT00988936|Drug|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with [F-18]RGD-K5
46319|NCT00991055|Drug|Pioglitazone|A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.
(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)
46320|NCT00025064|Drug|prednisolone|
46321|NCT00991068|Drug|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
46322|NCT00991081|Behavioral|Counseling|Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling
One week prior to the target quit date (TQD)
Two weeks post-TQD
Four weeks post-TQD
46323|NCT00991081|Behavioral|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
47006|NCT00024466|Drug|chemotherapy|
47007|NCT00987922|Device|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
47008|NCT00987935|Drug|Sorafenib|400 mg twice daily
47009|NCT00987935|Drug|BIBF 1120|Twice daily
47010|NCT00989768|Drug|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
47011|NCT00989768|Drug|Botulinum Toxin Type A/Dysport®|Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.
-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox.
47012|NCT00989781|Radiation|3-D Ultrasound|One time pelvic ultrasound
47013|NCT00989781|Drug|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
47014|NCT00989781|Drug|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
46061|NCT00993122|Drug|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
46062|NCT00993135|Drug|methotrexate|
46063|NCT00025116|Drug|gefitinib|
46064|NCT00993135|Other|medical chart review|
46065|NCT00993135|Procedure|assessment of therapy complications|
46066|NCT00993148|Drug|maraviroc|150 mg tab by mouth once daily for 96 weeks
46067|NCT00993148|Drug|darunavir|800 mg tab by mouth once daily for 96 weeks
46068|NCT00993148|Drug|ritonavir|100 mg capsule by mouth once daily for 96 weeks
46069|NCT00993161|Device|Motriplate|Number of contact couples
46070|NCT00993161|Device|Motriplate|Number of contact couples
46071|NCT00993174|Procedure|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
46072|NCT00993174|Procedure|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
47087|NCT01021176|Drug|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
47088|NCT01021189|Drug|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
47089|NCT01021189|Drug|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
47090|NCT01023854|Procedure|Continuous Paravertebral block|The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.
Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space.
47091|NCT01023867|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
47092|NCT01023880|Drug|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
47093|NCT01023919|Device|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
47094|NCT01023932|Device|Cochlear Implants|
47095|NCT01023945|Drug|ASP1941|oral
47096|NCT01023945|Drug|Placebo|oral
47097|NCT00027742|Biological|pegylated interferon alfa|
47098|NCT01023958|Drug|BI 6727, IV infusion|phase II
47099|NCT01023984|Procedure|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
47100|NCT01023984|Procedure|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
47101|NCT01024010|Drug|pentostatin|Given IV
47102|NCT01024010|Drug|cyclophosphamide|Given IV
47103|NCT01024010|Biological|ofatumumab|Given IV
47104|NCT01024010|Procedure|laboratory biomarker analysis|Correlative study
48107|NCT00027664|Biological|recombinant interferon alfa|
48108|NCT01023048|Other|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
48467|NCT01018459|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10^9 viral particles (vp)/mL, 10^10 vp/mL, 5 x 10^10 vp/mL, and 10^11 vp/mL.
48468|NCT01018459|Drug|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
48469|NCT01018472|Dietary Supplement|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
48470|NCT01018472|Other|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
48471|NCT01018485|Drug|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
48472|NCT00027365|Biological|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
48473|NCT01018498|Behavioral|Restricted FODMAPs diet|Restricted fermentable substrate diet
48474|NCT01018511|Drug|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
48475|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
48476|NCT01020812|Procedure|TACE|Standard of Care
48477|NCT01020812|Procedure|SBRT|Standard of Care
48478|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
48479|NCT01020825|Drug|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
48480|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
48481|NCT01020838|Drug|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
48482|NCT01020851|Behavioral|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
48483|NCT00027560|Drug|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
46324|NCT00991081|Drug|Pharmacotherapy|8-week course of genetically-tailored pharmacotherapy
Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)
Participants with the A2 allele (CC) were assigned to receive bupropion
46325|NCT00991081|Behavioral|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
46326|NCT00991081|Behavioral|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
46327|NCT00991107|Drug|HE3286|HE3286 20 mg (10 mg BID) for 28 days
46328|NCT00991120|Device|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
46329|NCT00991133|Drug|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
46330|NCT00991146|Drug|canakinumab|canakinumab
46331|NCT00025064|Drug|procarbazine hydrochloride|
46633|NCT00994058|Device|Electrical Inhibition (EI) Uterine Pacemaker|An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.
Patients with preterm contractions (< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS).
46634|NCT00025181|Biological|ipilimumab|
46635|NCT00994071|Drug|Temozolomide|
46636|NCT00994071|Drug|ABT-888|
46637|NCT00994084|Behavioral|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
46638|NCT00994084|Behavioral|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
46639|NCT00994097|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
46640|NCT00987272|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
46641|NCT00987272|Drug|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
46642|NCT00024414|Drug|DHA-paclitaxel|
46073|NCT00993187|Drug|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
46074|NCT00025129|Drug|laromustine|
46075|NCT00993187|Drug|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
46076|NCT00993187|Drug|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
46077|NCT00995670|Drug|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
46078|NCT00995683|Drug|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
46079|NCT00995683|Drug|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
46080|NCT00025259|Drug|prednisone|Given orally
46081|NCT00995696|Behavioral|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
46082|NCT00995709|Drug|AIN457|
46083|NCT00995709|Drug|AIN457|
46084|NCT00995709|Drug|Placebo|
46388|NCT00988962|Behavioral|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
46389|NCT00988975|Procedure|Insertion of pelvicol graft|Pelvicol graft
46390|NCT00988988|Drug|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
46391|NCT00988988|Drug|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
46392|NCT00988988|Drug|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
46393|NCT00989001|Drug|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
46394|NCT00989001|Drug|Placebo|Injection
46395|NCT00024934|Drug|B-Lymphocyte Stimulator (BLyS)|
46396|NCT00989014|Drug|CD07805/47|0.5% Topical Gel
46397|NCT00989014|Drug|CD07805/47|0.18% Topical Gel
46154|NCT00990912|Drug|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
46155|NCT00990912|Drug|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
46156|NCT00990925|Behavioral|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
46157|NCT00990925|Other|Usual Care|Care as usual
46158|NCT00990938|Drug|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
46159|NCT00990938|Drug|Saline|Subcutaneous injection once per week for four weeks
46160|NCT00993187|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
46161|NCT00993200|Genetic|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
46162|NCT00993200|Drug|Warfarin|Usual care warfarin dosing
46163|NCT00993213|Procedure|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
46164|NCT00993213|Other|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
46165|NCT00993226|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
46166|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
46167|NCT00993226|Drug|Bupivacaine HCl Treatment 1c|40 ml
46168|NCT00025142|Drug|FOLFOX regimen|
46169|NCT00993226|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
46170|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
46171|NCT00993226|Drug|Bupivacaine HCl Treatment 2c|40 ml
46172|NCT00993239|Drug|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
46173|NCT00993252|Procedure|CT Scan|CT scan
46174|NCT00993265|Drug|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
48484|NCT01020851|Behavioral|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
48485|NCT01020864|Drug|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
48486|NCT01020864|Drug|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
48487|NCT01020864|Drug|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
47520|NCT01019109|Device|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
47521|NCT01019122|Radiation|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
47522|NCT01019135|Behavioral|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
47523|NCT01019161|Drug|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
47524|NCT01019161|Drug|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
47525|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
47526|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
47527|NCT01019187|Procedure|Quality-of-Life Assessment|Ancillary Studies
47528|NCT00027417|Procedure|Cardiopulmonary bypass and cardiac surgery|
47529|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
47530|NCT01019187|Other|Placebo|Given orally
47531|NCT01019187|Procedure|Fatigue Assessment and Management|
47532|NCT01019187|Procedure|Sleep Disorder Therapy|
47533|NCT01019187|Drug|Armodafinil|Given orally
47534|NCT01019187|Procedure|Quality-of-life assessment|Ancillary studies
47535|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
46643|NCT00987285|Behavioral|CASM +|Computer Assisted Self Management plus Social Support
46644|NCT00987285|Behavioral|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
46645|NCT00987298|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
46646|NCT00987311|Dietary Supplement|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
46647|NCT00987311|Dietary Supplement|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
46648|NCT00987311|Dietary Supplement|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
46649|NCT00987324|Device|Taxus stent|Implantation of paclitaxel-eluting stent
46650|NCT00987324|Device|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
46651|NCT00987324|Device|Conventional Balloon Catheter|Ryuijin, Trek
46652|NCT00987337|Drug|Filibuvir|300 mg BID
46653|NCT00024427|Drug|fluorouracil|High dose 5-FU
46654|NCT00987337|Drug|Filibuvir|600 mg BID
46936|NCT00989729|Drug|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
46937|NCT00989742|Drug|Doxycycline|50mg od
46938|NCT00989742|Drug|Placebo|50mg od
46939|NCT00989755|Other|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
46940|NCT00989768|Drug|Botulinum Toxin Type A (Dysport®)|Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.
-Dysport®: 5 units will be injected in the left or right forehead side.
46941|NCT00992121|Drug|Pazopanib 2 week|Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).
Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.
46942|NCT00992121|Drug|Pazopanib 3 week|Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).
Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.
46398|NCT00989014|Drug|CD07805/47|0.07% Topical Gel
46399|NCT00989014|Drug|CD07805/47 placebo|Vehicle Topical Gel
46400|NCT00989027|Drug|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
46401|NCT00989027|Drug|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
46402|NCT00989027|Drug|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
46403|NCT00989027|Drug|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
46404|NCT00989027|Drug|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
46405|NCT00989040|Drug|usual treatment: Versatis|To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.
To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch.
46406|NCT00024986|Drug|Tenofovir DF|
46407|NCT00989053|Drug|escitalopram|10 mg/d for a duration of 8 weeks
46408|NCT00025064|Drug|vinblastine sulfate|
46409|NCT00991224|Biological|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
46410|NCT00991224|Other|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
46703|NCT00994097|Drug|Pemetrexed|Pemetrexed: 500 mg/m2 intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
46704|NCT00994110|Drug|Pasireotide (SOM230)|Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.
Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified.
46705|NCT00994110|Other|placebo|Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.
Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified.
46706|NCT00025181|Biological|tyrosinase peptide|
46175|NCT00993265|Drug|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
46176|NCT00993278|Dietary Supplement|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
46469|NCT00996203|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
46470|NCT00996203|Drug|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
46471|NCT00996216|Drug|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
46472|NCT00996216|Drug|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
46473|NCT00996229|Behavioral|Caloric restriction|20-30% CR for 6 months
46474|NCT00989053|Drug|placebo|1 pill per day for 8 weeks
46475|NCT00989079|Drug|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
46476|NCT00989079|Drug|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
46477|NCT00989092|Biological|darbepoetin alfa|Administered subcutaneously.
46478|NCT00989105|Other|immunohistochemistry staining method|
46479|NCT00989105|Other|laboratory biomarker analysis|
46480|NCT00989105|Other|pharmacological study|
46481|NCT00989105|Procedure|computed tomography|
46482|NCT00989105|Procedure|magnetic resonance imaging|
46483|NCT00025012|Drug|isotretinoin|
46484|NCT00989105|Procedure|single photon emission computed tomography|
46485|NCT00989105|Radiation|technetium Tc 99m demobesin-4|
46486|NCT00989118|Procedure|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
46487|NCT00989131|Drug|Paclical®|250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.
Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.
47536|NCT01019187|Procedure|Fatigue Assessment and Management|
47537|NCT01019187|Procedure|Management of Therapy|
47538|NCT01019187|Procedure|Sleep disorder therapy|
47539|NCT00027430|Drug|TheraDerm|
47540|NCT01019187|Procedure|cognitive assessment|
47541|NCT01019187|Procedure|Quality of Life assessment|Ancillary Studies
47542|NCT01019187|Other|Questionnaire Administration|Ancillary studies
47824|NCT01022424|Drug|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
47825|NCT01022437|Other|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
47826|NCT01022463|Drug|Ivabradine|Ivabradine 5 mg BId for 4 weeks
47827|NCT01022463|Drug|Atenolol|50 mg od for 4 weeks
47828|NCT01022476|Drug|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
47829|NCT00027612|Drug|carmustine|IV
47830|NCT01022489|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
47831|NCT01022489|Device|Placebo (sham coil) treatment|Sham coil treatment
47832|NCT01022502|Drug|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
47833|NCT01022502|Drug|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
47834|NCT01022515|Other|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
47835|NCT01022515|Other|usual follow up with regular EM66 & Cga levels assessment|Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.
Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels.
47836|NCT01022528|Drug|Dexamethasone (0.1 mg/kg)|
46943|NCT00992134|Drug|Rituximab, Bendamustine, Cytarabine|Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.
Four to six cycles. Recycle every 28 days.
46944|NCT00992147|Drug|Adipocell|autologous cultured adipocytes (ANTG-adip)
46945|NCT00992160|Drug|GW597599|GW597599 15mg tablet
46946|NCT00992160|Drug|Placebo|Placebo to match GW597599 15mg tablet
46947|NCT00992173|Drug|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg [3.7 MBq/kg] (a minimum dose of 1.0 mCi [37 MBq] but not to exceed 5.0 mCi [185 MBq]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
46948|NCT00992186|Drug|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
46949|NCT00992199|Drug|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
46950|NCT00025090|Drug|fluorouracil|
46951|NCT00992212|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
45998|NCT00995449|Other|Placebo Comparator|Placebo IV x5 doses
45999|NCT00995462|Behavioral|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
46000|NCT00995475|Drug|Fluticasone propionate|
46001|NCT00988481|Drug|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
46002|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
46003|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
46004|NCT00988494|Drug|Placebo ophthalmic solution|Topical ocular application
46707|NCT00994123|Drug|MM-121 (SAR256212) + erlotinib|MM-121 (SAR256212) = intravenous solution erlotinib = daily oral tablet
46708|NCT00994123|Drug|Erlotinib|erlotinib = daily oral tablet
46709|NCT00994136|Drug|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
46710|NCT00994149|Drug|Diazoxide|10mg/kg/d divide every 8 hours
46711|NCT00994149|Drug|Ora-plus|placebo, give every 8 hours.
46712|NCT00994162|Device|EZCARE Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
46713|NCT00994175|Drug|Pioglitazone|
46714|NCT00994188|Procedure|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
46715|NCT00994201|Other|DCE-MRI, DW-MRI and MRS|Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.
Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS.
46716|NCT00994214|Drug|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
46717|NCT00025181|Procedure|adjuvant therapy|
46718|NCT00994227|Procedure|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
47015|NCT00025038|Procedure|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
47016|NCT00989781|Drug|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
47017|NCT00989781|Drug|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
47018|NCT00989781|Drug|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
47019|NCT00989794|Device|GelrinC|Applied once during surgery
47020|NCT00989807|Drug|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
46488|NCT00989131|Drug|Taxol®|175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.
Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.
46489|NCT00989157|Drug|Duloxetine|Single dose of 60 mg of duloxetine
46490|NCT00989170|Behavioral|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
46777|NCT00991965|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
46778|NCT00991978|Other|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
46779|NCT00025077|Procedure|peripheral blood stem cell transplantation|
46780|NCT00991991|Genetic|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
46781|NCT00994240|Procedure|Electrodessication & Curettage|Electrodessication & Curettage 1 or 3 cycles
46782|NCT00994253|Drug|Prescribe Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
46783|NCT00994253|Drug|HCTZ|HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
46784|NCT00994266|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
46785|NCT00994266|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
46786|NCT00994279|Behavioral|Yoga|Yoga sessions
46787|NCT00994279|Behavioral|Education|Educational Wellness Group
46788|NCT00994292|Drug|YM150|oral
46789|NCT00994292|Drug|Placebo|oral
46790|NCT00025194|Drug|estramustine phosphate sodium|
47837|NCT01022528|Drug|Dexamethasone (0.2 mg/kg)|
47838|NCT01022528|Other|Saline|
47839|NCT01022541|Drug|Capecitabine|Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.
(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)
Courses as per detailed description above.
47840|NCT00027612|Drug|irinotecan hydrochloride|IV
47841|NCT01022541|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.
(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)
Courses as per detailed description above.
48109|NCT01023061|Drug|abiraterone acetate|Given PO
48110|NCT01023061|Drug|prednisone|Given PO
48111|NCT01023061|Drug|leuprolide acetate|Given via injection
48112|NCT01023061|Other|laboratory biomarker analysis|Correlative study
48113|NCT01023061|Radiation|external beam radiation therapy|Undergo radiotherapy
48114|NCT01023061|Drug|goserelin acetate|Given via injection
48115|NCT01023074|Behavioral|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
48116|NCT01023087|Drug|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
48117|NCT01023087|Drug|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
48118|NCT00000892|Drug|Levocarnitine|
48119|NCT00027664|Drug|thalidomide|
48120|NCT01023100|Drug|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
48121|NCT01023113|Procedure|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
48122|NCT01023113|Procedure|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
48123|NCT01023126|Behavioral|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
46005|NCT00988507|Drug|Ferroquine (SSR97193)|Pharmaceutical form: capsule
Route of administration: oral
46006|NCT00988507|Drug|Placebo|Pharmaceutical form: capsule
Route of administration: oral
46007|NCT00988507|Drug|artesunate|Pharmaceutical form: tablets
Route of administration: oral
46008|NCT00024557|Procedure|targeted fusion protein therapy|
46009|NCT00988520|Drug|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
46010|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
46011|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
46012|NCT00988520|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
46013|NCT00988520|Drug|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
46014|NCT00988533|Drug|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
46015|NCT00988546|Other|Computer based template for exam documentation|exam documentation performed using computer based template
46016|NCT00988546|Other|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
46017|NCT00988559|Biological|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
46018|NCT00988559|Device|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
46019|NCT00024557|Procedure|surgery|
46020|NCT00988559|Biological|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
46332|NCT00991159|Biological|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
46333|NCT00991172|Drug|REGN475|Single Subcutaneous injection dose level 1
46334|NCT00991172|Drug|REGN475|Single subcutaneous injection dose level 2
46335|NCT00991172|Drug|Placebo Injection|Placebo Subcutaneous injection
46336|NCT00991198|Drug|Topical oxygen|0.5% concentration of Topical oxygen
46337|NCT00991198|Drug|Topical oxygen|0.25% concentration topical oxygen
47021|NCT00989820|Drug|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
47022|NCT00989833|Drug|budesonide|400 yg x 1
47023|NCT00989833|Drug|terbutaline|0.4 mg as-needed
47024|NCT00989833|Drug|budesonide/formoterol|160/4.5 yg as-needed
47025|NCT00989846|Other|biomarker|measuring serum-biomarkers
47026|NCT00025038|Other|laboratory biomarker analysis|Correlative studies
47027|NCT00989859|Device|Plethysmographic monitoring|Plethysmographic monitoring
47028|NCT00989872|Drug|EDP-322|
47029|NCT00989885|Other|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
47030|NCT00989898|Other|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
47031|NCT00989911|Drug|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
47032|NCT00989937|Drug|Oxytocin|20 IU BID or 40 IU BID
47033|NCT00989937|Drug|Placebo|20 IU BID or 40 IU BID
47034|NCT00989950|Drug|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
47035|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
47036|NCT00992290|Biological|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
47037|NCT00025090|Drug|mitomycin C|
47038|NCT00992290|Biological|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
46085|NCT00995722|Drug|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
46086|NCT00995722|Drug|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
46087|NCT00995735|Procedure|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
46791|NCT00994305|Drug|N-acetylcysteine|600 mg bid po 0-7 PO
46792|NCT00994305|Drug|control|No treatment: standard care provided. No N-acetylcysteine administration.
46793|NCT00994318|Drug|FCM (Ferric carboxymaltose) high ferritin target|
46794|NCT00994318|Drug|FCM (Ferric carboxymaltose) low ferritin target|
46795|NCT00994318|Drug|Oral Iron (Ferrous sulphate)|
46796|NCT00994331|Procedure|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
47105|NCT01024010|Other|flow cytometry|
47106|NCT01024010|Genetic|protein expression analysis|Correlative study
47107|NCT01024023|Device|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
47108|NCT00027742|Drug|temozolomide|
47109|NCT01024036|Drug|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
47110|NCT01024036|Drug|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
47111|NCT01024036|Drug|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
47112|NCT01024062|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
47113|NCT01016015|Other|Laboratory Biomarker Analysis|Correlative studies
47114|NCT01016015|Drug|Temsirolimus|Given IV
47115|NCT01016028|Behavioral|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
47116|NCT01016028|Behavioral|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
47117|NCT01016028|Behavioral|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
47118|NCT01016041|Device|everolimus stent|stenting
48124|NCT01023139|Behavioral|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
48125|NCT01023152|Procedure|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
48126|NCT01023165|Procedure|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
48127|NCT01023178|Drug|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
48128|NCT01023178|Drug|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
48129|NCT01023178|Drug|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
48130|NCT00027677|Drug|halofuginone hydrobromide|
48488|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
48489|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
48490|NCT01020903|Procedure|Aprepitant|40 mg po pre-op
48491|NCT01020903|Drug|Placebo|Orally, pre-op
48492|NCT01020916|Procedure|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
48493|NCT01020916|Procedure|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
48494|NCT00027560|Drug|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
48495|NCT01020929|Device|Blunt Coude|Type of needle tip
48496|NCT01020929|Device|Quincke|Type of needle tip
48497|NCT01020929|Device|Trucath|Type of needle tip
48498|NCT01020942|Procedure|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
46338|NCT00991198|Drug|placebo|no O2
46339|NCT00991211|Drug|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
46340|NCT00991211|Drug|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
46341|NCT00991224|Biological|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
46342|NCT00993473|Drug|Neutral Protamine Hagedorn (NPH) insulin|NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U
Dose: titrated to achieve glycemic targets as described above for insulin glargine
46343|NCT00993473|Drug|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
46344|NCT00993486|Biological|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
46345|NCT00025142|Drug|oxaliplatin|
46346|NCT00993499|Drug|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
46347|NCT00993499|Drug|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
46348|NCT00993512|Drug|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
46349|NCT00993512|Drug|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
46350|NCT00993512|Other|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
46351|NCT00993525|Drug|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
46352|NCT00993538|Procedure|Blood sampling|
46353|NCT00993538|Procedure|Bone marrow aspiration|
46655|NCT00987337|Drug|Placebo|BID
46656|NCT00987350|Device|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
46657|NCT00987350|Device|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
46088|NCT00995735|Procedure|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
46089|NCT00995761|Drug|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
46090|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
46091|NCT00025259|Drug|vincristine sulfate|Given IV
46092|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
46093|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
46094|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
46095|NCT00995787|Drug|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
46096|NCT00995787|Drug|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
46097|NCT00995800|Drug|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
46098|NCT00995813|Biological|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
46099|NCT00995826|Drug|CS-8958|Inhaled CS-8958
46100|NCT00995826|Other|Placebo|Inhaled placebo
46101|NCT00995839|Drug|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
46102|NCT00025259|Radiation|radiation therapy|Patients undergo radiotherapy.
46103|NCT00995839|Drug|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
46104|NCT00988585|Dietary Supplement|DHA|600 mg/day for 6 weeks
46105|NCT00988598|Drug|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
46106|NCT00024570|Drug|IL13-PE38QQR|
46411|NCT00991237|Other|Pulsed Radiofrequency|Pulsed Radiofrequency
47119|NCT01016041|Device|paclitaxel stent|stenting
47120|NCT01016054|Biological|AGS-8M4|IV infusion
47121|NCT01016054|Drug|Pegylated liposomal doxorubicin (PLD)|IV infusion
47122|NCT00026975|Procedure|Hyperbaric Oxygen|
47123|NCT01016054|Drug|gemcitabine|IV infusion
47124|NCT01016054|Drug|carboplatin|IV infusion
47125|NCT01016067|Device|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
47126|NCT01016067|Procedure|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
46177|NCT00993278|Dietary Supplement|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
46178|NCT00993291|Procedure|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
46179|NCT00025142|Drug|fluorouracil|
46180|NCT00993291|Procedure|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
46181|NCT00993304|Drug|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
46182|NCT00993304|Drug|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
46183|NCT00993317|Drug|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
46184|NCT00993317|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
46185|NCT00995969|Drug|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
46186|NCT00995982|Biological|VRC-FLUDNA056-00VP|
46187|NCT00995995|Drug|Rosiglitazone|Rosiglitazone
46188|NCT00996008|Drug|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
48499|NCT01020942|Procedure|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
48500|NCT01023672|Drug|Armodafinil|150-250 mg armodafinil by mouth daily
48501|NCT01023685|Biological|CAD106|
48502|NCT01023698|Procedure|laser photocoagulation|Laser photocoagulation
48503|NCT01023711|Biological|Inactivated H1N1 vaccine|0.5 ml IM into Deltoid region of arm
48504|NCT01023711|Biological|Inactivated H1N1 vaccine|0.5 mL IM X 1 dose
48505|NCT00027716|Drug|bortezomib|
48506|NCT01023724|Drug|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
48507|NCT01023724|Drug|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
48508|NCT01023737|Drug|Hydroxychloroquine|The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
47234|NCT01016379|Other|biologic sample preservation procedure|
47235|NCT01018641|Biological|SA3Ag followed by Placebo|In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:
Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm
In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo.
47236|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
47237|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
47238|NCT01018641|Biological|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
47239|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
47240|NCT00027365|Biological|gp120W61D|
47241|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
46658|NCT00987363|Other|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
46659|NCT00987376|Device|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
46660|NCT00987389|Procedure|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
46661|NCT00987389|Drug|Glucocorticoids|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following either a standard regimen or a reduced regimen.
46662|NCT00987402|Other|Plain soap and water (PSW)|Presence or absence of infection
46663|NCT00987402|Other|Alcohol-based hand rub (ABHR)|Presence or absence of infection
46664|NCT00024427|Drug|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
46665|NCT00989391|Drug|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
46666|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
46667|NCT00989391|Drug|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
46952|NCT00992225|Drug|LY573636|Dose is adjusted to target a specific Cmax based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
46953|NCT00992238|Drug|Flavoxate Hydrochloride Tablets, 100mg|
46954|NCT00992238|Drug|Urispas® Tablets, 100mg|
46955|NCT00992264|Behavioral|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
46412|NCT00991250|Biological|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
46413|NCT00991250|Drug|Temodal® or Dacarbazine Medac®|Dacarbazine (5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.
A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver.
46414|NCT00991263|Genetic|gene expression analysis|
46415|NCT00991263|Genetic|polymerase chain reaction|
46416|NCT00991263|Other|laboratory biomarker analysis|
46417|NCT00991276|Drug|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
46418|NCT00991276|Drug|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
46419|NCT00025064|Drug|vincristine sulfate|
46420|NCT00991276|Drug|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
46421|NCT00991289|Drug|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
46422|NCT00991289|Drug|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
46423|NCT00991289|Drug|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
46424|NCT00991302|Behavioral|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
46425|NCT00991328|Procedure|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
46426|NCT00991341|Biological|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored <=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
48730|NCT01011842|Procedure|Radiotherapy|Standard of care
48731|NCT01011842|Procedure|Align RT|Standard of care
48732|NCT01013896|Other|Cystic Fibrosis Education|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
The Cystic Fibrosis Education serves as the attention control group.
48733|NCT01013909|Drug|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
48734|NCT01013909|Drug|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
48735|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
48736|NCT00026403|Radiation|radiation therapy|
48737|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
48738|NCT01013909|Drug|Lamisil Once|One application of Lamisil Once
48739|NCT01013935|Other|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
48740|NCT01013935|Other|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
48741|NCT01013948|Other|Non-Interventional|Non-Investigational Product (Survey Study)
48742|NCT01013961|Biological|alemtuzumab|Given IV
48743|NCT01013961|Biological|rituximab|Given IV
48744|NCT01013974|Drug|GSK573719|Inhaled micronised drug
48745|NCT01013974|Drug|Placebo|Lactose powder and containing magnesium stearate
48746|NCT01013987|Drug|maraviroc|maraviroc: one 150 mg pill twice daily
48747|NCT00026416|Biological|recombinant interferon alfa|
48748|NCT01013987|Drug|Raltegravir|raltegravir : one 400 mg pill twice daily
52434|NCT01030757|Radiation|Tomotherapy treatment|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days
Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours
Dose will be prescribed to the isodose line which covers at least 90% of the PTV
Dose homogeneity +/- 5%
52435|NCT01030770|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
52436|NCT01030770|Drug|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
52437|NCT01030783|Drug|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
52438|NCT01030783|Drug|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
52439|NCT01030796|Behavioral|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
52440|NCT01030809|Other|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
52441|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
52442|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
52443|NCT00028236|Drug|Gene-Transduced Autologous CD34+ Stem Cells|
52444|NCT01030848|Device|Total Knee Replacement (LCS rotating platform)|
52445|NCT01030861|Drug|Teplizumab|intravenous infusions
52736|NCT01033825|Drug|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
52737|NCT01033825|Drug|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
52738|NCT00028574|Drug|gabapentin|
52739|NCT01033825|Drug|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
52740|NCT01033825|Drug|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
52741|NCT01033825|Drug|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
52742|NCT01033838|Procedure|rectosigmoid resection|
52743|NCT01033851|Behavioral|Mindfulness Based Stress Reduction|8 week course
48805|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
48806|NCT01011855|Device|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
49115|NCT01014897|Device|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
49116|NCT01014910|Other|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
49117|NCT01014910|Device|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
49118|NCT01014923|Behavioral|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
49119|NCT01014936|Drug|MSC2156119J (EMD 1214063)|Cohorts of patients with c-Met alterations will be added at the MTD level in each regimen
49120|NCT01007604|Other|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
49121|NCT01007617|Device|LLLT :low level laser therapy|The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.
Main evaluation criteria: mucositis maximal intensity (WHO scale).
Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition.
49122|NCT01007630|Drug|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
49123|NCT01007630|Drug|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
49124|NCT01007643|Other|Wii Fit (TM) Interactive Video Game|Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
49125|NCT01007643|Other|Traditional Home Exercise Program|Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
49126|NCT00025766|Device|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
49127|NCT01007656|Dietary Supplement|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
52361|NCT01033279|Other|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
52362|NCT01033292|Drug|BSI-201|IV infusion, 5.6 mg/kg
52363|NCT01033305|Drug|CyCol™|Orally, once per day for 4 weeks
52364|NCT01033305|Drug|Placebo|Orally, once per day for 4 weeks
52365|NCT01033318|Drug|MK1809|single oral doses of MK1809
52366|NCT01033318|Drug|Comparator: Losartan|single oral doses of 100 mg Losartan
52367|NCT01033318|Drug|Comparator: Placebo|Placebo to MK1809
52651|NCT01033747|Drug|Deferasirox|5 mg/kg or 30 mg/kg orally daily
52652|NCT00028561|Other|pharmacological study|Correlative studies
52653|NCT01033760|Drug|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
52654|NCT01033760|Drug|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
52655|NCT01033773|Drug|Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin|Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
52656|NCT01033773|Behavioral|Diabetes survival skills self-management education|Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
52657|NCT01033799|Other|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
52658|NCT01033799|Other|Non fermented dairy product (control)|
52659|NCT01026103|Device|Tri Staple Technology stapler|This is a single arm study.
52660|NCT01026116|Drug|A|epirubicin/cyclophosphamide followed weekly paclitaxel
52661|NCT01026116|Drug|B|epirubicin/paclitaxel followed by weekly paclitaxel
52662|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
52967|NCT01064739|Other|Fixed Sodium Diet|
52968|NCT01064752|Drug|Minocycline|100 mg po bid for 8 weeks
52969|NCT00031473|Drug|Virazole (Ribavirin) Inhalation Solution|
52970|NCT01064778|Other|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
52971|NCT01064778|Other|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
52972|NCT01064791|Drug|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
52973|NCT01064791|Drug|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
53330|NCT01062854|Other|Soft earplugs are worn during sleep study|Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either "wears earplugs" or "no earplugs" groups.
53331|NCT01062867|Drug|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
53332|NCT01062880|Behavioral|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
53333|NCT00031187|Drug|SGN-15 (cBR96-doxorubicin immunoconjugate)|
53334|NCT01062893|Other|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
53335|NCT01062893|Other|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
53336|NCT01062906|Drug|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
53337|NCT01062906|Drug|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
52744|NCT01033851|Behavioral|Stress Management Education|8 week course
52745|NCT01033864|Drug|MMF|1 g per day b.i.d. p.o. for at least 1 month
52746|NCT01033864|Drug|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
52747|NCT01033864|Drug|Prednisone|5 mg per day p.o.
52748|NCT01033877|Biological|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
52749|NCT00000896|Biological|Hepatitis A Vaccine (Inactivated)|
52750|NCT00028587|Drug|bortezomib|Given IV
52751|NCT01033877|Biological|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d)
52752|NCT01033903|Drug|misoprostol|800 micrograms intravaginally ONCE
52753|NCT01033916|Other|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
52754|NCT01033929|Biological|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
52755|NCT01033942|Drug|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
52756|NCT01033942|Drug|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
52757|NCT01033942|Behavioral|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
52758|NCT01033955|Drug|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
53039|NCT01062360|Drug|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
53040|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
53041|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
53042|NCT01062399|Drug|everolimus|Given orally
49128|NCT01007669|Behavioral|Physical activity and Health check|Strength training, aerobic capacity training.
49129|NCT01007669|Behavioral|Health check only|Health check
49130|NCT01007682|Other|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
49431|NCT01010477|Drug|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
49432|NCT01010477|Behavioral|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
49433|NCT01010490|Procedure|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
49434|NCT01010490|Procedure|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
49435|NCT01010490|Procedure|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
49436|NCT01010503|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
49437|NCT01010516|Drug|High-dose rosuvastatin|40 of rosuvastatin daily
49438|NCT01010516|Drug|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
49439|NCT00026182|Other|questionnaire administration|Ancillary studies
49440|NCT01012830|Drug|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
49441|NCT00026312|Biological|Sargramostim|Given IV or SC
49442|NCT01012843|Drug|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
49443|NCT01012843|Drug|Placebo|oral Placebo tablets two times a day for 10 days
49444|NCT01012856|Behavioral|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
49445|NCT01012856|Behavioral|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
49446|NCT01012869|Device|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
52663|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
52664|NCT01026129|Drug|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
52665|NCT01026142|Drug|capecitabine [Xeloda]|1000 mg/m2 po twice daily for 14 days every 3 weeks
52666|NCT00027846|Drug|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
52667|NCT01026142|Drug|capecitabine [Xeloda]|1250 mg/m2 po twice daily for 14 days every 3 weeks
52668|NCT01026142|Drug|pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
52669|NCT01026142|Drug|trastuzumab [Herceptin]|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
52670|NCT01026155|Other|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
52955|NCT01062295|Device|Siesta-System|
52956|NCT01062295|Device|Standard headrest|
52957|NCT01062308|Procedure|Taping and Sham Taping|Taping shoulder with Hospiplast tape.
Taping the shoulder after acute stroke to prevent shoulder injury and pain.
Taping the shoulder after acute stroke and compare with sham taping group.
Treatments:
Positioning technique
Handling technique
Range of motion exercises
Taping technique
52958|NCT01062308|Procedure|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
52959|NCT01062334|Procedure|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
52960|NCT01062347|Biological|Zinc|
52961|NCT01064700|Device|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
52962|NCT01064713|Drug|Tesetaxel|Cohort A: 40 mg by mouth every 21 days.
Cohort B. 50 mg by mouth every 21 days.
52963|NCT01064726|Drug|Ibuprofen|800 mg oral
52964|NCT01064726|Drug|Fluticasone propionate|200 mcg intra-nasal
52965|NCT01064726|Drug|Placebo|Placebo
52966|NCT01064739|Dietary Supplement|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
53338|NCT01062919|Procedure|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
53339|NCT01062919|Procedure|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
53340|NCT01062932|Drug|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
53341|NCT01065259|Drug|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
53342|NCT01065272|Drug|Dexamethasone|0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.
1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days
53343|NCT01065272|Drug|Placebo|0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.
1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days
53344|NCT01065285|Biological|Evaluation of vaccines against flu|evaluate efficacy and tolerance
53345|NCT01065298|Biological|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of >40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
52368|NCT00028535|Biological|trastuzumab|Given IV
52369|NCT01033344|Biological|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
52370|NCT01033344|Biological|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
52371|NCT01033344|Biological|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
52372|NCT01033357|Device|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
52373|NCT01033357|Device|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
52374|NCT01033370|Drug|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes & titrated to the desired BP lowering effect to SBP goal of < 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
52375|NCT01033383|Dietary Supplement|Placebo|36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
52376|NCT01033383|Dietary Supplement|Cranberry Capsule|36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
53043|NCT01062399|Drug|temozolomide|Given orally
53044|NCT01062399|Radiation|3-dimensional conformal radiation therapy|Given 5 days a week for 6 weeks
53045|NCT01062399|Radiation|intensity-modulated radiation therapy|Given 5 days a week for 6 weeks
53046|NCT01062425|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiotherapy
53047|NCT01062425|Drug|Cediranib Maleate|Given PO
53048|NCT00031122|Other|No Intervention|There is no intervention in this study
53049|NCT01062425|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
53050|NCT01062425|Other|Laboratory Biomarker Analysis|Correlative studies
53051|NCT01062425|Other|Placebo|Given PO
53052|NCT01062425|Drug|Temozolomide|Given PO
53053|NCT01062438|Genetic|DNA analysis|
53054|NCT01062438|Genetic|RNA analysis|
53055|NCT01062438|Genetic|gene expression analysis|
53056|NCT01062438|Genetic|gene rearrangement analysis|
53057|NCT01062438|Genetic|mutation analysis|
53058|NCT01062438|Other|laboratory biomarker analysis|
53059|NCT00000906|Drug|Methadone hydrochloride|
53060|NCT00031135|Drug|Choline Chloride|
53061|NCT01062451|Drug|Perindopril|8 mg taken orally from days 0 through 7.
53062|NCT00031486|Drug|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
53402|NCT00030966|Drug|Placebo|Placebo monthly infusion for up to 116 weeks.
53403|NCT01062932|Drug|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
53404|NCT01062945|Drug|Placebo|Matching administration of a placebo pill.
49447|NCT01012882|Biological|sublingual immunotherapy with allergen extract|sublingual application
49448|NCT01012882|Biological|sublingual immunotherapy with placebo|sublingual application
49449|NCT01012895|Drug|BMS-790052|Tablets, Oral, 60 mg, once daily, 24 weeks
49450|NCT01012895|Drug|BMS-650032|Tablets, Oral, 600 mg, twice daily, 24 weeks
49451|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200mg, twice daily, 24 weeks
49452|NCT00026338|Drug|erlotinib hydrochloride|150 mg po daily
49453|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200 mg, once daily, 24 weeks
49759|NCT01006369|Drug|XELOX regimen|Capecitabine will be started at a dose of 1,000 mg/m2/day bid po (total daily dose = 2,000 mg/m2) for 14 days (28 doses) of the 21 day cycle. This cycle will be repeated every 21 days. Oxaliplatin will be started at a dose of 130 mg/m2, in 250 ml of D5W over 2 hours given day 1 of each cycle. This cycle will be repeated every 21 days.
49760|NCT01006369|Drug|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
49761|NCT01006395|Drug|Zoledronic acid|yearly infusion
49762|NCT01006395|Drug|Placebo|yearly infusion
49763|NCT00025649|Drug|doxorubicin hydrochloride|
49764|NCT01006408|Procedure|Low Level Laser|Low Level Laser twice a week for 8 weeks
49765|NCT01006408|Procedure|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
49766|NCT01006421|Dietary Supplement|GINGKO BILOBA|MEMOREX 60 MG BID
49767|NCT01006434|Other|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
49768|NCT01006447|Behavioral|Instructor contact|
49769|NCT01006447|Behavioral|Instructor contact|
49770|NCT01006460|Drug|Rhodiola rosea, L|3 Capsules twice a day
49771|NCT01008566|Drug|Sorafenib Tosylate|Given orally
49772|NCT01008592|Drug|levocetirizine or placebo|oral administration, single tablet, 5 mg.
49773|NCT01008605|Other|delivery system|syringe
48666|NCT01006915|Procedure|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
48667|NCT01006928|Other|Questionaire|Questionaire to mothers
48668|NCT01006941|Biological|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
48669|NCT01006954|Drug|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
48670|NCT01006954|Drug|Flare up|Flare up protocol in poor responders for IVF/ICSI
48671|NCT00000885|Drug|Adefovir dipivoxil|
48672|NCT00025662|Drug|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
48673|NCT01006967|Device|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
48674|NCT01006967|Other|Physical Therapy|Standard program of physical therapy for gait and balance
48675|NCT01006980|Drug|RO5185426|960 mg orally twice daily
48676|NCT01006980|Drug|dacarbazine|1000 mg/m2 iv every 3 weeks
48677|NCT01006993|Device|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
48678|NCT01007006|Device|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
48679|NCT01007019|Drug|YH4808 30mg|YH4808 30mg (single dose)
48680|NCT01007019|Drug|YH4808 50mg|YH4808 50mg (single dose)
48681|NCT01007019|Drug|YH4808 100mg|YH4808 100mg (single dose)
48682|NCT01007019|Drug|YH4808 200mg|YH4808 200mg (single dose)
48683|NCT00025662|Drug|Nexell Isolex system|CD34 selection/ T cell depletion used this system
48684|NCT01007019|Drug|YH4808|YH4808 400mg (single dose)
48685|NCT01007019|Drug|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
48686|NCT01009203|Drug|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
48687|NCT01009216|Drug|ABT-384|Doses will be administered daily for 5 days.
52377|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
52378|NCT01033396|Drug|Allegra|Fexofenadine single dose 60 mg
52379|NCT00028535|Drug|paclitaxel|Given IV
52380|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
52381|NCT01033396|Drug|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
52382|NCT01033396|Drug|Placebo|Placebo single dose
52383|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
52384|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
52385|NCT01025648|Drug|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 14 day washout period
52386|NCT00027833|Drug|leucovorin calcium|
52387|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
52388|NCT01025661|Other|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
52671|NCT01026194|Drug|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
52672|NCT01026194|Drug|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
52673|NCT01026207|Device|Polysomnography|Sleep study polysomnography compared with portable monitoring
52674|NCT01026220|Biological|bleomycin sulfate|Given IV or SC
52675|NCT01026220|Drug|doxorubicin hydrochloride|Given IV
52676|NCT01026220|Drug|liposomal vincristine sulfate|Given IV
52677|NCT00027846|Procedure|therapeutic conventional surgery|
48749|NCT01013987|Drug|Darunavir/ritonavir|darunavir : two 300 mg pills twice daily with meal
ritonavir: one 100 mg pill twice daily with meal
49053|NCT01009801|Drug|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
49054|NCT00026143|Biological|recombinant interferon alfa|Given SC
49055|NCT01009801|Other|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
49056|NCT01009814|Drug|BMS-663068 with or without ritonavir|8-day treatment with BMS-663068 with or without ritonavir
Group 1: BMS-663068 600 mg Q12H + ritonavir 100 mg Q12H
Group 2: BMS-663068 1200 mg QHS + ritonavir 100 mg QHS
Group 3: BMS-663068 1200 mg Q12H + ritonavir100 mg Q12H
Group 4: BMS-663068 1200 mg Q12H + ritonavir 100 mg QAM
Group 5: BMS-663068 1200 mg Q12H
49057|NCT01009827|Other|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
49058|NCT01009840|Drug|IV busulfan|PK-directed dosing of IV busulfan for 4 days
49059|NCT01009840|Drug|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m^2.
49060|NCT01009840|Procedure|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
49061|NCT01009853|Drug|Codeine Sulfate|15 mg tablet
49062|NCT01009866|Biological|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
49063|NCT01009879|Drug|Etanercept|Etanercept 50 mg SQ qweek
49064|NCT01009892|Drug|Codeine Sulfate|Tablet
49065|NCT00026143|Other|laboratory biomarker analysis|Correlative studies
49066|NCT01009905|Drug|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
49067|NCT01009918|Drug|Coreg CR®|Given orally
49068|NCT01009918|Drug|lisinopril|Given orally
49069|NCT01009918|Other|placebo|Given orally
49774|NCT01008618|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
49775|NCT01008618|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
49776|NCT01008631|Drug|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
49777|NCT01008644|Other|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
49778|NCT01008644|Other|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
49779|NCT00026065|Behavioral|Biofeedback|
49780|NCT01008657|Procedure|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
49781|NCT01008696|Drug|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
52935|NCT01031745|Behavioral|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
52936|NCT01031745|Other|Prize bowl drawings|Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive "bonuses" through prizebowl drawings to offset the inability to earn incentives.
52937|NCT01062152|Drug|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
52938|NCT01062165|Drug|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
52939|NCT01062178|Drug|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
52940|NCT01062191|Device|Aquacel AG, typical carboxymethylcellulose dressing|4" X 4", Aquacel silver sheet
52941|NCT00031096|Drug|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
52942|NCT01062191|Device|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
52943|NCT01062204|Device|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
52944|NCT01062204|Device|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
48993|NCT01012141|Drug|Docetaxel|
48994|NCT01012154|Device|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
48995|NCT01012167|Drug|Oxytocin|24 IU oxytocin or placebo in a total of 6 puffs (3 puffs per nostril)daily for 6 weeks
48996|NCT01012167|Drug|Galantamine or placebo Galantamine|Galantamine will be dispensed as follows: 4 mg bid x 7 days; 8mg bid x 7days, then 12 mg bid for the last 4 weeks.
48997|NCT01012167|Drug|Placebo|placebo-Galantamine 1 capsules twice a day and placebo-oxytocin 3 puffs in each nostril once a day.
48998|NCT01012193|Drug|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
48999|NCT01012206|Behavioral|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
49000|NCT01012219|Drug|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
49001|NCT01012219|Drug|Comparator: aspirin|81 mg oral tablet once daily for 7 days
49002|NCT00026286|Drug|medroxyprogesterone|
49003|NCT01012219|Drug|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
49004|NCT01012219|Drug|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
49005|NCT01012219|Drug|Comparator: placebo|placebo oral tablet once daily for 7 days
49006|NCT01012232|Drug|20 mL ropivacaine 5 mg/mL|
49007|NCT01012232|Drug|10 mL ropivacaine 10 mg/mL|
49008|NCT01012245|Other|no intervention|
49009|NCT01014533|Drug|Gabapentin or placebo dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. On the 8th night of medication, subjects return to the lab and sleep 3 more nights with the same procedures. Control subjects don't participate in the medication arm of the study; they just complete the first 3 baseline sleep nights.
49010|NCT01014546|Drug|Arsenic Trioxide|Given PO
49011|NCT01014546|Dietary Supplement|Ascorbic Acid|Given PO
49012|NCT01014546|Other|Laboratory Biomarker Analysis|Correlative studies
49013|NCT00000888|Drug|Zidovudine|
52678|NCT01026220|Drug|vinorelbine tartrate|Given IV
52679|NCT01026220|Drug|cyclophosphamide|Given IV
52680|NCT01026220|Drug|etoposide phosphate|Given IV
52681|NCT01026220|Drug|prednisone|Given IV
52682|NCT01026220|Biological|filgrastim|Given IV or SC
52683|NCT01026220|Drug|ifosfamide|Given IV
52684|NCT01026233|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
52685|NCT01026246|Drug|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
52686|NCT01028625|Behavioral|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
52687|NCT01028625|Other|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
52688|NCT01028638|Other|89Zr-bevacizumab PET scan|A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.
PET scans are made on day 1, day 15 and day 43.
52689|NCT01028651|Drug|Treprostinil sodium|Remodulin is supplied in 20 mL vials in concentrations of 1 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL. Remodulin can be administered as supplied or diluted for intravenous infusion with Sterile Water for Injection, 0.9% Sodium Chloride Injection, or Flolan® Sterile Diluent for Injection prior to administration.
Remodulin is indicated for subcutaneous (SC) or intravenous (IV) use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central intravenous line if the subcutaneous route is not tolerated, because of severe site pain or reaction. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min.
52974|NCT01064791|Drug|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
52975|NCT01064791|Drug|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
52976|NCT01064804|Drug|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
52977|NCT01064817|Drug|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
52978|NCT01064817|Drug|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
49070|NCT01009931|Drug|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
49071|NCT01009931|Drug|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
49072|NCT01009931|Drug|Choline magnesium trisalicylate|Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.
Up to 6 cycles.
49370|NCT01014949|Other|Coronary microcirculation assessment|Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014" coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine [140 ug/kg/min] to induce steady state maximal hyperemia.
49371|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
49372|NCT01014962|Drug|Placebo|Placebo oral once daily for 5 days
49373|NCT00026624|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
49374|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
49375|NCT01014962|Drug|Placebo|Placebo oral every 12 hours for 5 days
49376|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
49377|NCT01014962|Drug|Placebo|Placebo oral every 8 hours for 5 days
49378|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
49379|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
49380|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
49381|NCT01014988|Drug|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
49382|NCT01015001|Procedure|Active rTMS x sham (placebo) rTMS|Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations.
49383|NCT01015001|Procedure|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
52945|NCT01062230|Drug|Bortezomib (Velcade)|Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.
Patients will undergo three 21-day cycles.
52946|NCT01062243|Behavioral|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
52947|NCT01062256|Drug|Placebo|One placebo tablet administered orally as a single dose
52948|NCT01062256|Drug|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
52949|NCT01062256|Other|Buckwheat Honey|10 mL administered orally as a single dose
52950|NCT01062269|Drug|Cholestyramine|Cholestyramine 4 grams one time dose
52951|NCT01062269|Drug|Cholestyramine|Cholestyramine 12 grams one dose, one day
52952|NCT00031109|Biological|gp160 MN/LAI-2|
52953|NCT01062269|Drug|Tang|Tang one dose one day
52954|NCT01062282|Drug|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
53233|NCT01062568|Drug|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
53234|NCT01062594|Other|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
53235|NCT01062594|Other|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
53236|NCT01062594|Other|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
53237|NCT01062620|Drug|AXL1717|Phase I study with increasing dosage and treatment duration
53238|NCT01062633|Dietary Supplement|A, erythritol|2,5 g 3 times a day
53239|NCT01062633|Dietary Supplement|xylitol|2,5 g 3 times a day
53240|NCT01062633|Dietary Supplement|C, sorbitol|2,5 g 3 times aday
53241|NCT01062646|Behavioral|Multimodal music therapy|
49014|NCT00026494|Drug|vinorelbine tartrate|
49015|NCT01014546|Other|Pharmacological Study|Correlative studies
49313|NCT01007890|Other|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
49314|NCT01007903|Behavioral|Tai Chi exercise|12-week tai chi exercise class
49315|NCT01007916|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
49316|NCT01007916|Device|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
49317|NCT00025805|Drug|G-CSF|
49318|NCT01007929|Drug|14C-AZD1236|Oral solution 1mg/mL
49319|NCT01007942|Drug|everolimus, vinorelbine, trastuzumab|
49320|NCT01007942|Drug|Placebo + vinorelbine + trastuzumab|
49321|NCT01007968|Drug|LBH589|
49322|NCT01007994|Drug|New Medication: Enalapril, Isradipine, Propranolol|Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.
Dosing will be as follows:
ACEI: Enalapril < 40 kg starting dose 2.5 mg titrate to 5 mg > 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine < 40 kg 2.5 mg > 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol <40 kg starting dose 10 mg titrate to 20 mg >40 kg starting dose 20 mg titrate to 40 mg
49323|NCT01008007|Dietary Supplement|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
49324|NCT01010230|Device|LMHF mechanical stimulation active device|Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device ("vibrating") platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention.
49325|NCT01010230|Device|LMHF mechanical stimulation placebo device|Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device ("vibrating") platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention.
52979|NCT01064830|Drug|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
52980|NCT00000115|Drug|Acetazolamide|
52981|NCT00000230|Drug|Buprenorphine|
52982|NCT00000912|Drug|Abacavir sulfate|
52983|NCT01057290|Other|laboratory biomarker analysis|
52984|NCT01057303|Genetic|RNA analysis|
52985|NCT01057303|Genetic|gene expression analysis|
52986|NCT01057303|Genetic|reverse transcriptase-polymerase chain reaction|
52987|NCT01057303|Other|laboratory biomarker analysis|
52988|NCT01057316|Device|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
52989|NCT01057316|Device|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
52990|NCT01057316|Device|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
52991|NCT01057329|Drug|Atomoxetine|mg according to body weight
52992|NCT00030719|Drug|carboplatin|
52993|NCT01057329|Drug|Duloxetine|30 mg / die
52994|NCT01057329|Drug|Olanzapine|5mg 1 wwek and 10 mg from second week
52995|NCT01057329|Drug|Aripiprazole|5 mg from week 1, 10 mg from week 2
52996|NCT01057342|Drug|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
52997|NCT01057342|Drug|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
53346|NCT01065311|Behavioral|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
53347|NCT01065311|Behavioral|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
49384|NCT00026624|Drug|Keyhole-Limpet Hemocyanin|
49385|NCT01015001|Procedure|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
49386|NCT01015014|Drug|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
49387|NCT01015014|Drug|Placebo|0.9% sodium chloride for injection
49388|NCT01015027|Biological|REGN668|4 IV Cohorts (Dose 1, 2, 3, & 4)
49696|NCT01008566|Other|Laboratory Biomarker Analysis|Correlative studies
49697|NCT01010776|Drug|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
49698|NCT01010789|Drug|Armodafinil|flexible dose 150-250mg/day
49699|NCT01010789|Drug|Armodafinil|150-250mg/day; flexible dose
49700|NCT01010789|Drug|Matching placebo|Placebo comparator
49701|NCT01010802|Drug|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
49702|NCT01010815|Procedure|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
49703|NCT01010815|Other|stool collection|Stool will be collected from participants at study entry
49704|NCT01010815|Procedure|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
49705|NCT00026208|Drug|prednisone|40 mg/m2, Oral. Every other day. Taper 10 mg qod during last 2 weeks of chemotherapy
49706|NCT01010815|Other|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
49707|NCT01010828|Procedure|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
49708|NCT01010828|Procedure|Incision technique|Mini Mid-Vastus Approach
49709|NCT01010841|Dietary Supplement|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
49710|NCT01010841|Other|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
53242|NCT00031161|Drug|Dichloroacetate|
53243|NCT01062646|Behavioral|Community treatment as usual|
53244|NCT01062698|Drug|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
53245|NCT01062698|Procedure|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
53246|NCT01062711|Dietary Supplement|Whey or soy protein|Whey and casein are isolated milk proteins
53247|NCT01062724|Other|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
53248|NCT01062737|Drug|ASU|
53249|NCT01062750|Biological|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
53250|NCT01062763|Drug|spironolactone|25 to 50 mg once daily
53251|NCT01062763|Drug|placebo|addition of placebo 1 to 2 tablets daily
53252|NCT01062776|Biological|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
53253|NCT00031161|Behavioral|Low-tyrosin diet|
53254|NCT01062776|Biological|Placebo|No dehydration is induced
53565|NCT01060774|Drug|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
53566|NCT01060787|Procedure|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
53567|NCT01060787|Procedure|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
53568|NCT01060813|Dietary Supplement|Leucine supplements|leucine supplements
53569|NCT01060826|Other|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
53570|NCT00030992|Drug|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
53571|NCT01060826|Drug|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
49326|NCT01010243|Drug|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.
Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy
49327|NCT01010269|Device|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
49328|NCT01010269|Device|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
49640|NCT01013129|Procedure|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
49641|NCT01013129|Procedure|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
49642|NCT01013142|Drug|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
49643|NCT01013142|Drug|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
49644|NCT01013142|Drug|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
49645|NCT01013155|Drug|perindopril erbumine|8 mg tablet
49646|NCT01013168|Procedure|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
49647|NCT01013194|Other|Human Fetal Liver Cell Transplantation|Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.
Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.
Cell infusion: between 5 and 10x10^8 cells. Number of sessions: up to 2.
49648|NCT01013207|Device|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
49649|NCT01013207|Device|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
49650|NCT00026364|Drug|gefitinib|
49651|NCT01013207|Device|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
49652|NCT01013220|Other|Depression Product Detailing|two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits
technical assistance in purchasing high quality depression management products
53348|NCT01065311|Biological|Standard psychiatric care|Antidepressant medication and medical care.
Standard psychiatric outpatient care:
All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist
53349|NCT00031551|Drug|Etanercept|
53350|NCT01065337|Biological|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
53351|NCT01065337|Biological|bone marrow stem cells (BMC)|bone marrow stem cells
53352|NCT01065350|Drug|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
53353|NCT01065350|Drug|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
53354|NCT01065363|Behavioral|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
53355|NCT01057875|Other|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
53356|NCT01057888|Other|Autodialer|Autodialer telephone calls
53357|NCT01057888|Other|Letters|Mailed reminder letters
53358|NCT01057901|Drug|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
53359|NCT01057901|Drug|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
53360|NCT01057914|Dietary Supplement|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
53361|NCT01057914|Other|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
52389|NCT01025674|Behavioral|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
49711|NCT01010854|Drug|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
49712|NCT01010867|Drug|Lactobacillus plantarum strains 299 and 299v|Patients will receive a daily dose of Lactobacillus plantarum: 1 x10^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.
49713|NCT01010880|Drug|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
49714|NCT01010893|Biological|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
49715|NCT01010893|Biological|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
48750|NCT01014000|Device|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
48751|NCT01014000|Device|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
48752|NCT01014013|Drug|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
48753|NCT01014013|Drug|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
48754|NCT01014026|Other|Screening test|Two Vaginal self sampling devices and HPV test
48755|NCT01007019|Drug|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
48756|NCT01007019|Drug|YH4808 600mg|YH4808 600mg
48757|NCT01007019|Drug|YH4808 800mg (single dose)|YH4808 800mg (single dose)
48758|NCT01007019|Drug|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
48759|NCT01007019|Drug|Placebo|10 volunteers will be administered matched placebo.
48760|NCT01007019|Drug|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
48761|NCT01007032|Biological|IMC-A12|IMC-A12 intravenously
48762|NCT01007071|Drug|Human Growth hormone - nutropin|
48763|NCT00025675|Drug|gefitinib|
53572|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
53573|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
53574|NCT01063218|Other|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
53575|NCT01063231|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
53576|NCT01063244|Device|foley balloon only|place foley balloon only in cervix
53577|NCT01063244|Device|foley balloon with weight attached|foley balloon with weight attached
53578|NCT00000909|Drug|Aldesleukin|
53579|NCT00031278|Drug|CPG 7909|Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
53580|NCT01063257|Drug|Clofarabine|The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:
DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).
The DLa will be the following:
DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation.
53581|NCT01063270|Drug|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
53582|NCT01063270|Procedure|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
53583|NCT01063283|Drug|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
53584|NCT01063283|Drug|Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg|Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
52609|NCT01028586|Drug|Placebo|matching placebo tablets
52610|NCT01028599|Other|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
52611|NCT00027937|Drug|melphalan|
52612|NCT01028612|Radiation|thermal ablation with external beam radiation|thermal ablation with external beam radiation
52613|NCT01031004|Device|narafilcon B|contact lens
52614|NCT01031004|Device|etafilcon A|contact lens
52615|NCT01031017|Drug|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
49653|NCT01006122|Drug|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
49654|NCT01006148|Biological|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite. Following the conversion the material is no longer coral but a composite of highly resorbable calcium carbonate with a slower resorbing outer layer of calcium phosphate. The material retains the porous, interconnected architecture of coral which gives it a similar structure to cancellous bone, which provides a pathway for bony ingrowth.
48688|NCT01009229|Dietary Supplement|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
48689|NCT01009242|Biological|CDP6038|Single dose:
1 mg/kg CDP6038 IV
48690|NCT00026104|Drug|tipifarnib|Given orally
48691|NCT01009242|Biological|CDP6038|Single dose:
0.1mg/kg CDP6038 IV
48692|NCT01009242|Biological|CDP6038|Single dose:
1.0mg/kg CDP6038 SC
48693|NCT01009242|Other|Placebo IV|Single dose:
Placebo IV
48694|NCT01009242|Other|Placebo SC|Single dose:
Placebo SC
48695|NCT01009242|Drug|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
48696|NCT01009255|Drug|GSK239512|Histamine H3 Antagonist
48697|NCT01009255|Drug|Placebo|Placebo to match GSK239512
48698|NCT01009268|Procedure|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
48699|NCT01009281|Drug|AIN457|
48700|NCT01009294|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner) for up to 48 weeks.
48701|NCT00026104|Radiation|radiation therapy|Undergo radiation therapy
48702|NCT01009307|Genetic|polymorphism analysis|
52390|NCT01025687|Dietary Supplement|water with noncalorie sweetener|
52391|NCT01025687|Dietary Supplement|water with glucose|
52392|NCT01025687|Behavioral|TV program showed while feeding|
52393|NCT01025687|Behavioral|TV program showed while feeding|
52394|NCT01025700|Drug|Cesemat|1 mg capsule per day for 21 days
52395|NCT01025713|Drug|GS-9411|Inhaled GS-9411
52396|NCT01025713|Drug|Placebo|Inhaled Placebo
52397|NCT00027846|Biological|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC >1500/μl given subcutaneously or intravenously.
52398|NCT01025726|Behavioral|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
52399|NCT01025726|Behavioral|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
52400|NCT01025726|Behavioral|General Health Education|Host community events for chronic disease education
52401|NCT01025739|Device|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
52402|NCT01025752|Behavioral|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
52403|NCT01025752|Behavioral|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
52404|NCT01028157|Behavioral|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
52405|NCT01028157|Behavioral|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
52406|NCT01028170|Drug|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
48764|NCT01007084|Drug|Propranolol|40 mg
48765|NCT01007084|Drug|Propranolol ER|120 mg twice per day
48766|NCT01007084|Drug|Sugar pills|sugar pill
48767|NCT01007097|Drug|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
48768|NCT01007097|Drug|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
48769|NCT01007097|Drug|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
48770|NCT01007097|Drug|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
48771|NCT01007097|Drug|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
48772|NCT01007097|Drug|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
49073|NCT01009944|Drug|Lisinopril, Atenolol|once a day for 14 weeks
49074|NCT01009957|Drug|Everolimus|0.75 mg x 2 / day
49075|NCT01012258|Biological|Cetuximab + concomitant boost radiotherapy|Cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially
Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by
Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval
49076|NCT01012271|Other|MRI|MR arthrography is used to evaluate wrist abnormalities
49077|NCT01012284|Drug|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
49078|NCT01012297|Biological|Bevacizumab|Given IV
49079|NCT00026299|Drug|ZD1839|
49080|NCT01012297|Drug|Docetaxel|Given IV
49081|NCT01012297|Biological|Filgrastim|Given SC
49082|NCT01012297|Drug|Gemcitabine Hydrochloride|Given IV
49083|NCT01012297|Biological|Pegfilgrastim|Given SC
49084|NCT01012297|Other|Placebo|Given IV
52616|NCT01031017|Drug|placebo|placebo
52617|NCT01031030|Drug|cyclophosphamide|
52618|NCT01031030|Drug|epirubicin hydrochloride|
52619|NCT01031030|Drug|fluorouracil|
52620|NCT01031030|Drug|methotrexate|
52621|NCT00028288|Drug|Daclizumab|
52622|NCT01031030|Other|laboratory biomarker analysis|
52623|NCT01031030|Procedure|adjuvant therapy|
52624|NCT01031043|Drug|Bethanechol|Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
52625|NCT01031056|Procedure|Blood Draw|
52626|NCT01031056|Procedure|Frozen Tumor Specimens|
52627|NCT01031069|Biological|GSK Biologicals' HPV vaccine 580299|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
52628|NCT01031069|Biological|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
52629|NCT01031082|Procedure|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
52630|NCT01031095|Other|coronary intervention|elective coronary intervention
52631|NCT01031108|Drug|Placebo|For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
52632|NCT00028301|Drug|Atazanavir|
53255|NCT01065064|Procedure|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
53256|NCT00031499|Drug|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
53257|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
48703|NCT01009307|Other|laboratory biomarker analysis|
48704|NCT01009307|Other|medical chart review|
48705|NCT01009333|Device|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
48706|NCT01009333|Device|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
48707|NCT01009333|Device|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
48708|NCT01009346|Drug|RAD001|Dose Level -1 2.5mg/day
Dose Level 1 5mg/day*
Dose Level 2 10mg/day
MTD RAD001
48709|NCT01009346|Drug|Cetuximab|250mg/m2/week
48710|NCT01009346|Drug|Cisplatin|40mg/m2 Day 1, 8 every 28 days
49016|NCT01014559|Drug|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
49017|NCT01014559|Drug|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
49018|NCT01014572|Behavioral|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
49019|NCT01014572|Drug|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
49020|NCT01014572|Behavioral|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
49021|NCT01014585|Drug|Placebo|Placebo tablets administered orally twice daily
49022|NCT01014585|Drug|Milnacipran|Milnacipran tablets administered orally twice daily
49023|NCT01014598|Drug|Cisplatin|Given intra-arterially via isolated lung suffusion
49024|NCT01014598|Other|Pharmacological Study|Correlative studies
49025|NCT00026520|Biological|recombinant interferon alfa|
49026|NCT01014624|Drug|prasugrel|Prasugrel 10mg tablet administered once daily for 7 days.
After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria.
52690|NCT01028664|Device|SENSIMED Triggerfish|2-hour continuous IOP monitoring
52691|NCT01028677|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
52692|NCT01028677|Other|formulated solution containing all ingredients as Syntocinon Spray except for oxytocin|Treatment consists of 6 insufflations (0.1 metered dose/insufflation) twice daily for 6 weeks of a formulated solution that contains all ingredients in Syntocinon Spray except for oxytocin.
52693|NCT01028690|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
52694|NCT01028690|Dietary Supplement|Placebo|placebo
52695|NCT00027937|Drug|paclitaxel|
52696|NCT01028716|Drug|Cyclophosphamide|Given IV
52697|NCT01028716|Biological|Filgrastim|Given IV or SC
52698|NCT01028716|Drug|Fludarabine Phosphate|Given IV
52699|NCT01028716|Procedure|Laboratory Biomarker Analysis|Correlative studies
52700|NCT01028716|Drug|Mycophenolate Mofetil|Given PO
52701|NCT01028716|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
52702|NCT01028716|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
52703|NCT01028716|Drug|Tacrolimus|Given IV or PO
52704|NCT01028716|Radiation|Total-Body Irradiation|Undergo total-body irradiation
52705|NCT01028729|Drug|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
52706|NCT00027937|Drug|thiotepa|
52707|NCT01031147|Other|Examination|3D−TOF−MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
52708|NCT01031173|Biological|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
52709|NCT01031186|Drug|GSK356278|GSK356278
52710|NCT01031186|Drug|PLACEBO|PLACEBO
49085|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
49086|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
49087|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
49088|NCT01012310|Drug|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
49089|NCT01012323|Biological|NewGam|Intravenous Q 3 weeks, up to .08 Ml/kg
49090|NCT00026299|Drug|oxaliplatin|
49091|NCT01012323|Biological|NewGam|Q 4 weeks, Intravenous, up to .08 ml/kg
49092|NCT01012336|Drug|Aprepitant/Ramosetron/Dexamethasone|Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.
Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.
Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg.
49093|NCT01012349|Drug|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
49389|NCT01015040|Drug|solifenacin succinate suspension|Oral
49390|NCT01015040|Drug|solifenacin succinate tablet|Oral
49391|NCT01015053|Procedure|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
49392|NCT01008007|Drug|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
49393|NCT01008020|Dietary Supplement|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
49394|NCT01008033|Drug|IDP-108|Topical application once a day for 48 weeks
49395|NCT01008033|Drug|Vehicle|Topical application once a day for 48 weeks
49396|NCT00025818|Drug|Ophthalmic Emulsion|
49397|NCT01008046|Drug|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
53258|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
53259|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
53260|NCT01065077|Drug|Placebo|Infusion of placebo during 48h
53261|NCT01065103|Procedure|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
53262|NCT01065116|Drug|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
53263|NCT01065116|Drug|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
53264|NCT01065129|Drug|G-CSF|
53265|NCT01065129|Drug|Plerixafor|
53266|NCT01065129|Drug|Azacitidine|
53267|NCT00031512|Drug|Placebo|Placebo.
53268|NCT01065142|Procedure|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
53269|NCT01065194|Drug|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
53270|NCT01065194|Drug|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
53271|NCT01065207|Biological|blood test at day one|Epidemiological, clinical, virological, and immunological data will be collected.
Clinical events as neoplasia will be collected
53272|NCT01065220|Drug|Testolactone undecanoate|4ml i.m.
53273|NCT01065220|Drug|Lynestrenol|2/day
53274|NCT01065220|Drug|Cyproterone Acetate|50mg per day
53275|NCT01065220|Drug|Estradiol|100 microgram TTS twice a week
53276|NCT01065220|Drug|5-alpha reductase inhibitor|1mg daily
53277|NCT01065233|Genetic|DNA extraction|DNA extraction of blood sample for DNAship analysis
53293|NCT01057836|Behavioral|Stretching|
53294|NCT01057849|Drug|risperidone|3-6 mg per day
53295|NCT01057849|Drug|olanzapine|5-20 mg per day
49027|NCT01014624|Drug|clopidogrel|Clopidogrel 75 mg tablet administered once daily for 7 days.
After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria.
49028|NCT01014637|Drug|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
49029|NCT01014637|Drug|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
49030|NCT01014650|Drug|GLYX-13|single IV or SC dose
49031|NCT01007461|Drug|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
49032|NCT01007474|Device|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
49033|NCT01007474|Device|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
49034|NCT01007474|Device|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
49329|NCT01010282|Drug|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
49330|NCT01010282|Drug|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
49331|NCT01010282|Drug|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
49332|NCT00026182|Biological|rituximab|Given IV
49333|NCT01010295|Drug|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
49334|NCT01010308|Drug|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
49335|NCT01010321|Device|confocal microscopy|non-invasive imaging
49336|NCT01010334|Other|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
49337|NCT01010347|Procedure|Volar Splint|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
52711|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
52712|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
52998|NCT01057342|Drug|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
52999|NCT01057355|Procedure|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
53000|NCT01057368|Behavioral|Day of intensive meditation practice|Long-term meditators practice for ~6 hours of meditation at each time point
53001|NCT01057368|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
53002|NCT01057368|Behavioral|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
53003|NCT00030719|Drug|cyclophosphamide|
53004|NCT01057381|Drug|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
53005|NCT01057381|Drug|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
53006|NCT01057381|Drug|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
53007|NCT01057381|Drug|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
53008|NCT01057394|Device|Endoscopically Guided Ablation|Visually Guided Ablation using the EAS-AC Radiofrequency Ablation
53009|NCT01057407|Drug|ASP1585|oral
53010|NCT01057407|Drug|Sevelamer hydrochloride|oral
53011|NCT01059643|Drug|LY2523355|Dose determined by patient body surface area: 5 mg/m2, administered intravenously on days 1, 2, 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
53012|NCT01059643|Drug|pegfilgrastim|6 mg, administered subcutaneously 24 hours after third dose of LY2523355 on day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
53013|NCT01059656|Drug|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
53014|NCT01059669|Other|diagnostic test|
49398|NCT01008046|Drug|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
49399|NCT01008059|Drug|grapefruit juice|grapefruit juice consumed within 24 hours of inducing CYP3A liver activity rifampin 500mg daily for 5 days ketoconazole 400 mg daily for 3 days
49400|NCT01008059|Drug|delayed alfentanil|Alfentanil bolus .5-1.0mg IV, then labeled alfentanil administered orally 4 hours later
49401|NCT01008059|Drug|concomitant alfentanil|Alfentanil .5-1.0 mg IV + labeled alfentanil one time bolus
49402|NCT01008085|Device|Stentys coronary stent|Self-expanding Nitinol stent
49403|NCT01008085|Device|Balloon-expandable stent|VISION/Driver
49404|NCT01008098|Drug|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
49405|NCT01008111|Drug|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
49406|NCT01008111|Drug|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
49407|NCT00025883|Drug|Metreleptin|
49716|NCT00026208|Drug|vincristine|1.4 mg/m2; IV wk 2, 4, 6, 8
49717|NCT01010906|Drug|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
49718|NCT01010906|Drug|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
49719|NCT01010919|Dietary Supplement|Chicory root extract|
49720|NCT01013220|Other|Depression HEDIS detailing|academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition
technical assistance
49721|NCT01013233|Behavioral|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
49722|NCT01013233|Other|control group|no intervention
49723|NCT01013246|Other|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
53296|NCT01057849|Drug|Aripiprazole|10-30 mg per day
53297|NCT01057862|Drug|Naltrexone|Targeted dosage of 50mg PO daily
53298|NCT00030719|Procedure|peripheral blood stem cell transplantation|
53299|NCT01057862|Other|Placebo|Sugar pills daily PO
53300|NCT01057875|Other|caffeine|Starbuck's Grande Pike Roast coffee
53301|NCT00030901|Drug|L-selenomethionine placebo|Randomization between active L-selenomethionine and placebo
53302|NCT01060111|Drug|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
53303|NCT01060124|Drug|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
53304|NCT01060137|Drug|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
53305|NCT01060150|Drug|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
53306|NCT01060163|Drug|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
53307|NCT01060163|Drug|Saline|Saline served as placebo
53308|NCT01060176|Drug|Tranexamic Acid|High, medium and low dosage, loading dose followed by continuous infusion in operation
53309|NCT01060189|Drug|UTI & TA|Ulinastatin, tranexamic acid and the combination of the two
53310|NCT01060202|Drug|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
53311|NCT01060215|Procedure|Normal saline|20 cc normal saline injection into the knee joint
53312|NCT00030914|Drug|medroxyprogesterone|
53313|NCT01060228|Drug|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
53314|NCT01060228|Drug|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
53585|NCT01063348|Drug|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
49338|NCT01010347|Procedure|Cast|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
49339|NCT01010373|Drug|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
49340|NCT01010386|Procedure|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
49341|NCT01010386|Procedure|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
49342|NCT01012674|Other|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
49343|NCT01012687|Drug|perindopril erbumine|8 mg tablet
49344|NCT01012700|Drug|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
49345|NCT01012713|Drug|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
49346|NCT01012713|Drug|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
49347|NCT01012713|Procedure|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
49348|NCT01012726|Procedure|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
49655|NCT01006161|Drug|SCH 527123|Low dose
49656|NCT01006161|Drug|SCH 527123|Medium dose
49657|NCT01006161|Drug|SCH 527123|High dose
49658|NCT00000885|Drug|Levocarnitine|
49659|NCT00025649|Drug|busulfan|
49660|NCT01006161|Drug|SCH 527123|Placebo to match SCH 527123
49661|NCT01006174|Other|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
49662|NCT01006174|Other|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
49663|NCT01006174|Other|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
49664|NCT01006187|Drug|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
53015|NCT01059682|Drug|Placebo|Placebo orally once daily
53016|NCT01059682|Drug|dalcetrapib|Dalcetrapib 600 mg orally once daily
53017|NCT01059721|Procedure|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
53018|NCT01059734|Genetic|DNA analysis|
53019|NCT01059734|Genetic|RNA analysis|
53362|NCT01057914|Other|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
53363|NCT00030719|Radiation|radiation therapy|
53364|NCT01057927|Drug|OC000459|OC000459 capsules 2x100mg BID for 28 days
53365|NCT01057927|Drug|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
53366|NCT01057940|Procedure|DBE PEJ placement|One time procedure with follow-up telephone call.
53367|NCT01057953|Genetic|Blood drawn|Blood drawn for patient
53368|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
53369|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
53370|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
53371|NCT01057979|Behavioral|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
53372|NCT01057979|Behavioral|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
53373|NCT01057992|Device|Magnetic Esophageal Sphincter|Implantable device
53374|NCT00030732|Drug|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
53375|NCT01058005|Drug|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
53376|NCT01058005|Drug|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
53377|NCT01058005|Drug|glatiramer acetate|20 mg subcutaneous injection once daily
49724|NCT01013259|Drug|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
49725|NCT01013259|Drug|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
49726|NCT01013272|Drug|Entecavir|Entecavir 0.5mg orally daily
49727|NCT01013272|Drug|Lamivudine|Lamivudine 100mg orally, daily
49728|NCT00026364|Drug|irinotecan hydrochloride|
49729|NCT01013285|Biological|bevacizumab|
49730|NCT01013285|Drug|temozolomide|
49731|NCT01013285|Radiation|external beam radiation therapy|
49732|NCT01013298|Device|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
49733|NCT01013324|Drug|XL147 (SAR245408)|dosed as capsules taken orally daily
49734|NCT01013337|Procedure|acupuncture therapy|
49735|NCT01013337|Procedure|sham intervention|Placebo acupuncture
49736|NCT01013350|Drug|Cladribine|This is an observational study. Subjects who had already participated in the cladribine clinical trials will be observed.
49737|NCT01013363|Other|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
49738|NCT01013376|Drug|MC-1101|MC-1101 1.0%
49739|NCT00026364|Drug|leucovorin calcium|
48773|NCT01007097|Drug|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
48774|NCT00025688|Drug|carboplatin|
48775|NCT01007110|Dietary Supplement|DHA|Docosahexaenoic Acid (DHA) from algal oil
48776|NCT01007110|Other|Placebo|Placebo capsule
48777|NCT01007123|Drug|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
48778|NCT01007136|Device|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
53586|NCT01063348|Drug|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
53587|NCT01063361|Dietary Supplement|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
53588|NCT01063361|Dietary Supplement|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
53589|NCT01063374|Dietary Supplement|low glycemic diet instruction|
53590|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
53591|NCT01063374|Dietary Supplement|high cereal fibre diet instruction|
53592|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
53593|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
53594|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
53595|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
53596|NCT01065389|Behavioral|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
53597|NCT01065389|Behavioral|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
53598|NCT01065402|Dietary Supplement|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
53599|NCT00031551|Drug|Placebo|
53600|NCT01065402|Dietary Supplement|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
53601|NCT01065441|Biological|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10^7 cells
49665|NCT01006187|Drug|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
49666|NCT01006187|Other|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
49667|NCT01006187|Other|Distraction|By means of self-selected reading material or video
49668|NCT01006213|Behavioral|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
49669|NCT01006226|Drug|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
49670|NCT00025649|Drug|carboplatin|
49671|NCT01006239|Other|No study intervention|The is no study related intervention.
49672|NCT01006252|Drug|Tasisulam|Individualized dose dependent on patient's height, weight, and gender and is adjusted to target a specific exposure based on a patient's laboratory parameters, administered intravenously on day 1 of 28 day cycle, until disease progression.
49673|NCT01006252|Drug|Paclitaxel|80 mg/m2 administered intravenously on days 1, 8, and 15 of 28 day cycle, until disease progression
49674|NCT01006265|Drug|ACT-128800|ACT-128800 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally once daily
49675|NCT01008462|Drug|Melphalan|Given IV
49676|NCT01008462|Drug|Mycophenolate Mofetil|Given PO
49677|NCT01008462|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
48711|NCT01011725|Drug|MK0773|25 mg oral tablet b.i.d. MK0773 or 100 mg oral tablet b.i.d. MK0773, for 12 weeks
48712|NCT00026247|Procedure|radiofrequency ablation|
48713|NCT01011725|Drug|Placebo|Placebo oral tablet b.i.d for 12 weeks
48714|NCT01011751|Drug|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
48715|NCT01011751|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
48716|NCT01011751|Drug|Venlafaxine|Venlafaxine capsule.
48717|NCT01011751|Drug|Leuprorelin|Leuprorelin injection.
48718|NCT01011751|Drug|Flutamide|Flutamide tablet
53378|NCT01058018|Drug|RVX000222|RVX000222 or placebo twice a day for 12 weeks
53379|NCT01058031|Behavioral|MBSR|Mindfulness Based Stress Reduction
53380|NCT01058044|Other|Evaluation of adherence to 3 oral anticancer treatment using a " Medication Event Monitoring System "|Evaluation of adherence using a " Medication Event Monitoring System " (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy
53381|NCT01060293|Drug|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
53382|NCT01060293|Drug|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
52407|NCT01028170|Drug|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
52408|NCT01028209|Drug|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]PBR06, followed by PET imaging.
52409|NCT01028222|Drug|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
52410|NCT01028222|Drug|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
52411|NCT01028248|Drug|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
52412|NCT01028261|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
52413|NCT01028274|Dietary Supplement|Placebo|Two capsules, twice daily with meals for 12 weeks.
52414|NCT00027937|Biological|aldesleukin|
52415|NCT01028274|Dietary Supplement|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
52416|NCT01028274|Dietary Supplement|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
52417|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
52418|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
52419|NCT01028300|Device|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
52420|NCT01028313|Drug|LBH589|20 mg PO three times weekly
52421|NCT01028313|Drug|Methylprednisolone|1 mg/kg/day PO continuously
48779|NCT01007136|Device|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
48780|NCT01007149|Drug|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
48781|NCT01007149|Drug|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
48782|NCT01007175|Biological|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
48783|NCT01009346|Drug|Carboplatin|Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:
Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance.
48784|NCT00026117|Drug|BenFin|
48785|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
48786|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
48787|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
48788|NCT01009372|Behavioral|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
48789|NCT01009385|Procedure|cervical epidural steroid injection|After aseptic preparation and skin infiltration with 1% lidocaine
20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level
identification of the epidural space confirmed by injection of contrast medium under fluoroscope
injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).
Post-procedure, patients were observed for any adverse effects and followed with a neurological examination
48790|NCT01009385|Procedure|epidural pressure measurement|The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.
Identification of the epidural space and measurement of EP was performed with a closed measurement system.
49094|NCT01012349|Drug|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
49095|NCT01012362|Drug|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
49096|NCT01012362|Drug|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
49097|NCT01012375|Drug|AZD1446|10 mg capsule, oral dose
49098|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
53602|NCT01065441|Procedure|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
52633|NCT01031108|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
52634|NCT01031134|Behavioral|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
52635|NCT01031134|Other|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
52636|NCT01033643|Drug|Comparator: MK3614 multiple rising dose|Day 1 subjects will receive 0.50 mg twice a day every 12 hours. Day 2 subjects will receive 3 doses (0.50/0.50/0.25 mg) each 8 hours apart. Days 3-4 subjects will receive 3 doses of 0.50 mgs 8 hours apart. Days 5-14 subjects will receive 0.75 mgs twice a day every 12 hours.
52637|NCT01033643|Drug|Comparator: Placebo Panel A|Oral Placebo BID every 12 hours for 10 days
52638|NCT01033643|Drug|Comparator: Placebo Panel B-C|Oral Placebo in the AM, 0.25 mg in the PM 12 hours apart for 10 days
52639|NCT01033643|Drug|Comparator: Placebo Panel D|Day 1 subjects will receive oral placebo three times a day every 8 hours. Days 4-13 subjects will receive oral placebo twice a day every 12 hours.
52640|NCT01033643|Drug|Comparator: Placebo Panel E|Day 1 subjects will receive oral placebo twice a day every 12 hours. Day 2 subjects will receive 3 doses of oral placebo each 8 hours apart. Days 3-4 subjects will receive 3 doses of oral placebo 8 hours apart. Days 5-14 subjects will receive oral placebo twice a day every 12 hours.
52641|NCT00028561|Other|laboratory biomarker analysis|Correlative studies
52642|NCT01033656|Drug|anakinra|100 mg subcutaneous injection daily
52643|NCT01033669|Device|CRC-749|There is no drug being used. This is a device.
52644|NCT01033669|Device|Diskus|There is no drug being used. This is a device.
52645|NCT01033669|Device|Twisthaler|There is no drug being used. This is a device.
52646|NCT01033669|Device|Miat Monohaler|There is no drug being used. This is a device.
52647|NCT01033708|Behavioral|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
52648|NCT01033721|Drug|Palomid 529|comparison of different dosages of drug
48719|NCT01011751|Drug|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
48720|NCT01011764|Behavioral|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
48721|NCT01011777|Drug|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
48722|NCT01011790|Behavioral|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
48723|NCT00000887|Drug|Lamivudine|
48724|NCT00026260|Drug|semaxanib|
48725|NCT01011803|Other|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
48726|NCT01011816|Biological|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
48727|NCT01011816|Drug|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
48728|NCT01011829|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
49035|NCT00025753|Drug|rosiglitazone (Avandia)|
49036|NCT01007474|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
49037|NCT01007474|Device|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
49038|NCT01007500|Drug|Dexamethasone, Ondansetron|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
52422|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
52423|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
52424|NCT01028326|Biological|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
52425|NCT00027937|Biological|filgrastim|
52426|NCT01030692|Drug|Placebo|The placebo groups will receive the same dosage throughout the study.
52427|NCT01030692|Drug|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
52713|NCT01031212|Drug|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
52714|NCT00028301|Drug|Lopinavir/Ritonavir|
52715|NCT01031212|Drug|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
52716|NCT01031212|Drug|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
52717|NCT01031212|Drug|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
52718|NCT01031225|Drug|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
52719|NCT01031290|Device|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
52720|NCT01031303|Biological|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
52721|NCT01031316|Other|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
52722|NCT01031316|Other|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
52723|NCT01031329|Procedure|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
52724|NCT01031342|Procedure|Early colonoscopy|Colonoscopy within 12 hours of presentation
52725|NCT00028314|Drug|Abacavir sulfate|
52726|NCT01031342|Procedure|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
49099|NCT01014767|Drug|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
49100|NCT01014767|Drug|Vincristine|Standard Arm (1), Cycles 1 & 2 : 1.5 mg/m^2 IV over 15 minutes on day 5
Doxorubicin/cisplatin arm (2), Cycles 1 & 2: 1.5 mg/m^2/day (max. 2 mg), i.v. on days 8, 15
For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5
49101|NCT00026585|Drug|Tamoxifen|
49102|NCT01014793|Drug|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
49103|NCT01014806|Biological|Influenza VLP Vaccine|Single dose; 0.5mL
49104|NCT01014806|Biological|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
49105|NCT01014832|Drug|Intensive insulin therapy|Intensive insulin therapy
49106|NCT01014845|Biological|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
49107|NCT01014845|Biological|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
49108|NCT01014858|Drug|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
49109|NCT01014871|Drug|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
49110|NCT01014871|Drug|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
49111|NCT01014884|Other|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
49112|NCT00026611|Biological|Dryvax vaccine|
49113|NCT01014884|Other|Multidisciplinary team bimonthly visits either in person or via telephone.|
49114|NCT01014884|Other|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
49408|NCT01008124|Other|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
49409|NCT01008124|Other|Placebo maneuver|3 cycles placebo maneuver initial session.
52649|NCT01033734|Drug|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
52650|NCT01033747|Drug|Deferasirox|10 mg/kg or 30 mg/kg orally daily
53278|NCT00031512|Drug|Pleconaril (VP63843)|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
53279|NCT01065246|Drug|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
53280|NCT01065259|Drug|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
53281|NCT01057758|Drug|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
53282|NCT01057758|Drug|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
53283|NCT01057771|Behavioral|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
53284|NCT01057771|Behavioral|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
53285|NCT01057784|Procedure|Bariatric surgery.|Bariatric Surgery
53286|NCT01057797|Behavioral|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
53287|NCT00030719|Procedure|conventional surgery|
53288|NCT01057797|Behavioral|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
53289|NCT01057797|Behavioral|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
49039|NCT01007513|Procedure|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
49040|NCT01007513|Procedure|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
49041|NCT01007526|Other|concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation|concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
49042|NCT01007539|Dietary Supplement|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
49043|NCT01007539|Dietary Supplement|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
49044|NCT01007552|Drug|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
49045|NCT01007565|Procedure|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
49046|NCT00000885|Drug|Lamivudine|
49047|NCT00025753|Behavioral|Aerobic and weight lifting exercise training|
49048|NCT01007578|Device|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
49049|NCT01007591|Drug|LEO 80190|Applied once daily
49050|NCT01007591|Drug|Hydrocortisone|Applied once daily
49051|NCT01007604|Device|Peristaltic pulse PCD|Daily use for two hours
49052|NCT01009801|Drug|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
49349|NCT00026312|Other|Pharmacological Study|Correlative studies
49350|NCT01012739|Drug|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
49351|NCT01012739|Drug|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
52727|NCT01031355|Drug|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
52728|NCT01031355|Drug|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
52729|NCT01031355|Drug|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
52730|NCT01031368|Drug|cytarabine|Given IV
52731|NCT01031368|Drug|clofarabine|Given IV
52732|NCT01031368|Drug|filgrastim|Given SC
52733|NCT01031368|Procedure|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
52734|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
52735|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
53020|NCT01059734|Genetic|mutation analysis|
53021|NCT00030849|Drug|bexarotene|
53022|NCT01059734|Genetic|polymerase chain reaction|
53023|NCT01059734|Genetic|polymorphism analysis|
53024|NCT01059734|Other|laboratory biomarker analysis|
53025|NCT01059747|Other|no intervention applied|no intervention applied
53026|NCT01059760|Behavioral|Fasting|Volunteers will be asked to fast for 24-28 hours.
53027|NCT01059773|Drug|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
53028|NCT01059773|Drug|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
53029|NCT01059786|Drug|Pentostatin|28 patients to pentostatin 4 mg/m2 days 1 and 15 of each cycle.
49410|NCT01008137|Biological|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
49411|NCT01008137|Biological|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
49412|NCT01008150|Drug|Paclitaxel|
49413|NCT01008150|Drug|Trastuzumab|
49414|NCT01010399|Dietary Supplement|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
49415|NCT00000223|Drug|Buprenorphine|
49416|NCT00000886|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
49417|NCT00026182|Biological|recombinant interleukin-12|Given SC
49418|NCT01010399|Drug|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
49419|NCT01010412|Device|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
49420|NCT01010412|Device|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
49421|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
49422|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
49423|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
49424|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
49425|NCT01010425|Drug|Placebo|Placebo, s.c., single-dose
49426|NCT01010425|Drug|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
49427|NCT01010451|Procedure|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
49428|NCT00026182|Other|laboratory biomarker analysis|Correlative studies
49429|NCT01010451|Procedure|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
53290|NCT01057810|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
53291|NCT01057810|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
53292|NCT01057836|Behavioral|Neck endurance training|
53315|NCT01060241|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
53316|NCT01060254|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
53317|NCT01060254|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
53318|NCT01060267|Drug|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
53319|NCT01060267|Drug|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
53320|NCT01060280|Behavioral|Education on active management|Routine clinical practice plus education on active management.
53321|NCT01060280|Other|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
53322|NCT01060280|Other|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
53323|NCT00030914|Drug|venlafaxine|
53324|NCT01062789|Device|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
53325|NCT01062802|Drug|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
53326|NCT01062802|Other|Placebo|Placebo given once daily for 4 weeks.
53327|NCT01062815|Dietary Supplement|Parenteral Nutrition|Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
49352|NCT01012739|Drug|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
49353|NCT01012739|Drug|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
49354|NCT01012752|Biological|modified allergen extract|subcutaneous injections
49355|NCT01012752|Biological|Placebo|subcutaneous injections
49356|NCT01012765|Drug|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
49357|NCT01012765|Drug|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
49358|NCT01012765|Drug|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
49359|NCT01012778|Behavioral|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
49360|NCT00026312|Other|Quality-of-Life Assessment|Ancillary studies
49361|NCT01012791|Other|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
49362|NCT01012804|Genetic|western blotting|
49363|NCT01012804|Other|immunohistochemistry staining method|
49364|NCT01012804|Other|laboratory biomarker analysis|
49365|NCT01012817|Other|Laboratory Biomarker Analysis|Correlative studies
49366|NCT01012817|Other|Pharmacogenomic Study|Correlative studies
49367|NCT01012817|Other|Pharmacological Study|Correlative studies
49368|NCT01012817|Drug|Topotecan Hydrochloride|Given IV
49369|NCT01012817|Drug|Veliparib|Given PO
49678|NCT01008462|Drug|Tacrolimus|Given IV or PO
49679|NCT01008462|Radiation|Total-Body Irradiation|Undergo TBI
49680|NCT01008475|Biological|EMD 525797, Irinotecan and Cetuximab|Arm A: EMD 525797 (target dose: 500 mg) every 2 weeks + cetuximab 400 mg/m2, Day 1 Cycle 1, and afterwards 250 mg/m2 weekly + irinotecan 180 mg/m2 every 2 weeks
53030|NCT01059786|Drug|Rituximab|Rituximab 375 mg/m2 on day 1, 15 for 6 x 28-day cycles (all 68 patients)
53031|NCT01059786|Drug|Bendamustine|28 patients to bendamustine 90 mg/m2/day, days 1 and 2 each cycle
53032|NCT00030862|Drug|cisplatin|
53033|NCT01059799|Drug|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
53034|NCT01059799|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
53035|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
53036|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
53037|NCT00031109|Biological|Aluminum hydroxide|
53038|NCT01062360|Drug|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
53383|NCT01060293|Drug|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
53384|NCT01060332|Other|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
53385|NCT01060345|Drug|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
53386|NCT01060358|Procedure|method (non-surgical) to measure neuromuscular neutral zones|
53387|NCT01060371|Genetic|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
53388|NCT01060384|Drug|Lenalidomide|Dose Cohort -1^ 10mg daily on Days 1-21 every 28 days
Dose Cohort +1^^ 15mg daily on Days 1-21, every 28 days
Dose Cohort +2 20 mg daily on Days 1-21, every 28 days
Dose Cohort #3 25 mg daily on Days 1-21, every 28 days
^Used only if Dose Cohort +1 requires further reduction
^^Starting Dose Cohort in Phase I
53389|NCT01060384|Drug|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
53390|NCT01060397|Behavioral|Extended Brief Intervention|Frames motivational interviewing approach
49430|NCT01010464|Procedure|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
49740|NCT01013376|Drug|Vehicle|Vehicle
49741|NCT01013389|Procedure|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
49742|NCT01013389|Procedure|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
49743|NCT01013402|Drug|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
49744|NCT01013402|Drug|Human Insulin|0.1U/kg IV pulse.
49745|NCT01013415|Drug|IL-2 (~1.2M IU/m2)|IL-2 (~1.2M IU/m2) sq daily x 56 days
49746|NCT01006265|Drug|Placebo|ACT-128800 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally once daily
49747|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
49748|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
49749|NCT01006291|Drug|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
49750|NCT01006304|Drug|JNJ-39439335, Placebo|
49751|NCT01006317|Behavioral|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
49752|NCT00025649|Drug|cyclophosphamide|
49753|NCT01006317|Behavioral|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
49754|NCT01006317|Other|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
49755|NCT01006343|Other|Higher Protein (HP)|
49756|NCT01006343|Other|Lower Protein (LP)|
49757|NCT01006356|Drug|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
53328|NCT01062828|Procedure|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
53329|NCT01062841|Behavioral|Targeted Infection Control|Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.
52348|NCT01030666|Biological|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
52349|NCT01030666|Drug|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
52350|NCT01030666|Drug|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
52351|NCT01030666|Drug|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
52352|NCT00028158|Drug|G207, an oncolytic virus|
52353|NCT01030679|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
52354|NCT01030679|Drug|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
52355|NCT01030679|Drug|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
52356|NCT01030679|Drug|Placebo|orally, 1 tablet once daily for 8 weeks
52357|NCT00028522|Drug|R(+)XK469|Given IV
52358|NCT01033240|Drug|sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
52359|NCT01033253|Behavioral|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
52360|NCT01033266|Device|CPAP|CPET will be done on patients with overlap syndrome before and after CPAP treatment
49681|NCT01008475|Biological|EMD 525797, Irinotecan and Cetuximab|Arm B: EMD 525797 (target dose: 1,000 mg or as defined by SMC) every 2 weeks + cetuximab 400 mg/m2, Day 1 Cycle 1, and afterwards 250 mg/m2 weekly + irinotecan 180 mg/m2 every 2 weeks
49682|NCT01008475|Drug|Irinotecan and Cetuximab|Arm C: Cetuximab 400 mg/m2, Day 1 Cycle 1, and afterwards 250 mg/m2 weekly + irinotecan 180 mg/m2 every 2 weeks
49683|NCT00026039|Drug|estrogen|
49684|NCT01008488|Drug|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
49685|NCT01008514|Procedure|adjuvant therapy|
49686|NCT01008514|Radiation|accelerated partial breast irradiation|
49687|NCT01008514|Radiation|intracavitary balloon brachytherapy|
49688|NCT01008527|Drug|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
49689|NCT01008527|Biological|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
49690|NCT01008527|Biological|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
49691|NCT01008540|Biological|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
49692|NCT01008553|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
49693|NCT01008553|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
49694|NCT00026052|Drug|riluzole|
49695|NCT01008566|Biological|Cixutumumab|Given IV
48729|NCT01011829|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
53391|NCT00030966|Drug|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
53392|NCT01060397|Behavioral|Control|Usual care
53393|NCT01060410|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
53394|NCT01060410|Drug|Cyclophosphamide|intravenous injection, 0.2g, once every two days
53395|NCT01060410|Other|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
53396|NCT01060423|Drug|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
53397|NCT01060423|Drug|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
53398|NCT01060423|Device|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
53399|NCT01060436|Device|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
53400|NCT01060449|Other|LV stimulus intensity|The voltage and pulse duration used for programmed LV pacing
Arm 1: LV lead low output Arm 2: LV lead high output
53401|NCT01060462|Drug|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
52428|NCT01030692|Drug|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
52429|NCT01030692|Drug|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
52430|NCT01030692|Drug|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
52431|NCT01030718|Drug|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
52432|NCT00028171|Drug|Tacrolimus|
52433|NCT01030731|Drug|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
49758|NCT01006369|Biological|bevacizumab|Arm A: FOLFOX6 + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 5 mg/kg in 100 cc Normal Saline every 14 days on day one
Arm B: XELOX + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 7.5 mg/kg in 100 cc Normal Saline every 21 days
48791|NCT01009398|Other|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
48792|NCT01009424|Drug|R7103|escalating inhaled dose
48793|NCT01009437|Drug|ritonavir|Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.
Phase II: Dose will be maximum tolerated dose from Phase I.
48794|NCT01009437|Procedure|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
48795|NCT00026117|Other|placebo|
48796|NCT01009450|Procedure|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
48797|NCT01009450|Procedure|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
48798|NCT01009463|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
48799|NCT01009463|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
48800|NCT01009476|Drug|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
48801|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
48802|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
48803|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
48804|NCT00026273|Drug|FOLFIRI regimen|
49548|NCT01013012|Drug|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
49549|NCT01013012|Drug|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
49550|NCT01013025|Procedure|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
49551|NCT01013038|Procedure|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
49552|NCT01013038|Procedure|conventional PCI|balloon angioplasty and/or stent implantation
49553|NCT01013064|Drug|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
49554|NCT01013077|Drug|Optive|Use a minimum of 2 drops per day for 1 month.
49555|NCT01013077|Drug|Soothe|Use a minimum of 2 drops per day for 1 month.
49556|NCT01013077|Drug|New Emulsion|Use a minimum of 2 drops per day for 1 month.
49557|NCT01013090|Drug|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
49558|NCT00026351|Drug|pentostatin|
49559|NCT01013090|Drug|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
49560|NCT01013103|Drug|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
48599|NCT01006863|Drug|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
48600|NCT01006863|Drug|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
48601|NCT00025649|Procedure|peripheral blood stem cell transplantation|
49297|NCT01014767|Drug|Doxorubicin|Cycles 1 & 2: 25 mg/m²/day IV over 12 hrs on days 1-3
49298|NCT01014767|Drug|Etoposide|Standard Arm (1), Cycles 1 & 2:
100 mg/m2 IV over 1 hour on days 1-5
All Arms, Cycles 4-6:
100 mg/m2 IV over 1 hour on days 1-5
49299|NCT01014767|Drug|Irinotecan|Temozolomide Irinotecan arm (4), Cycles 1 & 2:
50 mg/m2/day x 5 days as 1 hour IV infusions
49300|NCT01014767|Drug|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
49301|NCT01014767|Drug|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
49302|NCT01007812|Device|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
49303|NCT01007838|Other|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
49304|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
49305|NCT01007838|Other|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
49306|NCT00025792|Drug|Pramipexole|
49307|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
49308|NCT01007851|Drug|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
49309|NCT01007851|Drug|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
49310|NCT01007864|Drug|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
49311|NCT01007864|Drug|pramipexole or ropinirole|continuation of pre-study treatment regimen
49312|NCT01007877|Other|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
49620|NCT01010737|Biological|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
49621|NCT01010737|Biological|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
49622|NCT01010737|Biological|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
50614|NCT01038778|Biological|Aldesleukin|Given IV
50615|NCT01038778|Procedure|Computed Tomography|Undergo FDG-PET/CT
50616|NCT01038778|Drug|Entinostat|Given PO
50617|NCT01038778|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
50618|NCT00028756|Drug|cisplatin|Given IV
50619|NCT01038778|Other|Laboratory Biomarker Analysis|Correlative studies
50620|NCT01038778|Other|Pharmacological Study|Correlative studies
50621|NCT01038778|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
50622|NCT01038791|Device|heated humidification|temperature 35°
50623|NCT01038791|Device|heat and moisture exchanger|single patient device
50624|NCT01038791|Device|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
50625|NCT01038804|Drug|YM155|intravenous infusion
50626|NCT01038804|Drug|Docetaxel|intravenous infusion
50627|NCT01038817|Drug|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
50628|NCT01038843|Drug|VA106483|Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.
Placebo: as above
50629|NCT00028756|Biological|filgrastim|Given SC
50630|NCT01038856|Drug|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
50631|NCT01038869|Drug|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
50632|NCT01038882|Drug|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of >2 min to maintain conscious sedation
50633|NCT01038882|Other|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
50634|NCT01038895|Drug|Ramipril|tablet; 10 mg; od; 3 months
49812|NCT01011036|Drug|clobazam|test substance
49813|NCT01011036|Drug|clonazepam|positive control
49814|NCT01011036|Drug|tolterodine|active placebo
49815|NCT01013415|Biological|T Cell infusion 5-10 x E9 T cells|Single infusion of T cells
49816|NCT01013428|Other|Ultrasound|Ultrasound will be used to evaluate tendons.
49817|NCT01013441|Biological|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
49818|NCT01013454|Drug|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload [drug amount loaded in each patch]) will be applied to the upper back over a single 24 hour period
48828|NCT01014104|Drug|Methylprednisolone|Administration of Methylprednisolone
48829|NCT01014104|Drug|Control|Normal salin injection
48830|NCT01014117|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
48831|NCT01014117|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
48832|NCT01014130|Radiation|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
48833|NCT01014130|Radiation|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
48834|NCT01014143|Drug|Fluoride|Half mouth toothbrushing twice a day for four days.
48835|NCT00026416|Procedure|adjuvant therapy|
48836|NCT01014143|Drug|Chlorhexidine digluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
48837|NCT01014143|Drug|Fluoride, triclosan|Half mouth Brushing twice daily
48838|NCT01014156|Drug|epoprostenol|titration up to 4 ng/kg/min
48839|NCT01014169|Behavioral|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
48602|NCT01009073|Drug|irinotecan (weekly schedule)|75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.
Note - The dose and schedule is subject to change based on the toxicities observed.
48603|NCT01009086|Drug|Placebo|SC injections
48604|NCT01009086|Drug|Ustekinumab 45 mg|SC injections
48605|NCT01009086|Drug|Ustekinumab 90 mg|SC injections
48606|NCT01009099|Other|breathing retraining|breathing retraining using a metronome
48607|NCT00026104|Drug|gemcitabine hydrochloride|Given IV
48608|NCT01009099|Other|exercise training|treadmill exercise training
48609|NCT01009112|Behavioral|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
48610|NCT01009112|Behavioral|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
48611|NCT01009125|Other|$2 cash|$2 cash incentive will be included in the mailed survey
48612|NCT01009125|Other|$5 cash|$5 cash incentive will be included in the mailed survey
48613|NCT01009138|Behavioral|Diabetes-Specific CBT (DS-CBT)|5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:
Problem Analysis and Definition
Problem Solving Intervention
Cognitive Restructuring
Activation of personal and social Resources
Goal Definition and Agreement
48614|NCT01009138|Behavioral|Standard Diabetes Education|Standard Diabetes Education Lesson including
Health Care and specific Topics (e. g. Blood Pressure)
Social Aspects of Living with Diabetes
Diabetes Complications
Sports, Activities and Exercise
Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes
Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy
48909|NCT01012076|Behavioral|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
48910|NCT01012089|Drug|Daptomycin|Daptomycin IV 5 mg/kg one time dose
48911|NCT01014208|Drug|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
48912|NCT01014221|Other|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
49623|NCT01010737|Biological|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
49624|NCT01010737|Biological|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
49625|NCT01010737|Biological|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
49626|NCT01010737|Biological|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
49627|NCT01010750|Drug|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
49628|NCT01010750|Drug|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
49629|NCT00026208|Drug|cyclophosphamide|650 mg/m2
49630|NCT01010750|Drug|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
49631|NCT01010763|Device|Total Hip Arthroplasty|Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
49632|NCT01013116|Biological|placebo|subcutaneous injections
49633|NCT01013129|Genetic|DNA analysis|saliva samples will be collected from men (probands) who join the study as well as from first degree relatives who join the study
49634|NCT01013129|Genetic|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
49635|NCT01013129|Other|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
49636|NCT01013129|Other|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
49637|NCT01013129|Other|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
49638|NCT00000888|Drug|Ritonavir|
49639|NCT00026364|Drug|fluorouracil|
48665|NCT01006889|Drug|Exenatide|Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the combination of bedtime insulin detemir (Levemir) and premeal insulin aspart (Novolog) three times daily, will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
50635|NCT01038895|Drug|Experimental|tablet; 300 mg; od; 3 months
50636|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe
Pre-incision: SLN is identified
Inject blue dye into patient's arm
Complete procedure (SLNB and/or ALND)
50968|NCT01036113|Drug|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
50969|NCT01036139|Drug|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
50970|NCT01036165|Device|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
50971|NCT00028691|Drug|chlorambucil|
50972|NCT01036243|Dietary Supplement|test formula 1|hydrolyzed formula with probiotics
50973|NCT01036243|Dietary Supplement|test formula 2|acidified hydrolyzed formula
50974|NCT01036243|Dietary Supplement|test formula 3|hydrolyzed formula without probiotics
50975|NCT01039428|Dietary Supplement|Placebo|Chewing for 30 min three times a day far after meal
50976|NCT00028769|Drug|nilutamide|
50977|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
50978|NCT01039441|Procedure|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
50979|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
50980|NCT01039441|Other|normal saline|
50981|NCT01039454|Drug|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
50982|NCT01039454|Drug|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
50983|NCT01039467|Device|Medtronic Adapta Dual Chamber Pacemaker|Medtronic Adapta Dual Chamber Pacemaker
50984|NCT01039506|Drug|CPT-11 based regimens|FOLFIRI, CPT-11+S-1, CPT-11
50985|NCT01039519|Drug|Ganetespib|Ganetespib 200 mg/m^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
48840|NCT01014195|Other|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
48841|NCT01014208|Drug|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
48842|NCT01007175|Biological|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
48843|NCT01007175|Biological|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
48844|NCT00025688|Drug|paclitaxel|
48845|NCT01007175|Biological|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
49155|NCT01010009|Dietary Supplement|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
49156|NCT01010009|Other|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
49157|NCT01010022|Drug|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
49158|NCT01010022|Drug|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
49159|NCT01010035|Other|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
49160|NCT01010048|Drug|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
49161|NCT01010061|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
49162|NCT01010061|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
48913|NCT01014221|Drug|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
48914|NCT01014234|Drug|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
48915|NCT00026429|Biological|denileukin diftitox|
48916|NCT01014234|Drug|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
48917|NCT01014247|Drug|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
48918|NCT01014247|Drug|Placebo|Single dose of matching tablet
48919|NCT01014260|Drug|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
48920|NCT01014260|Drug|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
48921|NCT01014273|Procedure|Percutaneous Coronary Intervention|
48922|NCT01014286|Other|No intervention|No study intervention for this trial
48923|NCT01014299|Other|Recruitment maneuver|Assigned interventions:
No intervention after tracheal intubation (control group)
Alveolar recruitment maneuver (RM group) immediately after intubation
48924|NCT01014312|Behavioral|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
49231|NCT01007799|Dietary Supplement|Vitamin D|12 weeks supplementation based on serum vitamin D levels
49232|NCT01007812|Device|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
49233|NCT01010113|Other|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
49234|NCT01010113|Other|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
49235|NCT01010126|Biological|Bevacizumab|Given IV
49236|NCT01010126|Drug|Temsirolimus|Given IV
49237|NCT01010139|Drug|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
50265|NCT00028860|Biological|filgrastim|
50266|NCT01040702|Dietary Supplement|sweetener pill|a capsule containing a sweetener pill
50267|NCT01040715|Biological|TNFa Kinoid|TNFa kinoid
50268|NCT01040715|Biological|TNF kinoid|IM administration 2 or 3 injections within 28 days
50269|NCT01040728|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
50270|NCT01040728|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
50271|NCT01040728|Drug|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
50272|NCT01040728|Drug|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
50273|NCT01040728|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
50274|NCT01040741|Other|Non-intervention observational study|Non-intervention observational study
50275|NCT01040754|Other|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
50276|NCT00028860|Drug|carboplatin|
50277|NCT01040767|Other|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
50278|NCT01040780|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
50279|NCT01040780|Drug|Gefitinib|250 mg every 24 hours by mouth
50280|NCT01042977|Drug|Placebo|matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
50552|NCT01041209|Behavioral|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
50553|NCT01041209|Behavioral|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
50554|NCT01041222|Drug|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
50555|NCT01041235|Drug|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
50986|NCT01039545|Drug|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
50987|NCT00000898|Drug|Ritonavir|
50988|NCT00028769|Drug|paclitaxel|
50989|NCT01039545|Drug|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
50048|NCT01045291|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
50049|NCT01045304|Drug|Iniparib|Pharmaceutical form: solution for infusion
Route of administration: intravenous
50050|NCT01045304|Drug|Gemcitabine|Pharmaceutical form: solution for infusion
Route of administration: intravenous
50051|NCT01045304|Drug|Carboplatin|Pharmaceutical form: solution for infusion
Route of administration: intravenous
50052|NCT00029224|Drug|zoledronic acid|
50053|NCT01045317|Drug|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
50054|NCT01045330|Behavioral|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
50055|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
50056|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
50057|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
50058|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
50059|NCT01037712|Drug|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
50060|NCT01037712|Drug|Placebo|placebo
50061|NCT00028730|Drug|cyclophosphamide|
50062|NCT01037725|Drug|AZD5847|Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.
Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal
50063|NCT01037725|Drug|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
49163|NCT01010061|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
49164|NCT01010087|Drug|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
49165|NCT00026169|Drug|imatinib mesylate|Given orally
49166|NCT01010100|Drug|Acarbose (Glucobay, BAYG5421)|50 mg TID
49167|NCT01010100|Drug|Placebo|50 mg TID
49168|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
49169|NCT01012375|Drug|Placebo|Matching capsule, oral dose
49170|NCT00026312|Biological|Aldesleukin|Given IV
49171|NCT01012388|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
49172|NCT01012401|Other|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
49478|NCT01005914|Drug|imatinib mesylate|600 mg/day
49479|NCT01005914|Drug|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
49480|NCT01005914|Drug|methylprednisolone|Day 1-3: 50mg IV BID
49481|NCT01005914|Drug|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
49482|NCT00025636|Procedure|bone marrow ablation with stem cell support|
49483|NCT01005914|Drug|vincristine sulfate|Day 4 & 11: 2 mg IV
49484|NCT01005927|Dietary Supplement|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
49485|NCT01005940|Device|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
49486|NCT01005966|Drug|Sodium Fluoride Toothpaste|Test product
49487|NCT01005966|Drug|Amine Fluoride Toothpaste|Test product
49238|NCT01010152|Drug|Codeine Sulfate|30 mg Tablet
49239|NCT01010178|Drug|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
49240|NCT01010191|Other|Sugar pill|
49241|NCT00026169|Other|laboratory biomarker analysis|Correlative studies
49242|NCT01010204|Drug|Varenicline (Chantix)|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
49243|NCT01010204|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
49244|NCT01010217|Drug|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
49245|NCT01010217|Drug|Fludarabine|40 mg/m^2 IV over 1 hour on Days -6, -5, -4, and -3.
49246|NCT01010217|Drug|Melphalan|140 mg/m^2 IV (or 100 mg/m^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
49247|NCT01010217|Drug|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
49248|NCT01010217|Drug|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
49249|NCT01010217|Procedure|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
49250|NCT01010217|Drug|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
49561|NCT01013103|Drug|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
49562|NCT01013116|Biological|modified allergen extract of house dust mites|subcutaneous injections
49563|NCT01005992|Procedure|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
50556|NCT01041248|Drug|Tocilizumab|8mg/kg every 2 weeks i.v.
50557|NCT00028873|Drug|laniquidar|
50558|NCT01041261|Dietary Supplement|BariatrX Essentials 360 Treatment|Medical food
50559|NCT01041274|Drug|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
50560|NCT01041274|Drug|Placebo|Placebo by mouth daily for 12 months.
50561|NCT01041274|Behavioral|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
50562|NCT01041274|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
50563|NCT01041274|Radiation|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
50564|NCT01043536|Drug|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
50565|NCT01043549|Device|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
50566|NCT01043549|Device|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
50567|NCT01043575|Drug|Rifapentine|During the first 8 weeks of therapy for TB participants > 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants < 45 kg participants will receive 450 mg orally given 5 days per week
50568|NCT01043575|Drug|Rifampin|During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
50569|NCT01043588|Procedure|TURP|TransUrethral Resection of the Prostate
50570|NCT01043588|Procedure|PVP|Photo selective Vaporization of the Prostate
50571|NCT01043601|Drug|Inhaled PT005|inhaled, twice daily for 1 week duration
50901|NCT01041846|Drug|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
50902|NCT01041859|Drug|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
50064|NCT01037738|Procedure|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
50065|NCT01037751|Behavioral|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
50066|NCT01037751|Behavioral|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
50344|NCT01038388|Drug|Vorinostat, Lenalidomide, Bortezomib, Dexamethasone|Level 1
25mg lenalidomide daily on days 1-14
1.3mg/m2 bortezomib daily on days 1, 4, 8, and 11
20 mg dexamethasone daily on days 1, 2, 4, 5, 8, 9, 11, 12
100mg vorinostat daily on days 1-14
Level 2
25mg lenalidomide daily on days 1-14
1.3mg/m2 bortezomib daily on days 1, 4, 8, and 11
20mg dexamethasone daily on days 1, 2, 4, 5, 8, 9, 11, 12
200mg vorinostat daily on days 1-14
Level 3
25mg lenalidomide daily on days 1-14
1.3mg/m2 bortezomib daily on days 1, 4, 8, and 11
20mg dexamethasone daily on days 1, 2, 4, 5, 8, 9, 11, 12
300mg vorinostat daily on days 1-14
50345|NCT01038401|Procedure|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
50346|NCT01038401|Biological|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
50347|NCT01038414|Behavioral|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
50348|NCT01038427|Drug|Mometasone Furoate|Test product - 200 mcg per day
50349|NCT01038427|Drug|Mometasone Furoate|Reference listed drug - 200 mcg per day
50350|NCT01038427|Drug|Placebo|Placebo
50351|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
50352|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
50353|NCT01040793|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
50354|NCT01040793|Drug|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
50355|NCT01040793|Drug|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
50356|NCT01040806|Behavioral|Usual care|Patients will receive their usual medical care
50357|NCT01040806|Behavioral|Health coaching|Peer health coaches will counsel patients with diabetes
50358|NCT00028860|Drug|gemcitabine hydrochloride|
49488|NCT01005966|Drug|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
49489|NCT01005966|Drug|Placebo|placebo and washout treatment
49490|NCT01005966|Drug|675 ppmf toothpaste|dose response
49491|NCT01005979|Drug|Lenalidomide, Rituximab, and Cyclophosphamide|COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
Patients will receive a total of 6-8 cycles.
49492|NCT01008150|Drug|Neratinib|
49493|NCT01008150|Drug|Doxorubicin|
49494|NCT01008150|Drug|Cyclophosphamide|
49495|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
49496|NCT00025896|Drug|recombinant human acid alpha-glucosidase (rhGAA)|
49497|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
49498|NCT01008163|Drug|YY-351|comparison of different dosages of drug
49499|NCT01008163|Drug|Placebo|comparison of different dosages of drug
48547|NCT01011426|Drug|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
48548|NCT01011426|Drug|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
48549|NCT01011439|Drug|Milciclib Maleate|150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.
Number of cycles: until disease progression or unacceptable toxicity.
48550|NCT01011452|Drug|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
48551|NCT00026234|Drug|oxaliplatin|Given IV
48552|NCT01011452|Drug|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
48553|NCT01011465|Drug|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
49564|NCT00025636|Procedure|peripheral blood stem cell transplantation|
49565|NCT01005992|Procedure|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
49566|NCT01006018|Drug|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
49567|NCT01006018|Drug|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
49568|NCT01006018|Drug|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
49569|NCT01006031|Drug|Pegylated interferon alfa-2a and Ribavirin|Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.
Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels.
49570|NCT01006044|Biological|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
49571|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
49572|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
49573|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
49574|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
49575|NCT00025649|Biological|filgrastim|
49576|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
48615|NCT01009151|Behavioral|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
48616|NCT01009151|Behavioral|Heart Care Self Tracker|Web-based Home Tele-monitoring System
50903|NCT01041859|Drug|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
50904|NCT01041872|Drug|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
50905|NCT00000227|Drug|Buprenorphine|
50906|NCT00000899|Drug|Nelfinavir mesylate|
50907|NCT00028886|Drug|thalidomide|
50908|NCT01041872|Drug|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
50909|NCT01041872|Drug|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
50910|NCT01041872|Drug|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
50911|NCT01041872|Drug|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
50912|NCT01041872|Drug|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
50913|NCT01041885|Device|INSTRUCT|INSTRUCT PolyActive scaffold implantation
50914|NCT01041911|Drug|Euphorbia tablets|50 mg, tablet, once daily, 14 days
50915|NCT01041911|Drug|Euphorbia tablets|100 mg, tablet, once daily, 14 days
50916|NCT01041911|Drug|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
50917|NCT01041911|Drug|Placebo tablets|placebo, tablet, once daily, 14 days
50918|NCT00028886|Drug|vincristine sulfate|
50919|NCT01041924|Other|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
50920|NCT01041924|Other|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
50921|NCT01044108|Drug|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
50359|NCT01040819|Drug|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients will continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. While on PIO, other non-diabetes drugs should not be changed, unless emergency. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin >162 mg/d, steroids and prostaglandin analogs will be prohibited. At baseline, and after 1, and 2 months of treatment the following samples will be taken: 1. Serum for lipid profile, ALT, AST, CK, creatinine, BUN, glucose, HbA1c (the biochemistry laboratory at UTMB) 2. Serum for 6-keto-PGF1a and 15-epi-lipoxin A4 3. Serum for hs-CRP 4. Urine for creatinine, 6-keto-PGF1a and 15-epi-lipoxin A4
50360|NCT01040832|Drug|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
50637|NCT01041287|Drug|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is >125/80 for the remaining 8 weeks
50638|NCT01041287|Drug|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is >125/80 for the remaining 8 weeks
50639|NCT01041300|Device|Magstim Rapid2 Stimulator|Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).
Total Duration of device: 15 minutes
50640|NCT01041300|Device|Brainsway Multi-channel Stimulator|Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).
Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).
Total Duration with Device: 2 hours and 30 minutes
50641|NCT00028873|Drug|paclitaxel|
50642|NCT01041313|Drug|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
50643|NCT01041313|Drug|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
50644|NCT01041326|Radiation|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
50645|NCT01041326|Procedure|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
50646|NCT01041352|Device|laryngeal mask|LMA Proseal
48554|NCT01011465|Drug|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
48555|NCT01011465|Behavioral|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
48556|NCT01011465|Behavioral|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
48557|NCT01011478|Drug|rosuvastatin|
48558|NCT01011478|Other|placebo|
48559|NCT01011491|Other|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 & 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
48560|NCT01011491|Other|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 & 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
48561|NCT01011517|Dietary Supplement|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
48562|NCT00026234|Drug|capecitabine|Given orally
48846|NCT01007175|Biological|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
48847|NCT01007188|Other|1.5PD almonds|average American diet plus 1.5 oz per day almonds
48848|NCT01007188|Other|3.0PD almonds|average American diet plus 3.0 oz per day almonds
48849|NCT01007188|Other|Base (without almonds)|average American diet without almonds
48850|NCT01007201|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
48851|NCT01007214|Procedure|Prostatectomy|Elective prostatectomy
48852|NCT01007227|Other|Lifestyle instruction|Instruction dietetic and exercise therapy
48853|NCT01007240|Device|polyethylenimine (PEI) nanoparticles.|
48617|NCT01009177|Drug|Bosentan|Bosentan 500 mg bid
48618|NCT00026104|Drug|paclitaxel|Given IV
48619|NCT01009177|Drug|Placebo|Placebo
48620|NCT01009190|Drug|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
48621|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
48622|NCT01009190|Drug|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
48623|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
48624|NCT01009203|Drug|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
48625|NCT01011530|Drug|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
48626|NCT01011543|Procedure|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
48627|NCT01011556|Drug|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
48628|NCT01011556|Drug|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
48629|NCT01011595|Procedure|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
48630|NCT01011595|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
48631|NCT01011595|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
48632|NCT01011608|Other|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
48633|NCT01011608|Other|standard hospital food|standard hospital diet ad. lib.
48634|NCT01011621|Drug|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
49986|NCT00026221|Biological|Bevacizumab|Given IV
49987|NCT01011231|Procedure|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
49988|NCT01011244|Biological|ADIPOPLUS|autologous cultured adipose-derived stem cells
1x10e7 cells/1cm2 depending on surface area of fistula
49989|NCT01011257|Drug|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
49990|NCT01011257|Drug|Clopidogrel|clopidogrel 75 mg bid
49991|NCT01011283|Drug|decitabine|decitabine 20 mg/m^2 /day intravenous (IV) infusion for 5 days every 28 days
49992|NCT01011283|Drug|azacitidine|azacitidine 75 mg/m^2 /day subcutaneous (SC) injection for 7 days every 28 days
49993|NCT01011296|Drug|PF-04427429|Single 0.2mg dose of intravenous infusion
49994|NCT01011296|Drug|PF-04427429|Single 1mg dose of intravenous infusion
49995|NCT01011296|Drug|PF-04427429|Single 3 mg dose of intravenous infusion
49996|NCT01011309|Biological|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
49997|NCT00026234|Drug|floxuridine|Given intra-arterially
49998|NCT01011309|Drug|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
49999|NCT01011322|Drug|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
50000|NCT01011322|Drug|placebo|placebo
50001|NCT01011335|Biological|Monovalent rAT|10, 25, 50 or 100 μg
50002|NCT01011335|Biological|Monovalent rLukS-PV|10, 25, 50 or 100 μg
50003|NCT01011335|Biological|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
50004|NCT01011335|Biological|Placebo with adjuvant|Placebo with adjuvant
50005|NCT01011335|Biological|Placebo|Placebo saline
50006|NCT01011348|Dietary Supplement|Coenzyme Q10|100mg/day for three months
50007|NCT01011348|Dietary Supplement|Coenzyme Q10|300mg/day for three months
50647|NCT01041352|Device|endotracheal tube|Unomedical endotracheal tube
50648|NCT01041378|Drug|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
50649|NCT01041391|Procedure|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
50650|NCT01041404|Drug|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
50651|NCT01041404|Drug|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
50652|NCT00028886|Biological|filgrastim|
50653|NCT01041404|Drug|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
50990|NCT01039558|Drug|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
50991|NCT01039558|Drug|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
50992|NCT01039558|Drug|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
50993|NCT01039571|Procedure|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
50994|NCT01039584|Drug|Butoconazole Nitrate Vaginal Cream|vaginal cream
50995|NCT01039584|Drug|Placebo|vaginal cream
50996|NCT01039584|Drug|Gynazole 1 vaginal cream|vaginal cream
50997|NCT01039597|Drug|ORE1001|Oral capsules containing 300 mg of the active, study drug
50998|NCT01039597|Drug|Placebo|placebo capsules
50999|NCT00028782|Drug|etanidazole|Given IV
51000|NCT01041937|Procedure|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
51001|NCT01041937|Procedure|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
51002|NCT01041950|Procedure|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
48854|NCT01007253|Drug|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
48855|NCT00025727|Drug|Lopinavir/Ritonavir|
48856|NCT01007253|Drug|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
48857|NCT01007253|Drug|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
48858|NCT01007253|Drug|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
48859|NCT01007266|Behavioral|Assignment of a Lay Patient Partner|
48860|NCT01007279|Drug|ROSUVASTATIN|40 mg before procedure
48861|NCT01007292|Drug|YM155|intravenous infusion
48862|NCT01007292|Biological|Rituximab|intravenous infusion
48863|NCT01007305|Procedure|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy
48864|NCT01007305|Procedure|Ovarian conservation|Both ovaries and fallopian tubes not removed at the time of hysterectomy
48865|NCT01007318|Procedure|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
48866|NCT00025727|Drug|Ritonavir|
48867|NCT01007318|Procedure|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
48868|NCT01009476|Drug|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
49173|NCT01012414|Drug|paricalcitol|2 mcg oral paricalcitol daily
49174|NCT01012414|Drug|placebo|placebo
49175|NCT01012427|Procedure|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase > 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
49176|NCT01012440|Device|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
49177|NCT01012440|Device|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
48925|NCT01014312|Behavioral|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
48926|NCT00026442|Drug|capecitabine|
48927|NCT01014325|Biological|Allergen extract|sublingual application
48928|NCT01014325|Biological|Placebo|sublingual application
48929|NCT01014338|Drug|Fosinopril|10mg od
48930|NCT01014338|Other|lactose|placebo
48931|NCT01014351|Drug|Paclitaxel|Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
48932|NCT01007331|Behavioral|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10^10 colony forming units pr day of probiotics
48933|NCT01007344|Dietary Supplement|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
48934|NCT01007344|Dietary Supplement|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
48935|NCT01007357|Device|Body MR imaging|Body MR imaging will be performed to optimize sequences
48936|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
48937|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
48938|NCT01007383|Drug|LEO 27847|First in man
48939|NCT01007396|Other|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
48940|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
48941|NCT00025727|Drug|GW433908|
48942|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
48943|NCT01007422|Behavioral|telephone-based intervention|
48944|NCT01007422|Other|communication intervention|
50008|NCT00026234|Drug|dexamethasone|Given intra-arterially
50009|NCT01011348|Dietary Supplement|Placebo|Three month period
50281|NCT00028938|Radiation|radiation therapy|
50282|NCT01042990|Other|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
50283|NCT01043003|Other|educational intervention|Undergo Bilingual Breast Cancer Educational Intervention
50284|NCT01043003|Procedure|quality-of-life assessment|Ancillary studies
50285|NCT01043003|Other|Questionnaire Administration|Ancillary studies
50286|NCT01043003|Other|psychosocial support for caregiver|Support for caregiver
50287|NCT01043003|Procedure|assessment of therapy complications|Ancillary study
50288|NCT01043003|Other|informational intervention|Undergo evaluation sessions
50289|NCT01043016|Procedure|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
50290|NCT01043029|Drug|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
50291|NCT01043029|Drug|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
50292|NCT00028951|Drug|fibrin sealant|
50293|NCT01043042|Other|No interventions will be used in this study|No interventions will be used in this study
50294|NCT01043068|Drug|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
50295|NCT01043094|Drug|Pitavastatin 4mg|Pitavastatin 4mg single dose
50296|NCT01043120|Drug|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
50297|NCT01043120|Drug|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
50298|NCT01043133|Behavioral|social marketing-based medical education intervention|social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
51003|NCT01041963|Drug|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
51004|NCT01041963|Drug|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
51005|NCT01041963|Drug|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
51006|NCT01041976|Behavioral|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
51007|NCT01041976|Behavioral|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
50067|NCT01037764|Procedure|alloHCT|[ alloHCT arm ] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.
BuFluATG conditioning; Bu 3.2 mg/kg*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.
Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1.
50068|NCT01037790|Drug|PD-0332991|Given orally, 125 mg QD on a 21-day
50069|NCT01037790|Other|pharmacological study|Correlative study
50070|NCT01037816|Drug|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
50071|NCT01037816|Other|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
50072|NCT00028730|Drug|fludarabine phosphate|
50073|NCT01037829|Other|Non-intervention observational study|Non-intervention observational study
50074|NCT01037842|Drug|Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
for 16 weeks
50075|NCT01037842|Drug|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
50076|NCT01037855|Other|Non-intervention observational study|Non-intervention observational study
49178|NCT01012453|Behavioral|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
49179|NCT01012479|Drug|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
49180|NCT01012492|Drug|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
49181|NCT00000887|Drug|Zidovudine|
49182|NCT00026312|Biological|Dinutuximab|Given IV
49183|NCT01012505|Other|adding pad with maternal milk in hte incubator|2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.
stopping intervention and for other 2 days recording infants data and taking saliva cortisol
49184|NCT01012518|Device|Standard PCT|The standard technique, performed without video guidance
49185|NCT01012518|Device|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
49186|NCT01014351|Drug|Carboplatin|Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle
49187|NCT01014351|Drug|Everolimus|Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
49188|NCT01014364|Drug|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
49189|NCT01014364|Drug|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
49500|NCT01008176|Behavioral|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
49501|NCT01008189|Behavioral|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
49502|NCT01008189|Behavioral|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
49503|NCT01008215|Other|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
48945|NCT01007422|Other|intervention by caregiver|
48946|NCT01007422|Other|medical chart review|
48947|NCT01007422|Other|survey administration|
49251|NCT01010217|Drug|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
49252|NCT00026169|Other|pharmacological study|Correlative studies
49253|NCT01010217|Drug|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
49254|NCT01010217|Drug|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery > 1000/mcl.
49255|NCT01012531|Biological|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
49256|NCT01012531|Biological|Subcutaneous injection with placebo|cluster schedule
49257|NCT01012544|Drug|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
49258|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
49259|NCT01012557|Biological|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
49260|NCT01012557|Biological|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
49261|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
49262|NCT00026312|Drug|Isotretinoin|Given PO
49263|NCT01012570|Drug|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
49264|NCT01012596|Behavioral|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
49265|NCT01012609|Other|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
50299|NCT01043146|Drug|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
50300|NCT01043146|Drug|placebo|intravenous 0.9 % NaCl
50301|NCT01043172|Drug|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
50302|NCT01043185|Drug|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
50303|NCT00028951|Procedure|surgical wound closure|
50572|NCT01043601|Drug|Inhaled Placebo|inhaled, twice daily for 1 week duration
50573|NCT00028977|Drug|herba scutellaria barbata|
50574|NCT01043601|Drug|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
50575|NCT01043614|Behavioral|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
50576|NCT01043640|Drug|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
50577|NCT01043640|Drug|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
50578|NCT01043640|Drug|Busulfan|Administered every 6 hours: If < or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
50579|NCT01043640|Procedure|Allogeneic stem cell transplantation|Administered > 24 hours after last dose of busulfan.
50580|NCT01043640|Drug|Cyclosporine A|2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:
If body weight is ≤ 40 kg dosing will be 3 times daily
If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).
50581|NCT01043640|Drug|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.
50582|NCT01043666|Drug|YM178|oral
50583|NCT01043666|Drug|Placebo|oral
50584|NCT00028977|Other|herba scutellaria Barbatae (HSB)|
50585|NCT01043666|Drug|tolterodine ER|oral
50586|NCT01043679|Drug|Utapine|Efficacy and Safety of Utapine
50077|NCT01037868|Other|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
50078|NCT01040299|Other|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
50079|NCT01040312|Drug|CPT-11 and platinum analogues|platinum analogues (cisplatin, carboplatin and nedaplatin)
50080|NCT01040325|Biological|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
50081|NCT01040325|Biological|TD Vaccine System|TD Vaccine System Containing Placebo Product
50082|NCT01040338|Drug|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
50083|NCT01040351|Procedure|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
50084|NCT01040390|Drug|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
50361|NCT01040832|Drug|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram [mg/kg] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
50362|NCT01040845|Drug|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
50363|NCT01040845|Drug|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
50364|NCT01040845|Drug|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
50365|NCT01040858|Behavioral|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
50366|NCT01040858|Other|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
50367|NCT01040871|Drug|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
50368|NCT01040871|Drug|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
49504|NCT01008228|Procedure|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
49505|NCT01008228|Procedure|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
49506|NCT01008254|Behavioral|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
49507|NCT00000885|Drug|Stavudine|
49508|NCT00025909|Procedure|Leukapheresis|
49509|NCT01008254|Behavioral|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
49510|NCT01008254|Other|No musical prompt|No intervention.
49511|NCT01008280|Drug|baclofen|baclofen 10 mg tid
49512|NCT01008280|Drug|placebo|placebo pill tid
49513|NCT01008293|Drug|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
49514|NCT01008293|Drug|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
49515|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
49516|NCT01010516|Drug|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
49517|NCT01010529|Other|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
49518|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
49266|NCT01012622|Drug|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
49267|NCT01012635|Other|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
49268|NCT01012635|Other|Meditation|Meditation: focus on a single word ("one") for the entire session.
49269|NCT01012635|Other|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
49577|NCT01006070|Procedure|kyphoplasty|surgical kyphoplasty
49578|NCT01006096|Drug|erlotinib|100mg tablet, once daily for 16 weeks
49579|NCT01006096|Other|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
49580|NCT01006122|Drug|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
49581|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
49582|NCT01008332|Biological|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
49583|NCT01008332|Biological|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
49584|NCT00025987|Device|Head and Neck Cooling System|
49585|NCT01008345|Drug|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
49586|NCT01008358|Biological|CP 675,206|
49587|NCT01008384|Dietary Supplement|Vitamin D3|50,000 units taken orally once a week for 8 weeks
49588|NCT01008397|Drug|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
49589|NCT01008410|Drug|Budesonide|2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
50587|NCT01043679|Drug|Seroquel|Efficacy and Safety of Seroquel
50588|NCT01046539|Drug|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
50589|NCT01046539|Drug|Placebo|0 mg
50590|NCT01046552|Procedure|preoperative ERCP and LC|preoperative ERCP followed by LC
50591|NCT01046552|Procedure|Intraoperative ERCP and LC|LC and intraoperative ERCP
50592|NCT01046565|Drug|adapalene cream 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
50593|NCT01046565|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
50922|NCT01044108|Drug|placebo|Placebo will be administered as a comparator at each dose level.
50923|NCT01044121|Other|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
50924|NCT01044134|Behavioral|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
50925|NCT01044147|Behavioral|VLM-S|Online program for weight loss - standard
50926|NCT01044147|Behavioral|VLM-M|Online program for weight loss - modulated
50927|NCT01044147|Behavioral|OGR|Online program for weight loss - resources
50928|NCT01044173|Device|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
50929|NCT01044186|Drug|ICL670|
50930|NCT01044199|Biological|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
50931|NCT00029029|Procedure|radiofrequency ablation|
50932|NCT01044199|Biological|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
50933|NCT01044212|Drug|Docusate|Docusate 100mg BID
50934|NCT01044212|Drug|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
50369|NCT00028860|Drug|ifosfamide|
50370|NCT01040871|Drug|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
50371|NCT01040871|Drug|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
50372|NCT01043185|Drug|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
50373|NCT01043198|Genetic|Clinical examination and blood sampling for biological and genetic analysis|Clinical examination and precise description of the phenotype (questionnaire)
Standardized screening with :
radiological (hands, feet, spine ; and renal ultrasonography)
biological (hormonal, metabolic, and "basic" genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))
50374|NCT01043211|Drug|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
50375|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
50376|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
50654|NCT01041404|Drug|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
50655|NCT01041417|Drug|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
50656|NCT01041417|Drug|Placebo|Saline injection
50657|NCT01043692|Other|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
50658|NCT01043718|Behavioral|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
50659|NCT01043718|Behavioral|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
48563|NCT01013714|Procedure|Bilateral cervicothoracic sympathectomy plux maximum medical therapy|Bilateral cervicothoracic sympathectomy which involves endoscopic removal of the lower one third to one half of the stellate ganglia together with the thoracic ganglia of T2 - T4 provides adequate cardiac denervation with no or minimal Horner's syndrome in long QT syndrome and recurrent angina. Though this procedure has been traditionally performed under general anesthesia most commonly using a supraclavicular approach, endoscopic techniques are now available, reducing both the duration and invasiveness of the procedure and hospitalization. Video-assisted thoracoscopic sympathectomy provides a minimally invasive endoscopic approach to this procedure that is safe and effective. Furthermore, the procedure can be completed in less than 45 minutes per side.
48564|NCT01013714|Drug|Maximum medical therapy|Patients assigned to this arm will receive ACC/AHA guideline recommended therapies for heart failure only and will undergo/will have already undergone ICD placement as indicated for their heart failure. Furthermore, they will be considered for catheter ablation of their arrhythmia and will undergo catheter ablation of their ventricular arrhythmias prior to randomization.
48565|NCT01013727|Radiation|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
48566|NCT01013740|Drug|Vinorelbine|Vinorelbine
48567|NCT01013740|Drug|Lapatinib|Lapatinib
48568|NCT01013740|Drug|Capecitabine|Capecitabine
48569|NCT01013753|Drug|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
48570|NCT01013753|Drug|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48571|NCT00026377|Radiation|radiation therapy|daily for 5 days each week
48572|NCT01013753|Drug|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48573|NCT01013753|Drug|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48574|NCT01013753|Drug|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
48575|NCT01013753|Drug|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48576|NCT01013766|Drug|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
48577|NCT01013766|Drug|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
48578|NCT01013779|Drug|Carboplatin|During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).
After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1.
48579|NCT01013779|Drug|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
49590|NCT01008410|Drug|Placebo|Placebo foam/25mL BID for 2 weeks followed by QD for 4 weeks
49591|NCT01008423|Drug|Budesonide|2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
49592|NCT01008423|Drug|Placebo|Placebo foam/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
49593|NCT01008436|Drug|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
49594|NCT01008436|Drug|Control|Traditional surgical Hemostasis
49595|NCT00025987|Device|Thermometer Pill|
49596|NCT01008449|Device|Surgical staples|Surgical staples will be used once for wound closure.
49597|NCT01008449|Device|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
48635|NCT00026247|Procedure|pain therapy|
48636|NCT01011621|Drug|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
48637|NCT01011634|Drug|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
48638|NCT01011660|Drug|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
48639|NCT01011673|Drug|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
48640|NCT01011673|Drug|Ketorolac|ketorolac 30mg IVSS
48641|NCT01011686|Biological|ANT-SM|autologous adipose-derived stem cell
48642|NCT01011699|Drug|nicotinamide|Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;
Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:
0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week).
48643|NCT01011699|Drug|sevelamer|Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.
Increase of sevelamer dose up to 12 tablets, as follows:
0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week).
48644|NCT01011699|Drug|cinacalcet|After 6 months of treatment, patient screening on PTH level:
For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH < 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be < 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia < 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.
A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l.
50935|NCT01044225|Drug|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
50936|NCT01044225|Drug|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
50937|NCT01044238|Drug|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
50938|NCT01044238|Drug|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
50939|NCT01044251|Drug|Frovatriptan|2.5 mg po bid for 10 days
50940|NCT01044251|Drug|Placebo|1 tab po bid for 10 days
50941|NCT01044264|Drug|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
50942|NCT00029042|Drug|Infliximab|
50943|NCT01044264|Drug|Placebo|Placebo
50010|NCT01011374|Drug|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
50011|NCT01011387|Procedure|NPWT System|Dressing change 3 times per week
50012|NCT01042561|Dietary Supplement|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
50013|NCT01042574|Drug|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
50014|NCT01042587|Other|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
50015|NCT01042587|Other|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
50016|NCT00028925|Drug|topotecan hydrochloride|
50017|NCT01042600|Device|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
50018|NCT01042600|Device|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
50019|NCT01042613|Procedure|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
50660|NCT01043731|Procedure|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
50661|NCT01043744|Drug|Artemether-Lumefantrine|Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:
1 tablet (for patients weighing 5-14 kg)
2 tablets (for patients weighing 15-24 kg)
50662|NCT01043757|Behavioral|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
50663|NCT01043770|Behavioral|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
50664|NCT00028990|Drug|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
50665|NCT01043783|Other|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
50666|NCT01043796|Other|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
50667|NCT01043796|Other|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
51008|NCT00028886|Procedure|bone marrow ablation with stem cell support|
51009|NCT01041989|Behavioral|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
51010|NCT01041989|Behavioral|Exercise|Guided muscle strength training and aerobic exercise.
51011|NCT01041989|Behavioral|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
51012|NCT01041989|Other|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
51013|NCT01042002|Behavioral|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
48580|NCT01013779|Radiation|Radiotherapy|Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions
Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions
48869|NCT01009502|Drug|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
48870|NCT01009515|Drug|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
48871|NCT01009528|Device|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
48872|NCT01009541|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
48873|NCT00026130|Drug|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
48874|NCT01009541|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
48875|NCT01009541|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
48876|NCT01009541|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
48877|NCT01009554|Device|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
48878|NCT01009554|Drug|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
48879|NCT01009567|Drug|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
48880|NCT01009567|Drug|Control|Receive human albumin 20% infusion
48881|NCT01009580|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
48882|NCT01009580|Drug|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
48883|NCT01009593|Drug|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
48884|NCT00026130|Drug|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
48885|NCT01009593|Drug|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
48645|NCT01013805|Radiation|External Beam Radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.
Weeks 8-10: as per Weeks 3-5
48646|NCT01013805|Drug|Oxaliplatin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
48647|NCT01013805|Drug|Fluorouracil|Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1
48648|NCT01013805|Drug|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
48649|NCT01013805|Procedure|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
48948|NCT01007422|Procedure|end-of-life treatment/management|
48949|NCT01007422|Procedure|pain therapy|
48950|NCT01007422|Procedure|psychosocial assessment and care|
48951|NCT01007435|Drug|Tocilizumab|Tocilizumab was supplied in vials.
48952|NCT00025740|Drug|clonazepam and paroxetine|
48953|NCT01007435|Drug|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
48954|NCT01007435|Drug|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
48955|NCT01007435|Drug|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
48956|NCT01007448|Drug|bexarotene|150 mg/m2/day oral bexarotene capsules
48957|NCT01007448|Drug|bexarotene|300 mg/m2/day oral bexarotene capsules
48958|NCT01007461|Drug|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started > 5 minutes but < 20 minutes (approximately) prior to coronary artery reperfusion.
48959|NCT01009632|Behavioral|Resonant voice|4-hr of resonant voice exercise
48960|NCT01009632|Behavioral|Voice rest|4-hr of complete refrain from any voice use
50020|NCT01042613|Procedure|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
50021|NCT01042626|Other|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
50022|NCT01042639|Behavioral|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
50023|NCT01042652|Drug|Raltegravir|Raltegarvir 400mg bid
50024|NCT01042665|Drug|latanoprost 0.005%|Active comparator
50025|NCT01042665|Drug|Placebo|Placebo comparator
50026|NCT01042678|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye
50027|NCT00028925|Radiation|WBRT|
50028|NCT01042691|Drug|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
50029|NCT01042704|Drug|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
50304|NCT01043185|Drug|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
50305|NCT01043185|Drug|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
50306|NCT01043185|Drug|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
50307|NCT01045720|Drug|Placebo|Placebo (starch)
50308|NCT01045733|Device|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
50309|NCT01045733|Device|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
50310|NCT01045733|Procedure|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
50311|NCT01045746|Device|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
50312|NCT01045746|Device|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
51014|NCT01042015|Device|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
51015|NCT01042015|Other|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
51016|NCT01042028|Drug|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
51017|NCT01042028|Drug|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
51018|NCT01042041|Drug|sorafenib tosylate|Given orally
51019|NCT00028886|Procedure|peripheral blood stem cell transplantation|
51020|NCT01042041|Drug|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
51021|NCT01044290|Other|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
51022|NCT01044290|Other|Attention Control|Subjects listened to a non-guided relaxation CD
51023|NCT01044303|Drug|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
51024|NCT01044316|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
51025|NCT01044329|Drug|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
51026|NCT01044329|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
51027|NCT00029107|Drug|Rituximab|anti-CD20 monoclonal antibody
51028|NCT01044342|Drug|AZD1446|capsule; single oral dose
51029|NCT01044342|Drug|AZD1446|capsule, single oral dose
49782|NCT01008696|Drug|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
49783|NCT01008709|Device|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
48886|NCT01009606|Other|Usual strategy|Usual strategy
48887|NCT01009606|Other|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
48888|NCT01009619|Drug|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
49190|NCT01014377|Device|VascuActive|
49191|NCT00026468|Drug|exisulind|
49192|NCT01014390|Device|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
49193|NCT01014403|Drug|enoxaparin|Enoxaparin 30 mg sq q 12 hours
49194|NCT01014403|Drug|placebo|vehicle
49195|NCT01014416|Drug|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
49196|NCT01014429|Drug|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
49197|NCT01014442|Drug|mycophenolate mofetil|1.5 g PO BID from Days 1 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
49198|NCT01014455|Behavioral|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
49199|NCT01014455|Behavioral|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
49200|NCT01014468|Drug|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
49201|NCT01014468|Drug|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
49202|NCT00026494|Drug|temozolomide|
49203|NCT01014481|Drug|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
49204|NCT01014494|Device|Adaprev|Class III Medical Device
49205|NCT01014507|Drug|8 cycles BEACOPPesc plus oral contraceptive|
48961|NCT01009632|Behavioral|Spontaneous speech|
48962|NCT01009645|Behavioral|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
48963|NCT01009645|Behavioral|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
48964|NCT00000885|Drug|Didanosine|
48965|NCT00026130|Radiation|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
48966|NCT01009645|Behavioral|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
48967|NCT01009645|Behavioral|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
48968|NCT01009658|Dietary Supplement|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
48969|NCT01009658|Dietary Supplement|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
49270|NCT01012635|Other|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
49271|NCT01012648|Drug|Fluid resuscitation|Volume resuscitation
49272|NCT01012648|Drug|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
49273|NCT00026312|Other|Laboratory Biomarker Analysis|Correlative studies
49274|NCT01012661|Device|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
49275|NCT01012661|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
49276|NCT01012674|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
49277|NCT01014650|Drug|IV normal saline|Single IV dose of normal saline
49278|NCT01014663|Behavioral|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
50313|NCT01045772|Drug|rilonacept|160mg of rilonacept 1x/week
50314|NCT00000901|Drug|Indinavir sulfate|
50315|NCT00029263|Drug|herbals|
50316|NCT01045798|Drug|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
50317|NCT01045798|Drug|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
50318|NCT01045811|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
50319|NCT01045811|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
50320|NCT01045837|Drug|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
50321|NCT01045837|Behavioral|Gluten free diet|Only gluten free diet will be given in this group
50322|NCT01045863|Drug|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
50323|NCT01045863|Drug|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
50324|NCT01045863|Drug|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
50594|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
50595|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
50596|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
50597|NCT00029380|Procedure|Cord Blood Transplantation|
50598|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
50599|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
50600|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
50601|NCT01046591|Procedure|Polysomnography|Overnight sleep studies will be performed on all children.
49784|NCT01008709|Device|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
49785|NCT01008748|Drug|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke >10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
49786|NCT01008748|Behavioral|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
49787|NCT01008748|Behavioral|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
49788|NCT01008748|Behavioral|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
49789|NCT01008761|Drug|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
49790|NCT00026078|Drug|docetaxel|
49791|NCT01008761|Drug|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
49792|NCT01010932|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
49793|NCT01010932|Other|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
49794|NCT01010945|Drug|erlotinib|administered orally
49795|NCT01010945|Drug|gemcitabine|administered intravenously
49796|NCT01010945|Drug|nab-paclitaxel|administered intravenously
49797|NCT01010958|Drug|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
49798|NCT01010971|Drug|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
48807|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
49206|NCT01014507|Drug|8 cycles BEACOPPesc plus Goserelin|
49207|NCT01014520|Drug|Gabapentin , Amitriptyline|Capsule, 300 mg, oral, single dose 2 hours before surgery
Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery
49208|NCT01014533|Drug|Gabapentin or placebo dispensed to subject.|Alcohol dependent subjects have polysomnography in the UM Sleep Lab for three nights, then are randomized to receive gabapentin or placebo for 11 days, (600mg at bedtime on night 1, 1200mg at bedtime on nights 2-10, and 600mg at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on night 8 of medication so their sleep data can be compared.
49209|NCT01007721|Drug|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
49519|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
49520|NCT01010555|Device|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
49521|NCT01010555|Device|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
49522|NCT01010555|Device|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
49523|NCT01010555|Device|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
49524|NCT01010568|Drug|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
49525|NCT01010581|Drug|SC12267 (4SC-101)|oral administration
49526|NCT00026182|Procedure|quality-of-life assessment|Ancillary studies
49527|NCT01010581|Drug|Placebo|oral administration
49528|NCT01010581|Drug|Methotrexate|oral administration
49529|NCT01010581|Drug|Folic Acid|oral administration
49530|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
49531|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment.
49532|NCT01010607|Device|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
49533|NCT01010607|Device|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
49279|NCT01014663|Behavioral|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
49280|NCT01014676|Dietary Supplement|Probiotic|
49281|NCT01014676|Other|Placebo|
49282|NCT00026520|Drug|thalidomide|
49283|NCT01014689|Drug|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
49284|NCT01014689|Drug|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
49285|NCT01014702|Device|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
49286|NCT01014702|Device|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
49287|NCT01014715|Other|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
49288|NCT01014728|Drug|propofol|100-200mcg/kg/min by infusion
49289|NCT01014728|Drug|sevoflurane|1-3% of sevoflurane (expired)
49290|NCT01014741|Drug|Ibutilide|0.25mg IV ibutilide after PV isolation prior to CFE ablation
49291|NCT01014741|Drug|Placebo|Placebo after PV isolation prior to CFE ablation.
49598|NCT01008462|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
49599|NCT01008462|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
49600|NCT01008462|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
49601|NCT01008462|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
49602|NCT01008462|Drug|Carmustine|Given IV
49603|NCT01008462|Drug|Cyclophosphamide|Given IV
49604|NCT01008462|Drug|Cytarabine|Given IV
49605|NCT01008462|Drug|Etoposide|Given IV
49606|NCT00026013|Drug|hypericum perforatum|
50602|NCT01046604|Drug|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
50603|NCT01046617|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
50604|NCT01046630|Drug|AZD6765|single infusion
50605|NCT01046630|Drug|Ketamine|single infusion
50606|NCT01046630|Drug|Placebo|single infusion
50607|NCT01046643|Drug|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
50608|NCT00029393|Procedure|Hematopoietic Stem Cell Transplantation|
50609|NCT01046643|Drug|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
50610|NCT01046643|Drug|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
50611|NCT01046656|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
50612|NCT01038752|Drug|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
50613|NCT01038765|Behavioral|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
50944|NCT01044277|Drug|Glutathione supplementation|500 mg, two times daily
50945|NCT01044277|Drug|Glutathione supplementation|125 mg, two times daily
50946|NCT01044277|Other|Placebo|2 times daily
50947|NCT01036009|Other|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
50948|NCT01036022|Drug|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
50949|NCT00028678|Drug|dalteparin|
48808|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
48809|NCT01011868|Drug|BI 10773 low dose|BI 10773 low dose
48810|NCT01011868|Drug|BI 10773 high dose|BI 10773 high dose
48811|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
48812|NCT01011881|Other|pleural level of procalcitonin|no intervention
48813|NCT01011894|Drug|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
48814|NCT01011907|Drug|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
48815|NCT00026273|Drug|fluorouracil|
48816|NCT01011907|Drug|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
48817|NCT01011920|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
48818|NCT01011920|Drug|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
48819|NCT01011920|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
48820|NCT01011920|Drug|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4
48821|NCT01014039|Procedure|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
48822|NCT01014052|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
48823|NCT01014078|Drug|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
48824|NCT00026416|Drug|thalidomide|
48825|NCT01014078|Drug|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
48826|NCT01014091|Biological|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
49534|NCT01010607|Device|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
49535|NCT01010620|Behavioral|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
49536|NCT01010633|Drug|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
49537|NCT00026195|Drug|irinotecan hydrochloride|
49538|NCT01010633|Drug|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
49539|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
48581|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
48582|NCT00000888|Drug|Lamivudine|
48583|NCT00026403|Drug|cisplatin|
48584|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
48585|NCT01006746|Other|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
48586|NCT01006759|Other|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
48587|NCT01006772|Other|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
48588|NCT01006785|Drug|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
48589|NCT01006785|Drug|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
48590|NCT00025649|Procedure|conventional surgery|
48591|NCT01006798|Other|Placebo|enteric coated capsule containing no vaccine virus
48592|NCT01006798|Biological|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
48593|NCT01006798|Biological|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
49607|NCT01008462|Drug|Fludarabine Phosphate|Given IV
49608|NCT01008462|Other|Laboratory Biomarker Analysis|Correlative study
49609|NCT01010646|Drug|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
49610|NCT01010646|Drug|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
49611|NCT01010646|Drug|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
49612|NCT01010659|Device|Lacrimal Tube|Lacrimal Tube
49613|NCT01010672|Drug|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
49614|NCT01010685|Procedure|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
49615|NCT01010698|Drug|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
49616|NCT01010711|Dietary Supplement|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
49617|NCT01010724|Drug|bIAP|
49618|NCT00026208|Drug|bleomycin|5 u/m2 IV week 2, 4, 6, 8
49619|NCT01010724|Drug|Placebo|
48650|NCT01013818|Drug|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
48651|NCT01013831|Drug|Erlotinib Hydrochloride|Given PO
48652|NCT01013831|Other|Laboratory Biomarker Analysis|Correlative studies
48653|NCT01013831|Other|Pharmacological Study|Correlative studies
48654|NCT00026403|Drug|gemcitabine hydrochloride|
48655|NCT01013844|Behavioral|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter > or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
50950|NCT01036035|Drug|Tolterodine|Comparison of different dosages of drug
50951|NCT01036035|Drug|Pilocarpine|Comparison of different dosages of drug
50952|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
50953|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
50954|NCT01036035|Drug|placebo capsule|Comparison of different dosages of drug
50955|NCT01036048|Device|drug eluting stent|pts with cabg disease treated with drug eluting stent
50956|NCT01036048|Device|bare metal stent|pts with cabg disease treated with bare metal stent
50957|NCT01036061|Drug|GSK618334 Low Dose|GSK618334 low dose
50958|NCT01036061|Drug|GSK618334 PET subjects|PET subjects
50959|NCT01036061|Drug|GSK618334 Medium Dose|Medium Dose
50960|NCT00028678|Radiation|radiation therapy|
50961|NCT01036061|Drug|GSK618334 High Dose|GSK618334 High Dose
50962|NCT01036087|Drug|Panitumumab|2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
50963|NCT01036087|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
50964|NCT01036087|Drug|Carboplatin|AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
50965|NCT01036087|Drug|5-Fluorouracil|500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
50966|NCT01036087|Drug|Epirubicin|100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
50967|NCT01036087|Drug|Cyclophosphamide|500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
50030|NCT01042704|Drug|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
50031|NCT01042704|Drug|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
50032|NCT01042704|Drug|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
48827|NCT01014091|Biological|GSK pandemic vaccine GSK2340269A|2 intramuscular injections
49131|NCT01007695|Drug|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
49132|NCT01007708|Drug|IDP-108|Topical application once a day for 48 weeks
49133|NCT01007708|Drug|Vehicle|Topical application once a day for 48 weeks
49134|NCT01007721|Drug|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
49135|NCT01007721|Drug|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
49136|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
49137|NCT00025766|Behavioral|Optimal Medical Therapy|Participants will receive optimal medical therapy.
49138|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
49139|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
49140|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
49141|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
49142|NCT01009970|Drug|Rituximab|375 mg/m2 day 1
49143|NCT00026156|Drug|docetaxel|
49144|NCT01009970|Drug|Cyclophosphamide|750 mg/m2 day 2
49145|NCT01009970|Drug|Vincristine|1,4 mg/m2 (max 2 mg) day 2
49146|NCT01009970|Drug|Prednisone|40 mg/m2 day 2-6
49147|NCT01009970|Drug|Doxorubicin|50 mg/m2 day 2
49148|NCT01009983|Biological|panitumumab|Given IV
49149|NCT01009983|Drug|paclitaxel|Given IV
49150|NCT01009983|Drug|carboplatin|Given IV
49151|NCT01009983|Procedure|laboratory biomarker analysis|Correlative study
48594|NCT01006811|Dietary Supplement|modified Atkins diet|Modified Atkins Diet administration
Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)
Fats (e.g. cream, butter, oils, ghee) encouraged.
Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.
Clear carbohydrate-fluids not restricted.
Calcium and multivitamin supplementation will be provided.
48595|NCT01006811|Other|modified Atkins diet|Modified Atkins Diet administration
Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)
Fats (e.g. cream, butter, oils, ghee) encouraged.
Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.
Clear carbohydrate-fluids not restricted.
Calcium and multivitamin supplementation will be provided.
48596|NCT01006824|Other|Capsule endoscopy|Capsule endoscopy
48597|NCT01006824|Other|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
48598|NCT01006850|Drug|Hydromorphone|2mg IV hydromorphone
48889|NCT01009619|Drug|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
48890|NCT01011920|Radiation|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
48891|NCT01011920|Drug|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
48892|NCT01011920|Other|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
48893|NCT01011933|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48894|NCT01011933|Drug|Selumetinib|Given PO
48895|NCT00026273|Drug|irinotecan hydrochloride|
48896|NCT01011946|Device|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
48897|NCT01011959|Biological|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
48898|NCT01011972|Drug|XMT-1107|XMT-1107 is administered IV once every 21 days.
48899|NCT01011998|Drug|Gleevec (imatinib), valproic acid|Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.
Gleevec will be continued at the dose the patient was taking at the time of entry onto the study.
48656|NCT01013857|Behavioral|Health coaching|Calling patients every week to discuss medication adherence
48657|NCT01013857|Behavioral|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
48658|NCT01013870|Drug|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
48659|NCT01013870|Drug|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
48660|NCT01013896|Behavioral|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
48661|NCT01006863|Drug|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine [group 5 (n=30)] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
48662|NCT01006876|Drug|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
48663|NCT01006876|Drug|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
48664|NCT01006876|Drug|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
48970|NCT01009671|Drug|ART 44|
48971|NCT01009671|Drug|ART 50|
48972|NCT01009697|Drug|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
48973|NCT01009736|Dietary Supplement|tomato-soy juice|
48974|NCT01009736|Other|laboratory biomarker analysis|
48975|NCT01009736|Other|pharmacological study|
48976|NCT00026143|Biological|recombinant interleukin-12|Given IV
48977|NCT01009736|Procedure|therapeutic conventional surgery|
50033|NCT01042704|Drug|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
50034|NCT01045161|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
50035|NCT01045174|Device|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
50036|NCT01045187|Radiation|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
50037|NCT01045187|Radiation|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
50038|NCT01045200|Other|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
50039|NCT01045213|Other|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
50040|NCT01045226|Procedure|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
50041|NCT00029211|Drug|Echinacea|
50042|NCT01045226|Other|Quality-of-Life assessment|Quality of Life Assessment
50043|NCT01045226|Other|Questionnaire Administration|Questionnaire Administration
50044|NCT01045239|Device|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
50045|NCT01045239|Device|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
50046|NCT01045265|Other|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
50047|NCT01045278|Drug|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
50325|NCT01045863|Drug|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
50326|NCT00029276|Procedure|Prefrontal transcranial magnetic brain stimulation|
49152|NCT01009983|Procedure|immunohistochemistry staining method|Correlative study
49153|NCT01009996|Procedure|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
49154|NCT00026156|Drug|vinorelbine tartrate|
49454|NCT01012895|Drug|Pegylated-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly
49455|NCT01012895|Drug|Ribavirin|Tablets, Oral
For subjects weighing < 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg
Twice daily (< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks
49456|NCT01012908|Dietary Supplement|Norzyme - Bergamo|2 - 8 tablets per day.
49457|NCT01012908|Dietary Supplement|Creon|2 - 8 tablets pet day
49458|NCT01012921|Device|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
49459|NCT01012921|Device|MembraGel|Device application at surgery
49460|NCT01012921|Other|Bio-Gide® membrane|Device application at surgery
49461|NCT01012934|Drug|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
49462|NCT01012934|Drug|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
49463|NCT00026338|Drug|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
49464|NCT01012947|Behavioral|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
49465|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
49466|NCT01005862|Drug|Placebo|Placebo
49467|NCT01005875|Drug|Sorafenib|Nexavar in bottles of 120 tables
49468|NCT01005875|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT
49469|NCT01005888|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
49470|NCT01005888|Drug|Placebo (saline)|
49471|NCT00025636|Drug|vincristine sulfate|
49472|NCT01005901|Drug|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
48900|NCT01012011|Drug|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
48901|NCT01012037|Drug|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
48902|NCT01012037|Drug|placebo|patient to receive placebo tablet(s) matching linagliptin
48903|NCT01012037|Drug|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
48904|NCT01012050|Device|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
48905|NCT01012050|Other|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
48906|NCT00026273|Drug|leucovorin calcium|
48907|NCT01012063|Drug|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
48908|NCT01012063|Drug|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
49210|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
49211|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
49212|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
49213|NCT01007721|Drug|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
49214|NCT01007721|Drug|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
49215|NCT00025779|Drug|methylphenidate|
49216|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
49217|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
49218|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
49219|NCT01007721|Drug|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
49220|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
48978|NCT01009749|Behavioral|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
48979|NCT01009749|Behavioral|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
48980|NCT01009762|Biological|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
48981|NCT01009775|Drug|YM155|intravenous infusion
48982|NCT01009775|Drug|Docetaxel|intravenous infusion
48983|NCT01009788|Drug|ABT-888|Capsules taken orally twice a day on days 1-7 of each 28 day cycle
48984|NCT01009788|Drug|temozolomide|capsules taken orally once a day on days 1 through 5 of a 28 day cycle
48985|NCT01012102|Biological|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
48986|NCT01012102|Biological|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
48987|NCT01012102|Biological|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
48988|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
48989|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
48990|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
48991|NCT00026286|Drug|conjugated estrogens|
48992|NCT01012141|Dietary Supplement|phytochemical|
49292|NCT01014767|Drug|Carboplatin|Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3
All Arms, Cycles 4 & 6: 350 mg/m2 IV over 2 hours on day 2 and 3
49293|NCT00026533|Drug|thalidomide|
49294|NCT01014767|Drug|Cisplatin|Cycles 1 & 2: 70 mg/m²/d IV over 6 hours on day 4
49295|NCT01014767|Drug|Cyclophosphamide|Standard Arm, Cycle 1: 1 g/m^2 IV over 1 hour on day 2 and 3
All Arms, Cycles 3 & 5: 1 g/m^2 IV over 1 hour on day 2 and 3
49296|NCT01014767|Drug|Dactinomycin|Cycles 1 & 2: 45 µg/kg/day (max. 2 mg), IV on day 1
50327|NCT01045863|Drug|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
50328|NCT01045876|Drug|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
50329|NCT01045876|Other|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
50330|NCT01045889|Other|Rituximab and CHOP regimen + PBSCT|
50331|NCT01045902|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
50332|NCT01038297|Drug|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
50333|NCT01038297|Drug|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
50334|NCT01038323|Other|CBT and milnacipran|Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week "starter pack". Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study.
50335|NCT01038323|Behavioral|CBT with a placebo|Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week "starter pack". Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study.
50336|NCT01038323|Drug|Educational with milnacipran|Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week "starter pack". Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study.
50337|NCT01038336|Behavioral|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
50338|NCT01038336|Behavioral|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
50339|NCT01038349|Other|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
50340|NCT01038362|Other|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
50341|NCT00028743|Drug|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
50342|NCT01038362|Other|No Almonds|NCEP Step 1 diet without almonds
50343|NCT01038375|Behavioral|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
49473|NCT01005901|Drug|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
49474|NCT01005914|Drug|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
49475|NCT01005914|Drug|cytarabine|Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
49476|NCT01005914|Drug|dexamethasone|Day 1-4; 11-14: 40 mg daily
49477|NCT01005914|Drug|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
49799|NCT00026208|Drug|Adriamycin|25 mg/m2
49800|NCT01010971|Drug|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
49801|NCT01010971|Drug|Placebo|Placebo HFA Nasal Aerosol once daily
49802|NCT01010984|Device|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicn will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
49803|NCT01010997|Device|Foresee Home|using the Foresee home device
49804|NCT01011010|Drug|doxorubicin hydrochloride|TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a "pruned tree" appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure.
49805|NCT01011010|Drug|mitomycin C|TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a "pruned tree" appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure.
49806|NCT01011010|Drug|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
49807|NCT01011010|Other|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
49808|NCT01011010|Other|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
49809|NCT01011023|Other|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
49810|NCT00000887|Drug|Nelfinavir mesylate|
49811|NCT00026208|Drug|Velban|6 mg/m2, IV wk 1, 3, 5, 7
49221|NCT01007721|Drug|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
49222|NCT01007721|Drug|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
49223|NCT01007747|Other|Geranium oil|Daily topical application over neuropathic pain
49224|NCT01007760|Other|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
49225|NCT01007773|Drug|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
49226|NCT00025779|Drug|guanfacine|
49227|NCT01007773|Drug|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP < 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
49228|NCT01007773|Drug|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
49229|NCT01007773|Drug|Propofol|Propofol will be titrated to an ICP < 20 mm Hg until achievement of sustained ICP control.
49230|NCT01007799|Dietary Supplement|vitamin D placebo|12 weeks of placebo
49540|NCT01012947|Behavioral|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
49541|NCT01012947|Behavioral|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
49542|NCT01012960|Drug|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
49543|NCT01012973|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
49544|NCT01012973|Other|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
49545|NCT01012986|Other|Assessment of reading skills|
49546|NCT01012999|Drug|sufentanil|Intra-nasal delivery, dosing range 0.5-1.0 mcg/kg, administered once at the beginning of the 30 minute study period
49547|NCT00026351|Biological|rituximab|
51576|NCT01032005|Other|double fortified salt|Refined salt of particle size < 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
51871|NCT01035086|Dietary Supplement|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
51872|NCT01035099|Drug|Letrozole|Letrozole titrated regimen may be started on day 2 of menstrual cycle:
Serum Estradiol level <150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;
51873|NCT01027143|Dietary Supplement|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
51874|NCT01027143|Drug|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
51875|NCT00027885|Radiation|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
51876|NCT01027156|Behavioral|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
51877|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
51878|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
51879|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
51880|NCT01027182|Drug|Raltegravir|One 400mg tablet on day 1.
51881|NCT01027195|Device|Bipolar Radiofrequency (Aquamantys 6.0)|
51882|NCT01027195|Device|Standard Bovie Electrocautery|
51883|NCT01027208|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
51884|NCT01027221|Radiation|neoadjuvant Photonradiation|single fraction, 4D planned, image guided, Radiation at a dose of 0,5 Gy in IMRT-technique 2 days before resection
51885|NCT01027221|Radiation|neoadjuvant Photonradiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
51886|NCT00027898|Drug|bortezomib|Given IV
55451|NCT00000901|Drug|Stavudine|
55452|NCT00029523|Drug|Intrathecal methotrexate|
55453|NCT01047254|Drug|placebo|
55454|NCT01047280|Dietary Supplement|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
55455|NCT01047280|Dietary Supplement|Safflower oil|3.5 g/d of safflower oil
55456|NCT01049347|Drug|paroxetine|40 mg oral, single dose, morning, 35 days
55457|NCT01049360|Drug|aclidinium bromide/formoterol fumarate combination|Aclidinium bromide with 2 dose levels of Formoterol fumarate compared with placebo, aclidinium bromide and formoterol fumarate delivered by inhalation twice daily for a 14 day period within four different treatment periods.
55458|NCT00029991|Drug|Gingko Biloba (Herb)|
55459|NCT01049360|Drug|aclidinium bromide/formoterol fumarate combination|Aclidinium bromide with 2 dose levels of Formoterol fumarate compared with placebo, aclidinium bromide and formoterol fumarate delivered by inhalation wice daily for a 14 day period within four different treatment periods.
55460|NCT01049360|Drug|aclidinium bromide|Aclidinium bromide with 2 dose levels of Formoterol fumarate compared with placebo, aclidinium bromide and formoterol fumarate delivered by inhalation twice daily for a 14 day period within four different treatment periods.
55461|NCT01049360|Drug|formoterol fumarate|Aclidinium bromide with 2 dose levels of Formoterol fumarate compared with placebo, aclidinium bromide and formoterol fumarate delivered twice daily for a 14 day period within four different treatment periods.
55462|NCT01049360|Drug|placebo|Aclidinium bromide with 2 dose levels of Formoterol fumarate compared with placebo, aclidinium bromide and formoterol fumarate delivered by inhalation twice daily for a 14 day period within four different treatment periods.
55463|NCT01049373|Drug|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
55464|NCT01049373|Drug|Placebo solution|10 drops, t.i.d, 15 weeks
55780|NCT01085617|Drug|cytarabine|
55781|NCT01085617|Drug|daunorubicin hydrochloride|
55782|NCT01085617|Drug|etoposide|
55783|NCT01085617|Drug|fludarabine phosphate|
55784|NCT00033358|Drug|norgestrel|Given orally
55785|NCT01085617|Drug|imatinib mesylate|
51941|NCT01035125|Behavioral|Self-management program|Participants will receive a one week inpatient self-management program
51942|NCT01035138|Drug|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
51943|NCT01035151|Behavioral|Sister to Sister|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
51944|NCT01035151|Behavioral|Control|Written Cessation Materials
51945|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
51946|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
51947|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
51948|NCT01035190|Drug|Budesonide|Inhalation, 200 µg/puff
52251|NCT01028014|Drug|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
52252|NCT01028014|Drug|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
52253|NCT01028014|Drug|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
52254|NCT01028014|Drug|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
52255|NCT01028014|Drug|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
52256|NCT00027924|Drug|fludarabine phosphate|
52257|NCT01028014|Drug|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
52258|NCT01028027|Drug|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
52259|NCT01028027|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
52260|NCT01028040|Drug|AZD3043|Intravenous, single dose
52261|NCT01028040|Drug|AZD3043|Infusion, single dose
52262|NCT01028053|Drug|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
55418|NCT01054235|Behavioral|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
55419|NCT01054248|Drug|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
55420|NCT01054248|Drug|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
55421|NCT01054248|Drug|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
55422|NCT01054261|Drug|avanafil|200 mg avanafil tablet QD
55423|NCT01054274|Device|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
55424|NCT01054274|Device|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
55425|NCT01054287|Other|Multifactorial falls prevention program|
55663|NCT01054599|Drug|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
55664|NCT01054612|Other|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
55665|NCT00030576|Drug|cisplatin|
55666|NCT01054625|Biological|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
55667|NCT01054638|Drug|HAART Treatment|Using pharmacy records, identify all patients with HAART dispensing during baseline & follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.
Subdivide person-time according to recent, past & non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), & Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).
Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline & follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs.
55668|NCT01054651|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
56030|NCT01083433|Behavioral|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
56031|NCT00033241|Drug|gemcitabine hydrochloride|
56032|NCT01083433|Device|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
56033|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
56034|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions during fast
56035|NCT01083472|Device|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
56036|NCT01083472|Procedure|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
56037|NCT01083485|Drug|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
56038|NCT01083485|Drug|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
56039|NCT01083498|Device|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
55103|NCT01048905|Drug|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children < 15 years of age.
55104|NCT01051011|Drug|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
55105|NCT01051011|Drug|metformin|as prescribed
55106|NCT00030238|Drug|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
55107|NCT01051011|Drug|taspoglutide|10mg sc weekly, 24 (-52) weeks
55108|NCT01051011|Drug|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
55109|NCT01051024|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
55110|NCT01051024|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
55786|NCT01085617|Drug|melphalan|
55787|NCT01085617|Drug|mercaptopurine|
55788|NCT01085617|Drug|methotrexate|
55789|NCT01085617|Drug|nelarabine|
55790|NCT01085617|Drug|pegaspargase|
55791|NCT01085617|Drug|vincristine sulfate|
55792|NCT01085617|Procedure|allogeneic hematopoietic stem cell transplantation|
55793|NCT01085617|Procedure|assessment of therapy complications|
55794|NCT01077557|Drug|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
55795|NCT00032422|Procedure|Acupuncture|
55796|NCT01077570|Drug|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
55797|NCT01077596|Drug|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
55798|NCT01077596|Drug|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
55799|NCT01077596|Drug|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
55800|NCT01077596|Drug|Regular use of any other antidepressant|Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An "other antidepressant" would be any antidepressant other than bupropion, a SSRI or a TCA.
55801|NCT01077609|Drug|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
54892|NCT01056120|Device|Pro Kinetic Energy bare metal stent|PCI
54893|NCT01056133|Other|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
52263|NCT01028066|Other|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
52264|NCT01030419|Behavioral|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
52265|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
52266|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
52267|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
52268|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
52269|NCT00028106|Drug|[123]I-MIBG|
52270|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
52271|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
52272|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
52273|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
51309|NCT01042379|Drug|AMG 479 (Ganitumab) plus Metformin|AMG 479 (Ganitumab) 12 mg/kg IV every 2 weeks during 12 week treatment cycle post-randomization; Metformin: 850 mg po every week during 12 weekly treatment cycles post-randomization
51310|NCT01042379|Drug|MK-2206 with or without Trastuzumab|Arm is closed. Agent graduated.
51311|NCT01042379|Drug|AMG 386 and Trastuzumab|AMG 386: 15 mg/kg IV every week during 12 weekly treatment cycles post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
51312|NCT01042379|Drug|T-DM1 and Pertuzumab|T-DM1: 3.6 mg/kg IV every 3 weeks (weeks 1, 4, 7, 10) post-randomization; Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization
51313|NCT01042379|Drug|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
51314|NCT01042379|Drug|Ganetespib|150 mg/m2 once weekly for 3 out of 4 weeks (Days 1, 8, 15 every 28 days)
51315|NCT00028912|Drug|carboplatin|
51316|NCT01042379|Drug|ABT-888|Arm is closed. Agent graduated.
55669|NCT01054651|Drug|Praziquantel|
55670|NCT01054677|Behavioral|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
55671|NCT01054690|Device|Bactiguard Infection Protection (BIP) Cathter.|
55672|NCT01054690|Device|Silicone Urinary Catheter|
55673|NCT01054703|Device|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
55674|NCT01054729|Drug|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
55675|NCT01047540|Drug|AIC316|Oral administration
55676|NCT01047540|Drug|Placebo|Oral administration
55677|NCT01047553|Drug|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
55678|NCT01047566|Drug|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
55679|NCT01047566|Drug|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
56025|NCT01080794|Device|Repetitive transcranial magnetic stimulation (rTMS)|DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.
M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).
Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS.
56026|NCT01080807|Drug|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
56027|NCT01083407|Other|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
56028|NCT01083420|Drug|Minocycline|Minocycline 0.2% mouthwash
56029|NCT01083420|Drug|Dexamethasone|Dexamethasone 0.01% mouthwash
55111|NCT01051037|Radiation|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
55112|NCT01051037|Radiation|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
55113|NCT01051050|Behavioral|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
55114|NCT01051050|Behavioral|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
55115|NCT01051063|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
55116|NCT01051076|Drug|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
55117|NCT00030238|Drug|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
55118|NCT01051089|Behavioral|Lifestyle modification|Exercise and diet education
55119|NCT01051102|Drug|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
55120|NCT01051102|Drug|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
55121|NCT01051115|Drug|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
55680|NCT01047579|Drug|Rivastigmine transdermal|
55681|NCT01047592|Drug|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
55682|NCT00029627|Drug|Yohimbine|
55683|NCT01047592|Drug|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
55684|NCT01047592|Drug|placebo|placebo,oral, for 12 weeks
55685|NCT01047605|Drug|Neurapas balance|6 tablets single dose
55686|NCT01047605|Drug|Pascoflair 425 mg|3 tablets , single dose
55687|NCT01047605|Drug|P-Tabletten weiß|3 tablets, single dose
54894|NCT01056146|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
54895|NCT01056146|Behavioral|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
54896|NCT01056159|Drug|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
54897|NCT01056159|Drug|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
54898|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|PegIFN alfa-2a (PEgasys) 180 ug/week
Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)
Treatment duration: 16 weeks
54899|NCT00030654|Drug|flutamide|
54900|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|PegIFN alfa-2a (PEgasys) 180 ug/week
Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)
Treatment duration: 24 weeks
54901|NCT01056198|Drug|Santyl|2 mm Santyl applied once daily.
54902|NCT01056198|Procedure|Control|Daily gauze and optional sharp debridement
54903|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
54904|NCT01048489|Behavioral|Health education in the high school|(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.
(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.
(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco.
54905|NCT00029770|Drug|Tylenol with codeine|
55181|NCT01048983|Drug|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
55182|NCT01048983|Drug|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
51317|NCT01042379|Drug|Neratinib|Arm is closed. Agent graduated.
51318|NCT01042379|Drug|PLX3397|1200 mg per day, 600mg BID, given orally in capsule form, combined with paclitaxel at 80 mg/m2 per week (for 12 weeks continuously)
51319|NCT01044810|Drug|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
51320|NCT01044823|Other|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
51321|NCT01044836|Biological|HD203|Injectable form
51322|NCT00000899|Drug|Cyclophosphamide|
51323|NCT00029172|Other|case management|
51324|NCT01044862|Drug|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
51325|NCT01044862|Drug|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
51326|NCT01044862|Drug|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
51327|NCT01044875|Procedure|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
51632|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
51633|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
51634|NCT01029353|Procedure|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
51635|NCT01029353|Procedure|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
51636|NCT00027989|Drug|pegylated liposomal doxorubicin hydrochloride|
51637|NCT01029366|Other|laboratory biomarker analysis|
51638|NCT01029366|Genetic|polymerase chain reaction|
51507|NCT01026545|Drug|Placebo|Optional cohort to match dose not greater than 1100 mg
51508|NCT01026545|Drug|PF-04287881|750 mg dose once daily for 10 days
51509|NCT00027872|Other|laboratory biomarker analysis|Correlative studies
51510|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
51511|NCT01026545|Drug|PF-04287881|1100 mg dose once daily for 10 days
51512|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
51813|NCT01029652|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
51814|NCT00028015|Drug|SarCNU|
51815|NCT01029652|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
51816|NCT01029652|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
51817|NCT01029652|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
51818|NCT01029678|Drug|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
51819|NCT01029678|Drug|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
51820|NCT01029678|Radiation|Radiotherapy|66Gy, 33 fractions, 6 week
51821|NCT01029691|Device|Positive Airway Pressure|Women will use positive airway pressure until delivery
51822|NCT01029704|Drug|EGT0001442|Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.
Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days.
51823|NCT01029704|Drug|Placebo capsules to match EGT0001442|Segment 1: Not applicable.
Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.
51824|NCT01029717|Device|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
51825|NCT00028028|Drug|temsirolimus|Given IV
51826|NCT01029717|Device|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
55688|NCT01047631|Behavioral|Functional circuit training and lifestyle counseling|Tests are performed at the beginning, and repeated after 12 and 24 weeks:
Measure general fitness levels such as walking, strength and balance.
Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.
Blood and urine tests and a heart ultrasound.
Questionnaires & activity measures.
Group assignment for 12 weeks:
-Exercise classes & activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.
Follow-up:
-Monthly phone calls during the 12 week follow up period.
55689|NCT01047631|Behavioral|Health education and independent walking|Tests are performed at the beginning, and repeated after 12 and 24 weeks.
Measure general fitness levels such as walking, strength and balance.
Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.
Blood and urine tests and a heart ultrasound.
Questionnaires & activity measures.
Group assignment for 12 weeks:
-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.
Follow-up:
-No follow up support
55690|NCT01047644|Other|Reduced port-flush schedule|3-month port-flushing
55691|NCT01047657|Behavioral|Low caloric diet plus orlistat and sibutramine|All subjetcs
55692|NCT01047670|Drug|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
55693|NCT00029666|Device|Neopulse Magnetic Stimulator|
55694|NCT01047683|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) 4 capsules/day for 40 weeks (Weeks 13-52)
55695|NCT01047683|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 2 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) 4 capsules/day for 40 weeks (Weeks 13-52)
55696|NCT01047683|Drug|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) for 40 weeks (Weeks 13-52)
55697|NCT01047683|Drug|Placebo|Placebo 2 capsules/day for 12 weeks (Weeks 1-12)
55698|NCT01047696|Device|Plancha|locally developed chimney stove
55699|NCT01049633|Drug|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
55718|NCT00030069|Drug|Dexamethasone|
55719|NCT01049815|Drug|sevelamer hydrochloride|800-3200 mg with each meal
55720|NCT01051986|Procedure|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
55721|NCT01051986|Procedure|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
55722|NCT01051999|Dietary Supplement|Glutamine|Oral glutamine powder
51887|NCT01027221|Radiation|neoadjuvant Photonradiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
51888|NCT01027234|Drug|AZD8418|Single oral dose
51889|NCT01027234|Drug|Placebo|single oral dose
51890|NCT01027247|Device|Ologen TM|
51891|NCT01027260|Drug|Itopride HCI 50 mg|Variable dosing
52190|NCT01030406|Drug|Drug C|Tablets
52191|NCT01030406|Drug|Drug D|Tablets
52192|NCT01030406|Drug|Placebo|Tablets
52193|NCT01030419|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
52194|NCT01033058|Drug|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
52195|NCT00028496|Biological|sargramostim|Given subcutaneously
52196|NCT01033058|Drug|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
52197|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
52198|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
52199|NCT01033071|Drug|Olmesartan medoxomil and hydrochlorothiazide|Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.
52200|NCT01033084|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
51639|NCT01029366|Genetic|reverse transcriptase-polymerase chain reaction|
51640|NCT01029366|Biological|anti-CD19-CAR retroviral vector-transduced autologous T cells|Given IV
51641|NCT01029366|Biological|genetically engineered lymphocyte therapy|
51642|NCT01032018|Drug|Sertraline, citalopram, or bupropion|Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.
Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam
51643|NCT01032018|Other|Standard care|Participants will receive standard of care from the current physicians
51644|NCT01032031|Dietary Supplement|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
51645|NCT01032031|Dietary Supplement|Placebo capsule|One capsule daily for 3 months
51646|NCT01032044|Device|Standard endoscopic treatment of BE|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
51647|NCT01032044|Device|pCLE guided endoscopic treatment of BE|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
51648|NCT01032057|Drug|capecitabine|
51649|NCT00028366|Drug|Fosamprenavir|
51650|NCT01032057|Drug|gemcitabine hydrochloride|
51651|NCT01032057|Procedure|quality-of-life assessment|
51949|NCT01035203|Behavioral|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
51950|NCT00028665|Biological|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
51951|NCT01035203|Behavioral|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
51952|NCT01035216|Drug|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
51953|NCT01035229|Drug|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
51827|NCT01029717|Device|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
51828|NCT01032356|Device|Wrist Extension Dynasplint|Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or "Experimental" group will add this therapy to their standard of care regimen
51829|NCT01032369|Other|Nutritional intervention and physical activity|Nutritional intervention:
Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.
Physical activity:
All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).
52128|NCT01035749|Biological|Placebo (saline)|One dose intramuscularly
52129|NCT01035775|Procedure|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
52130|NCT01035775|Procedure|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
52131|NCT01035788|Behavioral|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
52132|NCT01035788|Behavioral|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
52133|NCT01035801|Drug|IN-105|Prandial Oral Insulin
52134|NCT01035801|Drug|Insulin Lispro Injection|Insulin Lispro Injection
52135|NCT01035853|Drug|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
52136|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
52137|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
52138|NCT00028665|Radiation|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
52139|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
52140|NCT01035879|Drug|Sitagliptin|tablets and capsule once daily
52141|NCT01035879|Drug|placebo|tablets and capsule once daily
55723|NCT01051999|Dietary Supplement|L-alanine|L-alanine oral powder
55724|NCT00030368|Drug|bortezomib|Given IV
55725|NCT01052012|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; SABER™-Bupivacaine /Once
55726|NCT01052012|Drug|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
55727|NCT01052012|Drug|SABER™-Placebo|Injectable Solution; SABER™-Placebo/Once
55728|NCT01052025|Drug|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
55729|NCT01052038|Drug|Placebo administration|Placebo administration
55730|NCT01052038|Drug|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
55731|NCT01052038|Drug|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
55732|NCT01052051|Dietary Supplement|Vitamin D|Vitamin D 2000 IU/daily
55733|NCT01052051|Dietary Supplement|Calcium|Calcium 1200mg / daily
55734|NCT01052064|Device|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
55735|NCT00030368|Drug|paclitaxel|Given IV
55736|NCT01052077|Drug|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
55737|NCT01052077|Drug|Placebo|Placebo
55738|NCT01052077|Drug|ADT|
55739|NCT01052090|Drug|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
55740|NCT01052103|Drug|LY2140023|40mg, oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20mg or a maximum of 80mg.
56040|NCT01083524|Drug|Dichloroacetate Sodium|3 mg po bid for 28 weeks
56041|NCT01083524|Drug|Dichloroacetate Sodium|6.25 mg po bid
56042|NCT00033254|Radiation|radiation therapy|Undergo conventional radiation therapy
56043|NCT01083524|Drug|Dichloroacetate Sodium|12.5 mg po bid
52201|NCT01033084|Drug|Sertraline|Patient will receive sertraline 50mg/day.
52202|NCT01033084|Other|double placebo|double placebo arm (sham stimulation/placebo pill)
52203|NCT01033097|Drug|DNK333 5 mg|5 mg oral
52204|NCT01033097|Drug|Placebo to 5 mg|5 mg placebo oral
52205|NCT01033097|Drug|DNK333 25 mg|25 mg oral
52206|NCT00028496|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
52207|NCT01033097|Drug|Placebo to 25 mg|25 mg placebo oral
51248|NCT01037114|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
51249|NCT01037114|Biological|EngerixTM-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
51250|NCT01037114|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
51251|NCT01037127|Drug|GSK1120212|Daily oral dosing
51252|NCT00028717|Biological|rituximab|
51253|NCT01037140|Drug|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
51254|NCT01037140|Drug|placebo|oral placebo tablets similar to active comparator
51255|NCT01037166|Drug|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
51256|NCT01037179|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
51257|NCT01037192|Drug|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
51258|NCT01037192|Drug|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
51259|NCT01037205|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
51260|NCT01037205|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
51261|NCT01037218|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
51262|NCT01037218|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
51954|NCT01035229|Drug|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
51955|NCT01035229|Other|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
51956|NCT01035242|Behavioral|"association splitting"|"Association splitting" is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as "cancer - illness") and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as "cancer - (zodiac) sign", "cancer - great crab"). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened.
51957|NCT01027286|Device|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
51958|NCT00027898|Drug|carboplatin|Given IV
51959|NCT01027299|Device|Biventricular pacing|Optimised temporary biventricular pacing.
51960|NCT01027325|Other|Dietary Intervention|Starch digestibility and carbohydrate quantity
51961|NCT01027338|Other|Tai chi exercise|
51962|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
51963|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
51964|NCT01027364|Drug|Factor IX (rFIXFc)|
51965|NCT01027364|Drug|rFIX|
52274|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
52275|NCT01030458|Drug|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
52276|NCT01030458|Drug|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
52142|NCT01035905|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
52143|NCT01035905|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
52144|NCT01035944|Device|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
52145|NCT01035944|Device|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
52146|NCT01035983|Drug|Frovatriptan 2.5 mg|
52147|NCT01027715|Other|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
51181|NCT01039909|Drug|Placebo|For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
51182|NCT01039909|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
51183|NCT01039948|Biological|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
51184|NCT00028795|Procedure|adjuvant therapy|
51185|NCT01039948|Drug|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
51186|NCT01039961|Drug|losmapimod 1 mg|IV infusion
51187|NCT01039961|Drug|losmapimod|IV infusion (dose to be determined based on PK from first dose)
51188|NCT01039961|Drug|losmapimod 15 mg|oral, two 7.5 mg tablets
51189|NCT01039974|Drug|GSK962040|GSK962040. Planned doses per cohort as follows:
Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1
51190|NCT01039974|Drug|Ketoconazole|400 mg
51191|NCT01040000|Drug|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
51192|NCT01040013|Procedure|Laparoscopy|Laparoscopic Left-Colectomy
56044|NCT01083537|Drug|Cisplatin|1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.
Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn
Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour
56045|NCT01083537|Drug|Paclitaxel|2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.
Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo
Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn
Hydration: Infuse Paclitaxel in 250cc NS over 1 hour
56046|NCT01083550|Other|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
56047|NCT01085929|Procedure|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
56048|NCT01085929|Procedure|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
56049|NCT01085968|Behavioral|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. They are then instructed to repeat the string from memory. As performance improves (# correct), the strings of numbers get longer.
56050|NCT01085981|Drug|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
56051|NCT01085981|Drug|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
56052|NCT01085981|Drug|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
56053|NCT01085994|Other|Literature search|Literature search followed by systematic review and meta-analysis
56054|NCT01086020|Drug|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
56055|NCT00000918|Drug|Efavirenz|
56056|NCT00033371|Other|Questionnaire administration|Ancillary studies
55122|NCT01051128|Device|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
51263|NCT00028717|Drug|cyclophosphamide|
51264|NCT01037231|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU oxalobacter formigenes twice daily for 24 weeks
51265|NCT01037231|Drug|Placebo|placebo
51266|NCT01037244|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
51267|NCT01037244|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
51268|NCT01037283|Behavioral|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
51269|NCT01037296|Procedure|catheter ablation|ablation procedure performed with Hansen robotic navigation system
51270|NCT01037296|Procedure|catheter ablation|Ablation will be performed as normal treatment
51271|NCT01037309|Drug|PRO044 SC|Subcutaneous injection, once a week, for five weeks
51577|NCT01032018|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
51578|NCT01034319|Behavioral|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
51579|NCT01034332|Procedure|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
51580|NCT01034345|Drug|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
51581|NCT01034345|Drug|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
51582|NCT01034358|Biological|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
51583|NCT01034371|Procedure|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
51584|NCT00028600|Drug|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
51585|NCT01034371|Procedure|PCI-Drug eluting stents|PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.
Device: Polymer-based Sirolimus-Eluting Stents (SES).
52277|NCT01030471|Behavioral|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
52278|NCT01030510|Drug|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
52279|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
52280|NCT00028132|Drug|Tenofovir|
52281|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)
52282|NCT01030536|Drug|CAT-8015 Immunotoxin (Moxetumomab Pasudotox)|2-mL sized vials of CAT-8015 at a target concentration of 1.0 mg per vial
52283|NCT01030575|Drug|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
52284|NCT01030575|Drug|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
52285|NCT01030575|Drug|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
52286|NCT01030575|Drug|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
52287|NCT01030601|Drug|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
52288|NCT01033136|Behavioral|Cognitive-Processing Therapy|Participants will be randomly assigned to receive either MCET-V or cognitive processing therapy (CPT), a standard PTSD treatment. Patients in both the MCET-V and CPT conditions will receive 12, 90-minute sessions of individual therapy twice a week over a 6-week period.
52289|NCT00028509|Procedure|management of therapy complications|
52290|NCT01033149|Drug|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
51328|NCT01044888|Drug|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
51329|NCT01044901|Procedure|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
51193|NCT01042158|Drug|Ambrisentan monotherapy|ambrisentan 5 mgs daily and placebo qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
51194|NCT01042158|Drug|tadalafil and ambrisentan|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
51195|NCT01042184|Drug|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
51196|NCT01042184|Drug|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
51197|NCT01042184|Drug|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
51198|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
51513|NCT01026558|Drug|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
51514|NCT01026584|Drug|Aripiprazole|6 week prospective study
51515|NCT01026597|Drug|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
51516|NCT01026597|Drug|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
51517|NCT01026610|Drug|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
51518|NCT01026610|Drug|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
51519|NCT01026610|Drug|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
51520|NCT00027885|Biological|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
51521|NCT01026623|Biological|Cixutumumab|Given IV
51522|NCT01026623|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
51523|NCT01026623|Drug|Temsirolimus|Given IV
51524|NCT01026636|Drug|Ceftobiprole|
51525|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
55123|NCT01051141|Behavioral|Computer-delivered Brief Intervention (CBI)|The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a "change plan" tailored for each participant.
55124|NCT01053637|Drug|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
55125|NCT00030485|Drug|erlotinib hydrochloride|
55126|NCT01053637|Drug|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
55127|NCT01053650|Drug|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
55128|NCT01053663|Drug|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
55129|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
55130|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
55131|NCT01053689|Drug|Glimepiride tablets 1 mg|
55132|NCT01053702|Drug|R475|IV
55133|NCT01053702|Drug|Placebo|Placebo
55134|NCT01053728|Drug|SAR161271|Pharmaceutical form:Solution for injection
Route of administration: subcutaneous
55135|NCT01053728|Drug|Insulin glargine HOE901|Pharmaceutical form:Solution for injection
Route of administration: subcutaneous
55136|NCT00030498|Drug|erlotinib hydrochloride|Given orally
55137|NCT01053741|Biological|Autologous seminal fluid with Tc-99m/In-111 radiolabels|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
55138|NCT01053741|Other|Autologous lymphocytes labeled with In-111 in normosol vehicle with TC-99m DTPA incorporated|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
55139|NCT01053754|Biological|"long" synacthen stimulation test|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
55140|NCT01053767|Biological|Group B streptococcus (GBS) vaccine|No vaccine will be administered in this study. Only one study visit is required.
Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study.
51586|NCT01034371|Procedure|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
51587|NCT01034397|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
51588|NCT01034397|Drug|placebo|iv every 4 weeks for 24 weeks
51589|NCT01034397|Drug|non-biological DMARDs|stable dose at investigator's prescription
51590|NCT01034410|Drug|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
51591|NCT01034410|Drug|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
51592|NCT01034423|Dietary Supplement|Omega-3|Capsules with omega-3 fatty acids.
51593|NCT01034423|Dietary Supplement|sun flower oil|Capsules with sun flower oil.
51594|NCT01034436|Dietary Supplement|fatty acid quality and overweight|Duration 12 weeks
51595|NCT00028600|Drug|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
51596|NCT01034449|Other|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
51892|NCT01027260|Drug|Itopride HCI 100 mg|Variable dosing
51893|NCT01027260|Drug|Placebo|Variable dosing
51894|NCT01027273|Behavioral|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
51895|NCT01027273|Behavioral|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
51896|NCT01029730|Drug|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
51897|NCT01029730|Drug|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
51898|NCT01029730|Drug|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
51899|NCT01029743|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
51330|NCT01044927|Other|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
51331|NCT01044927|Other|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
51332|NCT01044953|Other|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
51333|NCT01044966|Drug|Intrathecal liposomal Ara-C + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
51334|NCT00029185|Drug|Dehydrex|
51335|NCT01044992|Radiation|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
51336|NCT01044992|Drug|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
51337|NCT01037335|Drug|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
51338|NCT01037348|Drug|ranibizumab 0.5mg|
51339|NCT01037374|Other|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
51340|NCT01037387|Drug|Control|Current treatment according to the ATS/ERS guidelines
51341|NCT01037387|Device|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
51342|NCT01037413|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
51343|NCT01037413|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
51652|NCT01032057|Radiation|3-dimensional conformal radiation therapy|
51653|NCT01032070|Drug|erlotinib|oral
51654|NCT01032070|Drug|etoposide|oral
51526|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
51527|NCT01026662|Procedure|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
51528|NCT01026662|Device|eMatrixCO2|
51529|NCT01026675|Procedure|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
51530|NCT01029067|Behavioral|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
51531|NCT01029067|Behavioral|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
51532|NCT01029080|Other|no interventions|No interventions
51533|NCT01029093|Other|no intervention, MRI and motor skill test|Two MR Investigations at two different times
51534|NCT01029106|Procedure|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
51830|NCT01032369|Other|Nutritional intervention, physical activity and behavioral treatment|Nutritional intervention:
Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.
Physical activity:
All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).
Behavioral treatment:
This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from "ONIM" in weekly group sessions.
51831|NCT00028379|Procedure|Transcranial magnetic stimulation (TMS)|
51832|NCT01032382|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
51833|NCT01032382|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
51834|NCT01032395|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
51835|NCT01032395|Biological|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
51836|NCT01032395|Biological|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
51837|NCT01032408|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
51838|NCT01032408|Biological|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
55700|NCT01049633|Drug|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
55701|NCT01049646|Drug|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
55702|NCT01049646|Drug|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
55703|NCT01049659|Behavioral|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
55704|NCT01049672|Drug|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
55705|NCT01049672|Drug|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
55706|NCT01049685|Drug|First-line Antiretroviral Therapy|Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background
Efavirenz: 01 capsules day, plus NRTI background
55707|NCT00030069|Drug|Calcitriol|
55708|NCT01049698|Behavioral|Resistance Training|3 d/wk resistance training
55709|NCT01049698|Behavioral|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
55710|NCT01049711|Drug|erythropoietin|
55711|NCT01049724|Other|Tear collection|Tear collection
55712|NCT01049750|Other|type 2 diabetic patients|males; type 2 diabetic patients
55713|NCT01049763|Drug|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
55714|NCT01049776|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
55715|NCT01049789|Behavioral|COMB - Combination Cognitive Behavioral Therapy and Medication Management|Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.
Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48.
55716|NCT01049789|Behavioral|TAU - Treatment as Usual|Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.
Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48.
51900|NCT01029743|Drug|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
51901|NCT01029756|Device|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
51902|NCT01029756|Device|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
51903|NCT01029769|Drug|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
51904|NCT00028028|Other|pharmacological study|Correlative studies
51905|NCT01029782|Drug|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
51906|NCT01029782|Drug|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
51907|NCT01029795|Drug|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
51908|NCT01029795|Drug|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
51909|NCT01029795|Drug|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
51910|NCT01029821|Drug|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
52208|NCT01033097|Drug|DNK333 100 mg|100 mg oral
52209|NCT01033097|Drug|Placebo to 100 mg|100 mg placebo oral
52210|NCT01033097|Drug|Betamethasone 4 mg|4 mg oral
52211|NCT01033097|Drug|DNK333 1mg|1 mg oral
52212|NCT01033097|Drug|Placebo to 1mg|1 mg placebo oral
52213|NCT01033110|Behavioral|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
52214|NCT01033123|Drug|BSI-201|IV infusion, 5.6 mg/kg
52215|NCT01033136|Behavioral|Multiple Channel Exposure Therapy-Veterans|Individual therapy design completed twice a week over a 6-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
51655|NCT01032083|Drug|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
51656|NCT01032083|Drug|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
51657|NCT01032109|Drug|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
51658|NCT01032122|Drug|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
51659|NCT01032135|Behavioral|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
51660|NCT00028366|Drug|Lopinavir/Ritonavir|
51661|NCT01032135|Behavioral|Telephone counseling|one telephone counseling session per week for 10 weeks.
51662|NCT01032135|Behavioral|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
51663|NCT01032135|Drug|medication management|Prescription for naltrexone
51664|NCT01032135|Behavioral|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
51665|NCT01032148|Drug|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
51666|NCT01034488|Biological|Suine|5000UI /mL
51667|NCT01034488|Biological|Suine|5000UI/mL
51668|NCT01034501|Device|sham procedure|non activated laser tip
51669|NCT01034501|Device|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
51670|NCT01034514|Device|Real-time Position Management system|Standard of Care
51671|NCT01034514|Device|Discovery ST multislice PET/CT scanner|Standard of Care
51672|NCT00028600|Drug|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
51673|NCT01034514|Device|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
51674|NCT01034514|Device|Pinnacle3 treatment planning system|Standard of Care
51675|NCT01034514|Device|SKYLight nuclear camera|Standard of Care
51839|NCT01032421|Procedure|IVF procedure|
51840|NCT01032434|Drug|sertraline|sertraline: 50-200mg/day
51841|NCT01032447|Behavioral|Navigator Support|Standard of Care
51842|NCT00000896|Drug|Indinavir sulfate|
51843|NCT00028405|Drug|LS 11(Taporfin Sodium)|
51844|NCT01032460|Device|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
51845|NCT01032460|Device|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
51846|NCT01032460|Device|intubate with the Airtraq device|intubate with the Airtraq device
51847|NCT01032486|Drug|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
51848|NCT01032499|Drug|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
51849|NCT01032499|Drug|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
51850|NCT01032512|Dietary Supplement|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
51851|NCT01032512|Dietary Supplement|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
52148|NCT01027728|Drug|CCX 354-C|Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;
Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and
Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days.
52149|NCT01027741|Behavioral|Phone Referral|Participants receive phone referral to cancer control and prevention services.
52150|NCT01027741|Behavioral|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
52151|NCT01027741|Behavioral|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
52152|NCT01027754|Drug|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
52153|NCT01027754|Drug|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
55717|NCT01049802|Device|repetitive transcranial magnetic stimulation to contralesional hemisphere|1 Hz rTMS to contralesional hemisphere in patients with stroke
55741|NCT01052103|Drug|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
55742|NCT01052103|Drug|Standard of Care|U.S. label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
55743|NCT01052116|Drug|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
55744|NCT01052116|Drug|Placebo|Placebo
55745|NCT01052129|Drug|Naproxen sodium|Naproxen Sodium Tablets 550 mg
55746|NCT00030368|Other|laboratory biomarker analysis|Correlative studies
55747|NCT01082874|Drug|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
55748|NCT01082874|Drug|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
55749|NCT01082887|Other|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
55750|NCT01082900|Other|Prophylactic CPAP Administration|EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)
CONTROL GROUP: Provision of standard care in the Delivery Room
55751|NCT01082913|Device|SSE|Use of SSE or not use of SSE
55752|NCT01082926|Biological|therapeutic allogeneic lymphocytes|Given intratumorally
55753|NCT00033202|Drug|Gimatecan® (ST-1481)|
55754|NCT01082926|Biological|aldesleukin|Given intratumorally
55755|NCT01082926|Other|laboratory biomarker analysis|Optional correlative studies
55756|NCT01082926|Procedure|positron emission tomography|Optional correlative studies
55757|NCT01082939|Drug|Fludarabine|25 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
52216|NCT01035242|Behavioral|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
52217|NCT01035255|Drug|LCZ696 200 mg BID|LCZ696 200 mg BID
52218|NCT01035255|Drug|Enalapril 10 mg BID|Enalapril 10 mg BID
52219|NCT01035268|Procedure|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
52220|NCT00028665|Biological|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
52221|NCT01035281|Drug|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
52222|NCT01035294|Behavioral|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
52223|NCT01035294|Behavioral|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
52224|NCT01035307|Genetic|gene expression analysis|
52225|NCT01035307|Genetic|microarray analysis|
52226|NCT01035307|Genetic|proteomic profiling|
51272|NCT01037309|Drug|PRO044 IV|Intravenous injection, once a week, for five weeks
51273|NCT01037322|Drug|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
51274|NCT00028717|Drug|doxorubicin hydrochloride|
51275|NCT01037322|Drug|placebo in drops|olive oil containing no drug given in drops twice daily
51276|NCT01040013|Procedure|left colectomy by laparotomy|PatientS will be operated by laparotomy
51966|NCT01027377|Drug|rFVIIIFc|Single dose
51967|NCT01027377|Drug|rFVIIIFc|Single dose
51968|NCT01027390|Behavioral|physical training exercise|physical exercise training at the work site during work time
51969|NCT00027898|Drug|etoposide|Given IV
51970|NCT01027416|Drug|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
51971|NCT01027429|Drug|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
51972|NCT01027429|Drug|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
51973|NCT01027429|Drug|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
51974|NCT01027442|Device|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
51975|NCT01027442|Device|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
51976|NCT01027442|Device|Dental Implants|Dental implants placed via conventional free-hand method
51977|NCT01027455|Device|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
51978|NCT01027455|Procedure|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
51979|NCT01027455|Procedure|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
51980|NCT00027898|Other|laboratory biomarker analysis|Correlative studies
51981|NCT01027468|Drug|Bevacizumab|intraocular bevacizumab injection
51982|NCT01027481|Drug|Lucentis|intravitreally administration of 0.05 ml Lucentis
51983|NCT01027494|Drug|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
51984|NCT01029912|Device|Electrical stimulator|6-week intervention
15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.
Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device.
51985|NCT01029925|Drug|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
52154|NCT01027767|Device|Molecular Breast Imaging|Molecular Breast Imaging
52155|NCT00000894|Drug|Cidofovir|
52156|NCT00027911|Biological|sargramostim|
52157|NCT01027780|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
52158|NCT01027793|Drug|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
52159|NCT01027793|Device|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
52160|NCT01027806|Drug|Montelukast|1 pill per day for 4 months
52161|NCT01027819|Device|Mobile bearing|Mobile bearing in total knee arthroplasty
52162|NCT01027819|Device|Fixed bearing|Fixed bearing in total knee arthroplasty
52163|NCT01027832|Drug|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
52164|NCT01027845|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
52165|NCT01027845|Biological|DTPa|Subcutaneous injection, 4 doses
52166|NCT01027858|Behavioral|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
51199|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
51200|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
51201|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
51202|NCT00028899|Drug|gemtuzumab ozogamicin|
51203|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
51204|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
51205|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
55758|NCT01082939|Drug|Cyclophosphamide|250 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
55759|NCT01082939|Drug|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
55760|NCT01082939|Drug|Rituximab|Cycle 1 (Week 1): 375 mg/m^2/day IV on Day 2 over 4- 6 hours
Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV on Day 2 over 4- 6 hours
54852|NCT01050608|Drug|62% ethanol based hand cleanser|CDC based guidelines with regard to utilization in the health care environment "the nest"
54853|NCT01050608|Behavioral|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
54854|NCT00030186|Drug|CEP-701 60mg|60mg orally 2 times a day for 28 days
54855|NCT01050608|Behavioral|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
54856|NCT01050621|Dietary Supplement|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
54857|NCT01050634|Drug|Aromasin (exemestane)|25mg oral tablet, daily, for >1yr
54858|NCT01050647|Drug|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
54859|NCT01050647|Other|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
54860|NCT01050660|Other|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
54861|NCT01050660|Other|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
54862|NCT01053169|Biological|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
54863|NCT01053169|Biological|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
54864|NCT01053169|Other|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
54865|NCT01053182|Procedure|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
54866|NCT01053182|Procedure|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
51277|NCT01040026|Other|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at <1x10e5/kg
51278|NCT00028795|Radiation|radiation therapy|
51279|NCT01040052|Biological|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
51280|NCT01040065|Procedure|distal clavicle resection|Presence of tenderness at 2 years after surgery
51281|NCT01040078|Biological|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
51282|NCT01040078|Biological|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
51283|NCT01040078|Biological|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
51284|NCT01040091|Drug|Emtricitabine (FTC)|200 mg once a day
51285|NCT01040091|Drug|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
51286|NCT01040091|Drug|Efavirenz (EFV)|600 mg once a day
51287|NCT01040091|Drug|Truvada|200 mg emtricitabine + 300 mg TDF once a day
51288|NCT01040104|Other|Skin sample|Taken from regularly discarded tissue during routine operation
51289|NCT00028821|Drug|2-methoxyestradiol|Given orally
51290|NCT01040104|Other|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
51291|NCT01040104|Other|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
51292|NCT01040104|Other|Blood taking|Blood taking on day 0
51293|NCT01040104|Other|Blood taking|Blood taking on day 90
51597|NCT01034462|Drug|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
51598|NCT01034462|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
51986|NCT01029938|Procedure|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
52291|NCT01033162|Behavioral|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:
Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)
Reduce patients' negative affect and increase their emotional well being
Improve patients' sense of social support
Improve patients' health self-efficacy
Improve patients' ratings of experience with cancer specialty care services
Improve patients' health related quality of life (HRQL)
Improve clinicians' ratings of quality of patient contacts
Reduce healthcare utilization and costs (obtained via the EMR)
52292|NCT01033175|Procedure|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
52293|NCT01033175|Procedure|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
52294|NCT01033188|Procedure|Single bundle|Procedure:
Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon.
52295|NCT01033188|Procedure|Double bundle|Procedure:
Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith & Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon.
52296|NCT01033201|Other|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
52297|NCT01033214|Device|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
52298|NCT01033227|Drug|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
52299|NCT01033240|Drug|CS-1008|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg, followed by 4 mg/kg if tolerated, followed by 6 mg/kg if tolerated.
52300|NCT00000226|Drug|Buprenorphine|
51206|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
51207|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
51208|NCT01042236|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
51209|NCT01042249|Other|Pelvic Floor Muscle training|12 week training program including home exercises
51210|NCT01042262|Other|Oxygen|100% Oxygen at a flow of 2 L/min
51211|NCT01042262|Other|Placebo|No oxygen flow
51212|NCT01042288|Drug|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
51213|NCT00028899|Drug|mitoxantrone hydrochloride|
51214|NCT01042288|Drug|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
51215|NCT01042288|Drug|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
51216|NCT01042301|Other|Blood samplings|
51217|NCT01042314|Drug|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
51218|NCT00029159|Drug|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
51219|NCT01044680|Dietary Supplement|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
51220|NCT01044693|Drug|Placebo|Placebo capsule
51221|NCT01044693|Drug|Nebivolol 5 mg|Nebivolol 5mg single oral dose
51222|NCT01044693|Drug|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
51535|NCT01029132|Drug|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
51536|NCT01029158|Drug|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
51537|NCT01029158|Drug|RN1006 (Avotermin)|250 ng, intradermal injection, twice
51538|NCT01029158|Drug|RN1006 (Avotermin)|205 ng, Intradermal injection, once
51539|NCT00027976|Drug|celecoxib|
54867|NCT01053195|Behavioral|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
54868|NCT01053208|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
54869|NCT01053221|Drug|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
54870|NCT01053221|Drug|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
55141|NCT01053780|Other|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
55142|NCT01053780|Behavioral|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
55143|NCT01053793|Other|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
55144|NCT01053806|Drug|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
55145|NCT01053819|Drug|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
55146|NCT01056211|Procedure|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
55147|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
55148|NCT01056224|Drug|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
55149|NCT01056237|Drug|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
55150|NCT01056237|Drug|Azathioprine|1.0-2.0mg/kg/d
55151|NCT01056250|Procedure|SILS cholangiography|intraoperative
55152|NCT00030654|Drug|ketoconazole|
55153|NCT01056263|Drug|axitinib: observational study|Non-interventional observational study
55154|NCT01056276|Drug|Bendamustine|80 mg/m2 IV Days 1 and 4; repeat cycles every 28-days
51599|NCT01034475|Drug|CPI-613|This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient & traditional stages):
Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered.
Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme.
51600|NCT01026688|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
51601|NCT00027885|Drug|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
51602|NCT01026688|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
51603|NCT01026701|Drug|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
51604|NCT01026714|Drug|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
51605|NCT01026714|Drug|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
51606|NCT01026714|Drug|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
51607|NCT01026727|Drug|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
51608|NCT01026727|Drug|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
51609|NCT01026740|Drug|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
51610|NCT01026753|Behavioral|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
51611|NCT01026792|Drug|Temsirolimus|Given IV
51612|NCT00027885|Drug|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
51613|NCT01026792|Other|Laboratory Biomarker Analysis|Correlative studies
51911|NCT01029834|Behavioral|family based lifestyle and behavioral counseling|16 group meetings
52301|NCT00000896|Drug|Lamivudine/Zidovudine|
51344|NCT01037426|Other|Fill out Questionnaire|Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect
History of falls and fractures during the 12 months before pacemaker implantation
Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)
History of falls and fractures during the 12 months after pacemaker implantation
Medical and Arrhythmia History
Cardiovascular Events
Cardiovascular Medication
Device programming information
51345|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
51346|NCT00028717|Drug|prednisone|
51347|NCT01037452|Drug|Lansoprazole|Tablet
51348|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide|Tablet
51349|NCT01037452|Drug|Placebo|Tablet
51350|NCT01037465|Drug|N-acetylcysteine|N-acetylcysteine
51351|NCT01037465|Drug|Placebo|Placebo
51352|NCT01037478|Drug|Resminostat (4SC-201)|oral administration
51353|NCT01037491|Drug|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
51354|NCT01037504|Drug|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
51355|NCT01037504|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
51356|NCT01037517|Drug|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
51357|NCT00028717|Drug|vincristine sulfate|
51358|NCT01037517|Other|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
51359|NCT01037530|Drug|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
51360|NCT01040130|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
51361|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high dose
51362|NCT00028821|Other|pharmacological study|Correlative studies
51540|NCT01029158|Drug|RN1006 (Avotermin)|500ng, intradermal injection, once
51541|NCT01029158|Drug|Juvista (Avotermin)|250 ng, intradermal injection, twice
51542|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
51543|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
51544|NCT01029158|Drug|RN1006 (Avotermin)|500 ng, intradermal injection, twice
51545|NCT01029158|Drug|Placebo|Placebo
51546|NCT01029171|Behavioral|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
51547|NCT01029171|Behavioral|control; usual care|Usual care as prescribed by geriatrician.
51548|NCT01029184|Other|commercialized complete cereals|complete cereals suitable for the weaning period
51549|NCT01029184|Other|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
51550|NCT00027976|Drug|Placebo|
51551|NCT01029197|Behavioral|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
51552|NCT01029197|Other|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
51553|NCT01029223|Drug|ivabradine|
51554|NCT01029223|Drug|metoprolol|
51555|NCT01029223|Drug|placebo|
51556|NCT01029236|Other|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
51557|NCT01031901|Drug|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
51852|NCT00028626|Drug|embolization therapy|
51853|NCT01034917|Drug|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
51854|NCT01034917|Drug|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
55155|NCT01056276|Drug|Bortezomib|1.3 mg/m2 IV Days 1, 4, 8, 11; repeat cycles every 28-days
55156|NCT01056276|Drug|Dexamethasone|40 mg PO Days 1, 2, 3, 4; repeat cycles every 28-days
55157|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
55158|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
55159|NCT01056289|Drug|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
55426|NCT01054287|Other|No falls prevention intervention|
55427|NCT00030550|Drug|thalidomide|
55428|NCT01054300|Drug|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (using 1 mg strength tablets), administered as a single dose
55429|NCT01054300|Drug|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (using 1 mg strength tablets) administered twice daily x 1 day
55430|NCT01054300|Drug|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (using 1mg strength tablets), administered as a single dose
55431|NCT01054300|Drug|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (using 1 mg strength tablets) administered twice daily x 1 day
55432|NCT01054300|Drug|Placebo|Placebo to Ertugliflozin
55433|NCT01047085|Procedure|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
55434|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
55435|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
55436|NCT01047098|Dietary Supplement|Placebo|Placebo capsule
55437|NCT01047111|Procedure|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
55438|NCT01047124|Other|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
51912|NCT01029834|Behavioral|counseling focused on the child|16 meetings
51913|NCT01029847|Drug|Adalimumab|Sc. inj. Humira 40 mg every other week for 42 to 48 weeks
51914|NCT01029847|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, and 4. Active treatment from week 6.
51915|NCT00028028|Other|laboratory biomarker analysis|Correlative studies
51916|NCT01029873|Drug|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
51917|NCT01029873|Biological|ALT-801|Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses
Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)
Stage 2: dose expansion (dose at MTD)
51918|NCT01029886|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly
51919|NCT01029886|Drug|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
51920|NCT01032551|Behavioral|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
51921|NCT01032564|Other|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
51922|NCT00028405|Device|Lumaflex Light Delivery Catheter|
51923|NCT01032590|Behavioral|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
51924|NCT01032603|Procedure|Bilateral lateral rectus recession (BLRrec)|Bilateral lateral rectus recession surgery
51925|NCT01032603|Procedure|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
51926|NCT01032616|Other|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
51927|NCT01032616|Other|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
51928|NCT01032629|Drug|Canagliflozin (JNJ-28431754)|One 100 mg or 300 mg capsule taken orally (by mouth) once daily
51363|NCT01040130|Drug|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
51364|NCT01040169|Device|Arginine/Calcium Carbonate|One application
51365|NCT01040169|Device|Mint Prophy paste - Fluoride free|one application
51676|NCT01034514|Drug|DTPA|1 mCi; inhalation
51677|NCT01034514|Drug|TECHNETIUM TC 99M MAA|3 mCi; iv
51678|NCT01034527|Other|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
51679|NCT01034527|Other|Speed Protocol|Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
51680|NCT01034540|Drug|POM3|4 g/day
51681|NCT01034540|Drug|Placebo|matching placebo capsule, 4 g/day
51682|NCT01034553|Drug|Aurora A kinase inhibitor MLN8237|Given orally
51683|NCT00028600|Drug|methotrexate|5mg/sq m/d IV infusion D 1,3,& 6: allo transpl
51684|NCT01034553|Drug|bortezomib|Given IV
51685|NCT01034566|Radiation|Proton Beam Radiation Therapy|
51686|NCT01034579|Other|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
51687|NCT01034579|Other|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
51688|NCT01034592|Drug|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
51689|NCT01034605|Dietary Supplement|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
51690|NCT01034618|Dietary Supplement|Protein hydrolyzation|
51691|NCT01034631|Drug|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
51692|NCT01034631|Drug|BNC105P|MTD as determined by Phase I portion
51855|NCT01034930|Procedure|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
51856|NCT01034943|Procedure|External fixation|Operation with external fixation and optional addition of k-wire
51857|NCT01034943|Procedure|Volar plate|Operation with a Synthes volar two column plate (TCP)
51858|NCT01034956|Device|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
51859|NCT01034982|Drug|AZD9668|20 mg
51860|NCT01034982|Drug|AZD9668|60 mg
51861|NCT01034995|Drug|SSR125543|Pharmaceutical form: capsule
Route of administration: oral
51862|NCT01034995|Drug|escitalopram|Pharmaceutical form: encapsulated tablets
Route of administration: oral
51863|NCT00028639|Drug|bortezomib|
51864|NCT01034995|Drug|placebo|Pharmaceutical form: capsule
Route of administration: oral
51865|NCT01035008|Procedure|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
51866|NCT01035021|Drug|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
51867|NCT01035034|Procedure|Hybrid MIDCAB/PCI|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.
Device: Polymer-based Sirolimus-Eluting Stents (SES).
51868|NCT01035034|Procedure|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
51869|NCT01035047|Other|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
51870|NCT01035073|Drug|Duloxetine|30-60 mg daily for 8 weeks
52167|NCT00027924|Drug|busulfan|
52168|NCT01027858|Behavioral|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
55439|NCT01047137|Behavioral|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
55440|NCT00029523|Drug|Intrathecal (injected into the spinal fluid) DepoCyt|
55441|NCT01047137|Behavioral|General Supportive Therapy|There is no focus on stress intervention.
55442|NCT01047189|Drug|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
55443|NCT01047189|Drug|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
55444|NCT01047189|Drug|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
55445|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
55761|NCT01082965|Drug|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
55762|NCT01082965|Drug|Placebo|matching placebo
55763|NCT01082978|Device|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
55764|NCT00033215|Drug|S-3304|
55765|NCT01082978|Device|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
55766|NCT01085526|Drug|Alutard phl prat|
55767|NCT01085552|Drug|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
55768|NCT01085565|Device|ExAblate 2100|Conformal Bone System
55769|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
55770|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
51929|NCT01032629|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily
52227|NCT01035307|Other|laboratory biomarker analysis|
52228|NCT01035320|Drug|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
52229|NCT01035333|Drug|Orlistat|60mg capsule three times a day for up to 6 months
52230|NCT01035346|Drug|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
52231|NCT00028665|Drug|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
52232|NCT01035346|Drug|Placebo|Single dose of a placebo
52233|NCT01035359|Procedure|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
52234|NCT01035359|Procedure|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
52235|NCT01035372|Dietary Supplement|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
52236|NCT01027871|Drug|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
52237|NCT01027871|Drug|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
52238|NCT01027884|Drug|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
52239|NCT01027884|Drug|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
52240|NCT01027897|Drug|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
52241|NCT01027910|Drug|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
52242|NCT01027910|Drug|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
52243|NCT01027923|Drug|Plerixafor|
52244|NCT01027923|Drug|Mitoxantrone|
52245|NCT00027924|Drug|cyclosporine|
52246|NCT01027923|Drug|Etoposide|
51693|NCT01026844|Drug|hydroxychloroquine|Taken orally once a day
51694|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
51695|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
51696|NCT00027885|Drug|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
51987|NCT01029938|Procedure|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
51988|NCT01029951|Procedure|manipulation|
51989|NCT01029951|Procedure|Mobilisation|
51990|NCT00028067|Drug|Atazanavir|
51991|NCT01029951|Device|Activator instrument|
51992|NCT01029964|Behavioral|Individually and in groups|During three year in a clinical setting.
51993|NCT01029990|Other|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
51994|NCT01029990|Other|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
51995|NCT01030016|Drug|atenolol|25 mg/day, twice a day for 6 weeks
51996|NCT01030029|Device|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point [2]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
51997|NCT01030029|Device|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
51998|NCT01030042|Drug|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
52169|NCT01030237|Other|FID 114657|1 drop both eyes four times a day for 6 weeks
52170|NCT01030237|Other|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
52171|NCT01030263|Other|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
52172|NCT01030263|Other|Random four-quadrant biopsies.|Random four-quadrant biopsies.
52173|NCT01030276|Other|Bright light therapy|Bright light therapy
52174|NCT01030276|Other|Inactive "placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
52175|NCT01030289|Device|transcranial direct current stimulation|transcranial direct current stimulation
52176|NCT01030302|Drug|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
52177|NCT00028106|Drug|[131]I-MIBG|
52178|NCT01030315|Drug|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
52179|NCT01030328|Drug|Placebo|2 sugar pills by mouth once a day.
52180|NCT01030328|Drug|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
52181|NCT01030341|Device|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
52182|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
52183|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
52184|NCT01030367|Drug|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
52185|NCT01030380|Device|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
52186|NCT01030393|Drug|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
52187|NCT01030406|Drug|Drug A|Tablets
52188|NCT00028106|Drug|6-[18F]Fluorodopamine|
52189|NCT01030406|Drug|Drug B|Tablets
55771|NCT01085578|Drug|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
55772|NCT01085591|Drug|CB-183,315|
55773|NCT00033358|Drug|ethinyl estradiol|Given orally
55774|NCT01085591|Drug|Placebo|
55775|NCT01085591|Drug|Vancomycin|
55776|NCT01085604|Other|Core Stabilization|The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.
Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.
Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.
Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning.
55777|NCT01085617|Biological|palifermin|
55778|NCT01085617|Biological|rituximab|
55779|NCT01085617|Drug|cyclophosphamide|
54871|NCT01053234|Dietary Supplement|Standardised meals|
54872|NCT00000902|Drug|Didanosine|
54873|NCT00030446|Drug|erlotinib hydrochloride|
54874|NCT01053247|Drug|0416|Topical 0416 test product applied twice daily for 2 weeks
54875|NCT01053247|Drug|Vehicle of 0416 test product|Vehicle of 0416 test product applied twice daily for 2 weeks
54876|NCT01053247|Drug|tacrolimus ointment 0.1%|Reference Product for 0416 test product. Apply twice daily for 2 weeks.
54877|NCT01053260|Behavioral|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
54878|NCT01053260|Behavioral|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
54879|NCT01053273|Procedure|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
54880|NCT01053273|Procedure|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
52247|NCT01027923|Drug|Cytarabine|
52248|NCT01027949|Drug|Treprostinil diethanolamine|Oral sustained release tablet, twice or thrice daily
52249|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training.
52250|NCT01027975|Procedure|laparoscopic Nissen/laparoscopic Thal|
51294|NCT01040117|Procedure|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
51295|NCT01040117|Procedure|Conventional neurorehabilitation treatment|The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.
Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position.
51296|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
51297|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
51298|NCT01042314|Drug|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
51299|NCT01042327|Device|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
51300|NCT01042327|Device|Fresenius FX100 dialyzer|
51301|NCT01042340|Other|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
51302|NCT01042353|Procedure|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
51303|NCT01042353|Procedure|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
51304|NCT00028912|Drug|bortezomib|
51999|NCT01030042|Drug|Irinotecan/Cetuximab|CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.
IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression.
52000|NCT01030055|Drug|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
52001|NCT00028067|Drug|Nelfinavir mesylate|
52002|NCT01030068|Behavioral|Yoga|Yoga twice weekly
52003|NCT01032694|Drug|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
52302|NCT01035554|Other|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
52303|NCT01035554|Other|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
52304|NCT00000896|Drug|Nevirapine|
52305|NCT00028665|Drug|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
52306|NCT01035554|Other|Usual Care|Standard care
52307|NCT01035554|Other|Printed Materials|National Institutes of Health Printed Materials on hypertension
52308|NCT01035567|Procedure|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
52309|NCT01035567|Procedure|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
52310|NCT01035580|Drug|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
52311|NCT01035580|Drug|curcumin|all patients received the drug
52312|NCT01035593|Procedure|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
52313|NCT01035593|Drug|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
52314|NCT01035606|Behavioral|training in goal-directed attention regulation|training in goal-directed attention regulation
52315|NCT01035606|Behavioral|brain health education|brain health education workshops
51223|NCT01044693|Drug|Sildenafil25 mg|Sildenafil 25 mg single oral dose
51224|NCT01044706|Drug|Bicalutamide|50 mg Oral Tablet
51225|NCT01044719|Drug|Ceftazidime|Ceftazidime 2g TDS IV
51226|NCT01044719|Drug|Tobramycin|Tobramycin 7mg/kg/day OD IV
51227|NCT01044719|Drug|Meropenem|Meropenem 2g TDS IV
51228|NCT01044732|Device|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
51229|NCT00029159|Drug|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
51230|NCT01044745|Drug|rituximab|Given IV
51231|NCT01044745|Drug|mycophenolate mofetil|Given IV or PO
51232|NCT01044745|Drug|tacrolimus|Given IV
51233|NCT01044745|Drug|anti-thymocyte globulin|Given IV
51234|NCT01044745|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
51235|NCT01044745|Other|laboratory biomarker analysis|Correlative studies
51236|NCT01044745|Biological|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
51237|NCT01044745|Drug|cyclophosphamide|Given PO or IV
51238|NCT01044745|Drug|fludarabine phosphate|Given IV
51239|NCT01044745|Drug|busulfan|Given IV
51240|NCT00029159|Other|placebo|an inactive substance
51241|NCT01044745|Radiation|total-body irradiation|Undergo TBI
51242|NCT01044745|Biological|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
51243|NCT01044745|Biological|immunosuppressive therapy|Undergo immunosuppressive therapy
51244|NCT01044758|Drug|Levetiracetam|50mg - 500 mg twice a day for two weeks.
51245|NCT01044758|Drug|Placebo|placebo capsule twice a day for two weeks
51246|NCT01044758|Drug|Placebo|placebo capsule twice daily for four weeks
54881|NCT01053299|Other|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
54882|NCT01053312|Drug|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of [18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels (MBq).
54883|NCT01053325|Drug|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
54884|NCT00030459|Drug|cisplatin|
54885|NCT01053325|Drug|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
54886|NCT01056042|Drug|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
54887|NCT01056081|Other|Inspiratory muscle training|The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).
The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training.
54888|NCT00030654|Drug|estramustine phosphate sodium|
54889|NCT01056094|Drug|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
54890|NCT01056107|Drug|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
54891|NCT01056107|Drug|Placebo|Placebo subcutaneous injection daily
55160|NCT01056302|Procedure|Surgical repair of maxillofacial trauma|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated outcome using the proposed software tool.
55161|NCT01056315|Drug|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
55162|NCT01056315|Drug|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
55163|NCT00000903|Drug|Efavirenz|
55164|NCT00030654|Drug|paclitaxel|
55165|NCT01056328|Device|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
55166|NCT01056328|Device|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
51305|NCT01042366|Biological|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
51306|NCT01042366|Procedure|Leukapheresis|All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.
51307|NCT01042379|Drug|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
51308|NCT01042379|Drug|AMG 386|15 mg/kg IV every week during 12 weekly treatment cycles post-randomization
51614|NCT01026805|Device|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
51615|NCT01026818|Drug|Tadalafil|Administered by mouth for 9 months
51616|NCT01026818|Drug|Placebo|Administered by mouth, daily or on demand for 9 months
51617|NCT01026831|Drug|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
51618|NCT01026831|Drug|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
51619|NCT01026844|Drug|erlotinib|Taken orally once a day
51620|NCT01029262|Drug|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
51621|NCT01029262|Other|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
51622|NCT01029275|Drug|Pre-treatment with octreotide|Pre-treatment with octreotide
51623|NCT01029288|Other|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
51624|NCT00000894|Drug|Ganciclovir|
51625|NCT00027989|Drug|gemcitabine hydrochloride|
52316|NCT00028665|Procedure|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
52317|NCT01035606|Behavioral|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
52318|NCT01035619|Drug|moxidectin|Single Dose Moxidectin 4 mg
52319|NCT01035645|Drug|GSK1070806|The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.
Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation.
55405|NCT01051596|Drug|Temozolomide and ABT-888|Temozolomide 150 mg/m2 once a day on Days 1-5 of each 28-day cycle ABT-888 40-mg orally BID on Days 1-7 of each 28-day cycle
55406|NCT01051609|Other|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
55407|NCT01051609|Other|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
55408|NCT01054170|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
55409|NCT01054170|Drug|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
55410|NCT01054183|Device|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
55411|NCT01054183|Device|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
55412|NCT01054196|Drug|lenalidomide|daily dose dependent on dose-escalation schedule
55413|NCT01054196|Drug|melphalan|100 mg/m2 given Days -2 and -1
55414|NCT01054209|Device|Warming with warming mattress|Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.
Inditherm Alpha systems, OTM1: 1900mm x 585mm
55415|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
55416|NCT00030537|Drug|erlotinib hydrochloride|
55417|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
51247|NCT01044771|Drug|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
51558|NCT01031914|Device|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
51559|NCT01031927|Drug|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
51560|NCT01031940|Device|macintosh laryngoscope|intubate with the macintosh laryngoscope
51561|NCT01031940|Device|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
51562|NCT01031940|Device|Airtraq device|intubate with the Airtraq device
51563|NCT00028327|Drug|Zidovudine|
51564|NCT01031953|Drug|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
51565|NCT01031953|Drug|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
51566|NCT01031953|Other|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
51567|NCT01031953|Procedure|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
51568|NCT01031966|Biological|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
51569|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
51570|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
51571|NCT01031979|Drug|Yohimbine|alpha-2 adrenergic receptor antagonist
51572|NCT01031979|Drug|Placebo|Placebo
51573|NCT01031992|Drug|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
51574|NCT00028353|Drug|GTX-006 (Acapodene)|
51575|NCT01031992|Drug|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
55167|NCT01056341|Drug|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
55168|NCT01056341|Drug|Placebo|Treatment with placebo for 6 months
55169|NCT01056380|Drug|Nitazoxanide|Tablets, 500 mg with food twice daily for 5 days
55170|NCT01056380|Drug|Placebo|Tablet, twice daily with food for 5 days
55171|NCT01048931|Procedure|single-port LAVH|single-port LAVH
55172|NCT01048944|Drug|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
55173|NCT01048944|Drug|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
55174|NCT01048944|Drug|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
55175|NCT01048957|Behavioral|Real Time Feedback Training|
55176|NCT01048970|Other|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
55177|NCT01048970|Dietary Supplement|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
55178|NCT01048983|Drug|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
55179|NCT01048983|Drug|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
55180|NCT00029848|Drug|Rimonabant (SR141716)|
55446|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
55447|NCT01047202|Biological|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
55448|NCT01047215|Drug|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
55449|NCT01047241|Drug|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
55450|NCT01047254|Drug|Elontril|flexible dose of Bupropion 150-300 mg
51626|NCT01029288|Other|Statin Choice Decision Aid|Statin Choice Cards
51627|NCT01029288|Other|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
51628|NCT01029288|Other|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
51629|NCT01029301|Device|Device: EndyMed Pro System for Skin Tightening|Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):
Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);
51630|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
51631|NCT01029340|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
51930|NCT01032642|Device|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
51931|NCT01032655|Drug|susceptibility test guided sequential therapy|susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid
plus either one of the following
Klaricid, 500 mg, bid
Cravit, 250 mg, bid
Tetracycline, 500 mg, bid
51932|NCT01032668|Drug|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
51933|NCT00028418|Drug|Clofarabine|
51934|NCT01032681|Biological|EMD 521873|Dose escalation steps:
Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)
Disease control and decision of continuation in patient who benefit from the treatment:
Every second cycle
51935|NCT01032681|Biological|EMD 521873|Dose escalation steps:
Group 2: CPA plus 0,6mg/kg - 0,9mg/kg
Disease control and decision of continuation in patient who benefit from the treatment:
Every second cycle
51936|NCT01032681|Biological|EMD 521873|Dose escalation steps:
Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)
Disease control and decision of continuation in patient who benefit from the treatment:
Every second cycle
51937|NCT01032694|Drug|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
51938|NCT01035099|Drug|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
51939|NCT00028652|Biological|interleukin-12 gene|
51940|NCT01035112|Procedure|MRI|
51418|NCT01045083|Drug|escitalopram|Oral single dose
51419|NCT01045083|Drug|methylphenidate|Oral single dose
51420|NCT00029198|Procedure|massage|15 massage given tid
51421|NCT01045083|Drug|RO4917523|Oral single dose
51422|NCT01045083|Drug|placebo|Oral single dose
51423|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
51424|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
51425|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
51426|NCT01045109|Dietary Supplement|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
51427|NCT01045109|Dietary Supplement|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
51428|NCT01045122|Drug|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
51429|NCT01045122|Drug|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
51430|NCT01045148|Radiation|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
51731|NCT01029574|Other|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
51732|NCT01032174|Drug|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
51733|NCT01032174|Drug|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
51734|NCT01032187|Drug|Meglumine antimoniate|20mg/kg/day IV for 20 days
51735|NCT01032187|Drug|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
51736|NCT01032200|Drug|Armodafinil|Given orally
51737|NCT00028366|Drug|Ritonavir|
51738|NCT01032200|Other|placebo|Given orally
51157|NCT01037036|Drug|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
51158|NCT01037049|Other|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
51159|NCT01037062|Drug|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
51160|NCT01037088|Drug|Cannabis|3.53% THC by weight
51161|NCT00000896|Drug|Stavudine|
51162|NCT00028717|Biological|filgrastim|
51163|NCT01037088|Drug|Cannabis|1.29% THC by weight
51164|NCT01037088|Drug|Cannabis|0.00% THC by weight
51165|NCT01037101|Behavioral|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
51166|NCT01037101|Behavioral|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
51167|NCT01037101|Drug|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
51168|NCT01037101|Drug|Placebo|50 mg placebo administered 30 minutes before the session
51169|NCT01039818|Radiation|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
51170|NCT01039818|Radiation|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
51171|NCT01039844|Drug|LOC-paclitaxel|Phase I Starting Dose: 100 mg/m^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.
Phase II Starting Dose: Maximum tolerated dose from Phase I.
51172|NCT01039857|Behavioral|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
51173|NCT00028795|Drug|temozolomide|
51174|NCT01039857|Behavioral|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
51175|NCT01039870|Procedure|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
51176|NCT01039870|Procedure|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
51177|NCT01039883|Drug|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
53486|NCT01060514|Drug|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
53487|NCT01060540|Genetic|genetic testing for type 2 diabetes|TCF7L2, PPARG, or KCNJ11
53488|NCT00030979|Drug|Donepezil|
53489|NCT01060540|Behavioral|Conventional risk counseling|Risk based on lifetime risk, fasting plasma glucose results, and family history.
52506|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
52507|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
52508|NCT00027937|Biological|sargramostim|
52509|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
52510|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
52511|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
52512|NCT01028417|Device|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
52513|NCT01028443|Drug|Sandimmune|
52514|NCT01028443|Drug|Artelose|
52515|NCT01028456|Other|Light Therapy|10,000 lux / 30 minutes a day
52516|NCT01028456|Other|100 lux|Placebo light
52517|NCT01028469|Device|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
52518|NCT01028482|Drug|Sertraline|group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months
group B- weekly psychotherapy- for 3 months
group C- sertraline 50-100 mg/day-for 3 months
52519|NCT00027937|Drug|busulfan|
52520|NCT01030874|Dietary Supplement|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
53204|NCT01057706|Other|chiropractic|spinal manipulation and mobilization
53205|NCT01057706|Behavioral|exercise|strengthening, stretching, balance
53206|NCT01057719|Other|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
53207|NCT01059942|Other|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
53208|NCT01059942|Other|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
53209|NCT01059955|Drug|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
53538|NCT01058213|Behavioral|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (~1-2 seconds for concentric and eccentric contraction) will be used.
53539|NCT01058213|Behavioral|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
53540|NCT01058226|Biological|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
53541|NCT01058239|Drug|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
53542|NCT01058239|Drug|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
53543|NCT01058252|Drug|Letrozole 2.5 mg, recFSH 75 IU|OVARIAN STIMULATION:
In previous cycles, cycle length and ovulatory status must be assessed and documented.
STEP 1: ANOVULATION by ORAL CONTRACEPTION
Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.
Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst > 10 mm).
Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.
STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).
On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.
Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder.
51739|NCT01032213|Drug|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
51740|NCT01032213|Drug|normal saline|Group S received the same volume of isotonic saline as same method.
51741|NCT01032239|Drug|intrathecal baclofen|ITB test, implant, 6 months follow-up
51742|NCT01032252|Other|Exercise intervention|16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.
Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training.
51743|NCT01032265|Behavioral|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
51744|NCT01032265|Behavioral|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
51745|NCT01032278|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
51746|NCT01032278|Behavioral|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
51747|NCT01032291|Drug|cetuximab|Intravenous infusions of cetuximab (400 mg/m^2 Cycle 1 Day 1, thereafter 250 mg/m^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
51748|NCT00028366|Drug|Tenofovir disoproxil fumarate|
51749|NCT01032291|Drug|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
51750|NCT01032304|Drug|Erdosteine|One 300 mg capsule twice a day
51751|NCT01032304|Drug|Placebo|One capsule twice a day
52048|NCT01035502|Drug|Elacytarabine plus idarubicin|Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.
It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy.
52049|NCT01035515|Drug|Placebo|Single dose oral capsule placebo comparator
52050|NCT01035515|Drug|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
52051|NCT01035515|Drug|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
52052|NCT01035528|Drug|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
51178|NCT01039883|Drug|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
51179|NCT01039896|Drug|Period I : SLM0807, Period II : HKB0701 and SLM0807|
51180|NCT01039896|Drug|Period I : HKB0710 and SLM0807, Period II : SLM0807|
51489|NCT01034228|Other|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
51490|NCT01034241|Dietary Supplement|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
51491|NCT01034241|Dietary Supplement|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
51492|NCT01034241|Dietary Supplement|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
51493|NCT01034241|Dietary Supplement|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
51494|NCT01034254|Biological|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
51495|NCT01034254|Biological|saline placebo|Vaccination of pregnant women with saline placebo.
51496|NCT01034267|Drug|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
51497|NCT01034293|Dietary Supplement|low feeding frequency (3x)|3 meals a day
51498|NCT00028600|Biological|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
51499|NCT01034293|Dietary Supplement|High feeding frequency (14x)|14 meals a day
51500|NCT01034306|Drug|CF101|orally q12h
51501|NCT01034306|Drug|Placebo control|orally q12 hours
51502|NCT01034319|Behavioral|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
51503|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
51504|NCT01026545|Drug|PF-04287881|1100 mg once daily for 10 days
51505|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
51506|NCT01026545|Drug|PF-04287881|Optional cohort with dose not greater than 1100 mg
52521|NCT01030874|Other|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
52522|NCT01030874|Other|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
52523|NCT01030874|Drug|Drug|Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily [Mukai 2002; Grubb 2003]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily [Low, 1997]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
52524|NCT01030887|Behavioral|Exercise programme|Moderate intensity exercise
52825|NCT01031472|Drug|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
52826|NCT01031485|Dietary Supplement|Milk peptides and plant sterols|
52827|NCT01031485|Other|Placebo|
52828|NCT01031498|Drug|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
52829|NCT01031498|Drug|Palonosetron|Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.
Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy.
52830|NCT01031511|Behavioral|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
52831|NCT01031511|Other|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
52832|NCT01031524|Biological|PfCS102|Antigen of the sporozoite protein
52833|NCT01031524|Biological|Montanide ISA 720|adjuvant alone
52834|NCT00028314|Drug|Nevirapine|
52835|NCT01031537|Biological|FSME-IMMUN 0.5ml Baxter|Vaccine
52836|NCT01031550|Drug|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
52837|NCT01033968|Procedure|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
52838|NCT00028587|Drug|paclitaxel|Given IV
53544|NCT01058252|Procedure|STEP-3: LH Suppression & Monitoring|Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.
• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.
The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)
No need of LH testing, or E2 testsing during the stimulated cycle.
53545|NCT01058252|Procedure|STEP-4: HCG Timing|IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:
E2 level is over 150 pg/ml/per mature follicle (> 15 mm)
Domminent follicle is greater than 18 mm in mean diameter
LH Remains as Baseline, OR
The day when Urinary LH Surge is positive
53546|NCT01058252|Procedure|STEP-5: OPU, ET, Cancellation|Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.
Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.
Maximum of 2 embryos are transferred, using ultrasound guided transfer.
Cancellation Criteria:
Poor patient compliance
Premature Ovulation
Premature LH Surge
Endometrium < 7 mm
Poor Follicular Development
E2 Level > 2,500 pg/ml
53547|NCT00030745|Procedure|conventional surgery|
52589|NCT01028482|Drug|placebo|placebo
52590|NCT01028482|Other|psychotherapy|psychotherapy
52591|NCT01028495|Drug|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
52592|NCT01028508|Drug|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
52593|NCT01028508|Procedure|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
52594|NCT01028521|Drug|CM3.1-AC100|Solution for sc injection, single ascending doses
52595|NCT01028521|Drug|Placebo|Solution for sc injection
52596|NCT01028534|Drug|Olmesartan and Azelnidipine|Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months
Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months
Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months
52597|NCT01028547|Drug|dexamethasone|single Bolus dose of dexamethasone 8mg
52598|NCT01028547|Other|normal saline|2 ml 0.9% saline
52599|NCT00000894|Drug|Probenecid|
52600|NCT00027937|Drug|cyclophosphamide|
52053|NCT01035528|Drug|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
52054|NCT01035541|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
52055|NCT01027520|Other|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
52056|NCT01027533|Other|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
52057|NCT01027546|Drug|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
52058|NCT01027559|Drug|Sertraline|For those in the Sertraline treatment condition, visits to dispense medications, check for side effects and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84 in depressed subjects. Depressed patients will be treated with Sertraline starting with a dose of 50 mg daily on Day 1 of the study. For patients showing inadequate evidence of antidepressant response, the Sertraline dose will be increased up to a maximum dose of 200 mg daily. The daily Sertraline dose can be decreased in 50 mg increments, or as clinically indicated, in the presence of side effects until two weeks prior to the end of the study. No further changes in dose will be permitted in study subjects after the 10th week until the study is completed.
52059|NCT01027559|Behavioral|Cognitive Behavioral Therapy|For those in the Cognitive Behavioral Therapy treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84 in depressed subjects. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed, and will have two sessions per week for the first two weeks, followed by one session per week for the duration of the twelve week study.
52060|NCT01027572|Device|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
52061|NCT01027598|Drug|Pazopanib|Pazopanib: 600 mg orally daily
52062|NCT00027898|Other|pharmacological study|Correlative studies
52063|NCT01027598|Drug|Erlotinib|Erlotinib: 150 mg orally daily
52064|NCT01027611|Drug|proparacaine HCL 0.5%|
52065|NCT01027611|Drug|proparacaine HCL 0.5% + 4% lidocaine solution|
51094|NCT01039805|Drug|Placebo|matching placebo
51095|NCT01039805|Drug|GSK962040 (75 mg)|Cohort 2 = 75 mg
51096|NCT01042041|Drug|cisplatin|Given via transarterial/hepatic chemoembolization
51097|NCT01042041|Drug|mitomycin C|Given via transarterial/hepatic chemoembolization
51098|NCT01042041|Procedure|transarterial chemoembolization|
53405|NCT01062945|Drug|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
53406|NCT00031187|Drug|Taxotere (docetaxel)|
53407|NCT01062958|Other|Neevo® (a medical food)|
53408|NCT01062958|Other|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
53409|NCT01062971|Drug|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
53410|NCT01062984|Procedure|Continuous Venovenous Hemofiltration (CVVH)|The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVHthe target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
53411|NCT01062984|Procedure|Continuous Venovenous Hemodialysis (CVVHD)|The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
53412|NCT01063010|Drug|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
53413|NCT01063010|Drug|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
53414|NCT01063023|Drug|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
53415|NCT01063023|Drug|BMS-650032|Tablets, Oral, 600 mg, BID
53416|NCT01063036|Drug|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
53417|NCT00031265|Procedure|Family Intervention Telephone Tracking|
53418|NCT01063036|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
53419|NCT01063049|Drug|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
52839|NCT01033981|Drug|Sunitinib|Treatment for mRCC as indication approved and physician criterium
52840|NCT01033994|Biological|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
52841|NCT01034007|Device|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
52842|NCT01034020|Drug|Nicotine|
52843|NCT01034046|Other|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
52844|NCT01034046|Other|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
52845|NCT01034111|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
52846|NCT01034111|Drug|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
53127|NCT00030875|Drug|bortezomib|
53128|NCT01059890|Drug|Fosfocine|
53129|NCT01059903|Drug|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
53130|NCT01059929|Drug|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
53131|NCT01059929|Drug|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
53132|NCT01059929|Drug|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
53133|NCT01059929|Drug|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS>+2)
53134|NCT01059929|Behavioral|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
53135|NCT01062451|Drug|Placebo|Placebo treatment daily.
53136|NCT01062451|Drug|Candesartan|16 mg taken orally from days 0 through 7.
53137|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
53138|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
53139|NCT01062477|Biological|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
52601|NCT01028560|Biological|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
52602|NCT01028560|Other|Standard of care|standard of care asthma and allergy treatment
52603|NCT01028573|Drug|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
52604|NCT01028573|Drug|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
52605|NCT01028573|Drug|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
52606|NCT01028573|Drug|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
52607|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
52608|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
52912|NCT01031589|Drug|TMC278 (Rilpivirine) LA; Placebo|
52913|NCT01031602|Behavioral|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
52914|NCT01031615|Behavioral|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
52915|NCT01031615|Behavioral|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
52916|NCT01031628|Drug|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
52917|NCT01031628|Drug|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
52918|NCT01031628|Drug|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
52919|NCT00028327|Drug|Lamivudine/Zidovudine|
52920|NCT01031667|Drug|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
52921|NCT01031680|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
51099|NCT01042041|Procedure|hepatic artery embolization|
51100|NCT01042054|Other|Standard optimised recovery protocol.|Epidural analgesia for the first 48 hours postoperatively.
Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.
Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.
Optimised recovery protocol followed throughout.
51101|NCT01042054|Other|Wound catheter plus patient-controlled analgesia.|Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.
Additional patient-controlled intravenous opiate analgesia available to patient during this time period.
Sham epidural catheter applied to the patient's back for purposes of blinding.
Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.
Optimised recovery protocol followed throughout.
51102|NCT01042067|Other|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
51103|NCT01042080|Device|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
51104|NCT01042080|Other|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
51105|NCT00028899|Drug|asparaginase|
51106|NCT01042093|Drug|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
51107|NCT01042093|Drug|Toradol|Toradol 30mg/ml (1 ml)
51108|NCT01042093|Drug|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
51109|NCT01042093|Drug|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
51110|NCT01042106|Drug|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
51111|NCT01042106|Drug|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
51112|NCT01042132|Procedure|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
51113|NCT01042132|Procedure|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
51114|NCT01042145|Drug|Prednisone|2 mgs/kg for 3 days
51115|NCT01042145|Drug|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
51431|NCT00029198|Procedure|Sham massage|non-massage touch
51432|NCT01045148|Radiation|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
52446|NCT01030874|Other|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
52447|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^7 CFU in 10 mL phosphate-buffered saline
52448|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^8 CFU in 10 mL phosphate-buffered saline
52449|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^9 CFU in 10 mL phosphate-buffered saline
52450|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^10 CFU in 10 mL phosphate-buffered saline
52451|NCT01033422|Drug|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
52452|NCT01033422|Drug|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
52453|NCT01033435|Other|No intervention|
52454|NCT00028535|Biological|recombinant interleukin-12|Given SC
52455|NCT01033448|Drug|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
52456|NCT01033448|Drug|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
52457|NCT01033461|Dietary Supplement|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
52458|NCT01033461|Dietary Supplement|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
52459|NCT01033461|Other|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
52460|NCT01033487|Drug|placebo|oral inhaled formulation, single dose
52461|NCT01033487|Drug|active comparator|oral inhaled formulation, single dose
52462|NCT01033487|Drug|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
52463|NCT01033487|Drug|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
52464|NCT01033487|Drug|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
53140|NCT01062490|Drug|Treosulfan|14 g/m2/d, day -6 to -4
53141|NCT01062503|Drug|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
53142|NCT01062516|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
53143|NCT01062516|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
53144|NCT00031148|Drug|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
53145|NCT01062529|Drug|Somatostatin|4 h of 150 microgram infusion
53146|NCT01062542|Procedure|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
53147|NCT01062555|Drug|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
53148|NCT01062555|Drug|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
53490|NCT01060540|Behavioral|eye disease counseling|addresses risk for age-related macular degeneration, glaucoma, cataracts
53491|NCT01060553|Other|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
53492|NCT01060566|Drug|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
53493|NCT01060566|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
53494|NCT01060579|Drug|AR-12286 0.5% ophthalmic solution|q.d. PM
53495|NCT01060579|Drug|AR-12286 0.25% Ophthalmic solution|q.d. PM
53496|NCT01060579|Drug|Latanoprost ophthalmic solution|q.d. PM
53497|NCT01060592|Device|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
52922|NCT01031680|Drug|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
52923|NCT01031693|Device|Transcranial Magnetic Stimulation|daily sessions for 5 days
52924|NCT01031706|Drug|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
52925|NCT01031706|Drug|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
52926|NCT01031719|Biological|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
52927|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
52928|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
52929|NCT01031732|Procedure|MIS-2 THA|MIS two-incision THA
52930|NCT00000895|Drug|Azithromycin|
52931|NCT00028327|Drug|Nelfinavir mesylate|
52932|NCT01031732|Procedure|MIS-WJ|MIS-Watson Jones THA
52933|NCT01031732|Procedure|MIS-AL THA|Transgluteal approach
52934|NCT01031732|Procedure|MIS-PL THA|Posterolateral approach
53210|NCT00030888|Drug|7-hydroxystaurosporine|
53211|NCT01059955|Drug|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
53212|NCT01059994|Drug|Placebo sildenafil|Oral, daily, 1 week.
53213|NCT01059994|Drug|Sildenafil|oral, 25mg, daily for 1 week
53214|NCT01060007|Radiation|External beam radiation|
53215|NCT01060007|Drug|Oxaliplatin|
53216|NCT01060007|Drug|Leucovorin|
53217|NCT01060007|Drug|5-FU|
53218|NCT01060007|Drug|Capecitabine|
53219|NCT01060020|Drug|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
51433|NCT01045161|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.
51434|NCT01045161|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks of treatment.
51435|NCT01037543|Drug|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
51436|NCT01037556|Drug|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
51437|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
51438|NCT01037582|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
51439|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
51440|NCT01037582|Drug|placebo|Subjects will be randomized to receive a single dose of placebo.
51441|NCT01037582|Drug|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
51442|NCT01037582|Drug|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
51443|NCT00028730|Biological|anti-thymocyte globulin|
51444|NCT01037595|Drug|turmeric|turmeric 500 md tid orally for 8 weeks
51445|NCT01037595|Drug|placebo|placebo 3 time orally for 8 weeks
51446|NCT01037595|Drug|turmeric|500 mg tid orally for 8 weeks
51447|NCT01037608|Drug|Sativex(Registered Trademark)|
51448|NCT01037608|Drug|THC|
51449|NCT01037621|Drug|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
51450|NCT01037634|Drug|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
51451|NCT01037647|Other|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
52465|NCT00028548|Drug|R(+)XK469|
52466|NCT01033500|Drug|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
52759|NCT01033955|Drug|Placebo|identical appearing encapsulated placebo.
52760|NCT01026246|Biological|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
52761|NCT01026259|Other|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
52762|NCT00000893|Drug|Nelfinavir mesylate|
52763|NCT00027859|Drug|docetaxel|
52764|NCT01026259|Other|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
52765|NCT01026285|Drug|Risperidone Long-Acting injectable or oral antipsychotics|According to label
52766|NCT01026298|Other|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
52767|NCT01026311|Drug|Coenzyme q 10|200 mg of Coenzyme q 10
52768|NCT01026311|Drug|placebo|1 placebo q d during treatment period
52769|NCT01026324|Drug|dinaciclib|Given IV
52770|NCT01026324|Other|pharmacological study|Correlative studies
52771|NCT01026324|Other|laboratory biomarker analysis|Correlative studies
52772|NCT01026337|Genetic|mutation analysis|Correlative study
52773|NCT01026337|Other|pharmacological study|Correlative study
52774|NCT00027859|Drug|estramustine phosphate sodium|
52775|NCT01026337|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
52776|NCT01026337|Drug|sunitinib malate|Given orally
52777|NCT01026337|Other|immunohistochemistry staining method|Correlative study
53498|NCT01060605|Drug|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
53499|NCT00030992|Drug|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
53500|NCT01063062|Drug|Methotrexate|methotrexate as per standard of care in clinical practice.
53501|NCT01063075|Drug|Cetuximab|Administered Intravenously
53502|NCT01063075|Drug|Carboplatin|Administered Intravenously
53503|NCT01063075|Drug|5 - Fluorouracil|Administered Intravenously
53504|NCT00031278|Drug|CPG 7909|Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
53505|NCT01063088|Biological|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
53506|NCT01063101|Dietary Supplement|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
53507|NCT01063101|Other|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
53508|NCT01063114|Radiation|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
52525|NCT01030900|Biological|campath|campath plus EPOCH and rituximab every 3 weeks for up to 6 cycles
52526|NCT01030900|Biological|Rituximab|rituximab plus EPOCH and campath every 3 weeks for up to 6 cycles
52527|NCT00000895|Drug|Nevirapine|
52528|NCT00028262|Drug|Cystagon|
52529|NCT01030900|Drug|EPOCH|EPOCH plus rituximab and campath every 3 weeks for up to 6 cycles
52530|NCT01030926|Drug|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
52531|NCT01030926|Drug|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
52532|NCT01030939|Drug|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
52533|NCT01030952|Drug|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
53220|NCT01060033|Other|MR Spectroscopy|
53221|NCT00000904|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
53222|NCT00030901|Drug|L-selenomethionine|Randomization between active L-selenomethionine and placebo
53223|NCT01060033|Other|Fat-Saturation and Diffusion-Weighted Imaging|
53224|NCT01060033|Other|Dynamic Contrast Enhancement MRI (MR-DCE)|
53225|NCT01060033|Other|Diffusion Tensor Imaging (DTI)|
53226|NCT01060059|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
53227|NCT01060059|Drug|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
53228|NCT01060072|Drug|Loteprednol etabonate|Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
53229|NCT01060072|Drug|Vehicle of Loteprednol Etabonate|Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
53230|NCT01060098|Drug|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
53231|NCT01060111|Drug|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
53232|NCT01060111|Drug|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
53548|NCT01058252|Procedure|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 30000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
53549|NCT01060618|Other|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
53550|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
51752|NCT01032317|Device|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
51753|NCT01032330|Device|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
51754|NCT01032343|Dietary Supplement|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
51755|NCT01032343|Dietary Supplement|Gelatine|One capsule daily for 3 months
51756|NCT01034631|Drug|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
51757|NCT00000896|Drug|Interleukin-12|
51758|NCT00028600|Drug|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
51759|NCT01034631|Drug|BNC105P|Patients to receive BNC105P monotherapy - 16 mg/m2 following progression on everolimus therapy.
51760|NCT01034657|Drug|oral LBH589/panobinostat|
51761|NCT01034657|Drug|oral LBH589/panobinostat + Epoetin Alfa HEXAL®|
51762|NCT01034670|Device|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
51763|NCT01034670|Device|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
51764|NCT01034670|Device|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
51765|NCT01034670|Drug|fluorescent Peptide|microdosing; Topical through the endoscope
51766|NCT01034670|Drug|fluorescein|100 mcg topical
51767|NCT01034670|Drug|indocyanine green|100 mcg topical
51768|NCT01034683|Drug|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
51769|NCT00028613|Radiation|iodine I 131 monoclonal antibody Lym-1|
51770|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
52778|NCT01026337|Other|laboratory biomarker analysis|Correlative study
52779|NCT01026350|Dietary Supplement|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
52780|NCT01026363|Drug|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
52781|NCT01026363|Drug|Calcitriol|0.25 mcg tablet once daily for 14 days
53063|NCT01064830|Drug|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
53064|NCT01064843|Device|Imtec MDI|4 Imtec MDI
53065|NCT01064856|Biological|adalimumab|40mg subcutaneous injection every other week up to week 12
53066|NCT01064856|Biological|placebo|placebo subcutaneous injection every other week up to week 12
53067|NCT01064856|Biological|adalimumab|40mg subcutaneous injection every other week, week 12 thru week 156
53068|NCT01064869|Behavioral|Pyscho-behavioural|A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:
1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour
This will be followed by an individualised package incorporating:
A structured asthma education programme, to address any gaps in asthma knowledge or requests for information
Motivational interviewing based on stages of change model to encourage change and adherence
Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients
53069|NCT01064882|Drug|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
53070|NCT01064882|Drug|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
53071|NCT01064882|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
53072|NCT01064895|Device|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
53073|NCT00031486|Drug|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
53074|NCT01064908|Device|OxyMask|Novel vortex oxygen delivery mask
53075|NCT01064921|Drug|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
52534|NCT01030952|Drug|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
52535|NCT01030965|Drug|GSK573719 125mcg|125mcg once-daily
52536|NCT01030965|Drug|GSK573719 250mcg|250mcg once-daily
52537|NCT01030965|Drug|GSK573719 500mcg|500mcg once-daily
52538|NCT01030965|Drug|Placebo|once-daily
52539|NCT00028275|Drug|Gamma Interferon 1b|
52540|NCT01030978|Behavioral|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
52541|NCT01030978|Behavioral|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
52542|NCT01033552|Drug|Cyclosporine A|Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.
52543|NCT01033552|Drug|Mycophenolate mofetil|15 mg/kg intravenous twice per day on days -3 through 30.
52544|NCT01033552|Procedure|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
52545|NCT00028561|Drug|ixabepilone|Given IV
52546|NCT01033552|Radiation|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
52547|NCT01033552|Procedure|Umbilical cord blood stem cell transplantation|UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
52847|NCT01034124|Drug|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
52848|NCT01034137|Drug|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
52849|NCT00028587|Drug|carboplatin|Given IV
52850|NCT01034137|Drug|placebo MTX|orally weekly
52851|NCT01034137|Drug|placebo TCZ|iv every 4 weeks
52852|NCT01034137|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
52853|NCT01034150|Device|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
53551|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
53552|NCT01060670|Device|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
53553|NCT01060670|Other|Conventional Wound Therapy|Conventional Wound Therapy
53554|NCT01060683|Biological|Hemoglobin determination + NaCl 0.9% bolus|
53555|NCT01060683|Biological|hemoglobin determination + Venofundin bolus|
53556|NCT01060696|Drug|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
53557|NCT01060722|Drug|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
53558|NCT01060722|Drug|Placebo|Single subcutaneous dose of placebo material
53559|NCT00030992|Drug|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
53560|NCT01060735|Dietary Supplement|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
53561|NCT01060748|Biological|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
53562|NCT01060748|Biological|Placebo|Placebo
53563|NCT01060761|Behavioral|Rehabilitation program|Patient and their relative receive three supportive, structured conversation with a trained nurse.
Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities
53564|NCT01060774|Drug|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
52320|NCT01035658|Drug|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
52321|NCT01035658|Drug|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
52322|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
51771|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
51772|NCT01034735|Biological|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
52066|NCT01027611|Drug|3.5% viscous lidocaine gel|
52067|NCT01027637|Other|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
52068|NCT01027650|Drug|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
52069|NCT01027650|Drug|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
52070|NCT01027663|Dietary Supplement|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
52071|NCT01027676|Drug|Study treatment|Gefitinib 250mg/QD plus vorinostat D1~7 & D15-21 / QD q 4weeks
52072|NCT01027689|Drug|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
52073|NCT00027911|Biological|NY-ESO-1 peptide vaccine|
52074|NCT01027689|Drug|alprazolam test sublingual tablet|1 mg tablet, single dose
52075|NCT01027702|Biological|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10^4, 4 x 10^4, 5 x 10^4, 6 X 10^4, 8 x 10^4, and 10 X10^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
52076|NCT01030068|Behavioral|Wellness|Health and wellness classes twice weekly
52077|NCT01030068|Other|Smoking cessation therapy|Smoking cessation therapy
52078|NCT01030081|Drug|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
52079|NCT01030081|Drug|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
52080|NCT01030094|Drug|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
52081|NCT01030094|Drug|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
52082|NCT01030094|Drug|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
52083|NCT01030094|Drug|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
53076|NCT01064921|Drug|cisplatin|Given IV
53077|NCT01064921|Radiation|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
53078|NCT01064921|Procedure|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
53079|NCT01064934|Procedure|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
53080|NCT01064934|Other|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
53420|NCT01063049|Drug|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
53421|NCT01063049|Drug|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
53422|NCT01063049|Drug|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
53423|NCT01063062|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
53424|NCT01065493|Behavioral|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
53425|NCT01065506|Behavioral|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
53426|NCT01065506|Drug|Nicotine Patch|Nicotine Patch
53427|NCT01065506|Behavioral|Wellness Program|Wellness Program
53428|NCT01065506|Behavioral|Aerobic Exercise|Aerobic Exercise
53429|NCT00000912|Drug|Amprenavir|
53430|NCT00031564|Biological|B7-1|
53431|NCT01065519|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
53432|NCT01065519|Device|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
53433|NCT01065532|Device|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
53434|NCT01065532|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
53435|NCT01065545|Drug|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
52854|NCT01034150|Device|Placebo stimulation|Placebo stimulation
52855|NCT01034163|Drug|Panobinostat|
52856|NCT01034163|Drug|Placebo|Placebo
52857|NCT01034176|Drug|levofloxacin|500 mg tablet, daily, 30 days
52858|NCT01034176|Drug|placebo|no dose, tablet, daily, 30 days
52859|NCT01034189|Drug|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
52860|NCT00028587|Other|laboratory biomarker analysis|Optional correlative studies
52861|NCT01034189|Drug|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
52862|NCT01034189|Drug|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
52863|NCT01034189|Radiation|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
52864|NCT01026402|Drug|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
52865|NCT01026415|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
52866|NCT01026415|Drug|rifampin|600 mg/day PO
52867|NCT01026415|Drug|midazolam|1 mg IV
52868|NCT01026415|Drug|ketoconazole|400 mg/day PO
53149|NCT01062555|Drug|Cyclosporine, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
53150|NCT01062555|Drug|Prograf, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
53151|NCT01062555|Drug|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
52323|NCT01028066|Behavioral|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
52324|NCT01028079|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
52325|NCT01028079|Drug|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
52326|NCT00027924|Drug|methotrexate|
52327|NCT01028079|Drug|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
52328|NCT01028092|Drug|Anti R-IL2 + Cyclosporine|anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)
Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0
cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2
corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
52329|NCT01028092|Drug|Thymoglobulin + Everolimus|Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days
Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0
everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml
corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
52330|NCT01028092|Drug|Anti R-IL2 + Cyclosporine then Everolimus|anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)
Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0
cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml
corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
52331|NCT01028105|Other|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
52332|NCT01028118|Other|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
52333|NCT01028131|Behavioral|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
51366|NCT01040195|Drug|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
52084|NCT01030107|Behavioral|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
52085|NCT00000895|Drug|Nelfinavir mesylate|
52086|NCT00028093|Drug|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
52087|NCT01030107|Behavioral|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
51116|NCT00028899|Drug|cytarabine|
51117|NCT01042158|Drug|Tadalafil monotherapy|tadalafil 20 mg once daily (qd) and placebo qd. Up-titration of study medications will occur at week 4 (tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
51118|NCT01044485|Drug|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
51119|NCT01044498|Drug|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
51120|NCT00029146|Procedure|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
51121|NCT01044498|Drug|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
51122|NCT01044511|Behavioral|Home visits|home visits by specialist nurse 2 times and 1 phonecall
51123|NCT01044511|Behavioral|standard|hotline
51124|NCT01044524|Radiation|SLV 334|2000 mg via i.v. solution
51125|NCT01044537|Drug|Placebo|Placebo to match PF-04937319 will be provided.
51126|NCT01044537|Drug|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
51127|NCT01044550|Procedure|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
51128|NCT01044550|Other|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
51129|NCT01044563|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
53436|NCT01065558|Drug|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
53437|NCT01065571|Dietary Supplement|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
53438|NCT01065571|Other|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
53439|NCT01065597|Device|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
53440|NCT01065610|Drug|Oxytocin|
53441|NCT00031577|Drug|paclitaxel|
53442|NCT01065610|Drug|Placebo|
52467|NCT01033526|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
52468|NCT01033526|Drug|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
52469|NCT01033539|Other|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
52470|NCT01033552|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
52471|NCT01033552|Drug|Fludarabine|40 mg/m^2/day intravenously on Days -5, -4, -3 and -2.
52472|NCT01033552|Drug|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
52473|NCT01025765|Drug|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
52474|NCT01025765|Drug|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
52475|NCT01025765|Drug|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
52476|NCT01025778|Drug|Clofarabine for remission induction|
52477|NCT00027846|Drug|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA <0.45m2 the dose is 12.5 mg/kg/day.
52478|NCT01025778|Drug|Etoposide for remission induction|
53152|NCT01062555|Drug|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
53153|NCT01062555|Drug|Low dose CNI (CSA or FK), Rapamune, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
53154|NCT01062555|Drug|Rapamune, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
53155|NCT00031161|Drug|Nitisinone (NTBC)|
53156|NCT01062568|Drug|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
53157|NCT01064960|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
53158|NCT01064973|Drug|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
53159|NCT00031499|Drug|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
53160|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (~5 minutes)
53161|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
53162|NCT01064986|Biological|Placebo|Saline vehicle (placebo)
53163|NCT01064986|Biological|Hydrocortisone|Hydrocortisone
53164|NCT01064999|Drug|Oxaliplatin|CRT:50mg/m2,IV,weekly*5 cycle CT: 130mg/m2,IV,d1,q 21 day
53165|NCT01064999|Drug|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
53166|NCT01064999|Radiation|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
53509|NCT01063127|Other|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
53510|NCT01063127|Other|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
51367|NCT01040195|Drug|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
51368|NCT01040208|Drug|flibanserin 2|100mg qhs
51369|NCT01040208|Drug|placebo|2 tablets qhs
51370|NCT01040208|Drug|flibanserin 1|50 mg qhs for 14 days then 100mg qhs
51371|NCT01040221|Drug|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
51372|NCT01040234|Procedure|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
51373|NCT00028821|Other|laboratory biomarker analysis|Correlative studies
51374|NCT01040247|Other|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
51375|NCT01040260|Other|Counseling|Smoking cessation counseling
51376|NCT01040260|Behavioral|Contingency management|Use of tangible rewards for abstinence from smoking
51377|NCT01040260|Drug|Nicotine patches|Nicotine patches
51378|NCT01040273|Drug|Bupivacaine|
51379|NCT01040273|Drug|Placebo|
51380|NCT01040286|Drug|Flurbiprofen|2.0 mg
51381|NCT01040286|Drug|Chlorhexidine|2.5mg
51382|NCT01040299|Device|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
51383|NCT01040299|Device|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
51384|NCT00000898|Drug|Nelfinavir mesylate|
51385|NCT00028834|Drug|gemcitabine hydrochloride|Given IV
51386|NCT01042379|Drug|Pembrolizumab|200 mg, IV combined with paclitaxel, given every three weeks (cycles 1, 4, 7, and 10).
51387|NCT01042392|Drug|Aliskiren|150 mg Aliskiren as film-coated tablet
51130|NCT01044563|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
51131|NCT00029146|Drug|best medical therapy|best current practice medical therapy
51132|NCT01044589|Device|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
51133|NCT01044589|Other|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
51134|NCT01044602|Other|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
51135|NCT01044602|Other|Best Medical Management|Standard of care.
51136|NCT01044602|Procedure|Roux-en-Y gastric bypass surgery|Surgical treatment.
51452|NCT01037660|Drug|Metformin|Metformin 1 gram per day
51453|NCT01037673|Procedure|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
51454|NCT00028730|Biological|filgrastim|
51455|NCT01037673|Procedure|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
51456|NCT01037686|Radiation|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
51457|NCT01037686|Behavioral|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
51458|NCT01037686|Device|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
51459|NCT01031758|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
51460|NCT01031784|Device|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
51461|NCT01031784|Device|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
51462|NCT01031810|Drug|tranylcypromine|MAO-Inhibitor 60mg-120mg
52479|NCT01025778|Drug|Cyclophosphamide for remission induction|
52480|NCT01025778|Drug|Clofarabine in conditioning before transplantation|
52481|NCT01025778|Drug|Thiotepa in conditioning before transplantation|
52482|NCT01025778|Drug|Melfalan in conditioning before transplantation|
52483|NCT01025778|Procedure|Haploidentical transplantation of T-cell depleted graft|
52484|NCT01025778|Procedure|Donor lymphocyte infusion|
52485|NCT01025791|Drug|MK8266|single rising oral doses of 0.1 to 24 mg of MK8266
52486|NCT01025791|Drug|Placebo|single dose administration of placebo oral capsule
52487|NCT01025817|Drug|Everolimus and tacrolimus|Everolimus:
Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets
Dose: 1.5 mg per day
Frequency: 0.75 mg twice daily
Tacrolimus:
Dose adjusted to maintain specific blood levels
52782|NCT01026376|Drug|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
52783|NCT01026376|Drug|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
52784|NCT01026389|Drug|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
52785|NCT00027859|Drug|ketoconazole|
52786|NCT01026389|Drug|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
52787|NCT01028729|Drug|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
52788|NCT01028755|Drug|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
52789|NCT01028768|Drug|Teduglutide|10 mg, one-time subcutaneous
52790|NCT01028781|Drug|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
52791|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
52792|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
53511|NCT01063140|Biological|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
53512|NCT01063140|Biological|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
53513|NCT01063153|Drug|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
53514|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone, Thalidomide|Induction therapy:
9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.
Maintenance therapy:
Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years.
53515|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
53516|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
53517|NCT01063192|Drug|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
53518|NCT01063192|Drug|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
53519|NCT01063205|Drug|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
53520|NCT01065857|Drug|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
53521|NCT01065870|Drug|Neoadjuvant gemcitabine, capecitabine, and docetaxel|6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.
Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.
Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.
52548|NCT01033565|Drug|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
52549|NCT01033578|Other|PVIC, TACE|PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.
TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
51697|NCT01026857|Drug|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
51698|NCT01026870|Drug|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
51699|NCT01026870|Drug|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
51700|NCT01026883|Other|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
51701|NCT01026896|Behavioral|Affected Arm Therapy + Mental Practice|Subjects will be administered 10 weeks of rehabilitative therapy targeting the affected arm. Mental practice of the rehabilitative exercises performed will occur directly after therapy.
51702|NCT01026896|Behavioral|Affected Arm Therapy + Stroke Information|Patients will be administered 10 weeks of rehabilitative therapy targeting their affected arms. Directly after their therapy sessions, subjects will be administered information on stroke and exercises targeting their affected arms.
51703|NCT01026909|Drug|Aristospan 20mg|Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
51704|NCT01026935|Device|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
51705|NCT01026948|Drug|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
51706|NCT01026948|Device|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
51707|NCT00000893|Drug|Efavirenz|
51708|NCT00027885|Procedure|adjuvant therapy|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
51709|NCT01026961|Drug|Phenylephrine HCL|Phenylephrine HCL 10mg
51710|NCT01026961|Drug|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
51711|NCT01026974|Biological|rMenB|
51463|NCT01031823|Behavioral|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
51464|NCT00028327|Drug|Efavirenz|
51465|NCT01031836|Drug|MEDI-545|Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses.
51466|NCT01031836|Drug|MEDI-545|Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses
51467|NCT01031836|Drug|MEDI-545|Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses.
51468|NCT01031836|Drug|MEDI-545|Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses.
51469|NCT01031836|Drug|MEDI-545|Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.
Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses
51773|NCT01034748|Drug|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
51774|NCT01034761|Behavioral|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
51775|NCT01034774|Drug|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
51776|NCT01034774|Drug|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
51777|NCT01034787|Drug|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.l
51778|NCT01034852|Procedure|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
51779|NCT01034878|Drug|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
51780|NCT01026974|Biological|rMenB+OMV NZ|
51781|NCT01026987|Drug|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
51782|NCT01026987|Drug|AMD3100|
51783|NCT01026987|Procedure|Leukapheresis|
52793|NCT01028807|Other|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
52794|NCT01028807|Other|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
52795|NCT01028820|Drug|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
52796|NCT01028833|Other|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
52797|NCT00027937|Procedure|bone marrow ablation with stem cell support|
52798|NCT01028846|Drug|Diazoxide|4mg-6mg/kg orally once before study
52799|NCT01028859|Drug|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 ~ mg/m2; Day 1, Day 8 every 3 weeks
52800|NCT01028872|Device|Intraocular lens|
52801|NCT01028872|Device|Intraocular lens|
53081|NCT01064947|Drug|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
53082|NCT01057420|Drug|oxygen inhalation|Inhalation of 80% oxygen via face mask
53083|NCT01057433|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
53084|NCT01057433|Drug|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
53085|NCT00030719|Drug|etoposide|
53086|NCT01057459|Other|laboratory biomarker analysis|Correlative studies
53087|NCT01057485|Procedure|AF ablation and AV node ablation|AF ablation and AV node ablation
53088|NCT01057485|Procedure|AV node ablation|AV node ablation
53089|NCT01057498|Drug|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
53090|NCT01057498|Drug|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
52550|NCT01033591|Behavioral|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
52551|NCT01033591|Behavioral|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
52552|NCT01033604|Procedure|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
52553|NCT01033604|Procedure|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
52554|NCT01033617|Procedure|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
52555|NCT01033630|Drug|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
52556|NCT00028561|Drug|carboplatin|Given IV
52557|NCT01033630|Drug|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
52558|NCT01033630|Drug|Placebo|Image-matched placebo, made with starch.
52559|NCT01033643|Drug|MK3614|0.25 mg BID every 12 hours for 10 days
52560|NCT01033643|Drug|Comparator: MK3614 .75 mg 1st|0.50 mg in the AM, 0.25 mg in the PM 12 hours apart for 10 days
52561|NCT01033643|Drug|Comparator: MK3614 titrating down dose|Day 1 subjects will receive 0.50 mg three times a day every 8 hours. Days 4-13 subjects will receive 0.50 mg twice a day every 12 hours.
52562|NCT01025856|Other|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
52563|NCT00027846|Drug|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA < 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
52564|NCT01025869|Device|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
52565|NCT01025882|Drug|gemcitabine hydrochloride|Given IV
52869|NCT01026415|Drug|brentuximab vedotin|1.2 mg/kg IV every 21 days
52870|NCT01026428|Drug|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
51712|NCT01029392|Drug|Vitamin D|2000iu once a day
51713|NCT01029405|Drug|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
52004|NCT01032720|Procedure|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
52005|NCT01032720|Procedure|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
52006|NCT01032733|Behavioral|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
52007|NCT01032733|Other|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
52008|NCT01032746|Other|educational intervention|
52009|NCT00028431|Biological|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
52010|NCT01032746|Other|internet-based intervention|
52011|NCT01032746|Procedure|evaluation of cancer risk factors|
52012|NCT01032746|Procedure|fecal occult blood test|
52013|NCT01032746|Procedure|screening colonoscopy|
52014|NCT01032759|Drug|Memantine|20 mg, BID
52015|NCT01032759|Drug|Placebo|BID
52016|NCT01032772|Behavioral|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
52017|NCT01032772|Behavioral|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
52018|NCT01032785|Device|no interventions|no interventions
52019|NCT01032798|Drug|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
52020|NCT00028483|Drug|cBR96-doxorubicin immunoconjugate|
52021|NCT01032824|Behavioral|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
52022|NCT01032824|Other|Group Arm|10-session didactic telephone group
51784|NCT01026987|Procedure|Stem Cell Infusion|
51785|NCT01027000|Biological|rituximab|
51786|NCT01027000|Drug|busulfan|
51787|NCT00027885|Procedure|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
51788|NCT01027000|Drug|cyclophosphamide|
51789|NCT01027000|Drug|fludarabine phosphate|
51790|NCT01027000|Drug|methotrexate|
51791|NCT01027000|Drug|sirolimus|
51792|NCT01027000|Drug|tacrolimus|
51793|NCT01027000|Procedure|allogeneic stem cell transplant|
51794|NCT01027013|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
51795|NCT01027013|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
52088|NCT01030120|Drug|etanercept|etanercept 50mg BIW S.Q.
52089|NCT01030120|Drug|placebo|placebo
52090|NCT01030133|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
52091|NCT01030146|Drug|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
52092|NCT01030159|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
52093|NCT01030185|Device|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
52094|NCT01030198|Device|RevLite (Laser Treatment)|
52095|NCT01030211|Procedure|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
52096|NCT01030211|Other|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
53091|NCT01057511|Drug|Crinone 8%|Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
53092|NCT01057511|Drug|Progesterone|Progesterone 20mg/ i.m./ Qd, 7 days totally.
53093|NCT01057524|Device|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
53094|NCT01057524|Other|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
53095|NCT01057537|Drug|polypill|The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):
Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.
53096|NCT00030719|Drug|isotretinoin|
53097|NCT01057537|Drug|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
53098|NCT01057550|Procedure|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
53099|NCT01057550|Procedure|TVT|Standard TVT as described by Ulmsten 1996
53100|NCT01057550|Procedure|Pelvicol|retropubic mid urethral sling made from Pelvicol
53101|NCT01057563|Device|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
53102|NCT01057563|Device|bare-metal stent (BMS)|BMS implantation
53103|NCT01057563|Device|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
53443|NCT01065623|Drug|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
53444|NCT01065636|Behavioral|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 24 weeks, and resistance exercise training 3-days/week for 24 weeks.
53445|NCT01065636|Behavioral|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 24 weeks, and aerobic exercise training 3-days/week for 24 weeks
53446|NCT01065636|Behavioral|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 24 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
53447|NCT01065649|Drug|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
52871|NCT01026428|Other|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
52872|NCT01026441|Device|Vela100 (Aesthetic)|6 treatments once a week
52873|NCT00027859|Drug|therapeutic hydrocortisone|
52874|NCT01026454|Drug|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
52875|NCT01026454|Drug|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
52876|NCT01026467|Drug|cisplatin|Given IV
52877|NCT01026467|Drug|carboplatin|Given IV
52878|NCT01026467|Other|questionnaire administration|
52879|NCT01026493|Drug|temozolomide|Given orally
52880|NCT01026493|Drug|veliparib|Given orally
52881|NCT01026506|Dietary Supplement|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
52882|NCT01026519|Drug|REGN88|Single dose of REGN88 and 43 day follow up.
52883|NCT01026519|Other|Placebo|Placebo to match REGN88 administration
52884|NCT00027872|Drug|tipifarnib|Given orally
52885|NCT01026532|Biological|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
52886|NCT01026545|Drug|PF-04287881|500 mg once daily for 10 days
52887|NCT01026545|Drug|Placebo|To match 500 mg dose once daily for 10 days
52888|NCT01026545|Drug|PF-04287881|750 mg once daily for 10 days
52889|NCT01028911|Drug|Placebo|Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.
Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
52890|NCT01028924|Drug|Teduglutide|subcutaneous (SC), single dose
52023|NCT01032824|Other|Book Arm|Book only.
52024|NCT01032837|Drug|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
52025|NCT01032837|Drug|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
52026|NCT01032837|Drug|Placebo|Matching placebo provided as capsules and as a suspension.
52334|NCT01028131|Behavioral|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
52335|NCT01028144|Behavioral|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
52336|NCT01028144|Behavioral|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
52337|NCT00027924|Procedure|peripheral blood stem cell transplantation|
52338|NCT01030614|Drug|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
52339|NCT01030614|Drug|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
52340|NCT01030627|Device|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
52341|NCT00028145|Behavioral|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
52342|NCT01030640|Other|placebo|single dose of the drug formulation
52343|NCT01030640|Biological|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
52344|NCT01030653|Drug|Voriconazole|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
52345|NCT01030666|Drug|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
52097|NCT00028093|Drug|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
52098|NCT01030224|Drug|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
52099|NCT01030224|Drug|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
52100|NCT01032876|Procedure|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
52101|NCT01032889|Drug|Deoxycholic acid injection|
52102|NCT00028483|Drug|docetaxel|
52103|NCT01032889|Drug|Placebo|Phosphate buffered saline placebo for injection
52104|NCT01032902|Device|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
52105|NCT01032915|Biological|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
52106|NCT01032915|Biological|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
52107|NCT01032915|Biological|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
52108|NCT01032915|Drug|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
51137|NCT01044628|Device|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
51138|NCT01044628|Device|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
51139|NCT01044654|Genetic|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
51140|NCT01044667|Drug|Myfortic|
51141|NCT01044680|Dietary Supplement|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
51142|NCT01036659|Drug|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
53448|NCT01065649|Drug|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
53449|NCT01065662|Drug|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
53450|NCT01058057|Drug|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
53451|NCT01058070|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
53452|NCT01058083|Drug|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
53453|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
53454|NCT00030732|Drug|Gemcitabine alone|Gemcitabine alone
53455|NCT01058083|Drug|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
53456|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
53457|NCT01058083|Drug|Placebo|Placebo, Oral, 0 mg, daily, 28 days
53458|NCT01058096|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine or placebo
53459|NCT01058096|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine or placebo
53460|NCT01058109|Other|calcium-rich diet|dietary calcium intake of 1500 mg/d
53461|NCT01058109|Other|Calcium rich diet|dietary intake of 1500 mg/d from food
53462|NCT01058122|Procedure|Collection of adverse drug events|
53463|NCT01058135|Other|Hi-maize starch (Low dose)|resistant starch
53464|NCT01058135|Other|Hi-maize starch (High-dose)|resistant starch
53465|NCT00030745|Drug|cisplatin|
52488|NCT00027846|Drug|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
52489|NCT01025817|Drug|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
52490|NCT01025830|Drug|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
52491|NCT01025830|Drug|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
53167|NCT01064999|Procedure|Surgery|Lower anterior resection or abdominoperineal resection
53168|NCT01065012|Drug|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
53169|NCT01065012|Drug|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
53170|NCT00031499|Drug|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
53171|NCT01065012|Drug|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
53172|NCT01065012|Drug|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
53173|NCT01065012|Drug|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
53174|NCT01065012|Drug|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
53175|NCT01065025|Drug|4SC-205|Repeated ascending oral doses of 4SC-205.
53176|NCT01065038|Drug|Anagrelide|
53177|NCT01065038|Drug|Hydroxyurea|
53178|NCT01065051|Drug|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
53179|NCT01065051|Drug|Placebo|Single oral dose
53180|NCT01057589|Drug|Cetuximab|Triplet Combination Therapy: 400 mg/m^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.
Maintenance Therapy: 250 mg/m^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity
53181|NCT01057589|Drug|Cisplatin|Triplet Combination Therapy: 75mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
53182|NCT01057589|Dietary Supplement|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
53183|NCT01057589|Dietary Supplement|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
53184|NCT01057615|Dietary Supplement|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
52346|NCT01030666|Drug|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
52347|NCT01030666|Procedure|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
51388|NCT01042392|Drug|Ramipril|Ramipril 5 mg was given in capsule form.
51389|NCT01042392|Drug|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
51390|NCT01042392|Drug|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
51391|NCT01042418|Other|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
51392|NCT01042431|Other|No Intervention|No intervention
51393|NCT00000899|Drug|Lamivudine|
51394|NCT00028925|Biological|filgrastim|
51395|NCT01042444|Device|GARDEX™|GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.
The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014" guide wires.
51396|NCT01042457|Drug|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
51397|NCT01042483|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
51398|NCT01042496|Drug|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
51399|NCT01042496|Procedure|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
51400|NCT01042509|Drug|Alemtuzumab and Rituximab combination|Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25)
51401|NCT01042522|Biological|Bleomycin Sulfate|Given IV
51402|NCT01042522|Drug|Carboplatin|Given IV
51143|NCT01036724|Device|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX[TM]) and measuring the amount of radiation exposure duration for each.
51144|NCT01036802|Drug|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
51145|NCT01036841|Drug|desmopressin tablet|Administration of desmopressine tablet
51146|NCT01036841|Drug|desmopressin MELT formulation|Administration of desmopressine MELT formulation
51147|NCT01036854|Drug|EUR-1025|oral, 24 mg, daily for 6 days
51148|NCT01036854|Drug|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
51149|NCT01036854|Drug|EUR-1025|orally, 8 mg, three times a day ove r6 consecutive days
51150|NCT00028704|Radiation|radiation therapy|
51151|NCT01036854|Drug|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
51152|NCT01036893|Drug|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
51153|NCT01036932|Drug|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
51154|NCT01036932|Drug|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
51155|NCT01037023|Drug|Topotecan|patients administrated Topotecan according to the prescribing information
51156|NCT01037036|Drug|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
51470|NCT01031836|Drug|MEDI-545 600|Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.
Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses.
51471|NCT01031849|Drug|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
51472|NCT01031862|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
51473|NCT01031875|Drug|pazopanib hydrochloride|
51474|NCT01031875|Radiation|fludeoxyglucose F 18|
51475|NCT00028327|Drug|Lamivudine|
52492|NCT01025843|Drug|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
52493|NCT01025843|Drug|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
52494|NCT01025843|Drug|Comparator: Pbo|Placebo
52495|NCT01025856|Other|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
52496|NCT01025856|Other|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
52497|NCT01025856|Other|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
52498|NCT01028339|Drug|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
52499|NCT01028339|Drug|Mannitol|Mannitol
52500|NCT01028352|Drug|Duloxetine|Patients will be treated with open-label duloxetine:
30 mg daily x 7 days, then
60 mg daily x 3 weeks, then
If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8
If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.
After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician.
52501|NCT01028365|Other|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
52502|NCT01028391|Drug|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
52503|NCT01028391|Drug|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
52504|NCT01028391|Drug|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
52505|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
52802|NCT01028872|Device|Intraocular lens|
52803|NCT01028885|Procedure|radiation therapy treatment planning/simulation|
52804|NCT01028885|Procedure|intensity-modulated radiation therapy|
53185|NCT01057615|Dietary Supplement|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
53522|NCT01065870|Drug|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.
Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.
Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.
Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.
Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm.
53523|NCT00031590|Drug|Cyclophosphamide|Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
53524|NCT01065883|Behavioral|community health worker|community health workers will provide education in the home
53525|NCT01065883|Behavioral|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
53526|NCT01065935|Drug|ALN-RSV01|Administered by nebulization once daily for 5 days
53527|NCT01065935|Drug|Normal Saline|Administered by nebulization once daily for 5 days
53528|NCT01065948|Device|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
53529|NCT01065961|Drug|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
53530|NCT01065961|Drug|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
53531|NCT01065974|Behavioral|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
53532|NCT01065974|Dietary Supplement|Meal Replacements|Weight loss using CBT and meal replacements.
53533|NCT01065974|Behavioral|Nutritrol|To make widespread nutritional changes to participants personal food environments.
53534|NCT00031590|Drug|Etoposide|Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).
53535|NCT01065987|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
53536|NCT01066000|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
53537|NCT01066013|Other|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
51403|NCT01042522|Drug|Cisplatin|Given IV
51404|NCT01042522|Drug|Etoposide Phosphate|Given IV
51405|NCT00028925|Drug|carboplatin|
51406|NCT01042522|Other|Laboratory Biomarker Analysis|Correlative studies
51407|NCT01042522|Drug|Paclitaxel|Given IV
51408|NCT01042535|Biological|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
51409|NCT01042535|Drug|1-methyl-d-tryptophan|Given orally (PO)
51714|NCT01029405|Drug|Placebo|Ointment B Vehicle applied once or twice daily
51715|NCT01029418|Drug|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
51716|NCT01029431|Device|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted & the evaluation described below will be conducted. The first LMA will then be removed & the other device inserted & assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment & before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, & inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
51717|NCT00028002|Drug|imatinib mesylate|Given orally
51718|NCT01029444|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
51719|NCT01029470|Drug|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
51720|NCT01029483|Other|Low carbohydrate diet|Ad libitum low carbohydrate diet (<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
51721|NCT01029483|Other|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
51722|NCT01029483|Other|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at ~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
51476|NCT01031888|Drug|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
51477|NCT01031888|Drug|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
51478|NCT01031901|Drug|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
51479|NCT01031901|Drug|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
51480|NCT01034202|Drug|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
51481|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
51482|NCT01034202|Drug|placebo|Placebo comparator
51483|NCT01034202|Drug|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
51484|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
51485|NCT01034215|Behavioral|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
51486|NCT01034215|Behavioral|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
51487|NCT00028600|Biological|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC >= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC > 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
51488|NCT01034228|Other|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
51796|NCT01027026|Other|Early discharge|The patients are discharged the same day as coronary angiography.
51797|NCT01027026|Other|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
51798|NCT00027885|Procedure|neoadjuvant therapy|Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
52805|NCT01028885|Procedure|image-guided radiation therapy|
52806|NCT01028885|Procedure|magnetic resonance imaging|
52807|NCT01028885|Procedure|computed tomography|
52808|NCT00027937|Procedure|in vitro-treated peripheral blood stem cell transplantation|
52809|NCT01028911|Drug|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
52810|NCT01031368|Other|laboratory biomarker analysis|Correlative studies
52811|NCT01031381|Drug|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
52812|NCT00028314|Drug|Atazanavir/Ritonavir|
52813|NCT01031381|Drug|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
52814|NCT01031394|Other|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
52815|NCT01031420|Drug|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
52816|NCT01031446|Drug|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
52817|NCT01031446|Drug|everolimus|Taken daily by mouth.
52818|NCT01031446|Drug|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
52819|NCT01031446|Other|laboratory biomarker analysis|Blood collection
52820|NCT01031459|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
52821|NCT01031472|Drug|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
52822|NCT01031472|Drug|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
52823|NCT00028314|Drug|Lopinavir/Ritonavir|
52824|NCT01031472|Drug|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
52566|NCT01025882|Radiation|stereotactic body radiation therapy|Given as a single fraction
52567|NCT01025895|Procedure|acl reconstruction - double bundle technique|
52568|NCT01025895|Procedure|acle reconstruction - single bundle technique|
52569|NCT01025908|Behavioral|Psychotherapy|Cognitive Behavioral Therapy
52570|NCT01025908|Behavioral|Supportative psychotherapy|Supportative psychotherapy
52571|NCT01025921|Drug|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
52572|NCT01025921|Other|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
52573|NCT01025934|Drug|Bevacizumab|
52574|NCT00027846|Drug|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA<0.45m2 the dose is 0.05mg/kg.
52575|NCT01025934|Other|sham|
52576|NCT01025960|Procedure|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
52577|NCT01025960|Procedure|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
52578|NCT01025999|Other|No intervention|
52579|NCT01026012|Drug|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
52580|NCT01026025|Device|Duet TRS|This is a single arm study.
52581|NCT01026038|Biological|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
52582|NCT01026051|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
52583|NCT01026064|Other|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
52584|NCT01026064|Drug|Azithromycin|Zithromax (250 mg oral capsule).
52585|NCT00027846|Radiation|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
52586|NCT01026064|Drug|Placebo|Matching placebo
51723|NCT01029496|Procedure|different time of umbilical cord clamping|for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.
control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.
for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):
experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.
control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table.
51724|NCT01029509|Drug|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
51725|NCT01029522|Drug|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
51726|NCT01029522|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
51727|NCT01029535|Device|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
51728|NCT00028002|Procedure|conventional surgery|Undergo surgical resection
51729|NCT01029561|Device|CPAP|Treatment with Continuous Positive Airway Pressure
51730|NCT01029561|Behavioral|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
52027|NCT01032850|Drug|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
52028|NCT01032876|Procedure|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
52029|NCT01035385|Drug|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
52030|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLE494
52031|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLF497
52032|NCT01035411|Drug|AZD9668|2 x 30 mg tablet variant 1
52033|NCT01035437|Drug|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
52034|NCT01035450|Device|Everolimus-eluting stent|Everolimus-eluting stent
52035|NCT00028665|Drug|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
52036|NCT01035450|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
51799|NCT01027052|Other|Hamburger meat patty with salt|hamburger meat cooked with salt
51800|NCT01027052|Other|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
51801|NCT01027065|Drug|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
51802|NCT01027065|Drug|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
51803|NCT01027104|Other|Education|Firearm injury prevention anticipatory guidance curriculum
51804|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
51805|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
51806|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
51807|NCT01029587|Drug|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
51808|NCT01029600|Procedure|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
51809|NCT01029600|Procedure|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
51810|NCT01029613|Drug|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
51811|NCT01029626|Procedure|Endoscopy|Realization of an upper GI endoscopy
51812|NCT01029639|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
52109|NCT01032928|Behavioral|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
52110|NCT01032941|Drug|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
53104|NCT01057576|Dietary Supplement|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
53105|NCT01057576|Dietary Supplement|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosage
53106|NCT01057589|Drug|Pemetrexed|Triplet Combination Therapy: 500 mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles
Maintenance Therapy: 500mg/m^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity
53107|NCT00030719|Drug|melphalan|
53108|NCT01059812|Drug|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
53109|NCT01059812|Drug|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
53110|NCT01059825|Drug|Placebo to Ertugliflozin|Tablet(s), 1 or 2, 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
53111|NCT01059825|Drug|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
53112|NCT01059825|Drug|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
53113|NCT01059825|Drug|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
53114|NCT01059825|Drug|100 mg sitagliptin|Tablet, 100 mg, once daily for 84 days
53115|NCT01059825|Drug|Placebo to Sitagliptin|Tablet, 100 mg, once daily for 84 days
53116|NCT00030862|Drug|irinotecan hydrochloride|
53117|NCT01059838|Behavioral|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
53118|NCT01059851|Drug|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with ~240 mL of water after an 8 hour fast
53119|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
53120|NCT01059864|Drug|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
53121|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
53122|NCT01059864|Drug|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
53123|NCT01059877|Device|1072nm infrared light stimulation|1072nm infrared light delivering 2.6J/sq cm over a 6 minute treatment period.
53124|NCT01059890|Drug|cefotaxime|
52587|NCT01026090|Drug|Dronedarone|Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)
52588|NCT01026090|Drug|Placebo (for dronedarone)|film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)
52891|NCT01028937|Device|Optimal Keratoplasty|Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
52892|NCT01028950|Drug|YM150|oral
52893|NCT01028963|Drug|Placebo|Placebo capsules once daily
52894|NCT01028963|Drug|pioglitazone|pioglitazone 30 mg tablet once daily
52895|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
52896|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group D)
52897|NCT01028976|Dietary Supplement|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
52898|NCT00027963|Drug|gabapentin|
52899|NCT01028976|Dietary Supplement|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
52900|NCT01028989|Dietary Supplement|Reduced Glycemic Load Diet|36-40% fat; 40-42% carbohydrate; 18-22% protein
Glycemic Load <=46 per 1000 calories
52901|NCT01028989|Dietary Supplement|Standard Diet|25-27% fat; 55-57% carbohydrate; 18-22% protein
Glycemic Load >=77 per 1000 calories
52902|NCT01029002|Drug|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
52903|NCT01029002|Other|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
52904|NCT01029015|Procedure|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
52905|NCT01029015|Procedure|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
52906|NCT01029041|Other|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
52907|NCT01029041|Other|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
52908|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.
Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.
52037|NCT01035463|Drug|lenalidomide|Given PO
52038|NCT01035463|Biological|rituximab|Given IV
52039|NCT01035463|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
52040|NCT01035463|Drug|carmustine|Given IV
52041|NCT01035463|Drug|etoposide|Given IV
52042|NCT01035463|Drug|cytarabine|Given IV
52043|NCT01035463|Drug|melphalan|Given IV
52044|NCT01035476|Behavioral|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
52045|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
52046|NCT00028665|Drug|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
52047|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
51071|NCT01039610|Drug|Moxifloxacin|40 mg single dose
51072|NCT01039623|Biological|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
51073|NCT01039636|Drug|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
51074|NCT01039662|Dietary Supplement|L-arabinose and indigestible dextrin|
51075|NCT01039662|Dietary Supplement|Placebo|
51076|NCT01039675|Drug|500mcg/25mcg once daily|GSK573719/GW642444
51077|NCT01039675|Drug|Placebo once daily|Inactive, excipients only
51078|NCT00028782|Procedure|therapeutic conventional surgery|Undergo surgery
51079|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
51080|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
51081|NCT01039688|Drug|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
52111|NCT01032954|Drug|Botulinum toxin|The following list shows the indications for eligibility and total doses that will be applied in each part of the face, according to the consensus meeting recommendations, at the 1 visit:
Upper face:
Crow's feet wrinkles - 70 U
Glabella - 50 U
Forehead - 40 U
Mid face:
Lower eyelid - 5 U
Nasal wrinkles - 20 U
Malar wrinkles - 10 U
Lower face:
Peri-oral wrinkles - 15U
Asymmetric smile or gummy smile - 5U
"Cellulitic chin" - 20U
Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.
Patients will be allocated in each group according to the total dose received at visit 1(described above). At visit 2, all the patients will receive a touch-up of a standard dose of 25 Units of Dysport®, distributed on the treated areas according patient's needs.
52112|NCT01032967|Procedure|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
52113|NCT00028496|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
52114|NCT01032967|Radiation|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
52115|NCT01032993|Dietary Supplement|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
52116|NCT01032993|Other|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
52117|NCT01033006|Procedure|Active Comparator: Arm 1: catheter injection|
52118|NCT01033006|Procedure|Active Comparator: Arm 2: transarterial injection|
52119|NCT01033006|Procedure|Active Comparator: Arm 3: catheter and transarterial injection|
52120|NCT01033019|Drug|LDE225 0.75%|0.75% cream
52121|NCT01033019|Drug|Vehicle|matching placebo cream to 0.75% LDE225 cream
52122|NCT01033032|Drug|Amrubicin|Phase I: dose escalating portion with the starting dose of amrubicin at 90mg/m2 IV q21 days. Dose escalations are as follows:
DL2 - 100mg/m2; DL3 - 110mg/m2; and DL4 - 120mg/m2. All cycles are q21 days
Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days
52123|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
52124|NCT01035671|Drug|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
52125|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
52126|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
52127|NCT00028665|Procedure|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
53125|NCT01059890|Drug|Metronidazole|
53126|NCT01059890|Drug|Ciprofloxacin|
53466|NCT01058135|Other|Control (starch)|rapidly digestible starch
53467|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
53468|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
53469|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
53470|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
53471|NCT01058174|Drug|micafungin|intravenous infusion
53472|NCT01058174|Drug|fluconazole|intravenous infusion
53473|NCT01058174|Drug|liposomal amphotericin B|intravenous infusion
53474|NCT01058174|Drug|caspofungin|intravenous infusion
53475|NCT01058200|Device|iCup|new vacuum extractor: sterile disposable plastic cup
53476|NCT00030745|Drug|gemcitabine hydrochloride|
53477|NCT01058200|Device|reference cup|reference cup of the obstetrical ward: metallic cup
53478|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
53479|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
53480|NCT01060475|Drug|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
53481|NCT01060475|Drug|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
53482|NCT01060488|Other|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
53483|NCT01060488|Other|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
53484|NCT01060501|Drug|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
53485|NCT01060514|Drug|Pazopanib|dose escalation, administered orally, daily
52909|NCT00027963|Other|placebo|
52910|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg.
52911|NCT01031550|Other|standard of care|standard of care
53186|NCT01057615|Dietary Supplement|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
53187|NCT01057615|Dietary Supplement|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
53188|NCT01057628|Drug|ASP1941|oral
53189|NCT01057628|Drug|placebo|oral
53190|NCT00000904|Biological|gp160 MN/LAI-2|
53191|NCT00030719|Drug|vincristine sulfate|
53192|NCT01057641|Procedure|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
53193|NCT01057641|Other|physiotherapy|physiotherapy
53194|NCT01057654|Drug|Pravastatin|Pravastatin 40 mg
53195|NCT01057654|Drug|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
53196|NCT01057667|Drug|RO5024048|1000mg bid po, 24 weeks
53197|NCT01057667|Drug|Ribavirin [Copegus]|1000mg or 1200mg po daily
53198|NCT01057667|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
53199|NCT01057680|Dietary Supplement|creatine monohydrate|Powder, 0.1 g per day, 12 months
53200|NCT01057680|Dietary Supplement|sugar placebo|powder, 0.1 g/day, 12 months
53201|NCT01057693|Drug|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
53202|NCT00030719|Procedure|bone marrow ablation with stem cell support|
53203|NCT01057693|Drug|Placebo|Placebo is supplied as capsules and given 3 times daily.
51082|NCT01039701|Drug|AZD1446|capsules, oral, 3 times daily
51083|NCT01039701|Drug|Placebo|capsules, oral, 3 times daily, 4 weeks
51084|NCT01039727|Other|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
51085|NCT01039727|Other|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
51086|NCT01039740|Drug|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
51087|NCT01039766|Drug|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
51088|NCT01039766|Drug|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
51089|NCT00028782|Other|laboratory biomarker analysis|Correlative studies
51090|NCT01039779|Behavioral|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
51091|NCT01039792|Drug|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
51092|NCT01039792|Dietary Supplement|Placebo|placebo
51093|NCT01039805|Drug|GSK962040 (50 mg)|Cohort 1 = 50 mg
51410|NCT01042535|Other|Laboratory biomarker analysis|Correlative studies
51411|NCT01042561|Dietary Supplement|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
51412|NCT01045005|Other|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non−harmful/non−toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
51413|NCT01045005|Other|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non−harmful/non−toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
51414|NCT01045018|Drug|Placebo|placebo 400 mg
51415|NCT01045018|Drug|Mesalamine|
51416|NCT01045018|Drug|Mesalamine|
51417|NCT01045057|Device|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
53708|NCT01058512|Drug|NOV-205|There will be 4 treatment Groups with 10 patients in each group:
Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days
Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days
Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days
Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days
53709|NCT01058525|Procedure|median nerve block|median nerve block performed using ultrasound guidance
53710|NCT01058525|Procedure|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
53711|NCT01058538|Drug|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
53712|NCT01058551|Device|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
53713|NCT00030771|Drug|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
53714|NCT01058564|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, magnetic esophageal sphincter
53715|NCT01058577|Device|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
53990|NCT01064050|Device|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
53991|NCT01064063|Device|Vanguard CR|The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
53992|NCT01064063|Device|AGC knee|The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
53993|NCT01064076|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
53994|NCT01064089|Drug|HSP990|
53995|NCT01064102|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
53996|NCT00000912|Drug|Indinavir sulfate|
53997|NCT00031395|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
58523|NCT01067092|Behavioral|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
58524|NCT01067105|Drug|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
58525|NCT01067118|Drug|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
58526|NCT01067118|Drug|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
58527|NCT01067131|Biological|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
58528|NCT01067131|Biological|PEV7C9|capsule intravaginal application contains excipient only
58529|NCT01067131|Biological|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
58530|NCT01067131|Biological|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
57589|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
57590|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
57591|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
57592|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 8.
57593|NCT00031824|Drug|hydroxychloroquine|
57594|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 8.
57595|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10^10vp at week 8.
57596|NCT01070420|Other|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min−1•kg−1) via Rt central femoral vein.
57597|NCT01070420|Other|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min−1•kg−1) via continuous peripheral vein.
57598|NCT01070433|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
54056|NCT01059253|Other|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
54057|NCT01059266|Drug|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
54058|NCT01059305|Drug|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
54059|NCT01059318|Drug|Everolimus|
54060|NCT01059318|Drug|Everolimus|
54061|NCT01059318|Drug|Everolimus|
54062|NCT01061541|Biological|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
54063|NCT01061541|Biological|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
54064|NCT01061554|Dietary Supplement|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
54065|NCT01061554|Dietary Supplement|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
54066|NCT01061580|Device|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
54067|NCT01061593|Dietary Supplement|Immunoxel|1 lozenge once per day
54068|NCT01061593|Other|Placebo|1 lozenge once per day
54069|NCT01061606|Drug|temsirolimus|Given IV
54070|NCT01061632|Procedure|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
54071|NCT01061632|Procedure|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
54072|NCT00000906|Drug|Saquinavir|
54389|NCT01047735|Procedure|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
54752|NCT01050439|Other|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
54753|NCT01050452|Drug|albendazole|albendazole (400 mg on dose)
54754|NCT01050452|Drug|mebendazole|mebendazole (500 mg one dose)
54755|NCT01050452|Drug|ivermectin|ivermectin (200 microgram/kg body weight)
54756|NCT00030147|Drug|Evista, Rimostil, Alora|
54757|NCT01050452|Drug|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
54758|NCT01050452|Drug|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
54759|NCT01050465|Other|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
54760|NCT01050478|Drug|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
54761|NCT01050478|Drug|Benzodiazepine|Participants may receive the benzodiazepine lorazepam [0-7.5 milligram (mg) per day] as needed for sedation or rescue medication at the investigator's discretion.
54762|NCT01050491|Drug|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
54763|NCT01050491|Drug|placebo|placebo, one per day, during one year. Bronchial fibroscopy
54764|NCT01050504|Other|Cytology Specimen Collection Procedure|Correlative studies
54765|NCT01050504|Other|Laboratory Biomarker Analysis|Correlative studies
54766|NCT01050517|Drug|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
54767|NCT00030160|Behavioral|Strength Training|
54768|NCT01050517|Drug|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
54769|NCT01050530|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
54770|NCT01050530|Drug|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
54771|NCT01050543|Drug|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
53835|NCT01056406|Behavioral|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
53836|NCT01056419|Procedure|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
53837|NCT01056419|Drug|Propylthiouracil|150-600 mg in two-three divided doses
53838|NCT00030654|Drug|releasing hormone agonist therapy|
54137|NCT01057030|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
54138|NCT01059331|Drug|Pregabalin|150 mg x 2 daily for 2 days
54139|NCT00000904|Biological|ALVAC-HIV MN120TMG (vCP205)|
54140|NCT00030810|Drug|Taxotere/Cisplatin|Taxotere/Cisplatin
54141|NCT01059331|Drug|Sugar pill|1 tablet x 2 daily, for 2 days
54142|NCT01059344|Drug|Mesalamin|4.8g/day, 800 mg tablets
54143|NCT01059357|Device|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
54144|NCT01059370|Procedure|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
54145|NCT01059383|Drug|VECAM 40/300|1 capsule, orally, once daily at bedtime.
54146|NCT01059383|Drug|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
54147|NCT01059396|Drug|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
54148|NCT01059396|Drug|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
54149|NCT01059396|Drug|placebo|placebo propranolol / carvedilol
54150|NCT01059409|Procedure|Meniscal Allograft|Meniscal Allograft
54151|NCT00030810|Procedure|conventional surgery|conventional surgery
54152|NCT01059422|Drug|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
57599|NCT01070433|Procedure|Standard of Care|
57600|NCT01070446|Dietary Supplement|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
57601|NCT01073033|Dietary Supplement|milk supplement 2|milk supplement without probiotics
57602|NCT00032019|Drug|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
57603|NCT01073046|Device|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
57604|NCT01073059|Drug|Valproic acid and Ertapenem|
57605|NCT01073072|Procedure|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
57606|NCT01073072|Procedure|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
57607|NCT01073085|Behavioral|Web-based automated "coaching" by e-mails|
57608|NCT01073085|Behavioral|Self-help guide|
57609|NCT01073098|Other|Vascular occlusion test|Reperfusion slope after vascular occlusion test
58175|NCT01066520|Drug|Diclofenac gel|2 g, 3 times daily topical during 14 days
58176|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
58177|NCT01069003|Device|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
58178|NCT01069016|Procedure|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
58179|NCT01069016|Procedure|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
58180|NCT01069042|Drug|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
54390|NCT01047735|Procedure|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
54391|NCT00029679|Drug|Gingko biloba|
54392|NCT01047735|Behavioral|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
54393|NCT01047748|Drug|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
54394|NCT01047748|Drug|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
54395|NCT01047761|Other|Exercise|3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity
Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises
54396|NCT01047774|Dietary Supplement|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
54397|NCT01047774|Dietary Supplement|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
54398|NCT01047787|Other|Polysomnography|examination for sleep disorders
54399|NCT01047800|Behavioral|Counseling|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:
First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions
Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions.
54400|NCT01047826|Procedure|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
54401|NCT01047826|Procedure|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
54402|NCT00029679|Drug|Borage oil|
54403|NCT01049815|Drug|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
54693|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
54772|NCT01050543|Drug|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
53818|NCT01063816|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
53819|NCT01063816|Drug|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
53820|NCT00031291|Drug|Anthrax Immune Globulin|
53821|NCT01063816|Drug|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
53822|NCT01063829|Drug|AIC246|Oral administration
53823|NCT01063829|Drug|AIC246|Oral administration
53824|NCT01063829|Drug|AIC246|Oral administration
53825|NCT01063829|Other|Placebo|Oral administration
53826|NCT01063842|Drug|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
53827|NCT01063842|Drug|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
53828|NCT01063855|Drug|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
53829|NCT01063855|Drug|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
53830|NCT01063855|Drug|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
53831|NCT00031317|Drug|Paroxetine|
53832|NCT01063868|Drug|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
53833|NCT01063868|Drug|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
53834|NCT01056393|Drug|ibalizumab|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg q2weeks, or 2000mg q4weeks.
54153|NCT01059435|Drug|AMG 785|Subjects will be randomized to receive 1 of 6 doses of AMG 785 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 785 or placebo as a weight-based dose of 0.1 mg/kg, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously (SC, under the skin), or 1 mg/kg or 5 mg/kg intravenously (IV, in the vein), while men will receive doses of 1 mg/kg or 5 mg/kg SC or IV.
54154|NCT01059435|Drug|Placebo|Subjects will be randomized to receive 1 of 6 doses of AMG 785 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 785 or placebo as a weight-based dose of 0.1 mg/kg, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously (SC, under the skin), or 1 mg/kg or 5 mg/kg intravenously (IV, in the vein), while men will receive doses of 1 mg/kg or 5 mg/kg SC or IV.
54155|NCT01059448|Drug|AMG 827|AMG 827 210 mg
54156|NCT01059461|Drug|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
54455|NCT01055015|Drug|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
54456|NCT01055015|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
54457|NCT01055028|Drug|Paclitaxel in combination with Bevacizumab|15 mg/kg, IV
54458|NCT01055041|Drug|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
54459|NCT01055041|Drug|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
54460|NCT01047839|Biological|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
54461|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
54462|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
54463|NCT01047852|Procedure|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
54464|NCT01047891|Drug|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
54465|NCT01047904|Device|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
58181|NCT01069055|Other|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
58182|NCT00031733|Biological|sargramostim|
58183|NCT01069055|Drug|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
58184|NCT01069055|Drug|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
58185|NCT01069081|Drug|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
58186|NCT01069081|Drug|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
58187|NCT01069081|Drug|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
58188|NCT01069094|Drug|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
58189|NCT01069094|Drug|Progenta|25 mg, administered as a once daily oral dose for 90 days.
58190|NCT01069094|Drug|Progenta|50 mg, administered as a once daily oral dose for 90 days.
58191|NCT01069094|Drug|Lucron Depot|3.75 mg IM monthly
58192|NCT01069094|Drug|Placebo|Administered as a once daily oral dose for 90 days.
58211|NCT01071460|Device|FlexStent Femoropopliteal Self-Expanding Stent System|Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy
Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:
Contralateral retrograde common femoral cross-over access or antegrade access
Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion
Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis
Deployment of an appropriately sized FlexStent® to cover target lesion
Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter
Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications
58212|NCT01071473|Other|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
58213|NCT01071486|Drug|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
58214|NCT01071499|Drug|Morphine|One dose of morphine (0.1 mg/kg)
58215|NCT01071499|Drug|Morphine|One dose of morphine (0.2 mg/kg)
54694|NCT01052896|Drug|Gabapentin|300mg po TID
54695|NCT01052896|Drug|Placebo|Look-alike of gabapentin 300mg given po tid
54696|NCT01052909|Drug|Glimepiride|Glimepiride tablets 1 mg
54697|NCT01052922|Other|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
54698|NCT00030420|Drug|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
54699|NCT01052922|Other|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
54700|NCT01052922|Other|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
54701|NCT01052935|Biological|Group B streptococcus (GBS) vaccine|No vaccine will be administered in this study. Only one study visit is required.
Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study.
54702|NCT01052948|Other|Retrospective study-|
54703|NCT01052948|Other|Retrospective study-|
54704|NCT01052948|Other|Retrospective study-|
54705|NCT01052948|Other|Retrospective study-|
54706|NCT01052961|Drug|Oseltamivir|oseltamivir 150 mg bd for 5 days
54707|NCT01055327|Drug|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
54708|NCT01055327|Drug|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
54709|NCT00030628|Radiation|radiation therapy|
54710|NCT01055340|Drug|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
54711|NCT01055340|Drug|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
54712|NCT01055340|Drug|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
54713|NCT01055366|Drug|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
54714|NCT01055379|Drug|Rasagiline|1 mg/day for 12 weeks; orally
53653|NCT01060917|Procedure|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
53654|NCT01060917|Device|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
53655|NCT01060930|Drug|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
53656|NCT01060943|Device|KOKEN|atelocollagen filler
1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
53657|NCT01063400|Other|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
53658|NCT01063426|Drug|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
53659|NCT01063426|Drug|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
53933|NCT01056614|Drug|tacrolimus|Given IV and orally
53934|NCT01056614|Drug|methotrexate|Given IV
53935|NCT01056614|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
53936|NCT01056614|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
53937|NCT01056614|Other|laboratory biomarker analysis|Correlative studies
53938|NCT01056627|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
53939|NCT00030667|Other|laboratory biomarker analysis|Correlative studies
53940|NCT01056640|Device|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
53941|NCT01056640|Other|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
54466|NCT01047917|Behavioral|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
54467|NCT01047930|Behavioral|Exercise|Each 3-day experimental period will include one of the following conditions:
Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;
Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;
No exercise - subject will watch television or read and they will be required to remain sedentary.
54468|NCT01047943|Drug|Topical application of STA-21 ointment for treatment of psoriasis|
54469|NCT01047956|Drug|Methadone; NAC|Methadone NAC
54470|NCT00029692|Drug|Ginseng|
54471|NCT01047956|Drug|Methadone|Methadone
54472|NCT01047969|Drug|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
54773|NCT01050556|Other|Placebo|daily, 24 weeks
54774|NCT01052974|Drug|ropivacaine|A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.
Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo.
54775|NCT01052987|Drug|Tranilast|Tranilast tablets, 300 mg, QD
54776|NCT00030433|Drug|gemcitabine hydrochloride|
54777|NCT01052987|Drug|Allopurinol|Allopurinol tablets 300 mg, QD
54778|NCT01052987|Drug|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
54779|NCT01052987|Drug|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
54780|NCT01052987|Drug|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
54781|NCT01053000|Drug|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
54782|NCT01053013|Biological|Cancer macrobead placement in abdominal cavity|8 macrobeads per kilogram
54783|NCT01053026|Drug|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
53998|NCT01064115|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
53999|NCT01064128|Procedure|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
54000|NCT01064128|Procedure|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
54001|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
54002|NCT01064141|Biological|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
54003|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
54004|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
54005|NCT01064154|Drug|Carvedilol|Carvedilol Tablets 25 mg
54006|NCT01064167|Drug|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
54007|NCT01064180|Drug|Carvedilol|Carvedilol Tablets 25 mg
54008|NCT00031395|Drug|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
54327|NCT01057238|Other|Intensive Communication System|Regular family meetings once a week, using a standard protocol
54328|NCT00030719|Biological|monoclonal antibody Ch14.18|
54329|NCT01057251|Drug|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
54330|NCT01057251|Drug|Placebo|5 mg or 20 mg once daily, oral administration
54331|NCT01057264|Drug|HAI Abraxane|Starting dose: 120 mg/m^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
54332|NCT01057264|Drug|Gemcitabine|Starting dose: 600 mg/m^2 by IV on Days 1 and 8 of 21 day cycle
54333|NCT01057264|Drug|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
54334|NCT01057264|Drug|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
54335|NCT01057277|Drug|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
54336|NCT01057290|Genetic|gene expression analysis|
53772|NCT01066130|Behavioral|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
53773|NCT01066130|Behavioral|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
53774|NCT01066143|Drug|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
53775|NCT01066156|Drug|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
53776|NCT01066169|Biological|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
53777|NCT01066182|Dietary Supplement|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
53778|NCT01058616|Drug|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
53779|NCT01058629|Device|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
53780|NCT01058642|Drug|ADL5747|
53781|NCT01058642|Drug|Placebo|
53782|NCT01058642|Drug|Pregabalin|
53783|NCT00030771|Radiation|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
53784|NCT01058655|Drug|RAD001|Taken orally once a day
53785|NCT01058655|Drug|AV-951|Taken orally once a day for 3 weeks followed by a 1 week break
53786|NCT01058668|Drug|Cariprazine low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
53787|NCT01058668|Drug|Cariprazine high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
53942|NCT01056653|Behavioral|Standard Dose|Two home visits
53943|NCT01056653|Behavioral|High Dose|Four home visits
53944|NCT01056653|Behavioral|Comparison Group|One home visit, information only
53945|NCT01056666|Device|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
53946|NCT01056666|Device|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
53947|NCT00030784|Drug|pegylated liposomal doxorubicin hydrochloride|
53948|NCT01058980|Procedure|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
53949|NCT01058980|Procedure|No additional ablation|Presence of dormant PV conduction, no additional ablation.
53950|NCT01058980|Procedure|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
53951|NCT01058980|Procedure|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
54261|NCT01061931|Procedure|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
54262|NCT01061970|Drug|Fispemifene|once daily for 4 weeks
54263|NCT01061983|Device|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
54264|NCT00031083|Genetic|Interferon-beta|
54265|NCT01061996|Drug|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
54266|NCT01062009|Drug|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
54267|NCT01062022|Behavioral|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
54784|NCT01053039|Drug|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
54785|NCT01053039|Drug|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
54786|NCT01053052|Procedure|Sonography with FemVue, and HSG|
54787|NCT00030433|Drug|irinotecan hydrochloride|
54788|NCT01053065|Drug|Atorvastatin - Cholestyramine - Sitosterol|
54789|NCT01053078|Drug|Naltrexone|1 month treatment
54790|NCT01053078|Drug|Naltrexone|Naltrexone 25 mg once daily with dose escalation to 50 mg BID to day 28
54791|NCT01053091|Behavioral|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
54792|NCT01053117|Other|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
54793|NCT01053130|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
53839|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
53840|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
53841|NCT01056458|Other|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
53842|NCT01056458|Other|sham acupressure|use only tape without ear adhesive beads under the same ways
53843|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.
53844|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
53845|NCT01056484|Behavioral|Mindfulness Based Relapse Prevention for Alcohol Dependence|All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and "traditional" cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study.
54337|NCT01057290|Genetic|protein expression analysis|
54338|NCT01057290|Other|fluorescence activated cell sorting|
54339|NCT00030719|Drug|busulfan|
54340|NCT01057290|Other|immunologic technique|
54341|NCT01052142|Biological|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
54342|NCT01052155|Other|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
54343|NCT01052168|Other|skills training|participants will train using different performance goals (based on different metrics)
54344|NCT01052181|Drug|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
54345|NCT01052181|Drug|placebo|2 sachets monthly for an year
54346|NCT01052194|Drug|Placebo|tablet, placebo b.i.d. for 12 weeks
54347|NCT01052194|Drug|VX-509|tablets, 25mg b.i.d. for 12 weeks
54348|NCT01052194|Drug|VX-509|tablet, 50 mg b.i.d. for 12 weeks
54349|NCT01052194|Drug|VX-509|tablet, 100 mg b.i.d. for 12 weeks
54350|NCT01052194|Drug|VX-509|tablet, 150 mg b.i.d. for 12 weeks
54351|NCT00030381|Drug|4'-iodo-4'-deoxydoxorubicin|Given IV
54632|NCT01055314|Drug|Ifosfamide|Given IV
54633|NCT01055314|Drug|Irinotecan Hydrochloride|Given IV
54634|NCT01055314|Other|Laboratory Biomarker Analysis|Correlative studies
54635|NCT01055314|Drug|Temozolomide|Given PO
54636|NCT01055314|Drug|Vincristine Sulfate Liposome|Given IV
54637|NCT01055327|Drug|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
54638|NCT01048125|Device|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
54639|NCT01048138|Drug|Biperiden Lactate|
53788|NCT01058668|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
54073|NCT00031070|Biological|Hepatitis A Vaccine (Inactivated)|
54074|NCT01061645|Drug|MOC31-PE|Immunotoxines
54075|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
54076|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
54077|NCT01061658|Other|Placebo|Placebo
54078|NCT01061671|Drug|simvastatin|40 mgms of simvastatin daily
54079|NCT01061671|Drug|Placebo|Matched placebo pill daily
54080|NCT01061697|Drug|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
54081|NCT01061710|Drug|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
54082|NCT01061723|Drug|Sarilumab|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
54083|NCT01061723|Drug|placebo|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
54084|NCT00031070|Drug|Efavirenz|
54085|NCT01061736|Drug|Sarilumab|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
54086|NCT01061736|Drug|Placebo (for sarilumab)|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
54087|NCT01061736|Drug|Methotrexate|Same weekly dose as received prior to enrollment
54088|NCT01061736|Drug|Folic Acid|According to local standard
54089|NCT01064193|Procedure|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
54090|NCT01064219|Drug|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
54091|NCT01064232|Drug|Risperidone|Risperidone Tablets 1 mg
54268|NCT01062022|Behavioral|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
54269|NCT01062048|Drug|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
54270|NCT01062048|Drug|Sulfonylurea|Sulfonylurea administered in general use according to the local label
54271|NCT01062048|Biological|Insulin|Insulin administered in general use according to the local label
54272|NCT01062061|Biological|VARIVAX™|Attenuated live varicella vaccine
54273|NCT01062087|Drug|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
54274|NCT01062100|Device|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
54275|NCT00031096|Drug|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
54276|NCT01062113|Drug|Celecoxib|Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with "moderate pain" or "severe pain"rated as 45.0 mm or more on the VAS
54277|NCT01062113|Drug|Celecoxib|Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
54278|NCT01062113|Drug|Placebo|Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
54279|NCT01062139|Drug|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
54570|NCT01050114|Drug|Oxybutynin ER|Oxybutynin ER in a 15 mg capsule will be taken daily for the course of the study.
54571|NCT01050127|Drug|ABT-436|See Arm Description for details.
54572|NCT01050127|Drug|Placebo|See Arm Description for details.
54573|NCT01050140|Dietary Supplement|high sugar diet|25% of dietary energy from fructose or glucose
54574|NCT01050153|Drug|Dalteparin sodium|Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
54575|NCT01050153|Drug|Dalteparin sodium/aspirin|Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
54576|NCT01050166|Other|Transplantation of labeled islets|
54577|NCT01050179|Other|carbon dioxide|sinusoidal carbon dioxide delivery
53846|NCT01056484|Other|"Wait-list" control|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
53847|NCT01056497|Drug|alpha lipoic acid|A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
53848|NCT01056510|Drug|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
53849|NCT00030654|Drug|vinblastine sulfate|
53850|NCT01056510|Drug|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
53851|NCT01056510|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
53852|NCT01056523|Drug|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
53853|NCT01056523|Drug|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
54157|NCT01059474|Drug|transdermal DMPS|12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.
Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS.
54158|NCT01059487|Other|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
54159|NCT01059500|Device|Pilot Phase|Non-intervention phase to test webtool technical reliability, accurate low PTP, and calibration.
54160|NCT01061749|Biological|Cixutumumab|Given IV
54161|NCT01061749|Other|Laboratory Biomarker Analysis|Correlative studies
54162|NCT01061749|Other|Pharmacological Study|Correlative studies
54163|NCT01061749|Drug|Selumetinib|Given PO
54164|NCT01061762|Behavioral|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
54165|NCT01061762|Behavioral|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
54640|NCT01048138|Drug|Placebo|
54641|NCT01048151|Biological|TNFerade™ Biologic|AdGVEGR.TNF.11D
54642|NCT01048164|Procedure|Massage|Chair Massage
54643|NCT01048177|Drug|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
54644|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
54645|NCT00029757|Drug|Estrogen|
54646|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
54647|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
54648|NCT01048203|Drug|ABR-215050|1 mg ABR-215050
54649|NCT01048216|Radiation|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
54650|NCT01048229|Drug|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
54651|NCT01048229|Drug|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
54652|NCT01048242|Drug|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
54653|NCT01048242|Drug|Placebo|placebo
54654|NCT01048255|Drug|VX-765|300mg Oral Tablet, 900mg TID
53716|NCT01058577|Procedure|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
53717|NCT01058603|Other|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
53718|NCT01058603|Other|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
53719|NCT01060943|Device|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
54092|NCT01064245|Drug|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
54093|NCT01064245|Other|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
54094|NCT01064258|Device|CPAP|CPAP at 4 cm H2O
54095|NCT01064258|Device|autoCPAP|autoCPAP working between 4 and 15 cm H2O
54404|NCT01049828|Other|No intervention|No treatment for tinnitus will occur in this study.
54405|NCT01049841|Drug|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
54406|NCT01049854|Drug|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
54407|NCT01049854|Drug|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
54408|NCT01049854|Drug|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
54409|NCT01049854|Drug|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
54410|NCT01049867|Procedure|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
54411|NCT01049880|Drug|Gemcitabine with escalating ascorbic acid|Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion
Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL.
54412|NCT00030082|Drug|isolated perfusion|
54413|NCT01049893|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
54578|NCT01050205|Behavioral|Group Lifestyle Balance Group or DVD|Participants assigned to Current Intervention will receive the intervention described below immediately after randomization.
GLB-GROUP: Members of the original DPP lifestyle team collaborated to adapt the individual intervention to a group-based program and to condense the program from 16 individual sessions delivered over 24 weeks to 12 group sessions delivered over 12-14 weeks. As in the original DPP lifestyle program, the goals of the GLBintervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity similar to a brisk walk.
GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the original Group Lifestyle Balance. GLB-DVD covers all of the sessions of the Group Lifestyle Balance program; sessions are portrayed by professional actors.
54579|NCT01050205|Behavioral|Delayed Intervention|Participants assigned to Delayed Intervention will receive the same intervention as Current Intervention Group, 12 months after randomization.
GLB-GROUP: Members of the original DPP lifestyle team collaborated to adapt the individual intervention to a group-based program and to condense the program from 16 individual sessions delivered over 24 weeks to 12 group sessions delivered over 12-14 weeks. As in the original DPP lifestyle program, the goals of the GLBintervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity similar to a brisk walk.
GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the original Group Lifestyle Balance. GLB-DVD covers all of the sessions of the Group Lifestyle Balance program; sessions are portrayed by professional actors.
54580|NCT00030121|Drug|recombinant human atrial natriuretic polypeptide|
54581|NCT01050218|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
54582|NCT01050231|Device|Type I Robotic Group (Functional activities and individual joints)|Subjects participate in 11 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder) , 3 days per week, 1 hour per day with the robotic exercise program.
54583|NCT01050231|Device|Type II Robotic therapy (Individual joints only)|Subjects participate in 11 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements as the patient plays interactive computer games.
54584|NCT01050244|Dietary Supplement|Whole soybean soymilk powder|
54585|NCT01052610|Drug|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
54586|NCT01052610|Drug|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
53660|NCT01063439|Drug|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
53661|NCT01063452|Device|Truvalve|Atkinson Product Design urinary slide valve
53662|NCT01063452|Other|Control (catheter drainage bag)|urinary catheter drainage bag
53663|NCT01063465|Device|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
53664|NCT00031278|Drug|CPG 7909|Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
54166|NCT00031070|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
54167|NCT01061762|Behavioral|Health Counseling|3-session of health improvement counseling to serve as an attention control.
54168|NCT01061775|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
54169|NCT01061788|Drug|AMG 479, Everolimus, Panitumumab|Dose Escalation Cohort #, Subjects, Everolimus, AMG 479
3-6 subjects, Study drug administered per dose level
3-6 subjects, Study drug administered per dose level
Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level
Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab
3-6 subjects, Study drug administered per dose level
3-6 subjects, Study drug administered per dose level
Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level
NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level
54170|NCT01061801|Behavioral|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
54171|NCT01061814|Drug|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
54172|NCT01061814|Drug|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
54173|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
54174|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
54473|NCT01047969|Procedure|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
54474|NCT01047982|Dietary Supplement|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
54475|NCT01047982|Other|folic acid 400 mcg|2 pills a day
54476|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.
54477|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2
Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.
54478|NCT01048008|Drug|DM-CHOC-PEN|DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.
At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.
The MTD will be where 2 DLTs are noted and the study is discontinued.
54479|NCT01049971|Device|wound protector|after minilaparotomy, the wound protector is applied
54480|NCT00030082|Drug|melphalan|
53720|NCT00031018|Drug|Aricept|
53721|NCT01060956|Other|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
53722|NCT01060956|Other|reporting "mixed growth" on urine culture|reporting "mixed growth" on urine culture
53723|NCT01060969|Drug|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
53724|NCT01060969|Drug|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
53725|NCT01060982|Device|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
53726|NCT01061008|Other|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
53727|NCT01061008|Other|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
53728|NCT01061021|Behavioral|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
53729|NCT01061021|Behavioral|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
53730|NCT01061034|Drug|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
53731|NCT00031018|Drug|IFN-alpha2A|
53732|NCT01061047|Drug|Ertapeneme|
53733|NCT01061060|Drug|Prostaglandin I2|oral
53734|NCT01061060|Drug|Placebo|oral
53735|NCT01061073|Drug|Omexel|
53736|NCT01061073|Drug|spasfon|
54009|NCT01064193|Procedure|biopsy|The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:
Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.
Insert carefully the pipelle de Cornier® in the uterus through the cervix.
Withdraw the piston to create a negative pression
Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several "in and out" cycle in order to collect a complete sample of the endometrium.
Withdraw the pipelle de Cornier® when filled with tissue
Reinsert internal piston to deposit sample in cup filled with a fixative.
54010|NCT01056679|Drug|Doxorubicine|50mg/m2 day 1 + 15
54414|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
54415|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
54416|NCT01049919|Device|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
54417|NCT01049919|Procedure|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
54418|NCT01049932|Drug|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
54715|NCT01055379|Drug|Placebo|Once daily for 12 weeks; orally
54716|NCT01055392|Drug|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
54717|NCT01055392|Drug|Placebo|Identical placebo tablets were administered twice-a-day for two years.
54718|NCT01055405|Drug|Sildenafil|Sildenafil 20mg TID orally
54719|NCT01055405|Other|Placebo|Placebo TID orally
54720|NCT00000903|Drug|Nelfinavir mesylate|
54721|NCT00030628|Procedure|surgery|
54722|NCT01055418|Dietary Supplement|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
54723|NCT01055431|Other|Control bread|Control bread
54724|NCT01055431|Other|Teff Bread|Teff bread
54725|NCT01055444|Drug|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
54726|NCT01055470|Drug|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
54727|NCT01055470|Drug|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
54728|NCT01055483|Drug|panobinostat/LBH589B|
54729|NCT01055496|Drug|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|Day 1:
Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)
Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)
Days 1-5:
Prednisone at 40 mg/m2
Each cycle is 3 weeks, with a maximum of 6 cycles total.
53665|NCT01063478|Drug|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
53666|NCT01063491|Procedure|bypass graft angiography|
53667|NCT01063504|Drug|teriparatide|
53668|NCT01063517|Drug|olaparib|100mg BID oral tablet continuous
53669|NCT01063517|Drug|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
53670|NCT01063517|Drug|Placebo|100mg BID oral tablet to match olaparib tablet
53671|NCT01063530|Device|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
53672|NCT01063530|Device|DIstilled water|Application of distilled water in cervical lesions
53673|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
53674|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
53675|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
53676|NCT01063569|Drug|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
53677|NCT01063569|Drug|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
53678|NCT01063582|Other|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
53679|NCT01063582|Procedure|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
53680|NCT01063595|Biological|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
53952|NCT01058993|Drug|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
54481|NCT01049971|Device|no wound protector|use of woven drape instead of wound protector
54482|NCT01049984|Drug|Rasagiline|1mg tablet daily for 18 weeks
54483|NCT01049984|Drug|Placebo|one tablet daily for 18 weeks
54484|NCT01050010|Other|MRI|dedicated extremity MRI
54485|NCT01050023|Device|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
54486|NCT01050023|Device|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
54487|NCT01050036|Procedure|autologous hematopoietic cell transplantation|Autologous peripheral blood stem cell (PBSCs) harvesting
After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy
Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy
Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.
Conditioning regimen for autologous HCT
Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)
Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)
Autologous cell infusion and waiting for engraftment
54488|NCT01050062|Drug|Telmisartan 80mg|Combination tablet
54489|NCT01050062|Drug|Telmisartan 40mg|Combination tablet
54490|NCT01050062|Drug|Hydrochlorothiazide 12.5mg|Combination tablet
54491|NCT00030095|Drug|2-methoxyestradiol|
54492|NCT01050075|Procedure|acupuncture therapy|acupuncture therapy
54493|NCT01050075|Drug|paclitaxel|Dosage to be determined by the treating physician
54794|NCT01053130|Behavioral|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
54795|NCT01053143|Biological|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
54796|NCT01053156|Drug|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
54797|NCT01053156|Drug|Placebo|Placebo will be given daily for 3 months.
54798|NCT00030446|Drug|carboplatin|
54799|NCT01055704|Drug|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
54800|NCT01055704|Drug|Codeine only|30 mg taken orally four times daily for 5 days
54801|NCT00030641|Drug|docetaxel|
54011|NCT01056679|Drug|DTIC|375mg/m2 day 1 + 15
54012|NCT01056679|Drug|Lenalidomide|day 1 - 21
54013|NCT00030667|Other|pharmacological study|Correlative studies
54014|NCT01056679|Drug|Vinblastine|6mg/m2 day 1 + 15
54015|NCT01056692|Drug|OC000459|Capsules twice daily for 15 days
54016|NCT01056692|Drug|Placebo|Capsules twice daily for 15 days
54017|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
54018|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
54019|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
54020|NCT01056705|Biological|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
54021|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
54022|NCT01056718|Drug|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
54023|NCT01056731|Drug|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
54024|NCT00030680|Radiation|radiation therapy|
54025|NCT01056744|Device|Percutaneous coronary intervention with stent implantation|Percutaneous coronary intervention with implantation of either:
- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),
or:
- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)
54026|NCT01056757|Drug|Ribavirin|1000 mg bid, po, q28days
54352|NCT01052220|Behavioral|BP education and BP self-regulation|The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.
The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done.
54730|NCT01055496|Drug|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|Day 1:
Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)
Day 2:
Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)
Days 1-4:
Dexamethasone at 40 mg
Each cycle is 3 weeks, with a maximum of 6 cycles total.
54731|NCT01048307|Device|Prontosan wound irrigation solution|Prontosan® Wound Irrigation Solution (experimental group):
• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound
Saline (control group):
cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
54732|NCT01048320|Drug|Gemcitabine|The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.
Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:
Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute.
53789|NCT01058681|Dietary Supplement|effect of metabolic variations on LH pulsatility|Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.
Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.
PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia.
53790|NCT01058694|Behavioral|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
53791|NCT01058707|Drug|MLN0128|MLN0128 will be administered orally with one of 4 different dosing schedules - once daily (QD), once weekly (QW), once daily for 3 days on;4 days off repeated each week (QDX3d QW), and once daily for 5 days on;2 days off repeated each week (QDX5d QW)
53792|NCT01058720|Dietary Supplement|Vitamin D3|2000 IU orally once daily for 12 weeks
53793|NCT01058733|Other|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
53794|NCT00030771|Procedure|Surgery|3-4 weeks after termination of radiotherapy
53795|NCT01058746|Other|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
53796|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|Antepartum Arm A: 200 mg/300 mg x 2 tablets for a total dose of 400 mg/600 mg orally once ideally at onset of labor or as soon as possible thereafter; 200 mg/300 mg (1 tablet) orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
Antepartum Arm C: 200 mg/300 mg orally once daily beginning at greater than or equal to 14 weeks gestation (at study entry) until Week 1 postpartum visit (up to 14 days)
Postpartum Arm A: 200 mg/300 mg orally once daily from Week 1 postpartum visit until completion of followup.
53797|NCT00031031|Drug|Kanglaite Injection (KLT)|
53953|NCT01059006|Procedure|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
53954|NCT01059019|Dietary Supplement|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
53955|NCT01059032|Other|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
53956|NCT01059045|Procedure|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
53957|NCT01059045|Other|Control|No intervention
53958|NCT00030797|Drug|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
53959|NCT01059058|Procedure|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
53960|NCT01059058|Procedure|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
53961|NCT01059058|Procedure|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
53962|NCT01059071|Drug|DFMO|Escalating doses of DFMO in a 3 +3 cohort design.
DFMO at current cohort Dose Level orally each day for 21 day cycles
Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID
53963|NCT01061411|Drug|Sunitinib Malate|Given PO
53964|NCT01061424|Behavioral|community health worker|community health worker provides home visits for education
53965|NCT00031057|Drug|Riboflavin|
53966|NCT01061424|Behavioral|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
53967|NCT01061437|Drug|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
54280|NCT01062139|Drug|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
54802|NCT01055704|Drug|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
54803|NCT01055704|Drug|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
54804|NCT01055717|Other|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
54805|NCT01055730|Other|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
54806|NCT01055743|Procedure|Radical resection|Radical resection of hepatocellular carcinoma
54807|NCT01055743|Drug|Fluorouracil Implants|Implanted during the surgical treatment
54808|NCT01055756|Drug|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
54809|NCT01055769|Drug|Linezolid|Linezolid OS 600 MG
Linezolid Tablet 600 MG
54810|NCT01055769|Drug|Linezolid|Linezolid Tablet 600 MG
Linezolid OS 600 MG
54811|NCT01055782|Device|Endoguide|Use of endoguide to facilitate completion of endoscopy
54812|NCT00030654|Drug|bicalutamide|
54813|NCT01055795|Drug|Bevacizumab, Everolimus and LBH589|Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589
3-6, All study drugs administered per dose level
3-6, All study drugs administered per dose level
3-6, All study drugs administered per dose level
Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds
54814|NCT01055808|Drug|Insulins|Individual dose and frequency and duration as determined by the treating physician
54815|NCT01055821|Drug|pegylated interferon and ribavirin|48 weeks
54816|NCT01055821|Biological|TG4040 + SOC|6 injections
57856|NCT01070862|Drug|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
57857|NCT01070862|Drug|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
57858|NCT01070862|Drug|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
57859|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
57860|NCT00031850|Drug|goserelin acetate|
54353|NCT01052220|Behavioral|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
54354|NCT01052233|Procedure|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
54355|NCT01052233|Procedure|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
54356|NCT01052246|Drug|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
54357|NCT01052246|Device|Pulsed dye laser|Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:
Wavelength 585 nm
Energy fluence 3 J/cm2
Pulse duration 0.35 msec
Spot size 7 mm
54358|NCT01052259|Drug|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
54359|NCT01052272|Drug|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
54360|NCT01052272|Drug|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
54361|NCT01052272|Drug|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
54362|NCT01054729|Drug|Placebo|Placebo to match sofosbuvir administered orally once daily
54363|NCT00000903|Drug|Lamivudine/Zidovudine|
54364|NCT00030576|Drug|erlotinib hydrochloride|
54365|NCT01054729|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
54366|NCT01054729|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
54367|NCT01054742|Drug|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
54368|NCT01054742|Drug|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
54655|NCT01048268|Drug|glucose-dependent insulinotropic polypeptide|For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.
For the following 40 minutes the volunteers will receive 2 pmol/kg body weight
53798|NCT01061151|Drug|Lamivudine-Zidovudine (3TC-ZDV)|Antepartum Arm B: 150 mg/300 mg orally twice daily beginning at greater than or equal to 14 weeks gestation (at study entry) through delivery and until 1 week postpartum visit (up to 14 days)
53799|NCT01061151|Drug|Lopinavir-ritonavir (LPV-RTV)|Antepartum Arm B: A daily dose of 400 mg/100 mg orally twice daily beginning at >/= 14 weeks gestation (at study entry) through 28 weeks gestation (through second trimester); daily dose of 600 mg/150 mg orally twice daily beginning at >/= 28 weeks gestation or at next visit (during third trimester) through delivery; daily dose of 400 mg/100 mg orally twice daily after delivery until Week 1 postpartum visit (up to 14 days).
Antepartum Arm C: dailly dose of 400 mg/100 mg orally twice daily beginning at > 14 weeks gestation (at study entry) through 28 weeks gestation (through second trimester); daily dose of 600 mg/150 mg orally twice daily beginning > 28 weeks gestation, or at the next visit (during third trimester) through delivery; daily dose of 400 mg/100 mg orally twice daily after delivery until week 1 postpartum visit (up to 14 days).
Postpartum Arm A: a total daily dose of 800 mg/200 mg orally twice daily from Week 1 postpartum visit until completion of followup.
53800|NCT01061177|Drug|Nilotinib|
53801|NCT01061190|Drug|Propranolol|oral application of 160 mg Propranolol for 30 days
53802|NCT01061203|Drug|Grazax|Treatment with 75.000 SQ-T once daily
53803|NCT01061203|Drug|Placebo|Tablet with no active grass component.
54096|NCT01064271|Drug|Risperidone|Risperidone Tablets 1 mg
54097|NCT01064284|Drug|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
54098|NCT00031395|Other|placebo|an inactive substance
54099|NCT01064284|Drug|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
54100|NCT01064297|Drug|Lamotrigine monotherapy|Lamotrigine monotherapy
54101|NCT01064297|Drug|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
54102|NCT01064297|Drug|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
54103|NCT01064310|Drug|pazopanib|oral anti-angiogenic treatment
54104|NCT01064310|Drug|sunitinib|oral anti-angiogenic treatment
54105|NCT01064323|Device|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
54106|NCT01064336|Drug|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
54107|NCT01064349|Drug|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
54281|NCT01062152|Drug|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM & 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
54282|NCT01064518|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) or Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
54283|NCT01064544|Procedure|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
54284|NCT01064557|Drug|all-trans retinoic acid (ATRA)|
54285|NCT01064570|Drug|all-trans retinoic acid (ATRA)|
54286|NCT00031447|Drug|Placebo|Placebo identical to oral acyclovir suspension in appearance and taste.
54287|NCT01064583|Other|cocoa|dissolved in water twice-daily intervention
54288|NCT01064596|Other|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
54289|NCT01064609|Procedure|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
54290|NCT01064609|Procedure|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
54291|NCT01064622|Drug|vismodegib|Given PO
54292|NCT01064622|Drug|gemcitabine hydrochloride|Given IV
54293|NCT01064622|Other|hydrocortisone/placebo|Given PO
54294|NCT01064635|Drug|Letrozole|letrozole for 2-3 years after Tam
54295|NCT01064635|Drug|Letrozole|Letrozole for 5 years after Tam
54296|NCT01064648|Drug|Cediranib Maleate|Given orally
54297|NCT00031460|Drug|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
54298|NCT01064648|Drug|Cisplatin|Given IV
54299|NCT01064648|Drug|Pemetrexed Disodium|Given IV
54300|NCT01064648|Other|Placebo|Given orally
54301|NCT01064661|Dietary Supplement|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10^10 cfu total bacteria per day)
54302|NCT01064661|Dietary Supplement|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10^10 cfu total bacteria per day)
57861|NCT01073553|Drug|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
57862|NCT01073566|Device|Finesse|Finesse Insulin Delivery Patch
57863|NCT01073566|Device|Pen/Syringe (Usual injection device)|Pen/Syringe
57864|NCT00032032|Drug|paclitaxel|
57865|NCT01073579|Drug|Sabril®|Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.
Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily.
57866|NCT01073605|Drug|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
57867|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
57868|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
57869|NCT01073618|Drug|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
57870|NCT01073631|Drug|voriconazole tablet|200 mg PO bid (orally, twice a day)
57871|NCT01073644|Drug|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
57872|NCT01073657|Other|Supported Education|Rehabilitation counseling using peers to achieve educational goals
57873|NCT01073657|Other|General Peer Support|Matched peer support for any personal goal other than education
57874|NCT01073670|Drug|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
57875|NCT00032032|Radiation|radiation therapy|
57876|NCT01073670|Drug|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
58139|NCT01074008|Drug|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
58140|NCT01074008|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
58141|NCT01074008|Other|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
54656|NCT00029770|Procedure|Chiropractic spinal manipulation|
54657|NCT01048268|Drug|Placebo|copy GIP infusion rates
54658|NCT01048281|Procedure|Blood draw|
54659|NCT01048281|Procedure|Tissue tumor biopsy|
54660|NCT01048294|Device|Original Energy Light,|9000 lux, 30 minutes in the morning
54661|NCT01048294|Device|Original Energy Light prototype|9000 lux 20 minutes in the morning
54662|NCT01048294|Device|Original Energy Light prototype|9000 lux 30 minutes in the morning
54663|NCT01050244|Dietary Supplement|Whole milk powder|
54664|NCT01050257|Drug|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
54665|NCT01050257|Drug|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
54666|NCT01050270|Drug|Ondansetron|4mgs iv bolus
54667|NCT01050270|Drug|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
54668|NCT01050270|Drug|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
54669|NCT00030147|Drug|Raloxefine (Evista)|
54670|NCT01050283|Procedure|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
54671|NCT01050309|Drug|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
54672|NCT01050322|Drug|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
54673|NCT01050322|Drug|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
54108|NCT01064362|Drug|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
54109|NCT00031434|Drug|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
54110|NCT01064362|Drug|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
54111|NCT01064375|Biological|tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
54112|NCT01064375|Device|Derma Vax (electroporation device)|Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
54113|NCT01064375|Biological|GM-CSF|GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
54114|NCT00030693|Biological|recombinant fowlpox-B7.1 vaccine|Given intratumorally
54115|NCT01056861|Drug|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
54116|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose
54419|NCT01049945|Drug|bendamustine hydrochloride|Given IV
54420|NCT01049945|Drug|lenalidomide|Given orally
54421|NCT01049945|Drug|dexamethasone|Given orally or IV
54422|NCT00030381|Other|pharmacological study|Correlative studies
54423|NCT01052285|Procedure|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
54424|NCT01052285|Procedure|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
54425|NCT01052285|Procedure|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
54426|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
54587|NCT00030407|Drug|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
54588|NCT01052623|Drug|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
54589|NCT01052636|Other|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
54590|NCT01052649|Other|Blood sampling|
54591|NCT01052662|Drug|Memantine|30mg/day Memantine orally everyday for 12 weeks
54592|NCT01052662|Drug|Memantine|15 mg/day Memantine orally everyday for 12 weeks
54593|NCT01052662|Drug|Placebo|Placebo orally everyday for 12 weeks
54594|NCT01052688|Other|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
54595|NCT01052701|Other|Ribavrin|Daily RBV alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV alone 600 mg orally every 12 hours (Body Weight >75 kg)
54596|NCT01052701|Drug|Abacavir plus Ribavirin|Daily RBV 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV 600 mg orally every 12 hours (Body Weight >75 kg)
PLUS
Daily ABC 300 mg orally every 12 hours
54597|NCT01052714|Behavioral|Behavioral Weight Loss Program|Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
54598|NCT00030407|Drug|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
54599|NCT01052727|Procedure|Laparoscopic Cholecystectomy|
54600|NCT01052766|Procedure|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
54601|NCT01052779|Drug|ferumoxytol|IV injection of ferumoxytol for a total cumulative dose of 1.02 g
54602|NCT01052779|Drug|iron sucrose|IV infusion of iron sucrose for a total cumulative dose of 1.0 g
58142|NCT01074021|Drug|Nimotuzumab|Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)
Radiotherapy:
IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.
CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin
Chemotherapy:
Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)
58143|NCT01074021|Drug|placebo plus chemoradiotherapy|Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy
Radiotherapy:
IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.
CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin
Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)
58144|NCT01074034|Device|B301 ASSURE Device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
58145|NCT01074047|Drug|Azacitidine|75 mg/m^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
58146|NCT01074047|Drug|Conventional Care Regimen|Physician pre-selects prior to randomization from one of the following:
Intensive chemotherapy (cytarabine 100-200 mg/m^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles
Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity
Best Supportive Care only; until study end
58147|NCT01074060|Drug|plerixafor|Given IV
58148|NCT00032084|Behavioral|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
58149|NCT01074060|Biological|filgrastim|Given SC
58150|NCT01074060|Drug|cyclophosphamide|Given IV
58151|NCT01074060|Procedure|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
58152|NCT01074060|Other|laboratory biomarker analysis|Correlative studies
58153|NCT01074073|Drug|Lurasidone HCl|lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).
Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).
On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast.
58154|NCT01074086|Drug|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
58493|NCT01072110|Procedure|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
54674|NCT01050322|Drug|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
53737|NCT01061099|Biological|Mesenchymal Stromal Cells|Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
53738|NCT01061112|Genetic|Pharmacogenetics|Fluconazole, tolbutamide, ketoprofen, flurbiprofen
53739|NCT01061151|Drug|Zidovudine (ZDV)|Antepartum Arm A: 300 mg orally twice daily beginning at greater than or equal to 14 weeks gestation (at study entry) through delivery
53740|NCT01061151|Drug|Nevirapine (NVP)|For women, 200 mg orally (one single dose) at onset of labor; for infants, oral suspension (dosing according to birth weight) once a day beginning as soon as possible after birth until there is no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever comes first.
Postpartum Arm B infants: NVP age-based daily dosing starting from Week 1 postpartum visit (day 6-14) and continuing for up to 2 weeks after complete breastfeeding cessation or completion of follow up, whichever comes first.
53741|NCT01063595|Biological|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
53742|NCT01063608|Biological|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
53743|NCT01063621|Drug|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
53744|NCT01063647|Drug|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
53745|NCT01063647|Drug|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
53746|NCT00031278|Drug|CPG 7909|Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
53747|NCT01063647|Drug|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
53748|NCT01063660|Drug|Treosulfan|14 g/m²/d day -6 to -4
53749|NCT01063686|Device|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
53750|NCT01063699|Procedure|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
54427|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
54428|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
54429|NCT01052298|Drug|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
54430|NCT01052311|Drug|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
54431|NCT01052311|Drug|Placebo|Placebo tablets once daily
54432|NCT01052311|Drug|Tredaptive|Tredaptive 1 g [Laropiprant 20 mg(LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
54433|NCT00000902|Drug|Zalcitabine|
54434|NCT00030394|Drug|imatinib mesylate|Given orally
54435|NCT01052324|Drug|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
54733|NCT01048320|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
54734|NCT01048320|Drug|Imatinib|Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.
Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total.
54735|NCT00029770|Drug|Acetaminophen|
54736|NCT01048333|Drug|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
54737|NCT01048333|Drug|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
54603|NCT01052792|Drug|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
54604|NCT01052805|Procedure|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
53681|NCT01065662|Drug|cediranib|Taken orally daily
53682|NCT01065675|Other|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
53683|NCT00031577|Radiation|radiation therapy|
53684|NCT01065688|Procedure|Roux-en Y reconstruction|surgical procedure
53685|NCT01065688|Procedure|Billroth-I reconstruction|surgical procedure
53686|NCT01065701|Drug|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
53687|NCT01065714|Drug|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
53688|NCT01065714|Drug|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
53689|NCT01065727|Other|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
53690|NCT01065727|Other|natalizumab|monthly natalizumab during 3 years
53691|NCT01065740|Other|Patient education|
53692|NCT01065753|Behavioral|Lifestyle Counseling|Diet control with exercise
53693|NCT01065766|Drug|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
53694|NCT00031590|Drug|Cisplatin|Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).
53695|NCT01065779|Drug|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
53696|NCT01065779|Drug|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
58494|NCT01072110|Procedure|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
58495|NCT01072123|Other|Quest for the Code|interactive asthma-based computer program
58496|NCT01072136|Other|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
58497|NCT01072136|Drug|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
58498|NCT01074567|Drug|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
58499|NCT01074593|Biological|Interferon beta-1a|12.000UI - single dose
58500|NCT01074593|Biological|Interferon beta-1a|12.000UI - Single dose
58501|NCT01074606|Device|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
58502|NCT01074619|Drug|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
58503|NCT01074619|Drug|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
58504|NCT01074632|Drug|Lurasidone HCl|
58505|NCT01074645|Drug|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
58506|NCT00032110|Other|laboratory biomarker analysis|Correlative studies
58507|NCT01074658|Device|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
58508|NCT01074671|Device|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
58509|NCT01074697|Drug|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
58510|NCT01074697|Drug|Placebo|Saline water
58511|NCT01074710|Drug|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
58512|NCT01074710|Drug|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
58513|NCT01074723|Dietary Supplement|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
53751|NCT01063712|Device|Nit-Occlud® PDA-R|Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.
The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure.
53752|NCT01063725|Dietary Supplement|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
53753|NCT01063725|Other|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
54027|NCT01056770|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
54028|NCT01056783|Drug|OC000459|OC000459 100mg, twice daily, tablet
54029|NCT01056783|Drug|Placebo|Placebo tablets to match OC000459 tablets, twice daily
54030|NCT01056796|Device|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
54031|NCT01056809|Procedure|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
54032|NCT01056822|Drug|1|Continue with same dose of MMF as patient was taking before randomisation
54033|NCT01056822|Drug|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
54034|NCT01056835|Drug|prostaglandin I2 analogue|
54035|NCT01059071|Drug|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
54036|NCT01059084|Drug|Valacyclovir|1000 mg tid
54037|NCT01059097|Procedure|Pancreaticoduodenectomy|
54038|NCT01059110|Drug|Salicylate ointment|cream, one application every night, for 90 days
54039|NCT01059110|Drug|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
54040|NCT01059110|Drug|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
54041|NCT00030797|Drug|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
54042|NCT01059110|Drug|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
54738|NCT01048333|Drug|Placebo|Placebo Diskus and Placebo Turbuhaler
54739|NCT01048346|Behavioral|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
54740|NCT01048359|Behavioral|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
54741|NCT01048359|Behavioral|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
54742|NCT01048359|Behavioral|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
54743|NCT01048385|Dietary Supplement|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
54744|NCT01048385|Dietary Supplement|Placebo|Treated with capsules containing the vehicle (Sesame oil).
54745|NCT01048398|Drug|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
54746|NCT00029770|Behavioral|Self-care|
54747|NCT01048398|Drug|paracetamol|Control group: intravenous paracetamol 1g
54748|NCT01048411|Drug|Naja-comp.|homeopathic remedy
54749|NCT01050426|Other|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
54750|NCT01050426|Other|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
53804|NCT01061216|Device|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
53805|NCT01061216|Device|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
53806|NCT01061229|Drug|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
53697|NCT01065805|Biological|18F-FLT|Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.
Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient
53698|NCT01065818|Drug|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-CRT and post-CRT prior to esophagectomy.
53699|NCT01065831|Behavioral|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
53968|NCT01061437|Drug|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
53969|NCT01061437|Drug|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
53970|NCT01061450|Drug|Simvastatin|80 mg once a day
53971|NCT01061450|Drug|Placebo|1 pill once a day
53972|NCT01061476|Device|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
53973|NCT01061476|Other|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
53974|NCT01061476|Other|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
53975|NCT01061489|Other|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
53976|NCT00031070|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
53977|NCT01061489|Other|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
53978|NCT01061502|Device|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
53979|NCT01061502|Device|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
53980|NCT01061515|Drug|Intraperitoneal Oxaliplatin|
53981|NCT01061515|Drug|Bevacizumab|
53982|NCT01061515|Drug|Capecitabine|
58514|NCT01074749|Device|Accent Pacemaker|Implantation of pacemaker
57568|NCT01067989|Drug|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|Cyclophosphamide Tab. 50mg, 1x1/day, continuously.
Capecitabine Tab. 500mg, 1+2/day, continuously.
Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.
Celecoxib Tab. 200mg, 1x2/day, continuously.
Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)
57569|NCT01068015|Other|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
57570|NCT01068028|Drug|ORM-12741|Ascending multiple doses to sequential panels
57571|NCT01068028|Drug|Placebo for ORM-12741|
57572|NCT01068041|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
57573|NCT01068054|Drug|tacrolimus|0.1% ointment,apply bid, 8 weeks
57574|NCT01068054|Drug|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
57575|NCT01068067|Other|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
57576|NCT01068067|Drug|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
57577|NCT01068093|Drug|Ezetimibe|10mg daily
57578|NCT00031694|Drug|paclitaxel|Given IV
57579|NCT01070355|Drug|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
57580|NCT01070355|Drug|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
57581|NCT01070368|Other|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
57582|NCT00031824|Drug|cyclosporine|
57583|NCT01070381|Device|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
57584|NCT01070381|Device|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
57585|NCT01070394|Drug|Lisdexamfetamine Dimesylate-LDX|
54043|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
54044|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
54045|NCT01059136|Drug|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
54046|NCT01059149|Device|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
54047|NCT01059162|Device|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
54048|NCT01059175|Device|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
54049|NCT01059175|Device|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
54369|NCT01054768|Dietary Supplement|alpha-lipoic acid and acetyl-L-carnitine|none to report
54370|NCT01054768|Drug|Placebo|none to report
54371|NCT01054781|Drug|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
54372|NCT01054794|Device|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
54373|NCT01054820|Drug|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
54374|NCT01054833|Procedure|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
54375|NCT00030589|Drug|bexarotene|
54376|NCT01054846|Other|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
54377|NCT01054846|Other|Bicycle helmet education only|As described under the respective arm
54378|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
54379|NCT01054859|Other|alcohol|0.5 g/kg alcohol
53807|NCT01061229|Other|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
53808|NCT00031044|Drug|Enfuvirtide|
53809|NCT01061242|Behavioral|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
53810|NCT01061255|Other|Evaluation of the stress|Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).
Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.
Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender.
53811|NCT01061268|Drug|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
53812|NCT01061268|Drug|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
53813|NCT01063777|Other|A 12 week exercise therapy program and patient education.|The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.
All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
53814|NCT01063777|Other|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
53815|NCT01063790|Behavioral|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
53816|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
53817|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
54117|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
54118|NCT01056874|Drug|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
54119|NCT01056900|Procedure|Autologous Chondrocyte Implantation|Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)
Directions and dosage:
Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.
54120|NCT01056913|Device|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
53983|NCT01061528|Drug|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
53984|NCT01061541|Biological|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
53985|NCT01061541|Biological|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
53986|NCT01061541|Biological|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
53987|NCT00031070|Drug|Cyclosporine|
53988|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
53989|NCT01064037|Drug|Placebo|Infusion during 48h
54303|NCT01064674|Other|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
54304|NCT01064687|Drug|LY2189265|
54305|NCT01064687|Drug|Exenatide|
54306|NCT01064687|Drug|Placebo|
54307|NCT01064687|Drug|Metformin|
54308|NCT00031460|Drug|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
54309|NCT01064687|Drug|Pioglitazone|
54310|NCT01064700|Device|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
54311|NCT01057173|Procedure|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
54312|NCT01057186|Dietary Supplement|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
54313|NCT01057186|Drug|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
54314|NCT01057199|Genetic|RNA analysis|
54315|NCT01057199|Genetic|gene expression analysis|
54316|NCT01057199|Genetic|mutation analysis|
54317|NCT00030719|Biological|filgrastim|
57586|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
57587|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
57588|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
58155|NCT01074099|Biological|BMAC|Injection of BMAC into ischemic myocardium during CABG
58156|NCT01074099|Procedure|CABG only|Control subjects will undergo CABG surgery without BMAC injection
58157|NCT01074112|Device|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
58158|NCT01066377|Dietary Supplement|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10^8 - 10^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested).
58159|NCT01066390|Biological|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
58160|NCT01066403|Drug|Pergolide|0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.
Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group.
58161|NCT01066416|Procedure|Endoscopic Sinus Surgery|
58162|NCT00031590|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
58163|NCT01066416|Other|medical therapy|Subjects will undergo surgery 6 months after randomization
58164|NCT01066429|Drug|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
58165|NCT01066442|Drug|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
58166|NCT01066468|Drug|Gleevec/Glivec|
58167|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
58168|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
54380|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD
54381|NCT01054872|Biological|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
54382|NCT01054872|Biological|HIV-1 recombinant Ad5 vaccine|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
54383|NCT01054885|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
54384|NCT01054885|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
54385|NCT01054885|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
54386|NCT01047709|Device|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
54387|NCT01047722|Drug|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
54388|NCT01047722|Procedure|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
54675|NCT01050335|Behavioral|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
54676|NCT01050348|Drug|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
54677|NCT01050348|Drug|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
54678|NCT01050361|Procedure|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
54679|NCT01050374|Drug|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
54680|NCT00030147|Drug|Rimostil|
54681|NCT01050374|Drug|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
54682|NCT01050387|Dietary Supplement|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
54683|NCT01050400|Genetic|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
54684|NCT01052831|Drug|Placebo|50-100 mg qd for 8 weeks
54121|NCT01056913|Other|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
54122|NCT01056926|Behavioral|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
54123|NCT01056926|Drug|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
54124|NCT01056926|Drug|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
54125|NCT00030693|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
54126|NCT01056939|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
54127|NCT01056939|Device|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
54128|NCT01056952|Procedure|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 > 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
54129|NCT01056952|Procedure|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher & Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 > 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
54130|NCT01056952|Procedure|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 > 90%
54131|NCT01056965|Drug|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
54132|NCT01056965|Drug|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
54133|NCT01056991|Other|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
54134|NCT01056991|Other|warming blanket|
54135|NCT01057017|Biological|intervention|
54136|NCT00030693|Other|laboratory biomarker analysis|Correlative studies
54436|NCT01052337|Drug|anaesthetics: sevofluorane|0.5%of sevofluorane with air
54437|NCT01052363|Drug|Bevacizumab, CA4P|
54438|NCT01052376|Device|Confocal endomicroscopy|
54318|NCT01057199|Genetic|protein expression analysis|
54319|NCT01057199|Other|fluorescence activated cell sorting|
54320|NCT01057199|Other|laboratory biomarker analysis|
54321|NCT01057212|Drug|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
54322|NCT01057212|Drug|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
54323|NCT01057225|Drug|carfilzomib|Given IV
54324|NCT01057225|Drug|cyclophosphamide|Given orally
54325|NCT01057225|Drug|thalidomide|Given orally
54326|NCT01057225|Drug|dexamethasone|Given orally
54605|NCT01052831|Drug|Naltrexone|50-100 mg qd for 8 weeks
54606|NCT01055236|Drug|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
54607|NCT00030615|Drug|decitabine|Given IV
54608|NCT01055249|Drug|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
54609|NCT01055249|Drug|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
54610|NCT01055262|Device|Heatwrap 1|8 hours continuous topically-applied heat
54611|NCT01055275|Device|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
54612|NCT01055301|Drug|bortezomib|
54613|NCT01055301|Drug|cisplatin|
54614|NCT01055301|Drug|cyclophosphamide|
54615|NCT01055301|Drug|dexamethasone|
54616|NCT01055301|Drug|doxorubicin hydrochloride|
54617|NCT01055301|Drug|etoposide|
54618|NCT00030615|Other|pharmacological study|Correlative studies
58169|NCT01066481|Drug|Placebo|Placebo three times daily for 6 months
58170|NCT01066494|Drug|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
58171|NCT01066520|Drug|Traumeel S ointment|2 g, 3 times daily topical during 14 days
58172|NCT01066520|Drug|Traumeel S gel|2 g, 3 times daily topical during 14 days
58173|NCT00000912|Drug|Nelfinavir mesylate|
58174|NCT00031616|Drug|brivudine phosphoramidate|
58193|NCT00031733|Biological|tyrosinase peptide|
58194|NCT01069107|Other|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
58195|NCT01069120|Drug|Proellex|2, 25 mg capsules once per day
58196|NCT01069120|Drug|Proellex|1, 25 mg capsule once per day
58197|NCT01069133|Drug|Rifaximin|550mg BID open-label
58198|NCT01069133|Drug|rifaximin|550mg PO BID
58199|NCT01069146|Procedure|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
58200|NCT01071356|Behavioral|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
58201|NCT01071356|Behavioral|Single session of Motivational Interviewing|
58202|NCT01071369|Drug|Xylocaine|0.5% Xylocaine
58203|NCT01071369|Drug|Xylocaine and Celestone|non-particulate Celestone
58204|NCT01071395|Drug|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
58205|NCT01071395|Drug|Placebo|Sugar pill given 3 times daily
54685|NCT01052844|Drug|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
54686|NCT01052844|Drug|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
54687|NCT00030420|Drug|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
54688|NCT01052857|Procedure|acupuncture|acupuncture application
54689|NCT01052870|Drug|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
54690|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
54691|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
54692|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
53754|NCT01063738|Dietary Supplement|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
53755|NCT01063738|Other|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
53756|NCT01063738|Other|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
53757|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
53758|NCT01063738|Dietary Supplement|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
53759|NCT01063751|Device|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
53760|NCT01063764|Drug|Levetiracetam|First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.
Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted.
54439|NCT01052389|Drug|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
54440|NCT01052389|Drug|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
54441|NCT00030589|Drug|methoxsalen|
54442|NCT01054885|Drug|Placebo|Placebo
54443|NCT01054898|Behavioral|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
54444|NCT01054898|Behavioral|usual community services|standard care for abused women in the community
54445|NCT01054911|Drug|Sunitinib|All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.
54446|NCT01054911|Procedure|Surgery|Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
54447|NCT01054937|Drug|4SC-203|i.v. administration
54448|NCT01054937|Drug|Placebo|i.v. administration
54449|NCT01054950|Behavioral|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
54450|NCT01054963|Behavioral|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
54451|NCT01054976|Drug|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
54452|NCT00030589|Procedure|UV light therapy|
54453|NCT01054989|Biological|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
54454|NCT01055002|Biological|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
54751|NCT01050439|Procedure|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
54619|NCT01055301|Drug|lenalidomide|
54620|NCT01055301|Drug|melphalan|
54621|NCT01055301|Drug|thalidomide|
54622|NCT01055301|Genetic|gene expression analysis|
54623|NCT01055301|Genetic|microarray analysis|
54624|NCT01055301|Other|laboratory biomarker analysis|
54625|NCT01055301|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
54626|NCT01055314|Biological|Cixutumumab|Given IV
54627|NCT01055314|Drug|Cyclophosphamide|Given IV
54628|NCT01055314|Biological|Dactinomycin|Given IV
54629|NCT00030615|Other|laboratory biomarker analysis|Correlative studies
54630|NCT01055314|Drug|Doxorubicin Hydrochloride|Given IV
54631|NCT01055314|Drug|Etoposide|Given IV
53700|NCT01065844|Drug|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
53701|NCT01065857|Drug|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
53702|NCT00030758|Biological|pegfilgrastim|
53703|NCT01058434|Drug|TKI258|
53704|NCT01058447|Drug|AZD1981|Oral tablet, 250 mg, single dose
53705|NCT01058460|Procedure|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
53706|NCT01058486|Behavioral|Self-Management and Motivational Interviewing|Post hospital discharge, patients will be referred (<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.
A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.
Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts.
53707|NCT01058499|Behavioral|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
58206|NCT01071408|Other|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
58207|NCT01071421|Device|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
58208|NCT00031889|Drug|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
58209|NCT01071434|Procedure|MR Imaging|
58210|NCT01071447|Other|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
58515|NCT01074762|Behavioral|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
58516|NCT01074775|Biological|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
58517|NCT00032123|Drug|erlotinib hydrochloride|
58518|NCT01074788|Behavioral|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
58519|NCT01074801|Other|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
58520|NCT01074801|Other|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
58521|NCT00031655|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
58522|NCT01067092|Behavioral|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
53761|NCT01066026|Device|Injection of hyaluronic acid in nasolabial folds|The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:
In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;
In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.
Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula.
53762|NCT01066039|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
53763|NCT01066052|Other|0.15 IU/kg/day GH|Group Q = 0.15 IU/kg/day (was interventional at the time of protocol writing)
53764|NCT01066052|Other|0.1 IU/kg/day GH|Group U = 0.1 IU/kg/day (was interventional at the time of protocol writing)
53765|NCT01066078|Other|Echocardiography and SonR recording|
53766|NCT01066091|Other|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
53767|NCT01066091|Other|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
53768|NCT00031590|Drug|Lomustine|Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).
53769|NCT01066091|Other|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
53770|NCT01066104|Drug|Xolair|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
53771|NCT01066117|Other|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
54050|NCT01059188|Drug|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
54051|NCT01059188|Drug|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
54052|NCT00030810|Radiation|Hyperfractionated|Hyperfractionated radiotherapy
54053|NCT01059188|Drug|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
54054|NCT01059188|Radiation|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
54055|NCT01059188|Procedure|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
56021|NCT01080768|Drug|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
56022|NCT01080768|Drug|Amlodipine|Amlodipine 5 mg/day.
56023|NCT01080768|Drug|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
56024|NCT01080768|Drug|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
54817|NCT01055821|Biological|TG4040 + SOC|13 injections
54818|NCT01055834|Drug|Eszopiclone 3 mg|Group A Period I, Group B Period II:
Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours.
Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.
Group B Period III:
Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.
Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast & the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration.
54819|NCT01055834|Drug|Eszopiclone 1 mg|Group A Period II, Group B Period I:
Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.
Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug.
54820|NCT01055847|Drug|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
54821|NCT01048411|Drug|Placebo|s.c. injection of NaCl-solution three times a week
54822|NCT01048424|Device|RESPeRATE|RESPeRATE is a commercially available, "walkman-like" device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate.
54823|NCT01048424|Other|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
54824|NCT01048437|Behavioral|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
54825|NCT01048437|Behavioral|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
54826|NCT01048450|Radiation|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
54252|NCT01059604|Drug|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
54253|NCT01059617|Biological|GSK Biologicals' FluLaval®|Intramuscular injection
54254|NCT01059617|Biological|Placebo (saline)|Intramuscular injection
54255|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
54256|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
54257|NCT01059630|Drug|RO5072759|Intravenous repeating dose
54258|NCT01059630|Drug|bendamustine|Intravenous repeating dose
54259|NCT00030849|Biological|recombinant interferon alfa|
54260|NCT01061918|Device|ReSTOR|20 patients in the ReSTOR group.
54553|NCT01048034|Drug|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
54554|NCT01048047|Drug|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
54555|NCT01048060|Procedure|Bone marrow specimen banking|
54556|NCT01048086|Drug|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children <12 kg.
54557|NCT01048086|Drug|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
54558|NCT01048099|Procedure|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
54559|NCT01048099|Drug|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
54560|NCT01048099|Drug|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
54561|NCT01048112|Biological|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
54562|NCT01048125|Device|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
54563|NCT00029731|Drug|Arginine hydrochloride|
55258|NCT01046942|Drug|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
55259|NCT01046955|Drug|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
55524|NCT01047293|Drug|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
55525|NCT01047306|Other|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
55526|NCT01047319|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
55527|NCT01047332|Device|Wallstent|Covered wallstent
55528|NCT00029523|Drug|Intrathecal cytarabine (also known as ara-C)|
55529|NCT01047332|Device|Non-Covered Wallstent|non-covered wallstent
55530|NCT01047345|Biological|V503|V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
55531|NCT01047345|Biological|Placebo to V503|Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
55532|NCT01047358|Drug|Aromasin|25 mg table QD
55533|NCT01047358|Drug|Aromasin|25 mg table QD
55534|NCT01047384|Procedure|acupuncture-moxibustion therapy|
55535|NCT01047384|Procedure|Regular therapy|
55536|NCT01047397|Drug|1278863A|25mg, 50mg, 100mg
55537|NCT01047397|Drug|Placebo|matching placebo
55538|NCT01047410|Other|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
55539|NCT00029536|Biological|Natural Progesterone|200mg Progesterone Lozenges and Matched Placebo Lozenges
55540|NCT01049425|Drug|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
55541|NCT01049438|Drug|nasal mupirocin|twice daily for 10 days
55542|NCT01049438|Drug|topical 3% hexachlorophene body wash|daily for 10 days
55032|NCT01053533|Drug|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction& supportive therapy and antivirus therapy when necessary
55033|NCT01053533|Drug|western therapy|supportive therapy and antivirus therapy when necessary
55034|NCT01053546|Behavioral|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
55035|NCT00030459|Drug|vinorelbine tartrate|
55036|NCT01053546|Other|questionnaire administration|Ancillary study
55327|NCT01054092|Drug|ASP1941|oral
55328|NCT01054105|Drug|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
55329|NCT01054118|Drug|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
55330|NCT01054118|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
55331|NCT01054118|Drug|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
55332|NCT01054118|Drug|Placebo|Placebo suspension and placebo capsule administered as single doses
55333|NCT01054131|Behavioral|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
55334|NCT01054144|Drug|Lenalidomide|Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;
Dose Level -4: Discontinue
55335|NCT00030524|Drug|gefitinib|
55336|NCT01054144|Drug|Prednisone|Starting Dose: 100 mg PO days 1-5 every 28 days;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;
Dose level -3: Discontinue
55337|NCT01054144|Drug|Dexamethasone|Starting Dose: 40 mg daily on days 1 - 4 every 28 days;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;
Dose level -3: Discontinue
55338|NCT01046981|Procedure|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
54827|NCT01048450|Procedure|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
54828|NCT01048450|Procedure|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
54829|NCT00029770|Drug|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
54830|NCT01048463|Drug|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
53854|NCT01058746|Other|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
53855|NCT01058759|Drug|Enoxaparin|
53856|NCT01058759|Other|No Enoxaparin|
53857|NCT01058772|Other|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score < 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
53858|NCT01058785|Biological|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
53859|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
53860|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
53861|NCT01058850|Biological|Rindopepimut|250 or 500 mcg; intradermal injection
53862|NCT01058863|Drug|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
53863|NCT00030784|Drug|ifosfamide|
53864|NCT01058863|Drug|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
53865|NCT01058863|Other|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
54564|NCT01048125|Behavioral|Mental Stress Test (Color Word Test)|A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word "green" is written in blue ink, they will say "blue." This mental stress procedure will be used to cause brief changes in heart rate and blood pressure.
54565|NCT01048125|Drug|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
54566|NCT01048125|Other|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
54567|NCT01050114|Drug|onaBoNT-A|onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.
Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder.
54568|NCT00000902|Drug|Lamivudine|
54569|NCT00030108|Drug|ixabepilone|
53641|NCT01060878|Drug|PYM50028|IMP
53642|NCT01060878|Drug|Placebo|Matching placebo comprising identical vehicle to active doses
53643|NCT01060891|Drug|colimycin|
53644|NCT01060904|Drug|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
53645|NCT01060904|Drug|doxorubicin|25 mg/m2 IV every 2 weeks
53646|NCT00000906|Drug|Ritonavir|
53647|NCT00031005|Procedure|modified stem cell transplant|
53648|NCT01060904|Drug|vinblastine|6 mg/m2 IV every 2 weeks
53649|NCT01060904|Drug|dacarbazine|375 mg/m2 IV every 2 weeks
53650|NCT01060904|Drug|bleomycin|10 units/m2 IV every 2 weeks
53651|NCT01060904|Drug|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
53652|NCT01060917|Device|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
55543|NCT00030004|Drug|midazolam|
55544|NCT01049438|Drug|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
55545|NCT01049451|Drug|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
55866|NCT00033358|Other|laboratory biomarker analysis|Correlative studies
55867|NCT01085630|Drug|pemetrexed disodium|Given IV
55868|NCT01085630|Other|clinical observation|
55869|NCT01085643|Drug|Lubiprostone|24mcg PO taken once
55870|NCT01085643|Drug|Placebo|24mcg placebo capsule taken once
55871|NCT01085656|Drug|OXi4503|Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.
Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.
Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent.
55872|NCT01085669|Device|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
55873|NCT01085682|Behavioral|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
55874|NCT01085682|Behavioral|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
55875|NCT01085695|Drug|rabeprazole|10 mg normal tablet
55876|NCT01085695|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
55877|NCT00033371|Drug|Celecoxib|Given 400 mg PO twice a day
55878|NCT01085695|Drug|rabeprazole|Type 2 granule containing rabeprazole 10 mg
55879|NCT01085695|Drug|rabeprazole|Type 3 granule containing rabeprazole 10 mg
55880|NCT01085708|Drug|rabeprazole|10 mg normal tablet
55881|NCT01085708|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
55339|NCT01046994|Procedure|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
55340|NCT01046994|Drug|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
55341|NCT01047007|Drug|MK1775|MK1775 capsule, dosage of 65 mg or 120 mg, orally twice daily on days 1-5 of a 21 day cycle.
55342|NCT01047007|Drug|Comparator: MK1775 in combination with 5-FU|MK1775 capsule, dosage ranging from 20 mg to 200 mg, orally twice or once daily on Days 1-5 in a 21 day cycle. 5-Fluorouracil, from 1000 mg/m2/day to 750 mg/m2/day, intravenous infusion for 4 consecutive days starting on Day 1.
55343|NCT01047007|Drug|Comparator: MK1775 in combination with 5-FU/CDDP|MK1775 capsule, dosage ranging between 20 mg to 200 mg, orally twice or once daily on Days 1-5 in a 21day cycle; 5-Fluorouracil, from 1000 mg/m2/day to 750 mg/m2/day, intravenous infusion for 4 consecutive days starting on Day 1; Cisplatin, between 60 mg/m2 to 100 mg/m2, intravenous infusion on Day 1.
55593|NCT01054586|Drug|Intervention A Standard dose|HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of <2.0.
55594|NCT01054586|Drug|Intervention B Reduced Dose|HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
55595|NCT01054586|Drug|Intervention C|HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
55596|NCT01047410|Other|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
55597|NCT01047423|Drug|Simvastatin|40mg encapsulated once daily for 12 weeks
55598|NCT01047423|Drug|Placebo|Encapsulated oral once daily for 12 weeks
55599|NCT01047436|Drug|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
55600|NCT01047436|Drug|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
55601|NCT01047449|Procedure|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
55602|NCT01047449|Dietary Supplement|Fish oil supplementation vs placebo|Fish oil supplementation [1g tablets (55% fish oils - EPA:DHA 33%:22%)] taken twice daily for 1 year post-op
55603|NCT01047462|Procedure|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
53866|NCT01058876|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
53867|NCT01058889|Device|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
53868|NCT01058902|Drug|Aspirin 75 mg|Aspirin 75 mg
53869|NCT01058902|Other|no aspirin|nothing
53870|NCT01058915|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
53871|NCT01058915|Drug|Rosuvastatin 40mg|Rosuvastatin 40mg/day
54175|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
54176|NCT01061853|Drug|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE*)1mg/ml bid during 3 months
54177|NCT00031070|Biological|Rabies Vaccine|
54178|NCT01061853|Drug|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE*)0.05% bid during 3 months
54179|NCT01061866|Drug|3-phthalimidoglutarimide (Thalidomide)|Thalidomide at 200 mg dosage bid was administered during a twelve month period.
54180|NCT01061905|Behavioral|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
54181|NCT01061905|Behavioral|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
54182|NCT01061905|Behavioral|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
54183|NCT01061918|Device|Tecnis MF|20 patients in the Tecnis MF group.
54184|NCT01064375|Drug|Cyclophosphamide|One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
54185|NCT01064388|Drug|AZD9742|IV infusion, 15 days
54186|NCT01064388|Drug|Placebo|IV infusion, 15 days
54187|NCT01064401|Biological|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
54188|NCT01064401|Drug|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
54189|NCT01064401|Biological|Interferon beta-1a|Interferon beta-1a for intramuscular injection
55183|NCT01048983|Behavioral|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
55184|NCT01049009|Drug|Nebivolol|Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then "cross over" to take 10 weeks of the comparator drug.
55185|NCT01049009|Drug|Metoprolol XL|Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then "cross over" to take 10 weeks of the comparator drug.
55186|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (<=) 14 years.
55187|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
55188|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to < 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
55189|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
55190|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
55191|NCT00029861|Drug|Rimonabant (SR141716)|
55192|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
55193|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
55194|NCT01051141|Behavioral|Intervener-delivered Brief Intervention (IBI)|The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a "change plan" tailored for each participant.
55195|NCT01051141|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
55196|NCT01051154|Dietary Supplement|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
55465|NCT01049386|Other|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
55882|NCT01085708|Drug|rabeprazole|Type 2 granules containing rabeprazole 10 mg
55883|NCT01085708|Drug|rabeprazole|Type 3 granules containing rabeprazole 10 mg
55884|NCT01085721|Drug|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
55885|NCT01085721|Drug|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
55886|NCT01085734|Drug|Avastin|1.25mg intravitreally
55887|NCT01085734|Drug|Osurdex|0.7mg intravitreally
54966|NCT01053507|Drug|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
54967|NCT01053507|Drug|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
54968|NCT01055509|Behavioral|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
54969|NCT00030628|Radiation|WBRT|
54970|NCT01055522|Drug|Arm 1: L19IL2 + Dacarbazine|RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.
Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.
Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.
DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first
54971|NCT01055522|Drug|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
54972|NCT01055522|Drug|ARM 2: L19IL2 + Dacarbazine|RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.
DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first
54973|NCT01055535|Drug|Microplasmin|125 µg intravitreal injection
54974|NCT01055561|Other|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
54975|NCT01055600|Drug|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
55604|NCT01047475|Drug|MB-6|6# TID with meal
55605|NCT01047475|Drug|Placebo|6# TID with meal
55606|NCT00029575|Device|Surgi-Vision Guidewire Coil|
55607|NCT01047488|Drug|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
55608|NCT01047488|Drug|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
55609|NCT01047488|Drug|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
55610|NCT01047488|Drug|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
55611|NCT01047501|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
55955|NCT01083329|Behavioral|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
55956|NCT01083329|Drug|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
55957|NCT01083329|Drug|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
55958|NCT01083342|Drug|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
55959|NCT01083368|Drug|temsirolimus|Given IV
55960|NCT01083368|Biological|bevacizumab|Given IV
55961|NCT01083368|Genetic|polymorphism analysis|Correlative studies
55962|NCT01083368|Other|laboratory biomarker analysis|Correlative studies
55963|NCT00033241|Drug|erlotinib hydrochloride|
55964|NCT01083381|Drug|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
55965|NCT01083381|Drug|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
55966|NCT01083394|Device|PTA|PTA using a conventional balloon
55967|NCT01083394|Device|PTA with PEB|PTA using a paclitaxel eluting balloon
54190|NCT00031434|Drug|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
54191|NCT01064401|Drug|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
54192|NCT01064414|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
54193|NCT01064414|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
54194|NCT01064440|Genetic|Low Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
54494|NCT01050075|Other|questionnaire administration|Ancillary study
54495|NCT01050075|Procedure|management of therapy complications|To be determined by the treating physician
54496|NCT01050088|Dietary Supplement|sucrose solution|5cc 5% sucrose solution P/O
54497|NCT01050088|Dietary Supplement|Saline|5cc saline p/o
54498|NCT01050101|Dietary Supplement|No fiber|The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.
Test meal consists of breakfast meals containing muffins and yogurt beverage/shake.
54499|NCT01050101|Dietary Supplement|Low GI high fiber viscous meal|Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).
Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake.
54500|NCT01050101|Dietary Supplement|Low GI high fiber non-viscous|Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).
Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake.
54501|NCT01052389|Drug|Haloperidol|Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.
Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day).
54502|NCT01052402|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
54503|NCT01052415|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
55466|NCT01049386|Procedure|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
55467|NCT01049399|Drug|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
55468|NCT01049399|Drug|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
55469|NCT00000228|Drug|Buprenorphine|
55470|NCT00000902|Drug|Nevirapine|
55471|NCT00030004|Procedure|spinal manipulation|
55472|NCT01049399|Drug|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
55473|NCT01049412|Drug|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
55474|NCT01049412|Drug|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
55475|NCT01049425|Drug|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
55476|NCT01049425|Drug|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
55477|NCT01049425|Drug|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
55478|NCT01049425|Drug|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
55479|NCT01051609|Behavioral|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
55480|NCT01051609|Other|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
55481|NCT00000902|Drug|Zidovudine|
55482|NCT00030342|Biological|sargramostim|
55483|NCT01051609|Procedure|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
55484|NCT01051622|Other|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
55485|NCT01051635|Drug|LMP 400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
54976|NCT01055639|Behavioral|In-Person Acceptance and Commitment Therapy|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
54977|NCT01055639|Behavioral|Telehealth Acceptance and Commitment Therapy|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
54978|NCT01055652|Drug|Dapagliflozin|10mg, oral, once daily
54979|NCT01055665|Other|cognitive behavior therapy|6 cognitive behavior therapy groups
54980|NCT00030641|Biological|oblimersen sodium|
54981|NCT01055678|Drug|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
55260|NCT00029497|Procedure|Acupuncture|
55261|NCT01046968|Dietary Supplement|Lepticore|300 mg twice daily
55262|NCT01046981|Procedure|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
55263|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
55264|NCT01049035|Biological|Pentacel®, M-M-R®II, Varivax®, Prevnar®, RotaTeq®, Engerix-B®|As in the prescribing information (All are licensed vaccines)
55265|NCT01049035|Biological|Pentacel®, M-M-R®II, Varivax®, Prevnar®, RotaTeq®, Engerix-B®|As in the prescribing information (All are licensed vaccines)
55266|NCT01049048|Dietary Supplement|Vitamin D3|2500 IU Vitamin D3
55267|NCT01049048|Dietary Supplement|Placebo|No (0 IU) vitamin D3 added to cookie.
55268|NCT01049061|Drug|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
55269|NCT01049074|Other|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
55270|NCT01049074|Other|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
55271|NCT00029874|Drug|Minocycline|
55272|NCT01049087|Radiation|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
55968|NCT01083394|Procedure|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
55969|NCT01083407|Drug|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
55970|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
55971|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
55972|NCT01085760|Drug|Vancomycin|Comparison of different drug doses
55973|NCT01085773|Behavioral|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
55974|NCT01085773|Behavioral|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
55975|NCT01085786|Drug|14-day sequential treatment|14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
55037|NCT01053546|Procedure|quality-of-life assessment|Ancillary study
55038|NCT01053559|Drug|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
55039|NCT01053572|Procedure|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
55040|NCT01053585|Drug|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
55041|NCT01053585|Drug|Placebo|Placebo single 'dose' 90 minutes prior to study
55042|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
55043|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
55044|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
55045|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
55046|NCT00030472|Drug|pegylated liposomal doxorubicin hydrochloride|
55047|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
55048|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
54504|NCT01052428|Drug|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
54505|NCT00030394|Other|laboratory biomarker analysis|Correlative studies
54506|NCT01052428|Drug|Placebo|Placebo 100 mg once a day for 2 years
54507|NCT01052454|Behavioral|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
54508|NCT01052467|Drug|Xamiol® Gel|Once daily application for about 4 weeks
54509|NCT01052480|Biological|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
54510|NCT01052480|Behavioral|Standard Care|Standard care for hospitalized people with influenza
54511|NCT01052493|Drug|PP 1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 2, 4, 8 mg.
54512|NCT01052493|Drug|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
54831|NCT01048463|Drug|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
54832|NCT01048463|Drug|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
54833|NCT01048463|Drug|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
54834|NCT01048463|Drug|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
54835|NCT01048476|Dietary Supplement|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
54836|NCT01048476|Dietary Supplement|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
54837|NCT01048476|Dietary Supplement|placebo|Dietary Supplement: placebo; daily supplementation one year
54838|NCT01048476|Drug|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
54839|NCT01050556|Dietary Supplement|folic acid|400 ug/d for 12 or 24 weeks
54840|NCT01050556|Dietary Supplement|folic acid|800 µg/d for 12 or 24 weeks
54841|NCT01050556|Dietary Supplement|creatine|3 mg/d for 12 weeks
55802|NCT01077609|Drug|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
55803|NCT01077622|Drug|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
55804|NCT01077635|Drug|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
55805|NCT01077648|Drug|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
55806|NCT00032435|Drug|PAL-40 Active|
55807|NCT01077661|Drug|Nebivolol|patients administrated Nebivolol according to the prescribing information
55808|NCT01077700|Drug|ABT-288 Low Dose|
55809|NCT01077700|Drug|Placebo|inactive substance
55810|NCT01077700|Drug|ABT-288 High Dose|
55811|NCT01077713|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
55812|NCT01077713|Drug|cisplatin|60mg/m2 on day 1 of each 3 week cycle
55813|NCT01077713|Drug|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
55814|NCT01077713|Drug|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
55815|NCT01080248|Drug|Gemcitabine|
55816|NCT01080248|Drug|Pazopanib|
55817|NCT01080261|Device|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System
55818|NCT01080300|Drug|Gabapentin Extended Release|Gabapentin ER 1800mg daily
55819|NCT01080300|Drug|Placebo|Sugar pill
55820|NCT00032825|Drug|Docetaxel|
55821|NCT01080313|Other|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
55273|NCT01049087|Radiation|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
55274|NCT01049100|Procedure|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
55275|NCT01049100|Other|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--> CT controlled biopsy
55276|NCT01049113|Drug|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
55277|NCT01049126|Other|ChemoFx|Chemoresponse Marker Assay
55278|NCT01049139|Behavioral|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
55279|NCT01049139|Behavioral|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
55280|NCT01049152|Device|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
55546|NCT01049451|Drug|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
55547|NCT01049464|Drug|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
55548|NCT01049464|Drug|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
55549|NCT01049477|Other|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
55550|NCT01049477|Other|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
55551|NCT01049490|Biological|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
55552|NCT01049503|Other|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
55553|NCT01049516|Behavioral|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
55554|NCT00030030|Drug|Silymarin (milk thistle)|
55049|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
55050|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
55051|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
55052|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
55053|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
55054|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
55055|NCT01053624|Procedure|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
55056|NCT01055847|Drug|Placebo|Saline Placebo
55057|NCT01055873|Biological|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
55058|NCT00030654|Drug|docetaxel|
55059|NCT01055886|Drug|nicotine patch|Nicotine patch, 7-21 mg.
55060|NCT01055886|Drug|placebo patch|placebo patch used from weeks 4-6
55061|NCT01055899|Biological|REGN88|Single SC Dose
55344|NCT01047033|Behavioral|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
55345|NCT01047033|Other|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
55346|NCT00029497|Drug|Amitriptyline|
55347|NCT01047046|Other|Retrospective chart review|This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.
The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out.
55348|NCT01047059|Drug|Erlotinib, Bevacizumab|Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
55349|NCT01047059|Drug|Fluoro-D-glucose|Tracer for PET imaging
54842|NCT01050556|Dietary Supplement|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
54843|NCT00030173|Drug|Epothilone D (KOS-862)|
54844|NCT01050569|Drug|Nicotine Patch|21 mg
54845|NCT01050569|Other|VLNC Cigarette|Cigarette where the tobacco contains <0.1 mg of nicotine yield.
54846|NCT01050569|Other|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
54847|NCT01050582|Drug|Risperidone|As per local prescribing practices
54848|NCT01050582|Drug|Other atypical antipsychotic drugs|As per local prescribing practices
54849|NCT01050595|Drug|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance <30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
54850|NCT01050595|Drug|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
54851|NCT01050608|Device|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
53872|NCT01058928|Other|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
53873|NCT01058941|Drug|lipoic acid and fish oil concentrate|lipic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
53874|NCT01061281|Device|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
53875|NCT01061281|Device|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
53876|NCT01061294|Procedure|Advanced CustomVue™ iLASIK procedure|
53877|NCT01061294|Device|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
53878|NCT01061307|Dietary Supplement|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
53879|NCT01061320|Drug|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
55822|NCT01080326|Device|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
54906|NCT01048502|Drug|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
54907|NCT01048502|Drug|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
54908|NCT01048502|Drug|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
54909|NCT01048515|Drug|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
54910|NCT01048528|Behavioral|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
54911|NCT01048541|Device|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
54912|NCT01048541|Device|SpeediCath|Catheter for intermittent catheterisation
54913|NCT01048554|Drug|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
54914|NCT01048554|Drug|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
54915|NCT01048567|Other|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
54916|NCT00029783|Procedure|Distant Healing|
54917|NCT01048567|Other|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
54918|NCT01048580|Drug|Perifosine + Capecitabine|Perifosine 50 mg qd + Capecitabine 1000 mg/m2 BID x 14 days
54919|NCT01048593|Drug|IBI-10090|Single intraocular injection
54920|NCT01048606|Behavioral|Placebo + exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)
Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist.
54921|NCT01050673|Device|VERSAJET|Hydro-surgery debridement
55555|NCT01049516|Behavioral|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
55556|NCT01049516|Behavioral|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
55557|NCT01049516|Behavioral|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
55558|NCT01049529|Dietary Supplement|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
55559|NCT01049529|Dietary Supplement|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
55560|NCT01049542|Drug|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
55888|NCT00033371|Other|Placebo|Given PO to match DFMO
55889|NCT01085734|Drug|Avastin|1.25mg intravitreally
55890|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
55891|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
55892|NCT01077726|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
55893|NCT01077739|Drug|fluorouracil (5FU)|standard FOLFOX regimen
55894|NCT00000916|Drug|Lamivudine/Zidovudine|
55895|NCT00032435|Drug|PAL-40 Placebo|
55896|NCT01077739|Drug|leucovorin|standard FOLFOX regimen
55897|NCT01077739|Drug|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
55898|NCT01077739|Drug|capecitabine [Xeloda]|standard XELOX regimen
55899|NCT01077739|Drug|oxaliplatin|standard XELOX or FOLFOX regimen
55900|NCT01077752|Drug|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
55350|NCT01047059|Drug|Fluoro-L-thymidine|FLT-PET tracer for imaging
55351|NCT01047059|Drug|Gadolinium-DPTA|Contrast agent for DCE-MRI imaging
55352|NCT01047072|Drug|fludarabine phosphate|Given IV
55353|NCT01047072|Radiation|total-body irradiation|Undergo total-body irradiation
55354|NCT01047072|Drug|tacrolimus|Given orally
55355|NCT01047072|Drug|mycophenolate mofetil|Given orally
55356|NCT01047072|Biological|rituximab|Given IV
55357|NCT00029510|Drug|Magnesium|
55358|NCT01047072|Drug|cyclophosphamide|Given orally
55359|NCT01047072|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
55360|NCT01047072|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
55361|NCT01049165|Drug|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
55362|NCT01049165|Drug|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
55363|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
55364|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
55612|NCT01047501|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 2 capsules/day for 12 weeks
55613|NCT01047501|Drug|Placebo|Placebo 4 capsules/day for 12 weeks
55614|NCT01047501|Drug|Placebo|Placebo 2 capsules/day for 12 weeks
55615|NCT01047514|Behavioral|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
55616|NCT01047527|Drug|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
55617|NCT00029614|Drug|Atomoxetine|
55618|NCT01047540|Drug|AIC316|Oral administration
55619|NCT01047540|Drug|AIC316|Oral administration
55620|NCT01047540|Drug|AIC316|Oral administration
53880|NCT00031044|Drug|Amdoxovir|
53881|NCT01061320|Drug|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
53882|NCT01061333|Drug|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
53883|NCT01061333|Drug|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
53884|NCT01061333|Drug|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
53885|NCT01061333|Drug|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
53886|NCT01061346|Other|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
53887|NCT01061346|Other|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
53888|NCT01061346|Other|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
53889|NCT01061359|Drug|Epirubicin: Observational Study|Observational: Chemotherapy
53890|NCT01061372|Drug|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
53891|NCT00031057|Drug|Thiamine hydrochloride|
53892|NCT01061372|Drug|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
54195|NCT01064440|Genetic|High Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
54196|NCT01064440|Other|Placebo|Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
54197|NCT01064453|Drug|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
54198|NCT01064466|Drug|ETOPOSIDE INJECTION|Generic Oncology Drug approved by USA FDA
54199|NCT01064466|Drug|CISPLATIN INJECTION|Generic Oncology Drug approved by USA FDA
54200|NCT01064479|Drug|Cisplatin|75 mg/m2 by vein (IV) once on Day 1 of every 3 week cycle 2 hours after receiving Docetaxel, up to 6 cycles.
54201|NCT00031447|Drug|Acyclovir|Oral suspension 300 mg/m^2/dose, 3 times per day (TID), for 6 months.
54922|NCT01050673|Procedure|Scalpel or blade|Conventional Surgical Debridement
54923|NCT01050686|Procedure|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
54924|NCT00030186|Drug|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
55197|NCT01051154|Dietary Supplement|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
55198|NCT00030264|Drug|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
55199|NCT01051167|Drug|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
55200|NCT01051180|Procedure|HALO|Ligation of haemorrhoidal arteries
55201|NCT01051193|Drug|Oxcarbazepine|
55202|NCT01051206|Drug|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
55203|NCT01051219|Drug|Losartan|50 milligrams to be taken orally, daily
55204|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
55205|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
55206|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
55207|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
55208|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
55209|NCT00030264|Drug|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
55210|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
55211|NCT01051245|Behavioral|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
55901|NCT01077752|Drug|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
55902|NCT01077752|Drug|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
55903|NCT01077752|Drug|NaCl|NaCl
55904|NCT01077765|Device|Eutrophill|Polyacrylamide Hydrogel
55905|NCT01077778|Procedure|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
55906|NCT00032448|Procedure|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
55907|NCT01077791|Behavioral|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
55908|NCT01077817|Drug|Alendronate|
55909|NCT01077817|Drug|Etidronate|
55910|NCT01077817|Drug|Ibandronate|
55911|NCT01077817|Drug|Risedronate|
55912|NCT01077817|Drug|Raloxifene|
54982|NCT01055678|Procedure|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
54983|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
54984|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
54985|NCT01055691|Drug|Metformin|metformin IR tablet 850 mg Oral Single dose
54986|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
54987|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
54988|NCT01055691|Drug|Metformin|metformin IR tablet 1000 mg Oral Single dose
54989|NCT01048606|Dietary Supplement|Phytoestrogens without exercise|Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.
Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions.
55621|NCT01049555|Other|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
55622|NCT01049568|Behavioral|Cell Phone Intervention|Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.
Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization.
55623|NCT01049581|Procedure|aquatic therapy|two hours per week, one hour per time, total 12 weeks
55624|NCT01049607|Procedure|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
55625|NCT00030043|Device|Penetrating auditory brainstem implant|
55626|NCT01049607|Procedure|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
55627|NCT01049620|Drug|RAD001, Capecitabine, Oxaliplatin|Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21
Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21
Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21
Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21
55628|NCT01049633|Biological|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
55629|NCT01049633|Drug|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
55630|NCT01049633|Biological|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
55976|NCT01085786|Drug|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
55977|NCT00033371|Drug|eflornithine|Given PO at 0.5 gm/m^2/day rounded down to the nearest 250 mg dose (BSA of < 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of > 2.6 = 1,250 mg/day).
55978|NCT01085799|Behavioral|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
55979|NCT01085812|Drug|F2695 SR|Drug: F2695 SR (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
55980|NCT01085812|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily.
54202|NCT01064479|Drug|Docetaxel|75 mg/m2 IV Day 1 of each 3 week cycle, up to 6 cycles.
54203|NCT01064479|Drug|Erlotinib|150 mg by mouth (PO) daily continuously.
54204|NCT01064479|Other|Placebo|Tablet by mouth (PO) daily continuously.
54205|NCT01064479|Drug|Carboplatin|AUC 6 mg.min/ml on Day 1 of each 21 day cycle for a maximum of 6 cycles.
54206|NCT01064492|Drug|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
54207|NCT01064505|Drug|QPI-1007 at various doses|Single Intravitreal Injection
54208|NCT01057030|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
54209|NCT01057043|Device|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
54210|NCT01057056|Other|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
54211|NCT01057069|Drug|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
54212|NCT01057069|Drug|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
54213|NCT01057069|Drug|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
54214|NCT01057082|Dietary Supplement|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
54513|NCT01052506|Drug|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
54514|NCT01052506|Drug|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
54515|NCT01052519|Other|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
54516|NCT00030394|Other|pharmacological study|Correlative studies
54517|NCT01052545|Behavioral|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
54518|NCT01052558|Device|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
55212|NCT01051245|Other|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
55213|NCT01053832|Device|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
55214|NCT00030498|Other|laboratory biomarker analysis|Correlative studies
55215|NCT01053845|Other|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
55486|NCT01051635|Drug|LMP 776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
55487|NCT01051648|Drug|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy
55488|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
55489|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
55490|NCT01051661|Biological|Placebo|Intramuscular injection, one dose
55491|NCT01051674|Other|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
55492|NCT01051687|Drug|Botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit.
55493|NCT00030342|Biological|therapeutic autologous lymphocytes|
55494|NCT01051700|Drug|GW786034|Investigational product
55495|NCT01051700|Other|Placebo|Placebo
55496|NCT01054313|Drug|Docetaxel (Taxotere)|Starting dose 30 mg/m^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
55497|NCT01054313|Drug|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
55498|NCT01054313|Drug|Prednisone|5 mg by mouth twice a day with prostate cancer.
54990|NCT01048606|Other|Phytoestrogens + exercise|Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.
Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist.
54991|NCT01048619|Drug|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
54992|NCT01048632|Drug|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
54993|NCT01048645|Drug|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
54994|NCT01048645|Other|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
54995|NCT00029796|Drug|soy isoflavones|
54996|NCT01048658|Drug|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
54997|NCT01048658|Other|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
55281|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
55282|NCT00029900|Drug|ADI PEG|
55283|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
55284|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
55285|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
55286|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
55287|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
55288|NCT01051258|Device|AeriSeal System|AeriSeal System for Lung Volume Reduction
55289|NCT01051271|Drug|midazolam|midazolam 1.5 mg
55981|NCT01085825|Procedure|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
55982|NCT01085838|Drug|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
55983|NCT01085851|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
55984|NCT01085851|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
55985|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
55986|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
55987|NCT01085890|Behavioral|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
55988|NCT00033371|Other|Laboratory biomarker analysis|Correlative studies
55989|NCT01085903|Drug|Modafinil|200 mg once daily with morning meal for three days
55990|NCT01085903|Drug|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days.
55991|NCT01077895|Procedure|CVVH|CVVH is started using following parameters:
Blood flow is started at 150 mL/min
Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.
In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution
Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)
55062|NCT01055899|Biological|REGN88|Single SC Dose
55063|NCT01055899|Biological|REGN88|Single SC Dose
55064|NCT01055912|Drug|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
55065|NCT01055912|Drug|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
55066|NCT01055925|Device|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
55067|NCT01055925|Device|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
55068|NCT01055938|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
54519|NCT01052558|Procedure|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
54520|NCT01052571|Procedure|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
54521|NCT01052584|Drug|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
54522|NCT01052584|Drug|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
54523|NCT01052584|Drug|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
54524|NCT01052597|Drug|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
54525|NCT01055041|Drug|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
54526|NCT01055067|Drug|Tivantinib (ARQ 197)|Capsule, 120 mg, BID (360 mg), approximately 112 days
54527|NCT01055080|Dietary Supplement|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
54528|NCT00030602|Biological|PSA prostate cancer vaccine|
54529|NCT01055106|Drug|GW05|vaginal gel once daily regimen A
54530|NCT01055106|Drug|GW05|vaginal gel once daily regimen B
54531|NCT01055106|Drug|GW05|vaginal gel once daily regimen C
54532|NCT01055106|Drug|Metronidazole|vaginal gel 0.75% once daily for 5 days
54533|NCT01055119|Dietary Supplement|Omega-3 fatty acids|duration: 4 month
53603|NCT01065441|Biological|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10^7 cells
53604|NCT01065441|Biological|AlloStim|intravenous AlloStim-TM at doses between 1 x 10^7 to 1 x 10^9 cells
53605|NCT01065441|Biological|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
53606|NCT01065441|Biological|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10^7 cells.
55499|NCT01054326|Other|Exercises|
55500|NCT01054339|Drug|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
55501|NCT00030563|Drug|irinotecan hydrochloride|
55502|NCT01054352|Drug|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
55503|NCT01054352|Drug|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
55504|NCT01054352|Drug|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
55823|NCT01080352|Drug|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
55824|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
55825|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
55826|NCT01080378|Procedure|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
55827|NCT01080391|Drug|Dexamethasone|40 mg PO or IV on Days 1, 8, 15, 22
55828|NCT01080391|Drug|Lenalidomide|25 mg PO on Days 1-21
55829|NCT01080391|Drug|Carfilzomib|20 mg/m2, 27 mg/m2
55830|NCT01080404|Procedure|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
55831|NCT00000916|Drug|Stavudine|
55832|NCT00032838|Drug|Yohimbine|
55833|NCT01080404|Device|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
55834|NCT01080417|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
55835|NCT01080430|Other|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
55290|NCT01051284|Radiation|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
55291|NCT01051310|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
55292|NCT01051323|Drug|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
55293|NCT01051336|Device|TARIS Placebo|
55294|NCT01051336|Procedure|Sham Procedure|
55295|NCT00030277|Procedure|high-intensity focused ultrasound ablation|
55296|NCT01051349|Biological|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
55297|NCT01051349|Biological|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
55298|NCT01051362|Drug|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
55299|NCT01051375|Behavioral|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
55300|NCT01051388|Drug|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
55301|NCT01051388|Drug|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
55302|NCT01051388|Drug|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
55303|NCT01051401|Drug|rosuvastatin|Given PO
55561|NCT01051713|Behavioral|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
55562|NCT01051713|Behavioral|Standard|Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the "Keeping Track" form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits.
55069|NCT00030654|Drug|doxorubicin hydrochloride|
55070|NCT01055951|Device|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
55071|NCT01055964|Drug|Tacrolimus|
55072|NCT01055990|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
55073|NCT01055990|Other|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
55074|NCT01056003|Other|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
55075|NCT01056016|Other|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
55076|NCT01056029|Drug|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
55077|NCT01056042|Drug|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
55078|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss).
55079|NCT00000902|Drug|Nelfinavir mesylate|
55080|NCT00029809|Behavioral|Chinese exercise modalities|
55365|NCT01049178|Drug|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
55366|NCT00029913|Other|Observation|Observation of participants who received HIV preventive vaccine and became infected.
55367|NCT01049178|Drug|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
53607|NCT01065441|Biological|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
53608|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
53609|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
53610|NCT00031564|Biological|Interleukin-2|
53611|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
53612|NCT01065454|Drug|Placebo|Placebo three times a day
53613|NCT01065467|Drug|LBH589|Taken orally three times per week.
53614|NCT01065480|Behavioral|Motivational Interviewing|Motivational interviewing is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
53615|NCT01065493|Other|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
53616|NCT01058265|Other|Integrative|Integrative Medicine medical evaluation.
53617|NCT01058265|Other|Standard|Standard general medical evaluation.
53618|NCT01058278|Procedure|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
53619|NCT01058291|Drug|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
53620|NCT01058291|Drug|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
53621|NCT01058304|Other|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
53893|NCT01061372|Drug|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
53894|NCT01061385|Device|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
53895|NCT01061385|Other|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
55836|NCT01080443|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
55837|NCT01080456|Drug|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
55838|NCT01080469|Drug|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
55839|NCT01080482|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
55840|NCT01082991|Other|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
55841|NCT01083004|Procedure|Indocyanine green|Using indocyanine green as intraoperative dye
55842|NCT01083004|Procedure|Brilliant blue arm|Using brilliant blue as intraoperative dye
54925|NCT01050686|Procedure|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
54926|NCT01050699|Drug|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
54927|NCT01050699|Drug|Midazolam and Fentanyl|Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.
Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)
Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)
54928|NCT01050712|Drug|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
54929|NCT01050712|Drug|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
54930|NCT01050738|Procedure|Position of catheter|Position of catheter for administration of local anestesia.
54931|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
54932|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
54933|NCT01050764|Device|ClinMACS|
54934|NCT01050764|Drug|Stem Cells|
55563|NCT01051726|Other|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
55564|NCT01051726|Other|None essential oil|Baby oil
55565|NCT01051765|Drug|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
55566|NCT01051778|Drug|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
55567|NCT01051778|Drug|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
55568|NCT01051791|Drug|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
55569|NCT00030342|Drug|fluorouracil|
55570|NCT01051804|Other|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
55571|NCT01051804|Other|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
55572|NCT01051817|Drug|AIN457|infusion 10 mg/Kg
55573|NCT01051817|Drug|Placebo|infusion
55574|NCT01051830|Other|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
55575|NCT01051830|Other|Rehabilitation program, nursing care|Rehabilitation program, nursing care
55576|NCT01051856|Device|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
55913|NCT01077869|Procedure|endoscopic examination|on a weekly basis during 7 weeks
55914|NCT01077869|Procedure|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
55915|NCT01077882|Behavioral|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
55916|NCT01077882|Behavioral|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
55368|NCT01049178|Drug|Placebo|
55369|NCT01049204|Drug|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
55370|NCT01049204|Drug|placebo|Placebo twice daily for 24 weeks
55371|NCT01049217|Drug|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
55372|NCT01049217|Drug|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
55373|NCT01049230|Radiation|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
55374|NCT01049243|Drug|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
55375|NCT01049256|Other|carbon dioxide|sinusoidal carbon dioxide administration
55376|NCT01049282|Biological|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
55377|NCT00029926|Drug|2-deoxy-2 [F-18] fluoro-2-d-glucose|
55378|NCT01049282|Biological|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
55379|NCT01049295|Dietary Supplement|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
55380|NCT01049295|Other|corn oil pearls|corn oil pearls 3 times a day
55381|NCT01049321|Dietary Supplement|DASH diet|
55382|NCT01049321|Dietary Supplement|a usual diabetic diet|
55383|NCT01049334|Drug|Placebo|Suck one lozenge until gone, every 3-6 hours as needed for pain
55384|NCT01049334|Drug|Flurbiprofen|Suck one lozenge until gone, every 3-6 hours as needed for pain
55385|NCT01049347|Drug|amitriptyline|150 mg oral, daily, single evening dose, 35 days
55631|NCT01049633|Drug|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
55632|NCT01049633|Drug|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
55633|NCT01049633|Drug|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
53896|NCT01061398|Procedure|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
53897|NCT01061398|Procedure|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
53898|NCT01061411|Drug|Dalteparin|Given SC
53899|NCT01061411|Other|Pharmacological Study|Correlative studies
53900|NCT01063881|Drug|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
53901|NCT01063894|Other|breakfast cereal|breakfast cereal and milk
53902|NCT01063894|Other|water|water
53903|NCT01063907|Drug|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
53904|NCT01063907|Drug|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
53905|NCT01063920|Drug|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
53906|NCT01063920|Drug|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
53907|NCT01063933|Drug|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
53908|NCT00031317|Drug|Clozapine|
53909|NCT01063946|Drug|Ombrabulin (AVE8062)|Pharmaceutical form:concentrate solution
Route of administration: intravenous infusion
53910|NCT01063959|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
53911|NCT01063959|Procedure|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
53912|NCT01063972|Behavioral|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
54215|NCT01057082|Dietary Supplement|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
54935|NCT00030186|Drug|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
54936|NCT01050777|Drug|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
54937|NCT01050777|Drug|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
54938|NCT01050777|Drug|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
54939|NCT01050777|Drug|Placebo|Placebo
54940|NCT01050790|Drug|Azacitidine|Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
54941|NCT01050803|Behavioral|FDSME group|In the intervention group, diabetes education sessions which are designed based on the "Intervention Mapping" will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
54942|NCT01050803|Behavioral|FDSME|In the intervention group, sessions which are designed based on the "Intervention Mapping" will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
54943|NCT01053338|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
55216|NCT01053858|Procedure|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
55217|NCT01053871|Drug|propofol|conscious sedation using propofol
55218|NCT01053871|Drug|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
55219|NCT01053884|Drug|Anidulafungin|standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.
Prophylaxis will be given until the recovery from neutropenia (ANC > 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture.
55220|NCT01053897|Biological|GBT009|Intradermal Injection following surgery
55221|NCT01053897|Biological|Placebo|Intradermal Injection following surgery
55222|NCT01053910|Drug|Ramipril|tablet of Ramipril once daily
55223|NCT01053923|Other|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
55224|NCT01053936|Drug|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
55917|NCT00032474|Drug|Ginkgo biloba extract|
55918|NCT01077882|Behavioral|Lifestyle factors and psycho-education|by dietician and psychiatrist
55919|NCT01077882|Other|no educational program|standard care without educational program
55920|NCT01080495|Procedure|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
55921|NCT01080508|Other|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
55922|NCT01080508|Other|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
55923|NCT00032890|Drug|glucosamine|
55924|NCT01080521|Procedure|Cognitive Assessment|Ancillary studies
55925|NCT01080521|Other|Quality-of-Life Assessment|Ancillary studies
55926|NCT01080534|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
55927|NCT01080547|Procedure|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
55928|NCT01080547|Drug|XELOX Chemotherapy|XELOX chemotherapy
55929|NCT01080547|Drug|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
55930|NCT01080547|Other|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
55931|NCT01080547|Other|Conventional Perioperative Treatment|Conventional treatment during perioperation period
55932|NCT01080547|Procedure|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
55933|NCT01080560|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
55934|NCT00032890|Drug|chondroitin sulfate|
55935|NCT01080586|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
54998|NCT01048671|Drug|Raltegravir|Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
55634|NCT01049633|Drug|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
55635|NCT01049633|Drug|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
55636|NCT00030056|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
55637|NCT01049633|Drug|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
55638|NCT01049633|Drug|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
55639|NCT01051869|Procedure|Simple decompression|Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.
In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken.
55640|NCT01051869|Procedure|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
55641|NCT00030355|Drug|homoharringtonine|
55642|NCT01051882|Biological|MSC-NTF cells transplantation (i.m.)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
55643|NCT01051882|Biological|MSC-NTF cells transplantation (i.t.)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
55644|NCT01051895|Other|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
54216|NCT01057095|Genetic|RNA analysis|
54217|NCT00000229|Drug|Buprenorphine|
54218|NCT00000904|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
54219|NCT00030693|Procedure|quality-of-life assessment|Ancillary studies
54220|NCT01057095|Genetic|gene expression analysis|
54221|NCT01057095|Genetic|reverse transcriptase-polymerase chain reaction|
54222|NCT01057095|Other|laboratory biomarker analysis|
54223|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg BID
54224|NCT01057108|Other|FOSTRAP Chewing Gum|40 mg BID
54225|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
54226|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
54227|NCT01057108|Other|Placebo chewing gum|
54228|NCT01057121|Other|Laboratory Biomarker Analysis|Correlative studies
54229|NCT01057121|Drug|Lenalidomide|Given PO
54230|NCT00030706|Drug|ixabepilone|
54231|NCT01057147|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
54232|NCT01057147|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
54233|NCT01057160|Drug|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
54234|NCT01057173|Procedure|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
54235|NCT01059500|Device|Intervention group, receive the numeric PTP estimate|Receive the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP <2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP >5.5%: proceed to provocative testing. For PE, PTP<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP>20% consider empiric anticoagulation with heparin if no contraindications.
54236|NCT01059500|Device|No Intervention|Standard (no webtool output)
55225|NCT00030511|Drug|fluorouracil|
55226|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
55227|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
55228|NCT01053962|Drug|SP-304|Subjects receiving SP-304 1.0 mg for 14 consecutive days
55229|NCT01053962|Drug|SP-304|Subjects receiving SP-304 3.0 mg for 14 consecutive days
55230|NCT01053962|Drug|SP-304|Subjects receiving SP-304 9.0 mg for 14 consecutive days
55231|NCT01053962|Drug|Placebo|Subjects receiving Placebo for 14 consecutive days
55232|NCT01053962|Drug|SP-304 0.3 mg|Subjects receiving SP-304 0.3 mg for 14 consecutive
55233|NCT01053988|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
55234|NCT01053988|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
55235|NCT01053988|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
55236|NCT00000903|Drug|Indinavir sulfate|
55237|NCT00030511|Procedure|conventional surgery|
55238|NCT01053988|Drug|Placebo|Placebo
55505|NCT01054352|Drug|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
55506|NCT01054378|Procedure|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
55507|NCT01054391|Device|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
55508|NCT01054404|Drug|Furosemide|Furosemide 0.3 mg/kg
55509|NCT01054404|Drug|Placebo|Placebo (up to 5mL)
55510|NCT01054430|Drug|avanafil|200 mg avanafil tablets QD
55511|NCT01054443|Drug|placebo to S-888711|Tablet
55512|NCT00030563|Procedure|adjuvant therapy|
54999|NCT01048671|Drug|ARV (non-raltegravir)|ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
55000|NCT01048684|Drug|Mannitol|Variation of mannitol dose
55001|NCT01048684|Drug|Mannitol|Variation of mannitol dose
55002|NCT01048697|Drug|Ethambutol|All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):
40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)
55003|NCT01048723|Drug|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
55004|NCT01048736|Behavioral|Exercise Only|4 d/wk of aerobic exercise
55005|NCT01050816|Procedure|Chondron(autologous chondrocyte) Implantation|Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)
Directions and dosage:
Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.
*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation.
55006|NCT01050829|Drug|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
55007|NCT01050829|Drug|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
55008|NCT00000902|Drug|Stavudine|
55009|NCT00030225|Biological|ELAD|
55010|NCT01050842|Drug|bicalutamide|Given orally
55011|NCT01050842|Drug|raloxifene|Given orally
55012|NCT01050842|Procedure|quality-of-life assessment|Ancillary study
55013|NCT01050855|Drug|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
55014|NCT01050855|Drug|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
55015|NCT01050855|Drug|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
55016|NCT01050868|Device|Accu-Chek Combo Kit mg DE/de|
55017|NCT01050907|Drug|miltefosine|2.5 mg/kg/day for 28 days
55992|NCT01077895|Procedure|ultrafiltration|ultra filtration is started at 100 mL/h and increased according to following protocol
Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:
Vasopressor or inotrope medication dose is increased by > 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)
When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV > 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h
If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued.
55993|NCT01077895|Procedure|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
55994|NCT01077908|Biological|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
55995|NCT01077908|Drug|Best available antiviral drug therapy|Intravenous ganciclovir 5mg/kg twice daily
Oral valganciclovir 900mg twice daily
Intravenous foscarnet 90 mg/kg twice daily
55996|NCT01077921|Drug|Propranolol|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
55997|NCT01077921|Drug|Placebo|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
55998|NCT01077934|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
55999|NCT00032487|Drug|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
56000|NCT01077947|Procedure|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
56001|NCT01077947|Procedure|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
56002|NCT01077960|Biological|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
56003|NCT01077973|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
56004|NCT01077973|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
56005|NCT01077973|Drug|Placebo|Single-dose of placebo
56006|NCT01077986|Drug|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
54237|NCT00030823|Biological|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
54534|NCT01055132|Device|Etafilcon A toric contact lens|contact lens to correct astigmatism
54535|NCT01055132|Device|Nelfilcon A toric contact lens|contact lens to correct astigmatism
54536|NCT01055145|Drug|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
54537|NCT01055158|Behavioral|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
54538|NCT01055158|Behavioral|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
54539|NCT00030602|Biological|incomplete Freund's adjuvant|
54540|NCT01055171|Drug|Propranolol|40 mg; Single Administration.
54541|NCT01055171|Drug|Placebo|40 mg; Single Dose.
54542|NCT01055184|Biological|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
54543|NCT01055197|Radiation|prophylactic cranial irradiation|Given 5 days per week for 2 weeks
54544|NCT01055197|Radiation|selective external radiation therapy|Given 5 days per week for 2-3 weeks
54545|NCT01055210|Device|Optimisation of VV delay|Programmed VV delay altered on device
54546|NCT01055223|Drug|TZD only (RSG or PIO or troglitazone)|Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
54547|NCT01055223|Drug|TZD + spironolactone|Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days.
54548|NCT01055223|Drug|TZD + amiloride|Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days.
54549|NCT01048021|Procedure|Supraclavicular Block|Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.
At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position.
55513|NCT01054443|Drug|S-888711|Tablet
55514|NCT01054443|Drug|S-888711|Tablet
55515|NCT01054443|Drug|S-888711|Tablet
55516|NCT01054456|Drug|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
55517|NCT01054469|Procedure|TAP block placement with placebo|20 ml of normal saline (placebo)
55518|NCT01054469|Procedure|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
55519|NCT01054482|Drug|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
55520|NCT01054482|Other|Pre-operative concurrent chemoradiation therapy|Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op & Post-Op: 2 cycles (total 4 cycles).
Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
55521|NCT01047280|Dietary Supplement|G-c9, t11|3.5 g/day of c9, t11 CLA
55522|NCT01047293|Drug|RAD011|RAD001 (everolimus) is a novel oral derivative of rapamycin.
RAD001 is being investigated as an anticancer agent based on its potential to act:
Directly on the tumor cells by inhibiting tumor cell growth and proliferation
Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells.
55523|NCT01047293|Drug|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
55843|NCT01083017|Drug|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
55844|NCT01083017|Behavioral|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
55845|NCT01083017|Drug|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
55846|NCT01083030|Procedure|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
55304|NCT01051401|Other|placebo|Given PO
55305|NCT01051401|Other|survey administration|Correlative study
55306|NCT00030290|Procedure|high-intensity focused ultrasound ablation|
55307|NCT01051401|Procedure|management of therapy complications|
55308|NCT01051414|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
55309|NCT01051414|Drug|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
55310|NCT01051427|Device|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
55311|NCT01051427|Device|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
55312|NCT01051440|Drug|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
55313|NCT01051440|Drug|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
55314|NCT01051466|Drug|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
55315|NCT01054001|Drug|sildenafil 100mg|sildenafil 100mg per oral twice a week
55316|NCT01054014|Drug|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
55317|NCT01054014|Drug|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
55318|NCT01054014|Drug|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
55319|NCT01054027|Drug|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
55320|NCT01054040|Other|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
55321|NCT01054066|Behavioral|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
55322|NCT01054079|Other|laboratory biomarker analysis|Correlative study
55323|NCT01054079|Procedure|quality-of-life assessment|Ancillary study
55324|NCT00030511|Radiation|radiation therapy|
56007|NCT01077986|Drug|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
55081|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
55082|NCT01048749|Other|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
55083|NCT01048749|Other|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
55084|NCT01048762|Other|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
55085|NCT01048762|Other|home training|one instruction in home based exercise training
55086|NCT01048788|Drug|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
55087|NCT01048801|Device|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
55088|NCT01048801|Other|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
55089|NCT01048814|Other|ChemoFx|Chemoresponse Marker Assay
55090|NCT01048827|Drug|Busulfan|1250 uMol*min (AUC to time 6 hrs)^
1400 uMol*min (AUC to time 6 hrs
1550 uMol*min (AUC to time 6 hrs)^
55091|NCT00029822|Drug|Alfuzosin (SL770499)|
55092|NCT01048853|Procedure|Conservative Surgery|Removal of the pelvic lymph nodes (pelvic lymphadenectomy)
55093|NCT01048866|Drug|Placebo|Suck one lozenge until gone, every 3-6 hours as needed for pain
55094|NCT01048866|Drug|Flurbiprofen|Suck one lozenge until gone, every 3-6 hours as needed for pain
55095|NCT01048879|Procedure|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
55096|NCT01048879|Procedure|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
55097|NCT01048892|Biological|Seneca Valley virus-001|
55098|NCT01048892|Drug|cyclophosphamide|
55099|NCT01048892|Other|laboratory biomarker analysis|
54550|NCT01048034|Drug|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
54551|NCT00000902|Drug|Ritonavir|
54552|NCT00029692|Drug|Ginkgo|
53622|NCT01058304|Other|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
53623|NCT01058317|Drug|Propranolol|Propranolol 2mg/kg divided twice daily
53624|NCT01058330|Other|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of 5 lower extremity exercises and 5 upper extremity exercises
53625|NCT00000904|Biological|ALVAC(1)120(B,MN)GNP (vCP1433)|
53626|NCT00030758|Biological|filgrastim|
53627|NCT01058343|Biological|IFN-K|3 to 4 IM injections over 3 months
53628|NCT01058369|Drug|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
53629|NCT01058382|Drug|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
53630|NCT01058382|Drug|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
53631|NCT01058395|Drug|Minocycline|Minocycline will be delivered in an open-label randomized study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
53632|NCT01058408|Radiation|Intensity modulated radiotherapy|Administered daily 5 days per week
53633|NCT01058408|Drug|RAD001|Taken orally once a day
53634|NCT01058408|Drug|cisplatin|Administered intravenously once a week
53635|NCT01058421|Procedure|intensive physical therapy|four week course of daily intensive physical therapy
53636|NCT01058421|Procedure|control group|four weeks of routine physical therapy
53637|NCT01060826|Drug|somatostatin|Intravenous bolus 250 micrograms
55847|NCT01083095|Biological|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
55848|NCT01083108|Procedure|Roux-en-Y Gastric Bypass|
55849|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
55850|NCT01083108|Behavioral|Caloric Restriction|
55851|NCT01083147|Device|FORESEE HOME|Home Monitoring
55852|NCT01083199|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
55853|NCT01083212|Drug|AZD1656|Single dose,oral tablet
55854|NCT01083212|Drug|Gemfibrozil|Oral tablet bid on day 1 - 5.
55855|NCT01083212|Drug|Placebo|Oral tablet bid on day 1-5
55856|NCT01083225|Behavioral|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
55857|NCT01083225|Behavioral|Treatment as usual|Treatment as usual, consultations
55858|NCT01083238|Drug|AZD5069|120mg single oral dose
55859|NCT01083251|Drug|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
55860|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
55861|NCT01083251|Drug|Peginterferon|180 mcg/week
55862|NCT01083251|Drug|Sebivo|Telbivudine 600 mg daily
55863|NCT01083251|Drug|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
55864|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
55865|NCT01085617|Radiation|total-body irradiation|
54944|NCT01053364|Device|NL-Prow interspinous spacer implant|Interspinous spacer implant
54945|NCT01053377|Drug|Tamiflu (verum)|
55325|NCT01054079|Other|questionnaire administration|Ancillary study
55326|NCT01054079|Drug|cinacalcet hydrochloride|Given PO
55577|NCT01051856|Procedure|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
55578|NCT01054495|Drug|Acupuncture|The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the "cun" measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes.
55579|NCT01054495|Device|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
55580|NCT00030563|Procedure|conventional surgery|
55581|NCT01054495|Device|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
55582|NCT01054508|Drug|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
55583|NCT01054521|Procedure|Temperature-controlled RF|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
55584|NCT01054521|Device|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
55585|NCT01054534|Procedure|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
55586|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
55587|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
55588|NCT01054560|Device|SOLITAIRE™ Device compared to MERCI® Device|SOLITAIRE™ Device (investigational device) compared with the commercially available device, MERCI® Device
55589|NCT01054573|Drug|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
55100|NCT01048892|Other|pharmacological study|
55101|NCT01048905|Drug|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children < 15 years of age.
55102|NCT00029835|Drug|Rimonabant (SR141716)|
55386|NCT01051479|Drug|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
55387|NCT01051505|Drug|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
55388|NCT00030303|Biological|recombinant 70-kD heat-shock protein|
55389|NCT01051505|Drug|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
55390|NCT01051518|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
55391|NCT01051531|Drug|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
55392|NCT01051544|Drug|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
55393|NCT01051544|Drug|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
55394|NCT01051557|Other|Laboratory Biomarker Analysis|Correlative studies
55395|NCT01051557|Drug|Perifosine|Given PO
55396|NCT01051557|Drug|Temsirolimus|Given IV
55397|NCT01051557|Procedure|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
55398|NCT01051570|Drug|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
55399|NCT00030342|Biological|recombinant interferon alfa|
55400|NCT01051570|Drug|RAD 001|5 mg orally starting on Day 2 then continuous
55401|NCT01051570|Drug|prednisone|5 mg orally twice a day starting on Day 1 then continuous
55402|NCT01051570|Other|laboratory biomarker analysis|Samples will be collected from archival tissue.
53638|NCT01060839|Behavioral|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
53639|NCT01060852|Behavioral|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
53640|NCT01060865|Drug|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
53913|NCT01063972|Behavioral|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
53914|NCT01063998|Other|Urine Marker|Urinary KIM-1 measurements
53915|NCT01064011|Procedure|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
53916|NCT01064011|Procedure|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
53917|NCT01064024|Drug|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
53918|NCT01064024|Drug|Placebo|Tablets, every 8 hours for 48 hours
53919|NCT00031343|Drug|highly active antiretroviral therapy (HAART)|
53920|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
53921|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
53922|NCT01056536|Behavioral|Structured intervention for the prevention of sexually transmitted infections (STI)|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
53923|NCT01056549|Drug|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
53924|NCT01056575|Drug|OC000459|OC000459 100mg tablet, twice daily
53925|NCT01056588|Behavioral|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
54946|NCT01053377|Drug|Tamiflu placebo|
54947|NCT01053390|Drug|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
54948|NCT01053390|Drug|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
54949|NCT01053403|Drug|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
54950|NCT01053416|Procedure|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
54951|NCT01053429|Drug|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
54952|NCT00030459|Drug|mitomycin C|
54953|NCT01053442|Dietary Supplement|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
54954|NCT01053442|Dietary Supplement|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
54955|NCT01053455|Device|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
54956|NCT01053468|Behavioral|Physical Activity Resource Kit|The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.
Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration).
54957|NCT01053468|Behavioral|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
54958|NCT01053481|Dietary Supplement|vitamin D|Vitamin D supplement
54959|NCT01053481|Behavioral|exercise program (rebounding on a trampoline)|40 days at 30 min/d
54960|NCT01053494|Procedure|massage therapy|Undergo massage therapy
54961|NCT01053494|Other|questionnaire administration|Ancillary studies
54962|NCT01053494|Procedure|quality-of-life assessment|Ancillary studies
54963|NCT00030459|Drug|vinblastine sulfate|
54964|NCT01053494|Other|intervention by caregiver|Undergo massage by caregiver
54965|NCT01053494|Procedure|standard follow-up care|Undergo standard follow-up care
55590|NCT01054573|Drug|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
55591|NCT00030563|Procedure|radiofrequency ablation|
55592|NCT01054573|Drug|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
55936|NCT01080599|Procedure|obturator nerve block|
55937|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
55938|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
55939|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
55940|NCT01080612|Drug|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
55941|NCT01080625|Drug|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
55942|NCT01080625|Drug|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
55943|NCT01080625|Drug|placebo control|10ml of normal saline is administered at the time of reperfusion
55944|NCT01080638|Drug|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
55945|NCT00032890|Drug|glucosamine and chondroitin sulfate combined|
55946|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
55947|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
55948|NCT01083277|Device|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
55949|NCT01083290|Drug|Spironolactone|single dose of one tablet; 25 mg tablet
55950|NCT01083290|Drug|Spironolactone|single dose of one tablet; 50 mg tablet
55951|NCT01083290|Drug|Spironolactone|single dose of one tablet; 100 mg tablet
55403|NCT01051570|Other|pharmacological study|Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2
55404|NCT01051583|Procedure|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
55645|NCT01051895|Other|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
55646|NCT01051921|Drug|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
55647|NCT01051921|Drug|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
55648|NCT01051921|Drug|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
55649|NCT01051934|Drug|SS1 (dsFv) PE38|
55650|NCT01051934|Drug|Paclitaxel|
55651|NCT01051934|Drug|Carboplatin|
55652|NCT00030355|Procedure|chemotherapy|
55653|NCT01051934|Drug|Bevacizumab|
55654|NCT01051947|Drug|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
55655|NCT01051947|Drug|Metoprolol|dosage prescribed prior to starting on study
55656|NCT01051960|Drug|Ambrisentan|Ambrisentan 5mg or 10mg once daily
55657|NCT01051973|Behavioral|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
55658|NCT01051973|Behavioral|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
55659|NCT01054586|Drug|Intervention D|HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
55660|NCT01054586|Drug|Intervention E|HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
53926|NCT01056588|Behavioral|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
53927|NCT01056601|Drug|Bortezomib|1.3 mg/m^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
53928|NCT00030667|Drug|imatinib mesylate|Given orally
53929|NCT01056601|Drug|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
53930|NCT01056614|Drug|fludarabine phosphate|Given IV
53931|NCT01056614|Drug|busulfan|Given IV
53932|NCT01056614|Biological|anti-thymocyte globulin|Given IV
54238|NCT01059526|Drug|ecallantide|30 mg SC
54239|NCT01059539|Drug|cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
54240|NCT01059552|Drug|vorinostat|vorinostat once daily for 12 weeks of therapy
54241|NCT01059565|Drug|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
54242|NCT01059565|Drug|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
54243|NCT01059578|Drug|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
54244|NCT01059578|Drug|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
54245|NCT01059578|Radiation|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
54246|NCT01059591|Drug|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
54247|NCT01059591|Drug|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
54248|NCT00030823|Biological|QS21|
54249|NCT01059591|Radiation|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and approximately 24 hours post-dose
54250|NCT01059604|Drug|Sumatriptan|Sumatriptan
54251|NCT01059604|Drug|Naratriptan|Naratriptan
55239|NCT01046825|Drug|COP, COPADM8, CYVE|Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.
COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.
COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, G-CSF. Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.
Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.
Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.
55240|NCT01046838|Drug|Sildenafil|40 mg three times daily for 9 weeks
55241|NCT01046838|Drug|Placebo|tablet 3 times daily for 9 weeks
55242|NCT01046851|Drug|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
55243|NCT01046851|Drug|Placebo|Placebo in a manner similar to the active comparator
55244|NCT01046864|Drug|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
55245|NCT01046864|Drug|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
55246|NCT01046864|Drug|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
55247|NCT01046864|Drug|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
55248|NCT01046864|Drug|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
55249|NCT00029484|Behavioral|Tai chi chih|
55250|NCT01046864|Drug|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
55251|NCT01046864|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
55252|NCT01046877|Device|Tympanostomy Tube Delivery System|Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
55253|NCT01046890|Drug|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
55254|NCT01046903|Drug|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
55255|NCT01046916|Drug|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
55256|NCT01046929|Dietary Supplement|limonene|oral dosing at 2 gram QD
55257|NCT01046942|Drug|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
55952|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
55953|NCT01083303|Behavioral|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
55954|NCT01083316|Drug|Bortezomib (Velcade) and Dexamethasone|Induction:
Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days
Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days
Conditioning:
Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4
Melphalan 70-100 mg/m2/day IV on days -2 and -1
55018|NCT01050920|Biological|Blood collection|
55019|NCT01050933|Drug|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
55020|NCT00030225|Other|Standard of care (Control)|
55021|NCT01050946|Biological|Haploidentical/cord transplant|Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.
Conditioning Regimens Choice of regimen at the discretion of the treating physician
Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)
Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)
Day 0 -Haploidentical donor and one umbilical cord blood unit infusion
55022|NCT01050959|Device|bion|
55023|NCT01050972|Behavioral|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
55024|NCT01050985|Drug|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
55025|NCT01050998|Drug|CAM3001|CAM-3001 10 mg SC every other week (total 7 doses)*
*2:1 randomisation CAM-3001:Placebo
55026|NCT01050998|Drug|CAM3001|CAM-3001 30 mg SC every other week (total 7 doses)*
*2:1 randomisation CAM-3001:Placebo
55027|NCT01050998|Drug|CAM3001|CAM-3001 50 mg SC every other week (total 7 doses)*
*2:1 randomisation CAM-3001:Placebo
55028|NCT01050998|Drug|CAM3001|CAM-3001 100 mg SC every other week (total 7 doses)*
*2:1 randomisation CAM-3001:Placebo
55029|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
55030|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
55031|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
55661|NCT01054599|Drug|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
55662|NCT01054599|Other|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
56008|NCT01077986|Drug|Everolimus|Everolimus will be administered daily, starting on day 1.
56009|NCT01080651|Drug|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
56010|NCT01080664|Drug|AS703569|Dose Escalation
Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:
Number of cycles: until progression or unacceptable toxicity develops.
Cohort Expansion
Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:
Number of cycles: until progression or unacceptable toxicity develops
56011|NCT01080664|Drug|AS703569|Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.
Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.
56012|NCT01080677|Drug|caffeine propranolol combination|
56013|NCT01080690|Procedure|EGD|In this arm EGD will be performed before EUS.
56014|NCT01080690|Procedure|EUS|In this arm EUS will be performed before EGD.
56015|NCT01080703|Other|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
56016|NCT01080716|Biological|WRSS1 vaccine|Single, oral dose of WRSS1
56017|NCT01080716|Biological|Placebo vaccine|Placebo vaccine
56018|NCT01080729|Drug|Recombinant-follicle stimulating hormone (r-FSH)|The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml [22 micrograms/0.5 ml]; 450 IU/0.75 ml [33 micrograms/0.75 ml]; or 900 IU/1.5 ml [66 micrograms/1.5 ml].
The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG).
56019|NCT00032890|Drug|celecoxib|
56020|NCT01080742|Drug|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
56738|NCT01082081|Drug|Paracetamol 1000 mg|Paracetamol 1000 mg
56739|NCT01082081|Drug|Paracetamol 500 mg|Paracetamol 500 mg
56740|NCT01082081|Drug|Placebo|Placebo
56741|NCT01082094|Biological|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
56742|NCT01082107|Other|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
56743|NCT01082120|Drug|AZD1656|Tablets orally, twice daily for 10 days
56744|NCT01082120|Drug|Pioglitazone|Tablet oral single dose for 10 days
56745|NCT00033111|Drug|Cabergoline|
56746|NCT01082133|Drug|Chemotherapy|Busulfan 0.4-1.0 mg/Kg/dose IV Q 12 hours X4 Doses Fludarabine 35 mg/m2/dose IV once daily X4 Doses Cyclophosphamide 10 mg/Kg/dose IV once daily X4 Doses Anti-thymocyte globulin - Thymoglobulin 2.5 mg/Kg/dose IV daily X4 Doses
56747|NCT01082133|Biological|Miltenyi CliniMACS|The CliniMACs device (Miltenyi Biotec, Auburn, CA) will be employed for the CD34 selection procedure. It consists of tubing, bags, and a pair of columns, placed at appropriate locations in the Tubing Set to facilitate the cell selection process.
56748|NCT01082146|Drug|Lurasidone|40 mg suspension, PO, for 7 days
56749|NCT01082159|Procedure|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
56750|NCT01082172|Device|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
56751|NCT01082185|Device|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
56752|NCT01084681|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
56753|NCT01084681|Device|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
57052|NCT01077284|Drug|Placebo|Placebo-matching capsules
57053|NCT01077297|Drug|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
56330|NCT01086982|Drug|Octreotide acetate LAR|30 mg, single dose
56331|NCT01086982|Drug|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
56332|NCT01087008|Drug|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
56333|NCT01087008|Other|No treatment control|Patients doesn't receive treatment
56334|NCT01087021|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form:solution for infusion
Route of administration: intravenous
56335|NCT01087034|Device|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
56336|NCT01087034|Radiation|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
56337|NCT01087034|Other|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
56338|NCT01087047|Device|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
56339|NCT01087060|Procedure|partial or radical nephrectomy|
56340|NCT00033410|Radiation|radiation therapy|
56630|NCT01079364|Drug|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
56631|NCT01079390|Device|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
56632|NCT01079416|Device|Capsule endoscopy, Esophagogastroduodenoscopy|
56633|NCT01081834|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
56634|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|50 ug
56635|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|50 ug
56636|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|100 ug
56637|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|100 ug
56638|NCT01081847|Other|Placebo|PLacebo: Isotonic saline solution
56639|NCT01081873|Drug|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
57112|NCT00033189|Drug|Coenzyme Q10|
57113|NCT01082861|Biological|Cervarix|Cervarix, HPV vaccin
57114|NCT01082861|Biological|Engerix-B|Engerix-B, HBV vaccin
57115|NCT01082874|Drug|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
57116|NCT01082874|Drug|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
57117|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
57118|NCT01085357|Procedure|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
57119|NCT01085357|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye.
57120|NCT01085370|Other|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
57121|NCT01085383|Drug|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
57122|NCT00033345|Drug|indole-3-carbinol|
57123|NCT01085422|Drug|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
57124|NCT01085422|Drug|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
57125|NCT01085435|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
57126|NCT01085448|Other|Core Stabilization|The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.
Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.
Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.
Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning.
57127|NCT01085474|Other|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
56180|NCT01078454|Drug|melphalan|Given PO
56258|NCT01078610|Biological|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
56259|NCT01078623|Drug|Aclidinium and Formoterol|Fixed Dose (I)
56559|NCT01081769|Drug|oral antipsychotics|daily treatment according to local label for maximally 24 months
56560|NCT00033046|Drug|Modafinil|
56561|NCT01081782|Drug|ONO-4641|0.15 mg once per day for 26 weeks
56562|NCT01081782|Drug|ONO-4641|0.1 mg once per day for 26 weeks
56563|NCT01081782|Drug|ONO-4641|0.05 mg once per day for 26 weeks
56564|NCT01081782|Drug|ONO-4641 placebo|Placebo once per day for 26 weeks
56565|NCT01081795|Drug|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
56566|NCT01081795|Drug|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
56567|NCT01081808|Biological|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
56568|NCT01081821|Drug|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
56569|NCT01081821|Drug|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
56570|NCT01081834|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
56571|NCT00033059|Drug|Tolcapone|
56572|NCT01081834|Drug|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
56573|NCT01084395|Behavioral|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
56882|NCT01076998|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
56883|NCT01076998|Other|Refresh PM Ointment|1 drop in each eye, one time
56884|NCT01077011|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
56885|NCT00032370|Procedure|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
56886|NCT01077011|Other|GenTeal Gel|1 drop in each eye, one time
56887|NCT01079793|Procedure|adjuvant therapy|
56888|NCT01079793|Radiation|intensity-modulated radiation therapy|
57191|NCT01074879|Dietary Supplement|Whey protein|Dietary supplement after training
57192|NCT00032136|Drug|exemestane|
57193|NCT01074879|Dietary Supplement|Milk protein|Dietary supplement after training
57194|NCT01074879|Dietary Supplement|Carbohydrates|Dietary supplement after training
57195|NCT01074892|Drug|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
57196|NCT01074892|Drug|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
57197|NCT01074892|Device|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
57198|NCT01074905|Drug|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
57199|NCT01074905|Drug|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
57200|NCT01074905|Drug|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
57201|NCT01074918|Drug|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
57202|NCT01074918|Drug|Potassium Chloride|Potassium Chloride
57203|NCT00032136|Drug|tamoxifen citrate|
56640|NCT01081886|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
56641|NCT01081886|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
56642|NCT00033072|Drug|Selegiline|
56643|NCT01081899|Other|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
56644|NCT01081912|Drug|Placebo|Capsules, no active substance, shells identical to active comparator capsules
56645|NCT01081912|Drug|Hydrocodone bitartrate|dosage form: capsule
Strengths 10mg, 20mg, 30mg, 40mg, 50mg
56646|NCT01081938|Drug|INSULIN GLARGINE|Pharmaceutical form: Lantus® (100 U/ml)
Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.
Dose regimen: Single daily dose of Insulin Glargine
56647|NCT01081938|Drug|INSULIN GLULISINE|Pharmaceutical form: Apidra® (100 U/ml)
Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device
Dose regimen:
Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine
56648|NCT01081951|Drug|olaparib|Oral dose capsule 200mg BID day 1-10 of every 21 day cycle, Oral dose capsule 400mg BID continuously after completion of combination therapy
56649|NCT01081951|Drug|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
56650|NCT01081951|Drug|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
56651|NCT01081951|Drug|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
56955|NCT01085136|Drug|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
56956|NCT00033332|Drug|pamidronate disodium|
56957|NCT01085136|Drug|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
56958|NCT01085149|Drug|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
56959|NCT01085162|Drug|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
56960|NCT01085175|Drug|LMI 1195|Single bolus intravenous injection of LMI 1195
56961|NCT01085188|Behavioral|ACC|Weekly community based behavioral counseling and case management
56181|NCT01078454|Drug|dexamethasone|Given PO
56182|NCT01078454|Drug|bortezomib|Given IV
56183|NCT01078480|Procedure|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
56184|NCT01078480|Procedure|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
56185|NCT01078493|Device|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
56186|NCT01078519|Drug|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
56187|NCT01078532|Other|SMART PHR|Patient receives an active PHR
56188|NCT01081002|Drug|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
56189|NCT01081041|Drug|Cetuximab|Administered intravenously
56190|NCT01081041|Drug|Cisplatin|Administered intravenously
56191|NCT01081041|Drug|Carboplatin|Administered intravenously
56192|NCT00032929|Drug|Selegiline|
56193|NCT01081041|Drug|5-Fluorouracil|Administered intravenously
56194|NCT01081054|Other|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
56195|NCT01081093|Procedure|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
56196|NCT01081106|Procedure|Low-Level Laser Therapy|A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.
administration.
56197|NCT01081119|Behavioral|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
56198|NCT01081132|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
56574|NCT01084395|Other|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
56575|NCT01084395|Other|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
56869|NCT01076842|Device|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
56870|NCT01076868|Drug|Primaquine|Primaquine x 14 days
56871|NCT01076881|Behavioral|exercise training|
56872|NCT01076894|Procedure|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
56873|NCT01076894|Procedure|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
56874|NCT00032357|Procedure|Ferritin reduction to 25 ng/ml by phlebotomy|
56875|NCT01076907|Other|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
56876|NCT01076907|Other|Control|Air will be used instead of warm water for unsedated colonoscopy.
56877|NCT01076920|Genetic|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
56878|NCT01076933|Procedure|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
56879|NCT01076933|Procedure|sham rTMS|sham rTMS
56880|NCT01076972|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
56881|NCT01076985|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
57204|NCT01074931|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.
The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study.
57205|NCT01074944|Drug|eliglustat tartrate|Oral Capsule in 50 mg or 100mg dosages
57206|NCT01074957|Device|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
57207|NCT01074957|Device|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
57208|NCT01074957|Other|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
57209|NCT01067235|Drug|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
56260|NCT01078623|Drug|Placebo|Placebo control
56261|NCT01078623|Drug|Formoterol|Formoterol dose
56262|NCT01078623|Drug|Aclidinium|Aclidinium dose
56263|NCT01078623|Drug|Aclidinium and Formoterol|Fixed dose (II)
56264|NCT01078649|Drug|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
56265|NCT01078662|Drug|olaparib|400mg (8 x 50mg capsules), oral BID until progression of the disease
56266|NCT00000916|Drug|Hydroxyurea|
56267|NCT00032591|Procedure|Weekly patient self-testing of prothrombin time|
56268|NCT01078675|Drug|rosuvastatin calcium|5 mg, oral, once daily, 24 months
56269|NCT01078675|Drug|rosuvastatin calcium|10 mg, oral, once daily, 24 months
56270|NCT01078675|Drug|rosuvastatin calcium|20 mg, oral, once daily, 24 months
56271|NCT01078701|Biological|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
56272|NCT01078701|Biological|Placebo|SPGN buffer
56962|NCT01077024|Other|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
56963|NCT01077037|Other|Decision Aid|Chest pain choice decision aid
56964|NCT01077050|Device|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
56965|NCT01077063|Procedure|paracentesis|surgical drainage of malignant ascites
56966|NCT01077063|Device|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
56967|NCT01077076|Drug|Zegerid|Zegerid taken once daily for 11 days.
56968|NCT01077076|Drug|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
56969|NCT01077076|Other|Placebo|Placebo taken once daily for 11 days.
56970|NCT01077102|Other|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
56971|NCT00032370|Procedure|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
56972|NCT01077115|Procedure|Laparoscopic cholecystectomy|
56973|NCT01077115|Procedure|Open Surgery|
56974|NCT01077154|Drug|Placebo|120mg SC once monthly for the first 6 months. 120mg SC every 3 months for the next 4 and a half years. Oral calcium (at least 500 mg) and vitamin D (at least 400 IU) for 5 years.
57270|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
57271|NCT01072617|Device|Transcranial magnetic stimulation via MagPro x100 device|Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.
Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system.
57272|NCT01072630|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
57273|NCT01072630|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
56199|NCT01081132|Other|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
56505|NCT01084369|Drug|Testosterone|NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.
Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable.
56506|NCT01084382|Dietary Supplement|Arthrospira platensis|Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.
One group will so haved received Arthrospira platensis for 24 weeks.
56507|NCT01084395|Behavioral|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
56508|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
56509|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
56510|NCT00033410|Drug|carboplatin|
56511|NCT01086800|Other|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
56512|NCT01086813|Drug|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
56513|NCT01086826|Drug|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
56514|NCT01086826|Drug|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
56515|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.
concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)
56516|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.
RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times.
56517|NCT01086839|Drug|sodium chloride 6%|one ampoule sodium chloride 6% per day
inhalation use
for 28 days
56683|NCT01084655|Drug|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
56684|NCT01076543|Other|Laboratory Biomarker Analysis|Correlative studies
56685|NCT01076543|Drug|Lenalidomide|Given PO
56686|NCT00032292|Drug|Visilizumab|
56687|NCT01076543|Drug|Temsirolimus|Given IV
56688|NCT01076556|Drug|Alvocidib Hydrochloride|Given IV
56689|NCT01076556|Drug|Cyclophosphamide|Given IV
56690|NCT01076556|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
56691|NCT01076556|Other|Pharmacological Study|Correlative studies
56692|NCT01076556|Biological|Rituximab|Given IV
56693|NCT01076569|Other|laboratory biomarker analysis|Correlative studies
56694|NCT01076582|Drug|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
56695|NCT01076582|Drug|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
56696|NCT01076595|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
56697|NCT00032305|Drug|Visilizumab|
56990|NCT01079988|Drug|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
56991|NCT01079988|Drug|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
56992|NCT01079988|Drug|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
56993|NCT01079988|Drug|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
56994|NCT01080027|Drug|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
56273|NCT01078714|Drug|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
56274|NCT01078727|Device|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
56275|NCT01078753|Drug|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
56276|NCT01078753|Drug|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
56277|NCT01078766|Other|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
56278|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.
Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
56279|NCT01081184|Biological|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
56576|NCT01084408|Device|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
56577|NCT01084408|Device|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
56578|NCT01084421|Behavioral|Computer-based parent-adolescent HIV communication|The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
56579|NCT00033293|Procedure|magnetic resonance imaging|Correlative studies
56580|NCT01084434|Dietary Supplement|probiotic|Bifidobacterium lactis HN019 10^9 CFU/day 1 sachet once a day for 7 weeks
56581|NCT01084434|Dietary Supplement|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
56582|NCT01084434|Dietary Supplement|Synbiotic|(Bifidobacterium lactis 10^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
56583|NCT01084434|Dietary Supplement|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
56584|NCT01084447|Device|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
57054|NCT01077310|Drug|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
57055|NCT01077310|Drug|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
57056|NCT01077323|Drug|exenatide|subcutaneous injection, dosing according to normal clinical practice
57057|NCT01077323|Drug|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
57058|NCT01077323|Other|No diabetes therapy|Subjects not diagnosed with diabetes
57059|NCT01077349|Procedure|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
57060|NCT00032383|Behavioral|Tai Chi|
57061|NCT01077349|Procedure|standard care|extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:
Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR
Diuresis < 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR
Or serum urea > 36 mmol/l OR
Or life threatening hyperkalemia
57062|NCT01077362|Drug|placebo|SC injections
57063|NCT01077362|Drug|ustekinumab 45 mg|SC injections
57064|NCT01077362|Drug|ustekinumab 90 mg|SC injections
57065|NCT01077375|Drug|Placebo|Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.
Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period.
57066|NCT01077375|Drug|Milnacipran|Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.
Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period.
57067|NCT01077388|Behavioral|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
57068|NCT01077401|Drug|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
56518|NCT01086839|Drug|sodium chloride 0,9%|one ampoule sodium chloride 0,9% per day
inhalation use
for 28 days
56519|NCT01086852|Biological|FACTOR X|Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.
Post surgery- FX trough levels of 50% should be achieved.
Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min.
56809|NCT01079741|Biological|NY-ESO-1 protein; Poly-ICLC; Montanide|Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.
Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
56810|NCT01079754|Drug|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
56811|NCT01079754|Drug|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
56812|NCT01079767|Drug|temsirolimus|
56813|NCT01079780|Biological|cetuximab|Given IV
56814|NCT00032747|Drug|Vasopressin V2 Receptor Antagonist|
56815|NCT01079780|Biological|ramucirumab|Given IV
56816|NCT01079780|Drug|irinotecan hydrochloride|Given IV
56817|NCT01079793|Drug|ixabepilone|
56818|NCT01082198|Biological|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
56819|NCT01082198|Biological|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
56820|NCT01082198|Biological|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
56821|NCT01082198|Biological|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
56822|NCT00033124|Behavioral|Behavior Therapy|
56823|NCT01082198|Biological|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
56824|NCT01082198|Other|flow cytometry|
56825|NCT01082198|Procedure|adjuvant therapy|
56826|NCT01082211|Other|circulating tumor cell analysis|
56995|NCT01080066|Other|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
56996|NCT01080079|Drug|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
56997|NCT00032799|Drug|natalizumab|
56998|NCT01080079|Other|Purified Water|Purified Water
56999|NCT01080092|Behavioral|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
57000|NCT01080092|Behavioral|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
57001|NCT01082484|Drug|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
57002|NCT01082484|Drug|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
57003|NCT01082484|Drug|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
57004|NCT01082497|Behavioral|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
57005|NCT01082510|Drug|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
57006|NCT01082510|Drug|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
57007|NCT01082523|Other|Text message reminders|Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
57008|NCT01082549|Drug|gemcitabine/carboplatin|i.v.
56057|NCT01086020|Drug|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
56058|NCT01086046|Drug|Low molecular weight heparin|Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour
Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days.
56059|NCT01086085|Drug|Adefovir|Adefovir 10 mg po once daily for 36 weeks
56060|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
56585|NCT01084447|Device|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
56586|NCT01084473|Drug|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
56587|NCT01084473|Drug|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
56588|NCT01084473|Drug|Placebo|0.9 % NaCl will be infused.
56589|NCT01084486|Drug|Metformin|
56590|NCT00000918|Drug|Ritonavir|
56591|NCT01087073|Behavioral|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
56889|NCT01079806|Drug|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
56890|NCT01079806|Drug|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
56891|NCT01079819|Drug|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
56892|NCT01079819|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
56893|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
56894|NCT00032760|Behavioral|Meditation|
56895|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
56896|NCT01079832|Radiation|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
56897|NCT01079832|Procedure|quality-of-life assessment|Ancillary studies
56898|NCT01079845|Behavioral|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
56118|NCT01083589|Drug|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
56119|NCT01083602|Drug|panobinostat|PAN 20 mg PO given TIW, weeks 1&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
56120|NCT01083602|Drug|bortezomib|
56121|NCT00033254|Drug|thalidomide|Given orally
56122|NCT01083602|Drug|dexamethasone|
56123|NCT01083615|Drug|custirsen sodium|Dose = 640 mg total dose. Study treatment starts with a Loading Dose Period ( 1 week) during which three infusions of study agent (custirsen) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel or cabazitaxel on a 21-day cycle with weekly study agent (custirsen) infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.
Patients will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol.
56124|NCT01083615|Drug|Isotonic, 0.9% sodium chloride|Dose = 640 mg total dose. Study treatment starts with a Loading Dose Period ( 1 week) during which three infusions of study agent (placebo) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel or cabazitaxel on a 21-day cycle with weekly study agent (placebo) infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.
Patients will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol.
56125|NCT01083615|Drug|docetaxel|Dose=75 mg/m2 total dose for each 21-day cycle. Administration of docetaxel begins after the Loading Dose Period and after administration of study agent (custirsen or placebo) on Day 1 of each 21-day cycle.
56126|NCT01083615|Drug|cabazitaxel|Dose=25 mg/m2 total dose for each 21-day cycle. Administration of cabazitaxel begins after the Loading Dose Period and after administration of study agent (custirsen or placebo) on Day 1 of each 21-day cycle.
56127|NCT01083628|Behavioral|Txt4Mood|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
56128|NCT01083641|Drug|Estradiol|10mg oral three times daily
56129|NCT01083654|Behavioral|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
56130|NCT01083654|Behavioral|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
56131|NCT01083667|Drug|Pyrimethamine|Open Label, dose escalating,
56827|NCT01082211|Other|laboratory biomarker analysis|
56828|NCT01082211|Other|questionnaire administration|
56829|NCT01082211|Procedure|adjuvant therapy|
56830|NCT01082211|Radiation|3-dimensional conformal accelerated partial breast irradiation|
56831|NCT01082224|Drug|iodinated contrast dye|
56832|NCT01082224|Drug|motexafin gadolinium|
57128|NCT01085474|Other|2|The best intervention used in the pilot study will be chosen and included in the main study.
57129|NCT01085487|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
57130|NCT01085487|Drug|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
57131|NCT01085487|Drug|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
57132|NCT01085500|Behavioral|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
57133|NCT00033358|Drug|medroxyprogesterone|Given intramuscularly
57134|NCT01085500|Procedure|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
57135|NCT01085513|Device|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
57136|NCT01085526|Biological|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
57137|NCT01077401|Drug|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
57138|NCT01077427|Device|Gemcitabine + Cisplatin + regional hyperthermia|Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²) Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²) Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course
* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17
57139|NCT00032396|Drug|Retisert Implant|
57140|NCT01077427|Drug|Gemcitabine|Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)
57141|NCT01077440|Genetic|DNA analysis|DNA analysis will be performed on samples collected.
56061|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
56062|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
56063|NCT01086150|Other|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
56064|NCT01086150|Other|Skin biopsy|Skin biopsy specimens will be processed and analyzed for nerve fiber count, nerve and skin morphology and sodium channel specific epitope expression in keratinocytes.
56065|NCT01086163|Drug|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
56066|NCT01086176|Device|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
56067|NCT00033384|Drug|CI-1040|
56068|NCT01077999|Drug|Carboplatin|Carboplatin AUC = 2 , weekly.
56069|NCT00032487|Drug|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
56070|NCT01077999|Drug|Paclitaxel|Paclitaxel 50 mg/m2, weekly
56071|NCT01077999|Drug|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
56072|NCT01077999|Radiation|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
56073|NCT01078012|Behavioral|Trained counselling|
56074|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
56075|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
56076|NCT01078038|Device|Cypher|Sirolimus-eluting stent implantation
56077|NCT01078038|Device|Xience V|Everolimus-eluting Stent implantation
56078|NCT01078051|Procedure|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
56378|NCT01081483|Drug|Placebo|See arm description for more information
56379|NCT01081535|Drug|ketorolac, fentanyl|intravenous PCA
56380|NCT01081548|Drug|atorvastatin|20 mg
56899|NCT01079858|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
56900|NCT01079871|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
56901|NCT01079884|Drug|esomeprazole 40 mg|40 mg daily for 4 weeks
56902|NCT01079897|Device|Atopiclair|topical applied cream, twice daily
56903|NCT01079897|Device|EHK02-01|topical applied cream containing 7% ectoine
56904|NCT01079910|Drug|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
56905|NCT00032773|Drug|pentostatin for injection|
56906|NCT01079910|Drug|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
56907|NCT01079923|Dietary Supplement|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
56908|NCT01079923|Dietary Supplement|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
56909|NCT01079936|Drug|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
56910|NCT01079936|Drug|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
56911|NCT01079936|Procedure|Stem Cell Infusion|Stem cell infusion on Day 0.
57210|NCT01067261|Device|Transcutaneous mechanical nerve stimulation (TMNS)|Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes.
57211|NCT00031655|Drug|cyclosporine|Given PO
57212|NCT01067261|Other|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
57213|NCT01067274|Drug|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
57214|NCT01067274|Drug|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
57215|NCT01067274|Drug|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
56132|NCT00000918|Drug|Lamivudine/Zidovudine|
56133|NCT00033254|Procedure|quality-of-life assessment|Ancillary studies
56442|NCT01078974|Drug|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
56443|NCT01078974|Drug|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
56444|NCT01078987|Procedure|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
56445|NCT01079000|Behavioral|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. This notification sheet will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
56446|NCT01079000|Behavioral|Involvement of a care manager|A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
56447|NCT01079000|Behavioral|Usual care|Usual care provided to asthma patients when discharged from the ED
56448|NCT01079013|Drug|treosulfan|12 g/m2 x 3 days
56449|NCT01079052|Drug|Famotidine|Tablets
56450|NCT00032630|Procedure|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
56451|NCT01079065|Drug|Famotidine|Tablets
56452|NCT01079078|Drug|Acetaminophen|
56453|NCT01079091|Device|Hepa Wash|Intervention frequency: 1-10 treatments (decision of the investigator)
Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)
56454|NCT01079091|Procedure|Standard Medical Therapy|Standard of care treatment
56455|NCT01079104|Device|Hepa Wash|Intervention frequency: 1-10 treatments (decision of the investigator)
Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)
56456|NCT01079104|Procedure|Standard Medical Therapy|Standard of care treatment
56457|NCT01079117|Drug|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
57142|NCT01077440|Genetic|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
57143|NCT01077440|Other|flow cytometry|Flow cytometry will be done on the samples collected.
57144|NCT01077440|Other|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
57145|NCT01077453|Drug|letrozole|Given orally
57146|NCT01077453|Other|quality-of-life assessment|Ancillary studies
57147|NCT01077453|Other|laboratory biomarker analysis|Correlative studies
57148|NCT01077466|Drug|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
56200|NCT01081145|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
56201|NCT01081145|Other|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
56202|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|Drug: SCH 900518
Biologic: Peginterferon alfa-2b(PegIntron)
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
56203|NCT00032942|Drug|Lofexidine|
56204|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|Drug: SCH 900518
Biologic: Peginterferon alfa-2b
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
56205|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.
Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.
56206|NCT01083706|Drug|azacitidine|Given SC or IV
56207|NCT01083706|Other|laboratory biomarker analysis|Correlative studies
56208|NCT01083719|Procedure|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
56209|NCT01083732|Drug|dabigatran etexilate|Experimental dose chosen based on age and weight
56210|NCT01083758|Drug|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
56381|NCT01081548|Drug|atorvastatin|20 mg
56382|NCT00032994|Behavioral|Behavior Therapy|
56383|NCT01081561|Drug|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
56384|NCT01081574|Drug|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
56385|NCT01081587|Procedure|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
56386|NCT01081587|Behavioral|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
56387|NCT01084096|Behavioral|Increasing use of Antenatal Corticosteroids (ACS)|Intervention clusters:
Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.
Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.
Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants.
56388|NCT01084109|Other|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
56389|NCT01084109|Other|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
56390|NCT01084122|Drug|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
56391|NCT01084135|Drug|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
56392|NCT01084135|Other|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
56393|NCT01084148|Drug|V0034CR01B|
56394|NCT01084148|Drug|V0034CR01B vehicle|
56395|NCT00033293|Biological|therapeutic immune globulin|Given IV
57216|NCT01067287|Drug|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
57217|NCT01067287|Biological|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
57218|NCT01067300|Procedure|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
57219|NCT01067313|Device|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
57220|NCT01067313|Device|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
57221|NCT01067326|Drug|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
57222|NCT00000912|Drug|Efavirenz|
57223|NCT00031655|Radiation|total-body irradiation|Undergo TBI
57224|NCT01067326|Drug|Placebo|1 pill per day by mouth for 4 months
57225|NCT01067339|Drug|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
57226|NCT01067339|Drug|placebo|placebo, by mouth, once daily for six months
57227|NCT01067352|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
57228|NCT01067365|Drug|Androxal|12.5 mg once daily
57229|NCT01067365|Drug|Androxal|25 mg once daily
56280|NCT01081197|Other|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
56281|NCT01081210|Other|Ultrasound examination|Screening with bedside ultrasound examination
56282|NCT01081223|Biological|Cancer vaccine plus immune adjuvant, plus activated white blood cells|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
56283|NCT01081249|Drug|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
56458|NCT01079117|Drug|Slow release oral morphine|
56459|NCT01079117|Drug|Methadone|
56460|NCT01081587|Other|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
56461|NCT01081600|Other|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
56754|NCT01084707|Drug|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
56755|NCT01084707|Drug|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
56756|NCT01084707|Drug|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
56757|NCT01084720|Drug|V0034 CR|
56758|NCT01084746|Behavioral|Tailored interactive intervention to increasing CRCS|The three arms of the intervention consist of no patient intervention, printed educational materials, or PC-based tailored interactive intervention.Patients in Group 1 will not receive a patient-directed intervention. Patients in Group 2 will receive generic printed educational materials about CRCS in the PEC when they arrive at the KSC Main Campus for their appointment. Patients in Group 3 will receive a tailored interactive PC-based intervention at a freestanding kiosk in the PEC.
56759|NCT01084759|Drug|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
56760|NCT01084759|Drug|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
56761|NCT00033306|Drug|Fluoropyrimidine|
56762|NCT01084772|Other|Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation or standard instrumentation, depending on randomization assignment.
56763|NCT01084772|Other|Total Knee Arthroplasty|TKA will be performed with VISIONAIRE patient matched instrumentation or standard instrumentation, depending on randomization assignment.
56764|NCT01084811|Procedure|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
56765|NCT01084824|Drug|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
56766|NCT01084824|Drug|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
56211|NCT01083771|Dietary Supplement|Olive Oil|Minimum of 3 tablespoon of olive oil per day
56212|NCT01083784|Drug|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
56213|NCT01083784|Drug|Control group|Control group
56214|NCT01083797|Drug|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
56215|NCT01083797|Drug|Chloral Hydrate|Initial dose=50 mg/kg
56216|NCT00033267|Drug|temsirolimus|Given IV
56217|NCT01083810|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
56218|NCT01083823|Other|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
56520|NCT01086865|Drug|Apetiviton BC|Administer the recommended dosage preferably one hour before the main meal:
Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily.
56521|NCT00033410|Drug|paclitaxel|
56522|NCT01086878|Drug|cotrimoxazole|Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:
less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim
greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim
56523|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
56524|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
56525|NCT01086904|Biological|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
56526|NCT01086917|Biological|PfSPZ Challenge|each volunteer to receive a single dose
56527|NCT01079130|Drug|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
56528|NCT00032630|Procedure|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
56529|NCT01079130|Drug|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
56530|NCT01079130|Drug|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
56698|NCT01076621|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
56699|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
56700|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
56701|NCT01076647|Drug|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
56702|NCT01076647|Drug|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
56703|NCT01076673|Biological|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
56704|NCT01076673|Drug|Hyaluronic Acid|Hyaluronic acid injections
56705|NCT01076686|Drug|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
56706|NCT01076699|Drug|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
56707|NCT01076699|Drug|0.125 mg RVX-100|This group is taking an average dose of RVX-100
56708|NCT00032331|Procedure|PET Imaging|
56709|NCT01076699|Drug|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
56710|NCT01076699|Drug|placebo|This group is taking a placebo
56711|NCT01076712|Other|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
56712|NCT01079429|Genetic|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
56713|NCT01079442|Other|Postoperative coffee|schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):
08:00 100mL beverage
12:00 100mL beverage
16:00 100mL beverage
56714|NCT00032708|Biological|Dryvax|
56715|NCT01079442|Other|water|The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:
08:00 100mL beverage
12:00 100mL beverage
16:00 100mL beverage
56716|NCT01079455|Drug|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
56717|NCT01079481|Drug|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
56284|NCT01081249|Drug|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
56285|NCT01081262|Biological|Bevacizumab|Given IV
56286|NCT00032955|Drug|Buprenorphine/naloxone|
56287|NCT01081262|Drug|Capecitabine|Given PO
56288|NCT01081262|Drug|Carboplatin|Given IV
56289|NCT01081262|Other|Laboratory Biomarker Analysis|Correlative studies
56290|NCT01081262|Drug|Oxaliplatin|Given IV
56291|NCT01081262|Drug|Paclitaxel|Given IV
56292|NCT01081262|Other|Quality-of-Life Assessment|Ancillary studies
56293|NCT01081275|Behavioral|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
56294|NCT01081275|Behavioral|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
56295|NCT01081288|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
56296|NCT01081301|Behavioral|Living with Hope Program|The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity "Stories of the Present". Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals.
56297|NCT00000232|Drug|Buprenorphine|
56298|NCT00000916|Drug|Zidovudine|
56299|NCT00032968|Drug|Buprenorphine/naloxone|
56300|NCT01081314|Behavioral|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
56592|NCT01087073|Behavioral|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
56767|NCT01084837|Drug|velcade|INDUCTIoN (Cycles 1-4)
Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment
Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)
For patients wich is not planned autotransplantation, add:
Cycles 5-8
Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment
Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)
EXTENSION TREATMENT(Cycles 9-12)
Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22
Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)
56768|NCT01084863|Drug|CT-P6|CT-P6: administered every 3 weeks
56769|NCT01084863|Drug|Herceptin|Herceptin: administered every 3 weeks
56770|NCT01084863|Drug|Paclitaxel|Paclitaxel: administered every 3 weeks
56771|NCT01084876|Drug|CT-P6|Administered every 3 weeks
57069|NCT01080105|Behavioral|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
57070|NCT01080105|Behavioral|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
57071|NCT01080105|Behavioral|Educational website|Participants will receive access to a static educational website for 12 weeks.
57072|NCT01080118|Device|Airtraq|Subjects were taught with the Airtraq video laryngoscope
57073|NCT01080118|Other|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
57074|NCT01080131|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
57075|NCT01080131|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
57076|NCT00032812|Drug|Raclopride|
57077|NCT01080131|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
57078|NCT01080131|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
57079|NCT01080144|Other|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
57080|NCT01080157|Device|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
57081|NCT01080183|Other|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
56531|NCT01079130|Drug|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
56532|NCT01079143|Drug|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
56533|NCT01079143|Drug|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
56534|NCT01079143|Drug|Myfortic|Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.
In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.
An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days.
56535|NCT01079143|Drug|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
56833|NCT00033150|Behavioral|Fast ForWord|
56834|NCT01082224|Other|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
56835|NCT01082237|Drug|Escitalopram|Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
56836|NCT01082250|Drug|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
56837|NCT01082263|Drug|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
56838|NCT01082276|Drug|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
56839|NCT01082289|Drug|Lurasidone|
56840|NCT01082302|Drug|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
56841|NCT01082302|Other|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
56718|NCT01079494|Other|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
57009|NCT01082549|Drug|gemcitabine/carboplatin plus Iniparib|i.v.
57010|NCT01082562|Drug|BMS-844421|Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg
SAD: Once, 1 Day
MAD: IV loading followed by 4 weekly doses, 29 Days
57011|NCT00033163|Drug|Adefovir dipivoxil|
57012|NCT01082562|Drug|0.9% sodium chloride injection solution|Injection solution, Subcutaneous, 37.5 mg
SAD: Once, 1 Day
MAD: IV loading followed by 4 weekly doses, 29 Days
57013|NCT01082575|Device|Oxygen Monitoring|No intervention
57014|NCT01082588|Drug|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
57015|NCT01082588|Drug|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
57016|NCT01082601|Procedure|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
57017|NCT01082614|Device|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV > 12%.
57018|NCT01082627|Drug|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
57019|NCT01082627|Other|common daily practice|common daily practice
57020|NCT01082640|Drug|Febuxostat|Febuxostat capsules
57021|NCT01082640|Drug|Placebo|Febuxostat placebo-matching capsules
57022|NCT00033163|Drug|Tenofovir disoproxil fumarate|
57023|NCT01082653|Biological|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
57024|NCT01082666|Device|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
57025|NCT01082666|Device|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
57026|NCT01085188|Behavioral|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
57027|NCT01085188|Behavioral|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
56593|NCT01087086|Behavioral|Crononutrition|After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period ("autonomy phase") in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.
56594|NCT01087086|Behavioral|American Heart Association|After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period ("autonomy phase") in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.
56595|NCT01087099|Drug|Albendazole|Treatment with albendazole
56596|NCT01087112|Behavioral|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
56597|NCT01087112|Behavioral|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
56598|NCT01087125|Drug|No Interventions|No Interventions
56599|NCT00033423|Biological|rituximab|
56600|NCT01087138|Behavioral|exercise|exercise class 3x's/week
56601|NCT01087138|Behavioral|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
56602|NCT01087151|Drug|ABT-263|Oral repeating dose
56603|NCT01087151|Drug|rituximab|Intravenous repeating dose
56604|NCT01087164|Behavioral|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
56605|NCT01087164|Behavioral|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
56606|NCT01087177|Other|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
56607|NCT01087190|Drug|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
56608|NCT01087203|Biological|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
56609|NCT01087203|Biological|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
56912|NCT00033150|Behavioral|Computer Assisted Language Intervention|
57082|NCT01080196|Other|RENEW vs TRAD|Subjects perform lower body resistance exercise via the RENEW protocol or via a "standard of care" protocol
57083|NCT01080209|Drug|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
57084|NCT01080209|Other|Sham|Patients who recieved sham in a previous study.
57085|NCT01080222|Drug|telaprevir|tablet, 1125-mg, twice daily
57086|NCT01080222|Drug|VX-222|capsule, 100-mg, twice daily
57087|NCT00032825|Drug|Ketaconazole|
57088|NCT01080222|Drug|ribavirin|tablet, 1000-mg for subjects weighing <75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
57089|NCT01080222|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
57090|NCT01080222|Drug|VX-222|capsule, 400-mg, twice daily
56134|NCT01086228|Device|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
56135|NCT01086241|Procedure|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
56136|NCT01086241|Procedure|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
56137|NCT01086254|Drug|Iniparib|Pharmaceutical form: solution for infusion
Route of administration: 60-minute IV infusion
56138|NCT01086254|Drug|gemcitabine|Pharmaceutical form: solution for infusion
Route of administration: 30-minute IV infusion
56139|NCT01086254|Drug|cisplatin|Pharmaceutical form: solution for infusion
Route of administration: 1- to 4-hour IV infusion, according to the local standard
56140|NCT01086267|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
56141|NCT01086267|Drug|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
56142|NCT01086267|Drug|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
56143|NCT01086332|Drug|Nelfinavir|1250 mg twice daily
56144|NCT00033397|Procedure|biopsy|
56842|NCT01082315|Drug|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
56843|NCT01082328|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
56844|NCT01084876|Drug|Herceptin|Administered every 3 weeks
56845|NCT01084876|Drug|Paclitaxel|Administered every 3weeks
56846|NCT01084889|Device|TiLOOP® Total 6 (Surgical mesh implantation)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans vaginal by the aid of surgical instruments to place the mesh arms.
56847|NCT01084902|Drug|Latanoprost|once daily
56848|NCT01084902|Drug|Brinzolamide|Two times daily
56849|NCT01084928|Behavioral|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
57149|NCT01077479|Drug|Metformin|Metformin 1500mg nocte for 6 months
57150|NCT00032409|Behavioral|Music therapy-based relaxation/stress reduction|
57151|NCT01077492|Other|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
57152|NCT01077505|Biological|albiglutide|albiglutide 50mg weekly subcutaneous injection
57153|NCT01077505|Drug|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
57154|NCT01077518|Drug|Ofatumumab and Bendamustine infusions (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
57155|NCT01077518|Drug|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
57156|NCT01077531|Drug|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
57157|NCT01077531|Drug|Matching placebo|Matching placebo for intravenous infusion
57028|NCT01085201|Drug|Lexiscan|Given as an infusion
57029|NCT01085214|Other|Laboratory Biomarker Analysis|Correlative studies
57030|NCT01085214|Drug|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
57031|NCT00033332|Drug|thalidomide|
56079|NCT01078051|Drug|optimal medical therapy|optimal medical therapy
56080|NCT00032487|Drug|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
56081|NCT01078129|Behavioral|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
56082|NCT01078129|Behavioral|non-CRT|waiting list
56083|NCT01078142|Drug|Temsirolimus, Rituximab, Bendamustin|Phase I:
Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)
56084|NCT01078168|Drug|Acitretin|30mg per day from Day 1 to Day 28
56085|NCT01078168|Drug|Placebo|Placebo
56086|NCT01078181|Procedure|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
56087|NCT01078194|Device|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
56088|NCT01078272|Other|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
56089|NCT01078272|Other|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
56090|NCT01078285|Behavioral|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
56091|NCT00032487|Drug|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm 2
56092|NCT01078285|Behavioral|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
56093|NCT01078298|Drug|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
56913|NCT01082341|Biological|Immunization with P. vivax irradiated sporozoites|Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.
14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials.
56914|NCT01082354|Drug|recombinant somatropin|as per standard practice
56915|NCT01082367|Drug|TOBI|TOBI (tobramycin inhaled solution)
56916|NCT01082367|Drug|Placebo to TOBI|Placebo to tobramycin
56917|NCT01082380|Drug|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of [14C]PF 02341066
56918|NCT01082393|Drug|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
56919|NCT01082393|Drug|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
56920|NCT01082393|Drug|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
56921|NCT01082393|Drug|cold cream|4 applications (day 1, day 3, day 6 and day 10)
56922|NCT01082406|Drug|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
56923|NCT00033150|Behavioral|Individual Language Intervention|
56924|NCT01082406|Drug|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
56925|NCT01082419|Device|ARFI measurement|ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a "light" apnea.
For group A the measurement is made by a second and a third investigator during the same examination.
56926|NCT01082419|Device|ARFI measurement|ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a "light" apnea.
For all other groups (B, C, D, E) ARFI is measured only once.
56927|NCT01082419|Device|ARFI measurement|ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a "light" apnea.
For groups F and G : ARFI is measured again after clinical healing.
56928|NCT01082432|Other|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
56929|NCT01082445|Drug|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
56930|NCT01082445|Drug|Placebo|Placebo
56145|NCT01086332|Drug|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
56146|NCT01086345|Radiation|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
56147|NCT01086345|Biological|bevacizumab|Given IV
56148|NCT01086345|Drug|irinotecan hydrochloride|Given IV
56149|NCT01086358|Drug|Usual prescribed triptan|usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
56150|NCT01086358|Drug|Treximet for migraine treatment|Treximet is the combination of sumatriptan 85 mg plus naproxen sodium 500mg
56151|NCT01086371|Other|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
56152|NCT01086371|Other|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
56153|NCT01086384|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
56154|NCT01086384|Drug|Fluticasone furoate|Inhaled corticosteroid
56462|NCT01081613|Other|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
56463|NCT01081626|Drug|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
56464|NCT01081639|Drug|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
56465|NCT01081639|Drug|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
56466|NCT00033007|Behavioral|Behavior Therapy|
56467|NCT01081652|Drug|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
56468|NCT01081652|Drug|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
56469|NCT01081678|Drug|Placebo|Placebo, subcutaneous (under the skin) injection
56470|NCT01081678|Drug|AMG 785 140 mg|140mg AMG 785, subcutaneous (under the skin) injection
57158|NCT01077544|Drug|Nilotinib|Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.
Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water.
57159|NCT01077557|Other|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
57160|NCT01072318|Drug|Letrozole|Letrozole 2.5mg
57161|NCT01072331|Drug|MP-513|MP-513 10 mg, once a day, for 4 weeks
57162|NCT01072331|Drug|MP-513|MP-513 20 mg, once a day, for 4 weeks
57163|NCT01072331|Drug|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
57164|NCT01072344|Drug|Chamomile (Matricaria recutita)|500 mg 3 times daily
57165|NCT01072357|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
57166|NCT01072357|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
57167|NCT00031954|Drug|paclitaxel|
57168|NCT01072370|Biological|Cord Blood Infusion|red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion
57169|NCT01072370|Biological|Intravenous Sham|intravenous infusion of 5% dextrose, ¼ normal saline solution
56219|NCT01083862|Behavioral|Educational Intervention - Text plus DVD/VHS|In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients "Living with Coronary Artery Disease." They also were given a booklet on the same subject material written at a 5th grade level.
56220|NCT01083862|Behavioral|Educational Intervention - Text Only|In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients "Living with Coronary Artery Disease." Subject material was written at a 5th grade level.
56221|NCT01083875|Drug|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
56222|NCT01083875|Drug|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
56223|NCT01083888|Drug|ASP1517|oral
56094|NCT01080807|Drug|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
56095|NCT01080820|Drug|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
56096|NCT01080820|Drug|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
56097|NCT00032903|Drug|Gimatecan® (ST 1481)|
56396|NCT01084161|Drug|N1539|5 mg IV once per day
56397|NCT01084161|Drug|N1539|7.5 mg IV once per day
56398|NCT01084161|Drug|N1539|15 mg IV once per day
56399|NCT01084161|Drug|N1539|30 mg IV once per day
56400|NCT01084161|Drug|placebo|IV placebo once per day
56401|NCT01084161|Drug|Morphine|morphine 10-15 mg IV once per day
56402|NCT01084161|Drug|N1539|60 mg IV once per day
56403|NCT01084174|Drug|Peanut powder|Delivered orally
56404|NCT01084174|Drug|Peanut extract|Delivered sublingually
56405|NCT01084174|Drug|Placebo extract|Delivered sublingually
56406|NCT00033293|Other|clinical observation|Undergo observation
56407|NCT01084174|Drug|Placebo powder|Delivered orally
56408|NCT01084187|Drug|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
56409|NCT01084200|Drug|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
56410|NCT01084200|Drug|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
56411|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
56412|NCT01086410|Drug|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
57230|NCT01067378|Other|Peer-led debriefing|
57231|NCT01067378|Other|Expert instructor debriefing|
57232|NCT01069913|Drug|BG00012|Sequence 1: Oral 240 mg BG00012 Standard Formulation & Following 7 day washout period, 240 mg BG00012 API.
Sequence 2: 240 mg BG00012 API & Following 7 day washout period, 240 mg BG00012 Standard Formulation.
57233|NCT00031785|Radiation|radiation therapy|
57234|NCT01069926|Drug|AZD1656|Single dose oral tablet
57235|NCT01069939|Drug|Esomeprazole|20mg, capsule, 72 weeks
57236|NCT01069939|Drug|Placebo|Placebo, capsule, 72 weeks
57237|NCT01069952|Device|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
57238|NCT01069965|Drug|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
57239|NCT01069965|Drug|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
57240|NCT01069965|Drug|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
57241|NCT01069965|Drug|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
57242|NCT01069965|Drug|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
57243|NCT01069965|Drug|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
57244|NCT00031798|Drug|methylphenidate hydrochloride|
57245|NCT01069991|Behavioral|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
57246|NCT01069991|Behavioral|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
57247|NCT01070004|Other|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
56471|NCT01081678|Drug|AMG785 70mg|AMG 785 70mg, subcutaneous (under the skin) injection
56472|NCT01081678|Drug|AMG 785 210mg|210mg AMG 785, subcutaneous (under the skin) injection
56473|NCT01081691|Biological|CNTO 5825|10 mg/kg single dose IV or matching placebo
56474|NCT01081691|Biological|CNTO 5825|3 mg/kg single dose IV or matching placebo
56475|NCT01081691|Biological|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
56476|NCT01081691|Biological|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
56477|NCT00033020|Behavioral|Behavior Therapy|
56478|NCT01081691|Biological|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
56479|NCT01081691|Biological|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
56480|NCT01081691|Biological|CNTO 5825|1 mg/kg single dose IV or matching placebo
56481|NCT01081704|Drug|ustekinumab|Single dose of 45 mg subcutaneous injection
56482|NCT01081704|Drug|ustekinumab|Single dose of 90 mg subcutaneous injection
56483|NCT01081717|Drug|systemic non-biological treatments|as prescribed
56772|NCT00033306|Drug|Irinotecan|
56773|NCT01076712|Other|Education Classes|Education Classes
56774|NCT01076725|Device|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
56775|NCT01076725|Device|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
56776|NCT01076764|Drug|Otamixaban (XRP0673)|Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion
56777|NCT01076764|Drug|Otamixaban matching placebo|Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion
56778|NCT01076764|Drug|Unfractionated Heparin|Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion
56779|NCT01076764|Drug|Unfractionated Heparin matching placebo|Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion
56224|NCT01083901|Behavioral|Resistance training|high intensity progressive resistance exercise training
56225|NCT01083927|Procedure|Rotational Narrow Strip Conjunctival Graft|Surgical technique
56226|NCT01083927|Procedure|Full Conjunctival Graft|Surgical technique
56227|NCT00033280|Drug|temozolomide|
56228|NCT01083940|Other|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
56229|NCT01083953|Drug|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
56230|NCT01086592|Other|Strong progressive strengthening exercises of lower limbs|Lower limb weight
56231|NCT01086592|Other|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
56232|NCT01086592|Other|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
56233|NCT01086605|Drug|pixantrone dimaleate|Given IV
56234|NCT00033397|Radiation|gadopentetate dimeglumine|
56235|NCT01086618|Drug|systemic chemotherapy|
56236|NCT01086618|Procedure|adjuvant therapy|
56237|NCT01086618|Procedure|quality-of-life assessment|
56238|NCT01086618|Procedure|therapeutic conventional surgery|
56239|NCT01086631|Drug|Rituximab|
56240|NCT01086657|Biological|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
56536|NCT01079143|Drug|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
56537|NCT01079169|Dietary Supplement|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
56538|NCT01079208|Other|test starter infant formula|infants are fed for 6 months with this starter formula
56539|NCT00032643|Drug|DITPA|
56540|NCT01079208|Other|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
56413|NCT01086410|Drug|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
56414|NCT01086423|Biological|Infanrix-IPV/Hib™|Intramuscular, three doses
56415|NCT01086423|Biological|Infanrix Hib™|Intramuscular, three doses
56416|NCT01086423|Biological|Poliorix™|Intramuscular, three doses
56417|NCT01086436|Biological|Rotarix ™|Oral, single dose
56418|NCT00033397|Procedure|radiomammography|
56419|NCT01086436|Biological|Placebo|Oral, single dose
56420|NCT01086449|Biological|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
56421|NCT01086462|Drug|GSK2239633|100 ug GSK2239633 containing approximately 10kBq [14C]-GSK2239633
56719|NCT01079520|Procedure|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
56720|NCT01079520|Procedure|Mediastinoscopy|Traditional surgical method to stage lung cancers
56721|NCT01079533|Behavioral|Stepped CRCS Interventions|In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the "dose" needed to encourage completion of CRCS.
56722|NCT01079533|Behavioral|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
56723|NCT01079559|Device|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
56724|NCT01079559|Device|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
56725|NCT00000916|Drug|Lamivudine|
57248|NCT01070004|Other|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
56301|NCT01083953|Drug|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
56302|NCT01083966|Drug|Bevacizumab (Avastin)|Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma
This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS
56303|NCT01083979|Drug|Liposomes|Intravesical instillation
56304|NCT01083992|Drug|Galvus (vitagliptin)|Galvus (vitagliptin)
56305|NCT01083992|Drug|Galvus + vitamin D|Galvus + vitamin D
56306|NCT01084005|Drug|linagliptin|patients receive linagliptin 5 mg tablets once daily
56307|NCT01084005|Drug|placebo|patients receive placebo matching linagliptin 5 mg once daily
56308|NCT01084018|Behavioral|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
56309|NCT00033280|Procedure|neoadjuvant therapy|
56310|NCT01084031|Drug|propofol|intravenous propofol with sevoflurane inhalation induction
56311|NCT01084044|Drug|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
56312|NCT01084057|Drug|vorinostat|Given orally
56313|NCT01084057|Drug|ixabepilone|Given IV
56314|NCT01084057|Other|laboratory biomarker analysis|Correlative studies
56315|NCT01084057|Other|pharmacological study|Correlative studies
56316|NCT01084070|Other|Early oral feeding|Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet "at will" indicated.
56317|NCT01084070|Other|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
56780|NCT00032331|Procedure|CT scan|
56781|NCT01076764|Drug|Eptifibatide|Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion
56782|NCT01076764|Drug|Eptifibatide matching placebo|Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion
56783|NCT01076777|Behavioral|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
56784|NCT01076777|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
56785|NCT01076790|Drug|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
56786|NCT01076790|Drug|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
56787|NCT01076803|Drug|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
56788|NCT01076816|Drug|dexmedetomidine|dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.
Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed.
56789|NCT01076816|Procedure|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
56790|NCT01076816|Procedure|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
57091|NCT01080235|Other|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
57092|NCT01080235|Other|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
57093|NCT01082679|Drug|Methadone|daily for 12 months
57094|NCT01082679|Drug|buprenorphine (Suboxone)|daily for 12 months
57095|NCT01082692|Biological|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
56541|NCT01079208|Other|control standard formula|infant are fed 6 months with this formula
56542|NCT01079221|Behavioral|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at < 90 % of peak power, 3 days/week for 6 weeks
56543|NCT01079234|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily
56544|NCT01079234|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
56545|NCT01079234|Drug|insulin aspart|At least three daily doses at meal-time
56546|NCT01079247|Other|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
56547|NCT01081717|Biological|non-anti-TNF biologics|as prescribed
56548|NCT01081717|Other|general population|non-treated cohort
56549|NCT00033033|Drug|Reserpine|
56550|NCT01081730|Biological|anti-TNF biologics|as prescribed
56551|NCT01081730|Other|general population|non-treated cohort
56552|NCT01081730|Biological|non-anti-TNF biologics|as prescribed
56553|NCT01081730|Biological|ustekinumab|as prescribed
56554|NCT01081730|Drug|systemic non-biological treatments|as prescribed
56555|NCT01081743|Other|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
56556|NCT01081756|Drug|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
56557|NCT01081756|Drug|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
56558|NCT01081769|Drug|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
56850|NCT01084941|Behavioral|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
56851|NCT01084941|Behavioral|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
56726|NCT00032721|Procedure|Reiki; Subtle energy therapy|
56727|NCT01079572|Other|in-person|Follow-up appointments will be completed in-person as per usual
56728|NCT01079572|Other|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
56729|NCT01082003|Drug|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
56730|NCT01082016|Other|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
56731|NCT01082029|Drug|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
56732|NCT01082029|Drug|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
57032|NCT01085240|Other|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
57033|NCT01085253|Other|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
57034|NCT01085266|Drug|Dimebon (latrepirdine)|
57035|NCT01085279|Device|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
57036|NCT01085279|Drug|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
57037|NCT01085292|Drug|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
57038|NCT01085292|Drug|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
57039|NCT01085305|Behavioral|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
57040|NCT01085305|Behavioral|TAU|Usual treatment for behavioral disorders
57041|NCT01085318|Drug|Rebif|44 mcg tiw
56318|NCT01084083|Biological|cetuximab|Given IV
56319|NCT01084083|Radiation|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
56320|NCT00033280|Radiation|radiation therapy|
56321|NCT01084083|Drug|Paclitaxel|Given IV, 90 mg/m^2 on days 1, 8 and 15
56610|NCT01079247|Other|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
56611|NCT01079260|Dietary Supplement|Standard ONS|Standard ONS
56612|NCT01079260|Dietary Supplement|High Energy, low volume ONS|High energy, low volume ONS
56613|NCT00032669|Drug|HAART|
56614|NCT01079273|Biological|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
56615|NCT01079286|Drug|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
56616|NCT01079299|Device|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
56617|NCT01079312|Device|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
56618|NCT01079312|Device|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
56619|NCT01079312|Drug|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
56620|NCT01079312|Drug|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
56621|NCT01079312|Drug|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
56622|NCT01079312|Drug|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
56623|NCT01079325|Drug|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
57096|NCT01082705|Drug|artemether-lumefantrine|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
57097|NCT01082705|Drug|Dihydroartemisinin-piperaquine|once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
57098|NCT01082718|Drug|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
57099|NCT01082731|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
57100|NCT00033176|Drug|Alpha Lipoic Acid|
57101|NCT01082731|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
57102|NCT01082744|Drug|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
57103|NCT01082744|Drug|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
57104|NCT01082770|Device|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
57105|NCT01082770|Device|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
57106|NCT01082796|Drug|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
57107|NCT01082809|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
57108|NCT01082822|Biological|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
57109|NCT01082848|Drug|aripiprazole|10 mg QD during 26 weeks
56155|NCT00033397|Procedure|magnetic resonance imaging|
56156|NCT01086397|Procedure|Urine sample collection|All subjects have non-invasive urine sample collection performed
56157|NCT01086410|Drug|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
56158|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
56852|NCT01084980|Drug|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
56853|NCT01084993|Drug|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
56854|NCT00033319|Dietary Supplement|folic acid|
56855|NCT01084993|Drug|Heparin|70 U/kg
56856|NCT01085006|Drug|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
56857|NCT01085006|Drug|Normal saline|Tranexamic acid in cases, normal saline in controls
56858|NCT01085019|Dietary Supplement|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
56859|NCT01085019|Dietary Supplement|Oregano|2.8g/day of oregano in capsules during 4 weeks.
56860|NCT01085019|Dietary Supplement|Ginger|2.8g/day of ginger in capsules during 4 weeks.
56861|NCT01085019|Dietary Supplement|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
56862|NCT01085019|Dietary Supplement|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
56863|NCT01085019|Dietary Supplement|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
56864|NCT01085032|Drug|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
56865|NCT00033319|Drug|acetylsalicylic acid|
56866|NCT01076842|Drug|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
56867|NCT01076842|Drug|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
56868|NCT01076842|Device|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
57170|NCT01072383|Drug|BT061|administration of BT061 either intravenous or subcutaneous
57171|NCT01072383|Drug|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
57042|NCT00000918|Drug|Amprenavir|
57043|NCT00033332|Drug|zoledronic acid|
57044|NCT01085331|Drug|Mek Inhibitor MSC1936369B|Part 1 or Safety Run-in Part:
Arm 1: Safety Run-in Arm 1 subjects will be dosed with Mek Inhibitor MSC1936369B orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle AND will be dosed with FOLFIRI at conventional doses on days 1 and 15 of the same 28 day cycle.
57045|NCT01085331|Drug|Mek Inhibitor MSC1936369B|Part 2 or Phase II Randomized part:
Arm 1: Part II Arm 1 subjects will be randomized to receive Mek Inhibitor MSC1936369B orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle at the recommended Phase II dose AND will be dosed with FOLFIRI at conventional doses on days 1 and 15 of the same 28 day cycle.
57046|NCT01085331|Drug|Placebo|Part 2 or Phase II Randomized part:
Arm 2: Part II Arm 2 subjects will be randomized to receive placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle AND will be dosed with FOLFIRI on days 1 and 15 of the same 28 day cycle.
57047|NCT01085331|Drug|FOLFIRI|Part 2 or Phase II Randomized part:
Arm 2: Part II Arm 2 subjects will be randomized to receive placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle AND will be dosed with FOLFIRI on days 1 and 15 of the same 28 day cycle.
57048|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
57049|NCT00032370|Procedure|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
57050|NCT01077284|Drug|Febuxostat|Febuxostat capsules
57051|NCT01077284|Drug|Allopurinol|Allopurinol capsules
56098|NCT01080820|Drug|Viread|One single oral dose of 300mg Viread.
56099|NCT01080833|Device|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
56100|NCT01080846|Drug|Misoprostol|600 mcg of sublingual misoprostol
56101|NCT01080859|Device|OCT|Optical coherence tomography
56102|NCT01080859|Device|OCT|Optical coherence tomography
56103|NCT01080872|Device|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
56104|NCT01080885|Behavioral|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
56105|NCT01080885|Behavioral|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
56624|NCT00032695|Drug|methionine|
56625|NCT01079325|Other|Saline|
56626|NCT01079338|Other|caffeine|
56627|NCT01079351|Drug|Intravenous Carbamazepine|10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
56628|NCT01079364|Drug|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
56629|NCT01079364|Drug|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
56931|NCT01082458|Drug|remifentanil / lidocaine|Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.
Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery.
56932|NCT01082471|Drug|Morphine 6-glucuronide|
56933|NCT01082471|Drug|Morphine|
56934|NCT00033150|Behavioral|Academic enrichment|
56935|NCT01085032|Drug|Placebo nicotine patch|Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.
The same step-down dosing algorithm as in the experimental condition is used.
56936|NCT01085045|Drug|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
56937|NCT01085045|Drug|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
56938|NCT01085045|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
56939|NCT01085045|Drug|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
56940|NCT01085045|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
56941|NCT01085045|Drug|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
56942|NCT01085058|Drug|lenograstim|
56943|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
56944|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
56945|NCT00033332|Drug|dexamethasone|
56159|NCT01078298|Drug|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
56160|NCT01078337|Procedure|bone marrow aspiration|
56161|NCT01078337|Procedure|peripheral blood sampling|
56162|NCT01078350|Procedure|tumor tissue aspiration|
56163|NCT01078350|Procedure|phlebotomy|
56164|NCT01078363|Drug|Ramipril or placebo|
56165|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
56166|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
56167|NCT00032500|Drug|Echinacea|
56168|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
56169|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
56170|NCT01078389|Drug|Febuxostat|Febuxostat capsules
56171|NCT01078389|Drug|Placebo for Febuxostat|Febuxostat placebo-matching capsules
56172|NCT01078415|Device|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
56173|NCT01078428|Other|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
56174|NCT01078428|Other|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
56175|NCT01078441|Drug|liposomal doxorubicin|Given IV
56176|NCT01078441|Drug|bortezomib|Given subcutaneously.
56177|NCT01078441|Drug|dexamethasone|Given orally
56178|NCT00032526|Drug|Corticosteroids|
56179|NCT01078441|Drug|cyclophosphamide|Given IV
56484|NCT01081717|Biological|anti-TNF biologics|as prescribed
56485|NCT01081717|Biological|golimumab|as prescribed
57172|NCT01072396|Drug|Tiotropium|double blind randomized crossover
57173|NCT01072396|Drug|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
57174|NCT01072409|Device|Nucleus 5 Cochlear implant|Cochlear implant surgery
57175|NCT01072409|Device|Cochlear implantation|Implantation
57176|NCT01072422|Behavioral|Counseling based on answers to the assessment protocol|Each patient in the Protocol arm will fill in a TTQ at baseline. On the basis of the patients' answers, the nurse will provide individual counseling aimed at helping this patient overcome obstacles to smoking cessation.
57177|NCT01072435|Device|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
57178|NCT00031967|Drug|therapeutic melatonin|
57179|NCT01072435|Device|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
57180|NCT01072448|Drug|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
57181|NCT01072448|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
57182|NCT01072461|Behavioral|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
57183|NCT01072461|Behavioral|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
57184|NCT01072461|Behavioral|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
57185|NCT01074814|Drug|(will be assigned based on molecular profile and RPMA)|treatment will be assigned based on IHC< FISH, DNA microarray and RPMA results
57186|NCT01074827|Other|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
57187|NCT01074840|Other|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
57188|NCT01074853|Drug|propranolol|10mg twice daily escalated to 80mg once daily
57189|NCT01074853|Drug|placebo|Matched placebo
57190|NCT01074866|Device|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
56106|NCT01080898|Other|tests|color photographs, FLUORESCEIN angiography and OCT
56107|NCT01080911|Drug|Morphine|spinal morphine 0.05 mg
56108|NCT00032916|Drug|NS2359|
56109|NCT01080911|Drug|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
56110|NCT01080924|Device|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
56111|NCT01080963|Drug|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
56112|NCT01080963|Drug|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
56113|NCT01080989|Other|diagnosis, treatment and education|Drug:
anti-intestinal parasitic drugs:
mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)
albendazole(400 mg bid * 7days) or Ivermectin(200 mcg/kg/day * 2 days) (For Strongyloidiasis).
Behavior:
Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.
Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents.
56114|NCT01081002|Drug|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
56115|NCT01083576|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
56116|NCT01083576|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
56117|NCT01083589|Drug|Imatinib Mesylate|Oral 400 mg daily
56422|NCT01086475|Drug|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
56423|NCT01086475|Drug|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
56424|NCT01086488|Drug|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
56425|NCT01086514|Procedure|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
56946|NCT01085084|Drug|Laquinimod|Laquinimod 0.5 mg + placebo oral once daily for 12 weeks
56947|NCT01085084|Drug|Laquinimod|Laquinimod 1 mg oral once daily for 12 weeks
56948|NCT01085084|Other|Placebo|Placebo oral once daily for 12 weeks
56949|NCT01085097|Drug|laquinimod|Laquinimod 0.5 mg or 1 mg
56950|NCT01085097|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF)
56951|NCT01085097|Drug|corticosteroids|corticosteroids
56952|NCT01085097|Drug|Placebo|Placebo
56953|NCT01085123|Drug|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
56954|NCT01085123|Drug|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
57249|NCT01070017|Other|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
57250|NCT01072474|Procedure|Capnography|Capnographic monitoring
57251|NCT01072474|Procedure|Standard monitoring|Standard monitoring
57252|NCT01072487|Procedure|Capnography|Monitoring of the capnography curve for early detection of apnea
57253|NCT01072500|Behavioral|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
57254|NCT00031967|Radiation|radiation therapy|
57255|NCT01072500|Behavioral|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
57256|NCT01072513|Other|Semen analysis|Semen analysis before and after proton radiation therapy.
57257|NCT01072526|Drug|euphrasia based homeopathic therapy and cyclosporin|ophthalmic solution; 1 drop both eyes twice daily
57258|NCT01072526|Drug|cyclosporin solution|ophthalmic solution; 1 drop both eyes twice daily
57259|NCT01072539|Drug|tigecycline|As prescribed by physician in usual clinical practice
56486|NCT01084200|Drug|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
56487|NCT01084213|Drug|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
56488|NCT01084213|Drug|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
56489|NCT01084226|Dietary Supplement|Rye-2008|
56490|NCT01084239|Radiation|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
56491|NCT01084252|Drug|SAR650984|Pharmaceutical form: solution for infusion
Route of administration: intravenous
56492|NCT00033293|Drug|cyclophosphamide|Given IV
56493|NCT01084265|Drug|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units [IU]) injection s.c. once daily.
56494|NCT01084265|Drug|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
56495|NCT01084265|Drug|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
56496|NCT01084278|Drug|Colchicine|Colchicine tablets
56497|NCT01084291|Biological|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
56498|NCT01084291|Other|Placebo injection|Subcutaneous injection of placebo
56499|NCT01084317|Other|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
56500|NCT01084330|Drug|AUY922|70mg/m2
56501|NCT01084330|Drug|Docetaxel|Docetaxel 75mg/m2
56502|NCT01084330|Drug|Irinotecan|Docetaxel or Iriniotecan
56503|NCT00033293|Drug|prednisone|Given orally
56504|NCT01084343|Biological|MYM-V101|Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.
Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks.
56791|NCT00000916|Drug|Indinavir sulfate|
56241|NCT01086657|Biological|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
56242|NCT01086670|Other|Physical Exercise|Our primary objectives are to: 1) characterize and compare lower extremity motor coordination in children with cerebral palsy (CP) across mobility levels and to children without CP; and 2) evaluate the effects of two home-based exercise programs on motor coordination, as well as other physical, functional and neurological outcomes in children with CP. We hypothesize children with CP will exhibit significant coordination deficits compared to those without CP and that each exercise program will lead to significant improvements in outcomes.
56243|NCT01086683|Behavioral|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
56244|NCT01086696|Drug|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
56245|NCT00033397|Drug|chemotherapy|
56246|NCT01086722|Drug|"karolinska cocktail"|The "karolinska cocktail" contains dextrometorphan, caffeine, losartan and omeprazol
56247|NCT01086735|Biological|donor lymphocyte infusion|Donor T-cell transduction
56248|NCT01086748|Drug|Risperidone|Administered orally.
56249|NCT01086748|Drug|Placebo|Administered orally.
56250|NCT01086748|Drug|LY2140023|Administered orally.
56251|NCT01086761|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye.
56252|NCT01086774|Other|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
56253|NCT01086787|Other|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
56254|NCT01078532|Other|usual care|Usual passive PHR
56255|NCT00032526|Behavioral|Classical conditioning to corticosteroid|
56256|NCT01078545|Drug|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
56257|NCT01078571|Biological|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
56426|NCT01086527|Drug|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
56427|NCT01086540|Biological|Rituximab|2 infusions, 1000 mg. each, 14 days apart
56428|NCT01086540|Other|Placebo|2 infusions 14 days apart
56429|NCT00033397|Procedure|ultrasound imaging|
56430|NCT01086553|Drug|budesonide|9mg budesonide OD
56431|NCT01086553|Drug|budesonide|3mg budesonide TID
56432|NCT01086566|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
56433|NCT01086579|Device|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
56434|NCT01086579|Device|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
56435|NCT01086592|Other|No intervention|Daily life activities
56436|NCT01078935|Dietary Supplement|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
56437|NCT01078948|Device|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
56438|NCT01078961|Drug|bortezomib|Given intravenously on days 1, 8 and 15 of each 28 day cycle
56439|NCT00032617|Procedure|Present Centered Therapy|therapy that focuses on current problems
56440|NCT01078961|Drug|sorafenib|400mg taken orally twice a day
56441|NCT01078974|Drug|pomalidomide|Taken orally once a day
56733|NCT00000916|Drug|Didanosine|
56734|NCT00033098|Drug|Metyrapone|
56735|NCT01082068|Drug|XL147 (SAR245408)|given orally once daily as tablets
56736|NCT01082068|Drug|XL765 (SAR245409)|given orally twice daily as capsules
56737|NCT01082068|Drug|letrozole (Femara)|given orally once daily as tablets
57260|NCT01072565|Other|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
57261|NCT01072565|Other|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
57262|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
57263|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
57264|NCT01072591|Drug|MEDI-578|intravenous infusion, once
57265|NCT00031980|Drug|cyclosporine|
57266|NCT01072591|Drug|Placebo for MEDI-578|Intravenous infusion, once
57267|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
57268|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
57269|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
56322|NCT01084083|Drug|Cisplatin|Given IV, 75 mg/m^2 on day 1
56323|NCT01086930|Device|ReJoyce Workstation|The device has two parts. The first part is a muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff, word on the forearm and triggered when the user clicks his/her teeth. The tooth clicks (vibrations) are detected by an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. This is turn stimulates the hand to open or close, allowing patients to grasp and release objects. The second part of the device is a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association. The device is currently being used in a study conducted through the University of Alberta.
56324|NCT01086930|Other|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units. This will be provided as part of regular physiotherapy, vocational, recreational and occupational therapy and provided by participants' usual treating therapists. These therapists will not be involved in administering the study-specific interventions.
56325|NCT01086943|Device|LT2420|
56326|NCT01086956|Drug|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
56327|NCT01086969|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
56328|NCT00000918|Drug|Saquinavir|
56329|NCT00033410|Drug|tirapazamine|
56792|NCT00032344|Procedure|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
56793|NCT01076829|Other|Spice polyphenols|spice
56794|NCT01076842|Drug|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
56795|NCT01079585|Dietary Supplement|Nutrigal Okara - 100|
56796|NCT01079598|Device|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
56797|NCT01079624|Other|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
56798|NCT01079637|Procedure|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
56799|NCT01079637|Procedure|Cast treatment|Cast treatment
56800|NCT01079663|Drug|Chlorhexidine 2.5 mg|
56801|NCT01079663|Drug|Placebo chip|
56802|NCT01079676|Drug|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
56803|NCT00032734|Drug|satavaptan (SR121463B)|
56804|NCT01079676|Drug|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
56805|NCT01079689|Other|needle stimulation|stimulation with acupuncture needles
56806|NCT01079702|Drug|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
56807|NCT01079702|Drug|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
56808|NCT01079715|Drug|Propranolol|Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).
In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.
In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.
In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:
Atropine.
Isoproterenol hydrochloride (isoprenaline.
Terlipressin.
Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
57110|NCT01082848|Drug|placebo|QD during 26 weeks
57111|NCT00000918|Drug|Indinavir sulfate|
57815|NCT00032175|Drug|capecitabine|
57816|NCT01075815|Drug|Recombinant human luteinizing hormone (rhLH)|
57817|NCT01075815|Drug|Recombinant follicle-stimulating hormone (rFSH)|
57818|NCT01075828|Drug|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
57819|NCT01075841|Drug|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
58078|NCT01066260|Dietary Supplement|Probiotic formulation|Twice a day for 24 days
58079|NCT01066260|Other|Placebo|Twice a day for 24 days
58080|NCT01066273|Device|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
58081|NCT01066299|Drug|Syntocinon®|single dose of OXT (24 IU)
58082|NCT00031590|Drug|Mesna|Given at a dose of 360mg/m2 by IV 15 minutes prior to every dose of cyclophosphamide and again after each dose of cyclophosphamide (Regimen B only).
58083|NCT01066299|Drug|inactive nasal spray|single dose (24 IU)
58084|NCT01066325|Behavioral|Neuro Emotional Technique|NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.
During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief.
58085|NCT01066325|Other|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
58086|NCT01066351|Drug|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
58087|NCT01066351|Drug|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
58088|NCT01066364|Drug|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
57323|NCT01070030|Drug|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
57324|NCT01070043|Drug|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
57325|NCT01070043|Drug|Valsartan|For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.
Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks
57326|NCT01070056|Behavioral|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
56358|NCT01078870|Drug|Placebo|1~2#/cap QD
56359|NCT01078909|Biological|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
56360|NCT01078922|Drug|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
56361|NCT01078935|Dietary Supplement|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
56362|NCT01081314|Behavioral|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
56363|NCT01081340|Behavioral|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
56364|NCT01081340|Behavioral|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
56365|NCT01081353|Drug|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
56366|NCT01081353|Drug|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
56367|NCT01081353|Drug|Aspirin Migraine|One effervescent tablet under fasting conditions
57386|NCT01067651|Device|Semi-Rigid Fiberglass softcast using the Ponseti Method|
57387|NCT01067677|Drug|Metaclopramide|0.5 mg/kg for rescue after PONV
57388|NCT01067677|Drug|Ondansetron|0.1 mg/kg (max 4 mg0
57389|NCT01067677|Drug|diphenhydramine|0.25 mg/kg (max 25 mg)
57390|NCT01067677|Drug|Saline|equal volume (5 ml)as experimental rescue medications
57391|NCT00031655|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
57392|NCT01067690|Drug|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
57393|NCT01067703|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
57394|NCT01067703|Procedure|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
57395|NCT01067716|Device|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
57396|NCT01067729|Device|AWBAT Wound Dressing|TBD
57397|NCT01067729|Device|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
57398|NCT01067755|Device|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
57669|NCT01070459|Behavioral|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
57670|NCT01070459|Behavioral|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
58347|NCT01066806|Other|observation|observe normal dairy intake
58348|NCT00031629|Biological|Pegfilgrastim|Given IV
58349|NCT01066819|Drug|peginterferon alfa-2a [Pegasys]|As prescribed by physician
58350|NCT01066832|Drug|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
58351|NCT01066845|Drug|tadalafil|prescribed in accordance with usual clinical practice
58352|NCT01066858|Drug|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
58353|NCT01066871|Drug|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
58354|NCT01066871|Drug|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
58355|NCT01066871|Drug|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
58356|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
58357|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
58358|NCT00031746|Dietary Supplement|soy protein isolate|25 mg daily
58359|NCT01069328|Drug|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
58360|NCT01069328|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenously
58361|NCT01069328|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
58362|NCT01069328|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenously
58363|NCT01069328|Drug|Paclitaxel|Paclitaxel 200 mg/m² intravenously
58364|NCT01069328|Drug|Carboplatin|Carboplatin AUC 6 intravenously
58365|NCT01069341|Drug|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
58366|NCT01069367|Biological|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
58367|NCT01069393|Other|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
58089|NCT01068821|Other|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
58090|NCT01068834|Genetic|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
58091|NCT01068847|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
58092|NCT01068860|Drug|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
58435|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
58436|NCT01066923|Drug|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
58437|NCT01066923|Other|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
58438|NCT01066923|Drug|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
58439|NCT01066923|Other|Passive cooling|Removing protective garments for passive cooling following exercise
58440|NCT01066923|Drug|Daily placebo|Placebo comparator for daily aspirin therapy
58441|NCT01066923|Drug|Acute placebo|Placebo comparator for acute aspirin therapy
58442|NCT01066949|Behavioral|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
58443|NCT01066949|Behavioral|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
58444|NCT00031642|Radiation|yttrium Y 90 ibritumomab tiuxetan|
58445|NCT01066962|Drug|darunavir/ritonavir QD + raltegravir BID|darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)
ritonavir 100 mg, 1 tablet once daily (QD)
raltegravir 400 mg, 1 tablet twice daily (BID)
58446|NCT01066962|Drug|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)
ritonavir 100 mg, 1 tablet once daily (QD)
tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)
58447|NCT01066988|Other|ORB Ocular Emulsion|lubricant eye drop
56368|NCT01081353|Drug|Aspirin Aspro|One effervescent tablet under fasting conditions
56369|NCT01081392|Biological|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
56370|NCT01081405|Other|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
56371|NCT00032981|Behavioral|Behavior Therapy|
56372|NCT01081418|Behavioral|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
56373|NCT01081431|Drug|Lenalidomide|10 mg d1-d21 of a 28-day cycle
56374|NCT01081444|Device|rTMS|effective and active cortical magnetic stimulations
56375|NCT01081444|Device|Placebo rTMS|non active cortical magnetic stimulation
56376|NCT01081457|Device|Deep brain stimulation|Comparison ON vs OFF
56377|NCT01081483|Drug|ABT-072|See arm description for more information
56675|NCT01084590|Behavioral|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
56676|NCT01084590|Behavioral|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
56677|NCT01084603|Drug|Oral Nicotine|A new l mg oral nicotine product
56678|NCT01084603|Drug|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
56679|NCT01084603|Drug|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
56680|NCT01084655|Drug|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
56681|NCT01084655|Drug|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
56682|NCT00033306|Drug|ixabepilone|
57671|NCT01070459|Behavioral|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
57672|NCT00000913|Drug|Ritonavir|
57673|NCT00031824|Drug|prednisone|
57674|NCT01070459|Behavioral|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
57675|NCT01070459|Behavioral|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
57676|NCT01070472|Drug|Misoprostol|titrated oral misoprostol solution
57677|NCT01070485|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
57678|NCT01070498|Drug|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
57679|NCT01070511|Drug|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose—10 mg— will be administered the afternoon before the study. The second dose -20 mg—will be administered the morning of the study.
57680|NCT01070511|Drug|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
57681|NCT01070524|Drug|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
57682|NCT01070524|Drug|Budesonide extrafine pMDI|Budesonide extrafine pMDI
57683|NCT01070524|Drug|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
57684|NCT00031824|Drug|tacrolimus|
57685|NCT01070537|Device|Bonfils fiberscope intubation|
57686|NCT01070550|Drug|peginterferon alfa-2a [Pegasys]|As prescribed by physician
57937|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
57938|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
57939|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
58368|NCT01069432|Other|No Intervention|No Intervention
58369|NCT00031746|Dietary Supplement|casein proteins|25 mg daily
57450|NCT01075334|Dietary Supplement|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
57451|NCT01075334|Dietary Supplement|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
57452|NCT01075347|Other|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
57453|NCT01075347|Other|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
57454|NCT00032149|Drug|mitoxantrone hydrochloride|
57455|NCT01075399|Drug|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with [F 18]HX4
57456|NCT01075412|Drug|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
57457|NCT01075425|Drug|bortezomib|Given IV
57458|NCT01075425|Drug|belinostat|Given IV
57459|NCT01075425|Other|laboratory biomarker analysis|Correlative studies
57460|NCT01075425|Genetic|western blotting|Correlative studies
57461|NCT01075425|Other|pharmacological study|Correlative studies
57462|NCT01075425|Other|flow cytometry|Correlative studies
57463|NCT01075438|Biological|Prevenar® (7-valent pneumococcal conjugate vaccine)|Pneumococcal vaccines (conjugate and polysaccharide)
Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later
57464|NCT01075438|Biological|Pneumovax® (pneumococcal polysaccharide vaccine)|Pneumococcal vaccines (conjugate and polysaccharide)
Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later
57465|NCT00032149|Drug|prednisolone|
57466|NCT01075464|Drug|MEGF0444A|Intravenous escalating dose
57467|NCT01075464|Drug|bevacizumab|Intravenous repeating dose
58448|NCT01066988|Other|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
58449|NCT01067014|Device|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
58450|NCT01067027|Dietary Supplement|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
58451|NCT01067053|Drug|bevacizumab, capecitabine, oxaliplatin|6 cycles (3 weeks each one) of:
bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.
capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.
oxaliplatin: 130/mg/m2(iv),1st day of each cycle.
After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine
58452|NCT01067066|Drug|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
58453|NCT01067066|Drug|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m^2 by mouth (PO) daily, Day 1 to 5.
58454|NCT01067079|Other|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
57529|NCT01073020|Procedure|Laparoscopic Adjustable Gastric Band|Allergan Adjustable Gastric Band (Device) compared to Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
57530|NCT01073020|Procedure|Roux-en-Y Gastric Bypass (Surgery)|Roux-en-Y Gastric Bypass (Surgery) versus Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
57531|NCT01073020|Other|Intensive Medical Diabetes & Weight Management|Intensive Medical Diabetes & Weight Management
57532|NCT01073020|Device|Allergan Adjustable Gastric Band|Allergan Adjustable Gastric Band (Device) compared to Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
57533|NCT01073033|Dietary Supplement|milk supplement 1|milk supplement with probiotics
57534|NCT01075464|Drug|paclitaxel|Intravenous repeating dose
57535|NCT01075477|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
57536|NCT01075490|Drug|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
57537|NCT01075490|Drug|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
57538|NCT01075503|Procedure|brachial plexus block|0.5% Ropivacaine 40ml
57539|NCT01075529|Drug|fluoxetine|fluoxetine 20 mg/d
57540|NCT01075542|Device|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
57541|NCT01075542|Device|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
58216|NCT01071499|Drug|Morphine|One dose of morphine (0.3 mg/kg)
58217|NCT01071512|Drug|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
58218|NCT01071525|Drug|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\Laropiprant
58219|NCT00031902|Biological|bleomycin sulfate|
58220|NCT01074112|Device|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
58221|NCT00032084|Drug|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
58222|NCT01074112|Procedure|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
58223|NCT01074112|Device|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
58224|NCT01074112|Device|Cardiac Ultrasound|Ultrasound views of the heart
58225|NCT01074125|Drug|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
58226|NCT01074138|Drug|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
58227|NCT01074151|Drug|duloxetine|any exposure to duloxetine that occurred during pregnancy
58228|NCT01074164|Other|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
58229|NCT01074164|Device|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
57327|NCT01070056|Behavioral|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
57328|NCT00031798|Procedure|quality-of-life assessment|
57329|NCT01070069|Device|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
57330|NCT01070069|Device|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
57940|NCT01070940|Drug|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
57941|NCT00031850|Drug|raloxifene|
57942|NCT01070979|Drug|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
57943|NCT01070979|Drug|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
57944|NCT01070979|Drug|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
57945|NCT01071005|Drug|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
57946|NCT01071005|Drug|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
57947|NCT01071018|Drug|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
57948|NCT01071018|Drug|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
57949|NCT01071031|Biological|HIV-v (Low Dose)|Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant
Administration: A single subcutaneous injection
57950|NCT01071031|Biological|HIV-v (High Dose)|High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant
Administration: A single subcutaneous injection
57951|NCT01071031|Biological|HIV-v (Control)|Adjuvant only or Water for injection only
Administration: A single subcutaneous injection
57952|NCT00031863|Drug|rofecoxib|
57953|NCT01071044|Drug|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
57954|NCT01073748|Drug|paracetamol|single dose of paracetamol 15mg/kg.
57955|NCT00000914|Drug|Ritonavir|
57956|NCT00032045|Biological|gp100 antigen|
57957|NCT01073761|Drug|darunavir/ritonavir then atazanavir/ritonavir|Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days
Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days
58288|NCT01071538|Drug|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
57468|NCT01067794|Drug|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
57469|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) [Original], single dose
57470|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
57745|NCT01068275|Procedure|lumbar plexus catheter|lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
57746|NCT01068275|Procedure|femoral nerve catheter|femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
57747|NCT01068275|Procedure|single-shot femoral block|single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
57748|NCT01068288|Procedure|Laparoscopic or open appendectomy|
57749|NCT01068288|Procedure|Expectant Management|A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.
For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy.
57750|NCT01068301|Drug|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
57751|NCT01068314|Other|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
57752|NCT01068327|Drug|gemcitabine hydrochloride|Given IV
57753|NCT01070615|Drug|Prucalopride|
57754|NCT01070628|Drug|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
57755|NCT01070628|Drug|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
57756|NCT01070641|Drug|Carvedilol|Carvedilol 12.5mg QD
57757|NCT01070641|Procedure|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
57758|NCT00031837|Drug|dalteparin|
57542|NCT00032149|Drug|vincristine sulfate|
57543|NCT01075555|Drug|pravastatin sodium|
57544|NCT01075555|Drug|sorafenib tosylate|
57545|NCT01075568|Dietary Supplement|Nutrigal Okara - 100|
57546|NCT01075581|Drug|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
57547|NCT01075581|Drug|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
57548|NCT01075620|Device|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
57549|NCT01075620|Device|LPS RP|non-posterior stabilized rotating platform design
57550|NCT01075633|Procedure|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
57820|NCT01068327|Drug|leucovorin calcium|Given IV
57821|NCT00031707|Other|placebo|
57822|NCT01068327|Drug|fluorouracil|Given IV
57823|NCT01068327|Drug|nelfinavir mesylate|Given PO
57824|NCT01068327|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
57825|NCT01068327|Radiation|hypofractionated radiation therapy|Undergo radiotherapy
57826|NCT01068327|Procedure|therapeutic conventional surgery|Undergo surgery
57827|NCT01068353|Biological|Etanercept|50 mg given as a once weekly subcutaneous injection
57828|NCT01068353|Other|Placebo|Placebo injection given once weekly
57829|NCT01068379|Procedure|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
57830|NCT01068379|Procedure|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
57831|NCT01068392|Drug|Oxaliplatin, Prednisolone|OXALIPLATIN+PREDNISOLONE (OX-P)
D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr
D1-5 Prednisolone 40-30-30 mg/day P.O
every 3 weeks
57331|NCT01070069|Device|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
57332|NCT01070095|Other|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
57333|NCT01070108|Drug|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
57334|NCT01070108|Drug|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
57335|NCT01070108|Drug|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
57336|NCT01070134|Behavioral|Mindfulness-based Behavioural Therapy (MIBT)|The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).
The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness.
57337|NCT01072643|Drug|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
57338|NCT01072656|Device|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
57339|NCT00031993|Drug|erlotinib hydrochloride|Given PO
57610|NCT01073111|Device|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
57611|NCT01073111|Device|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
57612|NCT01073111|Device|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
57613|NCT00032019|Drug|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
57614|NCT01073124|Procedure|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
57615|NCT01073150|Drug|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
58289|NCT01071551|Behavioral|Life-style intervention|The "Nutrition Enrichment and Healthy Living Model" (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care.
58290|NCT01071551|Behavioral|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
58291|NCT01071564|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
58292|NCT01071564|Other|Laboratory Biomarker Analysis|Correlative studies
58293|NCT01071564|Other|Pharmacogenomic Study|Correlative studies
58294|NCT01071564|Other|Pharmacological Study|Correlative studies
58295|NCT01071564|Drug|Vismodegib|Given PO
58296|NCT01071616|Drug|Cannabis Cigarette|
58297|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
58298|NCT00031902|Biological|rituximab|
58299|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
58300|NCT01071642|Drug|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
58301|NCT01071642|Drug|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
58302|NCT01071655|Drug|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1
BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly
BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly
58303|NCT01071655|Drug|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
58304|NCT01071681|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
58305|NCT01071694|Drug|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
57759|NCT01070654|Procedure|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
57760|NCT01070654|Device|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
57761|NCT01070667|Drug|Dronedarone|400mg orally once per day for 3 months
57762|NCT01070667|Drug|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
57763|NCT01070680|Drug|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
58026|NCT00031733|Biological|gp100 antigen|
58027|NCT01068769|Drug|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
58028|NCT01068782|Drug|XL184|given orally as capsules
58029|NCT01068795|Drug|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
58030|NCT01068808|Procedure|skin prick test|skin prick test to aeroallergen
58031|NCT01068821|Other|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
58032|NCT01071044|Drug|Placebo "30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
58033|NCT01071057|Drug|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
58034|NCT01071057|Drug|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
58035|NCT01071070|Drug|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
58036|NCT01071083|Drug|natalizumab|300 mg intravenous every 4 weeks
58037|NCT01071083|Drug|interferon beta 1-a|30 ug intramuscular once per week
57832|NCT00031720|Dietary Supplement|soy protein|Given orally
57833|NCT01068405|Drug|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
57834|NCT01068405|Drug|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
57835|NCT01068418|Dietary Supplement|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
57836|NCT01068431|Other|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
57837|NCT01068444|Drug|Pioglitazone|Name: GLITOS（Pioglitazone）
Dosage form: Tablets
Dose(s): 30mg
Dosing schedule: QD
Duration: 6 months
57838|NCT01068444|Drug|placebo|placebo 30 mg/d for 6 months
57839|NCT01068483|Drug|BKM120|
57840|NCT01068509|Biological|MUC1 Dendritic Cell Vaccine (Cvac)|Patients will receive vaccinations every four weeks for 24 weeks followed by injections every eight weeks for an additional 24 weeks.
57841|NCT01068522|Device|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
58093|NCT01068860|Drug|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
58094|NCT00000912|Drug|Adefovir dipivoxil|
58095|NCT00031733|Biological|incomplete Freund's adjuvant|
58096|NCT01068873|Drug|lopinavir/ritonavir plus maraviroc|Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
58097|NCT01068886|Procedure|External pancreatic stent|stent through pancreatic anastomosis
58098|NCT01068912|Drug|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
58099|NCT01068912|Drug|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
58100|NCT01068912|Drug|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
58101|NCT01068925|Drug|GSK1349572|GSK1349572 QD x 5 days
TPV/RTV 500/200mg BID x 7 days
GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days
58102|NCT01068938|Device|three different perimeters: HFA, Octopus, MATRIX|visual fields
57616|NCT01073163|Drug|Bendamustine|Bendamustine at 90 mg/m^2 IV on Days 1 and 2 of a 28-day cycle.
57617|NCT01073163|Drug|Rituximab|Rituximab at 375 mg/m^2 IV on Day 1 of a 28-day cycle.
57618|NCT01073176|Other|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
57619|NCT01073189|Drug|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
57620|NCT01073189|Drug|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
57621|NCT01073202|Drug|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
57622|NCT01073202|Drug|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
57623|NCT01075854|Drug|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
57624|NCT01075880|Drug|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
57625|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
57626|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
57627|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
57628|NCT01075919|Dietary Supplement|Placebo|1 g olive oil taken daily for 12 weeks
57877|NCT01073670|Drug|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
57878|NCT01073683|Procedure|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
57879|NCT01073683|Drug|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
57880|NCT01073696|Drug|granisetron IV|IV
57881|NCT01073696|Drug|granisetron patch|patch
58306|NCT01071720|Drug|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
57399|NCT01067768|Other|Daily review|Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: "Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.
The attending physician decides withdraw or no withdraw the urinary catheter
57400|NCT01067781|Biological|Heat-Labile Enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
57401|NCT01067781|Biological|Placebo|Travelers' Diarrhea Vaccine System
57402|NCT00031668|Radiation|radiation therapy|
57403|NCT01070134|Behavioral|PT (psychodynamic therapy)|The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).
The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions.
57404|NCT01070147|Other|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
57405|NCT00031798|Radiation|radiation therapy|
57406|NCT01070160|Drug|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
57407|NCT01070160|Drug|Metformin|per clinical care guidelines
57408|NCT01070186|Drug|Sunitinib|50mg/day for 4 weeks
57409|NCT01070186|Other|Tumor biopsy|Conducted prior to administration of sunitinib therapy
57410|NCT01070186|Procedure|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
57411|NCT01070186|Other|Biomarkers|Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.
Biomarker evaluation of tissue prior to 4 week administration of Sunitinib
57412|NCT01070199|Behavioral|liquid to liquid|• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the "Liquid to Liquid" session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid.
58038|NCT01071083|Drug|methylprednisolone|1000 mg intravenous every 4 weeks
58039|NCT01071083|Other|IV placebo|placebo intravenous every 4 weeks
58040|NCT01071083|Drug|glatiramer acetate|20 mg subcutaneous once daily
58041|NCT00031863|Procedure|adjuvant therapy|
58042|NCT01071096|Drug|OnabotulinumtoxinA|Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.
At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm.
58370|NCT01069445|Dietary Supplement|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
58371|NCT01069445|Dietary Supplement|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
58372|NCT01069445|Dietary Supplement|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
58373|NCT01069445|Behavioral|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
58374|NCT01069458|Other|The high protein diet group and the low fat diet group|The high protein diet (25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate) and the low fat diet (30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate)
58375|NCT01069471|Biological|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
58376|NCT01069484|Other|Postpartum pelvic floor muscle training|The training participants attend a supervised exercise class once a week led by an experienced physiotherapist and are prescribed daily home training over a period of 4 months. The PFM exercise protocol follows general principles for strength training; 3 sets 8-12 contractions close to maximum (Bø et al 1990, Haskell 2007). The emphasis will be on progression in force development. At week 4 during the intervention, the PFM strength will be assessed for each participant. The participants are provided with a DVD of the program (www.corewellness.co.uk). Adherence is reported in a training diary. The PFMT protocol has shown to be successful in former studies evaluating the effect of PFMT on urinary incontinence (Mørkved & Bø 1997, Bø et al 1990, Bø et al 1999, Mørkved et al 2003).
58377|NCT01071798|Drug|Rituximab|As prescribed by physician
58378|NCT01071811|Behavioral|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
58103|NCT01068951|Biological|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
58104|NCT01068964|Drug|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
58105|NCT01068964|Drug|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
58106|NCT00031733|Biological|recombinant interleukin-12|
58107|NCT01068977|Drug|bevacizumab|Repeating intravenous dose
58108|NCT01068977|Drug|MetMAb|Repeating escalating intravenous dose
58109|NCT01068977|Drug|MetMAb|Repeating intravenous dose
58110|NCT01069003|Drug|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
58111|NCT01069003|Drug|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
58112|NCT01071174|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
58113|NCT00031876|Drug|capecitabine|
58114|NCT01071174|Other|Placebo|Vaginal Ring containing no drug substance
58115|NCT01071187|Drug|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
58455|NCT01069497|Other|Prevention of infections program|The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:
a slide-show of recommendations (commented by an expert),
recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec.
58456|NCT01069510|Drug|Spironolactone|Spironolactone 25 mg daily for 12 months
58457|NCT01069510|Other|Placebo|Placebo daily for 12 months
58458|NCT00031759|Drug|imiquimod|
58459|NCT01069523|Drug|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
58460|NCT01069523|Drug|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
58461|NCT01069536|Drug|metoclopramide 10 mg|
57882|NCT01073709|Drug|Acetaminophen|
57883|NCT01073722|Device|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
57884|NCT01073722|Device|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
57885|NCT01076036|Device|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
57886|NCT01076049|Other|observation of SOP|standard treatment of infection
57887|NCT01076049|Device|IrriSept Irrigation|irrigation of the wound using IrriSept
57888|NCT01076062|Procedure|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
57889|NCT01076075|Drug|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
57890|NCT01076075|Drug|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
57891|NCT00000915|Behavioral|Vaccine preparedness|
57892|NCT00032188|Drug|bryostatin 1|Given IV
57893|NCT01076075|Drug|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
57894|NCT01076075|Drug|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
58230|NCT01074177|Drug|BIBW 2992|Taken orally once a day
58231|NCT01074190|Drug|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
58232|NCT00032084|Drug|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
57413|NCT01070199|Behavioral|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
57687|NCT01070563|Other|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
57688|NCT01070576|Other|no intervention|no intervention
57689|NCT01070602|Procedure|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
57690|NCT01073215|Behavioral|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
57691|NCT00032019|Drug|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
57692|NCT01073215|Behavioral|Family-Based Lifestyle Modification Program|The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).
Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management.
57693|NCT01073228|Drug|EVP-6124|
57694|NCT01073228|Drug|Placebo|
57695|NCT01073241|Procedure|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
57696|NCT01073241|Procedure|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
57697|NCT01073267|Radiation|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
57698|NCT01073280|Procedure|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
57699|NCT01073293|Biological|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
58379|NCT01071824|Procedure|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
58380|NCT01071824|Procedure|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
58381|NCT01071837|Drug|APG101|400mg weekly as intravenous infusion
58382|NCT01071837|Procedure|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
58383|NCT01071850|Drug|ASP1941|oral tablet
58384|NCT01071850|Drug|Metformin|oral tablet
58385|NCT01071850|Drug|Placebo|oral tablet
58386|NCT01071876|Drug|BF2.649|1 capsule in the morning before breakfast
57471|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) [Blended], single dose
57472|NCT01067807|Drug|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) [Blended], single dose
57473|NCT01067820|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
57474|NCT01067820|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
57475|NCT01067833|Drug|K201 Tablet|oral tablet, x28 days
57476|NCT01067833|Drug|Placebo Tablet|oral tablet, x28 days
57477|NCT01067846|Drug|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
57478|NCT00031681|Drug|7-hydroxystaurosporine|Given IV
57479|NCT01067846|Drug|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
57480|NCT01067846|Behavioral|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
57481|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
57482|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
57483|NCT01067859|Drug|Placebo|Infusion of placebo during 48 hours
58462|NCT01069562|Other|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
58463|NCT01069562|Other|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
58464|NCT01069575|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
58465|NCT01069601|Biological|Focetria (2x H1N1 vaccine with MF59 adjuvants)|7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
58466|NCT01069614|Device|TopClosure 3S System|
58467|NCT01069627|Drug|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
58468|NCT01069627|Drug|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
58469|NCT00031759|Procedure|Ablative or excisional therapy|
58470|NCT01069640|Biological|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
58471|NCT01069653|Biological|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
58472|NCT01069692|Drug|SBR759A|SBR759A 6g daily
58473|NCT01069692|Drug|SBR759A|Placebo Comparator 0g daily
58474|NCT01069692|Drug|SBR759A|SBR759A 3g daily
58475|NCT01069692|Drug|SBR759A|9g daily
57551|NCT01075633|Procedure|Colonoscopy with sedation|Colonoscopy with sedation
57552|NCT01075646|Drug|ropivacaine|Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.
Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.
Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h.
57553|NCT00032162|Drug|carboplatin|AUC 6 q4w
57554|NCT01075646|Drug|placebo|Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.
Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.
Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h
58233|NCT01074190|Drug|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
58234|NCT01074190|Drug|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
58235|NCT01074203|Drug|Nitazoxanide|Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.
Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery >12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses
All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given.
58236|NCT01074216|Drug|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
58237|NCT01074229|Drug|Placebo|placebo injection
58238|NCT01074229|Drug|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
58239|NCT01074229|Drug|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
58240|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
58241|NCT01066546|Drug|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
58242|NCT01066559|Procedure|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
58243|NCT01066559|Procedure|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
58244|NCT01066559|Biological|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
58245|NCT01066559|Biological|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
57700|NCT01073293|Biological|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
57701|NCT01073293|Biological|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
57702|NCT00032019|Drug|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
57703|NCT01073306|Biological|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
57704|NCT01073306|Other|Placebo|Subcutaneous injection of placebo
57958|NCT01073774|Behavioral|Side by side|
57959|NCT01073774|Behavioral|couples control condition|
57960|NCT01073787|Drug|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
57961|NCT01073800|Drug|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
57962|NCT01073800|Drug|placebo|placebo
57963|NCT01073813|Drug|Minocycline|100mg twice daily
57964|NCT01073826|Behavioral|Sport|
57965|NCT01073826|Drug|Tocilizumab|
57966|NCT01073826|Drug|Sitagliptin|
57967|NCT00032045|Biological|incomplete Freund's adjuvant|
57968|NCT01073839|Drug|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
57969|NCT01073852|Drug|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
57970|NCT01073852|Drug|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
57971|NCT01073865|Drug|ZD9393 (Zoladex)|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
57972|NCT01073865|Drug|ZD9393 (Zoladex)|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
57973|NCT01073878|Device|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
57974|NCT01073891|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
57484|NCT01067885|Device|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
57485|NCT01067898|Dietary Supplement|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
57486|NCT01067898|Other|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
57487|NCT01067898|Dietary Supplement|calcium carbonate|1000 mg calcium per os every day for one year
57488|NCT01067911|Dietary Supplement|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
57489|NCT00031681|Drug|irinotecan hydrochloride|Given IV
57490|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
57764|NCT01070680|Drug|sodium chlorid 0,9%|continuous intravenous infusion
57765|NCT01070693|Procedure|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
57766|NCT01070693|Device|Prolene Hernia System|Prolene Hernia System
57767|NCT01070693|Procedure|Lichtenstein technique|Lichtenstein technique
57768|NCT01070706|Drug|Paclitaxel,Gemcitabine,Sunitinib|To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.
If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15.
57769|NCT00031837|Drug|gemcitabine hydrochloride|
57770|NCT01070732|Drug|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
57771|NCT01070745|Drug|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
57772|NCT01070745|Drug|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
57555|NCT01075659|Drug|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
57556|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
57557|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
57558|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
57559|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
57560|NCT01067924|Behavioral|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
57561|NCT01067937|Procedure|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
57562|NCT01067950|Procedure|Isolated Pancreas Transplant|
57563|NCT01067950|Drug|Intensive Insulin Therapy|
57564|NCT01067963|Behavioral|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
57565|NCT01067963|Behavioral|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
57566|NCT01067976|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
57567|NCT00031681|Other|diagnostic laboratory biomarker analysis|Correlative studies
57842|NCT01068522|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
57843|NCT00031720|Dietary Supplement|isoflavones|Given orally
57844|NCT01068548|Other|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
57845|NCT01070784|Drug|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
57340|NCT01072669|Drug|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily[if the lower dose is tolerated] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
57341|NCT01072682|Device|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
57342|NCT01072695|Drug|GS-9256|75 mg BID x 28 days
57343|NCT01072695|Drug|GS-9190|40 mg BID x 28 days
57344|NCT01072695|Drug|Ribavirin|1000-1200 mg/day given BID
57345|NCT01072695|Drug|Peginterferon alfa-2a|180 ug q week
57346|NCT01072708|Other|Prospective cohort with an annual follow-up|Annualfollow-up including :
oral glucose tolerance test
dietary survey
biological evaluation
bacteriological and respiratory measures
dual-energy x-ray absorptiometry
physical activity survey
57347|NCT01072721|Other|Elastometry|Fibrosis detection with FIBROSCANN
57348|NCT01072734|Drug|Vaccine|Influenza vaccine
57349|NCT01072747|Biological|bovine heparin|5.000UI/mL bottle with 5mL
57350|NCT00031993|Other|laboratory biomarker analysis|Correlative studies
57351|NCT01072747|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
57352|NCT01072760|Procedure|K wire|Mallet finger treatment
57353|NCT01072773|Drug|bortezomib|1.3 mg/m^2, by IV on days 1, 8 and 15 every 28 days
57354|NCT01072773|Drug|cyclophosphamide|300 mg/m^2, orally, on days 1, 8, 15 & 22 every 28 days.
57355|NCT01072773|Drug|dexamethasone|40 mg, orally, on days 1, 8, 15 & 22 every 28 days
57356|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30)
57357|NCT01075139|Behavioral|Educational information|Educational handouts/brochures
57975|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
57976|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
57977|NCT01073904|Drug|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
57978|NCT00032045|Biological|ipilimumab|
57979|NCT01073904|Drug|Postinor 2|Single dose of 1.5 mg tablet
57980|NCT01073917|Other|Spontaneous Breathing|
57981|NCT01073917|Other|Pressure Controlled Ventilation|
58307|NCT01071772|Drug|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
58308|NCT01071785|Dietary Supplement|guar gum|guar gum 10g/day for six weeks
58309|NCT00031902|Drug|prednisolone|
58310|NCT01074255|Drug|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
58311|NCT01074268|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
58312|NCT01074268|Drug|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
58313|NCT00032084|Procedure|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
58314|NCT01074268|Drug|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
58315|NCT01074281|Drug|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
58316|NCT01074294|Drug|OPDC-34712 + Stimulant Therapy|Tablets, Oral, 0.25 or 1.0 mg OPDC-34712 and FDA approved stimulant therapy
58317|NCT01074294|Drug|Placebo + Stimulant Therapy|Placebo plus a FDA approved stimulant therapy
58318|NCT01074307|Drug|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
57773|NCT01070758|Drug|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
57774|NCT01070771|Device|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
57775|NCT01070784|Drug|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
57776|NCT01073345|Procedure|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
57777|NCT01073345|Procedure|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
57778|NCT01073345|Procedure|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
57779|NCT00032019|Drug|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
57780|NCT01073358|Procedure|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
57781|NCT01073371|Drug|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
58043|NCT01071096|Drug|Saline|155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.
At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm.
58044|NCT01071109|Procedure|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
58045|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
58046|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
58047|NCT01071122|Drug|Valsartan|Valsartan 160mg, Once daily
58048|NCT01071135|Drug|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
58049|NCT01071161|Drug|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
58050|NCT01071161|Drug|placebo|placebo
57846|NCT01070797|Biological|Multi-virus Specific T cells|Subjects will receive Multivirus specific T cells on one of the following dose levels:
Level One: 5 x 10^6 rCTLs/m2
Level Two: 1 x 10^7 rCTLs/m2
Level Three: 2 x 10^7 rCTLs/m2
Level Four: 5 x 10^7 rCTLs/m2
If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days.
57847|NCT01070810|Drug|D5W|Dextrose 5%
57848|NCT01070810|Drug|Thiamine|Thiamine 200mg in 50ml Dextrose 5%
57849|NCT00031837|Procedure|quality-of-life assessment|
57850|NCT01070823|Drug|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
57851|NCT01070836|Drug|natalizumab|Administered as specified in the treatment arm
57852|NCT01070849|Other|educational booklet|Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the "back book" of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell.
57853|NCT01070849|Other|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
57854|NCT01070849|Other|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
57855|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
58116|NCT01071187|Drug|Placebo|Placebo
58117|NCT01071200|Drug|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
58118|NCT01071200|Drug|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
57358|NCT01075152|Drug|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
57359|NCT01075152|Biological|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
57629|NCT00032175|Drug|gemcitabine hydrochloride|
57630|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
57631|NCT01075932|Dietary Supplement|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
57632|NCT01075932|Dietary Supplement|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
57633|NCT01075945|Drug|Dihydroartemisinin- piperaquine|three tablets per day
57634|NCT01075945|Drug|artemether- lumefantrine|twenty tablet in eight doses
57635|NCT01075971|Drug|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
57636|NCT01075971|Drug|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
57637|NCT01075984|Drug|Posaconazole|
57638|NCT01075984|Drug|Dextrose 5% in water|
57639|NCT01075997|Device|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
57640|NCT00032188|Biological|aldesleukin|Given subcutaneously
57641|NCT01075997|Device|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
57642|NCT01076010|Drug|Tivozanib|Tivozanib will be orally administered once daily, at least 1 hour before or 2 hours after ingesting any food or other medication, for as long as the subject tolerates treatment in the absence of disease progression or unacceptable toxicity. Study drug will be administered beginning on Day 1 of Cycle 1.
57643|NCT01076010|Drug|Sorafenib|Sorafenib will be orally administered twice daily (unless reduced in parent protocol). Sorafenib should be taken without food at least 1 hour before or 2 hours after ingesting any food or other medications. Study drug will be administered beginning on Day 1 of Cycle 1.
57644|NCT01076036|Device|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
58319|NCT01074307|Drug|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
58320|NCT01074320|Other|Other|Observational study
58321|NCT01074333|Drug|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
58322|NCT01074346|Drug|Interferon-β-1a|Interferon-β-1a according to the standard practice
58323|NCT01074359|Drug|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
58324|NCT00032097|Drug|motexafin gadolinium|
57414|NCT01070199|Behavioral|solid to liquid|• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as "Solid to Liquid". A demonstration of the "Solid to Solid" and "Solid to Liquid" phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The "Solid to Solid" phase container will contain cold water so the cube stays in solid form. The "Solid to Liquid" phase container will contain hot water that will quickly dissolve the cube into a liquid form.
57415|NCT01070199|Behavioral|solid to solid|Participants will be presented with dense gelatin cubes. These 1" x 1" x 1" cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage.
57416|NCT00031811|Drug|raloxifene|
57417|NCT01070212|Other|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
57418|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30-200,201)
57419|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30)
58051|NCT01073930|Drug|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
58052|NCT01073930|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
58053|NCT01073930|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
58054|NCT01073943|Drug|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
58055|NCT01073943|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
58056|NCT01073943|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
58387|NCT00031902|Drug|vincristine sulfate|
58388|NCT01071876|Drug|Placebo|1 capsule in the morning before breakfast
58389|NCT01071889|Drug|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
58390|NCT01071889|Drug|Placebo|Placebo - only excipients with no API
58391|NCT01071902|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
58392|NCT01071902|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
58393|NCT01071902|Other|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
58394|NCT01071902|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
58119|NCT01071226|Device|CliniMACS (CD+3, CD+19 depletion)|Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
58120|NCT01071226|Device|CliniMACS (CD 34+ positive selection)|Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
58121|NCT01071239|Device|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
58122|NCT01071252|Drug|AIN457|
58123|NCT01071252|Drug|Placebo|
58124|NCT00000913|Drug|Nelfinavir mesylate|
58125|NCT00031876|Drug|paclitaxel|
58126|NCT01071265|Procedure|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
58127|NCT01071265|Procedure|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
58128|NCT01071291|Drug|Niaspan|Niaspan™
58129|NCT01071291|Drug|Comparator: Placebo|Placebo
58130|NCT01071304|Drug|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
58131|NCT01071304|Drug|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
58132|NCT01071317|Drug|Naproxen|Naproxen 500mg PO bid prn headache
58133|NCT01071317|Drug|Sumatriptan|100mg po q day prn headache
58134|NCT01071317|Behavioral|Migraine education|Educational program available through HIH/ national library of medicine/ X-plain
58135|NCT01071317|Behavioral|Reenforcement of diagnosis|Patient told he/s he has migraine headache and how the headache meets migraine criteria
58136|NCT00031889|Drug|Exemestane|Exemestane
58137|NCT01071317|Other|Typical care|Care to be determined by attending physician
58138|NCT01071343|Device|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
58476|NCT01069692|Drug|SBR759A|12g daily
58477|NCT01069705|Drug|Tobramycin inhalation powder|Tobramycin inhaled powder
57645|NCT01068106|Device|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
57646|NCT01068106|Device|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
57647|NCT01068119|Procedure|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
57895|NCT01076075|Drug|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
57896|NCT01076075|Drug|Metformin|Phase A (Weeks 0-24): stable dose, as prescribed
by investigator, of metformin; Phase B (Weeks 24-
54): stable dose, as prescribed by investigator, of
metformin
57897|NCT01076075|Drug|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
57898|NCT01076088|Drug|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
57899|NCT01076088|Drug|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
57900|NCT01076088|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
57901|NCT01076088|Drug|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
57902|NCT01076088|Drug|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
57903|NCT00032188|Other|laboratory biomarker analysis|Correlative studies
57904|NCT01076127|Behavioral|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
57905|NCT01076127|Behavioral|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
57906|NCT01076140|Drug|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
57907|NCT01068561|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
57908|NCT01068574|Other|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
57420|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30-200,201)
57421|NCT01072786|Biological|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
57422|NCT00032006|Radiation|brachytherapy|
57423|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
57424|NCT01072799|Biological|Placebo|Two doses (Day 1 and Day 22); 0.5mL
57425|NCT01072799|Biological|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 & Day 22); 0.5mL
57426|NCT01072812|Drug|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
57427|NCT01072825|Other|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
57705|NCT01073319|Other|Placebo|Administration of placebo pill
57706|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
57707|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
57708|NCT01073332|Dietary Supplement|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
57709|NCT01073332|Dietary Supplement|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
57710|NCT01076140|Drug|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
57711|NCT01076153|Drug|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
57712|NCT01076166|Drug|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
57713|NCT01076218|Device|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
57714|NCT01076231|Radiation|proton beam radiation therapy|
58395|NCT01071915|Drug|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
58396|NCT01071928|Drug|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
58397|NCT01071928|Drug|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
58398|NCT00031915|Drug|imatinib mesylate|
58399|NCT01071941|Biological|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
58400|NCT01074398|Genetic|protein expression analysis|
58401|NCT01074398|Other|immunohistochemistry staining method|
58402|NCT01074398|Other|laboratory biomarker analysis|
58403|NCT01074411|Drug|Bortezomib|Given IP
58404|NCT00000914|Drug|Nelfinavir mesylate|
58405|NCT00032097|Radiation|radiation therapy|
58406|NCT01074411|Drug|Carboplatin|Given IP
58407|NCT01074411|Other|Laboratory Biomarker Analysis|Correlative studies
58408|NCT01074411|Other|Pharmacological Study|Correlative studies
58409|NCT01074424|Genetic|proteomic profiling|
58410|NCT01074424|Other|laboratory biomarker analysis|
57491|NCT01070212|Other|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
57492|NCT01070212|Other|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
58478|NCT01069757|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
58479|NCT01071954|Biological|Romiplostim|Starting Dose of 1µg/kg romiplostim or previous dose administered weekly
Individual Subject Dose Adjustment to a Maximum Dose of 10 µg/kg based on platelet count
Rescue Medications Allowed at Discretion of Investigator
Reduction in Concurrent ITP Therapies May Occur when Platelet Count is >50 x 109/L
58480|NCT01071967|Other|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
58481|NCT01071980|Other|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
58482|NCT01071993|Drug|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
58483|NCT01071993|Drug|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
58484|NCT01072019|Other|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
58485|NCT01072032|Device|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
58486|NCT01072045|Drug|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
58487|NCT01072045|Drug|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
58488|NCT00031928|Drug|mafosfamide|
58489|NCT01072058|Drug|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
58490|NCT01072071|Drug|furosemide|Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.
Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h.
58491|NCT01072097|Drug|Atorvastatin|Atorvastatin 20mg/day for 6 months
58492|NCT01072097|Drug|Placebo|Placebo for 6 months
57909|NCT01068587|Drug|MET/VEGFR2 inhibitor Foretinib|PhaseI and Phase II Arm A:
Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
57910|NCT01068587|Drug|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
57911|NCT01068587|Other|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
57912|NCT01068600|Drug|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
57913|NCT01068600|Drug|Placebo to indacaterol|Once daily via SDDPI
58246|NCT01066572|Drug|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
58247|NCT01066572|Drug|Placebo|Matched placebo; identical tablets to Lisinopril.
58248|NCT00031629|Drug|Gemcitabine Hydrochloride|Given IV
58249|NCT01066585|Drug|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
58250|NCT01066585|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
58251|NCT01066598|Drug|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
58252|NCT01066611|Drug|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
58253|NCT01066611|Drug|Placebo|CAL-263 10 mg or placebo once daily for 7 days
58254|NCT01066624|Drug|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
58255|NCT01066624|Other|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
58256|NCT01066624|Device|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
58257|NCT01066637|Drug|[18F](+/-)NOS|Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis
58258|NCT01066650|Device|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
58259|NCT00031629|Drug|Docetaxel|Given IV
57715|NCT01076231|Drug|cisplatin|Given IV
57716|NCT01076231|Drug|etoposide|Given IV
57717|NCT00032227|Procedure|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
57718|NCT01076231|Procedure|therapeutic conventional surgery|
57719|NCT01076244|Procedure|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
57720|NCT01076257|Behavioral|Modified Constraint-induced Movement Therapy|Home based CIT
Restriction of the less affected limb
Intensive practice using affected limb
Positive experience
Functional task (task)
57721|NCT01076270|Drug|plerixafor|Given SC
57722|NCT01076270|Biological|filgrastim|Given SC
57723|NCT01076270|Procedure|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
57724|NCT01076270|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
57982|NCT01073917|Other|Pressure Support Ventilation|
57983|NCT01076400|Drug|MK1775 + topotecan + cisplatin|Part 1: Dose escalation study. MK1775 capsules in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
57984|NCT01076400|Drug|Comparator: MK1775 + topotecan + cisplatin|Part 2, Arm 1: MK1775 capsules at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
57985|NCT01076400|Drug|Comparator: Placebo to MK1775 + topotecan + cisplatin|Part 2, Arm 2: Placebo to MK1775 capsules twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
57986|NCT01076413|Behavioral|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
57987|NCT01076413|Behavioral|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
57988|NCT00032240|Device|Shoe Insert|
57493|NCT01070225|Drug|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
57494|NCT01070238|Dietary Supplement|Isomaltulose|
57495|NCT01070251|Behavioral|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
57496|NCT01070251|Behavioral|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
57497|NCT01070264|Dietary Supplement|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
57498|NCT01070277|Drug|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
57499|NCT01070277|Drug|Placebo control|2 placebo pills X2 /day for 2 days followed by
1 placebo Pill X2 / day for 7 days
57500|NCT00031811|Procedure|quality-of-life assessment|
57501|NCT01070290|Drug|ARQ 197|120 mg capsule administered twice daily
57502|NCT01070290|Drug|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
57503|NCT01070303|Biological|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
57504|NCT01070316|Drug|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
57505|NCT01070329|Drug|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
57506|NCT01070329|Drug|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
57782|NCT01073384|Drug|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
57783|NCT01073397|Behavioral|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
57784|NCT01073423|Behavioral|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
57288|NCT01075087|Drug|Placebo|Bilateral TAP block using sterile normal saline.
57289|NCT01075087|Drug|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
57290|NCT00032149|Biological|bleomycin sulfate|
57291|NCT01075100|Drug|Ixabepilone|20 mg/m2 on Days 1 and 8
57292|NCT01075100|Drug|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
57293|NCT01075113|Drug|sorafenib tosylate|Given orally
57294|NCT01075113|Drug|vorinostat|Given orally
57295|NCT01075126|Drug|Depakote|
57296|NCT01075126|Drug|Lithium|
57297|NCT01075139|Behavioral|Brief Motivational Intervention|30 minute one-on-one meeting
57298|NCT01067391|Drug|tadalafil|20 mg tablet, administered once per study protocol
57299|NCT01067391|Drug|placebo|placebo tablet administered once per study protocol
57300|NCT00031655|Drug|fludarabine phosphate|Given IV
57301|NCT01067404|Biological|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
57302|NCT01067417|Drug|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
57303|NCT01067417|Drug|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
57304|NCT01067430|Drug|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
57305|NCT01067430|Drug|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
57306|NCT01067443|Drug|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
57307|NCT01067443|Drug|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
57308|NCT01067443|Drug|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
58260|NCT01066650|Device|Xience V (Everolimus-eluting stent)|Drug eluting stent
58261|NCT01066663|Drug|pyrimethamine|Taken orally once a day
58262|NCT01066676|Drug|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
58263|NCT01066676|Drug|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
58264|NCT01069159|Drug|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
58265|NCT01069159|Drug|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
57360|NCT00032149|Biological|filgrastim|
57361|NCT01075165|Other|silicone spray|application of silicone spray to predefined area qd 12 weeks
57362|NCT01075165|Other|saline spray|application of saline spray to predefined area qd 12 weeks
57363|NCT01075204|Drug|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
57364|NCT01075217|Drug|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
57365|NCT01075217|Drug|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
57366|NCT01075230|Procedure|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
57367|NCT01075243|Drug|Paracetamol 1000 mg|Paracetamol 1000mg
57368|NCT01075243|Drug|Paracetamol 650 mg|Paracetamol 650 mg
57369|NCT01075243|Drug|Placebo|Placebo
57370|NCT01075256|Device|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
57371|NCT00000914|Drug|Efavirenz|
57372|NCT00032149|Drug|cyclophosphamide|
57989|NCT01076426|Drug|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
57990|NCT01076426|Dietary Supplement|Oligosaccharide|oligosaccharide one pack per day
57991|NCT01076439|Drug|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
57992|NCT01076439|Drug|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
57993|NCT01076439|Drug|Saline Nasal Spray|Placebo
57994|NCT01076452|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
57995|NCT01076465|Other|Disease management program|1. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
57996|NCT01076465|Behavioral|Usual care|Usual care
57997|NCT01076478|Drug|Cilostazol|100 mg, 200mg tablet Cilostazol
57998|NCT01076491|Drug|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
57999|NCT00032279|Drug|Visilizumab|
58000|NCT01076504|Drug|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
58001|NCT01076504|Drug|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
58002|NCT01076504|Drug|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
58325|NCT01074359|Drug|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
58326|NCT01074372|Drug|REGN727|4 cohorts (dose 1, 2, 3, 4)
58327|NCT01074372|Drug|Placebo|4 cohorts (dose 1, 2, 3, 4)
58328|NCT01074385|Behavioral|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
58329|NCT01074398|Genetic|gene expression analysis|
58330|NCT01074398|Genetic|polymorphism analysis|
58331|NCT01066689|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
57785|NCT01073423|Behavioral|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
57786|NCT01073436|Other|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
57787|NCT01073449|Procedure|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
57788|NCT01073475|Other|There is no intervention associated with this study.|There is no intervention associated with this study
57789|NCT01073488|Behavioral|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
57790|NCT00032032|Drug|carboplatin|
57791|NCT01073501|Drug|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
57792|NCT01073501|Drug|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
57793|NCT01073527|Drug|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
57794|NCT01073527|Drug|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
57795|NCT01073540|Drug|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
57796|NCT01073540|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
57797|NCT01073553|Drug|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
57798|NCT01075672|Behavioral|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
58057|NCT00032058|Procedure|magnetic resonance imaging|
58058|NCT01073956|Procedure|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
57309|NCT01067456|Radiation|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
57310|NCT01067469|Drug|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
57311|NCT00031655|Drug|mycophenolate mofetil|Given PO
56341|NCT01087073|Behavioral|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
56342|NCT01087073|Behavioral|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
56343|NCT00032591|Other|High quality anticoagulation management (HQACM) with conventional monthly testing|HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
56344|NCT01078779|Drug|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
56345|NCT01078779|Drug|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
56346|NCT01078792|Other|CT pulmonary angio, blood tests|
56347|NCT01078805|Drug|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
56348|NCT01078818|Drug|IV trivalent saccharose hydroxide ferrous|Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up
1 month 1 oral placebo /24h
56349|NCT01078818|Drug|Oral ferrous fumarate|200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)
Postoperative Period:
200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet
56350|NCT01078818|Drug|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
56351|NCT01078831|Other|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
56352|NCT01078844|Drug|memantine|memantine 5-20 mg daily
56353|NCT01078844|Drug|Placebo|Look-alike placebo
56354|NCT00032617|Procedure|Prolonged Exposure|trauma-focused exposure therapy
57373|NCT01075256|Device|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
57374|NCT01075256|Device|Placebo toothpaste|Placebo toothpaste
57375|NCT01075282|Drug|Insulin Glargine|
57376|NCT01075282|Drug|LY2189265|
57377|NCT01075282|Drug|Metformin|
57378|NCT01075282|Drug|Glimepiride|
57379|NCT01075295|Behavioral|Behavioural Intervention for the Prevention of Weight Gain|The intervention consists of four steps:
STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2
STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake & physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3
STEP 3 (Nutrition & Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4
STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)
57380|NCT01075295|Other|TAU|Treatment as provided by individuals' existing healthcare providers
57648|NCT01068132|Drug|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
57649|NCT01068132|Drug|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
57650|NCT01068145|Drug|SCH 527123|Very low dose SCH 527123, once daily for 7 days
57651|NCT01068145|Drug|SCH 527123|Low dose SCH 527123, once daily for 7 days
57652|NCT01068145|Drug|SCH 527123|Medium dose SCH 527123, once daily for 7 days
57653|NCT01068145|Drug|SCH 527123|High dose SCH 527123, once daily for 7 days
57654|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
57655|NCT00000912|Drug|Levocarnitine|
57656|NCT00031694|Drug|bryostatin 1|Given IV
57657|NCT01068145|Drug|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
57658|NCT01068145|Drug|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
57659|NCT01068145|Drug|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
58332|NCT01066689|Drug|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
58333|NCT01066702|Biological|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
58334|NCT01066702|Procedure|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
58335|NCT01066715|Drug|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
58336|NCT01066715|Drug|Placebo|Sterile solution subcutaneously administered monthly for 6 months
58337|NCT00031629|Biological|Filgrastim|Given SC
58338|NCT01066728|Other|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
58339|NCT01066728|Drug|Theophylline|
58340|NCT01066741|Drug|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
58341|NCT01066741|Drug|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
58342|NCT01066754|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
58343|NCT01066767|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
58344|NCT01066780|Device|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
58345|NCT01066793|Drug|peginterferon alfa-2a [Pegasys]|As prescribed by physician
58346|NCT01066806|Behavioral|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
57428|NCT01072825|Biological|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
57429|NCT01072825|Other|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
57430|NCT01072825|Other|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
57431|NCT01072825|Other|Bone evaluation|PQCT scanner, BMD assessment
58059|NCT01073956|Procedure|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
58060|NCT01073956|Procedure|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
58061|NCT01073969|Other|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
58062|NCT01073969|Other|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
58063|NCT01073982|Dietary Supplement|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
58064|NCT01073995|Drug|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
58065|NCT01074008|Drug|ABT-450|50 mg capsules co-administered with ritonavir
58066|NCT01074008|Drug|ABT-072|50 mg tablet
58067|NCT01074008|Drug|ABT-333|400 mg tablet
58068|NCT00032058|Procedure|magnetic resonance spectroscopic imaging|
58069|NCT01074008|Drug|Ritonavir|100 mg capsules co-administered with ABT-450
58070|NCT01066182|Dietary Supplement|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
58071|NCT00031590|Drug|Vincristine|Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).
58072|NCT01066195|Drug|iressa|iressa 250mg per day every day
58073|NCT01066195|Drug|alimta|alimta 500mg/m2 every 3 weeks
58074|NCT01066234|Radiation|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
58075|NCT01066234|Drug|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
58076|NCT01066247|Drug|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
58077|NCT01066247|Drug|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
56355|NCT01078857|Other|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
56356|NCT01078870|Drug|Lexapro|10mg/cap 1~2# QD
56357|NCT01078870|Drug|Cymbalta|30mg/cap 30~60mg/QD
56652|NCT01081951|Drug|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
56653|NCT00033085|Drug|Ondansetron|
56654|NCT01081964|Drug|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
56655|NCT01081964|Drug|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
56656|NCT01081964|Drug|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
56657|NCT01081977|Procedure|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
56658|NCT01081977|Procedure|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
56659|NCT01081990|Drug|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
56660|NCT00033293|Other|laboratory biomarker analysis|Correlative studies
56661|NCT01084499|Drug|1st period - Reference drug|FEMARA Tab.[Letrozole 2.5mg] Novartis, Antineoplastics
56662|NCT01084499|Drug|1st period - Test drug|FERATRA Tab.[Letrozole 2.5mg] Yuhan Corporation, Antineoplastics
56663|NCT01084499|Drug|2nd period - Reference drug|FEMARA Tab.[Letrozole 2.5mg] Novartis, Antineoplastics
56664|NCT01084499|Drug|2nd period - Test drug|FERATRA Tab.[Letrozole 2.5mg] Yuhan Corporation, Antineoplastics
56665|NCT01084525|Drug|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
56666|NCT01084525|Drug|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
56667|NCT01084525|Drug|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
57660|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
57661|NCT01068158|Drug|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
57662|NCT01068158|Drug|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
57663|NCT01068171|Other|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
57664|NCT01068171|Other|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
57665|NCT01068184|Drug|AZD6553|Single or multiple oral dose
57666|NCT01068184|Drug|Placebo|single or multiple oral dose
57667|NCT00031707|Dietary Supplement|eicosapentaenoic acid|
57668|NCT01068197|Behavioral|Low Glycemic Load Diet versus Low Fat Diet|We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.
Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years.
57914|NCT01068613|Drug|QAX028|QAX028 60 mcg via inhalation device
57915|NCT01068613|Drug|QAX028|QAX028 20 mcg via inhalation device
57916|NCT00031720|Drug|Tamoxifen|
57917|NCT01068613|Drug|Tiotropium|Tiotropium via inhalation device
57918|NCT01068613|Drug|Placebo|Placebo to QAX028 via inhalation device
57919|NCT01068626|Drug|Rosuvastatin|10 mg once daily
57920|NCT01068626|Drug|Placebo for rosuvastatin|once daily
57921|NCT01068639|Behavioral|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
57922|NCT01068652|Drug|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
57923|NCT01068652|Drug|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
57432|NCT01072838|Radiation|APBI (Dose Escalation)|Accelerated, hypofractionated partial breast radiotherapy.
3 dose schemes followed for 6 months each.
57433|NCT00032006|Radiation|radiation therapy|
57434|NCT01072838|Device|Contura MLB Breast Brachytherapy Catheter|
57435|NCT01072851|Behavioral|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
57436|NCT01072851|Behavioral|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
57437|NCT01072851|Behavioral|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
57438|NCT01072864|Other|Walnuts|Consumption of 5 g of walnuts.
57439|NCT01072864|Other|Walnuts|Consumption of 20 g of walnuts.
57440|NCT01072864|Other|Walnuts|Consumption of 30 g of walnuts.
57441|NCT01075308|Drug|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
57442|NCT01075321|Drug|everolimus|Given orally
57443|NCT00032149|Drug|etoposide|
57444|NCT01075321|Drug|lenalidomide|Given orally
57445|NCT01075321|Other|laboratory biomarker analysis|Correlative studies
57446|NCT01075321|Genetic|polymorphism analysis|Correlative studies
57447|NCT01075321|Other|immunohistochemistry staining method|Optional correlative studies
57448|NCT01075321|Genetic|microarray analysis|Optional correlative studies
57449|NCT01075321|Genetic|fluorescence in situ hybridization|Optional correlative studies
57725|NCT01076283|Drug|Baclofen|Baclofen 10mg t.i.d.
57726|NCT01076283|Drug|Cyproheptadine|'active' placebo
57727|NCT01076322|Drug|Meptin® Swinghaler|Meptin® Swinghaler®
Ingredient: Procaterol HCL
Dosage form: 10g/puff
Dose(s): 10g
Dosing schedule: 20g (total 20g)
57728|NCT00032227|Other|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
58411|NCT01074437|Drug|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
58412|NCT01074437|Drug|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
58413|NCT01074437|Drug|Placebo|Liquid placebo will be given during the two month treatment trial.
58414|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
58415|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
58416|NCT00032110|Drug|erlotinib hydrochloride|Given orally
58417|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
58418|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
58419|NCT01074476|Dietary Supplement|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
58420|NCT01074476|Other|Placebo|Placebo tablets, twice per day for 3 months
58421|NCT01074502|Drug|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
58422|NCT01074528|Behavioral|mindfulness based stress reduction program|8-week mindfulness training program
58423|NCT01074541|Radiation|UVB|0.375 SED x 4 in a week
58424|NCT01074541|Radiation|UVB|0.75 SED x 4 in a week
58425|NCT01074541|Radiation|UVB|1.5 SED x 4 in a week
58426|NCT01074541|Radiation|UVB|3.0 SED x 4 in a week
58427|NCT00032110|Other|pharmacological study|Correlative studies
58428|NCT01074554|Drug|antibiotics|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD
58429|NCT01074554|Drug|lactose|lactose control tablets; one for each antibiotic with equivalent pills
58430|NCT01066871|Other|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
58431|NCT01066884|Drug|erlotinib [Tarceva]|150mg po daily
58432|NCT01066897|Drug|Pramipexole|
56668|NCT01084538|Drug|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
56669|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
56670|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
56671|NCT00033293|Drug|Corticotropin-Releasing Hormone|administered subcutaneously
56672|NCT01084551|Drug|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
56673|NCT01084577|Device|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
56674|NCT01084577|Device|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
56975|NCT01077154|Drug|Denosumab|120mg subcutaneously (SC) once monthly for 6 months. 120mg SC every 3 months for the next 4 and a half years. Oral calcium (at least 500 mg) and vitamin D (at least 400 IU) for 5 years.
56976|NCT01077167|Drug|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
56977|NCT01077180|Device|Implantation of the Rheos System|Open label
56978|NCT01077193|Procedure|Gastric Plication|A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.
The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.
At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
56979|NCT01077206|Drug|Simvastatin|80mg daily versus 40mg daily, for 21 days.
56980|NCT01077245|Drug|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
56981|NCT01077245|Drug|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
56982|NCT01079949|Drug|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
57924|NCT01068652|Drug|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
57925|NCT01068652|Drug|metformin|1000-2000 mg/day in combination with insulin treatment
57926|NCT01068665|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
57927|NCT00031720|Other|Placebo|Oral
57928|NCT01068665|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
57929|NCT01068678|Drug|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
57930|NCT01068678|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
57931|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
57932|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
57933|NCT01070888|Drug|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
57934|NCT01070888|Drug|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
57935|NCT01070927|Drug|RO4929097|80mg po daily, 3 days on 4 days off schedule
57936|NCT01070927|Drug|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
58266|NCT01069172|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
58267|NCT01069172|Procedure|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
58268|NCT00031733|Drug|alum adjuvant|
58269|NCT01069185|Procedure|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
58270|NCT01069185|Procedure|Routine endotracheal suctioning|Endotracheal suctioning every two hours
58271|NCT01069198|Drug|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged <5 and >=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
57729|NCT01076322|Drug|Ventolin® MDI|Ventolin® MDI
Ingredient: Salbutamol sulfate
Dosage form: 100g/puff
Dose(s): 100g
Dosing schedule: 200g (total 200g)
57730|NCT01076335|Drug|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
57731|NCT01076335|Drug|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
57732|NCT01076387|Procedure|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
57733|NCT01076387|Procedure|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
57734|NCT01068210|Behavioral|Exercise Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (~70%-100% VO2peak / ~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
57735|NCT01068210|Behavioral|Progressive Stretching|Stretching will be performed on stretching mats (i.e., no machines). Patients will be progressively trained to perform stretching exercises alternating between muscle groups / joints. Stretches will consist of prolonged holds held (under the maximum range of passive motion) initially for 20 secs and increasing to ≥60 secs/stretch.
57736|NCT01068223|Drug|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
57737|NCT01068223|Drug|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
57738|NCT01068223|Drug|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
57739|NCT01068236|Behavioral|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
57740|NCT01068249|Drug|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
57741|NCT01068249|Drug|RAD001 (Everolimus)|10 mg by mouth daily
57742|NCT01068262|Drug|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
57743|NCT00031707|Drug|megestrol acetate|
57744|NCT01068262|Drug|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
58003|NCT01076517|Device|Theraspheres|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
58004|NCT01076530|Drug|vorinostat|
58433|NCT00031642|Biological|rituximab|
58434|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
57507|NCT01070342|Device|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
57508|NCT01072864|Other|Walnuts|Consumption of 40 g of walnuts.
57509|NCT01072877|Drug|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
57510|NCT01072877|Drug|Placebo Vehicle|Placebo vehicle
57511|NCT00000231|Drug|Buprenorphine|
57512|NCT00000914|Drug|Indinavir sulfate|
57513|NCT00032019|Biological|filgrastim|Cycle 1: 300 ug (BW < = 70 kg) or 480ug (BW >70 kg) sub Q injection Day 6 until ANC > 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
57514|NCT01072890|Drug|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
57515|NCT01072929|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
57516|NCT01072929|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
57517|NCT01072942|Drug|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
57518|NCT01072942|Drug|Placebo|Placebo TID for 10 days
57519|NCT01072955|Biological|Bovine Heparin|5.000UI/mL bottle with 5mL
57520|NCT01072955|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
57521|NCT01072968|Drug|BF2.649|1 capsule per day in the morning before the breakfast
57522|NCT01072968|Drug|Placebo|1 capsule per day in the morning before the breakfast
57523|NCT01072981|Biological|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
57524|NCT00032019|Biological|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
56983|NCT01079949|Drug|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
56984|NCT01079949|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
56985|NCT01079949|Drug|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
56986|NCT00032786|Drug|natalizumab|
56987|NCT01079962|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
56988|NCT01079962|Drug|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
56989|NCT01079988|Drug|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
57312|NCT01067469|Drug|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
57313|NCT01067469|Drug|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
57314|NCT01067495|Behavioral|Cardiac rehabilitation|Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
57315|NCT01067508|Other|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
57316|NCT01067521|Drug|Glatiramer acetate (GA)|GA 40 mg administered 3 times a week by subcutaneous injection for a period of 12 months
57317|NCT01067521|Other|Placebo|Placebo comparator
57318|NCT01067534|Drug|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
57319|NCT01067547|Drug|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
57320|NCT01067547|Drug|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
57321|NCT01067599|Other|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
57322|NCT00031655|Other|laboratory biomarker analysis|Correlative studies
58272|NCT01069198|Other|Placebo|Placebo
58273|NCT01069237|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
58274|NCT01069237|Device|Clear Care|Lens Care Solution for contact lenses
58275|NCT01069250|Other|There are no interventions in this study|
58276|NCT01069263|Other|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
58277|NCT01069263|Drug|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
58278|NCT01069276|Other|No intervention in this study|No intervention in this study
58279|NCT00031733|Procedure|adjuvant therapy|
58280|NCT01069289|Drug|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
58281|NCT01069289|Drug|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
58282|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
58283|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
58284|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
58285|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
58286|NCT01069315|Procedure|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
58287|NCT01069315|Procedure|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
57381|NCT01067599|Other|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
57382|NCT01067599|Other|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
57383|NCT01067625|Device|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
57384|NCT01067638|Drug|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
57385|NCT01067651|Device|Plaster of Paris (POP) casting using the Ponseti Method|
58005|NCT01076530|Drug|temozolomide|
58006|NCT01076530|Other|diagnostic laboratory biomarker analysis|
58007|NCT01076530|Other|pharmacological study|
58008|NCT01068691|Procedure|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)
Blood pressure
Obstructive sleep apnea syndrome (OSAS)
Carotid-to-femoral pulse wave velocity (PWV)
Biological parameters
58009|NCT01068704|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, ~ 12 months depending on response
58010|NCT01068704|Drug|Lapatinib|Tablets, Oral, 1500 mg, once daily, ~ 12 months depending on response
58011|NCT01068704|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response
58012|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
58013|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
58014|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
58015|NCT00031733|Biological|MART-1 antigen|
58016|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
58017|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 500 mg, Once daily, single dose
58018|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 500 mg, Once Daily, single dose
58019|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 1000 mg, Once daily, single dose
58020|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 1000 mg, Once daily, single dose
58021|NCT01068743|Drug|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
58022|NCT01068743|Drug|metformin|Tablets, Oral, 850 mg, once daily, single dose
58023|NCT01068743|Drug|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
58024|NCT01068756|Drug|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
58025|NCT01068756|Drug|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
57525|NCT01072981|Drug|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
57526|NCT01072981|Radiation|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
57527|NCT01072994|Dietary Supplement|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
57528|NCT01073007|Drug|Simvastatin|Simvastatin 40 mgrs daily for three months.
57799|NCT01075685|Behavioral|interactive online programme to reduce alcohol consumption|The programme includes several steps:
personalized feedback on alcohol consumption and related risks
reviewing motivations and fears regarding drinking reduction
analyse of drinking habits
reduction goal setting
follow-up tools (alcohol diary, craving scales, well-being scales)
a final screen allowing participants to monitor their progress through graphs and automatically adapted comments.
57800|NCT01075685|Behavioral|Minimum information|This intervention includes:
information about hazardous drinking
an alcohol diary
57801|NCT01075698|Drug|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
57802|NCT01075698|Drug|ARB (Telmisartan)|Telmisartan 20-80 mg/day
57803|NCT01075711|Drug|Prednisone|According to SPC
57804|NCT00032162|Drug|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
57805|NCT01075724|Device|Patient Warming with Forced Air|Forced Air warming via BairHugger
57806|NCT01075724|Device|Resistive Warming|Resistive Warming via HotDog device
57807|NCT01075763|Drug|Interferon beta-1a|Interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per week (tiw)] administered subcutaneously (sc)
57808|NCT01075763|Drug|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
57809|NCT01075776|Drug|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
57810|NCT01075776|Drug|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
57811|NCT01075776|Drug|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
57812|NCT01075789|Drug|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
57813|NCT01075789|Drug|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
57814|NCT01075802|Drug|Tamoxifen|Dose escalation
59490|NCT01101932|Drug|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
59491|NCT00035126|Drug|epothilone b|
59492|NCT01101932|Drug|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
58531|NCT01067144|Drug|Gabapentin|1200mg Gabapentin preoperative dose, 300mg of Gabapentin three times a day postoperative doses for 72 hour post-surgical period.
58532|NCT00031655|Biological|donor lymphocytes|Given IV
58533|NCT01067144|Drug|Placebo|Active placebo given pre-operatively (0.5mg Lorazepam) in a single dose. 2 capsules of inactive placebo given three times a day post-operatively for the 72 hour post-surgical period.
58534|NCT01067157|Behavioral|LOGIC|Experimental group:
Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)
58535|NCT01067170|Device|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
58536|NCT01067183|Behavioral|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
58537|NCT01067222|Drug|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
58538|NCT01067222|Drug|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
58539|NCT01067222|Drug|Placebo|Placebo oral capsules, 4 capsules per day
58540|NCT01067235|Drug|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
58541|NCT01069770|Drug|Sunitinib|50mg daily(4 weeks on & 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
58542|NCT00000912|Drug|Saquinavir|
58543|NCT00031772|Procedure|psychosocial assessment and care|Questionnaire and telephone intervention
58544|NCT01069783|Drug|A3309|A3309 in two different dosage levels
58545|NCT01069783|Drug|A3309|A3309 in two different dosage levels for the duration of the study
58546|NCT01069783|Drug|Placebo|Placebo comparator once daily for the duration of the trial
58547|NCT01069796|Drug|Paclitaxel|80 mg/m² weekly
59378|NCT01099410|Procedure|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
59379|NCT01099423|Procedure|timing of surgery|
59380|NCT01099423|Genetic|gene expression analysis|
59381|NCT01099423|Other|biologic sample preservation procedure|
59382|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 35mg TID
59383|NCT01099423|Other|laboratory biomarker analysis|
59384|NCT01099423|Procedure|therapeutic conventional surgery|
59385|NCT01099436|Drug|cyclophosphamide|
59386|NCT01099436|Drug|docetaxel|
59387|NCT01099436|Drug|doxorubicin hydrochloride|
59388|NCT01099436|Drug|zoledronic acid|
59389|NCT01099436|Procedure|neoadjuvant therapy|
59390|NCT01099449|Drug|calcium gluconate|Given IV
59391|NCT01099449|Drug|magnesium sulfate|Given IV
59392|NCT01099449|Other|placebo|Given IV
59393|NCT00034814|Drug|Placebo|Enzyme-inducing placebo TID
59394|NCT01101672|Procedure|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
59704|NCT01102400|Drug|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
59705|NCT01102413|Drug|Monofer|Infusion or injections
59706|NCT01104766|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
59707|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral low dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
58611|NCT01103141|Device|Standard gauge-18 needle set|Groin access for vascular intervention
58612|NCT01103154|Drug|carvedilol|6.25mg per day, increase to 6.25mg bid
58613|NCT01103154|Drug|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
58614|NCT00035282|Drug|Comparator: placebo (unspecified)|
58615|NCT01103167|Behavioral|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
58616|NCT01103180|Drug|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
58617|NCT01103193|Drug|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
58618|NCT01105364|Other|pharmacological study|
58910|NCT01098435|Drug|Placebo|Capsules containing lactose and no active drug for daily oral administration
58911|NCT01098448|Other|scaling and root planing|scaling and root planing as a single therapy
58912|NCT01098448|Drug|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm
58913|NCT01098448|Drug|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
58914|NCT01098448|Other|surgery|periodontal surgery in residual pockets of >4mm
58915|NCT01098448|Drug|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
58916|NCT01098448|Other|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm and periodontal surgery in residual pockets of >4mm
58917|NCT00034671|Drug|Posaconazole oral suspension|
58918|NCT01098448|Other|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets >4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
58919|NCT01098448|Other|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets >4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets >5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
58920|NCT01098461|Biological|albiglutide|subcutaneous injection of albiglutide
58921|NCT01098461|Biological|placebo|subcutaneous injection of placebo to match albiglutide
59299|NCT01101581|Drug|90Y-epratuzumab tetraxetan|
59300|NCT01101581|Drug|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
59301|NCT01101594|Drug|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 & 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
59302|NCT01101607|Procedure|Distal Forearm Fracture Reduction|Fracture reduction
59303|NCT01101620|Drug|Levosimendan|
59304|NCT01101633|Dietary Supplement|Alginate|a 500 ml alginate beverage per meal test
59305|NCT00035074|Drug|Methotrexate|
59306|NCT01101633|Dietary Supplement|Alginate|a 330 ml alginate beverage per meal test
59307|NCT01101633|Dietary Supplement|Placebo|a 500 ml placebo beverage per meal test
59624|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
59625|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
59626|NCT01104727|Procedure|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
59627|NCT01104727|Procedure|Single-Port Cholecystectomy (SPC)|a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.
In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones.
59628|NCT01104740|Other|Biological sample collection|Blood (serum) sample collection
59629|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral low dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
59630|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral high dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
59631|NCT00035464|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
58691|NCT01103206|Drug|cinacalcet|Intake of a single tablet of cinacalcet
58692|NCT01103206|Drug|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
58693|NCT01103206|Drug|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
58694|NCT01103219|Dietary Supplement|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
58695|NCT01103232|Procedure|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
58696|NCT01103232|Procedure|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
58697|NCT00035295|Drug|MK0869, aprepitant|
58698|NCT01103245|Drug|Renin-Angiotensin-Aldosterone System (RAAS) Activation|Subjects will be receive a dose of Hydrochlorothiazide (HCTZ) for 12 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.
58991|NCT01105975|Drug|Rosuvastatin|Administered daily by mouth for 12 weeks
58992|NCT01105975|Drug|Placebo for LY2484595|Administered daily by mouth for 12 weeks
58993|NCT01105975|Drug|Placebo for Statins|Administered daily by mouth for 12 weeks
58994|NCT01105988|Other|Radiologic exams|FLT PET scan x 2 MRI scan x 2
58995|NCT01098474|Biological|Menjugate™|Intramuscular, 3 doses
58996|NCT01098487|Drug|Eltrombopag olamine|Thrombopoietin receptor agonist
58997|NCT00034684|Drug|Farnesyl Protein Transferase Inhibitor|
58998|NCT01098500|Drug|Tyrosine kinase inhibitors|Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
58999|NCT01098513|Drug|GSK1349572 formulation AP|GSK1349572 50 mg single dose fasted.
59000|NCT01098513|Drug|GSK1349572 formulation AW|GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
59708|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral high dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
59709|NCT01104779|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
59710|NCT01104792|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
59711|NCT01104805|Behavioral|Therapeutic Education System (TES)|Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
59712|NCT01104805|Behavioral|Treatment-as-Usual (TAU)|Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
59713|NCT01104818|Behavioral|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
59714|NCT01104831|Device|Cryotherapy|cooled sleeve placed over fracture site.
59715|NCT00035464|Drug|Placebo|placebo tablets, twice a day for 6 months
59716|NCT01104831|Device|Room temperature cuff|sleeve with room temperature water placed over fracture site.
59717|NCT01104844|Drug|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
59718|NCT01104844|Drug|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
59719|NCT01104844|Drug|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
58759|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
58760|NCT01100619|Drug|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
58761|NCT01100619|Drug|XL184|dosed with capsules daily
58922|NCT01098474|Biological|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
58923|NCT01098474|Biological|Tritanrix™ HB+Hib|Intramuscular, 3 doses
58924|NCT01098474|Biological|Prevnar™|Intramuscular, 3 doses
58925|NCT01098474|Biological|Polio Sabin™|Oral, 3 doses
58926|NCT00034983|Drug|Comparator: paroxetine HCL|
58927|NCT01100931|Drug|YM155|Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).
Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days.
58928|NCT01100931|Drug|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
58929|NCT01100931|Drug|Paclitaxel|200 mg/m^2 intravenous on day 1
59231|NCT01104012|Biological|Classification as "asthmatic" or "rhinitis only" via proteomic analysis|Proteomic profiles are established for each patient using plasma and serum samples
59232|NCT01104012|Biological|Classification as "asthmatic" or "rhinitis only" according to a metacholine test|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
59233|NCT01104025|Drug|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
59234|NCT01104025|Drug|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
59235|NCT01104025|Drug|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
59236|NCT01104025|Drug|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
59237|NCT00035386|Procedure|trans-right ventricular alcohol septal ablation (TRVASA)|
59238|NCT01104025|Drug|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
59632|NCT01104766|Drug|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
59633|NCT00034528|Drug|Fludarabine|30 mg/m^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
59634|NCT01097148|Drug|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
59635|NCT01097161|Behavioral|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
59636|NCT01097174|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
59637|NCT01097200|Device|Elevate mesh|The correction of the prolapse can be made by this new technique.
59638|NCT01097200|Device|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
59639|NCT01097213|Drug|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
58681|NCT00034944|Drug|MK0869, aprepitant|
58682|NCT01100502|Drug|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
58683|NCT01100502|Drug|placebo|Every 21 days by IV infusion
58684|NCT01100515|Other|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
58685|NCT01100515|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
58686|NCT01100528|Biological|recombinant interferon alfa-2b|Given SC 3 times a week for 24 weeks
58687|NCT01100528|Drug|dacarbazine|Given IV on days 1 and 29
58688|NCT01100528|Other|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
58689|NCT01100541|Device|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
58690|NCT01103193|Drug|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
59001|NCT01098513|Drug|GSK1349572 formulation AX|GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
59002|NCT01098526|Drug|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
59003|NCT01098526|Drug|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
59004|NCT01098539|Biological|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
59005|NCT01098539|Drug|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
59006|NCT01098565|Device|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
59007|NCT01098578|Drug|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
59008|NCT00034697|Drug|temozolomide|
59009|NCT01098591|Other|cell therapy|
59010|NCT01098604|Device|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
59011|NCT01098604|Device|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
59012|NCT01098630|Other|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
59013|NCT01098630|Other|Questionnaire Administration|Ancillary studies
59308|NCT01101633|Dietary Supplement|Placebo|a 330 ml placebo beverage per meal test
59309|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
59310|NCT01101646|Drug|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
59311|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
59312|NCT01101659|Drug|JNJ-40411813|500 mg as 20 mL of oral suspension
59313|NCT01101659|Drug|normal saline|single dose
59314|NCT01101659|Drug|ketamine|20 mL of oral suspension
59315|NCT01101659|Drug|Placebo|single dose
58762|NCT01100632|Dietary Supplement|Ginseng, vitamins, minerals|2 capsules per day
58763|NCT01100632|Other|Placebo - Gelatin capsule|2 capsules per day
58764|NCT01100645|Drug|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
58765|NCT00034957|Drug|Investigational drug|
58766|NCT01100645|Drug|Placebo|Excipient
58767|NCT01100658|Drug|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
58768|NCT01100658|Drug|Placebo|1 capsule per day for 1 week.
58769|NCT01100671|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
58770|NCT01100684|Drug|Asimadoline|0.5 mg Asimadoline BID
58771|NCT01100684|Drug|Placebo|Placebo
58772|NCT01100723|Drug|cinacalcet and/or active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/d as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
58773|NCT01100736|Drug|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
58774|NCT01100736|Drug|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
58775|NCT01100736|Drug|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
58776|NCT01103323|Drug|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
58777|NCT01103323|Other|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
58778|NCT01103336|Drug|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography
Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography
59239|NCT01104038|Behavioral|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
59240|NCT01104038|Behavioral|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
59241|NCT01104038|Behavioral|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
59242|NCT01104064|Device|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
59243|NCT01104064|Device|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
59244|NCT01104090|Device|C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and later indirect laryngoscopy
59245|NCT01104090|Device|C-MAC Indirect laryngoscopy|Patients for this arm will be intubated with C-MAC using indirect technique
59246|NCT01106391|Device|Cordis AAA stent graft system "INCRAFT TM"|
59566|NCT01099592|Drug|Citalopram|All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not < 8, the dose will increase to 40 mg.
59567|NCT01099605|Device|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
59568|NCT01099605|Device|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
59569|NCT01099618|Drug|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
59570|NCT01099618|Drug|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
59571|NCT01099618|Drug|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
59572|NCT01099631|Biological|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10^5, Level 2 = 10^6, Level 3 = 10^7, Level 4 = 10^8, Level 5 = 10^9, Level 6 = 10^10.
61009|NCT01089920|Other|Green tea|Infusion (tea bags) from commercially available green tea
61010|NCT01089920|Other|Coffee|Soluble coffee commercially available
60070|NCT01095705|Procedure|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
60071|NCT01095718|Behavioral|Errorless Learning|Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them".
The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.
The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.
During cueing the patient will mostly receive verbal and visual cues and if necessary physical help.
60072|NCT01095718|Behavioral|Modeling|The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.
The therapist does the steps, at the same time he/she uses verbal cues during the performance.
Then the therapist asks immediately to the patient to do the steps.
60073|NCT01095718|Behavioral|Trial and Error|The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.
The therapist does the steps, at the same time he/she uses verbal cues during the performance.
Then the therapist asks immediately to the patient to do the steps.
60074|NCT01095731|Drug|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
60075|NCT01095731|Drug|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
60076|NCT00034307|Drug|sitaxsentan sodium|
60077|NCT01095757|Drug|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is > 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
60078|NCT01095770|Procedure|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
60079|NCT01088048|Drug|Everolimus|Everolimus administered orally twice daily until disease progression
60080|NCT00033488|Procedure|annual screening|
60081|NCT01088048|Drug|Bortezomib|Bortezomib administered as a subcutaneous injection
60082|NCT01088048|Drug|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
60083|NCT01088048|Drug|Lenalidomide|Lenalidomide administered orally
59316|NCT00035087|Drug|epothilone b|
59317|NCT01104103|Device|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
59318|NCT01104103|Device|Standard elastic constricting band|Standard therapy
59319|NCT00035399|Procedure|Acupuncture|
59320|NCT01104142|Device|CGM|Continuous Glucose Monitoring System
59321|NCT01104155|Drug|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
59322|NCT01104155|Drug|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
59323|NCT01104181|Device|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
59324|NCT01104194|Dietary Supplement|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
59325|NCT01104194|Dietary Supplement|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
59326|NCT01104207|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
59327|NCT01104207|Device|placebo rTMS|placebo rTMS
59328|NCT01104233|Device|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
59640|NCT01097213|Drug|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
59641|NCT01097226|Other|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
59642|NCT01097226|Other|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
59643|NCT01097226|Other|Apple granules delivering 70 mg epicatechin|Delivered as a puree
59644|NCT00034528|Drug|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
59645|NCT01097226|Other|Water delivering no epicatechin|Delivered as flavoured water
58548|NCT01069796|Drug|Bevacizumab|10 mg/kg d1 d15
58549|NCT01069796|Drug|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 & 3
58550|NCT01069809|Biological|AGS-004|HIV-1 Immune Therapy
58551|NCT01069809|Biological|Placebo|Inactive Placebo Injection
58552|NCT01069822|Drug|AZD6765|IV solution
58553|NCT01069822|Drug|midazolam|
58554|NCT00031785|Drug|megestrol acetate|
58859|NCT01100866|Dietary Supplement|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
58860|NCT01100866|Other|Placebo|placebo capsules
58861|NCT01100879|Drug|Ferric carboxymaltose|Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.
Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).
Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
58862|NCT01100892|Drug|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
58863|NCT01100905|Other|Iron-containing food product|
58864|NCT01100918|Device|BiV ICD|Biventricular ICD
58865|NCT01100918|Device|ICD|Implantable Defibrillator
58866|NCT01103427|Device|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
58867|NCT01103440|Drug|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
58868|NCT01103440|Drug|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
58869|NCT01103453|Behavioral|Virtual Action Planning Supermarket (VAP-S) Software|The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.
We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention.
59573|NCT01099644|Biological|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
59574|NCT01099657|Behavioral|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
59575|NCT01099657|Behavioral|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
59576|NCT00034814|Drug|Placebo|Non-enzyme-inducing placebo TID
59577|NCT01099670|Drug|NRL001|Rectal suppository Placebo
59578|NCT01099670|Drug|Placebo|Placebo
59579|NCT01099683|Drug|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
59580|NCT01099683|Drug|Placebo|All subjects will receive rectal suppository containing placebo
59581|NCT01099696|Dietary Supplement|B. infantis 35624|B. infantis 35624 in white capsules
59582|NCT01099696|Dietary Supplement|placebo|white placebo capsules
59583|NCT01099709|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
59584|NCT01099709|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
58619|NCT00035529|Drug|Placebo|Solution, i.v infusion, 0 mg, Days 1 & 15 then monthly, 10 months.
58620|NCT01105364|Procedure|computed tomography|
58621|NCT01105364|Procedure|magnetic resonance imaging|
58622|NCT01105377|Drug|entinostat|Given orally
58623|NCT01105377|Drug|azacitidine|Given SC
58624|NCT01105377|Other|laboratory biomarker analysis|Correlative studies
58625|NCT01105390|Biological|rilotumumab|Given IV
58626|NCT01105390|Drug|cisplatin|Given IV
58627|NCT01105390|Drug|pemetrexed disodium|Given IV
60084|NCT01088074|Device|Histoacryl Tissue Adhesive|
60085|NCT01088074|Device|Dermabond|
60086|NCT01088074|Device|Staples|
60087|NCT01088074|Device|Monocryl 4-0|
60367|NCT01088620|Drug|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
60368|NCT01088633|Other|Exhaled particle analysis|At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.
Visit 3:
After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2.
60369|NCT01088646|Device|PillCam® Express Capsule Endoscopy Delivery System|The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.
Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.
The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free.
60370|NCT01088659|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
60371|NCT01088659|Drug|placebo|orally daily, 96 weeks
60372|NCT01088659|Drug|tenofovir|245mg po daily, 96 weeks
60373|NCT00033540|Drug|gemcitabine hydrochloride|1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
60374|NCT01088672|Procedure|Mechanical Thrombectomy|The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
60375|NCT01088685|Device|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
60376|NCT01091246|Biological|Q/LAIV (MEDI3250)|10 ^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
60377|NCT01091246|Biological|FluMist/B/Yamagata|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
60378|NCT00033683|Procedure|adjuvant therapy|
60379|NCT01091246|Biological|FluMist/B/Victoria|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
60380|NCT01091259|Drug|Irinotecan|
59646|NCT01097239|Device|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
59647|NCT01097252|Radiation|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
59648|NCT01097252|Drug|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
59649|NCT01097252|Drug|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
59650|NCT01097265|Drug|capecitabine|
59651|NCT01097265|Drug|oxaliplatin|
59652|NCT01097265|Other|active surveillance|
59653|NCT01097265|Other|laboratory biomarker analysis|
59654|NCT01097265|Procedure|adjuvant therapy|
59655|NCT00034528|Drug|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
59656|NCT01097265|Procedure|lymph node mapping|
59657|NCT01097265|Procedure|sentinel lymph node biopsy|
59658|NCT01097278|Dietary Supplement|cholecalciferol|Given orally
59659|NCT01099748|Drug|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
59660|NCT01099761|Biological|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
59661|NCT01099761|Biological|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
59662|NCT01099761|Biological|ACE-031 2.5 mg/kg q4wk|ACE-031 2.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
59663|NCT01099761|Other|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
58699|NCT01103245|Drug|Administration of Aliskiren, Spironolactone, or Placebo|Subjects will be receive a dose of Aliskiren, Spironolactone, or placebo for 4 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.
58700|NCT01103245|Drug|Increased Dose, Combination, or Placebo|Subjects will be receive either an increased dose of the present medication (Aliskiren or Spironolactone) or a combination of the two or a placebo for 4 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.
58870|NCT01103466|Device|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
58871|NCT01103466|Device|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
58872|NCT01103466|Device|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
58873|NCT00035321|Drug|Fluoxetine|
58874|NCT01103479|Behavioral|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
58875|NCT01103479|Behavioral|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
59171|NCT01106586|Drug|ATV Placebo|Placebo to match ATV administered orally once daily
59172|NCT01106586|Drug|RTV Placebo|Placebo to match RTV administered orally once daily
59173|NCT01106586|Drug|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
59174|NCT01106599|Drug|GDC-0623|Repeating oral dose
59175|NCT00035620|Drug|filgrastim|filgrastim
59176|NCT01106612|Procedure|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
59177|NCT01106612|Procedure|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
59178|NCT01106625|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
59179|NCT01106625|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
59180|NCT01106625|Drug|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
59181|NCT01106625|Drug|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
59182|NCT01106638|Behavioral|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
59183|NCT01098877|Drug|PF-04634817|Oral solution, up to 900mg, single dose after food
58628|NCT01105390|Other|laboratory biomarker analysis|Correlative studies
58629|NCT01105403|Drug|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
58630|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 & 15 then monthly, 10 months.
58631|NCT01105416|Behavioral|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
58632|NCT01105416|Behavioral|ESC|Enhanced standard care
58633|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
58634|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
58635|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
58636|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
58637|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
58638|NCT01105429|Drug|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
58639|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
58640|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
58641|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months.
58642|NCT01105429|Drug|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
58643|NCT01105429|Drug|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
58930|NCT01100944|Drug|PXD101 cisplatin+doxorbicin+cyclophosphamide|PXD101 will be given as a 48h CIVI starting on day 1, doxorubicin as a slow IV injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
58931|NCT01100957|Procedure|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
58932|NCT01100996|Other|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
58933|NCT01100996|Other|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
60381|NCT01091259|Drug|Bevacizumab|
60382|NCT01091272|Drug|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
60383|NCT01091272|Drug|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
60384|NCT01091272|Drug|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
60639|NCT01089140|Drug|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
60640|NCT01089140|Drug|Saline solution|Saline placebo
60641|NCT01089166|Drug|Metformin|
60642|NCT01089179|Drug|Metformin|
60643|NCT01089192|Drug|Metformin|
60644|NCT01089205|Drug|Metformin|
60645|NCT01089218|Drug|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
60646|NCT01091701|Biological|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
60647|NCT01091701|Other|Plasmalyte-A|Single IV dose of Plasmalyte-A
60648|NCT01091714|Dietary Supplement|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
60649|NCT01091714|Dietary Supplement|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
60650|NCT01091714|Dietary Supplement|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
60651|NCT01091727|Drug|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
60652|NCT01091740|Device|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
60653|NCT01091740|Device|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
60654|NCT01091753|Drug|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
60655|NCT00033696|Radiation|radiation therapy|
58701|NCT01103258|Procedure|high ligation and stripping (surgery)|surgery consisting of high ligation in combination with long saphenous stripping
58702|NCT01103258|Procedure|FOAM|duplex guided foam sclerotherapy
58703|NCT01103271|Other|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
58704|NCT01103284|Drug|DiaPep277|1.0 mg dose, administered as subcutaneous injection. Dosing schedule: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months
58705|NCT01103284|Drug|Placebo|40 mg mannitol, administered subcutaneously,
Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months
58706|NCT01103297|Device|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
58707|NCT01103310|Drug|BAY94-9392|
58708|NCT00035295|Drug|Comparator: placebo|
58709|NCT01103323|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
58710|NCT01105468|Device|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
58711|NCT01105481|Drug|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
58712|NCT01105481|Drug|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
58713|NCT01105494|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
58714|NCT01105507|Drug|canakinumab (company code: ACZ885D)|
58715|NCT00035542|Drug|Glucovance (metformin HCl/glyburide)|
58716|NCT01105520|Procedure|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
58717|NCT01105533|Drug|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
59014|NCT01098643|Other|computer-assisted intervention|
59015|NCT01098643|Other|medical chart review|
59184|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose after food
59185|NCT01098890|Drug|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
59186|NCT01098890|Drug|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
59187|NCT01098916|Radiation|Home X-rays|X-rays examinations performed at home
59188|NCT01098916|Radiation|X-rays in hospital|
59189|NCT01098955|Behavioral|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
59190|NCT00000919|Drug|Didanosine|
59191|NCT00034762|Drug|risperidone|
59192|NCT01098955|Behavioral|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
59193|NCT01098955|Drug|Varenicline|2 mg daily for 12 weeks
59194|NCT01098968|Behavioral|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
59493|NCT01101932|Drug|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
59494|NCT01101945|Drug|dutogliptin|400 mg QD
59495|NCT01101958|Device|Chartis Assessment System with Endobronchial Valve|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways. The endobronchial valve is designed to induce target lobe volume reduction.
59496|NCT01101971|Other|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
59497|NCT01101984|Drug|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
59498|NCT01101984|Drug|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
59499|NCT01101997|Device|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
59500|NCT01102010|Biological|Blood transfusion|An expanded indication for blood transfusion in the frail elderly
58934|NCT01101009|Drug|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
58935|NCT01101009|Drug|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
58936|NCT01101022|Drug|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
58937|NCT00035009|Drug|MK0869, aprepitant|
58938|NCT01101022|Other|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
58939|NCT01101035|Drug|Febuxostat|Febuxostat 40 mg or 80 mg (depending on serum uric acid levels), capsules, orally, once daily for up to 60 months.
58940|NCT01101035|Drug|Allopurinol|Allopurinol 200 mg to 600 mg (depending on renal function), capsules, orally, once daily for up to 60 months.
58941|NCT01101048|Drug|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
58942|NCT01101048|Drug|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
58943|NCT01101061|Drug|AMG 785|Subjects will be randomized to receive one of 3 dose levels of AMG 785 or equivalent volume of placebo administered as a single weight-based dose. Postmenopausal Japanese women will receive AMG 785 at a dose level of 1 mg/kg, 3 mg/kg, or 5 mg/kg. Postmenopausal non-Japanese women will receive AMG 785 at a dose level of 3 mg/kg.
58944|NCT01103570|Procedure|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
58945|NCT00035334|Drug|NC-503 (Anti-amyloidotic (AA) Agent)|
59247|NCT01106404|Device|RestoreSensor Neurostimulation System|Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned "ON" and manual when the AdaptiveStim feature of the device is turned "OFF".
59248|NCT01106417|Procedure|NeoFuse|Single Dose NeoFuse Surgical Implantation
59249|NCT01106417|Procedure|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
59250|NCT01106430|Drug|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
60656|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
60657|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
60658|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
60659|NCT01091792|Drug|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
60660|NCT01091818|Drug|dexmedetomidine|Dexemedethomidine is given as major sedative drug
60661|NCT01091818|Drug|Midazolam|Midazolam is given as major sedative drug
61011|NCT01089933|Procedure|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
61012|NCT01089933|Procedure|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
61013|NCT00033644|Biological|sargramostim|
61014|NCT01089959|Drug|Esomeprazole|40 mg daily for 7 days
61015|NCT01089959|Drug|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
61016|NCT01089972|Device|22 gauge catheter|radial artery cannulation using 22 gauge catheter
61017|NCT01089972|Device|20 gauge catheter|radial artery cannulation using 20 gauge catheter
61018|NCT01089985|Drug|Autologous serum eyedrops|3 times a day for the duration of the study
61019|NCT01092325|Drug|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
61020|NCT01092338|Drug|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
61021|NCT01092351|Drug|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
59016|NCT01098643|Other|questionnaire administration|
59017|NCT01098643|Other|survey administration|
59018|NCT01098656|Drug|lenalidomide|The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.
Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)
59019|NCT00034710|Drug|Capsaicin Patch|
59020|NCT01098695|Other|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
59021|NCT01101061|Drug|PLACEBO|Subjects will be randomized to receive one of 3 dose levels of AMG 785 or equivalent volume of placebo administered as a single weight-based dose. Postmenopausal Japanese women will receive AMG 785 at a dose level of 1 mg/kg, 3 mg/kg, or 5 mg/kg. Postmenopausal non-Japanese women will receive AMG 785 at a dose level of 3 mg/kg.
59022|NCT01101074|Other|This is non-intervention observational study|This is non-intervention observational study
59023|NCT01101087|Device|Taurolock|
59024|NCT01101087|Other|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
59025|NCT00035009|Drug|Comparator: paroxetine HCL|
59026|NCT01101100|Drug|AMG 827|210 mg SC or 140 mg SC
59027|NCT01101113|Drug|cinacalcet|cinacalcet 25mg qd or 50 mg qd
59028|NCT01101113|Drug|control|vit D + P binder
59029|NCT01101126|Other|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
59030|NCT01101126|Other|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
59031|NCT01101139|Drug|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
59032|NCT01101139|Drug|Placebo|Placebo: single intravenous injection Saline 0.9%
59033|NCT01101152|Drug|Desvenlafaxine succinate|Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;
1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day
59034|NCT01101165|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
59035|NCT01101165|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
59501|NCT01102023|Other|ordinary salt based- diet|
59502|NCT00035139|Drug|methylphenidate|
59503|NCT01102036|Other|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
59504|NCT01102036|Other|Yoghurt without probiotics|Yoghurt without probiotics
59505|NCT01102049|Dietary Supplement|fish, beef, fruit|
59506|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
59507|NCT00000235|Drug|Buprenorphine|
59508|NCT00000922|Drug|Abacavir sulfate|
59509|NCT00035438|Drug|St. John’s Wort|
59510|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
59511|NCT01104467|Other|Placebo|1 bolus injection of placebo IV
59512|NCT01104480|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
59513|NCT01104493|Biological|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
59514|NCT01104493|Other|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
58555|NCT01069861|Drug|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
58556|NCT01069874|Dietary Supplement|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
58557|NCT01069874|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
58558|NCT01069900|Drug|Moxifloxacin (Avelox, BAY12-8039)|For subjects 12 to less than (<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to < 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to < 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
58559|NCT01069900|Drug|Ertapenem|For subjects 13 to <18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to < 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
59251|NCT01106430|Drug|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
59252|NCT01106443|Procedure|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
59253|NCT01106443|Procedure|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
59254|NCT01106443|Procedure|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
59255|NCT00035607|Drug|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
59256|NCT01106443|Procedure|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
59257|NCT01106456|Behavioral|Experimental 1: All Nations Breath of Life program (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
59258|NCT01106456|Behavioral|Experimental 2: Nontailored program (NT)|The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current "best practice" recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
59259|NCT01106456|Other|Pharmacotherapy (e.g. Varenicline or Bupropion or NRT)|Pharmacotherapy (e.g. Varenicline or Bupropion or NRT)
59260|NCT01106469|Drug|JNJ-41443532|25mg tablet once daily
59261|NCT01106469|Drug|JNJ-41443532|250mg tablet once daily
59262|NCT01106469|Drug|JNJ-41443532|1500mg once daily (with 250mg tablets)
59263|NCT01106469|Drug|JNJ-41443532|100mg tablet once daily
59264|NCT01106469|Drug|JNJ-41443532|1000mg once daily (with 250mg tablets)
59265|NCT01106469|Drug|Placebo|Matching placebo
59266|NCT00035607|Drug|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
59585|NCT01099722|Drug|Flutiform|inhaler 2 puffs bd daily
59586|NCT01099722|Drug|Symbicort Turbohaler|2 puffs bd daily
59587|NCT00000920|Drug|Ritonavir|
61022|NCT00000919|Drug|Ritonavir|
61023|NCT00033813|Drug|Oxatomide (tinset)|
61024|NCT01092364|Behavioral|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
61025|NCT01092377|Dietary Supplement|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
61026|NCT01092377|Dietary Supplement|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
61027|NCT01092377|Other|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
61028|NCT01092377|Other|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
59785|NCT01102452|Dietary Supplement|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
59786|NCT01102465|Drug|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
59787|NCT01102478|Drug|losartan potassium / hydrochlorothiazide|100 mg / 25 mg tablet
59788|NCT01102491|Drug|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
59789|NCT01102504|Drug|Placebo|Placebo
59790|NCT01102504|Dietary Supplement|Ateronon|Tomato extract containing 28 mg lycopene/ day
59791|NCT01102517|Procedure|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
59792|NCT01102517|Procedure|axillary thoracotomy|axillary thoracotomy lobectomy
59793|NCT00035230|Drug|Topiramate|
59794|NCT01102595|Drug|Temozolomide|Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.
Temozolomide 75 mg/m2/d x 42-49 days
Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.
59795|NCT01102595|Drug|Bevacizumab|2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.
Bevacizumab 10 mg/kg every 15 days, three dosis.
59796|NCT01102595|Radiation|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
59329|NCT01104246|Drug|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
59330|NCT00035412|Drug|St. John’s Wort|
59331|NCT01104259|Drug|veliparib|Given PO
59332|NCT01104259|Drug|cisplatin|Given IV
59333|NCT01104259|Drug|vinorelbine tartrate|Given IV
59334|NCT01104259|Other|laboratory biomarker analysis|Correlative studies
59335|NCT01104259|Other|pharmacological study|Correlative studies
59336|NCT01104272|Device|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
59337|NCT01104298|Drug|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
59338|NCT01104298|Drug|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
59339|NCT01104311|Procedure|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
59340|NCT01104311|Procedure|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
59341|NCT00035425|Drug|linezolid|600mg every 12 hours
59342|NCT00035568|Drug|or Glyburide alone.|
59343|NCT01106157|Drug|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
59344|NCT01106157|Drug|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
59345|NCT01106157|Drug|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
59346|NCT01106170|Drug|Provex CV|dietary supplement, 2 capsules per day by mouth
59347|NCT01106170|Other|placebo|corn starch, 2 capsules per day by mouth
59348|NCT01106183|Dietary Supplement|transfer factor|capsules, 2 per day by mouth for 7 weeks.
59349|NCT01106183|Dietary Supplement|Placebo|cornstarch, 2 capsules per day by mouth.
58560|NCT01069900|Drug|Amoxicillin/Clavulanate|Subjects 2 years to < 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
58561|NCT01069900|Drug|Moxifloxacin placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
58562|NCT01069900|Drug|Ertapenem placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
58563|NCT01069900|Drug|Amoxicillin/Clavulanate placebo|Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
58564|NCT01072136|Drug|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
58565|NCT00031941|Drug|lenalidomide|
58566|NCT01072149|Drug|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
58567|NCT01072149|Device|placebo|placebo
58568|NCT01072162|Drug|Eltrombopag|25 mg tablet
58569|NCT01072162|Drug|Eltrombopag|25 mg powder for oral suspension
58570|NCT01072175|Drug|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
58571|NCT01072175|Drug|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
58572|NCT01072188|Device|Arginine/Calcium Carbonate|One time treatment
58876|NCT01103492|Device|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
58877|NCT01103505|Device|ForeseeHome|
58878|NCT01103518|Drug|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
58879|NCT01103531|Behavioral|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
58880|NCT01103531|Behavioral|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
59588|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 25mg TID
59589|NCT01099748|Drug|Methadone|Methadone 50 - 150 mg QD (Day 1)
59590|NCT01102062|Dietary Supplement|orange juice|
59591|NCT01102075|Device|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
59592|NCT01102075|Device|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
59593|NCT01102088|Radiation|Radiation Therapy|Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.
59594|NCT01102101|Drug|Remifentanil|Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
59595|NCT01102114|Biological|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
59596|NCT01102114|Biological|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
59597|NCT00000920|Drug|Zidovudine|
59598|NCT00035152|Drug|Paclitaxel and carboplatin|
59599|NCT01102127|Device|Elastography|Performance of US, elastography and FNA.
59600|NCT01102140|Drug|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
59601|NCT01102140|Drug|Sugar Pill|Matching sugar pill
59602|NCT01102153|Device|Coolgard|invasive cooling via femoral ICY-catheter
59603|NCT01102153|Device|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
58644|NCT01105429|Drug|Placebo|Capsule, Oral, (TBD), once daily, 2 days
58645|NCT01105455|Other|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
58646|NCT01105468|Device|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
59797|NCT01102608|Drug|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
59798|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
59799|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
59800|NCT01102647|Dietary Supplement|phytosterol ester|1.6 g phytosterols/day for 29 days
59801|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
59802|NCT01104857|Procedure|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
59803|NCT00035477|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
59804|NCT01104870|Drug|UT-15C|oral
59805|NCT01104883|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
59806|NCT01104883|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
58819|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
58820|NCT01105650|Drug|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m^2 3 times per week for 6 doses).
58821|NCT01098266|Drug|Placebo plus Best Investigator's Choice (BIC)|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:
Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
58822|NCT01098305|Drug|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
58823|NCT01098305|Behavioral|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
58824|NCT01098318|Dietary Supplement|Herbal extract|340-1,360 mg daily
58825|NCT00034632|Drug|Posaconazole oral suspension|
59350|NCT01106235|Biological|therapeutic autologous lymphocytes|Given IV
59351|NCT01106235|Biological|aldesleukin|Given SC
59352|NCT01106235|Drug|cyclophosphamide|Given IV
59664|NCT01099774|Drug|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
59665|NCT01099774|Drug|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
59666|NCT01099826|Behavioral|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
59667|NCT01099826|Behavioral|Motivational Interview|motivational interview by trained MI counselors by phone
59668|NCT00034827|Drug|CI-1040|
59669|NCT01099826|Behavioral|control|Usual care
59670|NCT01099839|Drug|ASP1941|oral
59671|NCT01099839|Drug|Miglitol|oral
59672|NCT01099852|Other|biological sample collection|blood sample collection
59673|NCT01099852|Other|quality of life questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
59674|NCT01099852|Other|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
59675|NCT01099878|Device|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
59676|NCT01099878|Device|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
59677|NCT01099891|Drug|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
59678|NCT01099891|Drug|Placebo|Placebo, Spray type, Twice a day
59679|NCT00034840|Drug|telmisartan, valsartan|
59680|NCT01099904|Drug|RO5024048|multiple oral doses for 5 days
58881|NCT01103557|Procedure|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
58882|NCT01103570|Procedure|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
58883|NCT01105663|Other|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
58884|NCT01105676|Procedure|skin biopsy|Two skin biopsies will be taken one time
58885|NCT01105702|Drug|Temozolomide|
58886|NCT01105702|Drug|Bevacizumab|
58887|NCT01105702|Drug|Lithium Carbonate|
58888|NCT01105702|Radiation|Radiation|
58889|NCT01105728|Procedure|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
58890|NCT00000922|Drug|Efavirenz|
58891|NCT00035555|Drug|Cyclosporine|Oral, capsule
58892|NCT01105754|Behavioral|Multifaceted Prompting Intervention MPI|Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.
Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form.
58893|NCT01105767|Drug|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
59195|NCT01098981|Device|Transcranial ultrasound as an adjunctive therapy to tPA|tPA per approved labeling administered over 60 minutes
Ultrasonic headframe with active insonation for 120 minutes
59196|NCT01098981|Drug|Standard of care tPA therapy for acute ischemic stroke|tPA per approved labeling administered over 60 minutes
Ultrasonic headframe with sham (inactive) insonation for 120 minutes
59197|NCT01098994|Dietary Supplement|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
59198|NCT01098994|Other|Dummy pills|Daily placebo administration for 8 weeks
58647|NCT01097889|Dietary Supplement|Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.|A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein
58648|NCT00034593|Drug|gemcitabine|
58649|NCT01097889|Dietary Supplement|RUSF (ready-to-use supplementary foods) Supplementary Plumpy®|Peanut-based fortified supplement
One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein
58650|NCT01097902|Drug|Ibuprofen|800 mg oral one time only
58651|NCT01097902|Drug|Placebo tablet|Placebo tablet oral one time only
58652|NCT01097928|Procedure|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
58653|NCT01097941|Biological|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
58654|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
58655|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
58656|NCT01097967|Other|CPAP|
58657|NCT01097980|Drug|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
58658|NCT01097980|Drug|Placebo|Placebo
58659|NCT00034606|Drug|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
58660|NCT01097993|Other|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
58661|NCT01097993|Other|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
58662|NCT01098006|Other|Blood withdrawal|Blood sampling
58663|NCT01098019|Drug|Xeomin|Patients will receive Xeomin only at Day 0.
58664|NCT01098019|Drug|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
58946|NCT01103583|Drug|Hydroxyurea|500 mg/die per os for two years
58947|NCT01103583|Other|placebo|500 mg/die per os for two years
58948|NCT01103609|Drug|Warfarin|Oral tablet od on Day 4
58826|NCT01098318|Drug|Sertraline|50-200 mg daily
58827|NCT01098318|Other|Lactose monohydrate|1-4 capsules daily
58828|NCT01098331|Other|counseling intervention|
58829|NCT01098331|Other|educational intervention|
58830|NCT01098331|Procedure|quality-of-life assessment|
58831|NCT01098331|Procedure|therapeutic conventional surgery|
58832|NCT01098331|Radiation|iodine I 125|
58833|NCT01098331|Radiation|palladium Pd 103|
58834|NCT01098344|Drug|Notch signaling pathway inhibitor MK0752|
58835|NCT01098344|Drug|gemcitabine hydrochloride|
58836|NCT00034645|Drug|Posaconazole oral suspension|
58837|NCT01098344|Other|imaging biomarker analysis|
58838|NCT01098344|Other|laboratory biomarker analysis|
58839|NCT01098344|Other|pharmacological study|
59130|NCT01101399|Drug|Ferric carboxymaltose|Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.
Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).
Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
59131|NCT01101412|Drug|Edetate Calcium Disodium|Given through CVC or PVC.
59132|NCT01101412|Drug|Ethanol|Given through CVC or PVC
59133|NCT00035048|Drug|aprepitant|
59134|NCT01103843|Drug|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
59135|NCT01103843|Drug|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
59681|NCT01099917|Drug|Maitake|Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.
Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test.
59682|NCT01102244|Drug|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
59683|NCT01102244|Drug|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
58718|NCT01105533|Drug|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
58719|NCT01105533|Drug|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
58720|NCT01105533|Drug|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
58721|NCT01105533|Drug|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
58722|NCT01105533|Drug|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
58723|NCT01105533|Drug|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
58724|NCT01105533|Drug|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
58725|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
58726|NCT00035542|Drug|metformin HCl|
58727|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
58728|NCT01105546|Drug|recombinant activated factor VII|90 µg/kg/day i.v.
58729|NCT01105546|Drug|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
58730|NCT01105572|Device|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
58731|NCT01098058|Other|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
58732|NCT01098071|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
58733|NCT00034619|Drug|ALIMTA|
59199|NCT01099007|Behavioral|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
59200|NCT01099007|Behavioral|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
59201|NCT01099046|Behavioral|Lifestyle|water intake, tympanic tubing, regular sleep
59202|NCT00034775|Drug|risperidone|
59203|NCT01099059|Drug|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
59204|NCT01099059|Drug|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)
59205|NCT01099072|Drug|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
59206|NCT01099072|Drug|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
59207|NCT01099085|Drug|Simvastatin|simvastatin 40 mg qd daily
59208|NCT01099085|Drug|Placebo|Placebo
59209|NCT01101412|Drug|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
59210|NCT01101412|Other|Hypertonic Saline|Given through CVC or PVC
59211|NCT01101438|Drug|metformin hydrochloride|Given orally
59212|NCT01101438|Other|placebo|Given orally
59213|NCT01101451|Drug|Cisplatin|Given IV
59214|NCT01101451|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
59215|NCT01101451|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
59216|NCT01101451|Other|Laboratory Biomarker Analysis|Correlative studies
59515|NCT01104506|Procedure|fMRI|
59516|NCT01104506|Procedure|mTMS|
59517|NCT01104519|Drug|Niaspan|Oral doses of 2000 mg of Niaspan once daily for 7 days.
58949|NCT01103609|Drug|Placebo|Oral tablet bd, stepwise increased
58950|NCT01103609|Drug|AZD1656|Oral tablet bd, stepwise increased
58951|NCT01103622|Drug|AZD1656|Oral tablet bd, step-wise increased dosage
58952|NCT01103622|Drug|Digoxin|Oral tablet od on Day 4
58953|NCT01103622|Drug|Placebo|Oral tablet bd, step-wise increased dosage
58954|NCT01103635|Biological|CD40 agonist monoclonal antibody CP-870,893|Given IV
58955|NCT01103635|Biological|tremelimumab|Given IV
58956|NCT00035347|Drug|IV azithromycin|500 mg once daily
58957|NCT01103635|Other|laboratory biomarker analysis|Correlative studies
58958|NCT01103648|Drug|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
58959|NCT01103648|Drug|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
58960|NCT01103648|Drug|Combination Simvastatin plus Ezetimibe|Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).
Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).
This Combination represents the experimental period of the present study.
58961|NCT01103661|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
58962|NCT01103674|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
58963|NCT01103687|Biological|Ad26.ENVA.01 (rAd26)|5 x 10^10 virus particles (VP) vaccine delivered intramuscularly (IM)
58964|NCT01103687|Biological|Placebo Vaccine|Placebo vaccine delivered IM
58965|NCT01103713|Drug|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
58966|NCT01103726|Drug|PF-02545920|1 and 5 mg tablets, 6 mg single dose
58967|NCT00000922|Drug|Indinavir sulfate|
59136|NCT01103856|Behavioral|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
59137|NCT01103856|Behavioral|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
59138|NCT01103895|Device|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output before and after cardiopulmonary bypass in adult patients.
59139|NCT01103908|Device|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology.
59140|NCT01103921|Other|Glucose|25% dose at 2-week intervention assigned to subjects.
59141|NCT01103921|Other|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
59142|NCT01103921|Other|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
59143|NCT01103921|Other|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
59144|NCT00035347|Drug|oral levofloxacin|500 mg once daily
59145|NCT01103934|Drug|Vitamin D3|4000 IU once daily
59146|NCT01103934|Drug|Placebo|Placebo taken once daily
59451|NCT01106690|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
59452|NCT01106690|Drug|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
59453|NCT01106690|Drug|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
59454|NCT01106703|Dietary Supplement|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
59455|NCT01106703|Other|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
59456|NCT01106716|Drug|Placebo|Placebo IV Infusion
58734|NCT01098084|Drug|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
58735|NCT01098097|Biological|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
58736|NCT01098097|Drug|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
58737|NCT01098110|Drug|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
58738|NCT01098110|Drug|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
58739|NCT01098110|Drug|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
59036|NCT00035022|Drug|BCX-1777|
59037|NCT01101178|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
59038|NCT01101178|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
59039|NCT01101191|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
59040|NCT01101191|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
59041|NCT01101204|Drug|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
59042|NCT01101217|Drug|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
59043|NCT01101217|Drug|placebo|placebo daily for 6 weeks
59044|NCT01101230|Other|Almonds|1.5 oz almonds/day
59045|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every week
59046|NCT01101243|Radiation|Broadband UVB|UVB dose: 4 SED every second week
59047|NCT00035035|Drug|GEMZAR|
59048|NCT01103726|Drug|placebo|matching placebo tablets, single dose
59049|NCT01103726|Drug|PF-02545920|1 mg tablets, 3 mg single dose
59050|NCT01103726|Drug|PF-02545920|5 mg tablets, 15 mg single dose
59518|NCT01104519|Drug|Comparator: Placebo|Oral doses of placebo once daily for 7 days.
59519|NCT01104532|Drug|ASP1941|oral tablet
59520|NCT00035451|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
59521|NCT01104532|Drug|sitagliptin|oral tablet
59522|NCT01104545|Drug|MK3614|single rising oral dose of MK3614
59523|NCT01104545|Drug|Comparator: Placebo|single dose oral placebo
59524|NCT01104558|Drug|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
59525|NCT01104571|Biological|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery
59526|NCT01104571|Drug|lapatinib ditosylate|Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.
Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.
59527|NCT01104571|Other|laboratory biomarker analysis|
59528|NCT01104571|Procedure|adjuvant therapy|
59529|NCT01104571|Procedure|neoadjuvant therapy|
59530|NCT01104571|Procedure|therapeutic conventional surgery|therapeutic conventional surgery
59531|NCT00035451|Drug|Placebo|tablets, twice daily for 6 months
59532|NCT01104584|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
59533|NCT01104597|Procedure|Flow Mediated Doppler (FMD)|Non-invasive assessment of flow-mediated dilation (FMD) will be performed using brachial artery ultrasound.
59534|NCT01096979|Drug|Placebo|Placebo
59535|NCT01096992|Drug|Bendamustine|Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)
Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)
59536|NCT01096992|Drug|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
59537|NCT01096992|Drug|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
58573|NCT01072188|Device|Nupro - Fluoride Free|Brush twice daily
59267|NCT01106469|Drug|JNJ-41443532|500mg once daily (with 250mg tablets)
59268|NCT01106482|Other|Serology blood draw|Blood draw only, no vaccine
59269|NCT01106495|Device|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
59270|NCT01099124|Drug|M2ES|polyethylene glycol rh recombinant endostatin
59271|NCT01099137|Drug|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
59272|NCT01099137|Drug|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
59273|NCT01099150|Dietary Supplement|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~900 mg of total flavan-3-ols and procyanidins.
59274|NCT00034788|Drug|Becaplermin|
59275|NCT01099150|Dietary Supplement|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~400 mg total flavan-3-ols and procyanidins.
59276|NCT01099150|Dietary Supplement|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
59277|NCT01099163|Dietary Supplement|Tonalin SG1000T FFA|
59278|NCT01099176|Drug|To compare monotherapies and combined therapy with each other|Each patient received two tablets per day. Time interval between pills - 12 hours.
In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets
59279|NCT01099202|Drug|Procrit (epoetin alfa)|Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
59280|NCT01099215|Biological|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
59281|NCT01099228|Other|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
59282|NCT01099228|Other|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
59283|NCT01099280|Drug|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
59284|NCT01099280|Drug|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
59457|NCT01106716|Drug|KAI-1678|KAI-1678 IV Infusion
59458|NCT01106716|Drug|Lidocaine|Lidocaine
59459|NCT01099449|Drug|oxaliplatin|
59460|NCT01099462|Drug|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
59461|NCT01099475|Procedure|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
59462|NCT01099475|Procedure|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
59463|NCT01099488|Procedure|Blood withdrawal|Blood sampling
59464|NCT01099501|Dietary Supplement|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
59465|NCT01099501|Dietary Supplement|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
59466|NCT01099501|Dietary Supplement|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
59467|NCT01099514|Drug|Nilotinib|D1~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
59468|NCT01099527|Drug|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
59469|NCT00034814|Drug|Talampanel|Enzyme-inducing Talampanel 35 mg TID
59470|NCT01099527|Drug|Capecitabine|dose escalation of capecitabine, everolimus
59471|NCT01099540|Drug|Pazopanib|Pazopanib 800 mg qd daily
59472|NCT01099553|Other|Educational video|Instructions to view an educational video about preparing for a colonoscopy
59807|NCT01104896|Drug|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
59808|NCT01104896|Drug|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
59809|NCT01104909|Procedure|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
59810|NCT01104909|Device|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
59051|NCT01103726|Drug|Placebo|matching placebo tablets, single dose
59052|NCT01103739|Drug|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
59053|NCT01103739|Drug|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
59054|NCT01103739|Drug|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
59055|NCT01103739|Drug|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
59056|NCT01103752|Other|no intervention, descriptive study|no intervention, descriptive study
59057|NCT01103765|Procedure|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
59058|NCT00035347|Drug|oral azithromycin|2 x 250 mg once daily
59059|NCT01103765|Procedure|stent deployment without post-dilatation|stent deployment without systematic post dilatation
59353|NCT00035581|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 24 weeks
59354|NCT01106235|Procedure|biopsy|Optional correlative studies
59355|NCT01106248|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
59356|NCT01106261|Procedure|Metastasectomy|Pulmonary Metastasectomy
59357|NCT01106261|Procedure|Active monitoring|Active monitoring
59358|NCT01106274|Radiation|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
59359|NCT01106287|Drug|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
59360|NCT01106287|Drug|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
59361|NCT01106326|Behavioral|Intervention|Teens participating in this study will have:
directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study
three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications).
58574|NCT01072201|Drug|Triclosan and Fluoride|Brush twice daily
58575|NCT01072201|Drug|Fluoride|Brush twice daily
58576|NCT00000913|Drug|Saquinavir|
58577|NCT00031954|Drug|carboplatin|
58578|NCT01072214|Drug|pazopanib|gw786034
58579|NCT01072214|Drug|pazopanib|gw786034
58580|NCT01072214|Drug|pazopanib|gw786034
58581|NCT01072214|Drug|Placebo|placebo
58582|NCT01072227|Procedure|Sample Collection|Tissue
58583|NCT01072240|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
58584|NCT01072253|Procedure|eye amputation|
58585|NCT01072266|Drug|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
58586|NCT01072279|Other|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
58587|NCT01072279|Other|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
58588|NCT00031954|Drug|gemcitabine hydrochloride|
58589|NCT01072292|Behavioral|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
58590|NCT01072305|Device|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
58591|NCT01072305|Device|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
58592|NCT00035269|Drug|Antibiotic|
58593|NCT01103024|Biological|AIN457|
58594|NCT01103024|Biological|Placebo|
58595|NCT01103037|Drug|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
59285|NCT00034801|Drug|olanzapine|
59604|NCT01102166|Other|Acapella with nebulization|st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.
The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.
nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe "T" between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.
Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases.
59605|NCT01102218|Drug|Erythropoietin|Standard of Care
59606|NCT01102218|Drug|Erythropoietin|Standard of Care
59607|NCT01102218|Drug|Pentoxifylline|400 mg qd po for 6 months
59608|NCT01102231|Drug|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
59609|NCT00035165|Drug|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
59610|NCT01102231|Drug|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
59611|NCT01102231|Radiation|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
59612|NCT01104597|Drug|Nitroglycerin 0.4 mg sublingual|Nitroglycerin 0.4 mg (a small tablet that dissolves under the tongue) will be given to dilate the arteries. Images of the arm will be recorded via non-invasive flow-mediated doppler for 5 minutes to assess for endothelium dysfunction. as outlined above.
59613|NCT01104610|Device|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
59614|NCT01104636|Drug|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
59615|NCT01104649|Drug|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
59616|NCT01104649|Drug|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
59617|NCT01104662|Drug|Vancomycin|
59618|NCT01104662|Drug|Daptomycin|
59619|NCT01104662|Drug|Semi-Synthetic Penicillin|
59620|NCT00035451|Drug|Sotalol|160 mg sot twice daily for 6 months
59621|NCT01104675|Drug|ENMD-2076|275 mg (or 250 mg for BSA < 1.65) per day in oral capsules in 28 day continuous cycles
59811|NCT01104922|Other|Cetuximab and stereotactic radiosurgery|Treatments Administered: - Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy); - Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: * Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) * Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery. Administration of cetuximab may or not be the same day that a fraction of SRS is given. Infusion reactions may occurring during the administration of cetuximab and rarely post-infusion.
59812|NCT01104935|Drug|trastuzumab|Trastuzumab: 1-year treatment
Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times "
59813|NCT01104935|Drug|chemotherapy|Chemotherapy: 12 to 24 weeks
Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC and CMF) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF.
59814|NCT00035477|Drug|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
59815|NCT01104948|Drug|DA-8031|
59816|NCT01104948|Drug|Placebo|
59817|NCT01104961|Device|Contact lens packaging solution|These test solutions are the intervention being tested.
59818|NCT01104961|Device|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
59819|NCT01104987|Drug|alendronate|One tablet of alendronate à 70 mg once a week during two years.
59820|NCT01105013|Drug|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
59821|NCT01105026|Device|Alveolar Bone Defect Regeneration Following Tooth Extraction|Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.
Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed.
59822|NCT01105052|Behavioral|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
58840|NCT01098357|Drug|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
58841|NCT01098357|Drug|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
58842|NCT01098357|Drug|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
59362|NCT01106352|Drug|Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
59363|NCT01106352|Drug|Docetaxel|Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m2 is allowed as per the approved docetaxel label.
59364|NCT00035594|Drug|pegfilgrastim|Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
59365|NCT01106365|Device|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
59366|NCT01099345|Procedure|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
59367|NCT01099345|Procedure|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
59368|NCT01099358|Drug|Cetuximab|Administered Intravenously
59369|NCT01099358|Drug|Cisplatin|Administered Intravenously
59370|NCT01099358|Drug|5 - Fluorouracil|Administered Intravenously
59371|NCT00034801|Drug|ziprasidone|
59372|NCT01099371|Other|exercise|progressive resistance training
59684|NCT01102257|Drug|Omega-3 EFA Supplement|The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:
2000 mg EPA 1000 mg DHA
59685|NCT01102257|Drug|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
59686|NCT01102270|Drug|Eszopiclone|3mg tablet once prior to sleep
59687|NCT01102270|Drug|Placebo|1 placebo capsule prior to sleep
59688|NCT01102283|Device|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
59689|NCT01102296|Biological|Hepatitis A vaccine|2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
59690|NCT00035178|Drug|Argatroban|
59691|NCT01102309|Device|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
58596|NCT01103037|Drug|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
58894|NCT01105767|Other|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
58895|NCT01105780|Drug|Placebo|Matching placebo
58896|NCT01105780|Drug|JNJ-41443532|250mg tablet once daily for 1 day
58897|NCT01105793|Drug|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
58898|NCT01105806|Behavioral|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
58899|NCT01105806|Behavioral|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
58900|NCT01105819|Procedure|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
58901|NCT01105819|Procedure|Chlorhexidine for standard oral care|A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).
This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
58902|NCT00035555|Drug|Mycophenolate mofetil (MMF)|Oral, capsule
58903|NCT01098383|Drug|Acetyl-Choline Esterase Inhibitors and Choline supplements|Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.
AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers & Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.
Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose.
58904|NCT01098383|Drug|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
58905|NCT01098409|Drug|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
58906|NCT00034658|Drug|Posaconazole|
58907|NCT01098409|Drug|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
59622|NCT01104701|Drug|exenatide once weekly|subcutaneous injection, 2 mg, once a week
59623|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
58665|NCT01098032|Device|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate >300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
58666|NCT01098032|Drug|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
58667|NCT01098058|Other|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
58668|NCT01100424|Device|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
58669|NCT00034918|Drug|ZD6474|
58670|NCT01100424|Other|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
58671|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
58672|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
58673|NCT01100450|Behavioral|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
58674|NCT01100463|Drug|Ointment|Twice daily lotion to prevent HFS
58675|NCT01100463|Drug|0.1% Uracil Ointment|Twice daily lotion to prevent HFS
58676|NCT01100476|Device|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
58677|NCT01100489|Radiation|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
58843|NCT01098357|Drug|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
58844|NCT00034970|Behavioral|Mindfulness-based at therapy|
58845|NCT01100736|Biological|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
58846|NCT01100762|Device|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
58847|NCT01100762|Device|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
58848|NCT01100762|Device|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
58849|NCT01100775|Drug|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
58850|NCT01100775|Drug|Galantamine or Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
58851|NCT01100788|Dietary Supplement|Short chain fructo-oligosaccharide (scFOS) 5 g|Dietary Supplement: scFOS 5 g
Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew.
58852|NCT01100788|Other|Placebo|Treatment without scFOS fiber
58853|NCT01100788|Dietary Supplement|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
58854|NCT01100801|Drug|TS-1 with cisplatin|
58855|NCT00034983|Drug|aprepitant|
58856|NCT01100801|Drug|TS-1 with oxaliplatin|
58857|NCT01100827|Other|EGFR mutation status in patients|
58858|NCT01100853|Drug|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
59147|NCT01103934|Drug|Fluticasone Propionate|200 mcg daily, intranasal
59692|NCT01102309|Other|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
59693|NCT01102322|Behavioral|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
59694|NCT01102335|Procedure|Transcatheter arterial chemoembolization (TACE)|The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
59695|NCT01102335|Drug|Telbivudine|anti-HBV drug
59696|NCT01102348|Other|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
59697|NCT01102361|Procedure|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
59698|NCT01102374|Drug|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
59699|NCT01102374|Drug|Standard Dose Vitamin D|Vitamin D 400-1000 IU per day
59700|NCT01102387|Drug|LAS41003|Once daily, topically
59701|NCT00035191|Drug|galantamine|
59702|NCT01102387|Drug|LAS189962|Once daily, topically
59703|NCT01102387|Drug|LAS189961|Once daily, topically
58740|NCT01098136|Other|Chiropractic|Manual treatment of musculoskeletal complaints
58741|NCT01098136|Other|Conventional medical intervention|Medical, physiotherapy
58742|NCT01098136|Other|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
58743|NCT01098149|Other|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
58744|NCT00000919|Drug|Zidovudine|
58745|NCT00034619|Drug|Oxaliplatin|
58746|NCT01098188|Drug|LFB-R603|intravenous administration, dose-escalation study
58747|NCT01098201|Drug|Certolizumab|Subcutaneous administration on a monthly basis for six months
58908|NCT01098422|Device|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
58909|NCT01098435|Drug|RDC-0313 (ALKS 33)|Capsules for daily oral administration
59217|NCT01101451|Other|Quality-of-Life Assessment|Ancillary studies
59218|NCT01101464|Drug|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
59219|NCT00035048|Drug|Comparator: placebo (unspecified)|
59220|NCT01101464|Drug|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
59221|NCT01101477|Procedure|TCI titration by different Cet.|Induction:
After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial" Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale "OAA/S" every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.
If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.
Maintenance:
The Cet will be increased according to the assigned regimens if:
Patients become irritant and interfere procedures.
Patients open eyes or talk to express uncomfortable.
The Cet will be decreased if:
Systolic blood pressure is less than 90mmHg;
Mean arterial blood pressure is less than 65mmHg;
Oxyhemoglobin saturation is less than 90 %
with any duration.
59222|NCT01101503|Drug|Intensive multifactorial group|Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.
The intensive multifactorial therapy group:
For blood glucose control, target HbA1c >=5.5%and <=6.0%,fasting blood glucose >=5.0 mmol/L and <=6.0 mmol/L, postprandial 2 hour glucose >= 6.0 mmol/L and <= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.
For blood lipids control, target LDL-C < =1.9 mmol/L, triglyceride < =1.5 mmol/L. The drugs include statin and fibrate.
For blood pressure control, target >=120/70 mmHg and <= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.
Others, such as aspirin.
59223|NCT01101503|Drug|conventional multifactorial therapy group|Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.
The conventional multifactorial therapy group:
For blood glucose control, target HbA1c >6.5%and <=7.0%,fasting blood glucose >6.0 mmol/L and <=7.0 mmol/L, postprandial 2 hour glucose > 7.8 mmol/L and <= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.
For blood lipids control, target LDL-C > 1.9 mmol/L and < =2.5 mmol/L, triglyceride > 1.5 mmol/L and < = 2.5 mmol/L. The drugs include statin and fibrate.
For blood pressure control, target >130/80 mmHg and <= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.
Others, such as aspirin.
59224|NCT01101529|Drug|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
59225|NCT01101529|Drug|Placebo|Placebo will be administered instead of Emend
59226|NCT01101542|Biological|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
59227|NCT01103973|Behavioral|Mind/Body Program|Ten week group mind/body program
58678|NCT01100489|Other|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
58679|NCT01100489|Procedure|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins < 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
58680|NCT00000920|Drug|Saquinavir|
58968|NCT00035347|Drug|ceftriaxone|1 gram once daily for 2 to 5 days
58969|NCT01105832|Drug|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
58970|NCT01105871|Drug|naloxone|4 mg naloxone in 10 ml saline given iv bolus
58971|NCT01105871|Drug|Placebo|10 ml of normal saline iv bolus
58972|NCT01105884|Procedure|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
58973|NCT01105884|Procedure|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
58974|NCT01105884|Procedure|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
58975|NCT01105884|Procedure|Hydrogel|All the subjects in this group will be treated with Hydrogel
58976|NCT01105884|Procedure|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
58977|NCT01105897|Procedure|Endometriosis surgery|Complete surgical excision of all visible endometriosis by multidisciplinary approach
58978|NCT01105910|Other|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
58979|NCT00035555|Drug|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
58980|NCT01105910|Other|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
58981|NCT01105923|Other|MAPLE|MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
58982|NCT01105936|Drug|Paracetamol|665 mg sustained release paracetamol caplets
58983|NCT01105936|Drug|Placebo|Placebo caplets
59148|NCT01103947|Device|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
59149|NCT01103947|Device|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
59150|NCT01103947|Device|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
59151|NCT01103947|Device|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
59152|NCT01103960|Drug|Telmisartan80mg+Amlodipine5mg|combination therapy
59153|NCT01103960|Drug|amlodipine 5mg|monotherapy
59154|NCT01103960|Drug|Telmisartan80mg+Amlodipine 5mg|combination therapy
59155|NCT00035360|Drug|PEG-Intron|
59156|NCT01106495|Drug|statin|statin as the standard treatment of hypercholesterolemia
59157|NCT01106508|Drug|LEQ506|
59158|NCT01106521|Radiation|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
59159|NCT01106534|Drug|DAPT|Compare 12 and 30 months of DAPT treatment in patients undergoing percutaneous coronary intervention (PCI) with stent placement
59160|NCT01106547|Drug|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
59161|NCT01106547|Drug|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
59162|NCT01106560|Procedure|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
59163|NCT00000922|Drug|Nevirapine|
59164|NCT00035620|Drug|pegfilgrastim|pegfilgrastim
59165|NCT01106560|Procedure|Standard postero-lateral approach|
59166|NCT01106586|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
59167|NCT01106586|Drug|ATV|Atazanavir 300 mg capsule administered orally once daily
59168|NCT01106586|Drug|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
59169|NCT01106586|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
58748|NCT01098240|Drug|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
58749|NCT01098240|Other|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
58750|NCT01098253|Behavioral|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
58751|NCT01098266|Drug|NGR-hTNF plus Best Investigator's Choice (BIC)|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:
Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
58752|NCT01100554|Device|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
58753|NCT01100567|Device|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
58754|NCT00034944|Drug|Comparator: placebo|
58755|NCT01100580|Dietary Supplement|low salt diet|Daily salt intake less than 4 g/day
58756|NCT01100580|Dietary Supplement|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
58757|NCT01100593|Procedure|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
58758|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
59060|NCT01103778|Drug|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). A second cycle is to be given a month later for non-responders.
59061|NCT01103791|Drug|Docetaxel-PNP|
59062|NCT01103817|Dietary Supplement|Vitamin D|Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.
If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily.
59063|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
59064|NCT01103830|Drug|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
59228|NCT01103973|Behavioral|Control|Spa gift certificates
59229|NCT01103986|Behavioral|Motivational/health literacy education (Test group)|Attend a 1-hour class to learn how to use the book "What to Do When Your Child Gets Sick."
59230|NCT01103986|Behavioral|Control Group|No intervention
59538|NCT01097018|Drug|Capecitabine|1000 mg/m2 BID/ Days 1-14
59539|NCT01097018|Drug|Perifosine|50 mg daily x 21 days
59540|NCT01097018|Drug|Placebo|1 pill daily x 21 days
59541|NCT01097031|Other|Infusion Intermittent|
59542|NCT01097044|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
59543|NCT01097044|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
59544|NCT00034515|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|
59545|NCT01097057|Drug|Carboplatin|Given IV
59546|NCT01097057|Drug|Etoposide|Given IV
59547|NCT01097057|Biological|Filgrastim|Given SC
59548|NCT01097057|Drug|Ifosfamide|Given IV
59549|NCT01097057|Procedure|Leukapheresis|Given through catheter
59550|NCT01097057|Drug|Plerixafor|Given SC
59551|NCT01097057|Biological|Rituximab|Given IV
59552|NCT01097070|Drug|Bevirimat|
59553|NCT01097083|Drug|Coriolus Versicolor|
59554|NCT01097096|Biological|CAD106|
59555|NCT00034528|Drug|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
59556|NCT01097096|Biological|CAD106|
59557|NCT01097096|Biological|CAD106|
59558|NCT01097096|Biological|CAD106|
58984|NCT01105949|Device|Marketed nasal strip|Marketed nasal strip
58985|NCT01105949|Device|NexGen AB 2R11|Nasal strip prototype
58986|NCT01105949|Device|NexGen JB Organic PET/PE|Nasal strip
58987|NCT01105975|Drug|LY2484595|Administered daily by mouth for 12 weeks
58988|NCT01105975|Drug|Atorvastatin|Administered daily by mouth for 12 weeks
58989|NCT01105975|Drug|Simvastatin|Administered daily by mouth for 12 weeks
58990|NCT00035568|Drug|Glucovance (metformin HCl/glyburide)|
59286|NCT01099306|Other|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
59287|NCT01099319|Dietary Supplement|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
59288|NCT01099319|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
59289|NCT01099332|Other|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
59290|NCT01099332|Other|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
59291|NCT01101542|Other|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
59292|NCT01101555|Drug|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
59293|NCT01101555|Other|Placebo|Placebo will be given to one member of each cohort.
59294|NCT00035061|Drug|pemetrexed|
59295|NCT01101568|Drug|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
59296|NCT01101568|Drug|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
59297|NCT01101568|Drug|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
59298|NCT01101581|Drug|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 & 3 (days 8 & 15).
59170|NCT01106586|Drug|Stribild Placebo|Placebo to match Stribild administered orally once daily
59473|NCT01099553|Other|Written instructions|Written instructions on preparing for a colonoscopy
59474|NCT01099566|Drug|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
59475|NCT01099566|Drug|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
59476|NCT01099579|Drug|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to <10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to <15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to <25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
59477|NCT01099579|Drug|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
59478|NCT01099579|Drug|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
59479|NCT01099579|Drug|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
59480|NCT00034814|Drug|Talampanel|Enzyme-inducing TLP 50mg TID
59481|NCT01101880|Biological|filgrastim|Given SC
59482|NCT01101880|Drug|clofarabine|Given IV
59483|NCT01101880|Drug|cytarabine|Given IV
59484|NCT01101893|Drug|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
59485|NCT01101893|Drug|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
59486|NCT01101893|Drug|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
59487|NCT01101906|Drug|OSI-906|OSI-906 administered orally
59488|NCT01101906|Drug|Placebo|Matching placebo administered orally
59489|NCT01101919|Drug|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
59065|NCT01103830|Other|Placebo and finally Moxifloxacin|3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.
1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning.
59066|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
59067|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
59068|NCT01103830|Other|Placebo and finally Moxifloxacin|3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.
1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning.
59069|NCT00035347|Drug|IV levofloxacin|500 mg once daily
59070|NCT01106001|Drug|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
59071|NCT01106001|Drug|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
59072|NCT01106014|Drug|Selexipag|Selexipag 200 mcg tablets
59073|NCT01106014|Drug|Placebo|Selexipag matching placebo tablets
59373|NCT01099384|Behavioral|Written self-help materials|Written materials to help adolescents stop tobacco use
59374|NCT01099384|Behavioral|Group behavioral counseling|group behavioral counseling (2 day weekend program)
59375|NCT01099397|Other|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
59376|NCT01099410|Procedure|Fiberoptic bronchoscopy|which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed ("lavaged") with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours.
59377|NCT01099410|Procedure|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
59559|NCT01097096|Biological|CAD106|
59560|NCT01097096|Biological|CAD106|
59561|NCT01097096|Biological|CAD106|
59562|NCT01097096|Biological|CAD106|
59563|NCT01097096|Biological|CAD106|
59564|NCT01097122|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
59565|NCT01097135|Drug|Duraprep Surgical Solution|
58597|NCT01103050|Drug|QAV680 + Cetirizine Placebo|
58598|NCT01103050|Drug|QAV680 + Cetirizine|
58599|NCT01103050|Drug|Cetirizine + QAV680 Placebo|
58600|NCT01103050|Drug|QAV680 Placebo + Cetirizine Placebo|
58601|NCT01103063|Drug|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
58602|NCT01103063|Drug|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
58603|NCT00035282|Drug|aprepitant|
58604|NCT01103076|Device|Polyamide HD membrane|Single use polyamide membrane
58605|NCT01103102|Drug|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
58606|NCT01103102|Drug|Placebo|Placebo
58607|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
58608|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
58609|NCT01103115|Dietary Supplement|Placebo|placebo tablets
58610|NCT01103141|Device|Micropuncture needle set|Groin access for vascular intervention
60914|NCT01089725|Biological|Placebo IV|1 ml placebo administered IV every 8 weeks
60915|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
60916|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
60917|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
60918|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
60919|NCT01089725|Biological|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
60920|NCT00033618|Other|laboratory biomarker analysis|Correlative studies
60921|NCT01089725|Biological|Placebo SC|1ml placebo administered SC every 8 weeks
60922|NCT01089738|Drug|PF-03382792 0.5mg|0.5 mg PF-03382792, qd, for 14 days or placebo
60923|NCT01089738|Drug|PF-03382792 1.5 mg|1.5 mg PF-03382792, qd, for 14 days or placebo
60924|NCT01089738|Drug|PF-03382792 5 mg|5 mg PF-03382792, qd, for 14 days or placebo
60925|NCT01089738|Drug|PF-03382792 15 mg|15 mg PF-03382792, qd, for 14 days or placebo
60926|NCT01092182|Drug|EPOCH-R|EPOCH-R every 21 days for 6 cycles
59976|NCT00000921|Drug|Prednisone|
59977|NCT01105221|Drug|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
59978|NCT01105234|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
59979|NCT01105247|Drug|PCI-32765|420 mg daily or 840 mg daily
59980|NCT01105273|Biological|anti-thymocyte globulin|On days -3 to -1
59981|NCT01105273|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
59982|NCT01105273|Drug|Fludarabine|30mg/M2 once daily IV on days -6 to -2
59983|NCT01105273|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
59984|NCT01105273|Procedure|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
60618|NCT01096784|Drug|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
60619|NCT01089049|Dietary Supplement|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
60620|NCT01089062|Drug|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
60621|NCT01089062|Drug|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
60622|NCT01089062|Drug|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
60623|NCT01089062|Drug|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
60624|NCT01089075|Drug|Hydrocortisone|20 mg po for 7 days (2 tablets)
60625|NCT00033566|Drug|S-3304|
60626|NCT01089075|Drug|Placebo|2 tablets po
60627|NCT01089088|Drug|cisplatin|Up to six 21 day chemotherapy cycles:
Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)
60628|NCT01089088|Drug|gemcitabine hydrochloride|Up to six 21 day chemotherapy cycles:
Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)
60629|NCT01089088|Drug|sunitinib malate|Up to six 21 day chemotherapy cycles:
Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)
60630|NCT01089101|Other|Laboratory Biomarker Analysis|Correlative studies
60631|NCT01089101|Other|Pharmacological Study|Correlative studies
60632|NCT01089101|Drug|Selumetinib|Given PO
60633|NCT01089127|Drug|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
60634|NCT01089127|Drug|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
60635|NCT01089127|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
60636|NCT00033592|Other|placebo|
60637|NCT01089127|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
60638|NCT01089140|Drug|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
60408|NCT01093807|Drug|Lercanidipine|10 mg once daily for 10 weeks
60409|NCT01093807|Drug|Lercanidipine|20 mg once daily for 10 weeks
60410|NCT01093807|Drug|Enalapril|10 mg once daily for 10 weeks
60411|NCT01093807|Drug|Enalapril|20 mg once daily for 10 weeks
60412|NCT01093807|Drug|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
60413|NCT00034086|Drug|Tenofovir disoproxil fumarate|
60414|NCT01093807|Drug|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
60415|NCT01093807|Drug|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
60416|NCT01093807|Drug|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
60417|NCT01093820|Drug|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
60418|NCT01093833|Device|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
60419|NCT01093833|Device|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
60420|NCT01093833|Device|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
60421|NCT01093846|Drug|AIN457|300mg every 4 weeks
60422|NCT01093846|Drug|AIN457|300mg every 2 weeks
60423|NCT01093846|Drug|Placebo AIN457|Placebo to AIN457
60424|NCT00034086|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
60425|NCT01093859|Drug|PRX-105|Sterile solution for intravenous injection
60426|NCT01093872|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions
Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC.
60427|NCT01093885|Drug|Ambrisentan|Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin
Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week.
60428|NCT01096251|Behavioral|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
59915|NCT01097616|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
59916|NCT01097616|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
60201|NCT01090973|Drug|LBH589|The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.
After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses.
60202|NCT01090999|Other|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
60203|NCT00033683|Drug|fluorouracil|
60204|NCT01091012|Drug|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
60205|NCT01091025|Other|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
60206|NCT01091038|Other|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
60207|NCT01091038|Other|Routine Care|Routine Care
60208|NCT01091051|Drug|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
60209|NCT00034047|Procedure|Acupuncture|
60210|NCT01093573|Other|flow cytometry|Correlative study
59985|NCT01105286|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
59986|NCT01105299|Drug|CJ anastrozole 1 mg tablet|
59987|NCT00035503|Drug|etiprednol dicloacetate|
59988|NCT01105312|Drug|letrozole|
59989|NCT01105312|Drug|panobinostat|
59990|NCT01105312|Genetic|RNA analysis|
59991|NCT01105312|Genetic|microarray analysis|
59992|NCT01105312|Genetic|reverse transcriptase-polymerase chain reaction|
59993|NCT01105312|Other|enzyme-linked immunosorbent assay|
59994|NCT01105312|Other|immunohistochemistry staining method|
59995|NCT01105312|Other|laboratory biomarker analysis|
59996|NCT01105338|Behavioral|Green tea drink|Green tea drink
59997|NCT01105338|Dietary Supplement|green tea capsules|green tea capsules
59998|NCT00035516|Drug|Epothilone|
59999|NCT01105338|Other|Green tea placebo capsules|Green tea placebo capsules
60000|NCT01105338|Dietary Supplement|Lycopene capsules|Lycopene capsules
60001|NCT01105338|Other|Lycopene placebo capsules|Lycopene placebo capsules
60283|NCT01088594|Drug|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
60284|NCT01088594|Drug|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
60285|NCT01091051|Drug|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
60286|NCT01091064|Other|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
60287|NCT01091077|Dietary Supplement|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
60288|NCT01091090|Behavioral|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
60992|NCT01087398|Procedure|Stem Cell Transplantation|Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:
Sibling full match
Other related full match
Sibling or other related with 1 mismatch antigen
Cord Blood
Haploidentical
60993|NCT01087398|Drug|Cyclosporin, Methotrexate (GVHD prophylaxis)|Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po
10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)
60994|NCT01087411|Behavioral|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
60995|NCT01087411|Behavioral|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
60996|NCT01087411|Dietary Supplement|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
60997|NCT01089751|Drug|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
60998|NCT01089751|Drug|placebo|Placebo once daily on an empty stomach for 14 weeks.
60999|NCT01089764|Behavioral|Couplelinks.ca website|Participation in the Couplelinks.ca program, an online intervention.
61000|NCT01089777|Device|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
61001|NCT01089790|Drug|Dutogliptin|400 mg tablet, once daily
61002|NCT00033631|Radiation|3D-CRT or IMRT|Given 5 days a week for 7.8 or 8.8 weeks
61003|NCT01089790|Drug|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
61004|NCT01089816|Biological|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
61005|NCT01089829|Other|Foot examination|Non-invasive neurological sensory testing
Non-invasive doppler assessment of peripheral arterial system
61006|NCT01089842|Behavioral|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
61007|NCT01089842|Other|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
61008|NCT01089855|Drug|Carbamazepine|
60763|NCT01094457|Drug|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
60764|NCT00034086|Biological|Haemophilus B Conjugate Vaccine|
60765|NCT01094470|Device|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
60766|NCT01094483|Drug|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
60767|NCT01094483|Drug|ASA|Asprin 81 mg enteric coated tablet
60768|NCT01094483|Drug|Placebo|
60769|NCT01094496|Biological|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
60770|NCT01094496|Drug|Chemotherapy|
60771|NCT01094509|Behavioral|Tai Chi|Tai Chi classes and exercises
60772|NCT01094509|Behavioral|Guided autobiography|Autobiographical writing in class and at home
60773|NCT01094509|Behavioral|Qigong|Qigong classes and exercises (exploratory)
60774|NCT01094509|Behavioral|Successful aging|Seminar series on the theme of successful aging
60775|NCT00000919|Drug|Amprenavir|
60776|NCT00034112|Procedure|osteopathic manipulative treatment|
60777|NCT01094509|Behavioral|Combination|Combination of Tai Chi exercises and autobiographical writing
60778|NCT01094509|Behavioral|Comparison|No assigned behavioral activity (exploratory)
60779|NCT01094522|Drug|Methadone|0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN ("as needed") doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain.
60780|NCT01094522|Drug|Morphine|0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN ("as needed") doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain.
60211|NCT01093573|Other|mutation analysis|Correlative study
60212|NCT01093573|Other|pharmacological study|Correlative study
60213|NCT01093573|Other|mass spectrometry|Correlative study
60214|NCT01093573|Other|protein expression analysis|Correlative study
60215|NCT01093586|Procedure|double-unit umbilical cord blood transplantation|Undergo transplantation
60216|NCT01093586|Other|cytogenetic analysis|Correlative studies
60217|NCT01093586|Procedure|bone marrow aspiration|Correlative studies
60218|NCT01093586|Other|fluorescence in situ hybridization|Correlative studies
60219|NCT01093586|Drug|busulfan|Given orally
60491|NCT01091532|Drug|UK-396,082|300mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
60492|NCT01091532|Drug|placebo|given orally twice daily for 14 days
60493|NCT01091532|Drug|UK-396,082|1000mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
60494|NCT01091532|Drug|placebo|given orally twice daily for 14 days
60495|NCT00033696|Drug|etoposide|
60496|NCT01093911|Biological|CDP7657|Ascending single doses of CDP7657
60497|NCT01093911|Other|Placebo|Placebo: 0.9% sodium chloride aqueous solution
60498|NCT01093924|Behavioral|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
60499|NCT01093937|Drug|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
60500|NCT01093963|Drug|Lisdexamfetamine|oral; 20-70mg/day
60289|NCT01091090|Behavioral|Control|Treatment as usual
60290|NCT00033683|Drug|methotrexate|
60291|NCT01091103|Drug|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
60292|NCT01091116|Drug|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
60293|NCT01091116|Drug|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
60294|NCT01091116|Drug|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
60295|NCT01091116|Drug|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
60296|NCT01091116|Drug|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
60297|NCT01091129|Device|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
60298|NCT01091142|Drug|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
60299|NCT01091142|Drug|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
60300|NCT01091155|Device|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
60301|NCT00033683|Drug|tamoxifen citrate|
60302|NCT01091168|Drug|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
60303|NCT01091168|Drug|alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
60304|NCT01091181|Procedure|Hysterotomy|at cesarean hysterotomy is performed 2 cm above or below the bladder insertion
60563|NCT01091571|Drug|Placebo|Placebo twice daily during seven consecutive days
60564|NCT01091571|Other|LPS|The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
60565|NCT01091584|Device|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
60566|NCT01091597|Procedure|usual PV ablation|usual PV ablation, per above
57274|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
57275|NCT01074970|Drug|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
57276|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
57277|NCT01074996|Drug|S-1|40-60mg bid , days 1-14, every 3 weeks
57278|NCT01074996|Drug|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
57279|NCT00032136|Procedure|adjuvant therapy|
57280|NCT01075022|Drug|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
57281|NCT01075022|Drug|Placebo|Placebo Capsule, Single Dose
57282|NCT01075048|Drug|Tivantinib (ARQ 197) + cetuximab + irinotecan|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Followed 60 minutes later with Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Cetuximab and Irinotecan are administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
57283|NCT01075048|Drug|Placebo + cetuximab + irinotecan|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes, then over 60 minutes at subsequent cycles. Followed 60 minutes later with Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Cetuximab and Irinotecan are administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
57284|NCT01075061|Other|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
57285|NCT01075061|Other|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
57286|NCT01075061|Other|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
57287|NCT01075074|Procedure|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
60385|NCT01091272|Drug|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
60386|NCT01091285|Device|Foley Catheter|Foley Catheter 16-19 H
60387|NCT01091285|Device|Double Balloon Catheter|Double Balloon Catheter for 16-19H
60388|NCT01091298|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
60781|NCT01094535|Drug|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
59838|NCT01097564|Genetic|COL4A1 genetic testing|genetic testing
59839|NCT01097577|Drug|pregabalin|1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
59840|NCT01100099|Dietary Supplement|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
59841|NCT01100112|Drug|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
59842|NCT01100125|Drug|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
59843|NCT01100125|Drug|insulin dose increase|insulin dose increase
59844|NCT01100151|Drug|RDC-1036 (ALKS 37)|Capsules for oral administration
59845|NCT01100151|Drug|Placebo|Capsules for oral administration
59846|NCT01100164|Drug|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
59847|NCT00034866|Drug|Protease inhibitor tipranavir|
59848|NCT01100164|Drug|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
59849|NCT01100177|Drug|Sunitinib|Sunitinib 37.5mg/m2/d
59850|NCT01100177|Radiation|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
59851|NCT01100203|Drug|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
59852|NCT01100216|Other|Nicotine Lozenge|4 mg for 12 days
59853|NCT01100216|Other|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
59854|NCT01100216|Other|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
60501|NCT01093963|Drug|Placebo|oral; 20-70mg/day
60502|NCT01093976|Drug|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
60503|NCT00034086|Drug|Lamivudine|
60504|NCT01093989|Dietary Supplement|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
60505|NCT01094002|Other|Occupational therapy intervention|Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.
Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.
Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities.
60506|NCT01094015|Drug|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
60507|NCT01094015|Other|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
60848|NCT01092143|Drug|BI671800|double blind randomized parallel group study
60849|NCT01092143|Drug|BI 671800|double blind randomized parallel
60850|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
60851|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
60852|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
60853|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
60854|NCT01092143|Drug|Fluticasone|double blind randomized parallel
60855|NCT01092143|Drug|BI 671800 Placebo|double blind randomized parallel
60856|NCT00033735|Drug|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
60857|NCT01092143|Drug|BI 671800 Placebo|double blind randomized parallel
60858|NCT01092156|Behavioral|Education|Education on Infant-led latching
60859|NCT01092169|Other|No intervention|
60567|NCT01091597|Procedure|Box isolation of pulmonary veins|as above
60568|NCT01091610|Other|no intervention|purely observational retrospective study. no interventions are planned.
60569|NCT00033696|Drug|paclitaxel|
60570|NCT01091623|Other|training|
60571|NCT01091623|Other|training|
60572|NCT01091623|Other|training|
60573|NCT01091636|Procedure|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
60574|NCT01091649|Drug|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
60575|NCT01091649|Drug|ritonavir|ritonavir see Arm Description for more information
60576|NCT01091649|Drug|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
60577|NCT01091662|Drug|Eslicarbazepine acetate 1600 mg|1600 mg once per day
60578|NCT01091662|Drug|Eslicarbazepine acetate 1200 mg|1200 once per day
60579|NCT01091675|Drug|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
60580|NCT00000919|Drug|Lamivudine/Zidovudine|
60581|NCT00033696|Drug|topotecan hydrochloride|
60582|NCT01091688|Behavioral|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
60583|NCT01094080|Other|breast milk|infants are breast fed
60584|NCT01094093|Drug|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
60585|NCT01094106|Drug|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
60586|NCT01094106|Drug|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
60927|NCT01092182|Drug|EPOCH-RR|EPOCH-R every 21 days for 3 cycles
60928|NCT01092195|Biological|Gardasil|3 separete 0.5 ml intramuscular
60389|NCT00033683|Radiation|radiation therapy|
60390|NCT01091298|Other|Placebo|Single dose (0.5 mL) of the placebo administered orally
60391|NCT01091311|Device|Blephasteam|Eye lid warming goggles
60392|NCT01091324|Drug|Dextromethorphan|60 mg, bid
60393|NCT01091324|Drug|Silymarin|150 mg , tid
60394|NCT01091324|Drug|sugar pill|placebo
60395|NCT01091337|Drug|Procaterol|Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes
+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
60396|NCT01091337|Drug|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
60397|NCT01091350|Device|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
60398|NCT01091350|Device|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
60399|NCT01091363|Drug|nicotine patch|8-week nicotine patch therapy
60400|NCT00033696|Biological|filgrastim|
60401|NCT01091376|Drug|Erlotinib|Erlotinib 150mg/day
60402|NCT01091376|Radiation|Thoracic radiotherapy|60-70Gy/30-35f
60403|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
60404|NCT01093794|Drug|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
60405|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
60406|NCT01093794|Drug|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
60662|NCT01091831|Drug|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
60663|NCT01091831|Drug|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
59855|NCT01100216|Other|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
59856|NCT01100242|Drug|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
59857|NCT01100255|Drug|Ketamine infusion|0.5mg/kg IV over 40 minutes
59858|NCT00034879|Drug|ZD1839 (Gefitinib)|
60139|NCT01093573|Drug|midostaurin|Given orally
60140|NCT01093573|Drug|azacitidine|Given IV
60141|NCT01093573|Other|laboratory biomarker analysis|Correlative study
60142|NCT01093573|Other|bone marrow aspiration|Correlative study
60143|NCT01093573|Other|liquid chromatography|Correlative study
60144|NCT01095770|Procedure|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
60145|NCT01095770|Device|Reveal XT|Reveal XT implantable loop recorder monitored group
60146|NCT01095770|Device|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
60147|NCT01095783|Procedure|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
60148|NCT01095783|Procedure|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
60149|NCT01095796|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
60150|NCT01095796|Drug|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
60151|NCT01095796|Drug|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
60152|NCT00034333|Drug|MTC-DOX for Injection|
60153|NCT01095796|Drug|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
60154|NCT01095809|Drug|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
60860|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
60861|NCT01094548|Drug|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
60862|NCT01094548|Drug|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
60863|NCT01094561|Drug|Synthetic Human Secretin|Twenty five patients will each undergo an S-MRCP and an S-EUS evaluation, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
60864|NCT00034125|Drug|LY353381|
60865|NCT01094574|Drug|Propranolol|30ng/ml IV, using a programmable infusion pump delivering medication over 3 hours
60866|NCT01094574|Drug|Alfentanil|100ng/ml IV, using a programmable infusion pump delivering medication over 3 hours
60867|NCT01094574|Drug|Placebo|Normal saline as placebo IV, using a programmable infusion pump delivering medication over 3 hours
60868|NCT01094587|Procedure|Sutureless gastroschisis closure|
59917|NCT01097616|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
59918|NCT01097629|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
59919|NCT00034580|Drug|olanzapine|
59920|NCT01097629|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
60929|NCT01092221|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, BID
60930|NCT01092221|Drug|Placebo|Placebo 1 capsule, 300 mg, BID
60931|NCT01092234|Other|Traditional ward|provision of care in a traditional unit/ward.
60932|NCT01092234|Other|Organizational change|Observational unit (new organizational unit) for organizing in-hospital care
60933|NCT00033748|Biological|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
60934|NCT01092247|Other|Nutritional support with Standard diet|Nutritional support with Standard diet
60935|NCT01092247|Other|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
60936|NCT01092286|Other|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
60937|NCT01092299|Drug|AZD1446|ER Fast, 90mg, p.o. capsule
60938|NCT01092299|Drug|AZD1446|ER Moderate, 90mg, p.o. capsule
60939|NCT01092299|Drug|AZD1446|ER Slow, 90mg, p.o. capsule
60940|NCT01092299|Drug|AZD1446|MR
60941|NCT01092299|Drug|AZD1446|IR, 90 mg p.o. capsule
60942|NCT01092299|Drug|Placebo|IR
60943|NCT01092299|Drug|Placebo|ER/MR
60944|NCT00033748|Biological|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
60945|NCT01092312|Device|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
60946|NCT01092312|Device|Vanguard Knee System with conventional Instruments|Use of Conventional instruments
60947|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
60948|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
60949|NCT01092325|Drug|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
60664|NCT01091831|Drug|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
60665|NCT01091831|Drug|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
60666|NCT00033709|Drug|temozolomide|
60667|NCT01091844|Procedure|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
60668|NCT01091857|Behavioral|STRIDE|
60669|NCT01091870|Drug|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
60670|NCT01094262|Drug|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
60671|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
60672|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
60673|NCT01094262|Drug|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
60674|NCT01094275|Drug|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
60675|NCT01094288|Drug|MLN8237 plus docetaxel|Patients will receive a standard starting dose of docetaxel on Day 1 in combination with escalating doses of MLN8237 administered orally twice/day Days 1 through 7, repeated in 21-day cycles, except Cycle 2 when the MLN8237 dosing will be for maximum 5 days starting on Day 3 and continuing through Day 7
60676|NCT01094301|Device|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the muscles in the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
60677|NCT01094314|Other|embryo culture medium|comparison between two types of embryo culture medium
60678|NCT01094340|Drug|Thalidomide|fixed dose over 8 clinic visits
61029|NCT01092390|Dietary Supplement|Lovaza (fish oil)|4 grams per day
60155|NCT01095809|Drug|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
60156|NCT01095822|Drug|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
60157|NCT01095835|Drug|peginterferon alfa-2a [Pegasys]|1
60158|NCT01095848|Biological|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
60159|NCT01095861|Device|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
60160|NCT01095861|Device|Control - standard flexible ETT (Mallinckrodt)|Control - standard flexible ETT
Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134
60429|NCT01096264|Other|SSI and SphygmoCor® evaluations|SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.
SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived.
60430|NCT01096277|Drug|Sitagliptin|oral tablets 100 mg per day for two weeks
60431|NCT01096277|Drug|Placebo|oral tablet, one per day for two weeks
60432|NCT00034359|Drug|Placebo|
60433|NCT01096277|Other|Control|no intervention
60434|NCT01096290|Drug|lubiprostone|24mcg BID, capsule, oral 30days
60435|NCT01096290|Drug|Matched placebo|Twice daily for 30days, oral
60436|NCT01096316|Behavioral|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
60437|NCT01096329|Drug|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
60438|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
60439|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
60440|NCT01096342|Drug|dinaciclib|Given IV
59921|NCT01097629|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
59922|NCT01097642|Drug|Cetuximab|Cetuximab will be given at 400mg/m^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m^2 IV over 60 minutes.
59923|NCT01097642|Drug|Ixabepilone|Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
59924|NCT01097668|Biological|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
59925|NCT01097681|Drug|ASP1941|oral
59926|NCT01100307|Drug|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
59927|NCT01100307|Other|sham injection|sham injection every 6 weeks
59928|NCT01100320|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
59929|NCT01100320|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
59930|NCT01100333|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
59931|NCT00034892|Drug|Olanzapine, risperidone|
60220|NCT00034047|Drug|Chinese Products|
60221|NCT01093586|Drug|cyclophosphamide|Given IV
60222|NCT01093586|Drug|anti-thymocyte globulin|Given IV
60223|NCT01093586|Drug|methylprednisolone|Given IV
60224|NCT01093586|Drug|cyclosporine|Given IV
60225|NCT01093586|Drug|mycophenolate mofetil|Given orally or IV
60226|NCT01093586|Other|flow cytometry|Correlative studies
60227|NCT01093586|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
60228|NCT01093599|Behavioral|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
60950|NCT01092325|Drug|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
60002|NCT01105338|Other|Tomato rich diet|Tomato rich diet
60003|NCT01105351|Dietary Supplement|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
60004|NCT01105351|Dietary Supplement|folic acid|folic acid 400 µg
60005|NCT01105364|Drug|antiangiogenesis therapy|
60006|NCT01105364|Drug|stabilized sulphur hexafluoride microbubble-based contrast agent|
60007|NCT01105364|Other|imaging biomarker analysis|
60008|NCT01097694|Drug|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
60009|NCT01097694|Drug|Placebo|Placebo
60010|NCT01097707|Drug|LY500307|Administered orally, daily for 24 weeks
60011|NCT01097707|Drug|Placebo|Administered orally, daily for 24 weeks
60012|NCT00034580|Drug|risperidone|
60013|NCT01097733|Other|Randomization of Pre-knowledge of CT coronary venography|
60014|NCT01097746|Drug|Carboplatin|AUC 5 by vein Day 1 of Cycles 1-6.
60015|NCT01097746|Drug|Paclitaxel|80 mg/m2 by vein (IV) over about 3 hours on Day 1 followed by Carboplatin, then on Days 8 and 15 of Cycle 1 Paclitaxel alone. On Day 1 of Cycles 2-6 Paclitaxel is followed by Carboplatin and Bevacizumab, then on Days 8 and 15 only Paclitaxel.
60016|NCT01097746|Drug|Bevacizumab|15 mg/kg IV over about 1 ½ hours on Day 1 of Cycles 2-6.
60017|NCT01097759|Procedure|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
60018|NCT01097772|Device|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
60019|NCT01097785|Drug|Simvastatin|40 mg, P.O.,daily for 30 days
60020|NCT01097785|Drug|Placebo|1 capsule daily for 30 days
60021|NCT01097798|Drug|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
60022|NCT01097798|Drug|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
61030|NCT01092403|Drug|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
61031|NCT01092403|Drug|Placebo|Placebo once daily by inhalation
61032|NCT01092416|Device|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
61033|NCT01092442|Procedure|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
61034|NCT00033839|Drug|Civamide (Zucapsaicin)|
61035|NCT01092455|Drug|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
61036|NCT01092468|Procedure|Diathermy|flap dissection with conventional diathermy
61037|NCT01092468|Procedure|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
61038|NCT01092481|Drug|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
61039|NCT01092507|Biological|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
61040|NCT01092507|Biological|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
61041|NCT01094834|Drug|DWP05195|tablets, oral administration, multiple administration
61042|NCT01094847|Drug|DWJ1252|tablet(oral) administration following the schedule of each arm
61043|NCT01094860|Drug|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
61044|NCT01094873|Biological|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
61045|NCT01094873|Biological|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
61046|NCT01094886|Drug|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
61047|NCT01094899|Radiation|Radiography|Radiography, microscanner, osteodensitometry
61048|NCT00034164|Drug|S-8184 Paclitaxel Injectable Emulsion|
60441|NCT01096342|Other|laboratory biomarker analysis|Correlative studies
60442|NCT01096355|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
60443|NCT00034372|Drug|oregovomab|
60444|NCT01096355|Other|diagnostic laboratory biomarker analysis|
60445|NCT01096355|Other|pharmacogenomic studies|
60446|NCT01096355|Other|pharmacological study|
60447|NCT01096368|Drug|liposomal vincristine sulfate|Given IV
60448|NCT01096368|Other|clinical observation|Patients undergo observation
60449|NCT01096368|Radiation|3-dimensional conformal radiation therapy|Patients undergo conformal radiotherapy
60450|NCT01096368|Drug|carboplatin|Given IV
60782|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
60783|NCT01096641|Behavioral|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
60784|NCT01096641|Behavioral|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
60785|NCT01096654|Other|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
60786|NCT00034463|Drug|multi-vitamins|
60787|NCT01096667|Drug|Placebo to Ertuglilflozin|pill(s) (1 mg and/or 5 mg and/or 25 mg) once daily for 28 days
60788|NCT01096667|Drug|1 mg Ertugliflozin|pill, 1 mg, once daily for 28 days
60789|NCT01096667|Drug|5 mg Ertugliflozin|pill, 5 mg, once daily for 28 days
60790|NCT01096667|Drug|25 mg Ertugliflozin|pill, 25 mg, once daily for 28 days
60791|NCT01096667|Drug|HCTZ 12.5mg|capsule, 12.5 mg, once daily for 28 days
60229|NCT01093599|Behavioral|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
60230|NCT01093612|Procedure|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
60231|NCT00034047|Drug|Nafarelin|
60232|NCT01093612|Radiation|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
60233|NCT01093612|Procedure|Biopsy|Correlative Studies
60234|NCT01093612|Other|Immunohistochemistry staining method|Correlative studies
60235|NCT01093612|Other|laboratory biomarker analysis|Correlative studies
60236|NCT01093612|Genetic|mutation analysis|Correlative studies
60237|NCT01093625|Device|Narafilcon B Contact Lens|
60238|NCT01093625|Device|Spectacles|spectacle wearers
60239|NCT01093638|Dietary Supplement|Insulin supplement|Premature infants will be fed with a formula supplemented with Insulin (400μU Insulin/ml formula)every 3 hours.
60240|NCT01095939|Drug|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
60241|NCT01095939|Drug|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
60242|NCT01095952|Device|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
60508|NCT01094028|Drug|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
60509|NCT01094041|Other|Gluten free diet|A 4-week gluten free diet provided
60510|NCT01094041|Other|Gluten rich diet|A 4-week gluten rich diet is provided
60511|NCT01094054|Procedure|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
60023|NCT00034593|Drug|ALIMTA|
60024|NCT01097811|Drug|Erythromycin|250 mg orally q.i.d.
60025|NCT01097811|Drug|Neomycin|1 g orally q.i.d.
60305|NCT01091194|Other|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
60306|NCT01091207|Drug|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
60307|NCT01091220|Biological|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
60308|NCT01091220|Biological|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
60309|NCT01091233|Procedure|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
60310|NCT01093638|Dietary Supplement|Placebo|Premature infants will receive a placebo supplemented infant formula every 3 hours
60311|NCT01093651|Drug|Sitagliptin|100 mg sitagliptin daily for 4-6 months
60312|NCT00034060|Drug|Etanercept|
60313|NCT01093651|Drug|Placebo|Daily placebo for 4-6 months
60314|NCT01093664|Biological|AFFITOPE AD02|s.c. injection
60315|NCT01093677|Drug|LIM-0705|Oral solution 750 mg LIM 0705 BID for 14 days.
60316|NCT01093677|Drug|Placebo|Oral solution placebo BID for 14 days.
60317|NCT01093690|Drug|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
60318|NCT01093690|Drug|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
60319|NCT01093703|Other|Medication Adjustment|Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.
Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.
Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.
Awake SBP>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time.
60320|NCT01093716|Device|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
61049|NCT01094899|Other|Urine and Blood sampling|mainly dosage of bones metabolism
60088|NCT01088087|Dietary Supplement|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
60089|NCT01088100|Genetic|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
60090|NCT01088126|Procedure|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
60091|NCT00033488|Procedure|comparison of screening methods|
60092|NCT01088139|Dietary Supplement|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
60093|NCT01088152|Behavioral|Celiac school|Structured education of adult celiac patients at 10 sessions.
60094|NCT01088152|Behavioral|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
60095|NCT01088165|Drug|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
60096|NCT01088165|Drug|Fumaric acid esters treatment group|First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).
Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period.
60097|NCT01088165|Other|Narrow band UVB radiation|No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.
Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation
60098|NCT01088178|Device|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
60099|NCT01088191|Biological|MSB-CAR001 Combined With Hyaluronan|Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan
Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan
60100|NCT01088191|Drug|Hyaluronan|Hyaluronan alone
60101|NCT01088204|Procedure|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
60102|NCT01090752|Drug|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
60792|NCT01096667|Drug|Placebo to HCTZ|capsule, 12.5 mg, once daily for 28 days
60793|NCT01096680|Drug|SPD489 20 mg|Single oral dose of 20 mg
60794|NCT01096680|Drug|SPD489 50 mg|Single oral dose of 50 mg
60795|NCT01096680|Drug|SPD489 70 mg|Single oral dose of 70 mg
60796|NCT01096680|Drug|Armodafinil|Single oral dose of 250 mg
60797|NCT00000234|Drug|Buprenorphine|
60798|NCT00000919|Drug|Lamivudine|
60799|NCT00034476|Drug|sPLA2 Inhibitor|
60800|NCT01096680|Drug|Placebo|Single oral dose
60801|NCT01096693|Drug|Urocortin 2, Urocortin 3|After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.
Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3.
59859|NCT01100255|Other|Saline|saline infusion
59860|NCT01100268|Drug|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
59861|NCT01100281|Behavioral|Neuropsychological examination|Examination including especially concept formation
59862|NCT01100281|Other|MRI|MRI performed in T1-weighted three dimensional sequence
59863|NCT01100294|Biological|Vaccination with FLUVAL P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml (total 3 μg HA), single dose.
59864|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
59865|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
59866|NCT00035243|Drug|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
59867|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
59868|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
60512|NCT01094054|Behavioral|Dietary and lifestyle modification|Dietary and lifestyle modification
Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm
60513|NCT01094067|Drug|ACT-050089|5 mg/h intravenously
60514|NCT00034086|Drug|Stavudine|
60515|NCT01094080|Other|standard infant formula|infants are fed a commercial formula
60516|NCT01094080|Other|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
60517|NCT01096524|Device|Kneehab|NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.
Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes.
60518|NCT01096550|Behavioral|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
60519|NCT01096550|Behavioral|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
60520|NCT01096563|Drug|AZD9164|Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).
The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose.
60521|NCT01096563|Drug|Placebo|Dry powder for inhalation via Turbuhaler, JSMAD.
60522|NCT01096576|Drug|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
60523|NCT01096576|Drug|placebo|orally twice daily for 5 days
60524|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
60525|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
60526|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
60527|NCT00034463|Drug|folic acid|
60869|NCT01094600|Drug|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
60870|NCT01094613|Drug|Delayed Release 6 mercaptopurine|Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.
Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets.
60321|NCT01093729|Drug|HM11260C|HM11260C 0.5mcg/kg or Placebo
60322|NCT01093729|Drug|HM11260C|HM11260C 2mcg/kg or Placebo
60323|NCT00000919|Drug|Abacavir sulfate|
60324|NCT00034086|Drug|Lopinavir/Ritonavir|
60325|NCT01093729|Drug|HM11260C|HM11260C 4mcg/kg or Placebo
60587|NCT01094119|Device|heated blanket|heated blanket
60588|NCT01094119|Device|heated pad|patients will be warmed with a heated pad during surgery.
60589|NCT01094132|Device|Multispectral Digital Colposcope (MDC)|The MDC has 2 components: an optical probe & a multispectral colposcope. The optical wand makes use of fluorescence & reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer & healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence & polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.
This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.
All study subjects will receive this same intervention.
60590|NCT01094145|Other|Deep brain stimulation|DBS in the Nucleus basalis Meynert
60591|NCT00034086|Drug|Zidovudine|
60592|NCT01094158|Drug|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
60593|NCT01094158|Drug|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
60594|NCT01094158|Drug|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
60595|NCT01094171|Biological|Poliorix TM|Intramuscular administration, 3 doses
60596|NCT01094171|Biological|Infanrix TM|Intramuscular administration, 3 doses
60597|NCT01094184|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks intravenously infusion according to chosen chemotherapy schedule
60598|NCT01094210|Drug|Fluorides, Topical|500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
60599|NCT01094223|Behavioral|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
60600|NCT01094223|Behavioral|Health Education|Psychoeducation group focused on various topics pertaining to physical health
60103|NCT01090752|Drug|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
60104|NCT01090765|Drug|TRC105|
60105|NCT01090778|Drug|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
60679|NCT00034086|Biological|Lyme Disease Vaccine Recombinant OspA|
60680|NCT01094353|Procedure|minisling ophira™|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
60681|NCT01094366|Procedure|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
60682|NCT01094366|Procedure|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
60683|NCT01094379|Procedure|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
60684|NCT01094379|Procedure|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
60685|NCT01094405|Biological|Recombinant Epstein-Barr Virus (EBV) Vaccine|
60686|NCT01094418|Other|Nerve conduction studies ( NCS) of the peripheral nerves|Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.
NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves.
60687|NCT01094444|Other|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
60688|NCT01094457|Drug|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
60689|NCT00034385|Drug|Valganciclovir|
60690|NCT01096368|Other|laboratory biomarker analysis|Optional correlative studies
60691|NCT01096381|Other|laboratory biomarker analysis|Blood collection
60692|NCT01096381|Other|questionnaire administration|Survey regarding baseline health and activity level.
60693|NCT01096407|Other|laboratory biomarker analysis|Collection of urine samples
60694|NCT01096407|Other|questionnaire administration|Completion of questionnaires
59869|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
59870|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
59871|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
59872|NCT01102673|Drug|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
59873|NCT01102673|Drug|Placebo|Placebo to match PF-04991532 will be provided
59874|NCT01102686|Drug|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
59875|NCT01102686|Drug|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
59876|NCT01102699|Drug|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
59877|NCT00035256|Drug|teriparatide|
59878|NCT01102712|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
59879|NCT01102764|Behavioral|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
59880|NCT01102764|Behavioral|In Person|PE therapy delivered in person at the VAMC
60161|NCT01095887|Drug|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
60162|NCT01095900|Procedure|conservative lateral internal sphincterotomy|
60163|NCT00034346|Drug|ABX-EGF|
60164|NCT01095900|Procedure|Intra-sphincteric Botulinum-toxin injection|
60165|NCT01095913|Drug|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
60166|NCT01095926|Drug|doxorubicin|blood sampling before, during and after doxorubicin administration
60167|NCT00033514|Biological|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
60871|NCT01094613|Drug|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
60872|NCT01094626|Drug|Secretin|A minimum of 15 patients, maximum of 30 patients, will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin provided by the Repligen Corporation, will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
60873|NCT01094639|Procedure|Scaling root planing|Deep gum cleaning with local anesthesia
60874|NCT01094639|Procedure|Supragingival Prophylaxis|Plaque removal
60875|NCT00034125|Drug|tamoxifen|
60876|NCT01094652|Dietary Supplement|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
60877|NCT01094652|Dietary Supplement|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
60878|NCT01096797|Drug|Sevoflurane|Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.
Anaesthesia maintenance: sevoflurane 2-3 %
Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg
Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg
60879|NCT01096810|Drug|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
60880|NCT01096823|Behavioral|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
60881|NCT00034489|Drug|gemcitabine|
60882|NCT01096836|Other|macronutrient and energy manipulation|
60883|NCT01096849|Drug|levofloxacin|Repeat intravenous infusion
60884|NCT01096849|Drug|plazomicin|Repeat intravenous infusion
60885|NCT01096849|Drug|placebo|Repeat intravenous infusion (used to maintain the blind)
60886|NCT01096862|Drug|ASP015K|oral
60887|NCT01096862|Drug|Placebo|oral
59932|NCT01100346|Drug|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
60601|NCT01094236|Behavioral|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
60602|NCT00034086|Drug|Didanosine|
60603|NCT01094249|Drug|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
60951|NCT01092325|Drug|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
60952|NCT01094665|Procedure|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
60953|NCT01094678|Device|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
60954|NCT01094691|Procedure|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
60955|NCT01094704|Drug|sodium chloride (7%)|4mL nebulized 7% sodium chloride
60956|NCT01094717|Device|excimer vs sham excimer|half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)
60957|NCT01094730|Device|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
60958|NCT01094730|Device|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
60959|NCT01094743|Device|galyfilcon A prototype lens|Silicone hydrogel contact lens
60960|NCT00034138|Drug|oregovomab|
60961|NCT01094743|Device|lotrafilcon B lens|Silicon Hydrogel contact lens
60962|NCT01094756|Dietary Supplement|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
60695|NCT01096407|Procedure|assessment of therapy complications|An assessment will be completed.
60696|NCT01096420|Procedure|acupuncture|Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.
Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).
Sterile disposable and steel needle (3210) were used .
The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi.
60697|NCT01096420|Drug|topiramate|The patients were submitted to the topiramate treatment also for 12 consecutive weeks.
The study phase consists of a 4-week titration and a 8-week maintenance period.
All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).
Study drug was administered daily in equally divided twice daily doses.
60721|NCT01089322|Drug|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
60722|NCT01089335|Procedure|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
60723|NCT01089348|Drug|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
60724|NCT01089348|Drug|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
60725|NCT01089361|Drug|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
60726|NCT01089361|Drug|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
60727|NCT00000233|Drug|Buprenorphine|
60728|NCT00000918|Drug|Zidovudine|
60729|NCT00033592|Drug|nicotine|
60730|NCT01089374|Radiation|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
60731|NCT01089387|Biological|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
60732|NCT01089413|Drug|bevacizumab [Avastin]|As prescribed by physician
60733|NCT01089426|Drug|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
60168|NCT01088204|Procedure|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
60169|NCT01088230|Other|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
60170|NCT01088230|Other|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
60171|NCT01088243|Drug|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
60172|NCT01088243|Drug|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
60173|NCT01088256|Drug|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
60174|NCT01088256|Drug|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
60175|NCT01088282|Procedure|Cataract surgery|Implantation of multifocal or monofocal IOL
60176|NCT01088295|Drug|Telmisartan|
60177|NCT01088308|Procedure|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
60178|NCT00033514|Drug|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
60179|NCT01088308|Procedure|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
60180|NCT01088334|Other|screening|CT-Chest/abdomen and mammography in women
60451|NCT01096368|Drug|cyclophosphamide|Given IV
60452|NCT01096368|Drug|etoposide|Given IV
60453|NCT01096368|Drug|cisplatin|Given IV
60454|NCT01088685|Device|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
60455|NCT01088698|Radiation|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
60456|NCT01088711|Drug|Omarigliptin|Once-weekly 50 mg capsule
60457|NCT01088711|Drug|Placebo|Once-weekly placebo capsule
59933|NCT01100359|Drug|carboplatin|
59934|NCT01100359|Drug|liposome-encapsulated doxorubicin citrate|
59935|NCT01100359|Other|laboratory biomarker analysis|
59936|NCT01100359|Procedure|quality-of-life assessment|
59937|NCT01100372|Drug|gemcitabine hydrochloride|
59938|NCT01100372|Drug|liposome-encapsulated doxorubicin citrate|
59939|NCT01100372|Procedure|quality-of-life assessment|
59940|NCT01100385|Dietary Supplement|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
59941|NCT01100385|Dietary Supplement|Placebo|Matched placebo capsule, taken once daily for 56 days
59942|NCT00034905|Drug|quetiapine fumarate vs risperidone|
59943|NCT01100398|Procedure|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
59944|NCT01100411|Device|Air Optix Aqua|Contact lens material: Lotrafilcon A
59945|NCT01100411|Device|Biofinity|Contact lens material: Comfilcon A
59946|NCT01100411|Device|Proclear|Contact lens material: Omafilcon A
59947|NCT01100411|Device|Acuvue Oasys|Contact lens material: Senofilcon A
59948|NCT01100411|Device|Acuvue 2|Contact lens material: Etafilcon A
59949|NCT01100411|Device|Purevision|Contact lens material: Balafilcon A
59950|NCT01100424|Device|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
59951|NCT01100424|Device|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
59952|NCT01102816|Other|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
60963|NCT01094769|Drug|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
60964|NCT01094769|Drug|Placebo|lactose capsule taken once daily
60965|NCT01094782|Other|Acupuncture, sham acupuncture or neither|Patients with radicular pain receiving acupuncture (Group 1), sham acupuncture (Group 2), or neither acupuncture nor sham acupuncture (Group 3);
60966|NCT01094782|Other|Acupuncture, sham acupuncture or neither|Healthy subjects (no pain) receiving acupuncture (Group 4), sham acupuncture (Group 5), neither acupuncture nor sham acupuncture (Group 6).
60967|NCT01094808|Drug|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
60968|NCT01094808|Drug|Placebo|Placebo capsules
60969|NCT01094808|Other|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
60026|NCT01097837|Other|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
60027|NCT01097850|Drug|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
60028|NCT01097863|Device|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
60029|NCT01097863|Device|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
60030|NCT01097863|Device|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
60031|NCT01097876|Drug|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
60032|NCT01097876|Drug|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
60033|NCT01093222|Drug|Erlotinib Hydrochloride|Given PO
60034|NCT01093222|Drug|Sorafenib Tosylate|Given PO
60035|NCT01093235|Biological|bevacizumab|
60036|NCT01093235|Drug|cyclophosphamide|
60037|NCT01093235|Drug|docetaxel|
60038|NCT01093235|Drug|epirubicin hydrochloride|
60734|NCT01089426|Other|Historical Controls|Standard of Care
60735|NCT01089439|Drug|Nitric oxide by inhalation INOMAX|Nitric oxide by inhalation INOMAX 800 ppm
40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours
60736|NCT01089439|Drug|Placebo|placebo
60737|NCT01089452|Drug|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
60738|NCT01091870|Drug|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
60739|NCT01091870|Drug|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
60740|NCT01091883|Device|Exablate treatment|MR Guided Focused Ultrasound
61050|NCT01094899|Other|Echography|body bones echography
61051|NCT01094912|Drug|opioids|
61052|NCT01094925|Drug|lactose|Single oral dose
61053|NCT01094925|Drug|Gabapentin 300mg|Single oral dose of 300mg gabapentin
61054|NCT01094925|Drug|Gabapentin 600mg|Single oral dose of 600mg gabapentin
61055|NCT01094951|Behavioral|ENGAGE|During Stage 1, study investigators will work with three Neighborhood Houses in implementing research assessments, referral patterns, and connections to mental health evaluation among their depressed senior clients. Investigators will train caseworkers to administer a brief depression screen and will also instruct caseworkers to refer depressed seniors to local community-based mental health or medical clinics. Data on successful connections to mental health evaluation will serve as the comparison to that achieved during Stage 2.
During Stage 2, study investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred mental health services (primary care physician, local mental health clinic).
61056|NCT01094964|Biological|BCG solution|
61057|NCT01094964|Biological|recombinant interferon alfa|
61058|NCT01094964|Drug|epirubicin hydrochloride|
61059|NCT00034177|Drug|S-8184 Paclitaxel Injectable Emulsion|
61060|NCT01094964|Drug|mitomycin C|
61061|NCT01094964|Other|laboratory biomarker analysis|
61062|NCT01094964|Procedure|hyperthermia treatment|
60458|NCT01088724|Drug|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
60459|NCT01088737|Drug|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
60460|NCT01088750|Drug|cyclophosphamide|
60461|NCT01088750|Drug|prednisolone|
60462|NCT00033553|Drug|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
60463|NCT01088750|Drug|vinblastine sulfate|
60464|NCT01088750|Other|watchful waiting|
60465|NCT01088750|Procedure|therapeutic conventional surgery|
60466|NCT01088763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
60467|NCT01088763|Other|diagnostic laboratory biomarker analysis|Correlative studies
60468|NCT01088763|Other|pharmacological study|Correlative studies
60469|NCT01088763|Drug|dexamethasone|Given IV
60470|NCT01088776|Dietary Supplement|n-3 Fatty Acid supplement|Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.
Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules.
60471|NCT01088776|Dietary Supplement|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
60802|NCT01096693|Drug|Saline placebo|After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.
Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
60803|NCT01089452|Drug|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
60804|NCT01089452|Drug|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
59953|NCT01102868|Device|Needle in acupuncture point Li11|Acupuncture needle in acupuncture point Li11
60243|NCT01095965|Behavioral|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
60244|NCT01095978|Drug|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
60245|NCT01095991|Drug|AZD1656|Oral tablet bd,
60246|NCT01095991|Drug|Sitagliptin|Oral tablet od
60247|NCT00034346|Drug|paclitaxel|
60248|NCT01096004|Drug|AZD4017|oral suspension, 1200mg, once daily, for 10 days
60249|NCT01096004|Drug|Placebo|
60250|NCT01096017|Drug|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
60251|NCT01096017|Drug|Salbutamol pMDI|200 μg, inhalation, single dose
60252|NCT01096017|Other|pMDI placebo pMDI|Placebo pMDI 2 inhalations
60253|NCT01096017|Other|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
60254|NCT01096030|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
60255|NCT01096043|Drug|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
60256|NCT01096043|Drug|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
60257|NCT01096043|Drug|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
60258|NCT00000919|Drug|Efavirenz|
60259|NCT00034346|Drug|carboplatin|
60260|NCT01096043|Drug|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
60261|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
60262|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
60263|NCT01096056|Biological|Fluarix|Intramuscular administration, 1 dose
60039|NCT01093235|Drug|fluorouracil|
60040|NCT01093235|Procedure|assessment of therapy complications|
60041|NCT01093235|Procedure|neoadjuvant therapy|
60042|NCT01093235|Procedure|quality-of-life assessment|
60043|NCT00034008|Behavioral|Healing Touch|
60044|NCT01093235|Procedure|therapeutic conventional surgery|
60045|NCT01093261|Drug|Placebo|Placebo:
continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days.
60046|NCT01093261|Drug|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
60047|NCT01093274|Drug|Sodium Picosulphate|2 Sachets
60048|NCT01093274|Drug|Polyethylene Glycol|3 Liters solution
60049|NCT01093300|Device|Paclitaxel-eluting balloon catheter|
60326|NCT01093729|Drug|HM11260C|HM11260C 8mcg/kg or Placebo
60327|NCT01093729|Drug|HM11260C|HM11260C 14mcg/kg or Placebo
60328|NCT01093742|Drug|HM10560A|Subcutaneously administrate at 0 hour on Day 1
60329|NCT01093742|Drug|Placebo|Placebo
60330|NCT01093755|Drug|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
60331|NCT01093755|Drug|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
60332|NCT01093768|Drug|Oxytocin|
60333|NCT01093768|Drug|Vasopressin|
60334|NCT01093781|Drug|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
60335|NCT00034086|Drug|Lamivudine/Zidovudine|
60336|NCT01096082|Drug|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
60337|NCT01096095|Drug|Placebo|Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
61063|NCT01094964|Procedure|quality-of-life assessment|
61064|NCT01094977|Drug|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
61065|NCT01094977|Drug|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
61066|NCT01094977|Drug|Saline Placebo|
61067|NCT00033436|Drug|carbogen|
61068|NCT01087411|Dietary Supplement|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
61069|NCT01087424|Drug|RminiCHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
61070|NCT01087437|Dietary Supplement|gastrolith calcium|
61071|NCT01087463|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
60106|NCT01090791|Device|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
60107|NCT01090791|Device|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
60108|NCT00033683|Drug|docetaxel|
60109|NCT01090804|Device|BreatheMAX breathing device|secretion clearance, breathing exercise
60110|NCT01090817|Drug|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
60111|NCT01090830|Drug|Belinostat, carboplatin, paclitaxel and bevacizumab|Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.
In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles.
60112|NCT01090843|Procedure|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
60805|NCT00033605|Drug|octreotide acetate|
60806|NCT01089465|Other|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
60807|NCT01089504|Drug|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
60808|NCT01089504|Drug|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
60809|NCT01089517|Drug|E10030 plus Lucentis|once a month intravitreal injection
60810|NCT01089517|Drug|Lucentis|10 mg/mL intravitreal injection monthly
60811|NCT01089530|Behavioral|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
60812|NCT01089543|Drug|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
60813|NCT01089543|Drug|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
60814|NCT01089543|Drug|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
60815|NCT01089543|Drug|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
60816|NCT00033605|Other|placebo|
60817|NCT01089556|Drug|Duloxetine|Administered orally
60818|NCT01089556|Drug|Pregabalin|Administered orally
60819|NCT01089556|Drug|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
60820|NCT01089569|Drug|Exenatide|refer to Arm detail
60821|NCT01089569|Drug|Insulin Glargine|refer to Arm detail
60822|NCT01089582|Other|No intervention|
60823|NCT01089595|Drug|Nilotinib|Nilotinib 400 mg po bid
60824|NCT01089595|Drug|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
59881|NCT01102777|Behavioral|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
60264|NCT01096082|Drug|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
60265|NCT00033527|Drug|INS316|
60528|NCT01096589|Device|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
60529|NCT01096602|Biological|DC AML Vaccine|Group 1: 3 doses of the vaccine at 4 week intervals Group 2: Given two weeks following CT-011 infusion
60530|NCT01096602|Drug|CT-011|Infusion given at 6 week intervals for a total of 3 doses
60531|NCT01096615|Dietary Supplement|Placebo|Description:
- capsule size 3
Composition of the product:
45 mg of microcristalline cellulose,
132 mg of maltodextrin,
3 mg of magnesium stearate.
Composition of the capsule:
46 mg of hypromellose,
1 mg of titanium dioxide.
Packaging:
Products are packaged in aluminium tubes of 30 capsules.
Storage:
The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.
The study products will be consumed daily for 7 weeks.
60532|NCT01096615|Dietary Supplement|Lactobacillus paracasei LP-33|Description:
minimum 2.0x109 CFU of Lactobacillus paracasei LP-33
capsule size 3 1 capsule daily together with a meal, with a glass of water.
60533|NCT01096628|Other|Chiropractic + Exercise|Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.
Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
60534|NCT01096628|Other|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
60535|NCT01088802|Drug|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
60536|NCT01088815|Drug|Gemcitabine, nab-Paclitaxel, GDC-0449|One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then
Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily
60537|NCT01088828|Other|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
60538|NCT01088841|Dietary Supplement|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
60539|NCT01088854|Device|CPAP|unique session of 30-minute of continuous airway positive pressure
60540|NCT01088867|Other|Acupuncture|Electroacupuncture
60338|NCT01096095|Drug|Sodium Phenylbutyrate|Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
60339|NCT01096108|Behavioral|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
60340|NCT01096108|Behavioral|Motivational and Problem-Solving|Counseling phone calls
60341|NCT00034359|Drug|ACH-126, 443 (beta-L-Fd4C)|
60342|NCT01096108|Behavioral|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
60343|NCT01096121|Drug|Enalapril|during 1 month : 0,2 mg/kg/day
then during 2 months (if no adverse event): 0,35 mg/kg/day
and then during 6 months (if no adverse event): 0,5 mg/kg/day
60344|NCT01096121|Drug|Placebo|Glucose
60345|NCT01096134|Biological|HPV Vaccine (Gardasil)|HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.
FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:
20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection
60346|NCT01096147|Device|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
60604|NCT01096706|Drug|NO clamp|After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
60605|NCT01096706|Drug|Saline|After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
60606|NCT01096706|Drug|Fluconazole|After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1.
60113|NCT01090843|Device|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
60114|NCT01090843|Device|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
60115|NCT01090856|Procedure|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
60116|NCT01090869|Behavioral|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
60698|NCT01096433|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
60699|NCT01096446|Drug|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
60700|NCT00034450|Drug|L-carnitine|
60701|NCT01096459|Procedure|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
60702|NCT01096472|Drug|LAS41003|Once daily
60703|NCT01096472|Drug|LAS189961|Once daily
60704|NCT01096472|Drug|LAS189962|Once daily
60705|NCT01096485|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of 1.5 mg coated tablet
60706|NCT01096485|Drug|Levonorgestrel (Postday)|Single dose of two 0.75 mg tablets
60707|NCT01096498|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
60708|NCT01096498|Drug|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
60709|NCT01096511|Drug|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
59882|NCT01102803|Behavioral|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
59883|NCT01102803|Drug|D-Cycloserine|D-Cycloserine
59884|NCT01102803|Drug|Placebo|Sugar Pill
59885|NCT01102816|Other|Individualized acupuncture treatment|Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.
Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.
Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)
59886|NCT01105065|Drug|Alphagan (brimonidine) 0.15%|One drop in each eye three times a day for 8 weeks.
59887|NCT01105078|Procedure|Flow rate|Different flow rate during cardiopulmonary bypass
59888|NCT00035490|Drug|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
59889|NCT01105091|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
59890|NCT01105091|Drug|Flolan®|Per Prescribing Information
59891|NCT01105104|Device|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
59892|NCT01105104|Device|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
59893|NCT01105117|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
59894|NCT01105117|Drug|Flolan®|per Prescribing Information
59895|NCT01105130|Drug|Placebo|Given orally
59896|NCT01105130|Dietary Supplement|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
59897|NCT01105130|Dietary Supplement|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
59898|NCT01105143|Behavioral|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
59899|NCT00035490|Drug|placebo|placebo tablet, once daily for one year
59900|NCT01105143|Behavioral|placebo|no intervention, only follow up
60541|NCT01088880|Drug|Canakinumab|
60542|NCT01088893|Drug|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
60543|NCT00033553|Drug|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
60888|NCT01096875|Drug|Atorvastatin|40mg/day once daily for two weeks prior to surgery
60889|NCT01096875|Drug|Placebo|1tb/day once daily for two weeks prior to surgery
60890|NCT01096888|Behavioral|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
60891|NCT01096901|Behavioral|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
60892|NCT00034502|Drug|ALIMTA|
60893|NCT01096914|Procedure|percutaneous radiofrequency ablation|Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge "cool-tip" needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
60894|NCT01096914|Procedure|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
60895|NCT01096927|Drug|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
60896|NCT01096940|Drug|AZD1656|Oral tablet, BID dose
60897|NCT01096940|Drug|simvastatin|Oral tablet, single dose
60898|NCT01096953|Behavioral|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
60899|NCT01096953|Behavioral|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
60900|NCT01096966|Drug|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
60901|NCT01089647|Drug|Placebo: sugar pill and salt water nasal spray|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
60607|NCT01096706|Drug|Aspirin|Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1.
60608|NCT01096706|Drug|Combined|Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.
This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.
Blood samples are taken as per previous arms.
60609|NCT01096719|Behavioral|Standard Behavioral Weight Loss Intervention|12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies
60610|NCT01096719|Behavioral|Dietary Goal: Reduction in Energy Density of Dietary Intake|Consume low ED foods (ED < 1.0) for at least 10 items consumed per day and limit high ED foods (ED > 3.0) to two items consumed per day.
60611|NCT00034489|Drug|pemetrexed|
60612|NCT01096719|Behavioral|Dietary Goal: Reduction of Energy Intake|Limit energy intake to 1200 to 1500 kcals/day and < 30% kcals from fat.
60613|NCT01096732|Drug|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
60614|NCT01096745|Drug|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
60615|NCT01096745|Drug|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
60970|NCT01094821|Drug|ATI-7505|3 mg three times daily for 9 days
60971|NCT00034151|Drug|S-8184 Paclitaxel Injectable Emulsion|
60972|NCT01094821|Drug|Placebo|Placebo capsule three times daily for 9 days
60973|NCT01094821|Drug|ATI-7505|10 mg ATI-7505 three times daily for 9 days
60974|NCT01094821|Drug|ATI-7505|20 mg ATI-7505 three times daily for 9 days
60975|NCT00033423|Radiation|yttrium Y 90 ibritumomab tiuxetan|
60976|NCT01087216|Device|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
60977|NCT01087216|Drug|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
60710|NCT01096524|Other|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
60711|NCT00034463|Drug|ALIMTA|
60712|NCT01096966|Drug|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
60713|NCT01096979|Drug|LIPO-102|subcutaneous injection
60714|NCT00034502|Drug|irinotecan|
60715|NCT01089218|Drug|control|no intervention with the same procedure of FB
60716|NCT00033592|Drug|bupropion hydrochloride|
60717|NCT01089231|Dietary Supplement|Fish oil|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
60718|NCT01089231|Dietary Supplement|Placebo (corn oil)|corn oil (6 capsules per day)
60719|NCT01089296|Other|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant`s condition allows it. The length of each treatment session will be adjusted dependent on the infant`s response and condition. Maximum treatment time is 10 minutes.
60720|NCT01089309|Drug|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
60741|NCT01091883|Radiation|Radiation|External Beam Radiation
60742|NCT01091896|Drug|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
60743|NCT01091896|Drug|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
60744|NCT01091909|Procedure|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
60745|NCT00033709|Drug|thalidomide|
60746|NCT01091922|Dietary Supplement|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
60747|NCT01091922|Dietary Supplement|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
60748|NCT01091948|Device|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
60749|NCT01091948|Device|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
60181|NCT01088347|Drug|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
60182|NCT01088347|Drug|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
60183|NCT01088347|Radiation|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
60184|NCT01088373|Drug|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
60185|NCT01088399|Drug|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
60186|NCT01088412|Drug|Somatropin (rDNA origin)|Dose, frequency and duration at discretion of attending physician.
60187|NCT01088425|Other|Observation|Alberta infant motor scale
Griffiths test
Kauffmann ABC
60188|NCT01088438|Behavioral|Contextualization workshop|A four-hour course on contextualization.
60189|NCT01090882|Drug|Bupivocaine|20ml 0.25% at beginning of operation
60190|NCT01090882|Drug|0.9% normal saline solution|20ml 0.9% NaCl
60191|NCT00000919|Drug|Indinavir sulfate|
60192|NCT00033683|Drug|epirubicin hydrochloride|
60193|NCT01090895|Drug|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
60194|NCT01090895|Drug|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
60195|NCT01090908|Drug|Antibiotic|
60196|NCT01090921|Drug|Bortezomib|Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.
Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone.
60197|NCT01090934|Device|High Resolution EEG|High Resolution EEG
60198|NCT01090934|Device|Stereo-electroencephalography|SEEG
60199|NCT01090947|Device|ProtoCAD|Aquiring acoustic signals from heart patients.
60902|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.3 mL, Intramuscular (IM)
60903|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular (IM)
60904|NCT01089673|Other|data collection|retrospective data collection
59954|NCT00035256|Drug|raloxifene HCl|
59955|NCT01102868|Device|IMS of the musculus pronator teres|Acupuncture needle in musculus pronator teres
59956|NCT01102881|Dietary Supplement|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
59957|NCT01102881|Dietary Supplement|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
59958|NCT01102881|Dietary Supplement|placebo|low fiber breakfast cereal and muffin
59959|NCT01102894|Device|SmartPill|SmartPill
59960|NCT01102907|Other|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
59961|NCT01102907|Other|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
59962|NCT01102920|Behavioral|Behavioural strategies to promote physical activity and weight loss|8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.
Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.
Treatments are provided by a physical therapist and a dietician.
59963|NCT01102920|Device|CPAP|CPAP-treatment as usual (during nights)
59964|NCT01102946|Drug|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
59965|NCT00035256|Drug|placebo|
59966|NCT01102946|Procedure|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
59967|NCT01102959|Device|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
59968|NCT01102972|Drug|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
59969|NCT01102972|Drug|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
60978|NCT01087229|Drug|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
60979|NCT01087229|Drug|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
60980|NCT01087242|Drug|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
60981|NCT01087255|Device|Electronic Pillbox Monitoring System|Daily exposure for six months
60982|NCT01087268|Other|questionnaire administration|
60983|NCT01087268|Procedure|gastrointestinal complications management/prevention|
60984|NCT01087268|Procedure|quality-of-life assessment|
60985|NCT01087294|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant
60986|NCT00033436|Dietary Supplement|niacinamide|
60987|NCT01087294|Biological|Anti-CD19-chimeric-antigen-receptor- transduced T cell|Patients receive T cells genetically engineered to express an anti-CD19 CAR. Whole PBMC will be cultured in the presence of 50 ng/mL anti-CD3 (OKT3) and 300 IU/mL aldesleukin.
60988|NCT01087294|Drug|Cyclophosphamide|180 mg/m2 IV infusion over 30 minutes on days -4, -3 and -2
60989|NCT01087294|Drug|Pentostatin|4 mg/m2 IV infusion over 30 minutes following the cyclophosphamide on day -4
60990|NCT01087359|Drug|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
60991|NCT01087398|Drug|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|For sibling full match:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg
For haploidentical:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
Fludarabine 160 mg/m^2
60050|NCT01093300|Device|Everolimus-eluting stent|
60051|NCT01093313|Behavioral|Cognitive therapy|
60052|NCT01093313|Behavioral|attention training|
60053|NCT01093326|Drug|Ponesimod 10 mg|Ponesimod 10 mg oral use
60054|NCT00034021|Drug|Ginkgo Biloba|
60055|NCT01093326|Drug|Ponesimod 20 mg|Ponesimod 20 mg oral use
60056|NCT01093326|Drug|Ponesimod 40 mg|Ponesimod 40 mg oral use
60750|NCT01091961|Procedure|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
60751|NCT01091974|Drug|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
60752|NCT01091974|Drug|Placebo Comparator|Placebo for 47 days
60753|NCT01091974|Behavioral|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
60754|NCT01091987|Behavioral|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
60755|NCT01092000|Behavioral|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
60756|NCT00033722|Dietary Supplement|folic acid|
60757|NCT01092000|Other|Education|Monthly exercise tips handout.
60758|NCT01092013|Behavioral|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
60759|NCT01092013|Behavioral|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
60760|NCT01092013|Behavioral|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
60761|NCT01092026|Other|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
60762|NCT01092039|Dietary Supplement|lactoferrin, L-Glutamine and beta-glucans|Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
59823|NCT01097499|Device|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
59824|NCT01097512|Drug|AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.
Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.
59825|NCT00034541|Drug|carboplatin|30-minute AUC = 6, infusion.
60200|NCT01090960|Drug|GDC-0068|Oral repeating dose
60472|NCT01088789|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.|A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.
The vaccine is administered every 6 months.
60473|NCT00033553|Drug|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 & 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
60474|NCT01088802|Radiation|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
60475|NCT01088802|Drug|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
60476|NCT01091389|Procedure|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
60477|NCT01091402|Procedure|autologous serum skin test, serum IL-18|
60478|NCT01091415|Procedure|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
60479|NCT01091428|Drug|MLN8237 + Paclitaxel|Phase 1:
MLN8237 administered orally twice daily on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel (Days 1, 8, 15) as an intravenous infusion repeated in 28-day cycles
60480|NCT01091428|Drug|MLN8237+Paclitaxel vs. Paclitaxel alone|Phase 2:
Arm 1:
MLN8237 administered orally twice daily on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel (Days 1, 8, 15) as an intravenous infusion repeated in 28-day cycles
Arm 2:
Paclitaxel will be administered as an intravenous infusion on Days 1, 8 and 15 of each 28-day cycle
60481|NCT01091454|Drug|brostallicin|Given IV
60482|NCT01091454|Drug|cisplatin|Given IV
60483|NCT01091493|Drug|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
60484|NCT00033696|Drug|carboplatin|
60485|NCT01091506|Other|Placebo|Placebo once a day for 12 weeks
60486|NCT01091506|Other|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
60487|NCT01091519|Other|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
60488|NCT01091519|Other|Toviaz(fesoterodine) without educational materials|No educational materials
59970|NCT01102985|Behavioral|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
59971|NCT01102985|Behavioral|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
59972|NCT01103011|Drug|ND0611|Continuous delivery of ND0611
59973|NCT01103011|Drug|ND0611|Solution of ND0611 delivered continuously
59974|NCT01103024|Biological|AIN457|
59975|NCT01103024|Biological|AIN457|
60266|NCT01088451|Drug|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
60267|NCT01088464|Biological|IMC-11F8|IMC-11F8 600 mg intravenously, Days 1 and 8 every 3 weeks
60268|NCT01088464|Biological|IMC-11F8|IMC-11F8 800 mg intravenously, every 2 weeks.
60269|NCT01088464|Biological|IMC-11F8|IMC-11F8 800 mg intravenously, Days 1 and 8 every 3 weeks
60270|NCT01088477|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
60271|NCT01088503|Drug|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
60272|NCT01088516|Drug|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
60273|NCT01088529|Drug|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
60274|NCT01088529|Drug|Prednisone|5 mg orally daily.
60275|NCT01088529|Drug|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
60276|NCT00000918|Drug|Stavudine|
60277|NCT00033527|Other|sputum cytology|
60057|NCT01093352|Procedure|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
60058|NCT01093365|Drug|Varenicline|0.0 mg orally twice per day for three days (placebo)
0.5 mg orally twice per day for three days
1.0 mg orally twice per day for three days
60059|NCT01093391|Device|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
60060|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
60061|NCT01095666|Drug|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
60062|NCT01095666|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
60063|NCT01095666|Drug|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
60064|NCT01095679|Drug|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
60065|NCT00034294|Drug|GT160-246|
60066|NCT01095679|Drug|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
60067|NCT01095692|Procedure|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
60068|NCT01095692|Procedure|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
60069|NCT01095705|Procedure|Conventional procedure|Local anaesthesia (Lidocaïne)
60347|NCT01096160|Drug|MK8226 1 mg QD|MK8266 1 mg once daily for 10 days, as oral capsule
60348|NCT01096160|Drug|MK8266 2 mg QD|MK8266 2 mg once daily for 10 days, as oral capsule
60349|NCT01096160|Drug|MK8266 4 mg QD|MK8266 4 mg once daily for 10 days, as oral capsule
60350|NCT01096160|Drug|MK8266 4 mg BID|MK8266 4 mg twice daily for 10 days, as oral capsule
59826|NCT01097512|Drug|AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.
Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.
59827|NCT01097525|Procedure|WFG PRK|
59828|NCT01097525|Procedure|WFG LASIK|
59829|NCT01097525|Procedure|WFO PRK|
59830|NCT01097525|Procedure|WFO LASIK|
59831|NCT01097538|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
59832|NCT01097538|Other|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
59833|NCT01097551|Drug|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
59834|NCT01097551|Drug|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
59835|NCT01097551|Drug|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
59836|NCT00034554|Biological|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5* patient safely completing the 2nd vaccination at the lower dose level.
59837|NCT01097551|Device|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
60117|NCT01093391|Device|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
60489|NCT01091532|Drug|UK-396,082|100mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
60490|NCT01091532|Drug|placebo|given orally twice daily for 14 days
60825|NCT01089608|Drug|Azithromycin|Eye drops, Dosage : 1.5%
1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
60826|NCT01089608|Drug|Povidone|Eye drops Single dose unit
1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
60827|NCT00033605|Radiation|radiation|
60828|NCT01089621|Drug|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
60829|NCT01089647|Drug|budesonide nasal spray and a montelukast pill|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
60830|NCT01092039|Dietary Supplement|Placebo Comparator|Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
60831|NCT01092052|Drug|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
60832|NCT01092065|Drug|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
60833|NCT01092065|Drug|Placebo|hard gelatin capsule to be taken bid for six weeks
60834|NCT00033722|Drug|lometrexol|
60835|NCT01092078|Behavioral|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
60836|NCT01092078|Behavioral|Patient Navigation|Patient navigation for colonoscopy.
60837|NCT01092091|Biological|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
60838|NCT01092104|Drug|TBR-652|TBR-652 25 mg
60839|NCT01092104|Drug|TBR-652 Matching Placebo|Matching Placebo
60840|NCT01092104|Drug|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
60841|NCT01092104|Drug|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
60842|NCT01092104|Drug|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
60278|NCT01088542|Behavioral|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
60279|NCT01088555|Drug|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
60280|NCT01088568|Procedure|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
60281|NCT01088568|Procedure|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
60282|NCT01088581|Drug|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
60544|NCT01088906|Drug|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
60545|NCT01088919|Drug|ASP1941|oral tablet
60546|NCT01088919|Drug|pioglitazone hydrochloride|oral tablet
60547|NCT01088932|Drug|SRX246|capsules
60548|NCT01088945|Behavioral|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
60549|NCT01088958|Dietary Supplement|Micronutrient powders (Sprinkles)|Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:
Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg
60550|NCT01088971|Dietary Supplement|Duolac7S|1 capsule two times everyday for 6 weeks
60551|NCT01088971|Dietary Supplement|starch|1capsule two times everyday for 6 weeks
60552|NCT01088984|Drug|Bendamustine|
60553|NCT01088997|Drug|milrinone lactate|Milrinone lactate will be given as an IV infusion for 24 hours.
60554|NCT00033553|Radiation|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
60555|NCT01089010|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
60351|NCT01096160|Drug|MK8266 4 mg TID|MK8266 4 mg three times daily for 10 days, as oral capsule
60352|NCT00034359|Drug|Lamivudine|
60353|NCT01096160|Drug|Comparator: Placebo|Placebo oral capsule (once, twice or three times daily) for 10 days
60354|NCT01096186|Drug|IPX066|IPX066
60355|NCT01096199|Drug|TS-ONE, Cisplatin, RAD001|
60356|NCT01096212|Drug|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
60357|NCT01096212|Drug|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
60358|NCT01096225|Biological|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
60359|NCT01088594|Drug|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
60360|NCT01088594|Drug|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
60361|NCT01088594|Drug|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
60362|NCT00033540|Drug|capecitabine|650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
60363|NCT01088594|Drug|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
60364|NCT01088607|Drug|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
60365|NCT01088620|Drug|Panitumumab|Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression.
60366|NCT01088620|Drug|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
60616|NCT01096771|Drug|ClinOleic 20%|96 hour continuous infusion.
60617|NCT01096771|Drug|Intralipid 20%|96 hour continuous infusion.
60118|NCT01093404|Procedure|Thrombus aspiration|Aspiration of thrombus material before angioplasty
60119|NCT01093417|Drug|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
60120|NCT01093430|Procedure|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
60121|NCT01093430|Procedure|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
60122|NCT00034021|Behavioral|Sex Therapy (genital focus)|
60123|NCT01093443|Drug|ovarian stimulation|rFSH with GnRH antagonists
60124|NCT01093443|Drug|ovarian stimulation|GnRH antagonist, rFSH, GnRH antagonist
60125|NCT01093469|Drug|Atopiclair Nonsteroidal Cream|
60126|NCT01093469|Other|Aquaphor Healing Ointment|
60127|NCT01093469|Drug|EpiCeram|
60128|NCT01093495|Device|CPAP|CPAP
60129|NCT01093495|Device|Nasal Cannula|Nasal Cannula
60130|NCT01093508|Drug|APD916|
60131|NCT01093521|Drug|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
60132|NCT01093521|Drug|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
60133|NCT00034034|Procedure|Acupuncture|
60134|NCT01093534|Drug|Placebo|Matching solifenacin placebo tablet
60135|NCT01093534|Drug|solifenacin|Tablet for oral administration
60136|NCT01093547|Procedure|Blood samples|Samples taken monthly
60137|NCT01093547|Procedure|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
60138|NCT01093560|Dietary Supplement|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
60407|NCT01093807|Drug|Placebo|once daily for 10 weeks
60843|NCT01092104|Drug|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
60844|NCT01092117|Device|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
60845|NCT00033735|Drug|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
60846|NCT01092130|Drug|Vitamin D|2000 IU vitamin D daily, for 6 weeks
60847|NCT01092143|Drug|BI671800|double blind randomized parallel group study
59901|NCT01105156|Behavioral|VEW Questionnaire|Patient Self reported questionnaire filled in.
59902|NCT01105169|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
59903|NCT01105169|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
59904|NCT01105182|Procedure|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
59905|NCT01105195|Other|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
59906|NCT01105195|Other|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
59907|NCT01105208|Drug|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
59908|NCT01105208|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
59909|NCT01105221|Device|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
59910|NCT00000922|Drug|Nelfinavir mesylate|
59911|NCT00035490|Drug|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
59912|NCT01097577|Drug|Placebo|1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
59913|NCT01097590|Device|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
59914|NCT01097590|Device|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
60556|NCT01089010|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
60557|NCT01089010|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
60558|NCT01089023|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
60559|NCT01091532|Drug|UK-396,082|UK-396,082 given orally, once on Days 1 & 14, and twice daily on Days 3-13.
The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
60560|NCT01091532|Drug|placebo|given orally, once on Days 1 & 14, and twice daily on Days 3-13.
60561|NCT01091545|Radiation|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
60562|NCT01091571|Drug|Dipyridamole|Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
60905|NCT01089686|Procedure|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
60906|NCT01089686|Procedure|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
60907|NCT01089699|Behavioral|online support group|online support group
60908|NCT01089699|Behavioral|online support group|online support group
60909|NCT00033618|Drug|ixabepilone|Given IV
60910|NCT01089699|Behavioral|home study support materials|self-study materials
60911|NCT01089725|Biological|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
60912|NCT01089725|Biological|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
60913|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
63084|NCT01110551|Drug|Placebo (ID)|Phosphate buffered saline administered intradermally.
63085|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered subcutaneously.
63086|NCT00036296|Drug|talampanel|75mg per day divided into 3 doses for 22 days
63087|NCT01113203|Behavioral|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
63088|NCT01113229|Drug|Misoprostol|two misoprostol tablets taken orally (400µg)
63415|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
63416|NCT01111136|Behavioral|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
63417|NCT01111149|Other|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
63418|NCT01111149|Drug|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
63419|NCT01111149|Drug|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
63420|NCT00036400|Drug|epoetin alfa|
63421|NCT01111162|Biological|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
63422|NCT01111188|Drug|PD 0332991|PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.
(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg
63423|NCT01111188|Drug|bortezomib|Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.
(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2
61243|NCT01095250|Drug|AIN457|
61244|NCT01095250|Drug|AIN457|
61245|NCT01095250|Drug|Placebo|
61246|NCT01095263|Device|DBS|130Hz, 90us pulsewidth, 4V Amplitude
61247|NCT01087723|Drug|Bivalirudin|
61248|NCT01087723|Drug|Heparin|
61541|NCT01117441|Drug|vincristine sulfate|see detailed protocol description
61542|NCT01117441|Drug|vindesine|see detailed protocol description
61543|NCT01117441|Drug|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
61544|NCT01117441|Drug|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
61545|NCT01117441|Radiation|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
61546|NCT01117454|Drug|flecainide|oral flecainide will be added to standard therapy with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
61547|NCT01117467|Other|Simulation scenario|Students performing their scenario will be paired, not solo
61548|NCT00036985|Procedure|thermal ablation therapy|
61549|NCT01117467|Other|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
61550|NCT01117493|Behavioral|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
61551|NCT01117493|Behavioral|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
61552|NCT01117519|Drug|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
61553|NCT01117532|Behavioral|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
61554|NCT01117545|Behavioral|EFT (Emotional Freedom Techniques)|Six sessions of EFT
62007|NCT01120340|Drug|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
62008|NCT01120340|Other|placebo|2 pills/day for ten days/month until 24 months
62009|NCT00037518|Drug|AMG 073|
62010|NCT01120366|Drug|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
62011|NCT01120366|Drug|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
62012|NCT01122446|Other|Placebo comparator|Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.
Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo.
62013|NCT01122446|Drug|Diamyd|20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.
Post diagnosis: One dose of Diamyd followed by one dose of placebo to children originally receiving Diamyd
62014|NCT01122459|Other|fluid administration|1.5mls/kg/hr fasting
62015|NCT01122472|Drug|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
62016|NCT01122472|Drug|Placebo|Daily for 3 weeks every 4 weeks for 24 months
61089|NCT01089998|Drug|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
61090|NCT01089998|Drug|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
61091|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
61092|NCT00033644|Drug|cisplatin|
61093|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
61094|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
61095|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
61096|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
61097|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
61098|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
61473|NCT01093131|Other|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
61474|NCT01093131|Drug|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
61475|NCT01093144|Device|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
61476|NCT01093157|Drug|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
61477|NCT00000919|Drug|Hydroxyurea|
61478|NCT00033956|Drug|M40403|
61479|NCT01093170|Drug|RNA-144101|Intravitreous administration of RNA-144101
61480|NCT01093183|Drug|lenalidomide|Given PO
61481|NCT01093183|Drug|cyclophosphamide|Given PO
61482|NCT01093183|Other|laboratory biomarker analysis|Correlative studies
61483|NCT01093183|Procedure|quality-of-life assessment|Ancillary studies
61484|NCT01093183|Other|questionnaire administration|Ancillary studies
61485|NCT01093196|Drug|Melphalan, Prednisone, Lenalidomide|Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period [different doses according to the age of patients (65-75 or >75 years old);oral Prednisone for 4 days followed by a 24 day rest period.
Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.
ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
61757|NCT01122121|Drug|Flutamide|Flutamide tablets
61758|NCT01122134|Drug|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
61759|NCT01124500|Drug|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
62087|NCT01118377|Radiation|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
62088|NCT01118390|Device|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
62089|NCT01120379|Device|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
62090|NCT01120392|Other|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
62091|NCT01120392|Other|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
62092|NCT01120405|Drug|Xenon|
62093|NCT01120405|Drug|Sevoflurane|
62094|NCT01120418|Drug|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
62095|NCT01120431|Other|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
62096|NCT01120431|Drug|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
62097|NCT00037531|Drug|Sirolimus (RAPAMUNE)|
62098|NCT01120444|Device|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
62099|NCT01120444|Device|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
62100|NCT01120457|Drug|BMS-936564 (Anti-CXCR4)|
62101|NCT01120470|Drug|OGX-427 and Prednisone|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
62102|NCT01120470|Drug|Prednisone|Control Arm:
Prednisone: 5 mg BID orally starting within 4 days following randomization
62103|NCT01120496|Drug|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
61160|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
61555|NCT01119612|Other|Placebo|Daily oral dose from enrollment until delivery
61556|NCT01119625|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
61557|NCT01119625|Biological|Infanrix-IPV/Hib|Intramuscular injection, one dose
61558|NCT01119638|Drug|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
61559|NCT00000237|Drug|Buprenorphine|
61560|NCT00000927|Drug|BufferGel|
61561|NCT00037141|Drug|dehydrated alcohol|
61826|NCT01122186|Behavioral|Education Attention Control|During the first two sessions participants watch the documentary "Rock bottom" to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary "Meth" which highlights issues of methamphetamine use through interviews with men in various stages of recovery.
61827|NCT01122199|Drug|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
61828|NCT01122238|Drug|Nicotine Patch|If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):
Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks.
61829|NCT01122238|Drug|Nicotine Gum|If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):
Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks.
61830|NCT01122238|Behavioral|Motivational Interviewing|Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the "good" aspects of smoking.
61831|NCT01122238|Behavioral|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
61832|NCT01122238|Other|No Intervention|No Intervention
61099|NCT01090024|Drug|Placebo|Patients receive placebo capsules
61100|NCT01090037|Drug|TRK-100STP high dose|
61101|NCT01090037|Drug|TRK-100STP low dose|
61102|NCT01090037|Drug|Placebo|
61103|NCT00033644|Drug|dacarbazine|
61104|NCT01090050|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
61105|NCT01090050|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
61106|NCT01090063|Drug|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
61107|NCT01090076|Dietary Supplement|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
61108|NCT01090089|Drug|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
61404|NCT01095510|Biological|CINRYZE|
61405|NCT01095523|Procedure|Laparotomy+ HIPEC +/- CRS|
61406|NCT00034268|Drug|LY900003|
61407|NCT01095549|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
61408|NCT01095549|Device|Placebo device|A device without far infrared therapy
61409|NCT01095562|Drug|ABT-126|ABT-126 Dose 1, ABT-126 Dose 2
61410|NCT01095562|Drug|Placebo|Placebo
61760|NCT01124513|Procedure|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
61761|NCT00038064|Drug|rHuEPO|150 IU/kg TIW
61762|NCT01124526|Drug|Rituximab Fludarabine Cyclophosphamide|Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:
RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)
61763|NCT01124539|Drug|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
61764|NCT01124552|Drug|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
61765|NCT01124552|Drug|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
61766|NCT01124552|Other|Vehicle|Vehicle Control
61767|NCT01124552|Drug|Placebo|Placebo Comparator
61768|NCT01124565|Drug|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
61769|NCT01124591|Behavioral|Brief motivational intervention|two session delivered two weeks apart
61770|NCT01124604|Drug|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
61771|NCT01124604|Drug|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
61772|NCT00038077|Drug|Seloken ZOK/Toprol-XL|50 mg
61773|NCT01124617|Drug|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
61774|NCT01124617|Drug|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
62084|NCT01118364|Other|Cannabis|a cigarette tobacco trade mark "Drum" with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving
62085|NCT01118364|Other|tobacco|a cigarette tobacco trade mark "Drum" 45 minutes before simulating or real driving
62086|NCT01118377|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
61161|NCT01087645|Drug|placebo|Subjects will be randomised to receive a single dose of placebo
61162|NCT01087658|Drug|Glutamine|Per os
61163|NCT01087658|Drug|Calcium and Magnesium|Intravenous
61164|NCT01087671|Drug|tafluprost|prostaglandin analogue
61165|NCT01087684|Procedure|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
61166|NCT01087684|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
61167|NCT01087697|Device|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
61168|NCT01087710|Other|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
61169|NCT01087710|Other|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
61170|NCT00033449|Drug|cisplatin|Given IV
61171|NCT01090102|Drug|Mesalamine (5-aminosalicylic acid, Apriso)|Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).
Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
61172|NCT01090102|Drug|Placebo|Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).
Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
61173|NCT01090115|Drug|ART-123|0.01ml/kg up to a volume of 1ml administered by IV boleus every 24 hours for six consecutive days
61174|NCT01090115|Drug|placebo|0.01 ml/kg up to a volume of 1ml administered by IV boleus every 24 hours for 6 consecutive days
61175|NCT00000918|Drug|Didanosine|
61176|NCT00033644|Drug|doxorubicin hydrochloride|
61177|NCT01090128|Drug|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
61178|NCT01090128|Drug|doxorubicin|50 mg/m2 every 3 weeks
61179|NCT01090128|Drug|cyclophosphamide|500 mg/m2 given every 3 weeks
61180|NCT01090141|Drug|Micafungin|100 mg IV infusion over 1 hour
61181|NCT01090141|Drug|Micafungin|300 mg IV infusion over 1 hour
61833|NCT01124669|Genetic|DNA analysis|
61834|NCT01124669|Genetic|mutation analysis|
61835|NCT01124669|Other|laboratory biomarker analysis|
61836|NCT01124682|Procedure|diagnostic cystoscopy|
61837|NCT00038077|Drug|Seloken ZOK/Toprol-XL|200 mg
61838|NCT01124682|Procedure|diffusion-weighted magnetic resonance imaging|
61839|NCT01124682|Procedure|implanted fiducial-based imaging|
61840|NCT01124682|Procedure|quality-of-life assessment|
61841|NCT01124682|Radiation|3-dimensional conformal radiation therapy|
62159|NCT01118455|Device|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
62160|NCT01118455|Drug|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
62161|NCT01118520|Drug|perindopril arginine|10mgs orally daily for the duration of the trial
62162|NCT01118520|Drug|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
62163|NCT01118520|Drug|placebo|one daily
62164|NCT01118533|Device|metal reusable blades MacIntosh|laryngoscope blades
62165|NCT01118533|Device|Single use plastic blades HEINE XP®|laryngoscope blades
62166|NCT00037037|Biological|sargramostim|
62167|NCT01118559|Drug|YM150|oral
62168|NCT01118572|Drug|YM177|oral
62169|NCT01118572|Drug|etodolac|oral
62170|NCT01118572|Drug|Placebo|oral
62171|NCT01118585|Procedure|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
62172|NCT01118598|Drug|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
61411|NCT01095575|Drug|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
61412|NCT01095588|Drug|200 mg Avanafil|2 X 100mg tablets avanafil
61413|NCT01095588|Drug|Placebo|2 tablets
61414|NCT01095601|Drug|Avanafil|Treatment A: 2x100 mg Formulation II avanafil tablet, fasted
Treatment B: 2x100 mg Formulation II avanafil tablet, fed
Treatment C: 2x100 mg Formulation I avanafil tablet, fasted
Treatment D: 1x50 mg Formulation II avanafil tablet, fasted
61415|NCT01095627|Other|Metacholine challenge|Exhaled breath analysis following metacholine challenge
61416|NCT01095640|Drug|adapalene 0.3% topical gel|once a day, 84 days
61417|NCT00034281|Drug|TAK-165|Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
61418|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
61419|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
61420|NCT01095653|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
61421|NCT01095653|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
61422|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
61423|NCT01087957|Other|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
61695|NCT01117636|Drug|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
61696|NCT01117649|Drug|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
61697|NCT01117649|Drug|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
61698|NCT01117649|Drug|balanced electrolyte solution|plasma adapted Ringer's solution
61699|NCT01117662|Drug|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
61700|NCT01117662|Drug|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
63014|NCT01115439|Drug|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
63015|NCT01115452|Drug|5% Potassium nitrate|5% potassium nitrate solution
63016|NCT01115452|Drug|2.5% Potassium nitrate|2.5% potassium nitrate solution
63017|NCT01115452|Other|Sterile water|Sterile water
63018|NCT00036855|Biological|rituximab|Given IV
63019|NCT01115465|Device|Macroplastique|Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
63020|NCT01115478|Dietary Supplement|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
63021|NCT01115478|Dietary Supplement|Zinc|Daily oral dose of 25 mg from enrollment until delivery
63022|NCT01115478|Other|Placebo|Daily oral dose from enrollment until delivery
63023|NCT01115491|Drug|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
63361|NCT00036738|Radiation|total-body irradiation|Undergo TBI
63362|NCT01113723|Device|CMAC|CMAC Device
63363|NCT01113736|Biological|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
63364|NCT01113749|Other|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
63365|NCT01113762|Device|articular surface replacement ASR, DePuy|posterolateral incision
63366|NCT01113762|Device|ReCap/Magnum modular head, Biomet|posterolateral incision
63367|NCT01113762|Device|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
63368|NCT01113762|Device|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
63369|NCT01113788|Device|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
63370|NCT01113801|Drug|LY2382770|Subcutaneous injection given monthly for 12 months
63371|NCT01113801|Drug|Placebo|Subcutaneous injection given monthly for 12 months
63372|NCT00036738|Drug|cyclosporine|Given IV or PO
61182|NCT01090154|Drug|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
61486|NCT01093196|Drug|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period [day 21 to 28]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
61487|NCT01093196|Drug|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
61488|NCT01093209|Device|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
61489|NCT00033982|Drug|Posaconazole|
61490|NCT01121653|Drug|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
61491|NCT01121666|Drug|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
61492|NCT01121692|Behavioral|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
61493|NCT01121692|Behavioral|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
61494|NCT01121692|Behavioral|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
61495|NCT01121705|Drug|Peg Interferon alpha2b + Ribavirin|B 1 I or II: Experimental
variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR
61496|NCT00037687|Drug|rPAF-AH|
61497|NCT01121718|Procedure|Sentinel Lymph Node Mapping|NIR-guided sentinel lymph node mapping with indocyanine green
63424|NCT01111201|Behavioral|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
63425|NCT01111214|Other|no intervention|There is no intervention. This is a non interventional study.
63426|NCT01111227|Drug|Propofol and isoflurane|Comparison of two anesthetic drugs
63427|NCT01111253|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.
In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days.
63428|NCT01111266|Device|xevonta|Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following "FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers". In addition blood samples will be collected for determination of removal rates of different small molecules and protein.
63429|NCT01111279|Biological|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
63430|NCT01111279|Biological|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
62272|NCT01120717|Drug|Placebo|capsules for inhalation, delivered by an SDDPI
62273|NCT01120730|Drug|fluid resuscitation|fluid resuscitation with HES
62274|NCT01120730|Drug|Fluid resuscitation|Fluid resuscitation in standardized fashion
62275|NCT00037583|Drug|Gemtuzumab Ozogamicin|
62276|NCT01122953|Drug|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
62277|NCT01122966|Drug|intraocular injections of bevacizumab|intracameral and subconjunctival injections
62278|NCT01122979|Drug|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
62279|NCT01122979|Drug|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
62280|NCT00037908|Procedure|Strength training|
62281|NCT01122979|Drug|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
61701|NCT00036998|Procedure|thermal ablation therapy|
61702|NCT01117675|Other|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
61703|NCT01117675|Other|Standard of Care|Standard of Care
61704|NCT01117688|Procedure|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
61705|NCT01117701|Procedure|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
61706|NCT01117714|Procedure|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
61707|NCT01117727|Device|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
61708|NCT01117740|Behavioral|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
61709|NCT01117753|Behavioral|OutPatient Treatment for Adolescents (OPT-A)|
61710|NCT01117753|Behavioral|Treatment As Usual|
61711|NCT01117766|Drug|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
61712|NCT01119898|Drug|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
61713|NCT01119911|Other|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
62017|NCT01122485|Other|PG201|two tablets
62018|NCT01122485|Other|Placebo|two tablets
62019|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
62020|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
62021|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
63373|NCT01113814|Device|FibroScan|
63374|NCT01113814|Device|Acoustic Radiation Force Impulse (ARFI)- Imaging|
63375|NCT01113827|Dietary Supplement|Olive Extract|Capsule form ingested 1x/day for 6 weeks
63376|NCT01113827|Dietary Supplement|Placebo|Placebo
63377|NCT01116310|Drug|Placebo|Bottles containing 60 capsules.
63378|NCT01116336|Drug|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
63379|NCT01116336|Dietary Supplement|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
63380|NCT00036881|Other|placebo|
63381|NCT01116349|Procedure|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
62491|NCT01119118|Drug|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
62492|NCT01119131|Drug|Vitamin D3|Vitamin D3 at 10,000 IU a day
62493|NCT01119131|Dietary Supplement|calcium|1000mg calcium daily
62494|NCT01119131|Other|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
62495|NCT01119144|Device|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
62496|NCT01119144|Device|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
62497|NCT01119157|Biological|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
62498|NCT01119170|Other|Starter formula|standard starter formula given from birth to 6 months of age
61498|NCT01121731|Drug|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
61499|NCT01121731|Drug|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
61775|NCT01124630|Drug|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
61776|NCT01124630|Drug|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
61777|NCT01124643|Biological|Replagal|0.2 mg/kg administered intravenously [IV] every other week
61778|NCT01124656|Drug|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
61779|NCT00037011|Biological|beta-glucan|
61780|NCT01117766|Drug|Placebo|BID dosing for 28 days
61781|NCT01117779|Device|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
61782|NCT01117792|Device|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
61783|NCT01117805|Behavioral|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
61784|NCT01117818|Biological|active: AFFITOPE AD02|vaccination
61785|NCT01117818|Biological|control: Placebo|vaccination
61786|NCT01117844|Radiation|Proton Radiation|Prons has been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
61787|NCT01117857|Drug|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
61788|NCT01117870|Other|Pulsed RadioFrequency|120 seconds at 42 degrees celsius
61789|NCT01117870|Other|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
61790|NCT00037011|Biological|monoclonal antibody 3F8|
62282|NCT01122979|Drug|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
62283|NCT01122992|Procedure|Limbal relaxing incision|
62284|NCT01123005|Procedure|PET Scan|radiation calculated per patient
62285|NCT01123005|Drug|EF5|10 mCi, IV
62286|NCT01123005|Drug|Carbogen|Calculated per patient
62287|NCT01123018|Behavioral|Memtrax Memory screening test|Memory Screening test
62288|NCT01123031|Drug|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
62289|NCT01123031|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
62290|NCT01123044|Biological|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
62291|NCT00037921|Procedure|Bacterial colonization|
62292|NCT01123044|Procedure|Medical Therapy|Under usual care treatment
62293|NCT01123057|Procedure|riboflavin-induced collagen cross-linking treatment|The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment.
The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application.
61342|NCT01087905|Drug|Nicotine gum|If < 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
61343|NCT00033462|Other|laboratory biomarker analysis|Correlative studies
61344|NCT01087905|Behavioral|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
61345|NCT01087918|Device|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
61346|NCT01087918|Other|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
61347|NCT01087931|Drug|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
61348|NCT01087931|Other|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
62022|NCT00000931|Behavioral|Risk-reduction counseling|
62023|NCT00037830|Drug|GM1 ganglioside|100 mg twice per day by subcutaneous injection
62024|NCT01122511|Drug|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
62025|NCT01122511|Biological|ranibizumab|Intravitreal injection of ranibizumab into study eye
62026|NCT01122511|Other|sham|Sham needle-less injection administered in the study eye
62027|NCT01122563|Drug|Solifenacin|oral
62028|NCT01122576|Device|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
62029|NCT01122576|Device|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
62030|NCT01122576|Device|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
62031|NCT01122589|Behavioral|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
62032|NCT01122589|Other|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
62033|NCT01122602|Drug|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
62034|NCT00037830|Drug|Placebo|Twice per day subcutaneous injection, equal volume as active drug
62035|NCT01122602|Drug|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
62036|NCT01122602|Drug|Placebo|Two placebo tablets
62037|NCT01122615|Drug|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
62038|NCT01122615|Drug|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
62039|NCT01125189|Drug|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
62040|NCT01125189|Drug|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
61109|NCT01090089|Drug|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
62499|NCT01119170|Other|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
62500|NCT00037063|Drug|Ascorbic acid|
62501|NCT01119183|Behavioral|No intervention for this arm|No educational literature will be offered to this group
62502|NCT01119183|Behavioral|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
62503|NCT01119183|Behavioral|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
62504|NCT01119196|Other|Icodextrin dialysate|use of alternate SOC dialysate
62505|NCT01119209|Drug|Ropivacaine|Approved by the Danish Medicines Agency
62506|NCT01119209|Drug|Saline|Approved by the Danish Medicines Agency
62507|NCT01119222|Drug|Gabapentin|Capsule, single 1200mg dose
62508|NCT01119222|Drug|Diphenhydramine|Tablet, single 50mg dose
62509|NCT01119222|Drug|Morphine|IV, single 10mg dose
62510|NCT01121042|Drug|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
62511|NCT01121055|Drug|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
62784|NCT01121575|Drug|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
62785|NCT01121575|Drug|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
62786|NCT01121588|Drug|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
62787|NCT01121601|Procedure|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
62788|NCT01121601|Procedure|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
62789|NCT01121614|Device|LOTUS|Device used to seal blood vessel
62790|NCT01121614|Device|Ethicon Harmonic Scalpel|
61791|NCT01117883|Other|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
61792|NCT01117896|Other|Chest compression on adult and pedi manikins|Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
61793|NCT01117896|Other|Use of stepstool during chest compressions|In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
62104|NCT01120496|Drug|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
62105|NCT01120509|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
62106|NCT01120522|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
62107|NCT01120535|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
62108|NCT00037544|Drug|ReFacto AF|
62109|NCT01120548|Other|ventilation therapy|The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.
There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.
Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient.
62110|NCT01120561|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
62111|NCT01122628|Device|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
62112|NCT01122641|Drug|Vildagliptin|Vildagliptin 50mg bid
62113|NCT01122641|Drug|Placebo|Matched tablets
62114|NCT01122667|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
62115|NCT01122680|Drug|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
62116|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
62117|NCT00037843|Drug|I-131 Iodocholesterol|
62118|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
61349|NCT01087944|Device|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
61350|NCT01087944|Device|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
61351|NCT01087957|Device|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
61352|NCT01090453|Biological|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
61353|NCT01090453|Biological|Menjugate®|3 co-administered doses
61354|NCT00033657|Drug|paclitaxel|Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29
Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles
61355|NCT01090453|Biological|Rotarix™|Oral, two doses
61356|NCT01090466|Drug|cisplatin|
61357|NCT01090466|Drug|gemcitabine hydrochloride|
61358|NCT01090466|Drug|temsirolimus|
61359|NCT01090466|Other|pharmacological study|
61360|NCT01090479|Drug|2% Chlorhexidine cloth|The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
61361|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
61362|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
61650|NCT01119859|Drug|Adalimumab|
61651|NCT01119859|Drug|Placebo to tocilizumab|
61652|NCT00037180|Drug|Celecoxib|
61653|NCT01119859|Drug|Placebo to adalimumab|
61654|NCT01119872|Other|Positive End-expiratory Pressure (PEEP)|All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.
Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment.
61655|NCT01119885|Drug|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
61110|NCT01092520|Drug|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
61111|NCT01092533|Drug|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
61112|NCT01092533|Drug|Decortin|Maintenance dose 5 mg/d
61113|NCT01092546|Drug|[18F]Flutemetamol|All subjects will receive an IV dose of [18F]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 MBq.
61114|NCT00033852|Procedure|Massage Therapy|
61115|NCT01092559|Drug|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
61116|NCT01092572|Drug|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
61117|NCT01092572|Drug|placebo|placebo 1 tablet once daily for 12 weeks
61118|NCT01092585|Drug|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.
In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met.
61119|NCT01092611|Procedure|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
61120|NCT01092611|Biological|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
61121|NCT01092624|Drug|Solifenacin|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
61122|NCT01092624|Drug|Placebo|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
61424|NCT01087970|Drug|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
62791|NCT01121614|Device|LigaSure bipolar vessel sealing device|
62792|NCT00037674|Drug|Topiramate|
62793|NCT01121627|Other|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
62794|NCT01121640|Procedure|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
62795|NCT01121640|Procedure|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
62796|NCT01121640|Procedure|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
62797|NCT01123967|Other|telephone counseling (TC)|free telephone counseling
62798|NCT01123967|Other|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
62799|NCT01123967|Other|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
62800|NCT01123980|Drug|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
62801|NCT00038012|Procedure|Platelet-pheresis|
62802|NCT01123980|Drug|metformin|China: Tablets, 500 mg. Min. 1500 mg/day.
Japan: Tablets, 250 mg. Min 500 mg/day.
62803|NCT01123980|Drug|glimepiride|China: Tablets, 2 mg. Min. 4 mg/day.
Japan: Tablets, 1 mg. Min. 4 mg/day.
62804|NCT01123980|Drug|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
63024|NCT01115491|Drug|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
63025|NCT01115504|Drug|Thiamine|300 mg daily for 30 days
63026|NCT01115517|Drug|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
63027|NCT01115517|Drug|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
63028|NCT01115530|Other|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
63029|NCT00036855|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
62119|NCT01122680|Drug|Placebo|placebo inhalation solution
62120|NCT01122693|Device|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
62121|NCT01122693|Device|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
62122|NCT01122706|Other|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
62123|NCT01122719|Device|Drug Eluting Stent|
62124|NCT01122771|Drug|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
61183|NCT01090167|Drug|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
61184|NCT01090180|Drug|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
61185|NCT01090180|Drug|Placebo (sugar pill)|inactive
61186|NCT01090193|Procedure|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
61187|NCT00033644|Drug|mitomycin C|
61188|NCT01090206|Dietary Supplement|Vitamin D and calcium|Doses will be based on Vitamin D levels
61189|NCT01090219|Procedure|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
61190|NCT01090232|Other|blood samples|
61191|NCT01090232|Other|blood samples|
61192|NCT01090245|Behavioral|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
61193|NCT01090245|Behavioral|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
61194|NCT01090258|Device|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate [RR], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
61195|NCT01090258|Other|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
61656|NCT01119885|Drug|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
61657|NCT01119898|Drug|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
61658|NCT01121887|Behavioral|Motivational Interviewing|Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.
Clients are offered a choice between "reactive treatment" (clients initiate all contact) and "proactive treatment" (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge.
61659|NCT01121900|Drug|Trazodone HCl|Dosage form: Extended-release caplets containing 300 mg trazodone HCl
Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours.
61660|NCT01121900|Drug|Trazodone HCl|Dosage form: Immediate-release tablets containing 100 mg trazodone HCl
Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period.
61661|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
61662|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
61663|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
61664|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
61665|NCT01121926|Drug|Trazodone HCl|Dosage form:
Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).
Dose regimen:
75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours.
61950|NCT00038103|Drug|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
61951|NCT01125007|Device|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
61952|NCT01125020|Drug|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
61953|NCT01125020|Drug|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
61425|NCT00033475|Biological|therapeutic allogeneic lymphocytes|
61426|NCT01087970|Drug|Cetuximab|Administered intravenously in combination therapy, for a maximum of 6 cycles.
After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.
61427|NCT01087970|Drug|Carboplatin|Administered intravenously, for a maximum of 6 cycles
61428|NCT01087970|Drug|Cisplatin|Administered intravenously, for a maximum of 6 cycles
61429|NCT01087983|Drug|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
61430|NCT01087983|Drug|Sirolimus|Starting oral dose 1 mg daily.
61431|NCT01087983|Drug|Metformin|Starting oral dose 1000 mg daily.
61432|NCT01087996|Biological|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
61433|NCT01087996|Biological|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
61434|NCT01088009|Drug|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
61435|NCT01088009|Drug|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
61436|NCT00033488|Other|cytology specimen collection procedure|
61437|NCT01088009|Drug|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
61438|NCT01088022|Drug|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
61439|NCT01088022|Drug|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
61440|NCT01088035|Drug|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
61441|NCT01088048|Drug|Idelalisib|Idelalisib tablet administered orally
63030|NCT01115530|Dietary Supplement|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
63031|NCT01115543|Drug|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
63032|NCT01115556|Drug|Ranibizumab|2.0 mg
63033|NCT01115556|Drug|Ranibizumab|0.5 mg
63034|NCT01115569|Drug|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
63035|NCT01107938|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
63036|NCT01107938|Drug|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
63037|NCT01107938|Drug|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
63038|NCT01107951|Drug|Rituximab and dexamethasone|Rituximab 100mg IV days 1,8,15,22.
Dexamethasone 40mg PO days 1-4 (four days)
63039|NCT01107964|Drug|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
63040|NCT01107964|Drug|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
63041|NCT01107977|Behavioral|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
63042|NCT01108003|Drug|broccoli sprout extract|Given orally
63043|NCT01108003|Other|laboratory biomarker analysis|Correlative studies
63044|NCT00000922|Drug|Stavudine|
63045|NCT00035958|Drug|Prednisone|
63382|NCT01116349|Device|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
63383|NCT01116362|Procedure|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
61196|NCT00033865|Behavioral|Yoga, Relaxation Exercises, Sleep Hygiene|Sleep hygiene and relaxation exercises, with additional yoga
61197|NCT01092663|Drug|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
61198|NCT01092663|Drug|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
61199|NCT01092676|Drug|Ibuprofen Regular Dosing|Regular dosing
61200|NCT01092676|Drug|PRN dosing Ibuprofen|PRN dosing Ibupofen
61201|NCT01092689|Drug|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies [14C]PhIP
61202|NCT01092702|Drug|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
61203|NCT01092715|Procedure|Spinal mobilization|Non thrust mobilization to the cervical spine
61500|NCT01121731|Drug|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
61501|NCT01121744|Device|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
61502|NCT01121757|Drug|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
61503|NCT01121757|Drug|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
61504|NCT01121770|Drug|fondaparinux sodium injection|1.5mg subcutaneously every day
61505|NCT01121783|Other|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
61506|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
61507|NCT00000931|Behavioral|Behavioral intervention|
61508|NCT00037700|Drug|anakinra|
61509|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
61510|NCT01124110|Behavioral|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
61954|NCT01125033|Drug|Vitamin C & Vitamin E|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
61955|NCT01125033|Drug|Vitamin C|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
61956|NCT01125033|Drug|Vitamin E|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
61957|NCT01118039|Other|immunohistochemistry staining method|
61958|NCT01118039|Other|laboratory biomarker analysis|
61959|NCT01118039|Other|pharmacological study|
61960|NCT01118039|Procedure|quality-of-life assessment|
61961|NCT01118052|Biological|EGEN-001|Given intraperitoneally
61962|NCT01118052|Other|Laboratory Biomarker Analysis|Correlative studies
61963|NCT01118065|Drug|everolimus|
61964|NCT01118078|Genetic|DNA methylation analysis|Undergo DNA methylation analysis
61965|NCT01118078|Genetic|gene expression analysis|Undergo gene expression analysis
61966|NCT00037024|Procedure|psychosocial assessment and care|
61967|NCT01118078|Genetic|microarray analysis|Undergo microarray analysis
61968|NCT01118078|Genetic|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
61969|NCT01118078|Other|diagnostic laboratory biomarker analysis|Correlative studies
61970|NCT01118091|Biological|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
62294|NCT01123057|Device|Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia|Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)
62295|NCT01123070|Biological|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
62296|NCT01123070|Biological|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
62297|NCT01123083|Biological|Otelixizumab|infusion
62298|NCT01123083|Biological|Placebo|Infusion
61442|NCT01088048|Drug|Rituximab|Rituximab administered intravenously
61714|NCT01119924|Drug|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
61715|NCT01119924|Drug|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
61716|NCT01119937|Drug|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
61717|NCT00037180|Drug|Irinotecan|
61718|NCT01119937|Drug|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
61719|NCT01119950|Drug|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
61720|NCT01119950|Drug|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
61721|NCT01119950|Drug|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
61722|NCT01119950|Drug|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
61723|NCT01119950|Drug|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
61724|NCT01119950|Drug|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
61725|NCT01119950|Drug|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
61726|NCT01119950|Drug|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
61727|NCT01119963|Drug|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
61728|NCT00037180|Drug|5-fluorouracil|
61729|NCT01119963|Drug|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
61730|NCT01119976|Behavioral|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
61731|NCT01119976|Behavioral|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
63384|NCT01116362|Procedure|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
63385|NCT01116388|Other|GFCF product with GFCF diet|Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.
Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks.
63386|NCT01116388|Other|product containing gluten and casein (milk protein) with GFCF diet|Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.
Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks
63387|NCT01116401|Drug|Leuprolide|Leuprolide acetate 3.75-mg intramuscular injection
Leuprolide is a widely used GnRH agonist. Leuprolide is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women.
Leuprolide can induce amenorrhea for 2-3 months after a depot injection is given. However, unpredictable menstrual bleeding and spotting can occur during this time period. Menstrual-cycle patterns will be monitored closely during the study. Although long-term administration of any GnRH agonist (i.e., >6 months) is associated with bone loss, bone effects are not expected in this protocol because GnRH agonist therapy will be used for only one month.
63388|NCT01116427|Biological|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
63389|NCT01116427|Drug|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
63390|NCT01116440|Drug|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
63391|NCT00036894|Drug|lenalidomide|
63392|NCT01116440|Drug|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
63393|NCT01108627|Drug|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
63394|NCT01108627|Drug|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
62512|NCT01121055|Drug|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
62513|NCT01121068|Other|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
62514|NCT01121081|Drug|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
61511|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
61512|NCT01124123|Drug|Bilastine|20 mg oral tablet
61513|NCT01124123|Drug|Bilastine|10 mg endovenous bilastine
61514|NCT01124136|Device|Neurostimulation|Implantation of neurostimulator
61515|NCT00038025|Drug|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
61516|NCT01124136|Other|Standard of Care Therapy|Standard of Care Therapy
61517|NCT01124149|Drug|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
61518|NCT01124162|Drug|Losartan|100 mg Tablet
61519|NCT01124162|Drug|Cozaar®|100 mg Tablet
61794|NCT01117909|Other|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
61795|NCT01117909|Other|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
61796|NCT01117922|Other|Psychological intervention|Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
61797|NCT01117922|Other|Usual Care Group|
61798|NCT01117935|Radiation|intensity modulated external beam radiation therapy|Low risk - 69.6 Gy in 2.4 Gy fractions to prostate
Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes
High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes
61799|NCT01119989|Dietary Supplement|amino-acid + fructose|
61800|NCT01120002|Drug|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
61801|NCT01120002|Drug|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
62299|NCT01123096|Procedure|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
62300|NCT01125371|Behavioral|Computerized brief alcohol intervention + IVR booster calls|1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
62301|NCT01125371|Behavioral|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
62302|NCT00038142|Drug|Doxorubicin|90 mg/m^2 IV over 30 min x 1 repeated every 3 weeks X 6.
62303|NCT01125371|Behavioral|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
62304|NCT01125384|Other|additional swabbing|physician swabs patient`s throat according to standard rules before referral of the patient to throat swabbing by nurse.
62305|NCT01125397|Behavioral|LEARN group|Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
62306|NCT01125410|Drug|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
62307|NCT01125410|Drug|Clindamycin|vaginal cream, 2%, once daily for 7 days
62308|NCT01125423|Drug|Milnacipran|Subject will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
62309|NCT01125423|Procedure|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
62310|NCT01125436|Dietary Supplement|Cholecalciferol|50,000 IU weekly for 6 months
62311|NCT01125436|Dietary Supplement|Cholecalciferol|Placebo weekly for 6 months
62312|NCT01125449|Drug|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
62313|NCT00038142|Drug|Cyclophosphamide|2.0 g/m^2 IV daily x 2 days repeated every 3 weeks X 6.
61363|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
61364|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
61732|NCT01119989|Dietary Supplement|control|
61733|NCT01119989|Dietary Supplement|Fructose+maltodextrin placebo|
61734|NCT01121952|Other|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
62041|NCT01125202|Behavioral|Social Cognitive Theory based dietary counseling paired with personal digital assistant based self-monitoring|The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targetted counseling and engaged the participant in problem solving around dietary issues.
62042|NCT01125202|Behavioral|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
62043|NCT00038129|Procedure|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
62044|NCT01125215|Drug|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
62045|NCT01125215|Drug|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
62046|NCT01125241|Drug|wuling capsule|orally, three tablets each time,three times a day
62047|NCT01125241|Drug|placebo of wuling capsule|orally, three tablets each time and three times a day
62048|NCT01125254|Drug|Amlodipine|5mg po for 12 months
62049|NCT01125267|Behavioral|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
62050|NCT01125267|Behavioral|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
62051|NCT01125280|Procedure|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
62052|NCT01125293|Drug|Everolimus|Taken orally on a daily basis
62053|NCT01125293|Drug|Rituximab|Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only
62054|NCT00038142|Drug|Vincristine|2.0 mg/m^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
62055|NCT01125293|Drug|Bortezomib|Given intravenously on days 1, 8 and 15 of every cycle
62056|NCT01125306|Device|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
62515|NCT01121081|Drug|Placebo|Drug: Alga Dunaliella Bardawil
4 capsules per day, 2 in the morning 2 in the evening for 3 month
62516|NCT01121107|Device|HeartPOD™ System or Promote® LAP System|HeartPOD system is a standalone for use in patients not requiring ICD or CRT-D therapy or who are already receiving ICD or CRT-D therapy.
Promote LAP system is a combination device for patients who require ICD or CRT-D therapy in addition to LAP monitoring.
62517|NCT00037609|Drug|Exisulind|125 mg taken by mouth twice daily.
62518|NCT01121120|Drug|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
62519|NCT01121120|Drug|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
62520|NCT01121133|Drug|navitoclax|Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
62521|NCT01121133|Drug|Rifampin|Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
62522|NCT01121146|Device|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
62523|NCT01121159|Procedure|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
62524|NCT01121185|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
62525|NCT01121185|Other|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
62526|NCT01121198|Drug|ASP1941|oral
62527|NCT01121198|Drug|placebo|oral
62528|NCT00037622|Drug|ACH-126, 443 (beta-L-Fd4C)|
62529|NCT01121211|Drug|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
62530|NCT01121211|Drug|Placebo|Placebo transdermal patch x 24 weeks
62531|NCT01121224|Device|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
62532|NCT01121224|Device|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
62533|NCT01121224|Drug|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
62534|NCT01121224|Drug|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
61802|NCT01120015|Drug|diacerein|Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
61803|NCT01120028|Drug|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously Two doses 24 hours apart
61804|NCT00037180|Drug|Leucovorin|
61805|NCT01120028|Drug|Basiliximab|20 mg intravenously Two doses 96 hours apart
61806|NCT01120028|Drug|Sirolimus|Sirolimus: target trough levels 5-10 ng/mL for first 6 months, then 5-8 ng/mL
61807|NCT01120028|Drug|Tacrolimus|Target trough level 5-12 ng/mL for first 6 months after basiliximab; 5-7 ng/mL for first six months after basiliximab. 5-7 ng/mL for all participants after 6 months.
61808|NCT01120041|Behavioral|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
61809|NCT01120041|Behavioral|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
61810|NCT01120041|Behavioral|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
61811|NCT01120041|Behavioral|health education|Traditional health education given during the prenatal phase and the postpartum phase
62125|NCT01122771|Drug|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
62126|NCT01122771|Drug|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
62127|NCT01122771|Drug|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
62128|NCT00037869|Drug|I-131 Metaiodobenzylguanidine|
62129|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
62130|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
62131|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
62132|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
61365|NCT00033657|Procedure|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
61366|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
61367|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
61368|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
61369|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
61370|NCT01090505|Drug|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
61371|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
61372|NCT01090518|Drug|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
61373|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
61374|NCT01090544|Device|Nasal Insufflation|Breathing therapy
61375|NCT01090557|Other|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
61376|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
61377|NCT01093014|Behavioral|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
61378|NCT01093014|Behavioral|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
61379|NCT01093014|Behavioral|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
61380|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
61381|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
62057|NCT01125319|Other|blood sample|
62058|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
62059|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
62060|NCT01125345|Procedure|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
62061|NCT01125358|Drug|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
61123|NCT01092624|Device|Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
61124|NCT01092650|Drug|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
61125|NCT01094990|Drug|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
61126|NCT01095003|Drug|Vinflunine plus Capecitabine|Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
61127|NCT01095003|Drug|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
61128|NCT00034177|Drug|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
61129|NCT01095016|Drug|Meptin swinghaler|Dose: 10ug/puff, 2 puffs daily
Frequency: QD (total 20ug/day)
Treatment duration: 2 days
61130|NCT01095016|Drug|Berotec|Dose: 100ug/puff, 2 puffs daily
Frequency: QD (total 200ug/day)
Treatment duration: 2 days
61131|NCT01095029|Device|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
61132|NCT01095042|Behavioral|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
61133|NCT01095055|Biological|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly
61134|NCT01095055|Biological|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly
62805|NCT01123993|Device|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
62806|NCT01124006|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
62807|NCT01124006|Other|Water for injection|Sterile water for injection
62808|NCT01124032|Drug|methylphenidate|a capsule containing 20 mg
62809|NCT01124045|Drug|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
62810|NCT01124045|Drug|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
62811|NCT01124058|Drug|warfarin|Patients will be randomized to re-start warfarin at their "maintenance" dose or at a "loading" dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose).
62812|NCT00038012|Drug|Carboplatin|
62813|NCT01124058|Drug|Warfarin|"Maintenance" dose is the amount of warfarin that a patient required to maintain a therapeutic INR.
62814|NCT01124071|Behavioral|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
62815|NCT01124071|Behavioral|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
62816|NCT01124097|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
62817|NCT01124097|Drug|Placebo|Tablets will be used.
62818|NCT01117285|Other|3-day post-graduate course|A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).
The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material.
63046|NCT01108016|Behavioral|Videoconferencing support group|
62133|NCT01124786|Drug|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
62134|NCT01124799|Drug|TMC435|one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
62135|NCT01124799|Drug|Placebo|placebo dose in the morning, at noon and in the evening, for 9 days
62136|NCT01124799|Drug|Ciprofloxacin|one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
62137|NCT01124812|Other|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:
Cohorts 1, 2 & 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 & 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 & 3. Treatment cycles will be repeated every 28 days.
Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.
Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).
Total treatment duration is 8-16 weeks
62138|NCT01124825|Device|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
62139|NCT01124825|Device|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
62140|NCT01124838|Drug|adalimumab|Subjects will be randomized into one of two arms. Arm 1 will receive adalimumab 80 mg subcutaneous (SC) loading dose at Baseline followed by 40 mg doses eow starting at Week 1. Arm 2 will receive matching placebo. Randomization will be a 1:1 ratio double masked fashion to the treatment groups using baseline immunosuppressant usage as the stratification factor.
62141|NCT01124838|Drug|prednisone|Based on the dose of corticosteroids at study entry, a pre-defined taper schedule will be followed that mandates discontinuation of corticosteroid therapy no later than Week 19. Subjects who enter this study on another corticosteroid will be converted to an equivalent dose of prednisone at Baseline.
61204|NCT01092715|Procedure|Massage|Sedative massage to cervical paraspinal muscles
61205|NCT01092715|Procedure|Neck exercises|Range of motion exercises to include foraminal opening
61206|NCT01092728|Drug|Dasatinib|100 mg daily.
61207|NCT00033878|Drug|Noni Extract|
61208|NCT01092728|Procedure|Surgical Resection|Complete surgical resection of tumor(s).
61209|NCT01092741|Drug|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
61210|NCT01092754|Procedure|MRI|contrast enhanced MRI
61211|NCT01092754|Procedure|MRI|contrast enhanced MRI
61666|NCT01121926|Drug|Trazodone HCl|Dosage form:
Immediate-release tablet containing 100 mg trazodone HCl
Dose regimen:
100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours.
61667|NCT01121939|Drug|Bevacizumab|15 mg/kg IV Day 1. The first dose should be administered over
90 minutes. If no adverse reactions occur after the initial dose, the second dose should
be administered over a minimum of 60 minutes. If no adverse reactions occur after the
second dose, all subsequent doses should be administered over a minimum of 30
minutes. Bevacizumab will be infused prior to pertuzumab.
61668|NCT00037752|Drug|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
61669|NCT01121939|Drug|Pertuzumab|840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.
If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later.
61670|NCT01121939|Drug|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
61671|NCT00038051|Drug|Hum-195/rGel|Starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
61672|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
61673|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
61674|NCT01124357|Device|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
61675|NCT01124357|Device|thermachoice|ThermachoiceTM III thermal balloon ablation
61676|NCT01124370|Device|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
61677|NCT01124383|Procedure|General anesthesia|For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
61135|NCT01095068|Behavioral|Physical exercise|
61136|NCT01095081|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
61137|NCT01095094|Drug|ritonavir|Given orally
61138|NCT01095094|Drug|lopinavir|Given orally
61139|NCT00034190|Drug|S-8184 Paclitaxel Injectable Emulsion|
61140|NCT01095107|Dietary Supplement|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
61141|NCT01095107|Dietary Supplement|Increased fat intake|increased fat intake : Intake > 50 grams of fat per day between meals and snacks
61443|NCT01088048|Drug|Bendamustine|Bendamustine administered intravenously
61444|NCT01088048|Drug|Ofatumumab|Ofatumumab administered intravenously
61445|NCT01088048|Drug|Fludarabine|Fludarabine administered orally
61446|NCT00033657|Radiation|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
61447|NCT01090570|Drug|PLX3397|Once-daily oral capsules
61448|NCT01090583|Other|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
61449|NCT01090596|Drug|Naproxen|500mg naproxen, twice daily for 7 days
61450|NCT01090596|Drug|Placebo|1 tab,twice a day for a seven days
61451|NCT01090609|Device|Stent implantation|Stent implantation
61452|NCT01090622|Drug|XPF-001|Oral capsule
61453|NCT01090622|Drug|Placebo|Oral capsule
61454|NCT01090648|Drug|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
61455|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen intravenous (IV) (single dose)
61456|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen subcutaneous (SC) (single dose)
63047|NCT01108029|Drug|memantine|2 tablets of 10 mg of memantine 1 time a day in the morning
63048|NCT01108029|Drug|placebo|2 tablets of placebo 1 time a day in the morning
63049|NCT01108042|Drug|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
63050|NCT01108055|Drug|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
63051|NCT01108055|Drug|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
63052|NCT01108068|Drug|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
63053|NCT01108081|Behavioral|Physical activity|Moderate-intensity physical activity
63054|NCT01108081|Behavioral|Diet|Dietary weight loss
63055|NCT01108081|Behavioral|Health education|Attention control intervention
63056|NCT00035958|Drug|Methotrexate|
63057|NCT01108094|Drug|Itraconazole|200 mg twice daily; oral
63058|NCT01108107|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
63059|NCT01108107|Drug|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
63060|NCT01108107|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
63061|NCT01108107|Drug|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
63062|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
63063|NCT00000923|Drug|Lamivudine|
63064|NCT00036270|Drug|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
63065|NCT01110486|Drug|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
63066|NCT01110486|Drug|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
63067|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
61212|NCT01092754|Drug|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
61213|NCT01092767|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
61214|NCT01092780|Drug|MK7288|10 mg capsule, orally, single dose
61215|NCT01092780|Drug|MK7288|two 10 mg capsules, orally, single dose
61216|NCT01092780|Drug|placebo to MK-7288|one or two capsules, orally, single dose
61217|NCT01092780|Drug|modafinil|two 100 mg tablets, orally, single dose
61218|NCT00033891|Drug|Infliximab|
61219|NCT01092780|Drug|placebo to modafinil|two 100 mg tablets, orally, single dose
61220|NCT01092793|Dietary Supplement|Krill|
61221|NCT01092793|Dietary Supplement|Fish oil|
61222|NCT01092806|Drug|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
61223|NCT01095159|Device|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
61224|NCT01095172|Drug|Rituximab|375mg/m^2, single dose given 2-4 weeks prior to transplantation
61225|NCT01095172|Drug|Tacrolimus|dose calculated to give levels of 3-7ng/ml
61226|NCT01095172|Drug|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
61227|NCT00034203|Drug|efalizumab|
61520|NCT01124175|Drug|Losartan|100 mg Tablets
61521|NCT01124175|Drug|Cozaar®|100 mg Tablets
61522|NCT01124188|Other|Combination Treatment with Higher-dose venlafaxine + PST-DP|Dosing of venlafaxine will range from 187.5-300 mg/day. Medication management and PST-DP will be delivered over the course of 10 sessions over 14 weeks.
61523|NCT01124188|Drug|Higher-dose venlafaxine and supportive management|The dose of venlafaxine will be between 187.5-300 mg/day. It will be offered with supportive management which encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
61971|NCT01118091|Biological|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10^8) and the administration of high-dose aldesleukin.
61972|NCT01118104|Other|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
61973|NCT01118117|Device|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
61974|NCT01118143|Behavioral|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
61975|NCT01118156|Other|Education|75-minute training teaching utilization of new standardized suicide nomenclature
61976|NCT01118208|Other|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
61977|NCT00037024|Procedure|quality-of-life assessment|
61978|NCT01118208|Other|Dispense as usual|Dispensing prescription medications in standard pill bottles.
61979|NCT01118221|Behavioral|pulmonary rehabilitation|structured exercise program
61980|NCT01118234|Drug|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
61981|NCT01118247|Procedure|Uncemented primary total hip arthroplasty|Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
61982|NCT01120210|Drug|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
61983|NCT01120210|Drug|Placebo|1-hour infusion of matching placebo on Day 1
61984|NCT01120210|Drug|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
61985|NCT01120223|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
61986|NCT00000928|Behavioral|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
61987|NCT00037479|Drug|ceftriaxone|
61988|NCT01120236|Drug|Bicalutamide|Given PO
61989|NCT01120236|Biological|Cixutumumab|Given IV
61457|NCT00033683|Drug|CMF regimen|
61458|NCT01090661|Drug|moxifloxacin hydrochloride (Avelox®)|400 mg of moxifloxacin intravenous (IV) single dose
61459|NCT01090661|Drug|placebo|placebo intravenous (IV) single dose
61460|NCT01090661|Drug|placebo|placebo subcutaneous (SC) single dose
61461|NCT01090674|Other|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
61462|NCT01090687|Radiation|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
61463|NCT01090687|Device|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
61464|NCT01090700|Drug|TMC435|TMC435 150 mg daily for 7 days
61465|NCT01090700|Drug|Escitalopram|Escitalopram 10 mg daily for 7 days
61735|NCT01121965|Procedure|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
61736|NCT01121978|Procedure|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
61737|NCT01121991|Drug|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
61738|NCT01122004|Drug|Pregabalin|
61739|NCT01122004|Drug|Pregabalin|
61740|NCT01122017|Procedure|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
61741|NCT01122030|Drug|0.1 mg of S-297995 or placebo|One tablet of 0.1 mg of S-297995 or one tablet of placebo
61742|NCT00037752|Behavioral|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
61743|NCT01122030|Drug|0.3 mg of S-297995 or placebo|Three tablets of 0.1 mg of S-297995 or three tablets of placebo
61744|NCT01122030|Drug|1 mg of S-297995 or placebo|One tablet of 1 mg of S-297995 or one tablet of placebo
61745|NCT01122030|Drug|3 mg of S-297995 or placebo|Three tablets of 1 mg of S-297995 or three tablets of placebo
61746|NCT01122030|Drug|0.03 mg of S-297995 or placebo|Oral solution (18 ml) containing 0.03 mg of S-297995 or 18 ml of sterile water containing placebo
63068|NCT01110486|Drug|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
63395|NCT01108627|Drug|foradil|open-labeled inhaled corticosteroids (ICS); foradil
63396|NCT00035997|Drug|Zometa|
63397|NCT01108653|Other|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
63398|NCT01108653|Other|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient`s sick-leave and follow-up.
63399|NCT01108666|Drug|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
63400|NCT01108692|Other|Telecardiology|Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.
A retrospective analysis will be performed at the end of the study to compare the results in the two groups.
63401|NCT01108705|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
63402|NCT01108705|Drug|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
63403|NCT01108718|Other|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
63404|NCT01108718|Other|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
63405|NCT01108731|Drug|Milnacipran|Patients will take an increasing number of 12.5mg pills for the first 9 days during the "ramp up" period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study.
63406|NCT01108731|Drug|Placebo|Patients will take an increasing number of placebo pills for the first 9 days during the "ramp up" period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study.
63407|NCT00036023|Drug|darbepoetin alfa|
63408|NCT01108744|Drug|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
63409|NCT01108744|Drug|mannitol|20% mannitol, dosed by patient's ideal body weight
63410|NCT01108757|Drug|Bactrim|Bactrim DS BID for 3 days
63411|NCT01108757|Other|Placebo|Corn starch capsules
61524|NCT01124201|Other|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
61525|NCT01124214|Procedure|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
61526|NCT00000936|Drug|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
61527|NCT00038038|Drug|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
61528|NCT01124227|Drug|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
61529|NCT01117441|Drug|cyclophosphamide|see detailed protocol description
61530|NCT01117441|Drug|cytarabine|see detailed protocol description
61531|NCT01117441|Drug|daunorubicin hydrochloride|see detailed protocol description
61532|NCT01117441|Drug|dexamethasone|see detailed protocol description
61533|NCT01117441|Drug|doxorubicin hydrochloride|see detailed protocol description
61534|NCT01117441|Drug|etoposide|see detailed protocol description
61535|NCT01117441|Drug|ifosfamide|see detailed protocol description
61536|NCT01117441|Drug|mercaptopurine|see detailed protocol description
61537|NCT00036985|Procedure|neoadjuvant therapy|
61538|NCT01117441|Drug|methotrexate|see detailed protocol description
61539|NCT01117441|Drug|prednisone|see detailed protocol description
61540|NCT01117441|Drug|thioguanine|see detailed protocol description
61812|NCT01120067|Behavioral|Intensive Treatment|Participants randomized to the PT condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
61990|NCT01120236|Drug|Goserelin Acetate|Given SC
61991|NCT01120236|Other|Laboratory Biomarker Analysis|Correlative studies
61072|NCT01087476|Drug|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
61073|NCT01087489|Drug|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
61074|NCT01087489|Drug|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
61075|NCT01087502|Drug|Glimepiride|1-4 mg daily after 12 weeks
61076|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
61077|NCT01087502|Drug|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
61078|NCT00033436|Radiation|radiation therapy|
61079|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
61080|NCT01087502|Drug|Linagliptin|5 mg once daily
61081|NCT01087515|Other|Blood donation|In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).
In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.
In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects.
61082|NCT01087528|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
61083|NCT01087541|Behavioral|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
61084|NCT01087554|Drug|Sirolimus|Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.
Expansion Phase starting dose: MTD from Escalation Phase.
61085|NCT01087554|Drug|Vorinostat|Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.
Expansion Phase starting dose: MTD from Escalation Phase.
Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.
61747|NCT01122030|Drug|0.01 mg of S-297995 or placebo|Oral solution (6 ml) containing 0.01 mg of S-297995 or 6 ml of sterile water containing placebo
61748|NCT01122043|Device|Endoglide|Device
61749|NCT01122056|Other|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
61750|NCT01122069|Other|Perflutren Lipid Microsphere ultrasound contrast|Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
61751|NCT01122082|Behavioral|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
61752|NCT01122108|Drug|Cholestyramine|Cholestyramine 12 grams, one time dose
61753|NCT00037791|Drug|(PN-152,243)/PN-196,444|
61754|NCT01122108|Drug|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
61755|NCT01122121|Drug|Leuprorelin SR|Leuprorelin SR injection
61756|NCT01122121|Radiation|Radiotherapy|Radiotherapy 70 +/- 4 Gy
62062|NCT01125358|Drug|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
62063|NCT01118260|Procedure|total intravenous anaesthesia|propofol and remifentanil
62064|NCT01118260|Procedure|spinal anaesthesia|bupivacaine and fentanyl
62065|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
62066|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
62067|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
62068|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
62069|NCT00000925|Drug|Optimune oral nutritional supplement|
62070|NCT00037037|Biological|MAGE-10.A2|
62071|NCT01118273|Drug|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
63412|NCT01108783|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
63413|NCT01111110|Device|Static then anti-static chamber|albuterol with Static then anti-static chambers
63414|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
62535|NCT01121224|Drug|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
62536|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
62537|NCT00037960|Procedure|Constrained Induced Therapy|
62538|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
62539|NCT01123408|Drug|Clozapine|500 mg/day
62540|NCT01123408|Drug|Olanzapine|20 mg/day
62541|NCT01123408|Drug|Haloperidol|20 mg/day
62542|NCT01123447|Procedure|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
62543|NCT01123447|Procedure|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
62544|NCT01123460|Other|enzyme-linked immunosorbent assay|
62545|NCT01123460|Other|laboratory biomarker analysis|
62546|NCT01123473|Drug|capecitabine|
62547|NCT01123473|Drug|cisplatin|
62548|NCT00037973|Behavioral|ventilation feedback|
62549|NCT01123473|Drug|epirubicin hydrochloride|
62550|NCT01123473|Drug|fluorouracil|
62551|NCT01123473|Drug|lapatinib ditosylate|
62552|NCT01123486|Drug|hydromorphone|hydromorphone 0.02 mg/kg
62553|NCT01123512|Device|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
61813|NCT01120080|Behavioral|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
61814|NCT01120080|Behavioral|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
61815|NCT00037206|Drug|Anidulafungin, VER002|
61816|NCT01120093|Drug|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
61817|NCT01120093|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
61818|NCT01120093|Drug|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
61819|NCT01122147|Drug|chamomilla tincture mouthwash|The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
61820|NCT01122147|Drug|placebo mouthwash|The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
61821|NCT01122160|Drug|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
61822|NCT01122160|Drug|placebo|Placebo with berries (blackberries + strawberries)
61823|NCT01122173|Device|Ablation|Atrial fibrillation ablation procedure
61824|NCT00037804|Drug|Irinotecan|
61825|NCT01122186|Behavioral|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
62142|NCT00038090|Drug|Dexamethasone|20 mg/m^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
61086|NCT01087554|Drug|Everolimus|Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.
Expansion Phase: MTD from Escalation Phase.
61087|NCT01089998|Drug|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
61088|NCT01089998|Drug|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
61382|NCT00033917|Drug|placebo|saline
61383|NCT01093040|Drug|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
61384|NCT01093040|Drug|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
61385|NCT01093040|Drug|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
61386|NCT01093053|Behavioral|Mind-Body Skills Groups|The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
61387|NCT01093053|Other|Standard Treatment|May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
61388|NCT01093066|Procedure|optimal TURB|The TURB will always try to be optically complete.
61389|NCT01093079|Procedure|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
61390|NCT01093079|Procedure|Open partial nephrectomy|Open partial nephrectomy
61391|NCT01093092|Dietary Supplement|Calcitriol|Given PO
61392|NCT01093092|Drug|Cisplatin|Given IV
61393|NCT00033943|Drug|deligoparin|
61394|NCT01093092|Drug|Gemcitabine Hydrochloride|Given IV
61395|NCT01093092|Other|Pharmacological Study|Correlative studies
61396|NCT01093118|Drug|TMI-358|Micro implant monthly x 3
61397|NCT01093118|Drug|MMI-467|Micro implant monthly x 3
61398|NCT01093131|Other|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
62072|NCT01118273|Drug|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
62073|NCT01118286|Drug|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
62074|NCT01118312|Drug|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day for 6 months
62075|NCT01118312|Other|Placebo|Intranasal placebo spray
62076|NCT01118325|Drug|ticagrelor|Drug oral treatment
62077|NCT01118325|Drug|clopidogrel|Drug oral treatment
62078|NCT01118351|Drug|sunitinib malate|Given orally
62079|NCT01118351|Other|immunohistochemistry staining method|Correlative studies
62080|NCT01118351|Other|TdT-mediated dUTP nick end labeling assay|Correlative studies
62081|NCT00037037|Biological|MART-1 antigen|
62082|NCT01118351|Other|light microscopy|Correlative studies
62083|NCT01118351|Other|laboratory biomarker analysis|Correlative studies
61142|NCT01095120|Drug|Tesetaxel|For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.
For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.
For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2.
61143|NCT01095133|Drug|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
61144|NCT01095133|Drug|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
61145|NCT01095159|Device|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
61146|NCT01087554|Drug|Temsirolimus|Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.
Expansion Phase: MTD from Escalation Phase.
61147|NCT01087567|Drug|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
62554|NCT01123525|Drug|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
62555|NCT01123538|Drug|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
62556|NCT01123538|Drug|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
62557|NCT01123551|Drug|nebulized morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
62819|NCT01117285|Other|Combined implementation strategy|The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.
OTs receive:
3-day post-graduate course
2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.
Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.
Discussion platform
Web-based registration system: Provides guidance in using the COTiD program for every individual client.
Regional meetings: successes and difficulties in using the COTiD are discussed.
Managers and physicians receive:
Information on the COTiD program through a website and newsletters.
Motivational reminders.
62820|NCT01117298|Drug|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
62821|NCT01117298|Drug|Placebo|Tab Placebo every alternate day for 8 weeks
62822|NCT00036985|Drug|doxorubicin hydrochloride|
62823|NCT01117311|Device|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
62824|NCT01117311|Device|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
62825|NCT01117337|Procedure|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
62826|NCT01117350|Drug|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
62827|NCT01117350|Drug|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
62828|NCT01117350|Drug|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
62829|NCT01117363|Other|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
62830|NCT01117376|Drug|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
62831|NCT01117376|Drug|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
62143|NCT01124838|Drug|prednisone|Based on the dose of corticosteroids at study entry, a pre-defined taper schedule will be followed that mandates discontinuation of corticosteroid therapy no later than Week 19. Subjects who enter this study on another corticosteroid will be converted to an equivalent dose of prednisone at Baseline.
62144|NCT01124838|Drug|adalimumab placebo|Placebo 80 mg subcutaneous (SC) loading dose at the Baseline study visit followed a week later by 40 mg placebo injections eow starting at Week 1.
62145|NCT01124851|Drug|ABT-652|See arm description for details
62146|NCT01124851|Drug|Placebo|See arm description for details
62147|NCT01124864|Drug|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
62148|NCT01124877|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
62149|NCT01124890|Device|percutaneous coronary intervention|
62150|NCT01124903|Procedure|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
62151|NCT01124916|Procedure|Robotic Assisted Laparoscopic ASC|robotic assisted laparoscopy for surgical repair of pelvic organ prolapse.
62152|NCT01118390|Other|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
62153|NCT01118403|Drug|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
62154|NCT01118403|Drug|Physiologic Sodium Chloride Solution as placebo|Physiologic Sodium Chloride Solution in the same presentation, appearance and amount of sultamicillin dilution every 6 hours for 4 doses.
62155|NCT00037037|Biological|NY-ESO-1 peptide vaccine|
62156|NCT01118416|Behavioral|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
62157|NCT01118429|Drug|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
61399|NCT01093131|Drug|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
61400|NCT01095458|Behavioral|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
61401|NCT01095471|Biological|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
61402|NCT01095484|Drug|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
61403|NCT01095497|Biological|CINRYZE|C1 esterase inhibitor (human)
61678|NCT01124383|Procedure|Local anesthesia with sedation|For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score < 4.
61679|NCT01124396|Drug|DSP-3025|
61680|NCT01124396|Drug|Placebo|
61681|NCT01124409|Radiation|EPID Verification|Set up error verification and correction by EPID
61682|NCT00038064|Drug|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
61683|NCT01124409|Radiation|CBCT verification|Setup error verification and correction by CBCT
61684|NCT01124422|Drug|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
61685|NCT01124422|Drug|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
61686|NCT01124435|Drug|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
61687|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
61688|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
61689|NCT01124474|Other|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
61148|NCT00033449|Drug|gefitinib|Given orally
61149|NCT01087567|Drug|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
61150|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
61151|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
61152|NCT01087580|Drug|Radiation Therapy|GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.
GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.
GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week.
61153|NCT01087593|Drug|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
61154|NCT01087619|Procedure|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
61155|NCT01087632|Dietary Supplement|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
61156|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
61157|NCT01087645|Drug|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
61158|NCT01087645|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
61159|NCT00033449|Radiation|radiation therapy|Undergo radiation therapy
61466|NCT01090700|Drug|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
61467|NCT01090713|Drug|lisdexamfetamine|oral; 20-70mg/day
61468|NCT00033683|Drug|cyclophosphamide|
61469|NCT01090713|Drug|Placebo control|20-70mg; oral
61470|NCT01090726|Device|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
61471|NCT01090726|Device|Airtraq|Airtraq being used for the actual intubation
61472|NCT01090739|Device|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
62832|NCT01117402|Radiation|Radiotherapy|Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.
Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions.
62833|NCT00036985|Procedure|conventional surgery|
62834|NCT01117428|Biological|Sym004|In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.
In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.
In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.
In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.
In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg.
63069|NCT01110499|Drug|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
63070|NCT01110499|Drug|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
63071|NCT01110499|Drug|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
63072|NCT01110499|Drug|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
63073|NCT01110499|Drug|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
63074|NCT01110499|Drug|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
63075|NCT00036283|Drug|Celecoxib|
63076|NCT01110499|Drug|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
63077|NCT01110499|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
63078|NCT01110512|Drug|Flavonid|Diosmin (450 mg) + hesperidin (50 mg)
1 tablet, 2 times per day.
63079|NCT01110512|Drug|Daflon|Diosmin (450 mg) + hesperidin (50 mg)
1 tablet, 2 times per day
63080|NCT01110525|Drug|AZD1981|4X100 mg per oral, twice daily for 28 days
63081|NCT01110525|Drug|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
63082|NCT01110525|Drug|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
63083|NCT01110551|Drug|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
62158|NCT01118429|Drug|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
61228|NCT01095172|Drug|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
61229|NCT01095172|Drug|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
61230|NCT01095172|Drug|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
61231|NCT01095185|Drug|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
61232|NCT01095185|Drug|Placebo|Simvastatin placebo
61233|NCT01095198|Device|offer of vaginal self collection|Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
61234|NCT01095198|Other|2nd reminder letter for Pap testing|Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
61235|NCT01095211|Drug|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
61236|NCT01095224|Biological|rAd35 Env A|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
61237|NCT01095224|Biological|rAd5 Env A|1 x 10^10 PU administered as 1 mL IM in deltoid
61238|NCT00000919|Drug|Nelfinavir mesylate|
61239|NCT00034229|Drug|Felbamate|
61240|NCT01095224|Biological|rAd5 Env B|1 x 10^10 PU administered as 1 mL IM in deltoid
61241|NCT01095237|Device|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
61242|NCT01095250|Drug|AIN457|
61690|NCT01124487|Dietary Supplement|The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers|
61691|NCT01117623|Drug|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61692|NCT01117623|Drug|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61693|NCT01117636|Drug|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter [mL]) between 14 hours post dental surgery.
61694|NCT01117636|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
61992|NCT01120236|Drug|Leuprolide Acetate|Given IM
61993|NCT01120236|Other|Pharmacological Study|Correlative studies
61994|NCT01120249|Drug|everolimus|Given orally
61995|NCT01120249|Other|placebo|Given orally
61996|NCT01120262|Genetic|gene expression analysis|
61997|NCT01120262|Genetic|polymorphism analysis|
61998|NCT00037492|Procedure|home-based sessions/family meetings with trained clinician|
61999|NCT01120262|Other|laboratory biomarker analysis|
62000|NCT01120275|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
62001|NCT01120275|Other|laboratory biomarker analysis|Correlative studies
62002|NCT01120288|Drug|EZN-2968|
62003|NCT01120301|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
62004|NCT01120314|Drug|OTAMIXABAN (XRP0673)|Form: solution for injection
Route: intravenous
62005|NCT01120327|Drug|Placebo|Placebo
62006|NCT01120327|Drug|Amlodipine|Amlodipine
62702|NCT01121471|Dietary Supplement|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
62703|NCT01121471|Dietary Supplement|Safflower OIl|8.0g/day safflower oil
62704|NCT01121484|Drug|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
62705|NCT01121484|Drug|placebo|Placebo tablets taken orally once daily.
62946|NCT01115322|Drug|Vehicle Foam with UVA and UVB irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62947|NCT01115322|Drug|Vehicle Foam with UVA and UVB and visible light irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62948|NCT01115322|Drug|No Treatment without irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62949|NCT01115322|Drug|No Treatment with UVA and UVB irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62950|NCT01115322|Drug|No Treatment with UVA and UVB and visible light irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62951|NCT01115335|Procedure|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
62952|NCT00036842|Drug|arsenic trioxide|
62953|NCT01115361|Behavioral|Family planning for postpartum women|A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.
B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.
C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.
D.Convenient offer of FP services to women attending vaccination services for their infants.
62954|NCT01115374|Procedure|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
62483|NCT01116895|Drug|LEO 22811|Oral solution
62484|NCT00036972|Biological|cintredekin besudotox|
62485|NCT01119092|Other|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
62486|NCT01119105|Drug|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
62487|NCT01119105|Drug|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
62488|NCT00000926|Drug|Nonoxynol-9|
62489|NCT00037063|Drug|Riboflavin|
62490|NCT01119105|Drug|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
62763|NCT01119586|Genetic|nucleic acid sequencing|
62764|NCT01119586|Genetic|polymerase chain reaction|
62765|NCT01119586|Genetic|polymorphism analysis|
62766|NCT01119586|Other|laboratory biomarker analysis|
62767|NCT01119599|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
62768|NCT01119599|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
62769|NCT00037128|Drug|GL701|
62770|NCT01119599|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
62771|NCT01119599|Other|Laboratory Biomarker Analysis|Correlative studies
62772|NCT01119599|Other|Pharmacological Study|Correlative studies
62773|NCT01119599|Drug|Temozolomide|Given PO
62774|NCT01119599|Procedure|Therapeutic Conventional Surgery|Undergo surgery
62775|NCT01119612|Dietary Supplement|Iron|Daily oral dose of 60 mg from enrollment until delivery
62776|NCT01121510|Device|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
63103|NCT01113372|Drug|Clopidogrel|Clopidogrel 75mg daily.
63104|NCT00036712|Procedure|pain therapy|
63431|NCT01113840|Behavioral|Exercise|Exercise classes three times per week in a controlled, supervised environment.
63432|NCT01113840|Behavioral|Control|Control group continues daily life as prior to randomization.
63433|NCT01113879|Behavioral|Aphasia therapy for anomia|The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.
63434|NCT01113879|Behavioral|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
63435|NCT01113879|Behavioral|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
63436|NCT01113892|Device|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
63437|NCT00036738|Drug|mycophenolate mofetil|Given PO
63438|NCT01113931|Drug|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
63439|NCT01113931|Drug|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
63440|NCT01113944|Behavioral|Program 1|
63441|NCT01113944|Behavioral|Program 2|
63442|NCT01113957|Drug|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
63443|NCT01113957|Drug|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
63444|NCT01113957|Drug|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
63445|NCT01113970|Drug|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
63446|NCT01113983|Drug|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transfemoral or transapical approach
63447|NCT01113996|Behavioral|Protein supplementation and strength training|Protein supplementation and strength training
63448|NCT00036738|Drug|fludarabine phosphate|Given IV
63449|NCT01113996|Dietary Supplement|Protein supplementation|Protein supplementation
62891|NCT01107639|Procedure|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
62892|NCT01107639|Procedure|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
63195|NCT01115738|Drug|Placebo|Loading dose administered once orally
63196|NCT01115751|Drug|LY2780301|Administered orally, daily for two 28-day cycles.
Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression.
63197|NCT01115777|Other|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
63198|NCT00036855|Biological|filgrastim|Given subcutaneously
63199|NCT01115790|Drug|LY2606368|LY2606368 IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
63200|NCT01115803|Drug|LY2584702|Supplied as 25 mg and 100 mg capsules, administered orally for two 28-day cycles.
Starting dose is 50mg. Dose will be subsequently increased to 100mg, 200mg, and 300mg.
63201|NCT01115803|Drug|Erlotinib|Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.
Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity.
63202|NCT01115803|Drug|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
Starting dose is 10mg. Doses may be reduced to 5mg if necessary due to toxicity.
63203|NCT01115842|Drug|Vitamin D|Vitamin D 4000IU per day for 5 days
63204|NCT01115855|Drug|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
63205|NCT01115855|Drug|Placebo|Placebo once daily or every once daily
63206|NCT01115868|Drug|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
63207|NCT01115868|Drug|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
63208|NCT01115868|Drug|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
63209|NCT01108276|Device|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
62955|NCT01115374|Device|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
62956|NCT01107730|Drug|Placebo|Placebo
63285|NCT01113632|Drug|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
63286|NCT01116089|Drug|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
63287|NCT01116089|Drug|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
63288|NCT01116102|Drug|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
63289|NCT01116115|Other|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
63290|NCT00000924|Drug|Nevirapine|
63291|NCT00036868|Drug|cyclophosphamide|
63292|NCT01116115|Other|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
63293|NCT01116128|Drug|dasatinib|100 mg QD continuously (from day 1 to day 28)
63294|NCT01116128|Drug|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
63295|NCT01116128|Drug|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
63296|NCT01116141|Drug|CH-4051|Different doses CH-4051 to be compared
63297|NCT01116141|Drug|Methotrexate (MTX)|20 mg MTX weekly
63298|NCT01116141|Drug|Folic Acid|1 mg folic acid daily
63299|NCT01116154|Drug|lenalidomide|Given orally
63300|NCT01116154|Drug|vorinostat|Given orally
63301|NCT01116154|Other|laboratory biomarker analysis|Correlative studies
63302|NCT00036868|Drug|fluorouracil|
63303|NCT01116167|Drug|Letrozole -Berberine|Letrozole
2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
Berberine
1.5g daily for 6 month.
62777|NCT01121523|Behavioral|Cue directed tactile stimulation|Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
62778|NCT01121536|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
62779|NCT01121549|Drug|Aromasin|25 mg daily continuously
62780|NCT01121562|Drug|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
62781|NCT00037661|Drug|INS365 Ophthalmic Solution|
62782|NCT01121575|Drug|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
62783|NCT01121575|Drug|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
63008|NCT01113190|Behavioral|Intervener-delivered Brief Intervention (IBI)|IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller & Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a "change plan" tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions.
63009|NCT01113190|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
63010|NCT01113190|Behavioral|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
63011|NCT01115387|Other|Observational-1|Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.
Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing.
63012|NCT01115387|Other|Observational-2|A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.
No prospective retina photographs but ongoing follow-up for reported changes in ARM status.
A saliva or blood sample for genetic testing.
63013|NCT01115426|Drug|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
63450|NCT01114009|Procedure|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
63451|NCT01114009|Procedure|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
63452|NCT01114022|Device|Experimental 1|oeso pharyngeal device
63453|NCT01114022|Device|Experimental|oeso pharyngeal device
62558|NCT01123551|Drug|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
62559|NCT00037973|Behavioral|exercise|
62560|NCT01123564|Drug|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
62561|NCT01123564|Radiation|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
62562|NCT01116895|Drug|Placebo|Placebo
62563|NCT01116908|Device|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
62564|NCT01116921|Device|Nasal continuous positive airway pressure (nCPAP)|nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
62565|NCT01116921|Device|Laryngeal Mask Airway (LMA) to deliver surfactant|Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)
62566|NCT01116947|Other|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
62567|NCT01116973|Other|PICC|Peripheral inserted catheter placement to take the reading
62568|NCT01116973|Other|PICC|Comparison of CICC with reading from PICC
62569|NCT01116986|Behavioral|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
63210|NCT01108289|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
63211|NCT01108302|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
63212|NCT01108315|Other|Report symptoms via web or phone-based system|The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
63213|NCT01108328|Dietary Supplement|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
62345|NCT01120756|Behavioral|Pathfinder Attention Process Training|We are developing a series of engaging game-based computerized training tools that target goal-directed attention regulation through intensive application and practice with monitored computer-assisted 'real world' simulated scenarios extended into real life situations. Training will occur in 3 phases, lasting a total of 6-8 weeks, approximately 36 hours of training (12 with in-person trainer interactions, and 24 at home). Patients will start with an on-site training program for 1 week. This phase will focus on goal-directed attention regulation training, including mindfulness-based attentional focus and re-direction. The second phase of training will involve 4-6 weeks of computerized training at home. Participants will complete training 5 days/week. Patients will then return to the study site for therapist-guided training for 1 week.
62346|NCT01120756|Behavioral|Brain Health Education with Motor Skills Training (EDU/MOTOR)|The Brain Health Education classroom training will be the same as described above. The homework will consist of educational DVDs and off-the-shelf computer games that are fun and engaging, requiring simple motor responses but do not engage higher level cognitive processing.
62347|NCT01120756|Behavioral|Tonic and Phasic Alertness Training (TAPAT)|The Tonic and Phasic Alertness Training (TAPAT) is designed to improve alertness at two levels: tonic attention of sustained attention and phasic alertness, or the capacity to rapidly and effectively interrupt an ongoing response pattern. Subjects will be presented objects on a computer screen and make speeded responses via button press to non-targeted objects and withhold button press to targeted objects.
62348|NCT01120756|Behavioral|Object Discrimination Training (ODT)|Object Discrimination Training (ODT) will use the same stimuli and stimulus delivery parameters as TAPAT but consist of a stimulus discrimination task in which subjects will only be required to discriminate object categories, using a unspeeded, forced-choice format.
62349|NCT01120769|Drug|Acetaminophen|single dose
62350|NCT01120769|Drug|Placebo|single dose
62351|NCT01120782|Device|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
62352|NCT01120782|Device|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
62353|NCT00037596|Drug|Gemtuzumab Ozogamicin|
62354|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
62355|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
63304|NCT01116167|Drug|Letrozole|Letrozole
2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
Berberine Placebo
5 tablet tds for 6 months
63305|NCT01116167|Drug|Berberine|Berberine
1.5g daily for 6 month.
Letrozole placebo
1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6.
63306|NCT01116180|Drug|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
62411|NCT01119066|Drug|Fludarabine|25mg/m2/ day x 5
62412|NCT01119066|Drug|Clofarabine|20mg/m2/ day x 5 (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
62413|NCT01119066|Procedure|(CliniMACS) T-cell depleted PBSC Transplant|
62414|NCT01119079|Other|Normal Saline|10ml Normal Saline instilled in the epidural space
62415|NCT01119079|Procedure|Administration of epidural anesthesia for labor|Standard procedure
62416|NCT01119092|Other|Sham ("laying of hands") intervention|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
62417|NCT01120834|Drug|azacytidine|Dose level 1: azacitidine 55 mg/m2 on days 1-5
Dose level 2: azacitidine 75 mg/m2 on days 1-5
Dose level 3: azacitidine 55 mg/m2 on days 1-5
Dose level 4: azacitidine 75 mg/m2 on days 1-5
Each cycle = 28 days. Subjects may receive up to 6 cycles.
62418|NCT01120834|Drug|vorinostat|Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.
Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.
Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.
Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.
Each cycle = 28 days. Subjects receive up to 6 cycles.
62419|NCT01120860|Device|MRI|MRI - routine imaging sequences, designed for anatomical quantification
62420|NCT01120873|Drug|Metamin 3D|Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
62421|NCT01120899|Drug|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
62422|NCT01120912|Drug|Oshadi Oral Insulin|Oral insulin single administration
62423|NCT00037596|Drug|cytarabine.|
62424|NCT01120925|Biological|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
62425|NCT01120925|Biological|CD133|5-15 X 106 cells in 20ML suspension IPV
62426|NCT01120925|Biological|Control|Injection of 20 ml Normal saline via IPV
59074|NCT01106027|Drug|Eculizumab|At the time of deceased donor kidney transplantation, patients will undergo one plasmapheresis prior to surgery.
Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.
Patients will be given 900 mg of eculizumab on Day 1 post-transplant.
Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant
At week 4, patients will be assessed for DSA. Patients with total DSA normalized values <5000 will stop eculizumab treatment. Patients with total DSA normalized values >5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar "discontinuation assessments" will be performed at week 9, 26, 39 and 52.
59075|NCT01106040|Drug|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
59076|NCT00035568|Drug|or Metformin HCl alone|
59077|NCT01106053|Drug|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
59078|NCT01106066|Drug|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
59079|NCT01106079|Drug|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
59080|NCT01106079|Drug|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
59081|NCT01106092|Biological|GSK2036874A vaccine|Intramuscular, single dose
59082|NCT01106092|Biological|Zilbrix™/Hib vaccine|Intramuscular, single dose
59083|NCT01106092|Biological|Poliorix™|Intramuscular, single dose
59084|NCT01106118|Drug|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
59085|NCT01106131|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
59086|NCT01106131|Drug|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
59087|NCT01098721|Drug|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
62570|NCT01116986|Behavioral|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
62571|NCT01116986|Behavioral|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
62572|NCT00036972|Procedure|adjuvant therapy|
63105|NCT01115582|Drug|Cholic acid|The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.
Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child.
63106|NCT01115595|Biological|Mite allergen extract|Dermatophagoides pteronyssinus from ALK company
63107|NCT01115608|Other|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
63108|NCT01115621|Other|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
63109|NCT01115634|Biological|Fibroblast|20 million cell in three injection
63110|NCT00036855|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
63111|NCT01115634|Biological|fibroblast and gel|20 million cell in three injection plus filler
63112|NCT01115634|Biological|Placebo|Injection of filler and cell carrier media
63113|NCT01115647|Dietary Supplement|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
63114|NCT01115647|Dietary Supplement|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
62356|NCT01120808|Procedure|Papertape|Application of paper tape to experimental arm
62357|NCT01120821|Drug|Gleevec|400 mg once daily for 12 months
62358|NCT01123096|Other|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
62359|NCT01123109|Procedure|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
62632|NCT01123759|Other|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
62633|NCT01123772|Drug|INO-8875|eye drops for 14 days in one eye
62634|NCT00037986|Device|Hearing Aids|Hearing aid use
62635|NCT01123772|Other|Placebo control|Matched placebo
62636|NCT01123785|Drug|INO-8875|eye drops for 14 days in one eye
62637|NCT01123785|Drug|Placebo|Matched vehicle-control
62638|NCT01123798|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
62639|NCT01123811|Drug|Cetuximab IF|Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
62640|NCT01123824|Drug|CLOPIDOGREL|Pharmaceutical form: tablets
Route of administration: oral
62641|NCT01123824|Drug|placebo|Pharmaceutical form: matching tablets
Route of administration: oral
62642|NCT01123837|Other|Intravenous fluid|The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.
The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery.
62643|NCT01123837|Other|D5LR or lactated ringers|The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.
The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction.
62644|NCT01123850|Device|Copios|Bone Void Filler
62427|NCT01120964|Drug|Intravenous L-Citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass, the addition of L-citrulline at a concentration of 200 umol/L or placebo to the filtration and hemoconcentration fluid utilized during cardiopulmonary bypass in addition to a 20mg/kg bolus 30 minutes after separation from cardiopulmonary bypass immediately followed by a continuous infusion of 9mg/kg/hr IV, and ending at 48 hours continuous infusion or discharge from the PCCU.
62428|NCT01120964|Drug|Placebo of Intravenous L-Citrulline|Placebo of Intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
62429|NCT01120990|Other|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
62430|NCT01121003|Behavioral|weight maintenance, low sugar diet|
62706|NCT01121497|Drug|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
62707|NCT01123863|Other|Brigance Preschool Screen -II|Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
62708|NCT01123863|Other|Brigance Preschool Screen -II|Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.
The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian.
62709|NCT01123876|Drug|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
62710|NCT01123889|Biological|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
62711|NCT01123889|Drug|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
62712|NCT01123902|Device|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
62713|NCT01123902|Device|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
59088|NCT01098734|Drug|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
59395|NCT01101672|Procedure|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
59396|NCT01101685|Drug|Escitalopram|7 days dosing of 10mg per day
59397|NCT01101685|Drug|Placebo|7 days dosing at 10mg daily
59398|NCT01101698|Drug|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
59399|NCT01101698|Drug|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
59400|NCT01101724|Behavioral|Mandated Rest, Intervention|In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating "No return to school" and "No Physical Activity" for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury.
59401|NCT01101737|Other|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
59402|NCT01101750|Biological|Quadrivalent HPV for types 6, 11, 16 and 18|Gardasil 0.5ml IM injection on day one, month 2, and month 6. Serum samples on day one, month 3 and month 7
59403|NCT01101776|Drug|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
59404|NCT00035100|Drug|epothilone b|
59405|NCT01101789|Procedure|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
59406|NCT01101789|Procedure|regular sutures for surgical wound closure|
59407|NCT01101802|Drug|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
59408|NCT01101802|Drug|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
59409|NCT01101815|Drug|Oral Naltrexone (ON)|48 weeks of oral naltrexone as compared to 48 weeks of implantable naltrexone
59410|NCT01101815|Drug|Implantable Naltrexone (IN)|48 weeks of implantable naltrexone as compared with 48 weeks of oral naltrexone
63115|NCT01115647|Behavioral|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
63116|NCT01115660|Behavioral|stroke education|call by medication coach 2 weeks after hospital discharge
63117|NCT01115673|Drug|Acetaminophen|Acetaminophen Caplet - single dose
63118|NCT01115673|Drug|Placebo Control|0 mg Caplet - single dose
63119|NCT01115686|Drug|Branched-chain aminoacids|Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.
The treatment will last 3 weeks.
63140|NCT01108237|Other|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
63141|NCT01108237|Device|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
63142|NCT01108250|Genetic|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
63143|NCT01108263|Drug|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
63144|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered intradermally.
63145|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
63146|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
63147|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
63148|NCT01110590|Drug|Placebo|Placebo
62645|NCT00037999|Procedure|Testosterone supplement|
62646|NCT01116986|Drug|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|If randomized to this condition:
After the target quit day:
Patch:
IF > 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.
IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.
Gum:
IF > 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks.
62647|NCT01116986|Drug|Pre-Quit Nicotine Gum|If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):
Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day.
62648|NCT01116986|Drug|Pre-Quit Nicotine Patch|If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):
Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day.
62893|NCT01107665|Drug|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
62894|NCT01107678|Other|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
62895|NCT01107691|Other|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
62896|NCT01107704|Behavioral|Family Support Intervention|Multifaceted family support intervention
62897|NCT01107717|Drug|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c < 6.5%
62898|NCT01107717|Drug|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c < 6.5%
62899|NCT01107730|Drug|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
62900|NCT00035932|Drug|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
62901|NCT01107730|Drug|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
62902|NCT01110304|Device|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
62903|NCT01110317|Drug|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
62714|NCT01123915|Biological|Opal-HIV-Gag(c) Low Dose|
62715|NCT01123915|Biological|Opal-HIV-Gag(c) Medium dose|
62716|NCT01123915|Biological|Opal-HIV-Gag(c) High dose|
62717|NCT00038012|Drug|Thrombopoietin|
62718|NCT01123915|Other|Dimethyl Sulfoxide|
62719|NCT01123928|Behavioral|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
62720|NCT01123941|Biological|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
62957|NCT01107743|Drug|Amlodipine/Atorvastatin|Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.
Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.
For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.
Amlodipine
Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.
Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin
Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.
Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily.
62958|NCT01107756|Drug|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
62959|NCT01107782|Drug|sildenafil|50 mg TDS orally until birth
62960|NCT01107782|Drug|placebo|50mg tid
62961|NCT01107795|Procedure|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
62962|NCT01107808|Drug|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
62963|NCT01107808|Drug|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
62964|NCT01107821|Device|Engenex™ pump and Bio-Dome™ Wound Dressing|Engenex™ pump and Bio-Dome™ Wound Dressing is used.
62965|NCT00035932|Drug|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
62966|NCT01107847|Procedure|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
59411|NCT01101841|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
59412|NCT01101841|Drug|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
59413|NCT01101867|Drug|Aspart|fixed dose
59720|NCT01104844|Drug|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
59721|NCT01104844|Drug|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
59722|NCT01104844|Drug|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
59723|NCT01104844|Drug|Placebo|2 placebo tablets
59724|NCT01104857|Procedure|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
59725|NCT01097278|Other|placebo|Given orally
59726|NCT01097304|Drug|Ursodiol|Given PO
59727|NCT01097304|Other|Laboratory Biomarker Analysis|Correlative studies
59728|NCT01097317|Drug|carboplatin|
59729|NCT01097317|Drug|vinorelbine tartrate|
59730|NCT01097317|Other|neuromuscular electrical stimulation|
59731|NCT01097317|Other|physiologic testing|
59732|NCT00000919|Drug|Stavudine|
59733|NCT00034541|Biological|cetuximab|400 mg/m2 i.v. over 120 minutes
59734|NCT01097317|Procedure|fatigue assessment and management|
59735|NCT01097317|Procedure|quality-of-life assessment|
59736|NCT01097330|Procedure|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
59737|NCT01097330|Drug|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
59738|NCT01097343|Drug|clopidogrel 75 mg|75 mg once daily
63149|NCT01110603|Drug|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
63150|NCT01110603|Drug|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
63151|NCT01110603|Drug|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
63152|NCT01110603|Drug|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
63153|NCT01110616|Drug|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
63154|NCT00036309|Drug|Duloxetine Hydrochloride|
63155|NCT01110616|Drug|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
63156|NCT01110616|Drug|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
63157|NCT01110629|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
63158|NCT01110629|Drug|Placebo|daily dose: 3 tablets TID for 8 weeks.
63454|NCT01114022|Device|experimental 3|oeso pharyngeal device
63455|NCT01114022|Device|Active comparator|oeso pharyngeal device
63456|NCT01114035|Genetic|blood samples and skin biopsies|to detect mutations
63457|NCT01114035|Genetic|Skin biopsies|to detect mutations
63458|NCT00036855|Other|laboratory biomarker analysis|Correlative studies
63459|NCT01115868|Drug|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
63460|NCT01115894|Drug|Naltrexone|100 mg oral dosage daily for 12 weeks
63461|NCT01115894|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
63462|NCT01115894|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
63463|NCT01115894|Drug|Placebo|Placebo
63464|NCT01115907|Device|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
63465|NCT01115920|Drug|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
62904|NCT01110330|Drug|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
62905|NCT01110330|Drug|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
62906|NCT01110330|Drug|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
62907|NCT01110343|Behavioral|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
62908|NCT00036244|Drug|RG1068 (Synthetic Human Secretin)|
63214|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
63215|NCT01108341|Drug|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
63216|NCT01108341|Drug|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
63217|NCT01108380|Procedure|Plasma pheresis, Right portal vein embolization|Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.
Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.
63218|NCT01108393|Drug|Agomelatine A|Agomelatine 25 mg film-coated tablet
Agomelatine 2x25mg film-coated tablet
63219|NCT01108393|Drug|Placebo|Placebo
63220|NCT01108406|Device|Sonitus SoundBite System|Non Surgical Bone Conduction Device
63221|NCT01108406|Device|SoundBite Hearing System|
63222|NCT01108419|Other|Fermented dairy product|
63223|NCT01108419|Other|milk-based non-fermented dairy product|
63224|NCT01108432|Other|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
63225|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
63226|NCT01108445|Drug|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
62967|NCT01107860|Device|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
62968|NCT01107860|Device|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
62969|NCT01107886|Drug|Saxagliptin|5 mg or 2.5 mg once daily
62970|NCT01107886|Drug|Placebo|
62971|NCT01107899|Drug|clopidogrel|taken orally, day one, single dose
62972|NCT01107899|Drug|prasugrel|taken orally, day one, single dose
62973|NCT01107912|Drug|prasugrel|administered orally, daily for 12 days
62974|NCT01107912|Drug|clopidogrel|Administered orally, daily for 12 days
62975|NCT01107925|Drug|prasugrel|Administered orally, daily for 12 days
63307|NCT01116180|Drug|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
63308|NCT01116193|Drug|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
63309|NCT01116206|Drug|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
63310|NCT01116206|Drug|Placebo|1 tablet, orally once dailyfor 12 weeks
63311|NCT01116219|Biological|bevacizumab, erlotinib|Bevacizumab 7.5 mg/kg i.v. every 3 weeks and
Erlotinib 150 mg p.o. daily until progression.
63312|NCT01108484|Behavioral|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
63313|NCT01108497|Procedure|Bone Marrow Aspiration|
63314|NCT01108510|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
63315|NCT01108510|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
63316|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
63317|NCT01108510|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
59739|NCT01097343|Drug|Clopidogrel 150 mg|clopidogrel 150 mg
59740|NCT01097356|Dietary Supplement|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
59741|NCT01097382|Drug|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
59742|NCT01097395|Drug|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
59743|NCT01097408|Drug|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
58779|NCT01103349|Drug|BI671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI617800 in patients with symptomatic asthma
58780|NCT01103349|Drug|Placebo|Patients receive placebo capsules and/or encapsulated tablets
58781|NCT01103349|Drug|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI671800 in patients with symptomatic asthma
58782|NCT01103362|Drug|flibanserin|all patients will receive open-label flibanserin 100mg
58783|NCT01103375|Drug|erlotinib hydrochloride|Given PO
58784|NCT01103375|Drug|isotretinoin|Given PO
58785|NCT00035308|Drug|Abetimus sodium (LJP 394)|
58786|NCT01103375|Other|laboratory biomarker analysis|Correlative study
58787|NCT01103375|Genetic|protein expression analysis|Correlative study
58788|NCT01103388|Drug|Rituximab|375 mg/m^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
58789|NCT01103401|Drug|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
58790|NCT01103401|Drug|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
58791|NCT01103414|Drug|Mitoglitazone|50 mg capsules, once daily for 84 days
58792|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
58793|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
58794|NCT01103414|Drug|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
63466|NCT01115933|Device|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
63467|NCT01115946|Drug|ASP1585|oral
63468|NCT01115946|Drug|enalapril|oral
63469|NCT00036868|Biological|trastuzumab|
63470|NCT01115959|Drug|valproic acid|treatment of 1 month dosage of 400 mg BID
63471|NCT01115959|Drug|placebo bid|
63472|NCT01115972|Drug|ASP1585|oral
63473|NCT01115972|Drug|valsartan|oral
63474|NCT01115985|Drug|ASP1585|oral
63475|NCT01115985|Drug|atorvastatin|oral
63476|NCT01115998|Other|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
63477|NCT01115998|Other|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
63478|NCT01116011|Drug|AZD7268|Capsule, Oral, BID
62573|NCT01116986|Behavioral|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
62574|NCT01116986|Behavioral|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
62575|NCT01116986|Drug|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|If randomized to this condition:
After the target quit day:
Patch:
IF > 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.
IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.
Gum:
IF > 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks.
62576|NCT01119222|Drug|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
62577|NCT00037063|Drug|Vitamin E|
63227|NCT01108445|Drug|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
63228|NCT01108458|Drug|Pertuzumab|iv, 840 mg, 420 mg
63229|NCT01108458|Drug|Erlotinib|PO, 150 mg
63230|NCT01108484|Behavioral|Exercise|Supervised exercise: Three 90-minutes sessions per week.
63231|NCT01108484|Behavioral|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
63232|NCT01110720|Drug|Placebo|Placebo Nasal Spray BID IN 52 weeks
63233|NCT01110746|Drug|Viaject 7|100IU/mL administered subcutaneously
63234|NCT01110746|Drug|LISPRO|100IU/mL administered subcutaneously
62360|NCT00037934|Device|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
62361|NCT01123122|Other|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
62362|NCT01123135|Drug|Estrogen cream|1gm of estrogen vaginal cream [EVC] at bed time 3 times a week
62363|NCT01123135|Drug|Placebo|Placebo
62364|NCT01123148|Device|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
62365|NCT01123161|Device|hypothermia|Hypothermia is induced using the Celsius Control™ System
62366|NCT01123161|Other|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
62367|NCT01123174|Behavioral|ALGOS algorithm of case management|If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a "chart resource" (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.
If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt.
62368|NCT01123187|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
62369|NCT01123200|Device|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
63318|NCT01108510|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
63319|NCT01108510|Drug|Placebo to match COBI|Placebo to match COBI administered orally once daily
63320|NCT01108510|Drug|Placebo to match RTV|Placebo to match RTV administered orally once daily
63321|NCT01108523|Device|HP828-101|
63322|NCT01108536|Device|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
63323|NCT01108549|Dietary Supplement|Ribose|Ribose 5 grams PO TID was taken daily
63324|NCT01108562|Drug|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
63325|NCT01108562|Other|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
63326|NCT01108575|Other|IMST|inspiratory muscle strength training
63327|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
63328|NCT01108575|Other|Sham IMST|sham inspiratory muscle strength training
62431|NCT01121003|Behavioral|weight maintenance, high fructose diet|
62432|NCT01121003|Behavioral|weight maintenance, high fructose diet+ exercise|
62433|NCT01121016|Drug|Montelukast|10mg, qn, 4 weeks
62434|NCT00000929|Drug|Nonoxynol-9|
62435|NCT00037609|Drug|Capecitabine|1000 mg/m^2 taken by mouth twice daily.
62436|NCT01121016|Other|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
62437|NCT01121029|Procedure|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
62438|NCT01121042|Drug|Ondansetron|8mg per day oral capsule
58795|NCT01103414|Drug|Placebo|Placebo, once daily for 84 days
58796|NCT00035321|Drug|Olanzapine|
58797|NCT01103427|Device|Internet-based behavioral coaching|Those in the "active comparator arm" will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile.
58798|NCT01103427|Device|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
58799|NCT01103427|Device|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
59089|NCT01098747|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
59090|NCT01098747|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
59091|NCT01098747|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
59092|NCT01098747|Drug|Placebo|Single-dose of placebo
59093|NCT01098760|Drug|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
59094|NCT01098786|Biological|Cell-derived A/H1N1 influenza HA vaccine|Single group vaccinated
59095|NCT01098812|Device|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
59096|NCT00034736|Drug|Levofloxacin|
59097|NCT01098812|Device|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
59098|NCT01098825|Other|web-based survey|Anonymous web-based survey
59099|NCT01098838|Drug|LCL161|
59100|NCT01098864|Device|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
59101|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose
62578|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
62579|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
62580|NCT01119261|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
62581|NCT01119261|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
62582|NCT01119274|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
62583|NCT01119274|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
62584|NCT01119287|Drug|Dexamethasone 0.1% ophthalmic suspension|Maxidex
62585|NCT01119287|Drug|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
62586|NCT01119287|Other|Inactive ingredients, used as placebo|Tears Naturale II
62587|NCT01119300|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
62588|NCT00037089|Drug|UFT (Tegafur/Uracil)|
62589|NCT01119300|Other|Standard care|Standard care
62590|NCT01119313|Drug|LAS 41002|LAS 41002, once daily
63120|NCT01115686|Drug|Placebo|Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.
The treatment will last 3 weeks.
63121|NCT00036855|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
63122|NCT01108107|Biological|Panitumumab|9 mg/kg intravenously on day 1 of a 3-weekly cycle
63123|NCT01108120|Drug|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
63124|NCT01108120|Drug|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
63125|NCT01108133|Drug|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
63126|NCT01108133|Drug|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
62370|NCT01123226|Procedure|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
62371|NCT00037934|Other|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
62372|NCT01123226|Procedure|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
62373|NCT01123239|Behavioral|Coached Care|Coached Care pairs patients with linguistically and ethnically matched peer "coaches", who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care.
62374|NCT01116570|Other|Control|No intervention
62649|NCT01116986|Drug|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|If randomized to both the Prequit Patch and Prequit Gum Conditions:
Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day.
62650|NCT01116999|Procedure|light guided tracheal intubation|Tracheal intubation light guided technique.
62651|NCT01117012|Drug|Ivacaftor|
62652|NCT01117025|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
62653|NCT00036972|Procedure|conventional surgery|
62654|NCT01117025|Procedure|Circumferential PVI+renal denervation|The procedure of AF ablation is the same like in the circumferential PV isolation.
After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
62655|NCT01117038|Drug|avanafil and enalapril|enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
62656|NCT01117038|Drug|avanafil and amlodipine|amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
62439|NCT01123239|Behavioral|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
62440|NCT01123252|Dietary Supplement|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
62441|NCT01123252|Dietary Supplement|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
62442|NCT01123265|Drug|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
62443|NCT01123265|Drug|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
62444|NCT01123278|Drug|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
62445|NCT01123278|Drug|Placebo|Placebo transdermal gel (5 gr)
62446|NCT01123291|Procedure|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
62447|NCT00000935|Biological|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
62448|NCT00037947|Procedure|Hearing in Multiple Sclerosis|
62449|NCT01123291|Procedure|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
62721|NCT01123941|Biological|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
62722|NCT01123954|Biological|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
62723|NCT01123967|Other|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
62724|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
62725|NCT01117116|Drug|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
62726|NCT01117116|Drug|budesonide and formoterol|80/4.5 two puffs twice daily
62727|NCT00036972|Procedure|neoadjuvant therapy|
59102|NCT01098877|Drug|PF-04634817|Oral solution, 1mg, single dose
59103|NCT01098877|Drug|PF-04634817|Oral solution, 3mg, single dose
59104|NCT01098877|Drug|PF-04634817|Oral solution, 10mg, single dose
59105|NCT01098877|Drug|PF-04634817|Oral solution, 30mg, single dose
59106|NCT01098877|Drug|PF-04634817|Oral solution, 100mg, single dose
59107|NCT00034749|Drug|Risperidone|
59108|NCT01098877|Drug|PF-04634817|Oral solution, 300mg, single dose
59109|NCT01098877|Drug|PF-04634817|Oral solution, 600mg, single dose
59110|NCT01098877|Drug|PF-04634817|Oral solution, 900mg, single dose
59414|NCT01101867|Drug|Aspart|dose based upon carbohydrate intake and total daily requirements
59415|NCT00035113|Drug|epothilone b|
59416|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
59417|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
59418|NCT01104337|Drug|Placebo|Treatment consisted of two matching placebo tablets three times a day.
59419|NCT01104350|Other|external radiation therapy with gemcitabine|All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.
Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)
Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)
Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)
59420|NCT01104363|Procedure|Snow white plaster 2. Kerr Co. Romulus, MI, USA.|Pick-up, splinted implants impressions.
59421|NCT01104363|Procedure|Primopattern LC gel|Pick-up, splinted implants impressions.
59422|NCT01104363|Procedure|Smart Dentin Replacement.|Pick-up, splinted implants impressions.
59423|NCT01104376|Drug|Efavirenz|In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.
In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
63127|NCT00035958|Drug|Etanercept|
63128|NCT01108133|Drug|Placebo|Placebo
63129|NCT01108146|Drug|Arm 1 Hydrocortisone 10 mg|Group 1: Administration of Hydrocortisone and/or Placebo in the following order:
1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone
63130|NCT01108146|Drug|Arm 2 Hydrocortisone 30 mg|Drug: Hydrocortisone 30 mg
Group 2: Administration of Hydrocortisone and/or Placebo in the following order:
1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo
63131|NCT01108159|Procedure|Blood Draw|
63132|NCT01108159|Procedure|Skin Biopsy|
63133|NCT01108172|Other|Virtual Ward|A multidisciplinary team to optimize medical and social care for patients residing in their own homes
63134|NCT01108172|Other|Usual care|The usual care provided to patients after discharge from hospital
63135|NCT01108198|Drug|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
63136|NCT01108198|Drug|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
63137|NCT01108211|Device|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
63138|NCT00035971|Drug|raloxifene HCI and alendronate Na|
63139|NCT01108224|Behavioral|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
63159|NCT01110642|Drug|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
63160|NCT01110655|Other|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
63161|NCT01110655|Other|Oral hypertonic saline|Oral 100mL bolus of 3% saline
63162|NCT01110668|Drug|Nilotinib|
63163|NCT01110681|Device|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|Submucosal injections. Re-treatment is allowed one month after initial treatment if the subject is still incontinent.
63164|NCT01110707|Drug|Recombinant human follicle stimulating hormone|After the pituitary desensibilization, all subjects were administered 300-450 IU of r-hFSH per day sc; afterwards, the dosage was adjusted according to the ovarian response. The administration of r-hFSH was terminated within the 36 hours prior to the administration of r-hCG.
63165|NCT00036335|Drug|Duloxetine Hydrochloride|
62657|NCT01117051|Drug|placebo|placebo
62658|NCT01117051|Drug|prucalopride|1 or 2 mg prucalopride once daily before breakfast
62659|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
62660|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
62661|NCT01119378|Other|Dual isotope technique|Dual isotope technique using stable isotopes
62662|NCT01119391|Behavioral|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
62663|NCT01119417|Drug|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
62909|NCT01110343|Behavioral|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
62910|NCT01110356|Drug|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
62911|NCT01110356|Other|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
62912|NCT01110369|Dietary Supplement|Protein drink|Protein drink twice a day during 6 months.
62913|NCT01110369|Other|Resistance exercise training|Resistance exercise training twice per week during 6 months.
62914|NCT01110369|Dietary Supplement|Placebo drink|Placebo drink twice a day during 6 months.
62915|NCT01110382|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
62916|NCT01110382|Drug|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
62728|NCT01117129|Drug|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
62729|NCT01117129|Drug|placebo|i.v. infusion on day 1 and 15
62730|NCT01117129|Drug|methotrexate|10-25 mg weekly
62731|NCT01117129|Drug|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
62732|NCT01117181|Drug|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
62733|NCT01117181|Drug|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
62734|NCT01117181|Other|Psychosocial intervention|The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.
The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:
Review and adjustment of the patient and caregiver supportive care plans
Emotional support and opportunity to ventilate feelings
Counseling regarding specific caregiving skills
Assistance with problem solving of specific issues that the caregiver brings to the sessions
Answers for questions regarding the educational materials
The educational materials will consist of a copy of the book The 36-Hour Day
62735|NCT01117194|Device|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
62736|NCT01117220|Drug|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
62737|NCT01117220|Drug|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
62976|NCT00035945|Drug|ISIS 14803|
62977|NCT01107925|Drug|clopidogrel|Administered orally, daily for 12 days
62978|NCT01110382|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
62979|NCT01110408|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
62980|NCT01110408|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
59424|NCT01104376|Drug|voriconazole|In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.
In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
59425|NCT01104389|Device|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
59426|NCT00035425|Drug|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
59427|NCT01104402|Device|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
59428|NCT01104415|Drug|Low Dose LX1606 - Day 1 (start)|150 mg LX1606 given three times daily for 14 days
59429|NCT01104415|Drug|Mid-low dose LX1606 - Day 15 (start)|250 mg LX1606 given three times daily for 14 days
59430|NCT01104415|Drug|Mid-high dose LX1606 - Day 29 (start)|350 mg LX1606 given three times daily for 14 days
59431|NCT01104415|Drug|High dose LX1606 - Day 43 (start)|500 mg LX1606 given three times daily for 14 days
59744|NCT00034541|Drug|paclitaxel|225 mg/m2, infusion
59745|NCT01097408|Drug|Placebo comparator|Placebo capsules
59746|NCT01097421|Drug|Pramipexole Extended Release|
59747|NCT01097434|Device|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
59748|NCT01097434|Device|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
59749|NCT01097460|Drug|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
59750|NCT01097473|Procedure|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
59751|NCT01097486|Biological|NeoFuse|Single Dose NeoFuse Surgical Implantation
59752|NCT01097486|Procedure|Allograft|Single Dose Allograft Surgical Implantation
59753|NCT01099930|Other|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.
Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant
63166|NCT01110707|Drug|Recombinant human luteinizing hormone (Luveris)|On the sixth day of COS, subjects assigned to the group r-hFSH + r-hLH were administered 150 IU r-hLH per day sc while they continue r-hFSH treatment with a separate injection. Administration of r-hLH was also suspended 36 hours before administering r-hCG.
63167|NCT01110720|Drug|Davunetide|Davunetide Nasal Spray 30 mg BID IN 52 weeks
63168|NCT01113385|Drug|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
63169|NCT01113398|Drug|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
63170|NCT01113398|Drug|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
63171|NCT01113411|Device|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
63172|NCT01113411|Other|Early and intensive exercise program|A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.
The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.
The patient will complete a daily diary to validate the frequency and intensity of the exercises.
63173|NCT01113411|Other|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
63174|NCT01113424|Drug|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
62314|NCT01125462|Other|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
62315|NCT01125475|Device|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
62316|NCT01125488|Device|LNG-IUS|levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
62317|NCT01125488|Drug|GnRH agonist (triptorelin)|GnRH agonist (triptorelin 3.75 mg, sc q28day)
62318|NCT01125501|Dietary Supplement|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources [Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)].
62917|NCT01110382|Drug|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
62918|NCT01110382|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
62919|NCT00036257|Drug|CP-461|
62920|NCT01112943|Other|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
62921|NCT01112943|Other|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
62922|NCT01112943|Other|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
62923|NCT01112969|Behavioral|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
62924|NCT01112969|Other|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
62925|NCT01112982|Other|Magnetic Resonance Imaging|An MRI (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
62926|NCT01112982|Other|Plain Radiographs|Plain radiographs of "index joint" will be obtained and reviewed by two independent readers (radiologists)
62927|NCT01112982|Drug|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is > 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
63235|NCT01110772|Device|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
63236|NCT01110772|Device|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
63237|NCT01110785|Biological|panitumumab|
63238|NCT01110785|Drug|simvastatin|
63239|NCT01110785|Other|laboratory biomarker analysis|
63240|NCT00036348|Drug|Aripiprazole|
63241|NCT01110798|Other|intraoperative complication management/prevention|
63242|NCT01110798|Procedure|assessment of therapy complications|
62981|NCT01110408|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
62982|NCT01110408|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
62983|NCT01110408|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
62984|NCT01110421|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
62985|NCT01110421|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
62986|NCT01110421|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
62987|NCT01110421|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
62988|NCT00036270|Drug|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
62989|NCT01110421|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
62990|NCT01110434|Drug|Topiramate|Topiramate (200 mg daily)
62991|NCT01110434|Drug|Placebo|Placebo (daily)
62992|NCT01110447|Drug|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
63329|NCT01108588|Drug|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
63330|NCT01108588|Drug|Aspirin|Aspirin 300 mg daily
63331|NCT01108588|Drug|Clopidogrel|Clopidogrel 75 mg daily
63332|NCT01108588|Drug|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
59754|NCT01099930|Other|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
59755|NCT01099943|Other|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
59756|NCT01099969|Device|Glidescope with Endotrol endotracheal tube|The patients receiving this intervention will be intubated using a Glidescope video laryngoscope with non-styletted Endotrol endotracheal tune
59757|NCT01099969|Device|Glidescope with styletted regular endotracheal tube|The patients receiving this intervention will be intubated using the glidescope videolaryngoscope and regular endotracheal tube with gliderite stylet.
59758|NCT01099969|Device|McGrath with Endotrol|The patients in this intervention will be intubated using McGrath videolaryngoscope and non-stlyetted Endotrol endotracheal tube
59759|NCT01099969|Device|McGrath with Styletted regular Endotracheal tube|The patients receiving this intervention will be intubation using McGrath videolaryngoscope and regular endotracheal tube with gliderite stylet.
59760|NCT01099995|Other|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
59761|NCT00034853|Drug|meloxicam oral suspension|
59762|NCT01099995|Other|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
58800|NCT01105572|Other|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
58801|NCT01105585|Device|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
58802|NCT01105585|Device|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
58803|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
58804|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
58805|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
58806|NCT00035542|Drug|glyburide|
62319|NCT01125514|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
62320|NCT01125514|Drug|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
62321|NCT01125514|Drug|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
62322|NCT01125514|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet
62323|NCT01125527|Biological|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
62324|NCT00037050|Drug|Vancomycin|
62325|NCT01118780|Drug|Duloxetine|Administered by mouth, daily for 10 weeks
62326|NCT01118780|Drug|Placebo|Administered by mouth, daily for 10 weeks
62327|NCT01118793|Drug|Clopidogrel|150 mg dosage of Clopidogrel for 7 to 10 days.
62328|NCT01118819|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
62329|NCT01118845|Drug|SyB L-0501|The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.
SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation.
62330|NCT01118845|Drug|Rituximab|The administration of rituximab at 375 mg/m^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
62331|NCT01118871|Drug|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
62332|NCT01118871|Drug|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
62333|NCT01118884|Drug|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
62591|NCT01119313|Drug|Active|Active, once daily
62592|NCT01119326|Procedure|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
62593|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 1, once daily
62594|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 2, once daily
62595|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 3, once daily
63243|NCT01110798|Procedure|gastrointestinal complications management/prevention|
63244|NCT01110798|Procedure|quality-of-life assessment|
63245|NCT01110798|Procedure|therapeutic conventional surgery|
63246|NCT01110811|Procedure|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
63247|NCT01110824|Drug|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
63248|NCT01110837|Other|Allergen|Allergen nasal challenge
63249|NCT01110837|Other|Placebo challenge|Placebo nasal challenge
63250|NCT01110876|Drug|Vorinostat|Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.
Phase II Dose: MTD from Phase I.
63251|NCT00036361|Drug|Aripiprazole|
63252|NCT01110876|Drug|Erlotinib|Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.
Phase II Dose: MTD from Phase I.
63253|NCT01110876|Drug|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
63254|NCT01110889|Drug|Agomelatine (AGO178C)|
63255|NCT01110889|Drug|Agomelatine (AGO178C)|
63256|NCT01110889|Drug|Placebo|
63257|NCT01110902|Drug|Agomelatine (AGO178C)|
63258|NCT01110902|Drug|Placebo|
62375|NCT01116583|Drug|Gabapentin|Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)
Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)
Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)
Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)
Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)
Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)
62376|NCT00036933|Biological|MUC-2-Globo H-KLH conjugate vaccine|
62377|NCT01116583|Drug|Placebo|Preoperatively (2 hours before surgery): 4 placebo capsules
Postoperative day 1: 1 placebo capsule x 2
Postoperative day 2: 1 placebo capsule x 3
Postoperative day 3: 1 placebo capsule x 4
Postoperative day 4: 1 placebo capsule x 4
Postoperative day 5: 1 placebo capsule x 4
62378|NCT01116596|Drug|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
63333|NCT01108601|Drug|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
63334|NCT01108614|Behavioral|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
63335|NCT01110915|Device|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
63336|NCT01110915|Device|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
63337|NCT01110928|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
63338|NCT00036374|Drug|Infliximab|
63339|NCT01110941|Drug|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40~60mg, Bid,p.o., day1~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
63340|NCT01110954|Drug|PD L 506|Two different doses will be compared
63341|NCT01110980|Other|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
63342|NCT01110980|Other|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
63343|NCT01111006|Device|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
62450|NCT01123304|Drug|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
62451|NCT01123317|Drug|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
58807|NCT01105611|Drug|Raltegravir|400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
58808|NCT01105611|Drug|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
58809|NCT01105624|Drug|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
58810|NCT01105624|Drug|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
58811|NCT01105637|Behavioral|Augmented Exercise Program|12 week (3 x per week) exercise prescription
58812|NCT01105650|Drug|Fludarabine|Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).
58813|NCT01105650|Drug|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
58814|NCT01105650|Drug|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
58815|NCT01105650|Biological|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10^7 cells/kg will be given.
58816|NCT01105650|Drug|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m^2 3 times per week for 6 doses).
58817|NCT00035555|Drug|Belatacept|Solution, intravenous
58818|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
59111|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every second week
59112|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every month
59113|NCT01101243|Other|Control group|No intervention
59114|NCT01101269|Drug|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
59115|NCT01101269|Drug|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
62596|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 4, once daily
62597|NCT01119339|Drug|LAS 41004|LAS 41004 , dosage 5, once daily
62598|NCT01119339|Drug|LAS 41004 dosage 6|LAS 41004, dosage 6, once daily
62599|NCT00037102|Drug|interferon beta 1a|
62600|NCT01119339|Drug|Placebo|Placebo, once daily
62601|NCT01119339|Drug|Reference|Reference, once daily
62602|NCT01119352|Drug|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
62603|NCT01119352|Drug|Placebo|Oral suspension, once daily. Totally 8 doses
62604|NCT01119365|Other|Bright light|Bright (1000 lux) light
62605|NCT01121237|Drug|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
62606|NCT01121250|Behavioral|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
62607|NCT01121250|Behavioral|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
62608|NCT00037635|Drug|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
62609|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
62610|NCT01121276|Drug|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
62611|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
62612|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
62854|NCT01112891|Drug|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
62855|NCT01112917|Device|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
62856|NCT01112917|Procedure|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
62379|NCT01116609|Drug|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
62380|NCT01116622|Drug|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
62381|NCT01116622|Drug|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
62382|NCT01116635|Drug|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
62383|NCT01116648|Drug|Cediranib Maleate|Given PO
62384|NCT01116648|Other|Laboratory Biomarker Analysis|Correlative studies
62385|NCT01116648|Drug|Olaparib|Given PO
62386|NCT01116648|Other|Pharmacological Study|Correlative studies
62387|NCT00036933|Biological|QS21|
62388|NCT01116661|Drug|5-Aminolevuline Acid|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
62389|NCT01116687|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
62390|NCT01116687|Other|laboratory biomarker analysis|Correlative studies
62391|NCT01116700|Drug|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
62392|NCT01116713|Drug|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
62664|NCT01119417|Drug|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
62665|NCT01119417|Drug|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
62666|NCT00037102|Drug|methotrexate|
62667|NCT01119417|Drug|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
62668|NCT01119417|Drug|Saline|2-3 IV saline infusions for 15 min each.
62669|NCT01119430|Drug|DU125530|20mg/twice a day
62452|NCT01123330|Behavioral|Motivational Interviewing|
62453|NCT01123343|Device|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
62454|NCT01123356|Drug|Ofatumumab|Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)
Treatment to be administered for up to 6 cycles
62455|NCT01123356|Drug|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
62456|NCT01123382|Device|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
62457|NCT01123382|Other|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
62458|NCT01116726|Behavioral|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
62459|NCT01116739|Device|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
62460|NCT01116739|Behavioral|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
62461|NCT00036946|Biological|ziv-aflibercept|
62462|NCT01116739|Other|Dental services delivered by the Indian Health Service.|
62463|NCT01116752|Other|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children <1 year old and 25% of those >1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
62464|NCT01116765|Other|no stimulation of the oral structure|
62465|NCT01116765|Other|stimulation of the oral structure|
62466|NCT01116778|Biological|eN-Lac®|One capsule with 2x10^9 colony forming unit (cfu) LP GMNL-32, once daily, po
62738|NCT00036985|Drug|cyclophosphamide|
62739|NCT01117233|Drug|PF-04427429|single intravenous infusion of 10 mg PF-04427429 or placebo
59116|NCT01101282|Device|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
59117|NCT01101308|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
59118|NCT01101308|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
59119|NCT01101321|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
59120|NCT01101321|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
59121|NCT00000920|Drug|Lamivudine|
59122|NCT00035035|Drug|ALIMTA|
59123|NCT01101334|Drug|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
59124|NCT01101334|Drug|erlotinib|Erlotinib; One 150mg tablet administered once daily
59125|NCT01101347|Device|Aneurysm-Embolization System|
59126|NCT01101360|Device|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
59127|NCT01101360|Device|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
59128|NCT01101360|Device|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
59129|NCT01101386|Drug|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
59432|NCT01104415|Drug|4-Week Open Label Dose Extension|Patients will enter 4-week extension period at optimal dose once achieved, based upon clinical response criteria and/or observation of dose-limiting toxicity.
59433|NCT01104415|Drug|72-Week Open Label Dose Extension|Upon completion of the 4-week stable-dose period, eligible subjects will have the option to continue treatment for an additional 72 weeks.
59434|NCT01104428|Drug|Placebo|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
59435|NCT01104428|Drug|"ziying" granules|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
59436|NCT01106638|Behavioral|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
62857|NCT00000923|Drug|Didanosine|
62858|NCT00036647|Drug|Tarceva (erlotinib HCl, OSI-774 )|
62859|NCT01115179|Drug|Saline|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
62860|NCT01115192|Procedure|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
62861|NCT01115192|Procedure|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
62862|NCT01115205|Behavioral|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
62863|NCT01115205|Behavioral|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
62864|NCT01115218|Procedure|Trabeculectomy|Trabeculectomy with mitomycin C
62865|NCT00036816|Biological|tyrosinase peptide|
62866|NCT01115244|Drug|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
62867|NCT01115257|Procedure|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
62868|NCT01115257|Procedure|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
62869|NCT01115270|Other|Non-invasive measures|assessment of cerebrovascular fluid movement
62870|NCT01115283|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
62871|NCT01115283|Behavioral|Video Games|Research participants will be asked to play "off-the-shelf" video games in our laboratory for a period of time (2 hrs/day, 5 days/week).
62872|NCT01115283|Behavioral|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
62873|NCT01115296|Dietary Supplement|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
63175|NCT01113424|Drug|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
62670|NCT01119430|Drug|Placebo|Similar pill as active comparator twice a day
62671|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
62672|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
62673|NCT01119456|Biological|IMC-RON8|5 mg/kg intravenously (i.v.)
Once a week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 1
62674|NCT01119456|Biological|IMC-RON8|10 mg/kg intravenously (i.v.)
Once a week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 2
62675|NCT01119456|Biological|IMC-RON8|15 mg/kg intravenously (i.v.)
Once a week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 3
62676|NCT01119456|Biological|IMC-RON8|15 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 4
62677|NCT00037115|Drug|interferon beta 1a|
62678|NCT01119456|Biological|IMC-RON8|20 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 5
62679|NCT01119456|Biological|IMC-RON8|25 or 30 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 6
62680|NCT01119456|Biological|IMC-RON8|30, 35, or 40 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 7
62681|NCT01119456|Biological|IMC-RON8|20 or 25 mg/kg intravenously (i.v)
Once every week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 8
62682|NCT01119469|Behavioral|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
62683|NCT01119482|Biological|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
62684|NCT01119508|Drug|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
62685|NCT01119508|Drug|Temozolomide|Induction Phase, 200 mg/m^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
62928|NCT01112982|Drug|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
62929|NCT01112995|Dietary Supplement|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
62930|NCT00036660|Drug|SarCNU|
62740|NCT01117233|Drug|PF-04427429|single intravenous infusion of 30 mg PF-04427429 or placebo
62741|NCT01117233|Drug|PF-04427429|single intravenous infusion of 100 mg PF-04427429 or placebo
62742|NCT01117233|Drug|PF-04427429|single intravenous infusion of 300 mg PF-04427429 or placebo
62743|NCT01117233|Drug|PF-04427429|single intravenous infusion of 1000 mg PF-04427429 or placebo
62744|NCT01117246|Device|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
62745|NCT01119521|Biological|BCG|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10^5 colony forming units (CFU) BCG.
62746|NCT01119521|Drug|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets [5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)].
62747|NCT00037115|Drug|methotrexate|
62748|NCT01119534|Drug|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
62749|NCT01119534|Drug|guaiacol suppository|2 times per day
62750|NCT01119534|Drug|Guaifenesin syrup|4.19 mL - 4 in 4 hours
62751|NCT01119547|Other|Exercise in a group|The patient do their individual exercise program in a group.
62752|NCT01119547|Other|Home exercise|The patient exercise their individual program at home during 6 v.
62753|NCT01119560|Other|laboratory biomarker analysis|Correlative studies
62754|NCT01119560|Other|questionnaire administration|Ancillary studies
62755|NCT01119573|Genetic|RNA analysis|
62756|NCT01119573|Genetic|microarray analysis|
62757|NCT01119573|Genetic|reverse transcriptase-polymerase chain reaction|
62758|NCT00037115|Drug|methylprednisolone|
62759|NCT01119573|Other|laboratory biomarker analysis|
62760|NCT01119586|Genetic|DNA analysis|
62761|NCT01119586|Genetic|genetic linkage analysis|
59437|NCT01106651|Drug|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
59438|NCT01106651|Drug|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
59439|NCT00035633|Drug|Entecavir|
59440|NCT01106651|Drug|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, metformin, insulin [all types]) and their combinations (sulfonylurea agent and insulin [all types], metformin and insulin [all types], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]) are used as per protocol specifications.
59441|NCT01106651|Drug|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
59442|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
59443|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
59444|NCT01106677|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
59445|NCT01106677|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
59446|NCT01106677|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
59447|NCT01106677|Drug|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
59448|NCT01106690|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
59449|NCT01106690|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
59450|NCT00035789|Drug|Entecavir|
59763|NCT01100008|Procedure|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
59764|NCT01100021|Drug|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
59765|NCT01100021|Drug|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
59766|NCT01100034|Drug|Etanercept|Expected duration of 24 weeks as one course
63176|NCT01113437|Drug|Omalizumab|Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.
Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE.
63177|NCT01113437|Drug|Placebo|Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.
Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE.
63178|NCT00036738|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
63179|NCT01113463|Drug|TPI 287|Starting dose of 160 mg/m^2 as a 60-minute (± 10 minutes) intravenous (IV) infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
63180|NCT01113476|Drug|Nab-paclitaxel|Starting dose of 50 mg/m^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
63181|NCT01113476|Drug|Bevacizumab|Starting dose of 5 mg/m^2 on Day 1 + 15 every 28 days (+/- 2 days)
63182|NCT01113476|Drug|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
63183|NCT01113489|Drug|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
63184|NCT01113489|Drug|placebo|1 ml b.i.d.
63185|NCT01113502|Drug|Eltrombopag|
63186|NCT01113515|Drug|Esmolol hydrochloride|
63187|NCT01113515|Drug|Esmolol hydrochloride|
63188|NCT01115699|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
63189|NCT01115712|Drug|Placebo|Placebo (to match pioglitazone 30 mg) once daily
63190|NCT01115712|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
63191|NCT01115712|Drug|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
63192|NCT01115725|Drug|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
63193|NCT01115738|Drug|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
62931|NCT01112995|Dietary Supplement|Sugar pill (placebo)|placebo identical to the active product will be given
62932|NCT01113008|Procedure|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
62933|NCT01113008|Procedure|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
62934|NCT01113021|Device|Photon stimulation by low level laser therapy|
62935|NCT01113034|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
62936|NCT01113034|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
62937|NCT01113047|Drug|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
62938|NCT01113073|Other|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
62939|NCT01113073|Other|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
62940|NCT01113073|Other|passive leg raising test|performing the passive leg raising test
62941|NCT00036686|Dietary Supplement|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
62942|NCT01113086|Device|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
62943|NCT01113099|Other|Academic detailing|Education of physicians by pharmacists regarding indications for statins in diabetic patients
62944|NCT01115322|Drug|Tazarotene Foam with UVA, UVB, and visible light|Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62945|NCT01115322|Drug|Vehicle Foam without irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
63259|NCT01113515|Drug|Esmolol hydrochloride|
63260|NCT00036738|Drug|imatinib mesylate|Given PO
63261|NCT01113515|Drug|Placebo gel|
62762|NCT01119586|Genetic|microarray analysis|
62993|NCT01110447|Other|Placebo|Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
62994|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
62995|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
62996|NCT01110473|Drug|ABT-348 and azacitidine|An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
62997|NCT01110473|Drug|ABT-348|An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
62998|NCT01113125|Drug|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
62999|NCT01113125|Drug|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
63000|NCT01113138|Dietary Supplement|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
63001|NCT01113138|Drug|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
63002|NCT01113151|Dietary Supplement|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
63003|NCT01113151|Other|Placebo|3 placebo tablets daily for 12 weeks
63004|NCT01113164|Drug|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
63005|NCT01113177|Device|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
63006|NCT00036686|Other|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
59767|NCT01100047|Drug|AZD5069|Oral suspension
59768|NCT01100047|Drug|Placebo|Oral suspension
59769|NCT01100060|Drug|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
59770|NCT01100060|Drug|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
59771|NCT01100060|Drug|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
59772|NCT00034853|Drug|naproxen oral suspension|
59773|NCT01100060|Drug|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
59774|NCT01100086|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
59775|NCT01100086|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
59776|NCT01102413|Drug|Iron Sulphate|Oral intake
59777|NCT01102426|Drug|plitidepsin + dexamethasone|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
59778|NCT01102426|Drug|dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
59779|NCT01102439|Drug|Clopidogrel|300 mg loading dose, then 75 mg daily
59780|NCT01102439|Drug|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
59781|NCT01102439|Drug|Aspirin|81 mg daily
59782|NCT00035204|Drug|galantamine|
59783|NCT01102439|Drug|Aspirin|325 mg daily
59784|NCT01102452|Dietary Supplement|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
62835|NCT01117441|Drug|PEG-L-asparaginase|see detailed protocol description
62836|NCT01112787|Drug|Sodium Laural Sulfate|Sodium Laural Sulfate
62837|NCT01112787|Drug|Distilled Water|Distilled Water
62838|NCT01112813|Drug|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
63194|NCT01115738|Drug|Clopidogrel|Loading dose administered once orally.
62334|NCT01118897|Radiation|Tomotherapy|Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)
Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.
Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy.
62335|NCT00037050|Drug|Oxacillin|
62336|NCT01118910|Drug|Vusion|Vusion will be applied to areas of intertrigo
62337|NCT01118923|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
62338|NCT01118923|Dietary Supplement|Placebo|3 placebo-tablets daily for 12 weeks
62339|NCT01118936|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
62340|NCT01118936|Dietary Supplement|Placebo|3 tablets of placebo daily for 12 weeks
62341|NCT01118949|Drug|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
62342|NCT01118962|Drug|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
62343|NCT01120756|Behavioral|Goal-based Self Management|Goal-based Self Management (GBSM) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
62344|NCT01120756|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
63262|NCT01113528|Other|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
63263|NCT01113528|Drug|Sugar pill|3 times daily
63264|NCT01113541|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
63265|NCT01113554|Other|questionnaire administration|
63266|NCT01113554|Behavioral|exercise intervention|
63267|NCT01113554|Procedure|quality-of-life assessment|
63268|NCT01113554|Other|survey administration|
63269|NCT01113554|Procedure|management of therapy complications|
63270|NCT01113554|Procedure|psychosocial assessment and care|
63271|NCT00036738|Drug|dasatinib|Given PO
63272|NCT01113567|Dietary Supplement|Lactose-free milk|3.5 g of lactose
63273|NCT01113567|Dietary Supplement|Whole milk|Whole milk with 24 g lactose
63274|NCT01113580|Biological|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
63275|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
63276|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
63277|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
63278|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
63279|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
63280|NCT01113606|Other|Obagi New-Derm System|
63281|NCT01113606|Other|Standard of Care|
63282|NCT00036738|Drug|nilotinib|Given PO
63283|NCT01113619|Drug|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
63284|NCT01113619|Drug|RP-G28 or placebo|Daily dosing
63007|NCT01113190|Behavioral|Computer-delivered Brief Intervention (CBI)|The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a "decisional balance" exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed.
63344|NCT01111019|Drug|Recombinant human growth hormone (Somatropin)|Recombinant human growth hormone (Somatropin) will be administered at 0.057 mg/kg/day subcutaneous injection for 3 years, 5 years or until near final height is reached, if applicable. Subjects still under treatment after 31 January 2011 will be treated with a dose reduced to 0.035 mg/kg/day until the end of the study.
63345|NCT01111045|Drug|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
63346|NCT01111045|Drug|Placebo|Placebo
63347|NCT01111058|Drug|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
63348|NCT01111058|Other|Placebo|
63349|NCT00036387|Drug|Infliximab|
63350|NCT01111084|Drug|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
63351|NCT01111097|Drug|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
63352|NCT01111110|Device|anti-static then static|Albuterol using static chambers
63353|NCT01113645|Procedure|Cerebral perfusion evaluation|The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
63354|NCT01113658|Device|SNaP Wound Care System|The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.
The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician.
63355|NCT01113671|Drug|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
62839|NCT01112826|Drug|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
62840|NCT01112839|Behavioral|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
62841|NCT01112839|Behavioral|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
62842|NCT01112852|Drug|pantoloc 40 mg|pantoloc iv. infusion per day
62843|NCT01112852|Drug|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
62844|NCT01112865|Device|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
62845|NCT01112865|Device|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
62846|NCT00036634|Drug|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
62847|NCT01112865|Device|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
62848|NCT01112865|Device|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
62849|NCT01112878|Drug|Sugar pill|Dosage form: capsule, by mouth
Dosage: not applicable
Frequency and Dosage:
once in the preoperative holding area and once before discharge from PACU
continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
62850|NCT01112878|Drug|Gabapentin|Dosage form: capsule, by mouth
Dosage: 600 mg
Frequency and duration:
once in the preoperative holding area and once before discharge from PACU
continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
62851|NCT01112878|Drug|Clonidine|Dosage form: capsule, by mouth
Dosage: 0.2 mg
Frequency and duration:
once in the preoperative holding area and once before discharge from PACU
continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
62852|NCT01112891|Drug|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
62853|NCT01112891|Drug|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
62613|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
62614|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
62615|NCT01121289|Drug|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
62616|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
62617|NCT01121289|Drug|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
62618|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
62619|NCT00037635|Drug|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
62620|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
62621|NCT01121302|Drug|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
62622|NCT01121302|Drug|Placebo|
62623|NCT01121328|Biological|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
62624|NCT01121328|Biological|Autologous cord blood transfusion|After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.
Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.
Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.
RBCs will be separated and kept till need (Hb less than 10 gm%).
62625|NCT01121341|Procedure|Vein harvesting|Endoscopic versus conventional vein harvesting
62626|NCT01123577|Other|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
62627|NCT01123616|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
62628|NCT01123655|Drug|APL A12|IND 103860: The study drug APL A12 is a man made (or synthesized) fragment similar to a portion of natural type II collagen, the major collagen found in joint cartilage. Cartilage is the tough, elastic tissue found in various parts of the body, including the joints. The best dose of APL A12 to use in patients with rheumatoid arthritis is not known.
62629|NCT01123681|Device|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
62630|NCT01123694|Other|Survey Study|Survey regarding quality of life
62393|NCT01116713|Drug|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
62394|NCT01116726|Behavioral|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
62395|NCT01118975|Drug|Vorinostat|300 mg 4 days on then 3 days off
As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off.
62396|NCT01118975|Drug|Lapatinib|1,250 mg once daily
62397|NCT01118988|Behavioral|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
62398|NCT00037050|Drug|Dicloxacillin|
62399|NCT01119001|Device|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
62400|NCT01119014|Drug|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
62401|NCT01119014|Drug|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
62402|NCT01119040|Procedure|Natural Orifice Translumenal Endoscopic Surgery|Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG "Rescue" in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG "Rescue" may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery.
62403|NCT01119053|Device|VNS Pulse Model 102|Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.
62404|NCT01119053|Device|VNS Pulse Model 102|Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
62405|NCT01119066|Radiation|total body irradiation|dose of 1375-1500 cGy
62406|NCT01119066|Drug|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
62407|NCT01119066|Drug|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
62408|NCT01119066|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
63356|NCT01113671|Drug|Placebo|includes inactive Ingredients
63357|NCT01113684|Device|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
63358|NCT01113710|Drug|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
63359|NCT01113723|Device|Fiberoptic bronchoscope|Fiberoptic bronchoscope device
63360|NCT00000923|Drug|Aldesleukin|
62467|NCT01116778|Other|Placebo|One placebo capsule, once daily, po
62468|NCT01116791|Procedure|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)
HIPC is administered immediately after CRS
62469|NCT01116804|Procedure|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
62470|NCT01116804|Procedure|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
62471|NCT01116804|Procedure|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
62472|NCT00000924|Drug|Stavudine|
62473|NCT00036959|Drug|ABT-751|
62474|NCT01116804|Procedure|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
62475|NCT01116817|Procedure|Lumbar puncture|Lumbar puncture at week 0
62476|NCT01116817|Procedure|Lumbar puncture|Lumbar puncture at week 0
62477|NCT01116830|Drug|RO4917838|10mg daily orally for 6 weeks
62478|NCT01116830|Drug|placebo|orally daily for 6 weeks
62479|NCT01116830|Drug|standard antipsychotic therapy|as prescribed
62480|NCT01116843|Drug|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
62481|NCT01116856|Other|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
62482|NCT01116882|Procedure|PCI|
63089|NCT01113242|Other|Neuropsychological Assessment|Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,…) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) <16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
63090|NCT01113255|Procedure|bench-evaluation, of three ventilators|to select in-VITRO the most appropriate ventilator for a given pathology.
63091|NCT01113268|Other|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
63092|NCT01113281|Biological|VPM1002 live vaccine|
63093|NCT00036712|Procedure|management of therapy complications|
63094|NCT01113281|Biological|commercially available live vaccine BCG|
63095|NCT01113294|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
63096|NCT01113307|Biological|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
63097|NCT01113320|Drug|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
63098|NCT01113320|Drug|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
63099|NCT01113333|Drug|placebo|Pharmaceutical form:injection
Route of administration: intra-articular
63100|NCT01113333|Drug|SAR113945|Pharmaceutical form:injection
Route of administration: intra-articular
63101|NCT01113346|Drug|Filtrum-STI (lignin hydrolytic)|For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.
For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days.
63102|NCT01113346|Drug|Placebo|For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.
For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days.
62631|NCT01123707|Drug|Aripiprazole/Escitalopram combination therapy|Aripiprazole/Escitalopram combination therapy: 3 mg/10 mg, 3 mg/20 mg, 6 mg/10 mg, 6 mg/20 mg, 12 mg/10 mg or 12 mg/20 mg
62874|NCT01115296|Other|Placebo|Placebo
62875|NCT01115309|Device|XprESS Balloon Device|Procedure completed with the XprESS Balloon Device
62876|NCT00000924|Drug|Nelfinavir mesylate|
62877|NCT00036829|Procedure|pain therapy|
62878|NCT01115322|Drug|Tazarotene Foam without irradiation|Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.
This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62879|NCT01115322|Drug|Tazarotene Foam with UVA and UVB irradiation|Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
62880|NCT01107574|Other|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
62881|NCT01107587|Biological|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
62882|NCT01107587|Biological|Placebo|Oral, two doses.
62883|NCT01107600|Procedure|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
62884|NCT01107613|Other|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader letter sent to the primary care provider outlining the needs of this patient.
62885|NCT01107626|Biological|bevacizumab|Given IV
62886|NCT01107626|Drug|pemetrexed disodium|Given IV
62887|NCT01107639|Biological|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
62888|NCT01107639|Drug|cisplatin|Cisplatin 75 mg/m2 1h infusion d1, 22
Cisplatin 25 mg/m2 1h infusion weekly x5
62889|NCT00035932|Drug|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
62890|NCT01107639|Drug|docetaxel|Docetaxel 75 mg/m2 1h infusion d1, 22
Docetaxel 20 mg/m2 1/2h infusion weekly x5
62409|NCT00037063|Drug|Thiamine hydrochloride|
62410|NCT01119066|Drug|Melphalan|70mg/m2/day x 2
62686|NCT01121354|Drug|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
62687|NCT01121354|Drug|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
62688|NCT01121380|Drug|BL-1021|BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.
Dosage:
Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 & 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.
62689|NCT01121380|Drug|1021|1021
62690|NCT00037648|Drug|Anakinra|anakinra
62691|NCT01121393|Drug|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
62692|NCT01121393|Drug|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related AE, dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
62693|NCT01121406|Drug|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
62694|NCT01121406|Drug|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
62695|NCT01121406|Drug|Topotecan|Patients receive topotecan in 3 or 4 week schedule
62696|NCT01121406|Drug|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
62697|NCT01121406|Drug|BI 6727|Patients receive BI 6727 infusion every 3 weeks
62698|NCT01121432|Procedure|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
62699|NCT01121445|Device|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
62700|NCT01121458|Drug|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP< 80 mmHg), hypertension (SBP>150 mmHg), tachycardia (120 beats per minute), bradycardia (<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
62701|NCT00037648|Drug|Placebo|placebo
64891|NCT01140165|Other|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
64892|NCT01140178|Drug|HPPH|Given IV
64893|NCT01140191|Drug|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
64894|NCT01140204|Device|Implantation of a bare metal stent|Bare Metal Stent
64895|NCT01140217|Drug|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
64896|NCT01140243|Dietary Supplement|LCPUFA|premature infant formula supplemented with LCPUFA
64897|NCT00039312|Other|Papanicolaou test|
64898|NCT01140269|Other|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
64899|NCT01140282|Other|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
64900|NCT01140282|Procedure|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
64901|NCT01140282|Procedure|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
64902|NCT01140282|Behavioral|exercise intervention|12 week exercise intervention
65172|NCT01140711|Procedure|fMRI imaging following visual stimulation of food and non-food images|fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.
fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.
Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 * w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape.
65173|NCT01142986|Behavioral|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
65174|NCT01142999|Drug|Sunflower oil|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
64471|NCT01141933|Other|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
64472|NCT01141933|Other|Usual care|This group receive the usual treatment only.
64473|NCT01141946|Procedure|thoracic ultrasound|All patients will receive pre-operative pleural-based ultrasound during their initial consultation.
64474|NCT01141946|Procedure|pleural aspiration|Before proceeding to pleural aspiration, a radiography of the chest will be performed in order to ascertain the presence of a pleural effusion.
64475|NCT01141972|Dietary Supplement|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
64476|NCT00039377|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
64477|NCT01144416|Biological|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
64478|NCT01144416|Biological|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
64479|NCT01144416|Drug|Placebo for SCH 900962|Supplied as a pre-filled syringe containing an identical solution when
compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall.
64480|NCT01144416|Drug|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
64481|NCT00039481|Drug|cyclophosphamide|Given IV
63595|NCT00036088|Drug|Olanzapine|
63596|NCT01109147|Other|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
63597|NCT01109147|Genetic|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
63746|NCT01109446|Biological|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
63747|NCT01109446|Procedure|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
63748|NCT01109446|Drug|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
63749|NCT01109459|Other|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
63750|NCT00036127|Drug|aripiprazole|
63751|NCT01109459|Other|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
63752|NCT01109472|Other|patient magazine|patient magazine individually tailored to patient's prior feedback
63753|NCT01109485|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|1-2 drops 4 times per day
63754|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
63755|NCT01109498|Drug|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
63756|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
63757|NCT01109498|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
63758|NCT01109511|Drug|naloxone|
63759|NCT01109511|Drug|oxycodone|
64028|NCT01115010|Device|Colonoscope stiffening device|"Firm" stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the "standard" wire and so on until cecal intubation is achieved or the procedure is abandoned.
64029|NCT01115023|Other|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
64030|NCT01115036|Drug|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
64031|NCT01115049|Drug|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
64400|NCT01144260|Drug|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
64401|NCT01144273|Procedure|Transversus abdominis plane block|This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.
To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.
Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.
After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity.
64402|NCT01144286|Drug|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
64403|NCT01144286|Drug|placebo|placebo, single dose
64404|NCT00039481|Drug|dexrazoxane hydrochloride|Given IV
64405|NCT01144299|Biological|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
64406|NCT01144312|Drug|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
64407|NCT01144325|Procedure|thoracoscopic esophagectomy|In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.
In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position.
64408|NCT01144338|Drug|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
64409|NCT01144338|Drug|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
64410|NCT01144351|Drug|ELND002|
64411|NCT01144351|Drug|Placebo|
64412|NCT01144364|Drug|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
64413|NCT01144377|Drug|LY2541546|Administered subcutaneously
64414|NCT01144377|Drug|Placebo|Administered subcutaneously
63524|NCT01111344|Dietary Supplement|Glizigen + Viusid|Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).
1 to 3.9 cm2 ______________3 daily applications
4 to 6.9 cm2 ______________4 daily applications
7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.
Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.
63817|NCT01106950|Procedure|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
63818|NCT00035815|Drug|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
63819|NCT01106950|Drug|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m^2 every other day for 6 doses).
63820|NCT01106963|Procedure|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
63821|NCT01106989|Drug|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
63822|NCT01107002|Procedure|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
63823|NCT01109524|Drug|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
63824|NCT01109550|Procedure|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
63825|NCT01109563|Behavioral|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
63826|NCT01109576|Behavioral|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
63827|NCT01109602|Other|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
63828|NCT01109615|Drug|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
63829|NCT01109615|Drug|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
63830|NCT01109628|Dietary Supplement|Protein drink|Twice a day during 6 months
63598|NCT01111474|Other|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
63599|NCT01111474|Radiation|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1J/cm2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (660nm).
63600|NCT01111487|Device|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
63601|NCT01111500|Device|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
63602|NCT01111500|Device|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
63603|NCT01111513|Drug|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
63604|NCT01111513|Drug|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
63605|NCT01111513|Drug|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
63606|NCT01111526|Drug|Panobinostat (LBH589)|Phase I, dose escalation levels for LBH589; patients treated with LBH589 PO three times a week (48 hours apart) every week for four weeks.
DL -1* 5 mg PO;
DL 1 10 mg PO (starting dose level);
DL 2 15 mg PO;
DL 3 20 mg PO;
DL 4 25 mg PO ;
*DL -1, represents a potential treatment dose for patients requiring a dose reduction from a higher dose level. In addition, dose level -1 may be used as a contingency dose level if the starting dose level of LBH589 is not tolerated in the initial cohort.
Phase II, patients treated with LBH589 PO (MTD to be determined) three times a week (48 hours apart) every week for four weeks
63607|NCT00036452|Drug|lopinavir/ritonavir|
63608|NCT01111539|Drug|Escitalopram|Escitalopram monotherapy
63609|NCT01111539|Drug|Aripiprazole|Aripiprazole monotherapy
63610|NCT01111539|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
63611|NCT01111552|Drug|Escitalopram|Escitalopram monotherapy
63612|NCT01111552|Drug|Aripiprazole|Aripiprazole monotherapy
63613|NCT01111552|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
63614|NCT01111565|Drug|Escitalopram|Escitalopram monotherapy
64032|NCT01115049|Drug|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
64033|NCT00036816|Biological|MART-1 antigen|
64034|NCT01115062|Drug|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
64035|NCT01115062|Drug|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
64036|NCT01115062|Drug|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
64037|NCT01115075|Other|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
64038|NCT01115075|Behavioral|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
64039|NCT01115088|Dietary Supplement|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
64040|NCT01115088|Dietary Supplement|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
64041|NCT01115088|Dietary Supplement|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
64042|NCT01115101|Drug|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
64341|NCT01136824|Other|Questionnaires|Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assesments:
Demographic & health Trait anxiety Quality of life Nausea Expectations Anxiety & total mood disturbance Nausea & vomiting Multiple symptoms
64342|NCT01136837|Other|primary pcı|
63525|NCT01111344|Dietary Supplement|Placebo|Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).
1 to 3.9 cm2 ______________3 daily applications
4 to 6.9 cm2 ______________4 daily applications
7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.
Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.
63526|NCT01111357|Biological|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
63527|NCT01111370|Device|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
63528|NCT01111383|Drug|tobramycin|300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 "on" cycles of 4 weeks duration during the 48-week period.
63529|NCT01111409|Device|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
63530|NCT01111422|Drug|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
63531|NCT01111448|Drug|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
63532|NCT00036439|Drug|Infliximab|
63533|NCT01111461|Drug|E7080|E7080 capsules are administered orally once a day in 28 day cycles to patients with advanced endometrial cancer and disease progression following first-line chemotherapy.
63534|NCT01114048|Drug|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1~28 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D 1~4, 15-18 Repeated every 28 days
Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days
Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration
63535|NCT00036738|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
63536|NCT01114061|Device|Insupatch|Applying heat to the infusion site using the insupatch device
63537|NCT01114087|Drug|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
63538|NCT01114100|Drug|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
63539|NCT01114100|Drug|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
63816|NCT01106950|Drug|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
64109|NCT01112423|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
64110|NCT01112436|Drug|periarticular injection of multidrug regimen|periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
64111|NCT01112436|Drug|none of medication preoperatively and intraoperatively|Patients in Group C wil receive none of medication preoperatively and intraoperatively
64112|NCT00036582|Drug|Clozapine|
64113|NCT01112449|Other|Placebo|no active medication
64114|NCT01112449|Dietary Supplement|selenomethionine|200 µg/day of selenomethionine (SM)
64115|NCT01112449|Dietary Supplement|low dose selenized-yeast|200 µg/day of SY
64116|NCT01112449|Dietary Supplement|high dose selenized-yeast|285 µg/day of SY
64117|NCT01112462|Drug|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
64118|NCT01112462|Drug|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
64119|NCT01112488|Other|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
64120|NCT01115101|Drug|Piritramid|Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes
Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded.
64121|NCT00036816|Biological|NA17-A antigen|
64122|NCT01115114|Behavioral|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
64123|NCT01115114|Behavioral|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
63882|NCT01107015|Device|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
63883|NCT01107015|Device|Patient-physician intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is "raw" patient data that have not been analyzed.
63884|NCT01107015|Device|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
63885|NCT01107028|Other|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
63886|NCT01107041|Behavioral|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
63887|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
63888|NCT00035828|Drug|ABX-IL8|
63889|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
63890|NCT01107054|Drug|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
63891|NCT01107054|Drug|placebo|A single oral dose of non-matched placebo on Day 4.
63892|NCT01107067|Drug|Sustanon|250 mg/21 days
63893|NCT01107093|Drug|CDB-2914 (ulipristal acetate)|single oral dose of 30 mg
63894|NCT01107093|Drug|Placebo|single oral dose
63895|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
64343|NCT01136850|Drug|chloroquine, sulphadoxine pyrimethamine, LLIN|> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.
< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.
Given at enrolment, 14-26 weeks gestation, by mouth.
64344|NCT01136850|Drug|azithromycin, sulphadoxine pyrimethamine, LLIN|sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).
Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation.
64345|NCT01136863|Drug|Felodipine|
64346|NCT01136863|Drug|Placebo|
64347|NCT01136876|Drug|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
64348|NCT00039117|Drug|cytarabine|Given IV
64349|NCT01136876|Drug|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
64350|NCT01136889|Other|PFMT|Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
64351|NCT01136902|Dietary Supplement|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
64352|NCT01136915|Drug|Iopamidol 370|one time administration for PCI
64353|NCT01136915|Drug|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
64354|NCT01136928|Drug|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
64355|NCT01136941|Drug|Zileuton|Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
64356|NCT01136954|Drug|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
64357|NCT01136967|Drug|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
64358|NCT01138943|Drug|Synthodont|15 ml, tree times/day for 07 days
Arm: Chlorhexidine alcohol-base mouthrinse
64359|NCT01138943|Drug|Soludent|15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days
Arm: Experimental: non alcohol chlorhexidine mouthrinse
64652|NCT01144897|Radiation|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
64833|NCT01142466|Drug|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
64834|NCT01142479|Drug|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
64835|NCT00039377|Other|laboratory biomarker analysis|Correlative studies
64836|NCT01142492|Drug|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
64837|NCT01142505|Drug|Mannitol|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
64838|NCT01142505|Drug|Montelukast|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
64839|NCT01142518|Drug|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
64840|NCT00039481|Other|pharmacological study|Correlative studies
64841|NCT01144663|Biological|Meningococcal vaccine GSK134612|4- or 3-dose intramuscular injection
64842|NCT01144663|Biological|MenC-CRM197|3-dose intramuscular injection
65119|NCT01135537|Biological|Thymoglobulin (rATG)|Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.
Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy.
65120|NCT01135550|Drug|High dose dexamethasone|Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.
If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.
65121|NCT01135550|Drug|Low dose dexamethasone|Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.
If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.
65122|NCT01135563|Drug|Vinblastine and Sirolimus|Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough
64124|NCT01115114|Behavioral|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
64415|NCT00039481|Drug|doxorubicin hydrochloride|Given IV
64416|NCT01144390|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
64417|NCT01144390|Drug|methadone maintenance treatment|methadone maintenance treatment
64418|NCT01144403|Drug|cyclophosphamide|as prescribed, 6 cycles
64419|NCT01144403|Drug|fludarabine|as prescribed, 6 cycles
64420|NCT01144403|Drug|mitoxantrone|as prescribed, 6 cycles
64421|NCT01144403|Drug|rituximab [Mabthera/Rituxan]|375 mg/m2 intravenously, day 1 of each 28-day cycle, up to 8 cycles
64422|NCT01136980|Device|Transoral Incisionless Fundoplication (TIF)|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
64423|NCT00039117|Drug|daunorubicin hydrochloride|Given IV
64424|NCT01136980|Other|Sham Procedure|The Sham procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
64425|NCT01137006|Biological|IMC-20D7S (Cohort 1A)|5 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle.
If 0 dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into cohort 2A.
64426|NCT01137006|Biological|IMC-20D7S (Cohort 2A )|10 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle.
If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A then enrollment into Cohort 3A.
64427|NCT01137006|Biological|IMC-20D7S (Cohort 3A )|20 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle.
If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A then enrollment into Cohort 4A.
64428|NCT01137006|Biological|IMC-20D7S (Cohort 4A )|30 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle.
65175|NCT01142999|Drug|Control group|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
65176|NCT01142999|Drug|Aquaphor ointment|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
65177|NCT01142999|Drug|Cetaphil cream|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
65178|NCT01143012|Other|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
65179|NCT01143012|Other|Control group|The control group will not attend the group eczema education session.
65180|NCT01143025|Drug|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
65181|NCT01143025|Drug|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
65182|NCT00039403|Other|pharmacological study|Correlative studies
65183|NCT01143025|Drug|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
65184|NCT01143038|Biological|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
65185|NCT01143051|Drug|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
65186|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
65187|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
65447|NCT01143545|Biological|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
65448|NCT01143545|Drug|Celecoxib|400 g po bid
65449|NCT01143545|Drug|cyclophosphamide|50 mg po bid
65450|NCT01143558|Procedure|Skin Biopsy|
65451|NCT01143558|Device|Xenodiagnosis|
65452|NCT01143558|Procedure|Blood Drawing|
65453|NCT00039442|Other|Laboratory Biomarker Analysis|Correlative studies
64653|NCT01144910|Other|methacholine challenge test|2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.
the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
64654|NCT01144910|Other|methacholine challenge test|2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.
the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
64655|NCT00039494|Drug|temozolomide|Given orally
64656|NCT01144923|Other|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
64657|NCT01144923|Procedure|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
64658|NCT01144923|Other|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
64659|NCT01144936|Drug|VX-985 or matching placebo|low dose
64660|NCT01144936|Drug|VX-985 or matching placebo|high dose
64661|NCT01144936|Drug|VX-985 or matching placebo|dose TBD
64662|NCT01144949|Drug|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
64663|NCT01144949|Drug|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
64664|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
64665|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
64666|NCT01137383|Drug|Pegaferon (pegylated interferon alpha 2a) + ribavirin|pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
64667|NCT01137396|Drug|Modafinil|Modafinil 400mg PO QDaily following up-titration for ~8weeks
64668|NCT01137396|Behavioral|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
64669|NCT01137435|Biological|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
65123|NCT01135576|Dietary Supplement|non-fortified fruit juices consumed as part of the usual diet|
65124|NCT01135576|Dietary Supplement|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
65125|NCT01135589|Drug|Micafungin|i.v.
65126|NCT01135602|Drug|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
65127|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
65128|NCT01135615|Drug|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
65129|NCT01135615|Drug|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
65130|NCT01135628|Other|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
65131|NCT01135628|Dietary Supplement|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
65132|NCT01135628|Drug|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
65133|NCT01135641|Drug|Rituximab|Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
65134|NCT01135641|Drug|Ciclosporine|
65135|NCT01135641|Drug|Corticosteroids|
65384|NCT01136096|Behavioral|General instruction and education|Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic
Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule
Without individualized exercise program and interview with a physiotherapist
65385|NCT01136122|Device|CPAP Treatment|Effective CPAP treatment for one month
65386|NCT01136135|Other|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
65387|NCT00039039|Radiation|radiation therapy|
65388|NCT01136148|Behavioral|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
65389|NCT01136161|Biological|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
64429|NCT01137006|Biological|IMC-20D7S (Cohort 1B)|10 mg/kg i.v. every 3 weeks
Administered every 3 weeks on days 1 and 22 of each treatment cycle.
If 0 dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into cohort 2B.
64430|NCT01137006|Biological|IMC-20D7S (Cohort 2B )|20 mg/kg i.v. every 3 weeks
Administered every 3 weeks on days 1 and 22 of each treatment cycle.
If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B then enrollment into Cohort 3B.
64431|NCT01137006|Biological|Biological/Vaccine: IMC-20D7S (Cohort 3B )|30 mg/kg i.v. every 3 weeks
Administered every 3 weeks on days 1 and 22 of each treatment cycle.
64432|NCT01137019|Device|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
63540|NCT01114113|Drug|pancelipase/placebo|ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical "trigger meals" and will not be given for the initial baseline "non-trigger" and baseline "trigger meal". In both of these arms, patients will also be swallowing the SmartPill Capsule.
63541|NCT01114113|Device|SmartPill capsule|Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
63542|NCT01114113|Device|SmartPill capsule|Measurement of intestinal transit of a "trigger meal" baseline by using the SmartPill capsule
63543|NCT01114113|Device|SmartPill capsule|SmartPill capsule
63544|NCT01114126|Drug|Neu-P11|comparison of different dosages of drug
63545|NCT01114126|Drug|Neu-P11 placebo|comparison of different dosages
63546|NCT00036738|Biological|therapeutic allogeneic lymphocytes|Given IV
63547|NCT01114139|Drug|Ferumoxytol|IV Ferumoxytol
63548|NCT01114139|Other|Placebo|IV Placebo
63549|NCT01114152|Drug|AZD9742|IV Formulation
63550|NCT01114152|Drug|Placebo|IV Formulation
63551|NCT01114165|Other|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
63552|NCT01114165|Other|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
63553|NCT01114178|Other|questionnaire|self completed questionnaire supervised by a technician
63554|NCT01114191|Drug|ABT-869|2.5mg [5 mg days 1, 8 and 12. 17.5 mg on days 13 and after]
65454|NCT01143584|Drug|Cabergoline|In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.
Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point.
65455|NCT01143584|Drug|cabergoline|In the Rapid escalation group schedule of cabergoline dosing will be as follows:
Begin with 0.5 mg twice a week
mg twice a week - second week 1.5 mg twice a week - third week
mg twice a week - fourth week
4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also >50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk.
65456|NCT01143597|Other|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
65457|NCT01143610|Procedure|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
65458|NCT01143610|Other|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
65459|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
65460|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
65461|NCT01143623|Other|Placebo|Placebo
65462|NCT01143636|Device|Transcranial Direct Current Stimulation|Stimulation will be given at 2 mA for a period of 20 minutes.
65463|NCT01143649|Device|Transcranial Stimulation|Subjects will be stimulated at 1 mA for 40 minutes.
65464|NCT00039455|Biological|trastuzumab|Given IV
65465|NCT01143662|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
65466|NCT01143662|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
65467|NCT01143688|Drug|albuterol|
65468|NCT01143688|Drug|placebo inhaler|
65803|NCT01134406|Device|Hydros Joint Therapy|Single intra-articular injection.
65804|NCT01134406|Device|Hydros-TA Joint Therapy|Single intra-articular injection
65805|NCT01134406|Device|Synvisc-One|Single intra-articular injection.
65806|NCT01134419|Other|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
63760|NCT01109524|Drug|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
63761|NCT00036140|Drug|Investigational drug|
63762|NCT01109524|Drug|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
63763|NCT01111773|Drug|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
63764|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
63765|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
63766|NCT01111799|Procedure|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
63767|NCT01111825|Drug|Temsirolimus|A treatment cycle will consist of 28 days, according to the following schedule:
Weekly temsirolimus given MTD dose from phase I IV (8mg) intravenously on days 1, 8, 15, and 22 Phase I Design A standard, 3+3, dose escalation schedule will be used. Between 6 and 12 patients will likely be necessary to determine the MTD of temsirolimus in combination with neratinib. There will be no intrapatient dose escalation. The starting dose of temsirolimus is 8 mg administered intravenously weekly (dose level 1). Three patients will initially be enrolled in each cohort.
Phase 1
Dose escalation cohort:
• Weekly temsirolimus (8mg) intravenously on Days 1, 8, 15, and 22, and then 15mg intravenously weekly starting on Day 29.
63768|NCT01111825|Drug|Neratinib|A treatment cycle will consist of 28 days, according to the following schedule:
Neratinib PO once daily with food, preferably in the morning. Between 6 and 12 patients will likely be necessary to determine the MTD of temsirolimus in combination with neratinib. There will be no intrapatient dose escalation. Three patients will initially be enrolled in each cohort.
Phase 1
Dose escalation cohort:
• Weekly temsirolimus (8mg) intravenously on Days 1, 8, 15, and 22, and then 15mg intravenously weekly starting on Day 29.
63769|NCT01111838|Drug|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
63770|NCT01111851|Drug|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
63771|NCT00036465|Behavioral|Treatment regimen change|
63772|NCT01111851|Drug|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
63773|NCT01111851|Drug|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
63774|NCT01111851|Drug|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
65390|NCT01136161|Biological|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
65391|NCT01136161|Biological|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
65392|NCT01136161|Biological|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
65393|NCT01136174|Drug|Placebo|Placebo BID for cohort 1,2,3
65394|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
65395|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
65396|NCT01138488|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
65397|NCT01138501|Drug|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
65398|NCT01138501|Drug|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
65399|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
65400|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
65401|NCT00039195|Biological|rituximab|
65402|NCT01138514|Drug|Placebo|Placebo
65741|NCT01126671|Drug|Supplemental Vitamin D|Two doses of daily supplemental vitamin D taken for 11 weeks.
65742|NCT01128998|Drug|S-1|Name:S-1
Dosage form: 20 mg or 25 mg / Capsule
Dosing schedule: 20-40 mg/m2 bid,po, 14 days on & 7 days off
65743|NCT01129011|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
65744|NCT01129011|Drug|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
65745|NCT01129024|Drug|0.5 mg of S-888711|tablet
65746|NCT01129037|Other|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased < 10% in response to receding VL: SV is optimized, no further VL required.
63555|NCT01114191|Drug|ketoconazole|400 mg days 6-11
63556|NCT01114204|Drug|Ferumoxytol|IV Ferumoxytol
63557|NCT00036751|Drug|imatinib mesylate|Given orally
63558|NCT01116219|Drug|bevacizumab, pemetrexed, cisplatin|Induction chemotherapy with
Bevacizumab 7.5 mg/kg i.v. and
Pemetrexed 500 mg/m2 i.v. and
Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with
Bevacizumab 7.5 mg/kg i.v. and
Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.
63559|NCT00036868|Drug|methotrexate|
63560|NCT01116232|Biological|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
63831|NCT01109628|Dietary Supplement|Placebo drink|Twice a day during 6 months
63832|NCT00036153|Drug|Tacrolimus (Prograf®)|
63833|NCT01109641|Device|diagnostic electrophysiology catheter|electrical measurements through a diagnostic electrophysiology catheter
63834|NCT01109654|Drug|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
63835|NCT01109680|Drug|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
63836|NCT01109693|Drug|Sertraline|Sertraline 50 mg/d or 100 mg/d for 6 more weeks
63837|NCT01109693|Drug|Mirtazapine|Augment with or switch to mirtazapine 15-45 mg/d
63838|NCT01109706|Other|biological parameters dosage|200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).
After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).
Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up.
63839|NCT01109732|Other|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
63840|NCT01111864|Dietary Supplement|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
63841|NCT01111890|Drug|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
63842|NCT01111890|Drug|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
65807|NCT01134419|Other|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
65808|NCT01134432|Drug|prednisolone + mabthera|Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.
Mabthera: 375 mg/m2 once a week for four weeks
65809|NCT01134432|Drug|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
65810|NCT00038948|Drug|Sirolimus|Sirolimus, Cyclosporine A & Tacrolimus are concentration controlled
65811|NCT01134445|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
65812|NCT01126684|Drug|Atorvastatin|10 mg of atorvastatin once daily for six months
65813|NCT01126684|Drug|Placebo|placebo once daily for six months
65814|NCT01126697|Drug|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
65815|NCT01126723|Other|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
65816|NCT01126723|Other|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
65817|NCT01126736|Drug|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
65818|NCT01126736|Drug|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
65819|NCT01126736|Drug|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
65820|NCT01126749|Drug|gemcitabine plus cisplatin|Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin
65821|NCT00038246|Drug|Paclitaxel (Taxol)|100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10
64903|NCT01140295|Drug|polyethylene glycol, senna|Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age >12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.
Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days.
64043|NCT00035867|Drug|TLK199 HCl Liposomes for Injection|
64044|NCT01107314|Other|Phlebotomy|Blood draws (total 48 cc blood)
64045|NCT01107327|Procedure|FDG-PET/CT|The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer "light up" on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also "lights up" in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project.
64046|NCT01107340|Device|AMIStem Hip System|
64047|NCT01107353|Drug|Imipramine Pamoate|75 mg capsule
64048|NCT01107366|Procedure|lupiae technique|it's a new hybrid technique for the treatment of aortic aneurism and dissection.
64049|NCT01107366|Procedure|lupiae technique|LUPIAE technique
Hybrid repair of thoracic or thoraco-abdominal aneurysms of different etiology and type A dissections with a two-stage procedure:
surgical arch reconstruction with a Dacron multibranched surgical prothesis
endovascular implantation of a thoracic stent graft
64050|NCT01107379|Device|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
64051|NCT01107392|Drug|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
64052|NCT01107392|Drug|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
64053|NCT01107405|Drug|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
64054|NCT00035880|Drug|ABX-CBL|
64055|NCT01107405|Drug|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
64056|NCT01107405|Drug|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
64057|NCT01107405|Drug|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
64058|NCT01107405|Drug|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
64059|NCT01107418|Drug|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
64060|NCT01107418|Drug|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
64061|NCT01107418|Drug|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
64062|NCT01107418|Drug|RO5185426|960 mg orally twice daily, from day 22 onward
65747|NCT00038467|Drug|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
65748|NCT01129050|Behavioral|Fish Oil|
65749|NCT01129050|Behavioral|Flax Seed Oil|
65750|NCT01129063|Drug|Clopidogrel|Pharmaceutical form : tablet
Route of administration: oral
65751|NCT01129089|Dietary Supplement|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
65752|NCT01129089|Dietary Supplement|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
65753|NCT01129089|Dietary Supplement|Micronutrient powder|Micronutrient powder for infant and young children
65754|NCT01129102|Drug|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
65755|NCT01129102|Drug|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
65756|NCT01129102|Drug|Placebo|Placebo for NPC-01
65757|NCT01129115|Behavioral|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
65758|NCT00038480|Drug|Lopinavir/Ritonavir|
65759|NCT01129115|Behavioral|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
65760|NCT01129115|Behavioral|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
65761|NCT01129115|Behavioral|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
65762|NCT01129128|Biological|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
64843|NCT01144663|Biological|MenC-TT|3-dose intramuscular injection
64844|NCT01144663|Biological|DTPa-HBV-IPV/Hib|4-dose intramuscular injection
64845|NCT01144663|Biological|Pneumococcal conjugate vaccine|4-dose intramuscular injection
64846|NCT01144676|Drug|dapivirine|25mg dapivirine per ring.
The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
63843|NCT00036491|Drug|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m^2
63844|NCT01111903|Drug|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
63845|NCT01111929|Drug|Counseling for LAM+ LNG-EC|They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.
They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.
64125|NCT01115127|Dietary Supplement|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
64126|NCT01115127|Dietary Supplement|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
64127|NCT01115127|Dietary Supplement|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
64128|NCT01115140|Drug|metformin plus placebo|metformin 850 mg cp, 2 cps daily
64129|NCT01115140|Drug|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
64130|NCT01115140|Drug|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
64131|NCT01115140|Drug|placebo alone|placebo cp, 2 cps daily
64132|NCT00036816|Biological|gp100 antigen|
64133|NCT01115153|Other|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
64134|NCT01115153|Other|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
64135|NCT01115179|Drug|propofol|Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
64136|NCT01115179|Drug|Intralipid 10%|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
64137|NCT01107444|Drug|LY2181308|Administered intravenously
64138|NCT01107457|Biological|ixekizumab|Administered subcutaneously
64904|NCT01140308|Drug|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
64905|NCT01140308|Drug|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
64906|NCT01140321|Drug|Neridronate|Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication "Osteogenesis Imperfecta".
64907|NCT01142531|Radiation|Chest CT scan|Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)
90 quality ref mAs with care-dose ON
120 kV
Pitch 1.4
Rotation time 0.33 s
Acquired images 64 x 0.6 mm
64908|NCT01142544|Other|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
64909|NCT01142557|Drug|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
64910|NCT01142570|Other|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
64911|NCT01142570|Other|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
64912|NCT01142570|Dietary Supplement|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
64913|NCT00039390|Drug|capecitabine|Given orally (PO)
64914|NCT01142570|Dietary Supplement|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
64915|NCT01142570|Dietary Supplement|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
64916|NCT01142596|Drug|Asenapine|Asenapine 5 mg twice daily (bid) for 4 or 6 weeks, then re-randomized to asenapine 5 mg bid or asenapine 10 mg bid
64917|NCT01142596|Drug|Asenapine|Asenapine 10 mg twice daily (bid) for 6 weeks, then re-randomized to asenapine 5 mg bid or asenapine 10 mg bid
64918|NCT01142609|Behavioral|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
65188|NCT01143064|Drug|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
64063|NCT01107418|Drug|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
64360|NCT01138956|Drug|N-acetylcysteine|N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
64361|NCT00000941|Drug|Nelfinavir mesylate|
64362|NCT00039195|Drug|prednisone|
64363|NCT01138956|Drug|Pentavalent antimonial|Pentavalent antimonial, 20mg/kg/day, 28 days, IV
64364|NCT01138969|Drug|esomeprazole|esomeprazole 20 mg qd for 6 months
64365|NCT01138982|Behavioral|Youth Mentoring program|
64366|NCT01138995|Device|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
64367|NCT01138995|Device|Ness L300|The Original Treatment Group will walk with the Ness L300 for 42 weeks, and the Original Control Group will walk with a "usual" ankle-foot orthosis (AFO)for 30 weeks, then be crossed over to walk with the Ness L300 for a total of 12 weeks.
64368|NCT01139008|Drug|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
64369|NCT01139008|Drug|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
64370|NCT01139021|Biological|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
64371|NCT01139034|Device|Self-designed surface functional electrical stimulator|Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
64372|NCT01139047|Drug|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
64373|NCT00039195|Drug|vincristine sulfate|
64374|NCT01139047|Drug|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
64375|NCT01139060|Behavioral|organized care program for chronic or recurrent depression|
64376|NCT01139099|Behavioral|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
64377|NCT01139125|Drug|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
64847|NCT01144676|Drug|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
64848|NCT01144676|Drug|dapivirine|25mg dapivirine per ring.
The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
64849|NCT01144676|Drug|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
64850|NCT01144689|Behavioral|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
64851|NCT00039494|Drug|erlotinib hydrochloride|Given orally
64852|NCT01144689|Behavioral|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
64853|NCT01144702|Drug|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
64854|NCT01144715|Device|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
64855|NCT01144715|Device|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
64856|NCT01144728|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
64857|NCT01144741|Other|STOP-FSS Survey|STOP-FSS Survey is a self-report measure that will be used to assess diagnosis- and feature-related outcomes.
64858|NCT01144741|Other|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
64859|NCT01144754|Drug|Rituximab|Calculated per patient
64860|NCT01144767|Behavioral|Computer-generated advisor|Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
65136|NCT00039130|Drug|Allopurinol|300 mg/day PO Days 1-14, course I
65137|NCT01138111|Drug|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
64139|NCT01107457|Drug|Placebo|Administered subcutaneously
64140|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
64141|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
64142|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
64143|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
64144|NCT01107496|Drug|SPN-812V|SPN CTM
64145|NCT00035906|Drug|DEX PS DDS®|
64146|NCT01107496|Drug|Placebo|Control
64433|NCT01137019|Device|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
64434|NCT00039117|Other|laboratory biomarker analysis|Correlative studies
64435|NCT01137032|Drug|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
64436|NCT01137045|Biological|SPEEDA and TRCS SPEEDA|For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.
For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.
For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI
64437|NCT01137058|Device|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
64438|NCT01137058|Device|SMBG group|Glucose control with self monitoring of blood glucose.
64439|NCT01139164|Drug|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
64440|NCT00039195|Procedure|peripheral blood stem cell transplantation|
64441|NCT01139164|Drug|Regimen B|Other malignancies not addressed in A or C
64442|NCT01139164|Drug|Regimen C|B-Cell Lymphomas
64443|NCT01139177|Device|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
64444|NCT01139190|Drug|PL3100|Oral administration
65189|NCT01143064|Drug|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
65190|NCT01143077|Drug|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
65191|NCT01143090|Drug|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
65192|NCT01143103|Device|Cough assist (Philips,respironics)|
65193|NCT00039403|Other|laboratory biomarker analysis|Correlative studies
65194|NCT01143103|Other|Usual respiratory therapy|
65195|NCT01135654|Other|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to "Helping Patients Who Drink Too Much".
65196|NCT01135667|Drug|clopidogrel|clopidogrel 150 mg once daily for 30 days
65197|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
65198|NCT01135667|Drug|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
65199|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
65200|NCT01135680|Drug|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
65201|NCT01135680|Drug|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
65202|NCT01135680|Drug|Moxifloxacin|single oral 400-mg dose on study Day 3
65203|NCT01135680|Drug|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
65204|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
65205|NCT01135706|Other|No Intervention|This study does not include an intervention but is observational in nature.
65206|NCT01135719|Procedure|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
65207|NCT01135732|Procedure|brush cytology|brush cytology during ERCP
65208|NCT00000941|Drug|Pravastatin sodium|
65209|NCT00039039|Drug|carboplatin|
64378|NCT01139138|Drug|Panitumumab|Panitumumab 6mg/kg IV every 14 days
64379|NCT01139138|Drug|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
64380|NCT01139138|Drug|Everolimus|Everolimus daily po (dosage varies with cohort)
63479|NCT01116011|Drug|Placebo|Capsule, Oral, BID
63480|NCT00036868|Drug|CMF regimen|
63481|NCT01116024|Device|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
63482|NCT01116037|Device|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
63483|NCT01116050|Drug|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
63484|NCT01116050|Drug|Placebo|5 tablets in opque introducer
63485|NCT01116063|Drug|Inhaled iloprost|Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
63486|NCT01116076|Behavioral|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
63487|NCT01108783|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
63488|NCT01108783|Drug|Placebo|(encapsulated) Tablets QD/14 days
63489|NCT01108809|Drug|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
63490|NCT01108835|Other|Comprehensive care programme|Intervention group:
Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions
Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)
Respiratory physician assessment and optimization of treatment
Patients will also be taught about a personalized action plan by the physician and respiratory nurse.
Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries.
63491|NCT01108848|Biological|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
63492|NCT00000922|Drug|Didanosine|
63493|NCT00036036|Drug|CP-461|
63494|NCT01108861|Device|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
63495|NCT01108861|Device|Plain old balloon angioplasty|Plain old balloon angioplasty
65138|NCT01138124|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
65139|NCT01138137|Drug|Paclitaxel|Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle
Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle
6 treatment cycles
65140|NCT01138137|Drug|N-acetylcysteine|A group of 5 subjects will be evaluated at each dose level.
On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.
6 treatment cycles
Dose escalation schema:
Level 1: 150mg/kg
Level 2: 300mg/kg
Level 3: 600mg/kg
Level 4: 800mg/kg
Level 5: 1000mg/kg
Level 6: 1200mg/kg
65141|NCT01138137|Drug|Cisplatin|Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion
6 treatment cycles
65142|NCT01138150|Drug|sumatriptan/naproxen sodium|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
65143|NCT01138150|Drug|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
65144|NCT01138163|Drug|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
65145|NCT01138176|Procedure|Cooling|Reduction of rectal temperature to 33.5 C
65146|NCT01138189|Procedure|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
65147|NCT00039156|Drug|ortataxel|
65148|NCT01138189|Procedure|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
65149|NCT01138202|Drug|LPV/r|LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
65150|NCT01138215|Biological|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
65151|NCT01138241|Other|Tc99mDTPA renal clearance|Tc99mDTPA renal clearance only for 200 patients
Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria
serum creatinine prior and during TDF
TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels
stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)
serum for cystanin C ( stored sample prior taking ARV and present time)
intensive 24 hours pharmacokinetic study of TDF in 20 patients
64445|NCT01139190|Drug|Naproxen|Oral administration
64446|NCT01139203|Drug|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
64447|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
64448|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
64449|NCT01139216|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
64450|NCT01139229|Other|hybrid everted esophagogastric anastomosis|
64451|NCT00039195|Radiation|radiation therapy|
64452|NCT01139229|Other|the conventional hand-sewn anastomosis|
64453|NCT01139229|Other|a stapled anastomosis|
63561|NCT01116232|Biological|rituximab|The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.
In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes.
63562|NCT01116232|Drug|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
63563|NCT01116232|Drug|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
63564|NCT01116232|Other|laboratory biomarker analysis|laboratory biomarker analysis
63565|NCT01116232|Procedure|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
63566|NCT01116232|Procedure|management of therapy complications|management of therapy complications
63567|NCT01116232|Procedure|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
63568|NCT01116245|Biological|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
65210|NCT01135745|Device|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
65469|NCT01143688|Procedure|placebo acupuncture|
65470|NCT01143701|Other|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
65471|NCT01143714|Drug|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
65472|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
65473|NCT01136187|Procedure|Access site in primary PCI|
65474|NCT00039052|Biological|interleukin-4 PE38KDEL cytotoxin|
65475|NCT01136200|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
65476|NCT01136213|Radiation|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
65477|NCT01136213|Other|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
65478|NCT01136213|Drug|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
65479|NCT01136226|Drug|Eligard (TM)|22.5 mg administered at baseline and Month 3
65480|NCT01136239|Drug|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
65481|NCT01136239|Drug|Placebo|Placebo (600mg twice daily)
65482|NCT01136252|Drug|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
65483|NCT01136278|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
65484|NCT01136278|Drug|Clonidine|150 μg per os
65485|NCT00039078|Radiation|yttrium Y 90 glass microspheres|
65486|NCT01136278|Drug|placebo|capsules identical to MDMA or clonidine
63496|NCT01108874|Drug|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
63497|NCT01108900|Drug|sildenafil|tables, 25,50,100 mg, on demand, 1 month
63498|NCT01108913|Drug|Bimosiamose|
63499|NCT01108913|Drug|Placebo|
63500|NCT01108926|Drug|Atripla®|All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
63775|NCT01111851|Drug|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
63776|NCT01111851|Drug|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
63777|NCT01111851|Drug|MK0999|I.V. infusion of MK0999 containing ~100 MBq (~3 mCi) containing ≤ 5 ug of MK0999)
63778|NCT01111864|Dietary Supplement|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
63779|NCT01114503|Drug|Methylprednisolone|Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
63780|NCT01114516|Drug|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
63781|NCT01114529|Drug|Everolimus|Early CNI to everolimus conversion
63782|NCT01114529|Drug|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
63783|NCT01114542|Drug|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
63784|NCT00000924|Drug|Ritonavir|
63785|NCT00036764|Other|laboratory biomarker analysis|Correlative studies
63786|NCT01114542|Drug|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
65403|NCT01138527|Other|MRI examination|45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
65404|NCT01138540|Other|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
65405|NCT01138553|Drug|Mifepristone|200mg capsules daily for 5-28 days
65406|NCT01138579|Drug|FBTA05|
65407|NCT01138605|Drug|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
65408|NCT01138605|Drug|ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
65409|NCT01138605|Drug|ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
65410|NCT01138605|Drug|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
65411|NCT01138605|Drug|ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
65412|NCT00039195|Drug|carboplatin|
65413|NCT01138605|Drug|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
65414|NCT01138605|Drug|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
65415|NCT01138605|Drug|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
65416|NCT01138605|Drug|ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
65417|NCT01138605|Drug|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
65418|NCT01138605|Drug|ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
65419|NCT01138605|Drug|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
65420|NCT01141140|Behavioral|Healthy|Favourable nutritional characteristics.
65421|NCT01141140|Behavioral|Diet|Benefits of an ingredient/nutrient for weight management
65422|NCT01141140|Behavioral|Unhealthy|Hedonic characteristics and less healthy ingredients.
63569|NCT01116245|Drug|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
63570|NCT00036881|Dietary Supplement|zinc sulfate|
63571|NCT01116258|Drug|AZD5847|oral suspension, 15 days
63572|NCT01116258|Drug|Placebo|oral suspension, 15 days
63573|NCT01116271|Drug|AZD6244|50 or 75mg, capsules, PO, BID, 28 days
63574|NCT01116271|Drug|Irinotecan|180mg/m2, IV, Day 1& 15 of each cycle
63575|NCT01116284|Procedure|Laparoscopic plication of an enlarged gastrojejunostomy|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
63576|NCT01116297|Device|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
63577|NCT01116310|Drug|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
63846|NCT01111942|Other|radiation combined with weekly carboplatin|recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;
Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.
Induction Triple Therapy Treatment with TPF:
Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta* 6 mg SC Day 5 (*Neupogen may be substituted at the investigator's discretion)
63847|NCT01111942|Procedure|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
63848|NCT01111955|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
63849|NCT01111955|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
63850|NCT01111955|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
63851|NCT01111955|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
63852|NCT01111955|Drug|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
65487|NCT01136291|Other|physical exercise|The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.
The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.
These women also received nutrition counseling and prenatal care.
65488|NCT01136304|Drug|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
65489|NCT01136317|Drug|Omeprazole|
65822|NCT01126749|Drug|E7389 in combination with gemcitabine plus cisplatin|Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin
65823|NCT01126762|Behavioral|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
65824|NCT01126762|Behavioral|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
65825|NCT01126801|Drug|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
65826|NCT01126801|Other|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
65827|NCT01126814|Drug|Imatinib (Gleevec)|
65828|NCT01126827|Behavioral|Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy|12 weekly group therapy sessions
65829|NCT01126840|Behavioral|Telephone Interview|The phone interview should take 30-45 minutes to complete.
65830|NCT01126840|Behavioral|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
65831|NCT01126853|Biological|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
65832|NCT00038259|Drug|Aldesleukin|
65833|NCT01126866|Drug|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
65834|NCT01126879|Dietary Supplement|genistein|Given orally
65835|NCT01129141|Procedure|Wait List Control|Wait List Control subjects will receive TTE after completing the 6-month questionnaires. Participants assigned to Wait List Control will be instructed that they are allowed to receive any services for their tinnitus that are available to them, and that they will receive TTE following completion of the 3- and 6-month questionnaires.
65836|NCT01129154|Drug|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
65837|NCT01129180|Drug|azacitidine|Given SC
63787|NCT01114555|Drug|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
63788|NCT01114568|Drug|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
63789|NCT01114568|Drug|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
63790|NCT01114568|Drug|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
63791|NCT01114581|Drug|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
63792|NCT01114581|Drug|Placebo|Placebo given as 2 tablets
63793|NCT01114607|Drug|GSK1605786 formulation B|GSK1605786 GSK formulation.
64064|NCT01107431|Dietary Supplement|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
64065|NCT00035893|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
64066|NCT01107431|Dietary Supplement|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
64067|NCT01107444|Drug|Docetaxel|Administered intravenously
64068|NCT01110018|Drug|GSK573719 (SOLUTION)|20μg /mL solution for IV and Oral dosing
64069|NCT01110018|Drug|GSK573719 (INHALATION POWDER)|500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
64070|NCT01110031|Biological|Ofatumumab|Anti-CD20 monoclonal antibody
64071|NCT01110044|Biological|251154 vaccine|Intramuscular, single dose
64072|NCT01110044|Biological|Infanrix hexa™|Intramuscular, four doses
64073|NCT01110044|Biological|Synflorix™|Intramuscular, four doses
64074|NCT01110044|Biological|Rotarix™|Oral, two doses
64075|NCT01110057|Drug|Placebo|Placebo to match GW856553
64076|NCT01110057|Drug|GS856553|GW586553 7.5mg bid
64077|NCT00036205|Drug|sumanirole|
65423|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel + acenocoumarol|Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring
Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent
65763|NCT01129128|Biological|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
65764|NCT01129128|Biological|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
65765|NCT01129141|Procedure|Telephone Tinnitus Education|Telephone Tinnitus Education (TTE) is a novel home-based telehealth program. TTI intervention involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education is provided by the Study Psychologist at weeks 1, 3, and 5, and by the Study Audiologist at weeks 2 and 4, and months 3 and 6.
65766|NCT01131884|Drug|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
65767|NCT01131884|Drug|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
65768|NCT01131897|Drug|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
65769|NCT01131910|Biological|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
65770|NCT01131910|Biological|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
65771|NCT01131910|Biological|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
65772|NCT01131923|Drug|Amlodipine|Amlodipine Tablets, 10 mg
65773|NCT00038675|Drug|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
65774|NCT01131936|Drug|Amlodipine|Amlodipine Tablets, 10 mg
65775|NCT01131949|Drug|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
65776|NCT01131962|Procedure|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
65777|NCT01131975|Drug|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
65778|NCT01131988|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
65779|NCT01132014|Biological|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
63853|NCT01111968|Biological|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
63854|NCT00036504|Drug|Insulin Lispro low mixture|
63855|NCT01111968|Biological|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
63856|NCT01111968|Biological|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
63857|NCT01111968|Biological|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
63858|NCT01111968|Biological|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
63859|NCT01114685|Dietary Supplement|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
63860|NCT01114685|Dietary Supplement|AlgaeCal-2|Taking 7 capsules a day for six months
63861|NCT01114698|Drug|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
63862|NCT00036777|Drug|7-hydroxystaurosporine|Given IV
63863|NCT01114698|Drug|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
63864|NCT01114698|Drug|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
64147|NCT01107509|Drug|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
64148|NCT01107522|Drug|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
64149|NCT01107522|Drug|CTO and Temodar®|Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.
Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.
64150|NCT01107522|Drug|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
64151|NCT01107535|Biological|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
65838|NCT00038493|Drug|Temozolomide and SCH66336|
65839|NCT01129180|Drug|bortezomib|Given IV
65840|NCT01129180|Procedure|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
65841|NCT01129193|Other|Pharmacodynamic Studies|Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).
Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3.
65842|NCT01129193|Other|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
64919|NCT01142622|Drug|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
64920|NCT01142622|Drug|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
64921|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
64922|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
64923|NCT01142648|Drug|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
64924|NCT00039390|Drug|gefitinib|Given PO
64925|NCT01142648|Drug|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
64926|NCT01142661|Drug|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
64927|NCT01142687|Dietary Supplement|dihydrocapsiate capsule|Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.
Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
64928|NCT01142700|Drug|BMS-824393|Capsule, Oral, 10 mg, once daily
64929|NCT00039507|Procedure|conventional surgery|
64930|NCT01144975|Drug|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
64931|NCT01144975|Drug|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
64932|NCT01144988|Drug|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
64078|NCT01110070|Device|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
64079|NCT01110070|Device|ChonDux|single use device
64080|NCT01110083|Drug|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
64081|NCT01110096|Behavioral|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
64082|NCT01110096|Behavioral|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
64083|NCT01110096|Behavioral|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
64084|NCT01110122|Dietary Supplement|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
64085|NCT01110135|Drug|bendamustine hydrochloride|Given IV
64086|NCT01110135|Drug|dexamethasone|Given PO
64087|NCT01110135|Biological|filgrastim|Given SC
64381|NCT01139151|Drug|3 Day Thiarabine|Starting dose 70 mg/m^2 IV over 1 hour (±15 minutes) daily x 3
64382|NCT01139151|Drug|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
64383|NCT01141738|Behavioral|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
64384|NCT01141738|Behavioral|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
64385|NCT01141764|Procedure|Positron Emission Tomography (PET) Scan|The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.
This process will be repeated with the stimulator "on" during the first PET image acquisition and "off" during the second PET image acquisition. "On" and "off" PET image acquisitions will be performed on two separate days.
64386|NCT01141764|Procedure|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
65780|NCT01132027|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
65781|NCT01132040|Drug|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
65782|NCT01132066|Other|tDCS|tDCS will lead to an increase in cortical excitability
65783|NCT01132066|Other|Sham|Sham will provide identical subjective sensation as tDCS
64861|NCT01144767|Behavioral|Comparison control condition|Weekly/biweekly sessions with a group facilitator to receive health education and information.
64862|NCT01137682|Drug|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
64863|NCT01137682|Drug|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
64864|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months.
64865|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
64866|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months
64867|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
64868|NCT01137708|Drug|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
64869|NCT00039130|Drug|etoposide|80 mg/sq m/day IV infusion Days 4 & 5 courses II, IV, VI
64870|NCT01137708|Drug|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
64871|NCT01137734|Device|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty rean, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
64872|NCT01137734|Device|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
64873|NCT01137747|Drug|Carfilzomib|
64874|NCT01137760|Dietary Supplement|Sucrose|5 g of sucrose daily for 8 weeks
64152|NCT01107548|Other|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
64153|NCT01107561|Other|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
64154|NCT01107561|Device|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
64155|NCT01107574|Drug|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
64156|NCT00035919|Genetic|Mx-dnG1 Retroviral Vector|
64157|NCT01107574|Procedure|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
64158|NCT01110187|Drug|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
64159|NCT01110187|Drug|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
64160|NCT00036218|Drug|ropinirole|
64161|NCT01110200|Drug|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
64162|NCT01110200|Drug|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
64454|NCT01139242|Behavioral|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
64455|NCT01139242|Behavioral|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
64456|NCT01139255|Behavioral|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
64457|NCT01139281|Drug|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
64933|NCT01145001|Behavioral|Cognitive Behavioural Therapy|Weekly CBT for all subjects
64934|NCT01145001|Behavioral|Contingency Management|incentives given for abstinence based on urine analysis
64935|NCT01145001|Drug|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
64936|NCT01145014|Drug|BI 660848|2 mg oral drinking solution
64937|NCT01145014|Drug|BI 660848|10 mg oral drinking solution
64938|NCT01145014|Drug|BI 660848|20 mg oral drinking solution
64939|NCT01145014|Drug|BI 660848|50 mg oral drinking solution
64940|NCT00039507|Procedure|radiofrequency ablation|
65211|NCT01135758|Drug|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
65212|NCT01135771|Other|glucose and insulin IV to alter blood glucose|
65213|NCT01135784|Dietary Supplement|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
65214|NCT01135784|Dietary Supplement|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
65215|NCT01135810|Behavioral|Hypnosis|
65216|NCT01135810|Behavioral|Meditation|
65217|NCT01135823|Procedure|Patient survey|
65218|NCT01135836|Procedure|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
65219|NCT01135836|Procedure|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
65220|NCT00039039|Drug|chemotherapy|
65221|NCT01135836|Procedure|Control group|CO2 was removed by passive exsufflation through the port site.
65222|NCT01138254|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
64387|NCT01141764|Other|Neuropsychological Testing|On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned "off" for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on.
64388|NCT01141777|Dietary Supplement|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
64389|NCT01141777|Dietary Supplement|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
64390|NCT01141790|Other|Music and voice message|
64391|NCT01141803|Dietary Supplement|Apples|550g of apples/day
64392|NCT00039377|Drug|leucovorin calcium|Given IV and PO
64393|NCT01141803|Dietary Supplement|Apple pomace|22g apple pomace/day
64394|NCT01141816|Other|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
64395|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
63501|NCT01108939|Drug|Antimalarial treatment|
63502|NCT01108939|Other|Observation|
63503|NCT01108978|Drug|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
63504|NCT00036062|Drug|Sivelestat|
63505|NCT01108978|Drug|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
63506|NCT01108991|Behavioral|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
63507|NCT01108991|Other|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
63508|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
63509|NCT00000923|Drug|Stavudine|
64875|NCT01137760|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
64876|NCT01137760|Dietary Supplement|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
64877|NCT01137773|Drug|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
64878|NCT01137773|Drug|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
64879|NCT01137786|Drug|Non ionic contrast media comparator|One time administration for PCI
65152|NCT01140594|Procedure|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
65153|NCT01140607|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form:solution for infusion
Route of administration: intravenous
65154|NCT01140620|Drug|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
65155|NCT00000942|Drug|Nevirapine|
65156|NCT00039325|Biological|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6 (for arm A) or 10^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
65157|NCT01140620|Drug|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
65158|NCT01140620|Drug|saline|saline infusion. Duration approximately 3 hours
65159|NCT01140620|Drug|placebo to match risperidone|placebo capsule to match risperidone 2 mg capsule
65160|NCT01140646|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
65161|NCT01140646|Other|questionnaire administration|Ancillary studies
65162|NCT01140646|Procedure|quality-of-life assessment|Ancillary studies
65163|NCT01140659|Procedure|Video-assisted sympathectomy|All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
65164|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
65165|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
64458|NCT01139281|Drug|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
64459|NCT01139294|Drug|hyaluronidase human injection|1ml sub-q with initiation of IVF's then every 24 hrs with a max dose of 3 inj. in 72 hours
64460|NCT01139307|Other|cell culture procedure|
64461|NCT01139307|Other|laboratory biomarker analysis|
64462|NCT01141868|Behavioral|Internet Intervention|online treatment for insomnia
64463|NCT01141881|Drug|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
64464|NCT01141894|Other|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
64465|NCT00039377|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
64466|NCT01141894|Other|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
64467|NCT01141907|Behavioral|Navigator Team Intervention|The intervention is aimed at controlling heart failure (HF) and preventing exacerbations and hospitalizations by improving self management behaviors with the support of the Home Automated Telemonitoring (HAT) system. The intervention will be delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention will be initiated during the index hospitalization or as soon as possible after randomization. The RN-CHN team will collaborate with the participants, their caregivers, and their usual source of HF care. Intervention strategies include tracking of weight and HF symptoms to provide automated feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and using a patient centered record to promote communication with providers.
64468|NCT01141907|Other|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
63578|NCT01109004|Drug|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
63579|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
65223|NCT01138254|Other|no intervention|no intervention
65224|NCT01138280|Device|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
65225|NCT01138293|Device|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
65226|NCT01138306|Genetic|gene expression analysis|
65227|NCT01138306|Genetic|mutation analysis|
65228|NCT00000941|Drug|Ritonavir|
65229|NCT00039169|Drug|ortataxel|
65230|NCT01138306|Other|flow cytometry|
65231|NCT01138306|Other|laboratory biomarker analysis|
65490|NCT01136317|Drug|Rabeprazole|
65491|NCT01136317|Drug|Lactose|
65492|NCT01136343|Other|lifestyle modified project|education, counseling
65493|NCT01136356|Drug|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
65494|NCT01136356|Drug|morphine|parenteral morphine may be administered multiple times each day
65495|NCT01138605|Drug|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
65496|NCT01138605|Drug|ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
65497|NCT01138618|Device|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
65498|NCT00039195|Drug|cyclophosphamide|
65499|NCT01138618|Device|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
65500|NCT01138631|Device|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
65501|NCT01138657|Drug|adalimumab|Subjects will be randomized into one of two arms. Arm 1 will receive adalimumab 80 mg subcutaneous (SC) loading dose at Baseline visit followed by 40 mg doses every other week starting at Week 1. Arm 2 will receive matching placebo. Randomization will be a 1:1 ratio double masked fashion to the treatment groups using baseline immunosuppressant usage as the stratification factor.
63510|NCT00036413|Drug|TCH346|
63511|NCT01111279|Biological|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
63512|NCT01111292|Drug|Inositol|Given PO
63513|NCT01111292|Other|Placebo|Given PO
63514|NCT01111292|Other|Laboratory Biomarker Analysis|Correlative studies
63515|NCT01111305|Drug|Reslizumab|
63516|NCT01111305|Drug|Diethylcarbamazine|
63517|NCT01111305|Other|Placebo|
63518|NCT01111318|Drug|BI 10773|2 tablets BI 10773 25 mg single dose
63519|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
63520|NCT01111331|Drug|Warfarin 25 mg|25 mg Warfarin single dose
63521|NCT00036426|Biological|FavId (Id-KLH) active immunotherapy|
63522|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
63523|NCT01111331|Drug|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
63794|NCT01114607|Drug|GSK1605786 formulation E|GSK1605786 GSK tablet formulation.
63795|NCT01114607|Drug|GSK1605786 formulation D|GSK1605786 GSK modified process formulation.
63796|NCT00036777|Drug|carboplatin|Given IV
63797|NCT01114607|Drug|GSK1605786 formulation C|GSK1605786 GSK direct-fill formulation.
63798|NCT01114607|Drug|GSK1605786 formulation A|GSK1605786 ChemoCentryx formulation.
63799|NCT01114620|Biological|(GSK2340274A) Arepanrix™|Intramuscular administration, one dose
63800|NCT01114646|Device|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
63801|NCT01114646|Device|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
63802|NCT01114672|Drug|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
63803|NCT01114672|Drug|Placebo|oral placebo once weekly
65166|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
65167|NCT00039338|Procedure|conventional surgery|Radial hysterectomy
65168|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
65169|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
65170|NCT01140672|Drug|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
65171|NCT01140698|Other|Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge|Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
65424|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel|Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily
Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent.
65425|NCT01141166|Behavioral|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
65426|NCT01141179|Drug|LEO 27847|2 mL (0.1 mg) dose of oral solution
65427|NCT01141192|Dietary Supplement|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
65428|NCT00039351|Drug|cyclophosphamide|
65429|NCT01141192|Dietary Supplement|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
65430|NCT01141205|Biological|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
65431|NCT01141205|Drug|Saline|1.2 ml saline intramuscularly
65432|NCT01141218|Other|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
65433|NCT01141231|Procedure|Acupuncture|Patients undergo acupuncture twice weekly for 4 weeks
65434|NCT01141244|Drug|temsirolimus|Given IV
65435|NCT01141244|Drug|temozolomide|Given orally
65436|NCT01141244|Drug|irinotecan hydrochloride|Given IV
65437|NCT01141244|Other|laboratory biomarker analysis|Correlative studies
63580|NCT01109017|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
63581|NCT01109030|Drug|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.
Chlordiazepoxide 10 mg each night for first three weeks
63582|NCT01109030|Drug|Placebo+ Citalopram+ Chlordiazepoxide|Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.
Chlordiazepoxide 10 mg each night for first three weeks
63583|NCT01109043|Drug|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
63584|NCT00036075|Drug|CP-461|
63585|NCT01109056|Drug|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
63586|NCT01109056|Drug|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
63587|NCT01109069|Drug|PCI-32765|Dose based on parent protocol
63588|NCT01109082|Procedure|posterior spine fusion|vertebrae are fused to straighten a spinal curve
63589|NCT01109095|Genetic|Genetically modified HER.CAR CMV-specific CTLs|HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:
1 x 10^6/m^2
3 x 10^6/m^2
1 x 10^7/m^2
3 x 10^7/m^2
1 x 10^8/m^2
63590|NCT01109121|Drug|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
63591|NCT01109121|Drug|Allopurinol|Allopurinol 400 mg, QD
63592|NCT01109121|Drug|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
63593|NCT01109134|Drug|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
63594|NCT01109134|Drug|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
63865|NCT01114724|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
63866|NCT01114737|Drug|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
63867|NCT01114737|Drug|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
63868|NCT01114750|Drug|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
65502|NCT01138657|Drug|prednisone|All subjects will receive a mandatory prednisone burst and taper schedule. All patients continuing in the study will be off prednisone no later than Week 15.
65503|NCT01138657|Drug|adalimumab placebo|Placebo 80 mg subcutaneous (SC) loading dose at the Baseline study visit followed a week later by 40 mg placebo injections every other week starting at Week 1.
65504|NCT01138657|Drug|prednisone|All subjects will receive a mandatory prednisone burst and taper schedule. All patients continuing in the study will be off prednisone no later than Week 15.
65505|NCT01138683|Procedure|ultrafiltration|Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
65506|NCT01138683|Drug|diuretics|Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
65507|NCT01138696|Other|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
65508|NCT01138696|Other|RX|X-rays and clinical investigation of the knee 20 years after surgery
65509|NCT00039195|Drug|doxorubicin hydrochloride|
65843|NCT01129193|Other|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
65844|NCT01129193|Drug|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
65845|NCT01129206|Drug|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
65846|NCT01129206|Drug|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
65847|NCT01129206|Radiation|fludeoxyglucose F 18|Correlative studies
65848|NCT01129206|Procedure|positron emission tomography|Correlative studies
65849|NCT00038506|Drug|abacavir/lamivudine/zidovudine|
65850|NCT01129219|Other|Strength training|Strength training for 24 weeks
65851|NCT01129232|Drug|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
65852|NCT01129232|Other|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
63804|NCT01106885|Behavioral|Medication Care Management (MCM)|Basic physical activity counseling
Notify PCP and facilitate initiation of antidepressants
Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks*
1/mo monitoring in continuation phase (mos. 4-12)*
Report & recommendations to PCP after each patient call
Note: *average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)
63805|NCT01106885|Behavioral|Cognitive-Behavioral Therapy (CBT)|Notify PCP
CBT Manual
Weekly CBT focused counseling for 12 weeks**
Monthly CBT in months 4-12**
Behavioral physical activity counseling
Report & recommendations to PCP after each patient call
Note: **average of 50 minutes of telephone time each
63806|NCT01106898|Drug|cyclophosphamide|Given IV
63807|NCT00035815|Drug|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
63808|NCT01106898|Drug|paclitaxel|Given IV
63809|NCT01106898|Biological|trastuzumab|Given IV
63810|NCT01106911|Device|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
63811|NCT01106924|Other|Probiotic|daily probiotic consumption
63812|NCT01106924|Other|Placebo|daily placebo consumption
63813|NCT01106950|Biological|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is < or = 8 x 10^7 nucleated cells/kilogram.
63814|NCT01106950|Drug|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
63815|NCT01106950|Drug|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
64088|NCT00036218|Drug|sumanirole|
64089|NCT01110135|Procedure|leukapheresis|Given IV
64090|NCT01110135|Other|laboratory biomarker analysis|Correlative studies
64091|NCT01110135|Other|flow cytometry|Correlative studies
64092|NCT01110135|Drug|etoposide|Given IV
64093|NCT01110148|Other|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
64094|NCT01110148|Other|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
64095|NCT01110161|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
65438|NCT01141257|Drug|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
65439|NCT00039351|Drug|prednisone|
65440|NCT01141270|Drug|AFOLIA|single sc injection, 225 IU
65441|NCT01141270|Drug|Gonal-f|single sc injection, 225IU
65442|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
65443|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
65444|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
65445|NCT01141296|Drug|fenofibrate|fenofibrate 200 mg PO daily for 1 year
65446|NCT01141296|Drug|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
65784|NCT00038688|Behavioral|Peer HIV Education Program|
65785|NCT01132079|Drug|cream treatment|
65786|NCT01132105|Device|Vestibular myogenic evoked potential analyzer|
65787|NCT01132118|Drug|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
65788|NCT01132131|Other|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
65789|NCT01134302|Procedure|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
65790|NCT01134302|Procedure|Hybrid Strategy|Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.
The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies.
65791|NCT01134315|Drug|Paricalcitol|
65792|NCT01134315|Drug|Calcitriol|
65793|NCT01134328|Drug|AC-150|1 drop in each eye for up to 14 days
65794|NCT01134328|Drug|AC-150A|1 drop in each eye once per day for up to 14 days
63869|NCT01114789|Other|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
63870|NCT01114802|Behavioral|Project Onward website + social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
63871|NCT01114802|Behavioral|Project Onward website|Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
63872|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
63873|NCT00036777|Other|pharmacological study|Correlative studies
63874|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
63875|NCT01114841|Drug|Tazarotene Foam|Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.
There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).
These patches will then be evaluated at 24, 48, and 72 hours.
There may be a second rest period and a second 48-hour patch application and evaluation, if required.
63876|NCT01114841|Drug|Vehicle Foam|Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.
There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).
These patches will then be evaluated at 24, 48, and 72 hours.
There may be a second rest period and a second 48-hour patch application and evaluation, if required.
63877|NCT01114854|Drug|Topiramate|
63878|NCT01114854|Drug|Topiramate|
63879|NCT01114880|Biological|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
63880|NCT01114880|Other|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
63881|NCT01114893|Drug|Travoprost 0.004%|1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
64163|NCT01110213|Behavioral|Physical activity|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
64164|NCT01110213|Behavioral|Fruit and vegetable|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
64165|NCT01110226|Drug|KML-001|KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 7.5 mg. The Dose will be increased until Maximum Tolerated Dose is established.
KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off.
64166|NCT01110226|Drug|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
65853|NCT01129245|Drug|celebrex|400 mg PO daily intermittently based on hormone and ultrasound findings
65854|NCT01129245|Drug|Placebo|
65855|NCT01129258|Drug|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
65856|NCT01129258|Drug|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
65857|NCT01132144|Procedure|Endometrial injury|Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.
Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.
Endometrial injury:
Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.
Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.
Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping.
65858|NCT01132144|Procedure|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
65859|NCT01132157|Drug|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
64630|NCT01142167|Procedure|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
64631|NCT00039377|Drug|tacrolimus|Given IV or PO
64632|NCT01142167|Procedure|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
64633|NCT01142180|Procedure|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
64634|NCT01142180|Procedure|No TAE|No TAE procedure will be performed after endoscopic treatment
64635|NCT01142193|Drug|USL255|
64636|NCT01142193|Drug|Placebo|
64637|NCT01142206|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
64638|NCT01142206|Behavioral|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
64639|NCT01142206|Behavioral|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
64096|NCT01110174|Other|PET CT imaging|imaging
64097|NCT01112332|Device|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
64098|NCT01112358|Drug|Follitropin alpha (r-FSH) and Lutropin alfa (r-hLH)|Recombinant-human luteinising hormone (r-hLH) was administered by subcutaneous (s.c.) route at a daily dose of 150 IU after administration of r-hFSH an GnRH antagonist. Administration of r-hFSH, GnRH antagonist, and r-hLH was stopped within 24 hours prior to r-hCG administration
64099|NCT01112358|Drug|Follitropin alpha (r-FSH)|Recombinant-human follicle stimulating hormone (r-hFSH) was administered by s.c. route at a daily dose of 225-450 IU/day and then adjusted according to ovarian response as determined by ovarian ultrasound (US) and/or serum E2 levels. This was then followed by administration of GnRH antagonist. Administration of r-hFSH, GnRH antagonist, and r-hLH was stopped within 24 hours prior to r-hCG administration.
64100|NCT01112371|Drug|Contractubex|Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.
Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in.
64101|NCT00036569|Biological|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
64102|NCT01112384|Drug|SB939|Given orally 3 times per week
64103|NCT01112397|Drug|AZD1480|continuous daily oral capsule
64104|NCT01112410|Other|Hypertonic saline|Hypertonic saline (6%) nebulised twice a day for 4 weeks.
(Randomised crossover trial)
64105|NCT01112410|Other|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
64106|NCT01112423|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
64107|NCT01112423|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
64108|NCT01112423|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
64396|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
64397|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
64398|NCT01141855|Drug|Champix|Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days
1mb b.d. for 70 days (full course 3 months)
64399|NCT01141855|Behavioral|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
65795|NCT01134328|Drug|AC-150B|1 drop in each eye once per day for up to 14 days
65796|NCT01134328|Drug|Vehicle|1 drop in each eye once per day for up to 14 days
65797|NCT01134341|Drug|Pralatrexate Injection|Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).
10 or 15 mg/m2, depending on cohort assignment.
Dose reductions allowed for protocol-specified criteria.
Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.
65798|NCT01134341|Drug|Bexarotene Capsules|150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.
Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.
Administered daily until criteria for study treatment discontinuation per the protocol are met.
65799|NCT00038935|Drug|ReFacto AF|
65800|NCT01134341|Dietary Supplement|Vitamin B12|1 mg intramuscular injection
Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).
65801|NCT01134341|Dietary Supplement|Folic Acid|1-1.25 mg orally
Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).
65802|NCT01134393|Drug|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
64880|NCT00039130|Drug|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
64881|NCT01137786|Drug|Non ionic contrast media comparator|one time administration for PCI
64882|NCT01137799|Drug|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
64883|NCT01137799|Drug|placebo|Once daily (single dose)
64884|NCT01137799|Drug|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
64885|NCT01140100|Drug|propofol|
64886|NCT00039299|Biological|therapeutic autologous lymphocytes|
64887|NCT01140100|Drug|thiopental,propofol|
64888|NCT01140113|Procedure|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
64889|NCT01140126|Drug|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
64890|NCT01140139|Biological|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
64167|NCT01110239|Procedure|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
64168|NCT01110252|Drug|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
64169|NCT01110252|Procedure|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
64170|NCT01110252|Genetic|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
64171|NCT00036231|Drug|RG1068 (Synthetic Human Secretin)|
64172|NCT01110265|Behavioral|attention training|
64173|NCT01110265|Behavioral|placebo training|
64174|NCT01110291|Drug|docetaxel + CEF|Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.
Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times.
64175|NCT01110304|Other|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
64176|NCT01112514|Drug|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
64177|NCT01112527|Drug|PF-00299804|Taken orally once a day
64178|NCT01112540|Drug|Morphine|0.1 mg/kg Intravenous bolus
64179|NCT00036608|Drug|Entecavir|
64180|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
64181|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Medical management
64469|NCT01141920|Behavioral|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
64470|NCT01141920|Behavioral|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
64640|NCT01142219|Drug|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
64641|NCT01142219|Drug|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
64642|NCT00000943|Biological|Hepatitis A Vaccine (Inactivated)|
64643|NCT00039377|Biological|filgrastim|Given SC
64644|NCT00039494|Radiation|3-dimensional conformal radiation therapy|
64645|NCT01144806|Behavioral|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
64646|NCT01144806|Dietary Supplement|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
64647|NCT01144832|Drug|ebastine|20 milligram capsule once daily
64648|NCT01144832|Drug|placebo capsule|one capsule once daily
64649|NCT01144845|Procedure|Thoracic surgery|Thoracoscopy or anterior thoracotomy
64650|NCT01144858|Other|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
64651|NCT01144884|Other|Procedure (education and exercise)|education/exercise
63742|NCT01109329|Biological|HMPV challenge virus|Single dose of 10^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
63743|NCT01109355|Other|lung mechanics ventilatory|To perform the evaluation of lung mechanics ventilatory mode was changed to control volume with the following parameters: tidal volume (Vt) = 8ml/kg weight, peak flow (PF) = 6 x minute volume, fraction of inspired O2 (FiO2) = 40%, respiratory rate (RR) = 16 bpm, sensitivity = 1 cmH2O. The following variables were monitored: PIC, Blood Pressure (BP), heart rate (HR), peak pressure in the airways (pp.) and plateau pressure of the respiratory system (Ppl.), these values were monitored with PEEP = 5 cmH2O. PEEP employed ranged from 0 to 14 cmH2O. To eliminate a possible physiological accommodation by the progressive increase of PEEP, the range of values was determined by drawing a sealed envelope for each patient, ranging from 2 to 2 cmH2O.
63744|NCT01109355|Other|Hemodynamic and intracranial pressure|At each value of PEEP the patient was ventilated for a period of five minutes to carry out monitoring of ICP, BP, HR, PPC and peripheral oxygen saturation (SpO2). The ICP monitoring catheter was kept closed for drainage and open for monitoring, since the arrival of the surgical block, was only open for drainage if there was an increase in ICP above 20 mmHg.
63745|NCT01109381|Drug|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
65659|NCT01128933|Procedure|Renal artery stenting|
64738|NCT01142336|Drug|Placebo|Placebo 1 tablet qHS for 1 year
64739|NCT01142349|Behavioral|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
64740|NCT01142349|Behavioral|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
64741|NCT01142349|Behavioral|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
64742|NCT01142362|Biological|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
64743|NCT01142388|Biological|Cixutumumab|Given IV
64744|NCT01145079|Device|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
64745|NCT01145092|Behavioral|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
64746|NCT01145105|Procedure|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
64747|NCT01145105|Procedure|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
64748|NCT01145131|Other|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
64749|NCT00039520|Drug|sulindac|
64750|NCT01145144|Drug|dehydroepiandrosterone crystalline fine powder|
64751|NCT01145157|Device|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
64752|NCT01145157|Device|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
64753|NCT01145157|Device|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
64754|NCT01145170|Radiation|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
64755|NCT01145170|Biological|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
65379|NCT01136044|Other|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
65380|NCT01136057|Biological|Collection of Anti-Influenza A Immune Plasma|
65381|NCT01136083|Behavioral|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
65382|NCT01136083|Other|Usual care|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
65383|NCT01136096|Behavioral|Physical activity promoting intervention|An interview with a physiotherapist
An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home
An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model
The daily record to check their body weight, exercise mode and duration
Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details
Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule
65725|NCT01126528|Dietary Supplement|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
65726|NCT01126541|Drug|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
65727|NCT01126567|Other|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
65728|NCT01126580|Drug|Metformin|
65729|NCT00038246|Drug|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
65730|NCT01126580|Drug|LY2189265|
65731|NCT01126580|Drug|Placebo (oral)|
65732|NCT01126580|Drug|Placebo (subcutaneous)|
65733|NCT01126593|Drug|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
65734|NCT01126593|Drug|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
65735|NCT01126606|Drug|Dermacid Silver (Lactic acid)|Liquid soap, daily use
65736|NCT01126606|Drug|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
61314|NCT00034242|Drug|high-dose intravenous immunoglobulin (IVIG)|
61315|NCT01095302|Drug|OMBRABULIN (AVE8062)|Pharmaceutical form:injection solution
Route of administration: intravenous infusion
61316|NCT01095302|Drug|cisplatin|Pharmaceutical form:injection solution
Route of administration: intravenous infusion
61317|NCT01095302|Drug|docetaxel|Pharmaceutical form:injection solution
Route of administration: intravenous infusion
61318|NCT01095315|Other|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
61319|NCT01095328|Other|screening|screening for Q-fever with a single blood sampling
61320|NCT01095341|Other|No intervention performed|
61321|NCT01095354|Drug|sodium chloride, salbutamol|Spirometry: all subjects Plethysmography and exhaled nitric oxide: >6 yrs
MBW: Facemask in children <9 yrs, mouthpiece for patients >11 yrs. Patients 9-11 yrs have MBW repeated using mouthpiece and facemask. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled during tidal breathing until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: inert gas patient inspires room air during tidal breathing. Patient exhales tracer gas until SF6 reaches <0.1%. Each test in duplicate and average is calculated. Once baseline test established, bronchodilator given and MBW repeated.
Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects. 15 minutes after bronchodilator spirometry and MBW repeated.
Induced sputum in asthma subjects >10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum.
61322|NCT01095367|Procedure|Seprafilm™|Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.
Seprafilm sheets are size 5" x 6" individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort.
61614|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
61615|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
61616|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
61617|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
61618|NCT01117571|Device|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
61619|NCT01117584|Drug|ASP1941|oral tablet
61620|NCT01117584|Drug|Placebo|oral tablet
61621|NCT01117597|Radiation|low RF exposure level|Exposure with 1.5 W/kg
64966|NCT01137877|Other|Milk based infant formula powder|milk based infant formula ad lib
64967|NCT01137877|Other|Investigational Infant Formula #1|Milk based infant formula ad lib
64968|NCT01137877|Other|Investigational Infant Formula #2|Milk based infant formula powder ad lib
64969|NCT01137877|Other|Human Milk|Human milk ad lib
64970|NCT01137890|Drug|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
64971|NCT01137890|Drug|Placebo|capsules administered in split doses at 22:00 and 09:00.
64972|NCT01137890|Drug|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
64973|NCT01137890|Behavioral|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
64974|NCT00039130|Drug|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
64975|NCT01137890|Behavioral|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
64976|NCT01137903|Procedure|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
64977|NCT01137903|Drug|Ciprofloxacin|500 mg/ 12 hours during 90 days
64978|NCT01137903|Drug|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
64979|NCT01137903|Drug|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
64980|NCT01137916|Drug|Imatinib|800 mg
64981|NCT01137942|Drug|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
64982|NCT01137955|Drug|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
64983|NCT01140334|Behavioral|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
64984|NCT00039312|Other|cytology specimen collection procedure|
65544|NCT01143792|Behavioral|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
64756|NCT01145183|Drug|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
64757|NCT01145183|Drug|Placebo|Matched placebo daily dosing
65037|NCT01145443|Other|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
65038|NCT01145456|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
65039|NCT01145456|Drug|gemcitabine hydrochloride|Given IV
65040|NCT01145456|Other|pharmacological study|Correlative studies
65041|NCT01145456|Other|laboratory biomarker analysis|Correlative studies
65042|NCT01145469|Genetic|DNA analysis|
65043|NCT01137955|Drug|Placebo|Placebo orally three times a day for 10 days total
65044|NCT01137968|Drug|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
65045|NCT00039130|Drug|prednisone|60 mg/sq m PO/day Days 1-7 course I
65046|NCT01137968|Drug|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
65047|NCT01137981|Drug|Any Antiretroviral Therapy|Any exposure to an antiretroviral therapy: Abacavir, Amprenavir, Delavirdine, Fosamprenavir, Lamivudine, Maraviroc, Zidovudine, Combivir (Zidovudine+Lamivudine), Epzicom (Abacavir+Lamivudine), and/or Trizivir (Abacavir+Lamivudine+Zidovudine)
65048|NCT01137994|Drug|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
65049|NCT01137994|Biological|Trastuzumab|monoclonal antibody directed to HER2 receptor
65050|NCT01137994|Drug|Docetaxel|Taxane chemotherapy
65051|NCT01137994|Drug|Paclitaxel|Taxane chemotherapy
65052|NCT01137994|Drug|Vinorelbine|Vinka alkaloid
65053|NCT01138007|Drug|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
65737|NCT01126645|Procedure|RFA|A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).
The study procedure guide will contain further instructions for RFA.
65738|NCT01126645|Procedure|Radioembolization (SIRT)|One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.
Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm.
65739|NCT01126658|Other|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
65740|NCT00038246|Drug|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
64821|NCT01142414|Drug|cisplatin|
64822|NCT01142414|Drug|fluorouracil|
64823|NCT01142414|Other|laboratory biomarker analysis|
64824|NCT00039377|Drug|cytarabine|Given IV
64825|NCT01142414|Procedure|adjuvant therapy|
64826|NCT01142414|Procedure|quality-of-life assessment|
64827|NCT01142414|Radiation|3-dimensional conformal radiation therapy|
64828|NCT01142414|Radiation|intensity-modulated radiation therapy|
64829|NCT01142427|Other|Laboratory Biomarker Analysis|Correlative studies
64830|NCT01142427|Other|Cytology Specimen Collection Procedure|Correlative studies
64831|NCT01142440|Behavioral|behavioral intervention|Dietary instructions
Oral hygiene instructions: GC plaque indicator kit
Antibacterial therapy: medident sol. one week a month, for 6 months
Fluorides: VOCO Profluorid varnish, once every 3 month
Restoration
Follow ups
64832|NCT01142453|Drug|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
61622|NCT00000924|Drug|Didanosine|
61623|NCT00036998|Procedure|conventional surgery|
61624|NCT01117597|Radiation|sham exposure|intervention with sham RF exposure
61625|NCT01117597|Radiation|high RF exposure|intervention with high RF exposure
61626|NCT01117610|Drug|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
61627|NCT01117610|Drug|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
61628|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61629|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61630|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61631|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61908|NCT01120197|Other|Exercise group|Weekly exercises
61909|NCT01120197|Other|Control Group|No Intervention, control group only
61910|NCT01120210|Drug|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
61911|NCT01120210|Drug|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
61912|NCT01122238|Drug|Nicotine Patch + Nicotine Gum|If randomized to both the Nicotine Patch and the Nicotine Gum conditions:
Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks.
61913|NCT01122251|Drug|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
61914|NCT00037817|Drug|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
65545|NCT01143805|Drug|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
65546|NCT01143805|Drug|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
65547|NCT00000943|Biological|Hepatitis B Vaccine (Recombinant)|
65548|NCT00039455|Other|laboratory biomarker analysis|Correlative studies
65549|NCT01143818|Drug|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
65550|NCT01143831|Dietary Supplement|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
65551|NCT01143857|Drug|Varenicline|Varenicline 2.0 mg/day or Placebo
65552|NCT01143870|Other|"Diabetes Report Card"|Enrolled participants will receive an individualized "diabetes report card" which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade.
65553|NCT01143883|Other|Silverlon|Silverlon dressings are gauze impregnated with silver ions
65554|NCT01143883|Other|Standard of Care Dressing|Standard dry gauze dressing
65555|NCT01143896|Other|Depression collaborative care model|The depression collaborative care arm will include a stepped-care model. The five steps are expected to include symptom and self-management monitoring by depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM will provide education about depression and depression treatment options, assess the patient's treatment preferences and barriers, assess the patient's current depression severity and mental health comorbidity, initiate a self-management plan, and assess treatment adherence. The DCM will use the alcohol screening and brief intervention. The DCM will also screen for street drug use and will recommend referral of participants who are using street drugs to the local substance abuse treatment programs.
65556|NCT01136369|Device|OSNA Breast Cancer System|For in vitro diagnostic use only.
The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).
Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required.
65557|NCT00039091|Biological|ipilimumab|Given IV
65558|NCT01136382|Drug|budesonide|pMDI, inhalation, bid, 6 weeks
65559|NCT01136382|Drug|placebo|pMDI, inhalation, bid, 6 weeks
65560|NCT01136395|Drug|Rituximab|375mg/m2 4 weeks before ABO incompatible LD transplantation
65054|NCT01138007|Drug|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
65055|NCT01138020|Behavioral|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
65056|NCT00039130|Drug|vincristine sulfate|2 mg IV push Day 1 courses II-VII
65057|NCT01138020|Behavioral|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
65311|NCT01135992|Drug|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
65312|NCT01136005|Other|cream|apply at least two times a day on face, chest and upper arms during the 6 week treatment period
65313|NCT00039039|Drug|paclitaxel|
65314|NCT01138384|Drug|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
65315|NCT01138384|Drug|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
65316|NCT00039182|Other|laboratory biomarker analysis|Correlative studies
65317|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
65318|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
65319|NCT01138410|Biological|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
65320|NCT01138423|Drug|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
65321|NCT01138423|Drug|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
65322|NCT01138423|Drug|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
62173|NCT01118598|Drug|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
62174|NCT01118611|Drug|Aurora B/C kinase inhibitor GSK1070916A|
62175|NCT01120574|Other|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
62176|NCT01120600|Drug|Odanacatib|One 50 mg tablet once weekly
62177|NCT01120600|Drug|Placebo for Odanacatib|One 50 mg tablet once weekly
62178|NCT01120613|Drug|Chronotherapy|Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:
ACE or ARB
Calcium Channel Blockers
Alpha Blocker
Beta Blocker
If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed.
62179|NCT01120626|Drug|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
62180|NCT01120626|Drug|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
62181|NCT01120639|Drug|Temozolomide|75 mg/m2/day, oral
61249|NCT01087736|Drug|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
61250|NCT01087736|Other|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
61251|NCT01087749|Drug|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
61252|NCT01087749|Drug|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
61253|NCT01087749|Drug|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
61915|NCT01122251|Drug|Lercanidipine or Valsartan|L10, L20, V80, V160
61916|NCT01122251|Drug|Placebo|Placebo of Lercanidipine and Valsartan
61917|NCT01122264|Drug|Tadalafil|Administered orally for 24 weeks.
61918|NCT01122264|Drug|Sildenafil Citrate|Administered orally for 24 weeks.
61919|NCT01122316|Drug|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
61920|NCT01122329|Dietary Supplement|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
61921|NCT01122329|Dietary Supplement|Placebo|
61922|NCT01122342|Drug|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
61923|NCT01122355|Drug|lipid modification|1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
61924|NCT01122368|Drug|micafungin|IV
61925|NCT00037817|Biological|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
61926|NCT01122368|Drug|placebo|IV
61927|NCT01122381|Drug|ethosuximide|ethosuximide (ESX)
61928|NCT01122381|Other|placebo comparator|placebo
61929|NCT01122394|Behavioral|TI|Tailored intervention based on the transtheoretical model
61930|NCT01122394|Behavioral|AP|Attention placebo
62242|NCT01118611|Other|pharmacological study|
62243|NCT00037037|Biological|tyrosinase peptide|
62244|NCT01118611|Procedure|diffusion-weighted magnetic resonance imaging + PET CT|
62245|NCT01118611|Radiation|fludeoxyglucose F 18 dynomic contrast|
62246|NCT01118624|Drug|Pralatrexate Injection|Intravenous (IV) push administration over 3-5 minutes.
Initial dose: 190 mg/m2
Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.
Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
65578|NCT01131520|Behavioral|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
65579|NCT01131520|Behavioral|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
65580|NCT01131533|Procedure|Vitrectomy|vitrectomy following intravitreal erythropoietin
65581|NCT01131546|Drug|Levamlodipine besylate|Once daily, 7AM - 10AM
65582|NCT01131546|Drug|Amlodipine maleate|Once daily, 7AM - 10AM
65583|NCT01131559|Drug|Lisdexamfetamine|Oral; 20-70mg/day
65584|NCT01131559|Drug|Placebo control|Oral; 20-70mg/day
65585|NCT01131572|Drug|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
65586|NCT01131585|Procedure|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
65587|NCT00038636|Drug|Lopinavir/ritonavir|
65588|NCT01131585|Drug|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
65589|NCT01131585|Drug|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
65590|NCT01131611|Behavioral|CBPT|Cognitive-Behavioral Based Physical Therapy
65591|NCT01131611|Other|Control-Attention|Standard of Care + weekly phone calls
65592|NCT01131624|Drug|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
65593|NCT01131624|Drug|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
65594|NCT01131637|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
65595|NCT01131637|Drug|placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
65596|NCT01131676|Drug|BI 10773 low dose|BI 10773 tablets once daily
65597|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
65323|NCT01138423|Drug|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
65324|NCT01138423|Drug|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
65325|NCT01138436|Drug|MEBO Wound Ointment (MEBO)|Topical application once a day
65326|NCT01138436|Procedure|Standard of Care|Application of Profore multilayer compression bandage system
65327|NCT00039195|Biological|filgrastim|
65660|NCT01128946|Drug|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
65661|NCT01128946|Drug|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
65662|NCT01128946|Drug|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
65663|NCT01128959|Drug|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
65664|NCT01128972|Drug|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
65665|NCT01128972|Drug|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
65666|NCT01128972|Drug|Sterile water|Sterile water rinse
65667|NCT00038467|Drug|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
65668|NCT01128985|Drug|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
65669|NCT01128985|Drug|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
65670|NCT01128985|Drug|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
65671|NCT01128985|Drug|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
65672|NCT01128998|Drug|Sorafenib|Name: Sorafenib
Dosage form: 200 mg / Tablet
Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1
65673|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
61254|NCT01087762|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
61255|NCT01087762|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
61256|NCT01087762|Other|Placebo|Matching Placebo to CZP injection.
61257|NCT00000918|Drug|Lamivudine|
61258|NCT00033449|Other|laboratory biomarker analysis|Correlative studies
61259|NCT01087775|Behavioral|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
61260|NCT01087788|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
61261|NCT01087788|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
61262|NCT01087788|Other|Placebo|Matching Placebo to CZP injection.
61263|NCT01087801|Drug|ChiRhoStim|Human Secretin for Injection
61264|NCT01087801|Drug|Placebo|Saline for Injection
61265|NCT01087814|Drug|Efavirenz|Subject will take efavirenz for 5 days.
61562|NCT01119638|Drug|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
61563|NCT01119651|Drug|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated & will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
61564|NCT01119664|Drug|SCH 721015|
61565|NCT01119677|Drug|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
61566|NCT01119690|Dietary Supplement|Cold-pressed turnip rapeseed oil (CTPRO)|In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.
In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO.
62247|NCT01118624|Dietary Supplement|Vitamin B12|1 mg intramuscular injection
Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate.
62248|NCT01118624|Dietary Supplement|Folic Acid|1.0-1.25 mg orally
Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate.
62249|NCT01118637|Behavioral|StopPulling.com|subsidized access to an interactive self-help website for TTM
62250|NCT01118663|Drug|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
62251|NCT01118663|Drug|Acetadote|Acetadote [old formulation] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
62252|NCT01118676|Drug|cilengitide, radiochemotherapy|Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.
The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).
After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy.
62253|NCT01118689|Drug|MLN0128|MLN0128 administered orally once daily for 28 days
62254|NCT00037050|Drug|Linezolid|
62255|NCT01118702|Drug|Ritalin-SR|3-20mg tablets, once
62256|NCT01118702|Drug|Concerta|one 54mg tablet, once
62257|NCT01118702|Drug|Novo-Methylphenidate ER-C|one 54mg tablet, once
62258|NCT01118715|Device|Compression glove|A compression glove worn during recovery from distal radius fracture
62259|NCT01118728|Drug|Sarilumab|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
62260|NCT01118741|Drug|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
62261|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
61323|NCT01095380|Other|Locomotor training|Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
61324|NCT01095406|Device|S1 ventilation|Ventilation with a O2 and CO2 controller
61325|NCT00034255|Drug|INGAP Peptide|
65598|NCT00038636|Drug|Ritonavir|
65599|NCT01131676|Drug|BI 10773 high dose|BI 10773 tablets once daily
64670|NCT01137448|Behavioral|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
64671|NCT01137461|Procedure|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
64672|NCT00039130|Drug|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
64673|NCT01137474|Drug|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
64674|NCT01137474|Drug|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
64675|NCT01137474|Drug|Oral antidiabetic agent|
64676|NCT01137474|Drug|Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB)|Patients were previously taking an ACE inhibitor or ARB
64677|NCT01137474|Drug|With or without insulin|Patients may or may not have been taking insulin
64678|NCT01137487|Procedure|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
64679|NCT01137487|Procedure|not monitoring of residual gastric volume|no measurements of residual gastric volume
64680|NCT01137513|Device|Observational Measurement of T-wave Alternans|Measurement is similar to typical EKG
64681|NCT01137513|Device|T-wave Alternans|T-Wave Alternans will be measured in an observational fashion
64682|NCT01137526|Drug|ABT-384|Subjects will take study drug once daily for 12 weeks
64683|NCT00039130|Drug|cytarabine|1 g/sq m/day IV infusion Days 4 & 5, courses II, IV, VI
64684|NCT01137526|Drug|donepezil|Subjects will take study drug once daily for 12 weeks.
64685|NCT01137526|Drug|placebo|Subjects will take study drug once daily for 12 weeks
64686|NCT01137539|Device|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
64687|NCT01137552|Drug|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
64688|NCT01137565|Drug|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
65674|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
65675|NCT01131689|Drug|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
65676|NCT01131702|Drug|Ranitidine|Ranitidine Tablets, 300 mg
65677|NCT01131728|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
65678|NCT01131741|Drug|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
65679|NCT01131741|Drug|Control|This group receives 3 mL of saline IV during operation.
65680|NCT01131754|Other|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
65681|NCT00038649|Drug|Gleevec|400 mg orally twice daily
64758|NCT01145209|Drug|Fludarabine Phosphate|Given IV
64759|NCT01145209|Biological|Ofatumumab|Given IV
64760|NCT00039546|Drug|cyclophosphamide|
64761|NCT01145209|Drug|Cyclophosphamide|Given IV
64762|NCT01145222|Drug|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
64763|NCT01145222|Drug|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
64764|NCT01145222|Drug|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
64765|NCT01145222|Drug|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
64766|NCT01145248|Device|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
64767|NCT01137578|Procedure|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
64768|NCT01137591|Drug|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
64769|NCT00000941|Drug|Atorvastatin calcium|
61567|NCT01119690|Dietary Supplement|milk fat|In dietary period of 6 to 8 weeks: 37.5 grams of butter.
In the 5-hour oral glucose and fat tolerance test: glucose and cream
61568|NCT01119703|Biological|Tetanus & Diphtheria booster vaccine (Td)|Tetanus & Diphtheria booster vaccine (Td), single intramuscular dose
61569|NCT01119703|Biological|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], intramuscular, two doses of standard three dose regimen (opposite arms)
61570|NCT01119703|Biological|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
61571|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
61572|NCT00037154|Drug|Saw Palmetto|
61573|NCT01119742|Drug|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
61574|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
61575|NCT01119742|Drug|Vehicle A|Twice daily application for 7 days
61576|NCT01119742|Drug|Vehicle B|Twice daily application for 7 days
61577|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
61578|NCT01121796|Dietary Supplement|Vitamin D|
61579|NCT01121796|Other|Water or milk|
61842|NCT01124682|Radiation|image-guided radiation therapy|
61843|NCT01124682|Radiation|selective external radiation therapy|
61844|NCT01124695|Drug|tamoxifen citrate|
61845|NCT01124695|Other|laboratory biomarker analysis|
61846|NCT01124708|Drug|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
61847|NCT01124708|Drug|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
61848|NCT00038077|Drug|Placebo|
61849|NCT01124721|Behavioral|Cognitive training|Cognitive computerized training for several days per week.
61326|NCT01095419|Other|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
61327|NCT01095419|Other|Control|no intervention
61328|NCT01095432|Procedure|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
61329|NCT01095445|Drug|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
61330|NCT01087840|Drug|Raltegravir|Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.
Arms: Raltegravir/Truvada Other Names: Isentress/Truvada
61331|NCT01087853|Drug|Crystalloid|2 litres intravenous infusion in 60 minutes
61332|NCT00033462|Drug|erlotinib hydrochloride|Given orally
61333|NCT01087853|Drug|Colloid|1 litre intravenous infusion over 30 minutes
61334|NCT01087866|Drug|Metformin|
61335|NCT01087866|Drug|Insulin|
61336|NCT01087879|Drug|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
61337|NCT01087879|Drug|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
61338|NCT01087879|Drug|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
61339|NCT01087892|Dietary Supplement|Probiotic drink containing the live strain|Probiotic drink contains no strain
61340|NCT01087892|Dietary Supplement|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
61341|NCT01087905|Drug|Nicotine patch|If > 10 cigs/day: one 21 mg nicotine patch per day
If < or = 10 cigs/day: one 14 mg nicotine patch per day
64689|NCT01137565|Drug|Placebo|Placebo to AMG 853
64690|NCT01137578|Procedure|Ultrasound|Ultrasounds to be performed on children with central venous catheters
64691|NCT01137578|Drug|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
64692|NCT01139762|Drug|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
64985|NCT01140334|Behavioral|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
64986|NCT01140347|Biological|Placebo|8 mg/kg IV every 2 weeks
64987|NCT01140347|Biological|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
64988|NCT01140347|Other|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
64989|NCT01140360|Drug|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
64990|NCT01140373|Biological|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 107 CAR+ T cells/kg, 3 x 107 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
64991|NCT01140373|Drug|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 107 CAR+ T cells/kg, 3 x 107 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
64992|NCT01140399|Drug|Furosemide or Furosemide and Dopamine|Patients randomized to pharmacological treatment receive
either intravenous diuretics at escalating doses up to 20 mg/h
or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m.
64770|NCT00039130|Drug|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
64771|NCT01137591|Drug|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
64772|NCT01137604|Drug|E7080|Will assess subjects with recurrent GBM who are bevacizumab-naïve. Approximately 98 subjects accrued in Cohort 1 will be randomized in a 1:1 ratio to receive 24 mg E7080 (Arm A), orally once daily or bevacizumab (Arm B) at a dose of 10 mg/kg intravenously every 2 weeks in 28-day cycles. A subject in Cohort 1 with disease progression following bevacizumab treatment may be enrolled in Cohort 3. The subject must be assigned a new Subject Identification Number.
64773|NCT01137604|Drug|E7080|Will assess subjects with recurrent grade 3 malignant glioma who are bevacizumab-naïve. Approximately 40 subjects in Cohort 2 will be treated with 24 mg E7080 orally, once daily in 28-day cycles.
64774|NCT01137604|Drug|E7080|Will assess subjects with recurrent GBM who have disease progression following prior bevacizumab treatment. Approximately 32 subjects will receive 24 mg E7080 orally, once daily in 28-day cycles in Cohort 3. Treatment will continue until disease progression, development of unacceptable toxicity, withdrawal of consent, or discontinuation of E7080 development by the Sponsor. The primary endpoint of each cohort is 6-month progression-free survival rate. The assessment will be made separately among the 3 cohorts.
64775|NCT01137630|Drug|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
64776|NCT01137630|Drug|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
65058|NCT01138033|Drug|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
65059|NCT01138046|Drug|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
65060|NCT01138072|Drug|GSK2248761|200mg once daily
65061|NCT01138072|Drug|Simvastatin|20 mg Simvastatin single dose
65062|NCT01138072|Drug|Atorvastatin|20 mg atorvastatin single dose
65063|NCT01138072|Drug|Rosuvastatin|10 mg rosuvastatin single dose
65064|NCT01138085|Drug|GSK1120212|MEK inhibitor
65065|NCT01138085|Drug|GSK2141795|AKT Inhibitor
65066|NCT01138098|Biological|Engerix™-B|Intramuscular, single dose
61850|NCT01124721|Behavioral|Cognitive training-placebo|Cognitive training that only minimally increases in difficulty
61851|NCT01124734|Drug|Interleukin-2|up to a maximum of 14 doses at 600,000 IU/kg
61852|NCT01124734|Drug|Interleukin-2|If complete response, patient would have one course of treatment. If patient has stable, disease, partial response or minor response, patient would have 2 courses courses.
61853|NCT01124734|Drug|Temozolomide|Patients would receive temozolomide at 75 mg/m2 beginning 28 days after discharge from receipt of the second cycle of high dose IL-2. Patients would take the medication at bedtime daily. Four weeks after cycle 2 of a course, they would take it for 21 days.
61854|NCT01124747|Drug|ASP1585|Oral
61855|NCT01124747|Drug|14C-Labeled ASP1585|Oral
61856|NCT01124760|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
61857|NCT01124760|Drug|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
61858|NCT01124760|Drug|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
61859|NCT00038090|Drug|Thalidomide|100 mg capsules by mouth daily each evening
61860|NCT01124786|Drug|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
61861|NCT01117948|Drug|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
61862|NCT01117948|Drug|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
61863|NCT00037024|Procedure|fatigue assessment and management|
61864|NCT01117961|Behavioral|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
62182|NCT01120639|Procedure|Stereotactic Radiosurgery|Standard of care
62183|NCT00037557|Drug|BeneFIX|
62184|NCT01120652|Behavioral|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
62185|NCT01120652|Behavioral|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
61632|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61633|NCT01117623|Drug|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
61634|NCT00036998|Procedure|neoadjuvant therapy|
61635|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
61636|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
61637|NCT01119781|Drug|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
61638|NCT01119794|Drug|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
61639|NCT01119807|Device|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
61640|NCT01119807|Device|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
61641|NCT00037167|Device|Exercise poles|
61642|NCT01119807|Device|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
61643|NCT01119820|Other|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
61644|NCT01119833|Drug|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
61645|NCT01119833|Drug|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
61646|NCT01119846|Drug|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
61647|NCT01119846|Drug|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
61648|NCT01119846|Drug|Sitagliptin|Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with "277" on one side.
64993|NCT01140399|Device|Ultrafiltration|All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight
less than 3 kg 200 ml/h
more than 3 kg and less than 5 kg 300 mlh
more than 5 kg 500 mlh
Criteria for achievement of target UF goals are removal of > 50% and <70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited
64994|NCT01140412|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
64995|NCT00039312|Procedure|annual screening|
64996|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
64997|NCT01142700|Drug|BMS-824393|Capsule, Oral, 30 mg, once daily
65255|NCT01140828|Drug|Rabeprazole Placebo|one tab once daily
65256|NCT01140841|Drug|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
65257|NCT01140841|Drug|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
65258|NCT01140854|Procedure|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
65259|NCT01140854|Other|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
65260|NCT01140867|Drug|zonisamide|zonisamide 100 mg tablet
65261|NCT01140880|Drug|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
65262|NCT01140893|Drug|Exenatide|Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.
From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time.
65263|NCT01140893|Drug|Placebo|Placebo
65264|NCT01140906|Drug|Placebo|capsules, daily, orally
65265|NCT00039338|Radiation|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
65266|NCT01140906|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
65267|NCT01140906|Drug|Duloxetine|encapsulated capsules, daily, orally
65067|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
65068|NCT01140412|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
65069|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
65070|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
65071|NCT01140425|Drug|PF-00232798|600 mg oral solution once daily x 7 days
65072|NCT01140425|Drug|PF-00232798|300 mg oral solution once daily x 7 days
65073|NCT01140425|Drug|Placebo|Oral solution once daily x 7 days
65074|NCT01140425|Drug|Moxifloxacin|400 mg tablet single dose
65075|NCT01140438|Drug|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
65076|NCT00039312|Procedure|colposcopic biopsy|
65077|NCT01140438|Drug|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
65078|NCT01140451|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (10 mg/kg with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner) for up to 48 weeks.
65328|NCT01138449|Drug|Vitamin A|Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
65329|NCT01138462|Other|intervention|5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.
Daily direct resident's environmental disinfection during decolonisation.
65330|NCT01138475|Drug|Paricalcitol|1 microgram by mouth daily for 6 weeks
65331|NCT01138475|Drug|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
65332|NCT01138475|Drug|Placebo|Inactive substance, one capsule daily for 6 weeks
65333|NCT01140971|Device|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
65334|NCT01140984|Drug|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
62186|NCT01120665|Drug|Estradiol valerate|estradiol valerate, 1 mg/day, orally.
62187|NCT01120665|Other|Aerobic training|Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)
62188|NCT01120665|Drug|Placebo|lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
62189|NCT01120665|Other|Control|The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
62190|NCT01120691|Drug|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
62191|NCT01120691|Drug|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
62192|NCT01120691|Drug|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
62193|NCT01120691|Drug|Salbutamol/albuterol|As needed throughout the study
62194|NCT00037570|Drug|Pantoprazole|
62195|NCT01122810|Procedure|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
62196|NCT01122823|Behavioral|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
61266|NCT01087814|Drug|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
61267|NCT01090271|Device|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
61268|NCT01090284|Device|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
61269|NCT00033657|Drug|cisplatin|Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29
Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
61649|NCT01119859|Drug|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
61931|NCT01122407|Drug|Trimethaphan, L-NMMA|Trimethaphan up to 5 mg/min L-NMMA 250 ug/Kg/min
61932|NCT01122407|Drug|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
61933|NCT01122420|Other|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
61934|NCT01122420|Other|Health Web Sites|Access to publicly available health-related web sites
61935|NCT01122433|Device|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
61936|NCT00037817|Drug|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
61937|NCT01124916|Procedure|Laparoscopic Abdominal Sacrocolpopexy|Laparoscopic repair of pelvic organ prolapse
61938|NCT00000936|Drug|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
61939|NCT00038103|Drug|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
61940|NCT01124929|Drug|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
61941|NCT01124929|Drug|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
61942|NCT01124942|Device|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
61943|NCT01124942|Device|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
61944|NCT01124955|Other|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
61945|NCT01124955|Other|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
61946|NCT01124968|Other|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
61947|NCT01124981|Drug|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
65268|NCT01140932|Drug|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
65269|NCT01140932|Behavioral|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
65270|NCT01140971|Drug|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
65271|NCT01143129|Drug|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
65272|NCT01143129|Drug|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
65273|NCT01143142|Behavioral|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
65600|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
65601|NCT00038870|Biological|Dendritic Cell Activated Lymphocyte|
65602|NCT01134042|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
65603|NCT01134042|Other|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
65604|NCT01134042|Other|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
65605|NCT01134055|Drug|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
65606|NCT01134055|Drug|placebo|placebo eye drops
65607|NCT01134055|Biological|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
65608|NCT01134068|Other|Evaluation of a modified DD cut-off to rule out PE|Evaluation of a modified DD cut-off to rule out PE
65609|NCT01134081|Biological|CelTx Apligraf|CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
65610|NCT01134094|Procedure|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
65335|NCT01140997|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
65336|NCT01140997|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
65337|NCT01141010|Other|Language|Plain language without psychological intervention
65338|NCT00039338|Radiation|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
65339|NCT01141010|Other|Language|Psychological linguistic intervention will be given
65340|NCT01141023|Drug|Datscan and AV-133|
65341|NCT01141036|Drug|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
65342|NCT01141036|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
65343|NCT01141049|Drug|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
65344|NCT01141049|Other|Placebo|Placebo, TID
65345|NCT01141062|Device|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
65682|NCT01131767|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
65683|NCT01131780|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
65684|NCT01131793|Device|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
65685|NCT01131806|Drug|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
65686|NCT01131806|Drug|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
65687|NCT01131819|Device|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
65688|NCT01131832|Dietary Supplement|Plant sterol|
61270|NCT01090297|Device|S8 Spirit 2|3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.
These 3 types of CPAP can be set in both mode of pressure.
61271|NCT01090297|Device|Somnosmart 2|3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.
These 3 types of CPAP can be set in both mode of pressure.
61272|NCT01090297|Device|Remstar Auto|3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.
These 3 types of CPAP can be set in both mode of pressure.
61273|NCT01090310|Drug|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
61274|NCT01090310|Drug|Placebo|Matching placebo to AIN457
61275|NCT01090323|Drug|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
61276|NCT01090349|Device|Implantation of an ICD/CRT-D device|The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.
61277|NCT01090349|Device|Merlin.NET PCN|The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
61278|NCT01090375|Other|Exercise|
61279|NCT01090375|Other|Non Exercise|
61280|NCT00033657|Drug|irinotecan hydrochloride|Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29
Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
61281|NCT01090401|Device|Linox smart S DX|ICD lead
61282|NCT01090414|Drug|Idelalisib|Idelalisib tablets administered orally
61283|NCT01090427|Drug|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
61284|NCT01090427|Drug|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
61285|NCT01090427|Other|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
61580|NCT01121796|Dietary Supplement|Vitamin D enriched milk|
61581|NCT01121809|Drug|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
61582|NCT01121809|Drug|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
61948|NCT01124981|Drug|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
61949|NCT01124994|Procedure|Endoscopic mucosal resection|Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
62262|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
62263|NCT01118754|Drug|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
62264|NCT01118767|Other|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
62265|NCT01120704|Drug|Short Term Combination Nicotine Replacement Therapy (patch + gum)|IF participant smokes >10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.
IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.
62266|NCT01120704|Drug|Long Term Combination Nicotine Replacement Therapy (patch + gum)|IF the participant smokes >10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.
IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.
62267|NCT01120704|Behavioral|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 & 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
62268|NCT01120704|Behavioral|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
65611|NCT01134094|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
65612|NCT00038883|Drug|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
65613|NCT01134107|Drug|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
65614|NCT01134107|Drug|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
65615|NCT01134120|Drug|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
65616|NCT01134133|Other|Anti-gurgling intervention|1. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
64693|NCT01139762|Drug|Placebo|Administered orally, once daily for 26 weeks
64694|NCT01139762|Drug|Finasteride|5mg administered orally, once daily for 26 weeks
64695|NCT01139775|Drug|Pemetrexed|Administered intravenously
64696|NCT00039234|Drug|histamine dihydrochloride|
64697|NCT01139775|Drug|Cisplatin|Administered intravenously
64698|NCT01139775|Drug|LY2603618|Administered intravenously
64699|NCT01139788|Drug|LY2624587|6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.
If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).
64700|NCT01139801|Drug|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration
64701|NCT01139801|Drug|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
64702|NCT01139814|Device|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
64703|NCT01139840|Dietary Supplement|vitamin D2|Study Supplement
64704|NCT01139840|Dietary Supplement|vitamin D3|Study Supplement
64705|NCT01139853|Device|Nasogastric Tube|Insertion of a 10 French Nasogastric tube prior to surgery
64706|NCT01139879|Device|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
65689|NCT01131832|Dietary Supplement|Placebo|
65690|NCT01131845|Drug|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
65691|NCT01131858|Drug|Vigantol|Vigantol 4000IU/day
65692|NCT00038662|Drug|Atrasentan|
65693|NCT01131858|Drug|Placebo|Placebo
65694|NCT01131871|Behavioral|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
65695|NCT01131871|Behavioral|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
65696|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
65697|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
65698|NCT01134185|Drug|prucalopride|single dose of 2 mg prucalopride
65699|NCT00038896|Drug|Venlafaxine ER|
65700|NCT01134198|Drug|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
65701|NCT01134198|Drug|placebo|placebo
65702|NCT01134211|Device|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
64777|NCT01137630|Drug|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
64778|NCT01137643|Other|biologic sample preservation procedure|All samples collected during routine clinical care.
64779|NCT01137643|Other|cytology specimen collection procedure|All Samples collected during routine clinical care.
64780|NCT01137656|Drug|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
64781|NCT00039130|Drug|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 & 5 courses III,V, VII
61583|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
61584|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
61585|NCT01121835|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
61586|NCT00037700|Drug|pegsunercept|
61587|NCT01121835|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
61588|NCT01121835|Drug|PREMIXED INSULIN|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico
25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only
61589|NCT01121848|Drug|Leucovorin|Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV
Dose regimen:
61590|NCT01121848|Drug|OXALIPLATIN|Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV
Dose regimen:
61591|NCT01121848|Drug|5-Fluorouracil|Pharmaceutical form: vials of 5 g/100mL Route of administration: IV
Dose regimen:
61592|NCT01121861|Procedure|Phacoemulsification with implantation of toric IOL|
61593|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
61594|NCT01121874|Procedure|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
61595|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
61596|NCT01121887|Behavioral|Standard treatment|Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.
Clients are offered a choice between "reactive treatment" (clients initiate all contact) and "proactive treatment" (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge.
61597|NCT00037713|Biological|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 & 10.
61865|NCT01117974|Procedure|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
62269|NCT01120704|Behavioral|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
62270|NCT01120704|Behavioral|Automated Adherence Prompting Phone Calls|Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.
Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 & 23.
62271|NCT01120717|Drug|QVA149|capsules for inhalation, delivered by an SDDPI
65232|NCT01138319|Genetic|DNA analysis|
65233|NCT01138319|Genetic|mutation analysis|
65234|NCT01138319|Genetic|polymerase chain reaction|
65235|NCT01138319|Other|laboratory biomarker analysis|
65236|NCT01138332|Genetic|western blotting|
65237|NCT01138332|Other|laboratory biomarker analysis|
65238|NCT01138345|Genetic|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
65239|NCT01138345|Genetic|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
65240|NCT00039182|Drug|erlotinib hydrochloride|Given orally
65241|NCT01138345|Other|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
65242|NCT01138345|Other|medical chart review|perform medical chart review for all subjects
65243|NCT01138345|Other|questionnaire administration|each cohort will be given the same questionnaire
65244|NCT01138358|Other|medical chart review|
65245|NCT01138358|Other|study of socioeconomic and demographic variables|
65246|NCT01138358|Other|survey administration|
65247|NCT01138358|Procedure|quality-of-life assessment|
65248|NCT01138371|Procedure|LDL Apheresis|LDL Apheresis
64707|NCT00000941|Drug|Saquinavir|
64708|NCT00039273|Biological|panitumumab|
64709|NCT01139892|Procedure|Surgical management|
64710|NCT01139892|Procedure|Endovascular management|
64711|NCT01139905|Other|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
64712|NCT01139931|Genetic|DNA methylation analysis|
64713|NCT01139931|Genetic|gene expression analysis|
64714|NCT01139931|Genetic|microarray analysis|
64715|NCT01139931|Genetic|polymorphism analysis|
64716|NCT01139931|Other|laboratory biomarker analysis|
64717|NCT01139944|Genetic|DNA methylation analysis|
64718|NCT01139944|Genetic|polymerase chain reaction|
64998|NCT01142700|Drug|BMS-824393|Capsule, Oral, 100 mg, once daily
64999|NCT01142700|Drug|Placebo|Capsule, Oral, 0 mg, once daily
65000|NCT01142700|Drug|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
65001|NCT01142700|Drug|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
65002|NCT01142713|Radiation|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
65003|NCT00039390|Other|pharmacological study|Correlative studies
65004|NCT01142726|Drug|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
65005|NCT01142726|Drug|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
65006|NCT01142726|Drug|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
65007|NCT01142726|Drug|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
65008|NCT01142739|Other|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
64782|NCT01137669|Other|Placebo|Placebo for Zoster Vaccine Live (ZOSTAVAX®) is sterile normal saline which will be obtained from the Fisher Repository in single-dose containers. 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. The placebo will be administered subcutaneously in the deltoid region.
64783|NCT01137669|Biological|Live attenuated herpes zoster vaccine|ZOSTAVAX® (Zoster Vaccine Live) is a live attenuated vaccine provided as a single-dose, sterile, lyophilized, preservative-free frozen formulation. The vaccine will be supplied in 3-mL glass vials. Sterile diluent will be used to reconstitute study vaccine. The reconstituted vial will be gently agitated to mix thoroughly. The entire contents of the reconstituted vaccine vial (approximately 0.65 mL) will be withdrawn into a syringe. The vaccine will be administered immediately subcutaneously in the deltoid region.
64784|NCT01137682|Drug|Pasireotide (SOM230)|Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or
Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks
64785|NCT01139957|Other|Questionnaire Administration|Ancillary studies
64786|NCT01139957|Procedure|Study of High Risk Factors|Ancillary studies
64787|NCT01139970|Other|Laboratory Biomarker Analysis|Correlative studies
64788|NCT01139970|Other|Pharmacological Study|Correlative studies
64789|NCT01139970|Drug|Temozolomide|Given PO
64790|NCT01139970|Drug|Veliparib|Given PO
64791|NCT01139983|Genetic|DNA analysis|
64792|NCT00039286|Procedure|radionuclide imaging|
64793|NCT01139983|Genetic|RNA analysis|
64794|NCT01139983|Genetic|fluorescence in situ hybridization|
64795|NCT01139983|Genetic|microarray analysis|
64796|NCT01139983|Genetic|polymerase chain reaction|
64797|NCT01139983|Genetic|reverse transcriptase-polymerase chain reaction|
65079|NCT01140464|Other|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
65080|NCT01140477|Device|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
65081|NCT01140477|Device|Accommodating Lens|Accommodating lens implanted after cataract extraction
65082|NCT01140490|Procedure|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
61866|NCT01117987|Drug|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
61867|NCT01117987|Drug|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
61868|NCT01118000|Procedure|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
61869|NCT01118013|Biological|anti-thymocyte globulin|
61870|NCT01118013|Biological|donor lymphocytes|
61871|NCT01118013|Biological|filgrastim|
61872|NCT01118013|Biological|therapeutic allogeneic lymphocytes|
61873|NCT01118013|Drug|busulfan|
61874|NCT00037024|Procedure|nutritional support|
61875|NCT01118013|Drug|fludarabine phosphate|
61876|NCT01118013|Drug|methotrexate|
61877|NCT01118013|Drug|mycophenolate mofetil|
61878|NCT01118013|Drug|tacrolimus|
61879|NCT01118013|Other|reduced-intensity transplant conditioning procedure|
61880|NCT01118013|Procedure|allogeneic hematopoietic stem cell transplantation|
61881|NCT01118013|Procedure|peripheral blood stem cell transplantation|
61882|NCT01118026|Drug|ABVD|doxorubicin 25 mg/m^2 IV bleomycin 10 units/m^2 IV vinblastine 6 mg/m^2 IV dacarbazine 375 mg/m^2 IV
61883|NCT01118026|Drug|BEACOPP|bleomycin 10 units/m^2 IV on Day 8 etoposide 200 mg/m^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m^2 IV on Day 1 cyclophosphamide 1250 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 8 procarbazine 100 mg/m^2 orally on Days 1-7 prednisone 40 mg/m^2 orally on Days 1-14
61884|NCT01118026|Radiation|radiation therapy|
61885|NCT00037024|Procedure|physical therapy|
65249|NCT01140737|Drug|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
65250|NCT01140763|Device|Sysmex's 5-blade lymph node cutter|A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either "reference" histopathology or "test" histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin & eosin (H&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed.
65251|NCT01140815|Device|Total Knee Replacement|Smith and Nephew Total Knee Replacement
65252|NCT01140815|Device|Deuce|Smith and Nephew Bicompartmental Knee Replacement
65253|NCT01140828|Drug|Rabeprazole|Rabeprazole 20mg once daily
65254|NCT00039338|Procedure|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
65510|NCT01138709|Device|Vitala|Vitala™ Continence Control Device
65511|NCT01138722|Radiation|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
65512|NCT01138735|Drug|adapalene/benzoyl peroxide|daily topical application for 12 weeks
65513|NCT01138735|Drug|Topical Gel Vehicle|daily topical application for 12 weeks
65514|NCT01138748|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
65515|NCT01138761|Behavioral|Nurse instruction|The dermatology nurse will give additional verbal and written instruction utilizing "teach-back" about skin care precautions and medication usage to the caregivers/parents in the "treatment" group.
65516|NCT01138774|Dietary Supplement|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
65517|NCT01141309|Drug|sorafenib with everolimus|Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles *Cycle = 4 weeks of treatment.
Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study.
65518|NCT01141322|Drug|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
65519|NCT01141322|Drug|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
65009|NCT01142739|Other|Clinical variables|Demography, Biological variables.
65010|NCT01142739|Other|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
65011|NCT01142765|Biological|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
65012|NCT01142765|Biological|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
65013|NCT01142765|Biological|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
65014|NCT00039390|Other|laboratory biomarker analysis|Correlative studies
65015|NCT01142765|Biological|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
65016|NCT01142765|Biological|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
65274|NCT01143168|Biological|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
65275|NCT01143181|Drug|CMX001|CMX001 administered orally twice weekly for up to 3 months. Treatment may be extended for up to 6 months depending on the patient's clinical response.
65276|NCT01143194|Dietary Supplement|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
65277|NCT01143194|Dietary Supplement|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
65278|NCT01143194|Dietary Supplement|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
65279|NCT01143194|Dietary Supplement|Placebo|1 capsule of placebo twice a day
65280|NCT00039416|Drug|imatinib mesylate|Given orally
65281|NCT01143207|Drug|Medroxyprogesterone acetate|Injectable hormonal contraceptive
65083|NCT01140503|Drug|Apremilast|Apremilast 20mg PO BID
65084|NCT01140516|Drug|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
65085|NCT01140516|Other|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
65086|NCT01140529|Drug|Dexmedetomidine|Bolus and continuous infusion
65087|NCT00039312|Procedure|comparison of screening methods|
65088|NCT01140529|Drug|Haloperidol|Bolus doses
65089|NCT01140529|Drug|Saline|Bolus and continuous infusion
65090|NCT01140542|Drug|Roflumilast|500µg, once daily
65091|NCT01140555|Device|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
65092|NCT01140568|Drug|nilotinib|400mg po (orally) BID (twice daily)
65093|NCT01140581|Drug|DRONEDARONE|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
65094|NCT01140594|Procedure|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
65095|NCT01142791|Device|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
65096|NCT01142804|Behavioral|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
65097|NCT01142843|Drug|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
65098|NCT01142856|Biological|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
65099|NCT01142869|Drug|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
65100|NCT00039403|Drug|7-hydroxystaurosporine|Given IV
65346|NCT01141075|Drug|Ataluren (PTC124)|Ataluren (PTC124) will be provided as a vanilla-flavored powder to be mixed with water. Ataluren (PTC124) will be taken 3 times per day, with dosing based on the patient's body weight. Ataluren (PTC124) will be taken at two different dose levels. In Cycle 1, the dose level is 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening for 28 days. In Cycle 2, the dose level is 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 28 days.
61886|NCT01118039|Drug|sunitinib malate|
62197|NCT01122836|Other|Massage|Therapeutic Massage
62198|NCT01122849|Device|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
62199|NCT01122849|Device|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
62200|NCT01122849|Device|Placebo Nasal Strip|Placebo strip
62201|NCT00037882|Drug|PEG-Intron|Once weekly injection.
62202|NCT01122862|Drug|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
62203|NCT01122862|Other|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
62204|NCT01122862|Other|Sterile water|Sterile water
62205|NCT01122875|Drug|MFGR1877S|Intravenous repeating dose
62206|NCT01122888|Drug|Cilengitide|Given IV
62207|NCT01122888|Other|Clinical Observation|Patients undergo a 2-week rest period
62208|NCT01122888|Other|Laboratory Biomarker Analysis|Correlative studies
62209|NCT01122901|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
62210|NCT01122901|Procedure|therapeutic conventional surgery|Undergo surgery
62211|NCT01122901|Other|pharmacological study|Correlative studies
62212|NCT00037895|Procedure|Ambulation training|
62213|NCT01122901|Other|laboratory biomarker analysis|Correlative studies
62214|NCT01122914|Drug|Anakinra|
62215|NCT01122927|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
62216|NCT01122940|Drug|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
62217|NCT01122940|Drug|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
62218|NCT01122953|Drug|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
65520|NCT00039351|Drug|vincristine sulfate|
65521|NCT01141335|Device|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
65522|NCT01141335|Device|Infinit® PTFE mesh (WL Gore)|A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
65523|NCT01141348|Behavioral|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
65524|NCT01141348|Behavioral|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
65525|NCT01141361|Procedure|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
65526|NCT01141374|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
65860|NCT01132157|Drug|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
65861|NCT01132170|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
65862|NCT01132183|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
65863|NCT00000940|Drug|Ritonavir|
65864|NCT00038701|Drug|TNP-470|
65865|NCT01132196|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
65866|NCT01132209|Procedure|Closure of the abdominal wall after midline incisions|Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
65867|NCT01132222|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
65868|NCT01132235|Biological|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
65869|NCT01132248|Drug|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
65870|NCT01132248|Drug|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
65282|NCT01143220|Other|No specific interventions|Observational investigation, only procedures according to local hospital standard.
65283|NCT01143233|Other|control formula|infants are fed a commercial hydrolyzed formula
65284|NCT01143233|Other|intervention formula 1|formula has hydrolysed protein and a different protein content
65285|NCT01143233|Other|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
65286|NCT01143233|Other|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
65287|NCT01143246|Drug|Terlipressin|Blinded terlipressin reconstituted with 5 mL of sterile 0.9% sodium chloride solution for injection will be administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
65288|NCT01143246|Drug|Placebo|Lyophilized mannitol reconstituted with 5 mL of sterile 0.9% sodium chloride solution administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
65289|NCT01143259|Drug|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
65290|NCT01143259|Drug|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
65291|NCT00039416|Other|laboratory biomarker analysis|Correlative studies
65292|NCT01143272|Drug|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
65617|NCT01134146|Radiation|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
65618|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status.
65619|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion.
65620|NCT01126346|Other|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
65621|NCT01126359|Drug|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
65347|NCT01141088|Device|Bona M-Hilar stent|After deployment of the first stent across the hilar stricture, the guidewire left across the primary stent was carefully withdrawn with an ERCP catheter, without pulling the guidewire back completely, and then was inserted, under fluoroscopic guidance, into the undrained contralateral hepatic duct through the central crossed mesh of the primary stent. Another uncovered metal stent was then introduced over the guidewire through the central crossed mesh and was deployed into the right hepatic duct.
65348|NCT01141114|Other|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
65349|NCT00039338|Drug|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
65350|NCT01141114|Other|Usual care|Usual care
65351|NCT01141127|Drug|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
65352|NCT01143272|Drug|Placebo|Placebo
65353|NCT01143285|Other|Early and active nutritional support.|The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
65354|NCT01143298|Drug|LEO 27847 oral solution|
65355|NCT01143311|Genetic|Arm A|4 distinct biopsies will be taken
in a non UV-exposed area (inner arm)
in a UV-exposed area (external surface of the forearm)
in a pretumoral region (actinic keratosis)
inside the tumor
65356|NCT01143324|Device|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
65357|NCT01143337|Drug|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
65358|NCT01143337|Drug|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
65359|NCT01143350|Other|Bras A (EHPAD Training and stimulation)|EHPAD of the group of Training / Stimulation will benefit:
after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.
of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD.
65360|NCT01143350|Other|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
65361|NCT00039429|Drug|atrasentan hydrochloride|
65362|NCT01143363|Behavioral|resting - control|
62219|NCT01125033|Drug|Vitamin C Placebo & Vitamin E Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
62220|NCT01125046|Biological|bevacizumab|Given IV
62221|NCT01125059|Drug|Methadone|0.2 mg/kg methadone IV bolus
62222|NCT01125059|Drug|Saline|3 mL saline IV bolus
61286|NCT01090440|Drug|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
61287|NCT01090453|Biological|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
61288|NCT01090453|Biological|Prevenar 13®|3 co-administered doses
61289|NCT01092819|Other|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
61290|NCT01092832|Drug|voriconazole|Subjects 12 - <18 yrs (excluding subjects 12 - 14 yrs weighing <50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.
Subjects 2 - <12 yrs, and subjects 12 - 14 weighing <50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).
Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days.
61291|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
61292|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
61293|NCT01092858|Drug|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
61294|NCT01092858|Drug|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
61295|NCT00033904|Drug|autologous human tumor-derived HSPPC-96|
61296|NCT01092884|Dietary Supplement|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
61297|NCT01092884|Other|Placebo|This placebo capsule will be taken orally three times daily
65871|NCT01132261|Other|"brain preservation' diet|dietetic evaluation and advice in small group for health diet
65872|NCT01132274|Procedure|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
65873|NCT01132274|Procedure|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
65874|NCT01132287|Other|FID 112903|lubricant eye drop FID 112903
65875|NCT00038714|Drug|SGN-00101|
65876|NCT01132300|Device|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
65877|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
65878|NCT01132313|Drug|BI 201335|40 weeks, QD
65879|NCT01134458|Behavioral|Web-Based Intervention|Health Dialog Cardiac Risk Calculator
Health Dialog's Living with Coronary Heart Disease
Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight
65880|NCT01134471|Device|Ostene|applied to sternal surface
65881|NCT01134471|Device|Bonewax|applied to sternal surface
64941|NCT01145014|Drug|BI 660848|100 mg oral drinking solution
64942|NCT01145014|Drug|BI 660848|150 mg oral drinking solution
64943|NCT01145014|Drug|BI 660848|200 mg oral drinking solution
64944|NCT01145014|Drug|BI 660848|400 mg oral drinking solution
64945|NCT01145014|Drug|BI 660848|600 mg oral drinking solution
64946|NCT01145014|Drug|BI 660848|10,0 mg immediate release tablet
64947|NCT01145014|Drug|BI 660848|50,0 mg immediate release tablet
64948|NCT01145014|Drug|Placebo|matching placebo (oral drinking solution and IR tablets)
64949|NCT01145027|Other|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
64950|NCT01145066|Dietary Supplement|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
65622|NCT01126359|Drug|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
65623|NCT01126385|Device|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
65624|NCT01126398|Procedure|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
65625|NCT01126411|Procedure|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
65626|NCT01126424|Drug|Solifenacin|tablet
65627|NCT01126424|Drug|Oxybutynin|capsule
65628|NCT01126424|Drug|Placebo|tablet
65629|NCT01126437|Drug|tiotropium 18 mcg|HandiHaler
65630|NCT00000937|Drug|Antibiotics|
65631|NCT00038220|Drug|Tenofovir DF|
65632|NCT01126437|Drug|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
65633|NCT01126437|Drug|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
65634|NCT01126450|Drug|lenalidomide|Given orally
65635|NCT01126450|Biological|cetuximab|Given IV
65636|NCT01126450|Other|mutation analysis|Correlative studies
65637|NCT01126450|Other|polymerase chain reaction|Correlative studies
64719|NCT00039286|Procedure|positron emission tomography|
64720|NCT01139944|Other|laboratory biomarker analysis|
64721|NCT01139957|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
64722|NCT01139957|Other|Quality-of-Life Assessment|Ancillary studies
64723|NCT01142232|Drug|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
65703|NCT01134211|Device|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
65704|NCT01134224|Drug|insulin degludec/insulin aspart|0.4 U/kg body weight injected subcutaneously (under the skin) once
65705|NCT01134224|Drug|insulin degludec/insulin aspart|0.6 U/kg body weight injected subcutaneously (under the skin) once
65706|NCT01134224|Drug|insulin degludec/insulin aspart|0.8 U/kg body weight injected subcutaneously (under the skin) once
65707|NCT01134224|Drug|biphasic insulin aspart 30|0.4 U/kg body weight injected subcutaneously (under the skin) once
65708|NCT01134224|Drug|biphasic insulin aspart 30|0.6 U/kg body weight injected subcutaneously (under the skin) once
65709|NCT01134224|Drug|biphasic insulin aspart 30|0.8 U/kg body weight injected subcutaneously (under the skin) once
65710|NCT00000940|Drug|Lamivudine|
65711|NCT00038909|Drug|BDDrFVII|
65712|NCT01134237|Drug|urokinase|intrapleural urokinase injection
65713|NCT01134237|Drug|placebo|Normal saline as a placebo for control arm
65714|NCT01134250|Drug|F16IL2 in combination with paclitaxel|Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.
Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent.
65715|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
65716|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
65717|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
65718|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
65719|NCT01134263|Biological|Placebo: NaCl 0.9%|0.5 mL, Subcutaneous (SC)
65720|NCT01134276|Procedure|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
65721|NCT01134289|Procedure|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
65722|NCT00038922|Drug|rhIL-11|
61298|NCT01092910|Device|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
61299|NCT01092923|Drug|sevoflurane on air/O2|sevoflurane on air/O2
61300|NCT01092923|Drug|sevoflurane in N2O/O2|sevoflurane in N2O/O2
61301|NCT01092936|Other|Rating Scale administration|Movement Disorder Society_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
61302|NCT01092949|Device|MRI|MRI, 45 minutes
61303|NCT01092962|Drug|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
61598|NCT01124240|Drug|Cilengitide|Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.
Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).
After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles.
61599|NCT01124253|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
61600|NCT01124266|Procedure|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
61601|NCT01124266|Procedure|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
61602|NCT01124279|Drug|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
61603|NCT01124292|Procedure|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
61604|NCT01124292|Device|Usability assessment|Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22" LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.
Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions.
61605|NCT01124305|Device|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
61606|NCT01124305|Device|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
64951|NCT00039520|Drug|docetaxel|
64952|NCT01145066|Dietary Supplement|fish oil|1.6g/day EPA and 1.08g/day DHA
64953|NCT01145066|Dietary Supplement|corn oil|contains 4.5 g/day linoleic acid
64954|NCT01145079|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent
64955|NCT01145079|Device|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
64956|NCT01145079|Device|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
64957|NCT01137799|Drug|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
64958|NCT01137799|Drug|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
64959|NCT01137799|Drug|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
64960|NCT01137812|Drug|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
64961|NCT01137812|Drug|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
64962|NCT01137812|Drug|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
64963|NCT00039130|Drug|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX <10nM, courses II-VII
65527|NCT01141374|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
65528|NCT01141426|Behavioral|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
65529|NCT01141426|Behavioral|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
64724|NCT01142232|Drug|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
64725|NCT01142245|Drug|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
64726|NCT01142245|Drug|Intravenous Esomeprazole|Esomeprazole IV 80mg loading bolus
Esomeprazole intravenous infusion 8mg/hr for 72 hours
64727|NCT01142258|Drug|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
64728|NCT01142258|Drug|Placebo|Inactive or inert pill which will be used as a comparator
64729|NCT01142271|Procedure|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
64730|NCT01142271|Procedure|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
64731|NCT01142284|Drug|Cilostazol, Probucol|Treatment Group 1 (control) No cilostazol or probucol
Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID
Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID
Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID
64732|NCT01142297|Device|dental implant and modified dental implant|standard SLA surface and chemically modified surface
64733|NCT00039377|Drug|etoposide|Given IV
64734|NCT01142310|Drug|Lamotrigine|Lamotrigine has a complex mechanism of action that appears to involve the inhibition of voltage-sensitive sodium channels resulting in a stabilization of membranes and inhibition of presynaptic glutamate release. Lamotrigine attenuates cerebral release of glutamate associated with cerebral ischemia in vitro and in vivo. Lamotrigine prevents cognitive and histologic changes in the hippocampus in animal models of ischemia. In patients with seizure disorders, decreases in plasma glutamate levels with lamotrigine are associated with a reduction in seizures. Lamotrigine or identical appearing placebo will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
64735|NCT01142310|Drug|Placebo|Placebo matching active medication in all other physical aspects.
64736|NCT01142323|Drug|fenofibrate|160 mg po daily
64737|NCT01142336|Drug|Simvastatin|Simvastatin 40mg qHS for 1 year
65017|NCT01142778|Drug|bevacizumab [Avastin]|15mg/kg iv, cycles 3-6
65018|NCT01142778|Drug|docetaxel|100mg/m2 iv, cycles 1-6
65019|NCT01142778|Drug|trastuzumab [Herceptin]|8mg/kg iv cycle 1, 6mg/kg iv cycles 2-6; plus an additional 12 cycles post surgery
65723|NCT01126515|Procedure|Computed Tomography Angiography|Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
65724|NCT01126528|Dietary Supplement|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
64798|NCT01139983|Other|laboratory biomarker analysis|
64799|NCT01139996|Drug|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
64800|NCT01139996|Drug|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
64801|NCT01140009|Biological|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
64802|NCT01140009|Biological|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
64803|NCT00039286|Radiation|fludeoxyglucose F 18|
64804|NCT01140022|Other|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
64805|NCT01140035|Other|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
64806|NCT01140061|Drug|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
64807|NCT01140061|Drug|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
64808|NCT01140061|Drug|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
64809|NCT01140061|Drug|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
64810|NCT01140061|Drug|Plain patch|Plain patch containing no MK-0873 or placebo
64811|NCT01140074|Drug|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
64812|NCT01140087|Procedure|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
64813|NCT00039377|Drug|cyclophosphamide|Given IV
64814|NCT01142388|Other|Laboratory Biomarker Analysis|Correlative studies
64815|NCT01142388|Drug|Paclitaxel|Given IV
61607|NCT00038038|Procedure|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
61608|NCT01124318|Drug|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
61609|NCT01124318|Drug|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
61610|NCT01124331|Procedure|Higher oxygen saturation target range (91%-95%)|higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
61611|NCT01124331|Procedure|Lower oxygen saturation (85%-89%)|Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
61612|NCT01124344|Drug|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
61613|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
61887|NCT01120093|Drug|Placebo|Placebo via inhalation in the morning and evening for 7 days
61888|NCT01120093|Drug|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
61889|NCT01120106|Drug|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
61890|NCT01120106|Drug|placebo|saline continuous infusion
61891|NCT01120119|Drug|Calcitriol|
61892|NCT01120132|Drug|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
61893|NCT01120132|Drug|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
61894|NCT00037219|Drug|Anidulafungin, VER002|
61895|NCT01120132|Drug|PA|Suspension of Prednisolone Acetate administered during 28 days
61896|NCT01120132|Drug|Placebo|Placebo solution administered during 28 days
61897|NCT01120158|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
61898|NCT01120158|Drug|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
61899|NCT01120171|Drug|Cyclophosphamide|Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.
Therapy will continue until maximum response,or unacceptable toxicity.
65530|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
65531|NCT00039351|Radiation|radiation therapy|
65532|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
65533|NCT01143714|Other|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
65534|NCT01143727|Drug|Santyl|Apply one 24-hr period sufficient to cover the wound.
65535|NCT01143727|Drug|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
65536|NCT00039455|Drug|alvocidib|Given IV
65537|NCT01143740|Drug|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
65538|NCT01143753|Drug|RO5212054|cohorts receiving escalating doses orally
65539|NCT01143766|Drug|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
65540|NCT01143766|Other|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
65541|NCT01143779|Drug|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
65542|NCT01143792|Behavioral|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
65543|NCT01143792|Behavioral|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
65561|NCT01136395|Procedure|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
65562|NCT01136395|Procedure|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
65563|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
65564|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
65565|NCT01136408|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
65020|NCT01145248|Device|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
65021|NCT01145326|Drug|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
65022|NCT01145326|Drug|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
65023|NCT01145339|Drug|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
65024|NCT00039546|Drug|epirubicin hydrochloride|
65025|NCT01145352|Drug|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
65026|NCT01145365|Other|Surgically established drainage of perianal fistulas &/or abscesses BEFORE medical tx|Surgical established drainage of perianal fistulas &/or abscesses will be done BEFORE patient begins medical therapy with Cimzia
65027|NCT01145391|Other|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
65028|NCT01145404|Drug|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
65029|NCT01145404|Drug|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
65030|NCT01145417|Drug|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
65031|NCT01145430|Other|Laboratory Biomarker Analysis|Correlative studies
65032|NCT01145430|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
65033|NCT01145430|Other|Pharmacological Study|Correlative studies
65034|NCT01145430|Drug|Veliparib|Given PO
65035|NCT00000944|Drug|Lamivudine|
65036|NCT00039546|Drug|gemcitabine hydrochloride|
65293|NCT01135862|Drug|platelets|6 packs of platelets will be administered
65294|NCT01135875|Other|GBM Patients|2 teaspoons of blood will be collected during select clinic visits.
65295|NCT01135875|Other|Normal Controls|2 teaspoons of blood will be collected once.
64816|NCT01142388|Other|Pharmacological Study|Correlative studies
64817|NCT01142401|Drug|Bortezomib|Given IV
64818|NCT01142401|Drug|Fulvestrant|Given IM
64819|NCT01142401|Other|Laboratory Biomarker Analysis|Correlative studies
64820|NCT01142414|Biological|panitumumab|
65101|NCT01142882|Behavioral|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
65102|NCT01142882|Behavioral|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
65103|NCT01142908|Behavioral|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
65104|NCT01142921|Device|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
65105|NCT01142921|Device|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
65106|NCT01142934|Device|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
65107|NCT01142947|Drug|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
65108|NCT01142960|Dietary Supplement|Starch|1350mg/day
65109|NCT01142960|Dietary Supplement|Vitamin C|500mg Vitamin C plus 850mg Starch/day
65110|NCT01142960|Dietary Supplement|Lycium Barbarum|1350mg/day
65111|NCT00000116|Drug|Vitamin A|
65112|NCT00000240|Drug|Buprenorphine|
65113|NCT00000943|Biological|HIV-1 Immunogen|
65114|NCT00039403|Drug|gemcitabine hydrochloride|Given IV
61900|NCT01120171|Drug|Liposomal-encapsulated doxorubicin|Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.
Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.
Therapy will continue until maximum response or unacceptable toxicity.
61901|NCT01120184|Drug|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
61902|NCT01120184|Drug|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
61903|NCT01120184|Drug|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
61904|NCT01120184|Drug|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
61905|NCT00037440|Genetic|Polymorphisms measured|
61906|NCT01120184|Drug|trastuzumab [Herceptin]|trastuzumab [Herceptin] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
61907|NCT01120184|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
62223|NCT00038116|Procedure|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
62224|NCT01125072|Other|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
62225|NCT01125085|Radiation|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy
Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.
Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.
Total treatment duration is up to 4 weeks
62226|NCT01125098|Other|PRO-CT values|continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection
continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability
stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability
stop antibiotics if all the PRO-CT values are < 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value < 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection.
62227|NCT01125111|Procedure|surgery(robot versus laparoscopy)|
62228|NCT01125124|Drug|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
62229|NCT01125137|Procedure|Removal of Keloid|Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
62230|NCT01125150|Drug|Metformin|Dosage to be determined by Endocrinologist
65566|NCT01136421|Drug|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
65567|NCT01136421|Drug|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
65568|NCT00039104|Drug|rebimastat|Given PO
65569|NCT01136447|Procedure|Ultrasound|Block catheter will be introduced using ultraosound
65570|NCT01136499|Drug|LBH589 (Panobinostat®)|40 mg MWF.
40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity.
65571|NCT01136525|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
65572|NCT01136538|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
65573|NCT01136551|Drug|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
65574|NCT01136564|Drug|Zemplar|2 capsules of 1 microgram daily
65575|NCT01136564|Drug|Placebo|2 capsules daily
65576|NCT01136577|Device|Phototherapy|Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
65577|NCT01131507|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
65882|NCT01134484|Drug|Velcade|INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)
REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)
65883|NCT01134484|Drug|Thalidomide|INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)
AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200
AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200
REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70
65296|NCT01135888|Device|Skin cooling devices|Cooling vest and cooling bandana
65297|NCT01135901|Behavioral|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
65298|NCT01135914|Drug|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
65299|NCT01135914|Procedure|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
65300|NCT01135927|Drug|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
65301|NCT01135927|Drug|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
65302|NCT00039039|Drug|cisplatin|
65303|NCT01135940|Device|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
65304|NCT01135940|Device|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
65305|NCT01135953|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
65306|NCT01135953|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
65307|NCT01135953|Other|Transcranial direct Stimulation (tDCS) and D-cycloserine|Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session.
65308|NCT01135966|Behavioral|Conventional resistance training program|Conventional resistance training program is followed.
65309|NCT01135966|Behavioral|Whole body vibration resistance training program|WBV training on FITVIBE
65310|NCT01135992|Drug|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
65638|NCT01126450|Genetic|polymorphism analysis|Correlative studies
65115|NCT01142986|Behavioral|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
65116|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
65117|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
65118|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
65363|NCT01143363|Behavioral|Moderate intensity exercise|
65364|NCT01143363|Behavioral|High intensity intermittent training|
65365|NCT01143363|Behavioral|Short sprint|
65366|NCT01143376|Behavioral|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
65367|NCT01143376|Behavioral|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
65368|NCT01143376|Behavioral|Moderate intensity exercise|
65369|NCT01143389|Device|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
65370|NCT01143402|Drug|Dacarbazine|Given IV
65371|NCT01143402|Other|Laboratory Biomarker Analysis|Correlative studies
65372|NCT00039442|Drug|Capecitabine|Given orally
65373|NCT01143402|Other|Quality-of-Life Assessment|Ancillary studies
65374|NCT01143402|Drug|Selumetinib|Given PO
65375|NCT01143402|Drug|Temozolomide|Given PO
65376|NCT01143441|Biological|DAC-HYP|
65377|NCT01136018|Procedure|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
65378|NCT01136031|Drug|Paclitaxel and irinotecan|In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)
100 100
100 120
135 120
135 160
every 3 week
62231|NCT01125150|Behavioral|Dietary Modification|To be determined by Endocrinologist
62232|NCT01125163|Dietary Supplement|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120cc/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted post-menstrual age.
62233|NCT01125163|Dietary Supplement|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted post-menstrual age
62234|NCT00038116|Procedure|placebo|sham surgery
62235|NCT01125176|Drug|thalidomide|50 mg oral dosing every other day
62236|NCT01125176|Drug|lenalidomide|varying oral doses every other day (max 25 mg/day)
62237|NCT01125176|Biological|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
62238|NCT01125189|Drug|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
62239|NCT01125189|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
62240|NCT01125189|Drug|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
62241|NCT01118611|Other|laboratory biomarker analysis|
61304|NCT01092962|Drug|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
61305|NCT01092975|Drug|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
61306|NCT00033917|Drug|indomethacin|an anti-inflammatory drug
61307|NCT01092988|Device|Exablate 2100|MR guided focused ultrasound
61308|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
61309|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
61310|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
61311|NCT01095263|Device|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
61312|NCT01095276|Drug|Pulmozyme (nebulized dornase alpha)|nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
61313|NCT01095276|Drug|Saline|Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
65884|NCT01134484|Drug|Dexamethasone|INDUCTION THERAPY
VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)
TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)
AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)
AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months
REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)
VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)
TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)
65885|NCT01134484|Procedure|Peripheral Blood Stem Cell (PBSC) collection|Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)
G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection
65886|NCT01134484|Procedure|First Autologous Transplantation|HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)
G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days
65887|NCT01134484|Procedure|Second Autologous Transplantation|HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)
G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days
65888|NCT00038948|Drug|tacrolimus|
65889|NCT01134497|Drug|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
65890|NCT01134497|Drug|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
65891|NCT01134510|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg vs Placebo twice weekly x 4 weeks
65892|NCT01134523|Drug|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
65893|NCT01134523|Drug|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
65894|NCT01134536|Drug|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight <20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight >=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
65895|NCT01134549|Drug|KAI-4169|Single IV injection 0.2, 2, 5, 10, 20, 40, or 60 mg
65896|NCT01134549|Drug|Saline|Single IV injection
65897|NCT01134562|Drug|Saline|Single IV injection
65898|NCT01126879|Other|placebo|Given orally
64964|NCT01137812|Drug|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
64965|NCT01137864|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
65639|NCT01126463|Drug|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
65640|NCT01126476|Other|Proton Radiotherapy|
65641|NCT01126502|Drug|alvespimycin hydrochloride|Given IV
65642|NCT00038233|Drug|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
65643|NCT01126502|Other|diagnostic laboratory biomarker analysis|
65644|NCT01126502|Other|pharmacogenomic studies|
65645|NCT01126502|Other|pharmacological study|
65646|NCT01126515|Procedure|Magnetic Resonance Imaging|Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
65647|NCT01128855|Drug|9 mg/kg GSK2402968|Weekly subcutaneous injection
65648|NCT01128855|Drug|12 mg/kg GSK2402968|Weekly subcutaneous injection
65649|NCT01128855|Other|Placebo|Weekly Placebo
65650|NCT01128868|Device|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
65651|NCT01128868|Device|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
65652|NCT01128881|Biological|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
65653|NCT01128894|Biological|albiglutide|albiglutide weekly subcutaneous injection
65654|NCT01128894|Drug|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
65655|NCT00000939|Drug|Hydroxyurea|
65656|NCT00038454|Drug|Hemolink (hemoglobin raffimer IV solution)|
65657|NCT01128920|Behavioral|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
65658|NCT01128920|Other|No intervention - assessment-only condition|No intervention is assigned in this condition
67891|NCT01165762|Drug|Immune Tolerance|Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.
The IDE used in this study is the column used for hematopoietic cell sorting.
67892|NCT01165775|Device|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
67893|NCT00041262|Drug|epirubicin hydrochloride|
67894|NCT01157949|Drug|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
67895|NCT01157962|Procedure|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
68249|NCT01163812|Procedure|Laparoscopic D2 distal gastrectomy|Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the "The Japanese Research Society for Gastric Cancer" for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved.
68250|NCT01163825|Drug|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
68251|NCT01156051|Drug|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
68252|NCT01156051|Drug|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
68253|NCT01156064|Device|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
68254|NCT01156064|Device|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
68255|NCT01156077|Drug|TR-701 FA|Oral TR-701 FA 200 mg will be given as a single oral dose
68256|NCT01156077|Drug|TR-701 FA|TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
68257|NCT01156103|Behavioral|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
65989|NCT01134588|Other|Touch screen questionnaire|
65990|NCT01134601|Procedure|Radiation Therapy|
65991|NCT01134601|Drug|Capecitabine|
65992|NCT01134601|Drug|AZD6244|
65993|NCT01134614|Biological|ipilimumab|Given IV
65994|NCT01134614|Biological|sargramostim|Given SC
65995|NCT01134627|Drug|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
66293|NCT00038311|Drug|PN-152,243)/PN-196,444|
66294|NCT01127620|Drug|Cetirizine|10 mg encapsulated tablets
66295|NCT01127620|Drug|Placebo|encapsulated tablets
66296|NCT01127633|Drug|Solanezumab|400 mg administered once every 4 weeks by intravenous infusion (IV) for 100 weeks
66297|NCT01127646|Drug|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
66298|NCT01127646|Drug|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
66299|NCT01127646|Drug|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
66300|NCT01127659|Drug|testosterone|intramuscular every 2 weeks
66301|NCT01127659|Drug|placebo|saline intramuscular every 2 weeks
66302|NCT01129817|Other|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
66303|NCT01129817|Other|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
66304|NCT01129830|Dietary Supplement|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
68314|NCT01161316|Drug|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|Treatment regimen.
mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours
Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.
68315|NCT01161329|Other|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
68316|NCT00041015|Drug|topotecan hydrochloride|
68317|NCT01161355|Drug|AZD9668|Tablets of AZD9668 and IV dose of [C14]AZD9668
68318|NCT01163838|Biological|Placebo|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
68319|NCT01163838|Biological|1 mg/kg every 2 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
68320|NCT01163838|Biological|2 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
68321|NCT01163838|Biological|4 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
68322|NCT00041132|Drug|doxorubicin|16.6 mg/m^2/day for days 5-7 of cycles 1,3,5,7
68323|NCT01163838|Biological|4 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
67365|NCT01159574|Drug|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
67366|NCT00040872|Procedure|syngeneic bone marrow transplantation|
67367|NCT01159587|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
67368|NCT01159587|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|On-demand treatment with product given only for bleeding episodes
67369|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
67370|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
67371|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose open label
66217|NCT01129674|Drug|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
66218|NCT01129687|Procedure|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
66219|NCT01129687|Procedure|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
66220|NCT00038545|Drug|Paclitaxel|
66221|NCT01129700|Radiation|Radiation: short-course preoperative chemoradiotherapy|Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).
Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day).
66222|NCT01129713|Drug|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
66223|NCT01129713|Drug|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
66224|NCT01129726|Device|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
66225|NCT01129739|Other|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
66226|NCT01129739|Other|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
66227|NCT01129752|Other|No intervention|there is no intervention for this study
66228|NCT01129765|Device|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
66229|NCT01129778|Drug|Zegerid (proton pump inhibitor)|
66230|NCT01129778|Procedure|Bravo pH monitoring|
66231|NCT00038545|Drug|Topotecan|
66232|NCT01129791|Behavioral|Raw Milk vs Pasteurized Cow's Milk vs Non-Dairy Milk|Participants underwent three 8-day milk phases (raw vs. two controls: pasteurized, soy) in randomized order separated by 1-week washout periods.
66233|NCT01129804|Behavioral|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
66522|NCT01125540|Device|Acuvue (Standard Daily Disposable Contact Lens)|
66523|NCT01125540|Device|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
66828|NCT01131026|Drug|Lansoprazole|capsule, 30 mg, twice a day for ten days
66829|NCT01131039|Drug|Gemcitabine/Bevacizumab|Gemcitabine: IV, days 1,8, and every 21 days
Bevacizumab: IV, day 1 and every 21 days until disease progression
66830|NCT01131052|Drug|Insulin Glargine|glargine once a day
66831|NCT01131052|Drug|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
66832|NCT00038610|Drug|Methotrexate|12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.
200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on day 1 of courses 2, 4, 6, 8.
66833|NCT01131052|Drug|Insulin glulisine|glulisine given as needed before meals
66834|NCT01131065|Drug|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
66835|NCT01131078|Drug|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
66836|NCT01131078|Drug|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m^2 twice daily (Day 2 to 15) or as 650 mg/m^2 twice daily on Days 1 to 21.
66837|NCT01131078|Drug|Irinotecan|Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
66838|NCT01131091|Drug|SK-0403|SK-0403 400 mg
66839|NCT01131104|Drug|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
66840|NCT01131130|Device|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
66841|NCT01131130|Device|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
66842|NCT01131130|Device|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
66843|NCT00038610|Drug|Cytarabine|100 mg intrathecally day 7 for courses 1, 3, 5, 7.
3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8.
66844|NCT01131143|Behavioral|Provider Voice|A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
66305|NCT01129843|Drug|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
66306|NCT01129856|Drug|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
66307|NCT01129856|Drug|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
66308|NCT01129882|Drug|Aripiprazole|Aripiprazole IM Depot - 300mg or 400mg
66309|NCT01129895|Behavioral|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
66310|NCT00038558|Drug|Filgrastim SD/01|
66311|NCT01129921|Device|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
66312|NCT01129921|Device|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
66596|NCT00038844|Drug|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
66597|NCT01133418|Other|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
66598|NCT01133431|Drug|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
66599|NCT01133431|Drug|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
66600|NCT01133444|Drug|Finasteride|Finasteride tablets 1 mg
66601|NCT01133457|Drug|Finasteride|Finasteride tablets 1 mg
66602|NCT01133470|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
66603|NCT01133483|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
66604|NCT01125696|Drug|Zidovudine/lamivudine/lopinavir-ritonavir|Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
67372|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose
67373|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
67374|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily low dose
67375|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
67376|NCT01159613|Other|Responders|Responders
67377|NCT01162213|Dietary Supplement|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
67378|NCT01162226|Behavioral|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
67379|NCT01162239|Drug|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.
67380|NCT00041067|Biological|trastuzumab|
67381|NCT01162239|Behavioral|Individual counseling|Five 90 minute individual counseling sessions.
67382|NCT01162239|Behavioral|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
67383|NCT01162239|Behavioral|individual counseling|Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.
67384|NCT01162252|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
67667|NCT01162824|Drug|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
67668|NCT01162824|Drug|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
67669|NCT01162837|Device|BEAM device|A red/blue LED device for the treatment of acne
66524|NCT01125553|Drug|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
66525|NCT01125566|Drug|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
66526|NCT01125566|Drug|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
66527|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
66528|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
66529|NCT01125592|Device|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
66530|NCT01125618|Other|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication
66531|NCT00038142|Biological|ImmTher|900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
66532|NCT01125618|Other|Routine services|Interventions in comparison villages are routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites
66533|NCT01125631|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 8 weeks (4 doses total)
66534|NCT01125631|Drug|Placebo|Placebo every 8 weeks (4 doses total)
66535|NCT01125644|Drug|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
66536|NCT01125657|Drug|YM150|oral
66537|NCT01125670|Drug|YM150|oral
66538|NCT01125683|Drug|AZD1446|Capsule, oral single and multiple dose
66539|NCT01125683|Drug|Donepezil|Capsule, oral and single dose
66540|NCT01125683|Drug|Placebo|Capsule, oral and single dose
66541|NCT01125696|Drug|Tenofovir/lamivudine/lopinavir-ritonavir|Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
66542|NCT00000936|Drug|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
66845|NCT01131143|Behavioral|Generic Voice|A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
66846|NCT01131156|Behavioral|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
65899|NCT01126879|Procedure|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
65900|NCT01126892|Drug|Nilotinib|
65901|NCT01126918|Behavioral|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
65902|NCT01126944|Device|heart mate II|left ventricular assist device
65903|NCT01126957|Drug|ketamine|Ketamine was given as a 0.5mg / Kg bolus.
65904|NCT01126957|Drug|placebo|Placebo
65905|NCT01126970|Drug|Placebo + Placebo|Placebo + Placebo
65906|NCT00038272|Drug|Mycophenolate mofetil|
65907|NCT01126970|Drug|400 mg velneperit (S-2367) + Placebo|400 mg velneperit (S-2367) + Placebo
65908|NCT01126970|Drug|Placebo + 120 mg Orlistat|Placebo + 120 mg Orlistat
65909|NCT01126970|Drug|400 mg velneperit (S-2367) + 120 mg Orlistat|400 mg velneperit (S-2367) + 120 mg Orlistat
65910|NCT01126983|Device|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
65911|NCT01126983|Device|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
65912|NCT01126996|Procedure|Venepuncture|Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
A booster dose of a MenC conjugate vaccine (optional).
65913|NCT01127009|Drug|bortezomib|Given IV
65914|NCT01127009|Drug|mitoxantrone hydrochloride|Given IV
65915|NCT01127009|Drug|etoposide|Given IV
65916|NCT01127009|Drug|cytarabine|Given IV
66605|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
66606|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
66607|NCT01125735|Device|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
66608|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
66609|NCT01125748|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
66610|NCT01125748|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
66611|NCT01125748|Drug|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
66906|NCT01128686|Other|No intervention|This study is retrospective chart review
66907|NCT01128699|Drug|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
66908|NCT00038415|Biological|CLL vaccine using DNA plasmid vector|
66909|NCT01128699|Device|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
66910|NCT01128712|Drug|Pregabalin|150 mg /day
66911|NCT01128712|Drug|Pregabalin|450 mg/day
66912|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
67670|NCT01162850|Dietary Supplement|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
67671|NCT01162850|Dietary Supplement|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
67672|NCT01162863|Drug|Lubiprostone|lubiprostone taken either at a dose of 8 mcg po bid for 28 days or 24 mcg po bid for 28 days
67673|NCT01165307|Drug|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
67674|NCT01165307|Device|Nova Sure Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
67675|NCT01165320|Drug|Caspofungin|
67676|NCT01165333|Drug|Cilengitide dose escalation|Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.
The Cilengitide dose (mg/m²/infusion)levels are as follows :
240
480
720
1200
1800
67677|NCT01165333|Drug|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
67678|NCT01165333|Radiation|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
67679|NCT01165333|Biological|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
67680|NCT01165333|Biological|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
67681|NCT01165333|Biological|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
67682|NCT00041210|Drug|vincristine sulfate|
67683|NCT01165346|Radiation|Fiducials|Implantation of fiducials
67959|NCT01163357|Other|laboratory biomarker analysis|Correlative studies
67960|NCT01163370|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
67961|NCT01163370|Other|exercise training|resistance training twice a week for 24 weeks
67962|NCT01163370|Other|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
67826|NCT01160367|Other|standard of care|Patient-family dyads will receive standard of care in health decision-making
67827|NCT01160380|Drug|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
67828|NCT00040937|Drug|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
67829|NCT01160380|Drug|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
67830|NCT01160393|Device|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
68190|NCT01158534|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
68191|NCT01158534|Other|immunologic technique|Correlative studies
68192|NCT00040872|Drug|cyclophosphamide|
68193|NCT01158534|Other|immunohistochemistry staining method|Correlative studies
68194|NCT01158534|Other|flow cytometry|Correlative studies
68195|NCT01158560|Dietary Supplement|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
68196|NCT01158560|Behavioral|Gargling|gargling with tap water, twice daily
68197|NCT01158560|Dietary Supplement|Placebo|matched placebo for active vitamin D
68198|NCT01158586|Drug|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
68199|NCT01158599|Biological|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
68200|NCT01158612|Drug|Growth Hormone|infusion of Growth hormone in the patella tendon.
68201|NCT01158625|Other|Change of time of administration|Change of time of administration
68202|NCT01158638|Behavioral|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
68203|NCT00000242|Drug|Carbamazepine|
68204|NCT00000951|Drug|Fluconazole|
68205|NCT00040872|Drug|doxorubicin hydrochloride|
65917|NCT00038272|Drug|Amdoxovir|
65918|NCT01127009|Other|flow cytometry|Correlative studies
65919|NCT01127022|Dietary Supplement|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline [from choline chloride] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
65920|NCT01127022|Dietary Supplement|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline [from choline chloride] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
65921|NCT01127035|Biological|sublingual immunotherapy|
66234|NCT01132664|Drug|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
66235|NCT01132664|Drug|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
66236|NCT01132677|Device|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
66237|NCT01132677|Drug|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
66238|NCT01132690|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
66239|NCT01132703|Drug|RP-1127 (Glyburide for injection)|RP-1127 is administered as a bolus followed by continuous infusion for 72 hours
66240|NCT01132703|Drug|Placebo (RP-1127 excipients, excluding active)|RP-1127 excipients, excluding active
66241|NCT01132716|Drug|Valacyclovir Hydrochloride|1000 mg caplet
66242|NCT01132729|Drug|Valacyclovir Hydrochloride|1000 mg caplet
66243|NCT00000940|Drug|Abacavir sulfate|
66244|NCT00038792|Drug|Recombinant Human Keratinocyte Growth Factor|
66245|NCT01132755|Procedure|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
66246|NCT01132768|Drug|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
68258|NCT01156116|Device|CPAP mask|The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.
________________________________________
68259|NCT00040742|Dietary Supplement|ginger|Given orally
68260|NCT01156116|Drug|Placebo|oral placebo tablet
68261|NCT01156129|Drug|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
68262|NCT01156129|Device|Arm B: Acupressure bracelet|Bioband
68263|NCT01156129|Dietary Supplement|sugar free gum|Orbit
68264|NCT01156142|Drug|doxepin hydrochloride|Oral rinse
68265|NCT01156142|Other|placebo|Oral rinse
68266|NCT01156155|Radiation|Digital xray of jaw and teeth|one time xray of jaw and teeth
67306|NCT01162200|Radiation|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
67307|NCT01164683|Behavioral|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
67308|NCT01164683|Other|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
67309|NCT01164696|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
67310|NCT01164709|Drug|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
67311|NCT01164709|Drug|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
67312|NCT01164722|Other|clinical observation|Patients undergo observation
67313|NCT01164722|Procedure|infrared photocoagulation therapy|Anal infrared coagulator ablation
67963|NCT01163383|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
67964|NCT01163383|Drug|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
67965|NCT01163396|Drug|Bevacizumab|
67966|NCT00041119|Drug|paclitaxel|Given IV
67967|NCT01163396|Drug|Irinotecan|
67968|NCT01163396|Drug|Oxaliplatin|
67969|NCT01163396|Drug|5-fluorouracil/leucovorin|
67970|NCT00000950|Drug|Isoniazid|
67971|NCT00040690|Drug|etoposide|
67972|NCT01155583|Drug|azacitidine|Given SC
67973|NCT01155583|Drug|lenalidomide|Given orally
67974|NCT01155583|Drug|dexamethasone|Given orally
67975|NCT01155583|Other|DNA methylation analysis|Correlative studies
67976|NCT01155583|Other|gene expression analysis|Correlative studies
67977|NCT01155583|Other|bone marrow aspiration|Correlative studies
67978|NCT01155583|Other|immunohistochemistry staining method|Correlative studies
67979|NCT01155583|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
67980|NCT01155583|Other|flow cytometry|Correlative studies
67981|NCT01155596|Behavioral|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
67982|NCT00040690|Drug|ifosfamide|
67983|NCT01155609|Procedure|quality-of-life assessment|Ancillary studies
68324|NCT01163838|Biological|8 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
68206|NCT01158651|Drug|RAD001 (Everolimus)|If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment "course" lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).
You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection.
68207|NCT01158664|Device|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
68208|NCT01161017|Drug|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
68209|NCT01161017|Drug|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
68210|NCT01161030|Other|almonds|
68211|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
67249|NCT01156883|Drug|methylprednisolone|
67250|NCT01156883|Drug|prednisone|
67251|NCT01156883|Drug|thioguanine|
67252|NCT01156883|Drug|vincristine sulfate|
67253|NCT01156883|Drug|vindesine|
67254|NCT00040794|Radiation|radiation therapy|Undergo radiotherapy
67255|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose in the fasting state.
67256|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
67257|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
67258|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
67259|NCT01156909|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.
Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period.
66247|NCT01132768|Drug|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
66248|NCT01132781|Drug|Theophylline (Intervention Group)|200 mg twice daily of slow release theophylline
66249|NCT01132781|Drug|Placebo (Placebo Group)|200 mg twice daily of placebo drug
66250|NCT01132794|Drug|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
66251|NCT01132794|Drug|Placebo|Intranasal nasal saline
66252|NCT01132807|Biological|Bleomycin Sulfate|Given IV
66253|NCT01132807|Drug|Doxorubicin Hydrochloride|Given IV
66254|NCT01132807|Drug|Procarbazine Hydrochloride|Given PO
66543|NCT00038155|Procedure|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
66544|NCT01128101|Drug|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
66545|NCT00038376|Drug|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
66546|NCT01128114|Drug|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
66547|NCT01128127|Behavioral|Group education, audit-feedback and computer support|Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.
Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.
CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines.
66548|NCT01128127|Behavioral|Audit-feedback and computer support|Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs
CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines.
66549|NCT01128127|Behavioral|Control|Usual intervention includes:
Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.
Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.
Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID.
67314|NCT01164735|Other|Laboratory Biomarker Analysis|Correlative studies
67315|NCT01164748|Radiation|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
67316|NCT00041210|Drug|ABVD regimen|
67317|NCT01164761|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
67318|NCT01164761|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
67319|NCT01164774|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
67320|NCT01164774|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
67321|NCT01164787|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
67322|NCT01164787|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
67323|NCT01164800|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
67324|NCT01164800|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
67325|NCT01164813|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
67611|NCT01157364|Drug|latanoprost 0.005%|One drop latanoprost 0.005% (Xalatan®) administered in the non-study eye once daily in the evening or in the non-study eye and study eye once daily in the evening for up to 24 months.
67612|NCT01157364|Drug|timolol vehicle (placebo)|One drop of timolol vehicle administered in the study eye in the morning and evening, and 1 drop of timolol vehicle administered in the non-study eye once daily in the morning, or 1 drop of timolol vehicle administered once in the morning in both eyes for up to 24 months. Timolol vehicle is administered for masking purposes.
67613|NCT01157377|Drug|AGN-214868|AGN-214868 injected into the bladder.
67614|NCT01157377|Drug|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
67615|NCT01157390|Other|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage & frequency: Fed as need Duration: at least 3 months
67616|NCT01157390|Other|Breast feeding|Breast feeding
67617|NCT00040846|Drug|fludarabine phosphate|Given IV
67618|NCT01157403|Biological|Autologous transplantation|Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
67619|NCT01157416|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
68325|NCT01163838|Biological|12 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
68326|NCT01163851|Biological|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
68327|NCT01163851|Biological|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
68328|NCT01163864|Behavioral|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
68329|NCT01163864|Behavioral|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
68330|NCT01163877|Dietary Supplement|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
68331|NCT01163890|Behavioral|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
68332|NCT01163890|Behavioral|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
68333|NCT00041132|Drug|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
68334|NCT01163903|Drug|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
68335|NCT01163903|Drug|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
68336|NCT01163929|Drug|paclitaxel|Paclitaxel:
80mg/m2 IV TRO 3 hours every 28 days for 4 cycles
Trastuzumab:
4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks
Everolimus: 10mg PO daily 16-18 weeks
68337|NCT01163942|Drug|G-CSF|Yes/no addition of G-CSF
68338|NCT01156168|Other|laboratory biomarker analysis|
68339|NCT01156181|Procedure|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
68340|NCT01156181|Procedure|control|Embryo transfer without any intervention
68341|NCT01156194|Drug|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
68342|NCT00040755|Drug|rebimastat|Given orally
67260|NCT01156922|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.
For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.
Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period.
67261|NCT01156935|Other|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
67262|NCT01156948|Drug|misoprostol|400ug vaginally the day before surgery
67263|NCT01156948|Drug|oral misoprostol|400ug misoprostol orally the day before the surgery
67264|NCT01156961|Drug|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
67265|NCT00040794|Other|laboratory biomarker analysis|Optional correlative studies
67266|NCT01159288|Biological|Dex2|Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.
Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)
Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks.
67267|NCT00040872|Procedure|conventional surgery|
67268|NCT01159301|Drug|entinostat|Given orally (PO)
67545|NCT01159886|Procedure|Ileal intubation|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.
Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed.
67546|NCT01159899|Procedure|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
67547|NCT01159912|Drug|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
67548|NCT01159912|Drug|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
67549|NCT01159912|Drug|Placebo|Placebo inhalation powder
67550|NCT01159925|Procedure|Serum sample|Serum samples collected
67551|NCT01159938|Drug|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
67552|NCT01159951|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
66550|NCT01128140|Behavioral|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
66551|NCT01128140|Behavioral|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
66552|NCT01128153|Drug|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
66553|NCT01128153|Drug|Placebo|tablet once daily for 24 weeks to be taken orally
66847|NCT01133756|Drug|Gemcitabine|Comparator dose and mode of administration: Gemcitabine (1000 mg/m2) given by IV infusion over 30 minutes on Day 1 and Day 8 of a 21-day cycle.
66848|NCT01133782|Procedure|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
66849|NCT01133795|Drug|Midodrine plus Albumin|MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
66850|NCT01133821|Drug|IPSRT plus placebo (IPSRT-PLA)|Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.
The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).
Medication Dosing
The research pharmacy will dispense medication in the following unit-dose packs:
Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
66851|NCT01133821|Drug|IPSRT plus quetiapine|Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.
The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).
Medication Dosing
The research pharmacy will dispense medication in the following unit-dose packs:
Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
66852|NCT01133847|Drug|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
66853|NCT00038857|Drug|Thiotepa|10 mg/kg on day -7
66854|NCT01133847|Behavioral|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
67620|NCT01157416|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
67621|NCT01157429|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
67622|NCT01157429|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
67623|NCT01157442|Behavioral|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
67624|NCT01157455|Procedure|Everolimus Drug Eluting Stent|Implantation
67625|NCT01157455|Drug|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
67626|NCT01157455|Drug|Clopidogrel|A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.
75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy.
67627|NCT01157455|Drug|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
67628|NCT00040846|Radiation|total-body irradiation|Undergo TBI
67629|NCT01157481|Drug|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
67896|NCT01157975|Drug|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
67897|NCT00040859|Drug|capecitabine|
67898|NCT01157975|Drug|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
67899|NCT01157988|Drug|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count > 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
67900|NCT01158001|Behavioral|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
67901|NCT01158014|Procedure|Fibrin Glue, Quixil|quixil 0.1 ml
67902|NCT01158014|Procedure|Suture|vicryl 10/0
67385|NCT01162252|Behavioral|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
67386|NCT01162278|Radiation|SBRT|Single fraction SBRT
67387|NCT01162304|Drug|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
67388|NCT01162304|Drug|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
67389|NCT01162317|Other|Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
67390|NCT01162317|Other|Sham Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
67391|NCT00041067|Drug|docetaxel|
67392|NCT01162330|Other|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
67393|NCT01164865|Device|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
67394|NCT01164865|Device|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
67395|NCT01164865|Device|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
67396|NCT01164891|Drug|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
67397|NCT01164904|Drug|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
67398|NCT01164917|Drug|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
67553|NCT00040898|Dietary Supplement|Sho-saiko-to|
67554|NCT01159964|Biological|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
67555|NCT01159977|Behavioral|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
67556|NCT01159977|Behavioral|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
67557|NCT01159977|Behavioral|Usual practice|No protected time provided.
67558|NCT01162551|Drug|Sirolimus and Methotrexate|Single Arm Efficacy Trial:
Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.
Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.
One cycle is 28 days.
67559|NCT00041080|Drug|tamoxifen citrate|Given orally
67560|NCT01162564|Device|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
67561|NCT01162577|Behavioral|Weight Concerns|Standard Quitline plus weight coaching
67562|NCT01162590|Biological|Rotarix ™|Oral, single dose
67563|NCT01162590|Biological|Placebo|Oral, single dose
67564|NCT01162603|Device|Goldmann and Perkins applanation tonometry|IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
67831|NCT01160419|Drug|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
67832|NCT01160419|Drug|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
67833|NCT01160419|Drug|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
67834|NCT01160419|Drug|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
67835|NCT01160432|Drug|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient`s individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week`s periods for four weeks.
67836|NCT01160445|Drug|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
67837|NCT01160445|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
67838|NCT01160458|Drug|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
66855|NCT01133847|Behavioral|Parent Training|Nine sessions on parenting a child with ADHD
66856|NCT01133847|Drug|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
66857|NCT01133847|Drug|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
66858|NCT01133847|Drug|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
66859|NCT01133860|Drug|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
66860|NCT01133873|Drug|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
66861|NCT01133873|Drug|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
66862|NCT01133886|Drug|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
66863|NCT01133899|Dietary Supplement|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
65922|NCT01127035|Biological|placebo|
65923|NCT01127048|Drug|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
65924|NCT01127048|Drug|Placebo|Suppositories containing no Ivy leaves dry extract
65925|NCT01129271|Drug|clopidogrel|Pharmaceutical form: tablet
Route of administration: oral
65926|NCT01129271|Drug|Matching placebo|Pharmaceutical form: tablet
Route of administration: oral
65927|NCT01129284|Drug|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
65928|NCT00038506|Drug|tenofovir|
65929|NCT01129310|Drug|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
65930|NCT01129323|Drug|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
65931|NCT01129336|Drug|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
67903|NCT01158027|Other|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
67904|NCT01158053|Device|FFR and VH-IVUS|Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) >48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent
No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.
All lesion level inclusion criteria and no exclusion criteria are met.
FFR followed by VH-IVUS of study lesion(s)
Any additional PCI based on routine clinical practice and FFR/IVUS data?
If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years
If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years
67905|NCT01158053|Device|IVUS and FFR|
67906|NCT01158066|Procedure|CT Cardiac|the patient will undergo cardiac CT
67907|NCT01158079|Drug|ALN-VSP02|The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
67908|NCT00040859|Drug|oxaliplatin|
67909|NCT01158092|Device|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
67910|NCT01158092|Other|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
67911|NCT01158105|Drug|Bortezomib|1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
67912|NCT01158118|Drug|Sargramostim|
67913|NCT01158118|Drug|Plerixafor|
68267|NCT01156155|Procedure|Blood draw|Three to four tablespoons of blood drawn.
68268|NCT01156155|Other|questionnaires|completed questionnaires regarding patient's health and functional ability.
68269|NCT01156155|Procedure|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
68270|NCT00040742|Other|placebo|Given orally
68271|NCT01156155|Other|Bilateral digital xray of hands|One time digital xray of hands
68272|NCT01156168|Genetic|DNA analysis|
68273|NCT01156168|Genetic|gene expression analysis|
68274|NCT01156168|Genetic|polymorphism analysis|
67399|NCT01164917|Drug|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
67400|NCT00041210|Drug|dacarbazine|
67684|NCT01165346|Radiation|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
67685|NCT01165359|Drug|ITX 5061|For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.
For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.
For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days.
67686|NCT01165359|Drug|Placebo ITX 5061|For Part A of the study: placebo, once a day for 3 days.
For Part B of the study: placebo, once a day for 14 days.
For Part C of the study: placebo, once a day for 28 days.
67687|NCT01165372|Drug|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
67688|NCT01165385|Drug|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
67689|NCT01165385|Drug|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
67690|NCT01165424|Drug|mometasone furoate|MFNS 50 μg spray device
3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.
12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning.
67691|NCT01165437|Device|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
67692|NCT01165450|Drug|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
67693|NCT00041210|Radiation|radiation therapy|
67694|NCT01157507|Drug|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
67695|NCT01157507|Procedure|Bladder overdistension|Bladder overdistension
67696|NCT01157507|Drug|Placebo|One single injection of placebo
67697|NCT01157533|Drug|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
67698|NCT01157546|Procedure|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
67699|NCT01157546|Procedure|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
67839|NCT00040937|Drug|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
67840|NCT01160484|Drug|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
67841|NCT01163032|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
67842|NCT01163032|Drug|Placebo|Placebo capsules, PO daily for 6 months
67843|NCT01163045|Procedure|thyroidectomy|total thyroidectomy and lobectomy
67844|NCT01163071|Drug|ABI-011|ABI-011
67845|NCT01163084|Drug|Goserelin Acetate|Given SC
67846|NCT01163084|Other|Laboratory Biomarker Analysis|Correlative studies
67847|NCT01163084|Drug|Leuprolide Acetate|Given IM
67848|NCT01163084|Drug|Vismodegib|Given PO
67849|NCT00041106|Other|laboratory biomarker analysis|Correlative studies
67850|NCT01163097|Drug|Palifermin|40 µg/kg IV bolus injections for three consecutive days
67851|NCT01163097|Drug|Heparin|Heparin continuous IV infusion
67852|NCT01163110|Dietary Supplement|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
68212|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
68213|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
68214|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
68215|NCT00040989|Procedure|enzyme inhibitor therapy|
68216|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
68217|NCT01161069|Drug|Placebo|Placebo in oral solution, given once daily for 14 days
65932|NCT01129336|Drug|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
65933|NCT01129349|Drug|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
65934|NCT01129362|Biological|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
65935|NCT01129362|Biological|Other Pertussis Vaccines|0.5 mL, Intramuscular
65936|NCT01129375|Drug|clopidogrel|Pharmaceutical form: tablet
Route of administration: oral
65937|NCT01129375|Drug|placebo|Pharmaceutical form: matching tablet
Route of administration: oral
65938|NCT01129375|Drug|omeprazole|Pharmaceutical form: delayed-release capsule
Route of administration:oral
65939|NCT00038519|Drug|Amprenavir/ritonavir|
65940|NCT01129388|Drug|clopidogrel|Pharmaceutical form: tablet
Route of administration: oral
65941|NCT01129388|Drug|Placebo|Pharmaceutical form: matching tablet
Route of administration: oral
65942|NCT01129388|Drug|omeprazole|Pharmaceutical form: delayed-release capsule
Route of administration:oral
65943|NCT01129401|Behavioral|Stonewall Project|The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
66255|NCT00038805|Drug|Mylotarg|
66256|NCT01132807|Drug|Vinblastine Sulfate|Given IV
66257|NCT01132807|Drug|Dacarbazine|Given IV
66258|NCT01132807|Drug|Cyclophosphamide|Given IV
66259|NCT01134731|Drug|Placebo|1-5 placebo capsules
66260|NCT01134757|Biological|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
66261|NCT01134783|Behavioral|Web-Only Curriculum|15 week web-only course teaching college students healthy eating, exercise, sleep and stress management strategies
66262|NCT01134783|Behavioral|Face-to-Face, In-Person Class|Face-to-face group sessions led by study intervention staff to increase healthful behaviors in the categories of diet, physical activity, stress management and sleep.
68275|NCT01156168|Genetic|protein expression analysis|
68276|NCT01156168|Other|immunohistochemistry staining method|
68277|NCT01158664|Device|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
68278|NCT01158677|Procedure|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
68279|NCT01158690|Other|resource card|the intervention group receives an envelop with resource card
68280|NCT01158690|Other|no resource card|the control group receives an envelop without resource card
68281|NCT01158703|Drug|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
68282|NCT01158703|Drug|sugar pill|sugar pill by mouth daily for 12 months
68283|NCT01158703|Drug|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
68284|NCT01158716|Other|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
68285|NCT00040872|Drug|etoposide|
68286|NCT01158729|Drug|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = [(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg] X (1 mL/175 Units)
68287|NCT01158729|Other|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = [(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg] X (1 mL/175 Units)
68288|NCT01158742|Other|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
68289|NCT01158742|Other|Glomerular Filtration Rate with Iohexol|used to determine kidney function
67326|NCT01164813|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
67327|NCT00041210|Drug|Stanford V regimen|
67328|NCT01164826|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
67329|NCT01164826|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
67330|NCT01164852|Procedure|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
67700|NCT01157559|Drug|Ziprasidone|8 week prospective study
67701|NCT00040846|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
67702|NCT01157572|Drug|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
67703|NCT01157572|Drug|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
67984|NCT01155609|Procedure|management of therapy complications|Discontinue supplement; treat symptomatically
67985|NCT01155609|Dietary Supplement|L-lysine|Given PO
67986|NCT01155622|Procedure|Endovascular Cooling|Infusion of <8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
67987|NCT01155635|Drug|Carvedilol|Use of Carvedilol with any dose
67988|NCT01155635|Drug|No Carvedilol|No use of Carvedilol
67989|NCT01155648|Device|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
67990|NCT01155648|Device|Chest wall compression for ten minutes in chest|
67991|NCT01155661|Drug|LY2216684|12mg to 18 mg administered orally, once daily for 54 weeks
67992|NCT01155700|Drug|omalizumab|
67993|NCT00040690|Drug|leucovorin calcium|
67994|NCT01155713|Drug|TKI258|
67995|NCT01155726|Device|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
67996|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
67997|NCT01158144|Drug|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
68218|NCT01161082|Drug|REGN727(SAR236553)|subcutaneous
68219|NCT01161095|Device|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
68220|NCT01161108|Drug|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
68221|NCT01161108|Drug|Fast Release Placebo|A matching FR MLT placebo will be compounded by the SickKids research pharmacy.
The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
68222|NCT01161108|Drug|Timed Release Melatonin (TR MLT)|3 mg capsules will be used.
The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
68223|NCT01161108|Drug|Timed Release Placebo|A matching TR MLT placebo will be compounded by the SickKids research pharmacy.
The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
68224|NCT01161121|Drug|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
68225|NCT01161121|Drug|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
68226|NCT00041015|Drug|cisplatin|
68227|NCT01161121|Drug|Adenosine|Injection of IV Adenosine for 2 minutes at rate of 140mg/kg to dilate coronary arteries and provoke maximal hyperemia
68228|NCT01161134|Drug|Meloxicam|Meloxicam Tablets 15 mg
68229|NCT01161147|Drug|Meloxicam|Meloxicam Tablets 15 mg
68230|NCT01161160|Biological|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
67269|NCT01159301|Drug|sorafenib tosylate|Given PO
67270|NCT01159301|Other|pharmacological study|Correlative studies
67271|NCT01159301|Other|laboratory biomarker analysis|Correlative studies
67272|NCT01159314|Procedure|Baerveldt Device surgical Procedure|Implant surgery
67273|NCT01159327|Drug|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
67274|NCT01159353|Drug|Insulin glulisine|Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
66263|NCT01134783|Behavioral|Web-Enhanced|This intervention arm will be a combination of the web-only version and the personal, face-to-face version
66264|NCT01134809|Procedure|Major abdominal surgery|All adult patients having major abdominal surgery
66265|NCT01134835|Other|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
66266|NCT01134835|Drug|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
66267|NCT00038974|Drug|Pegylated interferon|
66268|NCT01134848|Drug|Morphine|10mg IM
66269|NCT01134848|Drug|Neostigmine|1mg IM
66270|NCT01134848|Drug|0.9% saline|0.1 ml/kg
66271|NCT01134848|Drug|Secretin|1 unit/kg IV
66272|NCT01134848|Drug|0.9% saline|1ml IM
66273|NCT01134861|Drug|cisplatin|100 mg/m2 i.v. over 30-60 minutes, days 1 & 29
66274|NCT01134861|Drug|Etoposide|Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area < 1.7 m2
66275|NCT01134861|Drug|Vinblastine|5 mg/m2 i.v. bolus weekly first 5 weeks of RT
66276|NCT01134861|Radiation|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
66277|NCT01134861|Drug|Cisplatin|50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
66554|NCT01128166|Device|COGNIS CRT-D|Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the "conversion" of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion.
66555|NCT01128179|Drug|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
66556|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
66557|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
67331|NCT01156961|Drug|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
67332|NCT01156974|Behavioral|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
67333|NCT01156974|Behavioral|education only|patients receive education about care goals
67334|NCT01156987|Device|Magnetic resonance imaging|Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:
an IV line is placed by nurse,
patient is placed in the 4 T MRI scanner at CMRR,
initial scout images and manual linear shims are adjusted,
Pre-contrast SWIFT T1 weighted images and T1 map are obtained,
continuous SWIFT acquisition begins immediately before contrast injection,
contrast injection,
continuous SWIFT acquisition continues for 12 min after contrast,
late enhancement images may also be obtained.
10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.
67335|NCT01157000|Drug|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
67336|NCT01157013|Other|Positron emission tomography with fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
67337|NCT01157026|Dietary Supplement|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
67338|NCT01157026|Other|placebo plus tamoxifen|20mg tamoxifen daily
67339|NCT01157039|Dietary Supplement|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
67340|NCT01157052|Other|(supplement) Calcium and Magnesium|FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.
XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.
Ca2+/Mg2: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1 (Arm A) or cycle 2 (Arm B)
67341|NCT00000950|Drug|Pyridoxine hydrochloride|
67342|NCT00040807|Drug|docetaxel|
67343|NCT01157065|Drug|AL-78898A|Investigational treatment
67630|NCT01157481|Drug|Conventional therapy|Conventional therapy
67631|NCT01157494|Other|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
67998|NCT01158144|Drug|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
67999|NCT01158157|Biological|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
68000|NCT01158170|Radiation|Prophylactic cranial irradiation|25GY/10fraction
68001|NCT00040872|Biological|filgrastim|
68002|NCT01158170|Drug|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
68003|NCT01158183|Drug|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
68343|NCT01156194|Drug|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
68344|NCT01156194|Drug|Placebo|globule identical to true homeopathy comparators
68345|NCT01156207|Drug|Aliskiren|300mg Aliskiren qd for 6 month
68346|NCT01156220|Drug|Furosemide|Injection, 40 mg, single dose over 5 min
68347|NCT01156220|Drug|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
68348|NCT01156233|Procedure|Anesthesia induction|Cuff palpation technique: identification of the cuff position in the trachea by palpation.
68349|NCT01156233|Procedure|Anesthesia induction|Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
68350|NCT01156246|Drug|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
68351|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
68352|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
68353|NCT00000950|Drug|Pyrazinamide|
68354|NCT00040755|Other|laboratory biomarker analysis|Correlative studies
68355|NCT01156272|Device|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
68356|NCT01156285|Other|Filling in a patient questionnaire|Filling in a patient questionnaire
67275|NCT01159353|Drug|Insulin aspart|Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
67276|NCT01159366|Procedure|percutaneous coronary intervention|early timing
67277|NCT01159379|Drug|ertapenem|intravenous, 1 gram, once
67278|NCT00040872|Procedure|drug resistance inhibition treatment|
67279|NCT01159405|Radiation|Radiolabeled (99mTc) GP (Glycopeptide)|one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg & 20 mg of GP will be injected
67280|NCT01159418|Drug|Panobinostat (LBH589), Carboplatin and Paclitaxel|Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).
Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).
Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).
The treatment will be repeated every three weeks until disease progression.
67281|NCT01159431|Device|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
67282|NCT01159457|Biological|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
67283|NCT01159457|Biological|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
67284|NCT01159483|Drug|PF-04958242|oral PIB, single dose, 0.01 mg, 0.03 mg, 0.1 mg
67285|NCT01159483|Drug|PF-04958242|oral PIB, single dose, 0.3 mg, 0.6 mg*, 1.0 mg*
*Unlikely to be administered as expected to exceed exposure limits.
67286|NCT01159496|Drug|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
67287|NCT01159496|Drug|Placebo|Oral capsule, once daily for 14 days
67288|NCT00041054|Drug|exisulind|
67565|NCT01162603|Drug|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution
67566|NCT01162603|Drug|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution
67567|NCT01162616|Dietary Supplement|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
67568|NCT01162629|Device|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
66558|NCT01130467|Drug|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
66559|NCT01130467|Drug|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
66560|NCT01130467|Behavioral|behavioral modification|Parenting and teaching skill education
66561|NCT01130480|Device|Accu-Chek Integra Glucometer|
66562|NCT00038584|Drug|SCH66336|
66563|NCT01130493|Drug|IPX066|IPX066
66564|NCT01130493|Drug|Carbidopa/Levodopa/Entacapone|Carbidopa/Levodopa/Entacapone
66565|NCT01130506|Drug|Decitabine|Given IV
66566|NCT01130506|Drug|Vorinostat|Given orally
66567|NCT01130506|Drug|Cytarabine|Given IV
66568|NCT01130506|Other|Pharmacological Study|Correlative studies
66569|NCT01130506|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
66570|NCT01130519|Drug|Bevacizumab|Commercially available. Administered by intravenous infusion.
66571|NCT01130519|Drug|Erlotinib|Commercially available. Administered orally
66572|NCT01130532|Drug|Tadalafil|Administer orally
66573|NCT00038597|Drug|SCH66336|
66574|NCT01130532|Drug|Placebo|Administer orally
66575|NCT01130558|Other|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
66576|NCT01130571|Procedure|Xenografts and cell cultures|
66864|NCT00038857|Drug|Fludarabine|160 mg/m^2 over 4 days on days -6, -5, -4, -3
66865|NCT01133899|Dietary Supplement|GAA-4|4.8 grams of guanidinoacetic acid
66866|NCT01133899|Dietary Supplement|GAA-1|1.2 grams of guanidinoacetic acid
66867|NCT01133899|Dietary Supplement|PLACEBO|celulose
67632|NCT01159990|Biological|rAd5 Gag-Pol Env A/B/C|1×10^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
67633|NCT01159990|Biological|rAd5 Gag-Pol|5×10^9 PU rAd5 Gag-Pol delivered via intramuscular injection
67634|NCT01160003|Drug|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
67635|NCT01160003|Drug|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
67636|NCT01160029|Drug|Nateglinide|Nateglinide Tablets 120 mg
67637|NCT01160042|Drug|Metformin|Metformin Tablets 1000 mg
67638|NCT00040911|Procedure|electroacupuncture therapy|
67639|NCT01160042|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
67640|NCT01160055|Procedure|Middle ear fluid and urine.|Middle ear fluid and urine collection.
67641|NCT01160068|Drug|Metformin|Metformin Tablets 1000 mg
67642|NCT01160068|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
67643|NCT01160081|Other|Serum sample|Serum samples collected
67644|NCT01160094|Drug|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
67645|NCT01160107|Drug|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR > 50%; 2. The study stop (if PR <40% and grade 3-4 adverse events >25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are < 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are > 50% and PR rate > 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
67646|NCT01160120|Drug|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
67647|NCT01160133|Other|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
67648|NCT01160133|Other|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
68357|NCT01156311|Drug|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
68358|NCT01156324|Behavioral|Online Stress Management Group (Upliv)|Personalized online stress management program
68359|NCT01156324|Behavioral|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
68360|NCT01156350|Drug|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained < 2.5 x 104 CD3+ cells/kg
68361|NCT01156363|Procedure|Dialysis|regular haemodialysis or peritoneal dialysis
68362|NCT01156363|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
68363|NCT01156376|Device|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
67103|NCT01161628|Drug|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
67104|NCT01161641|Drug|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
67105|NCT01161641|Drug|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
67106|NCT01161641|Drug|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
67107|NCT01161654|Drug|naratriptan hydrochoride|2.5 mg tablet
67108|NCT01161667|Drug|naratriptan hydrochloride|2.5 mg tablet
67109|NCT01161693|Device|TROOP® elevation pillow|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
67110|NCT00041041|Other|laboratory biomarker analysis|Correlative studies
67111|NCT01161693|Device|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
67112|NCT01161693|Device|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
67113|NCT01161706|Other|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
67569|NCT01162642|Dietary Supplement|Green Tea|Green Tea 4 cups daily
67570|NCT00041080|Drug|thalidomide|Given orally
67571|NCT01162642|Other|Placebo|4 cups placebo tea for 6 weeks
67572|NCT01162655|Behavioral|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
67573|NCT01162681|Drug|A-623|High dose given subcutaneously once a week for up to 52 weeks
67574|NCT01162681|Drug|A-623|Low dose given subcutaneously once a week for up to 52 weeks
67575|NCT01162681|Drug|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
67576|NCT01162681|Other|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
67577|NCT01162694|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
67578|NCT01162694|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
67579|NCT01162707|Device|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
67580|NCT01162720|Procedure|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
67581|NCT00041080|Other|laboratory biomarker analysis|Correlative studies
67582|NCT01165450|Drug|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
67583|NCT01165463|Behavioral|SOPT basic training|10 hours of basic training
67584|NCT01165463|Behavioral|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
67585|NCT01165463|Behavioral|SOPT booster training|4 hours of subsequent booster-training
67853|NCT01163149|Drug|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (tota1 of 2.1 mg/kg/week)
67854|NCT01163149|Drug|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
66868|NCT01126138|Drug|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.
Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity
66869|NCT01126151|Behavioral|parent handbook|parent handbook
66870|NCT00038207|Drug|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
66871|NCT01126164|Behavioral|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
66872|NCT01126177|Drug|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
66873|NCT01126177|Drug|Placebo|Placebo (excipients of the SNG001 solution only)
66874|NCT01126190|Biological|Neugranin|Neugranin 40 mg administered approximately 24 hours following chemotherapy for 4 treatment cycles
66875|NCT01126190|Biological|Pegfilgrastim|Pegfilgrastim 6 mg administered approximately 24 hours following chemotherapy for 4 treatment cycles
66876|NCT01126203|Procedure|SLT|All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
66877|NCT01126203|Procedure|ALT|All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with ~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
66878|NCT01126216|Drug|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32,
66879|NCT01126216|Radiation|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
66880|NCT01126216|Drug|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33
66881|NCT00038220|Drug|Lopinavir/ritonavir|
65944|NCT01129414|Drug|Clopidogrel|Pharmaceutical form: tablet
Route of administration: oral
65945|NCT01129414|Drug|Placebo|Pharmaceutical form: matching tablet
Route of administration: oral
67914|NCT01158131|Behavioral|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
67915|NCT01160588|Drug|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
67916|NCT01160601|Drug|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
67917|NCT01160601|Drug|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
67918|NCT01160614|Drug|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
67919|NCT01160627|Other|Hydration|Saline hydration
67920|NCT01160627|Drug|Acetylcysteine|Acetylcystein tablets for 2 days
67921|NCT01160627|Drug|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
67922|NCT01160627|Drug|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
67923|NCT01160640|Drug|ceftriaxone, doxycycline, and placebo|ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo PO bid x 14 days
67924|NCT00040937|Drug|melphalan|st trans: 140 mg/m2 IV over 20 mins day -1
nd trans: 200mg/m2 IV over 20 mins day -1
67925|NCT01160640|Drug|ceftriaxone, doxycycline, metronidazole|ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days
67926|NCT01160653|Device|FES-IM|implantable Functional Electrical Stimulation
67927|NCT01160653|Other|Cognitive training|training of impaired cognitive processes
67928|NCT01160666|Drug|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
67929|NCT01160692|Dietary Supplement|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
67930|NCT01160692|Other|Placebo|Daily oral intake of matching placebo tablets for 3 months
67931|NCT01160705|Drug|docetaxel|
67114|NCT01161719|Behavioral|parent training|Behavioral management skill training
67115|NCT01161732|Procedure|Early surgery|Early surgery is performed within 2 months of randomization.
67116|NCT01161758|Other|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
67117|NCT01161758|Other|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
67118|NCT00041171|Other|placebo|
67119|NCT01164306|Behavioral|Healthy Lifestyle Behavior Choices|The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.
Parents will also be given health related information by mail to parallel the information students receive in school health classes.
67120|NCT01164306|Behavioral|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
66194|NCT01127438|Drug|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight < 60 kg and Age >/=65 years and ASA 3 or 4
66195|NCT01127438|Drug|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight <60 kg and Age >/=65 years and ASA 3 or 4
66196|NCT00038298|Drug|AMG 719|400 mg 3 times weekly
66197|NCT01127438|Drug|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
66198|NCT01127438|Drug|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
66199|NCT01127451|Drug|Denileukin diftitox|Test product: dose and mode of administration:
denileukin diftitox was originally administered by intravenous infusion over 30-60 minutes according to 1 of 2 treatment arms:
12 mcg/kg/day on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks);
12 mcg/kg/day on Days 1, 8, and 15 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks)
ARM 2 is now closed. Patients experiencing clinical benefit (irSD, irPR, or irCR per irRC) after 4 cycles of treatment, may continue their denileukin diftitox treatment for up to 8 cycles.
66200|NCT01127464|Drug|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
66201|NCT01127464|Drug|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
66202|NCT01127464|Drug|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
67855|NCT01163162|Drug|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
67856|NCT01163175|Other|Ruminant trans fats|Consumption of the 4 experimental diets:
a diet rich in ruminant TFA (8 g/day);
a diet moderately rich in ruminant TFA (4 g/day);
a diet rich in industrial TFA (8 g/d);
a control diet (minimal dietary TFA of industrial and ruminant sources).
67857|NCT01163201|Biological|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10^6/kg, 10 x 10^6/kg, 30 x 10^6/kg, 100 x 10^6/kg and 300 x 10^6/kg)
67858|NCT01163201|Biological|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10^6 cells/kg, 6 x 10^6 cells/kg, 9 x 10^6 cells/kg, 12 x 10^6 cells/kg, and 15 x 10^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
67859|NCT01163201|Drug|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m^2 over 1 hour
67860|NCT00041119|Drug|AC regimen|Given IV
67861|NCT01163201|Drug|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
67862|NCT01163201|Radiation|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
67863|NCT01163201|Biological|Umbilical cord blood transplantation|Infusion given on day 0
67864|NCT01163214|Drug|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
67865|NCT01163214|Drug|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
67866|NCT01163227|Drug|Placebo (single and multiple doses)|
67867|NCT01163227|Drug|AQW051 2 mg (single and multiple doses)|
67868|NCT01165645|Other|enzyme-linked immunosorbent assay|Correlative studies
67869|NCT01165645|Other|laboratory biomarker analysis|Correlative studies
67870|NCT01165658|Radiation|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
67871|NCT00041249|Drug|brostallicin|
67872|NCT01165671|Radiation|Carbon Ion Radiotherapy|Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
67873|NCT01165671|Radiation|Proton Radiotherapy|Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
65946|NCT01129414|Drug|Omeprazole|Pharmaceutical form: delayed-release capsule
Route of administration: oral
65947|NCT01129427|Drug|Clopidogrel|Pharmaceutical form: tablet
Route of administration: oral
65948|NCT01129427|Drug|Placebo|Pharmaceutical form: matching tablet
Route of administration: oral
65949|NCT01129427|Drug|Pantoprazole|Pharmaceutical form: delayed-release tablet
Route of administration: oral
65950|NCT00038519|Drug|Saquinavir/ritonavir|
65951|NCT01132313|Drug|BI 207127|4 weeks, low dose TID
65952|NCT01132313|Drug|BI 201335|24 weeks, QD
65953|NCT01132313|Drug|Ribavirin|16 weeks, according to label
65954|NCT01132313|Drug|Ribavirin|28 weeks, according to label
65955|NCT01132313|Drug|Ribavirin|28 weeks, according to label
65956|NCT01132313|Drug|BI 207127|40 weeks, high dose, TID
65957|NCT01132313|Drug|BI 207127|24 weeks, very high dose, BID
65958|NCT00038727|Behavioral|Group Lifestyle|Quarterly group lifestyle sessions
65959|NCT01132313|Drug|BI 207127|16 weeks, standard dose, BID
65960|NCT01132313|Drug|BI 201335|24 weeks, QD
65961|NCT01132313|Drug|Ribavirin|48 weeks, according to label
65962|NCT01132313|Drug|Ribavirin|40 weeks, according to label
65963|NCT01132313|Drug|BI 207127|16 weeks, high dose, TID
65964|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
65965|NCT01132313|Drug|BI 201335|28 weeks, QD
65966|NCT01132313|Drug|BI 201335|16 weeks, QD
65967|NCT01132313|Drug|Ribavirin|24 weeks, according to label
65968|NCT01132313|Drug|BI 201335|24 weeks, QD
65969|NCT00038727|Drug|Metformin|Administered as 850mg twice per day
67932|NCT01160705|Genetic|RNA analysis|
67933|NCT01160705|Genetic|reverse transcriptase-polymerase chain reaction|
67934|NCT01160705|Other|circulating tumor cell analysis|
68290|NCT01158755|Drug|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
68291|NCT01158781|Behavioral|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
68292|NCT01158820|Drug|dexmedetomidine and ketamine Study Medication|Experimental Dexmedetomidine 200 µg in 50 ml Ketamine 30 mg Ketamine 200 mg in 20 ml Midazolam 10 mg + Fentanyl 250 µg + saline 5 ml Benadryl 25 mg
68293|NCT01158820|Drug|placebo + Standard of Care of midazolam and fentanyl|Control Saline 50 ml Midazolam 2 mg + Fentanyl 50 µg Saline 20 ml Midazolam 10 mg + Fentanyl 250 µg + saline 5 ml Benadryl 25 mg
68294|NCT01158833|Other|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
68295|NCT01158846|Drug|prasugrel/bivalirudin|60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
68296|NCT00040872|Drug|isotretinoin|
68297|NCT01158846|Drug|clopidogrel/abciximab|600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
68298|NCT01158859|Drug|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
68299|NCT01161160|Biological|GSK Biologicals' - GSK2340272A|Intramuscular injection
68300|NCT01161186|Drug|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
68301|NCT01161199|Procedure|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
68302|NCT01161212|Other|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
68303|NCT01161212|Other|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
66203|NCT01127477|Drug|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
66204|NCT01127490|Drug|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
66205|NCT01127490|Procedure|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
66206|NCT01127503|Drug|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day [2000 mg/day if metyrosine]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
66207|NCT00038298|Drug|placebo to AMG 719|Placebo dose given 3 times weekly
66208|NCT01127503|Drug|Placebo|Placebo capsules were identically matched to Metyrosine.
66209|NCT00038545|Drug|Filgrastim SD/01|
66210|NCT01129648|Drug|BCX4208|Adminstered daily for 21 days
66211|NCT01129661|Biological|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
66505|NCT01133171|Behavioral|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
66506|NCT01133184|Biological|Sci B vac|Sci B vac
66507|NCT01133210|Drug|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
66508|NCT01133210|Other|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
66509|NCT01133223|Device|Penumbra™ System|Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)
66510|NCT01133223|Drug|Recombinant tissue plasminogen activator|Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
66511|NCT00038831|Drug|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
66512|NCT01133236|Dietary Supplement|Salt and fluid restriction|I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.
II: Control Prescription without sodium and fluid restriction.
68231|NCT01163695|Behavioral|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families—and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
68232|NCT01163708|Device|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
68233|NCT00041132|Drug|cytarabine|12 g/m^2 over days 3-4 of cycles 2,4,6,8
68234|NCT01163708|Device|Navigation System|
68235|NCT01163721|Drug|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
68236|NCT01163721|Drug|Placebo|Placebo to match ranolazine administered orally twice daily
68237|NCT01163734|Drug|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
68238|NCT01163734|Other|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
68239|NCT01163747|Biological|tocilizumab|Intravenous repeating dose
68240|NCT01163747|Drug|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
68241|NCT01163747|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
68242|NCT01163747|Biological|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
68243|NCT01163760|Device|etafilcon A|daily disposable contact lens
68244|NCT00041132|Drug|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
68245|NCT01163760|Device|ocufilcon D|daily disposable contact lens
68246|NCT01163773|Other|MILK|Consumption of the 2 experimental diets
Milk diet
Control diet
68247|NCT01163786|Drug|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
68248|NCT01163799|Drug|Alefacept (ASP0485)|Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
65970|NCT01132313|Drug|BI 201335|28 weeks, QD
66278|NCT00038974|Drug|Ribavirin|
66279|NCT01134861|Radiation|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
66280|NCT01134861|Radiation|Radiation therapy|69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
66281|NCT01134874|Behavioral|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
66282|NCT01134874|Behavioral|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
66283|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
66284|NCT01127529|Biological|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
66285|NCT01127542|Drug|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
66286|NCT01127555|Drug|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
66287|NCT01127568|Drug|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
66288|NCT01127581|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
66289|NCT01127581|Drug|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
66290|NCT01127594|Drug|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
68304|NCT01161225|Behavioral|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
68305|NCT00041015|Drug|etoposide|
68306|NCT01161225|Behavioral|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
67344|NCT01157065|Drug|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
67345|NCT01157078|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
67346|NCT01157078|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
67347|NCT01157091|Drug|pazopanib hydrochloride|Given orally
67348|NCT01157091|Other|laboratory biomarker analysis|Correlative studies
67349|NCT01157091|Other|immunologic technique|Correlative studies
67350|NCT01157104|Drug|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
67351|NCT01157104|Drug|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
67352|NCT01157104|Drug|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
67353|NCT01159509|Behavioral|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
67354|NCT00000952|Drug|Ritonavir|
67355|NCT00040872|Procedure|peripheral blood stem cell transplantation|
67356|NCT01159522|Drug|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
67357|NCT01159535|Behavioral|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
67358|NCT01159535|Behavioral|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
66513|NCT01133275|Drug|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
66514|NCT01133275|Drug|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
66515|NCT01133288|Device|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (~30 minutes per day) over a 3 month period.
66516|NCT01133301|Drug|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
66517|NCT01133301|Drug|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
66518|NCT01133327|Device|Carotid Artery Stenting|The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.
The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014" silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire.
66519|NCT01133340|Radiation|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
66520|NCT00038142|Drug|Dexrazoxane|900 mg/m^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
66521|NCT01125527|Biological|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
66808|NCT01128413|Biological|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
66809|NCT01128413|Biological|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
66810|NCT01128426|Other|No Intervention|No Intervention
66811|NCT01128439|Other|No intervention|No intervention
66812|NCT01128452|Drug|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
66813|NCT01128452|Drug|Placebo|HPMC Placebo capsules, once daily for 28 days
66814|NCT01128478|Procedure|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
67289|NCT01162018|Procedure|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
67290|NCT01162018|Other|placebo|
67291|NCT01162031|Drug|Velcade|IV
67292|NCT01162044|Other|Computer game|Playing with specially designed computer game while in emergency room
67293|NCT01162070|Other|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
67294|NCT01162070|Other|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
67295|NCT01162096|Device|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
67296|NCT01162109|Dietary Supplement|Zinc sulfate|A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.
A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis.
67297|NCT01162122|Biological|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
67298|NCT01162122|Biological|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
67299|NCT00041067|Biological|filgrastim|
67300|NCT01162135|Drug|Digoxin|The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.
It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose.
67301|NCT01162148|Behavioral|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
67302|NCT01162148|Device|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
67303|NCT01162148|Device|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
66291|NCT01127607|Drug|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
66292|NCT01127620|Drug|Bilastine|20 mg encapsulated tablets
66577|NCT01130584|Other|Pyruvate kinase isoform M2|
66578|NCT01130597|Drug|patiromer|Active investigational drug
66579|NCT01130597|Drug|spironolactone|
66580|NCT01130623|Drug|Pazopanib (GW786034)|
66581|NCT01130636|Drug|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
66582|NCT01130649|Device|HealthBuddy|Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
66583|NCT01133353|Drug|Tetrabenazine MR|Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
66584|NCT01133353|Drug|Placebo|1 to 5 tablets once per day depending on weight for 12 weeks
66585|NCT00038831|Procedure|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
66586|NCT01133366|Drug|warfarin sodium|25 mg of warfarin oral (single dose)
66587|NCT01133366|Drug|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
66588|NCT01133379|Device|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
66589|NCT01133379|Device|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
66590|NCT01133379|Device|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
66591|NCT01133392|Drug|Insulin lispro A|20 units (U) subcutaneously (SC).
66592|NCT01133392|Drug|Insulin lispro B|20 U subcutaneously (SC).
66593|NCT01133405|Drug|LY2886721|Oral capsules
66594|NCT01133405|Drug|Placebo|Oral capsules
67359|NCT01159535|Behavioral|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
67360|NCT01159548|Drug|Promethazine|
67361|NCT01159548|Drug|Promethazine|
67362|NCT01159561|Biological|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
67363|NCT01159574|Drug|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
67364|NCT01159574|Drug|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
67649|NCT00040911|Procedure|sham intervention|Undergo electroacupuncture therapy to sham points
67650|NCT01160159|Other|Tests|Arterial parameters
67651|NCT01160159|Other|Healthy volunteers|Arterial parameters and blood test
67652|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
67653|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
67654|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
67655|NCT01162720|Procedure|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
67656|NCT01162733|Drug|Vancomycin|15mg/kg
67657|NCT01162733|Drug|Vancomycin|30mg/kg
67658|NCT01162746|Drug|Intravitreal dexamethasone and intravitreal ranibizumab|Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.
Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT.
67659|NCT01162746|Drug|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
66815|NCT00038402|Drug|Fluorouracil|500 mg/m^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
66816|NCT01128517|Behavioral|Maternal education on complementary feeding|CF education to the mothers in intervention arm.
Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 & 2006).
First session --> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.
Second session -->breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.
Third session --> previous sessions recall. protein based and iron rich food encouragement.
The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm
66817|NCT01128517|Behavioral|Education|Maternal education on complementary food
66818|NCT01128530|Drug|JNJ-32729463|250 mg tablet twice daily
66819|NCT01128530|Drug|linezolid|600 mg tablet twice daily
66820|NCT01128530|Drug|JNJ-32729463 placebo|1 placebo tablet twice daily
66821|NCT01128530|Drug|linezolid placebo|1 placebo tablet, twice daily
66822|NCT01128543|Drug|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
66823|NCT01128556|Drug|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
66824|NCT01128556|Drug|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
66825|NCT01128569|Drug|Fluticasone Furoate|FF
66826|NCT01131026|Drug|Levofloxacin|tablet, 500 mg, once a day for ten days
66827|NCT01131026|Drug|Amoxicillin|tablet, 1000 mg, once a day for ten days
67121|NCT01164319|Procedure|Circumferential PVI and subcutaneous cardiac monitor implantation|The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
67122|NCT01164332|Other|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
67123|NCT01164345|Drug|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
67124|NCT01164384|Drug|Baminercept|
67304|NCT01162148|Device|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
67305|NCT01162174|Dietary Supplement|Oligonol|
67586|NCT01165476|Drug|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
67587|NCT01165502|Drug|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
67588|NCT01165502|Drug|Placebo|Placebo for compound CM3.1-AC100 s.c.
67589|NCT01165528|Procedure|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
67590|NCT01165541|Drug|Mirtazapine|mirtazapine (7.5-45mg)
67591|NCT01165541|Drug|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
67592|NCT00041223|Dietary Supplement|IH636 grape seed proanthocyanidin extract|
67593|NCT01165554|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
67594|NCT01165567|Drug|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
67595|NCT01165580|Drug|valganciclovir [Valcyte]|oral dose, Days 1 and 2
67596|NCT01165593|Other|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
67597|NCT01165606|Procedure|Chest physiotherapy|
67598|NCT01165632|Procedure|biopsy|Correlative studies
67599|NCT01165632|Procedure|computed tomography|Undergo computed tomography
67600|NCT01165632|Procedure|therapeutic conventional surgery|Undergo stereotactic craniotomy
67601|NCT01165632|Radiation|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
67602|NCT01165632|Radiation|radiation therapy|Undergo radiation therapy
67603|NCT00041236|Drug|exatecan mesylate|
67604|NCT01165632|Procedure|magnetic resonance imaging|Undergo magnetic resonance imaging
67605|NCT01165632|Procedure|positron emission tomography|Undergo positron emission tomography
66595|NCT01133418|Other|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
66882|NCT01126216|Radiation|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
66883|NCT01126229|Dietary Supplement|Placebo|2 capsules of placebo daily for 12 weeks
66884|NCT01126229|Drug|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
66885|NCT01126229|Drug|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
66886|NCT00038402|Drug|Cytoxan|500 mg/m^2 on Day 1 of each cycle for 4 cycles.
66887|NCT01128569|Drug|FF/Vilanterol (VI; GW642444M)|FF/VI
66888|NCT01128569|Drug|Placebo|Placebo Inhaler
66889|NCT01128582|Drug|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
66890|NCT01128582|Drug|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
66891|NCT01128595|Drug|FF/GW642444M|
66892|NCT01128595|Drug|GW642444M|
66893|NCT01128595|Drug|Fluticasone Furoate|
66894|NCT01128595|Drug|Placebo|
66895|NCT01128608|Procedure|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
66896|NCT01128608|Procedure|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
66897|NCT00038402|Drug|Epirubicin|75 mg/m^2 IV on Day 1 of each cycle for 4 cycles.
66898|NCT01128621|Drug|GSK1292263|Tablet
66899|NCT01128621|Drug|GSK1292263 matching placebo|Tablet
66900|NCT01128621|Drug|Sitagliptin|Tablet
67660|NCT01162759|Behavioral|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
67661|NCT01162785|Drug|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
67662|NCT01162798|Other|infant formula|test infant formula fed to infants until 6 months corrected gestational age
67663|NCT01162798|Other|control infant formula|commercially available infant formula
67664|NCT01162811|Behavioral|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
67665|NCT00000953|Drug|Acyclovir|
67666|NCT00041093|Drug|Docetaxel|Given IV
67935|NCT00040937|Drug|prednisone|maint: 50 mg/d PO every other day until progression
67936|NCT01160705|Other|laboratory biomarker analysis|
67937|NCT01160718|Drug|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
67938|NCT01160718|Drug|selumetinib|AZD6244 75 mg p.o. bid
67939|NCT01160731|Drug|cisplatin|
67940|NCT01160731|Drug|etoposide phosphate|
67941|NCT01163227|Drug|AQW051 15mg (single and multiple doses)|
67942|NCT01163227|Drug|AQW051 100mg (single dose), and 50mg (multiple doses)|
67943|NCT01163253|Drug|CP-690,550|5 mg oral BID
67944|NCT00041119|Drug|cyclophosphamide|Given IV
67945|NCT01163253|Drug|CP-690,550|10 mg oral BID
67946|NCT01163266|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
67947|NCT01163266|Drug|Placebo|Vortioxetine placebo-matching capsules
67125|NCT01164423|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
67126|NCT01164449|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
67127|NCT01164462|Biological|blood test: rapid finger-stick blood specimen test|
67128|NCT01164462|Biological|blood test: conventional test|
67129|NCT00041197|Drug|imatinib mesylate|Given orally (PO)
67130|NCT01164475|Drug|Granulocyte-colony stimulating factor (G-CSF)|
67131|NCT01164475|Drug|Fixed Dose Plerixafor|
67132|NCT01164475|Drug|Weight-Based Plerixafor|
67133|NCT01164488|Drug|danoprevir|Repeated daily doses
67134|NCT01164488|Drug|ritonavir|Repeated daily doses
67135|NCT01164488|Drug|ketoconazole|Repeated daily doses
67136|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
67137|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
67138|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
67139|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
67140|NCT00041197|Other|placebo|Given PO
67141|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
67142|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
66212|NCT01129661|Biological|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
66213|NCT01129674|Drug|LY2140023|Administered orally, twice daily for 104 weeks
66214|NCT01129674|Drug|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
66215|NCT01129674|Drug|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
66216|NCT01129674|Drug|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
67606|NCT01165632|Drug|fluorine F 18 fluorodopa|Given IV
67607|NCT01165645|Drug|lopinavir|Given orally
67608|NCT01165645|Drug|ritonavir|Given orally
67609|NCT01165645|Genetic|polymerase chain reaction|Correlative studies
67610|NCT01165645|Other|flow cytometry|Correlative studies
67874|NCT01165684|Drug|insulin aspart|Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.
Doses individually adjusted.
67875|NCT01165684|Drug|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
67876|NCT01165684|Drug|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
67877|NCT01165697|Other|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
67878|NCT01165710|Other|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
67879|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
67880|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
67881|NCT01165736|Drug|PF-05186462|single intravenous infusion of 100 microgram
67882|NCT00041262|Drug|cisplatin|
67883|NCT01165736|Drug|PF-05186462|single oral administration of 100 microgram
67884|NCT01165736|Drug|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
67885|NCT01165736|Drug|PF-05089771|single oral administration of 100 microgram PF-05089771
67886|NCT01165736|Drug|PF-05150122|single intravenous administration of 100 microgram PF-05150122
67887|NCT01165736|Drug|PF-05150122|single oral administration of 100 microgram PF-05150122
67888|NCT01165736|Drug|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
67889|NCT01165736|Drug|PF-05241328|single oral administration 100 microgram PF-05241328
67890|NCT01165749|Behavioral|stop exercising|
66901|NCT01128634|Drug|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
66902|NCT01128634|Drug|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
66903|NCT01128647|Dietary Supplement|Fructose:glucose drink|
66904|NCT01128647|Dietary Supplement|glucose drink|
66905|NCT01128673|Device|mRI|
65971|NCT01132313|Drug|BI 207127|24 weeks, standard dose, BID
65972|NCT01132313|Drug|BI 201335|24 weeks, QD
65973|NCT01132313|Drug|BI 201335|16 weeks, QD
65974|NCT01132313|Drug|BI 207127|16 weeks, high dose, BID
65975|NCT01132313|Drug|BI 201335|24 weeks, QD
65976|NCT01132313|Drug|Ribavirin|16 weeks, according to label
65977|NCT01132313|Drug|Ribavirin|16 weeks, according to label
65978|NCT01132313|Drug|BI 207217|28 weeks, high dose BID
65979|NCT01132313|Drug|BI 201335|16 weeks, QD
65980|NCT00038727|Behavioral|Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
65981|NCT01132313|Drug|BI 207127|24 weeks, high dose, TID
65982|NCT01132313|Drug|Ribavirin|48 weeks, according to label
65983|NCT01132313|Drug|BI 207127|4 weeks, high dose, TID
65984|NCT01134562|Drug|KAI-4169|Single IV injection
65985|NCT00038948|Drug|Cyclosporine A|
65986|NCT01134575|Drug|CMC-544 (Inotuzumab Ozogamycin)|First patients > 16 years and < 16 years receive CMC-544 at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle.
65987|NCT01134575|Drug|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
65988|NCT01134588|Other|Paper questionnaire|
67948|NCT01163279|Behavioral|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
67949|NCT01163305|Drug|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
67950|NCT01163331|Other|Singing Therapy|Singing therapy as a way to improve voice quality
67951|NCT01163357|Drug|bortezomib|Given IV
67952|NCT01163357|Drug|fludarabine phosphate|Given IV
67953|NCT01163357|Other|melphalan|Given IV
67954|NCT01163357|Radiation|total marrow irradiation|Undergo TMI
67955|NCT00041119|Drug|doxorubicin hydrochloride|Given IV
67956|NCT01163357|Drug|tacrolimus|Given IV and orally
67957|NCT01163357|Drug|sirolimus|Given orally
67958|NCT01163357|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
68307|NCT01161238|Other|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
68308|NCT01161264|Biological|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
68309|NCT01161277|Drug|Aripiprazole|Dose: 5-10 mg depending on subject weight
68310|NCT01161277|Drug|Haloperidol|Dose: 1-2 mg depending on subject weight
68311|NCT01161277|Drug|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
68312|NCT01161290|Behavioral|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
68313|NCT01161316|Drug|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|Treatment regimen:
mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours
Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.
67737|NCT01160250|Drug|vismodegib (GDC-0449)|Oral repeating dose
67738|NCT01160263|Drug|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.
123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.
67739|NCT01160276|Drug|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
67740|NCT01160276|Drug|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
67741|NCT01160289|Drug|LY2452473|Administered orally, once daily for 12 weeks
67742|NCT01160289|Drug|tadalafil|Administered orally, once daily for 12 weeks
67743|NCT01160289|Drug|placebo (tadalafil)|Administered orally, once daily for 12 weeks
67744|NCT01160289|Drug|placebo (LY2452473)|Administered orally, once daily for 12 weeks
67745|NCT01160302|Drug|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
67746|NCT00040937|Biological|sargramostim|PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis
1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery
67747|NCT01162863|Drug|Placebo|taken orally for 28 days
67748|NCT01162876|Drug|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
67749|NCT01162889|Drug|Placebo SC Injection|Single injection
68107|NCT01158417|Drug|Resveratrol 40 mg oral three times a day|Drug
68108|NCT01158417|Drug|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
68109|NCT01158430|Behavioral|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours
68110|NCT01158443|Behavioral|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
68111|NCT01158443|Behavioral|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
68112|NCT01158482|Procedure|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
68113|NCT01158495|Procedure|Intubation with a cuffed ET Tube|
68114|NCT00040872|Drug|cisplatin|
67247|NCT01156883|Drug|mercaptopurine|
67248|NCT01156883|Drug|methotrexate|
67526|NCT01157364|Drug|bimatoprost ophthalmic formulation C|Single dose of bimatoprost ophthalmic formulation C administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
67527|NCT01157364|Drug|bimatoprost ophthalmic formulation D|Single dose of bimatoprost ophthalmic formulation D administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
67528|NCT01157364|Drug|bimatoprost ophthalmic formulation E|Single dose of bimatoprost ophthalmic formulation E administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
67529|NCT00040846|Biological|alemtuzumab|Given IV
67530|NCT01157364|Drug|bimatoprost ophthalmic formulation F|Single dose of bimatoprost ophthalmic formulation F administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
67531|NCT01157364|Drug|Sham|Sham administration in the study eye on Day 1.
67532|NCT01157364|Drug|timolol 0.5%|Two drops timolol 0.5% (Timoptic®) administered in the study and non-study eyes once in the morning and once in the evening daily for up to 24 months.
67533|NCT01157364|Drug|bimatoprost ophthalmic solution 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
67534|NCT01159769|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
67535|NCT01159782|Other|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
67536|NCT01159808|Drug|INX-08189|3, 25 and 100 mg capsules; oral administration, single dose
67537|NCT01159808|Drug|Placebo|matching placebo capsules, oral administration, single dose
67538|NCT01159821|Drug|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
67539|NCT01159847|Drug|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
67540|NCT01159860|Procedure|cryosurgery|freezing of lesion with liquid nitrogen
67541|NCT01159860|Procedure|Curettage|the lesion will be anesthetized and destroyed with a curette.
67542|NCT00040885|Other|placebo|
64259|NCT01136668|Procedure|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
64260|NCT01136668|Procedure|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
64261|NCT01136733|Drug|Lenvatinib|taken orally,once a day
64262|NCT00000941|Drug|Simvastatin|
64263|NCT00039104|Other|laboratory biomarker analysis|Correlative studies
64264|NCT01136733|Drug|Everolimus|orally once a day
64265|NCT01136733|Drug|Lenvatinib plus Everolimus|orally once a day
64540|NCT01141972|Other|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
64541|NCT01141985|Device|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
64542|NCT01141998|Drug|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
64543|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. Week 0-10.
64544|NCT01141998|Radiation|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
64545|NCT01141998|Radiation|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
64546|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. From week 14 to 52.
64547|NCT01142011|Drug|Belimumab|The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).
The infusion will be administered over a minimum period of 1 hour.
64548|NCT01142024|Drug|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
64020|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
64021|NCT00036569|Procedure|adjuvant therapy|
64022|NCT01112267|Drug|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
64023|NCT01112280|Device|cap-assisted chromoendoscopy|A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy.
For chromoendoscopy, 0.15-0.2% indigocarmine was administered via irrigation cap .
64024|NCT01112293|Drug|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
64025|NCT01112306|Drug|ACT-293987|Tablets, twice daily
64026|NCT01112319|Device|Elf care|elfcare device
64027|NCT01112319|Other|control group|regular physiotherapy treatment
64323|NCT01144117|Drug|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
64324|NCT01144143|Drug|Infliximab|the study drug will be injected into the joint through a needle
64325|NCT01144143|Drug|Placebo|the placebo will be injected into the joint through a needle
64326|NCT01144143|Drug|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
64327|NCT01144156|Drug|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
64328|NCT01144169|Drug|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
64329|NCT00039481|Biological|oblimersen sodium|Given IV
64330|NCT01144182|Behavioral|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
64331|NCT01144195|Drug|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
64332|NCT01144221|Procedure|Intramyocardial Cell therapy|Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
68115|NCT01158495|Procedure|CT scan Radiation|
68116|NCT01160861|Drug|MEMP1972A|Repeating ascending dose
68117|NCT01160861|Drug|placebo|Repeating ascending dose
68118|NCT01160874|Other|Polysomnography|Sleep study monitoring
68119|NCT01160874|Other|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
68120|NCT01160874|Behavioral|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
68121|NCT01160874|Other|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
68122|NCT01160900|Procedure|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
68123|NCT01160913|Procedure|Continuous wound infusion|
68124|NCT01160913|Procedure|Continuous wound|
68125|NCT01160926|Drug|AZD6244|Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd
Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy
68126|NCT00040950|Drug|agatolimod sodium|
68127|NCT01160926|Drug|Cediranib (AZD2171)|10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od
Oral tablets
68128|NCT01160939|Other|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
68129|NCT01160952|Drug|itraconazole|the two groups are defined by different treatment duration
67164|NCT01156844|Drug|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
67165|NCT01156857|Drug|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
67166|NCT01156857|Drug|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
67167|NCT01156870|Drug|SAR566658|Pharmaceutical form:solution for infusion
Route of administration: intravenous
67543|NCT01159873|Drug|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
67544|NCT01159873|Drug|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
67808|NCT01157845|Device|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
67809|NCT01157858|Drug|Everolimus|2.5 mg every day orally
67810|NCT00040846|Drug|cyclosporine|Given IV or PO
67811|NCT01157858|Drug|Octreotide LAR|40 mg every 28 days IM
67812|NCT01157871|Drug|XRP0038 (NV1FGF)|Pharmaceutical form:solution
Route of administration: intramuscular
67813|NCT01157871|Drug|placebo|Pharmaceutical form:solution
Route of administration: intramuscular
67814|NCT01157897|Biological|Plasmodium vivax Malaria Protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B|Cohort 1 (15ug VMP001), Cohort 2 (30ug VMP001), Cohort 3 (60ug VMP001)
67815|NCT01157923|Device|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
67816|NCT01157936|Drug|Allopurinol|daily dosage
67817|NCT01157936|Other|placebo|daily dosage
67818|NCT01160315|Drug|Triptorelin|Triptorelin: intramusculAR injection every 3 months
67819|NCT01160315|Drug|Norethisterone acetate|5 mg/day per os until during chemotherapy
67820|NCT01160328|Drug|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
67821|NCT01160328|Drug|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
67822|NCT01160341|Drug|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
67823|NCT01160354|Drug|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
67824|NCT01160354|Drug|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
67825|NCT01160367|Other|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
64549|NCT01142024|Drug|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
64550|NCT00039377|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
64551|NCT01142037|Dietary Supplement|Cooked parsnips with parsley|Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
64552|NCT01142050|Biological|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
64553|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
64554|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
64555|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
64556|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
64557|NCT01142076|Drug|Xinju Xiaogao Prescription|treatment group
63668|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.
The auto-measures will be performed according the methodology recommended by HAS.
63669|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.
The auto-measures will be performed according the methodology recommended by HAS.
63670|NCT01109264|Drug|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
63671|NCT01109264|Drug|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
63672|NCT01109303|Procedure|TightRope System- Arthrex® / Dynamic Implant|Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
63673|NCT01109303|Procedure|Screw fixation - Synthes® / Static Implant|Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
63674|NCT01109316|Drug|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
63675|NCT00036114|Drug|aripiprazole|
63676|NCT01109316|Drug|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
64333|NCT01144234|Behavioral|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
64334|NCT01144234|Behavioral|Information letter|In this arm the pregnant women got an information letter
64335|NCT01144247|Drug|alloreactive CTL|cellular immunotherapy with alloCTL
64336|NCT01136785|Device|Continuous Positive Airway Pressure (CPAP) Therapy (active or placebo)|CPAP is approved for the treatment of Obstructive Sleep Apnea
64337|NCT00039117|Biological|oblimersen sodium|Given IV
64338|NCT01136798|Drug|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
64339|NCT01136798|Drug|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
64340|NCT01136811|Device|Computer assisted surgery|use of computer assisted surgical device in vascular surgery
completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure
64610|NCT01139645|Drug|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
64611|NCT01139671|Drug|Remifentanil|Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.
The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses.
64612|NCT01139684|Behavioral|Repeated sprint test|
64613|NCT00039234|Biological|aldesleukin|
64614|NCT01139697|Other|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
64615|NCT01139723|Drug|MINT1526A|Intravenous escalating dose
64616|NCT01139723|Drug|bevacizumab|Intravenous repeating dose
64617|NCT01139736|Dietary Supplement|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
64618|NCT01139749|Drug|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
64619|NCT01139749|Drug|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
64620|NCT00039377|Radiation|total-body irradiation|Undergo TBI
67168|NCT01159132|Drug|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
67169|NCT01159145|Drug|D961H|Oral, capsule
67170|NCT01159145|Drug|Omeprazole|Oral, tablet
67171|NCT00040872|Procedure|autologous bone marrow transplantation|
67172|NCT01159158|Drug|Nateglinide|Nateglinide Tablets 120 mg
67173|NCT01159171|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
67174|NCT01159171|Drug|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
67175|NCT01159171|Drug|oxaliplatin|40 mg/m2 iv weekly
67176|NCT01159197|Behavioral|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
67177|NCT01159210|Biological|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
67178|NCT01159223|Drug|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
67179|NCT01159236|Drug|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
67180|NCT01159236|Drug|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
67181|NCT01159236|Drug|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
67182|NCT00040872|Procedure|bone marrow ablation with stem cell support|
67183|NCT01159236|Drug|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
67463|NCT01162382|Device|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
63896|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
64182|NCT01112644|Drug|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
64183|NCT01112644|Other|Placebo (PLA)|Different daily doses; intake every 12 hours
64184|NCT01112670|Drug|Sitagliptin|sitagliptin 100 mg x 1 dose
64185|NCT01112670|Drug|atorvastatin|atorvastatin 40 mg x 5 doses
64186|NCT01112683|Drug|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
64187|NCT01112683|Drug|Placebo|These are identically-looking pills to those in the Memantine Arm.
64188|NCT01112696|Device|Sensor wear|All subjects to wear sensors
64189|NCT01112709|Behavioral|SCT-based Resistance Training exercise program|Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.
64190|NCT00036621|Drug|BMS-275291|
64191|NCT01112709|Other|Standard Intervention with minimal contact|This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
64192|NCT01112722|Biological|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
64193|NCT01112722|Biological|histamine|imitates pain and erythema of honeybee venom
64194|NCT01112735|Biological|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
64195|NCT01112735|Procedure|Standard of care|Standard of care
64196|NCT01112748|Drug|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
64197|NCT01112761|Device|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
64198|NCT01112774|Device|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
64199|NCT01112787|Drug|Tazarotene Foam|Tazarotene Foam
64200|NCT01112787|Drug|Vehicle Foam|Vehicle Foam
63677|NCT01109316|Drug|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
63678|NCT01111604|Biological|IMC-18F1|15 mg/kg I.V. infusion, administered every 2 weeks
63679|NCT01111604|Drug|mFOLFOX-6|Oxaliplatin: 85 mg/m² I.V. infusion q2 weeks
FA: 400 mg/m² I.V. infusion q2 weeks (or LFA: 200 mg/m2 q2 weeks if FA is unavailable).
5FU: 400 mg/m² bolus + 2400 mg/m² I.V. infusion q2 weeks
63680|NCT01111617|Procedure|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
63681|NCT01111630|Drug|recomon (Epoetin Beta)|administer once weekly
63682|NCT01111630|Drug|recomon (Epoetin Beta)|administer three times weekly
63683|NCT01111643|Device|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
63684|NCT01111656|Drug|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
63685|NCT01111656|Drug|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
63686|NCT00036452|Drug|stavudine|
63959|NCT01114971|Drug|Labetalol|Labetalol 5 mg/ml boluses will be given:
at the induction time
at the time before surgical incision, and
as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
63960|NCT01114971|Drug|Esmolol|Esmolol 10 mg/ml boluses will be given:
at the induction time
at the time before surgical incision, and
as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
63961|NCT00036790|Drug|motexafin gadolinium|
63962|NCT01114997|Drug|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
63963|NCT01114997|Drug|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
63964|NCT01114997|Drug|Lidocaine + Esmolol|Pre-induction: Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Maintenance Infusion rate after Induction:
Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)
63965|NCT01115010|Device|Colonoscope stiffening device|Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The "standard" stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the "firm" wire replaces the "standard" wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned.
64621|NCT01142102|Radiation|Radiation Therapy|A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.
Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.
Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV.
64622|NCT01142115|Device|Intermittent catheter CP063CC|intermittent catheterisation
64623|NCT01142115|Device|SpeediCath|intermittent catheterisation
64624|NCT01142128|Drug|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
64625|NCT01142128|Drug|Placebo to Nexium|one capsule per day for one month
64626|NCT01142128|Drug|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
64627|NCT01142128|Drug|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
64628|NCT01142141|Other|manual therapy, kinesiotherapy|
64629|NCT01142154|Drug|Prodarsan|Prodarsan TID, oral solution, 6-8 days
67704|NCT01157585|Drug|paliperidone ER|8 week prospective study
67705|NCT01157598|Device|bispectral index monitoring|parameter monitoring of bispectral index
67706|NCT01157611|Behavioral|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
67707|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
67708|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
67709|NCT01157650|Other|Autologous mesenchymal stem cells|The trial is divided in three phases:
I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.
II.- Treatment phase includes:
Liposuction procedure to obtain adipose tissue.
Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)
ASCs implant
III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant.
67710|NCT01157663|Other|Adapted balance training|during 8 weeks
67711|NCT01157663|Other|Balance Training|Balance training with unipedal standing during 8 weeks
67464|NCT01162395|Drug|AZD3514|Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
67465|NCT01162421|Biological|adalimumab|Study drug will be provided to patients in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Patients in standard of care (SOC) arm will receive treatment recommended by their study doctor. Adalimumab may be initiated in SOC patients after a minimum of 6 months.
67466|NCT01162421|Drug|Methotrexate|Patients in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
67467|NCT01162460|Drug|Eslicarbazepine acetate (BIA 2-093)|Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.
Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.
Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.
Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions.
67468|NCT01162473|Dietary Supplement|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
67469|NCT01162473|Drug|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
67470|NCT01162473|Other|Food Challenge|
67471|NCT01162486|Drug|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
67472|NCT00041067|Drug|vinorelbine|
67473|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
67474|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
67475|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
67476|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
67477|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
67478|NCT01162499|Drug|exendin-(9-39)|IV infusion of exendin-(9-39)for 5 hours
67479|NCT01162499|Other|placebo normal saline|saline infusion for 5 hours at 0.06 mL/kg/hr
67750|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
64201|NCT00036634|Drug|Tenofovir DF|Tenofovir DF tablet administered orally once daily
64202|NCT01141439|Drug|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
64482|NCT01144429|Biological|Allergoid, allergenic extract of 100% Birch|Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
64483|NCT01144442|Drug|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
64484|NCT01144442|Other|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
64485|NCT01144442|Procedure|Surgery|The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.
If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach.
64486|NCT01144442|Drug|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
64487|NCT01144442|Drug|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
64488|NCT01144455|Drug|Gemzar (Gemcitabine)|1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
64489|NCT01144455|Drug|TH-302|240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
64490|NCT01144455|Drug|TH-302|340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
64491|NCT01144494|Drug|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
64492|NCT00039481|Biological|filgrastim|Given SC
64493|NCT01144494|Drug|Artificial tears|Lubricating drops added three times a day for six weeks
64494|NCT01144507|Procedure|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
64495|NCT01144507|Other|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
64496|NCT01137071|Biological|Monoclonal antibody Hu3S193|30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated "orphan drug" by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation.
64497|NCT01137084|Drug|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
63966|NCT01115010|Device|Colonoscope stiffening device|"Standard" stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the "standard" wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the "firm" wire and so on until cecal intubation is achieved or the procedure is abandoned.
63967|NCT01107145|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
63968|NCT01107145|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
63969|NCT01107145|Drug|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
63970|NCT01107158|Biological|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
63971|NCT01107171|Drug|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
63972|NCT01107171|Drug|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
63973|NCT01107171|Drug|Placebo|Tang-min-Ling pills analogue 6g,tid,po
63974|NCT01107184|Procedure|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
63975|NCT01107184|Procedure|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
64266|NCT01136746|Drug|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
64267|NCT01136746|Drug|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
64268|NCT01136746|Drug|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
64269|NCT01136759|Drug|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
64270|NCT01136759|Other|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
64271|NCT01136772|Drug|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
64272|NCT01136772|Drug|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
64273|NCT01138787|Dietary Supplement|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
67712|NCT00040846|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
67713|NCT01157676|Other|Quality of Life Questionnaires|Quality of Life Questionnaires
67714|NCT01157676|Other|Get up and Go test|Timed Get up and Go test
67715|NCT01157676|Other|Hand Grip test|Hand grip strength test
67716|NCT01157702|Biological|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
67717|NCT01157715|Biological|intravitreal injection of KH902|
67718|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
67719|NCT01160172|Drug|Saline placebo|intramuscular vaccination according to protocol schedule
67720|NCT01160185|Drug|paclitaxel|paclitacel
67721|NCT01160185|Drug|cisplatin|cisplatin monotherapy
67722|NCT01160185|Drug|topotecan|topotecan
67723|NCT00040911|Procedure|quality-of-life assessment|Ancillary studies
67724|NCT01160198|Drug|ferrous ascorbate|100 mg elemental iron
67725|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
68004|NCT01158196|Device|infra-red diode laser|laser treatment of scar after keloid excision
laser treatment of surgery scar
68005|NCT01158209|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
68006|NCT01158222|Drug|sunitinib malate|Given orally
68007|NCT01158222|Other|laboratory biomarker analysis|Correlative studies
68008|NCT01158222|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
68009|NCT01158222|Genetic|polymorphism analysis|Correlative studies
68010|NCT01158235|Drug|LTX-109|1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
68011|NCT01158248|Biological|panitumumab|
67751|NCT00041106|Drug|gemcitabine hydrochloride|Given IV
67752|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
67753|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
67754|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
67755|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
67756|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
67757|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
67758|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
67759|NCT01162889|Drug|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
67760|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
67761|NCT01162902|Drug|Diltiazem treated group|Diltiazem 180mg for 9 months
67762|NCT00041106|Drug|cisplatin|Given IV
67763|NCT01162902|Drug|Bisoprolol treated group|Bisoprolol 5mg for 9 months
67764|NCT01162902|Drug|Candesartan treated group|Candesartan 32mg for 9 months
67765|NCT01162915|Biological|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
67766|NCT01162928|Drug|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
67767|NCT01162928|Drug|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
67768|NCT01162941|Other|Steroid refractory ITP|a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
67769|NCT01162954|Drug|DA-6034|
67770|NCT01162954|Drug|Placebo|
67771|NCT01162967|Drug|Benznidazole|Standard dosage
67772|NCT01162967|Drug|Posaconazole|
67773|NCT00041106|Drug|gefitinib|Given PO
64498|NCT01137084|Drug|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
64499|NCT01137097|Procedure|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
64500|NCT01137110|Drug|Levetiracetam short course|Levetiracetam 1000mg BID x 3 days
63615|NCT01111565|Drug|Aripiprazole|Aripiprazole monotherapy
63616|NCT01111565|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
63617|NCT01111578|Device|Enteral feeding tube|The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
63618|NCT00036452|Drug|emtricitabine|
63619|NCT01111591|Drug|Cox2 inhibitor (Celecoxib)|From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
63620|NCT01111604|Biological|IMC-1121B|8 mg/kg I.V. infusion, administered every 2 weeks
63621|NCT01114204|Drug|Iron Sucrose|IV Iron Sucrose
63622|NCT01114217|Drug|Ferumoxytol|IV Ferumoxytol
63623|NCT01114230|Drug|AGS-16M8F|IV
63624|NCT01114243|Device|Ultrasound imaging|
63625|NCT01114256|Procedure|FNA Biopsy|
63626|NCT01114282|Drug|velcade|
63627|NCT01114282|Drug|Pralatrexate|
63628|NCT01114295|Device|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
64274|NCT01138787|Dietary Supplement|Placebo spread|Single dose (30 gr) of regular light margarine
64275|NCT01138787|Dietary Supplement|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
64276|NCT00039195|Drug|etoposide|
64277|NCT01138826|Drug|Amlodipine - reference|10 mg tablet, single dose, with water
64278|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
64279|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
64280|NCT01138839|Drug|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
64281|NCT01138839|Drug|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
64282|NCT01138852|Drug|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
64283|NCT01138852|Drug|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
64284|NCT01138865|Device|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
64285|NCT01138865|Device|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
64558|NCT01142076|Drug|placebo|Therapeutic dose of 10%
64559|NCT01142089|Drug|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
64560|NCT01142089|Drug|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
64561|NCT01144533|Procedure|isotonic saline injection into the glenohumeral joint|Total volume of injection drugs: 8ml
isotonic saline 4ml + telebrix(contrast media) 4ml
The number of injections : only once during the study period
Injection site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
64562|NCT01144533|Procedure|steroid injection into the glenohumeral joint|Total volume of injection drugs: 8ml
triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml
The number of injections : only once during the study period
Injection Site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
68012|NCT00040872|Biological|monoclonal antibody 3F8|
68013|NCT01158248|Drug|cisplatin|
68014|NCT01158248|Radiation|brachytherapy|
68015|NCT01158248|Radiation|external beam radiation therapy|
68016|NCT01158261|Biological|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
68017|NCT01158274|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
68018|NCT01158274|Drug|capecitabine|Given orally
68019|NCT01158274|Other|laboratory biomarker analysis|Correlative studies
68020|NCT01158287|Drug|sorafenib tosylate|
68021|NCT01158287|Other|laboratory biomarker analysis|
68022|NCT01158300|Drug|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
68023|NCT00040872|Biological|sargramostim|
68024|NCT01160731|Drug|panobinostat|
68025|NCT01160731|Other|laboratory biomarker analysis|
68026|NCT01160731|Other|pharmacological study|
68027|NCT01160744|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
68028|NCT01160744|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
68364|NCT01158885|Drug|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
68365|NCT01158885|Drug|Cytarabine|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
68366|NCT01158885|Drug|Methotrexate|Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age
68367|NCT01158885|Drug|Cytarabine|Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.
If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.
Dose should be given according to age as defined below:
30 mg for patients age 1-1.99
50 mg for patients age 2-2.99
70 mg for patients >3 years of age
68130|NCT01160965|Drug|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
68131|NCT01160965|Drug|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
68132|NCT01160978|Drug|Simvastatin|80 mg simvastatin through nasogastric tube prior organ harvesting
68133|NCT01160978|Drug|Placebo|
68134|NCT01160991|Procedure|Glucose clamp technique|euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
68135|NCT01160991|Drug|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
68136|NCT01160991|Drug|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
68137|NCT00000952|Drug|Zidovudine|
68138|NCT00040989|Drug|BAY 56-3722|
68139|NCT01160991|Drug|Placebo|Placebo capsules are given at 8:00 a.m.
68140|NCT01161004|Drug|Sugammadex - Nacl 9/00|Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.
Nacl 9/00: same volume as Sugammadex
68141|NCT01161004|Drug|Nacl 9/00 - sugammadex|Nacl 9/00: same volume as Sugammadex
Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.
68142|NCT01163604|Drug|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
68143|NCT01163604|Drug|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
68144|NCT01163617|Device|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
68145|NCT01163617|Device|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
68146|NCT01163617|Device|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
68147|NCT01163617|Device|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
68148|NCT01163630|Drug|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
63629|NCT01114295|Radiation|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
63630|NCT01114308|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
63631|NCT00036751|Other|laboratory biomarker analysis|Correlative studies
63632|NCT01114308|Drug|placebo implant|Implant contains ethylene vinyl acetate
63633|NCT01114308|Drug|Buprenorphine|sublingual buprenorphine/naloxone tablets
63897|NCT01107119|Other|integrated care pathway|communication and follow-up program for integrated care
63898|NCT01107119|Other|usual care|
63899|NCT00035841|Drug|TLK286|
63900|NCT01109745|Other|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
63901|NCT01109745|Other|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
63902|NCT01109758|Drug|Fenofibrate|145 mg
63903|NCT00036153|Drug|Methotrexate|
63904|NCT01109771|Device|permanent mesh fixation|Permanent mesh fixation will be used.
63905|NCT01109771|Device|absorbable mesh fixation|Absorbable mesh fixation will be used.
63906|NCT01109784|Drug|prasugrel|prasugrel 10 mg/day
63907|NCT01109784|Drug|clopidogrel|clopidogrel per os 150mg/day
64563|NCT01144533|Procedure|sodium hyaluronate injection into the glenohumeral joint|Total volume of injection drugs: 8ml
sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml
The number of injections : only once during the study period
Injection Site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
64564|NCT01144533|Procedure|steroid and hyaluronate injection into the glenohumeral joint|Total volume of injection drugs: 8ml
triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml
The number of injections : only once during the study period
Injection Site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
64565|NCT01144546|Procedure|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
64566|NCT01144559|Procedure|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
64567|NCT01144559|Procedure|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
64568|NCT00039481|Other|laboratory biomarker analysis|Correlative studies
64569|NCT01144585|Procedure|remote ischemic preconditioning and postconditioning|RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done "after" CPB.
64570|NCT01144585|Procedure|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
64571|NCT01144611|Drug|bIAP bolus and 8h infusion|intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
64572|NCT01144611|Drug|placebo bolus and 8h infusion|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
64573|NCT01144624|Drug|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
63687|NCT01111669|Drug|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
63688|NCT01111669|Drug|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
63689|NCT01111682|Drug|Mannitol|0.9% normal saline infusion and boluses of mannitol
68368|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
68369|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
68370|NCT01158898|Drug|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
68371|NCT01158924|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
68372|NCT00040872|Drug|thiotepa|
68373|NCT01158937|Drug|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
68374|NCT01158950|Drug|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
68375|NCT01158950|Other|Placebo|Placebo (200mg) administered at study visit
68376|NCT01158950|Drug|Entacapone|Entacapone 200mg (single dose) administered at study visit
68377|NCT01158976|Dietary Supplement|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
68378|NCT01158976|Other|Placebo|soybean oils with strawberry flavoring
68379|NCT01158989|Device|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
68380|NCT01159002|Device|SmartPill|Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
67401|NCT01164930|Behavioral|Acceptance and Commitment Therapy|8-week ACT group
67402|NCT01164943|Procedure|Stimulation with human FSH|Human FSH
67403|NCT01164943|Procedure|Stimulation with recombinant FSH|Recombinant FSH
67404|NCT01164956|Drug|methylphenidate|taken orally
68149|NCT01163643|Drug|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
68150|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
67184|NCT01159236|Drug|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
67185|NCT01159236|Drug|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
67186|NCT01159249|Drug|Vildagliptin|
67187|NCT01159262|Drug|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
67188|NCT01159262|Drug|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
67189|NCT01159262|Drug|Dexmedetomidine|
67190|NCT01159275|Drug|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
67191|NCT01159275|Drug|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
67192|NCT01161771|Procedure|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
67193|NCT01161784|Dietary Supplement|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
67194|NCT01161784|Dietary Supplement|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
67195|NCT00000953|Drug|Sorivudine|
67196|NCT00041054|Drug|carboplatin|
67197|NCT01161810|Other|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
67198|NCT01161836|Drug|Iniparib|Solution for infusion
60-minute intravenous infusion
67199|NCT01161862|Device|Closed-loop blood glucose control with a bi-hormonal (insulin and glucagon) artificial pancreas|
67200|NCT01161862|Device|Closed-loop blood glucose control with an insulin-only artificial pancreas|
67201|NCT01161875|Device|Neurally Adjusted Ventilatory Assistance|In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:
facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation
helmet use with non-invasive pressure support ventilation mode to define adequate settings
helmet use with neurally adjusted ventilatory assist mode, based on previous settings
63908|NCT01109797|Behavioral|Transition Social Behavioral Intervention|If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to "taking ownership" of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study.
63909|NCT01109797|Behavioral|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
63910|NCT01109823|Drug|intravenous administration of levofloxacin|Intravenous administration of levofloxacin is used.
63911|NCT01109836|Behavioral|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
63912|NCT01109849|Behavioral|behavioral therapy|combination of individual and group parent training plus school consultation
63913|NCT01109849|Drug|12 hour methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
64203|NCT01141439|Drug|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
64204|NCT01141439|Drug|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
64205|NCT01141439|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
64206|NCT01141452|Drug|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
64207|NCT01141452|Drug|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
64208|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
64209|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
64210|NCT01141452|Drug|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
64211|NCT00000943|Biological|Tetanus Toxoid Vaccine|
64212|NCT00039364|Drug|imatinib mesylate|
64213|NCT01141452|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
63690|NCT01111682|Drug|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
63691|NCT01111695|Device|ApisSept|honey and ionic silver based dressing
63692|NCT01111708|Procedure|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
63693|NCT01111721|Behavioral|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
63694|NCT01111721|Behavioral|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
63695|NCT01111734|Dietary Supplement|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
63696|NCT01111734|Drug|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
63697|NCT00036452|Drug|tenofovir DF|
63698|NCT01111747|Procedure|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
63699|NCT01111747|Procedure|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
63700|NCT01114347|Dietary Supplement|Placebo|One placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
63701|NCT01114360|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
63702|NCT01114360|Drug|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
63703|NCT01114373|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
63704|NCT00036764|Drug|ixabepilone|Given IV
63976|NCT01107197|Dietary Supplement|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
63977|NCT00000922|Drug|Lamivudine|
63978|NCT00035854|Drug|Zyvox® / Linezolid|
63979|NCT01107197|Dietary Supplement|Control formula|Isonitrogenous isocaloric oral formula
67405|NCT01164969|Drug|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
67406|NCT01164982|Device|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
67407|NCT01164995|Drug|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
67408|NCT01165008|Drug|Anakinra|
67409|NCT01165021|Drug|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
67410|NCT01165021|Drug|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
67411|NCT00041210|Drug|doxorubicin hydrochloride|
67412|NCT01165034|Other|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
67413|NCT00040807|Drug|irinotecan hydrochloride|
67414|NCT01157104|Drug|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
67415|NCT01157117|Biological|Xolair® (omalizumab) placebo/milk OIT|Placebo for Xolair for 4 months followed by 12 months of milk OIT. after unblinding, will discontinue placebo for Xolair and continue milk OIT for an additional 12 months.
67416|NCT01157117|Biological|Xolair® (omalizumab)/milk OIT|Xolair for 4 months followed by 12 months of milk OIT. After unblinding, will continue receiving Xolair along with milk OIT for an additional 12 months.
67417|NCT01157130|Other|Exercise Regimen|Exercise instruction
67418|NCT01157143|Drug|XRP0038 (NV1FGF)|Pharmaceutical form : solution
Route of administration : intramuscular
67419|NCT01157156|Drug|XRP0038 (NV1FGF)|Pharmaceutical form:solution
Route of administration: intramuscular
68029|NCT00040937|Drug|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
68030|NCT01160744|Drug|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
67202|NCT01161888|Drug|Imiquimod|250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.
67203|NCT01161901|Procedure|blood sample|This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.
The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS.
67480|NCT01162512|Behavioral|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
67481|NCT01162525|Procedure|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
67482|NCT01165047|Drug|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
67483|NCT01165060|Drug|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
67484|NCT01165073|Dietary Supplement|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
67485|NCT01165073|Dietary Supplement|Normal oral intake & supplementation if necessary|Enteral nutrition
67486|NCT01165086|Other|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
67487|NCT01165099|Procedure|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
67488|NCT01165112|Drug|Bendamustine Hydrochloride|Given IV
67489|NCT01165112|Drug|Carboplatin|Given IV
67490|NCT01165112|Biological|Rituximab|Given IV
67491|NCT00041210|Drug|etoposide|
67492|NCT01165112|Drug|Etoposide|Given IV
67493|NCT01165112|Other|Laboratory Biomarker Analysis|Correlative studies
67494|NCT01165125|Drug|FF / GW642444|200mcg/25mcg Novel DPI
67495|NCT01165125|Drug|ketoconazole|400mcg overencapsulated tablets
67496|NCT01165125|Drug|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
64214|NCT01141465|Drug|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
64215|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
64216|NCT01141465|Drug|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
64217|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
64218|NCT01141465|Drug|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
64219|NCT01141465|Drug|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
64220|NCT01141478|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
64221|NCT01141478|Drug|Sorafenib|400 mg po bid
64222|NCT01141491|Biological|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
64223|NCT00039377|Drug|imatinib mesylate|Given PO
64224|NCT01141491|Biological|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
64225|NCT01141504|Dietary Supplement|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
64501|NCT01137110|Drug|Levetiracetam Long course|Levetiracetam 1000mg BID x hospital stay
64502|NCT00039117|Other|pharmacological study|Correlative studies
64503|NCT01137123|Drug|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
64504|NCT01137123|Procedure|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
64505|NCT01137123|Procedure|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
64506|NCT01137123|Procedure|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
63980|NCT01107223|Other|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
63981|NCT01107223|Other|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
63982|NCT01107236|Drug|IW-6118|Single dose
63983|NCT01107236|Drug|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
63984|NCT01107236|Drug|Naproxen Sodium|Single dose
63985|NCT01107249|Device|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
63986|NCT01107275|Biological|rabies vaccine|intradermal vaccination
63987|NCT01107288|Other|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
63988|NCT01107288|Other|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
63989|NCT01109862|Procedure|Hemiarthroplasty|Cemented bipolar HAP
63990|NCT01109875|Other|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
63991|NCT01109888|Drug|Cetrotide|
63992|NCT01109901|Procedure|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
63993|NCT01109901|Procedure|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
64286|NCT01138878|Other|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
64287|NCT00039195|Drug|ifosfamide|
64288|NCT01138878|Other|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
68031|NCT01160744|Drug|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
68032|NCT01160744|Drug|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
68033|NCT01160744|Drug|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
68034|NCT01160757|Device|ultrasound|ultrasound exposure on acute acne lesions
68035|NCT01160770|Drug|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
68036|NCT01160796|Drug|placebo|1x14-day course of treatment during 4 cycles
68037|NCT01160796|Drug|Lcr35®|1x14-day course of treatment during 4 cycles
68038|NCT01160809|Other|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
68039|NCT01160822|Biological|Canakinumab|Intra-articular injection
68040|NCT00040937|Procedure|peripheral blood stem cell transplantation|2-4 x 10^6/kg IV day 0
68041|NCT01160822|Drug|Placebo to canakinumab|Intra-articular injection
68042|NCT01160822|Drug|Naproxen|Tablets for oral administration
68043|NCT01160822|Drug|Placebo to Naproxen|Tablets for oral administration
68044|NCT01160835|Procedure|total knee arthroplastyinstruments|Quadriceps-sparing arthrotomy with side-cutting instruments
68045|NCT01160848|Drug|Area cleaned with saline water and occluded with Tegaderm|
68046|NCT01160848|Drug|Area cleaned with saline water|
68047|NCT01160848|Drug|Area cleaned with Ethyl alcohol solution|
68048|NCT01160848|Drug|Visonac left on the skin for 24 hours in facial area one|
68049|NCT01160848|Drug|Visonac wiped off after one hour|
68050|NCT01160848|Drug|Visonac left on the skin 24 hours in facial area two|
68051|NCT00040950|Biological|rituximab|
68071|NCT00041132|Biological|rituximab|375 mg/m^2 on day 1 of cycles 1-6
67497|NCT01165138|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
67498|NCT01165138|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
67499|NCT01165138|Drug|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
67500|NCT01165151|Behavioral|behavioral weight loss program|weekly, group-based lifestyle weight loss program
67501|NCT01165164|Other|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
67774|NCT01162993|Procedure|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
67775|NCT01163006|Other|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
67776|NCT01165216|Drug|Paclitaxel|IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
67777|NCT01165216|Drug|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
67778|NCT01165229|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
67779|NCT01165229|Biological|Placebo|Intramuscular injection.
67780|NCT00041210|Drug|prednisone|
67781|NCT01165242|Biological|Meningococcal vaccine GSK 134612|One intramuscular injection
67782|NCT01165242|Biological|Menactra®|One intramuscular injection
67783|NCT01165255|Drug|3. Exposure to other antidepressants during the first trimester comparison cohort|Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant ("other antidepressant monotherapy"), or more than one type of an antidepressant ("other antidepressant mono or polytherapy") during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy.
64507|NCT01137149|Behavioral|Behavioral Activation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
64508|NCT01137149|Behavioral|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
64509|NCT01137188|Dietary Supplement|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
64510|NCT01137201|Procedure|Suturing of mesenteric defects|
64511|NCT01137214|Device|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
64512|NCT00039208|Drug|fluorouracil|
64513|NCT01139320|Genetic|DNA analysis|
64514|NCT01139320|Genetic|polymerase chain reaction|
64515|NCT01139320|Other|laboratory biomarker analysis|
64516|NCT01139320|Other|pharmacological study|
64517|NCT01139333|Genetic|gene expression analysis|
63634|NCT01114321|Behavioral|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
63635|NCT01114334|Behavioral|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
63636|NCT01114334|Behavioral|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
64289|NCT01138878|Other|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
64290|NCT01138878|Other|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
64291|NCT01138904|Drug|irinotecan, oxaliplatin|OXIR: FOLFOX -> FOLFIRI
IROX: FOLFIRI -> FOLFOX
FOLFOX REGIMEN
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks
FOLFILI REGIMEN
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks
64292|NCT01138904|Drug|oxaliplatin, irinotecan|FOLFOX REGIMEN
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks
FOLFILI REGIMEN
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks
64293|NCT01138930|Drug|Berberine|1.5g daily for 3 month
64294|NCT01138930|Drug|Placebo|placebo daily
64295|NCT01141504|Dietary Supplement|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
64296|NCT01141517|Behavioral|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
64297|NCT01141530|Other|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
64298|NCT01141543|Drug|Plerixafor (mozobil)|Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.
Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
64299|NCT01141556|Drug|Selenase|After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
64300|NCT01141569|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
64301|NCT00039377|Drug|methotrexate|Given IT and IV
64302|NCT01141569|Other|Laboratory Biomarker Analysis|Correlative studies
64303|NCT01141595|Drug|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
64574|NCT01144624|Drug|Placebo|Intravenous infusion of a saline solution
68072|NCT01163565|Device|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
68073|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
68074|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
68075|NCT01155726|Device|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
68076|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
68077|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
68078|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
68079|NCT01155752|Drug|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
68080|NCT00040690|Drug|methotrexate|
68081|NCT01155752|Drug|placebo|identical placebo
68082|NCT01155765|Drug|Prasugrel|Prasugrel 10 mg/day for 15 days
68083|NCT01155765|Drug|Clopidogrel|Clopidogrel 150 mg/day for 15 days
68084|NCT01155778|Biological|Recombinant human heparan N-sulfatase|10 mg monthly via an IDDD
68085|NCT01155778|Biological|Recombinant human heparan N-sulfatase|45 mg monthly via an IDDD
68086|NCT01155778|Biological|Recombinant human heparan N-sulfatase|90 mg monthly via an IDDD
68087|NCT01155791|Drug|Docetaxel|IV 75 mg/m2
68088|NCT01155791|Drug|Biosyn|IV dosage varies
68089|NCT01155791|Drug|Prednisone|5mg, orally
67784|NCT01165255|Drug|2. Exposure to bupropion outside the first trimester comparison cohort|Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort ("bupropion exposure outside the first trimester") included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion ("bupropion monotherapy"), or bupropion and another type of an antidepressant ("bupropion mono-or polytherapy") during the period outside the first trimester.
67785|NCT01165255|Drug|1. Exposure to bupropion during the first trimester|Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion ("bupropion monotherapy"), or bupropion and another type of an antidepressant ("bupropion mono-or polytherapy"). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy.
67786|NCT01165268|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
67787|NCT01165281|Drug|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
67788|NCT01165281|Drug|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
68151|NCT00041132|Drug|cyclophosphamide|300 mg/m^2 on days 2-4 of cycles 1,3,5,7
68152|NCT01163643|Drug|Placebo Comparator: Vehicle|Placebo Comparator: Vehicle BID for 12 weeks.
68153|NCT01163643|Drug|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
68154|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension AM|2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
68155|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension PM|Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
68156|NCT01163656|Device|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
68157|NCT01163656|Device|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
68158|NCT01163682|Other|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
63637|NCT01114347|Dietary Supplement|cranberry type A pro anthocyandines|One gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water
63638|NCT01116453|Procedure|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
63639|NCT01116453|Procedure|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
63640|NCT01116466|Device|ActiGait|ActiGait - implantable drop foot stimulator
63641|NCT01116479|Other|Blood transfusion|Blood transfusion with packed erythrocytes
63642|NCT01116492|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
63643|NCT01116492|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
63644|NCT01116505|Dietary Supplement|Gluten-free diet|gluten-containing cereals removed from diet
63645|NCT01116518|Procedure|physiotherapy|
63646|NCT01116518|Procedure|acromioplasty|
63647|NCT00036920|Drug|canfosfamide hydrochloride|
63648|NCT01116518|Procedure|acromioplasty and rotator cuff reconstruction|
63649|NCT01116531|Drug|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
63650|NCT01116531|Drug|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is < 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
63914|NCT00000923|Drug|Indinavir sulfate|
63915|NCT00036166|Drug|FK463|
63916|NCT01109849|Behavioral|increased monitoring of growth|monthly weight, height and BMI checks
63917|NCT01109849|Drug|drug holiday|switch from seven day a week dosing to medication only on school days
64575|NCT01144637|Biological|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
64576|NCT01144637|Other|Placebo|0.5 ml TBS
64577|NCT01144650|Drug|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
64578|NCT01144650|Drug|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
64579|NCT00000944|Drug|Indinavir sulfate|
64580|NCT01137240|Procedure|gastric emptying scan|subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.
In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal.
64581|NCT00039130|Biological|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC>5000/ul courses II-VII
64582|NCT01137253|Drug|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
64583|NCT01137253|Drug|Placebo|Response to intrabrachial vasodilators during IV saline infusion
64584|NCT01137266|Device|TENS|TENS
64585|NCT01137292|Drug|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
64586|NCT01137305|Other|VR- training|Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: "camera and instrument navigation", "coordination", "grasping", "lifting and grasping", "clip applying" and "diathermy cutting" in different levels of difficulty- medium and hard referring to "time to complete task", "economy of instrument motion" and "tissue damage"; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training
64587|NCT01137318|Behavioral|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
64588|NCT01137331|Drug|K301|Liquid- applied once daily prior to bed
68381|NCT01159015|Drug|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
68382|NCT01159015|Drug|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
68383|NCT00040872|Drug|topotecan hydrochloride|
68384|NCT01161368|Drug|Lapatinib, Vinorelbine|Lapatinib 1250mg orally once daily continuously
plus
Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle.
68385|NCT01161381|Device|Estimation of nonlinear indices from Polysomnography|All subjects underwent full night polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) were extracted from three biosignals (airflow from a nasal cannula, thoracic movement and Oxygen saturation) providing input to a data mining application for the creation of predictive models for AHI.
68386|NCT01161394|Drug|Pioglitazone 15mg|
68387|NCT01161394|Drug|pioglitazone 30mg|
68388|NCT01161394|Drug|placebo|
68389|NCT01161407|Dietary Supplement|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
68390|NCT01161407|Dietary Supplement|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
68391|NCT01161420|Device|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
68392|NCT01161433|Behavioral|Virtually delivered spirometry quality improvement program|Sites in the intervention arm receive the virtually delivered QI program.
The program includes:
Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;
Case-based, interactive webinars; and
an Internet-based spirometry quality feedback reporting system.
68393|NCT00041028|Drug|EF5|
68394|NCT01161446|Behavioral|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
68395|NCT01161446|Device|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
68396|NCT01161459|Drug|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
68397|NCT01161459|Drug|FK506|capsule
68159|NCT01163682|Other|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The elecrto-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
68160|NCT01155856|Other|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
68161|NCT01155869|Drug|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
68162|NCT01155869|Drug|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
68163|NCT01155882|Procedure|Whipple at the Splenic Artery (WATSA)|
68164|NCT01155895|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
68165|NCT01155908|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
68166|NCT01155921|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
68167|NCT01155934|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
67204|NCT01161914|Drug|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
67205|NCT01161914|Drug|ISU302|administered by IV infusion for a dose of 60 U/kg
67206|NCT01161927|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
67207|NCT00041054|Drug|etoposide|
67208|NCT01161927|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
67209|NCT01161940|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
67210|NCT01161940|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
67211|NCT01161953|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
67212|NCT01161966|Drug|Zonisamide|Zonisamide capsules 100 mg
63918|NCT01109849|Dietary Supplement|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
63919|NCT01109862|Procedure|Total hip arthroplasty|All cemented THA
63920|NCT01111968|Biological|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
63921|NCT01111968|Biological|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
63922|NCT01111968|Biological|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
63923|NCT01111968|Biological|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
63924|NCT01111968|Biological|placebo group 14|All elements of the vaccine but antigen and adjuvant
63925|NCT01111981|Drug|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
63926|NCT00000236|Drug|Buprenorphine/naloxone|
63927|NCT00000923|Drug|Zidovudine|
63928|NCT00036517|Drug|PHY906|
63929|NCT01111994|Drug|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
63930|NCT01112020|Device|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
63931|NCT01112020|Device|Biopatch|Biopatch applied to 7 sites
63932|NCT01112020|Device|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
63933|NCT01112046|Procedure|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
63934|NCT01112046|Procedure|Laparoscopic resection|Surgical treatment performed under general anesthesia
63935|NCT01112059|Drug|Doxycycline|100 mg twice a day for 10 days
63936|NCT01112059|Other|placebo|placebo
63937|NCT01112072|Drug|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
64226|NCT01141504|Dietary Supplement|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
63705|NCT01114373|Drug|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
63706|NCT01114386|Procedure|Lung function testing, echocardiography, blood sampling|All patients will undergo to:
physical examination
6' Minute Walk test
pulmonary function testing (spirometry + volumes and reversibility testing)
carbon monoxide diffusing capacity (DLCO) with single-breathe technique
ECG
echocardiography
63707|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
63708|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
63709|NCT01114399|Dietary Supplement|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
63710|NCT01114425|Drug|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
63711|NCT01114425|Drug|Truvada®|
63712|NCT01114438|Device|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 6 months.
63713|NCT01114451|Procedure|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
63714|NCT01114490|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
63715|NCT00036764|Other|pharmacogenomic studies|Correlative studies
63716|NCT01114503|Drug|Otelixizumab - low dose|8 day dose rising intravenous infusions of a low dose of otelixizumab
63717|NCT01114503|Drug|Otelixizumab - medium low dose|8 day dose rising intravenous infusions of a medium low dose of otelixizumab
63718|NCT01114503|Drug|Otelixizumab - medium high dose|8 day dose rising intravenous infusions of a medium high dose of otelixizumab
63719|NCT01114503|Drug|Otelixizumab - high dose|8 day dose rising intravenous infusions of a high dose of otelixizumab
63720|NCT01114503|Drug|Otelixizumab|8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
63721|NCT01106729|Dietary Supplement|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
63722|NCT01106742|Dietary Supplement|AndoSan|AndoSan, 20mlx3, 12 days
68398|NCT01161472|Drug|4mg fesoterodine|4mg tablet once daily for 6 days
68399|NCT01161472|Drug|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
67420|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
67421|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
67422|NCT01157182|Drug|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
67423|NCT01157182|Drug|Activella®|1/0.5 mg Tablets
67424|NCT00040820|Drug|oxaliplatin|
67425|NCT01157195|Behavioral|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
67426|NCT01157195|Behavioral|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
67427|NCT01157208|Other|Low omega-6 plus high omega-3 diet|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
67428|NCT01157208|Other|Low omega-6 diet|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
67429|NCT01157221|Other|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
67430|NCT01157221|Other|EMSMTA|end-range mobilization/scapular mobilization treatment approach
67431|NCT01157234|Drug|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of < 140/ 90.
67432|NCT01157234|Drug|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure < 140/90.
67433|NCT01157247|Procedure|Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture|
67434|NCT01157260|Drug|Kremezin|AST-120 2g three times a day
67435|NCT00040833|Procedure|complementary or alternative medicine procedure|
67436|NCT01157286|Device|CPAP|PATIENTS DIADNOSSED WITH MILD TO SEVERE APNEA WILL BE TREATED WITH CPAP
67437|NCT01157312|Drug|clomiphene citrate +highly purified uFSH|
67213|NCT01161966|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
67214|NCT01161979|Drug|Zonisamide|Zonisamide capsules 100 mg
67215|NCT01161979|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
67216|NCT01161992|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
67217|NCT01162005|Drug|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
67218|NCT01164514|Biological|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
67219|NCT01164514|Biological|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
67220|NCT01164514|Drug|Placebo|Normal saline.
67221|NCT01164540|Drug|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
67222|NCT01164540|Drug|Placebo|Oral dose (od)
67223|NCT01164553|Biological|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
67224|NCT01164566|Procedure|endoscopic procedure|
67225|NCT01164566|Other|questionnaire administration|Ancillary studies
67226|NCT00041197|Other|laboratory biomarker analysis|Correlative studies
67502|NCT00000954|Drug|Doxorubicin hydrochloride|
67503|NCT00041210|Drug|mechlorethamine hydrochloride|
67504|NCT01165177|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
67505|NCT01165177|Biological|Placebo|Intramuscular injection
67506|NCT01165203|Biological|Herpes Zoster Vaccine 1437173A|intramuscular injection
67507|NCT01165203|Biological|Placebo|intramuscular injection
67508|NCT01165216|Drug|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
64227|NCT01141504|Dietary Supplement|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
64228|NCT01143909|Other|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
64229|NCT01143948|Drug|Glargine & Glulisine|Basal Glargine & bolus Glulisine
64230|NCT01143948|Drug|Regular insulin|Sliding scale regular insulin
64231|NCT00039455|Other|pharmacological study|Correlative studies
64232|NCT01143948|Drug|NPH & regular insulin|Basal NPH & bolus regular insulin
64233|NCT01143961|Device|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
64234|NCT01143974|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
64235|NCT01143987|Drug|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
64236|NCT01144000|Drug|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
64237|NCT01144013|Drug|dapivirine|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
64238|NCT01144013|Drug|placebo|Placebo vaginal ring containing no dapivirine
64239|NCT01144026|Biological|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
64240|NCT01144026|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
64241|NCT01144039|Drug|LG-group|
64242|NCT00039468|Drug|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
64243|NCT01144039|Drug|HG-group|
64244|NCT01144039|Drug|Placebo-group|
64245|NCT01144052|Drug|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])
63723|NCT00035802|Drug|Topiramate|Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.
OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months.
63994|NCT01109914|Biological|Dukoral|Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:
Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria* −Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)
63995|NCT00036179|Drug|FK463|
63996|NCT01109927|Drug|Insulin|Insulin treatment in accordance to glucose values
63997|NCT01109940|Biological|AIN457A|
63998|NCT01109953|Other|Breath-Hold PET/CT image set|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
63999|NCT01109966|Other|Special Medical Food|Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.
Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age.
64000|NCT01109966|Other|Special Medical Food|Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.
Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age.
64001|NCT01109979|Drug|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
64002|NCT01109979|Drug|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
64003|NCT01109992|Drug|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
64004|NCT01109992|Drug|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
64005|NCT01110005|Other|D5 Lactated Ringers Solution (D5LR)|IV fluid 125 ml/hr infusion rate
64006|NCT00036192|Drug|FK614|
64007|NCT01110005|Other|Lactated Ringers Solution (LR)|IV fluid 125 ml/hr infusion rate
67438|NCT00040872|Radiation|radiation therapy|
67439|NCT01159613|Other|Non Responders|Non Responders
67440|NCT01159626|Drug|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
67441|NCT01159626|Drug|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
68052|NCT01163409|Procedure|exercise training|exercise training comprises aerobic and strength training
68053|NCT01163409|Procedure|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
68054|NCT01163409|Procedure|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
68055|NCT01163422|Device|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
68056|NCT01163435|Drug|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
68057|NCT01163435|Drug|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
68058|NCT01163435|Drug|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
68059|NCT00041132|Biological|filgrastim|5 ug/kg
68060|NCT01163435|Drug|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
68061|NCT01163448|Radiation|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
68062|NCT01163461|Behavioral|speech therapy|individuals will receive 60 hours of behavioral speech therapy
68063|NCT01163474|Other|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
68064|NCT01163487|Drug|Dichloroacetate|25-50mg/kg per day; oral
67509|NCT01165216|Drug|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
67510|NCT01157312|Drug|clomiphene citrate|
67511|NCT01157325|Procedure|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
67512|NCT01157325|Procedure|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
67513|NCT01157338|Procedure|diagnostic cardiac catheterization|coronary intervention: angiography
67514|NCT01157338|Procedure|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
67515|NCT01157351|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
67516|NCT01157351|Drug|risperidone|flexible dosing as prescribed by the study doctor for 15 months
67517|NCT01157351|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
67518|NCT00040833|Procedure|pain therapy|
67519|NCT01157351|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
67520|NCT01157351|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
67521|NCT01157351|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
67522|NCT01157351|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
67523|NCT01157351|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
67524|NCT01157364|Drug|bimatoprost ophthalmic formulation A|Single dose of bimatoprost ophthalmic formulation A administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
67525|NCT01157364|Drug|bimatoprost ophthalmic formulation B|Single dose of bimatoprost ophthalmic formulation B administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
67789|NCT01165294|Drug|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
67790|NCT01165294|Drug|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
67791|NCT00041210|Drug|vinblastine sulfate|
64518|NCT01139333|Genetic|western blotting|
64519|NCT01139333|Other|flow cytometry|
64520|NCT01139333|Other|laboratory biomarker analysis|
64521|NCT01139346|Drug|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
64522|NCT01139359|Drug|darinaparsin|I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
64523|NCT00039208|Drug|irinotecan hydrochloride|
64524|NCT01139359|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
64525|NCT01139372|Other|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
64526|NCT01139385|Procedure|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
64527|NCT01139385|Procedure|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
64528|NCT01139398|Dietary Supplement|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
64529|NCT01139411|Behavioral|Behavioral Weight Control with Enhanced Parent Involvement|
64530|NCT01139411|Behavioral|Behavioral Weight Control with Minimal Parent Involvement|
64531|NCT01139424|Device|endoscopic suturing|endoscopic suturing of the anastomotic leak
64532|NCT01139437|Biological|Standard Dose HPIV2 Vaccine|10^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
64533|NCT01139437|Biological|Low dose HPIV2 vaccine|10^5 TCID50 administered in a single dose
64534|NCT00039208|Drug|leucovorin calcium|
64535|NCT01139437|Other|Placebo|Matched placebo
64536|NCT01139450|Drug|0417|Topical 0417 test product applied twice daily for 4 weeks
64537|NCT01139450|Drug|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
64538|NCT01139450|Drug|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
64008|NCT01112163|Device|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
64304|NCT01141608|Other|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
64305|NCT01141608|Other|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
64306|NCT01141634|Other|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
64307|NCT01141647|Behavioral|Vocational Rehabilitation|SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
64308|NCT01141660|Device|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
64309|NCT01141660|Device|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
64310|NCT01141712|Procedure|Autologous transplant|Patients will receive BCNU 300 mg/m^2 Day -6, Etoposide 100 mg/m^2 BID Days -5 to -2, Cytarabine 100 mg/m^2 BID Days -5 to -2, and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
64311|NCT01141725|Drug|bendamustine hydrochloride|Given IV
64312|NCT00039377|Drug|vincristine sulfate|Given IV
64313|NCT01141725|Drug|idarubicin|Given IV
64314|NCT01144078|Behavioral|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
64315|NCT01144091|Drug|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
64316|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
64317|NCT01144091|Drug|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
68065|NCT01163487|Device|EF5|21 mg/kg; IV
68066|NCT01163500|Dietary Supplement|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
68067|NCT01163500|Other|Placebo|Placebo controlled (dextrin)
68068|NCT01163526|Procedure|CT perfusion|
68069|NCT01163552|Procedure|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
68070|NCT00000954|Drug|Bleomycin sulfate|
68090|NCT01155804|Behavioral|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
68091|NCT00040690|Drug|vincristine sulfate|
68092|NCT01155817|Drug|Nilotinib|200, 400, 800, oral
68093|NCT01158313|Dietary Supplement|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
68094|NCT01158326|Drug|Resfenol|Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.
10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours.
68095|NCT01158326|Other|Placebo|10 ml of oral placebo every 6 hours for 48 hours
68096|NCT01158339|Behavioral|Arm 2: CBGT-ISE|Intervention with active performance of the feared movements during group sessions.
68097|NCT01158339|Behavioral|Arm 1: CBGT|Intervention according to previously mentioned methods.
68098|NCT01158352|Dietary Supplement|Nutritional supplementation formula|Nutritional supplementation formula
68099|NCT01158352|Dietary Supplement|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
68100|NCT01158365|Drug|LACTIC ACID (Dermacid)|Route of administration: local
68101|NCT01158365|Drug|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
67792|NCT01165307|Drug|Estradiol 30 mcg / Levonorgestrel 150 mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30 mcg estradiol and a 150 mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
67793|NCT01157741|Behavioral|C-C|Mx as H-C plus positioning follow up in the community clinic
67794|NCT01157741|Other|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
67795|NCT01157741|Other|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
67796|NCT01157741|Other|As C-C but with both SF & PS (C-SF+PS)|Giving both SF & PS
67797|NCT01157741|Other|H-C|Follow-up at Hospital
67798|NCT00000950|Drug|Rifampin|
67799|NCT00040846|Drug|mycophenolate mofetil|Given PO
67800|NCT01157754|Drug|levonorgestrel and ethynilestradiol|
67801|NCT01157767|Other|standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.|Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
67802|NCT01157780|Drug|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
67803|NCT01157793|Drug|r-hGH|r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
67804|NCT01157793|Drug|r-hGH|Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
67805|NCT01157806|Radiation|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
67806|NCT01157819|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
67807|NCT01157819|Drug|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
68168|NCT01155947|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
68169|NCT00040690|Radiation|radiation therapy|
68170|NCT01155960|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
64539|NCT01139463|Drug|Haloperidol or olanzapine|Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
63651|NCT01116531|Drug|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is < 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
63652|NCT01116544|Device|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
63653|NCT01116557|Device|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
63654|NCT01116557|Device|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
63655|NCT01116570|Other|Physical training|Physical training during 24 weeks
63656|NCT01109160|Drug|Azithromycin Dihydrate|Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.
Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
63657|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
63658|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
63659|NCT01109173|Other|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
63660|NCT01109173|Other|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
63661|NCT01109186|Other|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
63662|NCT01109199|Dietary Supplement|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
63663|NCT01109199|Dietary Supplement|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
63664|NCT00036101|Drug|aripiprazole|
64318|NCT00039468|Drug|thalidomide|400mg/day oral
64319|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
64320|NCT01144104|Behavioral|Public Service Announcement|
64321|NCT01144104|Behavioral|Interactive Multi-Media Computer Program|
64322|NCT01144104|Behavioral|Sleep Hygiene Video|
64589|NCT01137331|Drug|Placebo|Liquid- applied once daily prior to bed
64590|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
64591|NCT01137357|Dietary Supplement|Yoghurt with L.casei|Intake of yoghurt during 4 weeks
64592|NCT00039130|Biological|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV & VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
64593|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
64594|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Yoghurt with L. plantarum strain
64595|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
64596|NCT01137357|Dietary Supplement|Yoghurt|Intake of yoghurt during 4 weeks
64597|NCT01139489|Other|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
64598|NCT01139502|Behavioral|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
64599|NCT01139502|Behavioral|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
64600|NCT01139515|Drug|Eletriptan commercial tablet|20 mg tablet, single dose
64601|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
64602|NCT00039208|Drug|oxaliplatin|
64603|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
64604|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
68102|NCT01158378|Device|Adherus Dural Sealant|In situ polymerizing sealant
68103|NCT00040872|Drug|carboplatin|
68104|NCT01158391|Device|NTrainer® Intervention|NTrainer® Intervention is a patterned synthetic orocutaneous stimulation will be delivered through a NICU (green) Soothie silicone pacifier or a NICU Wee Soothie® (purple). It is critical that each subject uses only one type of pacifier for the intervention.
Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation three to four times daily during the first 30 minutes of a tube (gavage) feeding session or 30 minutes before oral feeding for 10 days distributed over a two week period.
Infants assigned to the control group will receive a sham stimulation program in which the infant will be offered the same type of NICU Soothie pacifier coupled to the receiver tube and handpiece, but not to the NTrainer System.
68105|NCT01158404|Drug|Notch Inhibitor|Dose Escalation: 2-120 mg administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28 day cycle.
Dose Confirmation: Dose determined by dose escalation administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28 day cycle.
Patients experiencing clinical benefit may continue treatment unless discontinuation criteria are met.
68106|NCT01158417|Drug|Placebo|oral
67143|NCT01156688|Drug|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
67144|NCT01156701|Drug|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
67145|NCT01156701|Other|No prophylaxis with Relenza|No prophylaxis with Relenza
67146|NCT01156714|Behavioral|treadmill training|walk on treadmill for aerobic exercise
67147|NCT01156714|Behavioral|computerized memory training|memory testing and training on computer program
67148|NCT01156740|Drug|Penicillin G, Benzathine|IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg)
67149|NCT01156740|Drug|Amoxicillin|750 mg/QD
67150|NCT00040794|Drug|paclitaxel|Given IV
67151|NCT01156753|Drug|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
67152|NCT01156753|Drug|"Investigator's Choice" chemotherapy|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
67153|NCT01156766|Device|- locking anterior plate|The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.
The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis.
67154|NCT01156779|Drug|SR-exenatide|Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
68171|NCT01155973|Behavioral|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
68172|NCT01155973|Other|Control group|SCORE oral information and counseling as standard practice care
68173|NCT01155986|Drug|Lidocaine 5% medicated plaster|Topical hydrogel plaster (700mg lidocaine)
68174|NCT01155986|Drug|Placebo topical plaster|Topical hydrogel plaster
68175|NCT01155999|Drug|T1225|one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
68176|NCT01155999|Drug|Tobramycin|1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
68177|NCT01156012|Drug|T2345|One drop of T2345
68178|NCT01156012|Drug|Prostaglandin|One drop
68179|NCT01156025|Drug|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
68180|NCT00040729|Genetic|mutation analysis|
68181|NCT01156025|Drug|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
68182|NCT01156038|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
68183|NCT01158508|Procedure|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
68184|NCT01158521|Drug|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
68185|NCT01158521|Procedure|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
68186|NCT01158534|Drug|celecoxib|Given orally
68187|NCT01158534|Biological|recombinant interferon alfa-2b|Given subcutaneously
68188|NCT01158534|Other|polymerase chain reaction|Correlative studies
68189|NCT01158534|Other|laboratory biomarker analysis|Correlative studies
63665|NCT01109212|Drug|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
63666|NCT01109212|Drug|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
63667|NCT01109225|Procedure|aldosteronemy determination|to take a sample of blood
63938|NCT01112085|Drug|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
63939|NCT00036543|Drug|Atrasentan|
63940|NCT01112085|Drug|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
63941|NCT01112098|Behavioral|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
63942|NCT01112111|Drug|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
63943|NCT01112137|Drug|Clopidogrel|
63944|NCT01112137|Drug|Clopidogrel|
63945|NCT01112137|Drug|Clopidogrel|
63946|NCT01112137|Drug|Clopidogrel|
63947|NCT01112150|Device|NormaTec Pump|Normatec Pump
63948|NCT01114893|Drug|Travoprost Vehicle|1 drop in each eye 8 times daily for 5 days
63949|NCT01114893|Drug|Travoprost (Groups A, B and C)|1 drop in each eye 8 times daily for 5 days
63950|NCT00036790|Drug|doxorubicin hydrochloride|
63951|NCT01114919|Behavioral|Check Your Drinking (CYD)|Internet based program of lower intensity as compared to the "Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence.
63952|NCT01114919|Behavioral|Alcohol Help Centre (AHC)|Internet based program of higher intensity as compared to the "Check Your Drinking" intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence.
63953|NCT01114945|Device|McGrath|Intubation with the McGrath device
63954|NCT01114945|Device|GlideScope|Intubation with the GlideScope device
63955|NCT01114945|Device|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
64605|NCT01139528|Procedure|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
64606|NCT01139541|Behavioral|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
64607|NCT01139580|Drug|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
64608|NCT01139580|Drug|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
64609|NCT01139606|Other|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
63724|NCT01106755|Device|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
63725|NCT01106755|Device|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
63726|NCT01106807|Drug|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
63727|NCT01106807|Drug|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
63728|NCT01106807|Drug|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
63729|NCT01106807|Drug|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
63730|NCT01106820|Other|Supervised progressive resistance training|Supervised progressive resistance training
63731|NCT01106820|Other|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
63732|NCT01106833|Drug|Sirolimus + calcineurin inhibitor + prednisone|The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.
Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day.
63733|NCT01106833|Drug|Sirolimus + prednisone|The target serum level for sirolimus is 3-12 ng/mL.
Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day.
63734|NCT00035802|Drug|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
67155|NCT01156792|Drug|FP 100|FP 100mcg BID
67156|NCT01156792|Drug|GSK2190915 100|GSK2190915 100mg QD (AM)
67157|NCT01156792|Drug|GSK2190915 300|GSK2190915 300mg QD (AM)
67158|NCT01156792|Drug|montelukast|montelukast 10mg QD (PM)
67159|NCT01156792|Drug|placebo|placebo BID
67160|NCT01156792|Drug|FP/SAL 100/50|FP/SAL 100/50mcg BID
67161|NCT00040794|Drug|carboplatin|Given IV
67162|NCT01156805|Other|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
67163|NCT01156844|Drug|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
67442|NCT01159626|Drug|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
67443|NCT01159626|Drug|Placebo|Oral single dose as matching placebo
67444|NCT01159626|Drug|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
67445|NCT01159626|Drug|Placebo|Oral multiple doses as matching placebo for 7 days
67446|NCT01159639|Drug|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
67447|NCT01159652|Drug|zaleplon|10 mg
67448|NCT01159652|Drug|zolpidem extended release|12.5 mg
67449|NCT00040885|Biological|infliximab|
67450|NCT01159652|Drug|bedtime placebo|placebo
67451|NCT01159652|Drug|middle of the night placebo|placebo
67452|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
67453|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
67454|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
67227|NCT01164579|Drug|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
67228|NCT01164579|Drug|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
67229|NCT01164579|Drug|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
67230|NCT01164592|Device|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
67231|NCT01164605|Drug|Raltegravir|60 tablets (30-day supply)
67232|NCT01164618|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
67233|NCT01164618|Other|Exercise|Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
67234|NCT01164631|Device|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
67235|NCT01164644|Drug|Arnica montana|Subjects will take twelve pills by mouth three times a day over four days.
67236|NCT01164644|Drug|Placebo|Subjects will take twelve pills by mouth three times a day over four days.
67237|NCT00041210|Biological|bleomycin sulfate|
67238|NCT01164657|Device|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
67239|NCT01156883|Drug|asparaginase|
67240|NCT01156883|Drug|cyclophosphamide|
67241|NCT01156883|Drug|cytarabine|
67242|NCT01156883|Drug|daunorubicin hydrochloride|
67243|NCT00040794|Drug|gefitinib|Given PO
67244|NCT01156883|Drug|dexamethasone|
67245|NCT01156883|Drug|doxorubicin hydrochloride|
67246|NCT01156883|Drug|ifosfamide|
63956|NCT01114945|Device|Video-Mac|Intubation with the Video-Mac device
63957|NCT01114958|Drug|Cisplatin, Thiosulfate|Cisplatin (150 mg/m^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m^2).
63958|NCT01114971|Drug|Fentanyl|Fentanyl 50 micrograms/ml boluses will be given:
at the induction time
at the time before surgical incision, and
as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
64246|NCT01144052|Drug|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
64247|NCT01144065|Procedure|Hair sampling for the measurement of cortisol and testosterone|Hair sampling for the measurement of cortisol and testosterone
64248|NCT01144078|Behavioral|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
64249|NCT01136590|Drug|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
64250|NCT01136590|Drug|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
64251|NCT00039104|Drug|zoledronic acid|Given IV
64252|NCT01136603|Device|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
64253|NCT01136642|Drug|Nicotrol|
64254|NCT01136655|Drug|80/2.25 μg Symbicort pMDI|inhalation
64255|NCT01136655|Drug|80/4.5 μg Symbicort pMDI|inhalation
64256|NCT01136655|Drug|Foradil Aerolizer 12 μg|inhalation
64257|NCT01136655|Drug|40 μg budesonide HFA pMDI|inhalation
64258|NCT01136655|Drug|placebo HFA pMDI|inhalation
63735|NCT01106846|Drug|Group A: Saline Group|Saline continuous infusion
63736|NCT01106846|Drug|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
63737|NCT01106859|Drug|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
63738|NCT01106859|Drug|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
63739|NCT01106859|Drug|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
63740|NCT01106859|Drug|Placebo|Placebo matching zopiclone
63741|NCT01106872|Drug|Bevacizumab, Gemcitabine, docetaxel and valproic acid|
64009|NCT01112176|Procedure|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
64010|NCT00036556|Drug|Atrasentan|
64011|NCT01112189|Procedure|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
64012|NCT01112189|Other|Compressed sleeve treatment|Week 1-2: With compressed sleeve treatment.
Week 3 -4: Without treatment.
Week 5 - 6: With compressed sleeve treatment
64013|NCT01112215|Drug|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
64014|NCT01112215|Drug|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
64015|NCT01112228|Procedure|Bariatric surgery|Gastric bypass, Sleeve gastrectomy, or Gastric banding
64016|NCT01112241|Drug|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
64017|NCT01112254|Procedure|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
64018|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
64019|NCT01112267|Drug|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
67455|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
67456|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
67457|NCT01159678|Behavioral|online psychoeducation|The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:
Important of sexuality to quality of life. & Definitions of sexual desire and arousal.
Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.
Sexual beliefs.
Mindfulness.
Genital anatomy and physiology.
Body Image.
Relationship satisfaction and communication.
Body-oriented mindfulness exercises (focusing and self-observation).
Using Thought records.
Mindfulness and the thought stream.
Sexual aids to boost arousal.
Moving on.
In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond.
67458|NCT01159704|Behavioral|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
67459|NCT01159704|Behavioral|HIV Counseling and Education Model|The C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that "structurally bracket confidential HIV antibody screening."
67460|NCT00040885|Drug|docetaxel|
67461|NCT01159730|Drug|VB-201 or Placebo|
67462|NCT01159756|Drug|Travacom|Travacom ophthalmic solution (1 drop per day)
67726|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
67727|NCT01160211|Drug|lapatinib|1000 mg by mouth once a day
67728|NCT01160211|Drug|trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
67729|NCT01160211|Drug|Aromatase inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
67730|NCT01160211|Drug|lapatinib|1500 mg by mouth once daily
67731|NCT01160224|Drug|GW766944|Drug: GW766944 (Active Drug Treatment)
67732|NCT01160224|Other|Placebo|This is placebo to match.
67733|NCT01160237|Biological|Pandemrix™|One dose intramuscular injection
67734|NCT00000952|Drug|Lamivudine|
67735|NCT00040937|Biological|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
67736|NCT01160237|Biological|Fluarix™/ Influsplit SSW® 2010/2011|One dose intramuscular injection
69761|NCT01148641|Dietary Supplement|Lipid-based supplement (LNS)|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days and thereafter, 20 g per day for 14 days.
69762|NCT01148667|Dietary Supplement|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
69763|NCT01148667|Dietary Supplement|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
70035|NCT01178879|Behavioral|Telehealth consultation|The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.
The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line.
70036|NCT01178892|Dietary Supplement|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
70037|NCT01178892|Dietary Supplement|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
70038|NCT01178892|Behavioral|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
70039|NCT01178892|Behavioral|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
70040|NCT01178892|Behavioral|Usual Activity|Women randomly assigned to the "Usual Activity" group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership.
70041|NCT01178905|Procedure|ultrashort heat inactivation|
70042|NCT01178931|Drug|Oral dydrogesterone|oral-2x10mg
70043|NCT01178931|Drug|Crinone 8% gel|vaginal-1x90mg
70044|NCT00042458|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
69328|NCT01150604|Behavioral|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
69329|NCT01150617|Drug|Insulin glargine plus insulin analogues|Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c<6.5% at the end of the follow-up.
Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of < 7.0% at the end of the follow-up.
69330|NCT01150630|Drug|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
69331|NCT01150630|Drug|cisplatin|30 mg/mq every 14 days for 6 months
69332|NCT01150630|Drug|epirubicin|30 mg/mq every 14 days for 6 months
69333|NCT01150630|Drug|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
69334|NCT00040326|Procedure|anteromesial temporal resection|surgical treatment for epilepsy
69335|NCT01153360|Drug|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
69336|NCT01153360|Drug|placebo|vitamin B12
69337|NCT01153373|Behavioral|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|All patients that give consent to participate in the study ("participants") who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only.
69338|NCT01153373|Behavioral|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
69339|NCT01153386|Drug|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
69340|NCT01153412|Other|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
68422|NCT01164059|Drug|Quetiapine|Quetiapine 400, 600, or 800 mg / day
68423|NCT01164059|Drug|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
68424|NCT01164059|Drug|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
68425|NCT01164085|Drug|Intravitreal Ketorolac|4mg of intravitreal ketorolac
68426|NCT01164098|Drug|Rituximab|Induction therapy
70109|NCT01176864|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy
70339|NCT01177163|Drug|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
70340|NCT01177163|Drug|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
70341|NCT01177176|Other|Extended Care Management|Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
70342|NCT01177176|Other|Standard Care|Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
70343|NCT01177189|Dietary Supplement|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
70344|NCT01177202|Biological|HAC1 Vaccine|Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
70345|NCT01177215|Procedure|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
70346|NCT01177228|Drug|Vedolizumab|Vedolizumab for intravenous infusion
70347|NCT01177228|Drug|Placebo|Placebo intravenous infusion
70348|NCT00042315|Procedure|Chemotherapy|
70349|NCT01177293|Drug|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
70350|NCT01177293|Drug|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
70351|NCT01177306|Drug|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
70352|NCT01177319|Drug|Glutathione|
70353|NCT01177332|Other|exercise|2 hours cycling exercise at 50 % of maximal power output
70354|NCT01177358|Drug|Botulinum Toxin Type A|A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.
5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy.
70744|NCT01175772|Drug|Cytophosphan, Celecoxib, Methotrexate|Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer
Cytophosphan tab 50 mg -1x1 per day, continuous
Celecoxib tab 200 mg - 1x2 per day, continuous
Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly
70745|NCT01175785|Procedure|umbilical cord blood transplantation|Undergo unmanipulated umbilical cord blood units
70746|NCT01175785|Drug|fludarabine phosphate|Given IV
69879|NCT01151761|Procedure|Stereotactic Body Radiotherapy|Standard of care
69880|NCT01151761|Drug|Gemcitabine100 mg/m2|100 mg/m2, IV
69881|NCT01180985|Device|comfilcon A|silicone hydrogel contact lens
69882|NCT01180998|Device|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
69883|NCT01180998|Device|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
69884|NCT00042783|Biological|SB-AS02B adjuvant|
69885|NCT01181011|Drug|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
69886|NCT01181024|Drug|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
69887|NCT01181024|Drug|RO5303253|Cohorts receiving single ascending doses
69888|NCT01181024|Drug|RO5303253|Single dose
69889|NCT01181024|Drug|RO5303253|Multiple doses
69890|NCT01181050|Drug|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
69891|NCT01181050|Drug|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
69892|NCT01181063|Drug|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
69893|NCT01181076|Dietary Supplement|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
69894|NCT01181089|Biological|Placebo|
69895|NCT00042796|Drug|decitabine|Given IV
70174|NCT01183871|Procedure|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
70175|NCT01183884|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.
Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in > or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2.
70176|NCT01176929|Other|Usual treatment and Prevention program|Prevention program of recurrent suicidal acts includes three interventions:
A series of three telephone calls ( the second week , one month and three months after discharge from hospital )
A systematic telephone contact with the referring physician
A telephone helpline for people who made a suicide attempt and referring physicians.
70177|NCT01176929|Other|Usual Treatment|Usual Treatment
70424|NCT01184586|Device|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
70425|NCT01184599|Drug|aliskiren|150 mg/day p.o.
70426|NCT01184612|Behavioral|Motivational Interviewing; MI|MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and "rolling" with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client.
70427|NCT01184625|Other|Physical Exercise|12 weeks of physical exercise.
70428|NCT01184638|Drug|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
70429|NCT01184638|Drug|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
70430|NCT01184651|Behavioral|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
70431|NCT01177371|Drug|cyclophosphamide|Given IV
70432|NCT01177371|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
70433|NCT00042315|Drug|tariquidar + vinorelbine|
70434|NCT01177371|Drug|methylprednisolone|Given IV or orally
68427|NCT01164111|Other|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
68428|NCT01156376|Device|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
68429|NCT00040768|Drug|bortezomib|Given IV
68430|NCT01156376|Device|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
68431|NCT01156389|Drug|Ritonavir and pyronaridine/artesunate|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and pyronaridine/artesunate 180 mg/60 mg (3 to 4 tablets once per day according to weight for 3 days).
68432|NCT01156389|Drug|pyronaridine/artesunate|Pyronaridine/artesunate 180 mg/60 mg (3 to 4 tablets once per day according to weight for 3 days).
68433|NCT01156402|Behavioral|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
68434|NCT01156415|Drug|AGO178|
68435|NCT01156415|Drug|AGO178|
68436|NCT01156441|Procedure|surgical mitral valve repair w/ mitral valve annuloplasty|Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.
Intraoperative transesophageal echocardiography will be performed on all study volunteers.
68437|NCT01156454|Procedure|X-ray|surgical specimen taken to radiology and contents x-rayed
68438|NCT01156467|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
68439|NCT01156467|Device|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
68719|NCT01152333|Drug|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
68720|NCT01152346|Drug|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
68721|NCT01152346|Drug|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
70355|NCT01177358|Drug|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
70356|NCT01177371|Drug|busulfan|Given orally
70679|NCT01184794|Drug|levobupivacaine|40 ml over 48 hours
70680|NCT01184807|Drug|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
70681|NCT01184820|Biological|BAY94-9027 + Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
70682|NCT01184820|Biological|BAY94-9027 + Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
70683|NCT01177813|Drug|BI10773|BI 10773 high dose tablets once daily
70684|NCT01177813|Drug|Sitagliptin|Sitagliptin tablets 100 mg once daily
70685|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
70686|NCT00042367|Drug|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
70687|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
70688|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
70689|NCT01177826|Procedure|Sample collection|Stool sample
70690|NCT01177839|Other|Screening sheets|Reviewing screening sheets
70691|NCT01177852|Drug|diphenhydramine + dropropizine + pseudoephedrine|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
Posology: The medicine treat will be as follows:
- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml
70692|NCT01177852|Drug|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|Dropropizine:
Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml
Pseudoephedrine hydrochloride + brompheniramine maleate:
Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml
70693|NCT01177865|Other|informational intervention|
69896|NCT01181089|Biological|Baminercept|
69897|NCT01181102|Drug|edoxaban|
69898|NCT01181102|Drug|enoxaparin sodium|
69899|NCT01181115|Drug|Avonex|Interferon treatment for MS
69900|NCT01181128|Drug|Factor VIII (rFVIIIFc)|
69901|NCT01181128|Drug|Advate®|
69902|NCT01181141|Drug|DU-176b (edoxaban)|
70161|NCT00042939|Biological|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
70162|NCT01183780|Drug|Folinic Acid|400 mg/m^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
70163|NCT01183780|Drug|5-Fluorouracil|400 mg/m^2 bolus immediately followed by 2400 mg/m^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
70164|NCT01183793|Radiation|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
70165|NCT01183806|Drug|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
70166|NCT01183806|Other|Exercise training program|Exercise training program
70167|NCT01183819|Behavioral|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
70168|NCT01183819|Behavioral|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
70169|NCT01183819|Behavioral|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
70170|NCT01183819|Behavioral|Control Games|Control games session 3 times a week for 12 weeks
70171|NCT01183845|Procedure|Colon Capsule Endoscopy|Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
70172|NCT00042939|Drug|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
70173|NCT01183858|Drug|Erlotinib [Tarceva]|Single daily oral dose
70435|NCT01177371|Drug|methotrexate|Given IV
70436|NCT01177371|Drug|cyclosporine|Given IV or orally
70437|NCT01177384|Drug|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
70438|NCT01177384|Drug|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
70439|NCT01177384|Drug|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
70440|NCT01177384|Drug|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
70441|NCT01177397|Drug|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
70442|NCT01177410|Drug|Placebo|placebo capsules once daily for 12 weeks
70443|NCT01177410|Drug|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
70747|NCT01175785|Drug|cyclophosphamide|Given IV
70748|NCT01175785|Procedure|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
70749|NCT01175785|Radiation|total-body irradiation|Undergo TBI
70750|NCT01175785|Drug|cyclosporine|Given IV
70751|NCT01175785|Drug|mycophenolate mofetil|Given IV and PO
70752|NCT00042289|Drug|capreomycin|Women will receive capreomycin as prescribed by their clinicians. (Dosage will vary for each participant.)
70753|NCT01175785|Other|laboratory biomarker analysis|Correlative studies
70754|NCT01175798|Drug|Cholecalciferol|50,000 IU PO weekly x 6 weeks
70755|NCT01175811|Drug|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
70756|NCT01175811|Drug|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
70757|NCT01175811|Drug|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
68722|NCT01152359|Behavioral|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
68723|NCT01152359|Behavioral|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
68724|NCT01152372|Procedure|Insulin, glucose and staple isotopes|
68725|NCT01152385|Drug|AZD1656|Oral tablet administered twice daily during 4 months
68726|NCT01152385|Drug|Placebo|administered twice daily during 4 months
68727|NCT01154595|Behavioral|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
68728|NCT01154608|Drug|Creon|
68729|NCT01154608|Other|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
68730|NCT01154621|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
68731|NCT01154621|Drug|Placebo|Sterile 5% dextrose solution
68732|NCT01154634|Drug|AZD2516, 5 mg|Capsule, oral
68733|NCT01154634|Drug|AZD2516, 16 mg|Capsule, oral
68734|NCT00040651|Drug|Fludarabine|
68735|NCT01154634|Drug|AZD2516, 40 mg|Capsule, oral
68736|NCT01154634|Drug|Placebo|Capsule, oral
68737|NCT01154647|Drug|citalopram|intravenous
68738|NCT01154647|Drug|1 ml 0.9 % NaCl|intravenous
70694|NCT01177865|Other|questionnaire administration|
70695|NCT01177904|Other|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
70696|NCT01177904|Other|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
69814|NCT01146327|Drug|PF-04620110|Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
69815|NCT01146327|Drug|PF-04620110|Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
69816|NCT01146327|Drug|PF-04620110|Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
69817|NCT01146327|Drug|Placebo|Multiple oral doses of placebo will be given once daily for 2 weeks.
69818|NCT01146340|Radiation|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
69819|NCT01146379|Other|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
69820|NCT01146418|Biological|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
69821|NCT01146418|Biological|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
69822|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
69823|NCT00039663|Drug|Gemfibrozil|
69824|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
69825|NCT01146444|Other|UV A and B irradiation|UV irradiation
69826|NCT01146457|Drug|Morphine|Active dosage
69827|NCT01146457|Drug|Saline|Saline Control
69828|NCT01146470|Dietary Supplement|RGC|dosage of Red Grape Cells once a day, during 3 months
69829|NCT01146470|Dietary Supplement|Placebo|dosage of Placebo once a day, during 3 months
69830|NCT01148758|Drug|RO5323441|cohorts receiving multiple doses iv
69699|NCT01151306|Drug|Lactose tablet|One tablet taken each evening for 6 weeks
69700|NCT01151319|Biological|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10^9 virus particles.
69701|NCT00040378|Drug|Placebo replacement for Selenium|1 placebo pill daily
69702|NCT01151319|Biological|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10^10 virus particles.
69703|NCT01151319|Biological|pSG2.HIVconsv|DNA at 4mg per dose.
69704|NCT01151319|Biological|MVA.HIVconsv|Attenuated poxvirus at 4x10^8 plaque forming units per dose.
69705|NCT01151319|Other|Placebo|Phosphate buffered saline
69978|NCT01181232|Drug|Zolpidem IR|oral
69979|NCT01181245|Drug|FG-3019|3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
69980|NCT01181258|Drug|Rituximab|375 mg/m^2 administered intravenously (IV) weekly * 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
69981|NCT01181258|Biological|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day * 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight < 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
69982|NCT01181258|Biological|Natural killer cells|administered intravenously 1.5 to 8 * 10^7 cells/kg on Day 0 (day of NK cell infusion)
69983|NCT01181258|Drug|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
69984|NCT01181258|Drug|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
69985|NCT01181258|Drug|Fludarabine|25 mg/m^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
69986|NCT01181271|Drug|Busulfan|0.8 mg/kg IV bolus Q6H on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
69987|NCT00042809|Drug|paclitaxel|Given IV
69988|NCT01181271|Drug|Etoposide|Etoposide 30 mg/kg IV bolus QD on day -4. The total daily dose of etoposide will be 30 mg/kg.
69989|NCT01181271|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
70758|NCT01175824|Drug|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
70759|NCT01175824|Drug|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
70760|NCT01175824|Drug|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
70761|NCT01175837|Other|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
70762|NCT01175837|Other|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
70763|NCT00000963|Drug|Didanosine|
70764|NCT00042289|Drug|moxifloxacin|Women will receive moxifloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
70765|NCT01175837|Other|laboratory biomarker analysis|Correlative studies
70766|NCT01177969|Behavioral|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
70767|NCT01177982|Behavioral|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
70768|NCT01177982|Behavioral|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
70769|NCT01177982|Behavioral|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
69603|NCT01151111|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
69604|NCT01151124|Biological|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
69605|NCT01151137|Drug|Dronedarone|Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)
69606|NCT01151137|Drug|Placebo (for Dronedarone)|film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)
69607|NCT00040378|Drug|Selenium|200mcg daily
69608|NCT01151176|Drug|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
69609|NCT01151176|Drug|Regular Insulin|Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:
Blood Glucose >141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; > 400=16U
70045|NCT01178944|Other|Laboratory Biomarker Analysis|Correlative studies
70046|NCT01178944|Drug|Oxaliplatin|Given IV
70047|NCT01178944|Drug|Pralatrexate|Given IV
70048|NCT01178957|Other|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
70049|NCT01178970|Behavioral|Resistance training|
70050|NCT01178983|Device|surface electromyography|Surface electromyography (SEMG) telebiofeedback
70278|NCT01179399|Drug|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
70279|NCT01179412|Drug|2% povidone-iodine|apply 4 times a day for one week
70280|NCT01179412|Drug|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
70281|NCT01179425|Other|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
70282|NCT01179438|Drug|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
70283|NCT01179451|Device|echocardiogram|echocardiogram
70284|NCT01179464|Drug|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
70285|NCT00042536|Drug|Naltrexone HCL/ Yohimbine HCL|
70286|NCT01179464|Drug|Simvastatin|40 mg once daily
70287|NCT01179477|Device|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
70288|NCT01179490|Drug|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
70289|NCT01179490|Drug|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
70290|NCT01181622|Drug|denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
70291|NCT00042835|Drug|cisplatin|Given IV
69831|NCT01148771|Drug|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
69832|NCT01148771|Drug|ertapenem|1 gram 30 minute infusion q24h for 3 days
69833|NCT01148784|Procedure|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
69834|NCT01148797|Drug|Canakinumab|
69835|NCT01148810|Drug|BAF312|
70110|NCT01176864|Procedure|Single-balloon enteroscopy|Single-balloon enteroscopy
70111|NCT01176877|Behavioral|Scripted lecture ("educational information talk")|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
70112|NCT01176890|Drug|GLP-1|1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
70113|NCT01176890|Other|Saline|Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied
70114|NCT01176903|Drug|Glycopyrrolate|pressurized metered dose inhaler
70115|NCT01176903|Drug|Tiotropium|inhalation powder, hard capsule
70116|NCT00042289|Drug|etonogestrel implant|Women will receive etonogestrel implant as prescribed by their clinicians. (Dosage will vary for each participant.)
70117|NCT01176903|Drug|placebo|pressurized metered dose inhaler
70118|NCT01176916|Drug|Aromasin (exemestane)|This is a NIS, the dosage, frequency and duration base on the LPD approved by SFDA.
70119|NCT01178996|Drug|Ribavirin|Ribavirin 1000 mg (<75 kg) or 1200 mg (>75 kg) daily with food divided in two doses orally for 48 weeks
70120|NCT01178996|Biological|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
70121|NCT00042458|Drug|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
70122|NCT01178996|Drug|Placebo|Placebo
70123|NCT01179009|Drug|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. [18% (0.0125 mg/kg-min.)
70124|NCT01179009|Drug|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
69990|NCT01181271|Drug|Mesna|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus TID on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
69991|NCT01181271|Drug|Phenytoin|Phenytoin 200 mg BID orally given on days -8, -7, -6, -5, and -4 for seizure prophylaxis.
69992|NCT01183481|Radiation|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
69993|NCT01183481|Drug|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
69994|NCT01183494|Drug|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1*1/*1 and UGT1A1*1/*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
69995|NCT01183507|Behavioral|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
69996|NCT00042926|Procedure|lymphangiography|
70229|NCT01181583|Behavioral|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
70230|NCT01181583|Behavioral|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
70231|NCT01181596|Device|ultrasound probing|Ultrasound probing and imaging data collection.
70232|NCT01181609|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
70233|NCT01183897|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.
Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops.
70234|NCT01183910|Dietary Supplement|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
70235|NCT01183910|Dietary Supplement|Calcium Carbonate|Oral Tablet Taken Twice a Day
70236|NCT01183923|Other|Broccoli Sprouts|Broccoli Sprouts will be eaten daily in a sandwich form.
70237|NCT01183936|Procedure|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
69610|NCT01151189|Biological|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
69611|NCT01151189|Biological|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
69612|NCT01151202|Drug|AG NPP709syrup|
69613|NCT01153802|Drug|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.
Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study.
69614|NCT01153815|Drug|GSK1358820(Botulinum toxin type A)|GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox")
69615|NCT01153815|Drug|placebo|placebo
69616|NCT01153828|Drug|Retapamulin|Prescription for retapamulin
69617|NCT01153828|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
69618|NCT00040521|Drug|Recombinant Human Interleukin-11 (rhIL-11)|
69619|NCT01153828|Drug|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
69620|NCT01153841|Biological|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
69621|NCT01153841|Biological|Infanrix hexa™|Intramuscular, 3 doses
68660|NCT01154582|Dietary Supplement|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
68661|NCT01154595|Dietary Supplement|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
68662|NCT01146756|Drug|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
68663|NCT01146769|Other|Pelvic floor exercise|Pelvic floor strengthening exercise
68664|NCT01146782|Device|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
70292|NCT01181622|Drug|0.9% w/v sodium chloride solution|0.9% w/v sodium chloride solution by oral inhalation three times daily
70293|NCT01181635|Behavioral|Psychotherapy|Standard psychotherapy for psychiatric disorders.
70294|NCT01181648|Behavioral|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
70295|NCT01181661|Behavioral|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
70296|NCT01181661|Behavioral|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
70632|NCT01179984|Device|Bard® LifeStent® Vascular Stent System|Stent Implantation
70633|NCT01179997|Device|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
70634|NCT01179997|Device|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
70635|NCT01180010|Procedure|Low Dose CT|A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or "slices" of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner.
70636|NCT01180023|Procedure|Sweeping|Sweeping of membranes during digital exam
70637|NCT01180036|Drug|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of CD19+ B cell count
70638|NCT01180036|Drug|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by HPLC, are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine >30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
70639|NCT01180049|Drug|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
70640|NCT00042653|Drug|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
70125|NCT01179009|Drug|placebo|IV saline (i.e. placebo ketamine)
70126|NCT01179035|Other|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
70127|NCT01179035|Other|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
70128|NCT01179048|Drug|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
70129|NCT01179048|Drug|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
70357|NCT01179503|Dietary Supplement|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
70358|NCT01179503|Dietary Supplement|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
70359|NCT01179516|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
70360|NCT01179516|Drug|Placebo|Vortioxetine placebo-matching capsules
70361|NCT01179529|Drug|Omalizumab (Xolair®)|
70362|NCT01179555|Behavioral|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
70363|NCT00042549|Device|Extracorporeal Shock Wave Lithotripsy|
70364|NCT01179555|Behavioral|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
70365|NCT01179568|Drug|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
70366|NCT01179568|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
70367|NCT01179568|Other|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
70368|NCT01179581|Drug|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
70369|NCT01179581|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
70370|NCT01179581|Drug|GLPG0634|multiple dose, capsule, 10 days
70238|NCT01183936|Procedure|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
70239|NCT01183949|Drug|AT7519M, Bortezomib|Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m^2/dose and will be increased to 27mg/m^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.
Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.
Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose.
70240|NCT00042939|Drug|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
70241|NCT01183962|Dietary Supplement|Vitamin D|Vitamin D 3000 IU daily
70242|NCT01183962|Other|No medication|No intervention
70243|NCT01184001|Drug|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
70244|NCT01184001|Drug|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
70245|NCT01184001|Drug|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
70246|NCT01184001|Drug|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
70574|NCT01182168|Drug|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
70575|NCT01182181|Drug|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
70576|NCT01182181|Drug|Anastrozole (Arimidex®)|1 mg Tablets
70577|NCT01182194|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
70578|NCT01182194|Drug|YAZ®|3 mg/0.02 mg Tablets
70579|NCT00042848|Drug|modafinil|
70580|NCT01182207|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
70581|NCT01182207|Drug|YAZ®|3 mg/0.02 mg Tablets
70582|NCT01182233|Radiation|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
68665|NCT01146795|Drug|Carboplatin, paclitaxel, and bevacizumab|Carboplatin will be administered at an AUC of 5-6 (at the discretion of the physician) day 1 every 3 weeks, paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks and bevacizumab 15 mg/kg day 1 every 3 weeks.
After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill ALL of the following criteria to be considered eligible for surgical exploration. 1) ≥50% reduction in pretreatment CA-125 and 2) No medical contraindications to surgery.
After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4.
68666|NCT01146808|Drug|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
68667|NCT00039741|Drug|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)
Prescribed per participant's doctor
68668|NCT01146821|Dietary Supplement|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight [IBW] fish oil in addition to standard care
68669|NCT01146821|Dietary Supplement|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight [IBW] fish oil in addition to standard care.
68670|NCT01146834|Drug|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
68671|NCT01146834|Drug|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
68672|NCT01146834|Drug|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C)
68673|NCT01146847|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
68674|NCT01146860|Drug|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
68675|NCT01146860|Drug|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
68676|NCT01146873|Drug|Efavirenz|Children are assigned to begin a EFV-based antiretroviral based regimen. Dosing of medication will follow standard guidelines based on body surface area calculations or on body weight depending on drug, and will be in accordance with the South African Treatment guidelines.
68972|NCT01149980|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
68973|NCT01149993|Drug|Myfortic (mycophenolic acid)|720mg twice a day for 7 days prior to transplantation
68974|NCT00040235|Procedure|magnesium|
68975|NCT01149993|Drug|Myfortic (mycophenolic acid)|720mg twice a day after transplant
70641|NCT01180049|Drug|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
70642|NCT01180062|Drug|Latanoprost|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
Duration of drug release is expected to be 3-6 months.
Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
70643|NCT01180062|Drug|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
70644|NCT01180062|Drug|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
69764|NCT01148680|Procedure|human pancreatic islet transplantation|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
69765|NCT01148693|Drug|gentamicin|10mg per 10ml of contrast media
69766|NCT01148693|Drug|Placebo|Distilled water
69767|NCT01148706|Device|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
69768|NCT01148719|Other|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
69769|NCT00040027|Drug|placebo + PEGinterferon alfa-2a|
69770|NCT01148732|Procedure|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
69771|NCT01148745|Drug|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
69772|NCT01151345|Drug|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
69773|NCT01151371|Device|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
69774|NCT01151371|Device|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
69775|NCT01151371|Device|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
69776|NCT01151384|Drug|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
70371|NCT01179581|Drug|placebo|multiple dose, capsule, 10 days
70372|NCT01179594|Drug|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
70373|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
70374|NCT00042549|Drug|ursodiol|
70375|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
70376|NCT01179594|Drug|placebo|orally daily, 24 weeks (weeks 12-36)
70377|NCT01179607|Drug|M0002|
70378|NCT01179607|Drug|Placebo|
70379|NCT01179620|Drug|Certoparin|Certoparin
70380|NCT01179633|Device|OPLON active patch|
70697|NCT00042367|Drug|Cycle B|Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.
Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.
Monitor weekly CBC/diff/plt. If ANC < 500/mm3 or platelets (unsupported) < 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.
Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1.
70698|NCT01177917|Other|Infant Formula|
70699|NCT01177943|Drug|Atomoxetine|Administered orally, once.
70700|NCT01177956|Biological|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab.
70701|NCT01177956|Drug|Cisplatin|Subjects will receive 75 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
70702|NCT01177956|Drug|5-Fluorouracil|Subjects will receive 750 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
70703|NCT01177969|Behavioral|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
70704|NCT01180075|Drug|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
70705|NCT01180075|Drug|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
70583|NCT01184274|Drug|SB939|Dose Levels for Part A
-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
(starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
70584|NCT01184287|Drug|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
70585|NCT01184300|Genetic|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
70586|NCT01184313|Procedure|aortic valve surgery with CPB|elective aortic valve surgery with CPB
70587|NCT01184326|Drug|pazopanib|Taken orally once daily
70588|NCT01184326|Drug|everolimus|Taken orally once daily
70589|NCT01184339|Device|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.
Approximately 5 hour rapid test.
70590|NCT01184352|Device|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
70591|NCT01184365|Behavioral|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
69706|NCT01151345|Drug|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
69707|NCT01153919|Other|laboratory biomarker analysis|Correlative studies
69708|NCT01153932|Drug|GSK2402968|Subcutaneous injection
69709|NCT01153932|Drug|matched placebo|Subcutaneous injection
69710|NCT01153958|Drug|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
69711|NCT01153958|Drug|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
69712|NCT00040547|Drug|Farnesyl Protein Transferase Inhibitor|
69713|NCT01153971|Drug|rituximab|1
68976|NCT01149993|Drug|Thymoglobulin (anti-thymocyte globulin)|up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
68977|NCT01149993|Drug|Thymoglobulin (anti-thymocyte globulin)|standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
68978|NCT01150006|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
68979|NCT01150019|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
68980|NCT01152801|Drug|Everolimus (RAD001)|
68981|NCT01152814|Biological|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
68982|NCT01152827|Drug|RAD001|RAD001 10 mg daily po medication.
Treatments will be continued until any of the following events occur
progression of disease
the subject develops unacceptable toxicity
consent to participate in the study is withdrawn
68983|NCT01152840|Drug|RAD001|RAD001 10 mg po daily medication
Treatments will be continued until any of the following events occur:
progression of disease,
the subject develops unacceptable toxicity,
consent to participate in the study is withdrawn.
68984|NCT01152853|Drug|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
68985|NCT01152866|Drug|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
68986|NCT01152879|Dietary Supplement|Home Parenteral Nutrition|Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
68987|NCT00040456|Drug|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
68988|NCT01152918|Behavioral|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
68989|NCT01152918|Behavioral|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
69278|NCT01155518|Drug|testosterone|intramuscular every 2 weeks
69279|NCT01155518|Drug|clomiphene|thrice a week
69777|NCT00040391|Drug|Investigational drug|
69778|NCT01151397|Drug|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
69779|NCT01151397|Drug|Peg + Ribavirin|Peg+ Ribavirin for 6 months
69780|NCT01151410|Drug|Aliskiren|Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg
Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg
High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
69781|NCT01151410|Drug|Enalapril|Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg
Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg
High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
69782|NCT01151423|Biological|anti-vWF Nanobody|10 mg i.v. bolus injection prior to plasma exchange, followed by 10 mg s.c. injection once or twice per day. Maximum treatment duration is limited to 90 days.
70051|NCT01178983|Device|surface electromyography|conventional biofeedback
70052|NCT01178996|Biological|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
70053|NCT01181271|Drug|Ursodiol|Ursodiol 300 mg TID orally given starting on day -8 and continuing daily until discharge for hepatic veno-occlusive disease (VOD) prophylaxis.
70054|NCT01181271|Other|Infusion of autologous peripheral blood stem cells|Infusion of autologous peripheral blood stem cells on Day 0.
70055|NCT01181271|Drug|Neupogen|Neupogen 5 mcg/kg SQ daily starting on day +1 until ANC is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
70056|NCT01181271|Drug|Fludarabine|Fludarabine 30 mg/m2/d will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
70057|NCT01181271|Drug|Busulfan|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
70058|NCT01181271|Other|Peripheral blood stem cell transplant|Donor PBSC will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10^6/kg of recipient's actual body weight
70059|NCT00000967|Drug|Interferon alfa-2a|
70060|NCT00042809|Biological|trastuzumab|Given IV
70061|NCT01181271|Drug|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg PO BID starting day -3.
70062|NCT01181271|Drug|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
70706|NCT01180075|Drug|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
70707|NCT01180075|Drug|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
70708|NCT01180075|Procedure|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
70709|NCT01180088|Procedure|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
70710|NCT00042653|Drug|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
70711|NCT01180101|Behavioral|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
70712|NCT01180101|Procedure|Bariatric Surgery|Patients will undergo bariatric surgery
69836|NCT01148810|Drug|Placebo|
69837|NCT01148823|Other|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
69838|NCT00040040|Drug|Bupropion|
69839|NCT01148823|Other|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
69840|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
69841|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
69842|NCT01148849|Biological|MGAH22|MGAH22 will be administered by IV infusion once per week for 4 weeks in the following dose escalation cohorts: 0.1, 0.3, 1.0, 3.0, and 6.0 mg/kg; and once every 3 weeks in the following dose escalation cohorts: 10.0, 15.0, and 18.0 mg/kg.
An additional cohort of up to 15 patients with breast or gastric cancer will be enrolled and treated at a dose of 15 mg/kg every three weeks.
69843|NCT01148875|Behavioral|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
69714|NCT01153984|Drug|erlotinib [Tarceva]|erlotinib [Tarceva] 150mg po daily
69715|NCT01153997|Drug|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
69716|NCT01153997|Drug|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
69717|NCT01153997|Drug|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
69718|NCT01153997|Drug|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
69719|NCT01154010|Device|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
69720|NCT01154010|Device|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
69721|NCT01154023|Behavioral|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 & 6 were delivered individually by phone.
69722|NCT01154036|Drug|ezetimibe 10 mg|
69723|NCT00040560|Drug|111In-DAC|
69724|NCT01154036|Drug|atorvastatin|
69725|NCT01154036|Drug|Comparator: rosuvastatin|
69726|NCT01154049|Biological|sm14 antigen plus adjuvant GLA|Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
69727|NCT01154062|Drug|Pazopanib|Pazopanib tablet
69997|NCT01183507|Behavioral|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
69998|NCT01183520|Dietary Supplement|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
69999|NCT01183533|Drug|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
70000|NCT01183559|Drug|ZD6474 (Zactima)|
70001|NCT01183572|Dietary Supplement|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
69280|NCT01155518|Drug|placebo|intramuscular saline injections every 2 weeks
69281|NCT01155518|Drug|placebo|oral
69282|NCT01155531|Drug|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
69283|NCT01155544|Behavioral|Behavioral Intervention|Preventing recurrence of substance use.
69284|NCT01147692|Biological|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
69285|NCT01147705|Drug|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
69286|NCT00039936|Behavioral|Partial Self Help|
69287|NCT01147705|Drug|Placebo|Same appearance/dosing as active drug.
69288|NCT01147718|Biological|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
69289|NCT01147731|Biological|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
69290|NCT01147744|Drug|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
69291|NCT01147744|Drug|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
69292|NCT01147744|Drug|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
69293|NCT01147744|Drug|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
69294|NCT01147744|Drug|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
69295|NCT01147744|Drug|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
69296|NCT01147744|Drug|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
69297|NCT00039962|Drug|thymalfasin (thymosin alpha 1)|
69298|NCT01147744|Drug|Placebo montelukast|Placebo capsule once daily in the evening
69299|NCT01147744|Drug|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
70063|NCT01181271|Drug|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
70064|NCT01181297|Other|Extensively Hydrolyzed Formula with a Probiotic|
70065|NCT01181297|Other|Extensively Hydrolyzed Formula without a Probiotic|
70066|NCT01181310|Drug|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
70067|NCT01181310|Drug|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
70068|NCT01181310|Drug|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
70069|NCT01181310|Drug|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
70070|NCT01181310|Drug|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
70297|NCT01181674|Drug|insulin glargine|sc injection
70298|NCT01181674|Drug|metformin|oral administration
70299|NCT01181674|Drug|acarbose|oral administration
70300|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
70301|NCT01181674|Drug|insulin glargine|sc injection
70302|NCT00042835|Drug|etoposide|Given IV
70303|NCT01181674|Drug|metformin|oral administration
70304|NCT01181674|Drug|acarbose|oral administration
70305|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
70306|NCT01181674|Other|Standard glycemic care|as informed by the current clinical practice guidelines
70307|NCT01181700|Drug|Treatment A|PF-00241939 300 ug using inhaler A
70308|NCT01181700|Drug|Treatment B|PF-00241939 300 ug using inhaler A
70309|NCT01181700|Drug|Treatment C|PF-00241939 300 ug using inhaler A
70310|NCT01181700|Drug|Treatment D|PF-00241939 300 ug using inhaler B
69844|NCT01148888|Drug|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
69845|NCT01148901|Drug|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
69846|NCT01148914|Other|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
69847|NCT01148953|Drug|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
69848|NCT01148953|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
69849|NCT00040053|Drug|Ondansetron|
69850|NCT01148966|Drug|aminolevulinic acid|Given PO
69851|NCT01148966|Other|laboratory biomarker analysis|Correlative studies
69852|NCT01148966|Procedure|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
69853|NCT01151540|Drug|E2080|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
69854|NCT01151553|Device|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
70130|NCT01179061|Drug|Apelin|Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.
Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.
Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine.
70131|NCT01179061|Drug|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
70132|NCT00000966|Drug|Azithromycin|
70133|NCT00042471|Drug|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
70134|NCT01179074|Procedure|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
70135|NCT01179074|Procedure|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
70002|NCT01183572|Dietary Supplement|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
70003|NCT01183572|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid
70004|NCT01183585|Drug|RO4917838 and Rosuvastatin|multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
70005|NCT01183598|Drug|tocilizumab [RoActemra/Actemra]|maintenance dose
70006|NCT01183611|Biological|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
70007|NCT00042926|Procedure|radionuclide imaging|
70008|NCT01183611|Biological|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
70009|NCT01183611|Biological|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
70010|NCT01183611|Biological|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
70011|NCT01183611|Biological|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
70012|NCT01183624|Other|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
70013|NCT01183624|Other|Placebo Patch|Control patch with no herbal ingredients
70014|NCT01176539|Device|Non-Contact Respiratory Rate Monitor|The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.
The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
70015|NCT01176552|Drug|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
70247|NCT01184014|Drug|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
70248|NCT01184014|Drug|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
70249|NCT01184027|Behavioral|nutrition /swallowing counseling|general nutrition and swalling information
70250|NCT01184027|Behavioral|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
70251|NCT00042952|Drug|imatinib mesylate|Given orally
69300|NCT01147744|Drug|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
69622|NCT01153854|Drug|Racecadotril|oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
69623|NCT01153854|Drug|Placebo groups|Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
69624|NCT01153867|Behavioral|Schema Focused Therapy|SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
69625|NCT01153880|Drug|Retapamulin|Prescription sales claim of retapamulin
69626|NCT01153880|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
69627|NCT01153893|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
69628|NCT01153893|Biological|InfanrixTM|Intramuscular injection, 1dose
69629|NCT00040534|Drug|Farnesyl Protein Transferase Inhibitor|
69630|NCT01153906|Other|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
69631|NCT01153919|Biological|romiplostim|Given subcutaneously
69632|NCT01153919|Drug|ribavirin|Given orally
69633|NCT01153919|Other|placebo|Given subcutaneously
69634|NCT01153919|Biological|PEG-interferon alfa-2a|Given subcutaneously
69635|NCT01145963|Other|Experimental pasta C|experimental pasta
69636|NCT01145976|Drug|Cy-ATG|Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.
Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
69637|NCT01145976|Drug|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
69638|NCT01145989|Drug|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
70311|NCT01181700|Drug|Treatment E|PF-00241939 300 ug using inhaler B
70312|NCT01181700|Drug|Treatment F|PF-00241939 300 ug using inhaler B
70313|NCT00042835|Drug|erlotinib hydrochloride|Given orally
70314|NCT01181700|Drug|Treatment G|PF-00241939 300 ug using inhaler B
70315|NCT01181726|Drug|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
70316|NCT01181726|Drug|Activella®|1 mg/0.5 mg Tablets
70317|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
70318|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
70319|NCT01184105|Drug|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
70320|NCT01184105|Drug|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
70645|NCT01182246|Drug|AXP107-11|The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.
A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).
AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa.
70646|NCT01182272|Drug|sorafenib tosylate|
70647|NCT01182272|Other|laboratory biomarker analysis|
70648|NCT01182272|Procedure|neoadjuvant therapy|
70649|NCT01182272|Procedure|therapeutic conventional surgery|
70650|NCT01182285|Drug|Valproic Acid|Week 1:
(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
70651|NCT01182285|Drug|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
70652|NCT00042861|Drug|7-hydroxystaurosporine|
70136|NCT01179100|Drug|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
70137|NCT01179113|Drug|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
70138|NCT01179126|Procedure|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
70139|NCT01181323|Biological|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
70140|NCT01181336|Biological|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
70141|NCT01181336|Biological|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
70142|NCT01181349|Other|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug[s]) are not specified in the protocol.
70143|NCT01181349|Other|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug[s]) are not specified in the protocol.
70381|NCT01179633|Device|Sham patch|
70382|NCT01179646|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
70383|NCT01179659|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
70384|NCT01179672|Drug|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
70385|NCT01181765|Biological|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
70386|NCT01181791|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
70387|NCT01181791|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
70388|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
70389|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
70252|NCT01184027|Behavioral|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
70253|NCT01184040|Behavioral|VIP CM|Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
70254|NCT01177085|Behavioral|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
70255|NCT01177098|Drug|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
70256|NCT01177098|Drug|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
70257|NCT00042302|Drug|tariquidar + paclitaxel/carboplatin|
70258|NCT01177111|Other|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
70259|NCT01177111|Other|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
70260|NCT01177124|Behavioral|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
70261|NCT01177137|Device|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
70262|NCT01177137|Device|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
70592|NCT01184365|Behavioral|Energy Management Program|The goal of the EnMP-2 is to control for group effects
70593|NCT00000969|Drug|Didanosine|
70594|NCT00042978|Biological|oblimersen sodium|Given IV
70595|NCT01184378|Dietary Supplement|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
70596|NCT01184391|Drug|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
69639|NCT01146002|Drug|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
69640|NCT01146015|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
69641|NCT01146028|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
68677|NCT01146873|Drug|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.Dosing of medication will follow standard guidelines based on body surface area calculations or on body weight depending on drug, and will be in accordance with the South African Treatment guidelines.
68678|NCT00039754|Drug|Holmium-166-DOTMP|
68679|NCT01146873|Drug|D4T|Children are assigned to stay on their current antiretroviral regimen which includes D4T. Dosing of medication will follow standard guidelines based on body surface area calculations or on body weight depending on drug, and will be in accordance with the South African Treatment guidelines.
68680|NCT01146873|Drug|Abacavir (ABC)|Children stop taking D4T and switch to an abacavir. Dosing of medication will follow standard guidelines based on body surface area calculations or on body weight depending on drug, and will be in accordance with the South African Treatment guidelines.
68681|NCT01149343|Biological|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
68682|NCT01149356|Drug|Exemestane|Given orally
68683|NCT01149356|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
68684|NCT01149356|Drug|Goserelin Acetate|Given subcutaneously to premenopausal patients
68685|NCT01149369|Drug|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
68686|NCT00040131|Drug|IL-10|
68687|NCT01149369|Drug|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
68688|NCT01149395|Drug|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
68689|NCT01149408|Drug|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
68690|NCT01149421|Drug|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
68691|NCT01149421|Drug|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
68692|NCT01149434|Drug|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
70653|NCT01182337|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
70654|NCT01182337|Drug|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
70655|NCT01182350|Drug|Bevacizumab|• Bevacizumab, 10 mg/kg IV, will be given at least three weeks from the biopsy and at least two weeks after start of the radiation therapy and then every 14 +/- 3 days concurrently with radiation therapy, during the interim period, and for up to 10 maintenance cycles.
70656|NCT01182350|Drug|Erlotinib|• The erlotinib dose will be 85 mg/m2/day given continuously during irradiation. Patients will then continue erlotinib at 85 mg/m2/day beginning immediately after completion of radiation therapy through the interim period, and to complete 10 cycles of maintenance therapy
70657|NCT01182350|Drug|Temozolomide|• The temozolomide dose will be 90 mg/m2/day given continuously during irradiation and then 200mg/m2/day for five days every 28 +/- 5 days to begin approximately 4 weeks after completion of the radiation therapy and to continue for 10 maintenance cycles.
70658|NCT01182350|Radiation|Irradiation|All patients will receive local radiotherapy(for approximately 7 weeks) to consist of 59.4Gy delivered using conventional conformal or other standard treatment planning with adjuvant bevacizumab
69783|NCT01151423|Biological|Placebo|10 mg i.v. bolus injection prior to plasma exchange, followed by daily 10 mg s.c. injection. Maximum treatment duration is limited to 90 days.
69784|NCT01151423|Other|Plasma exchange|Plasma exchange
69785|NCT01151436|Device|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
69786|NCT01151449|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
69787|NCT01151449|Other|laboratory biomarker analysis|Correlative studies
69788|NCT00040391|Drug|Irinotecan|
69789|NCT01151488|Other|Resistance Training|RT 3x/wk for 4 months
69790|NCT01151488|Other|Resistance Training + Nutritional Supplementation|RT 3x/wk for 4 months Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily Protein intake of 1.2 g/kg/d
70390|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
70391|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
70392|NCT00042835|Radiation|radiation therapy|Undergo radiotherapy
70393|NCT01181817|Other|fMRI and MRS|fMRI and MRS
70394|NCT01181830|Drug|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
70395|NCT01181830|Drug|placebo|administration of 8.1 mmol bid of placebo
70396|NCT01181856|Biological|MVA 85A|Single injection of 1 x 108 pfu MVA85A
70397|NCT01181869|Device|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
70398|NCT01181882|Dietary Supplement|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
70399|NCT01181895|Drug|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
70400|NCT01181895|Drug|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
70401|NCT01181895|Drug|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
70402|NCT01181895|Drug|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
70403|NCT00042835|Drug|docetaxel|Given IV
70713|NCT01180114|Behavioral|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
70714|NCT01180114|Other|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
70715|NCT01180127|Dietary Supplement|Flavanol containing food product|12 weeks, 2X/day, 20g serving
70716|NCT01180127|Behavioral|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
70717|NCT01180127|Dietary Supplement|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
70597|NCT01184391|Drug|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
70598|NCT01184404|Drug|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
70599|NCT01184417|Drug|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
70600|NCT01184417|Drug|placebo|100 m l saline
70601|NCT01184430|Device|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
70602|NCT01184443|Drug|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
70603|NCT01184456|Dietary Supplement|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
70604|NCT01177683|Drug|Filgrastim|Phase II component:
Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC >1000
70605|NCT01177696|Behavioral|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
70606|NCT01177709|Drug|Metformin|metformin 500- 2500 mg/day.
70607|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
70608|NCT00042354|Drug|clofarabine (IV formulation)|
70609|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
70610|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
70611|NCT01177722|Biological|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
70612|NCT01177735|Drug|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
69728|NCT01154088|Biological|Mencevax ACWY|One dose, Subcutaneous injection
69729|NCT01154088|Biological|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
69730|NCT01154101|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
68693|NCT01149434|Drug|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
68694|NCT01149460|Drug|Valacyclovir|Test 1000 mg Tablet
68695|NCT01149460|Drug|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
68696|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
68697|NCT00040144|Drug|ACH126, 433 (b-L-Fd4C)|
68990|NCT01152918|Behavioral|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
68991|NCT01152918|Behavioral|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
68992|NCT01152918|Behavioral|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
68993|NCT01152918|Behavioral|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
68994|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
68995|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
68996|NCT01152931|Drug|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
68997|NCT01155219|Drug|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
68998|NCT00040677|Drug|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
68999|NCT01155232|Drug|Teriparatide|Forteo (teriparatide)pen daily for 24 months
69000|NCT01155245|Drug|Forteo|Forteo pen
69001|NCT01155258|Drug|temsirolimus|Given IV
69002|NCT01155258|Drug|vinorelbine ditartrate|Given IV
69791|NCT01151501|Device|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) >92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2＞92%.
69792|NCT01151514|Other|Nephrologist referral|Nephrologist specialty, renal replacement therapy
69793|NCT01154127|Drug|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
69794|NCT00040560|Procedure|Diagnostic|
69795|NCT01154127|Drug|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
69796|NCT01154140|Drug|treatment|crizotinib 250mg orally continuous twice daily dosing
69797|NCT01154140|Drug|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
69798|NCT01154153|Drug|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
69799|NCT01154153|Drug|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).
For children who were >=2 to <6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.
For children who were >=6 yrs to <12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.
70071|NCT00042809|Drug|erlotinib hydrochloride|Given orally
70072|NCT01181323|Other|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
70073|NCT01181323|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
70074|NCT01181323|Other|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
70075|NCT01183637|Device|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
70718|NCT01180127|Behavioral|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
70719|NCT01180140|Device|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
70720|NCT01180153|Drug|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
70721|NCT00042666|Drug|LY317615|500 mg, oral, daily, up to six 28 day cycles
70722|NCT01180166|Drug|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
70723|NCT01180179|Drug|Lansoprazole|30mg once daily
70724|NCT01182376|Drug|Placebo|Placebo will be administered by the patient's team according to established guidelines.
70725|NCT01182389|Procedure|Robotic VT Ablation|Robotic VT Ablation
70726|NCT00042861|Drug|fluorouracil|
70727|NCT01182389|Other|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
70728|NCT01182402|Device|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
70729|NCT01182415|Procedure|High-dose chemotherapy with autologous stem cell transplant|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide followed by autologous stem cell transplant
70730|NCT01182428|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
70731|NCT01182428|Device|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
69855|NCT01151579|Drug|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
69856|NCT01151579|Drug|Albuterol|Nebulized albuterol 2.5mg
69857|NCT01151592|Drug|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
69858|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
69859|NCT00040391|Drug|5-fluorouracil|
69860|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
69731|NCT01154101|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
69732|NCT01154114|Drug|darapladib|darapladib 40 mg oral dose
69733|NCT01146132|Dietary Supplement|Luxembourg variant of Mediterranean diet + physical activity +/- wine|Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as "Luxembourg variant of the Mediterranean diet"
69734|NCT01146145|Drug|Ketamine|intravenous morphine titration combined to ketamine
69735|NCT01146158|Procedure|Axillary dissection for breast carcinomas|surgery Axillary dissection
69736|NCT01146171|Drug|BMS-844203 (CT-322)|Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
69737|NCT01146184|Device|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
69738|NCT01146197|Drug|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
69739|NCT01146210|Other|laboratory biomarker analysis|Correlative studies
69740|NCT01146223|Other|laboratory biomarker analysis|Correlative studies
69741|NCT00000944|Drug|Zidovudine|
69742|NCT00039624|Radiation|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
69743|NCT01146236|Device|Sutures|Orthopedic surgical wounds closed with sutures
69744|NCT01146236|Device|Staples|Orthopedic surgical wounds closed with metallic staples
69745|NCT01146249|Other|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
69746|NCT01146262|Other|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
70016|NCT01176565|Drug|Nicardipine hydrochloride|IV nicardipine will be initiated at a rate of 5 mg/hr and increased by 2.5 mg/hr increments will continue every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is > target SBP despite infusion of the maximum nicardipine dose for 30 min, a second agent can be used (Labetalol 5-20 mg IV bolus every 15 min) for another h.
69003|NCT01155271|Other|Rehabilitation|12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)
1 technical visit and 1 nursing visit every two months at home for the CPAP
69004|NCT01155284|Drug|Sitagliptin and Lansoprazole|Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo
Subjects age 11-17 years at Visit 2 will take 1 capsule once daily
Subjects age 18-45 years at Visit 2 will take 2 capsules once daily
69005|NCT01155284|Drug|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
69006|NCT01155297|Behavioral|Physical training|The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.
After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration.
69301|NCT01147757|Drug|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
69302|NCT01147770|Drug|progesterone|duration
69303|NCT01147783|Other|CT, MRI|
69304|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
69305|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
69306|NCT01147809|Drug|Eltrombopag olamine|thrombopoietin receptor agonist
69307|NCT01147809|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
69308|NCT00039962|Drug|PEGinterferon alfa-2a|
69309|NCT01147822|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
69310|NCT01147822|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
69311|NCT01150448|Drug|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
69312|NCT00040300|Drug|Racivir|
69313|NCT01150461|Drug|losartan|Losartan 50 mg b.i.d
69314|NCT01150461|Drug|placebo|Placebo b.i.d.
69315|NCT01150474|Drug|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
70076|NCT01183637|Procedure|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
70077|NCT01183650|Drug|Tadalafil|5 mg, administered orally, daily for 10 days
70078|NCT01183663|Drug|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
70079|NCT00000969|Drug|Zalcitabine|
70080|NCT00042926|Procedure|sentinel lymph node biopsy|
70081|NCT01183663|Drug|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
70082|NCT01183663|Drug|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
70083|NCT01183663|Drug|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
70084|NCT01183663|Drug|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
70085|NCT01183663|Drug|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
70086|NCT01183663|Drug|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
70087|NCT01183663|Drug|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
70088|NCT01183676|Drug|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
70089|NCT01183676|Drug|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
70090|NCT01183689|Behavioral|Self-regulation theory|Participants randomized to either of these two groups will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate either large or small changes.
70321|NCT01184118|Drug|fluticasone propionate|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
70322|NCT01184131|Other|Mentor Training|Four 2 hour sessions of Mentor Training
70323|NCT01184144|Drug|Pioglitazone|Pioglitazone, 30 mg, by mouth daily for 2 weeks
70324|NCT00042965|Drug|capecitabine|
70325|NCT01184157|Behavioral|Home screening|
69861|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
69862|NCT01151631|Device|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
69863|NCT01151644|Biological|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
69864|NCT01151657|Dietary Supplement|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
69865|NCT01151657|Dietary Supplement|Placebo|Placebo capsules containing maltodextrin
69866|NCT01151670|Drug|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
69867|NCT01151670|Drug|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
69868|NCT01151683|Dietary Supplement|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
69869|NCT01151683|Dietary Supplement|placebo|Two capsules of placebo per oral twice a day
69870|NCT00040391|Drug|Leucovorin|
69871|NCT01151696|Drug|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
69872|NCT01151696|Drug|Placebo|Placebo
69873|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection before vitrectomy
69874|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection after vitrectomy
69875|NCT01151735|Drug|C-1-esterase|1000 units of C-1-esterase inhibitor
69876|NCT01151735|Drug|C-1-esterase|1500 units of C-1-esterase inhibitor
69877|NCT01151735|Drug|placebo|placebo
69878|NCT01151748|Procedure|Intra-arterial infusion of chemotherapy|
70144|NCT01181362|Procedure|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
70017|NCT01176578|Other|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
70018|NCT01176591|Drug|Aprepitant|80 mg per session, oral administration.
70019|NCT01176591|Drug|Placebo|Placebo, one per session, oral administration
70020|NCT00042289|Drug|pretomanid|Women will receive pretomanid as prescribed by their clinicians. (Dosage will vary for each participant.)
70021|NCT01176604|Device|TheraSphere Treatment|Injection via arterial catheter of TheraSphere microspheres containing yttrium-90 (Y-90) to whole liver, lobar or segmental treatment delivered as a sequence of treatments using approximately 30 - 90 days apart.
70022|NCT01176617|Device|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
70023|NCT01176643|Other|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
70024|NCT01176669|Drug|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
70025|NCT01176695|Drug|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
70026|NCT01176695|Drug|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
70027|NCT01176708|Drug|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
70028|NCT01176708|Other|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
70029|NCT01176708|Other|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
70030|NCT01176721|Device|t-VNS verum|Active stimulation of the left auricle by t-VNS
70031|NCT00042289|Drug|atazanavir/ritonavir/tenofovir|Women will receive atazanavir/ritonavir/tenofovir as prescribed by their clinicians. (Dosage will vary for each participant.)
70032|NCT01176721|Device|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
70033|NCT01176734|Device|tVNS-Device|Active treatment with the t-VNS device.
70034|NCT01176747|Drug|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
69316|NCT01150474|Drug|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
69317|NCT01150487|Procedure|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
69318|NCT01150500|Device|MDT-4107 Zotarolimus-Eluting Coronary Stent|
69319|NCT01150526|Dietary Supplement|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
69320|NCT01150526|Dietary Supplement|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
69321|NCT01150526|Dietary Supplement|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
69322|NCT01150526|Dietary Supplement|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
69323|NCT00040313|Drug|pegaptanib sodium (Macugen)|
68400|NCT01161472|Drug|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
68401|NCT01161472|Drug|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
68402|NCT01161485|Behavioral|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
68403|NCT01163942|Drug|Early retreatment with ATG|Yes/no early retreatment with ATG
68404|NCT01163955|Other|Time to fatigue|5 minutes while playing video games
68405|NCT01163968|Behavioral|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
68406|NCT01163981|Other|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
68407|NCT01163994|Drug|ceftriaxone|intravenously, 2 g, qd, 15 days
68408|NCT01163994|Drug|doxycycline|orally, 100 mg, bid, 15 days
68409|NCT00041132|Drug|methotrexate|1000 mg/m^2 over days 2-3 of cycles 2,4,6,8
68410|NCT01163994|Other|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
70326|NCT01184157|Behavioral|Clinic screening|
70327|NCT01184170|Behavioral|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
70328|NCT01184183|Procedure|Comparing Accuseal Vs. Bovine Pericardial in CEA|Accuseal patch - The Goretex Company has since designed a new patch, "the Accuseal," which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.
Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis.
70329|NCT01184196|Drug|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
70330|NCT01184196|Drug|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
70331|NCT01184222|Device|great occipital nerve stimulation|Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
70332|NCT01184235|Drug|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
70333|NCT01184248|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
70334|NCT01184261|Behavioral|behavioral intervention|8 session behavioral intervention.
70335|NCT00042965|Drug|gemcitabine hydrochloride|
70336|NCT01177150|Drug|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
70337|NCT00042302|Drug|placebo + paclitaxel/carboplatin|
70338|NCT01177163|Drug|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
70659|NCT01182363|Behavioral|Project Solve Education|Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
70660|NCT01182376|Drug|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
70145|NCT01181375|Other|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
70146|NCT00042809|Other|laboratory biomarker analysis|Correlative studies
70147|NCT01181388|Procedure|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
70148|NCT01181388|Procedure|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
70149|NCT01181401|Drug|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
70150|NCT01181401|Drug|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
70151|NCT01181401|Radiation|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
70152|NCT01181414|Procedure|Atrio ventricular junction ablation with radio-frequency|Atrioventricular junction ablation by using radiofrequency energy.
70153|NCT01181414|Drug|Beta blocker/digoxine/amiodarone|Ventricular rate control by using drug treatment.
70154|NCT01181427|Drug|ABT-267|See arm description
70155|NCT01181427|Drug|Placebo|See arms description
70156|NCT01181427|Procedure|Blood Sample Collection|See arm description
70157|NCT01183767|Drug|Placebo|
70158|NCT01183780|Biological|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
70159|NCT01183780|Biological|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
70160|NCT01183780|Drug|Irinotecan|180 milligrams/square meter (mg/m^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
70404|NCT01181908|Drug|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
70263|NCT01177137|Behavioral|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
70264|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
70265|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
70266|NCT01177150|Drug|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
70267|NCT01179308|Other|General-epidural anesthesia and analgesia|General anesthesia will be induced with 1-3 µg/kg fentanyl (to a maximum of 150 µg) and 2-4 mg/kg propofol. Tracheal intubation will be facilitated by succinylcholine or a non-depolarizing muscle relaxant. Anesthesia will be maintained with sevoflurane in (80%-100%) oxygen, balance nitrogen, and fentanyl (0.5-1 µg/kg). The lungs will be mechanically ventilated to maintain end-tidal PCO2 near 40 mmHg. Normothermia — a distal esophageal temperature of 36°C — will be maintained with forced-air warming.
70268|NCT01179308|Other|Balanced general anesthesia and postoperative opioids|Patients will be pre-medicated with 0-3 mg IV midazolam and/or 0-2 μg/kg IV fentanyl. Prophylactic antibiotics will be given per surgical routine. An epidural catheter will be positioned at T4-T8 level before induction of anesthesia.
70269|NCT01179321|Other|Early referral to Dietitian for assessment and nutrition support|
70270|NCT01179334|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
70271|NCT01179334|Drug|Placebo|Placebo for 12 weeks
70272|NCT01179334|Drug|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
70273|NCT01179347|Drug|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
70274|NCT00042510|Biological|Treatment group|
70275|NCT01179347|Drug|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
68411|NCT01164007|Drug|bevacizumab [Avastin]|10 mg/kg iv, every 2 weeks
68412|NCT01164007|Drug|dacarbazine|800 mg/m2 iv, every 4 weeks
68413|NCT01164020|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
68414|NCT01164020|Other|Placebo (Dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
68415|NCT01164020|Other|Resistance training|resistance training twice a week for 24 weeks
68416|NCT01164033|Drug|RO5045337|single oral dose
68417|NCT01164046|Drug|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
68418|NCT01164046|Drug|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
68419|NCT01164059|Drug|Olanzapine|Olanzapine 10, 15, or 20 mg / day
68420|NCT00041132|Drug|vincristine|1.4 mg/m^2 on days 5 and 12 of cycles 1,3,5,7
68421|NCT01164059|Drug|Flupentixol|Flupentixol 6, 9, or 12 mg / day
68698|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
68699|NCT01149486|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
68700|NCT01149486|Drug|Hyzaar®|100/25 mg Tablets
68701|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
68702|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
68703|NCT01149525|Drug|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
68704|NCT01149525|Drug|Placebo|oral solution, twice per day (morning/evening), during 3 months
68705|NCT01149538|Drug|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
68706|NCT01149538|Dietary Supplement|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
68707|NCT01149564|Drug|iv ibuprofen|
68708|NCT00040157|Drug|ACH126-443 (Beta-L-Fd4C)|
70661|NCT01184651|Behavioral|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
70662|NCT01184664|Drug|Nicotine Patch|Varenicline + nicotine patch
70663|NCT00042991|Drug|gefitinib|Given orally
70664|NCT01184664|Drug|Placebo|Varenicline + placebo patch
70665|NCT01184664|Drug|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
70666|NCT01184677|Device|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
70667|NCT01184677|Device|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
70668|NCT01184690|Procedure|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
70669|NCT01184690|Procedure|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
70670|NCT01184703|Other|Low GI food|Comparison of carbohydrates in diabetic patients
70671|NCT01184716|Other|Vitamin D fortification|Bread and milk fortified with vitamin D3
70672|NCT01184755|Behavioral|Device-guided breathing|Participants instructed to practice daily for 15 minutes (guided and timed by the device used at home)
70673|NCT01184755|Behavioral|Device-guided breathing - used for 16 weeks|Participants are instructed to practice breathing using the RESPeRate device daily for 15 minutes (the session is timed and recorded on device used at home)
70674|NCT00042991|Radiation|radiation therapy|Undergo standard brain irradiation
70675|NCT01184755|Behavioral|Relaxation|Participants are instructed to use the device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
70676|NCT01184755|Device|RESPeRate|
70677|NCT01184755|Device|Sham RESPeRate|
70678|NCT01184781|Device|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
69800|NCT01154153|Drug|Placebo nasal spray|Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).
For children who were >=2 to <6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.
For children who were >= 6 yrs to <12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.
70405|NCT01181921|Drug|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
70406|NCT01181934|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
70407|NCT01181934|Drug|placebo|placebo - three times daily during each treatment period
70408|NCT01181934|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
70409|NCT01181947|Device|TEVAR|Thoracic endovascular aneurysm repair
70410|NCT01184456|Drug|Placebo|1 capsule per day for 90 days.
70411|NCT00042978|Drug|carboplatin|Given IV
70412|NCT01184482|Drug|cetuximab and lapatinib|Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly
Lapatinib: Start once daily on Day 1. Dose escalating cohorts:
750 mg (3 tabs)
1000 mg (4 tabs)
1250 mg (5 tabs)
70413|NCT01184495|Drug|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
70414|NCT01184495|Drug|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
70415|NCT01184508|Drug|Placebo|Administered orally once daily, for 12 weeks
70416|NCT01184508|Drug|LY2300559|300 mg administered orally once daily, for 12 weeks
70417|NCT01184534|Behavioral|Video|5 minute multimedia presentation (video)
70418|NCT01184534|Behavioral|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
70419|NCT01184547|Behavioral|Quality of Life questionaires|To assess Return to work and quality of life
70420|NCT01184560|Drug|Sibutramine|○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.
Treatment period: The total dosing period is 12 weeks.
Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily
Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
70421|NCT01184560|Drug|Orlistat|○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.
Treatment period: The total dosing period is 12 weeks.
Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily
Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
70422|NCT00042978|Drug|etoposide|Given IV
70276|NCT01179360|Other|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
70277|NCT01179373|Device|TMS, H coil|TMS, H Coil, High/ Low Frequency
70613|NCT01177761|Procedure|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
70614|NCT01177787|Device|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
70615|NCT01177787|Device|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
70616|NCT01177800|Drug|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
70617|NCT01177800|Drug|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
70618|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
70619|NCT00042367|Drug|Induction therapy (Regimen 1, Course 1, Cycle A1|2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.
12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.
Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.
3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.
Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)
70620|NCT01177813|Drug|BI 10773|BI 10773 low dose tablet once daily
70621|NCT01177813|Drug|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
70622|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
70623|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
70624|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
70625|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
70626|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
70627|NCT01179945|Other|non sodium benzoate containing test drinks|Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.
Each solution will be consumed over 5 minutes.
70628|NCT01179958|Behavioral|aerobic training|24 weeks of aerobic training, 4X/week
68709|NCT01152255|Drug|MK6186|Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose <= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose <= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
68710|NCT01152255|Drug|Comparator: Placebo|Placebo tablets taken orally for seven day
68711|NCT01152281|Other|Instrumental meta intervention|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
68712|NCT01152281|Other|Empowering meta-intervention|Empowering 30 min video with stories of people living with AIDS. Emphasizes individual control over behavior change.
68713|NCT01152281|Other|Control|Control messages to increase awareness of HIV risk
68714|NCT01152294|Behavioral|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
68715|NCT01152307|Behavioral|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
68716|NCT00040417|Procedure|Total Body Irradiation|
68717|NCT01152320|Behavioral|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
68718|NCT01152333|Drug|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
69007|NCT01155297|Behavioral|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
69008|NCT01155310|Drug|Helium/Oxygen 78%/22%|The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.
Patients will then receive the Air/Oxygen mixture with usual devices.
69009|NCT00040690|Biological|filgrastim|
69010|NCT01155310|Drug|Air/Oxygen|The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.
Patients will then receive the Air/Oxygen mixture with usual devices.
69011|NCT01155323|Device|etafilcon A|1-day soft contact lens
69012|NCT01155323|Device|omafilcon A|1-day soft contact lens
69013|NCT01155336|Drug|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
69801|NCT01154153|Drug|Claritin® Syrup|Children's Claritin® Syrup [5 mg of loratadine per 5 mL] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
69802|NCT01154166|Drug|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
69803|NCT01154166|Drug|Placebo|Placebo
69804|NCT01154179|Other|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
69805|NCT00040573|Drug|131I-TM-601|
69806|NCT01154192|Drug|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
69807|NCT01154192|Drug|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
69808|NCT01154218|Drug|crizotinib|Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.
Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.
Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.
Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC
69809|NCT01146288|Drug|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
69810|NCT01146301|Drug|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
69811|NCT01146314|Behavioral|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
69812|NCT00039663|Drug|Pravastatin|
69813|NCT01146327|Drug|PF-04620110|Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
70091|NCT00042926|Radiation|technetium Tc 99m sulfur colloid|
70423|NCT01184586|Device|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
70732|NCT01182441|Device|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
70733|NCT01182441|Drug|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
70734|NCT01182467|Radiation|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
70735|NCT01182480|Behavioral|Patient Relationship Management (PRM) Program|Patients will be contacted through SMS text messaging under the following circumstances:
7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.
3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages.
70736|NCT01182493|Device|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
70737|NCT00042861|Drug|leucovorin calcium|
70738|NCT01182506|Behavioral|Cogmed Working Memory Training Program|Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.
The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the "coach" (in this case, the PI and RSA) to review the training. A weekly "coach" phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home.
70739|NCT01182519|Behavioral|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
70740|NCT01182532|Other|Western therapy|Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.
Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;
70741|NCT00042289|Drug|amikacin|Women will receive amikacin as prescribed by their clinicians. (Dosage will vary for each participant.)
70742|NCT01175759|Drug|Skin test panel|Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L
Estradiol 1mmol/L
Estrone 3mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)
70743|NCT01175759|Drug|Skin test panel|Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L
Estradiol 1mmol/L
Estrone 3mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)
70629|NCT00042601|Drug|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
70630|NCT01179958|Behavioral|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
70631|NCT01179971|Dietary Supplement|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
69747|NCT01146262|Procedure|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
69748|NCT01146275|Radiation|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
69749|NCT01146288|Drug|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
69750|NCT01148537|Drug|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
69751|NCT01148563|Device|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
69752|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
69753|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
69754|NCT01148576|Drug|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
69755|NCT01148576|Drug|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
69756|NCT01148602|Other|LED stopwatch-clock timers|We will attach a large, "in-your-face" red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation.
69757|NCT01148615|Drug|Aflibercept (AVE0005)|Pharmaceutical form: solution for infusion
Route of administration: intravenous
69758|NCT00040027|Drug|thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|
69759|NCT01148615|Drug|Docetaxel (XRP6976)|Pharmaceutical form: solution for infusion
Route of administration: intravenous
69760|NCT01148628|Drug|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
69014|NCT01155336|Drug|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
69015|NCT01155349|Behavioral|InSight|A cognitive intervention designed to enhance speed of visual processing.
69016|NCT01155349|Other|No contact-control group|No contact-control group.
69017|NCT01155362|Biological|Human Placenta-Derived Cells PDA001 Intravenous Infusion|1 of 3 treatment doses (1 unit, 4 units, or vehicle control) intravenous infusion on days 0 and 7
69018|NCT01155375|Drug|Ferumoxytol|IV Ferumoxytol
69019|NCT01155375|Drug|Ferrous fumarate|oral iron preparation
69020|NCT00040690|Drug|cyclophosphamide|
69021|NCT01147328|Other|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
69022|NCT01147341|Drug|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
69023|NCT01147341|Drug|Placebo|prefilled saline syringe
69024|NCT01147354|Dietary Supplement|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
69025|NCT01147354|Other|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
69026|NCT00039871|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks
69027|NCT01147367|Behavioral|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
69028|NCT01147380|Biological|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
69324|NCT01150539|Other|16-week exercise training program|The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
69325|NCT01150539|Other|Control Group without PCOS|A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
69326|NCT01150565|Drug|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
69327|NCT01150578|Drug|No intervention|No intervention
70092|NCT01183702|Procedure|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
70093|NCT01183702|Other|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
70094|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
70095|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
70096|NCT01183728|Other|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
70097|NCT01183767|Drug|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
70098|NCT01176760|Drug|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
70099|NCT01176760|Other|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
70100|NCT01176773|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
70101|NCT01176786|Other|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
70102|NCT01176799|Drug|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
70103|NCT01176799|Drug|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
70104|NCT01176825|Behavioral|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
70105|NCT00042289|Drug|ethinyl estradiol oral contraceptive|Women will receive ethinyl estradiol oral contraceptive as prescribed by their clinicians. (Dosage will vary for each participant.)
70106|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
70107|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
70108|NCT01176851|Drug|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
70771|NCT01177982|Behavioral|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
70772|NCT01177982|Behavioral|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
70773|NCT01177982|Behavioral|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
70774|NCT01177982|Behavioral|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
70775|NCT01177982|Behavioral|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
70776|NCT01177995|Behavioral|Social Network Intervention|Social network leaders will communicate HIV prevention messages to members of their social networks.
70777|NCT01178008|Procedure|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
70778|NCT01178008|Procedure|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
70779|NCT01178021|Drug|Chloroquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2
70780|NCT01178021|Drug|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
70781|NCT00042367|Drug|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
70782|NCT01178034|Genetic|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
70783|NCT01180179|Drug|Famotidine|40mg once daily
70784|NCT01180192|Drug|oxygen|either 8 L/minute O2 via face mask for 2 hours
70785|NCT01180205|Drug|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
70227|NCT01181570|Drug|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
70228|NCT01181583|Behavioral|Tailored Internet-delivered CBT|This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are "prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
70556|NCT01179893|Procedure|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
70557|NCT01179906|Behavioral|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
70558|NCT01179906|Behavioral|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
70559|NCT01179919|Drug|Tamiflu|Capsule, 75 mg by mouth for 9 doses
70560|NCT01179932|Other|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
70561|NCT01179945|Other|benzoate containing test drinks|Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.
Each solution will be consumed over 5 minutes.
70562|NCT01182038|Device|BirthRite birthing seat|Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
70563|NCT01182051|Behavioral|CBT or relaxation training|8 weeks of CBT or relaxation training.
70564|NCT01182077|Drug|ASP015K|Oral
70565|NCT01182077|Drug|Midazolam|Oral
70566|NCT01182090|Procedure|Colposacropexy|In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
70567|NCT01182090|Procedure|Colposacropexy|In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
70568|NCT00042835|Other|laboratory biomarker analysis|Correlative studies
66056|NCT01132404|Drug|TAK-448|Phase 1 portion of study:
Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site
Phase 2 portion of the study:
Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months
66057|NCT01132417|Drug|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
66058|NCT01132430|Behavioral|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
66059|NCT01132430|Behavioral|Usual care|Standard medical care within 4-6 week period
66060|NCT01132443|Drug|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily
66061|NCT01132456|Device|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
66062|NCT01132469|Procedure|Endoscopic Submucosal Dissection|5-years follow-up after Endoscopic Submucosal Dissection
66063|NCT01132482|Drug|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
66064|NCT00038766|Drug|semapimod|semapipmod 60 mg IV x 5 days
66065|NCT01132482|Drug|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
66066|NCT01132495|Other|Stenting plus OMT|FFR guided PCI, plus OMT
66067|NCT01132495|Other|Standard of care|OMT alone
66369|NCT01127672|Drug|corticosteroid injection|Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.
This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.
The patient will be monitored for 10 minutes in clinic for adverse reactions.
66370|NCT00038337|Procedure|Health Literacy|
66371|NCT01127685|Device|Smart_Step weight bearing insole|The use of a weight-bearing measuring device in determining weight-bearing deficits following Anterior Cruciate Ligament Reconstruction
66372|NCT01127724|Drug|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
66373|NCT01127737|Behavioral|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
67036|NCT01164163|Drug|ruxolitinib phosphate|
67037|NCT01164163|Other|laboratory biomarker analysis|
67038|NCT01164163|Other|pharmacological study|
67039|NCT01164176|Drug|everolimus|
67040|NCT01164176|Other|laboratory biomarker analysis|
67041|NCT01164189|Biological|Bevacizumab|Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
67042|NCT01164189|Drug|Temozolomide|Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
67043|NCT01164202|Drug|sunitinib malate|
67044|NCT01164202|Procedure|quality-of-life assessment|
67045|NCT00041171|Drug|docetaxel|
67046|NCT01164202|Procedure|transarterial chemoembolization|
67047|NCT01164215|Drug|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
67048|NCT01164215|Drug|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
67049|NCT01164215|Drug|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
67050|NCT01164228|Drug|gemcitabine hydrochloride|Given IV
66129|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66130|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66131|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66132|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
66133|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66134|NCT00038532|Drug|Efavirenz|
66135|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66136|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
69903|NCT01181141|Drug|Enoxaparin sodium 20mg|
69904|NCT01181154|Drug|rituximab (Mabthera®)|1000 mg at day 1 and day 15
69905|NCT01181154|Drug|Placebo|equivalent volume total
69906|NCT00042796|Other|pharmacological study|Correlative studies
69907|NCT01181167|Drug|edoxaban|
69908|NCT01181167|Drug|enoxaparin sodium|
69909|NCT01183273|Procedure|Laparoscopic Surgery|laparoscopic gastric bypass will be performed using standard of care procedure.
69910|NCT01183286|Behavioral|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
69911|NCT01183286|Behavioral|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
69912|NCT00042926|Other|immunohistochemistry staining method|
69913|NCT01183299|Other|Dietary salt intake|
69914|NCT01183312|Drug|Flumazenil|Sublingual flumazenil
69915|NCT01183325|Device|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
69916|NCT01183351|Behavioral|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
69917|NCT01183364|Drug|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
69918|NCT01183390|Drug|Anastrozole|1 mg Tablets
69919|NCT01183390|Drug|Anastrozole|1 mg Tablets
69920|NCT01183416|Drug|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are ~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
70569|NCT01182116|Procedure|J Pouch|Comparing J pouch, side to end coloanal surgery
70570|NCT01182129|Drug|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
70571|NCT01182129|Drug|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
70572|NCT01182142|Drug|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
70573|NCT01182155|Procedure|Exhaled Breath Sampling|Standard of care
69686|NCT01151215|Drug|anastrozole|Tablet, oral, od
69687|NCT01151215|Drug|Placebo|Tablet, oral
69688|NCT01151228|Other|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
69689|NCT01151241|Procedure|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
69690|NCT00040378|Drug|Placebo replacement for vitamin E|1 placebo pill daily
69691|NCT01151241|Other|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
69692|NCT01151241|Other|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
69693|NCT01151254|Drug|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
69694|NCT01151254|Other|Propofol|Propofol for sedation in the CVICU
69695|NCT01151267|Other|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
69696|NCT01151267|Device|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
69697|NCT01151280|Device|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
69698|NCT01151306|Drug|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
66374|NCT01127737|Behavioral|Placebo|Completed surveys
66375|NCT01127750|Drug|FTY720|
66376|NCT01127763|Drug|RAD001|
66377|NCT01127763|Drug|Carboplatin|
66378|NCT01127776|Device|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
66379|NCT01127776|Other|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
66380|NCT01127789|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
66381|NCT00038350|Behavioral|Lingual Strengthening|8 week lingual strengthening exercise protocol
66382|NCT01127828|Other|Arla Yoghurt with no probiotic|two servings of 200 ml of investigational products per day
66383|NCT01127828|Other|Probiotic yoghurt (Cultura)|200 ml per day
66384|NCT01127841|Drug|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
66385|NCT01127867|Dietary Supplement|dietary intervention|dietary intervention
66386|NCT01127880|Drug|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
66387|NCT01127880|Drug|Placebo|.9% Normal Saline as a placebo
66388|NCT01127893|Biological|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
66389|NCT01127893|Biological|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
66672|NCT01133522|Biological|Evolocumab|Administered by subcutaneous injection
66673|NCT00038844|Drug|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
66674|NCT01133522|Biological|Placebo|Administered by subcutaneous injection
66675|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
66676|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
66677|NCT01133561|Drug|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
66137|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
66138|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66139|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66140|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66141|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
66142|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66143|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66144|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
66145|NCT01132521|Drug|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
66146|NCT01132521|Drug|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
66147|NCT01132547|Drug|cyproheptadine hydrochloride|Given orally
66148|NCT01132547|Other|placebo|Given orally
66149|NCT01132560|Genetic|RNA analysis|
66150|NCT01132560|Genetic|gene expression analysis|
66151|NCT00038766|Drug|semapimod|IV 30 mg x 5 days
66152|NCT01132560|Genetic|reverse transcriptase-polymerase chain reaction|
66153|NCT01132560|Other|laboratory biomarker analysis|
66154|NCT01132573|Drug|entinostat|Given PO
66155|NCT01132573|Drug|clofarabine|Given IV
66445|NCT01135472|Drug|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
66446|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
66447|NCT01135498|Drug|bevacizumab [Avastin]|Intravenous repeating dose
66448|NCT01135498|Drug|eloxatin|Intravenous repeating dose
69921|NCT01183429|Drug|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. *High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
70464|NCT01179737|Drug|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
70465|NCT01179750|Device|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
70466|NCT00042575|Drug|Duloxetine|
70467|NCT01179763|Other|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
70468|NCT01179776|Drug|Ilomedin|Ilomedin
70469|NCT01179776|Drug|Placebo|i.v saline
70470|NCT01179776|Drug|Ilomedin|
70471|NCT01179776|Drug|Ilomedin and standard low dose treatment|
70472|NCT01179789|Behavioral|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform
70473|NCT01179789|Dietary Supplement|VSL#3®|probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
70474|NCT01179789|Dietary Supplement|AISA-5203-L|fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
70475|NCT01179789|Dietary Supplement|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
70476|NCT01179802|Other|Strenuous Endurance exercise|"Jungfraumarathon": Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters.
70477|NCT00042588|Drug|Recombinant Chimeric Monoclonal Antibody|
70478|NCT01179828|Drug|Oxycodone 15mg|15mg single administration p.o.
70479|NCT01179828|Drug|Clobazam|20mg single administration p.o.
70480|NCT01181960|Drug|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
66913|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
66914|NCT01131182|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
66915|NCT01131182|Drug|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
66916|NCT01131182|Drug|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
66917|NCT01131195|Biological|bevacizumab, Paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.
66918|NCT01131195|Biological|Bevacizumab, Cyclophosphamide, Capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
66919|NCT00000939|Drug|Didanosine|
66920|NCT00038610|Drug|Mesna|600 mg/m^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
66921|NCT01131208|Genetic|gene expression analysis|
66922|NCT01131208|Other|laboratory biomarker analysis|
66923|NCT01131221|Other|laboratory biomarker analysis|
66924|NCT01131234|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
65996|NCT00038961|Drug|Fondaparinux Sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
65997|NCT01134627|Drug|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
65998|NCT01134653|Other|Jump Stretch|distraction with early mobilization
65999|NCT01134666|Drug|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
66000|NCT01134679|Behavioral|Multi-disciplinary disease management approach|Follow up with phone calls
66678|NCT01133561|Drug|actozone B|one tablet of vehicle without active ingredient pioglitazone
66679|NCT01133574|Drug|SLV354 capsules|20 mg
66680|NCT01133574|Drug|SLV354 capsules|60 mg
66681|NCT01133574|Drug|SLV354 capsules|120 mg
66682|NCT01133574|Drug|SLV354 capsules|250 mg
66683|NCT01133574|Drug|SLV354 capsules|500 mg
66684|NCT00000940|Drug|Amprenavir|
66685|NCT00038844|Drug|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
66686|NCT01133574|Drug|SLV354 capsules|750 mg
66687|NCT01133574|Drug|SLV354 capsules|1000 mg
66688|NCT01133574|Drug|SLV354 capsules|1250 mg
66689|NCT01133574|Drug|Placebo capsules|placebo
66690|NCT01133574|Drug|SLV354 capsules|low dose group 1
66691|NCT01133574|Drug|SLV354 capsules|high dose group 1
66692|NCT01133574|Drug|SLV354 capsules|low dose group 2
66693|NCT01133574|Drug|SLV354 capsules|high dose group 2
66694|NCT01133574|Drug|Placebo capsules|placebo
66695|NCT01133587|Other|wait list control|Patient-guided admissions contract regarding "patient-guided admissions" starting a year after.
66696|NCT00038844|Drug|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
66697|NCT01133587|Behavioral|admissions contract|contract regarding "patient-guided admissions" starting immediately
66975|NCT01128764|Behavioral|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
66976|NCT00038428|Drug|TLK286|
66977|NCT01128764|Behavioral|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
66449|NCT01135498|Drug|capecitabine [Xeloda]|Oral repeating dose
66450|NCT01135498|Drug|erlotinib [Tarceva]|Oral repeating dose
66451|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
66452|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
66453|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
66454|NCT01135511|Drug|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
66455|NCT01135511|Drug|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
66456|NCT01127893|Biological|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
66457|NCT01127906|Drug|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
66458|NCT00038363|Procedure|Rehabilitation|
66459|NCT01127906|Drug|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
66460|NCT01127906|Drug|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
66461|NCT01127906|Drug|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
66462|NCT01127906|Drug|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
66463|NCT01127919|Behavioral|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
66464|NCT01127919|Other|Cognitive Component|Provide general information about health and fitness
66465|NCT01127932|Behavioral|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
66466|NCT01127932|Behavioral|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
66467|NCT01127945|Drug|statin|adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy
acute heart failure therapy
66752|NCT01130974|Device|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
66753|NCT01130987|Other|Computerized handoff tool|Computer program that facilitates accurate transmission of patient information between residents
70481|NCT01181960|Drug|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
70482|NCT01181960|Drug|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
70483|NCT01181960|Drug|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
70484|NCT00000245|Drug|Desipramine|
70504|NCT01184066|Behavioral|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
70505|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
70506|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
70507|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
70508|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
70509|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
70510|NCT00042952|Procedure|therapeutic conventional surgery|Undergo surgical resection
70511|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
70512|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
70513|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
70514|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
70515|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
70516|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
70517|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
66001|NCT01134692|Drug|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
66002|NCT01134705|Drug|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
66003|NCT01134705|Drug|Placebo Nasal Aerosol|HFA Vehicle Aerosol
66004|NCT01134718|Drug|TMC435 (G006)|one morning dose of 150 mg
66005|NCT01134718|Drug|TMC435 (F021)|one morning dose of 150 mg
66006|NCT01134718|Drug|TMC435 (G007)|one morning dose of 150 mg
66007|NCT00038961|Other|Placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
66008|NCT01134731|Drug|paliperidone|1-5 mg daily (QD)
66009|NCT01134731|Drug|lithium|300-1500mg QD
66010|NCT01127061|Behavioral|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 80% of heart rate reserve and exercising 60 minutes 4-7 days per week.
66011|NCT01127074|Biological|KS24.22 cells|The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).
Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites.
66012|NCT01127087|Drug|Oxazyme|Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.
Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.
66013|NCT00038285|Procedure|Amputation Prevention|
66313|NCT01129934|Drug|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
66314|NCT01129934|Drug|morphine|Administration of intravenous morphine 0.1 mg/kg
66315|NCT01129947|Drug|DHEA|DHEA 25 mg tid
66316|NCT01129960|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
66317|NCT01129960|Drug|Placebo|Tablets will be used.
66978|NCT01128777|Behavioral|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
66979|NCT01128777|Behavioral|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
66980|NCT01128790|Other|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
66981|NCT01128790|Other|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
66982|NCT01128803|Procedure|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration > 2mm
66983|NCT01128816|Device|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
66984|NCT01128829|Other|Water|60 ml of water were drank 10 min before doing a OGTT
66985|NCT01128829|Other|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
66986|NCT01128842|Drug|Neratinib + Capecitabine|Neratinib: 240 mg, continuous daily OD Capecitabine: 1500 mg/m^2, BID
66987|NCT00038441|Drug|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
66988|NCT01128855|Drug|3 mg/kg GSK2402968|Weekly subcutaneous injection
66989|NCT01128855|Drug|6 mg/kg GSK2402968|Weekly subcutaneous injection
66990|NCT01131299|Other|Placebo|2 tablets PO 3 times a day for 12-14 weeks
66991|NCT01131299|Drug|Alpha-CD|2g PO 3 times a day for 12-14 weeks
66992|NCT01131325|Drug|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
66993|NCT01131351|Drug|OPC-67683|Dosage-500-800 mg Strength 250-400 mg Frequency b.i.d.
66068|NCT01132508|Device|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
66069|NCT01134874|Behavioral|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
66754|NCT01130987|Behavioral|Team training|Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
66755|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
66756|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
66757|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
66758|NCT00038610|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
66759|NCT01131000|Other|Normal Saline|Normal Saline, 100 ml, Single-dose
66760|NCT01131013|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
66761|NCT01131013|Drug|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
66762|NCT01131013|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
66763|NCT01133613|Drug|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
66764|NCT01133626|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
66765|NCT01133626|Drug|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
66766|NCT01133626|Drug|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
66767|NCT01133626|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
66768|NCT01133639|Drug|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
66769|NCT01133639|Drug|Placebo|Placebo plus standard of care
66770|NCT00038857|Procedure|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
66771|NCT01133652|Device|Veinviewer|Veinviewer machine
66772|NCT01133652|Device|Ultrasound|Ultrasound
66773|NCT01133652|Other|Conventional technique|Conventional IV placement by nurses
66774|NCT01133665|Drug|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
70518|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
70519|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
70520|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
70521|NCT00042952|Other|laboratory biomarker analysis|Correlative studies
70522|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
70523|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
70786|NCT01180205|Drug|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
70787|NCT01180205|Drug|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
70788|NCT01180205|Drug|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
70789|NCT01180218|Procedure|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
70790|NCT01180218|Procedure|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
70791|NCT00042679|Drug|Gemcitabine|
70792|NCT01180231|Drug|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
70793|NCT01180231|Other|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
70794|NCT01180244|Device|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
70795|NCT01180244|Device|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
70796|NCT01180283|Drug|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
70797|NCT01180296|Drug|oral micronized progesterone|400 mg oral micronized progesterone nightly from 16 to 34 weeks vs placebo
66318|NCT01129986|Device|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
66319|NCT01129999|Behavioral|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
66320|NCT01129999|Behavioral|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
66321|NCT00038558|Drug|Adriamycin|
66322|NCT01130012|Behavioral|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
66323|NCT01130012|Behavioral|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
66324|NCT01132807|Drug|Etoposide phosphate|Given IV
66325|NCT01132807|Drug|prednisone|Given PO
66326|NCT01132807|Drug|Radiation Therapy|Undergo radiation therapy
66327|NCT01132807|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
66328|NCT01132807|Procedure|computed tomography|Undergo FDG PET/CT
66329|NCT01132807|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
66330|NCT01132820|Drug|Cediranib Maleate|Given PO
66331|NCT00038818|Biological|CD8 Depleted Donor Lymphocyte|
66332|NCT01132820|Other|Laboratory Biomarker Analysis|Correlative studies
66333|NCT01132833|Other|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
66334|NCT01132833|Other|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
66335|NCT01132833|Other|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
66612|NCT01125761|Drug|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
66613|NCT01125761|Drug|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
66614|NCT00038168|Drug|Estramustine|Intravenous dose
66070|NCT01134887|Behavioral|Four Habits Model|The providers randomized to the intervention arm received training in Habit 1 of the Four Habits Model.
66071|NCT01134900|Other|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
66072|NCT01134926|Drug|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
66073|NCT01134952|Drug|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
66074|NCT01134965|Drug|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
66075|NCT00000239|Drug|Buprenorphine|
66076|NCT00000940|Drug|Stavudine|
66077|NCT00038987|Biological|Wetvax (APSV)|
66078|NCT01134965|Drug|Digoxin|Digoxin 0.5 mg as single dose
66079|NCT01134978|Behavioral|Practice Order|Blocked order - predictable
Random order - unpredictable
66080|NCT01134991|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
66081|NCT01135004|Procedure|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
66082|NCT01135017|Drug|Dronedarone|Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)
66083|NCT01135017|Drug|Placebo (for Dronedarone)|Film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)
66084|NCT01135030|Procedure|Total knee|Primary Total knee
66085|NCT01135043|Behavioral|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
66086|NCT01135043|Behavioral|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
66087|NCT01135056|Device|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
66088|NCT00039000|Drug|HSPPC-96 or Oncophage|
66390|NCT01130025|Drug|Warfarin|Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.
67051|NCT01164228|Drug|sunitinib malate|Given
67052|NCT01164267|Drug|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
67053|NCT01164280|Other|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
67054|NCT01164293|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
67055|NCT01164306|Behavioral|LifeSkills Training|LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.
Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions.
67056|NCT00000954|Drug|Vincristine sulfate|
67057|NCT01156545|Drug|BIBW 2992|BIBW 2992 40mg, once a day, oral intake, every day
67058|NCT01156545|Drug|simvastatin|simvastatin 40mg, once a day, oral intake, every day.
67059|NCT01156571|Drug|cangrelor P2Y12 (platelet) inhibitor|
67060|NCT01156571|Drug|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
67061|NCT01156571|Drug|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
67062|NCT01156584|Biological|Toca 511|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
67063|NCT00040781|Other|pharmacological study|Correlative studies
67064|NCT01156584|Drug|5-FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
67065|NCT01156597|Drug|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
67066|NCT01156610|Behavioral|Tobacco Treatment|Comparison of integrated cessation counseling tools with the normal standard of care.
Both the intervention and control clinics will be provided with tools for visit-based "best practices" for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.
Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol).
66156|NCT01132573|Other|pharmacological study|Correlative studies
70798|NCT01180296|Drug|Identical Placebo tablet|placebo taking nightly from 16 to 34 weeks
70799|NCT01180322|Drug|Cytarabine|Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)
Consolidation therapy:
Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).
Elderly patients (>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2).
70800|NCT01180322|Drug|Idarubicin|First induction therapy:
Arm A, C, D:
12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.
Arm B:
12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.
Second induction therapy:
Arm A, C, D:
12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)
Arm B:
12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups).
70801|NCT01180322|Drug|Etoposide|Induction therapy:
Arm A, C, D:
100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.
Arm B:
100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 6+8.
70802|NCT00042679|Drug|Carboplatin|
69922|NCT01183442|Drug|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
69923|NCT00042926|Procedure|conventional surgery|
69924|NCT01183455|Drug|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
69925|NCT01183455|Drug|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
69926|NCT01183468|Biological|Aralast NP 45 mg dose|- 45 mg/kg/week
69927|NCT01183468|Biological|Aralast NP 90 mg dose|- 90 mg/kg/week
69928|NCT01183468|Biological|Aralast NP 180 mg dose|- 180 mg/kg/week
69929|NCT01183481|Drug|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
69930|NCT00042289|Drug|delamanid|Women will receive delamanid as prescribed by their clinicians. (Dosage will vary for each participant.)
69931|NCT01176461|Biological|BMS-936558|BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen [HLA] unrestricted)
66615|NCT01125774|Drug|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
66616|NCT01125774|Drug|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
66617|NCT01125787|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
66618|NCT01125800|Drug|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
66619|NCT01125813|Biological|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
66620|NCT01125852|Procedure|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
66621|NCT01125852|Procedure|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
66622|NCT01125865|Device|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
66623|NCT01125865|Device|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
66624|NCT00000938|Drug|doxycycline|
66625|NCT00038376|Drug|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
66626|NCT01128179|Drug|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
66627|NCT01128192|Drug|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
66628|NCT01128218|Drug|Tumor fluorescence|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
66629|NCT01128244|Dietary Supplement|Vitamin B6|Subjects will receive vitamin B6 supplementation.
66630|NCT01128244|Procedure|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
66631|NCT01128257|Drug|alendronate|As prescribed by physician
66632|NCT01128257|Drug|ibandronate [Bonviva/Boniva]|As prescribed by physician
66925|NCT01131234|Drug|Cediranib Maleate|Given PO
66926|NCT01131234|Other|Pharmacological Study|Correlative studies
66391|NCT01130025|Drug|Innohep®|Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
66392|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
66393|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
66394|NCT01130064|Biological|QAX576|every 3 weeks via intravenous infusion
66395|NCT01130064|Drug|Placebo|every 3 weeks via intravenous infusion
66396|NCT01130077|Biological|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
66397|NCT01130077|Biological|Poly-ICLC|Vaccine given every 3 weeks
66398|NCT00038558|Drug|Bleomycin|
66399|NCT01130090|Device|Adjustment of back-up respiratory rate on bi-level ventilator|3 consecutive nights in randomized order, in either "S" (Spontaneous) mode, "ST" (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in "ST" (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort
66400|NCT01130103|Drug|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
66401|NCT01130103|Behavioral|Prolonged Exposure Therapy|Weekly for 10 weeks
66402|NCT01130129|Other|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
66403|NCT01130142|Drug|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
66404|NCT01130142|Drug|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
66405|NCT01130168|Drug|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
66406|NCT01130168|Drug|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
66407|NCT01130168|Drug|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
66408|NCT01130181|Drug|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
66409|NCT00038558|Drug|Vinblastine|
66410|NCT01130181|Drug|Placebo|Matching placebo
66157|NCT01132573|Other|laboratory biomarker analysis|Correlative studies
66158|NCT01132586|Drug|Lenalidomide|Given PO
66159|NCT01132586|Drug|Cytarabine|Given IV
66160|NCT01132586|Drug|Idarubicin|Given IV
66161|NCT01132586|Other|Pharmacological Study|Correlative studies
66162|NCT00038766|Drug|placebo|placebo IV
66163|NCT01132586|Other|Laboratory Biomarker Analysis|Correlative studies
66164|NCT01132599|Dietary Supplement|C-11 choline|
66165|NCT01132599|Radiation|18F-fluoromethylcholine|
66166|NCT01132612|Drug|AIN457|secukinumab
66167|NCT01132612|Drug|Placebo|placebo
66168|NCT01132625|Drug|AUY922|
66169|NCT01132638|Drug|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
66170|NCT01132638|Drug|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
66171|NCT01132651|Other|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
66172|NCT01132651|Other|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
66173|NCT00038779|Procedure|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
66174|NCT01132664|Drug|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
66175|NCT01135264|Behavioral|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
66176|NCT01135264|Behavioral|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
69932|NCT01176474|Biological|NY-ESO-1 157-165 (165V)|The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.
Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.
Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment.
69933|NCT01176474|Drug|Nivolumab|Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).
Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.
Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate.
69934|NCT01176474|Biological|gp100:280-288 (288V)|The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.
Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.
Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity.
69935|NCT01176474|Drug|Montanide ISA 51 vegetable grade (VG)|Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion.
69936|NCT01176474|Drug|Ipilimumab|Ipilimumab will be given at the following dosage: 3 mg/kg.
Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate.
70485|NCT00000967|Drug|Zidovudine|
70486|NCT00042835|Drug|paclitaxel|Given IV
70487|NCT01181973|Drug|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
70488|NCT01181973|Drug|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
70489|NCT01181973|Drug|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
70490|NCT01181973|Drug|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
70491|NCT01181986|Drug|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
70492|NCT01181986|Drug|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
70493|NCT01181986|Drug|Placebo SC|Placebo sc BID/10days
70494|NCT01181986|Drug|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
66927|NCT01131234|Other|Laboratory Biomarker Analysis|Correlative studies
66928|NCT01131247|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
66929|NCT01131260|Device|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
66930|NCT01131273|Drug|methadone|12 weeks of methadone maintenance with counseling
66931|NCT00038610|Drug|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
66932|NCT01131273|Drug|buprenorphine-naloxone (Suboxone) for 12 weeks|12 weeks of maintenance with counseling
66933|NCT01133912|Drug|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
66934|NCT01133925|Device|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
66935|NCT01133925|Device|Sirolimus Eluting Stent|Cypher stents implanted in overlap
66936|NCT01133925|Device|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
66937|NCT01133925|Device|Zotarolimus eluting stent|Endeavor stents implanted in overlap
66938|NCT01133951|Drug|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
66939|NCT01133951|Drug|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
66940|NCT00038857|Drug|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
66941|NCT01133964|Dietary Supplement|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
66942|NCT01133977|Drug|Dacarbazine|Dacarbazine (1000 mg/m2) IV infusion over 60 minutes on Day 1 of a 21-day cycle.
66943|NCT01133977|Drug|E7080|Test product: dose and mode of administration: E7080 will be provided as 1 mg, 4 mg, and 10 mg tablets. E7080 will be self-administered orally by patients, once-daily, over 3 weeks during each cycle. For the Phase Ib portion, the dose will be 16 mg, 20 mg, or 24 mg and for the Phase II portion, the dose will be the MTD as determined in the Phase Ib portion of the study.
Number of cycles of E7080: until disease progression or unacceptable toxicity develops.
66698|NCT01133600|Drug|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is <30ml/min.
66699|NCT01133600|Drug|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
66700|NCT01125878|Dietary Supplement|Placebo|placebo
66701|NCT00038168|Drug|Taxol|Intravenous dose
66702|NCT01125878|Dietary Supplement|Starch composite B|fiber mixture
66703|NCT01125878|Dietary Supplement|Starch composite C|fiber mixture
66704|NCT01125878|Dietary Supplement|Starch composite D|fiber mixture
66705|NCT01125891|Drug|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
66706|NCT01125891|Drug|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
66707|NCT01125904|Drug|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
66708|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
66709|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
66710|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
66711|NCT01125930|Drug|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
66712|NCT00038181|Drug|Thalidomide|
66713|NCT01125930|Drug|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
66714|NCT01125943|Drug|Acetylcholine|Intra-arterial infusion
66715|NCT01125943|Drug|Nitroprusside|Intra arterial infusion
66716|NCT01125943|Drug|Bevacizumab|Intra arterial infusion
66177|NCT01135290|Drug|Aquaphor|
66178|NCT01135290|Drug|HP828-101|
66468|NCT01127958|Device|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
66469|NCT00038363|Procedure|Subacute care|
66470|NCT01127958|Device|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
66471|NCT01127984|Drug|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
66472|NCT01127984|Procedure|drainage system|application of vacuum drainage system
66473|NCT01128023|Other|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
66474|NCT01128049|Behavioral|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
66475|NCT01128049|Procedure|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
66476|NCT01128049|Drug|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
66477|NCT01128075|Device|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
66478|NCT01128075|Device|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
66479|NCT01130233|Procedure|laparoscopic rectal resection|laparoscopic rectal resection
66480|NCT01130246|Drug|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
66481|NCT01130246|Drug|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
66482|NCT01130259|Drug|iniparib|5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
66483|NCT01130272|Drug|JNJ-27018966|oral tablets
70495|NCT01181986|Drug|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
70496|NCT01181999|Drug|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
70497|NCT00042835|Drug|carboplatin|Given IV
70498|NCT01182012|Behavioral|Lifestyle counseling|Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
70499|NCT01182025|Other|Western therapy|Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.
Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;
70500|NCT01182025|Drug|Xiyanping Injection|Dosage for child medication:
5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor.
70501|NCT01182025|Drug|Xiyanping Injection with western medicine|Symptomatic treatment using the same treatment methods in western therapy group;
Symptomatic treatment using the same treatment methods in Xiyanpin injection group.
70502|NCT01184053|Drug|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
70503|NCT01184066|Behavioral|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
70524|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
70525|NCT01177514|Drug|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
70526|NCT00042328|Drug|Valacyclovir|
70527|NCT01177540|Drug|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
70528|NCT01177540|Drug|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
70529|NCT01177553|Procedure|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
66014|NCT01127100|Drug|transdermal fentanyl matrix, gabapentin|transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.
Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained.
66015|NCT01127113|Other|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
66016|NCT01127113|Other|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
66017|NCT01127126|Drug|Bryophyllum pinnatum, Placebo in form of Lactose|Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.
Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d.
66018|NCT01127152|Procedure|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
66019|NCT01127165|Drug|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1~2 weeks to 3~4mg/kg/day.
66020|NCT01127165|Drug|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2~4 weeks to 6~8mg/kg/day.
66021|NCT01127178|Drug|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
66022|NCT01127191|Other|military equipment|Military exercise of 24 hours
66023|NCT01127204|Drug|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
66024|NCT00038298|Drug|Placebo|Placebo given 3 times weekly
66025|NCT01127204|Drug|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
66026|NCT01127217|Drug|amlodipine/losartan|amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
66027|NCT01127217|Drug|amlodipine|amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
66028|NCT01129440|Device|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
66029|NCT01129440|Device|Glass Ionomer Sealant|Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.
After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar.
66717|NCT01125956|Behavioral|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
66718|NCT01125956|Behavioral|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
66994|NCT01131364|Drug|F16IL2 in combination with doxorubicin|Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.
Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent.
66995|NCT01131377|Drug|acetazolamide|If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.
If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip.
66996|NCT01131377|Drug|Saline|They will receive saline 50ml via IV q 24h.
66997|NCT01131390|Device|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
66998|NCT01131416|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
66999|NCT00038623|Drug|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
67000|NCT01131429|Drug|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
67001|NCT01131429|Drug|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
67002|NCT01131429|Drug|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
67003|NCT01131429|Drug|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
67004|NCT01131429|Drug|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
67005|NCT01131429|Drug|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
67006|NCT01131455|Biological|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
67007|NCT01131468|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
67008|NCT01131481|Device|Intraocular lens|
66484|NCT01130272|Drug|Placebo|Matching placebo oral tablets twice daily
66485|NCT00038558|Drug|DTIC|
66486|NCT01130285|Genetic|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
66487|NCT01130298|Drug|Testosterone Gel 1.62%|5 grams
66775|NCT01133678|Drug|Everolimus escalating dose|Phase I Portion (2 21-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus escalating dose
66776|NCT01133678|Drug|Everolimus or Placebo|Phase II Portion (2 28-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus dose determined in phase I
66777|NCT01133691|Dietary Supplement|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
66778|NCT01133704|Biological|sipuleucel-T|
66779|NCT01133704|Biological|APC-Placebo|
66780|NCT01133730|Drug|Active treatment|US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
66781|NCT00038857|Drug|Melphalan|140 mg/m^2 on day -8
66782|NCT01133730|Drug|Placebo Arm|US-guided TFP block with 20ml of 5% dextrose solution
66783|NCT01133743|Drug|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
66784|NCT01133756|Drug|E7080|Test product: dose and mode of administration:
E7080 will be provided as 1 mg, 4 mg, and 10 mg tablets. E7080 will be self-administered orally by patients, once-daily, over 3 weeks during each cycle. For the Phase Ib portion, the dose will be 16 mg, 20 mg, or 24 mg and for the Phase II portion, the dose will be the MTD as determined in the Phase Ib portion of the study.
Number of cycles of E7080: until progression or unacceptable toxicity develops.
66785|NCT01133756|Drug|Carboplatin|Comparator dose and mode of administration: Carboplatin (AUC 4) given by IV infusion over 30 minutes on Day 1 of a 21-day cycle.
Number of cycles: approximately 6.
66786|NCT01125982|Drug|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
66787|NCT01125995|Radiation|early CCRT|patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.
radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy).
66788|NCT01125995|Radiation|late CCRT|patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.
radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy).
70530|NCT01177553|Device|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
70531|NCT01177566|Drug|pimecrolimus|pimecrolimus 1% cream twice daily
70532|NCT01177566|Device|topical medical device|Eletone cream three times daily
70533|NCT01177579|Dietary Supplement|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
70534|NCT01177592|Device|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
70535|NCT01177605|Other|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
70536|NCT01177631|Procedure|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
70537|NCT00042341|Drug|clofarabine (IV formulation)|
70538|NCT01177644|Drug|PDS 1.0|
70539|NCT01177657|Procedure|Stool sampling|Stool samples collected and checked for the presence of rotavirus
69642|NCT01146041|Drug|Rivastigmine|Rivastigmine 1.5 mg Capsules
69643|NCT01146054|Device|CyberKnife based stereotactic radiotherapy|Initial orthogonal images will be obtained to confirm location of fiducial seeds.
Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.
Quality assurance will be performed as per standard practice at each participating institution.
69644|NCT00039611|Drug|leucovorin calcium|
69645|NCT01146054|Drug|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv
69646|NCT01146054|Drug|Fludeoxyglucose (18F)|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv
69647|NCT01146067|Drug|Rivastigmine|Rivastigmine capsules 1.5 mg
66030|NCT01129453|Biological|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10^6, 10^7, 10^8, or 10^9 CFU per mL. Route: oral.
66336|NCT01132846|Other|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
66337|NCT01132846|Drug|Nesiritide|Active Comparator: Low Dose Nesiritide
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.
66338|NCT01132846|Drug|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
66339|NCT01132911|Drug|Vorinostat (SAHA)|
66340|NCT01132911|Drug|Velcade (PS-341, Bortezomib)|
66341|NCT01132950|Behavioral|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
66342|NCT00038831|Drug|Mylotarg|Starting dose 2 mg/m^2 over 2-hour intravenous infusion on day -12.
66343|NCT01132950|Other|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
66344|NCT01132963|Other|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
66345|NCT01132963|Other|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
66346|NCT01132976|Behavioral|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
66347|NCT01132976|Behavioral|Treatment as usual|No specific motivational interview
66348|NCT01132989|Drug|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and < 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
66349|NCT01135095|Radiation|low-dose imaging|The study is designed to assess the validity of a low dose (~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.
D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient
66350|NCT01135108|Drug|Placebo|Placebo IV Infusion
66351|NCT01135108|Drug|KAI-1678|KAI-1678 IV Infusion
67009|NCT01131494|Other|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
67010|NCT00038623|Drug|Rituximab|250 mg/m^2 in the vein over 6 to 8 hours on Day 1.
66089|NCT01135056|Drug|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
66090|NCT01135069|Drug|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
66091|NCT01135069|Drug|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
66092|NCT01135069|Drug|placebo microsphere gel|treatment of acne vulgaris
66093|NCT01135082|Biological|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
66094|NCT01127243|Procedure|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
66095|NCT01127243|Procedure|inpatient LSH|patients discharged home the day after the operation
66096|NCT01127256|Drug|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
66097|NCT01127256|Drug|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
66098|NCT01127269|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
66099|NCT01127282|Drug|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
66100|NCT01127282|Drug|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
66101|NCT00000238|Drug|Buprenorphine|
66102|NCT00000938|Drug|ceftriaxone|
66103|NCT00038298|Drug|AMG 719|50 mg 3 times weekly
66104|NCT01127295|Drug|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
66789|NCT01126008|Drug|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
66790|NCT01126021|Behavioral|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
66791|NCT01126021|Behavioral|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
67067|NCT01156623|Procedure|EBUS-TBNA|All included patients received TBNA for lymph node study via a flexible ultrasonic bronchoscope with a linear scanning probe on the tip (BF-UC206F-OL8, Olympus). The curved-probe scanned parallel to the insertion direction of bronchoscope, and the obtained images were linked to the ultrasound scanner (EU-2000C, Olympus) incorporated with Doppler-flow imaging. Each lymph node greater than 5mm in short axis measured by cursors was selected for subsequent TBNA with a 22-gauge (NA-201SX-4022, Olympus) needle in a condition of real-time EBUS guidance. A cytology examination was sent for pathologist blinded for the clinical history and image result of patients. When a tissue core was obtained by TBNA, the specimen was also sent for pathology study.
67068|NCT01156636|Drug|Sildenafil|50 mg 3 times/day for 1 year
67069|NCT01156636|Drug|Placebo|
67070|NCT01156649|Device|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
67071|NCT01156649|Device|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
67072|NCT01156662|Device|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
67073|NCT01156662|Device|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
67074|NCT00040781|Other|laboratory biomarker analysis|Correlative studies
67075|NCT01156675|Device|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
67076|NCT01156675|Device|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
67077|NCT01156688|Drug|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
67078|NCT01159028|Drug|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
67079|NCT01159028|Drug|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
69648|NCT01146080|Device|Promus Element|Promus Element implanted to treat coronary artery lesions.
69649|NCT01146080|Device|Promus|Promus stent implanted to treat coronary artery lesions
69650|NCT01146093|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
69651|NCT01146106|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
69652|NCT01146119|Biological|Multimeric-001, 500 mcg|Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
69653|NCT01146119|Biological|Adjuvanted PBS|Adjuvanted PBS was administered twice with an interval of 19-23 days.
69654|NCT01146119|Biological|PBS and TIV 15%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
69655|NCT00039611|Drug|oxaliplatin|
69656|NCT01146119|Biological|PBS and TIV 50%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
69657|NCT01146132|Dietary Supplement|Conventional diet +/- wine|usual eating habits
69658|NCT01148420|Drug|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
69659|NCT00000946|Biological|HIV p24/MF59 Vaccine|
69660|NCT00039988|Drug|Albuterol placebo|Oral placebo capsules will be taken daily
69661|NCT01148446|Drug|Cyclophosphamide|750 mg/mq IV, day 1
69662|NCT01148446|Drug|Cyclophosphamide|50 mg/mq IV, day 1
69663|NCT01148446|Drug|Doxorubicin|50 mg/mq IV, day1
69937|NCT01176474|Procedure|Apheresis Procedure|Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called "apheresis." Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug.
69938|NCT01176487|Other|questionnaire administration|
69939|NCT01176487|Procedure|quality-of-life assessment|
69940|NCT01176487|Radiation|3-dimensional conformal radiation therapy|
66352|NCT01135134|Drug|Mometasone furoate|The study drug is MFNS (50 μg spray device) and the dose will be:
5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks
12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks
66353|NCT01135134|Drug|Placebo|MF Placebo nasal spray and administration will be as follows:
5 to 11 years: one spray per nostril once daily in the morning for 2 weeks
12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks
66633|NCT01128270|Drug|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
66634|NCT01128270|Drug|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
66635|NCT01128270|Drug|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
66636|NCT00038389|Drug|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
66637|NCT01128270|Drug|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
66638|NCT01128296|Drug|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
66639|NCT01128296|Drug|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
66640|NCT01128309|Behavioral|Stress Reduction Intervention|eight week group program, plus daily homework practice
66641|NCT01128309|Behavioral|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
66642|NCT01128322|Drug|S-Amlodipine, Telmisartan|
66643|NCT01128322|Drug|S-Amlodipine|
66644|NCT01128322|Drug|Telmisartan|
66645|NCT01128322|Drug|Placebo|
66646|NCT01128335|Drug|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
66647|NCT00038402|Drug|Herceptin|Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.
66105|NCT01127308|Drug|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of [14C]ertugliflozin
66106|NCT01127321|Other|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
66107|NCT01127321|Biological|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
66108|NCT01127321|Biological|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
66109|NCT01127321|Biological|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
66411|NCT01130194|Other|Combination of treatment modalities|Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.
Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning.
66412|NCT01130220|Other|Focus Group|A single focus group will be held until a "saturation" of themes has been identified.
66413|NCT01130233|Procedure|robotic assisted rectal resection|robotic assisted rectal resection
66414|NCT01133015|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
66415|NCT01133015|Device|IVUS|intravascular ultrasound
66416|NCT01133028|Behavioral|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
66417|NCT01133028|Behavioral|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
66418|NCT00038831|Drug|Fludarabine|30 mg/m^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
66419|NCT01133041|Other|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
66420|NCT01133041|Other|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
66421|NCT01133054|Procedure|revascularization|surgery or stenting
66422|NCT01133080|Drug|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
66423|NCT01133080|Drug|placebo|placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.
From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.
67080|NCT01159041|Behavioral|Family Focused Treatment (FFT)|FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
67081|NCT01159041|Behavioral|Individual Treatment (IP)|The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
67082|NCT01159054|Drug|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
66179|NCT01135303|Device|VistaO2 device|Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
66180|NCT01135316|Drug|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
66181|NCT01135329|Drug|Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,|Fludarabine 30 mg/m2 IV once a day for 4 days Busulfan 0.8 mg/kg IV every 12 hours for 4 days Cyclophosphamide 50 mg/kg IV daily for 2 days
66182|NCT01135342|Behavioral|Weight Loss Regimen and Sleep Cognitive Behavioral Therapy|
66183|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
66184|NCT01135368|Drug|Lansoprazole|Lansoprazole capsules
66185|NCT01135381|Behavioral|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
66186|NCT01135394|Drug|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
66187|NCT01135407|Other|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.
The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions.
69941|NCT00000964|Drug|Ranitidine hydrochloride|
69942|NCT00042289|Drug|linezolid|Women will receive linezolid as prescribed by their clinicians. (Dosage will vary for each participant.)
69943|NCT01176487|Radiation|palliative radiation therapy|
69944|NCT01176487|Radiation|whole-brain radiation therapy|
69945|NCT01176500|Drug|(18)Fluciclatide|
69946|NCT01176513|Drug|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
69947|NCT01178723|Dietary Supplement|breakfast size|The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.
(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.
Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).
The instructions will be adapted to each patient individually
69948|NCT01178736|Procedure|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
69949|NCT01178736|Procedure|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
69950|NCT01178736|Procedure|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
69951|NCT01178736|Procedure|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
69952|NCT01178762|Drug|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
69953|NCT01178775|Behavioral|walking|use a pedometer for records steps.
69954|NCT01178788|Drug|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
69955|NCT00042406|Drug|HuMax-CD4|
70193|NCT01179139|Other|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith & Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
70194|NCT01179152|Drug|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
70195|NCT01179165|Other|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
66648|NCT01130662|Drug|combination therapy using decitabine and midostaurin|Cohort 1:
Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.
Cohort 2:
Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.
Cohort 3:
Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle.
66649|NCT00038610|Drug|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
66650|NCT01130675|Other|caffeinated coffee|8 oz. of caffeinated cofee/breakfast&noon meal. No intervention for 2nd arm.
66651|NCT01130688|Drug|Zileuton|Imatinib combined with Zileuton
66944|NCT01133990|Drug|FOLIRI|The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional). The 5-FU IV bolus (400 mg/m2) and CIV infusion (2400 mg/m2) over 46 hours is repeated on Days 15 and 16 of each cycle.
66945|NCT01133990|Drug|FOLIRI plus E7820|E7820 is administered orally in tablet form once daily, every day of each 28-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Phase II portion, the dose will be the MTD recommended Phase IB dose in combination with FOLFIRI, as determined during the Phase Ib portion of the study.
66946|NCT01133990|Drug|FOLFIRI plus Bevacizumab|Bevacizumab at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle
66947|NCT01134016|Drug|Antroquinonol|Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.
Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.
The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded.
66948|NCT01134029|Behavioral|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
66949|NCT01134042|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
66950|NCT01134042|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
66951|NCT01126242|Device|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
66424|NCT01133106|Behavioral|Brief pleasurable events/behavioral therapy|Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled "Coping with Depression".
Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients.
66425|NCT01133106|Other|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
66426|NCT01133119|Drug|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
66719|NCT01125969|Behavioral|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
66720|NCT01125969|Behavioral|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
66721|NCT01125969|Behavioral|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
66722|NCT01125982|Drug|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
66723|NCT00038194|Drug|imatinib mesylate|
66724|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
66725|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
66726|NCT01128335|Drug|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
66727|NCT01128348|Behavioral|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
66728|NCT01128361|Behavioral|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
66188|NCT01135407|Other|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
66189|NCT01135407|Other|Recording during computerized tests|Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
66190|NCT01127425|Procedure|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
66191|NCT01127425|Procedure|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
66192|NCT01127438|Drug|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight < 60 kg and Age < 65 years and ASAI and II)
66193|NCT01127438|Drug|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight <60 kg and Age <65 years and ASAI and II)
66488|NCT01130311|Drug|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
66489|NCT01130311|Drug|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
66490|NCT01130324|Drug|telavancin|Observational
66491|NCT01130337|Drug|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
66492|NCT01130337|Drug|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
66493|NCT01130337|Drug|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
66494|NCT01130376|Biological|GTU-MultiHIV B clade vaccine1mg|Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
66495|NCT01130376|Drug|Interleukin-2|5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
66496|NCT00000939|Drug|Stavudine|
66497|NCT00038571|Drug|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
66498|NCT01130376|Drug|GM-CSF|150 ug administered subcutaneously once daily 4 hours from IL-2 injections
70196|NCT01179191|Drug|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
70197|NCT00042484|Procedure|Community-level intervention & policy change|
70198|NCT01179204|Procedure|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
70199|NCT01179217|Drug|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
70200|NCT01179217|Drug|100% maltodextrin|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
70201|NCT01179230|Other|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
70202|NCT01179230|Other|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
70203|NCT01179256|Dietary Supplement|CURCUMIN|oral supplementation of curcumin 2000mg
70204|NCT01179256|Other|no intervention other than stopping study|no intervention other than stopping study
70205|NCT01179269|Drug|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
70206|NCT01179282|Biological|dust mite extract or placebo|intervention will be to stop study drug or placebo
70207|NCT01179295|Drug|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
70208|NCT00042497|Biological|autologous dexosomes loaded with tumor-specific peptides|
70209|NCT01179295|Drug|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
70210|NCT01179295|Drug|BAY86-9766|BAY86-9766 100 mg once a day (od)
70540|NCT01177683|Drug|Bendamustine|Phase I component:
Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4
70541|NCT01177683|Drug|Doxorubicin|Phase I and II components:
Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4
70542|NCT01177683|Drug|Bortezomib|Phase I and II components:
Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11
66952|NCT01126242|Device|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
66953|NCT01126242|Device|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
66954|NCT01126255|Drug|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
66955|NCT01126255|Drug|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
66031|NCT01129453|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
66032|NCT01129466|Dietary Supplement|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
66033|NCT01129466|Dietary Supplement|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
66034|NCT01129479|Drug|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
66035|NCT01129479|Drug|Placebo pill|Placebo pill each morning with food for 12 weeks.
66036|NCT01129492|Device|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
66037|NCT01129505|Behavioral|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.
Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.
Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies.
66038|NCT00038532|Drug|Amprenavir/ritonavir|
66039|NCT01129518|Biological|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.
Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.
66729|NCT01128361|Behavioral|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
66730|NCT01128374|Procedure|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
66731|NCT01128387|Drug|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
67011|NCT01161485|Behavioral|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
67012|NCT00041028|Other|flow cytometry|
67013|NCT01161485|Behavioral|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
67014|NCT01161498|Biological|Talimogene Laherparepvec|Administered by intratumoral injection
67015|NCT01161498|Radiation|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
67016|NCT01161498|Drug|Cisplatin|Administered by intravenous infusion
67017|NCT01161511|Biological|XmAb5574|Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
67018|NCT01161524|Drug|Perampanel|2 mg titrated up to 8-12mg maximum; taken once daily
67019|NCT01161524|Drug|Placebo|Matching Placebo taken once daily.
67020|NCT01161537|Drug|VX-770|Tablet.
66499|NCT01130376|Drug|Growth Hormone|4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
66500|NCT01130428|Device|Juvent 1000 Vibration Platform|As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.
The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading [38]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes.
66501|NCT01130441|Behavioral|psychotherapy|short problem-solving skills therapy intervention
66502|NCT01133145|Procedure|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
66503|NCT01133158|Drug|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv DEXAMETHASONE 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
66504|NCT01133171|Behavioral|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
66792|NCT01126034|Other|intervention letter|Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:
The name and medical record # of the patients involved
Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy
A reminder of the adverse effect of long-term metoclopramide therapy
A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients
A request that the physician document the discontinuation trial in the electronic medical record
66793|NCT01126047|Other|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
66794|NCT01126060|Drug|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
66795|NCT01126060|Procedure|Thyroidectomy|surgical removal of bilateral thyroid glands
66796|NCT00038194|Drug|docetaxel|
66797|NCT01126073|Drug|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
66798|NCT01126073|Drug|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
70543|NCT01177683|Drug|Bendamustine|Phase II component:
Bendamustine at at MTD IV over 1 hour, Days 1 and 4
70544|NCT01179828|Drug|Imipramine|75mg single administration p.o.
70545|NCT01179828|Drug|Tolterodine|1 mg single administration p.o.
70546|NCT01179841|Behavioral|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
70547|NCT01179841|Behavioral|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
70548|NCT01179841|Behavioral|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
70549|NCT01179854|Drug|Remegal|Drug/ placebo
70550|NCT01179867|Other|Electronic Medication Reconciliation|Electronic medication reconciliation includes:
at admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications
at discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient
the discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes
70551|NCT01179880|Drug|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
70552|NCT00000966|Drug|Pyrimethamine|
70553|NCT00042601|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
70554|NCT01179880|Drug|Placebo|Matching placebo for each step
70555|NCT01179893|Biological|IVIG|Intravenous immunoglobulin
69664|NCT01148446|Drug|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
69665|NCT01148446|Drug|Prednisone|75 mg/mq IV, days 1-5
66040|NCT01129518|Biological|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
66041|NCT01129531|Drug|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
66042|NCT01129531|Drug|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
66043|NCT01129544|Biological|Gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2)One time infusion of patient's transduced bone marrow cells.
66044|NCT01129557|Drug|Aliskiren|
66045|NCT01129557|Drug|Valsartan|
66046|NCT01132313|Drug|BI 201335|28 weeks, QD
66047|NCT01132313|Drug|Ribavirin|24 weeks, according to label
66048|NCT01132313|Drug|Ribavirin|24 weeks, according to label
66354|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
66355|NCT01135147|Behavioral|Diet|Dietary therapy and physical education
66356|NCT01135147|Procedure|Surgery|Adenotonsillectomy along with diet and physical therapy
66357|NCT01135173|Behavioral|Waterpipe smoking cessation|The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
66358|NCT01135186|Drug|sapropterin dihydrochloride|
66359|NCT01135199|Drug|pomalidomide (CC-4047|
66360|NCT01135212|Drug|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
66361|NCT01135212|Drug|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
66362|NCT01135212|Drug|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
67021|NCT01161537|Drug|Placebo|Tablet.
67022|NCT01161550|Drug|Granulocyte colony-stimulating factor (G-CSF)|
67023|NCT00041028|Other|immunohistochemistry staining method|
67024|NCT01161550|Drug|Cladribine|
67025|NCT01161550|Drug|Cytarabine|
67026|NCT01161550|Drug|All-Trans Retinoic Acid (ATRA)|
67027|NCT01161550|Drug|Midostaurin|
67028|NCT01161563|Drug|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
67029|NCT01161563|Drug|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
66110|NCT01127321|Biological|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
66111|NCT01127360|Drug|Bevacizumab|Intravitreal injections
66112|NCT01127360|Drug|Ranibizumab|Intravitreal injections
66113|NCT01127373|Radiation|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
66114|NCT00038298|Drug|AGM 719|200 mg 3 times weekly
66115|NCT01127386|Drug|Lenalidomide|25mg od, dose reduction according to toxicity
66116|NCT01127386|Drug|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
66117|NCT01127386|Other|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
66118|NCT01127412|Behavioral|Physical activity stimulating program|
66119|NCT01129570|Drug|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
66120|NCT01129583|Drug|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
66121|NCT01129583|Drug|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
66799|NCT01126086|Drug|otamixaban XRP0673|Pharmaceutical form: solution for injection
Route of administration: intravenous
66800|NCT01126099|Drug|Prazosin|4 mg capsules twice daily for 12 weeks
66801|NCT01126099|Drug|Placebo|Placebo capsules twice daily for 12 weeks
66802|NCT01126112|Biological|Panitumumab|Panitumumab: 6 mg/Kg Q2W
66803|NCT01126125|Dietary Supplement|Iodized oil|400 mg of iodine vs 100 mg of iodine as iodized oil
66804|NCT01126138|Drug|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
66805|NCT01128413|Device|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
66806|NCT01128413|Behavioral|CURVES Questionnaire|The CURVES (CardiovascUlar Response & Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
66807|NCT01128413|Biological|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, & 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
67083|NCT01159067|Drug|deferasirox|Given orally
67084|NCT01159080|Drug|routine dose tacrolimus and myfortic|oral regular dose of tacrolimus + usual dose of myfortic trough level of tacrolimus will be 2-5 pg/mL and oral myfortic dose will be 360mg b.i.d.
67085|NCT01159080|Drug|low dose tacrolimus and myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-4 pg/mL for 3 months after randomization and oral MPS dose increased to 720mg b.i.d.
67086|NCT01159093|Behavioral|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
67087|NCT01159093|Behavioral|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
67088|NCT00040872|Drug|vincristine sulfate|
67089|NCT01159093|Other|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
67090|NCT01159093|Other|Control|Usual care
69666|NCT01148446|Drug|Prednisone|60 mg/mq IV/PO, days 1-5
69667|NCT01148446|Drug|Epirubicin|50 mg/mq IV, day 1
69668|NCT01148446|Drug|Vinblastine|5 mg/mq IV, day 1
69669|NCT01148446|Drug|Rituximab|375 mg/mq IV, day 1
69670|NCT01148446|Drug|G-CSF|300 µg tot., SC; days 7-11
69671|NCT00040001|Drug|DTI-0009|
69672|NCT01148459|Biological|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
69673|NCT01148459|Biological|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.
The vaccine will be administered intramuscularly
69674|NCT01148459|Biological|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.
The vaccine will be administered intramuscularly.
69675|NCT01148472|Drug|Escitalopram|20mg once daily; orally
69676|NCT01148472|Drug|Duloxetine|60mg once daily; orally
69677|NCT01148485|Other|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
69678|NCT01148498|Drug|solanezumab|400mg administered once intravenously
69679|NCT01148511|Drug|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
69680|NCT01148524|Biological|No Vaccine|
69681|NCT01148524|Biological|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
69682|NCT00040014|Drug|exemestane|
69683|NCT01148537|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 * 20 mcg/h.
69684|NCT01148537|Drug|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 * 20.
69685|NCT01151215|Drug|AZD8931|Tablet, oral, bd
66363|NCT01135225|Device|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
66364|NCT01135225|Device|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
66365|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
66366|NCT01135251|Drug|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
66367|NCT01135251|Drug|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
66368|NCT01127672|Biological|platelet rich plasma|30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).
Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.
This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.
The patient will be monitored for 10 minutes in clinic for adverse reactions.
66652|NCT01130701|Other|Neoadjuvant capecitabine, panitumumab and radiation|Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.
Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.
After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients.
66653|NCT01130714|Behavioral|Exercise|Resistance training with resistance bands.
66654|NCT01130727|Other|green tea extract|1.21g of green tea extract (965 mg of flavonols)
66655|NCT01130727|Other|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
66656|NCT01130727|Other|placebo|placebo
66657|NCT01130727|Other|low polyphenol cocoa extract|placebo
66658|NCT01130740|Behavioral|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
66659|NCT01130753|Drug|Erlotinib|Erlotinib 150mg per day for 8 weeks
66660|NCT00038610|Drug|Cyclophosphamide|300 mg/m^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m^2) for courses 1, 3, 5, 7.
66122|NCT00000939|Drug|Efavirenz|
66123|NCT00038532|Drug|Saquinavir/ritonavir|
66124|NCT01129596|Drug|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
66125|NCT01129609|Device|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
66126|NCT01129622|Drug|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
66127|NCT01129635|Procedure|Cardiac Resynchronization Therapy (CRT) implantation|The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.
Arm: CRT Candidate
66128|NCT01129648|Drug|Placebo|Administered daily for 21 days
66427|NCT01133119|Drug|Standard of Care plus bupivacaine|Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.
Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician.
66428|NCT01133132|Behavioral|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
66429|NCT00038831|Drug|Melphalan|140 mg/m^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
66430|NCT01133132|Other|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
66431|NCT01135420|Behavioral|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
66432|NCT01135420|Other|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
66433|NCT01135433|Drug|ASP1941|oral
67091|NCT01159106|Other|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
67092|NCT01159106|Other|Neurally adjusted ventilatory assist (NAVA)|Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).
The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm.
67093|NCT01159119|Drug|EUR-1066-A|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
67094|NCT01159119|Drug|Zenpep|Capsules taken for daily for 28 days during treatment period 2
67095|NCT01159119|Drug|EUR-1066-B|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
67096|NCT01161576|Genetic|AAVrh.10CUhCLN2 vector|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
67097|NCT01161602|Drug|Pumosetrag|
67098|NCT01161602|Drug|Pumosetrag|
67099|NCT00041041|Drug|imatinib mesylate|Given PO
67100|NCT01161602|Other|Placebo|
67101|NCT01161602|Drug|Pumosetrag|
67102|NCT01161615|Drug|MRX-7EAT|Application of up to two patches for up to 7 days.
70178|NCT01176942|Dietary Supplement|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
70179|NCT01176955|Behavioral|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
70180|NCT01176955|Drug|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
70181|NCT01176968|Drug|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
70182|NCT01176968|Drug|Placebo|Matching placebo tablets
69956|NCT01178788|Drug|micronized Progesterone|daily administration of vaginal progesterone
69957|NCT01178788|Other|Control|Routine clinical cares as in the remnants two arm using drugs
69958|NCT01178814|Drug|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
69959|NCT01178827|Drug|trospium chloride|trospium chloride (60mg) once daily for 10 days
69960|NCT01178827|Drug|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
69961|NCT01178827|Drug|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
69962|NCT01178840|Device|WC then FC2|4 uses of WC followed by 4 uses of FC2
69963|NCT01178840|Device|FC2 then WC|4 uses of WC followed by 4 uses of FC2
69964|NCT01178853|Drug|Warfarin|Warfarin 5 mg once daily
69965|NCT01178853|Drug|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
69966|NCT00042432|Drug|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
69967|NCT01178853|Drug|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
69968|NCT01181180|Dietary Supplement|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
69969|NCT01181193|Other|Surgery|Craniotomy with total or partial removal of the brain tumor
69970|NCT01181193|Radiation|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
69971|NCT01181193|Drug|Temozolomide|75 mg/m2/day for entire period of radiotherapy
150-200 mg/m2/day for 5 days every 28 days, 6 cycles total
69972|NCT01181193|Drug|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
69973|NCT01181206|Procedure|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
69974|NCT01181219|Procedure|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
69975|NCT01181219|Procedure|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
66661|NCT01130766|Procedure|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
66662|NCT01130779|Drug|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
66663|NCT01130792|Dietary Supplement|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
66664|NCT01130792|Dietary Supplement|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
66665|NCT01130805|Drug|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
66666|NCT01130818|Drug|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
66667|NCT01130818|Drug|placebo|single dose, oral solution
66668|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), fasting
66669|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), after high fat breakfast
66670|NCT01133496|Drug|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
66671|NCT01133509|Drug|Gardasil|0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
66956|NCT01126268|Drug|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
66957|NCT00038220|Drug|Efavirenz|
66958|NCT01126281|Procedure|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
66959|NCT01126294|Dietary Supplement|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
66960|NCT01126294|Dietary Supplement|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
66961|NCT01126294|Dietary Supplement|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
66962|NCT01126307|Drug|Verapamil|80 mg tid
66963|NCT01126307|Drug|placebo|placebo tid
66964|NCT01126320|Device|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
66965|NCT01126320|Device|routine mechanical ventilator|routine mechanical ventilation
66434|NCT01135433|Drug|Placebo|oral
66435|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
66436|NCT01135433|Drug|metformin|oral
66437|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
66438|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
66439|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
66440|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
66441|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 1 mg, once on Day 1 only, 2 days
66442|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
66443|NCT01135459|Drug|CEP-33457|200 mcg of CEP-33457 was administered subcutaneously every 4 weeks for up to 20 weeks for a maximum of 6 doses.
66444|NCT01135459|Drug|Placebo|Matching placebo was administered subcutaneously every 4 weeks for 20 weeks for a maximum of 6 doses.
66732|NCT01128413|Device|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
66733|NCT01128413|Device|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
66734|NCT00038402|Drug|Taxol|225 mg/m^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.
66735|NCT01130831|Drug|Lanthanum carbonate|
66736|NCT00038610|Drug|Doxorubicin|50 mg/m^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
66737|NCT01130844|Drug|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
66738|NCT01130844|Drug|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
70183|NCT01176981|Drug|High Dose Methotrexate|Methotrexate will be given by IV at a dose of 12 gram/m2/dose.
The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days).
70184|NCT00042302|Procedure|Chemotherapy|
70185|NCT01176994|Device|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
70186|NCT01177007|Device|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
70187|NCT01177020|Other|Biological specimen|Biological specimen taken from placenta
70188|NCT01177033|Other|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
70189|NCT01177059|Genetic|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
70190|NCT01177072|Other|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
70191|NCT01177072|Other|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
70192|NCT01179126|Procedure|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
70444|NCT00000964|Drug|Foscarnet sodium|
70445|NCT00042315|Drug|placebo + vinorelbine|
70446|NCT01177410|Drug|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
70447|NCT01177423|Procedure|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
69976|NCT00042796|Other|laboratory biomarker analysis|Correlative studies
69977|NCT01181232|Drug|Zolpidem MR|oral
70211|NCT01179295|Drug|BAY86-9766|BAY86-9766 60 mg once a day (od)
70212|NCT00042809|Other|pharmacological study|Correlative studies
70213|NCT01181427|Drug|Cytochrome P450 inhibitor|See arm description
70214|NCT01181440|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
70215|NCT01181440|Other|Conventional care|Weekly application of conventional care
70216|NCT01181453|Device|Dermagraft|Weekly application of Dermagraft(R) with standard care
70217|NCT01181453|Other|Comparator|Weekly application of standard care
70218|NCT01181466|Device|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
70219|NCT01181479|Drug|AG200-15 transdermal patch|Transdermal patch containing ethinyl estradiol and levonorgestrel
70220|NCT01181479|Drug|Oral Contraceptive|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen
70221|NCT01181505|Drug|Tolterodine|
70222|NCT01181531|Drug|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
70223|NCT00042822|Drug|romidepsin|
70224|NCT01181531|Drug|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
70225|NCT01181544|Procedure|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
70226|NCT01181570|Drug|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
66966|NCT01126346|Behavioral|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
66967|NCT01126346|Behavioral|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
66968|NCT00038220|Drug|Lamivudine|
66969|NCT01128725|Other|Alzhamyd|The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments
psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy
Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.
In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards.
66970|NCT01128738|Drug|GSK1358820|Onabotulinum toxin type A
66971|NCT01128738|Drug|Placebo|Placebo
66972|NCT01128751|Procedure|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
66973|NCT01128751|Procedure|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
66974|NCT01128751|Procedure|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
66049|NCT01132326|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
66050|NCT01132352|Drug|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
66051|NCT01132365|Device|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
66052|NCT01132378|Procedure|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
66053|NCT00038753|Procedure|Vision Screening|
66054|NCT01132391|Drug|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
66055|NCT01132404|Drug|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
66739|NCT01130844|Drug|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
66740|NCT01130870|Device|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
66741|NCT01130870|Device|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
66742|NCT01130870|Device|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
66743|NCT01130909|Drug|AZD6765|75 mg
66744|NCT01130909|Drug|AZD6765|150 mg
66745|NCT01130909|Drug|Ketamine|0.5 mg/kg
66746|NCT01130909|Drug|Placebo|125 mL sterile NaCl 0.9%
66747|NCT00038610|Drug|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
66748|NCT01130922|Drug|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
66749|NCT01130922|Drug|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
66750|NCT01130948|Other|altitude exposure|exposure to 490m, 1700m and 2590m
66751|NCT01130974|Device|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
67030|NCT01161576|Genetic|AAVrh.10CUhCLN2 vector|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
67031|NCT01164124|Dietary Supplement|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
67032|NCT01164124|Other|Placebo|routine feedings
67033|NCT01164137|Behavioral|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
67034|NCT00041171|Drug|Hypericum perforatum|
67035|NCT01164150|Radiation|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
70448|NCT01177436|Biological|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
70449|NCT01177449|Procedure|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
70450|NCT01177475|Other|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
70451|NCT01177475|Other|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
70452|NCT01177488|Behavioral|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
70453|NCT01177501|Drug|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
70454|NCT01177514|Drug|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
70455|NCT00042562|Drug|duloxetine|
70456|NCT01179672|Drug|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
70457|NCT01179685|Procedure|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
70458|NCT01179698|Procedure|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
70459|NCT01179698|Procedure|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
70460|NCT01179711|Device|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
70461|NCT01179724|Drug|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
70462|NCT01179724|Drug|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
70463|NCT01179737|Drug|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
70770|NCT00042367|Drug|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
73017|NCT01203852|Drug|Metoprolol|Metoprolol 50 mg twice daily titrated to 100 mg twice daily
Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily.
73018|NCT01203852|Drug|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
73019|NCT01203878|Drug|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
73020|NCT01203878|Drug|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
73021|NCT01203917|Drug|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
73022|NCT01203930|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
73023|NCT01203930|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks
73024|NCT01203943|Drug|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
73025|NCT00044993|Biological|Ad5CMV-p53 gene|
73026|NCT01203943|Other|Placebo|Placebo
73027|NCT01203943|Drug|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
73028|NCT01203943|Drug|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
73029|NCT01203956|Device|SmartFlex|Device used with smartflex engaged.
73030|NCT01203956|Device|Standard|
73031|NCT01203969|Procedure|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
72111|NCT01173380|Other|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
72112|NCT01173380|Other|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
72113|NCT01173393|Procedure|PARAMEDIC COOLING|For patients randomised to paramedic cooling:
LMA/ Intubation and ventilation with 100% oxygen
Measure temperature using tympanic probe and record
Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR
If temperature >34.5ºC, infuse further 10mL/kg stat
After ROSC, infuse further (max 2 litres) ice-cold saline
If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg.
72114|NCT01173406|Behavioral|CPAP education|Standard CPAP education plus an session and one telephone follow up
72115|NCT00042172|Drug|Ginkgo Biloba Extract|
71067|NCT01183130|Device|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
71068|NCT01183143|Drug|Follitropin alpha (Gonal-F)|In a common setting, for OI the starting daily dose of Gonal-F will be 75-150 IU generally not exceeding beyond 225 IU. The starting dose of Gonal-F in IVF/ICSI will be 150-225 IU/day not exceeding beyond 450 IU/day.
71069|NCT01183156|Behavioral|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
71070|NCT01176227|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:
Lactobacillus gasseri KS-13 1.2
Bifidobacterium bifidum G9-1 0.15
Bifidobacterium longum MM-2 0.15
Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
71071|NCT01176227|Dietary Supplement|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
71362|NCT01172236|Drug|Lactoferrin|Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.
Control group: newborns (group B) will receive only standard therapy and they will be used as controls.
71363|NCT01172236|Drug|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
71364|NCT00041938|Drug|aspirin|325 mg per day
71365|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
71366|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
71367|NCT01172262|Procedure|MRI|This is an observational study, no intervention will occur.
71368|NCT01172275|Drug|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
71369|NCT01172275|Drug|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
72171|NCT01170949|Drug|Miltefosine|50 or 100 or 150mg per day
72172|NCT01170949|Drug|Placebo|Placebo
72173|NCT01170962|Drug|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
72174|NCT01170962|Drug|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
72175|NCT00041756|Drug|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
72176|NCT01170962|Drug|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
72177|NCT01170962|Drug|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
72178|NCT01170962|Drug|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
72179|NCT01170975|Drug|Tesetaxel 10 mg with and then without food|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
72180|NCT01170975|Drug|Tesetaxel 10 mg without and then with food|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
72181|NCT01170988|Procedure|T-Graft|T-Graft
72182|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
72183|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
72184|NCT01171014|Dietary Supplement|Placebo|Placebo, once a day for 14 days
72185|NCT01171027|Procedure|NOTES Cholecystectomy|The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
72186|NCT00041756|Drug|Placebo|One placebo tablet, twice daily for for one year
72187|NCT01173471|Drug|AZD4017|tablet, oral 2 tablets twice daily, 28 days
72188|NCT01173471|Drug|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
72189|NCT01173497|Drug|INIPARIB + irinotecan|21 day cycle
72439|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
72785|NCT01198067|Drug|Pomalidomide|Starting dose level 1 mg by mouth on days 1-28 of a 28 day cycle.
72786|NCT01198067|Drug|Pomalidomide|Starting dose level 1 mg by mouth on days 1-21 of a 28 day cycle.
72787|NCT01198080|Biological|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
72788|NCT00044395|Drug|Ruboxistaurin mesylate|
72789|NCT01198106|Drug|scopolamine|0.6 mg
72790|NCT01198106|Drug|cinnarizine|50 mg
72791|NCT01198119|Device|Location of the suspected lesions|The suspected lesions will be located before the excision, during the surgery.
With traditional light
NBI technique The images will be recorded and compared
72792|NCT01198119|Procedure|Biopsy|In case of suspected lesions detected by the NBI technique, this area is biopsied
72793|NCT01198119|Procedure|Lesion excision/Surgery|In case of positive biopsy, the suspected lesions is excised
72794|NCT00044694|Drug|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
72795|NCT01200368|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
72796|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
72797|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
72798|NCT01200381|Other|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
72799|NCT01200381|Other|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
72800|NCT01200381|Other|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
72801|NCT01200394|Drug|PF-00489791|Tablet, 20 mg once daily for 12 weeks
72802|NCT01200394|Drug|Placebo|Tablet, placebo once daily for 12 weeks
72803|NCT01200407|Drug|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
72804|NCT01200420|Drug|miravirsen|SC injection
72805|NCT00044694|Drug|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
73166|NCT01201148|Device|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
73167|NCT01201161|Drug|Ranibizumab|Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
73168|NCT01201161|Other|Sham injection|Simulation of intravitreal injection one week before pars plana vitrectomy
72237|NCT01168700|Drug|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
72238|NCT01168700|Drug|Placebo|Placebo 1.2 g per day for 12 weeks.
72239|NCT01168713|Drug|Levofloxacin|Levofloxacin once daily for 5 days:
Levofloxacin 750 mg PO Days 1-5
72240|NCT01168713|Drug|CEM-101|CEM-101 once daily for 5 days:
CEM-101 800 mg PO Day 1
CEM-101 400 mg PO Days 2-5
72241|NCT00041470|Drug|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
72242|NCT01168726|Behavioral|Protective Behavioral Strategies Feedback|Personalized feedback on use of protective behavioral strategies.
72243|NCT01168726|Behavioral|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
72244|NCT01168726|Behavioral|Alcohol Education|Educational information about harms associated with heavy drinking.
72245|NCT01171027|Procedure|Laparoscopic Cholecystectomy|This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
72246|NCT01171040|Other|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
72247|NCT01171053|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
72248|NCT01171053|Behavioral|Therapist support|Weekly therapist support without CBT-interventions
72249|NCT01171079|Device|application of oxidized regenerated cellulose|
72250|NCT01171092|Drug|bortezomib and G-CSF|Bortezomib injection:
1.3mg/m2 11 days before and 8 days before the stem cell collection
G-CSF injection:
10mcg/kg on days -4 to day -1 once daily
71370|NCT01172288|Drug|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
71371|NCT01172288|Drug|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
71372|NCT01172301|Dietary Supplement|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
71373|NCT01172314|Dietary Supplement|EAA+LEU vs total AA|15 g as a bolus
71374|NCT01172314|Dietary Supplement|Total AA vs EAA+LEU|15 g as a bolus
71375|NCT00041938|Drug|Warfarin|INR 2.5-3.0; target INR 2.75
71376|NCT01174524|Drug|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
71377|NCT01174524|Drug|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
71378|NCT01174537|Biological|New Castle Disease Virus|Patients will receive IV 1*10^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
71379|NCT01174550|Procedure|Coronary Angiography|Use of standard equipment for usual-care testing
71380|NCT01174550|Procedure|Stress Echocardiogram|Use of standard equipment for usual-care testing
71381|NCT01174550|Procedure|Nuclear Stress Test|Use of standard equipment for usual-care testing
71678|NCT01167686|Dietary Supplement|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
71679|NCT01167699|Drug|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
71680|NCT01167712|Biological|Bevacizumab|Given IV
71681|NCT01167712|Drug|Carboplatin|Given IV
71682|NCT01167712|Procedure|Computed Tomography|Correlative studies
71683|NCT01167712|Drug|Paclitaxel|Given IV
71684|NCT01167712|Procedure|Therapeutic Conventional Surgery|Undergo surgery
71685|NCT01167725|Biological|bevacizumab|Given IV
71686|NCT01167725|Biological|cetuximab|Given IV
72440|NCT01174030|Drug|Vehicle Gel|Vehicle Gel QD
72441|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
72442|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
72443|NCT01174030|Drug|Vehicle Gel|Vehicle Gel BID
72444|NCT01174043|Drug|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
72445|NCT01174056|Drug|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
72446|NCT01174056|Drug|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
72447|NCT01174056|Drug|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
72448|NCT00042224|Procedure|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
72449|NCT01174056|Drug|Pioglitazone|PPAR-gamma agonist
72450|NCT01174069|Procedure|NOTES assisted laparoscopic cholecystectomy|Surgical removal of the gallbladder using endoscopic instruments.
72451|NCT01174082|Biological|KLH Vaccine|Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.
Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.
72452|NCT01166438|Drug|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
72453|NCT00041288|Drug|fludarabine phosphate|
72454|NCT01166438|Drug|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
72455|NCT01166438|Drug|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
72456|NCT01166438|Drug|Trospium chloride|Oral Trospium XR 60mg once a day for up to 2 months
72457|NCT01166451|Dietary Supplement|Low-iron formula|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
72806|NCT01200420|Drug|saline|SC injection
73150|NCT01198600|Device|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
73151|NCT01198600|Device|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
73152|NCT01198613|Biological|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
73153|NCT00044512|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
73154|NCT01198613|Biological|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
73155|NCT01198626|Drug|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
73156|NCT01198626|Drug|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
73157|NCT01198626|Drug|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
73158|NCT01198639|Device|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
73159|NCT01198639|Device|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
73160|NCT01198665|Drug|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
73161|NCT01198678|Dietary Supplement|Boost Nutritional Supplement|Boost- Nutritional Supplement
73162|NCT01198691|Device|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
73163|NCT01198691|Device|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
73164|NCT00000979|Drug|Didanosine|
73165|NCT00044525|Drug|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
72251|NCT01171105|Drug|AZD5213|oral solution, multiple ascending doses
72252|NCT01171105|Drug|Placebo to AZD5213|
72253|NCT01171118|Drug|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
72254|NCT01171118|Drug|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
72516|NCT01174082|Biological|KLH-id Vaccine|Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.
72517|NCT01174082|Drug|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
72518|NCT01174082|Procedure|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
72519|NCT01174082|Procedure|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
72520|NCT01174108|Device|Miltenyi CD34 Reagent System|
72521|NCT01174108|Other|Donor derived G-CSF mobilized PBC|
72522|NCT01174121|Biological|Young TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).
72523|NCT00042224|Drug|Clozapine|Patients with psychotic symptoms will receive clozapine
72524|NCT01174121|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.)
72525|NCT01174121|Drug|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
72526|NCT01174121|Drug|Fludarabine|On day -5 to day -1: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
72527|NCT01174121|Drug|Pembrolizumab|Day -2, day 21, day 42, and day 63, Pembrolizumab 2mg/kg IV over approximately 30 minutes.
72528|NCT01174134|Other|Nutritional beverage|
72529|NCT01174160|Drug|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
71687|NCT01167725|Drug|FOLFIRI regimen|Given IV
71688|NCT00041327|Drug|lamivudine|150 mg bid
71689|NCT01167725|Drug|FOLFOX regimen|Given IV
71690|NCT01167725|Drug|capecitabine|Given IV
71691|NCT01167725|Drug|fluorouracil|Given IV
71692|NCT01167725|Drug|irinotecan hydrochloride|Given IV
71693|NCT01167725|Drug|leucovorin calcium|Given IV
71694|NCT01167725|Drug|mitomycin C|Given intraperitoneally
71695|NCT01167725|Drug|oxaliplatin|Given IV
71696|NCT01167725|Procedure|therapeutic conventional surgery|Patients undergo cytoreductive surgery
71697|NCT01167738|Drug|capecitabine|1250 mg/mq days 1-28 every 4 weeks
71698|NCT01167738|Drug|cisplatin|30 mg/mq on days 1 and 15 every 4 weeks
71699|NCT00041327|Drug|prednisone|60 mg/m2 given orally days 1-5
71700|NCT01167738|Drug|epirubicin|30 mg/mq on days 1 and 15 every 4 weeks
71701|NCT01170104|Procedure|TACE (Transcatheter arterial chemoembolization)|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
71702|NCT01170117|Drug|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
72037|NCT01173328|Behavioral|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
72038|NCT00042289|Drug|rifampicin|Women will receive rifampicin as prescribed by their clinicians. (Dosage will vary for each participant.)
72039|NCT01175577|Dietary Supplement|Betatene, sold as "Full Spectrum Carotenoid Complex"|One capsule per day with meals for 28 days
72040|NCT01175577|Other|Small carotenoid-rich meals|Single carotenoid-enriched soup or salad serving eaten daily
72041|NCT01175577|Other|Placebo|Safflower oil-filled capsules, one twice daily with meals
72042|NCT01175590|Drug|Besivance|Ocular administration to affected eye for 7 days
72724|NCT01203124|Drug|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
72725|NCT01203124|Drug|Placebo|Placebo
72726|NCT01203150|Other|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
72727|NCT01203176|Procedure|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
72728|NCT01203189|Drug|ketoconazole 2% foam|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
72729|NCT01203189|Drug|ketoconazole 2% shampoo|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
72730|NCT01203202|Drug|Clomipramine|15mg and 30mg on demand
72731|NCT01203215|Behavioral|2 print based physical activity interventions|physical activity promotion
72732|NCT01203228|Other|Reduced Intensity Conditioning|Busilvex®:
6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available)
Busulfan:
8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW
plus:
Fludarabine:
5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS
72733|NCT01203228|Other|Myeloablative conditioning|Busilvex®:
12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available):
Busulfan:
16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW
plus:
Cyclophosphamide:
120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW
72734|NCT00044954|Drug|mycophenolate mofetil|
72735|NCT01203241|Procedure|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
72736|NCT01203241|Procedure|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
72737|NCT01203254|Drug|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
72738|NCT01203254|Drug|Placebo|Placebo tablet: 3 times daily 2 tablets
72739|NCT01203267|Drug|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
72961|NCT01198275|Drug|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
72962|NCT01198275|Drug|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
72963|NCT00044434|Drug|bupropion (Wellbutrin)|
72964|NCT01198288|Other|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
72965|NCT01198288|Other|Standard Care|As describe in the standard care arm
72966|NCT01198314|Procedure|immunosuppression withdrawal|tapering off immunosuppressant
72967|NCT01198314|Procedure|continue of taking immunosuppressant|maintain immunosuppression
72968|NCT01198327|Drug|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
72969|NCT01198327|Other|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
72970|NCT01198340|Procedure|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
72971|NCT01198340|Procedure|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
72056|NCT01175720|Procedure|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
72057|NCT01175733|Drug|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
72058|NCT01175746|Drug|Nicardipine|
72059|NCT01175746|Drug|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
72060|NCT00041353|Procedure|study of high risk factors|
72061|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
72062|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
72063|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
72064|NCT01168310|Drug|Formoterol Fumarate|Inhalation Solution
72530|NCT01174160|Drug|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
72531|NCT01174173|Drug|Ranolazine|ranolazine 1000 mg PO BID for 3 months
72532|NCT01174186|Drug|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
72533|NCT01174199|Drug|vorinostat|Given orally
72534|NCT00042237|Behavioral|Schema Therapy|
72535|NCT01174199|Drug|temsirolimus|Given IV
72536|NCT01174199|Other|laboratory biomarker analysis|Correlative study
72537|NCT01174199|Procedure|positron emission tomography/computed tomography|PET scan
72807|NCT01200433|Drug|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
72808|NCT01200433|Drug|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
72809|NCT01200446|Dietary Supplement|Docosahexaenoic Acid|8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.
72810|NCT01200446|Dietary Supplement|Placebo Docosahexaenoic Acid|8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
72811|NCT01200459|Behavioral|Social/mobile weight loss promotion intervention.|Social/mobile intervention for weight loss promotion, compared to control group.
72812|NCT01200472|Drug|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
72813|NCT01200472|Drug|Placebo|Placebo capsules identical to apremilast
72814|NCT01200485|Drug|Rasburicase|0.15 mg/kg by vein over 30 minutes on day 1 of 21 day cycle, additional dose Days 2-5 at physician discretion.
72815|NCT01200485|Drug|Allopurinol|300 mg/day by vein over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
72816|NCT00044694|Drug|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
72817|NCT01200498|Drug|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
72818|NCT01200524|Drug|AZD2423|20 mg tablet
72116|NCT01173419|Device|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
72117|NCT01173419|Device|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
72118|NCT01173432|Device|continuous positive airway pressure|an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
72119|NCT01173471|Drug|AZD4017|tablet, oral, one tablet once daily, 28 days
72120|NCT01173471|Drug|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
72121|NCT01165788|Procedure|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
72122|NCT01165801|Procedure|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
72123|NCT01165814|Drug|Naproxen Tramadol|
72124|NCT01165840|Drug|Dapsone|100 mg PO x 1 dose
72125|NCT01165853|Other|Glucose|25% dose at 8-week intervention assigned to subjects.
72126|NCT01165853|Other|Fructose|25% dose at 8-week intervention assigned to subjects.
72127|NCT01165866|Drug|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
72128|NCT01165866|Drug|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
72129|NCT01165892|Drug|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
72388|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
72389|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
72740|NCT01203280|Other|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
72741|NCT01203293|Behavioral|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
73094|NCT01201057|Drug|0.5% SPL7013 Gel|Vaginal gel
73095|NCT01201057|Drug|1.0% SPL7013 Gel|Vaginal gel
73096|NCT01201057|Drug|3.0% SPL7013 Gel|Vaginal gel
73097|NCT00044746|Drug|Piperacillin/Tazobactam|
73098|NCT01201057|Other|Placebo Gel|Vaginal gel
73099|NCT01201070|Drug|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
73100|NCT01201096|Radiation|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
73101|NCT01201096|Procedure|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
73102|NCT01201122|Drug|Mesalamine|Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).
Patients will be randomized in blocks of six stratified by weight groups: 15- <30 kg, 30-40kg, >40kg.
For body wt. 15- <20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).
For body wt: 20- <30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).
For Body wt. 30- <40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).
For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening).
73103|NCT01204164|Drug|TG02 citrate|TG02 citrate capsules given orally.
73104|NCT00044993|Procedure|conventional surgery|
73105|NCT01204164|Drug|Carfilzomib|Carfilzomib per PI
73106|NCT01204164|Drug|Dexamethasone|Dexamethasone (Oral or IV)
73107|NCT01204177|Drug|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
73108|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
72065|NCT01168310|Drug|Placebo|Inhalation Solution
72066|NCT01168323|Behavioral|Online spaced education|Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
72067|NCT01168336|Drug|Betahistine standard formulation|betahistine 24 mg tablets
72068|NCT01168336|Drug|Betahistine Extended Release formulation|betahistine 32 mg tablets
72069|NCT01168336|Drug|Placebo|matching placebo
72070|NCT01168349|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
72071|NCT00041379|Drug|beta alethine|
72072|NCT01168375|Drug|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
72073|NCT01168375|Drug|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
72074|NCT01168401|Biological|Bivalent Norovirus Vaccine|2 Doses 28 days apart Cohort A: 18-49 Years
Cohort A1: IM Norovirus Bivalent VLP Vaccine (5/5 mcg)
Cohort A2: IM Norovirus Bivalent VLP Vaccine (15/15 mcg)
Cohort A3: IM Norovirus Bivalent VLP Vaccine (50/50 mcg)
Cohort A4: IM Norovirus Bivalent VLP Vaccine (150/150 mcg)
Cohort B: 50-64 years IM Norovirus Bivalent VLP Vaccine at the chosen dose from Cohort A
Cohort C: 65-85 years IM Norvirus Bivalent VLP Vaccine at the chosen dosage from Cohort A
Cohort D: 18-49 Years of Age IM Norovirus Bivalent VLP Vaccine at the Chosen Dosage from Cohort A
72075|NCT01168401|Biological|Saline|Two doses 28 days apart
72076|NCT01168414|Drug|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
72335|NCT00041756|Drug|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
72336|NCT01171209|Drug|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
72337|NCT01171261|Behavioral|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
72338|NCT01171274|Behavioral|Hatha Yoga|9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.
One class of 90 minutes per week, 10 minutes training at home each day.
72819|NCT01200524|Drug|AZD2423|50 mg tablet
72820|NCT01203319|Biological|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
72821|NCT00044954|Procedure|allogeneic bone marrow transplantation|
72822|NCT01203319|Biological|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
72823|NCT01203319|Biological|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
72824|NCT01203332|Behavioral|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
72825|NCT01203345|Drug|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
72826|NCT01203345|Drug|Placebo|An equal volume of 5 percent albumin solution
72827|NCT01203358|Drug|Exosurf|Infants received up to four intratracheal doses of the surfactant.
72828|NCT01203358|Drug|Survanta|Infants received up to four intratracheal doses of the surfactant.
73169|NCT01201174|Other|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
73170|NCT01201187|Drug|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
73171|NCT00044759|Drug|Piperacillin/Tazobactam (Tazocin)|
73172|NCT01201187|Drug|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
73173|NCT01201213|Drug|local anaesthetic injection|Single bolus of drug for pain relief in early labour
73174|NCT01201226|Other|Removal of half an ovary|Removal of half an ovary
73175|NCT01201239|Drug|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
73176|NCT01201252|Procedure|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
73177|NCT01201265|Drug|bevacizumab [Avastin]|15 mg/kg iv every 3 weeks
73178|NCT01201265|Drug|carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
72390|NCT01166425|Drug|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
72391|NCT01166425|Drug|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
72392|NCT01168934|Drug|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
72393|NCT01168947|Other|5% dextrose solution|The extracorporeal circuit of the dialysis machine will be primed and rinsed with a 5% dextrose solution instead of 0.9% saline.
72394|NCT01168960|Behavioral|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
72395|NCT01168973|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
72396|NCT01168973|Drug|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
72397|NCT01168973|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) (60 mg/m^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
72398|NCT01168986|Other|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
72399|NCT01168986|Other|Exercise|Participants perform an exercise to strengthen the deep neck flexors
72400|NCT00041470|Drug|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
72401|NCT01168999|Other|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
72402|NCT01168999|Other|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
72403|NCT01168999|Other|Enhanced sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, "The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
72404|NCT01169012|Drug|Clofarabine|Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
73109|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
73110|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
73111|NCT01204203|Drug|Zometa|Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
72190|NCT01173510|Drug|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
72191|NCT01173510|Drug|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
72192|NCT00042185|Behavioral|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
72193|NCT01173523|Drug|STA-9090|Peripheral IV over 60 to 150 minutes
72194|NCT01173536|Drug|GDC-0449|Oral repeating dose
72195|NCT01173536|Drug|moxifloxacin|Oral single dose
72196|NCT01173536|Drug|placebo|Oral repeating dose
72197|NCT01173549|Drug|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
72198|NCT01173549|Other|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
72199|NCT01173562|Drug|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
72200|NCT01173588|Other|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
72201|NCT01173601|Drug|LY2216684|Taken by mouth once daily
72202|NCT01173601|Drug|Placebo|Taken by mouth once daily for 11 weeks
72203|NCT00000961|Drug|Anti-HIV Immune Serum Globulin (Human)|
72339|NCT01171274|Behavioral|Information regarding exercises and behaviour|9 weeks of exercises practiced at home.
Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients.
72340|NCT01171287|Procedure|Driving with an Aircast Walker|
72341|NCT01171287|Procedure|Driving with a walking cast|
72342|NCT01171287|Procedure|Driving with a running shoe|
72343|NCT01171300|Other|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
72344|NCT01171300|Other|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
72345|NCT01171313|Drug|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
72346|NCT00000959|Drug|Isoniazid|
72347|NCT00041756|Drug|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
72348|NCT01171313|Drug|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
72349|NCT01171313|Drug|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
72350|NCT01171313|Drug|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
72351|NCT01171326|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
72352|NCT01171339|Other|Optimization strategy (complex intervention)|Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#
#Recommended standard: clinical practice guideline "Geriatrie" of the guideline group of Hesse (part 1 and 2)
72605|NCT01171794|Drug|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsquent day ( 4 doses total)
72606|NCT01171807|Drug|Dexamethasone 21-phosphate|6 monthly infusions of dexamethasone 21-phosphate loaded into autologous erythrocytes
72607|NCT01171820|Device|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
72608|NCT01171820|Device|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
73179|NCT01201265|Drug|gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
73180|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
73181|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
73182|NCT00044772|Drug|Venlafaxine ER|
73183|NCT01201278|Drug|Insulin LISPRO|Subcutaneous insulin lispro 8 U
73184|NCT01201291|Other|Normobaric oxygen|Fraction of inspired oxygen
73185|NCT01201304|Behavioral|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
73186|NCT01201304|Behavioral|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
73187|NCT01201304|Behavioral|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
73188|NCT01201304|Behavioral|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
73189|NCT01201317|Drug|AZD2423|20 mg tablet
72255|NCT00041756|Drug|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
72256|NCT01171118|Drug|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
72257|NCT01171131|Other|Blood/saliva sampling|one-time blood sample (~ 1 TBS) and saliva sample (~ 1 tsp)
72258|NCT01171144|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
72259|NCT01171144|Other|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
72260|NCT01171144|Other|Hospital discharge records|Reviewing the hospital discharge records
72261|NCT01171157|Other|Routine sample collection|Collection of routine nasal/throat swab samples
72262|NCT01171170|Drug|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
72666|NCT01195207|Biological|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
72667|NCT01195207|Biological|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
72668|NCT00044005|Drug|Lurasidone 80mg|Lurasidone 80mg oral tablet taken once daily
72669|NCT01195220|Behavioral|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
72670|NCT01195220|Behavioral|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
72671|NCT01195220|Behavioral|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
72672|NCT01195233|Drug|bioxtra|spray /mouth rinse
72673|NCT01195246|Biological|HEPLISAV|Intramuscular (IM) injection on Day1
72674|NCT01195246|Biological|Engerix-B|Intramuscular (IM) injection on Day 1
72675|NCT01195246|Biological|Fendrix|Intramuscular (IM) injection on Day 1
72676|NCT01195259|Drug|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
72677|NCT01195272|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
72678|NCT01195285|Procedure|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
72679|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily
72680|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
72681|NCT01197755|Drug|placebo|Placebo twice daily
72682|NCT01197768|Behavioral|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
72683|NCT01197781|Drug|FOSTAMATIN|Oral tablets - single dose
72204|NCT00042185|Behavioral|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
72205|NCT01173627|Drug|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
72206|NCT01173627|Drug|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
72207|NCT01173640|Drug|Midazolam|2 mg oral dose
72208|NCT01173640|Dietary Supplement|resveratrol (single dose)|1 g oral dose
72209|NCT01173640|Dietary Supplement|resveratrol (multiple dose)|1 g oral dose for 8 days
72458|NCT01166451|Dietary Supplement|High-iron formula|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
72459|NCT01166464|Behavioral|text messaging for smoking cessation|A 7-week program of daily text messages
72460|NCT01166464|Behavioral|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
72461|NCT01166477|Drug|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
72462|NCT01166477|Drug|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
72463|NCT01166490|Drug|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
72464|NCT00041288|Drug|methotrexate|
72465|NCT01166503|Procedure|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
72466|NCT01166503|Procedure|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
72467|NCT01166503|Procedure|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
72609|NCT01171833|Drug|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
72610|NCT01171833|Drug|Desflurane|6.0 vol% prefilled in a corrugated circuit.
72611|NCT01171833|Drug|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
72612|NCT00044681|Drug|risperidone|
72613|NCT01200056|Drug|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
72614|NCT01200069|Drug|Placebo infusion|Identically appearing placebo dose administered IV
72615|NCT01200069|Drug|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT
72616|NCT01200108|Drug|Budesonide|
72617|NCT01200108|Drug|Budesonide|
72618|NCT01200108|Drug|Budesonide|
72619|NCT01200121|Drug|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
72620|NCT01200121|Other|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
72621|NCT01200134|Other|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
72622|NCT01200147|Procedure|Biopsy|
72623|NCT00044694|Drug|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
72624|NCT01200147|Procedure|Dilation|
72625|NCT01200160|Drug|Niacin|
72626|NCT01200173|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
72972|NCT01198353|Drug|Ziprasidone|100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
72973|NCT01198366|Biological|AERAS-402 1.5 x 10^10 vp|
72263|NCT01171170|Drug|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
72264|NCT01171183|Drug|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
72265|NCT01173653|Other|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
72266|NCT01173653|Other|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
72267|NCT01173666|Procedure|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
72268|NCT01173666|Drug|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
72269|NCT01173679|Drug|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
72270|NCT00042185|Behavioral|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
72271|NCT01173679|Drug|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
72272|NCT01173679|Drug|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
72538|NCT01174212|Procedure|Prophylactic Antibiotics|Preoperative Antibiotics
72539|NCT01174212|Procedure|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
72540|NCT01174225|Device|Flexi T 380(+) IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
72541|NCT01166529|Procedure|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
72542|NCT01166542|Biological|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
72684|NCT01197781|Drug|Verapamil|Oral tablets - administered 3 times daily over 4 days
72685|NCT01197794|Drug|AZD1981|AZD1981 twice daily
73032|NCT01195883|Other|Crystalloid|All the patients will be given 5-7 ml/kg of crystalloid (lactated Ringer's) in the immediate preoperative period, which will be followed by 4 ml/kg/h crystalloid for maintenance normalized to ideal body weight [Men: Ideal Body Weight (in kilograms) = 52 kg + 1.9 kg for every 2.5 cm over 150 cm; Women: Ideal Body Weight (in kilograms) = 49 kg + 1.7 kg for every 2.5 cm over 150 cm]. For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. 9Patients will be randomized to:
Group 1 (Crystalloid Group): In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ®, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm9 (see Figure 1), an additional fluid bolus of 250 ml of LR will be given over a time period of 5 minutes.
73033|NCT01195883|Other|Colloid|All the patients will be given 5-7 ml/kg of crystalloid (lactated Ringer's) in the immediate preoperative period, which will be followed by 4 ml/kg/h crystalloid for maintenance normalized to ideal body weight [Men: Ideal Body Weight (in kilograms) = 52 kg + 1.9 kg for every 2.5 cm over 150 cm; Women: Ideal Body Weight (in kilograms) = 49 kg + 1.7 kg for every 2.5 cm over 150 cm]. For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. 9Patients will be randomized to:Group 2 (Colloid Group): In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ®, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm9(see Figure 1), an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a time period of 5 minutes.
73034|NCT01195896|Device|New NPWT system|According clinical routine (Instruction for Use)
73035|NCT01195922|Drug|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT & amp; PET scans will be done for tumor measurement.
73036|NCT01195948|Drug|B27PD|
73037|NCT01195948|Drug|Placebo|Capsule with no active ingredients to mimic B27PD
73038|NCT01195974|Drug|YASMIN|YASMIN for 21 days
73039|NCT01195974|Drug|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
73040|NCT01195974|Other|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
73041|NCT00044057|Drug|YM872 (zonampanel), t-PA (alteplase)|
73042|NCT01196000|Procedure|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
73043|NCT01196000|Procedure|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
73044|NCT01196000|Procedure|quality-of-life assessment|Ancillary studies
73045|NCT01196000|Other|questionnaire administration|Ancillary studies
73046|NCT01196013|Drug|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
72468|NCT01166503|Procedure|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
72469|NCT01166503|Procedure|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
72470|NCT01166516|Device|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
72471|NCT01169064|Device|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
72472|NCT01169064|Device|Cloth adhesive dressing|Dressing placed over surgical incision and remains for 3-5 days
72473|NCT01169077|Drug|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
72474|NCT00041483|Drug|Anecortave Acetate 15 mg sterile suspension|
72475|NCT01169077|Biological|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
72742|NCT01203293|Behavioral|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
72743|NCT01203306|Drug|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
72744|NCT00044018|Drug|CDC-501|
72745|NCT01195285|Procedure|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
72746|NCT01195298|Drug|Capecitabine and Bevacizumab|Drugs will be administered in 3-week cycles as follows:
Bevacizumab 15mg/kg via i.v. infusion on day 1
Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14.
72747|NCT01195311|Drug|INCB024360|INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
72748|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
72749|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
72750|NCT01195337|Behavioral|PA Prescription Plan|Exercise program and instructions.
72974|NCT00044447|Drug|Glimepiride|
72975|NCT01198366|Biological|AERAS-402 3.0 x 10^10 vp|
72976|NCT01198366|Biological|AERAS-402 1.0 x 10^11 vp|
72977|NCT01198366|Biological|Placebo|
72978|NCT01198379|Drug|aspirin|aspirin 100 mg qd for 3 years
72979|NCT01198379|Drug|Placebo|
72980|NCT01198392|Drug|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
72981|NCT01198392|Drug|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.
Number of Cycles: until progression or unacceptable toxicity develops.
72982|NCT01198405|Device|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
72983|NCT01198405|Drug|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
72984|NCT01198418|Behavioral|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
72985|NCT01200719|Device|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: < 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity ~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
72986|NCT01200732|Drug|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
72987|NCT01200745|Drug|Capsaicin patch|Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
72988|NCT01200758|Drug|MabThera subcutaneous|At cycle 1 on day 0, day 1 or day 2, MabThera is given as intravenous infusion 375 mg/m2. MabThera subcutaneous 1400 mg at cycle 2 on day 0 and at cycles 3-8 on day 1. In addition, standard chemotherapy is given. Additional maintenance treatment for a maximum of 12 cycles.
72989|NCT01200758|Drug|Mabthera intravenous|MabThera intravenous infusion 375 mg/m2 at cycle 1 on day 0, day 1 and day 2 and at cycles 2-8 on day 1. In addition, standard chemotherapy is given. Additional maintenance treatment for a maximum of 12 cycles.
72543|NCT01166542|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
72544|NCT01166542|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
72545|NCT00041288|Drug|mycophenolate mofetil|
72546|NCT01166542|Drug|Placebo|Placebo
72547|NCT01166555|Drug|PF-04236921|single subcutaneous dose
72548|NCT01166568|Device|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants, and followed for 24 months.
72549|NCT01166594|Drug|Bevacizumab|Intrableb injection
72550|NCT01166594|Drug|Control|intrableb BSS injection
72551|NCT01166633|Drug|pitavastatin|pitavastatin 2mg per daily
72552|NCT01166633|Drug|atorvastatin|atorvastatin 10mg per daily
72553|NCT01166646|Drug|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
72554|NCT01166646|Drug|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
72555|NCT01166659|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye.
72556|NCT00000243|Drug|Buprenorphine|
72557|NCT00000954|Drug|Didanosine|
72558|NCT00041288|Drug|tacrolimus|
72559|NCT01166685|Device|Everolimus-eluting stent|Everolimus-eluting stent
72829|NCT01203371|Drug|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
72830|NCT01203371|Drug|Tamsulosin|0,4 mg/day
72831|NCT01203384|Drug|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
72832|NCT00044954|Procedure|peripheral blood stem cell transplantation|
72833|NCT01203384|Drug|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
72834|NCT01203384|Drug|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
73047|NCT01196026|Biological|Fluarix™|One or two intramuscular injections
73048|NCT01196026|Biological|Havrix™ Junior|Two intramuscular injections
73049|NCT01196039|Drug|MEMP1972A|Intravenous repeating dose
73050|NCT01196039|Drug|placebo|Intravenous repeating dose
72130|NCT01165905|Drug|ON 01910.Na|The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
72131|NCT00000954|Drug|Zalcitabine|
72132|NCT00041262|Drug|fluorouracil|
72133|NCT01165905|Drug|Gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
72134|NCT01165931|Drug|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
72135|NCT01165944|Drug|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
72136|NCT01165970|Drug|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
72137|NCT01165970|Device|Saliva natura|Saliva substitute without restriction to be used
72138|NCT01165983|Drug|Placebo|0mg tablet, taken orally for 12 weeks daily
72139|NCT01165983|Drug|Aliskiren|150mg tablet, taken orally for 12 weeks daily
72140|NCT01165996|Other|flow cytometry|Correlative studies
72141|NCT01165996|Other|DNA methylation analysis|Correlative studies
72142|NCT01165996|Other|cytogenetic analysis|Correlative studies
72143|NCT00041262|Procedure|conventional surgery|
72144|NCT01165996|Drug|decitabine|Given subcutaneously
72145|NCT01165996|Genetic|microarray analysis|Correlative studies
72751|NCT01195337|Device|Pedometer|Step monitor for individual PA progress.
72752|NCT01195337|Behavioral|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
72753|NCT01195363|Drug|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
72754|NCT01195363|Drug|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
72755|NCT00044031|Biological|G17DT Immunogen|
72756|NCT01195376|Drug|BEZ235|
72757|NCT01195389|Device|Resonator|Treatment group vs. Placebo group
72758|NCT01195402|Procedure|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
72759|NCT01195415|Drug|Gemcitabine Hydrochloride|Given IV
72760|NCT01195415|Other|Laboratory Biomarker Analysis|Correlative studies
72761|NCT01195415|Drug|Vismodegib|Given PO
72762|NCT01195428|Drug|Simvastatin|Simvastatin 40 mg daily
73112|NCT01204216|Biological|re-infusion of biotin labeled cells|Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.
73113|NCT01204216|Biological|Re-infusion of biotin labeled cells|Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.
small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
73114|NCT01204216|Behavioral|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
73115|NCT00044993|Procedure|neoadjuvant therapy|
73116|NCT01204229|Behavioral|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
72077|NCT01168414|Drug|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
72078|NCT01168427|Device|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
72079|NCT01168440|Drug|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
72080|NCT01168453|Behavioral|head position change|AL-US distance measure using the ultrasound in two different head position
72081|NCT01168466|Behavioral|HEG Neurofeedback|Detects and displays real time variation in blood flow in outermost 1.5 cm of frontal cerebral cortex.
72082|NCT00041392|Drug|Magnesium|100 mg/kg
72083|NCT01170728|Device|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
72084|NCT01170741|Behavioral|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
72085|NCT01170754|Drug|Golytely vs. Miralax plus gatorade|4L of golytely vs. 255 grams of PEG-3350 mixed with 64 ounces gatorade for colonoscopy preparation.
72086|NCT01170767|Drug|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
72087|NCT01170767|Drug|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
72088|NCT01170780|Drug|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
72089|NCT01170780|Drug|Saline|2 ml IV
72090|NCT01170793|Behavioral|educative telephone coaching (ETC)|a 30 to 45 minutes phone call, by appointment, by the nurse
72091|NCT00041730|Biological|Id-KLH|
72835|NCT01203384|Drug|Placebo|oral tablet, placebo, once a day in the morning for 14 days
72836|NCT01203397|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
72837|NCT01203436|Procedure|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
72838|NCT01203436|Procedure|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
72839|NCT01203462|Other|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
72840|NCT01203462|Other|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
72841|NCT01203488|Drug|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
72842|NCT01203488|Other|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
72843|NCT00044954|Radiation|radiation therapy|
72844|NCT01203514|Drug|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
72845|NCT01203514|Other|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
72846|NCT01203540|Drug|NAABAK eyedrops|
72847|NCT01195480|Biological|Irradiated donor-derived Lymphoblastoid Cell Line|The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in > 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.
Vaccination will consist of 3 doses of 5 x 10^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion.
72848|NCT01195493|Other|Essential Oils solution|(Essential oils solution, Listerine®, Johnson & Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
72849|NCT01195493|Other|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
73190|NCT01204359|Radiation|Iodine 131|iodine 131，185、370、555mBq，6 months
73191|NCT01204372|Drug|Gemcitabine - Trastuzumab - Erlotinib|Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.
Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.
Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.
Erlotinib: oral route 100 mg/day from C1D1.
72146|NCT01168466|Behavioral|EEG Driven Photic Stimulation|A Brainmaster EEG monitors the variation brain's dominant frequency in real time, while a Procyon photic stimulation device provides visual stimulation at 1/2 Hz faster, encouraging or "entraining" a faster frequency. In half of the neurofeedback arm, EEG Driven Photic Stimulation will be provided during neurofeedback displaying dominant frequency and rewarding faster frequencies.
72147|NCT01168466|Behavioral|Peak Alpha Neurofeedback|A Pendant EEG with Bioexplorer software detects and displays the dominant alpha frequency in real time, rewarding faster frequencies.
72148|NCT01168479|Radiation|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
72149|NCT01168479|Radiation|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
72150|NCT01168492|Drug|ketamine|0.5mg/kg ketamine iv
72405|NCT01169025|Drug|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
72406|NCT01169025|Drug|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
72407|NCT01169038|Drug|levaquin; ethambutol; rifampin and azithromycin.|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD
**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway.
72408|NCT01171365|Drug|Placebo|Matched placebo inhaler two inhalations twice daily
72409|NCT01171378|Drug|Ofatumumab|1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.
Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks
72410|NCT01171391|Drug|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
72411|NCT00041769|Procedure|Therapeutic Drug Monitoring (TDM)|
72412|NCT01171391|Other|Placebo|Placebo on Day 1
73117|NCT01204229|Behavioral|Brief Motivational Intervention (BMI)|Integrate drinking intervention
73118|NCT01204242|Drug|Placebo|ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.
Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
73119|NCT01204242|Drug|Lidocaine|ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.
Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
73120|NCT01204255|Drug|lorazepam|Given topically
73121|NCT01196078|Drug|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
73122|NCT01196078|Drug|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
73123|NCT01196091|Drug|LY2127399|120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
73124|NCT01196091|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose
73125|NCT01196091|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
73126|NCT01196104|Drug|Technosphere® Insulin Inhalation Powder|
73127|NCT01196104|Drug|Insulin Aspart|Usual Care
73128|NCT01196104|Drug|Insulin Glargine|
73129|NCT00044083|Drug|Tolcapone|Tolcapone 200 mg tid: Placebo 1 week-Wash Out 1 week-Drug 1 week (or vice versa)
72210|NCT01165996|Genetic|gene expression analysis|Correlative studies
72211|NCT01165996|Other|pharmacological study|Correlative studies
72212|NCT01165996|Genetic|polymorphism analysis|Correlative studies
72213|NCT01166022|Other|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
72214|NCT01166035|Drug|Lenalidomide|Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.
Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.
Disease progression
Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.
Major violation of the study protocol.
Withdrawal of consent
Lost to follow up
Death
Suspected pregnancy
72092|NCT01170806|Drug|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
72093|NCT01170819|Device|Double balloon catheter|The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
72353|NCT01171352|Procedure|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
72354|NCT01171365|Drug|Ciclesonide|Inhaled ciclesonide 320mcg twice daily
72355|NCT01173822|Other|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
72356|NCT01173835|Behavioral|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
72357|NCT01173848|Drug|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
72358|NCT01173848|Drug|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
72359|NCT00042198|Behavioral|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
72360|NCT01173861|Behavioral|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
72361|NCT01173874|Drug|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
72362|NCT01173887|Drug|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
72363|NCT01173887|Biological|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
72364|NCT01173900|Biological|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
72365|NCT01173913|Drug|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
73192|NCT01204385|Procedure|Sample collection|Middle ear fluid and urine
73193|NCT00000985|Drug|Vidarabine|
73194|NCT00045032|Biological|trastuzumab|
73195|NCT01204398|Drug|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
73196|NCT01204411|Drug|Artesunate-amodiaquine fixed-dose combination|artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;
artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;
artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;
73197|NCT01204424|Device|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
73198|NCT01204424|Device|minimal invasive crestal sinus lift with the JEDER Systh.|The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.
The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the "percussion drill"). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore.
73199|NCT01204437|Drug|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
73200|NCT01204437|Drug|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
73201|NCT01204437|Drug|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
73202|NCT01204450|Drug|temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
73203|NCT01204450|Drug|valproic acid (VPA)|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
73204|NCT01204476|Biological|Cixutumumab|Given IV
73205|NCT00045032|Procedure|adjuvant therapy|
73206|NCT01204476|Drug|Everolimus|Given PO
73207|NCT01204476|Other|Laboratory Biomarker Analysis|Correlative studies
72273|NCT01173692|Drug|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
72413|NCT01171430|Device|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|3 Whole Body Dynamic Contrast Enhanced MRI:
1 WB-DCE-MRI before induction of chemotherapy(initial MRI).
1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).
1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI).
72414|NCT01171456|Drug|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
72415|NCT01171456|Drug|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
72416|NCT01171469|Biological|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
72417|NCT01171469|Drug|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
72418|NCT01171482|Drug|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
72686|NCT01197794|Drug|AZD1981|AZD1981 once daily
72687|NCT01197794|Drug|Placebo|Placebo to match AZD1981
72688|NCT00044356|Genetic|Allovectin-7®|
72689|NCT01197807|Procedure|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
72690|NCT01197807|Procedure|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
72691|NCT01197820|Device|MRI|Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.
In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.
Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed
72692|NCT01197833|Drug|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
72693|NCT01197833|Drug|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
72694|NCT01197833|Drug|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
72695|NCT01197846|Drug|Quetiapine|quetiapine 300 mg or 600 mg
72215|NCT01166035|Drug|Cetuximab|Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.
Treatment will continue until the occurrence of any of the following events.
Disease progression
Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.
Major violation of the study protocol.
Withdrawal of consent
Lost to follow up
Death
Suspected pregnancy
72216|NCT01166048|Drug|Duloxetine|Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)
day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg
day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg
72217|NCT01166048|Drug|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
72218|NCT00041262|Procedure|neoadjuvant therapy|
72219|NCT01166061|Biological|Placebo|Solution resembling active solution but without peptides
72220|NCT01166061|Biological|ToleroMune Grass|1 x4 administrations 4 weeks apart
72221|NCT01166074|Biological|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
72222|NCT01166087|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
72223|NCT01166100|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
72476|NCT01169090|Drug|SK-0403|SK-0403
72477|NCT01169090|Drug|Placebo|Placebo
72478|NCT01169090|Drug|Sitagliptin|Sitagliptin
72479|NCT01169103|Drug|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
72480|NCT01169103|Drug|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
72481|NCT01169116|Radiation|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
72482|NCT01169129|Other|surgery|resection of brain metastases
72483|NCT01169129|Radiation|radiosurgery|radiosurgery to brain metastases
72484|NCT01169142|Dietary Supplement|Vitamin D3|50,000 units of Vitamin D3 weekly
72485|NCT00000957|Biological|gp160 Vaccine (Immuno-AG)|
72366|NCT01173913|Drug|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
72367|NCT01173926|Drug|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
72627|NCT01200173|Other|2-Non fermented dairy product (control)|
72628|NCT01200186|Drug|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
72629|NCT01200186|Drug|Progestin Only Pills|At the discretion of the attending physician
72630|NCT01200212|Drug|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
72631|NCT01200212|Drug|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
72632|NCT01200238|Drug|STA-9090|Given intravenously once week for three weeks of a four week cycle
72633|NCT01200251|Drug|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
72634|NCT00044694|Drug|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
72635|NCT01200264|Drug|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
72636|NCT01202942|Other|Quest|Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
72637|NCT01202955|Drug|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
72638|NCT01202955|Drug|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
72639|NCT01202968|Procedure|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
72274|NCT01173692|Drug|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
72275|NCT01173718|Device|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
72276|NCT01173731|Drug|AFQ056|
72277|NCT01173744|Device|Gamma-3 Nail|Gamma-3 Nail (stryker)
72278|NCT01173744|Device|DHS|DHS (Zimmer)
72279|NCT01173757|Drug|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
72280|NCT01173770|Drug|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
72281|NCT00042198|Behavioral|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
72282|NCT01173770|Drug|ADC3680B|ADC3680B or Placebo for 7 days
72283|NCT01173770|Drug|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
72284|NCT01173796|Procedure|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
72285|NCT01173796|Procedure|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
72286|NCT01173809|Drug|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
72287|NCT01173809|Drug|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
72288|NCT01166126|Other|laboratory biomarker analysis|Correlative studies
72289|NCT01166139|Drug|Nilotinib (Tasigna)|Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
72290|NCT00041275|Drug|megestrol acetate|
72291|NCT01166152|Behavioral|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
72292|NCT01166165|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
72293|NCT01166165|Drug|Placebo|3 placebo tablets daily for 20 weeks
72294|NCT01166178|Drug|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
72696|NCT01197846|Drug|Placebo|Placebo
72697|NCT01197872|Other|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
72698|NCT01197885|Drug|IMAB362|Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
72699|NCT00044369|Procedure|Varicocele repair|
72700|NCT01197898|Biological|Collagenase Santyl Ointment|Topical daily application
72701|NCT01197898|Other|Placebo Comparator|Topical daily application
72702|NCT01197911|Drug|aleglitazar|single oral dose
72703|NCT01197924|Other|IRMf Bold|IRMf BOLD of the working memory
72704|NCT01200277|Procedure|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
73051|NCT01196052|Drug|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
73052|NCT00044070|Drug|YM872 (zonampanel)|
73053|NCT01196065|Drug|RO5313534|single oral dose
73054|NCT01196065|Drug|memantine|multiple doses to steady state
73055|NCT00044460|Drug|rosiglitazone|
73056|NCT01198431|Behavioral|Sleep duration|Duration of sleep per night
73057|NCT01198444|Drug|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
73058|NCT01198457|Drug|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
73059|NCT01198470|Device|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
73060|NCT01198483|Procedure|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
73061|NCT01198483|Procedure|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
72486|NCT00041483|Other|Photodynamic Therapy (PDT)|
72487|NCT01169142|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 units weekly
72488|NCT01169155|Other|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
72489|NCT01169181|Device|AMES + brain stimulation|Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
72490|NCT01169220|Drug|Go-Lytely|Bowel cleansing agent
72491|NCT01169220|Drug|Go Lytely|Bowel cleansing agent
72492|NCT01169233|Device|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
72493|NCT01169259|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
72494|NCT01169259|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
72495|NCT01169259|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
72496|NCT01169259|Dietary Supplement|Fish oil placebo|Fish oil placebo
72497|NCT00041496|Drug|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
72498|NCT01171508|Other|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
72763|NCT01195428|Drug|Placebo|Placebo
72764|NCT01195454|Drug|Insulin glargine (HOE901)|Pharmaceutical form: Lantus solution for injection
Route of administration: subcutaneous
72765|NCT01195454|Drug|Insulin glargine (HOE901)|Pharmaceutical form: New insulin glargine formulation solution for injection
Route of administration: subcutaneous
72766|NCT00000977|Biological|gp160 Vaccine (MicroGeneSys)|
72767|NCT00044044|Drug|Lurasidone 20 mg|Lurasidone 20mg/day tablets
72768|NCT01195467|Drug|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
72769|NCT01195480|Genetic|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10^8/m2
72770|NCT01197950|Device|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
72640|NCT01202994|Drug|18F-Flutemetamol|All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).
For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.
The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images.
72641|NCT01203007|Dietary Supplement|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
72642|NCT01203007|Dietary Supplement|Low antigen content diet|Low-antigen content diet for one month
72643|NCT01203020|Drug|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
72644|NCT01203020|Drug|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
72990|NCT01200758|Drug|Standard Chemotherapy|up to 8 cycles of standard chemotherapy consisted of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks.
72991|NCT01200771|Procedure|TEP|Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
72992|NCT00044707|Drug|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
72993|NCT01200784|Drug|Nicotinamide|dosage
72994|NCT01200797|Drug|SJG-136|Given IV
72995|NCT01200797|Other|laboratory biomarker analysis|Correlative studies
72996|NCT01200810|Other|placebo|Given orally
72997|NCT01200810|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
72998|NCT01200810|Drug|bicalutamide|Given orally
72999|NCT01200849|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
73000|NCT01200862|Drug|Investigational new drug company code: BGS649|
73001|NCT01200862|Drug|Placebo|
73002|NCT01200875|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
73003|NCT00000982|Drug|Zidovudine|
73004|NCT00044720|Drug|Rapamune|
72295|NCT01166178|Drug|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
72560|NCT01166685|Device|Bare-metal stent|Bare metal stent
72561|NCT01166685|Device|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
72562|NCT01166698|Drug|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
72563|NCT01166698|Drug|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
72564|NCT01166698|Drug|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
72565|NCT01169272|Device|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
72566|NCT01169298|Drug|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
72567|NCT01169311|Device|Hemorrhoidopexy|
72568|NCT01169324|Other|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
72569|NCT01169337|Other|Clinical Observation|Undergo observation
72570|NCT01169337|Other|Laboratory Biomarker Analysis|Correlative studies
72571|NCT01169337|Drug|Lenalidomide|Given PO
72572|NCT01169337|Other|Quality-of-Life Assessment|Ancillary studies
72573|NCT01169350|Radiation|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
72574|NCT01169350|Other|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
72575|NCT00041496|Other|Placebo|Placebo to match SB-207266
72576|NCT01169350|Procedure|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
72577|NCT01169350|Procedure|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
72578|NCT01169350|Other|laboratory biomarker analysis|Correlative studies
72579|NCT01169363|Genetic|proteomic profiling|
72580|NCT01169363|Other|flow cytometry|
72581|NCT01169363|Other|laboratory biomarker analysis|
73062|NCT01198496|Drug|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|<Study drugs and treatment steps> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
73063|NCT01198509|Drug|doxycycline|doxycycline - 100 mg twice per day, for 2 months
73064|NCT01198509|Drug|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
73065|NCT01198522|Drug|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.
Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29.
73066|NCT00044473|Drug|levofloxacin|
73067|NCT01198535|Biological|Cetuximab|Given IV
73068|NCT01198535|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
73069|NCT01198535|Other|Laboratory Biomarker Analysis|Correlative studies
72151|NCT01168505|Drug|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
72152|NCT01168531|Drug|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
72153|NCT01168531|Drug|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
72154|NCT01168531|Drug|placebo|vitamin B complex formula
72155|NCT01168544|Dietary Supplement|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
72156|NCT00041392|Drug|0.9% saline|Placebo
72157|NCT01168544|Dietary Supplement|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
72158|NCT01168544|Dietary Supplement|Vitamin D 800 IU /day|800 IU vit D3/day
72159|NCT01168557|Device|EIT (Electrical Impedance Tomography)|EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
72771|NCT01197950|Device|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
72772|NCT01197963|Procedure|Sleeve Gastrectomy and Ileal transposition|Laparoscopic sleeve gastrectomy with ileal transposition
72773|NCT01197963|Dietary Supplement|dietary and medical management|dietary and medical routine management patients are currently following with an endocrinologist.
72774|NCT01197976|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
72775|NCT01197976|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
72776|NCT00000979|Drug|Zidovudine|
72777|NCT00044382|Drug|CC-5013|
72778|NCT01197989|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
72779|NCT01197989|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
72780|NCT01198002|Drug|LY2127399|Administered Subcutaneously
72781|NCT01198002|Drug|Placebo every 2 weeks|Administered Subcutaneously
72782|NCT01198002|Drug|Placebo every 4 weeks|Administered Subcutaneously
72783|NCT01198028|Drug|Erlotinib|150 mg by mouth for 8 weeks.
73130|NCT01196117|Device|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
73131|NCT01196117|Device|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
73132|NCT01196130|Behavioral|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
73133|NCT01196130|Other|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
73134|NCT01196169|Drug|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
73005|NCT01200875|Procedure|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
73006|NCT01200901|Drug|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
73007|NCT01200914|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
73008|NCT01203748|Procedure|PVI|Pulmonary vein antrum isolation
73009|NCT01203748|Procedure|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
73010|NCT01203774|Drug|Glargine insulin|20-180 units per day
73011|NCT01203787|Drug|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
73012|NCT01203787|Drug|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
72094|NCT01170819|Drug|Dinoprostone 10 mg controlled-release vaginal insert|Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
72095|NCT01170845|Drug|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
72096|NCT01170858|Drug|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
72097|NCT01170858|Drug|glucose solutions|
72098|NCT01170871|Drug|Ixabepilone|
72099|NCT01170871|Drug|Pemetrexed|
72100|NCT01170884|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
72101|NCT01170884|Drug|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
72102|NCT01173328|Behavioral|Normal Breathing|
72103|NCT01173341|Other|Blood, Echocardiography, and Questionnaire Timepoints for Anthracycline abd Trastuzumab|Blood Draw is 16 ml at Pre-treatment and 12ml every 6 weeks during therapy Questionnaire is every 6 weeks during therapy.
1 Echo during pre-treatment, 1 Echo after anthracycline/before Trastuzumab, 1 Echo 3 months, 6 months, 9 months and 12 months of Trastuzumab
72104|NCT00042172|Drug|Donepezil|
72582|NCT01169376|Genetic|DNA analysis|
72583|NCT01169376|Genetic|DNA methylation analysis|
72584|NCT01169376|Genetic|RNA analysis|
72585|NCT01169376|Genetic|comparative genomic hybridization|
72850|NCT01195545|Device|Veritas® Collagen Matrix|biological mesh in hernia repair
72851|NCT01195558|Other|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
72852|NCT01195571|Biological|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
72853|NCT01195597|Device|E-Cigarette 7.2 mg nicotine|Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges ("Original" cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer
72854|NCT01195610|Behavioral|Dietary intervention|Instruction to diet for 6 month
72855|NCT00044044|Drug|Lurasidone 40mg|Lurasidone 40mg/day tablets
72856|NCT01195623|Procedure|preoperative duplex examination|
72857|NCT01195623|Procedure|Preoperative duplex|
72858|NCT01195636|Drug|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
72859|NCT01195636|Drug|Placebo|Twice daily application of Placebo ointment
72860|NCT01195649|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
72861|NCT01195662|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
72862|NCT01195662|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
72863|NCT01195675|Drug|BI 10773 (low)|single oral dose
72864|NCT01195675|Drug|Moxifloxacin|single oral dose
72865|NCT01195675|Drug|BI 10773 Placebo|2 times single dose
72866|NCT00044044|Drug|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
72867|NCT01195675|Drug|BI 10773 (high)|single oral dose
72160|NCT01168596|Drug|Rasagiline|Comparison of Rasagiline versus placebo.
Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
72161|NCT01168596|Drug|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
72162|NCT01168609|Procedure|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
72163|NCT01168635|Behavioral|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|The Spirometry 360 program includes:
"Spirometry Fundamentals™: A basic guide to lung function testing," a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;
Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;
Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic.
72164|NCT00041743|Behavioral|Group Cognitive Behavioral Therapy|
72165|NCT01170897|Drug|PEGPH20|PEGylated Recombinant Human Hyaluronidase
72166|NCT01170910|Procedure|Static incubation|Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.
72167|NCT01170910|Procedure|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
72419|NCT01171482|Drug|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
72420|NCT01171482|Drug|sorafenib|400 mg BID every 28 days
72421|NCT01171495|Dietary Supplement|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
72422|NCT00041782|Drug|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
72423|NCT01171495|Dietary Supplement|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
72424|NCT01171508|Device|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
72425|NCT01171508|Device|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
73135|NCT01196169|Drug|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if > one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of < 50 ml/min. Patients with creatinine clearance of < 50 ml/min will only receive one dose.
73136|NCT01196195|Drug|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
73137|NCT01196195|Drug|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
73138|NCT01196208|Drug|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
73139|NCT01196234|Drug|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
73140|NCT00044109|Device|Magnets|
73141|NCT01196234|Drug|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
73142|NCT01196247|Drug|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
73143|NCT01196260|Drug|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
73144|NCT01198574|Dietary Supplement|Iron group|Ferrous fumarate, 60 mg, weekly dose
73145|NCT01198574|Dietary Supplement|Vitamin A group|Retinol, weekly dose, 15,000 IU
73146|NCT01198574|Dietary Supplement|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
73147|NCT01198574|Dietary Supplement|Placebo group|folic acid only as placebo group
73148|NCT01198587|Drug|Zinc Sulfate|For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.
For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid.
73149|NCT01198600|Device|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
72224|NCT01166113|Drug|Pomalidomide, Cyclophosphamide, Prednisone|Induction
This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.
In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.
The dose level associated with an updated DLT is recommended for the next patient cohort.
Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d
In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.
Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d
72225|NCT01166126|Drug|temsirolimus|Given IV
72105|NCT01173341|Other|Blood, Echocardiography and Questionnaire for Trastuzumab|Echo at Pre-Treatment, 3 months, 6 months, 9 months and 12 months Blood Draw 16 ml at Pre-Treatment, 12 ml every 6 weeks during therapy Questionnaire at Pre-Treatment and every 6 weeks during therapy
72106|NCT01173341|Other|Blood, Echocardiography and Questionnaire for Anthracycline Regimen|Echocardiogram at Pre-anthracycline, Completion of anthracycline and 1 year after anthracycline initiation Blood Draw 16 ml at Pre-anthracycline, 12 ml during anthracycline, completion of anthracycline and 1 year after anthracycline initiation Questionnaire during Pre-anthracycline, during anthracycline, completion of anthracycline and 1 year after anthracycline initiation
72107|NCT01173354|Dietary Supplement|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
72108|NCT01173354|Dietary Supplement|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
72109|NCT01173367|Other|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
72110|NCT01173367|Other|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
72368|NCT01173926|Drug|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
72369|NCT01173926|Drug|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
72370|NCT00042211|Behavioral|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
72371|NCT01173939|Drug|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of <120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
72372|NCT01166308|Radiation|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
72373|NCT01166321|Radiation|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
72374|NCT01166334|Behavioral|WebQuit study group|Description withheld to protect integrity of study
72375|NCT01166334|Behavioral|WebQuit control group|Identity and description withheld to protect integrity of study
72868|NCT01195688|Drug|BI 638683 or placebo|oral doses given to 6 subjects per dose group
72869|NCT01195688|Drug|Placebo solution|oral doses given to 2 subjects per dose group
72870|NCT01195714|Drug|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
72871|NCT01198132|Dietary Supplement|Cholecalciferol (Vitamin D3)|Subjects will be receiving 100 000 International units (IU - 1 IU is biological equivalent of 0.025µg cholecalciferol) twice monthly, i.e. one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) during the 24-month period.
72872|NCT01198145|Drug|sulfasalazine|Given orally
73208|NCT01204476|Drug|Octreotide Acetate|Given IM
73209|NCT01204476|Other|Pharmacological Study|Correlative studies
73210|NCT01196273|Other|Comprehensive non invasive cardiovascular examination|The examination includes:
Anamnesis incl. admission form
Physical examination
Documentation of the medical therapy (incl. HAART)
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
6 minute walk test
Blood collection
Questionnaire to quality of life and health economics
73211|NCT01196286|Behavioral|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
73212|NCT01196286|Behavioral|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
73213|NCT01196312|Behavioral|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
73214|NCT01196338|Behavioral|Early weight-bearing and range of motion exercises|0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;
At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;
At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;
After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis.
73215|NCT01196338|Behavioral|non-weight bearing, no range of motion|0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;
At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;
At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;
After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis.
73216|NCT01196351|Other|Dietary Supplement: water with noncalorie sweetener|
73217|NCT00044135|Drug|clevudine (drug)|
72426|NCT01171508|Device|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
72427|NCT01171508|Procedure|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
72428|NCT01173939|Drug|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of <70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
72429|NCT01173965|Device|MEA|Microwave endometrial ablation device
72430|NCT01173965|Device|Novasure|Bipolar impedence control system
72431|NCT01173978|Behavioral|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
72432|NCT01173978|Other|No intervention|
72433|NCT01173991|Behavioral|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
72434|NCT01174004|Drug|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
72435|NCT01174004|Drug|placebo|placebo, tablet, once daily by mouth for 6 weeks
72436|NCT01174017|Radiation|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
72437|NCT00042211|Behavioral|Control|No treatment control
72438|NCT01174017|Radiation|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
72705|NCT01200277|Procedure|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
72706|NCT01200290|Drug|LY2127399|120mg administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
72707|NCT01200303|Procedure|non-cathartic CTC|non-cathartic, CAD-assisted CT Colonography
72708|NCT01200316|Procedure|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
72226|NCT01166126|Drug|selumetinib|Given orally
72227|NCT01168648|Behavioral|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
72228|NCT01168648|Other|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
72229|NCT01168661|Behavioral|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) >= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
72230|NCT00041431|Drug|Hormone Replacement Therapy|
72231|NCT01168661|Behavioral|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
72232|NCT01168661|Behavioral|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
72233|NCT01168674|Drug|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
72234|NCT01168674|Drug|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
72235|NCT01168687|Drug|Levetiracetam (Keppra)|Group A: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
Group B: Twenty moderate to heavy social alcohol users as described above will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
72236|NCT01168687|Drug|Placebo|
72499|NCT01171508|Other|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
72500|NCT01171508|Other|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
72376|NCT01166347|Device|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
72377|NCT01166347|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
72378|NCT01166373|Behavioral|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
72379|NCT01166373|Procedure|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
72380|NCT01166373|Procedure|ULS|uterosacral ligament suspension to suspend the vaginal apex
72381|NCT01166373|Behavioral|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
72382|NCT00041288|Drug|cyclosporine|
72383|NCT01166373|Other|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
72384|NCT01166386|Behavioral|FANCI|compresensive neubehavioral sessions with therapist administrating treatment components
72385|NCT01166386|Behavioral|FANCI|Watching DVDs chosen by participants on various topics.
72386|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
72387|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
72645|NCT01203046|Drug|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
72646|NCT00044954|Drug|cyclosporine|
72647|NCT01203072|Drug|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
72648|NCT01203072|Drug|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
72649|NCT01203072|Drug|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
72650|NCT01203072|Drug|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
72651|NCT01203072|Drug|Placebo|Matching placebo oral tablets, once daily for 2 weeks
72652|NCT01203098|Drug|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
72653|NCT01203098|Drug|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
73218|NCT01196351|Other|Activity: With noncalorie sweetener or glucose|
73219|NCT01196364|Other|Dietary Supplement: water with noncalorie sweetener|
73220|NCT01196364|Other|Activity: With noncalorie sweetener or glucose|
73221|NCT01196377|Drug|Albuterol|Nebulized albuterol
73222|NCT01196390|Drug|Carboplatin|Given IV
73223|NCT01196390|Other|Laboratory Biomarker Analysis|Correlative studies
73224|NCT01196390|Drug|Paclitaxel|Given IV
73225|NCT01196390|Other|Quality-of-Life Assessment|Ancillary studies
72022|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
72023|NCT01173224|Drug|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
72024|NCT01173224|Drug|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
72025|NCT01173237|Procedure|Use tracheal intubation for surfactant therapy|Surfactant endotracheal administration after tracheal intubation
72026|NCT01173237|Procedure|Use of Proseal laryngeal mask airway for surfactant therapy|Surfactant use by proseal laryngeal mask airway
72027|NCT01173250|Procedure|adding diverting ileostomy|
72028|NCT01173250|Procedure|omitting diverting ileostomy|
72029|NCT00042159|Device|repetitive transcranial magnetic stimulation|1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
72030|NCT01173263|Other|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
72031|NCT01173263|Other|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
72032|NCT01173263|Other|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
72709|NCT01200316|Procedure|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
72710|NCT01200316|Behavioral|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
72711|NCT01200329|Drug|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
72712|NCT01200329|Drug|Busulfan|32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient
AUC 4,000 by vein over about 3 hours on days -8 to -5.
72713|NCT00044694|Drug|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
72714|NCT01200329|Drug|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
72715|NCT01200329|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
72716|NCT01200329|Drug|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
72717|NCT01200342|Drug|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
72718|NCT01200342|Drug|Paclitaxel|175 mg/m^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
72719|NCT01200342|Drug|Carboplatin|Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.
The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC).
72720|NCT01200355|Drug|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
72721|NCT01200355|Drug|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
72722|NCT01200368|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
72723|NCT01200368|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
73070|NCT01198535|Other|Pharmacological Study|Correlative studies
73071|NCT01198548|Drug|leucovorin calcium|Given IV
73072|NCT01198548|Biological|bevacizumab|Given IV
73073|NCT01198548|Dietary Supplement|cholecalciferol|Given PO
73074|NCT01198548|Drug|fluorouracil|Given IV
72501|NCT01171521|Device|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
72502|NCT01171534|Device|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
72503|NCT00041795|Drug|leteprinim potassium (Neotrofin)|
72504|NCT01171534|Device|Vessel loop|Vessel loops and staples for fasciotomy closure
72505|NCT01171547|Drug|Daptomycin|once daily over 5 days
72506|NCT01171560|Procedure|endotracheal intubation|The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
72507|NCT01171573|Procedure|Venepuncture|Venepuncture - Taking blood
72508|NCT01171586|Behavioral|mDiet|The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily "pushed" and "pulled" text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics.
72509|NCT01171599|Behavioral|Fit4Life|As previously described, the purpose of this study is to develop a web and text message based weight loss intervention for childhood acute lymphoblastic leukemia survivors (ALL) survivor. The web and text message based intervention that is being developed will be evaluated in a separate ACS (American Cancer Society) funded trial randomized control trial. The web and text message based intervention (there are other intervention features that do not relate to the web & text based platforms that were developed as part of this NIH funded study) is a 16-week program that includes:
72510|NCT01171625|Device|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
72511|NCT01171638|Device|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
72512|NCT01171651|Drug|JX-594 followed by sorafenib|Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
72513|NCT01171664|Drug|Placebo|Tablet, one BID
72514|NCT00041808|Drug|MTC-DOX for Injection|
72515|NCT01171664|Drug|STAHIST|STAHIST in tablet form dosed one BID
72784|NCT01198054|Drug|Lenalidomide|Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.
In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease
72654|NCT01203098|Drug|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
72655|NCT01203111|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
72656|NCT01203111|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
72657|NCT00044954|Drug|fludarabine phosphate|
72658|NCT01195181|Drug|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
72659|NCT01195194|Drug|PRE-TRANSPLANT (PRE=before)|All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).
Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.
Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL).
72660|NCT01195207|Biological|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
72661|NCT01195207|Biological|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
72662|NCT01195207|Biological|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
72663|NCT01195207|Biological|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
72664|NCT01195207|Biological|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
72665|NCT01195207|Biological|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
73013|NCT01203813|Other|Electronic Decision Support|Physicians randomized to the intervention will receive:
Electronic alerts during office visits for patients with chronic kidney disease
Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program
73014|NCT00044980|Procedure|quality-of-life assessment|
73015|NCT01203826|Biological|Asfotase Alfa|
73016|NCT01203839|Radiation|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
72033|NCT01173276|Other|Sperm Washing with Intrauterine Insemination (IUI)|For semen samples, seminal fluid will be separated from sperm using a density gradient/swim-up separation technique. The purified sperm sample will be washed, and screened for HIV RNA using sensitive real-time RT-PCR. Samples with detectable traces of HIV RNA will not be used for insemination. Samples with no detectable traces of HIV RNA will be used for a standard intrauterine insemination of the female partner.
72034|NCT01173289|Radiation|External Beam Radiotherapy|Definition of target volume:
Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan
Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)
Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.
Radiation dose and planning
Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks
Dose prescription: 90% isodose volume of prescribed dose encompassed PTV
The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated.
72035|NCT01173302|Biological|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
72036|NCT01173315|Dietary Supplement|vitamin and mineral supplementation|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
71057|NCT01183039|Other|Training|20 sessions of training
71058|NCT01183052|Other|Training|20 sessions of training
71059|NCT01183065|Drug|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
71060|NCT01183078|Procedure|free-hand|Free-hand technique utilizes x-rays to find screw holes.
71061|NCT01183078|Procedure|Wand technique|Wand technique is utilized to find screw holes.
71062|NCT01183091|Procedure|Ablation of atrial fibrillation|Ablation of atrial fibrillation
71063|NCT00042887|Procedure|conventional surgery|
71064|NCT01183104|Drug|Sitagliptin, Glimepiride|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; GFR 30=< <50).
Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
71065|NCT01183117|Device|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
71066|NCT01183117|Device|PTA|balloon angioplasty
73075|NCT01198548|Drug|oxaliplatin|Given IV
73076|NCT01198548|Other|pharmacological study|Correlative studies
73077|NCT00044486|Drug|Posaconazole oral suspension|
73078|NCT01198561|Device|repetitive Transcranial Magnetic Stimulation|10 times repetitive TMS, high frequency
73079|NCT01200914|Procedure|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
73080|NCT01200927|Other|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
73081|NCT01200940|Other|Sucralose|
73082|NCT01200940|Other|Aspartame|
73083|NCT01200940|Other|Acesulfame-Potassium|
73084|NCT01200992|Biological|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
73085|NCT01200992|Biological|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
73086|NCT00044733|Drug|Mylotarg (gemtuzumab ozogamicin) Injection|
73087|NCT01201005|Dietary Supplement|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
73088|NCT01201005|Dietary Supplement|Sham injection|needle injection without any substance given
73089|NCT01201018|Drug|Oshadi D, Oshadi R|Oral administration
73090|NCT01201044|Drug|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 & D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
73091|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
73092|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
73093|NCT01201044|Drug|Gemcitabine，Nedaplatin, BAI|Drug: Gemcitabine, Nedaplatin, iV
Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI
72168|NCT01170923|Device|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
72169|NCT01170923|Device|CT|CT performed after 3 cycles of chemotherapy
72170|NCT01170936|Drug|canakinumab|Single dose of canakinumab 300mg s.c. injection
68641|NCT01152242|Drug|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
68642|NCT01152242|Drug|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
68929|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
68930|NCT01155050|Device|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
68931|NCT01147133|Drug|Plavix|1x75 mg
68932|NCT01147133|Drug|Kardogrel|1x75 mg
68933|NCT01147146|Drug|propofol, fentanyl, atracurium|general anesthesia
68934|NCT01147146|Drug|bupivacaine|spinal anesthesia
68935|NCT01147146|Drug|bupivacaine, Midazolam|spinal anesthesia & sedation
68936|NCT01147159|Other|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
68937|NCT01147172|Device|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
68938|NCT01147185|Device|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
68939|NCT00039832|Drug|Abciximab (ReoPro) and Reteplase (Retavase)|
68940|NCT01147185|Device|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
68941|NCT01147198|Dietary Supplement|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
68942|NCT01147198|Dietary Supplement|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
68943|NCT01147211|Drug|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
68944|NCT01147224|Drug|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
68945|NCT01147237|Device|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
68946|NCT01147250|Drug|lixisenatide (AVE0010)|Pharmaceutical form:sterile aqueous solution
Route of administration: subcutaneous
72326|NCT01168843|Other|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
72327|NCT01168882|Drug|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
72328|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
72329|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
72330|NCT01168908|Drug|Sildenafil|20mg tablet three times daily
72331|NCT00041470|Drug|Trastuzumab|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
72332|NCT01168921|Drug|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
72333|NCT01168934|Drug|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
72334|NCT01171183|Drug|Placebo|Placebo
72915|NCT01200693|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
72916|NCT01200693|Device|Zotarolimus eluting stent|Implantation of Zotarolimus eluting stent
72917|NCT01200706|Drug|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
72918|NCT01203540|Drug|Saline eyedrops|
72919|NCT01203553|Procedure|Abdominal surgery|Intraoperative mesh implantation
72920|NCT01203566|Procedure|LESS appendectomy|See under arms description
72921|NCT01203566|Procedure|Conventional 3-port laparoscopic appendectomy|See under arms description
72922|NCT01203592|Drug|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
72923|NCT01203618|Drug|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
72924|NCT01203631|Drug|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
72925|NCT00000984|Drug|CD4 Antigens|
69098|NCT01155011|Behavioral|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
69401|NCT01147952|Behavioral|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
69402|NCT01150643|Genetic|gene expression analysis|
69403|NCT01150643|Genetic|microarray analysis|
69404|NCT01150643|Genetic|polymerase chain reaction|
69405|NCT01150643|Genetic|polymorphism analysis|
69406|NCT01150643|Other|immunohistochemistry staining method|
69407|NCT01150643|Other|laboratory biomarker analysis|
69408|NCT01150656|Genetic|gene expression analysis|
69409|NCT01150656|Genetic|microarray analysis|
69410|NCT01150656|Genetic|protein expression analysis|
69411|NCT01150656|Genetic|reverse transcriptase-polymerase chain reaction|
69412|NCT00040326|Drug|antiepileptic drugs|pharmacotherapy
69413|NCT01150656|Genetic|western blotting|
69414|NCT01150656|Other|laboratory biomarker analysis|
69415|NCT01150656|Other|pharmacological study|
69416|NCT01150669|Other|laboratory biomarker analysis|Samples are analyzed in laboratory studies
69417|NCT01150682|Genetic|RNA analysis|
69418|NCT01150682|Genetic|reverse transcriptase-polymerase chain reaction|
69419|NCT01150682|Other|enzyme-linked immunosorbent assay|
69420|NCT01150682|Other|immunohistochemistry staining method|
69421|NCT01150682|Other|laboratory biomarker analysis|
68875|NCT01149746|Drug|Tamsulosin|Reference Listed 0.4 mg Capsule
68876|NCT00040209|Drug|JP 1730|
68877|NCT01149759|Drug|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
69161|NCT01153074|Device|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
69162|NCT01153100|Drug|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
69163|NCT01153113|Biological|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
69164|NCT01153113|Biological|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
69165|NCT01153126|Behavioral|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
69166|NCT01153139|Device|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
69167|NCT01153165|Drug|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
69168|NCT00040469|Drug|Busulfan|
69169|NCT01155050|Behavioral|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
69170|NCT01155050|Device|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
69171|NCT00040677|Drug|Low Dose ICA-17043|Low dose arm
69172|NCT01155063|Other|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
69173|NCT01155076|Dietary Supplement|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
69174|NCT01155076|Dietary Supplement|Placebo|Placebo taken twice a day for 8 weeks
69175|NCT01155089|Drug|Anastrozole|1 mg tablet
69176|NCT01155102|Drug|Anastrozole|1 mg tablet
68947|NCT01147250|Drug|placebo|Pharmaceutical form:sterile aqueous solution
Route of administration: subcutaneous
68948|NCT01147263|Other|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
68949|NCT01147276|Drug|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
68950|NCT00039858|Drug|Argatroban|
69232|NCT01153191|Procedure|Normal saline pressurized irrigation|same
69233|NCT01153191|Drug|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
69234|NCT01153204|Behavioral|Group Psychotherapy|
69235|NCT01153204|Other|Group Psychotherapy plus Sildenafil citrate|
69236|NCT01153204|Drug|Sildenafil citrate|
69237|NCT01153217|Drug|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
69238|NCT01153243|Drug|Ergocalciferol|Active Comparator: Ergocalciferol
The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
69239|NCT01153243|Drug|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
69240|NCT01153256|Drug|magnesium sulphate|The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
69241|NCT00040469|Drug|Cyclophosphamide|
69242|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
69243|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
69244|NCT01153269|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
69245|NCT01153295|Procedure|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
69246|NCT01153295|Procedure|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
72926|NCT00044967|Genetic|microsatellite instability analysis|
72927|NCT01203631|Drug|placebo|A single dose administered subcutaneously (s.c., under the skin)
72928|NCT01203644|Drug|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
72929|NCT01203644|Drug|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
72930|NCT01203657|Behavioral|Tai Chi|Tai Chi classes, 60 minutes, 2x week
72931|NCT01203670|Dietary Supplement|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
72932|NCT01203683|Behavioral|Active computer-based training|8 sessions across 4 weeks.
72933|NCT01203683|Behavioral|Inert computer training|8 sessions across 4 weeks.
72934|NCT01203696|Drug|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
72935|NCT01203696|Drug|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
72936|NCT01203709|Drug|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
72937|NCT00044980|Procedure|nutritional support|
72952|NCT01195792|Drug|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
72953|NCT01195805|Drug|Spironolactone|1 tablet twice a day for 28 days
72954|NCT01195805|Other|Placebo|1 tablet twice a day for 28 days
72955|NCT01195805|Drug|Amiloride|1 tablet twice a day for 28 days
72956|NCT01195818|Drug|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
72957|NCT01195831|Drug|Xamiol® gel|Once daily application
72958|NCT01195831|Drug|Calcipotriol scalp solution|Twice daily application
72959|NCT00044044|Drug|Placebo|Matching Placebo to Lurasdione and Haloperidol
72960|NCT01195844|Biological|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children < 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
69422|NCT01150695|Other|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
69423|NCT00040339|Procedure|hypothermia (body temperature lowered to 33°C or 91.4°F)|
69424|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine [approximately 1x10^9 colony forming units (cfu)/mL] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
68493|NCT00039663|Drug|Rosiglitazone|
68494|NCT01146522|Drug|Placebo|
68495|NCT01146535|Drug|Interferon-alpha|150 IU lozenges bid for 5 days
68496|NCT01146535|Drug|Oseltamivir|75 mg capsules bid for 5 days
68497|NCT01146535|Other|maltose|200 mg maltose lozenges bid for 5 days
68498|NCT01146548|Drug|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
68499|NCT01146561|Biological|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
68500|NCT01146561|Other|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
68501|NCT01146574|Biological|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
68502|NCT01146574|Biological|Placebo|Placebo
68503|NCT01146587|Device|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
68504|NCT00039702|Drug|[123] 5-I-A-85380|
68505|NCT01146587|Device|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
68506|NCT01146587|Other|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
68507|NCT01146600|Drug|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
68508|NCT01146600|Drug|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
68509|NCT01146613|Drug|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
69177|NCT01155115|Procedure|Sputum Collection|Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.
69178|NCT01155115|Procedure|Pulmonary Function Testing|Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.
69482|NCT01148043|Drug|Hydroxychloroquine|200 mg capsule, 2 capsules QD for 24 weeks.
69483|NCT01148043|Drug|cellulose|capsule, 2 capsules QD for 24 weeks
69484|NCT01148056|Radiation|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
69485|NCT01148069|Procedure|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
69486|NCT01148082|Procedure|Self administered Surveys|
69487|NCT01148082|Procedure|Interviews|
69488|NCT01148095|Drug|AZD2516|Oral, single, daily, 11 days
69489|NCT00039975|Drug|Diltiazem HCl|
69490|NCT01148095|Drug|Placebo|
69491|NCT01148108|Drug|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
69492|NCT01148121|Genetic|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
69493|NCT01148147|Drug|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
69494|NCT01148147|Drug|Placebo|Intracoronary Placebo administration
69495|NCT01148160|Drug|voriconazole|intravenous, oral administration
69496|NCT01148173|Drug|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
69497|NCT01148186|Behavioral|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
69247|NCT01153308|Other|Observational Study|This is an Observational study
69248|NCT01153321|Drug|AZD2423|100mg Oral dose od
69249|NCT01153321|Drug|AZD2423 Placebo|Oral dose od
69250|NCT01153334|Drug|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
69251|NCT01153347|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
69565|NCT01145937|Procedure|DALK|Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
69566|NCT01145950|Drug|LBEC0101|Etanercept 25mg, single dose
69567|NCT01145950|Drug|Enbrel|Etanercept 25mg, single dose
69568|NCT01145963|Other|Control pasta|control pasta
69569|NCT00039611|Drug|fluorouracil|
69570|NCT01145963|Other|Experimental pasta B|experimental pasta
69571|NCT01148199|Device|Self-expandable metalic stent|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
69572|NCT01148199|Device|Multiple plastic stents|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
69573|NCT00039988|Drug|Glatiramer acetate|20 mg administered subcutaneously daily
69574|NCT01148225|Drug|adalimumab|This study is a Phase 3, open-label multicenter study designed to evaluate long-term safety and efficacy of adalimumab in adult subjects with non-infectious intermediate-, posterior-, or pan-uveitis who have either discontinued from study M10-877 or M10-880 for having met "Treatment Failure" criteria or have successfully completed study M10-877 or M10-880.
69575|NCT01148264|Drug|olanzapine|1x10mg per day for three days
69576|NCT01148264|Drug|metoclopramide|3x10mg per day for three days
69577|NCT01148277|Drug|Propofol and Remifentnyl|Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
69578|NCT01148277|Drug|midazolam and fentanyl|Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
69579|NCT01148277|Drug|midazolam anf fentanyl|group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
69029|NCT01147393|Drug|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over ~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
69030|NCT01147393|Biological|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
69031|NCT01147406|Drug|N6022|This is an injectible formulation which will be given at 5, 15 & 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
69032|NCT01147406|Drug|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
69033|NCT01147419|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
69034|NCT01147419|Device|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
69035|NCT01147432|Drug|PF-04427429|Single dose IV infusion up to 300mg
69036|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
69037|NCT00039871|Drug|REBETOL (ribavirin; SCH 18908)|REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
69038|NCT01147432|Drug|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
69039|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
69040|NCT01147432|Other|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
69041|NCT01147445|Biological|Double Mutant Heat- Labile Toxin (dmLT)|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
69042|NCT01150032|Other|Bone quality complementary exams|realisation of following exams to evaluate fracture risk in osteopenic women:
hip and wrist Dual energy X-ray Absorptiometry (DXA)
wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)
hip Quantitative Computed Tomography (QCT)
High Resolution Digital X-Ray of calcaneum using BMA(tm) system
low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)
69043|NCT01150045|Drug|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
69044|NCT01150045|Drug|5-fluorouracil|Patients receive 400 mg/m^2 intravenous bolus then 2400 mg/m^2 continuous intravenous infusion over 46-48 hours.
68510|NCT01146613|Drug|Placebo|identical matched placebo x 2, 2xday, 13 weeks
68511|NCT01146626|Drug|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
68512|NCT01146626|Drug|Peg+ Ribavirine|Peg+ Ribavirine
68513|NCT01146639|Radiation|DynaCT|One extra set of images with DynaCT including one extra injection of contrast medium.
68514|NCT01146639|Drug|Iodixanol|One extra set of images with DynaCT including one extra injection of 50 ml contrast medium.
68799|NCT01152398|Biological|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
68800|NCT01152411|Other|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
68801|NCT01152437|Drug|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
68802|NCT01152437|Drug|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
68803|NCT01152450|Drug|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
68804|NCT01152450|Drug|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
68805|NCT01152450|Drug|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
68806|NCT01152463|Procedure|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
68807|NCT01152476|Drug|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
68808|NCT01152476|Drug|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
68809|NCT00040417|Drug|G-SCF (Granulocyte-colony stimulating factor)|
68810|NCT01152489|Device|Device: Buzzy|"Buzzy", the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back.
68811|NCT01152489|Device|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
68812|NCT01152515|Drug|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
69498|NCT01150812|Drug|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
69499|NCT01150838|Drug|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
69500|NCT01150851|Other|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
69501|NCT00000241|Drug|Flupenthixol|
69502|NCT00000946|Biological|rgp120/HIV-1 SF-2|
68573|NCT01154439|Drug|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
68574|NCT01154439|Drug|everolimus|Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).
Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10.
68575|NCT00040625|Drug|Pemetrexed|
68576|NCT01154439|Drug|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
68577|NCT01154439|Drug|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
68578|NCT01154452|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
68579|NCT01154452|Other|Laboratory Biomarker Analysis|Correlative studies
68580|NCT01154452|Other|Pharmacological Study|Correlative studies
68581|NCT01154452|Drug|Vismodegib|Given PO
68582|NCT00039741|Drug|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
68583|NCT01146652|Drug|SAR153191 (REGN88)|Pharmaceutical form: solution
Route of administration: subcutaneous
68584|NCT01146665|Behavioral|Computer-based Personalized Assessment Feedback|This type of brief intervention targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
68585|NCT01146665|Behavioral|Computer-based sham|Similar in format and duration as the Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
68586|NCT01146678|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection
Route of administration: subcutaneous
69580|NCT01148290|Procedure|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
69581|NCT01148290|Procedure|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
69582|NCT01148303|Drug|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
69583|NCT01148303|Drug|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
69584|NCT00039988|Drug|Albuterol|2 mg or 4 mg oral capsules taken daily
69585|NCT01148303|Drug|Placebo|Placebo
69586|NCT01148316|Drug|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
68643|NCT01154465|Procedure|Central Venous Catheter Insertion|The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.
The patients' skin disinfection before catheter insertion and care will follow the protocol:
Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).
Rinse with sterile water and then drying.
First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.
Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.
After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed.
68644|NCT01154465|Device|Ultrasound guidance|The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.
A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:
The anterior Boulanger's incision for the internal jugular vein;
2 cm below and medial to the femoral artery to the femoral incision. When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method.
68645|NCT01154478|Other|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
68646|NCT01154478|Other|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
68647|NCT00040625|Drug|Cisplatin|
68648|NCT01154478|Other|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
68649|NCT01154478|Other|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
68650|NCT01154491|Drug|Ferric carboxymaltose|Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.
Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.
68651|NCT01154491|Drug|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
69045|NCT01150045|Other|placebo|Patients receive placebo administered by mouth, once daily.
69046|NCT01150045|Drug|oxaliplatin|Patients receive 85 mg/m^2 intravenous over two hours.
69341|NCT01153425|Radiation|Virtual Bone Biopsy by Magnetic Resonance Imaging|The MRI involves virtual bone biopsy technology currently being developed. This new technology is not commercially or elsewhere available. It allows generation of 3D images of considerably smaller voxel size than the previous technology by employing new pulse sequences and advanced interpolation techniques. The enhanced resolution will enable capturing subtle remodeling-induced changes, such as reversal of the fenestration caused by prior osteoclastic resorption cavities. It will also permit measurement of trabecular thickness with increased accuracy and precision. Advances have also been made toward superior registration of follow-up scans relative to the baseline scans. This, we project, provides improved reproducibility and thus increased statistical power.
69342|NCT01153451|Other|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
69343|NCT01153464|Behavioral|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
69344|NCT00040482|Drug|ATG|
69345|NCT01153477|Behavioral|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
69346|NCT01153490|Behavioral|Behavioral Intervention|Substance-related
69347|NCT01153503|Procedure|TAP block|Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block
First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn
69348|NCT01153542|Drug|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
69349|NCT01153542|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
69350|NCT01153568|Dietary Supplement|Vitamin D 3|Patients will bew given a single capsule to take once daily
69351|NCT01153568|Other|placebo|placebo tablets
69352|NCT01145469|Genetic|gene expression analysis|
69353|NCT01145469|Genetic|polymorphism analysis|
68813|NCT01152528|Device|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
68814|NCT01152541|Drug|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
68815|NCT01152541|Drug|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
68816|NCT01152554|Drug|TC-5214|Tablet, oral, twice daily for 52 weeks
68817|NCT01152554|Drug|Placebo|Tablet, oral, twice daily for 52 weeks
68818|NCT01152580|Dietary Supplement|melatonin|3mg p.o. at bedtime daily
69099|NCT01155557|Device|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
69100|NCT01155557|Behavioral|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
69101|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
69102|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
69103|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
69104|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
69105|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
69106|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
69107|NCT00039884|Drug|NESP - Novel Erythropoiesis Stimulating Protein|
69108|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
69109|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
69110|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
69111|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
69112|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
68587|NCT01146678|Drug|Lixisenatide AVE0010|Pharmaceutical form:solution for injection
Route of administration: subcutaneous
68588|NCT01146691|Other|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
68589|NCT01146704|Dietary Supplement|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 12.5% protein and 57.5% carbohydrate.
68878|NCT01149772|Behavioral|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
68879|NCT01149785|Drug|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
68880|NCT01149785|Drug|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
68881|NCT01149785|Drug|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
68882|NCT01149798|Drug|Abraxane and Cisplatin combination|Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.
Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1.
68883|NCT01149811|Drug|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
68884|NCT01149811|Drug|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
68885|NCT01149824|Drug|Salvinorin A|
68886|NCT01149824|Drug|Placebo|
68887|NCT00040209|Drug|IV Levodopa|
68888|NCT01149837|Device|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
68889|NCT01149850|Biological|bevacizumab|Given IV
68652|NCT01154491|Drug|Placebo|Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.
Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.
68653|NCT01154504|Other|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
68654|NCT01154504|Procedure|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
68655|NCT01154504|Procedure|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
68656|NCT01154530|Other|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
68657|NCT01154569|Drug|Azithromycin|500 mg single dose
68658|NCT00040638|Drug|TLK286|
68659|NCT01154582|Dietary Supplement|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
68951|NCT01147289|Drug|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
68952|NCT01147289|Drug|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
68953|NCT01147302|Biological|Placebo|
68954|NCT01147302|Biological|C1 Esterase Inhibitor (Human)|
68955|NCT01147315|Procedure|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
68956|NCT01149850|Other|laboratory biomarker analysis|Correlative studies
68957|NCT01149850|Other|immunohistochemistry staining method|Correlative studies
68958|NCT01149850|Genetic|microarray analysis|Correlative studies
68959|NCT01149850|Genetic|DNA methylation analysis|Correlative studies
68960|NCT01149863|Drug|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
68961|NCT01149876|Other|Nu Skin Product|Thin layer of Nu Skin product applied to face.
69354|NCT01145469|Other|laboratory biomarker analysis|
69355|NCT01145469|Other|medical chart review|
69356|NCT00039546|Drug|paclitaxel|
69357|NCT01145482|Drug|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
68440|NCT00040781|Drug|gefitinib|Given orally
68441|NCT01156480|Drug|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
68442|NCT01156480|Drug|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
68443|NCT01156493|Other|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
68444|NCT01156519|Other|Salivary Cortisol|Day 1: 1st salivary cortisol at 23 hours
Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)
Day 3: serum cortisol at 8 am
Between Day 4 and Month 3: if serum cortisol at 8 am > 18ng/mL:
Cortisol for 24 hours
dexamethasone suppression test (2mg/j during 2 days)
Cortisol and ACTH cycle
Noriodocholesterol scintigraphy
68445|NCT00000947|Drug|Azithromycin|
68446|NCT00040404|Drug|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
68447|NCT01151761|Drug|Cisplatin|25 mg/m2, IV
68448|NCT01151761|Drug|Carboplatin|AUC 2, based on Calvert formula, IV
68449|NCT01151761|Drug|Capecitabine|1000 mg/m2, PO
68450|NCT01151761|Drug|5FU|200 mg/m2
68451|NCT01151787|Drug|cyclobenzaprine hydrochloride|15mg daily for 3 months
68452|NCT01151787|Drug|placebo|placebo
68453|NCT01151800|Other|Using IVR to maintain ACS patients on best practice guidelines|
68454|NCT01151813|Drug|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
69113|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
69114|NCT01147471|Device|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
69115|NCT01147471|Procedure|operative rib fixation surgery|
69116|NCT01147484|Drug|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
69117|NCT01147497|Drug|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
69118|NCT00039910|Drug|(PN-152,243)/ PN-196,444|
69119|NCT01147497|Drug|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
69120|NCT01147510|Drug|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
69425|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
69426|NCT01150747|Drug|ceftriaxone|250mg IM once
69427|NCT01150747|Drug|Azithromycin|1 gm once
69428|NCT01150760|Drug|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
69429|NCT01150786|Dietary Supplement|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
69430|NCT01150786|Other|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
69431|NCT01153581|Drug|17 beta estradiol, progesterone, ganirelix acetate|Antagon (for ganirelix acetate)--0.25 ml per day, subcutaneous injection estradiol 0.2 mg/day (patches) per day progesterone 200 mg per day, pills
69432|NCT01153581|Drug|17 beta estradiol, progesterone, ganirelix acetate|17 beta estradiol: 0.2 mg/day (patches) progesterone 200 mg/day ganirelix acetate 0.25 mg/day
69433|NCT01153594|Behavioral|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
69434|NCT00000948|Drug|ART|antiretroviral therapy for the treatment of HIV
68890|NCT01149850|Drug|temozolomide|Given orally
68891|NCT01152606|Drug|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
68892|NCT01152619|Drug|Placebo|Subcutaneous repeated dose
68893|NCT01152619|Drug|RO4989991|Subcutaneous repeated dose
68894|NCT01152632|Other|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
68895|NCT01152645|Drug|ARQ 197|Orally twice daily administration of ARQ 197
68896|NCT01152658|Biological|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
69179|NCT01155115|Procedure|Exhaled Nitric Oxide|The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
69180|NCT01155128|Behavioral|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
69181|NCT01155141|Drug|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
69182|NCT00040677|Drug|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
69183|NCT01155154|Drug|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
69184|NCT01155154|Drug|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
69185|NCT01155154|Drug|placebo|Two placebo capsules every 6 hours for 7 days
69186|NCT01155167|Drug|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
69187|NCT01155167|Other|Placebo|Placebo
69188|NCT01155180|Drug|Leptin|Hormone - daily self injections for 6 months
69189|NCT01155180|Drug|Placebo|Placebo
69190|NCT01155206|Drug|glucagon|glucagon 3ng/kg/min
68962|NCT01149876|Other|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
68963|NCT00040209|Drug|IV Apomorphine|
68964|NCT01149876|Drug|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
68965|NCT01149876|Other|CeraVe moisturizer|Thin layer of CeraVe applied to face.
68966|NCT01149889|Procedure|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
68967|NCT01149902|Biological|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
68968|NCT01149915|Drug|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
68969|NCT01149941|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
68970|NCT01149954|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
68971|NCT01149967|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
69252|NCT00040482|Drug|Cyclophosphamide|
69253|NCT01153347|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
69254|NCT01155388|Drug|Ferumoxytol|IV Ferumoxytol
69255|NCT01155388|Drug|Ferrous sulfate|Oral iron preparation
69256|NCT01155414|Other|Hydrolysate based infant formula|Infant formula ad lib
69257|NCT01155414|Other|Investigational Infant Formula A|Investigational infant formula ad lib
69258|NCT01155414|Other|Investigational Infant Formula B|Investigational infant formula ad lib
69259|NCT01155440|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
69260|NCT01155440|Procedure|Thoracic epidural block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
69261|NCT01155453|Drug|BKM120|
69262|NCT01155453|Drug|GSK1120212|
68455|NCT01151813|Drug|Placebo|Placebo
68456|NCT01151839|Procedure|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
68457|NCT00040404|Drug|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
68458|NCT01151839|Procedure|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
68739|NCT01154660|Other|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
68740|NCT01154673|Drug|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
68741|NCT01154673|Drug|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
68742|NCT01154673|Drug|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
68743|NCT01154673|Drug|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
68744|NCT01154686|Behavioral|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
68745|NCT00040651|Drug|Cyclophosphamide|
68746|NCT01154699|Device|Bi-level positive airway pressure (bi-level PAP)|Subjects will use bi-level PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
68747|NCT01154712|Device|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
68748|NCT01154712|Device|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
68749|NCT01154725|Behavioral|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
68750|NCT01154725|Behavioral|habitual patient education|habitual patient education
68751|NCT01146886|Drug|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
69435|NCT00040482|Drug|MESNA|
69436|NCT01153607|Drug|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
69437|NCT01153607|Drug|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
69438|NCT01153607|Drug|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
69439|NCT01153620|Drug|Lavasept 0.04%|Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.
Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.
Treatment Duration 60 minutes
69440|NCT01153620|Other|Ringer's Solution|Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.
Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes
68515|NCT01148979|Drug|Lisdexamfetamine Dimesylate 20-50 mg|Subjects given 30 mg study drug (Vyvanse vs. matched placebo) at baseline to take each morning. If 30 mg intolerable before next scheduled appointment, they can return to clinic and exchange 30 mg tablets for 20 mg tablets. Visit 3 dosage range is 20-40 mg/d. Now subjects have been taking either 30 or 20 mg of study medication per day. If clinical effects insufficient and side effects tolerable, subject's dose will be raised by 10 mg/d to 30 or 40 mg/d. If subjects receiving more than 20 mg/d experience uncomfortable side effects, their dose may be reduced to 20 mg at that visit. Visit 4 dosage range is 20-50 mg, study drug dose may be moved up or down by 10 mg based on clinical judgment, minimum of 20 mg, maximum of 50 mg/d. Study drug dosage must not change over the last 2 weeks (end of 4 weeks on study drug).
Arms: Sugar Pill , Lisdexamfetamine Dimesylate 20-50mg Other Names: Vyvanse
68516|NCT01148992|Drug|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
68517|NCT01148992|Drug|Placebo|0mg
68518|NCT01149005|Drug|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
68519|NCT01149005|Drug|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
68520|NCT01149018|Drug|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
68521|NCT01149018|Drug|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
68522|NCT00040066|Procedure|Cocaine (IV)|
68523|NCT01149031|Device|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
68524|NCT01149044|Procedure|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
68525|NCT01149057|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
69191|NCT01155219|Drug|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
69192|NCT01147575|Dietary Supplement|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
69193|NCT01147575|Dietary Supplement|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
69194|NCT01147588|Drug|lansoprazole|60 mg (2x30-mg capsule), once daily
69195|NCT00039936|Behavioral|Cognitive Behavior Treatment|
69196|NCT01147588|Drug|omeprazole|80 mg (2x40-mg capsule), once daily
69197|NCT01147588|Drug|esomeprazole|40 mg (1x40-mg capsule), once daily
69198|NCT01147588|Drug|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
69503|NCT00040365|Drug|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
69504|NCT01150851|Other|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
69505|NCT01150864|Device|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
69506|NCT01150877|Drug|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
69507|NCT01150890|Drug|AMG 827 350 MG|350 mg AMG 827 IV (in the vein)
69508|NCT01150890|Drug|AMG 827 210 MG|210 mg AMG 827 IV (in the vein)
69509|NCT01150890|Drug|AMG 827 700 MG|700 mg AMG 827 IV (in the vein)
69510|NCT01150890|Drug|Placebo|Placebo IV (in the vein)
69511|NCT01150903|Other|no intervention|non-interventional study
69512|NCT01150903|Other|no intervention|non-interventional study
69513|NCT01150916|Procedure|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
69263|NCT01155466|Drug|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
69264|NCT00040690|Drug|cytarabine|
69265|NCT01155466|Drug|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
69266|NCT01155466|Drug|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
69267|NCT01155466|Drug|Placebo to Preladenant Tablet|one tablet orally twice daily
69268|NCT01155466|Drug|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
69269|NCT01155466|Drug|Placebo to Rasagiline capsule|one capsule orally in AM
69270|NCT01155479|Drug|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
69271|NCT01155479|Drug|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
69272|NCT01155479|Drug|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
69273|NCT01155479|Drug|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
69274|NCT01155479|Drug|Placebo for Rasagiline 1 mg capsule|one capsule orally in AM
69275|NCT00040690|Drug|doxorubicin hydrochloride|
69276|NCT01155479|Drug|Placebo for Preladenant|one tablet orally twice daily
69277|NCT01155505|Drug|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
69587|NCT01148316|Behavioral|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
69588|NCT01148329|Device|Coronary stenting|The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
69589|NCT01148342|Drug|MDMA|
69590|NCT01148342|Drug|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 & amp; 1.6 mg/kg
69591|NCT01148368|Drug|fimasartan|single administration of fimasartan 120mg
69592|NCT01148394|Other|Multimodal rehabilitation|
68752|NCT01146886|Drug|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
68753|NCT01146899|Other|Provider Alert|Provider influenza vaccine alert
68754|NCT01146912|Other|Text Message|Text message vaccine reminders
68755|NCT01146912|Other|automated call|Automated call
68756|NCT01146925|Drug|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
68757|NCT01146925|Drug|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
69047|NCT00000946|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
69048|NCT00040248|Drug|Daclizumab|
69049|NCT01150045|Drug|leucovorin|Patients receive 400 mg/m^2 intravenous over two hours.
69050|NCT01150058|Genetic|western blotting|
69051|NCT01150058|Other|flow cytometry|
69052|NCT01150058|Other|laboratory biomarker analysis|
69053|NCT01150084|Other|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
69054|NCT01150084|Other|delayed treatment|to start at week 10
69055|NCT01150097|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
69056|NCT01150097|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
69057|NCT01150097|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
69058|NCT01150097|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
68526|NCT01149083|Drug|Carboplatin|Given IV
68527|NCT01149083|Other|Laboratory Biomarker Analysis|Correlative studies
68528|NCT01149083|Drug|Veliparib|Given PO
68529|NCT01149096|Biological|filgrastim|Given subcutaneously
68530|NCT01149096|Procedure|bone marrow donation|Undergo bone marrow harvest
68531|NCT01149096|Other|laboratory biomarker analysis|Optional correlative studies
68532|NCT01149109|Drug|Temozolomide and lomustine|
68533|NCT00040092|Drug|Virulizin®|
68534|NCT01149109|Drug|Temozolomide|
68535|NCT01149122|Drug|Gemcitabine/Oxaliplatin|GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
68536|NCT01149122|Drug|Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)|GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
68819|NCT01152580|Dietary Supplement|sugar pill|lactose p.o. at bedtime daily
68820|NCT00040430|Drug|111In-DAC|
68821|NCT01152593|Drug|Mupirocin|Intranasal cream given to patient after confirmation of colonization
68822|NCT01154738|Drug|Lidocaine|bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.
start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine
68823|NCT01154738|Drug|Placebo|NaCl 9/00 (same volume as in the lidocaine group)
start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00
68824|NCT01154751|Device|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
68825|NCT01154764|Drug|CG100649|I period: CG 100649 single dose 6 mg II period: Ketoconalzole + CG100649 at the same time washout period: 42 days
68826|NCT01154764|Drug|CG100649 and ketoconazole|I period: ketoconazole 400 mg + CG100649 6 mg II period: CG 100649 single dose 6 mg washout period: 42 days
68827|NCT00040651|Drug|Thymoglobulin|
68828|NCT01154777|Behavioral|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
68829|NCT01154790|Drug|CG100649|6 subjects: study drug 2 subjects: placebo
69514|NCT00040365|Radiation|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
69515|NCT01150929|Device|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
69516|NCT01150942|Biological|JE vaccine|3 times, IM
69517|NCT01150955|Dietary Supplement|Resveratrol|500 mg three times a day for five weeks.
69518|NCT01150955|Other|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
69519|NCT01150968|Behavioral|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
69520|NCT01150981|Drug|Rosiglitazone|One 8mg capsule daily for 6 weeks.
69521|NCT01150981|Drug|Placebo|One capsule daily for 6 weeks.
69522|NCT01150994|Behavioral|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
69523|NCT01153659|Drug|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
68590|NCT01146704|Dietary Supplement|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 25% protein and 45% carbohydrate.
68591|NCT01146704|Dietary Supplement|Very high protein diet group based on 1.4 gram of protein per pound of subject's lean body mass: 35% protein and 35% carbohydrate.|Very high protein diet, based on 1.4 gram of protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 35% protein and 35% carbohydrate.
68592|NCT01146717|Behavioral|Exercise|Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
68593|NCT00039741|Drug|NNRTIs (EFV, NVP)|Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)
Prescribed per participant's doctor
68594|NCT01146717|Behavioral|Balance training|A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
68595|NCT01146730|Behavioral|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
68596|NCT01146730|Behavioral|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
69593|NCT01148420|Drug|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
69594|NCT01151020|Device|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
69595|NCT01151033|Device|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
69596|NCT00040378|Drug|alphatocopherol|400 IU daily
69597|NCT01151046|Drug|MM-121 (SAR256212) and Exemestane|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
69598|NCT01151046|Drug|Placebo and Exemestane|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
69599|NCT01151059|Biological|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
69600|NCT01151072|Drug|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
69601|NCT01151085|Drug|Voriconazole|Voriconazole Intravenous Solution 200 mg:
Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.
Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:
administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.
Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.
However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.
In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.
Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
69602|NCT01151098|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
72586|NCT00041509|Drug|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
72587|NCT01169376|Genetic|mutation analysis|
72588|NCT01169376|Genetic|polymorphism analysis|
72589|NCT01169389|Procedure|Intraarticular injection|Durolane, one vial
72590|NCT01169389|Procedure|Intra-articular injection of 0.5% Bupivacaine|
72591|NCT01169402|Drug|Fluconazole|25mg/kg intravenously once weekly while on ECMO
72592|NCT01169415|Drug|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
69059|NCT00040261|Drug|Memantine HCL|
69060|NCT01150097|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
69061|NCT01150097|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
69062|NCT01152931|Dietary Supplement|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
69063|NCT00040456|Drug|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
69358|NCT01145482|Other|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
69359|NCT01145495|Other|Laboratory Biomarker Analysis|Correlative studies
69360|NCT01145495|Drug|Lenalidomide|Given PO
69361|NCT01145495|Biological|Rituximab|Given IV
69362|NCT01145508|Drug|Docetaxel|Given IV
69363|NCT01145508|Other|Laboratory Biomarker Analysis|Correlative studies
69364|NCT01145508|Drug|Prednisone|Given PO
69365|NCT01145508|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
69366|NCT01145508|Biological|Rilimogene-galvacirepvec|Given SC
69367|NCT00039546|Procedure|adjuvant therapy|
69368|NCT01145534|Drug|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
69369|NCT01145534|Other|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
69370|NCT01145547|Device|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
69371|NCT01145560|Drug|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
68830|NCT01154790|Drug|Placebo|6 subjects: study drug 2 subjects: placebo
68831|NCT01154790|Drug|Naproxen|6 subjects: study drug 2 subjects: placebo
68832|NCT01154803|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
68833|NCT01154803|Dietary Supplement|Micronutrient Powder (MNP)|2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
68834|NCT01154816|Drug|alisertib|Given orally
68835|NCT01154816|Other|pharmacological study|Correlative studies
68836|NCT01154816|Other|laboratory biomarker analysis|Correlative studies
68837|NCT01154829|Drug|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
68838|NCT00040651|Procedure|Leukapheresis|
68839|NCT01154829|Drug|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
68840|NCT01154855|Procedure|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
69121|NCT01147510|Drug|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
69122|NCT01147523|Drug|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
69123|NCT01147536|Biological|HSPPC-96|HSPPC-96 intradermal injection every week for 4 weeks, followed by an injection every other week for 8 weeks
69124|NCT01147549|Drug|[C14]AZD9668|Oral Solution 60 mg Single Dose
69125|NCT01147562|Procedure|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
69126|NCT01150110|Device|resilient occlusal splints|A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.
Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals.
69127|NCT01150123|Biological|Group B streptococcus (GBS) vaccine|The study will include two enrollment groups (340 subjects each). Each enrollment group will evaluate a high and low dose versus the presence or absence of adjuvant
69128|NCT01150123|Biological|Group B streptococcus (GBS) vaccine|Each enrollment group will evaluate a high and low dose versus dose of adjuvant
68597|NCT01146743|Procedure|EUS-guided gallbladder drainage|EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
68598|NCT01146743|Procedure|percutaneous transhepatic gallbladder drainage|Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
68599|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|Sequence of Interventions To Increase Cerebral Oxygen Saturation
Check head and cannula position
Increase mean arterial pressure
Increase pump flow
Increase systemic oxygenation
Increase PaCO2 > 45
Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses
Consider PRBC transfusion for Hct < 21%
68600|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
68601|NCT01149161|Procedure|Routine central neck dissection|Level VI neck node dissection during thyroid operation for micro PTC. Patient's Number of this group: 267
68602|NCT01149161|Procedure|Sentinel lymph node biopsy for central neck|Sentinel lymph node biopsy with methylen blue. Peritumoral injection in operating room, Patient's Number of this group: 267
68603|NCT01149174|Drug|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
68604|NCT00040105|Drug|Zarnestra (R115777)|Starting Dose:
300 mg by mouth (PO) Twice daily
68605|NCT01149200|Drug|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
68606|NCT01149200|Drug|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
68897|NCT01152658|Other|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
68898|NCT01152671|Drug|Placebo|single oral dose
68899|NCT01152671|Drug|RO5024048|single oral dose
68900|NCT00000948|Drug|Aldesleukin|Il-2
68901|NCT00040430|Procedure|Diagnostic|
68902|NCT01152697|Drug|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
68903|NCT01152697|Drug|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
72593|NCT01169415|Drug|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
72594|NCT01171677|Behavioral|IntenSati|IntenSati (a blending of the words "intention" and "sati," the Pali term for "mindfulness") combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. "I believe I will succeed", "I am strong" and "I am confident") that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to "stick in your head" long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem.
72595|NCT01171690|Drug|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
72596|NCT01171703|Device|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
72597|NCT01171703|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
72598|NCT01171716|Other|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
72599|NCT01171729|Biological|Autologous dendritic cell|Autologous dendritic cells pulsed with prostate cancer antigen and KLH
72600|NCT01171742|Procedure|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
72601|NCT01171755|Drug|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
72602|NCT01171781|Drug|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
72603|NCT00041808|Procedure|Chemotherapy|
72604|NCT01171781|Drug|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
72873|NCT01198145|Other|placebo|Given orally
72874|NCT01198158|Biological|Bevacizumab|Given IV
72875|NCT01198158|Drug|Everolimus|Given PO
72876|NCT00044408|Drug|Ruboxistaurin mesylate|
72877|NCT01198158|Other|Laboratory Biomarker Analysis|Correlative studies
69372|NCT01145560|Drug|Placebo|Placebo
69373|NCT01145573|Dietary Supplement|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
69374|NCT01145586|Drug|Lactase Oral Tablets|3 tablets/day for 42 days Take with breakfast, lunch and dinner
69375|NCT01145612|Drug|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
69376|NCT01145612|Drug|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
69377|NCT01145625|Drug|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
69378|NCT00039559|Other|Early detection|CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
69379|NCT01147835|Dietary Supplement|Chinese Licorice Root|Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
68459|NCT01151852|Drug|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
68460|NCT01151852|Drug|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
68461|NCT01151865|Drug|Dexmedetomidine|Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.
Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4.
68462|NCT01151865|Drug|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
68463|NCT01151878|Dietary Supplement|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
68464|NCT01151878|Dietary Supplement|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
68465|NCT01151904|Drug|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
68466|NCT01151904|Drug|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
69129|NCT01150123|Biological|Group B streptococcus (GBS) vaccine|Half of all vaccine recipients will receive a single active vaccine injection and half will receive two identical active vaccine injections (1 month apart)
69130|NCT01150123|Biological|Saline|A placebo group who receive saline will be included in each enrollment group
69131|NCT01150149|Behavioral|No face touch|
69132|NCT01150149|Device|Surgical face mask|
69133|NCT01150149|Device|Surgical face mask + no face touch|
69134|NCT00040274|Drug|DPC 817|
69135|NCT01150162|Drug|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
69136|NCT01150162|Drug|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
69137|NCT01150175|Procedure|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
69138|NCT01150175|Procedure|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
69139|NCT01150188|Dietary Supplement|Amino acids|11 g amino acids two times per day for eight weeks
69140|NCT01150188|Dietary Supplement|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
69141|NCT01150201|Drug|Aliskiren|For CKD treatment
69441|NCT01153633|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|The treatment procedures (after a 1 week run-in) include:
Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation
Secondary dressing to be a semi occlusive dressing
Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.
69442|NCT01153633|Device|Normal Saline and Placebo Gel|The treatment procedures (after a 1 week run-in) include:
Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation
Secondary dressing to be a semi occlusive dressing
Secure the dressing to the wound with tubifast and short stretch compression system
Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.
69443|NCT01153646|Genetic|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
68904|NCT01152697|Behavioral|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
68905|NCT01152710|Drug|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
68906|NCT01152723|Drug|Nicotine|2 mg, Single Dose
68907|NCT01152736|Drug|Nicotine|2 mg Single-dose
68908|NCT01152749|Drug|Nicotine|Single-dose of new NRT product
68909|NCT01152749|Drug|Nicotine Gum|Single-dose of marketed nicotine gum
68910|NCT01152762|Procedure|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
68911|NCT01152775|Other|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
68912|NCT00040443|Drug|CX516 (Ampalex®)|
68913|NCT01152775|Other|No Media|This group will not be exposed to multimedia
68914|NCT01152788|Drug|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
68915|NCT01152788|Drug|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
69199|NCT01147601|Drug|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
69200|NCT01147601|Drug|Control (placebo) group|Control (placebo) group
69201|NCT01147614|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
69202|NCT01147614|Behavioral|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
69203|NCT01147627|Drug|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
69204|NCT01147627|Drug|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
72878|NCT01198158|Other|Pharmacological Study|Correlative studies
72879|NCT01198171|Other|Laboratory Biomarker Analysis|Correlative studies
72880|NCT01198171|Other|Study of Socioeconomic and Demographic Variables|
72881|NCT01198184|Drug|temsirolimus|Given IV or PO
72882|NCT01198184|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
72883|NCT01198184|Other|laboratory biomarker analysis|Correlative studies
72884|NCT01198184|Other|pharmacological study|Correlative studies
72885|NCT01198197|Drug|NOP-1A|
72886|NCT01198210|Drug|saline|local peritonsillar infiltration of 2 ml saline,
72887|NCT00044421|Drug|Ruboxistaurin mesylate|
72888|NCT01198210|Drug|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
72889|NCT01198210|Drug|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
72890|NCT01198210|Drug|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
72891|NCT01198223|Drug|garlic , nystatin|mouthwash
72892|NCT01198236|Drug|Itraconazole|Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.
In transplant patients, the end of "at-risk period" is defined as a stable engraftment of 1*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells> 0.5*109/L).
If needed, the patients will take itraconazole solution orally after intravenous administration.
72893|NCT01198249|Drug|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
72894|NCT01198275|Drug|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
72895|NCT01198275|Drug|Placebo|1.0 g of olive oil,one capsule twice a day
73226|NCT01196390|Radiation|Radiation Therapy|Undergo radiation therapy
73227|NCT01196390|Procedure|Therapeutic Conventional Surgery|Undergo surgery
68467|NCT01151930|Drug|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
68468|NCT01154231|Drug|Nonacog Alfa (Genetical Recombination)|Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.
Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product ("Previously treated patients": hereinafter, "PTPs") or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time ("Previously untreated patients": hereinafter, "PUPs").
The definition of PUPs in this survey is "Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, "EDs") or less."
68469|NCT01154244|Other|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
68470|NCT01154257|Procedure|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
68471|NCT01154257|Procedure|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
68472|NCT01154270|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
68758|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
68759|NCT00039767|Drug|Lepirudin|
68760|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
68761|NCT01146951|Drug|Rufinamide (E2080)|Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.
Target maintenance dose:
15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)
68762|NCT01146951|Drug|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
68763|NCT01146964|Procedure|MSSICS|Manual super small incision cataract surgery
68764|NCT01146964|Procedure|Phacoemulsification|cataract surgery with Phacoemulsification
68765|NCT01146977|Other|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
69444|NCT01153659|Drug|E3810|RAB ER 50 mg capsule once per day on Days 1-5
69445|NCT01153659|Drug|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
69446|NCT00040482|Procedure|Radiation therapy|
69447|NCT01145625|Drug|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
69448|NCT01145638|Drug|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
69449|NCT01145638|Drug|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
69450|NCT01145664|Drug|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
69451|NCT01145664|Drug|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
69452|NCT01145664|Drug|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
69453|NCT01145677|Drug|Topiramate|Topiramate 100-300 mg/day orally twice per day
69454|NCT01145703|Dietary Supplement|RDA Vitamin D3 only|800 IU of Vitamin D3 daily for 6 months
69455|NCT01145703|Dietary Supplement|Vitamin D2/3 Repletion only|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
69456|NCT01145703|Other|Vitamin D2/3 Repletion + AEX|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
69457|NCT00039572|Drug|boronophenylalanine-fructose complex|
68537|NCT01149135|Device|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
68538|NCT01149135|Device|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
68539|NCT00040404|Drug|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
68540|NCT01151943|Other|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
68541|NCT01151943|Other|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
69205|NCT01147627|Drug|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
69206|NCT00000945|Drug|Probenecid|
69207|NCT00039936|Behavioral|Self Help|
69208|NCT01147640|Drug|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
69209|NCT01147640|Drug|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
69210|NCT01147653|Biological|Autologous Umbilical Cord Blood or Placebo|All participants will be treated with autologous cord blood reinfusion, but the time course will vary between groups and participants will be blinded to the order in which they receive infusions. Patients will be randomized to receive their autologous umbilical cord blood cells first or placebo first. Subjects will receive both infusions but will be randomized and blinded by which they are receiving first and second.
69211|NCT01147666|Drug|FG-4592|Different dose levels
69212|NCT01147666|Drug|Epoetin Alfa|Per current label instruction
69213|NCT01147666|Drug|FG-4592|Different dose levels
69214|NCT01147666|Other|Placebo|Inactive capsules matching appearance of FG-4592 capsules
69215|NCT01147666|Drug|Epoetin Alfa|Per current label instruction
69216|NCT01150331|Drug|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
69217|NCT01150331|Drug|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
69218|NCT01150344|Drug|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
69524|NCT01153672|Drug|vorinostat|Given PO
69525|NCT01153672|Other|laboratory biomarker analysis|Correlative studies
69526|NCT01153672|Procedure|biopsy|Optional correlative studies
69527|NCT01153672|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
69528|NCT01153672|Procedure|positron emission tomography|Correlative studies
69529|NCT01153672|Drug|anastrozole|Given PO
69530|NCT01153672|Drug|letrozole|Given PO
73228|NCT00000978|Drug|Zidovudine|
73229|NCT00044148|Drug|LY333531|
73230|NCT01196390|Biological|Trastuzumab|Given IV
73231|NCT01196403|Other|questionnaire administration|
73232|NCT01198704|Other|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
73233|NCT01198730|Drug|Acarbose|Acarbose 25 mg tid, titrate to 100 mg tid.
73234|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
73235|NCT01198756|Biological|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
73236|NCT01198756|Biological|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
73237|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
73238|NCT01198769|Biological|Rotarix TM|Oral, 2 doses
73239|NCT01198782|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
73240|NCT01198795|Drug|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
73241|NCT01198821|Drug|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
73242|NCT00044538|Drug|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
73243|NCT01198821|Drug|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
73244|NCT01198834|Drug|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
73245|NCT01198834|Drug|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
73246|NCT01198834|Drug|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
73247|NCT01198834|Drug|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
68766|NCT01146977|Other|Autologous HCT|After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.
If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue.
68767|NCT01146990|Drug|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
68768|NCT01147003|Drug|Investigational new drug, company code: BGG492|
68769|NCT01147003|Drug|Placebo|
68770|NCT00000945|Drug|Cidofovir|
68771|NCT00039780|Drug|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
68772|NCT01147003|Drug|Investigational new drug, company code: BGG492|
68773|NCT01147016|Biological|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
68774|NCT01149564|Drug|oral ibuprofen|
68775|NCT01149577|Drug|Olanzapine|06 weeks treatment with Olanzapine in a flexible dosage schedule.
68776|NCT01149590|Procedure|Computer Tomography Angiography|Computed tomography imaging
68777|NCT01149603|Device|HeartMate II Ventricular Assist Device|The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
69064|NCT01152931|Dietary Supplement|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
69065|NCT01152931|Dietary Supplement|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
69066|NCT01152931|Dietary Supplement|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
69067|NCT01152931|Dietary Supplement|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
69068|NCT01152931|Dietary Supplement|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
68542|NCT01151969|Behavioral|New multicomponent "7H" intervention|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
68543|NCT01151982|Behavioral|Psychosocial Intervention|The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.
We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.
The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.
The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources.
68544|NCT01151995|Other|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
68545|NCT01151995|Other|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
68546|NCT01152008|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
68547|NCT01152021|Drug|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
68548|NCT01152021|Drug|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
68549|NCT01152034|Behavioral|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
68550|NCT00040404|Other|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
68551|NCT01152047|Drug|oxytocin|40mU/min as infusion of oxytocin
68841|NCT01154868|Procedure|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
68842|NCT01154881|Drug|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
69531|NCT01153672|Drug|exemestane|Given PO
69532|NCT01153672|Genetic|gene expression analysis|Correlative studies
69533|NCT00040495|Drug|Pantoprazole|
69534|NCT01153685|Biological|Fluviral®|Intramuscular injection, one dose
69535|NCT01153698|Drug|dabigatran|anticoagulation
69536|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
69537|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
69538|NCT01153711|Drug|Ketoconazole|400 mg tablet
69539|NCT01153711|Drug|Ketoconazole|400 mg tablet
69540|NCT01153724|Drug|BI 1744|10 mcg solution for oral inhalation
69541|NCT01153724|Drug|Fluconazole|400 mg capsule
69542|NCT01153737|Other|Manual therapy (MT)|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
69543|NCT01153737|Other|TENS|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
69544|NCT00040508|Drug|Sirolimus|
69545|NCT01153750|Drug|Glivec|
69546|NCT01153763|Drug|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
69547|NCT01153776|Procedure|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
68607|NCT01149213|Device|transcranial direct current stimulation|tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
68608|NCT01149226|Drug|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
68609|NCT01149252|Other|Psoralait|Cream to be used as instructed.
68610|NCT01149252|Other|Placebo cream.|Cream to be used as instructed
72296|NCT01166178|Dietary Supplement|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
72297|NCT01166191|Radiation|Radiotherapy|Radiotherapy
72298|NCT01166204|Radiation|Radiotherapy|Radiotherapy
72299|NCT01166217|Drug|PF-04620110|The five treatments are:
A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state.
72300|NCT01166243|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
72301|NCT00041288|Biological|therapeutic allogeneic lymphocytes|
72302|NCT01166243|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
72303|NCT01166256|Device|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 >92% or PaO2 >65 mmHg.
72304|NCT01166256|Device|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 >92% or PaO2 >65 mmHg.
72305|NCT01166269|Biological|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
72306|NCT01166269|Biological|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
72307|NCT01166269|Other|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
72308|NCT01166282|Biological|adalimumab - blinded|blinded adalimumab BSA dosing 24mg/m^2, max 40 mg
72309|NCT01166282|Biological|placebo for adalimumab - blinded|blinded matching placebo for adalimumab, matching BSA dosing
72310|NCT01166282|Biological|Adalimumab - open label|open-label adalimumab BSA dosing 24mg/m^2, max 40 mg
72311|NCT01166308|Radiation|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
72312|NCT00041288|Drug|cyclophosphamide|
72313|NCT01168739|Dietary Supplement|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
69069|NCT01152931|Dietary Supplement|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
69070|NCT01152931|Dietary Supplement|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if > 1year. 50ug daily for 4 days if < 1 year.
69071|NCT01152931|Dietary Supplement|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if < 1 year. 10,000 IU orally daily for 4 days if > 1 year.
69072|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
69073|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
69074|NCT00040469|Drug|Campath -1H|
69075|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
69076|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if < 1 year. 25 mg orally daily for 4 days if > 1 year.
69077|NCT01152957|Behavioral|CARIÑO Project|Care Attention Resources Information Nutrition & Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
69078|NCT01152983|Device|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
69079|NCT01154920|Drug|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
69380|NCT01147848|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
69381|NCT01147848|Drug|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
69382|NCT01147848|Drug|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
69383|NCT01147848|Drug|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
69384|NCT01147861|Drug|GSK256073|5mg in the AM and 5mg in the PM
68843|NCT01154894|Other|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
68844|NCT01154907|Other|praziquantel|One day, 40mg/kg standard mass rx as recommended by WHO and local authorities
68845|NCT01154920|Drug|Paclitaxel|135 mg/m^2 weekly, Weeks 1 - 6
68846|NCT01147016|Drug|cyclophosphamide|As prescribed by physician, standard of care.
68847|NCT01147016|Drug|doxorubicin hydrochloride|As prescribed by physician, standard of care.
68848|NCT01147016|Drug|paclitaxel|As prescribed by physician, standard of care.
68849|NCT01147016|Other|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
68850|NCT01147016|Procedure|neoadjuvant therapy|As prescribed by physician, standard of care.
68851|NCT01147016|Procedure|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
68852|NCT01147029|Drug|angiogenesis inhibitor GSAO|
68853|NCT01147029|Other|laboratory biomarker analysis|
68854|NCT00039780|Drug|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
68855|NCT01147029|Other|pharmacological study|
68856|NCT01147029|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
68857|NCT01147042|Drug|IFN-gamma|
68858|NCT01147055|Drug|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
68859|NCT01147055|Drug|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
69142|NCT01150201|Drug|Losartan|Control
69143|NCT01150214|Procedure|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
69144|NCT01150253|Dietary Supplement|L. paracasei fermented milk|
68611|NCT01149265|Behavioral|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
68612|NCT01149265|Behavioral|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
68613|NCT01149278|Drug|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
68614|NCT01149278|Other|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
68615|NCT00000946|Biological|ALVAC-HIV MN120TMG (vCP205)|
68616|NCT00040105|Drug|Gleevec (Imatinib mesylate)|Starting Dose:
300 mg By Mouth (PO) daily
68617|NCT01149304|Drug|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
68618|NCT01149304|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
68619|NCT01149304|Drug|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
68620|NCT01149317|Procedure|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
68621|NCT01149330|Drug|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
68622|NCT01152086|Other|Mountain hiking in the Austrian and Bavarian Alps|Regularly supervised physical exercise training program.
Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;
Program:
Endurance training (performed within 70-85% of the maximum heart rate)
Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)
Stretching after hiking (ca. 5 min)
Short break at half-time (ca. 15 min)
68623|NCT01152099|Other|Compression Bandaging|Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.
If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied.
68916|NCT01155011|Behavioral|Phone counseling call|To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:
health check
step goal check
barrier identification
problem solving
specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring.
72314|NCT01168739|Dietary Supplement|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
72315|NCT01168752|Drug|Debio 0932|Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.
In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met.
72896|NCT01200524|Drug|Placebo|Placebo
72897|NCT01200537|Drug|Estradiol|This group of patients will receive estradiol patches prior to the IVF cycle.
72898|NCT01200537|Drug|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
72899|NCT01200563|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
72900|NCT01200563|Device|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
72901|NCT01200563|Device|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
72902|NCT01200589|Biological|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
72903|NCT00044694|Drug|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
72904|NCT01200589|Biological|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
72905|NCT01200602|Drug|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
72906|NCT01200602|Other|clinical observation|No treatment is given.
72907|NCT01200615|Behavioral|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
72908|NCT01200628|Behavioral|DEPITAC|heteroevaluation scale by a nurse during hospitalization
72909|NCT01200641|Drug|Melatonin|ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
72910|NCT01200641|Drug|Gabapentin|ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
69385|NCT01147861|Drug|GSK256073|10mg in the AM
69386|NCT01147861|Drug|GSK256073|50mg in the AM
69387|NCT00039975|Drug|Indinavir sulfate|
69388|NCT01147861|Drug|GSK256073|25mg in the AM and 25mg in the PM
69389|NCT01147861|Other|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
69390|NCT01147874|Procedure|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
69391|NCT01147887|Drug|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
69392|NCT01147900|Biological|Boostrix™|Intramuscular, single dose
69393|NCT01147900|Biological|Boostrix™-US formulation|Intramuscular, single dose
69394|NCT01147913|Behavioral|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
69395|NCT01147913|Behavioral|Attention Control Training|Four sessions of interpretation training for "filler" or neutral scenarios, unrelated to themes associated with depression.
69396|NCT01147926|Drug|Placebo|Placebo matched to Prucalopride tablet orally once daily.
69397|NCT01147926|Drug|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
69398|NCT00039975|Drug|Ritonavir|
69399|NCT01147939|Drug|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
69400|NCT01147939|Drug|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
68473|NCT01154283|Device|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
68474|NCT01154296|Behavioral|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
69145|NCT00040287|Behavioral|smoking cessation program|
69146|NCT01150266|Drug|Alteplase (tPA)|0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
69147|NCT01150292|Dietary Supplement|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
69148|NCT01150292|Dietary Supplement|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
69149|NCT01150305|Biological|blood sample|Peripheral whole blood sample, 5 ml
69150|NCT01150318|Drug|Administration of 131 iodine|100 mCi 131 iodine irradiation
69151|NCT01152996|Drug|Vortioxetine|Vortioxetine tablets
69152|NCT01153009|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
69153|NCT01153009|Drug|Duloxetine|Overencapsulated duloxetine delayed-release capsules
69154|NCT01153009|Drug|Placebo|Placebo-matching capsules
69155|NCT01153022|Other|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
69156|NCT01153035|Device|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
69157|NCT00040469|Drug|Dilantin|
69158|NCT01153048|Other|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
69159|NCT01153061|Device|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
69160|NCT01153061|Device|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
69458|NCT01145703|Other|Vitamin D2/3 Repletion + RT|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
68917|NCT01155011|Behavioral|Peer Mentoring|Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.
The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity.
68918|NCT01155011|Behavioral|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
68919|NCT01155011|Behavioral|Psychosocial support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
68920|NCT01155011|Behavioral|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
68921|NCT01155011|Behavioral|Group educational lectures|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
68922|NCT00040664|Drug|fosamprenavir|fosamprenavir oral suspension or tablet
68923|NCT01155011|Behavioral|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
68924|NCT01155011|Behavioral|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
68925|NCT01155024|Device|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
68926|NCT01155024|Device|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
68927|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
68928|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
69219|NCT01150344|Drug|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
72911|NCT01200641|Drug|placebo|ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
72912|NCT01200654|Drug|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
72913|NCT01200693|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
72914|NCT00044694|Drug|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
72938|NCT01203722|Other|Fludarabine, Cytoxan, TBI, Sirolimus + MMF|Pre-transplantation:
Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV
Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV
Day -1: 200 cGy TBI administered in a single fraction
Post-Transplantation Immunosuppression Consisting of:
Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV
Day 5: Sirolimus loading dose 6 mg PO once
Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)
Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL
72939|NCT01203722|Other|Fludarabine, Cytoxan, TBI, Tacrolimus + MMF|Pre-transplantation:
Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV
Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV
Day -1: 200 cGy TBI administered in a single fraction
Post-Transplantation Immunosuppression Consisting of:
Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV
Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)
Day 5 thru Day 180: Tacrolimus 1 mg administered IV QD
72940|NCT01203735|Drug|Valproic acid|800mg per day for entire period of RT
72941|NCT01203748|Procedure|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
72942|NCT01195727|Drug|Apixaban|
72943|NCT01195740|Behavioral|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
72944|NCT01195740|Behavioral|Enhanced Usual Care|Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a "bridge" between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team.
72945|NCT01195753|Biological|HHLivC|multiple infusion of liver cells
68475|NCT00000949|Drug|Aldesleukin|
68476|NCT00040586|Drug|Monoclonal Antibody J591|
68477|NCT01154309|Behavioral|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
68478|NCT01154322|Device|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
68479|NCT01154335|Drug|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
68480|NCT01154335|Drug|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
68481|NCT01154348|Drug|S-707106|Tablet, taken once daily with morning meal
68482|NCT01154348|Drug|Placebo|Placebo tablet, taken once daily with morning meal
68483|NCT01154348|Drug|Metformin, S-707106 plus metformin|Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
68484|NCT01154348|Drug|Metformin, placebo plus metformin|Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
68485|NCT01154361|Drug|Icatibant (subcutaneous) and plazebo (intravenous)|
68486|NCT01154361|Drug|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
68487|NCT00040586|Drug|Recombinant Interleukin-2|
68488|NCT01154374|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
68489|NCT01146483|Drug|Rosuvastatin, Pantoprazole|Rosuvastatin, 10 mg tablets, single dose on the morning
Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study.
68490|NCT01146496|Device|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
68491|NCT01146509|Drug|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
68492|NCT01146522|Drug|LCQ908|
68778|NCT01149616|Drug|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
68779|NCT01149616|Drug|placebo|placebo administered IV x1
69459|NCT01145716|Procedure|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
69460|NCT01145729|Behavioral|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
69461|NCT01145742|Behavioral|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
69462|NCT01145755|Drug|AZD2066|18 mg once daily
69463|NCT01145755|Drug|Placebo|
69464|NCT01145755|Drug|Duloxetine|60 mg once daily
69465|NCT01145768|Drug|TC-5214|4 mg tablet, oral, BID, group 1
69466|NCT01145768|Drug|TC-5214|TBD tablet, oral, BID, groups 2-6
69467|NCT01145768|Drug|Placebo|
69468|NCT00039585|Drug|imatinib mesylate|
69469|NCT01145781|Procedure|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
69470|NCT01145794|Behavioral|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
69471|NCT01147965|Biological|AD5 CEA Vaccine|AD5[E1-, E2b-]-CEA Vector Vaccine
69472|NCT01147978|Behavioral|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
69473|NCT01147991|Biological|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
69474|NCT01147991|Other|laboratory biomarker analysis|
69475|NCT01147991|Other|pharmacological study|
69476|NCT01148004|Drug|Fenofibrate|
69477|NCT01148004|Drug|Ritonavir|
69478|NCT00039975|Drug|Amlodipine|
69479|NCT01148004|Drug|Lopinavir/Ritonavir|
69480|NCT01148017|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
69220|NCT01150357|Drug|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
69221|NCT00040287|Behavioral|weight control program|
69222|NCT01150357|Drug|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
69223|NCT01150357|Drug|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
69224|NCT01150370|Device|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
69225|NCT01150383|Other|Physical exercise training with supplemental oxygen|Prior to the exercise training, an intervention-free control period with usual care is planned.
Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.
After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above).
69226|NCT01150383|Other|Physical exercise training with "room air supplementation"|Prior to the exercise training, an intervention-free control period with usual care is planned.
Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.
After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above).
69227|NCT01150409|Drug|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
69228|NCT01150409|Drug|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
69229|NCT01150422|Other|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
69230|NCT01150448|Drug|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
69231|NCT01153165|Drug|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
72946|NCT01195766|Drug|Ofatumumab|Ofatumumab in addition with ESHAP therapy
72947|NCT01195779|Biological|GSK Bio's influenza vaccine GSK2584786A, different formulations|Intramuscular injections
72948|NCT00044044|Drug|Haloperidol 10mg|Haloperidol 10mg/day tablets
72949|NCT01195779|Biological|GSK Bio's influenza vaccine GSK2321138A|Intramuscular injections
72950|NCT01195779|Biological|Fluarix™|Intramuscular injections
72951|NCT01195792|Drug|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
73248|NCT01198847|Behavioral|Dietary, physical activity and sleeping|The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.
73249|NCT01198860|Drug|CTH Chronic Hepatitis B|Drug:
Tenofovir/ 300mg daily Phyllanthus Cantoniensis Hornem/300mg daily Herba adenosmatis caerulei/150mg daily Herba Eclipta /150mg daily Vitamin C / 500mg daily
73250|NCT01198873|Drug|Dronedarone|Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)
73251|NCT01198873|Drug|Placebo (for Dronedarone)|film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)
73252|NCT01198886|Other|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
73253|NCT01201317|Drug|AZD2423|150 mg tablet
73254|NCT01201317|Drug|Placebo|Placebo
73255|NCT01201343|Drug|Interferon beta-1a|
73256|NCT00044785|Drug|triacetyluridine|
73257|NCT01201356|Drug|FTY720|
73258|NCT01201369|Device|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
73259|NCT01201369|Device|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
68780|NCT01149629|Drug|Droxidopa|One capsule containing 300 mg droxidopa, given once
68781|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
68782|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
68783|NCT01149642|Dietary Supplement|Oral Impact|The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.
This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes.
68784|NCT00040170|Biological|MVA-MUC1-IL2|
68785|NCT01149642|Dietary Supplement|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
68786|NCT01149655|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
68787|NCT01149655|Drug|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
68788|NCT01149668|Drug|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
68789|NCT01149681|Drug|APLIDIN (plitidepsin)|Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).
Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles.
68790|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
68791|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
68792|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
68793|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
68794|NCT01149707|Drug|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
68795|NCT00040183|Drug|Tarceva (erlotinib HCl, OSI-774)|
68796|NCT01149707|Drug|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
68797|NCT01149707|Drug|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
68798|NCT00040417|Drug|FK506|
69481|NCT01148030|Drug|3M Skin and Nasal Antiseptic|Intra-nasal dosing
68552|NCT01152073|Dietary Supplement|Placebo|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
68553|NCT01152073|Dietary Supplement|Second Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
68554|NCT01152073|Dietary Supplement|Third Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
68555|NCT01154374|Procedure|Standard of Care (sterile saline moistened gauze)|
68556|NCT01154387|Drug|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
68557|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
68558|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
68559|NCT01154387|Drug|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
68560|NCT01154387|Drug|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
68561|NCT01154387|Drug|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
68562|NCT01154400|Dietary Supplement|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
68563|NCT01154400|Dietary Supplement|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
68564|NCT00040599|Drug|hMN14 (labetuzumab)|
68565|NCT01154400|Dietary Supplement|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
68566|NCT01154400|Dietary Supplement|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
68567|NCT01154413|Behavioral|Intensive education of the doctor/nursing team on the protocol|
68568|NCT01154426|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
68569|NCT01154426|Drug|Gemcitabine Hydrochloride|Given IV
69548|NCT01153789|Procedure|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
69549|NCT01153789|Other|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
69550|NCT01145807|Drug|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
69551|NCT01145807|Drug|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
69552|NCT01145807|Drug|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
69553|NCT01145820|Dietary Supplement|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
69554|NCT01145833|Other|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
69555|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
69556|NCT01145846|Drug|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
69557|NCT01145859|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
69558|NCT00039611|Drug|FOLFOX regimen|
69559|NCT01145872|Behavioral|Mindfulness Based Cognitive Therapy|
69560|NCT01145872|Behavioral|Health Enhancement Program|
69561|NCT01145885|Drug|BI 6727|PLK-1 inhibitor
69562|NCT01145898|Drug|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
73260|NCT01201382|Behavioral|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
73261|NCT01201382|Behavioral|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
73262|NCT01201434|Dietary Supplement|Bio-25 probiotic|2 tablets per day for 6 months
73263|NCT01201499|Drug|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or ~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
73264|NCT01201499|Drug|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
73265|NCT01201525|Procedure|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
73266|NCT01201525|Procedure|Control|Part 2 of the surgical scar will serve as a within patient control.
72316|NCT01168765|Behavioral|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
72317|NCT01168778|Behavioral|Physician Workshop|Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
72318|NCT01168791|Drug|doxorubicin in combination with palifosfamide-tris|palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.
doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles.
72319|NCT01168791|Drug|doxorubicin in combination with placebo|doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.
placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles.
72320|NCT00041470|Drug|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
72321|NCT01168804|Drug|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
72322|NCT01168817|Drug|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
72323|NCT01168817|Drug|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
72324|NCT01168817|Drug|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
72325|NCT01168830|Device|AMS-3.0|
69080|NCT01154920|Drug|Cetuximab|PCC Arm: 400 mg/m^2 by vein over about 1-2 hours on Day 1; 250 mg/m^2 weeks 2 - 6.
C-TPF Arm: 400 mg/m^2 by vein over about 1-2 hours on Day 1; 250 mg/m^2 weeks 2,4,5,7, and 8.
69081|NCT01154920|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
69082|NCT00000950|Drug|Ethambutol hydrochloride|
69083|NCT00040651|Procedure|Self bone marrow transplant|
69084|NCT01154920|Drug|Cisplatin|100 mg/m^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
69085|NCT01154920|Drug|Fluorouracil|700 mg/m^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
69086|NCT01154920|Radiation|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
69087|NCT01154920|Other|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
69088|NCT01154933|Drug|exenatide 5 mcg|exenatide 5 mcg
69089|NCT01154933|Drug|exenatide 10 mcg|exenatide 10 mcg
69090|NCT01154933|Drug|placebo|saline sq
69091|NCT01154959|Drug|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
69092|NCT01154972|Procedure|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
69093|NCT01154985|Drug|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
69094|NCT00040664|Drug|ritonavir|ritonavir oral capsules or oral solution
69095|NCT01154985|Drug|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
69096|NCT01154985|Drug|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
69097|NCT01155011|Behavioral|Physical Activity|MIPARC will focus on 3 physical activity goals:
increasing walking behavior through gradually increasing step goals
increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,
reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months.
68570|NCT01154426|Other|Pharmacological Study|Correlative studies
68571|NCT01154426|Drug|Veliparib|Given orally
68572|NCT01154439|Drug|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
68860|NCT01147055|Drug|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
68861|NCT01147068|Biological|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
68862|NCT01147081|Biological|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
68863|NCT01147107|Drug|Raltegravir|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
68864|NCT01147107|Drug|Efavirenz|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
68865|NCT00039793|Procedure|Moderate-intensity and low-intensity bodywork therapy|
68866|NCT01147120|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
68867|NCT01147120|Procedure|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
68868|NCT01149707|Drug|Placebo Enema|Placebo Enema, once-daily, intrarectally
68869|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
68870|NCT01149720|Drug|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
68871|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
68872|NCT01149733|Drug|Tamsulosin|Test 0.4 mg Capsule
68873|NCT01149733|Drug|Tamsulosin|Reference Listed 0.4 Capsule
68874|NCT01149746|Drug|Tamsulosin|Test 0.4 mg Capsule
69563|NCT01145924|Procedure|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
69564|NCT01145937|Procedure|PET|Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty
68624|NCT01152099|Other|Manual Lymph Drainage (MLD) and Compression Bandaging|Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.
If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied.
68625|NCT01152112|Device|Myomectomy|Removal of fibroids and / or polyps
68626|NCT01152125|Other|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
68627|NCT01152138|Device|Open cells stent|Cobalt Chromium Stent with open cell design
68628|NCT00040417|Drug|FLUDARABINE|
68629|NCT01152138|Device|Closed Cells Stent|Cobalt Chromium stent with closed cell design
68630|NCT01152151|Device|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
68631|NCT01152151|Device|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
68632|NCT01152151|Device|Reminder letters|up to four reminder letters in september - december 2010
68633|NCT01152164|Behavioral|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
68634|NCT01152177|Device|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
68635|NCT01152190|Drug|Tadalafil|Administered orally, once daily for 8 weeks
68636|NCT01152190|Drug|Placebo|Administered orally, once daily for 8 weeks
68637|NCT01152203|Drug|Bendamustine|Starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle
68638|NCT01152203|Drug|Bevacizumab|10 mg/kg by vein on Days 1 & 15 of every 28 day cycle
68639|NCT00040417|Drug|CAMPATH-IH|
68640|NCT01152216|Drug|Dimebon|20 mg orally three times daily
74847|NCT01189448|Drug|Pyrimethamine/Sulfadiazine|Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.
Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy.
74848|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
74849|NCT01189448|Drug|Spiramycine|Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.
Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures
74850|NCT01189461|Drug|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
74851|NCT01189474|Device|Blephasteam|Eye lid warming goggles
74852|NCT01189487|Drug|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
74853|NCT01189500|Drug|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
74854|NCT01189500|Drug|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
74855|NCT01189513|Drug|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
74856|NCT01189526|Drug|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
74857|NCT01189526|Procedure|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
75101|NCT01189890|Drug|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
75102|NCT01189890|Drug|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
75103|NCT01189890|Drug|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
75104|NCT01189903|Drug|Regorafenib|
74758|NCT00043407|Drug|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
74759|NCT01189370|Drug|sorafenib|Sorafenib 400 mg twice daily, 7 days a week
Sorafenib 600 mg twice daily, days 1-5 per week
Sorafenib 800 mg twice daily, days 1-5 per week
Sorafenib 1000 mg twice daily, says 1-5 per week
74760|NCT01189383|Biological|IL15-DC Vaccine|Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
74761|NCT01189396|Drug|Albuterol Inhalation Powder|Albuterol dry powder inhaler, 180 mcg/inhalation, escalating dose 180 mcg, 180 mcg, 360 mcg, 720 mcg, at 30 min intervals, total cumulative dose 1440
74762|NCT01189396|Drug|Placebo Control|Placebo control contains only lactose in amounts identical to the lactose contained in A006. 1, 1, 2, and 4 inhalation at 30 min intervals.
74763|NCT01191632|Radiation|one time radiation|Radiation: one time Radiation with an intensity of
0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery
74764|NCT01191632|Radiation|No Radiation|Control group with 0Gy
74765|NCT00043680|Drug|Celecoxib|
74766|NCT01191645|Drug|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
74767|NCT01191645|Drug|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
74768|NCT01191645|Drug|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
74769|NCT01191645|Drug|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
74770|NCT01191684|Other|laboratory biomarker analysis|Correlative studies
74771|NCT01191684|Other|enzyme-linked immunosorbent assay|Correlative studies
74772|NCT01191684|Other|flow cytometry|Correlative studies
74773|NCT01191684|Other|immunoenzyme technique|Correlative studies
74774|NCT01191684|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
75161|NCT01187771|Procedure|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
75162|NCT01187771|Procedure|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
75163|NCT01187784|Behavioral|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
75164|NCT01187797|Other|Emotional stimulation|Increase of the physical correlates of an emotion
75165|NCT01187810|Drug|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
75166|NCT01187810|Drug|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
75167|NCT00043186|Drug|Denosumab|Denosumab for subcutaneous injection
75168|NCT01187810|Drug|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
75169|NCT01187823|Device|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
75506|NCT01222312|Drug|Docetaxel|75 mg/m2, d1 every 3 weeks
75507|NCT01222312|Drug|Docetaxel|50mg/m2, d1 every 2 weeks
75508|NCT01222325|Procedure|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
75509|NCT01222338|Biological|V-5 immunitor|once per day dosing for 2 months
75510|NCT01222351|Drug|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
75511|NCT01222364|Procedure|Standard Cord Clamping|Immediate clamping (<5 seconds) of the umbilical cord after delivery.
75512|NCT01222364|Procedure|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
74695|NCT01191580|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
74696|NCT01191580|Behavioral|Brief Supportive Psychotherapy|The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.
Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures.
74697|NCT01191593|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
74698|NCT01191593|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
74699|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
74700|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
74970|NCT01184859|Drug|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
74971|NCT01184859|Drug|Placebo|Placebo melt tablet for sublingual administration
74972|NCT01184872|Drug|Daptomycin|Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.
Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days.
74973|NCT01184872|Drug|Vancomycin or Semi-Synthetic Penicillins (SSPs)|Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.
Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days.
74974|NCT01184885|Drug|Hyper-CVAD|Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.
Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are < 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.
Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses.
75227|NCT01185418|Drug|amisulpride|
75228|NCT00043004|Procedure|conventional surgery|
75229|NCT01185418|Drug|lactose|
75230|NCT01185431|Dietary Supplement|Ficus carica (Fig paste)|Ficus carica paste 300g/day
75231|NCT01185431|Dietary Supplement|Placebo (Placebo paste)|Placebo composition 300g/day
75232|NCT01185444|Procedure|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
75233|NCT01185444|Procedure|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
75234|NCT01185470|Device|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
75235|NCT01185509|Drug|trastuzumab|Administered intravenously every 3 weeks.
75236|NCT01187849|Drug|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
75237|NCT01187862|Drug|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
75238|NCT01187875|Dietary Supplement|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
75239|NCT01187875|Dietary Supplement|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
75240|NCT00043186|Drug|Alendronate|Alendronate 70 mg tablets
75241|NCT01187875|Dietary Supplement|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
75589|NCT01222416|Radiation|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
75590|NCT01222429|Other|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
75591|NCT01222429|Other|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
75592|NCT01222442|Drug|AZD3199|Single dose, oral inhalation
75593|NCT01222442|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
75048|NCT01192178|Drug|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
75049|NCT01192178|Drug|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
75050|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
75051|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
75052|NCT01192204|Drug|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
75053|NCT01192204|Drug|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
75054|NCT01192217|Procedure|Modified thoracoscopic technique|Two-port thoracoscopic technique
75055|NCT01184963|Dietary Supplement|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
75056|NCT01184976|Biological|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
75057|NCT01184989|Drug|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
75058|NCT01185002|Other|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
75059|NCT01185002|Other|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
75060|NCT00043004|Biological|bevacizumab|
75061|NCT01185002|Other|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
75062|NCT01185015|Drug|Sigmart (nicorandil)|Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.
75063|NCT01185028|Drug|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
75064|NCT01185041|Dietary Supplement|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
75513|NCT00047021|Drug|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
75514|NCT01222377|Procedure|endoscopic surgery|Undergo endoscopic breast surgery
75515|NCT01222377|Procedure|quality-of-life assessment|Ancillary studies
75516|NCT01222390|Device|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
75517|NCT01222403|Biological|MF59-adjuvanted trivalent influenza subunit vaccine|
75518|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
75519|NCT01215370|Other|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
75520|NCT01215370|Other|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
75521|NCT01215396|Dietary Supplement|AminoVital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener.
75522|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
75523|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
75524|NCT01215409|Drug|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
75525|NCT01215422|Procedure|timed intubation|timed intubation
75526|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
74626|NCT01193998|Other|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
74627|NCT01194011|Behavioral|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
74628|NCT01194024|Other|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
74629|NCT01194037|Drug|recombinant variant of interferon-alpha 2b|SC, Weekly
74975|NCT01184885|Drug|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
74976|NCT01184898|Drug|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
74977|NCT01184898|Drug|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
74978|NCT01184898|Drug|Etoposide|100 mg/m2/day IV
74979|NCT01184898|Drug|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
74980|NCT00042991|Other|laboratory biomarker analysis|Correlative studies
74981|NCT01184911|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
74982|NCT01184924|Behavioral|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
74983|NCT01184937|Behavioral|Patient education program|All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the "Pro-Self education program". The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs.
74984|NCT01184950|Other|Trainer Curriculum|
74985|NCT01184963|Dietary Supplement|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
75222|NCT01185379|Dietary Supplement|Placebo|4 x 500 mg capsules to be taken daily for 6 months
75223|NCT01185405|Other|Use of different strategy for voriconazole dosage adjustment|Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (< 1 µg/ml: 50% increase, 1~5.5 µg/ml: no change, > 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
75224|NCT01185418|Drug|risperidone|
75225|NCT01185418|Drug|aripiprazole|
75226|NCT01185418|Drug|haloperidol|
75594|NCT00047034|Drug|eribulin mesylate|Given IV
75595|NCT01222442|Other|Placebo comparator|Single dose, oral inhalation
75596|NCT01222455|Drug|Fostamatinib|Oral tablets, single dose
75597|NCT01222468|Drug|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
75598|NCT01222468|Drug|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
75599|NCT01222494|Behavioral|Behavioral Weight Loss|The TODAY Lifestyle Program (TLP) is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, TLP will be modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of intensive weekly intervention with a 6-month maintenance phase with monthly in-person visits and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
75600|NCT01222494|Behavioral|Diet and Exercise Education|Participants assigned to this arm will receive medically validated, individualized diet and exercise education by a trained research professional.
75601|NCT01222520|Drug|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
75602|NCT01222520|Drug|Telmisartan|80 mg once a daily
75603|NCT01222533|Drug|Tiotropium medium|Tiotropium inhalation solution medium dose
75604|NCT01222533|Drug|Tiotropium low|Tiotropium inhalation solution low dose
75605|NCT00000997|Drug|Zalcitabine|
75606|NCT00047034|Other|pharmacological study|Correlative studies
75607|NCT01222533|Drug|Tiotropium high|Tiotropium inhalation solution high dose
75608|NCT01222533|Drug|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
75609|NCT01222533|Drug|Tiotropium placebo|Placebo inhalation solution
75610|NCT01222546|Drug|CH5132799|
74701|NCT01191619|Procedure|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
74702|NCT01193582|Biological|Prevenar|Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
3 doses starting from 212 days to < 12 months of age
75065|NCT01185054|Other|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
75304|NCT00043810|Drug|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
75305|NCT01192750|Other|laboratory biomarker analysis|
75306|NCT01192750|Other|medical chart review|
75307|NCT01192763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
75308|NCT01192763|Other|laboratory biomarker analysis|Correlative studies
75309|NCT01192763|Other|pharmacological study|Correlative studies
75310|NCT01192763|Procedure|neoadjuvant therapy|
75311|NCT01185509|Drug|vinorelbine|Administered intravenously once a week
75312|NCT01185535|Procedure|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
75313|NCT01185548|Drug|Tolbutamide|Administered orally
75314|NCT00043004|Procedure|radiofrequency ablation|
75315|NCT01185548|Drug|Tasisulam|Administered intravenously
75316|NCT01185561|Behavioral|psychoeducational intervention|1) education about how dysphoric symptoms (depressive symptoms, anxiety, and anger) affect glycemic control; 2) recognition of dysphoric symptoms; and 3) management of dysphoric symptoms using cognitive-behavioral skills. Supportive phone calls (weeks 10, 18) and booster sessions (weeks 14 and 22) and will be used to sustain the treatment effect.
75317|NCT01185561|Behavioral|usual medical care (control group).|Group I will receive usual medical care (control group).
75318|NCT01185574|Dietary Supplement|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
75319|NCT01185600|Biological|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
75320|NCT01185600|Biological|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
74630|NCT01194037|Drug|Peginterferon alfa-2a|SC Weekly
74631|NCT00000976|Drug|CD4-IgG|
74632|NCT00043979|Drug|F-18 Fluorodeoxyglucose|
74633|NCT01194063|Drug|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
74634|NCT01194076|Behavioral|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
74635|NCT01194089|Drug|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
74636|NCT01194089|Drug|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
74637|NCT01194102|Behavioral|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
74638|NCT01194102|Other|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
74639|NCT01194102|Other|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
74640|NCT01194115|Drug|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
74641|NCT01186653|Drug|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
74642|NCT01186653|Drug|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
74643|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
74644|NCT00043108|Procedure|conventional surgery|
74914|NCT01187199|Drug|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
74915|NCT00043121|Other|pharmacological study|Correlative studies
74916|NCT01187212|Drug|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
74917|NCT01187212|Drug|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
72009|NCT01170650|Drug|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
72010|NCT01170650|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
72011|NCT01170663|Biological|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
72012|NCT01170663|Drug|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
72013|NCT01170663|Drug|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
72014|NCT01170676|Behavioral|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
72015|NCT01170676|Behavioral|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
72016|NCT01170702|Drug|Placebo|Placebo
72017|NCT01170702|Drug|Group 2 - 15mL 0.25% ropivacaine per side|15mL 0.2% ropivacaine per side
72018|NCT00041717|Other|Placebo|Placebo
72019|NCT01170702|Drug|. Group 3|15mL 0.5% ropivacaine per side
72020|NCT01170702|Drug|15mL 0.75% ropivacaine per side|15mL 0.75% ropivacaine per side
72021|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
75084|NCT01187550|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit [IU]/kg body weight) per day by subcutaneous injection.
75085|NCT01187576|Behavioral|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
75086|NCT01187576|Behavioral|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
75087|NCT01187589|Device|Pulsehaler|
75088|NCT00043147|Drug|prednisone|
75089|NCT01187589|Drug|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
74703|NCT01193582|Biological|Prevenar|Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
2 doses starting from 12 months to < 24 months of age
74704|NCT01193582|Biological|Prevenar|Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
1 dose starting from 24 months to < 72 months of age
74705|NCT01193595|Drug|Ombrabulin (AVE8062)|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
74706|NCT01193595|Drug|bevacizumab|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
74707|NCT01193608|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
74708|NCT01193608|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
74709|NCT01193608|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
74710|NCT00043940|Drug|bivalirudin|Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.
74711|NCT01193608|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
74712|NCT01193608|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
74713|NCT01193608|Other|Placebo|Placebo, IV
74714|NCT01193621|Drug|haloperidol, PET|Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan
D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4
above doses will be administrated orally every 24 hours for 7 days.
74715|NCT01193634|Device|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
74716|NCT01193660|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
74717|NCT01193660|Drug|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
74718|NCT01193660|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
74719|NCT01193660|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
74986|NCT01187303|Drug|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
74987|NCT00043134|Drug|decitabine|
75105|NCT01189916|Procedure|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
75106|NCT01189929|Drug|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
75107|NCT01189929|Drug|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
75108|NCT01189929|Drug|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
75109|NCT01189942|Drug|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
75110|NCT00000246|Drug|Flumazenil|
75111|NCT00000972|Biological|Env 2-3|
75112|NCT01192217|Procedure|Axillary mini-thoracotomy|Axillary mini-thoracotomy
75113|NCT01192230|Drug|Endostatins|7.5mg/m2 qd *14d,q3w
75114|NCT00043758|Drug|Tolvaptan|
75115|NCT01192230|Drug|Docetaxel|75mg/m2 D1, q3w,4-6cycles
75116|NCT01192243|Drug|Gefitinib|250mg qd po d3-16
75117|NCT01192243|Drug|Pemetrexed|500mg/m2 venous infusion,D1,q3w
75456|NCT01188330|Behavioral|Conventional|no Comprehensive Geriatric assessment
75457|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
74918|NCT01187225|Drug|Fibrinogen concentrate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
74919|NCT01187225|Drug|Cryoprecipitate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
74920|NCT01187238|Drug|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
74921|NCT01187264|Drug|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
74922|NCT01187277|Behavioral|conventional therapy|conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
74923|NCT01187277|Device|conventional plus robotic gait assisted therapy|individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
74924|NCT01187290|Radiation|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
74925|NCT01189552|Behavioral|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet 8 times in 4 weeks during residential treatment.
74926|NCT01189591|Device|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
74927|NCT01189604|Drug|Placebo|Infusion of placebo, same infusion rates as for arm 2
74928|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
74929|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
74930|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
74931|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
75170|NCT01187823|Device|Nocturnal oxygen|Nocturnal use of oxygen
75171|NCT01187836|Drug|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
75172|NCT01187836|Drug|Placebo|Placebo administered for 14 hours.
75090|NCT01187615|Drug|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
75091|NCT01187615|Drug|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
75092|NCT01187628|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
75093|NCT01187654|Biological|AC133|intra coronary injection of bone marrow derived AC133+ cells
75094|NCT01187654|Biological|MNC|intra coronary injection of bone marrow derived MNC
75095|NCT01187654|Biological|CONTROL|autologous serum injection
75096|NCT01187680|Device|Spraygel|
75097|NCT01187680|Device|Control|Good surgical technique, no adhesion barrier
75098|NCT01189877|Procedure|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
75099|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
75100|NCT01189890|Drug|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
75343|NCT00043264|Drug|Rifampin|
75344|NCT01188070|Behavioral|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
75345|NCT01188083|Dietary Supplement|Fructose Drink|Fructose Based beverage 8 oz
75346|NCT01188083|Dietary Supplement|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
75347|NCT01188096|Drug|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
74988|NCT01187316|Device|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
74989|NCT01187316|Other|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
74990|NCT01187329|Other|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is <110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose > 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
74991|NCT01187329|Other|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose >150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose < 180 mg/dL.
74992|NCT01187355|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
74993|NCT01187355|Device|renu fresh Multi-Purpose Solution (MPS)|Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
74994|NCT01187355|Device|Contact lenses|Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
74995|NCT01187368|Device|EVAHEART Left Ventricular Assist System (LVAS)|continuous flow implantable left ventricular assist system (LVAS) for patients who are at risk of imminent death from severe left ventricular failure for use as a bridge-to-transplantation in candidates listed for cardiac transplant
74996|NCT01187407|Drug|LY2216684|Taken by mouth once daily
74997|NCT01187407|Drug|Placebo|Taken by mouth once daily
74998|NCT00043147|Drug|beclomethasone dipropionate|
74999|NCT01187433|Biological|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
75000|NCT01187433|Biological|NaCl 0.9%|0.5 mL, Subcutaneous
75001|NCT01187433|Biological|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
75002|NCT01187433|Biological|Meningococcal A+C vaccine|0.5 mL, Intramuscular
75003|NCT01187446|Procedure|TSEBT|12Gy
75004|NCT01187446|Drug|Vorinostat|Calculated per patient
75458|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
75459|NCT01190436|Drug|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
75460|NCT01190449|Biological|ofatumumab|Given IV
75461|NCT01190462|Biological|cetuximab|
75462|NCT01190462|Drug|simvastatin|
75463|NCT01190462|Other|laboratory biomarker analysis|
75464|NCT01190475|Drug|BGS649|
75465|NCT01190475|Drug|BGS649|
75466|NCT01190475|Drug|Placebo|
75467|NCT01190488|Behavioral|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
75468|NCT00043537|Drug|Fluoxetine|
75469|NCT01190488|Behavioral|Active Comparator|TAU
75470|NCT01190501|Device|complier device|The procedure of use of complier has to follow the recommendations for standardization of subject conditions.
Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites.
75471|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
75472|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
75473|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
75474|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
74578|NCT01186640|Drug|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|I. First treatment phase: Chemoimmunotherapy A-FMC
Alemtuzumab:
Cycle 1+2:
10 mg s.c., days 1-3
Cycle 3+4:
CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13.
75173|NCT01187849|Drug|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
75174|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
75175|NCT01189955|Procedure|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
75176|NCT01189955|Procedure|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
75177|NCT01189968|Drug|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
75178|NCT01189981|Behavioral|Lifestyle counseling|One health conversation at baseline
75179|NCT01189981|Behavioral|eHealth intervention|SMS based encouragements to intensive exercise
75180|NCT01189994|Procedure|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
75181|NCT01189994|Behavioral|Orientation|Orientation sessions focusing in fibromyalgia
75182|NCT01190007|Drug|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
75183|NCT01190020|Drug|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
75527|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
75528|NCT01215448|Dietary Supplement|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
75529|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
75348|NCT01188109|Drug|Gemcitabine|Standard of care chemotherapy and dosage
Dose - 1000 mg/m²
Schedule - Days 1 and 15; Q 28 days
75349|NCT01188109|Drug|Cisplatin|Dose - 50 mg/m²
Schedule - Days 1 and 15; Q 28 days
75350|NCT01188122|Device|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
75351|NCT01188135|Behavioral|Interactive voice messaging or Interactive voice messaging + psycho ed materials|Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
75352|NCT01188148|Drug|Memantine|5 mg per day of memantine
75353|NCT01188148|Drug|Placebo|
75354|NCT00043264|Drug|Azithromycin|
75355|NCT01188161|Device|Rotating Chair|Subjects will be spun in rotating chair
75356|NCT01190254|Drug|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
75357|NCT01190254|Drug|placebo|asenapine-matched placebo tablets for sublingual administration
75358|NCT01190267|Drug|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
75359|NCT00043459|Drug|intravenous T900607-sodium|
75360|NCT01190280|Procedure|Cholecystectomy operation|Cholecystectomy after randomization
75361|NCT01190293|Drug|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
75362|NCT01190306|Device|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
75363|NCT01190306|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
75364|NCT01190319|Other|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
75365|NCT01190319|Other|Placebo|Placebo beverage, 8 weeks
75366|NCT01190332|Procedure|endoscopic sphincterotomy by conventional method|
75719|NCT01215786|Drug|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
75720|NCT01215786|Drug|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
75242|NCT01187875|Dietary Supplement|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
75243|NCT01187888|Drug|Rasagiline|tablet once daily 1 mg 1 year
75244|NCT01187888|Drug|Sugar pill|tablet once daily one year
75245|NCT01187901|Drug|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
75246|NCT01187901|Drug|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
75247|NCT01187901|Drug|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
75248|NCT01187901|Drug|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
75249|NCT01187927|Biological|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
75250|NCT01187940|Behavioral|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
75251|NCT00043199|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
75252|NCT01187953|Drug|Prograf (tacrolimus)|Administered per current product labeling
75253|NCT01187953|Drug|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
75254|NCT01187966|Drug|Safinamide|
75255|NCT01187966|Drug|Safinamide|
75256|NCT01187966|Drug|Placebo|
75257|NCT01187979|Behavioral|Cash incentives|Cash incentives paid to learners for reaching pre-determined milestones
75258|NCT01187979|Behavioral|Life skills curriculum|Standard department of education lifeskills curriculum
75259|NCT01187992|Drug|Atorvastatin|80 mg/day
75260|NCT01188005|Device|n-CPAP|administration of continuous positive airway pressure through a nasal device
75261|NCT01188005|Device|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
74579|NCT01186640|Drug|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
74580|NCT01189032|Drug|DE-089 ophthalmic solution|
74581|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
74582|NCT01189032|Drug|Placebo ophthalmic solution|
74583|NCT01189045|Behavioral|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
74584|NCT01189045|Behavioral|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
74585|NCT01189058|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
74586|NCT01189058|Procedure|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for >90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
74587|NCT01189071|Drug|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
74588|NCT01189084|Biological|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
74589|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
74858|NCT01189552|Behavioral|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
74859|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
75530|NCT01215487|Procedure|Stem Cell and Mutational Assay|Laboratory blood testing
75531|NCT01215500|Radiation|Hypofractionated RT|RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:
For all sites the dose levels are as follows:
8 Gy/ fraction x 3 fractions = 24 Gy
10 Gy/fraction x 3 fractions = 30 Gy
12 Gy/fraction x 3 fractions = 36 Gy
14 Gy/fraction x 3 fractions = 42 Gy
16 Gy/fraction x 3 fractions = 48 Gy
18 Gy/fraction x 3 fractions = 52 Gy
20 Gy/fraction x 3 fractions = 60 Gy
75532|NCT01215513|Drug|Degarelix|
75533|NCT01215539|Drug|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
75534|NCT01215552|Drug|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
75535|NCT01215565|Drug|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
75536|NCT01215578|Drug|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
75537|NCT01215591|Procedure|Gradual weaning from Nasal CPAP in preterm neonates|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
75538|NCT01217749|Drug|ofatumumab|per package insert as an IV infusion
75539|NCT00046527|Drug|ABI-007|
75540|NCT01217762|Device|IRay|Low voltage stereotactic radiotherapy system
75541|NCT01217775|Drug|PH80|PH80 intranasal spray 800 nanograms
75542|NCT01217775|Drug|Placebo intranasal spray|Placebo intranasal spray
75543|NCT01217788|Drug|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
75544|NCT01217801|Drug|Ondansetron|
75545|NCT01217801|Drug|Ondansetron|
75546|NCT01217814|Drug|Sarilumab|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
75547|NCT01217814|Drug|Placebo|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
75721|NCT01215786|Drug|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
75722|NCT00046241|Drug|Extended-release bupropion hydrochloride|
75723|NCT01215799|Drug|Bafetinib|Bafetinib 240 mg bid
75724|NCT01215851|Drug|PA-824|200 mg tablet, once daily for 14 days
75725|NCT01215851|Drug|Pyrazinamide|Dosed by Weight
75726|NCT01215851|Drug|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
75727|NCT01215851|Drug|Rifafour|Rifafour e-275 275 mg
75728|NCT01215851|Drug|Moxifloxacin|moxifloxacin 400 mg
75729|NCT01215864|Drug|TCD-717|Patients will receive TCD-717 at the following dose levels:
2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m^2
75730|NCT01215877|Drug|Tesetaxel|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,
the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC < 1,500/mm3, a platelet count < 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.
for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles.
75731|NCT01215890|Drug|risedronate|
75732|NCT01215890|Drug|placebo|
75733|NCT00046254|Drug|Zoledronic Acid|
75734|NCT01215903|Dietary Supplement|Fish gelatin and omega-3 polyunsaturated fatty acid|
75735|NCT01215903|Dietary Supplement|Omega-3 polyunsaturated fatty acid|
75736|NCT01218035|Drug|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
75737|NCT01218048|Drug|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
75738|NCT01218048|Procedure|Surgery|Surgery for tumor
74800|NCT01193855|Procedure|functional magnetic resonance imaging|
74801|NCT01193855|Procedure|prostate biopsy|
75262|NCT01190085|Drug|Ghrelin|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
75611|NCT01222559|Drug|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
75612|NCT01222559|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
75613|NCT01215617|Behavioral|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
75614|NCT01215617|Behavioral|Control|Standard medical treatment
75615|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
75616|NCT01215630|Behavioral|Aerobic Interval Training|One interval training session
75617|NCT01215643|Drug|DEB025 1000 mg QD|1000 mg QD
75618|NCT01215643|Drug|DEB025 600 mg QD + RBV 400 mg BID|400 mg BID
75619|NCT01215643|Drug|DEB025 800 mg QD + RBV 400 mg BID|400 mg BID
75620|NCT01215643|Drug|DEB025 600 mg QD + peg-IFNα2a once weekly|IFNα2a once weekly
75621|NCT01215643|Drug|SOC (peg-IFNα2a once weekly + RBV 400 mg BID)|SOC (peg-IFNα2a once weekly + RBV 400 mg BID)
75622|NCT01215656|Dietary Supplement|Lactobacillus fermentum|
75623|NCT01215656|Dietary Supplement|Follow on formula without probiotics|
75624|NCT01215669|Biological|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
75625|NCT01215669|Biological|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
75626|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
75627|NCT01215669|Biological|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
75628|NCT01215669|Biological|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
75629|NCT01215682|Dietary Supplement|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
74860|NCT01191736|Behavioral|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
74861|NCT01191736|Behavioral|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
74862|NCT01191736|Behavioral|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
74863|NCT01191749|Drug|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
74864|NCT01191762|Drug|sevelamer carbonate|2400 mg with each meal for 4 weeks
74865|NCT01191762|Drug|placebo|3 tablets with each meal
74866|NCT01191775|Drug|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
74867|NCT01191788|Behavioral|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
74868|NCT00043706|Drug|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
74869|NCT01191788|Behavioral|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
74870|NCT01191801|Drug|vosaroxin and cytarabine|Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles
Cytarabine 1 g/m2 daily on days 1-5 (IDAC)
74871|NCT01191801|Drug|placebo and cytarabine|Placebo days 1 and 4: volume matched to vosaroxin
Cytarabine 1 g/m2 daily on days 1-5 (IDAC)
74872|NCT01191814|Procedure|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
74873|NCT01191814|Procedure|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
74874|NCT01191840|Drug|Vancomycin|Duration
74875|NCT01191840|Drug|Vancomycin|Duration
74876|NCT01191866|Behavioral|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
74877|NCT01191879|Other|Blood test|Blood test
75118|NCT01192243|Drug|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
74645|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
74646|NCT01186679|Procedure|laminectomy|surgical laminectomy with glial scar resection
74647|NCT01186679|Procedure|Intrathecal|direct into the CSF through lumbar puncture
74648|NCT01186692|Device|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVPA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
74649|NCT01186705|Drug|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
74650|NCT01186731|Drug|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
74651|NCT01186744|Drug|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
74652|NCT01186744|Drug|CP-690,550|10 mg oral BID
74653|NCT01186744|Drug|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
74654|NCT01186744|Drug|CP-690,550|5 mg oral BID
74655|NCT00000971|Drug|Clarithromycin|
74656|NCT00043108|Radiation|radiation therapy|
74657|NCT01186757|Drug|PF-03715455|PF-03715455 1.6 mg BID
74658|NCT01186757|Drug|PF-03715455|PF-03715455 4mg BID
74659|NCT01186757|Drug|PF-03715455|PF-03715455 10 mg BID
74660|NCT01186757|Drug|Placebo|Placebo
74661|NCT01186770|Drug|Methylnaltrexone bromide|oral tablets
74662|NCT01186770|Drug|Oral Placebo|oral tablets
74663|NCT01189136|Device|PTNS treatment|Electrical stimulation is received
74664|NCT01189136|Other|Sham treatment|No electrical stimulation is given
74802|NCT00043966|Drug|Lopinavir/ritonavir|
74803|NCT01193855|Procedure|ultrasound imaging|
74804|NCT01193868|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
74805|NCT01193868|Other|laboratory biomarker analysis|Correlative studies
74806|NCT01193868|Other|pharmacological study|Correlative studies
74807|NCT01193881|Drug|Erlotinib Hydrochloride|Given PO
74808|NCT01193881|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
74809|NCT01193881|Other|Laboratory Biomarker Analysis|Correlative studies
74810|NCT01193881|Other|Pharmacological Study|Correlative studies
74811|NCT01193894|Other|Profermin|Medical Food (food for special medical purposes)
74812|NCT01193894|Other|Fresubin|Medical food (food for special medical purposes)
74813|NCT00043966|Drug|Tenofovir DF|
74814|NCT01193907|Biological|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
74815|NCT01193907|Biological|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
74816|NCT01193907|Biological|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
74817|NCT01193907|Biological|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
74818|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
74819|NCT01193920|Other|Saline solution|Subjects received two injection of saline solution.
74820|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
74821|NCT01186926|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
74822|NCT01186939|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m^2/day.
75630|NCT01215682|Dietary Supplement|placebo|sweetened water
75631|NCT01215695|Device|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
75632|NCT01215695|Device|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
74720|NCT01193660|Other|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
74721|NCT00043953|Drug|Lopinavir/ritonavir|
74722|NCT01193686|Other|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
74723|NCT01193699|Drug|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
74724|NCT01193712|Procedure|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
74725|NCT01186783|Drug|ivabradine|Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
Day 1 and 2:
5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)
Day 3 and 4:
5,0 mg ivabradine b.i.d. if 60bpm≥heart rate<90bpm (acute renal failure: 70bpm≥heart rate <90bpm
7,5 mg ivabradine b.i.d. if heart rate ≥90bpm
74726|NCT01186796|Drug|Fulvestrant|Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:
(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.
**Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit).
74727|NCT01186809|Biological|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
74728|NCT01186822|Device|Lung Flute|Used twice daily
74729|NCT00043121|Drug|oxaliplatin|Given IV
74730|NCT01186835|Procedure|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
74731|NCT01186835|Procedure|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
74732|NCT01186848|Device|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
75119|NCT01192269|Dietary Supplement|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
75120|NCT01192282|Procedure|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
75121|NCT01192295|Drug|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
75122|NCT01192308|Drug|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
75123|NCT01192321|Device|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
75124|NCT01192321|Device|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
75125|NCT00043771|Drug|Tolvaptan|
75126|NCT01192360|Procedure|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
75127|NCT01192360|Procedure|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
75128|NCT01192373|Other|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
75129|NCT01192373|Other|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
75130|NCT01192399|Drug|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; initial dose of 600 mg weekly for 4 weeks, followed by 900 mg one week later, then maintenance of 900 mg every 2 weeks for duration of 12 weeks.
75131|NCT01192412|Procedure|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is >105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP <100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
75132|NCT01185145|Radiation|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
75133|NCT01185158|Drug|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
74665|NCT01189149|Procedure|IV fluids|Infants will be allocated to IV fluids
74666|NCT01189149|Procedure|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
74932|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
74933|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
74934|NCT01189617|Device|Formula PD-F-7619|Off-White to Beige Lotion
74935|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
74936|NCT01189643|Drug|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
74937|NCT01189656|Biological|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
74938|NCT01189669|Dietary Supplement|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
74939|NCT01189669|Dietary Supplement|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
74940|NCT01189682|Procedure|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
74941|NCT01189695|Drug|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
74942|NCT01189695|Drug|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
74943|NCT01189708|Device|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
74944|NCT01189708|Other|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
74945|NCT01189721|Drug|propofol, sevoflurane|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.
group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively.
74946|NCT01191918|Drug|Placebo plus Lithium|
74947|NCT01191944|Drug|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
74948|NCT01191944|Drug|pramipexole extended release tablet|0.375mg-4.5mg, once a day
75367|NCT01190332|Procedure|endoscopic sphincterotomy by rendezvous method|
75368|NCT01190345|Drug|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
75369|NCT01190345|Drug|no bevacizumab|no bevacizumab
75370|NCT00043511|Biological|pGA2/JS2 Plasmid DNA Vaccine|
75371|NCT01190358|Dietary Supplement|Placebo|Sugar pill containing maltodextrin.
75372|NCT01190358|Dietary Supplement|Meganatural Gold®|Meganatural Gold® contains 300mg of grape seed extract.
75373|NCT01190371|Drug|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
75374|NCT01190384|Other|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
75375|NCT01190384|Dietary Supplement|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
75376|NCT01190384|Other|Whole beans|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
75377|NCT01190397|Device|Warming goggles|
75378|NCT01190397|Device|warm and moist compresses|
75379|NCT01190410|Drug|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
75380|NCT01190410|Drug|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
75381|NCT00043537|Behavioral|Social Effectiveness Therapy for Children (SET-C)|
75382|NCT01190423|Behavioral|Out-Patient Psychotherapy Treatment|Individual and Group Therapy Sessions
75383|NCT01192763|Procedure|therapeutic conventional surgery|
75384|NCT01192776|Procedure|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
75385|NCT01192789|Drug|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
75386|NCT01192789|Other|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
74733|NCT01186848|Device|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
74734|NCT01186861|Drug|OSI-906|Tablet administered with food and with up to 200 mL of water
74735|NCT01186861|Drug|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
74736|NCT01186861|Drug|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
75005|NCT01187459|Dietary Supplement|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
75006|NCT01187459|Dietary Supplement|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
75007|NCT01187485|Drug|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
75008|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
75009|NCT01189734|Procedure|laparoscopic common bile duct exploration|
75010|NCT01189734|Procedure|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
75011|NCT01189747|Biological|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
75012|NCT01189747|Drug|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
75013|NCT01189760|Biological|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
75014|NCT01189760|Biological|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
75015|NCT01189760|Drug|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
75016|NCT01189773|Drug|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
75017|NCT01189786|Device|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
75018|NCT01189799|Behavioral|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
75475|NCT01190527|Radiation|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
75476|NCT01190540|Behavioral|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
75477|NCT01190540|Behavioral|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
75478|NCT01220089|Behavioral|Standard maintenance|Participants will receive written materials in months 7-18
75479|NCT01220089|Behavioral|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
75480|NCT01220102|Drug|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
75481|NCT01220128|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
75482|NCT01220128|Drug|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
75483|NCT00046865|Procedure|management of therapy complications|
75484|NCT01220128|Drug|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
75485|NCT01220128|Drug|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75486|NCT01220128|Drug|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
75487|NCT01220128|Drug|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
74949|NCT01191957|Drug|Busulphan plus Cyclophosphamide|I.V. Bu (Busilvex), 12.8 mg/kg:
Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest
Followed by:
Cyclophosphamide, 120 mg/kg iv:
Day -4: 60 mg/kg Day -3: 60 mg/kg
74950|NCT00043719|Drug|Calcium supplement with vitamin D|
74951|NCT01191957|Drug|Busulphan plus Fludarabine|I.V. Bu (Busilvex), 12.8 mg/kg:
Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:
Fludarabine, 4 x 40 mg/m² iv:
Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²
75184|NCT01190020|Drug|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
75185|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
75186|NCT01190033|Device|Neurotome OFF|In this intervention the neurotome will be unconnected.
75187|NCT01190033|Procedure|neurolysis|In this procedure the neurotome will be connected
75188|NCT01190046|Behavioral|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
75189|NCT01190059|Drug|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
75190|NCT01192412|Procedure|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is <80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is >85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
75191|NCT01192438|Procedure|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
75192|NCT01192464|Genetic|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
75193|NCT01192477|Other|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
75194|NCT00043784|Drug|enoxaparin|
75195|NCT01192490|Drug|Lidocaine|5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
75196|NCT01192490|Drug|Lubricant|KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
75387|NCT00043810|Drug|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
75388|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
75410|NCT01185743|Drug|ziprasidone|ziprasidone 40mg td
75411|NCT00043017|Radiation|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
75412|NCT01185743|Drug|placebo|placebo td
75413|NCT01185756|Radiation|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
75414|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
75415|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
75416|NCT01185782|Drug|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
75417|NCT01185782|Drug|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
75418|NCT01185795|Dietary Supplement|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
75419|NCT01185795|Dietary Supplement|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
75420|NCT01185808|Biological|Vitamin D|Vitamin D 5000IU/day for 6 weeks
75421|NCT01185821|Drug|BAF312|
75422|NCT00043030|Procedure|psychosocial assessment and care|
75423|NCT01185834|Device|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
75424|NCT01185847|Drug|RO5083945|intravenously, until disease progression
75425|NCT01185847|Drug|cisplatin|standard treatment, up to 6 cycles
75426|NCT01185847|Drug|gemcitabine|standard treatment, up to 6 cycles
75427|NCT01185847|Drug|pemetrexed|standard treatment, up to 6 cycles
75019|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
75020|NCT01189799|Other|Dual Recovery Anonymous/Treatment as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
75021|NCT01189812|Drug|Lithium Carbonate|300 mg one time per day for 4 weeks
75022|NCT01189812|Drug|Placebo|Take one time daily for 4 weeks
75023|NCT01189812|Drug|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
75024|NCT01189825|Behavioral|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
75263|NCT01190085|Drug|Ghrelin|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
75264|NCT01190085|Drug|Saline solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
75265|NCT01190098|Drug|Lacosamide|Subjects randomized to lacosamide according to the following schedule:
Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid
75266|NCT01190098|Drug|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
75267|NCT01190111|Biological|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
75268|NCT00043433|Drug|intravenous T900607-sodium|
75269|NCT01190137|Dietary Supplement|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
75270|NCT01190150|Drug|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
75271|NCT01190163|Drug|Dinoprostone|
75272|NCT01190163|Drug|Oxytocin|
75273|NCT01190176|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
75274|NCT01190176|Biological|Cervarix™|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
75275|NCT01190176|Biological|Placebo control|Subjects received 3 doses of the control [Al(OH)3] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
75488|NCT01220128|Drug|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
74590|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
74591|NCT01189110|Device|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
74592|NCT00043394|Drug|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
74593|NCT01189123|Biological|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
74594|NCT01189123|Biological|fluzone by sanofi pasteur|standard dose fluzone
74595|NCT01191398|Drug|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
74596|NCT01191398|Drug|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
74597|NCT01191398|Drug|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
74598|NCT01191411|Other|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
74599|NCT00000973|Drug|Leucovorin calcium|
74600|NCT00043628|Procedure|Stem Cell Mobilization|
74601|NCT01191411|Other|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
74602|NCT01191411|Other|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
74603|NCT01191424|Drug|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
75197|NCT01192503|Drug|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
75198|NCT01192503|Drug|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
75199|NCT01192516|Behavioral|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
75200|NCT01192516|Behavioral|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
75548|NCT01217814|Drug|Golimumab|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
75549|NCT01217814|Drug|methotrexate [MTX]|Pharmaceutical form: tablet or solution for injection
Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)
75550|NCT00046540|Drug|Liposome-encapsulated SN38|
75551|NCT01217814|Drug|Folic/folinic acid|Pharmaceutical form: tablet
Route of administration: oral
75552|NCT01217827|Behavioral|Clinical Reminder|
75553|NCT01217840|Drug|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
75554|NCT01217840|Drug|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
75555|NCT01217853|Device|SENSIMED Triggerfish|Contact lens-based device for continuous intraocular pressure monitoring
75556|NCT01217866|Procedure|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
75557|NCT01217879|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
75558|NCT01217892|Drug|dapagliflozin|2.5 mg tablet, taken orally, twice daily
75559|NCT01217892|Drug|dapagliflozin|5 mg tablet taken orally, twice daily
75560|NCT01217892|Drug|dapagliflozin|10 mg tablet taken orally, once daily
75561|NCT00046553|Drug|RU-486 (Mifepristone)|
75562|NCT01217892|Drug|metformin|>/= 1500 mg total daily dose, tablets taken orally, twice daily
75563|NCT01217892|Drug|placebo|placebo
75564|NCT01217905|Drug|AZD7687|Oral suspension
75428|NCT01185860|Drug|danoprevir|oral doses
75429|NCT01185860|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
75430|NCT01185860|Drug|placebo|oral doses
75431|NCT01185860|Drug|ribavirin|1000-1200mg/day po
75432|NCT01185860|Drug|ritonavir|oral doses
75433|NCT00043043|Drug|celecoxib|
75739|NCT01218048|Radiation|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
75740|NCT01218048|Drug|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
75741|NCT01218061|Other|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 5 years annual follow-up (V1, V2, V3, V4, V5) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank) Making a total of 6 visits (V0-V5) with 6 blood samples.
75742|NCT00000992|Drug|Itraconazole|
75743|NCT00046566|Behavioral|Complex Carbohydrate Dietary Supplements|40 grams of carbohydrate per day
75744|NCT01218074|Device|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
75745|NCT01218074|Device|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
75746|NCT01218087|Device|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
75747|NCT01218087|Device|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
75748|NCT01218100|Drug|nebivolol and lisinopril (free combination)|nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks
nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks
nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks
nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks
75276|NCT01190189|Biological|GSK580299 (Cervarix™)|3-dose schedule intramuscularly vaccination
75277|NCT01190202|Procedure|Blood sampling|Capillary blood samples collected by finger/heel prick
75278|NCT01190202|Procedure|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
75279|NCT00043446|Drug|intravenous T900607-sodium|
75280|NCT01190215|Biological|FluarixTM|One Intramuscular injection
75281|NCT01190215|Biological|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
75282|NCT01190228|Biological|Japanese encephalitis chimeric virus|0.5 mL (single dose), Subcutaneous
75283|NCT01190228|Biological|Japanese encephalitis chimeric virus|0.5 mL (single dose), Subcutaneous
75284|NCT01190228|Biological|Varicella vaccine|0.5 mL (single dose), Subcutaneous
75633|NCT01215708|Drug|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
75634|NCT01215721|Drug|Vesicare|5 mg daily
75635|NCT01215734|Biological|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
75636|NCT01215734|Biological|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
75637|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
75638|NCT01217918|Drug|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
75639|NCT01217931|Drug|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
75640|NCT01217931|Drug|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
75641|NCT01217931|Drug|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
75642|NCT01217944|Drug|Ranibizumab|0.5 mg ranibizumab intravitreal injection
75643|NCT00046566|Behavioral|Soy Protein Dietary Supplements|40 gram soy protein per day
75644|NCT01217944|Drug|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
74604|NCT01191424|Drug|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
74605|NCT01191450|Drug|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
74606|NCT01191450|Drug|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
74878|NCT01191892|Drug|carboplatin|
74879|NCT00043719|Drug|Nitroglycerin ointment|
74880|NCT01191892|Drug|gemcitabine hydrochloride|
74881|NCT01191892|Drug|vandetanib|
74882|NCT01191892|Drug|Placebo|Placebo of vandetanib tablet
74883|NCT01191905|Drug|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
74884|NCT01191905|Drug|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
74885|NCT01191918|Drug|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
74886|NCT01194115|Drug|placebo|placebo representing standard of care
74887|NCT01194128|Behavioral|Psychoeducational Support|The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
74888|NCT00043979|Biological|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
74889|NCT01194128|Behavioral|Information only control group|Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include "Caregiving and Depression," "End of Life Decision Making," and "Taking Care of You: Self-Care for Family Caregivers" from the Family Caregiver Alliance; and "Family Involvement in Nursing Home Care," "Problem Solving," and "Residents' Rights" from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information.
74890|NCT01194141|Behavioral|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
74891|NCT01194154|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
75565|NCT01217918|Drug|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
75566|NCT01217918|Drug|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
75567|NCT00046865|Procedure|nausea and vomiting therapy|
75568|NCT01220154|Drug|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
75569|NCT01220154|Drug|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
75570|NCT01220154|Drug|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
74667|NCT01189162|Device|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
74668|NCT01189175|Drug|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
74669|NCT01189175|Drug|BI 113823|single oral dose
74670|NCT01189188|Procedure|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
74671|NCT00000972|Biological|MTP-PE/MF59|
74672|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
74673|NCT01189188|Procedure|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
74674|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
74675|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
74676|NCT01189201|Drug|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
74677|NCT01189201|Drug|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
74678|NCT01189214|Drug|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
74679|NCT01189227|Procedure|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
75749|NCT01218100|Drug|nebivolol monotherapy|nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks
nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)
nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks
75750|NCT01218100|Drug|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
75751|NCT01218100|Drug|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
75752|NCT01218113|Biological|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
75753|NCT01218113|Drug|Placebo|1 or 3 doses according to protocol schedule
75754|NCT01220375|Drug|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
74823|NCT01186952|Behavioral|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
74824|NCT01186952|Behavioral|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
74825|NCT01186965|Behavioral|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
74826|NCT01186978|Radiation|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
74827|NCT01186991|Drug|MetMAb|Intravenous repeating dose
74828|NCT01186991|Drug|bevacizumab|Intravenous repeating dose
74829|NCT01186991|Drug|paclitaxel|Intravenous repeating dose
74830|NCT01186991|Drug|placebo|Intravenous repeating dose
74831|NCT00043121|Drug|fluorouracil|Given IV
74832|NCT01187017|Drug|Cyclophosphamide|60 mg/kg
74833|NCT01187017|Drug|Fludarabine|125 mg/m squared
74834|NCT01187043|Drug|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
75645|NCT01217944|Drug|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
75646|NCT01217944|Drug|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
75647|NCT01217957|Drug|Ixazomib|Ixazomib capsules
75648|NCT01217957|Drug|Lenalidomide|Lenalidomide capsules
75649|NCT01217957|Drug|Dexamethasone|Dexamethasone tablets
75650|NCT01217970|Drug|Ibudilast|Ibudilast oral 20mg BID for 7 days
75651|NCT01217970|Drug|Ibudilast|Ibudilast oral 50mg BID for 7 days
75652|NCT01217970|Drug|Ibudilast|Placebo oral BID 7 days
75653|NCT01217996|Behavioral|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
75654|NCT00046566|Behavioral|Milk Protein Dietary Supplements|40 grams of milk protein per day
74737|NCT01186887|Drug|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
74738|NCT01186887|Drug|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
74739|NCT01186900|Procedure|ultrasound-guided needle aspiration|one time drainage at time of randomization
74740|NCT00043121|Drug|leucovorin calcium|Given IV
74741|NCT01189253|Other|laboratory biomarker analysis|
74742|NCT01189253|Procedure|quality-of-life assessment|
74743|NCT01189266|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
74892|NCT01194154|Drug|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
74893|NCT01194167|Drug|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
74894|NCT01194180|Biological|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
74895|NCT01194180|Biological|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
75134|NCT01185171|Drug|ZD 1839 500mg|Optional Induction chemotherapy:
Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance [CC] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.
Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle.
75135|NCT01185184|Drug|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
75136|NCT01185197|Drug|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
75137|NCT01185197|Drug|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
75138|NCT00043004|Drug|fluorouracil|
75139|NCT01185210|Dietary Supplement|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
75140|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
75141|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
75142|NCT01185223|Drug|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
75143|NCT01185223|Drug|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
75144|NCT01185236|Drug|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
75145|NCT01185236|Drug|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
75146|NCT01185249|Procedure|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
74680|NCT01189227|Procedure|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
74681|NCT01189240|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
74682|NCT01189240|Biological|bevacizumab|Given IV
74683|NCT00043394|Drug|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
74684|NCT01189240|Other|laboratory biomarker analysis|Correlative studies
74685|NCT01189240|Other|pharmacological study|Correlative studies
74686|NCT01189253|Drug|doxorubicin hydrochloride|
74687|NCT01189253|Drug|trabectedin|
74952|NCT01191983|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered sc every 4 weeks
74953|NCT01191996|Biological|MIS416|MIS416 intravenously every week
74954|NCT01192009|Dietary Supplement|Leucine|7.2 g of leucine during 2 weeks
74955|NCT01192009|Dietary Supplement|Placebo|7.2 g of alanine during 2 weeks
74956|NCT01192022|Biological|TachoSil®|Intraoperative application as secondary hemostatic treatment
74957|NCT01192022|Device|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
74958|NCT01192035|Drug|Efavirenz or Nevirapine|2 NRTIs (lamivudine 150 mg "bis in die - twice a day" (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 NNRTI (efavirenz 600 mg "omne in die - once daily" (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz.
74959|NCT01192035|Drug|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
74960|NCT01192048|Other|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome sequencing.
74961|NCT00043732|Drug|SCIO-469|
74962|NCT01192074|Device|Ultrasound|Preprocedure ultrasound examination of the spine
74835|NCT01187056|Behavioral|Training programme|2 x 2 hours of training (workshops)
74836|NCT01187069|Behavioral|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
74837|NCT01187082|Behavioral|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
74838|NCT01187082|Behavioral|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
74839|NCT01187095|Behavioral|Expressive writing|3 consecutive days of writing
74840|NCT01187108|Drug|N-acetylcysteine|NAC 600 mg oral once daily
74841|NCT01187108|Drug|Acetazolamide|Acetazolamide 250 mg oral once daily
75389|NCT01192802|Drug|albendazole|single 1 tablet of 400 mg of albendazole
75390|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
75391|NCT01192815|Drug|erlotinib hydrochloride|Given orally or via gastronomy tube
75392|NCT01192815|Radiation|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
75393|NCT01192815|Other|pharmacogenomic studies|Optional correlative studies
75394|NCT01192815|Other|gene expression analysis|Correlative studies
75395|NCT01192815|Radiation|3-dimensional conformal radiation therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.
The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field.
75396|NCT01192815|Other|biopsy|Optional correlative studies
75397|NCT01192815|Other|pharmacological study|Optional correlative studies
75398|NCT00043823|Drug|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
74744|NCT01189266|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
74745|NCT01189266|Other|Laboratory Biomarker Analysis|Correlative studies
74746|NCT01189266|Drug|Vorinostat|Given PO
74747|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
74748|NCT01189279|Drug|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
74749|NCT01189279|Drug|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
74750|NCT01189279|Drug|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
74751|NCT01189292|Drug|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
74752|NCT01189292|Other|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
74753|NCT01189305|Behavioral|Behavioral Couples Therapy|Behavioral Couples Therapy
74754|NCT01189305|Behavioral|Individual Drug Counseling|Individual Drug Counseling
74755|NCT01189318|Drug|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4~28 50~150mg (increments and deduction of 50mg are allowed)
75025|NCT01189851|Device|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
75026|NCT01189864|Drug|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
75027|NCT01189864|Drug|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
75028|NCT01189864|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
75029|NCT01192113|Drug|Mecobalamin IV or IM injection|Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
75030|NCT01192126|Device|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
75031|NCT01192126|Device|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
75147|NCT01185262|Drug|Lenalidomida and Rituximab|Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.
Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.
If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).
In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1.
75148|NCT01185275|Device|Alair system|Bronchial thermoplasty
75149|NCT00000970|Drug|Foscarnet sodium|
75150|NCT00043004|Drug|leucovorin calcium|
75151|NCT01185288|Biological|Adalimumab|Adalimumab in pre-filled syringes
75152|NCT01185288|Drug|Methotrexate|Methotrexate capsule
75489|NCT01220128|Drug|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75490|NCT01220128|Drug|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75491|NCT01220128|Drug|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75492|NCT01220128|Drug|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
75493|NCT01220141|Drug|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
75494|NCT01222247|Drug|Corticosteroid|The active study drug, betamethasone, trade name Celestone Soluspan® manufactured by Schering Plough.
3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
75495|NCT01222260|Drug|Bendamustine|Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:
CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle
Available to qualifying subjects is the option to dose escalate to dose level (+)1:
120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study) 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)
75496|NCT01222260|Drug|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
74963|NCT01192087|Drug|Cetuximab|cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
74964|NCT01192100|Other|Dietary Interventions: Normal protein/protein-rich breakfast meals|The participants will complete, in randomized order, the following breakfast patterns at home (before school) for 6 days: 1) Breakfast Skipping; 2) Consumption of Normal Protein Breakfast Meals; and 3) Consumption of Protein-Rich Breakfast Meals. On the 7th day of each pattern (which will occur on Saturdays), the participants will report to the University of Missouri's Brain Imaging Center in the morning to complete the respective 12-h testing day.
74965|NCT01192113|Drug|Mecobalamin IV Injection|Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
74966|NCT01192113|Drug|Mecobalamin IM injection|Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
74967|NCT01184833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
74968|NCT01184846|Biological|10% liquid formulation of human immunoglobulin|
74969|NCT00042991|Other|pharmacological study|Correlative studies
75201|NCT01192529|Dietary Supplement|Supressi. T-Diet plus Range|Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.
Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months.
75202|NCT01192529|Dietary Supplement|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
75203|NCT01192542|Device|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
75204|NCT01192542|Device|enfilcon A lens|Marketed silicone hydrogel contact lens
75205|NCT00043797|Drug|Lidorestat (IDD 676)|
75206|NCT01192555|Biological|Neuroblastoma Vaccine|1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.
Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.
Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol.
75207|NCT01192555|Drug|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
75208|NCT01192568|Drug|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
75209|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
75399|NCT01192815|Other|laboratory biomarker analysis|Optional correlative studies
75400|NCT01192815|Other|questionnaire administration|Optional ancillary studies
75401|NCT01192815|Other|enzyme-linked immunosorbent assay|Optional correlative studies
75402|NCT01192815|Other|polymorphism analysis|Optional correlative studies
75403|NCT01192828|Drug|taurine|Take Taurine for 4 1/2 days, two doses per day
75404|NCT01192841|Other|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
75405|NCT01192854|Drug|Clevudine|Clevudine flexible dosages of 30 mg/day
75406|NCT01192854|Drug|Adefovir|Adefovir flexible dosages of 10 mg/day
75407|NCT01185704|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
75408|NCT01185730|Procedure|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
75409|NCT01185743|Drug|olanzapine|olanzapine 10mg od + placebo od
75434|NCT01188174|Drug|Clofarabine|The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
75435|NCT01188187|Drug|Custirsen Sodium, Docetaxel, Prednisone|Docetaxel/Prednisone on a 3-week cycle with weekly OGX-011 640 mg infusions until disease progression, unacceptable toxicity, or completion of 10 cycles
75436|NCT01188187|Drug|Docetaxel, Prednisone|Docetaxel/Prednisone on a 3-week cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
75437|NCT01188200|Other|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
75438|NCT01188200|Other|Standard food|Standard meal prior to test time
75439|NCT01188213|Dietary Supplement|Methylsulfonylmethane (MSM)|
75440|NCT01188226|Device|Denture teeth|Denture teeth made of nano hybrid composite material
75441|NCT01188252|Drug|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
75032|NCT01192139|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
75033|NCT01192139|Drug|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
75034|NCT00000973|Drug|Zidovudine|
75035|NCT00043745|Dietary Supplement|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
75036|NCT01192139|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
75037|NCT01192152|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
75038|NCT01192152|Drug|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
75039|NCT01192152|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
75040|NCT01192165|Drug|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
75041|NCT01192165|Drug|Docetaxel|Chemotherapy
75042|NCT01192165|Drug|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
75043|NCT01192165|Drug|Pemetrexed|Chemotherapy
75044|NCT01192165|Drug|Carboplatin|Chemotherapy
75045|NCT01192165|Drug|nab-Paclitaxel|Chemotherapy
75046|NCT00043745|Dietary Supplement|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
75047|NCT01192165|Drug|Cisplatin|Chemotherapy
75285|NCT01190241|Drug|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
75286|NCT01190254|Drug|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
75287|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
75288|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
75289|NCT01192594|Behavioral|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
75497|NCT01222273|Dietary Supplement|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
75498|NCT01222286|Drug|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
75499|NCT01222299|Drug|bepotastine besilate nasal product - low dose|sterile nasal product
75500|NCT01222299|Drug|bepotastine besilate nasal product - medium dose|sterile nasal product
75501|NCT01222299|Drug|bepotastine besilate nasal product - high dose|sterile nasal product
75502|NCT00047021|Drug|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
75503|NCT01222299|Drug|placebo comparator nasal product|sterile nasal product
75504|NCT01222312|Drug|Cisplatin|75 mg/m2, d1 every 3 weeks
75505|NCT01222312|Drug|Oxaliplatin|85 mg/m², d1 every 2 weeks
74607|NCT01191463|Other|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
74608|NCT01191463|Other|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
74609|NCT01191476|Drug|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
74610|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
74611|NCT00043654|Drug|Mifepristone|
74612|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
74613|NCT01191489|Device|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
74614|NCT01191489|Device|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
74615|NCT01191489|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
74616|NCT01191515|Device|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
74617|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
75210|NCT01185301|Drug|methotrexate|weekly oral capsule dosing
75211|NCT01185314|Procedure|Testing for mutation status|EGFR mutation test
75212|NCT01185327|Behavioral|Breastfeeding|Breastfeeding
75213|NCT01185340|Drug|LY2216684|12 mg to 18 mg Administered orally, once daily for 11 weeks
75214|NCT01185340|Drug|Placebo|Administered orally, once daily for 11 weeks
75215|NCT01185353|Drug|LY3009104|Administered orally
75216|NCT01185353|Drug|Placebo|Administered orally
75217|NCT00043004|Drug|oxaliplatin|
75218|NCT01185366|Drug|Everolimus|10 mg by mouth once a day.
75219|NCT01185366|Drug|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
75220|NCT01185379|Dietary Supplement|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
75221|NCT01185379|Dietary Supplement|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
75571|NCT01220167|Drug|Ondansetron|Participants were served dinner to ensure a minimum of 10 hours of fasting. Participants were dosed with a 3 day washout period between each administration.
Blood samples were obtained.
75572|NCT01220167|Drug|Ondansetron|Participants were served dinner to ensure a minimum of 10 hours of fasting. Participants were dosed with a 3 day washout period between each administration.
Blood samples were obtained.
75573|NCT01220180|Drug|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
75574|NCT01220180|Drug|pregabalin (Lyrica)|Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.
Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered.
75575|NCT01220180|Drug|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
75576|NCT01220206|Drug|Placebo|2 placebo capsules daily
75442|NCT01188265|Drug|Valproate|
75443|NCT00043277|Drug|Angiomax (bivalirudin)|
75444|NCT01188265|Drug|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
75445|NCT01188265|Drug|Placebo|VPA plus placebo
75446|NCT01188265|Drug|Dextromethorphan 30 mg|VPA & Dextromethorphan 30 mg per day
75447|NCT01188278|Drug|Imatinib|Drug being observed but not provided
75448|NCT01188304|Drug|aleglitazar|repeated daily doses
75449|NCT01188304|Drug|aspirin|repeated daily doses
75450|NCT01188304|Drug|placebo|repeated daily doses
75451|NCT01188317|Drug|aleglitazar|repeated daily doses
75452|NCT01188317|Drug|placebo|repeated daily doses
75453|NCT01188317|Drug|ibuprofen|repeated daily doses
75454|NCT00043303|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
75455|NCT01188330|Behavioral|WITH Comprehensive Geriatric assessment|Each month after randomization, a nurse practitioner will systematically review the intervention plan.
In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose
74562|NCT01186536|Dietary Supplement|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
74563|NCT01186549|Drug|Ephedrine 30microgram/kg|Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected
74564|NCT01186549|Drug|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected
74565|NCT01186549|Drug|ephedrine 70 microgram/kg|Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected
75290|NCT01192594|Behavioral|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
75291|NCT01192607|Device|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
75292|NCT01192633|Drug|GVP|Drug: gemcitabine, vincristine,cisplatin
cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks
75293|NCT00043810|Procedure|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
75294|NCT01192646|Behavioral|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
75295|NCT01192672|Behavioral|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
75296|NCT01192672|Behavioral|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
75297|NCT01192685|Device|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
75298|NCT01192698|Drug|IV interferon|IV interferon 5MU during anhepatic phase
75299|NCT01192711|Device|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
75300|NCT01192724|Drug|Cilostazol|100 mg BID, for 3 months
75301|NCT01192724|Drug|Aspirin|Aspirin 100 mg QD, for 1 year
75302|NCT01192724|Drug|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
75303|NCT01192750|Other|immunohistochemistry staining method|
75655|NCT01217996|Behavioral|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
75656|NCT01218009|Drug|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
74618|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
74619|NCT01193920|Other|saline solution|Subjects received one injection of saline solution.
74620|NCT00043966|Drug|Emtricitabine|
74621|NCT01193933|Drug|L-asparaginase|prolonged L-asparaginase application at 10.000 IU weekly in induction, once in two weeks in 14 weeks consolidation, twice a month in maintenance (total proposed dose 560.000 IU)
74622|NCT01193946|Dietary Supplement|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
74623|NCT01193972|Other|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
74624|NCT01193985|Device|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
74625|NCT01193998|Other|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
74896|NCT01194193|Drug|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
74897|NCT01194206|Radiation|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
74898|NCT01194219|Drug|Apremilast|
74899|NCT00043979|Drug|cyclophosphamide|Induction - 750 mg/m^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.
Transplant - 1200 mg/m^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3.
74900|NCT01194219|Drug|Placebo|Identical matching placebo
74901|NCT01194219|Drug|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
74902|NCT01194232|Drug|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
74903|NCT01194245|Drug|Insulin lispro|
74904|NCT00043121|Drug|capecitabine|Given orally
74905|NCT01187108|Drug|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
75577|NCT01220206|Drug|One POMx capsule daily|One POMx capsule, one placebo capsule daily
75578|NCT00046878|Drug|O6-benzylguanine|
75579|NCT01220206|Drug|2 POMx Capsules|2 POMx Capsules daily
75580|NCT01220219|Drug|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
75581|NCT01220219|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
75582|NCT01220219|Drug|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
75583|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
75584|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
75585|NCT01220232|Drug|Lersivirine|Lersivirine 750 mg QD for 10 days
75586|NCT01220245|Procedure|Heparin-bonded ePTFE endoluminal fem-pop bypass|Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
75587|NCT01220245|Procedure|Surgical femoro-popliteal bypass.|Surgical femoro-popliteal bypass.
75588|NCT01222416|Radiation|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
74688|NCT01191528|Device|capnostream 20, Oridian Medical 1987 ltd, Needham MA|Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.
End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals.
74689|NCT01191541|Drug|Ara-c|Drug: ATRA 25mg/m2 day until complete remission (CR)
Drug: As2O3 Induction:0.15-0.2mg/kg d1-28 iv Consolidation: 0.15-0.2mg/kg d1-28 iv in cycle 2 Drug: Idarubicin 10 mg/m2 days1-3 in Consolidation1 Drug: Ara-C some patients consolidation with Ara-C in cycles 3 and 4. Ara-c 1g/m2 d1-3 iv Drug: DNR 45 mg/m2 days1-3 in Consolidation 3 and 4
74690|NCT01191554|Drug|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
74691|NCT01191567|Procedure|VAC treatment|wound treatment with VAC-therapy
74692|NCT01191567|Procedure|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
74693|NCT00043667|Drug|Daclizumab|
74694|NCT01191580|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
74566|NCT01186549|Drug|lidocaine 0.5mg/kg|Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected
74567|NCT01186549|Drug|normal saline 2ml|Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected
74568|NCT01186562|Drug|Sitagliptin|100 mg PO daily
74569|NCT01186562|Drug|Placebo|Placebo
74570|NCT01186575|Other|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
74571|NCT01186588|Drug|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
74572|NCT00043108|Drug|paclitaxel|
74573|NCT01186601|Drug|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of </= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
74574|NCT01186614|Device|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
74575|NCT01186614|Device|ECMO|Insertion of peripheral VA ECMO
74576|NCT01186614|Procedure|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
74577|NCT01186614|Procedure|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
74842|NCT01189396|Drug|Active Comparator|Proventil HFA albuterol inhalation aerosol, 90 mcg/inhalation, 2, 2, 4, and 8 inhalations per dose a 30 min intervals, total accumulated dose 1440 mcg.
74843|NCT01189409|Drug|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
74844|NCT01189409|Drug|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
74845|NCT01189422|Drug|teplizumab or placebo|infusion or injection
74846|NCT01189435|Drug|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
75657|NCT01218009|Drug|Albuterol Spiromax|Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.
The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).
75658|NCT01218022|Drug|Losartan Potassium Tablets|
75659|NCT01220258|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
75660|NCT00000116|Drug|Nutritional Supplement|
75661|NCT00000249|Drug|40% N2O|40% inhaled N2O
75662|NCT00000995|Drug|Zidovudine|
75663|NCT00046878|Drug|carmustine|
75664|NCT01220271|Drug|LY2157299|Administered orally
75665|NCT01220271|Drug|Radiation|Administered as approved
75666|NCT01220271|Drug|Temozolomide|Administered orally
75667|NCT01220284|Drug|Satraplatin in combo with vinorelbine|Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)
Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks.
75668|NCT01220297|Drug|Sirolimus|12 mg loading dose, 4 mg QD, PO
75669|NCT01220297|Drug|Mycophenolate Mofetil|15 mg/kg TID, IV or PO
75670|NCT01220297|Drug|Carmustine|15 mg/kg, IV
75671|NCT01220297|Drug|VP-16|60 mg/kg, IV
75672|NCT01220297|Drug|cyclophosphamide|100-120 mg/kg, IV
75673|NCT01220310|Behavioral|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.|
75674|NCT00046891|Drug|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
74756|NCT01189331|Device|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
74757|NCT01189344|Drug|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
74906|NCT01187134|Behavioral|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
74907|NCT01187147|Dietary Supplement|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
74908|NCT01187160|Procedure|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
74909|NCT01187186|Drug|ASP1941|oral
74910|NCT01187199|Drug|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
74911|NCT01187199|Drug|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
74912|NCT01187199|Drug|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
74913|NCT01187199|Drug|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
75153|NCT01185301|Biological|adalimumab|Pre-filled syringe every other week
75154|NCT01187693|Other|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
75155|NCT00000971|Drug|Zidovudine|
75156|NCT00043186|Drug|Placebo|Placebo subcutaneous injection
75157|NCT01187719|Drug|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
75158|NCT01187732|Device|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
75159|NCT01187745|Other|CT Scan followed by ultrasound|A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
75160|NCT01187758|Behavioral|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
71589|NCT01167517|Other|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
71590|NCT01167530|Drug|Everolimus|First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.
71591|NCT01167556|Behavioral|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
71592|NCT01167569|Drug|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
71593|NCT00000955|Drug|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
71594|NCT00041327|Drug|cyclophosphamide|750 mg/m2 IV on day 5
71595|NCT01167569|Other|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
71596|NCT01167582|Biological|Red blood cell transfusion|Liberal versus restrictive transfusion
71597|NCT01167595|Other|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
71922|NCT01170546|Other|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
71923|NCT01170546|Other|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
71924|NCT01170546|Other|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
71925|NCT01170559|Device|Implantable Loop Recorder|
71926|NCT01170572|Other|No intervention|No intervention
71927|NCT00041704|Drug|Anidulafungin, VER002|
71928|NCT01173029|Drug|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
71350|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
71351|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
71352|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
71353|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
71354|NCT01172145|Drug|Modafinil|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
71355|NCT01172145|Drug|Placebo|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
71356|NCT01172171|Drug|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
71357|NCT01172171|Drug|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
71358|NCT01172184|Procedure|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
71359|NCT01172197|Drug|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
71360|NCT01172197|Drug|Ropivacaine|Bolus and infusion
71361|NCT01172223|Drug|Lapatinib|
71656|NCT01175330|Drug|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
71657|NCT00042289|Drug|nevirapine|Women will receive nevirapine as prescribed by their clinicians. (Dosage will vary for each participant.)
71658|NCT01175330|Drug|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
71659|NCT01175343|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
71660|NCT01175343|Other|Laboratory Biomarker Analysis|Correlative studies
71661|NCT01175356|Drug|cyclophosphamide|Given IV
71662|NCT01175356|Drug|topotecan hydrochloride|Given IV
71663|NCT01175356|Drug|cisplatin|Given IV
71664|NCT01175356|Drug|etoposide phosphate|Given IV
71136|NCT01183156|Behavioral|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
71137|NCT01183169|Drug|DEB025 600 mg QD + PegIFN + RBV|DEB025 600 mg QD + peg-IFNα2a once weekly + RBV BID
71138|NCT01183169|Drug|DEB025 800 mg QD + PegIFN + RBV|DEB025 800 mg QD + peg-IFNα2a once weekly + RBV BID
71139|NCT01183169|Drug|placebo + PegIFN + RBV|Patients will change to active treatment if cEVR not reached), with delayed onset of DEB025 600 mg QD + PegIFN + RBV treatment due to non-response to placebo + PegIFN + RBV)
71140|NCT00042900|Drug|pyroxamide|
71141|NCT01183169|Drug|placebo + PegIFN + RBV|Patients will change to active treatment if cEVR not reached), with delayed onset of DEB025 400 mg BID + PegIFN + RBV treatment due to non-response to placebo + PegIFN + RBV)
71142|NCT01183169|Drug|DEB025 400 mg BID + PegIFN + RBV|DEB025 400 mg BID + peg-IFNα2a once weekly + RBV BID
71143|NCT01183182|Device|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
71144|NCT01183208|Drug|Intervention A|A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
71145|NCT01183208|Drug|Intervention B|A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
71146|NCT01183208|Drug|Intervention C|A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
71147|NCT01183208|Drug|Intervention D|A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
71148|NCT01183208|Drug|Intervention E|A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
71149|NCT01183221|Drug|Syntocinon|One dose of 24 IU (3 sprays/nostril)
71150|NCT01183234|Drug|SPD544|two 30mg capsules, single oral dose
71151|NCT00042913|Biological|epratuzumab|
71152|NCT01183234|Drug|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
71153|NCT01183247|Drug|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
71855|NCT01172990|Procedure|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
71856|NCT01172990|Procedure|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
71857|NCT01173003|Drug|Mifepristone, misoprostol|
71858|NCT01173016|Drug|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
71859|NCT01175070|Drug|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen [TM]) 0.3mg every 6 weeks over a 30 week period.
71860|NCT01175083|Biological|GSK1024850A (SynflorixTM)|2, 3 or 4 intramuscular injection
71861|NCT01175083|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
70912|NCT01175967|Other|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
70913|NCT01175980|Other|Laboratory Biomarker Analysis|Correlative studies
70914|NCT01175980|Drug|Vorinostat|Given PO
70915|NCT01175993|Other|Exercise|Elliptical training focused on speed
70916|NCT01175993|Other|Mood Therapy|Bright light therapy
70917|NCT01176006|Procedure|Reduced-intensity hematopoietic stem cell|Stem cell transplant
70918|NCT01176006|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
70919|NCT01176006|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
70920|NCT00042289|Drug|ethionamide/prothionamide|Women will receive ethionamide/prothionamide as prescribed by their clinicians. (Dosage will vary for each participant.)
70921|NCT01176006|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
70922|NCT01176006|Drug|Equine ATG|ATG: 30 mg/kg IV once daily x 3 days on days -6, -5, and -4
70923|NCT01176006|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
71929|NCT01173042|Dietary Supplement|Peanuts|Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
71930|NCT01173042|Dietary Supplement|Glucose and whipping cream|An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
71931|NCT01173042|Dietary Supplement|Oil Blend|Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
71932|NCT01173055|Drug|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
71933|NCT01173055|Drug|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
71934|NCT00042146|Behavioral|Cognitive-behavior therapy|
71935|NCT01173068|Drug|Ertapenem|Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
71936|NCT01173081|Drug|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
71937|NCT01173081|Drug|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
71938|NCT01173094|Device|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
71939|NCT01173094|Device|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
70989|NCT01182961|Other|exercise group|standard of care exercise group to improve strength and balance
70990|NCT01182974|Drug|paracetamol|1 gr of paracetamol PO/PZ/PR
70991|NCT01182974|Drug|dypirone|1 gr PO/PZ/PR/IM
70992|NCT01182987|Behavioral|Dementia Care Management|The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.
Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution.
70993|NCT01183000|Procedure|Closure of the peritoneum at cs|
70994|NCT01183013|Drug|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
71665|NCT01175356|Drug|vincristine sulfate|Given IV
71666|NCT01175356|Drug|doxorubicin hydrochloride|Given IV
71667|NCT01175356|Radiation|iobenguane I 131|Given IV
71668|NCT00042289|Drug|rifampicin|Women will receive rifampicin as prescribed by their clinicians. (Dosage will vary for each participant.)
71669|NCT01175356|Procedure|therapeutic conventional surgery|Undergo surgery
71670|NCT01175356|Drug|busulfan|Given IV
71671|NCT01175356|Drug|melphalan|Given IV
71672|NCT01167634|Behavioral|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
71673|NCT01167634|Behavioral|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
71674|NCT01167660|Device|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
71675|NCT01167673|Dietary Supplement|coltect|green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
71676|NCT01167673|Dietary Supplement|Placebo|placebo
71677|NCT00041327|Drug|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
72001|NCT01170624|Device|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
72002|NCT01170637|Drug|Ibuprofen|200 mg oral administration (RhinAdvil(R))
72003|NCT01170637|Drug|Ibuprofen|200 mg oral administration (BI product)
72004|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (BI product)
72005|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
72006|NCT01170650|Drug|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
72007|NCT00041717|Drug|Fampridine-SR|25mg bid (twice daily)
72008|NCT01170650|Drug|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
71447|NCT01169779|Drug|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c <8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
71448|NCT00000958|Biological|MTP-PE/MF59|
71449|NCT00041574|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
71450|NCT01169792|Drug|tamoxifen|
71451|NCT01172327|Behavioral|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
71452|NCT01172327|Behavioral|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
71453|NCT01172340|Behavioral|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
71454|NCT01172340|Behavioral|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
71455|NCT01172353|Drug|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
71456|NCT01172353|Drug|saline|hydration with saline 1ml/Kg/h for 6 hours
71457|NCT01172379|Drug|E2007|Experimental 1 Drug: E2007
0.5 mg 1 tablet per day
71458|NCT01172379|Drug|E2007|Experimental 2 Drug: E2007
1.0 mg 1 tablet per day
71459|NCT01172379|Drug|E2007|Drug: E2007
2.0 mg 1 tablet per day
71460|NCT01172379|Other|Placebo Comparator|Placebo 1 tablet per day
71461|NCT00041977|Drug|doxycycline hyclate 20 mg twice daily|
71462|NCT01172392|Drug|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
71463|NCT01172392|Drug|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
71464|NCT01172405|Drug|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
70924|NCT01176019|Device|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
70925|NCT01176032|Drug|Aliskiren|Aliskiren 300 mg film coated tablets
70926|NCT01176032|Drug|Losartan|Losartan 100 mg tablets
70927|NCT01176032|Drug|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
70928|NCT01176032|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (<140/90 mmHg) had not been reached.
70929|NCT01176058|Drug|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
70930|NCT01178216|Biological|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
71211|NCT01174290|Drug|Placebo|D5W 0.2mL IV q6h
Study drug will be continued until one of the following study withdrawal/termination criteria is met:
Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.
The patient is discharged from the ICU at Tufts MC.
10 days of study drug administration occurs.
The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy.
71212|NCT01174303|Drug|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
71213|NCT01174303|Drug|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
71214|NCT01174316|Device|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
71215|NCT01174316|Device|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
71216|NCT01174329|Device|Automatic neuro-electrostimulation by "Saliwell Crown"|Continuous stimulation of the lingual nerve by "Saliwell Crown"
71217|NCT00000244|Drug|Dynorphin 1 - 13|
71218|NCT00000961|Drug|Zidovudine|
71219|NCT00042289|Drug|atazanavir/cobicistat|Women will receive atazanavir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
70995|NCT01183013|Drug|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
70996|NCT01176084|Behavioral|low carbohydrate diet|
70997|NCT00042289|Drug|terizidone/cycloserine|Women will receive terizidone/cycloserine as prescribed by their clinicians. (Dosage will vary for each participant.)
70998|NCT01176084|Behavioral|low carbohydrate diet and exercise|
70999|NCT01176097|Drug|AZD5658|oral suspension, escalating single doses
71000|NCT01176097|Drug|Placebo|oral suspension,single doses
71001|NCT01176110|Device|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
71002|NCT01176123|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia
71003|NCT01176136|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
71004|NCT01176149|Behavioral|SMBG plus intensive education|
71005|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
71006|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
71007|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
71281|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
71282|NCT01172119|Device|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
71283|NCT00000959|Drug|Pyridoxine hydrochloride|
71284|NCT00041925|Drug|CGT003 (E2F Duplex Decoy)|
71285|NCT01174368|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
71286|NCT01174381|Behavioral|lifestyle modification|Lifestyle modification for six months
72043|NCT01175590|Drug|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
72044|NCT01175603|Behavioral|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
72045|NCT01175616|Drug|Creatine|Creatine will be given at a dose of 5 grams per day to adult male veterans with SSRI-resistant depression for eight weeks. Creatine is dispensed as a powder.
72046|NCT01175642|Behavioral|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
72047|NCT01175642|Behavioral|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
72048|NCT01175655|Other|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
72049|NCT00042289|Drug|kanamycin|Women will receive kanamycin as prescribed by their clinicians. (Dosage will vary for each participant.)
72050|NCT01175668|Drug|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores <8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
72051|NCT01175668|Drug|Phenobarbital|Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.
NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores.
72052|NCT01175681|Procedure|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
72053|NCT01175694|Radiation|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
72054|NCT01175707|Drug|Daptomycin|
72055|NCT01175707|Drug|Vancomycin|
71072|NCT01176240|Drug|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
71073|NCT00042289|Drug|high dose isoniazid (INH)|Women will receive high dose INH as prescribed by their clinicians. (Dosage will vary for each participant.)
71074|NCT01176240|Other|Placebo|Placebo
71075|NCT01176253|Procedure|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
71465|NCT01172405|Drug|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
71466|NCT01172418|Drug|Alemtuzumab|used in conjunction with Thymoglobulin as combined Induction.
71767|NCT01175512|Drug|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
71768|NCT01175525|Drug|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
71769|NCT01175525|Drug|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
71770|NCT01175538|Drug|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
71771|NCT01175538|Drug|Lactulose|lactulose will be used in 30-60ml/day
71772|NCT01175564|Drug|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
71773|NCT01175564|Drug|Placebo|Placebo tablet, single dose and 6 days repeated dose
71774|NCT01175577|Dietary Supplement|Chlorophyll complex, Standard Process|One capsule, twice daily with meals for 28 days
71775|NCT01167738|Drug|gemcitabine|800 mg/mq on days 1 and 15 every 4 weeks
71776|NCT01167738|Drug|metformin|2 g days 1-28 every 4 weeks
71777|NCT01167751|Biological|MNC|Implantation of BM derived MNC
71778|NCT01167751|Biological|AC 133|Implantation of BM derived AC133
71779|NCT01167751|Biological|Control|Injection of cell carrier
71780|NCT01167764|Drug|tranexamic acid, placebo|tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
71781|NCT01167790|Procedure|buccal cavity examination|autofluorescence examination
71782|NCT01167803|Drug|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
71783|NCT01167803|Drug|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
71784|NCT00041327|Drug|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
71785|NCT01167816|Drug|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
71786|NCT01167829|Drug|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
71220|NCT01174329|Device|Patient-regulated neuro-electrostimulation by "Saliwell Crown"|On-demand stimulation of the lingual nerveby "Saliwell Crown"
71221|NCT01174355|Drug|ND0801|Confidential
71222|NCT01166711|Device|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|standard techniques will be used
maximal vasodilatation after nitro application
baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)
6 French guiding catheter at least
target lesion will be crossed with standard guidewire
direct stenting at the discretion of the investigator
if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)
full lesion coverage will be ensured (with one or more stents)
only insert assigned stent type
BMS needs to be fully embedded in vessel wall
post-dilation with high pressure is required before treatment with DEB
DEB will be inflated with nominal pressure (balloon equates to vessel diameter)
length of DEB should exceed the BMS by 2-3 mm on each side
if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)
71223|NCT01166711|Device|Coroflex Please (DES)|standard techniques will be used
maximal vasodilatation after nitro application
baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)
6 French guiding catheter at least
target lesion will be crossed with standard guidewire
direct stenting at the discretion of the investigator
if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)
full lesion coverage will be ensured (with one or more stents)
only insert assigned stent type
71224|NCT01166724|Drug|Sirolumus|Tacrolimus to Sirolimus
71225|NCT01166724|Drug|Tacrolimus|dosage per trough level
71530|NCT01169857|Drug|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
71531|NCT00041587|Drug|IL13-PE38QQR|
71532|NCT01169870|Drug|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
71533|NCT01169870|Drug|Paclitaxel|
71534|NCT01169883|Behavioral|Coping Peer Support|The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.
71535|NCT01169883|Behavioral|Doctor Asthma Messages|The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.
71536|NCT01169883|Behavioral|Coping Peer Asthma Messages|The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.
71287|NCT01174394|Procedure|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
71288|NCT01174394|Procedure|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
71289|NCT01174394|Procedure|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
71290|NCT01174394|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
71291|NCT01174407|Other|cd 35, cd21, cd55|Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
71292|NCT01174420|Device|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
71293|NCT00042289|Drug|darunavir/ritonavir|Women will receive darunavir/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
71294|NCT01174420|Drug|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
71295|NCT01174433|Device|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
71296|NCT01174446|Biological|BAX 326|Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX
Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1
71297|NCT01174446|Biological|BeneFIX|Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.
BeneFIX only used in Part 1 of this study.
Study Part 2 and 3 only utilized BAX326
71298|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
71598|NCT01167608|Other|No Intervention. This is a cross-sectional survey study.|No intervention.
71599|NCT01167634|Behavioral|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
71600|NCT00041587|Procedure|targeted fusion protein therapy|
71601|NCT01169935|Drug|Administration of intra-dermal Endorem|single dose, intradermal
71076|NCT01176266|Drug|asfotase alfa|
71077|NCT01176279|Procedure|Manual and automated washing of the peripherical lines|The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.
Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.
In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.
Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.
Additional line washing is made through the fast flow valve of the system BD DTXPlus ™.
71078|NCT01176279|Procedure|Automated washing of the peripherical lines|The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.
In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.
With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.
With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.
Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.
Line washing will be made through the fast flow valve of the system BD DTXPlus ™.
71079|NCT01176292|Device|Rotating Platform High-Flex Cruciate Substituting TKA|
71080|NCT01176292|Device|Rotating Platform Cruciate Substituting TKA|
71081|NCT01176318|Drug|Erdosteine|capsule 300mg twice daily for 10 days
71082|NCT01176318|Drug|Placebo|placebo capsule, twice daily for 10 days
71083|NCT01176331|Procedure|20 and 23 gauge pars plana vitrectomy|
71084|NCT00042289|Drug|bedaquiline|Women will receive bedaquiline as prescribed by their clinicians. (Dosage will vary for each participant.)
71085|NCT01176344|Drug|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
71086|NCT01178476|Device|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
71087|NCT01178515|Other|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
71088|NCT01178515|Other|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
71382|NCT01174550|Procedure|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
71383|NCT01174563|Drug|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
71384|NCT01174576|Other|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
71787|NCT01167829|Drug|Acyline|300 ug/kg injection on Day 0
71788|NCT01167855|Other|Asthma Education Sessions|Comprehensive asthma education sessions delivered via telemedicine.
71789|NCT01167855|Other|Asthma Health Assessment via Telemonitoring|Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
70858|NCT01178203|Drug|Placebo|Placebo
70859|NCT01178203|Drug|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
70860|NCT01178203|Drug|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
70861|NCT01178203|Drug|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
70862|NCT00000965|Drug|Zidovudine|
70863|NCT00042367|Drug|Regimen 2, Course 1|Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is < 1.012.
0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl
(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is > 2000 on two consecutive days, post ANC nadir.
70864|NCT01180322|Drug|Azacitidine|Induction therapy:
Arm B and C:
100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.
Arm D:
100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.
Maintenance therapy:
Arm B, C, D:
50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)
70865|NCT01180322|Drug|Lenograstim|Consolidation therapy:
subcutaneously daily beginning on day 10 until neutrophil count > 0.5 x 109/l.
70866|NCT01180335|Drug|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
70867|NCT01180335|Drug|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
70868|NCT01180348|Drug|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
70869|NCT01180348|Drug|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
70870|NCT01180374|Drug|Cannabidiol|Active Cannabidiol 5mg.
71537|NCT01169883|Behavioral|Asthma Supervision|A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
71538|NCT01169883|Behavioral|Music Tracks|Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
71539|NCT01169909|Drug|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
71540|NCT01169922|Behavioral|SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
71541|NCT01169922|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION|1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
71542|NCT01172470|Drug|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
71543|NCT01172470|Drug|Pemetrexed|Induction Chemotherapy:
4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.
Chemoradiotherapy:
Day 1,22, and 43through IV infusion over a period of 10 minutes
71544|NCT01172470|Drug|Carboplatin|Chemoradiotherapy:
Day 1, 22 and 4 through IV infusion over a period of 1 hour.
71545|NCT01172483|Procedure|general practice in primary care and education|education of chronic disorders in PC
71862|NCT01175083|Biological|Polio Sabin|4 oral doses
71863|NCT01175096|Drug|RAD001 (everolimus, Afinitor®)|RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.
2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days.
71864|NCT01175109|Drug|Imatinib + LBH589|Escalating doses of imatinib and LBH589 will be administered.
71865|NCT01175122|Biological|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
71866|NCT01175135|Drug|PF-02545920|5 mg tablet every 12 hours for 28 days
71867|NCT01175135|Drug|PF-02545920|15 mg tablet every 12 hours for 28 days
71868|NCT01175135|Drug|Placebo|One tablet/capsule every 12 hours for 28 days
71869|NCT00042289|Drug|efavirenz|Women will receive efavirenz as prescribed by their clinicians. (Dosage will vary for each participant.)
71870|NCT01175135|Drug|Risperidone|3 mg capsule every 12 hours for 28 days
71602|NCT01169935|Biological|Mantoux test|single dose, intradermal
71603|NCT01169935|Biological|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
71604|NCT01169935|Drug|Administration of Endorem|single dose, intravenous
71605|NCT01169948|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
71606|NCT01169974|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 & 3 minutes
71607|NCT01170013|Behavioral|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
71608|NCT01170013|Behavioral|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
71609|NCT01170026|Behavioral|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion & Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
71610|NCT01170026|Behavioral|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
71611|NCT00041587|Procedure|surgery|
71612|NCT01170039|Drug|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
71613|NCT01170039|Drug|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
71614|NCT01170052|Drug|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
71615|NCT01170052|Drug|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
71616|NCT01170052|Drug|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
71617|NCT01170065|Drug|BIBF 1120|Intermediate dose BIBF 1120 twice daily
71940|NCT01173107|Drug|colchicine|colchicine 1T tid
71941|NCT01173120|Device|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
71385|NCT01174589|Other|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
71386|NCT00042289|Drug|etravirine|Women will receive etravirine as prescribed by their clinicians. (Dosage will vary for each participant.)
71387|NCT01174602|Behavioral|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
71388|NCT01174602|Behavioral|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
71389|NCT01174641|Other|trans-cranial magnetic stimulation|1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
71390|NCT01174641|Other|trans-cranial magnetic stimulation|trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
71391|NCT01174654|Behavioral|Contingency management|A 12-week contingency management intervention
71392|NCT01174667|Procedure|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
71393|NCT01174667|Other|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
71394|NCT01174680|Procedure|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
71395|NCT01174693|Drug|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
71396|NCT01174693|Drug|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
71397|NCT00042289|Drug|elvitegravir/cobicistat|Women will receive elvitegravir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
71398|NCT01174706|Behavioral|Information prescriptions|One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
71399|NCT01167036|Other|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
71400|NCT01167049|Drug|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
71401|NCT01167062|Drug|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
71703|NCT01170117|Drug|Placebo|Control Group will receive placebo pill
70871|NCT01180374|Drug|Delta-9-THC|Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or "joint".
70872|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
70873|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
70874|NCT00042679|Drug|LY900003|
70875|NCT01180400|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
70876|NCT01180400|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
71154|NCT01183247|Drug|Everolimus|Add everolimus de novo to tacrolimus and MMF
71155|NCT01183247|Drug|Prednisone|Add prednisone de novo to tacrolimus and MMF
71156|NCT01183260|Device|Zimmer Trabecular Metal Revision Cup|Revision of the acetabular cup
71157|NCT01183260|Device|Zimmer Modular Cup|Revision of the acetabular cup
71158|NCT01183273|Procedure|Microlaparoscopic gastric bypass|microlaparoscopic gastric bypass will be performed using standard of care procedure.
71159|NCT01176344|Drug|Placebo|Inert placebo capsules once monthly for 2 years.
71160|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation of a heart assist device that provide counterpulsation without blood contact for an extended period.
71161|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
71162|NCT01176383|Genetic|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
71163|NCT01176396|Other|Caries prevention active intervention|Subjects will be treated related to their caries risk:
"Low Caries Risk"
The intervention and control treatments for low caries risk are the same:
4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months
"Moderate Caries Risk" In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.
"High Caries Risk" The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office.
71871|NCT01175148|Drug|Atorvastatin calcium (Lipitor)|40 mg PO daily
71872|NCT01175161|Device|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
71873|NCT01175200|Drug|Clopidogrel|antiplatelet agent
71874|NCT01175200|Drug|Prasugrel|antiplatelet agent
71875|NCT01175200|Drug|Lansoprazole|proton pum inhibitor
71876|NCT01175200|Drug|Placebo|placebo comparator similar to lansoprazole
71877|NCT01175213|Biological|Recombinant human hyaluronidase (rHuPH20) + Immune Globulin Subcutaneous Solution (IGSC)|Subjects will continue on the same doses of IGSC, adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).
71878|NCT01175226|Drug|BTA798|BTA798 twice daily
71879|NCT01175226|Drug|Placebo|Placebo twice daily
71880|NCT00000962|Drug|Nevirapine|
71881|NCT00042289|Drug|lopinavir/ritonavir|Women will receive lopinavir/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
71882|NCT01175239|Genetic|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
71883|NCT01175252|Other|Database analysis|Review and collect data from database
70931|NCT01178229|Other|Physiotherapy|The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.
The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.
Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.
All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them.
70932|NCT01178242|Procedure|Salivary Gland and Labial Mucous Membrane Transplantation|Minor salivary glands (SG) will be obtain "en block" from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures
70933|NCT01178255|Drug|homeopathic q-potencies|individualised homeopathic medicines
70934|NCT01178255|Drug|Placebo|placebo
70935|NCT01178255|Other|homeopathic case history taking type I|one special homeopathic technique for case history taking
71942|NCT01173159|Drug|Omegaven|For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
71943|NCT01173172|Radiation|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
71944|NCT01173198|Device|WAVEFRONT Optimized LASIK|30 patients
71945|NCT00042146|Drug|zolpidem|
71946|NCT01173198|Device|WAVEFRONT GUIDED LASIK|30 patients
71947|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
71948|NCT01175356|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
71949|NCT01175356|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
71950|NCT01175356|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
71951|NCT01175356|Radiation|external beam radiation therapy|Undergo radiotherapy
71952|NCT01175356|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
71953|NCT01175356|Drug|isotretinoin|Given PO
71954|NCT01175356|Other|pharmacological study|Correlative studies
71955|NCT00042289|Drug|ethambutol|Women will receive ethambutol as prescribed by their clinicians. (Dosage will vary for each participant.)
71956|NCT01175356|Other|questionnaire administration|Ancillary studies
71957|NCT01175356|Other|laboratory biomarker analysis|Correlative studies
71958|NCT01175369|Behavioral|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
71008|NCT00042289|Drug|para-aminosalicylic acid (PAS)|Women will receive PAS as prescribed by their clinicians. (Dosage will vary for each participant.)
71704|NCT01170130|Drug|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
71705|NCT01170143|Drug|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
71706|NCT01170156|Device|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
71707|NCT01170169|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
71708|NCT01170169|Drug|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
71709|NCT00041626|Genetic|INGN 201|
71710|NCT01170182|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
71711|NCT01170182|Device|Prilosec® 40 mg|Prilosec® 40 mg
71712|NCT01170195|Dietary Supplement|Calmera-Licorice Root Extract (Licogen)|100 mg per day
71713|NCT01170208|Device|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
71714|NCT01170221|Drug|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
71715|NCT01170221|Drug|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
71716|NCT01170234|Device|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
71717|NCT01170247|Drug|Ketamine|Intranasal Ketamine (100 mg/mL)
71718|NCT01170247|Drug|Ketamine|Intramuscular Ketamine
71719|NCT01170260|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
71720|NCT00041639|Drug|hMN14 (labetuzumab)|
71721|NCT01170260|Behavioral|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
71722|NCT01170260|Behavioral|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
71164|NCT01176396|Other|control treatment|Subjects will be treated related to their caries risk:
"Low Caries Risk"
The intervention and control treatments for low caries risk are the same:
4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months
"Moderate Caries Risk" "Control" group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).
"High Caries Risk" The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding).
71165|NCT01176409|Drug|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
71166|NCT01176409|Drug|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
71167|NCT01176422|Genetic|Blood sample|Blood samples will be collected before and after treatment completion.
71168|NCT00042289|Drug|clofazamine|Women will receive clofazamine as prescribed by their clinicians. (Dosage will vary for each participant.)
71169|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
71170|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
71171|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
71467|NCT01172418|Drug|Daclizumab|used in combination with Thymoglobulin as combined induction
71468|NCT01172431|Drug|Indapamide|Indapamide SR 1.5mg qd
71469|NCT01172431|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
71470|NCT01172444|Drug|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
71471|NCT01172444|Drug|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
71472|NCT00041990|Drug|decitabine (5-aza-2'deoxycytidine)|
71473|NCT01172444|Drug|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
71474|NCT01172457|Procedure|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
71475|NCT01172457|Procedure|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
71476|NCT01174719|Drug|volume replacement|Hydroxyethylstarch up to 50mL/kg/24 hrs
71477|NCT01174719|Drug|Humanalbumin 5%|Humanalbumin 5% up to 50 mL/kg/24 hours
71478|NCT01174719|Drug|volume replacement|up 10 50mL/kg/24 hours
70936|NCT01178255|Other|homeopathic case history type II|another type of homeopathic case history taking
70937|NCT01178268|Device|XIENCE V EECSS|Patients who will receive this stent.
70938|NCT01178268|Device|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
70939|NCT01178281|Drug|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
70940|NCT00042367|Drug|Regimen 2, Course, 1, Cycle C1|Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.
Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2.
70941|NCT01178281|Drug|Placebo|Placebo Comparator to active drug
70942|NCT01178294|Biological|OBI-1|Intravenous infusion
70943|NCT01178307|Behavioral|Questionnaires|10 minutes to complete 3 questionnaires for development of MDASI-GIST
70944|NCT01178307|Behavioral|Interview|Each interview will take approximately 30 minutes.
70945|NCT01178307|Behavioral|MDASI-GIST Questionnaire|Every 4 weeks for one year
70946|NCT01178320|Drug|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
70947|NCT01178346|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
71226|NCT00041288|Procedure|peripheral blood stem cell transplantation|
71227|NCT01166737|Procedure|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
71228|NCT01166750|Behavioral|CD-ROM|Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the "pain puzzle") as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material.
71009|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
71010|NCT01176188|Other|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
71011|NCT01176188|Other|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
71012|NCT01176201|Drug|SLV337 suspension|400 mg experimental
71013|NCT01176201|Drug|SLV337 capsule|5 x 200 mg immediate release capsule
71014|NCT01176214|Procedure|Early tracheostomy|Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the "treatment arm" will receive an early tracheostomy within 72h after symptom onset.
71015|NCT01176214|Procedure|Late tracheostomy|Compared to the "early tracheostomy"-group, those patients who have been randomized to "late tracheostomy" will undergo conventional tracheostomy between day 12 - 14 if extubation fails
71016|NCT01178372|Drug|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
71017|NCT00042367|Drug|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
71018|NCT01178372|Drug|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
71019|NCT01178385|Behavioral|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
71020|NCT01178385|Behavioral|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
71021|NCT01178411|Drug|ARQ 197 as monotherapy or in combination with other drug(s)|ARQ 197 as monotherapy or in combination with other drug(s) at the same dose(s), and same schedule(s) in which they were originally enrolled.
71299|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
71723|NCT01170273|Dietary Supplement|vitamin D|cholecalciferol
70803|NCT01182532|Drug|TCM Syndrome Differentiation and Treatment|Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.
Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.
Dosage: Adjusting by age and weight of patients. Decoction.
Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.
Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.
Dosage: Adjusting by age and weight of patients. Decoction.
70804|NCT01182532|Other|Western therapy plus TCM treatment|Symptomatic treatment using the same treatment methods in western therapy group;
Syndrome differentiation and treatment adopting the same methods in TCM treatment group.
70805|NCT01182545|Procedure|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
70806|NCT01182558|Other|Hypothenar muscle activation--maximum, voluntary, isometric|Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations ("single brief muscle twitch," 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs]).
70807|NCT01182558|Other|Thenar muscle activation--maximum, voluntary, isometric|Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations ("single brief muscle twitch," 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs]).
70808|NCT01182558|Other|EDB muscle activation--maximum, voluntary, isometric|Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations ("single brief muscle twitch," 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs]).
70809|NCT01182558|Other|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
70810|NCT00042874|Drug|alvocidib|Given IV
70811|NCT01182597|Drug|Pantoprazole (Pantoloc)|Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs
70812|NCT01182597|Drug|Lansoprazole (Takepron OD)|Lansoprazole (Takepron OD) 30mg q12h PO
70813|NCT01182610|Drug|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
70814|NCT01182610|Drug|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
70815|NCT01182610|Drug|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
70816|NCT01182610|Drug|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
71479|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
71480|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
71481|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
71482|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
71483|NCT01174732|Drug|Placebo|placebo, lactose inhalation carrier
71484|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
71485|NCT00042289|Drug|dolutegravir|Women will receive dolutegravir as prescribed by their clinicians. (Dosage will vary for each participant.)
71486|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
71487|NCT01174784|Device|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
71488|NCT01174810|Drug|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
71489|NCT01174823|Drug|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
71790|NCT01167855|Other|Provider Treatment Prompt|A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
71791|NCT01167855|Other|School Absenteeism|Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
71792|NCT01167855|Other|Prescription Filling Profile|Study personnel will monitor participants' prescription profiles.
71793|NCT01167868|Drug|FosD|oral tablet
71794|NCT01167868|Drug|Placebo|oral tablet
71795|NCT00041327|Drug|zidovudine|300 mg bid
71796|NCT01167881|Drug|BI 10773|Medium dose once daily
71797|NCT01167881|Drug|Glimepiride|1-4 mg once daily
71798|NCT01167881|Drug|Placebo|Placebo matching BI 10773
71799|NCT01167881|Drug|Placebo|Placebo matching Glimepiride
71229|NCT01166750|Behavioral|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
71230|NCT01166763|Drug|vitamin D3|oral capsules, 10,000 IU per week for 6 months
71231|NCT01166789|Drug|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
71232|NCT01166789|Drug|Placebo|2 capsules daily, taken in morning and evening
71233|NCT01166815|Dietary Supplement|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
71234|NCT01166815|Other|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
71235|NCT01166828|Behavioral|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
71236|NCT01166841|Procedure|PSVC line clamped|A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
71237|NCT00041288|Radiation|radiation therapy|
71238|NCT01169428|Behavioral|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
71546|NCT01172483|Other|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
71547|NCT01172496|Drug|treprostinil diethanolamine|Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
71548|NCT01172509|Drug|R-baclofen|oral R-baclofen at 0x2, 3, 10, and 25 mg
71300|NCT01174485|Procedure|exercise|combined resistance and aerobic training
71301|NCT01174498|Device|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
71302|NCT01174498|Device|t-VNS Sham stimulation|t-VNS Sham stimulation
71303|NCT01174511|Drug|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
71304|NCT00042289|Drug|darunavir/cobicistat|Women will receive darunavir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
71305|NCT01166854|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
71306|NCT01166867|Device|Photo-plethysmography monitoring|monitoring vital sign in infant
71307|NCT01166880|Device|Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
71308|NCT01166893|Device|Modulated Imaging and Laser Speckle Imaging|wound healing
71309|NCT01166906|Device|pain blocking|pain blocking
71310|NCT01166919|Device|Matrix Radiofrequency|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
71311|NCT01166932|Drug|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
71312|NCT01166932|Drug|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
71313|NCT01166945|Drug|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
71314|NCT01166945|Drug|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
71315|NCT00041301|Other|QoL assessment|qol questionnaires
71316|NCT01166958|Drug|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
71317|NCT01166958|Drug|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
71318|NCT01166971|Device|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
70817|NCT01182623|Other|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
70818|NCT01182636|Drug|Adapalene|0.1% Topical Gel
70819|NCT01182636|Drug|Differin®|0.1% Topical Gel
71089|NCT01178515|Other|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
71090|NCT01178528|Drug|ivabradine|7.5 mg bd
71091|NCT01178528|Drug|"Drug:Carvedilol" and "Drug:Ivabradine"|up to 12.5/5 mg bd
71092|NCT01178528|Drug|Carvedilol|25 mg bd
71093|NCT01178554|Behavioral|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
71094|NCT01178554|Behavioral|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
71095|NCT00042380|Drug|Novasoy|
71096|NCT01178554|Behavioral|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita & Weisz, 2004)
71097|NCT01178593|Other|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
71098|NCT01178632|Drug|Passiflora|01 tablet Passiflora p.o., b.i.d.
71099|NCT01178632|Drug|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
71100|NCT01178645|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
71101|NCT01178658|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
71102|NCT01178671|Drug|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
71103|NCT01178671|Drug|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
71104|NCT01178671|Other|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
71105|NCT01178697|Drug|Bevasizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
71800|NCT01167894|Drug|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
71801|NCT01167907|Drug|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
71802|NCT01167907|Drug|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
71803|NCT01170273|Dietary Supplement|placebo|placebo tablet
71804|NCT01170286|Biological|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
71805|NCT01170286|Biological|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
71806|NCT01170299|Dietary Supplement|dietary intervention|
71807|NCT01170299|Other|laboratory biomarker analysis|
71808|NCT01170299|Procedure|gastrointestinal complications management/prevention|
71809|NCT01170299|Procedure|management of therapy complications|
71810|NCT00041652|Drug|hMN14 (labetuzumab)|
71811|NCT01170299|Radiation|selective external radiation therapy|
71812|NCT01170312|Biological|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
70877|NCT01180413|Drug|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
70878|NCT01180413|Drug|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
70879|NCT01180413|Drug|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
70880|NCT01180413|Drug|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
70881|NCT01180426|Drug|CHR-2797|120mg once daily oral for 48 weeks
70882|NCT01180439|Device|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
71549|NCT00042003|Drug|decitabine (5-aza-2'deoxycytidine)|
71550|NCT01172522|Drug|Fexofenadine|Fexofenadine 1%
71551|NCT01172522|Drug|Placebo|Placebo
71552|NCT01172535|Drug|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
71553|NCT01172548|Drug|imatinib mesylate|
71554|NCT01172561|Behavioral|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
71555|NCT01172561|Behavioral|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
71556|NCT01172574|Other|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
71557|NCT01172587|Behavioral|Individual Substance Abuse Treatment|Fathers or mothers participate in individual substance abuse treatment.
71558|NCT01172600|Other|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
71559|NCT01172600|Other|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
71560|NCT01174888|Drug|etoposide|Patients receive etoposide IV over 1 hour
71561|NCT01174888|Drug|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
71884|NCT01167920|Other|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
71885|NCT01167933|Drug|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
71886|NCT01167946|Drug|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
71618|NCT01170065|Drug|BIBF 1120|High dose BIBF 1120 twice daily
71619|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 twice daily
71620|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 once daily
71621|NCT01170078|Drug|Epoetin Hospira|IV dose 3 times a week.
71622|NCT00041613|Genetic|INGN 201|
71623|NCT01170078|Drug|Epogen|IV dose 3 times a week
71624|NCT01170104|Drug|Sorafenib|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
71625|NCT00042016|Drug|decitabine (5-aza-2'deoxycytidine)|
71626|NCT01172626|Drug|valproate sodium|oral administration,15－30mg/kg,daily
71627|NCT01172626|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
71628|NCT01172626|Other|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
71629|NCT01172639|Other|randomisation|Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.
71630|NCT01172652|Drug|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
71631|NCT01172652|Drug|Placebo|Inactive control
71632|NCT01172691|Procedure|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
71633|NCT01172704|Behavioral|Skills Building - Motivational Interviewing|SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which "fit" their personal risk profile and values.
71634|NCT01172717|Drug|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
71635|NCT01172730|Device|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
71106|NCT00042393|Drug|Adefovir Dipivoxil|
71107|NCT01178697|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
71108|NCT01178710|Drug|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
71109|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
71110|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
71402|NCT01167062|Other|Placebo|One tablet OD for a maximum of 28 days
71403|NCT01167075|Dietary Supplement|Fresubin Original|
71404|NCT01167075|Dietary Supplement|Intestamin plus Fresubin Original|
71405|NCT01167088|Drug|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
71406|NCT00041314|Drug|exisulind|
71407|NCT01167088|Drug|Placebo|Placebo
71408|NCT01167101|Drug|Rebamipide|Rebamipide 100mg Tid for 28days
71409|NCT01167101|Drug|pantoprazole|pantoprazole 40mg qd for 28days
71410|NCT01167114|Drug|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
71411|NCT01167127|Drug|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
71412|NCT01167140|Device|Cryo-Touch II|Percutaneous treatment with the device
71413|NCT01167153|Drug|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
71414|NCT01167153|Drug|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
71415|NCT01167166|Drug|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
71416|NCT01167179|Behavioral|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
70883|NCT01180452|Procedure|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
70884|NCT01180465|Drug|LIPO-102|LIPO-102 High dose
70885|NCT00042718|Drug|levofloxacin, azithromycin, amoxicillin/clavulanate|
70886|NCT01180465|Drug|LIPO-102 Low|LIPO-102 Low dose
70887|NCT01180465|Drug|LIPO-102, Placebo|Placebo
70888|NCT01182649|Device|stent|coronary angioplasty with stent implantation
70889|NCT01182662|Other|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
70890|NCT01182662|Other|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
70891|NCT01182675|Drug|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
70892|NCT01182675|Drug|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
70893|NCT01182701|Behavioral|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
70894|NCT01182714|Procedure|immediate removal of in-dwelling catheter|
70895|NCT01182714|Procedure|24 hours delayed removal of catheter|
71172|NCT01176448|Device|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
71173|NCT01176448|Device|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
71174|NCT01176461|Biological|MART-1|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
71175|NCT01176461|Biological|NY-ESO-1|NY-ESO-1 peptide vaccine
71176|NCT01176461|Biological|gp100:209-217(210M)|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
71177|NCT01176461|Biological|gp100:280-288(288V)|gp100:280-288(288V) peptide vaccine
71887|NCT00041340|Drug|imatinib mesylate|Given orally
71888|NCT01167946|Drug|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
71889|NCT01167946|Drug|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
71890|NCT01167959|Procedure|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
71891|NCT01167959|Behavioral|Prodimed dietary intervention|3 months of using the prodimed diet
71892|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
71893|NCT01167985|Device|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
71894|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
71895|NCT01168011|Drug|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
71896|NCT01168024|Device|CINCOR™ System|Catheter based system to reduce and remove contrast media.
71897|NCT01168024|Drug|Peri-procedural hydration|Parenteral administration of fluids (saline or bicarbonate solutions) prior to and after a PCI procedure. This is considered to be minimum standard of care for CIN prevention.
71898|NCT00041340|Other|laboratory biomarker analysis|Correlative studies
70948|NCT01178346|Biological|Placebo|Placebo vaccine given 6 times over 6 months
70949|NCT01178359|Drug|nitrite|
70950|NCT01180478|Device|White Light|White Light Cystoscopy
70951|NCT01180478|Device|Narrow Band Imaging|Narrow Band Imaging
71636|NCT00042029|Drug|MK0869, aprepitant|
71637|NCT01172756|Drug|Riociguat (BAY63-2521)|0.5 mg single oral dose
71959|NCT01175382|Behavioral|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
71960|NCT01175382|Drug|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
71961|NCT01175395|Drug|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
71962|NCT01175408|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
71963|NCT01175408|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
71964|NCT01175408|Other|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
71965|NCT01175408|Other|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
71966|NCT00042289|Drug|isoniazid|Women will receive isoniazid as prescribed by their clinicians. (Dosage will vary for each participant.)
71967|NCT01168063|Drug|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
71968|NCT01168063|Drug|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|2 lines of treatments :
1) PPI + Amoxicillin + Clarithromycin for 7 days
1) PPI + Amoxicillin + Metronidazole for 14 days
71969|NCT01168128|Other|Tailored Change Strategy|e.g. Education, decision support tools
71970|NCT01168141|Drug|ZD4054|10mg ZD4054 daily in tablet form
71971|NCT01168154|Dietary Supplement|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
71972|NCT01168154|Dietary Supplement|placebo|placebo
71417|NCT00041314|Drug|gemcitabine hydrochloride|
71418|NCT01167192|Drug|Cisplatin|
71419|NCT01167192|Drug|Carboplatin|
71420|NCT01167192|Radiation|Radiation therapy|
71421|NCT01167192|Procedure|Mastectomy (recommended but not mandatory)|
71422|NCT01167205|Dietary Supplement|astaxanthin|astaxanthin 20mg for 12 weeks
71423|NCT01167231|Drug|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
71424|NCT01167244|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
71724|NCT01172808|Drug|Placebo|Placebo that represents comparator
71725|NCT01172808|Drug|tiotropium Respimat® high dose|IMP
71726|NCT01172808|Drug|50 mcg salmeterol HFA MDI|Active comparator
71727|NCT01172808|Drug|Placebo|Placebo that represents BI drug
71728|NCT01172808|Drug|Placebo|Placebo that represents BI drug
71729|NCT01172821|Drug|placebo|Placebo that represents BI drug
71730|NCT01172821|Drug|placebo|Placebo that represents comparator
71731|NCT01172821|Drug|placebo|Placebo that represents comparator
71732|NCT01172821|Drug|tiotropium Respimat® low dose|IMP
71733|NCT00042042|Behavioral|Family based educational program|
71734|NCT01172821|Drug|placebo|Placebo that represents BI drug
71735|NCT01172821|Drug|tiotropium Respimat® high dose|IMP
71736|NCT01172821|Drug|50 mcg salmeterol HFA MDI|Active comparator
71737|NCT01172821|Drug|placebo|Placebo that represents comparator
71738|NCT01172834|Behavioral|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
71739|NCT01172847|Drug|oseltamivir [Tamiflu]|multiple oral doses
71178|NCT01176461|Drug|Montanide ISA 51 VG|Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
71179|NCT01171846|Other|Pelvic Floor Muscle training|Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).
Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation.
71180|NCT01171859|Drug|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
71181|NCT00041821|Procedure|Nasal irritation thresholds and irritant provocation|
71182|NCT01171885|Drug|0.9% saline|20 ml of 0.9% saline
71183|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.25%.
71184|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.5%.
71185|NCT01171898|Drug|ARN-509 (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
71186|NCT01171898|Drug|ARN-509 (Phase 2)|ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
71187|NCT01171911|Drug|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
71188|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
71189|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
71190|NCT01171937|Drug|Risperidone|children get randomized to either placebo or active risperidone
71490|NCT01174823|Drug|placebo comparator ophthalmic solution|sterile ophthalmic solution
71491|NCT01174836|Other|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
71492|NCT01174849|Drug|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
70952|NCT01180491|Device|K101 nail solution|
70953|NCT01180504|Radiation|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
70954|NCT01180517|Procedure|Percutaneous coronary intervention (PCI)|balloon angioplasty
70955|NCT01180517|Procedure|PCI|balloon angioplasty
70956|NCT01180530|Device|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
70957|NCT01180543|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
70958|NCT00042731|Dietary Supplement|Lycopene|Daily administration as outlined in treatment arm(s)
70959|NCT01180543|Device|Placebo Patch|same as active patch
70960|NCT01180556|Dietary Supplement|Probiotics|Daily oral supplementation for four weeks
70961|NCT01180556|Dietary Supplement|Placebo|Placebo administration
70962|NCT01180569|Drug|lenalidomide|Patient enrollment FNA of palpable lymph node prior to escalation phase
Escalation phase of Lenalidomide:
Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase
Treatment phase of Lenalidomide:
15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles
70963|NCT01180582|Device|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
70964|NCT01180595|Device|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
70965|NCT01180595|Device|Trabecular Metal Monoblock Tibial Total Knee Component|
70966|NCT01180608|Other|MR Spectroscopy|During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:
gamma-aminobutyric acid (GABA)
glutamate (Glu)
glutamine (Gln)
N-acetylaspartate (NAA)
Choline-containing compounds (Cho)
Creatine plus phophocreatine (total creatine: Cr)
Myo-inositiol (Ins)
Choline (Cho)
Glucose (Glc)
Lactate (Lac)
70967|NCT01180621|Biological|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
70968|NCT01180634|Drug|MP-376 (Levofloxacin solution for Inhalation)|240 mg of MP-376 administered BID for 28 days
71973|NCT01168180|Other|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
71974|NCT00041353|Other|cytology specimen collection procedure|
71975|NCT01168180|Other|Ultrasound therapy and hot pack|
71022|NCT01178424|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
71023|NCT01178424|Behavioral|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
71024|NCT01178437|Device|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
71025|NCT01178450|Procedure|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
71026|NCT01178450|Drug|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
71027|NCT01178463|Other|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
71028|NCT00042367|Radiation|radiation therapy|Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.
8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons.
71029|NCT01178463|Other|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
71030|NCT01180660|Drug|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
71031|NCT01180660|Drug|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
71032|NCT01180673|Behavioral|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
71740|NCT01172847|Drug|rimantadine|multiple oral doses
71741|NCT01172860|Device|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
71742|NCT01172873|Drug|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
71743|NCT01172873|Behavioral|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
71744|NCT00000960|Drug|Zidovudine|
71745|NCT00042055|Drug|CP-461|
71746|NCT01172899|Procedure|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
71747|NCT01172899|Behavioral|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
70820|NCT01182636|Drug|Placebo|Gel Base
70821|NCT00042874|Drug|irinotecan hydrochloride|Given IV
70822|NCT01182649|Device|coronary stent|coronary angioplasty with stent implantation
70823|NCT01175850|Device|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
70824|NCT01175850|Device|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
70825|NCT01175863|Device|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
70826|NCT01175863|Device|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
70827|NCT01175876|Device|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
70828|NCT01175876|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
70829|NCT01175889|Device|E-Z Clean ACE Blade|The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
70830|NCT01175902|Drug|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
71493|NCT01174849|Drug|Prevenar13|The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.
Active ingredients
Each 0.5 mL dose contains:
2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium.
71494|NCT01174849|Drug|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
71495|NCT01174888|Drug|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
71496|NCT00042289|Drug|tenofovir alafenamide fumarate (TAF)|Women will receive TAF as prescribed by their clinicians. (Dosage will vary for each participant.)
71497|NCT01174888|Drug|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
71498|NCT01174888|Drug|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
71499|NCT01167257|Drug|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
71500|NCT01167257|Drug|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
71501|NCT01167270|Behavioral|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
71502|NCT00041327|Biological|filgrastim|5 ug/kg/d
71503|NCT01167270|Behavioral|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
71504|NCT01167283|Device|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
71505|NCT01167283|Device|Sham stimulation|Sham stimulation: 1 h; 5 times/week
71506|NCT01167296|Device|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
71507|NCT01167309|Drug|LEO 27847|First in patient
71813|NCT01170312|Other|Normal saline|Normal saline injection
71814|NCT01170325|Drug|Divalproex Sodium|
71815|NCT01170325|Drug|Placebo Comparator|
71239|NCT01169428|Behavioral|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors [e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information & education]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
71240|NCT01169467|Drug|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
71241|NCT00041509|Drug|Placebo|matching placebo, oral, BID for 28 days
71242|NCT01169467|Other|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
71243|NCT01169480|Behavioral|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
71244|NCT01169493|Device|VVI-40|Pacing mode set to VVI-40, RV only pacing
71245|NCT01169493|Device|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
71246|NCT01169493|Device|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
71247|NCT01169506|Device|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
71248|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
71249|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
71250|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
71251|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
71252|NCT00041535|Drug|OGT 918|
71253|NCT01169532|Drug|ridaforolimus|Given PO
71254|NCT01169532|Drug|vorinostat|Given PO
71255|NCT01169532|Procedure|biopsy|Optional correlative studies
71256|NCT01169532|Other|pharmacological study|Correlative studies
71257|NCT01169532|Other|laboratory biomarker analysis|Correlative studies
71033|NCT01180673|Behavioral|Control Condition|Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications "Your Guide to Lowering Blood Pressure"; and "Facts about the DASH Eating Plan." Sessions will be delivered by trained research assistants.
71034|NCT01180686|Device|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
71035|NCT01180686|Device|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
71319|NCT01166971|Device|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
71320|NCT01166984|Drug|AB103|AB103 intravenous one infusion
71321|NCT01166997|Device|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver < 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
71322|NCT01166997|Drug|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
71323|NCT01167010|Drug|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
71324|NCT01167010|Drug|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
71325|NCT01167010|Drug|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
71326|NCT00041314|Drug|carboplatin|
71327|NCT01167023|Drug|Prasugrel|Administered orally, once daily for 30 days.
71328|NCT01167023|Drug|Placebo|Administered orally, once daily for 30 days.
71329|NCT01167036|Device|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
71330|NCT01169584|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10^6 pfu/kg to 3 x 10^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
71331|NCT01169597|Drug|prednisone|prednisone 12.5 mg daily po
71332|NCT01169610|Drug|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
71333|NCT00041548|Drug|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
71334|NCT01169623|Other|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
70831|NCT01175902|Drug|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
70832|NCT00042289|Drug|levofloxacin|Women will receive levofloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
70833|NCT01175915|Other|Western therapy|Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;
No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.
Intervention time: 3-7 days; Follow-up time: 3 days.
70834|NCT01175915|Other|Reduning Injection|Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;
Reduning Injection, 0.5~15ml, depending on patient's condition, IV per day, or according to the instruction;
Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.
Intervention time: 3-7 days; Follow-up time: 3 days.
70835|NCT01175915|Other|Reduning Injection plus western therapy|General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;
Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;
Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.
Intervention time: 3-7 days; Follow-up time: 3 days.
70836|NCT01175928|Device|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
70837|NCT01175928|Device|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
71111|NCT01180790|Drug|Placebo|Powder in capsule once daily
71112|NCT01180790|Drug|Pegylated Interferon alpha-2a|180 ug once a week by subcutaneous injection
71113|NCT01180790|Drug|Ribavirin|400 mg or 600 mg (am) and 600 mg (pm) capsules taken orally twice daily
71114|NCT01180803|Device|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
71115|NCT01180803|Device|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
71116|NCT01180816|Drug|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
71117|NCT00042770|Procedure|dyspnea management|No talc
71118|NCT01180829|Behavioral|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
71119|NCT01180829|Behavioral|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
71120|NCT01180842|Other|Yoga treatment program|yoga program designed specifically for the patient with CF
71816|NCT01170338|Drug|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
71817|NCT01170338|Drug|control|this is the placebo that will help us maintain a blinded study
71818|NCT01170351|Drug|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
71819|NCT01170364|Drug|Sibutramine|1 week of active sibutramine (15mg)
71820|NCT01170390|Drug|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
71821|NCT00041665|Drug|Recombinant Human Keratinocyte Growth Factor|
71822|NCT01170390|Drug|Portia|30 mcg EE/0.15 mg LNG cyclically
71823|NCT01170390|Drug|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
71824|NCT01170429|Drug|Procaterol hydrochloride|25µg BID for 8 weeks
71825|NCT01170429|Drug|Meptin placebo|25µg BID for 8 weeks
71826|NCT01170442|Drug|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
71827|NCT01170442|Drug|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
71828|NCT01170442|Drug|Placebo|placebo orally, daily for six months
71829|NCT01170455|Device|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
71830|NCT01172912|Drug|ifosfamide|
71831|NCT01172912|Other|high-dose chemotherapy with autologous stem cell rescue|
71832|NCT00042068|Drug|Meloxicam|
71833|NCT01172912|Other|laboratory biomarker analysis|
71834|NCT01172912|Procedure|autologous hematopoietic stem cell transplantation|
71835|NCT01172912|Procedure|peripheral blood stem cell transplantation|
71836|NCT01172925|Drug|Tiotropium|Inhaler
71837|NCT01172925|Drug|Placebo|Inhaler
71838|NCT01172938|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
71258|NCT01169558|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to chemotherapy regimen
71259|NCT01169571|Drug|Dexmedetomidine|
71562|NCT01174914|Other|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
71563|NCT01174914|Drug|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
71564|NCT01174914|Drug|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
71565|NCT01174927|Drug|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
71566|NCT01174927|Other|Placebo|Saline
71567|NCT01174940|Drug|extracorporeal photopheresis|Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:
Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.
After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient.
71568|NCT00042289|Drug|TAF/cobicistat|Women will receive TAF/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
71569|NCT01174953|Drug|finasteride|Finasteride 5 mg once daily
Soy 4 capsules twice daily (160 mg total)
71570|NCT01174979|Drug|Caroverin|treatment with eardrops 2 times for 48 hours
71571|NCT01174992|Biological|Evicel|EVICEL is a human plasma derived fibrin sealant
71572|NCT01174992|Other|Sutures only|Standard of care
71573|NCT01175018|Drug|Anakinra|Anakinra 100 mg s.c. daily for 14 days
71574|NCT01175018|Drug|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
71575|NCT01175031|Device|REMstar Auto with A-Flex|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
71335|NCT01169636|Drug|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
71336|NCT01169636|Drug|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
71337|NCT01169636|Drug|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
71338|NCT01169636|Drug|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target AUC = 5mg/ml/min) by vein over 1 hour.
71339|NCT01169636|Drug|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
71638|NCT01172756|Drug|Riociguat (BAY63-2521)|1 mg single oral dose
71639|NCT01172756|Drug|Riociguat (BAY63-2521)|2 mg single oral dose
71640|NCT01172756|Drug|Placebo|single oral dose
71641|NCT01172769|Biological|Temsirolimus|After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.
Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered.
71642|NCT01172782|Drug|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
71643|NCT01172795|Behavioral|Relaxation session|30 minutes relaxation session (audiotape)
71644|NCT01172795|Behavioral|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
71645|NCT01172808|Drug|Placebo|Placebo that represents comparator
71646|NCT01172808|Drug|tiotropium Respimat® low dose|IMP
71647|NCT00042029|Drug|Comparator: placebo|
71648|NCT01172808|Drug|Placebo|Placebo that represents comparator
71649|NCT01175265|Other|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
71650|NCT01175278|Procedure|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
71121|NCT01180855|Drug|Placebo|Placebo pill nightly for 42 nights.
71122|NCT01180855|Drug|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
71123|NCT01180855|Other|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
71124|NCT01180894|Drug|Iron sucrose|100 mg IV TIW
71125|NCT01180894|Drug|Placebo|
71126|NCT01180933|Dietary Supplement|fish oil|400 mg of DHA and 150 mg of eicosapentaenoic acid per day
71127|NCT01180933|Dietary Supplement|folate|400 µg per day
71128|NCT00042783|Biological|D1/3-MAGE-3-His fusion protein|
71129|NCT01180933|Dietary Supplement|fish oil + folate|500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
71130|NCT01180933|Dietary Supplement|placebo|only vitamins and minerals as recommended, but no fish oil or folate
71131|NCT01180946|Dietary Supplement|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
71132|NCT01180946|Other|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
71133|NCT01180959|Drug|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
71425|NCT01169675|Drug|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
71426|NCT00041561|Drug|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
71427|NCT01169675|Drug|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
71428|NCT01169675|Drug|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
71429|NCT01169688|Other|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
71430|NCT01169701|Drug|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
71431|NCT01169701|Drug|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
71432|NCT01169701|Drug|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
70896|NCT01182727|Drug|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
70897|NCT00042874|Drug|fluorouracil|Given IV
70898|NCT01182753|Radiation|carbon ion therapy|Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E.
70899|NCT01182753|Radiation|proton therapy|Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E.
70900|NCT01182766|Drug|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
70901|NCT01182766|Drug|Placebo with brief behavioral enhancement therapy|placebo
70902|NCT01182779|Radiation|Carbon ion|Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E.
70903|NCT01182779|Radiation|Protons|Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E.
70904|NCT01182792|Dietary Supplement|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
70905|NCT01182792|Dietary Supplement|Placebo|1 month Placebo
70906|NCT01182805|Device|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
70907|NCT01182805|Device|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
70908|NCT01175967|Other|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
70909|NCT00042289|Drug|ofloxacin|Women will receive ofloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
70910|NCT01175967|Other|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
71576|NCT01175031|Device|REMstar Auto with A-Flex|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, decreased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
71577|NCT01175044|Procedure|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
71578|NCT01175044|Procedure|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
71579|NCT00042289|Drug|TAF/ritonavir|Women will receive TAF/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
71899|NCT01168037|Device|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
71900|NCT01168037|Procedure|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
71901|NCT01168050|Drug|Nilotinib|Nilotinib 400 mg twice per day
71902|NCT01170455|Device|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
71903|NCT01170468|Drug|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
71904|NCT00041678|Drug|aripiprazole|
71905|NCT01170468|Drug|Placebo|Placebo orally, daily for 2 years
71906|NCT01170494|Drug|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
71907|NCT01170494|Drug|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
71908|NCT01170494|Drug|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
71909|NCT01170494|Drug|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
71910|NCT01170494|Drug|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
71911|NCT01170494|Drug|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
71912|NCT01170494|Drug|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
71913|NCT01170494|Drug|placebo orally everyday|placebo orally everyday
71914|NCT01170507|Drug|vitamin D3 1000 IU orally daily for 5 months|
71651|NCT01175278|Other|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
71652|NCT01175291|Drug|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + MK-0646 (Investigational).
71653|NCT01175291|Drug|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
71654|NCT01175317|Procedure|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
71655|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
71976|NCT01168193|Other|No intervention|
71977|NCT01168206|Dietary Supplement|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
71978|NCT01168206|Dietary Supplement|1 capsule, 3 times per day|Placebo
71979|NCT01168219|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
71980|NCT01168219|Biological|Anti-Thymocyte Globulin|Given IV
71981|NCT01168219|Drug|Azacitidine|Given SC or IV
71982|NCT01168219|Drug|Busulfan|Given IV
71983|NCT01168219|Drug|Fludarabine Phosphate|Given IV
71984|NCT01168219|Other|Laboratory Biomarker Analysis|Correlative studies
71985|NCT00041353|Procedure|comparison of screening methods|
71986|NCT01168219|Drug|Methotrexate|Given IV
71987|NCT01168219|Other|Pharmacological Study|Correlative studies
71988|NCT01168219|Drug|Tacrolimus|Given PO or IV
71989|NCT01168232|Drug|ixabepilone|Given IV
71990|NCT01168232|Other|laboratory biomarker analysis|Correlative studies
71991|NCT01168245|Device|Sham-NICE-System|sham TMS and sham cognitive training
71992|NCT01168245|Device|NICE-System|TMS combined with cognitive training
71433|NCT01169714|Drug|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
71434|NCT01169714|Drug|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
71435|NCT01169714|Drug|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
71436|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
71437|NCT00041561|Drug|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
71438|NCT01169714|Drug|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
71439|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
71440|NCT01169740|Procedure|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
71441|NCT01169753|Drug|Placebo|Oral tablet every morning for 2 weeks
71442|NCT01169753|Drug|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
71443|NCT01169779|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
71444|NCT01169779|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
71445|NCT01169779|Device|Pen auto-injector|
71446|NCT01169779|Drug|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
71748|NCT01172912|Biological|filgrastim|
71749|NCT01172912|Biological|pegfilgrastim|
71750|NCT01172912|Drug|carboplatin|
71751|NCT01172912|Drug|cisplatin|
71752|NCT01172912|Drug|dexamethasone|
71753|NCT01172912|Drug|etoposide|
71754|NCT01175434|Other|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
70911|NCT01175967|Other|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
71191|NCT01171937|Drug|Placebo|Children get randomized to either placebo or risperidone
71192|NCT00041860|Procedure|Controlled Exposure to Environmental Contaminant|
71193|NCT01171950|Device|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
71194|NCT01171963|Biological|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
71195|NCT01171963|Biological|Placebo|Oral administration
71196|NCT01171963|Biological|Infanrix™|Intramuscular administration
71197|NCT01171963|Biological|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
71198|NCT01171976|Drug|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
71199|NCT01171989|Biological|GSK2202083A vaccine|Intramuscular, one dose.
71200|NCT01171989|Biological|Infanrix hexa™|Intramuscular, one dose.
71201|NCT01171989|Biological|Menjugate™|Intramuscular, one dose.
71202|NCT01174225|Device|Nova T IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
71203|NCT01174238|Drug|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
71204|NCT01174238|Drug|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
71205|NCT01174238|Drug|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
71206|NCT00042250|Drug|Chemotherapy for hematologic malignancy|
71207|NCT01174264|Other|Pharmacological Study|Correlative studies
71208|NCT01174264|Drug|Vismodegib|Given PO
71209|NCT01174277|Other|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
71915|NCT00000958|Biological|Env 2-3|
71916|NCT00041691|Drug|hMN14 (labetuzumab)|
71917|NCT01170507|Drug|vitamin D3 3000 IU orally daily for 5 months|
71918|NCT01170507|Drug|vitamin D3 5000 IU orally daily for 5 months|
71919|NCT01170507|Drug|Placebo orally daily for 5 months|
71920|NCT01170520|Device|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
71921|NCT01170533|Drug|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
70969|NCT00000966|Drug|Leucovorin calcium|
70970|NCT00042731|Dietary Supplement|Multivitamin|Daily administration as outlined in treatment arm(s)
70971|NCT01180634|Drug|Placebo|same volume and frequency as study drug
70972|NCT01180647|Drug|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
70973|NCT01180647|Behavioral|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
70974|NCT00000968|Biological|gp160 Vaccine (Immuno-AG)|
70975|NCT00042874|Drug|leucovorin calcium|Given IV
70976|NCT01182805|Device|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
70977|NCT01182831|Procedure|percutaneous fluoro guided celiac plexus neurolysis|It is percutaneous injection of neurolytic agent in and around the celiac ganglion
70978|NCT01182831|Procedure|EUS guided neurolysis|It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
70979|NCT01182844|Dietary Supplement|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
70980|NCT01182870|Drug|choleclaciferol|800-6000 IU cholecalciferol per day
70981|NCT01182883|Drug|IMC-A12|
70982|NCT01182883|Drug|Temsirolimus|
71993|NCT01168284|Behavioral|Coping Effectiveness Training|
71994|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
71995|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
71996|NCT00000956|Biological|gp160 Vaccine (MicroGeneSys)|
71997|NCT01170585|Drug|Rosuvastatin|All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
71998|NCT01170585|Drug|Placebo|Placebo
71999|NCT01170598|Other|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
72000|NCT01170611|Device|PACEMAKER SYMPHONY 2550|
71036|NCT01180699|Biological|Influenza vaccine: Vaxigrip or Fluviral and Intanza|Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
71037|NCT00042731|Dietary Supplement|Soy isoflavones|Daily administration as outlined in treatment arm(s)
71038|NCT01180712|Dietary Supplement|Mirtoselect|Male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.
Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days.
71039|NCT01180725|Dietary Supplement|Dried Plum|
71040|NCT01180725|Dietary Supplement|Metamucil|
71041|NCT01180738|Behavioral|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
71042|NCT01180738|Behavioral|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
71043|NCT01180751|Radiation|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
71044|NCT01180764|Drug|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
71045|NCT01180764|Drug|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
71046|NCT01180777|Device|etafilcon A (A)|Daily wear contact lens
71755|NCT01175447|Drug|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
71756|NCT01175460|Drug|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
71757|NCT01175473|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
71758|NCT01175473|Device|Pen auto-injector|
71759|NCT01175473|Drug|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
71760|NCT01175473|Device|Pre-filled pen injector|
71761|NCT01175473|Drug|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
71762|NCT01175486|Drug|Actos (Pioglitazone)|Actos 30 mg for 6 months
71763|NCT01175486|Drug|Acarbose|Acarbose 50 mg tid for 6 months
71764|NCT00042289|Drug|pyrazinamide|Women will receive pyrazinamide as prescribed by their clinicians. (Dosage will vary for each participant.)
71765|NCT01175499|Device|Direct Rigid Endoscopy|Laryngoscopy is performed under general anesthesia with a rigid laryngoscope. Mucosal surfaces of the oropharynx, hypopharynx, and glottis (base of tongue, vallecula, epiglottis, aryepiglottic folds, arytenoids, piriform sinuses, true and false vocal cords, and esophageal inlet) are systematically visualized. Areas of irregularity are biopsied with 2mm and/or 4mm cupped forceps. Esophagoscopy and bronchoscopy will be performed per the standard of care.
71766|NCT01175499|Device|Transnasal Flexible Endoscopy with Narrowband Imaging|Transnasal flexible endoscopy with and without narrowband imaging- additional diagnostic test. This examination is performed after topical intranasal anesthesia with 2% Pontocaine spray. A fiberoptic laryngoscope is passed into the nasal cavity to the pharynx where mucosal surfaces of the UADT can be visualized. The optics of a standard fiberoptic scope are generally considered to be inferior to direct visualization. The addition of narrowband imaging does not change the procedure, but enhances visualization of the mucosal vasculature. Biopsies are performed through a second channel in the endoscope with 1.8mm cupped forceps and will require an additional dose of topical anesthesia.
70838|NCT01175941|Drug|NRL001|10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
70839|NCT01175941|Drug|Placebo control|Matched placebo - administered as a 2 g suppository, once daily for 7 days
70840|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
70841|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
70842|NCT01178047|Drug|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
71210|NCT01174290|Drug|Haloperidol decanoate|IV q6h.
Study drug will be continued until one of the following study withdrawal/termination criteria is met:
Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.
The patient is discharged from the ICU at Tufts MC.
10 days of study drug administration occurs.
The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy.
71508|NCT01167322|Drug|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
71509|NCT01167335|Drug|BGG492|
71510|NCT01167335|Drug|Placebo|
71511|NCT01167348|Procedure|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
71512|NCT01167374|Radiation|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
71513|NCT00041327|Biological|recombinant interferon alfa|9 mU subcutaneously per day for one year
71514|NCT01167387|Dietary Supplement|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 600-800 mL
71515|NCT01167387|Other|placebo|The control group (n=330) will receive plain water with the same volume and timing of treatment.
71516|NCT01167400|Behavioral|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
71517|NCT01167400|Behavioral|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
71518|NCT01167413|Device|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
71519|NCT01167413|Other|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
71520|NCT01167426|Drug|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
71521|NCT01167426|Drug|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
71522|NCT01169805|Drug|Ondansetron|Ondansetron/single injection/4 mg/IV
71523|NCT01169805|Drug|Ramosetron|Ramosetron HCl/single injection/0.3mg/IV
71524|NCT01169805|Drug|Palonosetron|Palonosetron HCl/single injection/0.075mg/IV
70983|NCT01182922|Behavioral|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
70984|NCT01182948|Behavioral|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
70985|NCT01182948|Behavioral|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
70986|NCT00042874|Other|laboratory biomarker analysis|Correlative studies
70987|NCT01182961|Other|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
70988|NCT01182961|Other|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
71260|NCT01171989|Biological|NeisVac-C™|Intramuscular, one dose.
71261|NCT00041899|Drug|CDB-2914|
71262|NCT01171989|Biological|Synflorix™|Intramuscular, one dose.
71263|NCT01172002|Drug|Leflunomide|Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.
Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks.
71264|NCT01172002|Drug|Azathioprine|Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.
Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks.
71265|NCT01172015|Other|blood samples|
71266|NCT01172028|Drug|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
71267|NCT01172028|Drug|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
71268|NCT01172041|Device|Real time position management system|Device to monitor respiration by using optical monitoring of a marker block placed on the abdomen of the patient.
71269|NCT01172041|Device|LS PET/CT|PET/CT scanner for acquiring CT and PET images (3D and 4D)
71047|NCT01180777|Device|etafilcon A (B)|Daily wear contact lens
71048|NCT00042770|Other|talc|Given intrapleurally
71049|NCT01180777|Device|etafilcon A (C)|Daily wear contact lens
71050|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
71051|NCT01183013|Drug|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
71052|NCT00042887|Drug|mitomycin C|
71053|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
71054|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
71055|NCT01183013|Drug|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
71056|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
71340|NCT01169636|Drug|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
71341|NCT01169649|Drug|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
71342|NCT01169662|Dietary Supplement|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
71343|NCT01169662|Dietary Supplement|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
71344|NCT00041548|Drug|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
71345|NCT01169675|Drug|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
71346|NCT01169675|Drug|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
71347|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
71348|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
71349|NCT01169675|Drug|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
70843|NCT01178060|Other|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
70844|NCT01178060|Other|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
70845|NCT01178073|Drug|ambrisentan|ambrisentan (target dose: 10mg)
70846|NCT01178073|Drug|tadalafil|tadalafil (target dose: 40mg)
70847|NCT01178099|Drug|Prasugrel|Oral, daily for 12 days
70848|NCT01178112|Drug|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
70849|NCT01178112|Drug|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
70850|NCT01178112|Drug|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
70851|NCT00042367|Drug|Regimen 1 Course 2, IT mafosfamide|Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.
Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course
1.
70852|NCT01178112|Drug|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
70853|NCT01178112|Other|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
70854|NCT01178125|Drug|DR-102|
70855|NCT01178138|Drug|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
70856|NCT01178151|Drug|Everolimus|10mg daily orally
70857|NCT01178164|Genetic|Blood sampling for biological and genetic analysis|Clinical examination
Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
71134|NCT01180959|Drug|Erlotinib|150 mg by mouth once a day.
71135|NCT01180985|Device|galyfilcon A prototype lens|silicone hydrogel contact lens
71525|NCT01169805|Drug|Normal saline inj|normal saline injection 2ml
71526|NCT01169818|Drug|Insulin Glargine|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target
71527|NCT01169831|Other|Exercise Training|2 weeks of daily aerobic exercise training
71528|NCT01169831|Other|Exercise Cessation|Stopping all exercise for 2 weeks
71529|NCT01169844|Biological|AIN457A|
71839|NCT01172938|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
71840|NCT01172938|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
71841|NCT01172938|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
71842|NCT01172951|Other|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
71843|NCT00042081|Drug|CGT003 (E2F Duplex Decoy)|
71844|NCT01172951|Other|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
71845|NCT01172964|Drug|flucytosine|Given orally
71846|NCT01172964|Other|polymerase chain reaction|Correlative studies
71847|NCT01172964|Other|immunohistochemistry staining method|Correlative studies
71848|NCT01172964|Biological|gene therapy|Injected at the time of the surgery to resect the tumor
71849|NCT01172964|Other|pharmacological study|Correlative studies
71850|NCT01172964|Other|3-Tesla magnetic resonance imaging|Correlative studies
71851|NCT01172964|Other|laboratory biomarker analysis|Correlative studies
71852|NCT01172964|Procedure|therapeutic conventional surgery|Surgery to resect the tumor
71853|NCT01172964|Biological|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
71854|NCT00042094|Biological|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
71270|NCT01172041|Drug|18-FDG|15mCi
71271|NCT01172054|Biological|VAX128|one IM injection
71272|NCT00041899|Drug|COB-2914|
71273|NCT01172054|Biological|Placebo|One IM injection
71274|NCT01172067|Device|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
71275|NCT01172067|Device|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
71276|NCT01172080|Other|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
71277|NCT01172106|Behavioral|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
71278|NCT01172106|Behavioral|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
71279|NCT01172106|Behavioral|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
71280|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
71580|NCT01167439|Procedure|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
71581|NCT01167452|Drug|Sulfamethoxazole/trimethoprim|2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
71582|NCT00041327|Drug|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
71583|NCT01167465|Other|Moussik Diaper Rash Mousse|To be used as instructed
71584|NCT01167465|Other|Desitin Creamy Ointment|To be used as instructed
71585|NCT01167478|Dietary Supplement|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
71586|NCT01167478|Dietary Supplement|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
71587|NCT01167491|Biological|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
71588|NCT01167504|Other|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
77841|NCT01209468|Device|twinblock oral appliance|two-piece oral appliance
77842|NCT00000987|Drug|Doxorubicin hydrochloride|
77843|NCT00045539|Drug|methotrexate|
77844|NCT01209481|Behavioral|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
77845|NCT01209507|Other|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
77846|NCT01209520|Drug|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
77847|NCT01209520|Drug|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
77848|NCT01209520|Drug|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
77849|NCT01209520|Drug|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
78177|NCT00045370|Drug|temsirolimus|
78178|NCT01207804|Device|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
78179|NCT01207817|Other|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
78180|NCT01207830|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
78181|NCT01207843|Behavioral|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
78182|NCT01207856|Behavioral|specific cognitive rehabilitation|Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and "paper-and-pencil" tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises).
78183|NCT01207856|Behavioral|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
78184|NCT01207856|Other|no intervention|no intervention
77735|NCT01206946|Other|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
77736|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
77737|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
77738|NCT01209286|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
77739|NCT01209299|Genetic|DNA methylation analysis|
77740|NCT00045526|Drug|erlotinib hydrochloride|Given PO
77741|NCT01209299|Genetic|gene expression analysis|
77742|NCT01209299|Other|laboratory biomarker analysis|
77743|NCT01209312|Other|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
77744|NCT01209325|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
77745|NCT01209325|Other|laboratory biomarker analysis|
77746|NCT01209338|Behavioral|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
77747|NCT01209351|Drug|Placebo|placebo
77748|NCT01209351|Drug|teduglutide|teduglutide 4 mg
77749|NCT01209364|Device|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
77750|NCT01209377|Behavioral|standard|EMDR treatment with bilateral stimulation via eye movement
77751|NCT00045526|Other|laboratory biomarker analysis|Correlative studies
78079|NCT01207609|Procedure|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
78080|NCT01207622|Drug|Atomoxetine|
78081|NCT01207622|Drug|Placebo|
78082|NCT01207635|Procedure|Ductal Lavage Fluid Collection|Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
77056|NCT01208233|Drug|PF-03049423|6 mg of PF-03049423 daily for 90 days
77057|NCT01208233|Other|Placebo|Placebo of PF-03049423 daily for 90 days
77058|NCT01208259|Behavioral|Cognitive Behavioral Therapy (CBT)|
77059|NCT01208259|Behavioral|Interpersonal Therapy (IPT)|
77060|NCT01208272|Behavioral|Cognitive Behavioral Therapy (CBT)|
77061|NCT01208272|Behavioral|Interpersonal Therapy (IPT)|
77062|NCT01208285|Drug|VX-770|150 mg oral tablet
77317|NCT01211301|Other|Medifast 5 & 1 Plan|Participants randomized to the Medifast group will enroll online in the Medifast 5 & 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean & Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are >70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 & 1 Plan. The Medifast 5 & 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean & Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 & 1 Plan.
77318|NCT01211314|Drug|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
77319|NCT00045708|Drug|ixabepilone|Given IV
77320|NCT01211327|Drug|Cyclosporine A|Cyclosporine 2% eye drops
77321|NCT01211327|Drug|Dexamethasone|Dexamethasone 0,1% eye drops
77322|NCT01211340|Other|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
77323|NCT01211353|Behavioral|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
77324|NCT01211353|Behavioral|Education-Only|Educational information about alcohol use
77325|NCT01211366|Other|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
77326|NCT01211366|Other|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
77327|NCT01211379|Behavioral|FLU-FOBT Program|Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
77652|NCT01209208|Other|Placebo|0 g per day
77653|NCT01209221|Drug|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
77654|NCT00045513|Drug|fludarabine phosphate|
77655|NCT01209221|Drug|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
77656|NCT01209221|Drug|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
77657|NCT01209221|Drug|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
77658|NCT01209234|Behavioral|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
77659|NCT01209234|Drug|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
77660|NCT01209247|Other|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
77993|NCT01207544|Behavioral|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
77994|NCT01207544|Behavioral|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
77995|NCT01207557|Behavioral|Standard Education Only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
77996|NCT01209689|Drug|Tocilizumab|
77997|NCT00045565|Radiation|radiation therapy|Undergo radiation therapy
77998|NCT01209689|Drug|Placebo|
77999|NCT01209702|Biological|tocilizumab|Administered intravenously (iv) every 4 weeks
78000|NCT01209702|Drug|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
78001|NCT01209715|Drug|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
78002|NCT01209715|Drug|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
78003|NCT01209728|Other|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
77134|NCT01205867|Drug|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
77135|NCT01205880|Drug|Calcitriol ointment|twice daily
77136|NCT01205880|Drug|Clobetasol spray|twice daily
77137|NCT01205893|Device|Neovasc Reducer|Implantation of the Reducer
77138|NCT01208324|Drug|estradiol transdermal system|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
77139|NCT01208324|Drug|Amino acid|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
77140|NCT01208324|Drug|Placebo Patch|placebo
77141|NCT01208324|Drug|Placebo|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
77142|NCT01208337|Drug|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
77385|NCT01208818|Drug|Cyclophosphamide + Bortezomib + Dexamethasone regimen|Dosing regimen (21 day-cycle):
Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.
Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.
Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect.
77386|NCT01208818|Drug|Bortezomib +Dexamethasone regimen|Dosing regimen (21 day-cycle):
Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.
Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.
77387|NCT01208818|Device|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
77388|NCT01208818|Device|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient > 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
77389|NCT01208831|Drug|LDE225|
77390|NCT00000987|Drug|Vincristine sulfate|
77391|NCT00045474|Procedure|adjuvant therapy|
78083|NCT01207648|Drug|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
78084|NCT01207661|Biological|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
78085|NCT00045357|Biological|therapeutic autologous lymphocytes|
78086|NCT01207674|Other|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
78087|NCT01207687|Biological|bevacizumab|Given IV
78088|NCT01207687|Other|laboratory biomarker analysis|Correlative studies
78089|NCT01207687|Procedure|quality-of-life assessment|Ancillary studies
78090|NCT01207700|Behavioral|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
78091|NCT01207726|Drug|Azacitidine|Given SC
78092|NCT01207726|Drug|Entinostat|Given PO
78093|NCT01207726|Other|Laboratory Biomarker Analysis|Correlative studies
78094|NCT01209858|Drug|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
78095|NCT01209858|Drug|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
78096|NCT01209871|Biological|DNA Vaccine|Series of 3 autologous lymphoma immunoglobulin derived scFV-chemokine DNA vaccinations (Cohort 1 dose 500 μg; Cohort 2 dose 2500 μg) intramuscularly at 4-week intervals (+/- 3 business days) according to the following schedule: 0, 4, and 8 weeks.
77195|NCT01213524|Drug|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
77196|NCT01205893|Device|Control|Control - No device implanted
77197|NCT01205906|Behavioral|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
77198|NCT00045201|Drug|Irinotecan Hydrochloride|Given IV
77328|NCT01211392|Other|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
77329|NCT01211405|Drug|Low dose 3,4-methylenedioxymethamphetamine|30 mg MDMA administered p.o. once during each experimental session. Upon mutual agreement this maybe followed by a supplemental dose of 15 mg MDMA 1.5 to 2 hours later
77330|NCT00045708|Other|pharmacological study|Correlative studies
77331|NCT01211405|Drug|3,4-methylenedioxymethamphetamine|75 mg MDMA adminis5tered p.o. once at start of an experimental session. Upon mutual agreement, may be followed 1.5 to 2 hours later by a supplemental dose of 37.5 mg
77332|NCT01211405|Drug|3,4-methylenedioxymethamphetamine|125 mg MDMA administered p.o. at start of an experimental session. By mutual agreement, may be followed 1.5 to 2 hours later by a supplemental dose of 62.5 mg MDMA.
77583|NCT01211756|Drug|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
77584|NCT01211769|Drug|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
77585|NCT01211769|Drug|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
77586|NCT01211769|Drug|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
77587|NCT00045721|Procedure|neoadjuvant therapy|
77588|NCT01211769|Drug|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
77589|NCT01211782|Drug|caprylic triglyceride|oral, 20 gm, daily x 6 months
77590|NCT01211782|Drug|long-chain triglyceride|oral, 14 gm, daily x 6 months
77591|NCT01211795|Drug|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
77592|NCT01211795|Other|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
77593|NCT01211808|Drug|BMS-914832|Tablets, Oral, 30 mg, once, 1 day
77594|NCT01211808|Drug|Diltiazem|Tablets, Oral, 360 mg, once daily, 10 days
78004|NCT01209741|Drug|telcagepant potassium|[INTERVENTION NAME: MK-0974 12MoRT] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
78005|NCT01209741|Drug|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
78006|NCT01209741|Drug|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
78007|NCT01209767|Device|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
78008|NCT00045591|Drug|celecoxib|100 mg PO bid
78009|NCT01209767|Procedure|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
78010|NCT01209767|Other|Control|
78011|NCT01209780|Biological|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
78012|NCT01209780|Biological|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
77124|NCT01205841|Procedure|Thompson Test|As previously published
77125|NCT01205841|Procedure|Palpation of the fibula|Palpation of the fibula over its entire length.
77126|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
77127|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
77128|NCT01205841|Procedure|Malleolar Zone Algorithm|As previously published
77129|NCT00045201|Drug|Erlotinib Hydrochloride|Given orally
77130|NCT01205841|Procedure|Low Risk Exam|As previously published
77131|NCT01205841|Procedure|Bernese Ankle Rules|As previously published
77132|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
77133|NCT01205854|Device|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
77392|NCT01211418|Behavioral|Integrative Meditation|Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.
Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB & IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.
Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study.
77393|NCT01211418|Behavioral|Supportive Counseling|NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.
The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion.
77394|NCT01211431|Drug|Reference|Intrathécale morphine is used for post-cesarean pain control
77395|NCT01211431|Drug|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
77396|NCT01211444|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
77397|NCT01211457|Drug|sapacitabine and decitabine|decitabine will be administered in alternating cycles with sapacitabine
77398|NCT01211470|Drug|Daptomycin|Active Comparator: Daptomycin.
77399|NCT01211470|Drug|PMX-30063-investigational drug|Experimental: PMX-30063
77400|NCT00045721|Drug|O6-benzylguanine|
77661|NCT01209260|Device|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
77662|NCT01209260|Device|Mechanical Needle|Mechanical needle for transseptal access
77663|NCT01211821|Drug|metoprolol|Tablets, Oral, 200 mg, once, 1 day
77664|NCT01211821|Drug|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
77665|NCT01211834|Drug|tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
77666|NCT00045734|Drug|imatinib mesylate|Given orally
77667|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
77668|NCT01211834|Drug|Placebo|intravenously over 1 hour infusion every 4weeks
77199|NCT01205906|Behavioral|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
77200|NCT01205906|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
77201|NCT01205919|Behavioral|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
77202|NCT01205919|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
77203|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
77204|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
77205|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
77206|NCT01205932|Drug|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
77207|NCT01205958|Procedure|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
77208|NCT01205971|Behavioral|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
77209|NCT00045227|Biological|recombinant fowlpox-prostate specific antigen vaccine|
77210|NCT01205971|Behavioral|Preventive Dental Services|Written oral health educational materials
77211|NCT01205984|Drug|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
77212|NCT01205997|Drug|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
77458|NCT01208909|Procedure|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
77459|NCT01208922|Drug|Rifamycin SV MMX|800 mg per day
77460|NCT01208922|Drug|Ciprofloxacin|1 g per day
77595|NCT01214031|Device|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
77596|NCT01214044|Drug|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
77597|NCT00046033|Drug|Lopinavir/ritonavir|
77598|NCT01214057|Drug|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
77929|NCT01212406|Drug|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
77930|NCT01212432|Drug|Daptomycin|Daptomycin kinetics in CRRT
77931|NCT01212445|Drug|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
77932|NCT01212458|Drug|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
77933|NCT01212471|Drug|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
77934|NCT01212471|Drug|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
77935|NCT01212471|Drug|Placebo Comparator|sterile ophthalmic solution
77936|NCT01212484|Drug|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
77937|NCT00045773|Drug|Sertraline|50 - 200mg, once per day for 12 weeks.
77938|NCT01212484|Drug|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
77939|NCT01212497|Behavioral|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
73819|NCT01202461|Procedure|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.
IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken.
73820|NCT01202474|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
73821|NCT01202474|Drug|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
73822|NCT01202487|Drug|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
73823|NCT01202500|Procedure|reducing treatment to 3 months|The treatment will be stopped after 3 months
73824|NCT01202500|Procedure|registered length of treatment|The treatment procedure will follow the actual recommandation
73825|NCT01202513|Drug|Bimatoprost 0.03% topical ophthalmic solution|
73826|NCT01202552|Biological|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
74148|NCT01188486|Procedure|Stereotactic Body Radiation Therapy (SBRT)|standard of care
74149|NCT01188486|Drug|Iohexol|1 to 5 cc
74150|NCT00000971|Drug|Didanosine|
74151|NCT00043329|Drug|Actimmune Registry|as administered by physician
74152|NCT01188486|Radiation|Computed Tomography (CT)|For each patient, Chest CT scans will be obtained: 1 before and 2 after interstitial injection of water soluble contrast
74153|NCT01188486|Device|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
74154|NCT01188486|Device|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
74155|NCT01188486|Device|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
74156|NCT01188499|Drug|Birinapant|
74157|NCT01190709|Procedure|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
77669|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs
77670|NCT01211847|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 126 days
77671|NCT01211847|Drug|Placebo|Placebo matching DCCR
77672|NCT01211860|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
77673|NCT01211873|Drug|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
77674|NCT01211873|Drug|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
77675|NCT01211912|Drug|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
77676|NCT01211912|Drug|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
77677|NCT00045734|Other|laboratory biomarker analysis|Correlative studies
77678|NCT01211925|Procedure|distal venous arterialisation|The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
77679|NCT01211925|Drug|Aspirin|100 mg per day continuous
77680|NCT01211938|Radiation|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
77681|NCT01211938|Radiation|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
77682|NCT01211951|Drug|KCT-0809|
77683|NCT01211951|Drug|KCT-0809|
77684|NCT01211951|Drug|KCT-0809|
77685|NCT01211951|Drug|Placebo|
78013|NCT01209780|Biological|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children <4 years.
78014|NCT01209793|Biological|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
78015|NCT01209806|Drug|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
78016|NCT01209832|Drug|Tasisulam|Patient specific dose, administered intravenously, on day 1 of a 28 day cycle. Minimum of one (1) 28 day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
78185|NCT01210040|Dietary Supplement|Folic Acid|2.8mg
78186|NCT00045604|Drug|imatinib mesylate|
78187|NCT01210040|Dietary Supplement|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
78188|NCT01210053|Drug|malate Given orally|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
78189|NCT01210066|Drug|Fentanyl|IV fentanyl 1mcg/kg
78190|NCT01210066|Other|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
78191|NCT01210066|Other|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
78192|NCT01210079|Drug|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
78193|NCT01210079|Drug|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
78194|NCT01210118|Behavioral|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
77270|NCT01213615|Device|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
77271|NCT01213628|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
77272|NCT01213667|Drug|Ranibizumab|upload (three monthly injections), re-treatment as needed
77273|NCT01213680|Drug|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
77274|NCT01213680|Drug|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
77275|NCT01213693|Drug|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
77276|NCT01213693|Drug|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
77277|NCT01213706|Device|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
77278|NCT01213706|Device|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
77940|NCT01212510|Other|Blood sampling|blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
77941|NCT01212523|Drug|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
77942|NCT01212536|Device|Airtraq laryngoscopy|laryngoscopy and intubation
77943|NCT01212549|Procedure|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
77944|NCT01212549|Procedure|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
77945|NCT01204866|Drug|Valortim and Selected Components|• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.
Only one subject will be skin tested in a single day.
The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively
77946|NCT01204879|Behavioral|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
77063|NCT01208298|Device|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
77064|NCT01208311|Other|Ultrasound|Endoscopic ultrasound of the liver
77065|NCT00045435|Drug|mycophenolate mofetil|Given PO
77066|NCT01210781|Procedure|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
77067|NCT01210807|Device|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
77068|NCT01210807|Device|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
77069|NCT01210820|Device|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
77070|NCT00045630|Drug|gemcitabine|
77071|NCT01210833|Device|HandTutor System|Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
77072|NCT01210846|Drug|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
74158|NCT01190709|Procedure|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
74159|NCT01190722|Drug|etoricoxib|120 mg once daily for the 1st 6 postoperative days
74160|NCT01190722|Drug|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
74161|NCT00000973|Drug|Pyrimethamine|
74162|NCT00043550|Drug|Sertraline|Participants will receive sertraline.
74163|NCT01190735|Drug|Caffeine alkaloid|The following intervention will be provided for six consecutive weeks:
Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed.
74164|NCT01190748|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
74165|NCT01190748|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
74166|NCT01190761|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
74463|NCT01193530|Behavioral|Questionnaires|Weekly
74464|NCT01193530|Behavioral|Study Diaries|Daily logs
74465|NCT01193543|Dietary Supplement|calanus oil|1 gram twice daily
74466|NCT01193543|Dietary Supplement|olive oil|1 gram twice daily
74467|NCT01193556|Device|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
74468|NCT00043927|Drug|etoposide/cisplatin|
74469|NCT01193556|Device|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
74470|NCT01193582|Biological|Prevenar|Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
4 doses starting from 121 to < 212 days of age
74471|NCT01186406|Drug|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
78017|NCT01209832|Drug|Midazolam|1.2mg, administered orally once prior to the initiation of tasisulam therapy and once on day 8 after initiation of tasisulam therapy
78018|NCT01209845|Drug|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
78019|NCT00045591|Drug|Celecoxib|400 mg PO bid
78020|NCT01212562|Procedure|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
78021|NCT01212588|Drug|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
78022|NCT01212588|Drug|Placebo|3 tablets once daily for seven days
78023|NCT00045786|Drug|CC-1088|
78024|NCT01212614|Procedure|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
78025|NCT01212627|Drug|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
78026|NCT01212627|Drug|Ridaforolimus|
78027|NCT01212653|Drug|Simponi|Golimumab 50mg monthly
78028|NCT01212653|Other|0.9ml sodium chloride|0.9ml sodium chloride
78029|NCT01212666|Procedure|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
78030|NCT01212666|Procedure|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
78031|NCT01212679|Drug|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
78032|NCT01212679|Drug|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
78033|NCT01212692|Behavioral|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
78034|NCT00045799|Drug|Omeprazole sodium bicarbonate immediate release PWD/FS|
77143|NCT01208350|Behavioral|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
77144|NCT01208350|Behavioral|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
77279|NCT00045968|Drug|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
77280|NCT01213719|Dietary Supplement|creatine|20g/d throughout 10 days
77281|NCT01205997|Drug|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
77282|NCT01206010|Drug|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
77283|NCT01206010|Drug|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
77284|NCT01206010|Drug|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
77285|NCT01206023|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
77286|NCT01206036|Drug|Docetaxel|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
77850|NCT01209520|Procedure|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
77851|NCT01209520|Procedure|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
77852|NCT01209520|Drug|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
77853|NCT01209520|Drug|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
77854|NCT00045539|Drug|thiotepa|
77855|NCT01212263|Drug|Clomiphine citrate plus low dose uFSH|Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
77073|NCT01210872|Other|questionnaire administration|
77074|NCT01210872|Procedure|quality-of-life assessment|
77075|NCT01210872|Procedure|standard follow-up care|
77076|NCT01210885|Biological|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
77077|NCT01210898|Biological|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
77078|NCT01210911|Drug|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
77079|NCT01210911|Drug|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
77080|NCT01210911|Drug|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
77081|NCT00045630|Drug|paclitaxel|
77082|NCT01210911|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
77333|NCT01213862|Behavioral|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
77334|NCT01213875|Behavioral|Home based education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
77335|NCT01213888|Drug|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
77336|NCT01213888|Drug|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
77337|NCT01213901|Procedure|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
74472|NCT01186419|Drug|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
74473|NCT00043095|Drug|gemcitabine hydrochloride|
74474|NCT01186432|Drug|PDS 1.0|
74475|NCT01186445|Drug|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
74476|NCT01186445|Drug|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
74477|NCT01186458|Drug|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
74478|NCT01186458|Drug|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
74479|NCT01186458|Drug|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
74480|NCT01186471|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
74481|NCT01186471|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
74482|NCT01186471|Drug|placebo|placebo - three times daily during each treatment period
74483|NCT01186484|Drug|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
74484|NCT00043095|Drug|ixabepilone|
73504|NCT01196936|Procedure|Digital mammography|Correlative studies
73505|NCT01196936|Other|immunohistochemistry staining method|Correlative Studies
73506|NCT01199198|Drug|Placebo|Placebo by mouth once a day for 14 days.
73507|NCT01199211|Other|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
73508|NCT01199224|Drug|veliparib|veliparib formulation A
73509|NCT01199224|Drug|veliparib|veliparib formulation B
73510|NCT01199224|Drug|veliparib|veliparib formulation C
73511|NCT01199224|Drug|veliparib|veliparib formulation C
77145|NCT01208350|Behavioral|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
77146|NCT01208363|Dietary Supplement|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
77147|NCT01208376|Other|Fibroscan|Fibroscan and Serum Fibrose-marker
77148|NCT00045435|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
77149|NCT01208389|Biological|AAV2-hRPE65v2|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector to the contralateral, previously uninjected eye.
77150|NCT01208402|Drug|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
77151|NCT01208415|Device|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
77152|NCT01208428|Behavioral|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
77153|NCT01208428|Behavioral|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
77154|NCT01208441|Drug|letrozole|
77155|NCT01208441|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
77156|NCT01210989|Drug|Placebo|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
77157|NCT01211002|Radiation|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
77158|NCT01211002|Drug|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 ~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
77159|NCT00045630|Procedure|surgery|
77160|NCT01211028|Other|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
77401|NCT01211483|Drug|U3-1287|Liquid 70 mg/mL. One intravenous infusion every 3 weeks Until cancer gets worse or unacceptable side effects of the drugs or withdrawal of consent.
77856|NCT01212276|Drug|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
77857|NCT01212302|Drug|Optimizing ASA and clopidogrel treatment|ASA 100 mg, ASA 300 mg, ASA 500 mg
Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:
In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient.
77858|NCT01212315|Device|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
77859|NCT00045747|Drug|fluorouracil|
77860|NCT01212328|Other|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
77861|NCT01212328|Other|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
77862|NCT01212341|Biological|Allogeneic NK cells|
77863|NCT01212354|Radiation|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
77864|NCT01212367|Biological|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
77865|NCT01212367|Biological|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
77879|NCT01204840|Drug|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
77880|NCT01204840|Drug|Patch protocol|Group A (n=10; control group) will receive "patch protocol": 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped.
77881|NCT01204853|Drug|Sitaxentan|sitaxentan sodium 100 mg
77338|NCT01213914|Device|An FDA approved continuous renal replacement device|70ml/kg/hr for treatment group for 48 hours with the following requirements:
double lumen dialysis catheter should be placed in the internal jugular or femoral vein
Anticoagulation will be determined by prescribing physician
Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours
Blood flow rate will be set to ensure a filtration fraction of no more than 25%
Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours
Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized
All antibiotics will be dose adjusted for renal replacement therapy
77339|NCT01213914|Other|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
77340|NCT01213940|Behavioral|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
77341|NCT00046020|Drug|Venlafaxine ER|
77342|NCT01213940|Procedure|bariatric surgery|bariatric surgery for weight loss
77343|NCT01213966|Drug|OZ439|po, single dose
77344|NCT01213979|Drug|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
77345|NCT01213979|Drug|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
77346|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
77599|NCT01214057|Drug|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
77600|NCT01214070|Other|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
77601|NCT01214070|Behavioral|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
77602|NCT01214070|Behavioral|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
77603|NCT01214070|Behavioral|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
77604|NCT01214083|Drug|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
77605|NCT01214083|Drug|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
73512|NCT01199237|Drug|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
73513|NCT00044577|Drug|tenofovir|
73514|NCT01199237|Drug|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
73515|NCT01199237|Drug|Rocuronium|
73516|NCT01199237|Drug|Neostigmine|
73517|NCT01199237|Drug|Glycopyrrolate|
73518|NCT01199250|Other|Laboratory Biomarker Analysis|Correlative studies
73519|NCT01199263|Other|Laboratory Biomarker Analysis|Correlative studies
73520|NCT01199263|Drug|Paclitaxel|Given IV
73521|NCT01199263|Biological|Wild-type Reovirus|Given IV
73522|NCT01199276|Drug|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
73523|NCT01199276|Drug|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
73524|NCT00044616|Drug|Fluoxetine|
73525|NCT01199289|Drug|AMG 827|210 mg AMG 827 SC
73526|NCT01199289|Drug|Placebo|Placebo SC
73527|NCT01199289|Drug|AMG 827|140 mg AMG 827 SC
73528|NCT01199289|Drug|AMG 827|280 mg AMG 827 SC
73529|NCT01199302|Drug|AMG 827|350 mg AMG 827 administered intraveneously at baseline, week 4, and every 4 weeks thereafter.
73827|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
73828|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
73829|NCT00044889|Drug|clofarabine (IV formulation)|
73830|NCT01202578|Device|tympanostomy tube|tympanostomy tube delivery system
73831|NCT01202591|Drug|AZD4547|Tablet oral twice daily
77402|NCT01211483|Drug|Erlotinib|Tablet 150 mg. Once daily Until cancer gets worse or unacceptable side effects of the drugs or withdrawal of consent
77403|NCT01211496|Other|Resistance training|High speed or traditional resistance training, 3 sessions per week for 12 weeks
77404|NCT01211509|Drug|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
77405|NCT01211522|Drug|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
77406|NCT01211522|Drug|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
77407|NCT01211522|Drug|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
77408|NCT01211535|Device|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
77409|NCT01211535|Device|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
77410|NCT01214109|Drug|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
77411|NCT01214109|Drug|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
77412|NCT01214122|Drug|AZD9668|60 mg orally twice daily for 11 days
77413|NCT01214122|Drug|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
77414|NCT01214148|Device|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
77415|NCT00046033|Drug|Saquinavir|
77416|NCT01214161|Drug|2% lidocaine gel|Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.
Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room.
77417|NCT01214174|Drug|IBI-10090|
77418|NCT01214187|Drug|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
77882|NCT01204866|Biological|Valortim and selected Components|Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.
Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.
Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1
Histamine (1 mg/mL), positive control
Saline (0.9%), negative control
77883|NCT01207180|Other|Satisfaction survey|Patients will be given a satisfaction survey.
77884|NCT01207180|Other|Control group --- no intervention|Control group
77885|NCT01207193|Biological|cell injection|injection of mesenchymal cells to bone cyst defect
77886|NCT01207206|Drug|oral ketamine|The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).
The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception
77887|NCT00045305|Procedure|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
77888|NCT01207219|Behavioral|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
77889|NCT01207219|Behavioral|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
77890|NCT01207232|Behavioral|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
77891|NCT01207232|Behavioral|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
77892|NCT01207245|Other|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
77893|NCT01207258|Behavioral|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
77894|NCT01207271|Behavioral|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
78195|NCT01210118|Behavioral|Higher intensity intervention|Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the "5 Αs" (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided.
78196|NCT01210131|Drug|[18F]HX4|Intravenous injection
78197|NCT00045604|Drug|irinotecan hydrochloride|
77606|NCT01214083|Drug|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
77607|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration:0.6ug/kg/day for 10days
77608|NCT00046033|Drug|Ritonavir|
77609|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration 1.2ug/kg/day for 10 days
77610|NCT01214096|Drug|rhNRG-1|Vein infusion:0.6ug/kg/day for 10 days
77611|NCT01214096|Drug|placebo|Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
77612|NCT01214109|Drug|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
77613|NCT01214109|Drug|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
77614|NCT01206569|Drug|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
77615|NCT01206582|Biological|Hemin|10 iv infusions for 8 weeks
77616|NCT01206582|Biological|Albumin|10 iv infusions for 8 weeks
77617|NCT01206595|Drug|SKY0402|Single dose of SKY0402 administered as a nerve block
77618|NCT01206595|Drug|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
77947|NCT01204892|Procedure|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
77948|NCT00045123|Drug|tarenflurbil|
77949|NCT01204892|Procedure|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
77950|NCT01204905|Drug|Raltegravir and Maraviroc in combination|Raltegravir 400 mg tablet twice a day, ~12 hours (10 to 14 hours) apart
Maraviroc 300 mg tablet twice a day, ~12 hours (10 to 14 hours) apart
77951|NCT01204918|Drug|Riluzole|Riluzole 100mg PO for up to 8 weeks
77952|NCT01204918|Drug|placebo|placebo
77953|NCT01204957|Dietary Supplement|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
77954|NCT01204957|Dietary Supplement|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
73832|NCT01202591|Drug|Exemestane|Tablet oral once daily
73833|NCT01202591|Drug|Placebo|Tablet oral twice daily
73834|NCT01202591|Drug|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
73835|NCT01202630|Dietary Supplement|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
73836|NCT01194648|Procedure|high-intensity focused ultrasound ablation|
73837|NCT01194648|Procedure|multiparametric magnetic resonance imaging|
73838|NCT01194648|Procedure|quality-of-life assessment|
73839|NCT01194648|Procedure|transperineal prostate biopsy|
73840|NCT01194648|Procedure|transrectal prostate biopsy|
73841|NCT00000976|Drug|Zidovudine|
73842|NCT00043979|Drug|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
73843|NCT01194674|Drug|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
73844|NCT01194700|Drug|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
73845|NCT01194700|Drug|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
73846|NCT01194700|Drug|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
73847|NCT01194700|Drug|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
73848|NCT01194713|Behavioral|Sleep deprivation|subjects will undergo one night of full sleep deprivation
73849|NCT01194765|Other|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
74167|NCT01190761|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
74168|NCT01190774|Behavioral|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
77686|NCT01211964|Drug|LEO 22811|Oral administration of solution and tablet.
77687|NCT01211977|Drug|XOMA 052|
77688|NCT00000989|Drug|Zidovudine|
77689|NCT00045734|Other|pharmacological study|Correlative studies
77690|NCT01212094|Drug|Rituximab|
77691|NCT01214278|Drug|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
77692|NCT01214278|Drug|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
77693|NCT01214291|Drug|Toremifene|Toremifene 80mg daily
77694|NCT01214304|Other|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
77695|NCT01214304|Other|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
77696|NCT01214317|Procedure|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
77697|NCT00046033|Drug|Amprenavir|
77698|NCT01214330|Device|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
77699|NCT01214343|Drug|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
77700|NCT01214343|Drug|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
77701|NCT01214356|Drug|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
77702|NCT01214356|Drug|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
77703|NCT01214369|Procedure|Type of Supplementary Injection|Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
78198|NCT01210144|Drug|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
78199|NCT01210144|Drug|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (>) 16 millimeter (mm), and with estradiol (E2) > 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
78200|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
78201|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
78202|NCT01210170|Drug|Mometasone 200 mcg|participants received one of the intervention combinations on Day 1 of Week 1-4, in random order
78203|NCT01210170|Drug|placebo|participants received one of the intervention combinations on Day 1 of Week 1-4, in random order
78204|NCT01210170|Drug|mometasone 400 mcg|participants received one of the intervention combinations on Day 1 of Week 1-4, in random order
78205|NCT01210183|Drug|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
78206|NCT01212887|Biological|aldesleukin|
78207|NCT01212887|Drug|cyclophosphamide|
78208|NCT01212887|Drug|fludarabine phosphate|
78209|NCT01212887|Other|laboratory biomarker analysis|
78210|NCT01212887|Other|pharmacological study|
78211|NCT01212900|Drug|Statin Drugs|LDL. Cholesterol
78212|NCT00000249|Drug|30% N2O|30% inhaled N2O
78213|NCT00000989|Drug|Sargramostim|
78214|NCT00045864|Drug|Recombinant Human Interleukin-2 and Rituximab|
78215|NCT01212900|Other|HMG-CoA Reductase Inhibitors|Reduction
77287|NCT00045227|Biological|recombinant vaccinia prostate-specific antigen vaccine|
77955|NCT01204996|Drug|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
77956|NCT01204996|Drug|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
77957|NCT01204996|Drug|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
77958|NCT01204996|Drug|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
77959|NCT00045123|Procedure|adjuvant therapy|
77960|NCT01205009|Drug|Ovitrelle|One dose of Ovitrelle 250 mcg
77961|NCT01205022|Drug|irinotecan hydrochloride|Given IV
77962|NCT01205022|Drug|leucovorin calcium|Given IV
77963|NCT01205022|Drug|fluorouracil|Given IV
77964|NCT01205022|Biological|bevacizumab|Given IV
77965|NCT01205022|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
77966|NCT01205022|Other|laboratory biomarker analysis|Correlative studies
77967|NCT01205035|Drug|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
77968|NCT01205048|Device|Emervel Classic Lidocaine|20 mg/ml + 0.3% lidocaine
77969|NCT01205048|Device|Juvederm® Ultra|24mg/ml
77083|NCT01210937|Procedure|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
77084|NCT01210950|Biological|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
77085|NCT01210963|Device|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
77086|NCT01210976|Drug|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
77087|NCT01210976|Drug|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
74169|NCT01190774|Behavioral|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
74170|NCT01190787|Drug|velcade subcutaneous melphalan prednisone|INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
74171|NCT01190787|Drug|velcade cyclophosphamide prednisone|INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.
Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
74172|NCT01190787|Drug|velcade prednisone|INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
74173|NCT00043550|Drug|Pill Placebo|Participants will receive a pill placebo.
74174|NCT01193101|Drug|LCZ696|LCZ696
74175|NCT01193101|Drug|Placebo|matching placebo to LCZ696
74176|NCT01193114|Behavioral|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
74177|NCT01193114|Behavioral|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
74178|NCT01193127|Drug|OMS302 Solution|
74179|NCT01193127|Drug|OMS302 Mydriatic Solution|
74180|NCT01193127|Drug|OMS302 Anti-inflammatory Solution|
74181|NCT01193127|Drug|Balanced Salt Solution (BSS) Solution|
74182|NCT00043862|Drug|topotecan|
74183|NCT01193140|Drug|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
74184|NCT01193140|Drug|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
74185|NCT01193153|Drug|Placebo|monthly by i.m. injection for 15 months
74186|NCT01193153|Drug|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
74187|NCT01193166|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
77704|NCT01214382|Drug|Sertraline|Single dose sertraline 100 mg, tablet and solution
77705|NCT01214395|Drug|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
78035|NCT01212705|Device|Adaptive servoventilation|Background expiratory positive airway pressure with some inspiratory pressure support when needed
78036|NCT01212718|Drug|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
78037|NCT01212718|Drug|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
78038|NCT01212731|Radiation|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
78039|NCT01212731|Radiation|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
78040|NCT01212731|Behavioral|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
78041|NCT01212731|Device|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
78042|NCT01212744|Drug|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
78043|NCT01212757|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
78044|NCT01212757|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
78045|NCT00045799|Drug|Cimetidine IV|
78046|NCT00045136|Drug|melphalan|
78047|NCT01205061|Device|Emervel Deep Lidocaine|20 mg/ml + 0.3% lidocaine
78048|NCT01205061|Device|Juvederm® Ultra Plus|24 mg/ml
78049|NCT01205074|Device|13C Methacetin Breath Test|
78050|NCT01205074|Dietary Supplement|Grape fruit juice|
78051|NCT01205074|Drug|Non selective beta blocker - Propranolol|
78052|NCT01205074|Dietary Supplement|Ethanol|
78053|NCT01205087|Drug|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
77288|NCT01206036|Drug|Temsirolimus|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
77289|NCT01206049|Drug|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
77290|NCT01206049|Drug|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
77291|NCT01206049|Drug|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
77292|NCT01206049|Drug|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
77293|NCT01206049|Drug|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
77294|NCT01206062|Other|Intensive control of SBP|Participants in the Intensive arm have a goal of SBP <120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics
Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies.
77295|NCT01206062|Other|Standard BP arm|Participants in the Standard BP arm have a goal of SBP <140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
77296|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
77297|NCT01208558|Behavioral|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
77298|NCT01208558|Behavioral|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
77299|NCT01208571|Other|"Booster session"|Motivational interview
77300|NCT00045461|Drug|carboplatin|
77301|NCT01208584|Other|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
77302|NCT01208649|Drug|Exenatide|Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
77088|NCT01210989|Drug|Phyllanthus urinaria|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
77089|NCT01213329|Drug|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
77090|NCT01213342|Dietary Supplement|Omega-3 Fatty Acid|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:
EPA (Eicosapentaenoic Acid) 1300mg
DHA (Docosahexaenoic Acid) 900 mg
Other Omega-3's 360mg
Total Omega 3's 2560 mg
77091|NCT01213342|Dietary Supplement|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
77092|NCT01213355|Drug|Placebo|Capsule, single dose, oral, 1 day
77093|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
77094|NCT01213355|Drug|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
77095|NCT00045916|Drug|Venlafaxine|Participants will receive venlafaxine.
77096|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
77097|NCT01213355|Drug|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
77098|NCT01213355|Drug|scopolamine|injectable subcutaneous formulation, single dose, 1 day
77099|NCT01213355|Drug|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
77100|NCT01213355|Drug|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
77101|NCT01213355|Drug|Donepezil|Tablet, 10mg, single dose, 1 day
77102|NCT01213355|Drug|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
77103|NCT01213368|Drug|DRONEDARONE (SR33589)|Pharmaceutical form: tablets
Route of administration: oral
77347|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
77348|NCT01214005|Behavioral|smoking abstinence|3 days of biologically-confirmed smoking abstinence
77349|NCT01214018|Other|Questionnaires and interview|Questionnaires and interview
74485|NCT01186497|Drug|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
74486|NCT01186497|Drug|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
74487|NCT01186497|Drug|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
74488|NCT01186497|Drug|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
74489|NCT01186497|Drug|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
74490|NCT01186510|Procedure|lung perfusion|see literature of proceeding
74491|NCT01186510|Procedure|no lung perfusion|see literature of proceeding
74492|NCT01186523|Other|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
74493|NCT01186536|Dietary Supplement|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
74494|NCT01186536|Dietary Supplement|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
74495|NCT01188876|Drug|carboplatin|Given intravenously on Day 1 of each 28-day cycle
74496|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
74497|NCT01188876|Drug|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
74498|NCT01188889|Drug|RAD001|Dosing schedule of RAD001 for the Phase I portion:
Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD.
74499|NCT01188889|Drug|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
74500|NCT01188902|Dietary Supplement|walnut|walnut consumption 48 g/d
74501|NCT01188915|Procedure|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
74502|NCT01188928|Drug|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
74503|NCT01188928|Drug|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
78054|NCT01205100|Behavioral|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
78055|NCT01205126|Drug|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
78056|NCT01205126|Drug|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
77161|NCT01211067|Procedure|Lichtenstein hernioplasty|Mesh hernioplasty
Ultrapro mesh (Ethicon, Johnson & Johnson)
77162|NCT01211080|Drug|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
77163|NCT01211093|Procedure|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
77164|NCT01211093|Procedure|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
77165|NCT01211093|Procedure|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
77166|NCT01211106|Behavioral|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
77167|NCT01211106|Behavioral|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
77168|NCT01211119|Other|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
77169|NCT01211132|Device|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
77170|NCT00045669|Drug|imatinib mesylate|
77171|NCT01211132|Device|Standard|Without attaching a transparent cap to the tip of colonoscope.
77172|NCT01211145|Drug|Placebo|Placebo nasal spray
77173|NCT01211145|Drug|Zolmitriptan|0.5 mg nasal spray
77174|NCT01211145|Drug|Zolmitriptan|2.5 mg nasal spray
77866|NCT01212380|Drug|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
77867|NCT01212380|Other|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
77868|NCT01212380|Other|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
77869|NCT01204775|Drug|Placebo (Metformin)|Tablets, Oral, 0 mg, Once daily, 1-52 weeks
77870|NCT01204775|Drug|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
77871|NCT01204788|Procedure|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
77872|NCT01204788|Procedure|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
77873|NCT01204801|Device|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
77874|NCT01204801|Drug|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
77875|NCT00045110|Other|laboratory biomarker analysis|Correlative studies
77876|NCT01204814|Procedure|Laboratory Testing|Completion of behavorial questionnaire; HIV testing;CD4-positive T cell counts; Plasma viral HIV-1 RNA levels (viral load); Identification of drug resistance mutations in HIV-1 by standard and sensitive assays; Categorization of infection as recent or chronic using current incidence testing algorithms; Follow-up visits with laboratory evaluations
77877|NCT01204814|Other|Counseling/referral|Completion of behavorial questionnaire; HIV testing; Referred to HIV-prevention trial;
77878|NCT01204827|Device|13C Methacetin Breath Test (BreathID)|
77350|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
77351|NCT00045227|Biological|recombinant vaccinia-B7.1 vaccine|
77352|NCT01206075|Drug|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
77353|NCT01206088|Drug|nilotinib|administration of nilotinib as 2nd line
77354|NCT01206101|Drug|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
77355|NCT01206101|Drug|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
77356|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
77357|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
77358|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
77359|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
77360|NCT01206140|Other|Laboratory Biomarker Analysis|Correlative studies
77361|NCT01206140|Drug|Selumetinib|Given PO
77362|NCT00045227|Biological|sargramostim|
77363|NCT01206140|Drug|Temsirolimus|Given IV
77364|NCT01206153|Drug|metformin|
77365|NCT01206166|Drug|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
77366|NCT01206179|Biological|cell injection|Injection of mesenchymal cells in fractured zone
77619|NCT01206608|Drug|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
74504|NCT01188928|Drug|Calcipotriene|Topical suspension once daily for up to 8 weeks.
74505|NCT01188928|Drug|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
73530|NCT01199315|Drug|AZD1446|oral capsule, Moderate Release
73531|NCT01199315|Drug|Placebo|oral capsule
73532|NCT01199328|Drug|Aspirin|81mg Tablet oral, once daily
73533|NCT01199328|Drug|Esomeprazole|20 mg Tablet oral, once daily
73534|NCT01199341|Drug|AZD1981|100 mg per oral, twice daily for 14 days
73535|NCT00044616|Drug|Lithium|
73536|NCT01199341|Drug|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
73537|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
73538|NCT01201915|Drug|Vismodegib|Vismodegib was supplied in gelatin capsules.
73539|NCT01201928|Drug|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
73540|NCT00044798|Procedure|Sham rTMS|Participants will receive 15 treatments of sham rTMS over 3 weeks.
73541|NCT01201928|Drug|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
73542|NCT01201941|Other|e-Chasqui|The laboratory component of the PIH-EMR, termed "e-Chasqui," permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests.
73543|NCT01201954|Drug|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
73544|NCT01201967|Other|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
73545|NCT01201967|Other|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
73546|NCT01202006|Other|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
77175|NCT01211145|Drug|Zolmitriptan|5.0 mg nasal spray
77176|NCT01211158|Drug|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
77177|NCT01213407|Drug|Trivax, Temozolomide, Surgery, Radiotherapy|Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32
Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy
Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.
Break: weeks 7, 8, 9, 10.
Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31.
77419|NCT01214187|Other|Oxygen|Room air oxygen concentrations will be administered as placebo
77420|NCT01214200|Device|High Intensity Non Invasive Pos. Pressure|High Intensity Non Invasive Positive Pressure Ventilation (HINPPV) will be applied to hypercapnic chronic obstructive pulmonary disease (COPD) patients for a period of 3 months. The Respironics bilevel positive airway pressure (BiPAP) Synchrony device has a maximum inspiratory positive airway pressure (IPAP) setting of 30 cmH2O and will be used for all participants in the study. If it is determined through the titration study the participant requires an IPAP greater than 30 cmH2O, they will be placed on the Respironics Trilogy ventilator.
77421|NCT01214200|Device|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. All participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
77422|NCT01214226|Drug|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
77423|NCT01214226|Drug|placebo|prolonged-release tablets 3 time per day for 1 month
77424|NCT01214239|Drug|Placebo|once a day
77425|NCT01214239|Drug|Linagliptin|once a day
77426|NCT00046033|Drug|Tenofovir disoproxil fumarate|
77427|NCT01214252|Device|Permacol Surgical Implant|Permacol Surgical Implant
77428|NCT01214265|Device|EMKinetics non-invasive Magnetic neurostimulator|Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
77429|NCT01214278|Drug|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
77430|NCT01214278|Drug|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
77431|NCT01206270|Drug|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
77895|NCT01207271|Behavioral|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
77896|NCT01207284|Other|Physical Therapy|strengthening passive and active stretching balance training gait training
77897|NCT01207297|Drug|Tacrolimus|The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).
20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration.
77898|NCT00045305|Procedure|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
77899|NCT01207297|Drug|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
77900|NCT01207310|Behavioral|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
77901|NCT01207310|Drug|nicotine replacement|8 weeks' worth of nicotine patches
77902|NCT01207310|Device|alphanumeric pager|therapeutic messages to be delivered for three months
77903|NCT01207323|Drug|MEHD7945A|Intravenous escalating dose
77904|NCT01207336|Device|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
77905|NCT01209520|Drug|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
77906|NCT01209533|Drug|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
77907|NCT01209546|Other|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
77908|NCT01209546|Other|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
77909|NCT01209546|Other|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
77910|NCT01209546|Other|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
77620|NCT01206608|Drug|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
77621|NCT01206634|Procedure|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
77622|NCT00045292|Drug|valacyclovir|
77623|NCT01206634|Behavioral|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
77624|NCT01206647|Drug|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
77625|NCT01206660|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
77626|NCT01206660|Drug|placebo|Placebo administered to affected area twice a day for 28 days
77627|NCT01206673|Other|Blood sampling|One blood sampling is required for the research
77628|NCT01206686|Behavioral|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
77629|NCT01206686|Behavioral|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
77630|NCT01206686|Behavioral|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
77631|NCT01206699|Drug|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
77632|NCT01206699|Drug|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
77633|NCT00045305|Drug|Cyclosporine|Immunosuppressant
77634|NCT01206725|Other|Exercise|Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
77635|NCT01206738|Behavioral|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
77636|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
77637|NCT01209117|Drug|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
73547|NCT01202019|Other|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
73850|NCT01194778|Dietary Supplement|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
73851|NCT01194778|Dietary Supplement|vitamin K1|15 µg vitamin K1 per day during 12 weeks
73852|NCT01194778|Dietary Supplement|vitamin K2|15 µg vitamin K2 per day during 12 weeks
73853|NCT00043979|Drug|vincristine sulfate|Induction - 0.4 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
73854|NCT01194778|Dietary Supplement|vitamin K2|30 µg vitamin K2 per day during 12 weeks
73855|NCT01194778|Dietary Supplement|vitamin K2|45 µg vitamin K2 per day during 12 weeks
73856|NCT01194791|Drug|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
73857|NCT01194791|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
73858|NCT01194791|Drug|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
73859|NCT01194804|Drug|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
73860|NCT01194817|Device|High-Flexion Knee Replacement System using Cemented Fixation|
73861|NCT01194817|Device|High-Flexion Knee Replacement System using Cementless Fixation|
73862|NCT01194830|Drug|Linagliptin|Active drug 1 tablet PO QD
73863|NCT01197326|Device|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
73864|NCT00044291|Procedure|hormone therapy|
73865|NCT01197339|Behavioral|resonant voice|A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
73866|NCT01197339|Behavioral|voice rest|A 4-hr voice rest will be prescribed to subjects following vocal loading.
73867|NCT01197339|Behavioral|Breathy voice|A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.
73868|NCT01197339|Behavioral|Relaxation exercise|A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.
77432|NCT01206270|Drug|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
77433|NCT00045227|Drug|docetaxel|
77434|NCT01206283|Procedure|Modified Lund concept|After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:
Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);
Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;
Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;
Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.
Control of ICP, which can be in majority of patients, kept at values below 15 mmHg.
77435|NCT01206283|Procedure|Cerebral perfusion pressure-targeted therapy|ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);
Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);
No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;
Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes [Na, Cl and K]);
77706|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
77707|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
77708|NCT00000990|Drug|Zidovudine|
77709|NCT00046072|Drug|E5564|
77710|NCT01214421|Drug|Tolvaptan|Daily split-dose of tolvaptan titrated to the maximally tolerated dose. Starting daily tolvaptan dose of 45mg/15mg titrated to 60mg/30mg, then 90mg/30mg based on tolerability.
77711|NCT01214434|Device|Promiseb Topical Cream|topical non steroidal cream, twice daily
77712|NCT01214434|Other|Bland emollient|Eucerin cream twice daily
77713|NCT01214447|Other|No intervention|Observational study - no intervention
77714|NCT01206738|Behavioral|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
77715|NCT01206738|Behavioral|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
77716|NCT01206751|Other|Chest imaging technique and case presentation|
77717|NCT01206764|Drug|RAD001|
77718|NCT01206777|Drug|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
77719|NCT01206790|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
77911|NCT01209572|Device|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
77017|NCT01205620|Device|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
77018|NCT01205620|Other|No intervention|No intervention will be performed in the control group
77019|NCT01205633|Procedure|venous angioplasty|catheter venous angioplasty via femoral vein approach
77020|NCT01205646|Drug|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
77021|NCT01205646|Device|PET Scan|2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
77022|NCT01205672|Drug|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
77023|NCT01205685|Drug|OSI-906|In a pill form by mouth, twice a day (12 hours apart)
During the safety run portion of the study"
Dose level 2 = 150 mg twice a day
Dose level 1 = 100 mg twice a day
Dose level -1 = 100 mg twice a day
Dose level -2 = 100 mg twice a day
77024|NCT00045175|Drug|topotecan hydrochloride|
77025|NCT01205685|Drug|Erlotinib|During the safety run phase of the study:
Dose Level 2 = 100 mg/d
Dose Level 1 = 100 mg/d
Dose Level -1= 75 mg/d
Dose Level -2 = 50 mg/d
77026|NCT01205685|Drug|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
77027|NCT01205685|Drug|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
77028|NCT01205698|Other|Nutritional drink|
77029|NCT01205711|Drug|FOLFIRI regimen|
77030|NCT01205711|Drug|fluorouracil|
77031|NCT01205711|Drug|irinotecan hydrochloride|
77032|NCT01205711|Drug|leucovorin calcium|
77033|NCT01205711|Drug|zibotentan|
77034|NCT01205711|Other|laboratory biomarker analysis|
77035|NCT00045188|Drug|imatinib mesylate|Given PO
77970|NCT01207349|Behavioral|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
77971|NCT01207349|Behavioral|standard follow up|
77972|NCT01207375|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
77973|NCT01207375|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
77974|NCT00000986|Drug|Aldesleukin|
77975|NCT00045305|Radiation|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
77976|NCT01207388|Drug|Blinatumomab|Continuous intravenous infusion
77977|NCT01207401|Drug|Lidocaine|1% Lidocaine
77978|NCT01207414|Drug|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
77979|NCT01207427|Drug|Placebo|
77980|NCT01207427|Drug|ADL5945 0.1 mg|
77981|NCT01207427|Drug|ADL5945 0.25 mg|
77982|NCT01207440|Drug|Ponatinib 45 mg QD|45 mg tablet taken orally once daily (QD)
77983|NCT01207453|Drug|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
77984|NCT01207453|Drug|Placebo|
77985|NCT01207466|Device|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
77986|NCT00045318|Drug|exatecan mesylate|
77987|NCT01207466|Device|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
77988|NCT01207479|Device|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
77989|NCT01207492|Drug|nilotinib|Taken orally twice daily
77990|NCT01207505|Behavioral|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
73869|NCT01197339|Behavioral|Resonant voice and relaxation exercise|A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.
73870|NCT01197352|Behavioral|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
73871|NCT01197352|Behavioral|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
74188|NCT01193166|Drug|risperidone|flexible dosing as prescribed by the study doctor for 12 months
74189|NCT01193166|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
74190|NCT01193166|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
74191|NCT01193166|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
74192|NCT01193166|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
74193|NCT00043875|Drug|lamotrigine|
74194|NCT01193166|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
74195|NCT01193166|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
74196|NCT01193179|Drug|OPC-262|Oral administration of tablets for 52 weeks
74197|NCT01193192|Other|Neevo®|A prenatal "medical food" - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid
74198|NCT01193192|Other|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
74199|NCT01193205|Behavioral|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
74200|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
74201|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
74202|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
74203|NCT01186016|Behavioral|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
77720|NCT01206803|Drug|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg & daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
77721|NCT01206816|Drug|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
77722|NCT00045305|Drug|Methotrexate|Antimetabolite
77723|NCT01206829|Behavioral|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
77724|NCT01206829|Behavioral|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
77725|NCT01206842|Other|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
77726|NCT01206855|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
78057|NCT00000249|Drug|20% N2O|20% inhaled N2O
78058|NCT00000985|Drug|Acyclovir|
78059|NCT00045136|Procedure|peripheral blood stem cell transplantation|
78060|NCT01205126|Drug|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
78061|NCT01205139|Drug|TMC435|150 mg capsule once daily for 7 days
78062|NCT01205139|Drug|TDF|300 mg tablet once daily for 7 days
78063|NCT01205139|Drug|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
78064|NCT01205139|Drug|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
78065|NCT01205139|Drug|TMC278|25 mg tablet once daily for 11 days
78066|NCT01205139|Drug|TMC435|150 mg capsule once daily for 11 days
78067|NCT01205152|Biological|asfotase alfa|
78068|NCT01205165|Drug|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
78069|NCT01205178|Drug|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
77036|NCT01205711|Other|pharmacogenomic studies|
77037|NCT01205724|Drug|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
77038|NCT01205724|Drug|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
77039|NCT01205724|Drug|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
77303|NCT01208662|Drug|Lenalidomide|Oral, 25 mg/day, days 1-14 for 8 total cycles for Arm A. Oral, 25 mg/day, days 1-14 for 5 total cycles for Arm B.
Oral, 10-15 mg/day, daily for 12 months in maintenance for Arm A and Arm B.
77304|NCT01208662|Drug|Bortezomib|IV, days 1, 4, 8 and 11 for 8 total cycles for Arm A. IV, days 1, 4, 8 and 11 for 5 total cycles for Arm B.
77305|NCT01208662|Drug|Dexamethasone|Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 8 total cycles for Arm A. Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 5 total cycles for Arm B.
Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.
77306|NCT01208662|Procedure|Autologous Stem Cell Transplant|Stem cell transplant
77307|NCT01208688|Device|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
77308|NCT01208688|Device|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
77309|NCT01208688|Other|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
77310|NCT01208701|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
77311|NCT00045461|Drug|ifosfamide|
77312|NCT01208701|Drug|Unikalk|1 tablet Unikalk pr day for 5 days
77313|NCT01208714|Drug|Optimal medical therapy|Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.
All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c < 6.5%).
77314|NCT01211275|Biological|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
77991|NCT01207518|Behavioral|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
77992|NCT01207518|Behavioral|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
77104|NCT01213368|Drug|placebo|Pharmaceutical form: tablets
Route of administration: oral
77105|NCT01213381|Drug|Iniparib (SAR240550 - BSI-201)|Pharmaceutical form:sterile aqueous solution
Route of administration: intravenous
77106|NCT00045916|Drug|Lithium|Participants will receive lithium.
77107|NCT01213381|Drug|Gemcitabine|Pharmaceutical form:sterile aqueous solution
Route of administration: intravenous
77108|NCT01213381|Drug|Carboplatin|Pharmaceutical form:sterile aqueous solution
Route of administration: intravenous
77109|NCT01213394|Drug|mycophenolate mofetil|Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.
Target CNI trough levels in the Symphony study:
Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.
Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses* with a target trough level of 3-7 ng/mL (*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)
77110|NCT01213394|Other|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
77111|NCT01205737|Biological|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
77112|NCT01205737|Biological|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
77113|NCT01205750|Other|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
77114|NCT01205776|Device|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
77115|NCT01205776|Procedure|CABG|Those patients receiving CABG
77116|NCT01205802|Procedure|MHV reconstruction|MHV reconstruction with PTFE or homograft
77117|NCT00000985|Drug|Foscarnet sodium|
77118|NCT00045188|Other|laboratory biomarker analysis|Optional correlative studies
77119|NCT01205815|Other|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
74204|NCT01186016|Behavioral|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
74205|NCT01186029|Drug|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
74206|NCT01186042|Other|Observational|No intervention
74207|NCT01186055|Behavioral|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
74208|NCT01186068|Drug|V-101|Cream QD
74506|NCT01188941|Behavioral|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
74507|NCT00043394|Drug|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
74508|NCT01188954|Drug|doxycycline|50 ml/mg
74509|NCT01188954|Other|No intervention|Normal Saline/Water
74510|NCT01188967|Drug|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
74511|NCT01188967|Drug|Placebo|Placebo
74512|NCT01188993|Other|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
74513|NCT01189006|Drug|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
74514|NCT01189019|Drug|ranibizumab|2mg intravitreal injection monthly
74515|NCT01189019|Drug|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
74516|NCT01189032|Drug|DE-089 ophthalmic solution|
78070|NCT00045136|Radiation|holmium Ho 166 DOTMP|
78071|NCT01205178|Drug|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
78072|NCT01205178|Drug|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
78073|NCT01207557|Behavioral|Standard Education Plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
78074|NCT00045331|Genetic|proteomic profiling|
78075|NCT01207570|Procedure|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
78076|NCT01207570|Procedure|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
78077|NCT01207583|Other|Non-interventional observational study|Non-interventional observational study
78078|NCT01207596|Drug|Hydromorphone|Oral hydromorphone extended release, once daily
77178|NCT01213407|Drug|Temozolomide, Surgery, Radiotherapy|Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy
Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6
Break: weeks 7, 8, 9, 10
Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31
77179|NCT01213420|Other|Nivea Cream for scar hydration|3 applications per day during 6 months
77180|NCT01213420|Other|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
77181|NCT01213420|Other|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
77182|NCT01213420|Other|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
77183|NCT00045916|Procedure|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
77184|NCT01213433|Drug|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
77185|NCT01213446|Biological|Biostate|PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.
Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition.
77186|NCT01213459|Procedure|Cervical samples|Human papillomavirus detection and typing in cervical samples.
77315|NCT01211275|Drug|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
77316|NCT01211301|Behavioral|Food-based, Reduced Energy Diet Plan|Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
77564|NCT01209052|Other|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
77565|NCT01209065|Drug|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
77566|NCT01209065|Drug|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
77567|NCT01209065|Drug|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
77568|NCT01209078|Drug|GSK1322322|GSK1322322 1500mg BID
77569|NCT01209078|Drug|Linezolid|Linezolid 600mg
77570|NCT00045500|Drug|prednisone|
77571|NCT01209078|Drug|GSK1322322 placebo|Placebo
77572|NCT01209078|Drug|Linezolid placebo|placebo
77573|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
77574|NCT01211704|Drug|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
77575|NCT01211704|Drug|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
77576|NCT00045721|Procedure|conventional surgery|
77577|NCT01211717|Dietary Supplement|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
77578|NCT01211717|Other|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
77120|NCT01205828|Drug|temozolomide + ABT-888|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
Patents with stable disease or continued response to therapy will be treated and followed for a total of 6 cycles (6 months).
77121|NCT01205841|Procedure|Ottawa Ankle and Foot Rules|As previously published
77122|NCT01205841|Procedure|Buffalo Rule|As previously published
77123|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
77367|NCT01206205|Drug|Lenalidomide, Bortezomib|Induction:
3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14
Consolidation (2 months After ASCT):
2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14
Maintenance Phase:
3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months
77368|NCT01206218|Drug|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
77369|NCT01206218|Drug|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
77370|NCT01206257|Drug|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
77371|NCT01208714|Procedure|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
77372|NCT01208727|Procedure|postconditioning|Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.
77373|NCT01208740|Drug|Metformin|500 mg three times daily
77374|NCT01208740|Drug|Placebo|1 pill three times daily
77375|NCT01208753|Drug|GLPG0555|two different aqueous formulations
77376|NCT01208753|Drug|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
77377|NCT01208753|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
77378|NCT01208766|Drug|Bortezomib, Melphalan, Prednisone (VMP)|Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32
Melphalan _ 9 mg/m² _ p.o. _ days 1-4
Prednisone _ 60 mg/m² _ p.o. _ days 1-4
77379|NCT00045461|Procedure|hyperthermia treatment|
74517|NCT01191190|Drug|Ofatumumab/HDMP|High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.
Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.
Each patient will receive a maximum of 3 cycles (one cycle is 28 days)
74518|NCT01191203|Drug|Copper IUD|Copper IUD (CuT360)
74519|NCT01191203|Drug|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
74520|NCT01191216|Drug|1-methyl-d-tryptophan|
74521|NCT01191216|Drug|docetaxel|
74522|NCT01191216|Other|diagnostic laboratory biomarker analysis|
74523|NCT01191216|Other|pharmacological study|
74524|NCT01191229|Device|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
77542|NCT01206530|Drug|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
77543|NCT01206530|Drug|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
77544|NCT01206530|Drug|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
77545|NCT01206530|Drug|5-fluorouracil|Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.
Treatment Administration: Days 1-2
77546|NCT00045292|Drug|acyclovir sodium|
77547|NCT01206530|Drug|Bevacizumab|
77548|NCT01206543|Other|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
77549|NCT01209013|Procedure|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
77550|NCT01209013|Procedure|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
77551|NCT01209013|Procedure|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
77552|NCT01209013|Procedure|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
77553|NCT01209013|Procedure|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
77187|NCT01213459|Other|Data collection|Questionnaire completion
77188|NCT01213472|Biological|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
77189|NCT01213498|Drug|Atorvastatin|Zarator, 80 mg pr. day for 5 days
77190|NCT01213498|Drug|Unikalk|1 tablet Unikalk pr day for 5. days
77191|NCT01213511|Procedure|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
77192|NCT01213511|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
77193|NCT01213524|Behavioral|sensorimotor replacement|denicotinized cigarettes
77194|NCT00045942|Drug|PKC412, an inhibitor of FLT3|
77436|NCT01206296|Drug|Intraperitoneal Gemcitabine|Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2
Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles
77437|NCT01206322|Drug|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
77438|NCT01206322|Drug|Placebo|The acute effects of intranasal sterile saline.
77439|NCT01206335|Drug|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
77440|NCT01206348|Drug|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
77441|NCT01206361|Drug|XALACOM|Xalacom eye drops
77442|NCT01206361|Drug|Duotrav|Duotrav eye drops
77443|NCT01206361|Drug|Ganfort|Ganfort eye drops
77444|NCT00045266|Biological|ziv-aflibercept|
77445|NCT01206387|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
77579|NCT01211730|Drug|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
77580|NCT01211743|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
77581|NCT01211743|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
77582|NCT01211756|Drug|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
77912|NCT01209572|Device|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
77913|NCT01209585|Other|Blood samples|Subjects will have visits on Days 1, 30 and 120.
77914|NCT01209585|Other|Synovial fluid aspiration|Subjects will have visits on Days 1, 30, and 120.
77915|NCT00045565|Drug|arsenic trioxide|Given IV
77916|NCT01209585|Other|Synovial tissue sample|Subjects will have visits on Days 1, 30, and 120.
77917|NCT01209598|Drug|Palbociclib|Treatment will consist of either:
Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.
Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food.
77918|NCT01209611|Procedure|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
77919|NCT01209611|Procedure|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
77920|NCT01209637|Behavioral|exercise training|exercise training min. 4 times a day for at least 30 min
77921|NCT01209637|Behavioral|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
77922|NCT01209650|Drug|BIBW 2992|tablets
77923|NCT01209663|Other|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
77924|NCT01209676|Drug|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
77925|NCT01212380|Other|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
77380|NCT01208766|Drug|1 or 2 cycle(s) HDM (High Dose Melphalan)|- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2*
*Patients with renal insufficiency 100 mg/m2 only at day -3
If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.
77381|NCT01208766|Drug|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11
Lenalidomide _ 25 mg _ p.o. _ days 1-21
Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12
77382|NCT01208792|Procedure|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
77383|NCT01208792|Other|Blood Sample|a blood sample will be collected
77384|NCT01208805|Behavioral|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
77638|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
77639|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
77640|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
77641|NCT01209117|Drug|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
77642|NCT01209130|Drug|DCDT2980S|Intravenous repeating dose
77643|NCT00045513|Drug|7-hydroxystaurosporine|
77644|NCT01209130|Drug|rituximab|Intravenous repeating dose
77645|NCT01209143|Drug|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
77646|NCT01209143|Drug|Rosiglitazone|Rosiglitazone was supplied in tablets.
77647|NCT01209143|Drug|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
77648|NCT01209156|Drug|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of [18F]PBR111, followed by PET imaging.
77649|NCT01209195|Drug|MM-121 plus Paclitaxel|Cohort 1:
MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV
Cohort 2:
MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV
Intermediate doses between cohorts 1 and 2 may also be considered.
77650|NCT01209208|Drug|Budesonide|9 mg per day
77651|NCT01209208|Drug|Mesalamine|3 g per day
77554|NCT01209026|Drug|Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination|Novel dry powder inhaler
77555|NCT01209026|Drug|Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination|Novel dry powder inhaler
77556|NCT01209026|Drug|Placebo Inhaler|Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
77557|NCT01209026|Drug|Moxifloxacin 400mg|Film coated oral tablet
77558|NCT01209026|Drug|Moxifloxacin placebo|Film coated oral tablet
77559|NCT00045500|Drug|7-hydroxystaurosporine|
77560|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
77561|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
77562|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
77563|NCT01209052|Drug|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
77833|NCT01207128|Drug|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
77834|NCT01207180|Other|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
77835|NCT01209442|Drug|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
77836|NCT01209442|Radiation|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
77837|NCT01209455|Drug|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
77838|NCT01209455|Drug|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of ~12 mg/l. To achieve a desired concentration of ~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
77839|NCT01209455|Drug|Paracetamol|To achieve a local paracetamol concentration of ~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
77840|NCT01209468|Device|monobloc oral appliance|one piece oral appliance
77446|NCT01206387|Drug|placebo comparator|Placebo administered to affected area twice a day for 28 days
77447|NCT01206413|Dietary Supplement|Low glycemic index diet|
77448|NCT01206413|Dietary Supplement|High glycemic index diet|
77449|NCT01206413|Other|Home-based exercise intervention|
77450|NCT01206413|Other|Non-exercisers|
77451|NCT01206439|Drug|nebivolol|nebivolol 5 or 10 mg oral, daily
77452|NCT01206452|Drug|Ablation plus prednisone|Ablation procedure plus 60mg of oral prednisone 2 days before procedure, 1 day before procedure, and day of procedure
77453|NCT01206452|Drug|Ablation plus placebo|Ablation procedure plus placebo 2 days before procedure, 1 day before procedure, and day of procedure
77454|NCT01206465|Drug|pralatrexate|Given IV
77455|NCT01208870|Behavioral|Habituation theory and Pediatric Obesity|The intervention will consist of our traditional family based weight control intervention with elements of habituation theory included for the experimental group.
77456|NCT01208883|Other|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment [18F]FDG-PET for treatment adaptation
77457|NCT01208896|Drug|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
77727|NCT01206855|Other|Standard Postoperative Incision Care|Incision cleansing, topical creams, and dressing as needed
77728|NCT01206868|Procedure|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
77729|NCT01206868|Procedure|Control|Standard kidney transplantation
77730|NCT01206881|Drug|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
77731|NCT01206894|Procedure|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
77732|NCT01206907|Drug|oxymorphone IR|oxymorphone IR liquid
77733|NCT00045305|Drug|Photopheresis|Psoralens
77734|NCT01206946|Drug|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
77926|NCT00045760|Drug|Drotrecogin alfa (activated)|
77927|NCT01212380|Other|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
77928|NCT01212393|Behavioral|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
77040|NCT01208207|Drug|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
77041|NCT01208207|Drug|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
77042|NCT01208207|Drug|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
77043|NCT00045435|Radiation|total-body irradiation|Undergo TBI
77044|NCT01208207|Drug|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
77045|NCT01208207|Drug|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
77046|NCT01208207|Drug|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
77047|NCT01208207|Drug|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
77048|NCT01208207|Drug|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
77049|NCT01208207|Drug|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
77050|NCT01208207|Drug|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
77051|NCT01208220|Device|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
77052|NCT01208220|Biological|Collagenase Ointment|Apply TIW
77053|NCT01208233|Drug|PF-03049423|1 mg of PF-03049423 daily for 90 days
77054|NCT00045435|Drug|cyclosporine|Given PO
77055|NCT01208233|Drug|PF-03049423|3 mg of PF-03049423 daily for 90 days
73728|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
73729|NCT01202279|Drug|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
73730|NCT01202279|Device|Placebo|Placebo bid for 7 days
73731|NCT01202292|Behavioral|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
73732|NCT01202305|Procedure|Lymph node biopsy|Inguinal lymph node biopsy
73733|NCT01202331|Drug|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
73734|NCT01202344|Other|Additional x-ray images|Approximately 3 additional x-ray images following angioplasty (within 1 hour)
73735|NCT01202357|Behavioral|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
73736|NCT00044863|Biological|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
73737|NCT01202370|Drug|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 & 15 of a 21 day cycle (7.5 mg/m^2).
73738|NCT01202383|Behavioral|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
73739|NCT01202383|Behavioral|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
73740|NCT01202409|Drug|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
73741|NCT01194505|Other|Sciatic nerve block, posterior lumbar plexus block|Ultrasound and neurostimulator nerve blocks with ropivacaine
73742|NCT01194518|Behavioral|Lifestyle Intervention Program|
73743|NCT01194531|Device|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
73744|NCT01194557|Device|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
73745|NCT01194557|Drug|Lumartem|Presumptive treatment of malaria/fever
74457|NCT00043927|Drug|topotecan/cisplatin|
74458|NCT01193517|Drug|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
74459|NCT01193517|Drug|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
74460|NCT01193517|Drug|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
74461|NCT01193530|Device|Bright Light Therapy Device|30 minutes every day for 14 days.
74462|NCT01193530|Device|Dim Red Light Therapy Device|Initially 30 minutes every day for 14 days where red light device accounts for placebo.
73483|NCT01196728|Drug|CM3.1-AC100|SAD study with single ascending subcutaneous doses
73484|NCT00044213|Dietary Supplement|High Dose Vitamin Placebo|
73485|NCT01196741|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
73486|NCT01196741|Drug|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
73487|NCT01196741|Drug|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
73488|NCT01196754|Other|sevoflurane|
73489|NCT01196767|Drug|Ropivacaine (in one arm); catheterization (in both).|Parallel study with two groups:
ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.
same protocol, with normal saline instead of ropivacaine.
73490|NCT01196819|Procedure|DES implantation|Implant DES for CAD cases
73491|NCT01196832|Procedure|blood sample|blood sample for fibrocytes analysis
73492|NCT01196832|Procedure|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
73493|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
73494|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
73495|NCT00044226|Drug|ML-04A|
73496|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
74245|NCT01188655|Drug|Enbrel|The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.
74246|NCT01188668|Drug|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
74247|NCT01188668|Drug|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
74248|NCT01190813|Drug|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
74249|NCT01190813|Drug|Placebo|Oral placebo tid
74250|NCT01190813|Other|Patching|Two hours of daily patching
74251|NCT01190826|Drug|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
73267|NCT00044785|Drug|fluorouracil|
73268|NCT01201538|Drug|Nilotinib|
73269|NCT01201551|Drug|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
73270|NCT01201551|Drug|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
73271|NCT01201551|Drug|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
73272|NCT01201564|Procedure|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
73273|NCT01201564|Procedure|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
73274|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536|2 capsules od
73275|NCT01201577|Dietary Supplement|Active hexose correlated compound (AHCC)|One capsule tds
73276|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
73277|NCT01201577|Dietary Supplement|Corn starch placebo capsule|One capsule tds and two capsules od
73278|NCT01203969|Procedure|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
73988|NCT01197664|Other|laboratory biomarker analysis|Correlative studies
73989|NCT00044343|Drug|lapatinib|
73990|NCT01197664|Drug|fluorouracil|Given PO
73991|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
73992|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
73993|NCT01199900|Drug|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
73994|NCT00044655|Drug|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
73995|NCT01199900|Drug|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
73996|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
73997|NCT01199900|Drug|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
73998|NCT01199913|Other|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
73999|NCT01199926|Dietary Supplement|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
74000|NCT01199926|Drug|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
74001|NCT01199939|Drug|Etravirine|400mg once daily orally for 48 weeks
74002|NCT01199939|Drug|Ritonavir|100mg once daily orally for 48 weeks
74312|NCT01186315|Behavioral|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
74313|NCT01186315|Behavioral|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use & CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
74314|NCT01186328|Drug|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29.
74315|NCT01186328|Drug|Cytarabine|Given intrathecally on day -6 at the dose defined by age. Age 1-1.99 get 30 mg, age 2-2.99 get 50 mg, and age greater than or equal to 3 get 70 mg.
74062|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
74063|NCT01190553|Drug|Amantadine|Initiation: IV amantadine 200mg/500ml * 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
74064|NCT01190592|Other|Resistance Training with Milk Supplementation in Adolescents|On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.
On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day.
74065|NCT01190631|Device|Acrysof IQ (SN60WF) IOL|Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
74066|NCT01190644|Drug|ACE 011|35 mg subcutaneous (SC) dose on study Day 1, Day 43, Day 85
74067|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 14 days
74068|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 56 days
74069|NCT01190670|Drug|Tacrolimus|Oral and Intravenous
74070|NCT01190670|Drug|ASP015K|Oral
74071|NCT01190683|Drug|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
74072|NCT00043550|Behavioral|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
74073|NCT01190683|Drug|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
74074|NCT01190683|Drug|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
74075|NCT01190683|Other|lactose placebo|similar number of granules and tablets as active group
74076|NCT01190683|Other|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
74077|NCT01190696|Procedure|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
74078|NCT01190696|Device|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
73497|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
73498|NCT01196871|Drug|AT1001|Capsules, single dose
73499|NCT01196897|Device|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
73500|NCT01196910|Device|treatment by HLPFC coil|DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).
Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase.
73501|NCT01196923|Device|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
73502|NCT01196936|Drug|Tamoxifen Citrate|5 mg PO Daily
73503|NCT01196936|Drug|Placebo|1 tablet daily
73807|NCT01199757|Drug|Fluticasone furoate|cohort of patients receiving fluticasone furate
73808|NCT01199757|Drug|mometasone furoate|cohort receiving mometasone furoate
73809|NCT01199757|Drug|fluticasone propionate|cohort of patients on fluticasone propionate
73810|NCT00044655|Drug|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
73811|NCT01199770|Other|Control, small|control pasta, small portion
73812|NCT01202422|Drug|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
73813|NCT01202422|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
73814|NCT01202422|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
73815|NCT01202435|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
73816|NCT01202435|Drug|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
73817|NCT01202448|Procedure|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
73818|NCT00044876|Drug|CDB-2914|
73279|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 5mg/day for one year
73280|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 40mg/day for one year
73281|NCT01203995|Behavioral|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
73282|NCT00044993|Drug|docetaxel|
73283|NCT01203995|Behavioral|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
73284|NCT01204008|Procedure|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
73285|NCT01204008|Procedure|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
73286|NCT01204021|Behavioral|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
73287|NCT01204021|Behavioral|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
73588|NCT01196949|Other|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
73589|NCT01196949|Other|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
73590|NCT01196962|Device|Central venous catheter|Central venous catheter insertion to subclavian vein
73591|NCT00044278|Drug|lamotrigine|
73592|NCT01196975|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
73593|NCT01196975|Biological|FluLavalTM-VB|Single intramuscular dose
73594|NCT01196975|Biological|FluLavalTM-YB|Single intramuscular dose
73595|NCT01196988|Biological|Influenza vaccine GSK2321138A|intramuscular injections
73596|NCT01196988|Biological|FluarixTM|intramuscular injections
73597|NCT01196988|Biological|Influenza vaccine GSK2604409A|intramuscular injections
74316|NCT01188681|Other|TRU-016 and bendamustine|15 mg/kg and 20 mg/kg TRU-016 by IV infusion weekly for the first two 28-day cycles and then every 14 days for the next four 28-day cycles. Bendamustine (70 mg/m2) by IV infusion on Days 1 and 2 of each 28-day cycle.
74317|NCT01188681|Other|TRU-016 and bendamustine|TRU-016 (n = 33 patients), at selected dose from Phase 1b, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
74318|NCT01188681|Drug|Bendamustine|70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
74319|NCT01188694|Drug|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
74320|NCT00043368|Drug|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
74321|NCT01188694|Behavioral|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
74322|NCT01188694|Behavioral|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
74323|NCT01188707|Drug|Belinostat and Erlotinib|The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.
When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.
3 patients will be treated at each dose level.
74324|NCT01188720|Behavioral|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
74325|NCT01188733|Drug|Long acting octreotide 10mg|Comparison of different doses
74326|NCT01188733|Drug|Long acting Octreotide 30mg|Comparison of drug doses
74327|NCT01188733|Drug|Saline|Comparison of drug doses
73353|NCT00044785|Drug|leucovorin|
73354|NCT01201577|Drug|Azithromycin|250mg od
73355|NCT01201590|Dietary Supplement|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
73356|NCT01201590|Dietary Supplement|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
73357|NCT01201603|Dietary Supplement|orange juice|250ml of orange juice or a sugars matched orange drink
74079|NCT01192867|Drug|Placebo|Oral doses, once a day for 52 weeks
74080|NCT01192867|Drug|RO4917838|Oral dose level 1, once a day for 52 weeks
74390|NCT01186328|Drug|Methotrexate|Given intrathecally to patients with central nervous system 1 and central nervous system 2 disease at the dose defined by age below on days 15 and 36.
Age 1-1.99 get 8 mg, age 2-2.99 get 10 mg, age 3-8.99 get 12 mg and greater than or equal to age 9 get 15 mg.
74391|NCT01186354|Behavioral|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
74392|NCT01186367|Behavioral|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline. The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
74393|NCT01186367|Behavioral|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and and as well as the CPET performed at Week 8. The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
74394|NCT01186367|Behavioral|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes). All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
74395|NCT01186367|Other|Cardiopulmonary exercise test (CPET)|
74396|NCT00043082|Drug|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
74397|NCT01186367|Other|Blood draws|Complete blood count
74398|NCT01186380|Device|PET-512MC|Transesophageal Transducer
74399|NCT01186393|Behavioral|Control|Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
74400|NCT01186393|Behavioral|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
74401|NCT01186393|Behavioral|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
74402|NCT01186406|Drug|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
74403|NCT01186406|Radiation|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
75321|NCT01185613|Device|Therapy™ Cool Flex Ablation Catheter|The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.
The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter
IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.
Cool Point™ Irrigation Pump
Cool Point™ Tubing set
Data Logger
75322|NCT01185626|Other|SCP care|
75323|NCT01185639|Radiation|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
75675|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
75676|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
75677|NCT01220336|Behavioral|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model [Bodenheimer 2007] for 12 months.
75678|NCT01220349|Device|Echocardiographic 2D strain analysis|Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
75679|NCT01220362|Drug|Bupivacain 0.125%|Bupivacain 0.125%
75680|NCT01220362|Drug|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
75681|NCT01220375|Drug|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
75682|NCT01222572|Radiation|Stereotactic boost|
75683|NCT01222572|Radiation|Conventional RT|
75684|NCT01222572|Drug|Etoposide|
75685|NCT01222572|Drug|Cisplatin|
75686|NCT00047034|Other|laboratory biomarker analysis|Correlative studies
75687|NCT01222585|Drug|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with >=14 postnatal days and every 24 hours for infants <14 postnatal days.
75688|NCT01222611|Drug|Fosamprenavir|HAART including fosamprenavir boosted with ritonavir
73598|NCT01197001|Drug|Amlodipine plus Losartan|Amlodipine/Losartan low dose
73599|NCT01197001|Drug|Amlodipine, Losartan|Amlodipine, Losartan
73600|NCT01197014|Drug|Amlodipine plus Losartan|Amlodipine/Losartan high dose
73601|NCT01197014|Drug|Amlodipine, Losartan|Amlodipine, Losartan
73602|NCT00044291|Drug|atamestane|
73603|NCT01197027|Behavioral|Standard counseling|Standard HIV counseling
73604|NCT01197040|Drug|acid mycophenolic (Myfortic)|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
73605|NCT01197040|Drug|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
73606|NCT01199341|Drug|AZD1981|4 x 100 mg per oral, twice daily for 14 days
73607|NCT01199354|Procedure|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
73914|NCT01202643|Drug|Saline|One intrauterine saline infusions of 1 cc
73915|NCT01202656|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
73916|NCT00044902|Drug|epratuzumab|
73917|NCT01202656|Drug|Saline|intrauterine saline infusion 1 cc
73918|NCT01202669|Other|No intervention planned, observational study only.|No intervention planned, observational study only.
73919|NCT01202695|Drug|AVP-21D9|intravenously, single dose
73920|NCT01202695|Drug|Placebo|Placebo comparator
73921|NCT01202721|Drug|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
73922|NCT01202721|Drug|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
73923|NCT01202734|Drug|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
73924|NCT01202747|Device|LipiFlow System|In-office treatment for meibomian gland dysfunction
73358|NCT01201616|Other|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
73359|NCT01201616|Other|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
73360|NCT01201629|Device|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
73361|NCT01201629|Device|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
73362|NCT01201642|Drug|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
73363|NCT01201642|Device|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
73364|NCT00044785|Drug|camptosar|
73365|NCT01201642|Other|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
73366|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
73367|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
73368|NCT01201707|Procedure|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
73369|NCT01201707|Other|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
73370|NCT01201720|Procedure|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
73668|NCT01194453|Drug|cisplatin, dexamethasone,vitamin B12, folic acid|Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
73669|NCT01194453|Drug|cisplatin, gemcitabine|cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
74404|NCT01186406|Drug|Avastin|Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.
Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days.
74405|NCT01188772|Drug|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
74406|NCT01188772|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
73435|NCT01199133|Drug|Dpte and Dfar Allergen Extracts|300 IR, once a day, for one year.
73436|NCT01199133|Drug|placebo|once a day, for one year.
73437|NCT01199146|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
73438|NCT01199159|Drug|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
73439|NCT01199159|Drug|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
73440|NCT01199172|Behavioral|voice hygiene|subjects will receive voice hygiene training
73441|NCT01199172|Behavioral|VH + VP|subjects will be trained in voice hygiene and voice production training
73442|NCT00044577|Drug|lamivudine|
73443|NCT01199185|Behavioral|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
73444|NCT01199185|Behavioral|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
73445|NCT01199198|Drug|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
73446|NCT01201746|Procedure|Periodontal therapy|Scaling, root planning and oral hygiene instructions
73447|NCT00044798|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 treatments of rTMS over 3 weeks.
75689|NCT01222624|Drug|PankoMab-GEX™|
75690|NCT01222637|Drug|CetuGEX™|
75691|NCT01222650|Drug|KSO-0400|
75692|NCT01222650|Drug|KSO-0400|
75693|NCT01222650|Drug|Silodosin|
75694|NCT01222650|Drug|Placebo|
75695|NCT01222663|Device|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
74775|NCT01191697|Drug|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
74776|NCT00043693|Behavioral|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
74777|NCT01191697|Drug|trastuzumab|Given intravenously on day 1 of each treatment cycle
74778|NCT01191697|Drug|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
74779|NCT01191697|Drug|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
74780|NCT01191710|Other|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
74781|NCT01191723|Drug|MAP0004|3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
74782|NCT01191723|Drug|Inhaler Placebo|Placebo for Inhaler administered in Treatments A and C
74783|NCT01191723|Drug|Moxifloxacin|400mg encapsulated tablet administered in Treatment A as per protocol
74784|NCT01191723|Drug|Placebo Capsule|Placebo for Moxifloxacin administered in Treatment B and Treatment C
74785|NCT01191736|Behavioral|No training, assessed within 60 mins|Subjects receive no training in resuscitation
74786|NCT01191736|Behavioral|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
74787|NCT00043693|Behavioral|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
74788|NCT01191736|Behavioral|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
73925|NCT01202760|Drug|LY2127399|Administered Subcutaneously
73926|NCT01202760|Drug|Placebo every 4 weeks|Administered Subcutaneously
73927|NCT00000983|Drug|Zidovudine|
73928|NCT00044915|Drug|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
73929|NCT01202760|Drug|Placebo every 2 weeks|Administered Subcutaneously
73930|NCT01202773|Drug|LY2127399|Administered Subcutaneously
73931|NCT01202773|Drug|Placebo every 4 weeks|Administered Subcutaneously
73932|NCT01202773|Drug|Placebo every 2 weeks|Administered Subcutaneously
73933|NCT01202799|Drug|2% w/w diclofenac sodium topical gel|2% w/w diclofenac sodium topical gel
73934|NCT01202799|Drug|1.5% w/w diclofenac sodium topical solution|1.5% w/w diclofenac sodium topical solution
73935|NCT01202799|Drug|75 mg diclofenac sodium delayed release tablet|75 mg diclofenac sodium delayed release tablet
73936|NCT01202812|Dietary Supplement|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
73937|NCT01202812|Other|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
73938|NCT01202825|Drug|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
74252|NCT01190826|Drug|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
74253|NCT01190826|Drug|Placebo|Placebo administered once by inhalation
74254|NCT01190839|Biological|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
74255|NCT01190839|Drug|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
74256|NCT01190852|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
74257|NCT01190852|Drug|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
74258|NCT00043550|Drug|Venlafaxine|Participants will receive venlafaxine.
73670|NCT01194466|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
73671|NCT01194479|Drug|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
73672|NCT01194492|Radiation|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
73673|NCT01194505|Other|Sciatic, femoral, obturator nerve blocks|Ultrasound guided blocks with ropivacaine
73674|NCT00043979|Drug|melphalan|Transplant - 100 mg/m^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
73675|NCT01197053|Biological|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
73676|NCT01197053|Biological|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
73677|NCT01197066|Drug|Certolizumab Pegol|Certolizumab Pegol 200mg
73678|NCT01197079|Other|Survey|Self administered anonymous survey
73679|NCT01197092|Dietary Supplement|Mitochondrial preparations|Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:
ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)
73680|NCT01197092|Dietary Supplement|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
73681|NCT01197092|Device|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
73682|NCT00000248|Drug|Pergolide|
73683|NCT00000978|Drug|Zalcitabine|
73684|NCT00044291|Drug|toremifene|
73685|NCT01197092|Behavioral|Nutritional therapy|Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called "silent inflammation" (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts.
74003|NCT01199939|Drug|Darunavir|800mg once daily orally for 48 weeks
74004|NCT01199952|Behavioral|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
73448|NCT01201759|Drug|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
73449|NCT01201759|Drug|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
73450|NCT01201772|Drug|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
73746|NCT01194570|Drug|Placebo|Ocrelizumab placebo, 2 infusions separated by 14 days in each treatment cycle
73747|NCT01194570|Drug|methylprednisolone|100 mg iv 30 minutes prior to ocrelizumab or placebo infusion
73748|NCT01194570|Drug|ocrelizumab|2 intravenous infusions of 300 mg separated by 14 days in each treatment cycle
73749|NCT01194596|Behavioral|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
73750|NCT01194596|Behavioral|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
73751|NCT00043979|Drug|prednisone|Induction - 60 mg/m^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
73752|NCT01194609|Biological|Immune cell|InnoLak two consecutive weeks every 3 weeks for 3 times
73753|NCT01194609|Radiation|Low dose radiation|20cGy whole body radiation every three weeks for three times
73754|NCT01194622|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
73755|NCT01194622|Drug|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
73756|NCT01194622|Drug|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
73757|NCT01194635|Genetic|fluorescence in situ hybridization|
73758|NCT01194635|Genetic|gene expression analysis|
73759|NCT01194635|Genetic|polymerase chain reaction|
73760|NCT01194635|Genetic|protein analysis|
74789|NCT01191736|Behavioral|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
74790|NCT01193842|Other|Pharmacological Study|Correlative studies
74791|NCT00043953|Drug|Lamivudine/zidovudine|
74792|NCT01193842|Drug|Prednisone|Given PO
74793|NCT01193842|Biological|Rituximab|Given IV
74794|NCT01193842|Drug|Vincristine Sulfate|Given IV
74795|NCT01193842|Drug|Vorinostat|Given PO
74796|NCT01193855|Drug|dutasteride|
74797|NCT01193855|Drug|gadolinium-chelate|
74798|NCT01193855|Other|active surveillance|
74799|NCT01193855|Procedure|diffusion-weighted magnetic resonance imaging|
75066|NCT01185054|Other|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
75067|NCT01185067|Drug|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
75068|NCT01185080|Drug|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
75069|NCT01185080|Drug|Placebo|Nasal spray solution, intranasal, three times weekly for one month
75070|NCT01185080|Drug|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
75071|NCT00043004|Drug|FOLFOX regimen|
75072|NCT01185119|Drug|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
75073|NCT01185132|Radiation|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
75074|NCT01185132|Radiation|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
74259|NCT01190852|Drug|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
74260|NCT01190865|Biological|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
74261|NCT01190878|Drug|ISV-303|% of Bromfenac in DuraSite Dosed QD
74262|NCT01190878|Drug|ISV-303|% of Bromfenac in DuraSite Dosed BID
74263|NCT01190878|Drug|DuraSite Vehicle|Vehicle Dosed BID
74264|NCT01190878|Drug|Xibrom™|Xibrom dosed BID
74265|NCT01190891|Procedure|Manual Physical Therapy|Same as arm description
74266|NCT01190891|Procedure|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
74267|NCT01190917|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
74268|NCT01190917|Behavioral|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
74269|NCT00043563|Behavioral|Cognitive-Behavior Therapy|
74270|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
73288|NCT01204034|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
73289|NCT01204060|Other|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
73290|NCT01204060|Other|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
73291|NCT01204073|Drug|TAK-441|TAK-441 will be administered as an oral tablet as follows:
Patients enrolled in the dose escalation cohorts will receive:
A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed
Continuous daily dosing on Days 8 through 28 in Cycle 1
In subsequent cycles, continuous daily dosing over 21 days, repeated continuously
Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle
74005|NCT00044668|Drug|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
74006|NCT01199965|Drug|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
74007|NCT01199965|Drug|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
74008|NCT01199978|Radiation|Fractionated proton radiation|Given daily for approximately 5.5 weeks
74009|NCT01200004|Drug|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
74010|NCT01200004|Drug|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
74011|NCT01200004|Drug|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
74012|NCT01200017|Biological|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
74013|NCT01200030|Behavioral|electrical stimulation with exercises|electrical stimulation with exercises
74014|NCT01200030|Behavioral|placebo stimulation with exercises|placebo stimulation with exercises
74015|NCT01200043|Other|fructose restriction diet|fruits and vegetables only
74016|NCT00000981|Drug|Fiacitabine|
74017|NCT01202825|Drug|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
74018|NCT01202825|Drug|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
74019|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
74020|NCT01202825|Drug|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
74021|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
74022|NCT01202825|Drug|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
74023|NCT01202825|Drug|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
73761|NCT01194635|Genetic|protein expression analysis|
73762|NCT00043979|Drug|sirolimus|Initiated on day +3. Patients >40kg, the initial dose will be 2 mg every 24 hours orally. Patients <40 kg, the initial dose will be 1 mg/m^2.
73763|NCT01194635|Other|enzyme-linked immunosorbent assay|
73764|NCT01194635|Other|immunohistochemistry staining method|
73765|NCT01194635|Other|laboratory biomarker analysis|
73766|NCT01194648|Other|questionnaire administration|
73767|NCT01194648|Procedure|assessment of therapy complications|
73768|NCT00044291|Drug|letrozole|
74081|NCT00000974|Drug|Pentamidine isethionate|
74082|NCT00043823|Drug|Tarceva|100 mg By Mouth Daily for 3 Weeks
74083|NCT01192867|Drug|RO4917838|Oral dose level 2, once a day for 52 weeks
74084|NCT01192880|Drug|Placebo|Oral doses, once a day for 52 weeks
74085|NCT01192880|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
74086|NCT01192880|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
74087|NCT01192906|Drug|Placebo|Oral doses, once a day for 52 weeks
74088|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
74089|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
74090|NCT01192932|Radiation|Chest CT scan|Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)
90 quality ref mAs with care-dose ON
120 kV
Pitch 1.4
Rotation time 0.33 s
Acquired images 64 x 0.6 mm
74091|NCT01192971|Drug|Apatinib|apatinib p.o. once daily for 4 weeks
74092|NCT01192984|Biological|KW-0761|Intravenously 8 times at 1-week intervals
74093|NCT00043836|Drug|ALT-711|
74094|NCT01192997|Biological|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
74095|NCT01192997|Biological|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
75075|NCT01185145|Radiation|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
75076|NCT01187485|Drug|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
75077|NCT00043147|Drug|methylprednisolone|
75078|NCT01187485|Drug|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
75079|NCT01187498|Behavioral|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
75080|NCT01187498|Drug|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
75081|NCT01187511|Drug|GSK561679|
75082|NCT01187511|Drug|Placebo|
75083|NCT01187537|Procedure|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to < 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
75324|NCT01185665|Device|TENS|Transcutaneous Electrical Nerve Stimulator
75325|NCT00043017|Procedure|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
75326|NCT01185665|Device|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
75327|NCT01185678|Drug|Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)|One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
75328|NCT01185691|Device|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
75329|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
75330|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
75331|NCT01185704|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
73292|NCT01204086|Drug|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
73293|NCT00044993|Drug|doxorubicin hydrochloride|
73294|NCT01204086|Drug|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
73295|NCT01204099|Drug|Docetaxel|
73296|NCT01204099|Drug|PX-866|
73297|NCT01204112|Drug|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
73298|NCT01204125|Drug|paclitaxel|Pharmaceutical form:solution for infusion
Route of administration: intravenous
73299|NCT01204125|Drug|Iniparib (SAR2405550 -BSI-201)|Pharmaceutical form : solution for infusion
Route of administration :Intravenous
73300|NCT01204138|Drug|Apremilast|Apremilast 30mg BID
73301|NCT01204138|Drug|Placebo|Placebo BID
73302|NCT01204151|Behavioral|discrete-trial training|
73303|NCT01196403|Procedure|quality-of-life assessment|
73304|NCT01196403|Procedure|robot-assisted laparoscopic surgery|
73305|NCT01196403|Procedure|therapeutic conventional surgery|
73306|NCT01196403|Procedure|therapeutic laparoscopic surgery|
73307|NCT01196416|Drug|Cisplatin|Given IV
73308|NCT01196416|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
73309|NCT01196416|Other|Laboratory Biomarker Analysis|Correlative studies
73310|NCT01196416|Other|Pharmacological Study|Correlative studies
73608|NCT01199367|Drug|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
74328|NCT01188746|Behavioral|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
74329|NCT01188759|Drug|Voriconazole|For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:
Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.
For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:
Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.
Voriconazole therapy is to be given for 6-12 weeks.
74330|NCT01188759|Drug|Anidulafungin|Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).
Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole.
74331|NCT00043381|Drug|decitabine (5-aza-2'deoxycytidine)|
74332|NCT01188759|Drug|Voriconazole|For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:
Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.
For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:
Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.
Voriconazole therapy is to be given for 6-12 weeks.
74333|NCT01188772|Drug|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
74334|NCT01190930|Drug|Cyclophosphamide|Given IV
74335|NCT01190930|Drug|Cytarabine|Given IT, IV, or SC
74336|NCT01190930|Drug|Dexamethasone|Given orally (PO) or IV
74337|NCT01190930|Drug|Doxorubicin Hydrochloride|Given IV
74338|NCT01190930|Other|Laboratory Biomarker Analysis|Correlative studies
74339|NCT01190930|Drug|Leucovorin Calcium|Given PO
74340|NCT01190930|Drug|Mercaptopurine|Given PO
74341|NCT01190930|Drug|Methotrexate|Given IT, PO, or IV
74342|NCT01190930|Drug|Pegaspargase|Given IV
74343|NCT01190930|Other|Quality-of-Life Assessment|Ancillary studies
74344|NCT00043576|Drug|calcitriol|
74345|NCT01190930|Other|Questionnaire Administration|Ancillary studies
74346|NCT01190930|Drug|Thioguanine|Given PO
74096|NCT01193010|Procedure|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
74097|NCT01193010|Procedure|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
74098|NCT01193023|Other|Pressure Support|Ventilation under pressure support
74099|NCT01193023|Device|NAVA|Ventilation under NAVA
74100|NCT01193036|Behavioral|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
74101|NCT01193036|Behavioral|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
74102|NCT01193049|Drug|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
74103|NCT01193049|Drug|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
74104|NCT00043849|Drug|Quetiapine|
74407|NCT01188772|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
74408|NCT01188785|Drug|siG12D LODER|Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.
Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle.
74409|NCT01188798|Drug|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
74410|NCT01188798|Drug|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
74411|NCT01188811|Drug|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
74412|NCT01188811|Drug|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
74413|NCT00043394|Drug|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
74414|NCT01188824|Drug|Cilostazol|100 mg, bid p.o.
74415|NCT01188824|Other|placebo|1 tablet, bid
75332|NCT00043212|Drug|Dendritic cell immunotherapy|
75333|NCT01188005|Drug|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
75334|NCT01188018|Behavioral|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
75335|NCT01188018|Behavioral|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
75336|NCT01188018|Behavioral|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
75337|NCT01188031|Drug|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
75338|NCT01188031|Drug|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
75339|NCT01188057|Drug|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
75340|NCT01188057|Drug|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
75341|NCT01188070|Behavioral|Usual Care|Educational materials
75342|NCT01188070|Behavioral|Psycho-education|Educational group sessions
75696|NCT01222663|Device|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
75697|NCT00047047|Drug|gemcitabine hydrochloride|Given IV
75698|NCT01222676|Drug|cisplatin|
75699|NCT01222676|Drug|gemcitabine hydrochloride|
75700|NCT01222676|Drug|sorafenib tosylate|
75701|NCT01222676|Other|imaging biomarker analysis|
75702|NCT01222676|Other|laboratory biomarker analysis|
75703|NCT01222676|Procedure|computed tomography|
73609|NCT01199380|Behavioral|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
73610|NCT01199380|Behavioral|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
73611|NCT01199380|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
73612|NCT01199406|Drug|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
73613|NCT01199419|Procedure|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
73614|NCT01199432|Drug|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
73615|NCT00000980|Drug|Spiramycin|
73616|NCT00044629|Behavioral|Cognitive-Behavioral Therapy for Insomnia|
73617|NCT01199432|Drug|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
73618|NCT01199432|Drug|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
73619|NCT01199445|Dietary Supplement|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
73620|NCT01199458|Drug|alfentanil|20 mikrogr/kg
73621|NCT01199458|Drug|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
73622|NCT01199484|Other|Cow's milk|
73623|NCT01199497|Drug|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
73624|NCT01199497|Drug|Group 2|placebo
73939|NCT00044915|Drug|Placebo|All patients receive 1.25 mg of placebo
74347|NCT01190930|Drug|Vincristine Sulfate|Given IV
74348|NCT01190943|Genetic|DNA methylation analysis|
74349|NCT01190943|Genetic|RNA analysis|
73371|NCT01201733|Other|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
73372|NCT01201733|Other|Ultrasound therapy and hot pack|
73373|NCT01201746|Procedure|No treatment|No treatment
73374|NCT01204255|Drug|diphenhydramine hydrochloride|Given topically
73375|NCT01204255|Drug|haloperidol|Given topically
73376|NCT01204255|Other|questionnaire administration|Ancillary studies
73377|NCT01204255|Other|laboratory biomarker analysis|Correlative studies
73378|NCT01204268|Procedure|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
73379|NCT00045006|Drug|vorinostat|
73380|NCT01204268|Procedure|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
73381|NCT01204281|Other|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
73382|NCT01204294|Drug|Linagliptin|Linagliptin once daily
73383|NCT01204294|Drug|Linagliptin|Linagliptin once daily
73384|NCT01204294|Drug|Metformin|Metformin twice or three time per day
73385|NCT01204294|Drug|Metformin|Metformin twice or three time per day
73386|NCT01204294|Drug|Linagliptin|Linagliptin once daily
73387|NCT01204294|Drug|Linagliptin|Linagliptin once daily
73388|NCT01204294|Drug|Linagliptin|Linagliptin once daily
73389|NCT01204307|Drug|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
74416|NCT01188837|Other|Full Kinetic Chain Manipulative Therapy|Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.
Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.
This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.
74417|NCT01188837|Other|Full Kinetic Chain Rehabilitation|Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.
This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.
The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home
74418|NCT01188837|Other|Full Kinetic Chain Manipulative Therapy with Rehabilitation|This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.
This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.
74419|NCT01188850|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
74420|NCT01188863|Drug|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
74421|NCT01188863|Drug|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
74422|NCT01188863|Drug|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
73451|NCT01201785|Drug|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
73452|NCT01201798|Drug|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
73453|NCT01201798|Drug|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
73454|NCT01201811|Drug|Azacitidine|Participants received azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days for up to 6 cycles, unless they discontinued from the treatment. In addition, participants may have received best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
73455|NCT01201824|Procedure|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
73456|NCT01201837|Drug|Placebo|Weekly injection
73457|NCT01201837|Drug|CER-001|Weekly injection
73458|NCT00000982|Drug|Didanosine|
75704|NCT01222676|Procedure|neoadjuvant therapy|
75705|NCT01222676|Radiation|fludeoxyglucose F 18|
75706|NCT01222689|Drug|erlotinib hydrochloride|Given PO
75707|NCT01222689|Drug|selumetinib|Given PO
75708|NCT00047047|Drug|tanespimycin|Given IV
75709|NCT01222689|Other|laboratory biomarker analysis|Correlative studies
75710|NCT01222702|Drug|cadazolid|cadazolid (250 mg, 500 mg or 1000 mg), or matching placebo (in the treatment group receiving vancomycin) administered orally twice daily.
75711|NCT01222702|Drug|vancomycin|Vancomaycin 125 mg, or matching placebo (in the three treatment groups receiving cadazolid) administered orally four times daily.
75712|NCT01215747|Drug|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
75713|NCT01215747|Drug|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
75714|NCT01215760|Other|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
75715|NCT01215760|Other|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
75716|NCT01215773|Drug|Placebo|Matching to HEA 200 mg tablet, oral administration
75717|NCT01215773|Drug|BI 671800|High dose oral administration
75718|NCT01215773|Drug|BI 671800|Medium dose oral administration
74525|NCT01191229|Device|Crystalens AO|25 patients that are previously implanted
74526|NCT00043602|Behavioral|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
74527|NCT01191255|Drug|ferric citrate, ca acetate, sevelamer carbonate, placebo|All intervention doses will be based on serum phosphorus levels and/or drug label requirements
74528|NCT01191268|Drug|Insulin Glargine|
74529|NCT01191268|Drug|LY2189265|
74530|NCT01191268|Drug|Insulin Lispro|
73940|NCT01202825|Drug|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
73941|NCT01194830|Drug|Placebo|1 Tablet PO QD
73942|NCT00043979|Procedure|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
73943|NCT01194843|Drug|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
73944|NCT01194843|Drug|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
73945|NCT01194856|Drug|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
73946|NCT01194856|Drug|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
73947|NCT01194869|Drug|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
73948|NCT01194882|Drug|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
73949|NCT01194882|Drug|Insuplant|Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use
Dose regimen:
73950|NCT01194895|Other|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
73951|NCT01194895|Other|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
73952|NCT01194908|Drug|Decitabine, LBH589, Tamoxifen|Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2
Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2
Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2
Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2
Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2
Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2
73953|NCT00043979|Drug|Filgrastim|
73954|NCT01194934|Drug|NOX-A12|4 mg/kg daily IV for 5 days
73955|NCT01194934|Drug|NOX-A12|2 mg/kg daily IV for 5 days
73956|NCT01194934|Drug|Filgrastim|5 µg/kg SC daily for 5 days
73957|NCT01194934|Drug|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
73958|NCT01194947|Device|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
73390|NCT00045019|Other|quality-of-life assessment|QLQ-C30 SAT32
73391|NCT01204307|Drug|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
73392|NCT01204320|Procedure|Paclitaxel-coated Balloon|POBA
73686|NCT01197105|Biological|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
73687|NCT01197118|Radiation|sequence chemoradiotherapy|Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Postoperative chemotherapy regimen: see arm 2
73688|NCT01197118|Drug|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1~5, i.v.; leucovorin, 200 mg/m2/day on day 1~5, i.v.; every 21 days repeated, for 6 cycles.
73689|NCT01197144|Drug|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
73690|NCT01197144|Drug|Placebo|Subcutaneous, every other week for 4 weeks
73691|NCT01197157|Drug|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
73692|NCT01197157|Drug|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
73693|NCT01197170|Drug|Anastrozole|1 mg by mouth daily of a 28 day cycle.
73694|NCT01197170|Drug|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
73695|NCT01199510|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
73696|NCT01199510|Other|Standard of Care|Post Cataract Surgery Standard of Care
73697|NCT00044629|Drug|zolpidem tartrate (Ambien)|
73698|NCT01199523|Drug|Placebo|oral
73699|NCT01199523|Drug|mirabegron|oral
73459|NCT00044798|Drug|Citalopram|After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
73460|NCT01201850|Drug|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
73461|NCT01201863|Drug|Androgel (Testosterone Gel)|2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
73462|NCT01201863|Drug|Androgel Placebo|2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
73463|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
73464|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
73465|NCT01201902|Biological|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
73466|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
73467|NCT01204489|Behavioral|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
73468|NCT01204502|Biological|HSVTK retrovirally-transduced donor T lymphocytes|HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD
dose 1 5x104 cells/kg
dose 2 5x105 cells/kg
73769|NCT01197170|Drug|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
73770|NCT01197170|Drug|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
73771|NCT01197170|Drug|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
73772|NCT01197196|Behavioral|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
73773|NCT01197196|Other|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief [HLMR]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
74531|NCT01191281|Behavioral|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
74532|NCT01191281|Other|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
74533|NCT01191294|Other|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
74534|NCT01191320|Drug|Placebo|Placebo capsule 1x daily for 3 months
74535|NCT01191320|Drug|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
74536|NCT01191333|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
74537|NCT00043602|Behavioral|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
74538|NCT01191333|Device|Sham Device|Placebo Device that simulates active rTMS treatment
74539|NCT01191346|Other|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
74540|NCT01191359|Biological|oral immunotherapy|orally applied specific immunotherapy
74541|NCT01191372|Drug|placebo control|sterile saline for injection
74542|NCT01191372|Drug|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
74543|NCT01191385|Drug|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
74544|NCT01193725|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
74545|NCT01193725|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
74546|NCT01193725|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
73548|NCT01202032|Drug|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.
The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).
The therapy regimens for each dose level are respectively:
BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.
Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study.
73959|NCT01194960|Drug|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
74271|NCT00043888|Drug|fosamprenavir|
74272|NCT01193218|Drug|BI 10773|BI 10773 tablets low dose once a day
74273|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
74274|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
74275|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
74276|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-high dose once a day
74277|NCT01193218|Drug|BI 10773|BI 10773 tablets high dose once a day
74278|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
74279|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
74280|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
74281|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
74282|NCT00043888|Drug|COMBIVIR|
74283|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-low dose once a day
74284|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
74285|NCT01193244|Drug|Orteronel + prednisone|Orteronel and prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
74286|NCT01193244|Drug|Placebo + prednisone|Placebo and prednisone will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.
74287|NCT01193257|Drug|Orteronel + prednisone|Orteronel and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented
74288|NCT01193257|Drug|Placebo + prednisone|Placebo and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented
74289|NCT01193270|Drug|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
74290|NCT01193270|Drug|Placebo|Sterile water in volume equal to that of the comparator drug
73700|NCT01199523|Drug|moxifloxacin|oral
73701|NCT01199562|Procedure|infection prophylaxis and management|Undergo infection prophylaxis and management
73702|NCT01199562|Other|laboratory biomarker analysis|Correlative studies
73703|NCT01199562|Other|flow cytometry|Correlative studies
73704|NCT01199562|Genetic|DNA analysis|Correlative studies
73705|NCT01199562|Genetic|RNA analysis|Correlative studies
73706|NCT01199562|Procedure|management of therapy complications|undergo infection prophylaxis and management
74024|NCT01202825|Drug|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
74025|NCT01202838|Device|Composite Implant|Subjects receiving composite implants
74026|NCT00044928|Drug|Piperacillin/Tazobactam|
74027|NCT01202851|Other|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
74028|NCT01202851|Behavioral|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
74029|NCT01202851|Other|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
74030|NCT01202877|Drug|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
74031|NCT01202877|Drug|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
74032|NCT01202890|Drug|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.
Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
74033|NCT01202890|Drug|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
74034|NCT01202903|Drug|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
73774|NCT01197209|Biological|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
73775|NCT01197222|Device|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
73776|NCT01197235|Drug|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
73777|NCT01197235|Drug|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
73778|NCT01197248|Procedure|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
73779|NCT00044291|Drug|aromatase inhibition|
73780|NCT01197248|Procedure|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
73781|NCT01197261|Drug|Oxycodone naloxone prolonged release tablets|2 tablets/ day
73782|NCT01197261|Drug|Placebo tablets|2 tablets/ day
73783|NCT01197274|Device|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
73784|NCT01197287|Drug|QAK423A|
73785|NCT01197287|Drug|QAK423A|
73786|NCT01197287|Drug|QAK423A|
74105|NCT01193062|Drug|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
74106|NCT01193062|Drug|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
74107|NCT01185873|Drug|danoprevir|Repeated oral doses
74108|NCT01185873|Drug|ritonavir|Repeated oral doses
74109|NCT01185886|Genetic|gene expression analysis|
74110|NCT01185886|Genetic|mutation analysis|
73549|NCT01202058|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Design Original Protocol
Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
73550|NCT01202058|Device|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
73551|NCT00044811|Drug|Fexofenadine|
73552|NCT01202071|Drug|Rabeprazole sodium, 5 mg Tablets|Rabeprazole sodium Tablets, 5 mg administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast.
73553|NCT01194245|Drug|recombinant human hyaluronidase PH20|
73554|NCT01194245|Drug|Insulin aspart|
73555|NCT01194245|Drug|Insulin glulisine|
73556|NCT01194245|Drug|Insulin glargine|
73557|NCT01194258|Drug|Insulin lispro|
73558|NCT01194258|Drug|Insulin aspart|
73559|NCT00043979|Drug|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
73560|NCT01194258|Drug|Recombinant human hyaluronidase PH20|
73561|NCT01194258|Drug|Insulin glulisine|
73562|NCT01194258|Drug|Insulin glargine|
73563|NCT01194271|Drug|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
73564|NCT01194271|Drug|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
73565|NCT01194271|Procedure|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
73872|NCT01197365|Other|Infant formula with GOS, beta-palmitate, acidified milk|Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.
Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae
73873|NCT01197365|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
74291|NCT01193283|Drug|Cyclophosphamide|30 my/kg for 4 days
74292|NCT01193283|Drug|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
74293|NCT00043888|Drug|ritonavir|
74294|NCT01193296|Drug|Vildagliptin|
73311|NCT00044187|Drug|Sibutramine|
73312|NCT01196416|Drug|Temozolomide|Given PO
73313|NCT01196416|Drug|Vinblastine Sulfate|Given IV
73314|NCT01196429|Drug|Carboplatin|Given IV
73315|NCT01196429|Drug|Docetaxel|Given IV
73316|NCT01196429|Other|Laboratory Biomarker Analysis|Correlative studies
73317|NCT01196429|Drug|Paclitaxel|Given IV
73318|NCT01196429|Drug|Temsirolimus|Given IV
73319|NCT01196442|Other|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
73320|NCT01196442|Other|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
73321|NCT01196455|Drug|Capecitabine and Mitomycin C|Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks
Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks
73322|NCT00044213|Drug|EDTA|Participants will receive 40 infusions of standard chelation solution.
73323|NCT01196468|Other|HIV test (serological or salivary)|An HIV test will be offered to all patients accessing the healthcare setting for care of the "indicator" condition
73324|NCT01196468|Other|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
73325|NCT01196481|Drug|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD & capsule VSL#3 1 TDS for 2 year
73326|NCT01196481|Procedure|Endoscopic variceal ligation|In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
74035|NCT01202903|Drug|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
74036|NCT01202929|Procedure|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
74037|NCT00044954|Biological|therapeutic allogeneic lymphocytes|
74038|NCT01194999|Device|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
74039|NCT01195012|Behavioral|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
74040|NCT01195025|Drug|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
74041|NCT01195025|Drug|colloid|Infusion of starch 10 ml/kg over 30 min
74350|NCT01190943|Genetic|comparative genomic hybridization|
74351|NCT01190943|Genetic|gene expression analysis|
74352|NCT01190943|Genetic|microarray analysis|
74353|NCT01190943|Genetic|mutation analysis|
74354|NCT01190943|Other|laboratory biomarker analysis|
74355|NCT00043576|Drug|docetaxel|
74356|NCT01190969|Dietary Supplement|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
74357|NCT01190982|Drug|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
74358|NCT01190995|Drug|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
74359|NCT01190995|Drug|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
74111|NCT01185886|Genetic|polymorphism analysis|
74112|NCT01185886|Other|biologic sample preservation procedure|
74113|NCT01185886|Other|laboratory biomarker analysis|
74114|NCT01185886|Other|pharmacogenomic studies|
74115|NCT01185912|Procedure|Ventricle muscle tissue samples|
74116|NCT01185925|Drug|Sildenafil|Sildenafil, 50 mg 3 times/day
74117|NCT00043069|Dietary Supplement|calcium carbonate|
74118|NCT01185925|Drug|Placebo|Placebo
74119|NCT01185938|Drug|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
74120|NCT01185951|Drug|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
74121|NCT01185951|Device|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
74122|NCT01185951|Drug|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
74123|NCT01185951|Behavioral|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
74124|NCT01185951|Behavioral|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
74125|NCT01185951|Behavioral|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
74126|NCT01185964|Biological|IMC-3G3|IMC-3G3 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
74127|NCT01185964|Drug|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
74423|NCT01191021|Drug|Propofol Anesthesia|Volunteers will undergo propofol anesthesia for 90 min.
74424|NCT01191034|Drug|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.
This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod.
73874|NCT01197378|Drug|Cysteamine Bitartrate Delayed-release Capsules (RP103)|RP103 every 12H, supplied in 75 and 25mg capsules
73875|NCT00044291|Procedure|endocrine therapy|
73876|NCT01197391|Biological|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
73877|NCT01197404|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
73878|NCT01197404|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
73879|NCT01197417|Drug|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
73880|NCT01197417|Drug|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
73881|NCT01197430|Other|exercise training|
73882|NCT01197443|Behavioral|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
73883|NCT01197443|Behavioral|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
73884|NCT01199770|Other|Experimental B, small|experimental pasta, small portion
73885|NCT01199770|Other|Experimental pasta C, small|experimental pasta C, small portion
73886|NCT01199770|Other|control, medium|control pasta, medium portion
73887|NCT01199770|Other|experimental pasta B, medium|experimental pasta B, medium portion
73888|NCT01199770|Other|experimental pasta C, medium|experimental pasta C, medium portion
73889|NCT01199770|Other|NL|no pasta, water only
73890|NCT01199783|Drug|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
74209|NCT00000970|Drug|Ganciclovir|
74210|NCT00043069|Drug|Estrogen Antagonists|
73327|NCT01196494|Procedure|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
73328|NCT00044551|Drug|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
73329|NCT01198886|Other|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
73330|NCT01198899|Other|blood sampling|Blood sampling will be used.
73625|NCT01202071|Drug|Rabeprazole sodium, 10 mg Tablets|Rabeprazole sodium Tablets, 10 mg administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast.
73626|NCT01202071|Drug|Rabeprazole sodium, 20 mg Tablets|Rabeprazole sodium Tablets, 20 mg administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast.
73627|NCT01202071|Drug|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water, >=2 hours after the completion of breakfast.
73628|NCT01202084|Drug|Formoterol/Fluticasone|
73629|NCT01202084|Drug|Foraseq®|
73630|NCT01202084|Drug|Fluticasone|
73631|NCT01202097|Drug|Salmeterol/Fluticasone|
73632|NCT01202097|Drug|Seretide|
73633|NCT01202110|Drug|Propranolol|
73634|NCT00044824|Drug|Fexofenadine|
73635|NCT01202149|Device|Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)|
73636|NCT01202162|Drug|Desflurane|Administratino of Desflurane
73637|NCT01202162|Drug|Administration of Sevoflurane|Administration of Sevoflurane
73638|NCT01202175|Drug|Nebivolol|Oral nebivolol 2.5-5mg once daily
73639|NCT01202188|Drug|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
74360|NCT01191008|Drug|Latanoprost-timolol maleate fixed combination ophthalmic solution|Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "One drop should be applied to the affected eye(s) once daily".
74361|NCT01193348|Drug|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
74362|NCT01193361|Drug|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
74363|NCT01193361|Drug|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
74364|NCT01193361|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
74365|NCT01193361|Drug|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
74366|NCT01193361|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
74367|NCT00043888|Drug|TRIZIVIR|
74368|NCT01193374|Behavioral|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
74369|NCT01193374|Behavioral|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
73393|NCT01204320|Device|Paclitaxel-eluting Stent|Stenting
73394|NCT01204333|Drug|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
73395|NCT01204333|Drug|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
73396|NCT01204346|Other|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
73397|NCT01204346|Other|treatment as usual|less intensive and structured psychotherapeutic program
73398|NCT01196507|Drug|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
73399|NCT01196507|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
73400|NCT01196533|Device|Non invasive peripheral blood monitoring|non invasive monitoring
74425|NCT01191060|Drug|Lenalidomide, Bortezomib|Lenalidomide/Bortézomib/Dexamethasone cycles:
Number of cycles: 8 cycles for arm A
Cycle length
Dosage:
Lenalidomide: 25 mg/day on days 1-14 of each cycle
Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle
Maintenance phase (12 months):
Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed
74426|NCT01191060|Drug|Lenalidomide, Bortezomib|Lenalidomide Bortezomib Dexamethasone cycles:
Number of cycles: 5 cycles for arm B
Cycle length
Dosage:
Lenalidomide: 25 mg/day on days 1-14 of each cycle
Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle
Maintenance phase (12 months):
Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed
74427|NCT01191073|Device|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
74428|NCT00043589|Drug|donepezil|
74429|NCT01191073|Device|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
74430|NCT01191086|Drug|USL255|
74431|NCT01191099|Device|Pimonidazol|0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
74432|NCT01191112|Other|Peptide based enteral formula|Sole source nutrition as per HCP
74433|NCT01191125|Other|medical food with AN777|Two(220 mL)servings every day for six months
74434|NCT01191125|Other|oral nutritional formula|Two (220 mL) servings daily for six months
74435|NCT01191138|Procedure|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
74436|NCT01191138|Procedure|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
74437|NCT01191164|Procedure|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|Target Volumes: The surgical cavity will be assessed with US & CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.
Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.
Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre.
73469|NCT01204528|Drug|Zemplar|Vitamin D receptor activator (VDRA)
73470|NCT01204554|Drug|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
74211|NCT01186068|Other|vehicle|Cream QD
74212|NCT01186081|Radiation|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
74213|NCT01186081|Radiation|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
74214|NCT01186094|Device|Cypher|Sirolimus-eluting stent
74215|NCT01186094|Device|Endeavor Resolute|Zotarolimus-eluting Stent
74216|NCT01186107|Device|Endeavor Resolute stent|zotarolimus-eluting stent
74217|NCT01186107|Device|Cypher stent|sirolimus-eluting stent
74218|NCT01186120|Device|Biolimus A9-eluting stent|drug-eluting stent
74219|NCT01186120|Device|Everolimus-eluting stent|drug-eluting stent
74220|NCT01186146|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
74221|NCT00043069|Drug|risedronate sodium|
74222|NCT01186146|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
74223|NCT01186159|Drug|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
74224|NCT01186172|Drug|Ethanol-lock therapy|Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
74225|NCT01188512|Biological|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
74226|NCT01188512|Biological|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
74227|NCT01188525|Drug|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
74228|NCT01188538|Drug|Epiduo gel|Once daily application on the face in the evening for 12 weeks
74229|NCT01188538|Drug|BPO|Once daily application on the face in the evening for 12 weeks
73640|NCT01202188|Drug|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
73641|NCT01202188|Drug|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
73642|NCT01202188|Drug|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
73643|NCT01202188|Drug|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
73644|NCT01202201|Other|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
73645|NCT00044837|Drug|Medroxyprogesterone acetate|
73646|NCT01202214|Drug|1440115|
73647|NCT01202214|Drug|Placebo|matching placebo
73960|NCT01194960|Drug|TroVax + Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
73961|NCT01194973|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
73962|NCT01194986|Other|[11C]AZ12807110|Radioligand
73963|NCT01194986|Drug|AZD5213|
73964|NCT00043979|Procedure|Peripheral Blood Stem Cell donation|
73965|NCT01197469|Drug|Tadalafil|Tadalafil 10mg once daily for 3 months
73966|NCT01197469|Drug|Placebo|
73967|NCT00044291|Procedure|antiestrogen therapy|
73968|NCT01197508|Drug|TC-5214|Twice daily for 8 weeks.
73969|NCT01197508|Drug|Placebo|Twice daily for 8 weeks.
73970|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily
73971|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
73972|NCT01197521|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
73973|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily
73401|NCT01196546|Drug|vildagliptin/metformin|
73402|NCT01196559|Drug|Vinorelbine and Gemcitabine|Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
73403|NCT00044213|Drug|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
73404|NCT01196572|Procedure|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
73405|NCT01196585|Procedure|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
73406|NCT01196585|Procedure|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
73407|NCT01196598|Other|Exercises|Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.
The control group receive only lifestyle advice.
Followed by three months of home training with appointments each two weeks with physiotherapist.
73408|NCT01196611|Behavioral|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
73409|NCT01196611|Behavioral|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
73410|NCT01196624|Device|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
73411|NCT01196624|Device|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
73707|NCT01199562|Drug|ganciclovir|Given IV
73708|NCT00044629|Drug|Placebo|
73709|NCT01199562|Drug|valganciclovir|Given orally
73710|NCT01199562|Drug|foscarnet sodium|Given orally
73711|NCT01199562|Procedure|antiviral therapy|undergo infection prophylaxis and management
73712|NCT01199562|Genetic|polymerase chain reaction|Correlative studies
73713|NCT01199562|Genetic|protein expression analysis|Correlative studies
73714|NCT01199575|Drug|Revlimid, rituximab|Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
73471|NCT01204567|Other|Aerobic training|Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
73472|NCT01204580|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
73473|NCT00045045|Procedure|positron emission tomography|
73474|NCT01204593|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
73475|NCT01204593|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
73476|NCT01204606|Procedure|Arthroscopic rotator cuff repair with intraoperative periarticular injection|Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4 or 5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repaired of rotator cuff tear was done with suture anchors.
Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
Peripheral intravenous PCA(Patient Controlled Analgesia) was connected.
73477|NCT01204606|Procedure|Arthroscopic rotator cuff repair with non-injection of MMA drugs|Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4 or 5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repaired of rotator cuff tear was done with suture anchors.
43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
Peripheral intravenous PCA(Patient Controlled Analgesia) was connected.
73478|NCT01204619|Behavioral|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
73479|NCT01204658|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|Four doses will be administered intramuscularly, at approximately 2, 3, 4 and 12-15 months of age.
73480|NCT01204658|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|Four doses will be administered intramuscularly, at approximately 2, 3, 4 and 12-15 months of age.
73481|NCT01204658|Biological|Synflorix|Four doses will be administered intramuscularly, at approximately 2, 3, 4 and 12-15 months of age.
73482|NCT01196715|Procedure|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
73787|NCT01197300|Drug|zoledronic acid|
73788|NCT01197313|Other|Home-based exercise|
74230|NCT00043342|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
74547|NCT01193738|Procedure|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
74548|NCT01193764|Dietary Supplement|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
74549|NCT01193764|Dietary Supplement|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
74550|NCT01193777|Drug|L-Carnitine|4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
74551|NCT00043953|Drug|Saquinavir mesylate|
74552|NCT01193777|Drug|Normal Saline|Bolus followed by 1 L NS infusion over 12 hours.
74553|NCT01193790|Procedure|Coblation channeling|The combination of the energy and the fluid creates a "plasma" field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation.
74554|NCT01193803|Procedure|Microbiological cultures and Molecular biology|Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.
Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol.
74555|NCT01193816|Drug|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
74556|NCT01193816|Drug|Placebo|Placebo
74557|NCT01193842|Drug|Cyclophosphamide|Given IV
74558|NCT01193842|Drug|Doxorubicin Hydrochloride|Given IV
74559|NCT01193842|Drug|Etoposide|Given IV
73974|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
73975|NCT01197534|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
73976|NCT01197547|Device|Genesys HTA|Genesys HTA Endometrial Ablation
73977|NCT01197560|Drug|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
73978|NCT00044304|Drug|Imatinib Mesylate|Imatinib is a tyrosine kinase inhibitor that selectively inhibits bcr-abl, c-kit and the plateletderived growth factor receptor tyrosine kinases. Imatinib mesylate was approved by the FDA for use in patients with advanced phase CML and in patients in chronic phase failing first line interferon therapy and in as well as for the treatment of gastrointestinal stromal tumors. Drugs used to treat CML have historically been of benefit in the treatment of HES.
73979|NCT01197560|Drug|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m2 IV days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m2 IV days 1 and 15 every 28 days for 6 Cycles
73980|NCT01197560|Drug|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m2 IV day 1 for 21 days for 6 Cycles
74295|NCT01193296|Drug|Sitagliptin|
74296|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
74297|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
74298|NCT01186172|Drug|Antibiotic-lock|Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
74299|NCT01186185|Drug|Fludrocortisone|Fludrocortisone 0.2 mg by mouth daily for 30 days
74300|NCT01186198|Device|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
74301|NCT01186224|Drug|Plerixafor and G-CSF|G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.
The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily.
74302|NCT01186237|Procedure|Early urinary catheter removal|All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
73715|NCT01199575|Drug|Relapsed or refractory CLL. Lenalidomide and Rituximab|Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
73716|NCT01199588|Drug|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
73717|NCT01199588|Drug|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
73718|NCT01199588|Drug|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
73719|NCT00044642|Drug|Lorazepam|
73720|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
73721|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
73722|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
73723|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
73724|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
73725|NCT00044837|Drug|Estradiol|
74042|NCT01195025|Drug|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
74043|NCT01195025|Device|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
74044|NCT01195038|Biological|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
74045|NCT01195051|Other|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
74046|NCT01195077|Other|seaweed, spirulina, seaweed + spirulina|Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.
74047|NCT01195090|Drug|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
73789|NCT01199601|Behavioral|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
73790|NCT01199614|Drug|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
73791|NCT01199627|Drug|A|Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.
2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration.
73792|NCT01199627|Drug|B|Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.
2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration.
73793|NCT01199627|Drug|C|Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.
2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration.
73794|NCT01199640|Drug|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
73795|NCT01199653|Procedure|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
73796|NCT01199653|Procedure|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
73797|NCT01199666|Other|Text message|text message appointment and immunization reminders
73798|NCT01199679|Procedure|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
73799|NCT00044655|Drug|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
73800|NCT01199679|Procedure|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
73801|NCT01199705|Biological|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
73802|NCT01199718|Drug|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
73803|NCT01199731|Drug|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
73804|NCT01199731|Drug|GSK2248761 200 mg once daily|2 100mg capsules OAD
73805|NCT01199731|Drug|Etravirine|2 100mg tablets twice daily
74560|NCT01193842|Other|Laboratory Biomarker Analysis|Correlative studies
74561|NCT00043108|Drug|carboplatin|
73566|NCT01194284|Drug|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
73567|NCT01194297|Biological|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
73568|NCT01194297|Biological|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
73569|NCT01194310|Procedure|Combined cataract and glaucoma surgery|
73570|NCT00043979|Drug|doxorubicin hydrochloride|Induction - 10 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
73571|NCT01194336|Drug|Huperzine A|dosage form: tablet dose frequency: once only
73572|NCT01194336|Drug|Donepezil|dosage form: tablet dosage frequency: once only
73573|NCT01194336|Drug|Galantamine|dosage form: tablet dosage frequency: once only
73574|NCT01194336|Other|Placebo|dosage form: tablet dosage frequency: once only
73575|NCT01194375|Drug|Low Strength IDP-107|Once a day for 16 weeks
73576|NCT01194375|Drug|High Strength IDP-107|Once a day for 16 weeks
73577|NCT01194375|Drug|Placebo|Once a day for 16 weeks
73578|NCT01194388|Device|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
73579|NCT01194414|Drug|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week for a total of 24 weeks in the double-blind period.
73580|NCT00044265|Drug|ramipril|
73581|NCT01196936|Other|pharmacological study|Correlative Studies
73582|NCT01196936|Other|laboratory biomarker analysis|Correlative Studies
73583|NCT01196936|Genetic|protein expression analysis|correlative studies
74303|NCT01186250|Drug|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
74304|NCT01186250|Drug|Placebo|placebo taken daily for one year
74305|NCT00043069|Other|placebo|
74306|NCT01186263|Drug|MAA for diagnostic SPECT imaging|Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
74307|NCT01186263|Drug|Diagnostic B20- SPECT imaging.|Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
74308|NCT01186276|Dietary Supplement|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
74309|NCT01186276|Dietary Supplement|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
74310|NCT01186289|Drug|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
74311|NCT01186302|Other|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
73331|NCT01198912|Drug|placebo|during 56 days
73332|NCT01198912|Drug|doxycycline 100 mg|during 56 days
73333|NCT01198925|Drug|piperacillin continuous infusion|piperacillin continuous infusion
73334|NCT01198925|Drug|piperacillin extended infusion|piperacillin extended infusion
73335|NCT01198938|Other|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
73336|NCT01198964|Procedure|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
73337|NCT01198977|Behavioral|Brief telephone-based counseling|Motivational interviewing and exercise goal setting and problem solving
73338|NCT01198977|Other|Informational video|Mailed video of exercise programs
73339|NCT00044564|Drug|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
73340|NCT01198990|Behavioral|eating strategy/physical activity/positive affect/self affirmation component|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
74048|NCT00044005|Drug|Lurasidone 20 mg|Lurasidone 20mg oral tablet taken once daily for 6-months
74049|NCT01195090|Drug|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
74050|NCT01195103|Drug|Fospropofol disodium|10 mg/kg bolus
74051|NCT01195103|Drug|Fospropofol disodium|6.5 mg/kg bolus
74052|NCT01195103|Drug|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients <60 kg; 1.5 mg for patients ≥60 kg to <90 kg; or 2 mg for patients ≥90 kg
74053|NCT01195103|Drug|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients <60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
74054|NCT01195116|Drug|Dexmedetomidine|1 mcg/kg/hour
74055|NCT01195116|Drug|Normal Saline|1mcg/kg/hr
74056|NCT01195129|Device|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
74057|NCT01195129|Device|Non-hydrogel coils|Cerecyte or bare platinum coils
74058|NCT01195155|Dietary Supplement|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
74059|NCT00044005|Drug|Lurasidone 40 mg|Lurasidone 40mg oral tablets taken once daily
74060|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
74061|NCT00043537|Drug|Pill Placebo|
74370|NCT01193374|Behavioral|basic educational brochure|Booklet by ADA sent x 1.
74371|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
74372|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
74373|NCT01193400|Drug|Clofarabine|
74374|NCT01193400|Drug|Cytarabine|
74375|NCT01193426|Other|Ascite liquid puncture|Ascitic fluid obtained by paracentesis
73806|NCT01199744|Drug|zanamivir|zanamivir
74128|NCT00043069|Dietary Supplement|cholecalciferol|
74129|NCT01185964|Drug|dexrazoxane|Dexrazoxane given at 750 mg/m2 by intravenous injection on day 1 of the 21-day cycle prior to administration of each doxorubicin infusion during cycles 5-8 for prevention of cardiotoxicity.
74130|NCT01185977|Drug|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
74131|NCT01185977|Drug|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
74132|NCT01186003|Drug|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
74133|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
74134|NCT01188369|Drug|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
74135|NCT01188369|Drug|placebo drug|Intravenous infusion, colour identical to levosimendan
74136|NCT01188382|Procedure|CSF dynamic investigation|
74137|NCT01188408|Drug|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
74138|NCT01188421|Drug|Buprenorphine/naloxone|up to 8/2 mg SL per day
74139|NCT00043316|Drug|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
74140|NCT01188421|Drug|Clonidine|up to 0.8 mg per day (oral)
74141|NCT01188421|Drug|Tramadol ER|up to 600 mg per day
74142|NCT01188434|Behavioral|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
74143|NCT01188434|Behavioral|Services as Usual|Services as usual referred by child welfare
74144|NCT01188447|Procedure|Canadian C-Spine Rule|Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
74145|NCT01188460|Behavioral|Sleep diary|Completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
74146|NCT01188460|Behavioral|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
73584|NCT01196936|Other|pharmacogenomic studies|correlative studies
73585|NCT01196936|Other|questionnaire administration|Ancillary studies
73586|NCT01196936|Procedure|Fine needle aspiration|
73587|NCT01196936|Other|Quality of Life Assessment|Ancillary Studies
73891|NCT01199783|Drug|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
73892|NCT01199809|Drug|RO5310074|multiple ascending doses
73893|NCT00044655|Drug|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
73894|NCT01199809|Drug|Placebo|multiple doses
73895|NCT01199822|Biological|IMC-3G3|Cohort 1
10 mg/kg i.v., administered on Days 1 and 8, every 3 weeks
73896|NCT01199822|Biological|IMC-3G3|Cohort 2
20 mg/kg i.v., administered every 2 weeks
73897|NCT01199822|Biological|IMC-3G3|Cohort 3
15 mg/kg i.v., administered on days 1 and 8, every 3 weeks
73898|NCT01199835|Other|High Calcium intake from dairy products|High dietary intake of calcium from dairy products (~1200 mg/d)
73899|NCT01199848|Dietary Supplement|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
73900|NCT01199848|Dietary Supplement|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
73901|NCT01199848|Dietary Supplement|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
73902|NCT01199848|Dietary Supplement|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
73903|NCT01199848|Dietary Supplement|Placebonofiber|Placebo without Fiber
73904|NCT00044655|Drug|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
73905|NCT01199861|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
73906|NCT01199861|Drug|Placebo|Matching placebo capsules for oral administration.
73907|NCT01199861|Biological|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
73908|NCT01199861|Biological|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
73341|NCT01198990|Behavioral|eating strategy and physical activity goal|Subjects will be randomized to the small change eating strategy and a physical activity goal.
73342|NCT01199016|Procedure|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
73343|NCT01199016|Procedure|Nose/throat swab|To be performed at every study visit
73344|NCT01199016|Biological|Observational|Observational Study Only
73345|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
73346|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
73347|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
73348|NCT01199029|Drug|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
73349|NCT01199029|Drug|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
73350|NCT00044577|Drug|abacavir/lamivudine|
73351|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
73352|NCT01199029|Drug|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
73648|NCT01202227|Drug|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
73649|NCT01202240|Drug|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
73650|NCT01202253|Drug|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
73651|NCT01194414|Drug|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks for a total of 24 weeks in the double-blind period.
73652|NCT00043979|Drug|etoposide|50 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
73653|NCT01194414|Drug|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
74376|NCT01193452|Drug|S-1, Leucovorin|S-1 :
The initial dosage of S-1 is determined by the body surface area:
Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day
Leucovorin:
25mg twice per day po.
The treatment is given for one week,and no chemotherapy is given for the following one week.
74377|NCT01193452|Drug|leucovorin, 5-fluorouracil|leucovorin: 400mg/m2 intravenous infusion d1;
5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours
repeat every 2 weeks
74378|NCT00043901|Drug|lamotrigine|
74379|NCT01193465|Device|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
74380|NCT01193465|Device|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
74381|NCT01193465|Device|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
74382|NCT01193465|Device|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
74383|NCT01193478|Drug|GS-5885|tablet, oral, 3 mg once daily for 3 days
74384|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
74385|NCT00043082|Drug|carboplatin|intravenous q 4 weeks
74386|NCT01186328|Drug|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
74387|NCT01186328|Drug|Prednisone|40 mg/m2/day divided twice or three times a day given orally on days 1 through 29.
74388|NCT01186328|Drug|Vincristine|.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
74389|NCT01186328|Drug|Pegaspargase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23.
73412|NCT01196650|Drug|IN 10 003 formulation A|
73413|NCT01196650|Drug|IN 10 003 formulation B|
73414|NCT00044213|Dietary Supplement|High Dose Vitamin|
73415|NCT01196650|Drug|Placebo capsules|
73416|NCT01196663|Device|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
74147|NCT01188473|Other|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
74438|NCT01191177|Dietary Supplement|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
74439|NCT00043589|Procedure|Memory-training class|
74440|NCT01191177|Dietary Supplement|corn oil|supplied as 1gram transparent soft gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4gram a day
74441|NCT01193478|Drug|GS-5885|tablet, oral, 10 mg once daily for 3 days
74442|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
74443|NCT01193478|Drug|GS-5885|tablet, oral, 30 mg once daily for 3 days
74444|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
74445|NCT00000975|Drug|Itraconazole|
74446|NCT00043914|Drug|lamotrigine|
74447|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
74448|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
74449|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
74450|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
74451|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
74452|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
74453|NCT01193491|Drug|IPI-493|Capsules, ascending dose, multiple schedules
74454|NCT01193504|Drug|Pred Forte|Pred Forte BID for 4 weeks postop
74455|NCT01193504|Drug|Lotemax|Lotemax BID for 4 weeks postop.
74456|NCT01193517|Drug|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
73909|NCT01199874|Biological|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
73910|NCT01199887|Drug|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
73911|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
73912|NCT01202630|Dietary Supplement|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
73913|NCT01202643|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
74231|NCT01188551|Drug|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
74232|NCT01188551|Drug|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
74233|NCT01188551|Drug|Midazolam|Sedative given pre-op.
74234|NCT01188564|Drug|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
74235|NCT01188564|Drug|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
74236|NCT01188577|Drug|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
74237|NCT01188577|Drug|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
74238|NCT01188590|Device|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
74239|NCT01188603|Drug|flibanserin 100 mg dose every evening|all subjects receive flibanserin
74240|NCT01188616|Behavioral|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
74241|NCT00043355|Drug|interferon gamma-1b|500 mcg, oral, three times weekly
74242|NCT01188629|Behavioral|Safety Training|IT intervention focuses on safety in the home.
74243|NCT01188629|Behavioral|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
74244|NCT01188642|Behavioral|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
73654|NCT01194414|Drug|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
73655|NCT01194414|Drug|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
73656|NCT01194427|Drug|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
73657|NCT01194440|Drug|letrozole|Given orally
73658|NCT01194440|Drug|zoledronic acid|Given IV
73659|NCT01194440|Other|laboratory biomarker analysis|Correlative studies
73660|NCT01194440|Other|enzyme-linked immunosorbent assay|Correlative studies
73661|NCT01194440|Other|mass spectrometry|Correlative studies
73662|NCT01194440|Procedure|bone scan|Correlative studies
73663|NCT00043979|Drug|fludarabine phosphate|Induction - 25 mg/m^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.
Transplant - 30 mg/m^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3.
73664|NCT01194440|Procedure|quality-of-life assessment|Ancillary studies
73665|NCT01194440|Other|questionnaire administration|Ancillary studies
73666|NCT01194440|Other|pharmacogenomic studies|Correlative studies
73667|NCT01194440|Other|high performance liquid chromatography|Correlative studies
73981|NCT01197560|Drug|Rituximab|Suggested starting dose for Rituximab is 375 mg/m2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
73982|NCT01197560|Drug|Etoposide|Suggested starting doses for Etoposide are:
100 mg/m2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m2 oral days 1-10 every 28 days for 6 Cycles
73983|NCT01197573|Drug|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
73984|NCT01197612|Drug|pulmicort|applied to nasal packing after surgery
73985|NCT01197625|Biological|Dendritic cell vaccine|Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
73986|NCT01197664|Drug|paricalcitol|Given PO
73987|NCT01197664|Radiation|radiation therapy|Undergo radiotherapy
73417|NCT01196663|Device|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
73418|NCT01196676|Drug|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
73419|NCT01196676|Drug|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
73420|NCT01196689|Drug|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
73421|NCT01196715|Drug|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
73422|NCT01196715|Drug|Filgrastim|300 mcg vials twice a week, 3-4 days apart
73423|NCT01199042|Device|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
73424|NCT01199055|Drug|CS-7017|Drug: CS-7017 from 0.25 mg bid to 0.50 mg bid for up to 4~6 cycles (1 cycle: 3 weeks)
73425|NCT01199055|Drug|Carboplatin|Drug: Carboplatin IV, AUC of 6, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
73426|NCT01199055|Drug|Paclitaxel|Drug: Paclitaxel IV, 200mg/m2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
73427|NCT01199068|Drug|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice a daily
73428|NCT01199068|Drug|Erlotinib|Erlotinib 150 mg once daily
73429|NCT01199081|Drug|Dronedarone|Pharmaceutical form: tablet
Route of administration: oral (together with meal)
Dose regimen: 400 mg twice daily
73430|NCT01199107|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
73431|NCT00044577|Drug|abacavir|
73432|NCT01199107|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
73433|NCT01199107|Behavioral|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
73434|NCT01199120|Dietary Supplement|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
73726|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
73727|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
76931|NCT00045162|Drug|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 & 15. Q 4 weeks x 4 Cycles
76932|NCT01205516|Drug|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
76933|NCT01205516|Drug|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
76934|NCT01205529|Drug|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
76935|NCT01205542|Behavioral|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
76936|NCT01205542|Behavioral|Reference|Health check and advice to continue ordinary physical activity
75986|NCT01216345|Drug|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
75987|NCT01216371|Drug|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
75988|NCT01216371|Drug|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
75989|NCT00046332|Drug|GW810781|
75990|NCT01216384|Drug|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
75991|NCT01216384|Drug|placebo|Subjects will receive according to the dose group matching number of placebo tablets
75992|NCT01216397|Drug|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
75993|NCT01216397|Drug|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
75994|NCT01216410|Drug|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
75995|NCT01216410|Drug|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
75996|NCT01218477|Drug|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
75997|NCT01218490|Procedure|ovarian cancer surgery|
75998|NCT01218503|Behavioral|CHOICES - obese|Standard group behavioral weight loss treatment
80520|NCT01231347|Drug|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
80521|NCT01231347|Drug|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
79583|NCT01234584|Procedure|CPK Abutments|implants using CPK Abutments
79584|NCT01234597|Drug|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
79585|NCT01234597|Drug|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
79586|NCT01234610|Behavioral|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
79587|NCT01234610|Behavioral|Usual care control|Usual care, no active intervention
79588|NCT01234623|Other|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
79589|NCT01234636|Dietary Supplement|Placebo oil|Placebo oil of 4g/day
79590|NCT01234649|Drug|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
79591|NCT01234649|Drug|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
79592|NCT01234662|Procedure|SPA|Spinal anesthesia and opioids
79593|NCT00048152|Drug|Neoral|Low dose (target trough level 50-100ng/mL)
79594|NCT01234662|Procedure|CSE|CSE and epidural opioids
79595|NCT01234662|Procedure|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
79596|NCT01234675|Drug|Milnacipran|Placebo twice daily then 50 mg milnacipran or matching
79597|NCT01234675|Drug|Milnacipran|50 mg twice daily; then matching placebo twice daily
79598|NCT01234688|Other|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
80344|NCT01228500|Device|PriMatrix|Dermal Repair Scaffold
80345|NCT01228513|Drug|ZK245186|Daily topical application
80346|NCT01228513|Drug|Placebo (vehicle without active ingredient)|Daily topical application
80347|NCT01228526|Device|PriMatrix|
80348|NCT00047333|Drug|erlotinib hydrochloride|Given PO
80349|NCT01228539|Behavioral|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
80350|NCT01228539|Behavioral|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
80351|NCT01230983|Radiation|radiation therapy|Radiation to cranium
80352|NCT01230996|Drug|cisplatin|
80353|NCT01230996|Radiation|intensity-modulated radiation therapy|
80354|NCT01231009|Drug|Corticosteroids|Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
80355|NCT00047658|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
80377|NCT01233167|Drug|placebo|placebo 75mg po per day for 12 months
80378|NCT01233167|Drug|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
80379|NCT00048022|Drug|Dual Integrin Antagonist|
80380|NCT01233180|Other|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
80381|NCT01233180|Device|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
80382|NCT01233193|Behavioral|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
80383|NCT01233206|Drug|Metformin|Metformin pre-treatment and co-administration
80384|NCT01233206|Drug|Placebo administration|Placebo pre-treatment and co-administration
79520|NCT01236911|Other|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
79521|NCT01236924|Other|Global postural reeducation|
79522|NCT01236937|Device|Bellows-based breath hold device|Bellows-Based breath hold monitoring system:
The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed.
79523|NCT01236950|Drug|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
79524|NCT00048438|Drug|paricalcitol|
79525|NCT01236950|Drug|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
79526|NCT01236963|Drug|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
79527|NCT01236963|Device|Dental Floss|
79528|NCT01236976|Device|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It has adjustable ergonomic seating for the therapists, a dedicated computer, surge protector, battery backup, custom software and controls, and a closed-loop feedback system. A therapist/assistant is positioned behind the participant to stabilise the pelvis and trunk, and to assist with appropriate weight shifting and hip rotation during the step cycle. Two additional therapists are seated in front of the participant to provide manual assistance for the lower limbs to facilitate knee extension during stance and knee flexion and toe clearance during swing, maintaining appropriate alignment of the limbs. A fourth person controls the treadmill. This system is being used in US universities and rehabilitation facilities throughout North America and is registered with the FDA (Regulation Number 890.5380).
79529|NCT01236976|Device|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD). Surface electrodes will be applied to the quadriceps, gluteal, hamstrings and calf muscles according to a standardized protocol. The pedal cadence will be set to 15-50 rev•min-1. Stimulation intensity will be gradually increased to a maximum of 140 mA with a pulse width of 0.3ms and frequency of 35Hz (Eser et al. 2003; Fornusek & Davis, 2008). Participants will exercise at the maximal power output possible at their level of recovery. Participants will commence with 10 minutes of training and gradually build up to a period of 30 minutes. The frequency, power output at each minute, and training duration will be recorded at each training session.
79814|NCT01230229|Procedure|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
80096|NCT01230762|Drug|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
80097|NCT01232959|Device|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
80098|NCT01232972|Procedure|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
80099|NCT01232985|Device|RD047-26|RD047-26 emollient gel
80100|NCT01233024|Dietary Supplement|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
80101|NCT00047983|Dietary Supplement|Fish oil emulsion|
80102|NCT01233024|Dietary Supplement|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
80103|NCT01233024|Dietary Supplement|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
80104|NCT01233024|Dietary Supplement|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
80105|NCT01233024|Dietary Supplement|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
80106|NCT01233050|Drug|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
80107|NCT01233050|Drug|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
80108|NCT01233063|Behavioral|Physical Activity and Diet Intervention via Alive2|Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
80109|NCT01233076|Device|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
80110|NCT01233076|Device|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
80111|NCT01233089|Device|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
80112|NCT00048009|Drug|Dual Integrin Antagonist|
80113|NCT01233089|Device|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
79599|NCT01237028|Drug|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
79600|NCT01237041|Drug|Niacin|500 mg po four times on one of the inpatient days
79601|NCT01237041|Drug|Placebo|
79602|NCT01237054|Drug|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
79894|NCT01230320|Procedure|Denture fabrication technique|Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:
the reproduction of denture-bearing tissues by means of impression techniques and casts;
the registration of maxillo-mandibular relations;
try-in of artificial teeth and carved denture bases.
79895|NCT00047541|Drug|Alcon Investigational Agent|
79896|NCT01230346|Other|questionnaire administration|Ancillary studies
79897|NCT01230346|Other|survey administration|Ancillary studies
79898|NCT01230346|Other|counseling intervention|Telephone intervention
79899|NCT01230346|Other|educational intervention|Telephone intervention
79900|NCT01230359|Dietary Supplement|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
79901|NCT01230359|Other|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
79902|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
79903|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
79904|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
79905|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
79906|NCT00001004|Drug|Tumor Necrosis Factor|
79907|NCT00047554|Drug|Travoprost, 0.004% ophthalmic solution|
79908|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
79909|NCT01230411|Other|saline placebo|250 cc of placebo administered IV
79910|NCT01230411|Drug|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
80385|NCT01233219|Drug|morphine chlorhydrate|The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.
At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.
Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS<4 maximum x 3 daily.
Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h).
80386|NCT01233232|Drug|Placebo|Oral dose bid
80387|NCT01233232|Drug|AZD5069 50mg|Oral dose bid
80388|NCT01233232|Drug|AZD5069 80mg|Oral dose bid
80389|NCT01233245|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
80390|NCT00001006|Drug|AS-101|
80391|NCT00048035|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
80392|NCT01233258|Biological|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
80393|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
80394|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
80395|NCT01233271|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
80686|NCT01229111|Drug|oxaliplatin|Given IV
80687|NCT01229111|Drug|leucovorin calcium|Given IV
80688|NCT00047385|Device|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
80689|NCT01229111|Drug|fluorouracil|Given IV
80690|NCT01229124|Genetic|RNA analysis|
80691|NCT01229124|Genetic|nucleic acid sequencing|
80692|NCT01229124|Genetic|reverse transcriptase-polymerase chain reaction|
80693|NCT01229124|Other|laboratory biomarker analysis|
79815|NCT01230229|Other|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
79816|NCT01232452|Drug|Cixutumumab|Administered IV
79817|NCT01232478|Behavioral|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
79818|NCT01232491|Drug|insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
79819|NCT01232491|Dietary Supplement|dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
79820|NCT00047879|Biological|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
79821|NCT01232504|Drug|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
79822|NCT01232504|Drug|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
79823|NCT01232504|Drug|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
79824|NCT01232543|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
79825|NCT01232556|Drug|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
79826|NCT01232556|Drug|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
79827|NCT01232556|Drug|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
79828|NCT01232556|Drug|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
79829|NCT01232569|Drug|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
80094|NCT01230749|Drug|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
80095|NCT01230749|Drug|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
80450|NCT01231308|Procedure|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
80451|NCT01231308|Behavioral|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
80452|NCT00047697|Drug|Donepezil HCl|Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
80453|NCT01231321|Drug|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
80454|NCT01231334|Drug|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
80455|NCT01231334|Drug|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
80456|NCT01231347|Drug|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
80457|NCT01231347|Drug|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
80458|NCT01233479|Procedure|therapeutic surgical procedure|
80459|NCT01233479|Radiation|radiation therapy|
80460|NCT01233492|Drug|boron phenylalanine|
80461|NCT01233492|Drug|mannitol|
80462|NCT01233492|Other|biologic sample preservation procedure|
80463|NCT00048061|Drug|ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
80464|NCT01233492|Radiation|radiation therapy treatment planning/simulation|
80465|NCT01233505|Drug|veliparib|Given PO
80466|NCT01233505|Drug|capecitabine|Given PO
80467|NCT01233505|Drug|oxaliplatin|Given IV
80468|NCT01233505|Other|pharmacological study|Correlative studies
80469|NCT01233505|Other|laboratory biomarker analysis|Correlative studies
79911|NCT01230424|Drug|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
79912|NCT01230424|Drug|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
79913|NCT01230450|Procedure|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
79914|NCT01232660|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
79915|NCT01232673|Procedure|BMAC application in Critical Limb Ischemia|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
80169|NCT01230814|Drug|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
80170|NCT01230827|Drug|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
80171|NCT00047619|Procedure|Pulsatile Lavage|pulsatile lavage to wound bed
80172|NCT01230827|Drug|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
80173|NCT01230827|Drug|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
80174|NCT01230840|Dietary Supplement|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
80175|NCT01230840|Dietary Supplement|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
80176|NCT01230853|Drug|Active Comparator: A|BAN2401 Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
80177|NCT01230853|Drug|Placebo Comparator B|Placebo Matching Placebo Infusion
80178|NCT01230853|Drug|Active Comparator B|BAN2401 Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
80179|NCT01230853|Drug|Placebo Comparator A|Placebo Matching Placebo Infusion
80180|NCT01230866|Radiation|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
80181|NCT01230866|Radiation|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
80694|NCT01229137|Device|SRD-1 conversion|
80695|NCT01229150|Drug|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
80696|NCT01229150|Drug|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
80697|NCT01229150|Drug|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
80698|NCT01229163|Device|Automated Contingency Management (ACM) software|
80699|NCT00047385|Device|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
80700|NCT01229176|Biological|Vi-CRM197 vaccine|
80701|NCT01229176|Biological|Vi Polysaccharide (PS) vaccine|
80702|NCT01229176|Biological|Pneumococcal conjugate vaccine|
80703|NCT01229189|Dietary Supplement|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
80704|NCT01229189|Dietary Supplement|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
80705|NCT01229202|Drug|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
80706|NCT01229215|Drug|FCFD4514S|Repeating intravitreal injection
80707|NCT01229215|Drug|sham|Repeating sham injection
80708|NCT01229228|Drug|Naproxen Test|200-mg single dose
80709|NCT01229228|Drug|Naproxen Test|400-mg (2 x 200-mg)
79752|NCT01225159|Drug|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
79753|NCT01225159|Drug|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
79754|NCT01225172|Drug|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
79755|NCT01225172|Drug|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
76871|NCT01215344|Drug|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
76872|NCT01215344|Drug|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
76873|NCT01215344|Drug|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
76874|NCT01215344|Drug|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
76875|NCT01215357|Drug|Ecopipam|50mg tablets
76876|NCT01215370|Other|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
76877|NCT01215370|Other|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
76878|NCT01215370|Other|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
76879|NCT01210404|Drug|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
75933|NCT01218464|Drug|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
75934|NCT01218477|Drug|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
75935|NCT01220596|Drug|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
75936|NCT01220609|Drug|Ixabepilone|Given IV
75937|NCT01220609|Other|Laboratory Biomarker Analysis|Correlative studies
75938|NCT01220622|Drug|Nimodipine|Administration of nimodipine 30mg tid for 6 months
75939|NCT01220622|Drug|Placebo|Administration of placebo 30mg tid for 6 months
75940|NCT01220635|Behavioral|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
75941|NCT01220635|Behavioral|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
75942|NCT01220648|Drug|Nilotinib, interferon-alfa|
80470|NCT01233518|Device|FFR|Fractional flow reserve measured during cardiac catheterization
79530|NCT01236976|Other|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality. These may be provided in lying (e.g. supine, prone) and in weight-bearing positions (e.g. kneeling, standing). Task-specific practice of functional tasks, involving moving the upper body over and outside the base of support, will also be undertaken. Participants may also be given exercises in motor imagery, imagining movements of their body
79531|NCT01236976|Other|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
79532|NCT01236989|Procedure|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
79533|NCT01236989|Procedure|Non-anatomical liver resection|non-anatomical liver resection
79534|NCT01237015|Device|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
79535|NCT00001010|Drug|Zidovudine|
79536|NCT00048451|Drug|paricalcitol|
79537|NCT01239368|Procedure|Adoptive Immunotherapy|Th1.rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune-depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
79538|NCT01239368|Biological|Rapamycin-Generated Autologous Th1/Tc1 Cells|Six Th1.rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e5 to 15 x 10e6 cells/kg of body weight.
79539|NCT01239381|Radiation|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
79540|NCT01239394|Drug|ofatumumab|Weekly infusion for 8 weeks
79541|NCT00001012|Drug|AL 721|
79542|NCT00048711|Drug|N-acetylgalactosamine 4-sulfatase|
79543|NCT01239407|Behavioral|Culturally focused psychiatric consultation|The consultation is comprised of 3 visits:
1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).
1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.
2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).
3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person).
79544|NCT01239446|Other|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
79545|NCT01239459|Drug|Teriflunomide HMR1726|Pharmaceutical form:film coated tablet
Route of administration: oral administration on Day 1 under fasted condition
79546|NCT01239459|Drug|Cholestyramine|Pharmaceutical form:powder
Route of administration: oral administration 3 times per day on Day 54 and 55
75999|NCT01218516|Biological|farletuzumab|Combination Therapy: Farletuzumab (7.5 mg/kg) administered i.v. on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered i.v. on Week 1 of all additional cycles.
Monotherapy: Those subjects who experience clinical benefit from Combination Therapy (based on the investigator's assessment of tumor response) will go on to receive farletuzumab (7.5 mg/kg) i.v. administered on Week 1 of every 3-week cycle until documented radiographic progression, other protocol approved measures of disease progression, or study termination by the Sponsor.
76000|NCT01218516|Other|Placebo|Combination Therapy: Placebo (7.5 mg/kg) administered i.v. on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo (7.5 mg/kg) will be administered i.v. on Week 1 of all additional cycles.
Monotherapy: Those subjects who experience clinical benefit from Combination Therapy (based on the investigator's assessment of tumor response) will go on to receive placebo (7.5 mg/kg) i.v. administered on Week 1 of every 3-week cycle until documented radiographic progression, other protocol approved measures of disease progression, or study termination by the Sponsor.
76001|NCT00046748|Drug|Omalizumab|
76002|NCT01218516|Drug|Platinum Containing Doublet|Combination Therapy: At Week 1 of each 3-week cycle, farletuzumab or placebo will be given with one of three (3) acceptable chemotherapy regimens:
Carboplatin (area under the curve [AUC] 6) and paclitaxel (200 mg/m2)
Carboplatin (AUC 5) and pemetrexed (500 mg/m2)
Cisplatin (75 mg/m2) and pemetrexed (500 mg/m2) All protocol acceptable platinum containing regimens are administered on a three (3) weekly schedule for at least four (4), but no more than of six (6) cycles. Chemotherapy regimens cannot be changed once they are initiated.
76003|NCT01218529|Drug|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
76300|NCT01221298|Drug|ABT-450|tablets
76301|NCT01221298|Drug|ABT-072|tablets
76302|NCT01221298|Drug|Ribavirin|tablets
76303|NCT01221298|Drug|Ritonavir|capsules
76304|NCT01221311|Device|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
76305|NCT01221311|Device|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
76306|NCT01221337|Other|heparin free haemodialysis|Comparison of two haemodialyzers "VIE 2,1" versus "EVODIAL 2,2" in a strategy of heparin-free haemodialysis (HFH).
76307|NCT00046969|Drug|cisplatin|
76308|NCT01223807|Other|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
76309|NCT01223820|Drug|Capsaicin|5x nasal application in one day, 1 hour between each application
79756|NCT01225198|Dietary Supplement|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
79757|NCT01225198|Other|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
79758|NCT00000999|Drug|Zidovudine|
79759|NCT00047138|Procedure|adjuvant therapy|
79760|NCT01225211|Drug|Lumacaftor|Tablet
79761|NCT01225211|Drug|Ivacaftor|Tablet.
79762|NCT01225211|Drug|Lumacaftor Placebo|Matching placebo tablet.
79763|NCT01225211|Drug|Ivacaftor Placebo|Matching placebo tablet.
79764|NCT01225224|Drug|ASP015K|oral
79765|NCT01225224|Drug|Placebo|oral
79766|NCT01225237|Drug|Ramosetron|oral
79767|NCT01225237|Drug|Placebo|oral
79768|NCT01225250|Device|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
79769|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
79770|NCT00047138|Procedure|conventional surgery|
79771|NCT01227525|Device|Vibraject|The VibraJect clips onto the barrel of a conventional and intraligamentary dental syringe (and some disposable syringes) and vibrates the needle at a high frequency while injections are administered.
80356|NCT01231009|Other|Vestibular exercises|Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
80357|NCT01231061|Radiation|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
80358|NCT01231061|Radiation|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
75943|NCT00046917|Drug|cisplatin|Given IV
75944|NCT01220661|Drug|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
75945|NCT01220674|Other|cognitive testing|computer-based cognitive assessment
75946|NCT01220687|Drug|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
75947|NCT01220687|Other|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
75948|NCT01220700|Other|Triclosane|Triclosane coated suture material
75949|NCT01220700|Other|Control|Ordinary suture material
75950|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
76239|NCT01216748|Other|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
76240|NCT01216761|Drug|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
76241|NCT00000991|Drug|Dapsone|
76242|NCT00046384|Drug|aripiprazole|
76243|NCT01216761|Drug|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
76244|NCT01216761|Drug|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
76245|NCT01216774|Other|Strength training|Leg extension exercise:
Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM
76246|NCT01216787|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
76247|NCT01216787|Other|pharmacological study|
76248|NCT01216787|Procedure|therapeutic conventional surgery|
76249|NCT01216787|Other|laboratory biomarker analysis|Correlative studies
79547|NCT01239472|Drug|everolimus|Kidney transplant patients with living donors starting with the use of tacrolimus, mycophenolate sodium and prednisone without induction, and converted for use of mycophenolate sodium, everolimus, and prednisone after 90 days of kidney transplantation.
79830|NCT01232569|Drug|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
79831|NCT00047879|Drug|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
79832|NCT01232582|Device|Exablate treatment|MR guided Focused Ultrasound treatment
79833|NCT01232595|Drug|LFF571|
79834|NCT01232595|Drug|Vancomycin (POC)|
79835|NCT01232608|Behavioral|Exercise|12 months of exercise training
79836|NCT01232621|Other|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
79837|NCT01232647|Drug|Phylloquinone|1.0 mg daily for 18 months
79838|NCT01232647|Drug|Menaquinone (MK4)|MK4 45 mg daily for 18 months
79839|NCT01232647|Drug|placebo|placebo given daily for 18 months
79840|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
79841|NCT01225263|Drug|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
79842|NCT01225263|Dietary Supplement|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
79843|NCT01225263|Other|Placebo|Two placebo pills, taken twice daily for 6 months
79844|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms (or a corresponding volume of an authorised 0.9% saline solution in the placebo arm). The maintenance doses to be infused 7 times will be 0.4 g/kg, 1.0 g/kg or 2.0 g/kg every 21 (+/-4) days.
79845|NCT01225276|Drug|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses to be infused 7 times will be given every 21 (+/-4) days.
79846|NCT01225289|Dietary Supplement|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
79847|NCT01225289|Drug|Placebo|1 capsule per day for six months
76310|NCT01223859|Procedure|Interstitial soft palate surgery|Soft palate RF surgery in local anaesthesia
76311|NCT01223872|Other|interview|Standard Interview (2-15 years from last treatment)
Demographic data interview (pre-initial study interview)
76312|NCT01223872|Other|clinic visit and interview|REACH Clinic Visit(initial or regular)
Post-REACH Clinic Interview (3mos from initial or regular clinic visit)
Demographic data interview(pre-initial study interview)
76313|NCT00047099|Drug|tamoxifen citrate|
76314|NCT01223872|Other|interviews and clinic visit|Pre-REACH Clinic Interview(2-15 yrs from last treatment)
REACH Clinic Visit(initial or regular)
Post-REACH Clinic Interview(1mo from initial clinic visit)
Post-REACH Clinic Interview(3mos from initial or regular clinic visit)
Demographic data interview(pre-initial study interview)
76315|NCT01223885|Dietary Supplement|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
76316|NCT01223898|Drug|Tasigna|
76317|NCT01223911|Drug|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
76318|NCT01223911|Drug|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
76319|NCT01223924|Other|placebo|placebo
76615|NCT01217411|Radiation|Stereotactic radiosurgery (SRS)|Undergo SRS
76616|NCT01217411|Procedure|Cognitive assessment|Ancillary studies
76617|NCT01217411|Other|Laboratory biomarker analysis|Correlative studies
76618|NCT01217424|Other|questionnaire administration|
76619|NCT00000991|Drug|Zidovudine|
76620|NCT00046501|Drug|Lantus (insulin glargine [rDNA origin] injection)|
76621|NCT01217424|Procedure|aromatherapy and essential oils|
76622|NCT01217424|Procedure|management of therapy complications|
76623|NCT01217424|Procedure|massage therapy|
76624|NCT01217424|Procedure|psychosocial assessment and care|
76625|NCT01217424|Procedure|reflexology procedure|
80359|NCT01231074|Drug|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
80360|NCT01231100|Other|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
80361|NCT01231113|Drug|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
80362|NCT01231113|Drug|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
80363|NCT01231126|Drug|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
80364|NCT01231139|Drug|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
80365|NCT01231139|Drug|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
80366|NCT00001004|Drug|Interferon gamma-1b|
80367|NCT00047671|Drug|Citalopram|PDA Approved antidepressant
80368|NCT01231165|Drug|Amiloride|5mg/daily for 12th months
80369|NCT01231165|Drug|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
80370|NCT01231178|Dietary Supplement|Alginate beverage|The dosage is 3x500ml daily
80371|NCT01231178|Dietary Supplement|Control beverage|The dosage is 3x500ml daily
80372|NCT01231191|Drug|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
80373|NCT01231191|Drug|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
80374|NCT01231204|Procedure|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
80375|NCT01233154|Dietary Supplement|probiotic|
80376|NCT01233167|Drug|clopidogrel|clopidogrel 75 mg po per day for 12 months
80396|NCT01233284|Drug|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
76250|NCT01216800|Procedure|adjuvant therapy|
76251|NCT01216800|Procedure|assessment of therapy complications|
76252|NCT01216800|Procedure|quality-of-life assessment|
76253|NCT00046397|Drug|Modified Vaccinia Virus Ankara TBC-M|
76254|NCT01216800|Radiation|3-dimensional conformal radiation therapy|
76255|NCT01216800|Radiation|intensity-modulated radiation therapy|
76256|NCT01216813|Other|informational intervention|
76257|NCT01216813|Procedure|assessment of therapy complications|
76258|NCT01216813|Procedure|psychosocial assessment and care|
76259|NCT01216826|Drug|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
76260|NCT01216839|Drug|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
76261|NCT01216852|Drug|Losartan Potassium|100 mg tablet
76547|NCT01221753|Drug|Cisplatin|Given intravenously on day 1 of each cycle
76548|NCT01221753|Drug|5-fluorouracil|Given intravenously by pump over 4 days of each cycle
76549|NCT01221753|Radiation|Intensity modulated radiation therapy|Once daily 5 days per week for 6-7 weeks
76550|NCT01221753|Drug|carboplatin|Given intravenously once a week for 6-7 weeks
76551|NCT01221753|Drug|cetuximab|Given intravenously once a week for 6-7 weeks
76552|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
76553|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
76554|NCT01221792|Drug|Carvedilol|Oral, twice daily dosing using 3.125 mg tablets.
1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day).
76555|NCT01221792|Drug|Placebo|Non active comparator
76556|NCT01221818|Drug|E6007|E6007 25mg single dose or matching placebo
79848|NCT01225302|Drug|Linifanib|Low dose linifanib (once a day)
79849|NCT01225302|Drug|Linifanib|High dose linifanib (once a day)
79850|NCT00047138|Procedure|neoadjuvant therapy|
79851|NCT01225302|Drug|Carboplatin|Given on Day 1 of every 21-day cycle
80114|NCT01233089|Device|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
80115|NCT01233089|Device|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
80116|NCT01233102|Drug|Conserved Therapy|Conserved Therapy
80117|NCT01233102|Procedure|Hepatic artery infusion or Intravenous infusion|Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
80118|NCT01233154|Dietary Supplement|probiotic|
80119|NCT01225614|Device|Bilevel pressure ventilator|Nocturnal home ventilation
80120|NCT01225627|Other|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
80121|NCT01225627|Other|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
80122|NCT01225640|Drug|PNU-100480|600 mg twice daily (BID) for 14 days
80123|NCT01225640|Drug|PNU-100480|1200 mg once daily (QD) for 14 days
80124|NCT01225640|Drug|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
80125|NCT01225653|Drug|Latanoprost|Topical application
80126|NCT00047203|Drug|alvocidib|Given IV
80127|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
76626|NCT01219595|Other|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
76627|NCT01219608|Dietary Supplement|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
76628|NCT01219608|Dietary Supplement|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
76629|NCT00000994|Drug|Zidovudine|
76630|NCT00046852|Biological|therapeutic tumor infiltrating lymphocytes|
76631|NCT01219608|Dietary Supplement|Enteral Nutrition|Ordinary Enteral Nutrition
76632|NCT01219621|Procedure|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
76633|NCT01219647|Behavioral|exercise|subjects will participate in one of two forms of exercise
76634|NCT01219647|Behavioral|stretching|subjects will particiopate in supervised stretching as described in arm description.
76635|NCT01219673|Other|Placebo|1 by mouth twice a day.
76636|NCT01219673|Drug|Armodafinil|150 mg by mouth once a day.
76637|NCT01219673|Drug|Minocycline|100 mg by mouth twice a day.
76638|NCT01219673|Drug|Bupropion|100 mg by mouth twice a day.
76639|NCT01219686|Drug|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
76640|NCT01219686|Drug|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
76937|NCT01205555|Device|urine LH testing|The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :
13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.
If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (<8 IU\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\L) the insemination will be the next day.
76938|NCT01205568|Procedure|Transcatheter Cutting Balloon therapy|
76939|NCT01205568|Procedure|High Pressure Balloon Angioplasty|
76940|NCT01205581|Biological|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
80397|NCT01233284|Drug|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
80398|NCT01226030|Drug|M2ES 60mg|M2ES 60mg
80399|NCT01226043|Drug|Insulin Glargine|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
80400|NCT01226056|Drug|RAD001 in combination with sorafenib|Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.
The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).
Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.
80401|NCT01226069|Drug|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
80402|NCT01226069|Drug|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
80403|NCT00047255|Biological|trastuzumab|Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.
Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.
Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins.
80404|NCT01226069|Other|No application|No application
80405|NCT01226082|Device|Transcranial Direct Current Stimulation|Patients will recieve tDCS in a 5-day period of treatment
80406|NCT01226108|Device|Patch|One patch per day, Duration: three weeks, Administration: behind the ear
80407|NCT01226121|Biological|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
80408|NCT01226134|Drug|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
80409|NCT01226134|Drug|Placebo|placebo capsules,thrice a day for four weeks
80410|NCT01226147|Drug|Tamibarotene|4mg/day for 24 weeks.
80411|NCT01226160|Procedure|Postoperative face-down posturing|Postoperative face-down posturing for 10 days after surgery.
80412|NCT01226160|Procedure|Postoperative non-posturing group|avoid a face-up position only for 10 days after surgery
80413|NCT01226173|Device|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
76557|NCT00000996|Drug|Doxorubicin hydrochloride|
76558|NCT00046995|Drug|leucovorin calcium|
76559|NCT01221818|Drug|E6007|E6007 50mg single dose or matching placebo
76560|NCT01221818|Drug|E6007|E6007 100mg single dose or matching placebo
76561|NCT01221818|Drug|E6007|E6007 200mg single dose or matching placebo
76562|NCT01221818|Drug|E6007|E6007 400mg single dose or matching placebo
76563|NCT01221818|Drug|E6007|E6007 600 mg single dose or matching placebo
76564|NCT01221831|Drug|estetrol, P 1 and placebo tablets|6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-24: one estetrol tablet and one P1 tablet per day
Days 25-28: two placebo tablets per day
76565|NCT01221831|Drug|estetrol, P2 and placebo tablets|6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-24: one estetrol tablet and one P2 tablet per day
Days 25-28: two placebo tablets per day
76566|NCT01221831|Drug|Estradiol valerate, dienogest and placebo tablets|6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-26: one tablet of Estradiol valerate/dienogest per day
Days 26-28: one placebo tablet per day
76567|NCT01221844|Dietary Supplement|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
76568|NCT01221844|Drug|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
76569|NCT00046995|Procedure|adjuvant therapy|
76880|NCT01210417|Other|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
76881|NCT01210430|Drug|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
76882|NCT00045617|Drug|cisplatin|
76883|NCT01210430|Drug|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
76884|NCT01210430|Drug|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
76885|NCT01210443|Drug|Sitaxentan|sitaxentan sodium 100 mg
80128|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
80129|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
80130|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
80131|NCT01225679|Device|positive airway pressure, Non-invasive mechanic ventilation|Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.
Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O.
80132|NCT01225692|Behavioral|Head Injury Guideline|
80471|NCT01233531|Behavioral|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
80472|NCT01233531|Behavioral|B--No cash transfers|No monthly cash transfers
80473|NCT01233544|Procedure|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
80474|NCT00048061|Drug|ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
80475|NCT01233570|Drug|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
80476|NCT01233583|Drug|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
80477|NCT01233596|Device|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
80478|NCT01233609|Drug|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
80479|NCT01233609|Drug|Placebo|Dosage per subject weight- same schedule as the active comparator
80480|NCT01233622|Drug|Vildagliptin|
80481|NCT01233622|Drug|Placebo|
80482|NCT01233635|Other|no drug|none, no drug
80483|NCT01233635|Drug|start cozaar|start cozaar
80484|NCT01233635|Drug|continue cozaar|continue cozaar
76941|NCT01205581|Biological|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
76942|NCT00045175|Drug|7-hydroxystaurosporine|
76943|NCT01208064|Other|pharmacogenomic studies|
76944|NCT01208064|Other|pharmacological study|
76945|NCT01208064|Procedure|quality-of-life assessment|
76946|NCT01208090|Drug|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
76947|NCT01208090|Drug|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
76948|NCT01208103|Drug|Capecitabine|750 mg/m2 by mouth twice a day beginning on day 1-14 of 21 day cycle.
76949|NCT01208103|Drug|Oxaliplatin|130 mg/m2 by vein on day 1 over 2 hours of 21 day cycle.
76950|NCT01208103|Drug|Bevacizumab|7.5 mg/kg by vein on day 1 over 90 minutes of 21 day cycle.
76951|NCT01208116|Other|Cardiovascular events|Coronary intervention
Infarction
Congestive heart failure
Stroke
Cardiac death
76952|NCT01208129|Drug|NAB001|nail lacquer, once daily, 52 weeks
76953|NCT00045435|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
76954|NCT01208129|Drug|Placebo control|nail lacquer, once daily, 52 weeks
76955|NCT01208142|Other|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
76956|NCT01208142|Device|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
76957|NCT01208155|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
76004|NCT01218542|Radiation|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
76005|NCT01218555|Drug|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
76006|NCT01218555|Drug|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
76007|NCT01218568|Drug|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
79474|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
79475|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
79476|NCT01241708|Drug|Bortezomib|Bortezomib 1.6mg/m2 on day -4 and day -1
79477|NCT00001013|Drug|Sulfamethoxazole-Trimethoprim|
79478|NCT00048893|Biological|sargramostim|100 mcg daily for 4 consecutive days at the same site as the rF-CEA (6D)/Tricom vaccine. The first dose will be given with the vaccine.
79479|NCT01241721|Device|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
79480|NCT01241734|Drug|Revlimid|Stage I:
Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7
Stage III:
Lenalidomide 25mg days 1-21 every 28 days
79481|NCT01241747|Behavioral|Walking Exercise|3 times per week for 3 months
79482|NCT01241747|Behavioral|Control|Resistance training 3 times per week for 3 months
79483|NCT01241760|Drug|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
79484|NCT01241760|Drug|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
79485|NCT01241760|Drug|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
79486|NCT01241760|Drug|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
79487|NCT01241773|Drug|raltegravir|One 400 mg tablet twice daily for 7 days
79488|NCT01241773|Drug|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
79489|NCT00048893|Drug|cyclophosphamide|First induction chemotherapy: 2700 mg/m^2 per cycle (900 mg/m^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).
Second induction: 600 mg/m^2 per cycle (600 mg/m^2 intravenous over 1 hour day 1.
Immune depleting chemotherapy: 2400 mg/m^2 per cycle (600 mg/m^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4).
79490|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 7 days
76886|NCT01210456|Drug|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.
154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.
In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure.
76887|NCT01210469|Other|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
76888|NCT01210469|Other|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
76889|NCT01210482|Drug|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30~60 minutes. The dosage is to be appropriately reduced according to patients' status.
76890|NCT01210495|Drug|Axitinib (AG-013736)|Axitinib [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
76891|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
76892|NCT01210495|Drug|Placebo|Placebo [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
76893|NCT00045617|Drug|etoposide|
76894|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
76895|NCT01210521|Drug|Vitamin D|Vitamin D, (2000IU) will be administered orally, once a day, for one month.
76896|NCT01210534|Other|No intervention|No intervention
76897|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
76898|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
75951|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
75952|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
75953|NCT01220726|Drug|Botox/Placebo|Botox/Placebo injection
75954|NCT00046930|Biological|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
80485|NCT00048061|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly
80486|NCT01233648|Other|rate control via CRT-D and AVN ablation|rate control
80487|NCT01226212|Dietary Supplement|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
80488|NCT01226212|Dietary Supplement|Placebo|maltodextrose
80489|NCT01226225|Behavioral|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
80490|NCT01226225|Behavioral|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
80491|NCT01226238|Other|Online self-help|Provision of online self-help
80492|NCT01226251|Device|In vitro chair side test|Colour evaluation of a strip
79548|NCT01239485|Drug|Irinotecan|Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, & 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr
*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4.
79549|NCT01239498|Procedure|Injection of Saline + Lidocaine/Adrenaline|All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.
The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.
Injection of Saline + Lidocaine 1%
79550|NCT01239498|Procedure|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
79551|NCT01239511|Drug|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
79552|NCT01239524|Procedure|denervation of thoracodorsal nerve or saving the nerve|
79553|NCT00048724|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
79554|NCT01239537|Drug|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
79555|NCT01239550|Drug|Detemir|Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.
Insulin injections will be given subcutaneously preferably in the thigh or abdomen.
76008|NCT01218568|Drug|Lactulose|Lactulose 30-60 ml in two or three divided doses.
76009|NCT01218581|Drug|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
76010|NCT01218594|Drug|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
76011|NCT01218607|Drug|Bosentan|Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.
76012|NCT00046761|Drug|ONO-2506|
76013|NCT01218607|Drug|Placebo|Placebo will be taken twice daily for 16 weeks
76014|NCT01218620|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
76015|NCT01218620|Drug|Ketoconazole|Given PO
76016|NCT01218620|Drug|Rifampin|Given PO
76017|NCT01218620|Drug|Midazolam Hydrochloride|Given IV
76018|NCT01220739|Device|transcranial laser therapy|The NeuroThera® Laser System (NTS) is used in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
76019|NCT01220752|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
76020|NCT01220765|Device|Capnography|In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 > 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
76021|NCT01220778|Behavioral|Exercise|
76022|NCT01220791|Other|In vitro fertilization treatment for infertility|IVF treatment
76023|NCT01220817|Drug|3 POMx capsules|3 POMx capsules daily
76024|NCT01220817|Drug|1 POMx capsule|1 POMx capsule daily
76320|NCT01223924|Drug|M2ES|M2ES IV 7.5mg-90mg
76321|NCT01223937|Drug|Desmopressin|
76322|NCT01223937|Drug|Placebo|
79491|NCT01241773|Drug|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
79492|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 14 days
79772|NCT01227538|Other|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
79773|NCT01227551|Biological|CAVATAK (Coxsackievirus A21, CVA21)|Each patient will receive 10 intratumoral injections of CAVATAK. Each dose will contain up to 3 x 10^8.0 TCID50 virus in a maximum volume of 4 mL.
79774|NCT01227564|Biological|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
79775|NCT01227564|Biological|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
79776|NCT01227564|Other|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
79777|NCT01227577|Drug|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
79778|NCT01227590|Drug|Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
79779|NCT01227603|Drug|Nifedipine-candesartan FDC (BAY 98-7106)|Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
79780|NCT00047294|Drug|thalidomide|
79781|NCT01227603|Drug|Nifedipine GITS (Adalat LA, BAYA1040)|Single oral dose of 1 tablet of nifedipine GITS 60 mg
79782|NCT01227603|Drug|Candesartan (Atacand)|Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
79783|NCT01227616|Drug|Ferumoxytol|IV Ferumoxytol
79784|NCT01227616|Drug|Iron Sucrose|IV Iron Sucrose
79785|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79786|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79787|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79788|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79789|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
75955|NCT01220726|Drug|Botox/Placebo|Botox/Placebo injection
75956|NCT01223144|Behavioral|Iowa Gambling Task and Ekman facial recognition test|Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).
Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger).
75957|NCT01223157|Biological|Biological data|Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
75958|NCT01223170|Behavioral|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
75959|NCT01223170|Behavioral|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
75960|NCT01223170|Behavioral|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
75961|NCT00047073|Procedure|Surgery|Surgical resection.
75962|NCT01223170|Behavioral|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
75963|NCT01223183|Drug|hypertonic saline (7%)|single treatment by inhalation
75964|NCT01223183|Drug|isotonic saline|single treatment by inhalation
75965|NCT01223196|Drug|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
75966|NCT01223196|Drug|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
75967|NCT01223209|Drug|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
75968|NCT01223222|Drug|LTX-109|Topical administration. 3 times daily. 5 days.
76262|NCT01216865|Biological|umbilical cord mesenchymal stem cells|5*10/7 per ischemic limb
76263|NCT01216865|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
76264|NCT00046423|Drug|ABI-007|
76265|NCT01218880|Drug|M2ES 45mg|M2ES Dosage：45mg/m2
79556|NCT01241786|Drug|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and < 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
79557|NCT01241786|Drug|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
79558|NCT01241799|Procedure|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
79559|NCT01241799|Procedure|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
79560|NCT01241812|Behavioral|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
79561|NCT01241812|Behavioral|Usual care|Usual care - no intervention
79562|NCT00048893|Drug|doxorubicin hydrochloride|60 mg/m^2 per cycle (60 mg/m^2 slow intravenous push day 1).
79852|NCT01225302|Drug|Paclitaxel|Given on Day 1 of every 21-day cycle
79853|NCT01225315|Drug|Placebo|matching placebo administered orally twice daily
79854|NCT01225315|Drug|Reliever Medication|Salbutamol/albuterol (100 Ug/puff, metered dose inhaler [MDI])
79855|NCT01225315|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
79856|NCT01225328|Behavioral|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
79857|NCT01225341|Drug|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
79858|NCT01225341|Other|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
79859|NCT01225354|Drug|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
79860|NCT01225367|Device|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
76323|NCT01223976|Other|Tuberculin skin test and Quantiferon -TB Gold test|TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.
QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions.
76324|NCT00047099|Procedure|adjuvant therapy|
76325|NCT01223989|Other|hypocaloric diet balanced + nutrition education + ruled physical activity|
76326|NCT01224015|Drug|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
76327|NCT01224015|Biological|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
76328|NCT01224015|Biological|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
76329|NCT01224028|Drug|Tacrolimus|oral
76330|NCT01224028|Drug|Placebo|oral
76331|NCT01224041|Drug|Tacrolimus|oral
76332|NCT01216878|Drug|losartan potassium|100 mg tablet
76333|NCT01216891|Behavioral|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
76334|NCT01216904|Drug|nicotine patch|7 mg patches to be worn for 16 hours per day
76335|NCT01216904|Drug|placebo|placebo patch to be worn 16 hours per day
76336|NCT01216930|Other|Observation|Observation
76337|NCT01216943|Drug|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
76338|NCT01216956|Drug|Extended-release nicotinic acid versus placebo|Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
76339|NCT01216982|Drug|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
76641|NCT00046852|Drug|carmustine|
79790|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
79791|NCT00047294|Procedure|adjuvant therapy|
79792|NCT01227629|Drug|warfarin|comparator
79793|NCT01227629|Drug|dabigatran without ASA|dose comparison
79794|NCT01227629|Drug|dabigatran without ASA|dose comparison
80054|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
80055|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of the cycle.
80056|NCT01227954|Other|laboratory biomarker analysis|
80057|NCT01227954|Other|questionnaire administration|
80058|NCT00047320|Drug|etoposide|Given IV
80059|NCT01227954|Procedure|cognitive assessment|
80060|NCT01227954|Procedure|quality-of-life assessment|
80061|NCT01227954|Radiation|intensity-modulated radiation therapy|
80062|NCT01227954|Radiation|whole-brain radiation therapy|
80063|NCT01227967|Drug|Amantadine, Ribavirin, Oseltamivir|One capsule of Oseltamivir 75 mg x 2 - Total dose: 150 mg/day for 5 days; Three capsules of Ribavirin 200 mg for total of 600 mg x 2 - Total dose: 1200 mg/day for 5 days; One capsule of Amantadine 100 mg x 2 Total dose: 200 mg/day for 5 days
80064|NCT01227967|Drug|Oseltamivir|75 mg x 2 Total dose: 150 mg/day for 5 days
80065|NCT01227980|Drug|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
80066|NCT01227980|Drug|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
80067|NCT01227993|Drug|Finasteride|
80068|NCT01228006|Dietary Supplement|NatusGerin|1 capsule, 2 times a day.
80069|NCT00047320|Drug|ifosfamide|Given IV
76266|NCT01218893|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
76267|NCT01218893|Biological|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
76268|NCT01218893|Biological|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
76269|NCT01218893|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
76270|NCT00046826|Drug|docetaxel|
76271|NCT01218932|Drug|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
76272|NCT01218932|Drug|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
76273|NCT01218945|Procedure|Cell Culture|Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
76274|NCT01218958|Drug|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
76275|NCT01218958|Drug|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
76276|NCT01218958|Drug|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
76277|NCT01218958|Drug|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
76278|NCT01218971|Drug|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
76279|NCT01218971|Drug|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
76280|NCT01218984|Drug|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
76281|NCT00046826|Drug|estramustine phosphate sodium|
76282|NCT01218984|Drug|Medisorb naltrexone 150 mg|Single administration via IM injection.
76570|NCT01214824|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
79861|NCT00047138|Radiation|radiation therapy|
79862|NCT01225380|Drug|GS-9190|GS-9190 capsule, 20 mg BID, 16 or 24 weeks
79863|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 16 or 24 weeks
79864|NCT01227642|Other|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
79865|NCT01227642|Other|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
79866|NCT01227642|Other|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
79867|NCT01227655|Drug|BIA 9-1067|Capsules will be used.
79868|NCT01227655|Drug|Placebo|comparator
79869|NCT01227655|Drug|Levodopa|
79870|NCT00047307|Drug|alvocidib|Given IV
79871|NCT01227655|Drug|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
79872|NCT01227655|Drug|Benserazide|DOPA decarboxylase inhibitor
80133|NCT01225705|Drug|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
80134|NCT01225705|Drug|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
80135|NCT01225731|Biological|tildrakizumab|SC administration of tildrakizumab at assigned dose
80136|NCT01225731|Drug|Placebo|SC administration of Placebo
80137|NCT00047216|Drug|tipifarnib|
80138|NCT01225744|Drug|Cetuximab|Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.
Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA > 2 m2 .
80139|NCT01225744|Drug|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
76642|NCT01219686|Drug|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
76643|NCT01219699|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
76644|NCT01219699|Drug|Fulvestrant|In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.
Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection
76645|NCT01219712|Procedure|Colloids, dobutamin, levosimendan|: The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.
Hb would be optimized to > 90 g/l
SaO2 > 96%
Stroke volume index (SVI) > 30
Heart rate should ideally be < 80
Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal
76646|NCT01219725|Behavioral|Exercise training|6 months of moderate intensity exercise training 3 times per week
76647|NCT01219738|Drug|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
76648|NCT01219738|Drug|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
76649|NCT01219738|Drug|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
76650|NCT01219738|Drug|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
76651|NCT01219738|Drug|Placebo|A single inhaled dose of placebo from a DPI.
76652|NCT01221857|Drug|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
76653|NCT01221870|Drug|Tesetaxel once every 3 weeks|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
76654|NCT01221870|Drug|Tesetaxel once weekly|Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
76655|NCT01221883|Drug|Diazepam|Single dose 10mg Diazepam tablet
76656|NCT01221896|Procedure|C11-Choline PET/CT|
76657|NCT01221909|Drug|Tranexamic acid|Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
76658|NCT01221909|Drug|saline solution|5cc saline solution
76659|NCT01221922|Device|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
76660|NCT01221935|Other|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
80070|NCT01228006|Other|Placebo capsules|1 capsule, 2 times a day
80071|NCT01228019|Drug|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
80072|NCT01228032|Other|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
80073|NCT01228045|Drug|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
80074|NCT01228058|Procedure|RapidTEG test|The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
80414|NCT00047255|Drug|carboplatin|Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.
Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.
Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins.
80415|NCT01226186|Behavioral|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
80416|NCT01226186|Behavioral|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
80417|NCT01228552|Drug|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
80418|NCT01228552|Other|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
80419|NCT01228565|Other|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
80420|NCT01228565|Other|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
80421|NCT01228578|Dietary Supplement|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
80422|NCT01228591|Device|Acuvue Advance Plus|Silicone hydrogel contact lens.
80423|NCT01228591|Device|Acuvue Advance|Silicone hydrogel contact lens
76571|NCT01214837|Biological|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
76572|NCT01214837|Biological|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
76573|NCT01214837|Biological|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
76574|NCT01214850|Biological|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
76575|NCT01214850|Biological|MenACWY-CRM conjugate vaccine|
76576|NCT01214850|Biological|Japanese Encephalitis vaccine|
76577|NCT01214863|Device|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
76578|NCT00046137|Drug|raloxifene|
76579|NCT01214863|Device|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
76580|NCT01214863|Device|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
76581|NCT01214889|Biological|PENTAXIM™: DTacP IPV//PRP~T combined vaccine|0.5 mL, intramuscular
76582|NCT01214889|Biological|TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine|0.5 mL of each vaccine; intramuscular
76583|NCT01214902|Device|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
76584|NCT01214902|Behavioral|play|play which encourages the use of the hemiplegic hand
76585|NCT01214915|Drug|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
76586|NCT01214928|Drug|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
76587|NCT01214941|Drug|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
76588|NCT01214941|Drug|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
76589|NCT00046137|Drug|placebo|
76590|NCT01214941|Drug|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
80140|NCT01228084|Drug|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
80141|NCT01228084|Other|Laboratory biomarker analysis|Correlative studies
80142|NCT01228084|Other|Pharmacological study|Correlative studies
80143|NCT01228110|Drug|Hydrocortison|
80144|NCT00000250|Drug|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
80145|NCT00001002|Drug|Foscarnet sodium|
80146|NCT00047320|Drug|thiotepa|Given IV
80147|NCT01228110|Drug|Saline Solution|
80148|NCT01228123|Other|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
80149|NCT01228123|Other|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
80150|NCT01228136|Drug|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
80151|NCT01228136|Other|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
80152|NCT01228149|Procedure|Trabeculectomy|Filtrating glaucoma surgery, preoperative treatment will be assessed.
80153|NCT01228162|Procedure|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
80493|NCT01226264|Procedure|Diffusion weighted MRI (DW- MRI)|An MRI examination (including diffusion-weighted sequences) belongs to the standard protocol for patients with cervical uterine cancer. The additional burden is therefore restricted to an extra MRI scan during and/or early after therapy.
MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.
During the examination, an intravenous and vaginal contrast medium will be administered. In most cases, patients do not experience any discomfort and the use of these contrast agents is part of the clinical routine.
80494|NCT01226277|Drug|GDC-0917|Oral repeating dose
76661|NCT01221935|Other|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
76958|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
76959|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
76960|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
76961|NCT01208168|Drug|NAB001|nail lacquer, once daily, 52 weeks
76962|NCT01208168|Drug|Vehicle alone|nail lacquer, once daily, 52 weeks
76963|NCT01208181|Drug|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
76964|NCT00000987|Drug|Bleomycin sulfate|
76965|NCT00045435|Drug|fludarabine phosphate|Given IV
76966|NCT01208181|Drug|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
76967|NCT01208181|Drug|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
76968|NCT01208181|Drug|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
76969|NCT01208194|Drug|MGN1703|solution, 60 mg, twice a week, until progression
76970|NCT01208194|Drug|Placebo|solution, 60 mg, twice a week, until progression
76971|NCT01208207|Drug|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
76972|NCT01208207|Drug|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
76973|NCT01210560|Drug|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
76974|NCT01210573|Device|adjustment of LVAD or pacemaker|For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.
For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.
76975|NCT01210586|Behavioral|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
76976|NCT00045617|Radiation|radiation therapy|
80424|NCT01228604|Drug|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
80425|NCT00047333|Other|laboratory biomarker analysis|Correlative studies
80426|NCT01228617|Drug|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
80427|NCT01228617|Drug|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
80428|NCT01228630|Drug|Loratadine + pseudoephedrine|2 times per day for 28 days
80429|NCT01228643|Biological|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
80430|NCT01228643|Device|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
79493|NCT01241773|Drug|efavirenz|One 600 mg tablet once daily for 14 days
79494|NCT00048126|Drug|capecitabine [Xeloda]|1000mg po bid
79495|NCT01234363|Device|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
79496|NCT01234376|Device|Confocal laser endomicroscopy|Confocal laser endomicroscopy
79497|NCT01234389|Device|Electrochemical H. pylori detection method|Determination of H. pylori infection.
79498|NCT01234389|Device|IHC|Determination of H. pylori infection.
79499|NCT01234389|Device|C13-urea breath test|Determination of H. pylori infection.
79500|NCT01234389|Device|HUT|Determination of H. pylori infection.
79501|NCT01234402|Biological|Ramucirumab DP|10 mg/kg I.V.
Day 1 of every-21-day cycle
79502|NCT01234402|Biological|IMC-18F1|12 mg/kg I.V.
Days 1 and 8 of every-21-day cycle
79503|NCT01234402|Drug|Capecitabine|1000 mg/m2 orally
Twice a day for 14 days
76899|NCT01210560|Drug|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
76900|NCT01210560|Drug|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
76901|NCT01213004|Procedure|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
76902|NCT01213017|Drug|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
76903|NCT01213030|Drug|[F-18] FMISO|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
76904|NCT01213030|Drug|[F-18] HX4|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
76905|NCT01213043|Biological|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
76906|NCT00045903|Behavioral|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
76907|NCT01213043|Biological|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
76908|NCT01213056|Behavioral|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
76909|NCT01213069|Other|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
76910|NCT01213082|Drug|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
76911|NCT01213082|Drug|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
76912|NCT01213082|Drug|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
76913|NCT01213095|Drug|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
76914|NCT01213108|Behavioral|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
76915|NCT01213108|Behavioral|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
76916|NCT01213121|Drug|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
76917|NCT00045903|Behavioral|Stress Management Therapy (Cognitive Behavior Therapy)|
80495|NCT00047255|Drug|docetaxel|Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.
Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.
Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes.
80496|NCT01226290|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
80497|NCT01226303|Drug|ATRA|see the protocol
80498|NCT01226303|Drug|ATRA + IDA|see the protocol
80499|NCT01226316|Drug|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
80500|NCT01226316|Drug|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
80501|NCT01226316|Drug|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
80502|NCT01226316|Drug|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
80503|NCT01228695|Other|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
80504|NCT01228708|Other|Active implementation of a guideline for chronic disease|Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on "How to live with COPD" and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD
80505|NCT01228721|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
79563|NCT01241825|Other|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
79564|NCT01241825|Other|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
76977|NCT01210599|Drug|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
76978|NCT01210612|Device|five-toed socks|five-toed socks usage
76979|NCT01210625|Dietary Supplement|Nutrabiotix|Fiber supplement: 9mg or 12mg
80034|NCT01225497|Procedure|Eccentric exercise-Experimental group|Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
80035|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
80036|NCT00047190|Drug|tipifarnib|Given PO
80037|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
80038|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
80039|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
80040|NCT01225536|Drug|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
80041|NCT01225549|Drug|AZD5423|Suspension for nebulisation once daily 7 days
80042|NCT01225549|Drug|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
80043|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
80044|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
80045|NCT01225562|Drug|Ticagrelor 90 mg|Oral dose twice a day
80046|NCT01225562|Drug|Ticagrelor 60 mg|Oral dose twice a day
80047|NCT00047190|Other|laboratory biomarker analysis|Correlative studies
80048|NCT01225562|Drug|Ticagrelor Placebo|Oral dose twice a day
80049|NCT01225575|Drug|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.
The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect
79504|NCT01234415|Device|Rhinoplasty|Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
79505|NCT00048139|Drug|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
79506|NCT01234428|Procedure|Laparoscopic surgery|Gastric banding
79507|NCT01234428|Procedure|gastric banding|laparoscopic gastric banding
79508|NCT01234441|Dietary Supplement|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
79509|NCT01234441|Dietary Supplement|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
79510|NCT01234441|Behavioral|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
79511|NCT01234454|Drug|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
79512|NCT01234454|Drug|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
79513|NCT01234467|Drug|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
79795|NCT01227629|Drug|dabigatran without ASA|dose comparison
79796|NCT01230099|Behavioral|Supportive Information Team Group|A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
79797|NCT01230125|Drug|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
79798|NCT01230125|Drug|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
79799|NCT01230138|Drug|Placebo|Placebo tablets
79800|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 250mg TID
79801|NCT00047515|Drug|Alcon Investigational Agent|
79802|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 375mg BID
79803|NCT01230138|Drug|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
76918|NCT01213147|Drug|clomiphene citrate|100 mg per day oral for 7 days
76919|NCT01213147|Drug|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
75969|NCT01223235|Biological|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
75970|NCT01223248|Radiation|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
75971|NCT01216241|Drug|Daptomycin|8 mg/kg once daily
75972|NCT01216254|Device|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
75973|NCT01216267|Drug|Lansoprazole|lansoprazole 30 mg HS x 7 days
75974|NCT01216267|Drug|lansoprazole|lanzoprazole 30 mg HS for 7 days
75975|NCT01216280|Drug|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
75976|NCT01216280|Drug|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
75977|NCT01216280|Drug|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
75978|NCT00046319|Drug|BSF 208075|
75979|NCT01216293|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, capsules, orally, once daily for up to 26 weeks.
75980|NCT01216293|Drug|Esomeprazole|Esomeprazole 40 mg, capsules, orally, once daily for up to 26 weeks.
75981|NCT01216293|Drug|Placebo|Placebo-matching capsules, orally, once daily for up to 26 weeks.
75982|NCT01216306|Behavioral|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
75983|NCT01216319|Device|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
79565|NCT01241838|Device|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
79566|NCT01241851|Behavioral|Aerobic exercise|
79567|NCT01241851|Behavioral|Resistance exercise|
79568|NCT01241864|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
79569|NCT01241864|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
79570|NCT01241877|Dietary Supplement|astaxanthin|astaxanthin
79571|NCT01241877|Dietary Supplement|placebo|placebo
79572|NCT01241903|Drug|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
79573|NCT00048893|Drug|fludarabine phosphate|120 mg/m^2 (30 mg/m^2 per day intravenous over 30 minutes for 4 consecutive days (days 1-4)).
79574|NCT01234519|Drug|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
79575|NCT01234532|Drug|entinostat|Given PO
79576|NCT01234532|Drug|anastrozole|Given PO
79577|NCT01234532|Other|diagnostic laboratory biomarker analysis|Correlative studies
79578|NCT01234532|Procedure|therapeutic conventional surgery|Undergo mastectomy or lumpectomy
79579|NCT01234545|Drug|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
79580|NCT01234558|Drug|GLYX-13|single IV dose
79581|NCT01234584|Procedure|spk|implants using SPK Abutments
79582|NCT00048152|Drug|Corticosteroids|As prescribed
79873|NCT01227668|Drug|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
80050|NCT01225601|Behavioral|Tabacco discontinuation|Tabacco discontinuation
80051|NCT01227915|Drug|Tobradex|tobramycin 0.3% + dexamethasone 1%
80052|NCT01227928|Drug|Pazopanib|Pazopanib 800 mg daily for 24 months
80053|NCT01227928|Drug|Placebo comparator|Placebo 800 mg daily for 24 months
80311|NCT01225952|Device|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
80312|NCT01225952|Device|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
80313|NCT01225965|Device|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
80314|NCT01225965|Device|Placebo|Once daily inhalation of Placebo Inhalation Solution
80315|NCT01225978|Device|GeneInsight Clinic (GIC)|GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.
The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing.
80316|NCT00047242|Drug|irinotecan hydrochloride|
80317|NCT01225991|Drug|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
80318|NCT01226017|Other|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
80319|NCT01226030|Drug|M2ES 7.5mg|M2ES 7.5mg
80320|NCT01226030|Drug|M2ES 15mg|M2ES 15mg
80321|NCT01226030|Drug|M2ES 30mg|M2ES 30mg
80322|NCT01228331|Drug|Methylprednisolone|part of different chemotherapy blocks
80323|NCT01228331|Drug|Pegaspargase|part of different chemotherapy blocks
80324|NCT01228331|Drug|Thioguanine|part of different chemotherapy blocks
80325|NCT01228331|Drug|Vincristine sulfate|part of intravenous chemotherapy
79804|NCT01230138|Drug|FP187|Oral tablets, up to 3 times daily for 20 weeks.
79805|NCT01230151|Device|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
79806|NCT01230151|Device|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
79807|NCT01230177|Drug|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
79808|NCT01230190|Dietary Supplement|Ecologic ® Panda II|Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1*10^9 Colony Forming Units/g.
Composition: rice starch, maltodextrins, bacterial strains and mix of minerals.
79809|NCT01230190|Dietary Supplement|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
79810|NCT01230203|Procedure|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
79811|NCT01230216|Drug|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
79812|NCT00047528|Drug|Alcon Investigational Agent|
79813|NCT01230216|Drug|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
80075|NCT01228071|Drug|testosterone gel 2%|40 mg testosterone gel 2%
80076|NCT01230593|Drug|Tobradex Drops and Ointment|Tobradex drops will be given to the affected eye 3x/day, and Tobradex ointment will be given at night before bed.
80077|NCT01230593|Other|Hot Compresses|Hot compresses 3x/day to eyelids
80078|NCT01230606|Other|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
80079|NCT01230619|Drug|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
80080|NCT01230619|Drug|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
80081|NCT01230632|Dietary Supplement|high fat overfeeding|Dietary Supplement:3 days overfeeding
80082|NCT00047593|Drug|IOP Lowering Medications|
75984|NCT01216332|Drug|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
75985|NCT01216332|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
76283|NCT01218984|Drug|Medisorb naltrexone 300 mg|Single administration via IM injection.
76284|NCT01218984|Drug|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
76285|NCT01218984|Drug|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
76286|NCT01218997|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
76287|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
76288|NCT01221233|Other|Neuromuscular Electrical Stimulation plus Lumbar Stabilization Exercises|
76289|NCT01221233|Other|Lumbar Stabilization Exercises|
76290|NCT01221246|Drug|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
76291|NCT01221246|Drug|Matching Placebo (Bacteriostatic Saline) for GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
76292|NCT01221259|Drug|E2212|single ascending doses ranging from 10mg to 250mg
76293|NCT01221259|Drug|placebo|a single dose of matching placebo
76294|NCT01221272|Drug|Ranolazine|One 500 mg tablet in the evening on Day 1 of the period
One 500 mg tablet, twice daily on Days 2-3 of the period
Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)
76295|NCT01221272|Drug|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
76296|NCT00046969|Biological|epoetin beta|
79874|NCT01227668|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
79875|NCT01227681|Drug|granulocyte colony stimulating factor|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
placebo: Sodium Chloride (NaCl) 0.9 %
79876|NCT01227694|Other|Autologous MSC knee implantation|Isolation and "Ex-Vivo" expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.
79877|NCT01227707|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
79878|NCT01227707|Drug|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
79879|NCT01227707|Radiation|Radiation therapy|Total dose of 45 Gy over 38 days
79880|NCT01227707|Procedure|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
79881|NCT00047307|Drug|gemcitabine hydrochloride|Given IV
79882|NCT01227707|Drug|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
79883|NCT01227707|Drug|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
79884|NCT01227707|Drug|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
79885|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
79886|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
79887|NCT01227720|Drug|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
79888|NCT01230242|Device|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
79889|NCT01230255|Procedure|Percutaneous catheter drainage|Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
79890|NCT01230268|Other|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
79891|NCT01230281|Other|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
79892|NCT01230307|Drug|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
80326|NCT00047320|Procedure|peripheral blood stem cell transplantation|
80327|NCT01228331|Radiation|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
80328|NCT01228344|Other|Artemether-lumefantrine|
80329|NCT01228357|Drug|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
80330|NCT01228357|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
80331|NCT01228370|Drug|silodosin|silodosin 8mg once a day for 12 weeks
80665|NCT01226524|Drug|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
80666|NCT01226537|Drug|Taurine|500 mg taurine capsules twice per day for 6 months
80667|NCT01226550|Procedure|cytoreductive surgery and HIPEC|The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).
The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.
Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU).
80668|NCT01226563|Device|Sodium Alginate and Calcium Gluconate|4 mL (+/- 0.2 mL)administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
80669|NCT01226563|Device|Saline Solution|4 mL (+/- 0.2 mL)slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
80670|NCT01226576|Device|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
80671|NCT00047268|Drug|cytarabine|
80672|NCT01226589|Procedure|MRS|
80673|NCT01226602|Drug|AZD6140|P2Y12 receptor antagonist
80674|NCT01226602|Drug|Placebo|
80675|NCT01226615|Drug|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
80676|NCT01226615|Drug|Placebo|Two placebo capsules taken once a day for four months.
80677|NCT01226628|Biological|CNTO 2476|
80083|NCT01230645|Drug|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
80084|NCT01230645|Drug|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
80085|NCT01230671|Other|Yoga|A 12 week yoga session will be offered to women with breast cancer.
80086|NCT01230684|Procedure|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
80087|NCT01230697|Drug|Sorafenib|Sorafenib 800mg/die oral
80088|NCT01230710|Drug|Erlotinib|Erlotinib was supplied as tablets.
80089|NCT01230723|Device|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
80090|NCT01230723|Device|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
80091|NCT01230736|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
80092|NCT01230749|Drug|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
80093|NCT00047606|Drug|IOP Lowering Medications|
80431|NCT01228656|Drug|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
80432|NCT01228656|Drug|Mometasone furoate|Dermatologic ointment applied once a day
80433|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
80434|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
80435|NCT01228669|Drug|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
80436|NCT00047333|Other|pharmacological study|Correlative studies
80437|NCT01228682|Drug|Tolvaptan|Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
76297|NCT01221272|Procedure|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
76298|NCT01221272|Behavioral|Exercise|Treadmill stress test
76299|NCT01221285|Biological|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
76591|NCT01214954|Other|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
76592|NCT01214954|Other|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
76593|NCT01214967|Behavioral|Problem Solving Education|psycho-educational intervention
76594|NCT01214980|Device|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
76595|NCT01217333|Behavioral|Tele-CP|Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
76596|NCT01217346|Other|no intervention is involved in this study|no intervention is involved in this study
76597|NCT00046475|Drug|Midodrine Hydrochloride|
76598|NCT01217359|Drug|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
76599|NCT01217372|Dietary Supplement|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
76600|NCT01217385|Drug|systemic chemotherapy|
76601|NCT01217385|Other|laser spectroscopy|
76602|NCT01217385|Procedure|breast imaging study|
76603|NCT01217385|Procedure|magnetic resonance imaging|
76604|NCT01217385|Procedure|mammography|
76605|NCT01217385|Procedure|neoadjuvant therapy|
76606|NCT01217385|Procedure|therapeutic conventional surgery|
76607|NCT01217385|Procedure|ultrasound imaging|
79893|NCT01230307|Drug|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
80154|NCT01228175|Drug|Placebo|25mg look alike riboflavin tablets to match active study medication.
80155|NCT01228175|Drug|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
80156|NCT01228188|Procedure|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
80157|NCT00047320|Procedure|adjuvant therapy|
80158|NCT01228201|Behavioral|Moderate continuous training|Three training sessions per week in a total of 12 weeks
80159|NCT01228201|Behavioral|Aerobic interval training|Three training sessions per week in a total of 12 weeks
80160|NCT01228214|Drug|Placebo|Placebo 5mg/daily for 12 months
80161|NCT01228214|Drug|amiloride|5mg/daily for 12 months
80162|NCT01228227|Drug|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
80163|NCT01228227|Drug|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
80164|NCT01230775|Drug|Anagrelide retard|Week 1:
1x1 tablet/d of "Anagrelide retard" (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.
Week 2 "Anagrelide retard": Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.
Week 3 - Week 4 "Anagrelide retard" In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.
Maintenance Phase "Anagrelide retard" During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.
80165|NCT01230775|Drug|Placebo|Week 1:
x1 tablet/d of placebo will be administered in week 1.
Week 2
Placebo:
x1 tablet/d of placebo will be administered in week 2.
Week 3 - Week 4
Placebo:
In week 3 and week 4 the maximum dose is 4 tablets per day.
Placebo:
In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:
Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/
80166|NCT01230788|Drug|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
80167|NCT01230801|Biological|BMN 701|GILT-tagged recombinant human GAA
80678|NCT01226641|Device|Telemedicine|CPAP treatment with telemedicine system
80679|NCT01226641|Device|Standard care|Standard care, including CPAP
80680|NCT01226654|Other|Magnetic Resonance Imaging|Magnetic resonance Imaging, EDSS
80681|NCT01229072|Biological|Heparin sodic|Heparin sodic 150UI/kg
80682|NCT01229072|Biological|heparin liquemine|Heparin sodic 150UI/kg
80683|NCT01229085|Drug|memotasone + salicylic acid|mometasone 0,1% + salicylic acid 5%.
80684|NCT01229098|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
80685|NCT01229111|Drug|cediranib maleate|Given PO
79732|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
79733|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
79734|NCT01232309|Dietary Supplement|Placebo|3 x 500 mg capsules (tid)
79735|NCT01232374|Drug|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
79736|NCT01232374|Drug|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
79737|NCT01232374|Drug|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
79738|NCT01232374|Radiation|Radiotherapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
79739|NCT01232400|Drug|Esmolol|The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:
Heart rate less than 70 bpm.
Systolic blood pressure less than 120 mmHg
Maximum dose of esmolol of 200 mcg/kg/minute is reached.
79740|NCT01232413|Drug|Placebo|Oral
79741|NCT01232413|Drug|ASP1941|Oral
79742|NCT00001005|Drug|Aldesleukin|
79743|NCT00047840|Drug|Docetaxel|
80438|NCT01231204|Procedure|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
80439|NCT01231217|Other|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
80440|NCT01231217|Other|Coffee|Patients are recommended to drink as much coffee as they tolerate.
80441|NCT00047684|Behavioral|Brief Integrative Therapy|
80442|NCT01231230|Drug|fluticasone|220- mcg once
80443|NCT01231230|Drug|placebo inhalation|placebo inhalation once
80444|NCT01231230|Drug|Salmeterol|50 mcg salmeterol once
80445|NCT01231230|Drug|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
80446|NCT01231243|Procedure|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
80447|NCT01231256|Behavioral|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
80448|NCT01231269|Procedure|MRI scan|MRI scan without administration of contrast/without radiation
80449|NCT01231282|Procedure|Whole-body diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
79514|NCT01234467|Drug|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
79515|NCT01234493|Procedure|fixation|
79516|NCT00048139|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
79517|NCT01234506|Dietary Supplement|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
79518|NCT01234519|Drug|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
79519|NCT01236898|Drug|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
76608|NCT00046488|Drug|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
76609|NCT01217398|Biological|bevacizumab|
76610|NCT01217398|Drug|temozolomide|
76611|NCT01217398|Genetic|polymorphism analysis|
76612|NCT01217398|Other|pharmacogenomic studies|
76613|NCT01217411|Drug|Gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
76614|NCT01217411|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
76920|NCT01213160|Drug|AZD4547|film coated tablet, PO, twice daily
76921|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
76922|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
76923|NCT01213186|Drug|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5*10E6/kg for 48 weeks.
76924|NCT01205477|Drug|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
76925|NCT01205477|Drug|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
76926|NCT01205490|Other|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
76927|NCT01205503|Drug|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
76928|NCT01205503|Drug|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
76929|NCT01205503|Drug|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
76930|NCT01205503|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
80168|NCT01230814|Drug|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
80506|NCT01228734|Drug|Cetuximab + Oxaliplatin + 5FU/FA|Cetuximab will always be administered first, followed by oxaliplatin (85mg/m2, infused over 120 minutes) at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-fluorouracil (5-FU) (as a bolus of 400 mg/m2/day IV over 2-4 minutes followed by 600 mg/m2/day infused over 22-hour, on day 1 and day 2, every two weeks). All subjects will receive treatment until the occurrence of progressive disease (PD) or unacceptable toxicity to cetuximab.
80507|NCT01228734|Drug|Oxaliplatin + 5FU/FA|Oxaliplatin (85mg/m2, infused over 120 minutes) will always be administered first or simultaneously with oxaliplatin FA will be administered (at a dose of 200 mg/m2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m2/day IV over 2-4 minutes followed by 600 mg/m2/day infused over 22-hour, on day 1 and day 2, every two weeks). All subjects will receive treatment until the occurrence of progressive disease (PD) or unacceptable toxicity.
80508|NCT01228747|Drug|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
80509|NCT01228747|Drug|Placebo|Matching oral placebo tablets twice daily for 28 weeks
80510|NCT01228760|Drug|ASG-5ME|IV
80511|NCT01228773|Behavioral|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
80512|NCT00047346|Drug|erlotinib hydrochloride|Given PO
80513|NCT01228799|Procedure|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
80514|NCT01228799|Procedure|Canaloplasty|Canaloplasty with implant of suture
80515|NCT01228838|Drug|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
80516|NCT01228838|Drug|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
80517|NCT01228851|Other|Balance Training|Group balance training sessions three times a week for 8 weeks
80518|NCT01228864|Procedure|quality of life|survey
80519|NCT01228877|Other|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
79744|NCT01232413|Drug|Moxifloxacin|Oral
79745|NCT01232426|Procedure|Biodegradable Meniscus Arrow®|Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
79746|NCT01232426|Device|Mallet splint|Conservative treatment of the Mallet fracture with the traditional Mallet splint.
79747|NCT01232439|Drug|opioid receptor kappa antagonist|Starting dose of 2 mg, administered orally, once.
The potential dose range for this study is 0.2 mg to 30 mg
79748|NCT01232452|Drug|Pemetrexed|Administered intravenously (IV)
79749|NCT01232452|Drug|Cisplatin|Administered IV
79750|NCT01225133|Other|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
79751|NCT01225146|Drug|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
80332|NCT01228383|Biological|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
80333|NCT01228383|Biological|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
80334|NCT01228383|Biological|Placebo|Placebo intramuscularly on Day 0.
80335|NCT01228383|Biological|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
80336|NCT01228383|Biological|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
80337|NCT00047320|Radiation|radiation therapy|craniospinal irradiation
80338|NCT01228396|Drug|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
80339|NCT01228409|Drug|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
80340|NCT01228422|Biological|Interferon alpha 2a|3MUI
80341|NCT01228435|Drug|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
80342|NCT01228448|Procedure|PET scan|In-Room PET scan
80343|NCT01228474|Other|Select the Number of embryos to transfer|Select the Number of embryos to transfer
76781|NCT01215227|Drug|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
76782|NCT01215240|Device|Peritoneal dialysis|Prophylactic peritoneal dialysis
76783|NCT01215253|Drug|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
76784|NCT01215266|Drug|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
76785|NCT01215266|Drug|Placebo|Day 3-21 2x2 800 mg(milligram) daily
76786|NCT01215279|Drug|AZD2423|100 mg oral treatment once daily for 28 days
76787|NCT01215279|Drug|Placebo to AZD2423|Oral treatment once daily for 28 days
76788|NCT01217593|Procedure|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
76789|NCT01217593|Procedure|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
76790|NCT00046501|Drug|Lispro|
76791|NCT01217606|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
76792|NCT01217606|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
76793|NCT01217619|Drug|erlotinib|erlotinib 150mg/d continuously for 56 days
76794|NCT01217632|Drug|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
76795|NCT01217632|Drug|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
76796|NCT01217632|Drug|Entecavir|
76797|NCT01217645|Radiation|150 mg [14C] AZD6765|
76798|NCT01217658|Behavioral|The Happiest Baby on The Block|Those receiving the intervention will be trained in the infant soothing techniques outlined in "The Happiest Baby on the Block".
76799|NCT01217658|Behavioral|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
76800|NCT01217671|Biological|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
76235|NCT01223365|Drug|Hydrocodone bitartrate extended-release tablets|Hydrocodone bitartrate extended-release tablets (CEP-33237) will be administered at doses of 15, 30, 45, 60, and 90 mg every 12 hours. The tablets used in this study contain 15, 30, or 45 mg of hydrocodone bitartrate.
76236|NCT01223378|Drug|Experimental: BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
76237|NCT01223378|Drug|Latanoprost|0.005% ophthalmic solution, QD 28 days
76238|NCT01216748|Other|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
76526|NCT01219400|Drug|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
76527|NCT01219413|Drug|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
76528|NCT01219426|Other|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
76529|NCT01219452|Biological|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
76530|NCT01219465|Biological|umbilical cord mesenchymal stem cells|Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
76531|NCT01219517|Other|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
76532|NCT01219543|Drug|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
76533|NCT01219543|Drug|AZD1480 BID|Oral Dose, Capsule, BID Dosing
76534|NCT01219556|Drug|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
76535|NCT01219569|Drug|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
76536|NCT00046852|Biological|therapeutic autologous lymphocytes|
76537|NCT01219569|Drug|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
76538|NCT01219582|Drug|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
76539|NCT01219595|Other|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
76540|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
77540|NCT01206517|Drug|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
77541|NCT01206530|Drug|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
77813|NCT01206985|Other|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
77814|NCT01206998|Drug|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
77815|NCT01206998|Drug|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
77816|NCT01207011|Drug|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
77817|NCT00045305|Drug|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
77818|NCT01207011|Drug|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
77819|NCT01207024|Other|knee MRI|knee MRI before surgery (inclusion) and one year after
77820|NCT01207037|Procedure|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
77821|NCT01207050|Drug|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
77822|NCT01207050|Dietary Supplement|Placebo|Control treatment
77823|NCT01207063|Other|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
77824|NCT01207076|Biological|90Y-AHN-12|The intervention consists of two parts.
The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.
Dose escalation of nonradiolabeled AHN-12:
Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg
Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.
the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy.
77825|NCT01207089|Drug|AZD8329|AZD8329 Oral Solution 20mg/ml
77826|NCT01207089|Drug|Placebo|Placebo AZD8329 Oral Solution
77827|NCT01207102|Drug|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
77828|NCT00045305|Drug|Pentostatin|Purine analogue
75782|NCT01222767|Drug|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
75783|NCT01222780|Drug|Marqibo|Marqibo® will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.
The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.
Detailed pharmacokinetic studies will be performed during the first treatment cycle
75784|NCT01222806|Device|Repetitive Transcranial Magnetic Stimulation|
75785|NCT01222819|Drug|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
75786|NCT01222832|Drug|Bacitracin|Bacitracin soaked sponge
75787|NCT01222845|Drug|Test meal|Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
75788|NCT01222858|Behavioral|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
75789|NCT01222858|Behavioral|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
75790|NCT01222871|Drug|Triamcinolone|Triamcinolone
75791|NCT01222871|Drug|Triamcinolone|Nasopore Triamcinolone soaked sponge
75792|NCT00047047|Other|laboratory biomarker analysis|Correlative studies
76080|NCT01216631|Drug|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
76081|NCT01218620|Drug|Omeprazole|Given PO
76082|NCT01218620|Drug|Tolbutamide|Given PO
76083|NCT01218620|Drug|Dextromethorphan Hydrobromide|Given PO
76084|NCT01218620|Other|Pharmacological Study|Correlative studies
76085|NCT01218620|Other|Laboratory Biomarker Analysis|Correlative studies
76086|NCT00046774|Drug|MRA 003 US|
76087|NCT01218633|Drug|saline infusion|saline infused at 30ml/hour
76088|NCT01218633|Drug|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
76089|NCT01218633|Drug|Exendin-9,39 at low dose|infused at 30pmol/kg/min
76801|NCT00046514|Drug|ABI-007|
75850|NCT01220531|Drug|Mycophenolate mofetil|Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after thymus transplantation. If MMF is given, the dose is 15 mg/kg/dose every 8 hours IV or orally. MMF may be stopped at 35 days or continued for up to six months after thymus transplantation.
75851|NCT01220544|Biological|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain > 8 x 10e6 CD34+ cells/kg and < 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
75852|NCT01220557|Behavioral|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
75853|NCT01220557|Behavioral|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
75854|NCT01220570|Drug|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
75855|NCT01220570|Drug|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
75856|NCT01220570|Drug|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
75857|NCT01220583|Drug|cisplatin|Given IV
75858|NCT01220583|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
75859|NCT00046917|Drug|irinotecan hydrochloride|Given IV
75860|NCT01220583|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
75861|NCT01220596|Drug|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
75862|NCT01222949|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
75863|NCT01222962|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
75864|NCT01222975|Drug|Risperidone|orally disintegrating tablets
75865|NCT01222988|Dietary Supplement|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
75866|NCT00047060|Drug|Campath-1H|
76541|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
76542|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
76543|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
76544|NCT01221740|Drug|Savella|The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.
12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8
76545|NCT01221753|Drug|docetaxel|Given intravenously on day of each cycle
76546|NCT00046995|Drug|fluorouracil|
76861|NCT01215292|Drug|Dutasteride|2.5 mg PO daily, Day 3-10
76862|NCT01215292|Drug|Anastrozole|1 mg PO daily, Day 3-10
76863|NCT01215292|Drug|Placebo ketoconazole|placebo to mimic ketoconazole
76864|NCT01215318|Procedure|Feasability|
76865|NCT01215331|Drug|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
76866|NCT01215331|Drug|Metformin, glyburide and insulin|Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.
Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.
Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents.
76867|NCT01215344|Drug|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
76868|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
76869|NCT01215344|Drug|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
76870|NCT01215344|Drug|Dexamethasone|20 mg the day before and the day after receiving VELCADE
77829|NCT01207102|Drug|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
77830|NCT01207115|Drug|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
77831|NCT01207115|Drug|Placebo|Placebo capsules - twice daily for 8 weeks
77832|NCT01207115|Drug|Naproxen|Naproxen capsules - twice daily for 8 weeks
78158|NCT01205269|Drug|AZD8683, 200 mcg|Dry powder for inhalation, single dose
78159|NCT00045149|Biological|therapeutic tumor infiltrating lymphocytes|
78160|NCT01205282|Drug|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
78161|NCT01205282|Drug|Placebo|There will be a 2 week period of placebo run-in.
78162|NCT01205295|Other|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
78163|NCT01205308|Dietary Supplement|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
78164|NCT01207739|Drug|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
78165|NCT01207739|Drug|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
78166|NCT00045370|Biological|recombinant interferon alfa|
78167|NCT01207739|Drug|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
78168|NCT01207752|Drug|Systane Balance|Artificial tear emulsion drop
78169|NCT01207752|Drug|Optive Lubricant Eye Drops|Artificial tear eye drop
78170|NCT01207765|Drug|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
76090|NCT01218633|Drug|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
76091|NCT01218646|Biological|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
76092|NCT01218646|Biological|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
76093|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
76094|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
76095|NCT01218659|Drug|migalastat hydrochloride|oral AT1001 capsules and inactive reminder capsules taken every day
76096|NCT01218659|Biological|agalsidase|intravenous infusion in accordance with the local approved product labeling
76097|NCT00046787|Drug|OSI-211 (Liposomal Lurtotecan)|
76098|NCT01218672|Device|GreenLight XPS vs. TURP|GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.
Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
76099|NCT01218685|Biological|Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS|1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.
76100|NCT01218698|Drug|Losartan Potassium Tablets|
76396|NCT01214499|Procedure|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
76397|NCT01214499|Procedure|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
76398|NCT01214512|Other|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
76399|NCT00046085|Behavioral|Family Psychoeducational Program|Families are provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
75867|NCT01223001|Drug|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
75868|NCT01223001|Drug|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
76166|NCT01216683|Drug|bortezomib|Given IV
76167|NCT01216683|Drug|lenalidomide|Given orally
76168|NCT01216696|Drug|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
76169|NCT01216709|Dietary Supplement|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
76170|NCT00046371|Drug|THERATOPE® vaccine|
76171|NCT01216709|Other|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
76172|NCT01216709|Other|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
76173|NCT01216722|Other|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
76174|NCT01216735|Drug|Fluticasone|220 ug twice a day for 3 weeks
76175|NCT01216735|Drug|Placebo|Placebo for 3 weeks
76176|NCT01216748|Other|quiet breathing|Subjects were instructed to breath normally at room air.
76177|NCT01216748|Other|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
76178|NCT01218737|Drug|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.
This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15.
76179|NCT01218750|Procedure|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
77461|NCT01208935|Drug|Nicotine Patch|
77462|NCT01208935|Drug|Nicotine Gum|
77463|NCT01208948|Drug|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
77464|NCT01208961|Drug|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
77465|NCT00045474|Radiation|iodine I 125|
77466|NCT01208961|Drug|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
77467|NCT01208974|Procedure|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy with Immediate Breast Reconstruction followed by Prophylactic Nipple-Areolar Complex Radiation
77468|NCT01208974|Radiation|Prophylactic Nipple-Areolar Complex RT|Prophylactic NAC RT twice daily, for 5 days, preferable in consecutive working days.
77469|NCT01208974|Procedure|Immediate Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire.
77470|NCT01208974|Procedure|Axillary surgery|At surgeon's discretion.
77471|NCT01208974|Drug|Chemotherapy|Chemotherapy, if indicated, at the discretion of the treating physician
77472|NCT01208974|Radiation|Prophylactic Nipple-Areolar Complex RT|Nipple-sparing Mastectomy with Immediate Breast Reconstruction followed by Prophylactic Nipple-Areolar Complex Radiation
77473|NCT01208987|Other|Medication History was printed|
77474|NCT01209013|Device|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
77475|NCT01209013|Procedure|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
77476|NCT00045487|Drug|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
77477|NCT01211535|Device|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
77752|NCT01209377|Behavioral|fixed|EMDR treatment with fixed eyes
78171|NCT01207765|Drug|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
78172|NCT01207791|Behavioral|screening|Brief screening to assess eligibility and collect minimal baseline data
78173|NCT01207791|Behavioral|assessment|comprehensive substance use assessment
78174|NCT01207791|Behavioral|referral|referral to treatment if indicated or requested
78175|NCT01207791|Behavioral|Brief intervention|30-minute brief intervention session in ED
78176|NCT01207791|Behavioral|booster sessions|two 15-minute booster counseling sessions conducted by telephone
76980|NCT01210625|Dietary Supplement|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
76981|NCT01210638|Drug|Oxymorphone|10 mg tablet
76982|NCT01210651|Behavioral|Yoga Exercise|Yoga exercises performed during 90-minute sessions twice a week for a total of 8 weeks.
76983|NCT01210664|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10^8 cells. The second cohort will receive 0.4 x10^8 cells. The third cohort will receive 3.2 x10^8 cells. The fourth cohort will receive 26 x10^8 cells.
76984|NCT01210677|Drug|Prednisone|Prednisone 0.5 mg/Kg orally per day for 3 months
76985|NCT01210716|Device|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
76986|NCT01210729|Device|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
76987|NCT00045630|Drug|carboplatin|
76988|NCT01210742|Device|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
76989|NCT01210742|Other|Routine management|Routine non-operative management for knee OA (NICE guidelines)
76990|NCT01210755|Drug|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
76991|NCT01210755|Drug|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
76400|NCT01214564|Drug|PEP005 (ingenol mebutate) Gel|0.05%
76401|NCT01214577|Drug|PEP005 (ingenol mebutate) Gel|0.015%
76402|NCT01214590|Device|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
76403|NCT01214603|Drug|LY2090314|Administered intravenously
76404|NCT01214616|Drug|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
76405|NCT01214616|Drug|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
76406|NCT01214616|Drug|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
76407|NCT01214629|Drug|LY2523355|Administered intravenously on days 1, 2,3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125mg/m2.
76408|NCT01214629|Drug|LY2523355|Administered intravenously on Days 1, 2,3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4mg/m2.
76409|NCT01214629|Drug|pegfilgrastim|6 mg administered subcutaneously on day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
76410|NCT00046085|Behavioral|Customary care|Participants will receive care as usual.
76411|NCT01214642|Drug|pegfilgrastim|Administered subcutaneously
76412|NCT01214642|Drug|LY2523355|Administered intravenously
76413|NCT01214655|Drug|LY2523355|Administered intravenously for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met.
76723|NCT01219751|Drug|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
76724|NCT01219764|Drug|Rabeprazole, metronidazole, Clarithromycin, Amoxicillin|Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
76725|NCT01219777|Drug|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
76726|NCT01219777|Drug|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
76727|NCT01219777|Drug|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 & 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
76180|NCT01218789|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
76181|NCT01218802|Drug|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
76182|NCT00000993|Drug|Zidovudine|
76183|NCT00046800|Drug|OSI-211 (Liposomal Lurtotecan)|
76184|NCT01218802|Drug|Placebo|participants will take a sugar pill daily for 96 weeks
76470|NCT01221675|Radiation|IMP-288-Indium|Imaging
76471|NCT01221688|Procedure|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
76472|NCT01221688|Procedure|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
76473|NCT01221701|Behavioral|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
76474|NCT01221727|Drug|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
76475|NCT01221727|Drug|Midazolam|All subjects will receive two oral dose administrations of midazolam.
76476|NCT01214668|Drug|LY573636|Individualized dose is dependent on patients height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m2 of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met.
76477|NCT01214668|Drug|Liposomal Doxorubicin|40 mg/m2 on Day 1, given intravenously of each 28-day cycle
Patients may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m2 of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met.
76478|NCT01214681|Dietary Supplement|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
76479|NCT01214681|Dietary Supplement|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
76480|NCT01214681|Dietary Supplement|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
76481|NCT01214681|Dietary Supplement|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
77753|NCT01209377|Behavioral|no focus|trauma exposure without external focus
77754|NCT01209377|Procedure|EMDR|Eye Movement Desensitization and Reprocessing (EMDR)
77755|NCT01209390|Device|Chondromimetic|The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.
The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate.
77756|NCT01209403|Drug|Glucose-infusion|Continuous iv infusion of glucose
77757|NCT01209403|Drug|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
77758|NCT01209416|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
77759|NCT01209416|Drug|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
77760|NCT01209416|Other|Placebo|placebo tablets or saline infusion
77761|NCT01209429|Drug|GH hormone infusion|Norditropin 30 ng/kg/min
77762|NCT00045539|Drug|leucovorin calcium|
77763|NCT01209429|Behavioral|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
77764|NCT01209429|Behavioral|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
77765|NCT01209442|Drug|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
77766|NCT01212107|Drug|LY2874455|LY2874455 will be taken orally (capsules) once or twice daily for a minimum of (1) 28 day cycle.
Part A: dose escalation
2-200 mg, administered orally, once or twice daily for a minimum of one (1) 28 day cycle
Part B: dose confirmation
dose determined by Part A dose escalation, administered orally, once or twice daily for a minimum of one (1) 28 day cycle
Both parts: If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)
77767|NCT01212120|Biological|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
77768|NCT01212133|Drug|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
77769|NCT01212146|Dietary Supplement|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10^10 CFU.
76992|NCT01210768|Drug|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
76993|NCT01210768|Drug|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
76994|NCT01213186|Drug|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5*10E6/kg for 48 weeks.
76995|NCT01213199|Drug|Adapalene|Adapalene Gel 0.3%
76996|NCT01213212|Other|Caloric restriction|Caloric restriction.
76997|NCT01213212|Other|No intervention|Diet "ad libitum"
76998|NCT00045916|Procedure|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
76999|NCT01213238|Drug|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
77000|NCT01213238|Drug|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
76025|NCT01220830|Device|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
76026|NCT01220843|Drug|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
76027|NCT00046930|Biological|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
76028|NCT01220843|Drug|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
76029|NCT01220856|Drug|Reparixin|Reparixin + immunosuppression
76030|NCT01220869|Drug|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
76031|NCT01220882|Radiation|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
76032|NCT01220895|Biological|CMV-specific T-cells, single infusion following single positive CMV PCR result|Intravenous ganciclovir 5mg/kg twice daily
Oral valganciclovir 900mg twice daily
Intravenous foscarnet 90 mg/kg twice daily
76033|NCT01220908|Device|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
76034|NCT01220908|Device|Coils|Lung Volume Reduction Coil(s)
76728|NCT01219790|Radiation|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
76729|NCT01219790|Drug|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
76730|NCT01219803|Drug|High Dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,5 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
76731|NCT01219803|Drug|Mild dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
76732|NCT01219803|Drug|Low dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc, 150ml/bag, twice in a day
76733|NCT00046852|Drug|melphalan|
76734|NCT01219803|Drug|Placebo|The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
76735|NCT01219816|Drug|Epratuzumab|Combination of chemotherapy + Epratuzumab
76736|NCT01219816|Drug|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
76737|NCT01219842|Procedure|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
76738|NCT01219842|Other|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
76739|NCT01219855|Drug|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
76740|NCT01219855|Drug|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
76741|NCT01219855|Drug|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
76742|NCT01219855|Drug|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
76743|NCT01219855|Drug|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
75793|NCT01222884|Drug|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
75794|NCT01222884|Drug|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
75795|NCT01222897|Drug|Valacyclovir hydrochloride|
76482|NCT01214694|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
76483|NCT00046111|Drug|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
76484|NCT01214694|Behavioral|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
76802|NCT01217671|Other|Placebo|Placebo
76803|NCT01217697|Drug|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
Prednisone, type=equal, unit=mg, number=5, form=tablet, route=oral use, twice daily.
76804|NCT01217710|Behavioral|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
76805|NCT01217723|Biological|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
76806|NCT01217723|Other|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
76807|NCT01217736|Drug|aliskiren|single dose, tablet
76808|NCT01217736|Drug|placebo|single dose, tablet
76809|NCT01217736|Drug|VTP-27999|single dose, tablet
76810|NCT01217749|Drug|PCI-32765|420 mg PO daily
76811|NCT01219881|Drug|Sevoflurane|1.4 to 2.5% Sevoflurane
76812|NCT01219907|Biological|HER-2/neu peptide vaccine|Given intradermally
76813|NCT01219907|Drug|cyclophosphamide|Given IV
76814|NCT01219907|Biological|ex vivo-expanded HER2-specific T cells|Given IV
76815|NCT01219907|Other|laboratory biomarker analysis|Correlative studies
76816|NCT01219907|Other|flow cytometry|Correlative studies
77770|NCT01212146|Dietary Supplement|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
78097|NCT01209897|Behavioral|Smoking cessation booklet|
78098|NCT01209910|Other|Water|Subjects in this arm will be able to drink water with some conditions.
78099|NCT01209923|Device|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
78100|NCT01209936|Device|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
78101|NCT01209949|Drug|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
78102|NCT01209975|Procedure|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
78103|NCT01209988|Drug|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
78104|NCT00045604|Drug|cisplatin|
78105|NCT01209988|Other|No medication|No medication
78106|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 low dose
78107|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
78108|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
78109|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
78110|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
78111|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
78112|NCT01210014|Drug|zinc sulphate 220mg/day in one dosage|patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.
The clinical data were scored according to the size of lesions were scored subjectively.
the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.
76035|NCT01220921|Procedure|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
76036|NCT01220921|Procedure|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
76037|NCT01220947|Drug|Copegus|repeated oral dose
76038|NCT00046930|Drug|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
76039|NCT01220947|Drug|Copegus|repeated oral dose
76040|NCT01220947|Drug|Copegus|repeated oral dose
76041|NCT01223664|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
76042|NCT01223664|Drug|Conserved therapy|Oral or intravenous administration
76043|NCT01223677|Behavioral|Rumination Focused CBT|see arms
76044|NCT01223690|Drug|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
76045|NCT00047099|Drug|fluorouracil|
76046|NCT01223690|Drug|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
76340|NCT01216982|Drug|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
76341|NCT01216995|Biological|Dose A|ADRC Dose A
76342|NCT00046449|Drug|Investigational Seasonal Affective Disorder (SAD) Drug|
76343|NCT01216995|Biological|Placebo|Placebo Comparator
76344|NCT01217008|Biological|GRNOPC1|One injection of 2 million GRNOPC1 cells.
76345|NCT01217021|Drug|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]MNI-558, followed by PET imaging.
76346|NCT01217034|Drug|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
76347|NCT01217034|Procedure|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
75796|NCT01222910|Drug|Valacyclovir hydrochloride|
75797|NCT01222923|Drug|Risperidone|1 mg orally disintegrating tablets
75798|NCT01222936|Drug|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
75799|NCT01215916|Drug|LY573636|Individualized dose is dependent on patients height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once in a 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met.
75800|NCT01215916|Drug|Pemetrexed|375-500 mg/m2, intravenous dosing is completed once each 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met.
75801|NCT01215929|Drug|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
75802|NCT01215929|Drug|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
75803|NCT01215942|Drug|LY2127399|Administered Subcutaneously
75804|NCT01215955|Drug|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
75805|NCT01215955|Drug|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
75806|NCT01215968|Biological|LY2189265|1.5 mg administered subcutaneously
75807|NCT00000991|Drug|Sulfamethoxazole-Trimethoprim|
75808|NCT00046267|Drug|Niacin|
75809|NCT01215968|Drug|Placebo|Administered subcutaneously
75810|NCT01215981|Biological|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
75811|NCT01215981|Biological|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
76101|NCT01218711|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
76102|NCT01218724|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
76817|NCT01219907|Other|immunoenzyme technique|Correlative studies
76818|NCT01219920|Drug|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
76819|NCT00046852|Procedure|peripheral blood stem cell transplantation|
76820|NCT01219920|Drug|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
76821|NCT01219933|Drug|methylprednisolone|starting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule
76822|NCT01219933|Drug|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
75869|NCT01223014|Drug|AZD2423|AZD2423
75870|NCT01223027|Drug|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
75871|NCT01223027|Drug|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
75872|NCT01223040|Other|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
75873|NCT01223053|Drug|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
75874|NCT01223053|Drug|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
75875|NCT01223079|Drug|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
75876|NCT01223079|Drug|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
75877|NCT00047073|Drug|Rapamycin|Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.
Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.
Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same.
75878|NCT01223105|Procedure|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
75879|NCT01223105|Procedure|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
78113|NCT01210014|Drug|placebo: one dosage|patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.
The clinical data were scored according to the size of lesions were scored subjectively.
the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.
78114|NCT01212757|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
77213|NCT01205997|Drug|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
77214|NCT01208441|Procedure|therapeutic conventional surgery|
77215|NCT01208441|Procedure|breast biopsy|
77216|NCT01208441|Other|diagnostic laboratory biomarker analysis|
77217|NCT00045448|Drug|alvocidib|
77218|NCT01208441|Other|pharmacological study|
77219|NCT01208454|Drug|Isotretinoin|Given PO
77220|NCT01208454|Other|Laboratory Biomarker Analysis|Correlative studies
77221|NCT01208454|Other|Pharmacological Study|Correlative studies
77222|NCT01208454|Drug|Vorinostat|Given PO
77223|NCT01208467|Other|Laboratory Biomarker Analysis|Correlative studies
77224|NCT01208480|Drug|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
77225|NCT01208493|Other|preterm infant formula with high protein levels|minimum 3 weeks feeding until hospital discharge
77226|NCT01208493|Other|preterm standard infant formula|minimum 3 weeks feeding until hospital discharge
77227|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
77228|NCT00045448|Drug|docetaxel|
76348|NCT01217047|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
76349|NCT01217047|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
76350|NCT01217047|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
76351|NCT01218997|Drug|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
76352|NCT01219010|Biological|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
76353|NCT01219023|Drug|sildenafil citrate|Subjects will be given 2 types of topical creams, one containing 1% sildenafil and one containing placebo control. Subjects will be randomized to apply sildenafil cream to either the right or left hand/foot; placebo cream will be applied to the opposite hand/foot. The cream will be supplied to subjects with proper labeling to indicate right and left application assignment. Cream will be applied to each affected hand/foot two times per day.
76354|NCT01219036|Drug|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
76355|NCT01219049|Drug|Tyrosine|1000 mg / day
76356|NCT00046826|Drug|thalidomide|
76357|NCT01219049|Drug|Tyrosine|2000 mg / day
76358|NCT01219049|Drug|Placebo|Placebo daily
76662|NCT00047008|Drug|cisplatin|100 mg/m^2 intravenously on days 1, 22
76663|NCT01221935|Other|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
76664|NCT01221935|Other|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
76665|NCT01221948|Device|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
76666|NCT01221961|Device|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
76667|NCT01221974|Device|Essure Micro Insert|
76103|NCT01218737|Drug|0.3% gatifloxacin and 1.0% prednisolone acetate association|Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.
This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15.
76104|NCT01220947|Drug|daneprovir|repeated oral dose
76105|NCT01220947|Drug|danoprevir|repeated oral dose
76106|NCT01220947|Drug|danoprevir|repeated oral dose
76107|NCT01220947|Drug|danoprevir|repeated oral dose
76108|NCT01220947|Drug|peginterferon alfa-2a [Pegasys]|repeated subcutaneous injection
76109|NCT01220947|Drug|peginterferon alfa-2a [Pegasys]|repeated oral dose
76110|NCT01220947|Drug|peginterferon alfa-2a [Pegasys]|repeated subcutaneous injection
76111|NCT01220947|Drug|ritonavir|repeated oral dose
76112|NCT00000995|Drug|Ganciclovir|
76113|NCT00046930|Drug|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
76114|NCT01220947|Drug|ritonavir|repeated oral dose
76115|NCT01220960|Other|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
76116|NCT01220973|Drug|atorvastatin calcium|
76117|NCT01220973|Drug|celecoxib|
76118|NCT01220973|Other|laboratory biomarker analysis|
76119|NCT01220986|Procedure|Liver biopsy|0, 30, 60, 90 min post inflow-division
76120|NCT01220999|Drug|111In-CS-1008, CS-1008|CS-1008 will be given in 5 dose cohorts.
Weekly doses of CS-1008 are administered for 7 consecutive weeks in Cycle 1. On each dosing day, CS-1008 will be infused intravenously over approximately 30 minutes.
Cohort No.: Pts - Dose Day 1 - Day 8 - Day15,22,29 - Day 36 - Day 43
Cohort #1: 2-5 pts - 0.2 mg/kg - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #2: 2-5 pts - 1 mg/kg - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #3: 2-5 pts - 2 mg/kg - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #4: 2-5 pts - 4 mg/kg - 4 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #5: 2-5 pts - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Day 1 and Day 36 doses will be trace labelled with Indium-111 (111In-CS-1008)
Additional treatment cycles in suitable patients with stable disease or better at the day 44-50 reassessment may continue be given as weekly infusions of CS-1008 at 2 mg/kg per week. Disease reassessment is planned after every second 4-week cycle.
75880|NCT01223118|Procedure|Vitrification and PGD|Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
75881|NCT01223131|Drug|Insulin glargine (HOE901)|Pharmaceutical form:aqueous solution for injection
Route of administration: Subcutaneous
75882|NCT01223131|Drug|NPH insulin|Pharmaceutical form:aqueous solution for injection
Route of administration: Subcutaneous
75883|NCT01216033|Drug|111-In-ABY-025|Intravenous injection of the agent
75884|NCT01216046|Drug|VX-809|capsule, taken once daily
75885|NCT01216046|Drug|VX-770|tablet, taken once every 12 hours
75886|NCT00046293|Drug|Reopro|
75887|NCT01216046|Drug|VX-809 placebo|capsule, taken once daily
75888|NCT01216046|Drug|VX-770 placebo|tablet, taken once every 12 hours
76185|NCT01218815|Procedure|IRA stenting in culprit lesion only|stenting
76186|NCT01218815|Procedure|IRA stenting|Complete IRA revascularization
76187|NCT01218828|Other|LVEDP -Based hydration strategy|
76188|NCT01218828|Other|Standard hydration|
76189|NCT01218841|Dietary Supplement|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
76190|NCT01218841|Dietary Supplement|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
76191|NCT01218854|Device|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
76192|NCT01218867|Biological|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophospamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
76193|NCT01218867|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
76194|NCT00046813|Drug|Nicotine patch|
76195|NCT01218867|Biological|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
77229|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
77230|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
77231|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
77232|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
77478|NCT00045721|Drug|polifeprosan 20 with carmustine implant|
77479|NCT01211548|Other|contrast enhanced CT aortic angiography of the chest abdomen and pelvis|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
77480|NCT01211561|Drug|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
77481|NCT01211561|Drug|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
77482|NCT01211574|Behavioral|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
77483|NCT01211574|Behavioral|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
77484|NCT01211574|Behavioral|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
77485|NCT01211587|Drug|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
77486|NCT01211587|Drug|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
77487|NCT01211600|Other|Staples|Interrupted Ethicon Staples
77488|NCT01211600|Other|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
77489|NCT00045721|Procedure|adjuvant therapy|
77490|NCT01211613|Procedure|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
76668|NCT01221987|Procedure|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
76669|NCT01221987|Other|Data collection|Questionnaire completion
76670|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
76671|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
76672|NCT01214980|Other|Standard of care|Standard of care provided per site-specific protocol
76673|NCT01214993|Drug|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
76674|NCT01214993|Drug|Placebo|Placebo is a tablet with no drug in it.
76675|NCT01214993|Drug|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
76676|NCT01214993|Drug|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
76677|NCT00046150|Drug|Insulin glulisine (HMR1964)|
76678|NCT01215019|Drug|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
76679|NCT01215019|Drug|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
76680|NCT01215032|Drug|Metformin|Taken orally twice daily each 28-day cycle
77001|NCT01213238|Drug|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
77002|NCT01213251|Device|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
77003|NCT01213251|Device|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
77004|NCT01213264|Other|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
76121|NCT01221025|Drug|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
76414|NCT01217047|Behavioral|Mood assessment|If you do not already have an account, you will be signed up with "Mood24/7" (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.
76415|NCT01217060|Drug|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
76416|NCT00046462|Drug|Lantus (insulin glargine [rDNA origin] injection)|
76417|NCT01217060|Drug|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
76418|NCT01217060|Radiation|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
76419|NCT01217060|Procedure|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
76420|NCT01217060|Drug|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
76421|NCT01217073|Drug|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
76422|NCT01217073|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
76423|NCT01217073|Drug|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
76424|NCT01217073|Drug|Metformin|Metformin 500 mg oral tablet administered once or twice daily
76425|NCT01217073|Drug|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
76426|NCT01217086|Drug|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
76427|NCT00046462|Drug|Metformin|
76428|NCT01217099|Drug|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
76429|NCT01217099|Drug|azithromycin|control patients were iv azithromycin for 5 days.
76430|NCT01217112|Drug|GWP42003|100 mg capsules, PO, BD, 91 days
76431|NCT01217112|Drug|GWP42003|5 mg capsules, PO, BD, 91 days
76196|NCT01218867|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days
76197|NCT01218880|Drug|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
76198|NCT01218880|Drug|M2ES 15mg|M2ES Dosage：15mg/m2
76199|NCT01218880|Drug|M2ES 30mg|M2ES Dosage：30mg/m2
76200|NCT01221077|Drug|Erlotinib|Erlotinib administered orally
76201|NCT01221077|Drug|Placebo|As of 01 March 2013, the matching placebo is no longer being administered
76202|NCT01221090|Behavioral|PDA|Technological assistance
76203|NCT01221090|Behavioral|CDSMP|6-week classes
76204|NCT01221090|Behavioral|PDA/CDSMP|Combined technology and education
76205|NCT01221103|Drug|Combination of dexamethasone, ofatumumab and bendamustine|Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle
Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity
Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)
76485|NCT01214694|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
76486|NCT01214707|Other|Exercise|Exercise during EMU stay
76487|NCT01214720|Drug|bevacizumab [Avastin]|Intervenous repeating dose
76488|NCT01214733|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
76489|NCT01214746|Drug|Placebo|1 tablet Unikalk 1 time pr day for 5 days
76490|NCT01214746|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
76491|NCT01214759|Drug|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
76492|NCT01214759|Drug|Raltegravir|Raltegravir 400mg twice a day
76493|NCT01214772|Drug|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
76494|NCT00046137|Drug|teriparatide|
76495|NCT01214785|Behavioral|Provision of household latrines|WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
77491|NCT01211613|Device|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
77492|NCT01211613|Other|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
77493|NCT01211626|Drug|ANA773|ANA773 Tosylate Capsule
77494|NCT01211626|Drug|Placebo|Matching Placebo Capsule
77495|NCT01211665|Drug|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
77496|NCT01211665|Drug|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
77497|NCT01211691|Drug|KB004, Monoclonal Antibody|
77771|NCT01212159|Device|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
77772|NCT01212172|Device|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
77773|NCT01212172|Device|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
77774|NCT01212185|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
77775|NCT00045747|Drug|7-hydroxystaurosporine|
77776|NCT01212185|Other|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
77777|NCT01212211|Other|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
77778|NCT01212237|Procedure|fMRI Evaluation|Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
77779|NCT01212250|Drug|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
77005|NCT01213264|Drug|Sugammadex|Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.
As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling.
77006|NCT01213264|Drug|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.
As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling.
77007|NCT01213277|Other|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
77008|NCT01213277|Other|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
77009|NCT00045916|Drug|Nortriptyline|Participants will receive nortriptyline.
77010|NCT01213290|Device|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
77011|NCT01213290|Device|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
77012|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 weeks
77013|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96 weeks
77014|NCT01205594|Device|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
77015|NCT01205607|Device|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
77016|NCT01205607|Device|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
76047|NCT01223703|Drug|n-3 PUFAs|1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
76048|NCT01223703|Drug|Placebo|1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
76432|NCT01217112|Drug|GWP42004|5 mg capsules, PO, BD, 91 days
76433|NCT01217112|Drug|Placebo|0 mg capsules, QDS, PO, 91 days
76434|NCT01217125|Drug|Sirolimus|plasma levels between 4 and 8
76744|NCT00046852|Procedure|bone marrow ablation with stem cell support|
76745|NCT01219868|Behavioral|Physician-nurse team supervision|Physician-nurse team will supervise patient's flow in the ED
76746|NCT01219881|Drug|Desflurane|5.4 to 7.4% desflurane
76747|NCT01222013|Drug|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
76748|NCT00047008|Radiation|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
76749|NCT01222026|Drug|Strontium Ranelate + Ca/Vitamin-D|2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
76750|NCT01222026|Drug|Placebo|Placebo 1000mg Calcium 800 IE Vitamin-D
76751|NCT01222039|Drug|Conventional treatment|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
76752|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
76753|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
76754|NCT01222052|Drug|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks
Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks
76755|NCT01222078|Biological|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
76756|NCT01222091|Drug|Propranolol|
76757|NCT01222091|Drug|Placebo|
76758|NCT01222117|Biological|Plasmin|Plasmin prepared in 0.9% saline for injection
76496|NCT01214811|Device|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
76497|NCT01217151|Device|Hemodynamic monitoring|Hemodynamic monitoring based on the NICOM device
76498|NCT01217151|Other|Usual treatment|Hemodynamic monitoring based on common practice
76499|NCT00046462|Drug|Glyburide|
76500|NCT01217164|Dietary Supplement|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
76501|NCT01217177|Drug|everolimus|
76502|NCT01217190|Drug|Ondansetron Orally Dissolving Film|Two-wy cross-over study to compare ondansetron ODSF with Zofran ODT
76503|NCT01217190|Drug|Ondansetron Orally Disintegrating Tablet|Two way cross-over study to compare ondansetron ODSF with Zonfran ODT
76504|NCT01217190|Drug|Ondansetron OSF|Two way cross-over study to compare ondansetron ODSF with Zonfran ODT
76505|NCT01217203|Drug|IPH2101 combined to lenalidomide|Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)
Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)
76506|NCT01217216|Behavioral|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
76823|NCT01219959|Drug|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
76824|NCT01219959|Drug|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
76825|NCT01219985|Other|standard and respiratory-gated PET acquisitions|After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.
Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.
Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations.
76826|NCT01220011|Procedure|Fetoscopic laser surgery|Fetoscopic laser surgery
76827|NCT01220024|Drug|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
76828|NCT01220024|Drug|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
77780|NCT01212250|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
77781|NCT01212263|Drug|Step-up HP u FSH|HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
77782|NCT01204658|Biological|Prevenar 13|Four doses will be administered intramuscularly, at approximately 2, 3, 4 and 12-15 months of age.
77783|NCT01204658|Biological|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Four doses will be co-administered intramuscularly, at approximately 2, 3, 4 and 12-15 months of age.
77784|NCT00045045|Radiation|fludeoxyglucose F 18|
77785|NCT01204671|Biological|Influenza vaccine GSK2321138A|One intramuscular injection
77786|NCT01204671|Biological|FluarixTM|One intramuscular injection
77787|NCT01204671|Biological|Influenza vaccine GSK2604409A|One intramuscular injection
77788|NCT01204684|Biological|autologous tumor lysate-pulsed DC vaccination|
78115|NCT01212757|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
78116|NCT01212770|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
78117|NCT01212770|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
78118|NCT01212770|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
78119|NCT01212770|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
78120|NCT01212783|Behavioral|In-Home Cognitive Behavioral Therapy|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
78121|NCT01212783|Behavioral|Present-Centered Therapy|Present-Centered Therapy is a supportive psychotherapy.
78122|NCT01212809|Device|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
78123|NCT01212809|Device|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
78124|NCT00045812|Drug|SCH-58235|
78125|NCT01212822|Biological|bevacizumab|Given IV
76049|NCT01223716|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
76050|NCT01223716|Behavioral|Video Game|Research participants will be asked to play "off-the-shelf" video games in our laboratory for a period of time (2 hrs/day, 5 days/week).
76051|NCT01223716|Behavioral|Crossover (Occlusion therapy + Video Game)|Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
76052|NCT01223729|Drug|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
76053|NCT01223729|Other|placebo|placebo twice per day
76054|NCT01223742|Dietary Supplement|ACETYL-L-CARNITINE|2 g acetylcarnitine taken orally twice a day.
76055|NCT01223742|Drug|placebo|placebo twice per day
76056|NCT00047099|Drug|goserelin acetate|
76057|NCT01223755|Drug|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
76058|NCT01223755|Drug|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure <130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
76059|NCT01223768|Drug|Acetyl-l-Carnitine|2g per day
76060|NCT01223768|Drug|placebo|twice per day
76061|NCT01223781|Behavioral|Biofeedback-based motor learning for PD|Prior to freezing episodes, auditory stimulation is triggered
76062|NCT01216410|Drug|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
76063|NCT01216436|Biological|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
76359|NCT01219062|Drug|Morphine or 0.25 % Bupivacaine|Intrathecal Morphine 0.1 mg or periarticular infiltration with 0.25% Bupivacaine for 20 ml.
76360|NCT01219075|Dietary Supplement|soy isoflavones|Given orally
76759|NCT00047008|Radiation|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
76760|NCT01222117|Biological|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
75812|NCT01216007|Drug|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
75813|NCT01216007|Drug|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
75814|NCT01216020|Drug|cetuximab|Cetuximab is given according to the standard mode of administration: "loading dose" : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.
Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; "prophylactic" nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed.
75815|NCT01216020|Drug|cisplatin (associated to radiotherapy)|CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.
Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; "prophylactic" nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed.
75816|NCT00046683|Drug|alemtuzumab|
75817|NCT01218126|Drug|losmapimod|comparison of different dosages of drug
75818|NCT01218126|Drug|placebo|placebo comparison with active
75819|NCT01218165|Dietary Supplement|Probiotic drink|This group receives a probiotic drink daily for 6 week.
75820|NCT01218165|Other|Control Group|without intervention
75821|NCT01218178|Drug|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
75822|NCT01218178|Drug|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
75823|NCT01218204|Drug|10mg atorvastatin|10mg
76829|NCT01220037|Behavioral|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
76830|NCT00046865|Procedure|acupressure therapy|
76831|NCT01220050|Drug|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
76832|NCT01220050|Drug|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
76833|NCT01220063|Radiation|RSHF|10 Gy for 4 times (total 40 Gy)
76834|NCT01220063|Drug|irinotécan|40 mg/m² : Day 1 and day 8
76835|NCT01220076|Drug|tamoxifen|
76836|NCT01222156|Procedure|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
76837|NCT01222156|Device|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
76838|NCT01222169|Drug|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
76839|NCT01222182|Drug|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
76840|NCT01222195|Drug|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
76841|NCT01222195|Drug|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
75889|NCT01216059|Procedure|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
75890|NCT01216072|Drug|Fingolimod|0.5 mg/day oral capsule
75891|NCT01216072|Drug|Standard MS DMTs|
75892|NCT01216085|Drug|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
75893|NCT01216098|Behavioral|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
75894|NCT01216111|Drug|Paclitaxel Cisplatin|Paclitaxel 100 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15
1 cycle = 28days
PC*6
75895|NCT01216124|Drug|docetaxel oxaliplatin|docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2
1 cycle=21 days DO*6
78126|NCT01212822|Drug|oxaliplatin|Given IV
78127|NCT01212822|Drug|leucovorin calcium|Given IV
78128|NCT01212822|Drug|fluorouracil|Given IV
78129|NCT01212822|Procedure|therapeutic conventional surgery|Undergo surgical resection
78130|NCT01212822|Other|laboratory biomarker analysis|Correlative studies
78131|NCT01212835|Procedure|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
78132|NCT01212835|Procedure|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
78133|NCT01212848|Device|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
78134|NCT01212848|Device|Transcranial Magnetic Stimulation - Sham Comparator|The control group will receive an identical dosing schedule of "sham" repetitive TMS over three days.
78135|NCT00045838|Drug|VCR-HIVDNA006-00-VP|
78136|NCT01212861|Device|Suprachoroidal Dissection Instrument (SDI)|The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
77233|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
77234|NCT01208506|Drug|placebo|A single dose of NNC0114-0000-0005 placebo.
77235|NCT01208558|Behavioral|Diet A|Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.
Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day.
77236|NCT01211158|Drug|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
77237|NCT01211171|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
76361|NCT01219075|Other|placebo|Given orally
76362|NCT01219075|Other|questionnaire administration|Ancillary studies
76363|NCT01219075|Procedure|magnetic resonance imaging|Correlative studies
76364|NCT01219075|Procedure|biopsy|Correlative studies
76365|NCT01219075|Other|immunohistochemistry staining method|Correlative studies
76366|NCT01219075|Other|laboratory biomarker analysis|Correlative studies
76367|NCT00046839|Drug|celecoxib|
76368|NCT01219075|Procedure|mammography|Correlative studies
76369|NCT01219088|Drug|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
76370|NCT01219101|Drug|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
76371|NCT01219101|Drug|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
76372|NCT01219127|Other|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
76373|NCT01219140|Dietary Supplement|2 POMx Capsules|2 POMx Capsules daily
76374|NCT01219140|Dietary Supplement|2 placebo Capsules|2 placebo Capsules daily
76375|NCT01221350|Dietary Supplement|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
76376|NCT01221350|Dietary Supplement|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
76377|NCT01221363|Behavioral|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
76378|NCT01221376|Drug|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
75824|NCT01218204|Drug|80mg atorvastatin|80mg
75825|NCT01218204|Drug|GSK1292263 Placebo|Placebo
75826|NCT01218204|Drug|100mg GSK1292263|100mg
75827|NCT00046696|Drug|NM-3|
75828|NCT01218204|Drug|300mg GSK1292263|300mg
75829|NCT01218204|Drug|800mg GSK1292263|800mg
75830|NCT01218204|Drug|10mg ezetimibe|10mg
75831|NCT01218204|Other|Washout|No interventions - washout period
76122|NCT01221051|Procedure|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
76123|NCT01221051|Procedure|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
76124|NCT00046930|Drug|zosuquidar trihydrochloride|Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.
The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3.
76125|NCT01221064|Procedure|Early drainage removal|Drainage will be removed in postoperative day 1
76126|NCT01221064|Procedure|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
76127|NCT01221077|Drug|OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
76128|NCT01223391|Other|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
76129|NCT01223391|Other|No abdominal binder|Standing without abdominal binder for 3 minutes
76130|NCT01223404|Drug|Nicotine|Nicotine patch, 7 mg / 24 hrs, one single administration
76131|NCT01223404|Drug|Mecamylamine|Mecamylamine HCl, 7.5 mg p.o., one single administration
76132|NCT01223404|Drug|Placebo|Placebo patch and placebo capsule (filler: methylcellulose)
76133|NCT01223430|Drug|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal < 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
76134|NCT00047099|Drug|docetaxel|
75896|NCT01216137|Other|Exercise: Vestibular Rehabilitation|Balance and eye movement training
75897|NCT00046293|Drug|Retrovase|
75898|NCT01216137|Other|Exercise|Bicycle ergometry and stretching
75899|NCT01216163|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
75900|NCT01216163|Drug|Acetaminophen|Single-dose of acetaminophen (1000mg)
75901|NCT01216163|Drug|Placebo|Single-dose of placebo
75902|NCT01216176|Drug|Anastrozole|1 mg orally per day
75903|NCT01216176|Drug|ADZ0530|175 mg orally per day or as otherwise specified in protocol
75904|NCT01216176|Drug|Placebo|175 mg orally per day or as otherwise specified in protocol
75905|NCT01216176|Procedure|Pharmacokinetic studies|Blood draws at protocol-specified timepoints to determine pharmacokinetics of ADZ0530 and Anastrozole.
75906|NCT01216176|Procedure|Definitive Surgery|Breast Conserving Lumpectomy or Mastectomy - after completion of neoadjuvant therapy
75907|NCT01216176|Procedure|Core Biopsy|Core Biopsy at Baseline, snap frozen, paraffin-embedded
75908|NCT00046306|Drug|Antioxidants|
75909|NCT01216176|Genetic|Tumor Tissue Collection for Genetic and Molecular Studies|Recovery of tumor tissue at the time of definitive surgery - snap frozen, for correlative genetic and molecular studies.
75910|NCT01216241|Drug|Daptomycin|8 MG/KG IV
75911|NCT01216241|Other|Saline Placebo|50 ml normal saline once daily
75912|NCT01218308|Biological|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
76206|NCT01221116|Drug|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
76207|NCT00046930|Drug|Placebo|Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.
The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored.
76208|NCT01221129|Other|Acclimation|11 mg Zn/day as a controlled intake level
76209|NCT01221129|Other|Dietary zinc depletion|< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
77238|NCT01211184|Dietary Supplement|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
77239|NCT01211184|Dietary Supplement|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
77240|NCT00045682|Drug|Paclitaxel Poliglumex|Given IV
77241|NCT01211184|Behavioral|Fasting.|The patient is fasting from midnight before the surgery.
77242|NCT01211197|Drug|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
77243|NCT01211197|Drug|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
77244|NCT01211197|Drug|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
77245|NCT01211210|Drug|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
77246|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
77247|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
77248|NCT01211223|Drug|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
77249|NCT01211236|Other|application of wound dressing made of bio-bags (vitapads) containing maggots|
77498|NCT01213719|Dietary Supplement|betaine|2g/d throughout 10 days
77499|NCT01213719|Dietary Supplement|dextrose|dextrose (placebo), 20 g/d throughout 10 days
77500|NCT01213719|Dietary Supplement|creatine plus betaine|creatine (20g/d) plus betaine (2g/d) throughout 10 days
77501|NCT01213732|Other|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
77502|NCT01213745|Other|Intervention|
77503|NCT01213745|Other|Attention|
77504|NCT01213745|Other|Control|
77505|NCT01213758|Other|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
76681|NCT01215045|Device|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
76682|NCT01215071|Procedure|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
76683|NCT01215071|Procedure|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
76684|NCT01215084|Drug|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
76685|NCT01215097|Drug|Linagliptin|once a day
76686|NCT01215097|Drug|placebo|once a day
76687|NCT01215110|Drug|TMC207|
76688|NCT00046163|Drug|midodrine hydrochloride (ProAmatine®)|
76689|NCT01215110|Drug|Rifafour e-275 mg|
76690|NCT01215123|Drug|Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
76691|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
76692|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
76693|NCT01215136|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
76694|NCT01215149|Biological|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10^10 vp, delivered IM
76695|NCT01215149|Biological|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10^10 vp delivered IM
76696|NCT01215149|Biological|Placebo Control|Colorless 10mm Tris/HCl buffer
76697|NCT01217437|Biological|Bevacizumab|Given IV
76698|NCT01217437|Drug|Irinotecan Hydrochloride|Given IV
76699|NCT01217437|Drug|Temozolomide|Given PO
76135|NCT01223443|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
76136|NCT01223469|Device|Contact force assisted irrigated RF ablation|radiofrequency ablation of atrial fibrillation or SVT
76137|NCT01223521|Device|Post-abortal provision of intrauterine device|A Cu-IUD or LNG-IUS is inserted after abortion.
76138|NCT01223534|Drug|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
76139|NCT01223534|Drug|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
76140|NCT01223547|Other|Education|Participants are taught the principles of carb counting
76141|NCT01223547|Other|Education|Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
76142|NCT01223560|Drug|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
76435|NCT01217138|Device|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
76436|NCT01219153|Drug|Extended high dose letrozole regimen /GnRH antagonist protocol|Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .
Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
76437|NCT01219153|Drug|Short low dose letrozole regimen /GnRH antagonist protocol|Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.
Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
76438|NCT01219166|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
76439|NCT00046839|Radiation|radiation therapy|
76210|NCT01221129|Other|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
76211|NCT01221142|Device|Cincinnati Sub-Zero," Blanketrol III"|
76212|NCT01221181|Drug|Eculizumab|900 mg IV once a week x 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
Patients will be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitidis vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
76213|NCT01221194|Behavioral|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
76214|NCT01221194|Device|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
76215|NCT01221207|Device|Total Contact Cast|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
76216|NCT01221207|Device|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
76217|NCT01221207|Device|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
76218|NCT00046943|Drug|atrasentan hydrochloride|
76219|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
76220|NCT01223248|Radiation|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & within 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
76507|NCT01217216|Behavioral|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
76508|NCT01217229|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
77506|NCT01213771|Procedure|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
77507|NCT00045981|Drug|ALT-711|
77508|NCT01213784|Other|all antidiabetic drugs will be appliable|We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
77509|NCT01213810|Biological|Zostavax|Biological/Vaccine
77510|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
77511|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
77512|NCT01213836|Drug|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
77513|NCT01213836|Drug|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
77514|NCT01213836|Drug|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
77515|NCT01213836|Drug|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
77516|NCT01213849|Drug|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
77517|NCT01213849|Drug|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
77518|NCT00045994|Drug|ALT-711|
77519|NCT01213849|Drug|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
77789|NCT01204684|Biological|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
77790|NCT01204684|Biological|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
77791|NCT01204697|Drug|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
77792|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
77793|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally as monotherapy
77794|NCT01204710|Biological|IMC-3G3|15mg/kg I.V. Days 1 and 8
76700|NCT01217450|Drug|selumetinib|Given orally
76701|NCT01217450|Biological|cetuximab|Given IV
76702|NCT00046501|Drug|Humulin N|
75755|NCT01220375|Drug|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
75756|NCT01220375|Drug|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
75757|NCT00046891|Other|Placebo|Patients will take 1 tablet BID
75758|NCT01220388|Dietary Supplement|L-lysine|L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
75759|NCT01220388|Dietary Supplement|placebo|placebo, 3 times a day, orally, during meals
75760|NCT01220401|Behavioral|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
75761|NCT01220414|Drug|Naltrexone,|50 mg of naltrexone
75762|NCT01220414|Drug|Placebo|sugar pill
75763|NCT01220440|Drug|Methylphenidate|Methylphenidate:10mg x 3 for one week
75764|NCT01220440|Drug|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
75765|NCT01220440|Drug|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
75766|NCT01220466|Device|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
75767|NCT01220479|Behavioral|Exercise training program|Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.
Control groups are relatively inactive.
75768|NCT00046904|Biological|etanercept|
75769|NCT01220492|Drug|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 8 weeks.
76440|NCT01219179|Other|Sterile water feedings|Control group- no intervention
Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.
The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.
The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.
76441|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
76442|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
76443|NCT01219192|Drug|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
76444|NCT01219192|Drug|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
76445|NCT01219205|Procedure|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
76446|NCT01219218|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
76447|NCT01219231|Behavioral|Exercise|6 months of aerobic exercise
76448|NCT01219244|Behavioral|caloric restriction|6 months of caloric restriction (15 %)
76761|NCT01222117|Other|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
76762|NCT01222143|Drug|NOVE-HiDAC|NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.
During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10.
76763|NCT01222143|Drug|Nilotinib|The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.
During induction, nilotinib will be given orally on Days 1-12.
During consolidation, nilotinib will be given orally on Days 1-10.
76764|NCT01215162|Radiation|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
76765|NCT01215175|Biological|Adults-Adjuvanted V114|V114 vaccine, aluminum-adjuvanted, in adults
76766|NCT00046176|Drug|abacavir/lamivudine|
76509|NCT01217268|Behavioral|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
76510|NCT00046462|Drug|Thiazolidinedione|
76511|NCT01217281|Procedure|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
76512|NCT01217294|Procedure|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
76513|NCT01217294|Procedure|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
76514|NCT01217307|Drug|Metformin|Metformin 500mg twice daily during 4 months
76515|NCT01217307|Drug|Placebo|Placebo twice daily during 4 months
76516|NCT01217320|Dietary Supplement|creatine|5g/d throughout 12 weeks
76517|NCT01217320|Dietary Supplement|placebo (dextrose)|5g/d throughout 12 weeks
76518|NCT01217333|Behavioral|In-person CP|CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.
76519|NCT01219257|Biological|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
76520|NCT01219309|Dietary Supplement|Omega 3/6 fatty acids|3 capsules bid orally
76521|NCT01219309|Dietary Supplement|Placebo (olive oil)|3 capsules bid orally
76522|NCT01219322|Drug|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
76523|NCT01219322|Drug|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
76524|NCT01219348|Biological|IDO peptide vaccination|Vaccination every second week
76525|NCT00046852|Biological|pneumococcal polyvalent vaccine|
77795|NCT00045097|Drug|ixabepilone|
77796|NCT01204710|Drug|Mitoxantrone|Mitoxantrone 12 mg/m2 I.V. Day 1
Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m2)
77797|NCT01204723|Drug|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
77798|NCT01204723|Drug|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
77799|NCT01204749|Drug|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
77800|NCT01204749|Drug|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
77801|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
77802|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
77803|NCT01204762|Drug|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
77804|NCT01204762|Drug|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
77805|NCT01204762|Drug|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
77806|NCT00045110|Drug|erlotinib hydrochloride|Given orally
77807|NCT01204762|Drug|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
77808|NCT01204775|Drug|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
77809|NCT01204775|Drug|Placebo (Saxagliptin)|Tablets, Oral, 0 mg, Once daily, 1-52 weeks
77810|NCT01204775|Drug|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
77811|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
77812|NCT01206972|Drug|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
78137|NCT01212874|Drug|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
78138|NCT01212874|Drug|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
78139|NCT01212887|Biological|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
75770|NCT01220492|Drug|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
75771|NCT01220505|Procedure|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
75772|NCT01220518|Drug|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
76064|NCT01216449|Drug|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
76065|NCT01216449|Drug|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
76066|NCT00046345|Drug|Atazanavir (BMS-232632)|
76067|NCT01216475|Procedure|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
76068|NCT01216475|Procedure|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
76069|NCT01216488|Drug|Xylocaine|40 ml or 25 ml of Xylocaine injection
76070|NCT01216527|Procedure|Neo-adjuvant Chemoradiotherapy followed by Surgery|Radiotherapy combined with concomitant chemotherapy:
Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.
neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.
Number of cycles:two
surgery:Mckeown Modification Surgery and total two-field lymphadenectomy
76071|NCT01216527|Procedure|surgery|two field lymphadenectomy
76072|NCT01216553|Other|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
76073|NCT01216566|Device|Occiflex Device|This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
76074|NCT01216579|Other|mannitol (an airway challenge agent)|
76767|NCT01215175|Biological|Adults-Prevnar™|Prevnar™ vaccine in adults
76768|NCT01215175|Biological|Toddlers-Adjuvanted V114|V114 vaccine, aluminum-adjuvanted, in toddlers
76769|NCT01215175|Biological|Toddlers-Non-adjuvanted V114|V114 vaccine, non-adjuvanted, in toddlers
76770|NCT01215175|Biological|Toddlers-Prevnar™|Prevnar™ vaccine in toddlers
76771|NCT01215188|Biological|V114 Aluminum-adjuvanted|Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age
76772|NCT01215188|Biological|V114 Non-adjuvanted|Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age
76773|NCT01215188|Biological|Prevnar 13™|Four 0.5 mL IM doses of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age
76774|NCT01215201|Device|Diode Laser|Diode Laser is used in addition to the standard Scaling and root planing procedure.
76775|NCT01215214|Drug|midazolam|midazolam: 3mg iv
76776|NCT01215227|Drug|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
76777|NCT00000991|Drug|Pentamidine isethionate|
76778|NCT00046176|Drug|abacavir|
76779|NCT01215227|Drug|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
75832|NCT01218217|Drug|SQ109|SQ109 150 mg tablet
75833|NCT01218217|Drug|Rifampicin|Rifampicin 150 mg capsules
75834|NCT01218230|Drug|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
75835|NCT01218243|Device|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
75836|NCT01218256|Other|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
75837|NCT01218269|Device|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
76842|NCT00047008|Procedure|Conventional surgery for select patients|Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.
A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made.
76843|NCT01222208|Dietary Supplement|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
76844|NCT01222208|Dietary Supplement|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
76845|NCT01222221|Biological|glioblastoma multiforme multipeptide vaccine IMA950|
76846|NCT01222221|Biological|sargramostim|
76847|NCT01222221|Drug|temozolomide|
76848|NCT01222221|Other|laboratory biomarker analysis|
76849|NCT01222221|Other|pharmacological study|
76850|NCT01222221|Procedure|adjuvant therapy|
76851|NCT01222221|Radiation|radiation therapy|
76852|NCT01222234|Drug|Cholecalciferol|Cholecalciferol tablet, 50,000 units twice a week
76853|NCT00047021|Biological|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
76854|NCT01222234|Device|calcitriol|calcitriol 0.25 mcg every day
76855|NCT01222234|Drug|Cholecalciferol|Cholecalciferol tablet, 50,000 units twice a week
76856|NCT01215292|Drug|Acyline|300 mcg/kg on Day 1
76857|NCT00046176|Drug|lamivudine|
76858|NCT01215292|Drug|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
78140|NCT01205191|Behavioral|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
78141|NCT01205191|Behavioral|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
78142|NCT01205191|Behavioral|CBT|CBT for anxiety disorders
78143|NCT01205204|Drug|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
78144|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
78145|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
78146|NCT01205204|Drug|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
78147|NCT01205217|Drug|Lapatinib|Lapatinib 1000 mg orally once daily continuously
78148|NCT00045149|Biological|aldesleukin|
78149|NCT01205217|Drug|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
78150|NCT01205217|Drug|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
78151|NCT01205217|Drug|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
78152|NCT01205217|Drug|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
78153|NCT01205230|Drug|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
78154|NCT01205243|Drug|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
78155|NCT01205256|Drug|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
78156|NCT01205269|Drug|AZD8683, 50 mcg|Dry powder for inhalation, single dose
78157|NCT01205269|Drug|Placebo|Dry powder for inhalation, single dose
77250|NCT01211236|Other|application of classical hydrogel/alginate wound dressing|
77251|NCT00000988|Drug|Stavudine|
76075|NCT01216592|Other|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
76076|NCT01216605|Drug|Syntocinon 24 IU|
76077|NCT00046358|Drug|Lovostatin|
76078|NCT01216605|Drug|Placebo|
76079|NCT01216618|Device|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
76379|NCT01221389|Drug|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
76380|NCT01221402|Drug|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
76381|NCT01221428|Biological|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1*10/7).
76382|NCT01221441|Biological|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
76383|NCT01221441|Drug|Normal Saline|Single intraarticular injection of normal saline as a placebo control
76384|NCT01221454|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
76385|NCT00046969|Radiation|brachytherapy|
76386|NCT01221454|Drug|Conserved therapy|Oral or intravenous administration
76387|NCT01221467|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
76388|NCT01221493|Procedure|Cryo biopsy|Cryoprobe, Erbe Company
76389|NCT01221506|Drug|Pazopanib|800 mg PO QD x 28 days
76390|NCT01221506|Device|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
76391|NCT01221519|Drug|AZD1656|3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
75838|NCT00046709|Drug|Smoked Marijuana|
75839|NCT01218282|Behavioral|Home exercise training|20-30 min/day for at least 4 days/week
75840|NCT01218282|Behavioral|NO Exercise Training|No intervention
75841|NCT01218295|Device|Spirotiger®|training session :10 minutes twice a day X 4 weeks
75842|NCT01218308|Biological|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
75843|NCT01220531|Procedure|Blood Draw|Biological Mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow for testing of T cell identity in the complete DiGeorge subjects. If blood is not obtainable, then a buccal swab may be done.
75844|NCT01220531|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV prior to thymus transplantation. Each dose is given over 12 hours. RATGAM is usually given on days -5, -4, and -3 prior to thymus transplantation.
75845|NCT01220531|Drug|Cyclosporine|Csa may be given every 8 to 12 hours orally or IV before and after thymus transplantation. The Csa dose is dependent on T cell numbers and the target CSA trough levels. Csa is weaned as per protocol.
75846|NCT01220531|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 to 12 hours orally or IV before and after thymus transplantation. FK506 dose is dependent on T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
75847|NCT01220531|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and/or after thymus transplantation. Administration and dosage depends on T cell numbers. Steroids are weaned as per protocol.
75848|NCT00046917|Drug|alvocidib|Given IV
75849|NCT01220531|Drug|Basiliximab|A single dose of Basiliximab 5 mg/kg IV may be given. Administration of Basiliximab depends on T cell numbers and T cell activation. A single dose of Basiliximab may be given after the administration of rabbit anti-thymocyte globulin and before thymus transplantation. If Basiliximab is not given before thymus transplantation, and, depending on the T cell numbers and T cell activation, a single dose of Basiliximab may be given 3 to 5 days after thymus transplantation.
76143|NCT01223560|Other|Exercise|Exercise on tread mill
76144|NCT01223560|Dietary Supplement|Carbohydrate|Carbohydrate intake
76145|NCT00047099|Drug|epirubicin hydrochloride|
76146|NCT01223612|Drug|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
76147|NCT01223612|Procedure|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
76148|NCT01223625|Drug|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
76149|NCT01223625|Drug|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
76859|NCT01215292|Drug|ketoconazole 400|400 mg PO daily, Days 3-10
76860|NCT01215292|Drug|Ketoconazole 800|800 mg PO daily, Day 3-10
75913|NCT01218321|Biological|antiepileptic treatment|White blood cells from peripheral blood samples
75914|NCT01218334|Device|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
75915|NCT01218347|Drug|Rosuvastatin|20 mg once daily for 21 days
75916|NCT01218360|Drug|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
75917|NCT01218373|Device|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
75918|NCT00046722|Drug|Smoked Marijuana|
75919|NCT01218373|Device|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
75920|NCT01218386|Drug|Estradiol valerate|Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.
Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation.
75921|NCT01218399|Drug|Symbicort vs Budesonide in treating acute respiratory illness|use of either symbicort or budesonide
75922|NCT01218412|Behavioral|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
75923|NCT01218425|Drug|Methylphenidate 40 mg|Oral dose 40 mg
75924|NCT01218425|Drug|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
75925|NCT01218425|Drug|Domperidon 10 mg|Domperidon 10 mg
75926|NCT01218438|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
75927|NCT01218438|Drug|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
75928|NCT01218451|Biological|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
75929|NCT00046735|Drug|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
77252|NCT00045695|Drug|bortezomib|PS-341 bolus intravenous injection twice weekly* for 2 out of every 3 weeks
77253|NCT01211249|Drug|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
77254|NCT01211249|Drug|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
77255|NCT01211249|Drug|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
77256|NCT01211249|Drug|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
77257|NCT01211262|Drug|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of patients will be treated at the RP2D or MTD.
77258|NCT01213524|Drug|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
77259|NCT01213524|Other|usual brand smoking|participant smokes usual brand of cigarette
77260|NCT01213550|Drug|Chlorhexidine gluconate|
77261|NCT01213550|Drug|Placebo mouthrinse|
77262|NCT01213563|Drug|Actrapid insulin+Gloucose|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
77263|NCT01213563|Drug|Actrapid insulin|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
77264|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
77265|NCT01213576|Drug|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
77266|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
77267|NCT00000989|Drug|Ganciclovir|
77268|NCT00045955|Drug|Fexofenadine, Comparator = Montelukast|
77269|NCT01213576|Drug|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
76392|NCT01221532|Behavioral|SHHE Peridischarge Intervention|Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus
a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;
two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;
the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care.
76393|NCT01221545|Drug|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
76394|NCT01221545|Drug|Placebo|Placebo
76395|NCT01214486|Drug|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA < 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
76703|NCT01217450|Other|laboratory biomarker analysis|Correlative studies
76704|NCT01217450|Other|pharmacological study|Correlative studies
76705|NCT01217463|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
76706|NCT01217476|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
76707|NCT01217489|Procedure|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
76708|NCT01217502|Behavioral|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
76709|NCT01217502|Behavioral|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
76710|NCT01217515|Drug|Diltiazem hydrochloride 4% cream|3 times daily
76711|NCT01217515|Drug|Diltiazem hydrochloride 2% cream|3 times daily
76712|NCT01217515|Other|Placebo|3 times daily
76713|NCT00046501|Drug|Humulin L|
76150|NCT01223638|Other|Audiometry|Audiometry
76151|NCT01223651|Procedure|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
76152|NCT01216631|Drug|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
76153|NCT01216631|Drug|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
76154|NCT01216644|Drug|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
76155|NCT01216644|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
76156|NCT01216644|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
76157|NCT01216644|Drug|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
76158|NCT01216644|Drug|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
76159|NCT00046358|Drug|Ibuprofen|
76160|NCT01216644|Drug|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
76161|NCT01216644|Drug|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
76162|NCT01216657|Drug|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
76163|NCT01216670|Behavioral|remote patient's management|scheduled remote CareLink data transmission
76164|NCT01216683|Biological|rituximab|Given IV
76165|NCT01216683|Drug|bendamustine hydrochloride|Given IV
76449|NCT01219244|Behavioral|omega-3 supplementation|6 months of omega-3 supplementation
76450|NCT00046852|Biological|filgrastim|
76451|NCT01219244|Behavioral|resveratrol supplementation|6 months of resveratrol supplementation
76452|NCT01219244|Behavioral|Placebo|6 months of placebo intake
75930|NCT01218451|Biological|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
75931|NCT01218451|Biological|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
75932|NCT01218464|Drug|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 12 weeks.
76221|NCT00047073|Procedure|Supportive Care|Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.
Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.
If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented.
76222|NCT01223274|Device|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
76223|NCT01223274|Device|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
76224|NCT01223313|Device|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
76225|NCT01223326|Drug|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
76226|NCT01223326|Drug|Saline|Na Cl 0.9% infusion
76227|NCT01223339|Drug|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
76228|NCT01223339|Drug|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
76229|NCT01223339|Drug|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
76230|NCT01223339|Drug|Placebo|Placebo tablets administered once daily in the fed state for 7 days
76231|NCT01223352|Drug|bosentan|bosentan 2mg/kg b.i.d.
76232|NCT00000998|Drug|Trimetrexate glucuronate|
76233|NCT00047099|Drug|cyclophosphamide|
76234|NCT01223352|Drug|bosentan|bosentan 2mg/kg t.i.d.
77520|NCT01213849|Drug|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
77521|NCT01214473|Other|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
77522|NCT01214473|Other|Maltodextrin|Only maltodextrin as placebo
77523|NCT00045279|Biological|PEG-interferon alfa-2b|
77524|NCT01206465|Drug|fluorouracil|Given IV
77525|NCT01206465|Other|laboratory biomarker analysis|Correlative studies
77526|NCT01206465|Genetic|DNA analysis|Correlative studies
77527|NCT01206465|Other|high performance liquid chromatography|Correlative studies
77528|NCT01206465|Genetic|polymerase chain reaction|Correlative studies
77529|NCT01206465|Genetic|nucleic acid sequencing|Correlative studies
77530|NCT01206465|Other|pharmacological study|Correlative studies
77531|NCT01206465|Other|pharmacogenomic studies|Correlative studies
77532|NCT01206465|Genetic|polymorphism analysis|Correlative studies
77533|NCT01206478|Drug|Amitriptyline 1 mg/kg|Amitriptyline 1 mg/kg once daily at bedtime. At Visit 2, after participating in the study for ten weeks, children in both Groups 1 and 2 will receive a prescription for the appetite stimulant megestrol. The dose your child will receive depends on your child's age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
77534|NCT00000986|Drug|Zidovudine|
77535|NCT00045292|Drug|acyclovir|
77536|NCT01206478|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
At Visit 2, after participating in the study for ten weeks, children in both Groups 1 and 2 will receive a prescription for the appetite stimulant megestrol. The dose your child will receive depends on your child's age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
77537|NCT01206504|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
77538|NCT01206517|Drug|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
77539|NCT01206517|Drug|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
76714|NCT01217528|Device|device settings for group A|VT zone: 350ms VF zone: 280ms
76715|NCT01217528|Device|Device settings for group B|VT zone: 320ms VF zone: 250ms
76716|NCT01217541|Other|Education and Supervision|Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.
76717|NCT01217541|Other|Control|A control group of nursing home units that do not get any form of active intervention
76718|NCT01217567|Procedure|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
76719|NCT01217567|Procedure|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
76720|NCT01217580|Drug|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
76721|NCT01217580|Drug|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
76722|NCT00046852|Drug|cyclophosphamide|
75773|NCT01220531|Biological|Thymus Tissue for Transplantation|Potential thymus recipient subjects are screened for eligibility. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue is transplanted into the subject's quadriceps. Two to three months post-transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, skin biopsy conducted. Subjects undergo laboratory testing for approximately one year post-transplantation. At year 2 post-transplantation, subjects are contacted for data collection.
75774|NCT01222715|Biological|Bevacizumab|Given IV
75775|NCT01222715|Drug|Cyclophosphamide|Given IV
75776|NCT01222715|Other|Laboratory Biomarker Analysis|Correlative studies
75777|NCT01222715|Drug|Temsirolimus|Given IV
75778|NCT01222715|Drug|Vinorelbine Tartrate|Given IV
75779|NCT01222754|Drug|Lenalidomide|With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.
Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course.
75780|NCT01222754|Radiation|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
75781|NCT00047047|Drug|cisplatin|Given IV
76453|NCT01219244|Behavioral|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
76454|NCT01219244|Behavioral|2nd step: intervention + control|most effective dietary intervention plus control
76455|NCT01221558|Dietary Supplement|lycopene|
76456|NCT00046969|Radiation|radiation therapy|
76457|NCT01221571|Drug|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
76458|NCT01221597|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
76459|NCT01221597|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
76460|NCT01221610|Device|Passeo-18 Lux DRB|
76461|NCT01221610|Device|Standard PTA (POBA)|
76462|NCT01221623|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
76463|NCT01221623|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
76464|NCT01221636|Drug|Abatacept|Solution for injection, Intravenous, 750 mg, 1 day
76465|NCT01221649|Device|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
76466|NCT01221662|Drug|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
76467|NCT00046995|Drug|carboplatin|
76468|NCT01221675|Drug|Antibody TF2|preciblage with an antibody
76469|NCT01221675|Radiation|IMP-288-Lutetium|Internal Radiation
76780|NCT01215227|Drug|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
78701|NCT01235494|Other|polarised 3 helium|1 inhalation (= 1 litre)
78702|NCT01235507|Drug|methotrexate|stable dose as prescribed
78703|NCT01235507|Drug|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
78704|NCT00048230|Drug|bortezomib|
78705|NCT01235520|Drug|Placebo|Oral doses, once a day for 52 weeks
78706|NCT01235520|Drug|RO4917838|Oral dose level 1, once a day for 52 weeks
78707|NCT01235520|Drug|RO4917838|Oral dose level 2, once a day for 52 weeks
78708|NCT01235533|Dietary Supplement|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
78709|NCT01235546|Drug|Azithromycin|500 mg in 250 cc normal saline 1 time dose
78710|NCT01235546|Drug|Placebo|250 cc normal saline
78711|NCT01235559|Drug|Placebo|Oral doses, once a day for 52 weeks
79019|NCT00048594|Drug|aprepitant|
79020|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
79021|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
79022|NCT00001013|Drug|Pentamidine isethionate|
79023|NCT00048815|Drug|St. John's Wort|
79024|NCT01240980|Drug|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
79025|NCT01240980|Drug|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
79026|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
79027|NCT01240980|Drug|Placebo|Solution, Oral, 0 mg, once daily, 1 day
79028|NCT01240980|Drug|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
82345|NCT01261728|Drug|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
82346|NCT01261741|Drug|Memantine|Each subject will receive memantine 10mg tablets once daily
82347|NCT01261741|Drug|Placebo|Each subject will receive matching placebo tablets once daily
82348|NCT00050414|Drug|Dexamethasone|Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
82349|NCT01261754|Radiation|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
82608|NCT01252316|Other|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
82609|NCT01252316|Other|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
82610|NCT01244724|Drug|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
82611|NCT01244737|Drug|[18F] FLT|[18F] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
82612|NCT01244763|Drug|FG-4592|Different dose levels and schedules
82613|NCT01244776|Device|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
82614|NCT01244789|Drug|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
82615|NCT01244789|Other|observation|active observation
82616|NCT01244815|Drug|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
82617|NCT01244815|Drug|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
82618|NCT01244815|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
82619|NCT01244828|Drug|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
79087|NCT01236144|Drug|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
79088|NCT00001009|Drug|Dextran sulfate|
79089|NCT00048399|Drug|Fludarabine|
79090|NCT01236144|Drug|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
79091|NCT01238575|Other|placebo|Administered for up to 8 weeks.
79092|NCT01238575|Drug|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
79093|NCT01238588|Drug|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
79094|NCT01238614|Other|CHICA PSF plus JIT|
79095|NCT01238614|Other|CHICA maternal depression PSF|
79096|NCT01238614|Other|Control|
79097|NCT01238627|Drug|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
79098|NCT01238627|Drug|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
79099|NCT00048594|Drug|Comparator: placebo (unspecified)|
79100|NCT01238640|Drug|Code STD|2 mg Single-dose of experimental nicotine product coded "STD"
79400|NCT00048893|Biological|filgrastim|5 mcg/kg/day subcutaneously
79401|NCT01241643|Drug|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
79402|NCT01241656|Behavioral|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
82843|NCT01250353|Procedure|pterygium surgery|pterygium was removed surgically
82844|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
82845|NCT01250366|Drug|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
82846|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
82847|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
82848|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
82849|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
82850|NCT00049439|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
82851|NCT01250366|Drug|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
82852|NCT01250366|Drug|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
82853|NCT01250366|Drug|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
82854|NCT01250379|Drug|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
82855|NCT01250379|Drug|Chemotherapy|Standard chemotherapy (doublets not allowed)
82856|NCT01250392|Behavioral|The Effect of Active Choice on Nurse Visit Participation|The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.
The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment.
82857|NCT01250405|Drug|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
82858|NCT01252719|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
82859|NCT01252732|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
82882|NCT01245205|Other|pharmacological study|Correlative studies
82883|NCT01245205|Other|laboratory biomarker analysis|Correlative studies
81978|NCT01258738|Biological|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
81979|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
81980|NCT01258738|Other|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
81981|NCT01261078|Drug|Placebo|intrathecal 8 mg of bupivacaine only
81982|NCT01261078|Drug|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
81983|NCT01261078|Drug|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
81984|NCT01261078|Drug|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
81985|NCT01261078|Drug|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
81986|NCT00050375|Drug|oregovomab|
81987|NCT01261091|Procedure|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
81988|NCT01261091|Procedure|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
81989|NCT01261117|Drug|oral ibuprofen|oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
81990|NCT01261130|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
81991|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
81992|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
81993|NCT01261130|Biological|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
81994|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
81995|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
81996|NCT01261130|Biological|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
82620|NCT00049101|Drug|leucovorin calcium|
82621|NCT01244841|Procedure|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
82622|NCT01244854|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
82623|NCT01244867|Biological|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
82624|NCT01244867|Biological|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
82625|NCT01244867|Biological|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
82967|NCT01252953|Drug|anacetrapib|tablet, 100mg daily
82968|NCT01252953|Drug|placebo anacetrapib|tablet, 1 tablet daily
82969|NCT01252966|Behavioral|Cognitive Remediation Training (CRT)|Cognitive Remediation Training (CRT) is a 12-week standardized course of internet-based computerized cognitive exercises designed to buffer smokers against cognitive deficits that increase smoking relapse risk.
82970|NCT00049569|Drug|cytarabine|Given IT
82971|NCT01252966|Behavioral|Standard Care (SC)|Standard Care (SC) is a 12-week standardized course of internet-based deep breathing exercises, but do not contain the cognitive exercises designed to buffer smokers against cognitive deficits that increase smoking relapse risk found in the Cognitive Remediation Training.
82972|NCT01252979|Dietary Supplement|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
82973|NCT01252992|Genetic|Genetic analysis|identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;
Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.
One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction.
82974|NCT01252992|Radiation|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
82975|NCT01252992|Other|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
82976|NCT01252992|Other|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
82977|NCT01253005|Behavioral|Nutritional intervention|This study will investigate the effects of particle size of different triglyceride emulsions as well as the dynamics of intragastric structure formation and breakdown of the emulsions on GI function, the kinetics of the endocrine and the satiation response in healthy volunteers.
79403|NCT01241656|Behavioral|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
79404|NCT01241656|Behavioral|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
79405|NCT01241669|Drug|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
79406|NCT01241669|Drug|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
79407|NCT01234272|Drug|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
79408|NCT01234272|Drug|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
79409|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
79410|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
79411|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
79412|NCT01234285|Drug|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
79413|NCT00048126|Drug|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
79414|NCT01234298|Drug|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
78467|NCT01237535|Procedure|Insemination without luteal support|Routine insemination procedure without luteal support
78468|NCT01237548|Other|Smoking Narghile for 30 min|No Other intervention will be used
78469|NCT01237561|Other|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
82884|NCT01245231|Genetic|protein expression analysis|
82885|NCT01245231|Genetic|western blotting|
82886|NCT01245231|Other|flow cytometry|
82887|NCT01245231|Other|laboratory biomarker analysis|
82888|NCT00049114|Procedure|therapeutic conventional surgery|Undergo complete resection
82889|NCT01245231|Other|medical chart review|
82890|NCT01245244|Drug|Morphine|Morphine oral mixture
82891|NCT01245244|Other|orange juice|orange juice
82892|NCT01245270|Dietary Supplement|Bilberry capsule first, then control cap|Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).
Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time.
82893|NCT01245270|Dietary Supplement|Control capsule first then bilberry cap|Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).
Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time.
82894|NCT01245283|Other|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
82895|NCT01245283|Other|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
82896|NCT01245283|Other|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
82897|NCT01245296|Procedure|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
82898|NCT01245309|Procedure|scratching|endometrial scratching before COH in IVF
82899|NCT00049114|Other|laboratory biomarker analysis|Correlative studies
82900|NCT01245309|Procedure|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
81997|NCT00050388|Genetic|Allovectin-7®|
81998|NCT01261143|Drug|BK-C-0701|tablet, 8 weeks
82273|NCT00050414|Drug|Trabectedin|Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
82274|NCT01261663|Other|oral nutritional energy and protein enriched supplement (NOS)|
82275|NCT01261676|Other|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
82276|NCT01254136|Drug|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
82277|NCT01254136|Drug|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
82278|NCT01254136|Drug|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
82279|NCT01254162|Drug|MTC896 Gel|0.75% w/w gel applied daily for 28 days to the forehead
82280|NCT01254175|Biological|rHPIV3cp45 Vaccine|10^5 TCID^50 of rHPIV3cp45 vaccine, delivered as nose drops
82281|NCT01254175|Biological|Placebo Vaccine|Placebo vaccine, delivered as nose drops
82282|NCT00049582|Other|pharmacological study|Correlative studies
82283|NCT01254188|Drug|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
82284|NCT01254214|Behavioral|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
82978|NCT01245348|Genetic|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
82979|NCT01245361|Drug|Infliximab|Infliximab 3 mg/kg wk 0,2,6
82980|NCT01245361|Drug|sodium chloride|Group II : Placebo wk 0,2,6
82981|NCT01245374|Drug|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
82982|NCT01245387|Drug|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
82983|NCT01245400|Device|Z-Lig|ACL replacement
82984|NCT00049127|Drug|imatinib mesylate|Given PO
82985|NCT01245400|Device|allograft|ACL replacement
82067|NCT01258777|Drug|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
82068|NCT01258790|Device|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
82069|NCT01258790|Device|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
82070|NCT01258803|Drug|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
82071|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
82072|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
82073|NCT01258803|Drug|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
82074|NCT00050076|Drug|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
78470|NCT01237574|Other|Intervention according to the standard of care.|Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.
78471|NCT01237587|Drug|Duloxetine|Administered orally
78472|NCT01237587|Drug|Placebo|Administered orally
78473|NCT00048529|Drug|T900607-sodium intravenous|
78474|NCT01237600|Procedure|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
78475|NCT01237613|Device|Artelon|Artelon Tissue Reinforcement
78476|NCT01237639|Other|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
78477|NCT01240044|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
78478|NCT01240044|Procedure|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
78479|NCT01240057|Procedure|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
78480|NCT01240057|Other|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
78481|NCT01240070|Other|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
78482|NCT01240083|Device|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
78776|NCT01242904|Drug|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
78777|NCT01242917|Drug|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
78645|NCT01237951|Procedure|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
78646|NCT01237951|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
78647|NCT01237964|Drug|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
78648|NCT01237977|Drug|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
78649|NCT01237977|Drug|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
78650|NCT01240330|Device|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
78651|NCT01240356|Device|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
78652|NCT00048789|Procedure|Extracorporeal Photopheresis|
78653|NCT01240356|Device|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
78654|NCT01240356|Device|2-MHz ultrasound insonation +/- microbubbles|2-hours of hands-free ultrasound delivered to in the intracranial vessels. Intravenous microbubbles.
78956|NCT01243294|Device|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
78957|NCT01243294|Device|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
78958|NCT01243307|Drug|CT327 (or placebo) followed by placebo (or CT327)|During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.
During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.
78959|NCT01243320|Drug|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
78960|NCT01243320|Drug|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
78961|NCT01243333|Radiation|Multi-tracer PET exams|Initial scan will be done before starting the trial. The other two will be done about 25 to 32 days after the trial starts. Each of the 4 PET scans will be done with up to three of the tracers (FDG, FLT, and water) depending on the type of drug they are receiving and the tumor type. The timing of the PET scans will vary. Typically the first series of PET scans will be within a few days of each other but will be obtained within one week of each other. Similarly the follow-up series of PET scans at about 28 days will be within a few days of each other depending on scheduling issues but also within one week of each other.
78962|NCT00000251|Drug|30% N2O|
78963|NCT00001014|Drug|Trimetrexate glucuronate|
82285|NCT01254214|Behavioral|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
82286|NCT01254227|Drug|Deferasirox and Deferoxamine|
82287|NCT01254240|Device|UVA / UVB phototherapy|UVA / UVB phototherapy
82551|NCT01254591|Radiation|rubidium Rb-82|
82552|NCT01254604|Drug|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
82553|NCT01254604|Drug|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
82554|NCT01254617|Biological|Cetuximab|Given IV
82555|NCT01254617|Other|Laboratory Biomarker Analysis|Correlative studies
82556|NCT01254617|Drug|Lenalidomide|Given PO
82557|NCT00049595|Drug|dacarbazine|
82558|NCT01254630|Biological|V212|V212 viral antigen for HZ, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
82559|NCT01254630|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
82560|NCT01254643|Biological|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
82561|NCT01254656|Drug|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
82562|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
82563|NCT01254656|Drug|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
82564|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
82565|NCT01254656|Drug|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
82566|NCT01254656|Drug|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
82567|NCT01254669|Behavioral|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
79029|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
79030|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
79031|NCT01240980|Drug|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
79032|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
79033|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
79034|NCT00048828|Drug|Olanzapine|Participants will receive olanzapine for 12 weeks.
79035|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
79036|NCT01240993|Behavioral|Mentalization-Based Therapy for Substance Abusing Mothers|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions.
79037|NCT01240993|Behavioral|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study (i.e., pamphlets do not overlap significantly with the MTP treatment approach). Sample pamphlet topics include safety-proofing the home, routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
79038|NCT01241006|Drug|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
79339|NCT01234207|Device|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
79340|NCT01234233|Procedure|duration of preoperative active warming|duration of prewarming by "forced air warming"
79341|NCT01234259|Device|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
79342|NCT01236560|Drug|Temozolomide|Given PO
79343|NCT01236560|Drug|Vorinostat|Given PO
79344|NCT01236573|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
79345|NCT01236573|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
79346|NCT01236573|Biological|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
78778|NCT01242917|Drug|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
78779|NCT01242917|Drug|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
78780|NCT01242930|Drug|Standard of Care|Standard of Care
78781|NCT01242943|Drug|131I-L19SIP Radioimmunotherapy (RIT)|Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.
Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167.
78782|NCT00048997|Other|Observation|
78783|NCT01242956|Behavioral|verum group|video-based training after stroke
78784|NCT01242956|Behavioral|Placebo group|non-video group
78785|NCT01242982|Procedure|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
78786|NCT01242982|Procedure|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
78787|NCT01242995|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
78788|NCT01243008|Drug|Application of SHB001|Cohort 1: Application of SHB001 on the skin of right thigh
Cohort 2:
Application of SHB001 on the skin of right thigh
punch biopsies of treated skin areas
78789|NCT01243047|Drug|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
78790|NCT01235572|Procedure|quality-of-life assessment|Ancillary studies
78791|NCT01235585|Drug|Placebo|Oral doses, once a day for 52 weeks
78792|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
78793|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
78794|NCT01235598|Other|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
78795|NCT01235598|Biological|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
79101|NCT01238640|Drug|Code STE|2 mg Single-dose of experimental nicotine product coded "STE"
78964|NCT00049010|Other|immunohistochemistry staining method|
78965|NCT01243346|Drug|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
78966|NCT01243359|Drug|sunitinib malate|Given PO
78967|NCT01243359|Biological|bevacizumab|Given IV
78968|NCT01243359|Other|pharmacological study|Correlative studies
78969|NCT01243359|Other|laboratory biomarker analysis|Correlative studies
78970|NCT01243359|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
78971|NCT01243359|Procedure|positron emission tomography|Undergo FLT PET/CT
78972|NCT01243359|Procedure|computed tomography|Undergo FLT PET/CT
78973|NCT01243372|Genetic|mutation analysis|
78974|NCT01243372|Other|laboratory biomarker analysis|
78975|NCT00049023|Radiation|yttrium Y 90-edotreotide|
78976|NCT00048347|Drug|AVONEX|30µg IM every week for 12 weeks
78977|NCT01235884|Dietary Supplement|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
79278|NCT01238913|Procedure|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
79279|NCT01238926|Dietary Supplement|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
79280|NCT01238926|Other|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
79281|NCT01238926|Other|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
79282|NCT01238939|Drug|NK012 and 5-FU|NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
79283|NCT01238952|Drug|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
79284|NCT01238965|Drug|panobinostat|Given orally
82568|NCT00049595|Drug|doxorubicin hydrochloride|
82569|NCT01254682|Device|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
82570|NCT01249924|Device|Control|Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
82901|NCT01245322|Drug|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
82902|NCT01245335|Device|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
82903|NCT01245335|Device|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
82904|NCT01247896|Drug|PF-05190457|Single Dose 100 mg
82905|NCT00049283|Procedure|therapeutic conventional surgery|Undergo neck dissection
82906|NCT01247896|Drug|PF-05190457|Single Dose 300 mg
82907|NCT01247896|Drug|PF-05190457|Single Dose 600 mg
82908|NCT01247896|Drug|PF-05190457|Single Dose - to be determined with food
82909|NCT01247896|Drug|PF-05190457|Single Dose - to be determined
82910|NCT01247896|Drug|Placebo|Single Dose Placebo
82911|NCT01247909|Drug|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
82912|NCT01247922|Drug|Erlotinib|continuous oral Erlotinib 85 mg/m^2 per day
82913|NCT01247935|Other|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
82914|NCT01247935|Other|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
82915|NCT01247935|Other|Control|Patients are monitored for pain and discomfort
82916|NCT00049283|Other|laboratory biomarker analysis|Correlative studies
82917|NCT01247948|Procedure|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
79347|NCT00048412|Drug|CAMPATH 1H|
79348|NCT01236586|Drug|RO4929097|
79349|NCT01236586|Drug|Dexamethasone|
79350|NCT01236599|Other|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
79351|NCT01236612|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
79352|NCT01236612|Biological|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
79353|NCT01236612|Biological|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
79354|NCT01236612|Biological|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
79355|NCT01236612|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
79356|NCT01236625|Procedure|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
79357|NCT01236638|Drug|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
79358|NCT00048412|Drug|FK50|
78410|NCT01242267|Drug|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 400mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
78411|NCT01242280|Device|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
78412|NCT01242280|Device|Tamponade|Sengstaken-Blakemore tube
78413|NCT01242293|Other|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
78414|NCT01242293|Other|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
79102|NCT01238640|Drug|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
79103|NCT01238679|Drug|PF-04958242 0.03 mg|0.03 mg dose tablet every 12 hours for 14 days
79104|NCT01238679|Drug|PF-04958242 0.05 mg|PF-04958242 0.05 mg dose tablet every 24 hours for 14 days
79105|NCT01238679|Drug|Placebo|Placebo tablet every 12 hours or every 24 hours for 14 days
79106|NCT01238692|Drug|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
79107|NCT01238692|Drug|Rituximab|Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:
Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL).
79108|NCT01238705|Drug|Felodipine add Irbesartan|Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.
Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074.
79109|NCT01238705|Drug|Felodipine add Metoprolol|Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.
Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061.
79110|NCT00001011|Drug|Zidovudine|
79111|NCT00048607|Drug|aprepitant|
79112|NCT01238718|Drug|Lidocaine|lidocaine 1.5 mg/kg intravenously
79113|NCT01238718|Drug|Placebo|normal saline
79114|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
79115|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
79116|NCT01241084|Dietary Supplement|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
79117|NCT01241084|Dietary Supplement|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
79118|NCT01241097|Drug|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
79119|NCT01241110|Drug|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
79120|NCT01241110|Drug|azitromycin|azitromicin vs ofluxacin
79285|NCT01238965|Drug|fluorouracil|Given IV
79286|NCT01238965|Drug|leucovorin calcium|Given IV
79287|NCT01238965|Procedure|biopsy|Correlative studies
79288|NCT00048633|Drug|Chemotherapy|
79289|NCT01238965|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
79290|NCT01238965|Genetic|western blotting|Correlative studies
79291|NCT01238965|Other|laboratory biomarker analysis|Correlative studies
79292|NCT01238965|Genetic|gene expression analysis|Correlative studies
79293|NCT01238965|Genetic|RNA analysis|Correlative studies
79294|NCT01238965|Genetic|polymorphism analysis|Correlative studies
79295|NCT01238978|Drug|Vildagliptin|
79296|NCT01238978|Drug|"Usual Care"|
79297|NCT01238991|Biological|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
79298|NCT01241422|Drug|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
79299|NCT00048880|Drug|HeFi-1 Monoclonal Antibody|
78348|NCT01234844|Behavioral|guinea pigs|twice weekly pet therapy and twice weekly "usual " occupational therapy
78349|NCT01234857|Drug|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
78350|NCT00048165|Drug|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
78351|NCT01234857|Drug|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
78352|NCT01234857|Drug|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
82918|NCT01247948|Procedure|traditional spine surgery|traditional spine surgery without navigation assist
82919|NCT01247961|Drug|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
82920|NCT01247961|Other|Placebo|Normal saline
82921|NCT01247974|Device|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
82922|NCT01247987|Procedure|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
82923|NCT01247987|Procedure|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
81999|NCT01261156|Drug|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
82000|NCT01261156|Drug|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
82001|NCT01261169|Drug|Myfortic|Myfortic in uveitis
82002|NCT01261182|Other|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
82003|NCT01261182|Other|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
82004|NCT01261234|Drug|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
82005|NCT01263548|Drug|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
82006|NCT01263561|Procedure|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
82007|NCT00050648|Drug|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
82008|NCT01263561|Procedure|trabeculectomy|trabeculectomy filtering surgery
82009|NCT01263574|Drug|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards. The pre-measured volume of lock solution will then be injected into the catheter. The minimum dwell time of 4 hours will follow. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. On the other four days of the week, patients will receive heparin locks, per current standard of care. Volume of lock solution administered will be determined by catheter size.
78415|NCT01242293|Other|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
78416|NCT01242306|Drug|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
78417|NCT01242319|Behavioral|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
78418|NCT01242332|Drug|Pregabalin|75 mg po 2 hrs before surgery
78419|NCT00048932|Drug|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
78420|NCT01242345|Device|Capnography|Monitoring of the capnography curve for early detection of apnea
78421|NCT01242358|Device|Capnography|Capnographic monitoring
78422|NCT01242358|Device|Standard monitoring|Standard monitoring
78423|NCT01242371|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
78424|NCT01242371|Dietary Supplement|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
78425|NCT01242384|Device|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
78426|NCT01242397|Device|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
78427|NCT01242410|Device|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
78712|NCT01235559|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
78713|NCT01235559|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
78714|NCT01235572|Procedure|standard follow-up care|Undergo early discharge and standard outpatient care
78715|NCT00048295|Drug|Alicaforsen|
78716|NCT01235572|Other|medical chart review|Undergo early discharge and standard outpatient care
79121|NCT01241123|Procedure|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
79415|NCT01234298|Drug|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
79416|NCT01234298|Drug|Placebo|Placebo capsule taken once-daily for up to 26 weeks
79417|NCT01234311|Drug|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
79418|NCT01234311|Drug|Placebo|
79419|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
79420|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
79421|NCT01234337|Drug|Sorafenib(Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
79422|NCT01234337|Drug|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
79423|NCT01234337|Drug|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,
79424|NCT01236690|Drug|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
79425|NCT01236716|Drug|Albumin paclitaxel plus carboplatin|Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
79426|NCT01236716|Drug|Gemcitabine plus carboplatin|Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
79427|NCT01236742|Device|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
78353|NCT01234857|Drug|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
78354|NCT01234870|Drug|Gadolinium|
78355|NCT01234870|Drug|Adenosine|
78356|NCT01234883|Drug|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
78357|NCT01234883|Drug|saline|IV solutions dosed as clinically indicated for rehydration
78358|NCT01234896|Drug|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
78359|NCT01234896|Drug|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
78360|NCT01234896|Drug|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
78361|NCT00048165|Drug|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
78362|NCT00048477|Drug|L-NMMA and Sodium Nitrite|
78363|NCT01237223|Drug|Placebo of Aliskiren|Aliskiren placebo tablet
78364|NCT01237223|Drug|Placebo of Amlodipine|Amlodipine placebo capsule
78365|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
78366|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
78367|NCT01237236|Drug|LEE011|
78368|NCT01237249|Drug|Melphalan|
78655|NCT01240382|Drug|3% DE-089 ophthalmic solution|
78656|NCT01240382|Drug|0.1% sodium hyaluronate ophthalmic solution|
78657|NCT01240395|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of "decentering", meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
78658|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
82010|NCT01263613|Procedure|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
82011|NCT01263639|Other|Orthopaedic Attending Biosketch Card|The "intervention" group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
82012|NCT01263639|Other|Standard of care - No biosketch card|Standard of care
82013|NCT01263652|Drug|Diclofenac hydroxyethylpyrrolidine|IM/PO
82014|NCT01263652|Drug|orphenadrine|IM/PO orphenadrine
82015|NCT01263652|Drug|Tramadol|IM/PO tramadol
82016|NCT01263652|Drug|Dipyrone|PO/IM Dipyrone
82288|NCT01254240|Device|UVB phototherapy|UVB phototherapy
82289|NCT01254253|Device|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
82290|NCT01254266|Behavioral|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
82291|NCT01254266|Behavioral|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
82292|NCT01254266|Procedure|bariatric surgery|bariatric surgery.
82293|NCT00001021|Biological|rgp120/HIV-1MN|
82294|NCT00049595|Biological|bleomycin sulfate|
82295|NCT01256762|Drug|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
82296|NCT01256762|Drug|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
82297|NCT01256762|Drug|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
82298|NCT00049777|Drug|Unfractionated heparin|
82299|NCT01256775|Drug|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
82300|NCT01256775|Drug|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
82301|NCT01256788|Device|Euflexxa|4 injections of 2ml of Euflexxa
78717|NCT01238003|Other|Interpretation of blood test results|Interpretation of blood test results
78718|NCT01238016|Device|experimental|
78719|NCT01238029|Drug|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
78720|NCT01238042|Drug|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
78721|NCT01238055|Drug|Docetaxel + Sunitinib|Docetaxel 60 mg/m2 iv, every 3 weeks
Sunitinib 37.5 mg qd daily, every 3 weeks
78722|NCT00048555|Drug|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions
78723|NCT01238055|Drug|Docetaxel only|Docetaxel 60 mg/m2 iv
78724|NCT01238068|Device|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
78725|NCT01238094|Drug|Simvastatin|simvastatin 40 mg qd daily until disease progression
78726|NCT01238107|Drug|MT-102|BETA BLOCKER
78727|NCT01238120|Drug|Ibuprofen|200 mg BID and 8 hours apart
78728|NCT01238120|Behavioral|Home-Based Exercise (EXCAP)|A progressive walking and resistance band exercise program for a 6 week period
78729|NCT01238120|Drug|Placebo (sugar pill)|200mg BID and 8 hours apart
78730|NCT01238133|Drug|Carboplatin|Given IV
78731|NCT01238133|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
78732|NCT01238133|Other|Laboratory Biomarker Analysis|Correlative studies
78733|NCT00048568|Drug|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg < 60 kg); (750 mg 60-100 kg), )1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
78734|NCT01238133|Drug|Paclitaxel|Given IV
78735|NCT01238133|Other|Pharmacological Study|Ancillary studies
79039|NCT01241006|Drug|Prednisone|Prednisone 60mg PO q day for 5 days
79428|NCT01236742|Device|single-vision glasses|daily wear of spectacle glasses to correct vision
79429|NCT01236755|Device|single-vision glasses|Daily wear of glasses to correct vision
79430|NCT00048412|Procedure|Stem Cell Collection and Infusion|
82529|NCT01262105|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
82530|NCT01262118|Drug|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
82531|NCT01262131|Device|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
82532|NCT00050440|Drug|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
82533|NCT01262131|Device|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
82534|NCT01262131|Device|placebo therapy|Application of inactive magnetic fields using the Resonator device
82535|NCT01262144|Radiation|Radiotherapy|Radiotherapy for cervical cancer
82536|NCT01262157|Device|Extracorporeal Shockwave Therapy Generator (Vascuspec)|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
82537|NCT01262157|Device|Low intensity shock wave therapy|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
82538|NCT01262170|Dietary Supplement|CigRx Lozenge|lozenge made of dietary supplements
82539|NCT01262170|Other|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
82540|NCT01262183|Drug|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
82541|NCT01262183|Drug|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
82542|NCT01262196|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
82543|NCT01254591|Other|fluorescence angiography|
82544|NCT01254591|Other|laboratory biomarker analysis|
82545|NCT01254591|Procedure|infrared thermography|
78659|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
78660|NCT01240421|Drug|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
78661|NCT01240434|Procedure|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
78662|NCT01240447|Biological|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
78663|NCT00048802|Drug|Lithium|
78664|NCT01240447|Other|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
78665|NCT01240460|Drug|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
78666|NCT01240460|Drug|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
78667|NCT01240473|Drug|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
78668|NCT01240499|Other|Health-At-Every-Size (HAES)|HAES group: 14 weekly sessions.
Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.
SS group: 14 weekly sessions.
The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian & psychologist) are not counselors (as in HAES group) but only facilitators.
Outcome measures: For all women under study.
78669|NCT01242657|Behavioral|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
78670|NCT01242670|Biological|Ross River Virus Vaccine|Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
78978|NCT01235884|Dietary Supplement|Placebo|5 drops daily for 28 days
78979|NCT01235897|Drug|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
78980|NCT01235897|Drug|Paclitaxel|80 mg/m2 weekly - paclitaxel
78981|NCT01235897|Drug|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
82302|NCT01256788|Other|Saline|4 injections of 3 ml of sterile saline
82303|NCT01256801|Biological|cytokine|interleukin 2 2 million unit every week
82304|NCT01256814|Behavioral|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
82305|NCT01256853|Drug|MVA Vaccine|The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
82306|NCT01256866|Drug|Dexmedetomidine|
82307|NCT01256866|Drug|Midazolam|
82308|NCT01256879|Drug|cimetidine|cimetidine 200mg total dose (single dose) per arm
82309|NCT00049777|Drug|Low molecular weight heparin|
82571|NCT01249937|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
82572|NCT01249937|Drug|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
82573|NCT01249950|Other|feasibility|feasibility
82574|NCT00049387|Radiation|radiation therapy|Undergo partial brain radiation therapy
82575|NCT01249963|Dietary Supplement|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
82576|NCT01249963|Dietary Supplement|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
82577|NCT01249976|Other|blood culture|blood culture
82578|NCT01249989|Behavioral|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
79040|NCT01241019|Drug|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
79041|NCT01241032|Drug|Udenafil|200mg Single Oral Dose of
79042|NCT01241032|Dietary Supplement|Alcohol|Alcohol 39g / 240ml
79043|NCT01241071|Other|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
79044|NCT01241071|Other|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
79045|NCT00048828|Drug|Clozapine|Participants will receive 12 weeks of clozapine.
79046|NCT01243060|Drug|Almorexant|100mg
79047|NCT01243060|Drug|Almorexant|200mg
79048|NCT01243060|Drug|Zolpidem 10mg|10mg
79049|NCT00049010|Genetic|comparative genomic hybridization|
79050|NCT01243060|Drug|Placebo|One-time dose of Placebo
79051|NCT01243073|Drug|Imetelstat|
79052|NCT01243086|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
79053|NCT01243086|Drug|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
79054|NCT01243112|Drug|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
79055|NCT01243112|Drug|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
79056|NCT01243112|Drug|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
79057|NCT01243112|Drug|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
79058|NCT01243125|Drug|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
79059|NCT01243125|Drug|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
79060|NCT00049010|Genetic|cytogenetic analysis|
82546|NCT00049595|Drug|cyclophosphamide|
82547|NCT01254591|Procedure|magnetic resonance imaging|
82548|NCT01254591|Procedure|therapeutic conventional surgery|
82549|NCT01254591|Radiation|[18F]-ML-10|
82550|NCT01254591|Radiation|fludeoxyglucose F 18|
82803|NCT01245127|Drug|Ilaris|Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).
At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.
Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.
If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks.
82804|NCT01245140|Drug|alitretinoin|to receive verum (20 patients)
82805|NCT01245140|Drug|Placebo|to receive placebo (10 patients)
82806|NCT01245153|Other|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
82807|NCT01245153|Other|Pelvic floor muscle training (PFMT)|Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
82808|NCT01245166|Drug|Acarbose|Acarbose 50 mg, per orem, thrice daily
82809|NCT00049114|Biological|filgrastim|Given subcutaneously
82810|NCT01245166|Drug|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
82811|NCT01245179|Drug|panobinostat|Oral capsules taken Monday, Wednesday,Friday for 12 weeks:
I. 10mg 1 week on/3 weeks off, 10 mg/ 2 weeks on 2 weeks off, 10mg/continuous
II. 15mg 1 week on/3 weeks off, 15mg/ 2 weeks on 2 weeks off, 15mg/continuous
III. 20mg 1 week on/3 weeks off, 20mg/ 2 weeks on 2 weeks off, 20mg/continuous
82812|NCT01245205|Drug|Akt inhibitor MK2206|Given PO
82813|NCT01245205|Drug|lapatinib ditosylate|Given PO
82814|NCT01247792|Behavioral|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
82815|NCT00049283|Drug|docetaxel|Given IV
82816|NCT01247805|Drug|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
78982|NCT01235910|Drug|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
78983|NCT01235923|Drug|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
78984|NCT01235923|Drug|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
78985|NCT01235936|Drug|AKB-6548|Different dose levels
78986|NCT01235949|Biological|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
78987|NCT00048360|Drug|Extended-release bupropion hydrochloride|
78988|NCT01235949|Biological|Infanrix hexa|Intramuscular injection, 3 doses
78989|NCT01235949|Biological|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
78990|NCT01235949|Drug|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
78991|NCT01235949|Drug|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
78992|NCT01235962|Drug|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
78993|NCT01235962|Drug|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
78994|NCT01235975|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
78995|NCT01235975|Biological|MencevaxACWY TM|Subcutaneous injection
78996|NCT01235988|Drug|Eltrombopag|Eltrombopag 50mg & standard of care
78997|NCT01235988|Drug|Placebo|Placebo + standard of care
78998|NCT00048373|Drug|Etanercept|
78999|NCT01236001|Drug|Lacosamide|
79000|NCT01236014|Drug|Eltrombopag|Eltrombopag & standard of care
79001|NCT01236014|Drug|Romiplostim|Romiplostim & standard of care
79300|NCT01241422|Drug|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
82579|NCT01249989|Behavioral|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
82580|NCT01249989|Behavioral|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
82581|NCT01250002|Drug|Placebo|Placebo will receive the same volume of saline infusion.
82582|NCT01250002|Drug|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
82583|NCT01250041|Procedure|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
82584|NCT01250041|Procedure|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
82585|NCT00049400|Drug|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
82586|NCT01250054|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
82924|NCT01248000|Procedure|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
82925|NCT01248013|Behavioral|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
82926|NCT01248026|Other|Buttermilk|Consumption of the 2 experimental periods
buttermilk (45 g/d)
placebo (45 g/d,)
82927|NCT00049283|Other|pharmacological study|Correlative studies
82928|NCT01248052|Drug|LY2979165|administered orally
82929|NCT01248052|Drug|Placebo|administered orally
82930|NCT01248065|Drug|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
82931|NCT01248065|Drug|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
82932|NCT01250405|Drug|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
82933|NCT01250418|Drug|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
79061|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79359|NCT01236651|Drug|Meperidine|administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
79360|NCT01236651|Drug|Drotaverine|administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
79361|NCT01236664|Behavioral|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
79362|NCT01236664|Behavioral|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
79363|NCT01238991|Biological|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
79364|NCT00048646|Drug|IV Progesterone|
79365|NCT01238991|Biological|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
79366|NCT01239004|Drug|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
79367|NCT01239004|Drug|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
79368|NCT01239017|Biological|REGN475|
79369|NCT01239017|Other|Placebo|
79370|NCT01239030|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
79371|NCT01239043|Biological|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
79372|NCT01239043|Biological|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
79373|NCT01239056|Procedure|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
79374|NCT01239069|Drug|DE-110 ophthalmic suspension high dose|ophthalmic suspension; high dose; QID
79375|NCT00048659|Drug|YM598|
79376|NCT01239069|Drug|DE-110 ophthalmic suspension low dose|ophthalmic suspension; low dose; QID
79377|NCT01239069|Other|Placebo|DE-110 ophthalmic suspension vehicle;QID
82817|NCT01247805|Drug|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
82818|NCT01247805|Drug|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
82819|NCT01247818|Drug|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
82820|NCT01247818|Drug|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
82821|NCT01247818|Drug|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
83158|NCT01245686|Behavioral|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
83159|NCT01245712|Radiation|Accelerated Partial Breast Irradiation (APBI)|Two 3.4 Gy fractions administered per day, separated by at least 6 hours for a total of 34 Gy delivered in 10 fractions (5 - 6 days in a row).
83160|NCT01245725|Drug|Tirofiban (Aggrastat)|Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.
Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion.
83161|NCT01245725|Drug|Placebo|Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.
Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion.
83162|NCT01245751|Biological|Zoster Vaccine, Live|Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
83163|NCT01245764|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
83164|NCT01245764|Biological|Placebo|
83165|NCT01245777|Drug|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
83166|NCT00049140|Other|flow cytometry|
83167|NCT01245790|Drug|fostamatinib|Oral tablets, single dose
83168|NCT01245803|Drug|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
83169|NCT01245803|Drug|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
79301|NCT01241422|Drug|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
79302|NCT01241435|Drug|LY2216684|Administered orally
79303|NCT01241448|Drug|LY2409021|Administered Orally
79304|NCT01241448|Drug|Placebo|Administered Orally
79305|NCT01241461|Drug|LY2584702|Dose escalation starting at 50 mg. On day 1, subjects will receive a single oral dose. After a two day observation period, subjects will receive oral doses twice daily for a 28 day cycle.
Patients may continue 28 day cycles of twice daily dosing until discontinuation criteria are met.
79306|NCT01241474|Dietary Supplement|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
79307|NCT01241474|Dietary Supplement|Maize (corn) oil|6 x 1g capsules per day for 9 months
79308|NCT01241487|Drug|valsartan/amlodipine|160/10 mg
79309|NCT01241500|Drug|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
79310|NCT00048893|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|4 x 10^8 pfu given monthly subcutaneously for three doses in the first series and three doses on each of the intermediate and late re-immunizations (total 9 doses).
79311|NCT01241513|Drug|N Acetyl-Cysteine|4 days, 800 mg q.i.d. Oral
79312|NCT01241526|Other|Disease Management|Individual, group and phone education sessions
Telephone supporter follow-up
LTOT monitoring
79313|NCT01241526|Other|Usual site management|Usual education as per site protocol
Usual follow-up as per site protocol
LTOT monitoring
79314|NCT01241539|Drug|Dabigatran etexilate|150 mg capsule
79315|NCT01241539|Drug|Dabigatran etexilate|75 mg capsule
79316|NCT01241539|Drug|Dabigatran etexilate|110 mg capsule
79317|NCT01241552|Biological|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
79318|NCT01241552|Biological|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
79319|NCT01241552|Biological|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
82934|NCT01250431|Behavioral|EFT (Emotional Freedom Techniques)|10 EFT sessions
82935|NCT00049439|Drug|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
82936|NCT01250444|Other|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
82937|NCT01250457|Drug|topical Timolol|topical Timolol 0.5% solution applied twice daily
82938|NCT01250470|Other|Laboratory Biomarker Analysis|Correlative studies
82939|NCT01250470|Drug|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
82940|NCT01250470|Biological|Sargramostim|Given SC
82941|NCT01250483|Other|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
82942|NCT01250496|Drug|Aminophylline|75 mg of intravenous aminophylline
82943|NCT01250496|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
82944|NCT01250509|Behavioral|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
82945|NCT01250535|Drug|Warfarin|10 mg, po, single dose on day 7
82946|NCT00001019|Biological|rgp120/HIV-1 SF-2|
82017|NCT01263665|Device|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
82018|NCT00001026|Biological|rgp120/HIV-1IIIB|
82019|NCT00050648|Drug|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
82020|NCT01263678|Behavioral|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
82021|NCT01263678|Other|Usual Care|Patient views DA and completes post DA survey.
82022|NCT01263691|Biological|BioThrax|BioThrax
82023|NCT01263691|Biological|AV7909 Formulation 1|AV7909 Formulation 1
82024|NCT01263691|Biological|AV7909 Formulation 2|AV7909 Formulation 2
79378|NCT01239082|Procedure|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
79379|NCT01239082|Procedure|FIT|Annual FIT testing
79380|NCT01239095|Drug|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
78428|NCT01242423|Device|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
78429|NCT01234896|Drug|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
78430|NCT01234922|Drug|lisinopril|Given orally
78431|NCT01234922|Drug|losartan potassium|Given orally
78432|NCT01234922|Other|laboratory biomarker analysis|Correlative studies
78433|NCT01234922|Drug|benazepril hydrochloride|Given orally
78434|NCT01234922|Drug|ramipril|Given orally
78435|NCT01234935|Drug|dasatinib|Given orally
78436|NCT01234935|Drug|gemcitabine hydrochloride|Given IV
78437|NCT01234935|Other|laboratory biomarker analysis|Correlative studies
78438|NCT01234935|Genetic|mutation analysis|Correlative studies
78439|NCT00048165|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
78440|NCT01234935|Genetic|nucleic acid sequencing|Correlative studies
78441|NCT01234935|Other|immunohistochemistry staining method|Correlative studies
78442|NCT01234961|Behavioral|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
83170|NCT01245816|Drug|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
83171|NCT01245816|Drug|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
83172|NCT01245816|Drug|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
83173|NCT01248299|Drug|TPF|every 21 days:
Docetaxel [30 mg/m2, day 1 and day 8]
CisPlatin [60 mg/m2, day 1]
Fluoro-uracil [200 mg/m2/day by continous infusion]
Or every 21 days:
Docetaxel [50 mg/m2, day 1]
CisPlatine [70 mg/m2, day 1]
Fluoro-uracile [700 mg/m2 /day, day 1 to day 5]
83174|NCT00049309|Dietary Supplement|flaxseed|
83175|NCT01248299|Other|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
82226|NCT01259076|Procedure|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
82227|NCT00000251|Drug|0.4% isoflurane|
82228|NCT00001023|Drug|Rifabutin|
82229|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
82230|NCT01259076|Procedure|digital mammography|Undergo digital mammography at baseline and 1 year later.
82231|NCT01259076|Procedure|conventional surgery|Undergo gastric bypass surgery
82232|NCT01259089|Drug|erlotinib hydrochloride|Given orally
82233|NCT01259089|Drug|Hsp90 inhibitor AUY922|Given IV
82234|NCT01259089|Other|laboratory biomarker analysis|Correlative studies
82235|NCT01259089|Procedure|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
82236|NCT01259089|Genetic|mutation analysis|Correlative studies
82237|NCT01259089|Other|pharmacological study|Correlative studies
82238|NCT01259102|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
82239|NCT01259115|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
82240|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
78369|NCT01237249|Drug|Prednisone|
78370|NCT01237249|Drug|Velcade|
78371|NCT01237249|Drug|Revlimid|
78372|NCT01237249|Drug|Dexamethasone|
78373|NCT00048490|Device|transcranial magnetic stimulation (TMS)|
78374|NCT01237262|Drug|Adalimumab, etanercept, infliximab|Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.
Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks.
78375|NCT01237275|Drug|SSRI treated group|characterize in arm of a study (SSRI treated group)
78376|NCT01237288|Drug|Z-521|
78377|NCT01237301|Device|Continuous Glucose Monitoring (CGM)|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
78378|NCT01237327|Drug|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
78379|NCT01237327|Drug|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
78380|NCT01237340|Drug|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
78381|NCT01237353|Dietary Supplement|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
78382|NCT01237353|Drug|Rabeprazole|rabeprazole po daily x 5 days
78383|NCT01237366|Behavioral|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
78384|NCT00048503|Drug|ZARNESTRA, tipifarnib, R115777|
78385|NCT01237392|Device|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
78386|NCT01237405|Drug|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at ~1 minute) SPECT/CT of both knees; a late phase (at ~60 minutes) SPECT/CT image of both knees; and a late phase (at ~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
78387|NCT01239875|Procedure|cryotherapy|Undergo cryoablation
82025|NCT01263691|Biological|AV7909 Formulation 3|AV7909 Formulation 3
82026|NCT01263691|Biological|AV7909 Formulation 4|AV7909 Formulation 4
82027|NCT01263691|Drug|Control|Saline control
82028|NCT01263704|Drug|cyclophosphamide|150 mg/m2 on Days 1-3 of each 28-day cycle, 6 cycles
82029|NCT01263704|Drug|fludarabine|12.5 mg/m2 on Days 1-3 of every 28-day cycle, 6 cycles
82030|NCT01256359|Drug|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
82031|NCT01256359|Drug|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
82032|NCT01256372|Drug|AP214|AP214
82033|NCT00049699|Drug|laromustine|
82034|NCT01256372|Drug|Placebo|Placebo; intravenous infusion
82035|NCT01256385|Biological|Cetuximab|Given IV
82036|NCT01256385|Other|Laboratory Biomarker Analysis|Correlative studies
82037|NCT01256385|Drug|Temsirolimus|Given IV
82038|NCT01256398|Biological|Alemtuzumab|Given IV
82039|NCT01256398|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
82040|NCT01256398|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
82310|NCT01256892|Procedure|induction of labour|
82311|NCT01256905|Drug|Armodafinil|Armodafinil 150 mg
82312|NCT01256957|Device|HEPA filter|
82313|NCT01256983|Behavioral|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
82314|NCT01256983|Behavioral|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
78443|NCT01234961|Other|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
78444|NCT01234974|Drug|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
78445|NCT01234974|Drug|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
78446|NCT01235000|Biological|2010-11 trivalent inactivated influenza vaccine|A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
78736|NCT01238133|Procedure|Therapeutic Conventional Surgery|Undergo surgery
78737|NCT01238146|Drug|bendamustine hydrochloride|Given IV
78738|NCT01238146|Drug|obatoclax mesylate|Given IV
78739|NCT01238146|Biological|rituximab|Given IV
78740|NCT01238159|Radiation|CCRT+MIDLE chemotherapy|Patients are planned to be treated with CCRT plus MIDLE chemotherapy
78741|NCT01238172|Other|dietary education and counseling|
78742|NCT01238172|Other|prostate cancer foundation booklet|
78743|NCT01238185|Drug|acetylsalicylic acid|
78744|NCT00048568|Drug|Methotrexate|Tablets, Oral, >= 15 mg, weekly, 1 year
78745|NCT01238185|Genetic|gene expression analysis|
78746|NCT01240512|Drug|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
78747|NCT01240525|Other|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
78748|NCT01240525|Other|No DLI|Patients will not receive DLI as trial treatment
78749|NCT01240538|Biological|wild-type reovirus|Given IV
78750|NCT01240538|Drug|cyclophosphamide|Given PO
78751|NCT00048802|Drug|Olanzapine|
78752|NCT01240538|Other|laboratory biomarker analysis|Correlative studies
82241|NCT01259115|Drug|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
82242|NCT01259115|Drug|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
82243|NCT01259128|Drug|SER120 Nasal Spray 500 ng/day|SER120 Level 1
82244|NCT01259128|Drug|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
82245|NCT01259141|Drug|Moxifloxacin|0.4 Qd for 7days
82246|NCT01259141|Drug|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
82247|NCT01259180|Procedure|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
82248|NCT01259180|Procedure|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1~2inches away from real acupuncture point
82249|NCT01259193|Drug|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
82822|NCT01247818|Drug|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
82823|NCT01247831|Procedure|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
82824|NCT01247844|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
82825|NCT01247857|Drug|Ropivacaine 30 mg|Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.
Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
82826|NCT00049283|Radiation|radiation therapy|Undergo radiotherapy
82827|NCT01247857|Drug|Ropivacaine 30 mg|intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.
Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
82828|NCT01247857|Drug|Saline|Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
78388|NCT01239875|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
78389|NCT01239875|Other|laboratory biomarker analysis|Correlative studies
78671|NCT01242683|Behavioral|Vivamos Activos Fair Oaks Program|Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.
Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.
Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.
Usual primary care: Usual care provided at health center that is available to participants in all three study arms.
78672|NCT01242696|Procedure|Coronary artery stenting|Coronary artery stenting with drug eluting stents
78673|NCT01242722|Device|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
78674|NCT01242735|Behavioral|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
78675|NCT01242735|Behavioral|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
78676|NCT01242748|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
78677|NCT01242748|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
78678|NCT01242774|Drug|Panobinostat|Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
78679|NCT00048984|Other|laboratory biomarker analysis|Correlative studies
78680|NCT01242787|Drug|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
78681|NCT01242787|Drug|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
78682|NCT01242800|Procedure|palliative surgery|Undergo standard palliative surgery
78683|NCT01242800|Procedure|therapeutic conventional surgery|Undergo early surgery
78684|NCT01242800|Radiation|palliative radiation therapy|Undergo standard palliative radiotherapy
82315|NCT01256996|Procedure|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
82316|NCT01257009|Drug|Atorvastatin|6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
82317|NCT01259219|Drug|Mycobutin|Indication and Usage:
Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.
Dosage and Directions for use:
Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.
Identification:
Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder.
82318|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
82319|NCT01259245|Other|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
82320|NCT01259245|Other|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
82321|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
82322|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
82323|NCT01259284|Drug|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
82324|NCT01259284|Dietary Supplement|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
82325|NCT01259284|Other|Placebo|Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.
Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.
Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge.
82326|NCT01259297|Drug|Aliskiren|Aliskiren 150/300 mg once daily
82327|NCT01259297|Drug|Amlodipine|Amlodipine 5 mg
82328|NCT01259297|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
82587|NCT01252147|Other|No treatment|No treatment (intervention) will be provided in this study
82588|NCT01252160|Drug|QUTENZA|Cutaneous patch
82589|NCT01252186|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
78753|NCT01240538|Other|pharmacological study|Correlative studies
78754|NCT01240551|Drug|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
78755|NCT01240577|Drug|IPdR|
78756|NCT01240590|Drug|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
78757|NCT01240590|Drug|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
78758|NCT01240629|Other|laboratory biomarker analysis|Correlative study
79062|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79063|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79064|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79065|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
79066|NCT01243164|Other|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
79067|NCT01243177|Drug|Lacosamide|Lacosamide:
Strengths: 50 mg / 100 mg
Form: tablets
Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose
Duration: up to 118 weeks
79068|NCT01243177|Drug|Carbamazepine-Controlled Release|Carbamazepine-CR:
Strengths: 200 mg
Form: tablets
Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose
Duration: up to 118 weeks
79069|NCT01243190|Drug|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
79070|NCT01243203|Drug|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
79071|NCT00049010|Genetic|fluorescence in situ hybridization|
79072|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
79073|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
79074|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
82829|NCT01247870|Drug|Metformin|Metformin 1 g twice daily for 28-35 days
82830|NCT01247870|Drug|Placebo|Placebo
82831|NCT01247883|Drug|PF-04634817|single dose, 20mg, tablet
82832|NCT01247883|Drug|PF-04634817|single dose, 20mg, solution
82833|NCT01247896|Drug|PF-05190457|Single Dose 2 mg
82834|NCT01247896|Drug|PF-05190457|Single Dose 10 mg
82835|NCT01247896|Drug|PF-05190457|Single Dose 30 mg
82836|NCT01250314|Other|Biological, biochemical and genetic samples|*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone
Urinary samples :
Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample
*Assessment of possible determinants of fractures in man
Blood samples plasma (5 ml):
Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH
Homocysteine
IGF1
Extraction of DNA for a genetic polymorphism study:
Sample of 10 ml of blood on EDTA for DNA extraction.
Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor
Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way.
82837|NCT01250327|Device|Melody|insertion of a pulmonic valved stent
82838|NCT01250327|Device|bare stent|insertion of a bare metal stent
82860|NCT01252732|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
82861|NCT00049556|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
82862|NCT01252745|Drug|Testosterone|
82863|NCT01252745|Drug|Testosterone|
82864|NCT01252745|Drug|Testosterone|
82865|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 1|
82866|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 2|
82867|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 3|
82868|NCT01252758|Other|Placebo|
82869|NCT01252758|Drug|Albuterol|
82870|NCT01252758|Drug|Albuterol|
78685|NCT01242800|Radiation|radiation therapy|Undergo radiotherapy
78686|NCT01242813|Drug|ACZ885|
78687|NCT01242826|Drug|biphasic insulin aspart 50|A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
78688|NCT01242839|Device|CACICOL20|CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
79002|NCT01236014|Drug|Placebo|Placebo & standard of care
79003|NCT01236027|Other|no intervention|not applicable-no intervention
79004|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
79005|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
79006|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
79007|NCT01238510|Procedure|stent technique: Provisional fKBT|Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.
Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.
Stent type: Everolimus-eluting stent only
79008|NCT00048581|Drug|Abatacept|Vials, IV, ~10mg/kg abatacept, every 4 weeks, 5.5 years
79009|NCT01238510|Procedure|stent technique: Routine fKBT|Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.
Stent type: Everolimus-eluting stent only
79010|NCT01238523|Procedure|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
79011|NCT01238523|Procedure|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
79012|NCT01238536|Procedure|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
79013|NCT01238536|Procedure|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
79014|NCT01238536|Drug|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
82590|NCT01252186|Drug|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
82591|NCT01252186|Drug|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
82592|NCT01252199|Drug|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
82593|NCT01252199|Drug|Placebo|Placebo administered over 1 hour + standard of care
82594|NCT00049530|Biological|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
82595|NCT01252212|Behavioral|SMS medication adherence|SMS messages to cell phones.
82596|NCT01252212|Behavioral|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
82597|NCT01252225|Drug|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
82598|NCT01252225|Drug|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
82599|NCT01252225|Drug|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
82600|NCT01252238|Drug|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
82601|NCT01252238|Drug|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
82602|NCT01252238|Drug|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
82603|NCT01252251|Drug|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
82604|NCT01252277|Drug|Lovaza™|4 capsules daily for 6 months
82605|NCT00049543|Drug|gefitinib|Given PO
82606|NCT01252290|Drug|Lovaza™|4 capsules daily for 6 months
82607|NCT01252303|Behavioral|Nutrisystem|Nutrisystem meal replacements for 12 weeks
82947|NCT00049439|Drug|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
79075|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
79076|NCT01236040|Other|Placebo|Intramuscular injection, two doses
79077|NCT00048386|Biological|autologous neuroblastoma vaccine|A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.
79078|NCT01236053|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
79079|NCT01236066|Other|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children <5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
79381|NCT01239108|Drug|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
79382|NCT01239121|Other|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
79383|NCT01239121|Other|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
79384|NCT01239134|Biological|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
79385|NCT01239147|Other|Diet rich in whole grain|Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
79386|NCT00048672|Drug|Gleevec|Starting dose of 400 mg orally daily.
79387|NCT01239147|Other|Refined grain|Ready-to-eat breakfast cereals and other cereal products, low in whole grain
79388|NCT01239160|Device|Flexitouch System|A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between "normal" and "increased." The device is intended to be used for 60 minutes per day
79389|NCT00048893|Biological|recombinant vaccinia-CEA(6D)/TRICOM vaccine|rV-CEA (6D)/Tricom concomitantly with sargramostim (rGM-CSF). 1.2 x 10^8 pfu x 1 dose subcutaneously.
79390|NCT01241552|Drug|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
82871|NCT01252771|Other|PKM Algorithm|The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.
If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.
The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet.
82872|NCT00049556|Procedure|biopsy|
82873|NCT01252797|Radiation|Stereotactic Radiosurgery|Group A will start at dose level II: 15 Gy
Group B will start at dose level I: 12 Gy
82874|NCT01252810|Drug|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
82875|NCT01252823|Device|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
82876|NCT01252836|Device|AWBAT-D|Application of AWBAT-D bioengineered device
82877|NCT01252849|Device|iStent|Implantation of One iStent through a small temporal clear corneal incision.
82878|NCT01252849|Device|iStent|Implantation of Two iStents through a small temporal clear corneal incision
82879|NCT01252849|Device|iStent|Implantation of Three iStents through a small temperal clear corneal incision
82880|NCT01252862|Device|iStent|Implantation of two iStents through a small temporal clear corneal incision
82881|NCT01252875|Procedure|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
83176|NCT01248312|Device|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
83177|NCT01248312|Device|sentec monitor|transcutaneous monitoring
83178|NCT01248325|Drug|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
83179|NCT01248325|Drug|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
83180|NCT01248338|Drug|metoprolol succinate|once daily 50 or 100 mg for one year
83181|NCT01248338|Drug|Nebivolol|once daily 5 mg capsule for one year
83182|NCT01248351|Other|autologous stored platelets|Administration of autologous stored platelets
79015|NCT01238536|Drug|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
79016|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
79017|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
79018|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
79320|NCT01241552|Biological|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
79321|NCT01234103|Behavioral|Staying Safe & In Control: Increasing Knowledge and Building Skills to Prevent STIs and Unintended Pregnancy|Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors
79322|NCT01234116|Drug|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
79323|NCT01234129|Drug|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
79324|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
79325|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
79326|NCT00048100|Biological|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
79327|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
79328|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
79329|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
79330|NCT01234142|Drug|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
79331|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
82948|NCT01250535|Drug|Placebo|po, once a day, days 1 through 14
82949|NCT01250535|Drug|Lovastatin|40 mg, po, once a day, days 1 through 14
82950|NCT01250548|Biological|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
82951|NCT01250548|Other|Placebo|
82952|NCT01250561|Drug|Gabapentin|gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
82953|NCT01250561|Drug|Valacyclovir|valacyclovir 1000mg three-times daily x 7 days
82954|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
82955|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
82956|NCT01250587|Drug|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
82957|NCT01250600|Behavioral|Home exercise|Daily home exercise for 3 months
82958|NCT01252875|Procedure|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
82959|NCT00049556|Procedure|sentinel lymph node biopsy|
82960|NCT01252888|Device|iStents|Implantation of two iStents through a small temporal clear corneal incision
82961|NCT01252914|Device|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
82962|NCT01252927|Other|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
82963|NCT01252940|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
82964|NCT01252940|Drug|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
82965|NCT01252940|Drug|RTV|Ritonavir (RTV) was administered according to prescribing information.
79391|NCT01241565|Device|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
79392|NCT01241578|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
79393|NCT01241591|Drug|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
79394|NCT01241591|Drug|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
79395|NCT01241591|Biological|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
79396|NCT01241591|Other|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
79397|NCT01241617|Device|Duet TRS|Endo GIA stapler with integrated Duet TRS
79398|NCT01241617|Device|Endo GIA|Endo GIA stapler with Single Use Loading Units
79399|NCT01241630|Procedure|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
78447|NCT01235013|Drug|Maraviroc|150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
78448|NCT01235026|Dietary Supplement|Synbiotic|5g of the prebiotic "Oligofructose" + 1 g of the probiotic "Bifidobacterium animalis subsp. lactis Bb12" (4x10^10 CFU/g), twice a day, for 6 weeks.
78449|NCT01235026|Dietary Supplement|Placebo|6g of maltodextrin, twice a day for 6 weeks.
78450|NCT00048165|Drug|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
78451|NCT01235039|Drug|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
78452|NCT01235039|Drug|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
78453|NCT01235039|Drug|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
78454|NCT01237431|Dietary Supplement|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
78455|NCT01237444|Drug|lopinavir/ritonavir plus one nucleoside|ARM 1:
Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid
78456|NCT01237444|Drug|lopinavir /ritonavir plus two nucleosides|ARM 2:
3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype.
83183|NCT01248351|Other|administration of autologous stored platelets|administration of autologous stored platelets
83184|NCT01248351|Biological|autologous stored platelets|transfusion of autologous stored platelets
83185|NCT00049322|Biological|bevacizumab|Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.
Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose.
83186|NCT01248364|Drug|BI 10773|BI 10773 tablets once daily high dose
83187|NCT01248377|Procedure|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
83188|NCT01248390|Behavioral|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
83189|NCT01248403|Drug|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
83190|NCT01248403|Drug|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
83191|NCT01248416|Drug|Aromatase Inhibitor|
83192|NCT01248416|Drug|Growth Hormone|
83193|NCT01248416|Drug|Aromatase Inhibitor and Growth Hormone|
83194|NCT01248429|Biological|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
83195|NCT01248429|Other|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
83196|NCT00049335|Drug|capecitabine|1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, on Days 1-14 of 21 day cycle
82250|NCT01261468|Device|Active SCS|SCS IPG activated
82251|NCT00050401|Drug|MERREM I.V. 1g as a 30 minute infusion every 8 hours|
82252|NCT01261468|Device|Deactivated|SCS IPG deactivated
82253|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
82254|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
82255|NCT01261494|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
79332|NCT01234155|Behavioral|Exercise Training - Interval Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
79333|NCT01234155|Behavioral|Exercise - Continuous Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
79334|NCT01234181|Procedure|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10^7 BMSCs Sham Comparator: inject the same volume saline
79335|NCT01234194|Drug|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
79336|NCT01234194|Drug|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
79337|NCT00048113|Drug|Alicaforsen|
79338|NCT01234207|Device|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
78390|NCT01239875|Other|immunoenzyme technique|Correlative studies
78391|NCT01239875|Other|immunohistochemistry staining method|Correlative studies
78392|NCT01239875|Biological|autologous dendritic cell-tumor fusion vaccine|Given intradermally
78393|NCT01239888|Drug|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
78394|NCT01239888|Drug|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
78395|NCT01239888|Drug|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
78396|NCT01239927|Procedure|Primary sigmoid resection with end colostomy (Hartmann)|
78397|NCT00048737|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
78398|NCT01239927|Procedure|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
78399|NCT01239940|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
78400|NCT01239940|Device|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
78401|NCT01239953|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
78402|NCT01239953|Device|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
82966|NCT01252940|Drug|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
82041|NCT01256398|Drug|Cyclophosphamide|Given IV
82042|NCT01256398|Drug|Cytarabine|Given IV
82043|NCT01256398|Drug|Dasatinib|Given PO
82044|NCT00049712|Biological|etaracizumab|
82045|NCT01256398|Drug|Daunorubicin Hydrochloride|Given IV
82046|NCT01256398|Drug|Dexamethasone|Given PO or IV
82047|NCT01256398|Drug|Etoposide Phosphate|Given IV
82048|NCT01256398|Biological|Filgrastim|Given SC
82049|NCT01256398|Drug|Fludarabine Phosphate|Given IV
82050|NCT01256398|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
82051|NCT01256398|Other|Laboratory Biomarker Analysis|Correlative studies
82052|NCT01256398|Drug|Leucovorin Calcium|Given IV or PO
82053|NCT01256398|Drug|Melphalan|Given IV
82054|NCT01256398|Drug|Mercaptopurine|Given PO
82055|NCT00049725|Drug|Daclizumab|
82056|NCT01256398|Drug|Methotrexate|Given IT, IV, or PO
82057|NCT01256398|Biological|Pegfilgrastim|Given SC
82058|NCT01256398|Other|Pharmacological Study|Correlative studies
82059|NCT01256398|Drug|Tacrolimus|Given IV or PO
82060|NCT01256398|Drug|Vincristine Sulfate|Given IV
82061|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
82062|NCT01258751|Drug|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
78457|NCT01237457|Drug|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
78458|NCT01237470|Procedure|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
78459|NCT01237470|Procedure|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
78460|NCT01237483|Drug|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
78461|NCT01237496|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
78462|NCT00048516|Drug|paricalcitol capsule|
78463|NCT01237509|Device|Hypo device|
78464|NCT01237522|Drug|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
78465|NCT01237535|Drug|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
78466|NCT01237535|Drug|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
78759|NCT01240629|Other|questionnaire administration|Correlative study
78760|NCT01240629|Drug|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
78761|NCT01240642|Drug|ASA404|
78762|NCT00048802|Drug|Divalproex|
78763|NCT01240655|Drug|LCL161|
78764|NCT01240655|Drug|Paclitaxel|
78765|NCT01240681|Procedure|FLT PET and BOLD MRI scan|Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
78766|NCT01240694|Drug|CEP-33457|200 mcg of CEP-33457
78767|NCT01240707|Other|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
82256|NCT01261494|Drug|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
82257|NCT01261520|Behavioral|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
82258|NCT01261533|Device|foldable capsular vitreous body(FCVB)|FCVB with silicone oil inside is tamponaded into the vitreous cavity
82259|NCT01261546|Drug|Dexamethasone|Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present
Ranitidine 5 mg/kg IV, q.d. for 2 days
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.
82260|NCT01261546|Drug|Placebo|Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.
Ranitidine 5 mg/kg IV, q.d. for 2 days.
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
82261|NCT01261559|Device|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
82262|NCT00050401|Drug|MERREM I.V. 500 mg as a 3 hour infusion every 8 hours|
82263|NCT01261572|Drug|ASP3350|periodic injection
82264|NCT01261598|Procedure|Positron Emission Tomography|Positron Emission Tomography
82265|NCT01261611|Drug|Botulinum type A toxin (Dysport RU®)|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
82266|NCT01261611|Drug|Botulinum type A toxin (Dysport®)|I.M. injection on day 1 of treatment cycle 1.
82267|NCT01261611|Drug|Placebo|I.M. injection on day 1 of treatment cycle 1.
82268|NCT01261624|Drug|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
82269|NCT01261637|Drug|Saline placebo|20ml saline
82270|NCT01261637|Drug|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
82271|NCT01261650|Device|transcranial direct current stimulation|
82272|NCT01261650|Device|sham treatment|
82839|NCT00049439|Biological|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
82840|NCT01250327|Procedure|Surgery|conventional surgery methode
82841|NCT01250340|Drug|Aspirin|100 mg/day for 30 days
82842|NCT01250340|Drug|Placebo|1 cp day for 30 days
78403|NCT01239966|Device|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
78404|NCT01239992|Drug|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
78405|NCT01240005|Biological|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
78406|NCT01240018|Dietary Supplement|Probiotic|Parallel, randomized, controlled 2 arms study.
78407|NCT01240031|Other|Individualised nutritional therapy|Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:
Thorough sensory and nutrition assessment (questionnaire).
Nutrition plan adjusted daily according to the assessment.
Serving appetising, energy- and protein-dense meals, snacks and drinks.
78408|NCT00048750|Drug|Micafungin|IV
78409|NCT01240031|Other|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
78689|NCT01235416|Drug|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
78690|NCT01235429|Behavioral|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
78691|NCT00000250|Drug|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
78692|NCT00001008|Drug|Zidovudine|
78693|NCT00048217|Drug|T-1249|
78694|NCT01235429|Behavioral|Partners in Care|Diabetes self-management education
78695|NCT01235442|Drug|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
78696|NCT01235442|Drug|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
78697|NCT01235455|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
78698|NCT01235468|Biological|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
78699|NCT01235481|Device|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
78700|NCT01235481|Behavioral|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
82063|NCT00050076|Drug|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
82064|NCT01258764|Drug|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
82065|NCT01258764|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
82066|NCT01258777|Drug|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
82329|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
82330|NCT01259297|Drug|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
82331|NCT01259297|Drug|Placebo for Amlodipine|Placebo for Amlodipine
82332|NCT01259297|Drug|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
82333|NCT01259323|Biological|REGN668|Dose 1: REGN668 or placebo
82334|NCT01259323|Biological|REGN668|Dose 2: REGN668 or placebo
82335|NCT01259323|Biological|REGN668|Dose 3: REGN668 or placebo
82336|NCT01259336|Drug|Itraconazole|Tablet 200 mg twice daily for 6 months
82337|NCT01259336|Drug|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
82338|NCT01259349|Procedure|one percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
82339|NCT01259349|Procedure|40 percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
82340|NCT01261689|Drug|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
82341|NCT01261689|Other|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
82342|NCT01261702|Drug|Placebo|Normal saline IV
82343|NCT01261702|Drug|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
82344|NCT01261715|Procedure|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
78768|NCT01240720|Drug|131I-F16SIP Radioimmunotherapy (RIT)|Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.
Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V).
78769|NCT01240746|Biological|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
78770|NCT01242839|Device|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
78771|NCT00048997|Radiation|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
78772|NCT01242852|Procedure|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS & hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions & endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
78773|NCT01242865|Behavioral|Attention and Interpretation Therapy|Participants will receive a copy of the book, "Train Your Brain Engage Your Heart Transform Your Life" along with three handouts summarizing the contents of the book.
78774|NCT01242891|Device|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
78775|NCT01242904|Drug|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
79080|NCT01236079|Behavioral|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
79081|NCT01236092|Other|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
79082|NCT01236105|Drug|LY2624803|Administered orally (po), once.
79083|NCT01236105|Other|Activated Charcoal|Administered po
79084|NCT01236118|Drug|LY2439821|Administered subcutaneously
79085|NCT01236131|Other|no intervention|Not Applicable- no intervention
79086|NCT01236144|Drug|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
78270|NCT01208025|Other|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
78271|NCT01208038|Drug|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
78272|NCT01208051|Drug|Cediranib Maleate|Given PO
78556|NCT01237808|Drug|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
78557|NCT01237821|Drug|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
78558|NCT01240148|Drug|AZD3161 Placebo|
78559|NCT01240161|Drug|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
78560|NCT00048763|Drug|Pletal|
78561|NCT01240174|Behavioral|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
78562|NCT01240187|Drug|perampanel|Single dose of 6 tablets 2 mg orally
78563|NCT01240187|Drug|perampanel|Single dose of 1 tablet 12 mg orally
78564|NCT01240200|Drug|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
78565|NCT01240200|Device|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
78566|NCT01240213|Dietary Supplement|Vitamin D|2000 IU per day of Vitamin D
78567|NCT01240213|Dietary Supplement|Placebo|1 Placebo per day
78568|NCT01240226|Drug|GDC-0941|Oral repeating dose
78569|NCT01240226|Drug|GDC-0941|Oral repeating dose
78570|NCT01240226|Drug|ketoconazole|Oral repeating dose
78571|NCT00001013|Drug|Trimetrexate glucuronate|
78572|NCT00048776|Drug|Pletal|
78573|NCT01240252|Drug|Human insulin|U100 Humulin at a rate of 80 mU/m^2 surface area per minute one time over 4 hours
79273|NCT01236560|Biological|Bevacizumab|Given IV
79274|NCT01238887|Dietary Supplement|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
79275|NCT01238887|Dietary Supplement|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
79276|NCT01238900|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
79277|NCT00048620|Drug|N-acetylgalactosamine 4-sulfatase|
78327|NCT00048906|Drug|DRX005B|
78328|NCT01242176|Drug|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
78329|NCT01242202|Drug|ASP1941|oral
78330|NCT01242202|Drug|alpha glucosidase inhibitor|oral
78331|NCT01242215|Device|ASP1941|oral
78332|NCT01242215|Drug|Placebo|oral
78333|NCT01242215|Drug|Sulfonylurea|oral
78334|NCT01242228|Drug|ASP1941|oral
78335|NCT01242228|Drug|DPP-4 inhibitor|oral
78336|NCT01242241|Drug|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
78337|NCT01242241|Drug|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
78338|NCT00048932|Drug|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Day 1, 15, and 29.
78339|NCT01242254|Biological|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
80590|NCT01228890|Behavioral|AMPE|The AMPE components are similar to those employed in previous primary care based quality improvement/Chronic Care Model Interventions (patient education [psycho-education described below], provider training [described in Case Finding and Recruitment], active monitoring and referral [case management, discussed under assessments], physician and nurse education and routine contact with PCP [study design rationale]). This Internet site will focus on assisting parents and adolescents in early identification of need for treatment and will also target stigma and negative attitudes toward treatment of mental disorders we have previously identified as barriers to seeking and adhering to treatment.
80591|NCT01228903|Drug|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
80592|NCT00001003|Drug|Pentamidine isethionate|
80593|NCT00047346|Other|pharmacological study|Correlative studies
80594|NCT01228903|Other|Placebo|Placebo tablets with no active ingredient
80595|NCT01228916|Behavioral|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
80596|NCT01228929|Other|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
80597|NCT01228942|Device|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
80598|NCT01228994|Drug|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
80599|NCT01228994|Drug|placebo pill|placebo pill
80600|NCT01228994|Drug|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
79662|NCT01242059|Dietary Supplement|Control|Served in a tomato soup
79663|NCT01242072|Drug|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
79664|NCT00048893|Drug|Mesna|Percent equals fraction of total daily cyclophosphamide dose. Initial: 20% of cyclophosphamide dose given intravenously (IV) mixed with cyclophosphamide.
3 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 6 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 9 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO)
79665|NCT01242085|Procedure|trumatch group|these patient will have CT based customized knee instruments used for surgery
79666|NCT01242085|Procedure|control group|these patients will have standard instrumentation used for for knee replacement
78797|NCT01235624|Genetic|genetic analysis|
78798|NCT01235637|Drug|Alfentanil|dosage form: injectable drug, opioid analgesic morphine, intravenous drug.
Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.
Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.
78799|NCT00048308|Drug|pexelizumab|
78800|NCT01235637|Drug|Sufentanil|dosage form: injectable drug, opioid analgesic morphine, intravenous drug.
Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK
Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.
78801|NCT01235663|Behavioral|advisory support|regular advisory support to the prolong breast-feeding period
78802|NCT01235676|Behavioral|diet|calorie restriction to reduce weight gain
78803|NCT01235676|Behavioral|Exercise|Exercise to reduce weight gain
78804|NCT01235689|Biological|adalimumab|Subject will be assigned to this intervention during the study upon Success Criteria evaluations.
78805|NCT01235689|Drug|prednisone|All subjects will start this intervention upon enrollment into the study except those that Early Randomize and meet protocol specific criteria. Depending on the evaluation criteria subjects may continue this therapy or stop it during the study.
78806|NCT01235689|Drug|azathioprine|Subjects will start this therapy after moving through all other therapeutic options. This will be used in conjunction with adalimumab and once assigned to this intervention, the subject will continue taking it until they complete the study or discontinue.
78807|NCT01235702|Behavioral|12-week lifestyle modification|
78808|NCT01235715|Drug|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
78809|NCT01235728|Drug|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
78810|NCT00048321|Drug|ISIS 104838|
78811|NCT01235728|Drug|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
78812|NCT01238185|Genetic|protein expression analysis|
78813|NCT01238185|Other|laboratory biomarker analysis|
78814|NCT01238185|Other|questionnaire administration|
78815|NCT01238185|Procedure|biopsy|
78574|NCT01240265|Dietary Supplement|Vitamin D3|150,000 IU orally given once
78575|NCT01240265|Dietary Supplement|Vitamin D3|5000 IU given orally daily for 28 days
78576|NCT01240291|Dietary Supplement|Dipeptiven|Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
78577|NCT01240291|Dietary Supplement|normal saline|0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
78874|NCT01243515|Procedure|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
78875|NCT01243528|Other|Laboratory values|Laboratory values which represent nutritional status
78876|NCT01243541|Procedure|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
78877|NCT00049036|Drug|etoposide|Given IV
78878|NCT01243541|Other|questionnaire administration|Ancillary studies
78879|NCT01243541|Procedure|quality-of-life assessment|Ancillary studies
78880|NCT01235728|Drug|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
78881|NCT01235741|Drug|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
78882|NCT01235741|Drug|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
78883|NCT01235754|Drug|transdermal testosterone gel 1%|300 mcg once daily transdermal testosterone gel 1%
78884|NCT01235754|Drug|placebo gel|once daily transdermal placebo gel
78885|NCT01235767|Other|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
78886|NCT01235793|Drug|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
78887|NCT01235806|Radiation|MRI|MRI of the scaphoid bone fracture suspicion
78340|NCT01234792|Drug|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
78341|NCT01234805|Procedure|yoga therapy|Participates in yoga classes and yoga at home
78342|NCT01234805|Other|questionnaire administration|Ancillary studies
78343|NCT01234805|Procedure|quality-of-life assessment|Ancillary studies
78344|NCT01234818|Device|Mirena (LNG-IUS)|General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
78345|NCT01234831|Device|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
78346|NCT01234831|Other|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
78347|NCT01234844|Behavioral|care of guinea pigs|twice weekly sessions of care with guinea pigs
78634|NCT01237899|Drug|Eplerenone|Administered orally
78635|NCT01237925|Drug|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
78636|NCT01237925|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
78637|NCT01237938|Behavioral|Low Glycemic Diet|Changing to low glycemic diet
78638|NCT01237951|Drug|Palifermin|60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.
60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.
78639|NCT01237951|Drug|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
78640|NCT01237951|Drug|Gemcitabine|1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
78641|NCT01237951|Drug|Busulfan|32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.
Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.
78642|NCT01237951|Drug|Melphalan|60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
78643|NCT00001010|Drug|Acyclovir|
78644|NCT00048542|Drug|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
79667|NCT01234701|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
79668|NCT01234701|Procedure|Liver resection|Hepatectomy with an intention to cure
79669|NCT01234701|Other|Histopathology diagnosis of resected liver specimen|Histopathology diagnosis by expert pathologist.
79670|NCT01234714|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
79671|NCT01234714|Procedure|Major liver resection|Hepatectomy of >= 3 liver segments
79672|NCT00001008|Drug|Methadone hydrochloride|
79673|NCT00048152|Drug|Neoral|Standard dose (target trough level 150-300ng/mL)
79674|NCT01234740|Drug|bafetinib|Given orally
79675|NCT01234740|Procedure|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
79676|NCT01234740|Other|pharmacological study|Correlative studies
79677|NCT01234740|Other|liquid chromatography|Correlative studies
79678|NCT01234740|Other|mass spectrometry|Correlative studies
79679|NCT01234740|Other|laboratory biomarker analysis|Correlative studies
79680|NCT01234740|Genetic|protein expression analysis|Correlative studies
79681|NCT01234740|Genetic|western blotting|Correlative studies
79682|NCT01234740|Other|immunohistochemistry staining method|Correlative studies
79683|NCT01234740|Procedure|therapeutic conventional surgery|debulking craniotomy
79684|NCT00048152|Drug|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
79981|NCT01227863|Drug|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
79982|NCT01227863|Drug|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
79983|NCT01227876|Drug|Ster|prednisolone 1% ophthalmic suspension
79984|NCT01227876|Drug|Pred Fort|prednisolone 1% ophthalmic suspension
78816|NCT01238211|Drug|Cytarabine|Given IV
79122|NCT01241123|Drug|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
79123|NCT01241123|Radiation|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
79124|NCT01241123|Device|pedometers|to record the amount of ambulation
79125|NCT01241136|Procedure|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
79126|NCT00048841|Drug|alendronate|
79127|NCT01241136|Procedure|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
79128|NCT01241149|Procedure|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
79129|NCT01241162|Biological|Autologous dendritic cell vaccine with adjuvant|Week 1:
Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)
Weeks 2 and 3:
Vaccine: 3-5 E6 peptide pulsed DC (Mon)
Hiltonol applied topically to vaccine site before and after vaccination
79130|NCT01241175|Drug|Magnesium Sulfate|
79131|NCT01241175|Drug|normal saline|
79132|NCT01241188|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
79133|NCT01241188|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
79134|NCT01241201|Dietary Supplement|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
79135|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
79136|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 4) & matching placebo administered orally once daily
79137|NCT00048854|Drug|Sertraline|Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
79138|NCT01241214|Drug|Reference|Active matching reference administered once daily & matching placebo administered twice daily.
79139|NCT01241240|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
78888|NCT01235819|Drug|Insulin|Exenatide Sitagliptin
78889|NCT00048334|Drug|Depsipeptide, FR901228, FK228|
78890|NCT01235819|Drug|Sitagliptin|Sitagliptin 100 mg per day oral
78891|NCT01235819|Drug|Exenatide|Exenatide 10 micrograms daily twice
78892|NCT01235832|Other|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
79205|NCT01238861|Drug|MEDI-563|Subcutaneous repeating dose
79206|NCT01238861|Drug|MEDI-563|Subcutaneous repeating dose
79207|NCT01238861|Drug|MEDI-563|Subcutaneous repeating dose
79208|NCT01238861|Drug|Placebo|Subcutaneous repeating dose
79209|NCT01238874|Device|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
79210|NCT01238887|Dietary Supplement|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
79211|NCT01241240|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
79212|NCT01241253|Other|Whole cooked beans with rice meals|Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
79213|NCT01241279|Device|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
79214|NCT01241279|Device|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
79215|NCT01241292|Biological|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
79216|NCT01241292|Biological|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
80182|NCT00047619|Other|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
80183|NCT01233284|Drug|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
80184|NCT01233284|Drug|tiotropium bromide 1.25µg once daily|IMP
80185|NCT01233297|Drug|Azithromycin|10 mg/kg peroral for 3 consecutive days
80186|NCT01233297|Other|Placebo mixture|Placebo mixture containing no active substance.
80187|NCT00048048|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
80188|NCT01233349|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
80189|NCT01233349|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
80522|NCT01231360|Other|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
80523|NCT01231360|Other|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
80524|NCT01231373|Drug|polidocanol injectable foam, 0.125%|active placebo for blinding
80525|NCT00047710|Drug|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
80526|NCT01231373|Drug|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
80527|NCT01231373|Drug|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
80528|NCT01231373|Drug|Vehicle|injection of vehicle comparator
80529|NCT01231399|Drug|fluorouracil|Given IV
80530|NCT01231399|Drug|leucovorin calcium|Given IV
80531|NCT01231399|Drug|oxaliplatin|Given IV
80532|NCT01231399|Drug|everolimus|Given orally
79985|NCT01227889|Drug|GSK2118436|150 mg twice daily
79986|NCT00047320|Drug|carboplatin|Given IV
79987|NCT01227889|Drug|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
79988|NCT01227902|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
79989|NCT01227915|Drug|Tobracort|tobramycin 0.3% + dexamethasone 1%
79990|NCT01230450|Other|stand standard mid-urethral sling (TVT-O)|
79991|NCT01230463|Drug|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
79992|NCT01230463|Drug|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
79993|NCT01230476|Drug|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
79994|NCT00047567|Drug|zonisamide|
79995|NCT01230489|Biological|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
79996|NCT01230502|Drug|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy
Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.
Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.
Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples.
79997|NCT01230502|Other|data and sample collection|Group 2 : Donor specific regulation (DSR) + standard of care:
These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.
Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples
80246|NCT01228331|Drug|Doxorubicin hydrochloride|part of reinduction therapy
80247|NCT01228331|Drug|Etoposide phosphate|part of different chemotherapy blocks
80248|NCT01228331|Drug|Mercaptopurine|part of different chemotherapy blocks
80249|NCT01228331|Drug|Methotrexate|part of different chemotherapy blocks
80250|NCT01230879|Other|EFR and TDM|EFR : Pulmonary function test TDM : tomodensitometry
79140|NCT01243541|Procedure|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
79450|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
79451|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
79452|NCT01239186|Other|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
79453|NCT01239199|Other|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
79454|NCT01239212|Drug|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
79455|NCT00048698|Procedure|TMS|
79456|NCT01239225|Device|Abdominal ultra-sound|
79457|NCT01239225|Procedure|Abdominal ultrasound|
79458|NCT01239251|Other|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
79459|NCT01239277|Other|protein|20g protein
79460|NCT01239277|Other|protein and carbohydrate|20g protein and 20g carbohydrate
79461|NCT01239277|Other|protein and leucine|20g protein, 2.5g leucine
79462|NCT01239303|Dietary Supplement|Citrulline|single dose
79463|NCT01239303|Dietary Supplement|alanine|single dose
79464|NCT01239316|Other|Laboratory Biomarker Analysis|Correlative studies
79465|NCT01239316|Other|Pharmacological Study|Correlative studies
79466|NCT00048698|Procedure|EEG|
79467|NCT01239316|Drug|Vismodegib|Given PO
79217|NCT01241318|Drug|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
79218|NCT01241318|Procedure|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
79219|NCT00048854|Other|Treatment as usual (TAU)|At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
79220|NCT01241331|Drug|BLI1100|BLI110 topical cream
79221|NCT01241331|Drug|Vehicle cream|Vehicle topical cream
78273|NCT01208051|Other|Laboratory Biomarker Analysis|Correlative studies
78274|NCT01208051|Drug|Lenalidomide|Given PO
78275|NCT01208064|Drug|pazopanib hydrochloride|
78276|NCT01208064|Other|laboratory biomarker analysis|
78277|NCT00045422|Drug|imatinib mesylate|
78278|NCT01210196|Procedure|MRI|Cardiac MRI after 12 and 24 months.
78279|NCT01210209|Other|genome-wide association study|
78280|NCT00045617|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
78281|NCT01210222|Biological|Trebananib|Given IV
78282|NCT01210235|Behavioral|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
78283|NCT01210248|Other|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
78284|NCT01210261|Device|Compumedics Somnilink SPAP - Auto-titrating CPAP|Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.
Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.
All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment.
80533|NCT01231399|Other|laboratory biomarker analysis|Correlative studies
80534|NCT01231399|Other|immunohistochemistry staining method|Correlative studies
80535|NCT01231399|Genetic|microarray analysis|Correlative studies
80536|NCT00047710|Drug|Capecitabine|650mg/m^2 taken by mouth twice a day 15-52 during the radiotherapy.
80537|NCT01231412|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
80538|NCT01231412|Drug|Cyclosporine|Given PO or IV
80539|NCT01231412|Drug|Fludarabine Phosphate|Given IV
80540|NCT01231412|Drug|Mycophenolate Mofetil|Given PO
80541|NCT01231412|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
80542|NCT01231412|Drug|Sirolimus|Given PO
80543|NCT01231412|Radiation|Total-Body Irradiation|Undergo TBI
80544|NCT01231438|Drug|Renvela|800mg t.i.d. over 2 weeks
79603|NCT01237054|Other|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
79604|NCT01237054|Drug|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
79605|NCT01237067|Drug|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 & gt; carbo d8; B: carbo d1 & gt; olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
79606|NCT01237067|Drug|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 & gt; carbo d8; B: carbo d1 & gt; olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
79607|NCT01237080|Device|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
79608|NCT01237080|Device|Fastrach|The Fastrach is an intubation laryngeal mask.
79609|NCT00048464|Procedure|Infusion of Activated & Expanded Autologous T Cells|
80251|NCT01230892|Drug|Nebivolol|10 mg PO qday
80252|NCT01230892|Drug|Atenolol|100 mg PO qday
80253|NCT01230905|Radiation|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
80254|NCT01230918|Radiation|99mTc-NC100692|HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.
Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images.
80255|NCT01230931|Biological|Vitagel topical surgical hemostat|Vitagel is topical spray that results in coagulation. The components are as follows. Autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors. This is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
80256|NCT01230944|Procedure|Laparoscopic Nissen fundoplication|
80257|NCT01230944|Procedure|Open Nissen fundoplication|
80258|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
80259|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
80260|NCT00047632|Drug|Interferon gamma-1b|100 mcg, SQ, 3x per week
80261|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
80262|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
80263|NCT01230957|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
80264|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
80265|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
80266|NCT01230970|Drug|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
80267|NCT01230983|Drug|asparaginase|Given IV
80268|NCT01230983|Drug|cytarabine|Given IV
80601|NCT01229007|Biological|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
80602|NCT01229020|Other|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
79468|NCT01239342|Drug|Akt Inhibitor MK2206|Given PO
79469|NCT01239342|Drug|Everolimus|Given PO
79470|NCT01239342|Other|Laboratory Biomarker Analysis|Optional correlative studies
79471|NCT01239355|Drug|Akt Inhibitor MK2206|Given PO
79472|NCT01239355|Other|Laboratory Biomarker Analysis|Correlative studies
79473|NCT01241682|Biological|DC + CTX|3x 50x10e6 DC + cyclophosphamide
78500|NCT01242462|Other|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is >/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH >/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
78501|NCT01242475|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
78502|NCT01242475|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
78503|NCT01242488|Biological|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
78504|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
78505|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
78506|NCT01242488|Biological|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
78507|NCT00001013|Drug|Leucovorin calcium|
78508|NCT00048945|Drug|PEGASYS|
78509|NCT01242488|Biological|CDP6038|60 mg sc at Weeks 0, 4 and 8
78510|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 4 and 8
78511|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 4 and 8
78512|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
78513|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
78285|NCT01210261|Device|Resmed Autoset S8 - Auto-titrating CPAP|Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.
Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.
All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment.
78286|NCT01210287|Drug|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
78287|NCT01210326|Procedure|extaction|TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
78288|NCT01210326|Procedure|testicular sperm extraction|testicular sperm extraction
78289|NCT01210326|Procedure|testicular sperm aspiration|testicular sperm aspiration
78290|NCT01210339|Drug|Clopidogrel|Clopidogrel
78291|NCT00000987|Drug|Zidovudine|
78292|NCT00045617|Biological|monoclonal antibody GD2 anti-idiotype vaccine|
78578|NCT01240304|Drug|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
78579|NCT01240304|Radiation|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
78580|NCT01240304|Procedure|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
78581|NCT01242501|Behavioral|20-Min education session|Patients receive a single 20 min education session for STI/HIV information.
78582|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg twice daily
78583|NCT01242514|Drug|Fostamatinib|Fostamatinib 150mg once daily
78584|NCT00048958|Genetic|cytogenetic analysis|
78585|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg once daily
79610|NCT01237106|Other|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
79611|NCT01237119|Drug|Liraglutide|1.8 mg once daily, subcutaneous injection
79612|NCT01237119|Other|Liraglutide-placebo|1.8 mg once-daily, subcutaneous injection
79613|NCT01237171|Radiation|Cesium-131 Brachytherapy Seed|85 Gray Dose
79614|NCT01237197|Drug|Exenatide|Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
79615|NCT01237197|Drug|Placebo|Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
79616|NCT01237223|Drug|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
79617|NCT01237223|Drug|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
79618|NCT01237223|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
79619|NCT01237223|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
79620|NCT01239563|Drug|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
79916|NCT00047905|Behavioral|examine the process of prenatal genetic counseling|
79917|NCT01232686|Other|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
79918|NCT01232699|Behavioral|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
79919|NCT01232699|Behavioral|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
79920|NCT01232699|Behavioral|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
79921|NCT01232712|Biological|ImMucin, hGM-CSF|Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin
After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.
In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected.
79922|NCT01232725|Dietary Supplement|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
80603|NCT01229033|Procedure|Ablation|Ablation of atrial tachycardia
80604|NCT00047346|Other|laboratory biomarker analysis|Correlative studies
80605|NCT01229033|Procedure|Cardioversion|Cardioversion of atrial tachycardia
80606|NCT01229046|Drug|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
80607|NCT01229059|Dietary Supplement|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
80608|NCT00047710|Radiation|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
80609|NCT01231464|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
80610|NCT01231464|Drug|placebo|placebo
80611|NCT01231490|Drug|Placebo|Placebo
80612|NCT01231490|Drug|Naproxen|Capsule
80613|NCT01231503|Biological|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
80614|NCT01231503|Biological|Engerix™-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=< 7 days of age)
80615|NCT01231503|Biological|Tritanrix™ HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
80616|NCT01231503|Biological|BCG|1 dose, intradermal route, in shoulder at birth (=< 7 days of age)
80617|NCT01231503|Biological|OPV|4 doses, orally, at birth (=< 7 days of age) and at 6, 10 and 14 weeks of age
80618|NCT01231503|Biological|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
80619|NCT00047723|Drug|minocycline|
80620|NCT01231516|Drug|GSK1349572|50mg once daily
80621|NCT01231516|Drug|Raltegravir|400mg twice daily
80622|NCT01231516|Drug|GSK1349572 Placebo|Inactive placebo tablet once daily
78514|NCT01242488|Other|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
78515|NCT01242501|Behavioral|60 Minute HIV/STI risk reduction counseling|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
78516|NCT01235052|Radiation|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy [18F]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. [18F]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe [18F]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
78517|NCT01235065|Device|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
78518|NCT01235078|Device|EZ-IO|powered intraosseous vascular access system
78817|NCT01238211|Drug|Dasatinib|Given PO
78818|NCT01238211|Drug|Daunorubicin Hydrochloride|Given IV
78819|NCT01238211|Other|Laboratory Biomarker Analysis|Correlative studies
78820|NCT01238224|Drug|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
78821|NCT00048568|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
78822|NCT01238237|Drug|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
78823|NCT01238276|Drug|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
78824|NCT01238276|Device|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
78825|NCT01238289|Behavioral|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
78586|NCT01242527|Drug|placebo|4 capsules (1g) daily for 12 weeks
78587|NCT01242527|Drug|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
78588|NCT01242527|Drug|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
78589|NCT01242527|Drug|omefas|4 capsules (1g)daily for 12 weeks
78590|NCT01242566|Drug|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
78591|NCT01242579|Drug|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
78592|NCT01242579|Drug|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
78593|NCT01242579|Drug|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
78594|NCT01242579|Drug|Matching Placebo Gel|Matching placebo gel containing 2.5g
78595|NCT00048971|Genetic|mutation analysis|
78596|NCT01242592|Drug|Anti-Tuberculosis Treatment|
78597|NCT01242605|Drug|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
78893|NCT01235832|Other|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
78894|NCT01235832|Other|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
78895|NCT01235845|Biological|Biological: DC activated CIK combined with DC|Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.
DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations.
78896|NCT01235858|Procedure|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
78897|NCT01235858|Procedure|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
78898|NCT01235871|Drug|SB1578|JAK2 Inhibitor
78899|NCT01235871|Drug|Placebo|Control arm
79923|NCT01232738|Drug|rasagiline|rasagiline 2 mg daily for 12 months
79924|NCT01232751|Dietary Supplement|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
79925|NCT01232764|Other|Exposure to multi-disciplinary wound care team|Phase 1: In Person Support (3 mths)
Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.
Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.
All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting.
79926|NCT01232777|Drug|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
79927|NCT00047931|Drug|VRC-HIVDNA009-00-VP|
79928|NCT01232790|Dietary Supplement|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
79929|NCT01232790|Drug|Placebo|Placebo
79930|NCT01232803|Drug|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
79931|NCT01232803|Drug|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
79932|NCT01232803|Drug|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
79933|NCT01232829|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
80190|NCT01233362|Biological|Modified killed oral cholera vaccine at 14 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
80191|NCT01233362|Biological|Modified killed oral cholera vaccine at 28 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
80192|NCT01233375|Drug|CO-1.01|1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.
Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles.
80193|NCT01233388|Other|Text message surveillance|Text message surveillance for vaccine adverse events
80194|NCT01233401|Other|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
79685|NCT01234753|Other|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
79686|NCT01234766|Drug|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
79687|NCT01234766|Drug|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
79688|NCT01234766|Radiation|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
79689|NCT01234779|Drug|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
79690|NCT01234779|Drug|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
79691|NCT01234779|Drug|olanzapine|15 mg orally daily, 4 weeks
79692|NCT01234779|Drug|placebo|orally daily, 4 weeks
79693|NCT01234792|Drug|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
79694|NCT01234792|Drug|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
79695|NCT00048152|Drug|mycophenolate mofetil [CellCept]|1g po bid
79696|NCT01229930|Other|laboratory biomarker analysis|
79697|NCT00047489|Drug|ABT-751|
79698|NCT01229930|Other|pharmacological study|
79699|NCT01229930|Procedure|quality-of-life assessment|
79700|NCT01229943|Biological|Bevacizumab|Given IV
79701|NCT01229943|Drug|Everolimus|Given PO
79702|NCT01229943|Drug|Octreotide Acetate|Given IM
79703|NCT01229956|Genetic|DNA methylation analysis|
79704|NCT01229956|Genetic|gene expression analysis|
79705|NCT01229956|Genetic|microarray analysis|
79706|NCT01229956|Genetic|reverse transcriptase-polymerase chain reaction|
79707|NCT01229956|Other|laboratory biomarker analysis|
78826|NCT01238289|Behavioral|Control|This group continues with standard care at the community health center
78827|NCT01238302|Procedure|Conventional arthroscopic rotator cuff repair|Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
78828|NCT01238302|Procedure|Arthroscopic rotator cuff repair with PRP|Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
After tying sutures of the medial row, PRP gels were applied on the repair site.
The lateral row was secured using suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
78829|NCT01238315|Biological|HuCNS-SC|Surgery to implant human CNS stem cells
78830|NCT01240746|Biological|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
78831|NCT01240746|Biological|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to <9 years), Intramuscular
79141|NCT01243541|Procedure|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
79142|NCT01243554|Behavioral|Exercise|Exercise training at the hospital
79143|NCT01243567|Drug|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
79144|NCT01243567|Drug|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
79145|NCT01243580|Drug|Ortho-Cyclen (r)|an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
79146|NCT01243580|Drug|AG200-15 containing LNG and EE|transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
79147|NCT01243593|Procedure|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
79148|NCT00049036|Drug|doxorubicin hydrochloride|Given IV
79149|NCT01243593|Procedure|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
78900|NCT01238328|Drug|Conditioning regimen|For sibling full match:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg
For haploidentical:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
Fludarabine 160 mg/m^2
78901|NCT01238328|Drug|Graft-versus-host disease (GVHD) prophylaxis|Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po
10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)
78902|NCT00048581|Drug|Abatacept|Vials, intravenous (IV), ~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
78903|NCT01238328|Procedure|Stem Cell Transplantation|Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:
Sibling full match
Other related full match
Sibling or other related with 1 mismatch antigen
Cord Blood
Haploidentical
78904|NCT01238341|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
78905|NCT01238354|Behavioral|With friend|
78906|NCT01238354|Behavioral|Without friend|
78907|NCT01238367|Drug|turoctocog alfa|Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
78908|NCT01238380|Other|patient care pathway|Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.
Stage 2: Pancreatic auto-antibodies measurement (GAD65 & IA2); if negative progress to genetic testing.
Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.
Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change.
79222|NCT01241344|Drug|CMX001|Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW
79223|NCT01241357|Device|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
79224|NCT01241383|Drug|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
79225|NCT01241396|Other|Any MMY treatment|Any line of treatment for MMY
79226|NCT01241409|Drug|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
79227|NCT01241409|Drug|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
80195|NCT01233414|Behavioral|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
80196|NCT01233414|Other|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
80197|NCT01233440|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
80198|NCT00048061|Drug|ibandronate [Bonviva/Boniva]|2.5mg po daily
80199|NCT01233440|Biological|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
80200|NCT01233453|Device|the everolimus eluting ® stent|stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
80201|NCT01233453|Device|the Biolimus A9 eluting NOBORI® stent|stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
80202|NCT01233479|Drug|systemic chemotherapy|
80203|NCT01233479|Other|laboratory biomarker analysis|
80204|NCT01225744|Drug|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
80205|NCT01225744|Drug|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
80206|NCT01225757|Device|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
80545|NCT01231438|Drug|Etalpha|0.25ug o.d. for 2 weeks
80546|NCT01231451|Drug|DMPA|All subjects will take DMPA
80547|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2.5mg po daily
80548|NCT01233791|Drug|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
80549|NCT01233804|Other|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
79708|NCT00047502|Drug|Lonafarnib (SCH66336)|Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.
Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.
Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.
79709|NCT01229969|Other|Wii Fit Balance Games|Ski Slaloms and Table Tilt
79998|NCT01230502|Other|data and sample collection|Group 3 : Donor specific regulation (DSR) - standard of care:
These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months.
79999|NCT01230515|Other|Individual patient interview, focus group and structured survey|
80000|NCT01230515|Other|interview, focus group and structured survey|
80001|NCT01230515|Other|interview, focus group and structured survey|
80002|NCT01230515|Other|interview, focus group and structured survey|
80003|NCT01230541|Drug|Placebo|Daily, oral tablet
80004|NCT01230541|Drug|Udenafil|Daily tablet
80005|NCT00047580|Drug|tizanidine hydrochloride capsule|
80006|NCT01230554|Device|Daily disposable cosmetic tint lens|Bausch & Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
80007|NCT01230580|Drug|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
80008|NCT01230580|Drug|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
80009|NCT01230593|Drug|Tobrex Drops and Ointment|Tobrex drops will be given to the affected eye 3x/day, and Tobrex ointment will be given at night before bed.
80010|NCT01232842|Other|HUMARA assay|
80011|NCT01232842|Other|fluorescence activated cell sorting|
80012|NCT01232842|Other|laboratory biomarker analysis|
80013|NCT00047983|Dietary Supplement|Canola oil|
80014|NCT01232855|Genetic|protein expression analysis|
80015|NCT01232855|Genetic|western blotting|
79150|NCT01243606|Behavioral|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
79151|NCT01243606|Behavioral|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
79152|NCT01243619|Drug|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
79153|NCT01243632|Drug|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
79154|NCT01243645|Behavioral|biofeedback training|
79155|NCT01243658|Drug|Oxytocin|Oxytocin
79156|NCT01243671|Biological|Adalimumab|
79157|NCT01243684|Device|DTI - Diffusor Tensor Imaging|Radiology intervention
79158|NCT01243697|Drug|desogestrel|Tablets of 75 µg, once daily during 112 days
79159|NCT00049036|Drug|vincristine sulfate|Given IV
78216|NCT01212913|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
78217|NCT01212913|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
78218|NCT01212913|Drug|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
78219|NCT01212926|Device|Echographic analysis of myocardial deformation in 2D strain|
78220|NCT01212952|Drug|pomalidomide|Given orally
78221|NCT01212952|Drug|bortezomib|Given IV
78222|NCT01212952|Drug|dexamethasone|Given orally
78223|NCT01212952|Other|laboratory biomarker analysis|Optional correlative studies
78224|NCT01212952|Other|gene expression analysis|Optional correlative studies
78225|NCT00045877|Drug|Recombinant Human Interleukin-2 and Rituximab|
78226|NCT01212965|Drug|Selenium|400 μg once a day for 6 months by mouth
79228|NCT01241409|Drug|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
79229|NCT01233947|Drug|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
79230|NCT01233947|Drug|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
79231|NCT01233960|Drug|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
79232|NCT01233973|Other|video decision aid|video
79233|NCT01233999|Drug|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
79234|NCT00001007|Drug|Zidovudine|
79235|NCT00048087|Drug|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
79236|NCT01234012|Biological|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
79237|NCT01234025|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
79238|NCT01234025|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
79239|NCT01234025|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
79240|NCT01234025|Drug|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
78293|NCT01210339|Drug|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
78294|NCT01210352|Drug|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
78295|NCT01210365|Drug|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
78296|NCT01210365|Drug|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
78297|NCT01210378|Drug|Nitroglycerin patch|Nitroglycerin patch
78298|NCT01210391|Other|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
80550|NCT01233817|Other|Progressive strength training|the systematic increase in resistance weights
80551|NCT01233830|Drug|AZD2423|oral solution
80552|NCT01233830|Drug|Placebo|oral solution
80553|NCT01233843|Drug|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
80554|NCT01233843|Drug|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
80555|NCT01233843|Radiation|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
80556|NCT01233856|Drug|Lovaza|2000mg daily.
80557|NCT01233856|Dietary Supplement|Placebo (corn oil).|Placebo capsules consisting of corn oil
80558|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
80559|NCT01233869|Drug|Bosutinib|Once daily oral dose of 200 mg of bosutinib
80560|NCT01233869|Drug|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
80561|NCT01233869|Drug|Placebo|Once daily oral dose of placebo
80562|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
80563|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
80564|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
80565|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
80566|NCT01233895|Drug|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
80567|NCT01233895|Drug|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
80568|NCT01233921|Biological|palifermin|Given IV
79621|NCT01239563|Drug|Basiliximab|Intravenous 20mg, day 0&4
79622|NCT01239641|Procedure|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
80016|NCT01232855|Other|flow cytometry|
80017|NCT01232855|Other|laboratory biomarker analysis|
80018|NCT01232868|Biological|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
80019|NCT01232881|Procedure|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
80020|NCT01232881|Procedure|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
80269|NCT01230983|Drug|dexrazoxane hydrochloride|Given IV
80270|NCT01230983|Drug|doxorubicin hydrochloride|Given IV
80271|NCT00047645|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
80272|NCT01230983|Drug|leucovorin calcium|Given IV
80273|NCT01230983|Drug|mercaptopurine|Given orally
80274|NCT01230983|Drug|methotrexate|Given IV
80275|NCT01230983|Drug|prednisone|Given orally
80276|NCT01230983|Drug|therapeutic hydrocortisone|Given IT
80277|NCT01230983|Drug|vincristine sulfate|Given IV
80278|NCT01233648|Other|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
80279|NCT01233661|Other|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
80280|NCT01233687|Drug|AMG 102 and erlotinib|Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg
The first cohort of patients in the phase I portion will start at dose level 0 of AMG102.
80281|NCT01233700|Behavioral|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
80282|NCT01233700|Behavioral|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
80283|NCT01233713|Procedure|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
80284|NCT01233713|Procedure|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
78227|NCT01212978|Behavioral|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
78228|NCT01212991|Drug|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
78229|NCT01212991|Drug|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
78230|NCT01213004|Procedure|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
78231|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
78232|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
78519|NCT01235091|Behavioral|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
78520|NCT01235091|Behavioral|Standard Intervention plus Well-Woman Exam|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
78521|NCT01235091|Behavioral|Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
78522|NCT01235104|Procedure|Total nephrectomy|Total nephrectomy
78523|NCT00048165|Drug|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
78524|NCT01235117|Drug|azacitidine|
78525|NCT01235117|Other|laboratory biomarker analysis|
78299|NCT01210391|Other|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
78300|NCT01239771|Drug|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
78301|NCT01239771|Drug|Placebo|Two subjects in each cohort will be given placebo.
78302|NCT01239784|Behavioral|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
78303|NCT01239797|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
78304|NCT01239797|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
78305|NCT01239797|Drug|Dexamethasone (Oral)|On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.
On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug
78306|NCT01239797|Drug|Dexamethasone (IV)|On weeks without Elotuzumab dosing: Not Applicable (N/A)
On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug
78307|NCT00048737|Drug|Fludarabine|30 mg/m^2/day for 3 days
78308|NCT01239797|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
78309|NCT01239810|Drug|Hyaluronic Acid|Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
78310|NCT01239823|Other|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
78311|NCT01239823|Other|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
78598|NCT01242605|Drug|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
78599|NCT01242605|Drug|cisplatin|cisplatin: 25 mg/m*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
78600|NCT01242618|Biological|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
78601|NCT01242631|Drug|Everolimus|Everolimus 10 mg orally per day.
79623|NCT01239654|Device|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
79624|NCT01239667|Other|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
79625|NCT01239680|Drug|Glutamine|Intravenous 25 grams once over 6 hours
79626|NCT01239680|Drug|Ringer's Lactate|Intravenous 1 liter once over 6 hours
79627|NCT01239680|Drug|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
79628|NCT00048737|Drug|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
79629|NCT01239693|Dietary Supplement|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
79630|NCT01239693|Dietary Supplement|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
79631|NCT01239693|Dietary Supplement|LNS|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
79632|NCT01239706|Drug|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
79633|NCT01239719|Drug|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
79634|NCT01239719|Drug|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
79635|NCT01239732|Drug|Paclitaxel|175 mg/m2 on Day 1 every 3 weeks or at a dose of 80 mg/m2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
79636|NCT01239732|Drug|bevacizumab [Avastin]|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
79637|NCT01239732|Drug|carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
79638|NCT01239745|Drug|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
79639|NCT00048737|Drug|Rituximab|250 mg/m^2 on day 1 and day 8
79640|NCT01239758|Biological|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
80285|NCT01233726|Dietary Supplement|T-Diet plus Diabet IR|T-Diet plus Diabet IR is a complete normocaloric high protein diet, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
80286|NCT01233726|Dietary Supplement|ISOSOURCE PROTEIN FIBRE|Isosource protein fibre is a complete high protein diet with fibre mixture.
Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
80287|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
80288|NCT01233726|Dietary Supplement|GLUCERNA SELECT|Glucerna Select is a complete high protein special formula, with fiber, enriched in monounsaturated fatty acids, with slow absorption carbohydrates.
Group 3 will receive 25 kcal / kg • day for 28 days, via gastric or transpyloric.
80289|NCT01233739|Drug|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
80623|NCT01231516|Drug|Raltegravir Placebo|Inactive placebo tablet twice daily
80624|NCT01231529|Drug|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
80625|NCT01231542|Drug|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
80626|NCT01231542|Drug|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
80627|NCT01231542|Drug|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
80628|NCT01231555|Drug|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
80629|NCT01231555|Drug|GSK2248761 200 mg once daily|2x100 mg capsules
80630|NCT00047736|Drug|Tarceva (erlotinib HCl)|
80631|NCT01231555|Drug|Efavirenz 600 mg once daily|1x600mg tablet
80632|NCT01231568|Drug|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
80633|NCT01231568|Drug|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
80634|NCT01224067|Drug|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
80635|NCT01224080|Device|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
80636|NCT01224093|Drug|Chemotherapy|as prescribed
78526|NCT01235130|Drug|OMEGA-3|600mg, 2 caps, twice a day
78527|NCT01235130|Drug|Placebo soybean oil|600mg, 2caps twice a day
78528|NCT01235143|Drug|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
78529|NCT01235143|Drug|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
78530|NCT01235169|Device|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
78531|NCT01235195|Drug|sertraline hydrochloride|50 mg capsule, single-dose
78532|NCT01235195|Drug|sertraline hydrochloride|50 mg tablet, single-dose
78533|NCT01235208|Other|The "Dr. Fedon Lindbergs Vektcoach" Treatment|Diet and lifestyle treatment
78534|NCT00048204|Drug|GW597599B|
78535|NCT01235221|Drug|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
78536|NCT01237665|Drug|IXO regimen|IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.
Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22.
78832|NCT01240759|Drug|S-707106 dose 1|One S-707106 dose 1 tablet and 3 Placebo A tablets matching S-707106 dose 1- and dose 2 tablets and metformin
78833|NCT00048802|Drug|Risperidone|
78834|NCT01240759|Drug|S-707106 dose 2|One S-707106 dose 2 tablet and 3 Placebo A tablets matching S-707106 dose 1- and dose 2 tablets and metformin
78835|NCT01240759|Drug|S-707106 dose 3|Four S-707106 dose 2 tablets and metformin
78836|NCT01240759|Drug|Placebo|Four Placebo A tablets matching S-707106 dose 1- and dose 2 tablets and metformin
78837|NCT01240772|Device|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
78838|NCT01240772|Device|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
78839|NCT01240785|Drug|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
78840|NCT01240785|Drug|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
78602|NCT01242644|Device|pain pump containing ropivacaine|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
78603|NCT01242644|Device|saline pain pump with injectable medication|30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
78604|NCT01242644|Drug|ropivacaine, ketorolac , morphine sulfate|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
78605|NCT01242657|Behavioral|Physical Activity Module|Participants were provided pedometers in order to track specific "Step Goals", which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a "Challenge Log".
78606|NCT00048971|Genetic|polymorphic microsatellite marker analysis|
78607|NCT01235234|Drug|CF101|orally q12h
78608|NCT01235247|Behavioral|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
78609|NCT01235260|Other|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
78610|NCT01235260|Drug|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
78611|NCT01235273|Drug|Growth Hormone|growth hormone administration
78612|NCT01235273|Other|Placebo|standard placebo
78613|NCT01235286|Procedure|remote ischemic preconditioning|A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.
The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia.
78614|NCT01235325|Dietary Supplement|phylloquinone (vitamin K1)|1000 mcg phylloquinone (vitamin K1) once daily for 12 months
78615|NCT01235325|Dietary Supplement|placebo|placebo oil capsule
78909|NCT01238393|Drug|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
78910|NCT01238406|Device|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
78911|NCT01238406|Device|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
79934|NCT01232842|Genetic|cytogenetic analysis|
79935|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
79936|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
79937|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
79938|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 24 weeks
79939|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
79940|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
79941|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
79942|NCT01225380|Drug|GS-9256 placebo|placebo matching GS-9256 capsule BID, 24 weeks
79943|NCT00047164|Biological|ipilimumab|
79944|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
79945|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), 48 weeks
79946|NCT01225393|Drug|MLTA3698A|Subcutaneous repeating dose
79947|NCT01225393|Drug|adalimumab|Subcutaneous repeating dose
79948|NCT01225393|Drug|leflunomide|Stable dose if not on methotrexate
79949|NCT01225393|Drug|methotrexate|Stable dose if not on leflunomide
79950|NCT01225393|Drug|placebo|Subcutaneous repeating dose
79951|NCT01225406|Drug|Tenofovir|
79952|NCT01225419|Drug|Plerixafor, mozobil|Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
79953|NCT01225432|Other|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
79954|NCT00047177|Drug|Oxaliplatin|
80637|NCT00047099|Radiation|radiation therapy|
80638|NCT01224093|Drug|rituximab [MabThera/Rituxan]|as prescribed
80639|NCT01224106|Drug|gantenerumab|225 mg subcutaneous doses every 4 weeks for 104 weeks
80640|NCT01224106|Drug|gantenerumab|105 mg subcutaneous doses every 4 weeks for 104 weeks
80641|NCT01224106|Drug|placebo|subcutaneous doses every 4 weeks for 104 weeks
80642|NCT01224119|Device|Amplex|225 micrograms of B2A per cc of ceramic granules
80643|NCT01224119|Procedure|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
80644|NCT01224132|Drug|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
80645|NCT01224145|Drug|4, 5x5cm bupivacaine collagen sponges|
79710|NCT01229969|Other|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
79711|NCT01229982|Drug|Latanoprost-PPDS|Punctal Plug
79712|NCT01229995|Device|dental implants - zirconia abutmetns - prefabricated abutments|
79713|NCT01230008|Radiation|no drugs|Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
79714|NCT01230021|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
79715|NCT01230034|Drug|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
79716|NCT01230034|Drug|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
79717|NCT01230047|Behavioral|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
79718|NCT01230060|Device|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
79719|NCT00047502|Drug|Imatinib Mesylate (Gleevec)|Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.
Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day.
79720|NCT01230073|Device|Home-Monitoring|Home-Monitoring
79721|NCT01230073|Device|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
78841|NCT01240811|Drug|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
78842|NCT01240811|Drug|Levonorgestrel IUD|
78843|NCT01240811|Drug|Copper T380A IUD|
78844|NCT00048802|Drug|Quetiapine|
78845|NCT01240824|Drug|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
78846|NCT01240837|Other|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
78847|NCT01240837|Other|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
78848|NCT01240837|Other|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
78849|NCT01240850|Drug|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
78850|NCT01240850|Drug|Prednisone|
78851|NCT01240863|Drug|Hydrocodone|Hydrocodone at 15 to 90 mg, administered every 12 hours
78852|NCT01240863|Drug|Placebo|Matching Placebo
78853|NCT01240876|Drug|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
79160|NCT01236196|Behavioral|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
79161|NCT01236196|Behavioral|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
79162|NCT01236209|Other|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
79163|NCT01236209|Other|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
79164|NCT01236222|Behavioral|Cycling to school|Regular cycling to school
79165|NCT01236248|Behavioral|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home.
78912|NCT01238419|Device|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
78913|NCT00048581|Drug|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
78914|NCT01238419|Device|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
78915|NCT01238458|Drug|[18F]AV-45 PET amyloid binding imaging|This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
78916|NCT01238471|Drug|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
78917|NCT01238471|Drug|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
78918|NCT01238484|Other|Standard of care|shoe modification home stretching exercises
78919|NCT01238484|Device|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
78920|NCT01240889|Drug|Fluticasone|nasal spray
78921|NCT01240889|Drug|Fluticason|2 sprays per day in each nostril
78922|NCT01240902|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
78923|NCT01240902|Device|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
78924|NCT01240915|Drug|placebo|once every 7 days for 1- 3 doses
78925|NCT01240915|Drug|MultiStem low dose|1-3 doses
78926|NCT01240915|Drug|placebo|Single dose at week 8
78927|NCT01240915|Drug|MultiStem low dose|Single dose at week 8
78928|NCT01240915|Drug|placebo|Single dose Day 1
78929|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
78930|NCT00048802|Drug|Aripriprazole|
78931|NCT01240915|Drug|placebo|Single dose at week 8
79241|NCT01234025|Drug|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
79955|NCT01225445|Drug|Ramipril|2.5 mg daily
79956|NCT01225458|Other|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
80207|NCT01225770|Dietary Supplement|green tea|Gargling three times daily for 90 days
80208|NCT01225783|Other|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
80209|NCT01225796|Drug|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
80210|NCT01225822|Drug|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
80211|NCT01225822|Drug|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
80212|NCT00001000|Drug|Ampligen|
80213|NCT00047229|Biological|oblimersen sodium|
80214|NCT01225822|Drug|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
80215|NCT01225822|Drug|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
80216|NCT01225822|Drug|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
80217|NCT01225835|Drug|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
80218|NCT01225835|Drug|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
80219|NCT01225835|Drug|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
80220|NCT01225835|Drug|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
80221|NCT01225835|Drug|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
80222|NCT01225848|Drug|SU011248|blinded-SU011248 or Placebo given at 50 mg/day as single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks. Suty drug will be orally self administered once daily without regard to meals beginning on Day 1 of the study.
80223|NCT01225874|Drug|SC-PEG E. coli L-asparaginase|Given IM
79722|NCT01230086|Device|ICD Implantation without DFT testing|Implantation
79723|NCT01230086|Device|Upper limit of vulnerability testing|Upper limit of vulnerability testing
79724|NCT01230086|Device|T-wave shock with induction of ventricular fibrillation|Traditional safety margin testing for defibrillation threshold
79725|NCT01232283|Drug|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
79726|NCT01232283|Drug|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
79727|NCT01232283|Other|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
79728|NCT01232296|Drug|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
79729|NCT01232296|Drug|sorafenib|400 mg p.o. b.i.d.
79730|NCT01232309|Dietary Supplement|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
79731|NCT00047840|Drug|Placebo|
80021|NCT01232894|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
80022|NCT01232894|Drug|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
80023|NCT01232907|Drug|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
80024|NCT00047983|Dietary Supplement|Arginine|
80025|NCT01232920|Drug|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
79166|NCT01236261|Other|Non intervention|Non interventional study
79167|NCT01236287|Drug|Voclosporin|Subjects will receive voclosporin capsules, twice daily to maintain a trough level > 20 ng/mL.
79168|NCT01236300|Device|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
79169|NCT00048399|Drug|CAMPATH 1H|
79170|NCT01236313|Procedure|TEE report|Information will be collected during cardiac surgery.
79171|NCT01236326|Procedure|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
79172|NCT01236326|Procedure|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
79173|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
79174|NCT01236339|Procedure|LVP|Large Volume Paracentesis
79175|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
79176|NCT01236352|Drug|BMS-911543|
79177|NCT01236365|Drug|Atorvastatin|10 or 20 mg daily
79178|NCT01236365|Drug|Atorvastatin Placebo|10 or 20 mg daily
79179|NCT01236378|Drug|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
79180|NCT00048399|Drug|FK506|
79181|NCT01236391|Drug|PCI-32765|560 mg daily
78233|NCT01205334|Biological|Autologous CMV-specific CTL|CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.
At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion.
78234|NCT01205347|Drug|Simvastatin 80mg|Simvastatin 80mg once a day
78235|NCT01205347|Drug|Simvastatin 10mg|Simvastatin 10mg once a day
78236|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
79242|NCT01234038|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
79243|NCT01234038|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
79244|NCT01234038|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
79245|NCT01234038|Drug|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
79246|NCT00048100|Procedure|Apheresis|Apheresis for T-Cell collection
79247|NCT01234038|Drug|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
79248|NCT01234051|Drug|Docetaxel, Oxaliplatin|1. Treatment Schedule
1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.
1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days.
79249|NCT01234064|Device|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
79250|NCT01234064|Device|No Graduated Compression Stockings|No stockings will be applied.
79251|NCT01234077|Device|CPC M1|CPC M1
79252|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
79253|NCT01236430|Drug|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
79254|NCT01236430|Drug|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
79255|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
79256|NCT01236443|Drug|HPPH|3 mg/m2 IV
79257|NCT00048399|Procedure|Stem Cell Transplantation|
79258|NCT01236456|Drug|Cyclophosphamide|
79259|NCT01236469|Procedure|Echocardiogram|A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
79260|NCT01236482|Drug|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
80224|NCT00047229|Drug|doxorubicin hydrochloride|
80225|NCT01225874|Drug|cytarabine|Given IT
80226|NCT01225874|Drug|daunorubicin hydrochloride|Given IV
80227|NCT01225874|Drug|dexamethasone|Given orally
80569|NCT00048087|Drug|ZD1839|250 mg by mouth daily each day for 4 weeks.
80570|NCT01233921|Other|flow cytometry|Correlative studies
80571|NCT01233921|Other|laboratory biomarker analysis|Correlative studies
80572|NCT01233921|Other|pharmacological study|Correlative studies
80573|NCT01233934|Drug|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
80574|NCT01233934|Drug|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
80575|NCT01226329|Behavioral|Right Question Project - Mental Health (RQP-MH)|The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level "Care Manager."
80576|NCT01226329|Behavioral|Pamphlet|Participants in this group receive a handout called "Managing Your Mental Health" (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress.
80577|NCT01226342|Device|Transcutaneous electrical muscle stimulation|On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
80578|NCT00047255|Biological|trastuxumab|Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.
Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.
Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes.
80579|NCT01226355|Device|stent|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.
Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
80580|NCT01226368|Other|Biological Sample collection|Cervix cells
80026|NCT01232920|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
80027|NCT01232933|Device|VPS System|Use of the navigational VPS system during catheter placement
80028|NCT01232946|Drug|liraglutide|1.8mg subcutaneous qd for 3 months
80029|NCT01232946|Drug|insulin detemir|5units subcutaneous bid titrated to fasting glucose of <130mg/dL for 3 months
80030|NCT01232946|Drug|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose <130mg/dL for 3 months.
80031|NCT01225484|Procedure|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
80032|NCT01225484|Procedure|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
80033|NCT01225497|Procedure|Standard eccentric exercise|Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.
The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.
All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain.
80290|NCT01233739|Drug|Placebo|Administration of 2 capsules of placebo orally.
80291|NCT01233752|Drug|morphine chlorhydrate|The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.
At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.
Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).
Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h).
80292|NCT01233778|Dietary Supplement|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
80293|NCT01233778|Dietary Supplement|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
80294|NCT01233778|Dietary Supplement|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
80295|NCT01233778|Dietary Supplement|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
78237|NCT00045162|Drug|cisplatin|Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles
Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles
78238|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
78239|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
78240|NCT01205373|Drug|BI 671800|High dose oral drinking solution
78241|NCT01205386|Device|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
78242|NCT01205412|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
78243|NCT01205425|Other|PCI on the basis of coronary angiography|Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
78244|NCT01205425|Procedure|CT guided PCI|The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
78245|NCT01205438|Drug|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
78246|NCT01205438|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
78247|NCT01205438|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
78248|NCT00045162|Drug|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 & 3. Q 3 weeks x 4 Cycles
78249|NCT01205451|Drug|Botulinum toxin type A|Botulinum toxin type A
78250|NCT01205464|Drug|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
78251|NCT01205464|Drug|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
78537|NCT01237678|Drug|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
78538|NCT01237678|Drug|Carboplatin and Etoposide|
78539|NCT01237691|Behavioral|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
79261|NCT01236495|Drug|spinal morphine 0.3 mg|spinal morphine 0.3 mg
78312|NCT01239836|Behavioral|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
78313|NCT01239836|Behavioral|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
78314|NCT01239836|Behavioral|General health lecture|Participants will attend a lecture on general women`s health issues that does not address urinary incontinence.
78315|NCT01239849|Drug|Atorvastatin, 10mg, 20mg, 40mg|If initial LDL cholesterol between 100~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130~159 mg/dl is 20 mg, 160~220mg/dl is 40mg.
After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.
After 4 weeks treatment, recheck the LDL cholesterol
78316|NCT01239862|Other|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
78317|NCT01239875|Biological|dendritic cell vaccine therapy|Given intratumorally
78318|NCT00048737|Drug|Cyclophosphamide|750 mg/m^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
78319|NCT01242098|Drug|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
78320|NCT01242098|Drug|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
78321|NCT01242111|Drug|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
78322|NCT01242124|Procedure|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
78323|NCT01242124|Procedure|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
78324|NCT01242150|Device|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow >40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
80581|NCT01226381|Drug|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
80582|NCT01226394|Procedure|laparotomy plus HIPEC|Laparotomy + HIPEC
80583|NCT01226407|Drug|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
80584|NCT01226420|Drug|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
79641|NCT01239758|Biological|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
79642|NCT01239758|Biological|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
79643|NCT01241903|Drug|placebo|frequency and duration
79644|NCT01241916|Device|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
79645|NCT01241916|Device|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
79646|NCT01241929|Behavioral|video decision aid|video of CPR
79647|NCT01241942|Procedure|Transplantation of Lungs After Ex-vivo Perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
79648|NCT01241942|Device|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
79649|NCT01241955|Behavioral|video decision aid|video of CPR
79650|NCT01241968|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
79651|NCT01241968|Device|Placebo|Placebo
79652|NCT01241994|Other|AASD dialysis technique|
79653|NCT00048893|Drug|paclitaxel|160 mg/m^2 per cycle (53.3 mg/m^2 per day by continuous intravenous infusion over 24 hours for 3 consecutive days 1-3).
79654|NCT01242007|Other|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
80296|NCT01233778|Dietary Supplement|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
80297|NCT01233791|Drug|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
80298|NCT01225874|Drug|methotrexate|Given IT
80299|NCT01225874|Drug|pegaspargase|Given IM
80300|NCT01225874|Drug|prednisone|Given orally
80301|NCT01225874|Drug|vincristine sulfate|Given IV
80302|NCT01225887|Drug|Nintedanib|Given PO
80303|NCT01225913|Drug|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
80304|NCT01225913|Drug|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
80305|NCT00047242|Drug|7-hydroxystaurosporine|
80306|NCT01225926|Device|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
80307|NCT01225926|Device|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
80308|NCT01225939|Drug|AZD8329|tablet
80309|NCT01225939|Drug|AZD8329|Solution
80310|NCT01225952|Device|Crystalens AO|Bausch & Lomb model silicone multi-piece accommodating IOL.
80646|NCT01224171|Drug|vedolizumab|Vedolizumab for intravenous infusion
80647|NCT01224171|Other|Placebo|Placebo intravenous infusion
80648|NCT00047112|Drug|cisplatin|
80649|NCT01224184|Behavioral|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
80650|NCT01224184|Behavioral|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
80651|NCT01224197|Drug|TMC435|100 or 200 mg capsule, one single dose
78540|NCT01237691|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
78541|NCT01237704|Behavioral|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
78542|NCT01237704|Behavioral|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
78543|NCT00048542|Biological|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
78544|NCT01237730|Drug|cefuroxime|Use the cefuroxime as prophylaxis.
78545|NCT01237730|Drug|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
78546|NCT01237743|Device|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
78547|NCT01237756|Device|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
78548|NCT01237769|Drug|Vitamin D3|2200 IU/day
78549|NCT01237769|Behavioral|Lifestyle advice|Diet and exercise
78550|NCT01237782|Drug|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
78551|NCT01237782|Drug|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
78552|NCT01237795|Other|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
78553|NCT01237808|Drug|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
78554|NCT00048542|Biological|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
78555|NCT01237808|Drug|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o., days 1-3; (total dose 300 mg).
78854|NCT01240876|Drug|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
78855|NCT00048802|Drug|Ziprasidone|
78325|NCT01242150|Device|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
78326|NCT01242176|Drug|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
78616|NCT00048204|Drug|paroxetine|
78617|NCT01235338|Drug|LDX + Venlafaxine XR|Day 1-5 LDX 30mg
Day 6-10 LDX 50mg
Day 11-15 LDX 70mg
Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily
Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily
Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily
Day 31-34 Venlafaxine XR 150mg daily
Day 35-38 Venlafaxine XR 75mg daily.
78618|NCT01235338|Drug|Venlafaxine XR + LDX|Day 1-5 Venlafaxine XR 75mg
Day 6-10 Venlafaxine XR 150mg
Day 11-15 Venlafaxine XR 225mg
Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily
Day 21-25 Venlafaxine XR and LDX 50mg daily
Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily
Day 31-34 Venlafaxine XR 150mg
Day 35-38 Venlafaxine XR 75mg.
78619|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
78620|NCT01235364|Device|Foley catheter|The Foley catheter was placed with the digital method
78621|NCT01235364|Device|Foley catheter|The Foley catheter was placed with a speculum
78622|NCT01235377|Other|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
78623|NCT01235390|Dietary Supplement|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
78624|NCT01235403|Drug|Lacosamide|Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.
Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.
Taper phase if needed: 3 to 4 weeks
78625|NCT01237821|Drug|Effaclar|Topical, Bid, 12 weeks
78626|NCT01237847|Behavioral|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
78627|NCT01237847|Behavioral|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
78628|NCT01237847|Behavioral|Wait list comparison group|Wait list comparison group to receive intervention at later point.
78629|NCT01237860|Device|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
79655|NCT01242020|Drug|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
79656|NCT01242033|Dietary Supplement|red raspberries|single serving of one, two or four cups red raspberries
79657|NCT01242033|Dietary Supplement|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
79658|NCT01242046|Dietary Supplement|Caffeine|400 mg of caffeine in tablet form
79659|NCT01242046|Dietary Supplement|Placebo|Inert tablet
79660|NCT01242059|Dietary Supplement|yellow pea protein|Served in a tomato soup
79661|NCT01242059|Other|yellow pea fiber|Served in a tomato soup
79957|NCT01225458|Other|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
79958|NCT01225458|Other|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
79959|NCT01225471|Biological|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
79960|NCT01227720|Drug|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
79961|NCT01227733|Other|Breast Tumor Blocks|
79962|NCT01227746|Procedure|Tumor biopsies|
79963|NCT01227759|Drug|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
79964|NCT00047307|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
79965|NCT01227759|Drug|Placebo|Placebo containing no active ingredient
79966|NCT01227772|Biological|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
79967|NCT01227785|Device|INCEPTA ICD or CRT-D|
79968|NCT01227798|Drug|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
79969|NCT01227798|Drug|Placebo|Normal Saline
79970|NCT01227811|Drug|Darifenacin|Single oral dose Darisec(R) 15.0 mg
80652|NCT01224197|Drug|TMC435|100 or 200 mg capsule, once daily for 5 days
80653|NCT01224210|Drug|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
80654|NCT01224236|Drug|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
80655|NCT01224236|Drug|control|multivitamin solution without iron
80656|NCT01224249|Dietary Supplement|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
80657|NCT01224262|Biological|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
80658|NCT01224262|Biological|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
80659|NCT00047112|Drug|fluorouracil|
80660|NCT00047255|Drug|Docetaxel|Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.
Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.
Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins.
80661|NCT01226485|Drug|LY2940680|50 - 1000 mg administered orally for at least two 28 day cycles. Patients who demonstrate clinical benefit may receive treatment until discontinuation criteria are met.
80662|NCT01226498|Procedure|Red blood Cells auto-transfusion|Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
80663|NCT01226511|Drug|Duloxetine|Administered orally
80664|NCT01226511|Drug|Placebo|Administered orally
79431|NCT01236755|Device|ortho-k lenses|Nightly wear of lenses to correct vision in day time
79432|NCT01236768|Drug|Study Drug AG200-15, Contraceptives, Hormonal|Contraception; TCDS is applied and replaced every 7 days for 3 weeks, followed by a 1-week "patch free" period.
79433|NCT01236768|Drug|Levora, Contraceptives, Oral, Hormonal|one tablet will be taken each day for a 28 day cycle.
79434|NCT01236781|Device|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
78856|NCT01243385|Drug|metformin hydrochloride|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
78857|NCT01243398|Procedure|quality-of-life assessment|
78858|NCT01243411|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
78859|NCT01243424|Drug|linagliptin|linagliptin tablets 5mg QD
78860|NCT01243424|Drug|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
78861|NCT01243424|Drug|linagliptin placebo|linagliptin placebo
78862|NCT01243424|Drug|glimepride placebo|glimepiride placebo
78863|NCT01243437|Drug|ciprofloxacin|For adults and children aged > 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;
For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer.
78864|NCT01243437|Drug|doxyxcycline|For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;
For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer.
78865|NCT01243450|Drug|Tretinoin|Treatment of acne
78866|NCT00049036|Biological|rituximab|Given IV
78867|NCT01243450|Drug|placebo|treatment of acne
78868|NCT01243476|Drug|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
78869|NCT01243476|Other|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
78870|NCT01243489|Other|compliance supporting measures|Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service "Leben mit CML" or the use of a daily diary
78871|NCT01243502|Drug|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
78872|NCT01243502|Drug|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
78873|NCT01243515|Device|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
78630|NCT01237873|Drug|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
78631|NCT01237899|Drug|LY2623091|Administered orally
78632|NCT00048542|Drug|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
78633|NCT01237899|Drug|Placebo|Administered orally
78932|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
78933|NCT01240915|Drug|placebo|Single dose Day 1
78934|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
78935|NCT01240915|Drug|placebo|Single dose at week 8
78936|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
78937|NCT01240928|Drug|MSK-2206|Level 1: MK-2206 135mg weekly
78938|NCT01240928|Drug|Exemestane|Level 1: Exemestane - 25mg daily
78939|NCT01240928|Drug|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
78940|NCT01240941|Drug|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
78941|NCT00048815|Drug|Citalopram|
78942|NCT01240941|Drug|Exemestane|25 mg orally daily
78943|NCT01240941|Drug|Goserelin|3.6 mg orally monthly
78944|NCT01240954|Drug|OSIRIS|OSIRIS current practice
78945|NCT01240954|Drug|OSIRIS other concentration 1|OSIRIS new concentration 1
78946|NCT01240954|Drug|OSIRIS other concentration 2|OSIRIS new concentration 2
78947|NCT01240967|Drug|TC-5214|Oral tablets, single dose
78948|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
78949|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
78950|NCT01240980|Drug|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
79971|NCT01227811|Drug|Darifenacin|Single oral dose Enablex(R) 15 mg
79972|NCT01227824|Drug|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
79973|NCT01227824|Drug|raltegravir|raltegravir 400mg taken twice daily
79974|NCT01227824|Other|GSK1349572 Placebo|GSK1349572 placebo taken once daily
79975|NCT00047307|Other|laboratory biomarker analysis|Correlative studies
79976|NCT01227824|Other|ABC/3TC|Abacavir/Lamivudine background therapy once daily
79977|NCT01227824|Other|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
79978|NCT01227824|Other|raltegravir Placebo|raltegravir placebo taken twice daily
79979|NCT01227837|Dietary Supplement|placebo|placebo given to patients
79980|NCT01227837|Dietary Supplement|omga3|use of omega 3
80228|NCT01228240|Drug|Metformin|
80229|NCT01228253|Device|rTMS: repetitive transcranial magnetic stimulation|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
80230|NCT01228253|Device|SHAM rTMS: repetitive transcranial magnetic stimulation is off|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
80231|NCT01228266|Biological|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
80232|NCT00047320|Procedure|conventional surgery|
80233|NCT01228279|Other|DIANEAL|Weeks 1 to 6 (6 weeks):
CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night
CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night
Weeks 7 to 18 (12 weeks):
*same regimen as weeks 1 to 6, for both CAPD and CCPD patients
80234|NCT01228279|Other|EXTRANEAL|Weeks 1 to 6 (6 weeks):
CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night
CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night
Weeks 7 to 18 (12 weeks):
CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night
CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night
80235|NCT01228292|Drug|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
79435|NCT01236781|Device|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
79436|NCT01236794|Behavioral|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a ~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
79437|NCT01236807|Other|Possible coronary revascularization guided by MR perfusion imaging|Coronary revascularization guided by MR
79438|NCT01236807|Other|Possible coronary revascularization guided by coronary angiography with FFR measurement|Coronary revascularization guided by FFR
79439|NCT01236833|Drug|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
79440|NCT01236846|Dietary Supplement|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
79441|NCT00048425|Drug|Levosimendan|
79442|NCT01236846|Dietary Supplement|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
79443|NCT01236859|Drug|Gabapentin|Neurontin®, Pfizer
79444|NCT01236872|Dietary Supplement|Beetroot juice|250ml once of beetroot juice
79445|NCT01236872|Dietary Supplement|Water|250ml once of low-nitrate mineral water
79446|NCT01236885|Other|computer-assisted intervention|Undergo blood glucose management using Glucommander
79447|NCT01239160|Device|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
79448|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
79449|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
78483|NCT01240083|Device|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
78484|NCT01240083|Device|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
79182|NCT01236404|Drug|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
79183|NCT01236404|Drug|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
79184|NCT01236417|Behavioral|Exercising block|Exercising for 8 weeks using an elastic band
79185|NCT01236430|Drug|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
79186|NCT01238744|Dietary Supplement|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
79187|NCT01238744|Dietary Supplement|Control drink|Control drink
79188|NCT01238757|Other|Non-invasive Ventilation under Pressure Support|Non-invasive Ventilation under Pressure Support:
15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order
79189|NCT01238757|Other|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
79190|NCT01238770|Drug|Pazopanib|Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day
Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally
Phase II:
Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I.
79191|NCT01238783|Drug|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
79192|NCT00048607|Drug|Comparator: paroxetine HCL|
79193|NCT01238783|Drug|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
79194|NCT01238783|Drug|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
79195|NCT01238783|Drug|Vehicle|Topical ocular dosed 3 times per day for 3 days
79196|NCT01238796|Drug|telavancin|Intravenous
79197|NCT01238822|Drug|Methylphenidate|18 mg methylphenidate
79198|NCT01238822|Drug|placebo|Placebo
79199|NCT01238822|Drug|Methylphenidate|36 mg methylphenidate
79200|NCT01238822|Drug|Methylphenidate|54 mg methylphenidate
79201|NCT01238835|Device|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
79202|NCT01238848|Drug|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
78951|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
78952|NCT01243216|Device|Ultrasound|Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
78953|NCT01243242|Drug|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
78954|NCT01243268|Drug|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
78955|NCT01243281|Drug|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
79262|NCT01236495|Drug|spinal morphine 0.2 mg|spinal morphine 0.2 mg
79263|NCT01236508|Radiation|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
79264|NCT01236521|Drug|Analgesic and co-analgesic therapy|During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.
The Patients in the PHARM arm will be asked to sign an opioid treatment agreement at enrollment.
79265|NCT01236521|Behavioral|Pain self-management/coping skills treatment|There will be 8 sessions that will last a maximum of 45-minutes to optimize participants' attentiveness and performance required by the cognitive demands of pain coping skills training. Each session will adhere to a common structure organized into three parts: 1) check-in; 2) intervention, and 3) wrap-up. Prior to each session participants will be asked to rate the strength and perceived impact for up to four pain beliefs that participants and the psychologist identified together. The sessions will occur during the scheduled clinical contacts (by telephone or face-to-face depending on patient preferences) at: with one week of baseline, 2 and 4 weeks, and months 2, 3, and 4 and skills reinforced at months 6 and 9. The content of these sessions are designed to modify coping strategies found to be related to pain and disability. Briefly, patients will be trained in a variety of evidence-based skills found to help reduce pain and improve function.
79266|NCT01236534|Drug|Lubiprostone|24 mcg twice daily for 21 days.
79267|NCT01236534|Drug|Placebo|matching placebo twice daily for 21 days.
79268|NCT00048412|Drug|FLUDARABINE|
79269|NCT01236547|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
79270|NCT01236547|Drug|Paclitaxel|Given IV
79271|NCT01236547|Drug|Pazopanib Hydrochloride|Given PO
79272|NCT01236547|Other|Placebo|Given PO
80236|NCT01228292|Drug|Citrasate|Citrasate is infused as a dialysate
80237|NCT01228305|Drug|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
80238|NCT01228318|Drug|Zoledronic acid|A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.
80239|NCT01228331|Drug|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
80240|NCT01228331|Drug|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
80241|NCT01228331|Drug|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
80242|NCT01228331|Drug|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
80243|NCT00047320|Procedure|neoadjuvant therapy|
80244|NCT01228331|Drug|Daunorubicin hydrochloride|part of induction and reinduction therapy
80245|NCT01228331|Drug|Dexamethasone|part of reinduction therapy
80585|NCT01226446|Drug|vitamin D|Vitamin D on top of the standard treatment
80586|NCT01226459|Drug|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
80587|NCT01226459|Drug|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
80588|NCT01226472|Biological|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
80589|NCT01228890|Behavioral|CATCH-IT|The CATCH-IT 2-R intervention has a motivational (3 PCP motivational interviews at time 0, 1.5 months and 12 months and 3 coaching phone calls at 2 and 4 weeks and 18 months) and an Internet component (with separate adolescent [14 modules] and parent [5 modules] programs). This revised and expanded intervention will include a comprehensive approach to reducing modifiable risk factors and enhancing resiliency factors associated with increased or decreased risk of depression, respectively, proposed by Spence and Reinecke.148 The revised CATCH-IT "Tracker" will monitor time in study and deploy elements of the intervention based on time since enrollment, including computer and human elements (e.g. calls, doctor visits).
78485|NCT01240096|Drug|Mirtazapine|Mirtazapine 15 mg daily
78486|NCT00048750|Drug|Placebo|IV
78487|NCT01240109|Drug|Remifentanil|propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml
sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml
78488|NCT01240122|Device|Biotrue MPS|Multi-purpose contact lens care solution
78489|NCT01240122|Device|Investigational MPS|Multi-purpose contact lens care solution
78490|NCT01240135|Device|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
78491|NCT01240135|Device|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
78492|NCT01240135|Device|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
78493|NCT01240148|Drug|AZD3161|Single dose, intradermal injection
78494|NCT01240148|Drug|Lidocaine|Single dose, intradermal injection
78495|NCT01242436|Procedure|intravenous contrast administration|The additional burden is restricted to a WB-DWI scan before and during therapy.
MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.
During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.
78496|NCT00048932|Drug|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Every 28 days.
78497|NCT01242449|Drug|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
78498|NCT01242449|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
78499|NCT01242462|Procedure|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 & Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
78796|NCT01235598|Biological|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
79203|NCT00048607|Drug|Comparator: Placebo (Unspecified)|
79204|NCT01238848|Drug|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
78252|NCT01207869|Biological|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
78253|NCT01207869|Other|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
78254|NCT01207895|Device|PET imaging with [18F]-FLT|Up to three [18F]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
78255|NCT00045396|Drug|tipifarnib|Given orally
78256|NCT01207908|Drug|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
78257|NCT01207908|Other|Standard steroid treatment|Will complete all study related procedures and evaluations
78258|NCT01207921|Drug|Lenalidomide|
78259|NCT01207934|Dietary Supplement|placebo|saline placebo
78260|NCT01207934|Drug|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
78261|NCT01207934|Drug|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
78262|NCT01207947|Drug|Vardenafil (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
78263|NCT01207960|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
78264|NCT01207973|Drug|BI 113823|5 dose-groups of multiple oral doses of BI 113823
78265|NCT01207986|Radiation|Low dose computed tomography (CT)|
78266|NCT00045422|Biological|recombinant interferon alfa|
78267|NCT01207999|Procedure|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
78268|NCT01207999|Other|Data collection|Questionnaire completion
78269|NCT01208012|Drug|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
81800|NCT01258478|Other|Usual care|Usual care
81801|NCT01258491|Drug|Nicotinic Acids|
81802|NCT01258504|Drug|St. Johns Wort|Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.
Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20
81803|NCT01258517|Device|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
81804|NCT01258530|Drug|over-encapsulated oseltamivir|75 mg once
81805|NCT01258530|Drug|oseltamivir|75 mg once
81806|NCT01258543|Other|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
81807|NCT00050050|Drug|Drug therapy|
81808|NCT01258556|Dietary Supplement|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10*9 cfu/ml daily for 30 days.
81809|NCT01258556|Dietary Supplement|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
81810|NCT01258569|Drug|Entereg|Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
80860|NCT01226758|Biological|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
80861|NCT01226758|Biological|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
80862|NCT01226771|Drug|Ribavirin "loading" dose given|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
80863|NCT00047268|Procedure|biopsy|
80864|NCT01226771|Drug|"Priming" dose of ribavirin given|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
80865|NCT01226771|Drug|Group C ("Standard-of-Care")|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
80866|NCT01226784|Behavioral|Physcial activity|Strenght training Relaxation exercise
85410|NCT01274780|Drug|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
85411|NCT01274780|Drug|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
85412|NCT01274793|Drug|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
84468|NCT01280591|Drug|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
84469|NCT01280591|Drug|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
84470|NCT01280591|Drug|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
84471|NCT01280591|Drug|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
84472|NCT01280604|Drug|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
84473|NCT00052494|Drug|imatinib mesylate|
84474|NCT01280617|Drug|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
84475|NCT01280617|Drug|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
84476|NCT01283269|Behavioral|Computer Training|Computer brain fitness training
84477|NCT01283282|Drug|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
84478|NCT01283282|Drug|Placebo|Placebo PO qday for 6 weeks
84479|NCT01283308|Behavioral|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
84480|NCT01283308|Behavioral|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
84481|NCT01283321|Drug|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT < 155 seconds, post CPB, with evidence of significant microvascular bleeding
84482|NCT01283321|Other|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT <155 seconds post CPB with evidence of significant microvascular bleeding.
80925|NCT01224600|Other|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
80926|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit # 1
80927|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit #1
80928|NCT01224626|Drug|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
80929|NCT01224639|Biological|DENVax - Low Dose|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DENVax-1, DENVax-2, DENVax-3 and DENVax-4. Low dose contains: DENVax-1: 8 x 10^3 PFU, DENVax-2: 5 x 10^3 PFU, DENVax-3: 1 x 10^4 PFU, and DENVax-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU
80930|NCT01224639|Biological|DENVax - High Dose|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DENVax-1, DENVax-2, DENVax-3 and DENVax-4. High dose contains DENVax-1: 2 x 10^4 PFU, DENVax-2: 5 x 10^4 PFU, DENVax-3: 1 x 10^5 PFU, and DENVax-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. DENVax administered intradermally.
80931|NCT01224639|Biological|Placebo|Phosphate Buffered Saline (PBS)
80932|NCT01224652|Drug|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
80933|NCT00047138|Biological|dactinomycin|
80934|NCT01224652|Drug|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
81231|NCT01254786|Procedure|Non-dependent lung ventilation|the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.
Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min
Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min.
81232|NCT01254786|Procedure|Non-dependent lung ventilation|the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.
Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min.
Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min
81233|NCT01254799|Drug|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
81604|NCT01258101|Drug|ribavirin|800 mg orally daily
81605|NCT01258101|Drug|ribavirin|400 mg orally daily
81606|NCT01258114|Other|SPA treatment (ST)|Drug: spa treatment soon after randomization :
Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;
nutritional counseling (french nutritional recommendations booklet) ;
caloric restriction and physical training on demand (non mandatory).
81607|NCT01258114|Other|Non SPA treatment (NST)|Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the "French national guidelines for a healthy life style" brochure (given to the patient by the GP at baseline)
81608|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
81609|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
81610|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
81611|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
81612|NCT00050011|Drug|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
81613|NCT01258153|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
81614|NCT01258166|Procedure|Surgery or immobilization|
81615|NCT01258179|Other|Analysis of PSP and PAP from venous blood samples|to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
81616|NCT01260402|Device|Resynchronization using a transeptal approach|Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.
Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire
81617|NCT01260402|Device|Resynchronization using a coronary sinus approach|Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.
Devices used for procedure : RADI PressureWire, routine catheters chosen by operator
81618|NCT01260415|Drug|Panitumumab, Oxaliplatin, 5-FU|Panitumumab 6 mg / kg, given over 60 minutes
Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR
Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes
5FU 400 mg / m2, by bolus infusion
5FU 2400 mg / m2, given over 46 hours
81619|NCT01260428|Device|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
81922|NCT01263249|Procedure|Catheter Posterior to the Femoral Nerve|Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
85020|NCT01281358|Other|HOP-ON|A programme of activities which promote motor development
85021|NCT01281358|Other|SMILES|Details are provided on ways for parents to interact with their premature infants
85022|NCT01281384|Other|Advanced Imaging|
85023|NCT01281384|Other|Standard Imaging|
85024|NCT01281410|Procedure|Inspiratory Muscle Training|Inspiratory Muscle Training with Respifit (5 times per week)
85025|NCT01281410|Other|inspiratory muscle training|Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
85026|NCT01281423|Drug|Placebo|Oral BID
85027|NCT01281423|Drug|ANA598|Oral 200mg BID
85028|NCT01281423|Drug|Ribavirin|Ribavirin
85029|NCT01281423|Drug|Pegylated Interferon|Pegylated Interferon
85030|NCT00052520|Genetic|cytogenetic analysis|Correlative studies
85031|NCT01281436|Other|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
85032|NCT01281436|Other|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
85033|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
85034|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
85035|NCT01281462|Drug|Doripenem|500 mg doripenem IV q8h;
85036|NCT01281462|Drug|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
85037|NCT01281475|Drug|Levodopa/carbidopa|Levodopa/Carbidopa (4:1)
Dosages are based on levodopa.
Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
84483|NCT01283334|Drug|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
84484|NCT01283334|Drug|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
84485|NCT01283334|Drug|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
84486|NCT00052676|Procedure|radionuclide imaging|
84765|NCT01283581|Drug|Delafloxacin|300mg IV every 12 hours for 5-14 days
84766|NCT01283581|Drug|Linezolid|600mg IV every 12 hours for 5-14 days
84767|NCT01283581|Drug|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
84768|NCT01283594|Drug|Tozadenant (SYN115) 60 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 60 mg BID.
84769|NCT01283594|Drug|Placebo|White-coated, modified-oval placebo tablets.
84770|NCT00052689|Drug|bortezomib|Given IV
84771|NCT01283594|Drug|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
84772|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
84773|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
84774|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single sc injection
84775|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
84776|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
84777|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single sc injection
84778|NCT01276158|Procedure|Ultrasound|Ultrasound used to place arterial line
84779|NCT01276158|Procedure|Doppler|Doppler used to place arterial line
84780|NCT00052169|Drug|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
84781|NCT01276171|Procedure|Ultrasound|Participants will place arterial line using ultrasound technique
81234|NCT01257347|Behavioral|Electronically-measuring adherence to antihypertensive medications|During clinical visits with patients with uncontrolled hypertension, clinicians in the intervention arm will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (<10 minutes) in the interpretation and use of the report at the time of enrollment.
81235|NCT00049816|Behavioral|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
81236|NCT01257360|Drug|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
81237|NCT01257360|Radiation|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
81238|NCT01257373|Device|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
81239|NCT01257386|Drug|Asacol®|400mg tablets
81240|NCT01257386|Drug|Mesalazine|400mg tablets
81241|NCT01257399|Drug|Asacol®|400 mg tablets
81242|NCT01257399|Drug|Mesalazine|400mg tablets
81243|NCT01257412|Drug|Dapagliflozin|5mg Oral dose od
81244|NCT01257412|Drug|Dapagliflozin|10 mg Oral dose od
81245|NCT01257412|Drug|placebo|5/10 mg Oral dose od
81246|NCT00049816|Behavioral|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
81535|NCT01260350|Drug|LDV|Ledipasvir (LDV) tablets administered orally once daily
81536|NCT01260350|Drug|GS-9669|GS-9669 tablets administered orally once daily
81537|NCT01260350|Drug|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
81538|NCT01260363|Procedure|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
81539|NCT01260363|Procedure|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
81923|NCT00050622|Drug|Methylphenidate|
81924|NCT01263275|Device|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
81925|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
81926|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
81927|NCT01263288|Dietary Supplement|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
81928|NCT01263301|Device|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
81929|NCT01263314|Drug|MK-8266|Oral capsules, 0.1 mg potency
81930|NCT01263314|Drug|Placebo|Oral placebo capsules to match MK-8266 capsules
81931|NCT01263327|Biological|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
81932|NCT01263353|Drug|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
81933|NCT01263353|Drug|Everolimus followed by Pasireotide LAR + Everolimus|
81934|NCT00050622|Behavioral|Comprehensive behavioral treatment program|
81935|NCT01263366|Drug|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
81936|NCT01263379|Genetic|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)|Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering skin disease caused by absence of a protein known as type VII collagen. This trial will create a graft, which we call "LEAES", of the patient's own skin that has been genetically engineered in our lab to express this missing protein.
81937|NCT01263392|Device|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria & leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
81938|NCT01263418|Drug|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
81939|NCT01263431|Procedure|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
81940|NCT01256190|Biological|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
81941|NCT01256190|Device|Gelatin sponge|absorbable gelatin sponge for topical use
85038|NCT01281488|Procedure|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
85294|NCT01281852|Drug|Veliparib|Given PO
85295|NCT00052559|Other|laboratory biomarker analysis|Correlative studies
85296|NCT01281865|Other|diagnostic laboratory biomarker analysis|Correlative studies
85297|NCT01281865|Drug|everolimus|Given PO
85298|NCT01281865|Drug|imatinib mesylate|Given PO
85299|NCT01281878|Drug|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
85300|NCT01281891|Drug|LIA|Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
85301|NCT01281891|Drug|I/T morphine|Morphine special 0.1 mg injected intrathecally
85302|NCT01281904|Behavioral|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
85303|NCT01281904|Behavioral|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
85304|NCT01281917|Drug|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
85305|NCT01281917|Drug|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
85306|NCT00052572|Drug|ixabepilone|
85307|NCT01281930|Procedure|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
85308|NCT01281930|Procedure|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
85309|NCT01281943|Drug|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle
Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle
85310|NCT01281956|Drug|PRX-00023|selective 5HT1A agonist or placebo
85311|NCT01281969|Drug|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
85312|NCT01281969|Drug|Placebo|Normal saline, IV (in the vein), over 2 days
84782|NCT01276171|Procedure|Doppler|Participants will place arterial line using doppler technique
84783|NCT01276171|Procedure|Palpation|Participants will place arterial line using Palpation technique
84784|NCT01276184|Behavioral|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s) (phone call, letter, etc, as appropriate).
84785|NCT01276197|Other|Story-Telling DVD|DVD will contain both informational and story-telling components.
84786|NCT01276197|Other|Non-Storytelling DVD|DVD will contain only informational component.
85060|NCT01274195|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
85061|NCT01274221|Drug|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
85062|NCT00051935|Drug|Alglucosidase alfa|20 mg/kg (qow); intravenous
85063|NCT01274221|Other|Placebo|1 capsule per day for one week of the double-blind crossover phase
85064|NCT01276548|Drug|Genexol®-PM plus Carboplatin|
85065|NCT01276561|Procedure|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
85066|NCT00052221|Biological|epoetin alfa|
85067|NCT01276561|Procedure|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
85068|NCT01276587|Drug|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
85069|NCT01276600|Drug|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
85070|NCT01276613|Drug|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
85071|NCT01276613|Drug|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
85072|NCT01276626|Dietary Supplement|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
85073|NCT01276626|Other|Maltodextrin|Powder containing only maltodextrin
81540|NCT01260376|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
81541|NCT01260389|Behavioral|control|usual pharmacist care
81542|NCT00050206|Drug|Placebo|
81543|NCT01260389|Behavioral|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
81544|NCT01262859|Drug|bevacizumab|Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
81545|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
81546|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
81547|NCT01262872|Biological|Synflorix™|Intramuscular injection
81548|NCT01262872|Biological|Prevnar13™|Intramuscular injection
81549|NCT01262872|Biological|Tritanrix™-HepB/Hib|Intramuscular injection
81550|NCT01262872|Biological|Polio Sabin™|Orally
81551|NCT01262872|Biological|M-Vac™|Intramuscular injection
81552|NCT01262872|Biological|Stamaril™|Intramuscular injection
81553|NCT00050570|Behavioral|Web-based intervention to reduce eating disorder risk factors|
81554|NCT01262885|Drug|GSK2251052|500 mg tablet, dose levels detailed in Arm description
81555|NCT01262885|Drug|Placebo|matching placebo tablet
81556|NCT01262898|Drug|GSK962040 (5 mg tablet)|5 mg tablet
81557|NCT01262898|Drug|GSK962040 (25 mg tablet)|25 mg tablet
81870|NCT01256099|Behavioral|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
81871|NCT00049673|Drug|prednisone|Given orally
81741|NCT01260753|Drug|UR-63325|UR-63325
81742|NCT01260753|Drug|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
81743|NCT01263431|Procedure|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
81744|NCT01263444|Drug|Brinzolamide 1% / timolol 0.5% Fixed Combination|
81745|NCT01263444|Drug|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
81746|NCT01263457|Device|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
81747|NCT01263470|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
81748|NCT00050635|Drug|Sandostatin LAR Depot|
81749|NCT01263470|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
81750|NCT01263470|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
81751|NCT01263470|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
80798|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
80799|NCT01229293|Procedure|Articular Surface Replacement (ASR)|Articular surface replacement, DePuy, posterolateral approach used
80800|NCT01229293|Procedure|Standard Total Hip Arthroplasty (THA)|Device: Biomet 28mm
80801|NCT01229306|Procedure|Ablation|Ablation of atrial fibrillation
80802|NCT01229319|Drug|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
80803|NCT01229319|Drug|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
80804|NCT01229332|Drug|Saline|Continuous 24 h administration
80805|NCT01229332|Drug|Carbidopa|Continuous 24 h administration
80806|NCT01229345|Drug|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
80807|NCT01229358|Other|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
85313|NCT01274611|Device|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
85314|NCT01274624|Biological|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
85315|NCT00052000|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
85631|NCT01264861|Drug|Safinamide|Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.
Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.
Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food.
85632|NCT01264874|Drug|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
85633|NCT01264874|Other|placebo|For 3 years IU every 50 days
85634|NCT01264887|Drug|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
85635|NCT01264900|Behavioral|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
85636|NCT01264939|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
85637|NCT01264939|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
85638|NCT01264939|Drug|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
85639|NCT01264939|Drug|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
85640|NCT01264952|Procedure|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
The maximum duration of procedure is 90 minutes.
85641|NCT00050882|Drug|GM-611|
85642|NCT01264965|Drug|long acting oxycodone|10mg twice daily
85643|NCT01264965|Drug|extra strength acetaminophen|1,000 mg twice daily
80867|NCT01226797|Drug|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
80868|NCT01226797|Drug|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
80869|NCT01226823|Drug|Ursodeoxycholic Acid|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
80870|NCT01226823|Drug|Placebo|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
80871|NCT01226836|Other|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
80872|NCT01226849|Drug|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
80873|NCT01226875|Procedure|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
81172|NCT00050141|Drug|ZARNESTRA, tipifarnib, R115777|
81173|NCT01259674|Device|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
81174|NCT01259674|Other|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
81175|NCT01259687|Device|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
81176|NCT01259700|Behavioral|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
81177|NCT01259700|Behavioral|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
81178|NCT01259713|Drug|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
81872|NCT01256112|Behavioral|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
81873|NCT01256151|Drug|Alprazolam tablet|1 mg single dose of alprazolam conventional tablet
81874|NCT01256151|Drug|Alprazolam sublingual|1 mg single dose of alprazolam sublingual tablet
81875|NCT01256164|Device|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
81876|NCT01256164|Device|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
81877|NCT01256177|Drug|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
81878|NCT01256177|Drug|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
81879|NCT01258569|Drug|placebo|12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
81880|NCT01258582|Procedure|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
81881|NCT01258582|Procedure|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
81882|NCT01258595|Biological|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
81883|NCT01258595|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
81884|NCT01258608|Drug|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
81885|NCT00050063|Biological|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
81886|NCT01258608|Drug|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
81887|NCT01258608|Drug|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
81888|NCT01258621|Procedure|Laparoscopy|Laparoscopic distal pancreatectomy
80935|NCT01224665|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
80808|NCT00047424|Drug|simvastatin|
80809|NCT01229371|Biological|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
80810|NCT01231685|Drug|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
80811|NCT01231698|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
80812|NCT01231698|Other|control|standard treatment without strict heart rate control
80813|NCT00001005|Drug|Zidovudine|
80814|NCT00047762|Drug|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
80815|NCT01231711|Behavioral|Vets Prevail|The intervention has two primary components that are both delivered over the Internet:
The first component is a structured series of brief peer-to-peer instant messaging "Chats" structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).
The second component consists of six 30-minute "e-Learning Lessons" using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills.
80816|NCT01231724|Device|Allstate Nasal Spray|Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
80817|NCT01231724|Device|Placebo Nasal Spray|2 sprays in each nostril
81115|NCT01225068|Drug|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
81116|NCT01225081|Drug|ASP1941|oral
81117|NCT01225081|Drug|Placebo|oral
81118|NCT01225081|Drug|Pioglitazone|oral
81119|NCT01225094|Drug|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg. Final dose is administered the morning after repair.
81120|NCT01225094|Other|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg.
81121|NCT01225107|Dietary Supplement|Cranberry Extract|500mg TID
85644|NCT01264978|Device|Repetitive magnetic stimulation of the quadriceps muscle|During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.
Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.
Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).
Coils are cooled down to 5ºC before sessions.
84709|NCT00052351|Radiation|radiation therapy|
84710|NCT01278147|Behavioral|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
84711|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
84712|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
84713|NCT01278160|Drug|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
84714|NCT01278173|Drug|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
84715|NCT01278186|Procedure|Balloon angioplasty|Coronary angioplasty using the paclitaxel-coated balloon catheter
84716|NCT01278186|Procedure|Stent implantation|Coronary angioplasty using the paclitaxel-eluting stent
84717|NCT01278199|Other|Medicals measures|Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 > 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.
If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.
The administration of antibiotherapy by general mode according to the clinician appreciation.
The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation.
84718|NCT01278199|Other|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
84719|NCT01278212|Radiation|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
84720|NCT00052364|Drug|oxaliplatin|Given IV
84721|NCT01278225|Behavioral|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
84722|NCT01278225|Behavioral|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
81179|NCT01259713|Drug|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
81180|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
81181|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
81182|NCT01259726|Other|Placebo|10 mL placebo once daily for 14 days
81183|NCT00050154|Drug|ZARNESTRA, tipifarnib, R115777|
81184|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 14 days
81185|NCT01259739|Other|Cocoa|dissolved in water twice-daily intervention
81186|NCT01259752|Device|compression stockings|compression stockings
81187|NCT01259752|Other|standard non compressive stockings|standard non compressive stockings
81188|NCT01259765|Drug|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
81189|NCT01259765|Drug|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
81190|NCT01259791|Drug|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
81477|NCT01255254|Procedure|Gingival scaling|Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
81478|NCT01255280|Behavioral|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
81479|NCT01255280|Behavioral|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
81480|NCT01255293|Procedure|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
81481|NCT01255293|Procedure|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
81482|NCT01255306|Other|Optical coherence tomography|Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:
On 7th postoperative day
On 30th postoperative day
On 90th postoperative day
On 180th postoperative day
80936|NCT01224665|Procedure|therapeutic lymphadenectomy|Patients undergo standard or extended pelvic lymphadenectomy.
80937|NCT01224678|Dietary Supplement|vitamin D|Given orally
80938|NCT01224678|Other|placebo|Given orally
80939|NCT01224717|Drug|PTH134|
80940|NCT01224717|Drug|Placebo|
80941|NCT01224717|Drug|Forsteo|
80942|NCT01224730|Drug|perifosine|100 mg daily
80943|NCT01224743|Dietary Supplement|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
80944|NCT00047138|Drug|carboplatin|
80945|NCT01224743|Dietary Supplement|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
80946|NCT01224743|Dietary Supplement|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
80947|NCT01224756|Drug|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
80948|NCT00047268|Procedure|peripheral blood stem cell transplantation|
80949|NCT01226901|Drug|MK-4827|MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
80950|NCT01226914|Drug|EVICEL|EVICEL
80951|NCT01226927|Other|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
80952|NCT01226953|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
80953|NCT01226966|Drug|liraglutide|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
80954|NCT01226979|Radiation|High-dose endorectal brachytherapy|The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
80955|NCT01226992|Drug|Vancomycin|Oral Vancomycin:
Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral
80956|NCT01226992|Biological|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
81122|NCT01225107|Drug|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
81123|NCT00047138|Drug|vincristine sulfate|
81124|NCT01225120|Other|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
81125|NCT01225133|Other|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
81126|NCT01227356|Drug|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
81127|NCT01227369|Other|OPSAT-Q|A linguistically validated Korean version of OPSAT-Q
81128|NCT01227382|Procedure|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
81129|NCT01227395|Drug|Azithromycin|Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.
Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.
81130|NCT01227408|Drug|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
81131|NCT01227421|Drug|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
81132|NCT01227421|Drug|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
81133|NCT00047294|Drug|celecoxib|
81423|NCT01257737|Drug|HPN-100|HPN-100 will be administered orally three times daily (TID) with meals. The maximum recommended dose of HPN-100 in subjects weighing less than 20 kg is 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and is 11.48 mL/m2/day in heavier subjects (equivalent to 13g/m2/day of NaPBA). The maximum HPN-100 dose should be 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
81424|NCT01257750|Drug|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
81425|NCT01257763|Device|Transdermal Microchannel Skin System|A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
81426|NCT01257763|Device|Sham device|The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
81427|NCT00049946|Drug|risperidone|
84723|NCT01278225|Behavioral|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
84724|NCT01278238|Drug|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
84725|NCT01278238|Device|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
84726|NCT01278238|Other|Placebo|Neither phenylephrine nor lower limb bandaging
85316|NCT01274624|Drug|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
85317|NCT01274624|Drug|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
85318|NCT01274624|Drug|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
85319|NCT01274624|Drug|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
85320|NCT01274637|Drug|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
85321|NCT01274650|Procedure|Indirect Calorimetry|Indirect Calorimetry
85322|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
85323|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
85324|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
85325|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
85326|NCT00052013|Drug|PTK787/ZK 222584|
85327|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
85328|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
81483|NCT01255306|Drug|Local medical treatment of raised intraocular pressure|In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:
Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added.
81484|NCT01255345|Other|Chronic pelvic pain|A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
81485|NCT00049608|Drug|gemcitabine hydrochloride|
81486|NCT01255358|Drug|Dexamethasone|dexamethasone encapsulated in human erythrocytes. One infusion per month of about 10-15 mg of dexamethasone. The treatment covers 1 month of therapy-
81487|NCT01255371|Drug|Lopinavir|Evaluation of second line antiretroviral regimen including boosted lopinavir
81488|NCT01255371|Drug|Atazanavir|Evaluation of second line antiretroviral regimen including boosted atazanavir
81489|NCT01255397|Procedure|Male Infertility Protocol|Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.
Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.
When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.
35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.
If the follicle has collapsed than IUI will be performed
It the total motile sperm count is above 5 million sperm/ml then IUI will be done
If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI
6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple.
81490|NCT01255410|Biological|10^6 PFU rHMPV-Pa vaccine|Single dose of 10^6 PFU rHMPV-Pa vaccine delivered intranasally
81491|NCT01255410|Biological|10^5 PFU rHMPV-Pa vaccine|Single dose of 10^5 PFU rHMPV-Pa vaccine delivered intranasally
81811|NCT01258569|Drug|Entereg|oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
81812|NCT01260753|Drug|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
81813|NCT01260766|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
81814|NCT01260766|Device|Placebo Patch|same as active patch
81815|NCT00050323|Drug|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
81816|NCT01260779|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
81817|NCT01260792|Other|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
80957|NCT01227005|Biological|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
81247|NCT01257425|Drug|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.
Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85.
81248|NCT01257438|Device|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
81249|NCT01257438|Device|PTA only|Treatment of in-stent restenosis
81250|NCT01257451|Drug|Vildagliptin|vildagliptin 50mg bid
81251|NCT01257451|Drug|Placebo|Placebo 50mg bid
81252|NCT01257464|Drug|Sitagliptin|100mg po one dose
81253|NCT01257464|Drug|Placebo|Sugar pill po one dose
81254|NCT01257490|Behavioral|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
81255|NCT01257503|Drug|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
81256|NCT01257503|Drug|placebo|liquid made to look like the active homeopathic remedy
81257|NCT00001023|Drug|Clarithromycin|
81258|NCT00049829|Drug|Zoledronic Acid|
81259|NCT01259817|Drug|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
81260|NCT01259817|Drug|Aspirin|81 or 100 mg daily.
81261|NCT00001024|Drug|Zidovudine|
81262|NCT00050167|Drug|Paclitaxel|80 mg/m^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
81263|NCT01259830|Drug|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
81264|NCT01259830|Drug|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
81265|NCT01259856|Drug|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
81428|NCT01257776|Drug|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
81429|NCT01257789|Procedure|laparoscopic gastric bypass|laparoscopic gastric bypass
81430|NCT01257802|Drug|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
81431|NCT01257802|Drug|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
81432|NCT01257815|Drug|Ranibizumab|
81433|NCT01257828|Drug|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
81434|NCT01257828|Drug|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
81435|NCT01257841|Drug|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
81436|NCT01257841|Behavioral|Fasting|Complete fasting, save for water and multivitamin, for four days.
81437|NCT01260129|Drug|Silodosin|Silodosin 4 mg orally, twice daily after morning and evening meal
81438|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
81439|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
81440|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
81752|NCT01263470|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
81753|NCT01263470|Drug|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
81754|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
81755|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
81756|NCT01263483|Drug|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
85329|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
85330|NCT01274676|Device|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
85331|NCT01274676|Device|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
85332|NCT01274689|Other|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
85355|NCT01277042|Biological|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
85356|NCT01277042|Biological|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
85357|NCT01277068|Procedure|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
85358|NCT01279434|Drug|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
85359|NCT01279434|Drug|Vitamin E|Vitamin E 400 mg BD daily for 12 months
85360|NCT00052416|Drug|thalidomide|
85361|NCT01279447|Drug|0.25% Bupivacaine|10cc, single dose, US guided injection
85362|NCT01279447|Drug|Normal Saline|10cc, single dose, US guided injection
85363|NCT01279473|Drug|Nilotinib|
85364|NCT01279499|Drug|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
85365|NCT01279499|Drug|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
85366|NCT01279499|Drug|Propofol- Remifentanyl|Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).
Every rise of BP or HR > 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min
81818|NCT01260792|Other|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
81819|NCT01260805|Drug|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
81820|NCT01260805|Drug|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
81821|NCT01260818|Drug|Tranexamic Acid|1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
81822|NCT01260818|Drug|normal saline|100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
81823|NCT01260831|Other|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
81824|NCT01260831|Other|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
81825|NCT01260844|Drug|briakinumab|single dose briakinumab and 2 doses of CYP substrates
81826|NCT00050336|Drug|Lonafarnib (SARASAR)|
81827|NCT01260857|Drug|Aldazide|Aldazide 25 mg OD
81828|NCT01260870|Device|Cotavance Paclitaxel Coated Balloon|DEB
81829|NCT01260870|Device|Standard balloon angioplasty|POBA
81830|NCT01260883|Drug|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
80874|NCT01229371|Biological|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
80875|NCT01229384|Device|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
80876|NCT01229384|Device|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
80877|NCT01229397|Biological|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
81266|NCT01259856|Drug|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
81267|NCT01259856|Drug|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
81268|NCT01259869|Drug|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
81558|NCT01262898|Drug|GSK962040 (125 mg tablet)|125 mg tablet
81559|NCT01262898|Drug|Placebo|matching placebo tablet
81560|NCT01262911|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
81561|NCT01262911|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
81562|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
81563|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
81564|NCT00050583|Behavioral|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
81565|NCT01262924|Biological|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
81566|NCT01262937|Device|Confocal Imaging|Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
81567|NCT01262950|Other|portable motion detector|
81568|NCT01262963|Drug|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
81569|NCT01262976|Biological|GSK's investigational vaccine 692342|Intramuscular, 2 doses
81570|NCT01262976|Biological|Physiological saline|Intramuscular, 2 doses
81571|NCT01255436|Other|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
81572|NCT00049634|Drug|busulfan|
81573|NCT01255436|Other|Usual Care|Routine care of hypertensive patients that is based on recommendations of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. This consists of physician visits, advice and medication prescription by the healthcare provider. Patients receiving usual care do not receive SMS text reminders.
81574|NCT01255449|Drug|albuterol|400 mcg by inhalation
81757|NCT01263496|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
81758|NCT01263496|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
81759|NCT00050648|Drug|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
81760|NCT01263496|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
81761|NCT01263496|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
81762|NCT01263496|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
81763|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
81764|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
81765|NCT01263522|Other|different training programs|two different endurance programs and one strength endurance program
81766|NCT01263522|Other|control condition|unchanged lifestyle
81767|NCT01263535|Device|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
81768|NCT01255826|Procedure|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is < 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
81769|NCT01255826|Procedure|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
80818|NCT01231737|Drug|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
80819|NCT01231750|Drug|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
80820|NCT01231750|Other|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
80821|NCT01231763|Other|No intervention (not applicable)|No intervention (not applicable)
85367|NCT01279499|Drug|Propofol, Remifentanyl|Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).
The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR > 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min
85368|NCT01279512|Drug|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
85369|NCT01279512|Drug|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
85370|NCT01279525|Device|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
85371|NCT00052429|Drug|cisplatin|
85372|NCT01279538|Drug|ASKP1240|Intravenous (IV) infusion
85373|NCT01279538|Drug|Placebo|Intravenous (IV) infusion
85645|NCT01264991|Procedure|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
85646|NCT01267344|Drug|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
85647|NCT00051090|Drug|Abacavir|Administered orally twice daily in doses of 300 mg
85648|NCT01267344|Drug|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
85649|NCT01267357|Other|no intervention|
85650|NCT01267370|Dietary Supplement|Soy polysaccharide fiber|Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been "cleaned out", they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and > 10 years, 20 g/day.
The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.
Arms: Soy polysaccharide fiber, purified soy extract, with no fiber
Other Names:
Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)
85651|NCT01267383|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
80878|NCT01229397|Biological|Inflexal V|Inflexal V 0.5 mL administrated once only
80879|NCT01229410|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
80880|NCT01229410|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
80881|NCT01229423|Drug|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
80882|NCT01229436|Drug|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
80883|NCT00047424|Drug|ACE inhibitors|
80884|NCT01229449|Drug|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
80885|NCT01229449|Drug|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
80886|NCT01229449|Drug|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
80887|NCT01229449|Drug|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
80888|NCT01229449|Drug|Placebo|Two placebo tablets
80889|NCT01229462|Drug|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
80890|NCT01229462|Drug|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
80891|NCT01229462|Drug|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
80892|NCT01229462|Other|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
81191|NCT01259804|Dietary Supplement|Peanut oral immunotherapy|Daily doses of peanut flour
81192|NCT00050479|Drug|Celecoxib (Celebrex)|
81193|NCT01262196|Drug|Saline|Normal saline (0.9%) solution
81194|NCT01262209|Device|portable CCTV|This is a small handheld mini screen intended to improve reading.
81575|NCT01255462|Biological|LFG316|
81576|NCT01255462|Biological|LFG316|
81577|NCT01255462|Biological|LFG316|
81578|NCT01255462|Biological|LFG316|
81579|NCT01255475|Drug|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
81889|NCT01258634|Drug|Dexrazoxane|Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1
Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1
Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1
81890|NCT01258634|Drug|Doxorubicin|Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0
Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0
Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0
81891|NCT01258634|Drug|Cisplatin|Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol
Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol
Postoperative Chemotherapy for Poor Responders:
Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol
81892|NCT01258634|Drug|G-CSF|Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000
Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000
Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000
81893|NCT01258634|Drug|PEG-filgrastim|Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy
Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy
Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy
81894|NCT01258634|Drug|Etoposide|Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4
Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1
Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4
81895|NCT01258634|Drug|Ifosfamide|Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4
Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4
Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4
81896|NCT00050076|Drug|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
81897|NCT01260909|Device|Real-time kV/MV Prostate Imaging|The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
81898|NCT01260922|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
81899|NCT00050349|Drug|EPO906 epothilone B|
80822|NCT01231776|Other|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
80823|NCT01231789|Procedure|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
80824|NCT01231789|Procedure|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
80825|NCT00047775|Drug|BiDil|
80826|NCT01231802|Drug|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, & 15
80827|NCT01231802|Drug|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, & 16
80828|NCT01231802|Drug|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, & 17
80829|NCT01231802|Drug|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
80830|NCT01231815|Radiation|15O-H2O PET -|Assessment of coronary reserve using PET
80831|NCT01231815|Radiation|MRI|Assessment of coronary reserve using MRI
80832|NCT01231828|Drug|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
80833|NCT01231828|Drug|Lactulose|Lactulose (30-60 ml per day)
80834|NCT01231841|Drug|cyclosporine|Given orally
80835|NCT00047112|Procedure|neoadjuvant therapy|
80836|NCT01224405|Drug|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.
In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues.
80837|NCT01224405|Drug|Docetaxel|Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced >50%. Docetaxel treatment will be resumed when the serum PSA will rise by >50% from the lowest PSA level recorded and will be >10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
80838|NCT01224405|Drug|Continuous Docetaxel|Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced >50% or will reach a level <4 ng/mL.
81134|NCT01227421|Drug|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
81135|NCT01227434|Drug|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
85652|NCT01267396|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
85653|NCT01267409|Other|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
85654|NCT01267422|Drug|rAAV2-ND4|injection
85655|NCT01267435|Procedure|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
85656|NCT01267448|Drug|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
85657|NCT01267448|Drug|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
85658|NCT00051103|Drug|Investigational Cancer Drug|
85659|NCT01267448|Drug|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
85660|NCT01267461|Other|Tissue sample from tumor|Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
84727|NCT01280877|Device|Sham stimulation|tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
84728|NCT01280890|Behavioral|Staff training using VIPS|Staff training using the VIPS framework
84729|NCT01280890|Behavioral|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
84730|NCT01280890|Behavioral|Control group|Filmed traditional Lectures will be given to care staff
84731|NCT01280903|Behavioral|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
84732|NCT00001034|Drug|Ganciclovir|
84733|NCT00052520|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
81195|NCT01262209|Device|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
81196|NCT01262209|Device|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
81197|NCT01262222|Other|endothelial function testing|After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
81198|NCT01262235|Drug|TKM-080301|Repeat dose IV infusion.
81199|NCT01262261|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
81200|NCT01262274|Drug|Anastrozole|ANA is given 1mg daily for 24 weeks.
81201|NCT01262274|Drug|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
81202|NCT01262287|Drug|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
81203|NCT00001025|Drug|Didanosine|
81204|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
81205|NCT01262287|Drug|placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
81206|NCT01262300|Biological|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
81207|NCT01262313|Behavioral|Lifestyle Counseling|Participants in the intervention group will attend an 8-week group intervention discussing "Healthy Creations" lifestyle changes.
81208|NCT01262326|Other|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = <20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
81209|NCT01262339|Drug|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
81492|NCT01255410|Biological|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
81493|NCT01255423|Drug|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
81900|NCT01260922|Drug|Aricept®|10 mg Orally Disintegrating Tablet
81901|NCT01260935|Procedure|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
81902|NCT01260935|Procedure|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
81903|NCT01260948|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
81904|NCT01260948|Drug|Aricept®|10 mg Orally Disintegrating Tablet
81905|NCT01260961|Dietary Supplement|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
80958|NCT01227018|Drug|STA-9090|Given IV
80959|NCT00047281|Drug|celecoxib|
80960|NCT01227018|Radiation|Radiologic imaging|radiologic modalities used to evaluate response to treatment
80961|NCT01227018|Procedure|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
80962|NCT01227044|Drug|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
80963|NCT01227044|Other|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
80964|NCT01227057|Behavioral|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
80965|NCT01227057|Behavioral|Case Management|Case management
80966|NCT01227096|Device|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
80967|NCT01227135|Drug|hydroxychloroquine|
80968|NCT01227135|Drug|imatinib mesylate|
80969|NCT01227135|Genetic|cytogenetic analysis|
80970|NCT00047281|Drug|cyclophosphamide|
80971|NCT01227135|Genetic|polymerase chain reaction|
80972|NCT01227135|Other|laboratory biomarker analysis|
81136|NCT01227434|Drug|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
81137|NCT01227434|Procedure|Resection as clinical care|Indicated, intended, surgical resection as clinical care
81138|NCT01227460|Drug|Sitagliptin|pill/tablet form of 100mg each. will take one tablet a day throughout study
81139|NCT01227460|Drug|Sugar Pill|100mg tablet once a day
81140|NCT01227473|Behavioral|Mindfulness-based diabetes prevention education group|The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.
81141|NCT01227473|Behavioral|Conventional diabetes prevention education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
81142|NCT01227486|Device|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
81143|NCT01227512|Drug|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
81144|NCT00001002|Drug|Zidovudine|
81145|NCT00047294|Drug|temozolomide|
81146|NCT01227512|Other|Fluid Restriction|Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.
Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo "dose"
81147|NCT01229800|Drug|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
81148|NCT01229813|Drug|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
81149|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
81150|NCT00047463|Device|Placebo-CPAP|Placebo-CPAP
81151|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
84734|NCT01280903|Behavioral|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
84735|NCT01280916|Behavioral|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
84736|NCT01280929|Procedure|Panretinal Photocoagulation (PRP)|
84737|NCT01280929|Drug|Intravitreous injection of ranibizumab|
84738|NCT01280942|Behavioral|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
84739|NCT01280942|Device|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
84740|NCT01280955|Drug|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
84741|NCT01280968|Biological|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
85333|NCT01276951|Procedure|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
85334|NCT01276951|Procedure|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
85335|NCT01276951|Procedure|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
85336|NCT01276977|Drug|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
85337|NCT01276977|Drug|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
85338|NCT00052299|Drug|gemtuzumab ozogamicin|
85339|NCT01276990|Drug|BI 224436|Oral drinking solution
81494|NCT01255423|Drug|Placebo|Placebo, 4 times daily
81495|NCT01257867|Dietary Supplement|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
81496|NCT00049959|Drug|verteporfin PDT|
81497|NCT01257867|Dietary Supplement|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
81498|NCT01257893|Drug|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
81499|NCT01257893|Drug|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
81500|NCT01257906|Drug|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
81501|NCT01257906|Drug|ZIANA®|Topical Gel applied in the evening for 84 days
81502|NCT01257906|Drug|Vehicle Control|Topical Gel applied in the evening for 84 days.
81503|NCT01257919|Drug|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
81504|NCT01257919|Drug|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
81505|NCT01257932|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
81506|NCT01257945|Behavioral|Aerobic Exercise|
81507|NCT00049972|Drug|paroxetine CR|
81508|NCT01257945|Behavioral|Flexibility and Function exercise program|
81509|NCT01257945|Behavioral|Home exercise program|
81510|NCT01257958|Drug|19 nor vitamin d|
81511|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
81512|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
81513|NCT01257997|Biological|15N-Thymidine, 2H-Water|Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).
Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot).
81514|NCT01258010|Drug|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
80973|NCT01227135|Other|pharmacological study|
80974|NCT01229514|Other|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
80975|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
80976|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
80977|NCT01229527|Drug|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
80978|NCT01229540|Genetic|genetic analyzer|
80979|NCT01229553|Drug|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
80980|NCT01229566|Drug|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
81269|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
81270|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
81271|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
81272|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
81273|NCT00050167|Drug|Docetaxel|75 mg/m^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
81274|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
81275|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
81276|NCT01259921|Behavioral|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
81277|NCT01259934|Drug|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
81441|NCT01260155|Drug|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
81442|NCT01260155|Drug|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
81443|NCT00050180|Drug|Indinavir|
81444|NCT01260155|Drug|E5501|Treatment C: 40 mg new tablet formulation administered with food
81445|NCT01260181|Drug|erlotinib [Tarceva]|150 mg orally daily
81446|NCT01260194|Drug|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
81447|NCT01260207|Other|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
81448|NCT01260220|Procedure|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
81449|NCT01260220|Procedure|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
81450|NCT01260233|Other|Smoking cessation program|Smoking cessation program includes:
brief smoking cessation counselling by preadmission nurse (less than 5 minutes)
smoking cessation brochures
referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society
free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day
81451|NCT01260246|Drug|sitagliptin|pill, 100mg/daily for 6 months
81452|NCT01260246|Drug|placebo|placebo match for 6 months
81453|NCT01260259|Procedure|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
81454|NCT00050180|Drug|Saquinavir|
81455|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
85340|NCT01276990|Drug|BI 224436|Oral drinking solution
85341|NCT01276990|Drug|BI 224436|Oral drinking solution
85342|NCT01276990|Drug|BI 224436|Oral drinking solution
85343|NCT01276990|Drug|BI 224436|Oral drinking solution
85344|NCT01276990|Drug|BI 224436|Oral drinking solution
85345|NCT01276990|Drug|BI 224436|Oral drinking solution
85346|NCT01276990|Drug|BI 224436|Oral drinking solution
85347|NCT01276990|Drug|BI 224436|Oral drinking solution
85348|NCT01276990|Drug|Placebo|Oral drinking solution
85349|NCT00001033|Drug|Isoniazid|
85350|NCT00052299|Drug|idarubicin|
85351|NCT01277003|Device|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
85352|NCT01277003|Device|TENS|tow therapeutic points, each for 15 minutes
85353|NCT01277016|Drug|BMDex|BMDex:
cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle.
85354|NCT01277029|Other|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
85374|NCT01279551|Drug|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
85375|NCT01279551|Drug|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
85376|NCT01279564|Device|ETview TVT endotracheal tube|intubation
85377|NCT01279564|Device|Endotracheal tube|Intubation
85378|NCT01279577|Drug|Low dose TSO|Low dose TSO suspension
85379|NCT01279577|Drug|Medium dose TSO|Medium dose TSO suspension
85380|NCT01279577|Drug|High dose TSO|High dose TSO suspension
85381|NCT01279577|Drug|Placebo|Placebo solution
81831|NCT01260883|Drug|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
81832|NCT01260883|Drug|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
81833|NCT01260896|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
81834|NCT01260896|Drug|Effexor® XR|150 mg Extended-Release Capsule
81835|NCT01262989|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
81836|NCT01262989|Drug|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
81837|NCT01263002|Drug|clevudine, Adefovir|Nucleoside-analogue naive patient : Clevudine 30mg qd
Assess the complete virological response(HBV DNA < 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd
Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd
During medication of Clevudine, virological breakthrough : add adefovir 10mg qd
During treatment period, composite virological response : stop the medication and F/U for 2 years
Recurrence after stopping treatment(HBV DNA > 2,000IU/ml) retreat medication at composite virological response.
complete virological response: HBV DNA < 60 IU/ml
virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously.
81838|NCT01263015|Drug|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
81839|NCT00001026|Biological|gp160 Vaccine (Immuno-AG)|
81840|NCT00050583|Behavioral|CBT|Cognitive Behavioral Therapy
81841|NCT01263015|Drug|Atripla|Atripla once daily on an empty stomach
81842|NCT01263015|Drug|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
81843|NCT01263015|Drug|Abacavir/Lamivudine Placebo|matching placebo taken once daily
81844|NCT01263015|Drug|Dolutegravir placebo|matching placebo taken once daily
81845|NCT01263015|Drug|Atripla placebo|matching placebo taken once daily on an empty stomach
81846|NCT01263028|Drug|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
81847|NCT01263041|Drug|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
81848|NCT01263041|Drug|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
81278|NCT01259934|Drug|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
81279|NCT01259947|Drug|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
81280|NCT01259973|Drug|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
81281|NCT01262365|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
81282|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
81283|NCT01262378|Procedure|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
81284|NCT01262391|Drug|solifenacin suspension|oral suspension
81285|NCT01262417|Procedure|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
81286|NCT01262417|Procedure|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
81287|NCT01262430|Procedure|OtisMed|OtisMed Custom-fit Shapematching Guides
81580|NCT01255475|Drug|Placebo|Patients will receive placebo
81581|NCT01255488|Behavioral|Access to EBN-Search (without full-text manuscripts)|Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
81582|NCT01255501|Drug|NI-0701|
81583|NCT00049634|Drug|cyclophosphamide|
81584|NCT01255501|Drug|Placebo|
81585|NCT01255514|Drug|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
81586|NCT01255527|Drug|Bortezomib|Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
81587|NCT01255553|Radiation|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
81588|NCT01255579|Drug|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
81589|NCT01255579|Drug|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
81590|NCT01255592|Drug|AZD5069|Oral dose bid
81456|NCT01262677|Drug|placebo|matched to the active drug
81770|NCT01255839|Device|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
81771|NCT01255839|Drug|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
81772|NCT01255852|Drug|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
81773|NCT01255878|Device|occlusal stabilization splint|
81774|NCT01255878|Drug|Gabapentine|100 mg(1 capsule)three times per day for two months
81775|NCT01255891|Radiation|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
81776|NCT00001022|Drug|Zalcitabine|
81777|NCT00049660|Drug|capecitabine|
81778|NCT01255904|Drug|Dexmedetomidine|Intranasal dexmedetomidine 3mcg/kg
81779|NCT01255943|Behavioral|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
81780|NCT01255956|Device|Rapamycin eluting stent implantation|Rapamycin eluting stent implantation for in-stent restenosis treatment
81781|NCT01255956|Device|Paclitaxel eluting balloon catheter|Paclitaxel eluting balloon catheter for in-stent restenosis treatment
81782|NCT01255969|Other|Exercise|Personalized exercise program
81783|NCT01255995|Device|Capsular Tension Ring|Capsular Tension Ring
81784|NCT01256008|Behavioral|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
81785|NCT01256008|Behavioral|Clinical Management|Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.
Following are major elements:
Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible.
81786|NCT01258374|Drug|Raltegravir|Raltegravir, 400 mg bid
85382|NCT01282034|Procedure|Marrow stimulation - Drilling or Microfractures|Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.
Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective.
85383|NCT01282034|Device|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
85384|NCT01282047|Drug|Lenalidomide|oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
85385|NCT01282073|Drug|Mycophenolate mofetil, low dose steroid|Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 ~ 1000 mg bid per day (more than 50kg)
Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day
Duration: 48 weeks
85386|NCT00052585|Drug|irinotecan hydrochloride|Given IV
85387|NCT01282073|Drug|Cyclosporin, low dose steroid|Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)
Steroid: same dosage with active comparator goup
Duration: 48 weeks
85388|NCT01282138|Drug|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
85389|NCT01282138|Other|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
85390|NCT01282151|Drug|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
85391|NCT01282151|Drug|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
85392|NCT01282164|Procedure|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with T2DM, CAD, CVD, seizure
84450|NCT00052351|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
84451|NCT01277796|Device|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
84452|NCT01277809|Behavioral|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
81849|NCT01263054|Device|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
81850|NCT01263054|Other|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
80893|NCT01229475|Procedure|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
80894|NCT00047437|Behavioral|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
80895|NCT01229475|Procedure|Linear ablation|Linear ablation for AF ablation
80896|NCT01229488|Device|Intervention|Project was withdrawn before starting. There were no interventions
80897|NCT01231841|Other|flow cytometry|Correlative studies
80898|NCT00047788|Drug|ZD6474|
80899|NCT01231841|Biological|anti-thymocyte globulin|Given IV
80900|NCT01231854|Drug|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
80901|NCT01231854|Drug|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
80902|NCT01231880|Drug|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
80903|NCT01231880|Drug|Monthly IPT using DP|Given every month
80904|NCT01231880|Drug|Placebo given every month|No active ingredient
80905|NCT01231893|Procedure|olfactory mucosa ensheathing cell grafting, rehabilitation|In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.
80906|NCT01231893|Other|rehabilitation|In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
80907|NCT01231906|Drug|vincristine sulfate|Given IV
80908|NCT01231906|Drug|doxorubicin hydrochloride|Given IV
80909|NCT00047788|Drug|VEGF-receptor tyrosine kinase (KDR)|
81591|NCT01255592|Drug|Placebo|Oral dose bid
81592|NCT01255618|Device|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
81593|NCT01258049|Drug|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
81594|NCT01258049|Drug|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
81595|NCT01258062|Drug|GelVac™ nasal powder H5N1 influenza vaccine.|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
81596|NCT01258062|Drug|Placebo|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
81597|NCT01258075|Drug|Welchol for oral suspension placebo proxy|placebo proxy for Welchol for oral suspension, 0.625 grams colesevelam hydrochloride
81598|NCT01258075|Drug|Welchol for oral suspension|Welchol for oral suspension, 3.75 grams colesevelam hydrochloride
81599|NCT01258088|Drug|AN2728 Ointment|5mg/cm2, BID
81906|NCT01260961|Dietary Supplement|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
81907|NCT01260974|Drug|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
81908|NCT01260987|Drug|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
81909|NCT01260987|Drug|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
81910|NCT00050362|Drug|Rofecoxib and Bupivacaine|
81911|NCT01261000|Drug|Pegvisomant|Pegvisomant used as indicated
81912|NCT01261039|Radiation|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
81787|NCT01258374|Drug|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
81788|NCT01258387|Drug|Glial growth factor 2/ Neuregulin 1β3|
81789|NCT01258387|Other|Placebo|
80839|NCT01224405|Drug|Continuous Docetaxel|Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced >50% or will reach a level <4 ng/mL.
80840|NCT01224418|Drug|Tacrolimus|oral
80841|NCT01224431|Drug|jtip needleless lidocaine injection|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
80842|NCT01224444|Other|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
80843|NCT01224457|Drug|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
80844|NCT01224470|Drug|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
80845|NCT01224496|Drug|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
80846|NCT00047112|Radiation|radiation therapy|
80847|NCT01224509|Drug|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
80848|NCT01224509|Other|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
80849|NCT01224522|Procedure|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
80850|NCT01224522|Procedure|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
80851|NCT01224535|Dietary Supplement|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
80852|NCT01224548|Other|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
80853|NCT01224548|Other|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
80854|NCT01224561|Behavioral|Lipid overnutrition|During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
84453|NCT01280500|Other|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
84454|NCT01280500|Other|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
84455|NCT01280513|Dietary Supplement|High protein intake|30% of energy intake coming from proteins
84456|NCT01280513|Dietary Supplement|Low Protein intake|9% of energy intake coming from proteins
84457|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
84458|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
84459|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
84460|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
84461|NCT01280539|Device|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
84462|NCT00052494|Drug|cisplatin|
84463|NCT01280552|Biological|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
84464|NCT01280552|Biological|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
84465|NCT01280565|Drug|masitinib|masitinib 7.5 mg/kg/day
84466|NCT01280565|Drug|Dacarbazine|dacarbazine IV bolus at 1,000 mg/m2 once every three weeks
84467|NCT01280578|Device|Transcatheter PFO Closure|Transcatheter PFO Closure
84742|NCT01280968|Biological|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
84743|NCT01280981|Drug|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
80910|NCT01231906|Drug|cyclophosphamide|Given IV
80911|NCT01231906|Drug|ifosfamide|Given IV
80912|NCT01231906|Drug|etoposide|Given IV
80913|NCT01231906|Drug|topotecan hydrochloride|Given IV
80914|NCT01231906|Other|laboratory biomarker analysis|Correlative studies
81210|NCT01262352|Drug|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
81211|NCT01262352|Drug|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
81212|NCT01262365|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
81213|NCT01262365|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
81214|NCT01254682|Procedure|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
81215|NCT01254695|Device|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
81216|NCT01254708|Drug|Ambisome ®|liposomal amphotericin B
81217|NCT01254708|Drug|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
81218|NCT01254721|Drug|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
81219|NCT01254721|Drug|lithium|300mg tablet, oral
81220|NCT01254734|Procedure|transoral robotic surgery|Undergo transoral robotic microsurgery
81221|NCT01254734|Other|laboratory biomarker analysis|Correlative studies
81222|NCT01254734|Procedure|quality-of-life assessment|Ancillary studies
81223|NCT00049595|Drug|etoposide|
81224|NCT01254747|Device|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
81225|NCT01254747|Device|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
81913|NCT01261052|Device|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The "fading memory" designation refers to weighting recent errors more heavily than remote errors.
The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.
81914|NCT01261052|Device|The Adaptive Proportional Derivative Algorithm|The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The "fading memory" designation refers to weighting recent errors more heavily than remote errors.
The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.
81915|NCT01261065|Drug|carvedilol|Patients with heart failure and LVEF < 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight > 80 kg.
81916|NCT01263210|Biological|Prevenar|
81917|NCT01263223|Drug|LY2216684|Administered orally
81918|NCT01263223|Drug|Placebo|Administered orally
81919|NCT01263236|Drug|LY2940094|Administered orally
81920|NCT01263236|Drug|Placebo|Administered orally
81921|NCT01263249|Procedure|Catheter Anterior to the Femoral Nerve|Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
80981|NCT01229579|Drug|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
80982|NCT00047450|Drug|Citalopram (Celexa)|Citalopram for 3 months
80983|NCT01229579|Drug|Placebo|2.5 ml syrup daily with no elemental zinc from day 14 to 18 weeks of age.
80984|NCT01229592|Drug|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
80985|NCT01229592|Drug|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
80986|NCT01229605|Drug|Cyclophosphamide and docetaxel|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
80987|NCT01229618|Drug|Hyperpolarized Pyruvate (13C) injection|single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
80855|NCT01224587|Drug|D1000078|Oral, one single dose
80856|NCT01226732|Drug|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
80857|NCT01226745|Drug|ONO-4641 (MSC2430913A)|0.15 mg once per day for 225 weeks
80858|NCT01226745|Drug|ONO-4641 (MSC2430913A)|0.1 mg once per day for 225 weeks
80859|NCT01226745|Drug|ONO-4641 (MSC2430913A)|0.05 mg once per day for 225 weeks
81152|NCT01229813|Drug|low dose capecitabine|capecitabine 500 mg twice daily
81153|NCT01229826|Radiation|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
81154|NCT01229839|Other|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
81155|NCT01229839|Other|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
81156|NCT01229839|Other|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
81157|NCT01229852|Device|DSF-rTMS|Effective Transcranial Magnetic Stimulation
81158|NCT01229865|Drug|VB-111|
81159|NCT01229878|Dietary Supplement|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
81160|NCT01229891|Dietary Supplement|plain yogurt drink|daily intake of two bottle of plain yogurt drink
81161|NCT00047476|Drug|dexmethylphenidate(d-mph)|
81162|NCT01229891|Dietary Supplement|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
81163|NCT01229891|Dietary Supplement|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
81164|NCT01229904|Behavioral|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
81165|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 1|
84744|NCT01283386|Drug|fludarabine|20 mg/m2 iv or 32 mg/m2 orally Days 1-3 of each 28-day cycle, 6 cycles
84745|NCT01283386|Drug|rituximab [MabThera]|375 mg/m2 iv on Day 1 of cycle 1, 500 mg/m2 iv on Day 1 of cycles 2-6 (28-day cycles)
84746|NCT01283412|Drug|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
84747|NCT00001035|Drug|Zalcitabine|
84748|NCT00052676|Procedure|sentinel lymph node biopsy|
84749|NCT01283412|Drug|Dexmedetomidine|Dexmedetomidine 0.1~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
84750|NCT01283425|Device|InsuPatch|Heaters for single use and a permanent control unit.
84751|NCT01283438|Device|Barricaid|CE Marked Device
84752|NCT01283438|Device|Standard of Care|Standard Limited discectomy
84753|NCT01283451|Behavioral|Muscle contraction|Participants will perform a 30-60 second exercise designed to cause a temporary decrease in muscle oxygenation of a specific muscle group.
84754|NCT01283464|Drug|Retinol|1.0% cream
84755|NCT01283464|Drug|Tretinoin|0.02% cream
84756|NCT01283477|Device|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
84757|NCT01283477|Device|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
84758|NCT01283490|Device|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
84759|NCT00052676|Radiation|technetium Tc 99m sulfur colloid|
84760|NCT01283490|Device|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
84761|NCT01283503|Drug|BKM120|
84762|NCT01283516|Drug|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
84763|NCT01283542|Drug|Pasireotide LAR|
84764|NCT01283555|Drug|Tenofovir|Delivered using prefilled and user-filled applicator
81226|NCT01254747|Device|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
81227|NCT01254747|Device|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
81228|NCT01254760|Device|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
81229|NCT01254760|Device|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
81230|NCT01254773|Drug|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
81515|NCT01258010|Drug|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
81516|NCT01258023|Biological|Fluad 1x|15 µg antigen/strain:
A/California/07/2009 (H1N1) - like strain
A/Perth/16/2009 (H3N2) - like strain
B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml
81517|NCT01258036|Radiation|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
81518|NCT00049985|Drug|Darbepoetin Alfa|
81519|NCT01258036|Biological|Sampling|Urine and blood samples
81520|NCT01258036|Radiation|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
81521|NCT01260259|Procedure|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
81522|NCT01260272|Other|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
81523|NCT01260272|Other|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
81524|NCT01260285|Drug|Vardenafil|10 mg PO once
81525|NCT01260298|Device|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
81526|NCT01260311|Drug|Fesoterodine|Any dose of Fesoterodine
81527|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
80988|NCT01229631|Dietary Supplement|Juice plus+|Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)
80989|NCT01229631|Dietary Supplement|Placebo non active capsules|Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
80990|NCT01229644|Drug|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
80991|NCT01229670|Other|exercise|1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time
2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min
80992|NCT01229683|Procedure|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
80993|NCT00001003|Drug|Zidovudine|
80994|NCT00047450|Drug|Placebo|Placebo for 3 months
80995|NCT01229696|Procedure|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
80996|NCT01229696|Procedure|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
80997|NCT01231984|Device|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
80998|NCT01231997|Drug|Udenafil|100mg Single Oral Dose of
80999|NCT01232010|Drug|Mirodenafil|50mg Single Oral Dose of
81000|NCT01232023|Drug|Indobufen|Single Oral Dose of
81288|NCT01262430|Procedure|Computer Assisted Surgery (CAS)|Stryker Navigation System
81289|NCT01262443|Procedure|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
81290|NCT01262456|Drug|Desmopressin|
81291|NCT01262456|Drug|Placebo|
81292|NCT01262469|Drug|lapatinib + capecitabine|For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.
For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles.
81293|NCT00050518|Biological|Aventis Pasteur Smallpox Vaccine|
81166|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 2|
81167|NCT01229917|Other|Standard fruit juice|
81168|NCT01229930|Drug|carboplatin|
81169|NCT01229930|Drug|cediranib maleate|
81170|NCT01229930|Drug|paclitaxel|
81171|NCT01259661|Other|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
81457|NCT01262690|Drug|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
81458|NCT01262690|Drug|PF-05230901|Single dose SC
81459|NCT01262703|Device|ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
81460|NCT01262729|Procedure|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
81461|NCT01262729|Drug|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
81462|NCT01262742|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
81463|NCT01262742|Drug|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
81464|NCT00050557|Behavioral|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
81465|NCT01262742|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
81466|NCT01262742|Drug|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
81467|NCT01262742|Drug|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
81468|NCT01262755|Behavioral|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
85039|NCT01274026|Drug|sapropterin dihydrochloride|In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.
Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted.
85040|NCT00051909|Drug|LY451395|
85041|NCT01274039|Drug|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
85042|NCT01274052|Other|Meal test|Liquid meal test
85043|NCT01274065|Genetic|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
85044|NCT01274078|Biological|Blueberries|150 grams of frozen blueberries on the same day as exercise
85045|NCT01274091|Other|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
85046|NCT01274091|Other|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
85047|NCT01274104|Dietary Supplement|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
85048|NCT01274104|Other|Placebo|Placebo
85049|NCT01274117|Procedure|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
85050|NCT01274130|Drug|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
85051|NCT00051922|Biological|PolyEnv1|Recombinant vaccinia virus vaccine
85052|NCT01274143|Behavioral|TeleCARE|Personalized telephone-delivered cancer risk assessment.
85053|NCT01274143|Behavioral|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
85054|NCT01274156|Device|"MEDISPEC" treatment probe|300 shocks in 5 different anatomical locations of the penis.
85055|NCT01274156|Device|"MEDISPEC" Sham Probe|Sham probe applied same as treatment probe without energy
85056|NCT01274156|Device|"MEDISPEC" Low intensity shock waves|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
85057|NCT01274156|Device|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
81528|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
81529|NCT01260337|Behavioral|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
81530|NCT01260337|Other|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
81531|NCT00050206|Drug|Olanzapine|
81532|NCT01260350|Drug|SOF|Sofosbuvir (SOF) tablets administered orally once daily
81533|NCT01260350|Drug|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
81534|NCT01260350|Drug|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
81851|NCT00050596|Drug|MDX-010 / MDX-010 + Docetaxel|
81852|NCT01263067|Behavioral|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
81853|NCT01263067|Behavioral|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
81854|NCT01263080|Drug|mirtazapine and folic acid|mirtazapine 30mg QD,folic acid 0.4mg QD
81855|NCT01263080|Drug|mirtazapine, folic acid placebo|mirtazapine 30mg QD,folic acid placebo 1 tablet QD
81856|NCT01263080|Drug|mirtazapine placebo, folic acid|mirtazapine placebo 1 tablet QD,folic acid 0.4mg QD
81857|NCT01263080|Drug|mirtazapine placebo, folic acid placebo|mirtazapine placebo 1 tablet QD,folic acid placebo 1 tablet QD
81858|NCT01256021|Drug|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
81859|NCT01256034|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
81860|NCT00049660|Drug|vinorelbine tartrate|
81861|NCT01256047|Dietary Supplement|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
81294|NCT01262482|Drug|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
81295|NCT01262482|Drug|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
81296|NCT01262495|Other|cryopreservation|cryopreservation of testicular tissue
81297|NCT01262521|Dietary Supplement|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
81298|NCT01262521|Dietary Supplement|Water|150 ml Chapelle mineral water
81299|NCT01262534|Other|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
81300|NCT01262534|Other|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
81301|NCT01262534|Other|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
81302|NCT01262547|Device|Dermabrasion-Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
81303|NCT01262547|Procedure|Dermabrasion|Only dermabrasion (removal of epidermis) alone will be done at baseline.
81304|NCT00050531|Drug|Gleevec|400 mg orally twice daily.
81305|NCT01262560|Drug|Manuka honey|
81306|NCT00049595|Drug|prednisone|
81307|NCT01254799|Drug|Placebo|Placebo capsules twice daily for 5 days
81308|NCT01254825|Procedure|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
81309|NCT01254825|Procedure|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
81600|NCT01258088|Drug|AN2728 Vehicle|5mg/cm2 BID
81601|NCT00049998|Drug|topotecan|
81602|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
81603|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
81469|NCT01262768|Behavioral|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
81470|NCT01262794|Biological|CDP6038|100 mg/mL solution for injection, single dose
81471|NCT01262794|Biological|Placebo|0.9% sodium chloride for injection Single-dose
81472|NCT01262807|Other|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
81473|NCT01262820|Drug|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
81474|NCT01262846|Biological|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
81475|NCT00050557|Behavioral|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
81476|NCT01262846|Biological|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
81790|NCT01258413|Procedure|Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
81791|NCT01258413|Procedure|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
81792|NCT01258439|Drug|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
81793|NCT01258439|Drug|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
81794|NCT01258452|Drug|CHF 5074|Drug is administered to subject in a fasting state
81795|NCT01258452|Drug|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
81796|NCT00050050|Behavioral|Cognitive behavioral therapy|
81797|NCT01258465|Behavioral|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
81798|NCT01258465|Behavioral|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
81799|NCT01258478|Other|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
85058|NCT01274182|Biological|GP2013|1000 mg
85059|NCT01274182|Biological|rituximab|1000 mg
85393|NCT01282164|Procedure|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with T2DM, CAD, CVD, seizure
85394|NCT01282190|Behavioral|Motivational interview|Motivational interview
85395|NCT01282216|Biological|Hepatitis A|1440 ELISA units, or 1 mL, IM
85396|NCT01282216|Biological|PCV 13|0.5 mL IM
85397|NCT00052585|Drug|gefitinib|Given orally
85398|NCT01282229|Device|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
85399|NCT01282242|Drug|IV rt-PA|open-label
85400|NCT01282255|Drug|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
85401|NCT01282255|Drug|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
85402|NCT01282268|Drug|arbaclofen|orally disintegrating tablet
85403|NCT01274702|Other|Visual Reconstitutions Therapy|
85404|NCT01274702|Other|Saccadic Eye Movement Training|
85405|NCT01274715|Behavioral|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
85406|NCT01274728|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
85407|NCT00052026|Drug|carvedilol|low-dose carvedilol administered twice daily for 8 months
85408|NCT01274741|Behavioral|Creating Change (therapy model)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study are conducted once per week in hour-long sessions. The treatment focuses on exploring how PTSD and SUD arose and interacted across the patient's life, including, constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
85409|NCT01274741|Behavioral|Seeking Safety|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy specifically designed for integrated treatment of patients with current PTSD and SUD. It consists of 25 topics evenly divided among cognitive, behavioral, and interpersonal topics. Each topic provides a new theme relevant to both disorders; for this study we will offer 17 of the 25 topics and conduct one topic per session.
81862|NCT01256060|Drug|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
81863|NCT01256073|Drug|IPH2101|IPH2101 fully human anti-KIR monoclonal antibody
81864|NCT01256086|Drug|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
81865|NCT01256086|Drug|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
81866|NCT01256086|Drug|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
81867|NCT01256086|Drug|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
81868|NCT01256099|Behavioral|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
81869|NCT01256099|Behavioral|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
80915|NCT01231919|Drug|Akt inhibitor MK2206|Given PO
80916|NCT01231919|Other|diagnostic laboratory biomarker analysis|Correlative studies
80917|NCT01231919|Other|pharmacological study|Correlative studies
80918|NCT01231984|Device|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
80919|NCT01231984|Device|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
80920|NCT00047801|Drug|TLK286 in combination with docetaxel|
80921|NCT01224587|Drug|D1000082|Oral, one single dose
80922|NCT00047125|Radiation|radiation therapy|
80923|NCT01224587|Drug|D1000083|Oral, one single dose
80924|NCT01224587|Drug|D1000085|Oral, one single dose
81642|NCT00050609|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
81643|NCT01263119|Drug|Warfarin|administered orally
81644|NCT01263119|Drug|LY2216684|administered orally
81645|NCT01263132|Drug|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
81646|NCT01263132|Drug|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
81647|NCT01263145|Drug|Akt Inhibitor MK2206|Given PO
81648|NCT01263145|Other|Laboratory Biomarker Analysis|Correlative studies
81649|NCT01263145|Drug|Paclitaxel|Given IV
81650|NCT01263145|Other|Pharmacological Study|Correlative studies
81651|NCT01263158|Other|Expectancy of standard oxytocin treatment|
81652|NCT01263171|Drug|L-leucovorin|
81653|NCT00050609|Drug|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
81654|NCT01263171|Drug|fluorouracil|
81655|NCT01263171|Drug|leucovorin calcium|
81656|NCT01263171|Drug|oxaliplatin|
81657|NCT01263171|Procedure|adjuvant therapy|
81658|NCT01263171|Procedure|neoadjuvant therapy|
81659|NCT01263171|Procedure|therapeutic conventional surgery|
81660|NCT01263171|Radiation|radiation therapy|
81661|NCT01263197|Drug|LY2216684|administered orally
81662|NCT01263197|Drug|albuterol|administered orally
81663|NCT01263197|Drug|propranolol|administered orally
81108|NCT01225029|Other|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
81109|NCT01225042|Dietary Supplement|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
81110|NCT01225042|Dietary Supplement|placebo|placebo consisting of carrier material powder of identical appearance
81111|NCT01225055|Drug|Teriparatide|20 ug daily over 12 months
81112|NCT00047138|Drug|etoposide|
81113|NCT01225055|Device|vibration|10 min/day for 12 months
81114|NCT01225068|Drug|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
81409|NCT01255085|Dietary Supplement|yellow pea protein|Served in a tomato soup
81410|NCT01255085|Dietary Supplement|yellow pea fiber|Served in a tomato soup
81411|NCT01255085|Dietary Supplement|Control Tomato Soup|Served in a tomato soup
81412|NCT01255137|Drug|Axitinib|5 mg tab orally twice a day with food every 28 days
81413|NCT01255163|Drug|Exendin-4 (Exenatide)|
81414|NCT01255176|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
81415|NCT01255189|Device|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
81416|NCT01255189|Device|invos 5100|near infrared spectroscopy: invos 5100
81417|NCT00049608|Dietary Supplement|mistletoe extract|
81418|NCT01255215|Drug|Inhaled Nitric Oxide|Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
82418|NCT01259427|Behavioral|Ending Self Stigma (ESS)|Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
82419|NCT01259427|Behavioral|Health and Wellness Group|The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
82420|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
82421|NCT01259440|Behavioral|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
82422|NCT01259440|Behavioral|Usual Care|Consists of one week telephone call and one month clinic visit
82423|NCT01259453|Biological|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
82424|NCT01259466|Drug|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
82425|NCT01259479|Drug|Satraplatin|Orally, once daily for 5 days repeated every 28 days, dose-escalation
82426|NCT01259492|Drug|Placebo|Placebo Comparator: Placebo
82686|NCT01252368|Biological|hypertension|patients taking daily ACE inhibitors or sartanes
82687|NCT01252381|Other|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
82688|NCT01252407|Other|transcutaneous electrical nerve stimulation|Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
82689|NCT01252420|Drug|Enoxaparin|1.5mg/kg daily for 2 weeks
82690|NCT01252433|Other|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
82691|NCT01252459|Radiation|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
82692|NCT01252459|Radiation|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
82198|NCT01254084|Dietary Supplement|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
82199|NCT01254097|Dietary Supplement|Probiotic|Probiotic capsule, 2 capsules twice daily
82200|NCT01254123|Drug|Exenatide infusion|On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.
Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.
82201|NCT01254123|Drug|Placebo infusion.|On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.
Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.
82202|NCT01256554|Behavioral|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
82203|NCT01256567|Biological|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
82204|NCT01256567|Drug|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.
82205|NCT00001022|Drug|Didanosine|
82206|NCT00049764|Drug|Placebo|
82207|NCT01256580|Drug|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
82208|NCT01256580|Drug|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
82491|NCT00049803|Drug|sodium oxybate|
82492|NCT01257243|Drug|Syrup of guaifenesin|5ml each 4 hours
82493|NCT01257269|Other|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
82494|NCT01257295|Dietary Supplement|control: no fiber addition|liquid breakfast without addition of fiber
82495|NCT01257295|Dietary Supplement|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
81664|NCT00050609|Drug|placebo|Placebo tablet taken by mouth once a day for 8 weeks
81665|NCT01263197|Drug|placebo for LY2216684|administered orally
80710|NCT01231568|Drug|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
80711|NCT01231568|Drug|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
80712|NCT01231581|Drug|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
80713|NCT01231581|Drug|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
80714|NCT01231581|Drug|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
80715|NCT01231594|Drug|GSK2118436|Study Drug
80716|NCT01231594|Drug|GSK1120212|Study Drug
80717|NCT00047749|Drug|Prialt (ziconotide)|
80718|NCT01231594|Drug|Other approved anti-cancer agent|Study Drug
80719|NCT01231607|Drug|1mg Finasteride active|1mg finasteride active, by mouth once daily
80720|NCT01231607|Drug|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
80721|NCT01231607|Drug|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
80722|NCT01231607|Drug|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
80723|NCT01231607|Drug|Finasteride placebo|finasteride placebo, by mouth once daily
80724|NCT01231607|Drug|Dutasteride placebo|dutasteride placebo, by mouth once daily
80725|NCT01231620|Drug|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
80726|NCT01231620|Drug|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
80727|NCT01231620|Drug|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
80728|NCT00047762|Drug|Erlotinib (aka Tarceva or OSI-774)|
81419|NCT01255228|Other|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
81420|NCT01257698|Drug|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
81421|NCT01257711|Procedure|Roux-en-Y or Billroth II|Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
81422|NCT01257724|Other|SHARE (Synthesized HIV/AIDS Research Evidence)|SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:
an online searchable database of HIV-relevant systematic reviews;
monthly email updates highlighting new reviews;
access to user-friendly summaries produced by us or by others (when available);
links to scientific abstracts;
peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;
an interface for participants to leave comments in the records of systematic reviews in the database;
links to full-text articles (when publicly available); and
access to worksheets that help CBOs find and use research evidence
81728|NCT01260688|Drug|dasatinib|Given orally
81729|NCT01260688|Procedure|assessment of therapy complications|Ancillary studies
81730|NCT01260688|Other|laboratory biomarker analysis|Correlative studies
81731|NCT01260701|Drug|Akt Inhibitor MK2206|Given PO
81732|NCT01260714|Drug|Azacitidine|Given SC
81733|NCT01260714|Drug|Etoposide|Given IV
81734|NCT01260714|Other|Laboratory Biomarker Analysis|Correlative studies
81735|NCT00050297|Drug|YM598|
81736|NCT01260714|Drug|Mitoxantrone Hydrochloride|Given IV
81737|NCT01260727|Biological|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
81738|NCT01260727|Biological|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
81739|NCT01260727|Biological|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
81740|NCT01260727|Biological|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
82693|NCT01252511|Procedure|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
82694|NCT01252524|Drug|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
82695|NCT01252524|Drug|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
82696|NCT00049543|Other|laboratory biomarker analysis|Correlative studies
82697|NCT01252550|Dietary Supplement|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
82698|NCT01252550|Dietary Supplement|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
82699|NCT01252563|Drug|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
82700|NCT01252589|Other|HRQOL questionnaire|
82701|NCT01244880|Other|Saline|Saline infusion for 56 minutes
82702|NCT01244880|Other|Placebo|Placebo tablet single dose
82703|NCT01244880|Other|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
82704|NCT01244880|Other|Placebo|Placebo tablet single dose
82705|NCT01244893|Device|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
83054|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg / L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
83055|NCT01253187|Drug|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
83056|NCT01253200|Device|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
83057|NCT01253200|Device|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
83058|NCT01253213|Drug|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
83059|NCT01253226|Drug|LY2127399|Administered subcutaneously
82496|NCT01257295|Dietary Supplement|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
82497|NCT01257295|Dietary Supplement|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
82498|NCT01257295|Dietary Supplement|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
82499|NCT01257295|Dietary Supplement|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
82500|NCT01257334|Drug|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
82501|NCT01259505|Biological|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
82502|NCT01259518|Drug|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
82503|NCT00050102|Drug|MDX-010 (CTLA-4)|
82504|NCT01259518|Drug|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
82505|NCT01259531|Drug|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
82506|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
82507|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
82508|NCT01259557|Drug|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
82509|NCT01259570|Dietary Supplement|Group 1|Skimmilk enriched with VD encapsulated in CM
82762|NCT01250301|Other|De-nicotinised cigarettes + standard treatment|Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.
Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline).
82763|NCT01250301|Other|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
80729|NCT01231620|Drug|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
80730|NCT01231633|Drug|Ozurdex|Ozurdex, 0.7mg dexamethasone
80731|NCT01231633|Drug|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
80732|NCT01231646|Other|No intervention|No intervention. This is a cross-sectional study.
81040|NCT01224951|Drug|Beclomethasone|400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
81041|NCT01224964|Drug|Montelukast|Montelukast, 10 mg
81042|NCT01227148|Other|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
81043|NCT01227148|Other|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
81044|NCT01227174|Drug|Propofol|Procedural sedation will be achieved using propofol
81045|NCT01227187|Drug|Drotrecogin alfa activated|We plan to determine the optimal dose of Xigris needed to achieve PTT between 65 and 100 secs. The study will test different dose regimens of Xigris. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via the pre-filter arterial drip chamber via a standard intravenous pump. The PTT will be assessed from blood samples drawn at baseline,15,30,60,120 and 180 mins. The dose of Xigris will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains <65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
81046|NCT01227200|Drug|dypiron, tramadol|dypiron 4 ML, tramadol 50 mg flashtab
81047|NCT01227226|Drug|Artificial tears|Instill one drop of artificial tears
81048|NCT01227239|Drug|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
81049|NCT00047281|Drug|etoposide|
81050|NCT01227239|Drug|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
81051|NCT01227239|Radiation|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
81052|NCT01227252|Drug|LY2886721|5 mg up to 35 mg, administered orally as capsules, daily for 14 days
81053|NCT01227252|Drug|Placebo|Administered orally as capsules, daily for 14 days
82075|NCT01258803|Drug|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
82076|NCT01258803|Drug|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
82077|NCT01258816|Drug|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
82078|NCT01258829|Other|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
82079|NCT01258829|Other|ECHO optimisation|Standard ECHO optimisation method
82080|NCT01258842|Dietary Supplement|Bifidobacterium lactis HN019|B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
82081|NCT01258842|Dietary Supplement|Placebo|Placebo sachet, consumed once per day for 12 weeks
82082|NCT01258855|Biological|Aldesleukin|Given IV
82083|NCT01261247|Drug|panobinostat|Given orally
82084|NCT01261247|Other|laboratory biomarker analysis|Correlative studies
82085|NCT01261247|Genetic|western blotting|Correlative studies
82350|NCT01261754|Radiation|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
82351|NCT01261767|Drug|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
82352|NCT01261767|Drug|placebo|Placebo for subcutaneous (under the skin) injection
82353|NCT01261780|Device|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
82354|NCT01261780|Drug|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
82355|NCT01261793|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
82356|NCT01261793|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
82357|NCT01261793|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and Placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles.
82358|NCT01261806|Behavioral|Attachment and Biobehavioral Catch-up|
83060|NCT01253226|Drug|Placebo|Administered subcutaneously
83061|NCT01253252|Radiation|[18F] Fluorodeoxyglucose PET Scan Imaging|Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.
The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.
The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations.
83062|NCT01253252|Radiation|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
83063|NCT00049569|Drug|pegaspargase|Given IM
83064|NCT01253252|Biological|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
83065|NCT01253265|Drug|LY2439821|Administered subcutaneously
83066|NCT01253265|Drug|Placebo|Administered subcutaneously
83067|NCT01253278|Drug|LY2393910|as capsules, administered orally once daily for two weeks
83068|NCT01253278|Drug|Placebo|as capsules, administered orally once daily for two weeks
83069|NCT01253291|Drug|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
83070|NCT01253304|Drug|LY2189265|Subcutaneous (SC) injection
83071|NCT01253317|Drug|rhIGF-1|1) PHASE 1 (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in PHASE2.
82145|NCT01256515|Behavioral|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
82146|NCT01256515|Behavioral|Health Education Training|8 weeks of group training regarding health education techniques.
82147|NCT01256528|Procedure|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
82148|NCT01256541|Drug|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
82764|NCT01250314|Other|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
82765|NCT01252615|Behavioral|patient only|education, behavioral strategies, psychological interventions
82766|NCT01252615|Behavioral|patient and partner intervention|education, psychological support, behavioral strategies
82767|NCT01252628|Drug|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
82768|NCT01252628|Drug|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
82769|NCT01252628|Drug|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
82770|NCT01252628|Drug|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
82771|NCT00049556|Drug|gefitinib|
82772|NCT01252641|Biological|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
82773|NCT01252667|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
82774|NCT01252667|Drug|Clofarabine|Given IV
82775|NCT01252667|Drug|Cyclosporine|Given PO
82776|NCT01252667|Other|Laboratory Biomarker Analysis|Correlative studies
82777|NCT01252667|Drug|Mycophenolate Mofetil|Given PO
82778|NCT01252667|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
82779|NCT01252667|Other|Pharmacological Study|Optional correlative studies
82780|NCT01252667|Radiation|Total-Body Irradiation|Undergo TBI
82781|NCT01252680|Biological|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
82782|NCT00001020|Biological|rgp120/HIV-1MN|
82783|NCT00049556|Other|immunohistochemistry staining method|
83127|NCT01250873|Drug|Sertraline|administered orally
81054|NCT01227265|Drug|preladenant|2 or 5 mg preladenant tablet twice daily
81055|NCT01227265|Drug|Placebo to preladenant|Placebo tablet, orally, twice daily.
81056|NCT01227278|Drug|MEDI-563|SC injection every 28 days (3 doses) and every 56 days for the next (5 doses).
81057|NCT01227278|Other|Placebo|Placebo SC injection every 28 days (first 3 doses) and every 56 days for (next 5 doses).
81058|NCT01227291|Drug|SYL040012|SYL040012 ophthalmic drops, daily single dose administration
81352|NCT01257659|Procedure|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
81353|NCT01257659|Procedure|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
81354|NCT00049946|Drug|talnetant|
81355|NCT01257672|Drug|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
81356|NCT01257672|Drug|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
81357|NCT01257672|Drug|placebo|placebo
81358|NCT01259973|Drug|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
81359|NCT01259973|Drug|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
81360|NCT01259986|Procedure|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
81361|NCT00050167|Drug|Capecitabine|1500 mg/m^2 by mouth Twice Daily x 2 Weeks
81362|NCT01259999|Dietary Supplement|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
81363|NCT01260012|Dietary Supplement|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
81364|NCT01260012|Other|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
82359|NCT00050427|Drug|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
82360|NCT01261806|Behavioral|Developmental Education for Families|
82361|NCT01261819|Device|cystoscopy|
82362|NCT01261832|Drug|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
82363|NCT01261858|Device|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
82364|NCT01254266|Behavioral|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
82365|NCT01254279|Drug|CABAZITAXEL|Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
82366|NCT01254292|Drug|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
82367|NCT01254292|Drug|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
82368|NCT01254305|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
82626|NCT01244867|Biological|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
82627|NCT01244867|Biological|Placebo|2 doses given 21 days apart of the placebo
82628|NCT01244880|Other|Saline|Saline infusion for 56 minutes
82629|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg single dose
82630|NCT01244880|Other|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
PF-02545920 10 mg tablet
82631|NCT00049101|Drug|oxaliplatin|
82632|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg tablet single dose
82633|NCT01247454|Behavioral|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
82634|NCT01247454|Behavioral|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
82149|NCT01256554|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
82150|NCT01258855|Other|Laboratory Biomarker Analysis|Correlative studies
82151|NCT01258855|Biological|Ziv-Aflibercept|Given IV
82152|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
82153|NCT01258868|Drug|Celebrex|400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
82154|NCT01258868|Biological|Tumor cell vaccine|A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
82155|NCT01258907|Drug|MLDL1278A|Single intravenous dose
82156|NCT01258907|Drug|MLDL1278A|Repeating intravenous dose
82157|NCT01258907|Drug|placebo|Repeating intravenous dose
82158|NCT01258907|Drug|statin, stable dose|Repeating oral dose
82159|NCT01258920|Drug|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
82160|NCT01258933|Drug|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
82161|NCT01258959|Procedure|Ultrasound detection of local anesthetics spread|During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
82162|NCT01258972|Device|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
82163|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
82427|NCT01259492|Drug|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
82428|NCT01259492|Drug|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
82429|NCT01261884|Behavioral|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
83128|NCT01250886|Drug|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
83129|NCT01250886|Drug|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
83130|NCT01250886|Drug|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
83131|NCT00049465|Procedure|psychosocial assessment and care|
83132|NCT01250899|Dietary Supplement|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
83133|NCT01250912|Drug|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
83134|NCT01250925|Drug|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
83135|NCT01250925|Drug|OPTI-FREE® RepleniSH®|Contact Lens care regimen
83136|NCT01250925|Drug|Clear Care®|Contact lens care regimen
83137|NCT01253486|Behavioral|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
83138|NCT01253499|Drug|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
83139|NCT01253512|Drug|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
83140|NCT01253512|Drug|Placebo|Intravenous
83141|NCT01253525|Biological|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
83142|NCT01253525|Drug|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
83143|NCT01253538|Drug|Zidovudine (ZDV)|Antepartum Arm A: 300 mg orally twice daily beginning at greater than or equal to 14 weeks gestation (at study entry) through delivery
83144|NCT00049569|Drug|etoposide|Given IV
81365|NCT01260012|Dietary Supplement|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
81366|NCT01260012|Dietary Supplement|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
81367|NCT01260025|Drug|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
81368|NCT01260064|Procedure|Open appendectomy|The subjects will have traditional open appendectomy procedure.
81369|NCT01260064|Procedure|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
81666|NCT01263197|Drug|placebo for albuterol|administered orally
81667|NCT01263197|Drug|placebo for propranolol|administered orally
81668|NCT01255631|Device|PEMF Device|The PEMF device we will use in this study is FDA approved for "adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue" (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks.
81669|NCT00049634|Drug|cyclosporine|
81670|NCT01255631|Device|Sham PEMF Device|Inactive PEMF device, delivers no PMF
81671|NCT01255644|Drug|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
81672|NCT01255657|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
81673|NCT01255670|Drug|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
81674|NCT01255683|Drug|oral corticosteroid taper|This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
81675|NCT01255696|Biological|ALV003|
81676|NCT01255696|Biological|ALV003 placebo|
81677|NCT01255709|Drug|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
81678|NCT01255709|Drug|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
82635|NCT00001016|Drug|Leucovorin calcium|
82636|NCT00049244|Drug|ixabepilone|
82637|NCT01247454|Behavioral|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
82638|NCT01247467|Other|Breast Tumor Blocks|
82639|NCT01247493|Drug|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
82640|NCT01247519|Other|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
82641|NCT01247532|Behavioral|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
82642|NCT01247545|Procedure|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
82643|NCT01247545|Procedure|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
82644|NCT01247558|Other|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for >120 days
82645|NCT01247558|Other|Not treated with Metanx®|Non-treated comparative cohort
82646|NCT01247571|Drug|Pazopanib Hydrochloride|Given PO
82986|NCT01245413|Device|SenSura|Adhesive to stoma bag
82987|NCT01245413|Device|Athena|Adhesive to stoma bag
82988|NCT01245426|Drug|GW870086 2mg|oral inhalation
82989|NCT01245426|Drug|GW870086 4mg|oral inhalation
82990|NCT01245426|Drug|GW870086 Placebo|oral inhalation
82991|NCT01245426|Drug|GW870086 1mg|oral inhalation
82992|NCT01245426|Drug|GW870086 3mg|oral inhalation
82993|NCT01245439|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
82994|NCT01245452|Drug|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
82430|NCT01261884|Behavioral|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
82431|NCT01261897|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
82432|NCT01261897|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
82433|NCT01261910|Behavioral|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
82434|NCT01261923|Drug|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
82435|NCT00050427|Drug|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
82436|NCT01261949|Device|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
82437|NCT01261949|Device|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
82438|NCT01261962|Dietary Supplement|zinc|zinc sulfate, 35 mg twice daily for 4 months
82439|NCT01261962|Other|Placebo|Placebo, One capsule, twice daily for 4 months
82440|NCT01261975|Procedure|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
82441|NCT01261975|Procedure|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
82442|NCT01261988|Device|VIPER|Comparison of ostomy systems
82443|NCT01261988|Device|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
82444|NCT01262001|Drug|FG-3019|15 mg/kg (Cohort 1 and Cohort 1-Extension) and 30 mg/kg (Cohort 2 and Cohort 2-EX) by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years..
82706|NCT01244893|Device|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
82707|NCT01244906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
82209|NCT01256593|Drug|Pregabalin (Lyrica) capsule|Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily".
82210|NCT01256619|Drug|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
82211|NCT01256632|Drug|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
82212|NCT01256645|Other|blood transfusion|application of single units of red blood cell transfusions
82213|NCT01256658|Drug|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
82214|NCT01256671|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
82215|NCT01256684|Drug|Placebo|Placebo vaginal suppository
82216|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
82217|NCT00049777|Drug|Drotrecogin Alfa (Activated)|
82218|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
82219|NCT01256697|Dietary Supplement|Alga Dunaliella Bardawil|9-cis Rich Powder
82220|NCT01256697|Dietary Supplement|Alga Dunaliella Bardawill|9-cis Rich Powder
82221|NCT01256697|Other|Sugar pill|Sugar pill
82222|NCT01256710|Device|Implantation of the Trifecta Valve|Implantation of the bioprothesis valve, Trifecta Valve
82223|NCT01256736|Drug|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
82224|NCT01256736|Drug|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
81679|NCT01255709|Drug|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
81680|NCT00049634|Drug|methotrexate|
81681|NCT01255722|Drug|iobitridol|single IV injection
81682|NCT01255722|Drug|iopromide|Single IV injection
81683|NCT01255722|Drug|iomeprol|Single IV injection
81684|NCT01255748|Radiation|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
81685|NCT01255761|Biological|Certolizumab Pegol (CZP)|400 mg subcutaneous injection at Weeks 0, 2 and 4
200 mg subcutaneous injection every two weeks, Week 6 through Week 52
81686|NCT01255774|Drug|ranibizumab|An open-label, study of intravitreally administered ranibizumab
81687|NCT01255787|Drug|Vortioxetine|Vortioxetine tablets
80733|NCT01231659|Drug|Everolimus + Letrozole|
80734|NCT01231672|Biological|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
80735|NCT01231685|Drug|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
80736|NCT01224262|Biological|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
80737|NCT01224275|Other|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
80738|NCT01224288|Procedure|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
80739|NCT01224301|Behavioral|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
80740|NCT01224301|Behavioral|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
80741|NCT01224314|Other|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
80742|NCT01224327|Biological|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
82995|NCT00049127|Other|laboratory biomarker analysis|Optional correlative studies
82996|NCT01245452|Drug|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
82997|NCT01245465|Other|Profermin|Medical Food (food for special medical purposes)
82998|NCT01245491|Other|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
82999|NCT01245504|Other|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
83000|NCT01245517|Other|Education|Dietary Phosphorus Education Program
83001|NCT01245530|Drug|Aricept|Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks
83002|NCT01245530|Drug|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks
83003|NCT01245543|Drug|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
83004|NCT01245543|Drug|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
83005|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
83006|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
83007|NCT01248078|Drug|saline solution|100cc administered before skin incision
83008|NCT01248091|Procedure|Nitroprusside Gel|10 cc nitroprusside gel
83009|NCT01248091|Procedure|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
83010|NCT01248104|Drug|Tranexamic Acid|Infusion during cardiac surgery
82086|NCT00050401|Drug|MERREM I.V. 2g as a 3 hour infusion every 8 hours|
82087|NCT01261247|Genetic|DNA analysis|Correlative studies
82088|NCT01261247|Other|flow cytometry|Correlative studies
82089|NCT01261247|Other|pharmacological study|Correlative studies
82090|NCT01261247|Other|immunohistochemistry staining method|Optional correlative studies
82091|NCT01261260|Drug|Uridine|1 gram tablets BID for 7 days
82708|NCT01244932|Drug|bupivacaine 0.5%|Patients will be given bupivacaine 0.5% in different doses (up-down study).
82709|NCT01244945|Dietary Supplement|L. reuteri DSM 17938|L. reuteri will be administered at 1x10^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10^8 CFU/die) for 90 days.
82710|NCT00001014|Drug|Leucovorin calcium|
82711|NCT00049114|Drug|doxorubicin hydrochloride|
82712|NCT01244945|Other|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
82713|NCT01244958|Biological|Rituximab|1000 mg Rituximab infusion
82714|NCT01244958|Drug|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
82715|NCT01244971|Drug|Acarbose|100mg, 3 times daily
82716|NCT01244971|Behavioral|Exercise|Moderate combined exercise, 50 minutes 3 times per week
82717|NCT01244971|Other|Exercise + Acarbose|See respective monotherapy description
82718|NCT01244984|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
82719|NCT01244984|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
82720|NCT01244997|Procedure|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
82721|NCT01245010|Other|Water|Water and education will be provided
82722|NCT00049114|Drug|cyclophosphamide|Given IV
82723|NCT01245010|Other|Education|Education
82724|NCT01245023|Procedure|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
82725|NCT01245023|Procedure|Placebo-surgery|skin incisions without laparoscopy or related procedures
82726|NCT01247649|Device|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
82727|NCT01247675|Drug|ACP-001 (TransCon PEG hGH)|s.c., weekly injection
82225|NCT01259063|Drug|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
82510|NCT01259570|Dietary Supplement|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
82511|NCT01259570|Dietary Supplement|group 3|3% fat milk wherein the VD will be in CM
82512|NCT01259570|Dietary Supplement|Group 4|Placebo: un-enriched skimmilk.
82513|NCT01259583|Procedure|CO2|CO2 insufflation
82514|NCT00050128|Device|rTMS, Magstim|
82515|NCT01259583|Procedure|Warm water|warm water irrigation
82516|NCT01259596|Behavioral|psychotherapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
82517|NCT01259609|Procedure|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
82518|NCT01259622|Drug|saline|intravenous infusion
82519|NCT01259622|Drug|K201|intravenous infusion
82520|NCT01259635|Device|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
82521|NCT01259648|Drug|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
82522|NCT01259648|Drug|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
82523|NCT01259648|Drug|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
82524|NCT01262053|Other|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
80743|NCT01224327|Drug|Conserved therapy|Oral or intravenous administration
80744|NCT01224340|Behavioral|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
80745|NCT01224340|Behavioral|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
80746|NCT00000998|Drug|Leucovorin calcium|
80747|NCT00047112|Procedure|conventional surgery|
80748|NCT01224340|Other|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
80749|NCT01224353|Drug|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
80750|NCT01224353|Other|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
80751|NCT01224366|Drug|Vildagliptin|
80752|NCT01224366|Drug|Placebo|
81059|NCT01227304|Device|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
81060|NCT00047281|Drug|thalidomide|
81061|NCT01227317|Other|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
81062|NCT01227330|Behavioral|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
81063|NCT01227330|Behavioral|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
81064|NCT01229709|Behavioral|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
81065|NCT01229722|Device|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
81066|NCT01229722|Device|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
82092|NCT01261286|Drug|verapamil|
82093|NCT01261299|Drug|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
82094|NCT01261312|Drug|SGI-110|SGI-110 subcutaneous injection administered on Days 1-5
SGI-110 subcutaneous injection administered on Days 1-5 and 8-12
82095|NCT01261312|Drug|SGI-110|SGI-110 administered weekly on Days 1, 8 and 15
SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18
82096|NCT01261325|Drug|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
82097|NCT00050401|Drug|vancomycin I.V. 1 g every 12 hours|
82098|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
82099|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
82100|NCT01261325|Drug|Antiepileptic drugs with market authorization available per country|
82101|NCT01261338|Drug|olestra|non-absorbable dietary fat
82102|NCT01261364|Behavioral|GeneSightRx|Multi-genetic pharmacogenomic panel
82103|NCT01261364|Behavioral|Treatment as usual|Treatment as usual
82104|NCT01261377|Device|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
82105|NCT01261377|Drug|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
82106|NCT01261377|Device|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
82369|NCT01254305|Drug|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
82370|NCT01254305|Drug|Placebo|Matching placebo capsules, oral administration, once daily dosing
82371|NCT01254318|Other|Standard Care|Health-care interventions will be recorded, no additional procedures outside the standard of care will be required.
83072|NCT01253330|Other|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
83073|NCT01253356|Device|IABP|Insertion of intra-aortic balloon < or = 3 hours before noncardiac surgery and maintained > or = 12-24 hours after surgery
83074|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
83075|NCT00049127|Other|pharmacological study|Optional correlative studies
83076|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
83077|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
83078|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
83079|NCT01245569|Drug|Foster® 100/6 µg/unit dose|Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).
83080|NCT01245569|Drug|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
83081|NCT01245582|Drug|oxaliplatin (SR96669)|Pharmaceutical form:injection
Route of administration: intravenous
83082|NCT01245582|Drug|capecitabine|Pharmaceutical form:tablet
Route of administration: oral
83083|NCT01245582|Drug|sorafenib|Pharmaceutical form:tablet
Route of administration: oral
83084|NCT01245595|Drug|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
83085|NCT01245595|Drug|Placebo|Normal Saline
83086|NCT00049140|Drug|EF5|
83087|NCT01245608|Drug|Polypill|Polypill taken once daily for 5 years. Each pill contains ASA 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
83088|NCT01245621|Behavioral|Later entry group|Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and
Comprehensive Palliative Care Team Assessment & Management Plan.
82525|NCT01262053|Other|Active Intervention|The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type "dd76m" to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function.
82526|NCT01262053|Other|Control|Parallel control with no intervention
82527|NCT01262066|Behavioral|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
82528|NCT01262092|Drug|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
82784|NCT01252680|Biological|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
82785|NCT01252680|Biological|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
82786|NCT01252680|Biological|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
82787|NCT01252693|Drug|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
82788|NCT01252693|Drug|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
82789|NCT01252706|Behavioral|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
82790|NCT01252719|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
82791|NCT01245036|Drug|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.<50 kg and 600 mg/day if wt. >50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
82792|NCT01245049|Biological|Boostrix PolioTM|Single dose, intramuscular administration.
82793|NCT01245049|Biological|RepevaxTM|Single dose, intramuscular administration.
82794|NCT01245049|Biological|PriorixTM|Single dose, intramuscular or subcutaneous administration.
82795|NCT01245062|Drug|GSK1120212|MEK inhibitor
81067|NCT01229735|Drug|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
81068|NCT01229735|Drug|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
81069|NCT01229748|Behavioral|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
81070|NCT01229748|Behavioral|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
81071|NCT01229748|Behavioral|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
81072|NCT00047463|Device|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
81073|NCT01229761|Drug|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
81074|NCT01229761|Drug|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
81075|NCT01229761|Behavioral|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
81370|NCT01260064|Procedure|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
81371|NCT01260090|Device|Vagus nerve stimulation;|Name of the Device:
We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).
FDA Facility Registration Number: 1644487
81372|NCT00050180|Drug|Midazolam|
81373|NCT01260090|Device|No stimulation|Vagus nerve stimulation
81374|NCT01260103|Drug|Temozolomide|Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
81375|NCT01260103|Drug|ANP Therapy|Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
81376|NCT01260129|Drug|Silodosin|Silodosin 8 mg orally, once daily after morning meal
82372|NCT01254331|Drug|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
82373|NCT01254344|Drug|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
82374|NCT00049595|Biological|filgrastim|
82375|NCT01254344|Drug|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
82376|NCT01254344|Drug|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
82377|NCT01254344|Drug|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
82378|NCT01254357|Other|Questionnaire self report|Burn specific outcome measurement and global health measurement
82379|NCT01254370|Drug|Latanoprost|0.005%
82380|NCT01254370|Drug|Travatan Z|0.004%
82381|NCT01254383|Drug|Sildenafil Tablet|Tablet, 50 mg, Single Dose
82382|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
82383|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
82384|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
82385|NCT00049595|Biological|pegfilgrastim|
82386|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
82387|NCT01254409|Biological|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
82388|NCT01257022|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
82647|NCT00049257|Drug|carboplatin|Administered Day 1 of each cycle. AUC=6.
82648|NCT01247584|Genetic|DNA analysis|
82649|NCT01247584|Genetic|mutation analysis|
83089|NCT01245621|Behavioral|Early palliative care intervention|Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and
Comprehensive Palliative Care Team Assessment & Management Plan.
83090|NCT01245634|Drug|Placebo|iv infusion every 4 weeks, 32 weeks
82164|NCT01258972|Device|POBA|Balloon angioplasty
82165|NCT01258985|Behavioral|Tai Chi|12 weeks of Tai Chi
82166|NCT01258985|Behavioral|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
82167|NCT01258998|Drug|Akt inhibitor MK2206|Given PO
82168|NCT01258998|Other|laboratory biomarker analysis|Correlative studies
82169|NCT01259011|Behavioral|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
82170|NCT01259024|Device|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
82171|NCT01259050|Drug|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
82172|NCT01261390|Behavioral|Conservative Medical Therapy|All participants will meet with a research assistant who will provide ~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
82173|NCT00001025|Drug|Zidovudine|
82174|NCT00050401|Drug|tobramycin I.V. 5 mg/kg every 24 hours|
82175|NCT01261390|Behavioral|Active PAP with Behavioral Modification|In addition to receiving CMT and CPAP specialist-guided adherence support, participants randomized to active PAP with the BPA intervention would meet with a behavioral interventionist at the time of PAP prescription and one week later. Participants also would speak with the behavioral interventionist 6 times over the course of the study: at 3 weeks, 4 weeks, 8 weeks, 12 weeks, 5 months and 8 months after beginning CPAP, or until study follow-up is concluded. The duration of the initial behavioral promotion intervention is estimated to be 45 minutes long, with subsequent interventions 10 to 15 minutes long. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
82796|NCT01245062|Drug|Chemotherapy|Investigator Choice of DTIC or paclitaxel
82797|NCT01245075|Other|Deep brain stimulation|Deep brain stimulation on
82798|NCT00049114|Drug|tipifarnib|Given orally
82799|NCT01245075|Other|Placebo|deep brain stimulation off
82800|NCT01245088|Drug|chondroitin sulfate|400 mg orally three times daily for 8 weeks
82801|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
82802|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
83145|NCT01253538|Drug|Nevirapine (NVP)|For women, 200 mg orally (one single dose) at onset of labor; for infants with birth weight greater than or equal to 2,500 gm: 1.5 mL suspension orally once a day beginning as soon as possible after birth through 42 days of age or through the Week 6 study visit, whichever is later; for infants with a birth weight of 2,000 to 2, 499 gm: 1.0 mL suspension orally once a day beginning as soon as possible after birth through 42 days of age or until the Week 6 study visit, whichever is later; for infants with a birth weight of less than 2,000 gm: 2 mg/kg based on birth weight orally once a day beginning as soon as possible after birth through 3 weeks of age and 4 mg/kg based on weight at 3 weeks of age orally once a day beginning at 3 weeks of age through 42 days of age or through the Week 6 visit, whichever is later.
83146|NCT01253538|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|Antepartum Arm A: 200 mg/300 mg x 2 tablets for a total dose of 400 mg/600 mg orally once ideally at onset of labor or as soon as possible thereafter; 200 mg/300 mg (1 tablet) orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
Antepartum Arm C: 200 mg/300 mg orally once daily beginning at greater than or equal to 14 weeks gestation (at study entry) until Week 1 postpartum visit (up to 14 days)
83147|NCT01253538|Drug|Lamivudine-Zidovudine (3TC-ZDV)|Antepartum Arm B: 150 mg/300 mg orally twice daily beginning at greater than or equal to 14 weeks gestation (at study entry) through delivery and until 1 week postpartum visit (up to 14 days)
83148|NCT01253538|Drug|Lopinavir-ritonavir (LPV-RTV)|Antepartum Arm B: 200 mg/50 mg x 2 tablets for a dose of 400 mg/100 mg orally twice daily beginning at >/= 14 weeks gestation (at study entry) through 28 weeks gestation (through second trimester); 200 mg/50 mg x 3 tablets for a dose of 600 mg/150 mg orally twice daily beginning at >/= 28 weeks gestation or at next visit (during third trimester) through delivery; 200 mg/50 mg x 2 tablets for a dose of 400 mg/100 mg orally twice daily after delivery until Week 1 postpartum visit (up to 14 days).
Antepartum Arm C: 200 mg/50 mg x 2 tablets for a dose of 400 mg/100 mg orally twice daily beginning at > 14 weeks gestation (at study entry) through 28 weeks gestation (through second trimester); 200 mg/50 mg x 3 tablets for a dose of 600 mg/150 mg orally twice daily beginning > 28 weeks gestation, or at the next visit (during third trimester) through delivery; 200 mg/50 mg x 2 tablets for a dose of 400 mg/100 mg orally twice daily after delivery until week 1 postpartum visit (up to 14 days).
83149|NCT01253551|Drug|Treatment sequence AB|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
83150|NCT01253551|Drug|Treatment sequence BA|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
83151|NCT01253564|Drug|RO5185426|960 mg b.i.d. orally
81377|NCT01262560|Drug|Viscous lidocaine and magnesium aluminum oxide (Maalox®); Liquid or solid oxycodone|Standard supportive care
81378|NCT01262573|Procedure|Closure of vaginal cuff|Closure of the vaginal cuff
81379|NCT01262586|Drug|Vildagliptin|
81380|NCT01262586|Drug|Glimepiride|
81381|NCT01262599|Device|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
81382|NCT01262599|Device|Ivivi Torino II PEMF Device|The PEMF device to be employed in this study is FDA cleared for "adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue" (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours.
81383|NCT01262612|Drug|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
81384|NCT01262612|Drug|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
81385|NCT01262625|Device|CCTA|Complete diagnostic CCTA per protocol specifications.
81386|NCT00050531|Drug|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
81688|NCT01255787|Drug|Placebo|Vortioxetine placebo-matching tablets
81689|NCT01255800|Drug|IPI-926 and Cetuximab|Patients will receive Cetuximab IV every week.
Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day.
81690|NCT01255813|Device|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
81691|NCT00049634|Procedure|in vitro-treated peripheral blood stem cell transplantation|
81692|NCT01255813|Device|Stimulation (Full)|Stimulation applied above the perception threshold
81693|NCT01255813|Other|Control|No stimulation applied
81694|NCT01258192|Drug|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
82650|NCT01247584|Genetic|polymerase chain reaction|
82651|NCT01247584|Other|laboratory biomarker analysis|
82652|NCT01247623|Biological|GV1001|
82653|NCT01247636|Other|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
82654|NCT01247636|Other|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
82655|NCT01250054|Device|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
82656|NCT01250067|Procedure|Motor-related cortical potential (Procedure)|
82657|NCT01250080|Dietary Supplement|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
82658|NCT01250080|Other|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
82659|NCT01250093|Device|acupuncture|
82660|NCT01250106|Dietary Supplement|Lactobacillus reuteri|twice daily
82661|NCT01250119|Drug|erlotinib [Tarceva]|150 mg daily, orally
82662|NCT01250132|Other|Biological and behavioral explorations|Blood dosages:
biochemistry
pituitary gland
somatotropic axis
corticotropic axis
gonadotropic axis
thyrotropic axis
antidiuretic axis
Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)
82663|NCT01250145|Drug|LY333334|Transdermal patch
82664|NCT00049413|Biological|rituximab|
82665|NCT01250145|Drug|Placebo|Transdermal patch
83011|NCT00049296|Drug|docetaxel|Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined.
83012|NCT01248104|Drug|Aminocaproic Acid|Infusion during cardiac surgery
83013|NCT01248117|Drug|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
82176|NCT01261390|Device|Sham PAP|In addition to receiving CMT, participants in this treatment arm will receive a sham CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.
82177|NCT01261390|Device|Active PAP with RT Support|In addition to receiving CMT, participants would be scheduled to meet with the CPAP specialist again one week after initiating PAP to reinforce PAP use and make any adjustments in the mask or pressure setting. Thereafter, the CPAP specialist would meet with the participant in person at months 1, 3, 6, and 9, using the available data from the PAP monitor on PAP use, mask leak, and residual AHI to assist with troubleshooting. Adjustments to equipment (mask replacement, use of chin strap, addition of expiratory pressure release) would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the CPAP specialist would last ~ 15 minutes.
82445|NCT01262014|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
82446|NCT00050440|Drug|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
82447|NCT01262027|Drug|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
82448|NCT01262040|Other|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
82449|NCT01254409|Other|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
82450|NCT01254422|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous
82451|NCT01254422|Biological|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous
82452|NCT01254435|Procedure|Colonoscopy|Recording of colonoscopic extubation
82453|NCT01254448|Drug|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
82454|NCT01254448|Drug|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
82455|NCT01254461|Drug|AZD1981|100 mg per oral, twice daily for 8 days
82456|NCT01254461|Drug|AZD1981|4x100 mg per oral, twice daily for 8 days
82457|NCT00049595|Drug|ABVD regimen|
82458|NCT01254461|Drug|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
82459|NCT01254474|Device|Cardiac chambers mapping with MAP 4|
83152|NCT01253577|Device|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
83153|NCT01245673|Other|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion ~day 2 post-transplant. The target number of costimulated T-cells for infusion will be ~ 5 x 10e10 T-cells total in 100-500 mL total volume. On the designated infusion date, the T-cells will be harvested.
83154|NCT00001015|Drug|Ribavirin|
83155|NCT00049140|Other|bioluminescence|
83156|NCT01245673|Drug|Lenalidomide|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose lenalidomide for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
83157|NCT01245673|Biological|MAGE-A3, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF [+ coinjection of 2mg of Hiltonol®(Poly-ICLC)]
81942|NCT01256203|Drug|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
81943|NCT00049673|Drug|thalidomide|Given orally
81944|NCT01256203|Procedure|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
81945|NCT01256216|Device|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
81946|NCT01256229|Device|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
81947|NCT01256229|Device|hearing aids|This is the conventional therapy for deaf children with developmental delays.
81948|NCT01256242|Device|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
81949|NCT01256242|Procedure|Standard Suture Repair|standard suture repair
81950|NCT01256268|Drug|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
81951|NCT01256268|Drug|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
81952|NCT01256268|Drug|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
81695|NCT01258205|Drug|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
81696|NCT01258218|Device|Implantation of an Accent MRI device|Implantation of an Accent MRI device
81697|NCT01258257|Procedure|Insertion of a lumbar drain|In patients in the LD group, after insertion of the drain CSF is drained slowly and steadily at a rate of approximately 5 ml per hour. This leads to a planned daily CSF drainage of about 120 ml per day via lumbar route. To facilitate accuracy of drainage, regular drainage control every other hour and stopping in case of unwarranted excess drainage is strongly recommended by the principal investigators. In case of neurological decline suspiciously related to the lumbar drainage, the drain is closed immediately and may be gradually restarted after 12 to 24 hours, after performing a CCT scan. The drain is planned to remain in place until the control angiography on day 7 to 10 after the initial hemorrhage.
81698|NCT01258270|Procedure|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
81699|NCT01258270|Procedure|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
81700|NCT01258283|Other|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
81701|NCT00050011|Drug|Letrozole|Participants received Letrozole 2.5 mg daily.
81702|NCT01258296|Drug|Fentanyl|25 mcg/hr transdermal patch
81703|NCT01258296|Drug|Inactive patch|placebo patch (no drug)
81704|NCT01258309|Drug|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
81705|NCT01258309|Drug|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
80753|NCT01224379|Device|Topping off system|The intervention group will receive a "topping off" system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion).
80754|NCT01224379|Device|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
80755|NCT01224392|Other|Chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
80756|NCT01224392|Radiation|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
80757|NCT01224405|Drug|Docetaxel + LH-RH analogues|Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.
In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration.
83014|NCT01248130|Drug|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
83015|NCT01248143|Dietary Supplement|Green tea|9 gram per day
83016|NCT01248143|Dietary Supplement|FPP|2 sachets twice daily
83017|NCT01248195|Drug|Amisulpride open label|4-week open label amisulpride treatment
83018|NCT01248195|Drug|6-week amisulpride double blind treatment|6-week amisulpride double blind treatment
83019|NCT01248195|Drug|6-week olanzapine double blind treatment|6-week olanzapine double blind treatment
83020|NCT01248195|Drug|12-week clozapine open-label treatment|12-week clozapine open-label treatment
83021|NCT01248195|Behavioral|Psychosocial intervention|Psychosocial intervention
83022|NCT00001017|Drug|Fluconazole|
83023|NCT00049296|Drug|thalidomide|Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined.
83024|NCT01248208|Biological|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
83025|NCT00049439|Drug|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
83026|NCT01250652|Drug|Levocetirizine|20 mg levocetirizine for 5 days
83027|NCT01250652|Drug|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
83028|NCT01250691|Other|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
83029|NCT01250717|Drug|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
82460|NCT01254513|Drug|Docetaxel every 3 weeks + Prednisone|Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks
Prednisone 10 mg/day continuously
82461|NCT01254513|Drug|Docetaxel weekly+ Prednisone|Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)
Prednisone 10 mg/day continuously
82462|NCT01254526|Drug|GDC-0980|Oral repeating dose
82463|NCT01254526|Drug|bevacizumab|Intravenous repeating dose
82464|NCT01254526|Drug|paclitaxel|Intravenous repeating dose
82465|NCT01254539|Procedure|Laminectomy and bone marrow stem cells transplantation|Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.
T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
82728|NCT01247675|Drug|ACP-001 (TransCon PEG hGH)|s.c., weekly injection
82729|NCT00049257|Drug|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
82730|NCT01247675|Drug|ACP-001 (TransCon PEG hGH)|s.c., weekly injection
82731|NCT01247675|Drug|Human Growth Hormone|s.c., daily injection over 28 days
82732|NCT01247688|Drug|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
82733|NCT01247688|Drug|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
82734|NCT01247688|Radiation|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
82735|NCT01247688|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
82736|NCT01247701|Drug|Busulfan|Busulfan dosing will be as follows: Patients < 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients > 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
82737|NCT01247701|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours. The total dose to be given over 4 days is 200 mg/kg.
82738|NCT01247701|Drug|Fludarabine|Fludarabine 40 mg/m^2 will be given IV daily over 1 hour on Days -3, -2 and -1.
82739|NCT01247701|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
82740|NCT00049283|Drug|erlotinib hydrochloride|Given orally
82741|NCT01247714|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
81953|NCT01256281|Procedure|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
81954|NCT00049686|Drug|laromustine|
81955|NCT01256294|Drug|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
81956|NCT01256294|Drug|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
81957|NCT01256307|Other|training and educational program|8 weeks
81958|NCT01256307|Other|educational program|8 weeks
81959|NCT01256320|Other|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
81960|NCT01256320|Other|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
81001|NCT01232036|Drug|Glucophage 500mg|Single Oral Dose of
81002|NCT01232036|Drug|HL-018 500mg|Single Oral Dose of
81003|NCT01232036|Other|No administration of Drug|
81004|NCT01232049|Drug|Multiple Oral Dose of|Pitavastatin 4mg
81005|NCT01232049|Drug|Multiple Oral Dose of|Valsartan 320mg
81006|NCT01232075|Drug|Extended letrozole regimen|Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .
Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .
Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.
Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .
81007|NCT00047814|Drug|FK788|
81008|NCT01232075|Drug|Clomiphene citrate regimen|Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.
Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .
Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.
Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .
81009|NCT01232101|Device|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
81010|NCT01232127|Drug|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
80758|NCT01226667|Drug|Pregabalin|Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.
Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly.
80759|NCT00001001|Drug|Zidovudine|
80760|NCT00047268|Drug|mercaptopurine|
80761|NCT01226680|Drug|Tasocitinib|0.005% QD for 12 weeks
80762|NCT01226680|Drug|Tasocitinib|0.003% QD for 12 weeks
80763|NCT01226680|Drug|vehicle for Tasocitinib|vehicle QD for 12 weeks
80764|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
80765|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
80766|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
80767|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
80768|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
80769|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
80770|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
80771|NCT00047268|Other|laboratory biomarker analysis|
80772|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
80773|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
80774|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
81076|NCT01229761|Behavioral|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
81077|NCT01229774|Drug|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
81078|NCT01229774|Drug|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
82107|NCT01253720|Behavioral|PACE CALL/Fit4Life|The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.
The Fit4Life intervention includes:
Web-based weight loss program Text and Picture messages Counseling Calls Health Coach
82108|NCT01253733|Behavioral|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
82109|NCT01253759|Procedure|TTT + ICG-based PDT|
82110|NCT01253798|Other|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
82111|NCT01253811|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
82112|NCT01253824|Drug|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
82113|NCT01253824|Drug|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
82114|NCT01253837|Drug|L19TNFa|Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.
Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.
Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles.
82115|NCT01253863|Other|exploration|exploration of wound for determining damaged tissue
82116|NCT01253876|Dietary Supplement|soy milk, Caw's milk|
82117|NCT00049569|Drug|therapeutic hydrocortisone|Given IT
82118|NCT01253889|Drug|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
82119|NCT01253889|Other|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
82120|NCT01253902|Drug|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
82742|NCT01247714|Dietary Supplement|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
82743|NCT01247714|Dietary Supplement|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
82744|NCT01247714|Dietary Supplement|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
82745|NCT01247740|Drug|NuTRIflex Lipid peri|parenteral nutrition
82746|NCT01247740|Drug|compounded monobag|parenteral nutrition
82747|NCT01247753|Behavioral|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
82748|NCT01247779|Procedure|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
83091|NCT01245634|Drug|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
83092|NCT01245647|Drug|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
83093|NCT01245647|Other|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
83094|NCT01245660|Drug|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
83095|NCT01245673|Biological|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|On day +2 all patients will receive ~ 5 x 10e10 costimulated T-cells which have been primed in vivo with MAGE-A3/ Hiltonol® and PCV.
83096|NCT01248208|Biological|Intramuscular influenza injection ("flu shot")|Subjects < 2 years or > 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.
Age 6-36 months: 0.25 mL IM x 1; Age >36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose.
83097|NCT01248221|Drug|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
83098|NCT01248234|Drug|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
81011|NCT01232127|Drug|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
81012|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
81013|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
81014|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
81015|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
81016|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
81017|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
81018|NCT00047827|Drug|Micafungin|IV
81019|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
81020|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
81021|NCT01224756|Drug|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
81310|NCT01254838|Biological|HLA-A02 restricted HIG2|
81311|NCT01254851|Behavioral|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
81312|NCT01254864|Drug|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
81313|NCT01254864|Drug|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
81314|NCT01254864|Drug|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
81315|NCT01254864|Drug|Dasatinib|100 mg by mouth each day of a 28 day cycle.
81316|NCT01254877|Drug|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
81317|NCT00001022|Drug|Zidovudine|
81318|NCT00049595|Drug|procarbazine hydrochloride|
81319|NCT01254877|Drug|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
81320|NCT01254877|Drug|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
81079|NCT01229800|Drug|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
81080|NCT01232140|Other|CRP-guided antibiotic treatment|If CRP> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
81081|NCT01232153|Device|Non invasive ventilation|Non invasive ventilation
81082|NCT01232166|Other|Auscultation|
81083|NCT01232166|Other|Observation of symmetric chest movements|
81084|NCT01232166|Other|Tube depth|
81085|NCT01232166|Other|All three|
81086|NCT01232179|Procedure|conventional prp|pan retinal photocoagulation
81087|NCT01232179|Procedure|targeted prp|1200-1600 spot in far periphery retin, anterior equator
81088|NCT00047827|Drug|Liposomal Amphotericin B|IV
81089|NCT01232192|Behavioral|antenatal model|Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:
Midwife training
Pregnant women campaigning
Early detection with self pH detection
Treatment of bacterial vaginosis
81090|NCT01232205|Dietary Supplement|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
81091|NCT01232205|Dietary Supplement|Control|supplementation with milk
81092|NCT01232218|Other|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
81093|NCT01232218|Other|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
81387|NCT01262625|Device|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
82121|NCT01253902|Drug|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
82389|NCT01257035|Other|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
82390|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram on visit 5 single dose
82391|NCT00049790|Drug|recombinant human Angiostatin protein|
82392|NCT01257048|Drug|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
82393|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
82394|NCT01257061|Drug|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
82395|NCT01257061|Drug|Group 2|Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
82396|NCT01257074|Drug|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
82397|NCT01257074|Drug|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
82398|NCT01257087|Drug|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
82399|NCT01257113|Other|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
82400|NCT01257113|Other|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
82401|NCT01257126|Drug|diclofenac potassium|
82402|NCT00049790|Drug|paclitaxel|
82403|NCT01257126|Drug|nimesulide|
82404|NCT01257139|Procedure|Dual-agent therapy or docetaxel alone or best supportive care|ARM B: (245 patients)
Treatment if the SGS screening test is negative:
non epidermoid tumor:
Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.
epidermoid tumor:
Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management.
82405|NCT01257165|Drug|Zopiclone|Zopiclone pill 5 or 10 mg, given orally as a single dose.
83099|NCT01248234|Drug|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
83100|NCT01248234|Drug|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
83101|NCT01248247|Drug|Erlotinib|150 mg by mouth each day of a 28 day cycle.
83102|NCT01248247|Drug|AZD6244|100 mg by mouth daily of a 28 day cycle.
83103|NCT01248247|Drug|MK-2206|100 mg by mouth every week of a 28 day cycle.
83104|NCT01248247|Drug|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
83105|NCT00049309|Dietary Supplement|dietary intervention|
83106|NCT01248247|Drug|Erlotinib|150 mg by mouth daily of a 28 day cycle.
83107|NCT01248247|Drug|MK-2206|135 mg by mouth every week of a 28 day cycle.
83108|NCT01248260|Dietary Supplement|Folic Acid|4mg of higher strength folic acid once a day until delivery
82178|NCT01261403|Biological|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
82179|NCT01261403|Drug|Vehicle Controlled Placebo|Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7
Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7
82180|NCT01261416|Drug|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
82181|NCT01261429|Drug|Tasigna|The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.
The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes.
82182|NCT01261442|Procedure|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
82183|NCT01261455|Procedure|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
82184|NCT01253941|Other|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
81321|NCT01254890|Drug|Azacitidine|75 mg/m2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
81322|NCT01254890|Drug|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
81323|NCT01254903|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 Gy to spine in single session of radiation treatment.
81324|NCT01254929|Device|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
81325|NCT01254929|Device|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
81326|NCT01254942|Other|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
81327|NCT01254942|Other|Usual Care|
81328|NCT01254955|Biological|H1N1 vaccine Pandemrix|
81329|NCT00049595|Drug|vinblastine sulfate|
81330|NCT01254981|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
81331|NCT01254994|Drug|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
81620|NCT01260441|Other|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
81621|NCT01260454|Drug|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
81622|NCT01260467|Drug|memantine|10 milligrams orally twice a day
81623|NCT01260480|Other|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of [18F]-ML-10. The dose for each [18F]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
81624|NCT01260493|Other|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
81625|NCT00050232|Drug|AVP-923|
81626|NCT01260506|Drug|VB-111|
81627|NCT01260506|Drug|Bevacizumab|Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
81628|NCT01260519|Drug|Heparin|unfractionated heparin 2000 unites
81388|NCT01262638|Drug|ETC-1002|ETC-1002 daily for 12 weeks
81389|NCT01262638|Drug|Placebo|Placebo daily for 12 weeks
81390|NCT01262651|Drug|Sativex®|Administered orally with a spray into cheek (100 μl oromucosal spray administered twice daily up to a maximum of 10 sprays per day)
81391|NCT01262651|Drug|Placebo (GA-0034)|Administered orally with a spray into cheek
81392|NCT01262664|Drug|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
81393|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
81394|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
81395|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
81396|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
81397|NCT00050531|Drug|Sargramostim (GM-CSF)|125 mcg/m^2 three times per week subcutaneously.
81398|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
81399|NCT01255007|Other|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
81400|NCT01255020|Drug|α-Keto Acid with restricted protein diet|α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.
Restricted Protein Diet: Diet contain protein 1.0g/kg/d
81401|NCT01255020|Drug|Placebo plus restricted protein diet|placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.
Diet contain protein 1.0 g/kg/d.
81402|NCT01255033|Device|Monitoring of tissular oxygenation|Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices
Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device
81403|NCT01255046|Drug|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
81404|NCT01255046|Drug|STA-1|300mg/tab, 2 tab/tid for 72 weeks
81405|NCT01255046|Drug|placebo|2 tab/tid for 72 weeks
81406|NCT00049595|Drug|vincristine sulfate|
81407|NCT01255072|Procedure|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
82406|NCT01257165|Drug|Ethanol|50 mg per 70 kg body weight, given orally as a single dose
82407|NCT01257165|Drug|Placebo pill|Placebo pill identical to zopiclone pill, given orally as a single dose
82408|NCT01257165|Drug|Placebo drink|Placebo drink, given orally as a single dose
82666|NCT01250158|Device|Liver-PILP kit|Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.
The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.
The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.
The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen.
82667|NCT01250171|Biological|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
82668|NCT01250171|Biological|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
82669|NCT01250171|Biological|Placebo|The placebo solution for infusion contained 5% glucose.
82670|NCT01250184|Other|Physical therapy|Twelve sessions (3 per week)
82671|NCT01250184|Drug|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
82672|NCT01250184|Other|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
82673|NCT01250197|Drug|AR-12286|Ophthalmic Solution
82674|NCT01250210|Drug|levonorgestrel and ethinyl estradiol|pregnancy prevention
82675|NCT00049413|Drug|cyclophosphamide|
82676|NCT01250236|Drug|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
82677|NCT01250236|Drug|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
82678|NCT01250249|Biological|BCG Vaccine IP - Serum Institute of India|0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
82679|NCT01252329|Procedure|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
82680|NCT01252342|Drug|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
82185|NCT01253967|Procedure|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
82186|NCT00049582|Drug|decitabine|Given IV
82187|NCT01253967|Other|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
82188|NCT01253980|Drug|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
82189|NCT01253980|Drug|Placebo|Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.
Dose 20-30mg/kg 8 hourly for 5 days
82190|NCT01254006|Drug|forskolin, rutin and vitamins B1 and B2|
82191|NCT01254019|Drug|GSK2402968 6mg/kg/week|subcutaneous
82192|NCT01254045|Drug|placebo|intranasal placebo (48 international units)
82193|NCT01254045|Drug|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
82194|NCT01254045|Drug|oxytocin 48IU|intranasal oxytocin (48 international units)
82466|NCT01254539|Procedure|Intrathecal infusion of autologous bone marrow stem cells|Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.
Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
82467|NCT01254539|Procedure|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
82468|NCT00049595|Drug|BEACOPP regimen|
82469|NCT01254552|Drug|Iobitridol|Xenetix 350
82470|NCT01254565|Drug|KAI-4169|Subjects will be randomly assigned to receive KAI-4169 as an intravenous bolus three times weekly with hemodialysis for four weeks
82471|NCT01254565|Drug|Placebo|Subjects will be randomly assigned to receive placebo formulation as an intravenous bolus three times weekly with hemodialysis for four weeks
82472|NCT01254578|Other|Laboratory Biomarker Analysis|Correlative studies
82473|NCT01254578|Drug|Lenalidomide|Given orally
82474|NCT01254578|Other|Pharmacological Study|Correlative studies
82475|NCT01254591|Other|18F-fluoromisonidazole|
82476|NCT01257178|Drug|LY2624803|Administered orally
81629|NCT01260545|Drug|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
81630|NCT01260558|Device|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
81631|NCT01260558|Device|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
81632|NCT01260571|Drug|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
81633|NCT01260584|Drug|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
81634|NCT01260584|Drug|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
81635|NCT01260597|Behavioral|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
81636|NCT00050245|Drug|Rituximab|
81637|NCT01260597|Behavioral|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
81638|NCT01263093|Drug|Clopidogrel|Administered orally
81639|NCT01263093|Drug|LY2216684 + clopidogrel|Administered orally
81640|NCT01263106|Drug|LY2216684|Administered orally
81961|NCT01256346|Device|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
81962|NCT01258634|Drug|Mesna|Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)
Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)
Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)
81963|NCT01258634|Drug|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is <0.1 uM
81964|NCT01258647|Dietary Supplement|caterpillar cereal|A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
81408|NCT01255072|Procedure|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
81706|NCT01258322|Drug|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
81707|NCT01258335|Dietary Supplement|Omega 3|Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
81708|NCT01258335|Other|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
81709|NCT01258348|Drug|Drug: LY573636-sodium|Patient specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on day 4 of a 42 day (6 week) cycle.
Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of patients enrolled after MTD will receive albumin-tailored doses.
Patients may continue on treatment until clinical or objective disease progression.
81710|NCT01258348|Drug|Sunitinib|37.5 mg, administered orally, daily for 42 days (6 weeks). Patients may continue on treatment until clinical or objective disease progression.
81711|NCT01258361|Procedure|echocardiography|Echocardiography is performed for all patients
81712|NCT00001023|Drug|Azithromycin|
81713|NCT00050037|Procedure|CBT|
81714|NCT01260610|Drug|Tenofovir|300 mg of Tenofovir daily
81715|NCT01260610|Drug|Telbivudine|600 mg of Telbivudine daily
81716|NCT01260610|Drug|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
81717|NCT01260623|Drug|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
81718|NCT01260636|Drug|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
81719|NCT01260636|Drug|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
81720|NCT01260649|Drug|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg), followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
81721|NCT01260662|Drug|Propofol|1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
81722|NCT01260662|Drug|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
81723|NCT00001024|Drug|Didanosine|
82681|NCT01252342|Drug|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
82682|NCT01252355|Drug|Teriflunomide|Film-coated tablet
Oral administration
82683|NCT01252355|Drug|Placebo (for teriflunomide)|Film-coated tablet
Oral administration
82684|NCT01252355|Drug|Interferon-beta (IFN-beta)|Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.
Administration according to the package insert.
82685|NCT00049543|Other|placebo|Given PO
83030|NCT01250717|Drug|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
83031|NCT01250717|Drug|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
83032|NCT01250717|Drug|Zoladex|Given subcutaneously for 4 doses every three months
83033|NCT01250717|Drug|Casodex|Taken orally once a day for 6 months
83034|NCT01250717|Procedure|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
83035|NCT01250730|Drug|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
83036|NCT00049452|Drug|zoledronic acid|
83037|NCT01250730|Drug|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
83038|NCT01250730|Drug|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
83039|NCT01250743|Dietary Supplement|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
83040|NCT01250756|Biological|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
83041|NCT01250756|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
83042|NCT01250756|Biological|DTaP|0.5 mL per dose, 4 doses
83043|NCT01250769|Device|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
83044|NCT01250769|Device|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
83045|NCT01250782|Drug|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
82477|NCT01257191|Drug|Carbon Black|source: commercial
82478|NCT01257191|Drug|Diesel Exhaust Particles|source: diesel engine
82479|NCT01257191|Drug|Fine Concentrated Ambient Particles|source: concentrated ambient air
82480|NCT00049790|Drug|carboplatin|
82481|NCT01257191|Drug|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
82482|NCT01257191|Drug|Saline|Saline solution
82483|NCT01257204|Drug|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
82484|NCT01257204|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
82485|NCT01257204|Drug|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
82486|NCT01257204|Drug|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
82487|NCT01257230|Drug|tiotropium Respimat low dose|IMP
82488|NCT01257230|Drug|placebo Respimat|placebo representing comparator
82489|NCT01257230|Drug|tiotropium Respimat high dose|IMP
82490|NCT01257243|Drug|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
82749|NCT01247779|Procedure|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
82750|NCT01250262|Other|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
82751|NCT01250262|Other|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
82752|NCT01250262|Other|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
82753|NCT01250275|Other|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
81965|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
81966|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
81967|NCT01258673|Drug|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
81968|NCT01258673|Drug|Fimasartan|Fimasartan 60mg, 120mg
81969|NCT01258686|Drug|Silymarin|700mg thrice daily
81970|NCT01258686|Drug|Placebo|Placebo 700mg thrice daily
81971|NCT01258699|Drug|Thiocacid HR Tab 600mg|600mg for 1 day
81972|NCT00050076|Drug|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
81973|NCT01258699|Drug|BK-C-0701 320mg|320mg for 1 day
81974|NCT01258699|Drug|BK-C-0701 480mg|480mg for 1 day
81975|NCT01258712|Drug|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
81976|NCT01258712|Drug|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
81977|NCT01258725|Procedure|amnioinfusion procedure|Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
81022|NCT01224769|Drug|bendamustine +/- rituximab|
81023|NCT01224795|Drug|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
81024|NCT01224795|Drug|Placebo Comparator|Placebo Peramivir, administered intravenously.
81025|NCT01224808|Biological|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
81724|NCT00050271|Drug|Acetyl-L-carnitine|
81725|NCT01260662|Drug|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
81726|NCT01260675|Drug|Buprenorphine HCl/Naloxone HCl|
81727|NCT01260688|Drug|cediranib maleate|Given orally
80775|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
80776|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
80777|NCT01226706|Drug|botulinum toxin Type A|Botulinum toxin Type A 100U injected into the detrusor at Day 1
80778|NCT01226706|Drug|Placebo|Placebo injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
80779|NCT01226719|Drug|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
80780|NCT01226719|Drug|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
80781|NCT01226719|Drug|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
80782|NCT00047268|Procedure|allogeneic bone marrow transplantation|
80783|NCT01226719|Drug|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
80784|NCT01226719|Drug|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
80785|NCT01226732|Drug|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
80786|NCT00047411|Other|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
80787|NCT01229228|Drug|Naprosyn|single dose
80788|NCT01229228|Drug|Naprosyn|single dose
80789|NCT01229228|Drug|Placebo|single dose
80790|NCT01229241|Drug|local anesthetic|postoperative 48h epidural continuous infusion,
ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml
levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml
80791|NCT01229254|Drug|Amiodarone Group|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
80792|NCT01229254|Drug|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
83046|NCT01250782|Drug|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
83047|NCT00049465|Procedure|fatigue assessment and management|
83048|NCT01250795|Biological|HAI-05 Influenza Vaccine|injection, vaccine, twice every 3 weeks
83049|NCT01250795|Biological|HAI-05|injection, twice 3 weeks apart
83050|NCT01250795|Biological|HAI-05|vaccine injection, 2 doses, 3 weeks apart
83051|NCT01250795|Biological|HAI-05|vaccine injection 2 doses 3 weeks apart
83052|NCT01250795|Biological|HAI-05|placebo saline,
83053|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
82122|NCT01253902|Drug|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
82123|NCT01253915|Drug|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
82124|NCT01253915|Drug|Placebo|10 sec/nostril up to 4 times to treat a migraine
82125|NCT01253928|Drug|Pioglitazone|45mg qd for 4 months
82126|NCT01256411|Drug|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
82127|NCT01256411|Drug|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
82128|NCT01256411|Drug|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
82129|NCT01256424|Drug|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
82130|NCT01256424|Drug|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
82131|NCT00049751|Drug|Adalimumab|
82132|NCT01256424|Drug|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
82133|NCT01256424|Drug|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
82134|NCT01256437|Drug|Threolone ointment|ointment once daily for 1 month
82754|NCT01250275|Other|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
82755|NCT01250275|Other|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
82756|NCT01250275|Other|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
82757|NCT00049413|Drug|pentostatin|
82758|NCT01250275|Other|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
82759|NCT01250275|Other|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
82760|NCT01250275|Other|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
82761|NCT01250288|Other|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients & their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
83109|NCT01248273|Biological|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
83110|NCT01248286|Other|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
83111|NCT01248286|Other|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
83112|NCT01248299|Drug|FU-CDDP|every 21 days:
Fluoro-uracil [800 mg/m2, day 1 to day 5]
CisPlatin [75 mg/m2, day 1 or day 2]
83113|NCT01248299|Drug|LV5FU2-CDDP|every 14 days:
Elvorin [200 mg/m2, 2h IV, day 1 and day 2]
Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]
Fluoro-uracil [600 mg/m2, 22h continous infusion, day 1 and day 2]
CisPlatin [50 mg/m2, day 2]
81026|NCT01224821|Biological|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
81027|NCT01224834|Drug|Sublingual tablet of ragweed pollen allergen extract|administered once a day over 10 days
81028|NCT00047138|Drug|cyclophosphamide|
81029|NCT01224847|Drug|Tetracaine|1 gtt
81030|NCT01224847|Drug|Cocaine|1 gtt
81031|NCT01224847|Drug|Lidocaine|Lidocaine soaked pledget
81032|NCT01224860|Drug|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
81033|NCT01224860|Drug|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
81034|NCT01224886|Behavioral|Physical activity|Supervised exercise intervention
81035|NCT01224899|Procedure|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
81036|NCT01224912|Behavioral|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
81037|NCT01224925|Procedure|direct pulp capping over carious exposure|Dycal: covered with Fuji IX
81038|NCT01224925|Procedure|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, FujiIX
81039|NCT00047138|Drug|doxorubicin hydrochloride|
81332|NCT01254994|Drug|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
81333|NCT01257516|Drug|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
80793|NCT01229254|Drug|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
80794|NCT01229267|Biological|V212|0.5-mL subcutaneous injection administered ~30days (60 to 5 days) prior to HCT. Doses 2 through 4 will be administered 30, 60 and 90 days post-HCT.
80795|NCT01229267|Biological|Matching placebo|0.5-mL subcutaneous injection administered ~30days (60 to 5 days) prior to HCT. Doses 2 through 4 will be administered 30, 60 and 90 days post-HCT.
80796|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of darifenacin
80797|NCT00047411|Device|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
81094|NCT01232231|Drug|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
81095|NCT01232231|Behavioral|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
81096|NCT01232244|Other|GLP-1 infusion|1 pmol/kg/min
81097|NCT01232244|Other|Glucagon infusion|3ng/kg/min
81098|NCT01232244|Other|Oxyntomodulin infusion|3 pmol/kg/min
81099|NCT00047840|Drug|ZD6474|
81100|NCT01232244|Other|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
81101|NCT01232244|Other|Placebo|NaCl 9 g/L infusion
81102|NCT01232257|Drug|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
81103|NCT01232270|Drug|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
81104|NCT01224964|Drug|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
81105|NCT01224977|Drug|azithromycin|azithromycin 500 mg 3/week for 3 months
81106|NCT01224990|Procedure|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
81107|NCT01225016|Drug|Definity contrast agent|Thyroid ultrasound using contrast agent
82135|NCT01256437|Drug|ointment Synthomycine|ointment once daily for 1 month
82136|NCT01256437|Drug|Aqua cream lotion|ointment once daily for 1 month
82137|NCT01256450|Drug|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
82138|NCT01256450|Drug|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
82139|NCT01256463|Behavioral|HIV prevention intervention|
82140|NCT01256476|Drug|pitavastatin|pitavastatin 4 mg once daily (QD)
82141|NCT01256476|Drug|pravastatin|Pravastatin 40 mg once daily (QD)
82142|NCT00049764|Drug|Drotrecogin alfa (activated)|
82143|NCT01256489|Drug|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
82144|NCT01256502|Device|SERI® Surgical Scaffold|Breast reconstruction surgery
82409|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
82410|NCT01259362|Procedure|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
82411|NCT01259362|Procedure|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
82412|NCT01259375|Drug|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
82413|NCT01259388|Drug|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
82414|NCT01259401|Behavioral|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
82415|NCT01259401|Behavioral|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
82416|NCT01259414|Other|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
82417|NCT01259414|Other|Solvent with specific gravity quivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
83114|NCT01248299|Drug|FOLFOX|every 14 days:
Oxaliplatin [85 mg/m2 by 2h infusion, day 1]
Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]
Fluoro-uracil [600 mg/m2, by 22h continous infusion, day 1 and day 2]
Elvorin [500 mg/m2, day 1 and day 2]
83115|NCT01250795|Biological|HAI-05 vaccine|vaccine injection
83116|NCT01250795|Biological|plant derived vaccine|vaccine injection
83117|NCT01250795|Biological|vaccine|vaccine injection
83118|NCT01250808|Drug|Bortezomib/Dexamethasone/Melphalan|Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.
Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.
Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.
Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.
ASCT therapy:
Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times.
83119|NCT01250821|Drug|Menopur|The medication used in this study is the follicle-stimulating hormone "highly purified human menopausal gonadotrophin" (HP-HMG), Menopur, (Ferring a/s).
Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day.
83120|NCT00049465|Procedure|management of therapy complications|
83121|NCT01250834|Drug|Atorvastatin|Administered orally.
83122|NCT01250834|Biological|LY2189265|Administered subcutaneously.
83123|NCT01250847|Drug|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50~800mg Seroquel-XR once daily for total of 12 weeks.
83124|NCT01250860|Other|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
83125|NCT01250860|Behavioral|Sham therapy|
83126|NCT01250873|Drug|LY2216684|administered orally
82195|NCT01254071|Drug|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
82196|NCT01254084|Dietary Supplement|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
82197|NCT00049582|Other|laboratory biomarker analysis|Correlative studies
81334|NCT01257516|Drug|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
81335|NCT01257529|Drug|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
81336|NCT01257529|Drug|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
81337|NCT01257529|Drug|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
81338|NCT01257529|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
81339|NCT01257542|Drug|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
81340|NCT01257542|Drug|Placebo|A single 10 mL dose of matching placebo syrup
81341|NCT01257555|Device|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
81342|NCT01257568|Device|Rejuvenate Modular Hip|Rejuvenate Modular Hip
81343|NCT00049842|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
81344|NCT01257581|Drug|creatine|creatine monohydrate powder
81345|NCT01257581|Drug|tamoxifen|Tamoxifen citrate capsules
81346|NCT01257594|Drug|erlotinib|For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital "on call" to the operating room.
81347|NCT01257594|Procedure|Cytoreductive Surgery|Standard procedure
81348|NCT01257607|Drug|MIM-D3 Ophthalmic Solution|28 Days, BID
81349|NCT01257620|Dietary Supplement|Probiotic|Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
81350|NCT01257633|Procedure|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
81351|NCT01257646|Other|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
81641|NCT01263106|Drug|Theophylline|administered orally
83593|NCT01244035|Drug|Treatment B|MK-8266 0.1 mg orally every 2 hours (total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
83594|NCT01246583|Drug|Vehicle 1|Vehicle 1 twice daily for 4 weeks
83595|NCT01246583|Drug|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
83596|NCT01246583|Drug|Vehicle 2|Vehicle 2 twice daily for 4 weeks
83597|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,[1] thus helping to establish a periodontium that is free of disease.[2]
83911|NCT01249625|Device|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
83912|NCT01249625|Device|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
83913|NCT01249638|Drug|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
83914|NCT00049374|Drug|thalidomide|
83915|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
83916|NCT01249638|Drug|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
83917|NCT01249638|Drug|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
83918|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
83919|NCT01249651|Drug|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
83920|NCT01249664|Biological|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
83921|NCT01249664|Procedure|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
83922|NCT01249677|Drug|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
83923|NCT01249690|Drug|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
83924|NCT01249690|Drug|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
87760|NCT01293695|Behavioral|Structured attention control|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
87761|NCT01293721|Device|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
87762|NCT01293734|Other|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
87763|NCT01293734|Other|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
87764|NCT01293734|Other|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
87765|NCT00053560|Drug|Prasterone (GL701)|
87766|NCT01293734|Drug|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
87786|NCT01296321|Behavioral|Waitlist|Passive waitlist during 8-10 weeks.
87787|NCT00053820|Drug|fluorouracil|
87788|NCT01296334|Drug|morphine LO|intravenous infusion, 10 mg, once, 4 hours
87789|NCT01296334|Drug|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
87790|NCT01296334|Drug|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
87791|NCT01296334|Drug|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
87792|NCT01296334|Other|saline|intravenous infusion, 0.9% saline, once, 4 hours
87793|NCT01296347|Drug|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
87794|NCT01296360|Biological|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
87795|NCT01296360|Biological|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
87796|NCT01296386|Biological|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
83989|NCT00049244|Drug|capecitabine|
83990|NCT01247350|Drug|Placebo|Administered orally
83991|NCT01247363|Drug|LY2608204|Administered orally.
83992|NCT01247376|Device|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
84267|NCT01277575|Device|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
84268|NCT01280019|Procedure|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
84269|NCT01280032|Radiation|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
84270|NCT01280045|Procedure|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
84271|NCT01280058|Drug|Carboplatin|Given IV
84272|NCT00052455|Drug|temozolomide|
84273|NCT01280058|Other|Laboratory Biomarker Analysis|Correlative studies
84274|NCT01280058|Drug|Paclitaxel|Given IV
84275|NCT01280058|Biological|Wild-type Reovirus|Given IV
84276|NCT01280071|Drug|aminophylline|
84277|NCT01280110|Drug|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
84278|NCT01280110|Drug|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
84279|NCT01280123|Drug|Pioglitazone|Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd
Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated.
84280|NCT01280123|Drug|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
83431|NCT01246193|Drug|Combination Therapy|Drug: Telmisatan 80mg Tablet, Oral, Once Daily
Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily
83432|NCT01246206|Drug|Tacrolimus and Thymoglobulin|Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or "transplant." Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.
83433|NCT01246219|Drug|GH treatment (Genotropin)|4 years treatment with GH
83434|NCT01246219|Drug|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
83721|NCT01249222|Procedure|plasmapheresis|Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
83722|NCT01249222|Other|plasmapheresis|plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
83723|NCT01249235|Procedure|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
83724|NCT01249248|Device|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
83725|NCT01249261|Drug|Risedronate|5 mg/day
83726|NCT01249261|Drug|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 & 7 and no drug year 8
83727|NCT01249274|Drug|Progesterone|100mgs progesterone twice daily
83728|NCT01249274|Other|Placebo|Matched placebo pills to be taken twice daily
83729|NCT01249300|Other|No intervention|No intervention
83730|NCT01249326|Other|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
83731|NCT00049361|Drug|thalidomide|
83732|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
83733|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
84063|NCT01282463|Biological|Ramucirumab DP|Ramucirumab (DP): 10 mg/kg I.V. on day 1 of each 21-day cycle
84064|NCT01282463|Biological|IMC-18F1|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
84065|NCT01282476|Drug|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
84066|NCT01274910|Dietary Supplement|Capsules (Placebo)|Patient will receive capsules which not contain fish oil.
Treatment: 5 capsules per day
84067|NCT01274923|Device|"MEDISPEC" treatment probe|shock wave treatment
84068|NCT01274936|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
84069|NCT01274936|Drug|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
84070|NCT01274949|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
84071|NCT00052026|Drug|carvedilol|high-dose carvedilol administered twice daily for 8 months
84346|NCT01277666|Drug|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
84347|NCT01277666|Drug|GSK1605786A|500 mg once daily, administered orally for 12 weeks
84348|NCT01277666|Drug|Placebo|Placebo capsules, administered orally for 12 weeks
84349|NCT00052338|Drug|bortezomib|Given IV
84350|NCT01277679|Procedure|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
84351|NCT01277692|Drug|GSK2336805 10mg|single dose once daily
84352|NCT01277692|Drug|GSK2336805 30mg|single dose once daily
84353|NCT01277692|Drug|GSK2236805 100mg|single dose once daily
84354|NCT01277692|Drug|GSK2236805 200mg|single dose once daily
84355|NCT01277692|Drug|GSK2236805 10mg|repeat dose once daily for 7 days
84356|NCT01277692|Drug|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
84357|NCT01277692|Drug|GSK2236805 5mg|single dose in HCV infected patients
84358|NCT01277692|Drug|GSK2236805 30mg|single dose in HCV infected patients
87797|NCT01296412|Drug|sitagliptin|100 mg tablet, orally, once daily.
87798|NCT00001042|Biological|Syntex adjuvant formulation|
87799|NCT00053833|Drug|irinotecan|
87800|NCT01296412|Drug|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
87801|NCT01296412|Drug|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
87802|NCT01298778|Drug|Duramorph|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
87803|NCT01298778|Drug|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
87804|NCT01298791|Behavioral|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
87805|NCT01298791|Behavioral|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
87806|NCT00053976|Biological|daclizumab|
88090|NCT01302067|Drug|Placebo|Oral, 1 tablet per day, 12 weeks duration
88091|NCT00054119|Drug|Cositecan|Given IV
88092|NCT01302080|Drug|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
88093|NCT01302080|Behavioral|psychotherapy|Non-interventional study- as above
88094|NCT01302093|Drug|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
88095|NCT01302093|Drug|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
88096|NCT01302106|Drug|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
88097|NCT01302119|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
88098|NCT01302119|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
84281|NCT01280136|Behavioral|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
84282|NCT01280149|Biological|substance P|injections subcutaneously of substance P and low dose allergen or placebo
84283|NCT00001033|Drug|Rifampin|
84284|NCT00052455|Drug|vincristine sulfate|
84285|NCT01280149|Biological|substance P injections subcutaneously|injections of substance P for 8 weeks
84286|NCT01280162|Drug|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
83358|NCT01246167|Device|Philos|Conservative treatment versus Philos locking plate in 2 part fracture group.
Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group.
83359|NCT01246167|Device|Epoca|Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group
83360|NCT01246167|Other|Control group|Conservative control group
83361|NCT01246180|Drug|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
83362|NCT01246180|Drug|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
83363|NCT01248663|Procedure|antecolic reconstruction|see study arm description
83364|NCT01248663|Procedure|retrocolic reconstruction|see study arm description
83365|NCT01248676|Other|Multi-language Online Patient Education Module in addition to standard Patient Teaching|Patients are usually be given a 5-10 minute "new patient teaching" before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive "new patient teaching" from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment.
83366|NCT01248689|Other|concentration profile 1|IOP will be measured under this order of sevoflurane concentrations:
7%, 5%, 2%, 0.5%
83367|NCT01248689|Other|concentration profile 2|IOP will be measured under this order of sevoflurane concentrations:
7%, 2%, 5%, 0.5%
83368|NCT01248689|Other|concentration profile 3|IOP will be measured under this order of sevoflurane concentrations:
7%, 0.5%, 5%, 2%
83734|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
83735|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
83736|NCT01249352|Drug|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
83737|NCT01249352|Drug|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
83738|NCT01249352|Drug|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
83739|NCT01251744|Procedure|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
83740|NCT01251744|Procedure|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
84050|NCT01282346|Device|SOLX Gold Shunt|Single use implant
84051|NCT01282359|Other|Clinical practice group|Clinical practice group will not receive any specific education
84052|NCT01282359|Other|"Gold Standard" educational group|"Gold Standard" educational group will receive a formal program of structured and individualized education
84053|NCT01282359|Other|Intervention group|Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
84054|NCT01282385|Drug|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
84055|NCT01282385|Drug|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
84056|NCT00052585|Drug|fluorouracil|Given IV
84057|NCT01282398|Drug|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
84058|NCT01282398|Drug|placebo|the control group wiil take placebo pills for at least two years.
84059|NCT01282424|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
84060|NCT01282437|Radiation|Prophylactic Cranial Irradiation|18 fractions of 2Gy
12 fractions of 2.5Gy
10 fractions of 3 Gy
84061|NCT01282450|Radiation|Radiotherapy|Radiotherapy
84062|NCT01282463|Drug|Docetaxel|Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle
84359|NCT01277692|Drug|GSK2236805 100mg|single dose in HCV infected patients
84360|NCT00052338|Other|laboratory biomarker analysis|Correlative studies
84361|NCT01277705|Biological|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
84362|NCT01277705|Biological|Boostrix™|Intramuscular, single dose
84363|NCT01280214|Drug|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
84364|NCT01280227|Behavioral|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
84365|NCT00052468|Drug|TCG|
84366|NCT01280240|Drug|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
84367|NCT01280266|Drug|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
84368|NCT01280279|Other|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
84369|NCT01280292|Drug|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
83435|NCT00049166|Radiation|intensity-modulated radiation therapy|Undergo intensity modulated radiation therapy
83436|NCT01246232|Drug|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
83437|NCT01246232|Drug|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
83438|NCT01246258|Other|Utricular centrifugation test, vestibular evoked myogenic potentials & ocular counter-rolling test|Standard tests of balance function
83439|NCT01246284|Drug|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
83440|NCT01246284|Other|Normal saline|
88099|NCT01302132|Drug|ASP1941|Oral solution
88100|NCT01302145|Drug|ASP1941|Tablet
88101|NCT01302145|Drug|Metformin|Tablet
88102|NCT00054119|Other|Pharmacological Study|Correlative studies
88103|NCT01302145|Drug|Placebo|Tablet
88104|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
88105|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
88106|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
88107|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
88108|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
88109|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
88110|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
88111|NCT01294423|Drug|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
88112|NCT00053651|Behavioral|Survival Skills for Moms with New Babies|
87190|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
87191|NCT00053911|Drug|epirubicin hydrochloride|
87192|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
87193|NCT01297647|Procedure|urodynamic examination|Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.
Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux.
87194|NCT01297660|Other|Video-urodynamic examination|
83369|NCT01248702|Other|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
83370|NCT01248715|Drug|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
83371|NCT01248728|Dietary Supplement|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of NutraSea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
83372|NCT00049348|Drug|cisplatin|
83373|NCT01248741|Radiation|HDR prostate brachytherapy|HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a "boost" combined with external beam radiotherapy
83656|NCT01251731|Drug|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
83657|NCT01251731|Drug|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
83658|NCT01251731|Drug|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
83659|NCT01251731|Drug|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
83660|NCT01251744|Procedure|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
83661|NCT01251744|Procedure|Cord blood sample|Cord blood sample taken at the time of delivery.
83662|NCT01244035|Drug|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
83663|NCT01244035|Drug|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
83664|NCT01244035|Drug|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
83665|NCT01244035|Drug|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
83542|NCT00049348|Procedure|adjuvant therapy|
83543|NCT01248936|Drug|RO5185426|
83544|NCT01248949|Drug|MEDI3617|1 of 7 doses of MEDI3617 given (ex: Dose 1, 2, 3, etc) every 21 days in order to determine two safe and tolerated doses that will be used in the dose expansion phase as both Dose Level A and Dose Level B
83545|NCT01248949|Drug|MEDI3617 + Bev Q3W Dose Escalation|1 of 4 doses MEDI3617 + bev at 15mg/kg every 21 days
83546|NCT01248949|Drug|MEDI3617 + Bev Q2W Dose Escalation|1 of 4 doses MEDI3617 + bev at 10mg/kg every 28 days
83547|NCT01248949|Drug|Optional Dose Expansion|Up to 2 additional dose-expansion arms may be evaluated at the sponsor's discretion. MEDI3617 will be administered every 21 or 28 days as a single-agent or in combination with bevacizumab or chemotherapy depending on the dosing regimen that is selected.
83844|NCT01251874|Other|Fluorothymidine F-18|Correlative studies
83845|NCT01251874|Other|Laboratory Biomarker Analysis|Correlative studies
83846|NCT00049517|Drug|gemtuzumab ozogamicin (GO)|Given IV
83847|NCT01251874|Other|Pharmacological Study|Correlative studies
83848|NCT01251874|Procedure|Positron Emission Tomography|Correlative studies
83849|NCT01251874|Drug|Veliparib|Given PO
83850|NCT01251887|Dietary Supplement|Linoleic Acid|
83851|NCT01251887|Dietary Supplement|Docosahexaenoic Acid|
83852|NCT01251887|Dietary Supplement|Eicosapentaenoic Acid|
83853|NCT01251926|Drug|EZN-2208|
83854|NCT01251926|Drug|Bevacizumab|
83855|NCT01251939|Device|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
83856|NCT01251952|Drug|Denileukin Diftitox (Ontak)|After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.
Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.
83857|NCT01244360|Other|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
83858|NCT01244399|Dietary Supplement|Inositol|
83441|NCT01246297|Other|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
83442|NCT01246297|Other|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
83443|NCT01246310|Dietary Supplement|Inositol|
83444|NCT01246310|Dietary Supplement|Placebo|
83445|NCT01246323|Procedure|Spinal anesthesia with Fentanyl+ Morphine|Fentanyl 15 microgram Morphine 0.1-0.5 mg
83446|NCT00049166|Other|laboratory biomarker analysis|Correlative studies
83447|NCT01246336|Other|no intervention|no intervention
83448|NCT01246349|Behavioral|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
83449|NCT01248806|Radiation|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
83450|NCT01248819|Drug|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
83451|NCT00049348|Drug|fluorouracil|
83741|NCT00049517|Drug|busulfan|Given IV
83742|NCT01251744|Procedure|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
83743|NCT01251757|Other|Interactive Voice Recognition (IVR) phone calls|The IVR intervention consists of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls will fall into two basic types: simple refill reminders and "tardy" calls for those who are overdue for a refill. Calls occur monthly and are triggered by dispensing information in the EMR. Call features include the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls are triggered by and focus on use of ACE inhibitors, ARBs and statins, they will also include reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population.
83744|NCT01251757|Other|Educational mailings and follow-up for nonadherence|The mailed educational materials, mailed refill reminder letter and linkage to the PCP enhance the IVR intervention. Participant notification for overdue refills will be via regular mail, while providers will be notified electronically via the EMR. The educational mailing will include personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as FAQs about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
83925|NCT00001018|Drug|Letrazuril|
83926|NCT00049387|Drug|tipifarnib|Given PO
83927|NCT01249716|Dietary Supplement|individual nutritional therapy|individual nutritional therapy provided by a registered dietician by means of three follow-up home visits
83928|NCT00049517|Drug|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
83929|NCT01251965|Drug|Ruxolitinib|Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.
Phase II - MTD reached in Phase I.
83930|NCT01251978|Drug|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
83931|NCT01251978|Drug|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
83932|NCT01251991|Drug|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
84216|NCT01282632|Drug|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
84217|NCT01282645|Device|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
84218|NCT01282671|Other|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
84219|NCT01282684|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
84220|NCT00052598|Other|laboratory biomarker analysis|Correlative studies
84221|NCT01282684|Drug|Placebo|Matching placebo for PLX5622.
84222|NCT01282697|Drug|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
84223|NCT01282736|Behavioral|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
84224|NCT01282736|Behavioral|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
83666|NCT01244048|Dietary Supplement|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
83667|NCT00049062|Drug|anastrozole|
83668|NCT01244061|Drug|Varenicline|Varenicline 1mg twice daily
83669|NCT01244061|Drug|Placebo|Matched placebo twice daily
83670|NCT01244074|Behavioral|biofeedback training|
83671|NCT01244100|Drug|PL2200 fasted|Fasted state
83672|NCT01244100|Drug|PL2200 fed|Fed state
83673|NCT01244113|Drug|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
83674|NCT01244126|Drug|Intranasal fentanyl|2mcg/kg fentanyl IN
83675|NCT01244126|Drug|morphine IM|0.1 mg/kg morphine IM for postop pain
83676|NCT01244126|Drug|IV morphine|0.1 mg/kg morphine IV
83993|NCT01247389|Procedure|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
83994|NCT01247402|Device|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
83995|NCT01247402|Device|standard balloon angioplasty|standard balloon angioplasty
83996|NCT01247428|Device|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
83997|NCT01247441|Other|Clinical data|
83998|NCT01249742|Behavioral|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
83999|NCT01249794|Procedure|non invasive ventilation|continuous positive airways pressure
84000|NCT01249820|Drug|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
84001|NCT01249820|Drug|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
83859|NCT00049088|Biological|bevacizumab|Given IV
83860|NCT01244425|Drug|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
83861|NCT01244425|Other|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
83862|NCT01244438|Drug|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
83863|NCT01244451|Drug|Ofatumumab|Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.
83864|NCT01244451|Drug|Bendamustine|Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
83865|NCT01244464|Biological|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
83866|NCT01244477|Behavioral|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
84162|NCT01275183|Drug|raltegravir and cisplatin|Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours
Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19
Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles
Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles
Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles
84163|NCT01275196|Drug|Nilotinib|
84164|NCT01275196|Drug|Imatinib|
84165|NCT01275209|Drug|HCD122|
84166|NCT01275222|Drug|Everolimus + Imatinib|
84167|NCT01275248|Drug|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
84168|NCT01275248|Drug|Placebo|Oral tablet to match the experimental interventions
84169|NCT01275261|Behavioral|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
84170|NCT00052065|Drug|TLK286|
84171|NCT01277237|Drug|lactose tablet|placebo: lactose tablet 4g/day
84172|NCT00052312|Drug|doxorubicin hydrochloride|
84173|NCT01277250|Behavioral|Web-based smoking cessation program|Web-based smoking cessation program that includes a "transition coach" to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay.
83745|NCT01251770|Drug|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m2 body surface.
83746|NCT01251770|Drug|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m2 body surface.
83747|NCT01251783|Dietary Supplement|Infant Formula|Only Infant Formula without Lactobacillus, Metlin OR Metlos
83748|NCT01251783|Dietary Supplement|Exclusively breast milk|Children non randomized which mothers decided to feed them with exclusively breast milk
83749|NCT01251783|Dietary Supplement|Metlin+metlos+Lactobacillus GG|A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
83750|NCT01251783|Dietary Supplement|Metlin + Lactobacillus GG|A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
83751|NCT01251783|Dietary Supplement|Metlos + lactobacillus GG|A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
83752|NCT00049517|Drug|cyclophosphamide|Given IV
83753|NCT01251783|Dietary Supplement|Lactobacillus GG|An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
83754|NCT01251796|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
83755|NCT01251809|Drug|Oncaspar|2000 U/m2 BSA, single infusion
83756|NCT01251809|Drug|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
83757|NCT01251822|Drug|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
84072|NCT01274962|Drug|FOLFOX|Oxaliplatin* 85 mg/m2 IV in 500 mL of D5W over 120 minutes
Folinic Acid (Leucovorin)* 400 mg/m2 IV in 250 ml D5W over 120 minutes
5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid
5-Fluorouracil** 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.
Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.
If necessary the schedule may be modified +/- 3 days.
84073|NCT01274962|Radiation|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
84074|NCT01274975|Other|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
84075|NCT01274988|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
84076|NCT01274988|Other|methadone maintenance treatment|methadone maintenance treatment
84225|NCT01282749|Behavioral|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
84226|NCT01282749|Behavioral|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
84227|NCT01282762|Biological|HEPLISAV|0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.
HEPLISAV booster injection = one dose of 0.5 mL volume when needed.
84228|NCT01275274|Drug|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of < 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to < 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
84229|NCT01275274|Drug|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
83294|NCT01251107|Drug|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
83295|NCT01251120|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
83296|NCT01251120|Drug|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
83297|NCT01251133|Biological|LBVH0101 (Hib vaccine)|0.5mL
83298|NCT01251133|Biological|Hiberix™ Vaccine|0.5mL
83299|NCT01251146|Drug|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
83300|NCT01251146|Drug|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
83301|NCT01251159|Genetic|mutation analysis|
83302|NCT00049504|Drug|mycophenolate mofetil|Given orally
83303|NCT01251159|Genetic|polymerase chain reaction|
84002|NCT01249833|Drug|Oseltamivir|Oseltamivir 75mg BID for 5 days
84003|NCT01249846|Drug|PerioChip ®|
84004|NCT01249872|Drug|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
84005|NCT01249872|Drug|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
84006|NCT01249872|Drug|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
84007|NCT00049387|Drug|temozolomide|Given PO
84008|NCT01249872|Drug|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
84287|NCT01280175|Procedure|charcoal block|
84288|NCT01280175|Device|Aerochamber Plus spacer|
84289|NCT01280175|Drug|pMDI standard actuator|
84290|NCT01280188|Drug|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
84291|NCT01280188|Drug|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
84292|NCT01280201|Drug|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
84293|NCT01282762|Biological|Engerix-B|2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.
Engerix-B booster injection = one dose of 2.0 mL volume when needed
84294|NCT01282775|Behavioral|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
84295|NCT01282775|Behavioral|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
84296|NCT00052598|Other|flow cytometry|Correlative studies
84174|NCT01277263|Device|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
84175|NCT01277276|Device|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
84176|NCT01277289|Drug|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
84177|NCT01277302|Drug|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
84178|NCT01277315|Drug|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
84179|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
84180|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
84181|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
84182|NCT01277341|Drug|Placebo comparator|nasal spray
84183|NCT00052312|Drug|paclitaxel|
83239|NCT01253148|Device|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
83240|NCT01253161|Drug|Pasireotide Long Acting Release (LAR)|Intramuscular injection of Pasireotide LAR
83241|NCT01253174|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
83242|NCT01253174|Drug|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
83243|NCT01253174|Drug|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
83244|NCT00049569|Drug|prednisone|Given PO
83245|NCT01245829|Other|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
84077|NCT01275014|Drug|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
84078|NCT01275014|Drug|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
84079|NCT01275027|Dietary Supplement|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
84080|NCT01275040|Other|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
84081|NCT01275040|Other|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
84082|NCT00052039|Drug|interferon-gamma 1b|This study was terminated prior to enrollment.
84083|NCT01275053|Drug|leptin|0.01mg/kg
84084|NCT01275066|Drug|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
84085|NCT01275066|Drug|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
84086|NCT01275066|Drug|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
84087|NCT01275092|Device|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
84088|NCT01275105|Drug|Vehicle|one drop in each eye at designated visits
84089|NCT01277081|Drug|Paracetamol hot drink|Hot drink containing paracetamol
84090|NCT01277081|Drug|Paracetamol tablets|Paracetamol tablets
84091|NCT01277094|Drug|Placebo|Oral daily doses for 12 weeks
84370|NCT01280305|Drug|raloxifene|raloxifene 60 mg bid
84371|NCT01280305|Drug|placebo|Placebo bid
84372|NCT01280318|Procedure|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
84373|NCT01280331|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
84374|NCT01280331|Drug|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
83304|NCT01251159|Other|immunologic technique|
83305|NCT01251159|Other|laboratory biomarker analysis|
83306|NCT01251172|Procedure|hematopoietic stem cell mobilization|Undergo standard mobilization
83307|NCT01251172|Drug|melphalan|Given IV
83308|NCT01251172|Procedure|autologous hematopoietic stem cell transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
83309|NCT01251172|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
83310|NCT01251172|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
83311|NCT00049569|Drug|doxorubicin hydrochloride|Given IV
83312|NCT01253369|Drug|Pazopanib|
83313|NCT01253382|Biological|ecallantide|10 - 30mg subcutaneous injection.
83314|NCT01253395|Behavioral|Strength training|Daily supervised strength training.
83598|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
83599|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
83600|NCT01246622|Drug|cytarabine|Given IV
83601|NCT01246622|Drug|lenalidomide|Given PO
83602|NCT00001016|Drug|Trimetrexate glucuronate|
83603|NCT00049192|Biological|oblimersen sodium|Given IV
83604|NCT01246635|Device|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
83605|NCT01246635|Procedure|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
83606|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
83607|NCT01246648|Procedure|biopsy|dental extraction and gingival epithelial biopsy
84297|NCT01282788|Dietary Supplement|Caterpillar Cereal|Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
84298|NCT01282801|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
84299|NCT01282801|Drug|Effexor® XR|150 mg Extended-Release Capsule
84300|NCT01282814|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
84301|NCT01282814|Drug|Effexor® XR|150 mg Extended-Release Capsule
84302|NCT01282827|Device|rtACS (verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
84303|NCT01282827|Device|placebo stimulation|a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
84304|NCT01282840|Drug|Tolterodine SR|Tolterodine SR 4 mg qd
84305|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
84306|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
83374|NCT01248754|Procedure|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
83375|NCT01248780|Drug|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
83376|NCT01248780|Drug|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
83377|NCT01248780|Drug|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
83378|NCT01248793|Drug|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
83379|NCT01248793|Drug|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
83380|NCT01248793|Drug|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
83246|NCT01245842|Other|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
83247|NCT01245855|Drug|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
83248|NCT01245868|Drug|Lidocaine|
83249|NCT00049140|Other|immunohistochemistry staining method|
83250|NCT01245868|Drug|bupivacaine|
83251|NCT01245881|Device|Non-ablative fractional photothermolysis laser|Wavelength: 1,550 nm;
Energy: 15 mJ/MTZ;
Total coverage: 20%;
Total density: 1,048 MTZs/cm2;
Density per pass: 131 MTZ/cm2;
Number of passes: 8.
83252|NCT01245881|Other|broad-spectrum sunblock (SPF 50+)|
83253|NCT01245894|Drug|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
83254|NCT01245894|Drug|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
83255|NCT01245907|Behavioral|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
83548|NCT01248949|Drug|MEDI3617 + Weekly Pax Dose Escalation|IV infusions of MEDI3617 at MTD/OBD-1 or MTD/OBD Q2W (Days 1, 15) + 80 mg/m2 weekly paclitaxel (Days 1, 8, 15) every 28 days
83549|NCT01248949|Drug|MEDI3617 + Pax & Carbo Q3W Dos Esc|IV infusions of MEDI3617 at MTD/OBD-1 or MTD/OBD Q3W (Day 1) + AUC5 carboplatin (Day 1) + 175 mg/m2 paclitaxel (Day 1) evey 21 days
83550|NCT01248949|Drug|MEDI3617 + Gem & Carbo Q3W Dos Esc|IV infusions of MEDI3617 at MTD/OBD-1 or MTD/OBD Q3W (Day 1) + 1000 mg/m2 gemcitabine (Days 1, 8) + AUC4 carboplatin (Day 1) evey 21 days
83551|NCT01248949|Drug|Advanced Recurrent Ovarian Tumors|Up to 25 subjects to receive MEDI3617 at the MTD/OBD dose tested as a single-agent via IV infusion every 21 days
83552|NCT01248962|Drug|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
83553|NCT00049348|Procedure|conventional surgery|
83554|NCT01248962|Drug|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
83555|NCT01248975|Drug|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
84375|NCT01280331|Drug|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
84376|NCT00052468|Drug|TC|
84377|NCT01280344|Drug|Ipamorelin|Intravenously (IV)
84378|NCT01280357|Device|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
84379|NCT01280357|Device|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
84380|NCT01280370|Procedure|Abdominal surgery|intraoperative mesh implantation
84381|NCT01280383|Device|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
84382|NCT01280409|Drug|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
84383|NCT01280409|Drug|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
84384|NCT01280487|Drug|ZSTK474|Daily oral dosing for 21 days each cycle
84385|NCT01280500|Behavioral|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
84386|NCT01280500|Other|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
84387|NCT00052481|Procedure|quality-of-life assessment|
84388|NCT01280500|Other|usual care|No EMR
84389|NCT01282944|Behavioral|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
84390|NCT01282957|Behavioral|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10.
84391|NCT00052624|Biological|transferrin-CRM107|
84392|NCT01282957|Behavioral|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5
83452|NCT01248819|Drug|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
83608|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
83609|NCT01246687|Behavioral|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
83610|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.
Group A received SAFEx for 12 weeks then received no treatment for 12 weeks.
83611|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.
Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks.
83612|NCT01246713|Drug|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
83613|NCT01246713|Drug|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
83614|NCT00049192|Drug|imatinib mesylate|Given PO
83615|NCT01246726|Procedure|CT SCAN|Prior to radiotherapy + after radiotherapy completion
83616|NCT01246726|Procedure|MRI scan|Prior to radiotherapy + after completion of radiotherapy
83617|NCT01248975|Drug|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
83933|NCT01251991|Dietary Supplement|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
83934|NCT01251991|Dietary Supplement|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
83935|NCT01251991|Other|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
83936|NCT01252017|Drug|nilotinib|nilotinib (200mg/tab) 1 tab everyday
83937|NCT01252030|Device|physical activity monitors|physical activity monitors
83938|NCT01252056|Drug|Probucol|250mg,Bid
83939|NCT00049517|Procedure|Autologous HCT|Autologous hematopoietic cell transplantation
83940|NCT01252056|Drug|Probucol and Cilostazol|50-100mg,Bid
83941|NCT01252069|Drug|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
83381|NCT01251172|Other|laboratory biomarker analysis|Correlative studies
83382|NCT01251185|Device|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
83383|NCT00000251|Drug|0.2% isoflurane|
83384|NCT00001019|Biological|MTP-PE/MF59|
83385|NCT00049504|Genetic|polymerase chain reaction|Correlative studies
83386|NCT01251211|Drug|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
83387|NCT01251224|Other|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
83388|NCT01251224|Other|Education|This group will receive education about mouse IPM.
83389|NCT01251237|Drug|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
83390|NCT01251250|Other|laboratory biomarker analysis|Correlative studies
83391|NCT01251250|Genetic|western blotting|Correlative studies
83392|NCT01251250|Genetic|gene expression analysis|Correlative studies
83393|NCT01251250|Other|pharmacological study|Correlative studies
83394|NCT01251250|Other|flow cytometry|Correlative studies
83677|NCT01244139|Drug|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
83678|NCT00001014|Drug|Sulfamethoxazole-Trimethoprim|
83679|NCT00049062|Drug|gefitinib|
83680|NCT01244139|Drug|Placebo|IV infusion dummy drug
83681|NCT01244152|Behavioral|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
83682|NCT01244152|Behavioral|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
83556|NCT01248975|Drug|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
83557|NCT01251523|Behavioral|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
83558|NCT01251523|Behavioral|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
83559|NCT01251536|Drug|Dose escalation of cetuximab|Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)
Arm allocation at day 22:
Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly
83560|NCT01251536|Drug|Standard first line treatment with cetuximab + Folfiri|Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)
Arm allocation at day 22:
Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly.
83561|NCT01251549|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
83867|NCT01244490|Drug|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
83868|NCT01244490|Drug|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
83869|NCT01244490|Drug|Placebo Comparator|Placebo
83870|NCT00049088|Other|laboratory biomarker analysis|Correlative studies
83871|NCT01244503|Drug|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
83872|NCT01244516|Device|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
83873|NCT01244516|Device|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
83874|NCT01244516|Device|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
83875|NCT01244529|Device|galy A Plus|galyfilcon A Plus, BC: 8.3 or 8.7
83876|NCT01244529|Device|seno A|senofilcon A, BC:8.4 or 8.8
83453|NCT01248832|Behavioral|Telephone Counseling|Telephone counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by veteran counselors at the California Smokers' Helpline. The counseling protocol is similar to that used by the Helpline in previous efficacy studies for English and Spanish speakers. However, the counseling is modified to make it culturally appropriate for Asian language speakers by: capitalizing on first contact, proactively presenting the Helpline as a credible quit smoking program staffed by "experts" and avoiding the term "counseling" since it is associated with mental illness, and assuming a more authoritative role and directive counseling style, in keeping with subject expectations. Counseling is proactive so after the smoker calls in subsequent calls are made by the counselor, a process that reduces attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) that are scheduled according to the probability of relapse.
83454|NCT01248832|Behavioral|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
83455|NCT01248845|Other|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
83456|NCT01248858|Drug|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
83457|NCT01248871|Drug|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
83458|NCT01248871|Drug|volatile agent only during reperfusion|Active Comparator
83459|NCT01248871|Drug|propofol-remifentanil/sufentanil|Active Comparator
83460|NCT01248884|Biological|Infanrix hexa™|3 doses, intramuscular into left thigh
83461|NCT01248884|Biological|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
83462|NCT00049348|Drug|gemcitabine hydrochloride|
83463|NCT01248884|Biological|GSK217744|3 doses, intramuscular into left thigh
83464|NCT01248897|Other|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
83465|NCT01251315|Drug|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
83466|NCT01251315|Drug|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
83758|NCT01244204|Dietary Supplement|Vitamin D|Daily dose of 800IU of vitamin D
83759|NCT00049075|Drug|fludarabine phosphate|
83942|NCT01252069|Drug|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
83943|NCT01252082|Procedure|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
83944|NCT01252095|Drug|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
83945|NCT01252108|Drug|SQ109|300 mg SQ109 daily for 14 days
83946|NCT01252121|Other|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
83947|NCT01252121|Other|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
83948|NCT01252121|Other|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
83949|NCT01252134|Device|Biotrue multipurpose solution|Contact lens care solution
83950|NCT00049517|Procedure|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
83951|NCT01252134|Device|Sauflon Synergi multipurpose solution|Contact lens care solution
83952|NCT01252134|Device|OTE Elements multipurpose solution|Contact lens care solution
83953|NCT01252134|Device|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
83954|NCT01244581|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
84230|NCT01275287|Drug|Standard of care treatment|induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m^2 for patients > than 70 or with estimated Glomerular Filtration Rate (eGFR) < 20 ml/min) to be titrated up to 1 gm/m^2 depending on the 2 week white blood count (WBC) nadir > 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .
For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study.
84231|NCT01275287|Drug|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
84232|NCT01275300|Dietary Supplement|5 days of placebo followed by 600mg niacin|600 mg niacin
83683|NCT01244165|Device|Cytrix|
83684|NCT01244165|Other|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
83685|NCT01244178|Drug|Insulin|Intravenous Hyperinsulinemic therapy
83686|NCT01244178|Drug|Insulin|Standard Intravenous Insulin Therapy
83687|NCT01244191|Drug|Tivantinib (ARQ 197) plus erlotinib|ARQ 197 720 mg daily (360 mg oral tablets given twice a day) in combination with erlotinib 150 mg oral tablets, given once a day
83688|NCT01244191|Drug|ARQ 197 placebo plus erlotinib|ARQ 197 oral placebo tablets given twice a day in combination with erlotinib 150 mg oral tablets, given once a day
83689|NCT01246726|Procedure|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
83690|NCT01246739|Procedure|Adrenalectomy|Adrenalectomy (open or laparoscopic)
83691|NCT01246752|Biological|Human Stem Cell Transplantation|Human allogenic stem cells
83692|NCT01246752|Drug|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
83693|NCT01246791|Drug|NPC-01|NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
83694|NCT01246804|Drug|raltegravir single dose|single dose 400mg raltegravir
83695|NCT01246804|Drug|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
83696|NCT01246817|Drug|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
83697|NCT00049192|Other|laboratory biomarker analysis|Correlative studies
83698|NCT01246830|Radiation|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
83699|NCT01246830|Radiation|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
84009|NCT01249872|Drug|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
84010|NCT01249872|Drug|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
83877|NCT01244529|Device|galy A|galyfilcon A , BC: 8.3 or 8.7
83878|NCT01244555|Other|ultrasound|Twice weekly ultrasound sessions for 6 weeks
83879|NCT01244555|Other|massage|Twice weekly massage sessions for 6 weeks
83880|NCT01244568|Behavioral|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
83881|NCT00049088|Other|pharmacological study|Correlative studies
83882|NCT01247103|Drug|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
83883|NCT01247103|Drug|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
83884|NCT01247103|Other|Placebo|Placebo to match AZD4316
83885|NCT00049231|Drug|EF5|
83886|NCT01247129|Procedure|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
83887|NCT01247168|Drug|AZD2461|oral capsules, continuous dosing and intermittent dosing
83888|NCT01247181|Other|Mobile phone text message|Weekly message with motivational content
84184|NCT01277354|Behavioral|Cognitive Processing Therapy|CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify "stuck-points", i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others.
84185|NCT01277354|Behavioral|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
84186|NCT01277367|Behavioral|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
84187|NCT01277367|Behavioral|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
83760|NCT01244204|Dietary Supplement|Placebo|Identically appearing capsules
83761|NCT01244217|Drug|fexofenadine/Allegra (M016455)|Pharmaceutical form:dry syrup formulation to be suspended in water
Route of administration: oral
83762|NCT01244230|Drug|fexofenadine/Allegra (M016455)|Pharmaceutical form:dry syrup formulation to be suspended in water
Route of administration: oral
83763|NCT01244243|Device|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
83764|NCT01244256|Drug|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
83765|NCT01244256|Drug|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
83766|NCT01244269|Drug|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
83767|NCT01244269|Drug|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
83768|NCT01244269|Drug|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
83769|NCT01244269|Drug|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
83770|NCT00049088|Drug|docetaxel|Given IV
83771|NCT01244282|Procedure|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
83772|NCT01244295|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
83773|NCT01244295|Behavioral|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
83774|NCT01244334|Drug|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
83775|NCT01244334|Drug|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
84233|NCT01275300|Dietary Supplement|aspirin first|5 days taking 81 mg Aspirin followed by a single dose of 600 mg Niacin
84234|NCT01275300|Drug|81 mg Aspirin|5 days taking 81 mg Aspirin
84235|NCT01275300|Dietary Supplement|Niaspan|dosage
84236|NCT01275300|Drug|Celebrex and niacin|Data will be handled exactly like phase 1.
84237|NCT01275313|Device|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
84238|NCT00052078|Drug|Sertraline|Participants will take sertraline for 12 weeks.
84239|NCT01275313|Device|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
84240|NCT01275339|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
84241|NCT01275339|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
84242|NCT01275352|Drug|Eplerenone|Eplerenone 50 mg/day
84243|NCT01275352|Drug|placebo|placebo
84244|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
84245|NCT01277367|Behavioral|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
83315|NCT01253395|Behavioral|Aerobic exercise|Daily supervised aerobic exercise.
83316|NCT01253408|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
83317|NCT01253408|Drug|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
83318|NCT01253421|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
83319|NCT01253421|Drug|Placebo|single-dose placebo capsule
83320|NCT01253434|Drug|E2022|E2022 Type A patch
84011|NCT01249911|Dietary Supplement|Lreuteri|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
84012|NCT01249911|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
84013|NCT01249924|Device|auto-titrated CPAP|Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
84014|NCT00052429|Drug|fluorouracil|
84015|NCT01279590|Drug|PPD10558|PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then
PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks
84016|NCT01279590|Drug|Atorvastatin|Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then
Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks
84017|NCT01279590|Drug|Placebo|2 placebo capsules twice daily for 12 weeks
84018|NCT01279603|Drug|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
84019|NCT01279616|Drug|Fludarabine monophosphate|180 mg/m2 over 6 days.
84020|NCT01279616|Drug|Rituximab|375 mg/m2 on day -13 and day -3
84021|NCT01279616|Drug|Busulfan|AUC 1000-1200 microM.mt
84022|NCT01279616|Drug|ATG|2.5 mg/kg for 3 days
84023|NCT01279616|Drug|Cyclophosphamide|50 mg/kg on day +3
84024|NCT01279616|Drug|Mycophenolate mofetil|15 mg/kg q 8 hours
84025|NCT00052429|Procedure|adjuvant therapy|
84026|NCT01279616|Drug|Tacrolimus|0.03 mg/kg /d
84307|NCT00052611|Drug|celecoxib|
84308|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
84309|NCT01282866|Device|LightSheer Duet|LightSheer Duet HS handpiece
84188|NCT01277367|Behavioral|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
84189|NCT01277367|Behavioral|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
84190|NCT01279876|Drug|Melatonin|3mg oral, daily, one hour before sleep
84191|NCT01279902|Drug|3 Cycles of Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
84192|NCT00052455|Drug|lomustine|
84193|NCT01279915|Drug|ASP0456|oral
84194|NCT01279915|Drug|Placebo|oral
84195|NCT01279928|Procedure|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
84196|NCT01279928|Device|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
84197|NCT01279928|Procedure|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
84198|NCT01279928|Procedure|Laser Doppler Flowmetry|Examination of vascular flow
84199|NCT01279941|Behavioral|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
83256|NCT01245920|Biological|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
83257|NCT01245920|Other|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
83258|NCT01245933|Other|Analysis of sleep disturbances|The frequency and consequences of sleep disturbances in patients with COPD have not been thoroughly enough evaluated so far, and there are only a few studies in which polysomnography has been performed in COPD patients. Therefore the analysis of sleep disturbances, in particular overlap syndrome and restless leg syndrome is performed in 10 selected study centres. Randomly selected patients with COPD of all severities are evaluated by polysomnography at home
84092|NCT00052299|Drug|mitoxantrone hydrochloride|
84093|NCT01277094|Drug|RO5093151|Oral daily doses for 12 weeks
84094|NCT01277107|Drug|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
84095|NCT01277107|Drug|Placebo capsule|Identical placebo capsule
84096|NCT01277146|Drug|OMP-59R5|IV infusion
84097|NCT01277159|Drug|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
84098|NCT01277159|Drug|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
84099|NCT01277159|Drug|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
84100|NCT01277159|Drug|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
84101|NCT01277159|Drug|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
84102|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
84103|NCT00052312|Drug|cisplatin|
84104|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
84105|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
84106|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
84107|NCT01277185|Dietary Supplement|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
84108|NCT01277185|Dietary Supplement|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
84109|NCT01277211|Drug|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
84110|NCT01277211|Drug|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
83321|NCT01253434|Drug|E2022|E2022 Type B patch
83322|NCT00001021|Biological|rgp120/HIV-1IIIB|
83323|NCT00049569|Drug|imatinib mesylate|Given PO
83324|NCT01253434|Drug|E2022|E2022 Type C patch
83325|NCT01253434|Drug|E2022|E2022 Type D patch
83326|NCT01253434|Drug|E2022|E2022 Type E patch
83327|NCT01253447|Drug|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
83328|NCT01253447|Other|laboratory biomarker analysis|Correlative studies
83329|NCT01253460|Drug|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
83330|NCT01253460|Drug|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
83331|NCT01253460|Drug|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
83332|NCT01253473|Drug|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
83333|NCT01253473|Drug|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
83334|NCT00049569|Drug|cyclophosphamide|Given IV
83335|NCT01253473|Drug|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
83336|NCT01253486|Behavioral|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
83618|NCT01248975|Drug|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
83619|NCT01248975|Drug|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
83620|NCT01248975|Drug|Placebo capsule (PM)|Placebo capsule (PM)
83621|NCT01248988|Other|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
83622|NCT01249001|Drug|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
84310|NCT01282879|Drug|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
84311|NCT01282892|Procedure|excess of visceral fat|excess of visceral fat
84312|NCT01282892|Procedure|patients with NAFLD|patients with NAFLD
84313|NCT01282918|Device|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
84314|NCT01282918|Device|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
84315|NCT01282944|Behavioral|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
84316|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
84317|NCT01275378|Behavioral|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
84318|NCT01275378|Behavioral|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
84319|NCT01275391|Behavioral|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
84320|NCT00052078|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants will receive CBT for 12 weeks.
84321|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patient‟s success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
84322|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
84323|NCT01275430|Device|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
83395|NCT01251250|Genetic|fluorescence in situ hybridization|Correlative studies
83259|NCT01245946|Procedure|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
83260|NCT00049140|Procedure|biopsy|
83261|NCT01245946|Drug|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
83262|NCT01245959|Drug|Docetaxel, cisplatin and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
83263|NCT01248442|Drug|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
83264|NCT01248442|Drug|Placebo|Matching Placebo
83265|NCT01248455|Drug|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
83266|NCT01248468|Drug|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
83267|NCT01248468|Drug|Sumatriptan|100 mg Sumatriptan
83268|NCT01248468|Drug|Placebo|placebo
83269|NCT01248481|Drug|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
83270|NCT01248494|Drug|BEZ235|Dose level 1: 400mg PO BID
Dose level -1: 400mg PO in AM and 200mg PO in PM
Dose level -2: 200mg PO BID
83271|NCT01248494|Drug|BKM 120|Dose Level 1: BKM120, 100 mg PO daily
Dose level -1: BKM120, 80 mg PO daily
Dose Level -2: BKM120, 60 mg PO daily
83272|NCT01248494|Drug|Letrozole|All levels: 2.5mg/day PO
83273|NCT00049348|Biological|epoetin alfa|
83562|NCT01251562|Drug|Sterile Compound c31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
83563|NCT01251575|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
83564|NCT01251575|Drug|Cyclosporine|Given PO or IV
83565|NCT01251575|Drug|Fludarabine Phosphate|Given IV
84111|NCT01277224|Behavioral|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
84393|NCT01282970|Drug|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
84394|NCT01282970|Drug|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
84395|NCT01282983|Dietary Supplement|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
84396|NCT01282983|Dietary Supplement|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
84397|NCT01282996|Other|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
84398|NCT01283009|Drug|Methylprednisolone|Methylprednisolone or placebo will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
84399|NCT01283022|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
84400|NCT01283035|Drug|Akt Inhibitor MK2206|Given PO
84401|NCT01283035|Other|Laboratory Biomarker Analysis|Correlative studies
84402|NCT00052637|Drug|hexaminolevulinate|
84403|NCT01283048|Drug|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
84404|NCT01283061|Drug|Zafirlukast|Zafirlukast tablets 20 mg
84405|NCT01283100|Drug|GSK1349572|50mg once every 24 hours for 7 days
84406|NCT01283100|Drug|GSK2248761|200 mg once every 24 hours for 7 days
84407|NCT01283126|Procedure|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
84408|NCT01283139|Drug|Sifalimumab|IV Sifalimumab (200 mg) every 2 weeks for 4 weeks and then monthly for 44 weeks
84409|NCT01283139|Drug|Sifalimumab|IV Sifalimumab (600 mg) every 2 weeks for 4 weeks and then monthly for 44 weeks
83623|NCT01249001|Drug|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
83624|NCT00049348|Procedure|neoadjuvant therapy|
83625|NCT01249014|Device|warmed fluids|use of IV fluid warmer to warm fluid administered to patient
83626|NCT01249014|Device|Fluid warmer and warming blanket|patients will have IV fluids warmed through a belmont fluid warmer and warming blanket used (forced air will be warmed) a bair hugger device
83627|NCT01249027|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
83628|NCT01249040|Procedure|Physical therapy|
83629|NCT01249040|Procedure|steroid intraarticular injection|
83630|NCT01249079|Other|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
83631|NCT01249092|Drug|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
83632|NCT01249105|Drug|MK-2206|Taken orally once a week
83633|NCT01249118|Drug|GDC-0973/XL518|Each subject will receive a single IV dose and oral dose separated by 10 days
83634|NCT01249131|Drug|GDC-0973/XL518|Single oral dose tablet in a fasted state
83635|NCT00049348|Radiation|radiation therapy|
83636|NCT01249131|Drug|GDC-0973/XL518|Single oral dose tablet in a fed state
83637|NCT01249131|Drug|GDC-0973/XL518|Single oral dose capsules in a fasted state
83638|NCT01249144|Device|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
83955|NCT01244581|Drug|Placebo|Placebo mixture in two daily doses for 7 days
83956|NCT01244594|Other|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
83957|NCT01244607|Drug|Placebo|single i.v. administration
83958|NCT01244607|Drug|NI-0801|single i.v. administration
83959|NCT01244620|Drug|sitaxentan|sitaxsentan 100 mg QD for 6 days
83396|NCT00049504|Genetic|fluorescence in situ hybridization|Correlative studies
83397|NCT01251250|Biological|azadirachta indica|Given orally
83398|NCT01251250|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
83399|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
83400|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
83401|NCT01251276|Biological|1 dose at Day 1|1 dose 10μg/mL (1mL)
83402|NCT01251302|Other|Gene Expression Score (GES)|The gene expression score is a validated, quantitative blood-based diagnostic test measuring peripheral blood cell expression levels for 23 genes to determine the likelihood of obstructive coronary artery disease (at least one vessel with >=50% angiographic coronary artery stenosis)
83403|NCT01251315|Drug|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
83404|NCT01251315|Drug|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
83405|NCT01253577|Device|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
83406|NCT01253590|Behavioral|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
83407|NCT00049569|Biological|filgrastim|Given SC
83408|NCT01253603|Drug|QAW039 capsules once daily for 28 days|
83409|NCT01253603|Drug|Placebo to QAW039 capsules once daily for 28 days|
83410|NCT01253603|Drug|Fluticasone propionate inhaler twice daily for 28 days|
83411|NCT01253616|Device|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
83412|NCT01253629|Drug|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
83413|NCT01253629|Drug|Placebo|Placebo medication identical in appearance to active medication was provided
83566|NCT01251575|Other|Laboratory Biomarker Analysis|Correlative studies
83567|NCT00049504|Procedure|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
83568|NCT01251575|Drug|Mycophenolate Mofetil|Given PO
83569|NCT01251575|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
83570|NCT01251575|Drug|Sirolimus|Given PO
83571|NCT01251575|Radiation|Total-Body Irradiation|Undergo total-body irradiation
83572|NCT01251588|Biological|Matrix-Induced Autologous Chondrocyte Implant (MACI® Implant)|Implantation
83573|NCT01251588|Procedure|Microfracture|Arthroscopic Microfracture
83574|NCT01251601|Other|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
83575|NCT01251614|Biological|Adalimumab - Low Dose|0.4 mg/kg up to a maximum of 20mg every other week
83576|NCT01251614|Biological|Adalimumab - Standard Dose|0.8 mg/kg up to a maximum of 40mg every other week
83577|NCT00049036|Drug|cyclophosphamide|Given IV
83578|NCT01243905|Other|Treatment as usual|Treatment as usual administered by physicians
83579|NCT01243918|Other|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
83580|NCT01243931|Drug|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
83889|NCT01247181|Other|Usual care|Usual care provided at clinic
83890|NCT01247194|Drug|PPI-461|capsule, oral, once daily for 3 days
83891|NCT01247194|Drug|Placebo|capsules, oral, once daily for 3 days
83892|NCT01247207|Drug|Ataluren|Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
84410|NCT01283139|Drug|Sifalimumab|IV Sifalimumab (1200 mg) every 2 weeks for 4 weeks and then monthly for 44 weeks
84411|NCT01283139|Drug|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
84412|NCT01283152|Drug|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
87457|NCT01298024|Other|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
87458|NCT01298050|Procedure|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
87459|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
87460|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
87461|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
87462|NCT00053937|Drug|pirfenidone|
87463|NCT01298076|Drug|bevacizumab|Anti-VEGF drug for intravitreal injection
87464|NCT01298076|Drug|dexamethasone|Slow-release steroid formulation for intravitreal injection
87465|NCT01298089|Device|Carriazo Pendular microkeratome|
87466|NCT01298102|Biological|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
87467|NCT01298128|Drug|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
87468|NCT01298128|Drug|marvelon|marvelon 21 daily
87469|NCT01300754|Procedure|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
87470|NCT01300754|Procedure|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
87471|NCT01300754|Other|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
87472|NCT01300767|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
83960|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
83961|NCT01244620|Drug|sitaxsentan|sitaxsentan 100 mg QD for 6 days
83962|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
83963|NCT01244620|Drug|sitaxsentan|sitaxentan 100 mg QD for 6 days
83964|NCT00049101|Drug|erlotinib hydrochloride|
83965|NCT01244620|Drug|sildenafil|sildenafil 20 mg TID for 6 days
83966|NCT01244633|Drug|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
83967|NCT01244659|Drug|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
83968|NCT01244659|Drug|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
83969|NCT01244672|Procedure|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
83970|NCT01244672|Procedure|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
83971|NCT01244685|Device|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
83972|NCT01244698|Drug|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
83973|NCT01244698|Drug|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
84246|NCT01277367|Behavioral|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
84247|NCT01277406|Drug|4SC-201(Resminostat)|oral administration
84248|NCT01277406|Drug|FOLFIRI|i.v. administration
83700|NCT01246882|Behavioral|wireless sensor monitoring of walking-related physical therapy|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
83701|NCT01246882|Behavioral|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
83702|NCT01246908|Drug|Placebo|Placebo administered twice per day for six weeks.
83703|NCT01246908|Drug|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
83704|NCT01246921|Drug|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
83705|NCT01246934|Other|ASR METHOD|
83706|NCT01246947|Procedure|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
83707|NCT01246947|Other|Mitral surgery alone|Randomized to Mitral surgery alone
83708|NCT00049218|Biological|Autologous dendritic cell-adenovirus p53 vaccine|
83709|NCT01246960|Biological|Ramucirumab|Administered intravenously
83710|NCT01246960|Drug|Placebo|Administered intravenously
83711|NCT01246960|Drug|Oxaliplatin|Administered intravenously
83712|NCT01246960|Drug|Leucovorin|Administered intravenously
83713|NCT01246960|Drug|5-Fluorouracil|Administered intravenously
83714|NCT01246973|Drug|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
83715|NCT01249170|Other|Control comparison|Information from group that did not undergo new first year program
83716|NCT01249183|Biological|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
83717|NCT01249183|Biological|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
83718|NCT01249196|Drug|SK-PC-B70M|for dosage
83719|NCT01249209|Device|lifestyle advice|
83720|NCT00049361|Drug|temozolomide|
83893|NCT01247220|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
83894|NCT01247220|Procedure|Peripheral Laser|Angiography-directed peripheral laser
83895|NCT01247233|Radiation|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50Gy + Boost 16 Gy or Whole breast, either 40Gy in 15 fractions in 3 weeks or 42,5Gy in 16 fractions in 3 weeks
83896|NCT00049231|Other|immunohistochemistry staining method|
83897|NCT01247233|Radiation|Accelerated partial breast irradiation|Tumor bed 40Gy in 10 fractions, 2 fractions of 4Gy per day in 5 to 7 days.
83898|NCT01247246|Drug|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
83899|NCT01247246|Drug|Placebo|Placebo
83900|NCT01247259|Drug|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
83901|NCT01247272|Drug|Fluoxetine Hydrochloride|90 mg Capsules
83902|NCT01247272|Drug|PROZAC WEEKLY®|90 mg Capsules
83903|NCT01247285|Drug|Fluoxetine Hydrochloride|90 mg Capsules
83904|NCT01247285|Drug|PROZAC WEEKLY®|90 mg Capsules
83905|NCT01249547|Drug|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
83906|NCT01249573|Other|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
83907|NCT01249586|Other|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
83908|NCT01249599|Procedure|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
83909|NCT01249612|Other|Thermotherapy|Knee joint icing
83910|NCT01249612|Other|Thermotherapy|Elbow joint icing
87473|NCT01300767|Device|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
87474|NCT01300767|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
87475|NCT01300780|Drug|Etoricoxib|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours, Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
87725|NCT01298726|Other|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
87726|NCT01298726|Other|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
87727|NCT01298752|Drug|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
87728|NCT01298752|Drug|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
87729|NCT01298765|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
87730|NCT01301274|Drug|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
87731|NCT01301274|Drug|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
87732|NCT01301287|Drug|Chlorella|
87733|NCT01301300|Device|Disinfecting Cap|Replace standard practice with using the disinfecting cap
87734|NCT00054067|Drug|cisplatin|
87735|NCT01301313|Drug|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
87736|NCT01301313|Drug|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
87737|NCT01301326|Device|subthreshold and threshold laser treatment|subthreshold laser treatment
87738|NCT01301326|Device|Threshold laser treatment|threshold laser treatment
87739|NCT01301352|Other|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
87740|NCT01301378|Procedure|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
84249|NCT00052325|Dietary Supplement|mistletoe extract|
84250|NCT01277432|Other|Psychiatrist Interview|Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:
MINI
SSI-28 (somatization)
84251|NCT01277432|Other|Depression screening - control|All study participants will undergo;
a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal
a detailed psychological and behavioral assessments using validated questionnaires
several specialist questionnaires on depression, self care and quality of life
84252|NCT01277445|Dietary Supplement|Prebiotic|Inulin-fructan 15mg/day for 28days
84253|NCT01277445|Dietary Supplement|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
84254|NCT01277471|Behavioral|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
84255|NCT01277471|Behavioral|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
84256|NCT01277484|Drug|Decitabine|1. Dose finding study (cycle 1-cycle4)
Indicated dose for 5 consecutive days every 28 days
Cohort 1: 5mg/m2 of decitabine
Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model
84257|NCT01277497|Drug|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
84258|NCT01277497|Drug|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
84259|NCT01277510|Drug|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
84260|NCT00052338|Drug|gemcitabine hydrochloride|Given IV
84261|NCT01277510|Drug|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
84262|NCT01277510|Drug|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
84263|NCT01277523|Drug|tiotropium high dose|2 actuations once daily
84264|NCT01277523|Drug|placebo|2 actuations once daily
84265|NCT01277523|Drug|tiotropium low dose|2 actuations once daily
84266|NCT01277549|Device|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
83337|NCT01253486|Behavioral|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
84027|NCT01279629|Drug|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
84028|NCT01279642|Device|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
84029|NCT01279642|Other|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
84030|NCT01279655|Device|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
84031|NCT01279655|Behavioral|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
84032|NCT01279668|Drug|Montelukast|10mg tablets, once per day for 28 days.
84033|NCT01279668|Drug|Placebo|tablets, once per day for 28 days.
84034|NCT01279681|Biological|bevacizumab|Given IV
84035|NCT01279681|Drug|capecitabine|Given PO
84036|NCT00052429|Radiation|radiation therapy|
84037|NCT01279681|Drug|fluorouracil|Given IV
84038|NCT01279681|Drug|leucovorin calcium|Given IV
84039|NCT01279681|Drug|oxaliplatin|Given IV
84040|NCT01282268|Drug|placebo|orally disintegrating tablet
84041|NCT01282294|Device|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
84042|NCT01282307|Behavioral|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
84043|NCT01282320|Behavioral|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
84044|NCT01282333|Drug|gemcitabine hydrochloride|Given IV
84045|NCT00052585|Drug|leucovorin calcium|Given IV
84046|NCT01282333|Drug|veliparib|Given orally
84047|NCT01282333|Other|diagnostic laboratory biomarker analysis|Correlative studies
84200|NCT01279954|Drug|Abatacept|Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.
Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years.
84201|NCT01279967|Drug|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
84202|NCT01279980|Other|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
84203|NCT00052455|Drug|procarbazine hydrochloride|
84204|NCT01279980|Other|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
84205|NCT01279993|Procedure|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
84206|NCT01280006|Other|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
84207|NCT01280006|Drug|Indomethacin|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.
Indomethacin: 50 mg, Oral, three times per day for five days.
84208|NCT01280006|Drug|Celecoxib|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.
Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.
84209|NCT01280006|Drug|Placebo|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.
Placebo: Oral, three times per day for five days.
84210|NCT01282593|Other|Post-transcriptional regulation of CD9|2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.
Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples.
84211|NCT01282606|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
84212|NCT01282619|Drug|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
84213|NCT01282619|Drug|huperzine A|Tablet, 200µg twice a day, 24 weeks
84214|NCT01282619|Drug|Placebo|placebo orally twice a day
87741|NCT01301391|Drug|Milciclib Maleate|150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.
Number of cycles: until disease progression or unacceptable toxicity.
87742|NCT01301404|Dietary Supplement|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
87743|NCT01301417|Device|ColonRing™|Creation of a circular Compression Anastomosis
87744|NCT01301430|Drug|H-1PV|H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
87745|NCT00054067|Procedure|adjuvant therapy|
88071|NCT01299324|Device|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
88072|NCT01299337|Drug|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
88073|NCT01299350|Other|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
88074|NCT01299363|Behavioral|Dilator use|Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
88075|NCT01299376|Drug|losartan potassium (+) hydrochlorothiazide (+) amlodipine besylate (MK-0954E)|One tablet containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for up to 52 weeks.
88076|NCT01299376|Drug|losartan potassium (+) hydrochlorothiazide|One tablet containing 50 mg losartan potassium and 12.5 mg hydrochlorothiazide, orally, once daily, for 8 weeks.
88077|NCT01299376|Drug|Placebo to MK-0954E|One tablet containing placebo, orally, once daily, for 8 weeks.
88078|NCT00053989|Drug|cyclophosphamide|injection
88079|NCT01301989|Behavioral|Sleep Counselor Intervention|Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
88080|NCT00054106|Procedure|neoadjuvant therapy|
88081|NCT01301989|Other|Sleep Education Control|The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, "Information about Children's Sleep for Parents and Teachers"
83338|NCT01245959|Radiation|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
83339|NCT01245972|Procedure|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
83340|NCT01245985|Radiation|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
83341|NCT01245998|Drug|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
83342|NCT01245998|Drug|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
83343|NCT01246011|Drug|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
83344|NCT01246024|Device|ERG|scotopic and photopic ERG
83345|NCT01246037|Drug|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
83346|NCT00049166|Drug|erlotinib hydrochloride|Given orally
83347|NCT01246050|Other|3 days of training in HF management|HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds.
83348|NCT01246050|Other|Access to clinical pharmacist services|Including medication and disease teaching, adjustment and uptitration
83349|NCT01246050|Other|Quarterly analysis of physician compliance|Individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
83350|NCT01246063|Drug|carfilzomib|
83351|NCT01246063|Drug|pegylated liposomal doxorubicin (PLD)|
83352|NCT01246063|Drug|Dexamethasone|
83353|NCT01246076|Drug|Lenalidomide|
83354|NCT01246089|Drug|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
83355|NCT01246102|Drug|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
83356|NCT01246154|Other|EXERCISE TRAINING|EXERCISE TRAINING
83357|NCT00049166|Drug|cisplatin|Given IV
84048|NCT01282333|Other|pharmacological study|Correlative studies
84049|NCT01282333|Drug|cisplatin|Given IV
84324|NCT01275430|Other|Blind Placement|PICCs will be placed "blindly", without the use of any tip location/positioning device.
84325|NCT01275443|Drug|TMC278LA|300mg TMC278LA intramuscular injection
84326|NCT01275443|Drug|TMC278LA|150mg TMC278LA intramuscular injection
84327|NCT01275443|Drug|TMC278LA|1200mg TMC278LA intramuscular injection
84328|NCT01275443|Drug|TMC278LA|600mg TMC278LA intramuscular injection
84329|NCT01275456|Procedure|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
84330|NCT01275469|Drug|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
84331|NCT00052078|Drug|Placebo|Participants will take placebo capsules for 12 weeks.
84332|NCT01275469|Drug|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
84333|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
84334|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
84335|NCT01277575|Device|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
84336|NCT01277601|Drug|TDF|TDF 300 mg tablets administered orally once daily
84337|NCT01277601|Drug|PEG|PEG 180 µg administered via subcutaneous injection once weekly
84338|NCT00052338|Drug|carboplatin|Given IV
84339|NCT01277614|Behavioral|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
84340|NCT01277627|Drug|Nevirapine|nevirapine: 400 mg a day.
84341|NCT01277627|Drug|efavirenz, protease inhibitors|efavirenz: 600 mg a day
84215|NCT01282632|Drug|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
83274|NCT01248494|Drug|BKM120|Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly
Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly
Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly
83275|NCT01248520|Other|influenza vaccination/general health/pregnancy information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
83276|NCT01248520|Other|general health/pregnancy information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
83277|NCT01248546|Procedure|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
83278|NCT01248572|Device|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
83279|NCT01248585|Drug|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
83280|NCT01248585|Drug|Placebo|2 placebo tablets taken once daily for 5 days
83281|NCT01248611|Drug|fentanyl|nasally, dose titrated to effect
83282|NCT01248624|Behavioral|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
83283|NCT01248637|Drug|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 <= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
83284|NCT00049348|Biological|filgrastim|
83285|NCT01248650|Drug|nalfurafine hydrochloride|
83286|NCT01251107|Drug|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
83287|NCT01251107|Drug|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
83288|NCT01251107|Drug|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
83289|NCT01251107|Drug|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
88082|NCT01302002|Drug|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
88083|NCT01302015|Biological|RNL-Vascostem®|
88084|NCT01302028|Drug|ASP1941|oral
88085|NCT01302041|Drug|MDV3100|Oral
88086|NCT01302054|Drug|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
88087|NCT01302054|Drug|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
88088|NCT01302067|Drug|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
88089|NCT01302067|Drug|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
87172|NCT01295229|Procedure|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
87173|NCT01295229|Behavioral|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
87174|NCT01295268|Other|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
87175|NCT01295268|Other|Inert oil|A specified amount of inert oil will be applied daily to area.
87176|NCT01295281|Device|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
87177|NCT01295281|Device|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
87178|NCT01295294|Drug|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
87179|NCT01297556|Behavioral|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
87180|NCT00053911|Drug|docetaxel|
87181|NCT01297569|Drug|Ranibizumab|
87182|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
83639|NCT01249157|Device|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
83640|NCT01249170|Behavioral|First year program|Information on group that underwent new educational program
83641|NCT01251614|Drug|Methotrexate|0.4mg/kg/week up to a maximum of 25 mg per week
83642|NCT00049504|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
83643|NCT01251614|Biological|Adalimumab - Open-Label|0.4 mg/kg up to a maximum of 20 mg every other week or 0.8 mg/kg up to a maximum of 40mg every other week starting at Week 0 in Open-Label Period
83644|NCT01251627|Drug|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
83645|NCT01251640|Drug|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
83646|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
83647|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
83648|NCT01251653|Drug|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
83649|NCT01251653|Drug|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
83650|NCT01251666|Other|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
83651|NCT01251679|Behavioral|Hand washing|hand washing education and material
83652|NCT01251679|Device|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
83653|NCT00049517|Biological|sargramostim|Given IV or as an injection
83654|NCT01251692|Procedure|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
84342|NCT01277640|Drug|dapivirine|dosage form: gel 0.05%
dosage: 2.5g
frequency: once daily
duration: 7 days
84343|NCT01277640|Drug|matched placebo|dosage form: gel, no api
dosage: 2.5g
frequency: once daily
duration: 7 days
84344|NCT01277640|Drug|universal placebo|dosage form: gel, HEC-based
dosage: 2.5g
frequency: once daily
duration: 7 days
84345|NCT01277653|Device|tumor maker interval shortly|tumor maker interval every 3 month
83414|NCT01253642|Procedure|Biopsy of Prostate|Undergo transrectal ultrasonography (TRUS)-guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
83415|NCT01253642|Drug|Docetaxel|Given IV
83416|NCT01253642|Other|Laboratory Biomarker Analysis|Correlative studies
83417|NCT01253642|Drug|Phenelzine Sulfate|Given PO
83418|NCT00049569|Drug|leucovorin calcium|Given IV
83419|NCT01253655|Drug|PF-05212365|Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
83420|NCT01253668|Drug|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
83421|NCT01253668|Genetic|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
83422|NCT01253668|Other|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
83423|NCT01253668|Procedure|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
83424|NCT01253668|Genetic|Protein expression analysis|Correlative studies
83425|NCT01253668|Other|Immunohistochemistry|correlative studies
83426|NCT01253681|Drug|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
83427|NCT01253694|Drug|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
83428|NCT01253707|Drug|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
83429|NCT00049569|Drug|asparaginase|Given IM
83430|NCT01246193|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
83290|NCT01251107|Drug|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
83291|NCT00049504|Drug|tacrolimus|Given IV or orally
83292|NCT01251107|Drug|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
83293|NCT01251107|Drug|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
83581|NCT01243944|Drug|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
83582|NCT01243944|Other|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each subject. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
83583|NCT01243957|Drug|LY2216684|Administered orally
83584|NCT01243957|Drug|Fluoxetine|Administered orally
83585|NCT01243970|Drug|Phenylephrine|Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg *
* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg.
83586|NCT01243970|Drug|Ephedrine|Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. *
* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg.
83587|NCT01243983|Drug|LX211|Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:
Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.
Treatment Arm B: placebo p.o. b.i.d.
Dosage Form:
• Soft gelatin capsule
Duration of treatment:
• 24 weeks
83588|NCT00049036|Other|laboratory biomarker analysis|Correlative studies
83589|NCT01243996|Drug|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
83590|NCT01244009|Drug|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
83591|NCT01244022|Procedure|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
83592|NCT01244035|Drug|Treatment A|MK-8266 orally twice daily (1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
87183|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
87184|NCT01297595|Drug|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
87185|NCT01297608|Drug|caoted suppository|coated suppository with active drug
87186|NCT01297608|Drug|coated suppository|coated suppository with placebo
87187|NCT01297621|Procedure|reduction mammaplasty|conventional reduction mammaplasty
87188|NCT01297621|Other|control|follow up, questionnaire responses
87189|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
87746|NCT01301443|Drug|3 dose cohorts gene therapy|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
87747|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
87748|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
87749|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
87750|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
87751|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
87752|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
87753|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
87754|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
87755|NCT01301456|Biological|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
87756|NCT00054067|Procedure|conventional surgery|
87757|NCT01293669|Drug|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
87758|NCT01293682|Drug|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
87759|NCT01293695|Behavioral|Hypnosis|Hypnosis relaxation in five weekly sessions
83655|NCT01251718|Drug|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
83974|NCT01244711|Drug|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
83975|NCT00049101|Drug|fluorouracil|
83976|NCT01247298|Procedure|Trans- Arterial Chemoembolization|TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). This treatment involves accessing the major feeder artery to the liver tumor using a catheter passed through the femoral artery in the groin. This procedure is performed by the Interventional Radiologist. Once access is established, chemotherapy drugs and contrast material are injected directly into the tumor. This procedure is performed under sedation and does not usually require hospital stay. Patient will be given antiemetics (medication to stop or prevent nausea/vomiting), antibiotics, and pain relievers after the procedure, which patient may be asked to continue for several hours.
83977|NCT01247298|Procedure|Stereotactic Body Radiation Therapy (SBRT)|SRT(Stereotactic Radiation Therapy)is a technique of high precision radiation treatment.Liver is one of the body sites where SRT has been successfully used. During SBRT, patient will be asked to lie still on a treatment bed under the radiation machine.The physician uses sophisticated computers to direct the radiation beam to the tumor with great accuracy.The radiation physician will prescribe antiemetics before the treatment starts.Patient will not experience any pain or other side-effects during treatment, but may feel uncomfortable lying still for several minutes.A typical SBRT treatment may last 30 mins and there will be three treatments.Patient will be alone in treatment room, however they are constantly monitored throughout the procedure.They can communicate with the physician and technicians outside the room using a intercom.Patient will be able to listen to music during the procedure.
83978|NCT00049231|Procedure|biopsy|
83979|NCT01247311|Dietary Supplement|Dietary supplement|Placebo given orally 3xweek for six months
83980|NCT01247311|Dietary Supplement|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
83981|NCT01247311|Dietary Supplement|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
83982|NCT01247324|Drug|Ocrelizumab|600 mg iv every 24 weeks (dual infusions of 300 mg on Day 1 and 15 of Cycle 1, single infusion of 600 mg on Day 1 of each following cycle
83983|NCT01247324|Drug|Ocrelizumab placebo|Ocrelizumab dummy placebo iv according to schedule in ocrelizumab active group.
83984|NCT01247324|Drug|Rebif|8.8 mcg (Weeks 1+2) / 22 mcg (Weeks 3+4) / 44 mcg (Week 5 and following) subcutaneously 3 times weekly
83985|NCT01247324|Drug|Rebif placebo|Rebif dummy placebo SC according to schedule in Rebif active group.
83986|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
83987|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
83988|NCT01247350|Drug|LY3009104|Administered orally
85001|NCT01278758|Drug|ASA404, DMXAA or DXAA|
85002|NCT01278784|Device|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
85003|NCT01278784|Device|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
85004|NCT01278797|Drug|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
85005|NCT01278797|Drug|Amlodipine Monocomponent|Active Comparator
85006|NCT01278810|Drug|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
85007|NCT01278823|Procedure|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
85008|NCT01278823|Other|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
85009|NCT00052403|Drug|monoclonal antibody anti-anb3 integrin|
85010|NCT01278836|Procedure|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
85011|NCT01278849|Drug|ASA404|
85012|NCT01278862|Device|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
85013|NCT01278888|Procedure|Anterolateral thoracotomy|Standard anterolateral thoracotomy
85014|NCT01278888|Procedure|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
85015|NCT01281306|Drug|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
85016|NCT01281306|Drug|Placebo|Placebo was supplied as tablets in blister cards.
85017|NCT01281332|Device|Menopod|The mechanism of action of the device will not be revealed in advance.
85018|NCT01281332|Device|Inactive device|
85019|NCT00052520|Genetic|polymerase chain reaction|Correlative studies
85273|NCT01279304|Radiation|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
85274|NCT01279317|Dietary Supplement|placebo co-ingestion|25 ml water co-ingested with a glucose-containing beverage
84159|NCT00052052|Drug|interferon-gamma 1b|200 mcg, SQ, 3x per week
84160|NCT01275170|Drug|midazolam|midazolam hcl syrup, single 2.0 mg dose, orally
84161|NCT01275170|Drug|omeprazole|omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
83216|NCT01251107|Drug|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
83217|NCT01251107|Drug|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
83218|NCT01251107|Drug|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
83219|NCT01253018|Behavioral|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
83220|NCT01253018|Behavioral|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
83221|NCT01253044|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
83222|NCT00049569|Drug|methotrexate|Given IT
83223|NCT01253044|Behavioral|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
83224|NCT01253070|Drug|Daunorubicin Hydrochloride|Given IV
83225|NCT01253070|Drug|Sorafenib Tosylate|Given PO
83226|NCT01253070|Drug|Cytarabine|Given IV
83227|NCT01253070|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspirate
83228|NCT01253070|Procedure|Biopsy|Undergo biopsy
83229|NCT01253070|Other|Laboratory Biomarker Analysis|Correlative studies
83230|NCT01253070|Other|Quality-of-Life Assessment|Ancillary studies
83231|NCT01253070|Other|Questionnaire Administration|Ancillary studies
83232|NCT01253083|Behavioral|mobility training with dynamic body weight support|
83233|NCT00049569|Drug|vincristine sulfate|Given IV
85477|NCT01264692|Drug|Amlodipine|10 mg once daily for 28 ± 2 days
85478|NCT00050830|Drug|CI 1033|
85479|NCT01264705|Drug|bavituximab and sorafenib|Bavituximab:0.3,1.0,and 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
85480|NCT01264718|Behavioral|Effects of Parent Mentors on Insuring Minority Children|After random assignment to the Parent Mentor group,the minority low-income parent of a Medicaid/CHIP eligible child will meet with a Parent Mentor to receive instruction and help on completing, submitting, and maintaining Medicaid/CHIP insurance for their child.
85481|NCT01264731|Biological|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
84550|NCT01280643|Genetic|gene expression analysis|Correlative studies
84551|NCT01280643|Other|laboratory biomarker analysis|Correlative studies
84552|NCT01280643|Other|immunohistochemistry staining method|Correlative studies
84553|NCT01280643|Genetic|nucleic acid sequencing|Correlative studies
84554|NCT01280643|Genetic|protein expression analysis|Correlative studies
84555|NCT01280643|Genetic|polymerase chain reaction|Correlative studies
84556|NCT01280643|Genetic|DNA analysis|Correlative studies
84557|NCT01280669|Drug|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
84558|NCT01280669|Drug|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
84559|NCT01280682|Drug|rituximab|anti-CD20 monoclonal antibody 125mg/m^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
84560|NCT00052507|Drug|bortezomib|
84561|NCT01280695|Drug|Placebo|Placebo Capsules
84562|NCT01280695|Drug|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
84563|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
84564|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
84565|NCT01280695|Drug|Pioglitazone|Pioglitazone 45 mg Capsules
85215|NCT00052559|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
85216|NCT01281748|Drug|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
85217|NCT01281748|Other|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
85218|NCT01281761|Drug|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
85219|NCT01281774|Biological|CSL112|reconstituted high density lipoprotein
85220|NCT01281774|Biological|Placebo|Normal saline (0.9%)
85221|NCT01281787|Drug|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
85222|NCT01281787|Drug|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
85530|NCT01272336|Other|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
85531|NCT01272349|Other|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
85532|NCT01272349|Other|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
85533|NCT01272362|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
85534|NCT01272375|Drug|Treatment A|PF-04764793 250/50 using inhaler A
85535|NCT01272375|Drug|Treatment B|PF-04764793 250/50 using inhaler A
85536|NCT00051701|Drug|alemtuzumab|
85537|NCT01272375|Drug|Treatment C|PF-04764793 250/50 using inhaler A
85538|NCT01272375|Drug|Treatment D|PF-04764793 250/50 using inhaler A
85275|NCT01279317|Dietary Supplement|vinegar co-ingestion|25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
85276|NCT01279330|Other|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
85277|NCT00001033|Drug|Levofloxacin|
85278|NCT00052403|Procedure|monoclonal antibody therapy|
85279|NCT01279330|Other|Control|No intervention (Patients receive by mail the materials needed for stool samples).
85280|NCT01279343|Device|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
85281|NCT01279382|Behavioral|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
85282|NCT01279382|Behavioral|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
85283|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
85284|NCT01279408|Other|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
85285|NCT01279421|Behavioral|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
85286|NCT01279421|Behavioral|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
85287|NCT01281839|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
85288|NCT01281839|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
85289|NCT01281839|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
85290|NCT01281839|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
85291|NCT01281852|Drug|Cisplatin|Given IV
85292|NCT01281852|Other|Laboratory Biomarker Analysis|Correlative studies
85293|NCT01281852|Drug|Paclitaxel|Given IV
83234|NCT01253096|Drug|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
83235|NCT01253109|Device|SENSIMED Triggerfish|Contact lens-based device for continuous IOP monitoring
83236|NCT01253122|Drug|TRx0037|
83237|NCT01253135|Biological|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
83238|NCT01253135|Other|White Petrolatum|Topical application
83527|NCT01246557|Drug|Lenalidomide|Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.
REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
83528|NCT01246557|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
83529|NCT01246570|Behavioral|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
83530|NCT00049179|Drug|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
83531|NCT01246570|Other|Control|The patients will receive the usual care provided by the hospitals and the community health services
83532|NCT01246583|Drug|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
83533|NCT01248910|Behavioral|Alpine Skiing|
83534|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
83535|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
83536|NCT01248923|Drug|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
83537|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
83538|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
83539|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
83540|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
83541|NCT00001017|Drug|Amphotericin B|
84566|NCT01280708|Other|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
84567|NCT01280721|Drug|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
84568|NCT01280734|Drug|Circadin (R) 2 mg|One 2 mg tablet at 23:00
84569|NCT01280734|Drug|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
84570|NCT01280734|Drug|Placebo|One tablet or encapsulated tablet at 23:00
84571|NCT01283594|Drug|Tozadenant (SYN115) 120 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 120 mg BID.
84572|NCT01283594|Drug|Tozadenant (SYN115) 180 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 180 mg BID.
84849|NCT01283776|Drug|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
84850|NCT01283789|Drug|Lapatinib and RAD-001|Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.
Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning.
84851|NCT01283802|Procedure|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|Techniques are as follows:
Direct ultrasound exploration without any contrast agents.
IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);
IOCUS injection of an air bolus into the bile duct.
84852|NCT00052715|Radiation|radiation therapy|
84853|NCT01283815|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
84854|NCT01283815|Procedure|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
84855|NCT01283841|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
84856|NCT01283854|Behavioral|Supervised home-based exercise|Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.
Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. "somewhat hard").
85539|NCT01264731|Drug|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
85540|NCT01264757|Behavioral|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
85541|NCT01264757|Behavioral|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
85542|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
85543|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
85544|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
85545|NCT01264770|Drug|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
85546|NCT00050843|Drug|thalidomide|
85547|NCT01264770|Drug|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
85548|NCT01264783|Drug|RNS60|RNS60 for intravenous administration
84631|NCT01278108|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
84632|NCT00052351|Drug|paclitaxel|
84633|NCT01278108|Drug|GLPG0778|multiple dose, capsule, 7 days
84634|NCT01278108|Drug|placebo|multiple dose, capsule, 7 days
84635|NCT01278121|Dietary Supplement|Diet A|3 days, 6 meals a day
84636|NCT01278121|Dietary Supplement|Diet B|10 days, 6 meals a day
84637|NCT01278134|Drug|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
84638|NCT01278134|Drug|RO5024048|1000 mg bid orally, up to 24 weeks
85611|NCT01272388|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
85612|NCT01272414|Drug|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
85613|NCT01272414|Drug|Saline injection|Injection of 0.4cc 0.9% normal saline
85614|NCT01272427|Dietary Supplement|water with glucose|0.75 g/kg body weight of glucose added to water
85615|NCT00051714|Behavioral|Family-Based Preventive Intervention|
85616|NCT01272427|Dietary Supplement|water and whey protein|0.75 g/kg body weight of whey protein added to water
85617|NCT01272427|Dietary Supplement|water with noncaloric sweetener|0.15 g of sucralose added to water
85618|NCT01272466|Biological|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
85619|NCT01272492|Other|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
85620|NCT01272505|Procedure|converntional SILC|
85621|NCT01272505|Procedure|Harmonic scalpel Single incision laparoscopic cholecystectomy|
85622|NCT01272531|Drug|Mood stabilizer treatment|lithium or valproate
85623|NCT01272557|Drug|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
85624|NCT01272557|Drug|Sorafenib|Sorafenib 400 mg bid (oral) continuously
85625|NCT01272583|Drug|Sitagliptin|100 mg once daily for six weeks
85626|NCT00051727|Behavioral|Bridges to High School Project|
85627|NCT01272583|Drug|Placebo|placebo, once daily for six weeks
85628|NCT01272609|Drug|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
85629|NCT01272609|Device|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
85074|NCT01276639|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
85075|NCT01276639|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
85076|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
85077|NCT00052273|Drug|capecitabine|
85078|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
85079|NCT01276652|Behavioral|Environmental modification|For a subset of patients, the feasibility of delivering routine care according to classic day/night routines and of reducing exposure to environmental light and sound will be assessed.
85080|NCT01276665|Procedure|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
85413|NCT01274793|Device|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
85414|NCT01274793|Device|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
85415|NCT01274806|Other|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
85416|NCT01274819|Other|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
85417|NCT01274832|Device|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
85418|NCT00000252|Drug|0% N2O|
85419|NCT00001032|Drug|Zidovudine|
85420|NCT00052026|Drug|placebo|administered twice daily for 8 months
85421|NCT01274845|Other|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
85422|NCT01274884|Procedure|Tightrope fixation|Arthroscopic repair
85423|NCT01274897|Biological|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
85424|NCT01274897|Biological|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
85425|NCT01274910|Dietary Supplement|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|Patient will receive Fish Oil capsules (EPAX 6000 EE) .
Treatment: 5 capsules per day
84857|NCT01283867|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
84858|NCT01283893|Procedure|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
84859|NCT01283906|Device|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
84860|NCT01283906|Device|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
84861|NCT01283919|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
84862|NCT01276262|Drug|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
84863|NCT01276262|Drug|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
84864|NCT01276262|Drug|Placebo|Oral tablets BID, repeated doses for 21 days
85142|NCT01274273|Drug|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
85143|NCT01274273|Drug|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
85144|NCT01274299|Procedure|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
85145|NCT01274312|Procedure|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
85146|NCT00051948|Drug|TLK286|
85147|NCT01274325|Drug|Sereflo|Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
85148|NCT01274325|Drug|Seretide|Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
85149|NCT01274338|Biological|Ipilimumab|Given IV
85150|NCT01274338|Other|Quality-of-Life Assessment|Ancillary studies
85151|NCT01274338|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
85152|NCT01274351|Drug|Tasigna|
84639|NCT01278134|Drug|danoprevir|100 mg bid orally, up to 24 weeks
84640|NCT00052520|Biological|therapeutic allogeneic lymphocytes|Given IV
84641|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
84642|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
84643|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
84644|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
84645|NCT01280760|Other|Device: Neurally Adjusted Ventilatory Assistance|Device: Neurally Adjusted Ventilatory Assistance
In ICU following extubation NIV was performed as follows:
facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode
84646|NCT01280773|Device|Neurally adjusted ventilatory assist|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
84647|NCT01280786|Drug|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
84648|NCT01280799|Behavioral|Acceptance-based separated family treatment|Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
84649|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
84938|NCT01281228|Drug|placebo|saline infusion
84939|NCT01281254|Drug|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
84940|NCT01281254|Drug|Placebo plus PLD|Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.
PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
84941|NCT01281267|Procedure|Facial Allograft Transplantation|Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
85630|NCT01272622|Radiation|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
84413|NCT01275495|Behavioral|Telephone Assessment and Skill-Building Kit (TASK II)|
84414|NCT01275495|Behavioral|Information, Support, and Referral (ISR)|
84415|NCT01275508|Drug|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
84416|NCT01275521|Drug|BONT-A intra-prostatic injection|• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.
Interruption of the medical therapy 1 month after the injection;
84417|NCT01275521|Drug|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
84418|NCT01275547|Drug|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
84419|NCT01275547|Drug|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
84420|NCT00052091|Behavioral|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
84421|NCT01275560|Drug|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
84422|NCT01275560|Drug|CArbosylane|
84423|NCT01275573|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
84424|NCT01275586|Drug|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
84425|NCT01275599|Drug|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
84426|NCT01275599|Drug|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
85426|NCT01269606|Drug|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
85427|NCT01269606|Drug|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
85428|NCT01269619|Device|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
85429|NCT00051376|Drug|L-Arginine|
85430|NCT01269619|Device|Static back support|A standard wrap-around sacro lumbar support
85431|NCT01269632|Biological|blood sampling, specific biological exams and biobank and self administered questionnaires|HIV INFECTION at inclusion and annually up to 06 years follow-up
clinical and therapeutic evaluation by physician
biological: blood sampling, specific biological exams and biobank
self administered questionnaires
In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)
HIV UNINFECTED at inclusion and after 3 years follow up
clinical evaluation by physician
biological: blood sampling, specific biological exams and biobank
self administered questionnaires
84487|NCT01283347|Drug|18F-DTBZ|During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG
84488|NCT01283360|Other|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
84489|NCT01283360|Drug|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
84490|NCT01283373|Drug|DSTP3086S|DSTP3086S administered intravenously
84491|NCT01283373|Drug|DSTP3086S|Escalating intravenous dose
84492|NCT01283386|Drug|chlorambucil|10 mg/m2 orally on Days 1-7 of each 28-day cycle, 6 cycles
84493|NCT01283386|Drug|cyclophosphamide|150 mg/m2 iv or orally on Days 1-3 of each 28-day cycle, 6 cycles
84494|NCT01275651|Other|laboratory biomarker analysis|Correlative studies
84495|NCT00001032|Drug|Zalcitabine|
85153|NCT01274364|Other|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
85154|NCT01274364|Other|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
85155|NCT01274377|Biological|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
85156|NCT01274403|Drug|Melphalan, Prednisone and Thalidomide|
85157|NCT00051974|Drug|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
85158|NCT01274416|Behavioral|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
85159|NCT01276730|Drug|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
85160|NCT00052273|Drug|enzastaurin hydrochloride|
85482|NCT01267032|Behavioral|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
85483|NCT01267045|Behavioral|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
85484|NCT00051090|Drug|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
85485|NCT01267058|Biological|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
85486|NCT01267058|Biological|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
85487|NCT01267058|Biological|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
85488|NCT01267071|Drug|A|GSK962040 (50 mg, SD, oral)
85489|NCT01267071|Drug|B|14C GSK962040 (100 μg, SD, iv)
84942|NCT01281306|Drug|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
84943|NCT01281306|Drug|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
84944|NCT01273818|Drug|Gentamicin|80 mg gentamicin application intraoperatively
84945|NCT00051870|Device|Magstim Rapid Magnetic Stimulator|
84946|NCT01273831|Drug|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
84947|NCT01273831|Drug|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
84948|NCT01273844|Drug|Bortezomib|Bortezomib
84949|NCT01273857|Procedure|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
84950|NCT01273857|Procedure|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
84951|NCT01273883|Dietary Supplement|Magnesium|Magnesium 532 mg a day
84952|NCT01273883|Other|Placebo|matching form/dosage
84953|NCT01273896|Drug|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
84954|NCT01273909|Procedure|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
84955|NCT01273909|Procedure|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
84956|NCT00001031|Biological|rgp120/HIV-1 SF-2|
84957|NCT00051896|Drug|GBR 12909|
85223|NCT01281800|Procedure|Gemcitabine in long infusion|TREATMENT A:
Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid [Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT], vitamin B-12 [OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.
In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.
TREATMENT B:
Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.
In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy.
85224|NCT01281813|Drug|Darunavir|600 mg tablet, intake of 1 tablet twice a day in combination with ritonavir
84427|NCT01275612|Biological|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
84428|NCT01275625|Drug|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
83467|NCT00049504|Genetic|polymorphism analysis|Correlative studies
83468|NCT01251315|Drug|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
83469|NCT01251315|Drug|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
83470|NCT01251328|Procedure|General anaesthesia|general anaesthesia is performed according to the hospitals standard
83471|NCT01251328|Procedure|Sedation|Sedation is performed according to the hospitals standard
83472|NCT01251341|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
83473|NCT01251341|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
83474|NCT01251341|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
83475|NCT01251354|Drug|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
83476|NCT01251367|Drug|Dysport|I.M. (intramuscular) injection on day 1 of each treatment cycle.
83477|NCT01251380|Drug|Botulinum type A toxin (Dysport®)|IM (in the muscle) injection on day 1 of each treatment cycle.
83478|NCT00049504|Genetic|gene expression analysis|Correlative studies
83479|NCT01251393|Drug|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
83480|NCT01251393|Drug|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
83481|NCT01251406|Drug|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
83482|NCT01251406|Drug|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
83483|NCT01251406|Drug|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
84496|NCT00052091|Behavioral|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
84497|NCT01275664|Procedure|Adjuvant Therapy|Ancillary studies
84498|NCT01275664|Drug|Aprepitant|Given IV and PO
84499|NCT01275664|Drug|Carboplatin|Given IP
84500|NCT01275664|Drug|Cisplatin|Given IP
84501|NCT01275664|Drug|Dexamethasone|Given PO
84502|NCT01275664|Drug|Granisetron Transdermal Patch|Apply one patch to upper arm
84503|NCT01275664|Procedure|Management of Therapy Complications|Ancillary studies
84504|NCT01275664|Other|Questionnaire Administration|Ancillary studies
84505|NCT01275677|Drug|Cyclophosphamide|Given IV
84506|NCT01275677|Drug|Docetaxel|Given IV
84507|NCT00052104|Behavioral|Cognitive-Behavioral Family Systems Intervention|
84508|NCT01275677|Drug|Doxorubicin Hydrochloride|Given IV
84787|NCT01276210|Drug|sorafenib tosylate|Given PO
84788|NCT01276210|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
84789|NCT01276210|Other|laboratory biomarker analysis|Correlative studies
84790|NCT01276223|Drug|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
84791|NCT00052182|Biological|EP HIV-1090|
84792|NCT01276223|Other|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
84793|NCT01276236|Drug|Maraviroc|FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.
Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.
Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions.
84794|NCT01276249|Device|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
85490|NCT01267084|Drug|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
85491|NCT01267084|Drug|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
85492|NCT01267084|Drug|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
85493|NCT01267097|Behavioral|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
85494|NCT01267097|Behavioral|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
85495|NCT00051090|Drug|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
85496|NCT01267110|Other|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
84573|NCT01283594|Drug|Tozadenant (SYN115) 240 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 240 mg BID.
84574|NCT01283607|Behavioral|Digicoach|Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
84575|NCT01283620|Behavioral|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
84576|NCT01283620|Other|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
84577|NCT01283633|Device|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
84578|NCT01283646|Drug|Apevitin BC|3.5 to 5 ml 3 times a daily
85225|NCT01281813|Drug|ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
85226|NCT00052559|Procedure|therapeutic conventional surgery|Undergo surgery
85227|NCT01281813|Drug|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
85228|NCT01281813|Drug|ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
85229|NCT01274416|Behavioral|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
85230|NCT01274429|Drug|powdered peanut protein|Active peanut allergy will be confirmed in all subjects with Double Blind Placebo Controlled Food Challenge (DBPCFC) 2 gm peanut protein oral food challenge prior to entry into the study. Oral desensitization begins with the modified rush. The first dose is 0.1 mg of peanut protein, the dose is doubled every 30 minutes until a maximum of 6 mg of peanut protein. The daily dose will be given at home until the scheduled escalation visit. Subjects return for escalation visits in the Food Allergy Study Center (FACS) every two weeks. The maintenance phase begins once the subject reaches 2300mg. This dose is taken daily. The maintenance phase begins once the subject reaches 2300mg which they take daily at home. All subjects will have a Double-Blind Placebo-Controlled Food Challenge (DBPCFC) at the end of 18 months of POIT to assess for desensitization.
85231|NCT01274442|Other|anamnesis|To update the anamnesis.
85232|NCT01274442|Procedure|oral examination|A brief clinical oral examination will be performed.
85233|NCT01274442|Procedure|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
85234|NCT01274455|Genetic|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
85235|NCT01274481|Drug|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
85236|NCT01274507|Other|Medical tests|All participants will undergo medical tests and will be observed.
85237|NCT01274520|Device|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
85549|NCT01264783|Drug|Placebo|0.9% normal saline for injection
85550|NCT01264796|Behavioral|cullurally tailored diabetes education|lifestyle modification group education
85551|NCT01264809|Behavioral|Specific consultation for physical activity counseling|Specific consultation
83484|NCT01251419|Other|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
83485|NCT01251458|Drug|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
83486|NCT01251471|Drug|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
83487|NCT01251484|Drug|BIBF1120|Tablet 200 mg twice daily until progression
83488|NCT01251497|Behavioral|diabetes self-management education|
83776|NCT01244347|Drug|folic acid|
83777|NCT01244347|Drug|folic acid|
83778|NCT01244360|Dietary Supplement|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
83779|NCT01246973|Drug|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
83780|NCT01246986|Drug|LY2157299|Administered orally
83781|NCT01246986|Drug|Sorafenib|Administered orally
83782|NCT01246999|Biological|Trivalent Seasonal Live attenuated Influenza vaccine|0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
83783|NCT00049218|Drug|Carboplatin|
83784|NCT01246999|Biological|Seasonal Trivalent Influenza Vaccine 2010-2011|.25 mL given intramuscularly to children 24 to 25 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 36 months to 9 years of age, 2 doses given 28 day s apart.
83785|NCT01246999|Biological|Seasonal Influenza Vaccine TIV/LAIV|TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
83786|NCT01246999|Biological|Seasonal Influenza Vaccines LAIV/TIV|LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
83787|NCT01247012|Dietary Supplement|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
83788|NCT01247012|Dietary Supplement|Lipid minimization|1g/kg/day daily until infant receiving full enteral feeds
IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)
83789|NCT01247025|Other|No intervention|This study will not contain a specific intervention
84795|NCT01278251|Procedure|Distal Biceps Re-Insertion|
84796|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
84797|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
84798|NCT01278277|Dietary Supplement|Saffron supplementation|Saffron supplementation 20 mg
84799|NCT00052364|Other|laboratory biomarker analysis|Correlative studies
84800|NCT01278277|Other|placebo|placebo supplementation
84801|NCT01278290|Drug|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate aqueous 0.1 mg/m2 subcutaneous. Gonadorelin acetate 100 ug intravenous.
84802|NCT01278290|Drug|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
84803|NCT01278303|Device|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
84804|NCT01278316|Behavioral|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
84805|NCT01278316|Behavioral|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
85081|NCT01276665|Procedure|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
85082|NCT01276691|Drug|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
85083|NCT01276704|Drug|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
85084|NCT01276704|Drug|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
85085|NCT01276717|Drug|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
85086|NCT01276717|Drug|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
85087|NCT01278888|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
84579|NCT01283646|Drug|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
84580|NCT00052689|Drug|gemcitabine hydrochloride|Given IV
84581|NCT01283659|Other|Standard Imaging|
84582|NCT01283659|Other|Advanced Imaging|
84583|NCT01283672|Other|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
84584|NCT01283685|Other|breathing helium-hyperoxia|40% O2, 60% He
84585|NCT01283685|Other|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
84586|NCT01283698|Drug|Experimental: LAS 41004 dosage 1|dosage 1, once daily
84587|NCT01283698|Drug|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
84588|NCT01283698|Drug|Experimental: LAS 41004 dosage 3|dosage 3, once daily
84589|NCT01283698|Drug|Placebo Comparator: placebo|once daily
84590|NCT01283698|Drug|Reference|Active Comparator,once daily
84591|NCT00052715|Drug|poly ICLC|
84865|NCT01276275|Drug|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
84866|NCT01276288|Drug|BI 10773|multiple oral doses
84867|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
84868|NCT01276288|Drug|torasemide|multiple oral doses
84869|NCT00052195|Biological|SRL-172|5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
84870|NCT01276288|Drug|BI 10773|multiple oral doses
84871|NCT01276288|Drug|torasemide|multiple oral doses
84872|NCT01276288|Drug|BI 10773|multiple oral doses
84873|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
84874|NCT01276301|Drug|Verapamil|single dose verapamil
85552|NCT01264809|Behavioral|Consultation for physical activity counseling|Specific consultation
85553|NCT01264822|Drug|Rabeprazole Sodium|The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.
The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.
If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg.
85554|NCT01264835|Device|Slotted Anoscope|SA411
85555|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
85556|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
85557|NCT00050856|Drug|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
85558|NCT01267136|Drug|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg [=0.3 mL/kg] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
85559|NCT01267136|Drug|Tramadol suspension|Liquid tramadol 1.05 mg/kg [=0.3 mL/kg] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
85560|NCT01267175|Device|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
85561|NCT01267188|Drug|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
85562|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
85563|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
85564|NCT01267201|Drug|methylprednisolone|tablet 32 mg single dose
85565|NCT00051090|Drug|Efavirenz|Administered orally at a daily dose of 600 mg
85566|NCT01267214|Drug|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
85567|NCT01267214|Procedure|Osteotomy alone|no injection
85568|NCT01267227|Drug|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
85569|NCT01267227|Drug|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
83790|NCT01247038|Device|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
83791|NCT01247038|Device|Metal-on-Metal|Metal on Metal articulation
83792|NCT01247051|Procedure|Precoating|preoperative filling of heart lung machine with patients blood
83793|NCT01247051|Procedure|Standard priming|preoperative filling of heart lung machine with colloids
83794|NCT00049218|Drug|Etoposide|
83795|NCT01247064|Drug|Nebulized 3% saline|4 mL of nebulized 3% saline once
83796|NCT01247064|Drug|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
83797|NCT01247077|Other|selenium|200 ug selenium once daily
83798|NCT01247077|Other|placebo|
84112|NCT01277237|Drug|Omacor|Active comparator: omacor 4g/day
84113|NCT01279694|Drug|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
84114|NCT01279694|Drug|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
84115|NCT01279694|Drug|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
84116|NCT01279707|Biological|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
84117|NCT01279707|Biological|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
84118|NCT01279707|Biological|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
84119|NCT01279720|Biological|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
84120|NCT00052442|Drug|pralatrexate|
85088|NCT01278888|Procedure|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
85089|NCT01278914|Biological|Dendritic Cells (DC) prostate|
85090|NCT01278927|Behavioral|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
85091|NCT01278927|Behavioral|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
85092|NCT00052403|Procedure|anti-cytokine therapy|
85093|NCT01278927|Behavioral|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
85094|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
85095|NCT01278940|Biological|Dendritic Cells (DC) malignant melanoma|
85096|NCT01278953|Device|Catheter ablation for the treatment of paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
85097|NCT01278966|Other|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
85098|NCT01278979|Device|Objective measurements of perineal tears with "Peri-Rule"|Four measurements will be used in this study.
Depth of tear, from the fourchette into the greatest depth of the perineal body.
Length of tear, from the fourchette to the apex of the vaginal tear.
Length of tear, from the fourchette along perineal skin towards the anus.
Length of the perineal body, from the fourchette to outer margin of anus.
85099|NCT01278979|Other|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
85432|NCT01269645|Behavioral|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
85433|NCT01269658|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
85434|NCT01269658|Drug|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
85435|NCT01269671|Drug|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
84875|NCT01276301|Drug|BI 10773|single dose BI 10773
84876|NCT01276301|Drug|BI 10773|single dose BI 10773
84877|NCT01276314|Drug|anti-TNF a|25mg BIW, SC
84878|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
84879|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
84880|NCT00001033|Drug|Ethambutol hydrochloride|
84881|NCT00052208|Drug|gefitinib|Given PO
84882|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
84883|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
84884|NCT01276340|Device|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
84885|NCT01276353|Drug|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
84886|NCT01276353|Drug|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
84887|NCT01276366|Other|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
84888|NCT01276366|Other|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
85161|NCT01276730|Drug|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
85162|NCT01276756|Drug|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
85163|NCT01276756|Drug|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
85164|NCT01276756|Drug|Ribavirin|Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
85165|NCT01276769|Drug|Paclitaxel plus carboplatin|Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.
1 cycle = 21days 2-6cycles
84650|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
84651|NCT00052520|Biological|aldesleukin|Given SC
84652|NCT01280812|Behavioral|Pedometer only|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
84653|NCT01280838|Behavioral|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
84654|NCT01280838|Behavioral|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
84655|NCT01280851|Procedure|Magnetic Resonance Imaging|1 hour of MRI exam will be performed in addition to the standard of care procedures, using low dose of gadolinium-based contrast (not investigational drug).
84656|NCT01280877|Device|tACS|Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
84657|NCT00052637|Procedure|biopsy|
84658|NCT01283152|Drug|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
84659|NCT01283165|Behavioral|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
84660|NCT01283178|Radiation|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
84661|NCT01283178|Drug|cisplatin|Given IV
84662|NCT01283178|Radiation|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
84663|NCT01283178|Other|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
84664|NCT01283178|Procedure|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
84665|NCT01283178|Radiation|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
84121|NCT01279733|Genetic|Microarray analysis|Microarray performed on prenatal specimen:
Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.
Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed.
84122|NCT01279746|Device|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
84123|NCT01279785|Drug|123I-MIP-1072|Single IV dose
84124|NCT01279798|Biological|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
84125|NCT01279811|Other|Crossover of vasopressors|To evaluate the effect of different vasopressor agents on SCPP, a "crossover" intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine.
84126|NCT01279824|Behavioral|swallowing therapy|Standardized behavioral swallowing intervention
84429|NCT01275638|Drug|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
84430|NCT01277705|Biological|GSK Biologicals' IPV vaccine|Intramuscular, single dose
84431|NCT01277705|Biological|Revaxis®|Intramuscular, single dose
84432|NCT01277718|Drug|GDC-0973/XL518|Oral dose in a fasted state
84433|NCT01277718|Drug|GDC-0973/XL518|Oral dose in fed state
84434|NCT01277718|Drug|rabeprazole|Repeating oral dose
84435|NCT01277718|Drug|rabeprazole|Oral dose in fasted state
84436|NCT01277731|Drug|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
84437|NCT01277744|Procedure|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
85436|NCT01269671|Other|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
85437|NCT01269684|Drug|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
85438|NCT01269697|Dietary Supplement|Nutrof Total|2 capsules 2 times per day during 6 month
85439|NCT01269697|Dietary Supplement|Placebo Nutrof total|2 capsules 2 times per day during 6 month
85440|NCT00051389|Drug|Fosinopril|
85441|NCT01269723|Dietary Supplement|Broccoli sprout homogenate|Subjects will drink the broccoli shake homogenate
85442|NCT01269723|Dietary Supplement|Alfalfa sprout homogenate|Subjects will drink the alfalfa sprout homogenate.
85443|NCT01269736|Behavioral|Education|Online ECG monitoring education program and strategies to implement and sustain change
85444|NCT01272128|Drug|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
85445|NCT01272141|Drug|Lapatinib and Everolimus|Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily
85446|NCT01272154|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
85447|NCT01272167|Behavioral|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
85448|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
84509|NCT01275677|Other|Laboratory Biomarker Analysis|Correlative studies
84510|NCT01275677|Drug|Paclitaxel|Given IV
84511|NCT01275677|Other|Quality-of-Life Assessment|Ancillary studies
84512|NCT01275677|Biological|Trastuzumab|Given IV
84513|NCT01275716|Behavioral|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
85166|NCT01276769|Drug|Paclitaxel and epirubicin|Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.
1 cycle = 21days
2-6cycles
85167|NCT01276782|Drug|Levothyroxine|It is FDA approved drug for thyroid disease
85168|NCT01276795|Dietary Supplement|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
85169|NCT01276808|Procedure|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
85170|NCT01276808|Procedure|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
85171|NCT00052286|Drug|modafinil|
85172|NCT01276821|Drug|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
85173|NCT01276821|Drug|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
85174|NCT01276834|Drug|everolimus|comparison of everolimus-based and CNI-based immunosuppression
85175|NCT01276847|Drug|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing > 100 kg on Day 1, and Weeks 4 and 16
85176|NCT01276847|Drug|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
85177|NCT01276860|Device|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
85178|NCT01276873|Device|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
85179|NCT01276886|Drug|antibiotic|
85180|NCT01276886|Procedure|Colonic resection with or without stoma|
85497|NCT01267110|Other|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
85498|NCT01267123|Other|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
84666|NCT01283191|Behavioral|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
84958|NCT01273922|Biological|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
84959|NCT01273948|Drug|Bavituximab|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or
Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or
84960|NCT01273948|Drug|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
84961|NCT01273961|Device|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
84962|NCT01273974|Biological|intradermal influenza vaccine|0.25ml ,intradermal
84963|NCT01273974|Biological|intramuscular influenza vaccine|0.5ml,intramuscular
84964|NCT01273987|Procedure|Neobladder posterior wall suspended with round ligament of uterus|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
84965|NCT01274000|Drug|YM060|oral
84966|NCT01274000|Drug|placebo|oral
84967|NCT01276379|Drug|FOLFIRI (m)|FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
84968|NCT01276379|Drug|FOLFOX-6 (m)|FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
84969|NCT00052208|Radiation|radiation therapy|Undergo radiation therapy
84970|NCT01276379|Drug|Cetuximab|- 500 mg/m2 i.v. Every 2 weeks.
84971|NCT01276418|Device|CO2 laser|Ablation and coagulation of soft tissue
84972|NCT01276431|Drug|Buprenorphine transdermal patch|
84973|NCT01276444|Device|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
84438|NCT00001033|Drug|Pyrazinamide|
84439|NCT00052351|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
84440|NCT01277744|Drug|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
84441|NCT01277757|Drug|Akt inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
84442|NCT01277757|Other|laboratory biomarker analysis|Correlative studies
84443|NCT01277757|Other|pharmacological study|Correlative studies
84444|NCT01277770|Drug|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
84445|NCT01277770|Other|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
84446|NCT01277770|Drug|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
84447|NCT01277783|Device|Medtronic Model 6227ATS deflectable delivery catheter|Endocardial Left Ventricular pacing lead delivery
84448|NCT01277783|Device|Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter|Endocardial Left Ventricular pacing lead delivery
84449|NCT01277783|Device|Medtronic Model 3830|Endocardial Left Ventricular pacing
83489|NCT00049504|Radiation|total-body irradiation|Undergo total-body irradiation
83490|NCT01243710|Device|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
83491|NCT01243723|Drug|Eductyl suppository|One suppository every morning during 21 days
83492|NCT01243723|Drug|Placebo suppository|One suppository every morning during 21 days
83493|NCT01243736|Drug|Combination Prep|combination bowel preparation, which consists of:
drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;
drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;
drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;
lying on your right side for 30 minutes following the swallowing of the capsule endoscope.
83494|NCT01243762|Drug|dalotuzumab + MK-2206|Dalotuzumab (MK-0646) intravenously once weekly and MK-2206 by mouth once weekly in 28-day cycles
83495|NCT01243762|Drug|dalotuzumab + MK-0752|Dalotuzumab (MK-0646) intravenously once weekly and MK-0752 by mouth once weekly in 28-day cycles
84514|NCT01275729|Drug|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
84515|NCT01275742|Behavioral|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
84516|NCT01275755|Drug|Placebo|
84517|NCT01275755|Drug|ADL5945 0.25 mg|
84518|NCT00052117|Drug|capravirine|
84519|NCT01277809|Behavioral|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
84520|NCT01277822|Drug|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
84521|NCT01277822|Drug|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
84522|NCT01277822|Drug|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
84523|NCT01277822|Drug|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
84524|NCT01277835|Drug|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
84525|NCT01277835|Drug|Placebo|Saline Infusion at same rate as experimental arm
84526|NCT01277861|Drug|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
84527|NCT00052351|Biological|sargramostim|
84806|NCT01278329|Other|"Garbh Sanskar" audio cassette (Times Music Inc., Mumbai, India)|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
84807|NCT01278342|Drug|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
84808|NCT01278342|Drug|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
85499|NCT01269749|Radiation|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
85500|NCT01269749|Drug|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
85501|NCT01269762|Drug|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
85502|NCT01269775|Other|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
85503|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
85504|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
85505|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
85506|NCT00051402|Drug|Isoflavones|
85507|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
85508|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
85509|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
85510|NCT01269801|Drug|onabotulinumtoxinA|Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;
Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.
At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
85511|NCT01269801|Drug|JUVÉDERM|Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;
• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.
At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
85512|NCT01269814|Procedure|Gastroscopy|Gastroscopy
84592|NCT01283711|Device|apollo device|RF treatments for wrinkles and rhytides reduction
84974|NCT01276444|Device|transpulmonary thermodilution + central venous saturation|Described in details above
84975|NCT01276457|Drug|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
85238|NCT00051987|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
85239|NCT01274533|Drug|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
85240|NCT01274546|Device|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
85241|NCT01274559|Drug|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
85242|NCT01274559|Drug|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
85243|NCT01274585|Device|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
85244|NCT01274585|Device|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
85245|NCT01274598|Biological|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10^10 CFU by mouth twice daily for 28 days
85246|NCT01274611|Drug|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
85247|NCT01276899|Procedure|Needle core biopsies|No investigational products will be administered to subjects as part of this translational research study.
A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank.
85248|NCT00052299|Drug|cytarabine|
85249|NCT01276899|Procedure|Needle core biopsies of metastatic lesion|No investigational products will be administered to subjects as part of this translational research study.
Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank.
85250|NCT01276912|Drug|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
83496|NCT01243762|Drug|Dalotuzumab + MK-8669 (ridaforolimus)|Dalotuzumab (MK-0646) intravenously once weekly and MK-8669 orally daily for 5 consecutive days per week in 28-day cycles
83497|NCT01243775|Drug|Belotaxel|60 mg/m2 3 weekly (day 1)
83498|NCT01243775|Drug|Belloxa|70 mg/m2 3 weekly (day 2)
83499|NCT01243788|Drug|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
83500|NCT00049036|Drug|prednisone|Given orally
83501|NCT01243801|Drug|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
83502|NCT01243814|Device|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
83503|NCT01243814|Device|placebo injection|joint injection with saline solution for placebo
83504|NCT01243827|Drug|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
83505|NCT01243827|Drug|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
83506|NCT01243853|Dietary Supplement|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
83507|NCT01243866|Other|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
83799|NCT01247090|Drug|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU * 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
83800|NCT01247090|Drug|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU * 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
83801|NCT01247090|Drug|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
83802|NCT01249352|Radiation|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
83803|NCT01249365|Biological|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination
84809|NCT01278342|Drug|cabergoline|Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:
st week: 0.25 mg twice a week (0.50 mg/week)
nd week: 0.50 mg/week twice a week (1 mg/week)
rd week: 0.50 mg four times a week (2 mg/week)
th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)
84810|NCT00052377|Biological|aldesleukin|Given SC
84811|NCT01278355|Device|Ear acupuncture|Ear acupuncture
84812|NCT01278368|Procedure|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
84813|NCT01278368|Procedure|Pancreatic resection|Pancreatic resection
84814|NCT01278381|Procedure|Pancreaticoduodenectomy|Resection of pancreatic lesion
84815|NCT01278394|Drug|AN2690 Solution, 5.0%|Once daily application for 360 days
84816|NCT01278407|Drug|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
84817|NCT01278407|Drug|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
84818|NCT00052520|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
84819|NCT01280994|Drug|Xenon|Each subject will receive up to but not exceeding 5 doses of hyperpolarized 129Xenon gas during any given imaging session. One of these doses is used for calibrating the MRI scanner and will contain 200 ml Xe, and 800ml N2. Xenon Doses used for image acquisition will contain up to 100% xenon at a volume up to 1 liter. Subjects will receive no more than 4 doses consisting of 100% xenon at 1 liter.
Xenon will be administered with at least a 10 minute interval between doses to ensure that there is no imaging or health effect from residual xenon
84820|NCT01281007|Drug|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
84821|NCT01281007|Drug|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
84822|NCT01281033|Procedure|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
84823|NCT01281033|Procedure|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
85100|NCT01278992|Dietary Supplement|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
84593|NCT01275768|Procedure|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
84594|NCT01275781|Drug|[14C]-AZD9742|1000 mg intravenous over 2 hours
84595|NCT01275807|Device|acupuncture|10 sessions of acupuncture
84596|NCT01275807|Other|self care|physical exercice, diet, self help groups, psychological support
84597|NCT01275820|Dietary Supplement|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
84598|NCT01275833|Device|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
84599|NCT01275846|Device|Health Guide using AHA heart failure protocols and content|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
84600|NCT01275859|Drug|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
84601|NCT01275872|Other|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
84602|NCT01275885|Dietary Supplement|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
84603|NCT00052117|Drug|Kaletra|
84604|NCT01275885|Dietary Supplement|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
84605|NCT01275885|Dietary Supplement|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
84606|NCT01275911|Drug|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
84607|NCT01275911|Drug|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
84608|NCT01275924|Device|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
84609|NCT01275924|Device|Syndesmotic screw|Quadricortical syndesmotic screw
84610|NCT01275937|Drug|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
85251|NCT01276912|Behavioral|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
85252|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
85253|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
85254|NCT01276925|Device|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
85570|NCT01267227|Drug|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
85571|NCT01267227|Drug|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
85572|NCT01267240|Drug|Capecitabine|Given PO
85573|NCT01267240|Drug|Vorinostat|Given PO
85574|NCT01267253|Drug|brivanib alaninate|
85575|NCT01267253|Other|laboratory biomarker analysis|
85576|NCT00051090|Drug|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
85577|NCT01267266|Drug|saracatinib|Given orally
85578|NCT01267266|Other|hydrocortisone/placebo|Given orally
85579|NCT01267279|Drug|Zoledronic acid|Zoledronic acid per protocol
85580|NCT01267292|Drug|Buspirone|week 1 = 30 mg BID weeks 2-3 = 45 mg BID
85581|NCT01267305|Drug|Fondaparinux|2.5mg IH qd(8AM) after operation
85582|NCT01267305|Drug|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
85583|NCT01267305|Drug|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
85584|NCT01267331|Procedure|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
85585|NCT01267331|Procedure|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
83804|NCT01249378|Other|All subjects receive three sequences of a standard breakfast|All subjects receive three sequences of a standard breakfast containing :
10 g non emulsified
or 40 g non emulsified
or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions
83805|NCT00049361|Radiation|radiation therapy|
83806|NCT01249391|Device|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
83807|NCT01249404|Drug|Botulinum type A toxin (Dysport®)|I.M. injection on day 1 (single treatment cycle)
83808|NCT01249404|Drug|Placebo|I.M. injection on day 1 (single treatment cycle)
83809|NCT01249417|Drug|Botulinum type A toxin (Dysport®)|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
83810|NCT01249417|Drug|Placebo|I.M. injection on day 1 of a single treatment cycle.
83811|NCT01249430|Drug|Azacitidine|Given IV
83812|NCT01249430|Drug|Cytarabine|Given IV
83813|NCT01249430|Drug|Etoposide|Given IV
83814|NCT01249430|Other|Laboratory Biomarker Analysis|Correlative studies
83815|NCT01249430|Drug|Mitoxantrone Hydrochloride|Given IV
83816|NCT00049374|Biological|oblimersen sodium|
83817|NCT01249430|Other|Pharmacological Study|Correlative studies
83818|NCT01249443|Drug|vorinostat|Given PO
83819|NCT01249443|Other|diagnostic laboratory biomarker analysis|Correlative studies
84127|NCT01279837|Behavioral|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
84128|NCT01279850|Drug|Pregabalin (Lyrica) capsule|Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily".
84129|NCT01282502|Drug|Midostaurin|50 mg BID for 8 cycles
84130|NCT00052598|Biological|therapeutic allogeneic lymphocytes|Given IV
85101|NCT01279031|Device|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
85102|NCT01279031|Device|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
85103|NCT00052403|Procedure|antiangiogenesis therapy|
85104|NCT01279044|Behavioral|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications—beliefs, thoughts, and attitudes—that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
85105|NCT01279044|Behavioral|Standard HIV testing with information only|Standard HIV testing with information only
85106|NCT01279057|Drug|Fluticasone Furoate (Lek Pharmaceuticals ) Nasal Spray|110 mcg per day
85107|NCT01279057|Drug|Fluticasone furoate (Veramyst®) nasal spray|110 mcg per day
85108|NCT01279057|Drug|Placebo nasal spray|
85109|NCT01279070|Behavioral|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
85110|NCT01281488|Procedure|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
85111|NCT01281488|Drug|indocyanine green|Given IV
85112|NCT00052520|Other|staining method|Correlative studies
85113|NCT01281501|Drug|Normal saline|10 ml of 0.9% sodium chloride solution
85114|NCT01281501|Drug|Pantoprazole|80 mg of intravenous pantoprazole
85115|NCT01281501|Drug|Oral antacid|30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
85116|NCT01281501|Drug|Hyoscine butylbromide|20 mg of intravenous hyoscine butylbromide
85117|NCT01281514|Drug|everolimus|Given PO
85118|NCT01281514|Drug|carboplatin|Given IV
85119|NCT01281514|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
85120|NCT01281514|Other|laboratory biomarker analysis|Correlative studies
85121|NCT01281527|Drug|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
84889|NCT01276366|Other|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
84890|NCT01278407|Drug|Donepezil matched placebo|
84891|NCT01278420|Device|Tecnis MF|30 subjects will be implanted with the Tecnis MF
84892|NCT01278420|Device|ReSTOR|30 subjects will be implanted with ReSTOR
84893|NCT00001033|Drug|Pyridoxine hydrochloride|
84894|NCT00052377|Biological|recombinant interleukin-12|Given SC
84895|NCT01278433|Biological|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
84896|NCT01278446|Other|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
84897|NCT01278446|Other|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
84898|NCT01278459|Drug|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
84899|NCT01278472|Device|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
84900|NCT01278472|Device|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
84901|NCT01278485|Drug|Sulphonylurea|SU administered according to usual practice.
84902|NCT01278485|Drug|Metformn|Metformin administered according to usual practice.
84903|NCT01278498|Drug|Escitalopram|first week:5mg 2nd week~12 week:10mg
84904|NCT01278498|Drug|sugar pill|first week:5mg 2nd week~12 weeks:10mg
84905|NCT00052377|Other|laboratory biomarker analysis|Correlative studies
84906|NCT01278511|Other|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
84907|NCT01278537|Behavioral|Information|Booklet, motivational interviewing, brief advice
84908|NCT01278563|Behavioral|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
84909|NCT01278576|Drug|BOTOX-A®|200 units, single treatment only
84910|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
85586|NCT01269853|Drug|Bevacizumab|ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)
Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment
If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle
85587|NCT00001029|Drug|Zalcitabine|
85588|NCT00051415|Behavioral|Flaxseed-supplemented diet|
85589|NCT01269866|Drug|Cymbalta|Cymbalta 60 to 120 mg PO QD
85590|NCT01269879|Device|Flexi-Bar vibration device only|daily vibration training 10min twice
85591|NCT01269879|Device|Flexi-Bar + XCO-Trainer|XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.
In addition Flexi-Bar vibration training as in the referred active comparator group
85592|NCT01269892|Dietary Supplement|lactose-free milk|a milk without lactose
84667|NCT01283191|Behavioral|Education Control|Education class
84668|NCT00052637|Procedure|cystoscopy|
84669|NCT01283204|Drug|SP|<Every 3 weeks>
Day 1~14 : TS-1 80mg/m2/day (PO),
Day 1 : CDDP 60mg/m2/day IVF 2hours,
Day 15~21 : Rest.
84670|NCT01283204|Drug|FL/Tax|<Every q 3 weeks>
Day1 : Paclitaxel 175mg/m2 IVF for 2hours
Day1 : Leucovorin 20mg/m2 IVF for 1hour
Day1~3 : 5-FU 1000mg/m2 IVF for 24hours
84671|NCT01283204|Drug|FL/Doc|<Every q 3 weeks>
Day1 : Docetaxel 75mg/m2 IVF for 1hour
Day1 : Leucovorin 20mg/m2 IVF for 1hour
Day1~3 : 5-FU 1000mg/m2 IVF for 24hours
84672|NCT01283204|Drug|FOLFOX|<Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
84673|NCT01283217|Drug|DS|Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
84674|NCT01283217|Drug|SP|S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
84675|NCT01283230|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
84676|NCT01283243|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
84677|NCT01283256|Drug|zonisamide|zonisamide 100mg tablets
84131|NCT01282515|Drug|clobetasolpropionate|continuously treatment
84132|NCT01282515|Drug|hexaminolevulinate|one PDT treatment
84133|NCT01282528|Biological|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
84134|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
84135|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
84136|NCT01282554|Device|electrostimulation program (Rehab 400)|electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.
Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.
Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months.
84137|NCT01282567|Other|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
84138|NCT01282580|Dietary Supplement|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
84139|NCT01282580|Other|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
83197|NCT01250938|Behavioral|Early Social Interaction - Community Outreach (ESI-CO)|This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
83198|NCT01250951|Drug|Deferasirox|
83199|NCT01250964|Procedure|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
85122|NCT01281540|Drug|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
85449|NCT01272180|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
85450|NCT01272180|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
85451|NCT00051675|Drug|ING-1(heMAb)|
85452|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
85453|NCT01272193|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
85454|NCT01272193|Drug|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
85455|NCT01272206|Drug|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
85456|NCT01272206|Drug|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
85457|NCT01272219|Drug|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
85458|NCT01272219|Drug|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
85459|NCT01272219|Drug|placebo|Subject with no pre-diabetes at screening, receiving liraglutide placebo subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks, will continue to receive liraglutide placebo for 12 weeks (until week 68).
85460|NCT01272219|Drug|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
85461|NCT01272219|Drug|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
85462|NCT00001030|Drug|Rifabutin|
85463|NCT00051688|Drug|tezacitabine|
85464|NCT01272232|Drug|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
85465|NCT01264614|Behavioral|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
84911|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
84912|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
85181|NCT01279083|Drug|DE-112|Topical ocular solution
85182|NCT01279083|Drug|DE-112|Topical ocular solution
85183|NCT01279083|Drug|DE-112|Topical ocular solution
85184|NCT01279083|Drug|DE-112|Topical ocular solution
85185|NCT00052403|Procedure|antibody therapy|
85186|NCT01279083|Drug|DE-112 Vehicle Solution|Topical ocular solution
85187|NCT01279083|Drug|Timolol Maleate Solution|Topical ocular solution
85188|NCT01279096|Drug|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
85189|NCT01279109|Behavioral|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
85190|NCT01279109|Behavioral|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
85191|NCT01279122|Device|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
85192|NCT01279135|Radiation|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
85193|NCT01279135|Radiation|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
85194|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
85195|NCT01279187|Drug|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
85196|NCT00052403|Procedure|biological response modifier therapy|
85197|NCT01279187|Drug|Placebo|20ug per day, self administered injection, for 7 weeks
85198|NCT01279200|Other|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
84678|NCT01283269|Behavioral|Memory Support System|Training in use of a memory notebook system
84679|NCT00052676|Drug|patent blue V dye|
84680|NCT01275976|Drug|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
84681|NCT00052117|Drug|2 NRTIs|
84682|NCT01275976|Other|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
84683|NCT01275989|Other|Ear acupuncture|
84684|NCT01276002|Procedure|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
84685|NCT01276015|Drug|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
84976|NCT01276457|Drug|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
84977|NCT01276457|Drug|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
84978|NCT01276496|Drug|Cilengitide|Given IV
84979|NCT01276496|Other|Laboratory Biomarker Analysis|Correlative studies
84980|NCT00052208|Other|laboratory biomarker analysis|Correlative studies
84981|NCT01276496|Drug|Paclitaxel|Given IV
84982|NCT01276496|Other|Pharmacological Study|Correlative studies
84983|NCT01276509|Drug|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
84984|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
84985|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
84986|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
84987|NCT01276522|Drug|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
83200|NCT01250977|Drug|Donepezil|5 mg donepezil HCL (Aricept) Participants will be instructed to take one 5 mg pill every night before going to bed with a glass of water for 28 days. In case participants experience difficulty they will be allowed to take the study medication in the morning.
83201|NCT01250990|Drug|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
83202|NCT00049504|Drug|cyclophosphamide|Given IV
83203|NCT01250990|Other|Placebo|Placebo
83204|NCT01251003|Biological|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
83205|NCT01251029|Drug|N-acetylcysteine|1200 mg orally; 600mg i.v.
83206|NCT01251029|Drug|Siran (N-acetylcysteine)|
83207|NCT01251042|Device|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
83208|NCT01251055|Drug|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
83209|NCT01251055|Drug|Placebo|starch
83210|NCT01251068|Device|near infrared spectroscopy: invos 5100|duration:six hours
83211|NCT01251068|Device|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
83212|NCT01251068|Device|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
83213|NCT00049504|Drug|fludarabine phosphate|Given IV
83214|NCT01251081|Other|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
83215|NCT01251081|Other|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
83508|NCT01243866|Other|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
83509|NCT01243879|Other|Starvation|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
84528|NCT01277874|Device|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
84529|NCT01277874|Device|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
84530|NCT01277887|Behavioral|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
84531|NCT01277887|Behavioral|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
84532|NCT01277900|Procedure|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
84533|NCT01277913|Drug|Vitamin D3|1000 IU once daily for 12 months
84534|NCT01277913|Drug|Vitamin D3|500 IU once daily for 12 months
84535|NCT01277939|Behavioral|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
84536|NCT01277939|Behavioral|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
84537|NCT01277952|Device|Deep Brain Stimulation|Brain pace maker, implanted in the brain
84538|NCT00052351|Drug|cyclophosphamide|
84539|NCT01277965|Other|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
84540|NCT01277965|Other|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
84541|NCT01280643|Drug|fluorouracil|Given IV
84542|NCT01280643|Drug|leucovorin calcium|Given IV
84543|NCT01280643|Drug|oxaliplatin|Given IV
84544|NCT01280643|Drug|irinotecan hydrochloride|Given IV
84545|NCT01280643|Biological|bevacizumab|Given IV
84546|NCT01280643|Biological|cetuximab|Given IV
84547|NCT01280643|Drug|capecitabine|Given PO
85199|NCT01279200|Other|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
85200|NCT01279213|Drug|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
85201|NCT01279226|Device|Auralevée device|Single treatment with Auralevée device.
85513|NCT01269827|Drug|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
85514|NCT01269827|Drug|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
85515|NCT01269853|Drug|Bevacizumab|Experimental portion of this proposal:
This trial will have two experimental arms that will be open labeled and non-randomized.
ARM 1 (If the patient has multifocal disease or leptomeningeal disease)
Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.
If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.
Repeat Cycle
85516|NCT01272232|Drug|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
85517|NCT01272232|Drug|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
85518|NCT01272245|Drug|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
85519|NCT01272245|Drug|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
85520|NCT01272258|Drug|PRO 140|SC injection
85521|NCT01272258|Drug|Placebo|SC injection
85522|NCT01272284|Device|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
85523|NCT01272297|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
85524|NCT01272310|Biological|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.
Ribavirin - will be taken daily based on the patient body weight. If body weight is < 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening).
85525|NCT00051688|Drug|oxaliplatin|
85526|NCT01272323|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
84988|NCT01276535|Device|Erchonia MLS + Erchonia THL|The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.
The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.
Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.
The intent is to evaluate the effectiveness of Erchonia MLS & Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL
84989|NCT01278628|Other|exercise training|exercise class once a year
84990|NCT01278641|Behavioral|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
84991|NCT01278641|Behavioral|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
84992|NCT01278654|Behavioral|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
84993|NCT01278680|Behavioral|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
84994|NCT01278693|Drug|L-carnitine|500 mg,twice daily, 16 weeks
84995|NCT01278693|Drug|placebo|500 mg,twice daily, 16 weeks.
85255|NCT01276925|Procedure|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
85256|NCT01276925|Drug|Saline|Isotonic. 10 ml for the femoral nerve.
85257|NCT01276925|Procedure|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
85258|NCT01276925|Drug|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
85259|NCT00052299|Drug|etoposide|
85260|NCT01276938|Radiation|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
85261|NCT01276938|Radiation|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
85262|NCT01276951|Dietary Supplement|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
85263|NCT01276951|Procedure|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
83510|NCT01243905|Other|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
83511|NCT01246349|Behavioral|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
83512|NCT01246362|Drug|Control|Given placebo
83513|NCT01246362|Drug|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
83514|NCT01246375|Device|Dual energy X-ray absorptiometry|Device which measures bone density
83515|NCT01246401|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
83516|NCT01246427|Drug|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
83517|NCT01246427|Drug|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
83518|NCT01246440|Drug|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
83519|NCT00049179|Drug|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
83520|NCT01246453|Drug|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
83521|NCT01246466|Device|Hybrid ablation procedure|AtriCure Bipolar System plus a catheter ablation
83522|NCT01246479|Procedure|Blood draw|blood draw at Month 12, Month 24 and Month 36.
83523|NCT01246479|Biological|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
83524|NCT01246492|Dietary Supplement|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
83525|NCT01246505|Device|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
83526|NCT01246518|Drug|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
83820|NCT01249443|Other|pharmacological study|Correlative studies
84548|NCT01280643|Genetic|mutation analysis|Correlative studies
84549|NCT00052494|Drug|irinotecan hydrochloride|
84824|NCT01281059|Device|BreathID - Breath Test - 13C Octanoate|
84825|NCT01281072|Other|vaccine|
84826|NCT01281098|Procedure|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
84827|NCT01281098|Drug|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
84828|NCT01281111|Drug|Dimethyl Fumarate (BG00012)|
84829|NCT00052520|Other|laboratory biomarker analysis|Correlative studies
84830|NCT01281111|Drug|Aspirin|
84831|NCT01281111|Drug|BG00012 matching placebo|
84832|NCT01281111|Drug|ASA matching placebo|
84833|NCT01281124|Drug|Azacitidine|Given subcutaneously
84834|NCT01281124|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
84835|NCT01281124|Other|Pharmacological Study|Correlative studies
84836|NCT01281137|Genetic|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
84837|NCT01281137|Other|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
84838|NCT01281137|Procedure|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
84839|NCT01281150|Drug|Carboplatin|Given IV
84840|NCT00052520|Genetic|gene expression analysis|Correlative studies
84841|NCT01281150|Other|Laboratory Biomarker Analysis|Correlative studies
84842|NCT01281150|Drug|Paclitaxel|Given IV
84843|NCT01283724|Drug|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
84844|NCT01283737|Device|DBX Putty|OCD of the knee will be treated with DBX Putty
85527|NCT01272323|Biological|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
85528|NCT01272323|Biological|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
85529|NCT01272336|Drug|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
84611|NCT01275937|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
84612|NCT01275950|Behavioral|Health Education|Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.
Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.
Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute.
84613|NCT01277965|Other|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
84614|NCT01277965|Other|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
84615|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change
84616|NCT01277991|Drug|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
84617|NCT01277991|Drug|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
84618|NCT01277991|Drug|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
84619|NCT01277991|Drug|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
84620|NCT01278004|Drug|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
84621|NCT00052351|Drug|doxorubicin hydrochloride|
84622|NCT01278004|Drug|Placebo|Capsule
84623|NCT01278017|Drug|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
84624|NCT01278030|Procedure|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
85264|NCT01276951|Procedure|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
85265|NCT01279278|Other|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
85266|NCT00052403|Procedure|growth factor antagonist therapy|
85267|NCT01279291|Biological|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
85268|NCT01279291|Drug|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
85269|NCT01279291|Drug|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
85270|NCT01279291|Drug|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
85271|NCT01279304|Radiation|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
85272|NCT01279304|Radiation|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
85593|NCT01269892|Dietary Supplement|conventional milk|a milk with lactose
85594|NCT01269918|Drug|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
85595|NCT01269918|Drug|Dexmedetomidine|DEXMEDETOMIDINE 0.4-0.7MCG/KG/HR (0.006-0.012mcg/kg/min) THROUGHOUT THE PROCEDURE BASED ON HEMODYNAMICS
85596|NCT01269931|Procedure|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
85597|NCT01269970|Other|18-FDG-PET-CT|
85598|NCT01269983|Other|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
85599|NCT00051428|Procedure|Reiki (distant and direct-contact)|
83821|NCT01249443|Drug|carboplatin|Given IV
83822|NCT01249443|Drug|paclitaxel|Given IV
83823|NCT01249469|Other|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
83824|NCT01249495|Procedure|Sharp debridement|After use of local anestetics a sharp currette is used to debride slough and nonviable tissue from the ulcer surface until a healthy tissue is seen.
83825|NCT01249508|Other|nutrition label|
83826|NCT01249521|Drug|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
83827|NCT00049374|Drug|dexamethasone|
83828|NCT01249534|Other|gastroesophageal cancer surgery|gastroesophageal cancer surgery
83829|NCT01251822|Drug|Prucalopride|Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.
Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days.
83830|NCT01251835|Drug|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
83831|NCT01251835|Drug|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
83832|NCT01251835|Drug|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
83833|NCT01251848|Drug|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
83834|NCT00001020|Biological|rgp120/HIV-1IIIB|
83835|NCT00049517|Drug|cytarabine|Given as a continuous infusion
83836|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
83837|NCT01251848|Drug|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
83838|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
83839|NCT01251861|Drug|Akt Inhibitor MK2206|Given PO
83840|NCT01251861|Drug|Bicalutamide|Given PO
83841|NCT01251861|Other|Clinical Observation|Undergo clinical observation
84845|NCT01283737|Procedure|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
84846|NCT01283750|Behavioral|care coordination|dementia-related care coordination
84847|NCT01283763|Drug|Topical Imiquimod|16 weeks
84848|NCT01283763|Procedure|Conization|Large loop excision of the transformation zone
85123|NCT00052559|Biological|bevacizumab|Given IV
85124|NCT01281540|Drug|Placebo|one placebo tablet 4 times a day for 8 weeks
85125|NCT01281553|Drug|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
85126|NCT01281553|Drug|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
85127|NCT01281566|Drug|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
85128|NCT01281566|Drug|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
85129|NCT01281579|Drug|Canagliflozin 100 mg|Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
85130|NCT01281579|Drug|Canagliflozin 50 mg|Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
85131|NCT01281579|Drug|Canagliflozin 300 mg|Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
85132|NCT01281592|Drug|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
85133|NCT01281605|Behavioral|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(<110mg/dl).
85134|NCT00001035|Drug|Interferon alfa-2b|
85135|NCT00052559|Drug|fluorouracil|Given IV
85136|NCT01281605|Behavioral|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG>=110mg/dL, and by 4 IU/day if the FPG>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG < 70 mg/dL.
85137|NCT01274234|Device|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
84625|NCT01278056|Drug|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
84626|NCT01278082|Drug|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
84627|NCT01278082|Drug|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
84628|NCT01278095|Drug|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
84629|NCT01278095|Drug|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
84630|NCT01278108|Drug|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
84913|NCT01278589|Dietary Supplement|Placebo|Liquid (80g) without Plantago asiatica L. extract
84914|NCT01278602|Drug|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
84915|NCT01278615|Other|Laboratory Biomarker Analysis|Correlative studies
84916|NCT00052390|Biological|bevacizumab|
84917|NCT01278615|Drug|Selumetinib|Given PO
84918|NCT01281150|Other|Pharmacological Study|Correlative studies
84919|NCT01281150|Drug|Veliparib|Given PO
84920|NCT01281163|Drug|Akt Inhibitor MK2206|Given PO
84921|NCT01281163|Other|Laboratory Biomarker Analysis|Correlative studies
84922|NCT01281163|Drug|Lapatinib Ditosylate|Given PO
84923|NCT01281163|Other|Pharmacogenomic Study|Correlative studies
84924|NCT01281163|Other|Pharmacological Study|Correlative studies
84925|NCT01281176|Drug|Carboplatin|Given IV
84926|NCT00052520|Other|immunologic technique|Correlative studies
84927|NCT01281176|Other|Laboratory Biomarker Analysis|Correlative studies
84928|NCT01281176|Drug|Paclitaxel|Given IV
84929|NCT01281176|Other|Pharmacological Study|Correlative studies
85600|NCT01269996|Drug|Janumet, Lantus|In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.
Treatment groups:
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.
Group 2 - Janumet followed by Lantus insulin injection.
85601|NCT01269996|Drug|metformin, gliclazide, protaphane|In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.
Treatment groups:
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.
Group 2 - Janumet followed by Lantus insulin injection.
85602|NCT01270022|Other|Implementation|
85603|NCT01270022|Other|dissemination|
85604|NCT01270035|Drug|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
85605|NCT01270048|Drug|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
85606|NCT01270048|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
85607|NCT01272375|Drug|Treatment E|PF-04764793 250/50 using inhaler B
85608|NCT01272375|Drug|Treatment F|PF-04764793 250/50 using inhaler B
85609|NCT01272375|Drug|Treatment G|PF-04764793 250/50 using inhaler B
85610|NCT01272388|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
84686|NCT01276028|Procedure|Acupuncture|For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.
Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments.
84687|NCT01276041|Drug|pertuzumab in combination with trastuzumab and paclitaxel|The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
84688|NCT01276054|Radiation|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
84689|NCT01276054|Drug|methylene blue|Given subcutaneously
84690|NCT01276054|Drug|indocyanine green solution|Given subcutaneously
83842|NCT01251861|Other|Laboratory Biomarker Analysis|Correlative studies
83843|NCT01251874|Drug|Carboplatin|Given IV
84140|NCT01282593|Other|Impact of CD9 expression level on motility assays|1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.
Adhesion results will be validated on patient samples of B-ALL.
84141|NCT00000252|Drug|10% N2O|
84142|NCT00001035|Drug|Zidovudine|
84143|NCT00052598|Biological|aldesleukin|Given SC
84144|NCT01275105|Drug|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
84145|NCT01275105|Drug|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
84146|NCT01275105|Drug|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
84147|NCT01275118|Device|Tecnis Multifocal IOL|Presbyopia correcting IOL
84148|NCT00052039|Drug|azathioprine|This study was terminated prior to enrollment.
84149|NCT01275118|Device|crystalens Accommodating IOL|Presbyopia correcting IOL
84150|NCT01275131|Drug|Insulin aspart|
84151|NCT01275131|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
84152|NCT01275144|Drug|LY2216684|Administered orally
84153|NCT01275144|Drug|Placebo|Administered orally
84154|NCT01275144|Drug|Lorazepam|Administered orally
84155|NCT01275157|Drug|LY2452473|Administered orally as a liquid suspension
84156|NCT01275170|Drug|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
84157|NCT01275170|Drug|imipenem + cilastatin|250 mg IV over 30 minutes as a single dose
84158|NCT01275170|Drug|caffeine|caffeine caplet, single 200 mg dose, orally
85138|NCT01274247|Drug|Topical Benzocaine|Topical administration of a drop of benzocaine to the lingual frenulum
85139|NCT01274260|Drug|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
85140|NCT01274260|Drug|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
85141|NCT01274273|Drug|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
85466|NCT01264627|Behavioral|Mindful Breathing (MB) Intervention|The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely "following the breath," throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. As attention wanders to concerns, thoughts, events or ideas, the participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the eight training sessions with individual ambulatory breathing monitors.
85467|NCT00050817|Drug|clopidogrel (SR25990)|
85468|NCT01264627|Behavioral|Usual Care (UC) Control Condition|This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online "Healthy Lifestyle Programs". We will assess the extent to which participants in both MB and UC used these resources.
85469|NCT01264640|Drug|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
85470|NCT01264653|Drug|adrenalin|adrenalin 0.01%
85471|NCT01264666|Dietary Supplement|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
85472|NCT01264666|Dietary Supplement|Chinese Meijiao liquor|
85473|NCT01264666|Dietary Supplement|Water control|
85474|NCT01264679|Drug|Ferumoxytol|IV Ferumoxytol
85475|NCT01264692|Drug|ACT-280778|10 mg once daily for 28 ± 2 days
85476|NCT01264692|Drug|Placebo|Placebo oral capsules matching ACT-280778
84930|NCT01281176|Drug|Vorinostat|Given PO
84931|NCT01281189|Drug|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
84932|NCT01281189|Drug|Placebo|Oral tablet twice daily for up to 18 months.
84933|NCT01281202|Drug|Vigabatrin|Tablets
84934|NCT01281215|Behavioral|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
84935|NCT01281228|Drug|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
84936|NCT01281228|Drug|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
84937|NCT00052520|Other|flow cytometry|Correlative studies
85202|NCT01279252|Drug|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
85203|NCT01279265|Dietary Supplement|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
85204|NCT01279265|Dietary Supplement|Nutramigen A+|Hypoallergenic formula without lactobacillus
85205|NCT01279278|Other|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
85206|NCT01281618|Procedure|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
85207|NCT01281631|Drug|NP001|Low dose of NP001
85208|NCT01281631|Drug|NP001|High dose of NP001
85209|NCT01281631|Drug|Placebo|normal saline
85210|NCT01281644|Device|Diode Laser|810 nm diode laser
85211|NCT01281657|Drug|fingolimod|
85212|NCT01281670|Other|vibration|8 week vibration
85213|NCT01281696|Drug|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
85214|NCT01281696|Drug|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
84691|NCT01276054|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
84692|NCT00052130|Biological|CancerVax vaccine (CANVAXIN)|
84693|NCT01276054|Procedure|axillary lymph node biopsy|Undergo axillary lymph node biopsy
84694|NCT01276054|Procedure|bioimpedance spectroscopy|Correlative studies
84695|NCT01276054|Procedure|quality-of-life assessment|Ancillary studies
84696|NCT01276054|Other|lymphedema management|Undergo axillary reverse mapping
84697|NCT01276067|Drug|Donepezil|10 mg Tablet
84698|NCT01276080|Drug|Donepezil|10 mg tablets
84699|NCT01276093|Procedure|PVI ablation|Pulmonary Vein Ablation using RF.
84700|NCT01276093|Drug|Amiodarone|Amiodarone tablets
84701|NCT01276106|Drug|AC-201, 25mg|Capsule, 25mg BID
84702|NCT01276106|Drug|AC-201, 50mg|Capsule, 50mg BID
84703|NCT00052156|Biological|CancerVax vaccine (CANVAXIN)|
84704|NCT01276106|Drug|AC-201, 75mg|Capsule, 75mg BID
84705|NCT01276106|Drug|Placebo|Placebo BID
84706|NCT01278134|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
84707|NCT01278134|Drug|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
84708|NCT01278134|Drug|ritonavir|100 mg bid orally, up to 24 weeks
84996|NCT01278706|Procedure|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
84997|NCT01278732|Other|no intervention performed|no intervention is performed
84998|NCT00052390|Drug|doxorubicin hydrochloride|
84999|NCT01278745|Biological|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
85000|NCT01278745|Drug|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
85705|NCT01272765|Dietary Supplement|IHBG-10|500 mg IHBG-10
85706|NCT01272778|Drug|Lorazepam|Oral capsule, 0.2 mg, single acute dose
85707|NCT01264991|Procedure|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
85708|NCT01265004|Procedure|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
85709|NCT01265004|Procedure|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
85710|NCT01265004|Procedure|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
85711|NCT01265017|Drug|Estradiol, medroxyprogesterone, hydrocortisone, GH|Estradiol 1mg every 8 hours administered orally
Medroxyprogesterone 2.5 mg every 24 hours administered orally
Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally
Growth hormone 2 mg once a day administered by subcutaneous injection,
85712|NCT01265017|Drug|Matching placebo|matching placebo
85713|NCT00050895|Drug|Lopinavir/ritonavir|
85714|NCT01265030|Drug|Sirolimus|Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)
Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)
85715|NCT01265043|Other|Oral hygiene intervention|Oral health promotion intervention
86008|NCT01268137|Procedure|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
86009|NCT01268150|Drug|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
86010|NCT01268163|Drug|European Taxotere®|60-100 mg/m^2 IV
86011|NCT01268163|Drug|American Taxotere®|60-100 mg/m^2 IV
86012|NCT01268163|Drug|Hospira Docetaxel Injection|60-100 mg/m^2 IV
86013|NCT01268176|Dietary Supplement|cholecalciferol|50,000 IU once per month for 3 months
86014|NCT01268189|Device|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
86543|NCT01266512|Drug|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
86843|NCT01269593|Drug|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
86844|NCT01269606|Drug|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
86845|NCT01269606|Drug|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
86846|NCT01299493|Other|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
86847|NCT01299519|Behavioral|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
86848|NCT01299519|Behavioral|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
86849|NCT01299532|Device|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
86850|NCT01299558|Drug|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
86851|NCT01299558|Drug|fluticasone furoate|Single IV dose of FF (250mcg)
86852|NCT01299558|Drug|GW642444|Single IV dose of GW642444 (55mcg)
86853|NCT01299571|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
86854|NCT01299584|Drug|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
86855|NCT01299597|Drug|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
86856|NCT00053989|Drug|mycophenolate mofetil|oral
86081|NCT01265719|Other|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
86082|NCT01265719|Other|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
86083|NCT00050921|Drug|Keyhole-Limpet Hemocyanin|
86084|NCT01265732|Drug|PF-04191834|single dose, 100mg, dispersion
86085|NCT01265732|Drug|PF-04191834|single dose, 100mg, suspension
86086|NCT01265732|Drug|PF-04191834|single dose, 300mg, suspension
86087|NCT01265745|Drug|Normal Saline for Injection|Equivalent amounts to subjects weight, once over 120 minutes
86088|NCT01265745|Biological|MDX1303|a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
86089|NCT01265758|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
86090|NCT01265771|Device|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
86091|NCT01265771|Device|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
86092|NCT01265784|Drug|TP-434|
86093|NCT01265784|Drug|Ertapenem|
86094|NCT00050934|Drug|oxcarbazepine|
86381|NCT00051246|Behavioral|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
86382|NCT01268943|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
86383|NCT01268969|Procedure|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
86384|NCT01271257|Drug|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
86385|NCT01271270|Drug|Palomid 529|
86772|NCT01272011|Other|Breathing (Hypoxia) Treatment and Locomotor Training|Comparison of the effect of locomotor training with versus without a breathing (hypoxia) treatment. Individuals will be randomized to receiving hypoxia or normal room air. They will receive either the experimental or placebo comparator (whichever they were randomized to) preceding the locomotor training. All individuals, however, will receive locomotor training.
86773|NCT01272024|Behavioral|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
86774|NCT01272024|Behavioral|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
86775|NCT01272037|Drug|Anastrozole|Given PO
86776|NCT01272037|Drug|Exemestane|Given PO
86777|NCT01272037|Other|Laboratory Biomarker Analysis|Correlative studies
86778|NCT01272037|Drug|Letrozole|Given PO
86779|NCT01272037|Other|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
86780|NCT01272037|Drug|Systemic Chemotherapy|Given IV
86781|NCT01272037|Drug|Tamoxifen Citrate|Given PO
86782|NCT00051662|Drug|efalizumab|
86783|NCT01272050|Radiation|radiation therapy|RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.
Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration.
86784|NCT01272089|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
86785|NCT01272115|Behavioral|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
86786|NCT01264484|Device|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
86787|NCT01264497|Drug|TH9507|1 and 2 mg, sc daily for 12 weeks
85838|NCT01267864|Drug|Ketorolac|30g IVSS
85861|NCT01270451|Other|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
86154|NCT01273324|Device|ADM Cup|ADM Cup
86155|NCT01273337|Biological|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
86156|NCT01273337|Procedure|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
86157|NCT01273350|Device|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
86158|NCT01273376|Drug|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
86159|NCT01273389|Drug|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
86160|NCT01273389|Drug|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
86161|NCT00051831|Drug|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
86162|NCT01273402|Drug|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
86163|NCT01273428|Drug|HP011-101|
86164|NCT01273428|Device|HP-828-101|
86165|NCT01273428|Other|Standard Care|
86166|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
86167|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
86168|NCT01273454|Drug|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
86169|NCT01265823|Biological|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
86170|NCT01265849|Biological|LI plus CIZ|LI 400IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 weeks administered in combination with cyclophosphamide indomethacin and zinc (CIZ) as adjuvant therapy prior to SOC, surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100mg/m^2 intravenously to determine if LI plus CIZ affects the overall survival of subjects at median 3 years. Cyclophosphamide 300mg/m^2 is administered intravenously bolus 3 days prior to treatment with LI. Indomethacin 25mg capsules are administered orally beginning on day 1 of LI treatment up to 1 day prior to surgery. Multivitamin tablets or capsules with zinc (> or = to 15mg but not > 40mg) are administered orally beginning on day 1 of LI treatment up to 1 day prior to surgery.
86857|NCT01299597|Drug|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
86858|NCT01299597|Drug|SB649868|20mg daily given for 14 days.
86859|NCT01299610|Drug|GW870086 2.0%|White to slightly colored opaque cream
85918|NCT01267916|Device|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
85919|NCT01267916|Device|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
85920|NCT01267916|Device|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
85921|NCT01267916|Device|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
85922|NCT01267929|Procedure|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
85923|NCT01267929|Procedure|The conventional physical therapy|The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
85924|NCT00051155|Drug|Travoprost (0.004%)|
85925|NCT01267942|Drug|Enhancin|Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.
Oral dose of the same at the same dosage for the active comparator arm.
85926|NCT01267955|Other|Laboratory Biomarker Analysis|Correlative studies
85927|NCT01267955|Drug|Vismodegib|Given PO
85928|NCT01267968|Drug|GSK2251052|1500 mg (dosing detailed in Arm description)
85929|NCT01267981|Drug|Standard diet|After the lunch the day before the exploration, drink only clear liquids and stop solid food.
From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy.
85930|NCT01267981|Drug|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
85931|NCT01267981|Drug|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
85932|NCT01267994|Drug|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
85933|NCT01268020|Drug|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
86386|NCT01271283|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
86387|NCT01271283|Drug|Lenalidomide|Given orally
86388|NCT00051571|Drug|Docetaxel|
86389|NCT01271296|Dietary Supplement|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
86390|NCT01271296|Dietary Supplement|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
86391|NCT01271322|Radiation|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
86392|NCT01271335|Biological|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
86393|NCT01271348|Drug|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
86394|NCT01271348|Drug|placebo|Placebo tablet, q.d.
86395|NCT01271361|Procedure|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
86396|NCT01271361|Procedure|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
86397|NCT01271374|Drug|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
86398|NCT01271374|Drug|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
86399|NCT00051584|Drug|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
86400|NCT01271387|Drug|tasimelteon|20 mg tasimelteon capsules, PO single dose
86401|NCT01271413|Behavioral|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
86707|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
86708|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 0
86709|NCT00050791|Drug|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
86710|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
85839|NCT01267864|Drug|Valproate|1gm IVSS
85840|NCT01267877|Other|read unfavorable article prior to answering questions|article title: "Taking a hit on healthcare- why that's women's work"
85841|NCT01267877|Other|read favorable article prior to answering questions|read "A Backlash of Mistrust"
85842|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
85843|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
85844|NCT01267903|Biological|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
85845|NCT00051142|Drug|Latanoprost|
85846|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
85847|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
85848|NCT01267916|Device|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
85849|NCT01270373|Drug|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Adriamycin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
85850|NCT01270386|Drug|apatinib|Apatinib 750 mg p.o. once daily
85851|NCT01270386|Drug|placebo|placebo p.o. once daily
85852|NCT01270412|Biological|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
85853|NCT01270412|Drug|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
85854|NCT01270438|Drug|FOLFOX regimen|Given IV
85855|NCT01270438|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
85856|NCT01270438|Biological|bevacizumab|Given IV
85857|NCT01270438|Drug|oxaliplatin|Given IV
85858|NCT00051493|Drug|ALIMTA|
85859|NCT01270438|Drug|leucovorin calcium|Given IV
85860|NCT01270438|Drug|fluorouracil|Given IV
86171|NCT01265849|Other|Standard of Care (SOC)|Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) or for higher risk subjects (subjects determined at surgery to have positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m2 intravenously 1x weekly for 3 weeks on day 1 of weeks 1, 4 and 7 of radiotherapy
86460|NCT01269008|Device|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
86461|NCT01269021|Drug|mycophenolate mofetil plus lower dose of Prednisone|MMF 1.0-1.5g/d*6mons Prednisone 0.4-0.6 mg/kg/d
86462|NCT01269021|Drug|Prednisone in full dose|0.8-1mg/kg/d
86463|NCT01269034|Drug|Exenatide|1.25 mcg before the boost sub-cutaneously.
86464|NCT00051259|Drug|Extended-Release Bupropion Hydrochloride|
86465|NCT01269034|Drug|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
86466|NCT01269034|Drug|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
86467|NCT01269047|Drug|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
86468|NCT01269047|Drug|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
86469|NCT01269047|Drug|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
86470|NCT01269060|Procedure|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
86471|NCT01269086|Behavioral|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
86472|NCT01269099|Drug|IV-PCA|IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
86473|NCT01269099|Drug|Control|control group (No-PCA group)
86474|NCT01269112|Device|citrate regional anticoagulation|Patients randomly allocated to 2 treatment groups:
Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation
86475|NCT00051272|Drug|Extended-release Bupropion Hydrochloride|
86476|NCT01269112|Device|citrate regional anticoagulation|Patients randomly allocated to 2 treatment groups:
Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation
86477|NCT01269125|Drug|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
85934|NCT01268033|Drug|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
85935|NCT00051155|Drug|Latanoprost (0.005%)/Timolol (0.5%)|
85936|NCT01268033|Drug|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
85937|NCT01268046|Drug|Estradiol|1mg/day for 30 days administered through a capsule
86225|NCT01271088|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
86226|NCT01271114|Drug|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
86227|NCT01273610|Other|pharmacological study|
86228|NCT01273623|Device|Jetstream Atherectomy System|to perform atherectomy on calcified lesions
86229|NCT01273649|Device|cryotherapy|cryotherapy is given with other physical training
86230|NCT00051831|Drug|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
86231|NCT01273662|Drug|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
86232|NCT01273688|Behavioral|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
86233|NCT01273688|Device|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
86234|NCT01273701|Behavioral|Psychosocial intervention|The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.
-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)
-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.
-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1.
86235|NCT01273701|Behavioral|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
86236|NCT01273714|Procedure|thyroid resection|bilateral subtotal versus total thyroidectomy
86237|NCT01273727|Drug|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
86711|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
86712|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 4
86713|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
86714|NCT01264445|Biological|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
86715|NCT01264471|Procedure|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
86716|NCT01264471|Procedure|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
86717|NCT01266720|Biological|VEGFR1, VEGFR2|One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
86718|NCT01266720|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
86719|NCT01266733|Behavioral|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
86720|NCT01266733|Behavioral|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
86721|NCT01266746|Procedure|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
86722|NCT01266759|Drug|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
86723|NCT01266759|Drug|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
85771|NCT01272778|Drug|Lorazepam|oral capsule, 1.0 mg, single acute dose
85772|NCT01272778|Drug|Lorazepam|oral capsule, 2.0 mg, single acute dose
85773|NCT01272778|Drug|Placebo|oral capsule, single acute dose
86909|NCT01294813|Device|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
86910|NCT01294826|Drug|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
86911|NCT01294826|Drug|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
86912|NCT01294839|Device|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
86913|NCT01297049|Behavioral|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
86914|NCT00053885|Drug|vatalanib|
86915|NCT01297062|Drug|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
86916|NCT01297062|Drug|Moxifloxacin|Oral Moxifloxacin (400 mg)
86917|NCT01297062|Drug|Placebo comparator|IV Placebo (matching volume of placebo)
85954|NCT01270646|Device|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.
Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping.
85955|NCT00051506|Drug|carboplatin|
85956|NCT01270659|Drug|Fentanyl|Fentanyl buccal tablet 100 mcg once
85957|NCT01270659|Drug|Fentanyl|Fentanyl buccal tablet 200 mcg once
85958|NCT01273467|Drug|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
86478|NCT01271478|Drug|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
86479|NCT00001030|Drug|Clarithromycin|
86480|NCT00051584|Drug|Gemzar (Gemcitabine)|
86481|NCT01271504|Drug|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
86788|NCT01264510|Other|audiological test battery|routine audiological measurements.
86789|NCT00050791|Behavioral|Very Low Calorie Diet|placebo injections
86790|NCT01264523|Other|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
86791|NCT01264536|Dietary Supplement|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
86792|NCT01264536|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
86793|NCT01264549|Device|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
86794|NCT01264575|Drug|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
86795|NCT01264575|Drug|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
86796|NCT01264575|Drug|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
86797|NCT01264575|Drug|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
86798|NCT01264575|Drug|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
86799|NCT01264575|Drug|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
86800|NCT00050804|Drug|sertraline|
86801|NCT01264575|Drug|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
86802|NCT01264575|Drug|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
86015|NCT01268189|Device|Standard of care dressing|Xeroform control dressing applied to control wound
86016|NCT01268202|Drug|Pravastatin|Pravastatin 40mg/day during 12 months
86017|NCT00051181|Drug|Travoprost (0.004%)|
86018|NCT01268215|Drug|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
86019|NCT01268215|Drug|Pulmicort|Endotracheal instillation, once per week for three weeks
86020|NCT01268215|Other|Sham|None instilled through the endotracheal tube
86021|NCT01268267|Device|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
86022|NCT01268280|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
86023|NCT01268280|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
86024|NCT01268280|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
86025|NCT01270659|Drug|Oxycodone/acetaminophen|Oxycodone/acetaminophen 5/325 mg once
86026|NCT01270659|Drug|oxycodone/acetaminophen|Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
86027|NCT01270672|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
86028|NCT01270672|Drug|carvedilol|50 mg per os, single dose
86029|NCT01270672|Drug|placebo|capsules identical to MDMA or carvedilol
86030|NCT01270698|Drug|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
86320|NCT01263730|Behavioral|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
86321|NCT01263743|Behavioral|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
86322|NCT01263743|Behavioral|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
86323|NCT01263769|Drug|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
85774|NCT00051753|Drug|levofloxacin; amoxicillin/clavulanate|
85775|NCT01272791|Biological|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
85776|NCT01272791|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
85777|NCT01272804|Drug|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
85778|NCT01272804|Drug|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
85779|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
85780|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
85781|NCT01272830|Drug|Placebo|Two capsules taken twice daily with meals
85782|NCT01272830|Drug|Apatone®B|Two capsules taken twice daily with meals
85783|NCT01272856|Drug|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
85784|NCT01272869|Device|SenSura|The ostomy bag filter will be tested for a period of 14 days
85785|NCT00051766|Behavioral|Computer-based Intervention|
85786|NCT01272869|Device|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
85787|NCT01272882|Device|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
85788|NCT01272895|Device|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
85789|NCT01272908|Drug|rituximab|1000 mg intravenously on Days 1 and 15
85790|NCT01272921|Drug|Bupivacaine|Varying doses to determine the duration of analgesia
86095|NCT01265784|Drug|Placebo|Administered IV to maintain the blind.
85959|NCT01273467|Drug|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
85960|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
85961|NCT00051831|Drug|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
85962|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
85963|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
85964|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
85965|NCT01273493|Drug|Trabectedin|Trabectedin 0.58 or 1.3 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1.
85966|NCT01273493|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/m^2, 30 minutes prior to trabectedin.
85967|NCT01273506|Drug|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
85968|NCT01273506|Drug|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
85969|NCT01273532|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
85970|NCT01273532|Drug|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
86265|NCT01266031|Drug|Vorinostat|Phase II: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.
86266|NCT01266044|Procedure|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
86267|NCT01266044|Procedure|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
86268|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
86269|NCT01266044|Other|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
86270|NCT01266057|Drug|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
86803|NCT01264575|Drug|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
86804|NCT01264575|Drug|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
86805|NCT01264575|Drug|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
86806|NCT01264575|Drug|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
86807|NCT01264588|Other|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
85862|NCT01270464|Drug|Reslizumab|0.3 mg/kg, 3.0 mg/kg
85863|NCT01270464|Drug|Placebo|Matching placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
85864|NCT01270477|Other|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
85865|NCT01270490|Drug|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
85866|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
85867|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
85868|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
85869|NCT00051493|Drug|Carboplatin|
85870|NCT01270516|Drug|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
85871|NCT01270516|Drug|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
85872|NCT01270516|Drug|Saline|Control
85873|NCT01270529|Other|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
85874|NCT01270542|Drug|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
85875|NCT01270542|Other|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
85876|NCT01273090|Drug|imetelstat sodium|
86324|NCT01263782|Drug|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
86325|NCT01263782|Drug|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
86326|NCT01263782|Drug|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
86327|NCT00050661|Device|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
86328|NCT01263782|Drug|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
86329|NCT01263808|Drug|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
86330|NCT01263808|Drug|Indacaterol 300 µg|QD via SDDPI
86331|NCT01263808|Drug|Indacaterol 600 µg|QD via SDDPI
86332|NCT01263808|Drug|Placebo|QD via SDDPI
86333|NCT01263808|Drug|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
86334|NCT01263821|Procedure|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
86335|NCT01263821|Procedure|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
86336|NCT01263821|Procedure|Functional magnetic resonance imaging|Undergo functional MRI
86337|NCT01263821|Procedure|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
86338|NCT00050674|Drug|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
86339|NCT01263821|Procedure|Therapeutic conventional surgery|Undergo maximal surgical resection
86340|NCT01266070|Drug|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
86642|NCT01269242|Drug|placebo|bindarit-matching placebo tablets for 6 months.
86643|NCT01269255|Drug|TS-1 with Cisplatin|SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)
Step 1: Chemotherapy; TS-1/CDDP #2 cycles
Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP
Step 3: Surgery therapy
86644|NCT01269281|Drug|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
86645|NCT01269294|Drug|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
86096|NCT01265797|Device|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
86097|NCT01265797|Device|Sham Device|participant wears sham device for 20 minutes daily for 28 days
86098|NCT01265810|Other|supersaturated calcium-phosphate rinse|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
86099|NCT01265810|Other|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
86100|NCT01268293|Drug|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
86101|NCT01268306|Device|Use of B+L Biotrue multipurpose solution (MPS) with PureVision contact lenses|Subjects use Bausch & Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
86102|NCT01268319|Device|Embolic Protection Device (EPD)|The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014" steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient.
86103|NCT00051181|Drug|Latanoprost (0.005%)|
86104|NCT01268319|Device|Intracoronary Spectroscopy and Ultrasonic Evaluation|This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
86105|NCT01268319|Device|Angioplasty and Stent Implant|The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
86106|NCT01268332|Drug|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
86107|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
86108|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
86109|NCT01268358|Drug|Lamazym|Lamazym, ERT, infusion weekly
86110|NCT01268371|Device|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
86111|NCT01268371|Device|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
86271|NCT01266057|Drug|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
86272|NCT00050973|Drug|bexarotene|
86273|NCT01266057|Drug|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
86274|NCT00051207|Behavioral|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
86275|NCT01268605|Procedure|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
86276|NCT01268618|Dietary Supplement|Probiotic|2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:
Lactobacillus acidophilus NAS, 30 billion CFU
Bifidobacterium bifidum Malyoth, 120 billion CFU
Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU
86277|NCT01268618|Dietary Supplement|Placebo|2 capsules, 3x/day placebo capsules
86278|NCT01268631|Drug|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
86279|NCT01268631|Drug|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
86280|NCT01268644|Drug|Leptin ( Metreleptin )|weight based sub-cutaneous injection twice daily of Leptin
86281|NCT01268657|Behavioral|Education|Learning about anxiety
86282|NCT01268657|Behavioral|Relaxation Training|Learning skills to reduce tension
86283|NCT01268657|Behavioral|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
86584|NCT01271725|Drug|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
86585|NCT01271738|Procedure|Remove tumor only|No additional margins (tissue) removed at the initial surgery
86586|NCT01271738|Procedure|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
86587|NCT01271751|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
86588|NCT01271751|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
85877|NCT01273090|Other|laboratory biomarker analysis|
85878|NCT00051805|Behavioral|Promotion of adherence to ARV medications|
85879|NCT01273090|Other|pharmacological study|
85880|NCT01273103|Drug|200mg [14C]- GSK2248761|single oral suspension dose of [14C]- GSK2248761 200 mg
85881|NCT01273116|Other|CWS in Hospital|Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:
will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;
a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;
will be discussed at least once in a multidisciplinary meeting;
a structured medication review will be carried out by a geriatrician;
is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;
may receive a consult of a geriatrician, if judged necessary;
will receive extra attention on discharge arrangements.
Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients.
86172|NCT01265849|Biological|LI + SOC|LI is administered 400 IU (2.0mL) 1/2 peritumorally and 1/2 perilymphatically 5 times a week for three weeks prior to SOC to determine the contribution of CIZ on LI activity.
86173|NCT01265862|Procedure|Tracheal intubation through LMA-Fastrach®|Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube
86174|NCT00050947|Drug|oxcarbazepine|
86175|NCT01265862|Procedure|Tracheal intubation through I-gel®|Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
86176|NCT01265875|Drug|Human Secretin|Dose Escalation
86177|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
86178|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
86179|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
86180|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via ventimask at 6 LPM.
86181|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via non-rebreather at 12-15 LPM.
86182|NCT01265901|Drug|Sunitinib|as per label
86646|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
86647|NCT01269294|Drug|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
86648|NCT01269294|Drug|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
86649|NCT00051298|Drug|Olanzapine|
86650|NCT01269294|Drug|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
86651|NCT01269294|Drug|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
86652|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
86653|NCT01269307|Procedure|1:1 ketamine-propofol mixture sedation|Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.
May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine
86654|NCT01269307|Procedure|Propofol Sedation|Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.
May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol
86655|NCT01269320|Drug|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
86656|NCT01269333|Drug|omeprazole|omeprazole 20mg for 7 days
86657|NCT01269333|Drug|fluvoxamine|fluvoxamine 50mg for 7 days
86658|NCT01269333|Drug|placebo|placebo for 7 days
86659|NCT01269346|Drug|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle.
86660|NCT00051298|Drug|Placebo|
86661|NCT01269359|Procedure|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
85716|NCT01265056|Drug|Gabapentin|On Study day 1: 1200mg (single dose).
Study day 2,3: 300mg TID, 900mg daily.
Study day 4-7: 600mg TID 1800mg* daily.
Study day 8-11: 800mg TID 2400mg* daily [Optional increase to 2400 if pain scores are still 4 on NRS]
Study day 11: 1200mg TID 3600mg* daily [Optional increase to 3600 if pain scores are still >4 on NRS]
* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.
86112|NCT01268384|Drug|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
86402|NCT01271439|Drug|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
86403|NCT01271452|Biological|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
86404|NCT01271452|Biological|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
86405|NCT01271465|Procedure|Kidney Biopsy|biopsy of transplant kidney
86406|NCT01271478|Drug|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
86407|NCT01271478|Drug|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
86408|NCT01271478|Drug|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
86409|NCT01263821|Procedure|Quality-of-life assessment|Ancillary studies
86410|NCT01263821|Radiation|Radiation therapy treatment planning/simulation|Undergo IMRT planning
86411|NCT01263821|Radiation|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
86412|NCT01263821|Other|Questionnaire administration|Ancillary studies
86413|NCT01263834|Drug|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
86414|NCT01263834|Drug|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
86415|NCT01263847|Dietary Supplement|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
86416|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
86417|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
86418|NCT00050687|Drug|Gallium maltolate|
86419|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
86589|NCT00051636|Drug|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
86590|NCT01271764|Other|no drug|The role of G9a protein in patients with endometrial cancer
86591|NCT01271777|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
86592|NCT01271777|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
86593|NCT01271790|Drug|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
86594|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
86595|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
86596|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
86597|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg QD
86598|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
86599|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
86600|NCT01264159|Other|Usual treatment of patients with developing acute heart failure|
86601|NCT01264172|Procedure|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
86602|NCT01264172|Procedure|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
86603|NCT01264172|Procedure|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
86604|NCT01264198|Behavioral|Resistance Training|Supervised Resistance Training
86605|NCT01264211|Drug|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
86606|NCT00050778|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
85661|NCT01267474|Other|Nutritional education|A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.
All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.
Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.
All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts.
86183|NCT01265901|Biological|IMA901 plus GM-CSF|After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant will be applied for a period of 4 months while continuing treatment with sunitinib
86184|NCT01265901|Drug|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
86185|NCT00001026|Biological|HIVAC-1e|
86186|NCT00050960|Drug|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
86187|NCT01268462|Other|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
86482|NCT01271504|Drug|Sorafenib|E7050 given orally at 200, 300 or 400 mg once daily.
Sorafenib given orally, 400 mg twice daily.
86483|NCT01271517|Drug|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
86484|NCT01271517|Drug|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
86485|NCT01271517|Drug|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
86486|NCT01271530|Other|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
86487|NCT01271543|Device|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
86488|NCT01271556|Drug|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
86489|NCT01271556|Procedure|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
86490|NCT01271556|Other|Placebo|placebo, inhalatory (MDI) once
85717|NCT01265056|Drug|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
85718|NCT01265069|Drug|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
85719|NCT01265069|Drug|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
85720|NCT01265108|Drug|Iron sucrose.|Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
85721|NCT01265108|Drug|Normal saline|Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
85722|NCT01265121|Device|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
85723|NCT01265121|Other|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
85724|NCT00001026|Biological|rgp120/HIV-1 SF-2|
85725|NCT00050895|Drug|Efavirenz|
85726|NCT01265147|Drug|Cisplatin|40mg/m2/w
85727|NCT01267487|Drug|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
85728|NCT01267487|Drug|Heparin and protamine titration|Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.
Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve.
85729|NCT01267500|Procedure|Non surgical therapy|patching or fusion exercises
85730|NCT01267526|Device|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
85731|NCT01267552|Procedure|Non drains will be placed during operation|Non drains will be placed during operation
85732|NCT00001028|Drug|Pentamidine isethionate|
85733|NCT00051116|Drug|CC-5013|
85734|NCT01267552|Procedure|Closed suction drainage|Closed suction drainage will be placed during operation
86031|NCT01270711|Drug|Study Drug|non interventional study - usage as per usual care
86420|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
86421|NCT01263873|Device|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
86724|NCT00051077|Drug|Peginterferon-alfa-2A|
86725|NCT01266772|Drug|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
86726|NCT01266772|Drug|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
86727|NCT01266785|Drug|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
86728|NCT01266798|Behavioral|Portal|The portal was tailored to improve the lay public's' "healthy skepticism", or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.
A checklist for critical assessment of health information
Access to research databases for health information and an introduction to research methods and principles of science
A checklist to the consultation
86729|NCT01266811|Drug|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
86730|NCT01266811|Biological|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
86731|NCT01266824|Drug|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
86732|NCT01266837|Drug|Everolimus|10 mg p.o once daily
86733|NCT01266850|Biological|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
86734|NCT01269385|Biological|alemtuzumab|Given subcutaneously
86735|NCT01269385|Biological|rituximab|Given IV
86736|NCT01269385|Drug|PGG beta-glucan|Given IV
86737|NCT01269385|Other|flow cytometry|Correlative studies
86738|NCT01269385|Other|laboratory biomarker analysis|Correlative studies
86739|NCT01269385|Genetic|DNA analysis|Correlative studies
85662|NCT01267474|Other|Control|The control group received only three one-hour general sessions on health issues.
85663|NCT01267487|Drug|Heparin fixed doses|Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT > 480 sec. Supplemental doses of 50mg of heparin if ACT <480 sec during CPB.
Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
85664|NCT01270061|Behavioral|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
85665|NCT01270061|Behavioral|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
85666|NCT01270074|Drug|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
85667|NCT00051441|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|
85668|NCT01270074|Drug|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
85669|NCT01270087|Drug|Adalimumab|40 mg IV every 14 days
85670|NCT01270100|Behavioral|Recovery management|
85671|NCT01270113|Behavioral|contingency management|
85672|NCT01270126|Device|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
85673|NCT01270139|Procedure|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
85674|NCT01270139|Procedure|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
85675|NCT01270139|Device|Stenting|60 - in sirolimus-eluting stenting control
85676|NCT01270152|Drug|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
85677|NCT01270165|Drug|telbivudine|600mg, oral daily over 12 months
85971|NCT01273545|Drug|PRILIGY (dapoxetine hydrochloride)|The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
86491|NCT00051597|Drug|SGN-30 (monoclonal antibody)|
86492|NCT01271569|Drug|Fospropofol disodium|Fospropofol disodium： 0.5g
86493|NCT01271582|Drug|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks [irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)]
86494|NCT01271595|Other|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
86495|NCT01271608|Device|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
86496|NCT01271621|Device|Intubation|Endotracheal intubation
86497|NCT01271647|Drug|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
86498|NCT01271647|Drug|placebo|granules,18g per time,two times per day,six months
86808|NCT01264601|Biological|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
86809|NCT01266850|Biological|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
86810|NCT00051077|Drug|Ribavirin|
86811|NCT01266863|Other|E test method|E test strips directly applied to BAL
86812|NCT01266876|Drug|Alirocumab|Alirocumab two SC injections in the abdomen only.
86813|NCT01266876|Drug|Placebo|Placebo two SC injections in the abdomen only.
86814|NCT01266889|Device|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
86815|NCT01266902|Drug|Rilpivirine|25 mg once daily
86816|NCT01266928|Drug|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
86032|NCT01270724|Drug|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
86033|NCT00001029|Drug|Didanosine|
86034|NCT00051506|Drug|cisplatin|
86035|NCT01270737|Dietary Supplement|Whole soy (soy flour)|40g soy flour per day for six months
86036|NCT01270737|Dietary Supplement|daidzein|66mg daidzein per day for six months
86037|NCT01270737|Dietary Supplement|milk powder|40g low-fat dry milk per day for six months
86038|NCT01270750|Drug|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
86039|NCT01270763|Behavioral|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
86040|NCT01270763|Behavioral|Diabetes support and education|Behavioral intervention focused on diabetes support and education
86041|NCT01270776|Drug|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
86042|NCT01270776|Drug|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
86043|NCT01270789|Drug|Liraglutide|Liraglutide administered as once daily sc injection
86044|NCT01270789|Drug|placebo|placebo administered as once daily sc injection
86045|NCT00051532|Drug|Seocalcitol|
86046|NCT01270802|Drug|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
86047|NCT01270802|Drug|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
86048|NCT01270802|Drug|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
86049|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
86050|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
86051|NCT01272947|Drug|Diclofenac sodium|Topical gel 1%- 4 times daily
86740|NCT01269385|Genetic|fluorescence in situ hybridization|Correlative studies
86741|NCT00051311|Procedure|Stem cell transplantation|
86742|NCT01269385|Genetic|polymerase chain reaction|Correlative studies
86743|NCT01269385|Genetic|polymorphism analysis|Correlative studies
86744|NCT01269385|Genetic|mutation analysis|Correlative studies
85791|NCT01272921|Drug|Ropivacaine|Varying doses to determine the duration of analgesia
85792|NCT01272934|Drug|Diclofenac Sodium|Topical gel 1%-4 times daily
85793|NCT01272934|Other|Placebo|Topical gel-4 times daily
85794|NCT01265147|Drug|Nedaplatin|40mg/m2/w
85795|NCT01265173|Drug|Cefotaxime|3 g
85796|NCT01265173|Drug|Ceftriaxone|2 g
85797|NCT01265173|Drug|Ciprofloxacin|400 mg
85798|NCT01265186|Device|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
85799|NCT01265186|Device|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
85800|NCT01265199|Drug|AT-406 in combination with daunorubicin and cytarabine|Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.
85801|NCT01265251|Device|Computerized neuropsychological test|Computerized neuropsychological test battery.
85802|NCT01265251|Other|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
85803|NCT00050895|Drug|Stavudine|
85804|NCT01265264|Drug|ulodesine|Oral dose administered daily for 84 days.
85805|NCT01265264|Drug|Placebo|Oral dose administered daily for 84 days.
85806|NCT01265290|Device|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
85972|NCT00051831|Drug|Saquinavir|Will be administered as five hard gel capsules orally twice daily
85973|NCT01273558|Drug|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
85974|NCT01273571|Drug|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
85975|NCT01273584|Drug|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
85976|NCT01273584|Drug|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
85977|NCT01273610|Drug|Lapatinib|250 mg tablets
85978|NCT01273610|Drug|Trastuzumab|Intravenous injection
85979|NCT01273610|Other|laboratory biomarker analysis|
85980|NCT01265563|Drug|N-acetylcysteine placebo + silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient orally twice daily for three months
85981|NCT01265563|Drug|N-acetylcysteine active + silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily for three months
85982|NCT01265563|Drug|N-acetylcysteine placebo + silibin active|Dietary Supplement: silibin 480 mg orally twice daily for three months
(Other Name) Silibin-phosphatidylcholine placebo, Siliphos placebo
(Other Name) NAC placebo Dietary Supplement: silibin placebo excipient orally twice daily for three months
85983|NCT01265563|Drug|N-acetylcysteine active + silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily for three months
(Other Name): NAC Dietary Supplement: silibin 480 mg orally twice daily for three months Silibin-phosphatidylcholine, Siliphos Dietary Supplement: silibin placebo excipient orally twice daily for three months
(Other Name): Silibin-phosphatidylcholine, Siliphos Dietary Supplement: silibin placebo excipient orally twice daily for three months
85984|NCT01265563|Drug|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily for three months
85985|NCT01265576|Drug|Sorafenib|Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
85986|NCT01265576|Drug|VT-122 (propranolol plus etodolac)|Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
85987|NCT00050921|Drug|somatropin|
86284|NCT01268657|Behavioral|Behavioral Activation|Learning to initiate healthy activity
86817|NCT01266941|Drug|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
86818|NCT01266954|Drug|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
86819|NCT01266967|Drug|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
86820|NCT01266980|Drug|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
86821|NCT00051077|Procedure|Liver Biopsy|
86822|NCT01266993|Biological|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
86823|NCT01267006|Drug|GSK1325756|
86824|NCT01267006|Drug|Sugar Pill|
86825|NCT01267019|Behavioral|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
85882|NCT01273155|Drug|Belinostat|Patients divided into 4 cohorts based on level of liver dysfunction. Belinostat administered IV over 30 minutes. On day -7 (Cycle 1 only), all patients receive a single dose of 400 mg/m2 belinostat. On days 1 5 of each cycle, patients receive belinostat at a dose dependent on the level of hepatic dysfunction (125-1000 mg/m2/day)
85883|NCT01273168|Drug|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit
85884|NCT01273181|Biological|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
85885|NCT01273181|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
85886|NCT01273181|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
85887|NCT01273181|Drug|Fludarabine|25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
85888|NCT01273207|Drug|Inhaled Cyclosporine Solution|
85889|NCT00051818|Behavioral|Treatment interruption/reinitiation schedule|
86052|NCT01272947|Other|Placebo|Topical gel - 4 times daily
86341|NCT01266083|Biological|WT1 peptide vaccine|Six vaccinations of the WT1 peptide preparation (1.0 ml of emulsion) will be administered on weeks 0, 2, 4, 6, 8, and 10. All vaccinations will be administered subcutaneously with vaccination sites rotated among extremities. Patients who are clinically stable and have not had disease progression, may receive up to 6 more vaccinations administered appropriately every month.
86342|NCT01266096|Drug|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma and up to six (6) patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated GE STE PET/CT scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
86343|NCT01266109|Behavioral|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
86344|NCT01266109|Other|Usual Services (US)|Typical community-based substance abuse treatment services
86345|NCT01266122|Behavioral|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
86346|NCT01266135|Drug|QAX576|QAX576 10 mg/kg intravenous infusion
86347|NCT01266135|Drug|Placebo|Placebo to QAX576 intravenous infusion
86348|NCT01266148|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
86349|NCT00050986|Drug|Temozolomide|Starting Dose Level: 100 mg/m^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
86350|NCT01266148|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
86351|NCT01266148|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
86352|NCT01266148|Drug|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
86353|NCT01266148|Drug|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
86354|NCT01266161|Drug|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
86355|NCT01266161|Drug|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
86356|NCT01266174|Drug|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
85807|NCT01265290|Device|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
85808|NCT01265303|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
85809|NCT01265316|Device|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
85810|NCT01265329|Other|Negative selection|Sperm selection to continue the treatment with healthy sperm
85811|NCT01265342|Drug|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
85812|NCT01265342|Drug|Placebo|Placebo nebulised suspension twice a day for 10 days
86113|NCT01268397|Procedure|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
86114|NCT00001028|Drug|Dapsone|
86115|NCT00051194|Drug|Combination IOP Lowering Therapy|
86116|NCT01268397|Procedure|closed reduction and plaster treatment|closed reduction, below elbow plaster cast for 5 week
86117|NCT01268423|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
86118|NCT01268423|Procedure|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
86119|NCT01268449|Radiation|Low dose laser|5mv laser with a wavelength of 650nm
86120|NCT01268449|Radiation|Placebo|The act of radiating laser to the ear is done while the set is off.
86121|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
86122|NCT01270815|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
86123|NCT01270828|Drug|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
86124|NCT01270828|Drug|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
86125|NCT01270841|Drug|Placebo|Placebo capsule 1x daily for 3 months
86126|NCT00051545|Drug|Seocalcitol|
86285|NCT00051220|Behavioral|One-Session Treatment for Specific Phobias|
86286|NCT01268657|Behavioral|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
86287|NCT01268670|Drug|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
86288|NCT01268670|Drug|Oxycodone|Subjects will receive topical LET and oral oxycodone.
86289|NCT01268670|Other|Placebo|Subjects will receive topical LET and oral placebo.
86290|NCT01268683|Drug|RP-1127 (Glyburide for injection)|Bolus plus 72 hour IV infusion
86291|NCT01268709|Drug|Doxepin|
86292|NCT01268709|Drug|Nortriptyline|
86293|NCT01268709|Drug|placebo|
86294|NCT01268722|Device|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
86295|NCT01268722|Device|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
86296|NCT00051233|Procedure|World Wide Web-Based Psychoeducation|
86297|NCT01268735|Drug|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
86298|NCT00051558|Drug|Placebo|Injection placebo, daily, 36 months
86299|NCT01271114|Drug|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
86300|NCT01271127|Radiation|CT coronary angiography|patient will undergo one CT coronary angiography
86301|NCT01271140|Drug|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
86302|NCT01271153|Drug|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
86303|NCT01271153|Drug|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
86304|NCT01271166|Drug|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
85890|NCT01273233|Biological|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
85891|NCT01273233|Other|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
85892|NCT01273246|Biological|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
85893|NCT01273246|Biological|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
85894|NCT01273246|Biological|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
85895|NCT01273246|Biological|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
85896|NCT01265433|Biological|WT-1-vaccine Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
86188|NCT01268462|Other|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
86189|NCT01268462|Other|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
86190|NCT01268462|Other|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
86191|NCT01268488|Device|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
86192|NCT00051207|Behavioral|Interpersonal Psychotherapy (IPT)|
86357|NCT01266174|Drug|Placebo|Placebo to match eltoprazine
86358|NCT01266187|Procedure|adjuvant surgery + FOLFOX + cetuximab|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
86359|NCT01266187|Procedure|perioperative/Folfox + cetuximab|12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery
-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab
86662|NCT01269372|Device|PillCam Colon 2|Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).
Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon.
86663|NCT01269372|Device|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
86664|NCT00051636|Drug|Risedronate|Oral risedronate 30 mg capsules.
86665|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
86666|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
86667|NCT01271790|Drug|GS-9451 placebo|placebo matching GS-9451 tablet QD
86668|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
86669|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
86670|NCT01271803|Drug|GDC-0973|Oral repeated dose
86671|NCT01271803|Drug|vemurafenib|Oral repeated dose
86672|NCT01271829|Dietary Supplement|Avocado supplement|Calories from avocados replace calories of the control lunch
86673|NCT01271829|Dietary Supplement|Avocado included|Calories from avocados will be added to calories from the control lunch
86674|NCT01271855|Drug|B&O suppository|B&O suppository 16.2mg/30mg per rectum immediately after delivery, then every 8 hours for 24 hours following delivery
86675|NCT00051636|Drug|Placebo to Risedronate|Oral placebo of risedronate capsules.
86676|NCT01271855|Other|Control Group|A vegetable oil suppository (placebo) per rectum immediately after delivery, then scheduled every 8-hours for the first 24 hours.
86677|NCT01271868|Drug|Recombinant factor IX Product, IB1001|On-Demand or Prophylaxis
86678|NCT01271881|Other|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
86127|NCT01270841|Drug|topical testosterone|testosterone gel applied 1x daily for 3 months
86128|NCT01270841|Drug|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
86129|NCT01270854|Other|Plasmalyte A|Intravenous fluid
86130|NCT01270854|Other|Normal Saline|Intravenous fluid
86131|NCT01270867|Device|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
86132|NCT01270880|Drug|Hsp90 inhibitor STA-9090|Given IV
86133|NCT01270880|Other|laboratory biomarker analysis|Correlative studies
86134|NCT01270880|Genetic|polymerase chain reaction|Correlative studies
86135|NCT01270880|Other|enzyme-linked immunosorbent assay|Correlative studies
86136|NCT01270880|Genetic|RNA analysis|Correlative studies
86422|NCT01263873|Device|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
86423|NCT01263886|Drug|ombrabulin (AVE8062)|Pharmaceutical form:solution
Route of administration: intravenous
86424|NCT01263886|Drug|placebo|Pharmaceutical form:solution
Route of administration: intravenous
86425|NCT01263899|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
86426|NCT01263912|Dietary Supplement|Nutrition supplement containing Long Chain Polyunsaturated Fatty Acids (LCPUFA)|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
86427|NCT01263912|Dietary Supplement|Nutrition supplement containing Long Chain Polyunsaturated Fatty Acids (LCPUFA)|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
86428|NCT01263925|Drug|Alprostadil (Prostaglandin E1)|4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.
4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.
86429|NCT00050713|Drug|Sirolimus|
86430|NCT01263925|Drug|Pentoxifylline|4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.
4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.
86431|NCT01266200|Procedure|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
86305|NCT01271179|Procedure|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
86607|NCT01264211|Drug|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
86608|NCT01264224|Drug|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
86609|NCT01264237|Drug|Etoricoxib|90mg Tablet QD at 10:00a.m.
86610|NCT01264237|Drug|Placebo|One tablet QD at 10:00a.m.
86611|NCT01264250|Drug|AZD2927|Single dose of AZD2927
86612|NCT01264250|Drug|Placebo|Single dose of placebo
86613|NCT01264289|Drug|Finasteride|Finasteride Tablets 5 mg
86614|NCT01264302|Drug|Finasteride|Finasteride Tablets 5 mg
86615|NCT01264315|Drug|Lenalidomide|Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:
absolute neutrophil count >1x109/L without growth factors
platelet count >75x109/L without transfusion support
calculated/measured creatinine clearance: ≥20mL/minute
total bilirubin <2 x the upper limit of normal
AST (SGOT) and ALT (SGPT) <2.5 x upper limit of normal
<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD
Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart.
86616|NCT01264328|Drug|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
86617|NCT00050778|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ [CD4+] T-cell count was >=100*10^6 cells per liter).
86618|NCT01264341|Drug|Bevacizumab|Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
86619|NCT01264341|Drug|Temsirolimus|Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
86620|NCT01264354|Drug|Clevudine 30mg|Clevudine 30mg
86621|NCT01264354|Drug|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
86622|NCT01264354|Drug|Clevudine 20mg|Clevudine 20mg
86193|NCT01268501|Device|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
86194|NCT01268527|Drug|E6201|E6201 0.03% gel, topical once daily; E6201 0.1% gel, topical once daily; E6201 0.2% gel, topical once daily; gel vehicle, topical daily; calcipotriene (0.005%) topical, once daily.
86195|NCT01268527|Drug|E6201|E6201 .005% gel, topical once daily; E6201 0.01% gel, topical once daily; E6201 0.05% gel, topical once daily; gel vehicle, topical daily; calcipotriene(0.005%) topical, once daily.
86196|NCT01268540|Device|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
86197|NCT01268540|Device|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
86198|NCT01268553|Drug|Treprostinil|Transition to inhaled treprostinil
86199|NCT01268566|Drug|MEDI-575|MEDI-575 as an IV infusion.
86200|NCT01268579|Drug|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
86201|NCT01268592|Procedure|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
86202|NCT01268605|Procedure|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
86203|NCT01270945|Procedure|Standard of Care|
86499|NCT01263925|Drug|Placebo to Pentoxifylline oral|4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.
4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.
86500|NCT01263925|Drug|Placebo to Alprostadil (Prostaglandin E1) intravenous|4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.
4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.
86501|NCT01263938|Drug|Atorvastatin|For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.
For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day.
86502|NCT01263951|Drug|Everolimus|One 5 mg. tablet daily.
86503|NCT01263951|Drug|Sorafenib|200 mg. twice daily.
86504|NCT01263964|Procedure|coronary angiogram|coronary angiogram
86505|NCT01263977|Device|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
86679|NCT01271881|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
86680|NCT01271894|Drug|Efavirenz|600 mg once daily; given as 3 x 200 mg once
86681|NCT01271894|Drug|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
86682|NCT01271907|Drug|fludarabine|Fludarabine 25 mg/m^2 x 5 days
86683|NCT01271907|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
85735|NCT01267565|Other|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
85736|NCT01267578|Biological|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
85737|NCT01267604|Drug|Recombinant FSH (rFSH)|225IU
85738|NCT01267604|Dietary Supplement|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
85739|NCT01267643|Drug|Alefacept|Dose Escalation Schedule
Level -1 5 mg IV once weekly
Level 1 7.5 mg IV once weekly
Level 2 10 mg IV once weekly
Level 3 12.5 mg IV once weekly
85740|NCT01267669|Drug|Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
85741|NCT01267669|Drug|Placebo|Emergency EVL plus placebo infusion for 5 days
85742|NCT01267682|Behavioral|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
85743|NCT01267695|Drug|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
85744|NCT00051129|Drug|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
85745|NCT01267695|Procedure|conventional surgery|All the patients should receive elective surgery with R0 resection.
85746|NCT01267721|Procedure|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
85747|NCT01267734|Device|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
85748|NCT01267734|Device|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
85749|NCT01267734|Drug|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
86432|NCT01266200|Procedure|XIA|Treatment of the fracture with Xia and conventional operation technique
86433|NCT01266213|Drug|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
86434|NCT01266213|Drug|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
86435|NCT01266213|Drug|Goserelin|Goserelin s.c.
86436|NCT01266226|Device|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
86437|NCT01266226|Device|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
86438|NCT01266239|Procedure|kissing balloon inflation|Kissing balloon inflation following the MV stenting
86439|NCT01266239|Device|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
86440|NCT01266252|Drug|Dexmedetomidine|Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.
Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed.
86745|NCT01269398|Device|GO-LIF and SpineAssist SYSTEMS|
86746|NCT01269411|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
86747|NCT01269411|Procedure|therapeutic conventional surgery|Undergo surgery
86748|NCT01269411|Other|pharmacological study|Correlative studies
86749|NCT01269411|Other|laboratory biomarker analysis|Correlative
86750|NCT01269424|Biological|MGMTP140K-encoding retroviral vector|
86751|NCT01269424|Drug|O6-benzylguanine|
86752|NCT00051350|Behavioral|Diet therapy|
86753|NCT01269424|Drug|temozolomide|
86754|NCT01269424|Other|laboratory biomarker analysis|
86755|NCT01269424|Procedure|autologous hematopoietic stem cell transplantation|
86756|NCT01269424|Procedure|in vitro-treated peripheral blood stem cell transplantation|
86623|NCT01266603|Drug|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
86624|NCT00051051|Drug|CI-1033|
86625|NCT01266603|Biological|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
85678|NCT00051454|Biological|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
85679|NCT01270178|Drug|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
85680|NCT01270191|Drug|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
85681|NCT01270191|Drug|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
85682|NCT01270217|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
85683|NCT01272622|Other|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
85684|NCT01272635|Drug|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
85685|NCT01272635|Drug|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
85686|NCT01272635|Other|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
85687|NCT01272635|Drug|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
85688|NCT01272648|Behavioral|RePCa A|Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.
Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises
85689|NCT00051740|Behavioral|Cognitive Adaptation Therapy (CAT)|
85690|NCT01272661|Behavioral|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
85691|NCT01272661|Behavioral|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
86506|NCT01263990|Device|NexFin|noninvasive finger cuff system
86507|NCT01264003|Drug|sefazolin|In prophylaxis
86508|NCT00050726|Drug|Interleukin-2|
86509|NCT01264016|Device|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
86510|NCT01264029|Behavioral|Mindful Tai Chi Intervention|
86511|NCT01264029|Behavioral|Mindfulness Meditation|
86512|NCT01264029|Behavioral|Mall Walking|
86513|NCT01264029|Behavioral|Weekly Discussion|
86514|NCT01264042|Dietary Supplement|Ferrous Sulfate|60 mg with 200 mL water, single administration
86515|NCT01264068|Drug|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
86516|NCT01264081|Drug|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
86517|NCT01264094|Drug|Clevudine|clevudine 30 mg qd
86518|NCT01264120|Behavioral|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
86519|NCT00050765|Drug|MyoCell™ Autologous Myoblasts|
86826|NCT01267019|Behavioral|social cognitive training|30 sessions of social cognitive training without in vivo exercises
86827|NCT01267019|Behavioral|non-social skills training|30 sessions of skills training that has no specific social content
86828|NCT01267032|Behavioral|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
86829|NCT01267032|Behavioral|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
86830|NCT01269502|Device|"Temp Touch" Diabetica Solutions inc.|Daily measurement of skin temperature on feet for one year
86831|NCT01269502|Other|Inspection|Inspection of feet daily for one year
85750|NCT01267734|Drug|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
85751|NCT01270230|Behavioral|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
86053|NCT00051779|Drug|CAL|
86054|NCT01272960|Device|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
86055|NCT01272973|Drug|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
86056|NCT01272973|Drug|placebo|Placebo (oral) administered once daily for 10 weeks.
86057|NCT01272973|Drug|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
86058|NCT01272986|Device|ALOA IgG-Elisa|measurement of IgG Level in blood
86059|NCT01272986|Device|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
86060|NCT01273012|Drug|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
86061|NCT01273025|Dietary Supplement|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
86062|NCT01273038|Device|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
86063|NCT01273038|Device|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
86064|NCT00001031|Biological|rgp120/HIV-1MN|
86065|NCT00051792|Behavioral|yoga|
86066|NCT01273051|Drug|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
86067|NCT01273051|Radiation|radiotherapy|radiation 25x2 Gy
86068|NCT01273051|Procedure|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
86757|NCT01269424|Radiation|radiation therapy|
86758|NCT01269437|Drug|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
86759|NCT01269450|Drug|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
86760|NCT01269450|Drug|placebo|placebo 200mg vaginal tablets
86761|NCT01269463|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Methylphenidate Hydrochloride Extended Release Capsules to be dosed once daily
86762|NCT01269463|Drug|Placebo|Capsule without active drug
86763|NCT00051363|Device|Positive Pressure Respiration|Nightly nasal continuous positive airway pressure (CPAP)
86764|NCT01269476|Drug|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
86765|NCT01269476|Drug|Placebo|Same volumes and frequency as active.
86766|NCT01271972|Drug|nesvacumab (REGN910/ SAR307746)|
86767|NCT01271985|Drug|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
86768|NCT01271985|Other|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
86769|NCT01271998|Drug|TR-701 FA|200 mg, oral, once daily for 3 days.
85813|NCT01265355|Dietary Supplement|Anti-rotavirus protein|11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
85814|NCT00050895|Drug|Zidovudine|
85815|NCT01265355|Dietary Supplement|Maltodextrin|Maltodextrin 1 gm daily
85816|NCT01265368|Biological|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
85817|NCT01265394|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
85818|NCT01265420|Biological|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
85819|NCT01267760|Device|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
85820|NCT01267773|Behavioral|Integrated Treatment|
85692|NCT01272661|Behavioral|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
85693|NCT01272674|Other|exercise training|4 weeks supervised physical exercise training
85694|NCT01272700|Procedure|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
85695|NCT01272700|Procedure|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
85696|NCT01272713|Other|Oxygen therapy|Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min
In-hospital oxygen as per hospital protocol
85988|NCT01265576|Drug|Placebo|Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
85989|NCT01265589|Drug|surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
85990|NCT01265589|Drug|surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
85991|NCT01265602|Drug|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
85992|NCT01265602|Drug|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
85993|NCT01265602|Drug|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
85994|NCT01265615|Drug|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
85995|NCT01265615|Drug|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
85996|NCT01265615|Drug|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
85997|NCT01265615|Dietary Supplement|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
85998|NCT00050921|Biological|Hepatitis A virus, inactivated|
85999|NCT01265628|Procedure|perimetry|automated static perimetry with adapted GATE strategy
86832|NCT01269515|Drug|Etoricoxib|90 mg QD
86833|NCT01269528|Other|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
86834|NCT01269528|Other|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
86835|NCT01269528|Other|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
86836|NCT01269528|Other|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
86837|NCT01269528|Other|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
86838|NCT00051363|Device|Sham CPAP machine|Sham CPAP machine will be used for participants in the placebo group.
86839|NCT01269541|Drug|Mupirocin|Topical in the nose 3 times daily for 5 days
86840|NCT01269541|Drug|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
86841|NCT01269567|Procedure|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit < 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
86842|NCT01269567|Procedure|No pelvic drainage|no aspiration drain at the end of intervention
85897|NCT01265433|Biological|Montanide adjuvant + GM-CSF (This arm is closed)|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
85898|NCT01265446|Drug|Lidocaine 8mg + CPC 2mg|one single dose
85899|NCT01265446|Drug|Lidocaine 1mg + CPC 2mg|one single dose
86069|NCT01273051|Procedure|TEM surgery|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.
After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks.
86070|NCT01273064|Drug|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
86071|NCT01273064|Drug|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
86072|NCT01273064|Drug|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
86360|NCT00050986|Drug|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
86361|NCT01268748|Procedure|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
86362|NCT01268748|Procedure|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
86363|NCT01268761|Drug|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
86364|NCT01268761|Drug|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
86365|NCT01268787|Biological|EV71 vaccine|Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
86366|NCT01268813|Other|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
86367|NCT01268839|Drug|TMC278|25mg tablet once daily for 28 days
86368|NCT01268839|Drug|TMC278|25mg tablet once daily for 14 days
86369|NCT01268839|Drug|Efavirenz|600mg tablet once daily for 14 days
86370|NCT00051246|Behavioral|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
86371|NCT01268891|Drug|Placebo|Once daily; tablet; orally; 18 weeks
86372|NCT01268891|Drug|Azilect®|1 mg daily; tablet; orally; 18 weeks
85821|NCT01267786|Procedure|Liver surgery|hepatectomy
85822|NCT01267812|Drug|bortezomib|Given SC or IV
85823|NCT00051129|Other|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
85824|NCT01267812|Biological|rituximab|Given IV
85825|NCT01267812|Other|laboratory biomarker analysis|Correlative studies
85826|NCT01267812|Other|immunohistochemistry staining method|Correlative studies
85827|NCT01267812|Genetic|RNA analysis|Correlative studies
85828|NCT01267812|Genetic|gene expression analysis|Correlative studies
85829|NCT01267812|Genetic|DNA analysis|Correlative studies
85830|NCT01267812|Other|pharmacological study|Correlative studies
85831|NCT01267812|Other|pharmacogenomic studies|Correlative studies
85832|NCT01267812|Other|Questionnaire Administration|
85833|NCT01267825|Drug|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
85834|NCT00051142|Drug|Travoprost|
85835|NCT01267825|Drug|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
85836|NCT01267838|Procedure|PCI|PCI of bifurcation lesions with double stenting
85837|NCT01267864|Drug|Metoclorpamide|10mg IVSS
86137|NCT00051558|Drug|Teriparatide|20 micrograms/day, injection, 36 months
86138|NCT01270880|Other|spectrophotometry|Correlative studies
86139|NCT01270880|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
86140|NCT01270880|Genetic|gene expression analysis|Correlative studies
86141|NCT01270893|Drug|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
86142|NCT01270906|Drug|CHIR-258 (TKI258)|
86000|NCT01268059|Drug|Carboplatin/Paclitaxel/MEDI-575|Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6mg/mL*min) plus MEDI-575 at dose determined in the Dose Determination Phase. Carboplatin/paclitaxel and MEDI-575 to be given once every 21 days as an IV infusion for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
86001|NCT01268085|Other|Radiation Alert|A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part
86002|NCT01268085|Other|Control|Control with no inverention
86003|NCT01268098|Drug|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
86004|NCT01268111|Drug|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
86005|NCT01268111|Drug|Placebo|matching placebo
86006|NCT00051168|Drug|Travatan|Travoprost (0.004%) 1 drop each eye once daily
86007|NCT01268124|Drug|HTC-867|
86306|NCT01271179|Procedure|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
86307|NCT01271192|Procedure|surgical resection and adjuvant therapy|Postoperative:
Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
86308|NCT01271192|Procedure|Neoadjuvant followed by operation|Preoperative:
Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Postoperative:
Drug: fluorouracil Given IV continuously,Irinotecan Given IV
86309|NCT00051571|Drug|SGN-15|
86310|NCT01271218|Other|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
86311|NCT01271218|Other|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
86312|NCT01271231|Drug|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
85900|NCT01265459|Device|Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml|Durolane is an intraarticular hyaluronic acid preparation
85901|NCT01265485|Drug|coated suppository|Dose escalating study
85902|NCT00050895|Drug|Lamivudine|
85903|NCT01265498|Drug|obeticholic acid|25 mg daily for 72 weeks
85904|NCT01265498|Drug|placebo|placebo capsule, 25 mg daily for 72 weeks
85905|NCT01265511|Drug|Placebo|Oral tablets given bid for 28 days
85906|NCT01265511|Drug|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
85907|NCT01265511|Drug|peginterferon alfa 2a|180 ug prefilled syringe given once per week for up to 48 weeks
85908|NCT01265511|Drug|Ribavirin|tablets given bid for up to 48 weeks
85909|NCT01265524|Drug|CLP|Oral administration
85910|NCT01265524|Drug|Placebo|Oral administration
85911|NCT01265537|Drug|Tacrolimus|Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4
85912|NCT01265537|Drug|Tacrolimus|Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.
85913|NCT00050895|Drug|Tenofovir disoproxil fumarate|
85914|NCT01265550|Device|Nissen fundoplication|laparoscopic antireflux surgery
85915|NCT01265550|Drug|baclofen|Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.
The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved.
85916|NCT01265550|Drug|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
85917|NCT01267916|Device|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
86204|NCT01270958|Drug|Avamys aqueous nasal spray 110mcg|At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.
Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken.
86373|NCT01268904|Drug|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
86374|NCT01268917|Drug|aspirin|aspirin 100mg daily until the surgery day
86375|NCT01268917|Drug|aspirin|aspirin is stopped 5-7 days before operation
86376|NCT01268930|Procedure|Bipolar electrocautery for ovarian hemostasis|after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
86377|NCT01268930|Procedure|hemostatic matrix (FloSeal)|after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
86378|NCT01268943|Drug|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
86379|NCT01268943|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
86380|NCT01268943|Drug|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
86684|NCT01271907|Drug|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
86685|NCT01271907|Drug|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
86686|NCT00051636|Drug|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
86687|NCT01271920|Drug|AUY922|
86688|NCT01271920|Drug|Trastuzumab|
86689|NCT01271933|Drug|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
86690|NCT01271933|Drug|placebo|matching placebo tablet; given once daily
86691|NCT01271946|Device|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
86692|NCT01264367|Drug|Clevudine|30mg,QD
86693|NCT01264367|Drug|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
86694|NCT01264380|Drug|RO5185426|Single oral dose, fasted
86695|NCT01264380|Drug|RO5185426|Single oral dose, with high fat meal
86696|NCT01264380|Drug|RO5185426|Continuous administration, orally twice daily
86143|NCT01270919|Device|BioDuct Meniscal Repair Device|The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.
The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear.
86144|NCT01270932|Drug|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
86145|NCT01270945|Drug|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
86146|NCT01273259|Drug|DHEA Treatment|DHEA : 200 mg/day hard gelatine capsule
86147|NCT01273259|Drug|DHEA Treatment|DHEA : 25 mg/day hard gelatine capsule
86148|NCT01273272|Behavioral|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
86149|NCT01273272|Behavioral|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
86150|NCT00051831|Drug|Emtricitabine|Will be administered as one 200-mg capsule orally daily
86151|NCT01273285|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
86152|NCT01273298|Drug|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
86153|NCT01273298|Drug|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
86441|NCT00050999|Drug|ONTAK|
86442|NCT01266265|Drug|inhaled prostacyclin|Tyvaso
86443|NCT01266265|Drug|inhaled prostacyclin|As prescribed by the physician
86444|NCT01266265|Drug|prostacyclin|As prescribed by the physician
86445|NCT01266265|Drug|subcutaneous and intravenous prostacyclin|As prescribed by physician
86313|NCT01271231|Drug|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
86314|NCT01271231|Drug|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
86315|NCT01271244|Drug|Escitalopram|10-20mg daily for 12 weeks
86316|NCT00050661|Drug|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
86317|NCT01263704|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv Day 0 of Cycle 1, 500 mg/m2 iv Day 1 of Cycles 2-6
86318|NCT01263717|Drug|tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
86319|NCT01263717|Drug|placebo|Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
86626|NCT01266616|Biological|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
86627|NCT01266616|Biological|IL-12|Administered at Weeks 0, 4, and 12
86628|NCT01266616|Other|Placebo|Saline injections at Weeks 0, 4, and 12
86629|NCT01266642|Radiation|Hypofractionated Whole Breast Irradiation|42.56 Gy in 16 fractions delivered to the whole breast on consecutive treatment days.
Boost of 10 Gy in 4 fractions or 12.5 Gy in 5 fractions delivered on consecutive days beginning on treatment day following completion of whole breast irradiation.
86630|NCT01266642|Radiation|Conventionally Fractionated Whole Breast Irradiation|50 Gy in 25 fractions delivered to whole breast on consecutive treatment days.
Boost of 10 Gy in 5 fractions or 14 Gy in 7 fractions delivered on consecutive treatment days, beginning on treatment day following completion of whole breast irradiation.
86631|NCT01266655|Drug|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
86632|NCT01266655|Drug|Placebo|Placebo
86205|NCT00051558|Drug|Alendronate Sodium|10 mg/day, oral, 36 months
86206|NCT01270971|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
86207|NCT01270971|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
86208|NCT01270984|Drug|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
86209|NCT01270984|Drug|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
86210|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
86211|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
86212|NCT01271010|Drug|cyclophosphamide|250 mg/m2 intravenously or orally on Days 1-3 of cycles 1-6 of 28 days length each
86213|NCT01271010|Drug|fludarabine|25 mg/m2 intravenously or 40 mg/m2 orally on Days 1-3 of cycles 1-6 of 28 days lengths each
86214|NCT01271010|Drug|rituximab [MabThera]|375 mg/m2 intravenously on Day 1 of Cycle 1, then 500 mg/m2 intravenously on Day 1 of 5 cycles of 28 days lengths
86215|NCT01271023|Device|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
86216|NCT00051558|Drug|Placebo|Oral placebo, daily, 36 months
86217|NCT01271036|Device|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
86218|NCT01271049|Other|Novel Food Product|Novel food product containing essential oil blend
86219|NCT01271049|Other|Control Food Product|Control food product
86220|NCT01271062|Procedure|gastric bypass surgery|
86221|NCT01271062|Procedure|abdominal surgery|
86222|NCT01271062|Behavioral|very low caloric diet|
86223|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
86224|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
86520|NCT01264133|Drug|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
86697|NCT00001026|Biological|rgp120/HIV-1MN|
86698|NCT00050778|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was >=100*10^6 cells per liter).
86699|NCT01264393|Behavioral|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
86700|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
86701|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
86702|NCT01264432|Other|Laboratory Biomarker Analysis|Correlative studies
86703|NCT01264432|Other|Quality-of-Life Assessment|Ancillary studies
86704|NCT01264432|Radiation|Radiation Therapy|Undergo LDFWAR
86705|NCT01264432|Drug|Veliparib|Given PO
86706|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
85752|NCT01270230|Behavioral|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
85753|NCT01270256|Drug|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
85754|NCT01270256|Drug|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
85755|NCT01270269|Behavioral|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
85756|NCT01270269|Behavioral|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
85757|NCT00051467|Genetic|TNFerade|
85758|NCT01270282|Drug|AM-101 0.81 mg/mL|
86446|NCT01266265|Drug|oral ERA|As prescribed by physician
86447|NCT01266265|Drug|oral PDE5 inhibitors|As prescribed by physician
86448|NCT01266278|Other|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
86449|NCT01266278|Other|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
86450|NCT01266278|Other|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
86451|NCT01266291|Drug|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
86452|NCT00051012|Drug|ONTAK|
86453|NCT01266317|Drug|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
86454|NCT01266330|Dietary Supplement|Low Dairy|Less than 0.5 standard servings of dairy products per day
86455|NCT01266330|Dietary Supplement|Adequate Dairy|3.5 standard servings of dairy foods per day
86456|NCT01268969|Procedure|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
86457|NCT01268982|Procedure|socket preservation|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
86458|NCT01268995|Drug|Cyclosporine A|Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a "stop and go" protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
86459|NCT01268995|Drug|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
86770|NCT01272011|Other|Breathing (Hypoxia) Treatment|Hypoxia (breathing 1/3 less oxygen than what is present in normal room air) versus non hypoxia will be compared to determine whether respiratory drive can be increased following spinal cord injury.
86771|NCT00051636|Dietary Supplement|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
86633|NCT01266681|Drug|amiodarone|Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.
Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.
Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires
Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires
Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires
Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires
Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.
86634|NCT01266681|Drug|Dronedarone|Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.
Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.
Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires
Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires
Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires
Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires
Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.
86635|NCT00000251|Other|100% oxygen|Placebo
86636|NCT00001027|Drug|Pentamidine isethionate|
86637|NCT00051077|Drug|Adefovir dipivoxil|
86638|NCT01266694|Drug|Colchicines|oral form, 1 mg, once a day during 14 days
86639|NCT01266694|Drug|Placebo|oral form, placebo
86640|NCT01266707|Biological|antiangiogenic paptide vaccine|for drugs include administration time frame
86641|NCT01269242|Drug|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
85697|NCT01272713|Other|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
85698|NCT01272726|Behavioral|Education|Education on the genetics of ADHD and treatment options for ADHD
85699|NCT01272739|Dietary Supplement|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
85700|NCT00051740|Behavioral|Minimal Environmental Supports (MES)|
85701|NCT01272739|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
85702|NCT01272752|Dietary Supplement|IHBG-10|500 mg IHBG-10
85703|NCT01272752|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
85704|NCT01272765|Other|Placebo|Placebo
86521|NCT01264146|Procedure|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
86522|NCT01264146|Procedure|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
86523|NCT01264159|Device|Lung impedence-guided therapy|
86524|NCT01266369|Drug|masitinib|
86525|NCT01266382|Device|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
86526|NCT01266434|Drug|Simvastatin|10 mg once daily for 8 weeks
86527|NCT01266434|Drug|B1-6-12|1 tablet once daily for 8 weeks
86528|NCT01266447|Biological|Filgrastim|Given SC
86529|NCT01266447|Other|Laboratory Biomarker Analysis|Correlative studies
86530|NCT01266447|Biological|Pegfilgrastim|Given SC
86531|NCT00051025|Drug|ONTAK|
86532|NCT01266447|Drug|Topotecan Hydrochloride|Given IV
86533|NCT01266447|Drug|Veliparib|Given PO
86534|NCT01266460|Biological|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
86535|NCT01266460|Other|Laboratory Biomarker Analysis|Correlative studies
86536|NCT01266473|Other|Physiotherapy|Physiotherapy for Airway Clearance
86537|NCT01266486|Drug|Metformin|Extended release Metformin 1500mg once daily for 14-21 days
86538|NCT01266499|Drug|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
86539|NCT01266499|Drug|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
86540|NCT01266499|Drug|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
86541|NCT01266499|Drug|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
86542|NCT00051038|Drug|Entecavir|
85759|NCT01270282|Drug|Placebo|
85760|NCT01270308|Drug|Lansoprazole|Lansoprazole DR Capsules 30 mg
85761|NCT01270321|Drug|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
85762|NCT01270321|Drug|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide LAR 60mg i.m. once every 4 weeks
85763|NCT01270321|Drug|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide LAR 60mg i.m. once every 4 weeks
85764|NCT01270334|Other|PH meassurment|meassuring ph USING PROBE
85765|NCT01270347|Drug|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
85766|NCT01270347|Drug|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
85767|NCT01270360|Device|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
85768|NCT00051480|Genetic|TNFerade|
85769|NCT01270373|Drug|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Adriamycin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
85770|NCT01272778|Drug|Lorazepam|oral capsule, 0.5 mg, single acute dose
86073|NCT01273064|Drug|Placebo|Tablets identical in appearance to CTS-1027 containing inactive ingredients.
Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.
30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo).
86074|NCT01265641|Drug|AZD1981, 2000mg|Single oral dose, tablets
86075|NCT01265641|Drug|AZD1981, 200mg|Single oral dose, tablets
86076|NCT01265641|Drug|Moxifloxacin, 400mg|Single oral dose, capsule
86077|NCT01265641|Drug|Placebo|Single oral dose, tablets
86078|NCT01265667|Drug|CF101|orally q12h
86079|NCT01265667|Drug|Placebo|orally q12h
86080|NCT01265680|Drug|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
88005|NCT01301937|Drug|Meglumine antimoniate|Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:
High continuous dose: 20 mg/kg/day for 30 continuous days.
Low continuous dose 5 mg/kg/day for up to 120 continuous days.
There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat
Arms: High continuous dose, Low continuous dose
88006|NCT01301950|Other|Instrument|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
88007|NCT01301963|Drug|plerixafor|Given SC
88008|NCT01301963|Biological|filgrastim|Given SC
87112|NCT01300052|Drug|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
87113|NCT01300078|Drug|MF101|MF101 10 g/day MF101 15 g/day
87114|NCT01300104|Behavioral|Exercise|Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.
Restrictions: None.
87115|NCT01300104|Behavioral|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
87116|NCT01300104|Behavioral|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
87117|NCT01300130|Dietary Supplement|low docosahexaenoic acid formula|
87118|NCT01300130|Dietary Supplement|medium docosahexaenoic acid formula|
87119|NCT01300130|Dietary Supplement|high docosahexaenoic acid formula|
87120|NCT01300130|Dietary Supplement|breast milk|a non randomized group of breast milk fed infants was included
87121|NCT01300143|Other|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
87122|NCT00054002|Procedure|conventional surgery|Lung surgery
87123|NCT01300143|Other|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
87124|NCT01300156|Drug|Oxaliplatin-based chemotherapy (ESHAOx)|Etoposide 40 mg/m2, D1-4
Methylprednisolone 500mg, D1-5
Cytarabine 2 g/m2, D5
Oxaliplatin 130 mg/m2, D1
86256|NCT01265953|Dietary Supplement|Gelatin capsule containing cellulose and magnesium stearate|Four weeks placebo: 8 capsules (4 capsules B.I.D.) daily
86257|NCT01265979|Procedure|Whole body diffusion MRI|These studies will be performed on a 3 Tesla (T) MR system. A major advantage of 3T compared to 1.5T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
86258|NCT01266005|Drug|Clevudine|30mg,QD
86259|NCT01266005|Drug|Entecavir|0.5mg QD
86260|NCT01266018|Drug|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 will be administered intramuscularly (IM) at a fixed dose of 320 IU/m2 once weekly for a 4-week cycle
86261|NCT00050960|Drug|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks.
86262|NCT01266031|Drug|Vorinostat|Phase I: 400 mg by mouth once a day on days 1 to 7, and days 15 to 21 in a 28 day cycle.
86263|NCT01266031|Drug|Bevacizumab|Phase I: 10 mg/kg by vein on day 1 and 15 of a 28 day cycle.
86264|NCT01266031|Drug|Bevacizumab|Phase II: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.
86564|NCT01269190|Device|Widefield Multispectral Imaging Devices|Widefield multispectral imaging device used for imaging inside mouth: the Multi-spectral digital microscope (MDM) and/or the Identafi 3000 handheld system, and/or portable screening system (PS2 or PS2.1) both before and after Proflavine swabbing.
86565|NCT01269190|Device|High-Resolution Microendoscope (HRME)|High-resolution optical system used for imaging of inside mouth post proflavine application.
86566|NCT01269203|Drug|Curcumin|1000 mg per day
86567|NCT01269203|Other|Placebo|Administered daily same as Curcumin.
86568|NCT01269216|Drug|5-FU with leucovorin|5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
86569|NCT01269216|Drug|TS-1 with Irinotecan|Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
86570|NCT01269229|Drug|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -> 2400mg/m2 46hrs continuous
86571|NCT00001029|Drug|Zidovudine|
86572|NCT00051285|Drug|Enoximone placebo|Participants receive placebo to match enoximone
86573|NCT01269229|Radiation|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
86574|NCT01269242|Drug|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
87520|NCT01295853|Procedure|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
87521|NCT01295853|Procedure|t4 symapthicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
87522|NCT01295866|Device|nasal nitric oxide|
87523|NCT01295879|Drug|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
87524|NCT01295892|Drug|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
87525|NCT01295905|Device|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
87526|NCT01295905|Device|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
87527|NCT01298141|Biological|agalsidase alfa|Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)
Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly
87528|NCT01298154|Other|Dietary intervention|Dietary treatments with beverages
87865|NCT01294046|Device|Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches using the Prime Advanced Neurostimulator|Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches
87866|NCT00001042|Biological|Aluminum hydroxide|
87867|NCT00053612|Drug|Vitamin A|
87868|NCT01294059|Drug|Milnacipran|50 mg BID Oral x 6 Weeks
87869|NCT01296412|Drug|metformin|metformin tablets at a dose of ≥1500 mg per day
87870|NCT01296425|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
87871|NCT01296438|Drug|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
87872|NCT01296438|Drug|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
87316|NCT01303406|Drug|Idebenone|All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
87317|NCT00054210|Drug|carboplatin|
87318|NCT01303406|Drug|Placebo|
87319|NCT01303419|Other|DE-CEDM and CE-BMRI|Comparison between DE-CEDM and CE-BMRI
87320|NCT01303432|Dietary Supplement|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
87321|NCT01303432|Dietary Supplement|Yogurt|One yogurt (125mL) per day
87322|NCT01303445|Drug|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
87323|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
87324|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
87325|NCT01303445|Drug|Omeprazole alone|omeprazole 80 once daily for 7 days
87326|NCT01295450|Drug|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
87327|NCT01295463|Other|questionnaire administration|
87328|NCT01295463|Other|study of socioeconomic and demographic variables|
87329|NCT01295463|Procedure|assessment of therapy complications|
87330|NCT01295463|Procedure|fertility assessment and management|
87331|NCT01295463|Procedure|psychosocial assessment and care|
87332|NCT01295463|Procedure|quality-of-life assessment|
87333|NCT01295476|Genetic|gene expression analysis|
87334|NCT01295476|Genetic|microarray analysis|
87335|NCT01295476|Other|laboratory biomarker analysis|
87336|NCT00053768|Drug|vincristine sulfate|
87337|NCT01295489|Other|Laboratory Biomarker Analysis|Correlative studies
87125|NCT01300169|Behavioral|The Collaborative Assessment and Management of Suicidality|Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the "drivers" of suicidal ideation and behaviors.
87126|NCT01300169|Behavioral|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
87127|NCT01300182|Other|Whole body vibration therapy|The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
87128|NCT01300182|Other|Control|Conventional post-operative physical therapy exercises and rehabilitation.
87129|NCT01300208|Drug|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
87130|NCT01300234|Drug|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
87131|NCT01300234|Drug|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
87132|NCT01300247|Drug|Fludarabine|Intravenous repeating dose
87402|NCT01303614|Drug|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
87403|NCT01303627|Drug|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
87404|NCT01303640|Device|Biolimus-eluting stent|Biolimus-eluting stent
87405|NCT00054223|Procedure|psychosocial assessment and care|
87406|NCT01303640|Device|Everolimus-eluting stent|Everolimus-eluting stent
87407|NCT01303653|Procedure|endoscopic closure of gastrointestinal fistulas and perforations|novel endoscopic tissue closure devices will be used for endoscopic closure of gastrointestinal fistulas or perforations
87408|NCT01303666|Procedure|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
87409|NCT01303666|Procedure|TI of the knee|This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.
After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles.
87410|NCT01303679|Drug|Paclitaxel|IV, 80mg/m² at d1, d8, d15
86575|NCT01271660|Drug|Pregabalin|drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.
Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering
86576|NCT01271660|Drug|Placebo|drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.
Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering
86577|NCT01271686|Drug|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
86578|NCT00051623|Drug|Infliximab|
86579|NCT01271712|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
86580|NCT01271712|Drug|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
86581|NCT01271712|Drug|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
86582|NCT01271725|Drug|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
86583|NCT01271725|Drug|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
86899|NCT01294761|Drug|Raltegravir, Darunavir/r|An arm to change the regimen to: raltegravir and darunavir/ritonavir
Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID
from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
86900|NCT01294774|Drug|KRP203 - 1.2mg|
86901|NCT01294774|Drug|Placebo to KRP203 - 1.2 mg|
86902|NCT01294787|Drug|indacaterol and glycopyrronium bromide (QVA149)|
86903|NCT01294787|Drug|placebo|
86904|NCT01294787|Drug|tiotropium|
86905|NCT01294800|Drug|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
86906|NCT01294800|Drug|Placebo tablet to match Preladenant|tablets taken orally BID
86907|NCT00001042|Biological|Lipid A, Monophosphoryl|
86908|NCT00053703|Drug|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
87873|NCT01296451|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
87874|NCT01296451|Biological|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
87875|NCT01296451|Biological|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
87876|NCT01296464|Drug|Carbidopa|Capsules
87877|NCT00053846|Drug|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
87878|NCT01296490|Other|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
87879|NCT01296503|Drug|Thalidomide plus dexamethasone|D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.
The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event.
87880|NCT01296503|Drug|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
87881|NCT01296516|Behavioral|Non-intervention group|A pedometer and written material on a healthy lifestyle.
87882|NCT01296516|Behavioral|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
87883|NCT01296516|Behavioral|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
87884|NCT01296555|Drug|Fulvestrant|Select cohorts, as described in the Arms section, will receive fulvestrant 500 milligrams (mg) via intramuscular injection on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression.
86977|NCT01302613|Drug|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
86978|NCT01302613|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
86979|NCT01302613|Radiation|radiation|28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a "boost" of 3-5 fractions of 180 cGy subsequently delivered.
87338|NCT01295502|Drug|Carboplatin|Given IV
87339|NCT01295502|Drug|Cisplatin|Given IV
87340|NCT01295502|Radiation|External Beam Radiation Therapy|Undergo EBRT
87588|NCT00054210|Drug|paclitaxel poliglumex|
87589|NCT01303575|Behavioral|HIV, STI and Pregnancy Prevention Curriculum|A complete internet-based, "It's Your Game...Keep It Real" Intervention Program
87590|NCT01303575|Behavioral|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
87591|NCT01303588|Behavioral|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
87592|NCT01303588|Behavioral|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
87593|NCT01303601|Drug|olanzapine|Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.
daily 6 weeks
87594|NCT01303601|Drug|Starch|
87595|NCT01303614|Drug|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
87596|NCT01295918|Dietary Supplement|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
87597|NCT01295931|Drug|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
87598|NCT01295931|Procedure|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
87599|NCT00053807|Drug|fluorouracil|
87600|NCT01295944|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC x (CrCl + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician
87601|NCT01295944|Drug|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician.
87411|NCT01303679|Drug|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
87412|NCT01303679|Drug|Exemestane|daily 25 mg (1 pill) oral intake
87413|NCT01303705|Drug|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
87414|NCT01303705|Radiation|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
87415|NCT01303705|Drug|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
87416|NCT00054236|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
87417|NCT01303718|Device|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
87418|NCT01303718|Other|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
87668|NCT01303757|Behavioral|Dietary counselling|
87669|NCT01303770|Behavioral|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
87670|NCT00054236|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
87671|NCT01303770|Behavioral|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
87672|NCT01303783|Drug|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
87673|NCT01303783|Drug|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
87674|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
87675|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
87676|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
87677|NCT01303783|Drug|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
87195|NCT01297673|Procedure|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incicence degree and localization of vesico ureteral reflux based on the result of video urodynamics
87196|NCT01297686|Other|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
87197|NCT01297686|Other|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
87198|NCT01297686|Other|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
87199|NCT01300260|Drug|Placebo|Administered subcutaneously
87200|NCT01300260|Drug|Insulin|Administered intravenously
87201|NCT01300260|Drug|Glucose|Administered intravenously
87202|NCT01300260|Drug|Glucagon|Administered intravenously
87203|NCT01300273|Dietary Supplement|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
87204|NCT01300286|Drug|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
87205|NCT00054015|Drug|triapine|
87206|NCT01300299|Radiation|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within <2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
87767|NCT01293747|Drug|Estradiol + Progesterone|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
87768|NCT01293747|Drug|Estradiol + Progesterone|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
87769|NCT01293760|Other|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
87770|NCT01293760|Other|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
87771|NCT01293773|Device|Taxus Element stent|paclitaxel-eluting stent
87772|NCT01293773|Device|Integrity Resolute stent|ABT 578-eluting stent
87773|NCT01293773|Device|Xience Prime stent|Everolimus-eluting stent
86980|NCT01294852|Other|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]).
86981|NCT01294878|Drug|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
86982|NCT01294891|Other|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
86983|NCT01294917|Device|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
86984|NCT01294917|Device|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
86985|NCT01294917|Device|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
86986|NCT00053716|Drug|Liprostin [liposomal Prostaglandin E1]|
86987|NCT01294930|Other|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
86988|NCT01294943|Device|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
86989|NCT01294956|Other|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
86990|NCT01294956|Other|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
86991|NCT01294969|Drug|AL-4943A|Once daily topical ocular allergy medication used for 7 days
86992|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
86993|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
86994|NCT01294982|Drug|Placebo|Placebo Oral Capsules twice daily
87262|NCT01295450|Drug|Apevinat BC|Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).
Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily.
87263|NCT00053768|Drug|prednisone|
87602|NCT01295957|Behavioral|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
87603|NCT01295957|Behavioral|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
87604|NCT01295957|Other|control|advise and informal counseling
87940|NCT00053625|Procedure|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
87941|NCT01294163|Drug|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
87942|NCT01294163|Drug|Propofol|Hourly dose of 2-4 mg/kg
87943|NCT01294176|Drug|Lipoic Acid|Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
87944|NCT01294202|Drug|AT13387 and Imatinib|In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.
In part 2 an additional 6-9pts will be treated.
In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib.
87945|NCT01294215|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
87946|NCT01294241|Drug|Sericare®|Sericare® on one half of the skin lesion (each time when the wound dressing is changed, normally every 24-48 hours)
Non-adhesive wound dressings alone on the other half of the skin lesion
87947|NCT01294254|Drug|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
87948|NCT01294254|Procedure|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
87949|NCT01296594|Other|Usual Care|Usual Care
87950|NCT01296594|Behavioral|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
87678|NCT01303783|Drug|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
87679|NCT01303783|Drug|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
87680|NCT01303796|Drug|Sapacitabine and decitabine|Sapacitabine administered in alternating cycles with decitabine
87681|NCT00054236|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
87682|NCT01303796|Drug|Decitabine|Decitabine alone
87683|NCT01303809|Other|Enhanced Recovery After Surgey for Sleeve Gastrectomy|Intraoperative:
Pre-op carbohydrate loading
No pre-op GIK while NBM
Pre-medication
Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg
Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics
Fluid restriction
Standardised method of anaesthesia
Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites
10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure
Postoperative:
Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively
Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1
Post operative oxygenation
Incentive spirometry
Drains (e.g. IDC) removed in recovery
Full mobilisation 4-8 hours post op)
Early Follow up
87684|NCT01303822|Behavioral|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
87685|NCT01303835|Drug|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
87686|NCT01303835|Drug|Placebo|Randomized patients received placebo to be taken every night before bed.
88009|NCT01294267|Device|Impella 2.5 Circulatory Support system insertion|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
88010|NCT01294280|Other|Laboratory Biomarker Analysis|Correlative studies
88011|NCT00053638|Drug|efavirenz|
88012|NCT01294293|Drug|TLR8 Agonist VTX-2337|Given SC
88013|NCT01294293|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
88014|NCT01294293|Other|Pharmacological Study|Correlative studies
88015|NCT01294293|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
88016|NCT01294293|Drug|Paclitaxel|Given IV
88017|NCT01294306|Drug|Akt Inhibitor MK2206|Given PO
87774|NCT01293799|Behavioral|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
87775|NCT01293812|Drug|88% sucrose po solution|88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled "sucrose study" calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated).
87776|NCT00053573|Biological|Myozyme|20 mg/kg to 40 mg/kg qow
87777|NCT01293812|Drug|placebo po|The pharmacy will provide 2 syringes labeled "sucrose study" calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated).
87778|NCT01296269|Drug|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
87779|NCT01296269|Drug|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
87780|NCT01296282|Device|Medronics CRT Optivol Impedance Measurement|Pacemaker
87781|NCT01296282|Device|External Thoracic Impedance Measurement|
87782|NCT01296295|Behavioral|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
87783|NCT01296295|Behavioral|Smoking cessation advice|Brief smoking cessation advice
87784|NCT01296308|Other|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
87785|NCT01296321|Behavioral|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are "prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
87807|NCT01298804|Behavioral|Problem Solving Education and Activated Referral to Care|The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an "Activated" referral to more definitive services for those who have worsening symptoms over time.
87808|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
87264|NCT01297686|Other|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
87265|NCT01297686|Other|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
87266|NCT01297686|Other|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
87267|NCT00053911|Drug|fluorouracil|
87268|NCT01297686|Other|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
87269|NCT01297686|Drug|Dexamethasone|A 22-gauge, 1.5" needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area.
87270|NCT01297699|Drug|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
87271|NCT01297699|Drug|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
87272|NCT01297712|Device|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
87273|NCT01297725|Procedure|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
87274|NCT01297725|Procedure|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
87275|NCT01297738|Other|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
87276|NCT01297738|Other|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
87277|NCT01297738|Other|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
87951|NCT01296607|Drug|Urocortin 2|Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.
Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.
Protocol 4b: Reproducibility protocol (Visit 2 or 4)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
87952|NCT01296607|Drug|Urocortin 3|Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.
Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.
Protocol 4b: Reproducibility protocol (Visit 2 or 4)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
87055|NCT01302691|Drug|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
87056|NCT01302717|Device|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
87057|NCT01302717|Device|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
87058|NCT01302743|Drug|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
87059|NCT01302743|Dietary Supplement|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
87060|NCT01302743|Dietary Supplement|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
87061|NCT01302756|Other|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
87062|NCT00054158|Drug|thalidomide|
87063|NCT01302756|Dietary Supplement|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
87064|NCT01302769|Device|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
87065|NCT01302795|Drug|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
87066|NCT01302808|Drug|erlotinib hydrochloride|
87067|NCT01302808|Drug|romidepsin|
87068|NCT01302808|Other|laboratory biomarker analysis|
87069|NCT01302808|Other|pharmacological study|
88018|NCT01294306|Drug|Erlotinib Hydrochloride|Given PO
88019|NCT01294306|Other|Laboratory Biomarker Analysis|Correlative studies
88020|NCT01294306|Other|Pharmacological Study|Correlative studies
88021|NCT01294319|Drug|Mifepristone|
88022|NCT00053638|Drug|tenofovir|
88023|NCT01294319|Drug|Placebo|
88024|NCT01294319|Drug|Spironolactone|
88025|NCT01294332|Other|Rehabilitation|Aerobic Exercise Training
88026|NCT01294358|Drug|Gemcitabine|
88027|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
88028|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
88029|NCT01294384|Drug|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
88030|NCT01294397|Drug|Etanercept|All 44 subjects will continue to receive a 50-mg dose of etanercept once weekly.
88031|NCT01294397|Drug|Denosumab|All 44 subjects will receive a single 60-mg dose of denosumab.
87133|NCT00054002|Drug|porfimer sodium|iv
87134|NCT01300247|Drug|RO5072759|Intravenous repeating dose
87135|NCT01300247|Drug|bendamustine|Intravenous repeating dose
87136|NCT01300247|Drug|cyclophosphamide|Intravenous repeating dose
87137|NCT01300260|Biological|LY2189265|Administered subcutaneously
87138|NCT01302821|Radiation|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
87139|NCT00054158|Drug|vincristine sulfate|
87140|NCT01302834|Biological|cetuximab|Given IV
87809|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
87810|NCT01298830|Drug|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
87811|NCT01298843|Drug|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
87812|NCT01298856|Procedure|hydrotherapy|hydrotherapy and ankle taping and land-based
87813|NCT01298869|Biological|HPV-6/11/16/18 vaccine|HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
87814|NCT01298882|Drug|Diacerein|
87815|NCT01298882|Other|Placebo|
87816|NCT01298908|Procedure|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
87817|NCT00001042|Biological|rgp120/HIV-1 SF-2|
87818|NCT00053976|Drug|methylprednisolone|
87819|NCT01298908|Procedure|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
87820|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
87821|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
87822|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
87823|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
86918|NCT01297075|Behavioral|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
86919|NCT01297088|Drug|BAY86-9596|One single dose administration of a diagnostic agent
86920|NCT01297101|Drug|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
87529|NCT01298167|Device|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
87530|NCT01298180|Drug|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
87531|NCT00053950|Drug|pyrazoloacridine|Given IV
87532|NCT01298180|Procedure|DEXA, blood tests, H.G.P.O, osseous age.|SPW, GHD, SPW-B :
blood tests : centralized dosage H.G.P.O : adjusted to children's age.
87533|NCT01298180|Procedure|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
87534|NCT01298193|Drug|Aprepitant|Efficacy phase (second cycle)
87535|NCT01298219|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
87536|NCT01298219|Drug|Placebo|0 mcg capsules twice daily (BID)
87537|NCT01298232|Other|Cardiophonogram|Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
87538|NCT01298258|Drug|Aliskiren|Aliskiren 150mg
87539|NCT01298271|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
87540|NCT01298284|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
87541|NCT01298297|Drug|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
87542|NCT00053950|Biological|filgrastim|Given IV or SC
87543|NCT01298297|Drug|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
87544|NCT01298310|Drug|Xylocaine|1 mg/mL solution for injection
87545|NCT01298310|Drug|Xylocaine|10 mg/mL solution for injection
87546|NCT01298310|Drug|Placebo|solution for injection
87547|NCT01298323|Behavioral|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
87548|NCT01298323|Drug|Vandetanib|Treatment 300mg vandetanib opel label.
87070|NCT01302821|Biological|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
87071|NCT01302821|Drug|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
87072|NCT01295060|Drug|Octreotide|84 mg Octreotide Implant
87073|NCT01295073|Drug|Trientine Hydrochloride|Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.
All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery.
87074|NCT01295073|Other|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
87075|NCT01295086|Drug|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
87076|NCT01295086|Drug|Oxaliplatin|100 mg/m² day 1 every 3. week
87341|NCT01295502|Radiation|Internal Radiation Therapy|Undergo brachytherapy
87342|NCT01295502|Drug|Paclitaxel|Given IV
87343|NCT01295515|Drug|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
87344|NCT01295528|Device|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
87345|NCT01295554|Other|NCE MRA and CE MRA|Each patient will receive on the same day:
NCE MRA
CE MRA usually performed in the clinical routine
After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images.
87346|NCT01295567|Drug|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
87347|NCT00001042|Biological|Lipid A, Liposome-encapsulated monophosphoryl|
87348|NCT00053768|Radiation|radiation therapy|
87349|NCT01295567|Drug|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
87350|NCT01295580|Device|Hyaluronic acid, stabilized|Hyaluronic acid
87351|NCT01295580|Device|Hyaluronic acid|Hyaluronic acid
87352|NCT01295593|Drug|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
87141|NCT01302834|Drug|cisplatin|Given IV
87142|NCT01302847|Drug|Dolutegravir (DTG) tablet formulation|Stage I: Target dose of 1 mg/kg (maximum daily dose 100 mg), tablet(s) to be taken orally once or twice daily, depending on which other antiretroviral medications participants are receiving
Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily, depending on which other antiretroviral medications participants are receiving
87143|NCT01302847|Drug|DTG oral pediatric granules taken as suspension or granules|Stage I: Oral pediatric granules taken either as a suspension (1.6 mg/mL) or as granules, at a dose of approximately 0.64 mg/kg (maximum daily dose 64 mg) taken orally once or twice daily, depending on which other antiretroviral medications participants are receiving. Exact dose will vary, based on participants' weight.
Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily, depending on which other antiretroviral medications participants are receiving
87144|NCT01302860|Drug|ACZ885|
87145|NCT01302873|Drug|BGG492A|
87146|NCT01302873|Drug|BGG492A|
87147|NCT01302886|Drug|BHQ880|
87148|NCT01302899|Drug|Aliskiren|Aliskiren 150 mg (Tablet)
87149|NCT01302899|Drug|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
87150|NCT00054171|Drug|aminolevulinic acid hydrochloride|
87151|NCT01302899|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
87152|NCT01302899|Drug|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
87153|NCT01302899|Drug|Ramipril|Ramipril 10mg (Tablet)
87154|NCT01302912|Procedure|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
87155|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
87419|NCT01303731|Drug|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
87420|NCT01303731|Drug|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
87421|NCT01303744|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
87422|NCT01295632|Drug|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
87423|NCT01295632|Drug|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
86921|NCT01297114|Drug|Florbetaben|
86922|NCT01297140|Behavioral|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
86923|NCT01297153|Device|Intraocular Lens (Acrysof IOL)|IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
86924|NCT01297153|Device|No IOL|No IOL will be implanted in these eyes
86925|NCT00053898|Drug|anastrozole|1 mg/day and placebo for 5 years
86926|NCT01297166|Drug|LEO 27989 ointment|once daily application, 3weeks
86927|NCT01297166|Drug|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
86928|NCT01297166|Drug|Calcipotriol ointment|once daily application, 3weeks
86929|NCT01297166|Drug|Vehicle ointment|once daily application, 3weeks
86930|NCT01297179|Drug|Mirabegron|Oral
86931|NCT01297179|Drug|Minidril|Oral
86932|NCT01297179|Drug|Placebo|Oral
86933|NCT01297192|Drug|solifenacin succinate|Oral
86934|NCT01297192|Drug|mirabegron|Oral
86935|NCT01297205|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
86936|NCT00001042|Biological|MF59|
86937|NCT00053898|Drug|tamoxifen citrate|20 mg/day and placebo for 5 years
86938|NCT01299740|Behavioral|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
86939|NCT01299740|Other|Control Group|Treatment as usual
86940|NCT01299753|Drug|placebo|identically packed placebo
87207|NCT01300312|Drug|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
87208|NCT01300312|Drug|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
87549|NCT01298336|Drug|Clarithromycin|500 mg twice a day seven days a week
87550|NCT01298336|Drug|Moxifloxacin|400 mg per day seven days a week
87885|NCT01296555|Drug|GDC-0032|Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered PO once daily in 28-day cycles.
87886|NCT01296555|Drug|Letrozole|Select cohorts, as described in the Arms section, will receive letrozole 2.5 mg PO once daily in 28-day cycles until disease progression.
87887|NCT01296568|Drug|LY2603618|Administered intravenously
87888|NCT00053846|Drug|Placebo|Placebo
87889|NCT01296568|Drug|Pemetrexed|Administered intravenously
87890|NCT01296568|Drug|Gemcitabine|Administered intravenously
87891|NCT01296581|Drug|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
87892|NCT01298908|Procedure|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
87893|NCT01298921|Drug|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
87894|NCT01298921|Drug|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
87895|NCT01298934|Drug|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
87896|NCT01298947|Device|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
87897|NCT01298960|Drug|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
87898|NCT01298973|Drug|Viscoat|One group will receive Viscoat for incision closure
87899|NCT01298973|Drug|Saline|One group will receive Saline to irrigate the wound
87353|NCT01295606|Drug|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
87354|NCT01295619|Device|Dural sealant|A thin layer of I-020805 applied up to two times on the sutured dura mater
87355|NCT01297777|Drug|Imatinib Mesylate|In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.
In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity.
87356|NCT01297790|Other|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
87357|NCT01297790|Other|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
87358|NCT01297790|Other|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
87359|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
87360|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
87361|NCT01297816|Drug|placebo|100mg,BD, fo three month
87605|NCT01295970|Procedure|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
87606|NCT01295970|Procedure|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
87607|NCT01296009|Drug|Traditional Chinese medicine(Zhuyun Recipe)|The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
87608|NCT01296022|Device|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
87609|NCT01296022|Device|Implantation of transvenous ICD|Implantation of transvenous ICD
87610|NCT00053807|Procedure|adjuvant therapy|
87611|NCT01296035|Biological|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
87612|NCT01296048|Device|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
87613|NCT01296074|Drug|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
87614|NCT01296087|Drug|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
87424|NCT01295632|Drug|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
87425|NCT01295645|Drug|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
87426|NCT00053781|Drug|perifosine|
87427|NCT01295645|Other|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
87428|NCT01295671|Behavioral|Provision of beverages|Home delivery of specified beverage type
87429|NCT01295684|Other|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
87430|NCT01295684|Other|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
87431|NCT01295697|Drug|EZN-2208|Experimental
87432|NCT01295710|Biological|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
87433|NCT01295710|Biological|Placebo|250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
87434|NCT01295723|Radiation|Hypofractionated Whole Breast Radiation Therapy|Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)
Single reference dose per fraction: 2.7 Gy (ICRU)
Number of fractions: 15
Number of fractions per week: 5
Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)
Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy
87435|NCT01295723|Radiation|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
87436|NCT01295736|Drug|Sildenafil|Sildenafil 20 mg TID per os during 90 days
87437|NCT00053794|Drug|perifosine|
87438|NCT01295736|Drug|placebo|Placebo pills TID per os during 90 days
87439|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
87687|NCT01296087|Drug|Placebo|Matching placebo capsule given once daily on Days 1 to 28
87688|NCT01296100|Behavioral|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
87209|NCT01300325|Other|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
87210|NCT01300338|Device|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
87211|NCT01300338|Device|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
87212|NCT01300351|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
87213|NCT01300351|Drug|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
87214|NCT01300364|Drug|Reboxetine|8mg/day.
87215|NCT01300364|Drug|citalopram (SSRI)|30mg/day
87216|NCT00054028|Drug|suramin|Given IV
87217|NCT01300377|Drug|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
87218|NCT01300377|Drug|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
87219|NCT01300403|Other|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
87220|NCT01300403|Other|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
87221|NCT01300403|Other|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
87222|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg of mirtazapine daily initially. The dose will be increased by 7.5 mg for subjects weighing less than 50kg and up to 15 mg per week for subjects weighing more than 50kg. depending upon efficacy and tolerability.
87223|NCT01302977|Procedure|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
87224|NCT01302990|Biological|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
87225|NCT01303003|Drug|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
87900|NCT01298986|Procedure|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
87901|NCT00053989|Biological|anti-thymocyte globulin|iv
86995|NCT01294995|Dietary Supplement|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
86996|NCT01294995|Dietary Supplement|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
86997|NCT00053742|Drug|Modified Vaccinia Virus Ankara TBC-MVA|
86998|NCT01295034|Dietary Supplement|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
86999|NCT01295034|Drug|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
87000|NCT01295047|Drug|Atenolol|
87001|NCT01295047|Drug|VERAPAMIL|240 MG SR
87002|NCT01295047|Drug|Perindopril|4 MG
87003|NCT01297218|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
87004|NCT01297231|Other|MRI|Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).
During Tamoxifen Treatment:
Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.
Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.
Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated.
87005|NCT01297244|Drug|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
87006|NCT01297257|Device|Stent implantation|Single arm, open label stent implantation
87007|NCT01297270|Drug|BI201335|QD BI 201335
87008|NCT01297270|Drug|PegIFN/RBV|
87615|NCT00053950|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
87616|NCT01298388|Other|study of socioeconomic and demographic variables|
87617|NCT01298401|Biological|ganitumab|
87618|NCT01298401|Drug|capecitabine|
87619|NCT01298401|Drug|gemcitabine hydrochloride|
87620|NCT01298401|Radiation|3-dimensional conformal radiation therapy|
87621|NCT01298414|Genetic|RNA analysis|
87622|NCT01298414|Other|laboratory biomarker analysis|
87623|NCT01298466|Drug|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
87624|NCT01298479|Other|Uniject|single use container
87625|NCT01298492|Drug|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
87626|NCT00053950|Procedure|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
87953|NCT01296620|Drug|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
87954|NCT01296620|Drug|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
87955|NCT01296620|Drug|5% dextrose in water|Placebo
87956|NCT00053872|Drug|cisplatin|
87957|NCT01296633|Behavioral|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
87958|NCT01296646|Drug|Naltrexone|50 mg oral naltrexone once/day
87959|NCT01296646|Behavioral|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
87689|NCT01296100|Behavioral|Lifestyle intervention (physical activiy)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
87690|NCT01296113|Drug|Chemotherapy|Pemetrexed + Carboplatin
On D1 of a 21-day cycle:
Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:
Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:
Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance
• 4 cycles total
87691|NCT01296139|Drug|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
87692|NCT01296152|Drug|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
87693|NCT00053820|Biological|aldesleukin|
87694|NCT01296165|Behavioral|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value <0.05 will be deemed to represent statistical significance.
87695|NCT01296178|Drug|IDARUBICINE|Administration of chemotherapy induction
Idarubicin IV Dose of 12 mg/m2/day days 1 to 3
87696|NCT01296178|Drug|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
87697|NCT01296191|Drug|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
87698|NCT01296191|Drug|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
87699|NCT01296204|Drug|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
87700|NCT01296217|Procedure|lymph nod detection|
87701|NCT01296230|Procedure|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
87702|NCT01296243|Drug|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
88032|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
88033|NCT00053638|Drug|abacavir/lamivudine|
87476|NCT01300793|Drug|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 & 11 q. 28 days.
87477|NCT01300819|Other|Placebo|Placebo patches of 2, 4, 6 & 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.
Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.
87478|NCT00054041|Other|laboratory biomarker analysis|Correlative studies
87479|NCT01300819|Drug|Rotigotine|Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours
Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.
Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.
87480|NCT01300832|Procedure|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
87481|NCT01300845|Procedure|Humidification|From randomization, oxygen therapy is humidified
87482|NCT01300845|Procedure|No Humidification|oxygen therapy is never humidified
87483|NCT01300858|Drug|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
87484|NCT01303094|Drug|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
87485|NCT01303094|Other|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
87486|NCT00001044|Biological|rgp120/HIV-1MN|
87487|NCT00054197|Drug|gemcitabine hydrochloride|
87488|NCT01303107|Drug|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
87489|NCT01303120|Drug|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
87490|NCT01303120|Drug|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
87009|NCT01297270|Drug|BI201335|QD (once daily) BI 201335
87010|NCT01297270|Drug|Placebo|
87011|NCT01297283|Other|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
87012|NCT01297283|Other|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
87013|NCT00053898|Radiation|Radiation Therapy|Adjuvant radiation therapy
87014|NCT01297309|Drug|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
87015|NCT01297322|Other|Manual compression|Standard of Care
87278|NCT00053911|Drug|goserelin acetate|
87279|NCT01297738|Other|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
87280|NCT01297764|Drug|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)
15 15 300 40
20 15 300 40
20 25 300 40
20/27* 25 300 40
20/27* 25 400 40
87281|NCT01300429|Genetic|obtain tissue specimens|One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
87282|NCT01300442|Other|TEDS in COPD patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
87283|NCT01300442|Other|TEDS in healthy patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
87284|NCT01300455|Drug|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
87285|NCT01300455|Drug|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
87286|NCT00054028|Drug|paclitaxel|Given IV
87960|NCT01296646|Drug|Placebo|An inactive pill to control for non-pharmacological responses.
87961|NCT01296659|Drug|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
87962|NCT01296672|Drug|Finasteride|Finasteride 5mg every day by mouth for 3 months
87963|NCT01296672|Drug|Placebo|Placebo every day by mouth for 3 months
87964|NCT01296698|Drug|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
87965|NCT01296698|Drug|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
87966|NCT01296711|Biological|CDP6038|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
87967|NCT01298986|Procedure|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
87968|NCT01298999|Drug|YF476|Subjects will take YF476, 25 mg capsules, once daily, for three months.
87969|NCT01298999|Drug|Placebo|Subjects will take placebo pill (identical in appearance to YF476 pills) once daily for 3 months.
87077|NCT00053768|Biological|filgrastim|
87078|NCT01295086|Drug|Capecitabine|1250 mg/² continuously
87079|NCT01295086|Drug|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
87080|NCT01295099|Drug|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
87081|NCT01295099|Radiation|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
87082|NCT01295099|Drug|Triamcinolone|TAC 10mg in 1ml injected intralesional
87083|NCT01295112|Drug|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
87084|NCT01295112|Drug|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
88034|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
88035|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
88036|NCT00053872|Drug|lomustine|
88037|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
88038|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
88039|NCT01296750|Other|Early Physiotherapy start|Physiotherapy starting at one day post op
88040|NCT01296763|Drug|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
88041|NCT01296763|Drug|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
88042|NCT01296763|Drug|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
88043|NCT01296763|Drug|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
88044|NCT01296763|Drug|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
88045|NCT01296776|Other|wellness control group.|Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
88046|NCT01296776|Device|whole-body electromyostimulation|3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
88047|NCT00053872|Drug|vincristine sulfate|
88048|NCT01296789|Other|Tissue perfusion guided protocol|A tissue perfusion guided protocol is used to guide hemodynamic therapy
88049|NCT01296789|Other|Usual Care|Usual Care
88050|NCT01296802|Drug|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
88051|NCT01296815|Drug|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
88052|NCT01296841|Device|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
87491|NCT01303120|Drug|Patient-controlled analgesia|Patient controlled analgesia with morphine
87824|NCT01301469|Drug|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
87825|NCT01301469|Drug|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
87826|NCT01301482|Device|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
87827|NCT01301495|Device|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
87828|NCT01301508|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
87829|NCT01301508|Drug|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
87830|NCT00001044|Biological|Aluminum hydroxide|
87831|NCT00054067|Radiation|brachytherapy|
87832|NCT01301508|Drug|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
87833|NCT01301508|Drug|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
87834|NCT01301521|Drug|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
87835|NCT01301560|Radiation|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
87836|NCT01301560|Radiation|Observation|No local treatment
87837|NCT01301573|Biological|rAAV-GAD|
87838|NCT01301586|Drug|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
87839|NCT01301586|Drug|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
87840|NCT01301599|Drug|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
87841|NCT01301599|Drug|alpha blocker monotherapy|alpha blocker monotherapy group
87842|NCT00054067|Radiation|radiation therapy|
87287|NCT01300468|Drug|PHA-848125AC|
87288|NCT01300520|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
87289|NCT01300533|Drug|BIND-014|
87290|NCT01300546|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
87291|NCT01300546|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
87292|NCT01300559|Device|Tissuelink device|Tissuelink device plus Unipolar electrocautery
87293|NCT01300572|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
87551|NCT01298388|Other|medical chart review|
87552|NCT01298388|Other|questionnaire administration|
87553|NCT01300910|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
87554|NCT01300910|Procedure|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
87555|NCT01300923|Drug|Acamprosate|
87556|NCT01300962|Drug|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
87557|NCT01300962|Drug|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
87558|NCT00054054|Drug|cisplatin|
87559|NCT01300962|Drug|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
87560|NCT01300962|Drug|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
87561|NCT01300962|Drug|Lapatinib|lapatinib daily for 21 days in each cycle.
87562|NCT01300975|Drug|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
87085|NCT01295125|Device|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
87086|NCT01295125|Procedure|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
87087|NCT01295138|Drug|Lactulose|Lactulose liquid. 15mls twice daily
87088|NCT00053768|Drug|EPOCH regimen|
87089|NCT01295151|Drug|Etanercept|Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.
The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique.
87090|NCT01295151|Drug|Abatacept|Abatacept will be administered at a dose determined by body weight:
Body Weight (kg) Dose (mg) < 60kg = 500 mg
> or equal to 60kg and < or equal to 100kg = 750 mg > 100 kg = 1000mg
The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician.
87091|NCT01295151|Biological|Rituximab|Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).
In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.
Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given.
87092|NCT01295151|Drug|Adalimumab|Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.
The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique.
87093|NCT01297413|Biological|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
87094|NCT01297439|Procedure|suctioning of fetal nose and mouth during delivery|Normal delivery without "pushing" maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes).
87362|NCT01297816|Drug|Minocycline|100mg
87363|NCT00053911|Drug|tamoxifen citrate|
87364|NCT01297829|Drug|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
87365|NCT01297829|Other|IV Placebo|IV normal saline
87366|NCT01297842|Drug|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
87367|NCT01297842|Drug|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
87368|NCT01297855|Drug|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
87156|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
87157|NCT01302938|Drug|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
87158|NCT01302938|Drug|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
87159|NCT01302951|Drug|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
87160|NCT01302964|Drug|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
87161|NCT00054184|Drug|docetaxel|
87162|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg weekly for subject weighing less than 5 50kg and up to 15 mg weekly for subjects weighing more than 50kg depending upon efficacy and tolerability.
87163|NCT01295151|Drug|Certolizumab Pegol|Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.
The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique.
87164|NCT01295151|Drug|Infliximab|Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.
The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.
Further treatment will be prescribed at the discretion of the treating clinician.
87165|NCT01295151|Drug|Golimumab|Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.
Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.
The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice.
87166|NCT01295164|Device|classic aberrometer and aberrometer AOVIS-1|Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a "classic aberrometer".
87167|NCT01295164|Device|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
87168|NCT01295177|Drug|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
87169|NCT00053768|Drug|cyclophosphamide|
87170|NCT01295203|Behavioral|website assess|The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
87843|NCT01301599|Drug|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
87844|NCT01301612|Drug|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
87845|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
86941|NCT01299753|Drug|propranolol|20-40 mg q6-8h
86942|NCT01299766|Behavioral|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
86943|NCT01299766|Behavioral|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
86944|NCT01299779|Drug|PEG-SD|PEG-SD
Bisacodyl: two 5-mg tablets at 3 pm day prior
1L sports drink* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior
1L SD* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy
Same flavor, non-red Gatorade® for all patients.
86945|NCT01299779|Drug|PEG-ELS|1L + 500 cc clear liquids at 6 pm night prior
1L + 500 cc clear liquids starting 4 hours prior to colonoscopy
86946|NCT01299792|Other|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
86947|NCT00001042|Biological|MTP-PE/MF59|
86948|NCT00053989|Procedure|allogeneic bone marrow transplantation|iv
86949|NCT01299805|Drug|Vortioxetine|Encapsulated tablet
86950|NCT01299805|Drug|Placebo|Vortioxetine placebo-matching capsules.
86951|NCT01299831|Behavioral|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
86952|NCT01299831|Behavioral|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
86953|NCT01299831|Drug|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
86954|NCT01299831|Drug|Olbetam|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours.
86955|NCT01299844|Behavioral|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
86956|NCT01299857|Drug|Rituximab|375mg/m2
87563|NCT01300975|Procedure|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
87564|NCT01300975|Drug|placebo cream|topical emollient crean 3 times a day during 21 days
87565|NCT01300988|Drug|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
87566|NCT01300988|Drug|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
87567|NCT01301001|Drug|Gabapentin extended-release|Titration schedule: Week 0: 600 mg/d; Week 1: 1200 mg/d; Week 2: 1800 mg/d; Week 3: 2400 mg/d; Week 4: 3000 mg/d. If side effects are intolerable or do not diminish within 3-4 days, the AM dose will be decreased by 600 mg, and an increase will be attempted one more time. If this next increase again results in intolerable side effects, the study drug will be decreased to the previous dose (maximal tolerated dose) and continued for the remainder of the study (a minimal dose of 1200 mg/d will be permitted).
87568|NCT01301027|Drug|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
87569|NCT00054054|Drug|docetaxel|
87570|NCT01301027|Drug|Placebo|1 pill a day for 26 weeks
87902|NCT01298986|Procedure|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
87903|NCT01298986|Procedure|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
87904|NCT01301612|Radiation|Brachytherapy|Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.
Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week.
87905|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
87906|NCT01301612|Radiation|Radiation Therapy|Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.
Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.
Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.
28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week
87369|NCT01297855|Drug|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
87370|NCT01297868|Other|exercise|
87371|NCT01297894|Drug|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
87372|NCT01297894|Drug|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
87373|NCT01297907|Other|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
87374|NCT00053911|Procedure|adjuvant therapy|
87375|NCT01297907|Other|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
87376|NCT01297907|Other|Blood Test|Blood Tests (Eosinophil Count)
87377|NCT01297907|Other|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
87378|NCT01297920|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
87379|NCT01297920|Drug|Brinzolamide ophthalmic suspension, 1%|
87380|NCT01297920|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
87381|NCT01297933|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
87382|NCT01300572|Other|Pharmacological Study|Correlative studies
87383|NCT01300572|Radiation|Total-Body Irradiation|Undergo TBI
87384|NCT01300572|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
87627|NCT01298505|Drug|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
87628|NCT01298505|Drug|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
87629|NCT01298505|Drug|placebo|placebo given twice daily for 7 days
87630|NCT01298518|Drug|PF-04620110|5 mg of PF-04620110 given once daily
87631|NCT01298518|Drug|PF-04620110|2.5 mg of PF-04620110 given twice daily
87632|NCT01298518|Drug|Placebo|Matching placebo giving for 4 weeks
87171|NCT01295216|Behavioral|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
87440|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
87441|NCT01295762|Other|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
87442|NCT01295775|Drug|sulodexide|A (SULODEXIDE GROUP):
50 mg a day by oral route (1+1 capsules/day) for 360 days
B (PLACEBO GROUP):
Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A.
87443|NCT01295788|Device|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
87444|NCT01295788|Device|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
87445|NCT01297946|Device|Conventional continuous subcutaneous insulin infusion therapy|
87446|NCT01297946|Device|Dual-hormone closed-loop|
87447|NCT01297959|Drug|E-101 Solution 300 GU/ml|8 mL of E-101 Solution at a pMPO concentration of 300 GU/ml applied topically twice to surgical wound site (just after incision without penetration of the rectus fascia or linea alba and just prior to skin closure after closure of rectus fascia or linea alba).
87448|NCT00000117|Drug|Immunoglobulin|
87449|NCT00000252|Drug|30% N2O|
87450|NCT00001042|Biological|Threonyl Muramyl Dipeptide|
87451|NCT00053924|Drug|perifosine|
87452|NCT01297959|Drug|Saline solution|8 mL of Placebo topically twice to surgical wound site (just after incision without penetration of the peritoneal fascia and just prior to skin closure).
87453|NCT01297972|Biological|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
87454|NCT01297985|Behavioral|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses.
87455|NCT01297998|Drug|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
86957|NCT01299870|Drug|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
86958|NCT01299870|Drug|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
86959|NCT00053989|Procedure|peripheral blood stem cell transplantation|iv
87226|NCT01303003|Procedure|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
87227|NCT01303016|Dietary Supplement|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
87228|NCT01303029|Drug|Gemcitabine+erlotinib|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
87229|NCT01303029|Drug|Gemcitabine+erlotinib+capecitabine|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
87230|NCT01303042|Drug|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
87231|NCT00054184|Drug|paclitaxel poliglumex|
87232|NCT01303055|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
87233|NCT01303055|Drug|Metformin 750 mg|Metformin 750 mg, tablets, orally, thrice daily: two years
The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %.
87234|NCT01303068|Device|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
87235|NCT01303081|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
87236|NCT01303081|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
87237|NCT01303081|Behavioral|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
87907|NCT01301625|Device|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
87908|NCT01301651|Behavioral|balance training|30 minute each time, 2 times per week for 6 weeks.
87909|NCT01301664|Other|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
87910|NCT01301677|Drug|Hydrocortisone|Hydrocortisone liquid formulation
87911|NCT00054106|Drug|buserelin|
87912|NCT01301677|Drug|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
87913|NCT01301677|Drug|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
87914|NCT01301703|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
87915|NCT01301716|Drug|GDC-0980|Oral escalating dose
87916|NCT01301716|Drug|bevacizumab|Intravenous repeating dose
87917|NCT01301716|Drug|carboplatin|Intravenous repeating dose
87016|NCT01297322|Device|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
87017|NCT01297335|Drug|clonidine|Intrathecal Clonidine
87018|NCT01297348|Drug|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
87019|NCT01297348|Drug|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
87020|NCT01297361|Other|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
87021|NCT01297374|Behavioral|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
87022|NCT01297387|Other|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
87023|NCT01297400|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
87024|NCT00053911|Drug|anastrozole|
87025|NCT01297400|Procedure|Standard practice for partial thickness burns|Daily application of collagenase ointment with polysporin powder and covered with gauze dressings
87633|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
87634|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
87635|NCT01298531|Drug|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
87636|NCT01298544|Procedure|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
87637|NCT00053950|Other|laboratory biomarker analysis|Correlative studies
87638|NCT01298570|Drug|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, daily, per 7 day cycle
87639|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
87640|NCT01298570|Drug|Placebo|Placebo, oral administration, Days 4-10 and Days 18-24 of 28 day cycle +
87641|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
87642|NCT01301066|Drug|Pravastatin|Pravastatin 40 mg QD
87643|NCT01301079|Drug|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
87644|NCT01301079|Drug|Saline|Patients in group N (placebo) was administrated saline during surgery.
87645|NCT01301092|Biological|LY2189265|administered intravenous, subcutaneous or intramuscular
87646|NCT01301105|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
87647|NCT00054054|Drug|fluorouracil|
87648|NCT01301105|Behavioral|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
87970|NCT01299012|Drug|Liraglutide|Liraglutide s/c 0.6mg once daily.
87971|NCT01299025|Other|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
87972|NCT01299038|Drug|rosuvastatin|Taken orally once a day for 4 weeks
87456|NCT01298011|Drug|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
87703|NCT01296256|Drug|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
87704|NCT00053820|Biological|recombinant interferon alfa|
87705|NCT01296269|Drug|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
87706|NCT01298583|Behavioral|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
87707|NCT01298596|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
87708|NCT01298596|Procedure|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
87709|NCT01298609|Device|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
87710|NCT01298635|Procedure|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
87711|NCT01298635|Procedure|trabeculectomy|
87712|NCT00053950|Other|pharmacological study|Correlative studies
87713|NCT01298661|Other|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
87714|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00013%|Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
87715|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00033%|Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
87716|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.001%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
87717|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00267%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
87718|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.004%|
87719|NCT01298687|Drug|Travoprost Vehicle|Inactive ingredients used as an active comparator
87720|NCT01298700|Drug|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
87721|NCT01298700|Drug|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
87238|NCT01303081|Behavioral|Competitive Deposits (Pari-Mutuel)|Groups (or "cohorts") of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day "0's") near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
87239|NCT01303081|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
87240|NCT01295294|Drug|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
87241|NCT00053768|Drug|doxorubicin hydrochloride|
87492|NCT01303146|Drug|rhARSA|intravenous infusion 100U/kg every other week for 18 months
87493|NCT01303159|Device|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
87494|NCT01303172|Biological|IMM-101|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL)will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.
Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine.
87495|NCT01303172|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.
Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).
Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol.
87496|NCT01303198|Device|APAP - Therapy|automatic positive pressure therapy
87497|NCT01303224|Drug|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
87498|NCT00054197|Drug|paclitaxel poliglumex|
87499|NCT01303224|Drug|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
87500|NCT01303224|Drug|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
87501|NCT01303224|Drug|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
87502|NCT01303237|Drug|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
87026|NCT01299896|Other|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
87027|NCT01299896|Other|Usual Care|Standard therapy to help participants with smoking cessation.
87028|NCT01299909|Behavioral|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
87029|NCT01299909|Behavioral|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
87030|NCT01299922|Drug|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
87031|NCT01299922|Drug|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
87032|NCT01299935|Behavioral|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
87033|NCT01299935|Behavioral|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
87034|NCT01299948|Drug|Prednisolone|5 mg prednisolone orally per day
87294|NCT01300572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
87295|NCT01300572|Drug|Cyclosporine|Given PO or IV
87296|NCT01300572|Drug|Fludarabine Phosphate|Given IV
87297|NCT00054028|Other|pharmacological study|Correlative studies
87298|NCT01300572|Biological|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
87299|NCT01300572|Other|Laboratory Biomarker Analysis|Correlative studies
87300|NCT01300572|Drug|Mycophenolate Mofetil|Given PO or IV
87301|NCT01300572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
87302|NCT01303263|Behavioral|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
87973|NCT01299051|Behavioral|Steps to Health|Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:
Face-to-face visit with counselor during Month 1 to set specific health goals.
Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.
Monthly generic health education materials sent via e-mail.
Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments.
87974|NCT01299051|Behavioral|Steps to Health Plus!|The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:
Face-to-face visit with counselor at Month 1
Meeting with exercise physiologist in Month 2
Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)
Meeting with exercise physiologist during Month 5
Quarterly biometric feedback (Months 3, 6, 9, and 12)
Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments.
87975|NCT00053989|Biological|graft-versus-tumor induction therapy|iv
87976|NCT01299090|Device|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
87977|NCT01299103|Device|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
87978|NCT01299116|Drug|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
87979|NCT01299116|Drug|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
87980|NCT01299116|Drug|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
87981|NCT01299116|Drug|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
87982|NCT01299116|Drug|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
87983|NCT01299142|Drug|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
87984|NCT01299155|Device|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
87985|NCT01299155|Device|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
87986|NCT01301781|Drug|Placebo|BLI801 placebo - oral solution
87987|NCT01301794|Dietary Supplement|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
87988|NCT00054106|Drug|flutamide|
87095|NCT01297439|Procedure|Pushing maneuver|The "pushing" maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia.
87722|NCT01298713|Drug|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
87723|NCT00053963|Drug|romidepsin|Given IV
87724|NCT01298713|Drug|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
88053|NCT01296854|Other|Spa therapy|3 weeks of spa therapy
88054|NCT01296893|Behavioral|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
88055|NCT01296906|Behavioral|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
88056|NCT00053989|Biological|sargramostim|iv
88057|NCT01299181|Drug|Atorvastatin|80mg once daily orally
88058|NCT01299194|Drug|ATORVASTATIN|80mg once daily for 3 months
88059|NCT01299220|Drug|Acitretin|Acitretin 10 mg by mouth daily
88060|NCT01299233|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
88061|NCT01299246|Procedure|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
88062|NCT01299259|Behavioral|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
88063|NCT01299272|Drug|LY2216684|Administered orally
88064|NCT01299272|Drug|Placebo|Administered orally
88065|NCT01299285|Drug|LY3009104|Administered orally
88066|NCT01299298|Drug|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
87503|NCT01303250|Drug|balanced 6% hydroxyethylstarch 130/0.4|Fluid administration and optimization based on cardiac output findings during surgery.
87504|NCT01303250|Drug|balanced crystalloid|Fluid administration and optimization based on cardiac output findings during surgery.
87505|NCT01295814|Drug|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
87506|NCT01295814|Other|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
87507|NCT01295827|Drug|Pembrolizumab 1 mg/kg|IV infusion over 30 minutes on Day 1 of each cycle, at dose of 1 mg/kg
87508|NCT00053807|Biological|aldesleukin|
87509|NCT01295827|Drug|Pembrolizumab 3 mg/kg|IV infusion over 30 minutes on Day 1 of each cycle, at dose of 3 mg/kg
87846|NCT01293825|Drug|ziprasidone|Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the "offending agent". Study psychiatrist will switch the "offending agent" to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone.
87847|NCT01293838|Drug|Cipralex®|Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:
10 mg tablets: 28
20 mg tablets: 84
Total for 30 participants:
10 mg tablets: 840
20 mg tablets: 2520
Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:
*20 mg tablets: 84
Total for continuation study for all participants (assuming a 60% response rate, N=18):
*20 mg tablets: 1512
87848|NCT01293877|Procedure|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
87849|NCT01293903|Drug|Qiliqiangxin capsule|Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
87850|NCT01293903|Drug|Placebo|Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
87851|NCT01293916|Other|Spica casting|single versus double leg spica casting
87852|NCT01293942|Drug|irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab|IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
87853|NCT01293955|Drug|JOINS 200mg|1 tablet at each time, 3 times a day
87854|NCT01293955|Drug|Placebo|placebo of Joins 200mg
87855|NCT00053599|Drug|Simvastatin|
87303|NCT01303289|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
87304|NCT01303289|Dietary Supplement|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
87305|NCT01303302|Device|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
87306|NCT00054197|Drug|vinorelbine tartrate|
87307|NCT01303302|Device|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
87308|NCT01303315|Device|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
87309|NCT01303328|Drug|C1|Local application of the experimental gel or placebo gel.
87310|NCT01303341|Other|Laboratory Biomarker Analysis|Correlative studies
87311|NCT01303341|Other|Pharmacological Study|Correlative studies
87312|NCT01303341|Drug|Riluzole|Given PO
87313|NCT01303341|Drug|Sorafenib Tosylate|Given PO
87314|NCT01303354|Procedure|Lumbar Transforaminal Epidural Steroid Injection|
87315|NCT01303380|Drug|Canakinumab|
87571|NCT01301040|Drug|epirubicin, cyclophosphamide, docetaxel|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
87572|NCT01301053|Other|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
87573|NCT01301053|Other|Current UVA intensive care insulin protocol with "brakes"|Current UVA intensive care insulin protocol for insulin management with the addition of "brakes" which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose <70 mg/dl)and severe hypoglycemia (blood glucose<50 mg/dl).
87574|NCT01301066|Drug|Pitavastatin|Pitavastatin 4 mg QD
87575|NCT01303458|Behavioral|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
87096|NCT01297452|Drug|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
87097|NCT01297452|Drug|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
87098|NCT01297452|Drug|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
87099|NCT01297452|Drug|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
87100|NCT01297465|Drug|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
87101|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
87102|NCT00053911|Drug|cyclophosphamide|
87103|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
87104|NCT01297465|Drug|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
87105|NCT01297491|Drug|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
87106|NCT01297517|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
87107|NCT01297517|Drug|Brinzolamide ophthalmic suspension, 1%|
87108|NCT01297517|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
87109|NCT01297530|Drug|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
87110|NCT01297543|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
87111|NCT01297543|Drug|G-CSF|Background therapy
88067|NCT00053989|Biological|therapeutic allogeneic lymphocytes|iv
88068|NCT01299298|Drug|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
88069|NCT01299311|Behavioral|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
88070|NCT01299311|Behavioral|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
86880|NCT01302405|Drug|PRI-724|Dose escalation
86881|NCT00054132|Other|Laboratory Biomarker Analysis|Correlative studies
86882|NCT01302418|Device|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
86883|NCT01302431|Other|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
86884|NCT01302444|Drug|Tadalafil|Tadalafil 40mg for 12 weeks
86885|NCT01302444|Drug|Placebo|Placebo for 12 weeks
86886|NCT01302470|Procedure|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
86887|NCT01302470|Procedure|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
86888|NCT01302483|Drug|3% tetracaine HCL with 0.05% oxymetazoline HCL|1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
86889|NCT01302483|Drug|Lidocaine Injection|Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
86890|NCT01302496|Biological|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
86891|NCT01294696|Drug|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
86892|NCT01294709|Drug|telcagepant|
86893|NCT01294709|Drug|Placebo to telcagepant|
87856|NCT01293968|Drug|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
87857|NCT01293968|Drug|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
87858|NCT01293981|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
87859|NCT01294007|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
87860|NCT01294007|Procedure|Autograft bone|Iliac Crest and Local Autograft Bone
87861|NCT01294020|Drug|Advagraf|Oral
87862|NCT01294020|Drug|Prograf|Oral
87863|NCT01294033|Other|Fractional inspired oxygen (FiO2) 0.21|
87864|NCT01294033|Other|Fractional inspired oxygen 0.28|Supplemental oxygen
86960|NCT01299883|Other|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
86961|NCT01302509|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
86962|NCT00054145|Drug|perifosine|
86963|NCT01302522|Behavioral|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
86964|NCT01302535|Other|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
86965|NCT01302535|Other|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
86966|NCT01302548|Device|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
86967|NCT01302548|Procedure|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
86968|NCT01302561|Dietary Supplement|Sucrose|5 g of sucrose twice daily for 24 weeks
87576|NCT01303471|Drug|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
87577|NCT00054210|Drug|paclitaxel|
87578|NCT01303484|Dietary Supplement|Bi2muno® GOS|5.5g/day for 10 weeks
87579|NCT01303484|Dietary Supplement|Maltodextrin|5.5g daily for 10 weeks
87580|NCT01303497|Drug|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
87581|NCT01303497|Drug|Bevacizumab|Bevacizumab until progression or inacceptable toxicity :
During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV
After 6 cycles of chemotherapy : 15 mg/kg, IV
87582|NCT01303497|Procedure|Blood samples|Blood samples at different times :
Day 1
Day 8
Day 15
Day 29
Day 57
87583|NCT01303510|Biological|Inflexal V|Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Florida/4/2006-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
87584|NCT01303536|Drug|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
87585|NCT01303549|Drug|Anidulafungin|Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
87586|NCT01303549|Drug|Liposomal amphotericin B|Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
87587|NCT01303562|Other|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
87918|NCT01301716|Drug|cisplatin|intravenous repeating dose
87919|NCT01301716|Drug|paclitaxel|Intravenous repeating dose
87920|NCT01301716|Drug|pemetrexed|intravenous repeating dose
87921|NCT01301729|Drug|docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
87922|NCT00054106|Drug|custirsen sodium|
87923|NCT01301729|Drug|paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
87924|NCT01301729|Drug|trastuzumab [Herceptin]|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
87385|NCT01300585|Other|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
87386|NCT01300598|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
87387|NCT01300611|Drug|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
87388|NCT00001043|Biological|gp160 Vaccine (Immuno-AG)|
87389|NCT00054041|Biological|HspE7|Given subcutaneously
87390|NCT01300611|Drug|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
87391|NCT01300624|Behavioral|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
87392|NCT01300637|Drug|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
87393|NCT01300637|Drug|placebo|identical-appearing pill of placebo
87394|NCT01300650|Drug|Anakinra|Anakinra 100 mg subcutaneous injection daily
87395|NCT01300676|Drug|Tualang honey|This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.
Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
87396|NCT01300715|Procedure|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
87397|NCT01300728|Drug|NewGam 10% IVIG|Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.
87398|NCT01300741|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
87399|NCT01300741|Device|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
86894|NCT01294735|Drug|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
86895|NCT01294735|Drug|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
86896|NCT00053703|Drug|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
86897|NCT01294748|Device|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
86898|NCT01294748|Device|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
85938|NCT01268059|Drug|Carboplatin/Paclitaxel/MEDI-575|Subjects will receive carboplatin/paclitaxel and MEDI-575 every 21 days for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
85939|NCT01268059|Drug|Carboplatin/Paclitaxel|Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6 mg/mL*min) for up to 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
85940|NCT01270555|Drug|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
85941|NCT01270568|Other|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
85942|NCT01270568|Behavioral|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
85943|NCT01270568|Behavioral|Recollection|Subjects record daily events on a weekly basis for 8 weeks
85944|NCT00051506|Drug|ALIMTA|
85945|NCT01270581|Other|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
85946|NCT01270581|Other|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
86969|NCT01302561|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
86970|NCT01302574|Dietary Supplement|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
86971|NCT01302587|Drug|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
86972|NCT01302600|Drug|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
86973|NCT00054158|Drug|dexamethasone|
86974|NCT01302600|Drug|Placebo|0.1ml/kg once a day with food at dinner.
86975|NCT01302613|Drug|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
86976|NCT01302613|Drug|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
87242|NCT01295294|Drug|Placebo|3 times daily per oral during bleeding/spotting episodes
87243|NCT01295294|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
87244|NCT01295307|Drug|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
87245|NCT01295320|Procedure|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
87246|NCT01295333|Drug|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
87247|NCT01295333|Drug|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
87248|NCT01295346|Other|Head CT scan and blood draw|
87249|NCT01295359|Other|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
87250|NCT01295372|Drug|Zicronapine|7.5 mg/day; orally
87251|NCT01295372|Drug|Risperidone|5 mg/day; orally
87925|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
87926|NCT01301742|Drug|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
87927|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
87928|NCT01301755|Procedure|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
87929|NCT01301768|Other|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
87930|NCT01301781|Drug|BLI801|BLI801 laxative - oral solution
87931|NCT01294072|Dietary Supplement|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
87932|NCT01294072|Dietary Supplement|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
87933|NCT01294072|Other|No intervention|no treatment
87934|NCT01294098|Drug|Marcaine|0.75 cc/kg of 1/4% Marcaine
87935|NCT01294111|Behavioral|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
87936|NCT01294137|Device|ventilatory polygraphy|
87937|NCT01294150|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
87938|NCT01294150|Other|Cystoscopy|The Control Group will undergo cystoscopy.
87939|NCT01294163|Drug|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
87035|NCT00053989|Procedure|umbilical cord blood transplantation|iv
87036|NCT01299961|Drug|abatacept|125 mg once a week up to 12 months.
87400|NCT00054041|Procedure|therapeutic conventional surgery|Undergo large loop excision
87401|NCT01300741|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
87649|NCT01301131|Other|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
87650|NCT01301131|Other|control|usual oral care
87651|NCT01301157|Drug|M518101|Proper quantity twice a day
87652|NCT01301157|Drug|placebo|Proper quantity twice a day
87653|NCT01301157|Drug|Dovonex|Proper quantity twice a day
87654|NCT01301170|Procedure|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
87655|NCT01301183|Drug|RhIGF-1 with transdermal 17-beta estradiol|RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.
Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
87656|NCT01301183|Drug|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
87657|NCT01301196|Behavioral|Educational workshop|3h attendance at educational workshop plus self-monitoring
87658|NCT00054054|Radiation|radiation therapy|
87659|NCT01301222|Drug|Inj. Octreotide|100 mcg subcutaneously for 5 days
87660|NCT01301248|Other|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
87661|NCT01301248|Other|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
87662|NCT01301261|Drug|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
87663|NCT01301261|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
87664|NCT01301261|Drug|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
85947|NCT01270594|Behavioral|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
85948|NCT01270594|Behavioral|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
85949|NCT01270607|Procedure|Acupuncture|Treatment given twice per week for 4 weeks
85950|NCT01270620|Drug|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
85951|NCT01270620|Drug|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
85952|NCT01270633|Device|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
85953|NCT01270633|Other|Standard of Care|Following sharp debridement, moist wound therapy
86245|NCT01273779|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
86246|NCT01273779|Drug|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
86247|NCT01273805|Drug|Hydroxychloroquine|Pills taken orally twice a day
86248|NCT01273805|Drug|Hydroxychloroquine|Pills taken orally twice per day.
86249|NCT01273818|Drug|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
86250|NCT01273818|Drug|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
86251|NCT01265914|Biological|FP-01.1|Ascending doses of FP-01.1 will be administered
86252|NCT01265914|Biological|placebo|
86253|NCT01265927|Drug|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
86254|NCT01265940|Drug|Pazopanib as add-on to vinflunine|Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.
In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose.
86255|NCT01265953|Drug|sulforaphane glucosinolate capsules|Four weeks sulforaphane (SFN) glucosinolate capsules: 250 mg of broccoli seed extract (30 mg sulforaphane glucosinolate), 8 capsules (4 capsules B.I.D.) daily
87252|NCT00053768|Drug|etoposide|
87253|NCT01295385|Other|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after "cold pressor test" in a population of healthy volunteers.
87254|NCT01295385|Other|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
87255|NCT01295398|Device|nebulisations|
87256|NCT01295411|Device|Magnetic Resonance Imaging|
87257|NCT01295411|Other|EVALUATION NEUROPSYCHOLOGICAL|
87258|NCT01295424|Other|No intervention|Observational study, no interventions
87259|NCT01295437|Device|Vypro II mesh|partly absorbable mesh
87260|NCT01295437|Device|Premilene LP|lightweight mesh
87261|NCT01295437|Device|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
87510|NCT01295827|Drug|Pembrolizumab 10 mg/kg|IV infusion over 30 minutes on Day 1 of each cycle (every 2 or 3 weeks depending on study arm) at a dose of 10 mg/kg.
87511|NCT01295827|Drug|Pembrolizumab MEL|IV infusion over 30 minutes on Day 1 of each cycle
87512|NCT01295827|Drug|Pembrolizumab NSCLC|IV infusion over 30 minutes on Day 1 of each cycle
87513|NCT01295827|Drug|Pembrolizumab MEL Low Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
87514|NCT01295827|Drug|Pembrolizumab MEL High Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
87515|NCT01295827|Drug|Pembrolizumab NSCLC Low Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
87516|NCT01295827|Drug|Pembrolizumab NSCLC High Dose|IV infusion over 30 minutes every 2 or 3 weeks at dose determined during dose escalation
87517|NCT01295827|Drug|Pembrolizumab NSCLC Medium Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
87518|NCT01295840|Device|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
87519|NCT00053807|Biological|recombinant interferon alfa|
87037|NCT01299974|Other|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
87038|NCT01299987|Radiation|intraoperative radiotherapy|intraoperative single dose radiotherapy (20 Gy)
87039|NCT01300000|Other|Human Milk|ad lib
87040|NCT01300000|Other|Investigational infant formula|ad lib
87041|NCT01300000|Other|Milk based standard infant formula|ad lib
87042|NCT01300013|Drug|Placebo|48-hour infusion of placebo
87043|NCT01300013|Drug|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
87044|NCT01300026|Drug|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
87045|NCT01300052|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
87046|NCT00054002|Procedure|adjuvant therapy|Lung surgery
87047|NCT01302613|Procedure|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
87048|NCT01302639|Dietary Supplement|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
87049|NCT01302691|Drug|losartan potassium (+) hydrochlorothiazide (+) amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
87050|NCT01302691|Drug|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
87051|NCT00054158|Drug|doxorubicin hydrochloride|
87052|NCT01302691|Drug|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
87053|NCT01302691|Drug|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
87054|NCT01302691|Drug|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
87665|NCT01303744|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
87666|NCT01303744|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
87667|NCT01303744|Drug|Placebo|oral tablet, once a day in the morning for 12 weeks
87989|NCT01301807|Drug|Carfilzomib|Phase I starting dose 20 mg/m^2 by vein over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28 day cycle.
Phase Ib starting dose will be the maximum recommended dose from Phase I.
87990|NCT01301807|Drug|Panobinostat|Phase I starting dose 15 mg by mouth three times a week for first two weeks every 28 days.
Phase Ib group starting dose will be the maximum recommended dose from Phase I
87991|NCT01301820|Drug|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
87992|NCT01301820|Drug|Lenalidomide|lenalidomide 10mg/d (d1- d21)
87993|NCT01301833|Drug|teneligliptin|
87994|NCT01301833|Drug|glinide|
87995|NCT01301833|Drug|biguanide|
87996|NCT01301833|Drug|alpha-glucosidase inhibitor|
87997|NCT01301859|Behavioral|TIP|Treatment visits as usual with MD
87998|NCT01301872|Other|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
87999|NCT00054106|Procedure|conventional surgery|
88000|NCT01301898|Drug|GC1111_0.5mg/kg|
88001|NCT01301898|Drug|GC1111_1.0mg/kg|
88002|NCT01301898|Drug|Elaprase_0.5mg/kg|
88003|NCT01301911|Drug|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
88004|NCT01301924|Drug|Meglumine antimoniate|Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:
High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine.
88434|NCT01292330|Procedure|nutritional support before operation|nutritional support before operation for more than 4 days
88435|NCT01292343|Other|Colgate Total Toothpaste|Toothbrushing with Colgate Total Toothpaste
88748|NCT00001036|Drug|Interleukin-2, Polyethylene Glycolated|
88749|NCT00052923|Biological|rituximab|
88750|NCT01285856|Other|hair and saliva samples|Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.
Saliva sample, a method which gives similar results without the need for venous blood sampling.
88751|NCT01285869|Other|Multidimensional intervention|The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
88752|NCT01285882|Other|Representations|A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.
To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :
1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.
2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.
Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation.
88753|NCT01285908|Drug|Intravenous Norepinephrine Infusion|
88754|NCT01285921|Other|vestibular test before and after hippocampal surgery|Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)
HIT (testing semicircular canal function at high frequency).Results: Gain in %
VEMp (testing saccular function). Results: Amplitude in μV and latency in ms
ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s
Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S
88755|NCT01288300|Behavioral|Diabetes lecture|Diabetes self-management lecture
88756|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
88323|NCT01290029|Drug|Cinacalcet HCl|Single, oral dose of 0.25 mg/kg cinacalcet
88324|NCT00053196|Drug|busulfan|0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
88325|NCT01290042|Drug|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
88326|NCT01290042|Other|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
88327|NCT01290055|Biological|Yellow fever vaccine|Group 1: All participants will receive the yellow fever vaccine and will be asked to drink deuterium labeled water and will undergo serial blood draws over 1 year.
88328|NCT01290055|Biological|Yellow fever vaccine and D20 water|Eligible participants will receive the yellow fever vaccine and will drink D20 water
88329|NCT01290081|Other|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
88330|NCT01290094|Drug|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
88331|NCT01290107|Genetic|DNA analysis|
88332|NCT01290107|Genetic|gene rearrangement analysis|
88333|NCT01290107|Genetic|microarray analysis|
88334|NCT01290107|Genetic|polymerase chain reaction|
88335|NCT00053196|Drug|fludarabine phosphate|30 mg/sq m/day IVBP over 30 min Days -7 thru -3
88336|NCT01290107|Other|immunological diagnostic method|
88337|NCT01290107|Other|laboratory biomarker analysis|
88646|NCT00053417|Drug|20 mg fampridine-SR (4-aminopyridine, 4-AP)|2 week up titration (10 mg x 1 week, 15 mg x 1 week)
12 weeks stable dose (20 mg)
1 week down titration (15 mg x 3 days, 10 mg x 4 days)
88647|NCT01292733|Other|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
88648|NCT01285609|Drug|Paclitaxel|
88649|NCT01285609|Drug|Carboplatin|
88650|NCT01285635|Drug|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
88651|NCT01285635|Drug|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
88810|NCT01293461|Drug|Placebo|Subcutaneous injection
88811|NCT00053508|Biological|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
88812|NCT01293474|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
88813|NCT01293487|Biological|RN564|Intravenous, single dose with experimental dose
88814|NCT01293500|Procedure|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
88815|NCT01285934|Biological|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
89106|NCT01288898|Drug|ASP1941|Oral
89107|NCT01288898|Drug|Placebo|Oral
89108|NCT01288911|Drug|enzalutamide|capsules
89109|NCT01288911|Drug|Bicalutamide|tablets
89110|NCT01288924|Drug|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
89111|NCT01288937|Drug|Milnacipran|Patients will be randomly assigned to receive either milnacipran 100 mg/day (including a 1week dose titration period):
Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)
89112|NCT01288937|Drug|Placebo|Patients will be randomly assigned to placebo for 9wks (including a 1week dose titration period):
Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day
89113|NCT01288950|Dietary Supplement|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
89114|NCT01288963|Drug|IL-2|Observation only
89115|NCT00001038|Drug|Acyclovir|
89116|NCT00053118|Drug|carboplatin|IV
89117|NCT01288976|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
89118|NCT01288976|Drug|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
88251|NCT01292083|Other|immunohistochemistry staining method|Correlative studies
88252|NCT01292083|Genetic|polymerase chain reaction|Correlative studies
88253|NCT01292083|Genetic|western blotting|Correlative studies
88254|NCT01292083|Genetic|nucleic acid sequencing|Correlative studies
88255|NCT01292083|Procedure|therapeutic conventional surgery|Undergo definitive breast surgery
88256|NCT00053352|Other|laboratory biomarker analysis|Correlative studies
88257|NCT01292096|Other|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
88258|NCT01292109|Drug|sodium picosulphate|Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
88563|NCT01285518|Other|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
88564|NCT01285531|Device|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
88565|NCT01285544|Drug|Atorvastatin (Lipinon)|treatment of dyslipidemia administration : PO, qod
88566|NCT01285544|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
88567|NCT01285557|Drug|S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
88568|NCT01285557|Drug|Fluorouracil/cisplatin (control arm)|5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
88569|NCT01285570|Drug|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
88570|NCT01285570|Drug|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
88571|NCT00052910|Drug|leucovorin calcium|Given IV
88572|NCT01285570|Drug|5% dextrose in water|Placebo
88573|NCT01285583|Drug|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
88883|NCT01292772|Procedure|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
88884|NCT01292772|Radiation|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
88885|NCT01292785|Drug|Hormones|FtM will receive
1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and
if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).
MtF will receive
50mg cyproterone acetate daily (Androcur®)
estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is > 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is < 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and
2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss.
88886|NCT01292798|Drug|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
88887|NCT01292811|Device|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
88888|NCT01292811|Other|Conventional Occupational therapy|The Control group will receive conventional occupational therapy pertaining to hand function [15].
The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
88889|NCT01292824|Drug|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
89195|NCT01286610|Device|ProMedVi Vibrosphere|vibration therapy
89196|NCT01286610|Device|schwa-medico MUSKELaktiv|Electrical muscle stimulation
89197|NCT01286610|Device|Galileo Home Plus (ICU)|vibration therapy
89198|NCT01286636|Other|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
89199|NCT01286636|Other|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
89200|NCT01286649|Other|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
89201|NCT01286649|Other|Cell medium|Cell medium
89202|NCT01286675|Drug|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
89203|NCT01286688|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
88652|NCT01285648|Procedure|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
88653|NCT00052910|Radiation|radiation therapy|Given 5 days a week for 5 weeks
88654|NCT01285661|Drug|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
88655|NCT01285674|Drug|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
88656|NCT01285687|Device|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
88657|NCT01285700|Drug|Lamazym|ERT, infusion weekly
88658|NCT01285713|Drug|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
88659|NCT01285713|Drug|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
88660|NCT01285726|Other|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
88661|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
88662|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
88663|NCT01285752|Drug|AK106-001616|
88945|NCT01290939|Drug|lomustine|
88946|NCT00001040|Drug|Saquinavir|
88947|NCT00053248|Drug|imatinib mesylate|
88948|NCT01290939|Genetic|DNA methylation analysis|
88949|NCT01290939|Other|laboratory biomarker analysis|
89119|NCT01288976|Procedure|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
89120|NCT01288989|Biological|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
89121|NCT01289015|Drug|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
89122|NCT01289015|Drug|Placebo|Topical; applied once daily for two weeks
89123|NCT01289028|Drug|Nilotinib|
89124|NCT01289041|Drug|BKM120|
89125|NCT01289054|Drug|Tasigna|
89126|NCT01289054|Drug|Gleevec|
89127|NCT00053118|Drug|etoposide|IV
88174|NCT01302158|Drug|Glimepiride|oral
88175|NCT01302171|Drug|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
88176|NCT01302171|Procedure|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
88177|NCT01302184|Device|Lokomat®|Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.
A physical therapist supervised the treatment, adjusting treadmill speed and BWS.
Treatment was performed for 3 days/week, for 4 weeks
88178|NCT01302184|Device|Treadmill|Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.
A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.
Treatment was performed for 3 days/week, for 4 weeks.
88179|NCT01302197|Other|No intervention|longitudinal follow-up after stroke
88180|NCT01302210|Drug|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
88181|NCT01302236|Drug|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
88182|NCT00054132|Biological|Bevacizumab|Given IV
88183|NCT01302249|Drug|Latanoprost 0.005%|q.d.
88184|NCT01302249|Drug|AR-12286 Ophthalmic Solution 0.5%|
88574|NCT01285596|Drug|Mirabegron|oral
88575|NCT01285609|Drug|Ipilimumab|
88576|NCT01285609|Drug|Placebo|
88577|NCT01288040|Behavioral|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
88578|NCT00053027|Drug|cladribine|
88579|NCT01288053|Biological|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
88580|NCT01288066|Procedure|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
88581|NCT01288066|Procedure|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
88582|NCT01288079|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
88874|NCT01290848|Behavioral|Take TIME Health Campaign|Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.
Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.
Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children.
88875|NCT01290874|Drug|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
88876|NCT01290874|Drug|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
88877|NCT01290874|Drug|Formoterol|Formoterol 12 mcg twice daily for one year
88878|NCT00053248|Drug|arsenic trioxide|
88879|NCT01290887|Drug|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
88880|NCT01290900|Drug|NXL104|IV Solution
88881|NCT01290900|Drug|Ceftaroline|IV Solution
88882|NCT01292746|Device|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
89204|NCT01286701|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
89205|NCT00001036|Drug|Zidovudine|
89206|NCT00052936|Drug|doxorubicin hydrochloride|
89207|NCT01289080|Drug|OPC-34712|administered orally
89208|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
89209|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
89210|NCT01289106|Biological|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
89211|NCT01289119|Drug|Alogliptin|Alogliptin tablets
89212|NCT01289119|Drug|Placebo to alogliptin|Alogliptin placebo-matching tablets.
89213|NCT01289119|Drug|Metformin|Stable metformin dose
89214|NCT01289119|Drug|Pioglitazone|Stable pioglitazone dose
89215|NCT01289132|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
89216|NCT00053118|Procedure|bone marrow ablation with stem cell support|IV
89217|NCT01289132|Drug|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
89218|NCT01289132|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
89219|NCT01289132|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
88259|NCT01292122|Device|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
88260|NCT01292135|Drug|PCI-32765|420 mg daily
88261|NCT01292161|Drug|Silymarin|Tab 210 mg, 630 mg, daily, six months.
88262|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
88263|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
88264|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
88950|NCT01290939|Procedure|cognitive assessment|
88951|NCT01290939|Procedure|quality-of-life assessment|
88952|NCT01290952|Procedure|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
88953|NCT01290952|Procedure|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
88954|NCT01290965|Drug|Placebo|Oral tablet given once or three times daily for 15 consecutive days
88955|NCT01290965|Drug|SCY-635|oral capsule
88956|NCT01290978|Drug|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
88957|NCT01290978|Drug|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
88958|NCT00053261|Procedure|management of therapy complications|
88959|NCT01290991|Device|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
88960|NCT01291004|Drug|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
88961|NCT01291004|Drug|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
88962|NCT01291004|Drug|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
88963|NCT01291017|Drug|PD0332991|PD0332991 125 mg PO days 1 - 21
88964|NCT01291030|Dietary Supplement|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of > 1,9 mg/dl.
88965|NCT01291043|Other|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
88966|NCT01293045|Dietary Supplement|hydrolyzed collagen|10g/day at breakfast during 90 days
89274|NCT01286740|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
89275|NCT01286753|Drug|RO5185426|960 mg orally twice daily
88185|NCT01302249|Drug|Timolol maleate ophthalmic solution 0.5%|
88186|NCT01302275|Drug|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
88187|NCT01302288|Procedure|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
88188|NCT01302301|Procedure|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
88189|NCT01302314|Behavioral|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
88190|NCT01302327|Drug|Exenatide|Exenatide
88191|NCT01302340|Drug|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
88501|NCT01287988|Drug|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125umg of ocriplasmin in a previous phase III studies TG-MV-006 and TG-MV-007
88502|NCT01288001|Drug|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
88503|NCT01288027|Biological|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
88504|NCT01290224|Other|scrambler therapy|Undergo MC5-A therapy
88505|NCT01290224|Procedure|sham intervention|Undergo sham procedure
88506|NCT00053196|Drug|mycophenolate mofetil|15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
88507|NCT01290224|Other|questionnaire administration|Ancillary studies
88508|NCT01290237|Drug|intravenous vancomycin hydrochloride|see description of study arms
88509|NCT01290250|Other|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
88510|NCT01290263|Drug|Amgen 386|For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.
For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.
For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week.
88511|NCT01290263|Drug|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
90164|NCT01315756|Device|Use of Few Touch Application (FTA)|The users will receive a Smartphone with the diabetes diary application ("the Few Touch application"), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user.
90165|NCT01315756|Device|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
90166|NCT01315795|Drug|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
90167|NCT01315821|Drug|Saccharomyces boulardii|5 million units/day for 3 months
90168|NCT01315821|Drug|Placebo|Placebo for 3 months
90169|NCT01315847|Drug|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
90170|NCT01318187|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
90171|NCT01318187|Drug|Paracetamol|1 gr intravenous
90172|NCT01318187|Drug|Paracetamol|intravenous 1 gr
90173|NCT01318187|Drug|Morphine|0.1 mg/kg intravenous
90174|NCT01318200|Procedure|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
90175|NCT01318200|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
90176|NCT01318226|Drug|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
90177|NCT01318226|Drug|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
90178|NCT01318239|Procedure|DCE MRI|MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).
MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy.
90179|NCT01318252|Drug|AL-54478 0.005%|
88265|NCT01292187|Drug|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
88266|NCT01292187|Drug|Oral placebo at dinnertime|Oral placebo at dinnertime.
88267|NCT00053365|Drug|irofulven|Given IV
88268|NCT01292187|Drug|Oral calcitonin at bedtime|Oral calcitonin at bedtime
88269|NCT01292187|Drug|Oral placebo at bedtime|Oral placebo at bedtime
88270|NCT01292200|Behavioral|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
88271|NCT01292200|Behavioral|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
88272|NCT01284946|Drug|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
88273|NCT01284959|Drug|risperidone|risperidone 3mg, PO, 3 times
88274|NCT01284959|Drug|paliperidone ER|paliperidone ER 6mg, PO,3 times
88275|NCT01284959|Drug|placebo|lactose PO, 3times
88276|NCT01285024|Device|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
88277|NCT01285037|Drug|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
88278|NCT01285037|Drug|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
88583|NCT01288079|Drug|Duloxetine|Capsule, oral, once daily
88584|NCT01288079|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
88585|NCT01288092|Drug|BEZ235|
88586|NCT01288105|Device|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom >95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with <95% stent strut coverage will receive perioperative bridging.
88757|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
88758|NCT00053053|Dietary Supplement|Non-Juven Supplement|
88759|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
89054|NCT01291134|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
89055|NCT01291147|Drug|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
89056|NCT01291147|Drug|0.9% Saline|0.9% saline continous infusion for 48 hours
89057|NCT00053287|Drug|fludarabine phosphate|Fludarabine IV over 5-10 minutes on days 1-5.
89058|NCT01291160|Device|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
89059|NCT01291160|Other|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
89060|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
89061|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
89062|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
89063|NCT01293513|Other|Gradual anti-HIV treatment interruption|Gradual interruption of anti-HIV treatment: the interruption initially for a week, up to six weeks' interruption, and continuing anti-HIV treatment for two weeks between successive interruptions
89064|NCT01293526|Device|Control|Patients who respond will have leads will be placed using standard procedures.
89065|NCT01293526|Device|Experimental|Patients who respond will have their leads placed based on study measurements.
89066|NCT01293526|Device|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
88512|NCT01290276|Drug|Ond-PR1|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
88513|NCT01290276|Drug|Ond-PR1 + MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
88514|NCT01290276|Drug|Ond-PR2|Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
88515|NCT01290276|Drug|Ond-PR2 +_ MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
88516|NCT01290289|Other|Epidura, CSE & IV|Gp 1: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.
Gp 2: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.
Gp 3: received 50µg of E fentanyl analgesia & a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.
Gp 4: received analgesia: 50µg of E fentanyl & a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.
Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg.
88517|NCT00000252|Drug|20% N2O|
88518|NCT00001039|Drug|Clarithromycin|
88519|NCT00053196|Drug|tacrolimus|target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
88816|NCT01285934|Drug|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
88817|NCT01285947|Device|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
88818|NCT01285947|Other|Needle Application|30-gauge needle insertion into skin
88819|NCT01285947|Device|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
88820|NCT00052923|Drug|carmustine|
88821|NCT01285947|Device|Ulthera|Ultrasound Device at the following settings:
Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm
88822|NCT01285960|Device|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
88823|NCT01285986|Procedure|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
88824|NCT01285999|Device|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent
90180|NCT00001052|Biological|rgp120/HIV-1MN|
90181|NCT00055614|Procedure|adjuvant therapy|
90515|NCT01316445|Drug|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
90516|NCT01316458|Drug|STI571 (Glivec®)|
90517|NCT00055445|Drug|IdB 1016|
90518|NCT01316471|Behavioral|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
90519|NCT01316471|Other|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
90520|NCT01316497|Procedure|Remote ischemic preconditioning (RIPC)|RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
90521|NCT01316497|Procedure|Control|The cuff was applied on the leg without inflation in the control group.
90522|NCT01318837|Drug|solifenacin|oral
90523|NCT01318850|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
90524|NCT01318850|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
90525|NCT01318850|Other|Healthy controls|No intervention
90526|NCT01318889|Drug|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
88587|NCT01288131|Drug|Cyclosporine combine with mycophenolate mofetil|Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
88588|NCT01288131|Drug|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
88589|NCT00053040|Biological|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
88590|NCT01288144|Other|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
88591|NCT01288157|Drug|Golimumab|Single dose of 100 mg subcutaneously
88592|NCT01288157|Drug|Golimumab|Single dose of 50 mg subcutaneously
88593|NCT01288170|Drug|Nebcinal Tobi|
88594|NCT01288170|Drug|Tobi Nebcinal|
88595|NCT01288183|Procedure|sham tDCS|sham condition as delivered by the stimulator (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day
88596|NCT01288183|Procedure|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
88597|NCT01288196|Drug|Placebo IV|A single 30-minute IV infusion of placebo
88598|NCT01288196|Drug|CNTO 6785 1 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 1 mg/kg
88599|NCT01290341|Drug|Placebo|Topical; applied once daily for two weeks.
88600|NCT01290354|Drug|Lapatinib|Unlabelled, administered orally
88601|NCT01290354|Drug|[11C] lapatinib|Radiolabelled, administered intravenously
88602|NCT01290367|Biological|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
88603|NCT00053196|Procedure|allogeneic cell transplantation|2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
88890|NCT01292837|Drug|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
88891|NCT00053430|Drug|Thalidomide|Tablet taken orally daily
89067|NCT01293539|Drug|Melphalan hydrochloride|Drug administered intra-arterially (injection in the artery).
Standard dose:
2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (>3 years old)
Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.
Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.
Dose not to exceed 0.5mg/kg, per treatment cycle.
89068|NCT01293552|Biological|ANT-1207|single dose application
89069|NCT01293552|Biological|Vehicle|
89070|NCT00053508|Biological|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
89071|NCT01293578|Other|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
88113|NCT01294436|Drug|Dapagliflozin|Oral Dose 5 or 10 mg
88114|NCT01294449|Device|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
88115|NCT01294449|Device|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
88116|NCT01294462|Drug|Ticagrelor|90 mg, oral dose twice daily
88117|NCT01294462|Drug|Clopidogrel|75 mg, oral dose once daily
88118|NCT01294462|Drug|Acetylsalicylic acid ASA|Low Dose ASA
88119|NCT01294475|Behavioral|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
88120|NCT01294488|Behavioral|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
88121|NCT01294501|Other|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
88122|NCT01294527|Device|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
88123|NCT00053677|Drug|Naltrexone|
88124|NCT01294540|Drug|Drug: E2609|E2609 orally at varying ascending doses
88825|NCT01285999|Device|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent
88826|NCT01286012|Drug|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
88827|NCT01286012|Drug|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
88828|NCT01286012|Drug|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
88829|NCT01286012|Drug|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
88830|NCT01286025|Behavioral|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
88831|NCT00052923|Drug|cyclophosphamide|
88832|NCT01286025|Behavioral|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
88833|NCT01286038|Drug|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
88834|NCT01286051|Drug|Follistim administration|adminstation of FSH for ovulation induction
89128|NCT01289067|Drug|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
89129|NCT01291173|Drug|Placebo|Placebo capsule taken once daily for up to 11 weeks
89130|NCT01291186|Drug|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
89131|NCT01291186|Drug|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
89132|NCT01291186|Drug|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
89133|NCT01291186|Drug|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
89134|NCT00053287|Drug|thalidomide|Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
89135|NCT01291186|Drug|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
89136|NCT01291186|Drug|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
90527|NCT01318902|Drug|MLN9708|Patients will receive escalating doses of MLN9708 orally on Days 1, 8 and 15 of a 28-day cycle. If there is no hematologic response after completion of 3 cycles, dexamethasone will be added on Days 1 to 4 of every cycle beginning with Cycle 4. If there is no hematologic response after the completion of 6 cycles, patients will discontinue therapy.
90528|NCT01318915|Drug|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
90529|NCT00055653|Biological|filgrastim|
89619|NCT01284907|Dietary Supplement|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
89620|NCT01284907|Dietary Supplement|Placebo Drops|
89621|NCT01284920|Drug|MDV3100|oral
89622|NCT00052884|Drug|amifostine trihydrate|
89623|NCT01287364|Drug|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
89624|NCT01287377|Behavioral|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
89625|NCT01287377|Drug|Nicotine Patches|Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).
For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches.
89626|NCT01287390|Procedure|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
89627|NCT01287390|Procedure|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
89628|NCT01287390|Other|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
89629|NCT01287390|Other|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
89630|NCT00053001|Drug|thalidomide|
89631|NCT01287390|Other|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H&N 35).
89632|NCT01287403|Other|Refined wheat flour|A treated cereal flour mixed with milk.
88892|NCT01292863|Other|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
88893|NCT01292863|Other|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
88894|NCT01292876|Device|Extracellular Matrix|Extracellular Matrix
88895|NCT01292902|Other|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 < 88%.
88896|NCT01292902|Other|inspiratory muscle exercise|Equal to the group with chronic heart failure.
88897|NCT01292928|Device|Stent implantation|Stent implantation during the index procedure.
88898|NCT01292941|Device|Intermittent catheterisation|Speedicath, Intermittent catheterisation
88899|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
88900|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
88901|NCT01286077|Drug|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
88902|NCT01286090|Drug|Cisapride|One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
88903|NCT01286090|Drug|Placebo|One tablet taken orally 4 times a day for up to 8 weeks.
89220|NCT01289132|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
89221|NCT01289132|Drug|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
88125|NCT01294540|Drug|Placebo|Matching Placebo
88126|NCT01294553|Drug|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
88127|NCT01294566|Drug|GSK1322888|1 mg, 5 mg or 25 mg capsule
88128|NCT01296906|Behavioral|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
88129|NCT01296932|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
88130|NCT00053872|Procedure|adjuvant therapy|
88131|NCT01296945|Other|Kiosk|Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods
88132|NCT01296945|Other|paper|Participants will receive a paper handout with nutrition educational information.
88436|NCT01292343|Other|Colgate Regular Toothpaste|Toothbrushing with Colgate regular toothpaste
88437|NCT01292356|Drug|cetuximab|
88438|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
88439|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
88440|NCT01292395|Other|Dietary Protein Intake|Protein intakes within the current recommendation
88441|NCT00053391|Biological|recombinant CD40-ligand|
88442|NCT01292408|Drug|Hydrochloroquine|800 mg per os once, and then 400 mg per day
88443|NCT01292421|Biological|hepatitis B antigen peptide|Given PO
88444|NCT01292421|Other|placebo|Given orally (PO)
88445|NCT01292421|Other|immunoenzyme technique|Correlative studies
88446|NCT01292434|Behavioral|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
88447|NCT01292447|Drug|2% lidocaine gel|120mg lidocaine x 1
89137|NCT01291186|Drug|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
89138|NCT01291186|Drug|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
89139|NCT01291186|Drug|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
89140|NCT01291186|Drug|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
89141|NCT01291186|Drug|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
89142|NCT01291186|Drug|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
89143|NCT01291199|Drug|vardenafil|10 mg p.o. bid for 6 weeks
89144|NCT01291199|Drug|Placebo|Placebo p.o. 6 weeks bid
89145|NCT00053287|Drug|topotecan hydrochloride|Topotecan IV continuously over 72 hours.
89146|NCT01291212|Drug|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
89147|NCT01291212|Drug|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
89148|NCT01291225|Other|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
89149|NCT01291225|Behavioral|Educational campaign|Educational materials will be developed and distributed in Ross County.
89150|NCT01291238|Behavioral|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
89151|NCT01291277|Device|Endoscopic Variceal Ligation|Ligation of esophageal varices
88192|NCT01302340|Drug|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
88193|NCT01294566|Drug|Placebo|matching placebo capsules
88194|NCT01294579|Biological|Ofatumumab|1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase
1000 mg IV every 2 months for 2 years
88195|NCT01294579|Drug|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
89633|NCT01287403|Other|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
89634|NCT01287403|Other|Wholegrain wheat flour|A treated cereal flour mixed with milk.
89635|NCT01287403|Other|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
89636|NCT01287403|Other|Wholegrain barley flour|A treated cereal flour mixed with milk.
89637|NCT01287403|Other|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
89913|NCT01317732|Device|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
89914|NCT01317745|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
89915|NCT01317745|Drug|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
89916|NCT01317745|Biological|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
89917|NCT01317758|Drug|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
89918|NCT01317758|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
89919|NCT01317758|Biological|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
89920|NCT01317771|Procedure|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
89921|NCT01317784|Device|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
89922|NCT01317784|Device|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
89923|NCT00055588|Procedure|Locomotor training|
89924|NCT01317784|Device|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
89925|NCT01317784|Device|HIV only|Choice of 4 different tests for HIV only.
89926|NCT01317797|Drug|namilumab (MT203)|administered three times, subcutaneous in the abdomen
89222|NCT01289132|Drug|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
89223|NCT01289145|Behavioral|Motivational intervention|The motivational intervention promotes positive outcome expectancies on physical activity.
89224|NCT01289145|Behavioral|Volitional intervention|The volitional intervention promotes the formulation of action plans for physical activity.
89225|NCT01289145|Behavioral|Active Control|Participants receive a quiz on physical activity and sports.
89226|NCT01289171|Drug|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
89227|NCT00053118|Procedure|peripheral blood stem cell transplantation|IV
89228|NCT01289197|Behavioral|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
89229|NCT01289210|Drug|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
89230|NCT01289223|Drug|Bendamustine IV|
89231|NCT01291303|Procedure|Standard ventilation|Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:
-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that "optimized ventilation" mode, while the ventilator screen was obscured (numerical data were, however, always available).
89232|NCT01291316|Drug|Clonazepam|clonazepam, 1 mg, single oral dose
89233|NCT00053300|Drug|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
89234|NCT01291316|Drug|Tolterodine|Tolterodine 1,37mg, single oral dose
89235|NCT01291316|Drug|clobazam|clobazam 20 mg, single oral dose
89236|NCT01291329|Genetic|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
89237|NCT01291355|Other|Specific maternal position during the labor|women allocated to intervention group will be invited to adopt a posture all fours type:"support on the knees, torso tilted forward, back stretched" for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts.
88448|NCT01292447|Drug|Placebo gel|Inert gel x 1
88449|NCT01292460|Drug|Timolol/ FDC/ Placebo/ Tafluprost|Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).
Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).
88450|NCT01292473|Drug|Placebo|Placebo was supplied lyophilized in vials.
88451|NCT01292473|Drug|Omalizumab|Omalizumab was supplied lyophilized in vials.
88452|NCT00053391|Biological|therapeutic autologous dendritic cells|
88453|NCT01285284|Other|No music|No music will be administered by the headphones connected to the MP3 device.
88454|NCT01285297|Biological|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
88455|NCT01285310|Drug|Apremilast 30 mg|
88456|NCT01285310|Drug|Apremilast 20 mg|
88457|NCT01285310|Drug|Placebo|
88458|NCT01285323|Drug|Reslizumab|3.0 mg/kg, administered intravenously (iv) once every 4 weeks over 52 weeks (a total of 13 doses administered).
88760|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
88761|NCT01288326|Drug|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
88762|NCT01288339|Drug|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
88763|NCT01288339|Drug|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
88764|NCT01288352|Other|early standardised rhythm control|Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.
Early-onset rhythm control therapy can consist of:
Optimal antiarrhythmic drug therapy
Catheter ablation with the aim of pulmonary vein isolation (PVI),
Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.
All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences.
88196|NCT01294592|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
88197|NCT01294592|Drug|tamsulosin|Take 1 capsule daily when escalation criteria met
88198|NCT01294605|Biological|Boostrix™ (dTpa)|Intramuscular, 3 doses
88199|NCT00053690|Behavioral|Cognitive Behavior Treatment|
88200|NCT01294605|Biological|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
88201|NCT01294605|Biological|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
88202|NCT01294605|Biological|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
88203|NCT01294618|Drug|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
88204|NCT01294631|Drug|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.
Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35..
88205|NCT01294644|Drug|Deoxycholic acid injection|
88206|NCT01294644|Drug|Placebo|Phosphate buffered saline placebo for injection
88207|NCT01294657|Behavioral|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
88208|NCT01294657|Behavioral|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
88209|NCT01294670|Drug|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
88520|NCT01290302|Drug|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
88521|NCT01290302|Drug|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
88522|NCT01290315|Drug|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
88523|NCT01290315|Drug|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
89927|NCT01317797|Drug|Placebo|administered three times, subcutaneous in the abdomen
89928|NCT01317823|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
89929|NCT01317849|Drug|Folic Acid|0.8mg
89930|NCT01317849|Drug|Vitamin B6|10mg
89931|NCT01317849|Drug|Vitamin B12|500ug
89932|NCT01317849|Drug|placebo|0.8 mg
89933|NCT01320228|Dietary Supplement|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
90182|NCT01318252|Drug|Latanoprost 0.005%|
90183|NCT01318252|Drug|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
90184|NCT01318265|Drug|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
90185|NCT01318278|Drug|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
90186|NCT01318278|Drug|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
90187|NCT01318291|Behavioral|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
90188|NCT01318291|Behavioral|Control|Medical treatment alone
90189|NCT01318304|Other|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
90190|NCT01318317|Procedure|peripheral blood stem cell transplantation (PBSCT)|Undergo autologous PBSCT
90191|NCT01318317|Biological|filgrastim|Given IV
90192|NCT00055640|Biological|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
90193|NCT01318317|Genetic|polymerase chain reaction|Correlative studies
90194|NCT01318317|Biological|rituximab|Given IV
90195|NCT01320722|Drug|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
88279|NCT01285037|Drug|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
88280|NCT01285037|Drug|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
88281|NCT01285037|Drug|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
88282|NCT00001036|Drug|Thymalfasin|
88283|NCT00052884|Drug|melphalan|
88284|NCT01285050|Drug|Anti-HIV Agents|Interferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications.
88285|NCT01285050|Drug|raltegravir|HIV medication, 400 mg twice daily by mouth
88286|NCT01285050|Drug|Emtricitabine and tenofovir disoproxil fumarate|HIV medication, combination pill, once per day by mouth
88287|NCT01285063|Other|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.
Physical activity: physical trainings of 60 minutes each will be held twice a week.
behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle.
88288|NCT01285076|Other|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
88289|NCT01285089|Drug|activated recombinant human factor VII|Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
88290|NCT01287455|Drug|Vitamin D3 as "BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
88291|NCT01287455|Other|placebo|drops, 70 placebo drops, once weekly for 6 weeks
88292|NCT01287481|Behavioral|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
88293|NCT01287481|Behavioral|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
88765|NCT01288365|Behavioral|Exercise training|Exercise training program for 3 months (two times a week).
88766|NCT01288378|Drug|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
88767|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
88768|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
88769|NCT00053092|Biological|rituximab|
88770|NCT01288404|Drug|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
88771|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
88772|NCT01290614|Other|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR <30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
88773|NCT01290614|Other|Usual Care|Patients in the control arm will continue to receive "usual care" from their VA providers.
88774|NCT01290627|Device|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
89072|NCT01293591|Other|Controlled diet with or without garlic|Each subject will complete each treatment phase, and subjects will be randomly assigned to a sequence of dietary treatments. Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume one of two dietary treatments, consisting of either 1) 270 kcal white bread, 15 g margarine, and 5 g (0.175 oz.) of crushed garlic, or 2) 270 kcal white bread with 15 g margarine (during the control phase).
89073|NCT01293604|Other|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
89074|NCT01293617|Other|Blackberries|300 g blackberries daily for 5 days
89075|NCT01293617|Other|Gelatin|300 g gelatin per day for 5 days
89076|NCT01293630|Drug|Ombrabulin (AVE8062)|Pharmaceutical form:solution
Route of administration: intravenous
89077|NCT01293630|Drug|Paclitaxel|Pharmaceutical form:solution
Route of administration: intravenous
88524|NCT01290328|Drug|Epoetin Alfa|150 units/kg/weekly
88525|NCT01290341|Drug|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
88526|NCT01292486|Device|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
88527|NCT01292499|Behavioral|Psychotherapy|10 sessions (50 min)
88528|NCT01292499|Behavioral|Psychoeducation|7 sessions + 7 phone calls
88529|NCT01292499|Behavioral|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
88530|NCT01292512|Other|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
88531|NCT01292525|Drug|Tacrolimus|A control group continued conventional therapy, Tacrolimus (Prograf®) ("control" group) and will be followed in parallel group "withdrawal" that will stop treatment with Tacrolimus (Prograf®).
88532|NCT01292525|Drug|Placebo|Patients randomized to the "withdrawal"group will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the "withdrawal" group.
88533|NCT01292538|Device|Erchonia GLS|532 nm green diode low level laser light device
88534|NCT01292538|Device|Placebo laser|Sham light output with no therapeutic benefit
88535|NCT01292551|Drug|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
88536|NCT00053417|Drug|Placebo|Placebo for 15 weeks
88537|NCT01292551|Drug|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
88538|NCT01292564|Device|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
88835|NCT01286051|Drug|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
88836|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
88837|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
88838|NCT01288417|Drug|boceprevir|10 days of boceprevir 800mg TID
90196|NCT01320722|Drug|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
90197|NCT01320722|Drug|Placebo|Placebo soft gel once per week for 8 weeks
90198|NCT01320722|Drug|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
90199|NCT01320748|Behavioral|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
90200|NCT01320748|Behavioral|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
90201|NCT01320761|Drug|ATX-101-BA-free|ATX-101-BA-free
90202|NCT00055731|Drug|nilutamide|
90530|NCT01318915|Drug|Rituximab|375 mg/m^2 IV infusion on day -6 before transplant and on day 1 after transplant.
90531|NCT01318915|Drug|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
90532|NCT01318915|Drug|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
90533|NCT01318915|Drug|MMF|1 g twice daily on days 0 through 12
90534|NCT01318928|Drug|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
90535|NCT01318941|Drug|Ranibizumab|
90536|NCT01318941|Other|Ranibizumab|
90537|NCT01318954|Biological|Allergen immunotherapy|
90538|NCT01318967|Drug|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
90539|NCT01318980|Drug|GSK2190915 100mg milled tablet|Taken orally
90540|NCT00055653|Drug|busulfan|
90541|NCT01318980|Drug|[14C] radiolabelled GSK2190915 solution|Microtracer solution
90542|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
88294|NCT01287481|Behavioral|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
88604|NCT01290367|Procedure|Single injection of saline solution|Intradiscal control injection with saline solution
88605|NCT01290367|Procedure|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
88606|NCT01290367|Biological|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
88607|NCT01290380|Drug|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
88608|NCT01290393|Other|Data collection|Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
88609|NCT01290406|Drug|BEZ235|
88610|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
88611|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
88612|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
88613|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
88614|NCT00053196|Drug|allopurinol|300 mg/day PO Days -8 thru -1
88615|NCT01290419|Biological|Placebo|Placebo; Day 0 and Day 30
88616|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
88617|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
88618|NCT01290432|Dietary Supplement|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
88619|NCT01290445|Drug|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
88620|NCT01290445|Behavioral|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
88621|NCT01290445|Other|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
88622|NCT01290458|Dietary Supplement|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
89078|NCT01293630|Drug|Carboplatin|Pharmaceutical form:solution
Route of administration: intravenous
89079|NCT01293643|Drug|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
89080|NCT01293643|Drug|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
89081|NCT00053547|Drug|paricalcitol injection|
89082|NCT01293656|Other|No intervention.|There is no study intervention. Participants will be treated locally per site standards.
89083|NCT01293669|Drug|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
89084|NCT01286350|Behavioral|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
89085|NCT01286376|Dietary Supplement|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
89086|NCT01286376|Dietary Supplement|Maltodextrin|Maltodextrin
89087|NCT01286389|Other|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
88133|NCT01296945|Other|Kiosk PLUS paper|Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
88134|NCT01296945|Other|Kiosk PLUS web|Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
88135|NCT01296958|Drug|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
88136|NCT01296958|Behavioral|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
88137|NCT01296971|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
88138|NCT01296971|Drug|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
88139|NCT01296971|Drug|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
88839|NCT01288417|Drug|raltegravir|raltegravir 400mg single dose
88840|NCT01288430|Drug|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
88841|NCT01288443|Drug|Alirocumab|Two SC injections in the abdomen only.
88842|NCT01288443|Drug|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
88843|NCT01288443|Drug|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
88844|NCT00053092|Drug|cyclophosphamide|
88845|NCT01288469|Drug|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
88846|NCT01288469|Drug|Placebo (for alirocumab)|One SC injection in the abdomen only.
88847|NCT01288469|Drug|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
88848|NCT01288469|Drug|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
88849|NCT01288482|Device|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
88850|NCT01288482|Device|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
88851|NCT01288495|Dietary Supplement|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
88852|NCT01288495|Dietary Supplement|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
88853|NCT01288508|Dietary Supplement|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
88854|NCT01288508|Dietary Supplement|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
88855|NCT00053092|Drug|fludarabine phosphate|
89152|NCT01291290|Procedure|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
90543|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
90544|NCT01318980|Drug|GSK2190915 100mg enteric-coated tablet.|Taken orally
90545|NCT01318993|Drug|GSK1605786A|500 milligrams twice daily
90546|NCT01319006|Drug|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
90547|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
90548|NCT00055757|Drug|gemcitabine hydrochloride|Given IV
90549|NCT01321346|Drug|Cytarabine|All patients will receive 70 mg of intrathecal cytarabine on day "0" of course 1. The day "0" dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day "0" dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.
All patients will receive 70 mg of intrathecal cytarabine on day "29" of course 1-8 in conjunction with their disease evaluation.
90550|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
89347|NCT01284270|Other|Cardiac MRI|Cardiac MRI
89348|NCT01284283|Device|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
89349|NCT00052780|Biological|filgrastim|Given SC or IV
89350|NCT01284296|Drug|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
89351|NCT01284296|Device|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
89352|NCT01284309|Drug|Mirabegron|oral
89353|NCT01284309|Drug|Placebo|oral
89354|NCT01284322|Drug|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
89355|NCT01284335|Drug|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
89356|NCT01284335|Drug|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
89357|NCT01284335|Drug|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
88623|NCT01290471|Drug|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
88624|NCT01290484|Drug|Sildenafil|Sildenafil oral tablet three times daily
88625|NCT01292603|Drug|rituximab [MabThera]|6 cycles of intravenous MabThera
88904|NCT01286103|Drug|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
88905|NCT00052923|Drug|etoposide|
88906|NCT01286103|Drug|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
88907|NCT01286116|Device|Parachute Implant|Mechanical ventricular partitioning
88908|NCT01286129|Procedure|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
88909|NCT01286168|Device|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
88910|NCT01286168|Device|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
88911|NCT01286168|Procedure|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
88912|NCT01286168|Device|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
88913|NCT01286181|Behavioral|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
88914|NCT01286194|Drug|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
88915|NCT01288547|Dietary Supplement|theobromine|700 mg theobromine in gelatin capsules given one time only
88916|NCT01288547|Dietary Supplement|Caffeine|120 mg caffeine in capsules given one time only
88917|NCT01288547|Dietary Supplement|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
88140|NCT01296997|Dietary Supplement|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
88141|NCT00053872|Radiation|radiation therapy|
88142|NCT01296997|Other|placebo|the subjects consumed a bread without pentacalcium phosphate
88143|NCT01297010|Drug|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
88144|NCT01297010|Drug|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
88145|NCT01297023|Dietary Supplement|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d]
88146|NCT01297023|Dietary Supplement|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 [10µg/d]
88147|NCT01297023|Dietary Supplement|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d] and vitamin d3 (10µg/d]
88148|NCT01297023|Other|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
88149|NCT01297036|Drug|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
88150|NCT01297036|Drug|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
88151|NCT01299376|Drug|Placebo to losartan potassium (+) hydrochlorothiazide|One tablet containing placebo, orally, once daily, for 8 weeks.
88152|NCT01299389|Drug|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
88459|NCT00052897|Biological|HspE7|
88460|NCT01285323|Drug|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered.
88461|NCT01285349|Behavioral|Couple HIV/STI prevention intervention|
88462|NCT01285349|Behavioral|Couple-based HIV prevention|
88463|NCT01285349|Behavioral|Individual HIV/STI prevention|
88464|NCT01285349|Behavioral|Couple Wellness Promotion|
89153|NCT01291303|Procedure|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
89154|NCT01283932|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
89155|NCT00052728|Drug|tamoxifen citrate|
89156|NCT01283945|Drug|Lucitanib|Oral administration, once daily (qd), in fasting conditions.
Dose escalation - continuous schedule
Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)
Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)
89157|NCT01283971|Drug|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
89158|NCT01283971|Drug|adalimumab|Adalimumab 40 mg SC every 2 weeks.
89159|NCT01283971|Drug|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
89160|NCT01283971|Drug|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
89161|NCT01283971|Drug|methotrexate|Methotrexate 10-25 mg weekly.
89162|NCT01283971|Drug|folate|Folate at least 5 mg weekly.
89163|NCT01283984|Drug|AZD2115|Single dose, oral inhalation (nebuliser solution)
89164|NCT01283984|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
89165|NCT01283997|Other|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
89166|NCT00052728|Drug|tipifarnib|
89167|NCT01283997|Drug|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
89168|NCT01284010|Genetic|DNA analysis|
89169|NCT01284010|Genetic|fluorescence in situ hybridization|
89170|NCT01284010|Genetic|gene expression analysis|
89171|NCT01284010|Genetic|microarray analysis|
89172|NCT01284010|Genetic|mutation analysis|
89173|NCT01284010|Genetic|polymerase chain reaction|
89174|NCT01284010|Other|laboratory biomarker analysis|
89358|NCT01284335|Drug|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
89359|NCT01286870|Device|Mentor Becker 50 Expander/Breast Implant|The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc.
89360|NCT01286896|Drug|Sunitinib|Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.
After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses.
89361|NCT01286909|Dietary Supplement|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
89362|NCT01286922|Other|Behavioral: exercise|Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:
• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.
Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:
• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group.
89363|NCT01286935|Drug|Safinamide|
88398|NCT01287741|Drug|RO5072759|1000 mg iv every 21 days, 8 cycles (additional doses Days 8 and 15 of Cycle 1)
88399|NCT01287741|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv every 21 days, 8 cycles
88400|NCT01287754|Drug|erlotinib [Tarceva]|150 mg daily orally
88401|NCT00053014|Procedure|peripheral blood stem cell transplantation|
88402|NCT01287767|Behavioral|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
88403|NCT01287780|Device|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
88404|NCT01287793|Drug|tigecycline|intravenous, 200 mg, single dose
88405|NCT01287793|Drug|tigecycline|intravenous, 50 mg, single dose
88406|NCT01287793|Drug|moxifloxacin|oral tablet, 400 mg, single dose
88918|NCT01288547|Dietary Supplement|placebo|cellulose in capsules given one time only
88919|NCT01288560|Other|Advanced cardiac imaging|
88920|NCT01288560|Other|Standard Cardiac Imaging|
88921|NCT01288573|Drug|plerixafor|160 μg/kg subcutaneous (SC) injection
88922|NCT00053105|Drug|cisplatin|
88923|NCT01288573|Drug|plerixafor|240 μg/kg subcutaneous (SC) injection
88924|NCT01288573|Drug|plerixafor|320 μg/kg subcutaneous (SC) injection
89238|NCT01291381|Drug|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
89239|NCT01291381|Drug|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
89240|NCT01291394|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
89241|NCT01291407|Drug|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
89242|NCT01291407|Drug|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
89243|NCT01291407|Drug|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
89244|NCT00053300|Procedure|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
89245|NCT01291407|Drug|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
89246|NCT01291407|Drug|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
89247|NCT01291407|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
89248|NCT01291420|Biological|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
89249|NCT01291433|Drug|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
89250|NCT01291433|Drug|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
88465|NCT01285362|Drug|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
88466|NCT01285362|Drug|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
88467|NCT01285375|Device|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
88468|NCT01285375|Device|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
88469|NCT01285388|Drug|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
88470|NCT00052910|Drug|cisplatin|Given IV
88471|NCT01285401|Drug|VigantOL® oil plus interferon beta-1a (Rebif®)|VigantOL® oil 6,670 International Units/day (IU/d) (167 microgram per day [mcg/day]), orally administered for 4 weeks followed by 14,007 IU/d (350 mcg/d) orally administered for 44 weeks on top of Rebif® 44mcg three times per week (tiw) administered sub-cutaneously. Subjects who have already passed Week 48 at the time of approval of Protocol Amendment 5 in their country will be receive 14,007 IU/d (350 mcg/d) orally administered for 92 weeks.
88472|NCT01285401|Drug|Placebo plus interferon beta-1a (Rebif®)|Matching placebo daily, orally administered plus Rebif® 44 mcg tiw, sub-cutaneously.
88473|NCT01285401|Biological|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
88474|NCT01285414|Drug|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide & Radiation Therapy
88475|NCT01285414|Drug|Temozolomide & Radiation Therapy|Temozolomide & Radiation Therapy
88476|NCT01285453|Drug|vadimezan|
88477|NCT01285466|Drug|BEZ235 + paclitaxel|
88478|NCT01285466|Drug|BKM120 + paclitaxel|
88479|NCT01285466|Drug|BEZ235 + paclitaxel + trastuzumab|
88480|NCT01287806|Drug|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
88775|NCT01290627|Device|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
88776|NCT01290640|Device|DePuy fixed-bearing Total Condylar III (TC3) TKA|
88777|NCT01290640|Device|DePuy PFC Rotating Platform TC3 TKA|
88778|NCT01290653|Other|Dry needling|Deep dry needling until achieving twitch response of the muscle
88210|NCT00053703|Drug|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
88211|NCT01294683|Drug|ER niacin/laropiprant/simvastatin|One tablet containing 1 g extended release niacin, 20 mg laropiprant, and 40 mg simvastatin, orally, once daily.
88212|NCT01294683|Drug|ER niacin/laropiprant/simvastatin|Two tablets containing 1 g extended release niacin, 20 mg laropiprant, and 20 mg simvastatin, orally, once daily.
88213|NCT01294683|Drug|ER niacin/laropiprant|One or two tablets containing 1 g extended release niacin and 20 mg laropiprant, orally, once daily
88214|NCT01294683|Drug|Simvastatin|One tablet, containing 40 mg simvastatin, orally, once daily
88215|NCT01294683|Drug|Placebo to match simvastatin|One tablet, orally, once daily.
88216|NCT01289938|Drug|Metoclopramide|10 mg i.v. metoclopramide once
88217|NCT01289951|Drug|Raltegravir 400 mg/12hours|
88218|NCT01289951|Drug|Raltegravir 400 mg/12hours|
88219|NCT01289964|Procedure|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
88220|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88221|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88222|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88223|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
88224|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88225|NCT00053183|Radiation|radiation therapy|
88226|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88227|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88228|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88229|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88230|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88231|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88232|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88407|NCT01287793|Drug|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
88408|NCT01287793|Drug|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
88409|NCT01290120|Drug|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
88410|NCT01290133|Drug|GW597599|Single dose IV infusion
88411|NCT01290133|Drug|Placebo|Single dose IV infusion
88412|NCT01290146|Drug|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
88413|NCT01290146|Drug|Levosimendan|Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.
Starting doses will be based on baseline SBP levels
SBP ≥ 85-99mmHg: 0.05 mcg/kg/min
SBP ≥100 mmHg: 0.1 mcg/kg/min
88414|NCT01290159|Other|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
88415|NCT01290172|Drug|Administration of Somatostatin|6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.
5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days.
88727|NCT01293019|Procedure|Osteopathic treatment|Real treatment of osteopathy
88728|NCT00053443|Device|Medication Reminder System/Adherence Tracker|
88729|NCT01293019|Procedure|Sham Placebo|Sham treatment of osteopathy
88730|NCT01293019|Procedure|Usual care|Classical treatment of pain in cystic fibrosis patients
88731|NCT01293032|Procedure|neoadjuvant therapy|Undergo neoadjuvant therapy
88732|NCT01293032|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
88733|NCT01293032|Other|laboratory biomarker analysis|Correlative studies
88734|NCT01293032|Other|enzyme-linked immunosorbent assay|Correlative studies
89251|NCT01291433|Drug|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
89252|NCT01291433|Drug|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
89253|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
89254|NCT01284062|Other|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
89255|NCT01284075|Behavioral|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
88295|NCT01287494|Drug|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
88296|NCT01287507|Dietary Supplement|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
88297|NCT01287520|Drug|LY2090314|Administered intravenously
88298|NCT01287520|Drug|pemetrexed|Administered intravenously
88299|NCT00053014|Drug|cyclosporine|
88300|NCT01287520|Drug|Carboplatin|Administered intravenously
88301|NCT01287533|Drug|Ibandronate|monthly dosage of ibandronate 150mg
88302|NCT01287533|Drug|Placebo|monthly dosage of placebo
88303|NCT01287546|Drug|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
88304|NCT01287546|Drug|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
88305|NCT01287546|Drug|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
88306|NCT01287546|Drug|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
88307|NCT01287585|Drug|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
88308|NCT01287585|Drug|Placebo|weekly, intramuscular, until disease progression or toxicity.
88779|NCT01290653|Other|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
88780|NCT00053235|Genetic|Comparative Genomic Hybridization|Correlative studies
88781|NCT01290653|Other|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
88782|NCT01290666|Device|Fistula Plug|Bioabsorbable fistula plug
88783|NCT01290679|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
88784|NCT01290679|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
88785|NCT01290679|Drug|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
88786|NCT01290679|Drug|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
88787|NCT01290692|Biological|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
88788|NCT01290705|Behavioral|High exercise therapy|
88789|NCT01290705|Behavioral|Low exercise therapy|
88790|NCT01290718|Drug|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
88791|NCT00053235|Other|Laboratory Biomarker Analysis|Correlative studies
88792|NCT01290718|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
88793|NCT01290731|Drug|TMC435|100-mg capsule once daily for 12 weeks
88794|NCT01293292|Drug|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
88795|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
88796|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
88233|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
88234|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88235|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88539|NCT01292564|Device|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
88540|NCT01292577|Behavioral|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
88541|NCT01292577|Behavioral|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
88542|NCT01292590|Other|High fat meal|40 grams saturated fat
88543|NCT01292603|Drug|Cyclophosphamide|Days 1-3 of cycles 1-6
88544|NCT01292603|Drug|Fludarabine|Days 1-3 of cycles 1-6
88545|NCT01292603|Drug|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
88546|NCT01292603|Drug|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
88547|NCT00053417|Drug|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|2 week up titration (10 mg)
12 weeks stable dose (10 mg)
1 week down titration (10 mg)
88548|NCT01285466|Drug|BKM120 + paclitaxel + trastuzumab|
88549|NCT00052910|Drug|epirubicin hydrochloride|Given IV
88550|NCT01285479|Drug|Fingolimod|
88551|NCT01285492|Drug|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
88552|NCT01285492|Drug|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
88553|NCT01285505|Drug|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
88554|NCT01285505|Drug|alprazolam test sublingual tablet|0.5 mg tablet, single dose
88555|NCT01285518|Drug|PF-05231023|0.5 mg QD IV x 1 day
88556|NCT01285518|Drug|PF-05231023|1.5 mg QD IV x 1 day
88735|NCT01293032|Genetic|gene expression analysis|Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a "Recurrence Score" (RS).
88736|NCT01293032|Drug|systemic chemotherapy|Undergo chemotherapy
88737|NCT01293032|Drug|tamoxifen citrate|Undergo hormonal therapy
88738|NCT01293032|Drug|aromatase inhibition therapy|Undergo hormonal therapy
88739|NCT00001041|Biological|rgp120/HIV-1MN|
88740|NCT00053482|Biological|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
88741|NCT01285778|Drug|panitumumab, mytomicin C, 5-FU, radiation|Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:
First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks
Then Mitomycin C, 10mg/m2 on days 1 and 29
Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32
Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy.
88742|NCT01285804|Other|Cuffed ETT|Kimberly Clark
88743|NCT01285804|Other|Uncuffed ETT|Kimberly Clark
88744|NCT01285817|Drug|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
88745|NCT01285830|Dietary Supplement|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
88746|NCT01285830|Dietary Supplement|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
88747|NCT01285843|Procedure|Anterior Minimally Invasive Approach (AMIS)|
89036|NCT01288833|Device|Close focus HD NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
89037|NCT01288859|Other|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
89038|NCT01288859|Other|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
89039|NCT01288859|Other|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
88309|NCT01287598|Drug|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam|BAY73-4506 administered orally twice a day (bid) in a 21-day on / 7-day off schedule Group A: CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) at Cycle 1
88310|NCT00053014|Drug|fludarabine|
88311|NCT01287598|Drug|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone|BAY73-4506 administered orally twice a day (bid) in a 21-day on / 7-day off schedule Group B: CYP2C8 (rosiglitazone) at Cycle 1
88312|NCT01287611|Procedure|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
88313|NCT01287611|Procedure|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
88314|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88315|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88316|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88626|NCT01292616|Drug|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
88627|NCT01292629|Device|iSert 251 intraocular lens|aphakic intraocular lens
88628|NCT01292642|Behavioral|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
88629|NCT01292642|Drug|Nicotine Replacement Therapy|21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks
14 m g patch for 8 weeks, then 7 mg patch for 2 weeks
88630|NCT01292655|Drug|BMS-906024|
88631|NCT01292668|Drug|methyl-5-aminolevulinate hydrochloride cream|Applied topically
88632|NCT01292668|Drug|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
88633|NCT01292668|Procedure|laser therapy|Undergo laser light photodynamic therapy
88634|NCT01292681|Other|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
88635|NCT00053417|Drug|15 mg fampridine-SR (4-aminopyridine, 4-AP)|10 mg twice daily for 1 week
15 mg twice daily for 14 weeks
2 week up titration (10 mg x 1 week, 15 mg x 1 week)
12 weeks stable dose (15 mg)
1 week down titration (10 mg)
88636|NCT01292694|Drug|Losartan|Oral, single-dose, 50 mg tablet
88637|NCT01292694|Drug|Captopril|Oral, single-dose, 50 mg tablet
89088|NCT01286389|Behavioral|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
89089|NCT01286402|Drug|Bupropion SR|150mg, taken orally, taken daily for the 1st 3 days
300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment
89090|NCT01286402|Other|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
89091|NCT01286415|Behavioral|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
89092|NCT00052936|Biological|rituximab|
89093|NCT01286415|Behavioral|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
89094|NCT01286441|Drug|East Indian Sandalwood Oil ointment|During the Treatment Period, subjects will be randomized to one of the four treatment arms and will apply study medication (either placebo, 10% EISO, 20% EISO or 30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
89095|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
89096|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
89097|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
89098|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
89099|NCT01286454|Drug|fesoterodine|single dose of tablet
89100|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
89101|NCT01286467|Drug|PF-04449913|Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
89102|NCT01288872|Drug|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
89103|NCT01288885|Drug|ASP1941|Oral
88557|NCT01285518|Drug|PF-05231023|5 mg QD IV x 1 day
88558|NCT01285518|Drug|PF-05231023|15 mg QD IV x 1 day
88559|NCT01285518|Drug|PF-05231023|50 mg QD IV x 1 day
88560|NCT00052910|Drug|fluorouracil|Given IV
88561|NCT01285518|Drug|PF-05231023|100 mg QD IV x 1 day
88562|NCT01285518|Drug|PF-05231023|200 mg QD IV x 1 day
88856|NCT01288521|Drug|Tacrolimus + Ketoconazole|Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.
88857|NCT01288521|Drug|Tacrolimus alone|Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
88858|NCT01288534|Radiation|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
88859|NCT01290731|Drug|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
88860|NCT01290731|Drug|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
88861|NCT01290744|Drug|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
88862|NCT01290744|Drug|Placebo|Daily for 12 months
88863|NCT01290757|Drug|Dabigatran etexilate|150 mg Capsugel (T)
88864|NCT01290757|Drug|Dabigatran etexilate|150 mg Qualicaps (R)
88865|NCT01290770|Other|blood sample|blood sample at inclusion and 1 month after inclusion
88866|NCT01290783|Drug|Irintoecan|Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks.
8 months of treatment.
88867|NCT00053235|Genetic|Polymerase Chain Reaction|Correlative studies
88868|NCT01290783|Drug|HA-Irinotecan solution for Infusion|HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks
8 months of treatment.
89040|NCT01288859|Other|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
89041|NCT01288859|Other|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
89042|NCT01288859|Other|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
89043|NCT01291056|Other|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
89044|NCT01291056|Drug|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
89045|NCT01291069|Drug|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
89046|NCT00053287|Drug|carboplatin|Carboplatin IV over 24 hours on days 1-5
89047|NCT01291069|Drug|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
89048|NCT01291095|Drug|CISPLATIN|IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.
IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN
89049|NCT01291095|Radiation|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
89050|NCT01291108|Drug|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
89051|NCT01291108|Drug|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
89052|NCT01291108|Drug|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
89053|NCT01291121|Procedure|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
89364|NCT01286935|Drug|Safinamide|
89365|NCT01286935|Drug|Placebo|
88638|NCT01292694|Drug|Placebo|Oral, single administration, gelatin capsule filled with microcrystalline cellulose
88639|NCT01292707|Behavioral|Control|Standard national training
88640|NCT01292707|Behavioral|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
88641|NCT01292707|Behavioral|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
88642|NCT01292720|Drug|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
88643|NCT01292720|Drug|Placebo|Placebo in matching volumes
88644|NCT01292733|Other|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
88645|NCT01292733|Other|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
88925|NCT01288586|Device|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
88926|NCT01288599|Procedure|Laparoscopic surgery|Laparoscopic surgery where adnexectomy or cystectomy is performed.
88927|NCT01288612|Device|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
88928|NCT01288612|Device|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
88929|NCT01288625|Drug|Amifostine|500 mg sc, qod, 3 times per week
88930|NCT01288625|Radiation|Amifostine|500mg rinsing wash, qod, 3 times per week
88931|NCT01288638|Other|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
88932|NCT01288638|Other|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
89104|NCT00053118|Biological|filgrastim|IV
89105|NCT01288885|Drug|Placebo|Oral
88153|NCT01299389|Drug|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
88154|NCT01299402|Dietary Supplement|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
88155|NCT01299402|Dietary Supplement|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
88156|NCT01299415|Drug|Vadimezan™|
88157|NCT01299428|Device|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
88158|NCT01299441|Device|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
88159|NCT01299454|Drug|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
88160|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
88161|NCT00053989|Drug|fludarabine phosphate|iv
88162|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
88163|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
88164|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
88165|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
88166|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
88167|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
88168|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
88169|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
88869|NCT01290796|Device|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
88870|NCT01290822|Device|BiVP|Biventricular pacing
88871|NCT01290822|Device|AAI Pacing|Atrial pacing
88872|NCT01290835|Radiation|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
88873|NCT01290835|Radiation|stereotactic radiotherapy|
89175|NCT01284023|Other|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
89176|NCT01284036|Drug|PF-05230905|Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
89177|NCT00052754|Drug|gefitinib|
89178|NCT01284049|Drug|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
89179|NCT01284049|Drug|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
89180|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
89181|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
89182|NCT01286480|Behavioral|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
89183|NCT00052936|Drug|CHOP regimen|
89184|NCT01286493|Biological|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
89185|NCT01286558|Drug|40 mg telmisartan|once daily
89186|NCT01286558|Drug|5 mg amlodipine|once daily
89366|NCT01286948|Drug|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).
All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated.
89367|NCT01286961|Drug|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
89368|NCT00052936|Radiation|radiation therapy|
89369|NCT01286974|Drug|[14C]linifanib|[14C]linifanib, single administration, oral liquid
89370|NCT01286974|Drug|ABT-869, linifanib|linifanib once a day (QD), oral tablet
89371|NCT01286987|Drug|Talazoparib|Oral capsule with multiple dosage forms given once daily
89372|NCT01287013|Device|Xperguide CT|Imaging
89373|NCT01287013|Device|Computed Tomography|Imaging
89374|NCT01287026|Device|Balloon catheter for right heart catheterization|
89375|NCT01287026|Drug|Gadopentate Dimeglumine (Gadolinium); Contrast Agent|
89376|NCT01287026|Procedure|Right Heart Catheterization|
89377|NCT01287026|Procedure|Cardiac Real-time MRI|
89378|NCT01287026|Procedure|Vascular Hemostasis|
89379|NCT00052949|Drug|imatinib mesylate|Given orally
89380|NCT01289366|Device|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
89381|NCT01289379|Procedure|High Frequency Jet Ventilation|
89382|NCT01289379|Procedure|HFJV|
89383|NCT01289392|Device|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
89384|NCT01289392|Device|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
89385|NCT01289392|Behavioral|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
88933|NCT00053105|Drug|cytarabine|
88934|NCT01288651|Drug|Ferricarboxymaltose|Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.
Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject).
88935|NCT01288664|Drug|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
88936|NCT01288677|Drug|TMC649128|Escalated doses
88937|NCT01288690|Behavioral|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
88938|NCT01288716|Drug|Arbaclofen|
88939|NCT01290900|Drug|Placebo Infusion|IV Saline
88940|NCT01290900|Drug|Ceftazidime|IV Solution
88941|NCT01290900|Drug|Moxifloxacin|Tablet (1)
88942|NCT01290913|Drug|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
88943|NCT01290926|Drug|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
88944|NCT01290939|Biological|bevacizumab|
89256|NCT01284075|Behavioral|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
89257|NCT01284075|Other|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
89258|NCT01284088|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
89259|NCT00052780|Drug|O6-benzylguanine|Given IV
89260|NCT01284088|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
89261|NCT01284101|Device|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
89262|NCT01284101|Device|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
88170|NCT01299480|Biological|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
88171|NCT01299480|Biological|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
88172|NCT00053989|Drug|methylprednisolone|oral
88173|NCT01302158|Drug|ASP1941|oral
88481|NCT01287806|Drug|blank group|standard treatment
88482|NCT01287832|Drug|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
88483|NCT00053014|Radiation|radiation therapy|
88484|NCT01287832|Drug|Daptomycin|
88485|NCT01287845|Drug|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
88486|NCT01287845|Drug|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
88487|NCT01287858|Drug|AC430|Healthy volunteers will either receive AC430 or placebo.
88488|NCT01287884|Other|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
88489|NCT01287897|Drug|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
88490|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
88491|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
88492|NCT01287910|Other|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
88493|NCT01287936|Biological|SB623|SB623, a modified stem-cell product, will be administered at 3 dose levels. Each patient in one of three groups will be given a dose of 2.5, 5.0, or 10 million cells once. Each group will be completed before going to the next higher-dose group.
88494|NCT00053027|Biological|rituximab|
88495|NCT01287949|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
88496|NCT01287962|Drug|apatinib|750 mg，po，QD； 28 days every cycle
88497|NCT01287962|Drug|placebo|po，QD； 28 days every cycle
89187|NCT01286558|Drug|5 mg amlodipine|once daily
89188|NCT01286558|Drug|80 mg telmisartan|once daily
89189|NCT01286571|Drug|BI 135585|one oral single dose per subject
89190|NCT01286571|Drug|BI 135585|one oral single dose per subject
89191|NCT01286584|Drug|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
89192|NCT01286584|Drug|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
89193|NCT01286597|Dietary Supplement|dietary restriction|restrict intake of lactose
89194|NCT00052936|Drug|cyclophosphamide|
88236|NCT00053196|Biological|anti-thymocyte globulin|2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
88237|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88238|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88239|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88240|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88241|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88242|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
88243|NCT01289990|Drug|Sitagliptin 100mg|Sitagliptin once daily
88244|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
88245|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88246|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
88247|NCT00053196|Biological|G-CSF|5 ug/kg/day subQ injection Day 7 until ANC> 1000/uL for 3 consec days
88248|NCT01292070|Biological|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
88249|NCT01292083|Drug|azacitidine|Given IV
88250|NCT01292083|Other|laboratory biomarker analysis|Correlative studies
88416|NCT01290172|Drug|Administration of placebo|The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.
5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy.
88417|NCT00053196|Drug|methotrexate|5 mg/sq m/day IV infusion Days 1, 3, & 6 for HLA-identical donor transplants and Days 1, 3, 6, & 11 for MUD & 9/10 related donor transplants
88418|NCT01290185|Device|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
88419|NCT01290198|Drug|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
88420|NCT01290211|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
88421|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
88422|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
88423|NCT01290211|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
88424|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
88425|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
88426|NCT01292291|Procedure|transperineal prostate biopsy|
88427|NCT01292291|Procedure|transrectal prostate biopsy|
88428|NCT01292291|Procedure|ultrasound-guided prostate biopsy|
88429|NCT00001040|Drug|Zalcitabine|
88430|NCT00053378|Behavioral|Administration of elemental Ca during hypocalcemic ICU pts.|
88431|NCT01292304|Drug|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
88432|NCT01292317|Other|application of intravenous volume|weight based intravenous application of volume
88433|NCT01292317|Other|oral fluid application|oral fluid application
89263|NCT01284114|Drug|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
89264|NCT01284140|Behavioral|Sleep and circadian rhythm promotion|This multifaceted intervention will attempt to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. Supplemental bright lights and eyeshades and noise cancelling headphones will also be employed.
89265|NCT01284140|Behavioral|Usual care|Usual care.
89266|NCT01284166|Drug|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
89267|NCT01284179|Behavioral|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
89268|NCT01284179|Behavioral|Educational|Educational recordings regarding FCP and FGIDs.
89269|NCT01284192|Drug|ASP3026|Tablet
89270|NCT00001035|Drug|Didanosine|
89271|NCT00052780|Drug|temozolomide|Given PO
89272|NCT01286714|Device|CLIP OST|
89273|NCT01286727|Drug|BB3|intravenous drug
88317|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88318|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
88319|NCT01290003|Drug|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
88320|NCT01290016|Behavioral|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
88321|NCT01290016|Behavioral|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
88322|NCT01290016|Behavioral|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
88498|NCT01287975|Other|Occupational Therapy|Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.
Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.
Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
88499|NCT01287975|Device|BCI Haptic Knob|BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
88500|NCT01287975|Device|Haptic Knob|Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
88797|NCT01293318|Other|No intervention|No intervention
88798|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
88799|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
88800|NCT00053495|Biological|vaccinia virus (calf lymph): Dryvax|Group 5 dose: 1.0x10-8th PFU/ml
88801|NCT01293357|Drug|LEO 90105|Ointment
88802|NCT01293383|Drug|LEO 90105|Ointment
88803|NCT01293396|Drug|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
88804|NCT01293396|Drug|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
88805|NCT01293396|Drug|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
88806|NCT01293409|Other|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
88807|NCT01293422|Drug|Rifampicin|Rifampicin 600 mg daily for a week
88808|NCT01293448|Device|Cryoballoon Ablation|Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications." (K101825)
88809|NCT01293461|Drug|CBX129801|Subcutaneous injection
89827|NCT01317524|Dietary Supplement|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
89828|NCT01317524|Dietary Supplement|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
89829|NCT01317524|Dietary Supplement|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
89830|NCT00055549|Drug|Lorazepam|
89831|NCT01317537|Other|Electronic personal health record|
89832|NCT01317550|Drug|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
89833|NCT01317550|Other|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
89834|NCT01317550|Drug|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
89835|NCT01317550|Behavioral|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
89836|NCT01317563|Dietary Supplement|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
89837|NCT01317563|Dietary Supplement|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
89838|NCT01317576|Behavioral|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
89839|NCT01317589|Drug|fentanyl|T = 0
start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur
breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day
T=1
1 week
if necessary increase dose strong opioid with 50%
T=2 3 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T=3 5 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T = 4 9 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
90090|NCT01318070|Drug|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
90091|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
90092|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
90093|NCT01318083|Drug|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
90094|NCT01318096|Drug|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
89600|NCT00052845|Drug|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
89601|NCT01284738|Other|Physiopathology|Three sequential biological evaluations will be performed for each patient and will consist in :
the dosages of MP carried out by the UMR 608 in Marseille,
the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.
89602|NCT01284751|Other|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
89603|NCT01284764|Drug|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
89604|NCT01284777|Genetic|blood sample, thoracocentesis|20ml of blood only one thoracocentesis (the same that one for diagnostic)
89605|NCT01284790|Device|Cochlear implants|
89606|NCT01284803|Behavioral|an educational intervention|To elaborate an educational program for the management of depression in primary care
89607|NCT01284816|Procedure|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
89608|NCT01284829|Other|FDG-PET scan|
89609|NCT01284842|Other|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
89610|NCT01284855|Drug|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
89611|NCT00052884|Biological|filgrastim|
89612|NCT01284868|Drug|mirabegron|oral
89613|NCT01284868|Drug|Bisoprolol|oral
89614|NCT01284868|Drug|propranolol|oral
89615|NCT01284868|Drug|placebo|oral
89616|NCT01284881|Device|MRA|daily wear overnight
89617|NCT01284894|Device|Conventional manometry|Conventional esophageal manometry
89618|NCT01284894|Device|High resolution manometry|High resolution esophageal manometry
89894|NCT01315158|Drug|Propofol+Benzo/Opioids|Recommended Versed:
a. Prior to intubation
patient is < 50 kg = 1 mg Versed
patient is 50-75 kg = 1.5 mg Versed
patient is > 75 kg = 2 mg Versed
Recommended Fentanyl
Prior to intubation = 0.5 ug/kg
Total procedural dose = 1 ug/kg
89895|NCT01315171|Dietary Supplement|Medium chain triglycerides|4 tablespoons/day for 2 weeks
89391|NCT01289444|Behavioral|Healthy Living Control|Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.
3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides.
89392|NCT01289457|Drug|Clofarabine|Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.
Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle.
89393|NCT01289457|Drug|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
89394|NCT01289457|Drug|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
89395|NCT01289457|Drug|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
89396|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
89397|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
89398|NCT00053339|Drug|tamoxifen|
89399|NCT01291602|Drug|NXL104|IV Solution
89400|NCT01291602|Drug|CAZ104|IV Solution
89401|NCT01291602|Drug|Placebo|IV saline
89402|NCT01291615|Drug|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
89403|NCT01291615|Drug|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
89675|NCT01319955|Biological|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
89676|NCT01319968|Drug|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
89677|NCT01319981|Drug|Rituximab|In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
89678|NCT01319981|Drug|Imatinib|600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
90362|NCT01318538|Behavioral|group treatment for substance use disorders|This two-site clinical trial compares single-gender Women's Recovery Group (WRG) and an effective control condition, mixed-gender Group Drug Counseling (GDC). WRG is a new 12-session women-focused, manual-based relapse-prevention group therapy that uses a cognitive-behavioral approach. It is a 90-minute structured relapse prevention weekly group therapy with both women-focused content as well as an all-women group composition. The control condition, Group Drug Counseling (GDC), consists of 12 weekly 90-minute structured sessions and is conducted in a mixed-gender group composition and has no women-focused content. Both groups stress abstinence. Women are randomly assigned to one of the two conditions and the groups are conducted in a rolling group, open format at two sites, McLean Hospital in Belmont, MA and SSTAR in Fall River, MA.
90363|NCT01318551|Drug|BAY85-3934|single dose, 20 mg
90364|NCT01318551|Drug|BAY85-3934|single dose, 40 mg (optional)
90365|NCT01318551|Drug|BAY85-3934|single dose, 80 mg (optional)
90366|NCT01318564|Drug|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
90367|NCT01318564|Behavioral|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
90368|NCT01318590|Drug|Bupivacaine & Triamcinolone Acetonide|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
90369|NCT01318590|Other|No intervention except EUS procedure|EUS procedure without any drug injection
90370|NCT00055640|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
90371|NCT01318616|Other|Strength training of the hip adductors|Adductor strength training
90372|NCT01318642|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
90373|NCT01318642|Drug|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
90374|NCT01321008|Drug|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
90375|NCT01321021|Drug|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
90376|NCT01321034|Drug|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
90377|NCT01321047|Drug|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV)
90378|NCT01321047|Drug|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
90379|NCT01321060|Procedure|Aspiration|
90095|NCT01318096|Drug|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
90096|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
90097|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
90098|NCT01318109|Drug|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
90099|NCT00055601|Radiation|radiation therapy|Patients undergo pelvic radiotherapy.
90100|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
90101|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
90102|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
90103|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
90104|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
90105|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
90106|NCT01318148|Drug|caspofungin|Intermittent intravenous application of caspofungin
90107|NCT01318161|Drug|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
90108|NCT01318161|Drug|Morphine|Morphine via PCA pump
90109|NCT01318187|Drug|paracetamol|1 gr
90110|NCT00055614|Drug|topotecan hydrochloride|
90439|NCT01318642|Drug|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
90440|NCT01318655|Drug|NKTR-118|Tablet, Oral, Once daily
90441|NCT01318655|Drug|Placebo|Tablet, Oral, Once daily
90442|NCT01318668|Biological|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
89896|NCT01315184|Behavioral|Recovery Line Support System|Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.
The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback.
89897|NCT01315197|Other|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
89898|NCT01315210|Drug|D-Ribose Powder|5 g TID for 12 Weeks
89899|NCT01315210|Dietary Supplement|Placebo Powder|5 g TID for 12 Weeks
89900|NCT01315223|Other|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
89901|NCT01315236|Drug|Liposomal amikacin for inhalation (LAI)|Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.
89902|NCT00055263|Drug|DN-101|
89903|NCT01315236|Drug|placebo|Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time is the same as for Arikayce.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.
89904|NCT01315249|Drug|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
89905|NCT01315249|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
89906|NCT01315249|Drug|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
89907|NCT01315249|Drug|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
89908|NCT01317680|Device|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
89909|NCT01317693|Device|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
89910|NCT01317706|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
89911|NCT01317719|Procedure|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
89912|NCT00055575|Drug|Transderm Scopolamine|
89679|NCT01319981|Drug|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
89680|NCT00055692|Biological|bevacizumab|Given orally
89681|NCT01319981|Drug|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
89682|NCT01319981|Drug|Mesna|600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
89683|NCT01319981|Drug|VSLI|2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
89684|NCT01319981|Drug|Solu-Medrol|40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
89685|NCT01319981|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
89686|NCT01319981|Drug|Ara-C|3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
89687|NCT01322256|Procedure|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
89688|NCT01322256|Biological|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
89689|NCT01322269|Drug|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
89690|NCT00055822|Biological|oblimersen sodium|
89691|NCT01322282|Drug|Cetirizine|A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
89692|NCT01322282|Drug|Cetirizine|A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
89693|NCT01322308|Drug|pioglitazone|30 mg tablet QD (taken once daily)
89694|NCT01322308|Drug|placebo|tablet taken once a day
89695|NCT01322321|Drug|ACZ885|
89696|NCT01322321|Drug|Placebo|
89956|NCT01320397|Drug|Rostafuroxin|500 micrograms capsules
89957|NCT00055731|Drug|docetaxel|
89958|NCT01320397|Drug|Losartan|Losartan 50 mg once a day
90380|NCT00055731|Radiation|radiation therapy|
90381|NCT01321060|Procedure|Catheter drainage|
89463|NCT01287117|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
89464|NCT01287130|Drug|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
89465|NCT00052962|Procedure|Cytoreductive surgery|Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.
Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}.
89466|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
89467|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
89468|NCT01289496|Drug|Peg-interferon alpha-2a, Ribavirin|4 weeks RBV priming;
24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);
24 weeks Follow-Up
Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.
Ribavirin 200 mg tablets
89469|NCT00053131|Drug|mitoxantrone hydrochloride|
89470|NCT01289509|Drug|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
89471|NCT01289509|Drug|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
89472|NCT01289522|Biological|cetuximab IV|Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.
Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.
Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.
Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles
Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles
G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy.
89473|NCT01289522|Other|Biopsies|No intervention, only biopsy for translational project.
89474|NCT01289535|Procedure|Blood sample|Blood sample of 7 ml
89475|NCT01289548|Device|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
90443|NCT01318681|Drug|cetirizine 10 mg|cetirizine 10 mg over encapsulated
90444|NCT01318681|Drug|fluticasone furoate|nasal spray 25ug per dose
90445|NCT01318681|Drug|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
90446|NCT00055640|Genetic|microarray analysis|genetic testing
90447|NCT01318694|Drug|Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD|Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD for 24 or 48 weeks
90448|NCT01318694|Drug|Peg-IFN once weekly + Ribavirin BID + DEB025 400 mg BID|Peg-IFN once weekly + Ribavirin BID + DEB025 400 mg BID for 24 or 48 weeks
90449|NCT01318694|Drug|Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD|Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD for 48 weeks
90450|NCT01318694|Drug|PegIFN once weekly + Ribavirin + Placebo|PegIFN once weekly + Ribavirin + Placebo for 24 or 48 weeks
90451|NCT01318720|Other|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
90452|NCT01318733|Drug|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
90453|NCT01318746|Procedure|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
90454|NCT01318772|Device|Radiography and Fluoroscopy Imaging System|KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.
The system includes a new digital camera and a new image processor.
90455|NCT01318785|Other|Compression Armsleeves|Type: Compression Class II (according to RAL)
The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.
90456|NCT01318811|Drug|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
90457|NCT00055653|Biological|anti-thymocyte globulin|
89539|NCT00052962|Procedure|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.
Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m^2 and paclitaxel 125 mg/m^2.
Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}.
86238|NCT01273727|Drug|dexamethasone|intravitreal implant 0.7 mg duration 6 months
86239|NCT01273740|Procedure|External support|Bypass surgery with externally supported graft
86240|NCT01273753|Other|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
86241|NCT00051844|Drug|Capravirine|
86242|NCT01273766|Drug|deferasirox|Given orally
86243|NCT01273766|Other|laboratory biomarker analysis|Correlative studies
86244|NCT01273766|Other|enzyme-linked immunosorbent assay|Correlative studies
86544|NCT01266512|Radiation|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
86545|NCT01266512|Drug|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
86546|NCT01266525|Drug|SAR110894|Pharmaceutical form: Capsule
Route of administration: Oral
86547|NCT01266525|Drug|placebo (for SAR110894)|Pharmaceutical form: Capsule
Route of administration: Oral
86548|NCT01266525|Drug|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
86549|NCT01266551|Device|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
86550|NCT01266590|Drug|LY2216684|Administered orally
86551|NCT01266590|Drug|Digoxin|Administered orally
86552|NCT01269125|Procedure|IVF|Assisted Reproduction Technique.
86553|NCT01269138|Drug|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
86554|NCT01269138|Drug|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
86555|NCT01269138|Drug|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
86556|NCT01269138|Drug|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
86557|NCT01269138|Drug|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
89959|NCT01322880|Behavioral|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
89960|NCT01322906|Other|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
89961|NCT01322906|Other|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
89962|NCT01322906|Other|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
89963|NCT01322919|Procedure|Supracor|All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.
The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.
In addition to the treatment for the distance vision a central ablation component will be added to address the near vision.
89964|NCT01322958|Device|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
89965|NCT01322971|Drug|Metronidazole|Metronidazole 500mg orally twice daily for seven days
89966|NCT00055835|Drug|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
89967|NCT01322971|Drug|Placebo|Placebo will be administered orally twice daily for seven days
89968|NCT01322984|Behavioral|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
89969|NCT01322984|Behavioral|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
89970|NCT01322997|Device|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
89971|NCT01322997|Behavioral|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
90305|NCT01321008|Radiation|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
90306|NCT01321008|Drug|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
89476|NCT01289561|Drug|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
89477|NCT01289561|Drug|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
89478|NCT01289574|Drug|ASC-J9|Cream for twice daily topical application to the face
89759|NCT01317511|Dietary Supplement|Protein|Protein drink
89760|NCT01319981|Drug|G-CSF|10 mg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 109/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 109/L by day 21.
89761|NCT01319981|Drug|Pegfilgrastim|6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
89762|NCT01319981|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
89763|NCT01319994|Drug|Metformin|Metformin treatment
89764|NCT00055705|Biological|PV701|
89765|NCT01319994|Drug|Placebo|Placebo treament
89766|NCT01320007|Drug|Preset increase in frusemide dose|All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.
If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week.
89767|NCT01320007|Other|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
89768|NCT01320020|Drug|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
89769|NCT01320033|Drug|CD2475/101 40 mg Tablets|CD2475/101 40 mg Tablets once a day for 16 weeks
89770|NCT01320033|Drug|Doxycycline 100 mg Capsules|Doxycycline 100 mg Capsules once a day for 16 weeks
89771|NCT01320033|Drug|Placebo Tablet, and Placebo Capsule|Matching Placebo Tablet, Matching Placebo Capsule once a day for 16 weeks
89540|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg once daily (OD)
89541|NCT01287286|Dietary Supplement|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
89542|NCT01287286|Dietary Supplement|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
89543|NCT01287299|Other|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
89544|NCT01287299|Other|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
89545|NCT01287312|Procedure|Endoscopic repair of recurrent TEF by trichloroacetic acid aplications|
89546|NCT01287325|Drug|DNK333 100 mg twice daily|
89547|NCT01287325|Drug|Placebo|
89548|NCT01287338|Drug|Olopatadine|low dose
89549|NCT01287338|Drug|Olopatadine|high dose
89550|NCT00053001|Biological|epoetin alfa|
89551|NCT01287351|Drug|extra-fine hydrofluoroalkane beclometasone dipropionate|
89552|NCT01287351|Drug|Fluticasone propionate|
89553|NCT01287364|Drug|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
89554|NCT01289639|Drug|placebo|placebo 1 capsule po qd
89555|NCT01289665|Procedure|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
89556|NCT01289665|Procedure|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
89557|NCT01289678|Drug|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
89558|NCT01289691|Other|One Lung Ventilation|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
89559|NCT00053144|Drug|irinotecan hydrochloride|
86558|NCT01269151|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
86559|NCT01269164|Procedure|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
86560|NCT00051285|Drug|Enoximone|Participants receive oral enoximone
86561|NCT01269177|Device|Non invasive ventilation|Indications for the use of NIV are at least one of the following:
Respiratory Rate ≥ 30 bpm
PaO2/FiO2 < 200
pH < 7.35 and PaCO2 > 45 mmH
Contraindications for the use of NIV are at least one of the following:
Coma
Hemodynamic instability / shock
Lack of compliance
Indications for endotracheal intubation (ETI) are at least one of the following:
Respiratory or cardiac arrest
Coma
Hemodynamic instability
86562|NCT01269190|Drug|Proflavine|Swabbing of inside mouth with cotton-tip applicator soaked in 0.01% proflavine hemisulfate, a fluorescent dye which glows green in the dark, placed on proposed evaluation sites for up to 30 seconds.
86563|NCT01269190|Procedure|Imaging|Imaging of inside mouth with multi-spectral digital microscope (MDM), the Identafi 3000, or portable screening system (PS2 or PS2.1) done first prior to swab with normal white light and second post swabbing of mouth with Proflavine at high magnification with High-Resolution Microendoscope (HRME).
86860|NCT01299610|Drug|GW870086 0.2%|White to slightly colored opaque cream
86861|NCT01299610|Drug|FP 0.05%|White cream
86862|NCT01299610|Drug|Placebo|White to slightly colored opaque cream
86863|NCT01299623|Behavioral|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
86864|NCT01299636|Drug|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
86865|NCT01299662|Drug|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
86866|NCT01299701|Drug|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
86867|NCT00053989|Drug|tacrolimus|oral
86868|NCT01299727|Biological|rhHNS|Via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 4 years
86869|NCT00001044|Biological|QS-21|
86870|NCT00054132|Drug|Erlotinib Hydrochloride|Given PO
86871|NCT01302340|Drug|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
90307|NCT01321008|Drug|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
90308|NCT01321008|Drug|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
90309|NCT01323205|Drug|Antipsychotic medication|Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
90310|NCT01323218|Drug|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
90311|NCT01323231|Behavioral|XY-Zone|The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are "expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men" (Allen, 2009, p. i).
90312|NCT01323244|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
90313|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
90314|NCT01323257|Drug|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
90315|NCT01323257|Drug|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
90316|NCT01323257|Drug|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
90317|NCT01323257|Drug|TMC435|50 mg capsule once daily for 7 days (Trt F)
90318|NCT00001055|Biological|rgp120/HIV-1 SF-2|
90319|NCT00055848|Genetic|gene mapping|
90320|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
90321|NCT01323270|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
90322|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
90323|NCT01323270|Biological|Saline|0.5 mL dose, given at 0, 2 and 6 months.
89772|NCT01320046|Other|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|Patients will undergo the following evaluation:
Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.
Medical history.
Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).
Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.
Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours.
89773|NCT01320059|Drug|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
89774|NCT01320059|Procedure|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
89775|NCT00055718|Dietary Supplement|silymarin|
90029|NCT01320475|Drug|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
90030|NCT01320475|Drug|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
90031|NCT01320501|Drug|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
90032|NCT01320514|Drug|Fibrin Sealant (Artiss)|
90033|NCT01320527|Dietary Supplement|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
90034|NCT01320527|Other|Placebo|A mixture of 6 vitamins and nutriceuticals
90035|NCT01320553|Drug|1334 H 0.15%|1334H 0.15% eye drops (solution) will be administered in both eyes at 3 occasions
90036|NCT01320553|Drug|1334 H-0.3%|1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
90037|NCT01320553|Drug|1334 H-0.45%|1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
90038|NCT01320553|Drug|Placebo|Placebo eye drops (solution)will be administered in both eyes at 3 occasions
90039|NCT00055731|Drug|flutamide|
90040|NCT01320566|Device|AeriSeal System|Not applicable. Follow-Up study only.
90041|NCT01320579|Drug|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
89840|NCT01317589|Drug|methadone|T = 0
start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur
breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day
T=1
1 week
if necessary increase dose strong opioid with 50%
T=2 3 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T=3 5 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T = 4 9 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
89841|NCT00055562|Drug|CC 5013|
89842|NCT01317615|Drug|RAD001 + paclitaxel/carboplatin|
89843|NCT01317628|Behavioral|Tobacco smoke reduction trial intervention program|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
89844|NCT01317641|Drug|ODM-201|ODM-201 administered orally daily
89845|NCT01317654|Other|Observation|Collection of mortality data at 5 years post trial
89846|NCT01317667|Biological|RVEc|
89847|NCT01317680|Device|Omnispec model ED1000|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
89848|NCT01320098|Behavioral|Home-Based Parenting Program|The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.
Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.
Increasing the quality and quantity of positive interactions between you and your child
Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.
Improving your parenting skills. This program also includes between-session "homework tasks" so that you can practice the skills you have learned throughout the week.
89849|NCT01320098|Behavioral|Clinic-Based Parenting Program|The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.
The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.
Parents learn techniques and skills to promote positive interactions with their child, including:
Increasing the positive attention you give to your child.
Reducing the inappropriate use of commands, questions and criticisms.
Appropriate use of praise and physical attention (e.g., hugs) as rewards.
Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors.
89850|NCT01320098|Behavioral|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
89851|NCT01320111|Drug|Paclitaxel and Sorafenib|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
AND
pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day
86872|NCT01302353|Drug|Emulsified Isoflurane|
86873|NCT01302366|Drug|TBL12|
86874|NCT01302379|Drug|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
86875|NCT01302379|Drug|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
86876|NCT01302379|Behavioral|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
86877|NCT01302379|Behavioral|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
86878|NCT01302392|Drug|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days [Days 1, 2, 8, 9, 15, 16] for individual subjects).
86879|NCT01302392|Drug|Best Supportive Care|Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).
Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).
89934|NCT01320228|Dietary Supplement|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
89935|NCT00055731|Drug|buserelin|
89936|NCT01320241|Device|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
89937|NCT01320241|Device|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
89938|NCT01320254|Drug|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
89939|NCT01320254|Drug|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
89940|NCT01320267|Procedure|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
89941|NCT01320280|Drug|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
89942|NCT01320293|Drug|Adalimumab|40mg subcutaneously, every other week for 6 months
89943|NCT01320319|Other|Placebo|Capsule form, 960 mg to be taken three times a day.
89944|NCT01320319|Dietary Supplement|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
89404|NCT01291628|Device|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
89405|NCT01291641|Drug|HMGCoA reductase inhibitor|During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.
Dosage regimen: following the package insert of each HMGCoA reductase inhibitor
89406|NCT01291641|Drug|HMGCoA reductase inhibitor + probucol|In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.
Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)
89407|NCT01291641|Drug|HMGCA reductase inhibitor + probucol + cilostazol|In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.
Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route
89408|NCT01291654|Drug|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
89409|NCT00053339|Drug|trastuzumab|
89410|NCT01291654|Drug|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
89411|NCT01291654|Drug|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
89412|NCT01291693|Behavioral|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
89413|NCT01291693|Behavioral|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
89414|NCT01291706|Device|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
89415|NCT01291719|Device|glucose and insulin infusions|combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
89416|NCT01291732|Drug|Matching placebo|single dose of matching placebo
89417|NCT01291732|Drug|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
89418|NCT01284335|Drug|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
89419|NCT00052780|Other|pharmacological study|Correlative studies
90042|NCT00055835|Procedure|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
90043|NCT01323036|Dietary Supplement|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
90044|NCT01323049|Procedure|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
90045|NCT01323049|Procedure|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
90046|NCT01323062|Drug|Bavituximab|Administered 3 mg/kg weekly
90047|NCT01323075|Procedure|Truncal block|Patients will have a truncal block during hand or wrist surgery.
90048|NCT01323088|Other|Control|Standard care control (no exercise)
90049|NCT01323088|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
90050|NCT01323088|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
90382|NCT01321060|Drug|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
90383|NCT01321073|Device|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
90384|NCT01321086|Behavioral|Motivational Interviewing|9 sessions of MI from baseline to six months
90385|NCT01321086|Behavioral|PACE|9 sessions of PACE delivered from baseline to six months
90386|NCT01321099|Other|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
90387|NCT01321099|Other|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
90388|NCT01321099|Other|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
90389|NCT01321112|Drug|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
89852|NCT01320111|Drug|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
90111|NCT01320579|Drug|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
90112|NCT01320579|Drug|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
90113|NCT01320579|Drug|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
90114|NCT01320592|Drug|PD0332991|
90115|NCT01320592|Drug|Paclitaxel|
90116|NCT01320605|Biological|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
90117|NCT01320657|Device|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.
Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks.
90118|NCT01320683|Drug|oxaliplatin|Given IV
90119|NCT00001054|Drug|Valacyclovir hydrochloride|
90120|NCT00055731|Drug|goserelin acetate|
90121|NCT01320683|Drug|leucovorin calcium|Given IV
90122|NCT01320683|Drug|fluorouracil|Given IV
90123|NCT01320683|Biological|bevacizumab|Given IV
90124|NCT01320683|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
90125|NCT01320683|Other|laboratory biomarker analysis|Correlative studies
90126|NCT01320683|Other|pharmacological study|Correlative studies
90127|NCT01320683|Drug|irinotecan hydrochloride|Given IV
90128|NCT01320696|Biological|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
89945|NCT01320332|Drug|ASP3291|Oral tablets
89946|NCT00055731|Drug|cyproterone acetate|
89947|NCT01320332|Drug|Placebo|Oral tablets
89948|NCT01320345|Drug|Fenofibrate|Oral Fenofibrate 145mg given once daily for 12 months.
89949|NCT01320345|Drug|Inert lactose placebo|Oral matching inert lactose placebo given once daily for 12 months.
89950|NCT01320358|Drug|ECMPS-IEM|ECMPS-IEM
89951|NCT01320384|Other|O2 conventional|standard low flow therapy
89952|NCT01320384|Device|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
89953|NCT01320384|Device|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
89954|NCT01320397|Drug|Rostafuroxin|6 microgram capsules
89955|NCT01320397|Drug|Rostafuroxin|50 micrograms capsules
90203|NCT01320761|Drug|ATX-101-BA|ATX-101-BA
90204|NCT01320774|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
90205|NCT01320787|Drug|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
90206|NCT01320800|Behavioral|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
90207|NCT01320800|Behavioral|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
90208|NCT01320813|Procedure|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
90209|NCT01320813|Procedure|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
90210|NCT01320826|Procedure|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
89697|NCT01322334|Behavioral|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
89698|NCT01322347|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
89699|NCT01322347|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
89700|NCT01322360|Drug|Morphine Sulfate|
89701|NCT00000253|Drug|20% N2O|
89702|NCT00001055|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
89703|NCT00055822|Drug|fluorouracil|
89704|NCT01322386|Drug|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
89705|NCT01322399|Procedure|Structural Integration|Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as "the Ten Series," each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement.
89706|NCT01322399|Procedure|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
89707|NCT01322438|Drug|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
89708|NCT01322451|Drug|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
89709|NCT01322451|Drug|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
89710|NCT01322464|Drug|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
89711|NCT01314833|Drug|Epirubicin Cyclophosphamide Paclitaxel|1st -4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1
1 cycle = 21 days 5th-8th Cycle: Paclitaxel 80mg/m² D1，8，15
1 cycle = 21 days EC*4-P*4
89712|NCT01314859|Drug|Nifedipine|Oral Treatment with Nifedipine capsules (10mg)
Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).
Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.
Maximum Duration of the treatment: 48 hours.
90390|NCT01321125|Biological|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
90391|NCT00055757|Drug|tipifarnib|Given orally
90392|NCT01321125|Other|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
90393|NCT01323452|Drug|Entecavir|once daily
90394|NCT01323465|Drug|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
90395|NCT01323465|Drug|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
90396|NCT01323465|Drug|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
90397|NCT01323465|Drug|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
89479|NCT01289587|Behavioral|Physical activity intervention|36 sessions of physical activity offered at different frequencies
89480|NCT00053144|Drug|cytarabine|
89481|NCT01289600|Device|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
89482|NCT01289626|Drug|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
89483|NCT01289626|Drug|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
89484|NCT01289639|Drug|fenofibrate|micronized fenofibrate 200 mg 1 po qd
89485|NCT01289639|Drug|pioglitazone|pioglitazone 30 mg po qd
90129|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
90130|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
90131|NCT00055731|Drug|leuprolide acetate|
90458|NCT01318811|Drug|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
90459|NCT01318824|Procedure|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
90460|NCT01318824|Procedure|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
90461|NCT01321125|Biological|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
90462|NCT01321138|Procedure|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
90463|NCT01321138|Procedure|PCA morphine|Postoperative analgesia with self-administration iv morphine
90464|NCT01321151|Dietary Supplement|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
90465|NCT01321151|Dietary Supplement|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
90466|NCT01321164|Device|Full Body UV Therapy System UV 7002 plus fumaric acid esters|Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.
Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months
90467|NCT01321164|Drug|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
90468|NCT01321177|Behavioral|Integrated Treatment|Integrated program of treatments and services delivered by a coordinated team of providers that includes:
education about schizophrenia and its treatment for the participants and their family members
medication for symptoms and preventing relapse that uses a computerized decision support system
strategies for managing the illness and building personal resilience
help getting back to school or work using a supported employment/education model
90469|NCT01321177|Behavioral|Community Care|Standard mental health treatments and services offered at the local agency that may include :
medication for symptoms and preventing relapse
psychosocial therapy which may include a range of behavioral treatments and supportive services
Case management
90211|NCT01320852|Other|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
90212|NCT01320878|Drug|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
90213|NCT00055731|Drug|triptorelin|
90214|NCT01320878|Drug|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
90215|NCT01320878|Drug|distilled water|distilled water 2 ml per session
90216|NCT01320891|Behavioral|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
90217|NCT01323569|Drug|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
90218|NCT01323569|Drug|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
90219|NCT01323582|Drug|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
90220|NCT01323582|Drug|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
90221|NCT01323595|Drug|Celecoxib|Celecoxib 200mg PO BID x 6 days
90551|NCT01321359|Drug|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
90552|NCT01321385|Other|laboratory biomarker analysis|
90553|NCT01321385|Other|study of socioeconomic and demographic variables|
90554|NCT01321398|Other|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
89713|NCT01314859|Drug|Atosiban|Intravenously Treatment with Atosiban (7.5mg/ml)
Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.
Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.
Maximum Duration of the treatment: 48 hours.
89714|NCT01314872|Drug|MK-4618 low-dose|One low-dose tablet taken orally each morning, for 8 weeks.
89972|NCT01322997|Device|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
89973|NCT01323010|Drug|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
89974|NCT01323010|Drug|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg)
89975|NCT01323023|Behavioral|varies by project|
89976|NCT01323036|Dietary Supplement|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
89977|NCT01315262|Drug|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
89978|NCT01315275|Drug|Ranibizumab|
89979|NCT01315288|Other|One of 6 video presentation by one of 4 presenters|
89980|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
89981|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
89982|NCT00055302|Drug|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
89983|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
89984|NCT01315314|Drug|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
89985|NCT01315327|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
89986|NCT01315327|Drug|Olive oil|Placebo
89987|NCT01315340|Procedure|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
89486|NCT01291771|Procedure|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
89487|NCT01291784|Biological|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
89488|NCT00053352|Procedure|conventional surgery|
89489|NCT01291810|Biological|TNF Kinoid|TNF Kinoid
89490|NCT01291810|Biological|WFI|WFI
89491|NCT01291823|Drug|gefitinib|gefitinib 250mg/day
89492|NCT01291823|Radiation|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
89493|NCT01291849|Drug|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml−1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
89494|NCT01291862|Device|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
89495|NCT01291875|Procedure|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
89776|NCT01320085|Drug|MEK162|
89777|NCT01322464|Drug|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
89778|NCT01322464|Drug|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
89779|NCT01322464|Drug|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
89780|NCT00055822|Drug|leucovorin calcium|
89781|NCT01322477|Other|F18-FDG PET/CT|
90470|NCT00055757|Drug|cisplatin|Given IV
90471|NCT01321255|Drug|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
90472|NCT01321255|Drug|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
90473|NCT01321268|Dietary Supplement|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
89560|NCT01289691|Other|One Lung Ventilation|Patients in this group will be ventilated with only oxygen during one lung ventilation.
89561|NCT01289704|Other|TreSPE|treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.
Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.
Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.
Proprioceptive and postural kinesitherapy according to the Perfetti method.
Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls.
89562|NCT01289704|Other|SPE|Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.
Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.
Proprioceptive and postural kinesitherapy according to the neurocognitive method.
Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls.
89563|NCT01289730|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
89564|NCT01289743|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
89565|NCT01289756|Drug|Clomiphene|clomiphene once 100 mg oral
89566|NCT01289756|Drug|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
89567|NCT01289756|Drug|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
89568|NCT01289769|Drug|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
89569|NCT01289769|Drug|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
89570|NCT00001039|Drug|Ethambutol hydrochloride|
89571|NCT00053157|Biological|sargramostim|
89572|NCT01289782|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
89573|NCT01289782|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
90555|NCT01321411|Other|Near Infrared Spectroscopy|Healthy Volunteers:
Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.
Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.
90556|NCT01321411|Other|Near Infrared Spectroscopy|Clinical Volunteers:
Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.
Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.
90557|NCT01321437|Drug|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
Eighteen patients will be entered into the first stage of a 2-stage Simon Minimax design. If there is ≥ 1 response, 14 additional patients will be entered. Up to 28 additional patients (for a total of up to 60) may be treated in order to gain additional safety and activity information should the initial 2-stage trial be positive at the end of Stage 2. Multiple centers will be used to accrue patients in a 12-month period.
90558|NCT01321463|Drug|PH-797804|6 mg oral tablet once daily for 12 weeks
90559|NCT00001055|Biological|ALVAC-HIV MN120TMG (vCP205)|
90560|NCT00055757|Other|laboratory biomarker analysis|Correlative studies
90561|NCT01321463|Drug|Placebo|Placebo oral tablet once daily for 12 weeks
90562|NCT01321489|Drug|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
90563|NCT00054977|Drug|5-fluorouracil|IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
90564|NCT01313767|Drug|Botulinum Toxin type A|Botulinum Toxin type A
90565|NCT01313780|Drug|oxycodone and naloxone|Trade name is TARGIN. Oxycodone (10mg)/naloxone(5mg) or Oxycodone(20mg)/naloxone(10mg) tablets provided in 56-tablet box. Twice daily per oral
90566|NCT01313793|Drug|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
89638|NCT01287416|Behavioral|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
89639|NCT01287416|Behavioral|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
89640|NCT01287429|Other|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
89988|NCT01315353|Procedure|cervical cryotherapy|Participants will undergo cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
89989|NCT01315353|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Participants found to have CIN2+ by biopsy at any point during the study will be offered LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
89990|NCT01315366|Dietary Supplement|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
90324|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
90325|NCT01323283|Dietary Supplement|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
90326|NCT01323283|Dietary Supplement|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
90327|NCT01323296|Other|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
90328|NCT01323569|Drug|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
90329|NCT01323569|Drug|Placebo|16 placebo sprays and 4 placebo capsules
90330|NCT01316029|Procedure|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
90331|NCT01316042|Drug|sugar pill|2 pills per day for 12 months
90332|NCT01316042|Drug|Metformin, glucophage|2 212.5mg pills/day for 12 months
90333|NCT01316055|Drug|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
90334|NCT01316068|Drug|intravenous use of sulodexide followed by oral use|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
90335|NCT01316068|Drug|use of sulodexide orally only|Patients receive 1000 LSU per day orally for 52 weeks
90336|NCT00055367|Drug|Natalizumab|
90337|NCT01316081|Dietary Supplement|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg
Placebo Supplements: identical appearing tablets
90338|NCT01316094|Drug|ASP1941|oral
90339|NCT01316094|Drug|placebo|oral
89782|NCT01322490|Biological|PROSTVAC-V|
89783|NCT01322490|Biological|PROSTVAC-F|
89784|NCT01322490|Drug|GM-CSF|
89785|NCT01322490|Other|GM-CSF Placebo|
89786|NCT01322490|Biological|Placebo|PROSTVAC V/F Placebo
89787|NCT01322503|Biological|Norovirus|Norovirus challenge pool administered to each subject
89788|NCT01322542|Drug|YF476|
89789|NCT01322594|Biological|MEDI2338|MEDI2338 single intravenous (IV) dose (lowest dose)
89790|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
89791|NCT00055822|Drug|oxaliplatin|
89792|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
89793|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
89794|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (highest dose)
89795|NCT01322594|Other|Placebo|Placebo single IV dose
89796|NCT01322607|Behavioral|High-intensity Treadmill Exercise|High-intensity treadmill walking program
89797|NCT01322607|Behavioral|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
89798|NCT01322620|Other|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
89799|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
89800|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
89801|NCT01322646|Device|CarChipPro|On board driving monitor
90051|NCT01323101|Drug|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
90052|NCT01323114|Procedure|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
89574|NCT01289782|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
89575|NCT01291927|Procedure|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
89853|NCT01320137|Procedure|Blood withdrawal|Blood sampling
89854|NCT01320163|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
89855|NCT01320163|Device|Laryngeal Mask Airway|supra-glottic airway device
89856|NCT01320176|Biological|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
89857|NCT00055731|Drug|bicalutamide|
89858|NCT01320176|Biological|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
89859|NCT01320189|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
89860|NCT01320202|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
89861|NCT01320202|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
89862|NCT01320215|Procedure|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
89863|NCT01320215|Procedure|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
89864|NCT01320228|Dietary Supplement|Control|Alli treatment plus placebo (rice flour)
89865|NCT01320228|Dietary Supplement|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
89866|NCT01322659|Device|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
89867|NCT01322698|Biological|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
89641|NCT00001037|Biological|gp160 Vaccine (Immuno-AG)|
89642|NCT00053014|Biological|therapeutic allogeneic lymphocytes|
89643|NCT01287442|Procedure|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
89644|NCT01289782|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
89645|NCT01289808|Drug|Glucose 25%|1ml of glucose 25% once
89646|NCT01289808|Drug|Glucose 25%|1ml glucose once per os
89647|NCT01289821|Drug|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
89648|NCT01289821|Drug|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m² oxaliplatin as a 2 hour i.v. infusion.
89649|NCT01289821|Drug|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m² D/L-folinic acid or 200 mg/m² L-folinic acid) as a 2 hour i.v. infusion.
89650|NCT01289821|Drug|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m² 5 FU i.v. bolus injection immediately followed by a 2400 mg/m² 5 FU 46 hour i.v. infusion.
89651|NCT00053183|Procedure|conventional surgery|
89652|NCT01289834|Device|Hi-Fatigue Bone Cement|Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH & Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement" Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement.
89653|NCT01289834|Device|Palacos Bone Cement|Palacos Bone Cement has been used for 48 years and has a good reputation as the "gold standard" among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing
89654|NCT01289847|Biological|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
90222|NCT00055874|Biological|recombinant interferon alfa|
90223|NCT01323595|Drug|Sugar Pill|Sugar pill PO BID x 6 days
90224|NCT01323608|Drug|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
90225|NCT01323608|Drug|Placebo|Placebo
90340|NCT01316107|Drug|ASP1941|oral
90341|NCT01316107|Drug|nateglinide|oral
90342|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
89420|NCT01284335|Drug|LY573636|Individualized dose is dependent on patients height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met.
89421|NCT01284348|Drug|ACE-011 - 15 mg|15 mg subcutaneous injection every 42 days, up to 4 doses/cycles
89422|NCT01284348|Drug|ACE-011 - 30 mg|30 mg subcutaneous injection every 42 days, up to 4 doses/cycles
89423|NCT01284348|Drug|ACE-011 - 45 mg|45 mg subcutaneous injection every 42 days, up to 4 doses/cycles
89424|NCT01284361|Device|test and control intermittent urinary catheters|randomized cross-over
89425|NCT01284387|Biological|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
89426|NCT01284400|Other|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
89427|NCT01284413|Drug|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
89428|NCT01284439|Drug|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
89429|NCT01284439|Drug|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
89430|NCT00052780|Other|laboratory biomarker analysis|Correlative studies
89431|NCT01284452|Drug|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
89432|NCT01284452|Drug|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
89433|NCT01284465|Behavioral|Education and patient liaison combination|Group education sessions with Patient liaison using ecological momentary assessment principles
89434|NCT01284465|Behavioral|Control group|Group education sessions at baseline, 3 and 6 months
89435|NCT01284478|Drug|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
90053|NCT00055835|Radiation|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
90054|NCT01323114|Other|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
90055|NCT01323127|Procedure|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
90056|NCT01323140|Drug|testosterone matrix transdermal system|
90057|NCT01323153|Drug|dalcetrapib|Oral doses of 600 mg once daily for 20 weeks
90058|NCT01323153|Drug|placebo|Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
90059|NCT01323166|Procedure|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
90060|NCT01323192|Drug|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
90061|NCT01323192|Drug|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
90062|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
90063|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
90064|NCT00055848|Genetic|cytogenetic analysis|
90065|NCT01323205|Drug|Placebo|Placebo capsule (s) orally twice daily with a meal for 4 weeks.
90066|NCT01315418|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
90067|NCT01315418|Other|2-Non fermented dairy product (control)|
90068|NCT01315431|Drug|Tesetaxel plus capecitabine|Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.
At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol.
90069|NCT01315444|Drug|Stop PPI gradually|
90070|NCT01315444|Drug|Stop PPI gradually|
89868|NCT01322711|Drug|Atorvastatin|Atorvastatin 40 mg day
89869|NCT01322711|Drug|Placebo|Diet
89870|NCT01322724|Procedure|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
89871|NCT01322737|Procedure|Tissue Access and Resection System|This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
89872|NCT00055835|Drug|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
89873|NCT01322776|Drug|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m^2 i.v. on days 1~3 of each 28-day cycle cyclophosphamide i.v. on days 1~2 of each 28-day cycle
90132|NCT01320709|Drug|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
90133|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
90134|NCT01320722|Drug|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
90135|NCT01323309|Behavioral|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
90136|NCT01323309|Behavioral|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
90137|NCT00055848|Genetic|microarray analysis|
90138|NCT01323309|Behavioral|enhanced usual care (EUC)|We are therefore including what we refer to as an "enhanced" usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals.
90139|NCT01323335|Drug|IV Uric Acid|
90140|NCT01323335|Drug|IV Rasburicase|
90226|NCT01323621|Drug|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
90227|NCT01323621|Drug|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
90228|NCT01323621|Drug|Double-dummy placebo|inhalation powder
90229|NCT01323621|Drug|Salbutamol as needed|inhalation powder
90230|NCT01323634|Drug|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
90231|NCT01323634|Drug|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
90232|NCT01323647|Biological|PoliorixTM|Single dose, intramuscular administration
90233|NCT00055874|Drug|cytarabine|
90234|NCT01323647|Biological|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
90235|NCT01323660|Drug|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
90236|NCT01323660|Drug|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
90237|NCT01323660|Drug|GSK573719 125|125mcg QID
90238|NCT01323660|Drug|GSK573719 62.5|62.5mcg QID
90239|NCT01323660|Drug|GW642444 25|25mcg QID
90240|NCT01323660|Device|placebo|Comparator QID
90241|NCT01323673|Drug|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
90242|NCT01323673|Drug|Vehicle / Placebo|2 times a day, 14 total days of study treatment
90243|NCT01315847|Drug|[11C]MK-4232|Single intravenous doses of ~300 MBq [11C]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
90244|NCT01315860|Other|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
90245|NCT01315873|Drug|Bendamustine|On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m^2 after bortezomib . Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.
Patients will be treated until disease progression after at least one cycle of treatment.
90264|NCT01318317|Drug|plerixafor|Given IV
89436|NCT01284491|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
89437|NCT01284491|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
89438|NCT01284504|Drug|Celecoxib|200 mg tablet oral
89439|NCT01284517|Drug|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
89440|NCT01284517|Drug|Placebo|Equivalent to Lurasidone dosing
89441|NCT00052832|Dietary Supplement|doxercalciferol|
89715|NCT01314872|Drug|MK-4618 mid-low dose|One mid-low dose tablet taken orally each morning, for 8 weeks.
89716|NCT01314872|Drug|MK-4618 mid-high dose|One mid-high dose tablet taken orally each morning, for up to 60 weeks.
89717|NCT00001049|Drug|Zidovudine|
89718|NCT00055198|Drug|daptomycin|
89719|NCT01314872|Drug|tolterodine ER|One 4 mg capsule taken orally each morning, for up to 60 weeks.
89720|NCT01314872|Drug|Placebo for MK-4618|One or two tablets taken orally each morning for dose-duration of matched drug.
89721|NCT01314872|Drug|Placebo for tolterodine ER|One capsule taken orally each morning for dose-duration of matched drug.
89722|NCT01314872|Drug|MK-4618 high dose|Two tablets taken orally each morning, for up to 60 weeks.
89723|NCT01314885|Drug|PF-03715455|20mg, Inhaled, single dose
89724|NCT01314885|Drug|PH-797804|30mg, Oral, single dose
89725|NCT01314885|Drug|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
89726|NCT01314885|Drug|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
89727|NCT01314898|Drug|3 mg PF-03882845|3 mg PF-03882845, single oral dose
89728|NCT01314898|Drug|10 mg PF-03882845|10 mg PF-03882845, single oral dose
89729|NCT00055237|Biological|Bevacizumab|15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
89730|NCT01314898|Drug|30 mg PF-03882845|30 mg PF-03882845, single oral dose
90398|NCT01323465|Drug|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
90399|NCT00055861|Drug|docetaxel|Given IV
90400|NCT01323465|Drug|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
90401|NCT01323478|Drug|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
90402|NCT01323491|Drug|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
90403|NCT01323504|Other|Music|Patient are listen music during their local care
90404|NCT01323504|Other|no music|There are no music during the local care
90405|NCT01323517|Drug|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
90406|NCT01323530|Drug|Eribulin mesylate administration as a 2 to 5 min IV infusion at on Day 1|Oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles). If MTD is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m2 bid on Days 1-14(21-day cycles) depending on the toxicities observed and/or PK data when available. Eribulin as a 2 to 5 minute IV bolus or infusion in two different schedules and at three different dose levels.
90407|NCT01323530|Drug|Eribulin mesylate administration as a 2 to 5 min IV infusion on Day 1 and Day 8|Oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles). If MTD is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m2 bid on Days 1-14(21-day cycles) depending on the toxicities observed and/or PK data when available. Eribulin as a 2 to 5 minute IV bolus or infusion in two different schedules and at three different dose levels.
90408|NCT01323543|Device|Elaspine™|Implantation of device
90409|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
90410|NCT00055861|Other|laboratory biomarker analysis|Correlative studies
90411|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
90412|NCT01323569|Drug|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
90413|NCT01323569|Drug|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
90414|NCT01316237|Drug|GS-6620|GS-6620 tablet, 50 mg QD
90141|NCT01323348|Behavioral|Diabetes Education|The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):
Measurement of HbA1c in office with immediate feedback
Measurement of blood pressure with immediate feedback
Assessment of retinopathy risk with immediate feedback
Personalized risk assessment reports based on current HbA1c
Brief assessment of patient understanding of key issues with immediate feedback
Supplemental diabetes management educational materials (provided at baseline only)
Feedback to primary care provider
Email reminder to study participants with email access of individualized risk assessment findings
90142|NCT01323361|Procedure|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
90143|NCT01323374|Drug|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
90144|NCT01323374|Drug|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
90145|NCT01323374|Drug|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
90146|NCT01323374|Drug|Placebo|Oral, placebo TID
90147|NCT01323387|Device|Interbody Fusion|allograft spacer + anterior plate
90474|NCT01321268|Dietary Supplement|Viatmin E|oral, twice daily in morning and evening for 6 months
90475|NCT01321281|Dietary Supplement|AquaCal|AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.
The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
90476|NCT01321281|Dietary Supplement|AquaPT|AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.
The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
90477|NCT01321294|Procedure|laparoscopic anti-reflux surgery|
90478|NCT01321320|Other|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
90479|NCT01321333|Biological|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
90480|NCT01323686|Other|Imaging guided optimal LV lead placement|LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.
Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate <30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used.
90481|NCT00055874|Drug|hydroxyurea|
90482|NCT01323699|Behavioral|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
90483|NCT01323712|Dietary Supplement|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
90265|NCT01318317|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
90266|NCT01318330|Drug|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
90267|NCT01318356|Behavioral|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
90268|NCT01318356|Drug|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
90269|NCT01318356|Drug|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
90270|NCT00055640|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
90271|NCT01318369|Drug|Namisol|Single dose delta-9-tetrahydrocannabinol
90272|NCT01318369|Drug|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
90273|NCT01318382|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
90274|NCT01318395|Drug|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
90275|NCT01318395|Drug|Placebo|orally once per day
90276|NCT01318408|Drug|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
90277|NCT01318421|Drug|ELND002|
90278|NCT01318434|Drug|EB-1010 25mg BID|capsule once daily
90279|NCT01318434|Drug|SSRI Active|Active Comparator
90280|NCT01318434|Drug|EB-1010 50mg BID|Experimental Active
90281|NCT00055640|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
90282|NCT01318434|Drug|Placebo|Placebo comparator
90283|NCT01318447|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
89731|NCT01314898|Drug|100 mg PF-03882845|100 mg PF-03882845, single oral dose
89732|NCT01314898|Drug|Spironolactone|100 mg spironolactone, single oral dose
89733|NCT01314911|Drug|Oseltamivir|One capsule twice daily of 75 mg oseltamivir; total dose: 150 mg/day for 5 days
89734|NCT01314911|Drug|Oseltamivir Placebo|One capsule twice daily of oseltamivir placebo; total dose: 2 placebo capsules/day for 5 days
89735|NCT01314924|Dietary Supplement|Dark chocolate|70% cocoa
89736|NCT01314937|Drug|Mebendazole|Single-dose 500 mg mebendazole tablet
89737|NCT01314937|Other|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
89738|NCT01317303|Procedure|iTBS|190 seconds of intermittent theta-burst stimulation
89739|NCT01317329|Other|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
89991|NCT01315366|Dietary Supplement|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
89992|NCT01315379|Behavioral|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
89993|NCT00055315|Behavioral|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|
89994|NCT01315392|Procedure|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
89995|NCT01315392|Procedure|immediate wound closure|traumatic and surgical wounds closed at the initial surgical intervention
89996|NCT01315405|Behavioral|Emotional facial expression recognition tests|20 patients with an Idiopathic Parkinson's disease
+ 20 paired healthy volunteers (on sex, age, and education)
After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)
Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)
89997|NCT01317849|Drug|placebo|10mg
89998|NCT00055601|Drug|cisplatin|Given IV
89999|NCT01317849|Drug|placebo|500ug
90000|NCT01317862|Device|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
90415|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD
90416|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD
89496|NCT01291875|Procedure|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
89497|NCT01291901|Biological|NP2|NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
89498|NCT01291901|Biological|Placebo|The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
89499|NCT00053352|Drug|cisplatin|Given IV
89500|NCT01291914|Drug|FX005|Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
89501|NCT01291914|Drug|Placebo 1 (Carrier)|Single intra-articular injection
89502|NCT01291914|Drug|Placebo 2 (Diluent)|Single intra-articular injection
89503|NCT01284543|Device|Busin Glide for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye
89504|NCT01284556|Drug|Phenobarbital|tablet
89505|NCT01284556|Drug|Placebo tablet|tablet
89506|NCT01284569|Biological|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
89507|NCT01284569|Biological|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
89508|NCT01284582|Biological|ATH03|4 vaccinations
89509|NCT01284595|Drug|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
89510|NCT01284621|Drug|BI 10773|medium dose, oral administration
89511|NCT00052845|Drug|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
89512|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
89513|NCT01284621|Drug|BI 10773|medium dose oral administration
90484|NCT01323725|Behavioral|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
90485|NCT01323738|Behavioral|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
90486|NCT01323751|Drug|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
90487|NCT01323764|Device|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
90488|NCT01323790|Drug|NKTR-118|12.5 mg oral tablet once daily
90489|NCT01323790|Drug|NKTR-118|25 mg oral tablet once daily
90490|NCT01323790|Drug|Placebo|Placebo to NKTR-118
90491|NCT01323816|Other|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
90492|NCT00055874|Drug|imatinib mesylate|
90493|NCT01323829|Other|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
90494|NCT01323842|Procedure|EDTU|bedside ultrasound imaging by the treating emergency physician
89576|NCT01291927|Procedure|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
89577|NCT01291940|Other|Pediatric Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
89578|NCT01291940|Other|Adult Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
89579|NCT01291953|Procedure|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
89580|NCT01291953|Procedure|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
89581|NCT01291966|Behavioral|Motivational interview|
89582|NCT00053352|Drug|etoposide|Given IV
89583|NCT01291979|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
89584|NCT01291979|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
90284|NCT01318460|Drug|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
90567|NCT01313793|Drug|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
90568|NCT01313806|Device|Resonator|Treatment group vs. Placebo group
90569|NCT01313806|Device|Placebo|Inactive Resonator Device
90570|NCT01313819|Drug|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
90571|NCT01313832|Other|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
90572|NCT01313845|Drug|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
90573|NCT01313845|Drug|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
90574|NCT00055042|Drug|Vitamin E|
90575|NCT01313858|Drug|Simponi®|50 mg subcutaneous injection once monthly
90576|NCT01313884|Drug|Irinotecan|50 mg/m2/day x 5 days
90577|NCT01313884|Drug|Vincristine|2 mg/m2 (capped at 2mg total do)
90578|NCT01313884|Drug|Temozolomide|100 mg/m2/day x 5 days
90579|NCT01313884|Drug|Doxorubicin|75 mg/m2
90580|NCT01313884|Drug|Cytoxan|1200 mg/m2
90581|NCT01313884|Drug|Pegfilgrastim|6 mg
90582|NCT01313884|Drug|Mesna|240 mg/m2 in 50 ml NS
90583|NCT01313897|Drug|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
90584|NCT01313910|Dietary Supplement|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
90585|NCT00055068|Behavioral|Cognitive Behavioral Therapy (CBT)|
90001|NCT01317875|Drug|Ruxolitinib|Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)
Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count
90002|NCT01317888|Drug|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
90003|NCT01317901|Drug|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
90004|NCT01317901|Drug|bendamustine + rituximab|Rituximab by IV administration at 375 mg/m^2 on Day 2, and bendamustine by IV on Days 1 and 2 of each 28 day cycle.
90005|NCT01317914|Other|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
90006|NCT01317927|Drug|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
90007|NCT01317940|Dietary Supplement|Vitamin D and Calcium Citrate|Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)
Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months
90008|NCT01317953|Dietary Supplement|epigallocatechin gallate|Starting dose green tea catechin extract "EGCG" 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),
90343|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
90344|NCT01316133|Drug|tacrolimus|oral
90345|NCT01316146|Drug|CAR.CD30 T cells|Three dose levels will be evaluated:
Group One, 2x10^7 cells/m^2
Group Two, 1x10^8 cells/m^2
Group Three, 2x10^8 cells/m^2;
Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc.
90346|NCT01316172|Behavioral|5 Cs|education on consultation
90347|NCT00055380|Procedure|Oral cytobrushing|
90348|NCT01316185|Drug|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
90349|NCT01316198|Dietary Supplement|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
90350|NCT01316198|Dietary Supplement|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
89514|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
89515|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
89516|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
89517|NCT01284634|Drug|Cannabidiol|1 x 100 mg CBD/placebo twice daily (200 mg daily)
89802|NCT00055835|Drug|carboplatin|*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
89803|NCT01322646|Behavioral|Driver's Education|10 Session License to Learn Program.
89804|NCT01322646|Behavioral|STEER Program|8-session behavioral parent training and teen social skills/communication training program
89805|NCT01322646|Other|Driving Simulator Practice|Practice Driving on a driving simulator
89806|NCT01322659|Device|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
89807|NCT01314950|Behavioral|Home based occupational therapy|An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with "homework" each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs.
89808|NCT01314950|Behavioral|Best practices primary care|Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
89809|NCT00055250|Drug|Gemcitabine|
89810|NCT01314963|Device|Handheld Gamma Camera|Hand-held, portable, intraoperative gamma camera
89811|NCT01314976|Drug|Metronidazole|Metronidazole, oral suspension, 40mg/ml.
1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents.
89812|NCT01314976|Drug|Placebo|Placebo.
1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.
Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis.
89813|NCT01314989|Drug|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
89814|NCT01314989|Drug|Sugar pill|liquid placebo
89585|NCT01292005|Drug|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
89586|NCT01292005|Drug|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
89587|NCT01292031|Drug|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
89588|NCT01292031|Drug|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
89589|NCT01292044|Other|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
89590|NCT01292057|Drug|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
89591|NCT01292057|Drug|Placebo|Placebo to match active drug Aripiprazole for 8 days
89592|NCT01292070|Biological|Intradermal Human Fcγ1-Fel d1 fusion protein|Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.
Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.
89593|NCT00053352|Biological|bleomycin sulfate|Given IV
89594|NCT01292070|Biological|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
89595|NCT01292070|Biological|Positive Control - Histamine Prick|1.0 mg/mL
89874|NCT01322789|Biological|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
89875|NCT01322802|Biological|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
89876|NCT01322802|Other|laboratory biomarker analysis|Correlative studies
89877|NCT01322815|Drug|chemotherapy and GI-4000|Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks
89878|NCT01322815|Drug|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
89879|NCT01322828|Procedure|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
89880|NCT01322841|Other|CHICA Screening Module|The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia
89881|NCT01322841|Other|CHICA Screening Control|This was CHICA without the screening module
90586|NCT01313923|Drug|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
90587|NCT01316510|Dietary Supplement|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
90588|NCT01316510|Other|Placebo|Dilute Nutramigen formula
89655|NCT01289860|Dietary Supplement|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
89656|NCT01289860|Dietary Supplement|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
89657|NCT01289886|Drug|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
89658|NCT01289899|Drug|BR-A-657|120, 360mg or placebo 7days
89659|NCT01289912|Drug|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. RAD001 or matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.
Patients will be instructed to take 4.5 mg/m2 of RAD001 or matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.
89660|NCT01289925|Dietary Supplement|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
89661|NCT01289925|Other|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
89662|NCT00053183|Radiation|brachytherapy|
89663|NCT01289938|Drug|Diphenhydramine|Diphenhydramine 50 mg oral once
89664|NCT01319838|Drug|Isotretinoin|>12 kg: 160 mg/m2/day, given PO, divided BID <=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
89665|NCT01319851|Drug|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
89666|NCT01319864|Drug|Plerixafor Dose Escalation|Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose
Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy.
90351|NCT01316211|Device|Implantation of coflex™ after surgical decompression|The device will be implanted after surgical decompression in patients with spinal stenosis.
90352|NCT01316211|Procedure|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant
90353|NCT01318473|Device|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
90354|NCT01318486|Other|Heparin free dialysis technique|Saline flushes or predilution
90355|NCT01318486|Device|Evodial|Evodial dialyer
90356|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
90357|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
90358|NCT01318499|Other|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
90359|NCT00055640|Drug|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
90360|NCT01318525|Drug|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
90361|NCT01318525|Drug|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
89442|NCT01284530|Drug|TPM XR|Equivalent TDD in XR form, QD, for 22-39days
89443|NCT01284543|Device|Use of the Tan EndoGlide to insert donor graft|Using the Tan EndoGlide to insert donor graft into the eye
89444|NCT01287039|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
89445|NCT01287039|Drug|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
89446|NCT01287052|Drug|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
89815|NCT01315002|Drug|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
89816|NCT01315002|Drug|Placebo patch|Placebo patch
89817|NCT01315015|Other|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
89818|NCT01315028|Other|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
90071|NCT01315470|Drug|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
90072|NCT01315483|Other|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
90073|NCT00055328|Behavioral|Problem-Solving Treatment for Primary Care|
90074|NCT01315496|Drug|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
90075|NCT01315522|Device|ComVi stent|Endoscopic insertion of ComVi stent
90076|NCT01315522|Device|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
90077|NCT01315561|Other|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
90078|NCT01315574|Drug|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
90079|NCT01315574|Drug|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
90080|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|3 pulses at 50Hz repeated each 200 ms for 2 seconds
80% MT
20 days treatment
90081|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
90082|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
89882|NCT01322854|Radiation|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
89883|NCT00055835|Drug|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 & 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
89884|NCT01322867|Drug|alprazolam tablet|0,25 mg oral tablets given once
89885|NCT01322867|Drug|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
89886|NCT01322880|Behavioral|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
89887|NCT01315106|Device|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
89888|NCT01315119|Procedure|SPY Intra-Operative Angiography|Calculated per patient
89889|NCT01315132|Device|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
89890|NCT01315145|Procedure|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
89891|NCT00055250|Drug|placebo|
89892|NCT01315145|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
89893|NCT01315158|Drug|Propofol Alone|Recommended Propofol doses before considering crossover:
Induction: 2-2.5 mg/kg
Maintenance: 0.1-0.2 mg/kg/min
90148|NCT00055861|Biological|bevacizumab|Given IV
90149|NCT01323400|Drug|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
90150|NCT01323400|Other|Best supportive care|Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).
Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency.
90151|NCT01323426|Procedure|Periurethral injection|Periurethral injection of autologous muscle fibers
90152|NCT01323439|Device|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS
90153|NCT01315652|Behavioral|Auto-DAS|"Auto-DAS"Number of patients with a modification in their treatment between baseline and 6 months visits
90154|NCT01315665|Dietary Supplement|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
89667|NCT01319890|Procedure|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
89668|NCT00001053|Biological|Aluminum hydroxide|
89669|NCT00055679|Drug|fluorouracil|
89670|NCT01319903|Biological|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
89671|NCT01319916|Drug|ATX-101|ATX-101 2mg/cm2
89672|NCT01319929|Drug|LY2828360|Administered orally
89673|NCT01319929|Drug|Placebo|Administered orally
89674|NCT01319942|Other|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
90246|NCT00055354|Procedure|Acupuncture|
90247|NCT01315873|Drug|Bortezomib|On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m^2 followed by bendamustine given at 90 mg/m^2. Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.
Patients will be treated until disease progression after at least one cycle of treatment.
90248|NCT01315886|Drug|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
90249|NCT01315899|Drug|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
90250|NCT01315899|Drug|ORM-12471|Given as a single dose once during the study as per Williams crossover design
90251|NCT01315899|Drug|placebo|Given once as a single dose during the study as per Williams crossover design
90252|NCT01315912|Drug|Letrozole|2.5 mg /day for 5 days
90253|NCT01315938|Drug|Abatacept|abatacept will be given as intravenous infusions at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.
90254|NCT01315938|Drug|Abatacept|Subjects will be treated with abatacept for 6 months and receive a total of up to 7 doses (intravenous infusions) the infusions will be given with the following intervals: at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.
90255|NCT01315951|Biological|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
89447|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
89448|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
89449|NCT01287065|Drug|Placebo AM|Inhalation powder
89450|NCT01287065|Drug|Placebo PM|Inhalation powder
89451|NCT01287078|Drug|Cyclosporine Inhalation Solution|
89452|NCT01287091|Drug|GDC-0980|Oral tablet dose
89453|NCT01287091|Drug|GDC-0980|Oral capsule dose
89454|NCT00052949|Other|laboratory biomarker analysis|Correlative studies
89455|NCT01287091|Drug|GDC-0980|Oral tablet dose in fed state
89456|NCT01287091|Drug|GDC-0980|Oral repeating dose in fasting state
89457|NCT01287091|Drug|GDC-0980|Oral repeating dose in fed state
89458|NCT01287091|Drug|GDC-0980|Oral tablet in a fasting state
89459|NCT01287091|Drug|rabeprazole|Oral repeating dose
89460|NCT01287104|Biological|NK Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 105, 1 x 106 or 1 x 107) NK cells/kg by IV infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
89461|NCT01287104|Biological|Stem Cell Infusion|Transplant Day 0: & gt; 4 x 106/kg CD34+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day SQ from day 0 until ANC & gt; 5000/microliters x2
89462|NCT01287117|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
89740|NCT00055536|Drug|Natalizumab|
89741|NCT01317342|Device|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure < 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
89742|NCT01317368|Drug|Naropine|20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.
At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.
Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
89743|NCT01317368|Drug|Naropine|20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.
At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.
Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
90083|NCT01315626|Other|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
90084|NCT00055341|Drug|Peginterferon alfa-2a|
90085|NCT01315639|Biological|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
90086|NCT01315652|Behavioral|Comorbidities treatment|" Comorbidities treatment":Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up
90087|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
90088|NCT00055601|Drug|paclitaxel|Given IV
90089|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
90417|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
90418|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
90419|NCT00055393|Drug|Bupropion|
90420|NCT01316237|Drug|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
90421|NCT01316237|Drug|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
90422|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900mg , BID
90423|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900 mg
90424|NCT01316250|Drug|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
90425|NCT01316263|Biological|IMC-3G3|20 mg/kg intravenously (i.v.) every 14 days
90426|NCT01316276|Drug|Liposomal amikacin for inhalation|Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
90427|NCT01316302|Drug|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
90428|NCT01316302|Drug|Placebo|Matching placebo, taken QD for 12 weeks.
90155|NCT01315678|Drug|Liposomal amikacin for inhalation (Arikayce) using the PARI Investigational eFlow® Nebulizer.|Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
90156|NCT01315678|Drug|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment
90157|NCT01315691|Drug|Liposomal amikacin for inhalation|Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment.
90158|NCT01315691|Drug|Placebo for liposomal amikacin for inhalation|Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are the same as for Arikace™.
Placebo will be administered for 28 days.
90159|NCT01315704|Drug|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
90160|NCT01315730|Device|Tactile Stimulation|See Arms
90161|NCT00001049|Drug|Didanosine|
90162|NCT00055341|Drug|Ribavirin|
90163|NCT01315743|Behavioral|Team COOL|1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
90495|NCT01323855|Drug|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
90496|NCT01323881|Device|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
90497|NCT01323907|Drug|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
90498|NCT01323920|Drug|Bortezomib, Tacrolimus, Methotrexate|Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV
90499|NCT01323933|Drug|AB0024|Comparison of different dosages of drug
90500|NCT01323946|Biological|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
90256|NCT01315964|Dietary Supplement|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
90257|NCT00055354|Behavioral|Cognitive Behavioral Therapy|
90258|NCT01315977|Dietary Supplement|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
90259|NCT01315990|Drug|FOLFIRI + Cetuximab|Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).
FOLFIRI regimen
Administration Schedule:
Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)
Irinotecan 180 mg/m² iv , 90 min on day 1
Folic acid (racemic) 400 mg/m², 120 min on day 1
5-FU 400 mg/m² bolus on day 1
5-FU 2400 mg/m² iv over 46 h on day 1 to 2
90260|NCT01316003|Other|Optical coherence tomography|Optical coherence tomography
90261|NCT01316016|Dietary Supplement|Rose hip|40 g of rose hip powder daily for 6 weeks.
90262|NCT01318317|Biological|genetically engineered lymphocyte therapy|Receive ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR)
90263|NCT01318317|Other|laboratory biomarker analysis|Correlative studies
90285|NCT01318460|Drug|Placebo infusion|Twenty-four hour administration of placebo
90286|NCT01320891|Behavioral|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
90287|NCT01320904|Procedure|NMES|We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).
We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation.
90288|NCT01320904|Procedure|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
90289|NCT01320917|Device|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
90290|NCT01320917|Device|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
90291|NCT01320930|Behavioral|Pulmonary rehabilitation|
90292|NCT01320930|Behavioral|conventional care|
89744|NCT01317368|Other|Placebo|20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.
At the same time 40 mL Saline 0,9% will be given as wound infiltration.
Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
89745|NCT01317381|Procedure|Observational|Blood draw
89746|NCT01317420|Drug|BI 836845|Intravenous infusion once every three weeks
89747|NCT01317433|Drug|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
89748|NCT01317433|Drug|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
89749|NCT01317446|Drug|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
89750|NCT01317459|Behavioral|Guided self-determination|Group counselling
89751|NCT00001052|Biological|QS-21|
89752|NCT00055549|Drug|Dextromethorphan|
89753|NCT01317472|Drug|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
89754|NCT01317485|Procedure|Laparoscopic lavage and drainage|[CLOSED] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.
***This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues
89755|NCT01317485|Procedure|Sigmoidectomy with primary anastomosis|[OPEN] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
89756|NCT01317485|Procedure|Sigmoidectomy with end-colostomy|[OPEN] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
89757|NCT01317498|Other|Standard Care|CD4, liver function and CBC every 6 months
89758|NCT01317498|Other|Virological Monitoring|Viral Load test every 6 months
90009|NCT00055601|Drug|fluorouracil|Given IV
90010|NCT01317966|Drug|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
90011|NCT01317992|Drug|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
90012|NCT01317992|Drug|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
90429|NCT01316315|Drug|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
90430|NCT00055419|Biological|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
90431|NCT01316315|Drug|Placebo|Same as active
90432|NCT01316341|Drug|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
90433|NCT01316341|Drug|Placebo|patient to receive two placebos
90434|NCT01316341|Drug|Placebo|patient to receive two placebos
90435|NCT01316341|Drug|Placebo|patient to receive two placebos
90436|NCT01316341|Drug|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
90437|NCT01316354|Other|Bread types|Bread with 50 g available carbohydrate
90438|NCT01316367|Behavioral|PRECEDE HPE model|The model considers the influence of the following three factors on health-related behavior:
Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.
Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.
Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it.
89518|NCT01284634|Drug|Cannabidiol|2 x 100 mg CBD/placebo twice daily (400 mg)
89519|NCT01284634|Drug|Cannabidiol|4 x 100 mg CBD/placebo twice daily (800 mg daily)
89520|NCT01284647|Drug|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
89521|NCT01284647|Drug|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
89522|NCT00052845|Drug|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
89523|NCT01284660|Dietary Supplement|DHA|DHA ingested orally by heavy smokers
89524|NCT01284660|Dietary Supplement|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
89525|NCT01284673|Other|in vitro characterization of the cord blood stem cell|The quantitative and qualitative, functional characterization will insist on cell populations which could potentially participate to neuronal regeneration. and assessment such characteristics in conditions of cryo-preservation, compared to fresh cell preparation
89526|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
90501|NCT01323959|Biological|BoostrixTM Polio|Single dose, intramuscular administration.
90502|NCT01323972|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
90503|NCT00055874|Procedure|allogeneic bone marrow transplantation|
90504|NCT01316367|Behavioral|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
90505|NCT01316380|Drug|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
90506|NCT00055432|Drug|Gemzar and Alimta|
90507|NCT01316380|Drug|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
90508|NCT01316380|Drug|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
90509|NCT01316393|Other|XER2020|mucoprotective product
90510|NCT01316406|Drug|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
90511|NCT01316419|Drug|Telmisartan|Telmisartan 40mg or 80mg
90512|NCT01316419|Drug|amlodipine|amlodipine 5mg or 10mg
90513|NCT01316432|Drug|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
90514|NCT01316432|Other|Placebo|Placebo will be administered as a 24-hour SQ infusion
89596|NCT01284712|Biological|blood sample|blood sample coming from therapeutic bleeding in hospital
89597|NCT01284725|Drug|mycophenolate mofetil or azathioprine|
89598|NCT01284725|Other|immunosuppressive treatment discontinuation|
89599|NCT01284738|Other|Physiopathology|Three sequential biological evaluations will be performed for each patient and will consist in :
the dosages of MP carried out by the UMR 608 in Marseille,
the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.
In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units.
90293|NCT00055731|Procedure|conventional surgery|
90294|NCT01320943|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
90295|NCT01320943|Other|Stop TDF|Participants will stop TDF therapy
90296|NCT01320956|Behavioral|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
90297|NCT01320956|Other|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
90298|NCT01320969|Behavioral|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
90299|NCT01320982|Drug|minocycline|minocycline 100 mg/bid
90300|NCT01320982|Drug|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
90301|NCT01320982|Drug|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
90302|NCT01320982|Drug|placebo|placebo bid
90303|NCT01320995|Procedure|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
90304|NCT00055731|Procedure|neoadjuvant therapy|
89386|NCT01289405|Device|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
89387|NCT01289431|Drug|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
89388|NCT01289431|Drug|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
89389|NCT01289444|Behavioral|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
89390|NCT00053131|Drug|cytarabine|
90013|NCT01318005|Drug|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
90014|NCT01318005|Drug|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
90015|NCT01318005|Drug|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
90016|NCT01318031|Drug|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
90017|NCT01318031|Drug|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
90018|NCT01318044|Drug|Propofol and Thiopental|An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.
An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved
90019|NCT01320410|Drug|ISM®|
90020|NCT01320423|Procedure|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
90021|NCT01320436|Dietary Supplement|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
90022|NCT01320436|Drug|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
90023|NCT01320449|Drug|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
90024|NCT01320449|Behavioral|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
90025|NCT01320449|Other|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
90026|NCT01320462|Drug|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
90027|NCT01320462|Other|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
90028|NCT00055731|Drug|estramustine phosphate sodium|
89527|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
89528|NCT01284699|Procedure|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
89529|NCT01287130|Drug|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
89530|NCT01287182|Drug|Ateronon|Ateronon daily for 3 months
89531|NCT01287195|Drug|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to patients for 30 days with Omeprazole 20 mg daily.
89532|NCT01287208|Device|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
89533|NCT01287208|Device|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
89534|NCT01287221|Drug|Rifampicin|300 mg, 2 times daily
89535|NCT01287221|Drug|placebo|placebo
89536|NCT01287234|Other|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
89537|NCT01287247|Biological|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
89538|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg twice daily (BID)
89819|NCT01315028|Other|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
89820|NCT00055250|Drug|LY293111|
89821|NCT01315041|Drug|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
89822|NCT01315041|Drug|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
89823|NCT01315054|Behavioral|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
89824|NCT01315054|Behavioral|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
89825|NCT01315054|Other|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
89826|NCT01315093|Drug|Heparin, Low-Molecular-Weight|
92057|NCT01306552|Behavioral|Student-Intervention only group|One visit to the smoking prevention parcours offered by KARUNA e.V. ("Rauchst Du noch oder lebst Du schon?") during 7th grade.
The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php.
92058|NCT01306552|Behavioral|Multi-component Intervention|One visit to the smoking prevention parcours offered by KARUNA e.V. ("Rauchst Du noch oder lebst Du schon?") + one parent night with information about smoking prevention and one informational letter by mail
92059|NCT01306552|Behavioral|Control Group|One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. ("Kinderleicht gesund zu leben").
(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)
92060|NCT01306565|Drug|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
92061|NCT01306565|Drug|High dose atorvastatin|80mg daily atorvastatin for 72 hours
92062|NCT01306578|Drug|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
92063|NCT01306578|Procedure|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
92064|NCT01306591|Drug|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
92065|NCT01306591|Drug|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
92066|NCT00054392|Drug|carboplatin|
92067|NCT01306617|Drug|ABT-450|tablets
92068|NCT01306617|Drug|ABT-333|tablets
92069|NCT01306617|Drug|ribavirin|tablets
92070|NCT01306617|Drug|ritonavir|capsules
92071|NCT01308736|Drug|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
92072|NCT01308749|Drug|Oxytocin|Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.
Subjects ages 3-10 years old will be titrated up to a maximum dose of 24IU. Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU.
92073|NCT01308749|Drug|Placebo|Placebo Nasal Spray
91353|NCT01305356|Procedure|Autologous bone graft|Implantation of up to 9cc of autologous bone graft
91354|NCT01305369|Drug|Prasugrel|Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment "A" will be allocated to treatment "B", and vice versa.
91355|NCT01305395|Drug|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
91356|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
91357|NCT00054340|Biological|anti-thymocyte globulin|
91358|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
91359|NCT01305395|Drug|Sirolimus|Will start sirolimus after they develop CAV by angiogram
91360|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
91361|NCT01305408|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
91362|NCT01305408|Drug|Placebo|Matching placebo tablets, taken orally, once daily in the morning
91363|NCT01305421|Procedure|grip test|Muscle strength measurement by hand-held dynamometer
91639|NCT00054496|Drug|erlotinib hydrochloride|
91640|NCT01310725|Procedure|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
91641|NCT01310738|Drug|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
91642|NCT01310738|Drug|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
91643|NCT01310738|Drug|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
91644|NCT01310738|Drug|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
91645|NCT01310738|Drug|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
91646|NCT00001048|Drug|Filgrastim|
91647|NCT00054665|Drug|Cyclophosphamide|750 mg/m^2 day IV day 5 bolus. Repeat cycle every 21 days.
91648|NCT01310751|Drug|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
90601|NCT01316653|Behavioral|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase), phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
90602|NCT01316653|Behavioral|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
90603|NCT01316692|Other|laboratory biomarker identification and analysis|Correlative studies
90604|NCT00001052|Biological|Aluminum hydroxide|
90893|NCT01321957|Drug|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
90894|NCT01321957|Drug|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
90895|NCT01321970|Procedure|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
90896|NCT01321970|Procedure|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
90897|NCT01321970|Procedure|Coronary angiography|Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:
Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)
Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)
Circumflex (proximal, middle and distal) and collateral (first and second marginal)
90898|NCT01321983|Other|Inspiratory muscular training - IMT|
90899|NCT01321996|Procedure|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
90900|NCT00055809|Biological|PEG-interferon alfa-2b|Given SC
90901|NCT01322009|Drug|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
90902|NCT01322009|Drug|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
91274|NCT01307475|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
91275|NCT01307475|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
91276|NCT01307475|Other|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
91562|NCT01310634|Behavioral|Comprehensive intervention|Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
91563|NCT01310647|Drug|Testosterone|Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
91564|NCT01310647|Drug|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
91565|NCT01310647|Drug|CombEq|(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.
Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle.
91566|NCT01310673|Drug|Allopurinol|Allopurinol 300mg po QD for 30 days.
Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.
91567|NCT00054665|Drug|Vincristine|0.4 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
91568|NCT01310673|Drug|Placebo|Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.
Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.
91569|NCT01310699|Device|Technically Improved High Definition NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging.
91570|NCT01310712|Drug|Oxybutynin|5 mg every 12 hours for 6 weeks
91571|NCT01310712|Drug|placebo|placebo twice a day for 42 days.
91572|NCT01313312|Drug|Botulinum type A toxin (Dysport®)|500 U to 1500 U, I.M. (in the muscle) injection into upper limbs across 4 cycles of treatment with a minimum of 12 weeks between 2 injections.
91573|NCT01313325|Other|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
91574|NCT01313364|Device|25G x 1" Needle Autoinjector|All subjects will self-administer 4 IM injections using single-use autoinjectors.
91575|NCT01313377|Drug|gemcitabine hydrochloride|
90675|NCT01316718|Drug|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
90676|NCT01316718|Drug|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
90677|NCT01316731|Other|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
90678|NCT01316744|Drug|ketamine hydrochloride|
90679|NCT01316744|Other|pharmacogenomic studies|
90680|NCT01316744|Other|questionnaire administration|
90681|NCT00055471|Drug|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
90682|NCT01316744|Procedure|assessment of therapy complications|
90683|NCT01316744|Procedure|quality-of-life assessment|
90967|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
90968|NCT01319786|Other|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
90969|NCT01319786|Other|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
90970|NCT01319799|Other|Open heart surgery|TCD count of microembolic signals during surgical aortic valve replacement
90971|NCT01319812|Device|Astron/Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
90972|NCT01319825|Drug|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
90973|NCT01322061|Drug|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
90974|NCT01322087|Dietary Supplement|Nutritional intervention|The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.
All included patients received nutritional counseling and information about the new food concept by a clinical dietician.
Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient.
90975|NCT01322100|Device|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
91649|NCT01310751|Drug|distilled water|2 ml per session
91650|NCT01310764|Procedure|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
91651|NCT01310777|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
91652|NCT01310777|Drug|Brinzolamide 1% ophthalmic suspension|
91653|NCT01310777|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
91654|NCT01310790|Procedure|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was >30%.
Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.
Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain.
91655|NCT01310803|Drug|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
91656|NCT01310803|Other|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
91657|NCT01310816|Drug|IPI-926|Oral
91658|NCT00054665|Drug|Prednisone|60 mg/m^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
91659|NCT01310816|Drug|Placebo Arm|oral placebo
90744|NCT01314066|Drug|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
90745|NCT01314066|Drug|Placebo IV Solution|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
90746|NCT01314092|Biological|Autologous cultured adipose derived stem cells|low dose group: 1x10e7 cells/mL, high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
90747|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
90748|NCT01314105|Drug|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
90749|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
90903|NCT01322022|Behavioral|ParentTraining|5 sessions of individual parent training
90904|NCT01322022|Other|Parent Education|Parent Education to control for time and attention
90905|NCT01322048|Drug|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
90906|NCT01322048|Drug|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
90907|NCT01314391|Genetic|polymerase chain reaction|
90908|NCT01314391|Other|laboratory biomarker analysis|
91189|NCT01309854|Drug|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
91190|NCT01309854|Drug|pioglitazone|oral tablets, 30mg single dose per period
91191|NCT01309880|Device|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
91192|NCT01309880|Device|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
91193|NCT01309893|Device|Investigational Lens|Lenses worn on a daily wear basis for one week
91194|NCT01309893|Device|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
91195|NCT01309919|Device|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
91196|NCT01309919|Other|Diary|Subjects will keep a bleeding diary for three months
91197|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
91198|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
91199|NCT00001047|Drug|Rifabutin|
91200|NCT00054626|Drug|cisplatin|
91201|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
91202|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
91203|NCT01309932|Biological|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
91204|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
91576|NCT00001048|Drug|Zalcitabine|
91577|NCT00054938|Drug|ramipril|
91578|NCT01313377|Drug|oxaliplatin|
91579|NCT01313377|Other|clinical observation|
91580|NCT01313377|Procedure|adjuvant therapy|
91581|NCT01313377|Procedure|quality-of-life assessment|
91582|NCT01313390|Drug|docetaxel|
91583|NCT01313390|Drug|everolimus|
90663|NCT01314014|Drug|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
90664|NCT01314027|Drug|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.
Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months.
90665|NCT01314027|Drug|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
90666|NCT01314040|Other|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
90667|NCT01314040|Other|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
90668|NCT01314040|Other|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
90669|NCT00055081|Behavioral|Critical Time Intervention|
90670|NCT00055471|Drug|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
90671|NCT01316692|Procedure|biopsy|Correlative studies
90672|NCT01316692|Other|immunohistochemistry/tissue microarrays|Correlative studies
90673|NCT01316692|Genetic|TdT-mediated dUTP nick end labeling assay|Correlative studies
90674|NCT01316692|Other|mass spectrometry|Correlative studies
90976|NCT01322100|Drug|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
90977|NCT00055809|Biological|bevacizumab|Given IV
90978|NCT01322126|Device|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
90979|NCT01322139|Drug|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
90980|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
90981|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
90982|NCT01322139|Drug|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
90983|NCT01322152|Drug|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
91277|NCT00054444|Radiation|3-Dimensional Conformal Radiation Therapy|
91278|NCT01307475|Other|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
91279|NCT01307475|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
91280|NCT01307488|Drug|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
91281|NCT01307488|Drug|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
91282|NCT01307501|Device|Cryoablation|All patients will receive cryoablation of up to 5 metastatic lung tumors bilaterally.
91283|NCT01307527|Drug|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
91284|NCT01307527|Device|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
91285|NCT01307540|Device|phototherapy|low level light therapy, broad band light wavelengths.
90750|NCT01314118|Drug|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
90751|NCT01314131|Behavioral|Stimulation group|Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :
a cognitive and behaviour assessment : MMSE, BREF, NPI, IA
an interest questionnaire for patients. It contains 40 questions about activities.
the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named "Observational Measurement of Engagement ".
90752|NCT01314144|Drug|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
90753|NCT00055107|Drug|Nitazoxanide|
90754|NCT01314157|Other|Isostretching|12 interventions (two times per week) for 45 minutes
90755|NCT01314170|Device|Susanna Implant|device
90756|NCT01314183|Other|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
90757|NCT01314183|Other|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
90758|NCT01314196|Other|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
91049|NCT01312194|Procedure|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
91050|NCT01312194|Procedure|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
91205|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
91206|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
91207|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
91208|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
91209|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
91210|NCT01309932|Drug|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
91211|NCT00054626|Drug|gemcitabine hydrochloride|
91509|NCT01313104|Procedure|screening method|Undergo high resolution anoscopy
91510|NCT01305577|Drug|Placebo|Phosphate buffered saline placebo for injection
91511|NCT01305590|Other|Survey to Understand Medication Adherence among HIV Patients|We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a "Take-Medication-Get-Paid" plan; less commitment, in the form of an "Attend-Clinic-Get-Paid" plan; or if they would prefer to designate their own levels of commitment.
91512|NCT01305603|Drug|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
91513|NCT01305603|Procedure|Injection|Injection under ultrasound-guidance
91514|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
91515|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
91516|NCT00054340|Drug|cyclosporine|
91517|NCT01305629|Behavioral|Spiritual Self-Schema Therapy|The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the "addict" schema by proposing the construction of an alternate and competing schema: the "spiritual self." This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life.
92874|NCT01340781|Procedure|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
92875|NCT01340794|Other|Laboratory Biomarker Analysis|Correlative studies
91998|NCT01308684|Drug|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
91999|NCT01308684|Drug|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
92000|NCT01308697|Procedure|Operative fixation of flail chest|Plate fixation
92001|NCT01308697|Other|Non Operative management|Non Operative treatment of Flail Chest
92002|NCT01308710|Dietary Supplement|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
92003|NCT01308723|Drug|RO5323441|escalating doses iv
92004|NCT01308723|Drug|RO5323441|iv every 2 weeks
92005|NCT00054548|Other|laboratory biomarker analysis|Correlative studies
92006|NCT01308723|Drug|sorafenib|400 mg orally twice daily to once every other day
92007|NCT01308736|Drug|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
92008|NCT01311427|Behavioral|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
92009|NCT01311427|Behavioral|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
92010|NCT01311440|Other|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
92011|NCT01311466|Procedure|Liver transplantation|
92012|NCT01311479|Procedure|Osteopathic Manipulation Therapy|Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.
Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
91286|NCT01307553|Device|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
91287|NCT01307566|Device|Continuous Positive Airway Pressure CPAP|CPAP treatment
91288|NCT00054444|Drug|Cisplatin|Given IV
91289|NCT01307579|Drug|caspofungin acetate|Given IV
91290|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
91291|NCT01309945|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
91292|NCT01309945|Drug|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
91293|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
91294|NCT01309945|Drug|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
91295|NCT01309984|Drug|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
91296|NCT01309984|Drug|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
91297|NCT00054626|Procedure|adjuvant therapy|
91298|NCT01309997|Drug|imatinib mesylate|Given PO
91584|NCT01313390|Other|laboratory biomarker analysis|
91585|NCT01313390|Other|pharmacological study|
91586|NCT01313403|Other|Antidepressant (SSRI)|
91587|NCT01313416|Biological|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
91588|NCT00054938|Drug|Vitamins: B6, B12, and folate|
91589|NCT01313416|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
91590|NCT01313429|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
91591|NCT01313429|Biological|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
92074|NCT01308762|Biological|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg.
92340|NCT01309321|Behavioral|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
92341|NCT01309321|Behavioral|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
92342|NCT01309334|Procedure|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
92343|NCT01309334|Procedure|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
92344|NCT01309360|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
92345|NCT01312077|Drug|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
92346|NCT01312077|Drug|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
92347|NCT01312090|Biological|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (−30°Cand−60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
92348|NCT01312090|Behavioral|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
92349|NCT00054821|Procedure|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
92350|NCT01312103|Behavioral|Internet-based safety decision aid|Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:
Setting of priorities for safety; a "sliding bar" allows participants to establish priorities by making pairwise comparisons of importance between factors.
Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.
Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan.
91518|NCT01305642|Dietary Supplement|Individualized fortification of breast milk|Lactose, fat and protein content will be measured prior to breast milk fortification.
Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis.
91519|NCT01305655|Drug|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM, 36 hour levels >20 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
91520|NCT01305681|Device|LoFric® catheters during clean intermittent catheterization|LoFric® catheters during clean intermittent catheterization
91521|NCT01305694|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
91522|NCT01305707|Device|C-ECT|C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.
Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months.
90605|NCT01319006|Drug|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
90606|NCT01319006|Drug|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
90607|NCT01319019|Drug|GSK961081|Comparison of different doses and dosing regimens of the drug
90608|NCT01319019|Drug|Salmeterol|Positive control
90609|NCT00001053|Biological|HIV p17/p24:Ty-VLP|
90610|NCT00055653|Drug|cyclophosphamide|
90611|NCT01319019|Drug|Placebo|Placebo arm
90612|NCT01319032|Other|Extraction of whole blood|Extraction of DNA from whole blood
90613|NCT01319045|Drug|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
90614|NCT01319058|Procedure|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
90615|NCT01319071|Other|Blood sample|Extraction of blood sample from top-level athletes
90616|NCT01319097|Other|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
90617|NCT01319110|Dietary Supplement|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
92013|NCT01311492|Behavioral|Healthy Lifestyle Program|The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this "placebo exercise" activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes.
92014|NCT01311492|Behavioral|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
92015|NCT01311505|Drug|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
92282|NCT01304498|Biological|1 dose at Day 1, 1 dose at Month 2 and 1 dose at Month 6|1 dose 0.5 mL
92283|NCT01304511|Drug|Orgalutran|
92284|NCT01304524|Biological|VGX 3100|1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
92285|NCT01304524|Biological|Placebo|1ml of placebo delivered IM followed by electroporation at Day 0, week 4 and week 12.
92286|NCT00054288|Drug|irinotecan hydrochloride|
92287|NCT01304537|Drug|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
92288|NCT01304537|Drug|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
92289|NCT01304537|Drug|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
92290|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
92291|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
92292|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
92293|NCT01304563|Biological|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
92294|NCT01304576|Behavioral|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
92295|NCT01304576|Other|MRI|Cerebral MRI
92296|NCT01304589|Drug|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose)for 12 weeks - total treatment period is 18 weeks
91592|NCT01313429|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
91593|NCT01313468|Behavioral|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
91594|NCT01313468|Behavioral|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
91595|NCT01313468|Behavioral|Moderate continuous Training|47 minutes of Moderate continuous Training
91596|NCT01313481|Behavioral|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
91597|NCT01313481|Behavioral|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
91598|NCT01313494|Drug|Roflumilast|Roflumilast tablets
91599|NCT01305733|Drug|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
91600|NCT01305733|Other|saline injection|saline
91601|NCT00054340|Drug|methotrexate|
91602|NCT01305746|Drug|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
91603|NCT01305746|Drug|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
91604|NCT01305746|Drug|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
90684|NCT01316757|Biological|cetuximab|Given IV
90685|NCT01316757|Drug|paclitaxel|Given IV
90686|NCT01316757|Drug|carboplatin|Given IV
90687|NCT01316757|Drug|erlotinib hydrochloride|Given PO
90688|NCT01316757|Other|laboratory biomarker analysis|Correlative studies
90689|NCT01316770|Drug|Dexamethasone|
90690|NCT01316796|Drug|Sodium Nitrite Cream|
90691|NCT01316809|Drug|AZD8055|Patients will start at 120 mg once daily
90692|NCT00055484|Drug|zonisamide|
92351|NCT01312103|Behavioral|Usual Care Safety Plan|Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the "usual services" provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:
Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.
A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource.
92352|NCT01312116|Behavioral|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
92602|NCT01337869|Procedure|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
92603|NCT00057382|Drug|T138067 intravenous|
92604|NCT01340131|Drug|Combination Therapy|Drug: Telmisartan 40mg Tablet, Oral, Once Daily
Drug: S-amlodipine 5mg Tablet, Oral, Once Daily
92605|NCT01340157|Drug|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
92606|NCT01340170|Device|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
92607|NCT01340183|Drug|AZD5099|IV Dose
92608|NCT01340183|Drug|Placebo|IV Dose
92609|NCT01340196|Drug|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
92610|NCT01340209|Drug|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
92611|NCT00057577|Drug|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
92612|NCT01340209|Drug|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
92613|NCT01340209|Drug|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
92614|NCT01340222|Biological|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
92615|NCT01340235|Drug|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
90618|NCT01319110|Dietary Supplement|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
90619|NCT01319123|Device|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
90620|NCT01319162|Other|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
90621|NCT00055653|Drug|cyclosporine|
90622|NCT01319175|Other|Hip flexion strength training|
90623|NCT01319188|Drug|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
90624|NCT01319188|Procedure|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
90625|NCT01319188|Other|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
90909|NCT01314417|Drug|Methotrexate|400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
90910|NCT01314443|Other|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
90911|NCT01314443|Dietary Supplement|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
90912|NCT01314443|Other|Placebo|Participants will take placebo for 7 days
90913|NCT01314443|Behavioral|Smoking cessation|Participants will quit smoking without any pharmacological aids
90914|NCT01314456|Device|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
90915|NCT01314482|Drug|Minocycline|200mg bd for 3 days before surgery
90916|NCT01314495|Drug|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
90917|NCT00055133|Drug|Micellar Paclitaxel for Injection|
90918|NCT01314495|Drug|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
90919|NCT01314508|Drug|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
92297|NCT00054301|Procedure|adjuvant therapy|
92298|NCT01304602|Drug|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
92299|NCT01304602|Drug|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
92300|NCT01304615|Behavioral|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
92301|NCT01304615|Behavioral|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
92302|NCT01304615|Behavioral|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
92554|NCT01342445|Drug|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
92555|NCT01342445|Drug|Placebo|
92556|NCT01342458|Other|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
92557|NCT01342471|Behavioral|TV commercial stepping|Participants were instructed to stand and "briskly" step in place, or "briskly" walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention
92558|NCT01342471|Behavioral|30-min walk|Participants were instructed to use "brisk" walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention
92559|NCT01342484|Drug|placebo|comparison of different dosages of drug (low vs high) vs placebo
92560|NCT01342484|Drug|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
92561|NCT00057798|Genetic|loss of heterozygosity analysis|
92562|NCT01342484|Drug|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
92563|NCT01342497|Drug|isoniazide|Tablets, dosing 3 times daily, 12 weeks
92564|NCT01342497|Drug|placebo|tablets, dosing 3 times daily, 12 weeks
90693|NCT01316822|Drug|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
90694|NCT01316848|Drug|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
90695|NCT01316861|Drug|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
90696|NCT01316861|Drug|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
90697|NCT01316874|Drug|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
90698|NCT01316887|Drug|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
90699|NCT01316887|Drug|125mcg once-daily GSK573719|GSK573719
90700|NCT01316887|Drug|Placebo once-daily|inactive
90701|NCT01319240|Drug|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
90702|NCT01319240|Drug|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
90703|NCT01319266|Drug|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
90704|NCT00055653|Drug|fludarabine phosphate|
90705|NCT01319279|Drug|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
90706|NCT01319305|Device|FinESS Sinus Treatment|balloon sinuplasty
90707|NCT01319318|Procedure|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
90984|NCT01322178|Drug|Cetuximab; mFOLFOX6|Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1
Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h
repeated every two weeks for 4.5 months(9 cycles)
90985|NCT01322191|Drug|Morphine|A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
90986|NCT01322204|Drug|Codeine|One single oral dose of 1 mg/kg of codeine
90987|NCT01322230|Other|Control|Multimedia Control
90988|NCT00055809|Other|laboratory biomarker analysis|Optional correlative studies
90989|NCT01322230|Other|WISEMD Original|Current WISEMD
92616|NCT01340248|Drug|Dilatrend 64mg capsule|Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet
Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting
92617|NCT01340261|Behavioral|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
92618|NCT01340274|Behavioral|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
92619|NCT01340274|Behavioral|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
92939|NCT01338597|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
92940|NCT01338610|Biological|ESBA105 ophthalmic solution|
92941|NCT01338610|Other|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
92942|NCT01338623|Drug|Tansulosine|capsule 0,4 mg
92943|NCT01338636|Drug|ambrisentan|5 mg every day for 4 weeks. At Week 4 if ambrisentan 5 mg is tolerated the dose will be increased to 10 mg every day.
92944|NCT01338649|Device|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
92945|NCT00057447|Drug|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
92946|NCT01338649|Device|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
92947|NCT01338675|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
92948|NCT01338701|Procedure|Traditional Chinese Acupuncture|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
92949|NCT01340807|Other|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
92950|NCT01340820|Drug|AERAS-422|rBCG
92951|NCT01340820|Drug|BCG Tice|1-8 x 10^5 CFU
92952|NCT00057642|Drug|Venlafaxine Extended Release|
92953|NCT01340833|Drug|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK2118436, starting 1.75 hours after the oral dose
92954|NCT01340846|Drug|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
90920|NCT01314560|Other|Blood sample|Blood sample
90921|NCT01314573|Behavioral|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
90922|NCT01314573|Behavioral|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
90923|NCT01314586|Dietary Supplement|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
90924|NCT01314599|Drug|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.
Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183.
90925|NCT01314612|Behavioral|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
90926|NCT01314638|Other|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
90927|NCT01314651|Behavioral|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
90928|NCT00055146|Drug|ONTAK|
91212|NCT01309932|Drug|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
91213|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
91214|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
91215|NCT01312428|Device|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
91216|NCT01312428|Device|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
91217|NCT01312441|Drug|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
91218|NCT01312441|Drug|Placebo|Placebo by mouth once weekly for 6 months
91219|NCT01312454|Drug|AL-59412C injectable solution|Concentration 1 and Concentration 2
91220|NCT01312454|Drug|Travoprost injectable solution|
91221|NCT01312454|Drug|AL-59412C Vehicle|Inactive ingredients used as placebo
92565|NCT01342510|Drug|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
92566|NCT01342510|Drug|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
92567|NCT01335451|Drug|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
92568|NCT01335451|Drug|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
92569|NCT01335464|Drug|placebo|placebo matching BIBF1120, BID
92570|NCT00001061|Drug|Foscarnet sodium|
92571|NCT00057044|Behavioral|education and reminder|
92572|NCT01335464|Drug|BIBF 1120|BIBF1120 BID (twice daily)
92876|NCT01340794|Drug|Pazopanib Hydrochloride|Given PO
92877|NCT01342835|Drug|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
92878|NCT01342861|Dietary Supplement|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
92879|NCT00057811|Drug|methotrexate|Given IV or IT
92880|NCT01342874|Dietary Supplement|Inositol|inositol exposure in early GDM
92881|NCT01342887|Drug|cyclosporine|Given IV
92882|NCT01342887|Drug|pravastatin sodium|Given PO
92883|NCT01342887|Drug|mitoxantrone hydrochloride|Given IV
92884|NCT01342887|Drug|etoposide|Given IV
92885|NCT01342887|Procedure|bone marrow aspiration|Correlative studies
92886|NCT01342900|Device|connected to the InSpectra Monitor|
92887|NCT01342913|Drug|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
90990|NCT01322230|Other|Social Networking|Social networking feature
90991|NCT01322230|Other|Social Networking plus Emotional Design|social networking features plus user interface enhancements
90992|NCT01322243|Other|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
90993|NCT01322256|Procedure|Bone scintigraphy|Bone scintigraphy of the affected area
90994|NCT01322256|Procedure|Leukoscan|Scintigraphy with labeled neutrophils
90995|NCT01322256|Procedure|PET / CT|PET / CT of the affected area
90996|NCT01314677|Procedure|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
90997|NCT01314677|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
90998|NCT01314690|Other|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
90999|NCT01314703|Drug|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
91000|NCT01314703|Drug|70% isopropyl alcohol|10.5 ml applicator
91001|NCT01314716|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
91002|NCT01314716|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
91003|NCT01314729|Device|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
91004|NCT01314729|Device|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
91005|NCT00055159|Procedure|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
91299|NCT01309997|Biological|rituximab|Given IV
91300|NCT01309997|Other|laboratory biomarker analysis|Correlative studies
91301|NCT01309997|Other|questionnaire administration|Ancillary studies
91302|NCT01310010|Drug|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
91303|NCT01310036|Drug|erlotinib [Tarceva]|150 mg orally daily
92955|NCT01340846|Drug|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
92956|NCT01340846|Drug|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
92957|NCT01340846|Drug|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
92958|NCT01340846|Drug|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
92959|NCT01340859|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
92960|NCT01340872|Drug|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
92961|NCT01340872|Drug|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
91779|NCT01306032|Drug|ABT-888 + Cyclophospharmide|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
91780|NCT01306045|Drug|AZD6244|75 mg BID by mouth
91781|NCT01306045|Drug|MK-2206|200 mg once weekly by mouth
91782|NCT01306045|Drug|Lapatinib|1500 mg daily by mouth
91783|NCT01306045|Drug|Erlotinib|150 mg/day
91784|NCT01306045|Drug|Sunitinib|50 mg daily by mouth
91785|NCT00054353|Drug|melphalan|Given IV
91786|NCT01306045|Procedure|Molecular Profiling|Tumor profiling
91787|NCT01306058|Drug|TRC 105|15 mg/kg IV every 2 weeks
91788|NCT01306058|Drug|Sorafenib|400 mg bid continuously in a 28 days cycle
91789|NCT01306097|Drug|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
91790|NCT01306123|Drug|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
91791|NCT01306123|Drug|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
91222|NCT01312467|Drug|metformin hydrochloride|Given PO
91223|NCT00001048|Drug|Zidovudine|
91224|NCT00054860|Biological|EP HIV-1090|
91225|NCT01312467|Other|pharmacological study|Correlative studies
91226|NCT01312467|Other|laboratory biomarker analysis|Correlative studies
91227|NCT01312480|Other|5A's Model|The smoking cessation intervention is based on the 5A's model, which includes the following elements:
Ask if the patient smokes.
Advise every patient to quit.
Assess readiness to quit.
Assist in quitting and finding services.
Arrange for cessation services and follow-up.
91228|NCT01312480|Other|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
91229|NCT01312493|Drug|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
91230|NCT01312493|Radiation|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
91231|NCT01312519|Device|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
91232|NCT01312519|Device|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
91523|NCT01305707|Drug|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
91524|NCT01305720|Device|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
91525|NCT01307904|Other|Dates|Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
91526|NCT01307917|Dietary Supplement|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
91527|NCT00054470|Drug|tipifarnib|
91528|NCT01307930|Drug|Anidulafungin|Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
92888|NCT01342913|Drug|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
92889|NCT01342926|Drug|GSK933776|GSK933776
92890|NCT00057811|Drug|rasburicase|Given IV
92891|NCT01342926|Drug|Placebo|Placebo
92892|NCT01342939|Other|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
92893|NCT01342939|Other|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
92894|NCT01342939|Dietary Supplement|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
92895|NCT01342939|Other|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
92896|NCT01342939|Other|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
92897|NCT01342952|Drug|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
92898|NCT01342965|Drug|Erlotinib|Erlotinib was supplied as tablets.
92016|NCT00054717|Drug|Ritonavir(r)|
92017|NCT01311505|Drug|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
92018|NCT01311518|Drug|Drug: Placebo|Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
92019|NCT01311518|Drug|Drug: Injectable Thymosin beta 4|Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
92020|NCT01311531|Procedure|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
92021|NCT01311531|Procedure|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
92022|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
92023|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
92024|NCT01311570|Drug|Buprenorphine|In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.
From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician.
91304|NCT01310049|Drug|LEO 32731|Part 1 and 2: Oral single dose of oral solution or capsule
Part 3: Twice daily dose of oral solution or capsule for 7 days
91305|NCT01310075|Device|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
91306|NCT01310075|Device|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
91307|NCT01310088|Behavioral|Lifestyle intervention|Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
91308|NCT00054639|Biological|oblimersen sodium|Given IV
91309|NCT01310101|Drug|ofatumumab plus dexamethasone|Dose and schedule
Cycle 1:
Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18
Cycles 2 to 6 (cycles every 28 days):
Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18
91310|NCT01310114|Biological|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
91311|NCT01310114|Drug|Placebo|Thawed placebo
91312|NCT01310127|Drug|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
91313|NCT01310127|Drug|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
91314|NCT01310153|Procedure|prone positioning|
91315|NCT01310166|Drug|Fingolimod|
91316|NCT01312571|Behavioral|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
91317|NCT01312571|Behavioral|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
91318|NCT01312584|Dietary Supplement|Processed High-flavanol|
91319|NCT01312597|Other|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
91605|NCT01305772|Drug|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 & 4 of RT alone or weeks 1 & 4 of cisplatin/RT if they tolerated first dose of panitumumab.
91606|NCT01305772|Procedure|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
91792|NCT01306136|Behavioral|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
91793|NCT01306136|Behavioral|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
91794|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
91795|NCT01306162|Drug|Dabigatran etexilate|150 mg as single dose
91796|NCT00054353|Radiation|total-body irradiation|Undergo TBI
91797|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
91798|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
91799|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
91800|NCT01306175|Drug|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
90862|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
90863|NCT01317030|Other|Non-Contact Lens Wear|No intervention
90864|NCT01317043|Drug|Samarium/IMRT|Initially, patients will receive Samarium 153 2.0 mCi/kg as an IV injection by the radiation oncologist one time. Twelve weeks later toxicity and PSA response will be evaluated. Next patients will receive 3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa. If there is no PSA response at 24 weeks, patients will begin hormonal therapy at the discretion of their physicians for a suggested 2 year period.
90865|NCT00055497|Biological|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
90866|NCT01317043|Drug|Samarium ethylenediaminetetramethylenephosphonate|
90867|NCT01317069|Drug|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
90868|NCT01317082|Device|Acupressure|P 6 Pressure Point
90869|NCT01317095|Device|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
90870|NCT01317108|Drug|CMF Chemotherapy|
91529|NCT01307943|Other|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
91530|NCT01307943|Other|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
91531|NCT01307956|Biological|panitumumab|Given IV
91532|NCT01307956|Drug|oxaliplatin|Given IV
91533|NCT01307956|Drug|leucovorin calcium|Given IV
91534|NCT01307956|Drug|fluorouracil|Given IV
91535|NCT01307956|Radiation|radiation therapy|Undergo radiation therapy
91536|NCT01307956|Procedure|therapeutic conventional surgery|Undergo surgical resection
91537|NCT01307956|Other|laboratory biomarker analysis|Correlative studies
91538|NCT00054483|Drug|bortezomib|Given IV
91539|NCT01307956|Other|high performance liquid chromatography|Correlative studies
91540|NCT01307956|Genetic|DNA analysis|Correlative studies
91541|NCT01307956|Genetic|polymorphism analysis|Correlative studies
91542|NCT01307956|Other|pharmacological study|Correlative studies
91543|NCT01307956|Other|pharmacogenomic studies|Correlative studies
90626|NCT01319214|Drug|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
90627|NCT01319227|Procedure|Hip replacement|Hip arthroplasty with uncemented components
90628|NCT01319240|Drug|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
90629|NCT01321489|Drug|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
90630|NCT01321502|Drug|famciclovir|500 mg tablet
90631|NCT01321515|Drug|famciclovir|500 mg tablet
92025|NCT01303991|Other|Hexvix PDT with Karl Storz T-Light|
92026|NCT01304004|Other|Satiety|Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:
Experimental drinkable yogurt enriched in proteins and fibres
Placebo drinkable yogurt (isocaloric and isovolumetric)
92027|NCT01304017|Other|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
92028|NCT01304017|Other|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
92029|NCT01304030|Behavioral|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
92030|NCT01304030|Behavioral|Residency Training as usual|Residents will receive their typical didactic and clinical education
92031|NCT00054236|Drug|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
92032|NCT01304043|Drug|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
92033|NCT01304056|Device|Ventilatory therapy|
92034|NCT01304069|Drug|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
92035|NCT01304069|Drug|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
92303|NCT01304628|Drug|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
92304|NCT01304641|Other|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
92305|NCT01306968|Drug|hyperbaric oxygen|The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.
The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens ("door-to-door" time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute).
92306|NCT00054405|Biological|aldesleukin|Given IV
92307|NCT01306968|Other|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
92308|NCT01306981|Drug|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
91607|NCT01305772|Procedure|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
91608|NCT01305798|Other|Scheduling and Active Choice for Biometric Participation|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
91609|NCT01305811|Device|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
91610|NCT01305824|Drug|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
91611|NCT01305824|Drug|Placebo|Placebo administered at the time of AVF creation.
91612|NCT00054340|Procedure|allogeneic bone marrow transplantation|
91613|NCT01305824|Drug|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
91614|NCT01305837|Drug|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
91615|NCT01305850|Drug|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
91616|NCT01305850|Drug|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
91617|NCT01305850|Drug|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
91618|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
91619|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
91620|NCT01308021|Biological|Placebo|Placebo entero-coated capsules
90708|NCT01319331|Drug|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
90709|NCT01319344|Drug|Eplerenone|25 mg o.d. per os
90710|NCT01319357|Drug|Saxagliptin|orally 5 mg/d for 6 weeks
90871|NCT01317134|Device|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
90872|NCT01317134|Biological|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
90873|NCT01317147|Procedure|Roux-en-Y gastric bypass (RYGBP)|
90874|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
90875|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
90876|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
90877|NCT01319604|Device|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
90878|NCT01319604|Device|Tonometer|Tonometric assessment of IOP
90879|NCT01319617|Device|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
91149|NCT01304953|Drug|Group S+T|In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
91150|NCT01304966|Procedure|biopsy|excisional biopsy
91151|NCT00054327|Drug|cyclophosphamide|Given IV
91152|NCT01304979|Procedure|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
91153|NCT01304979|Procedure|Control|Indirect therapies that mimic direct therapy intervention
91154|NCT01304992|Dietary Supplement|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
91155|NCT01304992|Dietary Supplement|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
90632|NCT01321541|Drug|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
90633|NCT01321541|Drug|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
90634|NCT01321554|Drug|lenvatinib 24 mg administered orally, once a day|Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label lenvatinib and enter the Optional Open Label lenvatinib Treatment Period of the Extension Phase. Subjects who request to receive open label lenvatinib(at the time of confirmed progression) will be informed whether they received placebo or lenvatinib during the period of blinded study drug administration. Subjects who received lenvatinib will not be eligible for the open-label phase.
90635|NCT01321554|Drug|Placebo 24 mg administered orally, once a day|Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label lenvatinib and enter the Optional Open Label lenvatinib Treatment Period of the Extension Phase. Subjects who request to receive open label lenvatinib ( at the time of confirmed progression) will be informed whether they received placebo or lenvatinib during the period of blinded study drug administration.
90636|NCT01321567|Drug|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
90637|NCT00055770|Drug|erlotinib hydrochloride|Given orally
90638|NCT01321580|Device|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
90639|NCT01321606|Dietary Supplement|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10^10 organisms
90640|NCT01321606|Dietary Supplement|sugar pill (placebo)|Placebo identical to the active product will be given
90641|NCT01321619|Drug|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
90642|NCT01321619|Drug|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
90929|NCT01314651|Behavioral|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
90930|NCT01317160|Device|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
90931|NCT01317199|Drug|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
Phase II: to be determined after maximum tolerated dose in Phase I is established
92309|NCT01306981|Drug|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
92310|NCT01306994|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
92311|NCT01306994|Procedure|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
92312|NCT01306994|Other|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
92313|NCT01306994|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
92314|NCT01306994|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
92315|NCT01306994|Other|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
92316|NCT01306994|Other|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
92317|NCT00054418|Dietary Supplement|calcium carbonate|calcium 600 mg daily administered orally for one year
92318|NCT01307007|Drug|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
92319|NCT01307007|Drug|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
92573|NCT01335477|Drug|placebo|placebo matching BIBF 1120 BID
92574|NCT01335477|Drug|BIBF 1120|BIBF 1120 BID (twice daily)
92575|NCT01335490|Other|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
92576|NCT01335503|Dietary Supplement|AN-PEP|Endoprotease enzyme (AN-PEP)
92577|NCT01335516|Other|Glypressin (terlipressin)|Study drug (without placebo)
90711|NCT01319357|Drug|Placebo|orally for 6 weeks
90712|NCT01319370|Drug|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
90713|NCT01319370|Drug|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
90714|NCT01319383|Drug|Vorinostat|Drug administration - Step 1 - 400mg Vorinostat will be given as single doses by mouth at visits 2 and 5.
Step II - 400 mg VOR for 3 consecutive days a week (for a maximum of 8 weeks).
90715|NCT00055653|Drug|melphalan|
90716|NCT01319409|Procedure|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
90717|NCT01319409|Procedure|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
90718|NCT01319422|Drug|Pomalidomide|Comparison of different dosages and schedules of drug
90719|NCT01319435|Procedure|Collection of biological samples|Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).
Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces
90720|NCT01319448|Drug|Proguanil|Proguanil tablets, 1.5mg/kg/day
90721|NCT01319448|Drug|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
90722|NCT01321671|Drug|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
90723|NCT00055770|Drug|docetaxel|Given IV
90724|NCT01321671|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
90725|NCT01321684|Other|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
91006|NCT01314742|Other|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
91156|NCT01305018|Dietary Supplement|BCAA|7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
91157|NCT01305018|Dietary Supplement|Leucine|7 g of leucine + 7 g of alanine per day during 9 days
91158|NCT01305018|Dietary Supplement|Placebo|14 g of alanine per day during 9 days
91159|NCT01305031|Other|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
91160|NCT01305031|Other|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
91161|NCT01305044|Behavioral|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
91162|NCT01307280|Behavioral|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
91163|NCT01307293|Behavioral|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
91164|NCT01307306|Drug|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
91165|NCT00054431|Drug|decitabine|Given IV
91166|NCT01307306|Drug|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
91474|NCT01310361|Drug|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
91475|NCT01310387|Behavioral|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
91476|NCT01310400|Biological|Inflexal V|Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28
90932|NCT00055510|Drug|BO-653|
90933|NCT01317212|Drug|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
90934|NCT01317225|Drug|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
90935|NCT01317225|Drug|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
90936|NCT01317238|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
90937|NCT01317251|Other|Dietary intervention (without dairy products)|Control diet without dairy products
90938|NCT01317251|Other|Dietary intervention (high milk content)|Diet with a high content of milk (~1200 mg Ca/d from milk)
90939|NCT01317251|Other|Dietary intervention (high cheese content)|Diet with a high content of cheese (~1200 mg Ca/d from cheese)
90940|NCT01317264|Other|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
90941|NCT01317264|Other|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
90942|NCT01317264|Other|barley β-glucan|daily consumption of 5g β-glucan extracted from the barley-mutant mother "Bomi" in the form of milk drinks with the 3 main meals for 21 days
90943|NCT00055523|Drug|Adalimumab (D2E7)|
90944|NCT01317264|Other|mutant-barley β-glucan|daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant "lys. 5.f" in the form of milk drinks with the 3 main meals for 21 days
90945|NCT01317277|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group.
90946|NCT01317277|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
90947|NCT01317290|Dietary Supplement|n-3 PUFA free olive oil|negative control
91233|NCT01312532|Device|fixed-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson & Johnson, Leeds, UK
91234|NCT01312532|Device|mobile-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson & Johnson, Leeds, UK
91235|NCT00054873|Drug|tezacitabine|
92578|NCT01335529|Drug|Boceprevir, Peg-interferon alfa 2b and Ribavirin|Screen period from Week-8
Standard treatment from day 0 to week 4 (W4)
Three-drug-regimen (Boceprevir introduction) from W4 to W8
HCV RNA determination at W8 determines treatment group and participation duration:
If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,
If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done.
92579|NCT01335542|Procedure|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
92580|NCT01335542|Procedure|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
92581|NCT01335568|Procedure|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
92582|NCT00057057|Behavioral|Telephone Care|
92583|NCT01335581|Device|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
92584|NCT01335594|Procedure|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
92585|NCT01335607|Drug|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
92586|NCT01335607|Drug|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
92587|NCT01335620|Drug|Raltegravir|400 mg twice daily
92588|NCT01335646|Procedure|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
92899|NCT01342965|Drug|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
92900|NCT01342991|Procedure|Laser Haemorrhoidectomy|The intervention comprises laser haemorrhoidectomy
This procedure will be performed under local anaesthetic with sedation as a day case
The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.
Pre-operative local anaesthesia will be given
92901|NCT00001066|Drug|Didanosine|
92902|NCT00057811|Drug|leucovorin calcium|Given IV or orally
92903|NCT01336088|Drug|ADX48621|oral administration
92904|NCT01336088|Drug|Placebo|oral administration
91007|NCT01314742|Other|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
91008|NCT01314755|Dietary Supplement|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an `immune-enhancing` feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
91009|NCT01314755|Dietary Supplement|An iso-caloric, iso-nitrogenous control feed|
91010|NCT01314768|Behavioral|Brief intervention|Structured behavioural Brief intervention given by trained GPs
91011|NCT01314768|Other|Business as usual|GPs to treat patient as they have until now based on best established practice
91012|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
91013|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
91014|NCT01314781|Drug|solifenacin|solifenacin 5mg tablet once daily
91015|NCT01314781|Procedure|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
91016|NCT00055185|Drug|CD4-IgG2 (PRO 542)|
91017|NCT01314820|Other|normal saline injection|20 cc normal saline injection into knee joint
91018|NCT01314820|Other|sham injection|no saline injection
91019|NCT01314833|Drug|Docetaxel Cyclophosphamide|Docetaxel 75 mg/m² D1 Cyclophosphamide600 mg/m² D1
1 cycle = 21 days
TC*6
91020|NCT01314833|Drug|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1
1 cycle = 21 days 4th-6th Cycle: Docetaxel 100mg/m² D1
1 cycle = 21 days CEF*3-T*3
91021|NCT01309542|Drug|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
91022|NCT01309555|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
91023|NCT01309581|Drug|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
91024|NCT01309581|Drug|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
91025|NCT01309594|Procedure|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
91477|NCT01310400|Biological|Inflexal V|Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28
91478|NCT01310400|Biological|Agrippal|Agrippal influenza vaccine
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28
91479|NCT01310413|Biological|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
91480|NCT01310413|Biological|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
91481|NCT01310426|Other|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
91482|NCT01310452|Drug|insulin detemir|insulin detemir once daily with metformin
91483|NCT01310452|Drug|neutral protamine insulin|neutral protamine insulin once daily with metformin
91484|NCT00054665|Drug|Etoposide|50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
91485|NCT01310465|Drug|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
91486|NCT01310465|Drug|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
91487|NCT01310478|Drug|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
91488|NCT01310491|Behavioral|Health coaching|Telephone based health coaching supported by tele-monitoring.
91489|NCT01312948|Device|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
91801|NCT01306175|Drug|Digoxin|Digoxin 0.5 mg as single dose
91802|NCT01308281|Procedure|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
91803|NCT00054522|Drug|dexamethasone|
91804|NCT01308281|Procedure|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
91236|NCT01312545|Device|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
91237|NCT01312545|Device|Medpor|commercial porous polyethylene
91238|NCT01312558|Behavioral|Prudent diet group|
91239|NCT01312558|Behavioral|Mediterranean diet group|
91240|NCT00054327|Drug|cytarabine|Given IV
91241|NCT01305044|Behavioral|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
91242|NCT01305057|Other|Pyridoxine tri-isopalmitate|2% dosage, oil-in-water emulsion, twice a day, 28 days
91243|NCT01305070|Device|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
91244|NCT01305070|Device|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
91245|NCT01305083|Drug|Udenafil|Placebo-control
91246|NCT01305083|Drug|Placebo|Placebo
91247|NCT01305096|Other|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
91248|NCT01305109|Biological|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
91249|NCT01305109|Biological|Placebo|3 doses of 0.5 mL at 4 week intervals
91250|NCT01305122|Behavioral|neurocognitive tests|inclusion
1 year
3 years
5 years
91251|NCT00054327|Radiation|radiation therapy|Patients undergo total body irradiation
91252|NCT01305135|Drug|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
91253|NCT01305148|Device|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
91254|NCT01305161|Other|Blood simple|Single Blood simple at Day 1
91255|NCT01305174|Device|PROTEGE GPS stent vs. VISIO-PRO stent|Balloon expandable vs. selexpandable stent to treat stenosis or occlusion of common and external iliac artery disease
91544|NCT01307969|Drug|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
92905|NCT01336101|Device|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
92906|NCT01336127|Behavioral|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
92907|NCT01336140|Drug|Aminophylline|75 mg of intravenous aminophylline
92908|NCT01336140|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
92909|NCT01336153|Drug|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
92910|NCT00057135|Behavioral|Unit of use medication packaging|
92911|NCT01336153|Drug|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
92912|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
92913|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
92914|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
92915|NCT01336166|Biological|Placebo control|120 adults were assigned to receive 1 dose of placebo.
92916|NCT01336179|Procedure|Salvadora persica|twice daily use, two minutes interval
92917|NCT01336179|Procedure|Toothbrush|Twice daily use two minutes interval
92918|NCT01336192|Drug|Gemcitabine|Gemcitabine 1250mg/m^2 Day 1 and 8, 28 days per cycle until PD
92919|NCT01336192|Drug|Best supportive care|Best supportive care
92920|NCT01336205|Drug|NKTR-118|25 mg oral tablet once daily
92921|NCT00057135|Behavioral|Mailed reminders to patient when medication refills are due|
92036|NCT01304069|Drug|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
92037|NCT01304082|Drug|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
92038|NCT01304082|Drug|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
92039|NCT01304082|Drug|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
91320|NCT01312610|Dietary Supplement|High flavanone orange juice|High flavonone orange juice drink.
91321|NCT01312610|Dietary Supplement|Control orange juice|Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
91322|NCT00054873|Drug|5-fluorouracil|
91323|NCT01312623|Other|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
91324|NCT01312636|Drug|activated recombinant human factor VII|Data will be collected at the baseline visit and approximately once a year until end of study.
91325|NCT01312649|Behavioral|Experimental psychology methods (computer tests)|
91326|NCT01312675|Device|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
91327|NCT01312688|Other|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
91328|NCT01312714|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
91329|NCT01312714|Drug|Placebo|3 tablets of 1000 IU daily for 26 weeks
91330|NCT01312727|Other|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
91331|NCT01312740|Other|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
91332|NCT01312740|Other|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
91333|NCT00054886|Drug|SU-011,248|
91334|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
91335|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
91336|NCT01312779|Device|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
91337|NCT01312792|Other|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
91338|NCT01312792|Other|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
91805|NCT01308294|Biological|2 vaccine injections in 1 limb|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
91806|NCT01308294|Biological|2 vaccine injections in different limbs|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
91807|NCT01308294|Biological|2 vaccine injections in different limbs, the vaccine does not contain the MHC class II peptide MAGE-A3-DP4|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A peptide with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in different limbs.
91808|NCT01308307|Device|photorefraction|photorefraction is a name of device.
91809|NCT01308320|Drug|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
91810|NCT01308320|Drug|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
91811|NCT01308346|Device|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
91812|NCT01308346|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
91813|NCT01308359|Drug|IV glucose 5%|500 ml glucose 5% within 30 minutes
91814|NCT00054535|Biological|aldesleukin|
91815|NCT01308359|Drug|saline|saline
91816|NCT01308385|Other|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
91817|NCT01308411|Other|50% step down reduction in inhaled corticosteroid dose|All participants will have their inhaled corticosteroid dose reduced by 50%
91818|NCT01308424|Drug|BTL TML HSV|Sublingual micro-dosing for 7 days
90880|NCT01319630|Device|Sidestream Dark Field (SDF)|SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.
After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus.
91545|NCT01307982|Procedure|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
91546|NCT01307982|Procedure|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
91547|NCT01308008|Behavioral|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
91548|NCT01308008|Behavioral|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
91549|NCT00054483|Other|laboratory biomarker analysis|Correlative studies
91550|NCT01310504|Procedure|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
91551|NCT01310504|Procedure|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
91552|NCT01310530|Radiation|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
91553|NCT01310543|Behavioral|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
91554|NCT01310556|Other|ogtt for patients with coronary artery disease|75 g OGTT
91555|NCT01310582|Drug|Desflurane|
91556|NCT00054665|Drug|Doxorubicin|10 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
91557|NCT01310582|Drug|Sevoflurane|
91558|NCT01310595|Procedure|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
91559|NCT01310595|Procedure|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
91560|NCT01310608|Other|A-View|Pre-operative imaging of the thoracic aorta with A-View technique
91561|NCT01310621|Drug|Bovine surfactant|Dose of diluted surfactant : 20ml/kg
Type :Bovine surfactant
Phospholipid concentration: 5 mg/ml
Number of lavages to be given: 2 (10ml/kg each)
92040|NCT01304095|Drug|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
92041|NCT01304108|Other|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
92042|NCT00054249|Drug|T900607|
92043|NCT01304108|Other|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
92044|NCT01304108|Other|Usual Care|No addition to the baseline system for care
92045|NCT01304121|Device|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
92046|NCT01304134|Drug|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
92047|NCT01304134|Drug|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
92048|NCT01304147|Drug|Ketamine|A single dose of intranasal ketamine up to 50 mg
92049|NCT01306448|Device|Vibrant capsule|vibrating capsule
92050|NCT01306461|Drug|Timolol and Tafluprost|Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily
Treatment period 6 months
92051|NCT01306461|Drug|Fixed Dose Combination of tafluprost and timolol|Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.
For masking purposes also: vehicle for timolol administered twice daily
Treatment period 6 months
92052|NCT01306487|Procedure|Vitrectomy|Macular hole surgery
92053|NCT01306500|Procedure|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
92054|NCT01306513|Biological|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
92055|NCT00054353|Other|laboratory biomarker analysis|Correlative studies
92056|NCT01306539|Procedure|Stimulation of the subthalamic nucleus|Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
92320|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
92321|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
91339|NCT01305226|Drug|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
91340|NCT01305239|Drug|Aromasin|Aromasin 25 mg daily.
91621|NCT01308034|Drug|sunitinib|All patients will be treated with sunitinib (3 dose level) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.
Dose level 1 : 12.5 mg once daily Dose level 2 : 25 mg once daily Dose level 3 : 50 mg once daily. Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring.
91622|NCT01308047|Drug|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
91623|NCT01308060|Drug|Botulinum Toxin Type A|During part A, Azzalure will be adminitered at Baseline 60 Spey unit at canthal lines and compared with placebo.
91624|NCT01308073|Device|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
91625|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 12 cycles
91626|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 12 cycles
91627|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
91628|NCT00054483|Other|pharmacological study|Correlative studies
91629|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
91630|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
91631|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 6 cycles
91632|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 6 cycles
91633|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
91634|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
91635|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
90881|NCT01319630|Device|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
90882|NCT01319643|Drug|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
90883|NCT01319656|Behavioral|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
90884|NCT00055666|Drug|beclomethasone dipropionate|
90885|NCT01319669|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
90886|NCT01319682|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
90887|NCT01319682|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
90888|NCT01319695|Drug|corifollitropin alfa|100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg
90889|NCT01319695|Drug|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are >18mm
90890|NCT01319708|Procedure|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
90891|NCT01319708|Procedure|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
90892|NCT01321944|Other|Direct to Smoker Outreach Program|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the "5A" strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs.
91167|NCT01307319|Drug|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
90643|NCT01321632|Drug|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
90644|NCT01321645|Drug|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
90645|NCT01321658|Other|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
90646|NCT01321671|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
90647|NCT01313936|Drug|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
90648|NCT01313949|Other|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors.
90649|NCT01313962|Drug|Flufirvitide-3 0.05 mg single dose|Nasal Spray
90650|NCT01313962|Drug|Flufirvitide-3, 0.1 mg single dose|Nasal spray
90651|NCT01313962|Drug|Flufirvitide-3, 0.2 mg single dose|nasal spray
90652|NCT01313962|Drug|Flufirvitide-3, 0.4 mg single dose|Nasal spray
90653|NCT01313962|Other|Placebo|Nasal spray
90654|NCT01313988|Dietary Supplement|Plant sterols and fish oil|4 weeks intervention, 3 times daily
90655|NCT01313988|Dietary Supplement|Plant sterols|4 weeks intervention, 3 times daily
90656|NCT00000253|Drug|10% N2O|
90657|NCT00001048|Drug|Didanosine|
90658|NCT00055068|Behavioral|Relaxation Training|
90659|NCT01313988|Dietary Supplement|Placebo|4 weeks, 3 times daily
90660|NCT01314001|Drug|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
90661|NCT01314001|Drug|Placebo|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch
92322|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
92323|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
92324|NCT01307020|Drug|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
92325|NCT00054574|Biological|panitumumab|
92326|NCT01309191|Drug|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
92327|NCT01309191|Other|Placebo|
92328|NCT01309204|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
92329|NCT01309204|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
92330|NCT01309204|Drug|Brinzolamide 1% ophthalmic suspension|
92331|NCT01309204|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
92332|NCT01309217|Behavioral|Tobacco Tactics Intervention|At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card "Helping Smokers Quit: A Guide for Clinicians" developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals.
92333|NCT01309217|Other|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
92334|NCT01309230|Biological|Vigil™|intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)
92335|NCT01309243|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
92336|NCT00054587|Biological|Trastuzumab|8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
92337|NCT01309243|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
92338|NCT01309308|Procedure|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
92339|NCT01309308|Other|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
91636|NCT01308099|Device|Blood Pressure and Blood Flow|A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.
The study lasts about 2 hours.
91637|NCT01308112|Dietary Supplement|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
91638|NCT01308125|Procedure|PICSO|Baseline (hemodynamic) measurement
Intra coronary
Blood sampling
LAD occlusion: for 3 min or until pain with and without PICSO
Break recovery: the patient can recover from pain for 3 min
CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.
PICSO: start automatically and continued for 10 min.
PCI/PICSO: concomitantly for the whole duration of the PCI intervention.
24h Follow up: additional blood samples every 6 hours (4 times)
30 days follow up.
90726|NCT01321684|Other|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
90727|NCT01321697|Procedure|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
90728|NCT01321710|Behavioral|Sleep hygiene|This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.
It is administered to women during their last month of pregnancy.
90729|NCT01321710|Behavioral|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
90730|NCT01321710|Drug|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
90731|NCT01321723|Drug|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
90732|NCT01321723|Drug|Placebo|
90733|NCT01321723|Drug|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
90734|NCT00055770|Other|laboratory biomarker analysis|Correlative studies
90735|NCT01321736|Dietary Supplement|dietary fiber|mixture of fiber sources added to liquid nutrition product
90736|NCT01321749|Procedure|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
90737|NCT01321775|Drug|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|Neo-adjuvant doses (12 weeks):
Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.
Adjuvant doses:
Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)
91168|NCT01307319|Drug|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
91169|NCT01307332|Drug|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
91170|NCT01307345|Behavioral|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
91171|NCT01307358|Device|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
91172|NCT01307384|Device|Continuum(R) Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
91173|NCT01307397|Drug|RO5185426|960 mg twice daily orally
91174|NCT01307423|Drug|Apremilast 20mg|Apremilast 20mg twice daily, orally
91175|NCT01307423|Drug|Apremilast 30mg|Apremilast 30mg twice daily, orally
91176|NCT00054431|Other|laboratory biomarker analysis|Correlative studies
91177|NCT01307423|Drug|Placebo|Placebo
91178|NCT01307436|Biological|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
91179|NCT01307436|Biological|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
91180|NCT01307449|Biological|PNEUMOVAX and PREVNAR|Give either 1 dose of PNEUMOVAX or PREVNAR to all participants
91181|NCT01307449|Biological|Pneumovax or Prevnar|Receipt of one vaccination at D0
91182|NCT01307462|Drug|fluticasone propionate|Given inhaled PO
91183|NCT01307462|Drug|montelukast sodium|Given PO
91184|NCT01307462|Procedure|pulmonary function testing|Correlative studies
91185|NCT01307462|Other|questionnaire administration|Ancillary studies
91186|NCT01307462|Procedure|quality-of-life assessment|Ancillary studies
91187|NCT01309841|Drug|Placebo|Oral tablet once daily
91188|NCT00054613|Procedure|Extracorporeal Photopheresis|
90662|NCT01314001|Drug|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
90948|NCT01317290|Dietary Supplement|linseed oil|
90949|NCT01317303|Procedure|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
90950|NCT01317303|Procedure|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
90951|NCT01317303|Procedure|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
90952|NCT01319721|Procedure|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
90953|NCT01319721|Procedure|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
90954|NCT01319721|Procedure|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
90955|NCT00055679|Drug|cyclophosphamide|
90956|NCT01319734|Dietary Supplement|Vitamin C|Vitamin C supplementation 500mg
90957|NCT01319734|Drug|glyburide|this group receiving glyburide 5 mg alone
90958|NCT01319747|Procedure|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
90959|NCT01319747|Procedure|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
90960|NCT01319760|Device|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
90961|NCT01319760|Other|Control|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
90962|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
90963|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
90964|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
92589|NCT01337778|Behavioral|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
92590|NCT01337791|Drug|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
92591|NCT01337804|Drug|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
92592|NCT00057369|Drug|dalbavancin|
92593|NCT01337804|Drug|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
92594|NCT01337817|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
92595|NCT01337817|Other|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
92596|NCT01337830|Other|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
92597|NCT01337830|Other|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
92598|NCT01337843|Other|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
92599|NCT01337843|Other|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
92600|NCT01337856|Other|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
92601|NCT01337869|Procedure|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
92922|NCT01336205|Drug|Usual care|As prescribed by the investigator
92923|NCT01336218|Drug|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
90738|NCT01321788|Drug|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
90739|NCT01321788|Drug|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
90740|NCT01321801|Drug|Pregabalin|Preoperative administration of pregabalin 600mg
90741|NCT01321801|Drug|placebo|Preoperative administration of a matching placebo
90742|NCT01321814|Behavioral|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
90743|NCT01314040|Other|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
91026|NCT01309607|Drug|paclitaxel/carboplatin/lapatinib|Drug doses for the neoadjuvant regimen:
Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle
Carboplatin AUC of 2, day 1, 8 of a 21-day cycle
Lapatinib 750mg daily continuously
91027|NCT01309620|Dietary Supplement|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
91028|NCT01309620|Dietary Supplement|Placebo|Placebo, Twice Daily
91029|NCT01309633|Drug|12.5mg sunitinib with Cisplatin and Gemcitabine|1) Arm A
Day -6 to Day 0 (total 7 days):
Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
91030|NCT01309633|Drug|25mg Sunitinib alternating with Cisplatin and Gemcitabine|Arm B
Day -6 to Day 0 (total 7 days):
Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
91031|NCT00054587|Drug|Fluorouracil|500 mg/m², D1 and every 3 weeks
91032|NCT01309646|Biological|Infanrix™-IPV+Hib|Intramuscular, 3 doses
91033|NCT01309646|Biological|Infanrix™ IPV|Intramuscular, 3 doses
91034|NCT01309646|Biological|Hiberix™|Intramuscular, 3 doses
91035|NCT01309646|Biological|Synflorix™|Intramuscular, 3 doses
91036|NCT01309646|Biological|Rotarix™|Oral, 2 doses
91037|NCT01309659|Drug|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
91038|NCT01309659|Drug|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
91490|NCT01312961|Biological|SAR231893 (REGN668)|Pharmaceutical form:Solution in a 5 mL glass vial Route of administration: Subcutaneous injection
91491|NCT01312961|Drug|placebo|Pharmaceutical form:Solution in a 5 mL glass vial
Route of administration: Subcutaneous injection
91492|NCT01312961|Drug|Fluticasone/Salmeterol combination|
91493|NCT01312961|Drug|Fluticasone|
91494|NCT00054925|Behavioral|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
91495|NCT01312961|Drug|Albuterol|
91496|NCT01312987|Dietary Supplement|Lipid-based nutritional supplement|After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:
3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months
91497|NCT01313000|Procedure|Autologous fat transfer|Autologous fat transfer from abdomen to upper arms
91498|NCT01313013|Behavioral|question prompt sheet|
91499|NCT01313026|Procedure|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
91500|NCT01313039|Drug|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
91501|NCT01313052|Behavioral|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
91502|NCT01313052|Behavioral|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
91503|NCT01313065|Drug|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
91504|NCT01313078|Drug|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
91505|NCT00054925|Behavioral|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
91506|NCT01313104|Procedure|colposcopy|Undergo colposcopy
90965|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
90966|NCT00055679|Drug|epirubicin hydrochloride|
91256|NCT01305187|Device|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
91257|NCT01305200|Drug|supersaturated calcium phosphate rinse|Mouth rinse
91258|NCT01305200|Other|placebo|Mouth rinse
91259|NCT01305200|Other|questionnaire administration|Ancillary studies
91260|NCT01305200|Procedure|quality-of-life assessment|Ancillary studies
91261|NCT01305213|Biological|Bevacizumab|Given IV
91262|NCT00054327|Drug|Etoposide|infusion
91263|NCT01305213|Drug|Fosbretabulin Tromethamine|Given IV
91264|NCT01305213|Other|Laboratory Biomarker Analysis|Correlative studies
91265|NCT01305226|Drug|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
91266|NCT00054444|Drug|Topotecan Hydrochloride Liposomes|Given IV
91267|NCT01307462|Other|laboratory biomarker analysis|Correlative studies
91268|NCT01307462|Genetic|protein analysis|Correlative studies
91269|NCT01307462|Drug|azithromycin|Given PO
91270|NCT01307475|Other|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
91271|NCT01307475|Other|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
91272|NCT01307475|Other|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
91273|NCT01307475|Other|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
92924|NCT01336218|Drug|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
92925|NCT01336244|Drug|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
92926|NCT01336244|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
92927|NCT01336257|Other|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
92928|NCT01336270|Other|biological collection|to collect some human cell samples in melanoma
92929|NCT01338493|Procedure|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
92930|NCT01338506|Behavioral|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
92931|NCT01338532|Other|A 12 week supervised exercise program and patient education|The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.
All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
92932|NCT01338532|Other|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
92933|NCT01338558|Drug|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
92934|NCT00057434|Drug|multivitamin|
92935|NCT01338558|Drug|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
92936|NCT01338558|Drug|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
92937|NCT01338584|Behavioral|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
92938|NCT01338584|Behavioral|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
91039|NCT01309672|Drug|abiraterone acetate|
91040|NCT01309672|Drug|degarelix|
91041|NCT01309672|Drug|leuprolide acetate|
91042|NCT00054600|Drug|Methoxsalen|
91043|NCT01309672|Procedure|orchiectomy|
91044|NCT01309685|Drug|Varenicline|
91045|NCT01309698|Drug|Vildagliptin (LAF237)|
91046|NCT01309698|Drug|Voglibose|
91047|NCT01309698|Drug|Vildagliptin and Voglibose|
91048|NCT01312181|Behavioral|HIV/AIDS health education|A basic behavioral intervention used in the 3 arms including the Motivational Interview (MI), the two components of HealthCall (IVR, personalized feedback) and the advice+DVD educational control arm.
91341|NCT01305252|Drug|inhaled treprostinil|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
91342|NCT01305252|Drug|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
91343|NCT01305265|Device|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
91344|NCT01305278|Other|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
91345|NCT01305291|Other|placebo|
91346|NCT00054327|Procedure|Stem Cell Transfusion|
91347|NCT01305291|Dietary Supplement|digestion-resistant maltodextrin|
91348|NCT01305304|Other|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
91349|NCT01305304|Other|Other|No history of endurance sports activity
91350|NCT01305317|Drug|Lipitor|Atorvastatin 20mg daily for 6 months
91351|NCT01305343|Procedure|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
91352|NCT01305356|Device|Augment(tm) Injectable Bone Graft|Implantation of up to 9cc of Augment(tm) Injectable Bone Graft
91507|NCT01313104|Other|cervical Papanicolaou test|Undergo cervical Pap smear
91508|NCT01313104|Procedure|screening method|Undergo anal Pap smear
90589|NCT01316523|Drug|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
90590|NCT01316523|Drug|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
90591|NCT01316536|Other|provide headphones with music playing|Participants will be provided with music through headphones
90592|NCT01316536|Other|Sounds|recorded ICU sounds will be provided to participants through headphones
90593|NCT00055471|Drug|ZD4054 10 mg|1 x 10 mg oral tablets once daily
90594|NCT01316575|Device|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
90595|NCT01316575|Device|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
90596|NCT01316588|Procedure|Bare skin|Bare skin without plastic adhesive drape och microbial Sealant
90597|NCT01316601|Drug|QAX567|
90598|NCT01316614|Device|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
90599|NCT01316627|Behavioral|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
90600|NCT01316627|Behavioral|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
92796|NCT01342718|Dietary Supplement|Placebo herbal extract granule and placebo probiotics|The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
92797|NCT01342731|Drug|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
92798|NCT00057811|Drug|doxorubicin hydrochloride|Given IV, IT, or orally
92799|NCT01342744|Drug|Metformin|Metformin(850 mg) 1tab oral twice aday
92800|NCT01342744|Drug|Placebo|Placebo 1 tab oral twice a day
92801|NCT01342757|Drug|vorinostat|Given orally
92802|NCT01342757|Drug|temozolomide|Given orally
91919|NCT01311245|Behavioral|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
91920|NCT01311245|Behavioral|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
91921|NCT01311271|Device|repetitive transcranial magnetic stimulation (rTMS)|1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,
Real: unaffected M1 hotspot
Sham: coil perpendicular to scalp
91922|NCT01311284|Device|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
91923|NCT01311284|Device|Macintosh laryngoscope|intubate with the macintosh laryngoscope
91924|NCT00054704|Drug|Riluzole|
91925|NCT01311284|Device|McGrath|Intubate with McGrath device
91926|NCT01311284|Device|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
91927|NCT01311310|Other|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
91928|NCT01311323|Procedure|PCI|Percutaneous Coronary Intervention
92537|NCT01340066|Drug|UISH001|sublingual dosing, 1 drop 3 times a day
92538|NCT01340066|Drug|matching placebo|sublingual dosing,1 drop 3 times a day
92539|NCT01340079|Behavioral|virtual world|health education using virtual world Second Life
92540|NCT01340079|Behavioral|face to face|health education delivered in face to face groups
92541|NCT01340092|Other|Family Navigator|Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:
Help family identify key issues they need to address to get their child autism-specific services
Help family address barriers to obtaining these services and strategize approaches to overcome them.
92542|NCT01340105|Procedure|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
92543|NCT00001064|Drug|Allogenic Dendritic Cells|
92544|NCT00057577|Behavioral|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
92545|NCT01340105|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
92546|NCT01340118|Drug|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
92547|NCT01340131|Drug|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
92548|NCT01342367|Drug|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
92549|NCT01342367|Drug|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
92550|NCT00057798|Genetic|cytogenetic analysis|
92551|NCT01342367|Radiation|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
92552|NCT01342432|Other|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
92553|NCT01342432|Other|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
89346|NCT01284244|Device|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
92353|NCT01312116|Behavioral|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
92354|NCT01312129|Drug|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
92355|NCT01312129|Drug|Placebo|Placebo capsule x 3 doses 12 hours apart
92356|NCT01312155|Other|Intubation|Intubation, endotracheal
92357|NCT01312168|Device|Therapeutic CPAP|CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
92358|NCT01312168|Device|Subtherapeutic CPAP|Subtherapeutic CPAP ventilator, pressure <3 cmH2O, daily use at sleep, six months
92359|NCT01312181|Behavioral|HealthCall and Motivational Interviewing|A basic behavioral intervention used in the 3 arms including the Motivational Interview (MI), the two components of HealthCall (IVR, personalized feedback) and the advice+DVD educational control arm.
92360|NCT00054821|Procedure|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
92361|NCT01312181|Behavioral|Motivational Interviewing (MI)|A basic behavioral intervention used in the 3 arms including the Motivational Interview (MI), the two components of HealthCall (IVR, personalized feedback) and the advice+DVD educational control arm.
92362|NCT01304641|Other|Simvastatin Initiators|Retrospective database analysis no intervention performed.
92363|NCT01304693|Biological|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
92364|NCT01304693|Biological|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
92365|NCT00001045|Drug|Zidovudine|
92366|NCT00054301|Procedure|conventional surgery|Patients undergo excisional biopsy or surgery.
92367|NCT01304706|Drug|Fluocinolone Acetonide|0.2 μg/day
92368|NCT01304719|Behavioral|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
92369|NCT01304719|Behavioral|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
92370|NCT01304745|Behavioral|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
91851|NCT01313559|Other|Laboratory biomarker analysis|Correlative studies
91852|NCT01313572|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
91853|NCT01313572|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
91854|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
91855|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
92131|NCT01304290|Other|Hyperinsulinemic/normoglycemic clamp|Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called "normoglycemic, hyperinsulinemic clamp". Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours.
92132|NCT01306630|Drug|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
92133|NCT01306643|Drug|Idelalisib|Idelalisib tables 150 mg administered orally twice daily
92134|NCT01306656|Dietary Supplement|10,000 IU Vitamin D3|Month 1: 20,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.
Months 2-6: 10,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.
92135|NCT01306656|Dietary Supplement|Placebo|Month 1: Placebo once a week plus daily multivitamin with 400 IU vitamin D.
Months 2-6: Placebo every week plus daily multivitamin with 400 IU vitamin D.
92136|NCT01306669|Biological|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
92137|NCT01306669|Biological|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
92138|NCT00054392|Drug|gemcitabine hydrochloride|
92139|NCT01306682|Biological|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
92140|NCT01306682|Biological|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
92141|NCT01306695|Behavioral|New York University Caregiver Intervention (NYUCI)|The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is "ad hoc" counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease.
91929|NCT01311323|Procedure|CABG|Coronary Artery Bypass Graft
91930|NCT01311336|Drug|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
91931|NCT01311336|Drug|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
91932|NCT01311362|Drug|St. Johns wort|Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20
Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20
91933|NCT01311375|Dietary Supplement|w3 supplement in SCI|supplements(Mor DHA and Ca "500 mg" -D200 micro g" )( will be given in this group
91934|NCT01311375|Other|placebo|placebo+ capsule CA-D
91935|NCT00054717|Drug|Tipranavir|
91936|NCT01311401|Other|NONE intervention|NONE intervention
91937|NCT01311414|Drug|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
92207|NCT01304368|Procedure|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
92208|NCT01304381|Other|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
92209|NCT01304381|Other|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
92210|NCT01304394|Drug|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
92211|NCT01304420|Device|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
92212|NCT00054288|Drug|gemcitabine hydrochloride|
92213|NCT01304433|Drug|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
92858|NCT00057629|Behavioral|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
92859|NCT01340677|Drug|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
92860|NCT01340677|Drug|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
92861|NCT01340690|Dietary Supplement|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
92862|NCT01340690|Dietary Supplement|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
92863|NCT01340703|Procedure|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
92864|NCT01340716|Other|Intervention group -Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
92865|NCT01340716|Other|Control group -stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
92866|NCT01340729|Drug|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
92867|NCT01340742|Procedure|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
92868|NCT01340742|Procedure|Control|Cuff placed on arm uninflated for 30 minutes.
92869|NCT00057642|Drug|Sertraline|
92870|NCT01340755|Procedure|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
92871|NCT01340768|Drug|Sitagliptin|One 100 mg tablet taken orally once daily
92872|NCT01340768|Drug|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
92873|NCT01340768|Drug|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
92371|NCT01304745|Behavioral|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
92372|NCT01304758|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
92620|NCT01340287|Dietary Supplement|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
92621|NCT01340287|Dietary Supplement|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
92622|NCT00057590|Behavioral|Care manager outreach and monitoring|
92623|NCT01340300|Behavioral|Exercise training|Two supervised exercise sessions per week
92624|NCT01340300|Drug|Exercise training plus metformin|Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID
92625|NCT01340300|Drug|Metformin|Oral metformin QD for two weeks, then BID
92626|NCT01340300|Other|Educational information|educational information
92627|NCT01340326|Drug|high dose of valsartan|comparison of different dosages of drug
92628|NCT01340326|Drug|usual dose of valsartan|comparison of different dosages of drug
92629|NCT01342510|Drug|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
92630|NCT01342510|Drug|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
92631|NCT01342523|Other|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
92632|NCT01342523|Other|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
92633|NCT01342523|Other|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
92634|NCT00057798|Genetic|microarray analysis|
92635|NCT01342523|Other|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
92142|NCT01306695|Other|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. In addition, CHW will assess other health and social issues and provide information on existing resources on Northern Manhattan. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
92143|NCT01306708|Drug|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
92144|NCT01306721|Drug|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
92394|NCT01307033|Drug|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
92395|NCT01307033|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
92396|NCT01307033|Drug|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
92397|NCT01307046|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
92398|NCT01307046|Drug|Losartan|Tablet containing losartan potassium (100 mg), once daily
92399|NCT01307046|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
92400|NCT01307046|Drug|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
92401|NCT00054418|Drug|risedronate sodium|risedronate 35 mg weekly administered orally
92402|NCT01307046|Drug|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
92403|NCT01307059|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
92404|NCT01307072|Procedure|Vitrectomy|Vitrectomy. Diabetic retinopathy
92405|NCT01307085|Procedure|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
92406|NCT01307098|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose A of SBC-102 (sebelipase alfa)
92407|NCT01307098|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose B of SBC-102 (sebelipase alfa)
92408|NCT01307098|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose C of SBC-102 (sebelipase alfa)
92214|NCT01304446|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
92215|NCT01304472|Drug|Prasugrel|Prasugrel 10mg per day
92216|NCT01304472|Drug|Clopidogrel|Clopidogrel 150mg per day
92217|NCT01306760|Drug|Ketamine|Ketamine used as the anaesthetic during ECT.
92218|NCT01306760|Drug|Propofol|The standard anaesthetic used for ECT.
92219|NCT01306773|Drug|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing >= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
92220|NCT01306773|Drug|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
92221|NCT01306786|Drug|Quadruple therapy|First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.
Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d
92222|NCT01306786|Drug|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
92474|NCT01342328|Drug|Propofol|For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.
Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.
Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol.
92475|NCT01342341|Drug|Parafon Forte|Drug: Parafon Forte administered at study visit
Other: Placebo administered at study visit
92476|NCT01342354|Radiation|Stereotactic Radiation|Escalating Doses of SBRT in periods of three doses over 10 days
92477|NCT01342367|Drug|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
92478|NCT01335308|Behavioral|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
92479|NCT01335321|Drug|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
89276|NCT01286766|Drug|DCS (docetaxel with cisplatin with TS-1)|S-1: 70 mg/m2 #2 bid PO, D1-14
Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8
Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks.
89277|NCT01286766|Drug|DCF (docetaxel with cisplatin with 5-FU)|5-FU: 1,000 mg/m2 CI, D1-3
Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by
Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.
Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)
treatment is repeated until 4 cycles
89278|NCT01286779|Biological|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
89279|NCT01286805|Procedure|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
89280|NCT01286805|Procedure|Control|The control group will receive only a combined spinal-epidural.
89281|NCT01286818|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
89282|NCT00052936|Drug|prednisone|
89283|NCT01286818|Drug|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
89284|NCT01286818|Drug|levofolinate|IV infusion, 200 mg/m² every 2 weeks
89285|NCT01286818|Drug|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
89286|NCT01286831|Drug|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
89287|NCT01286844|Drug|GSK2190915A 5mg|Oral powder for dispersion in water
89288|NCT01286844|Drug|GSK2190915A 10mg|Oral powder for dispersion in water
89289|NCT01286844|Drug|GSK2190915A 25mg|Oral powder for dispersion in water
89290|NCT01286844|Drug|GSK2190915A 50mg|Oral powder for dispersion in water
89291|NCT01286844|Drug|GSK2190915A 100mg|Oral powder for dispersion in water
89292|NCT01286857|Device|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
89293|NCT00052936|Drug|vincristine sulfate|
88338|NCT01292213|Procedure|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
92636|NCT01342523|Other|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
92637|NCT01342523|Other|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
92638|NCT01342523|Other|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
92962|NCT01340885|Drug|Strattera|10-30 mg b.i.d. for 6 weeks
92963|NCT00001065|Drug|Amphotericin B|
92964|NCT00057668|Behavioral|Multi-Setting Early Intervention|
92965|NCT01340885|Drug|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
92966|NCT01340885|Other|Placebo|2-6 pills for 6 weeks
92967|NCT01340898|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
92968|NCT01340898|Biological|SynflorixTM|Intramuscular injection
92969|NCT01340898|Biological|Infanrix-IPV/HiberixTM|Intramuscular injection
92970|NCT01340911|Drug|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
92971|NCT01340911|Drug|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
92972|NCT01340937|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
92973|NCT01340937|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age
92974|NCT01340937|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
92975|NCT00057668|Behavioral|Community Intervention|
92976|NCT01340937|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
92977|NCT01343368|Biological|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
92409|NCT01307111|Drug|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
92410|NCT01307111|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
92411|NCT01307124|Drug|kaletra|The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.
Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW >35-50 kg 400/100 mg 300/75 mg
92412|NCT01309360|Drug|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
92413|NCT01309360|Drug|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
92414|NCT00054587|Drug|Cyclophosphamide|500 mg/m², D1 and every 3 weeks
92415|NCT01309360|Drug|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
92731|NCT01342718|Dietary Supplement|Herbal extract granule and placebo probiotics|The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
92732|NCT01335828|Device|Medical ultrasound device (ShearWave system)|Echography (all modes) and elastography "ShearWave" system
92733|NCT01335841|Device|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
92734|NCT01335854|Behavioral|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
92735|NCT01335854|Behavioral|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
92736|NCT01335867|Drug|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
92737|NCT01335867|Drug|Placebo|Placebo pills
92738|NCT01335880|Behavioral|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
92480|NCT01335321|Drug|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
92481|NCT00057018|Procedure|Constraint-induced movement therapy|
92482|NCT01335334|Drug|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
92483|NCT01335347|Biological|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
92484|NCT01335347|Biological|Placebo control|Capsules of the same size and shape as experimental groups
92485|NCT01335360|Drug|Nevirapine|200mg twice daily of nevirapine
92486|NCT01335373|Drug|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
92487|NCT01335386|Drug|KLYX|
92488|NCT01335386|Drug|Glycerine|
92489|NCT01335399|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
92490|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
92491|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
92803|NCT01342757|Procedure|magnetic resonance spectroscopic imaging|Undergo MRI
92804|NCT01342757|Other|survey administration|Ancillary studies
92805|NCT01342770|Other|Laboratory Biomarker Analysis|Correlative studies
92806|NCT01342770|Drug|Pioglitazone Hydrochloride|Given PO
92807|NCT01342770|Other|Quality-of-Life Assessment|Ancillary studies
92808|NCT01342783|Genetic|DNA analysis|
92809|NCT00057811|Drug|cyclophosphamide|Given IV
92810|NCT01342783|Genetic|RNA analysis|
92811|NCT01342783|Genetic|mutation analysis|
88339|NCT01292213|Procedure|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
88340|NCT01292213|Procedure|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
88341|NCT01292213|Procedure|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
88342|NCT01292213|Procedure|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
88343|NCT01292213|Other|Data collection|Questionnaire completion.
88344|NCT00053378|Drug|paricalcitol injection (Zemplar)|
88345|NCT01292226|Drug|mycophenolate mofetil|1 g PO BID for 24 weeks
88346|NCT01292226|Drug|antibody induction|According to manufacturer recommendation
88347|NCT01292226|Drug|Cyclosporine|According to manufacturer recommendation
88348|NCT01292226|Drug|corticosteroid|According to manufacturer recommendation
88349|NCT01292239|Drug|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
88350|NCT01292239|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
88351|NCT01292239|Drug|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
88352|NCT01292239|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
88353|NCT01292252|Biological|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
88354|NCT01292265|Biological|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
88355|NCT00053378|Behavioral|Effects on calcium regulation|
88356|NCT01292291|Other|biologic sample preservation procedure|
88357|NCT01292291|Other|laboratory biomarker analysis|
92978|NCT01343368|Biological|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
92979|NCT01343381|Drug|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
92980|NCT01343381|Drug|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
92981|NCT01343394|Biological|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
92982|NCT01343407|Drug|MK-1029 10 mg|Six capsules once daily for 5 days
92983|NCT01343407|Drug|MK-1029 100 mg|Five capsules once daily for 5 days
92075|NCT01308762|Biological|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
92076|NCT01308762|Biological|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
92077|NCT01308775|Behavioral|SIS.NET, Routine Follow-up|SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.
Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit.
92078|NCT01308801|Device|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
92079|NCT00054548|Other|pharmacological study|Correlative studies
92080|NCT01308801|Device|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
92081|NCT01308814|Drug|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
92082|NCT01308814|Drug|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
92083|NCT01308827|Procedure|Blood culture|A baseline blood culture will be obtained in all participants
92739|NCT01335880|Behavioral|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
92740|NCT01335893|Drug|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
92741|NCT01335906|Other|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
92742|NCT00057122|Drug|Isoniazid|300mg
92743|NCT01335932|Drug|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
92744|NCT01335932|Drug|Placebo|For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.
The placebo is an IV solution that does not contain any active medications.
92745|NCT01335945|Procedure|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
91856|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
91857|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
91858|NCT01313598|Drug|GLPG0187|continuous IV infusion
91859|NCT01313611|Drug|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
91860|NCT01313624|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
91861|NCT00054964|Drug|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
91862|NCT01313624|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
91863|NCT01313637|Drug|GSK573719/GW642444 125/25mcg|125/25mcg
91864|NCT01313637|Drug|GSK573719 125mcg|125mcg
91865|NCT01313637|Drug|GW642444 25mcg|25mcg
91866|NCT01313637|Drug|Placebo only|Placebo
91867|NCT01313650|Drug|62.5/25mcg|GSK573719/GW64244
92812|NCT01342783|Genetic|nucleic acid sequencing|
92813|NCT01342783|Other|laboratory biomarker analysis|
92814|NCT01342796|Biological|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
92815|NCT01342796|Biological|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
92816|NCT01342809|Behavioral|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
92817|NCT01342822|Device|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
92818|NCT01335984|Procedure|Telemonitoring|The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.
The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center.
92819|NCT01335984|Procedure|Telemonitoring & Telemedicine|The subjects who are assigned in the Telemonitoring & Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.
Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions.
92820|NCT01335984|Other|control group|- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).
The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
91938|NCT01303848|Other|Blood Sampling|Blood Sampling over 24 hours
91939|NCT01303861|Drug|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
91940|NCT01303861|Drug|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
88358|NCT01292291|Other|study of socioeconomic and demographic variables|
88664|NCT00052923|Biological|filgrastim|
88665|NCT01285752|Drug|AK106-001616|
88666|NCT01285752|Drug|Active comparator|
88667|NCT01285765|Drug|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
88668|NCT01288196|Drug|CNTO 6785 3 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 3 mg/kg
88669|NCT00053040|Procedure|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
88670|NCT01288196|Drug|CNTO 6785 10 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 10 mg/kg
88671|NCT01288196|Drug|CNTO 6785 SC|A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
88672|NCT01288196|Drug|Placebo SC|A single SC dose of placebo administered in up to 3 SC injections
88673|NCT01288209|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
88674|NCT01288209|Drug|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
88675|NCT01288209|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
88676|NCT01288222|Biological|KIR genotype|KIR genotype from unrelated donor.
88677|NCT01288222|Biological|Unrelated donor transplant|hematopoietic cell transplant performed per each center's guidelines
88678|NCT01288235|Radiation|Proton radiotherapy|5 days a week
88679|NCT01288248|Device|Airway laryngeal mask classic|This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.
The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned
88680|NCT00001038|Drug|Valacyclovir hydrochloride|
92084|NCT01308827|Procedure|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
92085|NCT01308840|Drug|Panitumumab|Day 1 and 15 = 6 mg/kg IV
92086|NCT01308840|Drug|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
92087|NCT01308840|Drug|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
92088|NCT01308853|Device|NASHA BE|Device: NASHA BE (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast.
92089|NCT01311583|Behavioral|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
92090|NCT01311596|Other|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
92091|NCT00054717|Drug|Comparator Protease Inhibitor (CPI)|
92639|NCT01342536|Behavioral|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.
The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.
Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)
92640|NCT01342549|Drug|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60mg per day. Usual dosage is between 1250mg to 2000mg per day
92641|NCT01342549|Drug|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
92642|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
92643|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
92644|NCT01342575|Procedure|Intra-operative exposure maneuvers|Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed
Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.
Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed
Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed
Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed
92645|NCT00057798|Procedure|conventional surgery|
91868|NCT01313650|Drug|62.5mcg|GSK573719
91869|NCT01306188|Biological|Breast cancer cohort|Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.
For each patient, the following analyses is performed:
The analysis of TCR and BCR repertoire diversity,
The phenotypic analysis of immune subpopulations,
The analysis of the global lymphopenia or subpopulations T,
The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.
91870|NCT01306188|Biological|Lung cancer cohort|Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.
For each patient, the following analyses is performed:
The analysis of TCR and BCR repertoire diversity,
The phenotypic analysis of immune subpopulations,
The analysis of the global lymphopenia or subpopulations T,
The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.
91871|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
91872|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
91873|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
91874|NCT00054353|Drug|mycophenolate mofetil|Given PO
91875|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
91876|NCT01306214|Drug|BI 10773|BI 10773 low dose once daily
91877|NCT01306214|Drug|BI 10773|BI 10773 high dose once daily
92145|NCT01306721|Drug|pseudoephedrine|Pharmaceutical form:tablet
Route of administration: oral
92146|NCT01306721|Drug|fexofenadine HCL matching placebo|Pharmaceutical form:tablet
Route of administration: oral
92147|NCT01306721|Drug|pseudoephedrine matching placebo|Pharmaceutical form:tablet
Route of administration: oral
92148|NCT01306747|Behavioral|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
92149|NCT00054392|Drug|paclitaxel|
92150|NCT01308866|Behavioral|Share decision tool|
92151|NCT00054561|Biological|recombinant interferon alfa|
92152|NCT01308879|Behavioral|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
92153|NCT01308892|Dietary Supplement|High flavanol chocolate|chocolate high in flavanols
91941|NCT01303861|Drug|Nicotine patches|Nicotine Replacement Therapy Groups:
For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or
For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
Varenicline and varenicline in combination with bupropion groups:
For smokers with high baseline CO: 42 mg/24 h for 1 week
For smokers with low baseline CO: 21 mg/24 h for 1 week
91942|NCT01303861|Drug|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
91943|NCT00001045|Drug|Nevirapine|
91944|NCT00054236|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
91945|NCT01303874|Drug|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
91946|NCT01303874|Drug|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
91947|NCT01303887|Drug|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
91948|NCT01303887|Drug|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
91949|NCT01303887|Drug|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
91950|NCT01303887|Drug|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
91951|NCT01303887|Drug|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
91952|NCT01303926|Drug|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
91953|NCT01303926|Drug|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
91954|NCT01303952|Drug|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
91955|NCT00054236|Procedure|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
92223|NCT01306838|Dietary Supplement|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
92224|NCT01306851|Drug|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
88681|NCT00053053|Dietary Supplement|Juven|
88682|NCT01288248|Device|endotracheal tube|This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.
The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age.
88967|NCT01293045|Dietary Supplement|wheat protein|10g/day at breakfast during 90 days
88968|NCT01293058|Drug|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
88969|NCT01293058|Drug|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
88970|NCT01293071|Other|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
88971|NCT01293084|Drug|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
88972|NCT01293084|Drug|7% saline|5mL 7% saline inhaled once over 20 minutes
88973|NCT01293097|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
88974|NCT01293097|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
88975|NCT01293123|Drug|Raltegravir|raltegravir 400 mg PO twice daily
88976|NCT00053482|Biological|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
88977|NCT01293123|Drug|Efavirenz|efavirenz 600 mg PO once daily
88978|NCT01293136|Procedure|Femoral nerve block|Ropivacaine
88979|NCT01293136|Drug|Intravenous opioids|Whatever opioids prescribed
88980|NCT01293149|Drug|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
88981|NCT01293149|Drug|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
88982|NCT01293162|Drug|Armolipid Prev|Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
88983|NCT01293175|Dietary Supplement|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
88984|NCT01293201|Drug|STAHIST|STAHIST dosed one tablet, BID
92646|NCT01342588|Procedure|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
92647|NCT01335646|Other|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
92648|NCT01335659|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
92649|NCT01335659|Device|IVUS|intravascular ultrasound
:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter
92650|NCT01335685|Drug|IXAZOMIB|
92651|NCT00057070|Procedure|Smoking cessation information, collection, and dissemination|
92652|NCT01335685|Drug|Melphalan 9 mg/m2|
92653|NCT01335685|Drug|Melphalan 6 mg/m2|
92654|NCT01335685|Drug|Prednisone|60 mg/m2
92655|NCT01335698|Drug|Atazanavir Sulphate|
92656|NCT01335698|Drug|Ritonavir|
92678|NCT01337934|Drug|Lactated Ringer|Lactated Ringer
92679|NCT01337934|Drug|Albumin|Albumin 4%
92680|NCT01337947|Drug|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
92681|NCT01337960|Behavioral|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
92682|NCT01337960|Behavioral|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
92683|NCT01337960|Behavioral|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
92684|NCT00057382|Drug|doxorubicin intravenous|
92154|NCT01308892|Dietary Supplement|Low flavanol chocolate|chocolate low in flavanols
92155|NCT01308892|Dietary Supplement|High fat challenge|Milkshake with 95g fat
92156|NCT01308905|Device|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
92157|NCT01308944|Drug|Propranolol|
92158|NCT01308957|Dietary Supplement|Omega-3 fatty acids|4 grams per day for 24 weeks
92159|NCT01308957|Dietary Supplement|corn oil|4 grams per day for 24 weeks
92160|NCT01308970|Behavioral|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
92161|NCT01308970|Behavioral|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
92162|NCT00054561|Dietary Supplement|vitamin E|
92163|NCT01308970|Behavioral|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
92164|NCT01308983|Drug|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
92165|NCT01308996|Device|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft [recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
92416|NCT01309373|Other|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
92417|NCT01309386|Drug|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
92418|NCT01309386|Drug|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
92419|NCT01309399|Drug|Teriparatide|six weeks of teriparatide
92420|NCT01309399|Other|placebo|placebo
92421|NCT01309412|Drug|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
92422|NCT01309425|Drug|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
92423|NCT01309425|Drug|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
92225|NCT01306864|Device|Hemospray Kit|Hemostasis of Arterial GI Bleeding
92226|NCT01306877|Device|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
92227|NCT00054405|Biological|recombinant interleukin-12|Given IV
92228|NCT01306877|Device|Endosurgery Proximate PPH03 Stapling Set|Surgical device
92229|NCT01306890|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
92230|NCT01306903|Device|MECC|Minimized extracorporeal circulation
92231|NCT01306903|Device|MOPS|Modified and optimized perfusion system Frankfurt
92232|NCT01306903|Device|Super MOPS|Super modified and optimized perfusion system Frankfurt
92233|NCT01306929|Drug|pridopidine|45mg bid
92234|NCT01306942|Drug|dasatinib plus trastuzumab plus paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg QD (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
92235|NCT01306955|Drug|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
92236|NCT01306955|Other|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
92237|NCT01309035|Procedure|Total Knee Arthroplasty|Surgery for OA knee pains
92238|NCT01309048|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
92239|NCT01309061|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
92240|NCT01309074|Drug|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
92241|NCT01309074|Drug|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
92242|NCT01309100|Device|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
92492|NCT00057031|Drug|DN-101 (calcitriol)|
88985|NCT01293201|Drug|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
88986|NCT01293214|Procedure|Limb transplantation|
88987|NCT00053495|Biological|Vaccinia virus: ACAM2000 smallpox vaccine|Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
88988|NCT01293227|Procedure|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
88989|NCT01293240|Device|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
89294|NCT01286870|Device|Mentor Becker 25 Expander/Breast Implant|The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc.
89295|NCT01289223|Other|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
89296|NCT01289236|Drug|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
89297|NCT01289236|Drug|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
89298|NCT01289236|Drug|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
89299|NCT01289262|Procedure|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
89300|NCT01289262|Procedure|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
89301|NCT01289275|Drug|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
89302|NCT00053131|Biological|filgrastim|
89303|NCT01289275|Behavioral|Telephone Counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by veteran counselors at the California Smokers' Helpline. The counseling protocol is similar to that used by the Helpline in previous efficacy studies. Counseling is proactive so after the smoker calls in subsequent calls are made by the counselor, a process that reduces attrition. The counseling group will receive proactive sessions initiated by quitline staff within 2 days of discharge, and a total of 6 individualized telephone counseling session that extend to two months post discharge. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) that are scheduled according to the probability of relapse. Counselors will use a structured protocol so that there will be a record for each counseling call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
92685|NCT01337973|Behavioral|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
92686|NCT01337973|Behavioral|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
92687|NCT01337973|Behavioral|E-TAU|Enhanced Treatment as Usual
92688|NCT01337986|Drug|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
92689|NCT01337986|Drug|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
92690|NCT01337999|Other|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
92691|NCT01338012|Drug|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
92692|NCT01338025|Drug|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
92693|NCT01340339|Device|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
92694|NCT01340339|Device|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
92984|NCT01343407|Drug|Placebo for MK-1029 10 mg|Six capsules once daily for 5 days
92985|NCT00057811|Drug|cytarabine|Given IT
92986|NCT01343407|Drug|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days
92987|NCT01343420|Biological|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
92988|NCT01343459|Radiation|HIOB|IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)
IOERT is performed on mobile or fixed linacs
Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).
WBRT
must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)
In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.
Single reference dose per fraction: 2,7 Gy (ICRU)
Number of fractions: 15, Number of fractions per week: 5
Total WBRT dose: 40,5 Gy
92989|NCT01343472|Behavioral|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
92990|NCT01343472|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
92424|NCT01309425|Drug|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
92425|NCT00054587|Drug|docetaxel|on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
92426|NCT01309425|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
92427|NCT01309438|Drug|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
92428|NCT01309438|Drug|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
92429|NCT01309438|Drug|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
92430|NCT01309438|Drug|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
92431|NCT01309451|Drug|Bevacizumab|intravitreal, 1.25mg., monthly
92432|NCT01309451|Drug|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
92433|NCT01309477|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
92434|NCT01309490|Drug|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
92435|NCT01309516|Behavioral|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
92436|NCT00054587|Drug|Epirubicin|100 mg/m², D1 and every 3 weeks
92746|NCT01335958|Drug|DMUC5754A|Escalating intravenous dose
92747|NCT01335971|Drug|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
92748|NCT01335971|Dietary Supplement|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
92749|NCT01335971|Other|Placebo|Microcrystalline cellulose once daily by mouth
92750|NCT01338025|Drug|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
92493|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
92494|NCT01335399|Drug|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
92495|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
92496|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
92497|NCT01335412|Biological|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
92498|NCT01335438|Device|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
92499|NCT01335438|Device|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
92500|NCT01337622|Procedure|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
92501|NCT01337635|Drug|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
92502|NCT01337674|Drug|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
92503|NCT00057356|Drug|conivaptan|IV
92504|NCT01337674|Drug|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
92505|NCT01337674|Drug|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
92506|NCT01337674|Drug|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
92507|NCT01337687|Drug|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
92508|NCT01337687|Drug|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
92509|NCT01337700|Drug|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
92510|NCT01337700|Drug|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
89304|NCT01289275|Behavioral|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
89305|NCT01289288|Behavioral|Mailed printed materials and in-office training|Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster
Two sessions of in-office training with two standardized patients
89306|NCT01289301|Drug|mTOR inhibitor (everolimus)|calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)
89307|NCT01289301|Drug|cyclosporine or tacrolimus|calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
89308|NCT01289314|Procedure|TLH|Total laparoscopic hysterectomy (TLH)
89309|NCT01289314|Procedure|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
88359|NCT01292291|Procedure|diffusion-weighted magnetic resonance imaging|
88360|NCT01292291|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
88361|NCT01292291|Procedure|multiparametric magnetic resonance imaging|
88362|NCT01292291|Procedure|quality-of-life assessment|
88363|NCT01285102|Device|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
88364|NCT01285102|Procedure|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
88365|NCT01285115|Drug|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
88366|NCT01285115|Drug|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
88367|NCT00052884|Procedure|bone marrow ablation with stem cell support|
88368|NCT01285115|Drug|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
92991|NCT01343485|Behavioral|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
92992|NCT01343498|Drug|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
92993|NCT01343511|Biological|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
92994|NCT01343511|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
92995|NCT01343537|Other|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
92996|NCT00057811|Drug|etoposide|Given IV
92997|NCT01343550|Other|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
92998|NCT01343563|Procedure|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
92999|NCT01336283|Other|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
93000|NCT01336283|Other|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
93001|NCT01336283|Other|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
93002|NCT00001061|Drug|Ganciclovir|
92092|NCT01311609|Other|Systane|Systane Lubricant Eye Drops [1-2 Drops in each eye four times daily (QID)]
92093|NCT01311622|Drug|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
92094|NCT01311622|Drug|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
92095|NCT01311635|Drug|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
92096|NCT01311635|Drug|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
92097|NCT01311635|Drug|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
92098|NCT01311648|Biological|Recombinant Factor VIII (BAY81-8973)|PTPs prophylaxis treatment 25-50 IU/kg at least 2x/week. PUPs 15 -50 IU/kg at least 1x/week
92751|NCT01338051|Biological|Gardasil|Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.
DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe.
92752|NCT00057395|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
92753|NCT01338077|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
92754|NCT01338077|Drug|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
92755|NCT01338090|Drug|89Zr-bevacizumab|Intravenous injection 120 MBq
92756|NCT01338090|Drug|Everolimus|Oral use, 10 mg per day
92757|NCT01338103|Drug|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
92758|NCT01338116|Other|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
92759|NCT01338129|Dietary Supplement|vitamin c|1000 mg of vitamin c for 45 days
92760|NCT01338129|Drug|placebo|placebo pills
92761|NCT01338142|Other|CCC|600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.
1.5 mg of 42Ca labeled CaCl2 through IV injection
92762|NCT01338142|Other|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
92763|NCT00057408|Drug|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
91878|NCT01306227|Drug|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
91879|NCT01306227|Drug|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
91880|NCT01306240|Procedure|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
91881|NCT01306240|Procedure|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
92511|NCT01337713|Other|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
92821|NCT00057122|Drug|Rifapentine|Rifapentine 900 mg
92822|NCT01335997|Drug|extended release (ER) niacin/laropiprant/simvastatin|1 or 2 tablets containing 1 g ER niacin, 20 mg laropiprant and 10 mg simvastatin, orally, once daily
92823|NCT01335997|Drug|ER niacin/laropiprant|1 or 2 tablets containing 1g ER niacin and 20 mg laropiprant, orally, once daily
92824|NCT01335997|Drug|simvastatin|1 or 2 tablets containing 10 mg simvastatin, orally, once daily
92825|NCT01335997|Drug|Placebo to simvastatin|1 or 2 tablets to match simvastatin, orally, once daily
92826|NCT01336010|Drug|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
92827|NCT01336010|Drug|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
92828|NCT01336023|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
92829|NCT01336023|Drug|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
92830|NCT01336023|Drug|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
92831|NCT01336049|Drug|Nimotuzumab|Nimotuzumab 200mg/week
92832|NCT00057122|Drug|Rifampin|Rifampin 600 mg
92833|NCT01336062|Drug|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
92834|NCT01336075|Procedure|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
92835|NCT01336075|Procedure|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
92836|NCT01338350|Drug|Placebo|Inhalation, solution
88369|NCT01285141|Biological|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
88370|NCT01285167|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
88371|NCT01285180|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
88372|NCT01285193|Behavioral|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
88373|NCT01285206|Device|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
88374|NCT01285219|Drug|pegylated filgrastim and ﬁlgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
88375|NCT01285219|Drug|ﬁlgrastim and pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
88376|NCT01285232|Drug|Anakinra|150 mg sc once daily during four weeks
88683|NCT01288261|Drug|paclitaxel|Given IV
88684|NCT01288261|Biological|bavituximab|Given IV
88685|NCT01288261|Other|laboratory biomarker analysis|Correlative studies
88686|NCT01288261|Other|pharmacological study|Correlative study
88687|NCT01288274|Other|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
88688|NCT01288300|Behavioral|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
88689|NCT00053209|Drug|gemcitabine hydrochloride|
88690|NCT01290497|Drug|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
88691|NCT01290497|Drug|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
88692|NCT01290497|Drug|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
88693|NCT01290510|Device|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
88694|NCT01290523|Device|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
92099|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
92100|NCT01311661|Drug|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
92101|NCT01311661|Drug|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
92102|NCT00001048|Drug|Cytarabine|
92103|NCT00054730|Drug|CX516 (Ampalex®)|
92104|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
92105|NCT01311661|Drug|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
92106|NCT01311661|Drug|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
92107|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 20 ug/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 ug/1.0 mL
92108|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 40 ug/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 ug/1.0 mL
92109|NCT01311687|Drug|pomalidomide|4 mg pomalidomide will be administered by mouth on Days 1-21 of each 28-day treatment cycle until disease progression
92110|NCT01311687|Drug|dexamethasone|For Subjects ≤ 75 years of age:
40 mg of low-dose dexamethasone will be administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression
For Subjects > 75 years of age:
20 mg low-dose dexamethasone will be administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression
92111|NCT01304147|Drug|placebo|Single dose of saline intranasal
92112|NCT01304160|Radiation|stereotactic body radiotherapy|30Gray in 5 fractions
92657|NCT01335711|Drug|ChronVac-C + SOC|IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.
SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
92658|NCT01335711|Drug|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
92659|NCT01335724|Drug|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
92660|NCT01335724|Drug|Placebo gel|Placebo gel
92661|NCT01335737|Behavioral|aerobic training|12 weeks of aerobic training, 4 times/week
91882|NCT01306253|Biological|Inflexal V|Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1
91883|NCT01306266|Drug|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
91884|NCT01306266|Drug|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
91885|NCT00000252|Drug|40% N2O|
91886|NCT00001046|Biological|MF59|
91887|NCT00054353|Drug|cyclosporine|Given PO
91888|NCT01306292|Drug|SonoVue|dose of 4.8 mL administered intravenously one time
91889|NCT01306292|Drug|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
91890|NCT01306305|Biological|Inflexal V|Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus
15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
91891|NCT01308463|Device|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
91892|NCT01308476|Procedure|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
91893|NCT01308476|Procedure|control group|no daily SMS to remind of treatment with tiotropium
91894|NCT00001047|Drug|Clarithromycin|
91895|NCT00054535|Biological|recombinant fowlpox-tyrosinase vaccine|
91896|NCT01308489|Procedure|therapeutic conventional surgery|Undergo posterior spinal tumor resection
91897|NCT01308489|Procedure|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
91898|NCT01308489|Procedure|quality-of-life assessment|Ancillary studies
92166|NCT01308996|Procedure|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
92167|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
92168|NCT01309009|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
92837|NCT01338376|Behavioral|Structured Education|All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.
Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS
Physician Activity: frequent insulin titration
92838|NCT01338376|Behavioral|Conventional Diabetes Education|The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.
Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia
Physician Activity: less frequent insulin titration
91956|NCT01303965|Drug|Sirolimus|Start on Day -3 and continue for 1 year
91957|NCT01303965|Drug|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
91958|NCT01303965|Drug|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
91959|NCT01303978|Drug|APD421|Single dose
91960|NCT01306318|Drug|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
91961|NCT01306318|Drug|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
91962|NCT01306331|Drug|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
91963|NCT01306331|Drug|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
91964|NCT01306357|Drug|Somatropin|4 mg or 10 mg delivered by needle-free device
91965|NCT01306370|Drug|Tranexamic Acid|Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
Each dosage: 2 ampoules of 500mg/5 mL/ampoule
91966|NCT01306370|Drug|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
91967|NCT00054353|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
91968|NCT01306370|Biological|Fibrin glue|Topical administration, before to close the surgical wound.
91969|NCT01306370|Other|Habitual haemostasis|The surgical habitual haemostasis.
91970|NCT01306383|Other|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
88695|NCT01290536|Device|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
88696|NCT01290549|Drug|DCDS4501A|Escalating intravenous dose
88697|NCT01290549|Drug|rituximab|375 mg/m2 iv, Day 1 of each 21-day cycle
88698|NCT01290562|Radiation|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
88699|NCT01290575|Drug|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
88700|NCT00053209|Drug|pemetrexed disodium|
88701|NCT01290575|Drug|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
88702|NCT01290575|Drug|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
88703|NCT01290575|Drug|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
88704|NCT01290575|Drug|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
88705|NCT01290575|Drug|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
88990|NCT01293253|Behavioral|Stair walking|Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
88991|NCT01293266|Drug|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
88992|NCT01286207|Drug|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
88993|NCT00052923|Procedure|peripheral blood stem cell transplantation|
88994|NCT01286207|Drug|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
88995|NCT01286207|Drug|Standard Care|Active standard care
88996|NCT01286220|Other|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
88997|NCT01286220|Other|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
88998|NCT01286233|Drug|Metformin|
88999|NCT01286233|Drug|Placebo|
92662|NCT00057083|Other|Telemedicine Care|
92663|NCT01335737|Behavioral|Wait list|wait list control condition
92664|NCT01335750|Other|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
92665|NCT01335750|Other|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
92666|NCT01335750|Other|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
92667|NCT01335750|Other|Multipurpose Solution #4|Saline Solution
92668|NCT01335763|Drug|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
92669|NCT01335776|Behavioral|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
92670|NCT01335776|Behavioral|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
92671|NCT01335789|Drug|Oxytocin|40 IUs
92672|NCT01335789|Drug|Saline|40 IUs
92673|NCT00057096|Procedure|On-site vs. referral methods of care|
92674|NCT01337882|Other|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin [100, 300 & 1000 pmol/min]; acetylcholine [5, 10 & 20 µg/min]) and -independent [sodium nitroprusside [2, 4 & 8 µg/min]; verapamil [10, 30 & 100 µg/min]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
92675|NCT01337895|Other|Low dairy|No more than 1 serving per day
92676|NCT01337895|Other|High dairy|4 or more servings per day
92677|NCT01337921|Dietary Supplement|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
92695|NCT01340365|Behavioral|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
92696|NCT01340365|Behavioral|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
92697|NCT00057603|Procedure|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
92169|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
92170|NCT01309022|Drug|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
92171|NCT01309022|Drug|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
92172|NCT01309022|Drug|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
92173|NCT00054561|Drug|isotretinoin|
92174|NCT01309022|Drug|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
92175|NCT01311700|Drug|Injectable (i.v.) metoprolol tartrate (up to 15 mg).|Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).
Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.
Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.
Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion.
92176|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Dose escalation will proceed until the MTD is identified.
92177|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Patients will be administered CEP-9722 at the MTD identified in Part 1.
92178|NCT00054743|Procedure|Blood draw|
92179|NCT01311739|Drug|Cyanocobalamin|
92180|NCT01311752|Procedure|surgical management of high grade lesions|Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.
Surgical sample will be collected to study human papillomavirus related genital pathology.
92181|NCT01311765|Other|Duration of antibiotic therapy limited to 8 days|Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
92182|NCT01311778|Drug|Cannabidiol|Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.
Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.
92183|NCT01311778|Drug|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
92184|NCT01311791|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
92185|NCT01311791|Drug|Standard medical therapy|as defined per protocol
92437|NCT01339871|Drug|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
91971|NCT01306396|Behavioral|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
91972|NCT01306409|Drug|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
91973|NCT01306409|Drug|ESA|Sequential application of three different ESA
91974|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
91975|NCT01306422|Other|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
92243|NCT01309100|Device|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
92244|NCT01309100|Device|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
92245|NCT01309113|Drug|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
92246|NCT00054561|Procedure|adjuvant therapy|
92247|NCT01309126|Biological|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
92248|NCT01309126|Drug|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
92249|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
92250|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
92251|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
92252|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
92253|NCT01309165|Behavioral|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
89000|NCT01286246|Drug|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
89001|NCT01286246|Drug|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
89002|NCT01286259|Drug|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
89003|NCT01286272|Drug|Bendamustine Hydrochloride|Given IV
89004|NCT00052923|Radiation|radiation therapy|
89005|NCT01286272|Drug|Bortezomib|Given IV or SC
89006|NCT01286272|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET
89007|NCT01286272|Other|Laboratory Biomarker Analysis|Correlative studies
89008|NCT01286272|Biological|Ofatumumab|Given IV
89009|NCT01286272|Procedure|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
89010|NCT01286298|Procedure|Laser gingivectomy|Gingivectomy by diode laser
89011|NCT01286298|Procedure|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
89012|NCT01286311|Behavioral|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
89310|NCT01289327|Drug|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (~2 minutes) or according to clinical judgment.
89311|NCT01289353|Drug|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
89312|NCT01289353|Radiation|3D-RT or IMRT|From week 2 to week 4 in the 6-week Carboplatin treatment:
Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy
89313|NCT00053131|Biological|sargramostim|
89314|NCT01291433|Drug|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
89315|NCT01291433|Drug|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
89316|NCT00053326|Drug|fenretinide|Given orally
92698|NCT01340391|Device|Omnicast|dorsal splint 2-5 weeks
92699|NCT01340404|Procedure|Stem cell transplantation|Stem cell transplantation
92700|NCT01340404|Procedure|Transfusion program|Transfusion program
92701|NCT01340417|Other|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
92702|NCT01340430|Drug|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
92703|NCT01340456|Drug|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
92704|NCT01340469|Biological|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
92705|NCT01340482|Drug|Biological KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
92706|NCT01340495|Radiation|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
92707|NCT01340508|Radiation|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
92708|NCT00057616|Drug|CC-5013|
92709|NCT01340521|Drug|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
92710|NCT01340534|Device|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
92711|NCT01340534|Procedure|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
92712|NCT01340547|Drug|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
92713|NCT01340547|Drug|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
92714|NCT01340560|Procedure|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
91819|NCT01308424|Drug|Matching placebo|sublingual dosing for 7 days
91820|NCT01308437|Biological|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
92438|NCT00057551|Drug|Venlafaxine XR|
92439|NCT01339871|Drug|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
92440|NCT01339884|Drug|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
92441|NCT01339897|Drug|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
92442|NCT01339897|Drug|Placebo|Same administration procedures as active
92443|NCT01339897|Drug|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
92444|NCT01339897|Drug|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
92445|NCT01339910|Drug|Fludarabine and Busulfan|(Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
92446|NCT01339910|Drug|Fludarabine and Melphalan|(Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2
92447|NCT01339910|Drug|Busulfan and Fludarabine|(Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
92448|NCT01339910|Drug|Busulfan and Cyclophosphamide|(Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
92449|NCT00057551|Drug|Mirtazapine|
92450|NCT01339910|Drug|Cyclophosphamide and Total Body Irradiation|(Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
92451|NCT01339923|Biological|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
92452|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
92453|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
92454|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses 2 months apart
92455|NCT01339923|Biological|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
92456|NCT01339923|Biological|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
92254|NCT01309165|Behavioral|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
92255|NCT01309178|Drug|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
92256|NCT01309178|Drug|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
92257|NCT00001047|Drug|Clofazimine|
92258|NCT01311869|Dietary Supplement|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
92259|NCT01311869|Dietary Supplement|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
92512|NCT01337713|Other|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
92513|NCT01337726|Behavioral|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
92514|NCT00001063|Drug|Stavudine|
92515|NCT00057356|Drug|placebo|IV
92516|NCT01337726|Behavioral|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
92517|NCT01337739|Drug|Placebo Comparator|Placebo administration (.9 normal saline sterile)
92518|NCT01337739|Drug|Active Comparator|Administration of Dexmedetomidine
92519|NCT01337752|Drug|BHQ880|
92520|NCT01337752|Drug|BHQ990|
92521|NCT01337765|Drug|BEZ235 + MEK162|
92522|NCT01337778|Behavioral|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
89317|NCT01291446|Dietary Supplement|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
89318|NCT01291459|Drug|MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir|MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
89319|NCT01291472|Drug|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
89320|NCT01291485|Behavioral|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
89321|NCT01291498|Device|High Intensity Focused Ultrasound|One or two HIFU sessions
89322|NCT01291511|Drug|Iloperidone|Iloperidone capsules/tablets will be administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
89323|NCT01291511|Drug|Placebo|Matching placebo capsules will be administered orally duins a bid schedule during the double-blind period.
89324|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
89325|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
89326|NCT01291524|Drug|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
89327|NCT00053326|Other|pharmacological study|Optional correlative studies
89328|NCT01291524|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
88377|NCT01285245|Drug|kineret|once daily 100 mg of kineret subcutaneously for 8 days
88378|NCT00052884|Procedure|peripheral blood stem cell transplantation|
88379|NCT01285258|Procedure|hysterectomy|excluding the uterus with saving ovaries
88380|NCT01285271|Drug|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
88381|NCT01285271|Drug|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
88382|NCT01285284|Other|Music|A previously defined list of songs will be administered by headphones to these patients.
91821|NCT01308437|Biological|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
91822|NCT01311076|Drug|Placebo|TAK-329 placebo-matching tablets, orally, single dose, one day.
91823|NCT01311102|Drug|Lidocaine|1.33 cc 2% liquid lidocaine
91824|NCT00054678|Device|MyoCath™|
91825|NCT01311102|Drug|Normal Saline|1.33cc normal saline
91826|NCT01311115|Behavioral|Group commitment contract|Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.
The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.
Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt.
91827|NCT01311115|Behavioral|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
91828|NCT01311128|Device|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This intervention will be repeated, for a second two-hour period, in the ICU postoperatively.
91829|NCT01311141|Drug|doripenem|doripenem once i.v.500mg
91830|NCT01311167|Drug|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
91831|NCT01311167|Drug|Placebo|Daily administration of 2 mg of placebo for 4 days
91832|NCT01311180|Drug|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
91833|NCT01311180|Drug|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
91834|NCT01311193|Other|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
91835|NCT00054691|Drug|Iressa|250 mg by mouth daily
92113|NCT01304186|Behavioral|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
92457|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
92764|NCT01338298|Drug|Aripiprazole|Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.
92765|NCT01338298|Drug|Placebo|The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
92766|NCT01338311|Drug|salbutamol|200mcg twice daily for a total of 7 doses
92767|NCT01338311|Drug|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
92768|NCT01338324|Drug|Simvastatin|Simvastatin 20 mg single dose on day 1
92769|NCT01338337|Drug|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
92770|NCT01338350|Drug|AZD5423|Inhalation, suspension
92771|NCT01340573|Drug|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
92772|NCT01340573|Drug|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.
92773|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
92774|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
92775|NCT00057629|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
92776|NCT01340599|Dietary Supplement|defined green tea catechin extract|Given PO
92777|NCT01340599|Other|placebo|Given PO
92778|NCT01340599|Other|immunohistochemistry staining method|Correlative studies
92779|NCT01340599|Other|immunoenzyme technique|Correlative studies
92780|NCT01340599|Other|questionnaire administration|Ancillary studies
92781|NCT01340599|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
92523|NCT01339949|Device|IRay|low voltage external beam radiosurgery
92524|NCT01339962|Other|Non-interventional|Non-interventional (retrospective chart reviews)
92525|NCT01339975|Biological|Biological sample|2 blood samples of 10mL + one urine sample
on pre-operative d-1/d, post-operative d1 and d5(+/-2),
one month post-operative,
at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises.
92526|NCT01339975|Biological|Biological sample|2 blood samples of 10mL + one urine sample
before starting the therapy
at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)
at the end of the study or at the date of disease progression.
92527|NCT01339988|Drug|Busulfan/Cyclophosphamide|Conditioning regimen:
Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days.
92528|NCT01340001|Procedure|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
92529|NCT01340014|Drug|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
92530|NCT01340014|Drug|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
92531|NCT01340027|Drug|Mirabegron|oral
92532|NCT00057564|Drug|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
92839|NCT00057408|Drug|Placebo|Matching Placebo
92840|NCT01338376|Drug|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
92841|NCT01338389|Dietary Supplement|CITICOLINE|Oral administration of CITICOLINE:
Form: Powder for solution Dosage: 800mg per day duration: 5 years
92842|NCT01338389|Dietary Supplement|PLACEBO|Oral administration of placebo:
Form: Powder for solution duration: 5 years
92843|NCT01338402|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
92844|NCT01338402|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
92845|NCT01338402|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
92846|NCT01338415|Drug|Bosentan|bosentan 2mg/kg b.i.d.
92847|NCT01338415|Drug|Bosentan|bosentan 2mg/kg t.i.d.
88383|NCT01287624|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
88384|NCT01287624|Drug|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
88385|NCT01287637|Procedure|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
88386|NCT01287637|Procedure|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
88387|NCT01287663|Drug|Permethrin impregnated|
88388|NCT01287663|Drug|no Permethrin impregnated|
88389|NCT01287689|Other|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
88390|NCT00053014|Drug|mycophenolate mofetil|
88391|NCT01287702|Dietary Supplement|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
88392|NCT01287702|Dietary Supplement|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
88393|NCT01287702|Dietary Supplement|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
88394|NCT01287715|Drug|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
88395|NCT01287715|Drug|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
88396|NCT01287728|Drug|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
88397|NCT01287741|Drug|CHOP chemotherapy|CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) iv every 21 days, 6 or 8 cycles
88706|NCT01290575|Drug|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
88707|NCT01290575|Drug|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
88708|NCT01290575|Drug|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
88709|NCT01290601|Drug|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
92114|NCT01304212|Drug|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
92115|NCT00054262|Drug|T900607|
92116|NCT01304212|Drug|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
92117|NCT01304212|Drug|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
92118|NCT01304212|Drug|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
92119|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
92120|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
92121|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
92122|NCT01304238|Drug|lepirudin|lepirudin
92123|NCT01304238|Drug|danaparoid|danaparoid
92124|NCT01304238|Drug|argatroban|argatroban
92125|NCT01304238|Drug|fondaparinux|fondaparinux
92126|NCT00054275|Drug|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
92127|NCT01304251|Other|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
92128|NCT01304251|Other|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
92129|NCT01304264|Device|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
92130|NCT01304277|Biological|agalsidase alfa|
92782|NCT01340599|Other|high performance liquid chromatography|Correlative studies
92783|NCT01340599|Other|mass spectrometry|Correlative studies
91899|NCT01308502|Device|Dx-pH probe|Dx-pH probe with 24 hour recording
91900|NCT01308515|Device|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
91901|NCT01308515|Device|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
91902|NCT01308528|Drug|Sodium enoxaparin|40 mg/mL
91903|NCT01308528|Drug|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
91904|NCT01308541|Drug|arm 1|Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.
Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
91905|NCT01308541|Drug|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
91906|NCT00054535|Biological|vaccinia-tyrosinase vaccine|
91907|NCT01308541|Drug|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
91908|NCT01308554|Drug|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
91909|NCT01308554|Drug|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
91910|NCT01308567|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form:solution
Route of administration: intravenous
91911|NCT01308567|Drug|Docetaxel (XRP6976)|Pharmaceutical form:solution
Route of administration: intravenous
91912|NCT01308567|Drug|Prednisone|Pharmaceutical form:tablet
Route of administration: oral
91913|NCT01308580|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form:solution
Route of administration: intravenous
91914|NCT01308580|Drug|Prednisone|Pharmaceutical form:tablet
Route of administration: oral
91915|NCT01308593|Device|Juvederm XC|Filler
91916|NCT01308593|Drug|Botox|26 units dosed one time
92848|NCT01338428|Behavioral|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge[ment]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
92849|NCT01338428|Behavioral|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
92850|NCT00057421|Drug|prednisolone|
92851|NCT01338441|Drug|Erythromycin|4mg/Kg, IV during 20 min once
92852|NCT01338441|Drug|Placebo|4mg/Kg, IV during 20 min once
92853|NCT01338454|Drug|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
92854|NCT01338467|Device|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
92855|NCT01338480|Other|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery.
92856|NCT01340664|Drug|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
92857|NCT01340677|Drug|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
91976|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
91977|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
91978|NCT00054353|Procedure|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
91979|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
91980|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
91981|NCT01306435|Other|Laser|3-week treatment with three Laser sessions per week
91982|NCT01306435|Other|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
88710|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
88711|NCT00053222|Drug|arsenic trioxide|
88712|NCT01290601|Drug|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
88713|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
88714|NCT01292941|Device|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
88715|NCT01292941|Device|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
88716|NCT01292941|Device|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
88717|NCT00053430|Drug|Thalidomide placebo|Placebo tablet taken orally daily
88718|NCT01292954|Dietary Supplement|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
88719|NCT01292967|Dietary Supplement|Low flavanol chocolate|48 mg of total flavanols from cocoa
88720|NCT01292967|Dietary Supplement|High-flavanol with sugar|high-flavanol containing 251 mg cocoa flavanols
88721|NCT01292967|Dietary Supplement|High flavanol Maltitol|high-flavanol containing 266 mg cocoa flavanols
88722|NCT01292980|Device|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
88723|NCT01292993|Drug|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
88724|NCT01292993|Drug|1000 mg metformin|1000 mg metformin given as a solid oral dose form
88725|NCT01293006|Drug|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants <65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
88726|NCT01293006|Drug|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
89013|NCT01286324|Dietary Supplement|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
89014|NCT01286324|Drug|Placebo Tablet|
92373|NCT01304771|Biological|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide [FOS], NutraFlora®).
92374|NCT01304784|Drug|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
92375|NCT01304784|Drug|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
92376|NCT01304784|Drug|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
92377|NCT00054301|Radiation|intraoperative radiation therapy|Patients undergo excisional biopsy or surgery followed by an intraoperative dose of radiation to the tumor cavity.
92378|NCT01304784|Drug|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
92379|NCT01304784|Drug|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
92380|NCT01304797|Drug|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
92381|NCT01304797|Drug|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
92382|NCT01304797|Drug|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
92383|NCT01304797|Drug|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
92384|NCT01304810|Biological|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
92385|NCT01304810|Biological|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
92386|NCT01307020|Drug|Placebo|Placebo, oral film-coated table, once
92387|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
92388|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
92389|NCT00001046|Biological|rgp120/HIV-1 SF-2|
92390|NCT00054418|Dietary Supplement|vitamin D|vitamin D 400 U daily administered orally for one year
92391|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
92392|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
91917|NCT01311219|Procedure|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
91918|NCT01311219|Procedure|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
92186|NCT01311804|Procedure|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
92187|NCT01311804|Procedure|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
92188|NCT01311817|Biological|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
92189|NCT00054756|Drug|TRH (Thyrotropin Releasing Hormone)|
92190|NCT01311830|Behavioral|Telephone Counseling|
92191|NCT01311830|Behavioral|Written Materials|
92192|NCT01311856|Behavioral|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
92193|NCT01311856|Behavioral|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
92194|NCT01311856|Behavioral|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
92195|NCT01311856|Behavioral|Exercise and Diet|15 minutes of strength exercise every other day, >30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
92196|NCT01304303|Drug|SPARC1023 I|IV administration
92197|NCT01304303|Drug|SPARC1023 II|IV administration
92198|NCT01304316|Drug|3% tetracaine hydrochloride plus 0.05% oxymetazoline hydrochloride|Each subject received the standard dose (3 sprays in each nostril with 4 minutes between each pair of sprays) followed 1 to 3 weeks later by the high dose (as 6 sprays in each nostril).
92199|NCT01304329|Drug|BI 10773|Medium dose oral administration
92200|NCT01304329|Drug|simvastatin|Medium dose oral administration
92201|NCT00054275|Drug|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
91983|NCT00054548|Biological|oblimersen sodium|Given IV
91984|NCT01308606|Drug|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
91985|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
91986|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
91987|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
91988|NCT01308606|Drug|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
91989|NCT01308619|Drug|Doxycycline|doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
91990|NCT01308619|Other|Placebo|Placebo, oral, one capsule daily in the morning
91991|NCT01308632|Drug|Temozolamide, irinotecan|Phase I trial:
TMZ will be administered in a fixed schedule as follows:
TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.
100 mg/m2 in a morning single dose on days 8 and 22
CPT-11 starting dose:
100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)
One cycle = 28 days
CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 .
91992|NCT01308645|Drug|SB injection|Infusion SB injection of 21.87 ml/m^2, IV route, 24 times for 4 months
91993|NCT01308658|Drug|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
91994|NCT00054548|Drug|paclitaxel|Given IV
91995|NCT01308658|Drug|ritonavir|on Day 3
91996|NCT01308671|Drug|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
91997|NCT01308671|Behavioral|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
92260|NCT01311882|Drug|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
92261|NCT01311882|Drug|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
92262|NCT00054795|Drug|Motexafin Gadolinium|
92263|NCT01311882|Drug|Zopiclone|1 x 7.5 mg Zopiclone tablet
92264|NCT01311882|Drug|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
92265|NCT01311882|Drug|Matching Placebo for MK-4305|Matching Placebo for MK-4305
89015|NCT00052936|Biological|filgrastim|
89016|NCT01286337|Procedure|bipolar vessel sealing|
89017|NCT01286337|Procedure|control|
89018|NCT01288729|Device|Sure-T or Quick-Set|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
89019|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
89020|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
89021|NCT01288742|Drug|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
89022|NCT01288742|Drug|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
89023|NCT00053105|Drug|methylprednisolone|
89024|NCT01288742|Drug|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
89025|NCT01288755|Drug|TMC278|One 25 mg tablet, once daily, for 11 days (TrtA and C)
89026|NCT01288755|Drug|Raltegravir|One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
89027|NCT01288768|Procedure|Knee arthroscopy|Knee arthroscopy within 4 weeks.
89028|NCT01288781|Drug|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
89029|NCT01288781|Drug|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
89030|NCT01288794|Drug|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
89031|NCT01288794|Drug|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
89032|NCT01288807|Drug|Milnacipram|Titration to 200mg PO daily
89033|NCT01288820|Drug|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
89034|NCT00053105|Drug|pixantrone dimaleate|
89035|NCT01288820|Drug|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
92393|NCT01307033|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
92715|NCT01342601|Device|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
92716|NCT01342601|Device|Placebo products|Nasal Spray and Eye drops without Ectoin
92717|NCT01342614|Drug|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
92718|NCT01342614|Drug|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
92719|NCT01342627|Drug|Sorafenib|Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.
In case of toxicities, dose reduction/interruption is permitted according to the protocol.
In case of disease progression Sorafenib administration will be discontinued.
92720|NCT01342640|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
92721|NCT01342653|Other|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
92722|NCT01342666|Dietary Supplement|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
92723|NCT01342666|Dietary Supplement|Cucumber consumption|Daily consumption of 300g of cucumber.
92724|NCT00057798|Procedure|neoadjuvant therapy|
92725|NCT01342679|Drug|dasatinib|100mg QD
92726|NCT01342692|Drug|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
92727|NCT01342692|Drug|Azacitidine associated with Valproic acid|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.
- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)
- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)
92728|NCT01342692|Drug|Azacitidine associated with Lenalidomide|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.
Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)
92729|NCT01342705|Procedure|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
92202|NCT01304329|Drug|simvastatin|Medium dose oral administration
92203|NCT01304329|Drug|BI 10773|Medium dose oral administration
92204|NCT01304342|Drug|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
92205|NCT01304342|Drug|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
92206|NCT01304342|Drug|Normal saline|Normal saline intravenously and intranasally
92458|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
92459|NCT01339936|Device|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
92460|NCT00057564|Drug|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
92461|NCT01339949|Device|IRay|low voltage external beam radiosurgery
92462|NCT01342250|Biological|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
92463|NCT01342250|Biological|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
92464|NCT01342263|Behavioral|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
92465|NCT01342276|Behavioral|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
92466|NCT01342289|Procedure|Bone Marrow Transplant|Preparative regimen consists of Fludarabine - 30 mg/m2/day , Cytoxan - 14.5 mg/kg/day , and Total Body Irradiation administered in a single fraction , with posttransplantation high-dose Cytoxan - 50 mg/kg IV, Mycophenolate mofetil - 15 mg/kg PO TID, and tacrolimus- starting dose is 1 mg IV QD.
92467|NCT01342302|Behavioral|Psychosocial Intervention for Couples|Intervention delivered on line
92468|NCT00001066|Drug|Zidovudine|
92469|NCT00057798|Drug|vinorelbine ditartrate|
92266|NCT01311895|Drug|H2O|2 mg IV hydromorphone
92267|NCT01311895|Drug|1+1|1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers "yes" to the question, "Do you want more pain medication?"
92268|NCT01311908|Procedure|Methods of gastrojejunostomy reconstruction|Roux-en-Y reconstruction in pancreaticoduodenectomy
92269|NCT01311947|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
92270|NCT01311960|Drug|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
92271|NCT01311960|Drug|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
92272|NCT01312012|Drug|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level > 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
92273|NCT00054808|Drug|gallium nitrate|
92274|NCT01312025|Procedure|conventional laparoscopic cholecystectomy|
92275|NCT01312025|Procedure|modified laparoscopic cholecystectomy|
92276|NCT01312038|Drug|Simethicone|single 125 mg chewable tablet
92277|NCT01312038|Drug|Placebo|chewable calcium tablet
92278|NCT01312064|Drug|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
92279|NCT01312064|Drug|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
92280|NCT01304485|Drug|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
92281|NCT01304498|Biological|1 dose at Day 1, 1 dose at Month 2 and 1 dose at Month 6|1 dose 0.5 mL
92533|NCT01340027|Drug|Solifenacin succinate|oral
92534|NCT01340027|Drug|Placebo|oral
92535|NCT01340040|Drug|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
92536|NCT01340053|Drug|RDX5791|Capsule, QD
89329|NCT01291537|Drug|Duodopa|
89330|NCT01291537|Drug|best médical treatment|
89331|NCT01291563|Drug|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
89332|NCT01291563|Drug|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
89333|NCT01291563|Drug|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
89334|NCT01291563|Drug|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
89335|NCT01291576|Procedure|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
89336|NCT01291576|Procedure|Rectal nodule excision|Either full thickness excision or rectal shaving
89337|NCT01291589|Behavioral|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
89338|NCT00001040|Drug|Zidovudine|
89339|NCT01284205|Biological|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
89340|NCT01284205|Biological|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
89341|NCT01284231|Drug|MEDI-565|MEDI-565 will be administered by IV infusion
89342|NCT01284231|Drug|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
89343|NCT01284231|Drug|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
89344|NCT01284231|Drug|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
89345|NCT01284244|Device|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
92730|NCT01342718|Dietary Supplement|Herbal extract granule and probiotics|The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)
91836|NCT01311206|Other|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
91837|NCT01311206|Other|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
91838|NCT01311219|Other|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
91839|NCT00054938|Behavioral|heart health educational program|
91840|NCT01313494|Drug|Placebo|Placebo tablets
91841|NCT01313494|Drug|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
91842|NCT01313507|Biological|NewGam|NewGam IV infusion
91843|NCT01313520|Drug|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
91844|NCT01313520|Drug|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
91845|NCT01313533|Drug|Polyarginine|Vein soak treated with polyarginine
91846|NCT01313533|Drug|Lactated Ringers Solution|Vein soak
91847|NCT01313546|Other|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
91848|NCT01313559|Drug|Pasireotide|Given IM
91849|NCT01313559|Drug|Everolimus|Given PO
91850|NCT00054951|Drug|MTC-DOX for Injection|
92470|NCT01342315|Drug|33525|Daily dosing
92471|NCT01342315|Drug|Placebo|Daily dosing
92472|NCT01342328|Other|Normal saline infusion|Normal saline infusion
92473|NCT01342328|Drug|Dexmedetomidine|Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.
We aim to achieve an RASS of -3 so that the subjects are "moderately sedated". This state of sedation will be maintained for 3-4 hours.
92784|NCT01340612|Device|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
92785|NCT01340612|Device|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
92786|NCT00057629|Behavioral|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
92787|NCT01340625|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
92788|NCT01340625|Drug|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
92789|NCT01340638|Device|cookgas mask|This group will be assigned to use cookgas mask
92790|NCT01340638|Device|LMA mask|LMA mask
92791|NCT01340651|Drug|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
92792|NCT01340664|Drug|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
92793|NCT01340664|Drug|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
92794|NCT01340664|Drug|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
92795|NCT01342718|Dietary Supplement|Placebo herbal extract granule and probiotics|The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).
The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)
94977|NCT01324492|Drug|RAD001|
94978|NCT01324505|Drug|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
94979|NCT01324505|Drug|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
94980|NCT01324505|Drug|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
94981|NCT01326871|Biological|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
94982|NCT01326884|Device|ZLP|ZLP Graft
94983|NCT01326897|Behavioral|Healthy Homes/Healthy Families|Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a "menu" of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings.
94984|NCT01326897|Behavioral|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
94985|NCT01326910|Drug|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
94986|NCT01326910|Device|Topical Cream|Topical cream applied twice daily (or as needed)
94987|NCT01326923|Drug|Cetuximab|Single arm phase II study of chemotherapy
94988|NCT00056134|Biological|recombinant CD40-ligand|
94989|NCT01326936|Behavioral|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
95314|NCT01361971|Procedure|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
95315|NCT01361984|Drug|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is ~9 minutes
95316|NCT00059839|Drug|mercaptopurine|Given by mouth
95317|NCT01361984|Drug|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
93114|NCT01338857|Drug|Sorafenib (Nexavar)|Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
Children/adolescents (< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily
Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily
NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily
93115|NCT01338870|Drug|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
93116|NCT01338870|Drug|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
93117|NCT01338870|Drug|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
93118|NCT01338870|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
93119|NCT01338870|Drug|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
93120|NCT01338870|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
93121|NCT01338883|Drug|Cenicriviroc 100 mg|100 mg CVC plus Truvada
93122|NCT00057473|Drug|carboplatin + irinotecan|Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.
93419|NCT01341704|Biological|MSP3-LSP/AlOH|30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)
Secondary administration (Boost):
Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1
93420|NCT01341704|Biological|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
93421|NCT01341704|Other|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
93422|NCT01334502|Drug|prednisone|PO
93423|NCT01334502|Drug|vincristine sulfate|IV
93424|NCT01334515|Biological|hu14.18-IL2 fusion protein|Given IV
93425|NCT01334515|Drug|isotretinoin|Given PO
93426|NCT01334515|Biological|sargramostim|Given SC
93427|NCT01334515|Other|laboratory biomarker analysis|Correlative studies
95373|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
95374|NCT01359332|Procedure|Moderate hypothermia|procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
95375|NCT00059592|Drug|Valacyclovir|
95376|NCT01359345|Drug|gadollinum|use of on injection gadollinum Iv for imaging
95377|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
95378|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
95379|NCT01359410|Device|Mesh reinforced staple line (SEAMGUARD)|Reinforce the pancreatic transaction with SEAMGUARD®
95380|NCT01359410|Device|Stapled without mesh reinforcement (PER-STRIPS DRY)|Stapled without mesh reinforcement (PERI-STRIPS DRY®)
95381|NCT01359423|Drug|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
95382|NCT01359423|Drug|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
95383|NCT01359436|Device|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
95384|NCT01359449|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
95385|NCT01359449|Biological|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
94206|NCT01325584|Drug|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
93341|NCT01334333|Drug|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
93342|NCT01334333|Drug|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
93343|NCT01334346|Other|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
93344|NCT01334346|Other|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
93345|NCT00056979|Drug|Anti-CD45|
93346|NCT01334346|Other|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
93347|NCT01334359|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
93348|NCT01334372|Behavioral|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
93349|NCT01334398|Behavioral|Health & Wellness|The specific content of the intervention was adapted from four existing evidence-based interventions: (1) "Healthy Lifestyles for People with Disabilities," (2) Promoting Wellness for Women with MS," (3) "Living Well with Disability," and (4) "Social Skills and TBI: A Workbook for Group Treatment."
93350|NCT01334424|Drug|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
93351|NCT01334450|Device|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
93352|NCT01334489|Device|Arabin Cervical Pessary|The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).
It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
93353|NCT01334502|Biological|rituximab|PO
93354|NCT01334502|Drug|cyclophosphamide|IV
93355|NCT01334502|Drug|doxorubicin hydrochloride|IV
93356|NCT00056979|Drug|FK506|
93357|NCT01334502|Drug|everolimus|PO
93358|NCT00057226|Drug|Radafaxine|
93359|NCT01336894|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
93655|NCT01342016|Drug|prednisone|oral
93656|NCT01342029|Drug|Ranolazine|This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.
500-1,000 mg po bid for 2 weeks
93657|NCT01342029|Drug|Placebo|500-1,000 mg po bid for 2 weeks
93945|NCT01327586|Behavioral|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
93946|NCT01327599|Drug|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
93947|NCT00056212|Behavioral|Exercise|
93948|NCT01327612|Drug|FOLFOX6|Oxaliplatin: 100mg/m2, IV in 500mL of D5W over 120 minutes on Day 1 Leucovorin: 400mg/m2, IV diluted in D5W over 120 minutes (concurrently with oxaliplatin) on Day 1 Fluorouracil: 400 mg/m2, IV bolus, after leucovorin, on Day 1 Fluorouracil: 2400mg/m2, CIV over 46 hours (single dose) start on Day 1 Cycle frequency: repeat every 14 days until disease progression or unacceptable toxicity
93949|NCT01327612|Biological|Conatumumab|Conatumumab is an investigational, fully human monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR-5.
93950|NCT01327612|Biological|Conatumumab|Conatumumab is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR5.
93951|NCT01327612|Biological|Ganitumab|Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
93952|NCT01327612|Biological|Bevacizumab|Recombinant humanized monoclonal antibody targeted against vascular endothelial growth factor (VEGF); angiogenesis inhibitor.
93953|NCT01327612|Biological|Ganitumab|Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
93954|NCT01327625|Drug|azithromycin + N-acetylcystein + inhaled corticosteroid|Azithromycin 500mg qd x 1 week --> 250mg qod x 6 months
N-acetylcystein 200mg tid x 6 months
Fluticasone 250mcg puff x2/day x 6 months
93955|NCT01327638|Drug|etoricoxib|Patients with SpA/AS who took etoricoxib
93956|NCT01327638|Drug|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
93957|NCT01327638|Drug|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
93958|NCT00056225|Drug|Folate|
93959|NCT01327651|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate, two nucleoside reverse transcriptase inhibitors.
93960|NCT01327664|Biological|AIN457|
93428|NCT01334541|Behavioral|SAFE VET|All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:
Risk Assessment
Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.
Clinical Follow-Up Protocol
93429|NCT01334554|Drug|Sildenafil|20 mg three times a day.
93430|NCT01334554|Drug|Placebo|No active drug
93431|NCT00001061|Drug|Sevirumab|
93432|NCT00056979|Drug|Fludarabine|
93433|NCT01334567|Drug|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
93434|NCT01334580|Behavioral|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
93435|NCT01334580|Behavioral|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
93436|NCT01334606|Device|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
93437|NCT01334606|Device|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
93722|NCT01337609|Other|Placebo (sugar pill)|1 pill daily for 60 days
93723|NCT01337609|Other|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
93724|NCT01337622|Procedure|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
93725|NCT01339689|Drug|Placebo|capsules, bid, up to 12 weeks
93726|NCT01339702|Other|The National Prehospital TBI Management Guidelines|In the post-implementation (after) cohort, implementation of the entire "bundle" of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients).
93727|NCT01339715|Procedure|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
94207|NCT01325597|Other|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
94208|NCT01325597|Other|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
94209|NCT01325597|Other|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
94210|NCT01325597|Other|Control group|No intervention
94211|NCT00056030|Biological|cetuximab|
94212|NCT01328028|Other|Data collection|Log sheet
94213|NCT01328041|Drug|dolutegravir|50 mg twice daily
94214|NCT01328054|Drug|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
94215|NCT01328054|Drug|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
94216|NCT01328067|Device|Exablate 2100|MRgFUS
94217|NCT00056264|Drug|Infliximab|
94218|NCT01328067|Procedure|Myomectomy|Non-Hysteroscopic Myomectomy
94219|NCT01328080|Radiation|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
94220|NCT01328093|Drug|LY2140023|Administered orally
94221|NCT01328093|Drug|Aripiprazole|Administered orally
94222|NCT01328106|Drug|GSK1120212|Repeating oral dose
94223|NCT01328119|Other|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
94224|NCT01328132|Drug|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
93281|NCT00057213|Drug|Radafaxine|
93360|NCT01336920|Drug|carfilzomib|Given IV
93361|NCT01336933|Drug|prednisone|Given PO
93362|NCT01336933|Drug|cyclophosphamide|Given IV
93635|NCT01339624|Drug|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
93636|NCT01339624|Drug|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
93637|NCT01339650|Drug|ABT-767|ABT-767 once or twice daily for a 28 day cycle
93638|NCT00057551|Drug|Sertraline|
93639|NCT01339663|Drug|cyclophosphamide|Given IV
93640|NCT01339663|Biological|aldesleukin|Given SC
93641|NCT01339663|Biological|autologous tumor cell vaccine|Receive T-APC via IV
93642|NCT01339663|Other|laboratory biomarker analysis|Correlative studies
93643|NCT01339663|Other|immunologic technique|Correlative studies
93644|NCT01339663|Other|immunohistochemistry staining method|Correlative studies
93645|NCT01339663|Genetic|polymerase chain reaction|Correlative studies
93646|NCT01339663|Biological|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
93647|NCT01339676|Drug|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
93648|NCT01339676|Drug|Placebo capsules|Identically appearing once weekly peroral placebo capsules
93649|NCT00057551|Drug|Escitalopram|
93650|NCT01339689|Drug|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
93651|NCT01342016|Drug|tacrolimus placebo|oral
93652|NCT01342016|Drug|leflunomide tablet|oral
93653|NCT00057785|Drug|cisplatin|100 mg/m^2 intravenously on days 1, 22, and 43 and 80 mg/m^2 intravenously on days 71, 99, and 127
93654|NCT01342016|Drug|leflunomide placebo|oral
93961|NCT01330628|Procedure|Balloon angioplasty|standard balloon catheters for PTA
93962|NCT01330641|Procedure|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
93963|NCT01330654|Drug|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
93964|NCT01330667|Dietary Supplement|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
93045|NCT01340937|Biological|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
93046|NCT01340950|Drug|zidovudine-lamivudine-nevirapine|48 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 400 mg orally twice daily
93047|NCT01340950|Drug|tenofovir-lamivudine-efavirenz|48 weeks of tenofovir disoproxil fumarate 300 mg orally daily, 3TC 300 mg orally daily, EFV 600 mg orally daily
93048|NCT01340976|Drug|LY2787106|Administered intravenously (IV).
93049|NCT01340976|Dietary Supplement|Iron Supplementation|Administered orally.
93050|NCT01340989|Procedure|alteration of the insufflation gas|addition of 4% oxygen
93051|NCT01340989|Procedure|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the peritoneum
humidification
set temperature of 32°C
93052|NCT01340989|Procedure|standard pneumoperitoneum|no intervention besides the use of CO2
93053|NCT01341002|Procedure|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 < 70% and guidelines
93054|NCT00057681|Drug|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
93055|NCT01341002|Procedure|Transfusion|transfusion based on guidelines
93056|NCT01341015|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
93057|NCT01341028|Procedure|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
93058|NCT01341028|Procedure|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
93059|NCT01341041|Biological|chlorine dioxide|one time wash with 50ppm CD solution
93728|NCT01339728|Procedure|far-infrared ray|The duration of far-infrared ray is 20 minutes.
93729|NCT01339741|Dietary Supplement|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
93730|NCT01339741|Drug|Placebo|Placebo, oral route, 12 weeks
93731|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
93732|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
93733|NCT01339780|Radiation|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
93734|NCT00057551|Drug|Bupropion SR or XL|
93735|NCT01339806|Behavioral|Cognitive Rehab|APT-III, Other standard individual and group interventions.
93736|NCT01339806|Behavioral|Brainworks|POSIT
93737|NCT01339806|Behavioral|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
93738|NCT01339819|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
93739|NCT01339819|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
93740|NCT01339845|Biological|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
94025|NCT01325337|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
94026|NCT00055978|Drug|celecoxib|Given orally. 400mg twice daily for 6 months.
94027|NCT01327677|Drug|Fentanyl|25-50 mcg every 20 minutes
94028|NCT01327677|Drug|Fentanyl|20mcg/demand dose with an 8 minute lock out
94029|NCT01327690|Behavioral|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
94030|NCT01327690|Behavioral|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
93282|NCT01336829|Drug|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
93283|NCT01336829|Drug|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
93284|NCT01336842|Drug|Panobinostat, Cisplatin, Pemetrexed|Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.
Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1.
93285|NCT01336881|Genetic|RNA analysis|
93286|NCT01336881|Genetic|gene expression analysis|
93287|NCT01336881|Genetic|microarray analysis|
93288|NCT01336881|Genetic|nucleic acid sequencing|
93289|NCT01336881|Other|diagnostic laboratory biomarker analysis|
93290|NCT01336894|Procedure|therapeutic conventional surgery|Undergo surgery
93291|NCT01336894|Radiation|iodine I 125|Undergo seed implant radiotherapy
93292|NCT00057499|Biological|IBC-VS01|IBC-VS01
93293|NCT01339026|Drug|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
93294|NCT01339026|Drug|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
93295|NCT01339039|Drug|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
93296|NCT01339039|Drug|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
93297|NCT01339039|Drug|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
93298|NCT01339039|Drug|Plerixafor|Daily administration for 5-9 days prior to surgery
93299|NCT01339039|Procedure|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 & 15).
93300|NCT01339052|Drug|BKM120|100 mg once daily, orally, for 28 days
94919|NCT01329666|Dietary Supplement|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
94920|NCT01329666|Dietary Supplement|Vitamin D3|Baseline:
50,000 IU/week for 8 weeks
Week 8:
Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.
Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks.
94921|NCT01329679|Dietary Supplement|5 Hour Energy|5 Hour Energy, 2oz twice daily for 7 days
94922|NCT01329679|Drug|Placebo|Water, lime juice and cherry flavoring
94923|NCT01329692|Behavioral|Lifestyle counseling|Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
94924|NCT01329705|Device|Ankle Dorsiflexion Dynasplint|Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or "Experimental" group will add this therapy to their standard of care regimen
94925|NCT01329705|Other|Standard of care|Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:
range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature
strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature
gait training to improve heel strike and toe off, stride length, and gait progression
sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion
no electric stimulation (e-stim) will be utilized
94926|NCT01329718|Other|Blood Sample|Blood sample collection
94927|NCT01329731|Drug|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
95257|NCT01354301|Drug|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
95258|NCT01354301|Drug|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
95259|NCT00058773|Drug|Infusion of EBV Specific Cytotoxic T-Lymphocytes|EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.
Each patient will receive two injections, 14 days apart.
95260|NCT01354301|Drug|Basiliximabe|days 0 and 4, according to the package insert instructions.
95261|NCT01354301|Drug|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
95262|NCT01354301|Drug|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
93060|NCT01341041|Biological|saline|one time wash with 50-100 cc normal saline
93061|NCT01341054|Other|mouthwash with Chamomilla|The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
93062|NCT01341054|Other|Standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
93063|NCT01341080|Drug|Varenicline|Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
93064|NCT01341080|Drug|Sugar pill|1mg twice daily for eight weeks after a one week dose escalation phase.
93065|NCT00057681|Drug|Valproate|Titrated until blood level is 111 to 125 ug/mL
93363|NCT01336933|Drug|etoposide|Given PO or IV
93364|NCT01336933|Drug|vincristine sulfate|Given IV
93365|NCT01336933|Drug|pralatrexate|Given IV
93366|NCT01336933|Other|laboratory biomarker analysis|Correlative studies
93367|NCT01336933|Genetic|comparative genomic hybridization|Correlative studies
93368|NCT01336933|Genetic|gene expression analysis|Correlative studies
93369|NCT00057239|Drug|Radafaxine|
93370|NCT01336933|Genetic|nucleic acid sequencing|Correlative studies
93371|NCT01336933|Genetic|mutation analysis|Correlative studies
93372|NCT01336933|Other|immunohistochemistry staining method|Correlative studies
93373|NCT01336933|Genetic|microarray analysis|Correlative studies
93374|NCT01336933|Genetic|RNA analysis|Correlative studies
93375|NCT01336946|Behavioral|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
93376|NCT01336946|Behavioral|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
93377|NCT01336959|Drug|BCT197 Part A|
95318|NCT01361997|Biological|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
95319|NCT01361997|Biological|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
95320|NCT01362010|Drug|Topical Minocycline Foam FXFM244|Topically applied once a day.
95321|NCT01362023|Behavioral|lifestyle counseling|In 3 academic years, the intervention program consisted of three components:
Classroom practice by HPA to highlight healthy lifestyle habits
Teaching practice by HPA using books designed to include the nutritional objectives
Parental activities included with their children
In each of 12 activities (1 h/activity), the classroom practice consisted of three components:
Experimental development of activities regarding each healthy lifestyle habit
Assessment of activity performed in classroom
An activity developed for use at home
95322|NCT01362036|Drug|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
95323|NCT01354314|Drug|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
95324|NCT01354314|Drug|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
95325|NCT01354314|Drug|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
95326|NCT01354314|Drug|Placebo|One capsule in the morning, three capsules in the evening
95327|NCT01354327|Dietary Supplement|Limicol|3 tablets / day during 4 months
95328|NCT00058786|Biological|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
94433|NCT01333592|Drug|KAD-1229|
94434|NCT01333605|Drug|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
93301|NCT01339052|Procedure|Surgery|Surgery
93583|NCT01341990|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
93584|NCT01341990|Device|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
93585|NCT01341990|Device|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
93586|NCT01342016|Drug|tacrolimus capsule|oral
93587|NCT01334736|Behavioral|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
93588|NCT01334736|Behavioral|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
93589|NCT01334736|Behavioral|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
93590|NCT01334762|Drug|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
93591|NCT01334762|Drug|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
93592|NCT01334775|Procedure|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
93593|NCT01334788|Other|sleep deprivation|Sleep restriction
93594|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
95263|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
95264|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
95265|NCT01356615|Drug|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
95266|NCT01356628|Drug|PD-0332991|PD-0332991, 125mg, 3 cycles
95267|NCT01356641|Drug|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
95268|NCT01356641|Procedure|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
95269|NCT01356654|Device|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
95270|NCT00059228|Drug|17 beta-estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
95271|NCT01356654|Device|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
95272|NCT01356667|Behavioral|DARTNA|3-hour protocol provided 2x/week over 12 weeks
95273|NCT01356667|Behavioral|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
95274|NCT01356680|Drug|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
95275|NCT01356680|Drug|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
95276|NCT01356680|Radiation|30Gy IF-RT (Involved-Field Radiotherapy)|
94376|NCT01325857|Procedure|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
94377|NCT01325857|Procedure|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
94378|NCT00056030|Drug|oxaliplatin|
94379|NCT01325870|Device|ACD-CPR|
94380|NCT01325870|Device|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
94381|NCT01325870|Procedure|S-CPR|standard manual CPR
93378|NCT01336959|Drug|Placebo|Placebo capsules
93379|NCT01336959|Drug|BCT197 Part B|Randomized Double-blind BCT197
93380|NCT00001062|Drug|Ganciclovir|
93381|NCT00057265|Drug|telbivudine or lamivudine|
93382|NCT01336972|Drug|tolvaptan|Daily split-dose of tolvaptan titrated weekly to the maximally tolerated dose. Starting daily tolvaptan dose of 45mg/15mg titrated to 60mg/30mg, then 90mg/30mg based on tolerability.
93383|NCT01336985|Drug|Irinotecan|
93384|NCT01336985|Procedure|Chemoembolization|
93385|NCT01336985|Device|Drug-Eluting Beads|
93386|NCT01336985|Procedure|Biopsy|
93387|NCT01336998|Dietary Supplement|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
93658|NCT01342042|Biological|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 [glucagon-like peptide-1] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
93659|NCT01342055|Drug|Apetrol ES|sequences of administered drugs
93660|NCT01342081|Drug|DE-111 ophthalmic solution|
93661|NCT01342081|Drug|Tafluprost ophthalmic solution 0.0015%|
93662|NCT01342081|Drug|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%|
93663|NCT01342094|Drug|DE-111 ophthalmic solution|
93664|NCT00057785|Drug|fluorouracil|1000 mg/m^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
93665|NCT01342094|Drug|Timolol ophthalmic solution 0.5%|
93666|NCT01342094|Drug|Placebo ophthalmic solution|
93667|NCT01342107|Device|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
94435|NCT01333618|Device|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
94436|NCT01333618|Device|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
94437|NCT01333631|Drug|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
94438|NCT01333670|Device|Prontosan wound irrigation solution|cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)
positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes
dressing with Prontosan Wound Irrigation solution
94439|NCT00056940|Behavioral|Safety Check approach|
94440|NCT01333670|Drug|Isotonic solution (saline or lactated ringer)|cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)
positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes
dressing with isotonic solution
94441|NCT01333696|Drug|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
94442|NCT01333709|Drug|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
94443|NCT01333709|Other|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
94444|NCT01333709|Radiation|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
94445|NCT01333709|Radiation|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
94446|NCT01333709|Procedure|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
94447|NCT01325987|Dietary Supplement|Vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
94716|NCT01326455|Device|Clo-Sur-P.A.D.|
94717|NCT01326468|Drug|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
93595|NCT01334801|Procedure|Blood Draw|Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:
BNP (Brain Natriuretic Peptide)
(PFA) Platelet Function Analyzer 100
von Willebrand Factor (vWF) antigen
(vWF) multimers
(vWF) *activity by latex aggregation
Plasma stored for development of new testing approaches
93887|NCT01330602|Behavioral|IMPRESS intervention|The key elements of the IMPRESS intervention include:
Promoting a healthy lifestyle
Supporting lifestyle and risk modification
Encouraging active self-management of risk and chronic disease
Improving coordination of care
Pharmacological therapy
93888|NCT01330615|Drug|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
93889|NCT01330615|Drug|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
93890|NCT01330628|Device|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
93891|NCT00056472|Other|placebo|tablet that ressembles sertraline but contains no medication
93892|NCT01332968|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv on Day 1 of Cycles 1-8 (21-day cycles) or Cycles 1-6 (28-day cycles); followed by 375 mg/m2 iv every 2 months in responders until disease progression, for up to 2 years
93893|NCT01332994|Drug|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
93894|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
93895|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
93896|NCT01333020|Other|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
93897|NCT01333033|Drug|Oxaliplatin|Given IV
93898|NCT01333033|Drug|Leucovorin Calcium|Given IV
93899|NCT01333033|Drug|Fluorouracil|Given IV
93900|NCT00056823|Drug|rhuFab V2 (ranibizumab)|
93901|NCT01333033|Drug|Carboplatin|Given IV
93902|NCT01333033|Drug|Paclitaxel|Given IV
93903|NCT01333033|Procedure|Positron Emission Tomography|Undergo PET/CT scan
93904|NCT01333033|Procedure|Computed Tomography|Undergo PET/CT scan
94382|NCT01325870|Device|Impedance Threshold Device (ITD)|
94383|NCT01325896|Drug|PEG-Intron sc injection|This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.
PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.
Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse.
94384|NCT01325909|Behavioral|Exercise programme|
94385|NCT01325922|Procedure|DFT Testing with a 50/50% tilt|
94386|NCT01325935|Drug|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
94387|NCT01325961|Radiation|Intensity-Modulated Radiation Therapy|
94388|NCT01328431|Other|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
94389|NCT01328444|Drug|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
94390|NCT01328444|Drug|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
94391|NCT00056303|Behavioral|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
94392|NCT01328444|Drug|GSK 573719 125|125mcg
94393|NCT01328444|Drug|GSK 573719 62.5|62.5mcg
94394|NCT01328444|Drug|GW642444 25|25mcg
94395|NCT01328444|Drug|Plb|Comparator
94653|NCT01329120|Procedure|Minimally invasive repair of pectus excavatum|Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
94654|NCT01329120|Procedure|Open surgical repair of pectus carinatum|Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
93668|NCT01342107|Device|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
93669|NCT01342107|Device|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
93670|NCT01342146|Drug|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
93671|NCT01342146|Drug|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
93672|NCT01342146|Drug|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
93673|NCT01342159|Procedure|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
93674|NCT01334866|Procedure|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
93675|NCT01334879|Drug|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
93676|NCT01334892|Drug|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
93965|NCT01330680|Dietary Supplement|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
93966|NCT01330680|Dietary Supplement|Decaffeinated coffee|40 mL dose of decaffeinated coffee
93967|NCT01330693|Drug|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
93968|NCT01330693|Drug|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
93969|NCT01330706|Drug|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
93970|NCT01330719|Procedure|Diseased periodontal treatment|Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to "fill" the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back.
93971|NCT00000253|Drug|30% N2O|
94718|NCT01326468|Drug|Cetuximab|All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.
Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy.
94719|NCT01326468|Drug|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
94720|NCT01326468|Device|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
94721|NCT01326481|Drug|TRC105|IV
94722|NCT01326494|Drug|Arm 1 Oral Cortico Steroids|Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.
Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )
94723|NCT01326507|Biological|Dosage de l'h-FABP|Dosage de l'h-FABP
94724|NCT01326520|Dietary Supplement|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
94725|NCT00056095|Drug|cyclosporine|
94726|NCT01326520|Dietary Supplement|diary product|The patients will consume daily 250 mL of a common dairy product.
94727|NCT01326533|Drug|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
94728|NCT01326533|Other|Placebo|Thirteen weeks of oral placebo provided as capsules
94729|NCT01326546|Drug|Therapeutic HBV vaccine, entecavir|Therapeutic HBV vaccine :900ug,per time,intramuscular injection; Entecavir:0.5mg,per day,oral intake.
94730|NCT01326546|Drug|Empty liposome, entecavir|Empty liposome: 900ug,per time,intramuscular injection; Entecavir:0.5mg,per day,oral intake.
94731|NCT01329198|Device|NeuroPace RNS® (responsive neurostimulation) System Deep Brain Stimulator|There will be a one month post-operative period during which stimulation is not turned on.
One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days.
94732|NCT01329224|Other|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
94733|NCT01329237|Other|dynamic physical exercise and OCT imaging|supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
93905|NCT01333033|Radiation|Radiation Therapy|Undergo RT
93906|NCT01333046|Biological|Antigen-Escalation Stage|Antigen-Escalation Stage
Each patient will receive 2 injections at the same dose (5 x 10^6 cells/m2), 28 days apart, according to the following schedules:
Schedule One:
Day 0: PRAME-specific T cells
Day 28: PRAME- and SSX-specific T cells
Schedule Two:
Day 0: PRAME- and SSX-specific T cells
Day 28: PRAME/SSX/MAGE-specific T cells
Schedule Three:
Day 0: PRAME/SSX/MAGE-specific T cells
Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells
Schedule Four:
Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells
Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells
94225|NCT01328132|Drug|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
94226|NCT01328145|Drug|Acetylsalicylic acid|500 mg /day
94227|NCT01328171|Drug|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
94228|NCT00056277|Drug|lamotrigine|
94229|NCT01328171|Drug|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
94230|NCT01328184|Drug|levonorgestrel|multiple doses
94231|NCT01328184|Drug|levonorgestrel|multiple doses
94232|NCT01328184|Drug|Ethinylestradiol|multiple doses
94233|NCT01328184|Drug|Microgynon + BI 10773|multiple doses BI 10773
94234|NCT01328184|Drug|Ethinylestradiol|multiple doses
94235|NCT01328197|Device|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
94236|NCT01328210|Procedure|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
94237|NCT01328223|Radiation|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
94238|NCT01331291|Drug|bosutinib|Taken orally
94239|NCT01331304|Drug|Lithium|600-900mg per day over 6 months
94240|NCT01331304|Drug|Quetiapine|100-800mg a day over 6 months
94241|NCT01331317|Drug|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
94242|NCT01331330|Device|Deep Brain Stimulation|Normal DBS Programming
94655|NCT01329133|Procedure|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
94656|NCT01329172|Other|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
94657|NCT00056355|Drug|UVADEX and UVAR XTS Photopheresis System|
94658|NCT01329172|Other|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
94659|NCT01329185|Drug|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
94660|NCT01329185|Drug|Placebo|1 capsule twice a day for 14 days prior to transplant date
94661|NCT01332110|Device|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
94662|NCT01332123|Device|Alignment perturbations|Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation, increased foot outward rotation, increased foot inward rotation (always 15 degrees from the neutral position)
94663|NCT01332149|Drug|Pregabalin|Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.
At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.
94664|NCT01332149|Drug|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
94665|NCT01332162|Device|Biventricular pacing|All patients will be pacing during two years
94666|NCT01332162|Device|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
94667|NCT00056641|Drug|lopinavir|
94668|NCT01332175|Device|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
94669|NCT01332175|Device|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
94670|NCT01332175|Procedure|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
94671|NCT01332188|Drug|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
94672|NCT01332188|Drug|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
93972|NCT00001059|Drug|Doxorubicin hydrochloride (liposomal)|
93973|NCT00056485|Behavioral|Pleasant Events-Based Behavioral Intervention|
93974|NCT01330719|Procedure|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
93975|NCT01330745|Other|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
93976|NCT01330758|Drug|AZD8931|40 mg AZD8931 wet granulation tablet formulation
93977|NCT01330758|Drug|AZD8931|40 mg AZD8931 roller compacted tablet formulation
93978|NCT01330771|Drug|hMG-HP/r-FSH|
93979|NCT01330784|Drug|hMG-HP|
93980|NCT01330810|Drug|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
93981|NCT01330823|Dietary Supplement|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
93982|NCT01330823|Dietary Supplement|Placebo|tartaric acid same dose like L-Carnitine as placebo
93983|NCT01333098|Drug|Mifepristone|300mg per day, by mouth, for 21-28 days
93984|NCT01333111|Drug|NNC-0156-0000-0009|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
93066|NCT01341093|Behavioral|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
93067|NCT01341093|Behavioral|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
93068|NCT01341106|Drug|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
93069|NCT01342991|Procedure|Laser Haemorrhoidectomy|The intervention comprises laser haemorrhoidectomy
This procedure will be performed under local anaesthetic with sedation as a day case
The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.
Pre-operative local anaesthesia will be given
93070|NCT01343004|Drug|Placebo|Placebo 0 mcg subcutaneous daily
93071|NCT01343004|Drug|BA058 80 mcg|BA058 80 mcg subcutaneous daily
93072|NCT01343004|Drug|teriparatide|teriparatide 20 mcg subcutaneous daily
94990|NCT01326949|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months to one year and lifelong aspirin were routinely prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction. Intravenous arginine and branched-chain amino acids and antibiotics were administered for five days as prophylactics for encephalopathy and operation-related infection, respectively. TIPS revision was planned if any evidence of shunt dysfunction was seen; thereafter, long-term anticoagulation was prescribed.
94991|NCT01326949|Procedure|ET+NSBB+AT|ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 3-4 weeks until the varices were obliterated or reduced to grade-I size. Gastric varices was treated by endoscopic injection using cyanoacrylate.
NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.
AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously at a starting dose of 1,000 U/h for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 5 mg/d for 6 months and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0).
94992|NCT01326962|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
94993|NCT01326988|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
94994|NCT01327014|Drug|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
94995|NCT01327014|Drug|Placebo|4 capsules twice a day for 12 weeks.
94996|NCT01327027|Drug|Vasopressin|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
94997|NCT01327027|Drug|Placebo|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
94998|NCT01327040|Other|light exposure|12-hour light exposure of approximately 200 lux
94999|NCT00056394|Behavioral|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
95000|NCT01329744|Drug|mecasermin|a subcutaneous injection twice a day
95001|NCT01329744|Drug|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
95002|NCT01329757|Drug|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
95003|NCT01329757|Drug|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
95004|NCT01329770|Dietary Supplement|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)
Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks
94243|NCT01331330|Device|Deep Brain Stimulation|Low Programming
94244|NCT01331343|Device|Guardian RT Telemetered Glucose Monitoring System|
94245|NCT01331356|Drug|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
94246|NCT00056550|Biological|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
94247|NCT01331369|Behavioral|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
93302|NCT01339065|Drug|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
93303|NCT00057499|Biological|IBC-VS01 placebo|IBC-VS01 placebo
93304|NCT01339078|Procedure|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
93305|NCT01339078|Procedure|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
93306|NCT01339091|Drug|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
93307|NCT01339091|Drug|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
93308|NCT01339104|Drug|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
93309|NCT01339117|Other|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
93310|NCT01339117|Other|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
93311|NCT01341444|Other|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
93312|NCT01341457|Drug|LY2603618|Administered intravenously
93313|NCT01341457|Drug|Gemcitabine|Administered intravenously
93314|NCT01341470|Drug|LY2495655|administered intravenously or subcutaneously
94928|NCT01329731|Drug|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
94929|NCT01332513|Drug|Investigational Medicinal Product (MR2)|
94930|NCT01332513|Drug|Investigational Medicinal Product (MR3)|
94931|NCT00056680|Behavioral|Infant massage|
94932|NCT01332513|Drug|Investigational Medicinal Product (MR4)|
94933|NCT01332513|Drug|Investigational Medicinal Product (MR5)|
94934|NCT01332513|Drug|Investigational Medicinal Product (IR)|
94935|NCT01332539|Other|no intervention|non-interventional study
94936|NCT01332552|Drug|GSK2485852 70 mg|single dose
94937|NCT01332552|Drug|GSK2485852 420 mg|single dose
94938|NCT01332552|Drug|placebo|single dose
94939|NCT01332552|Drug|placebo|Repeat dose, once daily for 3 days
94940|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
94941|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
94942|NCT00056680|Behavioral|Brazelton Neonatal Behavioral Assessment Scale|
94943|NCT01332552|Drug|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
94944|NCT01332552|Drug|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
94945|NCT01332552|Drug|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
94946|NCT01332552|Drug|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
94947|NCT01332565|Drug|GSK1349572|50mg tablet
94948|NCT01332578|Drug|Paracetamol|Present in both test and active comparator
94949|NCT01332578|Drug|Phenylephrine|Test product
94950|NCT01332578|Drug|Ascorbic Acid|Test product
94951|NCT01332591|Procedure|Percutaneous coronary intervention|PCI of significant stenoses of "non-infarct" coronary arteries
93073|NCT01343017|Other|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
93074|NCT01343043|Biological|NY-ESO-1(c259)T Cells|Cytoreductive chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
93075|NCT01343056|Behavioral|Four different methods of follow up of goal attainment post diabetes education shall be evaluated.|The four arms are described. All participants will receive a 6 week, 3 month and 6 month office visit where they will complete surveys and have blood work for HbA1C and Lipids.
93076|NCT01343069|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
93077|NCT01343082|Drug|DE-111 ophthalmic solution|
93078|NCT01343095|Device|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
93079|NCT00057811|Drug|prednisone|Given IV or orally
93080|NCT01343095|Device|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
93081|NCT01343121|Other|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
93082|NCT01343121|Other|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
93083|NCT01343121|Other|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
93388|NCT01339130|Behavioral|Computerized tests and Electrophysiological measurements|Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.
Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).
Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires.
93389|NCT01339143|Drug|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
93390|NCT01339143|Drug|pioglitazone|15mg, QD, PO, 16 weeks
93391|NCT00057512|Drug|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
95005|NCT01329770|Dietary Supplement|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
95006|NCT01329783|Other|maraviroc|No intervention is distributed during this trial.
95329|NCT01354327|Dietary Supplement|Placebo|3 tablets / day during 4 months
95330|NCT01354340|Dietary Supplement|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
95331|NCT01354340|Dietary Supplement|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
95332|NCT01354340|Other|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
95333|NCT01354353|Drug|LY2140023|Administered orally
95334|NCT01354353|Drug|Aripiprazole|Administered orally
95335|NCT01354366|Other|Infant formula|
95336|NCT01354379|Biological|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
95337|NCT01354379|Biological|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
95338|NCT01354392|Drug|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
95339|NCT00058799|Biological|Tumor Vaccine: CD40 LIGAND AND IL-2 GENE MODIFIED AUTOLOGOUS SKIN FIBROBLASTS AND TUMOR CELLS|CD40L AND IL-2 GENE MODIFIED AUTOLOGOUS SKIN FIBROBLASTS AND TUMOR CELLS dosed at 3 different levels starting at:
Leukemic Blasts 2x10^7 IL-2 Fibroblasts 2x10^7 CD40L Fibroblasts 2x10^5 TOTAL CELLS 4.02x10^7 Each patient will receive 3 injections of their gene modified leukemia cells, each injection separated by 1-2 wks. If there is evidence of response without excessive toxicity and if more transduced cells are available, the pt may receive up to 3 additional SC injections (injections 4-6) separated by 2 weeks.
95340|NCT01354405|Drug|Lanreotide|120 mg every 28 days intramuscular
95341|NCT01354418|Drug|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
95342|NCT01354418|Drug|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
95343|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
95344|NCT01356784|Behavioral|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
95345|NCT01356784|Behavioral|Health counselling|Health guidance (1,5h)
93315|NCT01341470|Drug|Placebo|administered intravenously or subcutaneously
93316|NCT00057720|Drug|TLK286 HCl for injection|
93317|NCT01341496|Biological|Epigenetically Modified Autologous Tumor|5x 10^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
93318|NCT01341496|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
93319|NCT01341496|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
93320|NCT01341509|Procedure|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
93596|NCT01334801|Other|Blood draw|Blood draw
93597|NCT00057005|Drug|Anti-CD45|Day-5 400 μg/kg
93598|NCT01334814|Device|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
93599|NCT01334840|Dietary Supplement|Bicarbonated mineral water|Volunteers fasted overnight consumed:
0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal
93600|NCT01334840|Dietary Supplement|Mineral water low in mineral content (control)|Volunteers fasted overnight consumed:
0.5 L of the control water without meal or, 0.5 L of the control water with meal
93601|NCT01334853|Other|No drug will be used|Biomarker
93602|NCT01334853|Other|No drug will be used|Biomarker
93603|NCT01337232|Behavioral|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
93604|NCT01337245|Drug|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
93605|NCT01337258|Drug|Dutasteride|dutasteride 0.5mg daily.
93606|NCT01337258|Drug|Placebo|Men taking placebo daily
93607|NCT01337271|Procedure|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
94952|NCT01332604|Drug|GDC-0980|Oral escalating dose
94953|NCT00056693|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
95277|NCT01356680|Radiation|30Gy IN-RT (Involved-Node Radiotherapy)|
95278|NCT01356693|Drug|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
95279|NCT01356693|Drug|Placebo|Placebo with mimicking characteristics of experimental drug
95280|NCT01356732|Drug|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
95281|NCT00059241|Behavioral|Parent-child communication education|
95282|NCT01356745|Drug|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
95283|NCT01356745|Drug|medical air|inhalation gas for inhalation use
95284|NCT01356758|Drug|biological treatment|patients treated with anti-psoriatic biological agents
95285|NCT01356771|Other|Surveys & Mailed Materials|Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.
Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.
The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.
Each survey will ask the participant about:
Current and past skin cancer screening practices
Current and past sun protection practices
Attitudes about skin cancer and sun protection
Knowledge of melanoma
95286|NCT01356784|Other|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
95287|NCT01359189|Device|ProxiScan (scintigraphic rectal probe)|ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: "The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
95288|NCT01359202|Biological|rfVIIa|80ug/kg IV bolus
95289|NCT01359202|Other|Standard saline solution|Saline
95290|NCT01359228|Drug|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
95291|NCT00059527|Behavioral|Healthy Youth Places: a behavior change model|
93392|NCT01339156|Drug|P3914|Part A:
The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.
Part B:
Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).
The investigational product will be administered orally to each subject with 240 mL of water.
Part C:
Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.
For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.
Part D:
Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
93393|NCT01339156|Drug|Placebo|Part A:
The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.
Part B:
Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).
The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.
Part D:
Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
93394|NCT01339169|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
93395|NCT01339182|Drug|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
93396|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
93397|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
93398|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
93399|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
93400|NCT01339195|Behavioral|French adaptation of NINDS-Canadian Stroke Network battery|clinical: post-stroke neurological follow-up assessment
neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery
MRI
93677|NCT01334905|Drug|YM178|oral
93678|NCT01334918|Drug|regadenoson|Administered by intravenous bolus.
93679|NCT00057005|Drug|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
93680|NCT01334918|Radiation|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
93681|NCT01334918|Radiation|Contrast|Administered by intravenous infusion.
93682|NCT01334918|Procedure|Single Photon Emission Computed Tomography|
95346|NCT01356797|Drug|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
95347|NCT01356797|Drug|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
95348|NCT01356810|Other|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
95349|NCT00059241|Behavioral|Service learning|
94448|NCT00056056|Drug|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
94449|NCT01325987|Other|Sugar pill|group: vitamin D2 50000 IU weekly once for 8 weeks
nd group: placebo weekly once for 8 weeks
94450|NCT01326000|Drug|FOLFIRI|standard iv chemotherapy
94451|NCT01326000|Drug|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
94452|NCT01326000|Drug|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
94453|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
94454|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
94455|NCT01326039|Drug|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
94456|NCT01326039|Drug|saline|perineural isotonic saline 20 ml
94457|NCT01326052|Procedure|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
94458|NCT01326052|Procedure|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
94459|NCT00056056|Drug|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
94460|NCT01326078|Drug|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
94461|NCT01326091|Other|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
94462|NCT01326104|Biological|TTRNA-xALT|TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
93608|NCT01337271|Procedure|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
93609|NCT01337297|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
93610|NCT01337310|Drug|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
93611|NCT00057330|Biological|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
93612|NCT01337323|Drug|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
93613|NCT01337336|Drug|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
93907|NCT01333046|Biological|Dose-Escalation Study of T Cells|Dose-Escalation Stage
Four different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:
DL1: Day 0 and Day 14: 5 x 10^6 cells/m^2
DL2: Day 0 and Day 14: 1 x 10^7 cells/m^2
DL3: Day 0 and Day 14: 2 x 10^7 cells/m^2
DL4: Day 0 and Day 14: 4 x 10^7 cells/m^2
93908|NCT01333059|Drug|Midazolam/Fentanyl|Sedative Control
93909|NCT01333059|Drug|Sedative Intervention|Intervention arm - Fentanyl and Midazolam will be replaced with placebo
93910|NCT01333072|Drug|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
93911|NCT00056836|Drug|rhuFab V2 (ranibizumab)|
93912|NCT01333072|Drug|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
93913|NCT01333085|Drug|carboplatin|
93914|NCT01333085|Drug|RAD001|
93915|NCT01333085|Drug|paclitaxel|
93916|NCT01324999|Drug|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
95292|NCT01359228|Drug|Placebo|Placebo 1 tablet three times a day for 14 days.
95293|NCT01359241|Procedure|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
95294|NCT01359241|Drug|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
94396|NCT01328457|Drug|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
94397|NCT01328470|Drug|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
94398|NCT01328483|Procedure|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
94399|NCT01328496|Genetic|Preparative Regimen|Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.
Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1.
94400|NCT01328522|Drug|SAR153191 (REGN88)|Pharmaceutical form:solution
Route of administration: subcutaneous
94401|NCT01328535|Drug|temozolomide|Given PO
94402|NCT00056303|Behavioral|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
94403|NCT01328535|Other|flow cytometry|Correlative studies
94404|NCT01328535|Other|staining method|Correlative studies
94405|NCT01328535|Procedure|biopsy|Optional correlative studies
94406|NCT01328535|Other|laboratory biomarker analysis|Correlative studies
94407|NCT01328574|Drug|TRC105|15 mg/kg intravenously
94408|NCT01328587|Drug|Eltrombopag|
94409|NCT01331694|Drug|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
94410|NCT01331694|Drug|tiotropium|patients initiating treatment with tiotropium
93683|NCT01334918|Procedure|Multidetector Computed Tomography|
93684|NCT01334931|Radiation|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
93685|NCT01334931|Radiation|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
93686|NCT01334944|Drug|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
93687|NCT01334957|Drug|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
93688|NCT01334983|Behavioral|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
93689|NCT01335009|Biological|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs.
93690|NCT00057005|Drug|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
93691|NCT01335022|Behavioral|lecture|6 lectures on cardiovascular disease covering obesity, diet & exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
93692|NCT01335035|Drug|deferasirox|
93693|NCT01335048|Drug|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
93694|NCT01335048|Drug|Clopidogrel|Clopidogrel 150 mg daily
93695|NCT01335061|Biological|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
93696|NCT01335061|Biological|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
93697|NCT01335074|Drug|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
93698|NCT01335087|Other|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
93985|NCT01333111|Drug|NNC-0156-0000-0009|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
93986|NCT01333111|Drug|NNC-0156-0000-0009|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
94463|NCT01326104|Biological|TTRNA-DCs|TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
94464|NCT01326117|Drug|tadalafil|7 days of Cialis for Daily Use (5mg)
94465|NCT01326130|Behavioral|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
94466|NCT01326143|Device|ORM Narval MRD|
94734|NCT01329250|Drug|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
94735|NCT01329263|Other|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
94736|NCT01329276|Drug|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
94737|NCT01329289|Drug|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
94738|NCT00056368|Drug|Anidulafungin|
94739|NCT01329289|Drug|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
94740|NCT01329289|Drug|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
94741|NCT01329302|Procedure|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
94742|NCT01329315|Behavioral|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
94743|NCT01329315|Behavioral|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
94744|NCT01329328|Device|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
94745|NCT01329341|Other|Service Dogs|Service dogs will be trained to help veterans with PTSD
94746|NCT01329354|Biological|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
93917|NCT00055952|Drug|exatecan mesylate|
93918|NCT01325012|Procedure|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
93919|NCT01325012|Procedure|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
93920|NCT01325025|Other|High-field MRI (3 Teslas)|anatomical location
conventional anatomical sequence T1, T2, FLAIR
diffusion tensor sequence (21 directions)
high angular resolution diffusion (HARDI) sequence
field map
reflexology T1, T2
spectroscopic imaging sequence
93921|NCT01325025|Other|High-field MRI (3 Teslas)|anatomical location
conventional anatomical sequence T1, T2, FLAIR
diffusion tensor sequence (21 directions)
high angular resolution diffusion (HARDI) sequence
field map
reflexology T1, T2
spectroscopic imaging sequence
93922|NCT01325038|Procedure|Isometric exercise|Isometric exercise several times/week for three months
93923|NCT01325051|Drug|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
93924|NCT01325077|Other|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
93003|NCT00057135|Behavioral|Note to Mental Health Provider when refill is overdue|
93004|NCT01336296|Drug|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant
93005|NCT01336309|Behavioral|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
93006|NCT01336322|Drug|Metformin|Metformin 850 mg bid
93007|NCT01336322|Drug|Sitagliptin|Sitagliptin 100 mg qd
93008|NCT01336322|Drug|Sitagliptin + Metfomin|Sitagliptin 100 mg qd + Metformin 850 mg bid
93009|NCT01336335|Device|CPAP|CPAP
93010|NCT01336348|Drug|Prasugrel|60 mg loading dose given orally at presentation
93011|NCT01336348|Drug|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
93012|NCT01336361|Other|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
94411|NCT01331694|Drug|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
94412|NCT01331707|Device|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
94413|NCT00001059|Drug|Filgrastim|
94414|NCT00056589|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
94415|NCT01331707|Device|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
94416|NCT01331720|Drug|hMG-HP|
94673|NCT01332188|Drug|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
94674|NCT01332188|Drug|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
94675|NCT01332201|Drug|Advagraf|oral
94676|NCT01332201|Drug|Prograf|oral
94677|NCT01332214|Drug|AZD2820|Subcutaneous Injection in abdomen or Thigh
94678|NCT00056654|Drug|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
94679|NCT01332214|Drug|Placebo|Subcutaneous Injection in abdomen or Thigh
94680|NCT01332227|Drug|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
94681|NCT01332227|Drug|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
94682|NCT01332227|Drug|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
94683|NCT01332227|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
94684|NCT01332240|Procedure|Endoscopic ultrasonography|in order to stage the mediastinum
94685|NCT01332253|Drug|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
94686|NCT01323985|Drug|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
94687|NCT01323985|Drug|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
94688|NCT01323998|Drug|5ARI|Dutasteride or Finasteride
93987|NCT01333124|Radiation|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
93988|NCT01333124|Radiation|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
93989|NCT00056862|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
93990|NCT01333137|Drug|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
93991|NCT01333137|Drug|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
93992|NCT01333150|Drug|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
93993|NCT01333150|Drug|Placebo|One single dose of placebo
93994|NCT01333163|Biological|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
93995|NCT01333163|Biological|Isotone NaCl|2 hours IV infusion.
93996|NCT01333176|Procedure|Point-of-care "finger-poke" HbA1c determination.|All volunteers receive finger-poke HbA1c test. Result: If < 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result >6.5: Counseled that they may have diabetes. Given requisition as above.
Estimates about how many have undiagnosed diabetes will be calculated.
Did the clients who were counseled to do so get follow-up blood tests?
Were all the formal diagnostic tests performed?
Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?
Did the family physicians find this useful?
93997|NCT01333176|Procedure|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
93998|NCT01333176|Procedure|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
93999|NCT01333176|Procedure|Blood test|HbA1c blood test
94000|NCT00056862|Drug|Peginterferon alfa-2a|180 mcg/week
94001|NCT01333176|Procedure|Blood test|HbA1c finger poke blood test
94002|NCT01325220|Drug|arbaclofen|10 mg bid
94747|NCT01329367|Other|Moderate weight loss intervention|A longitudinal intervention study in 44 overweight and obese adolescents (23 females and 21 males; mean age 11.5 years) for 10 weeks based on a calorie restricted diet (20-40%) according to obesity degree.
94748|NCT01329393|Behavioral|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
94749|NCT00056368|Drug|Fluconazole|
94750|NCT01329393|Behavioral|Illness Management and Recovery|Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
94751|NCT01332253|Other|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
94752|NCT01332266|Drug|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
95007|NCT01329796|Drug|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
95008|NCT01329796|Drug|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
95009|NCT01329809|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
95010|NCT00001058|Drug|Rifabutin|
95011|NCT00056407|Drug|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
95012|NCT01329822|Behavioral|Caloric restriction|Caloric restriction
95013|NCT01329835|Behavioral|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
95014|NCT01329835|Other|brochure|brochure given after randomization
95015|NCT01329861|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
95016|NCT01329874|Procedure|Type of block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
95017|NCT01329887|Drug|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
95018|NCT01329900|Drug|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
93013|NCT01336387|Drug|retinoid 9cUAB30|Given PO
93014|NCT00057135|Procedure|Aligning all prescriptions to fall due on same date|
93015|NCT01336387|Other|placebo|Given PO
93016|NCT01336387|Other|pharmacological study|Correlative studies
93017|NCT01336387|Other|laboratory biomarker analysis|Correlative studies
93018|NCT01336387|Other|cancer prevention|Disease prevention
93019|NCT01336400|Other|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
93020|NCT01336413|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
93021|NCT01336413|Drug|Placebo|Same as active comparator, except placebo dispensed.
93022|NCT01338701|Procedure|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
93321|NCT01341509|Procedure|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
93322|NCT01341509|Procedure|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
93323|NCT01341522|Procedure|MRI exam|MRI exam
93324|NCT01341522|Procedure|control|waiting room
93325|NCT01341535|Radiation|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
93326|NCT01341535|Radiation|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
93327|NCT00057720|Drug|topotecan hydrochloride for injection|
93328|NCT01341548|Drug|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
93329|NCT01341574|Procedure|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
94689|NCT01323998|Drug|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
94690|NCT01324011|Behavioral|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
94691|NCT01324024|Drug|Lisdexamfetamine|The purpose of this study is to assess whether or not lisdexamfetamine is effective in alleviating cognitive disruptions when compared to a placebo.
94692|NCT01324037|Other|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
94954|NCT01332604|Drug|bevacizumab|Intravenous repeating dose
94955|NCT01332604|Drug|capecitabine|Oral repeating dose
94956|NCT01332604|Drug|mFOLFOX6|Intravenous repeating dose
94957|NCT01332617|Drug|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|Simvastatin 80 mg PO daily starting day -2 through day 10.
Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly
Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.
Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.
Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8.
94958|NCT01332630|Drug|TPI 287|Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.
Starting Dose Phase II: Maximum tolerated dose from Phase I.
94959|NCT01324362|Drug|FSC 250/50mcg|Twice daily dosing
94960|NCT01324362|Drug|FSC500/50mcg|Twice daily dosing
94961|NCT01324375|Device|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
94962|NCT01324388|Biological|LY2189265|Administered subcutaneously
94963|NCT01324388|Drug|Metoprolol|Administered orally
94964|NCT00055887|Drug|paclitaxel|
94965|NCT01324388|Drug|Lisinopril|Administered orally
94966|NCT01324388|Drug|Placebo|Administered subcutaneously
93084|NCT01343134|Device|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
93085|NCT01343147|Other|Microwave diathermy|Deep tissue heating via microwave diathermy
93086|NCT01343147|Other|Superficial hyperthermia|Superficial heating via hot pack application
93087|NCT01343160|Device|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
93088|NCT01343173|Drug|Imatinib stop|To stop imatinib after inclusion.
93089|NCT01343186|Drug|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
93090|NCT00057811|Drug|methylprednisolone|Given IV or orally
93091|NCT01343186|Drug|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
93092|NCT01336439|Drug|Botulinum toxin type A (Meditoxin®)|In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.
After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The "M group" had an injection in masseter muscle. The "MT group" had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.
After 4 weeks, the subjects had a post-injection polysomnography.
93093|NCT01336452|Radiation|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
93094|NCT01336465|Drug|placebo|Repeating subcutaneous injection
93095|NCT00057148|Procedure|massage treatment|
93096|NCT01336465|Drug|rhuMAb Beta7|Repeating subcutaneous injection
93097|NCT01336478|Procedure|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
93098|NCT01336478|Procedure|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
93099|NCT01336530|Drug|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
93100|NCT01336530|Drug|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
95019|NCT01329900|Drug|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
95020|NCT01329900|Drug|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
95021|NCT01329900|Drug|Mesna|2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)
2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)
After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose.
95022|NCT01332630|Drug|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
95023|NCT01332630|Drug|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
95024|NCT01332630|Drug|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
95025|NCT01332643|Genetic|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
95350|NCT01356810|Other|Standard Care|Delirium management by the attending physician's preferences.
95351|NCT01356823|Biological|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
95352|NCT01356823|Biological|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
95353|NCT01356823|Biological|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
95354|NCT01356823|Biological|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
95355|NCT01356849|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
95356|NCT01356849|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
95357|NCT01356862|Drug|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
95358|NCT01356862|Drug|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
95359|NCT01356875|Drug|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
95360|NCT00059241|Behavioral|Classroom health curriculum|
95361|NCT01356875|Drug|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
93330|NCT01341574|Procedure|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
93331|NCT01341587|Device|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
93332|NCT01341600|Drug|Clopidogrel, Omeprazole|Over a 6 week period participants will be given:
75mg of clopidogrel for 8 days, at least 1 week washout, 150mg of clopidogrel for eight days, at least 1 week washout, 300mg of clopidogrel for eight days. Participants will have the option to participate in a final week in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
93333|NCT01341613|Dietary Supplement|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
93334|NCT01341613|Dietary Supplement|Placebo capsule|Twice per day (BID), 9 weeks
93335|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
93336|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
93337|NCT01334294|Device|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
93338|NCT01334307|Device|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
93339|NCT01334307|Device|Control|Standard of Care
93340|NCT01334320|Procedure|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
93614|NCT01337336|Drug|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
93615|NCT01337349|Drug|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
93616|NCT01337349|Drug|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
93617|NCT01337362|Procedure|Insulin clamp|Patients will be exposed to low bloodsugar
93618|NCT01337375|Drug|peginterferon alfa 2a [Pegasys]|sc weekly
93619|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv weekly
93620|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|sc twice weekly
93621|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv twice weekly
94967|NCT01324401|Drug|Peanut flour OIT|Patients will receive daily escalating dosages as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
94968|NCT01324427|Behavioral|virtual medical visit|At the pre-set time, the "Mobile Telehealth Cart" will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The "virtual medical visit" will take about 25 minutes. At the end of the "Virtual Medical Visit," the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their "virtual medical visits."
94969|NCT01324440|Biological|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
94970|NCT01324440|Biological|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
94971|NCT01324453|Procedure|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
95295|NCT01359254|Drug|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
95296|NCT01359254|Drug|Fludarabine|Fludarabine is given through the vein daily for 5 days.
95297|NCT01359254|Drug|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
95298|NCT01359254|Drug|Busulfan|Busulfan is given daily for 4 days.
95299|NCT01359254|Drug|Total Body Irradiation (TBI)|TBI is given twice on the last day.
95300|NCT01359267|Drug|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
95301|NCT01359280|Behavioral|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
95302|NCT00059553|Behavioral|Locomotor treadmill training with body weight support|
95303|NCT01359280|Behavioral|General Health Counseling|5 sessions of health improvement counseling
95304|NCT01359280|Behavioral|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
95305|NCT01359293|Drug|paliperidone palmitate|injections given at day 1, 8, then monthly for a year.
93101|NCT01336530|Drug|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
93102|NCT01336530|Other|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
93401|NCT01339208|Other|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
93402|NCT00057525|Biological|Anthrax|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
93403|NCT01341626|Behavioral|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
93404|NCT01341626|Behavioral|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
93405|NCT01341639|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age
93406|NCT00001066|Drug|Lamivudine|
93407|NCT00057720|Drug|doxorubicin HCl liposome injection|
93408|NCT01341639|Biological|INFANRIX hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
93409|NCT01341639|Biological|RotaTeq|RotaTeq 2 mL oral dose at 2, 3, and 4 months of age
93410|NCT01341639|Biological|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
93411|NCT01341639|Biological|ProQuad|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
93412|NCT01341652|Biological|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
93413|NCT01341652|Biological|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
93414|NCT01341678|Drug|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
95362|NCT01356888|Device|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
95363|NCT01356888|Device|Percutaneous Coronary Intervention (Orsiro DES)|stenting
95364|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
95365|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
95366|NCT01356914|Drug|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
95367|NCT01356914|Drug|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
95368|NCT01356927|Drug|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
95369|NCT01356927|Drug|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
95370|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
94467|NCT01326156|Device|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
94468|NCT01326169|Behavioral|Brief intervention|Telephone-delivered counseling
94469|NCT01326169|Behavioral|Standard care|No intervention
94470|NCT01328626|Drug|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
94471|NCT01328639|Other|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
94472|NCT01328639|Other|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
94473|NCT01328652|Drug|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
94474|NCT00056316|Behavioral|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
93622|NCT00057330|Biological|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
93623|NCT01337401|Drug|Cediranib|30mg once daily, oral until disease progression
93624|NCT01337401|Drug|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
93625|NCT01337414|Behavioral|VMS diary booklet|
93626|NCT01339533|Device|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
93627|NCT00057551|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|
93628|NCT01339546|Other|no intervention|
93629|NCT01339559|Drug|Brivaracetam|Tablet, Flexible dosing up to 200 mg/day, twice daily.
The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.
93630|NCT01339572|Drug|Plerixafor|240 mcg/kg/day based on ideal body weight will be given for the following conditions:
Pre-apheresis peripheral blood CD34+ count <20 cells/μL on day 5.
Estimated CD34+ cell collection is < 25% of target cell dose after 1 day of apheresis.
Estimated CD34+ cell collection is < 50% of target cell dose after 2 days of apheresis.
93631|NCT01339572|Drug|Filgrastim|All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:
Standard risk: 5 μg/kg SQ BID.
High risk: 10 μg/kg SQ BID.
93632|NCT01339585|Device|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
93633|NCT01339598|Device|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
93634|NCT01339611|Behavioral|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
93925|NCT01325090|Drug|BOTOX|A syringe of 1 ml contain 25 Allergan units.
93926|NCT01325090|Other|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
93927|NCT01325103|Procedure|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
93928|NCT00055965|Drug|carboplatin|
95306|NCT01359293|Drug|oral antipsychotics|haloperidol, palperidone, risperidone, perphenazine
95307|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
95308|NCT01361919|Procedure|No Feedback during CPR Testing or Training|A standard no "feedback" defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur.
95309|NCT01361919|Procedure|Feedback During CPR Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
95310|NCT01361919|Procedure|No Feedback During CPR Testing|A standard no "feedback" defibrillator (ZOLL M series) will be used for immediate testing and 12 week (retention) testing.
95311|NCT01361932|Other|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
95312|NCT01361945|Drug|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
95313|NCT01361958|Drug|NOMAC|
94417|NCT01331733|Drug|hMG-HP|
94418|NCT01331733|Drug|hMG + GnRH antagonist|
94419|NCT01331746|Drug|APD515|20 mg oromucosal-oral administration qds for 7 days
94420|NCT01331746|Drug|Placebo|qds for 7 days
94421|NCT01331759|Device|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
94422|NCT01331772|Other|Control arm|Dietetic follow-up only
94423|NCT01331772|Other|Intervention arm|Dietetic follow up + adapted physical activity
93415|NCT01341678|Dietary Supplement|NeutraPhos|Diet will be supplemented with NeutraPhos
93416|NCT01341678|Other|Diet Only|Diet containing 1500mg of phosphorus
93417|NCT01341691|Other|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
93418|NCT00057733|Procedure|psychosocial assessment and care|
93699|NCT01337414|Behavioral|Standard of Care|
93700|NCT01337427|Drug|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
93701|NCT01337440|Drug|UDCA|Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.
93702|NCT01337440|Drug|Sitagliptin|UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.
93703|NCT01337466|Radiation|[124I]FIAU|This is a single dose study of 2 mCi [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
93704|NCT01337492|Drug|Nexavar|400 mg of Sorafenib
93705|NCT01337505|Drug|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
93706|NCT00057343|Drug|Zevalin (ibritumomab tiuxetan)|
93707|NCT01337518|Drug|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
93708|NCT01337531|Drug|Gonal-F, Fostimon|dosage form
93709|NCT01337531|Drug|Gonal-F, Fostimon|injection, daily, 10-15 days
93710|NCT01337544|Other|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
93711|NCT01337557|Drug|Bepotastine|1.5% bid
93712|NCT01337570|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
93713|NCT01337570|Other|Placebo|Vaginal Ring containing no drug substance
93714|NCT01337570|Drug|Dapivirine|
94475|NCT01328665|Other|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
94476|NCT01328717|Device|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
94477|NCT01328730|Device|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
94478|NCT01328730|Device|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
94479|NCT01328743|Behavioral|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
94480|NCT01328756|Drug|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
94481|NCT01328769|Drug|Febuxostat|
94482|NCT01328769|Drug|Placebo|
94483|NCT01328782|Drug|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
94753|NCT01332266|Drug|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
94754|NCT00056667|Behavioral|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
94755|NCT01332279|Drug|everolimus|Given PO
94756|NCT01332279|Drug|erlotinib hydrochloride|Given PO
94757|NCT01332279|Procedure|biopsy|Correlative studies
94758|NCT01332279|Other|laboratory biomarker analysis|Correlative studies
94759|NCT01332279|Other|immunohistochemistry staining method|Correlative studies
94760|NCT01332279|Genetic|polyacrylamide gel electrophoresis|Correlative studies
93929|NCT01325116|Behavioral|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
93930|NCT01325168|Drug|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
93931|NCT01325168|Drug|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
93932|NCT01325181|Drug|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
93933|NCT01325181|Drug|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
93934|NCT01325194|Drug|liposomal cytarabine|50 mg intrathecally three times
93935|NCT01325207|Radiation|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
93936|NCT01325220|Drug|arbaclofen|5 mg bid
93937|NCT01327521|Drug|Cisplatin|Standard of Care
93938|NCT01327521|Device|SMANCS|Standard of Care
93939|NCT01327534|Drug|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
93940|NCT01327534|Drug|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
93941|NCT01327547|Drug|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
93942|NCT01327547|Drug|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
93943|NCT01327573|Drug|eculizumab|Eculizumab Induction 600mg IV every 7 days for 4 doses
Eculizumab 900mg IV 7 days later
Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks
93944|NCT01327586|Behavioral|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
93023|NCT01338701|Other|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
93024|NCT01338714|Other|Compound Herbal Formula (RHD-1)|100 ml/per day
94424|NCT01331785|Drug|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
94425|NCT00056628|Device|The COGNIShunt® System|
94426|NCT01331798|Device|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
94427|NCT01331798|Procedure|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
94428|NCT01331811|Other|Development of a diagnosis algorithm|At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:
interview on anamnesis
clinical examination
evaluation of HIV infection stage
hematology and biochemistry tests
CD4 count
HIV viral load
IGRA
chest radiograph
Abdominal ultrasonograph to detect abdominal lymphadenopathy
Tuberculin skin test
gastric aspirates, sputum and string tests according to the age of children
nasopharyngeal aspirate
stool sample
lymph node fine needle aspirate or other specimen collection if applicable
Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it.
94429|NCT01331824|Drug|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
94430|NCT01333566|Behavioral|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
94431|NCT01333566|Behavioral|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
94432|NCT01333579|Other|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
94693|NCT01324050|Behavioral|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
94694|NCT01324050|Behavioral|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
94695|NCT01324063|Biological|sargramostim|
94696|NCT00001056|Biological|gp160 Vaccine (Immuno-AG)|
94697|NCT00055874|Procedure|autologous bone marrow transplantation|
94698|NCT01324063|Drug|amsacrine|
93715|NCT01337583|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
93716|NCT01337583|Other|Placebo|Vaginal Ring containing no drug substance
93717|NCT00057343|Drug|Rituxan (rituximab)|
93718|NCT01337583|Drug|Dapivirine|
93719|NCT01337596|Drug|LY2951742|Administered subcutaneously
93720|NCT01337596|Drug|Placebo|Administered subcutaneously
93721|NCT01337609|Drug|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
94003|NCT01325220|Drug|arbaclofen|10 mg tid
94004|NCT00055965|Drug|cisplatin|
94005|NCT01325220|Drug|Placebo|tid
94006|NCT01325233|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
94007|NCT01325233|Drug|Placebo|500 ml normal saline, tiw, 2 weeks
94008|NCT01325259|Other|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
94009|NCT01325259|Radiation|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of [18F]AV-45
94010|NCT01325259|Radiation|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
94011|NCT01325259|Other|MRI|Magnetic Resonance Imaging
94012|NCT01325285|Device|RespirAct|Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:
Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)
10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)
20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)
Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)
250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)
500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)
Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)
94013|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
94014|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
94015|NCT00055965|Drug|gemcitabine hydrochloride|
94761|NCT01332279|Other|pharmacological study|Correlative studies
94762|NCT01332279|Radiation|external beam radiation therapy|Undergo EBRT
94763|NCT01332279|Genetic|microarray analysis|Correlative studies
94764|NCT01332292|Drug|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
94765|NCT00056667|Behavioral|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
94766|NCT01332292|Drug|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
94767|NCT01332305|Drug|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
94768|NCT01332305|Drug|Placebo|Placebo orally once daily
94769|NCT01332318|Drug|XP13512|XP13512 once daily for 16 days
94770|NCT01332318|Drug|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
95026|NCT01332656|Drug|Ombrabulin (AVE8062)|Pharmaceutical form:solution
Route of administration: intravenous
95027|NCT00056706|Procedure|Transient deafferentation|
95028|NCT01332656|Drug|Placebo|Pharmaceutical form:solution
Route of administration: intravenous
95029|NCT01332656|Drug|Paclitaxel|Pharmaceutical form:solution
Route of administration: intravenous
95030|NCT01332656|Drug|Carboplatin|Pharmaceutical form:solution
Route of administration: intravenous
95031|NCT01332669|Procedure|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
95032|NCT01332682|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
93025|NCT01338714|Other|dilute RHD-1|100 ml/per day
93026|NCT01338727|Behavioral|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
93027|NCT01338740|Drug|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
93028|NCT01338753|Other|Bevacizumab, docetaxel and doxorubicin followed by surgery|The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.
The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.
The surgical procedure will be done 4-6 weeks after completion of chemotherapy.
93029|NCT00000253|Drug|40% N2O|
93030|NCT00001063|Drug|Zidovudine|
93031|NCT00057447|Drug|Rituximab|375 mg per square meters, IV, 1x per week
93032|NCT01338766|Procedure|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
93033|NCT01338792|Drug|oxaliplatin|Given IV
93034|NCT01338792|Drug|pemetrexed disodium|Given IV
93035|NCT01338792|Other|questionnaire administration|Ancillary studies
93036|NCT01338792|Other|laboratory biomarker analysis|Correlative studies
93037|NCT01338792|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
93038|NCT01338792|Genetic|polymorphism analysis|Correlative studies
93039|NCT01338805|Drug|BGG492|
93040|NCT01338818|Drug|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
93041|NCT01338831|Drug|LFA102|
93042|NCT00057460|Drug|Talampanel|
93043|NCT01338844|Dietary Supplement|Myo-inositol|
93044|NCT01338844|Dietary Supplement|D-chito-Inositol|
94699|NCT01324063|Drug|cytarabine|
94700|NCT01324063|Drug|daunorubicin hydrochloride|
94701|NCT01324063|Procedure|quality-of-life assessment|
94702|NCT01324076|Drug|doxorubicin-eluting beads|
94703|NCT01324076|Drug|sorafenib tosylate|
94704|NCT01324076|Other|laboratory biomarker analysis|
94705|NCT01324076|Other|pharmacogenomic studies|
94706|NCT01324076|Other|pharmacological study|
94707|NCT01324076|Procedure|quality-of-life assessment|
94708|NCT00055874|Procedure|peripheral blood stem cell transplantation|
94709|NCT01324089|Dietary Supplement|Resveratrol|Resveratrol 2.5 grams
94710|NCT01326416|Other|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
94711|NCT01326442|Other|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
94712|NCT01326442|Dietary Supplement|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
94713|NCT01326455|Device|Terumo TR wristband|
94714|NCT00056095|Drug|cyclophosphamide|
94715|NCT01326455|Device|Terumo TR wristband|
94972|NCT01324453|Procedure|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
94973|NCT01324466|Drug|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
94974|NCT01324466|Drug|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
94975|NCT00055887|Drug|vinorelbine ditartrate|
94976|NCT01324479|Drug|INC280|
94016|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
94017|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
94018|NCT01325311|Drug|Cholecalciferol|Given PO
94019|NCT01325311|Drug|Genistein|Given PO
94020|NCT01325311|Other|Laboratory Biomarker Analysis|Correlative studies
94021|NCT01325311|Other|Pharmacological Study|Correlative studies
94022|NCT01325311|Other|Placebo|Given PO
94023|NCT01325324|Device|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
94024|NCT01325337|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
93103|NCT01336543|Drug|Chemotherapy following concurrent Chemoradiotherapy|NSCLC (Non-Small Cell Lung Cancer)
PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)
Radiation 59.4 Gy with 2 cycles of PE
(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles
(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles
93104|NCT01336556|Procedure|Oral appliance|Anterior mandibular repositioner: used for two months
93105|NCT01336569|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
93106|NCT00057161|Behavioral|Coordinated Representative Payeeship with Case Management|
93107|NCT01336582|Drug|taxotere|70 mg/m2 for age of ≥ 65
93108|NCT01336595|Device|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
93109|NCT01336595|Device|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
93110|NCT01336608|Drug|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
93111|NCT01336608|Drug|Vilanterol|Inhaled long acting beta-agonist
93112|NCT01336608|Drug|Placebo|Placebo
93113|NCT01336621|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
95033|NCT01332682|Behavioral|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
95034|NCT01332695|Drug|ST101|tablets for oral administration
95035|NCT01332695|Drug|Placebo|placebo to match
95036|NCT01332708|Behavioral|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
95037|NCT01332721|Drug|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
95038|NCT00056745|Biological|TBC-3B|
95039|NCT01332734|Drug|Magnesium Sulfate|2 gram in 1 hour
95040|NCT01332747|Drug|safoof e muhazzil|drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.
to be given in a dosage of 5 gms twice daily
95041|NCT01332747|Drug|compressed tablet of safoof e muhazzil|drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.
compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily
95042|NCT01332747|Drug|Atorvastatin|atorvastatin 10 mgs once daily
95043|NCT01332760|Other|narrow diameter heavy dental tool|8mm diameter, heavy periodontal tool made from steel
95044|NCT01324518|Drug|ORM-12741|60mg twice a day
95045|NCT01324518|Drug|ORM-12741|200mg twice a day
95371|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
95372|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
94831|NCT01329562|Drug|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
94832|NCT01329562|Drug|Placebo|A placebo tablet matching Treximet for oral administration.
94833|NCT01329588|Drug|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
94834|NCT01329588|Drug|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
94835|NCT01329601|Behavioral|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
94836|NCT00056394|Behavioral|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
94837|NCT01329601|Behavioral|booklet based training|Home based training of episodic memory using paper-pencil exercizes
94838|NCT01329614|Behavioral|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
94839|NCT01329614|Drug|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
94840|NCT01332331|Drug|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
94841|NCT01332331|Drug|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
94842|NCT01332344|Drug|Fluticasone propionate/salmeterol combination|Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
94843|NCT01332344|Drug|Inhaled corticosteroids|asthma subjects newly prescribed inhaled corticosteroids in clinical practice
94844|NCT00001059|Drug|Bleomycin sulfate|
94845|NCT00056667|Other|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
94846|NCT01332357|Drug|Fluticasone propionate/salmeterol combination ED MD|Receipt of fluticasone propionate/salmeterol combination from the ED physician
94847|NCT01332357|Drug|Fluticasone propionate/salmeterol combination OP MD|Receipt of fluticasone propionate/salmeterol combination from the OP physician
94369|NCT01325805|Behavioral|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
94370|NCT01325805|Behavioral|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
94371|NCT01325818|Drug|pravastatin, rosuvastatin|Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day
Active Comparator Intervention: Drug: rosuvastatin 20mg/day
94372|NCT01325831|Device|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
94373|NCT01325831|Device|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
94374|NCT01325844|Procedure|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
94375|NCT01325857|Procedure|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
94634|NCT01326390|Device|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
94635|NCT01326390|Procedure|DSA arteriogram- hepatic arteries|Standard of care
94636|NCT01326390|Procedure|CO2 aortogram|Standard of care
94637|NCT01326403|Drug|Tranexamic acid|GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
Group C - A control group will only receive placebo in the emergency room and in the OR.
94638|NCT01326416|Dietary Supplement|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
94639|NCT01328977|Behavioral|education|teaching
94640|NCT01328990|Drug|sulfadoxine-pyrimethamine plus amodiaquine|one dose of sulfadoxine-pyrimethamine 25/1.25 mg/kg plus three daily doses of amodiaquine, 10 mg/kg/day
94641|NCT01329016|Drug|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
94642|NCT01329016|Drug|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
91432|NCT01312935|Drug|PMX-60056|investigational drug
91433|NCT01305434|Dietary Supplement|Mulberry leaf extract effect on post prandial blood glucose|Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.
Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications.
91434|NCT01305447|Behavioral|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
91435|NCT01305447|Behavioral|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
91436|NCT01305447|Behavioral|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
91437|NCT00001045|Drug|Didanosine|
91438|NCT00054340|Drug|busulfan|
91439|NCT01305460|Drug|Azacitidine|Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.
Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.
Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.
Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go "off-study".
91718|NCT00054522|Dietary Supplement|calcitriol|
91719|NCT01308203|Drug|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
91720|NCT01308216|Procedure|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
91721|NCT01308229|Device|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
91722|NCT01308242|Drug|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
95105|NCT01329991|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
95106|NCT01329991|Drug|Placebo|Matching placebo for PLX5622
95107|NCT01330017|Drug|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
95108|NCT00056433|Drug|L-Arginine|
95109|NCT01330017|Drug|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
95110|NCT01332760|Other|large diameter light weight tool|Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
95111|NCT01332773|Procedure|Artery first procedure|early identification of SMA to evaluate infiltration
95112|NCT01332773|Procedure|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
95113|NCT01332786|Drug|Tigecycline|Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)
Level 1: 50 mg daily x 10 doses; 1 week rest
Level 2: 100 mg daily x 10 doses; 1 week rest
Level 3: 150 mg daily x 10 doses; 1 week rest
Level 4: 200 mg daily x 10 doses 1 week rest
Level 5: 250 mg daily x 10 doses; 1 week rest
Level 6: 300 mg daily x 10 doses; 1 week rest
Level 7: 350 mg daily x 10 doses; 1 week rest
95114|NCT01332799|Drug|allopurinol or placebo|Daily active drug (allopurinol administered orally) to be compared to daily placebo (sugar pill) administered orally for 3 years.
95115|NCT00056758|Biological|Autologous Dendritic Cell HIV Vaccination|
95116|NCT01332812|Drug|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
95117|NCT01332812|Other|control group|General anesthesia, without additional interventions
95118|NCT01332825|Other|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
95119|NCT01332838|Procedure|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
95401|NCT00059839|Drug|prednisone|Given by mouth
95402|NCT01362205|Drug|Dexmedetomidine|See arm details
95403|NCT01362205|Drug|Placebo|Sterile, clear saline 0.9%
95404|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
94848|NCT01332370|Drug|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
95183|NCT01330030|Drug|Selegiline|6mg/24 hrs for 8 weeks
95184|NCT01330030|Other|matching placebo|placebo/24hrs for 8 weeks
95185|NCT01330043|Behavioral|cognitive behavior therapy (CBT)|During open label treatment, all receive CBT and zyban and nicotine patch. At week 10 those who continue to smoke will be switched to varenicline through week 26. At week 10 those who are abstinent and report low levels of craving and low levels of depression symptoms will be withdrawn from study medications. Those who are abstinent but report difficulty with craving or depression symptoms will remain on zyban and NRT through week 26. Medication will not be available after week 26. All will receive CBT through week 26.
95186|NCT01330056|Procedure|FOPS|Functional organ preservation (FOPS) as a first-line treatment modality
Postoperative RT or CRT may be included for the patients of this group.
95187|NCT01330056|Radiation|CRT|Concurrent chemoradiotherapy as a first-line treatment modality
Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT
95188|NCT01330082|Other|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
95189|NCT01330082|Other|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
95190|NCT01330082|Other|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
95191|NCT00056433|Drug|Sildenafil|
95192|NCT01330095|Dietary Supplement|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
95193|NCT01330108|Drug|ambrisentan|ambrisentan 2.5mg, 5mg, & 10mg. Daily dosage.
95194|NCT01330121|Other|Pharmacist Counseling|Pharmacist Counseling includes but is not limited to:
Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity
95195|NCT01330134|Drug|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
95196|NCT01330134|Drug|lidocaine|1% lidocaine subcutaneous injection alone
95197|NCT01330173|Drug|Vismodegib|Given PO
95198|NCT01330173|Other|Pharmacological Study|Correlative studies
95199|NCT01330173|Other|Laboratory Biomarker Analysis|Correlative studies
94643|NCT01329016|Drug|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
94644|NCT01329029|Drug|Roflumilast|500 µg, once daily
94645|NCT01329029|Drug|Placebo|once daily
94646|NCT00056329|Drug|Placebo|Placebo twice daily for three years
94647|NCT01329042|Drug|Potassium-sodium citrate|The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
94648|NCT01329068|Behavioral|individual consult|regular individual consultations
94649|NCT01329068|Behavioral|group medical consult|group medical consult
94650|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
94651|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
94652|NCT01329107|Behavioral|Multimodal Intervention|Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.
After operation the intervention group will be mobilised in a fast speed compared to standard care.
94912|NCT01329614|Behavioral|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
94913|NCT01329627|Drug|Paclitaxel/doxorubicin/cyclophosphamide|Metronomic chemotherapy as described below:
Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;
Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
94914|NCT01329627|Drug|Paclitaxel/doxorubicin/cyclophosphamide|Metronomic chemotherapy as described below:
Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
94915|NCT01329640|Device|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;
Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks
94916|NCT01329653|Behavioral|aerobic training|12 weeks of aerobic training, 4X/week
94917|NCT01329653|Behavioral|Wait list|wait list control condition
94918|NCT00056394|Behavioral|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
91723|NCT01308255|Drug|Infliximab|Prior to week 26
Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)
Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.
Folic acid 5 mg daily except the day methotrexate is taken
Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity
91724|NCT01308255|Drug|Methylprednisolone|Steroid
91725|NCT01308255|Drug|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
91726|NCT01308255|Dietary Supplement|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
91727|NCT01308268|Drug|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (>= 2 years old) single dose, PO
91728|NCT01310842|Behavioral|Questionnaires|Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
91729|NCT01310842|Drug|Nicotine Patch Therapy|4 weeks of nicotine patch therapy
91730|NCT01310842|Behavioral|Counseling Sessions|5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
91731|NCT01310855|Drug|cediranib maleate|
91732|NCT01310855|Drug|gefitinib|
91733|NCT01310855|Drug|Placebo|
91734|NCT00054665|Drug|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycle every 21 days.
91735|NCT01310868|Drug|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
91736|NCT01310868|Drug|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
90820|NCT01321905|Dietary Supplement|Supplementation with vitamin D2/D3|Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.
Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.
95405|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
95406|NCT01354444|Drug|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
95407|NCT01354444|Drug|Placebo|a pill that will look like the active drug but will not contain any carvedilol
95408|NCT01354457|Drug|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
95409|NCT01354470|Drug|Modafinil|600 mg Modafinil capsule
95410|NCT00058812|Biological|EBV specific T cells|One injection of 2x10^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
95411|NCT01354483|Biological|Umbilical Cord Blood Mononuclear Cell|
95412|NCT01354483|Biological|Methylprednisolone|30mg/kg i.v. methylprednisolone
95413|NCT01354483|Drug|Lithium Carbonate Tablet|6 weeks
95414|NCT01354496|Drug|LY2409021 Reference Form|Administered orally
95415|NCT01354496|Drug|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
95416|NCT01354496|Drug|LY2409021 Test-High Formulation (high particle size)|Administered orally
95417|NCT01354496|Drug|LY2409021 Test-Low Formulation (low particle size)|Administered orally
95418|NCT01354522|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
95419|NCT01354522|Drug|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
95420|NCT01354535|Procedure|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
95421|NCT00058825|Biological|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
94503|NCT01331928|Drug|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
95200|NCT01330186|Other|FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
95201|NCT01330199|Other|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
95202|NCT00056446|Drug|Vatalanib|
94302|NCT01325779|Drug|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
94303|NCT00056030|Drug|leucovorin calcium|
94304|NCT01328236|Drug|Bortezomib|INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.
94305|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
94306|NCT01328236|Drug|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
94307|NCT01328236|Drug|Dexamethasone|INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.
94308|NCT01328249|Drug|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks
94309|NCT01328262|Other|Red blood cells|The subjects receive an amount of RBC's that has been calculated from their BSA.
94310|NCT01328262|Other|Red blood cells|The subjects in this group receive the prescribed number of redd blood cell units.
94311|NCT01328275|Drug|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
94312|NCT01328288|Drug|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
94313|NCT01328301|Other|Experimental|For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
91051|NCT01312233|Other|Medical Care|Participants allocated to all three treatment groups receive medical care over a 12‐week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self‐management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti‐inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.
91052|NCT01312233|Other|Dual Care|Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12‐week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity‐low amplitude or low velocity‐variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
91053|NCT01312233|Other|Shared Care|Participants allocated to Shared Care receive co‐managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
91054|NCT01312246|Device|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
91055|NCT01312259|Other|Changing the Interstim parameter of '' Frequency" in patients with Interstitial Cystitis|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
91056|NCT01312272|Drug|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
91057|NCT00054834|Drug|hLL2 (epratuzumab)|
91058|NCT01312272|Drug|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
91059|NCT01312285|Device|Resonator device|low level magnetic fields
91060|NCT01312298|Procedure|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
91061|NCT01312298|Procedure|Regional anesthesia|Patients will receive intrathecal anesthesia
91364|NCT01307579|Drug|fluconazole|Given IV or PO
91365|NCT01307579|Other|laboratory biomarker analysis|Correlative studies
91366|NCT01307592|Biological|rituximab|
91367|NCT01307592|Drug|gemcitabine hydrochloride|
91368|NCT01307592|Drug|lenalidomide|
90821|NCT01321918|Other|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
90822|NCT01321918|Other|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
90823|NCT01321931|Drug|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
90824|NCT00055783|Biological|apolizumab|
90825|NCT01321931|Drug|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
90826|NCT01321931|Drug|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
90827|NCT01314196|Other|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
90828|NCT01314209|Drug|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
90829|NCT01314222|Drug|BMS-954561|
90830|NCT01314222|Drug|Pregabalin|
90831|NCT01314222|Drug|Placebo matching BMS-954561|
90832|NCT00055120|Drug|Emtricitabine/tenofovir disoproxil fumarate|
90833|NCT01314222|Drug|Placebo matching Pregabalin|
90834|NCT01314248|Device|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
90835|NCT01314261|Drug|ABT-267|5 mg or 25 mg tablets
90836|NCT01314261|Drug|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
90837|NCT01314261|Drug|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
90838|NCT01314261|Other|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
90839|NCT01314274|Drug|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
91114|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
94504|NCT01331941|Drug|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
94505|NCT00056641|Drug|ritonavir|
94506|NCT01331941|Drug|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
94507|NCT01331954|Device|Ultrasonic ablation device|One or two HIFU procedures
94508|NCT01331967|Drug|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
94509|NCT01331980|Device|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
94510|NCT01331980|Device|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
94511|NCT01331993|Drug|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
94512|NCT01333891|Drug|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
94513|NCT01333891|Drug|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
94514|NCT01333891|Device|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
94515|NCT01333891|Device|Goldmann applanation tonometer|intraocular pressure measurements
94516|NCT01333891|Device|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
94517|NCT01333904|Drug|PUR118|inhaled
94518|NCT00056966|Drug|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
94519|NCT01333917|Drug|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
94520|NCT01333930|Other|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
94521|NCT01333930|Other|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
94314|NCT01328301|Other|Speed-stable treadmill training|Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
94315|NCT01328340|Other|weight training|Weight training performed 3 times a week for 12 weeks
94316|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
94317|NCT01328353|Other|telehealth plus aprn triage|aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
94318|NCT01328379|Drug|Dalfampridine-ER 5mg|5mg, twice daily
94578|NCT01332006|Procedure|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
94579|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|
94580|NCT00056641|Drug|saquinavir|
94581|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
94582|NCT01332019|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
94583|NCT01332032|Behavioral|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
94584|NCT01332032|Behavioral|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
94585|NCT01332032|Behavioral|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
94586|NCT01332045|Procedure|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
91369|NCT01307592|Drug|oxaliplatin|
91370|NCT01307605|Biological|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
91371|NCT01307605|Drug|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
91372|NCT01307618|Biological|NA17.A2 Peptide Vaccine|Given SC or ID
91373|NCT00054457|Drug|capecitabine|
91374|NCT01307618|Biological|Recombinant MAGE-3.1 Antigen|Given SC or ID
91375|NCT01307618|Biological|Recombinant Interleukin-12|Given SC or ID
91376|NCT01307618|Biological|MART-1 Antigen|Given SC or ID
91377|NCT01307618|Other|Laboratory Biomarker Analysis|Correlative studies
91378|NCT01307631|Drug|Akt Inhibitor MK2206|Given PO
91379|NCT01307631|Other|Laboratory Biomarker Analysis|Correlative studies
91380|NCT01307644|Behavioral|Web based weight loss|Using interactive website only, website plus a peer-led online support group, or website plus professional behavioral counseling to facilitate weight loss and maintenance, increase healthy eating, physical activity, and 4 behaviors from HPM
91381|NCT01307657|Other|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
91382|NCT01307670|Procedure|Operative treatment with intramedullary nailing|Open reduction and internal fixation with intramedullary nailing device
91383|NCT01307670|Procedure|Operative treatment with plate fixation.|Open reduction and internal fixation with plate and screws.
91384|NCT00001047|Drug|Ethambutol hydrochloride|
91385|NCT00054457|Drug|docetaxel|
91386|NCT01307683|Behavioral|Mindful Moms|8 weekly 2-hour sessions, 2 "booster" telephone sessions, and 1 postpartum "booster" session
91660|NCT01310829|Behavioral|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
91661|NCT01310829|Behavioral|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
91115|NCT00054613|Drug|Methoxsalen|
91116|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
91117|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
91118|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
91119|NCT01309789|Drug|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
91120|NCT01309802|Drug|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
91121|NCT01309828|Drug|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
91122|NCT01309828|Drug|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
91123|NCT01309841|Drug|NKTR-118|12.5 mg oral tablet once daily
91124|NCT01309841|Drug|NKTR-118|25 mg oral tablet once daily
91125|NCT01312311|Drug|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1
91126|NCT01312324|Drug|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
91127|NCT01312337|Drug|salvage iressa|Iressa 250mg per day until progression
91128|NCT01312350|Drug|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
91129|NCT01312350|Drug|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
91130|NCT01312363|Drug|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
91131|NCT00054847|Procedure|saphenous vein graft|Saphenous vein harvested from the arm is used as a conduit for CABG.
91132|NCT01312376|Biological|OC-DC vaccine|All subjects will receive a dose of 5-10 million cells of OC-DC intradermally
91133|NCT01312376|Drug|Bevacizumab|Patients will start receiving Bevacizumab at 15 mg/kg starting Day 30 and every 4 weeks thereafter until end of study.
91134|NCT01312376|Drug|cyclophosphamide 300 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous cyclophosphamide for 300 mg/m2/d for 3 days.
95082|NCT01327157|Procedure|occlusal adjustment, Dental cleaning|Visual analogue scale, before and after treatment. Dental cleaning at first query. Gnathostats models in the maximal intercuspal position before and after treatment Occlusal adjustment in the teeth that are causing some interference of jaw closure, reaching a maximum contact dental . It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this start to do occlusal adjustment. Will be held palpation of the large muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After this procedure starts the adjustment following the rules of Guichet
95083|NCT01327157|Procedure|Visual analog scale, Dental cleaning|Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving "visual analog scale" final
VAS at the first inquiry
VAS at the last inquiry
dental cleaning in the first inquiry
95084|NCT01327170|Procedure|Subthreshold diode micropulse laser|
95085|NCT01327183|Procedure|Percutaneous Coronary Intervention (PCI)|at least 1 hour and up to 24 hours after completion of drug infusion
95086|NCT00056407|Drug|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
95087|NCT01329900|Drug|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
95088|NCT01329900|Procedure|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
95089|NCT01329913|Drug|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
95090|NCT01329913|Drug|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
95091|NCT01329913|Drug|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
95092|NCT01329913|Drug|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
95093|NCT01329913|Drug|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
95094|NCT01329913|Drug|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
95095|NCT01329926|Procedure|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
95096|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
95097|NCT00056433|Drug|Hydroxyurea|
95098|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
95099|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
94587|NCT01332045|Procedure|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
94588|NCT01332058|Behavioral|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
94589|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
94590|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
94591|NCT00056641|Drug|amprenavir|
94592|NCT01332084|Other|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
94593|NCT01332097|Drug|BCT197|
94594|NCT01332097|Drug|Prednisone placebo|capsules
94849|NCT01332370|Drug|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
94850|NCT01332383|Drug|Naratriptan|
94851|NCT01332396|Drug|Lapatinib|
94852|NCT01332409|Drug|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
94853|NCT01332422|Drug|Salmeterol and Fluticasone|Collection of safety data
94854|NCT01332435|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
94855|NCT01332448|Drug|Orlistat 120|Orlistat 120mg tid
94856|NCT00056680|Behavioral|Psychoeducational video|
94857|NCT01332448|Drug|Orlistat 60|Orlistat 60mg tid
94858|NCT01332461|Drug|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
94859|NCT01332461|Drug|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
94860|NCT01332474|Drug|BOTOX|BOTOX
94861|NCT01332487|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
94862|NCT01332500|Drug|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
91662|NCT01310829|Behavioral|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
91663|NCT01313650|Drug|25mcg|GW642444
91664|NCT01313650|Drug|Placebo|Placebo
91665|NCT01313663|Drug|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
91666|NCT00054964|Drug|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
91667|NCT01313663|Drug|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
91668|NCT01313676|Drug|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
91669|NCT01313676|Drug|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
91670|NCT01313676|Drug|vilanterol|25mcg given once daily via novel dry powder inhaler
91671|NCT01313676|Other|Placebo|placebo comparator once daily via novel dry powder inhaler
91672|NCT01313689|Drug|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
91673|NCT01313689|Drug|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
91674|NCT01313702|Drug|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
91675|NCT01313702|Drug|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
91676|NCT01313702|Drug|usual care|the drugs used in clinical practice, defined by physician
91677|NCT00054977|Drug|GM-CT-01|IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
91678|NCT01313715|Biological|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
91679|NCT01313715|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
90759|NCT01316900|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
91135|NCT01312376|Drug|fludarabine 30 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous fludarabine 30 mg/m2/d for 3 days
91440|NCT01305499|Drug|Entinostat days 3, 10|Given orally on days 3, 10
91441|NCT01305499|Drug|5AC|
91442|NCT01305499|Drug|Entinostat days 10,17|Given orally on days 10, 17
91443|NCT01305512|Drug|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
91444|NCT01305525|Device|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
91445|NCT01305538|Drug|BMS-954561|
91446|NCT01305538|Drug|BMS-954561|
91447|NCT01305538|Drug|Placebo|
91448|NCT01305551|Drug|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
91449|NCT00054340|Drug|cyclophosphamide|
91450|NCT01305551|Drug|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
91451|NCT01305551|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
91452|NCT01305564|Device|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
91453|NCT01305577|Drug|Deoxycholic acid injection|
91454|NCT01307787|Other|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
91455|NCT01307787|Other|no intervention|waiting list control group with no intervention
91456|NCT01307800|Drug|LY2140023|Administered orally
91457|NCT01307800|Drug|Placebo|Administered orally
95100|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
95120|NCT01332838|Device|compression stockings (Sigvaris )|Specialized monoleg compression
95121|NCT01332851|Behavioral|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
95122|NCT01332851|Behavioral|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
95123|NCT01332864|Procedure|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
95124|NCT01332864|Procedure|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
95125|NCT01332877|Behavioral|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
95126|NCT00056797|Biological|ALVAC HIV vaccine (vCP1452)|
95127|NCT01332877|Behavioral|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
95128|NCT01332890|Other|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
95129|NCT01332890|Other|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
95130|NCT01332890|Other|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
95131|NCT01332890|Other|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
95132|NCT01324648|Other|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
95133|NCT01324661|Behavioral|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
95134|NCT01324674|Other|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
95135|NCT01324674|Other|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
95136|NCT01324687|Other|Telemedicine care|Availability of telemedicine
94863|NCT01332500|Drug|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
94864|NCT01332513|Drug|Investigational Medicinal Product (MR1)|
94865|NCT01324193|Dietary Supplement|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
94866|NCT01324219|Behavioral|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
94867|NCT01324219|Behavioral|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
94868|NCT01324232|Drug|AVP-923|AVP-923 capsules administered twice-a-day, over a 12 week period
94869|NCT01324245|Drug|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
95203|NCT01330238|Drug|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
95204|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
95205|NCT00059475|Drug|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
95206|NCT01359072|Other|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
95207|NCT01359085|Drug|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
95208|NCT01359085|Procedure|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
95209|NCT01359098|Drug|Ciprodex Otic Suspension|4 gtt b.i.d. for 7 days.
90760|NCT01316900|Drug|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
90761|NCT00055497|Biological|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
90762|NCT01316900|Drug|GW642444|25 mcg once-daily
90763|NCT01316900|Drug|tiotropium bromide|18 mcg once-daily
90764|NCT01316913|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
90765|NCT01316913|Drug|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
90766|NCT01316913|Drug|GSK573719|125 mcg once-daily
90767|NCT01316913|Drug|tiotropium bromide|18 mcg once-daily
90768|NCT01316926|Drug|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
90769|NCT01316926|Drug|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
90770|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams once daily
90771|NCT01316939|Drug|Placebo|Placebo
90772|NCT00055497|Biological|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
90773|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams twice daily
90774|NCT01316952|Drug|Carvedilol immediate release only|All dosages of carvedilol immediate release
90775|NCT01316952|Drug|Carvedilol extended release only|All dosages of carvedilol extended release
90776|NCT01316952|Drug|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
90777|NCT01316952|Drug|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
90778|NCT01316952|Drug|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
90779|NCT01316952|Other|No β-blocker|No β-blocker within the month prior to the index date
91062|NCT01304823|Dietary Supplement|lactisole|flavoring agent/sweet taste antagonist
91458|NCT01307813|Device|Overstitch Endoscopic Suturing System|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model
91737|NCT01310881|Drug|NSI-189 Phosphate|Once daily oral administration
91738|NCT01310894|Drug|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration of patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
91739|NCT01310920|Other|observation|genotyping
91740|NCT01310946|Other|Database|Database
91741|NCT01310959|Other|Database|Database
91742|NCT01310972|Other|Registry|Registry
91743|NCT01310985|Drug|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
91744|NCT01310998|Behavioral|High intensity exercise|4x4 intervals
91745|NCT00054678|Drug|MyoCell™|
91746|NCT01311011|Procedure|SCT|SCT
91747|NCT01311024|Biological|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
91748|NCT01311024|Biological|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
91749|NCT01311037|Other|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
91750|NCT01311050|Drug|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
91751|NCT01311076|Drug|TAK-329|TAK-329 50 mg, tablets, orally, single dose, one day.
91752|NCT01311076|Drug|TAK-329|TAK-329 200 mg, tablets, orally, single dose, one day.
91753|NCT01311076|Drug|Insulin|Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
91754|NCT01313117|Drug|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
91755|NCT01313143|Drug|AOP200704|Comparison of AOP200704 with Esmolol
95137|NCT00001057|Drug|Zidovudine|
95138|NCT00055913|Drug|erlotinib hydrochloride|Given orally
95139|NCT01324700|Drug|Escitalopram|Escitalopram is an Antidepressant
94248|NCT01331369|Other|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
94249|NCT01331382|Dietary Supplement|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
94250|NCT01331382|Other|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
94251|NCT01331395|Other|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
94252|NCT01331408|Device|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
94253|NCT01331421|Drug|exemestane|25 mg tablet
94254|NCT01331434|Drug|exemestane|25 mg tablet
94255|NCT01331447|Drug|exemestane|25 mg tablet
94256|NCT01331460|Behavioral|RBT|Intervention for Injection Drug Using Women:
Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors.
94257|NCT00056563|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
94258|NCT01331460|Other|Case-Management|Standard Intervention:
Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs
94259|NCT01331473|Procedure|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
94260|NCT01331473|Procedure|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
94261|NCT01331486|Dietary Supplement|Hawthorn|Hawthorn standardized extract liquid capsule
94262|NCT01333722|Drug|Hydrocodone/Acetaminophen Extended Release|
94263|NCT01333722|Drug|Placebo|Placebo tablet
95210|NCT01359098|Drug|Ciprodexa Otic Foam|0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
95211|NCT01359111|Device|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
95212|NCT01359124|Behavioral|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
95213|NCT01359124|Behavioral|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
95214|NCT01359124|Behavioral|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
95215|NCT01359137|Behavioral|Probation as usual|Routine probation with do deferred jail condition.
95216|NCT00059514|Behavioral|Modified Project Toward No Tobacco Use|
95217|NCT01359137|Behavioral|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
95218|NCT01359137|Behavioral|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
95219|NCT01359150|Drug|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
94319|NCT01328379|Drug|Dalfampridine-ER 10mg|10mg, twice daily
94320|NCT01328379|Other|Placebo|placebo, twice daily
94321|NCT01328392|Drug|Dexlansoprazole|30mg a day, 3 months
94322|NCT01328405|Device|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
94323|NCT01328418|Procedure|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
94324|NCT01331486|Dietary Supplement|Placebo capsule|Matched placebo liquid capsule
94325|NCT01331499|Device|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
94326|NCT01331499|Procedure|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
94327|NCT01331525|Biological|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
91063|NCT01304823|Other|mixed liquid meal|Ensure Plus
91064|NCT00054314|Drug|ortataxel|
91065|NCT01304836|Drug|Advagraf|oral
91066|NCT01304836|Drug|Mycophenolate Mofetil|oral
91067|NCT01304836|Drug|Simulect|IV
91068|NCT01304836|Drug|Corticosteroids|IV & oral
91069|NCT01304849|Drug|Escalated BEACOPP|Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:
Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm
91070|NCT01304862|Behavioral|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
91071|NCT01304862|Behavioral|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
91072|NCT01304888|Other|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
91073|NCT01304888|Other|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
91074|NCT01304888|Other|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
91075|NCT00054327|Drug|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
91076|NCT01304888|Other|Control|No benefits were provided
91077|NCT01304901|Drug|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
91756|NCT01313143|Drug|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
91757|NCT01313169|Other|EMR Reminder|EMR reminders displayed
91758|NCT01313169|Other|EMR Reminder + Panel management|EMR Reminder + Panel management
90840|NCT01314274|Drug|NaCl|10ml of 0.9% NaCl intranasal submucosal
90841|NCT01314300|Drug|Lidocaine|Lidocaine 5% plaster
90842|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable: SAPIEN XT™ vs. AVR; Inoperable: SAPIEN XT™ vs. SAPIEN®
90843|NCT00055120|Drug|Lopinavir/ritonavir|
90844|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable: SAPIEN XT ™vs. AVR
90845|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Inoperable: SAPIEN XT™ vs. SAPIEN®
90846|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable: SAPIEN XT™ vs. AVR
90847|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|High risk: SAPIEN 3™ vs. historical control; Intermediate risk: SAPIEN 3™ vs. historical control
90848|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|High risk: SAPIEN 3™ vs. historical control Intermediate risk: SAPIEN 3™ vs. historical control
90849|NCT01314339|Drug|Desloratadine|Desloratadine Tablets, 5 mg
90850|NCT01314352|Drug|Desloratadine|Desloratadine Tablets, 5 mg
90851|NCT01314378|Behavioral|Mindfulness Training|Eight session intensive behavioral training program for smokers
90852|NCT01314378|Behavioral|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
90853|NCT01314391|Genetic|mutation analysis|
90854|NCT00055120|Drug|Stavudine|
90855|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
90856|NCT01316991|Dietary Supplement|Chewing Gum|chewing gum will be provided
90857|NCT01316991|Dietary Supplement|No Gum|no chewing gum will be provided
90858|NCT01317004|Drug|Fingolimod|0.5 mg/day oral capsule
94264|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
94265|NCT00001060|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
94266|NCT00056953|Behavioral|Peer mentoring program|
94267|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
94522|NCT01333943|Procedure|Study Group: Experimental|The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
94523|NCT01333943|Procedure|Control Group|The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
94524|NCT01333956|Drug|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
94525|NCT01333956|Drug|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
94526|NCT01333956|Drug|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
94527|NCT01333956|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
94528|NCT01333969|Procedure|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
94529|NCT00056966|Drug|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
94530|NCT01333982|Other|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
94531|NCT00056056|Procedure|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
94532|NCT01326182|Behavioral|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
94328|NCT01331564|Behavioral|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
94329|NCT01331564|Behavioral|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
94330|NCT00056563|Other|best medical therapy|Participants will initially be randomized to DBS or to 6 months of "best medical therapy." BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months.
94331|NCT01331564|Behavioral|Control|Control women will receive non-weight related content during both time periods at the project website.
94332|NCT01331577|Behavioral|Cognitive Behavioural Training|Two day seminar
94333|NCT01331577|Behavioral|Integrative Kinesiology Intervention|Two day seminar
94334|NCT01331590|Drug|G-CSF|
94335|NCT01331590|Drug|Ifosfamide|
94336|NCT01331590|Drug|Etoposide|
94337|NCT01331590|Drug|Dexamethasone|
94338|NCT01331590|Drug|Mesna|
94339|NCT01331616|Drug|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
94340|NCT01331629|Other|ART-THERAPIE|8 sessions of art therapy during radiotherapy
94595|NCT01332097|Drug|BCT197 placebo|capsules
94596|NCT00056966|Radiation|Total Body Irradiation|Day-1 single dose 450 cGy
94597|NCT01334151|Drug|recombinant human insulin|Single doses of: 0.15 U/kg
94598|NCT01334164|Behavioral|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
94599|NCT01334164|Other|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
91387|NCT01307722|Other|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
91388|NCT01307748|Other|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
91389|NCT01310179|Genetic|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
91390|NCT01310192|Device|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
91391|NCT01310205|Drug|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
91392|NCT00054639|Biological|rituximab|Given IV
91393|NCT01310218|Other|extended postoperative dressing|2 weeks of bulky dressing
91394|NCT01310218|Other|short postoperative dressing|2 days bulky dressing followed by bandaid
91395|NCT01310231|Drug|Metformin|metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
Number of cycles: Until progression or unacceptable toxicity develops.
91396|NCT01310231|Drug|Placebo|Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
Number of cycles: until progression or unacceptable toxicity develops.
91397|NCT01310244|Drug|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
91398|NCT01310257|Other|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
91399|NCT01310270|Dietary Supplement|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
91400|NCT01310270|Dietary Supplement|Omega 3 Fatty Acid|4.4 gm/day for 1 month
91401|NCT01310283|Other|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
91402|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
90859|NCT01317004|Drug|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
90860|NCT01317017|Drug|Actimmune|All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.
Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.
Patients will return at one to two weeks for suture removal.
Clinical assessments done at every visit.
Patients will also be evaluated at each visit for any adverse events.
90861|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
91136|NCT01312376|Drug|ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells|All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109 (10-15 billion) T-cells with escalating doses in cohort 2 and 3.
91137|NCT01312389|Biological|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
91138|NCT01312389|Biological|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
91139|NCT01312389|Biological|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
91140|NCT01312402|Drug|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
91141|NCT01312402|Drug|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
91142|NCT00054847|Procedure|radial artery graft|Radial artery harvested from the arm is used as a conduit for CABG.
91143|NCT01312415|Drug|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
91144|NCT01312415|Drug|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
91145|NCT01304927|Other|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
91146|NCT01304953|Drug|Group P+P|In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
94533|NCT01326182|Behavioral|MAAS|Group-based intervention including asthma education and education regarding general child health
94534|NCT01326195|Behavioral|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
94535|NCT01326195|Behavioral|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
94536|NCT01326208|Procedure|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
94537|NCT01326221|Drug|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
94792|NCT00055887|Drug|cisplatin|
94793|NCT01324180|Drug|Doxorubicin|60 mg/m^2/day IV over 15 minutes on day 2
94794|NCT01324180|Drug|Intrathecal chemotherapy|IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.
30 mg for patients age 1-1.99
50 mg for patients age 2-2.99
70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age.
94795|NCT01326559|Drug|Docetaxel, Cisplatin, 5-FU and Cetuximab|Induction phase (Weeks 1-9):
Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles
Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles
Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles
Concurrent phase (weeks 10-16):
Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)
Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)
IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)
94796|NCT01326585|Drug|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
94797|NCT01326585|Drug|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
94798|NCT01326598|Device|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
94799|NCT01326611|Drug|Clarithromycin|
94800|NCT00056095|Drug|fludarabine phosphate|
94801|NCT01326611|Drug|Dextrose|
94802|NCT01326624|Device|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
94600|NCT01334177|Drug|TLR8 agonist VTX-2337|Given SC
94601|NCT01334177|Biological|cetuximab|Given IV
94602|NCT01334177|Other|laboratory biomarker analysis|Correlative studies
94603|NCT01334177|Other|pharmacogenomic studies|Correlative studies
94604|NCT01334203|Drug|Ranolazine|Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.
Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day.
94605|NCT01334216|Other|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
94606|NCT01334216|Other|CHICA Placebo|This was CHICA without the study module.
94607|NCT00056966|Procedure|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count >2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count >2 x 108/kg) will be substituted.
94608|NCT01334229|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
94609|NCT01334229|Drug|Placebo|Placebo for 6 weeks
94610|NCT01334242|Drug|Schedule A|Dosing 1 hour before breakfast
94611|NCT01334242|Drug|Schedule B|Dosing 0.5 hour before breakfast
94612|NCT01334242|Drug|Schedule C|Dosing immediately before breakfast
94613|NCT01334242|Drug|Schedule D|Dosing immediately before lunch
94614|NCT01334242|Drug|Schedule E|Split dose, dosing 1 hour before breakfast and dinner
94870|NCT01324258|Drug|GSK1120212|Part1 and Part2
94871|NCT01324258|Drug|Gemcitabine|Part2
94872|NCT01324271|Device|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
94873|NCT00055887|Drug|efaproxiral|
94874|NCT01324284|Drug|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
91403|NCT00054639|Other|laboratory biomarker analysis|Correlative studies
91680|NCT01313715|Biological|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
91681|NCT01313715|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
91682|NCT01313728|Drug|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
91683|NCT01313728|Drug|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
91684|NCT01313741|Device|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
91685|NCT01313754|Procedure|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
91686|NCT01313754|Procedure|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
91687|NCT01313767|Drug|Botulinum toxin type A|Botulinum toxin type A
91688|NCT01305850|Drug|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
91689|NCT01305863|Device|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
91690|NCT01305863|Device|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
91691|NCT01305876|Behavioral|yoga intervention|yoga session 2 x week over 3-1/2 months
91692|NCT01305889|Behavioral|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
91693|NCT00054340|Procedure|peripheral blood stem cell transplantation|
91694|NCT01305889|Drug|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
91695|NCT01305902|Behavioral|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
91696|NCT01305915|Behavioral|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
91147|NCT01304953|Drug|Group P+T|In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
91148|NCT01304953|Drug|Group S+P|In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
91459|NCT01307826|Other|massage|session - 20 minutes.
Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:
latissimus muscle of the back
major pectoral muscle
supraspinous and infraspinous muscles
teres minor muscle
serratus anterior muscle
deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.
A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation.
91460|NCT01307826|Other|massage|classical massage (Swedish massage)
91461|NCT00054470|Biological|trastuzumab|
91462|NCT01307839|Drug|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
91463|NCT01307839|Drug|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
91464|NCT01307852|Device|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
91465|NCT01307865|Drug|injectable poly-L-lactic acid|Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
91466|NCT01307878|Drug|chemotherapy ± targeted therapy|FOLFOX 6 ± targeted therapy
91467|NCT01307891|Drug|Abraxane|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
91468|NCT01307891|Drug|Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
94803|NCT01326637|Other|Patient Overview Document|The Intervention has two components:
Pre-visit care coordination:
5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.
The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.
Team Meeting:
On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD.
94804|NCT01326650|Drug|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
94805|NCT01326650|Drug|placebo|daily oral placebo supplement for three years
94806|NCT01326663|Drug|Medication Trial|
94807|NCT01326676|Drug|Polypill: Red Heart Pill|The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):
Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.
Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
95140|NCT01324700|Drug|Placebo|Inactive ingredient matching the active medication in appearance
95141|NCT01324739|Drug|human BNP-32|3pmol/kg/min infusion
95142|NCT01324752|Drug|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
95143|NCT01324752|Drug|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
95144|NCT01324752|Drug|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
95145|NCT01324765|Behavioral|TARGET|12-session group therapy twice weekly 6 weeks
95146|NCT01324765|Behavioral|SGT|12 sessions supportive group therapy twice weekly 6 weeks
95147|NCT01324778|Device|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
95148|NCT01324778|Device|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
95149|NCT00055913|Other|laboratory biomarker analysis|Correlative studies
95150|NCT01324791|Procedure|anti-reflux surgery|
95151|NCT01324817|Device|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
95152|NCT01324817|Device|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
94875|NCT01324297|Other|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
94876|NCT01324310|Drug|Romidepsin|Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
94877|NCT01324310|Drug|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
94878|NCT01324323|Drug|Romidepsin|14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
94879|NCT01324323|Drug|Rifampin|600 mg oral once daily on Days 4-8
94880|NCT01324336|Drug|6-Mercaptopurine|75 mg/m2/dose/day
94881|NCT01324349|Device|Veriset Hemostatic Patch|Topical hemostat
94882|NCT01324349|Device|Fibrin Sealant (TachoSil®)|Topical hemostat
94883|NCT01324362|Drug|Placebo|Twice daily dosing
94884|NCT00055887|Drug|gemcitabine hydrochloride|
94885|NCT01324362|Drug|Placebo|Twice daily dosing
94886|NCT01324362|Drug|FP 100mcg|Twice daily dosing
94887|NCT01324362|Drug|FP 250mcg|Twice daily dosing
94888|NCT01324362|Drug|FP 500mcg|Twice daily dosing
94889|NCT01324362|Drug|FSC 100/50mcg|Twice daily dosing
94890|NCT01326754|Drug|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
94891|NCT01326754|Drug|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
94892|NCT01326754|Drug|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
95220|NCT01359150|Drug|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
95221|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
95222|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
91697|NCT01305928|Other|Warm Hand-off|Warm Hand-Off
Staff brief intervention and warm hand-off (5 min):
Assess withdrawal, need for medication change
Describe warm hand-off process
Provide 2-page flyer
Perform call, leave room
Notify patients' nurse patient is talking to quitline
Quitline session (20 min):
Collect minimum data set
Explore thoughts/feelings toward quitting
Provide medication education
Build plan to stay quit
Schedule next call
Staff check-back (5 min):
Ask patient how session went
Ask if patient requests cessation medication script on discharge
90780|NCT01316965|Behavioral|Multifaceted prevention program HELP(Hospital Elder Life Program)|A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment
B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards
C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium.
90781|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
90782|NCT01316978|Drug|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
90783|NCT00055497|Biological|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
90784|NCT01319448|Drug|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
90785|NCT01319461|Device|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
90786|NCT01319461|Device|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
90787|NCT01319474|Other|Whole-leg compression ultrasound|Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
90788|NCT00055653|Drug|methylprednisolone|
90789|NCT01319487|Drug|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
90790|NCT01319487|Drug|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
90791|NCT01319487|Drug|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
90792|NCT01319513|Other|whey protein bolus|single dose of 25 g whey protein
90793|NCT01319513|Other|whey protein pulses|10 2.5 g pulses of whey protein
90794|NCT01319526|Genetic|DNA analysis|
90795|NCT01319526|Genetic|RNA analysis|
91469|NCT01307904|Other|Glucose|Each healthy and Diabetic volunteers received 50 grams of glucose
91470|NCT01310348|Device|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
91471|NCT01310348|Device|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
91472|NCT01310361|Drug|Amoxicillin|
91473|NCT00054665|Drug|PS-341|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
91759|NCT01313182|Drug|mupirocin calcium ointment, 2%|Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.
91760|NCT00054938|Drug|pravastatin|
91761|NCT01313182|Drug|Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
91762|NCT01313208|Drug|etanercept|Administered by subcutaneous injection once weekly.
91763|NCT01313208|Drug|Placebo|Placebo subcutaneous injection
91764|NCT01313208|Drug|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
91765|NCT01313221|Biological|etanercept|Administered by subcutaneous injection
91766|NCT01313221|Drug|Topical agents|Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:
hydrocortisone 2.5%
betamethasone valerate 0.1%
betamethasone dipropionate 0.05%
clobetasol 0.05%
calcitriol
calcipotriol plus betamethsone dipropionate 0.05%
91767|NCT01313234|Behavioral|Education|Theory based education and systematic daily assessment
91768|NCT01313247|Drug|paracetamol|1000 mg 4 times daily
91769|NCT01313247|Drug|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
91770|NCT01313273|Drug|Lanreotide, non steroidal anti androgens and LHRH-a|Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.
Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression.
91771|NCT00054938|Drug|aspirin|
95153|NCT01324830|Drug|day 1 to day 5|low to high dose
95154|NCT01324830|Drug|day 1 to day 14|low to high dose
95155|NCT01324843|Drug|EMLA Cream|
95156|NCT01324843|Drug|Aveeno Daily Moist|
95157|NCT01324843|Device|Derma Vax|
95158|NCT01324843|Procedure|Intradermal Electroporation|
95159|NCT01324843|Procedure|Visual Analogue Scale|
95160|NCT01327183|Drug|RO4905417|5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
95161|NCT01327183|Drug|RO4905417|20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
95162|NCT01327183|Drug|placebo|iv infusion, completed at least 1 hour and up to 24 hours before PCI
95163|NCT00056160|Drug|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
94268|NCT01333761|Device|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
94269|NCT01333774|Drug|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
94270|NCT01333787|Dietary Supplement|Dietary Fiber Mixture|During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.
The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg.
94271|NCT01333800|Drug|Beclomethasone|200 to 400 mcg per day for 6 months
94272|NCT01333800|Drug|Ciclesonide|80 to 160 mcg per day for 6 months
94273|NCT01333813|Biological|Engerix-B™ Kinder|Intramuscular, single dose
94274|NCT01333826|Behavioral|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
95223|NCT01361789|Drug|parecoxib, valdecoxib, etoricoxib|40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.
After retraction of parecoxib from the market:
Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery
95224|NCT01361789|Drug|Dexamethasone|8 mg IV
95225|NCT01361789|Drug|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
95226|NCT01361802|Drug|Ambroxol Spray|low dose Ambroxol Spray
95227|NCT01361802|Drug|Ambroxol Spray|medium dose Ambroxol Spray
95228|NCT00059826|Radiation|radiation therapy|
95229|NCT01361802|Drug|Ambroxol Spray|high dose Ambroxol Spray
95230|NCT01361802|Drug|Placebo Spray|Placebo Spray
95231|NCT01361815|Device|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
95232|NCT01361828|Procedure|Electrophysiology|Visual Evoked Potential and Elctroretinogram
95233|NCT01361841|Drug|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
95234|NCT01361841|Drug|travoprost, latanoprost and bimatoprost|one drop once a day for life
95235|NCT01361854|Device|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
95236|NCT01361867|Other|Lokomat|The subject is put into the Lokomat and the program will vary between free walking and perturbed walking.
95237|NCT01361880|Behavioral|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
95238|NCT01361893|Other|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
95239|NCT00059839|Drug|doxorubicin hydrochloride|Given IV
94341|NCT00056576|Drug|Zonisamide|
90796|NCT01319526|Other|laboratory biomarker analysis|
90797|NCT01319539|Drug|Akt Inhibitor MK2206|Given PO
90798|NCT01319539|Procedure|Therapeutic Conventional Surgery|Undergo surgery
90799|NCT00055653|Procedure|umbilical cord blood transplantation|
90800|NCT01319539|Other|Pharmacological Study|Correlative studies
91078|NCT01304901|Drug|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
91079|NCT01304927|Drug|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
91080|NCT00054418|Other|placebo|placebo tablet weekly administered orally for one year
91081|NCT01307137|Behavioral|Peer-led intervention|An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.
Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.
Weight management success is defined as a loss of at least 5% of the weight since enrollment
Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.
The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills.
91082|NCT01307137|Behavioral|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
91083|NCT01307176|Behavioral|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
91084|NCT01307189|Drug|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
91085|NCT01307189|Drug|Placebo|Placebo diskus inhalation powder, once daily
91086|NCT01307202|Drug|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
91087|NCT01307202|Drug|Placebo|Placebo will match the the gabapentin pill and will be given orally.
91088|NCT01307215|Drug|Ropivacaine|20mLs of 0.5%
91772|NCT01313273|Drug|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
91773|NCT01313286|Drug|LY2608204 Reference|Administered orally
91774|NCT01313286|Drug|LY2608204 Test|Administered orally.
91775|NCT01313299|Drug|Botulinum type A toxin (Dysport®)|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
91776|NCT01313299|Drug|Botulinum type A toxin (Dysport®)|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
91777|NCT01313299|Drug|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
91778|NCT01306019|Drug|Busulfan|Pre gene therapy conditioning regimen
94771|NCT01332318|Drug|Placebo|XP13512 placebo once daily for 16 days
94772|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
94773|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
94774|NCT01324102|Behavioral|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
94775|NCT01324115|Drug|NG-nitro-L-arginine|
94776|NCT01324115|Other|laboratory biomarker analysis|
94777|NCT01324115|Other|pharmacological study|
94778|NCT01324115|Procedure|computed tomography|
94779|NCT01324115|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
94780|NCT01324128|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
94781|NCT00055887|Drug|carboplatin|
94782|NCT01324128|Drug|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
94783|NCT01324128|Drug|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
94784|NCT01324141|Drug|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of RT.
94275|NCT01333839|Other|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
94276|NCT01333852|Drug|metformin up to 2500mg/d|metformin up to 2500mg/d
94277|NCT00056966|Drug|ANTI-CD45|400ug/kg Day-5 through Day-2
94278|NCT01333852|Drug|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
94279|NCT01333852|Drug|placebo|placebo
94280|NCT01333865|Drug|Memantine|Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.
During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated.
94281|NCT01333878|Biological|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
94282|NCT01325610|Dietary Supplement|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
94538|NCT01326234|Behavioral|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
94539|NCT01326234|Behavioral|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking. Participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
94540|NCT01326247|Other|thermal waters nasal irrigation|The first group (group 1) has practiced crenotherapy with "hyper-mineral chloride sodium water" aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution.
94541|NCT01326273|Procedure|Lymphopheresis|Lymphopheresis
94542|NCT00056069|Other|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
94543|NCT01326273|Procedure|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
94544|NCT01326273|Procedure|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
94545|NCT01326273|Procedure|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
94546|NCT01326299|Other|Carbohydrate placebo|dissolve in water and consume with meal
94342|NCT01331655|Drug|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
94343|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
94344|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
94345|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
94346|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
94347|NCT01331681|Procedure|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
94348|NCT01333982|Other|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
94349|NCT01333995|Behavioral|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
94350|NCT01334008|Biological|Blood sampling|30ml of patient peripherical blood will be collected
94351|NCT01334021|Procedure|Tumor Biopsy|The amount of tumor collected for this study will be about the size of the tip of a pencil.
94352|NCT01334021|Other|Breast Cancer Registry|For 5 years, the study staff will review medical records to see how patients are responding to any breast cancer therapies received.
94353|NCT01334034|Drug|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
94354|NCT01334034|Drug|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
94355|NCT01334034|Drug|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
94356|NCT01334047|Biological|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
94357|NCT00056966|Drug|Fludarabine|Day-8 through Day-5 30 mg/m2
91089|NCT01307215|Drug|Ropivacaine|30mLs of 0.33%
91090|NCT01307215|Drug|Ropivacaine|40mLs of 0.25%
91091|NCT00054431|Drug|imatinib mesylate|Given orally
91092|NCT01307228|Other|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
91404|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
91405|NCT01310309|Device|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
91406|NCT01310322|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
91407|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
91408|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
91409|NCT01310322|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
91410|NCT01310335|Device|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
91411|NCT01312805|Other|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
91412|NCT01312818|Drug|Bortezomib|1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
91413|NCT01312818|Drug|Vorinostat|180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
91414|NCT01312818|Drug|Dexamethasone|6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.
91415|NCT01312818|Drug|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
91416|NCT00054899|Biological|EP2101|
91417|NCT01312818|Drug|Imatinib mesylate|For Ph+ acute lymphoblastic leukemia (ALL) patients only:
Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16.
91418|NCT01312831|Other|Vitamin B12 (cyanocobalamin)|
94785|NCT01324141|Drug|5-Fluorouracil|5-FU will be delivered as 1000mg/m2/day as 96 hour continuous infusion beginning on day 1 and 29.
94786|NCT01324141|Drug|Mitomycin-C|MMC will be delivered at a dose of 10mg/m2 on days 1 and 29
94787|NCT01324141|Procedure|Radiation Therapy|RT will be delivered to a total dose of 50-54 Gy based on tumor characteristics.
94788|NCT01324180|Drug|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
94789|NCT01324180|Drug|Vincristine|1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
94790|NCT01324180|Drug|Dexamethasone|10 mg/m^2/day divided BID
Take dexamethasone by mouth days 2-15
94791|NCT01324180|Drug|PEG-asparaginase|2500 IU's/m^2/day
Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23
If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.
Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol.
95046|NCT01324518|Drug|Placebo for ORM-12741|Placebo twice a day
95047|NCT01324531|Procedure|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
95048|NCT01324531|Procedure|Bankart repair|Bankart repair based on surgeon's preference
95049|NCT00055887|Procedure|radiation therapy|
95050|NCT01324544|Drug|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
95051|NCT01324557|Procedure|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
95052|NCT01324570|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
95053|NCT01324583|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form:solution
Route of administration: intravenous
95054|NCT01324583|Drug|prednisolone|Pharmaceutical form:tablet
Route of administration: oral
94547|NCT01326299|Other|Nutritional ingredient|Dissolve in water and consume with meals
94548|NCT01326299|Other|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
94549|NCT01326299|Other|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
94550|NCT01326299|Other|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
94551|NCT01326312|Drug|GTx-758|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
94552|NCT01328808|Drug|Acetaminophen/APAP|In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.
In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute
94553|NCT01328821|Drug|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
94554|NCT01328821|Drug|CTP-499|400 mg immediate release capsule
94555|NCT01328834|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
94556|NCT01328860|Biological|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
94808|NCT01326676|Drug|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
94809|NCT01326689|Drug|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
94810|NCT01326702|Drug|Bendamustine Hydrochloride|Given IV
94811|NCT00056095|Procedure|allogeneic bone marrow transplantation|
94812|NCT01326702|Other|Pharmacological Study|Correlative studies
94813|NCT01326702|Biological|Rituximab|Given IV
94814|NCT01326702|Drug|Veliparib|Given PO
94815|NCT01326715|Drug|Mangafodipir (Teslascan)|Contrast Agent
94816|NCT01329406|Drug|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
94817|NCT01329406|Drug|Placebo|1 tablet by mouth twice daily for 28 days
94358|NCT01334060|Biological|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
94615|NCT01334255|Drug|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
94616|NCT01334268|Device|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
94617|NCT01334268|Device|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
94618|NCT00056979|Drug|CAMPATH-1H|
94619|NCT01326312|Drug|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
94620|NCT00001058|Drug|Indinavir sulfate|
94621|NCT00056082|Drug|celecoxib|Celecoxib daily for 12 months
94622|NCT01326312|Drug|GTx-758|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
94623|NCT01326325|Drug|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
94624|NCT01326325|Drug|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
94625|NCT01326338|Drug|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
94626|NCT01326351|Procedure|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
94627|NCT01326351|Procedure|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
94628|NCT01326351|Behavioral|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
94629|NCT01326364|Procedure|Stereotactic body radiotherapy|Standard of Care
91419|NCT01312844|Drug|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
91420|NCT01312857|Drug|panitumumab|All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.
All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles
91421|NCT01312857|Drug|Randomization to No Panitumumab|All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.
All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles
91422|NCT01312870|Dietary Supplement|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
91423|NCT01312870|Other|standard hospital diet|standard hospital diet
91698|NCT01305928|Other|Fax|Fax
Staff standard in-patient session: (30 minutes):
Assess withdrawal, need for medication change
Conduct assessment of smoking history, interest in quitting
Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting
Provide 2-page flyer
Provide medication education
Build plan to stay quit
Describe fax-referral process
Ask if patient requests cessation medication script on discharge
91699|NCT01305941|Drug|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
91700|NCT01305941|Drug|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
91701|NCT01305941|Drug|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
91702|NCT01305967|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, Intravenous route, 16times for 2.5 months
91703|NCT01305980|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
91704|NCT00054353|Drug|fludarabine phosphate|Given IV
91705|NCT01305993|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
91706|NCT01306006|Biological|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
91707|NCT01306019|Other|Gene-modified CD34+ Hematopoietic stem cells|Infusion of transduced autologous CD34+ Hematopoietic stem cells
91708|NCT01308138|Behavioral|Exercise training|exercise training
91709|NCT01308138|Procedure|remote ischemic preconditioning|remote ischemic preconditioning
91710|NCT01308151|Other|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
95055|NCT01324596|Drug|Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone|Chemotherapy
95056|NCT01324596|Drug|Bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone|Chemotherapy
95057|NCT01324622|Device|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
95058|NCT01324622|Procedure|laminectomy|standard procedure
95059|NCT01324635|Drug|Panobinostat|Given PO
95060|NCT00055913|Biological|bevacizumab|Given IV
95061|NCT01324635|Radiation|Stereotactic body radiation therapy|Undergo SBRT
95062|NCT01324635|Procedure|Quality-of-life assessment|Ancillary studies
95063|NCT01324635|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
95064|NCT01324648|Behavioral|Telephone-supported self-help and GP treatment as usual|Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered "brief" in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing.
95386|NCT01362049|Other|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
95387|NCT01362049|Other|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
95388|NCT01362075|Procedure|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
95389|NCT01362075|Procedure|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
95390|NCT00059839|Drug|methotrexate|Given IV and intrathecally
94818|NCT01329419|Drug|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
94819|NCT01329432|Procedure|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
94820|NCT01329432|Procedure|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
94821|NCT01329445|Other|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
94822|NCT01329484|Behavioral|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
94823|NCT01329484|Behavioral|Cognitive training|Cognitive training using a computerized system
94824|NCT01329484|Other|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
94825|NCT00056381|Drug|Anidulafungin|
94826|NCT01329497|Other|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
94827|NCT01329510|Device|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
94828|NCT01329549|Drug|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
94829|NCT01329549|Drug|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
95164|NCT01327222|Drug|Bevacizumab|1.25 mg intravitreal bevacizumab
95165|NCT01327235|Drug|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
95166|NCT01327235|Drug|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
95167|NCT01327261|Drug|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
95168|NCT01327274|Device|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery to both place and later explant the Magnimplant or Magnetic Mini-Mover device. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25). Patients will be seen in clinic at least monthly until treatment is complete.
94630|NCT01326364|Drug|Iodixanol|IV, calculated per patient
94631|NCT01326364|Drug|Iohexol|IV, Calculated per patient
94632|NCT00056095|Biological|therapeutic allogeneic lymphocytes|
94633|NCT01326377|Drug|ON 01910.Na Concentrate|ON 01910 Na 1800 mg/24h
94893|NCT01326767|Drug|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
94894|NCT01326767|Drug|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
94895|NCT01326780|Drug|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
94896|NCT00056095|Procedure|peripheral blood stem cell transplantation|
94897|NCT01326780|Drug|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
94898|NCT01326780|Drug|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
94899|NCT01326780|Other|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
94900|NCT01326793|Other|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
94901|NCT01326806|Behavioral|Families Talking Together|The intervention will take place in a primary health care clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with an interventionist for approximately 30 minutes while her child is being examined by a physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
94902|NCT01326806|Behavioral|Active Control on Hygiene & Nutrition|The active control group will take place in a primary health care clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 30 minutes while her child is being examined by a physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
94903|NCT01326832|Device|Primoris|Total hip arthroplasty with the new Primoris femoral component
94904|NCT01326845|Drug|Deferasirox|
94905|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
94906|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
91711|NCT01308164|Device|MD Logic Pump Advisor|Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
91712|NCT01308177|Drug|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
91713|NCT01308190|Drug|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
91714|NCT01308190|Radiation|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
91715|NCT01308190|Procedure|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
91716|NCT01308190|Procedure|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
91717|NCT01308203|Drug|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
90801|NCT01319539|Other|Laboratory Biomarker Analysis|Correlative studies
90802|NCT01319552|Procedure|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
90803|NCT01319552|Procedure|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
90804|NCT01319565|Drug|Aldesleukin|720,000 IU/kg IV over 15 minute every eight hours (+/- 1 hour) for up to 5 days.
90805|NCT01319565|Drug|Cyclophosphamide|60 mg/kg/day for 2 days IV
90806|NCT01319565|Drug|Fludarabine|25 mg/m(2)/day IVPB daily over 15-30 minutes for 5 days.
90807|NCT01319565|Drug|Young Tumor Infiltrating Lymphocytes|Autologous young TIL infusion will be administered intravenously over 20 to 30 minutes (minimum 1 X 10(9) and up to a maximum of 2 X 10(11) lymphocytes).
90808|NCT01319565|Procedure|1200 Gy Irradiation|2Gy of TBI twice a day for 3 days (total dose 12 Gy)
90809|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
90810|NCT00055653|Radiation|radiation therapy|
90811|NCT01321827|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
95391|NCT01362101|Behavioral|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:
Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.
Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol.
95392|NCT01362114|Drug|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
95393|NCT01362114|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
95394|NCT01362127|Drug|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
95395|NCT01362127|Radiation|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
95396|NCT01362140|Drug|Darbepoetin alfa|500 mcg Q3W
95397|NCT01362140|Drug|Placebo|Q3W
95398|NCT01362153|Drug|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
95399|NCT01362153|Drug|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
95400|NCT01362192|Device|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:
Spot Size: 5 mm
Fluence: 13-15 J/cm2
Pulse Duration: 40 ms
Epidermal contact-cooling: 5° Celsius
94484|NCT01328782|Drug|Bupivacaine 0.25%|Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)
Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)
All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg
94485|NCT00056316|Behavioral|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
94486|NCT01328782|Drug|Ropivacaine 0.20%|Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)
Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)
All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg
94487|NCT01328795|Other|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
94488|NCT01331837|Drug|Etanercept|50 mg subcutaneously weekly until switch to another RA therapy or up to 5 years.
95169|NCT01327300|Drug|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
95170|NCT01327300|Other|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
95171|NCT01327313|Biological|EMD525797|250mg of EMD525797 intravenously every 2 weeks, until DLT, PD or unacceptable toxicity develops.
95172|NCT01327313|Biological|EMD525797|500mg of EMD525797 intravenously every 2 weeks, until DLT, PD or unacceptable toxicity develops.
95173|NCT01327313|Biological|EMD525797|1000 mg of EMD525797 intravenously every 2 weeks, until DLT, PD or unacceptable toxicity develops.
95174|NCT00056160|Drug|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
95175|NCT01327313|Biological|EMD525797|1500 mg of EMD525797 intravenously every 2 weeks, until DLT, PD or unacceptable toxicity develops.
95176|NCT01327326|Drug|Naltrexone|Oral, 50 mg, 1 Time Dose
95177|NCT01327326|Drug|Placebo|Oral, 1 Time Dose
95178|NCT01327339|Drug|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
95179|NCT01327352|Drug|Oshadi D|oral administration
95180|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
95181|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
95182|NCT01330017|Drug|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
94283|NCT01325623|Device|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
94284|NCT01325636|Other|Cell therapy|Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.
A second injection could be made at day 21
94907|NCT00056134|Biological|denileukin diftitox|
94908|NCT01326858|Drug|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
94909|NCT01326871|Drug|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
94910|NCT01326871|Drug|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
94911|NCT01329614|Behavioral|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
95240|NCT01361906|Behavioral|Sensomotoric training|The intervention will be given once a week (2h per occasion) for twelve weeks.
Each occasion is planned to have the following structure:
10 min initial conversation about how participants are feeling today and how it felt after the last time.
70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today.
95241|NCT01361919|Procedure|Feedback during CPR training|Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Students will be told to perform compressions on top of the accelerometer pad. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal "hands-off" time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool. This data will be used to correct the students' performance by visually demonstrating the difference between ideal and suboptimal CPR performance.
95242|NCT01354145|Drug|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
95243|NCT01354158|Drug|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
95244|NCT01354171|Device|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
95245|NCT01354184|Drug|CRD007|
95246|NCT01354184|Drug|CRD007 matching placebo|
95247|NCT01354210|Behavioral|SMS Text Message Reminder|Daily
95248|NCT00058760|Behavioral|NIA intervention (after school health promotion didactic program)|
95249|NCT01354223|Device|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
95250|NCT01354223|Device|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
90812|NCT01321827|Drug|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
90813|NCT00055770|Other|pharmacological study|Correlative studies
90814|NCT01321840|Procedure|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
90815|NCT01321853|Other|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
90816|NCT01321853|Other|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
90817|NCT01321866|Procedure|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
90818|NCT01321866|Procedure|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
90819|NCT01321879|Drug|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
91093|NCT01307254|Procedure|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
91094|NCT01307267|Drug|PF-05082566|Intravenous, Dose escalation, once per month
91095|NCT01307267|Drug|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
91096|NCT01307267|Drug|PF-05082566|IV, Dose escalation, once per month
91097|NCT01307280|Behavioral|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
91098|NCT01307280|Behavioral|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
91099|NCT01309724|Other|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
91100|NCT01309737|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
91101|NCT01309737|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
91102|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
94489|NCT01331837|Drug|Tocilizumab|8 mg/kg intravenously every 4 weeks until switch to another RA therapy or up to 5 years.
94490|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
94491|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
94492|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
94493|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
94494|NCT00056641|Drug|tipranavir|
94495|NCT01331850|Drug|RO5024048|1000 mg oral doses twice a day for 24 weeks
94496|NCT01331850|Drug|danoprevir|100 mg oral doses twice a day for 24 weeks
94497|NCT01331850|Drug|ritonavir|100 mg oral doses twice a day for 24 weeks
94498|NCT01331863|Procedure|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
94499|NCT01331876|Behavioral|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
94500|NCT01331902|Other|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
94501|NCT01331902|Other|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
94502|NCT01331915|Biological|Theravac|Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.
Injection: intradermally and subcutaneously.
95065|NCT01324648|Behavioral|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
95066|NCT00056134|Biological|therapeutic autologous dendritic cells|
95067|NCT01327053|Drug|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
95068|NCT01327066|Drug|Droxidopa|600 mg, single oral dose
94285|NCT01325649|Procedure|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
94286|NCT01325649|Radiation|long course 5-FU bases radiochemotherapy|
94287|NCT01325675|Behavioral|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
94288|NCT01325688|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
94289|NCT01325688|Device|Aluminium disk|
94290|NCT01325688|Device|OpSite(TM) disk|
94291|NCT01325701|Drug|PCI-32765|
94292|NCT00056030|Drug|fluorouracil|
94293|NCT01325714|Behavioral|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
94294|NCT01325714|Behavioral|Enhanced Usual Care|In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain.
94295|NCT01325727|Other|Brief computerized feedback|Brief computerized feedback
94296|NCT01325727|Other|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
94297|NCT01325740|Drug|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
94298|NCT01325753|Procedure|cryotherapy|Undergo CT-guided CA
94299|NCT01325753|Procedure|quality-of-life assessment|Ancillary studies
94300|NCT01325766|Other|Yoga|Yoga 2 sessions per week for 8 weeks
94301|NCT01325779|Drug|heparin|subcutaneous heparin 5000 units every 8 hours
94557|NCT01328873|Other|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
94558|NCT01328886|Drug|Omalizumab|omalizumab lyophilized 150 mg injection
94559|NCT01328899|Device|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
95251|NCT01354249|Dietary Supplement|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
95252|NCT01354262|Dietary Supplement|Vitamin D|600 IU daily oral supplementation
95253|NCT01354262|Dietary Supplement|Vitamin D|50,000 IU supplementation bi-monthly
95254|NCT01354275|Other|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
95255|NCT01354275|Other|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
95256|NCT01354288|Other|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
94359|NCT01334073|Drug|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
94360|NCT01334086|Drug|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
94361|NCT01334099|Biological|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
94362|NCT01334099|Radiation|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
94363|NCT01334112|Drug|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
94364|NCT01334125|Drug|Metformin|Metformin 1000 mg once daily by mouth for 9 months
94365|NCT01334125|Drug|Placebo|2 capsules once daily by mouth for 9 months
94366|NCT01334138|Other|A 4-week diet, low in sodium.|Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.
Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires.
94367|NCT01334151|Drug|Insulin LISPRO|Single doses of: 0.15 U/kg
94368|NCT01325792|Device|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
91103|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
91104|NCT00054600|Procedure|Extracorporeal Photopheresis|
91105|NCT01309750|Radiation|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
91106|NCT01309763|Biological|AFFITOPE AD03|s.c. injection
91107|NCT01309763|Biological|AFFITOPE AD03 + Alum|s.c. injection
91108|NCT01309776|Drug|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
91109|NCT01309776|Drug|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
91110|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
91111|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
91112|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
91113|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
91424|NCT01312883|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
91425|NCT01312909|Drug|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
91426|NCT01312909|Drug|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
91427|NCT00054912|Biological|EP2101|
91428|NCT01312909|Drug|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
91429|NCT01312922|Drug|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
91430|NCT01312922|Drug|Citalopram|oral once daily administration
91431|NCT01312922|Drug|Pipamperone|oral once daily administration
95069|NCT01327066|Drug|Droxidopa|2000 mg, single oral dose
95070|NCT01327066|Drug|Moxifloxacin|400 mg, single oral dose
95071|NCT01327066|Drug|Placebo|Placebo matching Droxidopa or Moxifloxacin
95072|NCT01327079|Drug|Methadone|If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.
Administration of inulin:
Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated.
95073|NCT01327079|Drug|Methadone|If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.
Administration of inulin:
Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated.
95074|NCT01327092|Other|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
95075|NCT01327105|Device|TVU|Use of transvaginal ultrasound to determine location of micro-insert
95076|NCT01327118|Drug|Prostaglandin F2alpha|intravenous injection
95077|NCT00001058|Drug|Ritonavir|
95078|NCT00056147|Drug|denufosol tetrasodium (INS37217)|
95079|NCT01327118|Drug|Isoton sodium chloride|intravenous injection
95080|NCT01327144|Drug|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
95081|NCT01327144|Drug|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
95101|NCT01329965|Drug|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline—salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
95102|NCT01329978|Drug|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
95103|NCT01329978|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
95104|NCT01329978|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
94560|NCT00001058|Drug|Clarithromycin|
94561|NCT00056329|Drug|Vitamin E|1,000 international units twice daily for three years
94562|NCT01328912|Other|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
94563|NCT01328912|Other|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
94564|NCT01328925|Drug|Nitazoxanide|Nitazoxanide Oral Suspension dose based on age:
Age <12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days
94565|NCT01328938|Biological|GCPGC 3.6mg|Stage I:Single blinded
94566|NCT01328938|Biological|GCPGC 6mg|Stage I: Single blinded;
94567|NCT01328938|Biological|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
94568|NCT01328938|Biological|GCPGC 6mg|Experimental: Stage II
94569|NCT01328951|Drug|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
94570|NCT01328951|Drug|Erlotinib|Erlotinib will be adminisered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
94571|NCT01328951|Drug|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
94572|NCT00056329|Drug|multivitamin|once daily for three years
94573|NCT01328964|Drug|Fluticasone propionate|fluticasone propionate 44 mcg
94574|NCT01328964|Drug|Budesonide|budesonide
94575|NCT01328964|Drug|Montelukast|montelukast
94576|NCT01331993|Drug|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
94577|NCT01331993|Drug|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
94830|NCT01329549|Drug|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
97682|NCT01351129|Drug|Formulation 2|150-mg modified release capsule, short duration (single dose)
96806|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
96807|NCT01344967|Drug|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
96808|NCT01344980|Procedure|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
96809|NCT01344980|Procedure|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
96810|NCT01344980|Behavioral|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
96811|NCT01344980|Behavioral|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
96812|NCT00057941|Drug|anastrozole|Given orally
96813|NCT01347359|Behavioral|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
96814|NCT01347359|Behavioral|Standard of care|"Standard of care" is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program).
96815|NCT01347372|Behavioral|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
96816|NCT01347385|Procedure|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
96096|NCT01360697|Other|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
96097|NCT01360710|Drug|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
96098|NCT01360710|Drug|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
96099|NCT01360736|Behavioral|Safety Planning - Military (SAFE MIL)|The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
96100|NCT01360749|Drug|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
96101|NCT00059761|Radiation|radiation therapy|
96102|NCT01360749|Drug|Placebo|Placebo dose: 2 g for 10 cm2.
96103|NCT01360762|Drug|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
96104|NCT01353170|Other|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
96105|NCT01353183|Procedure|colonoscopy or rectosigmoidoscopy|Usual procedure
96379|NCT01356290|Drug|Celecoxib|50-400mg, oral bid, daily, 1 year
96380|NCT01356290|Drug|Fenofibric acid|90mg/m2, oral, daily, 1 year
96381|NCT01356290|Drug|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
96382|NCT00059189|Device|Magstim Rapid Magnetic Stimulator|
96383|NCT01356290|Drug|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
96384|NCT01356290|Drug|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
96385|NCT01356290|Drug|Liposomal cytarabine|25-35mg, intrathecal, every four weeks, alternating with intrathecal etoposide phosphate, 1 year
96386|NCT01356303|Drug|cisplatin, docetaxel|All patients met the eligibility criteria will undergo treatment with chemotherapy.
Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles.
96387|NCT01356316|Biological|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
97123|NCT01345474|Drug|D-methionine, oral liquid suspension|Two daily doses of up to 100mg/kg/day of D-met for 18 days
97124|NCT01345474|Other|Placebo Comparator|Equal volume placebo.
97125|NCT01345487|Other|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
97126|NCT01345487|Other|Animal protein|Protein in the form of minced pork/beef
97127|NCT01345500|Other|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
97128|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
97129|NCT01347853|Drug|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
97130|NCT01347853|Drug|Placebo|Intranasal post-surgery for up to 5 days total
97131|NCT01347866|Drug|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
97132|NCT01347866|Drug|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
97133|NCT01347866|Drug|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
97134|NCT01347866|Drug|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
97135|NCT00058188|Drug|calcium gluconate|Given orally
97136|NCT01347879|Drug|Visonac PDT|cream application prior to illumination with red light
97137|NCT01347879|Drug|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
97138|NCT01347892|Other|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
97139|NCT01347905|Other|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
96019|NCT01363180|Behavioral|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
96020|NCT01363180|Other|No stress condition|
96021|NCT01363193|Drug|Lean Body Weight-based heparin dose|For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.
Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = [9270 x weight (kg)] / [6680+216 x BMI] Female = [9270 x weight (kg)] / [8780+244 x BMI]
96315|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
96316|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
96317|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
96318|NCT01356277|Behavioral|Action-focused problem-solving|An Adherence Support Team (AST), consisting of the patient, one or both parents (or primary caregiver), and the study facilitator, will be formed for each participant in the intervention arm. "Action-focused problem-solving" is informed by two complementary behavioral approaches: problem-solving and implementation intentions.
Implementation intentions are concrete action plans in which an individual specifies, in an if-then or when-then contingency format, when, where, and how he or she will perform a behavior (e.g. "When I come home from school, then I will place my medication on the kitchen counter next to the microwave.").
96319|NCT01358643|Other|Three home-based diet and exercise programs|All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.
Thirty OEF/OIF veterans with BMI > 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program.
96320|NCT01358656|Procedure|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith & Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
96659|NCT01349595|Drug|Bortezomib|Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month "hiatus". At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area).
96660|NCT01349608|Behavioral|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
96661|NCT00058292|Drug|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
96662|NCT01349634|Other|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
96663|NCT01349647|Biological|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
95710|NCT01357564|Other|Tailored Activity Program|Intervention Protocol: In session #1, the interventionist, an occupational therapist (OT), meets with the caregiver and introduces the intervention goals. The OT provides and reviews a 3-ring binder which contains written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed will be a copy of Mace and Rabins' book, The 36 Hour Day. The OT will interview the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT will also observe interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale (DRS-2).
95711|NCT01357577|Behavioral|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
95712|NCT01357590|Device|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
95713|NCT01357603|Biological|Glargine|dosage form: Subcutaneous injection
95714|NCT00059670|Procedure|Shaker Exercise vs. Traditional Dysphagia Therapy Regime|
95715|NCT01359878|Drug|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
95716|NCT01359904|Other|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
95717|NCT01359930|Other|placebo|matching placebo
96388|NCT01356329|Drug|Enoxaparin, Heparin|Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)
). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician.
96389|NCT01356342|Biological|AdimFlu-S 2010-2011, inactivated|The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL
6 months~<3 years;0.25 mL per injection2 injections at 4 weeks apart
3~<9 years;0.5 mL per injection2 injections at 4 weeks apart
9~<18 years;0.5 mL per injection1 injections
96390|NCT01356355|Drug|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
96391|NCT01356355|Drug|Placebo|One capsule twice a day daily till ureteral stent in situ
96392|NCT01356355|Drug|Tolterodine|One capsule twice a day daily till ureteral stent in situ
96393|NCT00059202|Drug|Ursodeoxycholic Acid|
96394|NCT01356368|Drug|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
96395|NCT01356381|Drug|Vildagliptin|Dosage 50mg b.i.d.
96396|NCT01356381|Drug|Placebo|50mg bid
96397|NCT01358747|Drug|BEACOPPesc|
96398|NCT01358747|Drug|BEACOPPesc - ABVD - PET2|
95488|NCT00059839|Drug|vinblastine sulfate|Given IV
95489|NCT01362270|Device|Acupuncture Therapy|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
95490|NCT01362283|Other|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
95491|NCT01362296|Drug|GSK1120212|Oral once daily
95492|NCT01362296|Drug|docetaxel|IV once every 3 weeks
95493|NCT01362309|Drug|d-cycloserine.|50 mg administered on two occasions.
95494|NCT01362322|Biological|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
95495|NCT01362322|Biological|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
95496|NCT01362348|Drug|pazopanib eye drops|10 mg/mL (1 drop) four times daily
97140|NCT01347918|Device|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
97141|NCT01347918|Dietary Supplement|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
97394|NCT01348308|Drug|Placebo|Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.
Duration: 72 weeks.
97395|NCT01348321|Drug|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
97396|NCT00058214|Drug|perifosine|Given orally
97397|NCT01348334|Procedure|Synthetic sling surgery|An incision of inverted A shape was inflicted on the anterior vaginal wall(AVW)of the vagina.The upper part of A shaped incision was formed into an island belonging to the vaginal wall.This patch was 3×4cm in most of the patients.Proximal AVWwas dissected as a flap.Synthetics mesh materials were first sutured onto the upper part of the A on the vaginal island with absorbable vicrly sutures.Then,with 2polypropilen sutures,these meshes were fixed on both the right and left sides of this island in a helical manner to form a suspension and using curved Kishner needles,the prolene sutures were transferred to suprapubic area.These sutures were ligated on the rectus fascia in a crosswise manner.The mobile lower wing was advanced onto the island and was sutured onto the vaginal skin with intermittent sutures using 3-0 monocryl sutures.After cystoscopy,the prolene sutures were ligated crosswise in the suprapubic region.Special attention was paid notto create much tension on the mesh material.
97398|NCT01348347|Drug|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
97399|NCT01348347|Drug|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
97400|NCT01348347|Drug|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
97401|NCT01348386|Drug|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
97402|NCT01348386|Drug|Placebo|
97403|NCT01348412|Drug|oxaliplatin|130 mg/m²Every 21 days
97404|NCT01348412|Drug|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
97405|NCT01348412|Drug|other intravenous chemotherapy drugs|
97406|NCT01348425|Device|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
97407|NCT00058214|Other|laboratory biomarker analysis|Correlative studies
96321|NCT01358656|Procedure|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
96322|NCT01358669|Drug|Denosumab|60mg denosumab by injection as a single dose
96323|NCT01358669|Other|Placebo|Placebo by injection as a single dose
96324|NCT01358695|Biological|ANT-1207|The interventions differ by dose of investigational product applied.
96325|NCT01358695|Biological|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
96326|NCT01358695|Biological|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
96647|NCT01347151|Device|The glidescope video laryngoscopy|
96648|NCT01347151|Device|The Pentax airwayscope|
96649|NCT01347164|Behavioral|RISE life coaching intervention|6 2-hour sessions
96650|NCT01347164|Behavioral|HIV Counseling|Standard one-hour HIV counseling session
96651|NCT01347177|Procedure|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
96652|NCT01347177|Procedure|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
96653|NCT01347190|Biological|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
96654|NCT01347190|Biological|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
96655|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
96656|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
96657|NCT00058084|Drug|ixabepilone|Given IV
96658|NCT01349582|Procedure|surgical clipping|clipping of the aneurysm following invasive brain surgery
95718|NCT01359930|Drug|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
95719|NCT01359943|Biological|secukinumab (AIN457)|Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
95720|NCT01359943|Drug|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
95721|NCT01359956|Drug|Dacarbazine|900 mg / m2 every 3 weeks
95722|NCT01359956|Drug|Fotemustine|100 mg / m2 every 3 weeks
95723|NCT01359956|Drug|Interferon Alfa-2b|5 M units every 3 weeks
95724|NCT01359969|Drug|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
95725|NCT00059683|Procedure|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
95726|NCT01359982|Drug|RRx-001|Dose level 1 (10 mg/m2)
95727|NCT01359982|Drug|RRx-001|Dose Level 2 (16.7 mg/m2)
95728|NCT01359982|Drug|RRx-001|Dose Level 3 (24.6 mg/m2)
96022|NCT01363206|Biological|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
96023|NCT01363206|Biological|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
96024|NCT01363232|Drug|BKM120 + MEK162|
96025|NCT01363245|Behavioral|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
96026|NCT01363245|Behavioral|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
96027|NCT00059930|Drug|FOLFOX regimen|
96028|NCT01363258|Behavioral|Managing Oral Hygiene Using Threat Reduction (MOUTh )|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
96029|NCT01363258|Procedure|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
95497|NCT01362361|Drug|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
95498|NCT01362361|Drug|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
95499|NCT00059839|Drug|vincristine sulfate|Given IV
95500|NCT01362374|Drug|GDC-0068|Oral escalating dose
95501|NCT01362374|Drug|docetaxel|Repeating intravenous dose
95502|NCT01362374|Drug|enzalutamide|Oral repeating dose
95503|NCT01362374|Drug|mFOLFOX6|Repeating intravenous dose
95504|NCT01362374|Drug|paclitaxel|Oral repeating dose
95505|NCT01362387|Other|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
95506|NCT01354561|Procedure|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
95507|NCT01354574|Other|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
95508|NCT01354574|Other|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
95788|NCT00059319|Procedure|multiple aorta clamps with antegrade cardioplegia|
95789|NCT01357616|Drug|Brinzolamide 1% ophthalmic suspension|
95790|NCT01357616|Drug|Timolol 0.5% ophthalmic solution|
95791|NCT01357642|Drug|Epinephrine inhalation aerosol|Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
95792|NCT01357642|Drug|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine
95793|NCT01357642|Drug|epinephrine inhalation aerosol|epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
95794|NCT01357655|Drug|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
97408|NCT01348425|Device|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
97409|NCT01348438|Device|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
97410|NCT01348451|Device|surgical implantation|human spinal cord stem cell implantation in ALS patients
97411|NCT01348464|Procedure|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
97739|NCT01346644|Other|Infant formula|Powder infant formula
97740|NCT01346657|Drug|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
97741|NCT01346670|Drug|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
97742|NCT01346683|Device|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
97743|NCT01346696|Device|OsseoSpeed™ TX implants|OsseoSpeed™ TX implants of length 6 mm
97744|NCT01349088|Drug|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
97745|NCT01349088|Drug|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
97746|NCT01349088|Drug|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
97747|NCT01349101|Radiation|Total Body Irradiation|Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)
Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)
97748|NCT01349101|Drug|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days.
97749|NCT00058253|Drug|docetaxel|Given IV
97750|NCT01349101|Drug|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
97751|NCT01349101|Drug|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
97752|NCT01349101|Drug|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
97753|NCT01349101|Drug|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
97622|NCT01343953|Procedure|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
97623|NCT01343966|Drug|MABT5102A|Repeating subcutaneous injection
96740|NCT01349751|Drug|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
96741|NCT01349751|Drug|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
96742|NCT01349777|Drug|Pregrel®|Pregrel® 75mg daily for 12 months
96743|NCT01349777|Drug|Plavix®|Plavix® 75mg daily for 12 months
96744|NCT01349790|Drug|NewGam 10%|NewGam 10% is a newly developed human normal immunoglobulin solution ready for intravenous administration (IGIV
96745|NCT00058292|Drug|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
96746|NCT01349803|Drug|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
96747|NCT01349803|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
96748|NCT01349803|Drug|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
96749|NCT01349803|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
96750|NCT01349816|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
96751|NCT01349816|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
96752|NCT01349816|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
96753|NCT01349829|Biological|HAVpur Junior|≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)
Vaccination schedule: single doses at 0 and 6 months
96754|NCT01349829|Biological|Havrix 720 Junior|≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)
Vaccination schedule: single doses at 0 and 6 months
96755|NCT01349842|Biological|Blood sampling|20ml of patient peripherical blood will be collected
96756|NCT00058292|Procedure|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
96030|NCT01355679|Device|Guided Therapy|A total of 14 neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
96031|NCT01355692|Device|Nd: YLF laser treatment|grid selective retinal treatment
96032|NCT01355705|Drug|Amrubicin|40, 60, or 80 mg/m2; iv
96033|NCT01355705|Drug|Lenalidomide|10 or 15 mg daily; po
96034|NCT01355705|Drug|Dexamethasone|40 mg weekly; po
96035|NCT01355705|Drug|Aspirin|81 or 325 mg daily; po
96036|NCT01355718|Drug|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
96037|NCT01355757|Device|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
96038|NCT00001076|Biological|ALVAC-HIV MN120TMG (vCP205)|
96039|NCT00058929|Drug|treprostinil sodium|
96040|NCT01355757|Drug|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
96041|NCT01355783|Drug|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
96327|NCT00059475|Drug|Glycoprotein 100 (GP100): 209-217 (210M)|
96328|NCT01358708|Drug|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
96329|NCT01358708|Drug|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
96330|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
96331|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
96332|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
96333|NCT01358734|Drug|Azacitidine-single agent|Azacitidine at 75 mg/m2/day subcutaneous on Days 1-7
96817|NCT01347385|Procedure|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
96818|NCT01347398|Procedure|PSG|Sleep study made by PSG (polysomnography)
97070|NCT01350206|Procedure|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
97071|NCT01350219|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
97072|NCT01350232|Drug|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
97073|NCT01350232|Drug|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
97074|NCT01350232|Device|Cellular Infusions|Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.
97075|NCT01350232|Radiation|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
97076|NCT01350232|Drug|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
97077|NCT01350232|Drug|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
97078|NCT01350232|Drug|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
97079|NCT00058331|Biological|epoetin alfa|
97080|NCT01350232|Procedure|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
97081|NCT01350245|Radiation|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
97082|NCT01350245|Biological|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
97083|NCT01350245|Drug|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
97754|NCT01349101|Genetic|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
97755|NCT01349114|Drug|aliskiren 300 mg once daily|aliskiren 300 mg daily
97756|NCT01349114|Drug|Placebo/sugar pill|Sugar pill/placebo
97757|NCT01349127|Drug|Cholecalciferol (Vitamin D3)|Once daily, 20µg (800IU) dose of vitamin D3, vitamin D3 is taken for 12-weeks while lactating, commencing 10-14 days post-partum.
97758|NCT01349127|Drug|Cholecalciferol (Vitamin D3)|Once daily, 20µg (800IU) dose of vitamin D3, vitamin D3 is taken for 12-weeks while lactating, commencing 10-14 days post-partum.
97759|NCT01349127|Drug|Calcium Carbonate|Once daily, 500mg dose of calcium in a tablet form, taken for 12-weeks while lactating, commencing 10-14 days post-partum.
96874|NCT01345032|Other|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
96875|NCT01345045|Drug|ABT-639|ABT-639 Twice Daily for six weeks.
96876|NCT01345045|Drug|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
96877|NCT01345045|Drug|Placebo|Placebo twice daily for 6 weeks.
96878|NCT01345058|Drug|lacosamide, levetiracetam|Lacosamide will be added to levetiracetam: minimum of 200mg/day, to be titrated as follows:
Week 1: 50mg twice a day
Week 2: 100mg twice a day.
96879|NCT00057941|Drug|gefitinib|Given orally
96880|NCT01345084|Radiation|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
96881|NCT01345084|Drug|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
96882|NCT01345084|Drug|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
96883|NCT01345097|Device|Total Hip Arthroplasty|Total Hip Arthroplasty
96884|NCT01345123|Behavioral|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
96885|NCT01345123|Behavioral|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
96757|NCT01349842|Other|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
96758|NCT01349855|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
96759|NCT01349868|Drug|PT005 MDI|PT005 MDI taken as two inhalations
96760|NCT01349868|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
97014|NCT01352572|Drug|antidepressant non-response|Antidepressants administration for 6 weeks under therapeutic dose nonresponders
97015|NCT01352585|Drug|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
97016|NCT01352598|Radiation|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
97017|NCT01352611|Drug|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
97018|NCT01352624|Behavioral|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
97019|NCT01352637|Drug|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
97020|NCT00058474|Radiation|radiation therapy|Given 5 days a week for 5-6 weeks
97021|NCT01352637|Drug|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
97022|NCT01352637|Drug|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
97023|NCT01352637|Drug|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
97024|NCT01352650|Drug|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg and cohort 2 will receive plerixafor at a dose of 580 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
97025|NCT01345253|Drug|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
97026|NCT01345266|Procedure|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
97027|NCT00001067|Drug|Zidovudine|
96334|NCT01358734|Drug|Lenalidomide - single agent|Lenalidomide 50 mg/day by mouth x 28 days for the first 2 cycles and lenalidomide 25 mg/day by mouth x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg/day by mouth
96335|NCT01358734|Drug|Lenalidomide in combination with azacitidine|Repeated cycles of azacitidine 75 mg/m2/day subcutaneous on Days 1-7 and lenalidomide 50 mg/day by mouth on Days 8-28 followed by a 14-day break plus best supportive care
96336|NCT01361087|Other|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
96337|NCT01361100|Device|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
96338|NCT00059800|Radiation|boron neutron capture therapy|
96339|NCT01361113|Drug|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
96340|NCT01361126|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
96341|NCT01361152|Device|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
96342|NCT01361152|Device|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
96343|NCT01361178|Drug|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
95422|NCT01354535|Procedure|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
95423|NCT01354548|Device|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
95424|NCT01356940|Drug|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
95425|NCT00059254|Drug|Oleic acid|
95426|NCT01356940|Drug|placebo|identical placebo tablet administered bid for four weeks
95427|NCT01356953|Other|Aerobic exercise|Intensity of aerobic exercise
97084|NCT01350245|Drug|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
97085|NCT01350245|Drug|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
97086|NCT01350245|Device|Hematopoietic stem cell transplantation (HSCT)|One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.
97087|NCT01350258|Drug|Fludarabine|Part of the conditioning regimen
97337|NCT01350570|Drug|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
97338|NCT01350583|Drug|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
97339|NCT01350596|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
97340|NCT00058370|Radiation|iodine I 131 monoclonal antibody 3F8|
97341|NCT01350596|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
97342|NCT01350609|Drug|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
97343|NCT01350609|Drug|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
97344|NCT01350622|Drug|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
97345|NCT01350622|Drug|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
97346|NCT01350635|Biological|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
97347|NCT01350674|Procedure|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
97348|NCT01350700|Other|Scars assessment & QOL|Scar assessment and quality of life questionnaires
97349|NCT01353001|Behavioral|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
96886|NCT01345136|Drug|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
96887|NCT01345149|Behavioral|Diet + Exercise|Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.
Exercise: Individual counselling
96888|NCT01345162|Drug|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
96889|NCT01345162|Drug|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
96890|NCT00057941|Drug|fulvestrant|Given intramuscularly
96891|NCT01345162|Drug|intraoperative analgesia|ketorolac 30 mg iv
96892|NCT01347450|Dietary Supplement|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
96893|NCT01347463|Procedure|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
97142|NCT01347931|Device|Breathe NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator system during selected activities of daily living.
97143|NCT01347944|Drug|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
97144|NCT01347957|Other|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
97145|NCT01347957|Other|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
97146|NCT00058188|Drug|zoledronic acid|Given IV
97147|NCT01347970|Drug|carvedilol|Given PO
97148|NCT01347970|Other|placebo|Given PO
97149|NCT01350258|Drug|Thiotepa|Part of the conditioning regimen
97150|NCT01350258|Radiation|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
97151|NCT00058357|Drug|lidocaine|
97152|NCT01350258|Biological|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
97028|NCT00057954|Procedure|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
97029|NCT01345279|Drug|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
97030|NCT01345279|Drug|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
97031|NCT01345279|Drug|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
97032|NCT01345292|Device|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
97275|NCT01352741|Drug|Tapentadol PR with Pregabalin|Tapentadol PR 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
97276|NCT01352741|Drug|Tapentadol PR open label maintenance|100 - 400 mg per day Tapentadol PR orally administered twice daily
97277|NCT01352767|Device|InsuPad|Heating pad
97278|NCT01345591|Procedure|Fat Grafting|
97279|NCT01345604|Procedure|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
97280|NCT01345604|Procedure|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
97281|NCT01345630|Drug|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
97282|NCT01345630|Drug|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
97283|NCT01345630|Drug|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
97284|NCT01345630|Drug|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
97285|NCT01345630|Drug|placebo for maraviroc|placebo for maraviroc
97286|NCT01345643|Other|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
97287|NCT01345643|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
95428|NCT01356966|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
95429|NCT01356966|Drug|Placebo|2 placebo pills PO BID for12 weeks
95430|NCT01356966|Dietary Supplement|Folate|Folate 1 mg daily for 12 weeks
95431|NCT01356979|Procedure|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
95432|NCT01356992|Drug|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
95433|NCT01357005|Other|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
95434|NCT01357031|Drug|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
95435|NCT01357031|Drug|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
95436|NCT00059267|Drug|HBIG, Epivir, Hepsera|
95437|NCT01357031|Drug|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
95438|NCT01357044|Dietary Supplement|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
95439|NCT01357044|Dietary Supplement|Placebo|Tablets, two in the morning and two in the evening
95729|NCT01359982|Drug|RRx-001|Dose Level 4 (33 mg/m2)
95730|NCT01359982|Drug|RRx-001|Dose Level 5 (55.0 mg/m2)
95731|NCT01359982|Drug|RRx-001|Dose Level 6 (83 mg/m2)
95732|NCT01360021|Drug|Symbicort|Breath actuated metered dose inhaler
95733|NCT01360021|Drug|Symbicort|Actuation counter pressured metered dose inhaler
95734|NCT01360021|Drug|Budesonide|Actuation counter pressured metered dose inhaler
95735|NCT01360034|Drug|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
95736|NCT00059696|Procedure|Constraint-Induced Movement Therapy|
97350|NCT01353001|Behavioral|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
97351|NCT01353001|Behavioral|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
97352|NCT00058552|Drug|Pertuzumab (rhuMAb 2C4)|
97683|NCT01351129|Drug|Formulation 3|150-mg modified release capsule, long duration (single dose)
97684|NCT00058422|Drug|doxorubicin hydrochloride|
97685|NCT01351142|Other|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
97686|NCT01351155|Device|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
97687|NCT01351168|Drug|Levodopa|CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
97688|NCT01351168|Drug|Zolpidem first dose|Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
97689|NCT01351168|Drug|Zolpidem second dose|Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
97690|NCT01351168|Drug|sugar pill|a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
97691|NCT01351181|Behavioral|Leaflet|Advice Leaflet
97692|NCT01351181|Behavioral|Exercise Advice|Leaflet
97693|NCT01351181|Behavioral|Normal Care|Normal Care
97694|NCT01351194|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
97695|NCT00058422|Drug|prednisone|
97153|NCT01350258|Drug|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
97154|NCT01350258|Device|Hematopoietic stem cell transplantation (HSCT)|One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.
97155|NCT01350271|Drug|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
97156|NCT01350271|Drug|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
97157|NCT01350271|Drug|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
97158|NCT01350284|Dietary Supplement|Cinnamon|acute oral administration of 3 g cinnamon
97159|NCT01350284|Dietary Supplement|Placebo control|3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
97160|NCT01350297|Procedure|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
97412|NCT01350713|Drug|povidone iodine|one local application of 10% povidone iodine ointment
97413|NCT01350739|Procedure|intraumbilical incision|vertical, intraumbilical incision
97414|NCT00001073|Drug|Isotretinoin|
97415|NCT00058370|Radiation|radiation therapy|
97416|NCT01350739|Procedure|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
97417|NCT01350752|Behavioral|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
97418|NCT01350752|Behavioral|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
97419|NCT01350752|Behavioral|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
97288|NCT00057954|Drug|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
97289|NCT01345656|Drug|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
97290|NCT01345656|Drug|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
97291|NCT01345656|Drug|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
97292|NCT01345656|Drug|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
97293|NCT01345656|Drug|Placebo|Placebo tablets for duration of 4 weeks
97294|NCT01345656|Drug|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
97295|NCT01345669|Drug|Placebo|Once daily
97624|NCT00057837|Drug|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
97625|NCT01343966|Drug|MABT5102A|Repeating intravenous infusion
97626|NCT01343966|Drug|placebo|Repeating subcutaneous injection
97627|NCT01343966|Drug|placebo|Repeating intravenous infusion
97628|NCT01343992|Behavioral|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
97629|NCT01343992|Behavioral|No bedrest|Patients will not rest in bed after the embryo transfer.
97630|NCT01344005|Other|caregiver-related intervention or procedure|
97631|NCT01344005|Other|questionnaire administration|
97632|NCT01344005|Procedure|quality-of-life assessment|
97633|NCT01344005|Procedure|radiography|
97634|NCT01344018|Procedure|therapeutic conventional surgery|
97635|NCT00057837|Drug|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
97636|NCT01344018|Radiation|3-dimensional conformal radiation therapy|
95737|NCT01360034|Drug|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
95738|NCT01360060|Drug|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
95739|NCT01360086|Biological|cetuximab|
95740|NCT01360086|Drug|cisplatin|
95741|NCT01360086|Drug|fluorouracil|
95742|NCT01360086|Drug|leucovorin calcium|
95743|NCT01363024|Drug|MFGR1877S|Intravenous escalating dose
95744|NCT01363037|Drug|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
95745|NCT01363037|Drug|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
95746|NCT01363037|Other|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
95747|NCT01363037|Drug|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
95748|NCT01363050|Drug|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
95749|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
95750|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
95751|NCT00001080|Biological|Influenza Virus Vaccine|
96042|NCT01355796|Drug|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
96043|NCT01355796|Drug|Xylo-pentane-1,2,3,4 5-pentol|5 ml of 15 % aerosolized 2 times per day
96044|NCT01355809|Drug|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
96045|NCT01355809|Drug|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
96046|NCT01355809|Drug|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
97696|NCT01351194|Procedure|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
97697|NCT01351207|Other|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
97698|NCT01351220|Behavioral|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
97699|NCT01351220|Behavioral|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
97700|NCT01351233|Procedure|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
96819|NCT01347398|Procedure|MicroMESAM system|Sleep study made by MicroMESAM system
96820|NCT01347411|Procedure|CPAP|Treatment with CPAP
96821|NCT01347424|Drug|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3－4h， d1～15，q3w
96822|NCT01347424|Drug|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
96823|NCT00058097|Drug|tipifarnib|Given orally
96824|NCT01347437|Behavioral|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team—is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
96825|NCT01347450|Dietary Supplement|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
96826|NCT01349868|Other|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
96827|NCT01349881|Drug|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
96828|NCT01349881|Drug|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
97420|NCT01350765|Behavioral|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
97421|NCT01350765|Behavioral|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
97422|NCT01350804|Biological|Secukinumab (AIN457)|Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
97423|NCT01350804|Biological|Placebo|
97424|NCT01350804|Biological|Abatacept|
97425|NCT01350817|Drug|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
97426|NCT00058396|Biological|lumiliximab|
97427|NCT01350817|Drug|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
97428|NCT01350830|Procedure|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
97760|NCT00058266|Dietary Supplement|genistein|Given orally
97761|NCT01349127|Drug|Placebo - gelatin capsule|Once daily, one gelatin capsule containing 0µg (0IU) of vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
97762|NCT01349140|Drug|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
97763|NCT01349153|Behavioral|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
97764|NCT01349153|Behavioral|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
97765|NCT01349166|Behavioral|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
97766|NCT01349179|Device|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
97637|NCT01344031|Drug|Akt Inhibitor MK2206|Given PO
97638|NCT01344031|Drug|Anastrozole|Given PO
97639|NCT01344031|Drug|Fulvestrant|Given IM
97640|NCT01344031|Other|Laboratory Biomarker Analysis|Correlative studies
97641|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
97642|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
97643|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
97644|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 1.
97645|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 2.
97646|NCT01346319|Drug|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
96761|NCT01349868|Drug|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
96762|NCT01351844|Behavioral|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
96763|NCT01351844|Behavioral|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
96764|NCT01351857|Other|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
96765|NCT01351870|Radiation|Standard Fractionation Regimen|1.8 Gy daily, 5 fractions per week
Cranio-spinal axis:
23.4 Gy in 13 fractions of 1.8 Gy
Posterior fossa:
30.6 Gy in 17 fractions of 1.8 Gy
96766|NCT01351870|Radiation|Hyperfractionated Radiotherapy|1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week
Craniospinal axis:
36 Gy in 36 fractions of 1 Gy
Posterior fossa:
24 Gy in 24 fractions of 1 Gy
Tumour Bed:
8 Gy in 8 fractions of 1 Gy
96767|NCT01351883|Dietary Supplement|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
96768|NCT01351896|Other|Laboratory Biomarker Analysis|Correlative studies
96047|NCT01355822|Drug|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
96048|NCT01355822|Drug|Placebo control|orally, twice daily
96049|NCT01355835|Device|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
96050|NCT00058942|Device|home drinking water treatment device|
96051|NCT01355848|Behavioral|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
96052|NCT01355861|Behavioral|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
96053|NCT01355874|Drug|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
96054|NCT01355874|Drug|Placebo|Placebo ointment BID for 14 days during double blind.
96055|NCT00059358|Drug|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
96056|NCT01358149|Other|cocoa-based food|single intake of cocoa-based food
96057|NCT01358149|Other|cocoa-based food|Single intake of cocoa-based food
96058|NCT01358162|Other|Placebo|Placebo given orally, daily for 14 consecutive days
96059|NCT01358162|Drug|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
96060|NCT01358175|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
96061|NCT01358175|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
96062|NCT01358175|Drug|Placebo|Placebo
96063|NCT01358201|Drug|vINCRISTINE|
96064|NCT01358201|Drug|Dexamethasone|
96065|NCT01358201|Drug|Methotrexate|
96344|NCT01361191|Drug|R-MEGACHOP|If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT
If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5
R-IFE: 2 cycles every 21 days:
IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.
ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3).
96829|NCT01349881|Drug|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
96830|NCT01349881|Drug|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
96831|NCT00058292|Radiation|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
96832|NCT01349894|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
96833|NCT01349907|Drug|Asenapine|One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
97088|NCT01352780|Behavioral|Motivational interviewing|Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.
Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client`s perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening.
97089|NCT01352793|Biological|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
97090|NCT01352793|Biological|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
97091|NCT01352806|Procedure|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
97092|NCT00058526|Biological|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
97093|NCT01352832|Other|Interactive DVD|An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate "stories" through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor.
97094|NCT01352832|Other|Usual Care|Usual Care
97095|NCT01352845|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
97096|NCT01352845|Other|Placebo|0.5 mL dose, given at 0, 2 and 6 months
97097|NCT01352858|Drug|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
97098|NCT01352858|Drug|Arthroscopy & saline irrigation alone|
97767|NCT01351246|Behavioral|CBT Based Self-help Workbook + Counseling Telephone|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual "Therapy program for children with hyperactive and oppositional problem behavior THOP" (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book "Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior" (Döpfner, Schürmann, & Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
97768|NCT01351259|Device|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
97769|NCT01351272|Drug|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
97770|NCT01351285|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
97771|NCT01351298|Drug|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
97772|NCT00058422|Drug|vincristine sulfate|
97773|NCT01351298|Drug|0.05% xylometazoline hydrochloride|Decongestant
96894|NCT01347515|Other|olive oil|Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.
Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day.
96895|NCT01347528|Behavioral|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
96896|NCT01347541|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
96769|NCT01351896|Drug|Lenalidomide|Given PO
96770|NCT01351896|Other|Pharmacological Study|Correlative studies
96771|NCT00058461|Biological|rituximab|Given IV
96772|NCT01351896|Biological|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
96773|NCT01351909|Drug|Cyclophosphamide|Given PO
96774|NCT01351909|Other|Laboratory Biomarker Analysis|Correlative studies
96775|NCT01351909|Drug|Veliparib|Given PO
96776|NCT01351922|Other|No treatment given|Patients will fill out a questionaire by interview.
96777|NCT01351935|Drug|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
96778|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
96779|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
96780|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
97033|NCT01345292|Drug|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
97034|NCT01345292|Drug|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
97035|NCT01345318|Biological|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
97036|NCT01345318|Biological|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
97037|NCT01345331|Behavioral|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
97038|NCT01345344|Behavioral|Cognitive Behavioral Therapy|Practicing certain strategies such as relaxation and changing negative thoughts about pain.
97039|NCT00057954|Drug|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
96345|NCT01361204|Dietary Supplement|Theanine|Taking 4 tablets of theanine two times daily for 16 days
96346|NCT01361217|Drug|Fluoxetine|1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.
96347|NCT01361230|Device|"Sedation Trial Monitor" is the name of the device used.|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
96348|NCT01361243|Behavioral|NOURISH+|6 week face-to-face parent intervention.
96349|NCT00059813|Biological|recombinant interferon alfa|Given SC
96350|NCT01361243|Behavioral|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
96351|NCT01361256|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
96352|NCT01361256|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
96353|NCT01361269|Drug|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
96354|NCT01361295|Procedure|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
96355|NCT01353664|Drug|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
96356|NCT01353690|Biological|AMDC|Cell Treatment
96357|NCT01353703|Biological|Infanrix hexa™|Intramuscular, three doses
96358|NCT00058617|Genetic|Injection of EBV Specific CTLs|Each patient will receive two injections, 14 days apart, according to the following dosing schedules:
Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2
Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2
Group Three Day 0 1x10^8 cells/m2 Day 14 2x 10^8 cells/m2
If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.
96359|NCT01353716|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
95440|NCT01357070|Dietary Supplement|Brocco-sprout homogenate|Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
97099|NCT01352871|Behavioral|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
97100|NCT01352871|Drug|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
97101|NCT01352884|Drug|AMP-224|Escalating doses of AMP-224
97102|NCT01352884|Drug|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
97103|NCT00058539|Drug|rhuMAb 2C4 (pertuzumab)|
97104|NCT01352910|Device|rTMS|120 pulses 0.2 Hz
97105|NCT01352910|Device|Sham rTMS|120 pulses 0.2 Hz
97106|NCT01352923|Other|blood test|preparation of blood platelets
97107|NCT01352962|Drug|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
97353|NCT01353014|Other|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
97354|NCT01353014|Other|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
97355|NCT01353027|Drug|Placebo|Normal saline
97356|NCT01353027|Drug|AVI-6002|Single intravenous administration
97357|NCT01353040|Drug|AVI-6003|Single intravenous administration
97358|NCT01353040|Drug|Placebo|Single intravenous administration
97359|NCT01353066|Drug|Intensive Medical Treatment|
97360|NCT01353066|Other|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
97361|NCT01353079|Biological|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
97362|NCT01353079|Biological|Placebo|Placebo: Glycero-COCAs sublingual
97363|NCT00001075|Drug|Ritonavir|
97364|NCT00058578|Drug|Cyclophosphamide|
96897|NCT01347541|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
96898|NCT01347541|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
96899|NCT01347541|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
96900|NCT00058097|Radiation|radiation therapy|Undergo radiation therapy
96901|NCT01347554|Device|Everolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
96902|NCT01347554|Device|Zotarolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
96903|NCT01347567|Other|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
96904|NCT01347580|Drug|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
96905|NCT01347580|Drug|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
96906|NCT01347593|Drug|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
96907|NCT01350011|Behavioral|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
96908|NCT01350011|Behavioral|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
97161|NCT01350310|Procedure|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
97162|NCT00058370|Drug|cisplatin|
97163|NCT01350310|Procedure|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
97164|NCT01350310|Procedure|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
97165|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
97040|NCT01345344|Behavioral|Education|Giving participants information about pain and how to change perceptions of pain.
97041|NCT01345357|Drug|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
97042|NCT01345357|Drug|Gemcitabine|Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
97043|NCT01345357|Drug|Cisplatin|Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
97044|NCT01347710|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
97045|NCT01347723|Other|scrambler therapy|Undergo scrambler therapy
97046|NCT01347723|Other|questionnaire administration|Ancillary studies
97047|NCT01347723|Procedure|management of therapy complications|Undergo scrambler therapy
97048|NCT01347736|Other|scrambler therapy|Undergo scrambler therapy
97049|NCT01347736|Other|questionnaire administration|Ancillary studies
97050|NCT01347736|Procedure|dermatologic complications management/prevention|Undergo scrambler therapy
97296|NCT01345669|Drug|Afatinib|Once daily
97297|NCT01345682|Drug|Afatinib|Once daily
97298|NCT01345682|Drug|Methotrexate|Weekly
97299|NCT00057954|Drug|Methotrexate (MTX)|The dose of Methotrexate is based on the corrected ideal body weight for patients with > 33% above ideal weight.
Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)
97300|NCT01345708|Drug|prednisone, low dose rituximab|Patients with "warm" AIHA will receive:
Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)
Patients with CHD will receive:
Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)
97301|NCT01348139|Drug|AZD3199|Inhaled via single inhaler device (SID)
97302|NCT01348139|Drug|AZD3199|Inhaled via Turbuhaler inhaler
95441|NCT01357070|Dietary Supplement|Alfalfa sprout homogenate|Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
95442|NCT01357096|Behavioral|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
95443|NCT01357096|Other|Traditional group|CAD education fryers
95444|NCT01357109|Drug|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
95445|NCT01357109|Drug|Placebo|Matched placebo bid
95446|NCT01357122|Device|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
95447|NCT00059280|Biological|Myozyme|20 mg/kg qow or 40mg/kg qow
95448|NCT00059605|Genetic|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
95449|NCT01359462|Drug|tolvaptan|Drug: tolvaptan
tablet, 15mg, Qd, for 7 days.
95450|NCT01359475|Procedure|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
95451|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
95452|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
95453|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
95454|NCT01359488|Drug|VRS-317|VRS-317 Single dose
95455|NCT01359488|Drug|VRS-317|VRS-317 Single dose
95456|NCT01359501|Drug|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
95457|NCT01359501|Drug|Placebo|Start to take the powder of Placebo 3g*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
95458|NCT01359514|Drug|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
95459|NCT00059618|Drug|PS-341 (Bortezomib)|Starting dose 0.8 mg/m^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
95460|NCT01359514|Drug|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
95461|NCT01359553|Other|Intra-articular ultrasound imaging of knee joint during arthroscopy|
97365|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields|Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):
30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon
97366|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields (PEMF)|Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):
30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)
97367|NCT01353105|Procedure|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
97368|NCT01353118|Biological|gastric bypass|Optimise glucose control within 3 months before operation
97369|NCT01353144|Drug|aspirin|aspirin, 100 mg, qd x 8 weeks
97370|NCT01345721|Biological|MenACWY-CRM|
97371|NCT01345734|Drug|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
97372|NCT01345747|Device|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
97373|NCT01345773|Procedure|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
97374|NCT01345786|Drug|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
97701|NCT01344044|Device|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
97702|NCT01344057|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
97703|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
97704|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
97705|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
97706|NCT00057850|Drug|cisplatin|
97707|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
97708|NCT01344083|Drug|T1210|2 drops T1210 once a day
97709|NCT01344083|Drug|Olopatadine hydrochloride|2 drops once a day Olopatadine
97166|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
97167|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
97168|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)
97169|NCT01350336|Device|Alair System|Treatment of airways with the Alair System
97170|NCT01350349|Behavioral|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
97171|NCT00058461|Other|laboratory biomarker analysis|Correlative studies
97172|NCT01352299|Device|TrueView|Laryngoscopy performed with TrueView laryngoscope
97173|NCT01352312|Drug|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
97174|NCT01352312|Drug|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
97175|NCT01352312|Drug|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
97176|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
97177|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
97178|NCT01352338|Drug|Lenalidomide, endoxan, prednisone|dose-finding
97179|NCT01352338|Drug|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
97180|NCT01352351|Behavioral|Breastfeeding promotion intervention|Breastfeeding counseling during monthly microcredit meetings
Weekly cell phone messages about breastfeeding
97429|NCT01350830|Procedure|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
97430|NCT01350843|Dietary Supplement|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
97431|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage low
97303|NCT01348139|Other|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
97304|NCT01348152|Drug|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
97305|NCT01348152|Drug|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
97306|NCT01348165|Drug|BI 137882|Medium dose powder for oral solution
97307|NCT01348165|Drug|BI 137882|High dose powder for oral solution
97308|NCT01348165|Drug|Placebo|Powder for oral solution
97309|NCT00058201|Drug|leucovorin calcium|Given IV
97310|NCT01348165|Drug|BI 137882|Low dose powder for oral solution
97311|NCT01348178|Procedure|Follow-up|Follow-up
97312|NCT01348191|Procedure|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
97313|NCT01348204|Other|quercetin|health food supplement
97314|NCT01348217|Radiation|Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph node|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
97315|NCT01348217|Radiation|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
97316|NCT01348217|Radiation|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
97317|NCT01348217|Drug|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
97647|NCT01346319|Drug|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
97648|NCT01346332|Device|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
97649|NCT01346358|Biological|IMC-CS4|
97650|NCT00058006|Procedure|adjuvant therapy|
97651|NCT01346371|Drug|Bepreve (bepotastine ophthalmic solution) 1.5%|Must add drops twice a day every day while enrolled in trial.
97652|NCT01346384|Device|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
95462|NCT01359553|Other|Non-invasive ultrasound imaging of knee|
95752|NCT00059904|Biological|aldesleukin|
95753|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing <50 kg.
95754|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
95755|NCT01363089|Drug|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
95756|NCT01363089|Drug|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
95757|NCT01363102|Procedure|SOMS|Apply a number to mobilization goal for patient
95758|NCT01363115|Dietary Supplement|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
95759|NCT01363115|Dietary Supplement|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
95760|NCT01363115|Behavioral|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
95761|NCT01363128|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses on Days 1,2,3 (total dose 1800 mg/m2) for courses 1,3,5,7.
95762|NCT01363128|Drug|Mesna|600 mg/m^2 by vein over continuous infusion daily for 24 hours, starting approximately 1 hour prior to Cyclophosphamide and completing by approximately 12 hours after last dose of Cyclophosphamide for courses 1,3,5,7.
95763|NCT00059904|Biological|rituximab|
95764|NCT01363128|Drug|Doxorubicin|50 mg/m^2 by vein over 24 hours on Day 4 via central venous catheter after last dose of Cyclophosphamide given for courses 1,3,5,7.
95765|NCT01363128|Drug|Vincristine|2 mg by vein on Day 4 and Day 11 for courses 1,3,5,7.
95766|NCT01363128|Drug|Dexamethasone|40 mg by vein or mouth daily on Days 1 - 4 and Days 11 - 14 for courses 1,3,5,7.
95767|NCT01355094|Device|"Stampede" VAC|The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.
Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing.
95768|NCT01355120|Drug|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
97710|NCT01344122|Other|KPI training only|See comparison arm description.
97711|NCT01344122|Other|KPI plus OLI|See experimental arm description.
97712|NCT01344135|Dietary Supplement|Dietary supplementation|Phase A, Rehabilitation (4 months): 3 nutritional supplements daily
Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)
Phase C, Follow-up (3 months): no supplementation
97713|NCT01344135|Dietary Supplement|Placebo supplement|Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily
Phase B, Maintenance (8 months): No supplementation
Phase C, Follow-up (3 months): No supplementation
97714|NCT01344135|Behavioral|Nutritional counselling|Phase A, Rehabilitation (4 months): No counselling
Phase B, Maintenance (8 months): Nutritional counselling (4x)
Phase C, Follow-up (3 months): No counselling
Aim:
Optimising dietary intake to physical activity pattern and energy expenditure.
Minimize deterioration of dietary intake during acute exacerbations.
Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.
Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle.
97715|NCT01344135|Behavioral|Feedback on physical activity level|Phase A, Rehabilitation (4 months): No exercise counselling
Phase B, Maintenance (8 months): Exercise counselling (2x)
Phase C, Follow-up (3 months): No exercise counselling
Aim:
Integration of exercise behaviour into daily routine
Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)
Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle
97716|NCT01344148|Drug|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
97717|NCT00057850|Drug|ixabepilone|
97718|NCT01344161|Dietary Supplement|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
96834|NCT01349907|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam [up to 4 mg/day] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
96835|NCT01349920|Drug|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
96836|NCT01349933|Drug|Akt inhibitor MK2206|Given PO
96837|NCT01349959|Drug|Azacitidine|Given SC
96838|NCT01349959|Drug|Entinostat|Given PO
96839|NCT01349959|Other|Laboratory Biomarker Analysis|Correlative studies
96840|NCT01349959|Other|Pharmacological Study|Correlative studies
97432|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage high
97433|NCT01343706|Drug|BI 409306|low dose solution for oral administration
97434|NCT01343706|Drug|BI 409306|low dose solution for oral administration
97435|NCT01343706|Drug|BI 409306|medium dose solution for oral administration
97436|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
97437|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
97438|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
97439|NCT01343719|Drug|BI 661051|low dose solution for oral administration
97440|NCT00057811|Other|laboratory biomarker analysis|Correlative studies
97441|NCT01343719|Drug|BI 661051|low dose solution for oral administration
97442|NCT01343719|Drug|BI 661051|low dose solution for oral administration
97443|NCT01343719|Drug|BI 661051|high dose solution for oral administration
97444|NCT01343719|Drug|BI 661051|high dose solution for oral administration
97445|NCT01343719|Drug|BI 661051|low dose tablet
97446|NCT01343719|Drug|Placebo|solution for administration
97447|NCT01343719|Drug|BI 661051|medium dose tablet
97448|NCT01343732|Device|Deep TMS|deep transcranial magnetic stimulation
97449|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
97450|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
97451|NCT00001067|Drug|Lamivudine|
97774|NCT01351298|Drug|Isotonic normal saline|Placebo
97775|NCT01351311|Other|Exercise|Resistance Training exercise with swiss ball
97776|NCT01351311|Other|Drug treatment|Drug treatment
97653|NCT01346410|Radiation|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
97654|NCT01346423|Behavioral|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
97655|NCT01346423|Behavioral|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
97656|NCT01346436|Procedure|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
97657|NCT01346449|Behavioral|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
97658|NCT01346449|Behavioral|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
97659|NCT01346449|Behavioral|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
97660|NCT01348906|Procedure|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
97661|NCT01348919|Drug|CEP-18770|administered on days 1, 8, and 15 of each 28-day cycle
97662|NCT01348919|Drug|Lenalidomide|administered 25 mg on days 1 through 21 of each 28-day cycle
97663|NCT01348919|Drug|Dexamethasone|administered 40 mg on days 1, 8, 15, and 22 of each 28-day cycle
96781|NCT01351948|Biological|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
96782|NCT00058461|Drug|carboplatin|Given IV
96783|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 112. IM injections
96784|NCT01351961|Biological|blood sampling|take a sample of blood, 46 ml
96785|NCT01351961|Procedure|brain MRI and TEP cerebral|magnetic resonance imaging
96786|NCT01344824|Drug|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
96066|NCT00001077|Dietary Supplement|Multivitamin and mineral supplements|Oral tablets taken daily
96067|NCT00059358|Drug|Ribavirin|Oral tablet taken daily
96068|NCT01358201|Drug|Cytosine arabinoside|
96069|NCT01358214|Behavioral|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
96070|NCT01358227|Drug|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
96071|NCT01358240|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
96072|NCT01358240|Drug|Vehicle Foam|Vehicle Foam applied once a day for 4 week
96073|NCT01358240|Drug|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
96074|NCT01358240|Other|Placebo Cream|Placebo cream applied once a day for 4 weeks
96075|NCT01358253|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
96076|NCT01358253|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
96077|NCT01358253|Drug|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
96078|NCT00059358|Drug|Peginterferon alfa-2b|Subcutaneous injection
96079|NCT01358253|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
96080|NCT01358253|Drug|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
96081|NCT01358253|Drug|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
96082|NCT01358253|Drug|Rituximab|Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).
Maintenance:375 mg/m2 IV in 6th month and 12th month.
96083|NCT01360593|Drug|Capecitabine|Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:
Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles.
96084|NCT01360593|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:
12 Gy x 3 fractions (36 Gy total) This will be given every other day.
96841|NCT01349972|Drug|alvocidib|Given IV
96842|NCT00058305|Drug|bryostatin 1|Given IV
96843|NCT01349972|Drug|daunorubicin hydrochloride|Given IV
96844|NCT01349972|Drug|mitoxantrone hydrochloride|Given IV
96845|NCT01349972|Drug|cytarabine|Given IV
96846|NCT01349985|Other|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
96847|NCT01349985|Other|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
96848|NCT01349998|Drug|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
96849|NCT01351961|Other|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
96850|NCT01351961|Other|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
96851|NCT01351961|Procedure|Vascular explorations|Pulse wave velocity, VWF, IMT
96852|NCT01351961|Biological|Urine sample|
96853|NCT01352000|Behavioral|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
96854|NCT01352013|Dietary Supplement|Omega-3 (oil)|5ml daily with breakfast for 56 days.
96855|NCT01352013|Dietary Supplement|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
97108|NCT01352962|Drug|Carboplatin|AUC 5** IVPB over 30 min x 1
97109|NCT01352962|Drug|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
97110|NCT01352988|Drug|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
97111|NCT01345370|Drug|Temozolomide|According to sites procedures
97112|NCT01345370|Radiation|Radiation Therapy|According to sites procedures
97113|NCT01345383|Procedure|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
97777|NCT01351324|Dietary Supplement|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
97778|NCT01351337|Procedure|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
97779|NCT01351350|Drug|MLN0128 + paclitaxel|MLN0128 will be orally administered QDX3d QW or QDX5d QW in combination with IV paclitaxel on Days 1, 8 and 15 of each cycle
97780|NCT01351350|Drug|MLN0128 + paclitaxel + trastuzumab|MLN0128 will be orally administered QDX3d QW or QDX5d QW in combination with IV paclitaxel on Days 1, 8 and 15 of each cycle and IV trastuzumab on Days 1, 8, 15 and 22 of each cycle
97781|NCT01351363|Device|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
97782|NCT01351363|Device|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
97783|NCT00058422|Radiation|indium In 111 ibritumomab tiuxetan|
97784|NCT01351376|Device|Low Level Laser Therapy|Placebo LLL combined with CDT
97785|NCT01344187|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
97786|NCT01344187|Drug|Placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
97787|NCT01344200|Drug|Celecoxib|All patients, on day of first scheduled LP, will receive celecoxib suspension 10 mg/kg by mouth 180 mins before their scheduled LP. Prior to beginning the second cycle of chemotherapy the patients will be randomly allocated to either of 2 cohorts (CSF dose timing cohort versus dose escalation cohort). The CSF dose timing cohort patients will be assigned to receive celecoxib 10 mg/kg at a predetermined time (60 mins, 120 mins, 300 mins and 900 mins before LP+/- BM) and they will rotate in chronological order for four chemotherapy cycles to complete the remaining time points of interest. The dose escalation cohort patients, at the beginning of each cycle of chemotherapy, will be administered either 6 or 14 mg/kg celecoxib 180 mins before LP for a total of 4 chemotherapy cycles.
Approximately 8-12 hours after the first dose, each patient will be required to ingest a second dose of celecoxib suspension (one half of the premedication dose) with food.
97788|NCT01344213|Drug|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
97789|NCT01344213|Drug|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
97790|NCT01344213|Drug|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
97791|NCT01344213|Drug|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
96626|NCT01344655|Drug|Placebo|placebo
96787|NCT01344824|Drug|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
96788|NCT01344837|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
96789|NCT01344837|Other|Immunohistochemistry Staining Method|Correlative studies
96790|NCT00057928|Drug|gemcitabine hydrochloride|
96791|NCT01344837|Other|Medical Chart Review|Correlative studies
96792|NCT01344837|Genetic|Microarray Analysis|Correlative studies
96793|NCT01344837|Other|Study of Socioeconomic and Demographic Variables|Correlative studies
96794|NCT01344837|Genetic|Western Blotting|Correlative studies
96795|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
96796|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
96797|NCT01344876|Drug|OPB-51602|once daily during the treatment period
96798|NCT01344902|Drug|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
96799|NCT01344915|Procedure|Locked knee brace|
96800|NCT01344915|Procedure|Locked knee brace|
96801|NCT00057928|Drug|paclitaxel|
96802|NCT01344928|Behavioral|HIT exercise intervention|
96803|NCT01344928|Behavioral|Aerobic exercise intervention|
96804|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
96805|NCT01344954|Drug|Rivaroxaban|Administered orally as a capsule once a day for 35 days
97051|NCT01347749|Behavioral|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
97052|NCT01347749|Behavioral|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
97053|NCT00058149|Drug|oxaliplatin|
96085|NCT01360606|Radiation|Stereotactic Body Radiation Therapy|SBRT:
Patients will receive one of the following radiation regimens:
50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.
60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.
75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.
96360|NCT01353729|Drug|600 mg zanamivir + moxifoxacin placebo|600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
96361|NCT01353729|Drug|1200 mg zanamivir + moxacin placebo|1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
96362|NCT01353729|Drug|zanamivir placebo + moxifloxacin placebo|zanamivir Placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
96363|NCT01353729|Drug|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
96364|NCT01353742|Drug|Lamivudine|100mg tablet
96365|NCT01353742|Drug|Adefovir dipivoxil|10mg tablet
96366|NCT01353742|Drug|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
96367|NCT01353755|Drug|Grass pollen specific immunotherapy|Strength 1 (0.78μg/mL)
Strength 2 (6.25μg/mL)
Strength 3 (50μg/mL)
Strength 4 (200μg/mL)
The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo.
96368|NCT01353755|Drug|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
96369|NCT00058656|Procedure|Infusion of Activated & Expanded Autologous T Cells|
96370|NCT01353768|Other|retrospective chart review|retrospective chart review
96371|NCT01353781|Drug|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
96372|NCT01353794|Drug|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
96373|NCT01353807|Dietary Supplement|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
96374|NCT01353807|Dietary Supplement|Olive oil|4 1-g gelatine capsules with virgin olive oil
96375|NCT01353820|Dietary Supplement|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( >10E8 to <5.10E9 cfu/ml of L. delbruckii lactis )
97114|NCT01345396|Behavioral|Health education about asthma|Three face-to-face appointments (<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
97115|NCT01345422|Other|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
97116|NCT01345435|Procedure|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
97117|NCT00057954|Radiation|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
97118|NCT01345435|Procedure|Telemonitoring & Telemedicine|The Telemonitoring & Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
97119|NCT01345435|Other|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
97120|NCT01345448|Drug|Brimonidine|0.1% Brimonidine Lotion, dosed once.
97121|NCT01345448|Drug|Placebo Lotion|Placebo Lotion dosed once.
97122|NCT01345461|Device|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
97375|NCT01345786|Drug|Phase 3 NOMAC-E2 "Batch A"|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program ("Batch A") orally in the morning on Day 1 for all periods
97376|NCT01345786|Drug|Phase 3 NOMAC-E2 "Batch B"|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program ("Batch B") orally in the morning on Day 1 for all periods
97377|NCT01345799|Drug|TRK-170|
97378|NCT01345799|Drug|Placebo|
97379|NCT00057967|Biological|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
96627|NCT01344668|Other|Enhanced Diabetes Education|Provide enhanced diabetes education
96628|NCT01344668|Other|Standard Diabetes Education|Provide Standard Diabetes Education
96629|NCT01344681|Drug|Micafungin sodium|Treatment period (active treatment): an average 14 days
Dosage:
- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)
Administration Method:
Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever.
96630|NCT01344681|Drug|Itraconazole|Treatment period (active treatment): an average 14 days
Dosage:
- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)
Administration Method:
Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever.
96631|NCT01347073|Drug|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
96632|NCT01347086|Drug|Matching placebo (low dose)|single dose of matching placebo
96633|NCT01347086|Drug|BI 207127 NA (medium dose)|Single does of BI 207127 NA
96634|NCT00001070|Drug|Oral Vitamin C|
96635|NCT00058058|Radiation|gadopentetate dimeglumine|
96636|NCT01347086|Drug|BI 207127 NA (low dose)|single dose of BI 207127 NA
96637|NCT01347086|Drug|Matching placebo (medium dose)|Single dose of matching placebo
96638|NCT01347086|Drug|BI 207127 NA (high dose)|Single dose of BI 207127 NA
96639|NCT01347086|Drug|Matching placebo (high dose)|Single dose of matching placebo
96640|NCT01347099|Behavioral|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
96641|NCT01347099|Behavioral|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
96642|NCT01347112|Drug|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
96643|NCT01347112|Drug|placebo|sugar pill twice daily for 12 weeks
96644|NCT01347125|Device|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
96645|NCT01347138|Other|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
97054|NCT01347762|Drug|Nabilone|nabilone titrated to 1 mg by mouth twice daily
97055|NCT01347762|Drug|Placebo|one placebo capsule by mouth twice daily
97056|NCT01347775|Device|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
97057|NCT01347775|Device|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
97058|NCT01347788|Drug|cabozantinib|Cabozantinib PO QD
97059|NCT01347801|Drug|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
97060|NCT01347801|Drug|Placebo (Saline)|Normal saline (NaCl 0,9%)
97061|NCT01347801|Drug|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
97062|NCT01347801|Other|OGTT|Oral glucose tolerance test with 75 g glucose
97063|NCT01347801|Other|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
97064|NCT00001071|Drug|Filgrastim|
97065|NCT00058188|Dietary Supplement|cholecalciferol|Given orally
97066|NCT01347814|Drug|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
97067|NCT01347814|Drug|Placebo|Homeopathic (Sugar) pill-Placebo
97068|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
97069|NCT01350206|Procedure|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
97318|NCT01348230|Other|No interventions.|No interventions.
97319|NCT01348243|Drug|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
97320|NCT00058201|Other|clinical observation|No intervention
96376|NCT01356277|Device|Electronic pillbox monitoring, dose reminders, and feedback|The multi-dose pillbox is coupled, using wireless technology, to a personalized, password-protected, medication management website. When a compartment of the dose box is opened, a signal is sent, and a date and time "stamp" is recorded in the electronic record of the patient to whom the device is registered. Adherence data collected with the device is fed back to participants in the intervention group. The pillboxes provide one, or any combination, of the following dose reminder methods: device light flashing, email, or text messages. The reminder method may be changed any time. The devices require only a power supply. Neither a phone line nor an Internet connection is required.
96377|NCT01356290|Drug|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
96378|NCT01356290|Drug|Thalidomide|3mg/kg, oral, daily, 1 year
95463|NCT01359553|Other|Quantitative MRI imaging of knee|
95464|NCT01359553|Other|Contrast-enhanced CT imaging of knee|
95465|NCT01359566|Drug|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
95466|NCT01359566|Drug|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
95467|NCT01359566|Drug|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
95468|NCT01359566|Drug|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
95469|NCT01359579|Drug|varespladib methyl|Single oral 500 mg dose
95470|NCT00059618|Drug|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
95471|NCT01359592|Biological|rituximab|
95472|NCT01359592|Drug|cyclophosphamide|
95473|NCT01359592|Drug|doxorubicin hydrochloride|
95474|NCT01359592|Drug|prednisone|
95475|NCT01359592|Drug|vincristine sulfate|
95476|NCT01359592|Other|R-CHOP regimen|
95477|NCT01359592|Other|laboratory biomarker analysis|
95478|NCT01362218|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
95479|NCT01362218|Drug|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
95480|NCT01362231|Drug|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
97380|NCT01345812|Drug|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
97381|NCT01345812|Drug|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
97382|NCT01345825|Other|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
97383|NCT01345838|Procedure|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
97384|NCT01345851|Radiation|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
97385|NCT01345851|Other|laboratory biomarker analysis|Correlative studies
97386|NCT01345851|Radiation|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
97387|NCT01345851|Drug|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
97388|NCT01345851|Drug|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
97389|NCT01345851|Radiation|stereotactic body radiation therapy|Undergo hypofractionated RT
97390|NCT00057980|Drug|celecoxib|
97391|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
97392|NCT01345864|Drug|Scopolamine + Donepezil 5 mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
97393|NCT01348308|Drug|Maraviroc (Celsentri)|Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.
Duration: 72 weeks.
97719|NCT01344161|Dietary Supplement|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
97720|NCT01344174|Drug|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
97721|NCT01346449|Behavioral|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
97722|NCT00058019|Drug|ixabepilone|Given IV
96646|NCT00058071|Drug|amifostine trihydrate|
95696|NCT01355094|Device|KCI AbThera|The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.
Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing.
95697|NCT01357460|Device|Implantation of intrabronchial valves (IBV) (Spiration IBV)|In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of "new" air during inspiration.
95698|NCT01357486|Drug|sorafenib|patients receiving sorafenib 400 mg - twice a day
95699|NCT01357486|Drug|Pravastatin|patients receiving pravastatin 40 mg - once a day
95700|NCT01357486|Drug|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
95701|NCT01357486|Other|patients receiving best supportive care|palliative management
95702|NCT01357499|Device|blood pressure cuff|A Blood pressure cuff and and the musclestimulator pads will be applyed to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeted for 3 times.
Device: WelchAllyn, USA; Flexiport Reusable Bloodpressure Cuff 12L
95703|NCT01357499|Device|blood pressure cuff + electric musclestimulator|A Blood pressure cuff and and the musclestimulator pads will be applyed to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeted for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
Device 1: bloodpressure cuff (WelchAllyn, USA; Flexiport Reusable Bloodpressure Cuff 12L) Device 2: musclestimulator (gbo, Germany; HiToP 191)
95704|NCT00059319|Procedure|single aorta clamp with retrograde cardioplegia|
95705|NCT01357512|Device|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
95706|NCT01357525|Radiation|Stereotactic Body Radiation Therapy (SBRT)|An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:
12 Gy x 3 fractions (36 Gy total)
95707|NCT01357538|Drug|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
95708|NCT01357538|Drug|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
97321|NCT01348243|Drug|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
97322|NCT01348256|Drug|Dendritic cells vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
97323|NCT01348269|Drug|Aclasta|1 x intravenous non-current drip (infusion)
97324|NCT01348269|Drug|Placebo|NaCl Solution
97325|NCT01348282|Drug|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
97326|NCT01348282|Drug|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
97327|NCT01348295|Other|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
97328|NCT01350531|Behavioral|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
97329|NCT00058370|Procedure|adjuvant therapy|
97330|NCT01350531|Behavioral|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
97331|NCT01350544|Behavioral|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary. This description is subject to change after consideration by the community advisory board.
97332|NCT01350557|Other|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
97333|NCT01350557|Other|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
97334|NCT01350570|Other|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
97335|NCT01350570|Other|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
97336|NCT01350570|Other|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
97664|NCT01348945|Other|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
95481|NCT01362244|Drug|Mepolizumab|750 mg of mepolizumab by IV infusion
95482|NCT01362244|Drug|Placebo|Placebo by IV infusion
95483|NCT01362244|Drug|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
95484|NCT01362257|Drug|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
95485|NCT01362257|Drug|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
95486|NCT00000254|Drug|0.2% isoflurane|
95487|NCT00001079|Drug|Megestrol acetate|
95769|NCT01355133|Biological|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
95770|NCT01355159|Drug|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
95771|NCT01355159|Drug|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
95772|NCT01355172|Biological|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
95773|NCT01355198|Dietary Supplement|Cysteine (as n-acetylcysteine) and glycine|Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
95774|NCT01355198|Dietary Supplement|Cysteine/glycine|Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
95775|NCT00058851|Procedure|Manual lymph drainage|
95776|NCT01355224|Genetic|FTO variant|Relative risk estimates will be presented based on individuals'risk for obesity based on genotype results.
95777|NCT01355224|Behavioral|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
95778|NCT01355263|Drug|iron and vitamin a|
95779|NCT01355276|Drug|Cinitapride|cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
95780|NCT01355276|Drug|domperidone|10 mg for each dose ,30 mg/daily, for 4 weeks
97723|NCT01346462|Behavioral|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
97724|NCT01346475|Drug|valacyclovir|1000 mg orally three times daily for 5 weeks
97725|NCT01346475|Drug|Valacyclovir|500 mg orally once daily for 5 weeks
97726|NCT01346514|Behavioral|LifeSkills Training/Intensive Case Management|Assertive community treatment / intensive case management. Veterans assigned to the AHCM condition will have a case manager who is integrated with the interdisciplinary treatment team. The AHCM will meet with the Veteran weekly, assist the Veteran with potential housing options, support the Veteran in continuing addiction treatment and psychiatric care, visit the Veteran in the community when appropriate, and obtain point of care urine toxicology testing to assess abstinence with the goal of addressing substance use issues proactively. The AHCM will educate the Veteran on needed basic life skills using existing manuals
97727|NCT01346514|Behavioral|Time and attention control|Veterans assigned to the control condition will attend a weekly housing group where housing options are discussed.
97728|NCT01346540|Drug|BIBF 1120|VEGF inhibitor
97729|NCT01346540|Drug|Placebo|BIBF 1120 placebo
97730|NCT01346553|Device|ESVV device|wearing the ESVV device for 6 hours
97731|NCT01346566|Device|Cionni Modified Capsule Tension Ring|Cionni ring was used to fixate the capsular bag to the sclera and IOL was implanted in-the-bag
97732|NCT01346579|Other|laboratory biomarker analysis|Correlative sciences
97733|NCT00058032|Other|screening questionnaire administration|
97734|NCT01346592|Biological|Trivalent split influenza vaccine (TIV)|
97735|NCT01346592|Biological|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
97736|NCT01346592|Biological|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
97737|NCT01346631|Other|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
97738|NCT01346644|Other|Infant formula|Powder infant formula
96856|NCT00058461|Biological|filgrastim|Given SC
96857|NCT01352026|Drug|Metformin|
95709|NCT01357551|Behavioral|Interventions|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact with the interventionist will gradually taper over time.
96002|NCT01360554|Drug|Active Comparator (erlotinib)|Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
96003|NCT01360554|Drug|Placebo erlotinib|placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
96004|NCT01360554|Drug|Placebo PF00299804|placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
96005|NCT00059761|Drug|cisplatin|
96006|NCT01360567|Dietary Supplement|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
96007|NCT01360567|Dietary Supplement|Placebo|500 mg . one capsule of placebo, 3 times per day
96008|NCT01360593|Drug|Gemcitabine|Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:
Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles.
96009|NCT01363128|Drug|Ofatumumab|2000 mg by vein on day 1 and 11 +/- 2 days for courses 1 and 3. (Ofatumumab given at dose of 300 mg on day 1 of cycle 1. Subsequent infusions given at dose of 2000 mg).
2000 mg by vein on Days 1 and 8 for courses 2 and 4.
96010|NCT01363128|Drug|Methotrexate|12 mg intrathecally (6 mg via Ommaya reservoir) on Day 2 of courses 1,3,5,7.
200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on Day 1 of courses 2,4,6,8.
96011|NCT01363128|Drug|Cytarabine|100 mg intrathecally on Day 7 for courses 1,3,5,7.
3 g/m^2 by vein over 2 hours every 12 hours for 4 doses on Days 2 and 3 for courses 2,4,6,8.
96012|NCT01363141|Other|Regular AGE Diet|Regular AGE Diet
96013|NCT01363141|Other|Low AGE Diet|One year reduction in dietary AGE intake.
96014|NCT01363154|Other|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
96015|NCT01363154|Other|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
96016|NCT00059917|Drug|polyglutamate camptothecin|
96017|NCT01363154|Other|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
96018|NCT01363167|Dietary Supplement|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
97665|NCT00058240|Drug|alvocidib|Given IV
97666|NCT01348958|Device|iDXA knee software|Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.
During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done
97667|NCT01348971|Dietary Supplement|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
97668|NCT01348971|Other|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
97669|NCT01348984|Drug|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
97670|NCT01348984|Drug|placebo patch|group 2 = placebo patch
97671|NCT01348997|Behavioral|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
97672|NCT01348997|Behavioral|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
97673|NCT01349010|Drug|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
97674|NCT01349010|Drug|Placebo|1 tablet bid. p.o for 8 weeks
97675|NCT01349023|Other|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
97676|NCT00058253|Drug|tanespimycin|Given IV
97677|NCT01349036|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
97678|NCT01349049|Drug|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
97679|NCT01349049|Drug|PLX3397|The drug product is available in capsule form, to be taken orally.
97680|NCT01349062|Drug|"Kallunk oxide (Immunotherapy) "|The study will be assigned Arm 1 above 450 cu/mm^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of "Kallunk oxide(Immunotherapy) + Long Pepper", that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as "Kallunk oxide" and appropriate drug carrier antidote. The drug assigns to 0.200 mg "Kallunk oxide" molecules with 499.800 mg "Antidote"( This antidote was used as a carrier of "Kallunk oxide" molecules), respectively, for children and adults. Dosage: 500 mg for children and adults. This powder form sample size product will be administered once daily dose on 5 days treatment. The Botanical name of the antidote is "Piper Longum".
97681|NCT01349075|Radiation|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
95781|NCT01355289|Drug|E5501/Avatrombopag maleate|All subjects will initiate open-label, once-daily treatment with E5501 at a dose of 20 mg.
After Treatment Period B1, E5501 will be administered in a flexible-dose design. During Treatment Periods B2 and B3, the E5501 dose may be titrated up or down in accordance with their individual response, within the range of a minimum of 5 mg and a maximum of 50 mg.
95782|NCT01355289|Drug|Placebo|Placebo was given orally for up to 21 days once daily.
95783|NCT01355302|Drug|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
95784|NCT01355302|Drug|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
95785|NCT01355302|Drug|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
95786|NCT00058851|Procedure|Combined physiotherapy|
95787|NCT01357616|Drug|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
96086|NCT01360632|Drug|OPC-34712 + ADT|Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
96087|NCT01360632|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
96088|NCT01360632|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
96089|NCT01360645|Drug|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
96090|NCT00059761|Drug|irinotecan hydrochloride|
96091|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
96092|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
96093|NCT01360658|Drug|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
96094|NCT01360671|Drug|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
96095|NCT01360697|Other|JADE|The nurse will complete the CA using standardized protocol including blood & urine tests, eye & feet examination.
Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.
Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications & healthy lifestyles, perform self blood glucose monitoring as appropriate.
At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight & blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.
After the FU visit, the patients will see the nurse or HCA again to clarify any issues & concerns, reinforce compliance & record any changes in medications.
After each FU visit, the HCA will generate summary reports to be given to patients & doctors to promote sharing of information.
96858|NCT01352039|Biological|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
96859|NCT01352039|Biological|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
96860|NCT01352052|Other|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
96861|NCT01352065|Drug|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
96862|NCT01352065|Drug|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
96863|NCT01352065|Drug|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
96864|NCT01352091|Drug|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
96865|NCT01352091|Drug|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
96866|NCT01352104|Behavioral|PEP-TE|PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the "coercive interaction process" (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses.
96867|NCT00058461|Drug|methotrexate|Given IT
96868|NCT01352117|Drug|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
96869|NCT01344993|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
96870|NCT01345006|Biological|MA09-hRPE|Cohort 1 50,000 cells
Cohort 2 100,000 cells
Cohort 2a Better Vision 100,000 cells
Cohort 3 150,000 cells
Cohort 4 200,000 cells
96871|NCT01345019|Drug|Denosumab|Denosumab 120 mg SC
96872|NCT01345019|Drug|Zoledronic acid|Zoledronic acid 4 mg (adjusted for renal function) IV over at least 15 minutes Q4W (n = 760)
96873|NCT01345032|Other|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
97538|NCT00057837|Drug|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
97539|NCT01343823|Drug|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
97540|NCT01343823|Drug|placebo|Administered as two SC 3 mL injections
97541|NCT01343823|Drug|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
97542|NCT01343823|Drug|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
97543|NCT01343836|Other|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
97544|NCT01343836|Other|Saline|Intratendinous saline injection with eccentric exercises
97545|NCT01343862|Drug|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
97546|NCT01343862|Drug|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
97547|NCT01343875|Procedure|tear of the distal tendon in the biceps muscle|
97548|NCT01343888|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
97549|NCT00057837|Drug|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
97550|NCT01343888|Drug|BI 201335|BI 201335 once daily high dose
96664|NCT01349647|Biological|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16.
96665|NCT01349660|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
96666|NCT01349660|Drug|BKM120|BKM120 orally (PO) once daily
96667|NCT01349673|Drug|Budesonide Foam|2mg/25ml BID for 2 weeks followed by 2mg/25ml QD for 4weeks
96668|NCT01349686|Procedure|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
96669|NCT01349686|Procedure|Fasting|No intake of fluids during labour.
96670|NCT01349699|Drug|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
97255|NCT01352663|Biological|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
97256|NCT01352663|Biological|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
97257|NCT01352689|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
97258|NCT01352689|Drug|Combination Therapy|Drug: Telmisatan 80mg Tablet, Oral, Once Daily
Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily
97259|NCT01352702|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
97260|NCT00058487|Drug|epirubicin hydrochloride|
97261|NCT01352702|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
97262|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
97263|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
97264|NCT01352715|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
97265|NCT01352715|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
97266|NCT01352715|Drug|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
97267|NCT01352715|Drug|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
97268|NCT01352715|Drug|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
97269|NCT01352715|Drug|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
97270|NCT01352715|Drug|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
97271|NCT00058487|Drug|thalidomide|
97272|NCT01352715|Drug|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
97273|NCT01352728|Drug|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
94101|NCT01325363|Device|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
94102|NCT01325376|Behavioral|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
93182|NCT00057174|Drug|Disease management of gastroesophageal reflux disease|
93183|NCT01336647|Drug|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
93184|NCT01336647|Drug|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
93185|NCT01336660|Biological|equine F(ab')2 antivenom|Calculation of the expected dose of Study Drug for effective treatment of envenomation by the species tested, assuming maximal venom injection and treatment of children within 5 hours of sting, projects a range of effective dose between 1 and 4 vials administered intravenously. Because it is not currently possible to judge, on an individual clinical basis, which patients have received the largest doses of scorpion venom, this protocol uses a single dose of 4 vials, intravenous, as the most likely dose to ensure efficacy in the largest number of subjects.
Lyophilized placebo consisting of inactive excipient materials, and its packaging will be indistinguishable from the active drug.
93186|NCT01336660|Other|Standard of care plus placebo|Intensive care support as needed plus placebo
93187|NCT01336686|Drug|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
93188|NCT01336686|Drug|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
93189|NCT01336686|Drug|Placebo comparator|Matching placebo once daily for 4 weeks
93190|NCT01336686|Drug|Colchicine|0.6 mg colchicine daily for flare prophylaxis
93191|NCT01336699|Biological|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
93192|NCT01336699|Biological|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
93193|NCT00057187|Behavioral|Contracting, Prompting and Reinforcing|
93194|NCT01336699|Other|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
93195|NCT01336712|Procedure|Peripheral Blood Stem Cell Transplant|Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.
Fludarabine 30 mg/m^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4
93196|NCT01336725|Behavioral|Teaching life style changes|Single group: Teaching, group sessions, physical activity
93857|NCT01327495|Drug|Testosterone 1% gel (or placebo) + acyline (or placebo)|Placebo acyline subcutaneous injection every 2 weeks + daily placebo gel applied transdermally x 12 weeks
Acyline subcutaneous injection (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline subcutaneous injection (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline subcutaneous injection (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline subcutaneous injection (300µg/kg every two weeks) + testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline subcutaneous injection (300µg/kg every two weeks) + testosterone 1% gel 15 g daily applied transdermally x 12 weeks
93858|NCT00056199|Drug|EYE001|
93859|NCT01327508|Device|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
93860|NCT01327508|Other|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
93861|NCT01327521|Device|CyberKnife|Standard of Care
93862|NCT01327521|Procedure|TACE|Standard of Care
93863|NCT01327521|Drug|CT Contrast|Standard of Care
93864|NCT01327521|Drug|doxorubicin|Standard of Care
94167|NCT01333397|Drug|Botulinum type A toxin (Dysport RU)|I.M. (in the muscle) injection on day 1 (single treatment cycle)
94168|NCT01333397|Drug|Botulinum type A toxin (Azzalure)|I.M. on day 1 (single treatment cycle)
94169|NCT00056875|Drug|recombinant human keratinocyte growth factor|
94170|NCT01333397|Drug|Placebo|I.M. on day 1 (single treatment cycle)
94171|NCT01333410|Drug|tacrolimus ointment|2 applications per days for 6 months
94172|NCT01333410|Drug|Mometasone furoate|2 applications per day for 6 months
94173|NCT01333423|Drug|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
94174|NCT01333423|Drug|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
94175|NCT01333436|Other|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
94176|NCT01333449|Drug|Decitabine|20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
94177|NCT01333462|Biological|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
96671|NCT01349699|Drug|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
96672|NCT00058292|Drug|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
96673|NCT01349699|Drug|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
96674|NCT01349699|Drug|Placebo|At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.
At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol.
96675|NCT01349725|Drug|ARRY-502|Oral; multiple dose, escalating
96676|NCT01351662|Behavioral|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
96677|NCT01351675|Drug|Placebo|Oral, once daily
96678|NCT01351675|Drug|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
96679|NCT01351688|Drug|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
96680|NCT01351714|Procedure|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
96681|NCT01351740|Drug|atazanavir|switch to unboosted atazanavir 400 mg daily
96942|NCT01352299|Device|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
96943|NCT01352299|Device|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
96944|NCT01352299|Device|Miller|Laryngoscopy performed with Miller Laryngoscope
96945|NCT00001074|Drug|Didanosine|
96946|NCT01345162|Drug|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
97274|NCT01352741|Drug|Tapentadol PR|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
97605|NCT01351038|Drug|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
97606|NCT01351064|Other|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
97607|NCT00058422|Drug|cyclophosphamide|
97608|NCT01351077|Other|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
97609|NCT01351090|Drug|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
97610|NCT01351090|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
97611|NCT01351090|Drug|Placebo|Intranasal
97612|NCT01351103|Drug|LGK974|
97613|NCT01351116|Radiation|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
97614|NCT01351116|Radiation|EBR|EBR of 20 Gy in 5 daily fractions over one week
97615|NCT01351129|Drug|Formulation 1|150-mg immediate release tablet (single dose)
97616|NCT01343888|Drug|Placebo|
97617|NCT01343927|Behavioral|Yoga Class|Standardized 12 week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once a week at community health centers.
97618|NCT01343927|Behavioral|Physical therapy|12 weeks of individual physical therapy. Weeks 1-5, 2 sessions per week. Weeks 6-8, one session per week. Weeks 9-12, one session every other week. Total of 15 sessions.
97619|NCT01343927|Behavioral|Education|Education intervention receives "The Back Pain Helpbook" and periodic newsletters addressing back pain and self care. Also, continue with usual care.
97620|NCT01343940|Behavioral|Project dulce|Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a "Dulce family partner") supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation.
97621|NCT01343940|Behavioral|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
93197|NCT01336725|Other|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
93198|NCT01336725|Other|Teaching|Morbid obesity group attend 40 hours of group sessions
93199|NCT01336738|Drug|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
93200|NCT01336738|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
93201|NCT01336738|Drug|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
93488|NCT01341769|Other|Dietary Intervention|
93489|NCT01341782|Drug|paricalcitol|
93490|NCT01341782|Drug|maxacalcitol|
93491|NCT01341782|Drug|paricalcitol placebo|
93492|NCT00057746|Radiation|Prophylactic Cranial Irradiation (PCI)|Given once or twice daily
93493|NCT01341782|Drug|maxacalcitol placebo|
93494|NCT01341808|Biological|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
93495|NCT01341834|Drug|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
93496|NCT01341847|Procedure|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
93497|NCT01341847|Procedure|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
93498|NCT01341873|Other|educational intervention|Undergo APN FCI
93499|NCT01341873|Other|psychosocial support for caregiver|Undergo APN FCI
93500|NCT01341873|Procedure|quality-of-life assessment|Ancillary studies
93501|NCT01341873|Other|questionnaire administration|Ancillary studies
93502|NCT01341886|Drug|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
94178|NCT01333462|Other|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
94179|NCT01333475|Drug|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
94180|NCT00056927|Behavioral|Anti-smoking Socialization Program|
94181|NCT01333488|Device|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
94182|NCT01333488|Drug|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
94183|NCT01333501|Drug|Fingolimod|
94184|NCT01333501|Drug|Interferon beta 1b|
94185|NCT01333514|Drug|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
94186|NCT01333514|Drug|aspart|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
94187|NCT01333527|Procedure|No Sling|Early range of motion
93259|NCT01343654|Behavioral|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
93260|NCT01343667|Device|Gore Flow Reversal System|Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
93261|NCT01343667|Device|Gore Embolic Filter|Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
93262|NCT01343680|Drug|Heparin|5ml 10 units/ml IV heparin 3 times per week
93263|NCT01343680|Drug|Normal saline|10ml normal saline IV weekly
93264|NCT01343706|Drug|Placebo|Solution for oral administration
93265|NCT01343706|Drug|Placebo .|Immediate release solid oral dosage
93266|NCT00057811|Drug|hydrocortisone sodium succinate|Given IT
93267|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage medium
93268|NCT01336738|Drug|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
96947|NCT01345175|Drug|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
96948|NCT01345175|Drug|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
96949|NCT01345188|Drug|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
96950|NCT01345188|Drug|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
96951|NCT01345201|Biological|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
96952|NCT01345214|Drug|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
96953|NCT01345227|Procedure|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
96954|NCT01345240|Biological|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
96955|NCT00057941|Other|laboratory biomarker analysis|Correlative studies
96956|NCT01345240|Biological|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
96957|NCT01345240|Biological|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
96958|NCT01345240|Biological|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
97202|NCT01345526|Device|Reconval Cream|
94031|NCT01327703|Drug|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
94032|NCT01327703|Drug|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
94033|NCT01327729|Drug|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
94034|NCT01327742|Device|Relay Thoracic Stent-Graft|Device implant
94035|NCT00056225|Drug|Vitamin B6|
94036|NCT01327755|Dietary Supplement|Selenium|Selenium yeast containing selenomethionine 200 mcg per day for 2 years
94037|NCT01327755|Other|Placebo|Same number of pills, frequency, and duration as selenium intervention.
94038|NCT01327768|Procedure|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
94039|NCT01327781|Other|Laboratory Biomarker Analysis|Correlative studies
94040|NCT01327781|Other|Pharmacological Study|Correlative studies
94041|NCT01327781|Other|Questionnaire Administration|Ancillary studies
94042|NCT01327781|Drug|Z-Endoxifen Hydrochloride|Given PO
94043|NCT01327794|Genetic|polymorphism analysis|
94044|NCT01327794|Other|immunologic technique|
94045|NCT01327794|Other|laboratory biomarker analysis|
93123|NCT01338883|Drug|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
93124|NCT01338883|Drug|Sustiva + Truvada|Sustiva plus Truvada
93125|NCT01338896|Drug|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
93126|NCT01338909|Drug|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
93503|NCT01334658|Procedure|Phacoemulsification cataract surgery|A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
93504|NCT00056992|Drug|ADI-PEG 20|
93505|NCT01334658|Drug|Glucose-bicarbonate-Ringer Lactate (GBRL)|A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
93789|NCT01330355|Drug|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
93790|NCT01330355|Drug|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
93791|NCT00056459|Drug|Vatalanib|
93792|NCT01330381|Drug|prucalopride|prucalopride
subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml
subjects with weight >50 kg: prucalopride 2 mg tablet once daily
93793|NCT01330381|Drug|Placebo|Matching oral solution or oral tablets given once daily
93794|NCT01330381|Drug|PEG 4000|
93795|NCT01330394|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
93796|NCT01330407|Procedure|cryopreserved skin allografts.|
93797|NCT01330407|Procedure|Cultured Epidermal Autografts|
93798|NCT01330420|Behavioral|Relaxation Response Resiliency Program for Depression|The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:
Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.
Examination and reversal of negative thought patterns.
Physical movement, including stretching and yoga.
Healthy eating and other positive lifestyle behaviors.
Goal setting.
93799|NCT01330433|Device|CoSeal Surgical Spray Group|A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.
The dose regimen is as follows:
Patients weighing < 3kg will receive 1ml of CoSeal
Patients weighing 3-10kg will receive 1-2ml of CoSeal
Patients weighing >10kg will receive 2-4ml of CoSeal
93800|NCT01330446|Drug|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
93269|NCT01336738|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
93270|NCT00057200|Procedure|Telephone, videophone care|
93271|NCT01336751|Drug|Insulin glargine|solution for subcutaneous injection
93272|NCT01336751|Drug|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
93273|NCT01336764|Behavioral|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
93274|NCT01336764|Behavioral|Control|Unguided listening to radio/music.
93275|NCT01336803|Drug|Feraheme|5 mg Fe/kg iv
93276|NCT01336803|Procedure|MR Scan|Standard of Care
93277|NCT01336816|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
93278|NCT01336816|Other|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
93279|NCT01336829|Drug|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
93280|NCT01336829|Drug|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
93566|NCT01339520|Behavioral|Control|Standard of care for diabetes subjects
93567|NCT00057759|Drug|sildenafil citrate|
93568|NCT01341899|Procedure|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
93569|NCT01341912|Biological|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
93570|NCT01341925|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
97203|NCT01345539|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, adrenal, and liver sites were being treated, both lung sites could be treated Monday, Wednesday, and Friday, the liver on Tuesday, Thursday and the following Tuesday, and the adrenal on Monday, Wednesday, Friday of the second week.
97204|NCT01345552|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
97205|NCT01345565|Drug|human hepatocytes|The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.
We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant.
97206|NCT01345578|Drug|human hepatocyte transplantation|Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.
The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.
If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation.
97207|NCT01345578|Radiation|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
97208|NCT00057954|Drug|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
97209|NCT01347970|Other|pharmacogenomic studies|Correlative studies
97210|NCT01347970|Other|laboratory biomarker analysis|Correlative studies
97211|NCT01347970|Procedure|quality-of-life assessment|Ancillary studies
97212|NCT01347970|Genetic|polymorphism analysis|Correlative studies
97213|NCT01347970|Genetic|microarray analysis|Correlative studies
97214|NCT01347970|Genetic|polymerase chain reaction|Correlative studies
93127|NCT01338909|Drug|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
93128|NCT01338922|Other|Insulin Pump Therapy|Continuous subcutaneous insulin infusion therapy
93129|NCT01338922|Other|Multiple daily injection therapy (usual care)|Multiple daily injection therapy
93130|NCT01338935|Drug|CW 002|For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.
For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.
For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage *.
For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.
*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1).
93131|NCT01338935|Drug|CW 002|Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.
Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002
Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002
Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002
Bolus doses of ED95 are determined in Part I of the study.
93132|NCT01341132|Procedure|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
93133|NCT01341145|Behavioral|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
93134|NCT01341145|Behavioral|Relaxation|12-week progressive muscle relaxation program (active control)
93135|NCT01341158|Drug|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
93136|NCT01341184|Drug|Rifabutin|Rifabutin 300 mg orally on days 20-41
93137|NCT01341184|Drug|Rifampin|Rifampin 600 mg orally on days 20-41
93138|NCT01341184|Drug|TMC207|TMC207 400 mg orally on days 1 and 29
93139|NCT00057681|Drug|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
93140|NCT01341197|Other|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
93438|NCT01334619|Procedure|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
93801|NCT01330446|Other|Placebo|1 by mouth every morning for a 28 day cycle.
93802|NCT00056472|Drug|Olanzapine|10-20mg/day
93803|NCT01332890|Other|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
93804|NCT01332890|Other|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
93805|NCT01332903|Drug|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
93806|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
93807|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
93808|NCT00056797|Drug|Interleukin-2|
94103|NCT00055978|Other|placebo|Given orally
94104|NCT01325376|Behavioral|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
94105|NCT01325389|Dietary Supplement|Myo-Mel|
94106|NCT01325389|Dietary Supplement|Placebo|
94107|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
94108|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
94109|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
94110|NCT01325415|Drug|NKTR-118|25 mg tablet
94111|NCT01325415|Drug|moxifloxacin|400 mg tablet
94112|NCT01325415|Drug|Placebo|tablet
94113|NCT01325428|Drug|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
94114|NCT00001057|Drug|Didanosine|
94115|NCT00055991|Drug|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
93571|NCT01341925|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
93572|NCT01341925|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
93573|NCT01341938|Drug|Commit® nicotine lozenges (4 mg).|Participants will be provided with instructions on the proper use of the lozenge and instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day.
93574|NCT01341938|Behavioral|Phone Counseling|Three phone counseling sessions to assist in cessation from use of all tobacco.
93575|NCT01341938|Behavioral|Self-help materials|Participants receive the "Enough Snuff" video and printed guide providing strategies for tobacco cessation.
93576|NCT01341951|Drug|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
93577|NCT01341964|Drug|Clopidogrel|600mg (2 pills)
93578|NCT00057759|Other|Placebo|Placebo
93579|NCT01341964|Drug|Aspirin|325mg (1 pill)
93580|NCT01341964|Drug|Aspirin|81mg (1 pill)
93581|NCT01341977|Device|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
93582|NCT01341977|Device|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
93865|NCT01327521|Drug|Epirubicin|Standard of Care
93866|NCT01327521|Drug|5-fluorouracil|Standard of Care
93867|NCT01327521|Drug|Mitomycin C|Standard of Care
93868|NCT01327521|Drug|Gemcitabine|Standard of Care
93869|NCT00056212|Behavioral|Yoga|
93870|NCT01330446|Behavioral|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
93871|NCT01330459|Drug|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
97551|NCT01343888|Drug|BI 201335|BI 201335 once daily low dose
97552|NCT01346098|Procedure|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
97553|NCT01346098|Procedure|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
97554|NCT01346124|Radiation|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
97555|NCT01346137|Drug|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
97556|NCT01346163|Drug|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
97557|NCT01346163|Other|Placebo|Placebo will be used as a comparator to the active arm.
97558|NCT01346176|Other|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
97559|NCT00057993|Drug|exemestane|
97560|NCT01346189|Behavioral|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
97561|NCT01346215|Biological|heparin sodium|5000 UI/mL
97562|NCT01346215|Biological|heparin sodium|5000 UI/mL
97563|NCT01346228|Behavioral|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
97564|NCT01346241|Behavioral|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
97565|NCT01346254|Drug|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
97566|NCT01346254|Drug|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
93439|NCT01334632|Procedure|Continuous interscalene block|The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
93440|NCT01334632|Procedure|PCA morphine|Postoperative with iv self-administration of morphine
93441|NCT01334645|Other|Copeptin|Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.
Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.
Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.
The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected
93442|NCT01337011|Other|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
93443|NCT01337037|Device|VATS lobectomy using modified equipments|the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.
Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep.
93444|NCT01337037|Procedure|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
93445|NCT01337037|Procedure|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
93446|NCT00057278|Drug|gabapentin|
93447|NCT01337037|Procedure|Open lobectomy|standard lobectomy procedure by thoracotomy approach
93448|NCT01337050|Drug|PF-03446962|PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
93449|NCT01337063|Other|Mentored medication reconciliation quality improvement|Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of "best practice" guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls.
94116|NCT01325428|Drug|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
94117|NCT01325441|Drug|BBI608|
94118|NCT01325441|Drug|Paclitaxel|
94119|NCT01327859|Drug|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
94120|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
94121|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
94122|NCT01327872|Drug|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
94123|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
94124|NCT00001058|Drug|Ethambutol hydrochloride|
94125|NCT00056238|Drug|NC-758 (Anti amyloidotic [Aß] agent)|
93202|NCT01338935|Drug|CW 002|In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.
Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.
Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus.
93203|NCT00057473|Drug|irinotecan|Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.
93204|NCT01338948|Procedure|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
93205|NCT01338961|Procedure|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
93206|NCT01338974|Genetic|gene expression analysis|
93207|NCT01338974|Genetic|proteomic profiling|
93208|NCT01338974|Other|flow cytometry|
93209|NCT01338974|Other|laboratory biomarker analysis|
93210|NCT01338987|Procedure|Allogeneic HSC Transplantation|Allogeneic HSC Transplantation
93872|NCT01330459|Drug|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
93873|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
93874|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
93875|NCT01330485|Behavioral|ART|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
93876|NCT01330485|Behavioral|CFT-C|The CFT-C is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
93877|NCT01330485|Behavioral|i-CBT-D (individual cognitive therapy for depression)|Individual cognitive therapy for depression (iCBT-D) will cover a 4-month period with 16 (weekly) sessions (à 50 minutes) in total. Treatment will follow a manualized protocol that is based upon procedures developed by Hautzinger (2003) and that includes: (1) psychoeducation on depression, introducing the CBT-based treatment rationale; (2) behavioral activation; (3) cognitive restructuring, training of social skills, stress reduction and relapse prevention.
93878|NCT01330524|Drug|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
93879|NCT01330524|Other|placebo|2mg placebo
93880|NCT00056472|Drug|Sertraline|150-200mg/day
93881|NCT01330550|Dietary Supplement|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
93882|NCT01330563|Drug|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
93883|NCT01330576|Procedure|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
93884|NCT01330576|Procedure|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
93885|NCT01330589|Drug|Placebo|Non-active placebo for 7 days: PO/TID
93886|NCT01330589|Drug|St. Johns Wort|For 7 days: 300mg PO/TID
94188|NCT01333527|Procedure|Sling|Patients will use the sling for 6 weeks, as per usual care
94189|NCT01333540|Drug|TD-1211|Escalating doses
94190|NCT01333540|Drug|Placebo|Placebo once daily
94191|NCT00056940|Behavioral|Stages of Change|
94192|NCT01333553|Device|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
97567|NCT01346254|Behavioral|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
96682|NCT01351740|Drug|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
96683|NCT01351753|Drug|Metformin|
96684|NCT01351753|Drug|Orlistat|
96685|NCT00058461|Drug|ifosfamide|Given IV
96686|NCT01351753|Drug|Topiramate|
96687|NCT01351753|Drug|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
96688|NCT01351766|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
96689|NCT01351792|Drug|Foster® 100/6 µg/unit dose|Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).
96690|NCT01351792|Drug|Symbicort® Turbohaler® 200/6 μg/actuation|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
96691|NCT01351805|Drug|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
96692|NCT01351805|Dietary Supplement|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
96693|NCT01351805|Other|placebo pill|placebo
96694|NCT01351818|Drug|Growth Hormone|
96695|NCT01351831|Other|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
96696|NCT00058461|Drug|etoposide|Given IV
96697|NCT01351831|Other|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
96698|NCT00057915|Biological|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
96699|NCT01344694|Other|patient with liver fat|30 patient with liver fat
93741|NCT01339845|Behavioral|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
93742|NCT01339858|Drug|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
93743|NCT01339858|Other|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
93744|NCT01342172|Drug|Lenalidomide|Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least "stable disease" will proceed with "maintenance" lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression.
93745|NCT00057785|Radiation|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume [CTV] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
93746|NCT01342185|Device|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
93747|NCT01342185|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
93748|NCT01342185|Drug|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
93749|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
93750|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
93751|NCT01342198|Drug|erythromycin|A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
93752|NCT01342211|Biological|Placebo|Intravenous placebo monthly during treatment phase.
93211|NCT01338987|Drug|Lupron|Lupron: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients & lt; 18 years) between day -13 and day -20 pre-HSCT but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients & gt; 18 years and as a 3 month injection (adult preparation) for patients & lt; 18 years
93212|NCT01338987|Drug|18F FLT|18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days)
93213|NCT01338987|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg IV on days -4 and -3 (for Adults & gt; 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric & lt; /= 22 years)
93214|NCT00057486|Drug|IL-12|
93215|NCT01338987|Drug|Methotrexate|Methotrexate:10 mg/m2 IV on day +1, and 5 mg/m2 IV Days + 3, 6, 11
93216|NCT01338987|Drug|Tacrolimus|Tacrolimus:0.02 mg/kg/day CIV on day -1.
93217|NCT01338987|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
93218|NCT01339000|Drug|Glycosylated Recombinant Human Interleukin-7|CYT 107 20 microgram/kg / dose, by IM injection
93219|NCT01339000|Biological|Diphtheris/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
93220|NCT01339000|Biological|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
93221|NCT01339000|Biological|Pneumaococcal Vaccine|Pneumaococcal Vaccine will be administered according to the randomization schedule per protocol.
93506|NCT01334658|Drug|Balanced Salt Solution (BSS®)|A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
93507|NCT01334671|Drug|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
93508|NCT01334684|Drug|Metformin|Metformin, pills, 850 mg three times a day for three months
93509|NCT01334697|Drug|recombinant human cardiotrophin-1|Single dose intravenous administration
93510|NCT01334697|Other|Placebo|Single dose intravenous administration
93511|NCT01334710|Drug|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
94193|NCT01325454|Device|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
94194|NCT01325480|Device|Cardiac Pacing|
94195|NCT01325493|Drug|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
94196|NCT01325493|Drug|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
94197|NCT01325506|Other|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
94198|NCT01325519|Other|video decision aid|video
94199|NCT01325532|Device|Cranial Electrical Stimulation via FW-100 Fisher Wallace Cranial Stimulator|CES current - 100Hz, symmetrical rectangular biphasic, 20% duty cycle current for 20-minutes, 5 days/week for 3 weeks.
94200|NCT00056004|Drug|zileuton|
94201|NCT01325532|Device|CES Sham via FW-100 Fisher Wallace Cranial Stimulator|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
94202|NCT01325545|Other|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
94203|NCT01325558|Biological|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
94204|NCT01325571|Drug|Tacrolimus capsule|oral
94205|NCT01325571|Drug|Placebo|oral
97181|NCT01352364|Other|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
97182|NCT00058474|Drug|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
97183|NCT01352390|Behavioral|Planning Prompt|A prompt to have their child their health test reminder mailing to color
97184|NCT01352390|Behavioral|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
96700|NCT01344694|Other|pts. with excess of visceral fat|pts. with excess of visceral fat
96701|NCT01344694|Other|control|30 control subjects
96702|NCT01344707|Drug|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
96959|NCT01345240|Biological|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
96960|NCT01345240|Biological|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
96961|NCT01345240|Biological|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
96962|NCT01345240|Biological|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
96963|NCT01345253|Drug|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
96964|NCT01347619|Other|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
96965|NCT01347619|Other|Toolkit, Periodic Audit/Feedback, Educational Messages|Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a "Medicaid Utilization Report" developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis.
96966|NCT01347619|Other|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
96967|NCT01347632|Drug|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
96968|NCT00058123|Drug|poly ICLC|
96969|NCT01347645|Drug|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
93753|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
93754|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
94046|NCT00056225|Drug|Vitamin B12|
94047|NCT01327794|Other|medical chart review|
94048|NCT01327846|Drug|Canakinumab|
94049|NCT01327846|Drug|Placebo|
94050|NCT01327859|Drug|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
94051|NCT01327859|Drug|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
94052|NCT01330849|Behavioral|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
94053|NCT00056498|Drug|Placebo|Placebo capsule daily for 16 weeks
94054|NCT01330849|Other|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
94055|NCT01330875|Other|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
94056|NCT01330901|Drug|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
94057|NCT01330927|Drug|VA106483|Once daily oral dose of placebo for 2 nights
Once daily oral dose of 0.5 mg VA106483 for 2 nights
Once daily oral dose of 1 mg VA106483 for 2 nights
Once daily oral dose of 2 mg VA106483 for 2 nights
Once daily oral dose of 4 mg VA106483 for 2 nights
Placebo: as above
94058|NCT01330940|Dietary Supplement|Orange soda|32 ounces per day
94059|NCT01330953|Drug|Placebo|Administered intravenously
94060|NCT01330953|Drug|LY2928057|Administered intravenously
94061|NCT01330966|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
94062|NCT01330979|Drug|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
94063|NCT01330992|Other|Ocular light or darkness exposure|Ocular light or darkness exposure
93512|NCT01334723|Drug|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
93513|NCT01334723|Drug|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
93514|NCT01334736|Behavioral|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
93515|NCT00057005|Drug|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
93516|NCT01337128|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
93517|NCT00057291|Behavioral|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
93518|NCT01337128|Procedure|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
93519|NCT01337128|Procedure|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
93520|NCT01337128|Procedure|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
93521|NCT01337128|Procedure|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
93809|NCT01332929|Drug|Bevacizumab|5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.
For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.
For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week.
93810|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
93811|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
93812|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
93813|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
97185|NCT01352403|Procedure|gastric bypass|
97186|NCT01352403|Behavioral|intensive life style intervention|
97187|NCT01352416|Other|Atrial fibrillation|Once patient is in atrial fibrillation, the study drug is still continued. Patients will also be treated with standard drug therapy that their doctor chooses
97188|NCT01352416|Other|Atrial fibrillation|Once the patient goes into atrial fibrillation, the study drug is still continued. Patient will also be treated with standard drug therapy that their doctor chooses
97189|NCT01352429|Radiation|Proton Therapy|
97190|NCT01352429|Radiation|IMRT|
97191|NCT01352442|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
97192|NCT01352455|Procedure|Hemodialysis|5 days per week hemodialysis
97193|NCT00058474|Drug|fluorouracil|225 mg/m2 IV daily continuous infusion
97194|NCT01352468|Other|Multifaceted cognitive training|Four computerized training tasks
97195|NCT01352481|Other|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
97196|NCT01352494|Drug|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
97197|NCT00057954|Procedure|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10^6 CD34/kg
97198|NCT01345500|Other|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
97199|NCT01345500|Other|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
97200|NCT01345513|Other|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
97201|NCT01345526|Device|Reconval K1 Cream|
97452|NCT00057837|Biological|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery > 10,000 dL.
97453|NCT01343745|Drug|Placebo|pressurised metered dose inhaler
96970|NCT01347645|Drug|E7820|Test product: dose and mode of administration:
E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.
The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle).
96971|NCT01347658|Dietary Supplement|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
96972|NCT01347671|Drug|GRT6005|25µg/day once daily
97215|NCT01347970|Other|enzyme-linked immunosorbent assay|Correlative studies
97216|NCT01347970|Other|questionnaire administration|Ancillary studies
97217|NCT00058201|Drug|fluorouracil|Given IV
97218|NCT01347983|Drug|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
97219|NCT01347996|Drug|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg [16,400 IU/kg] body weight twice daily for 10, 21 day cycles
97220|NCT01348009|Drug|Tesetaxel-capecitabine-cisplatin|Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.
Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.
97221|NCT01348048|Other|Specialised palliative care (SPC)|The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
97222|NCT01348074|Drug|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
97223|NCT01348087|Drug|AFQ056|
97224|NCT01348100|Drug|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
97225|NCT01348100|Drug|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
97226|NCT01348100|Drug|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
97227|NCT01348113|Other|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
94064|NCT00056498|Drug|Risperdal|Risperdal 4 mg per day for 16 weeks
94065|NCT01331005|Drug|nepafenac 0.1% drops|One drop three times per day for one year
94066|NCT01331005|Other|Nepafenac Vehicle|Placebo
94067|NCT01331018|Procedure|Harvest Procedure|Undergo bone marrow harvest
93141|NCT01341236|Other|different nutrional regimen|compare bolus versus intermittent nutrition
93142|NCT01341236|Other|comparison of different feeding regimens|compare intermittent versus bolus nutrition
93143|NCT01341249|Drug|Experimental DW224aa|DW224aa tablet, single dose
93144|NCT01341249|Drug|Experimental DW224a|DW224a capsule, single dose
93145|NCT01341262|Drug|Thalidomide|INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)
AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200
AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200
93146|NCT01341262|Drug|Dexamethasone|INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)
AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)
AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)
93147|NCT01341262|Drug|Zoledronic acid|INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)
AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)
AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)
93148|NCT01341262|Drug|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
93149|NCT01341262|Drug|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
93150|NCT00057707|Drug|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
93151|NCT01341275|Biological|hepatitis B vaccine|10 ug dose, one-time administration
93152|NCT01341275|Biological|hepatitis B vaccine|20 ug dose, one-time administration
93153|NCT01341301|Radiation|Total Body Irradiation|Undergo TBI
93154|NCT01341301|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
93155|NCT01341301|Drug|Cyclophosphamide|Given IV
93156|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
93814|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
93815|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
93816|NCT01332955|Drug|Telaprevir|Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir
Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz
93817|NCT01332955|Biological|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
93818|NCT01332955|Drug|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
93819|NCT00001059|Drug|Vincristine sulfate|
93820|NCT00056810|Drug|4-aminopyridine (4-AP)|
93821|NCT01332968|Drug|RO5072759|1000 mg iv on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-8 (21-day cycles) or Cycles 2-6 (28-day cycles); followed by 1000 mg iv every 2 months in responders until disease progression, for up to 2 years
93822|NCT01332968|Drug|chemotherapy|CHOP (6 cycles of 21 days), CVP (8 cycles of 21 days), Bendamustine (6 cycles of 28 days). Patients with follicular lymphoma are receiving either CHOP, CVP or Bendamustine as background chemotherapy as selected by each participating site at study start. Background chemotherapy for patients with non-follicular lymphoma will be chosen by the site individually for each patient.
93823|NCT00055926|Drug|CP-724,714|
93824|NCT01324843|Procedure|Present Pain Intensity|
93825|NCT01324843|Procedure|McGill Pain Questionnaire|
93826|NCT01324843|Procedure|Skin Assessment|
94126|NCT01327885|Drug|Eribulin mesylate 1.4 mg/m2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
94127|NCT01327885|Drug|Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV|Administration of dacarbazine at a dose of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 selected by the PI or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
94128|NCT01327898|Behavioral|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
94129|NCT01327898|Behavioral|individual resilience counseling|one individual resilience counseling session
94130|NCT01327911|Biological|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
97454|NCT01343758|Other|5% dextrose in normal saline|Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
97455|NCT01343771|Drug|DHEA (Prasterone) + ERT (Aviane)|Micronized oral DHEA in a dose of 50 mg daily + ERT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse, 20 mcg ethinyl estradiol + 0.1 mg levonorgestrel for 9 months)
97456|NCT01343771|Other|Placebo|A placebo tablet will be developed by the Children's Hospital Pharmacy. Both treatments (DHEA+ERT and placebo) will be administered in a gelatin capsule.
97457|NCT01343784|Other|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
97458|NCT01345864|Drug|Scopolamine + Donepezil 10mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
97459|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
97460|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 15 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
97461|NCT01345877|Procedure|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
97462|NCT01345890|Procedure|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
97463|NCT01345903|Procedure|therapeutic conventional surgery|Undergo robotic-assisted surgery
97464|NCT01345916|Drug|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
97465|NCT01345916|Drug|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
97466|NCT00057980|Drug|epirubicin hydrochloride|
97467|NCT01345916|Drug|BDP DPI 2 months|BDP DPI 2 months
97468|NCT01345929|Drug|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
97469|NCT01345929|Drug|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
97470|NCT01345942|Drug|RO5428029|Single oral dose
97471|NCT01345968|Drug|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
97472|NCT01345968|Drug|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
97792|NCT00057863|Drug|Paclitaxel|Given IV
97228|NCT00058201|Drug|gemcitabine hydrochloride|Given IV
97229|NCT01348126|Drug|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
97230|NCT01348126|Drug|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
97231|NCT01350349|Behavioral|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
97232|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
97568|NCT01346267|Procedure|Real Acupressure Band|Acupressure wristband
97569|NCT01346267|Procedure|Placebo Acupressure Band|Sham wristband
97570|NCT00058006|Drug|celecoxib|
97571|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
97572|NCT01348685|Other|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
97573|NCT01348685|Other|The effect of solid vs. liquid forms of whey protein on food intake|
97574|NCT01348724|Drug|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
97575|NCT00058227|Biological|rituximab|Given IV
97576|NCT01348737|Drug|AZD3839|Single Oral Dose
97577|NCT01348737|Drug|AZD3839 Placebo|Single Oral Dose
97578|NCT01348750|Other|Healing Touch & Guided Imagery|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.
HT complements traditional health care and is used together with other approaches to health and healing.
Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing.
97579|NCT01348763|Drug|Maraviroc|Maraviroc 150 mg daily
97580|NCT01348776|Device|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
97581|NCT01348789|Device|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
93157|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
93158|NCT01343212|Other|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
93159|NCT01343225|Drug|atripla|once a day
93160|NCT01343225|Drug|darunavir ritonavir raltegravir|as directed
93161|NCT01343238|Behavioral|Diet|12 week diet behavior modification
93162|NCT01343238|Behavioral|Exercise|12 week exercise behavioral intervention
93450|NCT01337076|Device|cochlear implant|Cochlear implant surgery
93451|NCT01337089|Drug|Sativex®|Sativex® oromucosal spray administered orally with a spray into cheek
93452|NCT01337102|Procedure|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
93453|NCT01337102|Procedure|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
93454|NCT01337115|Procedure|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
93455|NCT01337115|Procedure|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
93456|NCT01339221|Procedure|Stool samples|Stool samples collected and checked for the presence of rotavirus
93457|NCT01339234|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
93458|NCT01339247|Drug|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
93459|NCT01339247|Drug|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
93460|NCT01339260|Drug|Netupitant and Palonosetron|
93461|NCT01339260|Drug|Palonosetron|
94131|NCT01327924|Drug|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
94132|NCT01327937|Device|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
94133|NCT01327937|Other|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
94134|NCT01327963|Device|Transoral Incisionless Fundoplication (EsophyX)|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following the standardized TIF2 protocol.
94135|NCT01327976|Device|Active, implantable, intra abdominal vagal blocking medical device (Maestro RC2 System)|Active device will deliver VBLOC Therapy
94136|NCT00056251|Procedure|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
94137|NCT01327976|Device|Active, implantable, intra abdominal vagal blocking medical device (Maestro RC2 System)|Control device will deliver no VBLOC Therapy
94138|NCT01328002|Drug|Milnacipran|Maximum tolerated dose (50, 75, or 100 mg/day tablets) determined at start of study; for 8 weeks
94139|NCT01328002|Drug|Placebo|matching placebo tablets daily
94140|NCT01328015|Drug|Oxybutynin 5 mg pills|½ pill oral 12/12h for 3 days
01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks.
94141|NCT01328028|Other|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
94142|NCT00056511|Drug|Fresh garlic or garlic supplements|
94143|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
94144|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
94145|NCT01331083|Drug|PX-866|PX-866: 8mg orally taken daily
93222|NCT01339000|Biological|Hepatitis A Vaccine|Hepatitus A Vaccine will be administered according to the randomization schedule per protocol.
93223|NCT01339000|Biological|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
93224|NCT01339013|Device|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
93225|NCT01341301|Drug|Tacrolimus|Given IV or PO
97793|NCT01344226|Drug|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
97794|NCT01344239|Procedure|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
97795|NCT01344252|Drug|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
97796|NCT01344278|Behavioral|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
97797|NCT01344291|Drug|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
97798|NCT01344304|Drug|Aprepitant / Fosaprepitant|Aprepitant:
125 mg PO on day 1 80 mg PO on days 2 to 3
Fosaprepitant:
150 mg IV on day 1
97799|NCT01344343|Other|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
97800|NCT01344356|Radiation|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
97801|NCT01344356|Radiation|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
97802|NCT01344369|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
97803|NCT00057863|Drug|Oxaliplatin|Given IV
97804|NCT01344369|Drug|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
97805|NCT00058032|Procedure|annual screening|
97806|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
97807|NCT01346722|Other|Diet- CR|conventional rice-based diet
97808|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
97809|NCT01346722|Other|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
97810|NCT01346735|Other|No intervention|
97811|NCT01346748|Drug|statin|Sinvastatin 80 mg per day - 21 days versus placebo
97812|NCT01346761|Behavioral|BRCA1/BRCA2 Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor either over the telephone or in-person. Counseling sessions will be audiotaped for quality control of intervention.
97582|NCT01348802|Behavioral|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
97583|NCT01348802|Behavioral|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
97584|NCT01348828|Device|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
97585|NCT01348841|Other|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
97586|NCT00058227|Other|pharmacological study|Correlative studies
97587|NCT01348854|Device|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
96703|NCT01344720|Drug|etoricoxib|At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become "non-responders" between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered "non-responders" and will be randomized to receive either titration of their monotherapy or combination treatment.
Group 1 "non-responders" will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die.
96704|NCT01344720|Drug|oxycodone|At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become "non-responders" between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered "non-responders" and will be randomized to receive either titration of their monotherapy or combination treatment.
Group 2 "non-responders" will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy).
96705|NCT01344759|Drug|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
96706|NCT01344759|Drug|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
96707|NCT01344772|Procedure|Internal fixation|Two cannulated screws are placed under x-ray guidance
96708|NCT01344772|Procedure|Total hip arthroplasty|A total hip arthroplasty is performed through a standard posterior approach
96709|NCT00057928|Drug|cisplatin|
96710|NCT01344785|Procedure|Intramedullary nailing|All patients will be treated with Intramedullary nailing
93462|NCT01339260|Drug|Dexamethasone|
93463|NCT01339273|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
93464|NCT01339273|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
93465|NCT01339286|Drug|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
93466|NCT00057525|Biological|Alhdryogel or PBS|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
93755|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
93756|NCT00057798|Drug|gemcitabine hydrochloride|
93757|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
93758|NCT01342224|Biological|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment. Tadalafil is taken by mouth daily from the start of therapy to completion of therapy with doses held only in preparation for surgery.
93759|NCT01342237|Drug|HDCT 1(TTC), HDCT2(MEC)|TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)
MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)
93760|NCT01342250|Biological|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
93761|NCT01335087|Device|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
93762|NCT01335126|Other|Emulsion type artificial tear|2 types of artificial tears
93763|NCT00057005|Drug|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
93226|NCT01341301|Drug|Mycophenolate mofetil|Given IV or PO
93227|NCT01341301|Procedure|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
93228|NCT01341301|Other|Laboratory biomarker analysis|Correlative studies
93229|NCT01341340|Device|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
93230|NCT00057707|Procedure|Functional MRI|
93231|NCT01341353|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
93232|NCT01341353|Drug|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
93233|NCT01341366|Other|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
93234|NCT01341366|Other|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
93235|NCT01341379|Drug|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
93236|NCT01341392|Drug|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
93237|NCT01341392|Drug|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
93238|NCT01341392|Drug|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
93239|NCT01341405|Drug|CG100649|capsule, 2 mg, once daily for 28 days
93240|NCT01341405|Drug|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
93241|NCT00057707|Procedure|Neuropsychological Testing|
93242|NCT01341405|Drug|CG100649|capsule, 4 mg, once daily for 28 days
93522|NCT01337128|Procedure|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
93523|NCT01337141|Other|Control|7 face-to-face visits.
97813|NCT01346774|Drug|Cranberry powder capsules|2 cranberry powder capsules twice a day
96909|NCT01350024|Procedure|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
96910|NCT01350024|Procedure|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
96911|NCT00058305|Drug|vincristine sulfate|Given IV
96912|NCT01350037|Drug|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
96913|NCT01350037|Drug|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
96914|NCT01350050|Drug|articaine|Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.
In dentistry, articaine is used both for infiltration and block injections.
96915|NCT01350050|Other|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
96916|NCT01350063|Drug|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
96917|NCT01350063|Device|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
96918|NCT01350063|Other|No intervention|
96919|NCT01350076|Drug|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
96920|NCT01350076|Drug|restricted fluid regimen|Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).
Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index
96921|NCT01350089|Drug|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
96922|NCT00001072|Biological|rgp120/HIV-1 SF-2|
96711|NCT01344798|Biological|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
96712|NCT01344811|Procedure|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
96713|NCT01344811|Other|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
96714|NCT01344824|Biological|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
96715|NCT01344824|Drug|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
96716|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
96717|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
96973|NCT01347671|Drug|GRT6005|75 µg/day once daily
96974|NCT01347671|Drug|GRT6005|200 µg/day once daily
96975|NCT01347671|Drug|Matching Placebo|Once daily
96976|NCT01347684|Behavioral|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
96977|NCT01347684|Drug|Standard care using current drugs|Standard Drug therapy
96978|NCT01347697|Procedure|Reconstruction with an acellular porcine collagen implant|Reconstruction of floor of lesser pelvis with an acellular porcine collagen implant after extended excision of rectum including levator muscles in advanced low rectal cancer.
96979|NCT00058149|Drug|gemcitabine hydrochloride|
96980|NCT01347697|Procedure|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
96981|NCT01350089|Drug|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
96982|NCT01350089|Drug|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
93764|NCT01335139|Biological|Grazax|
93765|NCT01335139|Biological|Alutard SQ|
93766|NCT01335139|Other|Placebo|
93767|NCT01335152|Behavioral|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
93768|NCT01335165|Drug|ALXN1102|Single Ascending Dose IV
93769|NCT01335165|Drug|ALXN1103|Single Ascending Dose IV or SC
93770|NCT01335178|Behavioral|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project [parents.org.il];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
93771|NCT01335191|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
94068|NCT01331018|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
94069|NCT01331018|Other|Laboratory Biomarker Analysis|Correlative studies
94070|NCT01331044|Dietary Supplement|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered ~ 125 kcal/kg in 1st 24 hours, ~ 150 kcal/kg in 2nd 24 hours, then~200k cal/kg by the third day).
94071|NCT01331044|Dietary Supplement|Khichuri and Halwa|Day 1: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day 125kcal/kg.day
Day 2: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 150kcal/kg.day
Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 175kcal/kg.day
Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 3 feed per day & khichuri 10gm/kg; 3 feed per day 200kcal/kg.day
Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) & halwa 20gm/kg; 3 feed per day & khichuri 20gm/kg; 3 feed per day 200kcal/kg.day
94072|NCT01331057|Other|NEEL test|An assessment for children in French with items extracted from the NEEL test
94073|NCT01331057|Other|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
94074|NCT01331057|Other|Interview|For parents of children include in the study: A semi -structured interview
94075|NCT01333189|Other|Weight-bearing biofeedback exercise|Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.
Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games.
93524|NCT01337141|Device|Telecare system|5 telematic visits and 2 face-to-face visits.
93525|NCT01337154|Drug|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
93526|NCT01337154|Drug|Placebo|Tablets, orally, daily
93527|NCT01337167|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
93528|NCT00057304|Drug|Insulin sensitizer|
93529|NCT01337167|Biological|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
93530|NCT01337167|Biological|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
93531|NCT01337167|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
93532|NCT01337167|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
93533|NCT01337167|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
93534|NCT01337167|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
93535|NCT01337167|Biological|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
93536|NCT01337193|Other|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
93537|NCT01337193|Other|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
93538|NCT01337206|Device|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
93539|NCT00057317|Drug|Ro 205-2349|
93540|NCT01337206|Procedure|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
93541|NCT01337219|Drug|Tobramycin|
93542|NCT01339338|Procedure|warming the contrast media|warm the contrast media with 37℃ water-bathing
93543|NCT01339351|Behavioral|Therapeutic Group by Teleconference|10 sessions
93544|NCT01339364|Other|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
96923|NCT00058305|Other|laboratory biomarker analysis|Correlative studies
96924|NCT01350089|Drug|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
97473|NCT01345981|Drug|Lidocaine|dosage 20 mg and 40 mg
97474|NCT01345994|Procedure|electro-acupuncture|acupuncture stimulation with electricity
97475|NCT01346007|Biological|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
97476|NCT01346059|Drug|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
97477|NCT00000254|Drug|40% Nitrous oxide|Used as pain assay positive control
97478|NCT00001068|Drug|Lamivudine|
97479|NCT00057993|Biological|trastuzumab|
97480|NCT01346059|Drug|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
97481|NCT01346072|Drug|tolvaptan|oral, 30 mg, single dose, one time administration
97482|NCT01346085|Drug|CNI free immunosuppression|Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
97483|NCT01348477|Procedure|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
97484|NCT01348490|Drug|Ruxolitinib (INCB018424)|Ruxolitinib (INCB018424), 5 mg bid
97485|NCT01348503|Drug|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
97486|NCT01348503|Drug|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
97487|NCT01348516|Drug|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
97488|NCT01348516|Drug|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
97489|NCT00058227|Drug|alvocidib|Given IV
96983|NCT01350102|Drug|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
96984|NCT01350102|Drug|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
96985|NCT01350102|Procedure|Hemoglobin A1c|Hemoglobin A1c levels will be performed and reviewed every three months to assess its relationship to wound healing
96986|NCT01350102|Dietary Supplement|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
96987|NCT01350115|Drug|LDE225|supplied as 100 mg capsules
96988|NCT01350115|Drug|Placebo|supplied in capsules
96989|NCT01350128|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
96990|NCT00058318|Drug|capecitabine|Capecitabine will be given 625 mg/m^2 (1250 mg/m^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
96991|NCT01350128|Drug|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
96992|NCT01350128|Other|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
96993|NCT01350141|Other|Placebo|An infusion lasting approximately 60 minutes
97233|NCT00058370|Drug|lomustine|
97234|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
97235|NCT01350362|Drug|tideglusib|500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
97236|NCT01350362|Drug|Placebo|Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
97237|NCT01350375|Drug|Botox|
97238|NCT01350375|Drug|Saline|
97239|NCT01350388|Drug|Febuxostat|80 mg/day of febuxostat for 6 months
97240|NCT01350388|Drug|Sugar pill|1 pill a day for 6 months
97241|NCT01350401|Biological|NY-ESO-1|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells
97242|NCT01350414|Device|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
94076|NCT01333189|Other|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
94077|NCT01333202|Other|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
94078|NCT01333228|Other|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
94079|NCT01333241|Behavioral|Lifestyle behavior intervention|6 months of group education and individual teaching and coaching.
94080|NCT01333254|Procedure|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
94081|NCT01333267|Drug|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
94082|NCT01333267|Drug|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
93163|NCT01343238|Behavioral|Diet and Exercise|12 week diet and exercise behavioral modification intervention
93164|NCT01343277|Drug|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
93165|NCT00057811|Biological|filgrastim|Given subcutaneously
93166|NCT01343277|Drug|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
93167|NCT01343290|Drug|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
93168|NCT01343303|Drug|Placebo|Placebo tablet/capsule every 12 hours for 21 days
93169|NCT01343303|Drug|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
93170|NCT01343303|Drug|Naproxen|500 mg capsule every 12 hours for 21 days
93171|NCT01343303|Drug|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
93172|NCT01343316|Device|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
93827|NCT01324856|Procedure|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
93828|NCT01324856|Procedure|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
93829|NCT01324869|Biological|KH902|Intravitreal injection of 0.5mg/eye/time KH902
93830|NCT01324882|Device|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
93831|NCT01324882|Device|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
93832|NCT01324908|Procedure|extracorporeal photopheresis|Undergo ECP
93833|NCT01324908|Other|laboratory biomarker analysis|Correlative studies
93834|NCT00055939|Drug|exatecan mesylate|
93835|NCT01324921|Other|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
93836|NCT01324921|Other|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
93837|NCT01324921|Other|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
93838|NCT01324934|Drug|ATG-Fresenius S|Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.
(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids).
93839|NCT01324947|Drug|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of a 28-day cycle until progressive disease (PD) or unacceptable toxicity
93840|NCT01324960|Drug|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
93841|NCT01324960|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
93842|NCT01324973|Behavioral|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
97490|NCT01348529|Behavioral|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
97491|NCT01348542|Drug|Trazodone|50 mg once a day, for 3 months
97492|NCT01348542|Behavioral|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with consultations held on a weekly basis.
97493|NCT01348555|Drug|Bronchodilatator|
97494|NCT01348555|Drug|Bronchodilatator|
97516|NCT01350921|Drug|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
97517|NCT01350921|Drug|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
97518|NCT01350934|Drug|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
97519|NCT01350934|Drug|Calcitriol|0.25 μg once daily orally
97520|NCT01350934|Dietary Supplement|Calcium 500 mg|one 500 mg tablet once daily
97521|NCT01350947|Drug|5-Azacitidine|Administered on Days 1-7 of each Cycle.
Subcutaneous administration:
To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.
The 5-azacitidine suspension is administered subcutaneously.
Intravenous Administration:
5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.
97522|NCT01350960|Drug|SPC5001|3 weekly SC injections
97523|NCT01350960|Drug|Saline 0.9%|3 weekly SC injections
97524|NCT01350960|Drug|SPC5001|3 weekly SC injections
97525|NCT01350960|Drug|SPC5001|3 weekly SC injections
97526|NCT00058422|Biological|filgrastim|
97527|NCT01350960|Drug|SPC5001|3 weekly SC injections
97528|NCT01350960|Drug|SPC5001|3 weekly SC injections
97529|NCT01350973|Drug|TAK-085|TAK-085 2 g, capsules, orally, once daily for up to 12 weeks.
97530|NCT01350973|Drug|TAK-085|TAK-085, 2 g, capsules, orally, twice daily for up to 12 weeks.
97531|NCT01350973|Drug|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
97243|NCT01350427|Dietary Supplement|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
97244|NCT00058370|Drug|vincristine sulfate|
97245|NCT01350427|Dietary Supplement|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
97246|NCT01350427|Dietary Supplement|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
97247|NCT01350440|Biological|IVIG|Intravenous Immune Globulin
97248|NCT01350453|Behavioral|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
97249|NCT01350453|Behavioral|Standard Care|Participants will receive their usual care from their NHS provider.
97250|NCT01350492|Behavioral|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
97251|NCT01350505|Behavioral|Light exposure|30 minutes of experimental light exposure during the night
97252|NCT01350518|Dietary Supplement|Benefiber|Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.
Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten.
97253|NCT01350518|Dietary Supplement|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
97588|NCT01348867|Other|Structured care led by a nurse consultant|For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:
i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.
ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit.
97589|NCT01348880|Drug|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
97590|NCT01348880|Drug|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
97591|NCT01348893|Behavioral|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
93173|NCT01343329|Drug|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
93174|NCT01343329|Drug|Propranolol prn|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
93175|NCT01343342|Dietary Supplement|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
93176|NCT00057811|Biological|rituximab|Given IV
93177|NCT01343355|Drug|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
93178|NCT01343368|Drug|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
93179|NCT01336634|Drug|Dabrafenib|Dabrafenib study treatment will be provided by GSK as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt).
93180|NCT01336634|Device|Trametinib|Trametinib study treatment will be provided as 0.5 mg and 2 mg tablets. Each tablet will contain 0.5 mg or 2 mg of trametinib parent (present as the DMSO solvate)
93181|NCT01336647|Drug|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
93467|NCT01339299|Drug|recombinant luteinizing hormone (r-LH)|administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
93468|NCT01339299|Drug|recombinant human chorionic gonadotropin (r-hCG)|administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
93469|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
93470|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
93471|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
93472|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
93843|NCT01324986|Procedure|Laparoscopic anti-reflux surgery|
94146|NCT01331109|Drug|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
94147|NCT01331122|Drug|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
94148|NCT01331135|Drug|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
94149|NCT01331148|Drug|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
94150|NCT01331148|Other|Placebo|placebo with daily calcium/Vitamin D soft chews
94151|NCT01331161|Biological|ZOSTAVAX|shingles vaccine, one dose
94152|NCT01331174|Device|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
94153|NCT00056524|Drug|AVP-923|
94154|NCT01331187|Procedure|Pocket-size ultrasonography|Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
94155|NCT01331187|Other|Usual care|No intervention, except for usual care (goal-directed diagnostics)
94156|NCT01331213|Drug|Pregabalin|FDA approved medication (capsules) at 200mg dose.
94157|NCT01331213|Drug|Placebo|Placebo capsules
94158|NCT01331226|Behavioral|telephone counseling 3 sessions|3 sessions of telephone counseling
94159|NCT01331226|Behavioral|telephone counseling 1 session|1 session of telephone counseling
94160|NCT01331226|Behavioral|written materials only|written materials only
94161|NCT01331239|Drug|LCI699|
94162|NCT01331252|Other|semi-recumbent|Patient rests in a semi-recumbent body position
94163|NCT01331252|Other|supine|Patient rests in a supine position
94164|NCT00056537|Drug|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
97532|NCT01350986|Behavioral|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual "Treatment program for children with hyperactive and oppositional problem behavior (THOP)" (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book "Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior" (Döpfner, Schürmann, & Lehmkuhl, 2006).
97533|NCT01343797|Other|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
97814|NCT01346774|Drug|Placebo powder capsules|2 placebo capsules twice a day
97815|NCT01346787|Drug|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
97816|NCT00058045|Biological|aldesleukin|
97817|NCT01346800|Drug|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
97818|NCT01346800|Drug|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
97819|NCT01346826|Drug|Standard 2 hours-infusion|Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7.
97820|NCT01346826|Drug|Accelerated 1 hour-infusion|Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7.
97821|NCT01346826|Drug|Accelerated 30 minutes-infusion|Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5.
97822|NCT01346839|Behavioral|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
97592|NCT01350986|Behavioral|Non-Directive Self-Help Workbook + Counseling Telephone Calls|In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on "Parent effectiveness training" (Gordon, 1970) and "Teaching children self-discipline at home and at school" (Gordon, 1989).
97593|NCT01350999|Drug|TAK-085|TAK-085 2 g, capsules, orally, once daily for up to 52 weeks.
97594|NCT01350999|Drug|TAK-085|TAK-085 2 g, capsules, orally, twice daily for up to 52 weeks.
97595|NCT01350999|Drug|Eicosapentaenoic acid-ethyl|EPA-E 0.6 g, capsules, orally, three-times daily for up to 52 weeks
97596|NCT00058422|Biological|rituximab|
97597|NCT01351012|Other|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
97598|NCT01351012|Other|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
97599|NCT01351012|Other|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
97600|NCT01351012|Other|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
97601|NCT01351012|Other|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
97602|NCT01351025|Drug|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
97603|NCT01351025|Drug|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
97604|NCT01351025|Drug|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
96718|NCT01347229|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
96719|NCT01347242|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
96720|NCT01347255|Drug|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
96721|NCT01347255|Drug|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
96722|NCT01347255|Drug|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
93473|NCT01339325|Procedure|Cholecystectomy|Standard laparoscopic cholecystectomy The first cannula is inserted with an "open laparoscopy" technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.
Laparo-endoscopic single site cholecystectomy
The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an "open laparoscopy" technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips.
93474|NCT01341717|Drug|Sitagliptin|100 mg once daily for 6 months
93475|NCT01341717|Drug|Glimepiride|1 mg/2 mg/3 mg once daily
93476|NCT01341717|Drug|Metformin|>=1000 mg twice daily
93477|NCT01341717|Drug|Insulin|TDD > 10 IU once/twice daily
93478|NCT01341730|Drug|Atorvastatin 20mg|20 mg QD for 3 months
93479|NCT01341730|Drug|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
93480|NCT01341743|Drug|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
93481|NCT00057733|Procedure|quality-of-life assessment|
93482|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
93483|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
93484|NCT01341756|Radiation|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
93485|NCT01341769|Other|Dietary Intervention|
93486|NCT01341769|Other|Dietary Intervention|
93487|NCT01341769|Other|Dietary Intervention|
93772|NCT01335191|Other|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
93773|NCT01335204|Drug|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
93774|NCT00057005|Radiation|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
94165|NCT01331278|Procedure|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
94166|NCT01331278|Procedure|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
93243|NCT01341418|Procedure|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
93244|NCT01341418|Procedure|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
93245|NCT01341431|Drug|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
93246|NCT01341444|Device|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
93247|NCT01343576|Dietary Supplement|milk fat|45 g milk fat per day in 4 weeks
93248|NCT01343589|Dietary Supplement|milk fat|39 g milk fat per day in 12 weeks
93249|NCT01343602|Behavioral|mod. Constraint-Induced Movement Therapy|Therapists of the intervention group are trained in "CIMT at home". During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training.
93250|NCT01343602|Other|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
93251|NCT01343615|Procedure|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
93252|NCT01343615|Procedure|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
93253|NCT01343628|Drug|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
93254|NCT01343628|Drug|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
97823|NCT01346852|Drug|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
97824|NCT01349192|Drug|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: <40kg : 15mg/kg daily for 14 days divided every 12 hours.
97825|NCT01349192|Drug|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: <40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
97826|NCT01349192|Drug|Minocycline|only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.
Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: < 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day.
97827|NCT01349192|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
96925|NCT01352117|Drug|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET will be escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle can be delayed for a maximum of 14 days. ET must not be initiated prior to 7 days after the last dose in each cycle before starting the next cycle. ET may be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who cannot tolerate escalation of the ET dose to 100 mg/day will be treated for a maximum of six cycles. Duration based on participant response to dosage.
96926|NCT01352130|Drug|Ondansetron|Intravenous Ondansetron 8 mgs
96927|NCT01352130|Drug|Granisetron|Intravenous Granisetron 1 mgs
96928|NCT01352143|Drug|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
96929|NCT01352143|Drug|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
96930|NCT01352182|Drug|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
96931|NCT01352195|Behavioral|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
96932|NCT01352208|Drug|ASP9521|oral
96933|NCT01352221|Drug|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
96934|NCT00058461|Drug|cytarabine|Given IT
96935|NCT01352221|Drug|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
96936|NCT01352234|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
96723|NCT01347255|Drug|Daivobet® ointment|once daily application, 4 weeks
96724|NCT01347268|Procedure|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
96725|NCT01347268|Procedure|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
96726|NCT00058084|Drug|mitoxantrone hydrochloride|Given IV
96727|NCT01347281|Procedure|Injection of [18F]HX4|Before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:
[18F]HX4 PET scans; 444 MBq (12 mCi) [18F]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.
Venous blood sampling: before injection of [18F]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): [18F]FDG PET in treatment position
96728|NCT01347294|Drug|Bleomycin|Intralesional
96729|NCT01347294|Drug|Fibrovein|Intralesional
96730|NCT01347294|Drug|Bleomycin + Fibrovein|Intralesional
96731|NCT01347307|Radiation|stereotactic body radiotherapy|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
96732|NCT01347307|Radiation|stereotactic body radiotherapy|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
96733|NCT01347320|Other|Preoperative MRI|Preoperative staging
96734|NCT01347333|Radiation|Stereotactic body radiosurgery|36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)
96735|NCT01347333|Radiation|Stereotactic Body Radiotherapy|26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
96736|NCT01347346|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
96737|NCT00058084|Drug|prednisone|Given orally
96738|NCT01349725|Drug|Placebo|Oral; matching placebo
96739|NCT01349738|Drug|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
96994|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
96995|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
96996|NCT01350154|Drug|Sildenafil|20 mg in gelatine capsules, oral, three times daily
93775|NCT01335217|Procedure|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
93776|NCT01335243|Procedure|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
93777|NCT01335256|Drug|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
93778|NCT01335269|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
93779|NCT01335295|Drug|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
93780|NCT01335308|Behavioral|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
93781|NCT01335308|Behavioral|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
93782|NCT01330290|Drug|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
93783|NCT01330303|Drug|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
93784|NCT01330303|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
93785|NCT01330316|Drug|BI 201335|BI 201335 for 24 weeks
93786|NCT01330316|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
93787|NCT01330329|Behavioral|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
93788|NCT01330329|Behavioral|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
93255|NCT00057811|Drug|vincristine sulfate|Given IV
93256|NCT01343641|Drug|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
93257|NCT01343641|Drug|Placebo|Inactive Pill used as a comparator
93258|NCT01343654|Behavioral|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
93545|NCT00001063|Drug|Didanosine|
93546|NCT00057538|Behavioral|Mantram Repetition|
93547|NCT01339364|Other|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
93548|NCT01339364|Other|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
93549|NCT01339377|Device|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
93550|NCT01339390|Behavioral|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
93551|NCT01339390|Behavioral|MOVE!|As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a "clinical reminder." This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs.
93552|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
93553|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
93554|NCT01339429|Device|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
93555|NCT01339442|Drug|BKM120|
93556|NCT01339442|Drug|Fulvestrant|
93557|NCT00057551|Behavioral|Supportive Therapy|
93558|NCT01339442|Procedure|biopsy|Correlative studies
96937|NCT01352234|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
96938|NCT01352247|Procedure|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
96939|NCT01352247|Procedure|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
96940|NCT01352273|Drug|MEK162 + RAF265|
96941|NCT01352286|Genetic|Autologous Genetically modified T cells|Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.
Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above.
97495|NCT01348568|Dietary Supplement|low glycemic index diet with canola oil bread|
97496|NCT01348568|Dietary Supplement|High fiber diet|
97497|NCT01348581|Device|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
97498|NCT01348607|Drug|methylphenidate hydrochloride|Given orally
97499|NCT01348607|Drug|modafinil|Given orally
97500|NCT00001072|Biological|ALVAC-HIV MN120TMGNP (vCP300)|
97501|NCT00058227|Drug|fludarabine phosphate|Given IV
97502|NCT01348607|Drug|placebo|Given orally
97503|NCT01348620|Device|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)
97504|NCT01348620|Procedure|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
97505|NCT01348646|Behavioral|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
96997|NCT01350154|Drug|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
96998|NCT01350167|Procedure|Screening|Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.
Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.
96999|NCT01350193|Device|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
97000|NCT01350193|Other|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
97001|NCT00058318|Drug|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
97002|NCT01352494|Drug|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
97003|NCT01352507|Drug|Tadalafil|Administered Orally
97004|NCT01352507|Drug|Sildenafil|Administered Orally
97005|NCT01352520|Drug|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
97006|NCT01352533|Procedure|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
97007|NCT01352533|Procedure|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
97008|NCT01352533|Procedure|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
97009|NCT00058474|Drug|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
97010|NCT01352546|Biological|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
97011|NCT01352559|Drug|responders|Antidepressants administration for 6 weeks under therapeutic dose
97012|NCT01352559|Drug|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
97013|NCT01352572|Drug|antidepressant response|Antidepressants administration for 6 weeks under therapeutic dose responders
97254|NCT01352650|Drug|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
94083|NCT01333267|Drug|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
94084|NCT00056862|Drug|Ribavirin|800 mg/day
94085|NCT01333280|Behavioral|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
94086|NCT01333280|Behavioral|Treatment as usual|Receive usual treatment at the programs
94087|NCT01333293|Drug|injections|subcutaneous injections
94088|NCT01333306|Procedure|Transcranial direct current stimulation (tDCS)|
94089|NCT01333332|Drug|Capecitabine|Capecitabine
94090|NCT01333332|Radiation|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
94091|NCT01333358|Drug|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
94092|NCT01333371|Procedure|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
94093|NCT01325337|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
94094|NCT01325337|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
94095|NCT01325337|Drug|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
94096|NCT01325350|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
94097|NCT01325350|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
94098|NCT01325350|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
94099|NCT01325350|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
94100|NCT01325350|Drug|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
93559|NCT01339455|Procedure|AHSCT|AHSCT Procedure:
Mobilization and Harvesting:
Cyclophosphamide
Rituximab
GSCF
Dexamethasone
Apheresis
Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):
Cyclophosphamide
MESNA
Rabbit ATG
Rituximab
Methylprednisolone
Stem Cell infusion
GSCF
93560|NCT01339468|Drug|Advagraf|oral
93561|NCT01339468|Drug|Prograf|oral
93562|NCT01339468|Drug|Prograf|intravenous
93563|NCT01339481|Drug|abatacept|Intravenous Infusion
93564|NCT01339494|Dietary Supplement|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
93565|NCT01339520|Behavioral|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
93844|NCT01327391|Procedure|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
93845|NCT01327391|Procedure|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
93846|NCT01327430|Dietary Supplement|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
93847|NCT00056173|Drug|GTI-2040|
93848|NCT01327443|Behavioral|Weight loss|Nutritional counseling
93849|NCT01327443|Behavioral|Exercise|Under direct supervision
93850|NCT01327456|Behavioral|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
93851|NCT01327469|Drug|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
93852|NCT01327469|Drug|Albendazole 400mg|Albendazole 400mg
93853|NCT01327469|Drug|Mebendazole 500mg|Mebendazole 500mg
93854|NCT01327469|Drug|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
93855|NCT01327469|Drug|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
93856|NCT01327482|Drug|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
97506|NCT01348659|Drug|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
97507|NCT01348659|Drug|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
97508|NCT01348685|Other|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
97509|NCT01350856|Drug|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
97510|NCT01350856|Drug|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
97511|NCT01350869|Device|Xience|Patients with Xience
97512|NCT01350882|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
97513|NCT01350882|Drug|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
97514|NCT01350908|Other|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
97515|NCT00058422|Biological|darbepoetin alfa|
97534|NCT01343810|Behavioral|Mindfulness Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
97535|NCT01343810|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
97536|NCT01343823|Drug|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
97537|NCT01343823|Drug|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
99703|NCT01372384|Drug|erlotinib [Tarceva]|150 mg orally daily
99704|NCT01372410|Drug|GSK573719|125 mcg once daily
99705|NCT01372410|Drug|GSK573719|62.5 mcg once daily
99706|NCT01372410|Drug|GSK573719|31.25 mcg once daily
99707|NCT01372410|Drug|GSK573719|15.6 mcg once daily
99708|NCT01372410|Drug|GSK573719|31.25 mcg twice daily
99709|NCT01365000|Drug|NKTR118 Formulation 3a|Oral dose, 25 mg
99710|NCT01365013|Behavioral|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
99711|NCT01365013|Behavioral|Control group|Standard advice for lifestyle change
99712|NCT01365026|Behavioral|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
99713|NCT01365039|Device|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
99714|NCT01365039|Device|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
99715|NCT01365052|Drug|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
99716|NCT01365052|Drug|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
99717|NCT00060125|Other|laboratory biomarker analysis|Correlative studies
99718|NCT01365065|Drug|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
99719|NCT01365078|Dietary Supplement|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
100054|NCT01372839|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
100055|NCT01372839|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
100056|NCT01372865|Drug|Mometasone furoate|
97838|NCT01349270|Drug|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
97839|NCT00058279|Biological|aldesleukin|
97840|NCT01349270|Drug|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
97841|NCT01349283|Biological|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
97842|NCT01349283|Biological|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
97843|NCT01349296|Drug|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
97844|NCT01349309|Behavioral|Swallowing Exercise Group|Swallowing Exercises
Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.
Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)
Super Supraglottic Swallow:
Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)
Tongue Hold Maneuver:
Gently hold your tongue in between your front teeth and swallow your saliva.
Tongue Retraction:
Pull the back of your tongue to the back of your mouth and hold.
Mendelsohn Maneuver:
Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds.
97845|NCT01351376|Device|Low Level Laser|Active LLL combined with CDT
98136|NCT01422291|Drug|Dexketoprofen|50 mg
98137|NCT01422291|Drug|Paracetamole|1 gr
98138|NCT01422304|Drug|Sugammadex|Sugammadex 4 mg/kg intravenously
98139|NCT00065897|Procedure|Transabdominal chorionic villus sampling (TA CVS)|
98140|NCT01422304|Drug|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
98141|NCT01422304|Drug|Placebo to neostigmine|Normal saline (NaCl 0.9%)
98142|NCT01422304|Drug|Placebo to sugammadex|Normal saline (NaCl 0.9%)
98143|NCT01422317|Drug|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
98144|NCT01422317|Drug|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
98145|NCT01422330|Drug|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
100119|NCT01370655|Drug|MK-7145|MK-7145, capsules, orally, 6 mg in 2 divided doses (3 mg and 3 mg, given 4 hours apart) per day
100120|NCT01370655|Drug|MK-7145|MK-7145, capsules, orally, 3 mg in 2 divided doses (2 mg and 1 mg, given 4 hours apart) per day
100121|NCT01370655|Drug|Hydrochlorothiazide (HCTZ)|HCTZ, capsules, orally, two 12.5 mg capsules, once daily
100122|NCT01370655|Drug|Placebo to MK-7145|placebo capsules, orally, twice per day (given 4 hours apart)
100123|NCT01370655|Drug|Placebo to HCTZ|placebo capsules, orally, two capsules, once daily
100124|NCT00060567|Drug|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
100125|NCT01370668|Behavioral|Functional remediation|The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.
The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management.
100126|NCT01370668|Behavioral|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
100127|NCT01370668|Behavioral|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
100128|NCT01370681|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001|
100129|NCT01370681|Drug|Period I : CJ30001, Period II : HKB0701 and SLM0807|
100130|NCT01370694|Drug|MK-8808|
100131|NCT01370694|Drug|cyclophosphamide|
100132|NCT01370694|Drug|vincristine|
100133|NCT01370694|Drug|prednisolone|
99219|NCT01414374|Drug|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
99220|NCT01414374|Drug|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
99221|NCT01416701|Dietary Supplement|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
99222|NCT01416727|Other|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
99562|NCT01367301|Radiation|brachytherapy|Undergo HDR brachytherapy
99563|NCT01367301|Radiation|intensity-modulated radiation therapy|Undergo IMRT
99564|NCT01367301|Other|laboratory biomarker analysis|Correlative studies
99565|NCT00060359|Drug|Carboplatin|Given IV
99566|NCT01367314|Drug|NVC-422|Dermal Gel applied 3 times per day for 7 days
99567|NCT01367327|Behavioral|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
99568|NCT01367327|Behavioral|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
99569|NCT01367340|Behavioral|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
99570|NCT01369758|Device|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
99571|NCT00060489|Drug|SEROQUEL (quetiapine fumarate) Tablets|
99572|NCT01369771|Drug|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
99573|NCT01369797|Other|specific intervention|Patients included in the "specific intervention" group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed.
99574|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 20 mg capsule
99575|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 40 mg capsule.
99576|NCT01369836|Drug|Placebo|A single oral dose of matched placebo.
99577|NCT01369849|Drug|Akt Inhibitor MK2206|Given PO
99578|NCT01369849|Drug|Bendamustine Hydrochloride|Given IV
99579|NCT01369849|Other|Laboratory Biomarker Analysis|Correlative studies
99580|NCT01369849|Biological|Rituximab|Given IV
99581|NCT01369862|Biological|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
99851|NCT01370226|Behavioral|TBI|Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a "change plan" tailored for each participant.
99852|NCT00060528|Drug|Recombinant Human GM-CSF|
100188|NCT01368419|Drug|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
100189|NCT01368419|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
100190|NCT01368432|Drug|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
100191|NCT01368445|Drug|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM & PM)
100192|NCT01368445|Drug|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
100193|NCT00001083|Drug|Indinavir sulfate|
100194|NCT00060398|Drug|dexamethasone|
100195|NCT01368445|Drug|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM)
100196|NCT01368458|Other|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
100197|NCT01368458|Other|No Intervention|Patients assigned to the continuation of their combination antipsychotic treatment will remain on their previously prescribed medications for the duration of the study, and evaluated with the same procedures
100198|NCT01368471|Device|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
100199|NCT01368471|Device|Control BMS or DES|Control BMS or DES
100200|NCT01368484|Dietary Supplement|Sunflower oil|1500 mg sunflower/day for 10 weeks
100201|NCT01368484|Dietary Supplement|Docosahexanoic acid|1500mg/day for 10 weeks
100202|NCT01370733|Device|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
100203|NCT01370759|Other|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
98146|NCT01422343|Procedure|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
98147|NCT01422369|Drug|Pitavastatin (NK-104)|Pitavastatin (NK-104) 4mg once daily (QD)
98148|NCT01422369|Drug|Darunavir/Ritonavir (Prezista)|Darunavir/Ritonavir (Prezista) 800 mg/100 mg
98149|NCT01422382|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
98150|NCT00001111|Drug|Zidovudine|
98151|NCT00065910|Behavioral|Caregiver joint attention intervention|
98152|NCT01422382|Drug|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
98153|NCT01422395|Procedure|Freezing|Vitrification
98154|NCT01422408|Drug|Fluocinonide Cream|Given topically
98155|NCT01422408|Procedure|Management of Therapy Complications|Receive fluocinonide cream
98156|NCT01422408|Other|Questionnaire Administration|Ancillary studies
98157|NCT01422421|Other|intensive control|use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
98158|NCT01414777|Drug|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
98458|NCT01415440|Drug|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
98459|NCT01415453|Procedure|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
98460|NCT01417650|Radiation|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
98461|NCT01417650|Radiation|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
98462|NCT00065273|Drug|clozapine|
98463|NCT01417663|Drug|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
98464|NCT01417663|Behavioral|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
98465|NCT01417676|Radiation|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
99223|NCT01416727|Other|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
99224|NCT00065195|Procedure|Nonmoving touch therapy|
99225|NCT01416740|Procedure|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
99226|NCT01416740|Drug|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
99227|NCT01416753|Device|UCR|BVM-based regulation of ultrafiltration and conductivity
99228|NCT01416753|Device|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
99229|NCT01416766|Other|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
99230|NCT01416779|Behavioral|Writing Intervention|Finding Balance Writing Intervention
99231|NCT01416792|Procedure|Centrifugation|
99232|NCT01416792|Procedure|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
99233|NCT01416805|Behavioral|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
99504|NCT01372059|Other|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
99582|NCT00000254|Drug|0.4% isoflurane|
99838|NCT01367847|Behavioral|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
99839|NCT01367860|Procedure|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
99840|NCT01367860|Procedure|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
99841|NCT01367873|Drug|Placebo|Oral, matching number of placebo capsule(s) with active arm
99842|NCT01367873|Drug|VIA-3196|Oral, capsule(s)
99843|NCT01370187|Drug|Montelukast|Montelukast 4mg daily for 2 months
99844|NCT01370200|Procedure|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
99845|NCT01370213|Drug|Preparative Regimen|Preparative Regimen:
1) fludarabine 40 mg/m^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,
99846|NCT01370213|Biological|NK Cells|CD3^- CD19^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
99847|NCT01370213|Drug|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
99848|NCT01370213|Biological|Anti-thymocyte globulin|rabbit anti-thymocyte globulin will be administered on day -5 (0.5 mg/kg) and day -4 (2.5 mg/kg) pretransplant per institutional guidelines
99849|NCT01370213|Biological|Donor TCR α/β-depleted Cells|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10^6/kg) on day 0
99850|NCT01370226|Behavioral|CBI|The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a "change plan" tailored for each participant.
100204|NCT01370772|Drug|Rituximab|Cycle 1 Rituximab : 375 mg/m² i.v on day 1
Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days
100205|NCT01370772|Drug|Rituximab|Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15
Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days
100206|NCT01370772|Drug|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
100207|NCT01370772|Drug|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
99291|NCT01414426|Other|pharmacological study|Correlative studies
99292|NCT01414439|Behavioral|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
99293|NCT01414465|Drug|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
99294|NCT01414478|Other|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
99295|NCT01414504|Biological|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
99296|NCT01414504|Biological|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
99297|NCT01414504|Biological|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
99298|NCT00064974|Drug|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
99299|NCT01414504|Biological|Control|control, 0.1mL Pneumovax at 3-5yrs
99300|NCT01414517|Dietary Supplement|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
99301|NCT01414517|Dietary Supplement|Maltodextrin|a non-prebiotic carbohydrate
99302|NCT01414530|Drug|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
99303|NCT01414530|Drug|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
99304|NCT01369342|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
99305|NCT00060437|Drug|perifosine|
98466|NCT01417689|Other|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
98467|NCT01417702|Device|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
98468|NCT01417715|Device|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
98469|NCT01417741|Device|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
98470|NCT01417754|Drug|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
98471|NCT01417767|Drug|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
98472|NCT01417767|Drug|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
98473|NCT00065273|Drug|olanzapine|
98474|NCT01417780|Drug|AB103 0.25 mg/kg|Active
98475|NCT01417780|Drug|AB103 0.5 mg/kg|Active
98476|NCT01417780|Drug|NaCl 0.9%|Placebo
98477|NCT01417793|Behavioral|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
98478|NCT01417806|Drug|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
98765|NCT01421004|Drug|TKI258|
98766|NCT00065702|Drug|Active liquid remedy|
98767|NCT01421017|Radiation|Radiation|
98768|NCT01421017|Drug|Imiquimod|
98769|NCT01423227|Behavioral|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
98770|NCT01423240|Drug|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
98771|NCT01423240|Drug|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
98772|NCT01423240|Drug|Placebo|Placebo once daily orally in the evening
99505|NCT01372059|Other|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
99506|NCT00001083|Drug|Zidovudine|
99507|NCT00060762|Behavioral|Interpersonal Therapy|20 sessions of interpersonal therapy were provided over a 6-month period
99508|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
99509|NCT01372072|Device|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
99510|NCT01372085|Drug|LY2584702 Reference Formulation|Administered orally
99511|NCT01372085|Drug|LY2584702 Test Formulation|Administered orally
99512|NCT01372085|Drug|Placebo|Administered orally
99513|NCT01372098|Behavioral|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
99514|NCT01372111|Drug|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
99515|NCT01372111|Radiation|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
99516|NCT01372124|Drug|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
99517|NCT01372137|Drug|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
99518|NCT00060762|Behavioral|Behavioral Weight Loss Treatment|20 sessions of behavioral weight loss treatment were provided over a 6-month period
99519|NCT01372137|Other|Glucose 5%|Placebo
99520|NCT01364649|Drug|Vortioxetine|Vortioxetine tablets
99777|NCT01372618|Drug|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
99643|NCT01367366|Procedure|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
99644|NCT01367379|Procedure|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
99645|NCT01367379|Other|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2~4 times/month)
99646|NCT01367392|Device|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
99647|NCT00060359|Drug|Paclitaxel Poliglumex|Given IV
99648|NCT01367405|Procedure|Surgical decompression|Surgical decompression within 24 hour postinjury
99649|NCT01367405|Procedure|Conservative treatment|Usual conservative treatment without surgery
99650|NCT01367418|Drug|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
99651|NCT01367418|Drug|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
99652|NCT01367431|Dietary Supplement|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
99653|NCT01367444|Drug|SAR422459|Pharmaceutical form:Prefilled syringes Route of administration: subretinal injection
99654|NCT01367457|Other|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
99655|NCT01367470|Dietary Supplement|VSL#3 probiotic preparation|VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
99656|NCT01367470|Other|Placebo VSL#3|Placebo VSL#3 is a base of corn starch containing no active ingredient.
99657|NCT01367483|Drug|IV methylnaltrexone (MNTX)|
99658|NCT00060359|Other|Pharmacological Study|Correlative studies
99659|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 1
99660|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 2
99661|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 3
99662|NCT01367496|Drug|IV Methylnaltrexone (MNTX)|
99663|NCT01367509|Drug|Methylnaltrexone (MNTX)|
99306|NCT01369342|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
99307|NCT01369342|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
99308|NCT01369355|Drug|Placebo|Responders to ustekinumab: Form=solution for injection, route=Subcutaneous use. One SC injection q4w
99309|NCT01369355|Drug|Ustekinumab|Responders to ustekinumab:
Form=solution for injection, route=Subcutaneous use. One SC injection q12w
99310|NCT01369355|Drug|Ustekinumab|Responders to ustekinumab: type=1, unit=mg, number=90, form=solution for injection, route=Subcutaneous use. One SC injection q8w
99311|NCT01369355|Drug|Ustekinumab|Nonresponders to IV induction ustekinumab: type=1, unit=mg, number=90, form=solution for injection, route=Subcutaneous use. One SC injection at Week 0
99583|NCT00001083|Drug|Nevirapine|
99584|NCT00060502|Drug|Infliximab; Gemcitabine|
99585|NCT01369862|Biological|Placebo|SPGNH buffer
99586|NCT01369875|Drug|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
99587|NCT01369875|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
99588|NCT01369875|Biological|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
99589|NCT01369875|Biological|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
99590|NCT01369888|Drug|Cyclophosphamide|60 mg/m^2, intravenous (IV) (in the vein) x 2 days
99591|NCT01369888|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
99592|NCT01369888|Biological|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
99593|NCT01369888|Drug|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
99594|NCT01369901|Behavioral|A functional exercise program|
99595|NCT00060515|Drug|RG2133 (2',3',5'-tri-O-acetyluridine)|
99596|NCT01372150|Drug|desvenlafaxine succinate sustained release|Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
100057|NCT01372865|Drug|Mometasone furoate|
100058|NCT00060918|Drug|carvedilol|
100059|NCT01372878|Device|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
100060|NCT01372878|Procedure|Colonoscopy|Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.
Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon.
100061|NCT01372904|Drug|Dexamethasone Phosphate|0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.
The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level.
100062|NCT01372930|Drug|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
100063|NCT01372930|Drug|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
100064|NCT01372943|Biological|"synthetic stool" or pure cultures of probiotic intestinal bacteria|"synthetic stool" or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI
100065|NCT01372969|Drug|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
100066|NCT01372982|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
100067|NCT01365585|Drug|sildenafil citrate|Sildenafil citrate, 20mg oral tablets, taken at least three times daily
100068|NCT01365598|Drug|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
100069|NCT01365611|Drug|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
100070|NCT01365611|Drug|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
100071|NCT01365624|Drug|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
100072|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
99778|NCT01372631|Device|miniature spectral imaging system|Use of miniature spectral imaging system
99779|NCT01372631|Device|Bench-top optical spectrometer|Use of bench-top optical spectrometer
99780|NCT01372631|Device|High resolution microendoscope|Use of high resolution microendoscope
99781|NCT01372644|Drug|SOM 230 / Pasireotide|
99782|NCT00060866|Drug|Propranolol|
99783|NCT01372657|Other|biometry calculation|
99784|NCT01372670|Drug|Hydroxyzine|Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:
15-29 Kg 10 mg TID 30-44 Kg 20 mg TID
≥ 45 Kg 30 mg TID
99785|NCT01372670|Drug|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
99786|NCT01372670|Other|Placebo|Placebo given 3 times per day
99787|NCT01372683|Other|Dietary Intervention|Comparison of oat based breakfast cereals
99788|NCT01372696|Other|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
99789|NCT01372709|Device|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
99790|NCT01372722|Device|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
99791|NCT01372722|Device|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
99792|NCT01372735|Radiation|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
99793|NCT00060892|Genetic|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
99794|NCT01372735|Radiation|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
99795|NCT01372748|Other|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
99796|NCT01372748|Other|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
99797|NCT01372761|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
99664|NCT01367522|Drug|SC Methylnaltrexone (MNTX)|
99992|NCT01365559|Drug|Group A: Carfilzomib & Non-IMiD Regimen|Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.
Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.
Maintenance regimen maybe administered if patient does not progress while on study.
99993|NCT01365559|Drug|Group B: Carfilzomib & IMiD containing regimen.|Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.
Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.
Maintenance regimen maybe administered if patient does not progress while on study.
99994|NCT01365572|Device|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
99995|NCT01368081|Drug|Placebo (high dose)|Placebo tablets once daily
99996|NCT01368094|Procedure|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
99997|NCT01368094|Procedure|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
99998|NCT01368107|Drug|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
99999|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
100000|NCT01368107|Drug|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
100001|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
100002|NCT01368120|Device|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
100003|NCT01368120|Device|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
100004|NCT00060385|Drug|prednisone|
100005|NCT01368120|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
100006|NCT01368146|Device|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
99597|NCT01372150|Drug|fluoxetine|Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
99598|NCT01372150|Drug|placebo|Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
99599|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
99600|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
99601|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
99602|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
99603|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
99853|NCT01370239|Biological|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
99854|NCT01370265|Drug|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
99855|NCT01370265|Drug|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
99856|NCT01370265|Drug|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
99857|NCT01370278|Other|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
99858|NCT01370278|Other|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
99859|NCT01370291|Other|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
99860|NCT01372995|Dietary Supplement|Enteral Vitamin D3 50,000 IU|Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
99861|NCT01372995|Dietary Supplement|Enteral Vitamin D3 100,000IU|Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)
99862|NCT00060918|Drug|metoprolol|
99161|NCT01419093|Other|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on [feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
99162|NCT01419106|Device|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
99163|NCT00065455|Drug|Vitamin A|
99164|NCT01419119|Drug|Cholecalciferol|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
99165|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
99166|NCT01419119|Drug|Cholecalciferol|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
99167|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
99168|NCT01419132|Drug|Furosemide|125-250 mg furosemide bid
99169|NCT01419132|Drug|Furosemide|125-250 mf furosemide bid
99170|NCT01419145|Other|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
99171|NCT01419145|Other|Standard care|Standard cancer care
99172|NCT01419171|Device|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
99173|NCT01421524|Drug|PCNSL|Intermittent dose and schedule from the DLBCL-2 cohort in up to 10 relapsed or refractory PCNSL subjects
99174|NCT01421550|Procedure|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
99175|NCT01421550|Procedure|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
99176|NCT01421563|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
99177|NCT01421576|Dietary Supplement|High fat meal|offer high fat-meal in the morning before drug intake.
100134|NCT01370707|Drug|Metformin|1000~1500mg/day, 24weeks
100135|NCT00060580|Procedure|Raman scattering spectroscopy|
100136|NCT01370707|Drug|CJ-30001/CJ-30002|0.6/1500mg~0.9/1500mg/day, 24weeks
100137|NCT01370720|Dietary Supplement|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
100138|NCT01370720|Other|Placebo|tablets, 2tablets/day, 12 weeks
100139|NCT01370733|Device|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
100140|NCT01373112|Procedure|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
100141|NCT01373112|Procedure|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
100142|NCT01373138|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
100143|NCT01373151|Drug|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
100144|NCT00060931|Drug|metoprolol|
100145|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
100146|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
100147|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
100148|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
100149|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
100150|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
100007|NCT01368146|Device|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
100008|NCT01368146|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
99111|NCT01421524|Drug|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are > 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
99112|NCT01421524|Drug|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
99113|NCT01421524|Drug|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
99114|NCT01413984|Behavioral|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
99115|NCT01414010|Dietary Supplement|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
99116|NCT01414010|Dietary Supplement|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
99117|NCT01414010|Drug|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
99118|NCT01414023|Behavioral|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
99119|NCT01414023|Behavioral|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
99120|NCT01414036|Other|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
99121|NCT00064922|Behavioral|Behavior Therapy|
99122|NCT01414036|Behavioral|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
99863|NCT01372995|Dietary Supplement|Inactive substance|Inactive substance given enterally for 5 days.
99864|NCT01373008|Drug|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
99865|NCT01373021|Drug|Fentanyl|Fentanyl 2500mcg+NS50ml
99866|NCT01373021|Drug|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
99867|NCT01373034|Dietary Supplement|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
99868|NCT01373034|Dietary Supplement|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
99869|NCT01373047|Biological|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
99870|NCT01373060|Drug|ASP1941|oral
99871|NCT01373060|Drug|Placebo|oral
99872|NCT01373073|Other|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
99873|NCT00060931|Drug|carvedilol|
100208|NCT00060606|Procedure|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
100209|NCT01370798|Drug|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
100210|NCT01370798|Drug|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
100211|NCT01370798|Procedure|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
100212|NCT01370798|Radiation|Wrist X ray|Wrist X ray to follow the degree of bone maturation
100213|NCT01370798|Procedure|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
100214|NCT01370811|Drug|OC oral solution treatment A|
100215|NCT01370811|Drug|OC oral solution treatment B|
100216|NCT01370811|Drug|OC oral solution treatment C|
100217|NCT01370811|Drug|OC oral solution treatment D|Placebo
99178|NCT00001111|Drug|Nevirapine|
99442|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
99443|NCT01364584|Drug|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
99444|NCT01364584|Drug|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
99445|NCT00001080|Drug|Lamivudine|
99446|NCT00060099|Biological|HspE7|
99447|NCT01364597|Drug|Brivaracetam (BRV)|Subjects must be able to tolerate at least 0.5 mg/kg of brivaracetam twice daily (bid). The maximum allowable brivaracetam dose is 5.0 mg/kg/day (2.5 mg/kg bid), not to exceed a dose of 200 mg/day for subjects with body weight >40 kg. Subjects <7 years of age will receive oral solution.
Subjects ≥7 years of age will receive tablets and should transition from the oral solution to the equivalent oral tablet dose. The maximum BRV tablet dose allowed in this study will be 200 mg/day (100 mg bid).
Subjects will continue to receive brivaracetam in this study for at least 3 years, or until approval for BRV has been obtained for pediatric subjects in their age range, or until the investigational product development is stopped by the Sponsor.
For subjects who prematurely discontinue the study, brivaracetam will be down titrated over a maximum of 4 weeks (Down-Titration Period).
99448|NCT01364610|Device|Bravo|Bravo pH Monitoring System sited manometrically.
99449|NCT01364610|Device|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
99450|NCT01364623|Drug|Low dose testosterone nasal gel|Single dose administration
99451|NCT01364623|Drug|Medium dose testosterone nasal gel|Single dose Administration
99452|NCT01364623|Drug|High dose testosterone nasal gel|single dose Administration
99453|NCT01364623|Drug|Medium dose testosterone nasal gel|multiple dose administration
99454|NCT01367015|Other|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
99455|NCT01367015|Other|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
99456|NCT01367028|Drug|Trastuzumab, Docetaxel|6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 100 mg/m2 by 60 min i.v. infusion
99457|NCT01367028|Drug|Trastuzumab, Docetaxel, Bevacizumab|6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg
99458|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD|6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion
100151|NCT01373151|Drug|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
100152|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
99234|NCT01416805|Behavioral|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
99235|NCT00065208|Behavioral|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
99236|NCT01416818|Drug|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
99237|NCT01416818|Drug|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
99238|NCT01419184|Drug|Daptomycin|
99239|NCT00001108|Drug|Stavudine|
99240|NCT00065468|Drug|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
99241|NCT01419184|Drug|Vancomycin|
99242|NCT01419197|Drug|Trastuzumab emtansine|The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change > 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
99243|NCT01419197|Drug|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (eg, tamoxifen or aromatase inhibitor) or dual-agent (eg, aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
Participants who had documented progressive disease (PD) were eligible to cross over to receive trastuzumab emtansine 3.6 mg/kg. Patients who crossed over remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.
The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information.
99244|NCT01419210|Other|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
99245|NCT01419210|Other|Educational Presentations|Attend a two-hour presentation each week for four weeks
99246|NCT01419210|Other|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
99247|NCT01419210|Other|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
99123|NCT01414049|Procedure|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
99124|NCT01414049|Procedure|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
99125|NCT01414062|Other|Arm A|Participants randomized to Arm A will meet one on one with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the NYC-based not-for-profit, God's Love We Deliver
99383|NCT01367002|Drug|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
99384|NCT00060346|Drug|cyclophosphamide|Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.
The drug should be administered as a rapid IV infusion over 5 to 30 minutes.
99385|NCT01369433|Drug|tivozanib (AV-951) + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
99386|NCT01369433|Drug|tivozanib (AV-951)|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
99387|NCT01369446|Device|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
99388|NCT01369459|Behavioral|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
99389|NCT00060450|Drug|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
99390|NCT01369472|Drug|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
99391|NCT01369485|Device|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
99392|NCT01369485|Device|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
99393|NCT01369498|Drug|Simtuzumab|Simtuzumab 200 mg or 700 mg administered intravenously over approximately 30 minutes every 2 weeks
100218|NCT01370824|Procedure|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
100219|NCT00060606|Procedure|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
100220|NCT01370824|Procedure|Surgical excision|Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.
After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds.
100221|NCT01370837|Other|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
100222|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
100223|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
100224|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
100225|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
99030|NCT01413828|Drug|Trastuzumab, anthracycline|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
99031|NCT01413841|Drug|Nasal oxygen|3 l oxygen
99032|NCT01413841|Drug|Regular nasal air|3 l nasal air
99033|NCT00064857|Drug|Pycnogenol|
99034|NCT01413854|Drug|sugar pill|One tablet two times daily during four weeks
99035|NCT01413854|Drug|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
99036|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
99037|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
99459|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD+Bevacizumab|6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg
99460|NCT01367041|Procedure|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
99720|NCT01365078|Dietary Supplement|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
99721|NCT01365091|Drug|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
99722|NCT01365091|Drug|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
99723|NCT01365091|Drug|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
99724|NCT01365091|Drug|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
99725|NCT01365091|Drug|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
99726|NCT01365104|Drug|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
99727|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder [one 20 U, two 20 U and one 40 U cartridges)
99728|NCT00060138|Biological|monoclonal antibody CAL|
99729|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder [one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)])
99730|NCT01365130|Drug|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
99731|NCT01365143|Procedure|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
99732|NCT01365143|Procedure|Open Radical Prostatectomy|Open radical prostatectomy
99733|NCT01367535|Drug|Oral Paroxetine|
99734|NCT01367535|Drug|SC Placebo|
99735|NCT00060372|Drug|ipilimumab|Given IV
99736|NCT01367548|Drug|IV Methylnaltrexone (MNTX)|
99737|NCT01367548|Drug|Placebo|
99738|NCT01367561|Drug|Naloxone|
99248|NCT01419236|Drug|Testosterone Solution 2%|Administered topically
99249|NCT01419236|Drug|Placebo Solution|Administered topically
99250|NCT01419249|Other|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
99521|NCT01364649|Drug|Escitalopram|Escitalopram tablets
99522|NCT01364649|Drug|Placebo|Vortioxetine Placebo-matching capsules
99523|NCT00060112|Biological|oblimersen sodium|Given IV
99524|NCT01364662|Drug|SPN-810|administered orally
99525|NCT01364662|Drug|Placebo|administered orally
99526|NCT01364675|Drug|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
99527|NCT01364675|Drug|Placebo tablet|Identical Placebo Tablet
99528|NCT01364688|Drug|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
99529|NCT01364688|Drug|no drug|no drug
99530|NCT01364701|Drug|Sildenafil 100 mg|4 tablets for on demand use
99531|NCT01364701|Drug|Tadalafil 20 mg|4 tablets on demand
99532|NCT01364701|Drug|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
99533|NCT01364727|Drug|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
99534|NCT00060112|Drug|gemcitabine hydrochloride|Given IV
99535|NCT01364740|Device|Smart Watch PMP-300E|Compare data collected from PMP-300E (SmartWatch) Type III portable monitoring device to Type II in-lab polysomnography data.
99536|NCT01364740|Device|SmartWatch PMP-300E|Compare data collected from PMP-300E (SmartWatch) portable monitoring device to In-Lab monitored polysomnography data.
99537|NCT01364792|Drug|Valaciclovir|4 times 2 grams valaciclovir per day, administrated orally, for seven days.
99394|NCT01369498|Drug|Ruxolitinib|In stage 2, participants will be on a stable dose of ruxolitinib and will continue their treatment in combination with simtuzumab
99395|NCT01369511|Drug|LY2495655|Administered subcutaneously
99396|NCT01369511|Drug|Placebo|Administered subcutaneously
99397|NCT01369550|Other|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
99398|NCT01369550|Other|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
99665|NCT01367535|Drug|SC Methylnaltrexone (MNTX)|
99666|NCT01367535|Drug|IV Methylnaltrexone (MNTX)|
99667|NCT01369901|Behavioral|A stretching exercise program|
99668|NCT01369927|Biological|Shigella Sonnei O-SPC/rBRU|
99669|NCT01369979|Procedure|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
99670|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
99671|NCT01370005|Drug|BI 10773|BI 10773 high dose once daily
99672|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
99673|NCT01370005|Drug|BI 10773|BI 10773 low dose once daily
99674|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
99675|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
99676|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose used will depend on the patient's body weight. For example, a patient weighing 150 pounds would be infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients will be admitted to hospital for infusion. The I.V. infusion will be approximately 1 teaspoon/minute. Patients will receive weekly infusions of Zemaira® for 8 or 12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood will be collected (IRB approval #R04-003). The blood sample will be used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
99677|NCT00060528|Drug|Recombinant Fowlpox-GM-CSF|
99678|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose used was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of Zemaira® for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
99038|NCT01413880|Drug|FLAM|Flavopiridol will be administered daily for 3 days by 60 minute intravenous (IV) beginning Day 1 Cytosine Arabinoside (ara-C) will be administered by continuous IV infusion beginning on Day 6 Mitoxantrone will be administered by IV infusion over 60-120 minutes on Day 9
99039|NCT01413880|Drug|7&3|Cytosine arabinoside (ara-C) 100 mg/m2/day will be administered by continuous IV infusion for a total of 7 days beginning Day 1
Daunorubicin 90 mg/m2 /day will be administered IV over 30-60 minutes Days 1, 2, 3
99040|NCT01413893|Drug|linifanib|QD daily
99041|NCT01413906|Drug|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
99042|NCT01413932|Drug|HT-2157|QD oral dosing
99043|NCT01413932|Drug|Placebo|QD oral dosing
99044|NCT00064896|Procedure|MRI|
99045|NCT01413958|Drug|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
99046|NCT01413958|Drug|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
99047|NCT01413958|Drug|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
99048|NCT01416337|Drug|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
99049|NCT01416350|Drug|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
99050|NCT01416350|Drug|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
99051|NCT01416350|Drug|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
98094|NCT01416961|Drug|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
98095|NCT01416961|Drug|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
98096|NCT01416974|Drug|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
98097|NCT01416974|Biological|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
98098|NCT01417000|Biological|GVAX Pancreas|
98099|NCT01417000|Biological|CRS-207|
99739|NCT01367561|Drug|IV Methylnaltrexone (MNTX)|
99740|NCT01367561|Drug|Placebo|
99741|NCT01367574|Drug|SC MNTX|Dose 1
99742|NCT01367574|Drug|SC MNTX|Dose 2
99743|NCT01367574|Drug|SC MNTX|Dose 3
99744|NCT01367587|Drug|IV Methylnaltrexone|
100073|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
100074|NCT00060255|Drug|carmustine|iv
100075|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
100076|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
100077|NCT01365650|Drug|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
100078|NCT01365650|Drug|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
100079|NCT01365650|Drug|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
100080|NCT01365663|Drug|SPC4955|3 Weekly SC injections
100081|NCT01365663|Drug|SPC4955|3 Weekly SC injections
100082|NCT01365663|Drug|SPC4955|3 Weekly SC injections
100083|NCT01365663|Drug|SPC4955|3 Weekly SC injections
100084|NCT01365663|Drug|SPC4955|3 Weekly SC injections
100085|NCT00060255|Drug|cyclophosphamide|iv
100086|NCT01365663|Drug|Saline 0.9%|3 Weekly SC injections
100087|NCT01365676|Drug|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
100088|NCT01365676|Drug|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
99538|NCT01364805|Drug|Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
99539|NCT01364831|Behavioral|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
99540|NCT01364844|Drug|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
99541|NCT01364857|Genetic|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
99798|NCT01372761|Drug|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
99799|NCT01365156|Procedure|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
99800|NCT01365156|Radiation|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
99801|NCT01365169|Device|Smart phone|Answer questions sent by the phone (all study groups). Some participants will video-record swallowing exercises or device usage (Pre-Pilot, Arms 3 and 4).
99802|NCT01365169|Device|Accelerometers (Arms 1 and 2)|These devices are worn on a belt around the waist, and record activity.
99803|NCT01365169|Device|Blood Pressure Monitor (Arms 1 and 2)|This device is used at home to measure blood pressure and pulse rate.
99804|NCT01365169|Other|Telephone Surveys|On days 1, 3, and 6 of each 5-day sensor usage period, study personnel will call participants to ascertain functionality, acceptability, and overall satisfaction regarding use of sensing devices.
99805|NCT00060138|Drug|zoledronic acid|
99806|NCT01365169|Other|Home Visit|For the first 10 patients enrolled in the trial, a home visit to be made on day 2, to ascertain if there were any problems related to home set-up.
99807|NCT01365169|Device|Home Health Hub and Modem (All study groups)|These devices collect data from other home devices, and send this data (over the internet) to study researchers.
99808|NCT01365169|Device|Carbon Monoxide (CO) Monitor (Arm 4)|This device captures the CO level expelled in one breath.
99809|NCT01365169|Device|Heat Rate Monitor (Arm 1)|This device is worn on a chest strap, and measures heart rate.
99810|NCT01365169|Device|Global Positioning System (GPS) Device (Arm 1)|This device describes location on a map, but not location within a building.
99679|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of Zemaira® for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
99680|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The alpha-1-Proteinase Inhibitor dose used was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
99681|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
100009|NCT01368159|Device|Compression Stockings|The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The "Class I compression" versus "The two class III compressions" contrast will also be studied.
100010|NCT01368172|Behavioral|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
100011|NCT01368198|Other|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
100012|NCT01368198|Other|OPTIVE™|One instillation of the eye drop in each eye
100013|NCT01368211|Biological|Mirasol-treated Platelets|Mirasol-treated platelet units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of >32%
Cell count > 800x103/µL
100014|NCT01370512|Drug|Droxidopa|100 mg t.i.d. for 2 days; then 200 mg t.i.d. for another 2 days
100015|NCT01370512|Drug|Pyridostigmine Bromide|180 mg daily for 4 days
100016|NCT00060554|Procedure|percutaneous coronary intervention (PCI)|
100017|NCT01370525|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
100018|NCT01370538|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
100019|NCT01370551|Drug|Gynoflor|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
100020|NCT01370564|Drug|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
98100|NCT01417000|Drug|Cyclophosphamide|
98101|NCT01417013|Other|Systane Ultra|Lubricant Eye Drops
98102|NCT00065221|Drug|Ginger|
98103|NCT01417013|Other|Optive|Lubricant eye drops
98104|NCT01417026|Drug|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
98105|NCT01417052|Drug|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
98106|NCT01417052|Drug|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
98107|NCT01417052|Drug|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
98108|NCT01417052|Drug|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
98109|NCT00065546|Other|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
98110|NCT01419756|Device|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
98111|NCT01419769|Device|AXIOS Stent & Delivery System|The AXIOS Stent & Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.
Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.
Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal.
98112|NCT01419782|Other|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
98113|NCT01419795|Drug|lenalidomide|Given PO
98414|NCT01422876|Drug|low dose FDC placebo|once daily
98415|NCT01422876|Drug|low dose FDC placebo|once daily
98416|NCT01422876|Drug|high dose BI 10773 placebo|once daily
98417|NCT01422876|Drug|low dose FDC|once daily
98418|NCT01422876|Drug|high dose FDC placebo|once daily
100089|NCT01365715|Procedure|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
100090|NCT01365715|Procedure|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
100091|NCT01365728|Procedure|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
100092|NCT01368224|Dietary Supplement|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.
Oral route.
100093|NCT00060385|Drug|vincristine sulfate|
99179|NCT00065806|Drug|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
99180|NCT01421589|Drug|Growth hormone treatment|Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
99181|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
99182|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
99183|NCT01421628|Other|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
99184|NCT01421641|Drug|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
99185|NCT01421641|Drug|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
99186|NCT01421654|Device|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
99187|NCT01421654|Device|S9 Elite|S9 Elite Flow Generator
99188|NCT01421667|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
99189|NCT01421667|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion
99190|NCT00065819|Behavioral|HIV Symptom Education Program|
99811|NCT01365169|Other|Surveys|After training about each device, completion of a survey about that training.
99812|NCT01365182|Behavioral|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
99813|NCT01365182|Behavioral|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
99814|NCT01365195|Drug|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
99815|NCT01365195|Drug|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
99816|NCT00060151|Drug|pazopanib hydrochloride|
99817|NCT01365195|Drug|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
99818|NCT01365208|Drug|Chemotherapy|platinum-based chemotherapy
100153|NCT01373151|Drug|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
100154|NCT01373151|Drug|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
100155|NCT00060944|Drug|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
100156|NCT01373164|Drug|LY2157299|Administered orally twice daily for 14 days followed by 14 days of rest. Dose escalation will proceed if none of the first 3 participants experience a dose limiting toxicity (DLT) during the first cycle of treatment. If 1 of 3 participants experiences a DLT, the cohort will be expanded to include an additional 3 participants. If 2 or more participants experience a DLT, then the sponsor and investigator will jointly decide whether to reduce the dose to 20 mg BID for Cohort 1 or recruit into an additional cohort at an intermediate dose for Cohorts 2 and 3.
Phase 2 recommended dose will be based on review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b Cohorts. Dose will be administered orally twice daily for 14 days followed by 14 days of rest.
100157|NCT01373164|Drug|Gemcitabine|Administered intravenously once per week for 7 weeks followed by a week of rest and then once per week for 3 weeks of every 4 weeks.
100158|NCT01373164|Drug|Placebo|Administered orally twice daily for 14 days followed by 14 days of rest.
100159|NCT01365741|Other|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
100160|NCT01365754|Procedure|standard|fusion
100161|NCT01365754|Procedure|new|dynamic stabilization
100162|NCT01365780|Procedure|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
100021|NCT01370590|Drug|Atorvastatin|20 mg tablet administered orally once daily
100022|NCT01370590|Drug|Ezetimibe|10 mg tablet administered orally once daily
100023|NCT01370590|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
100024|NCT01370590|Drug|Placebo to atorvastatin|Administered orally once daily
100025|NCT01370590|Drug|Placebo to ezetimibe|Administered orally once daily
100026|NCT01370590|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
100027|NCT00060567|Drug|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
100028|NCT01370603|Drug|Atorvastatin|40 mg tablet administered orally once daily
100029|NCT01370603|Drug|Ezetimibe|10 mg tablet administered orally once daily
99126|NCT01414062|Behavioral|Arm B|Participants randomized to Arm B will be scheduled to attend a series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
99127|NCT01414075|Drug|FG-4592|Tiered, weight-based dosing with or without oral or intravenous iron supplementation
99128|NCT01414088|Other|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
99129|NCT01414088|Other|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
99130|NCT01414088|Other|glucose 5%|infusion, 23 ml/kg, during 50 minutes
99131|NCT01414101|Drug|ISIS CRP Rx or Placebo|
99132|NCT00064935|Procedure|Endometrial biopsy|
99133|NCT01414114|Drug|KAI-4169|KAI-4169 will be administered IV thrice weekly for 12 weeks. Dose will be titrated to effect.
99134|NCT01414140|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
99135|NCT01416493|Drug|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
99136|NCT00001108|Drug|Saquinavir|
99137|NCT00065182|Drug|Docetaxel|
98419|NCT01422876|Drug|BI 10773 low dose|low dose once daily
98420|NCT01422876|Drug|high dose BI 10773 placebo|once daily
98421|NCT01422876|Drug|high dose BI 10773 placebo|once daily
98422|NCT00065975|Procedure|chiropractic|
98423|NCT01422876|Drug|linagliptin|once daily
98424|NCT01422876|Drug|low dose FDC placebo|once daily
98425|NCT01422876|Drug|linagliptin placebo|once daily
98426|NCT01422876|Drug|BI 10773 low dose placebo|once daily
98427|NCT01422876|Drug|linagliptin placebo|once daily
98428|NCT01422876|Drug|low dose BI 10773 placebo|once daily
98429|NCT01422876|Drug|linagliptin placebo|once daily
98430|NCT01422876|Drug|high dose BI 10773 placebo|once daily
98431|NCT01422876|Drug|BI 10773 low dose placebo|once daily
98432|NCT01422876|Drug|low dose BI 10773 placebo|once daily
98433|NCT00065975|Procedure|acupuncture|
98434|NCT01422876|Drug|linagliptin placebo|once daily
98435|NCT01422889|Device|ION™ Coronary Stent System|This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
98436|NCT01422902|Other|Plasticity-based Cognitive Training|
98437|NCT01422902|Other|Non-plasticity-based Training|Computer games
98438|NCT01422915|Drug|Colestipol|1 gram tablets. Phase 1: 1 gram morning and bedtime for 90 days; Phase 2: 2 grams morning and bedtime for 90 days.
98439|NCT00065065|Drug|Placebo|pill that looks identical to rosiglitazone
98725|NCT00065338|Behavioral|Exercise and behavior modification|Participants will undergo 1000 kcal/day caloric restriction (relative to experimentally determined weight-maintenance caloric needs) for 8 weeks during one phase of study. Additional 11 week period consists of 8 weeks of caloric restriction with an additional daily walking program.
99191|NCT01421680|Dietary Supplement|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
99192|NCT01421693|Drug|Ceftriaxone|≥2-<14 years - 60mg/kg/ once daily for 7 days
14 years and older - 2g once daily for 7 days
Intravenous infusion. Vials of crystalline powder.
99193|NCT01421693|Drug|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
99194|NCT01421706|Drug|Sibutramine-clopidogrel|Sibutramine-clopidogrel
99195|NCT01421706|Drug|sibutramine-Clarithromycin|sibutramine-Clarithromycin
99196|NCT01421719|Drug|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
99197|NCT01414153|Drug|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
99198|NCT01414153|Drug|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
99461|NCT01367054|Drug|Metformin|500 mg tablet
99462|NCT01367054|Drug|Glifage|500 mg tablet
99463|NCT01367080|Drug|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
99464|NCT00060346|Drug|Doxorubicin|Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation.
99465|NCT01367080|Drug|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
99466|NCT01367106|Procedure|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
99467|NCT01367119|Drug|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
99468|NCT01367119|Drug|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
99469|NCT01367132|Procedure|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
99470|NCT01367145|Drug|OMACOR|4 capsules OMACOR 1g per day
99471|NCT01367145|Drug|Placebo|4 capsules placebo per day
99472|NCT01367158|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
100163|NCT00060255|Drug|etoposide|iv
100164|NCT01365793|Other|Intravenous fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
100165|NCT01365793|Other|intravenous fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
100166|NCT01365793|Other|intravenous fluid|0.45% saline fluid
100167|NCT01365793|Other|Intravenous fluid|0.9% saline fluid
100168|NCT01365819|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
100169|NCT01365819|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
100170|NCT01365832|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
99251|NCT00065468|Drug|CCI-779|25 mg of CCI-779 given Intra Venously once per week
99252|NCT01419262|Drug|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
99253|NCT01419262|Drug|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
99254|NCT01419275|Drug|Xenon as contrast agent|
99255|NCT01419288|Other|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
99256|NCT01421745|Other|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
99257|NCT01421758|Behavioral|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
99258|NCT01421758|Behavioral|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
99138|NCT01416506|Other|No Drug|It's a surveillance
99139|NCT01416519|Procedure|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
99140|NCT01416519|Procedure|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
99141|NCT01416545|Behavioral|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
99142|NCT01416545|Behavioral|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
99143|NCT01416558|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks
Given until progression, unacceptable toxicity, patient's request or withdrawal from Study
99144|NCT01416571|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
99399|NCT01369550|Other|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
99400|NCT00060463|Behavioral|Increased access to emergency contraceptive pills|
99401|NCT01369576|Drug|Placebo|3.75-7.5mg 14 doses 4 weeks
99402|NCT01369576|Drug|Zopiclone|3.75-7.5mg 14 doses 4 weeks
99403|NCT01369589|Drug|P-552|P-552 oral rinse ( 10 mL containing 5 mg P-552)
99404|NCT01369589|Drug|Vehicle rinse|Water for Injection
99405|NCT01369602|Drug|PF-04991532|single dose 300-mg
99406|NCT01369602|Drug|PF-04991532|single dose 300-mg
99407|NCT01369602|Drug|PF-04991532|single dose 300-mg
99408|NCT01371838|Drug|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
99409|NCT01371838|Drug|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
98726|NCT01418209|Drug|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
98727|NCT01418209|Drug|Placebo|The placebo is an inactive pill that looks like the active medication.
98728|NCT01418222|Drug|5-FU|Intravenous repeating dose
98729|NCT01418222|Drug|FOLFOX regimen|Intravenous repeating dose
98730|NCT01418222|Drug|Placebo|Intravenous repeating dose
98731|NCT01418222|Drug|bevacizumab [Avastin]|Intravenous repeating dose
98732|NCT01418222|Drug|leucovorin|Intravenous repeating dose
98733|NCT01418222|Drug|onartuzumab [MetMAb]|Intravenous repeating dose
98734|NCT01418235|Biological|MVA-C + gp140/MF59|SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.
Placebo comparator: Placebo administered at Months 0, 1, 3, 6
98735|NCT01418235|Biological|MVA-C + gp140/MF59|SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6
Placebo comparator: Placebo administered at Months 0, 1, 3, 6
98736|NCT00000256|Drug|80% N2O|
98737|NCT00001108|Drug|Lamivudine|
98738|NCT00065351|Drug|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
98739|NCT01418235|Biological|DNA-C2 + MVA-C|SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6
Placebo comparator: Placebo administered at Months 0, 1, 3, 6
98740|NCT01418235|Biological|DNA-C2 + MVA-C + gp140/MF59|SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6
Placebo comparator: Placebo administered at Months 0, 1, 3, 6
98741|NCT01420848|Other|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
99473|NCT01367158|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
99474|NCT01367158|Biological|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
99475|NCT00060346|Drug|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
99476|NCT01369602|Drug|PF-04991532|single dose 300-mg
99477|NCT01369615|Drug|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
99478|NCT01369628|Drug|Atacicept|Regimen 1: Atacicept 25 mg weekly for 12 weeks
Regimen 2: Atacicept 75 mg weekly for 12 weeks
Regimen 3: Atacicept 150 mg weekly for 12 weeks
99479|NCT00060476|Drug|rofecoxib|
99480|NCT01369641|Procedure|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
99745|NCT01367600|Drug|SC Methylnaltrexone (MNTX)|
99746|NCT00001082|Drug|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
99747|NCT00060372|Drug|therapeutic allogeneic lymphocytes|Given IV
99748|NCT01367613|Drug|SC Methylnaltrexone|
99749|NCT01367626|Drug|letrozole|2.5 mg tablet
99750|NCT01367626|Drug|letrozole|2.5 mg tablet
99751|NCT01367639|Behavioral|Inquiry Based Stress Reduction (IBSR) program|The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named "The Work", enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life
99752|NCT01367652|Drug|Letrozole|2.5 mg tablet
99753|NCT01367652|Drug|Letrozole|2.5 mg Tablet
99754|NCT01367665|Drug|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
99755|NCT01367678|Device|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
99259|NCT01421771|Drug|Antihypertensive Agents|Study formulary consists of ACE/ARB, B-Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.
ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator
99260|NCT00065832|Behavioral|Reading Instruction|
99261|NCT01421771|Other|Dry weight Challenge|Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
99262|NCT01421771|Dietary Supplement|Extend dialysis treatment time and re-challenge estimated dry weight|Extend dialysis treatment time and re-challenge estimated dry weight
99263|NCT01421784|Other|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
99264|NCT01421797|Drug|Dexamethasone|1 mg PO
99265|NCT01421797|Drug|Cortrosyn|single IV bolus of 0.25 mg will be administered
99266|NCT01421810|Drug|Dexamethasone|1 mg PO
99267|NCT01421810|Drug|r-hCG (Ovidrel)|25 mcg IV
99268|NCT01421823|Drug|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
99269|NCT01421823|Drug|Placebo|2 weeks local treatment with placebo ointment
99270|NCT01421836|Procedure|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
99542|NCT01364870|Device|Placebo TENS|Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide "treatment" at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working.
99543|NCT01364870|Device|Intense TENS (EMPI Select TENS)|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
99544|NCT01367197|Behavioral|exercise training|group based exercise training
99545|NCT01367210|Drug|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
99546|NCT01367210|Drug|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
99547|NCT01367223|Dietary Supplement|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
99410|NCT01371851|Drug|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
99411|NCT01371877|Drug|Vitamin D3|Vitamin D 4000 IU per day for 3 months
99412|NCT01371877|Drug|Vitamin D3|Vitamin D 600 IU per day
99413|NCT01371968|Drug|alfentanil|Alfentanil is administered intravenously at the end of surgery.
99414|NCT01371981|Drug|Asparaginase|Given IM
99415|NCT01371981|Drug|Bortezomib|Given IV
99416|NCT00060710|Drug|CP-461|
99417|NCT01371981|Drug|Cytarabine|Given IT or IV
99418|NCT01371981|Drug|Daunorubicin Hydrochloride|Given IV
99419|NCT01371981|Drug|Etoposide|Given IV
99420|NCT01371981|Other|Laboratory Biomarker Analysis|Correlative studies
99421|NCT01371981|Drug|Mitoxantrone Hydrochloride|Given IV
99422|NCT01371981|Other|Pharmacological Study|Correlative studies
99423|NCT01371981|Other|Quality-of-Life Assessment|Ancillary studies
99424|NCT01371981|Other|Questionnaire Administration|Ancillary studies
99682|NCT01370031|Drug|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
99683|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
99684|NCT01370031|Drug|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
99685|NCT01370044|Drug|Carbogen|3 minutes administration of carbogen
99686|NCT01372228|Biological|Enriched Hematopoetic Stem Cell Transplantation|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
99687|NCT00060801|Drug|BIIL 283 BS (Amelubent)|
99688|NCT01372241|Behavioral|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
99052|NCT01416363|Drug|A|Single dose Firategrast immediate release formulation
99053|NCT01416363|Drug|B|Single dose Firategrast modified release formulation
99054|NCT00065169|Drug|Celecoxib|
99055|NCT01416363|Drug|C|Single dose Firategrast simulated gastro-retentive formulation
99056|NCT01416363|Drug|D|Repeat dose Firategrast immediate release formulation
99057|NCT01416363|Drug|E|Repeat dose Firategrast modified release formulation
99058|NCT01416363|Drug|F|Repeat dose Firategrast simulated gastro-retentive formulation
99059|NCT01416376|Drug|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
99060|NCT01416376|Drug|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
99061|NCT01416389|Drug|LY2523355|Administered intravenously
99062|NCT01416389|Drug|Ixabepilone|Administered intravenously
99063|NCT01416389|Drug|pegfilgrastim|Administered intravenously
99064|NCT01416389|Drug|filgrastim|Administered intravenously
99065|NCT00065182|Drug|Topotecan/Docetaxel combination|
99066|NCT01416402|Drug|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
99067|NCT01416402|Drug|Febuxostat|80 mg once daily orally for 5 weeks
99068|NCT01416402|Drug|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
99069|NCT01416415|Other|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
99070|NCT01416415|Other|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
99071|NCT01416428|Drug|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
99072|NCT01416441|Drug|aripiprazole|Open-label Once-weekly formulation of aripiprazole as a flexible-dose regimen
99756|NCT01367678|Device|i-Gel extraglottic airway device|Directly measured mucosal pressures
99757|NCT01367691|Device|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
99758|NCT00060385|Drug|CHOP regimen|
99759|NCT01367704|Behavioral|"Coaching Boys Into Men" program|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
99760|NCT01370044|Drug|Placebo|3 minutes administration of oxygen
99761|NCT01370057|Device|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
99762|NCT00060528|Drug|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
99763|NCT01370070|Drug|MK-2206|200mg weekly repeated q 28 days
99764|NCT01370083|Behavioral|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
100094|NCT01368237|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
100095|NCT01368250|Procedure|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
100096|NCT01368263|Drug|goserelin acetate|Given SC
100097|NCT01368263|Drug|letrozole|Given PO
100098|NCT01368263|Drug|anastrozole|Given PO
100099|NCT01368263|Drug|chemotherapy|Standard chemotherapy
100100|NCT01368263|Procedure|Surgery|
100101|NCT01368276|Biological|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
100102|NCT01368276|Drug|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
100103|NCT01368289|Procedure|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
100104|NCT00060385|Radiation|radiation therapy|
99548|NCT01367223|Dietary Supplement|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
99549|NCT01367236|Drug|standard care|atazanavir 300 mg daily
ritonavir 100 mg daily
tenofovir 245 mg daily*
emtricitabine 200 mg daily*
99550|NCT01367236|Drug|novel treatment|darunavir 800 mg daily
ritonavir 100 mg daily
lamivudine 300 mg daily** and abacavir 600mgs daily**
maraviroc 150 mg once daily
99551|NCT01367249|Drug|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
99552|NCT01367249|Drug|Placebo|Sterile ophthalmic solution
99553|NCT01367262|Drug|LY2886721|Administered orally
99554|NCT00060346|Drug|Vincristine|Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
Given as IV push over 1 minute, using extravasation precautions.
99555|NCT01367275|Drug|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
99556|NCT01367275|Drug|Irinotecan|180 mg/m^2 by vein on Day 1 of a 14 day cycle.
99557|NCT01367288|Drug|Zometa + Neoadjuvant therapy|4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
99558|NCT01367288|Drug|Neoadjuvant therapy|4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
99559|NCT01367301|Drug|paclitaxel|Given IV
99560|NCT01367301|Drug|carboplatin|Given IV
99819|NCT01365221|Drug|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
99820|NCT01365221|Drug|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
99821|NCT01365234|Device|Pacing Lead|Implant and follow up of Model 20066 lead
99822|NCT01365247|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
99823|NCT01367717|Dietary Supplement|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
99689|NCT01372254|Behavioral|Standard Treatment|Participants will receive a standard, individual smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 5, 90-minute group sessions over an 4-5 week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BAD-AS condition.
99690|NCT01372254|Behavioral|BAD-AS|BAD-AS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 5, 90-minute individual sessions over a 4-5 week period.
99691|NCT01372254|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
99692|NCT01372267|Behavioral|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
99693|NCT01372267|Behavioral|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
99694|NCT01372280|Drug|Reminyl|Galantamine Hydrobromide Tablets 4 mg
99695|NCT01372293|Drug|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
99696|NCT01372306|Drug|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
99697|NCT01372345|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
99698|NCT00060814|Other|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
99699|NCT01372358|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
100030|NCT01370603|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
100031|NCT01370603|Drug|Placebo to atorvastatin|Administered orally once daily
100032|NCT01370603|Drug|Placebo to ezetimibe|Administered orally once daily
100033|NCT01370603|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
100034|NCT01370616|Drug|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
100035|NCT01370616|Drug|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
100036|NCT01370616|Drug|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
99073|NCT01416480|Drug|Theobromine 300mg|Capsule, b.i.d.
99074|NCT01416480|Drug|Levodropropizine 10mg|Syrup, t.i.d.
99075|NCT01418794|Device|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
98114|NCT01419795|Biological|rituximab|Given IV
98115|NCT01419795|Other|pharmacological study|Correlative studies
98116|NCT01419795|Other|laboratory biomarker analysis|Correlative studies
98117|NCT01419808|Procedure|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
98118|NCT01419808|Procedure|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
98119|NCT01419821|Drug|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
98120|NCT00065546|Other|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
98121|NCT01419821|Other|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
98122|NCT01419834|Biological|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over ~30 minutes
98123|NCT01419847|Drug|Ciclopirox|
98124|NCT01419847|Drug|Placebo|
98125|NCT01419860|Procedure|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
98126|NCT01419873|Drug|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
98127|NCT01419899|Behavioral|Brief motivational intervention|A 20-30 minute motivational based discussion
98128|NCT01419912|Dietary Supplement|soy milk|
98129|NCT01419912|Dietary Supplement|cow's milk|
98130|NCT01419925|Biological|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
100105|NCT01368302|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
100106|NCT01368315|Drug|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
100107|NCT01368315|Drug|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
100108|NCT01368315|Drug|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
100109|NCT01368315|Drug|No intervention|No intervention to one out of four test fields marked on the patient's back.
100110|NCT01368328|Dietary Supplement|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
100111|NCT01368341|Drug|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
100112|NCT01368341|Drug|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
100113|NCT01368341|Drug|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
99199|NCT01414153|Drug|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
99200|NCT01414153|Drug|sham injection|administered monthly for 4 months
99201|NCT01414166|Drug|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
99202|NCT01414166|Drug|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
99203|NCT01414205|Drug|Obinutuzumab|Obinutuzumab (RO5072759) Repeating intravenous dose.
99204|NCT01414218|Behavioral|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
99205|NCT00001107|Drug|AmBisome|
99206|NCT00064961|Behavioral|Individualized dietary-control and exercise program|
99207|NCT01414231|Drug|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
99208|NCT01414244|Dietary Supplement|Glutamine Supplementation|Oral Glutamine
99824|NCT01367717|Dietary Supplement|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
99825|NCT01367743|Drug|epinephrine/norepinephrine|perfusion of commercial epinephrine or norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
99826|NCT01367756|Drug|RO4995819|multiple oral doses, Days 10-16
99827|NCT01367756|Drug|citalopram|multiple oral doses, Days 1-16
99828|NCT01367756|Drug|placebo|multiple oral doses, Days 10-16
99829|NCT01367769|Other|No intervention|There will be no intervention in this study.
99830|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
99831|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
99832|NCT00060385|Drug|EPOCH regimen|
99833|NCT01367808|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
99834|NCT01367808|Drug|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
99835|NCT01367808|Drug|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
99836|NCT01367834|Drug|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
99837|NCT01367847|Behavioral|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon & Forehand) for parents of 3 to 8 y.o. children with externalizing problems
100171|NCT01365845|Radiation|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
100172|NCT01365845|Radiation|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
100173|NCT01365858|Other|Rehabilitation|The experimental group patients receive rehabilitation by training "Virtual Action Planning - Supermarket" on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy).
100037|NCT01370616|Drug|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
100038|NCT00001083|Drug|Lamivudine|
100039|NCT00060567|Drug|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
100040|NCT01370629|Drug|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
100041|NCT01372774|Radiation|stereotactic radiosurgery|Undergo RT
100042|NCT01372774|Radiation|whole-brain radiation therapy|Undergo radiotherapy (RT)
100043|NCT01372787|Procedure|Assessment of Therapy Complications|Ancillary studies
100044|NCT01372787|Other|Medical Chart Review|Ancillary studies
100045|NCT01372787|Other|Quality-of-Life Assessment|Ancillary studies
100046|NCT00001084|Drug|Indinavir sulfate|
100047|NCT00060905|Drug|Divalproex Sodium (Depakote ER)|
100048|NCT01372787|Other|Questionnaire Administration|Ancillary studies
100049|NCT01372813|Drug|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
100050|NCT01372826|Drug|NKTR118 Group1|Oral dose, 25 mg
100051|NCT01372826|Drug|NKTR118 Group 2|Oral dose, 25 mg
100052|NCT01372826|Drug|NKTR118 Group3|Oral dose, 25 mg
100053|NCT01372826|Drug|NKTR118|Oral dose, 25 mg
99145|NCT01416584|Behavioral|employment based reinforcement|Methadone, which can reduce injection heroin use and injection-related HIV risk, will be used. Participants will be offered to enroll in methadone treatment and given access to a Therapeutic Workplace. Participants who are deemed eligible (N=162) will be randomly assigned to one of three groups. All groups will be invited to work in the Therapeutic Workplace and will be prescribed methadone for 6 months.
99146|NCT01416597|Biological|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
99147|NCT01416623|Drug|henatinib|Henatinib Maleate Tablets
99148|NCT00065195|Procedure|Moving touch therapy|
99149|NCT01416636|Drug|Treprostinil sodium|
98131|NCT01422239|Behavioral|Standard Treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
98132|NCT01422252|Device|Vigi'Fall®|Precocious fall detection device
98133|NCT01422278|Other|Rehabilitation|Three weeks of rehabilitation in Hospital.
98134|NCT01422291|Drug|paracetamol|1 gr
98135|NCT01422291|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
98440|NCT01415245|Device|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
98441|NCT01415271|Other|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
98442|NCT01415284|Drug|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
98443|NCT01415297|Drug|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
98444|NCT01415336|Drug|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
98445|NCT01415336|Drug|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
98446|NCT01415349|Drug|SSP-002358|1 mg, oral, once
98447|NCT01415349|Drug|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
98448|NCT01415362|Device|Transcranial Direct Current Stimulation|For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.
The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit.
98449|NCT01415375|Behavioral|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
98450|NCT00065078|Procedure|Home dispensing of contraception|
98451|NCT01415375|Behavioral|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
98452|NCT01415388|Dietary Supplement|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
99209|NCT01414244|Dietary Supplement|Placebo|Oral Placebo
99210|NCT01414244|Drug|Glutamine|
99211|NCT01414257|Drug|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
99212|NCT01414283|Drug|PSMA ADC|PSMA ADC administered IV
99213|NCT01414296|Drug|PSMA ADC|PSMA ADC administered IV
99214|NCT01414335|Dietary Supplement|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
99215|NCT01414335|Other|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
99216|NCT01414348|Behavioral|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
99217|NCT00064961|Behavioral|Weight-management and smoking cessation maintenance|
99218|NCT01414348|Behavioral|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
99481|NCT01369641|Drug|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
99482|NCT01369641|Other|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
99483|NCT01369641|Drug|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
99484|NCT01369654|Behavioral|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
99485|NCT01369667|Dietary Supplement|Vitamin D3|
99486|NCT01369667|Other|Placebo|
99487|NCT01369680|Drug|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
99488|NCT01369693|Procedure|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
99489|NCT01369706|Device|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
100174|NCT00060255|Drug|melphalan|oral
100175|NCT01365871|Procedure|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
100176|NCT01365897|Drug|Modafinil|Modafinil 200mg
100177|NCT01365910|Drug|linifanib|Given PO
100178|NCT01365923|Drug|remifentanil|remifentanil effect site-TCI 2-4ng/ml
100179|NCT01365923|Drug|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
100180|NCT01365936|Drug|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
100181|NCT01365936|Drug|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
100182|NCT00060398|Biological|epoetin alfa|
100183|NCT01368367|Other|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
100184|NCT01368380|Behavioral|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
100185|NCT01368393|Procedure|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
100186|NCT01368393|Procedure|Sham acupuncture|Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. "Pseudostimulation" will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
100187|NCT01368406|Behavioral|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
99271|NCT00065845|Procedure|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
99272|NCT01421836|Procedure|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
99150|NCT01416649|Drug|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
99151|NCT01416662|Drug|gemcitabine hydrochloride|
99152|NCT01416688|Procedure|assessment of therapy complications|Will be given by questionnaire
99153|NCT01416688|Procedure|psychosocial assessment and care|Will be given by questionnaire
99154|NCT01416688|Procedure|quality-of-life assessment|Will be given by questionnaire
99155|NCT01416701|Dietary Supplement|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
99156|NCT01419015|Device|Transcatheter aortic valve implantation (SAPIEN XT NovaFlex delivery system)|Transcatheter aortic valve implantation via transfemoral approach.
99157|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =>90 mL/min)
99158|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr <30 mL/min)
99159|NCT01419067|Procedure|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
99160|NCT01419067|Radiation|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
99425|NCT01371981|Drug|Sorafenib Tosylate|Given PO
99426|NCT01371994|Drug|solifenacin succinate|oral
99427|NCT00060749|Drug|Docosahexaenoic Acid (DHA) Dietary Supplement|
99428|NCT01371994|Drug|Placebo|oral
99429|NCT01372007|Drug|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
98453|NCT01415401|Drug|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
98454|NCT01415414|Drug|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
98455|NCT01415427|Drug|BMN 110 - Weekly|In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.
In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo.
98456|NCT01415427|Drug|BMN 110 - Every Other Week|In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.
In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo.
98457|NCT01415440|Drug|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
98742|NCT01420848|Other|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
98743|NCT00001110|Procedure|Bronchoalveolar lavage|
98744|NCT00065676|Procedure|Oral glucose tolerance test|
98745|NCT01420861|Drug|GTx-758|two GTx 758 tablets per day
98746|NCT01420874|Drug|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
98747|NCT01420874|Biological|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
98748|NCT01420887|Procedure|Continuous Passive Motion|Continuous passive motion.
98749|NCT01420887|Procedure|Physical Therapy|Physical therapy.
98750|NCT01420900|Device|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
98751|NCT01420900|Device|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
98752|NCT01420913|Drug|Pregabalin|Pregabalin 300mg a day
98753|NCT01420926|Drug|Bortezomib|Given SC
99490|NCT00060476|Drug|Comparator: placebo (unspecified)|
99491|NCT01369719|Drug|osveral|receive 20 mg/kg daily orally
99492|NCT01369719|Drug|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
99493|NCT01369732|Drug|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
99494|NCT01369732|Drug|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
99495|NCT01369745|Drug|Prednisolone|Prednisolone 2.7 mg daily
99496|NCT01369745|Drug|dipyridamole|dipyridamole 360 mg daily
99497|NCT01369745|Drug|Prednisone|Prednisone 5 mg daily
99498|NCT01369745|Drug|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
99499|NCT01369745|Other|placebo|
99500|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
99501|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
99502|NCT01372046|Behavioral|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
99503|NCT01372046|Behavioral|Training|memorandums, staff meetings
99765|NCT01370083|Behavioral|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
99766|NCT01370096|Drug|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
99767|NCT01370096|Drug|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
99768|NCT01370122|Other|Survey|
99273|NCT01421849|Procedure|Denture implantation|In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.
Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.
The total duration of the study will be 12 to 18 months.
99274|NCT01421862|Genetic|DNA methylation analysis|
99275|NCT01421862|Genetic|RNA analysis|
99276|NCT01421862|Genetic|gene expression analysis|
99277|NCT01421862|Genetic|microarray analysis|
99278|NCT01421862|Genetic|mutation analysis|
99279|NCT01421862|Genetic|nucleic acid sequencing|
99280|NCT01414387|Procedure|Carotid filter|Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.
The filter used for this trial is the RX accunet embolic protection system manufactured by abbott.
99281|NCT01414387|Procedure|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
99282|NCT01414400|Other|Blood draw for culture|Blood will be drawn and sent for culture.
99283|NCT01414413|Other|Home assessment and initiation of ART|Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
99284|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
99285|NCT01414426|Drug|vandetanib|Given PO
99286|NCT01414426|Other|placebo|Given PO
99287|NCT00064961|Behavioral|Smoking Cessation program|
99288|NCT01414426|Other|immunohistochemistry staining method|Correlative studies
99289|NCT01414426|Other|laboratory biomarker analysis|Correlative studies
99290|NCT01414426|Procedure|biopsy|Correlative studies
99561|NCT01367301|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
99430|NCT01372007|Drug|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
99431|NCT01372020|Other|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
99432|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
99433|NCT01364571|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
99434|NCT00060086|Dietary Supplement|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
99435|NCT01364571|Procedure|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
99436|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
99437|NCT01364571|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
99438|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
99439|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
99440|NCT01364571|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
99441|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
99700|NCT01372371|Biological|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
99701|NCT01372371|Biological|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
99702|NCT01372371|Biological|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
98754|NCT01420926|Drug|Decitabine|Given IV
98755|NCT00065689|Device|high-intensity light therapy|
98756|NCT01420926|Other|Laboratory Biomarker Analysis|Correlative studies
98757|NCT01420926|Other|Pharmacological Study|Correlative studies
98758|NCT01420926|Other|Quality-of-Life Assessment|Ancillary studies
98759|NCT01420926|Other|Questionnaire Administration|Ancillary studies
98760|NCT01420952|Drug|[11C]LY2428703|
98761|NCT01420965|Drug|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
98762|NCT01420965|Other|Sipuleucel-T (Provenge)|Vaccine
98763|NCT01420965|Drug|Cyclophosphamide|Low dose- Immune Enhancer
98764|NCT01420978|Procedure|CSF Diversion|CSF drainage
97828|NCT00058266|Procedure|conventional surgery|Patients undergo surgery
97829|NCT01349192|Drug|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
97830|NCT01349192|Drug|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
97831|NCT01349192|Behavioral|Environmental Decontamination|wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.
wash all linens and towels in hot water once weekly for three weeks.
97832|NCT01349205|Drug|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
97833|NCT01349205|Drug|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
97834|NCT01349205|Drug|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
97835|NCT01349218|Biological|potassium level capillary blood|potassium level capillary blood will be check through a small amout of blood was withdrawn from a vein or from a capillary stick.
97836|NCT01349231|Drug|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
97837|NCT01349257|Drug|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
99769|NCT01370135|Drug|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
99770|NCT01370148|Drug|conivaptan hydrochloride|Intravenous
99771|NCT01370161|Procedure|Transjugular intrahepatic portosystemic shunt|A 8 mm Fluency stent will be used, that will be dilated to 8 or 10 mm according to the hemodynamic response. The aim will be to reduce the portal pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.
Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices, in association with a PPG below 16 mmHg
After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted
99772|NCT01370161|Drug|Non-selective beta blocker + Endoscopic treatment|Patients will begin treatment with non-selective beta-blockers (either propranolol or nadolol). After an initial dose of 40 mg, the dose of propranolol/nadolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm or up to the maximum tolerated dose, within the limit of 160 mg twice a day (bid) for propranolol or to a maximum of 160 mg for nadolol.
The first elective session of endoscopic band ligation should be performed within the first 7-14 days. The following sessions will be performed at 14 + 3 days intervals until variceal eradication (defined as disappearance of the varix, impossibility of suctioning the varix, or a maximum of six continued sessions). Once eradication is achieved, a control endoscopy will be performed one month later for confirmation. The following endoscopies will be scheduled at 6 and 12 months of inclusion and yearly thereafter. If varices reappear, new band ligation will follow.
99773|NCT00060528|Drug|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
99774|NCT01370174|Other|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
99775|NCT01372592|Procedure|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
99776|NCT01372605|Other|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
100114|NCT01368354|Behavioral|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
100115|NCT01370642|Drug|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
100116|NCT01370642|Drug|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
100117|NCT01370642|Biological|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
100118|NCT01370642|Drug|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
96616|NCT01344564|Drug|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
96617|NCT01344590|Other|Normal Saline|Standard saline procedure will be utilized.
96618|NCT01344590|Other|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
96619|NCT01344616|Behavioral|lifestyle support|computer-based lifestyle improvement support and clinician support
96620|NCT00057889|Biological|ipilimumab|
96621|NCT01344629|Drug|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
96622|NCT01344629|Drug|Telmisartan|Telmisartan 80 mg tablet
96623|NCT01344629|Drug|Amlodipin|Amlodipin 5mg tablet
96624|NCT01344655|Drug|Atimos®|Formoterol 12 μg pMDI
96625|NCT01344655|Drug|Serevent™|Salmeterol 25 µg pMDI
99604|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
99605|NCT00060762|Behavioral|Guided Self Help|10 sessions of guided self help were provided over a 6-month period
99606|NCT01372163|Drug|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
99607|NCT01372176|Other|Early Goal-Directed Nutrition|Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).
Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.
Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN).
99608|NCT01372176|Other|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
99609|NCT01372202|Drug|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
99610|NCT01372202|Drug|Cisplatin|Paclitaxel and cisplatin:
Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.
Cisplatin and 5-fluorouracil:
5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.
Cisplatin 75 mg/m² days 1, 29.
99611|NCT01372202|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
99093|NCT01419002|Procedure|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
99094|NCT01421368|Drug|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
99095|NCT01421368|Drug|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
99096|NCT01421407|Device|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
99097|NCT00065767|Drug|Raloxifene|
99098|NCT01421433|Drug|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
99099|NCT01421433|Drug|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
99100|NCT01421459|Drug|LY2963016|Administered subcutaneously
99101|NCT01421459|Drug|Lantus|Administered subcutaneously
99102|NCT01421459|Drug|OAMs|Administered orally
99103|NCT01421472|Drug|MM-121 (SAR256212) plus paclitaxel|Treatment of MM-121 (SAR256212) IV plus standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
99104|NCT01421472|Drug|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
99105|NCT01421485|Behavioral|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
99106|NCT01421485|Behavioral|Treatment as Usual|Treatment in community, case management
99107|NCT01421498|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: placebo, 5.0% Frequency: BID Duration: 12 weeks
99108|NCT00065806|Drug|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
99109|NCT01421511|Drug|TR-701 FA|TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion
TR-701 FA Tablets, 200 mg, orally once daily
99110|NCT01421511|Drug|Linezolid|Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion
Linezolid Tablets, 600 mg, orally every 12 hours
96170|NCT01358409|Drug|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
96171|NCT01358435|Biological|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
96172|NCT01358435|Biological|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
96173|NCT01358448|Behavioral|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
96174|NCT01360775|Behavioral|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
96175|NCT01360788|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
96176|NCT01360814|Procedure|quality-of-life assessment|Ancillary studies
96177|NCT01360814|Behavioral|telephone-based intervention|Receive multidisciplinary structured intervention
96178|NCT01360814|Other|questionnaire administration|Ancillary studies
96179|NCT01360814|Other|counseling intervention|Receive multidisciplinary structured intervention
96180|NCT01360814|Behavioral|exercise intervention|Receive multidisciplinary structured intervention
96181|NCT01360814|Other|educational intervention|Receive multidisciplinary structured intervention
96182|NCT00059787|Drug|paclitaxel|Given IV
96183|NCT01360814|Behavioral|telephone-based intervention|Receive standard care
96184|NCT01360814|Procedure|standard follow-up care|Receive standard care
96185|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
96186|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
95642|NCT01359722|Drug|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
95643|NCT01359735|Biological|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
95644|NCT01359735|Biological|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
95645|NCT01359748|Device|Reference sphygmomanometer|* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
95646|NCT01359748|Device|Sphygmomanometer under test|Electronic Oscillometric method.
95926|NCT01362790|Biological|SS1(dsFv)PE38 - lot FIL129J01|Regimen A:
Cycle 1: assigned dose level on days 10, 12 and 14 of 30 day cycle Cycles 2-4: assigned dose level on days 2, 4 and 6 of 21 day cycle
95927|NCT01362803|Drug|AZD6244|AZD6244 orally every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable PD
95928|NCT01362829|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
95929|NCT01362868|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
95930|NCT01362894|Device|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
95931|NCT01362894|Device|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
95932|NCT01362907|Device|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
95933|NCT01362907|Device|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
95934|NCT00059891|Procedure|conventional surgery|
95935|NCT01362933|Procedure|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
95936|NCT01362946|Behavioral|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
95937|NCT01362946|Behavioral|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
95938|NCT01362959|Drug|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
99612|NCT01372202|Drug|5-Fluorouracil|Oxaliplatin and 5-fluorouracil:
Oxaliplatin 85 mg/m2 days 1, 15, 29.
5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)
Cisplatin and 5-fluorouracil:
5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.
Cisplatin 75 mg/m² days 1, 29.
99613|NCT01372202|Radiation|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
99614|NCT01372202|Procedure|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
99615|NCT01364883|Biological|Vaccination Schedule One|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
99616|NCT00060112|Other|pharmacological study|Correlative studies
99617|NCT01364883|Biological|Vaccination Schedule Two|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
99618|NCT01364883|Biological|Vaccination Schedule Three|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
99619|NCT01364883|Biological|Vaccination Schedule Four|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
99620|NCT01364883|Biological|Vaccination Schedule Five|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
99874|NCT01373073|Other|Control human milk fortifier|Control human milk fortifier to be added to human milk
99875|NCT01373086|Drug|LFF269|
99876|NCT01373086|Drug|Eplerenone|
99877|NCT01373086|Drug|Placebo|
99878|NCT01373099|Procedure|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
99879|NCT01373099|Procedure|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
99369|NCT01366859|Dietary Supplement|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
99370|NCT01366859|Dietary Supplement|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
99371|NCT01366885|Drug|Vitamin D3|4000 IU D3 capsule oral/day for entire pregnancy. 6000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
99372|NCT01366898|Drug|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
99373|NCT00060346|Biological|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
99374|NCT01366924|Dietary Supplement|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
99375|NCT01366924|Other|Endurance exercise|60 minute endurance exercise session
99376|NCT01366950|Behavioral|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
99377|NCT01366963|Behavioral|Seated Measurements|The following measurements will take place in a seated position:
Ruff 1 & 7 (visual search and attention processes) Trails A & B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)
99378|NCT01366963|Behavioral|Standing Measurements|The following will be measured in a standing position (at least 5 minutes)
Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test
99379|NCT01366963|Behavioral|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
99380|NCT01366976|Drug|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
99381|NCT01366989|Device|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
99382|NCT01367002|Drug|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
99642|NCT01367353|Procedure|surgery or debulking surgery|surgery or debulking surgery
96465|NCT00000254|Other|Sham comparator|0% isoflurane in oxygen
96466|NCT00001075|Drug|Lamivudine|
96467|NCT00058721|Drug|I-123-5-IA85380|
96468|NCT01353911|Drug|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
96469|NCT01353911|Drug|Ribavirin|300 mg to 700 mg orally twice daily.
96470|NCT01353924|Biological|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
96471|NCT01353924|Biological|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
96472|NCT01353937|Drug|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
96473|NCT01353963|Drug|desvenlafaxine succinate|50 mg tablet once daily
96474|NCT01353976|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
96475|NCT01356394|Other|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
96476|NCT01356407|Drug|PICOPREP|
96477|NCT01356407|Drug|PEG-ELS|
96478|NCT01356420|Dietary Supplement|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
96479|NCT01356433|Drug|oral vitamin C|cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
96480|NCT01356433|Drug|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
96481|NCT01356446|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
96482|NCT00059215|Drug|Prasugrel (CS-747)|Administered orally
96483|NCT01356459|Device|Mepilex Border Dressing|Soft silicone self adherent dressing
96484|NCT01356472|Drug|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
95939|NCT01362959|Other|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
95940|NCT01362998|Drug|Preservative free morphine|3mg given epidurally during the Cesarean section.
95941|NCT01362998|Drug|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
95942|NCT01363011|Drug|Stribild|Stribild® (elvitegravir [EVG] 150 mg/cobicistat [COBI] 150 mg/emtricitabine [FTC] 200 mg/tenofovir disoproxil fumarate [TDF] 300 mg) single-tablet regimen (STR) administered orally once daily.
95943|NCT01363011|Drug|COBI|Cobicistat (COBI, /co) 150 mg tablet administered with food orally once daily
95944|NCT01363011|Drug|ATV|Atazanavir (ATV) 300 mg tablet administered orally once daily
95945|NCT00059891|Procedure|management of therapy complications|
96243|NCT01358487|Behavioral|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
96244|NCT01358500|Drug|Fentanyl|Intravenous infusion using STANPUMP
96245|NCT01358526|Drug|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
96246|NCT01358526|Drug|Placebo|Placebo tablets to match OXN taken orally every 12 hours
96247|NCT01358539|Behavioral|Pain education|Patients receiving pain education
96248|NCT01358552|Other|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
96249|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
96250|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
96251|NCT00059462|Drug|Interleukin-2 SA|HAART and Bay 50-4798
96252|NCT01358578|Drug|Placebo|Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
96253|NCT01358578|Drug|secukinumab (AIN457)|secukinumab (AIN457) 150mg or 300mg subcutaneous
96254|NCT01358578|Drug|etanercept|etanercept 50mg subcutaneous
99880|NCT01365247|Behavioral|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
99881|NCT01365247|Behavioral|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
99882|NCT01365260|Device|MM-II|Single intraarticular (knee) injection of MM-II
99883|NCT01365260|Device|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
99884|NCT00001081|Drug|Nitazoxanide|
99885|NCT00060203|Drug|brostallicin|Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
99886|NCT01365273|Device|Mepitel One|Dressing
99887|NCT01365286|Drug|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
99888|NCT01365286|Drug|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
99889|NCT01365312|Drug|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
99890|NCT01365312|Drug|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
100226|NCT01363284|Drug|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
100227|NCT01363297|Drug|Inotuzumab Ozogamicin|Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.
Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2.
100228|NCT01363310|Drug|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
100229|NCT01363310|Drug|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
100230|NCT00059930|Drug|dexamethasone|
100231|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 1
100232|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 2
100233|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 3
95795|NCT01357655|Drug|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
95796|NCT01357681|Drug|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
95797|NCT01357681|Drug|Placebo|Placebo
95798|NCT01357694|Behavioral|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
95799|NCT00059332|Drug|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
95800|NCT01357707|Genetic|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
95801|NCT01357720|Biological|Quinvaxem|A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at Weeks 6, 10 and 14
95802|NCT01357720|Biological|Quinvaxem/Tritanrix|A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), inactive pertussis bacteria (>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at Weeks 6, 10 and 14
95803|NCT01357733|Other|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
95804|NCT01357746|Procedure|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
95805|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
95806|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
95807|NCT01357772|Drug|Tamoxifen|at daily dose of 5 mg for a total treatment time of 3 years
96106|NCT01353209|Drug|Letrozole|2.5 mg daily for twelve months
96107|NCT01353209|Drug|Placebo|sugar pill given daily for twelve months
96108|NCT01353222|Biological|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein.
96109|NCT00058578|Drug|Mesna|
96110|NCT01353222|Other|Standard of Care|Standard of care
96485|NCT01356485|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
96486|NCT01356485|Drug|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
95574|NCT01359670|Drug|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
95575|NCT01359683|Device|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
95576|NCT01359696|Drug|GDC-0425|Oral escalating dose
95577|NCT01359696|Drug|gemcitabine|Intravenous repeating dose
95578|NCT01359709|Drug|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
95579|NCT00059644|Drug|Ecraprost in lipid emulsion|
95580|NCT01362400|Drug|IPI 504 plus Docetaxel|450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle
75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)
95581|NCT01362400|Drug|Placebo plus Docetaxel|450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle
75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)
95582|NCT01362426|Drug|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
95583|NCT01362439|Drug|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
95584|NCT00059852|Drug|erlotinib hydrochloride|
95585|NCT01362452|Genetic|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
95586|NCT01362452|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0.
95587|NCT01362465|Procedure|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
95588|NCT01362491|Drug|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
95589|NCT01362491|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
95590|NCT01362491|Drug|Placebo|Single-dose of placebo
96255|NCT01358591|Dietary Supplement|High calcium milk|High calcium milk (9 mg/kgBM)
96256|NCT01358591|Dietary Supplement|Control|Regular Milk
96257|NCT01358604|Genetic|polymerase chain reaction|
96258|NCT01358604|Genetic|protein expression analysis|
96259|NCT01358604|Genetic|western blotting|
96260|NCT01358604|Other|flow cytometry|
96261|NCT01358604|Other|immunohistochemistry staining method|
96262|NCT00059462|Drug|HAART|HAART alone
96263|NCT01358604|Other|laboratory biomarker analysis|
96264|NCT01358617|Other|diagnostic laboratory biomarker analysis|Correlative studies
96265|NCT01360866|Drug|OPC-34712 + ADT|Tablets, Oral, 0.5 - 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
96553|NCT01354041|Behavioral|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
96554|NCT01354054|Procedure|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
96555|NCT01354054|Procedure|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
96556|NCT01354054|Procedure|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
96557|NCT01354067|Behavioral|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
96558|NCT01354067|Behavioral|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
100234|NCT01363323|Drug|Placebo|
100235|NCT01363323|Drug|Moxifloxacin|
100236|NCT01363336|Drug|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
100237|NCT01363349|Drug|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
100238|NCT01363349|Drug|Risperidone|
100239|NCT01363362|Procedure|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
100240|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
100241|NCT00059930|Drug|floxuridine|
100242|NCT01363375|Procedure|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
100243|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
100244|NCT01363388|Drug|Placebo|BID for 84 days
100245|NCT01363388|Drug|CCX168|BID for 84 days
100246|NCT01363401|Biological|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
100247|NCT01363401|Other|Control group|No treatment of HYNR-CS inj
100248|NCT01363414|Drug|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
100249|NCT01365949|Genetic|microarray analysis|
99312|NCT01369355|Drug|Ustekinumab|if then respond, one SC injection q8w
99313|NCT01369368|Drug|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
99314|NCT01369381|Procedure|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
96111|NCT01353235|Drug|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
96112|NCT01353235|Drug|usual care|no drug administered
96113|NCT01353248|Drug|GS-5885|tablet, 30 mg QD
96114|NCT01353248|Drug|Tegobuvir|capsule, 30 mg BID
96115|NCT01353248|Drug|GS-9451|tablet, 200 mg QD
96116|NCT01353248|Drug|ribavirin tablet|(weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
96117|NCT01353248|Drug|GS-5885|tablet, 90 mg QD
96118|NCT01353274|Drug|Micamlo|Telmisartan plus Amlodipine T40/A5
96119|NCT01353300|Genetic|DNA analysis|
96120|NCT00058578|Drug|G-CSF|
96121|NCT01353300|Genetic|cytogenetic analysis|
96122|NCT01353300|Genetic|gene expression analysis|
96123|NCT01353300|Genetic|gene rearrangement analysis|
96124|NCT01353300|Genetic|mutation analysis|
96125|NCT01353300|Genetic|polymerase chain reaction|
96126|NCT01353300|Genetic|polymorphism analysis|
96127|NCT01353300|Other|laboratory biomarker analysis|
96128|NCT01353300|Other|medical chart review|
96129|NCT01353313|Drug|Hydrocortisone|Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:
4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then
1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
96399|NCT00059475|Drug|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
96400|NCT01358760|Drug|Placebo|Placebo vaginal suppository
96401|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
95591|NCT01362517|Biological|Quinvaxem|A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at 2, 3 and 4 months of age
95592|NCT01362530|Drug|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
95593|NCT01362530|Drug|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
95870|NCT01355445|Drug|Vincristine-Irinotecan-Temozolomide|D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind)
D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)
D1 to D5: Irinotecan 50 mg/m²/d, IV
cycle / 21 days
95871|NCT01355458|Drug|CD07805/47 gel|applied topically once daily
95872|NCT01355458|Drug|Placebo|applied topically once daily
95873|NCT01355471|Drug|CD07805/47 Gel|applied topically once daily
95874|NCT01355471|Drug|Placebo|applied topically once daily
95875|NCT01355484|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
95876|NCT01355484|Drug|placebo|subject will receive placebo for the duration of the trial
95877|NCT00058864|Device|Energy absorbing and distributing trochanteric pad|
95878|NCT01355497|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the duration of the trial.
95879|NCT01355497|Drug|placebo|subject will receive placebo for the duration of the trial
95880|NCT01355523|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
95881|NCT01355523|Drug|Placebo|6 mg oral placebo daily 1 hour before bedtime
95882|NCT01355549|Biological|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
95883|NCT00059332|Drug|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
95884|NCT01357798|Drug|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
96559|NCT01354080|Other|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
96560|NCT01354080|Other|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
96561|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
96562|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
96563|NCT00058747|Drug|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
96564|NCT01354106|Device|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
96565|NCT01354119|Procedure|Aortic stent-graft|Early intervention with aortic stent-graft
96566|NCT01354132|Drug|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
96567|NCT01354145|Drug|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
96568|NCT01349452|Drug|Artificial tear|Artificial tear 5 times per day
96569|NCT01349465|Drug|No treatment|No treatment was given as this is an observational study.
95647|NCT01359761|Behavioral|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
95648|NCT01359774|Other|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
95649|NCT01359774|Other|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
95650|NCT01359787|Drug|Mapracorat|Daily topical application
95651|NCT00059657|Drug|Ecraprost in lipid emulsion|
95652|NCT01359787|Drug|Vehicle without active|Daily topical application
95653|NCT01359813|Drug|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
99315|NCT01369394|Other|Behavioral: Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any "live" server or website.
99316|NCT00060450|Drug|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
99317|NCT01369407|Other|No Intervention|Not an interventional study
99318|NCT01369420|Device|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
99319|NCT01369433|Drug|tivozanib (AV-951) + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib (AV-951) will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
99320|NCT01369433|Drug|tivozanib (AV-951) + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
99321|NCT01369433|Drug|tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
99322|NCT01369433|Drug|tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
99323|NCT00060684|Drug|dexamethasone|
99324|NCT01371630|Drug|Ara-C|Intrathecal ara-C 100 mg on Day 8 of cycles 1, 3, 5, 7.
Ara-C 0.5 g/m2 by vein twice a day for 4 doses - Days 2 and 3 of cycles 2, 4, 6, and 8.
99325|NCT01371643|Drug|Octreotide LAR|
99326|NCT01371643|Procedure|transsphenoidal surgery|
99327|NCT01371656|Drug|levofloxacin|Given PO or IV
99328|NCT01371682|Drug|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
99329|NCT01371708|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
99891|NCT01365325|Other|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
99892|NCT01365325|Other|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
96402|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
96403|NCT01358773|Other|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
96404|NCT01358786|Procedure|quilting suture|quilting sutures and drains
quilting sutures but no drains
96405|NCT01358799|Device|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
96406|NCT01358812|Drug|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
96407|NCT01358825|Procedure|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
96408|NCT01358838|Device|ablative 10600 nm fractional laser therapy|Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.
Half of the scar, or one of two comparable scars, will receive no treatment at all.
96409|NCT01358851|Procedure|Cryotherapy|1-2 times during the treatment time
96410|NCT00059475|Drug|Montanide ISA 51|
96411|NCT01358851|Drug|LAS41005|once daily
96412|NCT01358864|Drug|BI 201335|BI 201335 once a day (QD) for 24 weeks
96413|NCT01358864|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
96414|NCT01358864|Drug|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
96415|NCT01358864|Drug|Placebo|Placebo to BI201335 for 24 weeks
96416|NCT01358877|Drug|Chemotherapy|6-8 cycles of standard chemotherapy (non-anthracycline based or anthracycline-based)
96417|NCT01358877|Drug|pertuzumab|840 mg iv loading dose in Cycle 1, followed by 420 mg iv every 3 weeks, 52 weeks
96418|NCT01358877|Drug|placebo|iv every 3 weeks, 52 weeks
96419|NCT01358877|Drug|trastuzumab [Herceptin]|8 mg/kg iv loading dose in Cycle 1, followed by 6 mg/kg iv every 3 weeks, 52 weeks
95509|NCT01354587|Drug|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
95885|NCT01357798|Drug|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
95886|NCT01357811|Drug|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
95887|NCT01357811|Drug|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
95888|NCT01357824|Procedure|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
96187|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent [%] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
96188|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
96189|NCT01360840|Other|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
96190|NCT01360840|Other|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
96191|NCT01360853|Drug|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
96192|NCT01360853|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
96193|NCT00059787|Drug|carboplatin|Given IV
96194|NCT01360853|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
96195|NCT01353326|Device|Cormet|Cementless hip resurfacing system
96196|NCT01353326|Device|Conserve|Cemented hip resurfacing system
96197|NCT01353339|Drug|Levofloxacin|500mg, PO, once daily for 3 months
96198|NCT01353352|Other|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
96199|NCT01353378|Drug|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
95654|NCT01359826|Drug|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
95655|NCT01359839|Behavioral|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
95656|NCT01359852|Drug|[11C] JNJ-42491293|Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
95657|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
95658|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.
Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain
95659|NCT01359852|Drug|[11C] JNJ-42491293|Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
95660|NCT01359865|Procedure|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at <0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
95661|NCT01359878|Drug|Fibrinogen Concentrate|2 gram intra venous
95662|NCT01362686|Drug|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
95946|NCT01363011|Drug|DRV|Darunavir (DRV) 800 mg tablet administered orally once daily
95947|NCT01355562|Drug|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
95948|NCT01355575|Drug|Rifaximin|Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
95949|NCT01355588|Drug|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
95950|NCT01355588|Drug|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
95951|NCT01355588|Drug|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
95952|NCT00058890|Drug|gabapentin|
99893|NCT01365338|Drug|Placebo|oral solution, single dose
99894|NCT01365338|Drug|PF-04958242|oral solution, single dose; 0.075mg
99895|NCT01365338|Drug|PF-04958242|oral solution, single dose; 0.15mg
99896|NCT00060242|Drug|fosbretabulin disodium|Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
99897|NCT01365351|Other|Growth hormone|Drug given by prescription
99898|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
99899|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
99900|NCT01365377|Other|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
99901|NCT01365390|Other|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to < 6 years) or since birth (for subjects aged < 1 year) will be recorded in the electronic case report form.
99902|NCT00060385|Drug|cyclophosphamide|
99903|NCT01367886|Drug|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
99904|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
99905|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
99906|NCT01367951|Procedure|Surgical fixation|The fractures will be reduced and stabilized by use of plates and screws
Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.
Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.
Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted.
99907|NCT01367964|Drug|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
99929|NCT00060554|Drug|fondaparinux sodium|
95510|NCT01354600|Other|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of ~120 minutes/day or no daily exercise (sedentary)
95511|NCT01354613|Drug|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
95512|NCT01354613|Drug|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
95513|NCT01354626|Other|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
95514|NCT00058825|Drug|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
95515|NCT01354626|Other|low-protein|The control group will get a diet which is according to healthy eating guidelines.
95516|NCT01354652|Drug|entecavir, lamivudine|entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.
lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.
95517|NCT01354665|Biological|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
95518|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
95519|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
95520|NCT01354691|Drug|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
95521|NCT01354704|Drug|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
95522|NCT01354717|Drug|Brand Carac|treatment of actinic keratosis
95523|NCT01354717|Drug|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
95524|NCT01354717|Other|Placebo cream|treatment of actinic keratosis
95525|NCT00001075|Drug|Zidovudine|
95526|NCT00058825|Procedure|Stem Cell Transplant|Day 0: Donor stem cells infused.
95527|NCT01357122|Procedure|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
96200|NCT01353391|Drug|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
96201|NCT01353391|Drug|Placebo Comparator|Sugar Pill
96202|NCT01353404|Drug|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
96203|NCT01353404|Drug|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
96204|NCT01353404|Drug|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
96205|NCT00058578|Procedure|Total Body Irradiation|
96206|NCT01353404|Drug|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
96487|NCT01356498|Biological|pegloticase|8 mg intravenous infusion
96488|NCT01356511|Drug|Conventional-dose prednisone group|Prednisone, po, 1 mg/kg/d, for 4 weeks.
96489|NCT01356511|Drug|High-dose dexamethasone group|Dexamethasone, po, 40 mg/d, for 4 days.
96490|NCT01356524|Drug|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
96491|NCT01356550|Drug|RO4917838|single oral dose
96492|NCT01356563|Behavioral|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
96493|NCT00001076|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
96494|NCT00059215|Drug|Clopidogrel|Administered orally
96495|NCT01356602|Drug|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
96496|NCT01356602|Drug|Canakinumab lyophilized powder|Canakinumab lyophilized powder
96497|NCT01356602|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide
96498|NCT01356602|Drug|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
96499|NCT01356615|Drug|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
95953|NCT01355588|Drug|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
95954|NCT01355601|Other|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
95955|NCT01355601|Other|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
95956|NCT01355614|Drug|QAX576|
95957|NCT01355614|Drug|Infliximab|
95958|NCT01355627|Procedure|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
95959|NCT01355627|Procedure|Current Practice|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.
In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®.
95960|NCT01355640|Other|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
95961|NCT01355640|Other|non-nutritive sucking|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is "Goodbaby") to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry.
95962|NCT01355653|Device|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
95963|NCT00058903|Drug|sertraline|
95964|NCT01355653|Device|marketed heatwrap|heatwrap, topical, one time application, 8 hour duration
96266|NCT01360918|Device|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
96267|NCT01360918|Other|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
96268|NCT01360944|Drug|LAS41004|once daily, topical, 100 microgram
96269|NCT01360944|Drug|reference|once daily, 100 microgram
99930|NCT01370304|Other|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
99931|NCT01370304|Other|sham rTMS and active Venlafaxine|rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region
Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks
99932|NCT01370317|Drug|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
99933|NCT01370317|Drug|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
99934|NCT01370330|Drug|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present over 120 minutes.
99935|NCT01370343|Drug|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
99936|NCT01370343|Drug|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
99937|NCT01370356|Drug|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
99938|NCT01370356|Drug|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
99939|NCT01370369|Drug|Testosterone|
99940|NCT00060554|Drug|heparin|
99941|NCT01370408|Drug|Palonosetron, ondansetron, dexamethasone|Day x-y of IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
99942|NCT01370434|Drug|PAD combination|Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11
Doxorubicin 9 mg/m2/d iv on D 1-4
Dexamethasone 40mg/d po or iv on D1-4, 8-11
99943|NCT01370447|Drug|EPI-743|EPI-743 is administered as a dose escalation from 50 mg bid to 100 mg tid
99944|NCT01370460|Drug|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
99945|NCT01370460|Drug|Placebo|100mL 0.9% sterile saline
99946|NCT01370486|Drug|melatonin|melatonin cp 2 mg 1x/d for 1 month
99947|NCT01370486|Drug|placebo|placebo cp 1x/d for 1 month
99948|NCT01370499|Drug|LY2216684|Administered orally
95528|NCT01357135|Drug|Metformin|
95808|NCT01357772|Drug|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
95809|NCT01357785|Procedure|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
95810|NCT01360086|Procedure|adjuvant therapy|
95811|NCT01360086|Procedure|neoadjuvant therapy|
95812|NCT01360086|Procedure|quality-of-life assessment|
95813|NCT01360086|Procedure|therapeutic conventional surgery|
95814|NCT00059709|Procedure|Mediated Negotiation Training|
95815|NCT01360125|Genetic|proteomic profiling|
95816|NCT01360125|Other|flow cytometry|
95817|NCT01360125|Other|laboratory biomarker analysis|
95818|NCT01360138|Procedure|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
95819|NCT01360151|Drug|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
95820|NCT01360164|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
95821|NCT01360177|Procedure|124 PET/CT imaging|Standard of Care
95822|NCT01360177|Drug|Na134I|25 to 150 mCi
95823|NCT01360177|Drug|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
95824|NCT01360177|Drug|Tri-iodothyronine|20 mg/day x 2
95825|NCT00059722|Drug|ZD6474|
95826|NCT01360190|Drug|fluoxetine|fluoxetine 20 mg. daily
95827|NCT01360203|Other|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
96500|NCT01358890|Other|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
96501|NCT01358903|Drug|RO5429083|Cohorts receiving multiple escalating doses iv
96502|NCT01358903|Drug|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
96503|NCT01358916|Other|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
96504|NCT01358929|Drug|Placebo|Placebo to RO6807952
96505|NCT01358929|Drug|RO6807952|Escalating subcutaneous dose
96506|NCT01358955|Other|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
96507|NCT01358955|Other|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
96508|NCT01358968|Drug|LY2603618|Administered intravenously.
95594|NCT01362530|Drug|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
95595|NCT00059852|Drug|gemcitabine hydrochloride|
95596|NCT01362530|Drug|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
95597|NCT01362530|Drug|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
95598|NCT01362530|Drug|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
95599|NCT01362530|Drug|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
95600|NCT01362530|Drug|Emetogenic chemotherapy|Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
96270|NCT01360957|Dietary Supplement|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
96271|NCT01360970|Biological|hepatitis A vaccine ( HAVRIX or EPAXAL)|1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval
96272|NCT01360996|Drug|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
96273|NCT01361009|Drug|pramipexole|as prescibed by the investigator
96274|NCT00059787|Drug|erlotinib|Given PO
96275|NCT01361022|Drug|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
96276|NCT01361022|Drug|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
96277|NCT01361035|Other|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
96278|NCT01361048|Drug|oral metronidazole|2 gm oral once
96279|NCT01361048|Drug|neo penotran forte|neo penotran forte intravaginal twice a day for 7 days
96280|NCT01361048|Drug|neo penotran forte once a day|neo penotran forte intravaginally once a day for 7 days
96281|NCT01361074|Behavioral|In Vivo Exposure for Animal Phobia following Öst´s guidelines|In vivo exposure is applied using "one-session treatment" guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way.
96570|NCT01349478|Device|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
96571|NCT00058292|Biological|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
96572|NCT01349491|Drug|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
96573|NCT01349491|Drug|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
99949|NCT00060827|Device|Head Impact Recording Technology (HIRT)|
99950|NCT01372410|Drug|GSK573719|15.6 mcg twice daily
100250|NCT01365949|Genetic|protein analysis|
100251|NCT01365949|Other|immunohistochemistry staining method|
100252|NCT00060255|Drug|thiotepa|iv
100253|NCT01365949|Other|laboratory biomarker analysis|
100254|NCT01365962|Genetic|gene expression analysis|
100255|NCT01365962|Other|immunohistochemistry staining method|
100256|NCT01365962|Other|laboratory biomarker analysis|
100257|NCT01365962|Other|mass spectrometry|
100258|NCT01366001|Drug|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
100259|NCT01366001|Drug|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
100260|NCT01366001|Drug|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
100261|NCT01366014|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
100262|NCT01366014|Drug|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
100263|NCT00060255|Procedure|autologous bone marrow transplantation|iv
100264|NCT01366014|Drug|Placebo; oral|matching placebo
100265|NCT01366066|Device|Transcutaneous mechanical nerve stimulation|A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.
A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.
100266|NCT01366079|Procedure|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
100267|NCT01366079|Procedure|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
100268|NCT01366092|Drug|Interleukin-2|Daily subcutaneous IL-2 (1 x 10^6 IU/m^2/day) for self-administration for 12 weeks followed by 4-week hiatus
95828|NCT01360216|Behavioral|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
96130|NCT01353313|Drug|Placebo|Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:
4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then
1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
96131|NCT00058578|Procedure|Leukopheresis|
96132|NCT01355874|Drug|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
96133|NCT01355900|Procedure|Total knee arthroplasty performed under tourniquet|Comparison of the different tourniquet tactics.
96134|NCT01355926|Other|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
96135|NCT01355926|Other|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
96136|NCT01355939|Procedure|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
96137|NCT01355952|Dietary Supplement|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
96138|NCT00058955|Drug|sodium oxybate, triazolam and pentobarbital|sodium oxybate, triazolam and pentobarbital
96139|NCT01355965|Biological|Autologous T cells|
96140|NCT01355978|Device|Breathe Technologies Noninvasive Open Ventilation (NIOV™) System|Subjects will report their tolerance and comfort while using the test ventilation system, while exercising, doing activities of daily living, and while resting. Subjects will use the test ventilation system for 6 hours a day for 5 days.
96141|NCT01355991|Drug|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
96142|NCT01355991|Drug|Salmeterol|50mcg inhalation twice daily for two weeks
95601|NCT01354743|Drug|Dysport|Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region
Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.
Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits.
95602|NCT01354743|Device|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
95603|NCT01354769|Device|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
95604|NCT01354782|Drug|Roflumilast|Period I: single dose of roflumilast 500 μg orally in the morning.
Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days.
95605|NCT01354795|Procedure|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
95606|NCT01354795|Procedure|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
95607|NCT01354808|Drug|Dual Anti-Platelet Therapy (DAPT)|Loading: aspirin 300mg + clopidogrel 600mg
Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month
95608|NCT01354808|Drug|Triple Anti-Platelet Therapy (TAPT)|Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg
Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month
95609|NCT01354821|Procedure|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
95889|NCT01357837|Drug|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
95890|NCT01357837|Drug|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
95891|NCT01357837|Drug|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
95892|NCT01357837|Drug|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
95893|NCT01357850|Drug|GSK716155|GSK716155
95894|NCT00059345|Procedure|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
95895|NCT01357850|Drug|Placebo|Placebo
95896|NCT01357863|Drug|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
95897|NCT01357876|Other|Metformin|withdrawral
96574|NCT01349517|Procedure|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
96575|NCT01349517|Procedure|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
96576|NCT01349517|Procedure|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
96577|NCT01349517|Procedure|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
96578|NCT01349530|Other|Evaluating of usual care|RESEARCH IN CURRENT CARE
96579|NCT01349530|Other|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
96580|NCT01349543|Biological|RSV A Memphis 37|Intranasal administration
96581|NCT01349556|Drug|Tretinoin|tretinoin 0.025% cream
96582|NCT00058292|Drug|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
96583|NCT01349569|Drug|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
96584|NCT01349569|Biological|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
96585|NCT01349569|Biological|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection.
96586|NCT01349582|Procedure|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
96587|NCT01349582|Other|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
96588|NCT01349582|Procedure|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
95663|NCT01362686|Drug|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
95664|NCT01362699|Drug|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
100269|NCT01366105|Device|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
100270|NCT01366118|Drug|Therapeutic target tailored chemotherapy|All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.
Ch combination schema was customized based on:
Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.
When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen
99330|NCT01371721|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
99331|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
99332|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
99333|NCT01371734|Drug|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
99334|NCT00060684|Drug|rituximab|
99335|NCT01371747|Drug|patiromer|Patiromer starting dose: 8.4 g/day, 16.8 g/day, and 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response.
99336|NCT01371747|Drug|patiromer|Patiromer starting dose: 16.8 g/day, 25.2 g/day and 33.6 g/day, orally, as a divided dose, twice daily . The dose of patiromer could be titrated based on participant's serum potassium response.
99337|NCT01371760|Procedure|Venous PTA|PTA of the internal jugular and/or azygous vein
99338|NCT01371760|Other|Catheter Venography|The patients will undergo catheter venography but not PTA
99339|NCT01371773|Procedure|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
99340|NCT01371786|Drug|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
99341|NCT01371786|Drug|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
99342|NCT01371799|Drug|Drug|Placebo
99343|NCT01371799|Drug|Drug|4mg and 8mg Study drug
99344|NCT01371812|Drug|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
99345|NCT00060697|Behavioral|Adolescent sexual activity education for mothers|
96143|NCT01356004|Drug|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
96144|NCT01356004|Drug|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
96145|NCT01356017|Drug|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
96420|NCT01358890|Other|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
96421|NCT00001077|Dietary Supplement|Peptamen|Solution received daily
96422|NCT00059475|Drug|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
96423|NCT01361295|Procedure|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
96424|NCT01361308|Drug|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
96425|NCT01361308|Drug|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
96426|NCT01361334|Drug|Pazopanib|800 mg QD p.o.
96427|NCT01361347|Dietary Supplement|milk|milk for milk allergic children (1:25 dilution, whole milk)
96428|NCT00001079|Drug|Testosterone enanthate|
96429|NCT00059813|Biological|oblimersen sodium|Given IV
96430|NCT01361373|Drug|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
96431|NCT01361373|Drug|placebo|placebo for 2 weeks
96432|NCT01361399|Drug|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
96433|NCT01361399|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
96434|NCT01361399|Drug|Lidocain|Single oral application of Lidocain (as lozenge)
96435|NCT01361399|Drug|Placebo|Single oral application of Placebo (as lozenge)
96436|NCT01361412|Biological|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
95898|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
95899|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
95900|NCT01357902|Drug|lamotrigine|
95901|NCT01357915|Procedure|Blood sampling|Blood samples will be collected at 2 time points:
At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.
At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects.
95902|NCT01357954|Other|Regular physiotherapy|The child's regular physiotherapy
95903|NCT01357954|Other|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
95904|NCT01357967|Drug|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
95905|NCT00059345|Procedure|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
95906|NCT01360281|Other|Neuromuscular Electrical Stimulation|
95907|NCT01360281|Other|ECR|Resisted exercises
95908|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis|Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG
Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks
150mg EGCG two times daily (p.o.) over the course of three years.
Colonoscopy after 3 years
95909|NCT00059722|Drug|Placebo|
96207|NCT01353404|Drug|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
96208|NCT01353404|Drug|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
96209|NCT01353417|Other|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
96210|NCT01353443|Procedure|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
96211|NCT01353456|Drug|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
96212|NCT01353456|Drug|Normal Saline|Same volume as dexmedetomidine given
95665|NCT01362699|Drug|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
95666|NCT01362712|Radiation|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
95667|NCT00059878|Biological|recombinant interferon gamma|
95668|NCT01362725|Device|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
95669|NCT01362738|Procedure|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
95670|NCT01362738|Procedure|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
95671|NCT01362751|Other|No intervention|This study is an observational cohort study > no interventions
95672|NCT01362764|Drug|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
95673|NCT01362764|Drug|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
95674|NCT01362764|Drug|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
95675|NCT01362777|Behavioral|In-patient rehabilitation|Individualized exercise training (IET):
Duration : 24 sessions during 4 weeks
IET session (2h) contains:
15' start warming up muscles
30' muscle strengthening exercise for arms and abdominal muscles
45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.
15' stretching
15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.
Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe.
95676|NCT01362777|Behavioral|Educational activities alone|Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :
Physiological mechanisms of apneas/hypopneas
Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)
Beneficials effects of CPAP and/or advanced mandibular orthosis
Description of sleep stages and physiological roles of sleep
Known effects of exercise on sleep and metabolism
Importance of good nutritional status and sleep hygiene on quality of life
How to apply theses lessons of rehabilitation in daily life
95677|NCT01362790|Drug|Pentostatin|Regimen A: Cycle 1: 4 mg/m2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m2 on days 1 and 5 of 25 day cycle
95678|NCT00059878|Drug|voriconazole|
95965|NCT01355666|Device|DermaTherapy® Linen and underpads.|DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.
Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics.
99346|NCT01371812|Drug|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
99347|NCT01371825|Drug|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with LAL Deficiency. Dosing will occur once weekly for up to three years.
99348|NCT01364428|Drug|insulin degludec|Injected subcutaneously, (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.
Dose was individually adjusted.
99349|NCT00060021|Procedure|management of therapy complications|
99350|NCT01364441|Drug|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
99908|NCT01367990|Drug|Norepinephrine|The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp "risk zone." Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments).
99909|NCT01368003|Drug|STA9090|200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
99910|NCT01368003|Drug|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
99911|NCT01368016|Drug|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
99912|NCT01368016|Drug|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
99913|NCT00060385|Drug|doxorubicin hydrochloride|
99914|NCT01368029|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
99915|NCT01368029|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
99916|NCT01368055|Radiation|70 Gy/CGE|Low Risk
99917|NCT01368055|Radiation|72.5 Gy/CGE|Intermediate Risk
99918|NCT01368068|Drug|Tibolone|2.5mg/oral/daily
99919|NCT01368068|Drug|Escitalopram|10mg/oral/daily
99920|NCT01368068|Drug|Natvia|serving size: 0.09g per tablet
99921|NCT01368081|Drug|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
96437|NCT01361412|Biological|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
96438|NCT01361425|Drug|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
96439|NCT01361425|Drug|placebo|placebo 500mg 8/8h, orally
96440|NCT00059813|Other|pharmacological study|Correlative studies
96441|NCT01361438|Other|Total therapy approach|Total therapy approach
96442|NCT01361464|Drug|Tipifarnib|Given PO
96443|NCT01361464|Other|Laboratory Biomarker Analysis|Correlative studies
95529|NCT01357135|Drug|Sitagliptin|
95530|NCT01357135|Drug|Sulfonylurea|
95531|NCT01357135|Drug|Antihyperglycemic Medication|
95532|NCT01357148|Drug|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
95533|NCT01357161|Drug|MK-1775|MK-1775 capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
95534|NCT01357161|Drug|Placebo|placebo to MK-1775, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
95535|NCT01357161|Drug|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
95536|NCT01357161|Drug|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
95537|NCT00059306|Drug|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
95538|NCT01357187|Other|Scheduled removal of posterior instrumentation with AmnioFix|
95539|NCT01357187|Other|Scheduled removal of posterior instrumentation without AmnioFix|
95540|NCT01357200|Other|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
95541|NCT01357213|Drug|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
95542|NCT01357213|Other|Placebo|Normal saline 100 ml
95543|NCT01357239|Drug|AFQ056|
96213|NCT01353469|Drug|Insulin human/Insuman Comb 25 (HR1799)|Pharmaceutical form:Suspension
Route of administration: Subcutaneous
96214|NCT01353469|Drug|Insulin human/Novolin® 30R|Pharmaceutical form:Suspension
Route of administration: Subcutaneous
96215|NCT01353482|Drug|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
96216|NCT00058591|Biological|Intravenous injection of EBV specific CTLS|The dose levels for this study are as follows:
Level Dose
2 x 107 CTLs/m2
5 x 107 CTLs/m2
1 x 108 CTLs/m2
If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals.
96217|NCT01356030|Procedure|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
96218|NCT00058968|Drug|Duloxetine hydrochloride|
96219|NCT01356043|Drug|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
96220|NCT01356043|Drug|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
96221|NCT01356056|Device|Kinesia HomeView|Quantifies motor symptom severity in the home
96222|NCT01356069|Other|SB-APP|SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.
SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms
96509|NCT01358968|Drug|Desipramine|Administered orally
96510|NCT00059475|Drug|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
96511|NCT01358968|Drug|Pemetrexed|Administered intravenously
96512|NCT01358968|Drug|Gemcitabine|Administered intravenously
96513|NCT01358981|Drug|LY2881835|Administered orally
96514|NCT01358981|Drug|Placebo|Administered orally
96515|NCT01359007|Drug|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
95966|NCT01357967|Drug|Seroquel XR adjunctive|Quetiapine group:
seroquel XR 50mg Day 1 --> 50mg Day 2 --> 150mg Day 3 --> 150mg Day 4 --> adjustment usually at hs but can be daytime
95967|NCT01357980|Drug|Botulinum type A toxin (Dysport®)|750 U intra detrusor injection on Day 1 (single dose)
95968|NCT01357980|Drug|Placebo|Intra detrusor injection on Day 1 (single dose)
95969|NCT01357993|Drug|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
95970|NCT01358006|Drug|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
95971|NCT01358006|Drug|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
95972|NCT01358019|Drug|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
95973|NCT01358032|Behavioral|an in-home cognitive behavioral program|The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) & 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
95974|NCT01358045|Drug|Diclofenac|Application on the lesion 2 times a day 8 weeks.
95975|NCT01358045|Drug|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
95976|NCT00059345|Other|Usual Care|Usual care for knee osteoarthritis
95977|NCT01358045|Drug|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
95978|NCT01358058|Radiation|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
95979|NCT01358071|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
95980|NCT01358071|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
95981|NCT01358071|Drug|Doxorubicin|60 mg/m^2 iv every 3 weeks for a maximum of 8 cycles
95982|NCT01358084|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
99922|NCT01368081|Drug|BI 10773|BI 10773 low dose tablet once daily
99923|NCT01368081|Drug|Placebo (low dose)|Placebo tablets once daily
99924|NCT00060385|Drug|etoposide|
99925|NCT01368081|Drug|BI 10773|BI 10773 high dose tablet once daily
99926|NCT01370291|Other|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
99927|NCT01370291|Other|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
99928|NCT01370304|Other|active rTMS and active Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks
99951|NCT01372410|Drug|Tiotropium|18 mcg once daily
99952|NCT01372410|Drug|Placebo|once or twice daily
99953|NCT01372423|Drug|Lubiprostone|24 mcg capsules
99954|NCT01372423|Drug|Placebo|24 mcg capsules
99955|NCT01372449|Drug|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but <60 kg, and 6 mg for subjects weighing ≥ 20 kg but < 40kg.
99956|NCT01372449|Drug|Placebo|
99957|NCT01372462|Device|Breathe Technologies Noninvasive Open Ventilation (NIOV™) System|Subjects will perform incremental exercises to assess and confirm their constant work rate (CWR). They will then perform randomized condition exercises at that CWR with and without supplemental oxygen for comparison.
99958|NCT01372475|Device|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
99959|NCT01372475|Procedure|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
99960|NCT00060840|Drug|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
99961|NCT01372488|Procedure|Suture self removal|Suture self removal
99962|NCT01372488|Procedure|Suture removal by family doctor or clinic|As above
99963|NCT01372501|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
95544|NCT01357239|Drug|Placebo|
95545|NCT01357252|Drug|vildagliptin|
95546|NCT01357252|Drug|Placebo|
95547|NCT01357265|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
95548|NCT00059306|Drug|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
95549|NCT01357278|Procedure|Rehabilitation and patient education|Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.
Patient education will be offered every eight week.
95550|NCT01357291|Behavioral|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
95551|NCT01357291|Behavioral|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
95829|NCT01360229|Procedure|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
95830|NCT01360229|Other|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
95831|NCT01360242|Procedure|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
95832|NCT01360242|Procedure|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
95833|NCT01362543|Other|Cognitive behavioural therapy (stress management)|Following a manual
95834|NCT01362543|Other|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
95835|NCT01362556|Drug|Sodium bicarbonate|Administration of a calculated amount of sodium bicarbonate 8% [SB] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].
Formula: SB [ml] = -BE * kg * 0.1
95836|NCT01362556|Drug|Sodium Chloride|Administration of a calculated amount of sodium chloride 0.9% [SC] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].
Formula: SC [ml] = -BE * kg * 0.1
95837|NCT01362582|Drug|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
95838|NCT00059865|Drug|gemcitabine hydrochloride|
96516|NCT01359020|Drug|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
96517|NCT01359046|Device|silver SPC|subject randomized to receive Bardex IC Silver impregnated catheter
96518|NCT01359046|Device|standard SPC|subject randomized to receive standard catheter
96519|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
96520|NCT01361555|Drug|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
96521|NCT00059826|Biological|interferon-alfa-2b|IV
96522|NCT01361555|Drug|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
96523|NCT01361568|Drug|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
96524|NCT01361568|Drug|Placebo|Single i.v. dose administered preoperatively
96525|NCT01361568|Drug|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
96526|NCT01361568|Drug|Placebo|Single i.v. dose administered postoperatively for pain
96527|NCT01361594|Other|Regular insulin (intensive treatment)|Titration of the IV insulin rate for glucose goal 100-140 mg/dL
96528|NCT01361594|Other|Regular Insulin (conventional treatment)|Titration of the IV insulin rate for glucose goal 141-180 mg/dl
96529|NCT01361607|Drug|Sativex®|Administered orally with a spray into cheek (100 μl oromucosal spray administered twice daily up to a maximum of 10 sprays per day)
95610|NCT01354821|Procedure|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
95611|NCT00058825|Radiation|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
95612|NCT01354834|Drug|hMG|Patients with a condition
95613|NCT01354847|Device|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
96282|NCT01361074|Behavioral|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using "one-session treatment" guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli.
96283|NCT01353482|Drug|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
96284|NCT01353482|Drug|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
96285|NCT01353482|Drug|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
96286|NCT01353495|Device|APM Graft (BIOTAPE XMTM)|Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.
96287|NCT01353508|Drug|LCZ696|200 mg and 400 mg tablets
96288|NCT01353508|Drug|Valsartan|160 mg tablets
96289|NCT01353521|Procedure|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
96290|NCT01353534|Biological|A/H5N1 Antigen|A/H5N1 Antigen
96291|NCT01353534|Drug|Vaccine Enhancement Patch|Vaccine Enhancement Patch
96292|NCT01353573|Radiation|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
96293|NCT00058604|Biological|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
96294|NCT01353573|Radiation|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
96295|NCT01353586|Device|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
96296|NCT01353599|Drug|Mometasone furoate|220mcg once daily, for eight weeks
99964|NCT01372527|Other|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
99965|NCT01372540|Drug|Arry-520|Part 1A Starting Dose: .75 mg/m2 by vein on Days 1, 2, 15 and 16.
99966|NCT01372540|Drug|Carfilzomib|Part 1A Starting Dose: 20/27 mg/m2 by vein on Days 1,2 8,9 and 15,16.
Part 1B Staring Dose: 20 mg/m2 dosing will be only on cycle 1 days 1 and 2, then starting 20/36 mg/m2 by vein on Days 1,2 8,9 and 15,16.
Dose Expansion Group: MTD of Part A and Part B.
99967|NCT01372540|Drug|Dexamethasone|Part 1A and 1B, Part 2A and 2B: 4 mg by mouth or by vein on Days 1, 2, 8, 9 and 15, 16.
99968|NCT01372540|Drug|Filgrastim|under the skin beginning on Day 3 or 4, and Day 17 or 18 of every cycle, and continue 1 time each day for 5-7 days.
99969|NCT01372566|Device|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
99970|NCT01372566|Other|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
99971|NCT00060840|Drug|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
99076|NCT01418807|Procedure|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
99077|NCT01418807|Procedure|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
99078|NCT01418820|Device|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
99079|NCT00065442|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
99080|NCT01418820|Device|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
95839|NCT01362595|Drug|leucine|Dosage of leucine will be dependent on body surface area (BSA):
leucine 700 mg/m2/dose by mouth three times a day
95840|NCT01362608|Drug|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
95841|NCT01362608|Drug|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
95842|NCT01362634|Behavioral|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
95843|NCT01362634|Behavioral|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
95844|NCT01362647|Procedure|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
95845|NCT01362647|Procedure|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
95846|NCT01362660|Other|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
95847|NCT01362673|Drug|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
96146|NCT01356017|Drug|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
96147|NCT01356030|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
96148|NCT01358253|Drug|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
96149|NCT01358253|Drug|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
96150|NCT01358253|Drug|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
96151|NCT01358266|Drug|DE-109|Low dose
96152|NCT01358266|Drug|DE-109|Medium dose
96153|NCT01358266|Drug|DE-109|High dose
96154|NCT00059371|Procedure|male circumcision|
96155|NCT01358279|Procedure|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
95614|NCT01354860|Other|Moxibustion treatment plus usual care|Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.
Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.
We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes.
95615|NCT01354860|Other|Usual care alone group|Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.
Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline.
95616|NCT01354886|Drug|FSH-GEX™|
95617|NCT01354886|Drug|Comparator 1|
95618|NCT01354886|Drug|Comparator 2|
95619|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
95620|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
95621|NCT01357317|Drug|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
95622|NCT01357330|Drug|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
95623|NCT01357330|Drug|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
95624|NCT01357343|Other|Chiropractic|Spinal manipulation and active and passive therapy.
95625|NCT00001076|Biological|rgp120/HIV-1 SF-2|
95910|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis followed by placebo|Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG
Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks
Placebo two times daily (p.o.) over the course of three years
Colonoscopy after 3 years
95911|NCT01360333|Other|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
96297|NCT01353625|Drug|CC-115|Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).
Part B: Optimal dose schedule is administered in 28-day cycles until disease progression.
96589|NCT01349582|Procedure|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
96590|NCT01351493|Drug|placebo|placebo Gel, once or twice per day, 12weeks
96591|NCT01351519|Drug|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
96592|NCT01351532|Behavioral|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
96593|NCT01351532|Behavioral|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
96594|NCT00058435|Biological|abagovomab|
96595|NCT01351545|Drug|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
96596|NCT01351558|Other|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
96597|NCT01351558|Other|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
96598|NCT01351558|Other|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
96599|NCT01351597|Drug|docetaxel/ oxaliplatin|docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks
oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks
96600|NCT01351610|Biological|PTA + Infusion of MSC_Apceth|percutaneous transluminal angioplasty followed by infusion of MSC_Apceth
96601|NCT01351610|Procedure|PTA|percutaneous transluminal angioplasty only
96602|NCT01351623|Drug|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
99081|NCT01418872|Other|Didactic Concerts|The activity we are going to test consists in a communication and spreading strategy.
The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.
Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.
Students will be invited to take the playbill as a bookmark format and a cup is inscribed: "I am a heart-saver", so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered.
99082|NCT01418898|Other|Dietary Intervention|Nutrient fortified oat beverage
99083|NCT01418911|Other|questionnaire|questionnaire only
99084|NCT01418937|Biological|CervarixTM (GSK580299)|Three intramuscular injections
99085|NCT01418950|Other|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
99086|NCT01418963|Drug|RO5285119|single and multiple ascending oral doses
99087|NCT01418963|Drug|placebo|single and multiple oral doses
99088|NCT01418976|Behavioral|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
99089|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
99090|NCT00065442|Biological|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
99091|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
99351|NCT01364441|Drug|Placebo|Placebo dosed in the same manner as ONO-2952
99352|NCT01364454|Other|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
99353|NCT01364467|Drug|Placebo|Children aged 7-11 years old will receive placebo 200 mg TID, while children older than 12 will receive Placebo 400 mg TID.
99354|NCT01364467|Drug|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
99355|NCT01364480|Device|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
96156|NCT01358292|Procedure|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
96157|NCT01358292|Procedure|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
96158|NCT01358305|Other|Protein Blend|Single intake of approximately 20 grams of total protein
96159|NCT01358318|Other|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
96160|NCT01358331|Drug|MK-8353|
96161|NCT01358344|Drug|Pantoprazole|40 mg delayed‑release tablet administered orally in the morning of Days 1-7
96162|NCT01358344|Drug|SCH 530348 (high percentage)|2.5 mg tablet containing ~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
96163|NCT01358344|Drug|SCH 530348 (standard percentage)|2.5 mg tablet containing ~23% API as free base (STANDARD) administered orally on the morning of Day 5
96164|NCT01358357|Drug|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
96165|NCT00059384|Behavioral|Concentration-controlled therapy|
96166|NCT01358357|Drug|Placebo|20-80 mg flexible dose
96167|NCT01358383|Drug|naproxen|250mg, oral dose
96168|NCT01358383|Drug|esomeprazole|20mg, oral dose
96444|NCT01361516|Other|Anaesthesia and Lithotripsy|The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
96445|NCT01361529|Drug|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
96446|NCT01361542|Drug|anti TNF alpha agent|Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
96447|NCT01361542|Drug|Anti TNF alpha therapy|Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
96448|NCT01361555|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
96449|NCT01361555|Drug|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
96450|NCT01353820|Dietary Supplement|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
95912|NCT01360346|Procedure|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
95913|NCT01360346|Procedure|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
95914|NCT01360359|Other|Core Stabilization|3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education
Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.
Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning.
95915|NCT01360359|Other|Trunk Motion and Fitness|3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education
Stage 2: trunk muscle conditioning exercises
Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises
95916|NCT01360372|Drug|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
95917|NCT01360372|Drug|Saline injection|Saline 0.4 to 0.8 ml injection
95918|NCT01360398|Procedure|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
95919|NCT01360398|Procedure|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
95920|NCT00001078|Biological|Hepatitis A Vaccine (Inactivated)|
95921|NCT00059722|Drug|ZD1839|
95922|NCT01360398|Procedure|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
95923|NCT01360398|Procedure|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
95924|NCT01360398|Procedure|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
95925|NCT01362790|Biological|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: assigned dose level on days 10, 12 and 14 of 30 day cycle Cycles 2-4: assigned dose level on days 2, 4 and 6 of 21 day cycle Regimen B: Cycle 1: assigned dose level on days 18, 20 and 22 of 38 day cycle Cycles 2-4: assigned dose level on days 6, 8 and 10 of 25 day cycle
96223|NCT01356069|Other|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
96603|NCT01351636|Drug|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
96604|NCT01351636|Drug|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
96605|NCT00058448|Drug|docetaxel|
95679|NCT01362790|Drug|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
95680|NCT01354886|Drug|Placebo|
95681|NCT01354925|Drug|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
95682|NCT01354925|Drug|Standard of care|Standard of care during Ramadan according to physicians decision
95683|NCT00058825|Drug|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
95684|NCT01354938|Drug|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
95685|NCT01354951|Other|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
95686|NCT01354964|Drug|Vitamin D|Weekly oral vitamin D drops, weight-based calculated dosage, taken on the same day each week for 4 months.
95687|NCT01354977|Drug|Resveratrol|1,000mg twice daily for 28 days
95688|NCT01354990|Drug|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
95689|NCT01355016|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
95690|NCT01355029|Behavioral|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
99356|NCT01364493|Drug|Trastuzumab+Capecitabine+Oxaliplatin|Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.
Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.
Oxaliplatin 130mg/m2 d1; q3w, 6 cycles
99357|NCT01364506|Other|Water aerobic exercise|The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).
The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11.
99358|NCT01364519|Drug|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
99359|NCT01364519|Drug|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
99360|NCT00060021|Procedure|pain therapy|
99361|NCT01364532|Procedure|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
99362|NCT01364532|Procedure|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
99363|NCT01364545|Dietary Supplement|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
99364|NCT01364545|Dietary Supplement|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
99365|NCT01364558|Drug|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
99366|NCT01364558|Drug|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
99367|NCT01364571|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
99368|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
99621|NCT01364883|Biological|Vaccination Schedule Six|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
99622|NCT01364883|Biological|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
99623|NCT01364896|Procedure|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:
Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)
High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria
Anal cytology testing
96451|NCT01353833|Drug|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
96452|NCT01353846|Other|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
96453|NCT01353846|Drug|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
96454|NCT00058682|Drug|Anidulafungin|
96455|NCT01353859|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for a total of 6 infusions
96456|NCT01353859|Drug|methotrexate|10-25 mg orally weekly
96457|NCT01353872|Dietary Supplement|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
96458|NCT01353872|Dietary Supplement|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
96459|NCT01353898|Drug|MK-1972|MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
96460|NCT01353898|Drug|Placebo to MK-1972|Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
96461|NCT01353911|Drug|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
96462|NCT01353911|Drug|Boceprevir|Four 200 mg capsules orally three times daily.
96463|NCT01353911|Drug|Placebo for Grazoprevir|Orally once daily in AM.
96464|NCT01353911|Drug|Placebo for Boceprevir|Four capsules orally three times daily.
95552|NCT01357304|Behavioral|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
95553|NCT01359592|Radiation|fludeoxyglucose F 18|
95554|NCT01359592|Radiation|selective external radiation therapy|
95555|NCT01359592|Radiation|yttrium Y 90 ibritumomab tiuxetan|
95556|NCT00001077|Dietary Supplement|NuBasics|Solution or dietary bar received daily
96224|NCT01356082|Device|CNAP|Non-invasive blood pressure monitor
96225|NCT01356095|Other|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
96226|NCT01356095|Other|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
96227|NCT01356108|Device|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
96228|NCT01356121|Drug|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
96229|NCT00058968|Drug|placebo|
96230|NCT01356121|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
96231|NCT01356147|Drug|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
96232|NCT01356147|Drug|Sham therapy|No therapy will be given to placebo arm
96233|NCT01356160|Drug|GS-5885|tablet, 30 mg QD
96234|NCT01356160|Drug|GS-9451|tablet, 200 mg QD
96235|NCT01356160|Biological|peginterferon alfa-2a|(solution for injection) 180 µg/week
96236|NCT01356160|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
96237|NCT01356160|Drug|GS-9451 Placebo|Placebo to match GS-9451 QD
96238|NCT01358448|Behavioral|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
96239|NCT01358461|Biological|Blood sampling|Blood sampling
96240|NCT00059436|Behavioral|Mental effort in muscle strengthening|
96241|NCT01358461|Other|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
95691|NCT01355068|Drug|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
95692|NCT01355068|Drug|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
95693|NCT01355081|Drug|Vortioxetine|Vortioxetine tablets
95694|NCT00058838|Drug|sumanirole|
95695|NCT01355081|Drug|Placebo|Vortioxetine placebo
95983|NCT01358084|Drug|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
95984|NCT01358084|Other|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
95985|NCT01358110|Other|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
95986|NCT01358110|Other|Care as usual|Standard care as usual which may or may not include palliative care consultation
95987|NCT01360398|Other|Data collection|Patient interview, diary cards review and questionnaires completion
95988|NCT01360398|Other|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
95989|NCT01360424|Drug|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
95990|NCT01360437|Drug|Prasugrel|Prasugrel 10mg/day
95991|NCT01360437|Drug|Ticagrelor|Ticagrelor 90mg twice a day
95992|NCT01360450|Drug|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between < 9.
95993|NCT01360450|Drug|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
95994|NCT00059735|Drug|E7070|
95995|NCT01360463|Behavioral|Behavioral Drug and Risk Counseling (BDRC)|The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as "contracts" and these contracts are reviewed and revised at each subsequent session.
99624|NCT01364909|Other|Exercise|The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.
According to level of sedation and stability they may also perform sitting exercises
99625|NCT01364909|Other|Usual practice|These patients will not receive exercise early in their intensive care admission
99626|NCT01364922|Drug|hydrocodone/acetaminophen extended release|
99627|NCT00060112|Other|laboratory biomarker analysis|Correlative studies
99628|NCT01364922|Drug|Placebo|
99629|NCT01364948|Other|Coconut oil application|Four ml coconut oil application twice daily for first week
99630|NCT01364948|Other|No oil application|Oil application was not done
99631|NCT01364961|Dietary Supplement|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
99632|NCT01364974|Drug|ASP015K|oral
99633|NCT01364974|Drug|Placebo|oral
99634|NCT01364987|Drug|ASP015K|oral
99635|NCT01364987|Drug|Mycophenolate Mofetil|oral
99636|NCT01365000|Drug|NKTR118 Formulation 1|Oral dose, 25 mg
99637|NCT01365000|Drug|NKTR118 Formulation 2|Oral dose, 25 mg
99638|NCT00060125|Drug|tipifarnib|Given orally
99639|NCT01365000|Drug|NKTR118 Formulation 3|Oral dose, 25 mg
99640|NCT01365000|Drug|NKTR118 Formulation 1a|Oral dose, 25 mg
99641|NCT01367340|Behavioral|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
99972|NCT01372579|Drug|eribulin mesylate|Given IV
99973|NCT01372579|Drug|carboplatin|Given IV
99974|NCT01372579|Procedure|biopsy|Correlative studies
95557|NCT00059631|Drug|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
95558|NCT01359605|Drug|varespladib methyl|500 mg oral suspension
95559|NCT01359618|Drug|TC-5214|Single dose, oral tablets
95560|NCT01359618|Other|Placebo comparator|Single dose, oral tablets
95561|NCT01359618|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
95562|NCT01359618|Other|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
95563|NCT01359644|Drug|PSI-7977|Tablets, oral, 400 mg, once daily
95564|NCT01359644|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily
95565|NCT01359644|Drug|Ribavirin|Tablets, oral, 200 mg
95566|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
95567|NCT01359657|Biological|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
95568|NCT00059631|Drug|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
95569|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
95570|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
95571|NCT01359657|Biological|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
95572|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
95573|NCT01359670|Drug|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
95848|NCT01362673|Drug|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
95849|NCT00059865|Drug|pemetrexed disodium|
95850|NCT01362673|Drug|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
96242|NCT01358487|Behavioral|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
96530|NCT01361607|Drug|Placebo (GA-0034)|Administered orally with a spray into cheek
96531|NCT01361620|Drug|aspirin|aspirin 81mg, 7-10 days
96532|NCT00059826|Drug|cisplatin|IV
96533|NCT01361633|Drug|d-cycloserine|single oral administration of 250 mg d-cycloserine
96534|NCT01361633|Drug|Sugar Pill|Single oral administration 250 mg Sugar Pill
96535|NCT01361646|Drug|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
96536|NCT01361659|Procedure|shockwave treatment|9 treatments in 3 months
96537|NCT01361698|Behavioral|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
96538|NCT01361711|Biological|alemtuzumab|Given SC
96539|NCT01361711|Biological|ofatumumab|Given IV
96540|NCT01361711|Procedure|biopsy|Correlative studies
96541|NCT01361724|Behavioral|Physical therapy|Physical therapy program for people with PD--one on one with a PT
96542|NCT01361724|Behavioral|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
96543|NCT00059826|Drug|5-fluorouracil|IV
96544|NCT01361724|Behavioral|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
96545|NCT01361750|Procedure|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
96546|NCT01361763|Drug|Dabigatran|110 mg twice daily
96547|NCT01361763|Drug|Antiplatelets|100mg once a day
96548|NCT01361776|Biological|FSME-immune|0.5 ml im as scheduled in the 4 arms
96549|NCT01353976|Other|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
95996|NCT01360463|Behavioral|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
95997|NCT01360476|Dietary Supplement|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
95998|NCT01360476|Dietary Supplement|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
95999|NCT01360541|Procedure|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
96000|NCT01360541|Other|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
96001|NCT01360554|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
96298|NCT01353638|Drug|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
96299|NCT01353651|Device|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
96300|NCT01353651|Device|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
96301|NCT01356173|Drug|GDC-0349|Oral escalating dose
96302|NCT01356186|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
96303|NCT00058981|Drug|DiaPep277|
96304|NCT01356199|Dietary Supplement|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
96305|NCT01356199|Dietary Supplement|PLACEBO|PLACEBO. 6 per day for 8 months.
96306|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
96307|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
96308|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
99975|NCT01365390|Other|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
99976|NCT01365403|Drug|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
99977|NCT01365403|Drug|carbamazepine|multiple oral doses, Days 1-24 of study period 2
99978|NCT01365429|Device|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
99979|NCT01365455|Drug|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
99980|NCT00060255|Drug|busulfan|iv
99981|NCT01365455|Drug|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
99982|NCT01365468|Drug|Everolimus|
99983|NCT01365481|Drug|Valsartan|40/80/160 w2-78:80/160/320mg, oral, by mouth, once daily
99984|NCT01365494|Biological|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
99985|NCT01365507|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
99986|NCT01365507|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
99987|NCT01365520|Drug|turoctocog alfa|A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
99988|NCT01365533|Drug|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
99989|NCT01365533|Drug|Placebo|Placebo, one tablet once daily, orally
99990|NCT01365546|Biological|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
99991|NCT00060255|Drug|carboplatin|iv
99092|NCT01419002|Radiation|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
95851|NCT01362673|Drug|Placebo|Oral single dose as matching placebo
95852|NCT01362673|Drug|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
95853|NCT01362673|Drug|Placebo|Oral multiple doses as matching placebo for 12 days
95854|NCT01362686|Drug|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
95855|NCT01363011|Drug|NRTI|Participants will receive 2 investigator-selected nucleoside reverse transcriptase inhibitors (NRTIs), which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
95856|NCT01355328|Procedure|laser and radiofrequency|different laser and radiofrequency with different fluences
95857|NCT01355341|Drug|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
95858|NCT01355354|Drug|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
95859|NCT01355354|Drug|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
95860|NCT01355367|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
95861|NCT01355380|Drug|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
95862|NCT01355393|Biological|HER-2/neu peptide vaccine|Given ID
95863|NCT01355393|Biological|sargramostim|Given ID
95864|NCT01355393|Drug|rintatolimod|Given ID
95865|NCT01355393|Other|laboratory biomarker analysis|Correlative studies
95866|NCT00058851|Procedure|Compression bandaging|
95867|NCT01355406|Device|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
95868|NCT01355432|Other|Observation|There is no intervention, this is an observational study.
95869|NCT01355445|Drug|Vincristine, Irinotecan|D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)
D1 to D5: Irinotecan 50 mg/m²/d, IV
cycle / 21 days
96169|NCT01358396|Other|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
96550|NCT01354015|Device|DRMS|USE OF TEXT MESSAGING SYSTEM
96551|NCT01354028|Other|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
96552|NCT00058734|Biological|Dendritic Cells Pulsed with HIV antigens|
95626|NCT00059306|Other|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure—either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
95627|NCT01357343|Other|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
95628|NCT01357356|Drug|SER120 (750 ng/day)|
95629|NCT01357356|Drug|SER120 (1000 ng/day)|SER120 (1000 ng/day)
95630|NCT01357356|Drug|SER120 (1500 ng/day)|
95631|NCT01357356|Drug|Placebo|
95632|NCT01357369|Procedure|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
95633|NCT01357382|Other|Low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
95634|NCT01357395|Drug|Amuvatinib|Amuvatinib 300 mg PO TID
95635|NCT01357421|Drug|TT301|Single iv dose of TT301
95636|NCT01357421|Drug|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
95637|NCT00059306|Other|placebo|an inactive substance
95638|NCT01357434|Behavioral|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
95639|NCT01357447|Drug|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
95640|NCT01357447|Drug|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
95641|NCT01359722|Drug|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
96309|NCT01356225|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
96310|NCT01356225|Drug|Placebo|IN placebo
96311|NCT01356238|Other|MRC media|Culture media
96312|NCT01356238|Other|Sydney IVF media|Culture media
96313|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
96314|NCT00058994|Drug|anecortave acetate|
96606|NCT01351649|Behavioral|middle school physical activity intervention for girls|Both the "Girls on the Move" intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our "Girls on the Move" intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model.
96607|NCT01344525|Procedure|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
96608|NCT00001067|Drug|Stavudine|
96609|NCT00057876|Radiation|radiation therapy|Induction: Patients receive gemcitabine 600 mg/m^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.
Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy.
96610|NCT01344525|Procedure|Gastric Banding|Gastric Banding
96611|NCT01344525|Procedure|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
96612|NCT01344525|Procedure|Roux-en-Y Bypass|Roux-en-Y Bypass
96613|NCT01344538|Drug|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
96614|NCT01344538|Dietary Supplement|Placebo Capsule|2.0 g per day
96615|NCT01344551|Dietary Supplement|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
101571|NCT01393561|Drug|Group 1|Brompheniramine + phenylephrine
101572|NCT01393561|Drug|Group 2|Placebo
101573|NCT01393574|Drug|Melatonin|3 mg for body weight <40kg, 6 mg for body weight >40kg, once a day 30-60 minutes before sleep
101574|NCT01393574|Drug|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
101575|NCT01393587|Procedure|Taking blood samples|
101576|NCT01393600|Drug|NBI-98854|12.5 mg powder in bottle once daily for 14 days
101577|NCT01393600|Drug|NBI-98854|50 mg powder in bottle once daily for 14 days
101578|NCT01393600|Drug|Placebo|Solution containing no active substance
101579|NCT01393613|Drug|OPC-34712|Higher dose tablet, once daily, for six weeks,
101580|NCT00062751|Drug|Letrozole|Letrozole 2.5 mg daily
101581|NCT01393613|Drug|OPC-34712|Middle dose tablet, once daily, for six weeks
101582|NCT01393613|Drug|OPC-34712|Lower dose tablet, once daily, for six weeks
101583|NCT01393613|Drug|Placebo|Placebo, once daily, for six weeks
101584|NCT01393626|Drug|Placebo|oral tablets twice daily
101585|NCT01393626|Drug|CP-690,550|oral tablets twice daily
101586|NCT01393626|Drug|CP-690,550|oral tablets twice daily
101587|NCT01393639|Drug|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
101850|NCT01386840|Other|Severe Pneumonia - Home Management|For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.
Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the "patient discharge counselling checklist". Mothers will be given a "study patient data card" with contact Numbers.
101851|NCT01386853|Drug|Pitavastatin|2 mg QD
101852|NCT01386853|Drug|Atorvastatin|10 mg QD
101853|NCT00062140|Procedure|allogeneic bone marrow transplantation|
102328|NCT01382680|Device|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
102329|NCT01382693|Behavioral|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
102654|NCT01380756|Drug|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
102655|NCT01380769|Drug|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
102656|NCT01380769|Other|Best Supportive Care|best supportive care
102657|NCT01380782|Drug|BIBF 1120|200 mg BID oral for 28 day cycle
102658|NCT01380795|Biological|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
102659|NCT01380808|Drug|capecitabine and pseudomonas aeruginosa combination|capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
102660|NCT01380821|Radiation|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
102661|NCT01380834|Drug|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
102662|NCT01380834|Drug|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
102663|NCT01380847|Genetic|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
102664|NCT01383564|Procedure|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
102665|NCT01383577|Procedure|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
102666|NCT01383577|Procedure|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
102667|NCT01383590|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
102668|NCT01383603|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
101912|NCT01384552|Other|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
101913|NCT01384565|Drug|G-CSF+EPO|Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)
G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
Arms: G-CSF+EPO Drug: Placebo
Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
101914|NCT01384565|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
101915|NCT01384578|Drug|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
101916|NCT01384578|Drug|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
101917|NCT01384591|Drug|N-acetylcysteine|50 mg/kg/dose. They get this the night before with dinner, at 6am when fasted and at 11am with a meal.
101918|NCT01384591|Drug|Losartan|25mg/dose. They get this the night before with dinner, at 6am when fasted and at 11am with a meal.
101919|NCT00061997|Dietary Supplement|inositol|
101920|NCT01384591|Other|PLacebo losartan and placebo NAC|Placebo losartan and placebo NAC is administered 3 times.
101921|NCT01384617|Procedure|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
101922|NCT01384617|Procedure|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
101923|NCT01384630|Drug|RA-18C3|200 mg subcutaneous injection
102176|NCT01374490|Drug|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
102177|NCT01374503|Biological|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
102178|NCT01374503|Biological|Placebo|single or multiple i.v. administration
102179|NCT01377233|Drug|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
102180|NCT01377233|Drug|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
102575|NCT01383330|Drug|DW-ES(A)|625mg
102576|NCT01383330|Drug|DW-ES(B)|625mg
102577|NCT01383343|Biological|Bevacizumab|Given IV
102578|NCT01383343|Drug|Fluorouracil|Given IV
102579|NCT01383343|Drug|Irinotecan Hydrochloride|Given IV
102580|NCT01383343|Drug|Leucovorin Calcium|Given IV
102581|NCT01383343|Drug|Sorafenib Tosylate|Given PO
102582|NCT00061945|Drug|imatinib mesylate|Given PO
102583|NCT01383356|Drug|Metformin Single Tablet|Metformin medium doseTablet
102584|NCT01383356|Drug|Linagliptin/Metformin Combo|Fixed dose combination
102585|NCT01383356|Drug|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
102586|NCT01383395|Drug|simvastatin/cilostazol|
102587|NCT01383408|Other|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
102588|NCT01383434|Procedure|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
102589|NCT01383447|Drug|entinostat|Given PO
102590|NCT01383447|Drug|imatinib mesylate|Given PO
102591|NCT01383447|Other|laboratory biomarker analysis|Correlative studies
102592|NCT01383447|Other|pharmacological study|Correlative studies
102593|NCT00061945|Drug|methotrexate|Given IT, IV, and PO
102594|NCT01383447|Genetic|western blotting|Correlative studies
101700|NCT01389102|Drug|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
101701|NCT01389102|Drug|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
101702|NCT01389102|Drug|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
101982|NCT01391624|Drug|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
101983|NCT01391637|Biological|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
101984|NCT01391650|Procedure|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
101985|NCT01391663|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
101986|NCT01391663|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
101987|NCT01391663|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
101988|NCT01391676|Procedure|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
101989|NCT00001090|Biological|APL 400-047|
101990|NCT00062569|Behavioral|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
101991|NCT01391689|Dietary Supplement|diindolylmethane|Given PO
101992|NCT01391689|Dietary Supplement|placebo|Given PO
101993|NCT01391715|Drug|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
101994|NCT01391715|Drug|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
101995|NCT01391728|Behavioral|Active Lifestyle all your Life|Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme "Active lifestyle all your life" with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves.
101996|NCT01391741|Other|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
101997|NCT00001087|Drug|Adefovir dipivoxil|
101998|NCT00062010|Biological|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
101999|NCT01384734|Drug|BMS-663068|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
102669|NCT01383616|Device|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
102670|NCT01383629|Behavioral|Counselling|Preoperative counselling
101490|NCT01393223|Drug|LP-08 80mg|
101491|NCT01393223|Drug|Normal Saline Placebo|
101492|NCT01393223|Drug|LP-08 20mg|
101493|NCT01393275|Other|rehabilitation exercise intervention|exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week
15 minutes warm up, 30 minutes strength endurance training - once a week
101494|NCT00062738|Drug|Nortriptyline|nortriptyline 25 - 75 mg q hs
101495|NCT01393275|Other|placebo control group|exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week
15 minutes warm up, 30 minutes strength endurance training - once a week
101496|NCT01393288|Drug|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
101497|NCT01393288|Drug|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
101498|NCT01393288|Drug|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
101499|NCT01393301|Behavioral|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Cognitive-behavioral therapy for smoking cessation, cognitive behavioral therapy for anxiety, nicotine replacement therapy (nicotine patch)
101500|NCT01393314|Device|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
101501|NCT01386177|Drug|Doxazosin|3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.
1 day (-16h) before MDMA: 8 mg doxazosin per os.
101502|NCT01386177|Drug|placebo|capsules identical to MDMA or doxazosin
101503|NCT01386190|Other|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
102181|NCT01377233|Drug|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
102182|NCT01377246|Drug|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
102183|NCT01377246|Other|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
102184|NCT01377259|Other|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
102185|NCT01377285|Drug|ARB|Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan
102186|NCT00061412|Behavioral|Comprehensive program to improve reading and writing skills|
102187|NCT01377285|Drug|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
102188|NCT01377285|Drug|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
102189|NCT01377298|Drug|Pazopanib|200mg/tablet, 800mg/day PO.
102190|NCT01377311|Procedure|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
102191|NCT01377324|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with ~200MBq 18F-FES
102192|NCT01377337|Drug|sodium bicarbonate|1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.
Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion).
102193|NCT01377350|Device|"Pneumedicare"s monitoring system.|50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
102508|NCT00061126|Drug|ABX-EGF|
102509|NCT01375218|Other|Pavlik Brace|Pavlik Brace
102510|NCT01375218|Other|Plastizote Brace|Plastizote Brace
102511|NCT01375231|Procedure|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
102512|NCT01375231|Procedure|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
101703|NCT01389128|Other|protocol with non pharmacological resources|application protocol using the combination of non-pharmacological resources: standing upright pelvic mobility in the ball, alternating stance associated with lumbosacral massage and shower;
101704|NCT01389154|Procedure|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
101705|NCT01389167|Drug|Vivitrol|An extended release naltrexone formulation for intramuscular injection
101706|NCT01389167|Drug|Naltrexone (oral)|Naltrexone 50 mg pills, daily
101707|NCT01389167|Behavioral|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
101708|NCT01389167|Behavioral|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
101709|NCT00062322|Drug|cisplatin|
101710|NCT01389180|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
101711|NCT01389180|Behavioral|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
101712|NCT01389180|Behavioral|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
101980|NCT01391611|Drug|Pazopanib|800 mg; PO
101981|NCT01391624|Drug|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
102250|NCT01374581|Drug|Quinine + Clindamycin|this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;
Quinine:
9 to < 11 kg: ½ tablets 12 to < 19 kg: 1 tablets per dose 20 to < 27 kg: 1½ tablets per dose 28 to < 35 kg: 2 tablets per dose
Clindamycin syrup:
10 mg/kg twice daily
102251|NCT01374620|Drug|Paclitaxel dose escalation|Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.
The Paclitaxel dose (mg/infusion) levels are as follows:
40
60
70
75
80
85
90
102252|NCT01374620|Drug|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
102253|NCT01374620|Drug|Cyclophosphamide|D1 to D28: 50 mg x 2/day/cycle
1 cycle = 28 days
102254|NCT01374620|Biological|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
102255|NCT01374633|Drug|1: Sevoflurane|Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
102256|NCT01374646|Behavioral|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
102257|NCT01374672|Other|laboratory biomarker analysis|Correlative studies
102258|NCT01374698|Drug|Aspirin|Aspirin 325 mg
102259|NCT01374711|Drug|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
102260|NCT00061087|Other|Placebo|Placebo
102261|NCT01374711|Drug|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
102262|NCT01374711|Other|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
102263|NCT01374724|Behavioral|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
102264|NCT01374724|Behavioral|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
102265|NCT01377389|Drug|Degarelix|80 mg subcutaneous once a month for 8 months
102266|NCT01377415|Drug|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
102267|NCT01377428|Drug|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
102268|NCT01377428|Drug|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
101504|NCT01386216|Device|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
101505|NCT01386229|Drug|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
101506|NCT01386229|Drug|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
101507|NCT00000255|Drug|Nitrous oxide|
101508|NCT00001087|Drug|Lamivudine|
101509|NCT00062101|Drug|celecoxib|Given PO
100564|NCT01366508|Other|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
100565|NCT01368965|Device|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
100566|NCT01368978|Device|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
100567|NCT01368991|Device|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
100568|NCT01368991|Procedure|Conventional closure|conventional closure, no kryptonite applied
100569|NCT01369004|Behavioral|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
100570|NCT01369017|Drug|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
100571|NCT01369017|Drug|Placebo|Injection of NS
100572|NCT01369030|Other|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
100573|NCT01369043|Dietary Supplement|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
102513|NCT01375244|Drug|Lisinopril|Tablets, 10 mg, single dose
102514|NCT01375244|Drug|Zestril|Tablets, 10 mg, single dose
102515|NCT01375257|Drug|Oral treatment with antibiotics for endocarditis|
102516|NCT01375257|Drug|Guideline treatment with parenteral antibiotics|
102517|NCT01375270|Procedure|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
102518|NCT01377922|Drug|Amifampridine Phosphate|30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets).
102519|NCT01377922|Drug|Placebo|Matching number of tablets to the individual patient's tablet count of active at baseline.
102520|NCT01377948|Behavioral|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
102521|NCT01377961|Drug|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.
The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks.
102522|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
102523|NCT01377961|Other|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
102524|NCT01377961|Other|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
102525|NCT00061477|Drug|Pemetrexed|
101642|NCT01391117|Drug|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
101643|NCT01391117|Drug|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
101644|NCT01391117|Drug|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
101645|NCT01391130|Drug|LY2510924|Administered subcutaneously
101646|NCT01391130|Drug|Sunitinib|Administered orally
102696|NCT00061165|Behavioral|School + family changes promoting healthy eating + activity|
102697|NCT01375569|Drug|TRC105|
102698|NCT01375582|Drug|B & L Soothe Lubricant Eye Drops|Eye Drop
102699|NCT01375582|Drug|Liposic EDO|Eye Drop
102700|NCT01375582|Drug|OcuFresh Eye Wash|Saline drop
102701|NCT01375608|Drug|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
102702|NCT01375634|Drug|Midazolam|2 mg intravenous over 2 minutes For patients >60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
102703|NCT01375647|Biological|IPV|Administered per protocol
102704|NCT01375647|Biological|Rotarix|Administered per protocol
102705|NCT01375660|Drug|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
102706|NCT01375660|Drug|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
102707|NCT00061178|Drug|rhuMAb VEGF (Bevacizumab)|
102708|NCT01375673|Other|Exercise|Walking Strength Training Bicycling
102709|NCT01375699|Drug|Doxorubicin|As prescribed by treating provider
102710|NCT01375699|Drug|Sildenafil|100 mg capsule once daily at least 7 days prior to scheduled first dose of doxorubicin and continue daily dosing through 2 weeks from scheduled last doxorubicin dose
102711|NCT01378273|Other|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
102712|NCT01378286|Drug|ARTESUNATE + AMODIAQUINE|Pharmaceutical form:
Route of administration:
102713|NCT01378286|Drug|Chloroquine|Pharmaceutical form:tablet Route of administration: oral
101785|NCT01389284|Drug|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
101786|NCT01389284|Drug|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
101787|NCT01389297|Behavioral|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
102269|NCT01377441|Drug|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
102595|NCT01383447|Other|immunohistochemistry staining method|Correlative studies
102596|NCT01375270|Procedure|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
102597|NCT00061139|Behavioral|Pediatric Constraint-Induced Movement therapy|
102598|NCT01375296|Device|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
102599|NCT01375296|Other|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
102600|NCT01375309|Dietary Supplement|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5*10to9th bacteria per day
102601|NCT01375309|Dietary Supplement|Placebo contains dextrin|0.5 of dextrin
102602|NCT01375322|Drug|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
102603|NCT01375322|Drug|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
102604|NCT01375335|Drug|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
102605|NCT01375348|Drug|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
102606|NCT01375361|Drug|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
102607|NCT01375361|Drug|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
102608|NCT00061139|Behavioral|Conventional pediatric motor rehabilitation therapy|
102609|NCT01375374|Drug|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
102610|NCT01375374|Drug|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
102611|NCT01375387|Drug|Lacosamide|100 mg oral tablet, single dose
102612|NCT01375387|Drug|Lacosamide|Lacosamide 2 X 100 mg tablet
101854|NCT01386866|Drug|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of [14C]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
101855|NCT01386879|Drug|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
101856|NCT01386892|Other|No intervention|There is no intervention for this study
101857|NCT01386905|Device|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
101858|NCT01386918|Device|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
101859|NCT01386931|Procedure|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
101860|NCT01386931|Procedure|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
101861|NCT01386970|Drug|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
101862|NCT01386983|Drug|5ARI|Dutasteride or Finasteride
101863|NCT01386983|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
101864|NCT00062140|Procedure|peripheral blood stem cell transplantation|
101865|NCT01386996|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
101866|NCT01386996|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
101867|NCT01387022|Drug|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
102115|NCT01379846|Biological|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
102116|NCT00001086|Drug|Abacavir sulfate|
102117|NCT00061698|Behavioral|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
101647|NCT00062465|Drug|TwHF|
101648|NCT01391143|Biological|MGA271|Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.
Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles.
101649|NCT01391156|Drug|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
101650|NCT01391156|Drug|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
101651|NCT01391169|Other|seromuscular flap enforcement|seromuscular flap enforcement
101652|NCT01391182|Other|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
101653|NCT01391182|Other|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
101654|NCT01391195|Device|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
101655|NCT01384019|Procedure|c-PCI|conventional PCI without Guard wire
101656|NCT01384032|Dietary Supplement|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
101657|NCT01384032|Dietary Supplement|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
101658|NCT01384032|Dietary Supplement|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
101924|NCT01384643|Drug|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
101925|NCT01384656|Drug|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
101788|NCT01389297|Behavioral|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
101789|NCT01389323|Drug|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
101790|NCT01389323|Drug|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
101791|NCT01389323|Drug|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
101792|NCT01389349|Other|Acupuncture|Battlefield acupuncture protocol
101793|NCT00062322|Procedure|conventional surgery|
101794|NCT01389349|Other|Sham Control|Sham control acupuncture
101795|NCT01389362|Drug|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
101796|NCT01389362|Drug|Placebo comparator|2 sachets to be taken daily
101797|NCT01389375|Device|FemoSeal®|Closure device for femoral artery access closure
101798|NCT01391351|Other|blood samples|blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:
On Day 1 of the first course of chemotherapy
On Day 1 of the second course of chemotherapy
Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
At the end of chemotherapy
101799|NCT01391377|Drug|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
101800|NCT01391377|Drug|Sugar pill|Placebo
101801|NCT01391390|Drug|Melatonin|10mg/day, 12-week treatment
101802|NCT01391390|Drug|Placebo|10mg/day, 12-week treatment for TD
101803|NCT01391403|Drug|Artemisinin|400 mg/day
101804|NCT01391403|Other|Placebo|400mg/day
101805|NCT00062504|Drug|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
101806|NCT01391429|Behavioral|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
101807|NCT01391442|Biological|blood and urine samples|58 ml of blood 120 ml of urine
101808|NCT01391442|Genetic|blood sample|11 ml of blood
102613|NCT01375387|Drug|Lacosamide|Lacosamide 4 X 100mg tablet
102614|NCT01375387|Other|Placebo 3|Placebo - 3 tablets
102615|NCT01375387|Other|Placebo 4|Placebo - 4 tablets
102616|NCT01375387|Other|Placebo 2|Placebo - 2 tablets
101713|NCT01391208|Drug|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
101714|NCT01391221|Drug|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
101715|NCT01391234|Radiation|STAT RT planning and delivery workflow|Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.
Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.
Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques.
101716|NCT00062478|Drug|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
101717|NCT01391260|Other|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
101718|NCT01391273|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
101719|NCT01391273|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
101720|NCT01391286|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
101721|NCT01391286|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
101722|NCT01391299|Biological|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
101723|NCT01391299|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
101724|NCT01391312|Biological|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
102118|NCT01379872|Other|Non-Interventional Study|This is a non-interventional study
102119|NCT01379885|Behavioral|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
102120|NCT01379885|Behavioral|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
102121|NCT01379898|Drug|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
102122|NCT01379898|Drug|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
102123|NCT01379911|Other|Yogurt|
102124|NCT01379924|Behavioral|Modules|
102125|NCT01379924|Other|No intervention|
102126|NCT01379924|Other|No intervention|
102127|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
102128|NCT00061711|Drug|Hormone Replacement Therapy|
102129|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
102130|NCT01379937|Biological|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
102131|NCT01382056|Other|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
102132|NCT01382069|Drug|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
102133|NCT01382069|Drug|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
102450|NCT01380366|Procedure|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
101926|NCT01384682|Drug|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
101927|NCT01384695|Drug|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
101928|NCT01384695|Drug|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
101929|NCT01384708|Drug|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
101930|NCT01387048|Drug|differin|0.1% gel, once daily in the evening
101931|NCT01387048|Drug|skinoren|12 weeks treatment, the following 24 months only observation
101932|NCT01387061|Procedure|hepatic resection|surgical resection of the liver for multiple HCC
101933|NCT01387074|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
101934|NCT01387087|Drug|ASP015K|oral
101935|NCT01387087|Drug|Placebo|oral
101936|NCT00001087|Drug|Stavudine|
101937|NCT00062140|Radiation|radiation therapy|
101938|NCT01387100|Behavioral|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
101939|NCT01387113|Other|Computed tomography perfusion imaging|As per standard of care at CPMC
101940|NCT01387126|Dietary Supplement|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
101941|NCT01387139|Drug|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
102194|NCT01377350|Device|"Pneumedicare"s monitoring system|Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
102195|NCT01377376|Drug|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
102365|NCT01377610|Drug|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
102366|NCT01377610|Drug|Buprenorphine|Following detoxification with buprenorphine [8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
102367|NCT00061451|Drug|Gemcitabine|
102368|NCT01377610|Drug|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
102369|NCT01377636|Drug|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
102370|NCT01377662|Drug|OND-PR002 and MPh-IR|Drug: OND-PR002
Single daily oral doses of 8 mg Ond-PR002
Drug: MPh-IR
Single daily oral doses of 20 mg MPh-IR
102371|NCT01377662|Other|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
102372|NCT01380236|Drug|ASM8|
102373|NCT01380249|Drug|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
102374|NCT01380275|Drug|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
102375|NCT01380275|Drug|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
102376|NCT01380288|Drug|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
102377|NCT01380301|Drug|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
102378|NCT01380301|Drug|Miltefosine alone|short course (half)
102379|NCT00061763|Drug|Deferasirox|
102380|NCT01380314|Drug|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
101725|NCT01391312|Drug|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
101726|NCT01391325|Drug|Allopurinol|Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
101727|NCT00062491|Drug|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
101728|NCT01391338|Drug|ASP3652|Oral
102000|NCT01384734|Drug|BMS-663068|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
102001|NCT01384734|Drug|BMS-663068|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
102002|NCT01384734|Drug|BMS-663068|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
102003|NCT01384734|Drug|Raltegravir|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
102004|NCT01384734|Drug|Raltegravir|Tablets, Oral, 400 mg, twice daily (BID), 96 weeks
102005|NCT01384734|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
102006|NCT01384734|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily (QD), 96 weeks
102007|NCT01384734|Drug|Ritonavir|Tablets, Oral, 100 mg, Once daily, 96 weeks
102008|NCT01384734|Drug|Atazanavir|Capsules, Oral, 300 mg, Once daily, 96 weeks
102009|NCT00062010|Drug|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
102010|NCT01384747|Drug|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
102011|NCT01384747|Drug|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
102012|NCT01384760|Behavioral|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
102451|NCT01380366|Procedure|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
102452|NCT00061776|Drug|Capsaicin Dermal Patch|
102453|NCT01380366|Other|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
102454|NCT01380366|Other|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
102455|NCT01380366|Other|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
102456|NCT01380379|Behavioral|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
102457|NCT01380405|Behavioral|education intervention|Individual or collective education interventions about the correct use of inhalers.
session in the management of inhalers in the collective or individual programmed.
Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons.
102458|NCT01380431|Drug|Lisinopril|Tablets, 40 mg, single oral dose
102459|NCT01380431|Drug|lisinopril|Tablets, 40 mg, single, oral dose
102460|NCT01380431|Drug|Lisinopril|50% of subjects received the Par formulated product.
102461|NCT01380444|Procedure|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
102462|NCT01380444|Procedure|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
102463|NCT00061789|Drug|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
102464|NCT01380457|Drug|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
101588|NCT01393639|Drug|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
102196|NCT01377376|Drug|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
102197|NCT00061425|Drug|radiolabeled epratuzumab|
102198|NCT01377389|Drug|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
102199|NCT01377389|Drug|Leuprolide|7.5 mg intramuscular once a month for 8 months
102200|NCT01377389|Drug|Goserelin|3.6 mg subcutaneous once a month for 8 months
102201|NCT01379937|Biological|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
102202|NCT01379976|Drug|Acetylcarnitine|ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).
Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.
102203|NCT01379976|Drug|Placebo|ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).
Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.
102204|NCT01379989|Drug|Carboplatin|Carboplatin AUC 5
102205|NCT01379989|Drug|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
102206|NCT01379989|Drug|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
102207|NCT01380015|Other|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
102208|NCT01380015|Other|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
102209|NCT00061711|Drug|Cimicifuga racemosa (Black Cohosh)|
102210|NCT01380028|Drug|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
102211|NCT01380028|Drug|placebo|placebo
102212|NCT01380054|Behavioral|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
102381|NCT01380314|Drug|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
102397|NCT01382797|Drug|ALKS 37|Capsules for oral administration
102398|NCT01382797|Drug|Placebo|Capsules for oral administration
102399|NCT01382810|Drug|Altaire Gel forming solution|Three times a day for two months
102400|NCT01382810|Drug|Refresh Tears|Three times a day for two months
102401|NCT00061945|Drug|cyclophosphamide|Given IV
102402|NCT01382823|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
102403|NCT01382862|Other|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
102404|NCT01382875|Other|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
102405|NCT01382888|Drug|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
102406|NCT01382888|Drug|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
102407|NCT01374906|Drug|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
102408|NCT01374906|Drug|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
102409|NCT01374919|Drug|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
102410|NCT01374932|Device|CPAP|Continuous positive airways pressure (CPAP)
102411|NCT00061113|Drug|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
102412|NCT01374945|Device|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
102013|NCT01384760|Behavioral|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
102014|NCT01384773|Other|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
102015|NCT01384773|Device|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
102016|NCT01384799|Drug|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
102270|NCT01377441|Drug|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
102271|NCT01377467|Drug|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
102272|NCT00061438|Drug|meropenem|
102273|NCT01377480|Drug|Posaconazole|POS 40 mg/mL oral suspension
102274|NCT01377480|Drug|Placebo for posaconazole|Placebo oral suspension
102275|NCT01377480|Drug|Benznidazole|BNZ 100 mg oral tablet
102276|NCT01377493|Dietary Supplement|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
102277|NCT01377506|Behavioral|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
102278|NCT01377506|Behavioral|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
102279|NCT01377519|Procedure|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
102280|NCT01377519|Procedure|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
101589|NCT01386320|Procedure|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
101590|NCT01386333|Drug|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
101591|NCT01386333|Drug|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
101592|NCT01386346|Drug|Azacitidine|50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles.
101593|NCT01386346|Drug|Azacitidine|75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles.
101594|NCT01386346|Drug|Azacitidine|75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
101595|NCT01386346|Drug|Oxaliplatin|130 mg/m2 IV on Day 3 of each 21 day cycle. Repeat for a total of 3 cycles.
101596|NCT01386346|Drug|Oxaliplatin|130 mg/m2 IV on Day 5 of each 21 day cycle. Repeat for a total of 3 cycles.
101597|NCT01386346|Drug|Epirubicin|50 mg/m2 IV on Day 3 of each 21 day cycle. Repeat for a total of 3 cycles.
101598|NCT00062114|Biological|rituximab|
101599|NCT01386346|Drug|Epirubicin|50 mg/m2 IV on Day 5 of each 21 day cycle. Repeat for a total of 3 cycles.
101600|NCT01386346|Drug|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 and will be taken without interruption for each 21-day cycle.
101601|NCT01386346|Drug|Capecitabine|625 mg/m2 orally twice daily beginning on Day 5 and will be taken without interruption for each 21-day cycle.
101602|NCT01386359|Drug|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
101603|NCT01386372|Drug|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
101604|NCT01386372|Other|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
101605|NCT01386385|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
101606|NCT01386385|Drug|Carboplatin|Given IV
102526|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
102527|NCT01377961|Other|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
102528|NCT01377974|Drug|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
102529|NCT01377974|Drug|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
102530|NCT01377987|Drug|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
102531|NCT01377987|Drug|Placebo|4 mg/kg, once daily before bed, for 7 days
102532|NCT01378039|Drug|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
102533|NCT01378065|Device|Restorelle Direct Fix A&P|Restorelle Direct Fix A&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
102534|NCT01378078|Device|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
102535|NCT01378078|Device|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
102536|NCT00000118|Device|Sustained-Release Intraocular Drug Delivery System|
102537|NCT00000254|Drug|0.6% isoflurane|
102538|NCT00001085|Drug|Zidovudine|
102539|NCT00061477|Drug|Gemcitabine|
102540|NCT01380483|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
102541|NCT01380496|Drug|doxycycline monohydrate|tablet, 100 mg, single, oral dose
102542|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
102543|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
102544|NCT01380509|Drug|Metronidazole|Capsules, single-dose, fasting
102545|NCT01380509|Drug|Flagyl|Capsules, single-dose, fasting
102546|NCT01380522|Drug|Metronidazole|Capsules, single-dose, fed
102413|NCT01374971|Drug|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
101528|NCT01388855|Drug|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
101529|NCT01388855|Drug|Placebo|Pills made to look like vitamin D but have no medication in them
101530|NCT01388868|Other|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
101531|NCT01388868|Other|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
101532|NCT01388868|Other|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
101533|NCT01388881|Other|Music Education|The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the "classical" elements/music.
101534|NCT01388907|Other|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
101535|NCT01388907|Device|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
101536|NCT01388920|Drug|Tesamorelin|
101537|NCT00001087|Drug|Zalcitabine|
101538|NCT00062296|Biological|rituximab|
101539|NCT01388933|Drug|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
101540|NCT01388933|Drug|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
101541|NCT01388946|Drug|Ropivacaine 0.75|Infusion of ropivacaine 0.75 at a rate 2 ml/h is administered, beginning after the induction of anesthesia and discontinued 24 hours postoperatively.
101542|NCT01388946|Drug|Normal Saline|Infusion of normal saline at a rate 2 ml/h is administered, beginning after the induction of anesthesia and discontinued 24 hours postoperatively.
101543|NCT01390948|Drug|bevacizumab [Avastin]|Chemoradiation period: 10 mg/kg intravenously every 2 weeks for 6 weeks. TMZ treatment break: 10 mg/kg intravenously every 2 weeks for 4 weeks. Adjuvant TMZ period: 10 mg/kg intravenously every 2 weeks for 12 cycles
102281|NCT01377532|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
102282|NCT01377545|Procedure|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
102283|NCT00061451|Drug|Pemetrexed|
102284|NCT01377545|Procedure|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
102285|NCT01380093|Drug|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
102286|NCT01380106|Drug|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
102287|NCT01380106|Drug|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
102617|NCT01375400|Drug|Aspirin|Administration of 300 mg of aspirin, per os.
102618|NCT01375400|Biological|blood sample|2 blood samples will be performed
102619|NCT00001084|Drug|Zidovudine|
102620|NCT00061152|Drug|Capsaicin Dermal Patch|
102621|NCT01375413|Behavioral|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
102622|NCT01378091|Drug|Lenalidomide|Standard combination phase I dose escalation:
Starting dose:
10 mg daily of oral lenalidomide on Days 1-14 every 21 days 21 days and a starting dose of docetaxel 60 mg/m2 IV on Days 1 of every 21 days.
Prednisone will be given at 5 mg BID, daily.
Lenalidomide dose will be escalated up to 40 mg and docetaxel to 75 mg/m2
102623|NCT01378104|Drug|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
102624|NCT01378104|Drug|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
102625|NCT01378117|Drug|Sitagliptin|Sitagliptin 50-100mg po once daily
101607|NCT01386385|Other|Laboratory Biomarker Analysis|Correlative studies
101868|NCT01387048|Drug|skinoren|gel 15%, twice daily, 36 weeks
101869|NCT01389375|Device|ExoSeal®|Closure device for femoral artery access closure
101870|NCT01389375|Other|Manual compression|Conventional manual compression
101871|NCT01389388|Drug|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
101872|NCT01389401|Drug|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
101873|NCT01389414|Drug|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
101874|NCT01389414|Drug|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
101875|NCT00062322|Procedure|neoadjuvant therapy|
101876|NCT01389427|Drug|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101877|NCT01389427|Drug|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101878|NCT01389427|Drug|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101879|NCT01389427|Drug|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101880|NCT01389427|Drug|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101881|NCT01389427|Drug|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101882|NCT01389427|Drug|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
102547|NCT00061802|Drug|risperidone, quetiapine|
102548|NCT01380522|Drug|Flagyl|Capsules, single-dose, fed
101659|NCT01384045|Other|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
101660|NCT01384058|Drug|ezetimibe|ezetimibe 10 mg per day for six weeks
101661|NCT01384058|Drug|simvastatin|Simvastatin 20 mg per day for six weeks
101662|NCT01384058|Drug|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
101663|NCT00061945|Other|pharmacological study|Correlative studies
101664|NCT01384071|Device|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
101665|NCT01384071|Device|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
101666|NCT01384084|Procedure|POP repair plus mini-sling|For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.
A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh.
101667|NCT01384084|Procedure|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
101668|NCT01384110|Dietary Supplement|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
101669|NCT01384149|Device|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
101670|NCT01384149|Device|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
101671|NCT01384162|Drug|sNN0029|ICV infusion
101672|NCT01384175|Procedure|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
101673|NCT01386398|Other|laboratory biomarker analysis|
101544|NCT00062439|Procedure|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
101809|NCT01391442|Other|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
101810|NCT01391442|Other|Stanislas ancillary study : MRI examination with GRICS technique|
101811|NCT01391455|Procedure|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
101812|NCT01391468|Dietary Supplement|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
101813|NCT01391468|Dietary Supplement|Cornstarch|placebo will be given in 6 months
101814|NCT01391481|Drug|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
101815|NCT01391481|Drug|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
101816|NCT00062530|Biological|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
101817|NCT01391494|Biological|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
101818|NCT01391494|Biological|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
101819|NCT01391494|Biological|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
101820|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
101821|NCT01391494|Biological|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
101822|NCT01391494|Biological|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
101823|NCT01391494|Biological|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
101824|NCT01384422|Drug|GLPG0634|
101825|NCT01384435|Drug|KPS-0373|
101826|NCT01384435|Drug|KPS-0373|
102626|NCT01378117|Drug|glargine|glargine once daily
102627|NCT01378117|Drug|lispro|lispro before meals
102628|NCT01378143|Drug|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
102629|NCT01378156|Biological|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
102630|NCT01378182|Genetic|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
102631|NCT01378195|Behavioral|CBT-based program for dementia caregivers|Participants will receive a CBT-based program [Cognitive Behavioral Therapy], containing videos, workbook, and website.
102632|NCT00061490|Behavioral|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
102633|NCT01378195|Behavioral|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
102634|NCT01378208|Behavioral|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.
DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)
28 days of dietary monitoring
28 days measurement by pedometer DAY 1, DAY 28 & DAY 56: Test 1
Oral glucose tolerance test with stable isotopes
Fat and muscle biopsies DAY 2, DAY 29 & DAY 57: Test 2
DXA scanning
Resting Metabolic Rate Measurement
VO2max test on bicycle
Cognitive testing
MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 & DAY 48: Test 3
Actiheart for 3 days
72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION
Fasting from 7am - 9pm
28 days of dietary monitoring
28 days measurement by pedometer
101729|NCT01391338|Drug|Placebo|Oral
101730|NCT01391351|Other|blood samples|blood samples in patients receiving Taxol and carboplatin chemotherapy :
On Day 1 of the first course of chemotherapy
On Day 1 of the second course of chemotherapy
Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
At the end of chemotherapy
101731|NCT01384175|Procedure|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
101732|NCT00061958|Drug|arsenic trioxide|Given IV
101733|NCT01384175|Procedure|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
101734|NCT01384188|Drug|ONO-5334|150 mg for 5 days administered in the morning or in the evening
101735|NCT01384188|Drug|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
101736|NCT01384214|Biological|botulinum toxin Type A|750 U at Visit 1
101883|NCT01389427|Drug|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101884|NCT01389427|Drug|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
102134|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
102135|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
102136|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
102137|NCT01382095|Biological|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
102138|NCT00061893|Drug|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
102139|NCT01382121|Behavioral|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
102140|NCT01382121|Behavioral|Control|watching a video unrelated to the fitness test and self-efficacy
102141|NCT01382134|Drug|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
102142|NCT01382134|Drug|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
102143|NCT01382147|Drug|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
102144|NCT01382160|Biological|adalimumab|40 mg every two weeks, by subcutaneous way
102145|NCT01382199|Drug|Lactoferrin|
102146|NCT01382212|Drug|paricalcitol|Capsules, open-label, single-arm
102147|NCT01382225|Drug|Sodium Hyaluronate Ophthalmic Solution, 0.18%|
102148|NCT01382225|Other|Vehicle|Inactive ingredients used as run-in and placebo comparator
102149|NCT00061906|Drug|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
102150|NCT01382238|Drug|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
102151|NCT01382238|Drug|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
101674|NCT01386411|Genetic|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
101675|NCT01386450|Drug|AZD6244|BID until toxicity or progression of disease.
101676|NCT01386489|Biological|VRC-HIVDNA016-00-VP|
101942|NCT01387139|Drug|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
101943|NCT01387165|Drug|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
101944|NCT01387178|Drug|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
101945|NCT01387178|Drug|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
101946|NCT01387191|Drug|Epoprostenol|
101947|NCT01387204|Drug|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
101948|NCT00062179|Drug|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
101949|NCT01387217|Drug|GSK2018682|GSK2018682
101950|NCT01387217|Drug|Placebo|Matched Placebo
101951|NCT01387230|Drug|GSK573719|62.5 mcg
101952|NCT01387230|Drug|GSK573719|125mcg
101953|NCT01387230|Other|Placebo|Placebo
101954|NCT01387243|Drug|Orlistat|60 mg
101955|NCT01387256|Drug|medical abortion|pregnancy termination with drugs
101956|NCT01387269|Drug|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
101957|NCT01389427|Drug|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101827|NCT01384435|Drug|KPS-0373|
101828|NCT01384435|Drug|KPS-0373|
101829|NCT01384435|Drug|Placebo|
101830|NCT01384448|Procedure|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
102075|NCT01391832|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
102076|NCT01391832|Device|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
102077|NCT01391845|Drug|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
102078|NCT00062582|Drug|Roflumilast|
102079|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
102080|NCT01391845|Drug|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
102081|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
102082|NCT01391858|Drug|lyrica|150mg of pregabalin/placebo
102083|NCT01384799|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
102084|NCT01384799|Radiation|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
102085|NCT01384812|Drug|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
102086|NCT00062010|Drug|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
102087|NCT01384812|Drug|isoton sodium chloride|intravenous injection for 25 min
101737|NCT01384227|Drug|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
101738|NCT01384240|Drug|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
101739|NCT01384253|Other|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
101740|NCT01384253|Biological|trastuzumab|4 mg/kg.
101741|NCT01384279|Drug|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
101742|NCT01384292|Drug|NKTR-118|12.5 mg oral tablet once daily
101743|NCT00061984|Biological|pegfilgrastim|
101744|NCT01384292|Drug|NKTR-118|25 mg oral tablet once daily
101745|NCT01384292|Drug|Placebo|Oral treatment
101746|NCT01384318|Other|Manometer|Measuring cuff pressure
101747|NCT01384331|Drug|Marvelon|7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules
21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms
21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days
21 days daily oral placebo capsules Treatment will be for one cycle of 21 days
101748|NCT01384344|Other|observational|Observation during a physical exercise
101749|NCT01384383|Drug|GS-5885|GS-5885 30 mg tablet administered orally once daily
102017|NCT01387269|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
102018|NCT01387282|Drug|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
102019|NCT00062179|Drug|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
102020|NCT01387282|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
102021|NCT01387295|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
102022|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
102152|NCT01382264|Other|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
102153|NCT01382277|Drug|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
102154|NCT01382290|Procedure|MRI|
102155|NCT01382303|Drug|Pentoxifylline|Pentoxifylline 400mg three times a day
102156|NCT01382303|Drug|Placebo|placebo tablet three times a day
102465|NCT01380457|Drug|Marinol|Capsules, 10 mg, single-dose, fasting conditions
102466|NCT01380483|Drug|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
102467|NCT01382901|Drug|Ferric Carboxymaltose (FCM)|
102468|NCT01382901|Drug|Placebo|
102469|NCT01382914|Other|chlorhexidine 0.12%|twice daily, 10 ml, topical
102470|NCT01382940|Drug|rituximab|1000 mg in 250 mL intravenous infusion
102471|NCT01382940|Drug|methotrexate|10 to 25 mg/week (oral or parenteral)
102472|NCT00061945|Drug|daunorubicin hydrochloride|Given IV
102473|NCT01382940|Drug|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
102474|NCT01382940|Drug|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
102475|NCT01382940|Drug|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
102476|NCT01382953|Device|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
102477|NCT01382979|Behavioral|AlcoholEdu for College|Online course for college freshmen.
102478|NCT01383018|Device|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
102479|NCT01383031|Procedure|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
101958|NCT01389440|Drug|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
101959|NCT01389453|Procedure|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7—14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
101960|NCT01389466|Biological|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
101961|NCT01389466|Biological|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
101962|NCT01389479|Biological|Fluviral™|Intramuscular, single dose
101963|NCT01389479|Biological|Fluzone®|Intramuscular, single dose
102213|NCT01380080|Drug|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
102214|NCT01380080|Drug|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
102215|NCT01380080|Drug|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
102216|NCT01380080|Drug|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
102217|NCT01380080|Drug|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
102218|NCT01380080|Drug|Isoniazid|INH 300 mg orally once daily
102219|NCT01380093|Drug|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
102220|NCT00061711|Drug|Multibotanical phytoestrogen formula|
102221|NCT01380093|Drug|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
102222|NCT01382316|Behavioral|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
102223|NCT01382316|Behavioral|Usual care|Group format, six weekly education sessions about alcohol and drugs
102088|NCT01384838|Behavioral|Counseling|Nutritional, lifestyle and sports counseling
102089|NCT01384838|Behavioral|physical activity|counseling and controlled physical activity
102090|NCT01384851|Drug|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
102091|NCT01384851|Drug|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
102092|NCT01384851|Drug|Refresh Contacts|One drop both eyes four times daily for two weeks
102093|NCT01384864|Drug|proflavine|2-6 ml of 0.01% proflavine
102414|NCT01374971|Procedure|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
102415|NCT01374984|Biological|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
102416|NCT01374997|Other|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
102417|NCT01375010|Drug|Vitamin D3|All subjects will be provided with supplements that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 and will be instructed to take one twice daily with breakfast and dinner. Participants will then be block randomized in a 1:1 ratio with randomly varying block sizes of 2, 4 or 6 to 2000 IU vitamin D3 (Group A) or placebo (Group B). Group A will receive a total of 3000 IU/day, the dose and Group B will receive 1000 IU/day.
102418|NCT01375010|Drug|Placebo|Participants will then be block randomized in a 1:1 ratio with randomly varying block sizes of 2, 4 or 6 to 2000 IU vitamin D3 (Group A) or placebo (Group B). Group A will receive a total of 3000 IU/day, the dose and Group B will receive 1000 IU/day.
102419|NCT01375023|Radiation|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
102420|NCT01375023|Biological|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
102421|NCT01375049|Drug|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
102422|NCT00061113|Drug|fluoxetine|20mg, QD x 16 weeks
102423|NCT01375062|Other|analyse and proliferate the cells|Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.
Digestion of the biopsies through controlled enzymes
Replication of the cells
Selection undifferentiated cells
Expansion of the purification cells population
Characterization of the cell population
Assessment of pluripotent and germinal cell potential.
Possible maturation of the cells.
102424|NCT01375075|Drug|LY2484595|Administered orally
102023|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 3, single dose
102024|NCT01387308|Drug|Fostamatinib|Oral tablets, 100 mg, single dose
102025|NCT01387308|Drug|Fostamatinib|Oral tablets, 150 mg, single dose
102026|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
102027|NCT01387321|Drug|BYL719|
102028|NCT01387334|Behavioral|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
102029|NCT01387347|Drug|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
102030|NCT00062179|Drug|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
102031|NCT01387347|Drug|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
102032|NCT01387360|Device|Supracor|The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.
The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances.
102033|NCT01387373|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
102034|NCT01387399|Procedure|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|Classical "3+3" dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)
102035|NCT01387425|Drug|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
102036|NCT01387425|Drug|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
102037|NCT01387464|Drug|ISV-303|% of Bromfenac in DuraSite dosed QD
102288|NCT01380119|Biological|V7|experimental arm
102289|NCT01380119|Other|placebo|placebo pill
102290|NCT01380132|Procedure|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
102291|NCT01380145|Biological|recMAGE-A3 Protein plus AS15 Adjuvant|Eight intramuscular immunizations with 300 mcg recMAGE-A3 Protein plus AS15 Adjuvant
102292|NCT01380158|Device|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
102480|NCT01383031|Procedure|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
102481|NCT01383044|Procedure|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
102482|NCT01383044|Drug|carvedilol|carvedilol 6.25mg-12.5 mg per day
102483|NCT00001087|Drug|Efavirenz|
102484|NCT00061945|Drug|vincristine sulfate|Given IV
102485|NCT01383057|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
102486|NCT01383070|Behavioral|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
101608|NCT01386385|Drug|Paclitaxel|Given IV
101609|NCT00062114|Radiation|yttrium Y 90 ibritumomab tiuxetan|
101610|NCT01386385|Other|Placebo|Given PO
101611|NCT01386385|Drug|Veliparib|Given PO
101612|NCT01386398|Drug|bortezomib|
101613|NCT01386398|Drug|vorinostat|
101614|NCT01388959|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
101615|NCT01388985|Biological|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
101616|NCT01388998|Other|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
101617|NCT01389024|Drug|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an absolute neutrophil count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
101618|NCT01389024|Drug|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
102224|NCT01382329|Biological|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
102225|NCT00061919|Drug|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
102226|NCT01382342|Drug|Rasagiline|1 mg daily
102227|NCT01382342|Drug|Placebo|1 mg daily
102228|NCT01382368|Drug|Sildenafil|Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
102229|NCT01382407|Drug|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
102230|NCT01382420|Procedure|surgery|adrenalectomy
102231|NCT01382433|Procedure|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
102549|NCT01380535|Drug|ECP(Methoxsalen)+Corticosteroids+Cyclosporine or Tacrolimus|ECP UVADEX dose (TBD) administered during Wks 2-10 (2x/wk), Wks 11-18 (2x/wk every 2 wks), and Wks 19-26 (2x/wk every 4 wks) along with corticosteroids at a dose of 1.0 mg/kg prednisone, or equivalent, daily, tapered to 0.125 mg/kg daily by Wk 24 and maintained at that dose until Wk 28.
102550|NCT01380535|Drug|Corticosteroids/Cyclosporine/Tacrolimus|1.0 mg/kg prednisone, or equivalent, daily, tapered to 0.125 mg/kg daily by Wk 24 and maintained at that dose until Wk 28 administered with cyclosporine or Tacrolimus (dose of cyclosporine/Tacrolimus should be consistent with local institutional practice).
102551|NCT01380548|Dietary Supplement|Placebo|Placebo; once/day; for 12 weeks
102552|NCT01380548|Dietary Supplement|Iron alone|Iron (3 mg); once/day; for 12 weeks
102553|NCT01380548|Dietary Supplement|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
102554|NCT01380548|Dietary Supplement|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
102555|NCT01380548|Dietary Supplement|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
102556|NCT01380561|Drug|asimadoline|10mg [14]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
102557|NCT01380600|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10^6 pfu/kg, 1x10^7 pfu/kg, 3x10^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
102558|NCT00001086|Drug|Efavirenz|
102559|NCT00061815|Biological|cetuximab|400 mg/m2 IV
102425|NCT01375075|Drug|Placebo|Administered orally
102426|NCT01375075|Drug|Atorvastatin|Administered orally
102427|NCT01375088|Drug|propolis|15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
102428|NCT01377675|Other|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
102429|NCT01377740|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
102430|NCT01377753|Device|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
102431|NCT01377779|Drug|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
101545|NCT01390948|Drug|temozolomide (TMZ)|Chemoradiation period: 75 mg/m2 per day for 6 weeks. Adjuvant TMZ period: 150 mg/m2 at Cycle 1 and 200 mg/m2 thereafter per day on day 1-5 per week every 28 days for 12 cycles
101546|NCT01390961|Drug|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
101547|NCT01391000|Procedure|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
101548|NCT01391000|Procedure|TENS|Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.
Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA.
101549|NCT01391013|Drug|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
101550|NCT01391013|Drug|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
101551|NCT01391013|Drug|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
101552|NCT01391026|Behavioral|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
101553|NCT01391039|Drug|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
101554|NCT01391052|Drug|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
101555|NCT00001088|Drug|Bupivacaine hydrochloride|
102293|NCT01380184|Drug|ridaforolimus|4 enteric coated tablets (ECT), each containing 10 mg ridaforolimus, orally (total 40 mg), on Day 1 and Days 8-12 of Cycle 1, and then once daily for 5 consecutive days in all subsequent cycles
102294|NCT00061750|Drug|ICL670|
102295|NCT01380197|Drug|Morphine|Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).
102296|NCT01380197|Drug|Nubain|Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).
102297|NCT01380223|Drug|placebo|I.V. infusion of placebo for 8 hr
102298|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
102299|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
102300|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
102301|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
102302|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
102303|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
102304|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
102305|NCT00061750|Drug|deferoxamine|
102306|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
102307|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
102308|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
102635|NCT01378234|Behavioral|Enhanced Discharge Planning Program transitional care|Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:
Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs
Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment
Supporting caregivers to reduce stress and burden
101619|NCT01389037|Behavioral|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
101620|NCT00062296|Drug|epirubicin hydrochloride|
101621|NCT01389037|Behavioral|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
101622|NCT01389050|Radiation|Intensity-Modulated Radiotherapy|Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
101623|NCT01389050|Radiation|Daily Cone Beam CT|Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
101624|NCT01389063|Drug|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
101885|NCT01389427|Drug|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101886|NCT00062322|Radiation|radiation therapy|
101887|NCT01389427|Drug|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
101888|NCT01391494|Biological|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
101889|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
101890|NCT01391494|Biological|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
101891|NCT00062543|Procedure|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
101892|NCT01391494|Biological|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
101893|NCT01391494|Biological|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
101894|NCT01391494|Biological|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
101895|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
101896|NCT01391494|Biological|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
102560|NCT01380613|Behavioral|Workshop|10 session intervention
102561|NCT01380613|Behavioral|Workshop control|1 session intervention on standard HIV/STD information
102562|NCT01380626|Procedure|exercise training|strength and endurance training, 5 time per week.
102563|NCT01380639|Other|whole body vibration training|performing squats for 3x3 minutes while using vibration platform three times a week
102564|NCT01380652|Procedure|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
102565|NCT01380665|Device|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
102566|NCT01383252|Procedure|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
102567|NCT01383265|Procedure|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
102568|NCT01383265|Procedure|Water method|Control method will use plain water with water method for screening colonoscopy
101677|NCT01386489|Biological|VRC-HIVADV014-00-VP|
101678|NCT01386502|Biological|p53: 264-272 peptide|
101679|NCT00062127|Drug|irinotecan hydrochloride|Given IV
101680|NCT01386502|Drug|CT-011|
101681|NCT01386528|Drug|NNC-0156-0000-0009|The patients will receive NNC-0156-0000-0009 at screening just prior to and during surgical intervention, administered intravenously (into the vein).
101682|NCT01386541|Drug|BYK324677|capsules, administered orally
101683|NCT01386554|Drug|Repository Corticotropin Injection|Acthar (80 U two times per week) given SC for 6 months
101684|NCT01386554|Drug|Placebo|Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.
Placebo given SC for 6 months (80 U two times a week).
101685|NCT01386567|Drug|Androxal (enclomiphene citrate)|capsules oral 1x a day
1 year
101686|NCT01386567|Drug|Testim (topical testosterone)|topical
1 tube
1x a day
1 year
101687|NCT01386580|Drug|2B3-101|IV every 21 days
101688|NCT01386580|Drug|Trastuzumab|IV every 21 days
101556|NCT00062439|Radiation|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
101557|NCT01391052|Other|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
101558|NCT01391065|Radiation|MR PET Guided Brachytherapy|
101559|NCT01391078|Device|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
101560|NCT01391078|Device|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
101561|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
101562|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
101563|NCT01393496|Other|red blood cell transfusion|Implementation of "liberal" guidelines for red blood cell transfusions in extremely low birth weight infants
101564|NCT01393496|Other|red blood cell transfusion|Implementation of "restrictive" guidelines for red blood cell transfusions in extremely low birth weight infants
101831|NCT01384448|Procedure|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
101832|NCT01384474|Other|Diffusion of a surgical safety checklist|Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;
A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:
First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;
Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication
Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms
101833|NCT00061984|Drug|ifosfamide|
101834|NCT01384500|Other|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
101835|NCT01384513|Drug|Fludarabine|Given IV
101836|NCT01384513|Drug|Busulfan|Given IV
101837|NCT01384513|Radiation|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
101838|NCT01384513|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
102636|NCT01378247|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
102637|NCT01378273|Drug|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
102638|NCT01380678|Drug|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
102639|NCT01380678|Drug|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
102640|NCT01380691|Drug|LY2216684|Administered orally
102641|NCT01380691|Drug|LY2216684 Placebo|Administered orally
102642|NCT00061815|Drug|oxaliplatin|85 mg/m2 IV
102643|NCT01380691|Drug|Alcohol Placebo containing beverage|Administered orally
102644|NCT01380691|Drug|Alcohol containing beverage|Administered orally
102645|NCT01380704|Drug|ABT-436|QD Days 1-7
102646|NCT01380704|Drug|Matching Placebo|QD Days 1-7
102647|NCT01380717|Drug|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
102648|NCT01380717|Drug|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
102649|NCT01380730|Biological|Evolocumab|Administered by subcutaneous injection
102650|NCT01380730|Other|Placebo to Evolocumab|Administered by subcutaneous injection
102651|NCT01380743|Drug|duvoglustat hydrochloride|Single oral dose
102652|NCT01380756|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
102653|NCT00061815|Drug|leucovorin|200 mg/m2 IV
101750|NCT01384383|Drug|GS-9451|GS-9451 200 mg tablet administered orally once daily
101751|NCT01384383|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
101897|NCT01391507|Drug|0.9 % sodium chloride|Monthly intravenous injection for 6 months
101898|NCT01391507|Drug|COR-1|Monthly intravenous injection for 6 months
101899|NCT01391507|Drug|Standard therapy for heart failure|All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
101900|NCT01391520|Drug|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
101901|NCT01391520|Drug|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
101902|NCT00062543|Device|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
101903|NCT01391533|Drug|SAR125844|Pharmaceutical form:solution
Route of administration: intravenous
101904|NCT01391546|Biological|1 dose at Day 0|1 dose 0.65 mL
101905|NCT01391559|Drug|arformoterol|15 mcg administered via nebulizer
102157|NCT01374308|Biological|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
102158|NCT01374308|Drug|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
102159|NCT01374321|Drug|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
102160|NCT01374321|Drug|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
102161|NCT01374373|Biological|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
102162|NCT01374386|Other|Exergaming|Exergaming equipment will be available for use at the YMCA daily. Exergames include a mixture of aerobic and resistance exercise activities. The Exergames include: WaterRowers, GameCyle System, Gamercize Pro Steppers, Expresso Bikes, Dogfight Simulators, and Dance Dance Revolution
102163|NCT01374399|Behavioral|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
102164|NCT00061074|Drug|Nicotrol|
102165|NCT01374425|Drug|5-fluorouracil|5-fluorouracil 400 mg/m^2 intravenous bolus and subsequent 2400 mg/m^2 intravenous infusion over 46 hour, administered every 2 weeks until disease progression or unacceptable toxicity.
101689|NCT01386580|Drug|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
101690|NCT00062127|Drug|thalidomide|Given orally
101691|NCT01386580|Drug|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
101692|NCT01386593|Drug|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
101693|NCT01386593|Drug|"Basel" Cocktail|
101694|NCT01386593|Drug|Basel cocktail + Rifampicin|
101695|NCT01386606|Drug|Androxal (enclomiphene citrate)|capsule oral
1X a day 6 weeks
101696|NCT01386606|Drug|Testosterone|topical gel
1X a day 6 weeks
101697|NCT01386619|Biological|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing >1 10e7 NK cells/kg bodyweight (BW) and < 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
101698|NCT01386632|Drug|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
101699|NCT01389102|Drug|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
101964|NCT01389492|Other|frozen meat cutlets meal|250 g of meat cutlets
101965|NCT01389492|Other|meat meals|250 g of meat meal for 4 days
101966|NCT00062335|Radiation|radiation therapy|
101967|NCT01389505|Procedure|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
101968|NCT01389505|Procedure|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
101969|NCT01389518|Drug|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
101970|NCT01389518|Drug|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
101971|NCT01389531|Procedure|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
101839|NCT01384513|Drug|Cyclophosphamide (CY)|Given IV
101840|NCT01384513|Drug|Tacrolimus|Given IV or PO
101841|NCT01384513|Drug|Mycophenolate mofetil|Given IV
101842|NCT01384513|Device|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
101843|NCT01384513|Procedure|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
101844|NCT00061984|Procedure|multimodality therapy|
101845|NCT01384539|Drug|Cholecalciferol|
101846|NCT01384539|Drug|Calcitriol|
101847|NCT01384552|Other|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
101848|NCT01386827|Biological|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
101849|NCT01386827|Biological|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
102094|NCT01384877|Drug|Lidocaine|10mg/kg by subcutaneous infusion over 5.5 hours
102095|NCT01384877|Drug|Placebo (normal saline)|Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
102096|NCT01384890|Radiation|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
102097|NCT00062023|Drug|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
102098|NCT01384890|Radiation|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
102099|NCT01384903|Drug|KW-3357|Intravenous infusion once a day
102100|NCT01384903|Drug|Plasma-derived antithrombin|Intravenous infusion once a day
102101|NCT01384916|Behavioral|Yoga|2x weekly
102102|NCT01384916|Behavioral|Healthy Living Workshop|2x weekly
102103|NCT01384942|Behavioral|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
101752|NCT01384383|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
101753|NCT01384396|Drug|KW-3357|Intravenous infusion once a day
101754|NCT00061984|Drug|doxorubicin hydrochloride|
101755|NCT01384409|Drug|KW-3357|Intravenous infusion once a day
101756|NCT01386632|Drug|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
101757|NCT01386645|Other|low glycemic index diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index <35) for 4 weeks with all food provided by the Human Nutrition Lab
101758|NCT00062127|Other|pharmacological study|Correlative studies
101759|NCT01386645|Other|high glycemic index diet plus placebo|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
101760|NCT01386645|Drug|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
101761|NCT01386658|Drug|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
101762|NCT01386671|Drug|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
101763|NCT01386671|Drug|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
101764|NCT01386710|Drug|Bevacizumab and Carboplatin|Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier
Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.
If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.
Repeat Cycle
101765|NCT01386710|Drug|Bevacizumab and Carboplatin|Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier
Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment
If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle
101766|NCT01386723|Other|Observational study|Observation of subjects as they discontinue the use of eltrombopag
102038|NCT01387464|Drug|Bromday™|Bromday™ (0.09% Bromfenac) dosed QD
102166|NCT01374425|Drug|Bevacizumab|Bevacizumab 5 milligram per kilogram (mg/kg) of body weight administered as intravenous infusion, every 2 weeks until disease progression or unacceptable toxicity.
102167|NCT01374425|Drug|Irinotecan|Irinotecan 180 mg/m^2 administered as intravenous infusion over 2 hour, every 2 weeks until disease progression or unacceptable toxicity.
102168|NCT01374425|Drug|Leucovorin|Leucovorin 400 milligram per meter square (mg/m^2) or at dose deemed appropriate by investigator administered as intravenous infusion over 2 hour, every 2 weeks until disease progression or unacceptable toxicity.
102169|NCT01374425|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 administered as intravenous infusion over 2 hour, every 2 weeks until disease progression or unacceptable toxicity.
102170|NCT01374438|Drug|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
102171|NCT01374438|Drug|Placebo|Placebo capsules given once daily for 90 days
102172|NCT01374451|Drug|Everolimus|Everolimus 10 mg,qd p.o. (by mouth, daily)
102173|NCT01374451|Drug|Pasireotide + Everolimus|Pasireotide LAR 60 mg q28d i.m. ( once every 28 days intramuscularly) and everolimus 10mg. qd p.o. (by mouth, daily)
102174|NCT01374464|Other|Interscalene brachial plexus block|4 different administrations of levobupivicaine will be applied:
High Volume, High Concentration = 15mls of 0.75% levobupivicaine
High Volume, Low Concentration = 15mls of 0.5% levobupivicaine
Low Volume, High Concentration = 5mls of 0.75% levobupivicaine
Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine
102175|NCT00061087|Drug|Methylphenidate|Methylphenidate 80mg/day
102487|NCT01383096|Drug|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
102488|NCT01383096|Drug|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
102489|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
102490|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
102491|NCT01383109|Drug|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
102492|NCT01375101|Drug|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
102493|NCT01375101|Drug|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
102494|NCT01375114|Drug|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
102495|NCT01375114|Dietary Supplement|Placebo|Placebo by mouth twice daily for 4 weeks.
101972|NCT01389544|Drug|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
101973|NCT01389544|Drug|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
101974|NCT01389544|Drug|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
101975|NCT01389557|Drug|Dihydroartemisinin-piperaquine with primaquine|P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
P. vivax: DHP (3 days) + primaquine (14 days)
101976|NCT01389570|Procedure|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
101977|NCT01391598|Drug|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
101978|NCT00062556|Drug|Niacin Extended Release and Lovastatin Tablets|
101979|NCT01391598|Drug|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
102232|NCT01382433|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
102233|NCT01382433|Behavioral|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
102234|NCT01382446|Drug|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
102235|NCT01382446|Other|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
102236|NCT00061919|Drug|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
102237|NCT01382472|Drug|Rosuvastatin 40 mg|40 mg per operative in PPCI, the 40 daily during hospital stay
102104|NCT01384942|Behavioral|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
102105|NCT01384968|Dietary Supplement|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
102106|NCT01384981|Procedure|pulmonary rehabilitation|
102107|NCT01384994|Drug|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
102108|NCT00062023|Drug|Sulindac|Patients receive oral sulindac twice daily for 12 months.
102109|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
102110|NCT01379768|Device|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
102111|NCT01379781|Behavioral|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
102112|NCT01379807|Drug|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
102113|NCT01379820|Device|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
102114|NCT01379846|Biological|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
102432|NCT01377779|Drug|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
102433|NCT01377792|Drug|Hypertonic saline|comparison of different dosages of drug
102434|NCT00061464|Drug|pemetrexed|
102435|NCT01377818|Procedure|ventilation|positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.
Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night).
102436|NCT01377818|Procedure|excecise training|The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:
20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.
Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)
102437|NCT01377818|Procedure|Both|both types of intervention
102438|NCT01377844|Drug|EGT0001442|
102039|NCT01387477|Drug|Lactate|Infusion of 66 mmol of lactate
102040|NCT01387477|Drug|Glucose|Infusion of 33 mmol of glucose
102041|NCT00062179|Other|Placebo|placebo 3-7 days before first dose of chemotherapy
102042|NCT00062348|Drug|boronophenylalanine-fructose complex|
102043|NCT01389583|Drug|AUY922|70 mg/m2 60-min i.v. infusion weekly
102044|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
102045|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
102046|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
102047|NCT01389609|Drug|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
102048|NCT01389609|Drug|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
102049|NCT01389609|Drug|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
102050|NCT01389622|Other|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
102051|NCT01389622|Other|acupuncture|random points + digital pressure
102052|NCT01389648|Other|Pre Operative|Pre operative chest physiotherapy treatment
102053|NCT00001087|Drug|Didanosine|
102054|NCT00062348|Drug|sodium borocaptate|
102055|NCT01389661|Other|Autologous Mesenchymal Stem Cells|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
102496|NCT01375114|Behavioral|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
102497|NCT00061113|Drug|placebo + CBT|single fixed morning dose X 16 weeks
102498|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
102499|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
102500|NCT01375140|Drug|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
102501|NCT01375140|Drug|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
102502|NCT01375140|Drug|Prednisone|Prednisone will be added for patients who have not responded after 3 cycles of therapy.
30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
102503|NCT01375153|Drug|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours.
102504|NCT01375179|Drug|KRP203|
102505|NCT01375179|Drug|Placebo matching KRP203|
102506|NCT01375205|Other|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
102507|NCT01375205|Other|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
101625|NCT01389076|Drug|Low dose methotrexate and Bexxar|Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the "dosimetric" infusion and the "therapeutic" infusion to improve distribution of these doses throughout the body. Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
101626|NCT01389089|Other|ice gel pack|ice gel pack combined with elevation
101627|NCT01389089|Other|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
101628|NCT01389089|Device|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
101629|NCT01389102|Drug|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
102238|NCT01382472|Drug|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
102239|NCT01382485|Other|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
102240|NCT01382485|Other|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
102241|NCT01374516|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
102242|NCT01374516|Biological|Placebo: NaCl 0.9% solution|0.5 mL, Subcutaneous
102243|NCT01374542|Procedure|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
102244|NCT01374568|Drug|sitagliptin|sitagliptin 100mg daily
102245|NCT01374568|Other|Placebo|1 pill daily
102246|NCT01374581|Drug|Artemether/Lumefantrine|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).
Weight in kg Number of tablet per dose Age 5 to < 15 kg 1 tablet per dose 15 to < 25 kg 2 tablets per dose 25 to < 35 kg 3 tablets per dose
102247|NCT01374581|Drug|Artesunate/Amodiaquine|Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to < 9kg):1 tablet (25 mg/675mg) for 3 days
1 to 5 years (= 9 kg to < 18 kg)1 tablet(25mg/67,5mg)for 3 days
102248|NCT00001084|Drug|Stavudine|
102249|NCT00061087|Drug|Bupropion|Bupropion 400mg/day
102569|NCT01383278|Behavioral|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
102570|NCT01383278|Behavioral|Screening and resource provision|Screening and resource provision
102571|NCT00061945|Biological|filgrastim|Given SC
102572|NCT01383317|Device|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
102573|NCT01383317|Device|Sham RIPC|Disposable sterile thigh tourniquet
102574|NCT01383330|Drug|megace|800mg
102439|NCT01377844|Drug|Placebo|
102440|NCT01377857|Behavioral|Monetary Incentive|$1, $5, or $10 incentive
102441|NCT01377857|Behavioral|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
102442|NCT01377857|Behavioral|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
102443|NCT01377870|Biological|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
102444|NCT01377870|Biological|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
102445|NCT00061464|Drug|gemcitabine|
102446|NCT01377883|Other|standard|Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.
Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.
Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure.
102447|NCT01377883|Behavioral|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
102448|NCT01377909|Drug|statin|daily statin orally for 48 weeks
102449|NCT01380366|Drug|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
101565|NCT01393509|Drug|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed.
101566|NCT01393522|Drug|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then will taper down.
101567|NCT01393522|Drug|Placebo|Tablet will be titrated 1 tablet once a day increased per protocol to 2 tablets twice a day, with a starting dose of 12.5mg per day to 50 mg twice a day
101568|NCT01393548|Drug|brompheniramine + phenylephrine|Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.
OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient.
101569|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
101570|NCT01393548|Drug|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
102309|NCT01382498|Drug|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
102310|NCT01382498|Drug|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
102311|NCT01382511|Drug|Simvastatine|80 mg
102312|NCT01382537|Device|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
102313|NCT01382537|Device|InterX 5000|Placebo treatment
102314|NCT01382550|Drug|long-lasting OAT or 12-month OAT|The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.
According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.
The occurrence of surgery, trauma, prolonged immobilization (>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded.
102315|NCT00061932|Drug|bortezomib|Given IV
102316|NCT01382589|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
102317|NCT01382589|Device|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
102318|NCT01382602|Biological|AMDC|Cell Treatment
102319|NCT01382602|Biological|Placebo Control|Placebo treatment
102320|NCT01382641|Device|Hoya AF-1 IOL|The patients will be assessed for three months
102321|NCT01382641|Device|Revital vision|The patients will be assessed for three months.
102322|NCT01382654|Drug|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
102323|NCT01382654|Drug|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
102324|NCT01382654|Drug|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
102325|NCT01382654|Drug|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
102326|NCT00061932|Drug|irinotecan|Given IV
102327|NCT01382654|Drug|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
101630|NCT01389102|Drug|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
101631|NCT00062309|Radiation|radiation therapy|
101632|NCT01391104|Drug|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
101633|NCT01391104|Drug|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
101634|NCT01391117|Drug|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
101635|NCT01391117|Drug|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
101636|NCT00062452|Other|This is not an interventional study.|The study was intended to evaluate esophageal motility mechanisms within the cohort.
101637|NCT01391117|Drug|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
101638|NCT01391117|Drug|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
101639|NCT01391117|Drug|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
101640|NCT01391117|Drug|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
101641|NCT01391117|Drug|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
101906|NCT01391559|Drug|salmeterol|50 mcg delivered vis Diskus
101907|NCT01391572|Radiation|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
101908|NCT01391572|Radiation|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
101909|NCT01391572|Drug|cisplatin|
101910|NCT01391572|Drug|fluorouracil|
101911|NCT01391585|Other|Text Message prompts|In this single armed intervention, patients will receive text message prompts
98372|NCT01415232|Device|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
98373|NCT01417507|Procedure|cognitive assessment|Undergo neurocognitive assessment
98374|NCT01417507|Procedure|magnetic resonance imaging|Undergo MRI
98375|NCT01417507|Other|laboratory biomarker analysis|Correlative studies
98376|NCT01417507|Other|questionnaire administration|Ancillary studies
98377|NCT01417507|Procedure|quality-of-life assessment|Ancillary studies
98378|NCT01417546|Drug|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
98379|NCT01417572|Drug|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
98380|NCT00065273|Drug|risperidone|
98381|NCT01417585|Behavioral|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
98669|NCT01420783|Drug|SAR302503|Pharmaceutical form:capsule
Route of administration: oral
98670|NCT01420796|Other|Swallowing exercise|Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.
This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
98671|NCT01420796|Other|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
98672|NCT01420796|Other|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
98673|NCT01420822|Drug|Fluticasone|Collection of safety data
98674|NCT01420835|Other|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
102357|NCT01374893|Behavioral|Control|Usual care
102358|NCT01377558|Other|Aerobic endurance training intervention|The aerobic endurance training group will use cardiovascular training devices
week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week
week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week
week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week
102359|NCT01377558|Other|Strength endurance training intervention|The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)
week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week
week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week
week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week
102360|NCT01377558|Other|Combined aerobic endurance and strength endurance training|week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week
week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week
week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week
102361|NCT01377571|Biological|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
102362|NCT01377584|Behavioral|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
102363|NCT01377584|Behavioral|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
102364|NCT01377597|Drug|ranibizumab|
102382|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
102383|NCT01380327|Other|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume [w/v]) was achieved.
98848|NCT00065715|Dietary Supplement|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = < 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
97899|NCT01347034|Procedure|External Beam Radiation Therapy (RT)|Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28
Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.
Day 78-91: First post-operative visit
Days 91-365: Clinical follow-up
Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival.
97900|NCT01347034|Biological|Autologous Dendritic Cells|Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.
Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities.
97901|NCT01347060|Drug|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
97902|NCT01347060|Drug|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
97903|NCT01349322|Radiation|Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy|Patients undergo whole breast radiotherapy by 3D-CRT or IMRT
97904|NCT01349322|Radiation|Higher per daily radiation therapy|Patients undergo higher per daily radiation therapy
97905|NCT01349322|Radiation|Concurrent boost radiotherapy|Patients undergo concurrent boost radiotherapy
97906|NCT01349322|Radiation|Standard per daily radiation therapy|Patients undergo standard per daily radiation therapy
97907|NCT01349322|Radiation|Sequential boost radiotherapy|Patients undergo sequential boost radiotherapy
97908|NCT00058279|Biological|ipilimumab|
97909|NCT01349335|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
97910|NCT01349335|Drug|Tolvaptan|tablet, 30 mg, Qd, 7 days
97911|NCT01349335|Drug|placebo|tablet, 30 mg, Qd, 7days.
97912|NCT01349348|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
97913|NCT01349348|Drug|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
97914|NCT01349348|Drug|placebo|tablet, 7.5/15mg , Qd, 7days.
98612|NCT01422811|Behavioral|Multicomponent strategy to reduce avoidable length of stay|The strategy comprises two integrated components:
Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;
Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team.
98613|NCT01422811|Other|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
98614|NCT01422850|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
98615|NCT01422863|Behavioral|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
98902|NCT01418469|Dietary Supplement|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
98903|NCT01418469|Dietary Supplement|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
98904|NCT01418469|Dietary Supplement|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
98905|NCT01418469|Dietary Supplement|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
98906|NCT01418482|Device|Mepilex Border Ag|Dressing
98907|NCT01418495|Other|Cytology Specimen Collection Procedure|Correlative studies
98908|NCT01418495|Other|Pharmacological Study|Correlative studies
98909|NCT01418508|Behavioral|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
98910|NCT01418508|Behavioral|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
98911|NCT01418521|Drug|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
98912|NCT00065403|Device|Acupuncture|
98913|NCT01418521|Drug|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
98914|NCT01418534|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
98675|NCT01420835|Other|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
98676|NCT01422928|Procedure|Medical Acupuncture|Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.
Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the "pecking" technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:
GV.14
LI.11 (bilateral)
SP.6 (bilateral)
SP.10 (bilateral)
ST.36 (bilateral)
Additional points may be added based on the symptom concerns reported.
98677|NCT01422941|Device|CAVU Attune Device|The CAVU Attune device is used with LAGB.
98678|NCT01422954|Drug|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
98679|NCT01422954|Drug|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
98680|NCT01422954|Biological|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
98681|NCT00001112|Drug|Zidovudine|
98682|NCT00065988|Device|Dispersed phase amalgam restoration /composite restoration|
98979|NCT01416324|Drug|0.1 mg GSK2330672|
98980|NCT01416324|Drug|0.3 mg GSK2330672|
98981|NCT01416324|Drug|1 mg GSK2330672|
98982|NCT01416324|Drug|3 mg GSK2330672|
98983|NCT00065156|Drug|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
98984|NCT01416324|Drug|10 mg GSK2330672|
98985|NCT01416324|Drug|30 mg GSK2330672|
98986|NCT01416324|Drug|60 mg GSK2330672|
98987|NCT01416337|Drug|GSK1120212|2 mg single dose tablet on Day 1 of study
102384|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
102385|NCT01380340|Other|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
102386|NCT01380353|Other|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner [B].
102387|NCT01382706|Genetic|fluorescence in situ hybridization|Correlative studies
102388|NCT01382706|Other|laboratory biomarker analysis|Correlative studies
102389|NCT01382719|Drug|bremelanotide|Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.
Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
102390|NCT00061945|Drug|allopurinol|Given PO
102391|NCT01382732|Drug|Carbetocin|Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
102392|NCT01382732|Drug|Oxytocin|Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
102393|NCT01382745|Drug|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
102394|NCT01382745|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
102395|NCT01382771|Drug|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
102396|NCT01382771|Drug|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
102693|NCT01375504|Behavioral|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
102694|NCT01375504|Behavioral|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
102695|NCT01375556|Drug|Ethanol|
97915|NCT01349361|Procedure|Daylight mediated photodynamic therapy|
97916|NCT01349374|Other|skin biopsy|Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
97917|NCT01349387|Drug|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
97918|NCT01349400|Other|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
98224|NCT01419977|Drug|Placebo|Normal saline solution, administered by nursing staff once daily
98225|NCT01419977|Drug|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
98226|NCT01419990|Drug|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
98227|NCT01419990|Drug|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
98228|NCT01419990|Drug|Placebo|Placebo oral capsules, qd, 10 days
98229|NCT01420003|Procedure|Bone Marrow Aspiration|3 per study
98230|NCT01420003|Procedure|Tonsil Biopsy|Optional upon completion of study
98231|NCT01420016|Behavioral|Prioritized Clinical Decision Support|Eighteen primary care clinics will be blocked on size and on patient characteristics, and each clinic randomly assigned to one of 2 study arms. All consenting PCPs will be allocated to the study arm that their clinic is assigned to and the estimated 400 eligible adults with 10-year CVR >= 10% under the care of each consenting physician will be allocated to the same treatment arm as their PCP.
98232|NCT01420042|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
98233|NCT01420042|Drug|Placebo|Lemon flavoured cordial and Water for Injection
98234|NCT01422421|Other|standard control|use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
98235|NCT01422434|Drug|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
98236|NCT01422434|Drug|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
98237|NCT01422434|Drug|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
98238|NCT00065923|Drug|Topiramate|
98915|NCT01418547|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
98916|NCT01418560|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
98917|NCT01418573|Other|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
98918|NCT01418573|Other|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
98919|NCT01418573|Other|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
98920|NCT01418586|Drug|Torrent's Alfuzosin Extended Release Tablet|
98921|NCT01418599|Drug|Torrent's Alfuzosin Extended Release Tablet|
98922|NCT01421134|Drug|Placebo|Placebo
98923|NCT01421147|Drug|LY2963016|Administered subcutaneously
97980|NCT01414543|Other|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
97981|NCT01414556|Other|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
97982|NCT00064987|Procedure|Testicular biopsy|Outpatient surgical procedure.
97983|NCT01414556|Other|saline|
97984|NCT01414569|Drug|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
97985|NCT01414582|Device|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
97986|NCT01414582|Other|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
97987|NCT01414595|Genetic|DNA analysis|
97988|NCT01414595|Genetic|DNA methylation analysis|
97989|NCT01414595|Genetic|RNA analysis|
97990|NCT01414595|Genetic|gene expression analysis|
97991|NCT01414595|Genetic|polymorphism analysis|
98988|NCT01418612|Drug|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
98989|NCT00065416|Procedure|massage|
98990|NCT01418625|Drug|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
98991|NCT01418651|Drug|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
98992|NCT01418664|Dietary Supplement|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
98993|NCT01418677|Drug|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
98994|NCT01418677|Drug|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
98995|NCT01418677|Drug|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
98996|NCT01418703|Device|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
98997|NCT01418703|Device|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
98063|NCT01422200|Biological|2011-2012 seasonal flu vaccine|the 2011-2012 seasonal flu vaccine will be given by intramuscular injection
98064|NCT01422213|Drug|Placebo|capsules; daily; orally
98065|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
98066|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
98067|NCT01422226|Drug|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
98068|NCT00065897|Procedure|Amniocentesis|
98069|NCT01422226|Other|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
98070|NCT01422239|Behavioral|Tailored treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
98773|NCT01423253|Drug|Lurasidone|Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
98774|NCT01423266|Procedure|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
98775|NCT01423292|Procedure|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
98776|NCT01423292|Drug|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
98777|NCT01423292|Drug|Placebo|placebo
98778|NCT01423305|Drug|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
98779|NCT00066027|Drug|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
98780|NCT01423305|Drug|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
98781|NCT01423318|Drug|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
98782|NCT01423318|Drug|placebo|single dose subcutaneously
98783|NCT01423357|Other|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
98784|NCT01423370|Drug|YHD1023|5g oral once daily
98785|NCT01423370|Drug|YHD1023|5g oral twice a day
98786|NCT01423370|Drug|YHD1023|10g oral once daily
98787|NCT01423370|Drug|Cialis|5mg oral once daily
98788|NCT01423370|Drug|Placebo|Oral
97846|NCT01351389|Behavioral|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
98239|NCT01422447|Other|regular intervention|the subjects in the control group live in the used model
98240|NCT01422447|Other|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
98241|NCT01422460|Biological|Platelet Rich Plasma|Platelet Rich Plasma (Preparation Rich in Growth Factors)
intra articular injection 2ml
Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)
98242|NCT01422473|Device|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
98243|NCT01422486|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
98534|NCT01415505|Drug|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
98535|NCT01415518|Drug|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
98536|NCT01415518|Drug|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
98537|NCT00065117|Drug|ZD6126|
98538|NCT01415518|Drug|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
98539|NCT01415531|Drug|Nebivolol|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
98540|NCT01415531|Drug|Placebo|Dose-match placebo
98541|NCT01415557|Other|Non-Fortified Control Product|Non-Fortified Control Beverage
98542|NCT01415557|Other|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
98543|NCT01415583|Drug|Dexamethasone|0.5mg/kg (max dose 20mg)
98544|NCT01415596|Drug|salbutamol|
98545|NCT01415596|Drug|Placebo|
98546|NCT01415622|Device|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
98547|NCT01417845|Behavioral|High Intensity Exercise Training|High intensity resistance and aerobic training
Resistance training is performed 2 days per week for 3 months
Aerobic training is performed on the same days as resistance training and 1 additional day per week.
97992|NCT01414595|Other|laboratory biomarker analysis|
97993|NCT00064987|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
97994|NCT01414595|Other|medical chart review|
97995|NCT01414608|Drug|Carboplatin|Given IV
97996|NCT01414608|Drug|Cisplatin|Given IV
97997|NCT01414608|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
97998|NCT01414608|Radiation|Internal Radiation Therapy|Undergo brachytherapy
97999|NCT01414608|Drug|Paclitaxel|Given IV
98000|NCT01414608|Other|Quality-of-Life Assessment|Ancillary studies
98001|NCT01414621|Other|atrial tissue sample|atrial tissue sample from CABG patient
98002|NCT01414634|Biological|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
98301|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
98302|NCT00001108|Drug|Didanosine|
98303|NCT00065572|Drug|ZD6126|
98304|NCT01420055|Drug|fingolimod|
98305|NCT01420081|Drug|PF-05212384|154mg IV weekly
98306|NCT01420081|Drug|PF-05212384|154mg IV weekly
98307|NCT01420081|Drug|PF-05212384|154mg IV weekly
98308|NCT01420094|Drug|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.
98309|NCT01420094|Drug|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
98310|NCT01420094|Drug|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
98311|NCT01420133|Other|Regimen|regimen normal in salt and sugar
98071|NCT00064987|Drug|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
98072|NCT01414647|Dietary Supplement|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
98073|NCT01414647|Other|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
98074|NCT01414660|Procedure|transplantation|transplantation of islet, kidney or liver
98075|NCT01414673|Drug|HCG|5000 IU
98076|NCT01414686|Other|Commercially-Available Interactive Video Games|Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included "Wii Sports" and "Wii Fit"; PS games included the EyeToy "Play 2" and "Kinetic". Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.
Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours.
98077|NCT01414699|Behavioral|Variety|These conditions will have snack served with an increase of fruit variety.
98078|NCT01414699|Behavioral|Non-Variety|These conditions will receive a snack without a variety of fruit.
98079|NCT01414712|Other|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
98080|NCT01414725|Other|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al [2009]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
98382|NCT01417585|Behavioral|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
98383|NCT01417598|Other|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
98384|NCT01417598|Other|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
97847|NCT01351389|Behavioral|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
97848|NCT01351402|Procedure|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
97849|NCT01351415|Drug|Standard of care treatment|Investigator's choice of standard of care treatment on Day 1 every 21 days until unacceptable toxicity or withdrawal of consent
97850|NCT01351415|Drug|bevacizumab [Avastin]|7.5 or 15 mg/kg intravenously on Day 1 every 21 days until unacceptable toxicity or withdrawal of consent
97851|NCT01351428|Drug|Nifedipine|30-60 mg, twice daily
97852|NCT01351441|Behavioral|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
97853|NCT01351441|Other|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
97854|NCT00001074|Drug|Hydroxyurea|
97855|NCT00058422|Radiation|yttrium Y 90 ibritumomab tiuxetan|
97856|NCT01351441|Other|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
97857|NCT01351441|Behavioral|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
97858|NCT01351454|Behavioral|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
97859|NCT01351454|Behavioral|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
97860|NCT01351480|Biological|abatacept|Abatacept administered SC weekly at 125 mg dose
98159|NCT01414777|Drug|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
98548|NCT01417845|Behavioral|Moderate Intensity Exercise Training|Moderate intensity resistance and aerobic training
Resistance training is performed on 2 days per week for 3 months.
Aerobic training is performed on the same days as resistance training and 1 additional day per week.
98549|NCT00065299|Behavioral|Restricted phenylalanine diet|
98550|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
98551|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
98552|NCT01417897|Drug|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
98553|NCT01417897|Drug|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
98554|NCT01417897|Drug|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
98555|NCT01417923|Drug|vitamin D|P.O.4000 units Vit D per day for 6 weeks
98849|NCT01421082|Device|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
98850|NCT01421095|Drug|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
98851|NCT01421108|Behavioral|Framing (Gain-framed messages)|The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene", emphasizes the benefits of brushing, and flossing.
98852|NCT01421108|Behavioral|Framing (Loss-framed messages)|The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.
The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing.
98853|NCT01421121|Biological|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
98854|NCT01421121|Biological|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
98855|NCT01421121|Biological|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
98856|NCT01421121|Biological|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
98857|NCT01421121|Biological|Placebo|0.5ml placebo, two doses, 28 days interval
98858|NCT01421134|Drug|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
98312|NCT01420133|Other|Standard regimen|with diet low in salt and sugar
98313|NCT01420146|Drug|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
98314|NCT00065572|Drug|Placebo|
98315|NCT01420159|Drug|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
98316|NCT01420172|Other|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
98317|NCT01420185|Genetic|RNA analysis|
98318|NCT01420185|Genetic|gene expression analysis|
98319|NCT01420185|Genetic|microarray analysis|
98320|NCT01420185|Genetic|reverse transcriptase-polymerase chain reaction|
98321|NCT01420185|Other|laboratory biomarker analysis|
98322|NCT01420198|Behavioral|Lifestyle intervention|Increased physical activity and improved food habits
98323|NCT01420211|Drug|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
98616|NCT01422876|Drug|high dose FDC|once daily
98617|NCT01422876|Drug|BI 10773 high dose|once daily
98618|NCT01415622|Procedure|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
98619|NCT00065117|Drug|Placebo|
98620|NCT01415635|Dietary Supplement|Nutritional intervention using|The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called "Delights of Herlev Hospital").
98621|NCT01415648|Other|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
98622|NCT01415648|Other|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
98385|NCT01417611|Procedure|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
98386|NCT01417624|Other|CMR Guidance in terms of guiding LV lead implantation|Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.
The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only.
98387|NCT01417637|Radiation|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
98388|NCT01417637|Radiation|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
98389|NCT01420250|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
98390|NCT01420250|Drug|Anti-Androgen Therapy: Bicalutamide|Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)
Will continue once daily until the final day of IMRT
98391|NCT01420250|Genetic|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)
Will continue for 24 months after IMRT
Total administered duration and agent used must be documented on the case report form
98392|NCT01420263|Procedure|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
98683|NCT01422954|Biological|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
98684|NCT01422954|Drug|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
98685|NCT01422967|Behavioral|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
98686|NCT01422980|Other|1- Test dairy product containing specific ingredients|
98687|NCT01422980|Other|2- Control dairy product without specific ingredients|
98160|NCT01414790|Procedure|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
98161|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
98162|NCT00065013|Behavioral|strength training|
98163|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg per day
98164|NCT01414816|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
98165|NCT01414829|Procedure|Gastroscopy|The reason for gastroscopy will be not related to the study
98166|NCT01414842|Device|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
98167|NCT01414842|Device|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
98168|NCT01414855|Drug|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
98169|NCT01414855|Drug|cyclophosphamide|750 mg/m^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
98170|NCT01414855|Drug|doxorubicin|50 mg/m^2 IV, Day 1 of each 21-cycle, 6 cycles.
98171|NCT01414855|Drug|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
98172|NCT01414855|Drug|vincristine|1.4 mg/m^2 IV, Day 1 of each 21-day cycle, 6 cycles.
98173|NCT00065026|Behavioral|Physical activity opportunities for low-income women|
98174|NCT01414868|Drug|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
98175|NCT01414881|Drug|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
98176|NCT01414881|Drug|Placebo|Placebo administered subcutaneously (SC) once weekly
98177|NCT01414894|Other|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
98178|NCT01414894|Other|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
98179|NCT01414907|Behavioral|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
98859|NCT00065715|Other|Blinded placebo|Blinded placebo - Coated tablet
98860|NCT01404039|Device|Transcranial Direct Current Stimulation|Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
98861|NCT01404052|Device|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
98862|NCT01404065|Procedure|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
98863|NCT01404078|Drug|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
98864|NCT01404078|Drug|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
97919|NCT00001072|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
97920|NCT00058292|Biological|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
97921|NCT01349400|Procedure|Hernia repair|Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.
These are all standard techniques in incisional hernia repair.
97922|NCT01349413|Drug|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
97923|NCT01349413|Other|Placebo|Identical looking placebo
97924|NCT01349426|Device|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
97925|NCT01349439|Drug|Propranolol|1mg per Kg (participant weight)
97926|NCT01349439|Drug|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
97927|NCT01349452|Drug|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
98623|NCT01415661|Other|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
98624|NCT01415674|Drug|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
98625|NCT01415687|Drug|Polyethylene Glycol-Based Lavage|Split dose Polyethylene Glycol-Based Lavage (2L + 2L)
If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.
If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours.
98626|NCT01415687|Drug|Pico-Salax (Magnesium Citrate) plus Bisacodyl|If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.
If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre.
98627|NCT01415700|Device|Functional electrical stimulator|The stimulator is surgically implanted
98628|NCT01415700|Device|feet orthosis|feet orthosis specifically mold
98629|NCT01415713|Drug|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
98630|NCT00065117|Drug|5-fluorouracil|
98924|NCT01421147|Drug|Lantus|Administered subcutaneously
98925|NCT01421147|Drug|Insulin Lispro|Administered subcutaneously
98926|NCT01421160|Drug|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
98927|NCT01421173|Drug|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
98928|NCT01421173|Drug|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
98929|NCT01421173|Drug|Busulfan|AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.
Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5.
98930|NCT01421173|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
98931|NCT01421173|Procedure|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
98688|NCT01422993|Other|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
98689|NCT01423006|Procedure|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
98690|NCT01423019|Dietary Supplement|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
98691|NCT01423019|Dietary Supplement|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
98692|NCT01423019|Other|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
98693|NCT00066001|Drug|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
98694|NCT01423032|Drug|bendamustine|100 mg/m² iv, day 1+2, q4w
98695|NCT01415765|Drug|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
98696|NCT01415765|Drug|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
98697|NCT01415765|Drug|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
98698|NCT01415765|Drug|Vincristine|CIV on days 1-4 of every 21 day cycle
98699|NCT00001108|Drug|Nelfinavir mesylate|
98700|NCT00065117|Drug|leucovorin|
98701|NCT01415765|Drug|Cyclophosphamide|IV on day 5 of each 21 day cycle
98702|NCT01415765|Drug|Doxorubicin|CIV on days 1-4 of each 21 day cycle
98703|NCT01415765|Drug|Rituximab|IV on day 1 of each 21 day cycle
98998|NCT01418716|Other|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
98180|NCT01414920|Drug|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
98479|NCT01417819|Other|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
98480|NCT01417832|Drug|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
98481|NCT01417832|Drug|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
98482|NCT01420406|Other|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
98483|NCT01420419|Other|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
98484|NCT01420419|Other|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
98485|NCT01420432|Biological|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
98486|NCT01420445|Drug|YHD001 dose level 1|three times daily / 7 days
98487|NCT01420445|Drug|YHD001 dose level 2|three times daily / 7 days
98488|NCT01420445|Drug|Pelargonium sidoides extract|6-9mL three times daily / 7 days
98489|NCT01420445|Drug|placebo|three times daily / 7 days
98490|NCT01420458|Drug|Experimental|Bioequivalence of two drug formulations
98491|NCT00065637|Drug|Teriparatide|Synthetic human parathyroid hormone
98492|NCT01420471|Drug|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
98493|NCT01420471|Other|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
98494|NCT01420484|Other|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
98495|NCT01420497|Drug|intra-articular infiltration|intra articular infiltration
97928|NCT01419301|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
97929|NCT01419314|Device|Splinting application to the lower extremities|Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
97930|NCT01419314|Device|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
97931|NCT01419327|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
97932|NCT01419340|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
97933|NCT01419353|Drug|estradiol valerate|2 mg P.O / day for 1-6 days.
97934|NCT00065468|Drug|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
97935|NCT01419366|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
97936|NCT01419392|Drug|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
97937|NCT01419392|Drug|matching placebo|orally, 4 times per day for 21 days
98244|NCT01422499|Drug|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
98245|NCT01422512|Biological|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
98246|NCT01422525|Procedure|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
98247|NCT01422538|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
98248|NCT01422538|Drug|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
98249|NCT00065936|Drug|Naltrexone hydrochloride|
98932|NCT00065728|Drug|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
98933|NCT01421173|Drug|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
98934|NCT01421173|Drug|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
98935|NCT01421173|Drug|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
98936|NCT01421173|Drug|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
98937|NCT01421186|Drug|MOR03087 phase 1 dose escalation|Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.
In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.
98938|NCT01421186|Drug|MOR03087|MOR03087 will be administered according to the MTD or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
98939|NCT01421186|Drug|Dexamethasone|Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
98940|NCT01421186|Drug|Pomalidomide|Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
98941|NCT01421186|Drug|Lenalidomide|Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
98942|NCT01421199|Procedure|Myringotomy|tube placement for children with multiple ear infections
98003|NCT01414647|Dietary Supplement|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
98004|NCT01416818|Drug|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
98005|NCT01416831|Other|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
98999|NCT01418716|Other|Passive diffusion (usual implementation strategy)|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
99000|NCT00065429|Drug|BB-10901|I.V. Infusion - See "Arms" for dosage - Once/Week for three weeks - Until Progression of disease.
99001|NCT01418729|Drug|Pravastatin|Treatment:
Patients will be randomized in two groups, A and B:
Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.
Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
99002|NCT01418742|Drug|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
99003|NCT01418742|Drug|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
99004|NCT01418755|Biological|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
99005|NCT01418768|Other|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
99006|NCT01418794|Device|High dose rapamycin stent|Concentration of rapamycin is 2.5%
99007|NCT01421212|Biological|Hepatitis B Immune Globulin (Boca HBVIg)|Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).
Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study.
99008|NCT01421225|Procedure|Closed-loop therapy|Subjects' insulin dose will be adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.
99009|NCT01421225|Procedure|Standard Insulin Pump Therapy|Patients will receive standard insulin pump therapy as per their usual home insulin protocol.
99010|NCT01421238|Behavioral|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
99011|NCT01421264|Drug|Gabapentin|300mg capsules by mouth
99012|NCT01421277|Drug|Statin Therapy|Investigator's choice of any statin.
99013|NCT01421290|Procedure|Surgery|Knee surgery
98496|NCT01420497|Drug|epidural infiltration|epidural infiltration
98497|NCT01420510|Drug|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
98498|NCT01420510|Drug|Placebo vaginal gel|Application of a placebo vaginal gel
98789|NCT01423396|Other|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
98790|NCT00066040|Drug|Cervitec chlorhexidine varnish|
98791|NCT01423396|Other|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
98792|NCT01423409|Device|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
98793|NCT01423409|Device|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
98794|NCT01423435|Drug|TRK-100STP|oral
98795|NCT01415908|Other|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
98796|NCT01415921|Drug|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
98797|NCT01415934|Other|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
98798|NCT01415947|Device|V Chordal|V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae "off-pump" . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords.
98799|NCT01415960|Drug|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
98800|NCT01415973|Dietary Supplement|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
98801|NCT01415973|Dietary Supplement|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
98802|NCT01415986|Drug|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
98803|NCT01415986|Device|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
98250|NCT01422538|Other|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
98251|NCT01422551|Behavioral|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
98252|NCT01422551|Behavioral|a psycho-educational control|a single-day psycho-educational seminar
98253|NCT01422564|Device|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
98254|NCT01422564|Device|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
98255|NCT01422577|Device|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
98256|NCT01422577|Device|White light Endoscopy|White light Endoscopy
98257|NCT00001108|Drug|Ritonavir|
98258|NCT00065039|Behavioral|Promotion of a healthy diet and physical activity|
98259|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
98260|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
98261|NCT01414933|Other|Biopsy|Breast metastases biopsy
98262|NCT01414946|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
98556|NCT01417936|Biological|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
98557|NCT01417949|Other|Time of starting antiretroviral therapy|Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART ("immediate" or "deferred"). The day of receiving the randomization sheet will be defined as baseline visit.
98558|NCT01417975|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
98559|NCT01417975|Behavioral|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
98560|NCT00065312|Drug|naveglitazar|
98561|NCT01417988|Drug|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
98006|NCT01416831|Drug|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
98007|NCT01416844|Biological|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
98008|NCT01416857|Other|RDDT|
98009|NCT01416870|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
98010|NCT01416870|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
98011|NCT01416883|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
98012|NCT00065208|Behavioral|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
98013|NCT01416896|Procedure|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
98014|NCT01416896|Procedure|Hemodialysis using a new venous needle, the "BME needle"|Hemodialysis using a new venous dialysis needle or the "BME needle"
98015|NCT01416896|Procedure|Hemodialysis using a new venous needle, the "BME needle"|One hemodialysis using a new venous needle, the "BME needle"
98016|NCT01416896|Procedure|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
98017|NCT01416909|Other|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
98018|NCT01416909|Other|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
98019|NCT01416909|Other|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
98324|NCT01420211|Device|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
98325|NCT00065585|Procedure|Accupuncture|
98326|NCT01420224|Other|Commercial airline flight|Normal scheduled passenger flight
98081|NCT01414725|Other|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
98082|NCT00065000|Behavioral|Water, Cafeteria and Staff Health Promotion|
98083|NCT01414725|Other|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
98084|NCT01414738|Radiation|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
98085|NCT01414751|Behavioral|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
98086|NCT01414751|Behavioral|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
98087|NCT01414764|Other|Autologous conditioned plasma (ACP)|10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.
First injection at approximately 10 days post-operatively
Second Injection at approximately 21 days post-operatively
98088|NCT01414764|Drug|Placebo|10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.
First injection at approximately 10 days post-operatively
Second Injection at approximately 21 days post-operatively
98089|NCT01416948|Drug|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
98090|NCT01416948|Drug|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
98091|NCT00065208|Behavioral|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
98092|NCT01416948|Drug|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
98804|NCT01416012|Behavioral|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
98805|NCT00065130|Drug|insulin NPH|
98806|NCT01416012|Behavioral|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
98807|NCT01416012|Behavioral|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
97861|NCT01351493|Drug|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
97862|NCT01344382|Behavioral|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
97863|NCT01344382|Behavioral|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
97864|NCT01344395|Drug|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
97865|NCT01344395|Drug|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
97866|NCT01344408|Procedure|Computer-training|The computer-training program "Move IT To Improve IT" is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation
97867|NCT01344421|Procedure|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
97868|NCT01344447|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
97869|NCT01344460|Drug|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
97870|NCT01344473|Device|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
98562|NCT01417988|Drug|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
98563|NCT01418001|Drug|Gemcitabine and Docetaxel in Combination with Pazopanib|Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.
Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first .
98564|NCT01418027|Other|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
98565|NCT01418027|Other|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
98566|NCT01418053|Drug|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
98567|NCT01418053|Drug|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
98568|NCT01420562|Procedure|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
98569|NCT01420575|Behavioral|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
98570|NCT01420575|Behavioral|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
98571|NCT01420601|Drug|Temsirolimus|The usual adult dosage of this drug is 25 mg as temsirolimus once weekly by intravenous drip infusion for 30 to 60 minutes. The dosage may be appropriately reduced, depending on patient condition.
98865|NCT01404091|Drug|LY2940094|Administered orally
98866|NCT01404104|Drug|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
98867|NCT00063973|Other|laboratory biomarker analysis|Correlative studies
98868|NCT01404117|Drug|Laquinimod 0.6|Laquinimod 0.6 capsule
98869|NCT01404117|Drug|Laquinimod 1.2|Placebo
98870|NCT01404117|Other|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
98327|NCT01420237|Device|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
98328|NCT01420250|Drug|Cabazitaxel|Administered weekly on the same day of radiation according to the following infusion levels:
Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;
98329|NCT01422590|Drug|Sitagliptin|Single oral administration of sitagliptin 100 mg
98330|NCT01422590|Drug|Mitiglinide|Single oral administration of mitiglinide 10 mg
98331|NCT01422590|Drug|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
98332|NCT00065936|Procedure|Transcutaneous sensory nerve stimulation|
98333|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
98334|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
98335|NCT01422616|Drug|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus [maximum bolus dose of 9mg] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
98336|NCT01422616|Drug|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
98337|NCT01422616|Other|Intensive blood pressure (BP) lowering|Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.
The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
98338|NCT01422616|Other|BP management policies|Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.
The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
98339|NCT01422629|Device|Ultrasonic ablation device|High Intensity focused ultrasound treatment
98340|NCT01422642|Device|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
98631|NCT01415726|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 ~ 7 hrs.
98093|NCT01416961|Radiation|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
98393|NCT01420263|Procedure|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
98394|NCT01420289|Device|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
98395|NCT01420289|Behavioral|Excercise|Treadmill walking 45 minutes once daily
98396|NCT00065611|Drug|Oral dexamethasone|Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.
Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.
over 36 weeks.
98397|NCT01420302|Procedure|Nurse directed insulin titration|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
98398|NCT01420302|Procedure|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
98399|NCT01420328|Drug|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin
98400|NCT01420341|Drug|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
98401|NCT01420341|Drug|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
98402|NCT01420367|Drug|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
98403|NCT01420393|Procedure|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
98404|NCT01420393|Other|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
98405|NCT01420406|Other|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
98406|NCT01420406|Other|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
98407|NCT00065624|Drug|lipoic acid|
98408|NCT01420406|Other|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
97871|NCT00057876|Drug|Gemcitabine|Induction: Patients receive the first cycle of gemcitabine 1000 mg/m^2 intravenously once per week for 6 weeks followed by 1 week rest.
Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles.
97872|NCT01344486|Procedure|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
97873|NCT01344486|Procedure|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
97874|NCT01344499|Procedure|Carbon dioxide|standard pneumoperitoneum with 100% CO2
97875|NCT01344499|Procedure|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
97876|NCT01344499|Drug|Adept|instillation of 1 liter of fluid at the end of laparoscopy
98181|NCT01414920|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
98182|NCT01414920|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
98183|NCT01414920|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
98184|NCT01417052|Drug|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
98185|NCT01417052|Drug|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
98186|NCT01417052|Drug|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
98187|NCT01417052|Drug|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
98188|NCT00065234|Procedure|Acupuncture|
98189|NCT01417052|Drug|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
98190|NCT01417052|Drug|Placebo|Matching placebo dosing in capsule form
98191|NCT01417065|Drug|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
98192|NCT01417078|Drug|Diazepam|single-dose; dosage in mg, based on patient body weight
98193|NCT01417091|Drug|BPS804|
98194|NCT01417104|Drug|Aliskiren|150 mg/300mg
98195|NCT01417104|Drug|Placebo|150mg/300mg
98871|NCT01404130|Drug|Isotretinoin|0.5-1mg/kg daily for 4-6 months
98872|NCT01404143|Procedure|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
98873|NCT01404143|Procedure|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
98874|NCT01404156|Drug|Epirubicin cisplatin 5-Fluorouracil|Three 21-day cycles ECF preoperatively:
Epirubicin (50 mg per square meter of body-surface area) by intravenous bolus on day 1 Cisplatin: 60 mg per square meter intravenously with hydration on day 1 5-Fluorouracil: 200 mg per square meter daily for 21 days by continuous intravenous infusion
98875|NCT01413620|Dietary Supplement|dl-alpha-tocopheryl acetate|Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
98876|NCT01416077|Other|fluid optimisation|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
Crystalloid infusion (2,5 ml/kg/t) throughout surgery
3 ml/kg Volulyte (artifical colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase > 10% is observed. A new dose is given if SV decreases more than 10% from the last value.
If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI > 2,5.
If despite CI > 2,5 Mean Arterial Pressure <65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65.
98877|NCT00065130|Drug|insulin aspart|
98878|NCT01416103|Other|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
98879|NCT01416103|Other|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
97938|NCT01419405|Drug|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
97939|NCT01419405|Drug|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
97940|NCT01419405|Drug|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
97941|NCT01419431|Procedure|Laparoscopic resection|Inflammatory response in laparoscopic surgery
98632|NCT01415739|Other|laboratory biomarker analysis|Correlative studies
98633|NCT01415752|Biological|rituximab|Given IV
98634|NCT01415752|Drug|bendamustine hydrochloride|Given IV
98635|NCT01415752|Drug|bortezomib|Given IV or SC
98636|NCT01415752|Drug|lenalidomide|Given PO
98637|NCT01418066|Drug|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
98638|NCT01418066|Drug|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
98639|NCT01418079|Device|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
98640|NCT00065325|Drug|Fulvestrant|intramuscular injection
98641|NCT01418092|Drug|ALKS 37|Capsules for oral administration
98642|NCT01418092|Drug|Placebo|Capsules for oral administration
98643|NCT01418105|Procedure|Videofluroscopic swallow study (VFSS)|Barium, radiation
98644|NCT01418105|Procedure|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
98645|NCT01418105|Procedure|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
98646|NCT01418118|Drug|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
98647|NCT01418118|Drug|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
98648|NCT01418118|Drug|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
98649|NCT01418118|Drug|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
98650|NCT01418131|Drug|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
98651|NCT00065325|Drug|Exemestane|oral capsule
98652|NCT01418131|Drug|Placebo|Placebo
98943|NCT00065741|Drug|silymarin|
98409|NCT01422876|Drug|high dose FDC placebo|once daily
98410|NCT01422876|Drug|low dose FDC placebo|once daily
98411|NCT00065975|Procedure|massage therapy|
98412|NCT01422876|Drug|high dose FDC placebo|once daily
98413|NCT01422876|Drug|high dose FDC placebo|once daily
98704|NCT01415765|Drug|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
98705|NCT01415778|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
98706|NCT01415778|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
98707|NCT01415791|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
98708|NCT01415804|Device|endoprosthesis|Thoracic aortic stentgraft
98709|NCT01415817|Other|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
98710|NCT01415830|Biological|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
98711|NCT00065117|Drug|oxaliplatin|
98712|NCT01415830|Biological|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
98713|NCT01415856|Device|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
98714|NCT01415856|Device|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
98715|NCT01415882|Drug|Cyclophosphamide|Given PO
98716|NCT01415882|Drug|Dexamethasone|Given PO
98717|NCT01415882|Drug|Ixazomib Citrate|Given PO
98718|NCT01415882|Other|Laboratory Biomarker Analysis|Correlative studies
98719|NCT01415895|Drug|ATNC05 - a study drug capsule|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
98720|NCT01415895|Drug|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
98196|NCT01417143|Drug|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
98197|NCT01417156|Drug|BIBF 1120|
98198|NCT01417169|Drug|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting <50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
98199|NCT00065247|Behavioral|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
98200|NCT01417182|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
98201|NCT01417195|Drug|Bravelle|
98202|NCT01417195|Drug|Menopur|
98203|NCT01417208|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
98204|NCT01417221|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
98499|NCT01420523|Drug|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
98500|NCT01420536|Procedure|Occlusal scheme|Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.
Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts.
98501|NCT01420549|Drug|Rosuvastatin + Ezetimibe|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.
98502|NCT00065637|Drug|Placebo teriparatide|Placebo injections
98503|NCT01420549|Drug|Simvastatin + Ezetimibe|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.
98504|NCT01423032|Drug|Fludarabine|25 mg/m² iv, days 1-5, q4w
98505|NCT01423058|Drug|Momelotinib|In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.
In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles.
97942|NCT01419444|Behavioral|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
97943|NCT01419457|Drug|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
97944|NCT01419457|Drug|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
97945|NCT00065507|Drug|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
97946|NCT01419457|Drug|Favipiravir|800 mg Single Dose
97947|NCT01419470|Drug|dapoxetine|multiple dosing
12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine
97948|NCT01419483|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
97949|NCT01419496|Genetic|protein expression analysis|
97950|NCT01419496|Other|flow cytometry|
97951|NCT01419496|Other|laboratory biomarker analysis|
97952|NCT01419509|Genetic|DNA methylation analysis|
97953|NCT01421862|Other|laboratory biomarker analysis|
97954|NCT01421875|Genetic|DNA methylation analysis|
97955|NCT00065858|Drug|BufferGel|
97956|NCT01421875|Genetic|RNA analysis|
97957|NCT01421875|Genetic|gene expression analysis|
97958|NCT01421875|Genetic|microarray analysis|
97959|NCT01421875|Genetic|nucleic acid sequencing|
97960|NCT01421875|Other|laboratory biomarker analysis|
97961|NCT01421901|Drug|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
97962|NCT01421901|Procedure|appendectomy|
98263|NCT01414946|Other|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient`s measured resting energy expenditure.
98264|NCT01414972|Drug|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
98944|NCT00064805|Behavioral|Cognitive Therapy to Improve Reading|
98945|NCT01413633|Procedure|cholecystectomy|single incision laparoscopic cholecystectomy
98946|NCT01413646|Dietary Supplement|Walnut Supplementation|Eight weeks of walnut supplementation
98947|NCT01413646|Dietary Supplement|No walnut supplementation|Eight weeks without walnut supplementation
98948|NCT01413659|Biological|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
98949|NCT01413672|Device|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
98950|NCT01413685|Other|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
98951|NCT01413711|Drug|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
98952|NCT01413750|Drug|Paclitaxel|Given IV
98953|NCT01413750|Drug|Carboplatin|Given IV
98954|NCT01413750|Drug|Vorinostat|Given PO
98955|NCT00064831|Drug|Black Cohosh Extract (BCE)|
98956|NCT01413750|Other|Placebo|Given PO
98957|NCT01413750|Other|Laboratory Biomarker Analysis|Correlative studies
98958|NCT01413763|Drug|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
98959|NCT01413763|Drug|Placebo cream|placebo cream applied daily for 2 weeks
98960|NCT01413776|Dietary Supplement|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
98961|NCT01413789|Drug|Dermatix|1 application of Dermatix
98962|NCT01413789|Drug|Kelocote|1 application of Kelocote
98963|NCT01413789|Drug|BAP scar gel|1 application of BAP scar gel
98964|NCT01413789|Drug|Alhydran|1 application of Alhydran
98965|NCT01413789|Drug|Bap Scar Care T|1 application of BAP Scar Care T
98721|NCT01415908|Device|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
98722|NCT00065130|Drug|human insulin|
98723|NCT01418183|Procedure|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
98724|NCT01418209|Drug|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
99014|NCT01421290|Other|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
99015|NCT01421303|Drug|Enbrel|Enbrel
99016|NCT01421316|Radiation|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
99017|NCT00065754|Drug|placebo|
99018|NCT01421329|Behavioral|Control|don't receive anything
99019|NCT01421329|Behavioral|Intervention|Receive weekly emails, information about the benefits of exercise, and compensation.
99020|NCT01421342|Drug|Augmenting: Antidepressant + Aripiprazole|Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
99021|NCT01421342|Drug|Augmenting: Antidepressant + Bupropion-SR|Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
99022|NCT01421342|Drug|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
99023|NCT01421355|Drug|Atazanavir|The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
99024|NCT01421368|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
98506|NCT01423084|Biological|Serogroup B meningococcal vaccine|All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.
A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination
98507|NCT01423110|Biological|BYM338|
98508|NCT01423110|Biological|Placebo|
98509|NCT01423123|Drug|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
98510|NCT01423123|Biological|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
98511|NCT01423123|Drug|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
98512|NCT01423136|Device|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
98513|NCT00066014|Procedure|Implant Overdenture Treatment|All overdenture treatment modalities were provided to each subject using a crossover design.
98514|NCT01423149|Drug|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
98808|NCT01416012|Behavioral|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
98809|NCT01416025|Drug|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
98810|NCT01416038|Biological|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
98811|NCT01416038|Drug|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
98812|NCT01416051|Dietary Supplement|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
98813|NCT01416051|Other|Placebo|100% milk fat
98814|NCT01416064|Drug|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
98815|NCT01418261|Device|Renal denervation (Symplicity Catheter System)|Symplicity Catheter System
98265|NCT01414972|Drug|placebo|1 cap placebo/day for 3 month
98266|NCT01414985|Biological|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
98267|NCT01414998|Behavioral|Stress Ball vs Nicotine-free E-Cigarette|In a cross over design, participants will be randomly allocated to:
use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.
use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.
One week later participants will complete the other arm.
98268|NCT01414998|Behavioral|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|In a cross over design, participants will be randomly allocated to:
use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.
smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.
One week later participants will complete the other arm.
98269|NCT00065039|Behavioral|Avoidance of Alcohol, Drugs, and Tobacco|
98270|NCT01415011|Drug|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
98271|NCT01415024|Procedure|second LV lead in CRT|second LV lead in CRT
98272|NCT01415037|Procedure|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
98273|NCT01415050|Device|Whole body vibration|15 times WBV
98274|NCT01415063|Procedure|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
98275|NCT01415063|Procedure|TACE-RFA|TACE first, then RFA within 2 weeks
98276|NCT01415076|Procedure|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
98277|NCT01417299|Dietary Supplement|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
98278|NCT01417312|Dietary Supplement|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
98279|NCT01417312|Dietary Supplement|Placebo|Daily intake of placebo capsules for 3 months
98572|NCT01420614|Procedure|Femoral approach|diagnostic and interventional procedures by femoral artery access
98020|NCT01416935|Other|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
98021|NCT01419509|Genetic|microarray analysis|
98022|NCT01419509|Genetic|polymerase chain reaction|
98023|NCT01419509|Other|laboratory biomarker analysis|
98024|NCT00065507|Drug|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
98025|NCT01419522|Other|Gait Training Method|Treadmill training at constant velocity
98026|NCT01419535|Drug|Mifepristone|
98027|NCT01419548|Drug|ABT-888|
98028|NCT01419548|Drug|Carboplatin|
98029|NCT01419548|Drug|Paclitaxel|
98030|NCT01419587|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
98031|NCT01419600|Drug|AZD8683|Single Dose Inhaled IMP via Turbuhaler
98032|NCT01419600|Drug|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
98033|NCT01419613|Behavioral|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
98034|NCT01419613|Behavioral|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
98035|NCT00065533|Drug|pemetrexed|
98036|NCT01419639|Drug|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
98037|NCT01419652|Other|hold hypoglycemic meds|continue versus hold hypoglycemic medications
98038|NCT01419665|Biological|GP2013|Type: Biological/Vaccine
99025|NCT01413789|Drug|Scar Ban Elastic|1 application of Scar Ban Elastic
99026|NCT01413802|Procedure|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
99027|NCT01413815|Dietary Supplement|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
99028|NCT01413815|Other|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
99029|NCT01413828|Drug|Trastuzumab, Anthracycline|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
102056|NCT01389674|Procedure|2D-strain echo|2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.
Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis.
102057|NCT01389687|Biological|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
102058|NCT01389700|Drug|SAR279356|Pharmaceutical form: solution for infusion
Route of administration: intravenous infusion
102059|NCT01389700|Drug|placebo|Pharmaceutical form: solution for infusion
Route of administration: intravenous infusion
102060|NCT01389713|Drug|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
102061|NCT01389713|Drug|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
102062|NCT01389726|Behavioral|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
102063|NCT01391741|Other|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
102064|NCT01391754|Behavioral|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
102065|NCT01391754|Other|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
102066|NCT01391754|Behavioral|Services As Usual|Home based services not using the SafeCare model
102067|NCT00062569|Behavioral|Caregiver reminiscence with coaching|BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a "crib sheet" for caregiver use conversationally prior to and during the bath
102068|NCT01391754|Other|Uncoached|No in vivo coached quality control or fidelity monitoring
98816|NCT01418261|Other|Renal angiogram|Renal angiogram
98817|NCT01418261|Drug|Maintained base-line anti-hypertensive medications|Subject must be on full tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic that is expected to be maintained for at least 6 months from randomization.
98818|NCT01418274|Drug|danoprevir|oral doses of danoprevir
98819|NCT01418274|Drug|escitalopram|oral doses of escitalopram
98820|NCT01418274|Drug|ritonavir|oral doses of ritonavir
98821|NCT01418300|Drug|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
98822|NCT01418339|Drug|aripiprazole|Flexible dose of once-weekly aripiprazole tablets
98823|NCT00065364|Behavioral|Newborn Individualized Developmental Care Assessment Program|
98824|NCT01418339|Drug|Placebo|Dose of matching placebo tablets for 8 weeks
98825|NCT01418352|Drug|aripiprazole 52.5 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
98826|NCT01418352|Drug|Matching Placebo|Matching Placebo once-weekly for 8 weeks
98827|NCT01418352|Drug|Aripiprazole 77.5 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
98828|NCT01418352|Drug|Aripiprazole 110 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
98829|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
97877|NCT01344499|Drug|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
97878|NCT01344512|Drug|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
97879|NCT01344512|Drug|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
97880|NCT01344512|Drug|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
97881|NCT01346865|Drug|Cilostazol|Cilostazol 100mg bid
97882|NCT01346865|Drug|Placebo|Placebo 1tablet bid
98573|NCT01420614|Procedure|Radial approach|diagnostic and interventional procedures by radial artery access
98574|NCT01420627|Biological|EZN-2279|weekly administration of EZN-2279 via IM injection
98575|NCT01420627|Biological|Adagen|
98576|NCT01420640|Behavioral|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
98577|NCT00065650|Drug|Vedic Medicine|
98578|NCT01420640|Behavioral|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
98579|NCT01420640|Behavioral|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
98580|NCT01420640|Behavioral|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
98581|NCT01420640|Behavioral|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
98582|NCT01420653|Drug|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
98583|NCT01420653|Drug|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
98584|NCT01420653|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
98585|NCT01420653|Drug|Placebo|placebo, three tablets four times a day, with food for 48 hours
98586|NCT01420666|Drug|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
98587|NCT01420666|Drug|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
98588|NCT00065650|Behavioral|Vedic Medicine|
98589|NCT01420666|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
98590|NCT01420666|Drug|Placebo|placebo, three tablets four times a day, orally, with food
98591|NCT01420679|Drug|Pralatrexate Injection|Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).
Initial dose: 30 mg/m2
Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.
98592|NCT01422720|Drug|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
98593|NCT01422733|Drug|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
98039|NCT01419665|Biological|rituximab|Type: Biological/Vaccine
98040|NCT01419678|Other|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
98341|NCT01422642|Device|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
98342|NCT01422668|Other|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
98343|NCT00065949|Drug|magnesium sulfate|
98344|NCT01422681|Device|minimally invasive extracorporeal carbon dioxide removal|The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).
Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min).
98345|NCT01422707|Drug|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
98346|NCT01422707|Drug|dexamethasone|1 mg PO twice
98347|NCT01422707|Drug|Cosyntropin (ACTH)|250 micrograms IV twice
98348|NCT01415089|Behavioral|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
98349|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 1: 50 ug
98350|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
98351|NCT00065052|Behavioral|Behavior modification|
98352|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
98353|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
98354|NCT01415102|Drug|Placebo|Inhaled
98355|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
98356|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
98357|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
102069|NCT01391767|Device|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
102070|NCT01391793|Drug|Placebo|Twice daily for 3 days
102071|NCT01391793|Drug|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
102072|NCT01391819|Other|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
102073|NCT01391819|Procedure|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
102074|NCT01391832|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
102330|NCT01382693|Behavioral|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
102331|NCT01382706|Drug|docetaxel|Given IV
102332|NCT01382706|Drug|lapatinib ditosylate|Given PO
102333|NCT01382706|Other|immunohistochemistry staining method|Correlative studies
102334|NCT01374724|Behavioral|Informational Pamphlet|The National Cancer Institute Pamphlet "Clearing the Air" was provided to subjects.
102335|NCT01374724|Behavioral|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
102336|NCT01374737|Drug|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
102337|NCT01374750|Drug|Sirolimus|Sirolimus
102338|NCT01374750|Drug|m-TOR inhibitor free|calcineurin inhibitors
102339|NCT01374763|Drug|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
102340|NCT00061100|Behavioral|Behavior Therapy-RISE|manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter
102341|NCT01374763|Drug|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
97883|NCT01346917|Drug|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
97884|NCT00058045|Biological|recombinant human stem cell factor|
97885|NCT01346917|Drug|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
97886|NCT01346930|Drug|Macitentan|10 mg, tablet, once daily
97887|NCT01346943|Device|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
97888|NCT01346969|Drug|EXC 001|Single-dose administered by injection four different times
97889|NCT01346969|Drug|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
97890|NCT01346969|Drug|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
97891|NCT01346969|Drug|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
97892|NCT01346982|Drug|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
97893|NCT01346995|Other|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
97894|NCT01346995|Other|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
97895|NCT00058058|Procedure|magnetic resonance imaging|
97896|NCT01347008|Drug|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
97897|NCT01347008|Drug|Placebo|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
97898|NCT01347021|Procedure|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
98205|NCT01417234|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
98206|NCT01417247|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
98207|NCT01417273|Dietary Supplement|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
98594|NCT01422733|Drug|dexamethasone|1 mg PO twice
98880|NCT01416116|Drug|QUTENZA|topical
98881|NCT01416116|Drug|Lidocaine|topical
98882|NCT01416116|Drug|Tramadol|oral
98883|NCT01416129|Device|Standard of care socket|Amputees' preferred socket.
98884|NCT01416129|Device|Prosthetic brimless socket|Study socket
98885|NCT01416142|Device|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
98886|NCT01416142|Device|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
98887|NCT01416155|Drug|natalizumab|
98888|NCT00065143|Drug|clofarabine|
98889|NCT01416168|Other|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
98890|NCT01416181|Drug|natalizumab|Administered as specified in the treatment arm
98891|NCT01416181|Drug|Placebo|Matched placebo in part 1
98892|NCT01416194|Drug|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
98893|NCT01416194|Drug|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
98894|NCT01416194|Drug|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
98895|NCT01416207|Drug|Avonex|4 weekly injections of Avonex (IM)
98896|NCT01418404|Other|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
98897|NCT01418417|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
98898|NCT01418430|Drug|CHOP-daclizumab|
98358|NCT01415102|Drug|Placebo|Inhaled
98359|NCT01415128|Drug|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
98360|NCT01415128|Drug|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
98361|NCT01415128|Drug|Desipramine|Single dose of Desipramine (50 mg) for 1 day
98653|NCT01418144|Procedure|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
98654|NCT01418144|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
98655|NCT01418157|Drug|Acetazolamide|125 mg twice daily until 4380 meters altitude
98656|NCT01418157|Drug|Placebo|Twice daily
98657|NCT01418170|Other|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
98658|NCT01418183|Procedure|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
98659|NCT01418183|Procedure|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
98660|NCT01420692|Drug|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
98661|NCT01420692|Drug|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
98662|NCT01420718|Drug|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
98663|NCT01420718|Drug|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
98664|NCT01420744|Drug|BT086|BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.
Infusion rate:
Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period.
102342|NCT01374776|Drug|Double blind, randomized, placebo controlled inter|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
102343|NCT01374789|Drug|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
102344|NCT01374789|Drug|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
102345|NCT01374802|Drug|Darunavir|400 mg tablet for oral administration
102346|NCT01374802|Drug|Ritonavir|tablet for oral administration
102347|NCT01374802|Drug|BI 201335|
102348|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
102349|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
102350|NCT01374828|Drug|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
102351|NCT00061100|Behavioral|Standard prevention Education|standard psychosocial Education for HIV/hepatitis prevention
102671|NCT01383642|Other|No intervention, observational study|
102672|NCT01383655|Drug|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
102673|NCT00061945|Drug|mercaptopurine|Given PO
102674|NCT01383655|Drug|Placebo|NaCl
102675|NCT01383668|Drug|sirolimus|Given PO
102676|NCT01383668|Drug|gold sodium thiomalate|Given IM
102677|NCT01383668|Other|pharmacological study|Correlative studies
102678|NCT01383668|Genetic|RNA analysis|Correlative studies
102679|NCT01383668|Genetic|polymerase chain reaction|Correlative studies
102680|NCT01383681|Other|No treatment|There was no treatment in this study.
102681|NCT01383694|Drug|Piperine|
98208|NCT01417273|Drug|Drug: placebo|1 cap placebo/day for 12 month
98209|NCT01417286|Radiation|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
98210|NCT00065260|Drug|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
98211|NCT01417299|Dietary Supplement|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
98212|NCT00065546|Other|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
98213|NCT01419925|Biological|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
98214|NCT01419925|Biological|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
98215|NCT01419925|Biological|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
98216|NCT01419938|Device|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
98217|NCT01419938|Device|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
98218|NCT01419951|Behavioral|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
98219|NCT01419951|Other|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
98220|NCT01419951|Behavioral|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
98221|NCT01419964|Drug|Group 01|ACH24
98222|NCT01419964|Drug|Group 02|Placebo
98223|NCT00065559|Drug|celecoxib|
98515|NCT01423162|Other|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
98516|NCT01423162|Other|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
98899|NCT01418443|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
98900|NCT01418456|Drug|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
98901|NCT00065390|Drug|Pyrimethamine|
97963|NCT01421914|Other|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
97964|NCT01421927|Drug|Lenalidomide|Start between Day+100 and Day+120 post-transplant
- Initial dose: 5 mg/day every day
In the absence of thrombocytopenia < 75000/mm3 or neutropenia < 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.
- Duration
until persistent stringent complete response for 3 months
or progression defined by IMWG criteria12
or unacceptable toxicity
or one year after transplant
97965|NCT01421940|Drug|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
97966|NCT00065871|Behavioral|Contraceptive Screening by Pharmacist|
97967|NCT01421940|Drug|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
97968|NCT01421953|Device|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
97969|NCT01421966|Biological|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
97970|NCT01421966|Biological|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
97971|NCT01421979|Dietary Supplement|Energy Drink, Taurine, Caffeine|
97972|NCT01421992|Drug|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
97973|NCT01421992|Drug|Placebo|one tablet placebo per day during 3 weeks
97974|NCT01422005|Other|Simultaneous Bimanual training|Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.
Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy.
97975|NCT01422005|Other|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
97976|NCT01422018|Drug|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
98665|NCT01420744|Drug|1% Human Albumin infusion|1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.
Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.
Treatment will be administered over a 5-day period.
Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)
98666|NCT01420757|Procedure|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
98667|NCT00065663|Genetic|GAM501|
98668|NCT01420770|Drug|SAR302503|Pharmaceutical form:capsule
Route of administration: oral
98966|NCT00064844|Behavioral|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
98967|NCT01413789|Drug|Bap Scar Care S|1 Application of Bap Scar Care S
98968|NCT01413789|Drug|Mepiform|1 application of Mepiform
98969|NCT01416220|Drug|Lithium|Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.
Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l.
98970|NCT01416220|Drug|Paroxetine|Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.
Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
98971|NCT01416233|Procedure|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
98972|NCT00065143|Drug|Ara-C|
98973|NCT01416246|Procedure|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is < or = to 50 and/or age > 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
102682|NCT01383707|Drug|5-FU|Participants will receive 5-FU 400 mg per meter-squared (mg/m^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m^2, continuous infusion over 46 hours up to 12 cycles.
102683|NCT01383707|Drug|Bevacizumab|Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
102684|NCT00061945|Drug|leucovorin calcium|Given IV and PO
102685|NCT01383707|Drug|Levofolinic acid|Participants will receive levofolinic acid 200 mg/m^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
102686|NCT01383707|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
102687|NCT01375426|Drug|Oral amoxicillin|
102688|NCT01375439|Other|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
102689|NCT01375452|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
102690|NCT01375465|Device|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
102691|NCT01375491|Drug|Doxycycline|generic doxycycline 100mg twice daily
102692|NCT01375491|Other|Placebo|Placebo comparator to doxycycline
101767|NCT01386736|Drug|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
101768|NCT01386736|Drug|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
101769|NCT00062140|Drug|cyclophosphamide|
101770|NCT01386749|Procedure|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
101771|NCT01386762|Other|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
101772|NCT01386788|Other|There is no intervention planned (observational)|No intervention foreseen
98517|NCT01423175|Drug|Clofarabine, ara-C|
98518|NCT01423175|Drug|FLAMSA|
98519|NCT01423188|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
98520|NCT01423188|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
98521|NCT01423214|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
98522|NCT01423214|Procedure|Laparoscopic surgery|Conventional laparoscopic procedures
98523|NCT01423227|Behavioral|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
98524|NCT00066027|Drug|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
98525|NCT01415466|Drug|Cresto|tablet, 20mg
98526|NCT00065104|Drug|DHEA|
98527|NCT01415466|Drug|Olmetec|tablet, 40mg
98528|NCT01415466|Drug|Cresto, Olmetec|tablet, 20mg and 40mg
98529|NCT01415479|Behavioral|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
98530|NCT01415479|Behavioral|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
98531|NCT01415479|Behavioral|Default|Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the "Default" intervention since it attempts to shift the "default" choice from "no screening" to FIT.
98532|NCT01415492|Behavioral|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
98533|NCT01415492|Behavioral|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
98830|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
97977|NCT01414543|Other|Information Sheet|Providing the Participant with information regarding the aim of the experiment
97978|NCT01414543|Other|Consent|Providing a consent form for participants. The participant is aware of his or her rights
97979|NCT01414543|Other|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
98280|NCT01417351|Dietary Supplement|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
98281|NCT01417351|Dietary Supplement|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
98282|NCT01417364|Drug|Testosterone enanthate|100 mg. IM weekly throughout study
98283|NCT01417364|Drug|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
98284|NCT01417364|Drug|Placebo|Injected IM weekly throughout study
98285|NCT01417377|Drug|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
98286|NCT00001108|Drug|Nevirapine|
98287|NCT00065260|Drug|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
98288|NCT01417390|Drug|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
98289|NCT01417390|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
98290|NCT01417403|Drug|hydroxychloroquine|Given PO
98291|NCT01417403|Radiation|radiation therapy|Undergo radiotherapy
98292|NCT01417429|Drug|Galantamine|8mg/a day or placebo
98293|NCT01417429|Drug|IV Nicotine|1.0 mg/70 kg of nicotine against saline
98294|NCT01417442|Genetic|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
98295|NCT01417468|Behavioral|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
98974|NCT01416259|Drug|Withdraw treatment|
98975|NCT01416272|Device|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
98976|NCT01416298|Other|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and > 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching >10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after >10% is achieved is acceptable and now will be put into standard clinical practice.
98977|NCT01416311|Drug|Eltrombopag|
98978|NCT01416324|Drug|placebo|
98041|NCT01419691|Drug|auranofin|6 mg twice a day for a total of 12 mg total daily dose
98042|NCT01419704|Device|Enriched Hematopoetic Stem Cell Transplantation|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
98043|NCT01419717|Drug|denosumab|120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab is approved and available for sale (expected to be approximately 1 year of treatment per subject)
98044|NCT01419730|Drug|Vitamin D3|Vitamin D3 50,000 IU
98045|NCT01419730|Behavioral|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
98046|NCT00065871|Behavioral|Contraceptive Prescribing by Pharmacist|
98047|NCT01422083|Procedure|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
98048|NCT01422096|Drug|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if > 37.5 kg im once
98049|NCT01422096|Drug|Dexamethasone|dexamethasone 1 mg PO twice
98050|NCT01422096|Drug|recombinant human chorionic gonadotropin|r-hCG 25 micrograms IV twice
98051|NCT01422109|Drug|YH14659|YH14659 capsule by oral
98052|NCT01422109|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
98053|NCT01422122|Drug|Vitamin D3|4000 mg per day, one tablespoon syrup per day
98054|NCT01422122|Drug|Placebo|one table spoon Syrup per day
101773|NCT01386827|Biological|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml > 2 years later
101774|NCT01386827|Biological|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml > 2 years later
101775|NCT01389193|Drug|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
101776|NCT01389193|Drug|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
101777|NCT01389219|Other|Intervention|A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;
Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron & vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.
Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.
5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections.
101778|NCT01389232|Device|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
101779|NCT01389245|Device|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
101780|NCT01389258|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
101781|NCT01389271|Drug|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
101782|NCT00062322|Drug|irinotecan hydrochloride|
101783|NCT01389284|Drug|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
101784|NCT01389284|Drug|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
102352|NCT01374841|Drug|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
102353|NCT01374841|Other|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
102354|NCT01374854|Biological|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
102355|NCT01374854|Drug|traditional therapy|exogenous insulin injection daily
102356|NCT01374893|Behavioral|Exercise|The intervention group will perform the multi-session per day training program
98831|NCT01418378|Device|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
98832|NCT01418378|Device|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
98833|NCT01418391|Procedure|Transversus Abdominis Plane block|TAP BLOCK:
dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12~18 hours upon to the regional anesthetics choose
98834|NCT00065377|Drug|Glucosamine Hydrochloride|
98835|NCT01418404|Other|Noxious TS|hot, cold alternately, noxious TS in study A
98836|NCT01418404|Other|Innocuous TS|warm, cool alternately, Innocuious TS in study A
98837|NCT01418404|Other|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
98838|NCT01418404|Other|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
98839|NCT01418404|Other|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
98840|NCT01421017|Drug|Cyclophosphamide|
98841|NCT01421030|Procedure|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
98842|NCT01421043|Drug|triazolam liquid oral drops|0.25 mg single dose oral drops
98843|NCT01421043|Drug|triazolam tablets|0.25 mg single oral dose
98844|NCT01421056|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
98845|NCT01421056|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
98846|NCT01421056|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
98847|NCT01421069|Drug|etanercept|Subjects aged <18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).
Subjects aged greater than or equal to 18 years or >62 kg will receive etanercept SC at a dose of 50 mg QW.
98296|NCT01417468|Behavioral|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
98297|NCT01417481|Dietary Supplement|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
98298|NCT00065260|Drug|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
98299|NCT01417481|Dietary Supplement|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
98300|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
98595|NCT01422733|Drug|Cosyntropin|250 micrograms IV twice
98596|NCT01422733|Drug|r-hCG (Ovidrel)|25 mcg IV twice
98597|NCT01422746|Drug|Metformin|500-1000 mg PO BID (X12 weeks)
98598|NCT00065962|Drug|secretin, synthetic porcine|
98599|NCT01422746|Drug|Dexamethasone|1 mg PO twice
98600|NCT01422746|Drug|Cosyntropin|250 micrograms IV twice
98601|NCT01422746|Drug|r-hCG (Ovidrel)|25 mcg IV twice
98602|NCT01422759|Drug|Spironolactone|50-100 mg PO BID (X 12 weeks)
98603|NCT01422759|Drug|Dexamethasone|1 mg PO twice
98604|NCT01422759|Drug|Cosyntropin|250 micrograms IV twice
98605|NCT01422759|Drug|r-hCG (Ovidrel)|25 mcg IV twice
98606|NCT01422772|Biological|VM202RY|0.5mg intramuscular injection
98607|NCT01422772|Biological|VM202RY|1mg intramuscular injection
98608|NCT01422772|Biological|VM202RY|2mg intramuscular injection
98609|NCT00065962|Drug|secretin, biologically derived porcine|
98610|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
98611|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
98055|NCT01422135|Drug|AG200-15|A transdermal contraceptive delivery system for LNG and EE. A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
98056|NCT01422148|Drug|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
98057|NCT00065884|Drug|Valproate|
98058|NCT01422148|Drug|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
98059|NCT01422161|Drug|Botulinum Toxin commonly known as BOTOX®|A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.
The control group will receive a placebo injection. There will be 1 treatment cycle during the 9 week study.
98060|NCT01422174|Procedure|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
98061|NCT01422187|Drug|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
98062|NCT01422200|Biological|2011-2012 seasonal flu vaccine|The 2011-2012 seasonal flu vaccine will be given by subcutaneous injection.
98362|NCT00065065|Drug|Rosiglitazone|4mg orally twice daily for 12 weeks
98363|NCT01415141|Drug|Peginterferon alfa-2a|180ug subcutaneously, weekly
98364|NCT01415141|Drug|Ribavirin|Administered orally twice a day as follows:
weight < 75kg - 1000mg weight ≥ 75kg - 1200mg
98365|NCT01415141|Drug|telaprevir|750mg every 8 hours, orally
98366|NCT01415154|Device|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
98367|NCT01415193|Procedure|Selective Tibial Nerve block|Use of selective pain block.
98368|NCT01415193|Procedure|Sciatic Nerve Block|Use of Sciatic Nerve Block
98369|NCT01415206|Behavioral|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
98370|NCT01415206|Behavioral|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
98371|NCT01415219|Other|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
104825|NCT01407081|Behavioral|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
104826|NCT00001096|Biological|QS-21|
104827|NCT00064181|Drug|capecitabine|
104828|NCT01407094|Drug|Sertraline|50-200mg/day
104829|NCT01407094|Drug|Placebo|1-4 pills per day
104830|NCT01407094|Drug|BupropionXL|150-450 mg/day
104831|NCT01407107|Drug|nitroglycerin|0.2mg/hr nitroglycerin transdermal patch daily
104832|NCT01407120|Behavioral|New Beginnings Program|A preventive intervention for divorced families.
104833|NCT01407133|Device|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic "pseudo-dose" on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months.
104834|NCT01407133|Device|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
104835|NCT01407185|Other|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
104836|NCT01407198|Drug|Nilotinib|Orally, daily 200 - 400 mg BID
104837|NCT01407198|Radiation|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
104838|NCT00064181|Drug|celecoxib|
104839|NCT01407211|Dietary Supplement|vitamin A|25000 IU/day vitamin A 6 months
1 Cap/Day
1 cap placebo/day for 6 month
104840|NCT01407224|Behavioral|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
104861|NCT01409499|Drug|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
104141|NCT01410786|Procedure|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
104142|NCT01410799|Drug|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
104143|NCT01410812|Behavioral|Control|Receive weekly emails asking participants about their exercise and receive cash.
104144|NCT01410812|Behavioral|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
104145|NCT01410812|Behavioral|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
104146|NCT01410825|Biological|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
104147|NCT00064415|Drug|Salmeterol|Salmeterol MDI, 42 mcg BID
104148|NCT01410838|Other|Broth|200 mL of sodium chloride containing broth, consumed three times per day
104149|NCT01410838|Other|Broth|200 mL of MSG containing broth consumed three times per day
104150|NCT01410851|Other|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
104151|NCT01410864|Device|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
104152|NCT01410864|Other|Control|Devices or drugs used to seal the dura (other than DuraSeal)
104153|NCT01410890|Biological|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
104154|NCT01410903|Device|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
104155|NCT01410916|Drug|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
104156|NCT01410929|Procedure|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
104157|NCT01410942|Other|Placebo|Capsules by mouth twice daily.
104450|NCT01393639|Drug|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
104451|NCT01393639|Drug|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
104589|NCT01408927|Other|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
104909|NCT01400022|Other|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
104910|NCT01400048|Dietary Supplement|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
104911|NCT01400048|Dietary Supplement|Placebo control|60mg Ascorbic acid
104912|NCT01400074|Drug|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
104913|NCT01400087|Device|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
104914|NCT01400100|Drug|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
104915|NCT01400100|Drug|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
104916|NCT01400113|Drug|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
104917|NCT01400113|Drug|Placebo|Placebo Sublingual Tablet, single-dose
104918|NCT01400139|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
104919|NCT00063635|Drug|Metformin|500 mg, twice daily
104920|NCT01400152|Device|Additional active warming|Chemical heat pad applied to the upper torso
104921|NCT01400165|Drug|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
104922|NCT01400165|Drug|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
104923|NCT01400165|Drug|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
104924|NCT01402557|Behavioral|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
104925|NCT01402570|Dietary Supplement|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
104926|NCT01402583|Drug|PEG IFN/Ribavirin|PEG IFN/Ribavirin
104072|NCT01413295|Other|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
104073|NCT01413347|Procedure|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
104074|NCT01413347|Procedure|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
104075|NCT01413360|Drug|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
104373|NCT01413542|Drug|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
104374|NCT01413542|Drug|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
104375|NCT01413542|Drug|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
104376|NCT01413542|Drug|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
104377|NCT00064792|Drug|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
104378|NCT01413555|Other|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
104379|NCT01413568|Drug|POL6326|
104380|NCT01413568|Procedure|Leukapheresis|
104381|NCT01413568|Procedure|PBSC Transplant|
104382|NCT01413581|Drug|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
104383|NCT01413581|Drug|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
104384|NCT01413594|Behavioral|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
104385|NCT01413607|Device|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
104386|NCT01413607|Device|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
104657|NCT01406782|Genetic|gene expression analysis|
104658|NCT01406782|Genetic|polymerase chain reaction|
104659|NCT01406782|Other|laboratory biomarker analysis|
104660|NCT01406795|Device|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
104661|NCT01406808|Behavioral|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
104662|NCT00064142|Other|laboratory biomarker analysis|Correlative studies
104663|NCT01406821|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
104664|NCT01406821|Procedure|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
104984|NCT01397305|Drug|[6R] 5,10-methylenetetrahydrofolate|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
104985|NCT01397305|Drug|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
104986|NCT01397331|Drug|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
104987|NCT01397331|Drug|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
104988|NCT01400165|Procedure|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
104989|NCT01400191|Drug|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
104990|NCT01400217|Drug|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
104991|NCT01400217|Drug|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
104992|NCT01400230|Procedure|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
104452|NCT00062764|Drug|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
104453|NCT01393639|Drug|prednisone|5 mg capsule once daily for 8 weeks
104454|NCT01393639|Other|prednisone|10 mg capsule once daily for 8 weeks
104455|NCT01393639|Other|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
104456|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
104457|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
104458|NCT01393652|Drug|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
104459|NCT01393665|Drug|PENNEL capsule|hard capsule DDB 25mg & GO 50mg in cap .......... 1 capsule
1 or 2 capsule, T.I.D
104460|NCT01393665|Drug|Placebo|Placebo
104461|NCT01393678|Drug|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
104462|NCT01393678|Drug|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg & garlic oil 50mg ............. 1cap
104463|NCT00062790|Drug|Dutasteride|
104464|NCT01393691|Behavioral|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
104465|NCT01393691|Behavioral|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
104466|NCT01393704|Drug|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
104467|NCT01393717|Drug|brentuximab vedotin|Given IV
104468|NCT01393717|Other|laboratory biomarker analysis|Correlative studies
104469|NCT01393717|Genetic|protein expression analysis|Correlative studies
104470|NCT01393730|Drug|Abiraterone acetate|1000 mg orally, once per day
104471|NCT01393730|Drug|Dutasteride|3.5 mg orally once per day
104927|NCT01402596|Drug|Midazolam|0,4 mg per kg - intranasal midazolam - once
104928|NCT01402596|Drug|Chloral Hydrate|50 mg per kg, rectal
103990|NCT01412957|Other|Best Supportive Care|Best supportive care treatment as determined by the investigator.
103991|NCT00064740|Behavioral|relaxation response|
103992|NCT01412957|Drug|Panitumumab|Panitumumab administered intravenously 6 mg/kg every 14 days.
103993|NCT01412970|Other|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
103994|NCT00001095|Drug|Zidovudine|
103995|NCT00064077|Drug|Gemcitabine Hydrochloride|
103996|NCT01405742|Drug|Recombinant factor VIII|In this arm, 40 IU/kg recombinant factor VIII will be given once-weekly by intravenous injection for 26 weeks, with up to two rescue doses per week for bleeds. At 26 weeks after a 4-day washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly by intravenous injection until week 52.
103997|NCT01405755|Behavioral|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
103998|NCT01405768|Drug|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
103999|NCT01405768|Drug|Non-buffered lidocaine|
104000|NCT01405794|Drug|32ppm Silver Particle|Oral silver dose of 32ppm
104001|NCT01405794|Drug|Placebo|Sterile Water No Silver
104002|NCT01405807|Drug|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
104003|NCT01405820|Drug|natalizumab IV|natalizumab for IV Infusion
104004|NCT01405820|Drug|natalizumab SC|natalizumab for Subcutaneous Injection
104005|NCT01405820|Drug|IV Placebo|Intravenous placebo to natalizumab
104006|NCT00064077|Drug|Paclitaxel|Given IV
104007|NCT01405820|Drug|SC Placebo|Subcutaneous placebo to natalizumab
104008|NCT01405833|Drug|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
104009|NCT01405833|Drug|Placebo|Single dose IV matched placebo
104387|NCT01406366|Behavioral|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
104388|NCT01406366|Behavioral|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
104389|NCT00064116|Biological|rituximab|Rituximab 375 mg/m² i.v. day 1
104390|NCT01406379|Procedure|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
104642|NCT01404442|Drug|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
104643|NCT01404442|Drug|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
104644|NCT01404455|Other|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
104645|NCT01406756|Drug|Methotrexate|Given IT and IV
104646|NCT01406756|Drug|Pegaspargase|Given IV
104647|NCT01406756|Drug|Prednisone|Given PO or IV
104648|NCT01406756|Radiation|Radiation Therapy|Undergo radiation therapy
104649|NCT01406756|Drug|Thioguanine|Given PO
104650|NCT01406756|Drug|Vincristine Sulfate|Given IV
104651|NCT00064142|Other|placebo|Applied topically
104652|NCT01406769|Procedure|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
104653|NCT01406769|Procedure|Lymphadenectomy|Undergo lymphadenectomy
104654|NCT01406769|Procedure|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
104655|NCT01406782|Biological|rituximab|
104656|NCT01406782|Genetic|DNA analysis|
104993|NCT01400243|Drug|Nicotine|Nicotine patch 7mg
104994|NCT00063635|Dietary Supplement|Vitamin E|400 IU, twice daily
104995|NCT01400243|Drug|Placebo Patch|Placebo patch
104996|NCT01400256|Drug|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
104997|NCT01400269|Behavioral|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
104998|NCT01400282|Device|High frequency spinal cord stimulation|
104999|NCT01400308|Drug|Mupirocin + Chlorhexidin|Treatment after protocol described in the "Consensus document and GEIH-SEIMC SEMPSPH" Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)
104076|NCT01413373|Radiation|cone beam computed tomography|A CBCT is performed for all patients in this study
104077|NCT01413373|Radiation|computer tomography|One computer tomography examination before surgery
104078|NCT01413386|Device|biliary stent|palliative treatment for malignant patients
104079|NCT00001107|Drug|Fluconazole|
104080|NCT00064779|Procedure|surgery|
104081|NCT01413399|Drug|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
104082|NCT01413412|Procedure|Ventral hernia repair using full thickness skin graft|25 patients
104083|NCT01413412|Procedure|Ventral hernia repair using mesh|25 patients
104084|NCT01413438|Procedure|Craniotomy|
104085|NCT01413451|Drug|Amatuximab (MORab-009)|
104725|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg Ferrous sulfate
104726|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg ferrous sulfate
104727|NCT01404533|Dietary Supplement|Ferrous sulfate|6 mg ferrous sulfate
104728|NCT01404546|Other|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
104729|NCT01404546|Other|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
104730|NCT01404559|Device|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
104731|NCT01404559|Device|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
104732|NCT01404559|Device|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
104733|NCT01404572|Drug|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
104734|NCT00063999|Drug|paclitaxel|Given IV
104735|NCT01404572|Drug|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
104736|NCT01404572|Drug|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
104737|NCT01404585|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
104738|NCT01404585|Drug|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
104739|NCT01404585|Drug|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
104740|NCT01406873|Drug|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
104741|NCT00064142|Other|pharmacological study|Correlative studies
104742|NCT01406873|Drug|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
104743|NCT01406886|Behavioral|Eating rate|
104744|NCT01406899|Behavioral|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
104010|NCT01405846|Drug|Gefitinib|250mg od for 6 months
104011|NCT01405872|Other|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
104012|NCT01405885|Biological|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
104013|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
104307|NCT01406327|Drug|Ambrisentan|
104308|NCT01406340|Drug|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
104309|NCT01406353|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
104310|NCT01408446|Drug|Placebo|Capsule 48mg three times a day after meals 8 weeks
104311|NCT01408459|Dietary Supplement|Tomato Product|Motivational Telephone Counseling weekly
104312|NCT00064272|Dietary Supplement|ginger extract|Given orally
104313|NCT01408459|Dietary Supplement|Control|No Motivational telephone Counseling
104314|NCT01408472|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
104315|NCT01408485|Device|Therapy™ Cool Flex™ Irrigated Ablation System|The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:
Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter
IBI 1500T9 V1.43 RF Generator
104316|NCT01408498|Drug|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
104317|NCT01408511|Drug|Mapracorat|Application of the investigational product on the affected skin areas
104318|NCT01408524|Drug|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
104319|NCT01408524|Drug|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
104320|NCT01408537|Biological|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
104321|NCT01408550|Drug|NPB-01|Intravenous immunoglobulin
104322|NCT01408550|Drug|Placebo|Physiological saline
100551|NCT01366430|Procedure|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
100552|NCT01366430|Procedure|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
100553|NCT01366430|Procedure|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
100554|NCT01366443|Procedure|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
100555|NCT00060307|Drug|erlotinib hydrochloride|Given orally
100556|NCT01366443|Procedure|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
100557|NCT01366443|Procedure|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
100558|NCT01366456|Device|Moxibustion|Comparison of different kinds of moxibustion
100559|NCT01366482|Device|Cotavance Drug-Eluting Balloon|Treatment with a Paclitaxel-coated angioplasty balloon (without preceding plaque excision)
100560|NCT01366482|Device|TurboHawk/SilverHawk Device followed by a Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
100561|NCT01366482|Device|TurboHawk/SilverHawk Device followed by a Cotavance Drug-Eluting Balloon (N=25)|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
100562|NCT01366495|Behavioral|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
100563|NCT01366508|Other|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
100853|NCT00062374|Drug|cisplatin|Given IV
100854|NCT01389908|Drug|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
100855|NCT01389921|Other|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
100856|NCT01389934|Drug|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
104086|NCT01413477|Drug|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
104087|NCT01413490|Drug|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
104088|NCT01413503|Radiation|131I-MIBG|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
104089|NCT01413516|Behavioral|Smoking counseling|Counseling sessions provided by a trained smoking counselor along with placebo during 1st day of study
104090|NCT01405885|Biological|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
104091|NCT01405885|Biological|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
104092|NCT01405898|Dietary Supplement|beetroot juice|Beetroot juice 4 weeks 250ml daily
104093|NCT01405898|Dietary Supplement|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
104094|NCT01405911|Drug|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
104391|NCT01406379|Procedure|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
104392|NCT01406392|Drug|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
104393|NCT01406392|Drug|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
104394|NCT01406405|Procedure|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
104395|NCT01406418|Biological|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
104396|NCT01406418|Biological|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
104397|NCT01406418|Biological|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
104862|NCT01409512|Procedure|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
104863|NCT01409538|Other|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
104864|NCT01409538|Other|Control condition|This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the "active" intervention is a placebo, and the comparison condition is a no-intervention control.
104865|NCT01409551|Procedure|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
104866|NCT01409551|Procedure|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
104867|NCT01409564|Drug|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
104868|NCT01411852|Drug|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
104869|NCT01411852|Drug|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
104870|NCT00064649|Device|Transurethral Needle Ablation (TUNA) Therapy|type of minimally invasive surgical therapy for BPH
104871|NCT01411865|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
104872|NCT01411865|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
104323|NCT00001100|Drug|ganciclovir|
104324|NCT00064272|Other|placebo|Given orally
104325|NCT01408563|Drug|Fludarabine|30 mg/m2/day IV x 6 days
104326|NCT01408563|Drug|Melphalan|100 mg/m2/day IV x 1 day
104327|NCT01408563|Radiation|Total Body Radiation|200 cGy on Day 0
104328|NCT01408563|Biological|Cord Blood|2 cord blood units IV
104590|NCT01408927|Other|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
104591|NCT01408953|Biological|bevacizumab|Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.
A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient.
104592|NCT01408966|Dietary Supplement|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
104593|NCT01408966|Dietary Supplement|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
104594|NCT01408979|Drug|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
104595|NCT01408979|Drug|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
104596|NCT01408992|Procedure|Audiometry|Standard hearing test performed by audiologists
104597|NCT01408992|Other|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
104598|NCT01409005|Drug|Gemcitabine and UFTE chemotherapy|Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15
UFTE : 200mg/m2 PO q 8 hr, Days 1~21
Interval: every 4 weeks
104599|NCT00064324|Drug|perifosine|Given orally
104600|NCT01409018|Drug|Itraconazole|pharmacokinetics
104601|NCT01409031|Drug|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
104602|NCT01409031|Other|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
100857|NCT01389934|Drug|Placebo|Women of this group be infused saline 2 ml / h for 48h.
100858|NCT01389973|Drug|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
100859|NCT01389973|Drug|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
100860|NCT01389973|Drug|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
100861|NCT01389973|Drug|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
100862|NCT01389986|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
100863|NCT01389999|Other|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
100864|NCT00062374|Procedure|conventional surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
100865|NCT01390012|Drug|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
100866|NCT01390012|Drug|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
100867|NCT01392079|Drug|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
100868|NCT01392105|Drug|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
100869|NCT01392105|Drug|Control group|No additional treatment of mesenchymal stem cells
100870|NCT01392131|Dietary Supplement|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
100871|NCT01392131|Other|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
101144|NCT01385592|Drug|AFQ056|
101145|NCT00062036|Drug|fludarabine phosphate|
101146|NCT01385592|Drug|Placebo|
104398|NCT01406418|Biological|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
104399|NCT01406418|Biological|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
104400|NCT00001096|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
104401|NCT00064116|Drug|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
104402|NCT01406418|Biological|Placebo|Administered as a single 2-hour intravenous infusion
104403|NCT01406431|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
104404|NCT01406431|Drug|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
104405|NCT01406444|Drug|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
104406|NCT01406444|Drug|Risedronate|Risedronate 35mg PO one time weekly
104407|NCT01406444|Drug|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
104408|NCT01406470|Drug|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
104409|NCT01408628|Behavioral|Internet Insulin Education|Offer and assess the safety and effectiveness of a synchronous ("live") interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of < 7.0% using an established treat-to-target algorithm.
104410|NCT01408641|Drug|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
104411|NCT01408641|Drug|Placebo|Placebo capsules without topiramate
104665|NCT01406834|Behavioral|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
104666|NCT01406847|Other|Spinal Manipulation|High velocity low amplitude joint-biased intervention
104667|NCT01406847|Other|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
104668|NCT01406847|Other|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
104669|NCT01406860|Drug|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
104873|NCT01411878|Behavioral|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
103934|NCT01407926|Other|Nurse-Led Mental Health Promotion Intervention|The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
103935|NCT01407952|Device|HydroCoil Embolic System|HydroCoil Embolic System
103936|NCT01407952|Device|Control (bare platinum coils)|bare platinum coils
103937|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
103938|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
103939|NCT01407978|Biological|Vaccination with Fluval P monovalent influenza vaccine|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose.
103940|NCT01407978|Biological|Vaccination with Fluval AB|Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose.
103941|NCT01407978|Biological|Vaccination with Fluval AB Novo|Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose.
103942|NCT01407991|Other|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
103943|NCT01407991|Other|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
103944|NCT00064233|Drug|dasatinib|
103945|NCT01408004|Drug|Pazopanib|Tablet 800mg qd til progression
103946|NCT01408004|Drug|Everolimus|tablet 10 mg qd til progression
103947|NCT01408004|Drug|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
103948|NCT01408004|Drug|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
104603|NCT01409044|Other|Music|Music listening for the treatment group. Music is from MusicCure selection "Dreams". Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively.
104604|NCT01409083|Device|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
104605|NCT01409096|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
104606|NCT01411371|Drug|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
104929|NCT01402609|Procedure|seamless discharge|The intervention will consist of discharges being conducted with the use of the computer-enabled communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
104930|NCT01402609|Procedure|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
104931|NCT01402622|Drug|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
104932|NCT01402635|Device|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
104933|NCT00063895|Other|pharmacological study|Correlative studies
104934|NCT01402648|Dietary Supplement|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
104935|NCT01402648|Dietary Supplement|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
104936|NCT01402674|Drug|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
104937|NCT01402700|Device|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
104938|NCT01402713|Biological|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
101147|NCT01385631|Drug|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
101148|NCT01385631|Drug|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
101149|NCT01385644|Other|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
101150|NCT01385657|Drug|REGN668 (SAR231893)|Dose 1 or placebo
101151|NCT01385657|Drug|REGN668 (SAR231893)|Dose 2 or placebo
101152|NCT01385670|Device|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
101153|NCT01385683|Drug|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
101154|NCT01388114|Device|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
101155|NCT00062257|Drug|irofulven|
101156|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
101157|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
101158|NCT01388153|Drug|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
101159|NCT01388166|Procedure|Education|Education
101160|NCT01388179|Device|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
101161|NCT01388205|Behavioral|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
101162|NCT01388231|Behavioral|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
104670|NCT01406860|Drug|Metoclopramide|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses.
104671|NCT01406860|Drug|Diphenhydramine|Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
104672|NCT01409096|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
104673|NCT01409122|Drug|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
104674|NCT01409122|Drug|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
104675|NCT01409122|Drug|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
104676|NCT00064324|Other|laboratory biomarker analysis|Correlative studies
104677|NCT01409122|Drug|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
104678|NCT01409122|Drug|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
104679|NCT01409135|Drug|AGS-22M6E|IV Infusion
104680|NCT01409135|Drug|ASG-22CE|IV Infusion
104681|NCT01409148|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
104682|NCT01409161|Drug|ATRA|45 mg/m2 daily by mouth beginning Day 1 (in 2 divided doses approximately 12 hours apart) for Course 1 (Induction) and during Weeks 1-2 and 5-6 of Courses 2-5 (Consolidation).
104683|NCT01409161|Drug|ATO|0.15 mg/kg by vein over 1 hour (+/- 10 minutes) daily beginning on day 1, Course 1 (Induction) then over 1-2 hours for 5 days total during Weeks 1-4 of Courses 2-5 (Consolidation). Each course is about 8 weeks.
104684|NCT01409161|Drug|GO (Gemtuzumab ozogamicin)|9 mg/m2 by vein may be given one time during weeks 1-4 (Induction).
104685|NCT01409161|Drug|Methylprednisolone|50 mg by vein daily for 5 days followed by rapid taper starting on day 6 (Induction).
105000|NCT01400308|Device|Prontoderm MRSA Kit|Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
Prontoderm® is a Class III medical device
105001|NCT01400334|Radiation|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine [HED, 20 mCi (740 MBq)] to quantify sympathetic nerve function, b) 13N-ammonia [NH3, 20 mCi (740 MBq)] for regional perfusion, and c) 18F-2-deoxyglucose [FDG; 6.5 mCi (241 MBq)] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
103949|NCT01410409|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
103950|NCT01410409|Behavioral|Patient education|The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, "Lær at leve med kronisk sygdom (Learn to live with chronic illness)" by The National Board of Health, Denmark and "Artrosskolan Spenshult" in Sweden.
104239|NCT01410968|Drug|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
104240|NCT01411020|Procedure|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
104241|NCT01411046|Other|No intervention|No intervention
104242|NCT00064428|Other|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
104243|NCT01411059|Behavioral|yoga|yoga classes 2 times per week for 32 weeks
104244|NCT01411072|Drug|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
104245|NCT01411072|Drug|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
104246|NCT01411085|Drug|Risperidone + Desipramine|
104247|NCT01411098|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
104248|NCT01411098|Radiation|intensity-modulated radiation therapy|Undergo IMRT
104249|NCT01411098|Drug|cisplatin|Given IV
104250|NCT01411098|Drug|etoposide|Given IV
104251|NCT01411111|Drug|Rosuvastatin 10 mg|days 1-14
104252|NCT01411111|Drug|GSK2190915 30mg|1x30mg tablet, days 8-14
104253|NCT00001104|Drug|Zidovudine|
104254|NCT00064428|Drug|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
104255|NCT01411111|Drug|GSK2190915 100mg|1x100mg tablet, days 8-14
104256|NCT01411124|Drug|gabapentin enacarbil|600 mg investigational compound
104939|NCT01402713|Biological|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
104940|NCT01402726|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
104941|NCT01402739|Other|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
104942|NCT01402739|Other|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
104943|NCT01394653|Drug|YM060|oral, with water
104944|NCT01394679|Radiation|Radiolabeled (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
104945|NCT01394679|Radiation|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
104014|NCT01405885|Biological|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
104015|NCT01405885|Biological|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
104016|NCT01405885|Biological|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
104017|NCT00064077|Other|Quality-of-Life Assessment|Ancillary studies
104018|NCT01405885|Biological|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
104019|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
104020|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
104021|NCT01408004|Drug|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
104022|NCT01408004|Drug|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
104023|NCT01408030|Drug|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
104024|NCT01408030|Drug|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
104025|NCT01408030|Drug|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
104026|NCT01408030|Drug|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
101468|NCT01390844|Drug|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
101469|NCT01390857|Drug|Valaciclovir|
101470|NCT01390870|Drug|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
101471|NCT01390883|Drug|Fondaparinux Sodium|
101472|NCT01390896|Drug|Fondaparinux Sodium|
101473|NCT01390909|Drug|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
101474|NCT01390922|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
101475|NCT01390935|Other|guideline adherence|guideline adherence of physician
101476|NCT01390948|Radiation|Radiotherapy|Chemoradiation period: 1.8 Gy per day delivered on days 1-5 per week for 6 weeks (Children in the young patient cohort will not receive radiotherapy)
101477|NCT01393119|Drug|GTx-758|
101478|NCT01393132|Drug|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
101479|NCT01393132|Drug|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
101480|NCT01393145|Drug|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
101481|NCT01393145|Drug|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
101482|NCT01393158|Drug|Apremilast|30 mg by mouth twice daily for a total of 124 weeks.
101483|NCT00062738|Drug|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
101484|NCT01393171|Device|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
101485|NCT01393171|Procedure|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
101486|NCT01393171|Procedure|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
101487|NCT01393184|Drug|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
105002|NCT01400360|Other|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
105003|NCT01400373|Device|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
105004|NCT01400386|Other|Coffee bioavailability trial|Coffee bioavailability trial
105005|NCT01402752|Biological|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
105006|NCT00063895|Other|pharmacogenomic studies|Correlative studies
105007|NCT01402765|Device|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
105008|NCT01402765|Device|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
105009|NCT01402791|Other|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
105010|NCT01402817|Drug|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
105011|NCT01402830|Other|Visual analogue scales (EVAs)|This scale measures the pain intensity.
105012|NCT01402843|Drug|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
105013|NCT01402856|Other|Education|Education 2007-2008 school year, Phillipsburg HS in Phillipsburg, NJ & Southern Lehigh HS in Center Valley, PA agreed to take part in an educational program (EP) targeting HS students on the risks of distracted driving. The EP was 60-min long & utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, & interactive games simulating distracted driving.
Freedom & Liberty HS's in Bethlehem, PA will serve as the study's control group. These schools will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
Groups/Cohorts: Southern Lehigh, PA School District , Phillipsburg, NJ School District
105014|NCT01402869|Drug|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
104095|NCT01405911|Drug|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
104096|NCT01405911|Drug|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
104257|NCT01411124|Drug|diphenhydramine|50 mg active comparator
104258|NCT01411124|Drug|placebo|placebo
104259|NCT01411137|Drug|IPX066|CD-LD extended release
104260|NCT01411150|Drug|Creatine Monohydrate|Up to 30 grams daily creatine monohydrate
104261|NCT01411163|Drug|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
104262|NCT01411176|Drug|Menthol|20 mL NPO-11 in a prefilled plastic syringe
104263|NCT01413100|Drug|Mycophenolate Mofetil|Given PO
104536|NCT01411345|Procedure|Urine Sample Collection|Urine sample collection prior to radiation therapy, during last week of radiation therapy, 3 months and 2 years post-radiation therapy.
104537|NCT01411345|Procedure|Blood Sample Collection|Plasma and Serum sample collection prior to radiation therapy, during last week of radiation therapy, 3 months and 2 years post-radiation therapy.
104538|NCT01411345|Behavioral|EPIC SF-12 Questionnaire|Expanded Prostate Cancer Index Composite-Sf12 (EPIC SF12) quality of life questionnaire prior to radiation therapy, during last week of radiation therapy, 6 weeks, 3 months, 9 months, 15 months and yearly to 5.25. years post-radiation therapy.
104539|NCT01411345|Behavioral|MAC-PC Questionnaire|Memory Anxiety Scale for Prostate Cancer patients (MAX-PC) questionnaire prior to radiation therapy, during last week of radiation therapy, 6 weeks, 3 months, 9 months, 15 months and yearly to 5.25. years post-radiation therapy.
104540|NCT01411358|Biological|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
104541|NCT01411358|Biological|elderly aged over 60|one dose of 0.5mL AdimFlu-S
104542|NCT01411371|Procedure|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
104543|NCT00064584|Drug|CT53518|
104544|NCT01404156|Other|Carboplatin paclitaxel plus concurrent radiotherapy|5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:
paclitaxel: 50 mg / m2 IV over 1 hour
carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.
Dose specifications:
Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.
Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment .
104545|NCT01404169|Drug|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
104027|NCT00064246|Biological|rituximab|Given IV
104028|NCT01408043|Drug|plerixafor|Given SC
104029|NCT01408043|Biological|filgrastim|Given SC
104030|NCT01408043|Drug|etoposide|Given IV
104031|NCT01408043|Procedure|leukapheresis|Undergo apheresis
104032|NCT01408056|Drug|Timolol 0.5% Gel Forming Solution (GFS)|Dose-based escalation schedule for topical application:
4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day
8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day
104033|NCT01408056|Drug|Mupirocin 2% Ointment|Topical application twice per day for 60 days
104034|NCT01408069|Drug|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
104035|NCT01408069|Drug|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
104036|NCT01408082|Drug|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
104329|NCT01408576|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
104330|NCT01408576|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
104331|NCT01408589|Drug|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
104332|NCT01408602|Drug|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
104333|NCT01408602|Drug|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
104334|NCT01408602|Drug|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
104335|NCT00064285|Drug|alvocidib|
104336|NCT01408615|Drug|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
104337|NCT01411176|Drug|Placebo|The placebo is included same additives as active comparator.
104338|NCT01411189|Drug|Menthol|20 mL NPO-11 in prefilled syringe
104339|NCT00064428|Drug|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
101488|NCT01393197|Other|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
101489|NCT01393210|Dietary Supplement|beta-glucan 1.3D-1.6D|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
104519|NCT01408888|Drug|Sitagliptin|Administered orally
104520|NCT01408901|Behavioral|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
104521|NCT01408901|Other|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
104522|NCT01408901|Drug|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M^2 subcutaneously three times weekly for two weeks.
104523|NCT01411332|Behavioral|IPSS Questionnaire|International Prostate Symptom Score (IPSS) questionnaire prior to radiation therapy, during last week of radiation therapy, 6 weeks, 3 months and every 6 months up to 5.25 years post-radiation therapy.
104524|NCT01411332|Procedure|Ultra-Sound Guided Biopsy|Ultra-Sound Guided Biopsy prior to radiation therapy and 2 - 2.5 years post-completion of radiation therapy.
104525|NCT01411332|Procedure|Prostate Fiducial Marker Placement|Prostate Fiducial Marker implanted in prostate tissue during Ultrasound Guided Biopsy prior to radiation therapy, within 4 weeks after enrollment.
104526|NCT01411332|Procedure|Blood Sample Collection|Plasma and serum sample collection prior to radiation therapy, during last week of radiation therapy, 3 months post-radiation therapy and within 2 months of 2 year Ultrasound-Guided prostate biopsy.
104527|NCT01411332|Procedure|DCE-MRI|Dynamic Contrast Enhanced MRI of Pelvis/Prostate prior to radiation therapy. 3 months post-completion of radiation therapy, and within 2 months of 2 year Ultrasound guided prostate biopsy
104528|NCT01411332|Procedure|CT Simulation|CT Simulation prior to radiation therapy.
104529|NCT01411332|Procedure|MRI Simulation|MRI Simulation prior to radiation therapy.
104530|NCT01411332|Procedure|Bone Scan|Bone Scan as needed
104531|NCT01411345|Radiation|Standard Salvage Radiation Treatment (SSRT)|Patients will receive 68 Gy in 2 Gy fractions to the prostate bed clinical target volume (CTV).
104532|NCT00064571|Procedure|vocal fold reinnervation|
104097|NCT00064077|Drug|Topotecan Hydrochloride|Given IV
104098|NCT01405911|Drug|Placebo for Sitagliptin 50 mg|1 tablet orally once daily for 8 weeks
104099|NCT01405924|Drug|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
104100|NCT01405924|Drug|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
104101|NCT01405924|Drug|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
104102|NCT01405924|Drug|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
104103|NCT01405937|Drug|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
104104|NCT01405937|Biological|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
104105|NCT01405937|Drug|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
104106|NCT01405950|Drug|Zanaflex Capsules|0.025 mg/kg
104107|NCT01405950|Drug|Zanaflex Capsules|0.05 mg/kg
104108|NCT00064077|Drug|Vinorelbine Tartrate|Given IV
104109|NCT01405950|Drug|Zanaflex Capsules|0.075 mg/kg
104110|NCT01405950|Drug|Zanaflex Capsules|0.1 mg/kg
104111|NCT01405963|Drug|AMG 157 Matching Placebo|Matching placebo administered as multiple IV doses in subjects with mild atopic asthma
104112|NCT01405963|Drug|AMG 157|One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.
104113|NCT01405976|Device|diet, oxygen, noninvasive ventilation, CPAP|diet, oxygen, noninvasive ventilation, CPAP
104114|NCT01405989|Drug|darexaban|oral
104115|NCT01405989|Drug|ketoconazole|oral
104116|NCT01406002|Drug|darexaban|oral
104117|NCT01406002|Drug|Rifampicin|oral
104546|NCT01404169|Drug|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
104547|NCT00001095|Drug|Lamivudine|
104548|NCT00063986|Procedure|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
104549|NCT01404182|Biological|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
104550|NCT01404195|Dietary Supplement|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
104551|NCT01404208|Drug|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
104874|NCT01411878|Behavioral|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
104875|NCT01411891|Device|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
104876|NCT01411904|Device|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
104877|NCT01411917|Procedure|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
104878|NCT01411930|Drug|Intramuscular olanzapine, aripiprazole|1st clamp: single intramuscular 10.0 mg dose of olanzapine
2nd clamp: single intramuscular 9.75 mg dose of aripiprazole
104879|NCT01411930|Drug|Intramuscular aripiprazole, olanzapine|1st clamp: single intramuscular 9.75 mg dose of aripiprazole
2nd clamp: single intramuscular 10.0 mg dose of olanzapine
104880|NCT01404767|Drug|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
104881|NCT01404767|Drug|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
104340|NCT01411202|Drug|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
104341|NCT01411202|Other|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
104342|NCT01411215|Drug|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
104343|NCT01411228|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
104344|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
104345|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
104346|NCT01411241|Biological|Placebo|0.5 mL, subcutaneous
104347|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
104348|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
104349|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
104350|NCT00064441|Drug|OPC-6535 Tablets (drug)|
104351|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
104607|NCT01411384|Procedure|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
104608|NCT01411384|Device|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
104609|NCT01411397|Other|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
104610|NCT01411397|Other|mesh repair|mesh repair of strangulated hernia without resection
104533|NCT01411345|Radiation|Mapped Tumor Salvage RT (MTSRT)|Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the GTV defined by DCE-MRI will receive 2.2 Gy per day for a total of 74.8 Gy (biological equivalent to 77.5 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).
104534|NCT01411345|Procedure|DCE-MRI of Pelvis/Prostate|Dynamic Contrast Enhanced-MRI of the Pelvis/Prostate prior to radiation therapy, 3 months, 9 months and 2 years post-radiation therapy
104535|NCT01411345|Procedure|Ultrasound Prostate Bed Biopsy|Optional Ultrasound Prostate Bed Biopsy prior to radiation therapy; 2 - 2.5 years post radiation therapy.
104784|NCT01411722|Device|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
104785|NCT01411735|Drug|Enalapril|2.5mg titrated up to 10mg twice daily
104786|NCT01411735|Drug|placebo|2.5mg titrated up to 10mg twice daily.
104787|NCT01411748|Dietary Supplement|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
104788|NCT01411748|Drug|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
104789|NCT01411761|Dietary Supplement|Reflor|5 million unit/day, first 15 day of life
104790|NCT01411761|Other|serum physiologic|1 cc added to one feeding in a day
104791|NCT01411774|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
104792|NCT00064649|Device|Transurethral Microwave Thermotherapy (TUMT)|type of minimally invasive surgical therapy for BPH
104793|NCT01411774|Drug|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
104794|NCT01411774|Drug|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
104412|NCT01408654|Behavioral|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
104413|NCT01408667|Drug|TRC150094|50 mg Tablets once a day
104414|NCT01408667|Other|Placebo|Tablets once daily
104415|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
104416|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
104417|NCT01408680|Dietary Supplement|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
104418|NCT00064285|Drug|imatinib mesylate|
104419|NCT01408693|Procedure|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
104420|NCT01408693|Procedure|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
104421|NCT01408706|Device|Prostate gland immobilization with rectal balloon|Device: Prostate gland immobilization with rectal balloon (Miller enema air tip or Radiadyne Prostate Immobilizer Treatment Device) to fix prostate location and displace rectal tissue during radiation therapy.
104422|NCT01408719|Dietary Supplement|Control|Minimal beta-glucan
104423|NCT01408719|Dietary Supplement|3g LMW beta-glucan|3grams beta-glucan
104424|NCT01408719|Dietary Supplement|5g LMW beta-glucan|5 grams beta-glucan
104425|NCT01408719|Dietary Supplement|3g HMW beta-glucan|3 grams of high molecular weight beta-glucan
104426|NCT01408732|Drug|Sodium tetradecyl sulfate (sotradecol)|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
104427|NCT01408745|Device|Sternumfix|sternotomy closure with Sternumfix
104428|NCT01408745|Procedure|steel wire|sternotomy closure with steel wire
104429|NCT00064298|Dietary Supplement|fruit and vegetable extracts|Given orally
104882|NCT01404780|Device|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
104883|NCT00064025|Drug|medroxyprogesterone|
104884|NCT01404780|Device|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
104885|NCT01404793|Drug|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
104886|NCT01404806|Drug|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
104887|NCT01404819|Drug|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
104888|NCT01404819|Drug|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
104889|NCT01404832|Drug|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
103951|NCT01410409|Procedure|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
103952|NCT01410409|Other|Insoles|The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.
103953|NCT01410435|Drug|Monofer|Infusion according to current HB level
103954|NCT01410448|Drug|Everolimus|Immediate introduction of everolimus + low Cyclosporin + steroids
103955|NCT01410448|Drug|Myfortic+ Everolimus|Delayed introduction of everolimus (delayed introduction) + low Cyclosporin + steroids
103956|NCT01410461|Device|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
103957|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
103958|NCT01410461|Device|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
104611|NCT01411410|Drug|Paclitaxel|Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles
The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)
Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted.
104612|NCT01411410|Drug|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
104613|NCT01411423|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
104614|NCT01411436|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
104615|NCT01411449|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
104616|NCT00064610|Drug|VELCADE TM (bortezomib) for Injection|
104617|NCT01411462|Device|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
104618|NCT01411475|Other|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
104619|NCT01411501|Other|acupuncture|Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).
Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.
Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks.
104620|NCT01411501|Drug|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
104621|NCT01404299|Other|Control|- No intervention, except monthly home visits
104946|NCT01394692|Procedure|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
104947|NCT01394692|Procedure|standard microsurgery|microsurgical tumor resection
104948|NCT01394705|Device|BodyMedia|Accelerometer
104949|NCT00062868|Biological|LMP1/2 CTLs (Group B)|Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One
Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2
Dose Level Two
Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2
Dose Level Three
Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2
104950|NCT01394718|Drug|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
104795|NCT01411787|Behavioral|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
104796|NCT01411800|Drug|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
104797|NCT01411800|Drug|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
104798|NCT01411826|Behavioral|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
104799|NCT01411826|Behavioral|Information Only|Information from CDC website on colon cancer screening.
104800|NCT01411839|Behavioral|Cognitive-Behavioral Therapy AD|Therapeutic intervention, one-on-one and face-to-fact, over multiple sessions
105117|NCT01403051|Drug|Placebo for vitamin D3|A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
105118|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
105119|NCT01395004|Drug|GSK2110183|Drug will be administered as 125 mg capsules once daily.
105120|NCT01395017|Drug|dasatinib|GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
105121|NCT00062907|Biological|Recombinant DNA- pVAX/L523S|
105122|NCT01395017|Drug|Placebo|Matching Placebo
105123|NCT01395030|Drug|Fluoromethylcholine (FCH) PET/CT Imaging|Investigational New Drug Radiopharmaceutical Imaging Agent - Single Dose Administration
105124|NCT01395043|Procedure|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
105125|NCT01395043|Drug|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
105126|NCT01395069|Drug|Nepafenac 0.1%|1 drop QID for 1 month
105127|NCT01395069|Drug|Ketorolac 0.5%|1 drop QID for 1 month
105128|NCT01395069|Other|Placebo (sterile saline drops)|1 drop QID for 1 month
104430|NCT01411293|Other|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
104431|NCT01411306|Other|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
104686|NCT01409174|Drug|Ipilimumab|Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.
Phase II dose: Maximum tolerated dose (MTD) from Phase I.
104687|NCT00064324|Other|pharmacological study|Correlative studies
104688|NCT01409174|Drug|Temozolomide|200 mg/m^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
104689|NCT01409174|Drug|Cisplatin|25 mg/m^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
104690|NCT01409174|Drug|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
104691|NCT01409174|Drug|Interleukin-2|9 million IU/m^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
104692|NCT01409187|Drug|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
104693|NCT01409187|Drug|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
104694|NCT01409187|Drug|Interleukin-2 (Aldesleukin)|9 million IU/m^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
104695|NCT01411514|Drug|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
104696|NCT01411514|Drug|Placebo|Placebo tablets. They will be administered during 25 days
104697|NCT01411540|Dietary Supplement|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
104698|NCT01411553|Other|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
104699|NCT01411566|Behavioral|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
104700|NCT01411566|Behavioral|regular treatment|regular treatment
104701|NCT00064623|Drug|Capsaicin Dermal Patch|
103959|NCT01410474|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
103960|NCT01410500|Drug|Carfilzomib|Patients will receive carfilzomib on 28-day cycles until disease progression, unacceptable toxicity, commercial availability, or the trial is terminated.
103961|NCT01410513|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
103962|NCT01410539|Device|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
103963|NCT01410539|Drug|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
103964|NCT01410552|Device|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
103965|NCT01410565|Drug|Apaziquone|Apaziquone 4 mg in 40 mL diluent
103966|NCT01410565|Drug|Placebo|Placebo for Double Blind Phase
103967|NCT01410591|Device|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
103968|NCT00064402|Drug|Salmeterol|Salmeterol MDI 42 mcg BID
103969|NCT01410591|Device|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
104264|NCT01413100|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
104265|NCT01413100|Drug|Plerixafor|Given SC
104266|NCT00064766|Drug|doxycycline|
104267|NCT01413100|Other|Quality-of-Life Assessment|Ancillary studies
104268|NCT01413100|Other|Questionnaire Administration|Ancillary studies
104269|NCT01413113|Drug|pazopanib hydrochloride|Given PO
104270|NCT01413113|Radiation|iodine I 131|Given IM
104271|NCT01413126|Dietary Supplement|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
104272|NCT01413139|Device|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
104951|NCT01394718|Other|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
104952|NCT01394731|Drug|Acetaminophen|
104953|NCT01394731|Drug|Meperidine|
104954|NCT01394757|Drug|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
104955|NCT01394770|Drug|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
104956|NCT01394783|Device|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
104957|NCT01394783|Device|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
104958|NCT01394796|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
104959|NCT01394796|Drug|Placebo|No active treatment is given.
104960|NCT00062868|Biological|LMP1/2 CTLs (Group C)|Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One
Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2
Dose Level Two
Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2
Dose Level Three
Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2
104961|NCT01394809|Behavioral|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
104962|NCT01394835|Drug|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
104963|NCT01394835|Drug|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
104964|NCT01394835|Drug|AAT|Inhalation twice daily' 160mg
104037|NCT01408082|Drug|Azasite|Azasite twice daily for 2 weeks
104038|NCT00064246|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
104039|NCT01408082|Drug|Dexamethasone|Dexamethasone twice daily for 2 weeks
104040|NCT01408082|Other|Vehicle|Vehicle twice daily for 2 weeks
104041|NCT01408095|Drug|LY2608204|Administered orally
105129|NCT01395095|Other|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
105130|NCT01395095|Other|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
105131|NCT01395095|Other|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
105132|NCT00001091|Drug|Nelfinavir mesylate|
105133|NCT00062907|Biological|Recombinant adenovirus- Ad/L523S|
105134|NCT01395108|Drug|Nemonoxacin|oral once daily
104200|NCT01406106|Dietary Supplement|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
104201|NCT01406119|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
104202|NCT00064090|Drug|triapine|
104203|NCT01406132|Drug|ASP015K|oral
104204|NCT01406145|Drug|ASP0777|oral tablet
104205|NCT01406145|Drug|Placebo|oral tablet
104206|NCT01406158|Drug|Solifenacin Succinate Formulation A|oral suspension
104207|NCT01406158|Drug|Solifenacin Succinate Formulation B|oral suspension
104208|NCT01406158|Drug|Solifenacin Succinate|oral tablet
104209|NCT01406171|Drug|Isavuconazole|oral
104210|NCT01406171|Drug|Midazolam|Oral
104702|NCT01411592|Other|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
104703|NCT01411592|Other|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
104704|NCT01411605|Behavioral|Exercise training|12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).
Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol.
105015|NCT01402869|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
105016|NCT01402882|Drug|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
105017|NCT00063895|Other|laboratory biomarker analysis|Correlative studies
105018|NCT01402895|Other|Exercise|Transversus abdominus exercise
105019|NCT01402895|Other|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
105020|NCT01402908|Drug|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
105021|NCT01402908|Other|Placebo|Lactose lyophilized powder
105022|NCT01402921|Device|V0322 BC|Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).
The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)
3 months duration daily treatment
105023|NCT01402934|Procedure|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
105024|NCT01394848|Device|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
105025|NCT01394848|Drug|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
105026|NCT01394848|Drug|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
105027|NCT01394861|Device|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
105028|NCT01394874|Behavioral|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
105029|NCT00062881|Drug|Intrathecal Mafosfamide|
104273|NCT01413152|Biological|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
104274|NCT01413178|Drug|Busulfan|Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
104275|NCT01413178|Drug|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
104276|NCT01413178|Other|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
104277|NCT00064779|Drug|IL13-PE38QQR|
104278|NCT01413178|Drug|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
104279|NCT01413178|Drug|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
104280|NCT01413178|Procedure|Stem cell transplant|Stem cell infusion on Day 0.
104281|NCT01413191|Biological|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
104282|NCT01413191|Other|Laboratory biomarker analysis|Correlative studies
104283|NCT01413204|Drug|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
104284|NCT01413204|Drug|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
104285|NCT01413204|Drug|Placebo|The patients will receive Placebo orally for 24 weeks.
104286|NCT01413230|Drug|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
104552|NCT01404208|Drug|Placebo|Sugar pill
104553|NCT01404234|Drug|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
104554|NCT01404247|Other|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
104555|NCT01404247|Procedure|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
104556|NCT01404260|Drug|gefitinib|gefitinib 250mg/d every cycle d15-25,and gefitinib 250mg/d from d15 of last cycle until disease progression
104557|NCT01404273|Behavioral|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
104042|NCT01408095|Drug|Glimepiride|Administered orally
104043|NCT01408108|Procedure|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original "sandwich" sub-lay technique).
104044|NCT01408108|Procedure|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.
In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used).
104045|NCT01410604|Drug|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
104046|NCT01410604|Drug|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
104047|NCT01410617|Procedure|hemodialysis|3 sessions hemodialysis before CABG
104048|NCT01410630|Procedure|FLT-PET/CT|Standard of Care
104049|NCT01410630|Procedure|FDG-PET/CT|Standard of Care
104050|NCT01410630|Drug|FLT|5 mCi IV
104051|NCT01410643|Other|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
104052|NCT01410656|Behavioral|Telephone Implementation Intention|Telephone implementation intention counseling
104053|NCT01410656|Behavioral|Self-completed implementation intention|Self-administered implementation intention intervention
104054|NCT00064402|Drug|Placebo|Placebo BID
104055|NCT01410669|Behavioral|Motivational interviewing (MI)|MI is a "client-centered" counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).
In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline.
104352|NCT01411241|Biological|Placebo|0.5 mL, subcutaneously
104353|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
104354|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
104355|NCT01411254|Drug|Betamethasone Microsphere (DE-102） Low Dose|
104211|NCT01406184|Other|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived domains of family functioning. For each domain found to be at risk, the nurse intervenes directly to support the mother or connects the mother with ongoing evidence-based interventions in the community
104212|NCT01408290|Biological|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
104213|NCT01408290|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
104214|NCT01408303|Drug|Olive oil, 4g|Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
104215|NCT01408303|Drug|omega-3-carboxylic acids, 2g|Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
104216|NCT00064259|Drug|cisplatin|Given IV
104217|NCT01408303|Drug|omega-3-carboxylic acids, 4g|Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
104218|NCT01408316|Drug|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
104801|NCT01404598|Drug|naproxcinod 750 bid|naproxcinod 750 bid
104802|NCT01404598|Drug|naproxcinod 3000 mg od|naproxcinod 3000 mg od
104803|NCT01404598|Drug|naproxen 500 mg bid|naproxen 500 mg bid
104804|NCT01404611|Drug|DF289|Ear drops
104805|NCT01404611|Drug|DF277|Ear drops
104806|NCT00064012|Drug|bortezomib|
104807|NCT01404611|Drug|DF289 plus DF277|Ear drops
104808|NCT01404637|Drug|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
104809|NCT01404637|Drug|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
104810|NCT01404650|Drug|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
105030|NCT01394887|Drug|Metformin|850 mg of metformin twice daily over 12 weeks
105031|NCT01394887|Drug|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
105032|NCT01394900|Behavioral|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
105033|NCT01394900|Behavioral|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
105034|NCT01394913|Drug|Reumatocept (etanercept)|50mg each week for 30 weeks
105035|NCT01394913|Drug|Enbrel (etanercept)|50mg each week for 30 weeks
104118|NCT01408121|Other|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
104119|NCT01408134|Other|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
104120|NCT01408147|Behavioral|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
104121|NCT01408160|Drug|Cytarabine|Given IV
104122|NCT00064246|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
104123|NCT01408160|Biological|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
104124|NCT01408160|Other|Laboratory Biomarker Analysis|Correlative studies
104125|NCT01408160|Other|Pharmacological Study|Correlative studies
104126|NCT01408173|Drug|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
104127|NCT01408186|Drug|Rabeprazole|Rabeprazole 20 mg daily
104128|NCT01408186|Drug|Famotidine|Famotidine 40mg daily
104129|NCT01408199|Drug|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
104558|NCT01404286|Behavioral|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
104559|NCT00063999|Biological|filgrastim|Given by injection
104560|NCT01404299|Dietary Supplement|Nutritional Supplementation|- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
104561|NCT01406626|Behavioral|Health Navigator|Health navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
104562|NCT01406639|Drug|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
104563|NCT01406652|Procedure|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
104564|NCT01406678|Procedure|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
104565|NCT01406678|Procedure|Control|Coronary artery bypass surgery without remote ischemic preconditioning protocol
104566|NCT01406678|Drug|isoflurane+sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
104567|NCT01406691|Device|Flashes|three hours of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during three hours immediately prior to desired waketime
104568|NCT01406704|Drug|Rosiglitazone|Rosiglitazone (8 mg/day)
104890|NCT01404845|Dietary Supplement|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
104891|NCT01404845|Dietary Supplement|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
104892|NCT01404858|Behavioral|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
104893|NCT01404871|Drug|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily
104894|NCT00064025|Genetic|microarray analysis|
104356|NCT01411254|Drug|Betamethasone Microsphere (DE-102） High Dose|
104357|NCT01411254|Drug|Sham|
104358|NCT01411267|Drug|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
104359|NCT01411267|Drug|Cytarabine|1000 mg/m2/day IV given every 12 hours on days 1 through 5.
IT cytarabine given intrathecally to patients with AML on day "0" of course 1 and 2. Dose defined by age
30 mg for patients age 1-1.99 years of age
50 mg for patients age 2-2.99 years of age
70 mg for patients >3 years of age
104360|NCT01411267|Drug|Etoposide|150 mg/m2/day IV on days 1 through 5.
104361|NCT00064454|Drug|OPC-6535 Tablets (drug)|
104362|NCT01411267|Drug|Methotrexate|IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age
104363|NCT01411280|Drug|methylphenidate|Ritalin 10mg, Ritalin 20mg
104364|NCT01411293|Other|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
104365|NCT01413516|Behavioral|Smoking counseling|Counseling sessions provided by trained smoking counselor along with varenicline
104366|NCT00064792|Drug|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
104367|NCT01413516|Drug|Placebo|Sugar pill without any active medication
104368|NCT01413516|Drug|Varenicline|Varenicline (an approved medication for smoking cessation)
104369|NCT01413529|Behavioral|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
104370|NCT01413529|Behavioral|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
104371|NCT01413542|Drug|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
104372|NCT01413542|Drug|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
104811|NCT01404663|Biological|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
104812|NCT01404676|Drug|Vildagliptin and metformin|Effects on glycemic variability, oxidative stress, and endothelial cell function.
104813|NCT01404676|Drug|Glimepiride and metformin|Effects on glycemic variability, oxidative stress,and endothelial cell function.
104814|NCT01404689|Drug|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
104815|NCT01404689|Other|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
104816|NCT01404702|Drug|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
104817|NCT00064012|Drug|docetaxel|
104818|NCT01404702|Biological|Aldesleukin|Dose Level 1: 3 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle
Dose Level 2: 6 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle
104819|NCT01404715|Drug|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
104820|NCT01404715|Drug|Imatinib|A single oral dose of 600 mg of imatinib
104821|NCT01404741|Procedure|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
104822|NCT01404741|Procedure|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
104841|NCT01407237|Drug|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
104842|NCT01407263|Procedure|Lymph node template|Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence.
104843|NCT01407263|Procedure|Transverse versus vertical closure|Transverse versus vertical closure of the port site incision
104844|NCT01407263|Drug|antibiotic prophylaxis|One vs. three days of antibiotic prophylaxis at catheter removal
104845|NCT01409395|Drug|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
104846|NCT01409395|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
104130|NCT01408212|Procedure|Acupuncture treatment|Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.
Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22
Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)
104131|NCT01408225|Procedure|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
104132|NCT01408238|Biological|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
104133|NCT00064259|Biological|oblimersen sodium|Given IV
104134|NCT01408264|Device|Conventional 0.035 guidewire|0.035 guidewire
104135|NCT01408264|Device|Olympus Visiglide 0.025 guidewire|0.025 guidewire
104136|NCT01408277|Biological|Santyl|2 mm Santyl applied once daily
104137|NCT01408277|Procedure|Control|Standard Care
104432|NCT01411306|Procedure|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
104433|NCT01411319|Radiation|Lattice Extreme Ablative Dose (LEAD) Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined GTV volumes on Day 1.
104434|NCT01411319|Radiation|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard IMRT starting on Day 2.
104435|NCT01411319|Behavioral|EPIC SF-12 Questionnaire|Expanded Prostate Cancer Index Composite-SF12 (EPIC-SF12) quality of life questionnaire prior to radiation therapy, last week of radiation therapy, 6 weeks, 3 months, 9 months, 15 months and yearly thereafter up to 5.25 years.
104436|NCT01411319|Behavioral|MAX-PC Questionnaire|Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) prior to radiation therapy, last week of radiation therapy, 6 weeks, 3 months, 9 months, 15 months and yearly thereafter up to 5.25 years.
104437|NCT00064467|Drug|Extended-release bupropion (HCl)|
104438|NCT01411319|Behavioral|IPSS Questionnaire|International Prostate Symptom Score (IPSS) prior to radiation therapy, last week of radiation therapy, 6 weeks, 3 months, 9 months, 15 months and every 6 months thereafter up to 5.25 years.
104439|NCT01411319|Procedure|Blood Sample Collection|Plasma and Serum collection prior to radiation therapy, 24 hours post-LEAD RT, last week of radiation therapy, 6 weeks, 3 months, within 2 months of 2 year biopsy
104895|NCT01404871|Drug|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including >8 weeks at max dose 50mg daily
104896|NCT01404871|Drug|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including >8weeks at 120mg daily
104897|NCT01404884|Procedure|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
104898|NCT01404897|Other|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
104899|NCT01404897|Other|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
104900|NCT01404897|Other|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
104901|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
104902|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
104903|NCT01399996|Dietary Supplement|A capsule containing the probiotic|A capsule taken daily will provide between 10x^y9 and 10x^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
104904|NCT01400009|Drug|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
104905|NCT01400009|Drug|Placebo|Standard Placebo made of Lactose 100 mg
104906|NCT01400022|Other|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
104907|NCT00001094|Drug|Saquinavir|
104908|NCT00063622|Drug|Matching placebo|Daily
103970|NCT01412827|Radiation|1/2 dose of 99mTc OR 201Tl tracers|Rest: Imaging will occur 30 to 60 minutes after injection of tracer.
Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer.
104622|NCT01404312|Drug|Rifapentine (RPT)|RPT dosing will be based on participants' weight:
Participants who weigh 30 kg to less than 35 kg will receive 300 mg once daily (administered as two 150-mg tablets).
Participants who weigh 35 kg to less than 45 kg will receive 450 mg once daily (administered as three 150-mg tablets).
Participants who weigh greater than 45 kg will receive 600 mg once daily (administered as four 150-mg tablets).
104623|NCT01404312|Drug|Isoniazid (INH)|Participants will receive one 300-mg tablet or three 100-mg tablets of INH once daily.
104624|NCT01404312|Dietary Supplement|Pyridoxine (Vitamin B6)|Participants will receive 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
Participants receiving 25 mg of pyridoxine will take one 25-mg tablet once daily with INH.
Participants receiving 50 mg of pyridoxine will take two 25-mg tablets once daily with INH.
104625|NCT01404325|Drug|standard therapy|centre specific CNI-based triple drug immunosuppression
104626|NCT01404325|Drug|Everolimus (RAD001) as add-on|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
104627|NCT01404325|Drug|RAD001|
104628|NCT01404338|Drug|Halobetasol 0.05% ointment|
104629|NCT01404338|Drug|Placebo Ointment|
104630|NCT00063999|Drug|carboplatin|Given IV
104631|NCT01404351|Device|PEAK PlasmaBlade|
104632|NCT01404351|Procedure|Scalpel and Traditional Electrosurgery|
104633|NCT01404364|Drug|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
104634|NCT01404364|Drug|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
104635|NCT01404377|Procedure|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
104636|NCT01404390|Drug|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
104637|NCT01404390|Drug|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
104638|NCT01404403|Device|Rapid System|
104639|NCT01404429|Drug|Methotrexate|Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
104640|NCT01404442|Drug|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
104847|NCT01409408|Drug|Aliskiren|300 mg of aliskiren daily for 8 weeks.
104848|NCT01409408|Drug|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
104849|NCT00064337|Drug|dexamethasone|
104850|NCT01409421|Behavioral|motivational interviewing|counseling intervention
104851|NCT01409421|Behavioral|three phone calls to remind patients to take their eye drops|reminder phone calls
104852|NCT01409434|Drug|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
104853|NCT01409447|Device|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
104854|NCT01409460|Procedure|Oburator Nerve block|Use of selective pain block.
104855|NCT01409460|Procedure|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
104856|NCT01409473|Radiation|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
104857|NCT01409486|Other|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
104858|NCT01409499|Procedure|hepatic resection|palliative hepatectomy followed by sorafenib
104859|NCT01409499|Procedure|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
104860|NCT00064337|Drug|melphalan|
105135|NCT01395121|Drug|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
105136|NCT01395134|Device|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
105137|NCT01395147|Drug|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
105138|NCT01397552|Drug|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
105139|NCT01397552|Drug|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
105140|NCT01397565|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
104440|NCT01411319|Procedure|Urine Sample Collection|Urine sample collection prior to radiation therapy, 24 hours post-LEAD RT, last week of radiation therapy, 6 weeks, 3 months, within 2 months of 2 year biopsy
104441|NCT01411319|Procedure|Prostate Biopsy|Prostate biopsy prior to radiation therapy and 2 - 2.5 years post-completion of radiation therapy.
104442|NCT01411319|Procedure|CT Simulation|Prior to radiation therapy.
104443|NCT01411319|Procedure|MRI Simulation|Prior to radiation therapy
104444|NCT01411319|Procedure|Fiducial Gold Marker Placement|Four (4) gold markers will be implanted in the prostate gland during prostate biopsy prior to radiation therapy.
104445|NCT01411332|Radiation|Standard Fractionated Intensity Modulated Radiotherapy (SIMRT)|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
104446|NCT01411332|Radiation|Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT)|Dose escalation to the Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.35 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
104447|NCT01411332|Behavioral|EPIC SF-12 Questionnaire|Expanded Prostate Cancer Index Composite-SF12 (EPICSF-SF12) quality of life questionnaire prior to radiation therapy, during the last week of radiation therapy, 6 weeks, 3 months, 9 months, 15 months, and yearly up to 5.25 years after radiation therapy.
104448|NCT00064571|Procedure|vocal fold medialization|
104449|NCT01411332|Behavioral|MAX-PC Questionnaire|Expanded Prostate Cancer Index Composite-SF12 (EPICSF-SF12) quality of life questionnaire prior to radiation therapy, during the last week of radiation therapy, 6 weeks, 3 months, 9 months, 15 months, and yearly up to 5.25 years after radiation therapy.
104705|NCT01411618|Other|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
104706|NCT01411631|Dietary Supplement|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
104707|NCT01411657|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
104708|NCT01411670|Drug|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
104709|NCT01411670|Drug|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
104710|NCT01411670|Drug|Placebo comparator|Standard treatment
104711|NCT01411683|Device|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
103971|NCT01412840|Other|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
103972|NCT01412840|Other|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
103973|NCT01412853|Other|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
103974|NCT01412866|Behavioral|Electronic decision support system with CO monitor feedback|Web-based electronic decision support system (EDSS) with carbon monoxide monitor and health-checklist
103975|NCT01412866|Behavioral|Electronic decision support system without CO monitor feedback|Web-based electronic decision support system (EDSS) with health-checklist feedback alone
103976|NCT01412879|Biological|rituximab|Given IV
103977|NCT01412879|Drug|bendamustine hydrochloride|Given IV
103978|NCT01412879|Drug|cyclophosphamide|Given IV
103979|NCT01412879|Drug|cytarabine|Given IV
103980|NCT00064727|Drug|Avanclia (Rosiqlitazone)|
103981|NCT01412879|Drug|dexamethasone|Given PO or IV
103982|NCT01412879|Drug|doxorubicin hydrochloride|Given IV
103983|NCT01412879|Drug|leucovorin calcium|Given PO or IV
103984|NCT01412879|Drug|methotrexate|Given IV
103985|NCT01412879|Drug|vincristine sulfate|Given IV
103986|NCT01412892|Drug|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
103987|NCT01412918|Device|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
103988|NCT01412944|Drug|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
103989|NCT01412944|Drug|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
104287|NCT01413243|Drug|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
104288|NCT00064779|Procedure|targeted fusion protein therapy|
104641|NCT00063999|Drug|cisplatin|Given IV
104965|NCT01394848|Device|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
104966|NCT01397201|Drug|BI 54903|2 puffs b.i.d. BI54903 via Respimat inhaler
104967|NCT00063232|Drug|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
104968|NCT01397201|Drug|Placebo|2 puffs placebo BI54903 via Respimat inhaler
104969|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
104970|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
104971|NCT01397214|Drug|Megace F|Megace F oral suspension
104972|NCT01397214|Drug|Megace OS|Megace oral suspension
104973|NCT01397227|Biological|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
104974|NCT01397227|Biological|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
104975|NCT01397227|Biological|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
104976|NCT01397240|Drug|Albis Tab|2 Tab, twice a day, 12 weeks
104977|NCT01397240|Drug|Placebo|2 Tab, twice a day, 12 weeks
104978|NCT00063258|Drug|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
104979|NCT01397253|Other|Automated communication tools|Automated communication tools will include:
PCP notification of patient admission and location
Data on medications begun on admission
Automated alerts on changes in patient status and location while the patient is hospitalized
Links to the EMR and to hospital physician contact information on all email alerts
Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP
Automatic reporting to PCPs of test results pending at discharge
Electronic delivery of final discharge summaries
104980|NCT01397266|Procedure|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
104981|NCT01397266|Procedure|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
105141|NCT01397565|Procedure|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
105142|NCT01397578|Drug|MABT5102A|Repeating subcutaneous injection
105143|NCT01397578|Drug|MABT5102A|Repeating intravenous infusion
105144|NCT01397578|Drug|placebo|Repeating subcutaneous injection
105145|NCT01397578|Drug|placebo|Repeating intravenous infusion
105146|NCT01397591|Biological|Ofatumumab|Given intravenously
105147|NCT01397591|Drug|Bortezomib|Given intravenously
105148|NCT00063297|Drug|R209130|
105149|NCT01397604|Drug|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
105150|NCT01397604|Drug|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
105151|NCT01397604|Other|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
105152|NCT01397617|Device|NobelActive Internal implant|
105153|NCT01397617|Device|NobelActive External implant|
105154|NCT01397617|Device|NobelReplace Tapered Groovy implant|
105155|NCT01397630|Drug|Oxytocin|Accelerated Oxytocin Titration
104219|NCT01408329|Device|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
104220|NCT01408342|Drug|Alemtuzumab and Rituximab|Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3
Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25
Cyclosporine 3 mg/kg starting day 21
104221|NCT01408355|Drug|PF-06273588|Intravenous, 50 microgram, single dose
104222|NCT01408355|Drug|PF-06273588|Oral solution, 50 microgram, single dose
104223|NCT01408368|Procedure|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
104712|NCT00001105|Drug|F105 Monoclonal Antibody (Human)|
104713|NCT00064636|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
104714|NCT01411696|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
104715|NCT01411709|Drug|Vitano|two 200mg tablets per day for 14 days
104716|NCT01404468|Device|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
104717|NCT01404468|Other|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
104718|NCT01404468|Device|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
104719|NCT01404481|Device|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
104720|NCT01404507|Drug|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
104721|NCT01404507|Device|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
104722|NCT01404507|Other|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
104723|NCT00063999|Drug|doxorubicin hydrochloride|Given IV
104724|NCT01404520|Other|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
105036|NCT01394926|Drug|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
105037|NCT01394939|Biological|JX-594|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
105038|NCT01394939|Drug|Irinotecan|180 mg/m2 IV every 2 weeks.
105039|NCT01394952|Drug|Dulaglutide|Administered subcutaneously
105040|NCT00062894|Drug|Iodine I 131 Tositumomab|
105041|NCT01394952|Drug|Placebo|Administered subcutaneously
104289|NCT01406197|Drug|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
104290|NCT00064103|Biological|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
104291|NCT01406197|Drug|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
104292|NCT01406197|Drug|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
104293|NCT01406223|Drug|Varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
104294|NCT01406223|Drug|Bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
104295|NCT01406223|Drug|Nicotine patches|Placebo Group: 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
Nicotine Replacement Therapy (NRT) Group:21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
Varenicline and varenicline in combination with bupropion groups: 21 mg/24 h for 1 week before the quit date
104296|NCT01406236|Procedure|Transradial PCI|Transradial PCI
104297|NCT01406236|Procedure|Transfemoral PCI|Transfemoral PCI
104298|NCT01406249|Drug|SP|Drug: S-1:
S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.
Drug: Cisplatin:
Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle.
104299|NCT01406249|Drug|XP|Drug: Capecitabine:
Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Drug: Cisplatin:
Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
104300|NCT01406262|Biological|Albiglutide|once weekly subcutaneous injection
104301|NCT00064103|Other|laboratory biomarker analysis|Correlative studies
104302|NCT01406262|Drug|Moxifloxacin|oral tablet
104303|NCT01406275|Drug|Amoxicillin and clavulanate|
104304|NCT01406288|Other|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
104305|NCT01406301|Drug|fondaparinux|fondaparinux
104306|NCT01406314|Drug|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
104982|NCT01397279|Biological|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
104983|NCT01397279|Biological|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
104056|NCT01410682|Other|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
104057|NCT01410682|Other|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
104058|NCT01410695|Drug|masitinib|
104059|NCT01410695|Drug|masitinib|
104060|NCT01410695|Drug|methotrexate|
104061|NCT01410708|Drug|Dasatinib|
104062|NCT01410721|Behavioral|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
104063|NCT01410721|Behavioral|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
104064|NCT01410734|Drug|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
104065|NCT00064415|Drug|arformoterol|Arformoterol inhalation solution, 50 mcg QD
104066|NCT01410747|Drug|Tacrolimus|oral
104067|NCT01410760|Other|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
104068|NCT01410773|Device|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
104069|NCT01413269|Radiation|radiotherapy|one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
104070|NCT01413282|Radiation|Cardiac CT|Calcium scan and CT coronary angiography
104071|NCT01413295|Drug|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
104224|NCT01408368|Procedure|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
104225|NCT01408381|Other|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
104226|NCT01408394|Drug|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
104227|NCT00064259|Drug|fluorouracil|Given IV
104228|NCT01408394|Drug|90 mg controlled release form|This is the 90 mg controlled release form
104229|NCT01408394|Drug|180 mg controlled release form|This is the 180 mg controlled release capsule
104230|NCT01408407|Other|Aveeno cream|Apply cream on irradiated area twice a day
104231|NCT01408407|Other|Alkagin paste|Apply Alkagin paste three times a day.
104232|NCT01408420|Procedure|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP > 60 mmHg during extracorporeal circulation is used.
104233|NCT01408433|Other|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
104234|NCT01408433|Other|Double embryo transfer|two (2) embryo transfer of untested embryos
104235|NCT01408446|Drug|Menthol|Capsule 48mg three times a day after meals 8 weeks
104236|NCT01410942|Other|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
104237|NCT01410955|Dietary Supplement|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
104238|NCT01410955|Dietary Supplement|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
104823|NCT01404754|Drug|Lactose (inactive placebo)|Placebo in an equivalent weight to MDMA will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
104824|NCT01404754|Drug|3,4-methylenedioxymethamphetamine|125 mg MDMA will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 62.5 mg may be administered 1.5 to 2.5 hours later.
105042|NCT01394965|Procedure|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
105043|NCT01394978|Other|Control|Standard surgical techniques including staples and sutures.
105044|NCT01394978|Device|ProGEL Pleural Air Leak Sealant|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG).
105045|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
105046|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
105047|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
105048|NCT01397357|Other|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
105049|NCT00063258|Drug|Paclitaxel|Planned dose of 200 mg/m^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
105050|NCT01397370|Drug|GLPG0492|Oral solution
105051|NCT01397370|Drug|Placebo|Oral solution
105052|NCT01397396|Procedure|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
105053|NCT01397409|Drug|AGN-150998|AGN-150998 Intravitreal injection.
105054|NCT01397409|Drug|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
105055|NCT01397409|Other|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
105056|NCT01397422|Drug|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
105057|NCT01397448|Drug|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
104138|NCT01408290|Biological|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
104139|NCT01408290|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
104140|NCT01410786|Procedure|Conventional Instrumentation|Standard Oxford surgical instruments
104569|NCT01406704|Drug|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
104570|NCT00064129|Biological|Sargramostim|Given SC
104571|NCT01406704|Drug|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
104572|NCT01406717|Drug|Exenatide, Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily in the thigh, abdomen, or upper arm within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart).
104573|NCT01406730|Other|exercise|16 week of periodized progressive running exercise 2-4 times/week
104574|NCT01406743|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
104575|NCT01406756|Drug|Clofarabine|Given IV
104576|NCT01406756|Drug|Cyclophosphamide|Given IV
104577|NCT01406756|Drug|Cytarabine|Given IT, IV or SC
104578|NCT01406756|Drug|Dexamethasone|PO or IV
104579|NCT01406756|Drug|Doxorubicin Hydrochloride|Given IV
104580|NCT01406756|Drug|Etoposide|Given IV
104581|NCT00064142|Drug|halofuginone hydrobromide|Applied topically
104582|NCT01406756|Drug|Hydrocortisone Sodium Succinate|Given IT
104583|NCT01406756|Other|Laboratory Biomarker Analysis|Correlative studies
104584|NCT01406756|Drug|Leucovorin Calcium|Given PO or IV
104585|NCT01406756|Drug|Mercaptopurine|Given PO
104586|NCT01408914|Drug|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
104587|NCT01408927|Other|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
104588|NCT00064311|Drug|ravuconazole|
101382|NCT01390779|Device|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
101383|NCT01390792|Drug|Zanamivir hydrate|
101384|NCT01392716|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
101385|NCT01392755|Drug|danoprevir|oral doses of danoprevir
101386|NCT01392755|Drug|omeprazole|oral doses of omeprazole
101387|NCT01392755|Drug|ranitidine|oral dose of ranitidine
101388|NCT00062673|Drug|Placebo|
100460|NCT01366300|Drug|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
100461|NCT01366300|Procedure|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
100462|NCT01366313|Drug|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
100463|NCT01366313|Drug|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
100464|NCT01366313|Drug|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
100465|NCT01366326|Drug|Methylnaltrexone bromide|Subcutaneous MNTX
100466|NCT01366339|Drug|Oral methylnaltrexone|
100467|NCT01368783|Drug|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
100468|NCT01368783|Drug|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
100469|NCT01368783|Drug|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
100470|NCT00060411|Biological|bevacizumab|Given IV
100471|NCT01368796|Biological|Agriflu|0.5mL dose IM vaccination
100472|NCT01368796|Biological|Fluad|0.5mL dose of vaccine given IM
101135|NCT01385553|Behavioral|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
101136|NCT01385553|Behavioral|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
101137|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
101138|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
101139|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
101140|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
101141|NCT01385566|Biological|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
101142|NCT01385566|Biological|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
101143|NCT01385579|Other|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
101451|NCT01388777|Procedure|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
101452|NCT01388777|Procedure|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
101453|NCT01388790|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
101454|NCT01388790|Drug|Cisplatin|Cisplatin 60 mg/m^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
101455|NCT01388790|Drug|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
100941|NCT01390025|Biological|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
100942|NCT01390038|Device|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
100943|NCT01390051|Drug|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
100944|NCT01390051|Drug|tinzaparin|Dose 4,500 IE daily
100945|NCT01390064|Biological|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
100946|NCT01390077|Drug|Nitisinone|Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
100947|NCT01390103|Other|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
100948|NCT00062374|Procedure|positron emission tomography/computed tomography|Undergo FDG-PET/CT
100949|NCT01390116|Dietary Supplement|Aged garlic extract|2 aged garlic extract capsules taken twice daily
100950|NCT01390116|Dietary Supplement|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
100951|NCT01390129|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
100952|NCT01390129|Procedure|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
100953|NCT01390142|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
100954|NCT01390142|Procedure|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
101227|NCT01385696|Device|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
101228|NCT00062049|Biological|recombinant interleukin-7|
101229|NCT01385696|Device|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
101230|NCT01385735|Drug|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
101231|NCT01385735|Drug|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
101232|NCT01385748|Drug|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
100396|NCT01371006|Drug|low dose|efavirenz single dosing once daily
100711|NCT01364259|Procedure|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
100712|NCT01364298|Drug|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram [mg] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
100713|NCT01364298|Drug|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
100714|NCT01364311|Dietary Supplement|Vitamac® Tag and Nacht capsules|Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.
Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks
100715|NCT01364324|Drug|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
100716|NCT01364337|Other|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
100717|NCT01364337|Other|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
100718|NCT01364350|Other|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
100719|NCT01364363|Procedure|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
100720|NCT00060021|Procedure|acupuncture therapy|
100721|NCT01364376|Drug|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|FOLFOX:
oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles
SOX:
oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy
100722|NCT01364389|Drug|AIN457|3 mg/kg
100723|NCT01364389|Drug|ACZ885|3 mg/kg
100724|NCT01364389|Drug|Prednisone|20 mg
100725|NCT01364389|Drug|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
100473|NCT01368796|Biological|Intanza|0.5mL dose vaccine given IM
100474|NCT01368796|Biological|Vaxigrip|0.5mL dose vaccine given IM
100475|NCT01368809|Drug|Saline|2 ml at induction 1-2 ml boluses as needed
100476|NCT01368809|Drug|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
100477|NCT01368835|Device|Ulthera treatment|treatment of cheeks and upper neck area of face
100478|NCT01368848|Drug|Bevacizumab|3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging
-> further 3 cycles BCD Q3W -> Bevacizumab Q3W until progression
100479|NCT01368848|Drug|Cisplatin|3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging
-> further 3 cycles BCD Q3W
100480|NCT01368848|Drug|Docetaxel|3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging
-> further 3 cycles BCD Q3W
100785|NCT01389830|Behavioral|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
100786|NCT01389856|Drug|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
100787|NCT01389856|Drug|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
100788|NCT01389869|Biological|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
100789|NCT01389869|Biological|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
100790|NCT01389869|Biological|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
100791|NCT01389869|Biological|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
100792|NCT01391871|Device|OCT|Optical coherence tomography
100793|NCT01391871|Device|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
100794|NCT01391897|Behavioral|psychotherapy|"multimodal complex psychotherapy"
100795|NCT01391923|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
100796|NCT01391936|Procedure|Tension Band Wiring|AO technique of TBW for fixation of fracture.
101456|NCT00062439|Drug|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
101457|NCT01390805|Drug|Valaciclovir Hydrochloride.|
101458|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) will be administered orally in successive 21-day cycles. Dose escalation will proceed until Maximum Tolerated Dose (MTD) is reached. Once the MTD is reached, enrollment will begin in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts will enroll subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
101459|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) will be administered orally in successive 21-day cycles. Dose escalation will proceed until MTD is reached. Once the MTD is reached, enrollment will begin in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts will enroll subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
101460|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) will be administered orally in successive 21-day cycles. Dose escalation will proceed until MTD is reached. The maximum tolerated dose of MSC1936369B (pimasertib) will be combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
101461|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) will be administered orally in successive 21-day cycles. Dose escalation will proceed until MTD is reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) will be combined with a lower dose of MSC1936369B (pimasertib).
101462|NCT01390831|Device|THERMOCOOL® Catheter|Catheter-based renal denervation
101463|NCT01390844|Drug|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
101464|NCT01390844|Drug|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
101465|NCT01390844|Drug|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
101466|NCT01390844|Drug|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
101467|NCT00062439|Drug|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
100544|NCT00060294|Radiation|yttrium Y 90 ibritumomab tiuxetan|
100545|NCT01366365|Drug|methylnaltrexone|
100546|NCT01366365|Drug|placebo|
100547|NCT01366378|Drug|methylnaltrexone|
100548|NCT01366391|Drug|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
100549|NCT01366417|Drug|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
100550|NCT01366417|Drug|70% isopropyl alcohol|Curity Alcohol Prep Pads
101233|NCT01385748|Drug|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
101234|NCT01385748|Drug|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
101235|NCT01385761|Device|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
101236|NCT01385761|Device|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
101237|NCT01385774|Procedure|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
101238|NCT01385774|Other|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
101239|NCT00062062|Drug|carboplatin|
101240|NCT01385800|Biological|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
101241|NCT01385800|Biological|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
101242|NCT01385826|Drug|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
101243|NCT01385826|Drug|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
101244|NCT01388361|Drug|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
101245|NCT00062270|Drug|docetaxel|
100314|NCT01370928|Device|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
100315|NCT01370928|Device|Standard colonoscope|Screening colonoscopy
100316|NCT01370941|Dietary Supplement|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
100317|NCT01370941|Dietary Supplement|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
100726|NCT01364402|Drug|Epoetin beta|50,000U intravenously
100727|NCT01364402|Drug|Saline 0.9%|normal saline intravenously
100728|NCT01364415|Drug|Pasireotide LAR|
101009|NCT01387867|Procedure|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
101010|NCT01387880|Drug|Everolimus|Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.
Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan.
101011|NCT01387880|Drug|Everolimus|1.66 mg per day up to 7½ mg per day
101012|NCT01387893|Behavioral|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
101013|NCT00062231|Procedure|management of therapy complications|
101014|NCT01387906|Drug|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
101015|NCT01387919|Behavioral|Prolonged fasting|48 hours of fasting
101016|NCT01387932|Device|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
101017|NCT01387932|Procedure|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
101018|NCT01387945|Behavioral|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
101019|NCT01387958|Drug|LCQ908|
101020|NCT01387958|Drug|Placebo|
101021|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
101022|NCT01390168|Behavioral|Tailored Internet-administrated CBT-Treatment|This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are "prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
100797|NCT01391936|Procedure|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
100798|NCT00062595|Drug|phylloquinone (K1)|
100799|NCT01391949|Behavioral|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
100800|NCT01391949|Behavioral|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
100801|NCT01391962|Drug|Cediranib|Cediranib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
100802|NCT01391962|Drug|Sunitinib|Sunitinib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
100803|NCT01391975|Procedure|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
100804|NCT01391988|Procedure|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
101076|NCT00062036|Drug|cyclophosphamide|
101077|NCT01387997|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
101078|NCT01388010|Other|1-Fermented Probiotic Dairy Product (test)|
101079|NCT01388010|Other|2-Milk-based non-fermented dairy product(control)|
101080|NCT00001087|Drug|Zidovudine|
101081|NCT00062244|Biological|oblimersen sodium|Given IV
101082|NCT01388023|Dietary Supplement|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
101083|NCT01388036|Drug|esmolol|consecutive infusions of esmolol and normal saline (placebo)
100574|NCT01369056|Behavioral|Advanced Adherence Counseling (AdvAdh)|Advanced Adherence Counseling (AdvAdh) consists of three individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using NextStep Counseling approach. The intervention targets: 1) accurate information about antiretroviral treatment (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenges contexts.
100575|NCT00060424|Procedure|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
100576|NCT01369069|Drug|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
100577|NCT01369069|Drug|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
100578|NCT01369082|Drug|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
100872|NCT01392144|Procedure|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
100873|NCT01392144|Behavioral|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
100874|NCT01392157|Device|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
100875|NCT00062608|Behavioral|Written self-disclosure|
100876|NCT01392157|Device|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
100877|NCT01392157|Device|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
100878|NCT01392157|Device|LNG-IUS|100 women will receive an LNG-IUS
100879|NCT01392170|Drug|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
100880|NCT01392183|Drug|Pazopanib|800 mg by mouth daily in 4 week study cycle.
100881|NCT01392183|Drug|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
100882|NCT01392183|Behavioral|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
100883|NCT01392183|Drug|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
100318|NCT00060619|Behavioral|relaxation training|
100319|NCT01370954|Other|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
100320|NCT01370967|Other|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
100321|NCT01370967|Other|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
100322|NCT01370967|Other|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
100323|NCT01363414|Drug|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
100324|NCT01363440|Drug|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
100325|NCT01363440|Procedure|Macular Laser Photocoagulation|Laser therapy
100326|NCT00059930|Drug|fluorouracil|
100327|NCT01363466|Procedure|hysterectomy|
100328|NCT01363479|Drug|Oral palonosetron|
100329|NCT01363479|Drug|I.V. palonosetron|
100330|NCT01363479|Drug|Dexamethasone|
100331|NCT01363492|Biological|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
100332|NCT01363505|Device|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
100333|NCT01363531|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
100334|NCT01363544|Other|Neurofeedback|30 sessions of theta/beta neurofeedback within 10 weeks.
100335|NCT01363544|Behavioral|Exercise|30 sessions of individual sports training during 10 weeks.
100648|NCT01366573|Other|Placebo|Placebo
100649|NCT00060320|Dietary Supplement|black cohosh|
100650|NCT01366599|Drug|HEC or MEC|Any HEC or MEC, including aprepitant
101023|NCT01390168|Behavioral|Waitlist|active waitlist
101024|NCT01390181|Drug|Cozaar|Angiotensin II Receptor Blocker
101025|NCT01390207|Other|16mm triggering|Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:
• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound.
101026|NCT01390220|Drug|USL261|
101308|NCT00001090|Drug|Sargramostim|
101309|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
101310|NCT01393470|Procedure|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
101311|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.
Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs.
101312|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
101313|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
101314|NCT01385839|Procedure|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
101315|NCT01385839|Procedure|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
101316|NCT01385852|Procedure|microcoaxial phacoemulsification|conventional longitudinal ultrasound
101317|NCT01385865|Dietary Supplement|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
101318|NCT01385865|Dietary Supplement|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
101319|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
101084|NCT01388049|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
101085|NCT01388062|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
101086|NCT01388075|Drug|Rifampicin|oral, 450 mg/day , 7 days
101087|NCT01388088|Drug|Spironolactone|25 mg twice a day
101088|NCT01388088|Drug|Amiloride|5 mg twice a day
101089|NCT01388088|Drug|Placebo|twice a day
101389|NCT01392755|Drug|ritonavir|oral doses of ritonavir
101390|NCT01392768|Drug|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
101391|NCT01392768|Drug|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
101392|NCT01392794|Drug|YM060|oral, without water
101393|NCT01392807|Drug|NKTR-118|25 mg Oral tablets, single dose
101394|NCT01392820|Drug|TC-5214|Tablet, Oral, twice daily
101395|NCT01392820|Drug|Placebo|Tablet, Oral, twice daily
101396|NCT01392833|Drug|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
101397|NCT01392833|Drug|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
101398|NCT01392833|Drug|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
101399|NCT00062686|Drug|GW572016|
100884|NCT01392196|Procedure|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
100885|NCT01392209|Other|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
100886|NCT00062621|Procedure|Combined bone marrow and kidney transplant|
100887|NCT01392222|Behavioral|Focus groups|The focus groups will cover the following issues
Perceptions of thyroid cancer and disease status
Sources of information used in papillary microcarcinoma treatment decision-making
Treatment decision-making processes and influential factors
Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)
Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)
Views about how to improve acceptability of active surveillance as a disease management option
100888|NCT01385124|Drug|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
100889|NCT01385137|Dietary Supplement|omega-3 fatty acid|Given orally
100890|NCT01385137|Other|placebo|Given orally
101163|NCT01388231|Behavioral|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
101164|NCT01388244|Other|Screening|Screening by risk factor assessment (FRAX) followed by DXA
101165|NCT01388244|Other|Control|Observation by use of register data
101166|NCT00062270|Drug|cisplatin|
101167|NCT01388257|Procedure|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
101168|NCT01388257|Procedure|Simple seton drain removal|Patients are simply followed after seton drain removal.
101169|NCT01388270|Device|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
101170|NCT01388322|Drug|Enoxaparin|40 mg (4000 IU) women <80 kg at the time of randomization or 60 mg (6000 IU) women> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
101171|NCT01388335|Drug|warfarin|Administered orally
101172|NCT01388335|Drug|enzastaurin|Administered orally
100651|NCT01366612|Drug|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.
rATG on days -3, -2 and -1
100652|NCT01366612|Drug|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.
rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1
100653|NCT01366625|Device|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
100654|NCT01366638|Drug|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
100655|NCT01366638|Drug|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
100656|NCT01366638|Drug|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
100657|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age.
100658|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.
100659|NCT01369095|Drug|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
100660|NCT01369095|Drug|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
100661|NCT00060424|Other|Laboratory Biomarker Analysis|Correlative studies
100662|NCT01369108|Device|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
100663|NCT01369108|Device|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
100664|NCT01369121|Drug|XERECEPT|BID dosing, subcutaneous for 1 year
100665|NCT01369134|Device|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
100666|NCT01369147|Other|0.6x measured REE|Dose of calories administered to subjects while in the study
100667|NCT01369147|Other|1.0 x measured REE|Dose of calories given to subject while in the study
101320|NCT00062062|Drug|gefitinib|
101321|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
101322|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
101323|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
101324|NCT01385891|Drug|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
100397|NCT01371006|Drug|normal dose|efavirenz once daily
100398|NCT01371006|Drug|low dose|Efavirenz single dosing once daily
100399|NCT01371032|Device|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
100400|NCT01371032|Device|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
100401|NCT01371045|Other|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
100402|NCT00060619|Behavioral|cognitive coping skills|
100403|NCT01371058|Drug|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
100404|NCT01371058|Drug|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
100405|NCT01371058|Drug|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
100406|NCT01371084|Behavioral|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
100407|NCT01371084|Behavioral|Pedal@Work|Worksite wellness program.
100408|NCT01371097|Other|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
100409|NCT01371110|Drug|Ketamine|Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
100410|NCT01371110|Drug|Midazolam|Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
101400|NCT01392859|Drug|levocetirizine|5mg liquid or capsule, daily, five days
101401|NCT01392859|Other|placebo|placebo will be given in liquid or capsule form to match levocetirizine, for five days
101402|NCT01392872|Other|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
101403|NCT01392898|Drug|liraglutide|liraglutide 1.8 mg q.d.
101404|NCT01392898|Drug|Insulin|insulin dosed according titration scheme
101405|NCT01392911|Drug|Rifampicin|High dose rifampicin
101406|NCT01392924|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
101407|NCT01392937|Device|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
101408|NCT01392937|Device|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
101409|NCT01392950|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
101410|NCT00062699|Drug|Zemplar (paricalcitol injection)|
100481|NCT00060424|Drug|Cyclosporine|Given PO
100482|NCT01368874|Device|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
100483|NCT01368887|Drug|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
100484|NCT01368887|Other|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
100485|NCT01368887|Drug|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
100486|NCT01368887|Drug|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
100487|NCT01368900|Device|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
100488|NCT01368926|Drug|RO4917523|single oral doses
101173|NCT01388348|Device|Dynamic Urine Vibration "Holter"|each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration "Holter" and then urodynamically by pressure flow study
101174|NCT01388361|Drug|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
101175|NCT01388361|Drug|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
101176|NCT01390389|Drug|Coenzyme Q10|Single pill consists of 400 mg and is delivered PO.
CoQ10 dosing guidelines:
Visit 1 (baseline) start at 400mg once a day for two weeks
Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks
The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above.
101177|NCT01390402|Drug|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
101178|NCT01390402|Drug|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
101179|NCT00001088|Biological|APL 400-047|
101180|NCT00062400|Procedure|psychosocial assessment and care|
101181|NCT01390402|Procedure|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
101182|NCT01390402|Drug|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
101183|NCT01390402|Drug|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
101510|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
101511|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
101512|NCT01386242|Other|Saline Injection|Saline Injection, 1mL, im,three times per week
101513|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
101514|NCT01386255|Drug|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
101515|NCT01386255|Drug|placebo|placebo
101516|NCT01386268|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
100955|NCT01390142|Procedure|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
100956|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
100957|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
100958|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
100959|NCT00062374|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
100960|NCT01392222|Behavioral|Focus groups|The focus groups will cover the following issues:
Perceptions of thyroid cancer and disease status
Sources of information used in papillary microcarcinoma treatment decision-making
Treatment decision-making processes and influential factors
Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)
Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)
Views about how to improve acceptability of active surveillance as a disease management option
100961|NCT01392235|Drug|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
100962|NCT01392287|Drug|Memantine|Dosing Form: Tablet
Dosage: 5mg, 10 mg
Description:
Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.
Memantine HCl Dosing Schedule:
5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8
100963|NCT01392300|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
100964|NCT01392300|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
100965|NCT01392313|Dietary Supplement|Carnitine|Carnitine Ingestion
100966|NCT01392326|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
100967|NCT01392326|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
100968|NCT01392326|Drug|Placebo Comparator|Placebo Comparator
100969|NCT00062634|Behavioral|Female condom skills training|
100411|NCT01371136|Procedure|curricular training|Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an "easy", "medium" and "hard" level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver.
100412|NCT01371149|Other|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
100413|NCT00060619|Behavioral|parent education|
100414|NCT01371162|Drug|RO5428029|Multiple ascending doses
100415|NCT01371162|Drug|placebo|multiple doses
100729|NCT01364428|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.
Dose was individually adjusted.
100730|NCT01366664|Drug|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
100731|NCT00060320|Other|placebo|
100732|NCT01366664|Drug|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days)
100733|NCT01366677|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
100734|NCT01366690|Behavioral|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
100735|NCT01366703|Device|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
100736|NCT01366716|Behavioral|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
100737|NCT01366716|Behavioral|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
100738|NCT01366729|Device|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
100739|NCT01366729|Device|Cane walking|All walking activities must take place with cane from waking until sleeping
100489|NCT01368926|Drug|RO4917523|multiple oral doses
100490|NCT01368926|Drug|placebo|oral doses
100491|NCT01368952|Device|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
100492|NCT00060424|Drug|Fludarabine Phosphate|Given IV
100493|NCT01371175|Biological|MVA.HIVA|2.5x10^8 pfu MVA or placebo
100494|NCT01371201|Drug|Sunitinib|sunitinib 37.5 mg per day
100495|NCT01371201|Drug|Placebo|Placebo 37.5 mg per day
100496|NCT01371214|Behavioral|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
100497|NCT01371227|Drug|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
100498|NCT00060632|Drug|ridaforolimus|Administered intravenously once weekly for 4 weeks (1 cycle).
In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
100499|NCT01371240|Drug|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
100500|NCT01371253|Other|Nintendo wii balance training|
100501|NCT01371253|Other|EVA-soles|
100805|NCT01391988|Procedure|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
100806|NCT01392014|Drug|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
100807|NCT01392014|Drug|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
100808|NCT01392027|Procedure|Blood Draw|Blood draw for research specimens only
100809|NCT00062595|Drug|menatetranone (MK4)|
101517|NCT01386281|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
101518|NCT01386294|Drug|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
101519|NCT01386294|Drug|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
101520|NCT00062101|Other|laboratory biomarker analysis|Correlative studies
101521|NCT01386320|Procedure|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
101522|NCT01388816|Drug|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
101523|NCT01388829|Drug|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
101524|NCT01388829|Drug|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
101525|NCT01388842|Drug|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
101526|NCT00062283|Drug|L-alanosine|
101527|NCT01388842|Drug|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
100579|NCT01369095|Drug|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C&D)
100580|NCT01369095|Drug|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C&D)
100581|NCT01369095|Drug|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B&C)
100582|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
100583|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
100584|NCT01371344|Drug|Tacrolimus|oral
100585|NCT01371357|Drug|TEST 1|2.4 g/day of guanidinoacetic acid
100970|NCT01392339|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
101246|NCT01388374|Other|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
101247|NCT01388387|Other|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
101248|NCT01388400|Other|conventional occupational therapy|upper limb exercises
101249|NCT01388400|Device|video capture virtual reality|virtual reality delivered uppe limb exercises
101250|NCT01388413|Drug|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
101251|NCT01388426|Device|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
101252|NCT01388439|Drug|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants < 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants > 38 weeks PMA. Dosing in infants < 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants > 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants > 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
101253|NCT01388452|Device|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
101254|NCT01388465|Behavioral|Mobile phone text messaging|Daily assessment followed by feedback
101255|NCT01388478|Drug|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with Dr. Burns prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
101256|NCT00062270|Drug|gefitinib|
101257|NCT01388491|Drug|desogestrel/ethinyl estradiol and ethinyl estradiol|
101258|NCT01388491|Drug|desogestrel/ethinyl estradiol|
100740|NCT01366768|Other|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
100741|NCT01366768|Other|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
100742|NCT00001082|Drug|Adefovir dipivoxil|120 mg tablet taken orally daily
100743|NCT00060333|Radiation|radiation therapy|
100744|NCT01366781|Other|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
100745|NCT01366794|Other|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
100746|NCT01366820|Drug|NNZ-2566|Solution for intravenous infusion.
Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours.
100747|NCT01366833|Radiation|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
101027|NCT01390220|Drug|Placebo|
101028|NCT01390233|Drug|Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel in the vagina.
101029|NCT01390233|Device|Urinary Balloon Catheter|Pre-induction cervical ripening using a urinary balloon catheter device.
101030|NCT01390233|Other|Combined Urinary Catheter & Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel injected through a urinary balloon catheter placed in the lower uterine segment.
101031|NCT00062374|Procedure|positron emission tomography/computed tomography|Undergo FLT-PET/CT
101032|NCT01390246|Drug|bupropion SR 150 mg tablets or matched placebo|Bupropion SR tablets or matched placebo. We will administer a 12-week course of therapy, 150 mg bid/placebo x 12 weeks. Subjects will be dispensed a 30 day supply at a time. They will be instructed to begin using study medication (bupropion SR 150 mg/matched placebo orally for 3 days, then BID for 4 days) on study visit day 1, which will be approximately 1 week prior to their quit date. Thereafter, they will continue to dose BID for 12 full weeks of therapy.
101033|NCT01390246|Behavioral|Smoking Cessation Counseling|The behavioral counseling will include 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the study nurse.
101034|NCT01390259|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
100810|NCT01392053|Other|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
100811|NCT01392066|Behavioral|questionnaire|Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.
The questionnaire is administered at baseline and 5- and 12-months follow up.
100812|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
100813|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
100814|NCT01384994|Drug|Panitumumab|6 mg/kg BW every 2 weeks
100815|NCT01384994|Drug|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
100816|NCT01384994|Drug|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
100817|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
100818|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
100819|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
100820|NCT01385007|Behavioral|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
100821|NCT00062023|Drug|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
101090|NCT01388101|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
101091|NCT01390272|Behavioral|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
101092|NCT01390285|Device|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
100586|NCT01371357|Drug|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
100587|NCT01371357|Drug|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
100588|NCT01371357|Drug|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
100589|NCT01371370|Other|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
100590|NCT00060671|Drug|rituximab|
100591|NCT01371370|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
100592|NCT01371370|Other|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
100593|NCT01371383|Dietary Supplement|Omega-3 fatty acids|1.6~2.8 gram/day (5 capsules)
100594|NCT01371383|Dietary Supplement|placebo|5 gram/day (5 capsules)
100595|NCT01371396|Other|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
100596|NCT01371396|Other|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
100597|NCT01371409|Other|continuous theta burst stimulation|80% active motor threshold, 600 pulses
100598|NCT01371422|Other|Paravertebral Block (PVB)|The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).
In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level.
100599|NCT01371422|Other|Saline|Ultrasonography and local infiltration of saline will only be performed
100891|NCT01385150|Genetic|mutation analysis|
100892|NCT01385150|Genetic|protein analysis|
100893|NCT01385150|Other|laboratory biomarker analysis|
100894|NCT01385150|Other|liquid chromatography|
100895|NCT01385150|Other|mass spectrometry|
101259|NCT01388504|Drug|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
101260|NCT01388504|Other|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
101261|NCT01388517|Drug|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
100336|NCT01363544|Drug|methylphenidate|The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
100337|NCT00059930|Drug|leucovorin calcium|
100338|NCT01363557|Other|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
100339|NCT01363557|Drug|Gefitinib (IRESSA)|250 mg/day
100340|NCT01363570|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
100341|NCT01363583|Drug|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
100342|NCT01363583|Drug|normal saline|0.5-1.5 ml/hour during 4 days
100343|NCT01363596|Other|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
100344|NCT01363609|Drug|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
100345|NCT01363609|Drug|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration < 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
100346|NCT00001082|Drug|Levocarnitine|500 mg tablet taken orally daily
100347|NCT00060255|Procedure|bone marrow ablation with stem cell support|iv
100348|NCT01366131|Drug|paclitaxel|Intravenous repeating dose
100349|NCT01366131|Drug|placebo|Intravenous repeating dose
101035|NCT01390259|Device|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
101036|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
101037|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
101038|NCT01390272|Behavioral|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
101039|NCT00062647|Drug|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
101040|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
101041|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
101042|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
101325|NCT01385930|Behavioral|Lifestyle counseling|Lifestyle counseling
101326|NCT01385956|Drug|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
101327|NCT01385956|Drug|Gemcitabine|Fixed dose: 1000mg/m^2 weekly x3 then 1 week off
101328|NCT01385969|Device|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
101329|NCT01385969|Device|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
101330|NCT01385969|Device|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
101331|NCT00062062|Drug|paclitaxel|
101332|NCT01385982|Other|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
101093|NCT01390285|Device|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
101094|NCT00062374|Other|fluorine F 18 fluorothymidine|Undergo FLT-PET/CT
101095|NCT01390298|Other|Observational|Observational study only
101096|NCT01390311|Drug|Azacitidine|
101097|NCT01390311|Drug|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
101098|NCT01390311|Biological|Donor Leukocyte Infusion (DLI)|
101099|NCT01390324|Drug|Fixed-dose combination of naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
101100|NCT01390324|Drug|Naratriptan|Tablets containing naratriptan 2,5 mg
101101|NCT01390324|Drug|Naproxen|Tablets containing naproxen 500 mg
101102|NCT01390337|Drug|AC220|Oral Liquid
101103|NCT01390337|Drug|daunorubicin|Intravenous Infusion
101104|NCT01390337|Drug|cytarabine|Intravenous Infusion
101105|NCT00062387|Drug|perifosine|
101106|NCT01390350|Drug|Canakinumab|150mg subcutaneous injections on day 0
101107|NCT01390350|Drug|Placebo|150mg subcutaneous injections on day 0
101108|NCT01390363|Other|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
101411|NCT01385995|Device|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
101412|NCT01386008|Device|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
101413|NCT01386008|Device|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
100896|NCT01385163|Behavioral|Treatment as usual|Standard psychosocial counseling
100897|NCT00062036|Biological|aldesleukin|
100898|NCT01385163|Behavioral|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
100899|NCT01385163|Behavioral|Cognitive Processing Therapy|group 12 session intervention
100900|NCT01385176|Device|Vagal Nerve Stimulation|Patients randomized to therapy arm with receive right vagal nerve stimulation. Patients randomized to control arm will not receive right vagal nerve stimulation for the first 6-months post-implant, after which they will also receive therapy.
100901|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
100902|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
100903|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
100904|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel with 1 μg GLA-AF|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
100905|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel with 1 μg GLA-AF|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
100906|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel with 1 μg GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
100907|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel with 5 μg GLA-AF|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
100908|NCT00062036|Biological|filgrastim|
100909|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel with 5 μg GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
100910|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel with 5 μg GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
100911|NCT01385202|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
100912|NCT01385215|Drug|Fluzone|0.5 ml/15 micrograms
100913|NCT01385215|Drug|Fluzone|0.5 ml/60 micrograms
101184|NCT01390402|Procedure|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
101185|NCT01390402|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
100350|NCT01366144|Drug|Carboplatin|Given IV
100351|NCT01366144|Other|Laboratory Biomarker Analysis|Correlative studies
100352|NCT01366144|Drug|Paclitaxel|Given IV
100353|NCT01366144|Other|Pharmacological Study|Correlative studies
100354|NCT01366144|Drug|Veliparib|Given PO
100355|NCT01366157|Genetic|microarray analysis|
100356|NCT01366157|Genetic|protein expression analysis|
100668|NCT01369147|Other|1.3 X measured REE|Dose of calories given to subject while in the study
100669|NCT01369160|Behavioral|Quality of Life measures|measuring QOL with different therapies
100670|NCT01369173|Other|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
100671|NCT01369186|Drug|Morphine|i.v. bolus injection
100672|NCT00001083|Drug|Ritonavir|
100673|NCT00060424|Drug|Mycophenolate Mofetil|Given PO
100674|NCT01369186|Drug|Placebo|i.v. bolus injection
100675|NCT01369199|Drug|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
100676|NCT01369212|Drug|Tenofovir|300 mg daily for 192 weeks (4 years)
100677|NCT01369212|Drug|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
100678|NCT01369225|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
100679|NCT01369225|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
100680|NCT01369225|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
101333|NCT01385995|Device|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
101334|NCT01388517|Drug|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
101335|NCT01388530|Device|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
101336|NCT01388543|Drug|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
101337|NCT01388556|Behavioral|Tango dancing|Twice weekly tango dance classes
101338|NCT00062270|Drug|gemcitabine hydrochloride|
101339|NCT01388569|Other|flow cytometry|
101340|NCT01388569|Other|immunologic technique|
101341|NCT01388569|Other|laboratory biomarker analysis|
101342|NCT01388582|Device|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
101343|NCT01388582|Device|Implanon|60 mcg/day contraceptive implant
101344|NCT01388582|Drug|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
101345|NCT01388582|Device|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
100416|NCT01371175|Biological|DNA.HIVA|0.5mg DNA.HIVA or placebo
100417|NCT01371175|Biological|MVA.HIVA|5x10^6 pfu MVA or placebo
100418|NCT01371175|Biological|MVA.HIVA|5x10^7 pfu MVA or placebo
100419|NCT01363609|Drug|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
100420|NCT01363648|Drug|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
100421|NCT00059930|Drug|oxaliplatin|
100422|NCT01363648|Drug|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
100423|NCT01363661|Drug|Coruno|Molsidomine 16 mg tablet, per os, once a day
101414|NCT01386034|Drug|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-[1-13C]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
101415|NCT01386047|Other|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
101416|NCT01386060|Other|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
101417|NCT01386073|Drug|FreshKote|Three times a day for three months
101418|NCT01386073|Drug|Systane|three times a day for three months
101419|NCT00062075|Drug|romidepsin|Given IV
101420|NCT01386086|Drug|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
101421|NCT01386099|Drug|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
101422|NCT01386099|Drug|Placebo|Placebo twice a day for 12 weeks.
101423|NCT01386112|Drug|EUR-1100|Active oral medication
101424|NCT01386112|Drug|placebo|matching placebo
101425|NCT01386125|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
101426|NCT01386125|Drug|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
101427|NCT01386138|Behavioral|Psycho-education|Receive RBT education and peer-support in a group format.
101428|NCT01386138|Behavioral|Experimental|Receive RBT education and a pro-active counseling method
101429|NCT01386151|Drug|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
101430|NCT00062101|Drug|erlotinib hydrochloride|Given orally (PO)
100502|NCT01371266|Dietary Supplement|Honey|60.7 grams orally daily times 14 days
100503|NCT01371266|Dietary Supplement|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
101186|NCT01390402|Drug|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
101187|NCT01390402|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
101188|NCT01390428|Drug|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
101189|NCT01390441|Biological|MK-8808 500 mg/m^2|Intravenously on Day 1 (500mg/m^2) and Day 15 (500mg/m^2) consistent with product labeling information.
101190|NCT01390441|Biological|Rituximab 500 mg/m^2|Intravenously on Day 1 (500mg/m^2) and Day 15 (500mg/m^2).
101191|NCT00062426|Biological|bevacizumab|
101192|NCT01390441|Drug|Methotrexate|Stable oral dose (10-25 mg/week orally)
101193|NCT01390441|Biological|MabThera (rituximab) 500 mg/m^2|Intravenously on Day 1 (500mg/m^2) and Day 15 (500mg/m^2).
101194|NCT01390441|Biological|Rituxan (rituximab) 500 mg/m^2|Intravenously on Day 1 (500mg/m^2) and Day 15 (500mg/m^2).
101195|NCT01390441|Biological|MK-8808 1000 mg|Two infusions consisting of 1000 mg of MK-8808 will be administered intravenously to participants in the extension study with the first occurring at study Week 54 and the second at study Week 56. An additional two infusions consisting of 1000 mg of MK-8808 will be administered intravenously, at the discretion of the treating physician, to participants in the extension study with the first occurring at study Week 80 and the second at study Week 82.
101196|NCT01390454|Procedure|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
101197|NCT01390454|Procedure|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
101198|NCT01390454|Procedure|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
101199|NCT01390467|Drug|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
101200|NCT01392950|Device|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
101201|NCT01392963|Drug|Clostridium botulinum toxin type A neurotoxin complex|Botulinum Toxin Type A: Neurotoxin Complex
101202|NCT01392963|Other|0.9% NaCl solution|0.9% NaCl Solution: Placebo Comparator
101203|NCT01392976|Drug|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
100681|NCT01369225|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
100682|NCT01369225|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
100683|NCT01369238|Device|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2~3days/wk, for 1 month
100684|NCT01371539|Device|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
100685|NCT01371552|Device|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
100686|NCT01371552|Device|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
100687|NCT00060684|Drug|Pixantrone (BBR 2778)|
100688|NCT01371552|Device|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
100971|NCT01392352|Drug|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
100972|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
100973|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
100974|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
100975|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
100976|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
100977|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
100978|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
100979|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
100980|NCT01385228|Drug|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
100981|NCT01385228|Drug|Pazopanib|Dose Level "Xb" - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg.
100424|NCT01363661|Drug|Placebo|Placebo (16 mg tablet, per os; once-daily)
100425|NCT01363674|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
100426|NCT01363687|Device|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
100427|NCT01363700|Drug|DE-114 ophthalmic solution|
100428|NCT01363700|Drug|Placebo ophthalmic solution|
100429|NCT01363700|Drug|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
100430|NCT01363713|Drug|DE-114 ophthalmic solution|
100431|NCT01363752|Drug|Advagraf|oral
100432|NCT00059930|Procedure|adjuvant therapy|
100433|NCT01363752|Drug|Mycophenolate Mofetil|oral
100434|NCT01363752|Drug|Sirolimus|oral
100435|NCT01363752|Drug|Corticosteroids|i.v. and oral
100436|NCT01363765|Other|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
100437|NCT01363765|Other|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
100438|NCT01363778|Drug|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
100748|NCT01366833|Procedure|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
100749|NCT01366846|Other|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
100750|NCT00060424|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
100751|NCT01369238|Drug|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
100752|NCT01369251|Behavioral|Hygiene|
100504|NCT01371266|Dietary Supplement|CHO (sugar)|50 grams daily orally times 14 days
100505|NCT01371279|Device|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
100506|NCT01371292|Behavioral|Transformational Teaching|Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.
100507|NCT01371292|Behavioral|Standard Educational Practices|Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
100508|NCT01371305|Drug|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
100509|NCT00001083|Drug|Stavudine|
100510|NCT00060645|Drug|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
100511|NCT01371305|Drug|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
100512|NCT01371318|Other|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
100513|NCT01371331|Drug|Tacrolimus granules|oral
100514|NCT01371344|Drug|Tacrolimus granules|oral
100515|NCT01363830|Behavioral|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
100516|NCT01363830|Behavioral|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
100517|NCT01363843|Drug|FOLFOX6|FOLFOX6
100518|NCT01363843|Radiation|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
100519|NCT01363843|Procedure|Surgery|
100520|NCT01363869|Dietary Supplement|green tea extracts 2 gm/day|Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.
Total dosage is 2 grams per day.
100271|NCT01366131|Drug|MEGF0444A|Intravenous repeating dose
100272|NCT01366131|Drug|bevacizumab|Intravenous repeating dose
100273|NCT01366131|Drug|carboplatin|Intravenous repeating dose
100274|NCT01368497|Drug|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
100275|NCT01368510|Behavioral|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
100276|NCT01368510|Behavioral|Waitlist|Minimal contact waitlist weekly for 4 weeks
100277|NCT00060411|Drug|erlotinib hydrochloride|Given IV
100278|NCT01368523|Drug|nilotinib|
100279|NCT01368536|Drug|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
100280|NCT01368536|Drug|Amlodipine|Amlodipine 5 mg and 10 mg capsule
100281|NCT01368536|Drug|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
100282|NCT01368536|Drug|Placebo of Valturna Tablet|Matching placebo of valturna tablet
100283|NCT01368536|Drug|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
100284|NCT01368549|Other|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
100285|NCT01368562|Drug|Methylnaltrexone|SC
100286|NCT01368575|Procedure|CABG|CABG
100287|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
100288|NCT00060411|Drug|fluorouracil|Given IV
100289|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
100290|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
100291|NCT01368575|Procedure|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
100982|NCT01385228|Drug|Prednisone|5mg Prednisone given twice daily days 1-21.
100983|NCT01385228|Drug|Pegfilgrastim|
100984|NCT00062036|Biological|incomplete Freund's adjuvant|
100985|NCT01385241|Behavioral|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
100986|NCT01385267|Procedure|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
100987|NCT01385280|Biological|therapeutic estradiol|Given orally (PO)
100988|NCT01385280|Drug|exemestane|Given PO
100989|NCT01385280|Other|laboratory biomarker analysis|Correlative studies
100990|NCT01385280|Other|enzyme-linked immunosorbent assay|Correlative studies
100991|NCT01385293|Drug|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
101262|NCT01388517|Drug|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
101263|NCT01390480|Drug|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
101264|NCT01390493|Behavioral|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
101265|NCT00062426|Drug|capecitabine|
101266|NCT01390506|Drug|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
101267|NCT01390506|Drug|Placebo|0,9% sodium chloride is administered intravenously
101268|NCT01390519|Other|everolimis|
101269|NCT01390532|Device|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (>85% PHR).
Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA).
101270|NCT01390545|Drug|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
100753|NCT01369251|Procedure|Usual alcohol care|
100754|NCT01369264|Device|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
100755|NCT01369264|Device|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
100756|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
100757|NCT01369277|Drug|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
100758|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
100759|NCT01369290|Drug|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
100760|NCT01369290|Drug|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
100761|NCT00060424|Radiation|Total-Body Irradiation|Undergo TBI
100762|NCT01369290|Drug|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
100763|NCT01369290|Other|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
100764|NCT01369290|Drug|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
100765|NCT01369303|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
101043|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
101044|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
101045|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
100822|NCT01385020|Drug|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
100823|NCT01385033|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
100824|NCT01385046|Behavioral|Project Fit|physical activity and nutrition education
100825|NCT01385059|Drug|axitinib|Given PO
100826|NCT01385059|Procedure|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
100827|NCT01385059|Other|enzyme-linked immunosorbent assay|Correlative studies
100828|NCT01385059|Other|laboratory biomarker analysis|Correlative studies
100829|NCT01385072|Biological|Double matched sibling transplantation|Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.
Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS.
100830|NCT01385098|Dietary Supplement|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
100831|NCT01385111|Procedure|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
100832|NCT00062023|Other|Sulindac Placebo|Oral sulindac placebo twice daily.
100833|NCT01385111|Procedure|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
100834|NCT01387490|Behavioral|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
100835|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
100836|NCT01387503|Procedure|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
100837|NCT01387516|Behavioral|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
100292|NCT01368588|Radiation|radiation therapy|Undergo RT using IMRT or 3D-CRT
100293|NCT01368588|Radiation|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
100600|NCT01371435|Drug|Paroxetine|
100601|NCT00060671|Drug|Pixantrone (BBR 2778)|
100602|NCT01371448|Drug|Paroxetine|
100603|NCT01371461|Drug|Paroxetine|
100604|NCT01371474|Drug|Paroxetine|
100605|NCT01371487|Drug|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
100606|NCT01371513|Other|continuous screening|practice patterns for screening prostate cancer
100607|NCT01371526|Drug|depot tetracosactide|1mg, 3x weekly by sc injection
100608|NCT01371539|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
100609|NCT01364012|Drug|placebo|15 mg iv on Day 1 of each 3-week cycle
100610|NCT01364025|Procedure|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
100611|NCT01364051|Drug|Cediranib Maleate|Given PO
100612|NCT01364051|Other|Laboratory Biomarker Analysis|Correlative studies
100613|NCT01364051|Other|Pharmacological Study|Correlative studies
100614|NCT01364051|Drug|Selumetinib|Given PO
100615|NCT00059995|Biological|iratumumab|
100616|NCT01364064|Drug|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
100617|NCT01364077|Drug|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
100618|NCT01364077|Drug|Placebo|Matched placebo
100619|NCT01364090|Drug|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
100620|NCT01364090|Drug|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
101271|NCT01390558|Procedure|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
101272|NCT01390571|Drug|olaparib|
101273|NCT01390571|Drug|temozolomide|
101274|NCT01390571|Genetic|gene expression analysis|
101275|NCT01390571|Genetic|protein expression analysis|
101276|NCT00062426|Drug|fluorouracil|
101277|NCT01390571|Other|laboratory biomarker analysis|
101278|NCT01390571|Other|pharmacological study|
101279|NCT01390571|Procedure|diffusion-weighted magnetic resonance imaging|
101280|NCT01390571|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
101281|NCT01390571|Procedure|therapeutic conventional surgery|
101282|NCT01390584|Biological|bleomycin sulfate|
101283|NCT01390584|Drug|ABVD regimen|
101284|NCT01390584|Drug|BEACOPP regimen|
101285|NCT01390584|Drug|cyclophosphamide|
100357|NCT01366157|Other|immunohistochemistry staining method|
100358|NCT00060255|Procedure|peripheral blood stem cell transplantation|iv
100359|NCT01366157|Other|laboratory biomarker analysis|
100360|NCT01366170|Genetic|microarray analysis|
100361|NCT01366170|Genetic|protein expression analysis|
100362|NCT01366170|Genetic|western blotting|
100363|NCT01366170|Other|flow cytometry|
100364|NCT01366170|Other|immunohistochemistry staining method|
100365|NCT01366170|Other|laboratory biomarker analysis|
100366|NCT01366170|Other|mass spectrometry|
101046|NCT01392391|Procedure|Task Oriented Exercise Training|Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.
Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to "Get with the Guidelines"
101047|NCT01392391|Procedure|Stroke Care "Get with the Guidelines"|Post-stroke care is applied according to the recommendations of the American Stroke Association "Get with the Guidelines" adapted for Jamaica
101048|NCT01392430|Other|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
101049|NCT01392443|Drug|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength is 5 mg/tablet INC424 phosphate (free base equivalent). Medication labels will be in the local language and comply with the legal requirements of each country. equivalent).
101050|NCT00062647|Drug|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
101051|NCT01392456|Procedure|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
101052|NCT01392469|Drug|Imatinib|
101053|NCT01392495|Drug|Imatinib|200 mg or 400 mg qd
101054|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
101055|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
101056|NCT01392534|Drug|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
101057|NCT01392547|Drug|vatreptacog alfa (activated)|1-3 doses per bleeding episode
101058|NCT01385358|Procedure|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
101346|NCT01388582|Device|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
101347|NCT01388595|Drug|FLUTICASONE PROPRIONATE|1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
100838|NCT01387542|Drug|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
101109|NCT01390363|Other|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
101110|NCT01390376|Drug|DAAOI-1|DAAOI-1 1g
101111|NCT01390376|Drug|DAAOI-1|DAAOI-1 2g
101112|NCT01390376|Drug|placebo|starch pill
101113|NCT01392547|Drug|eptacog alfa (activated)|1-3 doses per bleeding episode
101114|NCT01392560|Drug|BI 10773|Oral once daily
101115|NCT01392573|Drug|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
101116|NCT00001090|Biological|ALVAC-HIV MN120TMG (vCP205)|
101117|NCT00062660|Drug|Tipranavir|Tipranavir 250 mg soft elastic capsules
101118|NCT01392573|Drug|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
101119|NCT01392586|Procedure|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
101120|NCT01392586|Other|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
101121|NCT01392599|Procedure|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
101122|NCT01392612|Drug|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
100621|NCT01364103|Other|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
100622|NCT01364129|Procedure|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
100623|NCT01364142|Procedure|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
100624|NCT01364155|Drug|LIM-0705|
100914|NCT01385228|Drug|Pazopanib|Dose Level "Xa" - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg.
100915|NCT01387633|Other|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
100916|NCT01387646|Behavioral|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
100917|NCT01387659|Procedure|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
100918|NCT01387672|Drug|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
100919|NCT01387672|Other|Placebo|Placebo ointment
100920|NCT00062231|Drug|amoxicillin-clavulanate potassium|
100921|NCT01387711|Drug|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
100922|NCT01387724|Genetic|RNA analysis|
100923|NCT01387724|Genetic|polymerase chain reaction|
100924|NCT01387724|Genetic|protein expression analysis|
100925|NCT01387724|Genetic|proteomic profiling|
100926|NCT01387724|Genetic|western blotting|
100367|NCT01366183|Procedure|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
100368|NCT01366183|Drug|Carboplatin|Undergo chemotherapy
100369|NCT00060255|Radiation|radiation therapy|body x-ray
100370|NCT01366183|Biological|Filgrastim|Undergo chemotherapy
100371|NCT01366183|Drug|Paclitaxel|Undergo chemotherapy
100372|NCT01366183|Other|Pharmacological Study|Correlative studies
100373|NCT01366183|Other|Quality-of-Life Assessment|Ancillary studies
100374|NCT01366183|Other|Questionnaire Administration|Ancillary studies
100375|NCT01366196|Drug|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
100376|NCT01366196|Drug|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
100377|NCT00060411|Drug|leucovorin calcium|Given IV
100378|NCT01368653|Behavioral|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
100379|NCT01368653|Behavioral|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
100689|NCT01371565|Drug|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
100690|NCT01371578|Drug|GS-5885 tablet|30 mg active tablet
100691|NCT01371578|Drug|GS-9451 tablet|two active 100 mg tablets
100692|NCT01371578|Biological|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
100693|NCT01371578|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
100694|NCT01371591|Device|Video capsule endoscopy (Pillcam Eso2)|Administration of wireless video capsule in the ED.
100695|NCT01371604|Drug|IDX184|IDX184 50 mg tablet administered orally
101348|NCT01388595|Drug|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
101349|NCT00062270|Procedure|conventional surgery|
101350|NCT01388595|Drug|PLACEBO|4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported & QP release tested in UK : DHP Clinical supplies, Powys, UK
101351|NCT01388621|Drug|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
101352|NCT01388621|Drug|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
101353|NCT01388621|Drug|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
101354|NCT01388621|Drug|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
101355|NCT01388621|Drug|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
101356|NCT01388621|Drug|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
101357|NCT01390584|Drug|vincristine sulfate|
101358|NCT01390584|Other|laboratory biomarker analysis|
101359|NCT01390584|Procedure|computed tomography|
101360|NCT01390584|Radiation|fludeoxyglucose F 18|
101361|NCT01390584|Radiation|selective external radiation therapy|
101362|NCT00062426|Drug|oxaliplatin|
101363|NCT01390597|Genetic|DNA analysis|
101364|NCT01390597|Genetic|cytogenetic analysis|
101365|NCT01390597|Genetic|gene mapping|
101366|NCT01390597|Genetic|mutation analysis|
101367|NCT01390597|Genetic|polymerase chain reaction|
101123|NCT01392625|Procedure|Transendocardial injection|Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 36 patients in two groups:
Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
101124|NCT01392625|Biological|Autologous hMSCs|
101125|NCT01392625|Biological|Allogeneic hMSCs|
101126|NCT01392638|Other|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
101431|NCT01386151|Drug|Saline placebo|Normal (0.9%) saline will be used as a placebo.
101432|NCT01386164|Biological|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
101433|NCT01386164|Biological|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
101434|NCT01386177|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
101435|NCT01388647|Drug|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
101436|NCT01388647|Drug|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
101437|NCT01388647|Drug|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
101438|NCT00062270|Procedure|neoadjuvant therapy|
101439|NCT01388660|Drug|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I & II Day 1 (crossover manner)
101440|NCT01388660|Drug|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I & II Day 1 (crossover manner)
101441|NCT01388673|Procedure|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
101442|NCT01388712|Dietary Supplement|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10^8CFU).
101443|NCT01388712|Dietary Supplement|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
100927|NCT01387724|Other|enzyme-linked immunosorbent assay|
100928|NCT01387724|Other|immunohistochemistry staining method|
100929|NCT01387724|Other|laboratory biomarker analysis|
100930|NCT01387724|Other|liquid chromatography|
100931|NCT00062231|Drug|ciprofloxacin|
100932|NCT01387724|Other|mass spectrometry|
100933|NCT01387737|Drug|TA-7284-Low|TA-7284-Low
100934|NCT01387737|Drug|TA-7284-High|TA-7284-High
101204|NCT01392976|Drug|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
101205|NCT01392989|Drug|CIK cells|Standard of care
101206|NCT01392989|Drug|Cyclosporine|5 mg/kg, po
101207|NCT01392989|Drug|Mycophenolate Mofetil|15 mg/kg, oral
101208|NCT01392989|Drug|Thymoglobulin|7.5 mg/kg, IV
101209|NCT01393015|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
101210|NCT00062699|Drug|Calcijex|
101211|NCT01393015|Device|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
101212|NCT01393028|Other|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
101213|NCT01393028|Other|Standard care|Standard care according to international guidelines
101214|NCT01393041|Device|Angio-Seal VIP|Vascular Closure Device
101215|NCT01393054|Drug|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
101216|NCT01393067|Device|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
101217|NCT01393067|Device|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
100696|NCT01371604|Biological|Peginterferon alfa-2a (Peg-IFN)|Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
100697|NCT01371604|Drug|Ribavirin (RBV)|Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
100698|NCT00060684|Drug|fludarabine|
100699|NCT01371604|Drug|Placebo|Matching placebo to IDX184 50 mg tablet administered orally
100700|NCT01371617|Drug|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
100701|NCT01371630|Drug|Inotuzumab Ozogamycin|Phase I: 1.3 mg/m2 by vein over 1 hour (+/- 15 min) on Day 3 of the first cycle, then 0.8 mg/m2 by vein for Cycles 3, 5, 7 for a total of 4 doses.
Phase II: 1.3 mg/m2 by vein on Day 3 of Cycle 1 and 1.0 mg/m2 by vein on Day 2 or 3 for Cycles 2, 3, 4 as determined in Phase I.
Cycle is 28 days.
100702|NCT01371630|Drug|Rituximab|375 mg/m2 by vein on Day 2 and Day 8 of Cycles 1 - 4. The first dose of rituximab will be given as a slow infusion over 6-8 hours.
100703|NCT01371630|Drug|Cyclophosphamide|150 mg/m2 by vein over 3 hours twice a day Days 1 - 3 for Cycles 1, 3, 5, 7.
100704|NCT01371630|Drug|Mesna|300 mg/m2 by vein continuous infusion daily for 24 hours, starting 1 hour prior to cyclophosphamide for Cycles 1, 3, 5, 7.
100705|NCT01371630|Drug|Vincristine|2 mg by vein on Day 1 and Day 8 of Cycles 1, 3, 5, 7.
100706|NCT01371630|Drug|Dexamethasone|20 mg by vein or by mouth on Days 1-4 and 11-14 of Cycles 1, 3, 5, 7.
100707|NCT01371630|Drug|Pegfilgrastim|6 mg subcutaneously on Day 4 of Cycles 1 - 8.
100708|NCT01371630|Drug|Methotrexate|Intrathecal methotrexate 12 mg (6 mg via ommaya) on Day 2 (+ 2 days) - cycles 1, 2, 3, and 4.
Methotrexate 50 mg/m2 by vein followed by 200 mg/m2 continuous infusion over approximately 22 hours on Day 1 for cycles 2, 4, 6, and 8.
100709|NCT00060008|Radiation|gadopentetate dimeglumine|
100710|NCT01364259|Drug|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
100992|NCT01385306|Device|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
100993|NCT01385319|Device|Bare metal stent implantation|After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:
Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.
Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.
Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.
100439|NCT01363791|Other|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
100440|NCT01363804|Drug|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
100441|NCT01363817|Drug|BMS-906024|
100442|NCT01363817|Drug|Dexamethasone|
100443|NCT00001080|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
100444|NCT00059930|Procedure|conventional surgery|
100445|NCT01366209|Drug|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
100446|NCT01366209|Drug|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
100447|NCT01366222|Dietary Supplement|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
100448|NCT00060268|Drug|HPPH|iv
100449|NCT01366235|Drug|chloroquine phosphate 1000 mg|1000 mg, 1day
100450|NCT01366261|Device|semirigid thoracoscopy|thoracoscopy with semirigid instrument
100451|NCT01366261|Device|rigid thoracoscopy|thoracoscopy with rigid instrument
100452|NCT01366274|Other|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
100453|NCT01366274|Other|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
100454|NCT01366287|Drug|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
100455|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
100456|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
100457|NCT01366300|Drug|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
101444|NCT01388738|Drug|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg*3 times per day) per os
101445|NCT01388738|Drug|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
101446|NCT01388738|Drug|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
101447|NCT01388751|Procedure|night splinting|splint finger at night for 4 weeks
101448|NCT01388764|Drug|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
101449|NCT00062270|Radiation|radiation therapy|
101450|NCT01388777|Device|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
100521|NCT01363869|Dietary Supplement|green tea extracts 4 gm/day|Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.
Total dosage is 4 grams per day.
100522|NCT01363869|Dietary Supplement|green tea extracts 6 gm/day|Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.
Total dosage is 6 grams per day.
100523|NCT01363882|Other|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
100524|NCT01363882|Other|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
100525|NCT00059943|Drug|docetaxel|
100526|NCT01363895|Procedure|Percutaneous closure of LAA|Percutaneous closure of LAA
100527|NCT01363895|Procedure|Catheter ablation of AF|Catheter ablation of AF
100528|NCT01363908|Drug|SPD602|
100529|NCT01363921|Device|HCO 1100|Dialysis treatment with HCO1100
100530|NCT01363934|Drug|GC1113|Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.
Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.
100531|NCT01363934|Drug|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
100532|NCT01363947|Drug|DNIB0600A|Intravenous escalating dose
100533|NCT01363973|Device|VITALSTIM transcutaneous electrical stimulation|
101218|NCT01393080|Drug|Nimotuzumab and TP regimen|TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression.
101219|NCT01393080|Drug|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
101220|NCT01393093|Procedure|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
101221|NCT00062712|Drug|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
101222|NCT01393106|Drug|Idelalisib|Idelalisib tablets administered orally
101223|NCT01393119|Drug|GTx-758|
101224|NCT01393119|Drug|GTx-758|
101225|NCT01393119|Drug|GTx-758|
101226|NCT01385683|Drug|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
100294|NCT01368601|Procedure|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
100295|NCT01368614|Device|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
100296|NCT01368614|Device|Respironics OnmiLab BiPAP S mode|Currently cleared NIV therapy modality
100297|NCT01368614|Device|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
100298|NCT01368627|Device|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
100299|NCT01370837|Other|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
100300|NCT01370863|Drug|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
100301|NCT01370863|Drug|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
100302|NCT01370876|Drug|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
100303|NCT01370889|Drug|resveratrol|Given PO
100994|NCT01385319|Device|zotarolimus eluting stent|After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:
Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.
Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.
Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.
100995|NCT00001087|Drug|Saquinavir|
100996|NCT00062036|Biological|interleukin-2 gene|
100997|NCT01385332|Procedure|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
100998|NCT01385332|Procedure|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
100999|NCT01385345|Drug|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
101000|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
101001|NCT01387763|Drug|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
101002|NCT00062231|Drug|moxifloxacin hydrochloride|
101003|NCT01387828|Procedure|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
101004|NCT01387828|Procedure|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
101005|NCT01387841|Behavioral|yoga|Postures,relaxation techniques
101006|NCT01387841|Behavioral|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
101007|NCT01387867|Procedure|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
101008|NCT01387867|Procedure|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
101286|NCT01390584|Drug|dacarbazine|
101287|NCT00062426|Drug|leucovorin calcium|
101288|NCT01390584|Drug|doxorubicin hydrochloride|
100458|NCT01366300|Other|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
100459|NCT00060294|Biological|rituximab|
100766|NCT01369316|Procedure|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
100767|NCT01369316|Procedure|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
100768|NCT01369329|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
100769|NCT01369329|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
100770|NCT01369329|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
100771|NCT01389726|Behavioral|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
100772|NCT01389726|Behavioral|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader & 1 peer leader over the course of 11 weeks.
100773|NCT00062348|Procedure|conventional surgery|
100774|NCT01389739|Other|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
100775|NCT01389752|Drug|LY2216684|Administered orally
100776|NCT01389752|Drug|Activated Charcoal|Administered orally
100777|NCT01389765|Drug|LY2216684|Administered orally
100778|NCT01389778|Drug|Metformin ER|Metformin ER 1500 mg for 12 weeks
100779|NCT01389778|Drug|Metformin|
100780|NCT01389791|Drug|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
100781|NCT01389791|Drug|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
100782|NCT01389791|Drug|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
100534|NCT01363986|Drug|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
100535|NCT01363999|Drug|atorvastatin|single dose of atorvastatin on day 1
100536|NCT00059982|Drug|perifosine|
100537|NCT01363999|Drug|dalcetrapib|single dose of dalcetrapib on day 1
100538|NCT01364012|Drug|bevacizumab [Avastin]|15 mg/kg intravenously (iv) on Day 1 of each 3-week cycle
100539|NCT01364012|Drug|carboplatin|AUC 6.0 iv on Day 1 of each 3-week cycle, up to 6 cycles
100540|NCT01364012|Drug|paclitaxel|175 mg/m2 iv on Day 1 of each 3-week cycle, up to 6 cycles
100541|NCT01366339|Drug|Oral placebo|
100542|NCT01366352|Drug|MNTX tablet (Formulation 1)|
100543|NCT01366352|Drug|MNTX tablet (Formulation 2)|
100839|NCT01387555|Biological|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
100840|NCT01387555|Other|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
100841|NCT01387568|Drug|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg−1.h−1. and were continued up to 6 hours postoperatively
100842|NCT01387568|Drug|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg−1.h−1,and were continued up to 6 hours postoperatively
100843|NCT01387594|Procedure|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
100844|NCT00062205|Drug|imatinib mesylate|
100845|NCT01387594|Drug|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
100846|NCT01387607|Drug|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
100847|NCT01387607|Drug|placebo|Placebo, twice daily
100848|NCT01387620|Drug|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
100304|NCT01370889|Other|laboratory biomarker analysis|Correlative studies
100305|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
100306|NCT01370902|Drug|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
100307|NCT00060619|Behavioral|thermal biofeedback|
100308|NCT01370902|Drug|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
100309|NCT01370902|Drug|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
100310|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
100311|NCT01370902|Drug|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
100312|NCT01370915|Drug|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
100313|NCT01370915|Drug|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
100625|NCT01364155|Drug|Placebo capsules|
100626|NCT00060008|Radiation|fludeoxyglucose F 18|
100627|NCT01364181|Drug|Udenafil|Udenafil 50mg qd po
100628|NCT01364194|Drug|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
100629|NCT01364194|Drug|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
100630|NCT01364207|Other|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
100631|NCT01364207|Other|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
100632|NCT01364220|Drug|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
100633|NCT01364220|Other|Placebo tablet|Placebo tablet, once daily, for 14 days
100634|NCT01364233|Device|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
101289|NCT01390584|Drug|etoposide|
101290|NCT01390584|Drug|prednisone|
101291|NCT01390584|Drug|procarbazine hydrochloride|
101292|NCT01390584|Drug|vinblastine|
101293|NCT01393327|Behavioral|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
101294|NCT01393340|Drug|Omalizumab|Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.
Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab.
101295|NCT01393340|Drug|Placebo|Placebo
101296|NCT01393353|Other|Cognitive Training|
101297|NCT00062738|Other|placebo|matching placebo
101298|NCT01393353|Other|computer game|
101299|NCT01393366|Other|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
101300|NCT01393366|Other|Usual Practice|None, only usual practice.
101301|NCT01393392|Behavioral|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
101302|NCT01393392|Behavioral|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
101303|NCT01393405|Drug|Methotrexate|Induction period (week 1-16) (Open label):
25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily
Maintenance period (week 17-48) (Randomization):
25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
or
Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
101304|NCT01393444|Device|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
101305|NCT01393457|Drug|levodopa/carbidopa|800/200 mg/d
101306|NCT01393457|Drug|Ropinirole|2 or 4 mg/d
101307|NCT01393457|Drug|Placebo|sugar pill
100783|NCT01389817|Device|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
100784|NCT00062374|Drug|irinotecan hydrochloride|Given IV
101059|NCT01385358|Procedure|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
101060|NCT01385371|Biological|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
101061|NCT01385371|Biological|Placebo for SCH 697243|One dissolving tablet sublingually once daily
101062|NCT01385384|Device|NeuRx RA/4 diaphragmatic pacemaker|Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.
The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.
Sites that provide the optimal response (greater region and magnitude) are noted.
Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed.
101063|NCT01385397|Other|Preceptorship and virtual community|
101064|NCT01385410|Behavioral|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
101065|NCT00062036|Biological|therapeutic tumor infiltrating lymphocytes|
101066|NCT01385423|Drug|Preparative Regimen|Fludarabine 25 mg/m^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (*if < 4 months from prior transplant, omit day -4 dose)
101067|NCT01385423|Biological|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
101068|NCT01385449|Procedure|interscalene catheter|interscalene catheter
101069|NCT01385449|Procedure|interscalene block|interscalene block
101070|NCT01385475|Behavioral|RT|8 week RT Intervention
101071|NCT01385488|Behavioral|self-monitoring of arm volume|bioelectrical impedance
101072|NCT01385501|Other|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
100849|NCT01387633|Other|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
100850|NCT01389882|Procedure|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
100851|NCT01389895|Drug|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
100852|NCT01389895|Drug|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
101127|NCT01392638|Drug|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
101128|NCT00062673|Drug|Duloxetine|
101129|NCT01392677|Drug|dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
101130|NCT01392677|Drug|placebo|matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
101131|NCT01392690|Behavioral|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
101132|NCT01392703|Drug|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
101133|NCT01392703|Drug|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
101134|NCT01392703|Drug|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
100635|NCT01364233|Device|MotifMESH|Surgical mesh
100636|NCT01364246|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
100637|NCT01366521|Biological|Mepolizumab|Monoclonal antibody
100638|NCT00060307|Other|laboratory biomarker analysis|Correlative studies
100639|NCT01366534|Biological|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
100640|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
100641|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
100642|NCT01366547|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
100643|NCT01366547|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
100644|NCT01366547|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
100645|NCT01366560|Drug|Active|GSK962040 125mg
100646|NCT01366560|Drug|Placebo|Matching Placebo
100647|NCT01366573|Drug|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
100935|NCT01387750|Other|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
100936|NCT01387750|Other|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
100937|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
100938|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
100939|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
100940|NCT01390025|Biological|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
100380|NCT01368653|Drug|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
100381|NCT01368666|Device|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
100382|NCT01368679|Procedure|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
100383|NCT01368692|Procedure|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
100384|NCT01368692|Procedure|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
100385|NCT01368705|Dietary Supplement|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
100386|NCT01368705|Dietary Supplement|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
100387|NCT01368705|Dietary Supplement|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
100388|NCT00060411|Drug|oxaliplatin|Given IV
100389|NCT01368718|Procedure|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
100390|NCT01368731|Procedure|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
100391|NCT01368744|Device|OSNA Breast Cancer System|For in vitro diagnostic use only.
The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).
Groups: OSNA Breast Cancer System
100392|NCT01368757|Drug|Revlimid|Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients
The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.
Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen.
100393|NCT01368770|Other|Coronary CTA|Coronary CTA using standard protocols
100394|NCT01368770|Other|Stress MPI SPECT|Stress MPI using standard protocols
100395|NCT01368783|Drug|atazanavir|400 mg/day for 2 days
101073|NCT01385527|Behavioral|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
101074|NCT01385527|Drug|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
101075|NCT01385540|Behavioral|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
101368|NCT01390597|Other|laboratory biomarker analysis|
101369|NCT01390623|Drug|Ceftriaxone|Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.
The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria.
101370|NCT01390649|Biological|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
101371|NCT01390662|Dietary Supplement|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
101372|NCT01390662|Dietary Supplement|placebo|one tablet of sugar pill pr. day, for 24 weeks.
101373|NCT00062439|Drug|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 & 36. In any appropriate vehicle over 60 minutes
101374|NCT01390701|Device|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
101375|NCT01390701|Drug|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
101376|NCT01390714|Drug|E3710|Arm A:
E3710 40 mg→RPZ 10 mg→E3710 20 mg
RPZ 10 mg→E3710 20 mg→E3710 40 mg
E3710 20 mg→E3710 40 mg→RPZ 10 mg
Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration.
101377|NCT01390714|Drug|E3710|Arm B:
E3710 40 mg→E3710 80 mg→EPZ 40 mg
E3710 80 mg→EPZ 40 mg →E3710 40 mg
EPZ 40 mg→E3710 40 mg→E3710 80 mg
Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration.
101378|NCT01390727|Device|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
101379|NCT01390727|Other|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
101380|NCT01390753|Dietary Supplement|Human donor milk|
101381|NCT01390766|Drug|Azathioprine|
103288|NCT00060983|Procedure|Functional electrical stimulation|
103289|NCT01373801|Device|Control|Standard packing gauze roll bandage.
103290|NCT01373827|Device|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
103561|NCT01404988|Other|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
103562|NCT00064025|Procedure|neoadjuvant therapy|
103563|NCT01405014|Behavioral|Hold Me Tight|Relationship enhancement group
103564|NCT01405027|Procedure|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
103565|NCT01405027|Other|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
103566|NCT01405053|Drug|Rufinamide|rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
103567|NCT01407276|Drug|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
103568|NCT01407289|Drug|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
103569|NCT01407302|Other|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
103570|NCT01407315|Device|GlucoMenDay|Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.
An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.
This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once.
103571|NCT00064181|Drug|fluorouracil|
103572|NCT01407315|Device|GlucoMenDay|Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.
Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.
This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice.
103573|NCT01407341|Procedure|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
107055|NCT01437462|Drug|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
107056|NCT01437475|Biological|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
107057|NCT01437488|Drug|Cabazitaxel|Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days
Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion
Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator
107058|NCT01439841|Other|Control|No intervention
107059|NCT01439854|Drug|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
107060|NCT00001122|Drug|Stavudine|
107061|NCT00067366|Behavioral|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
107062|NCT01439854|Drug|Placebo|Patients are treated with placebo
107389|NCT01437943|Drug|Placebo|Take 1 tablet (0 mg) daily for 180 days.
107390|NCT01437969|Genetic|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
107391|NCT01437982|Drug|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
107392|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
107393|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
107394|NCT01437995|Drug|Fluticasone Diskus|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
107395|NCT01438008|Drug|24% sucrose po solution|CHEO pharmacy department will provide syringes labeled "NICU Pain Relief Study" containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure.
107396|NCT01438008|Drug|Placebo po|CHEO pharmacy department will provide syringes labeled "NICU Pain Relief Study" containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure
107397|NCT00067093|Drug|Unfractionated heparin|
107398|NCT01438021|Other|pharmacological study|Correlative studies
106654|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
106655|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
106656|NCT01441388|Drug|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
106657|NCT01441388|Drug|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
106658|NCT01441401|Drug|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
106659|NCT01441414|Biological|PF-04856884|15 mg/kg/week intravenously [IV] until toxicity or disease progression
106660|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
106661|NCT00067613|Other|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
106662|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
106663|NCT01441427|Drug|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
106664|NCT01441427|Drug|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
106665|NCT01441427|Drug|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
106666|NCT01441427|Drug|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
106667|NCT01441427|Drug|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
106668|NCT01441440|Drug|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
106981|NCT01439789|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
106982|NCT01439789|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
106983|NCT01439802|Device|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
106984|NCT01439815|Drug|Fluticasone Propionate Nasal Spray|50 mcg QD
106985|NCT01439815|Drug|Saline Nasal Spray|two sprays in each nostril once daily
107316|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
107317|NCT01437852|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal keratinocytes (NIKS®).
107318|NCT01437865|Drug|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
107319|NCT01437878|Drug|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
107320|NCT01437878|Drug|Placebo|matching placebo
107321|NCT01437904|Procedure|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
107322|NCT01437904|Procedure|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
107323|NCT01437917|Other|20% amylose bread|20% amylose bread
107324|NCT01437917|Dietary Supplement|10% amylose bread|10% amylose bread
107325|NCT01437917|Dietary Supplement|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
107326|NCT00067093|Drug|LMW heparin|
107327|NCT01437930|Dietary Supplement|n-3 PUFA|products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder
linseed oil (20g/d)(PPM, Magdeburg)
echium oil (20g/d) (HARKE Nutrition)
microalgae powder(12g/d)(HARKE Nutrition)
107328|NCT01440283|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
106450|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
106451|NCT01438697|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
106452|NCT01438710|Drug|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
106453|NCT01438710|Drug|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
106454|NCT01438723|Drug|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
106724|NCT01439308|Drug|Placebo|SB-705498 placebo
106725|NCT01439308|Drug|SB-705498|12mg intranasal SB-705498
106726|NCT00067301|Drug|Polyunsaturated Fatty Acids (PUFA)|
106727|NCT01439321|Biological|Eltrombopag|Switched to Eltrombopag
106728|NCT01439321|Biological|Romiplostim|Switched to Romiplostim
106729|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
106730|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
106731|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
106732|NCT01439347|Drug|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m2 (without any dose cap) as an IV infusion over 60 minutes
106733|NCT01439347|Drug|Vincristine Sulfate Injection (VSI)|1.4 mg/m2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes
106734|NCT01441596|Drug|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
106735|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
106736|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
107399|NCT01438021|Drug|methotrexate|Given intraventricularly
107400|NCT01438034|Drug|kisspeptin 112-121|0.24 nmol/kg
107401|NCT01438060|Drug|Aripiprazole (BMS-337039)|Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks
Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks
107402|NCT01438060|Drug|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
107403|NCT01438073|Drug|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
107404|NCT01438073|Drug|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
107405|NCT01438086|Drug|mecasermin|Intracoronary bolus
107406|NCT01438086|Drug|mecasermin|Intracoronary bolus
107407|NCT01438086|Drug|0.9% sodium chloride injection|Intracoronary bolus
107408|NCT00067093|Drug|Vitamin K antagonist (VKA)|
106518|NCT01434576|Biological|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
106519|NCT01434576|Biological|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
106520|NCT01436383|Other|Hypoxic exposure|Hypoxic exposure
106521|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
106522|NCT01436396|Biological|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
106523|NCT01436396|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
106524|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
106525|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months
106526|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
106527|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
106528|NCT01436396|Biological|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
106669|NCT01441440|Drug|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
106907|NCT01441518|Other|Home care|Home care, sometimes called "ambulatory care" or "outpatient", was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia .
106908|NCT01441518|Other|Hospital care|Hospital care, sometimes called "acute care", was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.
The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.
All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists.
106909|NCT01441531|Drug|gabapentin 600 mg po|Given one hour before surgery
106910|NCT01441531|Drug|Placebo pill given one hour before surgery|Placebo pill given
106911|NCT00067639|Drug|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
106912|NCT01441544|Behavioral|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
106913|NCT01441557|Drug|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
106914|NCT01441570|Drug|Nebivolol|Subject will take nebivolol daily for 12 weeks.
106915|NCT01441570|Drug|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
106916|NCT01441583|Device|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
106917|NCT01441583|Device|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
106918|NCT01441596|Drug|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
106919|NCT01435109|Behavioral|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
106920|NCT01435109|Behavioral|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
107329|NCT01440309|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
107330|NCT01440309|Drug|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
107331|NCT01440322|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
107332|NCT01440322|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
107333|NCT00067444|Drug|Paroxetine CR|
107334|NCT01440335|Drug|Oral R,R'-Fenoterol|
107335|NCT01440335|Drug|Oral Racemic Fenoterol|
106442|NCT01436305|Drug|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
106443|NCT01436331|Other|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
106444|NCT01436331|Behavioral|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
106445|NCT01436357|Biological|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10^8 plaque forming units (pfu) intramuscularly on day 56.
106446|NCT01436357|Biological|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose, intramuscularly on day 0.
106447|NCT01436357|Other|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
106448|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
106449|NCT00067002|Procedure|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
106737|NCT00067639|Procedure|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
106738|NCT01441622|Device|AL539 (SRETT)|recording data with AL539 (SRETT)
106739|NCT01441635|Other|Placebo|Placebo
106740|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 1
106741|NCT01441635|Other|Placebo|Placebo
106742|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 2
106743|NCT01441635|Drug|Elagolix Dose 1 plus estradiol/norethindrone acetate|Elagolix Dose 1 plus estradiol/norethindrone acetate
106744|NCT01441635|Other|Placebo|Placebo
106745|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 3
106746|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 4
106986|NCT01439828|Drug|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
106987|NCT01439841|Dietary Supplement|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
106988|NCT01439841|Dietary Supplement|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
106989|NCT01441765|Biological|DC/RCC fusion vaccine|Vaccination once per cycle on Day 8 of treatment cycles 2-4
106990|NCT00067665|Other|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
106991|NCT01441778|Drug|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
106992|NCT01441778|Drug|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
106993|NCT01441791|Procedure|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
106994|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
106529|NCT00067002|Procedure|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
106530|NCT01436396|Biological|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
106531|NCT01436396|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
106532|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
106533|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
106534|NCT01436409|Other|echography|echography during labor
106535|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
106536|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
106537|NCT01436422|Biological|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
106538|NCT01436435|Device|Jetstream Atherectomy System|Atherectomy
106799|NCT01439360|Biological|Varivax/ProVarivax|Intramuscular injection administered to subjects more than 12 months of age
106800|NCT01439360|Biological|Varilrix|Subcutaneous injection administered to subjects more than 12 months of age
106801|NCT01439373|Drug|GSK2336805|Active Investigational Drug
106802|NCT01439373|Drug|Pegylated interferon alfa-2a|Standard of Care drug
106803|NCT01439373|Drug|Ribavirin|Standard of Care drug
106804|NCT01439373|Drug|GSK2336805 Matching Placebo|Placebo of Investigational Drug
106805|NCT01439386|Procedure|Catheter ablation|PVAI with or without CTI ablation
106806|NCT01439386|Procedure|Catheter ablation|CTI ablation only
106807|NCT01439399|Drug|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
106808|NCT01439399|Drug|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
106921|NCT01435109|Behavioral|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
106922|NCT01435122|Drug|Axitinib|Axitinib Administration as outlined in Arm description
106923|NCT01435135|Biological|ALVAC-HIV|1 mL per injection containing 10^6 CCID50/dose administered
107254|NCT01440270|Drug|Neo-adjuvant Erbitux-based chemotherapy|Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks
Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Arms: Neo-adjuvant Erbitux-based chemotherapy
107255|NCT01433432|Drug|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
107256|NCT01433445|Drug|panobinostat|Given 3 times a week, every other week in 28-day cycles.
107257|NCT01433445|Drug|ruxolitinib|Given twice daily in 28-day cycles.
107258|NCT01433458|Drug|RLX030A|RLX030 is administered as a continuous 24 hour infusion
107259|NCT00066729|Biological|NY-ESO-1 peptide vaccine|
107260|NCT01433471|Drug|Trichuris suis ova|2,500 eggs by mouth every two weeks for 12 weeks
107261|NCT01433484|Behavioral|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
107262|NCT01433484|Behavioral|Maintenance of Weight Loss--Experimental|
107263|NCT01433497|Drug|masitinib|6 mg/kg/day
107264|NCT01433497|Drug|placebo|masitinib matching placebo
107265|NCT01433510|Drug|Grazax|1 tablet/day - pre and co-seasonal
107266|NCT01433523|Drug|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
107267|NCT01433523|Drug|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
107268|NCT01433523|Drug|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
103236|NCT01376557|Drug|Placebo|Subjects will receive placebo once daily.
103237|NCT01376570|Behavioral|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. The voucher for the first drug-free urine is worth $2.50, and with each subsequent drug-free urine, the voucher increases by $2.50. When participants have urines with opiates or cocaine, the value of the voucher is reset back to baseline ($2.50). The maximum possible earnings for achieving continued abstinence over the intervention period is $1320. The vouchers are part of the intervention, they are not participant compensation.
103505|NCT01409564|Drug|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
103506|NCT01409590|Behavioral|Exercise program|Homogenous exercise program in local fitness centers
103507|NCT01409590|Behavioral|Diet|Weigh loss diet program prescribed by a professional nutritionist
103508|NCT00064337|Drug|thalidomide|
103509|NCT01409603|Drug|darexaban|oral
103510|NCT01409603|Drug|Naproxen|oral
103511|NCT01409616|Drug|darexaban|oral
103512|NCT01409616|Drug|darexaban (double dose)|oral
103513|NCT01409616|Drug|Acetyl Salicylic Acid|oral
103514|NCT01409616|Drug|clopidogrel|oral
103515|NCT01409629|Behavioral|Computer game|Participants will play a computer game
103516|NCT01409642|Behavioral|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
103517|NCT01409642|Behavioral|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
103518|NCT01409642|Behavioral|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
103519|NCT00064337|Procedure|peripheral blood stem cell transplantation|
103520|NCT01409655|Behavioral|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
106995|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
106996|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
106997|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
106998|NCT01441817|Procedure|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
106999|NCT01441830|Device|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
107000|NCT01441843|Drug|Lorazepam|Once 1mg <75kg body weight, 1.5mg 75kg and >75kg body weight, IV, before surgery
107001|NCT00067678|Drug|soy protein|
107002|NCT01441843|Drug|NaCl 0.9% (Sodium Chloride)|Once 1ml <75kg body weight, 1.5ml 75kg or >75kg body weight, IV, before surgery
107003|NCT01441856|Procedure|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
107336|NCT01440348|Procedure|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
107337|NCT01440361|Drug|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
107338|NCT01440361|Drug|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
107339|NCT01440374|Drug|eltrombopag|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
107340|NCT01440374|Drug|placebo|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
107341|NCT01440387|Biological|FLULAVAL® QUADRIVALENT|Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
107342|NCT01440400|Procedure|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
107343|NCT01440413|Biological|Blood and tumor sample|Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.
Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional).
107344|NCT00067457|Drug|alosetron|
103574|NCT01407341|Procedure|bone graft|Receive beta tricalcium-phosphate bone graft
103575|NCT01407341|Procedure|quality-of-life assessment|Ancillary studies
103576|NCT01407341|Other|questionnaire administration|Ancillary studies
103577|NCT01407354|Device|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
103870|NCT01410357|Behavioral|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
103871|NCT01410370|Radiation|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
103872|NCT01410370|Drug|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
103873|NCT01410383|Drug|Placebo|Tablets taken daily
103874|NCT01410383|Drug|Eprotirome|Tablets taken daily
103875|NCT01410383|Drug|Eprotirome|Tablets taken daily
103876|NCT01410409|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
103877|NCT01410409|Drug|Paracetamol|1 g x 4/day
103878|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
103879|NCT01410409|Drug|Burana|400 mg x 3/day for three weeks
103880|NCT01410409|Drug|Pantoprazol|20mg x 1/day for three weeks
103881|NCT01412671|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
103882|NCT01412684|Procedure|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
103883|NCT01412697|Behavioral|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
103884|NCT01412710|Drug|Cholecalciferol|4000 IU or 6000 IU given once daily, orally for 6 months.
103885|NCT01412723|Other|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
107269|NCT01433549|Device|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
107270|NCT00066729|Biological|incomplete Freund's adjuvant|
107271|NCT01433549|Device|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
107272|NCT01433562|Drug|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
106381|NCT01438671|Procedure|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
106382|NCT00067171|Behavioral|Behavior Therapy|
106383|NCT01438671|Procedure|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
106384|NCT01438684|Drug|RPh201|400 microliter s.c. twice a week for 3 months
106385|NCT01438684|Drug|Saline|400 microliter Saline solution s.c. twice a week for 3 months
106386|NCT01438697|Behavioral|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
106387|NCT01440933|Drug|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
106388|NCT01440933|Drug|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
106389|NCT01440946|Drug|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
106390|NCT01440946|Drug|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
103521|NCT01409668|Dietary Supplement|L. Amylovorus|L. Amylovorus
103522|NCT01409668|Dietary Supplement|L. Fermentum|L. Fermentum
103523|NCT01409694|Drug|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
103524|NCT01409694|Drug|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
103816|NCT01412658|Dietary Supplement|Glycerol placebo|Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
A food diary is maintained daily.
103817|NCT01405391|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
103818|NCT01405404|Behavioral|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
103819|NCT01405404|Other|Parent Training|12-session group on parenting skills and child behavior management
103820|NCT00064051|Drug|triapine|
103821|NCT01405417|Procedure|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
103822|NCT01405430|Biological|Bevacizumab + blood samples|Bevacizumab will be administered according to investigators appreciation.
Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.
103823|NCT01405456|Drug|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
103824|NCT01405456|Other|placebo and lifestyle|placebo pill daily and lifestyle counseling
107345|NCT01440426|Procedure|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
107346|NCT01440426|Device|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
107347|NCT01440439|Drug|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
107348|NCT01440439|Drug|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
107349|NCT01433601|Behavioral|Enhanced Treatment Support (ETS)|An "internal supporter" - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. An"external supporter" - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup.
107350|NCT01433614|Drug|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
107351|NCT01433614|Drug|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
107352|NCT00066742|Drug|tirapazamine|Given IV
107353|NCT01433614|Drug|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
106455|NCT01438723|Drug|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
106456|NCT01438736|Drug|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
106457|NCT00067184|Device|Toitu 320/325|Fetal monitor
106458|NCT01438736|Drug|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
106459|NCT01438749|Drug|Placebo|Single dose
106460|NCT01438749|Drug|RO4917838|Single doses (3 dose levels)
106461|NCT01438749|Drug|diazepam|Single dose
106462|NCT01438762|Behavioral|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
103886|NCT01412723|Other|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
103887|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
103888|NCT00064714|Drug|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
103889|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
103890|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
106887|NCT01439568|Drug|Carboplatin|Administered intravenously
106888|NCT00067340|Drug|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
106889|NCT01439568|Drug|Etoposide|Administered intravenously
106890|NCT01439581|Device|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
106891|NCT01439594|Device|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Esophagus with OFDI system
106892|NCT01439607|Other|Bone marrow and blood sampling|Bone marrow and blood sampling
106893|NCT01439620|Device|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of biliary tract with OFDI system
106894|NCT01439633|Device|MGH Optical Frequency Domain Imaging (OFDI) system|Imaging of esophagus with OFDI system
106895|NCT01439646|Other|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
106896|NCT01439659|Behavioral|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
106897|NCT01439659|Dietary Supplement|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
106898|NCT01441440|Drug|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
106899|NCT01441453|Procedure|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
106900|NCT00067626|Dietary Supplement|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
106391|NCT01440959|Drug|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
106392|NCT01440972|Other|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
106393|NCT01440972|Other|low intensity resistance training|low intensity resistance training without partial blood flow restriction
106394|NCT00067548|Drug|EKB-569|
106395|NCT01440985|Drug|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
106396|NCT01440985|Drug|Nicotine|Nicotine gum 4 mg, Lot number GC962A
106397|NCT01440985|Drug|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
106670|NCT01434732|Procedure|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
106671|NCT01434745|Drug|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5mg/kg/day
106672|NCT01434745|Dietary Supplement|Lactose|Lactose will be administered in a capsule formula.
106673|NCT01434810|Procedure|Window tinting film for filtered sunlight phototherapy|Six hours per day of filtered sunlight phototherapy for 1 to 10 days.
106674|NCT01434810|Device|Conventional phototherapy|Conventional phototherapy unit will be used for infants randomized to this arm for 1 to 10 days.
106675|NCT01434823|Other|Nocturnal coverage|The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.
For the Intensivist Sleep and Work sub-study:
Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage.
106676|NCT01434836|Other|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
106677|NCT00066794|Drug|cytarabine|ind: 200 mg/m2/d cont IV days 2-74
106678|NCT01434836|Other|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
106679|NCT01434849|Drug|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
106680|NCT01434849|Drug|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
106681|NCT01434862|Drug|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
103825|NCT01405469|Other|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
103826|NCT01405482|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
103827|NCT01405482|Other|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
103828|NCT01405495|Procedure|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
103829|NCT01405508|Drug|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Phase
103830|NCT01405508|Drug|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Phase
103831|NCT00064064|Drug|gemcitabine hydrochloride|
102923|NCT00061867|Drug|pegylated liposomal doxorubicin hydrochloride|
102924|NCT01381315|Procedure|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur <3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
102925|NCT01381315|Procedure|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative—that the lymphedema rate is <0.13 for subjects undergoing ALND—if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
102926|NCT01381341|Drug|linifanib|QD on Day 1 of Periods 1 and 2
102927|NCT01383720|Device|Transcatheter aortic valve implantation with the Lotus Valve System|The Lotus Valve System consists of the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter, a delivery system for guidance and placement of the Lotus Valve.
102928|NCT01383733|Drug|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
102929|NCT01383746|Device|Yttrium microsphere injection|Radiation therapy
106463|NCT01438762|Other|Information, education and physiotherapy|Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.
In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class.
106464|NCT01438775|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
106465|NCT01438788|Other|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
106466|NCT01438801|Drug|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS <0).
106467|NCT01438814|Drug|metformin placebo|metformin placebo tablets 500mg
106468|NCT00067210|Device|Head and Neck Cooling System|
106469|NCT01438814|Drug|linagliptin placebo|linagliptin placebo tablets 5mg
106470|NCT01438814|Drug|metformin|metformin tablets 500mg
106471|NCT01441076|Drug|Anakinra|Anakinra/Kineret[registered] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
106472|NCT01441102|Drug|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
106473|NCT01441115|Procedure|Radiation Therapy|
106747|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 5
106748|NCT00067652|Behavioral|Education and awareness about body image issues.|
106749|NCT01441635|Drug|Elagolix Dose 2 plus estradiol|Elagolix Dose 2 plus estradiol
106750|NCT01441635|Drug|Elagolix Dose 2 plus cyclical progesterone|Elagolix Dose 2 plus cyclical progesterone
106751|NCT01441648|Other|contact lens wear|tinted contact lens wear
106752|NCT01441674|Behavioral|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
106753|NCT01441687|Other|laboratory biomarker analysis|Correlative studies
106901|NCT01441466|Other|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
106902|NCT01441479|Device|In Vitro Diagnostic Device aid in diagnosing|
106903|NCT01441492|Procedure|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
106904|NCT01441492|Procedure|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
106905|NCT01441505|Drug|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
106906|NCT01441505|Drug|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
107158|NCT01440088|Drug|TH-302 in Combination with Doxorubicin|300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.
Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.
Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.
Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302.
107159|NCT01440088|Drug|Doxorubicin|Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.
Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.
Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
107160|NCT00067392|Procedure|Dental Implant|Dental Implant 4 month time frame
107161|NCT01440101|Drug|Natalizumab (BG00002)|
107162|NCT01440101|Drug|Placebo|
107163|NCT01440114|Drug|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
107164|NCT01440114|Drug|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
107165|NCT01440127|Drug|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
107166|NCT01440140|Other|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
107167|NCT01440140|Other|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
107168|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
107169|NCT01433263|Drug|BYM338 active drug|
107170|NCT01433263|Drug|Placebo|
106682|NCT01434862|Device|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
106683|NCT01434862|Drug|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
106684|NCT01434888|Drug|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
106685|NCT01434888|Drug|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
106686|NCT01434888|Drug|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
106687|NCT01434901|Drug|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
106924|NCT01435135|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
106925|NCT01435135|Biological|ALVAC-HIV Placebo|1 ml per injection
106926|NCT01435135|Biological|AIDSVAX B/E Placebo|1 ml per injection
106927|NCT01435148|Procedure|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
106928|NCT01435161|Drug|Nifedipine,|Nifedipine 30-60mg/day
106929|NCT00066807|Drug|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
106930|NCT01435161|Drug|Telmisartan|Telmisartan 80-160mg/day
106931|NCT01435174|Drug|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
106932|NCT01435174|Procedure|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
106933|NCT01435174|Procedure|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
106934|NCT01435200|Drug|Intravenous iron|Intravenous iron 200 mg add in 0.9% NSS 100 ml infused within 15 minutes after every cycles of chemotherapy
106935|NCT01435213|Drug|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
106936|NCT01435213|Drug|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
102930|NCT01383759|Drug|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|The treatment has three phases:
1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks.
102931|NCT01383772|Procedure|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
102932|NCT01383785|Other|Intracoronary direct injection|Abciximab bolus dosage: 0,125 mg/kg.
Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory.
102933|NCT01383785|Other|Intracoronary and distal injection by aspiration device|Abciximab bolus dosage: 0,125 mg/kg.
Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C.
102934|NCT01383785|Other|Intracoronary distal injection by aspiration catheter device|Abciximab bolus dosage: 0,125 mg/kg.
Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter.
102935|NCT00001087|Drug|Levocarnitine|
102936|NCT00061945|Biological|alemtuzumab|Given SC
102937|NCT01383798|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
103238|NCT01376570|Behavioral|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
103239|NCT01376596|Behavioral|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
103240|NCT01376596|Behavioral|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
103241|NCT01376700|Biological|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
106754|NCT01441687|Procedure|transrectal prostate biopsy|Undergo prostate biopsy
106755|NCT01441700|Procedure|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
106756|NCT01441752|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
106757|NCT01441765|Drug|CT-011|CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
106758|NCT01434901|Drug|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
106759|NCT01434914|Drug|octenisept®|Cutaneous solution
106760|NCT01434914|Drug|Placebo|Cutaneous use
106761|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
106762|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
106763|NCT01434940|Other|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
106764|NCT01434953|Behavioral|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
107004|NCT01441856|Procedure|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
107005|NCT01441869|Drug|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
107006|NCT01441869|Drug|Diabex|Extended release oral tablets, 1000 mg, single dose
107007|NCT01441869|Drug|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
107008|NCT01441869|Drug|Diabex|Extended release oral tablets, 500 mg, single dose
107009|NCT01441869|Drug|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
107171|NCT01433276|Drug|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
107172|NCT01433276|Drug|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
107173|NCT00066716|Procedure|conventional surgery|Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.
Operation will be performed within 6-12 hours from the last dose of celecoxib.
Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.
107174|NCT01433289|Drug|Polyphenon E|There will be three treatment arms, each consisting of 8 participants. Two participants in each study arm will be randomized to receive placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding arm will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each arm is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
107495|NCT01440582|Drug|Dexamethasone|Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.
Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.
Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle.
107496|NCT01440582|Behavioral|Symptom Questionnaire|Completed on day 1 of each cycle.
107497|NCT01440595|Drug|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
107498|NCT01440595|Drug|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
107499|NCT01440595|Drug|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
107500|NCT00001122|Drug|Didanosine|
107501|NCT00067496|Drug|Modafinil|
107502|NCT01440595|Drug|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
107503|NCT01440608|Drug|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
107504|NCT01440608|Drug|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
107505|NCT01440608|Dietary Supplement|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
107506|NCT01440621|Drug|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
106937|NCT01435213|Drug|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
106938|NCT01435213|Other|Cold pressor test|30-45 min cold pressor test of the foot
106939|NCT01435213|Drug|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
106940|NCT00066807|Procedure|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
106941|NCT01435213|Drug|Placebo|A single dose of placebo (capsules) administered orally
106942|NCT01435226|Drug|GS-5885|Drug: GS-5885 tablet
GS-5885 tablet, 90 mg, QD
106943|NCT01435226|Drug|GS-9451|Drug: GS-9451 tablet
GS-9451 tablet, 200 mg QD
106944|NCT01437098|Device|MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
106945|NCT01437111|Drug|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
107273|NCT01433562|Drug|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
107274|NCT01433575|Drug|RO4917838|10 mg single oral dose
107275|NCT01433575|Drug|RO4917838|20 mg single oral dose
107276|NCT01433588|Device|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
107277|NCT01433588|Other|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
107278|NCT01435707|Other|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
107279|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
107280|NCT01435707|Other|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
107281|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
107282|NCT01435720|Biological|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
107283|NCT01435720|Biological|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
103242|NCT01379170|Drug|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
103243|NCT01379183|Drug|Erythromycin|200 mg suspension
103244|NCT01379183|Drug|Placebo|200 mg suspension
103245|NCT01379183|Procedure|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
103246|NCT01379183|Other|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
103247|NCT01379196|Drug|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
103248|NCT00061633|Drug|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
103249|NCT01379209|Drug|RGI-2001|RGI-2001 is a liposomal formulation of the α-galactosylceramide class of compound [(2S,3S,4R)-1-o-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol]. RGI-2001 is provided as an intravenous administration after AHSCT is complete. A single administration of RGI-2001 will be used in this trial. The study will last for 101 days in total; 29 days for safety and 101 days for evaluation of GvHD.
103250|NCT01379222|Device|Endurant Stent Graft System|The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
103525|NCT01409694|Drug|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
103526|NCT01409707|Behavioral|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
103527|NCT01409707|Behavioral|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
103528|NCT01411956|Other|24-minute video episode of patient education TV sitcom "White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
103529|NCT00064649|Drug|Finasteride and Alfuzosin|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
107010|NCT01441882|Drug|Dasatinib|Dasatinib will be administered at a starting dose of 140 mg by mouth once daily. Tablets come in 50 mg and 20 mg. Thus, 4 tablets will be taken once daily (20mg + 20mg + 50 mg + 50 mg) for a total of 140 mg daily. Dasatinib should be taken around the same time each day.
107011|NCT01441908|Drug|Pravastatin|40mg or 80mg dose 28 days for 6 month period
107012|NCT01435226|Drug|tegobuvir|tegobuvir 30 mg BID
107013|NCT01435226|Drug|placebo to match tegobuvir|tegobuvir placebo BID
107014|NCT01435226|Drug|placebo to match RBV|Ribovirin placebo BID
107015|NCT01435226|Drug|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
107016|NCT01435239|Device|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
107017|NCT01435239|Device|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
107018|NCT01435252|Drug|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
107019|NCT00066807|Radiation|radiation therapy|Radiation therapy to the conserved breast is required. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields).
107020|NCT01435265|Behavioral|Standard nurse education|Standard-of-care education from a dermatology nurse on the proper use of adalimumab
107354|NCT01433627|Other|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
107355|NCT01433627|Other|trans-radial and long-term bivalirudin infusion|Trans-radial intervention: will be performed according to institutional guidelines and established local practice.
Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.
107356|NCT01433627|Other|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
107507|NCT01440621|Drug|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
107508|NCT01440634|Other|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
107509|NCT01433835|Other|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
107510|NCT01433861|Procedure|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
107511|NCT01433874|Procedure|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
107512|NCT01433874|Procedure|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
106611|NCT01436500|Drug|150mg Ifetroban Injection|Cohort 4: 150 mg Ifetroban Injection administered IV over 60 minutes once daily During 72-hr treatment period. Total of 3 doses of CTM will be administered.
106612|NCT01436500|Other|5% Dextrose in Water|5% Dextrose in Water
106613|NCT01436513|Drug|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
106614|NCT00067002|Drug|Melphalan|140 mg/m2 by vein on Day -8.
106615|NCT01436513|Drug|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
106616|NCT01436513|Drug|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
106617|NCT01436513|Drug|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
106618|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
106619|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
106620|NCT01436539|Drug|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
107284|NCT01435720|Biological|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
107285|NCT00066872|Drug|imiquimod|
107286|NCT01435720|Biological|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
107287|NCT01435746|Behavioral|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
107288|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
107289|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
107290|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
107291|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
107292|NCT01435759|Drug|Antidepressant + Placebo|oral, once daily for 8 weeks
107293|NCT01435772|Biological|BMN 701|GILT-tagged recombinant human GAA
106398|NCT01440998|Drug|Carboplatin|Given IV
106399|NCT01440998|Drug|Dasatinib|Given PO
106400|NCT01440998|Other|Laboratory Biomarker Analysis|Correlative studies
106401|NCT01440998|Drug|Paclitaxel|Given IV
106402|NCT01441011|Behavioral|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
106403|NCT01441011|Behavioral|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
106404|NCT01441024|Drug|DAS181|20 mg per day of DAS181-FO3 for 5 days
106405|NCT00067561|Drug|Alosetron|
106406|NCT01441024|Other|Placebo|20 mg per day of Lactose for 5 days
106407|NCT01441037|Drug|Danazol|
106408|NCT01441063|Drug|Zidovudine|Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)
106409|NCT01441063|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks
103530|NCT01411956|Other|Placebo video|The control group watched a 25-minute patient education video on depression.
103531|NCT01411969|Drug|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
103532|NCT01411995|Drug|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to IUD insertion
103533|NCT01411995|Drug|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to IUD insertion
103534|NCT01412008|Drug|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
103535|NCT01412034|Drug|CER-001|Biweekly infusion
103536|NCT01412060|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of 3.0 to 9.0 mg cariprazine during the open-label phase and then randomized when they will receive cariprazine or placebo
103537|NCT01412060|Drug|Placebo|Dose-matched placebo, once daily oral administration
103538|NCT01412073|Drug|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
103539|NCT01412073|Drug|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby & the placenta
103540|NCT00064662|Procedure|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
103832|NCT01405508|Drug|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Phase
103833|NCT01405508|Other|Placebo|100 mg twice daily (BID) for 7 days during Run-In Phase
103834|NCT01405521|Biological|Vaccine placebo (excipients only)|single oral dose,
103835|NCT01405521|Biological|Ty21a|3 oral doses, alternate days
103836|NCT01405521|Biological|M10ZH09 vaccine|single oral dose
103837|NCT01407770|Other|laboratory biomarker analysis|Genetic
103838|NCT01407770|Other|questionnaire administration|Genetic
107357|NCT01433627|Other|Trans-femoral and Short-term bivalirudin|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.
Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI.
107358|NCT01433627|Other|trans-femoral and long-term bivalirudin infusion|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.
Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.
107359|NCT01433627|Other|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
107360|NCT01433653|Behavioral|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
107361|NCT01433666|Drug|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
107362|NCT01433666|Drug|Placebo|Acute intervention: single administration, capsulated form.
107363|NCT01435798|Drug|Dex3Lido3|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107364|NCT01435798|Drug|Dex3Lido4|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107365|NCT00066885|Drug|calcitriol + docetaxel|
107366|NCT01435798|Drug|Dex4Lido1|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107367|NCT01435798|Drug|Dex4Lido2|All PO drugs given QID; all IV drugs delivered over 30 minutes.
106474|NCT01441115|Drug|ECI301|
106475|NCT01441128|Drug|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
106476|NCT00067574|Behavioral|Structured treatment interruption|
106477|NCT01441128|Drug|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
106478|NCT01441167|Biological|PfSPZ|
106479|NCT01441180|Drug|GS7977|drug intervention
106480|NCT01441180|Drug|RBV|drug intervention
106621|NCT01436539|Drug|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
106622|NCT01436565|Drug|MM-121 (SAR256212)|Pharmaceutical form:solution
Route of administration: Intravenous
106623|NCT01436565|Drug|SAR245408|Pharmaceutical form:tablet
Route of administration: oral
106624|NCT01436578|Drug|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
106625|NCT00001119|Drug|Lamivudine|
106626|NCT00067002|Drug|Thiotepa|5 mg/Kg by vein on Day -7.
106627|NCT01438970|Device|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
106628|NCT01438996|Biological|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
106629|NCT01439009|Drug|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
106630|NCT01439009|Drug|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
106631|NCT01439022|Behavioral|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
107175|NCT01433302|Procedure|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
107176|NCT01433315|Behavioral|sleep restriction|restricted sleep
107177|NCT01433328|Drug|Lidocaine|Lidocaine
107178|NCT01433328|Drug|Placebo|Placebo
107179|NCT01433354|Drug|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
107180|NCT01433367|Device|CerPass® Total Disc Replacement|Single level cervical disc disease
107181|NCT01433380|Drug|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
107182|NCT01433380|Drug|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
107183|NCT01433393|Drug|TAK-875|
106410|NCT01441063|Drug|Valganciclovir (VGC)|Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
106411|NCT01434264|Procedure|Energy healing|"Healer-Ringen", a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair.
106412|NCT01434277|Other|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
106413|NCT01434290|Radiation|hypofractionated radiation therapy|Given twice a week for 2½ weeks (36.25 fractions)
106414|NCT01434303|Drug|Entinostat|Given PO
106415|NCT01434303|Other|Laboratory Biomarker Analysis|Correlative studies
106416|NCT01434303|Drug|Lapatinib Ditosylate|Given PO
106417|NCT01434303|Biological|Trastuzumab|Given IV
106418|NCT01434316|Drug|Dinaciclib|Given IV
106419|NCT01434316|Other|Laboratory Biomarker Analysis|Correlative studies
106420|NCT01434316|Other|Pharmacological Study|Correlative studies
106421|NCT00066768|Other|pharmacological study|Correlative studies
106688|NCT00066794|Drug|daunorubicin hydrochloride|ind: 45 mg/m2/d cont IV days 2-74
106689|NCT01434901|Drug|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
106690|NCT01434901|Drug|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
106691|NCT01436604|Other|Cardiac MRI|The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.
After establishing a good quality ECG synchronization, the following sequences are carried out successively:
Sequences locating anatomical
T2 black blood (such as ESF)
rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex
T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage.
106692|NCT01436617|Other|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
103839|NCT01407770|Procedure|adjuvant therapy|Genetic
103840|NCT01407770|Procedure|assessment of therapy complications|Genetic
103841|NCT01407770|Procedure|quality-of-life assessment|Genetic
103842|NCT01407770|Radiation|3-dimensional conformal radiation therapy|Genetic
103843|NCT01407770|Radiation|breast irradiation|Genetic
103844|NCT01407770|Radiation|external beam radiation therapy|Genetic
103845|NCT01407770|Radiation|hypofractionated radiation therapy|Genetic
103846|NCT00064207|Procedure|adjuvant therapy|
103847|NCT01407770|Radiation|intensity-modulated radiation therapy|Genetic
103848|NCT01407770|Radiation|whole breast irradiation|Genetic
103849|NCT01407783|Behavioral|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
103850|NCT01407796|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|
103851|NCT01407796|Drug|[18F](+/-)NOS|
103852|NCT01407809|Device|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
103853|NCT01407822|Drug|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
103854|NCT01407822|Drug|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
102938|NCT01383798|Dietary Supplement|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
102939|NCT01383811|Other|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
106481|NCT01441193|Biological|HIV-1 Tat/delta-V2 Env combined vaccine|
106482|NCT01441193|Biological|HIV-1 delta-V2 Env vaccine|
106483|NCT01441193|Biological|HIV-1 Tat vaccine 7.5 microg|
106484|NCT01441193|Biological|HIV-1 Tat vaccine 30 microg|
106485|NCT01441206|Drug|rifampin|Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)
Cohort 1:
Dosing will be as follows:
GA at birth < 32 weeks - PNA < 14 days: 10 mg/kg QD GA at birth < 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA < 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD
106486|NCT01441219|Device|Colon 2|Ingest one colon 2 capsule
106487|NCT00067600|Behavioral|Diet with increased fruits, vegetables, and calcium|
106488|NCT01441232|Drug|LX4211|400 mg of LX4211 administered as two 200 mg tablets
106489|NCT01441232|Drug|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
106490|NCT01441245|Drug|furosemide infusion|Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
106491|NCT01441258|Behavioral|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
106492|NCT01441258|Behavioral|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
106493|NCT01441258|Behavioral|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
106494|NCT01434420|Genetic|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
106765|NCT01434953|Behavioral|Unlabeled prehypertension|A study physician informs subjects of their blood pressure level. The term "prehypertension" is not used and associated health risks are not discussed.
106766|NCT00066807|Drug|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
107184|NCT00066716|Procedure|neoadjuvant therapy|Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.
Operation will be performed within 6-12 hours from the last dose of celecoxib.
Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.
107185|NCT01433393|Drug|TAK-875|
107186|NCT01433393|Drug|Placebo|
107187|NCT01433406|Drug|TAK-875|
107188|NCT01433406|Drug|TAK-875|
107189|NCT01433419|Drug|TAK-875|
107190|NCT01433419|Drug|TAK-875|
107191|NCT01435499|Drug|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
107192|NCT01435512|Behavioral|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
107193|NCT01435538|Behavioral|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
107194|NCT01435551|Other|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
107195|NCT01435564|Behavioral|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
107196|NCT01435564|Behavioral|pedometer only|Participants in this group will receive only a pedometer.
107216|NCT01437644|Drug|botulinum toxin intramuscular injection|A single dose of active drug or placebo will be administered immediately prior to surgery.
The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo.
107217|NCT01437657|Drug|Placebo|matching RO4917523 placebo orally daily, 6 weeks
107218|NCT01437657|Drug|RO4917523|0.5 mg orally daily, 6 weeks
107219|NCT01437657|Drug|RO4917523|1.5 mg orally daily, 6 weeks
107220|NCT01437670|Drug|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
107221|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
106693|NCT01436630|Other|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
106694|NCT01436643|Drug|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
106695|NCT01436643|Drug|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
106696|NCT01436643|Drug|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
106697|NCT01436643|Drug|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
106698|NCT01436656|Drug|LGX818|
106699|NCT01436695|Device|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
106700|NCT01436721|Device|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
106701|NCT00067002|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
106702|NCT01436734|Other|Fasting glycemia|no intervention
106703|NCT01436734|Other|Hypoglycemia|Insulin induced hypoglycemia
106704|NCT01436747|Drug|Paricalcitol|2 micrograms daily, peroral, 24 weeks
106946|NCT01437137|Device|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
106947|NCT01437137|Device|i-gel™|Insertion of I-gel
106948|NCT01437150|Device|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
106949|NCT01437150|Procedure|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
106950|NCT00067015|Drug|goserelin acetate|
102940|NCT01383811|Other|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
102941|NCT01383824|Device|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
102942|NCT01383837|Behavioral|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
102943|NCT01383837|Behavioral|Health Promotion|Health Promotion Intervention
102944|NCT01383850|Other|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
102945|NCT01376063|Drug|FG-4592|FG-4592 on days 3,5,7,9
Rosiglitazone maleate on days 1 and 9
102946|NCT01376076|Drug|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
102947|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
102948|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
102949|NCT01376089|Drug|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
102950|NCT01376089|Drug|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
102951|NCT01376102|Drug|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
102952|NCT01376115|Drug|Nelarabine|
102953|NCT01376128|Drug|Paroxetine|
102954|NCT00061256|Drug|Calcium carbonate|
102955|NCT01376141|Drug|Sumatriptan|
102956|NCT01376154|Drug|Lamivudine|
102957|NCT01376167|Drug|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
103251|NCT01379235|Other|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
103252|NCT01379248|Device|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
106767|NCT01434966|Other|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
106768|NCT01434966|Other|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
106769|NCT01434966|Other|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
106770|NCT01435005|Other|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
106771|NCT01435005|Other|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
106772|NCT01435018|Drug|Coformulated EFV/FTC/TDF|The following ART regimens may be used:
EFV/FTC/TDF (Atripla®) 200 mg/300 mg/600 mg orally once daily at bedtime or
FTC/TDF 200 mg/300 mg (Truvada®) orally once daily at bedtime plus EFV (Stocrin®) 600 mg orally once daily at bedtime or
FTC/TDF 200 mg/300 mg (Truvada®) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or
FTC/TDF 200 mg/300 mg (Truvada®) orally once daily plus PI/r at standard dosing
106773|NCT01436812|Procedure|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
106774|NCT00067002|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6.
106775|NCT01436812|Procedure|positive end expiratory pressure|PEEP 0 cmH2O
106776|NCT01436825|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
106777|NCT01436838|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
106778|NCT01436851|Biological|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
106779|NCT01436864|Biological|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
107222|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
107223|NCT00067041|Drug|Remodulin (treprostinil sodium) Injection|
107224|NCT01437696|Other|placebo|No liquid cholecalciferol will be added to the food.
107225|NCT01437709|Biological|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
107226|NCT01437709|Other|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 & 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
107227|NCT01437722|Drug|1% SPL7013 Gel|vaginal gel
107228|NCT01437722|Drug|3% SPL7013 Gel|vaginal gel
107229|NCT01437722|Drug|placebo gel|vaginal gel
107230|NCT01437735|Drug|QAW039|QAW039 po
107231|NCT01437735|Drug|Comparator leukotriene receptor antagonist (LRTA)|leukotriene receptor antagonist (LRTA)
107232|NCT01437735|Drug|Placebo|Placebo
107233|NCT01437748|Drug|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
107234|NCT00067080|Drug|ICL670, deferoxamine|
107513|NCT01433874|Procedure|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
107514|NCT00000257|Drug|0% N2O and 20% N2O|
107515|NCT00001119|Drug|Abacavir sulfate|
107516|NCT00066742|Radiation|radiation therapy|Undergo radiation therapy
107517|NCT01433874|Procedure|Control group|Co2 was removed by passive exsufflation through the port site.
107518|NCT01433887|Drug|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
106951|NCT01437163|Device|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
106952|NCT01437163|Device|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
106953|NCT01437176|Device|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
106954|NCT01437176|Device|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
106955|NCT01437189|Drug|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
106956|NCT01437215|Device|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
106957|NCT01437228|Drug|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
106958|NCT01437228|Drug|placebo|NO İNTERVENTİON
106959|NCT01437254|Drug|CPERT|Single 340 MBq CPERT scan in first 10 subjects
106960|NCT01437254|Drug|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
106961|NCT00067015|Procedure|assessment of therapy complications|
106962|NCT01437267|Biological|Vi-CRM197 vaccine|
106963|NCT01437267|Biological|Pneumococcal conjugate vaccine|
106964|NCT01437267|Biological|Vi Polysaccharide (PS) vaccine|
106965|NCT01437280|Biological|CGTG-102|VP=virus particle
Dose Level 1: 3x10^10 VP/injection
Dose Level 2: 1x10^11 VP/injection
Dose Level 3: 3x10^11 VP/injection
Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).
Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.
The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.
Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used.
106966|NCT01437293|Drug|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
107294|NCT01435798|Drug|Dextromethorphan placebo, Lidocaine placebo|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107295|NCT01435798|Drug|Dex1Lido2|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107296|NCT00066872|Procedure|conventional surgery|
103253|NCT01379261|Procedure|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
103254|NCT01379274|Drug|Lenalidomide and azacitidine combination|lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.
Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy.
103255|NCT01379287|Drug|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
103256|NCT01379300|Drug|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
103257|NCT01379300|Drug|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
103258|NCT01379313|Procedure|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
103259|NCT01381666|Drug|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
103260|NCT01381679|Drug|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
103261|NCT01381692|Drug|Bortezomib|Given IV or SC
103262|NCT01381692|Drug|Dexamethasone|Given PO
103263|NCT00061893|Drug|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
103264|NCT01381692|Other|Laboratory Biomarker Analysis|Correlative studies
103265|NCT01381692|Other|Quality-of-Life Assessment|Ancillary studies
103266|NCT01381692|Biological|Rituximab|Given IV
103267|NCT01381692|Drug|Temsirolimus|Given IV
103268|NCT01381705|Biological|rituximab|
103269|NCT01381705|Genetic|DNA analysis|
103270|NCT01381705|Genetic|gene expression analysis|
103271|NCT01381705|Genetic|polymorphism analysis|
107021|NCT01435265|Behavioral|Additional nurse education|Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
107022|NCT01435278|Device|Glucosanol|2 tablets taken 3 times a day.
107023|NCT01435291|Drug|Advagraf Capsule|Other Names:
FK506E
MR4
tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent
107024|NCT01435291|Drug|Prograf Capsule|Other Names:
FK506E
MR4
tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent
107025|NCT01435304|Device|method of returning residual CPB blood ( Hemobag®)|The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
107026|NCT01435317|Device|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
107027|NCT01435330|Drug|BVS857|
107028|NCT01435330|Drug|Placebo|
107029|NCT01435343|Drug|fludarabine|30 mg/m2/day intravenously on days 1 to 4
107030|NCT00001119|Drug|Efavirenz|
107031|NCT00066846|Biological|bevacizumab|
107032|NCT01435343|Drug|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
107033|NCT01437319|Device|lotrafilcon A|To be used during run-in phase only.
107034|NCT01437319|Device|comfilcon A|To be assigned at randomization at phase 2 only.
107035|NCT01437319|Device|balafilcon A|To be assigned at randomization during phase 2 only.
107036|NCT01437319|Other|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
107037|NCT00067015|Procedure|quality-of-life assessment|
107038|NCT01437358|Other|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
107519|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
107520|NCT01433887|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
107521|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
107522|NCT01433900|Drug|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
107523|NCT01433900|Drug|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
107524|NCT01433913|Drug|metformin hydrochloride|Given PO
107525|NCT01433913|Other|placebo|Given PO
107526|NCT01433913|Other|laboratory biomarker analysis|Correlative studies
107527|NCT00066742|Other|laboratory biomarker analysis|Correlative studies
107528|NCT01433952|Dietary Supplement|Thiamine|Vitamin B1
107529|NCT01433952|Dietary Supplement|Placebo|Placebo
107530|NCT01433965|Drug|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
107531|NCT01433978|Drug|Eltrombopag|administered orally as 25mg, 50mg, or 75mg in a flexible dose design
107532|NCT01433978|Drug|E5501 - Avatrombopag maleate|administered orally as 5mg, 10mg, 20mg, or 40mg in a flexible dose design
107533|NCT01433991|Drug|E7050 plus Lenvatinib|Dose escalation will begin at low doses of both E7050 and lenvatinib, then gradually increase in future cohorts until a recommended combination dose is identified. This recommended dose will be used to treat patients with Glioblastoma and Melanoma in later groups in this study.
107534|NCT01436084|Drug|SB1518|400 mg taken orally, once daily without regard of food, 28 day cycle.
106632|NCT01439022|Behavioral|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
106633|NCT00001122|Drug|Efavirenz|
106634|NCT00067262|Drug|Divalproex Sodium Extended-Release Tablets|
106635|NCT01439035|Device|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of Duodenum with OFDI system
106636|NCT01439061|Device|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
107297|NCT01435798|Drug|Dex1Lido3|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107298|NCT01435798|Drug|Dex1Lido4|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107299|NCT01435798|Drug|Dex2Lido1|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107300|NCT01435798|Drug|Dex2Lido2|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107301|NCT01435798|Drug|Dex2Lido3|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107302|NCT01435798|Drug|Dex2Lido4|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107303|NCT01435798|Drug|Dex3Lido1|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107304|NCT01435798|Drug|Dex3Lido2|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107305|NCT01437748|Drug|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
107306|NCT01437761|Device|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
107307|NCT01437774|Device|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
107308|NCT01437787|Drug|SAR302503|Pharmaceutical form:capsule
Route of administration: oral
107309|NCT01437787|Drug|Placebo|Pharmaceutical form:capsule
Route of administration: oral
107310|NCT01437800|Drug|Glimepiride/extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
107311|NCT01437813|Drug|Glimepiride/extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
107312|NCT01437826|Drug|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
107313|NCT01437826|Drug|placebo|placebo had an identical appearance as intervention
107314|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
107315|NCT00067093|Drug|SanOrg34006|
106422|NCT01434316|Drug|Veliparib|Given PO
103541|NCT01412086|Drug|No Intervention|No Intervention.
103542|NCT01412099|Behavioral|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
103543|NCT01412099|Behavioral|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
103544|NCT01412125|Other|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
103545|NCT01412125|Other|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
103546|NCT01404910|Device|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
103547|NCT01404923|Drug|anti spasmodic agents|best standard of care prescriptions
103548|NCT01404923|Drug|alverine citrate, simeticone|on-demand therapy
103549|NCT01404936|Drug|Interferon-2A|4 (x106 IU/m^2) subcutaneously on days 1-4.
103550|NCT00001095|Drug|Stavudine|
103551|NCT00064025|Procedure|conventional surgery|
103552|NCT01404936|Drug|Adriamycin|25 mg/m^2 by vein on day 4.
103553|NCT01404936|Drug|Bleomycin|10 mg/m^2 by vein on day 4.
103554|NCT01404936|Drug|Velban|6 mg/m^2 by vein on day 4.
103555|NCT01404936|Drug|Dacarbazine|375 mg/m^2 by vein on day 4.
103556|NCT01404949|Drug|Tretinoin and Arsenic Trioxide|See Detailed Description
103557|NCT01404962|Biological|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
103558|NCT01404975|Other|Thoracic paravertebral block (PVB)|We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.
Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.
Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines.
107039|NCT01437371|Drug|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
107040|NCT01437384|Drug|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
107368|NCT01435798|Drug|Dex4Lido3|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107369|NCT01435798|Drug|Dex4Lido4|All PO drugs given QID; all IV drugs delivered over 30 minutes.
107370|NCT01435811|Biological|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
107371|NCT01435824|Drug|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
107372|NCT01435824|Drug|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
107373|NCT01435837|Drug|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
107374|NCT01435837|Drug|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
107375|NCT01435837|Drug|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
107376|NCT00066898|Drug|AGI-1067|
107377|NCT01435837|Drug|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
107378|NCT01435850|Procedure|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
107379|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
107380|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
107381|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
107382|NCT01435876|Procedure|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
107383|NCT01435876|Procedure|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
106637|NCT01439074|Device|Mepilex Ag|Dressing
106638|NCT01439074|Drug|Silver sulphadiazine|Cream
106639|NCT01439087|Device|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
106640|NCT01439100|Drug|Oxycodone/Naloxone Prolonged Release tablets|
106641|NCT01439100|Drug|Placebo|Dummy tablet
106642|NCT01439113|Procedure|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
106643|NCT01439126|Drug|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
106644|NCT01439126|Drug|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
106645|NCT00067288|Behavioral|Meaning-Centered Group Psychotherapy|
106646|NCT01439152|Drug|BAY94-9343|BAY94-9343 will be administered intravenously in this study. The starting dose for this first-in-man study is 0.15 mg/kg administered as a 1 hour infusion every 21 days.
106647|NCT01439152|Drug|BAY94-9343 (Expansion)|BAY94-9343 will be administered intravenously in this study. The dose for this expansion cohort is 5.5mg/kg administered as a 1 hour infusion every 21 days
106648|NCT01439152|Drug|BAY94-9343 (1.8 mg/kg)|BAY94-9343 will be administered intravenously in this study. The dose for this cohort is 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
106649|NCT01439152|Drug|BAY94-9343 (2.2 mg/kg)|BAY94-9343 will be administered intravenously in this study. The dose for this cohort is 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
106650|NCT01439165|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
106651|NCT01439165|Biological|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
106652|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
106653|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
107197|NCT01435577|Drug|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
107198|NCT00066859|Drug|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
107199|NCT01435577|Drug|Matching Placebo|Maximum 12 administrations over 48 hours
106423|NCT01434329|Genetic|DNA methylation analysis|
106424|NCT01434329|Genetic|gene expression analysis|
106425|NCT01434329|Genetic|microarray analysis|
106426|NCT01434329|Other|laboratory biomarker analysis|
106427|NCT01434329|Other|medical chart review|
106428|NCT01434342|Drug|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, & 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
106429|NCT01434355|Other|laboratory biomarker analysis|Correlative studies
106430|NCT01434355|Other|questionnaire administration|Ancillary studies
106431|NCT01434381|Biological|Pfs25-EPA/Alhydrogel|
106432|NCT00066781|Drug|gemcitabine hydrochloride|Given IV
106433|NCT01434394|Drug|Neo-adjuvant Erbitux-based chemotherapy|Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks
Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
106434|NCT01434407|Other|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
106435|NCT01436305|Drug|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
106436|NCT01436305|Drug|MMF|All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.
Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily.
106437|NCT01436305|Biological|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication[s])
106438|NCT00066989|Drug|Staphylococcus aureus Immune Globulin (Human) 5%|
106439|NCT01436305|Drug|Short-term Tac|Short-term (3 months)
106440|NCT01436305|Drug|tacrolimus|maintenance
103559|NCT01404988|Behavioral|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
103560|NCT01404988|Behavioral|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
103855|NCT01407835|Biological|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
103856|NCT01407848|Drug|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
103857|NCT00001096|Biological|rgp120/HIV-1MN|
103858|NCT00064207|Radiation|radiation therapy|
103859|NCT01407848|Drug|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
103860|NCT01407861|Other|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
103861|NCT01407861|Other|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
103862|NCT01407874|Drug|Placebo|Oral dose administered daily for 84 days.
103863|NCT01410331|Biological|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
103864|NCT01410331|Biological|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
103865|NCT01410344|Drug|Fludarabine and Busulfan|RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:
Days -6 to -2: Flu (30 mg/m^2/day, total dose of 150 mg/m^2)
Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m^2 IV, respectively)
Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.
Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.
103866|NCT01410344|Drug|Fludarabine and Melphalan|RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m^2, Melphalan total dose: less than or equal to 150 mg/m^2. Recommended regimen:
Days -5 to -2: Flu (30mg/m^2/day, total dose of 120 mg/m^2)
Day -1: Mel (140mg/m^2)
Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.
103867|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
103868|NCT01410344|Drug|Busulfan and Fludarabine|MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:
Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively)
Days -5 to -2: Flu (30 mg/m^2/day, total dose of 120 mg/m^2)
Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.
Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.
107384|NCT01435876|Procedure|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
107385|NCT01435876|Procedure|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
107386|NCT01435902|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
107387|NCT00066937|Drug|nortriptyline|Effect of nortriptyline
107388|NCT01437943|Drug|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
106495|NCT01434446|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
106496|NCT01434459|Drug|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
106497|NCT01434472|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
106498|NCT01434472|Drug|Cyclosporine|Given PO
106499|NCT01434472|Drug|Fludarabine Phosphate|Given IV
106500|NCT01434472|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
106501|NCT01434472|Drug|Mycophenolate Mofetil|Given PO
106502|NCT00066781|Drug|irinotecan hydrochloride|Given IV
106503|NCT01434472|Other|Pharmacological Study|Correlative studies
106504|NCT01434472|Biological|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
106505|NCT01434472|Radiation|Total-Body Irradiation|Undergo TBI
106506|NCT01434472|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
106507|NCT01434498|Drug|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
106508|NCT01434498|Drug|GS-9451 tablet|GS-9451 tablet, 200 mg QD
106509|NCT01434498|Drug|tegobuvir capsule|tegobuvir capsule, 30 mg BID
106510|NCT01434498|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
106511|NCT01434498|Drug|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
106512|NCT01434498|Device|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
107200|NCT01435590|Procedure|Curette v/s endocervical brush|
107201|NCT01435603|Behavioral|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
107202|NCT01435603|Behavioral|Advice PLUS Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
107203|NCT01435616|Drug|Glargine|Administered by subcutaneous injection
107204|NCT01435616|Drug|LY2605541|Administered by subcutaneous injection
107205|NCT01435629|Drug|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
107206|NCT01435642|Other|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
107207|NCT01435655|Drug|tafamidis|tafamidis meglumine 20 mg QD
107208|NCT01435668|Behavioral|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
107209|NCT00066859|Dietary Supplement|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
107210|NCT01435668|Behavioral|Simple written advice|Patients receive an information leaflet.
107211|NCT01435694|Behavioral|Lokomat (Hocoma, Switzerland)|
107212|NCT01435694|Behavioral|Conventional Therapy|
107213|NCT01437605|Drug|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
107214|NCT01437618|Drug|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by
IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by
OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with
l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by
5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks
107215|NCT01437631|Procedure|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
106441|NCT01436305|Biological|Belatacept|maintenance
106705|NCT01436747|Drug|Placebo|2 micrograms daily, peroral, 24 weeks
106706|NCT01436786|Other|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
106707|NCT01436799|Drug|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
106708|NCT01436799|Drug|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
106709|NCT01436799|Drug|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
106710|NCT01436799|Drug|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
106711|NCT01439178|Drug|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
106712|NCT01439191|Drug|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
106713|NCT01439191|Drug|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
106714|NCT01439204|Biological|Abatacept (BMS-188667)|Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
106715|NCT00067288|Behavioral|Standard Supportive Group Psychotherapy|
106716|NCT01439230|Drug|Donepezil|10 mg Tablet
106717|NCT01439230|Drug|Aricept®|10 mg Tablet
106718|NCT01439243|Drug|Donepezil|10 mg Tablet
106719|NCT01439243|Drug|Aricept®|10 mg Tablet
106720|NCT01439256|Device|Electronic pill tray direct reporting to physician (Telephone-Linked Care: Hypertension 2- Electronic Pill Tray)|This is an electronic monitoring system designed to compile the dosing history of subjects prescribed oral medications. The system is comprised of a standard plastic pill tray with daily compartments that contain micro-electronic circuits that register times when the closure is opened and when it is closed. This information is sent to the patient's physician.
106721|NCT01439256|Behavioral|Patient self reporting of medication adherence|Subjects will use an electronic pill tray, though this information is NOT sent to the patient's physician. Instead, the physician must rely on the patient's self-reporting of his/her medication adherence.
103869|NCT01410344|Drug|Cyclophosphamide and Total Body Irradiation|MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:
Days -7 to -4: TBI (total dose of 1200-1420 cGy)
Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)
Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight.
102958|NCT01376167|Drug|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
102959|NCT01376167|Drug|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
102960|NCT01376167|Drug|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
102961|NCT01376167|Drug|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
102962|NCT01376167|Drug|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
102963|NCT01376167|Drug|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
102964|NCT01376167|Drug|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
102965|NCT00061256|Drug|Vitamin D|
102966|NCT01376167|Drug|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
102967|NCT01376167|Drug|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
102968|NCT01376167|Drug|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
102969|NCT01376180|Drug|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
102970|NCT01376193|Drug|Naratriptan|Collection of safety data
102971|NCT01378741|Drug|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
102972|NCT01378741|Drug|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
102973|NCT01378754|Drug|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
102974|NCT01378754|Drug|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
102975|NCT01378754|Drug|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
106513|NCT00066794|Biological|filgrastim|5 mcg/kg/d IV or SC starting apx day 15
106514|NCT01434511|Biological|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
106515|NCT01434524|Drug|LIVACT|LIVACT contains 13.0 g of free amino acids
106516|NCT01434550|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
106517|NCT01434550|Radiation|Tissue, Blood, Research Imaging (TBRI)|Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess
Necrosis/apoptosis
Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)
1. Aposense-PET imaging
106780|NCT01436877|Device|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
106781|NCT01436890|Drug|Revamilast|Tablet. Low dose, Once daily for 12 weeks
106782|NCT01436890|Drug|Revamilast|Medium dose, Once daily for 12 weeks
106783|NCT01436890|Drug|Revamilast|High dose, Once daily for 12 weeks
106784|NCT01436890|Drug|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
106785|NCT00067002|Drug|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
106786|NCT01436903|Device|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
106787|NCT01436916|Drug|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
106788|NCT01436916|Drug|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
106789|NCT01436929|Drug|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
106790|NCT01436929|Drug|Placebo|Placebo 1tab bid
106791|NCT01436942|Behavioral|Exercise|The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.
A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.
Dose: 12 weeks. Three times a week, 60 minutes.
106792|NCT01436955|Drug|Placebo|multiple oral doses
107235|NCT01440153|Other|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
107236|NCT01440153|Other|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
107237|NCT01440166|Drug|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
107238|NCT00067405|Drug|Intravenous micronutrient therapy|
107239|NCT01440166|Other|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
107240|NCT01440179|Drug|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
107241|NCT01440192|Biological|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 & 8
107242|NCT01440205|Behavioral|Easy list of healthy habits|The recipient will be prompted to check off "yes" or "no" to healthy habits that most people will find fairly easy.
107243|NCT01440205|Behavioral|Challenging list of healthy habits|The recipient will be prompted to check off "yes" or "no" to healthy habits that most people will find fairly difficult.
107244|NCT01440205|Behavioral|Control|No check box element
107245|NCT01440231|Drug|Placebo|Matching placebo administered by subcutaneous injection, once weekly
107246|NCT01440231|Drug|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
107247|NCT01440231|Drug|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
107248|NCT01440231|Drug|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
107249|NCT00067431|Drug|Divalproex Sodium (Depakote® Sprinkle Capsules)|
107250|NCT01440231|Drug|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
107251|NCT01440244|Procedure|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
107252|NCT01440257|Drug|Placebo|Placebo capsules once daily
107253|NCT01440257|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
106722|NCT01439269|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
106723|NCT01439282|Drug|E7389 (eribulin mesylate) and capecitabine|eribulin mesylate (E7389) and capecitabine Eribulin 1.4 mg/m2 intravenously over 2 - 5 minutes Day 1 and Day 8 plus capecitabine 900 mg/m2 orally BID Days 1 - 14 of a 21-day cycle for 4 cycles
106967|NCT01437306|Drug|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
106968|NCT01439672|Dietary Supplement|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to ~100mg/dl at 1100.
106969|NCT00067340|Other|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
106970|NCT01439698|Device|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
106971|NCT01439711|Drug|letrozole|
106972|NCT01439711|Procedure|MRI|
106973|NCT01439711|Procedure|conventional surgery|
106974|NCT01439724|Device|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
106975|NCT01439724|Device|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
106976|NCT01439750|Drug|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
106977|NCT01439750|Drug|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
106978|NCT01439750|Drug|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
106979|NCT01439776|Dietary Supplement|Vit D|800IU/day
106980|NCT00067353|Drug|Fluoride varnish|
102976|NCT01378767|Dietary Supplement|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
103272|NCT01381705|Other|laboratory biomarker analysis|
103273|NCT01381705|Other|medical chart review|
103274|NCT00061893|Drug|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. [Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.]
103275|NCT01381718|Drug|modafinil|Given PO
103276|NCT01381718|Other|placebo|Given PO
103277|NCT01381731|Drug|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
103278|NCT01381731|Drug|placebo|opthalmic solution 2 drops in each eye QID
103279|NCT01381744|Biological|Flagellin/F1/V|Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
103280|NCT01381744|Other|Placebo|Phosphate buffered saline (PBS) used as diluent and placebo.
103281|NCT01381770|Biological|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
103282|NCT01381783|Procedure|Phacoemulsification|Phacoemulsification under topical anesthesia
103283|NCT01381796|Drug|NP101|comparison of NP101 with minor patch modifications
103284|NCT01381796|Drug|sumatriptan succinate|tablet, 100 mg
103285|NCT01373762|Behavioral|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
103286|NCT01373775|Other|Patient charts reviewing|Reviewing chart and identifying risk factors
103287|NCT01373801|Device|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
106793|NCT01436955|Drug|RG1662|Cohorts receiving multiple oral doses
106794|NCT01436968|Biological|ProstAtak™(AdV-tk) + valacyclovir|Patients will receive three courses of ProstAtak™ each consisting of AdV-tk injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
106795|NCT01439360|Biological|Influenza vaccine GSK2321138A|Intramuscular injection
106796|NCT01439360|Biological|Havrix Junior|Intramuscular injection administered to subjects aged 12 months or older
106797|NCT01439360|Biological|Prevenar 13|Intramuscular injection administered to subjects less than 12 months of age
106798|NCT00067301|Drug|Citalopram|
107041|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose, twice per day
107042|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC low dose, twice per day
107043|NCT01437397|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
107044|NCT01437397|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
107045|NCT01437397|Drug|placebo|Inhaled dose-matched placebo, twice per day
107046|NCT01437410|Procedure|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
107047|NCT01437423|Biological|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
107048|NCT00067015|Radiation|radiation therapy|
107049|NCT01437436|Procedure|ventilation tube|ventilation tube insertion
107050|NCT01437449|Drug|Docetaxel|30 mg/m2 iv
107051|NCT01437449|Drug|Cisplatin|30 mg/m2 iv
107052|NCT01437449|Drug|Cetuximab|C1: 400 mg/m2, thereafter 250 iv
107053|NCT01437449|Drug|Carboplatin|AUC 2 iv
107054|NCT01437462|Drug|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
106362|NCT01436266|Drug|Folic acid|2mg buccally 2 hours prior to procedure
106363|NCT01436279|Drug|Mifepristone|200 mg po 20-24 hours prior to the procedure
106364|NCT01436279|Device|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
106365|NCT01436292|Drug|5% human albumin solution (HAS)|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:
≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; < 10 gr/L: 150 g of 5% HAS.
106366|NCT01438515|Other|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
106367|NCT01438528|Device|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
106368|NCT01438541|Device|Window|Dressing
106369|NCT01438554|Drug|Pazopanib|
106370|NCT01438554|Drug|GSK1120212|
106371|NCT00067158|Drug|nicotine transdermal system|
106372|NCT01438567|Drug|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
106373|NCT01438567|Drug|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
106374|NCT01438580|Drug|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
106375|NCT01438580|Drug|aspirin|100mg aspirin was administrated every day
106376|NCT01438593|Procedure|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
106377|NCT01438606|Biological|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
106378|NCT01438606|Biological|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
106379|NCT01438632|Device|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
106380|NCT01438645|Device|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
103146|NCT01376401|Drug|Bendamustine|
103147|NCT00061308|Drug|Topotecan|
103148|NCT01376401|Drug|Velcade|
103149|NCT01376401|Drug|Prednisone|
103150|NCT01376414|Other|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
103151|NCT01376427|Drug|Dexamethasone|Dexamethasone
103152|NCT01376427|Drug|Methotrexate|Methotrexate
103153|NCT01376427|Drug|Vincristine|Vincristine
103154|NCT01376440|Other|household water treatment|household water treatment with 1.25% sodium hypochlorite
103155|NCT01376453|Drug|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
103156|NCT01376453|Drug|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m^2 daily through a catheter in a large vein continuously until the last day of radiation.
103157|NCT01376453|Radiation|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
103158|NCT00061308|Drug|Gemcitabine|
103159|NCT01376466|Other|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
103160|NCT01376479|Biological|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
103161|NCT01376479|Biological|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
103162|NCT01376479|Biological|Placebo|Phosphate Buffered Saline (PBS)
103163|NCT01376492|Other|Functioning assessment|The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
103164|NCT01376492|Other|Quality of sleep assessment|The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
103165|NCT00061594|Drug|rhuFab V2 (ranibizumab)|
103166|NCT01379027|Behavioral|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
103815|NCT01412658|Dietary Supplement|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
102906|NCT01378689|Other|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
102907|NCT00061542|Drug|Timolol Gel-forming Solution (timolol maleate)|
102908|NCT01378702|Drug|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
102909|NCT01378715|Drug|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
102910|NCT01381198|Procedure|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
102911|NCT01381211|Drug|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
102912|NCT00061854|Drug|soblidotin|
102913|NCT01381211|Drug|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
102914|NCT01381224|Other|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
102915|NCT01381237|Behavioral|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
102916|NCT01381250|Behavioral|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
102917|NCT01381263|Behavioral|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
102918|NCT01381263|Other|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
102919|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
103592|NCT01409759|Procedure|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
103593|NCT01409772|Drug|Ethanol Lock|Ethanol Lock
103594|NCT01409811|Drug|zoledronic acid|Given IV
103595|NCT01409811|Other|laboratory biomarker analysis|Correlative studies
103596|NCT01409811|Procedure|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
103911|NCT01405612|Drug|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
103912|NCT01405625|Other|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
103913|NCT01405625|Other|AAAAI standard of care written action plan|
103914|NCT01405638|Behavioral|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
103915|NCT01405638|Behavioral|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
103916|NCT00064077|Drug|Cisplatin|Given IV
103917|NCT01405651|Drug|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
103918|NCT01405651|Drug|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
103919|NCT01405664|Other|Weight-Bearing as Tolerated|WBAT immediately after surgery
103920|NCT01405677|Biological|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
103921|NCT01405677|Biological|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
103922|NCT01405677|Biological|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
103923|NCT01405703|Other|xrays|xrays from 2 week postop to 5 year postop
103924|NCT01405716|Behavioral|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
103925|NCT01405716|Behavioral|Health Education|8-week health education program
103368|NCT01373970|Drug|Placebo|Placebo, one tablet daily for 12 weeks
103369|NCT01373970|Drug|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
103370|NCT01373983|Drug|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
103371|NCT01373996|Device|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.
A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System.
103372|NCT01374022|Other|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
103373|NCT01374022|Other|ARDSNet Strategy|Conventional mechanical ventilation strategy.
103374|NCT01374035|Other|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
103375|NCT01374061|Device|Classical intubation|Classical intubation
103376|NCT00061035|Biological|Transgenic Lymphocyte Immunization Vaccine (TLI)|
103377|NCT01374061|Device|GLIDESCOPE|GLIDESCOPE intubation
103653|NCT01407458|Other|Upper Limb Exercises|Upper limb exercises
103654|NCT01407458|Other|Normal physical exercises|Exercises usually done by children in physical education classes
103655|NCT00064181|Drug|leucovorin calcium|
103656|NCT01407471|Drug|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
103657|NCT01407471|Drug|Clobetasol + Placebo|One application 6 days a week during 4 weeks
103658|NCT01407471|Drug|Placebo + Spironolactone|One application 6 days a week during 7 weeks
103659|NCT01407471|Drug|Placebo + Placebo|One application 6 days a week during 7 weeks
103660|NCT01407484|Drug|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
103661|NCT01407484|Drug|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
103167|NCT01379040|Other|Cystic Fibrosis patients|
103428|NCT01382004|Drug|Azithromycin|Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.
Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
103429|NCT01382017|Drug|Lacosamide|Lacosamide 200 or 400 mg
103430|NCT01382017|Drug|Placebo|Placebo
103431|NCT01382017|Drug|Carbamazepine|Carbamazepine 600 mg
103432|NCT00001087|Drug|Nelfinavir mesylate|
103433|NCT00061893|Drug|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
103434|NCT01382030|Drug|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
103435|NCT01382056|Other|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
103436|NCT01382056|Other|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
103437|NCT01374100|Behavioral|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
103438|NCT01374100|Behavioral|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
103439|NCT01374113|Drug|50mg safinamide|50 mg safinamide on Day 1
103440|NCT01374126|Drug|Artesunate|Artesunate alone
103441|NCT01374126|Drug|Azithromycin + Artesunate|Combination of azithromycin + artesunate
103442|NCT01374139|Drug|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
102920|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
102921|NCT01381276|Other|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
102922|NCT01381289|Drug|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
103222|NCT01373710|Drug|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
103223|NCT01373723|Other|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
103224|NCT01373736|Drug|123I-meta-iodobenzylguanidine|
103225|NCT01373749|Drug|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
103226|NCT01373749|Drug|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
103227|NCT01376505|Biological|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
103228|NCT01376518|Procedure|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
103229|NCT01376531|Procedure|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
103230|NCT01376544|Device|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
103231|NCT00061321|Drug|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
103232|NCT01376557|Drug|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
103233|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
103234|NCT01376557|Drug|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
103235|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
103926|NCT01405742|Drug|Recombinant factor VIII|In this arm, 40 IU/kg recombinant factor VIII will be given thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 4-day washout period, 40 IU/kg recombinant factor VIII will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds.
103927|NCT01407874|Drug|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
103928|NCT01407874|Drug|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
103929|NCT01407887|Drug|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
103930|NCT01407900|Drug|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
103931|NCT01407900|Drug|5% Dextrose in Water|four hour infusion IV
103932|NCT01407913|Procedure|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
103933|NCT00064220|Drug|soblidotin|
102992|NCT01381354|Dietary Supplement|Full Spectrum vitamin|Two capsules daily.
102993|NCT01381354|Dietary Supplement|Essential - hydroxytyrosol|Two capsules twice daily.
102994|NCT01381354|Dietary Supplement|Maltodextrin fiber supplement|One scoop daily.
102995|NCT00061867|Procedure|hyperthermia treatment|
102996|NCT01381354|Dietary Supplement|Mineral boost (magnesium)|Two capsules daily
102997|NCT01381354|Dietary Supplement|Niacinamide|500 mg daily
102998|NCT01381354|Dietary Supplement|Methyl B12|Methyl B12 1000 mcg daily
102999|NCT01381354|Dietary Supplement|Taurine|one gram daily
103000|NCT01381354|Dietary Supplement|creatine|one teaspoon daily
103001|NCT01381354|Dietary Supplement|thiamine|100 mg daily
103002|NCT01381354|Dietary Supplement|riboflavin|200 mg daily
103003|NCT01381354|Dietary Supplement|N acetylcysteine|1 gram daily
103004|NCT01381354|Dietary Supplement|alpha lipoic acid|300 mg twice daily
103005|NCT01381354|Dietary Supplement|L acetyl carnitine|500 mg twice daily
103662|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
103663|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
103664|NCT01407497|Biological|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
103665|NCT01407497|Biological|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
103666|NCT00064194|Dietary Supplement|selenium|
103667|NCT01407510|Drug|Mapracorat|Application of the investigational product on the affected skin areas
103668|NCT01407523|Drug|Levetiracetam|Formulation: concentrate for solution for infusion
Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)
Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day
Frequency: twice daily
103669|NCT01407536|Device|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
103670|NCT01407549|Behavioral|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
103671|NCT01407562|Drug|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
102774|NCT01383226|Procedure|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
102775|NCT01383239|Other|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
102776|NCT01383239|Other|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
102777|NCT01383252|Procedure|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
103443|NCT01374139|Drug|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
103444|NCT00061048|Biological|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
103733|NCT01405313|Device|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
103734|NCT01405313|Device|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
103735|NCT01405326|Biological|adalimumab|40mg sc. every two weeks for six months
103736|NCT00064051|Drug|gemcitabine hydrochloride|
103737|NCT01405339|Device|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
103738|NCT01405339|Device|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
103739|NCT01405352|Dietary Supplement|Vitamin A|25000 IU/day vitamin A 4 months
1 Cap/Day
1 cap placebo/day for 4 month
103740|NCT01405365|Drug|Metronidazole|Metronidazole 400mg TID for 10 days
103741|NCT01405365|Drug|Placebo|Placebo pill TID for 10 days
103742|NCT01405365|Procedure|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
103743|NCT01405378|Device|Robot therapy and transcranial direct current stimulation|Administration of Robot Therapy:
Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:
Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2).
103744|NCT01407562|Drug|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
103745|NCT01407575|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
103746|NCT01407575|Drug|Placebo|matched placebo
103747|NCT01407588|Procedure|Magnetic navigation|Ablation with use of the magnetic navigation system
103748|NCT00064194|Dietary Supplement|soy protein isolate|
103749|NCT01407588|Procedure|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
104745|NCT01406912|Other|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
104746|NCT01406912|Other|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
105058|NCT01397448|Drug|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
105059|NCT01397448|Drug|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
105060|NCT00001091|Drug|Stavudine|
105061|NCT00063258|Drug|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
105062|NCT01397461|Drug|ozenoxacin placebo|cream
105063|NCT01397461|Drug|retapamulin 1% ointment|ointment
105064|NCT01397461|Drug|ozenoxacin 1% cream|1% cream
105065|NCT01397474|Other|PPTFM|Peripheral Perfusion Targeted Fluid Management
105066|NCT01397487|Procedure|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
105067|NCT01397500|Drug|Genotropin|Genotropin administered sc once a day by patient or caregiver.
105068|NCT01397500|Drug|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
105069|NCT01397513|Drug|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
105070|NCT01397539|Drug|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
105071|NCT01397539|Other|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
105072|NCT00063284|Device|Magstim Rapid Magnetic Stimulator|
105073|NCT00063635|Drug|Matching placebo|Twice daily
105074|NCT01400412|Drug|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
103006|NCT00001087|Drug|Ritonavir|
103007|NCT00061880|Drug|forodesine hydrochloride|
103008|NCT01381354|Dietary Supplement|methyl folate|1000 mcg one pill four times a week
103009|NCT01381354|Dietary Supplement|coenzyme Q|100 mg daily
103010|NCT01381354|Behavioral|meditation|meditation 15 minutes daily
103011|NCT01381354|Behavioral|self massage|self massage of hands, feet, ears 15 minutes daily
103012|NCT01381354|Behavioral|learning|completing puzzles or learning 15 minutes daily
103013|NCT01381354|Dietary Supplement|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
103014|NCT01381367|Biological|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
103015|NCT01381367|Drug|Normal Saline|normal saline, 0.5ml given subcutaneously
103016|NCT01381380|Procedure|Manual therapy|Manual therapy, once a week for 8 weeks
103310|NCT01376739|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
103311|NCT01376752|Procedure|maximal cytoreductive surgery|maximal cytoreductive surgery with or without HIPEC For HIPEC : the cisplatin will be used at 75mg/m2
103312|NCT01376765|Drug|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
103313|NCT01376765|Other|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
103314|NCT01376765|Biological|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
103315|NCT01376778|Drug|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
103316|NCT00061360|Drug|Sirolimus (Rapamune)|
102778|NCT01375712|Dietary Supplement|Fermented milk containing Lactobacillus casei strain Shirota|A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of Lactobacillus casei strain Shirota.
102779|NCT01375712|Dietary Supplement|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
102780|NCT01375738|Procedure|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30~40cm from the new gastric-jejunal junction.
102781|NCT01375738|Procedure|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
102782|NCT01375751|Biological|Evolocumab|Administered by subcutaneous injection
102783|NCT01375751|Biological|Placebo|d by subcutaneous injection
102784|NCT01375764|Biological|Evolocumab|Administered by subcutaneous injection
102785|NCT00061217|Device|Unrectified prosthetic socket|
102786|NCT01375764|Drug|Ezetimibe|Administered orally once a day
102787|NCT01375764|Other|Placebo to Evolocumab|Administered by subcutaneous injection
102788|NCT01375777|Biological|Evolocumab|Administered by subcutaneous injection
102789|NCT01375777|Drug|Ezetimibe|Administered orally once a day
102790|NCT01375777|Other|Placebo to Evolocumab|Administered by subcutaneous injection
102791|NCT01375790|Device|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
103082|NCT00001086|Drug|Indinavir sulfate|
103083|NCT00061568|Drug|Sirolimus (Rapamune )|
103084|NCT01378962|Drug|erlotinib [Tarceva]|150 mg orally once a day for 12 months
103085|NCT01378975|Drug|vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal
103086|NCT01378988|Drug|Dexmedetomidine|For sedation according to protocol
103750|NCT01407601|Dietary Supplement|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
103751|NCT01407614|Procedure|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
103752|NCT01407627|Dietary Supplement|Fructose|Subjects will be randomized to one of 2 sequences:
Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
102846|NCT01383460|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
102847|NCT01383486|Drug|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
102848|NCT01383486|Drug|Advil|Commercially available Advil; oral caplet upon incidence of pain
102849|NCT00061945|Drug|cytarabine|Given IV
102850|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
102851|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
102852|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
102853|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
102854|NCT01383512|Device|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
102855|NCT01383512|Other|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
102856|NCT01383525|Device|Direct application of Selective Laser Trabeculoplasty|Direct application of SLT using "DIO-DENT 10" DENTAL DIODE LASER SYSTEM to the conjunctiva over the TM
102857|NCT01383525|Device|Direct application of SLT in Open Angle Glaucoma|Direct application of Selective Laser Trabeculoplasty in Open Angle Glaucoma
102858|NCT01383538|Drug|FOLFIRINOX, IPI-926|Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.
Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.
Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.
5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.
IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle.
102859|NCT01383551|Behavioral|"Becoming Parents" intervention|A "Becoming Parents" programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education.
102860|NCT00061945|Drug|trimethoprim-sulfamethoxazole|Given PO
105075|NCT01400412|Drug|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
105076|NCT01400412|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
105077|NCT01400412|Drug|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
105078|NCT01400412|Drug|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
104158|NCT00064428|Drug|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
104159|NCT01410942|Drug|Methylphenidate|Starting dose 5 mg by mouth twice daily.
104160|NCT01410942|Behavioral|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
104161|NCT01410942|Other|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
104162|NCT01410942|Other|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
104163|NCT01412983|Device|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
104164|NCT01412983|Device|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
104165|NCT01412996|Procedure|surgery|single ACCESS laparoscopic cholecystectomy
104166|NCT01412996|Other|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
104167|NCT01413022|Drug|Oxaliplatin|
104168|NCT01413022|Drug|Irinotecan|
104169|NCT01413022|Drug|Leucovorin|
104170|NCT01413022|Drug|Fluorouracil|
104171|NCT00064753|Drug|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
104172|NCT01413022|Other|laboratory biomarker analysis|Correlative studies
104173|NCT01413022|Other|flow cytometry|Correlative studies
103317|NCT01376804|Drug|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
103318|NCT01376817|Drug|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
103319|NCT01376817|Drug|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
103320|NCT01376869|Dietary Supplement|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
103321|NCT01376869|Other|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
103322|NCT00061633|Drug|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
103323|NCT01379313|Procedure|1:1 ratio|I:E ratio of 1:1 is applied.
103324|NCT01379313|Procedure|2:1 group|Inverse I:E ratio of 2:1 is applied.
103325|NCT01379313|Procedure|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
103326|NCT01379326|Drug|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
103597|NCT01409824|Other|CDSS|Clinical Decision Support System
103598|NCT01409837|Drug|Lisinopril|The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug "DY1" while group B was started on the coded drug "DZ2". Both "DY1" and "DZ2" were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug "DZ2" while group B changed to drug "DY1". There was no intervening washout period. The codes were concealed until after the data analysis.
103599|NCT01409850|Device|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
103600|NCT01409850|Device|Soft splint|
103601|NCT00064350|Drug|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
103602|NCT01409863|Procedure|laser and standard diamond fraise dermabrasion|standard dermabrasion, CO2 laser resurfacing
103603|NCT01409876|Radiation|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
103604|NCT01409889|Behavioral|Diabetes Prevention Program|
103087|NCT01379001|Drug|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
103088|NCT01379001|Drug|Placebo|IM or PO placebo
103089|NCT01379001|Drug|Donepezil|donepezil 5mg PO x 1
103090|NCT01379014|Behavioral|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
103091|NCT01379014|Other|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
103092|NCT01379027|Behavioral|Pure self-help Internet CBT for depression|Internet, CBT, Depression
103093|NCT01379027|Behavioral|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
103094|NCT01381393|Drug|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
103095|NCT00061893|Drug|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. [Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.] .
103096|NCT01381406|Drug|TIO|Patients receiving tiotropium bromide at index within the study period.
103097|NCT01381406|Drug|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
103098|NCT01381419|Drug|GSK1144814|Single dose.
103099|NCT01381419|Drug|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
103100|NCT01381419|Drug|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
103101|NCT01381432|Drug|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
103102|NCT01381445|Drug|GW870086X 0.2%|White to slightly coloured opaque cream
103103|NCT01381445|Drug|GW870086X 2%|White to slightly coloured opaque cream
103378|NCT01374087|Other|Brachytherapy + Decapeptyl® SR 22.5mg Triptorelin|Brachytherapy: Low dose rate or high dose rate. Triptorelin: Single injection (22.5 mg), intramuscular injection, preferably 2 months before brachytherapy.
103379|NCT01374087|Radiation|Brachytherapy|Brachytherapy: Low dose rate or high dose rate.
102861|NCT01383564|Procedure|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
102862|NCT01375829|Other|Pharmacological Study|Correlative studies
102863|NCT01375829|Drug|Temsirolimus|Given IV
102864|NCT01375842|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1|Intravenous (IV) infusion repeating dose
103168|NCT01379079|Drug|Acetylsalicylic acid|aspirin intake at bedtime
103169|NCT01379079|Drug|Acetylsalicylic acid lysinate|aspirin intake on awakening
103170|NCT01379092|Device|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
103171|NCT01379092|Device|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
103172|NCT01379105|Other|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
103173|NCT01379105|Other|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
103174|NCT01379144|Drug|latanoprost 75 ug|Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
103175|NCT01379144|Drug|latanoprost 100 ug|Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
103176|NCT00061620|Drug|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
104174|NCT01413022|Other|immunohistochemistry staining method|Correlative studies
104175|NCT01413022|Other|pharmacological study|Correlative studies
104176|NCT01413022|Drug|PF-04136309|
104177|NCT01413035|Biological|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
104178|NCT01413048|Drug|Carvedilol 25mg|Tablet, q.d.
104179|NCT01413048|Drug|AGSCT101 12.5mg|Tablet, q.d.
104180|NCT01413061|Procedure|Subtalar Arthrodesis|
104472|NCT01393730|Drug|Prednisone|5 mg orally once per day
104473|NCT01393743|Drug|perampanel|
104474|NCT00062803|Drug|SR34006|
104475|NCT01393743|Drug|Placebo comparator|
104476|NCT01393756|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
104477|NCT01406483|Other|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
104478|NCT01406496|Drug|insulin|Three different timings of insulin delivered by a pump
104479|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
104480|NCT00064129|Biological|Ipilimumab|Given IV
104481|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
104482|NCT01406522|Drug|Oral tacrine|Tacrine, 160 mg per day, four times daily
104483|NCT01406522|Drug|Oral placebo|Microcrystalline cellulose
104484|NCT01406535|Drug|Vardenafil|5 mg vardenafil per os twice daily
104485|NCT01406535|Other|Placebo|5 mg placebo per os twice daily
104486|NCT01406548|Drug|BPS804|
104487|NCT01406548|Drug|Placebo|
103605|NCT01409889|Behavioral|Healthy Living Program|
103606|NCT01409915|Drug|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
103607|NCT01409915|Drug|Saline -- placebo comparator|subcutaneous injection
103608|NCT01409928|Device|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
103609|NCT01412138|Other|genetic analysis|To identify by flow cytometry through technique of "Side Population" the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.
In vitro culture conditions for cell proliferation.
To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.
Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group.
103610|NCT01412151|Drug|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
103611|NCT01412164|Device|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
103612|NCT01412177|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
103613|NCT01412177|Drug|Placebo|Single intratympanic injection of placebo
103614|NCT00064662|Procedure|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
103615|NCT01412190|Device|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
102714|NCT01378299|Drug|Testosterone Cypionate|DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.
Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-,
(178)-. Its molecular formula is CvH400a, and the mole
102715|NCT01378312|Biological|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
102716|NCT00061503|Drug|Travoprost|
102717|NCT01378312|Biological|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
102718|NCT01378325|Drug|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
102719|NCT01378325|Drug|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
103380|NCT01376882|Dietary Supplement|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
103381|NCT01376882|Dietary Supplement|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
103382|NCT01376882|Dietary Supplement|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
103383|NCT01376882|Dietary Supplement|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
103384|NCT01376895|Behavioral|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
103385|NCT00061373|Drug|Aspirin|A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
103386|NCT01376895|Behavioral|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
103387|NCT01376908|Drug|Kuvan®|Kuvan® tablets contain 100 milligram (mg) of sapropterin dihydrochloride.
Study Period (26 weeks): Starting Kuvan® dose is 10 mg/kg/day and may be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
Phe-restricted diet:
Study Period (26 weeks): Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
103388|NCT01376908|Other|Phenylalanine (Phe)-restricted diet|During Study Period (26 weeks): Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
103389|NCT01376921|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
103390|NCT01376934|Procedure|procedure hysteroscopy|office hysteroscopy with gas or saline solution
103391|NCT01376960|Procedure|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
103392|NCT01376986|Behavioral|physical, psychological and social activation|
103393|NCT01376999|Drug|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
103672|NCT01407562|Drug|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
103177|NCT01379144|Drug|latanoprost 125 ug|Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
103178|NCT01379144|Drug|latanoprost 50 ug|Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
103179|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
103180|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
103445|NCT01374152|Other|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
103446|NCT01374178|Drug|LY2963016|Administered subcutaneously
103447|NCT01374178|Drug|Lantus|Administered subcutaneously
103448|NCT01374191|Drug|onabotulinum toxin type-A|1 injection of Btx-A
103449|NCT01374191|Other|placebo|1 injection of saline solution
103450|NCT01374191|Drug|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
103451|NCT01374217|Drug|Tadalafil, Cialis|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
103452|NCT01374230|Procedure|Total knee arthroplasty|Surgical implantation of total knee components for the treatment of osteoarthritis.
103453|NCT01374269|Other|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
103454|NCT01374269|Drug|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
103455|NCT00061061|Behavioral|Behavior Therapy|
103456|NCT01374282|Drug|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
103457|NCT01374295|Other|video|watch a 3 minute video
104488|NCT01406548|Drug|BPS804|
104489|NCT01406548|Drug|Placebo|
104490|NCT01406548|Drug|BPS804|
104491|NCT00064129|Other|Laboratory Biomarker Analysis|Correlative studies
104492|NCT01406548|Drug|Placebo|
104493|NCT01406561|Drug|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
104494|NCT01406561|Drug|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
104495|NCT01406574|Drug|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
104496|NCT01406574|Drug|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
104747|NCT01406925|Drug|Placebo control|Placebo cream
104748|NCT01406925|Drug|NRL001 cream|Cream for single-dose intra-anal application
104749|NCT01406938|Drug|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
104750|NCT01406938|Drug|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
104751|NCT01406964|Other|CAT test|A CAT test is performed in order to diagnose tubal factor causes
104752|NCT00064181|Drug|FOLFIRI regimen|
104753|NCT01406964|Other|Histerosalpingography|A Histerosalpingography is performed.
104754|NCT01406977|Drug|BPS804|
104755|NCT01407003|Drug|LIK066|Participants will receive a single or multiple doses of LIK066
104756|NCT01407003|Drug|Placebo|Participants will receive a single or multiple doses of a matching placebo
104757|NCT01407016|Drug|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
104758|NCT01407042|Procedure|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
102720|NCT01378351|Other|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
102721|NCT01378364|Drug|AbGn-168H|single very low dose of AbGn-168H i.v.
102722|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H i.v.
102723|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
102724|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
102725|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
102726|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
102727|NCT00061516|Drug|BETAXON (levobetaxolol HCl)|
102728|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H i.v.
102729|NCT01378364|Drug|AbGn-168H|single high dose of AbGn-168H i.v.
102730|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H s.c.
102731|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
102732|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
102733|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H s.c.
102734|NCT01378377|Drug|MEK inhibitor MSC1936369B and Temsirolimus|The starting dose of MSC1936369B will be 45mg QD.
The starting dose of Temsirolimus will be 12.5 mg/week
Dosing of MSC1936369B and Temsirolimus will occur in combination: MSC1936369B will be taken orally, QD, on days 1-15 and temsirolimus will be infused IV on days 1, 8 and 15 in successive 21-day cycles. Dose escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
Number of Cycles: The treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent by the subject.
103017|NCT01373216|Drug|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
103018|NCT01373229|Drug|Lenalidomide + Plerixafor (+ Rituximab)|Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Cohort 3: 0.42 mg/kg
Cohort 4: 0.54 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.
103019|NCT01373242|Drug|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
103020|NCT01373242|Drug|Placebo Glycerin SLIT|Liquid glycerin extract will be administered under the tongue
103673|NCT01409993|Drug|Administration of Sildenafil or Placebo|Subjects with prediabetes will have a baseline hyperglycemic (Aim 1) or a euglycemic (Aim 2) and then receive sildenafil or placebo for 3 months. Another hyperglycemic or euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
103674|NCT01410019|Other|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
103675|NCT01410032|Procedure|Plate fixation|Reconstruction plate
103676|NCT00064363|Drug|talampanel|
103677|NCT01410032|Procedure|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
103678|NCT01410045|Procedure|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
103679|NCT01410058|Dietary Supplement|Moringa oleifera|leaf powder
103680|NCT01410084|Dietary Supplement|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
103681|NCT01410084|Dietary Supplement|Vitamin E|400 IU vitamin E once monthly for 5 months
103682|NCT01410097|Behavioral|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
103683|NCT01410097|Behavioral|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
103684|NCT01410110|Behavioral|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
103685|NCT01410110|Behavioral|Work Therapy|20 hours per week of work therapy
103686|NCT01410123|Other|Integrated Stepped Care (ISC)|At risk drinking:
Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy
Alcohol abuse/dependence:
Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare
Moderate Alcohol + Liver Disease:
Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy.
103687|NCT00064376|Drug|paricalcitol|
103688|NCT01410123|Other|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (diet, exercise, smoking cessation, ART adherence) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
103689|NCT01410136|Procedure|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
103690|NCT01410149|Other|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
103458|NCT01374295|Other|standard education|Receives standard verbal education from healthcare provider
103459|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
103460|NCT01377038|Other|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
103461|NCT01377051|Drug|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
103462|NCT01377051|Drug|Placebo|Dry powered, same to study drug, only one inhalation
103463|NCT01377064|Behavioral|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
103464|NCT01377064|Other|Standard Care Group|No intervention, the group will be followed under their standard medical care.
103465|NCT01377077|Procedure|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
103753|NCT01407640|Procedure|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
103754|NCT01407653|Procedure|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
103755|NCT01407653|Procedure|Usual care|Classical care
103756|NCT01407666|Procedure|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
103757|NCT01407679|Drug|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
103758|NCT01407731|Genetic|protein expression analysis|
103759|NCT00064194|Dietary Supplement|vitamin E|
103760|NCT01407731|Genetic|western blotting|
103761|NCT01407731|Other|laboratory biomarker analysis|
103762|NCT01407744|Other|laboratory biomarker analysis|Correlative studies
103763|NCT01407757|Genetic|DNA analysis|
103764|NCT01407757|Genetic|gene expression analysis|
103765|NCT01407757|Other|laboratory biomarker analysis|
103766|NCT01407757|Other|pharmacogenomic studies|
104759|NCT01407055|Behavioral|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
104760|NCT01407055|Behavioral|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
104761|NCT01407068|Biological|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
104762|NCT01409200|Other|ADT Therapy|ADT for 8 weeks (specific drugs/dose/frequency not mandated by protocol) then up to 6 more months of hormone therapy following assignment to study group.
104763|NCT01409200|Drug|Axitinib|5 mg by mouth twice a day for 30 day cycle.
104764|NCT01409200|Procedure|Prostatectomy|Radical prostatectomy and pelvic lymph node dissection approximately 8 months after androgen deprivation therapy (ADT) with or without open label Axitinib.
104765|NCT00064337|Biological|filgrastim|
104766|NCT01409226|Device|3.0-T MRI|Participants undergo MRI prior to biopsy.
105079|NCT01400412|Drug|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
105080|NCT01400412|Drug|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
105081|NCT01400425|Drug|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose
105082|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
105083|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
105084|NCT00063648|Biological|EBV-specific autologous CTL|
105085|NCT01400451|Drug|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
105086|NCT01400451|Drug|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
103021|NCT01373255|Procedure|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
103022|NCT01373281|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
103023|NCT01373281|Biological|Placebo: NaCl 0.9%|0.5 mL, Subcutaneous
103024|NCT00060944|Drug|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
103025|NCT01373294|Drug|bacilli calmette-guerin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
103026|NCT01373294|Drug|lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
103027|NCT01373307|Behavioral|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
103028|NCT01373320|Behavioral|Lay health advisor interactions|For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.
For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening.
103029|NCT01373333|Drug|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
103030|NCT01373346|Procedure|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
103031|NCT01373359|Drug|Misoprostol|400 µg sublingual misoprostol
103032|NCT01373359|Drug|Oxytocin|10 IU IM
103033|NCT01373372|Drug|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
103327|NCT01379339|Drug|Cabazitaxel 10mg/m2|Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
103328|NCT01379339|Drug|Cabazitaxel 12.5mg/m2|Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
102792|NCT01375790|Other|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
102793|NCT01375803|Dietary Supplement|Novel dietary fiber|oral consumption in beverage
102794|NCT01375803|Dietary Supplement|Novel dietary fiber|Oral consumption in beverage
102795|NCT01375803|Other|Placebo|Oral consumption in beverage
102796|NCT00061217|Device|Rectified prosthetic socket|
102797|NCT01375816|Drug|FOLFIRI 1-Bevacizumab|
102798|NCT01375816|Drug|fluorouracil|
102799|NCT01375816|Drug|irinotecan hydrochloride|
102800|NCT01375816|Drug|leucovorin calcium|
102801|NCT01375816|Drug|liposome-encapsulated irinotecan hydrochloride PEP02|
102802|NCT01375816|Drug|Bevacizumab|
102803|NCT01375829|Drug|Ixabepilone|Given IV
102804|NCT01378390|Drug|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgey standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell susupension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
102805|NCT01378390|Drug|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgey standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
102806|NCT01378416|Drug|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m^2 of decitabine.
102807|NCT00061516|Drug|AZOPT (brinzolamide)|
102808|NCT01378429|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
102809|NCT01378429|Drug|Placebo|Placebo
103767|NCT01407770|Genetic|DNA analysis|Genetic
103768|NCT01407770|Genetic|gene expression analysis|Genetic
103769|NCT01407770|Other|enzyme-linked immunosorbent assay|Genetic
103770|NCT00064207|Drug|gemcitabine hydrochloride|
103771|NCT01407770|Other|flow cytometry|Genetic
103772|NCT01410188|Drug|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
103773|NCT01410188|Drug|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
103774|NCT00064389|Drug|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
103775|NCT01410201|Drug|Dexamethasone Intravtireal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
103776|NCT01410214|Drug|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
102865|NCT00061230|Behavioral|biofeedback-monitored relaxation training|
102866|NCT01375855|Procedure|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
102867|NCT01375868|Biological|Silgard|vaccination with tetravalent antiviral vaccine
102868|NCT01375881|Drug|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
102869|NCT01375894|Device|imitation assessment using the 5-dt "data glove".|measuring the speed of the hand during imitation
102870|NCT01375907|Drug|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
102871|NCT01375920|Drug|Metyrapone|500 milligrams to be taken twice a day orally
102872|NCT01375920|Drug|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
102873|NCT01375933|Biological|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
102874|NCT01375946|Drug|AG200-15|A transdermal contraceptive delivery system for LNG and EE. A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
102875|NCT01375959|Dietary Supplement|resveratrol|resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
105087|NCT01400464|Drug|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
105088|NCT01400477|Drug|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
105089|NCT01400477|Other|Placebo|Placebo Comparator
105090|NCT01400490|Dietary Supplement|EPA-DHA Study|6 weeks of dietary supplementation
105091|NCT01400503|Drug|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
105092|NCT01400516|Drug|Teriparatide|20 mcg, subcutaneous injection, 1 injection per day
105093|NCT01400542|Device|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
105094|NCT01400542|Device|No treatment|no treatment
105095|NCT00063674|Behavioral|Nutrition Education|
105096|NCT01402947|Drug|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
105097|NCT01402947|Drug|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
104181|NCT01413074|Other|Peritoneal Dialysis treatment|PD treatment
104182|NCT00064753|Device|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
104183|NCT01413074|Other|Hemodialysis treatment|HD treatment
104184|NCT01413087|Biological|Biological/Vaccine: BC-819|Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.
After randomization patients will receive gemcitabine at a dose of 1000mg/m2 + 8 mg doses of BC-819 or gemcitabine at a dose of 1000mg/m2 + 12 mg doses of BC-819
104185|NCT01413100|Biological|Anti-Thymocyte Globulin|Given IV
104186|NCT01413100|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
103329|NCT01379339|Drug|Cabazitaxel 15mg/m2|Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
103330|NCT01379339|Drug|Cabazitaxel 17.5mg/m2|Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
103331|NCT01379339|Drug|Cabazitaxel 20mg/m2|Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
103332|NCT01379365|Device|Cryo-Touch III|Percutaneous treatment with the device
103333|NCT00061646|Drug|ABT-510/Thrombospondin-1 mimetic|
103334|NCT01379378|Device|Artificial urinary sphincter|Standard of care
103335|NCT01379378|Device|InVance Sling|Standard of care
103336|NCT01379378|Device|AdVance Sling|Standard of care
103337|NCT01379378|Device|Virtue Sling|Standard of care
103338|NCT01379378|Drug|Contigen|2.5-10 cc
103339|NCT01379391|Drug|Recombinant Human Thrombopoietin (rHTPO)|Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.
Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT.
103340|NCT00061893|Drug|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
103341|NCT01381809|Drug|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
103616|NCT01412190|Other|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
102810|NCT01378442|Other|fitness training program|Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.
Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.
Control:The control group will not receive fitness training program but maintain the usual life style.
103104|NCT01381445|Drug|Clobetasol Propionate|White cream
103105|NCT01381445|Drug|Placebo|White to slightly coloured opaque cream
103106|NCT00061893|Drug|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
103107|NCT01381458|Drug|FSC|fluticasone propionate / salmeterol xinofoate combination
103108|NCT01381458|Drug|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
103109|NCT01381471|Drug|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
103110|NCT01381484|Drug|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
103111|NCT01381497|Drug|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
103112|NCT01381497|Drug|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
103113|NCT01381510|Drug|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
103114|NCT01381523|Drug|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
103115|NCT01373411|Drug|Placebo|Placebo 1 pill BID for 90 days
103116|NCT01373437|Device|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
103117|NCT01373450|Drug|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
103118|NCT01373450|Drug|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
103119|NCT01373450|Drug|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
102876|NCT00061243|Biological|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
102877|NCT01375959|Drug|Placebo|3 placebo capsules orally twice a day for 6 weeks
102878|NCT01375972|Drug|S-1 plus cisplatin|S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks
102879|NCT01375972|Drug|Gemcitabine plus Cisplatin|Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks
102880|NCT01375985|Drug|AVI-7100|Single intravenous administration
102881|NCT01375985|Drug|Placebo|Single intravenous administration
102882|NCT01375998|Drug|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea
102883|NCT01376011|Dietary Supplement|quercetin/placebo|Quercetin 500mg once per day versus placebo
102884|NCT01376037|Device|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
102885|NCT01376037|Device|inactive placebo laser device|non-therapeutic light application
102886|NCT01376050|Device|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
103181|NCT01381523|Drug|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
103182|NCT01381536|Drug|GSK1550188 1mg/kg or 10mg/kg|IV one shot
103183|NCT00061893|Drug|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
103184|NCT01381549|Drug|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
103185|NCT01381549|Drug|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
103186|NCT01381549|Other|Placebo|saline placebo
103187|NCT01381562|Drug|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
103188|NCT01381562|Drug|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
104187|NCT01413100|Drug|Cyclophosphamide|Given IV
104188|NCT01413100|Biological|Filgrastim|Given SC
104189|NCT01413100|Other|Laboratory Biomarker Analysis|Correlative studies
104190|NCT01406015|Drug|Spironolactone|50 mg daily for 6 weeks
104191|NCT00064090|Drug|cytarabine|
104192|NCT01406015|Drug|Placebo|Placebo once daily for 6 weeks
104193|NCT01406028|Behavioral|Phone calls|Phone calls to offer emotional support
104194|NCT01406041|Biological|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
104195|NCT01406054|Other|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
104196|NCT01406067|Behavioral|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
104197|NCT01406067|Behavioral|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
104198|NCT01406080|Drug|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
104199|NCT01406080|Drug|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
104497|NCT01406587|Drug|PP4001|50 mg, 1 dose every 12 hours x 4 doses
104498|NCT01406587|Drug|PP4001|100 mg, 1 dose every 12 hours x 4 doses
104499|NCT01406587|Drug|PP4001|200 mg, 1 dose every 12 hours x 4 doses
104500|NCT01406587|Drug|Placebo|Placebo, 1 dose every 12 hours x 4 doses
104501|NCT01406600|Drug|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24~48 hours from optimal ovarian stimulation status.
104502|NCT00064129|Other|Pharmacological Study|Correlative studies
104503|NCT01406613|Other|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
103617|NCT01412203|Behavioral|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
103618|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
103619|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|
103620|NCT01412229|Drug|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
103621|NCT01412229|Drug|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
103622|NCT01412229|Drug|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
103623|NCT01412242|Other|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
103624|NCT01412281|Biological|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
103625|NCT00064701|Drug|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
103626|NCT01412281|Biological|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
103627|NCT01405053|Drug|Any other approved AED|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
103628|NCT01405066|Behavioral|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
103629|NCT01405066|Behavioral|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
103630|NCT01405079|Drug|Gefitinib|Gefitinib 250 mg/day oral daily for 24 months or disease progression or unacceptable toxicity
103120|NCT01373450|Drug|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
103121|NCT01373450|Drug|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
103122|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
103123|NCT01373463|Drug|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
103124|NCT00060944|Drug|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
103394|NCT01377012|Biological|Secukinumab (AIN457)|Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
103395|NCT01377012|Biological|Placebo|
103396|NCT00061373|Drug|tinzaparin sodium|A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
103397|NCT01377025|Drug|Placebo|two tablets in the morning and two in the evening.
103398|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
103399|NCT01379404|Device|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
103400|NCT01379417|Dietary Supplement|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
103401|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intramuscularly
103402|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intradermal
103403|NCT00061646|Drug|Carboplatin/Taxol|
103404|NCT01379443|Other|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
103405|NCT01379456|Procedure|physiotherapy|exercises, 20 sessions over 10 weeks
103189|NCT01381562|Other|Placebo|saline placebo
103190|NCT01381575|Biological|GSK Biologicals' HPV vaccine 580299|Subjects will receive 2 or 3 doses of HPV vaccine administered intramuscularly
103191|NCT01381588|Other|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
103192|NCT01381601|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
103193|NCT01381614|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
103194|NCT00061893|Drug|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
103195|NCT01381627|Drug|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
103196|NCT01381627|Drug|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
103197|NCT01381640|Drug|Marketed paracetamol|marketed formulation
103198|NCT01381640|Drug|Experimental paracetamol formulation|Experimental formulation
103466|NCT01377077|Procedure|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
103467|NCT00001085|Drug|Lamivudine|
103468|NCT00061373|Drug|eptifibatide|Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
103469|NCT01377103|Drug|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
103470|NCT01377129|Procedure|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
103471|NCT01377129|Procedure|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
103472|NCT01377155|Drug|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
104504|NCT01408758|Other|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
104505|NCT01408758|Other|No VCRT, only physician counseling at visits|No intervention
104506|NCT01408797|Procedure|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
104507|NCT01408797|Drug|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
104508|NCT01408797|Procedure|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
104509|NCT01408810|Drug|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
104510|NCT01408836|Procedure|Plasma exchange|Plasma exchange
104511|NCT01408836|Drug|Intravenous methyl prednisolone|Intravenous methyl prednisolone
104512|NCT01408836|Drug|Methyl prednisolone|methyl prednisolone
104513|NCT01408849|Drug|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
104514|NCT00064298|Dietary Supplement|placebo|Given orally
104515|NCT01408849|Drug|Omeprazole|Standard therapy
104516|NCT01408862|Other|venous puncture|Blood for in vitro studies will be drawn
104517|NCT01408875|Device|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
104518|NCT01408888|Biological|LY2189265|Administered subcutaneously
104767|NCT01409226|Procedure|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
104768|NCT01409239|Drug|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
104769|NCT01409239|Drug|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
104770|NCT01409278|Procedure|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
104771|NCT01409278|Procedure|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
102735|NCT00061815|Drug|5-fluorouracil|400 mg/m2 IV
102736|NCT01380860|Procedure|Colostomy with mesh implantation|Colostomy with mesh implantation
102737|NCT01380860|Procedure|Simple colostomy|Colostomy with no mesh implantation.
102738|NCT01380873|Drug|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
102739|NCT01380873|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
102740|NCT01380873|Drug|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
102741|NCT01380886|Other|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
102742|NCT01380886|Other|Infant formula powder|powdered infant formula to be fed ad libitum
102743|NCT01380899|Procedure|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
102744|NCT01380912|Drug|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
102745|NCT01380938|Drug|Peginterferon alpha-2a + Ribavirin|Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight < or > 75 kg for 24 weeks (Arm A).
Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).
These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)
102746|NCT00061815|Drug|5-fluorouracil|600 mg/m2 IV
102747|NCT01380951|Drug|telbivudine|telbivudine 600mg/d 96 weeks
102748|NCT01380977|Behavioral|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
102749|NCT01380990|Genetic|EF1αS-ADA lentiviral vector transduced patient Cd34+ cells|EF1αS-ADA lentiviral vector transduced patient Cd34+ cells will be infused in a volume of ~10-20 mls/kg intravenously over 30-45 minutes.
102750|NCT01381003|Genetic|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
102751|NCT01381016|Drug|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
102752|NCT01381016|Drug|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
102753|NCT01381016|Drug|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
103406|NCT01379469|Drug|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated, and the placebo group will receive encapsulated tablets without CBZ.
103407|NCT01379469|Drug|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
103408|NCT01379482|Drug|Multimodal treatment|3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.
Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.
Neo-adjuvant chemotherapy:
Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)
Hyperthermic intraoperative chemotherapy:
Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)
Early postoperative chemotherapy:
5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)
103409|NCT01379495|Behavioral|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
103691|NCT01410149|Other|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
103692|NCT01410149|Other|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
103693|NCT01410162|Drug|Tacrolimus|tacrolimus extended release capsules vs Prograf
103694|NCT01410175|Device|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
103695|NCT01410188|Drug|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
103696|NCT01412294|Drug|Capecitabine, Cisplatin|Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
103697|NCT01412307|Drug|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
103698|NCT01412307|Drug|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
103699|NCT01412307|Other|Bio-specimen Retention|Samples with DNA and without DNA
103700|NCT01412320|Other|Cocoa|dissolved in water twice daily
103701|NCT01412320|Other|Cocoa|dissolved in water twice daily
103702|NCT01412333|Drug|Rebif|8.8 mcg (Weeks 1+2) / 22 mcg (Weeks 3+4) / 44mcg (Week 5 and following) subcutaneously 3 times weekly, 96 weeks
103473|NCT01377168|Drug|oral naltrexone|
103474|NCT01377168|Drug|Placebo pill|
103475|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
103476|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
103477|NCT01377194|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
103478|NCT01377207|Procedure|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
103479|NCT00061386|Behavioral|Nutrition and physical activity program|
103480|NCT01377220|Drug|11C-Choline|11C-Choline : 6MBq/kg on direct intravenous on one minute.
103481|NCT01377233|Drug|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
103482|NCT01377233|Drug|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
103483|NCT01379560|Drug|unoprostone isopropyl|unoprostone isopropyl (3 drops)
placebo (3 drops)
103484|NCT01379573|Drug|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
103485|NCT01379586|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
103777|NCT01410214|Drug|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
103778|NCT01410227|Biological|Recombinant von Willebrand factor (rVWF) with or without rFVIII (Advate)|Intravenous administration
103779|NCT01410240|Procedure|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
103780|NCT01410240|Drug|FLOSEAL Hemostatic Matrix + Standard of care|FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.
+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used
104772|NCT01409278|Procedure|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
104773|NCT01409304|Device|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
104774|NCT01409317|Device|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
104775|NCT01409317|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
104776|NCT00001101|Drug|ceftriaxone|
104777|NCT00064337|Drug|cyclophosphamide|
104778|NCT01409330|Dietary Supplement|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
104779|NCT01409343|Drug|TrasGEX™|
104780|NCT01409356|Behavioral|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
104781|NCT01409369|Drug|RO4995819|single oral dose
104782|NCT01409369|Drug|activated charcoal|orally 3 times daily, Days 1-7
104783|NCT01409382|Behavioral|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
105098|NCT01402960|Device|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.
For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.
For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.
For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)
105099|NCT01402973|Other|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
105100|NCT00063934|Biological|oblimersen sodium|Given IV
102754|NCT01381055|Drug|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
103034|NCT01373398|Drug|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
103035|NCT00060944|Drug|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
103036|NCT01373411|Drug|ticagrelor|ticagrelor 90 mg BID for 90 days
103037|NCT01376206|Drug|Fluticasone|Collection of safety data
103038|NCT01376219|Other|asthma control test|results of asthma control testing collected
103039|NCT01376232|Drug|GSK1278863|GSk1278863 100mg
103040|NCT01376232|Drug|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
103041|NCT01376232|Drug|Gemfibrozil|600 mg Gemfibrozil
103042|NCT00001085|Drug|Amprenavir|
103043|NCT00061269|Procedure|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
103044|NCT01376245|Drug|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
103045|NCT01376245|Drug|Placebo|matching placebo
103046|NCT01376258|Drug|5ARI|dutasteride or finasteride
103047|NCT01376271|Drug|Paroxetine|
103048|NCT01376284|Drug|Dutasteride|Collection of safety data
103049|NCT01376297|Drug|Netupitant and Palonosetron|
103050|NCT01376297|Drug|Aprepitant|
103051|NCT01376297|Drug|Palonosetron|
103052|NCT01376297|Drug|Dexamethasone|
103053|NCT01376310|Drug|GSK1120212|up to 2 mg/day
103054|NCT00061282|Drug|Clotrimazole|One retention enema, administered nightly
103055|NCT01376310|Drug|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
103703|NCT01412333|Drug|Rebif placebo|Rebif dummy placebo sc according to schedule in Rebif active group B
103704|NCT01412333|Drug|ocrelizumab|600 mg iv every 24 weeks (dual infusions of 300 mg on Day 1 and 15 of Cycle 1, single infusion of 600 mg on Day 1 of each following cycle), 96 weeks
103705|NCT00064701|Drug|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
103706|NCT01412333|Drug|ocrelizumab placebo|Ocrelizumab dummy placebo iv according to schedule in ocrelizumab active group A
103707|NCT01412346|Other|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
103708|NCT01412359|Drug|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
103709|NCT01412372|Drug|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
103710|NCT01412372|Drug|Placebo|This is an inactive pill
103711|NCT01412385|Biological|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
102811|NCT01378455|Other|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
102812|NCT01378455|Other|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
102813|NCT01378468|Other|oral triglyceride tolerance test (not a therapeutic "intervention" as such but a new diagnostic test)|see Ebinger et al., IJS, 2010
102814|NCT01378481|Drug|Vorinostat|Given PO
102815|NCT01378481|Radiation|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
102816|NCT01378481|Other|Laboratory Biomarker Analysis|Correlative studies
102817|NCT01378481|Other|Pharmacological Study|Correlative studies
102818|NCT00061529|Drug|Brimonidine Tartrate Ophthalmic Solution|
102819|NCT01378481|Procedure|Therapeutic Conventional Surgery|Undergo neurosurgery
103781|NCT01410253|Other|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
103782|NCT01410253|Other|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
103783|NCT01410253|Other|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
103784|NCT01410253|Other|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
103785|NCT00000256|Drug|60% N2O|
103786|NCT00001101|Drug|doxycycline|
103787|NCT00064389|Drug|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
103788|NCT01410266|Other|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
103789|NCT01410279|Other|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
103790|NCT01410292|Other|GI and fiber meals|meals with different fiber content and glycemic index
103791|NCT01410292|Other|meals|four different meal regarding GI and fiber content
103792|NCT01410331|Biological|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
103793|NCT01410331|Biological|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
103794|NCT01412437|Dietary Supplement|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
103795|NCT01412437|Drug|sapropterin dihydrochloride|20 mg/kg for 4 months
102887|NCT00061256|Drug|Alendronate|
102888|NCT01376050|Device|Placebo Laser|Placebo Laser has no therapeutic output emitted.
102889|NCT01378520|Drug|inert powder|oral once
102890|NCT01378533|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d*8cycles
105101|NCT01402986|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the immunoglobulin G4 (IgG4) subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
105102|NCT01402999|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
105103|NCT01403012|Other|Withdrawal of venous blood samples|Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)
Laboratory measurements:
Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes
105104|NCT01403025|Drug|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
105105|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 1 for 84 days
105106|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 2 for 84 days
105107|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 3 for 84 days
105108|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
105109|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 5 for 84 days
105110|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 6 for 84 days
105111|NCT00063934|Drug|doxorubicin hydrochloride|Given IV
105112|NCT01403038|Drug|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
105113|NCT01403051|Drug|EFV/FTC/TDF|FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
105114|NCT01403051|Drug|Calcium Carbonate|Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
105115|NCT01403051|Drug|Vitamin D3|One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
105116|NCT01403051|Drug|Placebo for calcium carbonate|A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
103891|NCT01412736|Drug|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
103892|NCT01412762|Behavioral|patient interviews|The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
103056|NCT01376310|Drug|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
103057|NCT01376310|Drug|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
103058|NCT01376310|Drug|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
103059|NCT01376310|Drug|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
103342|NCT01381809|Drug|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
103343|NCT01381822|Drug|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
103344|NCT01381835|Drug|TMC435|150 mg capsule once daily for 7 days
103345|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients <8 weeks CA.
103346|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients >=8 weeks CA.
103347|NCT01381861|Biological|Chimeric monoclonal antibody (TRC105) to CD105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
103348|NCT01381874|Drug|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
103349|NCT01381874|Drug|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
103350|NCT01381874|Drug|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
103351|NCT00061893|Procedure|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
103352|NCT01381887|Drug|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
103353|NCT01381887|Drug|Canagliflozin 300mg/Placebo|Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.
Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods.
103354|NCT01381887|Drug|Canagliflozin 300mg/Canagliflozin 150mg|Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.
Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods.
102820|NCT01378507|Behavioral|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
102821|NCT01378520|Drug|ketoconazole|600 mg capsule oral once
102822|NCT01381081|Biological|platelet-rich plasma|a single intra-articular injection
102823|NCT01381081|Drug|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
102824|NCT01381094|Drug|AKB-6548|oral dose administered once daily for 42 days
102825|NCT01381094|Drug|Placebo|oral placebo administered once daily for 42 days
102826|NCT01381107|Drug|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
102827|NCT01381107|Drug|Placebo|Sublingual administration once daily for 7 consecutive days.
102828|NCT01381120|Drug|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
102829|NCT01381120|Drug|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
103125|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
103126|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
103127|NCT01373463|Drug|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
103128|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
103129|NCT01373463|Procedure|Lobectomy|Surgery
103130|NCT01373463|Procedure|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
103131|NCT01373476|Drug|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
103132|NCT01373476|Drug|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
102891|NCT01378546|Drug|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
102892|NCT01378559|Other|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
102893|NCT01378585|Drug|DLBS1033|3 x 490 mg DLBS1033 daily
102894|NCT01378585|Drug|Placebo|3 x 1 tablet daily
102895|NCT01378598|Other|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
102896|NCT00061542|Drug|BETOPTIC S (betaxolol HCl)|
102897|NCT01378611|Device|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
102898|NCT01378624|Other|Bronchoscopy|In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.
The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies.
102899|NCT01378637|Device|AMES- Leg therapy|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
102900|NCT01378650|Drug|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
102901|NCT01378650|Drug|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
102902|NCT01378676|Drug|Placebo|Three matching placebo tablets once daily for 14 days (Part A) or three matching placebo tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
102903|NCT01378676|Drug|CK-2017357|One 125 mg CK-2017357 tablet and two matching placebo tablets once daily for 14 days (Part A) or one 125 mg CK-2017357 tablet and two matching placebo tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
102904|NCT01378676|Drug|CK-2017357|Two 125 mg CK-2017357 tablets and one matching placebo tablet once daily for 14 days (Part A) or two 125 mg CK-2017357 tablets and one matching placebo tablet once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
102905|NCT01378676|Drug|CK-2017357|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A) or three 125 mg CK-2017357 tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
103199|NCT01381653|Other|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
103200|NCT01381666|Drug|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
103893|NCT01412775|Behavioral|short-term group intervention program|The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.
The study includes three weekly sessions, Each session will be 90 minutes in duration.
103894|NCT01412788|Procedure|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
103895|NCT01412788|Procedure|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
103896|NCT01412801|Biological|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
103897|NCT01412814|Device|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
103898|NCT01412814|Other|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
103899|NCT00064727|Drug|Avandia (Rosiglitazone)|
103900|NCT01405560|Drug|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
103901|NCT01405560|Biological|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
103902|NCT01405560|Drug|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
103903|NCT01405573|Other|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
103904|NCT01405573|Drug|sorafenib|400 mg twice a day
103905|NCT00064064|Drug|triapine|
103906|NCT01405586|Drug|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
103907|NCT01405586|Drug|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
103908|NCT01405586|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
103909|NCT01405599|Drug|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
103910|NCT01405612|Drug|Midazolam|Single oral administration on Day 1 or Day 5
103355|NCT01381887|Drug|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
103356|NCT01381900|Drug|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
103357|NCT01381900|Drug|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
103358|NCT01381900|Drug|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
103359|NCT01381900|Drug|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
103631|NCT01405079|Drug|Vinorelbine/Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles or disease progression or unacceptable toxicity.
103632|NCT01405092|Device|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
103633|NCT00064038|Drug|dexamethasone|Given orally
103634|NCT01405092|Device|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
103635|NCT01405118|Drug|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
103636|NCT01405131|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
103637|NCT01405131|Drug|methylprednisolone|tablets 32 mg single dose
103638|NCT01405144|Drug|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
103639|NCT01405144|Procedure|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
103640|NCT01405157|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
103641|NCT01405157|Drug|methylprednisolone|tablets 16 mg single dose
103642|NCT01405170|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
103643|NCT01405170|Drug|methylprednisolone|tablets 32 mg single dose
103644|NCT00064038|Drug|lenalidomide|Given orally
103133|NCT01373489|Device|Technology-Assisted Case Management (TACM with the FORA 2-in-1 Telehealth System)|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time.
103134|NCT01373502|Device|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
103135|NCT00060957|Drug|Botulinum toxin type A|
103136|NCT01373502|Device|Taxus Liberté Stent|Taxus Liberté Coronary Stent
103137|NCT01373515|Biological|DCP-001|4 bi-weekly vaccinations
103138|NCT01373528|Drug|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
103139|NCT01373541|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
103140|NCT01376336|Device|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
103141|NCT01376349|Drug|prasterone|Applied vaginally
103142|NCT01376349|Other|placebo|Applied vaginally
103143|NCT01376362|Drug|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
103144|NCT01376375|Procedure|Acupuncture|
103410|NCT01379508|Drug|Telbivudine 600mg|
103411|NCT01379508|Drug|Tenofovir disoproxil fumarate 300mg|
103412|NCT01379521|Drug|everolimus|
103413|NCT01379521|Drug|everolimus placebo|
103414|NCT00061659|Drug|ABT-510 - Thrombospondin-1 mimetic|
103415|NCT01379534|Drug|TKI258|
103416|NCT01379547|Behavioral|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
103201|NCT01373541|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
103202|NCT01373554|Drug|Placebo|30mig/bid or 60mg/bid P.O
103203|NCT01373554|Drug|Oltipraz|30mig/bid or 60mg/bid P.O
103204|NCT01373567|Drug|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
103205|NCT01373580|Device|The Raindrop Corneal Inlay|
103206|NCT01373593|Drug|lidocaine|
103207|NCT00001084|Drug|Lamivudine|
103208|NCT00060970|Procedure|Physical Therapy|
103209|NCT01373593|Drug|Placebo|
103210|NCT01373606|Drug|Terlipressin|
103211|NCT01373619|Drug|Ivabradine|ivabradine titrated to 7.5 mg BID
103212|NCT01373632|Device|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
103213|NCT01373632|Device|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
103214|NCT01373645|Device|Yinyi stent|subjects with Yinyi stent implantation
103215|NCT01373658|Device|Yinyi stent|subjects with Yinyi stent implantation
103216|NCT01373671|Device|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
103217|NCT01373684|Drug|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
103218|NCT01373684|Drug|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
103219|NCT00060983|Procedure|Body weight supported locomotor training|
103220|NCT01373697|Drug|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
103221|NCT01373697|Drug|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
103486|NCT01379586|Drug|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
102977|NCT01378780|Behavioral|Educational intervention for diet and physical activity|The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
102978|NCT01378780|Behavioral|Educational message on skin cancer awareness|Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
102979|NCT00061568|Procedure|Radiotherapy|
102980|NCT01378793|Behavioral|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
102981|NCT01378793|Behavioral|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
102982|NCT01378806|Behavioral|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
102983|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
102984|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
102985|NCT01378832|Procedure|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
102986|NCT01378845|Drug|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
102987|NCT01378845|Drug|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
102988|NCT01381354|Other|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
102989|NCT01381354|Device|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
102990|NCT01381354|Other|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
103645|NCT01405183|Other|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
103646|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
103647|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
103648|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
103649|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
103650|NCT01407432|Drug|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
103651|NCT01407445|Drug|Placebo|1 tablet/ oral/ 3 times a day for 90 days
103652|NCT01407445|Drug|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
102755|NCT01381055|Drug|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
102756|NCT01381068|Device|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
102757|NCT00061815|Biological|cetuximab|250 mg/m2 IV
102758|NCT01383122|Device|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
102759|NCT01383122|Device|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
102760|NCT01383135|Drug|FPPRGD2|radiopharmaceutical administered for imaging, up to 14 mCi i.v.
102761|NCT00061945|Drug|dexamethasone|Given PO and as eye drops
102762|NCT01383148|Biological|TG4010|TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.
Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.
First line therapy:
Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab
Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin
Maintenance therapy:
• Pemetrexed or erlotinib for eligible patients and according to labeling.
102763|NCT01383148|Drug|placebo|Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.
First line therapy: as in Arm 1
Maintenance therapy: as in Arm 1
102764|NCT01383161|Drug|Curcumin|Six 465 milligram capsules (containing 30 mg of curcumin each) per day for 18 months.
103417|NCT01379547|Behavioral|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
103418|NCT01379560|Drug|unoprostone isopropyl|unoprostone isopropyl (2 drops)
placebo (2 drops)
103419|NCT01381900|Drug|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
103420|NCT01381926|Drug|exenatide|exenatide 5mcg sq twice daily and exenatide 10mcg twice daily
103421|NCT00061893|Radiation|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
103422|NCT01381926|Drug|placebo|placebo twice daily
103423|NCT01381952|Radiation|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
103424|NCT01381952|Radiation|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
103425|NCT01381965|Procedure|Vitreous surgery for macular hole|Vitreous surgery for macular hole
103426|NCT01381991|Device|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
103427|NCT01382004|Drug|Penicillin-G-benzathine|Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.
Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
103712|NCT01412385|Biological|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
103713|NCT01412385|Biological|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
103714|NCT01412398|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CCPD who have received Fosrenol for hyperphosphatemia
103715|NCT01412411|Behavioral|Nutritionl Education|to assess the change in behaviour
103716|NCT00064701|Drug|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
103487|NCT01379599|Behavioral|brief motivation intervention|brief psychosocial counseling (20 minutes at the time of an ER visit)
103488|NCT01379612|Other|Ultrasonic Elastography|Non-invasive
103489|NCT00061672|Drug|ABT-510 - Thrombospondin-1 Mimetic|
103490|NCT01379625|Drug|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
103491|NCT01379651|Other|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
103492|NCT01379664|Drug|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
103493|NCT01379664|Drug|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
103494|NCT01379677|Drug|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
103495|NCT01379677|Drug|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
103496|NCT01379690|Other|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
103497|NCT01379716|Other|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
103498|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
103499|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
103500|NCT00061698|Behavioral|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
103501|NCT01379742|Device|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
103502|NCT01379742|Device|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
103503|NCT01379768|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
103504|NCT01379768|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
102991|NCT01381354|Dietary Supplement|Omega 3 fatty acids|4 grams daily by mouth.
103291|NCT01373853|Procedure|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
103292|NCT01373853|Procedure|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
103293|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target defined using both fMRI during hallucinations occurence and tractography.
Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
103294|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
103295|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
103296|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
103297|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
103298|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
103299|NCT00060996|Drug|Remodulin® (treprostinil sodium) Injection|
103300|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
103301|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
103302|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
103303|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
103304|NCT01373892|Procedure|Bariatric surgery|
103305|NCT00061347|Procedure|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
103306|NCT01376713|Biological|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
103307|NCT01376713|Biological|Ofatumumab plus Dacarbazine|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.
Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks.
102765|NCT01383161|Other|Placebo|Six 465 milligram capsules per day for 18 months.
102766|NCT01383174|Behavioral|Peer Support Program|Work with a trained counselor who is a breast cancer survivor
Meet 8 times in-person over the 8 week program with the counselor
Counselor helps participant develop a personalized support program to help her improve her quality of life
Receives information on breast cancer, its treatments, and stress management
102767|NCT01383187|Procedure|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
102768|NCT01383187|Procedure|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
102769|NCT01383200|Drug|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
102770|NCT01383200|Drug|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
102771|NCT01383213|Other|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
102772|NCT00061945|Drug|asparaginase|Given SC
102773|NCT01383213|Other|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
103060|NCT01376310|Drug|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
103061|NCT01376310|Drug|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
103062|NCT01376323|Drug|GSK256073 1mg|GSK256073 1mg capsule
103063|NCT01376323|Drug|GSK256073 5mg|GSK256073 5mg capsule
103064|NCT01376323|Drug|GSK256073 10mg|GSK256073 10mg capsule
103065|NCT00061295|Procedure|Body weight support treadmill training|
103066|NCT01376323|Drug|GSK256073 25mg|GSK256073 25mg capsule
103067|NCT01376323|Drug|Placebo|placebo capsule
103068|NCT01376323|Drug|Sitagliptin 100mg|Sitagliptin 100mg capsule
103069|NCT01378858|Behavioral|Varenicline treatment as usual or directly observed therapy|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
103070|NCT01378871|Drug|IMTOX-25|This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mls contains 2.5 mg IMTOX-25 15 mg/m²/cycle IV; The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7.
103071|NCT00061568|Drug|Alemtuzumab (Campath )|
103717|NCT01412411|Dietary Supplement|Oral Iron Supplementation along with Nturition Eductaion|
103718|NCT01412411|Dietary Supplement|Multiple micronutrient fortification plus Nutrition Education|
103719|NCT01412424|Drug|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
103720|NCT01405235|Drug|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
103721|NCT01405235|Drug|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
103722|NCT01405248|Drug|Butylphthalide|20 mg/time per os three times a day. 180days
103723|NCT01405248|Drug|Placebo|20 mg/time per os three times a day. 180days
103724|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
103725|NCT00064038|Other|placebo|Given orally
103726|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
103727|NCT01405261|Drug|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
103728|NCT01405261|Drug|oral placebo|Subjects will be randomised to receive a single dose of placebo.
103729|NCT01405274|Other|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
103730|NCT01405287|Device|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
103731|NCT01405300|Dietary Supplement|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver ~1200 kcal.
103732|NCT01405300|Dietary Supplement|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver ~1200 kcal.
102830|NCT01381133|Behavioral|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
103796|NCT01412437|Drug|sapropterin dihydrochloride|
103797|NCT01412450|Device|nitinol stent|implantation of one Protégé EverFlex stent
103798|NCT01412463|Device|stent placement|pre-dilation of the study lesion is mandatory
stent placement with 1 Protégé Everflex+ stent
only 1 stent is allowed within the study protocol
post-dilation may be performed but is not mandatory
103799|NCT01412489|Device|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
103800|NCT01412502|Other|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
103801|NCT00064701|Drug|mycophenolate mofetil|Oral
103802|NCT01412515|Drug|everolimus|everolimus per os 10mg per day
103803|NCT01412528|Other|Allergen extracts|
103804|NCT01412541|Procedure|Standard Uncoated Angioplasty Balloon|Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
103805|NCT01412541|Device|Moxy Drug Coated Balloon|Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
103806|NCT01412567|Drug|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
103807|NCT01412567|Drug|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
103808|NCT01412580|Drug|Folic Acid|Pill, 0.6mg given in 2002-2004, duration of pregnancy
103809|NCT01412593|Biological|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
103810|NCT01412606|Procedure|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
103811|NCT01412632|Drug|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
103812|NCT00001106|Drug|Zidovudine|
103813|NCT00064714|Drug|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
103814|NCT01412645|Dietary Supplement|Resveratrol|500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or
1 placebo 2 times daily for 4 months
103308|NCT01376726|Biological|Sub C gp140 Vaccine|Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.
Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.
103309|NCT01376726|Biological|MF59C.1 Adjuvant|Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.
Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.
103578|NCT01407354|Other|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
103579|NCT01407380|Drug|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
103580|NCT01407393|Device|Glucosanol|2 tablets 3x daily for 12 weeks
103581|NCT01407393|Device|Placebo|2 tablets 3x daily for 12 weeks
103582|NCT00064181|Drug|irinotecan hydrochloride|
103583|NCT01407406|Drug|BIIB023 - low dose IV Dose|
103584|NCT01407406|Drug|BIIB023 - high dose IV Dose|
103585|NCT01407419|Other|Treatment Acceleration|Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.
Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of "traditional" or "biologic" Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)
103586|NCT01407419|Other|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
103587|NCT01407432|Drug|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
103588|NCT01409707|Behavioral|Healthy lifestyles sessions|
103589|NCT01409720|Other|exercise|tailored isometric physical exercise
103590|NCT00064350|Drug|Sorafenib|Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.
Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.
Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death.
103591|NCT01409733|Device|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
103072|NCT01378871|Other|IMTOX-25|Imtox-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.
103073|NCT01378884|Drug|Domperidone|Patient to receive treatment with Domperidone
103074|NCT01378897|Device|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
103075|NCT01378910|Drug|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
103076|NCT01378923|Behavioral|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
103077|NCT01378923|Behavioral|TAU|have access to standard jail programs and services
103078|NCT01378936|Behavioral|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
103079|NCT01378936|Behavioral|Motivational Interview only|45 minute Motivational Interview session
103080|NCT01378949|Drug|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
103081|NCT01378949|Drug|Morphine|Morphine 1 mg/cc
103360|NCT01373905|Procedure|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
103361|NCT01373905|Procedure|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
103362|NCT01373918|Drug|Intralipid|The subject will receive 1 gm/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
103363|NCT01373918|Drug|Intralipid|The subject will receive 3 gm/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
103364|NCT01373931|Drug|LY2216684|Administered orally
103365|NCT00061022|Drug|NXY-059|
103366|NCT01373931|Drug|Ortho Cyclen|35 mcg ethinyl estradiol and 250 mcg norgestimate administered orally
103367|NCT01373931|Drug|Placebo|Administered orally
102831|NCT01381133|Behavioral|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
102832|NCT00061841|Behavioral|exercise|
102833|NCT01381133|Behavioral|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
102834|NCT01381146|Behavioral|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
102835|NCT01381146|Behavioral|TAU|have access to other jail programs and services
102836|NCT01381159|Behavioral|Motivational Interviewing|Brief MI sessions focused on medication adherence within 4-6 week period
102837|NCT01381159|Behavioral|Control|Standard medical care and contact time matched to the active intervention within 4-6 week period
102838|NCT01381172|Device|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
102839|NCT01381172|Other|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
102840|NCT01381185|Drug|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
102841|NCT01383447|Other|flow cytometry|Correlative studies
102842|NCT01383447|Genetic|polymerase chain reaction|Correlative studies
102843|NCT01383447|Other|high performance liquid chromatography|Correlative studies
102844|NCT01383447|Other|mass spectrometry|Correlative studies
102845|NCT01383460|Drug|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
103145|NCT01376388|Drug|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
105372|NCT01403649|Behavioral|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
105373|NCT00063947|Drug|gemcitabine hydrochloride|Given IV
105374|NCT01403649|Other|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
105375|NCT01403662|Drug|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
105376|NCT01395576|Device|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
105377|NCT01395589|Drug|Vitamin D|patients with asthma with exacerbation will be admitted to the inpatient/short stay unit for the treatment of moderate-severe asthma .
Patients will be included after obtaining a verbal consent. Blood sample for 25OH cholecalciferol level will be sent before discharge. Patients with vitamin D deficiency will be called to receive either daily oral vitamin D or single injection of intramuscular vitamin D and level of vitamin D will be repeated at 3,6,12 months.
105378|NCT01395602|Drug|Cabergoline|cabergoline 0.5 mg twice weekly
105379|NCT01395602|Other|placebo|1 pill twice weekly
105380|NCT01395628|Drug|in vitro sensitivity-directed chemotherapy|
105684|NCT01398670|Biological|Insulin Lispro|a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50
The drugs would be administered subcutaneously
105685|NCT01398670|Biological|Insulin Lispro|Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50
The drugs would be administered subcutaneously
105686|NCT01398696|Procedure|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
105687|NCT01398696|Procedure|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
105688|NCT01398709|Other|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
105689|NCT01398709|Other|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
105690|NCT01398722|Other|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
105691|NCT01398722|Other|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
108873|NCT01424072|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
108874|NCT00066079|Procedure|massage|
108875|NCT01424098|Behavioral|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
108876|NCT01424111|Drug|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
109151|NCT01459978|Other|CUmulative SUM (CUSUM) Chart|Intervention is described as follows:
Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).
Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose
109152|NCT01459991|Other|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
109153|NCT01459991|Other|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
109154|NCT01460004|Device|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
109155|NCT01460017|Procedure|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
109156|NCT00069745|Drug|Satraplatin|
109157|NCT01460017|Procedure|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
109158|NCT01460030|Drug|Cinacalcet HCl|Oral administration
109159|NCT01460043|Drug|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
109160|NCT01453140|Drug|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off.
109161|NCT01453153|Drug|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
109162|NCT01453153|Drug|PEGPH20+ gemcitabine|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Gemcitabine given at 1000mg/m2. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
109568|NCT01461226|Behavioral|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
109569|NCT01461226|Behavioral|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
109570|NCT01461239|Procedure|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
109571|NCT01461239|Procedure|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
109572|NCT01461239|Procedure|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
109573|NCT01461252|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
109574|NCT01461252|Procedure|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
109575|NCT00069875|Drug|Gemcitabine|
109576|NCT01461265|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
109577|NCT01461278|Device|iStent supra|Cataract surgery and implantation of one iStent supra
109578|NCT01461278|Procedure|Cataract surgery|Cataract surgery alone
109903|NCT01458873|Drug|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
109904|NCT01458873|Drug|diluted sodium bicarbonate 2.1%|50ml
109905|NCT01458873|Drug|normal saline|50ml
109906|NCT01458886|Drug|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
109907|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
109908|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
109909|NCT01458886|Drug|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
109070|NCT01453075|Drug|Valacyclovir|Valacyclovir 1.5 mg po bid
109071|NCT01453075|Drug|Placebo|Matching placebo twice daily
109072|NCT01453088|Drug|Melphalan|Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.
Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.
Dosing will be based on body surface area calculated using actual body weight
Stem cell infusion:
Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.
Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).
109073|NCT01453088|Drug|Bortezomib|Bortezomib:
Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.
109074|NCT01453101|Drug|Fludarabine monophosphate, melphalan, Bortezomib|Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.
Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2
Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.
109075|NCT01453114|Behavioral|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
109076|NCT00068822|Device|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
109077|NCT01453127|Drug|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
109078|NCT01453127|Device|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
109079|NCT01453140|Drug|Cyclophospahmide and Sirolimus|On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are >40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.
One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily.
109080|NCT01453140|Drug|Low dose IL-2, Cyclophosphamide and Sirolimus|Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.
IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide.
109081|NCT00069095|Drug|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
109333|NCT01453452|Behavioral|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
109669|NCT00068952|Drug|Carmustine (BCNU)|
109670|NCT01453959|Other|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
109671|NCT01453972|Behavioral|Long distanse moderate training|Moderate exercise
109672|NCT01453972|Behavioral|Long interval training|High-intensity exercise, long duration
109673|NCT01453972|Behavioral|Short interval training|High intensity exercise, short duration
109674|NCT01453985|Procedure|Full-Thickness-Gastroplication|
109675|NCT01453998|Biological|Infanrix hexa™|Single dose, licensed formulation, intramuscular into right thigh
109676|NCT01453998|Biological|Prevenar 13®|Single co-administered dose, intramuscular into left thigh
109677|NCT01453998|Biological|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
109678|NCT01454011|Drug|Testosteron 250mg injection|The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
109679|NCT01454011|Drug|Testosterone 50mg transdermal application|Application of testosterone 50mg transdermal gel in every night
109680|NCT00068952|Drug|Lomustine (CCNU)|
109681|NCT01454024|Device|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
109682|NCT01454024|Device|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
109683|NCT01454037|Procedure|Prostate cryotherapy|cryoablate the prostate
109684|NCT01454037|Procedure|Radical prostatectomy|Remove prostate
109685|NCT01454037|Procedure|Radiation|Radiate prostate
109686|NCT01454063|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
109687|NCT01454063|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
109163|NCT01453166|Other|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
109164|NCT01453166|Other|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
109165|NCT01453166|Other|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
109412|NCT01460537|Drug|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
109413|NCT01453517|Behavioral|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
109414|NCT01453530|Drug|Sugammadex|A single dose of sugammadex 2 mg/kg iv
109415|NCT01453530|Drug|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
109416|NCT00001144|Drug|Modified bone marrow stem cell transplantation|
109417|NCT00068874|Behavioral|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
109418|NCT01453530|Other|Placebo|Placebo
109419|NCT01453543|Other|deep transverse friction massage|For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.
109420|NCT01453556|Procedure|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
109421|NCT01453569|Drug|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
109422|NCT01453569|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
109910|NCT01458899|Drug|TC-5214|Oral tablets, single 4mg dose
109911|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
109912|NCT00069641|Biological|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
109913|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
109914|NCT01458912|Drug|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
109915|NCT01458912|Drug|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
109916|NCT01458925|Device|The P1 Check-Cap capsule|The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
109917|NCT01458938|Other|treatment plan|Data Collection Study
109918|NCT01458951|Drug|tofacitinib|10 mg oral BID
109919|NCT01458951|Drug|Placebo|Placebo oral BID
109920|NCT01452191|Behavioral|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
109921|NCT01452191|Behavioral|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
109922|NCT01452204|Other|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
109923|NCT01452217|Drug|Secretin|Secretin 1 IU/kg over 3 min
109924|NCT01452230|Behavioral|Supervised physical activity|Supervised physical activity
109925|NCT01452243|Drug|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
109010|NCT01429142|Behavioral|AIMS counseling|The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:
-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.
Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo.
109334|NCT01453452|Other|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
109335|NCT01453452|Procedure|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
109336|NCT01453465|Genetic|RNA analysis|
109337|NCT01453465|Genetic|gene expression analysis|
109338|NCT00068861|Drug|clomiphene citrate|
109339|NCT01453465|Genetic|polymerase chain reaction|
109340|NCT01453465|Genetic|protein expression analysis|
109341|NCT01453465|Other|laboratory biomarker analysis|
109342|NCT01453478|Drug|GSK1325756|CXCR2 antagonist
109343|NCT01453491|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
109344|NCT01453504|Drug|DHAP|Dexamethasone, Cytarabine, Cisplatin
109345|NCT01453504|Drug|Everolimus|
109346|NCT01455558|Drug|Pletaal|Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state
Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state
Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart
109347|NCT01455571|Drug|HM781-36B|Q1DX14/2W for 3W HM781-36B
109348|NCT01455584|Drug|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
109349|NCT01455597|Drug|Estradiol Vaginal Gel|Estradiol vaginal gel containing 0.017 mg estradiol per gram, 3X weekly for 40 weeks
109350|NCT01455636|Other|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
109351|NCT01455636|Dietary Supplement|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
109668|NCT01453959|Drug|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
108807|NCT01423994|Procedure|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate <50 bpm, High Heart Rate >165 bpm, and Pause > 3 seconds.
108808|NCT01424007|Behavioral|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
108809|NCT01424020|Other|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
108810|NCT01426256|Dietary Supplement|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
108811|NCT01426269|Drug|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads), oral, one capsule daily in the morning
108812|NCT01426269|Drug|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
108813|NCT01426269|Drug|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
108814|NCT01426282|Other|no intervention|no intervention
108815|NCT00066274|Drug|irinotecan hydrochloride|
108816|NCT01426282|Other|health education|15 minutes health education given by nurse according to " The Chinese Resident Meals Guide " , "National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005" , " Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults " , " Guideline for diagnosis and treatment of patients with chronic stable angina "," Guideline for prevention and treatment overweight and obesity in chinese adults "
108817|NCT01426295|Device|Caphosol|The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)
The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.
Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.
The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0.
108818|NCT01426295|Drug|Bicarbonate de sodium|Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.
Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®.
108819|NCT01426321|Other|Imaging guided LV lead positioning|LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate "optimal" cardiac vein segment is then chosen using the CT images.
108820|NCT01426334|Drug|dasatinib|Given PO
108821|NCT01426334|Other|diagnostic laboratory biomarker analysis|Correlative studies
109423|NCT01453569|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
109424|NCT01453582|Drug|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
109425|NCT01453582|Drug|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
109426|NCT01453595|Drug|BEZ235|BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.
Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily
109427|NCT01453608|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
109428|NCT00068874|Behavioral|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
109429|NCT01453608|Drug|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
109748|NCT00069862|Drug|Deferitrin (GT56-252)|
109749|NCT01461083|Drug|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of [18F]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not >10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
109750|NCT01461096|Biological|Quadrivalent HPV Vaccine|Participants will receive one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
109751|NCT01461096|Biological|Placebo Vaccine for Male Participants Only|Participants will receive one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
109752|NCT01461096|Biological|Placebo Vaccine for Female Participants Only|Participants will receive one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
109753|NCT01461109|Drug|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
109754|NCT01461148|Biological|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
109755|NCT01461161|Drug|bardoxolone methyl|oral, single dose
109756|NCT01461174|Drug|Modafinil|200 mg tablet, single dose
109757|NCT01461174|Drug|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
109758|NCT01461174|Drug|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
109011|NCT01429155|Genetic|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
109012|NCT01429168|Drug|Etoricoxib|One 60-mg tablet orally daily
109013|NCT01429168|Drug|Placebo for etoricoxib|One 60-mg tablet orally daily
109014|NCT01429181|Drug|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
109015|NCT01429194|Procedure|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
109016|NCT01429246|Dietary Supplement|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
109017|NCT01429246|Dietary Supplement|Salt Substitute|Estimated 30 grams per day per household member
109018|NCT01429259|Drug|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
109019|NCT00066417|Procedure|peripheral blood stem cell transplantation|
109020|NCT01429272|Drug|Minocycline|100 mg po bid for 6 weeks
109021|NCT01457404|Behavioral|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
109022|NCT01457404|Behavioral|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
109023|NCT01457417|Drug|DKN-01|DKN-01 will be administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: Study group of 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) are met or the highest planned dose study group is completed. Cycle 1 will define the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method will be guided by the incidence of DLTs during the first cycle. PART B - Dose Confirmation: Once the MTD has been established or the highest planned dose level is completed, 300 mg of DKN-01 will be administered as IV on days 1 and 15 of every 28 day cycle.
109024|NCT01457430|Drug|Icatibant|30 mg subcutaneous dose of Icatibant
109025|NCT00069381|Behavioral|Psychotherapy treatment|
109026|NCT01457469|Other|questionnaire administration|Ancillary studies
109579|NCT01461291|Device|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
109580|NCT01461291|Procedure|Cataract surgery|Cataract surgery alone
105316|NCT01397994|Drug|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
105317|NCT01397994|Drug|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
105318|NCT01398007|Procedure|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
105319|NCT01398020|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
105320|NCT01398020|Drug|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
105321|NCT01398033|Device|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
105322|NCT01398033|Device|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
105323|NCT00063336|Behavioral|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
105324|NCT01398046|Drug|Dasatinib|dasatinib (100mg) PO x1
105325|NCT01398046|Drug|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
105625|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
105626|NCT01401465|Drug|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
105627|NCT01401465|Drug|mometasone|200 mcg mometasone aqueous nasal spray once daily
105628|NCT01401491|Drug|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
105629|NCT00063804|Drug|AMD070|
105630|NCT01401491|Drug|clozapine plus placebo|clozapine 300 mg/day plus placebo
105631|NCT01401504|Drug|ASP3026|oral
105632|NCT01401517|Drug|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
105633|NCT01401530|Biological|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
105634|NCT01401543|Drug|LY2452473|Administered orally
108822|NCT01426334|Other|pharmacological study|Correlative studies
108823|NCT01426334|Drug|cyclosporine|Given PO
109082|NCT01455064|Device|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
109083|NCT01455090|Drug|BMS-650032|
109084|NCT01455090|Drug|BMS-790052|
109085|NCT01455090|Drug|BMS-791325|
109086|NCT01455090|Drug|Ribavirin|
109087|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response
109088|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response
109089|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
109090|NCT01455116|Procedure|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
109091|NCT01455129|Drug|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
109092|NCT00069095|Drug|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m^2 was administered simultaneously with leucovorin in a 2 h infusion.
109093|NCT01455129|Drug|placebo|placebo, once daily, inhaled by HandiHaler
109094|NCT01455142|Drug|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
109095|NCT01455155|Other|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
109096|NCT01455155|Other|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
109097|NCT01455181|Drug|NPSP558|50, 75, 100 μg
109098|NCT01455194|Drug|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
109099|NCT01455207|Behavioral|Neuropsychological testing|assessment of memory, executive functions and ataxia
105692|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
105693|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
105694|NCT00063401|Drug|Carboplatin|AUC = 6 Day1, six 21-day cycles
105695|NCT01398748|Drug|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
105696|NCT01398761|Other|Signout tool|Electronic signout tool
105697|NCT01398787|Device|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
105698|NCT01398787|Device|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
105699|NCT01398839|Device|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
105700|NCT01398839|Drug|Riboflavin|Both treatment and sham groups will receive riboflavin
105701|NCT01398852|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
105702|NCT01398852|Device|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
105703|NCT01401543|Drug|Tadalafil|Administered orally
105704|NCT01401543|Drug|LY900010|Administered orally
105705|NCT01401556|Other|case management|
105972|NCT01393977|Procedure|rehabilitation of limb function|only receive rehabilitation of limb function
105973|NCT01393977|Procedure|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
105974|NCT01393990|Drug|LY2228820|Administered orally
105975|NCT00062803|Drug|Acenocoumarol VKA|
105976|NCT01394003|Drug|LY2584702|administered orally
105977|NCT01394016|Drug|LY2835219|Administered orally, daily for 28-day cycles for two planned cycles. For Part G only in addition to LY2835219 as above, fulvestrant is administered as specified in the label. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
109581|NCT01461304|Drug|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
109582|NCT01461317|Drug|rhuMAb Beta7|Repeating subcutaneous injection
109583|NCT01461330|Other|DASH diet plus exercise|DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat
Exercises: the recommended physical activity will consist of using a pedometer during the experimental period.
109584|NCT01461330|Other|ADA diet|Adoption of ADA diet.
109585|NCT01453790|Behavioral|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
109586|NCT00068952|Drug|Edotecarin|
109587|NCT01453803|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
109588|NCT01453816|Procedure|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
109589|NCT01453829|Procedure|Harvesting and Isolation of Stem Cells|This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be implanted into the Internal Carotid Artery and intravenously.
109590|NCT01453842|Dietary Supplement|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
109591|NCT01453842|Dietary Supplement|Olive oil|Carrot and olive oil and 1½ g of paracetamol
109592|NCT01453842|Dietary Supplement|Carrot|Carrot and 1½ g of paracetamol
109593|NCT01453855|Drug|Travoprost ophthalmic solution, 0.003%|
109594|NCT01453855|Drug|Travoprost ophthalmic solution, 0.004%|
109595|NCT01453868|Other|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
109596|NCT01453868|Other|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
105635|NCT01403675|Procedure|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
105636|NCT01403688|Procedure|RPFNA|Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).
Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment
Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding
105637|NCT01403701|Behavioral|Physical therapy|pelvic floor physical therapy
105638|NCT01403714|Procedure|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
105639|NCT01403740|Drug|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
105640|NCT01403779|Radiation|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
105641|NCT01403792|Drug|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
105642|NCT01403805|Biological|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
105912|NCT01396486|Drug|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
105913|NCT01396499|Drug|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
105914|NCT01396512|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
105915|NCT01396512|Biological|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
105916|NCT00063141|Drug|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
105917|NCT01396525|Device|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
105918|NCT01396551|Device|Implantation of anchored Beacon transponder in the lung|Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
109100|NCT01455207|Biological|blood draw|hepatic markers, red blood markers and vitamin markers
109101|NCT01455207|Genetic|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
109102|NCT01455207|Other|Brain imaging examination|MRI, DTI and PET examinations
109103|NCT00069095|Drug|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m^2 in a 2 h infusion.
109352|NCT01455636|Other|No hand sanitizer|All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.
No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed
109353|NCT01455636|Dietary Supplement|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
109354|NCT01455649|Drug|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
109355|NCT00069108|Drug|Leucovorin|As prescribed, in 2 week cycles
109356|NCT01455649|Drug|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
109357|NCT01455675|Drug|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
109358|NCT01455675|Drug|Placebo|Placebo, 70 ml gargling solution, once daily
109359|NCT01455688|Drug|early HAART|Initiation of HAART within 5 days of ICU admission
109360|NCT01455688|Drug|Late HAART|Initiation of HAART after ICU discharge
109361|NCT01455701|Drug|Tocilizumab [RoActemra/Actemra]|Tocilizumab infusions every 2 weeks for 12 weeks
109362|NCT01455727|Other|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
109363|NCT01455727|Other|Usual care|Control patients received usual care directed by their physician.
109364|NCT01455740|Other|Medication Adherence among HIV/AIDS Patients|If patients are interested and available, they will be scheduled for a first study visit ("study visit 1") involving enrollment and baseline data collection. The second ("study visit 2"), third ("3"), fourth ("4"), and fifth ("5") study visits will be used to implement the intervention with financial incentives and will involve data collection. The sixth ("6") will involve only data collection; there should be time during the sixth to complete chart extraction—for hospital, pharmacy, and clinical records.
Subjects will be told that study visit 5 is "the end of the study", although we "may follow up later". Study visit 6 will be an unanticipated meeting.
105978|NCT01394016|Drug|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks as specified in the label in Part G only.
105979|NCT01394029|Drug|deferasirox|
105980|NCT01394042|Device|Proxiscan device|All patients will be imaged with the device
105981|NCT01394055|Drug|RM-131|100 μg subcutaneously once
105982|NCT01394055|Drug|Placebo|Matching placebo volume subcutaneously once
105983|NCT01394081|Other|Enhanced Enrollment or Engagement (EEE) Intervention Outreach A|A consists of motivational interviewing, education outreach, and patient navigation.
105984|NCT01394081|Other|Outreach B - modified EEE|Consists of education and patient navigation
105985|NCT01394081|Other|Outreach C (Control)|Outreach C is education only (about VA resources and medical care)
105986|NCT00062816|Drug|ISIS 14803, peginterferon alfa, ribavirin|
105987|NCT01394094|Behavioral|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
105988|NCT01394120|Drug|Targeted Therapy Tailored Treatment|Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen
Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX
TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX
TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI
TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine
TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent
TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib
105989|NCT01394120|Drug|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
105990|NCT01396564|Drug|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
105991|NCT01396577|Drug|perampanel|3 x 2 mg perampanel once per day
105992|NCT01396577|Drug|perampanel|6 mg perampanel once per day
105993|NCT01396590|Drug|Perampanel|6 x 2 mg perampanel once per day
106273|NCT01399853|Biological|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
106274|NCT01399853|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
106275|NCT01399866|Drug|D-cycloserine|2 single weekly doses, 50 mg capsule
106276|NCT01399866|Drug|Placebo|
109617|NCT01456143|Drug|Proflavine|swabbing the area to be imaged prior to tumor resection with .01% proflavine hemisulfate, a fluorescent dye. Will be placed on site for approximately 30-45 seconds.
109618|NCT00069121|Drug|Oxaliplatin|As prescribed, in 2 week cycles
109619|NCT01456143|Device|High Resolution Microendoscope|Use of this imaging system after application with proflavin
109620|NCT01456143|Device|Identafi 3000|use of this system to obtain optical images
109621|NCT01456156|Radiation|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
109622|NCT01456169|Drug|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
109623|NCT01456169|Drug|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
109624|NCT01456182|Drug|AFX-2|Dose level 1
109625|NCT01456182|Drug|AFX-2|Dose level 2
109626|NCT01456182|Drug|AFX-2|Dose level 3
109627|NCT01456182|Drug|AFX-2|Dose level 4
109628|NCT01456182|Drug|AFX-2|Dose level 5
109629|NCT00069121|Drug|Leucovorin|As prescribed, in 2 week cycles.
109630|NCT01456195|Drug|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
109631|NCT01456195|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 24 weeks.
109632|NCT01456195|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 24 weeks.
109633|NCT01458496|Behavioral|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
109634|NCT01458509|Behavioral|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
105919|NCT01396564|Drug|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
105920|NCT01399125|Drug|Rivastigmine Patch|Once-daily target patch size 10 cm²
105921|NCT00063453|Dietary Supplement|Selenium|selenium (200 μg/d L-selenomethionine)
105922|NCT01399125|Drug|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
105923|NCT01399125|Drug|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
105924|NCT01399125|Drug|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
105925|NCT01399138|Dietary Supplement|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
105926|NCT01399151|Dietary Supplement|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
105927|NCT01399151|Dietary Supplement|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
105928|NCT01399151|Dietary Supplement|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
105929|NCT01399164|Other|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
105930|NCT01399216|Dietary Supplement|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
105931|NCT01399216|Dietary Supplement|Placebo|for 8 weeks
106218|NCT01402544|Drug|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
106219|NCT01402557|Behavioral|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
106220|NCT00000256|Drug|40% N2O|
106221|NCT00001095|Drug|Amprenavir|
106222|NCT00063895|Drug|erlotinib hydrochloride|Given PO
106223|NCT01402557|Behavioral|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
109365|NCT01458028|Drug|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
109366|NCT01458041|Drug|Iloprost (Ilomedin, BAYQ6256)|Prescription and treatment of Iloprost will be decided by physicians
109367|NCT01458054|Drug|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
109368|NCT00069537|Device|The GlucoWatch® G2™ Biographer (GW2B)|
109369|NCT01458054|Drug|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
109370|NCT01458067|Drug|GSK2636771|Oral capsules
109688|NCT01454076|Drug|IXAZOMIB Capsule B formulation|Applicable to all Arms:
After completion of Cycle 1, patients receive a 4.0- mg dose of IXAZOMIB Capsule B formulation on Days 1, 8, and 15 of a 28-day schedule; however, starting with Cycle 4 and beyond patients will have the option of escalating to the 5.3-mg dose at the discretion of the investigator and the Millennium clinician.
The maximum duration of treatment is 12 months after completion of Cycle 1 (13 months in total) unless it is determined that a patient would derive benefit from continued therapy beyond 12 cycles.
109689|NCT01454076|Drug|IXAZOMIB Capsule A formulation|
109690|NCT01454076|Drug|ketoconazole|
109691|NCT01456208|Drug|Para-aminohippuric Acid|Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated "PAH".
109692|NCT01456208|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
109693|NCT01456208|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
109694|NCT01456221|Dietary Supplement|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
109695|NCT01456221|Dietary Supplement|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
109696|NCT01456234|Drug|Oseltamivir|Oseltamivir 75 mg BID
106277|NCT01399879|Other|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
106278|NCT01399892|Dietary Supplement|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
106279|NCT01399905|Drug|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
106280|NCT00063622|Dietary Supplement|Vitamin E|800 IU daily
106281|NCT01399918|Drug|everolimus and bevacizumab|Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
106282|NCT01399970|Other|Mobile Teleconsultation Arm (MTA)|In addition to a face-to-face visit at baseline, patients will conduct "mobile visits" at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.
106283|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
106284|NCT01399996|Dietary Supplement|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
106285|NCT01438450|Drug|Oral|Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.
Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week
106286|NCT01438450|Other|Supportive|No specific therapy will be given
106287|NCT01438463|Biological|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
106288|NCT00067145|Behavioral|Face-to-face maintenance program|
106289|NCT01438463|Biological|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
105381|NCT01395628|Other|cell proliferation assay|
105382|NCT00062972|Drug|glucose|
105383|NCT01395628|Other|fluorescence activated cell sorting|
105384|NCT01395628|Other|laboratory biomarker analysis|
109926|NCT01452256|Drug|Desflurane|4-6 Vol %
109927|NCT01452256|Drug|Propofol|TIVA to achieve BIS value of 40-60
109928|NCT01452269|Behavioral|Deaf Weight Wise program|Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.
Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).
The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program.
109929|NCT00068744|Drug|cisplatin|
109930|NCT01452295|Drug|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
109931|NCT01452308|Biological|Simtuzumab|
109932|NCT01452321|Procedure|repetitive transcranial magnetic stimulation (rTMS)|20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.
Site: Left Dorsolateral Prefrontal Cortex
109933|NCT01452334|Biological|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
109934|NCT01452347|Drug|warfarin 1mg|comparator warfarin
109935|NCT01452347|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
109936|NCT01452347|Drug|dabigatran etexilate low dose|active treatment (low)
109937|NCT01452347|Drug|warfarin 5mg|comparator warfarin
109938|NCT01452347|Drug|dabigatran etexilate high dose|active treatment (high)
109939|NCT01452347|Drug|warfarin 3mg|comparator warfarin
109940|NCT00068744|Drug|fluorouracil|
109941|NCT01452373|Drug|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
109942|NCT01452373|Drug|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
109943|NCT00069017|Other|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D&C Yellow #10.
109944|NCT01454284|Drug|Glargine|Administered by subcutaneous injection
106224|NCT01394471|Drug|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
106225|NCT00062855|Genetic|Gene Modified Neuroblastoma Cells|The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.
A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).
At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
106226|NCT01394484|Other|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
106227|NCT01394484|Dietary Supplement|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
106228|NCT01394497|Drug|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco‑regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross‑clamping.
106229|NCT01394510|Drug|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
106230|NCT01394523|Drug|Bupivacaine|0.25% or 0.5%
106231|NCT01394536|Device|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
106232|NCT01394536|Device|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
106233|NCT01394562|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
105326|NCT01398046|Drug|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
105327|NCT01398059|Other|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
105328|NCT01398059|Other|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
109697|NCT01456247|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
109698|NCT00069121|Drug|5 FU|As prescribed, in 2 week cycles
109699|NCT01456247|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
109700|NCT01456247|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
109701|NCT01456247|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
109702|NCT01456247|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
109703|NCT01456247|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
109704|NCT01456260|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
108824|NCT01426347|Drug|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
108825|NCT01426347|Drug|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
108826|NCT00066274|Drug|leucovorin calcium|
108827|NCT01426360|Other|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
108828|NCT01426360|Other|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
108829|NCT01426373|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
108830|NCT01426386|Drug|FE 999049|
108831|NCT01426386|Drug|Gonal - F|
108832|NCT01428791|Behavioral|BRIGHTEN Heart Virtual Team intervention|BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health & health behavior change for 6 - 12 months, including:
• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows.
108833|NCT01428804|Device|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
108834|NCT01428817|Drug|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
105385|NCT01395628|Other|microscopy|
105386|NCT01395641|Genetic|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
105387|NCT01395654|Drug|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
105388|NCT01395667|Other|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
105389|NCT01395693|Device|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
105390|NCT01395706|Procedure|ICG Fluorescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.
A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
10 mg (5mg/ml)per injection are applicated
105391|NCT01395719|Other|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
105392|NCT01395732|Drug|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
105393|NCT00062985|Behavioral|mail-based weight counseling|
105394|NCT01395745|Drug|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
105395|NCT01395745|Drug|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
105396|NCT01395758|Drug|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
105397|NCT01395758|Drug|Pemetrexed, docetaxel or gemcitabine|A single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to approved labeling.
105398|NCT01395771|Behavioral|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
105399|NCT01398111|Drug|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
105400|NCT01398111|Drug|Glycopyrrolate|glycopyrrolate pMDI
105401|NCT01398111|Drug|Formoterol|formoterol pMDI
105402|NCT01398111|Drug|Placebo|placebo pMDI
105706|NCT01401556|Other|Multifaceted quality improvement intervention|
109945|NCT01454284|Drug|LY2605541|Administered by subcutaneous injection.
109946|NCT01454284|Drug|Insulin Lispro|Administered subcutaneously
109027|NCT01457469|Procedure|quality-of-life assessment|Ancillary studies
109028|NCT01457469|Other|counseling intervention|Undergo counseling session
109029|NCT01457469|Other|internet-based intervention|Receive enhanced quitline intervention
109030|NCT01457469|Behavioral|telephone-based intervention|Receive enhanced quitline intervention
109031|NCT01457469|Other|educational intervention|Receive usual care plus
109032|NCT01457469|Drug|nicotine replacement therapy|Receive nicotine replacement patches
109033|NCT01457469|Other|educational intervention|Receive enhanced quitline intervention
109034|NCT01457482|Other|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
109035|NCT01457482|Other|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
109036|NCT00001146|Drug|OmegaBrite|
109037|NCT00069407|Procedure|Electroconvulsive Therapy|Electroconvulsive therapy
109038|NCT01457495|Biological|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
109039|NCT01457495|Biological|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
109040|NCT01457495|Biological|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
109041|NCT01457508|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
109042|NCT01457508|Biological|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
109043|NCT01457508|Biological|Hib (Hiberix™)|Three doses administered intramuscularly
109044|NCT01457521|Drug|Ibuprofen|Ibuprofen
105329|NCT01398059|Other|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
105330|NCT01398072|Drug|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
105331|NCT01398072|Drug|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
105332|NCT01398072|Drug|Doxycycline|An oral dose of 100 mg once daily.
105333|NCT01398072|Drug|Placebo|Oral dose of one table once daily.
105334|NCT00063362|Drug|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
105335|NCT01398085|Radiation|I131 1.1 GBq|Radio-iodine
105336|NCT01398098|Drug|Sodium phosphate|32 tablets
105337|NCT01400763|Dietary Supplement|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
105338|NCT01400763|Dietary Supplement|Placebo beverage|Placebo beverage
105339|NCT01400776|Drug|WC3011 Vaginal Gel|WC3011 Vaginal Gel administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
105340|NCT01400776|Drug|Vehicle|Vehicle Vaginal Gel administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
105341|NCT01400789|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
105342|NCT01400802|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
105343|NCT01400815|Drug|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.
105344|NCT01400815|Drug|Active Control Cigarettes|The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional "light" cigarette.
Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.
105345|NCT01400828|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
105643|NCT00063947|Radiation|radiation therapy|Undergo radiotherapy
105644|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
108835|NCT01428817|Drug|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
108836|NCT01428817|Drug|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
108837|NCT00066417|Procedure|bone marrow transplantation|
108838|NCT01428817|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
108839|NCT01428817|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
108840|NCT01428830|Procedure|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
108841|NCT01428830|Procedure|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
108842|NCT01428843|Drug|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
108843|NCT01428843|Drug|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
109104|NCT01455220|Drug|Tysabri ® (Natalizumab)|IV, monthly
109105|NCT01455233|Drug|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
109106|NCT01457547|Biological|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
109107|NCT01457547|Biological|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
109108|NCT01457560|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
109109|NCT00069420|Behavioral|Cognitive Motivational Behavior Therapy|
109110|NCT01457560|Biological|OPV|One dose administered orally
109111|NCT01457573|Drug|Solifenacin (Vesicare) 5 mg orally at the same time.|Drug: Tamsulosin 0.4 mg in combination with Solifenacin 5 mg
All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg and Solifenacin (Vesicare) 5 mg orally at the same time.
109112|NCT01457586|Biological|Blood transfusion|Blood transfusion in perioperative period.
109113|NCT01457586|Biological|No blood transfusion|No transfusion in the perioperative period.
109114|NCT01457599|Procedure|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
109115|NCT01457612|Dietary Supplement|Strawberry|20g twice per day (BID) in beverage
105707|NCT01401569|Behavioral|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
105708|NCT00063817|Drug|MEDI-507|T-cell depleting antibody
105709|NCT01401582|Other|Provision of a "Dementia Care Manager"|Home-visits of trained "Dementia Care Manager (DCM)" at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers.
105710|NCT01401595|Drug|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 30 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
105711|NCT01401608|Device|RF Ablation|Ablation of arrhythmogenic ventricular tissue
105712|NCT01401621|Behavioral|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
105713|NCT01401621|Behavioral|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
105714|NCT01401621|Behavioral|Control|No scratch-off element
105715|NCT01401634|Other|Oral water|2 Liters of water given orally
105716|NCT01401634|Other|Intravenous normal saline|2 Liters Intravenous normal saline
105717|NCT01401647|Drug|amiodarone|300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
105718|NCT01401647|Drug|Lidocaine|120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
105719|NCT00063817|Procedure|Combined kidney and bone marrow transplant|kidney and bone marrow transplant from same donor
105720|NCT01401647|Other|Normal saline|6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
105721|NCT01401660|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
109045|NCT01459744|Behavioral|Communication training for cardiologists.|Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.
Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.
Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills.
109046|NCT01459744|Other|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
109047|NCT01459757|Other|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
109597|NCT00068952|Drug|Temozolomide|
109598|NCT01453881|Device|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
109599|NCT01453881|Device|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
109600|NCT01453894|Behavioral|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
109601|NCT01453907|Drug|ETI-204, "Anthim"|intravenously, single dose
109602|NCT01453907|Drug|placebo|intravenously, single dose
109603|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
109604|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
109605|NCT01453933|Drug|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
109606|NCT01453946|Drug|Entocort|Entocort capsules, taken orally, 6 mg daily.
109607|NCT00069121|Drug|Oxaliplatin|As prescribed, in 3 week cycles
109608|NCT01456078|Drug|177Lu-DOTA-TATE|177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.
Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy.
109609|NCT01456091|Behavioral|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
105645|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
105646|NCT01403805|Other|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
105647|NCT01403818|Drug|ASP1941|oral
105648|NCT01403818|Drug|Mitiglinide calcium hydrate|oral
105649|NCT01403831|Other|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
105650|NCT01403844|Other|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
105651|NCT01403844|Other|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
105652|NCT01403844|Other|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
105653|NCT01403844|Other|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
105654|NCT01396070|Drug|Brentuximab vedotin|1.8 mg/kg; IV
105655|NCT00063024|Behavioral|Weight-bearing physical activity|
105656|NCT01396083|Drug|Ranibizumab|
105657|NCT01396083|Drug|Dexamethasone implant and sham injections|
105658|NCT01396109|Procedure|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
105659|NCT01396109|Procedure|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
105660|NCT01396122|Procedure|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
105661|NCT01396135|Drug|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
105662|NCT01396135|Drug|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
105663|NCT01396135|Drug|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
109116|NCT01457612|Dietary Supplement|Placebo1|Placebo Beverage 1 without fiber
109117|NCT01457612|Dietary Supplement|Placebo2|Placebo Beverage 2 with Fiber
109118|NCT01457638|Procedure|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
109119|NCT01457638|Procedure|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
109120|NCT00069433|Procedure|Social skills and symptom management training|
109121|NCT01457651|Procedure|Alveolar recruitment|Four approaches:
CPAP 40 cm H2O
Peak pressure 40 cm H2O
PEEP 15 cm H2O for 300 sec
no intervention (controls)
109122|NCT01457664|Drug|Placebo|Placebo to RO4995819 once daily for 14 days
109123|NCT01457664|Drug|RO4995819|RO4995819 doses once daily for 14 days
109124|NCT01457677|Drug|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
109125|NCT01457677|Drug|RO4995819|5 mg oral once daily for 6 weeks
109126|NCT01457677|Drug|RO4995819|15 mg oral once daily for 6 weeks
109127|NCT01457677|Drug|RO4995819|30 mg oral once daily for 6 weeks
109371|NCT01458080|Drug|eltrombopag|eltrombopag
109372|NCT01458093|Other|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
109373|NCT01458106|Drug|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
109374|NCT01458106|Drug|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
109375|NCT01458119|Drug|migalastat HCl 150mg|Provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken taken on the days between migalastat HCl.
109376|NCT01458132|Drug|GSK2248761|Treatment with GSK2248761
109377|NCT01458145|Behavioral|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
105722|NCT01401673|Drug|Indantadol|Titration
105994|NCT01396590|Drug|Perampanel|12 mg perampanel once per day
105995|NCT01396616|Device|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
105996|NCT01396629|Procedure|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
105997|NCT00001091|Drug|Lamivudine|
105998|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
105999|NCT01396642|Other|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
106000|NCT01396655|Drug|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
106001|NCT01396668|Drug|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
106002|NCT01396681|Drug|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
106003|NCT01396694|Other|Questionnaire|Questionnaire
106004|NCT01396707|Drug|Herceptin+XELOX|Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression
Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks
Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)
Oxaliplatin 130 mg/m2 i.v. on day 1
106005|NCT01396720|Drug|fluvoxamine|Fluvoxamine 100mg daily, 7 days
106006|NCT01396720|Drug|citalopharm|Citalopharm 20mg daily, 7 days
106007|NCT01396733|Drug|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
109610|NCT01456104|Biological|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
109611|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
109612|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
109613|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
109614|NCT01456117|Drug|Placebo|Pioglitazone matching placebo once daily for up to 14 days.
109615|NCT01456130|Drug|Alogliptin|Alogliptin tablets
109616|NCT01456130|Drug|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
109635|NCT01458509|Behavioral|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
109636|NCT01458509|Behavioral|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
109637|NCT01458509|Behavioral|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
109638|NCT01458522|Drug|Lacosamide - 'Crossover'|If any of the following occurs, the subject will have reached the end of the first treatment arm and will "cross over" and begin receiving the other drug, ie, the one not originally administered:
The subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period.
The subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period.
The subject experiences an AE that precludes further use of the first study drug.
If crossover occurs, the subject will "start over" with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
109639|NCT01458522|Drug|Fosphenytoin - 'crossover'|If any of the following occurs, the subject will have reached the end of the first treatment arm and will "cross over" and begin receiving the other drug, ie, the one not originally administered:
The subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period.
The subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period.
The subject experiences an AE that precludes further use of the first study drug.
If crossover occurs, the subject will "start over" with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
105932|NCT00001094|Drug|Nelfinavir mesylate|
105933|NCT00063479|Drug|Zoledronic Acid|
105934|NCT01399242|Drug|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
105935|NCT01399255|Biological|Insulin lispro|Dosage form- Subcutaneous Injection
105936|NCT01399268|Drug|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
105937|NCT01399268|Drug|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
105938|NCT01399307|Procedure|Liposuction|Elective Liposuction
105939|NCT01399320|Procedure|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
105940|NCT01399333|Dietary Supplement|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
105941|NCT01399333|Dietary Supplement|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
105942|NCT01402037|Device|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
105943|NCT01402050|Drug|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
105944|NCT01402050|Device|FOLEY BALLOON|INDUCTION OF LABOR
105945|NCT00063830|Drug|Alicaforsen|
105946|NCT01402063|Drug|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
105947|NCT01402063|Drug|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
105948|NCT01402076|Drug|Tasimelteon|20mg daily dosing, Days 4-20
109378|NCT01458171|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
109379|NCT00069537|Device|The Continuous Glucose Monitoring System (CGMS™)|
109380|NCT01458184|Behavioral|PhoneCare system|The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through "virtual visits" and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation).
109381|NCT01458197|Drug|Tarafenacin 0.2 mg|Capsule, qd, 12 weeks
109382|NCT01458197|Drug|Placebo|Capsule, qd, 12 weeks
109383|NCT01458197|Drug|Tarafenacin 0.4 mg|Capsule, qd, 12 weeks
109384|NCT01458210|Drug|Ortho-Cyclen|Administered orally
109385|NCT01458210|Biological|Dulaglutide|Administered subcutaneously
109386|NCT01458223|Drug|Antibiotic|Ancef or Vancomycin
109387|NCT01458223|Drug|Antibiotic|Ancef or Vancomycin
109388|NCT01458236|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
109389|NCT01460368|Drug|Moxifloxacin|Administered orally
109390|NCT01460381|Drug|LY2216684|Administered orally
109391|NCT01460381|Drug|Quinidine|Administered orally
109705|NCT01456260|Drug|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
109706|NCT01456260|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
109707|NCT01456260|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
109708|NCT01456260|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
109709|NCT00069134|Dietary Supplement|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
109710|NCT01456260|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
106008|NCT01396759|Procedure|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
106290|NCT01438463|Biological|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
106291|NCT01438463|Biological|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
106292|NCT01438463|Biological|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
106293|NCT01438476|Procedure|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
106294|NCT01438476|Procedure|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
106295|NCT01438476|Behavioral|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
106296|NCT01438476|Behavioral|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
106297|NCT01438489|Biological|MEDI-546|Low dose of MEDI-546 administered as an intravenous infusion at the predetermined intervals
106298|NCT01438489|Biological|MEDI-546|High dose of MEDI-546 administered as an intravenous infusion at predetermined intervals
106299|NCT00067145|Behavioral|Internet maintenance program|
106300|NCT01438489|Other|Placebo|Matching placebo to MEDI-546 administered as an intravenous infusion at predetermined intervals
106301|NCT01438502|Drug|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
106302|NCT01438515|Drug|Rifampin|600mg po once daily x 7 days
106303|NCT01438515|Drug|Doxycycline|100mg po twice daily x 7 days
106304|NCT01438515|Other|2% mupirocin ointment|~ 1cm applied to the anterior nares twice daily for 7 days
109640|NCT01458535|Drug|ABT-450/r|tablet (ABT-450), capsule (ritonavir)
109641|NCT00069602|Device|Continuous Glucose Monitoring System (CGMS)|
109642|NCT01458535|Drug|ABT-267|tablet
109643|NCT01458535|Drug|ribavirin|tablet
109644|NCT01458548|Drug|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
109645|NCT01460732|Device|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
109646|NCT01460758|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
109647|NCT01460758|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
108767|NCT01431365|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
108768|NCT01431365|Behavioral|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
108769|NCT01431391|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
108770|NCT01431391|Drug|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
108771|NCT01431404|Biological|Etanercept (Enbrel)|prefilled syringe, SC
108772|NCT01431404|Biological|HD203|HD203, prefilled syringe, SC injection
108773|NCT01431430|Drug|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
108774|NCT01431430|Drug|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
108775|NCT00001119|Drug|Indinavir sulfate|
108776|NCT00066599|Drug|voriconazole|
108777|NCT01431443|Other|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
108778|NCT01431443|Other|Placebo Chocolate|Placebo intervention
105949|NCT01402076|Drug|Rosiglitazone|4mg, single dose, Days 3 and 20
105950|NCT01402076|Drug|Midazolam|10mg, single dose, Days 1 and 18
106234|NCT01394562|Other|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
106235|NCT01394575|Radiation|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
106236|NCT00062868|Biological|LMP1/2 CTLs (Group A)|Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One
Day 0: 2 x 10^7 cells/m2; Day 14: 2 x 10^7 cells/m2
Dose Level Two
Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2
Dose Level Three
Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2
106237|NCT01394588|Device|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
106238|NCT01394614|Biological|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
106239|NCT01394627|Drug|Eplerenone|100mg x 2
106240|NCT01394640|Biological|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
106241|NCT01397149|Drug|Eltrombopag|Phase I:
Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to > 400,000/µl).
Phase II:
Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I.
106242|NCT01397162|Drug|Fluticasone propionate|2 puffs b.i.d. via HFA MDI matching placebo inhaler
106243|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
106244|NCT00063206|Drug|DVS-233 SR|
106245|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
106246|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
106247|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
106248|NCT01397162|Drug|Placebo|2 puffs b.i.d. via placebo Respimat inhaler
106249|NCT01397162|Drug|Placebo|2 puffs b.i.d. via placebo Respimat inhaler
109711|NCT01456273|Procedure|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
109712|NCT01458548|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
109713|NCT01458561|Device|BioFoam Surgical Matrix|Surgical adjunct to control bleeding in open liver surgery
109714|NCT01458561|Device|Gelfoam Plus|Surgical adjunct in control of bleeding in open liver surgery
109715|NCT01458574|Drug|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
109716|NCT01458574|Drug|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
109717|NCT01458574|Drug|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
109718|NCT01458587|Drug|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
109719|NCT00069602|Device|GlucoWatch G2TM Biographer (GW2B)|
109720|NCT01458587|Drug|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
109721|NCT01458600|Drug|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
109722|NCT01458600|Drug|Methimazole|T Methimazole 5 mg 3x2 for 18 months
109723|NCT01458600|Drug|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
109724|NCT01458600|Drug|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
109725|NCT01458600|Drug|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
109726|NCT01458626|Drug|mirtazapine|mirtazapine 30mg QD
109727|NCT01458626|Drug|paroxetine 20mg QD|paroxetine 20mg QD
108844|NCT01428882|Drug|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
108845|NCT01428882|Drug|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
106305|NCT01440790|Dietary Supplement|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
106306|NCT01440803|Drug|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
106307|NCT01440803|Drug|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
105403|NCT01398124|Biological|Cyclin B1 Peptide|vaccine
105404|NCT01398150|Dietary Supplement|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
105405|NCT01398150|Dietary Supplement|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
105406|NCT01398163|Other|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
105407|NCT00063362|Drug|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
105408|NCT01398163|Other|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervential 2 (control)
105409|NCT01398163|Other|3 - No product|Arm 3 - Intervention 3 (no product)
105410|NCT01398176|Dietary Supplement|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
105411|NCT01398176|Dietary Supplement|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
105412|NCT01398189|Drug|clozapine|C-11 clozapine
105413|NCT01398202|Dietary Supplement|vitamin D3|20 micrograms per day for 10 weeks
105414|NCT01398202|Dietary Supplement|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
105415|NCT01398202|Dietary Supplement|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
105416|NCT01398202|Dietary Supplement|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
105417|NCT01398215|Procedure|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
105418|NCT00063362|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
108779|NCT01431456|Drug|Dabigatran|
108780|NCT01431456|Drug|Rivaroxaban|
108781|NCT01431456|Drug|Nadroparin|
108782|NCT01431469|Dietary Supplement|Cow's milk|Powdered Whole Cow's Milk
108783|NCT01431469|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
108784|NCT01431495|Drug|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
108785|NCT01431495|Drug|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
108786|NCT01431508|Drug|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
108787|NCT00066612|Drug|irinotecan hydrochloride|Irinotecan will be given 250 mg/m^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
108788|NCT01431521|Drug|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
108789|NCT01431521|Drug|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
109048|NCT01459770|Other|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
109049|NCT01459770|Other|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
109050|NCT01459783|Behavioral|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
109051|NCT01459796|Drug|Rilonacept|Regimen 1
109052|NCT01459796|Drug|Placebo|Regimen 2
109053|NCT01459796|Drug|Allopurinol|Background Treatment
109054|NCT00069719|Drug|Glaucoma therapy|
109055|NCT01459809|Drug|GLIMEPIRIDE|Pharmaceutical form: oral
Route of administration: oral
106250|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
106251|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
106252|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
105346|NCT01400828|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
105347|NCT00001094|Drug|Delavirdine mesylate|
105348|NCT00063726|Drug|bortezomib|
105349|NCT01400828|Drug|Placebo|(encapsulated) Tablets QD/14 days
105350|NCT01400841|Device|HAART 300 Annuloplasty Device|Aortic Regurgitation
105351|NCT01400854|Drug|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
105352|NCT01400867|Drug|Ceftaroline fosamil|Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)
Subjects < 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)
105353|NCT01400867|Drug|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)
Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed
105354|NCT01400867|Drug|Cephalexin or Clindamycin or Linezolid|Possible oral switch on or after study day 4.
Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO.
105355|NCT01400893|Device|SCD|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
105356|NCT01400906|Drug|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
105357|NCT01400906|Drug|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
105358|NCT01400906|Drug|lactose powder|lactose powder in dry powder device : placebo comparator
105359|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
108846|NCT01428895|Procedure|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
108847|NCT01428895|Other|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
108848|NCT00066417|Procedure|chemotherapy|
108849|NCT01428908|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
108850|NCT01428908|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
108851|NCT01431521|Drug|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
108852|NCT01431534|Drug|ridaforolimus|Ridaforolimus supplied as 10 mg enteric-coated tablets, orally, at escalating doses starting at 22 mg/m^2 based on body surface area (BSA), for 5 consecutive days each week in consecutive 28-day cycles
108853|NCT01431547|Drug|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m^2, and escalated for successive cohorts of participants until MTD is found
108854|NCT01431547|Drug|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
108855|NCT01431547|Drug|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
108856|NCT01431560|Device|fixation of the ankle fracture (Solco )|fixation with metallic implant
108857|NCT01431560|Device|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
108858|NCT00066625|Drug|oxaliplatin|Given IV
108859|NCT01431573|Behavioral|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
108860|NCT01431573|Device|lightbox|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
109128|NCT01457690|Drug|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
105419|NCT01398228|Behavioral|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
105420|NCT01398241|Drug|RO5267683|Multiple ascending doses
105421|NCT01398241|Drug|placebo|Multiple ascending doses
105422|NCT01398254|Procedure|Radial access site vs. Femoral Access site|Comparison of different access site for primary percutaneous coronary intervention:radial access site versus femoral access site.
105423|NCT01398267|Drug|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
105723|NCT01401699|Device|optical frequency domain imaging (OFDI) system|Imaging of esophagus with OFDI system
105724|NCT01404013|Drug|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
105725|NCT01404013|Drug|Montelukast|Montelukast 10mg ,every night, for 8 weeks
105726|NCT00063960|Drug|irinotecan hydrochloride|
105727|NCT01404013|Drug|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
105728|NCT01404026|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
105729|NCT01404039|Behavioral|Motor Learning with Visual Feedback|This task will consist of tracing a set of symbols using the index finger of the left hand. Subjects will do this task for 20 minutes. Subjects will repeat this activity until the end of that time. The speed will be measured using a timer, and accuracy will be measured using the computer program Image Java, NIH, USA.
105730|NCT01404039|Behavioral|Motor Learning without Visual Feedback|In this group, subjects will be asked to use the index finger of their left hand to draw a square while wearing a blindfold. The task will be performed with the subject sitting and arms supported. The square will have four pins, one at each corner, to give feedback of where they need to scroll. This task will be performed for a total of 20 minutes.
105731|NCT01404039|Behavioral|Motor Learning -- Control Group|In this group, subjects will perform the following sequences of movements:
Pronation and supination of the forearm
Flexion and extension of wrist
Abduction and adduction of fingers
Open and close hand movements
These tasks will be performed for 20 minutes (5 minutes for each sequence) in a single session.
105732|NCT01404039|Behavioral|Somatosensory Learning with Visual Feedback|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille. The subject will be able to see the braille letters as he/she learns the letters.
105733|NCT01404039|Behavioral|Somatosensory Learning without Visual Feedback|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille while blindfolded.
109056|NCT01459809|Drug|METFORMIN|Pharmaceutical form: oral
Route of administration: oral
109057|NCT01459835|Behavioral|media diet|advice and tips and tools for healthy non violent TV viewing
109058|NCT01459835|Behavioral|nutritional intervention|advice on healthy eating
109059|NCT01459848|Behavioral|block play|30 minutes of block play
109060|NCT01459848|Behavioral|baby dvd|30 minutes of dvd viewing
109061|NCT01459861|Procedure|Canal Block and Capsular Injection|Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
109062|NCT01459861|Procedure|Femoral Nerve Block with Tibial Nerve Block|Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
109063|NCT01459874|Behavioral|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
109064|NCT01459887|Drug|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
109065|NCT00068809|Procedure|Short Cycle Antiretroviral Therapy|
109066|NCT01453036|Procedure|UBT test & Gastroenterology with biopsy c silver stain|UBT test & Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group >> intervention
109313|NCT01460316|Biological|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
109314|NCT01460329|Device|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
109315|NCT00069784|Drug|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
109316|NCT01460342|Drug|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
109317|NCT01460342|Drug|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
109318|NCT01460355|Drug|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
109319|NCT01460355|Drug|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
109320|NCT01460368|Drug|LY2409021|Administered orally
105360|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
105361|NCT01403545|Drug|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
105362|NCT00063947|Drug|erlotinib hydrochloride|Given orally
105363|NCT01403545|Other|Placebo|5% glucose infusion over 120 minutes
105364|NCT01403558|Behavioral|Cognitive behavioral therapy with motivational interwiewing|CBT combined With MI
105664|NCT01396135|Drug|Placebo|Single dose of placebo given as a matching number of oral tablets
105665|NCT01396135|Drug|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
105666|NCT00063037|Behavioral|Behavioral modification - nutrition education|
105667|NCT01396135|Drug|Placebo|Multiple doses of placebo given as a matching number of oral tablets
105668|NCT01396148|Drug|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
105669|NCT01396148|Drug|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
105670|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
105671|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
105672|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
105673|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
105674|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
105675|NCT01396174|Behavioral|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
105676|NCT01396174|Behavioral|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
109129|NCT01457690|Drug|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
109130|NCT01457690|Drug|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
109131|NCT00069446|Drug|rhuMAb VEGF (telbermin)|
109132|NCT01457703|Drug|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
109133|NCT01457703|Drug|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
109134|NCT00069732|Behavioral|qigong|
109135|NCT01459887|Drug|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
109136|NCT01459900|Procedure|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
109137|NCT01459900|Procedure|Renal angiography|Renal angiography by femoral access.
109138|NCT01459913|Drug|Telaprevir|Tablet
109139|NCT01459913|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
109140|NCT01459913|Drug|Ribavirin|Tablet
109141|NCT01459926|Drug|TD-1211|once daily
109142|NCT01459926|Drug|TD-1211|Once daily
109143|NCT01459926|Drug|TD-1211|Once daily
109144|NCT01459926|Drug|Placebo|Once daily
109145|NCT00069732|Behavioral|acupressure-TAT|
109146|NCT01459939|Dietary Supplement|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
109147|NCT01459939|Dietary Supplement|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
109148|NCT01459952|Dietary Supplement|Rose hip Liquid|Rose hip Liquid, 20 ml BID
109149|NCT01459965|Procedure|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
109150|NCT01459965|Procedure|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
105734|NCT01404039|Behavioral|Control Group - Sensory Task without Learning|This group will perform a task for sensory activation, without a learning task. Subjects will be instructed to put their hand on the desk with their palm facing up. During the 20 minute intervention period, the study staff will touch the subject's hand with items of different textures.
105735|NCT01404039|Behavioral|Control Group -- no sensory or learning task|This group will perform no task during the intervention period. The subject will sit quietly with their hand placed palm-up on a desk for the duration of the intervention period.
105736|NCT01404039|Behavioral|Observational Task|Subjects in this group will watch a 10 second video of a right-handed person performing movements of their left index finger at a 1 Hz rate on a screen at a distance of 1 meter away. Subjects will be instructed to watch the video without any other specific instruction.
105737|NCT00063973|Drug|cilengitide|Given IV
105738|NCT01404039|Behavioral|Control Group -- Observational Task|Subjects in this group will be asked to watch a video of random geometric forms for the same duration of time as those in the observational task group.
106009|NCT01399333|Dietary Supplement|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
106010|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
106011|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
106012|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
106013|NCT01399359|Behavioral|Counseling session|
106014|NCT01399359|Other|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
106015|NCT01399359|Other|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
106016|NCT01399359|Other|online questionnaire|
106017|NCT01399372|Biological|rituximab|Given IV
106018|NCT01399372|Drug|cytarabine|Given IV
106019|NCT01399372|Drug|methotrexate|Given IV
106020|NCT01399372|Drug|procarbazine hydrochloride|Given PO
106021|NCT01399372|Drug|vincristine sulfate|Given IV
106022|NCT00063570|Drug|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
109321|NCT01460368|Drug|Placebo|Administered orally
109322|NCT01453387|Drug|MSC2015103B|An Expansion Cohort at the MTD or any other suitable dose level may be utilized to further characterize the safety profile and pharmacodynamics of the drug.
109323|NCT01453400|Drug|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
109324|NCT01453400|Drug|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
109325|NCT01453400|Drug|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
109326|NCT01453413|Other|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
109327|NCT00068861|Drug|metformin XR|
109328|NCT01453426|Drug|BG00012 Dose 1|
109329|NCT01453426|Drug|BG00012 Dose 2|
109330|NCT01453439|Behavioral|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
109331|NCT01453439|Behavioral|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
109332|NCT01453452|Behavioral|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be < 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
109648|NCT00069823|Drug|Placebo proton pump inhibitor|Placebo proton pump inhibitor
109649|NCT01460758|Device|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
109650|NCT01460771|Device|TDCS (Transcranial Direct-current Stimulation)|active TDCS
109651|NCT01460771|Device|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
109652|NCT01460797|Other|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
109653|NCT01460810|Other|1000CsK Silicon Oil Tamponade|Details covered in arm description
105677|NCT00063050|Behavioral|Physical activity and nutrition intervention|
105678|NCT01398592|Drug|Sitagliptin|100mg sitagliptin po qd
105679|NCT01398605|Other|Exercise training|Different dose of exercise training
105680|NCT01398618|Drug|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
105681|NCT01398644|Other|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
105682|NCT01398657|Drug|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
105683|NCT00063401|Drug|Paclitaxel|175 mg/m2 Day 1, six 21-day cycles
105951|NCT01402089|Drug|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
105952|NCT01402089|Drug|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
105953|NCT01402089|Drug|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
105954|NCT01402089|Drug|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
105955|NCT01402102|Dietary Supplement|Aged garlic powder|Aged garlic powder(6.0g/day)
105956|NCT00063843|Biological|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
105957|NCT01402102|Dietary Supplement|Placebo powder|Placebo powder(6.0g/day)
105958|NCT01402115|Dietary Supplement|Polycan|polycan 150 mg/d for 12 weeks
105959|NCT01402115|Dietary Supplement|Placebo|Placebo 150mg/d for 12 weeks
105960|NCT01402128|Dietary Supplement|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
105961|NCT01402128|Dietary Supplement|Placebo|Placebo for 12 weeks
105962|NCT01402141|Dietary Supplement|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
105963|NCT01402141|Dietary Supplement|Placebo|Placebo(35g/day) for 12 weeks
105964|NCT01402154|Biological|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
109392|NCT01460407|Drug|LY2216684|Administered orally
109393|NCT00069784|Drug|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
109394|NCT01460407|Drug|Clarithromycin|Administered orally
109395|NCT01460420|Drug|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
109396|NCT01460420|Drug|Len (lenalidomide)|Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.
Maintenance therapy and dose reduction pre-specified.
109397|NCT01460433|Procedure|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
109398|NCT01460446|Device|Aviva Expert blood glucose meter|
109399|NCT01460446|Device|Aviva Nano blood glucose meter|
109400|NCT01460459|Behavioral|a specific frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:
high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly
109401|NCT01460472|Biological|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
109402|NCT01460472|Other|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
109403|NCT01460498|Drug|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
109404|NCT00001180|Drug|Ovine Corticotropin-Releasing Hormone (oCRH)|
109405|NCT00069784|Drug|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
109406|NCT01460498|Drug|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
109407|NCT01460498|Drug|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
109408|NCT01460511|Drug|Epinephrine Inhalation Aerosol|250 mcg (2 inhalations), 4 times daily
109409|NCT01460537|Drug|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
109410|NCT01460537|Drug|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
106023|NCT01399372|Radiation|whole-brain radiation therapy|Undergo radiotherapy
106024|NCT01399398|Procedure|Brain Scan-PET|
106025|NCT01399398|Procedure|Brain Scan-MRI|
106026|NCT01399398|Procedure|Arterial Line|
106027|NCT01399398|Procedure|Venous Line|
106028|NCT01399398|Procedure|Blood Sampling|
106029|NCT01399424|Drug|CP|Immunization
106030|NCT01399450|Drug|paliperidone|paliperidone augmenting on ongoing medication
106031|NCT01399463|Device|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
106032|NCT01399463|Device|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
106033|NCT00063570|Drug|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
106308|NCT01440816|Biological|interleukin-12 gene|Given IT
106309|NCT01440816|Biological|electroporation-mediated plasmid DNA vaccine therapy|Undergo electroporation-mediated plasmid DNA vaccine therapy
106310|NCT00067522|Behavioral|Future Planning Perspectives program|
106311|NCT01440829|Drug|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
106312|NCT01440842|Other|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
106313|NCT01440842|Other|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
106314|NCT01440855|Other|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
106315|NCT01440855|Other|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
109654|NCT01460823|Procedure|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
109655|NCT01460836|Drug|Tobramycin solution for inhalation|
109656|NCT01460836|Drug|Aztreonam lysine for inhalation|
109657|NCT01460875|Biological|recombinant interferon alfa-2b|Given SC
109658|NCT01460875|Other|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
109659|NCT00069836|Drug|Rosiglitazone/metformin|
109660|NCT01460888|Drug|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
109661|NCT01460888|Radiation|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
109662|NCT01460901|Biological|Tri-virus specific cytotoxic t-cells|Infusion of donor derived tri-virus specific cytotoxic t-cell post allogeneic stem cell transplantation
109663|NCT01460927|Device|TriActive+ RF|Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special "skin contact identification" system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts.
109664|NCT01460940|Drug|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
109665|NCT01460940|Drug|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
109666|NCT01460953|Behavioral|health literacy training video|participants will watch a training video
109667|NCT01460966|Procedure|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
108790|NCT01431521|Drug|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
108791|NCT01423864|Drug|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 > FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
108792|NCT01423890|Genetic|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
105965|NCT01402154|Biological|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
105966|NCT01402167|Procedure|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
105967|NCT00063856|Biological|Wetvax (APSV)|
105968|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
105969|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 & 22 (cycle 1); days 8 &22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
105970|NCT01393964|Drug|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
105971|NCT01393964|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
106253|NCT01397175|Device|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
106254|NCT01397175|Device|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
106255|NCT00063219|Drug|MAC-321|
106256|NCT01397175|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
106257|NCT01397188|Device|PiCCO|transpulmonary thermodilution technique
106258|NCT01397188|Other|sham, no intervention|no intervention
106259|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
106260|NCT01397201|Drug|BI 54903|2 puffs b.i.d. BI54903 medium range via Respimat inhaler
106261|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo BI54903
106262|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
106263|NCT01397201|Drug|Fluticasone|2 puffs b.i.d. 110mcg Fluticasone propionate HFA MDI
109411|NCT01460537|Drug|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
109728|NCT01458639|Drug|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
109729|NCT01458639|Drug|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
109730|NCT00069615|Device|GlucoWatch® G2™ Biographer (GW2B)|
109731|NCT01458652|Drug|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
109732|NCT01458665|Procedure|Conventional arthroscopic rotator cuff repair|Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
109733|NCT01458665|Procedure|Arthroscopic rotator cuff repair with PRP|Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
After tying sutures of the medial row, PRP gels were applied on the repair site.
The lateral row was secured using suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
109734|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
109735|NCT01460966|Procedure|Thrombus aspiration catheter|Thrombus aspiration catheter only
109736|NCT01460979|Drug|Temsirolimus|25mg weekly intravenous until progression
109737|NCT00069849|Drug|ABT-089|
109738|NCT01460992|Procedure|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
109739|NCT01461005|Device|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
109740|NCT01461018|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
109741|NCT01461031|Drug|nefopam|nefopam infusion for postoperative 24 hours
109742|NCT01461031|Drug|normal saline (control)|normal saline infusion for postoperative 24 hours
109743|NCT01461057|Drug|capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
106316|NCT01440868|Procedure|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher & Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm ).
106317|NCT01440881|Drug|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
106318|NCT01440881|Drug|Placebo|infuses at 0.01MCG/KG/min for 48 hours
106319|NCT01440894|Device|Comparison test|Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.
DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D.
106320|NCT01440907|Other|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
106321|NCT00067535|Drug|Cocaine-Related Disorders|
106322|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
106323|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
106324|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
106325|NCT01434134|Drug|Metoprolol|Tablet, target dose 100 mg once daily
109297|NCT01457950|Drug|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
109298|NCT01457989|Drug|retigabine/ezogabine|dose range up to 1200 mg/day
109299|NCT01458002|Other|Tailored Internet Communication with Relational Agent|The Tailored Internet Intervention will include a "relational agent" component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site.
109300|NCT01458002|Other|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
109301|NCT01458015|Drug|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
109302|NCT01458028|Drug|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
109303|NCT01460212|Drug|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
109304|NCT00069758|Drug|SDX-105|
108793|NCT01423903|Drug|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
108794|NCT00066066|Drug|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
108795|NCT01423916|Drug|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
108796|NCT01423916|Drug|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
108797|NCT01423916|Drug|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
108798|NCT01423916|Drug|Placebo|OPC-34712 placebo
108799|NCT01423929|Drug|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
108800|NCT01423929|Device|Room air|Fitting of Oxymask TM
108801|NCT01423955|Drug|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
108802|NCT01423955|Drug|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
108803|NCT01423968|Biological|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
108804|NCT01423968|Other|saline|
108805|NCT00066066|Drug|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
108806|NCT01423994|Procedure|pacemaker|A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.
Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.
Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.
Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on.
109067|NCT01453049|Drug|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
109068|NCT01453049|Drug|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
109069|NCT01453062|Drug|Arzerra|Treatment with Arzerra
106264|NCT01397201|Drug|BI 54903|2 puffs BI54903 via Respimat inhaler
106265|NCT01399814|Behavioral|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000~2500ml crystalloid was administered on the days following operation
106266|NCT01399827|Drug|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
106267|NCT01399827|Drug|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
106268|NCT01399840|Drug|BMN 673|Oral capsule with multiple dosage forms given once daily
106269|NCT00063622|Drug|Pioglitazone|30 mg daily
106270|NCT01399853|Biological|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
106271|NCT01399853|Biological|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
106272|NCT01399853|Biological|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
105365|NCT01403571|Dietary Supplement|Salba (Salvia hispanica L.)|Approximately 30g/day over 48 weeks
105366|NCT01403597|Device|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
105367|NCT01403610|Drug|TH-302|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
105368|NCT01403610|Drug|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
105369|NCT01403623|Procedure|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
105370|NCT01403623|Procedure|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
105371|NCT01403636|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
109744|NCT01461057|Drug|cisplatin|80 mg/m2 on Day 1 of each cycle
109745|NCT01461057|Drug|pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
109746|NCT01461057|Drug|pertuzumab|840 mg once every three weeks
109747|NCT01461057|Drug|trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
108861|NCT01431573|Drug|Lithium Carbonate|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
108862|NCT01431573|Drug|Armodafinil|Armodafinil (Nuvigil®) 150 mg once or twice daily will be offered to patients to help maintain wakefulness. If excessive sleepiness remains, 250 mg will be offered with the option of a second dose of 150 mg 15 hours later (but not within 15 hours of intended sleep). Patients having experience with armodafinil will be offered the dose suggested by their prior experience.
108863|NCT01431586|Drug|JDtic|The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.
Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug.
108864|NCT01431599|Radiation|short-course radiation|33Gy/10 fractions
108865|NCT01431612|Drug|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
108866|NCT01431612|Drug|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
108867|NCT01431612|Drug|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
108868|NCT01424033|Drug|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
108869|NCT01424046|Drug|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
108870|NCT01424046|Drug|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
108871|NCT01424059|Other|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
108872|NCT01424072|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
109305|NCT01460212|Behavioral|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
109306|NCT01460225|Drug|lubiprostone|24 micrograms twice daily for 1 week
109307|NCT01460251|Drug|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
109308|NCT01460277|Procedure|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
109309|NCT01460277|Procedure|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
109310|NCT01460290|Drug|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
109311|NCT01460303|Device|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered "passed" when a patient is able to void adequately and spontaneously (without the assistance of a catheter).
109312|NCT01460303|Device|Transurethral catheter with leg bag|Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered "passed" when a patient is able to void adequately and spontaneously (without the assistance of a catheter).
109561|NCT01458457|Other|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
109562|NCT01458470|Drug|Memantine|oral tablet, 1 BID, 24 weeks
109563|NCT00069576|Behavioral|self blood glucose monitoring|
109564|NCT01458470|Other|Placebo|oral tablet, 1 BID, 24 weeks
109565|NCT01458483|Device|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
109566|NCT01461200|Other|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
109567|NCT01461213|Drug|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
106145|NCT01402414|Radiation|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
106146|NCT01402427|Drug|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
106147|NCT01402427|Drug|Placebo|Intraarterial administration of 10 mL saline.
106148|NCT01402440|Drug|AEB071|
106149|NCT01394354|Drug|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
106150|NCT01394354|Drug|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
106151|NCT01394367|Other|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
105229|NCT01397708|Drug|INXN-1001|4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)
7 oral daily doses of INXN-1001 per study cycle
maximum of 6 study cycles
1 Expansion cohort at a single dose level at or below MTD (160mg/day)
105230|NCT01397734|Drug|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
105231|NCT01397786|Drug|OPC-34712|Phase A: 1-2 mgs/day by mouth, max of 4 wks.
Phase B: 1-4 mgs/day by mouth, up to 52 weeks
105232|NCT01397799|Drug|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
105233|NCT01397812|Device|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
105234|NCT01397812|Device|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
105235|NCT00063323|Drug|Bupropion|
105236|NCT01397825|Drug|Alisertib (MLN8237) + Rituximab + Vincristine|Phase 1, Part 1: Safety lead-in cohort combining alisertib (MLN8237) as an enteric coated tablet (ECT) orally twice/day Days 1-7 & rituximab as an intravenous (IV) infusion on Day 1 in a 21 Day cycle for up to 8 cycles
Phase 1, Part 2: Alisertib (MLN8237) as an ECT orally twice/day Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV Days 1 & 8 in a 21 Day cycle for up to 8 cycles
Phase 2: Alisertib (MLN8237) as an ECT orally twice/day Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV Days 1 & 8 in a 21 Day cycle for up to 8 cycles
Following 8 cycles of treatment (or early discontinuation of rituximab) all patients with documented disease response or stabilization may continue with alisertib (MLN8237) single-agent therapy up to 2 years
105237|NCT01397838|Drug|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
105238|NCT01397851|Device|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
105906|NCT01396434|Biological|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
105907|NCT01396447|Drug|Placebo|Placebo was supplied in capsules.
105908|NCT01396447|Drug|Cariprazine|Cariprazine was supplied in capsules.
105909|NCT01396460|Other|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
105910|NCT01396473|Behavioral|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
105911|NCT01396486|Drug|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
106203|NCT01399788|Drug|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
106204|NCT01399801|Procedure|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
106205|NCT01399801|Procedure|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
106206|NCT01399814|Behavioral|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000~1500ml crystalloid was administered on the days following operation
106207|NCT01402453|Behavioral|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
106208|NCT01402453|Behavioral|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
106209|NCT00063882|Radiation|radiation therapy|Given as external beam radiation therapy over 5 weeks
106210|NCT01402466|Behavioral|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
106211|NCT01402466|Behavioral|Project Bridge|Arm 2
107125|NCT01437488|Procedure|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
107126|NCT01437488|Biological|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
107127|NCT01437501|Drug|Broccoli Sprout Extract Beverage|Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
107128|NCT01437501|Drug|placebo beverage|100 mL of dilute pineapple and lime juice daily for 84 days.
107129|NCT01437514|Radiation|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
107130|NCT01437527|Behavioral|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
107131|NCT01437527|Behavioral|therapy as usual|Body image therapy as usual
107132|NCT01437540|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol high dose twice per day
107133|NCT01437540|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
107134|NCT01437553|Device|iMAP|IVUS and iMAP analysis for acute coronary syndromes
107135|NCT00067028|Drug|Idarubicin|Clofarabine + Idarubicin:
10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
Clofarabine + Idarubicin plus Ara-C:
6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
107136|NCT01437566|Drug|GDC-0941|Repeating oral dose
107458|NCT00066937|Behavioral|cognitive-behavioral treatment|Study cognitive-behavioral treatment
107459|NCT01435980|Drug|Exenatide|basal treatment and Exenatide
107460|NCT01435993|Drug|GSK1223249|Intravenous infusion
107461|NCT01435993|Other|Saline placebo|placebo intravenous infusion
107462|NCT01436032|Drug|N1539|IV
107463|NCT01436032|Drug|N1539|IV
107464|NCT01436032|Drug|N1539|IV
107465|NCT01436032|Drug|Ketorolac Tromethamine|IV
105173|NCT01400620|Drug|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
105174|NCT01400633|Drug|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
105175|NCT01400646|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
105466|NCT01403987|Behavioral|Lecture|During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
105467|NCT01403987|Other|Pocket Card Reference|A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
105468|NCT01403987|Behavioral|Pager|The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a "tap," the pager number will correlate with the letters, "TAPS," or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure.
105469|NCT01404000|Drug|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
105470|NCT01395784|Drug|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
105471|NCT01395797|Drug|Pioglitazone|0, 15, and 45 mg per day.
105472|NCT01395797|Drug|Placebo|Placebo - Heroin
105473|NCT01395810|Drug|NNC-0156-0000-0009|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
105474|NCT01395810|Drug|NNC-0156-0000-0009|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
105475|NCT00062985|Behavioral|phone-based weight counseling|
105476|NCT01395810|Drug|NNC-0156-0000-0009|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
105477|NCT01395810|Drug|NNC-0156-0000-0009|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
105239|NCT01397864|Drug|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
105240|NCT01397877|Drug|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
105241|NCT01397890|Drug|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
105242|NCT01397890|Drug|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
105243|NCT01397929|Drug|BAL101553|Intravenous administration
105244|NCT01397942|Other|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
105245|NCT01397955|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
105246|NCT01400659|Procedure|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
105539|NCT01403376|Biological|Influenza vaccine|Inactivated, split-virion influenza vaccine 2011-2012
One administration by intramuscular or intradermal route as per product specification
105540|NCT01403389|Drug|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
105541|NCT00001095|Drug|Nevirapine|
105542|NCT00063934|Other|pharmacological study|Optional correlative studies
105543|NCT01403389|Drug|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
105544|NCT01403415|Drug|Dexamethasone|Given PO or IV
105545|NCT01403415|Other|Laboratory Biomarker Analysis|Correlative studies
105546|NCT01403415|Drug|Methotrexate|Given IT
105547|NCT01403415|Drug|Mitoxantrone Hydrochloride|Given IV
105548|NCT01403415|Drug|Pegaspargase|Given IV
105549|NCT01403415|Other|Pharmacological Study|Correlative studies
105550|NCT01403415|Drug|Temsirolimus|Given IV
105551|NCT01403415|Drug|Vincristine Sulfate|Given IV
106212|NCT01402479|Drug|Ramipril|ramipril 2.5mg twice a day
106213|NCT01402492|Drug|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
106214|NCT01402492|Drug|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
106215|NCT01402505|Procedure|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
106216|NCT01402518|Procedure|Per-oral enodscopic myotomy|
106217|NCT01402531|Drug|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
105303|NCT01395511|Device|Acupuncture|Tool : Acupuncture Seirin SJ 0.16 * 40 (mm) / SJ 0.18 * 50 (mm) L-type needles were used for the study.
Made from stainless steel needle SEIRIN JAPAN
105304|NCT01395524|Drug|NKTR-118|12.5 mg oral tablet once daily
105305|NCT01395524|Drug|NKTR-118|25 mg oral tablet once daily
105306|NCT01395524|Drug|Placebo|Oral tablet intake once daily
105307|NCT00062972|Drug|donepezil|
105308|NCT01395537|Drug|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
105309|NCT01395537|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
105310|NCT01395537|Drug|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
105311|NCT01395563|Behavioral|strength training|strength training, high intensity, twice up to 3 times per week
105312|NCT00063336|Behavioral|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
105313|NCT01397968|Drug|YKP3089|Capsule, dose to be titrated
105314|NCT01397968|Drug|Placebo|Placebo capsule
105315|NCT01397981|Behavioral|Gait retraining|Changing the kinematics of walking
107466|NCT01436032|Drug|Placebo|IV
107467|NCT01436045|Drug|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
107468|NCT01436045|Drug|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
107469|NCT00066937|Drug|Nortriptyline|
107470|NCT01436058|Biological|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
107471|NCT01436071|Drug|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
107472|NCT01436071|Drug|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
107473|NCT01438125|Other|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
107474|NCT01438125|Other|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
107475|NCT01438138|Other|diagnostic laboratory biomarker analysis|Correlative studies
107476|NCT01438151|Drug|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
107477|NCT01438177|Drug|Velcade|
107478|NCT01438177|Drug|Cyclophosphamide|
107479|NCT01438177|Drug|Chloroquine|
107480|NCT01438190|Drug|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
106595|NCT01434667|Behavioral|APOE genotype disclosure and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
106596|NCT01434667|Behavioral|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
106597|NCT01434680|Biological|MenC-CRM LIQ|One dose of MenC-CRM vaccine, liquid formulation
106598|NCT01434680|Biological|MenC-CRM ROS|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.
105478|NCT01395823|Dietary Supplement|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
105479|NCT01395823|Other|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
105480|NCT01395849|Drug|Salmeterol and Fluticasone|
105481|NCT01395862|Drug|Salmeterol and Fluticasone|
105482|NCT01395875|Drug|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
105778|NCT01398943|Drug|L-NMMA|dosage range = 4 mg/kg/min
105779|NCT01398943|Dietary Supplement|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
105780|NCT01398956|Drug|Levetiracetam|formulation: tablet or dry syrup
strength: 250 mg tablet, 500 mg tablet, dry syrup 50%
dosage: Sb ≥16 years and ≥4 and <16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and <16 years (<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day
frequency: twice daily
105781|NCT00063427|Drug|MAC-321|
105782|NCT01398969|Procedure|Fresh Human Biotherapy|Patients will receive fresh fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
105783|NCT01398969|Procedure|Frozen-and-Thawed Human Biotherapy|Patients will receive frozen-and-thawed fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
105784|NCT01401712|Procedure|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
105785|NCT01401712|Procedure|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
105786|NCT01401725|Behavioral|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
105787|NCT01401725|Behavioral|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
105788|NCT01401725|Other|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
105789|NCT01401751|Device|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
105790|NCT00001095|Drug|Indinavir sulfate|
105552|NCT01403428|Other|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
105553|NCT00063934|Other|laboratory biomarker analysis|Optional correlative studies
105554|NCT01403441|Device|Radiosurgical Neuromodulation using the Cyberknife|
105555|NCT01403454|Behavioral|Interactive Health Communication Application|web-based application
105556|NCT01403454|Behavioral|No Intervention: Usual Care|Usual care person to person dialysis modality intervention.
105557|NCT01403467|Device|Continuous positive airway pressure|CPAP 8 cmH2O
105558|NCT01403493|Behavioral|Patient education|
105559|NCT01403506|Drug|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
105560|NCT01403532|Drug|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
105561|NCT01395940|Drug|KLH-2109|
105562|NCT00063011|Behavioral|Weight bearing exercise|
105839|NCT01398995|Other|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
105840|NCT01399008|Drug|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
105841|NCT01399008|Drug|Allopurinol|Allopurinol 300 mg as active comparator
105842|NCT01399008|Drug|Colchicine|0.6 mg colchicine daily as flare prophylaxis
105843|NCT01399008|Drug|Placebo|Placebo
105844|NCT01399021|Other|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
105845|NCT00063453|Dietary Supplement|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
105846|NCT01399021|Other|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
106809|NCT00067314|Drug|Edotecarin|
106810|NCT01439399|Drug|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
106811|NCT01439399|Drug|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
106812|NCT01439412|Procedure|Acupuncture and standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.
The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji ("Jiaji") bilaterally in the segments of the L2-L4 for 5 minutes.
106813|NCT01439412|Other|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
106814|NCT01439425|Behavioral|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
106815|NCT01439438|Drug|Topiramate coated tablet|Test formulation
106816|NCT01439438|Drug|Topamax® coated tablet|Reference formulation
106817|NCT00067691|Procedure|Acupuncture|
107063|NCT01439867|Drug|Cinacalcet HCl|This is a multicenter, 26-week, single-arm, open-label, safety study. Subjects will remain on study for 26 weeks or until time of kidney transplantation, whichever comes first. All subjects, in addition to receiving cinacalcet, will receive standard of care, which may include vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs).
107064|NCT01439880|Biological|Evolocumab (AMG 145) and standard of care|Evolocumab (AMG 145) is a fully human monoclonal antibody against PCSK9. Standard of care therapy is per local practice; this could include prescribed therapies and/or dietary/exercise regimes
107065|NCT01439880|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
107066|NCT01439893|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
107067|NCT01439893|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
107068|NCT01439906|Procedure|Surgical correction of the deformity|Three different surgical techniques are used:
lumbar fusion vs thoraco-lumbar fusion
iliac fixation vs fixation to the sacrum
posterior + interbody fusion vs posterior interbody fusion
106599|NCT01434680|Biological|MenC-CRM EMV|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
106600|NCT01434693|Biological|Trichuris suis ova|single dose
106601|NCT00066794|Drug|cyclosporine|ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
106602|NCT01434693|Other|Placebo|
106603|NCT01434706|Other|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
106604|NCT01434732|Procedure|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
106605|NCT01436474|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
106606|NCT01436487|Biological|MultiStem|single infusion 1-2 days following ischemic stroke
106607|NCT01436487|Biological|Placebo|single infusion 1-2 days following ischemic stroke
106608|NCT01436500|Drug|5mg Ifetroban Injection|Cohort 1: 5 mg Ifetroban Injection administered IV over 60 minutes once daily; During 72-hr treatment period. Total of 3 doses of CTM will be administered.
106609|NCT01436500|Drug|15mg Ifetroban Injection|Cohort 2: 15 mg Ifetroban Injection administered IV over 60 minutes once daily During 72-hr treatment period. Total of 3 doses of CTM will be administered.
106610|NCT01436500|Drug|50mg Ifetroban Injection|Cohort 3: 50 mg Ifetroban Injection administered IV over 60 minutes once daily During 72-hr treatment period. Total of 3 doses of CTM will be administered.
106866|NCT01437020|Drug|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
106867|NCT01437020|Drug|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
105791|NCT00063817|Drug|Cyclosporine A|Immunosuppressant
105792|NCT01401764|Other|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
105793|NCT01401790|Device|Telehomecare (Intelligent Distance Patient Monitoring)|Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for
Automatic download of blood glucose levels
Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team
Changes in treatment plan by the diabetes professionals
E mail exchanges between families and health care professionals
Reinforcement of teaching program
105794|NCT01401790|Other|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
106075|NCT01394237|Other|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
106076|NCT01394250|Device|Buzzy|Cold, Vibrational Device
106077|NCT01394250|Drug|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
106078|NCT01394263|Drug|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
106079|NCT01394263|Drug|Zoladex goserelin implant|goserelin implant injection.
106080|NCT01394289|Biological|Lolium allergen extract|This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
106081|NCT00062842|Drug|Irinotecan|
106082|NCT01394341|Drug|Liraglutide|Daily sc. injection, individual dosage
106083|NCT01394354|Drug|Vorinostat|Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.
The dose level of Vorinostat will be escalated in each new cohort:
if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o.
106084|NCT01394354|Drug|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
106085|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
106086|NCT01396759|Procedure|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
105847|NCT01399047|Drug|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
105848|NCT01399047|Drug|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
105849|NCT01399073|Behavioral|virtual reality setup|testing for neglect in a virtual reality setup
105850|NCT01399073|Behavioral|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
105851|NCT01399073|Other|c-mri|structural and functional (resting state) imaging
105852|NCT01399086|Drug|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
105853|NCT01399099|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
105854|NCT01399112|Behavioral|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
105855|NCT01401842|Other|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
105856|NCT00063817|Drug|Rituximab|B-cell suppressor
106152|NCT01394380|Other|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
106153|NCT01394393|Behavioral|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, & Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
106154|NCT01394393|Behavioral|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive—behavioral treatment approach described by Cooper and colleagues (Cooper & Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
107069|NCT01439919|Drug|SSR411298|Form: tablet
Route: oral administration with food
107070|NCT01439919|Drug|Placebo (for SSR411298)|Form: tablet
Route: oral administration with food
107071|NCT01439932|Device|algometer|Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.
The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people [Andrew 1987]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). [Linda et al 2007]
107072|NCT00067366|Behavioral|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
107073|NCT01439945|Drug|magnesium oxide|Given PO
107074|NCT01439945|Other|placebo|Given PO
107075|NCT01439958|Drug|Inhalation|Twice daily inhalation for a maximum of three years.
107076|NCT01439971|Biological|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
107077|NCT01439971|Biological|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
107078|NCT01439971|Biological|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
107079|NCT01439971|Biological|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
107080|NCT01439984|Drug|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
107409|NCT01438112|Biological|CG0070 adenovirus vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
107410|NCT01438112|Other|Control Arm: Quadruple Choice|Quadruple Choice Treatment Options:
I. Mitomycin C II. Interferon III. Valrubicin IV. Gemcitabine
107411|NCT01440452|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
107412|NCT01440452|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
106868|NCT01437046|Drug|Doxazosin|Doxazosin 16mg/day
106869|NCT00067015|Drug|bicalutamide|
106870|NCT01437046|Drug|Placebo|
106871|NCT01437059|Drug|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
106872|NCT01437059|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
106873|NCT01437072|Other|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
106874|NCT01439451|Procedure|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
106875|NCT01439464|Device|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
106876|NCT01439464|Device|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
106877|NCT00067327|Drug|Inosine|
106878|NCT01439490|Other|FES-PET|Patients undergo FES-PET prior to obtaining histology
106879|NCT01439503|Behavioral|Intervention|The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right "fit and feel" of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to "sexualize" condoms.
106880|NCT01439516|Behavioral|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
106881|NCT01439529|Other|Device programming: nominal|CRT device is programmed to nominal values
106882|NCT01439529|Other|Programming optimization by QRS|CRT device is programmed by QRS optimization
106883|NCT01439542|Radiation|Stereotactic Body Radiation|Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week
Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week
106884|NCT01439542|Drug|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
106885|NCT01439555|Drug|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
106886|NCT01439568|Drug|LY2510924|Administered subcutaneous injection
107137|NCT01437566|Drug|GDC-0941|Repeating oral dose
106087|NCT01396759|Procedure|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
106088|NCT01396772|Behavioral|PREPARE education program|PREPARE stands for "Prediabetes Research and Education Promoting Activity and Responsible Eating" and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity.
106089|NCT01396772|Other|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
106090|NCT01396785|Drug|33525|Daily for 14 days
106091|NCT01396785|Drug|Placebo|Daily for 14 days
105176|NCT01400646|Drug|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
105177|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
105178|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
105179|NCT01400646|Drug|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
105180|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
105181|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
105182|NCT00063687|Drug|Oxypurinol|
105183|NCT01400659|Procedure|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
105184|NCT01403064|Biological|ALD518|IV
105185|NCT01403064|Drug|0.9% saline|IV Infusion
105186|NCT01403077|Device|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
106155|NCT01394393|Dietary Supplement|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
106156|NCT00062855|Procedure|Skin Biopsy|
106157|NCT01394406|Drug|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
106158|NCT01394406|Drug|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
106159|NCT01394419|Drug|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
106160|NCT01394419|Drug|Saline|Equal volume of normal saline
106161|NCT01394432|Procedure|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
106162|NCT01394445|Drug|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
106163|NCT01394445|Drug|Placebo|continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours
PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg
106164|NCT01394458|Other|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
106165|NCT01394458|Drug|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
105247|NCT01400672|Biological|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
105248|NCT01400672|Drug|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
105249|NCT01400672|Radiation|Radiation therapy|Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby "sensitizing" residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy.
105250|NCT01400685|Drug|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
105251|NCT01400685|Drug|Bendamustine|90 mg/m^2 IV days 1-2 of each cycle for 6 cycles
107413|NCT01440452|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
107414|NCT01440452|Behavioral|Mood assessment|If you do not already have an account, you will be signed up with "Mood24/7" (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.
107415|NCT01440478|Drug|LY2140023|Administered orally
107416|NCT01440478|Drug|Ammonium chloride|Administered orally
107417|NCT00067470|Drug|Placebo|
107418|NCT01440478|Drug|Sodium bicarbonate|Administered orally
107419|NCT01440491|Other|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
107420|NCT01440504|Other|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
107421|NCT01440517|Drug|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
107422|NCT01440530|Behavioral|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
107423|NCT01440530|Other|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
107424|NCT01440543|Procedure|Water immersion insertion AND CO2 insufflation|room temperature water infused by water pump into the colon just to facilitate scope insertion
CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection
107425|NCT01440543|Procedure|Water immersion insertion|room temperature water infused by water pump into the colon just to facilitate scope insertion
standard room air insufflation during colonoscope withdrawal and mucosal inspection
106539|NCT01436448|Drug|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
106540|NCT00067002|Drug|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
107138|NCT01437566|Drug|GDC-0980|Repeating oral dose
107139|NCT01437566|Drug|fulvestrant|Repeating intramuscular injection
107140|NCT01437566|Drug|placebo|Repeating oral dose
107141|NCT01437566|Drug|placebo|Repeating oral dose
107142|NCT01437579|Procedure|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
107143|NCT01437579|Procedure|cystoscopy|cystoscopy under general anesthesia
107144|NCT01437592|Drug|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
107145|NCT01437605|Drug|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
107146|NCT00067028|Drug|Ara-C|Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
107147|NCT01439997|Drug|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
107148|NCT01440010|Radiation|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
107149|NCT00067379|Procedure|interceptive orthodontic treatments|orthodontic procedures
107150|NCT01440023|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
107151|NCT01440023|Behavioral|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
107152|NCT01440023|Behavioral|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
107153|NCT01440036|Procedure|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
107154|NCT01440049|Other|Prospective Observational|this is an observational study non interventional
107155|NCT01440062|Drug|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
107156|NCT01440062|Drug|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
105187|NCT01403090|Device|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
105188|NCT00063934|Drug|docetaxel|Given IV
105189|NCT01403103|Dietary Supplement|cholecalciferol|Given PO
105190|NCT01403103|Procedure|biopsy|Correlative studies
105191|NCT01403103|Genetic|protein expression analysis|Correlative studies
105192|NCT01403103|Other|enzyme-linked immunosorbent assay|Correlative studies
105193|NCT01403103|Other|laboratory biomarker analysis|Correlative studies
105194|NCT01403103|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
105195|NCT01403116|Drug|oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
105483|NCT01395875|Drug|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium [IPR]).
105484|NCT01395888|Drug|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
105485|NCT01395888|Drug|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
105486|NCT00063011|Behavioral|Calcium rich diet|
105487|NCT01395901|Drug|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
105488|NCT01395901|Drug|Ondansetron|Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for >40 kg;
13 years to less than 17 years dose: 4 mg
105489|NCT01395901|Drug|Placebo to Ondansetron|
105490|NCT01395901|Drug|Placebo to Palonosetron|
105491|NCT01395914|Drug|Anamorelin HCl|
105492|NCT01395914|Drug|Placebo|
105493|NCT01395927|Drug|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
105494|NCT01395927|Drug|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
105252|NCT01400685|Drug|Rituximab|375 mg/m^2 IV day 1 (cycle 1), 500 mg/m^2 day 1 (cycles 2-6)
105253|NCT01400698|Drug|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
105254|NCT01400698|Drug|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
105255|NCT00063700|Procedure|reducing exposure to marketing pressures|
105256|NCT01400698|Other|Observation only|Subjects were only observed.
105257|NCT01400711|Other|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
105258|NCT01400711|Other|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
105259|NCT01400724|Dietary Supplement|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
105260|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
105261|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
105262|NCT01400750|Drug|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
105263|NCT01400750|Drug|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
105264|NCT01400763|Dietary Supplement|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
105265|NCT01400763|Dietary Supplement|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
105563|NCT01395953|Drug|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
105564|NCT01395953|Drug|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
105565|NCT01395966|Drug|DF289|Ear drops
106541|NCT01436474|Drug|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
106542|NCT01438814|Drug|metformin|metformin tablets 500 mg
106543|NCT01438814|Drug|linagliptin|linagliptin tablets 5mg
106544|NCT01438827|Drug|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
106545|NCT01438827|Drug|Placebo|Suspension for Injection, Every 6 weeks for one year
106546|NCT01438840|Drug|E5501 - Avatrombopag maleate|Administered orally as 5mg, 10mg, 20mg, 30mg or 40mg in a flexidose design. Starting dose of 20 mg, with dose titration down to 5 mg or up to 40 mg as per specified guidelines.
106547|NCT01438840|Drug|E5501 - Avatrombopag maleate Matching Placebo|Matching Placebo administered orally as 5mg, 10mg, 20mg, 30mg or 40mg in a flexidose design. Starting dose of 20 mg, with dose titration down to 5 mg or up to 40 mg as per specified guidelines.
106548|NCT01438853|Biological|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
106549|NCT01438853|Drug|Placebo|Single intravenous dose of saline control
106550|NCT00067236|Drug|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
106551|NCT01438866|Other|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
106552|NCT01438866|Other|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
106553|NCT01438892|Drug|tDMARDs|Traditional DMARDs for RA
106554|NCT01438892|Drug|biodmards|Biologic DMARDs
106555|NCT01438905|Other|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
106556|NCT01438905|Other|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
107157|NCT01440075|Other|Cardiac evaluation|complete cardiac evaluation with :
Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping
107481|NCT00067119|Drug|Aggrenox|
107482|NCT01438190|Drug|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
107483|NCT01438203|Procedure|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
107484|NCT01438203|Procedure|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
107485|NCT01438229|Device|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
107486|NCT01438242|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
107487|NCT01438281|Drug|SYL1001|SYL1001 eye drops. topical administration
107488|NCT01438294|Other|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
107489|NCT01438294|Other|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
107490|NCT01438307|Drug|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
107491|NCT01440569|Drug|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
107492|NCT01440582|Drug|Panobinostat|Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.
Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.
Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.
Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle.
105495|NCT01395940|Drug|KLH-2109|
105496|NCT01398267|Drug|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
105497|NCT01398267|Drug|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
105498|NCT01398280|Drug|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
105499|NCT01398280|Drug|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
105500|NCT01398293|Drug|danoprevir|100 mg single dose orally
105501|NCT00001094|Drug|Lamivudine/Zidovudine|
105502|NCT00063362|Drug|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
105503|NCT01398293|Drug|danoprevir|400 mg single dose orally
105504|NCT01398293|Drug|danoprevir placebo|single oral dose
105795|NCT01401803|Drug|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
105796|NCT01401816|Other|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
105797|NCT01401829|Behavioral|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
105798|NCT01401829|Behavioral|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
105799|NCT01401829|Behavioral|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
105800|NCT01401842|Other|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
105566|NCT01395966|Drug|DF277|Ear drops
105567|NCT01395966|Drug|DF289 plus DF277|Ear drops
105568|NCT01395979|Behavioral|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
105569|NCT01395979|Behavioral|Supportive Psychotherapy|Eight weekly sessions
105570|NCT01395979|Behavioral|Sexual Risk Reduction Intervention|Two weekly sessions.
105571|NCT01395992|Drug|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
105572|NCT01395992|Drug|asenapine|asenapine 10 mg tablet, SL BID for 182 days
105573|NCT00001091|Drug|Nevirapine|
105574|NCT00063024|Behavioral|Increased calcium intake|
105575|NCT01396005|Drug|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
105576|NCT01396005|Drug|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
105577|NCT01396005|Drug|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
105578|NCT01396031|Behavioral|Physical Therapy|Standard of care
105579|NCT01396044|Other|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
105580|NCT01396044|Other|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
105581|NCT01396057|Drug|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
105582|NCT01396057|Other|Dexamethasone Implant|Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
105857|NCT01401868|Drug|ME-143|experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
106818|NCT01441921|Dietary Supplement|Pistachios|Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.
Total duration of intervention and follow-up is nine months.
106819|NCT01441921|Other|control diet|Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.
Total duration of intervention and follow-up is nine months.
106820|NCT01441934|Drug|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
106821|NCT01441934|Drug|Sugar pills|placebo t.i.d.
106822|NCT01441947|Drug|Cabozantinib|Part of combination arm
106823|NCT01441947|Drug|Fulvestrant|part of combination arm
106824|NCT01441960|Drug|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
106825|NCT01441960|Drug|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
106826|NCT01441973|Biological|Elotuzumab (BMS-901608; HuLuc63)|
106827|NCT01441986|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
106828|NCT00067704|Behavioral|Trauma writing|
106829|NCT01441986|Drug|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
106830|NCT01441986|Drug|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
106831|NCT01441986|Drug|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
106832|NCT01441999|Device|Less rigid rod|Titanium rod with semi rigid end
106833|NCT01441999|Device|Rigid Rod|Rigid Titanium rods
106834|NCT01442012|Other|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
106835|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
106836|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
107493|NCT01440582|Drug|Bortezomib|Induction Therapy (Part A, 21-day cycles): 1.3 mg/m^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.
Induction Therapy (Part B, 28-day cycles): 1.3 mg/m^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8.
107494|NCT01440582|Drug|Lenalidomide|Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.
Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.
Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle.
106326|NCT01434134|Drug|Placebo|Tablet, target dose 100 mg once daily
106327|NCT01434134|Drug|Candesartan|Tablet, target dose 32 mg once daily
106328|NCT01434134|Drug|Placebo|Tablet, 32 mg once daily
106329|NCT01434147|Drug|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
106330|NCT01434160|Drug|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
106331|NCT01434173|Drug|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
106332|NCT01434173|Drug|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
106333|NCT00066768|Drug|gemcitabine hydrochloride|Given IV
106334|NCT01434186|Drug|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
106335|NCT01434186|Drug|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
106336|NCT01434186|Drug|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
106337|NCT01434186|Drug|Saxagliptin|Tablet, Oral, 2.5 mg for body weight 30kg to ≤ 50kg, Daily, Day 1 through week 52
106338|NCT01434186|Drug|Saxagliptin|Tablet, Oral, 5 mg for the body weight >50 kg, Daily, Day 1 through week 52
106339|NCT01434199|Procedure|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
105801|NCT01383850|Other|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
105802|NCT01383876|Behavioral|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
105803|NCT00061945|Drug|acyclovir|Given PO
105804|NCT01383876|Behavioral|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
105805|NCT01383889|Other|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
105806|NCT01383902|Other|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
105807|NCT01383928|Drug|IXAZOMIB + Lenalidomide + Dexamethasone|Ph 1: Patients will receive escalating doses of IXAZOMIB orally on Days 1,4,8&11; plus dexamethasone orally on Days 1,2,4,5,8,9,11&12 at 20mg in Cycles 1-8/10mg in Cycles 9-16 & lenalidomide 25mg orally on Days 1-14 of a 21-day cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients who have stable or responding disease will continue treatment in the maintenance therapy portion of the study.
Ph 2: Patients will receive IXAZOMIB orally at the maximum tolerated dose or recommended phase 2 dose on Days 1,4,8,11, plus dexamethasone orally on Days 1,2,4,5,8,9,11&12 at 20mg in Cycles 1-8/10mg in Cycles 9-16 and lenalidomide 25mg orally on Days 1-14 of a 21-day cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease will continue treatment in the maintenance therapy portion of the study.
106092|NCT01396811|Drug|33525|Daily for 14 days
106093|NCT01396811|Drug|Placebo|Daily for 14 days
106094|NCT01396824|Other|No intervention|No intervention
106095|NCT01396837|Device|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
106096|NCT00063154|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
106097|NCT01396863|Procedure|HDF during the first examination|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.
During the second examination the patient will receive treatment with low flux hemodialysis.
MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment.
106098|NCT01396863|Procedure|HD during the first examination|The patient will receive treatment with low flux hemodialysis during the first examination.
During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.
MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment.
106099|NCT01396876|Behavioral|clown|a distraction technique is performed by a clown during venipuncture
105858|NCT01401907|Other|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
105859|NCT01401920|Other|leg elevation|bilateral passive leg elevation for 30 seconds
105860|NCT01401920|Other|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
105861|NCT01401920|Other|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
105862|NCT01401920|Other|control group|supine position without passive leg elevation or trendelenburg position
105863|NCT01401933|Drug|Linifanib|QD on Days 1 and 13
105864|NCT01401933|Drug|Rifampin|QD on Days 5-16
105865|NCT01401946|Drug|soy isoflavones|
105866|NCT01401946|Drug|Placebo|
105867|NCT00063817|Drug|Corticosteroids|Immunosuppressant
105868|NCT01401959|Drug|eribulin mesylate|1.4 mg/m2 IV Days 1 and 8, every 21 days
105869|NCT01401959|Drug|Trastuzumab|6 mg/kg IV Day 1 every 21 days
105870|NCT01401985|Drug|TD-1211|Capsules once daily
105871|NCT01402011|Procedure|shoulder injections|injections of 1 mL of solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
105872|NCT01402024|Drug|Aprepitant|The patient on study group with weight category of 15-40 kg will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and
The patient with weight category of 41-65 kg in study group will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg
105873|NCT01402024|Drug|Placebo|Patient on control group with weight category of 15-40 kg will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and
The patient on control group with weight category of 41-65 kg will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule).
106166|NCT01396915|Dietary Supplement|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
106837|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
107081|NCT01442038|Drug|Placebo|Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.
Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
107082|NCT01442051|Procedure|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB < 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB <7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
107083|NCT01442064|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
107084|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
107085|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
107086|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
107087|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
107088|NCT01442090|Drug|Everolimus|Oral daily dose
107089|NCT01442090|Drug|GDC-0980|Oral daily dose
107090|NCT01442103|Device|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
107091|NCT00067717|Behavioral|Distance healing|
107092|NCT01442116|Procedure|stress echocardiography|safety and efficacy of stress echocardiography
107093|NCT01442129|Biological|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
107094|NCT01442129|Biological|Control Solution|Injection of control solution during the LVAD implantation.
106340|NCT01434212|Drug|Interferon Alfa-2b, Ribavirin|Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.
Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.
106341|NCT01434225|Drug|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
106342|NCT01434238|Other|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
105424|NCT00063752|Drug|PI-0824|
105425|NCT01400919|Device|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
105426|NCT01400932|Drug|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
105427|NCT01400932|Drug|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
105428|NCT01400945|Drug|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
105429|NCT01400958|Drug|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
105430|NCT01400958|Drug|Placebo|Placebo x 42 days; THEN, No More Placebo
105431|NCT01400984|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
105432|NCT01400997|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
105433|NCT01401010|Drug|Doripenem|500 mg every 8 hours
105434|NCT01401010|Drug|doripenem|1000 mg every 8 hours
105435|NCT00063765|Drug|Ciliary Neurotrophic Factor Implant NT-501|
105436|NCT01401023|Drug|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
105437|NCT01401036|Device|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
105438|NCT01401036|Procedure|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
106100|NCT01396889|Drug|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
106101|NCT01396889|Drug|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
106102|NCT01396902|Behavioral|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
106103|NCT01396902|Behavioral|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
106104|NCT01399515|Drug|Valproic Acid|One 500mg tablet by mouth daily
106105|NCT01399554|Behavioral|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
106106|NCT01399567|Behavioral|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
106107|NCT01399580|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
106108|NCT01399580|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
106109|NCT01399593|Drug|Eculizumab|IV administered over 35-45 minutes
105196|NCT01403116|Drug|topical testosterone gel 1%|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
105197|NCT01403129|Procedure|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
105198|NCT01403129|Procedure|ARFI Ultrasound exam|Acoustic radiation force (ARFI) ultrasound exam. Corneal tissue displacements at the epithelial surface, at Bowman's membrane, and at the posterior corneal surface will be measured, pre and post toneburst. Measurements will be taken in both eyes.
105199|NCT00063934|Biological|filgrastim|Given SC
105200|NCT01403155|Biological|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
105201|NCT01403168|Other|OSTEOPATHY + conventional analgesic treatments|5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.
The conventional analgesic treatments will be administered in the 15 days following the enrollment.
106167|NCT01396928|Procedure|Colonic reservoir|Type of reservoir to be performed
106168|NCT01396941|Behavioral|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
106169|NCT00063193|Drug|minocycline|
106170|NCT01396967|Device|surgery|cataract surgery
106171|NCT01396993|Procedure|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
106172|NCT01396993|Procedure|Breast Surgery|Breast conserving therapy without defect correction
106173|NCT01397006|Drug|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
106174|NCT01397019|Drug|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
106175|NCT01397032|Behavioral|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
106176|NCT01397032|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
106177|NCT01397045|Other|VATS|Video-assisted lung segmentectomy
106178|NCT01397045|Procedure|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
106179|NCT01397071|Other|Avocado|Fresh Avocado
106180|NCT00063193|Drug|creatine|
106181|NCT01397071|Other|No Avocado|No Avocado
106182|NCT01397084|Drug|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
106183|NCT01397097|Drug|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
106184|NCT01397097|Drug|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
106185|NCT01397110|Other|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
105266|NCT00063713|Drug|VELCADE TM (bortezomib) for Injection|
107095|NCT01442142|Behavioral|CAAT: Appetite Awareness|Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the "hunger meter" - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks.
107426|NCT01440543|Procedure|CO2 insufflation|- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
107427|NCT01440569|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally with food once daily
107428|NCT00067470|Drug|N-acetylgalactosamine 4-sulfatase|
107429|NCT01440569|Drug|DRV|Darunavir (DRV) 800 mg (2 x 400 mg tablets) administered orally with food once daily
107430|NCT00066742|Drug|cisplatin|Given IV
107431|NCT01433666|Drug|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
107432|NCT01433679|Behavioral|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
107433|NCT01433692|Behavioral|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
107434|NCT01433705|Procedure|Rb-82 and N-13 ammonia imaging|Intravenous administration of Rb-82 and N-13. Images will be acquired according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
107435|NCT01433705|Procedure|F-18 FDG imaging|Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for "viability protocol imaging" with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) "inflammation protocol imaging" using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol.
107436|NCT01433718|Procedure|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
107437|NCT01433731|Drug|placebo for SHAPE (SHP-141)|topical gelled solution
107438|NCT01433731|Drug|SHAPE (SHP-141) 0.1% BID|topical gelled solution
107439|NCT01433731|Drug|SHAPE (SHP-141) 0.5% BID|topical gelled solution
107440|NCT01433731|Drug|SHAPE (SHP-141) 1.0% BID|topical gelled solution
105439|NCT01401049|Drug|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
105440|NCT01401049|Drug|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
105441|NCT01401062|Drug|Fresolimumab|
105442|NCT01401062|Radiation|Radiation Therapy|
105443|NCT01401075|Drug|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
105444|NCT01401075|Drug|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
105445|NCT01401088|Device|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
105739|NCT01404039|Behavioral|Mental Imagery|Subjects will be seated in a chair and will be asked to keep their arm and hand muscles fully relaxed. They will then be asked to imagine repetitive movement of the left index finger to the left thumb for 5 minutes. Subjects will then be asked to imagine sequential movement of left finger to left thumb (thumb to 2nd, 3rd, 4th, 5th) for 5 minutes. Subjects will be asked to imagine sequential and repetitive finger movements of the left hand, for a duration of 10 minutes.
105740|NCT01404039|Behavioral|Control Group - Mental Imagery|Subjects will be asked to perform simple mental math calculations for 20 minutes. (ex. adding or subtracting a one digit number from a starting number (1+1=2; 2+1=3; 3+1= 4 and so on.)
105741|NCT01396187|Drug|PF-05231023|5 mg IV twice a week for 4 weeks
105742|NCT01396187|Drug|PF-05231023|25 mg IV twice a week for 4 weeks
105743|NCT01396187|Drug|PF-05231023|100 mg IV twice a week for 4 weeks
105744|NCT01396187|Drug|PF-05231023|200 mg IV twice a week for 4 weeks
105745|NCT01396187|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
105746|NCT01396200|Drug|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
105747|NCT01396200|Drug|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
105748|NCT01396213|Drug|Larazotide Acetate 0.5 mg|Larazotide Acetate at 0.5 mg TID
105749|NCT01396213|Drug|Larazotide Acetate 1 mg|Larazotide Acetate 1 mg TID
105750|NCT01396213|Drug|Larazotide Acetate 2 mg|Larazotide Acetate 2 mg TID
105202|NCT01403168|Other|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
105203|NCT01403181|Drug|Boceprevir|In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.
Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data.
105204|NCT01403194|Device|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
105205|NCT01403207|Other|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
105206|NCT01395173|Procedure|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
105207|NCT01395173|Procedure|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
105208|NCT01395186|Procedure|varicocelectomy|varicocelectomy for painful varicocele
105209|NCT01395199|Drug|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
105210|NCT01395238|Behavioral|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
105211|NCT01395251|Drug|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
105212|NCT00062933|Procedure|Laparotomy|
105505|NCT01398293|Drug|moxifloxacin|400 mg single dose orally
105506|NCT01398293|Drug|moxifloxacin placebo|single oral dose
105507|NCT01398293|Drug|ritonavir|100 mg single dose orally
105508|NCT01398293|Drug|ritonavir placebo|single oral dose
105509|NCT01398306|Other|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
105510|NCT01398319|Behavioral|Group Brief Alcohol Intervention|Intervention includes identifying reasons for joining the military, roadblocks to successful completion of training, information about alcohol, two anonymous self-assessments, information on quantity-based alcohol consumption in order to reduce the risk of incidents.
105267|NCT01403220|Procedure|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
105268|NCT01403220|Procedure|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
105269|NCT01403233|Dietary Supplement|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
105270|NCT01403233|Dietary Supplement|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
105271|NCT00063934|Biological|pegfilgrastim|Given SC
105272|NCT01403233|Dietary Supplement|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
105273|NCT01403246|Drug|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
105274|NCT01403259|Drug|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
105275|NCT01403272|Device|DermaTherapy® Linen and underpads.|DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.
Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics.
105276|NCT01403285|Drug|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
105277|NCT01403285|Biological|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
105278|NCT01403285|Biological|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
105279|NCT01403285|Drug|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
105280|NCT01403298|Behavioral|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
105281|NCT01403298|Other|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
105282|NCT00063934|Procedure|therapeutic conventional surgery|Undergo surgical resection
105283|NCT01403311|Drug|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
105284|NCT01403324|Drug|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
107441|NCT00066742|Drug|etoposide|Given IV
106557|NCT01438918|Drug|SD-6010|200 mg tablets once a day for 2 years
106558|NCT01438918|Drug|SD-6010|50 mg tablets once a day for 2 years
106559|NCT01438918|Drug|Placebo|Placebo tablets once a day for 2 years
106560|NCT01438931|Drug|DA-9501|Dexmedetomidine hydrochloride variable dose
106561|NCT00067236|Drug|Placebo tablet|placebo tablet, twice a day for 90 days
106562|NCT01438931|Drug|placebo|
106563|NCT01438944|Drug|Nicabate 21mg Transdermal Nicotine Replacement Therapy (NRT)Patch|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
106564|NCT01438957|Drug|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
106565|NCT01438957|Drug|Placebo|
106566|NCT01441271|Procedure|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution [GoLytely®; Braintree Laboratories] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes [500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days] via a Malecot catheter [24 French] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole [500mg q8 hours] for 10 days.
106567|NCT01441271|Procedure|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
106568|NCT01441284|Drug|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
106569|NCT01441284|Drug|placebo|placebo
106570|NCT00067600|Behavioral|Increased high impact activity and resistance training|
106571|NCT01441297|Drug|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
106572|NCT01441310|Procedure|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
106573|NCT01441323|Behavioral|Control|delayed intervention - they receive intervention classes (ST + N) at the end of the study that is not compared to the other groups.
106574|NCT01441323|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
105751|NCT00063076|Drug|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
105752|NCT01396213|Drug|placebo|Placebo
105753|NCT01396226|Drug|AZD2927|A single dose of AZD2927 administered as an iv infusion
105754|NCT01396226|Drug|Placebo|A single dose of placebo administered as an iv infusion
105755|NCT01396239|Drug|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
105756|NCT01396239|Other|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
105757|NCT01396252|Drug|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
105758|NCT01396252|Drug|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
105759|NCT01396252|Drug|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
106034|NCT01399476|Procedure|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
106035|NCT01399476|Procedure|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
106036|NCT01399489|Behavioral|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
106037|NCT01399502|Behavioral|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
106038|NCT01402167|Procedure|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
106039|NCT01402180|Biological|Nimotuzumab|
106040|NCT01402180|Radiation|Radiation therapy|
106041|NCT01402180|Radiation|radiation therapy|
106042|NCT01402180|Drug|chemotherapy|
106043|NCT01402180|Drug|chemotherapy|
105511|NCT01398332|Device|Stent graft (EXCLUDER)|Endovascular repair
105512|NCT01398345|Behavioral|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
105513|NCT00063375|Behavioral|Computer Based Cognitive Behavioral Therapy|
105514|NCT01398358|Behavioral|Parents of Preschoolers Series|The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.
The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. "Family Links" and "Parent Pages" are sent home to reinforce content from school to home.
105515|NCT01398358|Behavioral|Incredible Years Series|The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.
For the Child component ("Dinosaur School"), 60, 15-20 minute lessons are delivered during "Circle Time" in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.
Teachers are trained in classroom management strategies.
105516|NCT01401140|Drug|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
105517|NCT01401140|Drug|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
105518|NCT01401153|Other|Skipping lunch|Just water.
105519|NCT01401166|Drug|Trastuzumab subcutaneously|Trastuzumab subcutaneously was supplied in either a single-use injection device or in vials for injection with a hand-held syringe.
105520|NCT01401166|Drug|Trastuzumab intravenously|Trastuzumab intravenously was provided in vials as a freeze-dried lyophilisate.
105808|NCT01383941|Drug|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
105809|NCT01383954|Drug|Voltaren|All subjects will be prescribed diclofenac gel: 4 grams applied QID to the affected knee. Subjects will take a maximum dosage of 32g/day
105810|NCT01383967|Drug|LY2979165|Administered orally
105811|NCT01383967|Drug|placebo|Administered orally
105583|NCT01396057|Other|Sham injection|Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
105584|NCT01398371|Drug|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
105585|NCT01398371|Drug|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
105586|NCT01398384|Drug|Nitric Oxide|MI size at 48-72 hours
105587|NCT01398384|Drug|MI size at 48-72 hours|Placebo gas
105588|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
105589|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
105590|NCT01398423|Drug|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
105591|NCT01398423|Drug|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
105592|NCT00063388|Biological|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
105593|NCT01398436|Procedure|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
105594|NCT01398449|Radiation|Elective nodal irradiation (ENI)|
105595|NCT01398449|Other|Adjuvant chemotherapy only|
105596|NCT01398462|Drug|CWP232291|IV Infusion
105597|NCT01398475|Drug|LY3009104|Administered orally
105598|NCT01398488|Behavioral|Patient education|Patient education by health care professional compared to education via tablet PC
105599|NCT01398501|Drug|Sorafenib|Oral, 200 to 400 mg QD or BID
105600|NCT01398514|Drug|Escitalopram|Escitalopram 10mg/day or matched pill placebo
105601|NCT01398527|Other|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
105602|NCT01398540|Biological|IXIARO|2 immunizations (0,5ml) with a 28 day interval
106575|NCT01441323|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
106576|NCT01441336|Procedure|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
106838|NCT01442038|Drug|Ranolazine|Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.
Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
106839|NCT00001125|Biological|Varicella Virus Vaccine (Live)|
106840|NCT00067704|Behavioral|Writing about daily events|
106841|NCT01435018|Drug|Etoposide|Beginning on day one of the chemotherapy cycle, ET will be given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there is no Grade ≥ 2 toxicity attributable to ET after the first cycle, the dose will be escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there is no Grade ≥ 2 toxicity attributable to ET, the dose will be escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.
Treatment with ET will continue for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the A5263/AMC 066 CMC, has determined that alternative therapy is required, whichever occurs first.
106842|NCT01435018|Drug|Bleomycin and Vincristine (BV)|BV will be administered on day one of each chemotherapy cycle.
Vincristine sulfate will be administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion will be followed by bleomycin as detailed below.
Bleomycin sulfate will be administered at a dose of 15 units/m2 over 10 minutes every 3 weeks.
Treatment with BV will continue for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the A5263/AMC 066 CMC, has determined that alternative therapy is required, whichever occurs first.
106843|NCT01435018|Drug|Paclitaxel (PTX)|Paclitaxel will be administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m2 Body Surface Area (BSA) every 3 weeks.
106844|NCT01435031|Device|CTO Treatment Device|Subjects receiving at least 1 of the following for the treatment of CTO:
XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent
HT PROGRESS and/or HT PILOT guide wires in recanalization
MINI-TREK Coronary Dilatation Catheter in predilatation
106845|NCT00066807|Drug|exemestane|Exemestane (Aromasin®) 25 mg orally daily, preferably after food, until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
106846|NCT01435044|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
106847|NCT01435044|Drug|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
106848|NCT01435044|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
106849|NCT01435044|Drug|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
106044|NCT01402193|Drug|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
106045|NCT01402193|Drug|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
106046|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
106047|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
106048|NCT00063869|Drug|Etanercept|
106049|NCT01402206|Behavioral|Structured patient-centered follow up of depression|All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.
The control group receives treatment as usual (no intervention).
106050|NCT01402219|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
106051|NCT01402219|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
106052|NCT01402245|Biological|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
106343|NCT01434251|Other|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
106344|NCT00066768|Other|laboratory biomarker analysis|Correlative studies
106345|NCT01436162|Drug|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
106346|NCT01436175|Drug|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
106347|NCT00066950|Device|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
106348|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
105812|NCT01383980|Dietary Supplement|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
105813|NCT01383993|Drug|Voriconazole|Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.
Notes:
If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.
Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.
(IV = Intravenous; POS = Powder for oral suspension)
105814|NCT00061945|Other|laboratory biomarker analysis|Correlative studies
105815|NCT01383993|Drug|Voriconazole|Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.
Notes:
If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.
Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.
(IV = Intravenous; POS = Powder for oral suspension)
105816|NCT01384019|Device|distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))|The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
105817|NCT01396278|Drug|Fluticasone propionate|2 puffs BID 88 mcg Fluticasone propionate HFA MDI
105818|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
105819|NCT01396278|Drug|Fluticasone propionate|2 puffs BID 220 mcg Fluticasone propionate HFA MDI
105820|NCT01396278|Drug|Placebo|2 puffs BID placebo matching BI54903 Respimat
105821|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
105822|NCT00063102|Drug|ABT-751|
105823|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
105824|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
105825|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
105826|NCT01396291|Drug|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
106110|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
106111|NCT01399606|Drug|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
106112|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
106113|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
105603|NCT00063401|Biological|Cetuximab:|400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
105874|NCT01402037|Drug|Glucose|Glucose 20% intravenous
105875|NCT01393769|Drug|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
105876|NCT01393782|Drug|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
105877|NCT01393795|Drug|Qutenza|8% patch
105878|NCT01393795|Drug|Tegaderm|No active drug
105879|NCT01393808|Drug|Paricalcitol|1-month Paricalcitol 2mcg/day
105880|NCT01393808|Other|placebo|1-month Placebo Treatment
105881|NCT01393821|Drug|menadione topical lotion|Given topically
105882|NCT01393821|Other|placebo|Given topically
105883|NCT00062803|Drug|(LMW)heparin|
105884|NCT01393821|Other|questionnaire administration|Ancillary studies
105885|NCT01393821|Procedure|management of therapy complications|Given menadione topical lotion
105886|NCT01393834|Procedure|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
105887|NCT01393834|Procedure|Milking of the cord|Milking of the cord 4 times in 10 seconds
105888|NCT01393886|Procedure|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
105889|NCT01393899|Drug|Placebo|oral tablets twice daily
105890|NCT01393899|Drug|CP-690,550|oral tablets twice daily
106850|NCT01435044|Drug|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
106851|NCT01435057|Procedure|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
106852|NCT01435070|Procedure|Kirschner wire fixation|The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.
A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment.
107096|NCT01442142|Behavioral|CRST: Volcravo|Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka "volcravo - the craving volcano"). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause.
107097|NCT01442142|Behavioral|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
107098|NCT01435343|Drug|cytarabine|2 g/m2/day intravenously on days 1 to 4
107099|NCT01435343|Drug|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
107100|NCT01435343|Drug|plerixafor|intravenously from days 1 to 4
107101|NCT01435356|Biological|recMAGE-A3 + AS15 ASCI|5 doses will be administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
107102|NCT01435356|Biological|Placebo|5 doses will be administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
107103|NCT01435369|Drug|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
107104|NCT01435382|Biological|PF-04950615|Dose A - single-dose intravenous infusion
107105|NCT01435382|Biological|PF-04950615|Dose B - single-dose subcutaneous injection
107106|NCT01435382|Biological|PF-04950615|Dose C - single-dose subcutaneous injection
107107|NCT00066846|Drug|fluorouracil|
107108|NCT01435382|Biological|PF-04950615|Dose D - single-dose subcutaneous injection
107109|NCT01435395|Drug|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
107110|NCT01435408|Other|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
106349|NCT01436188|Procedure|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
106350|NCT01436188|Procedure|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
106351|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
106352|NCT01436188|Procedure|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
106353|NCT01436201|Drug|Digoxin|Administered orally
106354|NCT01436201|Biological|Dulaglutide|Administered as subcutaneous injection
106355|NCT01436214|Drug|APC-100|Daily oral, dose escalation, 28-day cycle(s)
106356|NCT01436227|Drug|Pazopanib|800 mg by mouth once daily for a 4 week cycle.
106357|NCT01436240|Behavioral|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
106358|NCT00066963|Device|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
106359|NCT01436253|Behavioral|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
106360|NCT01436253|Drug|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
106361|NCT01436266|Drug|Misoprostol|200 mcg buccally prior to procedure
105446|NCT00063778|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
105447|NCT01401101|Other|quality improvement|Care Manager (CM) intervention
105448|NCT01401101|Other|Treatment-as-Usual|The TAU condition will consist of only the clinician education and patient screening without written feedback.
105449|NCT01401114|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
105450|NCT00063947|Other|laboratory biomarker analysis|Correlative studies
106114|NCT01399619|Drug|BI201335|BI201335 for 12w
106115|NCT01399619|Drug|BI201335 24W|BI201335 for 24w
106116|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
106117|NCT01399619|Drug|Bi 201335|BI 201335 for 24 w
106118|NCT01399632|Behavioral|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
106119|NCT01399632|Behavioral|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
106120|NCT01399645|Drug|Liraglutide-metformin vs insulin-metformin|Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.
Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU.
106121|NCT00063583|Drug|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
106122|NCT01399658|Procedure|Image-guided brachytherapy|MRI-guided application of brachytherapy
106123|NCT01399671|Other|vestibular stimulation|vestibular stimulation
106124|NCT01399684|Drug|MEGF0444A|Intravenous repeating dose
106125|NCT01399684|Drug|bevacizumab|Intravenous repeating dose
106126|NCT01399684|Drug|mFOLFOX6|Intravenous repeating dose
106127|NCT01399684|Drug|placebo|Intravenous repeating dose
106128|NCT01399697|Drug|methotrexate|orally, Week 1 - 16
106129|NCT01399697|Drug|methotrexate|orally, Week 17-28
106130|NCT01399697|Drug|placebo|methotrexate placebo orally, Week 17-28
106131|NCT01402284|Drug|Carfilzomib|Cycle 1: 20 mg/m2 IV infusion over 30 minutes on days 1 and 2, then 36 mg/m2 IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m2 IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
106132|NCT01402284|Drug|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination CRd, patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
106133|NCT01402284|Drug|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
105891|NCT01393899|Drug|CP-690,550|oral tablets twice daily
105892|NCT01393912|Drug|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
106186|NCT01397123|Other|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
106187|NCT01397149|Drug|Placebo|Dosage form, frequency and duration exactly as experimental arm.
106188|NCT01399697|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 28 weeks
106189|NCT00063596|Drug|Vitamin A supplementation|
106190|NCT01399710|Procedure|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
106191|NCT01399710|Procedure|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
106192|NCT01399710|Device|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
106193|NCT01399723|Drug|Amoxicillin|Oral 45mg/kg 12 hourly
106194|NCT01399723|Drug|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
106195|NCT01399736|Procedure|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
106196|NCT01399736|Procedure|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
106197|NCT01399749|Other|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
106198|NCT01399762|Device|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
107111|NCT01435408|Other|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
107112|NCT01435408|Other|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
107113|NCT01435434|Device|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
107114|NCT01435447|Drug|FLu-Bu-Cy (Fludarabine/Busulfan and Cyclophosphamide)|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
107115|NCT01435460|Drug|Loteprednol etabonate 0.2%|1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
107442|NCT01433744|Procedure|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
107443|NCT01433757|Drug|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
107444|NCT01433757|Drug|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
107445|NCT01433770|Drug|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
107446|NCT01433835|Drug|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
107447|NCT01435902|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
107448|NCT01435915|Drug|Ropinirole|
107449|NCT01435928|Drug|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
107450|NCT01435928|Drug|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
107451|NCT01435941|Drug|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
105451|NCT01403857|Other|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
105452|NCT01403857|Other|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
105453|NCT01403870|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
105454|NCT01403883|Behavioral|Standard Care|Psychological & enterostomal therapy clinics on demand only
105455|NCT01403883|Behavioral|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
105456|NCT01403896|Drug|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
105457|NCT01403896|Drug|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
105458|NCT01403909|Device|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
105459|NCT01403909|Procedure|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
105460|NCT01403922|Drug|TC-5214|Tablet oral bid days 1 to 7
105461|NCT00063960|Drug|floxuridine|
105462|NCT01403922|Drug|TC-5214|Tablet oral bid days 8 to 14
105463|NCT01403948|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
105464|NCT01403974|Drug|BI 836845|Intravenous infusion once every week
105465|NCT01403987|Behavioral|Residency Program Teaching|The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
105760|NCT01396252|Drug|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
105761|NCT01396252|Drug|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
105762|NCT00063089|Drug|S. aureus Immune Globulin Intravenous (Human) 5%|
105763|NCT01396265|Drug|Afatinib|single dose
105213|NCT01395277|Dietary Supplement|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
105214|NCT01395277|Dietary Supplement|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
105215|NCT01395290|Drug|cholecalciferol|20.000 IU per week, oral
105216|NCT01395316|Drug|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
105217|NCT01395329|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
105218|NCT01395329|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
105219|NCT01395329|Drug|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
105220|NCT01395342|Other|Exercise using stationary bicycle|Before exercise, blood pressure and heart rate are measured in the sitting position.
Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.
The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.
After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position.
105221|NCT01395355|Behavioral|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
105222|NCT01395355|Behavioral|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
105223|NCT00062946|Drug|(18F)fallypride|
105224|NCT01395381|Drug|Placebo|placebo given once
105225|NCT01395381|Drug|Albendazole|single dose albendazole given at the time of enrollment
105226|NCT01397682|Other|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
105227|NCT01397695|Drug|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
106199|NCT01399775|Procedure|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
106200|NCT00063609|Drug|zoledronic acid|
106201|NCT01399775|Procedure|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
106202|NCT01399788|Drug|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
105285|NCT01403337|Other|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
105286|NCT01403337|Other|Control|A Blood Pressure cuff inflated to 40-50 mmHg
105287|NCT01403350|Device|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
105288|NCT01395394|Drug|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
105289|NCT01395394|Other|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
105290|NCT01395407|Radiation|Radiosurgery dose escalation|Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).
Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)
Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)
21 18 15
23 20 17
25 22 19
105291|NCT01395420|Drug|CAZ104|IV Infusion
105292|NCT01395420|Drug|CAZ104|IV Infusion
105293|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
105294|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
105295|NCT01395433|Drug|Escitalopram|1 x 20 mg, single dose
105296|NCT00062959|Behavioral|Going Places: School program to prevent problem behavior|
105297|NCT01395459|Behavioral|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
105298|NCT01395459|Behavioral|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
107452|NCT01435941|Drug|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
107453|NCT01435954|Drug|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
107454|NCT01435954|Drug|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
107455|NCT01435967|Other|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
107456|NCT01435980|Procedure|Gastric Bypass|basal treatment and Gastric Bypass
107457|NCT00001119|Biological|Hepatitis B Vaccine (Recombinant)|
106577|NCT01441349|Drug|IP chemotherapy|Irinotecan/cisplatin (IP) chemotherapy
Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8.
Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 & 8
Every 21 days
106578|NCT01441349|Drug|IP chemotherapy plus simvastatin|Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8
Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1& 8.
Every 21days.
Simvastatin 40 mg per day orally D1of cycle 1
106579|NCT01441362|Procedure|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
106580|NCT01441362|Procedure|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
106581|NCT00000257|Drug|0% N2O and 30% N2O|
106582|NCT00001123|Drug|Ribavirin|
106583|NCT00067613|Other|Benchmarking Management Practices|The Benchmarking intervention included:
Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.
Training in Continuous Quality Improvement (CQI) Techniques
Review of best existing evidence
Site visits to the Centers with the Lowest Rates of BPD
Selection of Practices to change: Each site team selected practices for modification at their own center
106584|NCT01441388|Drug|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
106585|NCT01434576|Drug|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
105764|NCT01396265|Drug|Afatinib|single dose
105765|NCT01396265|Drug|Rifampicin|multiple doses
105766|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
105767|NCT01396278|Drug|Placebo|2 puffs BID placebo matching BI54903 Respimat
105768|NCT01398865|Procedure|PET scan and MRI scan|PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).
MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space.
105769|NCT01398878|Behavioral|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
105770|NCT00063414|Drug|Alicaforsen|
105771|NCT01398891|Other|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
105772|NCT01398917|Procedure|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
105773|NCT01398917|Procedure|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
105774|NCT01398930|Other|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
105775|NCT01398943|Drug|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
105776|NCT01398943|Drug|non-acetylated salicylate|3,000 mg per day for 4 days
105777|NCT01398943|Dietary Supplement|High Fat Meal|The high-fat meal ([900 calories], 50 g of fat, 14 g of saturated fat, 225 mg of cholesterol) will consist of an Egg McMuffin®, Sausage McMuffin®, and two hash brown patties (McDonald's Corporation®). Additional water will be allowed ad libidum. The P.I. along with others have used this meal to attenuate FMD in healthy adults with the mechanism suggested to be through an increase in lipemia induced oxidative stress.
106053|NCT01402245|Biological|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
105228|NCT01397708|Biological|INXN-2001|approximately 1.0 x 1012 viral particles (vp) per injection
one intratumoral injection of INXN-2001 per study cycle
maximum of 6 study cycles
105521|NCT01401166|Biological|Recombinant humanized hyaluronidase|Both the single-use injection device and the vials for injection with a hand-held syringe contained 2000 units/mL of recombinant humanized hyaluronidase as a permeation enhancer.
105522|NCT01401179|Drug|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
105523|NCT00063778|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
105524|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
105525|NCT01401192|Drug|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 & cisplatin 70mg/m2 D1 every 3 weeks
105526|NCT01401192|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 & cisplatin 70mg/m2 every 3 weeks
105527|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
105528|NCT01401205|Other|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
105529|NCT01401218|Other|Electronic Medical Record (EMR) Review|measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.
potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,
105530|NCT01401231|Behavioral|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
105531|NCT01401231|Other|Usual care|Continued usual care (could include referral for medication or psychotherapy)
105532|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
105533|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
105534|NCT00063791|Drug|Bortezomib|
105535|NCT01401257|Drug|PXT3003|Liquid,5 ml, twice a day, 12-month treatment
105299|NCT01395472|Behavioral|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
105300|NCT01395472|Behavioral|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
105301|NCT01395485|Drug|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
105302|NCT01395498|Other|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
105604|NCT01398553|Device|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
105605|NCT01398553|Other|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
105606|NCT01398566|Behavioral|SuperBetter play|average 10 min of game play per day for 6 week period
105607|NCT01398579|Procedure|Gastroscopy|20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.
Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE.
105608|NCT01398592|Drug|Vildagliptin|50mg vildagliptin bid
105609|NCT01401257|Drug|PXT3003|Liquid,5 ml, twice a day, 12-month treatment
105610|NCT01401257|Drug|PXT3003|Liquid,5 ml, twice a day, 12-month treatment
105611|NCT01401257|Other|Placebo|Liquid,5 ml, twice a day, 12-month treatment
105612|NCT01401270|Behavioral|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
105613|NCT01401283|Device|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
105614|NCT01401296|Behavioral|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
105615|NCT01401296|Behavioral|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
105616|NCT01401322|Drug|Lenalidomide|50 mg; po
105617|NCT01401335|Behavioral|Questionnaires|questionnaires at entry, month 4, 8 and 12
105618|NCT00063804|Drug|Ritonavir|
106586|NCT01434589|Behavioral|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
106587|NCT01434602|Drug|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; dose escalation from 5mg to 10 mg daily
106588|NCT01434602|Drug|sorafenib|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; dose escalation from 400 mg bid, 7 days on and 7 days off to 800 mg bid
106589|NCT00001119|Drug|Amprenavir|
106590|NCT00066794|Biological|sargramostim|250 mcg/kg/d IV or SC starting apx day 15
106591|NCT01434615|Device|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
106592|NCT01434615|Other|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
106593|NCT01434628|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
106594|NCT01434641|Other|myocardial perfusion SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
106853|NCT01435070|Procedure|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
106854|NCT01435083|Drug|Desmopressin|120 µg, oral lyophilisate, sublingual use
106855|NCT01435096|Drug|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
106856|NCT00066807|Drug|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
106857|NCT01436968|Biological|Placebo + valacyclovir|Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
106858|NCT00067002|Radiation|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
106054|NCT01402258|Behavioral|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
106055|NCT01402271|Drug|carboplatin|
106056|NCT01402271|Drug|paclitaxel|
106057|NCT01402271|Drug|pazopanib hydrochloride|
106058|NCT01402271|Other|laboratory biomarker analysis|
106059|NCT00063882|Radiation|iodine I 125|Given as interstitial seeds
106060|NCT01402271|Other|pharmacological study|
106061|NCT01394133|Drug|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
106062|NCT01394146|Other|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
106063|NCT01394159|Procedure|22G Procore biopsy needle|Acquire tissue with the 22G Procore biopsy needle
106064|NCT01394159|Procedure|22G FNA needle|Acquire tissue with the 22G FNA needle
106065|NCT01394185|Drug|Dronabinol|Participants receive dronabinol
106066|NCT01394185|Drug|Placebo|Participants receive placebo
106067|NCT01394211|Drug|anastrozole|Given PO
106068|NCT00000256|Drug|20% N2O|
106069|NCT00001091|Drug|Ritonavir|
106070|NCT00062829|Behavioral|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
106071|NCT01394211|Drug|pazopanib hydrochloride|Given PO
106072|NCT01394211|Procedure|therapeutic conventional surgery|Undergo definitive surgery
106073|NCT01394224|Drug|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
105536|NCT01403363|Drug|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
105537|NCT01403376|Drug|teriflunomide|Film-coated tablet
Oral administration
105538|NCT01403376|Drug|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
105827|NCT01396291|Drug|placebo|asenapine-matched placebo, sublingual tablets, BID
105828|NCT01396304|Device|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
105829|NCT01396304|Device|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
105830|NCT01396317|Drug|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
105831|NCT01396330|Behavioral|stress|3 professional safe drive training courses each lasting 30 minutes
105832|NCT01396356|Procedure|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
105833|NCT00063128|Drug|insulin|Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.
Inject into abdomen only.
105834|NCT01396369|Drug|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
105835|NCT01396369|Drug|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
105836|NCT01396382|Drug|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
105619|NCT01401361|Device|Contact Therapy Cool Path ablation system in conjunction with EnSite Velocity Contact system|The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
105620|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
105621|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
105622|NCT01401413|Drug|ramelteon|8 mg nightly for 30 nights
105623|NCT01401413|Drug|placebo|placebo control i pill nightly for 30 nights
105624|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
105893|NCT01393925|Drug|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
105894|NCT00062803|Drug|Warfarin VKA|
105895|NCT01393938|Other|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
105896|NCT01393951|Biological|ASP7374|subcutaneous and intramuscular
105897|NCT01393964|Drug|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
105898|NCT01396395|Drug|Nicorandil|Nicorandil 5 mg will be administered 3 times a day (tid)
105899|NCT01396408|Drug|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
105900|NCT01396408|Drug|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
105901|NCT01396421|Drug|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
105902|NCT01396421|Drug|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
105903|NCT01396421|Drug|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
105904|NCT01396421|Drug|Placebo|Placebo, once daily, for six weeks
105905|NCT00063128|Drug|human insulin inhalation powder (HIIP)|Administer HIIP within 15 minutes before meals.
Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.
Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin
106859|NCT01436981|Procedure|CABG|Preparation of artery mammaria interna
106860|NCT01436994|Procedure|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
106861|NCT01436994|Procedure|Dose Titration|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.
Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.
Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
106862|NCT01436994|Drug|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
106863|NCT01436994|Drug|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
106864|NCT01436994|Drug|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
106865|NCT01437007|Drug|TKM-080301|
107116|NCT01435460|Drug|Olopatadine 0.1%|1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
107117|NCT01435473|Procedure|Cardiac Surgery|
107118|NCT00066846|Drug|leucovorin calcium|
107119|NCT01435486|Drug|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
107120|NCT01435486|Drug|Normal saline|Placebo with an equivalent volume of normal saline.
107121|NCT01435499|Biological|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
107122|NCT01437488|Drug|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
107123|NCT00001119|Drug|Zidovudine|
107124|NCT00067028|Drug|Clofarabine|30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.
106074|NCT01394224|Drug|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
105156|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
105157|NCT01397643|Other|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
105158|NCT01397656|Procedure|Bystander CPR using 30:2 ratio versus continuous compression|Participants will use 2 CPR techniques, one with 30 compressions to 2 ventilations and the other with continuous compressions without ventilation
105159|NCT00063310|Drug|Leuprolide acetate|
105160|NCT01397669|Procedure|Colon biopsy, lymph node biopsy, lumbar puncture|Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
105161|NCT01400555|Drug|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
105162|NCT01400555|Drug|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
105163|NCT01400555|Drug|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
105164|NCT01400555|Drug|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
105165|NCT01400568|Drug|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
105166|NCT01400568|Drug|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
105167|NCT01400581|Behavioral|Collaborative Care Intervention|See description of Intervention arm
105168|NCT01400594|Drug|HTU-520 Patch|Terbinafine hydrochloride patch
105169|NCT01400594|Other|Placebo Patch|Treatment with Placebo Patch
105170|NCT01400607|Biological|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
105171|NCT00063674|Behavioral|After-school dance class|
105172|NCT01400607|Other|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
105837|NCT01398982|Drug|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
105838|NCT01398982|Drug|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
106134|NCT01402297|Drug|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
106135|NCT01402310|Other|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
106136|NCT01402323|Other|time point of tooth extraction|
106137|NCT01402336|Drug|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
106138|NCT01402336|Drug|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
106139|NCT01402375|Drug|Oral Opioid Pain Medicine|In the first trial, patients will take 1 dose of either Hydrocodone or Codeine combined with Acetaminophen every 4 hours as needed for pain.
In the second trial, patients will take 1 dose of either oxycodone or Codeine combined with Acetaminophen every 4 hours as needed for pain.
106140|NCT00063882|Radiation|palladium Pd 103|Given as interstitial seeds
106141|NCT01402388|Behavioral|Group lifestyle programme|
106142|NCT01402401|Drug|AUY922 + Trastuzumab|
106143|NCT01402414|Radiation|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
106144|NCT01402414|Radiation|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
108289|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|Atropin 10µg/kg
Fentanyl 2µg/kg, repeat max. two times
Mivacurium 200µg/kg
108290|NCT01427998|Dietary Supplement|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
108291|NCT00066391|Drug|cisplatin|
108292|NCT01427998|Other|placebo|placebo
108293|NCT01428024|Device|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and week 12.
108294|NCT01428024|Device|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and week 12.
108295|NCT01428037|Drug|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
108296|NCT01428037|Drug|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
108297|NCT01428050|Drug|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
108298|NCT01428050|Drug|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
108299|NCT01428063|Drug|Daclatasvir|
108300|NCT01428063|Drug|Asunaprevir|
108301|NCT01428063|Drug|Peginterferon alfa-2a|
108302|NCT00066391|Drug|irinotecan hydrochloride|
108303|NCT01428063|Drug|Ribavirin|
108304|NCT01428076|Drug|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
108597|NCT00066053|Procedure|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
108598|NCT01423604|Drug|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
108599|NCT01423604|Drug|Placebo|Placebo matching ruxolitinib
108600|NCT01423617|Dietary Supplement|Zenoctil|3 tablets 2 times daily
108601|NCT01423617|Other|Placebo|3 tablets 2 times daily
108602|NCT01423630|Dietary Supplement|Probiotics and fruit fibre|probiotics and fruit fibre
111791|NCT01448109|Drug|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
112120|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
112121|NCT01472029|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:
Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle
Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle
Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle
Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle
5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle
112122|NCT01472029|Drug|Post-operative treatment trastuzumab mono therapy|Trastuzumab mono therapy for 9 cycles:
Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle
112123|NCT01472042|Other|Banyan Biomarkers|Biomarkers to detect specific proteins.
112124|NCT01472055|Drug|Fludarabine|Fludarabine 40 mg/m^2 once a day intravenous administration over 30 min
Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr
Population pharmacokinetics analysis
Comparative analysis of population pharmacokinetics in pediatric and adult patients
Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate
112125|NCT00070317|Procedure|Therapeutic Conventional Surgery|Undergo radical hysterectomy
112126|NCT01472068|Device|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
112127|NCT01474083|Drug|Placebo|Dose-matched placebo. Oral administration.
112128|NCT00070499|Other|Laboratory Biomarker Analysis|Correlative studies
112129|NCT01474096|Other|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
112130|NCT01474109|Drug|macitentan 3mg|macitentan 3mg tablet once daily
112131|NCT01474109|Drug|macitentan 10mg|macitentan 10mg tablet once daily
112132|NCT01474109|Drug|placebo|matching placebo once daily
112133|NCT01474122|Drug|macitentan 3mg|macitentan tablet 3mg once daily
112134|NCT01474122|Drug|macitentan 10mg|macitentan tablet 10mg once daily
112135|NCT01474122|Drug|placebo|matching placebo once daily
112136|NCT01474135|Drug|0.25% AR-12286 / 0.004% travoprost|
112137|NCT01474135|Drug|0.5% AR-12286, 0.004% travoprost|
108667|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
108668|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
108669|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
108670|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
108671|NCT01431209|Drug|oral JAK inhibitor INCB18424|Patients receive ruxolitinib phosphate (oral JAK inhibitor INCB18424) PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
108672|NCT01431209|Other|laboratory biomarker analysis|Correlative studies
108673|NCT01431209|Other|pharmacological study|Correlative studies
108674|NCT01431222|Device|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
108675|NCT00066573|Drug|exemestane|Given orally
108676|NCT01431235|Behavioral|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
108677|NCT01431261|Other|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
108678|NCT01431261|Behavioral|Pain management|Educational sessions in pain management 4 times
108679|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
108680|NCT01431274|Drug|tiotropium|low dose
108681|NCT01431274|Drug|olodaterol|one dose only
108682|NCT01431274|Drug|tiotropium|high dose
108683|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
107760|NCT01424579|Other|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
107761|NCT01424579|Other|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
107762|NCT01424592|Device|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
112041|NCT01474018|Drug|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
112042|NCT00070499|Drug|Imatinib Mesylate|Given PO
112043|NCT01474031|Other|biomechanics|Time interval: pre-op - 3m - 6m - 12m
Assessment of all subjects:
XR with magnification marker
Biodex force measurement in flexion and extension and mid flexion (with EMG if possible)
Gait analysis with surface EMG and trunk markers:
Unipodal standing: 3 trials Right and 3 trials Left on FP
Level walking: 3 trials Right and 3 trials Left on FP
Chair rise: 3 trials, both legs on FP
Stair ascent: 3 trials Right and 3 trials Left on first FP
Stair descent: 3 trials Right and 3 trials Left on first FP
Squat: 3 trials, both legs on FP
Bipodal squat: 3 trials Right and 3 trials Left on FP
Functional scores (HHS, UCLA, HOOS, SF-36)
Assessment of final 5 subjects per group:
CT pre and post at 6w (pre: pelvis-knee and post: hip)
MRI pre and 1 y post
Accelerometer 1 week
112044|NCT01474044|Drug|Gastropylor Complex Capsules|3 pills, three times a day, after meal
112045|NCT01474044|Other|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
112046|NCT01474057|Behavioral|DESTRESS-PC|An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A "DESTRESS Nurse" will train the participant to use the website and will monitor their progress and report key information back to the primary care physician.
112047|NCT01474057|Other|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
112048|NCT01474070|Device|Intraocular Pressure Measurement|Intraocular pressure is messured with goldmann applanation tonometer (GAT) and with the dynamic contour tonometer (DCT)
112049|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
112050|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
112051|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
112352|NCT01479283|Drug|5-Days Prophylactic Cefazolin* Antibiotic Regimen|Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.
Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.
Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered.
112353|NCT01479296|Biological|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
112354|NCT01479296|Biological|rAd5 env A|Given intramuscularly
111444|NCT01450033|Behavioral|e-Communication with mentor|Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
111445|NCT01450046|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
111446|NCT01450072|Device|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
111447|NCT01450072|Other|Control arm|Venography and sham angioplasty
111448|NCT01450085|Other|GeneXpert|Point of care GeneXpert
111449|NCT01450085|Other|LED Microscopy|Point of care LED Microscopy
111450|NCT01450098|Drug|LY2484595 Reference Formulation (RF)|Administered orally
111451|NCT01450098|Drug|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
111452|NCT01450111|Drug|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
111453|NCT00068523|Procedure|allogeneic bone marrow transplantation|
111454|NCT01450111|Drug|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
111455|NCT01450111|Drug|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
111456|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
111457|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
111458|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
111459|NCT01450124|Drug|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
111460|NCT01450137|Drug|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
111461|NCT01450137|Drug|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
112138|NCT01474135|Drug|0.004% Travoprost|
112139|NCT00070525|Drug|tipifarnib|Given orally
112140|NCT01474148|Device|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
111227|NCT00068055|Drug|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
111228|NCT01444443|Other|Open-loop control|Blood glucose controlled by patient
111229|NCT01444469|Drug|Zithromax|250mg * 2 capsules once daily for three days
111230|NCT01444469|Drug|Placebo|Lactose powder
111231|NCT01444482|Biological|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
111232|NCT01444482|Biological|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
111233|NCT01444495|Radiation|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
111234|NCT01444495|Procedure|Surgery|Total mesorectal excision of rectal cancer
111235|NCT01444508|Drug|Ringer-lactate "SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
111236|NCT01446965|Device|wearable defibrillator|LifeVest wearable defibrillator
111237|NCT01446978|Biological|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
111238|NCT01446978|Biological|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
111239|NCT01446991|Drug|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
111240|NCT01446991|Drug|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
111241|NCT01447017|Drug|DPK-060|DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
107763|NCT01424605|Procedure|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
107764|NCT01424618|Drug|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
107765|NCT01424618|Drug|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
107766|NCT01424631|Procedure|single incision laparoscopic appendectomy|
107767|NCT01424631|Procedure|conventional laparoscopic appendectomy|
107768|NCT01426932|Other|Video recording of Head Impulse Test|Video recording of Head Impulse Test
107769|NCT01426945|Genetic|protein expression analysis|
107770|NCT01426945|Other|immunohistochemistry staining method|
107771|NCT01426945|Other|laboratory biomarker analysis|
107772|NCT01426958|Drug|afatinib|standard therapeutic dose
107773|NCT01426958|Drug|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
107774|NCT00066300|Procedure|allogeneic bone marrow transplantation|
107775|NCT01426958|Drug|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
107776|NCT01426971|Drug|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
107777|NCT01426971|Drug|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
107778|NCT01426984|Drug|methylphenidate|a capsule containing 20 mg
107779|NCT01427010|Radiation|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography ([18F]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
107780|NCT01427023|Device|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
108062|NCT01430221|Other|Structured & Guided Education|
108063|NCT01430234|Drug|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
112355|NCT01479296|Biological|rAd5 env B|Given intramuscularly
112356|NCT01479296|Biological|rAd5 env C|Given intramuscularly
112357|NCT01479296|Biological|rAd5 gag-pol|Given intramuscularly
112358|NCT01479296|Biological|Placebo Vaccine|Given intramuscularly
112359|NCT00071214|Biological|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
112360|NCT01479309|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
112361|NCT01479309|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
112362|NCT01479348|Drug|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|
112363|NCT01479361|Drug|Atovaquone 750 mg twice daily|
112364|NCT01479361|Drug|Atovaquone 1500 mg twice daily|
112365|NCT01479374|Drug|AL-4943A ophthalmic solution|
112366|NCT01479374|Drug|AL-4943A vehicle|Inactive ingredients used as placebo
112367|NCT01479374|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
112368|NCT01479387|Drug|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
112369|NCT01479426|Dietary Supplement|EFLA400|EFLA400(960mg/day)for 12 weeks
112370|NCT00071227|Drug|Triamcinolone Acetonide (TAC-PF)|
112371|NCT01479426|Dietary Supplement|Placebo|Placebo(960mg/day) for 12 weeks
112372|NCT01479439|Drug|Losartan|Form: suspension, tablet. Dosage & frequency: age 6-16 = 0.7mg/kg once daily; age >16 = 50mg once daily. Duration: 6 months
112373|NCT01479452|Procedure|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
112374|NCT01479452|Other|Usual care|Non-surgical obesity treatment
111442|NCT00068523|Procedure|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
111443|NCT01450033|Behavioral|Peer Mentoring|Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
112024|NCT01471847|Drug|BEZ235 + Trastuzumab Phase l/Phase ll)|Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.
Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy).
112025|NCT01471847|Drug|Lapatinib + Capecitabine (Phase II)|If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.
Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.
All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start
112026|NCT01471860|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
112027|NCT01471873|Procedure|Corneal Collagen Cross-linking (CXL)|The same surgical procedure was applied to all CXLG patients that included:
Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
112028|NCT01471886|Drug|Ketorolac Tromethamine|Every 8 hours for 4 days.
112029|NCT01471886|Drug|Naproxen|Every 8 hours for 4 days.
112030|NCT01471899|Drug|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
112031|NCT01471899|Drug|Naproxen|2 tablets every 8 hours for 4 days
112032|NCT00070317|Procedure|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
112033|NCT01471912|Procedure|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
112034|NCT01473953|Drug|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
112035|NCT01473966|Dietary Supplement|coffee|patients will receive a cup of coffee at room temperature orally twice daily
111242|NCT01447017|Drug|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
111243|NCT01447043|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
111244|NCT00068341|Biological|trastuzumab|Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
111517|NCT01447589|Drug|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
111518|NCT01447589|Radiation|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
111519|NCT01447602|Behavioral|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
111520|NCT01447615|Behavioral|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
111521|NCT01450150|Device|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
111522|NCT01450150|Device|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
111523|NCT00068523|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
111524|NCT01450163|Drug|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
111525|NCT01450163|Drug|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
111526|NCT01450176|Drug|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
111527|NCT01450176|Drug|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
108064|NCT01430247|Other|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
108065|NCT00066469|Drug|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
108066|NCT01430260|Drug|Ciclesonide|200 ㎍ once daily
108067|NCT01430260|Drug|Levocetirizine|5mg once daily
108068|NCT01430260|Drug|Ciclesonide & Levocetirizine|Omnaris (ciclesonide) 200 ㎍ once daily
Levocetirizine 5mg once daily
108069|NCT01430286|Behavioral|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
108070|NCT01430286|Behavioral|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
108071|NCT01430299|Device|Integra Accell Evo3|Prospective use Integra Accell Evo3
108072|NCT01430312|Drug|azelaic acid pre-foam formulation|
108073|NCT01430312|Drug|Vehicle pre-foam formulation|
108074|NCT01430312|Drug|Water|
108075|NCT01432717|Biological|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
108076|NCT00066690|Radiation|radiation therapy|Ovarian irradiation
108077|NCT01432717|Other|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
108078|NCT01432730|Drug|AF-219|Oral tablets, BID
108079|NCT01432730|Drug|Placebo|Oral tablets, BID
108080|NCT01432743|Procedure|NavX Fusion|Using NavX Fusion to guide catheter ablation
108081|NCT01432743|Procedure|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
108082|NCT01432756|Behavioral|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
108083|NCT01432769|Dietary Supplement|dietary supplement high in energy and protein|patients in the "standardized diet" will receive extra 500 kcal from the dietary supplement
108233|NCT00066482|Drug|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children < 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
108234|NCT01430572|Drug|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
108235|NCT01430572|Drug|Everolimus|Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.
Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase.
108236|NCT01432522|Drug|Epinephrine|Intranasal epinephrine 5 mg /spray
Intramuscular epinephrine 0.3 mg
Intranasal saline spray
108237|NCT01432535|Drug|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
108238|NCT01432548|Procedure|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
108239|NCT01432561|Drug|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 & 4 which must occur within a 14 day period.
108240|NCT01432574|Biological|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
108241|NCT01432587|Drug|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
108242|NCT01432600|Drug|Pomalidomide|Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone is determined, we will proceed with the second phase of the trial which is a randomized phase II study comparing pomalidomide and dexamethasone and pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
108243|NCT01432600|Drug|Dexamethasone|Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone is determined, we will proceed with the second phase of the trial which is a randomized phase II study comparing pomalidomide and dexamethasone and pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
108244|NCT00066690|Procedure|oophorectomy|Surgical
108536|NCT01425905|Other|The Blues Program|
108537|NCT01425905|Other|Hey Durham|
108538|NCT00066248|Drug|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
108539|NCT01425918|Behavioral|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
112036|NCT01473966|Dietary Supplement|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
112052|NCT01476098|Drug|SB-705498|400 or 600mg oral SB-705498
112053|NCT01476124|Drug|morphine Placebo|Morphine Placebo
112054|NCT01476124|Drug|GEn 600 mg|Gabapentin enacarbil 600 mg
112055|NCT01476124|Drug|Morphine|morphine extended release 60 mg
112056|NCT00070694|Drug|MDL100.907|
112057|NCT01476124|Drug|GEn Placebo|Gabapentin enacarbil placebo
112058|NCT01476137|Drug|GSK1120212|MEK inhibitor
112059|NCT01476137|Drug|GSK2110183|AKT inhibitor
112060|NCT01476163|Drug|migalastat HCl|150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
112061|NCT01476176|Drug|Experimental paracetamol|experimental paracetamol with caffeine
112062|NCT01476176|Drug|Paracetamol marketed formulation|marketed formulation containing caffeine
112063|NCT01476189|Drug|Experimental paracetamol formulation|experimental
112064|NCT01476189|Drug|Marketed paracetamol|Marketed paracetamol
112065|NCT01476189|Drug|Higher dose marketed paracetamol|Higher dose marketed paracetamol
112066|NCT01476202|Drug|nicotine|nicotine in the form of a mouth strip, lozenge and gum
112067|NCT00070707|Drug|Nasonex|
112068|NCT01476215|Drug|Paracetamol fast dissolution suspension|
112069|NCT01476215|Drug|Paracetamol medium dissolution suspension|
112070|NCT01476215|Drug|Paracetamol slow dissolution suspension|
112071|NCT01476215|Drug|Paracetamol|
112072|NCT01476228|Device|EEG recording|EEG recording
112073|NCT01476241|Procedure|PEG tube placement|Percutaneous endoscopic gastrostomy
112074|NCT01476267|Drug|dalcetrapib|Single oral radiolabeled dose
108603|NCT01423656|Drug|LEO 29102|
108604|NCT01423656|Drug|Placebo|Placebo Comparator: LEO 29102 vehicle
108605|NCT01423682|Behavioral|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
108606|NCT01423695|Drug|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
108607|NCT01423708|Drug|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of >5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels <5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
108608|NCT00066053|Procedure|Referral|
108609|NCT01423721|Drug|Bromihexine hydrochloride syrup|syrup
108610|NCT01423721|Drug|Bromihexine hydrochloride granules|granules
108611|NCT01423734|Other|magnetic resonance imaging (MRI)|Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.
During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center.
108612|NCT01423747|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
108613|NCT01423747|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
108614|NCT01423747|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
107703|NCT01429415|Drug|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
107704|NCT01429428|Other|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
107705|NCT01429428|Other|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
107706|NCT01429441|Drug|Ocriplasmin|0.125 mg single intravitreal injection
108365|NCT01425632|Drug|TAU-284|TAU-284 High
108366|NCT00066196|Biological|Integrin + Dacarbazine|supplied in other formulations
108367|NCT01425632|Drug|Placebo|Placebo
108368|NCT01425645|Other|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
108369|NCT01425658|Drug|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
108370|NCT01425658|Drug|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
108371|NCT01425658|Drug|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
108372|NCT01425697|Other|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
108373|NCT01428089|Drug|Placebo|Placebo
108374|NCT01428128|Drug|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
108375|NCT01428141|Drug|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
108376|NCT01428154|Drug|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
108377|NCT01428180|Drug|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
108378|NCT01428180|Procedure|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
108379|NCT01428193|Drug|Flutamide|Subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day.
108380|NCT00066391|Procedure|neoadjuvant therapy|
108381|NCT01428193|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
108382|NCT01428193|Drug|estrace|0.5-1 mg once a day for seven days
108383|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
108540|NCT01425918|Behavioral|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
108541|NCT01425931|Procedure|Heart Lung machine|measurement of microcirculation with O2C device
108542|NCT01425957|Procedure|Lumbar puncture|All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).
Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36).
108543|NCT01425970|Drug|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
108544|NCT01428388|Drug|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
108545|NCT01428401|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
108546|NCT01428401|Other|Placebo|at a rate of 3 g three times per day
108547|NCT01428414|Drug|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
108548|NCT01428414|Drug|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
108549|NCT01428414|Drug|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
108550|NCT01428414|Drug|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
108551|NCT00066417|Drug|fludarabine phosphate|
108552|NCT01428427|Drug|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
108553|NCT01428427|Drug|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
107637|NCT01431846|Behavioral|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
107638|NCT01431859|Biological|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
107639|NCT01431859|Other|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
112075|NCT01476280|Drug|palonosetron|0.075mg immediately before induction of anesthesia
112076|NCT01476280|Drug|Ramosetron|0.3mg immediately before induction of anesthesia
112077|NCT01476306|Other|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
111169|NCT01446952|Drug|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
111170|NCT01449565|Drug|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
111171|NCT01449578|Drug|Dexpramipexole|Oral Tablet at varying doses
111172|NCT01449578|Drug|Dexpramipexole Placebo|Oral tablet at varying doses
111173|NCT01449591|Drug|BFH772 1% ointment|
111174|NCT01449591|Drug|Vehicle ointment|
111175|NCT01449591|Drug|Noritate® 1% cream|
111176|NCT01449604|Radiation|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
111177|NCT00068510|Biological|therapeutic autologous dendritic cells|
111178|NCT01449604|Radiation|stereotactic radiosurgery|Radio surgery 12 Gy
111179|NCT01449617|Drug|Aspirin plus clopidogrel|Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.
Aspirin will be given at the dose of 100-325mg/day.
111180|NCT01449630|Drug|LY3031207|Administered orally
111181|NCT01449630|Drug|Placebo|Administered orally
111182|NCT01449630|Drug|Celecoxib|Administered orally
111183|NCT01449643|Device|Threshold|
111184|NCT01449643|Device|Sham Threshold|
111185|NCT01449656|Device|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
111186|NCT01449656|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
111187|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
107707|NCT01429441|Other|Sham injection|Sham injection
107708|NCT01429454|Drug|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
107709|NCT01429454|Drug|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
107710|NCT01429467|Device|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
107711|NCT01429480|Procedure|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
107712|NCT01429480|Procedure|Preoperative Ultrasound Guided Posterior TAP Block|
107713|NCT00066430|Device|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
107714|NCT01429480|Drug|Patient controlled analgesia|
107715|NCT01429493|Radiation|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
107716|NCT01429493|Radiation|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
107717|NCT01429493|Radiation|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
107718|NCT01429506|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
107719|NCT01429506|Drug|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
107720|NCT01429519|Drug|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
107721|NCT01429532|Procedure|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
108684|NCT01431274|Device|Respimat|Respimat inhaler
108685|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
108686|NCT00066586|Drug|exemestane|exemestane 25 mg once daily x 1 year
108687|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
108688|NCT01431287|Drug|tiotropium|low dose or high dose
108689|NCT01431287|Drug|tiotropium|low dose or high dose
108690|NCT01431287|Drug|olodaterol|one dose only
108691|NCT01431287|Device|Respimat|Respimat inhaler
108692|NCT01431300|Drug|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
108693|NCT01431313|Drug|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
108694|NCT01431326|Drug|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
108695|NCT01431339|Drug|IV Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
108696|NCT01431339|Drug|Vancomycin/Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
108697|NCT00066586|Drug|Placebo|placebo once daily x 1 year
108698|NCT01423747|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
108699|NCT01423747|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
108700|NCT01423747|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
108701|NCT00001112|Drug|Interferon gamma-1b|
108702|NCT00066066|Procedure|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
108703|NCT01423760|Biological|Tecemotide|Arm 1 is the treatment arm. Subjects who receive Tecemotide (L-BLP25) in a feeder trial will continue to be treated with Tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
107640|NCT01431885|Procedure|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
107641|NCT01431885|Procedure|Cervical change|Diagnosis will be made by digital examination of cervical change
107642|NCT01431898|Drug|GS-9669 tablets|
107643|NCT00066638|Drug|Romidepsin|Given IV
107644|NCT01431898|Drug|Placebo to Match GS-9669 tablet|
107645|NCT01431911|Drug|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
107646|NCT01431911|Drug|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
107647|NCT01431924|Drug|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
107648|NCT01431924|Drug|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
107649|NCT01431937|Drug|GSK2018682|Active Drug
107650|NCT01431937|Drug|Placebo|Placebo
107651|NCT01424332|Drug|Darexaban|oral
107652|NCT01424332|Drug|Acetyl Salicylic Acid (ASA)|oral
107653|NCT01424345|Drug|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
107654|NCT01424345|Drug|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
107655|NCT00066092|Drug|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
107656|NCT01424358|Other|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
107657|NCT01424384|Drug|Citalopram|Neurophysiological testing.
107943|NCT01427283|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
107944|NCT01427296|Drug|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
111188|NCT00068523|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
111189|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
111190|NCT01449695|Behavioral|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
111462|NCT01442493|Other|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
111463|NCT01442493|Other|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
111464|NCT00067769|Behavioral|treatment as usual|Routine clinical care.
111465|NCT01442506|Other|biopsies|taking biopsies
111466|NCT01442506|Other|biopsy|biopsy
111467|NCT01442519|Biological|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
111468|NCT01442519|Drug|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
111469|NCT01442532|Drug|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
111470|NCT01442532|Drug|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
111471|NCT01442532|Drug|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
111472|NCT01442532|Drug|Placebo|Form=tablet, route=oral use, for 14 days
111473|NCT01442532|Drug|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
108005|NCT01432509|Other|Prediabetes screening and prospective follow-up over 5 years|The study period per patient is 5 years. The planned schedule of the study is as follows :
Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and < 1,26 g/l) or fasting blood glucose ≥ 1 g/l and < 1,10 g/l with HbA1c ≥ 6,5%.
First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).
Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.
End of study visit
108006|NCT01424904|Dietary Supplement|DGB-01 Supplementation|Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.
Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.
108007|NCT01424930|Drug|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
108008|NCT01424930|Drug|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
108009|NCT00066157|Drug|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
108010|NCT01424943|Behavioral|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
108011|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
108012|NCT01424956|Device|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
108013|NCT01424982|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hrs for 6 doses days 1,2,3 (total dose 1800mg/m2) for Odd Courses 1,3,5,7.
108014|NCT01424982|Drug|Mesna|600 mg/m^2 by vein continuous infusion daily for 24 hours for Odd Courses 1,3,5,7.
108015|NCT01424982|Drug|Doxorubicin|50 mg/m2 by vein over 24 hrs via central venous catheter on Day 4 of Odd Courses 1,3,5,7.
108016|NCT01424982|Drug|Vincristine|2 mg by vein on day 1 and day 11 of Odd Courses 1,3,5,7.
Maintenance Therapy Starting Dose: 2 mg by vein on day 1 approximately every 28 days for 24 months.
108017|NCT01424982|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1-4 and days 11-14 of Odd Courses 1,3,5,7.
108018|NCT01424982|Drug|Ponatinib|Odd Courses 1,3,5,7: 45 mg by mouth daily days 1-14 for Course 1. For subsequent courses 3, 5, and 7, 30 mg by mouth daily.
Even Courses 2,4,6,8: 30 mg by mouth daily.
Maintenance Therapy Starting Dose: 30 mg by mouth daily and 15 mg by mouth daily in patients who have achieved complete molecular response.
108019|NCT01424982|Drug|G-CSF (Filgrastim)|Even and Odd Courses: 10 mcg/kg subcutaneously daily (or 5mcg/kg twice daily) until post-nadir granulocytes >1.0 x 109/L.
108704|NCT01423760|Other|No intervention|Observation arm for survival of all subjects who do not receive anymore or have never received Tecemotide (L-BLP25)
108705|NCT01423773|Device|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
107781|NCT01427036|Procedure|MISS|Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.
Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.
skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate.
107782|NCT01427036|Procedure|PHS|Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.
Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.
Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a " L " detaching the vastus lateralis to expose the external surface of the femur on the length of the plate.
107783|NCT01427049|Device|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
107784|NCT01427062|Other|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
107785|NCT00066300|Procedure|peripheral blood stem cell transplantation|
107786|NCT01427062|Other|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
107787|NCT01427075|Procedure|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
107788|NCT01427088|Device|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
107789|NCT01429545|Drug|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
107790|NCT00066443|Biological|pegfilgrastim|Dose escalation schedule A&B = 6mg fixed dose once per cycle on day 2
107791|NCT01429571|Other|No intervention|No intervention
107792|NCT01429584|Drug|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
107793|NCT01429584|Drug|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
107945|NCT01427296|Drug|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
107946|NCT01427309|Biological|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
107947|NCT01427309|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
107948|NCT01427322|Drug|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
107949|NCT00066326|Drug|imatinib mesylate|
107950|NCT01427322|Radiation|Radiation therapy|Standard radiation therapy
107951|NCT01427335|Drug|calcium|intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.
Intravenous infusion was performed within 30 minutes
107952|NCT01427335|Drug|0.9 % saline|0.9 % saline intravenous infusion
107953|NCT01427348|Procedure|with assistant|head extension by an assistant during direct laryngoscopy
107954|NCT01427348|Procedure|without assistant|without head extension by an assistant during direct laryngoscopy
107955|NCT01427387|Drug|ASP0456|oral
107956|NCT01427387|Drug|Placebo|oral
107957|NCT01427400|Drug|Botulinum Toxin-A|100 Units diluted in 25cc saline
107958|NCT01427400|Drug|Saline|Dispensed in a 25cc syringe
107959|NCT01427426|Dietary Supplement|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
107960|NCT00066326|Drug|tanespimycin|
107961|NCT01429909|Device|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2*.
107962|NCT01429935|Drug|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
107963|NCT01429935|Drug|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
107964|NCT01429935|Other|placebo|capsules contain starch
107965|NCT01429961|Drug|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1~14
111474|NCT01442545|Drug|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
111475|NCT00067782|Drug|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
111476|NCT01442558|Drug|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
111477|NCT01442571|Device|Hyaluronic Acid Injection|
111478|NCT01442571|Drug|Saline Injection|
111734|NCT01442961|Procedure|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
111735|NCT01442961|Procedure|vaginal : vaginal hysterectomy|Vaginal hysterectomy
111736|NCT01442974|Drug|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
111737|NCT01442987|Drug|Irbesartan/Atorvastatin A|once daily, P.O. 8week
111738|NCT01442987|Drug|Irbesartan|once daily, P.O. 8week
111739|NCT01442987|Drug|Atorvastatin A|once daily, P.O. 8week
111740|NCT00067847|Behavioral|State-directed nutrition policy change|
111741|NCT01442987|Drug|Placebo|once daily, P.O. 8week
111742|NCT01442987|Drug|Irbesartan/Atorvastatin B|once daily, P.O. 8week
111743|NCT01442987|Drug|Atorvastatin B|once daily, P.O. 8week
111744|NCT01443013|Other|Renal Transplant|urinary sample at month 3, 6 and 12
111745|NCT01443026|Drug|Lycopene 30mg|Lycopene 30 mg.
111746|NCT01443026|Drug|Placebo|Placebo
111747|NCT01443039|Drug|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
111748|NCT01443052|Other|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
111749|NCT01443065|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
108020|NCT00066157|Drug|Medroxyprogesterone|2.5mg tablet daily for 12 months
108305|NCT01428089|Drug|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
108306|NCT01430585|Drug|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
108307|NCT01430585|Drug|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
108308|NCT01430585|Drug|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
108309|NCT01430598|Procedure|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
108310|NCT01430598|Other|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
108311|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
108312|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
108313|NCT01430624|Behavioral|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
108314|NCT00001119|Biological|Tetanus Toxoid Vaccine|
108315|NCT00066482|Drug|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children < 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
108316|NCT01430624|Behavioral|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
108317|NCT01430637|Genetic|DNA analysis|
108318|NCT01430637|Genetic|RNA analysis|
108319|NCT01430637|Genetic|gene expression analysis|
108320|NCT01430637|Genetic|mutation analysis|
108321|NCT01430637|Genetic|nucleic acid sequencing|
108322|NCT01430637|Genetic|polymerase chain reaction|
107794|NCT01429610|Drug|Rituximab+mVPDL|Induction:
Dauno 90 mg/m2/d by civ (d1-3)
Vinc 2 mg iv (d1, 8)
Pred 60 mg/m2/d po (d1-14)
for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)
Rituximab 375mg/m2/d (d8)
Consolidation A (cycle1)
D 45 mg/m2/day by continuous iv (d1, 2)
V 2 mg iv (d1, 8)
P 60 mg/m2/day po (d1-14)
for Ph(-): L-asp (d1-14) for Ph(+): Imatinib
Rituximab 375mg/m2/d (d8)
Consolidation B (cycles2&4)
Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)
Eto 150 mg/m2/d iv over 3 hr (d1-4)
Rituximab 375mg/m2/d d8
Consolidation C (cycles 3&5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)
Leucovorin 50 mg/m2 iv every 6hr for 3 doses,
Rituximab 375mg/m2/d (d8&22)
Maintenance (for 2 years)
- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd
Consider alloHCT
108084|NCT01432782|Drug|Placebo|Saline 4 ml
108085|NCT01432782|Drug|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
108086|NCT01432795|Device|Gliding aids for medical compression stockings|Each subject tests devices:
3 gliding aids for stockings with closed tips
3 gliding aids for stockings with open tips
2 stocking butlers using
3 medical compression stockings with open tip, compression class 3 (36-46mmHg)
3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)
2 superimposed compression stockings class 1 (18 - 21 mmHg)
108087|NCT00066703|Drug|exemestane|Given orally
108088|NCT01432821|Other|Apomorphine (Experimental product)|Dosage Form: Injection Dosage: 1 or 5 mg / kg
Route of administration: Subcutaneous
Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.
Two injections will be made by visiting during visits 2 and 3.
The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:
Sequence A during visit 2 followed by sequence B during visit 3
or sequence B during visit 2
108089|NCT01432834|Other|Laser in situ keratomileusis (LASIK)|During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH & Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the "S001 Wellington" nomogram for the "wavefront optimised" protocol.
108090|NCT01432834|Other|Photorefractive keratectomy (PRK)|The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the "S001 Wellington" nomogram for the "wavefront optimised" protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected.
108091|NCT01424982|Drug|Prednisone|Maintenance Therapy Starting Dose: 200 mg by mouth daily days 1-5 approximately every 28 days with vincristine for 24 months.
108092|NCT01424982|Drug|Pegfilgrastim (Neulasta)|Even Courses: Neulasta may replace G-CSF at a dose of 6 mg subcutaneously on Day 5.
Odd Courses: Neulasta may replace G-CSF at 6 mg subcutaneously on Day 4.
108245|NCT01432600|Drug|Cyclophosphamide|Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone is determined, we will proceed with the second phase of the trial which is a randomized phase II study comparing pomalidomide and dexamethasone and pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
108246|NCT01432613|Procedure|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
108247|NCT01432626|Drug|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
108248|NCT01432639|Other|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
108249|NCT01432665|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
108250|NCT01432665|Drug|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
108251|NCT01432665|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
108252|NCT01432691|Procedure|THA (Total hip arthroplasty) versus Hemi (hemialloplastik)|THA vs hemi
108253|NCT01432704|Drug|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
108254|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
108255|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
108256|NCT01425359|Drug|Ranolazine|
108257|NCT01425359|Drug|Ranolazine placebo|
108258|NCT01425385|Other|Near infrared spectroscopy monitoring|This is an observational study without interventions
108259|NCT01425385|Other|Autoregulation monitoring|There are no interventions in this observational study
108260|NCT01425398|Drug|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
111750|NCT01443065|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
111751|NCT00067860|Drug|recombinant human growth hormone|
111752|NCT01445509|Drug|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
111753|NCT01445509|Drug|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
111754|NCT01445522|Drug|ABT-888|
111755|NCT01445522|Drug|Cyclophosphamide|
111756|NCT00068172|Drug|PI-88|
112078|NCT00070720|Behavioral|Opinion Leaders, Academic Detailing, Reminders, and Feedback|
112079|NCT01476306|Other|Usual care|Patients in this group will receive care as they usually do with the physician.
112080|NCT01476319|Other|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
112081|NCT01476332|Drug|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
112082|NCT01478542|Drug|Liposomal Vincristine|
112083|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv once daily
112084|NCT01478542|Drug|Ricover-scheme rituximab|
112085|NCT01478542|Drug|optimised rituximab-schedule|
112086|NCT01478555|Drug|ISV 101|Bromfenac in DuraSite
112087|NCT01478568|Drug|mirabegron|oral
112088|NCT01478568|Drug|desipramine|oral
112089|NCT01478581|Drug|PCI-32765|
112090|NCT01478581|Drug|Dexamethasone|
112091|NCT01478594|Drug|Tivozanib|Capsules for oral administration
112092|NCT01478594|Drug|Bevacizumab|Solution for intravenous infusion
108323|NCT01430637|Other|laboratory biomarker analysis|
108324|NCT01430637|Other|pharmacogenomic studies|
108325|NCT01430650|Drug|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
108615|NCT01423747|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
108616|NCT01425970|Drug|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
108617|NCT01425970|Drug|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
108618|NCT01425970|Drug|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
108619|NCT01425970|Biological|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
108620|NCT01425970|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
108621|NCT00000257|Drug|0% N2O and 10% N2O|
108622|NCT00001113|Drug|Interferon alfa-n1|
108623|NCT00066248|Drug|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
108624|NCT01425970|Drug|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
108625|NCT01425970|Drug|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
108626|NCT01425983|Dietary Supplement|amino acid composition (asn01)|Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.
Duration: 12 weeks
108627|NCT01425983|Other|Placebo|Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.
Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.
Duration: 12 weeks
108628|NCT01425996|Drug|Lipotecan® (TLC388)|Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT
Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT
Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT
Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)
Cohort A"x": TLC388 "MTD" x 6 dose + 3DCRT
108629|NCT01426009|Drug|EP-101|EP-101 Dose 1 administered once daily for 7 days
108630|NCT01426009|Drug|EP-101|EP-101 Dose 2 administered once daily for 7 days
108631|NCT01426009|Drug|EP-101|EP-101 Dose 3 administered once daily for 7 days
108093|NCT01425008|Drug|MLN2480|Dose Escalation Phase: patients will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Patients may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the patient discontinues for any other reason. If it is determined that a patient would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Patients will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the patient discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a patient would derive benefit from continued therapy beyond 12 months.
108094|NCT01425034|Other|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
108095|NCT01425034|Other|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
108096|NCT00066157|Drug|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
108384|NCT01428219|Drug|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
108385|NCT01428232|Other|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
108386|NCT01428232|Other|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
108387|NCT01428245|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
108388|NCT01428245|Drug|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
108389|NCT01428258|Dietary Supplement|Amino Acid (AA) Diet Given First|The intervention compares the usual amino acid (AA) low-phenylalanine (phe) dietary therapy with a new dietary therapy for PKU, a low-phe diet containing foods and beverages made from glycomacropeptide (GMP). PKU subjects in the AA Diet-GMP Diet Arm will follow their usual AA diet for 3 weeks followed by a 3 wk wash out period. They will then replace all of the protein equivalents provided in their diet by AA formula with foods and beverages made from GMP using Glytactin as provided by Cambrooke Foods, LLC. Each dietary treatment period will maintain constant intake of total protein and phe and last for 3 weeks in subjects living at home.
108390|NCT01428258|Dietary Supplement|Glycomacropeptide (GMP) diet given first|The intervention compares a new low-phenylalanine (phe) dietary therapy for PKU, a diet containing foods and beverages made from GMP using Glytactin provided by Cambrooke Foods LLC, with the usual amino acid (AA) low-phe dietary therapy. PKU subjects in the GMP Diet-AA Diet Arm will follow the GMP diet that will replace all of the dietary protein equivalents provided by AA formula with foods and beverages made from GMP for 3 weeks followed by a 3 wk wash out period. They will then follow the usual AA diet for 3 weeks. Each dietary treatment period will maintain constant intake of total protein and phe and last for 3 weeks in subjects living at home.
108261|NCT01425398|Drug|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
108554|NCT01428440|Radiation|18FML10|apoptosis imaging radio ligand
108555|NCT01428453|Drug|250mg rilapladib|Experimental Drug
108556|NCT01428453|Drug|placebo|Placebo comparator
108557|NCT01428466|Drug|GSK2585823|CLDM1%/BPO3%
108558|NCT01428466|Drug|Benzoyl peroxide 3%|Benzoyl peroxide 3%
108559|NCT01428466|Drug|Benzoyl peroxide 5%|Benzoyl peroxide 5%
108560|NCT01428466|Other|Vehicle|placebo
108561|NCT01428479|Drug|GR121167 Solution|
108562|NCT00066417|Drug|methylprednisolone|
108563|NCT01428492|Drug|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
108564|NCT01428492|Drug|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
108565|NCT01428492|Drug|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
108566|NCT01428505|Radiation|[18F]PBR111|radioligand to assess binding to TSPO
108567|NCT01428518|Drug|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
108568|NCT01428531|Drug|Fondaparinux Sodium|
108569|NCT01428544|Drug|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
108570|NCT01431014|Drug|Dexamethasone"low-dose"|5mg
108571|NCT01431014|Drug|Dexamethasone"high-dose"|15 mg
108572|NCT01431040|Other|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
112093|NCT01478594|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
112094|NCT00071097|Drug|TMC114/rtv|600mg TMC114/100mg rtv twice daily
112095|NCT01478607|Drug|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
112096|NCT01478620|Drug|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
112097|NCT01478633|Drug|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
112098|NCT01478646|Other|conventional breathing therapy|duration: 60 minutes.
112099|NCT01478646|Other|reflectory breathing therapy|duration: 60 minutes.
112100|NCT01478659|Dietary Supplement|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
111191|NCT01449695|Behavioral|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
111192|NCT01449695|Behavioral|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
111193|NCT01449708|Drug|TIVA NoNarc|patients in both groups receive antiemetic prophylaxis
patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively
postop management in both groups is similar in both groups
111194|NCT01449721|Drug|Intravenous fluid|0.9% Sodium chloride intravenous fluid
111195|NCT01449747|Drug|Sitagliptin|Sitagliptin (100mg, per oral) once a day.
111196|NCT01451853|Drug|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
111197|NCT01451853|Drug|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
111198|NCT01451853|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
111199|NCT01451866|Other|resistance training|hypertrophic resistance training
111200|NCT01451866|Other|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
108632|NCT01426009|Drug|EP-101|EP-101 Dose 4 administered once daily for 7 days
108633|NCT01426009|Drug|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
108634|NCT00066274|Drug|FOLFIRI regimen|
108635|NCT01426009|Drug|Tiotropium bromide|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
108636|NCT01426009|Drug|Ipratropium bromide|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
107722|NCT01429545|Drug|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
107723|NCT01431950|Drug|fluticasone furoate|Inhaled corticosteroid
107724|NCT01431950|Drug|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
107725|NCT01431963|Drug|Lamictal|No comparison.
107726|NCT00066638|Other|Laboratory Biomarker Analysis|Correlative studies
107727|NCT01431976|Drug|Lamictal|No comparison
107728|NCT01431989|Drug|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
107729|NCT01431989|Drug|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
107730|NCT01432015|Drug|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
107731|NCT01432015|Drug|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
107732|NCT01432015|Other|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
107733|NCT01432015|Other|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
107734|NCT01432028|Drug|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
107735|NCT01432028|Drug|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
107736|NCT01432041|Behavioral|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
107737|NCT00066651|Biological|SS1(dsFv)-PE38 immunotoxin|
108391|NCT01430689|Biological|Inactivated Influenza Vaccine Trivalent Types A and B|Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once
Household and Woman/Infant surveillance
Home visits weekly until the infant is born and reaches 6 months of age
If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained
108392|NCT01430689|Biological|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|Pregnant Women - Randomized to receive IM injection of Menactra once
Household and Woman/Infant surveillance
Home visits weekly until the infant is born and reaches 6 months of age
If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained
108393|NCT01430702|Device|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
108706|NCT01423773|Device|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
108707|NCT01423773|Device|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
108708|NCT01423786|Dietary Supplement|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
108709|NCT01423799|Dietary Supplement|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
108710|NCT01423799|Dietary Supplement|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
108711|NCT01423812|Drug|Twice-daily Darunavir/ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
108712|NCT01423812|Drug|Once-daily Darunavir/ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
108713|NCT00066066|Drug|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
108714|NCT01423825|Biological|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
108715|NCT01423825|Biological|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
108716|NCT01423825|Other|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
108717|NCT01423838|Drug|Solifenacin|5 mg, oral, once in a day
108573|NCT01431040|Other|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
108574|NCT01431053|Drug|aspirin|Aspirin 50mg po daily
108575|NCT01431053|Drug|Exemestane|Exemestane 25mg po daily
107658|NCT01424384|Drug|GSK424887|Neurophysiological testing
107659|NCT01424384|Drug|Plactebo To Match|Neurophysiological testing
107660|NCT01424397|Drug|SB-705498|12mg intranasal
107661|NCT01424397|Drug|FP|200ug intranasal
107662|NCT01424397|Drug|placebo|placebo intranasal
107663|NCT01424423|Drug|Placebo|Placebo
107664|NCT01424423|Drug|GSK1223249|I.V. Infusion
107665|NCT01424436|Biological|GSK933776|1mg/kg dose group
107666|NCT00066118|Device|Dental amalgam restorations|
107667|NCT01424436|Biological|GSK933776|3mg/kg dose group
107668|NCT01424436|Biological|GSK933776|6mg/kg dose group
107669|NCT01424449|Radiation|[11C]PHNO|examine the effects of [11C]PHNO mass carry-over and displaceable binding
107670|NCT01424449|Drug|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
107671|NCT01424462|Drug|A|Single dose treatment IR formulation
107672|NCT01424462|Drug|B|Low Extended release single dose
107673|NCT01424462|Drug|C|Medium extended release formulation
107674|NCT01424462|Drug|D|High extended release rate single dose
107675|NCT01424475|Genetic|Healthy|Healthy Volunteers
107676|NCT01424475|Genetic|PKD Patients|PKS Patients
107677|NCT00001113|Drug|Interferon alfa-2a|
111201|NCT00068692|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
111202|NCT01451879|Drug|Rituximab|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
111203|NCT01451879|Drug|Miglustat|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
111204|NCT01451892|Other|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
111205|NCT01451892|Other|patient education|overweight individuals participating in a patient education program
111206|NCT01451905|Drug|Liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
111207|NCT01451905|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
111208|NCT01451918|Drug|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
111209|NCT01451931|Other|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
111479|NCT01442584|Procedure|ovarian transplantation|ovarian transplantation
111480|NCT01442597|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
111481|NCT00068068|Procedure|Photodynamic therapy|
111482|NCT01444846|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
111483|NCT01444859|Dietary Supplement|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
111484|NCT01444859|Dietary Supplement|Placebo|Daily placebo for 10 weeks
111485|NCT01444872|Drug|TRV120027|IV infusion
111486|NCT01444872|Drug|Normal Saline|IV infusion
111487|NCT01444885|Drug|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
107738|NCT01432067|Other|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
107739|NCT01432067|Other|Classic physical activities|Daily physical activities based on a standard guide
107740|NCT01432080|Drug|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
107741|NCT01432080|Drug|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
107742|NCT01432080|Drug|Montelukast|Montelukast 10 mg PO qhs for 3 months
107743|NCT01432080|Drug|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
108021|NCT01424982|Drug|Rituximab|Odd Courses: 375 mg/m2 by vein on days 1 and 11 of Cycles 1 and 3 for patients with CD20 expression (>20% by flow cytometry).
Even Courses: 375 mg/m2 by vein on days 1 and 8 of cycles 2 and 4 for patients with CD20 expression (>20% by flow cytometry).
108022|NCT01424982|Drug|Methotrexate|12 mg intrathecally (6mg via Ommaya reservoir) on day 2 for Odd Courses.
200 mg/m2 by vein over 2 hours (+ 1 hr) followed by 800 mg/m2 over 22 hours on day 1 for Even Courses.
108023|NCT01424982|Drug|Cytarabine|CNS prophylaxis: 100 mg intrathecally day 7 for Even and Odd Courses.
Even Course 2,4,6,8: 3g/m2 by vein over 3 hours every 12 hours for 4 doses on days 2, 3.
108024|NCT01424982|Drug|Solu-medrol ( Methyl Prednisolone)|50 mg by vein every 12 hours for 6 doses days 1-3 of Even Course 2,4,6,8.
108025|NCT01424982|Drug|Citrovorum (Leucovorin)|Even Courses 2,4,6,8 on Days 2 - 5: Rescue 50 mg by vein or mouth followed by 15 mg by vein or by mouth every 6 hours for 8 doses beginning 12 hours post Methotrexate completion, i.e. approximately 36 hours from start of Methotrexate.
108026|NCT01427426|Other|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
108027|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Consult
108028|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Control - Standard of Care
108029|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Newsletter
108030|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Parent Letter
108031|NCT01427478|Drug|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
108032|NCT01427478|Drug|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
108033|NCT01427491|Device|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
108718|NCT01423838|Drug|Oxybutynin|5 mg, oral, three times in a day
108719|NCT01423851|Drug|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
108720|NCT01423864|Drug|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
108721|NCT01426061|Other|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
108722|NCT01426061|Other|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
108723|NCT01426061|Other|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
108724|NCT01426074|Drug|Bevacizumab 5 mg/kg|Intravenously every two weeks
111711|NCT01450475|Procedure|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
111712|NCT01450488|Drug|masitinib|masitinib 3 mg/kg/day
111713|NCT01450488|Drug|masitinib|masitinib 6 mg/kg/day
111714|NCT01450514|Drug|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
111715|NCT00068575|Biological|Recombinant Interferon Alfa|3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
111716|NCT01450514|Drug|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
111717|NCT01450566|Drug|Lidocaine|Use of lidocaine
111718|NCT01450566|Drug|Saline|Saline
111719|NCT01450579|Biological|ASP7373|Intermuscular administration
111720|NCT01450579|Biological|Placebo|Intramuscular administration
111721|NCT01450592|Other|No drug|Diabetic Population
111722|NCT01450592|Other|No drug|Non-Diabetic Population
107678|NCT00066131|Procedure|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
107679|NCT01426750|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
107680|NCT01426763|Biological|CINRYZE with rHuPH20|
107681|NCT01426776|Procedure|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
107966|NCT01429974|Other|amniometer model po1|The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.
The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform.
107967|NCT01429987|Drug|plecanatide|Subjects receive experimental study drug for 12 weeks.
107968|NCT00066456|Drug|Chemosensitization/Potentiation Therapy|
107969|NCT01430000|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
107970|NCT01430013|Drug|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
107971|NCT01430039|Procedure|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
107972|NCT01430039|Procedure|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
107973|NCT01430052|Drug|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
107974|NCT01430052|Drug|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
107975|NCT01430065|Drug|ASP015K|oral
107976|NCT01430065|Drug|Tacrolimus|oral
107977|NCT01430078|Drug|ASP015K|oral tablet
107978|NCT01430078|Drug|ASP015K|solution via oral capsule
107979|NCT00066456|Drug|Docetaxel|Given IV
111488|NCT01444898|Drug|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
111489|NCT01444911|Device|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
111490|NCT01444911|Device|Vaginal Dilator|Still vaginal dilator with lubricant.
111491|NCT01444924|Drug|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
111492|NCT00068068|Procedure|Phototherapy|
111493|NCT01444924|Drug|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
111494|NCT01444976|Drug|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
111495|NCT01444976|Behavioral|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
111496|NCT01444976|Drug|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
111497|NCT01444989|Other|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
111498|NCT01444989|Other|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
111757|NCT01445535|Biological|Rituximab|Rituximab will be given with siplizumab and EPOCH (combo chemo) every 21 days
111758|NCT01445535|Drug|EPOCH|EPOCH (combo chemo)will be given with siplizumab and rituximab every 21 days
111759|NCT01445535|Biological|Siplizumab|Siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
111760|NCT01445548|Drug|Sirolimus|
111761|NCT01445561|Drug|Interleukin-2 (100,000 international units)|100,000 international units/m2 daily for 5 days
111762|NCT01445561|Drug|Interleukin-2 (200,000 international units)|200,000 international units/m2 daily for 5 days
108034|NCT01427491|Device|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
108035|NCT01427504|Drug|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
108036|NCT00066339|Drug|gefitinib|
108037|NCT01427517|Drug|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
108038|NCT01427530|Device|Deep Brain Stimulation|Deep Brain Stimulation
108039|NCT01427543|Behavioral|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
108040|NCT01427569|Drug|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
108326|NCT00066482|Drug|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children < 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
108327|NCT01430650|Drug|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
108328|NCT01430676|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
108329|NCT01432860|Behavioral|In-person counseling|The design is a 3 [in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care] X 7 [baseline, 4, 8, 12, 16, 20, and 24 month follow-up] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
108330|NCT01432860|Behavioral|Workbook|Participants will read a workbook and perform skills training exercises.
108331|NCT01432860|Behavioral|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
108332|NCT01432873|Drug|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
108333|NCT01432873|Drug|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
108334|NCT01432886|Drug|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
108335|NCT01432912|Behavioral|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
111723|NCT01450605|Drug|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
111724|NCT01442922|Other|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
111725|NCT01442922|Other|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
111726|NCT01442935|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
111727|NCT01442935|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
111728|NCT01442935|Drug|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
111729|NCT00067834|Device|Pulsing electromagnetic field (PEMF)|
111730|NCT01442935|Drug|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
111731|NCT01442935|Drug|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
111732|NCT01442935|Drug|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
111733|NCT01442935|Drug|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
111983|NCT01476033|Dietary Supplement|nutraceutical group|6 capsules of supplement or placebo for 8wk
111984|NCT01476046|Drug|GSK1995057 single dose|Single intravenous dose
111985|NCT00070681|Procedure|Polysomnography|
111986|NCT01476046|Drug|Placebo|Single intravenous dose
111987|NCT01476059|Other|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
111988|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
111989|NCT01476072|Other|MRI scan|MRI scan only, methodology study with no other intervention
111990|NCT01476085|Radiation|ML10|[18F]ML10 radioligand apoptosis biomarker
111991|NCT01476098|Drug|Placebo|SB-705498 placebo
111992|NCT01478386|Device|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
107980|NCT01430091|Drug|Prasugrel (clinical formulation)|Administered orally
107981|NCT01430091|Drug|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
107982|NCT01430104|Drug|Teriparatide|Administered subcutaneously during the Treatment Period
107983|NCT01430104|Drug|Aspara-CA 600 mg|Administered orally throughout the study
107984|NCT01430104|Drug|Alfarol 1.0 µg|Administered orally throughout the study
107985|NCT01430117|Biological|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
108262|NCT01425411|Drug|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
108263|NCT00066170|Drug|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
108264|NCT01425424|Other|Vitamin D supplementation|Vitamin D
108265|NCT01425450|Drug|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
108266|NCT01425450|Drug|HF1020 placebo|Single dose: HF1020 placebo capsule
108267|NCT01425463|Drug|Ferrous (II) Glycine Sulphate Complex|Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).
Administered orally with water.
108268|NCT01425463|Drug|Polyferose|Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).
Administered orally with water.
108269|NCT01425463|Other|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
108270|NCT01425463|Other|Placebo to Polyferose|Administered orally with water.
108271|NCT01425476|Drug|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
108272|NCT01425476|Drug|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
108273|NCT01425476|Drug|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
108274|NCT00066170|Drug|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
111763|NCT01445587|Drug|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
111764|NCT01445587|Drug|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
111765|NCT01445587|Drug|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
111766|NCT01445587|Drug|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
111767|NCT00068185|Drug|Black cohosh|
111768|NCT01445600|Drug|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
111769|NCT01445613|Device|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
111770|NCT01447953|Other|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
111771|NCT01447966|Behavioral|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
112101|NCT01478659|Dietary Supplement|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
112102|NCT01478672|Procedure|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
108336|NCT00066703|Drug|tamoxifen citrate|Given orally
108337|NCT01432925|Procedure|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
108338|NCT01432938|Biological|dulaglutide|Administered subcutaneously
108339|NCT01432938|Drug|Warfarin|Administered orally
108340|NCT01432951|Drug|Enzastaurin|Administered orally
108341|NCT01432964|Procedure|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
108342|NCT01432977|Drug|paracetamol /droperidol|
108637|NCT01426022|Other|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
108638|NCT01426022|Behavioral|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
108639|NCT01426035|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
108640|NCT01426048|Other|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
108641|NCT01428570|Device|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
108642|NCT01428583|Drug|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
108643|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ lower dose (10^8 TU) at weeks 0, 8 and 16.
108644|NCT00066417|Drug|therapeutic allogeneic lymphocytes|
108645|NCT01428596|Biological|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
108646|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ higher dose (10^9 TU) at weeks 0, 8 and 16.
108647|NCT01428596|Biological|Saline solution|saline solution 1.0 ml SQ at weeks 0, 8 and 16.
111993|NCT01478399|Drug|PB1023 Injection|90 mg Dose
111994|NCT01478412|Other|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
111995|NCT01478425|Device|Lipidic Microemulsion|Topical nasal, twice a day
111996|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
111997|NCT01478425|Device|Saline|Topical Nasal, twice a day
111998|NCT01478438|Device|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
111999|NCT01478451|Behavioral|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
112000|NCT01478451|Other|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
112001|NCT01478464|Other|Massage|The hamstring muscle will be massaged with a "massage roller" for ten minutes.
112002|NCT01478477|Dietary Supplement|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
112003|NCT01478477|Other|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
112004|NCT01478477|Other|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
112333|NCT01476631|Behavioral|Walking|7 days prior to baseline participants must wear a blinded pedometer
At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale.
112334|NCT01476657|Drug|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
112335|NCT00070824|Procedure|acupuncture|
112336|NCT01476670|Other|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
112337|NCT01476683|Drug|Racecadotril|Film-coated tablet
112338|NCT01476683|Drug|Racecadotril|Racecadotril Powder Blend
112339|NCT01476683|Drug|Racecadotril|Marketed Capsule
112340|NCT01476683|Drug|Racecadotril|Marketed Film-coated Tablet
108275|NCT01425502|Behavioral|DQIP Intervention|The DQIP intervention comprises of:
Educational outreach
Information technology application
Financial incentives
108276|NCT01425515|Behavioral|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
108277|NCT01425528|Drug|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
108278|NCT01427907|Drug|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
108279|NCT01427907|Drug|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
108280|NCT00066378|Drug|gefitinib|
108576|NCT01431066|Device|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
108577|NCT01431066|Device|ActiPatch PRFE Device|Actipatch PRFE device
108578|NCT00066547|Biological|monoclonal antibody HuHMFG1|
108579|NCT01431079|Behavioral|HPV vaccine acceptability|One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
108580|NCT01431092|Drug|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
108581|NCT01431092|Drug|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
108582|NCT01431105|Drug|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
108583|NCT01431118|Other|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
108584|NCT01431118|Other|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
108585|NCT01431131|Procedure|Ridge preservation intrasocket graft|Intrasocket mineralized cancellous allograft
108586|NCT01431131|Procedure|Intrasocket graft plus a facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
108587|NCT01431144|Procedure|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
112103|NCT01478685|Drug|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
112104|NCT01478685|Drug|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
112105|NCT01471925|Drug|Nexium®|
112106|NCT01471925|Drug|Esomeprazol (40mg) + Sdium Bicarbonate (721mg)|
112107|NCT01471951|Other|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
112108|NCT01471964|Drug|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
112109|NCT01471977|Other|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
112110|NCT01471990|Drug|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
112111|NCT01471990|Drug|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
112112|NCT01472003|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
112113|NCT01472003|Drug|ABT-806i|ABT-806i will be administered by intravenous infusion.
112114|NCT00070317|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
112115|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
112116|NCT01472016|Drug|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
112117|NCT01472016|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
112118|NCT01472016|Drug|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
112119|NCT01472016|Drug|erlotinib|Erlotinib will be taken orally daily.
111210|NCT01451931|Radiation|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
111211|NCT01451931|Other|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
111212|NCT00068692|Other|laboratory biomarker analysis|Correlative studies
108648|NCT01428609|Procedure|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
108649|NCT01428622|Device|Respimat|aqueous and ethanolic solution
108650|NCT01428622|Device|Respimat|aqueous and ethanolic solution
108651|NCT01428622|Device|Respimat|aqueous and ethanolic solution
108652|NCT01428622|Device|Respimat|aqueous and ethanolic solution
108653|NCT01428622|Device|Respimat|aqueous and ethanolic solution
108654|NCT01428622|Device|Respimat|aqueous and ethanolic solution
108655|NCT00066417|Drug|thiotepa|
108656|NCT01428622|Device|Respimat|aqueous and ethanolic solution
108657|NCT01428622|Drug|Olodaterol|aqueous solution
108658|NCT01428622|Drug|Olodaterol|aqueous solution
108659|NCT01428622|Drug|Olodaterol|aqueous solution
107744|NCT01432093|Other|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
107745|NCT01432093|Other|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
107746|NCT01432106|Drug|Aliskerin/Valsartan and Rampiril|Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of < 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.
(However, all non-study medication will be manipulated, initially.)
107747|NCT01424488|Drug|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
107748|NCT01424488|Drug|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
112341|NCT01476696|Drug|Prasugrel|Administered orally
112342|NCT01476722|Device|OPTI-FREE PureMoist multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
112343|NCT01476735|Other|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
112344|NCT01476748|Device|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
112345|NCT01476761|Device|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
112346|NCT00001234|Genetic|human glucocerebrosidase cDNA|
112347|NCT00070837|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
112348|NCT01476774|Drug|Buprenorphine Transdermal System|Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.
maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .
112349|NCT01476774|Drug|Buprenorphine Transdermal System|Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.
maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .
112350|NCT01476787|Drug|Rituximab|375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
112351|NCT01476787|Drug|Lenalidomide|20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
111421|NCT01447394|Biological|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
111422|NCT01447394|Biological|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
111423|NCT01447394|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
111424|NCT00068367|Drug|erlotinib hydrochloride|150 mg per day, daily until disease progression
111425|NCT01447407|Biological|NDV-3 vaccine with alum administered IM|One dose administered IM
111426|NCT01447407|Biological|NDV-3 vaccine without alum administered IM|One dose administered IM
111427|NCT01447407|Biological|Placebo administered ID|One dose saline placebo administered ID
108588|NCT01431144|Procedure|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
108589|NCT00066573|Drug|anastrozole|Given orally
108590|NCT01431157|Procedure|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
108591|NCT01431157|Other|No nasal oxygen|Patients will have no intervention for sleep apnea
108592|NCT01431170|Drug|Besivance|Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
108593|NCT01431170|Drug|Polytrim|Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
108594|NCT01431183|Behavioral|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
108595|NCT01431196|Biological|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
108596|NCT01423604|Drug|Capecitabine|Capecitabine starting dose - 2000 mg/m^2 or 1000 mg/m^2 twice a day (NOTE: Frequency of administration may be adjusted during the study.)
107682|NCT01426789|Drug|Placebo|Matching placebo to secukinumab I.V.
107683|NCT01426789|Drug|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
107684|NCT01426802|Drug|vildagliptin|Drug 50mg vildagliptin bid
107685|NCT00001114|Drug|Interferon alfa-2b|
107686|NCT00066300|Drug|cyclosporine|
107687|NCT01426815|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
107688|NCT01426815|Drug|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
107689|NCT01426828|Biological|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
107690|NCT01426841|Radiation|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
107691|NCT01426854|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
107692|NCT01426854|Other|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
111213|NCT01451944|Behavioral|education|home asthma case management and education
111214|NCT01451957|Other|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)]
111215|NCT01451957|Other|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
111216|NCT01451957|Other|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
111217|NCT01444378|Device|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the SFA and/or proximal popliteal artery using either of these devices.
111218|NCT01444391|Device|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
111219|NCT01444404|Drug|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
111220|NCT01444417|Drug|romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Subjects will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10^9/L and ≤ 200 x 10^9/L.
111221|NCT01444417|Drug|Placebo|The starting dose is 1 µg/kg administered weekly by subcutaneous injection. Subjects will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10^9/L and ≤ 200 x 10^9/L.
111222|NCT01444430|Drug|Symbicort pMDI|80/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment
111223|NCT01444430|Drug|Symbicort pMDI|160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment
111224|NCT01444430|Drug|budesonide pMDI|80 μg x 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment
111225|NCT01444430|Drug|budesonide pMDI|160 μg x 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment
111226|NCT01444443|Device|Closed-loop control|Blood glucose controlled by algorithm
111499|NCT01445002|Biological|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
111500|NCT01445002|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
107749|NCT01424501|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|Intramuscular injection, 2 doses
107750|NCT01424501|Biological|Placebo|Intramuscular injection, 2 doses
107751|NCT01424514|Drug|SB-705498|12mg intra nasal
107752|NCT01424514|Drug|Placebo|Placebo intra nasal
107753|NCT01424540|Drug|GSK2336805 150mg|Single Dose
107754|NCT01424540|Other|Placebo|Single Dose
107755|NCT01424553|Other|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
107756|NCT01424566|Drug|Sativex®|100 μl oromucosal spray administered twice daily up to a maximum of 10 sprays per day
107757|NCT00066131|Procedure|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
107758|NCT01424566|Drug|Placebo (product code GA0034)|Matching placebo: oromucosal spray, containing excipients, peppermint flavored
107759|NCT01424579|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
108041|NCT01427569|Other|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
108042|NCT01427582|Drug|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
108043|NCT01427595|Drug|Metformin|500-2000 mg PO BID (X12 weeks)
108044|NCT01427595|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)
108045|NCT01427595|Drug|estrace|oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
108046|NCT01427608|Drug|Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
108047|NCT00001114|Drug|Didanosine|
108048|NCT00066352|Drug|bortezomib|
108049|NCT01427608|Drug|Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
111428|NCT01447407|Biological|NDV-3 vaccine without alum administered ID|One dose administered ID
111429|NCT01447420|Drug|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
111430|NCT01447420|Drug|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
111431|NCT01447433|Drug|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
111432|NCT01447433|Behavioral|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
111433|NCT01447459|Behavioral|Reinforced Asthma Education|Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.
At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study.
111434|NCT01447472|Drug|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
111435|NCT00001129|Behavioral|Medication Manager|
111436|NCT00068380|Drug|imatinib mesylate|Given orally
111437|NCT01447485|Drug|Valsartan (VAL489)|
111438|NCT01450020|Other|questionnaire administration|Ancillary studies
111439|NCT01450020|Other|counseling intervention|Undergo PN session
111440|NCT01450020|Other|survey administration|Ancillary studies
111441|NCT01450020|Procedure|quality-of-life assessment|Ancillary studies
112005|NCT01478477|Other|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
112006|NCT01478477|Procedure|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
112007|NCT00071097|Other|Control Group|Control Group, no intervention
112008|NCT01478477|Procedure|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
112009|NCT01478490|Drug|mirabegron|oral
107693|NCT01426867|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
107694|NCT01426867|Drug|Brinzolamide ophthalmic suspension, 1%|
107695|NCT01426867|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
107696|NCT01426880|Drug|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
107697|NCT00066300|Drug|fludarabine phosphate|
107698|NCT01426880|Drug|background treatment|background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.
Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).
107699|NCT01426906|Drug|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
107700|NCT01426906|Drug|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
107701|NCT01426919|Other|Head CT scan and blood draw within 12 hours of injury|
107702|NCT00066430|Procedure|infrared photocoagulation therapy|
107986|NCT01432405|Drug|Pioglitazone|Type 2 diabetic subjects will be randomized to receive either pioglitazone 45 mg daily orally or exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
107987|NCT01432418|Other|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
107988|NCT01432431|Procedure|spiritual therapy|Undergo palliative spiritual care
107989|NCT01432431|Other|questionnaire administration|Ancillary studies
107990|NCT01432431|Other|survey administration|Ancillary studies
107991|NCT01432431|Other|counseling intervention|Undergo palliative spiritual care
107992|NCT00066690|Drug|tamoxifen citrate|Given orally
107993|NCT01432431|Other|psychosocial support for caregiver|Undergo palliative spiritual care
111501|NCT01445002|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
111502|NCT01445002|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
111503|NCT00001128|Drug|Paromomycin sulfate|
111504|NCT01447498|Other|Screening for risk factors for ulcer bleeding|Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:
screening and risk assessment
control group
All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.
Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.
Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.
points: Age: < 60: 0; 60-69: 1; 70-79: 2; >=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___
111505|NCT01447511|Drug|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
111506|NCT01447511|Drug|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
111507|NCT01447511|Drug|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
111508|NCT01447524|Behavioral|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
111509|NCT01447537|Other|Exercise + relaxation|Exercise + relaxation
111510|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
111511|NCT01447550|Drug|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
111512|NCT01447563|Drug|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
111513|NCT00068380|Other|laboratory biomarker analysis|Correlative studies
111514|NCT01447563|Drug|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
111515|NCT01447576|Drug|ADT|Once daily dosing during the duration of the study.
111516|NCT01447576|Drug|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
108050|NCT01430130|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
108051|NCT01430143|Behavioral|Exercise|Daily exercise for 12 weeks.
108052|NCT01430156|Drug|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
108053|NCT01430156|Drug|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
108054|NCT00066469|Biological|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: < 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: < 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
108055|NCT01430169|Biological|AA4500|Two injections of AA4500 0.58 mg 24 hours apart
108056|NCT01430182|Drug|Methadone|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
108057|NCT01430182|Drug|Morphine|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
108058|NCT01430195|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
108059|NCT01430195|Procedure|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
108060|NCT01430208|Procedure|resectoscopy|hysteroscopy for myomas G0 and/or polyps
108061|NCT01430221|Behavioral|Mindfulness-based Personalized Health Planning|
108343|NCT01432977|Drug|paracetamol / ondansetron|
108344|NCT01432990|Device|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
108345|NCT01432990|Other|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
108346|NCT01433003|Procedure|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
108347|NCT00066716|Drug|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
108348|NCT01425541|Drug|estrace|0.5-1 mg once a day PO for 7 days
108349|NCT01425541|Drug|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
112010|NCT01478490|Drug|metoprolol|oral
112011|NCT01478503|Drug|mirabegron OCAS|oral
112012|NCT01478503|Drug|Placebo|oral
112013|NCT01478516|Procedure|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
112014|NCT01478529|Drug|mirabegron OCAS|oral administration
112015|NCT01478529|Drug|mirabegron|iv administration
112016|NCT01478542|Drug|Conventional Vincristine|
112017|NCT01471782|Drug|blinatumomab|intravenous infusion
112018|NCT01471808|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
112019|NCT01471808|Drug|CSII, Metformin, Pioglitazone|CSII for 2~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
112020|NCT01471808|Drug|CSII, Sitagliptin|CSII for 2~4 weeks combined with sitagliptin 100mg/d for 3 months
112021|NCT00070317|Procedure|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
112022|NCT01471821|Drug|antiretroviral treatment|antiretroviral treatment
112023|NCT01471834|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
112037|NCT01473979|Procedure|Surgical closure of the poststernotomy wound infection|Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.
Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone.
112038|NCT01473992|Device|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
112039|NCT01473992|Device|Otto Bock Genium|Study knee.
112040|NCT01474005|Device|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
107994|NCT01432431|Procedure|psychosocial assessment and care|Undergo palliative spiritual care
107995|NCT01432444|Drug|Aripiprazole (Abilify®) IM Depot Injection|400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.
Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013.
107996|NCT01432457|Drug|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
107997|NCT01432457|Drug|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
107998|NCT01432457|Drug|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
107999|NCT01432470|Drug|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
108000|NCT01432470|Drug|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
108001|NCT01432483|Drug|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
108002|NCT01432496|Drug|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
108003|NCT00066690|Drug|triptorelin|Given intramuscularly
108004|NCT01432496|Drug|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
108281|NCT01427920|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
108282|NCT01427933|Biological|Ramucirumab (IMC-1121B)|Administered intravenously
108283|NCT01427933|Drug|Eribulin|Administered intravenously
108284|NCT01427946|Drug|IPI-504|
108285|NCT01427946|Drug|Everolimus|
108286|NCT01427972|Drug|LY2623091|Administered orally
108287|NCT01427972|Drug|Eplerenone|Administered orally
108288|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|Atropin 10µg/kg
Mivacurium 200µg/kg immediately followed by
Fentanyl 2µg/kg
111772|NCT01447979|Device|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
111773|NCT01447992|Device|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
111774|NCT01448005|Device|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
111775|NCT01448018|Drug|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
111776|NCT00068406|Drug|cisplatin|
111777|NCT01448018|Procedure|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
111778|NCT01448031|Drug|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
111779|NCT01448031|Drug|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
111780|NCT01448044|Drug|BMS-790052 (NS5A Replication Complex Inhibitor)|
111781|NCT01448044|Drug|Placebo matching BMS-790052|
111782|NCT01448044|Drug|Pegylated-interferon alfa 2a|
111783|NCT01448044|Drug|Ribavirin|
111784|NCT01448057|Drug|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
111785|NCT01448057|Drug|Paracetamol (500 mg) tablets|Paracetamol (500 mg) tablets
111786|NCT01448070|Drug|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
111787|NCT00068406|Procedure|adjuvant therapy|
111788|NCT01448083|Other|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
111789|NCT01448096|Drug|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
111790|NCT01448096|Procedure|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
108350|NCT01425554|Other|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
108351|NCT01425554|Other|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
108352|NCT01425554|Other|Air-plethysmography of the neck|Air-plethysmography of the neck
108353|NCT01425554|Other|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
108354|NCT01425567|Drug|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
108355|NCT00066196|Biological|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
108356|NCT01425580|Drug|liraglutide|1.8 mg s.c. (QD)
108357|NCT01425580|Drug|glimepiride|4 mg p.o. (QD)
108358|NCT01425580|Drug|Metformin|500 mg p.o. (BID)
108359|NCT01425606|Other|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
108360|NCT01425619|Biological|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
108361|NCT01425619|Drug|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
108362|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
108363|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
108364|NCT01425632|Drug|TAU-284|TAU-284 Low
108660|NCT01428622|Drug|Olodaterol|aqueous solution
108661|NCT01428622|Drug|Olodaterol|aqueous solution
108662|NCT01428622|Drug|Olodaterol|aqueous solution
108663|NCT01428622|Drug|Olodaterol|aqueous solution
108664|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
108665|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
108666|NCT00066417|Procedure|allogeneic bone marrow transplantation|
107867|NCT01427218|Other|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
108151|NCT01430442|Drug|BMS-927711|Capsule, Oral, 10mg, One time, One dose
108152|NCT01433016|Drug|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
108153|NCT01433029|Other|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
108154|NCT01433029|Other|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
108155|NCT01433042|Device|capsule endoscopy|capsule endoscopy procedure
108156|NCT01433055|Drug|Minocycline|Minocycline Dosing:
Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.
108157|NCT01433055|Drug|Placebo|Placebo Dosing:
Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.
108158|NCT01433068|Device|NBTXR3|One intratumor implantation by injection
108159|NCT01433081|Drug|Placebo infusion of .9 normal saline|administration of .9 normal saline
108160|NCT01433081|Drug|administration of magnesium sulfate|administration of magnesium sulfate
108161|NCT01433094|Behavioral|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
107629|NCT01431794|Drug|LDE-225|Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.
Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
107630|NCT01431794|Drug|Gemcitabine|Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.
Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
107631|NCT01431794|Drug|nab-paclitaxel|Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.
Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
107632|NCT00066625|Other|pharmacological study|Correlative studies
107633|NCT01431807|Drug|SYR-472|oral, for up to 52 weeks.
107634|NCT01431820|Drug|Luliconazole Solution, 10%|Topical
107635|NCT01431820|Drug|Vehicle Solution|Topical
107636|NCT01431833|Drug|TR-701 FA|Oral single dose 200 mg
107921|NCT01424839|Radiation|ventricular irradiation|Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)
Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles
Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)
107922|NCT01424839|Drug|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
107923|NCT01424839|Drug|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
107924|NCT01424839|Radiation|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
107925|NCT01424852|Dietary Supplement|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
107926|NCT00066144|Drug|Red clover|
107927|NCT01424865|Genetic|fluorescence in situ hybridization|
107928|NCT01424865|Other|immunohistochemistry staining method|
107929|NCT01424865|Other|immunologic technique|
108947|NCT01431677|Procedure|Muscle Biopsy|
108948|NCT01431690|Drug|warfarin|A single 25 mg dose of warfarin
108949|NCT01431690|Drug|omefas|4 x 1 g capsule dose of Epanova®
108950|NCT01431690|Drug|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
108951|NCT01431716|Drug|EFI/ACT-385781A|
108952|NCT00066625|Other|laboratory biomarker analysis|Correlative studies
108953|NCT01431729|Other|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
108954|NCT01431742|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
108955|NCT01431755|Device|Restylane SubQ|Treatment with up to 2 ml of the product
108956|NCT01431755|Device|Restylane SubQ Lidocaine|Treatment with up to 2 ml of the product
109219|NCT01460095|Other|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
109220|NCT01460108|Device|AeriSeal System|20 mL
109221|NCT01460121|Device|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
109222|NCT01460121|Device|Placebo|
109223|NCT00069745|Drug|Prednisone|
109224|NCT01460134|Drug|CDX-1127|Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one "cycle" of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
109225|NCT01460134|Drug|CDX-1127|Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
109890|NCT01456559|Other|Lower body negative pressure (LBNP)|The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.
Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20.
109891|NCT01456572|Dietary Supplement|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
109892|NCT01456572|Dietary Supplement|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
109893|NCT00000104|Procedure|ERP measures of attention and memory|
109894|NCT00000119|Device|Heparin Surface-Modified Intraocular Lens|
109895|NCT01458821|Behavioral|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
109896|NCT01458834|Behavioral|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
109897|NCT01458834|Behavioral|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
109898|NCT01458847|Drug|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
109899|NCT01458847|Drug|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
109900|NCT00001155|Drug|cyclophosphamide|
109901|NCT00069628|Device|Continuous Glucose Monitoring System (CGMS)|
109902|NCT01458847|Drug|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
108725|NCT00066274|Drug|FOLFOX regimen|
108726|NCT01426087|Drug|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
108727|NCT01426087|Procedure|endoscopic therapy|gastroscope plus EIS/EVL/HI
108162|NCT00001119|Drug|Ritonavir|
108163|NCT00066716|Drug|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
108164|NCT01433094|Behavioral|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
108451|NCT01425827|Drug|duloxetine HCL|60 mg/day duloxetine for 16 weeks
108452|NCT00066404|Biological|recombinant adenovirus-hIFN-beta|
108453|NCT01428271|Other|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
108454|NCT01428284|Drug|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
108455|NCT01428297|Drug|BPR277 ointment (controlled application)|
108456|NCT01428297|Drug|Placebo (Vehicle)|
108457|NCT01428297|Drug|BPR277 ointment|
108458|NCT01428297|Drug|Placebo (Vehicle)|
108459|NCT01428297|Drug|BPR277|
108460|NCT01428297|Drug|Placebo (Vehicle)|
108461|NCT01428310|Dietary Supplement|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
108462|NCT01428310|Dietary Supplement|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
108463|NCT00066417|Drug|cyclophosphamide|
108464|NCT01428323|Device|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
108465|NCT01428336|Procedure|ACTH stimulation test|1 ug cortrosyn dose
108466|NCT01428336|Procedure|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
108467|NCT01428336|Procedure|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
107930|NCT01424865|Other|laboratory biomarker analysis|
107931|NCT01424891|Drug|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
107932|NCT01424891|Drug|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
107933|NCT01424891|Drug|Placebo|treatment with placebo over 8 weeks
107934|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation A
107935|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
107936|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
107937|NCT01427270|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
107938|NCT00066313|Procedure|adjuvant therapy|
107939|NCT01427270|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
107940|NCT01427270|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
107941|NCT01427283|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
107942|NCT01427283|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
108225|NCT01430507|Drug|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
108226|NCT01430520|Drug|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
108227|NCT01430520|Drug|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
108228|NCT01430533|Drug|azelaic acid pre foam formulation|
108229|NCT01430533|Drug|Vehicle pre foam formulation|
108230|NCT01430533|Drug|Water|
108231|NCT01430559|Drug|Meloxicam|7.5mg x2 once a day for 12 weeks
108232|NCT01430559|Drug|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
109226|NCT01460134|Drug|CDX-1127|Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
109227|NCT01460147|Other|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
109228|NCT01460160|Drug|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
109229|NCT01460173|Other|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
109230|NCT01460186|Other|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
109231|NCT01460199|Drug|CTP-499|3 X 200 mg tablets (QD for 2 weeks)
3 x 200 mg tablets (BID for 2 weeks)
109232|NCT01460199|Drug|placebo|tablets
109233|NCT01453205|Drug|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
109234|NCT01453205|Procedure|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
109488|NCT01460602|Drug|MTD of Velcade, Nipent and Rituxan established in Part 1|One of the following dose levels will be chosen and used in Part 2:
(VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
(VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
(VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
(VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
109489|NCT01460615|Drug|Hydrocortisone|
109490|NCT01460628|Drug|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. At the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio.
109491|NCT01460654|Drug|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
109492|NCT01460654|Drug|Alendronate|Alendronate (Fosamax) 70mg every week.
109493|NCT01460654|Drug|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
109494|NCT00069823|Drug|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
108728|NCT01426100|Drug|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
108729|NCT01426100|Drug|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
108730|NCT01426100|Drug|Telmisartan 80mg|Telmisartan 80mg monotherapy
108731|NCT01426113|Drug|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
108732|NCT01426113|Drug|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
108733|NCT01426113|Drug|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
108734|NCT01426126|Drug|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
108735|NCT01426139|Device|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
108736|NCT00066274|Drug|fluorouracil|
108737|NCT01426165|Drug|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
108738|NCT01426178|Device|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|After written information and consent, patients are randomised in two groups: NAVA first or PSV first.
They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter.
108739|NCT01426191|Drug|xinzhijun|durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)
1.5-3.0g,iv,bid or tid for 5-12 days;
Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days
108740|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
108741|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
108742|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
108743|NCT01428622|Drug|BI54903|ethanolic solution
108744|NCT01428622|Drug|BI54903|ethanolic solution
108745|NCT01428622|Drug|BI54903|ethanolic solution
108746|NCT01428622|Drug|BI54903|ethanolic solution
108468|NCT01428336|Procedure|Insulin tolerance test|subjects will undergo an insulin tolerance test
108469|NCT01428336|Procedure|1 ug cortrosyn test|Subjects will undergo an ACTH test using a 1 ug dose cortrosyn
108470|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
108471|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
108472|NCT01428362|Drug|VI-1121|
108473|NCT01428362|Drug|Placebo|
107568|NCT01438424|Drug|Lamivudine|Oral, 100 mg, daily
107569|NCT01438437|Procedure|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
107570|NCT01438437|Procedure|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
107571|NCT01440647|Procedure|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
107572|NCT01440647|Procedure|Extubation to CPAP|After extubation infants were placed on CPAP
107573|NCT01440673|Drug|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
107574|NCT00067509|Drug|emergency contraception (estrogen/progesterone)|
107575|NCT01440686|Drug|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
107576|NCT01440686|Drug|Placebo|Tablets, oral administrations
107577|NCT01440699|Biological|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
107578|NCT01440712|Drug|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
107579|NCT01440712|Drug|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
107580|NCT01440725|Biological|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
107581|NCT01440725|Procedure|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
109759|NCT00069862|Drug|desferoxamine (DFO)|
109760|NCT01461187|Other|exercise during pregnancy|supervised aerobic physical exercises twice a week.
109761|NCT00068991|Behavioral|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
109762|NCT01454076|Drug|rifampin|
109763|NCT01454076|Drug|Drug: clarithromycin|
109764|NCT01454089|Drug|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
Patients will receive chemotherapy consisting of up to 6 cycles of gemcitabine and cisplatin.
109765|NCT01454089|Drug|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
Patients will receive chemotherapy consisting of up to 6 cycles of gemcitabine and cisplatin.
109766|NCT01454089|Drug|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
Patients will receive chemotherapy consisting of up to 6 cycles of gemcitabine and cisplatin.
109767|NCT01454102|Biological|Nivolumab|
109768|NCT01454102|Drug|Gemcitabine|
108877|NCT01424111|Other|Healthy Control|No Treatment
108878|NCT01424124|Drug|YHD001 dose level 1|Tablet, three times daily / 8 weeks
108879|NCT01424124|Drug|YHD001 dose level 2|Tablet, three times daily / 8 weeks
108880|NCT01424124|Drug|Singulair|Tablet, one times daily / 8 weeks
108881|NCT01424124|Drug|Placebo|Tablet, one times daily / 7 days
108882|NCT01424137|Device|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
108883|NCT01424137|Device|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
108884|NCT01424137|Device|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
108885|NCT00066079|Behavioral|relaxation|
108886|NCT01424150|Other|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
108887|NCT01424150|Other|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
109495|NCT01460654|Drug|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
109496|NCT01460667|Drug|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
109497|NCT01460667|Drug|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
109498|NCT01460693|Drug|Imatinib|Oral Imatinib 100mg daily
109499|NCT01460693|Drug|Dasatinib|Oral Dasatinib 100mg daily
109500|NCT01460706|Drug|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
109501|NCT01460719|Biological|V212|V212 viral antigen for HZ, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
109502|NCT01453647|Other|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
109503|NCT01453660|Other|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
109833|NCT01458808|Other|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
109834|NCT01458808|Other|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
109835|NCT01461343|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
109836|NCT00069875|Drug|LY293111|
109837|NCT01461356|Procedure|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
109838|NCT01461356|Procedure|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
109839|NCT01461369|Drug|Diclofenac|35 mg bid Capsules
109840|NCT01461369|Drug|Diclofenac|35 mg tid Capsules
109841|NCT01461369|Drug|Placebo|Capsules
107795|NCT01429623|Drug|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
107796|NCT01429623|Drug|Placebo|Placebo comparator
107797|NCT01429636|Behavioral|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
107798|NCT01429636|Behavioral|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
107799|NCT01429649|Procedure|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
107800|NCT01429662|Behavioral|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
107801|NCT00066443|Drug|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
107802|NCT01429662|Behavioral|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
107803|NCT01429675|Drug|bonviva|150mg Ibandronate once a month
107804|NCT01429688|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
107805|NCT01429701|Drug|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
107806|NCT01429701|Drug|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
107807|NCT01429714|Device|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
107808|NCT01432119|Device|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
107809|NCT00066664|Genetic|proteomic profiling|
107810|NCT01432119|Drug|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
107811|NCT01432119|Drug|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
107582|NCT01440738|Behavioral|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
107583|NCT01440751|Device|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
107584|NCT01440751|Drug|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
107585|NCT00067522|Behavioral|User-independent contraception program|
107586|NCT01440764|Drug|Furosemide|Subjects will inhale 80mg of furosemide aerosol over the course of 5-10 min. There will be a single administration of aerosol furosemide and either aerosol albuterol or aerosol saline in each subject, as well as an IV furosemide dose to control for systemic effects. Each intervention will occur on a separate day.
107868|NCT01427218|Behavioral|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
107869|NCT00066313|Drug|vandetanib|
107870|NCT01427218|Behavioral|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
107871|NCT01427218|Other|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
107872|NCT01427231|Dietary Supplement|glucose|The effect of a glucose solution on cognitive performance will be measured.
107873|NCT01427231|Dietary Supplement|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
107874|NCT01427231|Dietary Supplement|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
107875|NCT01427244|Drug|trastuzumab|monoclonal antibody
107876|NCT01429714|Device|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
107877|NCT01429740|Drug|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
107878|NCT01429740|Drug|Placebo|Placebo oral solution or capsules
107879|NCT01429753|Other|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
108888|NCT01424163|Drug|Single dose reduced|Treatment 1 (Part A)
108889|NCT01424163|Drug|Single dose standard|Treatment 2 (Part A)
108890|NCT01424163|Drug|Multiple Dose|Treatment 3 (Part A)
108891|NCT01424163|Drug|Multiple Dose|Part B
108892|NCT01424176|Drug|Dexpramipexole (dose 1)|
108893|NCT01424176|Drug|Dexpramipexole (dose 2)|
108894|NCT01426399|Drug|LC15-0444|LC15-0444 50mg qd (8 days once daily)
108895|NCT01426399|Drug|Metformin|Metformin 1000 mg bid (8 days twice daily)
108896|NCT01426399|Drug|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
108897|NCT01426412|Drug|LY3015014 (intravenously)|Administered intravenously over 30-90 minutes
108898|NCT01426412|Drug|Placebo (intravenously)|Administered intravenously only over 30-90 minutes
108899|NCT00066274|Drug|oxaliplatin|
108900|NCT01426412|Drug|LY3015014 (subcutaneously)|Administered subcutaneously
108901|NCT01426412|Drug|Placebo (subcutaneously)|Administered subcutaneously
109166|NCT00068822|Procedure|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
109167|NCT01453179|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
109168|NCT01453179|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
109169|NCT01453192|Drug|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
109170|NCT01453205|Drug|MEDI-551|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
109842|NCT01461382|Other|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
109843|NCT01461382|Other|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
109844|NCT01461408|Behavioral|Health Education Session|The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect—their hairdressers—will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.
The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during "down times" in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26.
109845|NCT01461421|Behavioral|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
109846|NCT01461421|Behavioral|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
109847|NCT00001181|Drug|Testolactone|
109848|NCT00069875|Drug|cisplatin|
109849|NCT01461421|Behavioral|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
109850|NCT01461421|Behavioral|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
109851|NCT01461434|Device|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
108957|NCT01431768|Device|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
108958|NCT01431781|Drug|Stilamin+common daily treatment|dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.
Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory.
108959|NCT01431781|Other|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
107812|NCT01432119|Procedure|Break-Through Scan|Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.
107813|NCT01432132|Behavioral|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
108097|NCT01425060|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
108098|NCT01425060|Other|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
108099|NCT01425073|Other|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
108100|NCT01425086|Device|Embrace, PCM, warming blanket|Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm "micro-environment".
108101|NCT01425099|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
108102|NCT01425099|Drug|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
108103|NCT01425112|Procedure|Phacoemulsification|Surgery for complications of trabeculectomy
108104|NCT01425125|Drug|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
108105|NCT01425151|Device|i-Gel|Oropharyngeal leak pressure Insertion success
108106|NCT01425151|Device|ProSeal|Oropharyngeal leak pressure Insertion success
108107|NCT00066157|Drug|Placebo|Placebo tablet daily for 12 months
108108|NCT01425164|Drug|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
108109|NCT01425164|Drug|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
108110|NCT01425177|Procedure|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
108111|NCT01425190|Drug|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
107880|NCT00066443|Drug|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
107881|NCT01429753|Device|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
107882|NCT01429766|Other|Respiratory Training|All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one "Spiroball" device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed
st visit Within one day of the date of simulation
nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)
107883|NCT01429779|Drug|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
107884|NCT01429792|Drug|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
107885|NCT01429792|Drug|ribavirin [Copegus]|standard treatment, orally daily
107886|NCT01429805|Device|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
107887|NCT01429818|Drug|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
108165|NCT01433107|Drug|Terbinafine|1% single application
108166|NCT01433107|Drug|Terbinafine Placebo|single application
108167|NCT01433120|Dietary Supplement|Lactobacillus paracasei ssp paracasei F19|10^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
108168|NCT01425203|Drug|Boceprevir|boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
108169|NCT01425203|Drug|Placebo|boceprevir-matched placebo four 200-mg capsules PO TID.
108170|NCT01425203|Biological|peginterferon alfa-2b|peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
108171|NCT01425203|Drug|Ribavirin|ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
108172|NCT01425216|Drug|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
108173|NCT01425229|Drug|Bosentan|Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14
Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14
108174|NCT00001113|Drug|Zidovudine|
109171|NCT01453205|Drug|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
109172|NCT01453205|Drug|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min [800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
109173|NCT01455233|Drug|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
109174|NCT01455246|Drug|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
109175|NCT01455246|Drug|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
109176|NCT01455259|Biological|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
109177|NCT01455272|Procedure|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
109178|NCT01455285|Device|transcutaneous electrical nerve stimulation|
109179|NCT01455298|Other|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
109430|NCT01453621|Other|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
109431|NCT01453634|Drug|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
109432|NCT01453634|Drug|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
109433|NCT01455753|Other|The effect of proximity on flu shot participation|The investigators will move the location of the flu shot clinic to a high traffic area in our partner company's second headquarters building. After that clinic is complete, the investigators will then host a flu shot clinic in our partner company's first headquarters building, also in a high traffic area, which will not be publicized until the first flu shot clinic is complete.
108960|NCT01424202|Device|Mechanical Insufflation Exsufflation|After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.
On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.
The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse.
108961|NCT01424215|Drug|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
108962|NCT00066092|Drug|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
108963|NCT01424228|Drug|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
108964|NCT01424228|Drug|prucalopride|Prucalopride 2 mg daily before breakfast
1 mg for subjects >65 years; in case of insufficient response 2 mg at week 2 or week 4
108965|NCT01424241|Drug|Sandostatin LAR|This will be a open label dose escalation study of Sandostatin LAR 10 Mg, 20Mg, 30 Mg up to 40 mg if necessary.
108966|NCT01424254|Device|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
108967|NCT01424254|Procedure|Push-Enteroscopy|currently recommended standard
108968|NCT01424267|Device|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
108969|NCT01424280|Drug|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
108970|NCT01424280|Drug|Placebo|Single dose of matching placebo tablets
108971|NCT01424293|Device|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
108972|NCT01424293|Device|The SPY® Intraoperative Imaging System|
108973|NCT00066092|Drug|filgrastim|Filgrastim given daily for PBPC mobilization
109235|NCT01453218|Drug|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
109236|NCT01453231|Procedure|thighplasty|Plastic surgery of thigh
109237|NCT00068835|Behavioral|Lindamood-Bell training for dyslexia|
108112|NCT01427621|Procedure|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
108113|NCT01427634|Behavioral|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
108114|NCT01427634|Other|Usual Care|Receive usual care as provided by the VAD clinical team.
108394|NCT01430715|Other|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, > 5th % to < 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
108395|NCT01430741|Other|Getting To Outcomes|GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, "carrying out" an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations.
108396|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation and linkages to community-based resources. The core intervention utilized within MISSION-Vet is Critical Time Intervention (CTI), which addresses the situational and motivational barriers related to engagement in care and places a primary focus on housing placement and support. CTI is supplemented with thirteen manual-guided Dual Recovery Therapy (DRT) mental health and substance abuse psychoeducation sessions, delivered by a case manager, to address mental health and substance abuse issues. DRT sessions are intended to assist the Veteran with developing more self efficacy and motivation for maintaining sobriety and stability. We have also supplemented CTI by adding Peer Support Technicians (PSTs). PSTs can reduce in-patient utilization, substance abuse, social isolation and other symptoms by role modeling healthy behaviors.
108397|NCT01430754|Drug|tasimelteon|20 mg tasimelteon capsules, daily
108398|NCT01430754|Drug|Placebo|Placebo capsules, daily
108399|NCT00066482|Procedure|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
108400|NCT01430780|Drug|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
108401|NCT01430780|Drug|control group|placebo
108175|NCT00066170|Drug|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
108176|NCT01425242|Drug|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
108177|NCT01425242|Drug|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
108178|NCT01425268|Device|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
108179|NCT01425268|Procedure|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
108180|NCT01425281|Device|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
108181|NCT01425281|Device|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
108182|NCT01425307|Drug|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
108474|NCT00001115|Drug|Acyclovir|
108475|NCT00066417|Drug|cyclosporine|
108476|NCT01428375|Drug|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
108477|NCT01428375|Other|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
108478|NCT01428388|Drug|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
108479|NCT01430793|Drug|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
108480|NCT01430793|Drug|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
108481|NCT01430793|Drug|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
108482|NCT01430806|Drug|Dronedarone arm|PO Dronedarone 400 mg BID
109434|NCT00069108|Drug|Oxaliplatin|As prescribed, in 3 week cycles
109435|NCT01455779|Device|Lyrette|The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.
The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment.
109436|NCT01455792|Procedure|Biopsies using image fusion|MRI and soft image fusion guided biopsy
109437|NCT01455792|Procedure|Gold standard biopsy|Gold standard TRUS biopsy
109438|NCT01455805|Device|Minuteman Fusion Implant|The Minuteman™ interspinous interlaminar fusion device consists of a central threaded portion that has a two-part wing plate hinged near its proximal end, with spikes on the extended distal end of the wing plate, and a multi-spiked end cap plate that is located at the distal end of the device and is retained and tightened in place with a locking hex nut. Compression between the spiked wing plate and the spiked end cap plate serves to fix the spinous processes in place and to facilitate fusion, together with bone graft fusion material placed within the device. The threaded external body has been designed to provide ease of distraction and insertion via a minimally invasive surgical procedure.
109439|NCT01455805|Procedure|surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis
109440|NCT01455831|Drug|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
109441|NCT01455831|Drug|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
109442|NCT01455844|Drug|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
109443|NCT01455844|Other|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
109444|NCT01455844|Drug|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
109445|NCT00069108|Drug|Oxaliplatin|As prescribed, in 2 week cycles
109769|NCT01454102|Drug|Cisplatin|
109770|NCT01454102|Drug|Pemetrexed|
109771|NCT01454102|Drug|Paclitaxel|
109772|NCT00068991|Behavioral|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
109773|NCT01454102|Drug|Carboplatin|
109774|NCT01454102|Drug|Bevacizumab|
109238|NCT01453257|Drug|Tailored Chemotherapy|Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:
K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU
109239|NCT01453270|Device|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
109240|NCT01453270|Other|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
109241|NCT01453283|Drug|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
109242|NCT01453296|Drug|GW642444|GW642444 25 μg; Novel dry powder inhaler
109243|NCT01453296|Drug|Placebo|Matching placebo; Novel dry powder inhaler
109244|NCT01453309|Procedure|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
109245|NCT01453309|Procedure|No Cell Saver|Cell Saver will not be available during surgery
109246|NCT01453348|Biological|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly on day 1.
109247|NCT01453348|Biological|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 & 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
109248|NCT00068848|Behavioral|Quick start oral contraceptive initiation|
109249|NCT01453348|Biological|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
109250|NCT01453348|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
109251|NCT01453361|Biological|Vigil™ Vaccine|
109252|NCT01453374|Drug|VIVITROL 380mg|380 mg IM injection given once monthly
109253|NCT01453387|Drug|MSC2015103B|Once weekly administration schedule: Days 1, 8, and 15 of a 21-day cycle (Schedule 1) dosing will begin at 150 mcg
Three times weekly administration schedule: Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle (Schedule 2) dosing will begin at 150 mcg
108402|NCT01430793|Drug|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
108403|NCT01433120|Dietary Supplement|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
108404|NCT01433120|Dietary Supplement|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
108405|NCT01433133|Biological|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
108406|NCT01433159|Drug|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
108407|NCT01433159|Drug|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
108747|NCT01428622|Drug|BI54903|ethanolic solution
108748|NCT00066417|Procedure|biological therapy|
108749|NCT01428622|Drug|BI54903|ethanolic solution
108750|NCT01428622|Drug|BI54903|ethanolic solution
108751|NCT01428635|Drug|Eltrombopag|Starting dose 50 mg by mouth daily. Dose escalation allowed every 2 weeks to 100 mg, 150 mg, 200 mg and 300 mg according to platelet response (except for patients of East Asian ancestry who receive starting dose of 25 mg daily). Treatment cycle defined as daily continuous dosing.
108752|NCT01428648|Behavioral|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
108753|NCT01428661|Drug|tasimelteon|20 mg once daily
108754|NCT01428661|Drug|placebo|once daily
108755|NCT01428674|Other|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
108756|NCT01428674|Other|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
108757|NCT01428687|Behavioral|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
108758|NCT01428687|Behavioral|No change in sleep|This group is taught to maintain their current sleep habits.
108759|NCT00066417|Procedure|bone marrow ablation with stem cell support|
108483|NCT01430806|Drug|Dronedarone|Dronedarone PO 400 MG BID
108484|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
108485|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
108486|NCT00066482|Biological|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
108487|NCT01430858|Device|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
108488|NCT01430858|Other|Vibration therapy|Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion & strain gauge readings will be captured.
Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion & strain gauge readings will be captured.
Power Plate Pro5 Two amplitude settings will be tested, described as low & high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion & strain gauge readings will be captured.
108489|NCT01430884|Other|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
108490|NCT01430910|Drug|CAZ104|IV infusion
108491|NCT01430910|Drug|Avibactam|IV infusion
108492|NCT01430910|Drug|Ceftazidime|IV infusion
107587|NCT01440777|Behavioral|Go! to Sleep|The online program provides various tools for the delivery of the intervention including:
Daily articles
Daily activities to help get the sleep you need
Daily sleep improvement recommendations
Audio recorded relaxation exercises
Daily e-mails from your program coach
Personal progress charts
An online sleep log and daily sleep score
107588|NCT01440790|Dietary Supplement|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
107589|NCT01440790|Dietary Supplement|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
107590|NCT01440790|Dietary Supplement|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
107591|NCT01433991|Drug|Lenvatinib plus E7050|The recommended dose for the combination of E7050 plus lenvatinib determined from the Dose escalation phase will be given to subjects to confirm it as the MTD. This recommended dose will be used to treat patients with Glioblastoma and Melanoma in later groups in this study.
109775|NCT01454102|Drug|Erlotinib|
109776|NCT01454102|Biological|Ipilimumab|
109777|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
109778|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
109779|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
109780|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
109781|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
109782|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
109783|NCT00068991|Behavioral|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
109784|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
109785|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
109786|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
109787|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
109788|NCT01456273|Procedure|Therapeutic Encounter|Group B (who receive care "Therapeutic Encounter") will be divided in subgroup B1, which will receive the "Drug Therapy Classic" and 2 in group B who received placebo.
109789|NCT01456286|Drug|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
109790|NCT01456299|Drug|Remifentanil 1|"Remifentanil 1": "The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml.
109791|NCT01456299|Drug|Control|The control group, which received an infusion of normal saline
109792|NCT01456299|Drug|Remifentanil 2|"Remifentanil 2": "The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml.
108902|NCT01426425|Device|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
108903|NCT01426438|Drug|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
109504|NCT01453660|Other|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, & urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure & heart rate, including orthostatics & Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, & urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
109505|NCT01453686|Drug|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
109506|NCT01453686|Drug|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
109507|NCT01453712|Radiation|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
109508|NCT00068913|Drug|Dichloroacetate|
109509|NCT01453712|Radiation|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
109510|NCT01453725|Biological|Golimumab|Golimumab 50 mg SC injection every 4 weeks
109511|NCT01453725|Biological|Placebo|Placebo SC injection every 4 weeks
109512|NCT01453738|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
109513|NCT01453738|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
109514|NCT01453751|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The second arm consists of an IV push only with ASCs
109515|NCT01453764|Procedure|Harvesting and Implantation of stem cells|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using the and isolated in the laboratory. The ASCs will be delivered via intravenous injection and intrathecally.
109516|NCT01453777|Procedure|harvesting and implantation of adipose derived stem cells|Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.
109517|NCT01453790|Behavioral|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
109518|NCT01455909|Drug|sitagliptin|sitagliptin oral 100 mg/day
108760|NCT01428713|Drug|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
108761|NCT01428713|Drug|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
108762|NCT01428726|Drug|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
108763|NCT01428739|Device|MRS|Procedure
108764|NCT01428791|Behavioral|Generations older adult membership program|Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:
• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops.
108765|NCT01431352|Drug|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
108766|NCT01431352|Drug|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
107814|NCT01432132|Behavioral|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
107815|NCT01432145|Drug|6-Mercaptopurine|The dose of 6MP will be 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. Tablets should be taken at roughly the same time each day. One cycle is 28 days. Treatment is given continuously (see table below) until disease progression.
107816|NCT01432145|Drug|Methotrexate|Methotrexate (20 mg/m2) will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously (see table below) until disease progression.
107817|NCT01432158|Biological|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
107818|NCT01432158|Biological|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
107819|NCT01432171|Drug|Lacosamide|Starting dose: 50 mg by mouth twice a day.
107820|NCT00001119|Drug|Lamivudine/Zidovudine|
107821|NCT00066677|Biological|bevacizumab|
107822|NCT01432171|Other|Placebo|To be taken by mouth twice daily.
107592|NCT01433991|Drug|E7050 plus lenvatinib or lenvatinib alone plus E7050 add-on therapy|Phase 2 Cohort 1 Arm A: E7050 will be taken once daily for 28 day cycles starting C1D1 in combination with lenvatinib at Recommended phase 2 (RP2) dose Arm B: E7050 at RP2 dose will be added on to single agent lenvatinib at time of disease progression.
107593|NCT01433991|Drug|E7050 plus Lenvatinib|Phase 2 Cohort 2:
Arm C: E7050 will be taken once daily for 28 day cycles starting C1D1 in combination with lenvatinib at Recommended phase 2 (RP2) dose
107594|NCT01433991|Drug|E7050|Phase 2 Cohort 2: Arm D: E7050 will be taken alone at 400 mg daily for 28 day cycles.
107595|NCT00066768|Drug|suramin|Given IV
107596|NCT01434004|Behavioral|Lifestyle counseling|Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.
Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations.
107597|NCT01434017|Drug|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
107598|NCT01434017|Drug|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
107599|NCT01434017|Drug|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
107600|NCT01434030|Behavioral|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
107601|NCT01434069|Drug|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
107602|NCT01434069|Drug|FOLFIRI Infusion|Standard therapy of FOLFIRI
107888|NCT01429818|Drug|Metformin|1000 mg tablets once daily for eight weeks
107889|NCT01429831|Drug|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
107890|NCT01429844|Drug|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
107891|NCT00001118|Drug|Enfuvirtide|
107892|NCT00066456|Radiation|3-Dimensional Conformal Radiation Therapy|
108904|NCT01426438|Drug|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
108905|NCT01426438|Drug|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
108906|NCT01426451|Other|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
108907|NCT01426451|Other|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
108908|NCT01426464|Drug|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
108909|NCT01426490|Dietary Supplement|Vitamin C|Vitamin C, 100 mg/d
108910|NCT00066300|Biological|graft-versus-tumor induction therapy|
108911|NCT01426490|Dietary Supplement|Vitamin B6|Vitamin B6, 50mg/d
108912|NCT01426490|Dietary Supplement|Folic acid|Folic acid 400 microgram/d
108913|NCT01426490|Dietary Supplement|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
108914|NCT01426516|Device|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
108915|NCT01426529|Drug|Para-aminohippuric Acid|Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated "PAH".
108916|NCT01426529|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
108917|NCT01428908|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
108918|NCT01428908|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
109180|NCT01455311|Procedure|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
109181|NCT00069095|Drug|Fluorouracil 400 mg/m^2|
109182|NCT01455311|Procedure|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
109519|NCT00001145|Drug|KLH|
109520|NCT00069108|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
109852|NCT01461447|Biological|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
109853|NCT01461460|Drug|TR-701 FA 1200 mg|6 tablet of T-701 FA
109854|NCT01461460|Drug|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
109855|NCT01461460|Drug|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
109856|NCT01461460|Drug|Placebo|6 placebo tablets
109857|NCT01461473|Device|Positive Airway Pressure|Participants who are randomized to the Positive Airway Pressure treatment group will receive adequate Positive Airway Pressure (PAP) pressure setting through standard clinical polysomnography (PSG) study.
109858|NCT01454115|Drug|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
109859|NCT01454115|Drug|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
109860|NCT01454128|Behavioral|exercise|36 session supervised exercise intervention
109861|NCT01454141|Other|Cognitive Control Training|Three sessions of CCT.
109862|NCT01454141|Other|Peripheral Vision Task|Three sessions of PVT.
109863|NCT01454154|Drug|Glyburide|RP-1127 (Glyburide for Injection) delivered as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
109864|NCT00001145|Drug|Bacteriophage|
109865|NCT00069017|Biological|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
109866|NCT01454154|Drug|Placebo|Placebo delivered as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
109867|NCT01454180|Drug|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.
Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.
Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily
FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.
107823|NCT01432184|Procedure|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
107824|NCT01432197|Other|ADL intervention|1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
107825|NCT01432210|Other|Post-prandial Feeding Study|
107826|NCT01432223|Drug|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
107827|NCT01432236|Drug|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
107828|NCT01432236|Drug|placebo|placebo capsules twice a day for 14 weeks
107829|NCT01432249|Drug|Enbrel group|will be decided by treating physicians
107830|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
107831|NCT00066144|Drug|Cimicifuga racemosa|
107832|NCT01424644|Biological|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.
Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®.
108115|NCT01427647|Procedure|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
108116|NCT01427660|Behavioral|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
108117|NCT01427660|Behavioral|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
108118|NCT01427673|Procedure|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
108119|NCT01427686|Drug|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
108120|NCT01427686|Drug|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
107893|NCT01429844|Drug|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
107894|NCT01429870|Drug|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
107895|NCT01429896|Other|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
107896|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
107897|NCT00066677|Drug|docetaxel|
107898|NCT01432275|Device|Self monitoring blood glucose system|Use the comparator system for 7 days, then the InsuLinx system for 7 days in blood glucose mode only. Then 10 days using the InsuLinx system with insulin calculator.
107899|NCT01432275|Device|Self monitoring blood glucose system|Use the InsuLinx system for 7 days in blood glucose mode only, then use the comparator system for 7 days. Then 10 days using the InsuLinx with insulin calculator.
107900|NCT01432301|Drug|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
107901|NCT01432314|Other|Radiation therapy|A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.
C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).
D. Dose:
i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT.
107902|NCT01432314|Other|Transarterial chemoembolization|A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.
C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop.
107903|NCT01432327|Device|SenseWear display|Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.
The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals.
108183|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
108184|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
108185|NCT01425320|Drug|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
108186|NCT00066170|Drug|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
109183|NCT01455324|Device|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
109184|NCT01455337|Drug|pentoxifylline|400mg tid
109185|NCT01455337|Drug|Prednisolone|40mg qd
109186|NCT01455350|Procedure|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
109187|NCT01455350|Drug|lidocaine|10 weeks of daily topical 5% lidocaine application
109188|NCT01455363|Procedure|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
109189|NCT01455363|Other|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
109190|NCT01455363|Other|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
109191|NCT01455376|Drug|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
109192|NCT00069095|Drug|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
109193|NCT01457703|Drug|Recombinant LH|Used to stimulate ovarian function in women.
109194|NCT01457703|Drug|Letrozole|An aromatase inhibitor.
109195|NCT01457716|Drug|Budesonide|Single inhalation
109196|NCT01457716|Drug|Formoterol|Single inhalation
109197|NCT01457716|Device|Easyhaler|Inhaler device
109198|NCT01457716|Device|Turbohaler Forte|Inhaler device
109199|NCT01457729|Behavioral|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
109200|NCT01457742|Device|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
109201|NCT00069459|Drug|Extended-release Bupropion Hydrochloride|
109202|NCT01457742|Device|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
109446|NCT01455857|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
109868|NCT01454180|Drug|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.
Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.
Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily
FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.
108974|NCT01424306|Other|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
108975|NCT01424306|Other|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
108976|NCT01424306|Other|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
108977|NCT01424319|Drug|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
108978|NCT01424319|Drug|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
108979|NCT01424319|Drug|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
108980|NCT01426529|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
108981|NCT01426542|Drug|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
108982|NCT01426542|Other|No medication, but routine heart surgery|No medication, but routine heart surgery
108983|NCT01426555|Other|FES-Rowing|FES- Rowing Exercise
108984|NCT00066300|Biological|therapeutic allogeneic lymphocytes|
108985|NCT01426555|Drug|Zoledronic acid|5 mg IV single dose
108986|NCT01426568|Behavioral|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
108121|NCT00066365|Biological|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
108122|NCT01427699|Drug|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
108123|NCT01427738|Drug|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
108124|NCT01427738|Drug|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
108125|NCT01427751|Drug|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
108126|NCT01427751|Biological|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
108127|NCT01427764|Device|manual and ultrasonic instruments|The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.
The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®).
108128|NCT01427803|Drug|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
108129|NCT01430312|Drug|Sodium lauryl sulfate|
108130|NCT00066469|Drug|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
108131|NCT01430325|Drug|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
108408|NCT01433172|Biological|GM.CD40L.CCL21 Vaccinations|This is a dual-agent, phase I study with an expansion of each group at the recommended Phase II dose. Eligible patients are enrolled and the study design and treatment. Eligible patients are entered in cohorts of three at the first dose level. Doses are not escalated over the course of treatment of an individual patient.
Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
108409|NCT00066716|Drug|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
108410|NCT01433172|Biological|GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 106 irradiated H1944 tumor cells, 7.5 X 106 irradiated H2122 cells, and containing 15 X 106 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
108187|NCT01425320|Drug|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
108188|NCT01427816|Drug|KCT-0809|
108189|NCT01427816|Drug|KCT-0809|
108190|NCT01427816|Drug|Placebo|
108191|NCT00066365|Procedure|conventional surgery|thoracotomy
108192|NCT01427829|Behavioral|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
108193|NCT01427842|Drug|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
108194|NCT01427855|Other|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
108195|NCT01427855|Other|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
108196|NCT01427855|Other|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
108197|NCT01427855|Other|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
108198|NCT01427855|Other|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
108199|NCT01427855|Other|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
108200|NCT01427868|Drug|LB80380 maleate salt|183 mg (150 mg as a free base)
108493|NCT01430923|Drug|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
108494|NCT01430923|Drug|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
109447|NCT01455857|Other|ITCA placebo|Formulation in DUROS (no exenatide)
109448|NCT01455870|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
109449|NCT01455870|Drug|sitagliptin|oral sitagliptin 100 mg/day
109450|NCT01455883|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
109451|NCT01455883|Drug|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
109452|NCT01455896|Drug|ITCA 650|exenatide in DUROS
109453|NCT01455896|Other|ITCA placebo|placebo in DUROS
109454|NCT01455909|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
109455|NCT01458236|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
109456|NCT00001151|Drug|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
109457|NCT00069550|Drug|dextromethorphan|
109458|NCT01458249|Drug|E7389|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
109459|NCT01458262|Other|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
109460|NCT01458275|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
109461|NCT01458275|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
109462|NCT01458275|Drug|Placebo|Placebo - one actuation per nostril
109463|NCT01458288|Drug|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
109464|NCT01458301|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
109465|NCT01458301|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
109466|NCT01458301|Drug|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
108987|NCT01426581|Behavioral|Teach-To-Goal|Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback" or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
108988|NCT01426581|Behavioral|Brief Intervention|Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
108989|NCT01426607|Device|AMO|
108990|NCT01426620|Dietary Supplement|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
108991|NCT01426633|Drug|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
109254|NCT01455389|Drug|DOTAP:Chol-fus1|Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.
109255|NCT01455389|Drug|Erlotinib|Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.
109256|NCT01455389|Drug|Dexamethasone|8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-fus1 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).
109257|NCT01455389|Drug|Diphenhydramine|50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol FUS1
109258|NCT01455415|Drug|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
109259|NCT01455415|Drug|placebo|matching placebo 3 time a day
109260|NCT01455428|Drug|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
109261|NCT01455428|Drug|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
109262|NCT01455441|Other|Training and liraglutide|
109263|NCT01455441|Other|Training and placebo|
109264|NCT00069095|Drug|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
109265|NCT01455467|Device|One iStent|Implantation of one iStent in conjunction with cataract surgery
109266|NCT01455467|Device|Two iStent|Implantation of two iStent in conjunction with cataract surgery
109267|NCT01455480|Drug|RPh201, botanical drug product|topical
108411|NCT01433185|Other|Text message|Text messages sent to women before and after delivery
108412|NCT01433198|Other|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
108413|NCT01433224|Genetic|DNA methylation analysis|
108414|NCT01433224|Genetic|RNA analysis|
108415|NCT01433224|Genetic|mutation analysis|
108416|NCT01433224|Genetic|nucleic acid sequencing|
108417|NCT01433224|Genetic|polymerase chain reaction|
108418|NCT01433224|Genetic|polymorphism analysis|
108419|NCT01433224|Other|laboratory biomarker analysis|
108420|NCT00066716|Procedure|adjuvant therapy|Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.
Operation will be performed within 6-12 hours from the last dose of celecoxib.
Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.
Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year.
108421|NCT01433224|Other|medical chart review|
108422|NCT01433237|Genetic|RNA analysis|
108423|NCT01433237|Genetic|gene expression analysis|
108424|NCT01433237|Other|laboratory biomarker analysis|
108425|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
108426|NCT01425697|Other|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
108427|NCT01425723|Biological|rFIXFc|Administered as specified in the treatment arm.
107535|NCT01436097|Behavioral|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
107536|NCT01436097|Behavioral|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
108495|NCT01430949|Procedure|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
108496|NCT01430975|Drug|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
108497|NCT00066508|Drug|bortezomib|
108498|NCT01430975|Drug|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
108499|NCT01431001|Device|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
108500|NCT01423448|Other|bulletin board|An asynchronous online bulletin board for people with experience of depression
108501|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
108502|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
108503|NCT01423487|Drug|Metformin|0.5g bid 26 weeks
108504|NCT01423487|Other|Starch tablets|0.5g bid 26 weeks
108505|NCT01423500|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
108506|NCT00066040|Drug|Duraphat fluoride varnish|
108507|NCT01423500|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
108508|NCT01423500|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
108509|NCT01423500|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
108510|NCT01423500|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
108511|NCT01423500|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
108512|NCT01423500|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
108513|NCT01423513|Other|Fibular Taping|Tape with be applied with tension.
108514|NCT01423513|Other|Sham Taping|Tape will be applied without tension
109467|NCT01458301|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
109468|NCT00069550|Drug|donepezil hydrochloride|
109793|NCT01456312|Drug|Peginterferon alfa-2a|Duration and combination
109794|NCT01456312|Drug|Entecavir|combination
109795|NCT01456325|Drug|Placebo|Repeating intravenous dose
109796|NCT00069160|Drug|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
109797|NCT01456325|Drug|erlotinib [Tarceva]|Repeating oral dose
109798|NCT01456325|Drug|onartuzumab [MetMAb]|Repeating intravenous dose
109799|NCT01456338|Behavioral|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
109800|NCT01456338|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
109801|NCT01456351|Drug|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
109802|NCT01456351|Drug|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
109803|NCT01456364|Drug|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
109804|NCT01456364|Drug|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
109805|NCT01456377|Drug|predinose oral|1 mg for kg for 3 wekees
109806|NCT01456377|Drug|placebo group|use a oral placebo
109807|NCT00069160|Drug|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
109808|NCT01456390|Device|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
109809|NCT01456403|Other|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
109810|NCT01456429|Procedure|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
109268|NCT01455493|Drug|GDC-0980|Oral daily dose
109269|NCT01455506|Drug|Decitabine plus Fludarabine and Busulfan|Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient >20% above ideal body weight
Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.
Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.
Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.
Hematopoietic cells will be infused on day 0.
109270|NCT01455519|Drug|Hydromorphone ER|Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
109271|NCT01455532|Drug|Iniparib (SAR240550-BSI-201)|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
109272|NCT01455532|Drug|Gemcitabine|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
109273|NCT01455532|Drug|Carboplatin|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
109521|NCT01455922|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
109522|NCT01455922|Drug|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
109523|NCT01455935|Drug|Anti-platelets and statin|
109524|NCT01455935|Drug|alteplase|Full dose Intravenous thrombolysis
0.9 mg/kg
Maximum dose is 90 mg
10% of the dose will be given over one minute
90% of the dose will be infused over 1 hour
Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications
Neuro checks every 5 minutes during the infusion
Neuro checks every hour after the infusion for 24 hours
109525|NCT01455935|Procedure|intra arterial intervention|Intra arterial Activase (Maximum dose of 22 mg)
MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)
PENUMBRA device (no standard time frame for how long the procedure takes)
109526|NCT01455948|Device|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
109527|NCT01455948|Procedure|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
109528|NCT01455974|Other|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
109529|NCT01456000|Device|EAS-AC (HeartLight)|Pulmonary vien isolation
109530|NCT01456000|Procedure|Control Arm Ablation|Treatment with standard ablation.
107537|NCT01436097|Behavioral|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
107538|NCT01436097|Behavioral|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
107539|NCT01436110|Drug|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
107540|NCT01436110|Drug|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
107541|NCT00066950|Drug|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
107542|NCT01436110|Drug|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
107543|NCT01436123|Other|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
107544|NCT01436123|Device|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
107545|NCT01436136|Other|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
107546|NCT01436136|Other|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
107547|NCT01436149|Drug|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
107548|NCT01436149|Drug|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
107833|NCT01424644|Biological|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.
Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®.
107834|NCT01424657|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography
107603|NCT01434082|Behavioral|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
107604|NCT01434095|Procedure|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
107605|NCT01434108|Drug|Ornithine-phenylacetate|Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.
Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days.
107606|NCT00066768|Drug|docetaxel|Given IV
107607|NCT01434121|Drug|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
107608|NCT01434121|Drug|Placebo|
107609|NCT01429272|Drug|Aspirin|81 mg po bid for 6 weeks
107610|NCT01429272|Drug|placebo|placebo for minocycline and/or aspirin
107611|NCT01429285|Drug|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
107612|NCT01429285|Drug|Usual care|Attending administers any IV opioid in any dose he chooses
107613|NCT01429298|Drug|2 mg IV hydromorphone|2 mg IV hydromorphone
107614|NCT01429298|Drug|Usual care|Attending administers IV opioid of his choosing
107615|NCT01429337|Drug|Midostaurin|Midostaurin 25 mg soft gelatin capsules. The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour-break), from Day 1 to Day 6. On day 7, midostaurine will be administered only in the morning.
107616|NCT01429350|Drug|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
107617|NCT01429350|Device|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
107618|NCT00066417|Procedure|radiation therapy|
107619|NCT01429363|Procedure|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
109811|NCT01456442|Device|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
109812|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
108919|NCT01428921|Behavioral|Theory based education and brief motivation interview|Standard education programme as described above,
Plus
Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration
Follow-up phone call would be arranged within 1 week after using CPAP.
Video, slides and booklets would be used as education media.
108920|NCT01428947|Procedure|Arterial approach|Randomization to right radial or femoral approach
108921|NCT01428960|Dietary Supplement|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
108922|NCT01428973|Drug|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
108923|NCT01428973|Drug|Sirolimus|Tablets. 6 mg loading dose on day −3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
108924|NCT01428986|Drug|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
108925|NCT00001116|Drug|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
108926|NCT00066417|Procedure|leukocyte therapy|
108927|NCT01428999|Dietary Supplement|probiotics|probiotics 1 pack (2g) bid for three weeks
108928|NCT01429012|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
108929|NCT01429012|Other|Culture medium without MSC.|2 ml of culture medium.
108930|NCT01429025|Biological|rituximab|IV
108931|NCT01429025|Drug|bendamustine|IV
108932|NCT01429025|Drug|lenalidomide|PO
109531|NCT00069121|Drug|capecitabine [Xeloda]|1000mg/m2 iv bid on days 1-15 of each 3 week cycle
109532|NCT01456013|Device|RenalGuard Therapy|Induced Diuresis with matched replacement
109533|NCT01456013|Drug|Standard Therapy|Standard of care for patients at risk of CIN
109534|NCT01456026|Dietary Supplement|Glycated beta-lactoglobulins.|oral, 20 g, single administration
109535|NCT01456026|Dietary Supplement|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
109536|NCT01456039|Drug|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
109537|NCT01456052|Drug|500 mg LX1606 QD|500 mg LX1606 administered orally once daily (QD)
109538|NCT01456052|Drug|500 mg LX1606 TID|500 mg LX1606 administered orally three times daily (TID)
109539|NCT01456052|Drug|Placebo|Matching placebo administered orally
109540|NCT01456065|Biological|Procure|The IMP (Investigational Medical Product) consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
109869|NCT01454206|Behavioral|iSBIRT|Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at "high risk" will complete an internet-based program encouraging them to change their substance use.
109870|NCT01454219|Other|Bakery and confectionary products|Control product: Glucose solution, Test products: 11 bakery and confectionary products
109871|NCT01454232|Other|stools sampling|stools sampling at baseline, 1, 3 and 12 months
109872|NCT01454232|Other|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
109873|NCT01454245|Drug|JNJ-39439335|Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
109874|NCT01454245|Drug|JNJ-39439335|Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.
or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.
109875|NCT01454271|Procedure|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
109876|NCT01456442|Device|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
107835|NCT01424657|Procedure|MRCP|magnetic resonance cholangiopancreatography
107836|NCT01424670|Drug|Delamanid|100mg BID for 2 months and 200mg QD for 4 months
107837|NCT01424670|Drug|Placebo|Matching Placebo
107838|NCT01424670|Drug|Optimized Background Regimen (OBR)|• Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
107839|NCT01424670|Drug|Antiretrovirals (ARVs)|• HIV treatment (i.e. ARVs) will be based on WHO guidelines and recommendations, and in compliance with local/national guidelines for HIV in South Africa (each site).
107840|NCT01424709|Drug|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
107841|NCT01424709|Drug|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
107842|NCT00066144|Drug|Trifolium pratense|
107843|NCT01424722|Device|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
107844|NCT01424735|Drug|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
107845|NCT01424748|Dietary Supplement|Tahitian Noni Juice|noni fruit juice
107846|NCT01424748|Dietary Supplement|Placebo|Placebo juice
107847|NCT01424761|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
107848|NCT01424761|Other|Placebo|Placebo :starch
107849|NCT01424774|Drug|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
108132|NCT01430325|Drug|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
108133|NCT01430351|Drug|Temozolomide|150 m/m2 by mouth 1 time each day on alternate weeks on Days 1-7 and Days 15-21 of every 28 day cycle.
108134|NCT01430351|Drug|Memantine|30 mg by mouth twice a day for a 28 day cycle.
108135|NCT01430351|Drug|Mefloquine|250 mg by mouth 1 time a day on Days 1-3 of the first week, then on Monday, Wednesday, and Friday of every week after that for a 28 day cycle.
107620|NCT01429376|Other|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
107904|NCT01432327|Device|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
107905|NCT01432327|Device|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
107906|NCT01432327|Behavioral|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
107907|NCT01432340|Biological|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
107908|NCT00066690|Drug|exemestane|Given orally
107909|NCT01432353|Drug|DFRF4539A|multiple ascending doses
107910|NCT01432366|Other|SC anti-TNF|Subcutaneous (SC) anti-TNF
107911|NCT01432379|Biological|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year
107912|NCT01432405|Drug|Pioglitazone and exenatide|Type 2 diabetic subjects will be randomized to receive either pioglitazone 45 mg daily orally or exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
107913|NCT01424813|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
107914|NCT01424813|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
107915|NCT00066144|Drug|Black cohosh|
107916|NCT01424826|Drug|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
107917|NCT01424826|Drug|Rifampicin|< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days > 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
107918|NCT01424826|Drug|Raltegravir|800 mg bd for 4 days
108933|NCT01429038|Biological|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
108934|NCT01429051|Drug|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
108935|NCT01429051|Drug|Placebo|Matching intranasal placebo spray
108936|NCT01429064|Drug|ODM-201|ODM-201 administered orally daily
108937|NCT00066417|Procedure|non-specific immune-modulator therapy|
108938|NCT01429077|Drug|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
109203|NCT01457781|Drug|Nitric Oxide|0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
109204|NCT01457781|Other|Placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%)
109205|NCT01457781|Drug|Nitric Oxide|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
109206|NCT01457794|Other|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
109207|NCT01457807|Drug|AZD3241 ER formulation 1|Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
109208|NCT01457807|Drug|Placebo|Placebo will be administered with the same intervention scheme as intervention 1 and 2
109209|NCT01457807|Drug|AZD3241 Alternative titration scheme with formulation 1 or 2|50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
109210|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
109211|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
109212|NCT00069498|Drug|5-aminosalicylic acid|
109213|NCT01457820|Drug|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
109214|NCT01457833|Device|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
109877|NCT01456468|Drug|Oral all-trans retinoic acid (ATRA)|The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.
The specific intervention is the addition of daily oral ATRA (45 mg/m^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process.
109878|NCT01456481|Drug|midodrine hydrochloride|Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
109879|NCT01456481|Drug|matching placebo|The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
109880|NCT01456494|Other|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
109881|NCT01456494|Other|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
109882|NCT00069160|Other|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
109883|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
109884|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
109885|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
108992|NCT01426646|Drug|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
108993|NCT01426646|Drug|S-1 plus cisplatin|S-1 plus cisplatin every 3 weeks, a total of eight cycles
S-1: 40mg/m2 orally twice daily (days 1-14)
Cisplatin: 60mg/m2 IV on day 1
108994|NCT01426659|Behavioral|parental stimulation according to protocol|verbal stimulation every day image of the Protocol "Dire et Faire"
108995|NCT00066300|Drug|cyclophosphamide|
108996|NCT01426672|Other|Monovision Correction (with the help of glasses or contact lenses)|
108997|NCT01426698|Procedure|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
108998|NCT01426724|Drug|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
108136|NCT01430351|Drug|Metformin|1000 mg by mouth twice a day for a 28 day cycle.
108137|NCT01430364|Device|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
108138|NCT01430364|Device|BIOSS Lim|
108139|NCT01430364|Device|CarloS|
108140|NCT01430377|Procedure|SB predilatation|Initial SB [predilatation.
108141|NCT00066469|Drug|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
108142|NCT01430377|Procedure|No SB predilatation|Without SB predilatation
108143|NCT01430390|Biological|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells.
108144|NCT01430403|Biological|Omalizumab+Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
108145|NCT01430403|Drug|Fluticasone+Conventional Therapy|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
108146|NCT01430403|Biological|Placebo omalizumab+Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
108147|NCT01430403|Biological|Placebo fluticasone+Conventional Therapy|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
108148|NCT01430416|Drug|AEB071|
108149|NCT01430429|Drug|NI-0801|
108150|NCT01430442|Drug|Placebo matching BMS-927711|Capsule, Oral, 0mg, One time, One dose
108428|NCT01425736|Drug|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
108429|NCT01425736|Drug|Nimotuzumab and Chemotherapy|Nimotuzumab treatment:(200mg/w,18weeks );
Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );
107919|NCT01424839|Radiation|craniospinal irradiation|Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)
Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)
Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
107920|NCT01424839|Drug|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
108201|NCT01427868|Drug|LB80380 free base|150 mg
108202|NCT00066378|Drug|anastrozole|
108203|NCT01427881|Drug|cyclophosphamide|Given IV
108204|NCT01427881|Drug|cyclosporine|Given IV
108205|NCT01427881|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
108206|NCT01427881|Radiation|total-body irradiation|Undergo TBI
108207|NCT01427881|Drug|fludarabine phosphate|Given IV
108208|NCT01427881|Drug|busulfan|Given IV
108209|NCT01427881|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
108210|NCT01427894|Other|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
108211|NCT00066482|Biological|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children < 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
108212|NCT01430442|Drug|BMS-927711|Capsule, Oral, 25mg, One time, One dose
108213|NCT01430442|Drug|BMS-927711|Capsule, Oral, 75mg, One time, One dose
108214|NCT01430442|Drug|BMS-927711|Capsule, Oral, 150mg, One time, One dose
108215|NCT01430442|Drug|BMS-927711|Capsule, Oral, 300mg, One time, One dose
108216|NCT01430442|Drug|BMS-927711|Capsule, Oral, 600mg, One time, One dose
108217|NCT01430442|Drug|Sumatriptan|Capsule, Oral, 100mg, One time, One dose
108218|NCT01430455|Drug|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
109215|NCT01457833|Device|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
109216|NCT01460043|Drug|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
109217|NCT01460069|Drug|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
109218|NCT01460069|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
109469|NCT01458301|Drug|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
109470|NCT01458314|Other|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
109471|NCT01458314|Other|Rehabilitation without NIV|Training in patients without NIV adoption
109472|NCT01458327|Drug|3,4-methylenedioxymethamphetmine (MDMA)|125 mg MDMA followed by 62.5 mg 1.5 to 2.5 hours later
109473|NCT01458340|Drug|TD-9855|Once daily
109474|NCT01458340|Drug|TD-9855|Once daily
109475|NCT01458340|Drug|Placebo|Once daily
109476|NCT01458353|Procedure|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
109477|NCT01458353|Procedure|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
109478|NCT01458366|Drug|Bendamustine|Phase 1: Given via IV at the following dose levels:
Level 1: 70 mg/m2
Level -1: 50 mg/m2
Level 2: 90 mg/m2
Level 3: 120 mg/m2
Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.
109479|NCT00069563|Behavioral|Reaching Educators, Children, and Parents (RECAP)|
109480|NCT01460537|Drug|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
108999|NCT01426737|Drug|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
109000|NCT01429090|Procedure|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
109001|NCT01429090|Drug|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
109002|NCT01429090|Drug|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
109003|NCT01429090|Procedure|Measurement of salivation|Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM "M"® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing
109004|NCT01429090|Procedure|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
109005|NCT01429090|Procedure|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
109006|NCT01429116|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
109007|NCT01429129|Drug|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
109008|NCT00066417|Procedure|peripheral blood lymphocyte therapy|
109009|NCT01429142|Behavioral|Usual care|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
109274|NCT01455532|Drug|Placlitaxel|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
109275|NCT00069108|Drug|5 FU|As prescribed, in 2 week cycles
109276|NCT01455532|Drug|Pegylated liposomal doxorubicin|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
109277|NCT01457846|Drug|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
109278|NCT01457846|Drug|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
109279|NCT01457859|Drug|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
109280|NCT01457859|Other|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
109281|NCT01457872|Behavioral|Strength-based case management|Strength-based case management
108430|NCT00066222|Drug|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
108431|NCT01425749|Biological|recMAGE-A3 + AS15 ASCI|Injections will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
108432|NCT01425762|Other|Drug Dose|100 versus 200 mcg IT morphine
108433|NCT01425775|Drug|vitamin D 25(OH)D|2000IU/day for 12 months
108434|NCT01425775|Other|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
108435|NCT01425788|Biological|Osiris Phleum pratense|
108436|NCT01425788|Biological|Osiris Phleum pratense|
108437|NCT01425788|Biological|Osiris Phleum pratense|
108438|NCT01425801|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108439|NCT01425801|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108440|NCT01425801|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108441|NCT00066222|Drug|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
108442|NCT01425801|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108443|NCT01425801|Drug|Reference|Pressurized inhalation suspension, Once daily , single dose
108444|NCT01425801|Drug|Placebo|Dry powder inhalation or Pressurized inhalation
108445|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108446|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108447|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108448|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
108449|NCT01425814|Drug|Reference|Dry powder inhalation (capsule),single dose
108450|NCT01425814|Drug|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
108219|NCT01430468|Procedure|Glenoid Positioning System|Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
108220|NCT01430481|Dietary Supplement|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
108221|NCT01430507|Drug|Revamilast|Tablet, Low dose, Once daily for 12 weeks
108222|NCT00066482|Biological|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC > 5,000/uL
108223|NCT01430507|Drug|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
108224|NCT01430507|Drug|Revamilast|Tablet, High dose, Once daily for 12 weeks
108515|NCT01423526|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
108516|NCT01423526|Drug|Placebo|Placebo tablets, oral administration, single administrations
108517|NCT00066040|Drug|xylitol gum from Fennobon, Finland|
108518|NCT01423539|Drug|bendamustine|Intravenous repeating dose\n
108519|NCT01423539|Drug|navitoclax|Oral repeating dose\n
108520|NCT01423539|Drug|rituximab|Intravenous repeating dose\n
108521|NCT01423565|Device|Deep Brain Stimulation (Medtronic, Activa PC)|Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently "crossed over" to receive the other type of stimulation
108522|NCT01423578|Behavioral|Hatha Yoga (HY)|3 Sessions of yoga instruction
108523|NCT01423578|Behavioral|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
108524|NCT01423578|Behavioral|Smoking Cessation Counseling|4 smoking cessation counseling visits.
108525|NCT01423591|Drug|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
108526|NCT01423591|Drug|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
108527|NCT00066222|Radiation|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
109481|NCT01460550|Procedure|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
109482|NCT01460550|Procedure|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
109483|NCT00069784|Device|reusable pen device for insulin injection|
109484|NCT01460563|Drug|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
109485|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
109486|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
109487|NCT01460589|Procedure|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
109813|NCT01458691|Procedure|Steroid injection into the glenohumeral joint|Group: Steroid
Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)
The number of injections : only once during the study period
Injection site : glenohumeral joint
Material : 25-gauze spinal needle
The intra-articular injections were performed using ultrasonographic guidance.
109814|NCT01458691|Procedure|Allogeneic PRP injection into the glenohumeral joint|Group: Allogeneic PRP
Total volume of injection drugs: 4ml
The number of injections : only once during the study period
Injection site : glenohumeral joint
Material : 25-gauze spinal needle
The intra-articular injections were performed using ultrasonographic guidance.
109815|NCT01458704|Other|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
109816|NCT01458717|Drug|Neoadjuvant chemoradiation|Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡
4 weeks rest, re-evaluation for resectability
operation
start maintenance chemotherapy within 4~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle
109817|NCT01458717|Procedure|Upfront surgery|Operation at time of diagnosis
Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡
start maintenance chemotherapy within 4~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle
109818|NCT00069615|Device|Continuous Glucose Monitoring System™ (CGMS)|
109819|NCT01458730|Drug|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
109820|NCT01458743|Drug|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
109821|NCT01458743|Drug|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
109282|NCT01457872|Behavioral|Control condition - referral only|Referral only
109283|NCT01457885|Drug|Clofarabine/Busulfan x 4|Clofarabine IV dose level: 40 mg/m2/day x 5 days
Busulfan IV dose level: 3.2 mg/kg daily x 4 days
109284|NCT00069511|Drug|UT-231B|
109285|NCT01457885|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
109286|NCT01457898|Device|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
109287|NCT01457911|Drug|Glimepiride and Metformin hydrochloride combination (HOE490)|Pharmaceutical form:tablet Route of administration: oral
109288|NCT01457911|Drug|Glimepiride (HOE490)|Pharmaceutical form:tablet Route of administration: oral
109289|NCT01457924|Drug|Ofatumumab 3mg|3mg of investigational product
109290|NCT01457924|Drug|Ofatumumab 30mg|30mg of investigational product
109291|NCT01457924|Drug|Ofatumumab 60mg|60mg of investigational product
109292|NCT01457924|Drug|Placebo|Placebo
109293|NCT01457937|Drug|Pegylated Interferon, Ribavirin, Boceprevir|PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)
or
PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)
109294|NCT01457950|Drug|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
109295|NCT00069524|Drug|oyster mushroom|
109296|NCT01457950|Drug|placebo|double-blind phase: placebo subcutaneous injection, single dose
109541|NCT01456065|Biological|Procure|The IMP consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
109542|NCT01458366|Drug|Ofatumumab|Phase II
Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3
Cycles 2 and 3: 1000 mg via IV on Day 1
109543|NCT01458366|Drug|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
109544|NCT01458366|Drug|Etoposide|Phase II: 1000 mg/m2 via IV on Days 1, 2, and 3 of each cycle
109545|NCT01458366|Procedure|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
107549|NCT01436162|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
107550|NCT01438307|Drug|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
107551|NCT00001122|Drug|Nelfinavir mesylate|
107552|NCT00067119|Drug|Clopidogrel|
107553|NCT01438320|Dietary Supplement|Quercetin|Bioflavonoid
107554|NCT01438333|Dietary Supplement|lactobacillus brevis tablets|5 tablets a day for 6 weeks
107555|NCT01438333|Dietary Supplement|PLACEBO|5 tablets a day for 6 weeks
107556|NCT01438346|Behavioral|Substance Abuse Education|10 weeks of usual care for substance abuse.
107557|NCT01438346|Behavioral|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
107558|NCT01438359|Drug|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
107559|NCT01438359|Drug|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
107560|NCT01438359|Drug|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
107561|NCT01438372|Drug|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
107562|NCT01438372|Drug|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
107563|NCT00067132|Procedure|Juven (nutritional), HMB (nutritional)|
107564|NCT01438398|Procedure|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
107565|NCT01438398|Procedure|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
108528|NCT01425827|Drug|placebo|similar looking tablets to the active agent for 16 weeks
108529|NCT01425840|Drug|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
108530|NCT01425853|Drug|Chondroitin/Glucosamine (Droglican)|Experimental
108531|NCT01425853|Drug|Celecoxib|Active comparator
108532|NCT01425866|Behavioral|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
108533|NCT01425879|Drug|Akt Inhibitor MK2206|Given PO
108534|NCT01425879|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
108535|NCT01425879|Other|Pharmacological Study|Correlative studies
107621|NCT01429376|Other|Blood tests|First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).
Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.
Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR.
107622|NCT01429376|Other|Questionnaires|Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.
All questionnaires were completed on the day of initial pulmonary function tests and three months later.
107623|NCT01429376|Other|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
107624|NCT01429402|Drug|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
107625|NCT01429402|Drug|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
107626|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
107627|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
107628|NCT01429415|Drug|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
109822|NCT01458769|Drug|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
109823|NCT01458769|Drug|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
109824|NCT01458769|Drug|C-10297|C-10297 200 mg, oral, single dose
109825|NCT01458769|Drug|C-10299|C-10299 200 mg, oral, single dose
109826|NCT01458769|Drug|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
109827|NCT01458769|Drug|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
109828|NCT01458769|Drug|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
109829|NCT00069628|Device|GlucoWatch® G2™ Biographer (GW2B)|
109830|NCT01458769|Drug|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
109831|NCT01458782|Procedure|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
109832|NCT01458795|Procedure|Endovenous laser ablation|
108939|NCT01429077|Drug|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
108940|NCT01431625|Other|Combined Training (endurance and strength exercises)|All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:
.- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.
- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: "pulls Chest," "Shoulder press," "Butterfly," "Leg extension" and "Leg curls." The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient.
108941|NCT00066625|Drug|bortezomib|Given IV
108942|NCT01431638|Drug|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
108943|NCT01431651|Dietary Supplement|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
108944|NCT01431664|Drug|multikinase inhibitor AT9283|
108945|NCT01431664|Other|laboratory biomarker analysis|
108946|NCT01431664|Other|pharmacological study|
109546|NCT01458366|Procedure|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
109547|NCT01458366|Genetic|Stem Cell Transplant (STC)|For potential transplant candidates:
Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee
Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee
109548|NCT01458379|Drug|Paliperidone Palmitate|Long acting injectable
109549|NCT01458379|Drug|Risperidone|Oral
109550|NCT01458392|Biological|Dalantercept|Subcutaneous dose of dalantercept once every 3 weeks.
109551|NCT01458405|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, intracoronary infusion of 25 Million cardiosphere-derived cells or placebo
109552|NCT00069576|Behavioral|nutritional counseling|
109553|NCT01458418|Drug|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
109554|NCT01458418|Other|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
109555|NCT01458418|Drug|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
109556|NCT01458431|Drug|Levobupivacaine|continuous levobupivacaine subfascial infusion
109557|NCT01458431|Drug|NaCl|continuous NaCl subfascial infusion
109558|NCT01458444|Device|Non invasive ventilation (VNI)|BIPAP® vision
109559|NCT01458444|Device|Non invasive ventilation|OPTIFLOW system
109560|NCT01458457|Other|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
109886|NCT01456520|Drug|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
109887|NCT01456520|Drug|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
109888|NCT01456546|Drug|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
109889|NCT01456546|Drug|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
107566|NCT01438411|Drug|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
107567|NCT01438424|Drug|Entecavir|Tablets, Oral, 1.0 mg, once daily
107850|NCT01424800|Device|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
107851|NCT01427114|Drug|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
107852|NCT01427127|Drug|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
107853|NCT01427140|Other|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
107854|NCT01427140|Other|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
107855|NCT01427153|Procedure|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
107856|NCT01427153|Procedure|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
107857|NCT01427166|Other|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
107858|NCT00066300|Radiation|radiation therapy|
107859|NCT01427192|Drug|acetazolamide|250 mg bid
107860|NCT01427192|Other|Supplemental oxygen|Oxygen deliverded by nasal cannula
107861|NCT01427192|Procedure|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
107862|NCT01427192|Other|Room air|Room air applied via sham oxygen concentrator
107863|NCT01427192|Drug|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
107864|NCT01427205|Drug|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
107865|NCT01427205|Drug|OSI-906|150 mg by mouth twice a day.
107866|NCT01427205|Other|Placebo|Placebo taken by mouth twice daily.
110068|NCT01456819|Biological|Mononuclear cells|Intramuscular administration into the ischemic limb
110069|NCT01456858|Other|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
110070|NCT01459133|Drug|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
110071|NCT01459146|Drug|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
110072|NCT01459146|Drug|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
110073|NCT01459146|Drug|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
110074|NCT01459159|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
110075|NCT01459172|Other|limonene containing massage oil|daily massage application to the breast for 4 weeks
110076|NCT00069654|Procedure|Forearm blood flow study|
110352|NCT01452919|Drug|Placebo|Administered orally
110353|NCT00068783|Other|laboratory biomarker analysis|Correlative studies
110354|NCT01452932|Other|Physiotherapy|The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.
The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.
Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.
The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them.
110355|NCT01452932|Other|Yoga|The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.
The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.
No instruments were needed for this intervention.
110356|NCT01452958|Biological|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
110357|NCT01452958|Biological|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
110358|NCT01452997|Drug|NSAI treatment|Ibuprofen 5% gel
110359|NCT01452997|Drug|Steroid treatment|Steroid intervention with 0.05% w/w clobetasone butyrate.
113595|NCT01467648|Drug|Doripenem|(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.
Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem.
113596|NCT01470170|Drug|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
113870|NCT01470417|Drug|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
113871|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
113872|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
113873|NCT01470456|Drug|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
113874|NCT01470456|Drug|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
113875|NCT01470469|Drug|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
113876|NCT01470469|Drug|Placebo|Once-daily oral dosing in the evening for 12 weeks.
113877|NCT00070265|Procedure|therapeutic conventional surgery|Undergo surgical resection
113878|NCT01470482|Procedure|No use of tourniquet|Tourniquet is not applied i 25 pts
113879|NCT01470482|Procedure|Tourniquet|Use of tourniquet
113880|NCT01470495|Other|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
113881|NCT01470495|Other|RFA|treat Recurrent HCC with RFA
113882|NCT01470508|Behavioral|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
113883|NCT01470508|Behavioral|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
113884|NCT01463423|Procedure|SABR|Standard of Care
113885|NCT01463436|Dietary Supplement|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
110408|NCT01443104|Device|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
110409|NCT01443117|Biological|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
110410|NCT00067860|Behavioral|diet modification|
110411|NCT01443117|Biological|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
110412|NCT01443117|Biological|Placebo Vaccine|Administered as a 0.5 mL IM dose
110413|NCT01443130|Drug|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
110414|NCT01443130|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
110697|NCT01446159|Drug|Aromatase Inhibitor|aromatase inhibitor
110698|NCT00068250|Drug|temozolomide|
110699|NCT01448824|Drug|Placebo|Administered orally
110700|NCT01448824|Drug|Ketoconazole|Administered orally
110701|NCT01448837|Drug|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
110702|NCT01448837|Drug|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
110703|NCT01448850|Biological|MEDI8968 SC for 12 months|Drug
110704|NCT01448850|Biological|Placebo SC for 12 months|Simulated medical intervention
110705|NCT01448863|Other|Culture medium metabolomic analysis|During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.
The frozen media culture is analyzed for the metabolomic profile.
110706|NCT01448889|Drug|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
110707|NCT00068445|Other|Placebo|
110708|NCT01448889|Drug|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
111092|NCT01449565|Drug|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
111093|NCT00068692|Drug|capecitabine|Given orally
111094|NCT01451541|Drug|Placebo|Placebo - one dose per nostril
111095|NCT01451554|Behavioral|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
111096|NCT01451554|Behavioral|Usual Care|self-help booklets
111097|NCT01451567|Behavioral|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
111098|NCT01451580|Drug|Lipo-Dox|
111099|NCT01451593|Drug|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
111100|NCT01451593|Drug|Placebo|placebo identical in appearance to active IMP (phenytoin)
111101|NCT01451606|Drug|Duloxetine|30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
110195|NCT00068757|Other|pharmacological study|
110196|NCT01452724|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
110197|NCT01452737|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Golytely the day prior to procedure.
110198|NCT01452737|Drug|2L Golytely/bisacodyl|Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
110199|NCT01452750|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
110200|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
110201|NCT01452750|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
110202|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
110203|NCT01452750|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
110204|NCT01452750|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
110481|NCT01450813|Drug|Dose 3b|Rocuronium dose 0.4 mg/kg + Remifentanil infusion of 8ng ml-1
110482|NCT00068588|Biological|GTI-2040|Given IV
110483|NCT01450813|Drug|Dose 4b|Rocuronium dose 0.6 mg/kg + Remifentanil infusion of 8ng ml-1
110484|NCT01450826|Drug|Aprepitant|On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
110485|NCT01450826|Drug|Ondansetron|On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
110486|NCT01443143|Dietary Supplement|Usual Diet|During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to "Eat how you would normally eat if you were not in this study."
110487|NCT01443169|Drug|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110488|NCT01443169|Drug|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110489|NCT01443169|Drug|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110490|NCT01443169|Drug|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
110491|NCT00067873|Behavioral|Diet|
110492|NCT01443169|Drug|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
110493|NCT01443169|Drug|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110782|NCT01446250|Drug|DEB025 plus peg-IFN alpha 2a and ribavirin fixed duration treatment|Patients will receive Peg-IFN once weekly injection plus Ribavirin BID plus DEB025 400mg BID for 48 weeks.
110783|NCT01446250|Drug|DEB025 plus peg-IFN alpha 2a and ribavirin response guided treatment duration|Patients will receive Peg-IFN once weekly injection plus Ribavirin BID plus DEB025 400mg BID for either 24 or 48 weeks.
110784|NCT01446250|Drug|Boceprevir plus peg-IFN alpha 2a and ribavirin per label response guided treatment|Patients will receive Peg-IFN once weekly injection plus Ribavirin BID for 4 weeks followed by Peg-IFN once weekly injection plus Ribavirin BID plus boceprevir 800 mg TID for 24, 32 or 44 weeks per boceprevir label.
110785|NCT01446263|Procedure|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
113886|NCT01463436|Dietary Supplement|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
113887|NCT01463449|Procedure|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
113888|NCT00001189|Procedure|radiotherapy|
113889|NCT00070018|Drug|doxorubicin hydrochloride|50 mg/m^2
113890|NCT01463475|Procedure|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
114134|NCT01461694|Device|Intense Pulsed Light (IPL)|Half Face Treated with IPL
114135|NCT01461694|Device|Alexandrite Laser|Half face treated with Alexandrite Laser
114136|NCT01461707|Behavioral|Mobile phone-based physical activity program|Participants in the intervention group will receive an activity monitor and the mobile phone based physical activity intervention.
114137|NCT01461720|Other|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
114138|NCT01461720|Biological|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
114139|NCT01461733|Drug|amiodarone|standard dose amiodarone
114140|NCT01461733|Drug|Placebo|placebo delivered blinded
114141|NCT01461746|Drug|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
114142|NCT01461746|Drug|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
114143|NCT00069927|Drug|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
114144|NCT01461746|Radiation|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
114145|NCT01461759|Drug|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
114146|NCT01461759|Drug|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
114147|NCT01463878|Dietary Supplement|Jevity - Control Diet|Control Diet
114148|NCT01463891|Drug|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
110709|NCT01448902|Drug|OC000459|OC000459 200mg bid for 8 days
110710|NCT01448902|Drug|Placebo|Placebo bid for 8 days
110711|NCT01448915|Behavioral|Contigent voucher incentive (CVI)|Subjects receive vouchers based on adherence to clinical visits and HCV medication.
110712|NCT01448928|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
110713|NCT01448941|Procedure|Temporary extraarticular plate fixation|Arm 1: arthrodesis TMT 1 Arm: 2 temporary extraarticular plate fixation TMT 1
110714|NCT01448954|Drug|ADC3680B oral|Once daily for 28 days
110715|NCT01448954|Drug|Placebo oral|Once daily for 28 days
110716|NCT01448980|Procedure|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
110717|NCT01448980|Procedure|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
110718|NCT00068458|Dietary Supplement|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
110719|NCT01448993|Drug|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
111023|NCT00001135|Drug|Nevirapine|
111024|NCT00068731|Dietary Supplement|lycopene|
111025|NCT01452152|Drug|prasugrel|Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
111026|NCT01444040|Device|iStent inject|Implantation of two iStent inject devices
111027|NCT01444040|Drug|Travoprost|Travoprost drops
111028|NCT01444066|Procedure|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
111029|NCT01444092|Drug|Entocort|Entocort capsules, oral
111030|NCT01444105|Device|iStent|Implantation of two iStent devices
111031|NCT00068029|Drug|Sandostatin LAR|
111032|NCT01444105|Other|SLT|Laser treatment
111033|NCT01444118|Biological|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
110205|NCT01452763|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
110206|NCT00068770|Radiation|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
110207|NCT01454830|Other|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
110208|NCT01454843|Procedure|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
110209|NCT01454843|Procedure|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
110210|NCT01454869|Drug|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
110211|NCT01454869|Drug|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
110212|NCT01454882|Behavioral|Effects of Clothing|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
110213|NCT01454882|Behavioral|Effects of Temperature|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
110214|NCT01454882|Behavioral|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
110473|NCT01450800|Drug|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
110474|NCT01450800|Drug|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
110475|NCT01450813|Drug|Dose 1a|Rocuronium dose 0 mg/kg + Remifentanil infusion of 2ng ml-1
110476|NCT01450813|Drug|Dose 2a|Rocuronium dose 0.2 mg/kg + Remifentanil infusion of 2ng ml-1
110477|NCT01450813|Drug|Dose 3a|Rocuronium dose 0.4 mg/kg + Remifentanil infusion of 2ng ml-1
110478|NCT01450813|Drug|Dose 4a|Rocuronium dose 0.6 mg/kg + Remifentanil infusion of 2ng ml-1
110479|NCT01450813|Drug|Dose 1b|Rocuronium dose 0 mg/kg + Remifentanil infusion of 8ng ml-1
110480|NCT01450813|Drug|Dose 2b|Rocuronium dose 0.2 mg/kg + Remifentanil infusion of 8ng ml-1
110786|NCT00068250|Radiation|radiation therapy|
110787|NCT01446276|Dietary Supplement|Resveratrol|500 mg 3 times daily for six month
110788|NCT01446276|Other|Placebo|1 placebo tablet 3 times daily for six month
110789|NCT01446289|Biological|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
110790|NCT01446289|Biological|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
110791|NCT01446302|Dietary Supplement|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
110792|NCT01446315|Behavioral|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
110793|NCT01446315|Behavioral|Asthma APGAR tools|Usual care
110794|NCT01446328|Drug|Amisulpride|Tablets, dose range 50-1200 mg/ day
110795|NCT01446328|Drug|Aripiprazole|Tablets, dose range 5-30 mg/ day
110796|NCT01446328|Drug|Olanzapine|Tablets, dose range 2.5-20 mg/ day
110797|NCT00068263|Radiation|radiation therapy|
110798|NCT01449032|Biological|MSC|No of cells after culture expansion
110799|NCT01449032|Biological|Saline|3 cc saline
110800|NCT01449045|Drug|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
110801|NCT00068458|Other|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
110802|NCT01449045|Drug|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
111102|NCT01451606|Drug|Placebo|To serve as placebo for duloxetine. Administration schedule same as for active drug.
111103|NCT01451619|Drug|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
111104|NCT00068692|Drug|fluorouracil|Given IV
111105|NCT01451619|Drug|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
111106|NCT01451632|Drug|MM-121 (SAR256212)|MM-121 (SAR256212) (IV) plus Cetuximab (IV) and Irinotecan (IV)
114149|NCT01463904|Procedure|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
114150|NCT00070018|Biological|Indium-111 ibritumomab tiuxetan|5 mCi
114151|NCT01463917|Drug|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
114152|NCT01463917|Drug|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
114153|NCT01463930|Behavioral|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
114482|NCT01462175|Drug|RO5503781|Multiple ascending doses orally, once weekly x 3 followed by 13 days of rest
114483|NCT01462175|Drug|RO5503781|Multiple ascending doses orally, daily x 5 followed by 23 days of rest
114484|NCT01462188|Procedure|Immediate stenting|Primary coronary stenting
114485|NCT01462188|Procedure|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
114486|NCT01462201|Device|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
114487|NCT01462214|Drug|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
114488|NCT01462227|Drug|Naltrexone High Dose|Naltrexone 100mg for two administrations.
114489|NCT01462227|Drug|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
114490|NCT01462240|Device|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
114491|NCT00069953|Drug|paclitaxel|During induction therapy, patients receive 200 mg/m^2/day by IV over 2 hours on days 1 and 29.
114492|NCT01462253|Drug|Clofarabine, Cyclophosphamide|The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
Clofarabine concentrate for solution for infusion should be filtered using a 0.2 micron filter and diluted to a final concentration between 0.15 mg/mL and 0.4 mg/mL with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS), or 5% dextrose injection (D5W) USP or EP prior to infusion.
Cyclophosphamide should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of cyclophosphamide may be injected intravenously without further dilution or may be infused following further dilution: Dextrose Injection, USP (5% dextrose), Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride), 5% Dextrose and Ringer's Injection.
114493|NCT01462266|Drug|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
111034|NCT01444131|Drug|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
111035|NCT01444131|Drug|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
111036|NCT01444144|Other|Fracture union|Retrospective records review post-operatively until fracture resolved.
111037|NCT01444157|Other|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
111038|NCT01444170|Dietary Supplement|dicreatinol sulfate|nutritional supplement
111039|NCT01444170|Drug|placebo sugar pill|
111040|NCT01444183|Behavioral|Focused Attention A|The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.
Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.
111041|NCT01444183|Behavioral|Focused Attention B|The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.
Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.
111042|NCT00068029|Drug|Pegvisomant|
110136|NCT01454830|Behavioral|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
110137|NCT00069095|Drug|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
110138|NCT01456858|Other|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
110139|NCT01456871|Procedure|Guided insertion of electrodes|Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.
110140|NCT01456871|Procedure|Electromyographic (EMG) recording|EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).
110141|NCT01456884|Behavioral|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
110016|NCT01452451|Drug|Placebo|Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
110017|NCT01452464|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
110018|NCT01452477|Drug|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
110019|NCT01452477|Drug|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
110020|NCT01452490|Device|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
110021|NCT01452503|Device|Path Female Condom|comparison between 3 types of female condoms
110022|NCT01452503|Device|FC2 female condom|comparison between 3 types of female condoms
110297|NCT01455025|Drug|Plerixafor granulocyte-colony stimulating factor|Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.
Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5
110298|NCT01455051|Drug|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
110299|NCT00001145|Drug|rhuCD40L|
110300|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
110301|NCT01457183|Device|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
110302|NCT00069316|Drug|Omr-IgG-am|
110303|NCT01457209|Other|Acupuncture|Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.
Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks.
110304|NCT01457222|Behavioral|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
110305|NCT01457222|Behavioral|Music relaxation|Music relaxation 10 minutes daily
111107|NCT01451632|Drug|Irinotecan|MM-121 (SAR256212) (IV) plus Cetuximab (IV) and Irinotecan (IV)
111108|NCT01451632|Drug|Cetuximab|MM-121 (SAR256212) (IV) plus Cetuximab (IV) and Irinotecan (IV)
111109|NCT01451645|Drug|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
111110|NCT01451645|Drug|placebo|daily placebo dosing for 16 weeks
111111|NCT01451645|Drug|allopurinol|background therapy
111112|NCT01451658|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
111113|NCT01451697|Behavioral|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
111114|NCT01451697|Behavioral|Control (Placebo)|The control condition will involve relaxation training.
111115|NCT00068692|Drug|leucovorin calcium|Given IV
111116|NCT01451710|Drug|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
111117|NCT01451723|Drug|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
111118|NCT01444261|Dietary Supplement|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
111119|NCT01444261|Other|control|No dietary supplements
111120|NCT01444274|Device|Obalon Gastric Balloon(s)|One or two balloons administered per patient
111121|NCT01444287|Device|narafilcon B|test product
111122|NCT00001128|Drug|Interleukin-12|
111123|NCT00068042|Drug|Pegvisomant|
111124|NCT01444287|Device|Polymacon|marketed product
114113|NCT01468558|Drug|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
114114|NCT01468558|Drug|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
110360|NCT01453010|Other|Self-directed Upper Limb SaeboFlex Training|Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.
Participants are closely monitored at least once a week by a saebo-trained therapist.
110361|NCT01453023|Drug|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
110362|NCT01453023|Drug|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
110363|NCT01453036|Procedure|23S rRNA point mutation test of Helicobacter pylori|mutation test group>> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group >> no intervention
110364|NCT01448109|Drug|Sterile air filled vial|the "sterile air filled vial" (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days
110365|NCT01448122|Other|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
110366|NCT01448135|Other|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
110367|NCT01448135|Other|Osmolite 1.2|High protein enteral formula
110368|NCT01448148|Other|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
110644|NCT00068601|Drug|goserelin acetate|Given subcutaneously
110645|NCT01451086|Biological|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
110646|NCT01451099|Biological|Autologous cultured dermal cells|A piece of occipital scalp is taken from the subject. The dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
110647|NCT01451112|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
110648|NCT01451125|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
110649|NCT01451138|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
110142|NCT01456884|Behavioral|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
110143|NCT01456897|Drug|OPC-34712|orally administered once daily
110144|NCT01456910|Behavioral|Resistance Training Program|Frequency, volume, repetitions, load, interval
110145|NCT01456923|Other|Treatment with chemotherapy|
110146|NCT00069251|Drug|Bupropion|
110147|NCT01456923|Other|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
110148|NCT01456923|Procedure|surgery|
110149|NCT01456936|Drug|Placebo|Triple dummy placebo for each treatment arm
110150|NCT01456936|Drug|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
110151|NCT01456936|Drug|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
110152|NCT01456936|Drug|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
110153|NCT01456949|Device|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
110154|NCT01456975|Procedure|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
110415|NCT01443143|Other|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
110416|NCT01445626|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
110417|NCT01445639|Drug|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
110418|NCT01445639|Drug|Normal saline|as placebo
110419|NCT01445652|Device|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
110306|NCT01457235|Other|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
110307|NCT01457248|Device|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
110308|NCT01457248|Device|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
110309|NCT01457261|Drug|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
110310|NCT01457274|Other|Sedation depth|The intervention is the depth of sedation targeted in this study.
Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.
It is expected that those patients randomised to "deep" sedation will require a higher dose of sedative medication to achieve their target BIS value (<60) than those in the "light" sedation group (BIS 70-80).
110587|NCT00067912|Drug|Duloxetine Hydrochloride|
110588|NCT01443312|Genetic|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
110589|NCT01443325|Drug|lidocaine patch|1 patch for 12 hours within each 24 hours period
110590|NCT01443338|Drug|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
110591|NCT01443338|Drug|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
110592|NCT01443364|Biological|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
110593|NCT01443377|Biological|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
110594|NCT00001128|Drug|Azithromycin|
110595|NCT00068237|Procedure|Submandibular salivary gland transfer|
110596|NCT01445899|Drug|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
110597|NCT01445899|Drug|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
114115|NCT01468571|Drug|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
114116|NCT01468571|Drug|Placebo|Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.
So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks.
114117|NCT01468584|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
114118|NCT01468584|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
114119|NCT01468584|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
114120|NCT00001202|Drug|Testolactone|
114121|NCT00070200|Drug|topotecan hydrochloride|
114122|NCT01461616|Drug|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
114123|NCT01461616|Drug|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
114124|NCT01461616|Drug|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
114125|NCT01461642|Other|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
114126|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
114127|NCT01461655|Drug|marketed topical NSAID|once daily application, 4 weeks
114128|NCT01461655|Drug|vehicle gel|once daily application, 4 weeks
114129|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
114130|NCT01461668|Drug|Retapamulin|Two times a day for 5 days
114131|NCT01461668|Drug|Placebo|Two times a day for 5 days
114132|NCT00069927|Drug|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
114133|NCT01461681|Procedure|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
110650|NCT01451151|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
110651|NCT01451164|Drug|OPC-34712|orally administered once daily
110652|NCT01451164|Drug|OPC-34712|orally administered once daily
110653|NCT01451164|Drug|OPC-34712|orally administered once daily
110654|NCT01451164|Drug|Placebo|orally administered once daily
110655|NCT00068614|Biological|HER-2/neu peptide vaccine|
110656|NCT01451177|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
110657|NCT01443403|Drug|Placebo once daily|Subjects will receive placebo tablets
110658|NCT01443403|Drug|0.1 mg of S-297995 once daily|Subjects will receive S-297995 tablets and placebo tablets
110659|NCT01443403|Drug|0.2 mg of S-297995 once daily|Subjects will receive S-297995 tablets and placebo tablets
110660|NCT01443403|Drug|0.4 mg of S-297995 once daily|Subjects will receive S-297995 tablets
110661|NCT00001127|Biological|Influenza virus vaccine (CAIV-T)|
110662|NCT00067912|Drug|Venlafaxine Extended Release|
110968|NCT01446549|Procedure|Deep Brain Stimulation|Deep Brain Stimulation implantation
110969|NCT01446562|Biological|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
110970|NCT01446575|Drug|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
110971|NCT01446575|Drug|Placebo controlled|Placebo pill 1 tablet twice daily
110972|NCT01446588|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
110973|NCT00068302|Drug|sirolimus|3-6 subjects will be enrolled into each dose level
110974|NCT01446601|Device|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
110420|NCT01445652|Other|Spectacles|Spectacles per current prescription
110421|NCT01445678|Drug|CXA-201 and metronidazole|CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
110422|NCT01445678|Drug|Meropenem|Meropenem IV infusion (1000mg q8h) for 4-14 days
110423|NCT01445691|Drug|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
110424|NCT00068198|Biological|Dryvax|
110425|NCT01445704|Dietary Supplement|Probiotics|The probiotic supplementation will use lactic acid bacteria in the "ProbioMax DF™" supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05.
110426|NCT01445704|Dietary Supplement|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
110427|NCT01445730|Dietary Supplement|Fructose|fructose drink 75 g/day per day while consuming a self-selected ad libitum diet
110428|NCT01445730|Dietary Supplement|Fructose|3 month fructose diet 75 g/day while consuming isocaloric diet
110429|NCT01445743|Biological|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
110430|NCT01445756|Drug|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
110431|NCT01445756|Drug|Placebo|Placebo; no topical lidocaine administered
110720|NCT01448993|Drug|Placebo|
110721|NCT01449006|Drug|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
110722|NCT01449019|Drug|exendin(9-39)amide|intravenous infusion of exendin(9-39)
110723|NCT01449019|Drug|saline|intravenous infusion of saline
110724|NCT01449019|Other|duodenal meal|duodenal perfusion of a meal
110725|NCT01449019|Other|duodenal saline|duodenal perfusion of saline
110598|NCT01445925|Procedure|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
110599|NCT01445925|Procedure|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
110600|NCT01445925|Drug|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
110601|NCT01445938|Drug|SAR97276A|Pharmaceutical form:solution for injection
Route of administration: intramuscular
110602|NCT01445938|Drug|arthemeter + lumefantrine (ACTs)|Pharmaceutical form:tablet
Route of administration: oral
110603|NCT01445951|Drug|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
110604|NCT01445951|Drug|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
110901|NCT01449188|Other|saline|USP saline IV solution used as placebo for ondansetron IV.
110902|NCT01449201|Drug|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
110903|NCT01449214|Procedure|Ultrasound|Ultrasound-guided technique
110904|NCT01449214|Procedure|Landmarking|Landmark-guided technique
110905|NCT01449240|Other|No treatment|
110906|NCT00068484|Drug|topotecan hydrochloride|Given IV
110907|NCT01449253|Drug|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
110908|NCT01449253|Drug|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
110909|NCT01449266|Drug|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
110910|NCT01449279|Drug|Ipilimumab|Patient specific, calculated, iv
110911|NCT01449279|Radiation|Radiation Therapy|Standard of care
114377|NCT01469013|Drug|LY3009104|Capsules administered orally
114378|NCT01469013|Drug|Placebo|Capsules administered orally
114379|NCT01469013|Drug|LY3009104|Tablets administered orally
114380|NCT01469013|Drug|Placebo|Tablets administered orally
114381|NCT01469026|Radiation|PET/CT or Conventional diagnostics including CT|Radiation:
PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.
CT. iv.contrast medium (Ultravist 370 mg I/ml).
114382|NCT01461954|Drug|FST-100|FST-100
114383|NCT01461954|Drug|FST-100 Vehicle|FST-100 Vehicle
114384|NCT01461967|Drug|Placebo|Single ascending doses
114385|NCT01461967|Drug|RO5508887|Single ascending doses
114386|NCT00069953|Biological|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
114387|NCT01461967|Drug|RO5508887|Single doses
114388|NCT01461980|Biological|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
114389|NCT01461980|Biological|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
114390|NCT01461980|Biological|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
114391|NCT01461993|Biological|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
114392|NCT01461993|Biological|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
114393|NCT01461993|Biological|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
114394|NCT01462006|Drug|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
114395|NCT01462006|Other|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
110975|NCT01446614|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
110976|NCT01446627|Other|There is no intervention for this study|None, no intervention made.
110977|NCT01446640|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10^6 MSCs per kg; intrathecal administration of up to 1x10^6 MSCs per kg.
110978|NCT01446653|Behavioral|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
110979|NCT01446653|Behavioral|Video|Video arm will provide information via documentary video
110980|NCT01446653|Behavioral|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
110981|NCT01446679|Drug|atrovastatin|oral
110982|NCT01446705|Other|Active Health Information Exchange|Patients selected to share data between the VA & external healthcare agencies.
110983|NCT01446718|Biological|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
110984|NCT00001129|Device|Electronic Medication Reminder System|
110985|NCT00068315|Drug|bortezomib|Given IV
110986|NCT01446731|Biological|mRNA transfected dendritic cell|Autologues monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.
5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration).
110987|NCT01449292|Device|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
110077|NCT01459185|Drug|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
110078|NCT01459198|Biological|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10^5 or 10^6 plaque-forming units (PFU), depending on study arm.
110079|NCT01459198|Biological|Placebo vaccine|Given intranasally once at a baseline study visit
110080|NCT01459211|Drug|Lenalidomide & Dexamethasone|Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:
Oral Dexamethasone (20mg daily, days 1-4),
Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity
110726|NCT01451190|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
110727|NCT01451203|Drug|Placebo|Subcutaneous (SC)
110728|NCT01451203|Drug|CZP|SC
110729|NCT01451203|Drug|methotrexate (MTX)|oral
110730|NCT01451229|Drug|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
110731|NCT01451242|Other|no intervention is made|no intervention is made
110732|NCT01451268|Drug|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
110733|NCT01451268|Drug|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
110734|NCT01451294|Drug|Administration of phenylephrine|Phenylephrine: 50-100µg
110735|NCT00068653|Drug|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
110736|NCT01451294|Drug|Administration of ephedrine|Ephedrine: 5- 10 mg
110737|NCT01451320|Drug|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
110738|NCT01451320|Drug|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
110739|NCT01451320|Drug|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
110740|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
111043|NCT01444196|Drug|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
111044|NCT01444209|Radiation|Iodine Implants|Interstitial Radioactive Iodine Implants
111045|NCT01444235|Drug|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
111046|NCT01444235|Drug|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
110912|NCT01451723|Other|Placebo|Matching placebo capsules
110913|NCT01451736|Drug|paliperidone palmitate|long-acting injectable
110914|NCT01451736|Drug|risperidone|oral
110915|NCT01451749|Drug|Shenwu Capsule|1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.
Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months.
110916|NCT01451749|Drug|Donepezil|This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.
Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months.
110917|NCT01451762|Drug|.9 normal saline|.9 normal saline administered before surgery.
110918|NCT01451762|Drug|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
110919|NCT01451762|Drug|50 mg diphenhydramine IV|50 mg diphenhydramine administered IV before surgery
110920|NCT00068692|Drug|irinotecan hydrochloride|Given IV
110921|NCT01451775|Drug|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
110922|NCT01451775|Drug|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
110923|NCT01451775|Drug|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
110924|NCT01451788|Device|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
110023|NCT01452503|Device|Medtech female condom|comparison between 3 types of female condoms
110024|NCT01452516|Device|nanOss Bioactive BVF|NanOss Bioactive, combined with local autograft and bone marrow aspirate,which will be used in the posterolateral gutter
110025|NCT00068744|Radiation|radiation therapy|
110026|NCT01452529|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
110027|NCT01452529|Drug|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
110028|NCT01452542|Drug|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
114396|NCT01462019|Device|Photobiomodulation|the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.
The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions.
114397|NCT00001182|Procedure|current standard of care treatments|
114728|NCT01530737|Drug|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
114729|NCT01530737|Other|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
114730|NCT01530763|Drug|Ceftaroline fosamil|Treatment Group 1:
Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)
Children < 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)
114731|NCT01530763|Drug|Ceftriaxone|Treatment group 2:
75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)
114732|NCT01530763|Drug|amoxicillin clavulanate|Oral Switch for Treatment Groups 1 and 2:
PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)
114733|NCT00076024|Drug|Placebo|5 mg twice daily [bid] continuous dosing
114734|NCT01533038|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
114735|NCT01533038|Procedure|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
114736|NCT01533077|Drug|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
114737|NCT01533077|Drug|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
114738|NCT01533090|Drug|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
114739|NCT01533090|Drug|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
110081|NCT01459237|Drug|Acthrel|Ovine Corticorelin
110082|NCT01459250|Drug|AGO178C|
110083|NCT01459263|Device|ClariVein|Using the ClariVein device, the GSV will be occluded.
110084|NCT01459276|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
110085|NCT01459276|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
110086|NCT01459289|Other|leaflet|
110087|NCT00069654|Procedure|Brachial artery reactivity study|
110088|NCT01459289|Other|counseling and leaflet|
110089|NCT01459315|Drug|dolutegravir|Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
110090|NCT01459328|Radiation|Radiotherapy|Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day
Injected Leucovorin 20 mg/m2/day for 5 days
110091|NCT01459328|Radiation|Radiotherapy|Conventional long course chemo-radiation:
Radiation 50Gy in 25 daily fractions over 5 weeks
Bolus 5 Fluorouracil 350mg/m2/d for 5 days
Injected Leucovorin 20mg in both the first and last (5th) week of radiation
Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks.
110092|NCT01452568|Drug|Aspirin|150mg/daily for three months, starting day after surgery
110093|NCT01452568|Drug|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
110094|NCT01452581|Other|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
110369|NCT01448148|Other|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
110370|NCT00068406|Procedure|conventional surgery|
110371|NCT01448174|Drug|Atorvastatin|Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:
atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or
placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks.
110372|NCT01448200|Drug|PPI-668|capsules
111047|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg once daily
111048|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg bid
111049|NCT01446731|Drug|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
111050|NCT01446744|Radiation|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
111051|NCT01446744|Radiation|palliative radiotherapy|Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:
Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions
Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions
Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions
Liver: 20 Gy in 5 fractions if standard institutional practice
111052|NCT01446757|Procedure|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
111053|NCT01446757|Procedure|control group|No intervention
111054|NCT01446770|Device|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
111055|NCT01446783|Drug|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
111056|NCT01446783|Drug|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
111057|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
111058|NCT00068315|Drug|fludarabine phosphate|Given IV
111059|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
111060|NCT01446809|Drug|Doxorubicin Hydrochloride|Given IV
110155|NCT01457001|Drug|25-OH-D vitamin|
110156|NCT01457014|Device|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
110157|NCT00069264|Drug|E7389|E7389 Dose-escalation starting at 0.25 mg/m^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
110029|NCT01452542|Drug|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
110030|NCT01452555|Behavioral|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
110031|NCT01454518|Procedure|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
110032|NCT01454518|Procedure|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
110033|NCT01454531|Drug|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
110034|NCT01454544|Biological|AIT Tablet|1 tablet per day in 12 months
110035|NCT01454557|Other|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
110036|NCT01454583|Drug|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
110037|NCT01454583|Drug|ACE-I/ARB|
110038|NCT01454583|Drug|No RAS-inhibition|
110039|NCT01454596|Biological|Anti-EGFRvIII CAR transduced PBL|On day 0 (one to four days after the last dose of fludarabine),cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
110040|NCT01454596|Drug|Aldesleukin|IV Aldesleukin(based on total body weight) over 15 minute approximately every eight hours (+/- one hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
110041|NCT00069069|Drug|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
110042|NCT01454596|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
110043|NCT01454596|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
110311|NCT01457300|Other|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
110312|NCT01457339|Drug|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
110313|NCT00069355|Drug|Propranolol|
114740|NCT01533116|Drug|BIA 9-1067|
114741|NCT01533116|Drug|Placebo|
114742|NCT01533116|Drug|levodopa/carbidopa|
114743|NCT01533116|Drug|levodopa/benserazide|
114744|NCT00076336|Drug|Lamivudine|100mg/day oral tablet for 104 weeks
114745|NCT01533129|Drug|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
113829|NCT01465659|Drug|pazopanib hydrochloride|Given PO
113830|NCT01465685|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
113831|NCT01465685|Drug|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
113832|NCT01465685|Drug|Placebo|capsules identical to MDMA or methylphenidate
113833|NCT01465698|Behavioral|Exercise|The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.
The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study
113834|NCT00001191|Drug|Omeprazole|
113835|NCT00070135|Biological|Anti-Thymocyte Globulin|Given IV
113836|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
113837|NCT01467986|Drug|Temozolomide|Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).
Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
113838|NCT01467999|Drug|Guanfacine|Guanfacine, 4mg given once daily
113839|NCT01468012|Drug|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
113840|NCT01468012|Drug|Placebo|matched placebo for LCE condition dosed twice daily
110373|NCT01448200|Drug|Placebo|capsules
110374|NCT01448213|Drug|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
110375|NCT01448213|Drug|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
110376|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
110377|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
110378|NCT01448252|Biological|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
110379|NCT01448252|Biological|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
110380|NCT01448265|Procedure|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
110381|NCT00068406|Radiation|radiation therapy|
110382|NCT01448278|Procedure|"All-inside"|The "All-inside" technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation.
110383|NCT01448278|Procedure|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
110384|NCT01448291|Drug|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
110385|NCT01450631|Device|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
110663|NCT01443416|Biological|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
110664|NCT01443416|Biological|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
110665|NCT01443429|Drug|beraprost sodium(BPS)|
110158|NCT01457014|Device|Continuous positive airway pressure|continuous positive airway pressure
110159|NCT01457014|Device|servo ventilation manual|servo ventilation titrated in manual mode
110160|NCT01459367|Drug|TAK-438|In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
110161|NCT01459367|Drug|TAK-438|In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
110162|NCT01459367|Drug|Lansoprazole|In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks.
110163|NCT01459380|Biological|Bevacizumab|Given IV
110164|NCT01459380|Drug|Carboplatin|Given IV
110165|NCT01459380|Other|Laboratory Biomarker Analysis|Correlative studies
110166|NCT00069654|Procedure|Treadmill exercise test|
110167|NCT01459380|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
110168|NCT01459380|Drug|Veliparib|Given PO
110169|NCT01459393|Drug|5-ALA Photodynamic Therapy|
110170|NCT01459393|Drug|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
110171|NCT01459406|Dietary Supplement|Glucose|500 ml water drink containing 40g glucose
110172|NCT01459406|Dietary Supplement|Fructose|500 ml water drink containing 40g fructose
110173|NCT01459406|Dietary Supplement|Fructan|500 ml water drink containing 40g fructan
110174|NCT01459406|Dietary Supplement|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
110175|NCT01459419|Drug|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
110314|NCT01457339|Drug|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
110315|NCT01457352|Drug|SPARC0921|
110316|NCT01457352|Drug|Placebo0921|
110317|NCT01457391|Behavioral|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
110318|NCT01457391|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
110319|NCT01457391|Behavioral|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
110320|NCT01459601|Drug|Cabergoline|0,5mg per week
110321|NCT01459614|Drug|Gemcitabine|IV at 10mg/m2/min (50 minutes for 500mg/m2) on Days 4 and 11
110322|NCT01459614|Drug|Taxotere|IV on Days 4 and 11
110323|NCT01459614|Drug|Xeloda|orally, twice a day Days 1-14
110324|NCT01459614|Drug|Cisplatin|IV Days 4 and 11
110325|NCT01459627|Other|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
110326|NCT01459627|Other|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
110327|NCT01459640|Drug|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
110328|NCT01459640|Biological|Autologous bone marrow-derived mesenchymal stem cells|Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid "Orthovisc" (3rd injection in a three-weekly injection regimen)
110329|NCT01459666|Drug|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
110330|NCT00001165|Drug|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
110331|NCT00069706|Drug|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
110332|NCT01459666|Drug|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
110605|NCT01445951|Drug|Insulin Aspart in combination with a basal insulin|Injectable insulin
110606|NCT00068237|Radiation|Post-operative radiation therapy|
113841|NCT01468025|Drug|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
113842|NCT01468025|Other|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
113843|NCT00070187|Procedure|peripheral blood stem cell transplantation|
113844|NCT01468025|Drug|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
113845|NCT01468038|Drug|Trazodone|active trazodone and sentra pm-like placebo
113846|NCT01468038|Other|Sentra PM|Active Sentra PM and trazodone-like placebo
113847|NCT01468038|Drug|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
114398|NCT00069953|Drug|cisplatin|During induction therapy, patients receive 15 mg/m^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m^2/day by IV over 1 hour beginning on days 57-61.
114399|NCT01462032|Behavioral|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
114400|NCT01462032|Behavioral|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
114401|NCT01462045|Behavioral|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
114402|NCT01462058|Dietary Supplement|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
114403|NCT01462058|Drug|Placebo|Placebo, daily, 12 weeks
114404|NCT01462097|Behavioral|Aerobic exercise training|12 months of aerobic exercise
114405|NCT00070057|Other|laboratory biomarker analysis|Correlative studies
114406|NCT01464320|Drug|Placebo Comparator|Placebo
114407|NCT01464346|Device|Enlite Sensor|
114408|NCT01464359|Drug|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
114409|NCT01464359|Drug|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m^2 intravenously over 1 hour.
114410|NCT01464359|Radiation|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
110666|NCT01443442|Drug|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
110667|NCT01443442|Drug|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
110668|NCT01443455|Behavioral|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
110669|NCT01443455|Behavioral|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
110670|NCT01443455|Behavioral|delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
110671|NCT01443481|Drug|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
110672|NCT01443494|Other|NE|norepinephine
110673|NCT00067925|Behavioral|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
110674|NCT01443507|Other|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
110675|NCT01446016|Drug|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
110676|NCT00068250|Biological|rituximab|
110988|NCT01449292|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
110432|NCT01445769|Drug|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 & 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10^9/L at wk 12 or ≥ 150 x 10^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets <100 x 10^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level < 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
110433|NCT01445782|Drug|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
110434|NCT01445782|Drug|Placebo|Multiple dose, oral inhalation (nebuliser solution)
110435|NCT00068211|Drug|ILX651|
110436|NCT01445795|Drug|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
110437|NCT01448304|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
110438|NCT01448317|Drug|alirocumab SAR236553 (REGN727) (Solution)|Pharmaceutical form:solution Route of administration: subcutaneous
110439|NCT01448317|Drug|alirocumab SAR236553 (REGN727) (Lyophilized formulation)|Pharmaceutical form:Lyophilized formulation Route of administration: subcutaneous
110440|NCT01448317|Drug|Placebo (Solution)|Pharmaceutical form:solution Route of administration: subcutaneous
110441|NCT01448317|Drug|Placebo (Lyophilized formulation)|Pharmaceutical form:Lyophilized formulation Route of administration: Subcutaneous
110442|NCT01448330|Drug|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
110443|NCT01448343|Device|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
110444|NCT00001131|Drug|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10^6 mIU per day for the entire duration of therapy
110445|NCT00068419|Drug|tamoxifen citrate|Given orally
110446|NCT01448356|Procedure|temperature and humidity|The volunteer is exposed to a controlled environment with a chamber setting of:
25°C and 45% humidity;
25°C and 65% humidity;
30°C and 45% humidity;
30°C and 65% humidity
After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition.
110447|NCT01448369|Device|Blephasteam|10 minute treatment twice daily
110448|NCT01448369|Device|EyeGiene|10 minute treatment, twice daily
110607|NCT01445964|Drug|Atenolol|Atenolol oral administration
110608|NCT01445964|Drug|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
110609|NCT01445964|Drug|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
110610|NCT01445990|Device|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
110611|NCT01446003|Drug|MK-8457|10 x 10-mg capsule twice daily (BID) for 10 days
110612|NCT01446003|Drug|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
110613|NCT01446016|Drug|Taxane|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
110614|NCT01446016|Drug|Taxotere|Chloroquine 250mg po daily together with Taxotere 75 mg/m2 administered intravenously over one hour every three weeks
110615|NCT01446016|Drug|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
110616|NCT01448629|Device|Standard Care|Participants are using their own product and this procedure is called "Standard Care".
Standard Care are the participants own products and may consist of several manufacturer and brand names.
110617|NCT01448629|Device|River|River is a new developed product with Coloplast as manufacturer
110618|NCT01448642|Drug|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
110619|NCT01448642|Drug|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
110620|NCT01448681|Other|No treatment|No treatment
110621|NCT01448694|Other|No treatment|No treatment, only collecting observational data.
110622|NCT01448707|Drug|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
110623|NCT01448707|Drug|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
110624|NCT01448720|Drug|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
110625|NCT00068432|Drug|Gemcitabine Hydrochloride|Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
114411|NCT01464359|Drug|Cyclophosphamide|On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.
Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours.
114412|NCT01464359|Drug|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
114413|NCT01464359|Drug|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if <12 kg) intravenously every 6 hours
114414|NCT01464359|Biological|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
114415|NCT01464359|Biological|Interleukin-2|First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m^2 every other day for a total of 6 doses.
Second Course of IL-2 (day +60):
Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source.
114416|NCT00070070|Biological|BCG vaccine|
114441|NCT01466608|Drug|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
114442|NCT01466634|Procedure|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
114443|NCT01466647|Drug|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
114444|NCT01466660|Drug|Afatinib|afatinib once daily
114445|NCT01466660|Drug|gefitinib|Gefitinib once daily
114446|NCT01466673|Drug|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
114447|NCT01466673|Drug|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
114448|NCT01466686|Radiation|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide.
110989|NCT01449305|Device|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
110990|NCT01449318|Device|Thermal Sensory Analyzer (Senselab)|Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.
To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.
To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C).
110991|NCT01449344|Drug|Rituximab|Rituximab 375mg/m² IV , day 1
110992|NCT00068484|Drug|bortezomib|Given IV
110993|NCT01449344|Drug|High dose Ara-C|Ara-C 2000 mg/m² (patients >65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
110994|NCT01449344|Drug|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
110995|NCT01449344|Drug|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
110996|NCT01449357|Drug|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
110997|NCT01449370|Drug|MLN1117|oral administration of MLN1117, daily and intermittent schedules.
110998|NCT01449383|Dietary Supplement|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
110999|NCT01449383|Dietary Supplement|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
111000|NCT01449396|Other|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
111001|NCT01449396|Procedure|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
111002|NCT01449396|Procedure|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
111003|NCT00068484|Other|pharmacological study|Correlative studies
111004|NCT01449409|Other|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
111005|NCT01449422|Device|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
110449|NCT01448369|Device|Hot compresses|10 minute treatment, twice daily
110450|NCT01448382|Device|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
110741|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
110742|NCT01451333|Drug|Efavirenz|600mg qd; 3 x 200mg qd
110743|NCT01451333|Drug|Efavirenz|400mg qd; 2 x 200mg
110744|NCT01451346|Dietary Supplement|B. Infantis 35624|One sachet daily for 12 weeks
110745|NCT01451359|Device|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
110746|NCT00068653|Drug|ZD1839|ZD1839 250 mg po every day, taken with or without food.
110747|NCT01451385|Drug|COV795|2 tablets COV795 taken every 12 hours
110748|NCT01451398|Drug|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
110749|NCT01451398|Drug|Technosphere Powder|Placebo Comparator
110750|NCT01451411|Drug|Conivaptan hydrochloride|Intravenous
110751|NCT01443520|Drug|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
110752|NCT01443520|Drug|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
110753|NCT01443520|Drug|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
110754|NCT01443533|Behavioral|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
110755|NCT01443546|Drug|HCG|hCG Trigger
110756|NCT01443546|Drug|Lupron Trigger|leuprolide acetate 2 mg SQ
110757|NCT01443546|Drug|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
110758|NCT01443559|Genetic|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
110759|NCT01443559|Genetic|homogenic cornea|homogenic corneas were sterilised by radiation
110760|NCT00067938|Drug|lamotrigine|Lamotrigine
110925|NCT01451801|Biological|Twinrix|A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.
Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin.
110926|NCT01451814|Behavioral|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
110927|NCT01451814|Drug|Nicotine polacrilex|8 weeks of nicotine patch
110928|NCT01451814|Behavioral|Relaxation training|Instructions in progressive muscle relaxation
110929|NCT01451814|Behavioral|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
110930|NCT01451827|Drug|Tolvaptan MR|50/80 mg capsules
110931|NCT00068692|Drug|oxaliplatin|Given IV
110932|NCT01451827|Drug|Tolvaptan IR|60/30 mg capsules
110933|NCT01451827|Drug|Placebo|tablet
110934|NCT01451840|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
110935|NCT01451840|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
110936|NCT01451853|Drug|SPI-1005 Low Dose|Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Arms: Low Dose
Other Names:
200 mg Ebselen
110937|NCT01443871|Other|Pure water|Subject will assigned inhale Pure water
110938|NCT01443884|Dietary Supplement|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
110939|NCT01443884|Dietary Supplement|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
110940|NCT01443897|Dietary Supplement|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
110941|NCT01443897|Dietary Supplement|placebo capsule|0 IU vitamin D2
110942|NCT01443897|Other|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
114449|NCT01466686|Drug|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
114450|NCT00070174|Drug|cytarabine|
114451|NCT01469039|Drug|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
114452|NCT01469039|Drug|Placebo|Placebo for IM injection, given monthly
114453|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
114454|NCT00070213|Drug|capecitabine|
114455|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
114456|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
114457|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
114458|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
114459|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
114460|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
114746|NCT01533129|Drug|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
114747|NCT01533142|Procedure|Bariatric surgery|Patients will be treated with one of two bariatric procedure::
sleeve gastrectomy or gastric bypass
114748|NCT01533142|Procedure|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
114749|NCT01533155|Drug|Nektar 118|Oral 25 mg tablet
114750|NCT01533155|Drug|Quinidine|Oral 200 mg tablet
114751|NCT01533155|Drug|Quinidine placebo|Oral Tablet
114752|NCT01533155|Drug|Morphine|10 mg/ml, intravenously
114753|NCT01533168|Genetic|cytogenetic analysis|
114754|NCT01533168|Genetic|nucleic acid sequencing|
110095|NCT01452581|Drug|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
110096|NCT01452594|Drug|Diphenylcyclopropenone|Topical administration
110097|NCT00068757|Biological|trastuzumab|
110098|NCT01452594|Drug|Placebo|Placebo
110099|NCT01452607|Drug|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
110100|NCT01452607|Drug|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
110101|NCT01452633|Drug|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
110102|NCT01452633|Drug|Saline will be injected at the study port site prior to incision|Injection will precede incision
110103|NCT01452633|Drug|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
110104|NCT01452633|Drug|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
110105|NCT01452646|Other|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
110106|NCT01452659|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
110107|NCT01452659|Drug|TAK-385|TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
110108|NCT00068757|Drug|lonafarnib|
110109|NCT01452659|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
110110|NCT01452659|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
110111|NCT01452672|Radiation|Radiotherapy|RT 40 Gy in 15 fractions
110112|NCT01452672|Radiation|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
110113|NCT01452685|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
110761|NCT01443572|Drug|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
110762|NCT01443572|Drug|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
111061|NCT01446809|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
111062|NCT01446809|Drug|Ifosfamide|Given IV
111063|NCT01446809|Other|Laboratory Biomarker Analysis|Correlative studies
111064|NCT01446809|Drug|Pazopanib Hydrochloride|Given PO
111065|NCT01446809|Other|Pharmacological Study|Correlative studies
111066|NCT01446809|Other|Placebo|Given PO
111067|NCT01446809|Procedure|Therapeutic Conventional Surgery|Undergo surgery
111068|NCT01446822|Device|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
111069|NCT00068315|Biological|rituximab|Given IV
111070|NCT01449422|Device|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
111071|NCT01449435|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
111072|NCT01449448|Drug|Ketorolac|Subacromial injection
111073|NCT01449448|Drug|Triamcinolone|Subacromial Injection
111074|NCT01449461|Drug|AP26113|30 mg tablet(s) taken orally and increasing in increments until the maximum tolerated dose (MTD) is identified
111075|NCT01449474|Device|Patient matched instruments|The patients undergo TKA with using patient matched instruments
111076|NCT01449474|Device|Jig based instruments|The patients undergo TKA with using jig based instruments
111077|NCT01449487|Drug|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
111078|NCT00068484|Other|laboratory biomarker analysis|Correlative studies
110943|NCT01443897|Other|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
110944|NCT01443897|Other|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
110044|NCT01454609|Drug|0.9% Normal saline|Saline
110045|NCT01454609|Drug|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
110046|NCT01454609|Device|Bupivacaine with clonidine (combination)|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
Clonidine - 0.5 - 1 microgram/ kg
110047|NCT01454622|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
110048|NCT01454622|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
110049|NCT01454635|Drug|Sertraline|dosage,frequency and duration
110050|NCT01454661|Dietary Supplement|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
110051|NCT01454661|Dietary Supplement|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
110052|NCT00069082|Drug|Civamide (Zucapsaicin)|Nasal Solution 0.01%
110053|NCT01456728|Dietary Supplement|Progastria|All subjects will receive 2 x 20 mg omeprazole per day for 28 days.
L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days.
110054|NCT01456728|Dietary Supplement|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
110055|NCT01456741|Procedure|EBNA with ROSE|The patients in this arm will undergo:
A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation
B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed
C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography
114755|NCT00076336|Drug|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
114756|NCT01533168|Other|diagnostic laboratory biomarker analysis|
114757|NCT01533168|Other|laboratory biomarker analysis|
114758|NCT01533168|Other|medical chart review|
114759|NCT01526486|Procedure|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
114760|NCT01526499|Drug|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
114761|NCT01526499|Drug|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
114762|NCT01526512|Drug|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
114763|NCT01526525|Drug|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
114764|NCT01526525|Drug|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
114765|NCT01526525|Drug|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
114766|NCT01526525|Drug|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
114767|NCT00075699|Drug|vincristine sulfate|
113848|NCT01468038|Drug|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
113849|NCT01468051|Biological|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
113850|NCT01468051|Biological|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
113851|NCT01468064|Genetic|Autologous BMSCs transplantation|The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.
The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.
110114|NCT01452685|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
110115|NCT01452685|Drug|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
110386|NCT01450631|Device|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
110387|NCT00001133|Drug|Indinavir sulfate|
110388|NCT00068575|Drug|Cisplatin|30 mg/m^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
110389|NCT01450644|Other|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
110390|NCT01450657|Dietary Supplement|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 & 4, three capsules three times daily (270 CFU's). Months 5 & 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 & 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
110391|NCT01450670|Dietary Supplement|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
110392|NCT01450683|Drug|Itraconazole|600 mg/day oral (PO)
IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
110393|NCT01450696|Drug|capecitabine|1600 mg/m2 orally daily Days 1-14 of each 3-week cycle, 6 cycles
110394|NCT01450696|Drug|cisplatin|80 mg/m2 iv on Day 1 of each 3-week cycle, 6 cycles
110395|NCT01450696|Drug|trastuzumab [Herceptin]|8 mg/kg iv loading dose, followed by 6 mg/kg iv every 3 weeks
110396|NCT01450696|Drug|trastuzumab [Herceptin]|8 mg/kg iv loading dose, followed by 10 mg/kg iv every 3 weeks
111079|NCT01449487|Drug|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
111080|NCT01449500|Dietary Supplement|L. reuteri|Chewable tablet, one tablet/day for 28 days
111081|NCT01449500|Dietary Supplement|Placebo|Chewable tablet, one tablet per day for 28 days
111082|NCT01449513|Drug|Ingenol mebutate|0.05% Ingenol mebutate Gel once daily for 2 consecutive days
111083|NCT01449513|Drug|Placebo Gel|Gel vehicle of PEP005
110176|NCT01459419|Drug|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
110177|NCT00069706|Drug|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
110178|NCT01459432|Other|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
110179|NCT01459445|Drug|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
110180|NCT01459458|Behavioral|Family Planning-based Partner Violence Intervention|The intervention includes three major components:
Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.
Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.
Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed.
110181|NCT01452685|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
110182|NCT01452685|Drug|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
110183|NCT01452698|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
110184|NCT00068757|Drug|paclitaxel|
110185|NCT01452698|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks.
110186|NCT01452698|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks.
110187|NCT01452698|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
110056|NCT00069238|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
110057|NCT01456741|Procedure|standard EBNA|The patients in this arm will undergo:
A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.
B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed
C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography
110333|NCT01459679|Device|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
110334|NCT01459679|Device|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
110335|NCT01459679|Device|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
110336|NCT01459679|Drug|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
110337|NCT01459692|Other|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
110338|NCT01459705|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
110339|NCT01459705|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
110340|NCT01459705|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
110341|NCT01459718|Drug|Deferasirox|Deferasirox monotherapy treatment of intensive iron chelation treatment. Medication label will comply with the Greek legal requirements and be printed in Greek. A subject identifier will be entered on the medication label.
110342|NCT00069706|Drug|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
110343|NCT01459718|Drug|Deferasirox + Deferoxamine|Deferasirox-DFO regimen for intensive iron chelation treatment. Medication labels will comply with the Greek legal requirements and will be printed in Greek. A subject identifier will be entered on the medication label.
110344|NCT01452867|Device|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
110345|NCT01452880|Drug|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
110346|NCT01452880|Drug|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
113852|NCT01468064|Genetic|Autologous EPCs transplantation|The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.
The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.
113853|NCT01468064|Genetic|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
113854|NCT00070200|Biological|filgrastim|
113855|NCT01468077|Drug|Tocilizumab|8 mg/kg infusion
113856|NCT01468103|Procedure|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
113857|NCT01468103|Procedure|Laser Iridotomy|alternative choice to surgical iridectomy
113858|NCT01468129|Other|Cell Saver|
113859|NCT01470339|Drug|duloxetine|duloxetine 60mg once a day for 5 weeks
113860|NCT01470352|Drug|Doluxetine|30 mg/d
113861|NCT01470352|Drug|Placebo|suger pill 30mg/d
113862|NCT01470365|Procedure|quality-of-life assessment|Ancillary studies
113863|NCT01470365|Radiation|intensity-modulated radiation therapy|Undergo IMRT
113864|NCT01470365|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
113865|NCT01470378|Procedure|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
113866|NCT00070265|Drug|capecitabine|Given orally
113867|NCT01470391|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
113868|NCT01470391|Procedure|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
113869|NCT01470417|Drug|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
114417|NCT01464372|Device|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
114418|NCT01464372|Device|Sham Nerve Stimulation Device|Use of the sham device
114419|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
110397|NCT01450709|Dietary Supplement|Kibow Biotics|6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
110398|NCT01450722|Procedure|bypass surgery, stent placement|bypass surgery, stent placement
110399|NCT00068575|Drug|Fluorouracil|175 mg/m^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
110400|NCT01443065|Drug|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
110677|NCT01446029|Device|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
110678|NCT01446042|Drug|Testosterone|Intranasal testosterone
110679|NCT01446042|Drug|Testosterone|Intranasal testosterone
110680|NCT01446055|Device|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
110681|NCT01446055|Device|Ficoll conventional cell processing method|Comparison of different cell processing methods
110682|NCT01446068|Dietary Supplement|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
110683|NCT01446081|Behavioral|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
110684|NCT01446094|Drug|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
110685|NCT01446107|Other|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
110686|NCT01446107|Other|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
110687|NCT00068250|Drug|methotrexate|
110688|NCT01446107|Other|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
110689|NCT01446107|Other|placebo control|application of water onto tooth surface every year
110690|NCT01446120|Drug|NPH-Insulin Injection|
110188|NCT01452711|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
110189|NCT01452711|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
110190|NCT01452711|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
110191|NCT01452711|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
110192|NCT01452724|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
110193|NCT01452724|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
110194|NCT01452724|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
110451|NCT01448395|Drug|[14C]NXL104|500mg/100mL intravenous solution
110452|NCT01448421|Device|SMT Embolic Deflection Device|The SMT Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
110453|NCT01448434|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
110454|NCT01448434|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
110455|NCT01448447|Device|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
110456|NCT00068419|Drug|sulindac|Given orally
110457|NCT01448447|Device|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
110458|NCT01448473|Other|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
110459|NCT01448473|Other|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
110460|NCT01448486|Drug|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
110461|NCT01450722|Procedure|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
110462|NCT01450735|Device|MANOS CTR™|The MANOS device is a carpal tunnel blade used to release the transverse carpal ligament in order to provide relief for Carpal Tunnel Syndrome.
110463|NCT01450748|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
110347|NCT01452893|Procedure|Spiroergometry|At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.
At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP).
110348|NCT01452906|Drug|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
110349|NCT01452906|Drug|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
110350|NCT01452906|Drug|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
110351|NCT01452919|Drug|LY2140023|Administered orally
110626|NCT01448733|Drug|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
110627|NCT01448746|Drug|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
110628|NCT01448759|Other|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
110629|NCT01448772|Drug|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
110630|NCT01448772|Drug|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
110631|NCT01448785|Device|abiliti system implant|Subjects will receive implanted abiliti System.
110632|NCT01448785|Device|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
110633|NCT01448798|Procedure|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
110634|NCT01448798|Procedure|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
110635|NCT01448811|Device|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI＞40, titrate up propofol dosage, AAI＜25, titrated down propofol dosage.
110636|NCT00068445|Drug|lamotrigine|
110637|NCT01448811|Procedure|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
110638|NCT01448824|Drug|LY2484595|Administered orally
114420|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237 mL
114421|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
114422|NCT01464398|Behavioral|Stress reduction|8 weekly sessions
114423|NCT01464398|Behavioral|Stress reduction with Health education|8 weekly sessions
114424|NCT01464424|Drug|Travoprost 0.004% ophthalmic solution|
114425|NCT01464424|Drug|Bimatoprost 0.01% ophthalmic solution|
114426|NCT01464437|Drug|AMG 151|Drug: AMG 151 50 mg BID
114427|NCT00070070|Biological|NY-ESO-1 peptide vaccine|
114428|NCT01464437|Drug|Placebo|Placebo
114429|NCT01466504|Procedure|skin punch biopsy|Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.
114430|NCT01466517|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
114431|NCT01466517|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
114432|NCT01466530|Drug|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
114433|NCT01466530|Drug|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
114434|NCT01466543|Drug|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
114435|NCT01466543|Drug|Placebo|Placebo
114436|NCT01466556|Other|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
114437|NCT01466569|Drug|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
114438|NCT01466569|Drug|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
114439|NCT00070174|Drug|cyclosporine|
114440|NCT01466595|Drug|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
114461|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
110691|NCT01446120|Drug|Insulin loaded Orally Dissolved Films (insulin-ODF|
110692|NCT01446133|Drug|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
110693|NCT01446133|Drug|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
110694|NCT01446146|Behavioral|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
110695|NCT01446146|Behavioral|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
110696|NCT01446159|Drug|MEDI-573|MEDI-573
111006|NCT01451970|Other|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
111007|NCT01451996|Drug|Claritin|Subject will be given 10mg Claritin tablet.
111008|NCT01452009|Drug|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
111009|NCT01452009|Drug|TRAVATAN®|TRAVATAN® administered one drop once daily
111010|NCT01452022|Device|Inductigraft|Synthetic bone graft
111011|NCT01452035|Other|Exercise|single session of exercise
111012|NCT00068718|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
111013|NCT01452074|Other|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
111014|NCT01452074|Other|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
111015|NCT01452087|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
111016|NCT01452100|Drug|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
110464|NCT01450748|Drug|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
110465|NCT01450761|Biological|Ipilimumab|
110466|NCT01450761|Biological|Placebo matching Ipilimumab|
110467|NCT01450761|Drug|Etoposide|
110468|NCT01450761|Drug|Cisplatin|
110469|NCT01450761|Drug|Carboplatin|
110470|NCT01450774|Drug|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
110471|NCT00068575|Radiation|Radiation Therapy|External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
110472|NCT01450774|Drug|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
110763|NCT01443585|Device|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
110764|NCT01443624|Drug|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
110765|NCT01443650|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
110766|NCT01443663|Biological|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
110767|NCT01443676|Drug|Bevacizumab|Bevacizumab will be added to radiotherapy
110768|NCT01443676|Radiation|Radiation therapy|Radiation therapy
110769|NCT01443689|Biological|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
110770|NCT01443689|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
110771|NCT00067951|Drug|rosiglitazone/metformin|
110772|NCT01443689|Drug|Conventional therapy|Participants will be given conventional therapy only.
110773|NCT01443702|Drug|Lapis Judaicus|2 g capsule per day.
110774|NCT01443702|Drug|Placebo|2 g capsule per day.
110639|NCT01451047|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
110640|NCT01451060|Drug|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
110641|NCT01451060|Drug|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
110642|NCT01451073|Biological|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
110643|NCT01451086|Biological|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
110945|NCT00067990|Drug|Losartan|For the first 14 days after subject is randomized they will take 50mg of losartan. After the 14 days the dose will be increased to 100mg of losartan daily.
110946|NCT01443923|Drug|Boceprevir|
110947|NCT01443923|Drug|Peg-Interferon-alfa 2B|
110948|NCT01443923|Drug|Ribavirin|
110949|NCT01443936|Biological|Ad4-H5-VTN vaccination-tonsillar route|
110950|NCT01443936|Biological|Ad4-H5-vaccination-oral route|
110951|NCT01443962|Other|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
110952|NCT01443962|Other|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
110953|NCT01443975|Procedure|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
110954|NCT01443988|Device|iStent|Implantation of two iStent devices
110955|NCT01443988|Drug|Travoprost|Travoprost drops
110956|NCT00068029|Drug|Pegvisomant/ Sandostatin LAR|
110957|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
110958|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
110959|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
114462|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
114463|NCT01469065|Drug|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
114464|NCT01469065|Drug|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
114465|NCT00070213|Drug|fluorouracil|
114466|NCT01469078|Drug|Monofer®|Single Bolus Injections
114467|NCT01469091|Behavioral|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
114468|NCT01469104|Other|3 day fast|Subjects will fast for 72 hours
114469|NCT01469104|Other|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
114470|NCT01469117|Other|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
114471|NCT01469130|Drug|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
114472|NCT01469143|Drug|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
114473|NCT01469143|Drug|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
114474|NCT01469156|Drug|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
114475|NCT01469169|Drug|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
114476|NCT01462097|Behavioral|Health Education|12 months of health education sessions
114477|NCT01462123|Other|endoscopic assessment of colonic polyps|
114478|NCT01462136|Drug|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
114479|NCT01462149|Drug|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
114480|NCT00069953|Drug|fluorouracil|During induction therapy, patients receive 650 mg/m^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
111017|NCT01452100|Other|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
111018|NCT01452113|Drug|Vildagliptin|one 50 mg tablet per os
111019|NCT01452126|Drug|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
111020|NCT01452139|Genetic|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19*2 & ABCB1 3435 TT)
111021|NCT01452139|Drug|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
111022|NCT01452152|Drug|clopidogrel|clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
110116|NCT01454661|Dietary Supplement|Placebo|Microcrystalline cellulose is used as placebo.
110117|NCT01454674|Other|2, 5 & 10 Vegetable doses|2,5 & 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers & tomatoes consumed for 3 week intervals
110118|NCT01454687|Procedure|Grafting of Autologous Cultured Revertant Keratinocytes|Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas
110119|NCT01454700|Device|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
110120|NCT01454700|Other|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
110121|NCT01454726|Other|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
110122|NCT01454726|Other|drug|the Western medical treatment alone.
110123|NCT01454739|Drug|rFVIIIFc|Administered as specified in the treatment arm.
110124|NCT01454752|Drug|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
110125|NCT01454752|Other|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
110126|NCT00069082|Drug|Sodium Chloride|Nasal Solution 10%
110127|NCT01454765|Other|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
110775|NCT01443715|Behavioral|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
110776|NCT01446185|Device|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
110777|NCT01446211|Drug|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
110778|NCT01446211|Drug|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .
Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).
110779|NCT01446224|Drug|Pazopanib|Patients treated with pazopanib
110780|NCT01446224|Drug|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
110781|NCT01446237|Other|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
111084|NCT01449526|Device|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
111085|NCT01449526|Device|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
111086|NCT01449539|Drug|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
111087|NCT01449552|Drug|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
111088|NCT01449552|Procedure|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
111089|NCT00068497|Drug|gefitinib|Given orally
111090|NCT01449552|Other|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
111091|NCT01449552|Other|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
110960|NCT01444014|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
110961|NCT01444027|Behavioral|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
110962|NCT00068289|Drug|bortezomib|
110963|NCT01446510|Other|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
110964|NCT01446523|Drug|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
110965|NCT01446523|Drug|Lactulose|Syrup 30 ml BD for 12 weeks
110966|NCT01446536|Other|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
110967|NCT01446549|Other|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
110058|NCT01456754|Dietary Supplement|low feeding frequency (3x)|3 meals a day
110059|NCT01456754|Dietary Supplement|High feeding frequency (14x)|14 meals a day
110060|NCT01456767|Dietary Supplement|Probiotics|Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10^11 life bacteria are consumed by each participant.
Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells.
110061|NCT01456780|Drug|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
110062|NCT01456780|Drug|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
110063|NCT01456780|Drug|Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops|Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.
110064|NCT01456793|Behavioral|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
110065|NCT01456806|Other|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
110066|NCT01456819|Biological|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
110067|NCT00069238|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
114481|NCT01462149|Drug|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
113579|NCT01467505|Drug|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
113580|NCT01467518|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
113581|NCT01467518|Drug|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
113582|NCT01467531|Drug|Dolutegravir|50mg q 24h
113583|NCT01467531|Drug|Rlipivirine|25mg q24h
113584|NCT01467531|Drug|GSK1265744|30mg q24h
113585|NCT01467544|Other|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
113586|NCT01467557|Device|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
113587|NCT01467557|Device|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
113588|NCT01467570|Dietary Supplement|oral rehydration solution Hipp ORS Apple 200|Volume of the solution calculated by weight:
fast oral rehydration in 3-4 hours by mouth
ORS given for ongoing losses until diarrhea stops (maintenance phase)
113589|NCT00070187|Drug|cytarabine|Given IV
113590|NCT01467570|Dietary Supplement|ESPGHAN ORS|Volume of the solution calculated by weight:
fast oral rehydration in 3-4 hours by mouth
ORS given for ongoing losses until diarrhea stops (maintenance phase)
113591|NCT01467583|Drug|Fondaparinux|2.5 mg every 48 hours
113592|NCT01467596|Device|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
113593|NCT01467622|Procedure|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
113594|NCT01467635|Device|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
110128|NCT01454778|Drug|Paclitaxel|Paclitaxel coating in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
Paclitaxel Dosage:
Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon* Popliteal: 1.8 mg/inflation of balloon* Tibial: 1.4 mg/inflation of balloon*
not to exceed 10mg total dose
110129|NCT01454791|Drug|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
110130|NCT01454791|Other|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
110131|NCT01454804|Drug|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
110132|NCT01454804|Drug|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
110133|NCT01454804|Drug|Trastuzumab (Herceptin®)|4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.
Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase
110134|NCT01454804|Drug|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
110135|NCT01454817|Behavioral|Quality of life|Improving Quality of Life
110401|NCT01443065|Drug|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
110402|NCT01443065|Drug|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
110403|NCT01443078|Drug|pemetrexed plus cisplatin|All enrolled pts will undergo baseline CT & FDG PET scan & imaging of the brain (MRI or CT). For all pts who undergo breath-hold PET/CT in addition to their free-breathing (FB) PET/CT scan, the FDG PET response assessment, which drives protocol decisions, will be derived from FB-PET studies only. Pts with non-squamous histology will be tx with pemetrexed 500 mg/m2 & cisplatin 75 mg/m2 delivered every 3 weeks for 2 cycles. Patients with squamous histology will be treated with gemcitabine 1250 mg/m2 on days 1 & 8 & cisplatin 75 mg/m2 on day 8 of a 21 day cycle or 2 cycles. Pts who are not eligible for cisplatin may receive carboplatin at AUC = 5 instead of cisplatin. Patients treated with carboplatin + gemcitabine must receive a lower starting dose of gemcitabine 1000 mg/m2. Following 2 cycles of platinum-based chemo, ps will undergo a repeat FDG PET and CT scan to measure treatment response. Responders will receive additional cycles of their first-line therapy with a goal of 4 cycles.
110404|NCT01443078|Drug|vinorelbine and docetaxel|Those who fail to respond will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1, followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
110405|NCT01443091|Other|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
110406|NCT01443091|Other|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
110407|NCT01443104|Device|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
111150|NCT01446874|Procedure|Intensive Brushing Regimen|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution Intubation with tapered polyurethane cuff endotracheal tube with subglottic drainage (Mallinckrodt™ Sealguard™ Evac Endotracheal Tube, Covidien, Mansfield, MA) intraoperatively and postoperatively as indicated, based upon standard clinical practice.
The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group.
111151|NCT01446887|Other|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
111152|NCT01446900|Drug|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
111153|NCT01446900|Drug|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
111154|NCT01446913|Device|Standard CPAP Intervention|
111155|NCT01446913|Behavioral|Enhanced CPAP Intervention|
111156|NCT00068328|Procedure|psychosocial assessment and care|
111157|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
111158|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
111159|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
111160|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
111161|NCT01446926|Biological|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
111162|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
111163|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
111164|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
111165|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
111166|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
111167|NCT00068328|Procedure|quality-of-life assessment|
111168|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
110584|NCT01443247|Drug|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
110585|NCT01443260|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
110586|NCT01443273|Other|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
110881|NCT01446484|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
110882|NCT01446484|Drug|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
110883|NCT01446484|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
110884|NCT01446484|Drug|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
110885|NCT01446484|Drug|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
110886|NCT01446484|Procedure|Kidney transplantation|Living related kidney transplantation
110887|NCT01446497|Drug|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
110888|NCT01446497|Drug|Timolol|Twice per day, 1 drop at each time
110889|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.
12 months follow-up:
capsule/day (350 mg resveratrol-enriched grape extract) for 6 months
capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months
110890|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.
12 months follow-up:
capsule/day (350 mg resveratrol-enriched grape extract) for 6 months
capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months
110891|NCT01449123|Drug|Mannitol challenge test & reversibility test|Patients perform an asthma control test (ACT) to establish if they are "well controlled" or "symptomatic". All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness
110892|NCT01449136|Other|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
110893|NCT00000257|Drug|0% N2O and 40% N2O|
110894|NCT00001131|Drug|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
111865|NCT00070486|Drug|celecoxib|given PO
111866|NCT01473719|Behavioral|motivational intervention|7-session individual motivationally-based intervention
111867|NCT01473719|Behavioral|health education|7 individual sessions focusing on health education
111868|NCT01473732|Drug|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml. Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Both for one year.
111869|NCT01473732|Drug|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml. Myfortic Min. 360 mg bid and Max. 720 mg bid Both for one year.
111870|NCT01473745|Procedure|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
111871|NCT01473745|Procedure|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
112204|NCT01472133|Other|Recording of 12 lead ECG|Recording of 12 lead ECG
112205|NCT01472133|Other|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
112206|NCT01472133|Other|Recording of chest wall movement|Recording of chest wall movement
112207|NCT01472133|Other|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
112208|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
112209|NCT00070343|Biological|oblimersen sodium|
112210|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
112211|NCT01472146|Drug|cyclophosphamide, Adriamycin, Docetaxel, Trastuzumab, Zolendronic acid|Experimental:
AC,Docetaxel,Trastuzumab,Zolendronate
Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles
Drug: Docetaxel
Docetaxel 100 mg/m2 every 21 days for 4 cycles.
Drug: Trastuzumab
Trastuzumab 8mg/kg [loading dose] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.
Drug: zolendronic acid
Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy
112212|NCT01472159|Behavioral|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
112213|NCT01472172|Device|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
112214|NCT01472185|Drug|Ranolazine|Ranolazine tablets administered orally twice daily.
111664|NCT01445340|Drug|Romidepsin (FR901228)|
111665|NCT01445366|Device|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
111666|NCT01445366|Device|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
111667|NCT01445379|Drug|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
111668|NCT01445392|Biological|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 & amp; 5 of a 21 day cycle for 2 cycles
111669|NCT01445392|Drug|Pemetrexed|500 mg/m2 on day 1 of each 21 day cycle until disease progression
111670|NCT01445392|Drug|Cisplatin|75 mg/m2 on day 1 of each 21 day cycle until disease progression
111671|NCT01445392|Biological|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
111672|NCT01445405|Drug|Bortezomib (Velcade, PS-341)|
111673|NCT01445405|Drug|Cetuximab|
111674|NCT00068133|Genetic|Plasmid based Gene Transfer product-VLTS-589|
111675|NCT01445405|Drug|Cisplatin|
111676|NCT01445405|Procedure|Radiation Therapy|
111928|NCT00000258|Drug|Nitrous oxide 30% & placebo|
111929|NCT00001212|Drug|prednisone|
111930|NCT00070317|Procedure|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
111931|NCT01471704|Drug|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
111932|NCT01471704|Drug|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
111933|NCT01471717|Drug|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
111934|NCT01471717|Drug|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
110226|NCT01457053|Other|Ultrafiltration|Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.
Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety.
110227|NCT01457066|Behavioral|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
110228|NCT01457092|Device|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
110229|NCT01457105|Device|Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)|Metal stents placement in the main biliary duct during ERC
110230|NCT00069277|Drug|E7389|
110231|NCT01457118|Drug|NKTR-102|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. Patients who previously received a dose of NKTR-102 < 145 mg/m2 will continue at the lower dose on this study.
110232|NCT01457131|Drug|Fludarabine|50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
110233|NCT01457131|Drug|Cyclophosphamide|60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
110234|NCT01457131|Other|IL-12 & amp; Anti-NY ESO1 TCR PBL|10(7) cells to 3 X 10(10) cells
110235|NCT01457144|Drug|RiBVD|Every cycle:
Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2
110236|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
110237|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
110238|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
110239|NCT01459471|Procedure|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
110240|NCT01459484|Drug|Mifamurtide arm|PRE SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
All the product are used as commercial formulation
110895|NCT00068471|Drug|anidulafungin|
110896|NCT01449149|Radiation|Proton Therapy|
110897|NCT01449162|Drug|masitinib 6 mg/kg/day|6 mg/kg/day
110898|NCT01449162|Drug|placebo|placebo matching masitinib 6 mg/kg/day
110899|NCT01449188|Drug|ondansetron|FDA approved drug used to treat nausea and vomiting
110900|NCT01449188|Drug|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
110003|NCT01459107|Drug|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
110004|NCT01459120|Other|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
110005|NCT01459120|Other|Pitso|Health care workers propose the integrated service package including VCT through community gatherings ("Pitso").
110006|NCT01452399|Procedure|Shave margins|Partial mastectomy with shave margins.
110007|NCT01452399|Procedure|No Shave Margins|Partial mastectomy without shave margins.
110008|NCT01452412|Drug|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
110009|NCT01452412|Drug|Placebo|To be taken on the same schedule as the active arm
110010|NCT01452425|Device|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
110011|NCT01452425|Device|INVOS assessment|Near Infraread spectroscopy, non invasive
110012|NCT01452425|Device|EMG assessment|Electromyography, non invasive
110013|NCT01452438|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
110014|NCT00068744|Drug|mitomycin C|
110015|NCT01452451|Drug|HM11260C|1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
112215|NCT01472185|Drug|Placebo|Placebo to match ranolazine administered orally twice daily.
112216|NCT01472185|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
112217|NCT01472185|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
112218|NCT01472198|Drug|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
112219|NCT01472198|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
112220|NCT00070343|Drug|dacarbazine|
112221|NCT01472198|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
112222|NCT01472211|Device|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
112223|NCT01472211|Device|placebo filter|filter purifies water
111303|NCT01444521|Drug|irinotecan and cisplatin|irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.
14 days as a cycle, up to 8 cycles.
111304|NCT00068055|Drug|Placebo|Normal Saline.
111305|NCT01444534|Device|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
111306|NCT01444534|Device|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
111307|NCT01444547|Drug|paclitaxel and cisplatin|Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.
14 days as a cycle, up to 8 cycles.
111308|NCT01444573|Device|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
111309|NCT01444586|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
111310|NCT01444612|Drug|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
111935|NCT01471717|Drug|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
111936|NCT01471717|Drug|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
111937|NCT01471717|Drug|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
111938|NCT01471717|Drug|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
111939|NCT01471730|Drug|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 [mm] − MCF [mm]) * body weight [kg] / 140 [m] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
111940|NCT01471730|Drug|Saline solution|Normal saline will be administered to control patients.
111941|NCT00070317|Drug|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
111942|NCT01471730|Drug|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds [M1] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
111943|NCT01471743|Dietary Supplement|Impact Advance Recovery (R)|
111944|NCT01471743|Dietary Supplement|Ensure Plus (R)|
111945|NCT01471756|Procedure|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
112278|NCT01479049|Drug|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
112279|NCT01479062|Behavioral|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
112280|NCT01479062|Behavioral|Usual Care|Placebo Control
112281|NCT01479075|Drug|central insulin|4x 40mU intranasal insulin
112282|NCT01479075|Drug|Placebo|
112283|NCT00071188|Drug|Paclitaxel|
110241|NCT01459484|Other|3 drugs arm|High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen
PRE-SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT:
Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2
Total lenght 34 weeks
All the product are used as commercial formulation
110514|NCT01445795|Drug|Placebo BID Fasted|Placebo BID fasted x7 days
110515|NCT01445808|Behavioral|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
110516|NCT01445808|Behavioral|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
110517|NCT00068237|Procedure|Surgery for the primary and neck nodes|
110518|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
110519|NCT01445821|Procedure|Cytoxan rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit anti-thymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 g/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastrim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
110520|NCT01445821|Procedure|Cytoxan rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastrim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
110521|NCT01445847|Drug|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
110522|NCT01445847|Other|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
110523|NCT01445860|Drug|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
110524|NCT01445873|Drug|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
110525|NCT01445886|Drug|Indigo Naturalis Oil Extract|The participants applied indigo naturalis oil extract topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
110526|NCT01445886|Drug|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
110527|NCT01445899|Drug|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
111528|NCT01450189|Behavioral|Standard HIV prevention messages|The standard counseling (SC) arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
111529|NCT01450189|Behavioral|5 counselor-delivered sessions|The behavioral intervention (BI) arm consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
111530|NCT01450189|Drug|ARVs with raltegravir and emtricitabine/tenofovir disoproxil fumarate|The behavioral intervention and antiretroviral (BIA) arm consists of the same behavioral intervention plus antiretroviral drugs (ARV) with raltegravir (400mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300mg daily) orally for 12 weeks.
111792|NCT01475617|Dietary Supplement|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
111793|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
111794|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
111795|NCT01475617|Dietary Supplement|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
111796|NCT01475617|Dietary Supplement|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
111797|NCT01475630|Procedure|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
111798|NCT01475630|Procedure|control|relaxation
111799|NCT01475643|Drug|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
111800|NCT01475643|Drug|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
111801|NCT01475656|Drug|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
111802|NCT00070642|Drug|Chemotherapy|Chemotherapy in three-week cycles until disease progression:
dacarbazine 850mg/m2
111803|NCT01475669|Biological|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
111804|NCT01475669|Biological|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
111805|NCT01475695|Drug|14C GSK2251052|1500 mg iv dose GSK2251052
111311|NCT01444612|Drug|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
111312|NCT01444612|Drug|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
111313|NCT01444612|Drug|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
111314|NCT01444625|Other|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
111315|NCT00068068|Drug|Talaporfin sodium (LS11)|
111316|NCT01444625|Other|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
111317|NCT01444638|Device|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
111318|NCT01444651|Drug|Tadalafil|20 mg Tadalafil taken once a day for 3 months
111319|NCT01444651|Drug|Placebo|Placebo tablet taken by mouth once a day for 3 months
111320|NCT01444664|Procedure|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
111591|NCT00068393|Drug|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
111592|NCT01447628|Drug|Ferinject or CosmoFer|Intravenous, 1000 mg iron
111593|NCT01447641|Other|Polysomnography|Overnight physiological recording of sleep
111594|NCT01447641|Other|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
111595|NCT01447654|Drug|Losartan|100 mg for 12 months.
111596|NCT01447654|Drug|Placebo|100 mg for 12 months.
111597|NCT01447667|Procedure|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
111598|NCT01447693|Procedure|application of ointment (olive-omega 3 ointment)|
111599|NCT01447706|Drug|MM-121 (SAR256212) + Paclitaxel|MM-121 (SAR256212) (IV) plus standard dosing Paclitaxel (IV)
111600|NCT01447706|Drug|Paclitaxel|Standard dosing Paclitaxel (IV)
112284|NCT01479088|Drug|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value <180 pg/mL as tolerated by the patient
112285|NCT01479101|Other|MammaPrint 70-gene expression profile|
112286|NCT01479101|Other|BluePrint 80 gene expression profile|
112287|NCT01479114|Drug|rh-GCSF|10 ug/kg/day intravenously for 3 days
112288|NCT01479127|Drug|ABT-SLV187|
112289|NCT01479127|Drug|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
112290|NCT01479127|Device|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
112291|NCT01472237|Other|Nutritional intervention|Modification of diet
112292|NCT01472250|Drug|Clinical chemo-drugs|Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:
Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel
112293|NCT01472263|Drug|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
112294|NCT01472263|Drug|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
112295|NCT01472276|Behavioral|Web-based program|Provided with the web-based program
112296|NCT01472289|Other|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
112297|NCT00070382|Drug|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
112298|NCT01472302|Device|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
112299|NCT01472302|Device|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
111379|NCT01442376|Drug|Placebo to Palonosetron|
111380|NCT00067769|Behavioral|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
111381|NCT01442415|Behavioral|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
110528|NCT01448499|Drug|Clozapine|escalating dose of clozapine up to 900 mg/day
110529|NCT01448499|Drug|Amisulpride|escalating dose of amisulpride up to 800 mg/day
110530|NCT01448499|Drug|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
110821|NCT01451437|Drug|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
110822|NCT01451450|Drug|QGE031|QGE031 liquid for subcutaneous injection.
110823|NCT01451450|Drug|Placebo|Placebo liquid for subcutaneous injection.
110824|NCT01451489|Drug|FK506|FK506:0.05-0.1mg/kg/d
110825|NCT00001133|Drug|Ritonavir|
110826|NCT00068666|Drug|temozolomide|
110827|NCT01451489|Drug|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
110828|NCT01451502|Biological|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
110829|NCT01451515|Drug|Prednisone|Given orally (PO).
110830|NCT01451515|Drug|Vincristine|Given intravenously (IV).
110831|NCT01451515|Drug|Daunorubicin|Given IV.
110832|NCT01451515|Drug|PEG-asparaginase|Given intramuscularly (IM) or IV.
110833|NCT01451515|Drug|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
110834|NCT01451515|Drug|Doxorubicin|Given IV.
110835|NCT01451515|Drug|Cyclophosphamide|Given IV.
110836|NCT01451515|Drug|Cytarabine|Given IV or IT.
110837|NCT00068666|Radiation|radiation therapy|
110838|NCT01451515|Drug|Thioguanine|Given PO.
110839|NCT01451515|Drug|Clofarabine|Given IV.
111806|NCT01475708|Drug|Doxycycline|100 mg PO bid, 14 days
111807|NCT01475721|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
111808|NCT01475721|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
111809|NCT01475721|Drug|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
111810|NCT01475721|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
111811|NCT01475721|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
111812|NCT01475721|Drug|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
112141|NCT01474161|Drug|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
112142|NCT01474161|Drug|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
112143|NCT01474161|Drug|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
112144|NCT01474161|Drug|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
112145|NCT01474161|Drug|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
112146|NCT01474161|Drug|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
112147|NCT01474174|Biological|trivalent influenza vaccine|Given IM
112148|NCT01474174|Other|laboratory biomarker analysis|Correlative studies
112149|NCT01474187|Drug|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
112150|NCT00070538|Drug|cytarabine|
112151|NCT01474187|Drug|Capecitabine|625mg/m2,bid,d1-5,qw
112152|NCT01474187|Radiation|Radiotherapy|50Gy for whole pelvis
112153|NCT01476332|Drug|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
111601|NCT01447719|Drug|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
111602|NCT00068393|Drug|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
111603|NCT01447732|Drug|CEP-37250/KHK2804|Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.
Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.
111604|NCT01447758|Drug|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
111605|NCT01447758|Drug|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
111606|NCT01447771|Behavioral|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
111607|NCT01447784|Biological|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
111608|NCT01450254|Other|Control|No intervention will be prescribed to the control group during participation in the study.
111609|NCT01450267|Drug|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
111610|NCT01450267|Drug|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
111872|NCT01473758|Drug|Roflumilast|500 µg tablet, od, oral administration in the morning after breakfast
111873|NCT01473758|Drug|Placebo|tablet, od, oral administration in the morning after breakfast
111874|NCT01473771|Behavioral|Caring Letter (email)|Participants will be emailed "letters" for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period.
111875|NCT01473784|Procedure|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
111876|NCT00070486|Drug|gemcitabine hydrochloride|given IV
111877|NCT01473784|Procedure|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
111382|NCT01442428|Drug|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
111383|NCT01442428|Drug|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
111384|NCT01442428|Drug|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
111385|NCT01442428|Drug|Placebo|Atorvastatin placebo
111386|NCT01442454|Other|chronic pancreatitis|No intervention, subjects followed through surgery
111387|NCT01442480|Dietary Supplement|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
111388|NCT01442480|Dietary Supplement|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
111389|NCT01444677|Drug|MB12066|MB12066 100mg
111390|NCT01444677|Drug|MB12066|MB12066 200mg
111391|NCT01444677|Drug|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
111392|NCT00068068|Device|LED-based light infusion device|
111393|NCT01444690|Drug|Dimiracetam|Capsules for oral administration twice daily
111394|NCT01444690|Drug|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
111395|NCT01444703|Other|licorice solution|licorice (0.5 g)
111396|NCT01444703|Other|sugar solution|sugar (5 g).
111397|NCT01444716|Drug|Ofatumumab|Starting dose: 300 mg by vein during week 1, then 2000 mg in weeks 2, 3 and 4, then monthly during months 2-12.
111398|NCT01444729|Drug|Xiapex|Xiapex administration will follow SMPC
111399|NCT01444729|Procedure|surgery|Non-pharmacological treatment
111400|NCT01444742|Drug|Clofarabine|Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)
111401|NCT01444742|Drug|Cytarabine|Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)
111677|NCT01445418|Drug|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.
Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
110840|NCT01451515|Drug|Methotrexate|Given IV or IT.
110841|NCT01451515|Drug|Mercaptopurine|Given PO.
110842|NCT01451515|Drug|Dexamethasone|Given PO or IV.
110843|NCT01451515|Drug|Hydrocortisone|Given IT.
110844|NCT01451515|Drug|Etoposide|Given IV.
110845|NCT01451528|Biological|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
109947|NCT01454310|Device|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
109948|NCT01454310|Device|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
109949|NCT01454323|Other|Bone marrow mononuclear cells|Intracoronary infusion of autologous bone marrow-derived mononuclear cells
109950|NCT01454336|Biological|Cell injection|MSCs introduced into portal vein
109951|NCT01454349|Drug|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
109952|NCT01454349|Drug|Placebo|Single intraprostatic injection of matching placebo
109953|NCT01454362|Drug|Nicotine|Inhalation of nicotine.
109954|NCT00069030|Biological|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
109955|NCT01454375|Behavioral|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
109956|NCT01454388|Other|breakfast|
109957|NCT01454401|Device|LeucoPatch device|weekly treatment
109958|NCT01454414|Other|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
109959|NCT01454440|Drug|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure) vs placebo.
109960|NCT01454453|Drug|amisulpride|4-10 weeks treatment, 25-100mg daily
112154|NCT01476332|Drug|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
112155|NCT01476345|Drug|LY2963016|Administered subcutaneously
112156|NCT01476345|Drug|Lantus|Administered subcutaneously
112157|NCT01476358|Dietary Supplement|Vitamin A (retinyl palmitate).|Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth
Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth
112158|NCT01476371|Behavioral|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here & Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
112159|NCT01476384|Dietary Supplement|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
112160|NCT00070733|Drug|testosterone enanthate|
112161|NCT01476384|Dietary Supplement|Placebo|250 ml water
111245|NCT01447056|Biological|LMP specific T cells|Three dose levels will be evaluated:
Dose Level 1: 2×10^7 cells/m2; Dose Level 2: 1×10^8 cells/m2; Dose Level 3: 2×10^8 cells/m2
If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection.
111246|NCT01447069|Drug|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains <100 bpm
111247|NCT01447095|Drug|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
111248|NCT01447095|Drug|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
111249|NCT01447095|Drug|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
111250|NCT01447108|Device|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.
The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping.
111251|NCT01447121|Device|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
111252|NCT01447147|Drug|Placebo|Placebo capsules once daily
111253|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
111254|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
111878|NCT01473797|Drug|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
111879|NCT01473810|Biological|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
111880|NCT01473810|Biological|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
111881|NCT01473810|Biological|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
111882|NCT01473810|Biological|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
111883|NCT01473823|Dietary Supplement|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
111884|NCT01475760|Other|K2CG chewing gum (60mg chitosan)|Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:
Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).
If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42
111885|NCT01475786|Genetic|Low Dose: 16 mg VM202|Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:
Day 0 - 32 injections / calf:
16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
16 injections of 0.5mL of normal saline / calf
Day 14 - 32 injections / calf:
16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
16 injections of 0.5mL of normal saline / calf
111886|NCT01475786|Genetic|High Dose: 32 mg VM202|Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:
Day 0
32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14
32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)
111887|NCT01475786|Genetic|Placebo (Normal Saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
111888|NCT01475799|Device|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
112224|NCT01472211|Other|disinfection tablets|government promoted tablets disinfect water
112225|NCT01474200|Device|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
112226|NCT01474200|Drug|IV Loop Diuretics (LD)|IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of the"Diuretic strategies in patients wth acute decompensated heart failure" (DOSE) trial.
111678|NCT01445431|Other|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
111679|NCT01445431|Other|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
111680|NCT01445444|Behavioral|Habit Reversal Training|8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).
The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.
components:
Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.
Session 2. implement habit reversal, including awareness training, competing response training, and social support.
Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy.
111681|NCT01447784|Biological|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
111682|NCT01447797|Drug|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
111683|NCT01447810|Other|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
111684|NCT01447849|Drug|lubiprostone|24mcg twice a day (BID) 1 week
111685|NCT01447849|Drug|Placebo|Placebo pills twice a day for one week.
111686|NCT00068393|Drug|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
111687|NCT01447862|Drug|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
111688|NCT01447862|Drug|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
111689|NCT01447875|Other|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
111690|NCT01447875|Drug|propofol or mexmedetomidine|
111691|NCT01447888|Drug|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
111692|NCT01447888|Other|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
109961|NCT01454466|Procedure|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
109962|NCT01454479|Drug|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
109963|NCT01454505|Drug|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
109964|NCT01454505|Other|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
109965|NCT00069056|Procedure|Laser Treatment|
109966|NCT00000258|Drug|Nitrous oxide 10% & placebo|
110242|NCT01459497|Radiation|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
110243|NCT01459497|Radiation|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
110244|NCT01459510|Behavioral|Play Nicely Program|Multi media educational intervention
110245|NCT01459523|Procedure|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
110246|NCT00069706|Other|AL-12182 Ophthalmic Solution Vehicle|Placebo
110247|NCT01459523|Procedure|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
110248|NCT01459523|Procedure|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
110249|NCT01459523|Procedure|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
110250|NCT01459549|Procedure|Roux-en-Y choledochojejunostomy|Roux-en-Y choledochojejunostomy must be operated
110251|NCT01459562|Drug|NI-0501|
110252|NCT01459562|Drug|Placebo|
111255|NCT00068341|Drug|carboplatin|Cycle 1-8 Day 1 or 2 AUC = 6 IV
111256|NCT01447160|Drug|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
111257|NCT01447173|Drug|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
111258|NCT01449760|Other|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
111259|NCT01449760|Other|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
111260|NCT01449773|Dietary Supplement|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
111261|NCT00068523|Drug|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
111262|NCT01449773|Dietary Supplement|Placebo|5 capsules/day containing corn and soybean oil
111263|NCT01449786|Drug|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
111264|NCT01449786|Drug|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
111265|NCT01449786|Other|placebo drops|25 µg of placebo daily administered sublingually as drops over 16 weeks
111531|NCT01450202|Other|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
111532|NCT01450202|Other|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
111533|NCT01450215|Drug|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
111534|NCT00068549|Drug|Gemcitabine Hydrochloride|Given IV
111535|NCT01450228|Drug|KI1001|Prolonged release melatonin 2mg
111536|NCT01450228|Drug|Placebo KI1001|Placebo KI1001 tablets
111537|NCT01450241|Other|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
111538|NCT01450241|Other|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
111539|NCT01450254|Device|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
112227|NCT01474213|Drug|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
112228|NCT01474213|Drug|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
112229|NCT01474226|Dietary Supplement|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
112230|NCT01474226|Dietary Supplement|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
112231|NCT01474239|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
112232|NCT01474239|Drug|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
112233|NCT00070538|Drug|laromustine|
112234|NCT01474252|Drug|RSI|All medications are administered only one dose before intubation
Anesthetics:
Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg
Neuromuscular blocking agents:
Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg
Opioid:
Fentanyl 1-2ug/kg
112235|NCT01474265|Drug|Varenicline|0.5-2 mg per day, oral use
112236|NCT01474265|Drug|Placebo|1-2 tablets per day, oral use
112237|NCT01474265|Drug|Nicorette TX|10-15 mg per day, transdermal use (patches)
112238|NCT01474278|Drug|Placebo|Single dose
112239|NCT01474278|Drug|RO5028442|Single dose
112240|NCT01474304|Drug|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
112241|NCT01474317|Device|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
111321|NCT01444677|Drug|MB12066|MB12066 300mg
111322|NCT01444677|Drug|MB12066|MB12066 400mg
111323|NCT01447186|Behavioral|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
111324|NCT01447186|Behavioral|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
111693|NCT01447914|Drug|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
111946|NCT01471769|Behavioral|Pain management video|6-minute video
111947|NCT01471769|Behavioral|Falls Prevention Video|6-minute video
111948|NCT01473836|Drug|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
111949|NCT01473836|Drug|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
111950|NCT01473875|Drug|SBC-102|SBC-102 is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with LAL Deficiency.
111951|NCT00001213|Drug|Cysteamine|
111952|NCT00070486|Drug|zileuton|given PO
111953|NCT01473888|Drug|T89(Dantonic)|capsule, 225mg B.I.D.
111954|NCT01473901|Drug|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
111955|NCT01473901|Drug|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
111956|NCT01473914|Dietary Supplement|Low dose: supplemental zinc, selenium and vitamin E|ZINC 25mg (AS ZINC SULFATE)
SELENIUM 50 mcg (AS SODIUM SELENITE)
VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU
111957|NCT01473914|Dietary Supplement|Standard renal vitamin: B and C renal vitamin|BIOTIN 300 MCG
D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG
FOLIC ACID 1 MG
NIACINAMIDE 20 MG
VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG
VITAMIN B12(CYANOCOBALAMIN) 6 MCG
VITAMIN B2 (RIBOFLAVIN) 1.7 MG
VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG
VITAMIN C (ASCORBIC ACID) 100 MG
INERT FILLER (CORNSTARCH)
111958|NCT01473914|Dietary Supplement|Medium dose: supplemental zinc, selenium and vitamin E|ZINC 50 mg (AS ZINC SULFATE)
SELENIUM 75 mcg (AS SODIUM SELENITE)
VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU
110253|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
110254|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
110255|NCT01459588|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
110256|NCT01459588|Drug|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
110257|NCT00069706|Drug|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
110258|NCT01452763|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
110259|NCT01452763|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
110260|NCT01452763|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
110531|NCT01448512|Behavioral|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
110532|NCT01448512|Other|Usual Care|4 time matched sessions focused on health education
110533|NCT01448525|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
110534|NCT00068419|Other|laboratory biomarker analysis|Correlative studies
110535|NCT01448525|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
110536|NCT01448538|Drug|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
110537|NCT01448551|Behavioral|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
111540|NCT01442597|Behavioral|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
111541|NCT01442597|Behavioral|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
111542|NCT01442610|Drug|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
111543|NCT01442610|Drug|Placebo|Placebo 1tablet once daily for 8 weeks
111544|NCT01442623|Other|Vestibular Rehabilitation|The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.
Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program.
111545|NCT00067782|Drug|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
111546|NCT01442636|Device|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
111547|NCT01442649|Drug|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
111548|NCT01442649|Drug|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
111549|NCT01442649|Drug|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
111813|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
111814|NCT01475734|Biological|albiglutide|subcutaneous injection
111815|NCT01475734|Biological|placebo|subcutaneous injection
111816|NCT01475760|Other|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
111817|NCT01478074|Drug|Fludarabine|30 mg/m2 daily from day -6 through -2
111818|NCT01478074|Biological|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10^6 cells/Kg
111819|NCT00071058|Drug|XR9576 (Tariquidar)|
111820|NCT01478074|Biological|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
111325|NCT01447186|Behavioral|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
111326|NCT01447199|Behavioral|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
111327|NCT01447212|Drug|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
111328|NCT01447212|Drug|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
111329|NCT01447212|Drug|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
111330|NCT01447212|Drug|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
111331|NCT00068341|Drug|docetaxel|Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
111332|NCT01447225|Drug|MM-121 (SAR256212) plus Gemcitabine|MM-121 (SAR256212) (IV) plus Gemcitabine (IV)
111333|NCT01447225|Drug|MM-121 (SAR256212) plus Carboplatin|MM-121 (SAR256212) (IV) plus Carboplatin (IV)
111334|NCT01447225|Drug|MM-121 (SAR256212) plus Pemetrexed|MM-121 (SAR256212) (IV) plus Pemetrexed (IV)
111335|NCT01447225|Drug|MM-121 (SAR256212) plus Cabazitaxel|MM-121 (SAR256212) (IV) plus Cabazitaxel(IV)
111336|NCT01447238|Device|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.
The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual.
111337|NCT01447251|Behavioral|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS <4.5, moderate risk as PreDx DRS ≥4.5 and <8.0, and high risk as PreDx DRS ≥8.0.
111338|NCT01447264|Procedure|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
111611|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0
111612|NCT01450280|Biological|ChAd63 CS, MVA CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
111959|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
111960|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
112300|NCT01472315|Drug|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
112301|NCT01472315|Drug|Placebo|Placebo pills were taken in same way as active comparator
112302|NCT01472328|Procedure|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
112303|NCT01472328|Procedure|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
112304|NCT01472354|Behavioral|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
112305|NCT01472367|Drug|Metformin|Metformin oral tablets twice daily. Participants on a metformin daily dose of 1000, 1250, or 1275 mg at screening will be switched to a metformin daily dose of 1000 mg (500 mg twice a day); 1500, 1700, or 1750 mg will be switched to a metformin daily dose of 1700 mg (850 mg twice a day); 2000 mg or more will be switched to a metformin daily dose of 2000 mg (1000 mg twice a day).
112306|NCT01472367|Drug|Sitagliptin + Metformin FDC|Sitagliptin + metformin FDC oral tablet 50/500, 50/850, or 50/1000 mg dosed twice daily.
112307|NCT01472367|Drug|Placebo to Metformin|Matching placebo to metformin administered twice daily.
112308|NCT00070382|Drug|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
112309|NCT01472367|Drug|Placebo to Sitagliptin + Metformin FDC|Matching placebo to sitagliptin + metformin FDC oral tablet administered twice daily.
112310|NCT01472367|Biological|Insulin|Participants who enter the study on background insulin will continue on the same dose and formulation of insulin throughout the study. If rescue therapy is necessary, participants who are not on background insulin will intiate insulin and those that entered the study on insulin will uptitrate their background insulin dose.
112311|NCT01472367|Biological|Insulin glargine|Participants who are not on background insulin therapy during the base study may initiate insulin glargine during the extension period if their fasting fingerstick glucose is >130 mg/dL and their fasting state A1C is greater than 7.5%.
112312|NCT01474356|Other|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
112313|NCT01474369|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
110538|NCT01448564|Other|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
110539|NCT01448564|Other|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
110540|NCT01448603|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
110541|NCT01448603|Biological|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
110542|NCT01448616|Drug|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
110543|NCT01448616|Drug|Placebo Vaginal Gel|Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects — negative or positive — on study endpoints.
110544|NCT01448616|Drug|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
110545|NCT00068432|Drug|Celecoxib|Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
110546|NCT01448616|Drug|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
110846|NCT01451541|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
110847|NCT01451541|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
110848|NCT01443715|Behavioral|Treatment as Usual|Standard treatment in the community
110849|NCT01443728|Drug|Vitamin D3|Vitamin D3 100,000 IU orally once a month
110850|NCT01443728|Drug|Vitamin D3|Vitamin D3 12,000 IU orally once a month
110851|NCT01443741|Other|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
110852|NCT01443754|Procedure|LIMA-LAD surgical revascularization|Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:
use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;
minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another.
111821|NCT01478087|Device|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
111822|NCT01478113|Drug|Amphetamine-dextroamphetamine (AMPH)|The amphetamine-dextroamphetamine will be in a pill formulation. The dosage of the amphetamine-dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
111823|NCT01478113|Drug|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
111824|NCT01478113|Behavioral|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
111825|NCT01478126|Drug|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
111826|NCT01478126|Drug|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2*weight/24. Infusion starts in operating room and ends next day after the surgery.
111827|NCT01478139|Procedure|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
111828|NCT01478139|Procedure|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
111829|NCT01478152|Other|Drug-like Medical Device: Ectoin Inhalation Solution|After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.
The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose.
111830|NCT00001239|Drug|FLAC with GM-CSF|
111831|NCT00071071|Drug|HuMax-CD4|
112162|NCT01476397|Other|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
112163|NCT01476397|Other|Test infant formula|partially hydrolyzed whey formula with probiotic
112164|NCT01476410|Drug|brentuximab vedotin|Given IV
112165|NCT01476410|Drug|doxorubicin hydrochloride|Given IV
112166|NCT01476410|Drug|vinblastine|Given IV
112167|NCT01476410|Drug|dacarbazine|Given IV
112168|NCT01476410|Procedure|quality-of-life assessment|Ancillary studies
111613|NCT00068549|Drug|Cisplatin|Given IV
111614|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0
111615|NCT01450280|Biological|ChAd63, MVA CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
111616|NCT01450293|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|1x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
111617|NCT01450293|Biological|AdCH63 ME-TRAP, MVA ME-TRAP|5x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
111618|NCT01450306|Drug|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
111619|NCT01450306|Behavioral|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
111620|NCT01450306|Drug|Placebo|
111621|NCT01450319|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) every alternate week until disease progression, death, or consent withdrawal.
111622|NCT01450332|Device|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
111623|NCT01450345|Drug|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
111624|NCT00068549|Radiation|Radiation Therapy|Undergo whole pelvis radiotherapy
111625|NCT01450358|Other|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
111626|NCT01450371|Device|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
111627|NCT01450371|Device|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
111628|NCT01450384|Drug|sorafenib tosylate|Given PO
111629|NCT01450384|Drug|pemetrexed disodium|Given IV
111630|NCT01450384|Other|laboratory biomarker analysis|Correlative studies
111631|NCT01450384|Procedure|biopsy|Optional correlative studies
111632|NCT01450397|Biological|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
112314|NCT01474369|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
112315|NCT01474369|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
112316|NCT01474382|Drug|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
112317|NCT01474382|Other|Sham injection|No drug administered, simulation of injection used in same manner as drug
111402|NCT01444768|Other|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
111403|NCT00068068|Device|Light emitting diodes (LED)|
111404|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
111405|NCT01444781|Biological|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
111406|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
111407|NCT01444807|Drug|sorafenib|sorafenib 400 mg bid
111408|NCT01444820|Radiation|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
111409|NCT01444820|Radiation|conventional|The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.
The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.
For patients with T3b, the whole SV is to be treated to 7600 cGy.
111410|NCT01444833|Drug|Candesartan|32 mg per day duration 6 months
111411|NCT01444846|Drug|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
111412|NCT01444846|Drug|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
111413|NCT01444846|Drug|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
111414|NCT01447303|Other|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
111415|NCT01447316|Other|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
110853|NCT01443754|Procedure|PCI|State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.
Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites.
110854|NCT00067964|Behavioral|small changes in physical activity and diet|
110855|NCT01443780|Dietary Supplement|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
110856|NCT01443806|Drug|Oseltamivir|75 mg, one time
110857|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.
The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines.
110858|NCT01443819|Other|Physical Therapy|Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).
Please note: There will be another PT evaluation at the end of 6 weeks.
110859|NCT01443819|Other|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
110860|NCT01443832|Dietary Supplement|Fe57 and Fe58-FeSO4 stable isotopes|[57Fe] and [58Fe]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
110861|NCT01443845|Drug|Roflumilast|Roflumilast 500 µg, oral administration, once per day
110862|NCT01443845|Drug|Placebo|Dose-matched placebo, oral administration, once per day.
110863|NCT01443858|Drug|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
109967|NCT00001146|Drug|Ethyl Eicosapentaenoic Acid|
109968|NCT00069173|Behavioral|Project FAB (Fitness and Bone)|
109969|NCT01456585|Other|Gemcitabine|
109970|NCT01456585|Drug|CP-870,893|
109971|NCT01456598|Procedure|Laparoscopic gastrectomy|After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.
The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection
After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.
As the reconstruction, one of the techniques among Billroth type I, Billroth type II and Roux en Y is applied and there is no limitation on use of appliance.
112169|NCT01476410|Genetic|DNA analysis|Optional correlative studies
112170|NCT01476410|Genetic|RNA analysis|Optional correlative studies
112171|NCT00070733|Drug|duastride|
112172|NCT01476410|Radiation|fludeoxyglucose F 18|Correlative studies
112173|NCT01476410|Procedure|positron emission tomography|Correlative studies
112174|NCT01476410|Other|laboratory biomarker analysis|Optional correlative studies
112175|NCT01476410|Other|immunohistochemistry staining method|Optional correlative studies
112176|NCT01476410|Genetic|polymorphism analysis|Optional correlative studies
112177|NCT01476423|Drug|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
112178|NCT01476436|Other|Low carbohydrate dietary advice|Dietary advice
112179|NCT00071110|Procedure|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20—on the crown of the head and yin tang—on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
112180|NCT01478685|Drug|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2
112181|NCT01478698|Drug|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
112182|NCT01478698|Drug|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
111266|NCT01449799|Drug|GSK961081 800 microgramme dose|To be provided via a combination of 4 inhalers - one 400 microgramme GSK961081 Diskus inhalation, a second 400 microgramme GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
111267|NCT01449799|Drug|Fluticasone Propionate 500 microgramme dose|To be provided via a combination of 4 inhalers - one 250 microgramme fluticasone propionate Diskus inhalation, a second 250 microgramme fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
111268|NCT01449799|Drug|GSK961081 800 microgramme and Fluticasone Propionate 500 microgramme separately|To be provided via a combination of 4 inhalers - one 400 microgramme GSK961081 Diskus inhalation, a second 400 microgramme GSK961081 Diskus inhalation, one 250 microgramme fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgramme Diskus inhalation
111889|NCT01475812|Other|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
111890|NCT01475825|Drug|mipomersen sodium 200 mg|200 mg (200 mg/mL in a volume of 1 mL), subcutaneous injections
111891|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
111892|NCT01475825|Drug|Placebo|Placebo vehicle for subcutaneous injection.
111893|NCT01475825|Drug|mipomersen sodium 70 mg|70 mg (140 mg/mL in a volume of 0.5 mL), subcutaneous injections
111894|NCT01475838|Drug|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
111895|NCT01475838|Drug|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
111896|NCT01475838|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
111897|NCT01475838|Drug|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
111898|NCT01475851|Drug|GSK548470 300 mg tablet|Blue tablets containing 300 mg of tenofovir disoproxil fumarate
111899|NCT01475864|Procedure|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
111900|NCT01475877|Drug|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
111901|NCT01475890|Dietary Supplement|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
111902|NCT00070655|Drug|SR34006 (idraparinux sodium) Injection|
111903|NCT01475890|Dietary Supplement|Placebo|Once a day for 12 months.
111904|NCT01475903|Procedure|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
111905|NCT01475916|Behavioral|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
111906|NCT01478282|Drug|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
111907|NCT01478295|Behavioral|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
111908|NCT00071084|Drug|HuMax-CD4|
111416|NCT01447329|Other|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
111417|NCT01447329|Drug|Standard Treatment|
111418|NCT01447342|Device|Cryo-Touch II|Percutaneous treatment with the device
111419|NCT01447355|Drug|cholecalciferol|Given PO
111420|NCT01447368|Drug|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
111694|NCT01447914|Other|Diagnostic laboratory biomarker analysis|Correlative studies
111695|NCT01447914|Other|Questionnaire administration|Ancillary studies
111696|NCT01447914|Procedure|Quality-of-life assessment|Ancillary studies
111697|NCT00068393|Drug|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
111698|NCT01447927|Drug|metformin hydrochloride|Given PO QD and BID
111699|NCT01447927|Other|placebo|Given PO QD and BID
111700|NCT01447940|Device|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
111701|NCT01447953|Other|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
111702|NCT01450410|Drug|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
111703|NCT01450410|Drug|Placebo|Placebo treatment will last for 12 weeks.
111704|NCT00068549|Radiation|Internal Radiation Therapy|Undergo brachytherapy
111705|NCT01450423|Behavioral|Physical activity|Participation in a 10-week supervised cardio exercise program two-three times a week. Each training session consists of 10 minutes of warm-up, 20 minutes treadmill run/walk and 30 minutes cycling. Heart rate (HR) is monitored during each session. Week 1-5: at least 15 minutes above 75% of HRmax in each session. Week 6-10: at least one session above 75% HRmax.
109972|NCT01456598|Procedure|Open gastrectomy|After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.
The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection
After lymph node dissection, one of the techniques among Billroth type I, Billroth type II and Roux en Y is applied and there is no limitation on use of appliance.
109973|NCT01456611|Drug|Diclofenac|Diclofenac Sodium Gel 1%
109974|NCT01456611|Drug|Placebo|Placebo Topical Gel
109975|NCT01456624|Drug|Megace|800mg
109976|NCT01456624|Drug|DW-ES(B)|625mg
109977|NCT01456637|Behavioral|CBT for insomnia|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
109978|NCT01456650|Drug|Glyburide|Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:
Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening.
109979|NCT00069186|Drug|Creatine Monohydrate|
109980|NCT01456663|Drug|AFQ056|
109981|NCT01456676|Drug|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
109982|NCT01456689|Drug|LGH447|
109983|NCT01456689|Drug|midazolam|
109984|NCT01456702|Procedure|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
109985|NCT01456715|Biological|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
110261|NCT01452763|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
110262|NCT01452763|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
110263|NCT01452776|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
110264|NCT01452776|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
111269|NCT01449799|Drug|GSK961081 800 microgramme Fluticasone Propionate 500 microgrammes in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgramme of GSK961081 and 250 microgramme of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgramme of GSK961081 and 250 microgramme of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
111270|NCT01449812|Biological|Infanrix+Hib™|Intramuscular, one dose
111271|NCT01449812|Biological|Poliorix™|Intramuscular, one dose
111272|NCT00068523|Drug|cyclosporine|oral cyclosporine on days -1 to 100
111273|NCT01449825|Drug|Pazopanib use|Treatment with pazopanib
111274|NCT01449825|Drug|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
111275|NCT01449838|Drug|Colistimethate sodium|active
111276|NCT01449838|Drug|Saline|placebo
111277|NCT01449864|Radiation|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
111278|NCT01449877|Drug|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
111279|NCT01449890|Behavioral|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
111280|NCT01442142|Behavioral|Control group|Control group for the combined Children's Appetite Awareness Training (CAAT)/Cue Reactivity and Sensitivity Training (CRST)14-week program.
111281|NCT01442168|Drug|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
111282|NCT01442168|Drug|atovaquone/proquanil|malanil according to label
111283|NCT01442181|Procedure|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
111284|NCT00067730|Drug|Drotrecogin Alfa (activated)|
111550|NCT01442649|Drug|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
111551|NCT01442649|Drug|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
111552|NCT01442649|Drug|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
111909|NCT01478295|Other|Control Group/Usual Care:|Control Group/Usual Care:
Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
112242|NCT01474330|Drug|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
112243|NCT01474330|Drug|Placebo|Placebo capsule
112244|NCT00070551|Biological|GTI-2040|Given IV
112245|NCT01474343|Genetic|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
112246|NCT01476436|Other|Continue usual diet|Blood and urine samples every 3 weeks. Participants continue to eat usual diet with no change in level of physical activity
112247|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
112248|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
112249|NCT00070759|Drug|Daclizumab|
112250|NCT01476475|Drug|Insulin glargine /lixisenatide fixed ratio combination (HOE901/AVE0010)|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
112251|NCT01476475|Drug|Insulin glargine (HOE901)|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
112252|NCT01476475|Drug|Metformin|Route of administration: oral
112253|NCT01476475|Device|re-usable pen-type self-injector device|
112254|NCT01476475|Device|disposable self injector device|
112255|NCT01476488|Drug|tacrolimus|
112256|NCT01476501|Drug|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
112257|NCT01476514|Other|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
112258|NCT01476527|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
112259|NCT01476540|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
111706|NCT01450436|Other|Peapod assessment|EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.
After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old).
111707|NCT01450449|Radiation|Radiotherapy|25 Gy in 5 daily fractions over 1 week
111708|NCT01450449|Radiation|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
111709|NCT01450462|Dietary Supplement|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
111710|NCT01450462|Dietary Supplement|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
111961|NCT01473940|Biological|ipilimumab|Given IV
111962|NCT01473940|Drug|gemcitabine hydrochloride|Given IV
111963|NCT00070499|Drug|Dasatinib|Given PO
111964|NCT01473940|Other|laboratory biomarker analysis|Correlative studies
111965|NCT01473953|Drug|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
111966|NCT01475929|Dietary Supplement|Probiotic supplement|A single strain probiotic supplement given at two doses
111967|NCT01475942|Dietary Supplement|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
111968|NCT01475955|Drug|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
111969|NCT01475955|Drug|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
111970|NCT01475955|Drug|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
111971|NCT01475955|Drug|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
111972|NCT01475955|Drug|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
111973|NCT00001228|Drug|Interferon|
110265|NCT01452789|Drug|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
110266|NCT01452789|Drug|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
110267|NCT01452802|Device|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
110268|NCT00001136|Biological|ALVAC-HIV MN120TMG (vCP205)|
110269|NCT00068770|Drug|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
110270|NCT01452802|Drug|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
110271|NCT01452815|Drug|Placebo|Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
110272|NCT01452815|Drug|10mg TZP-102|One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
110273|NCT01452815|Drug|20mg TZP-102|Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
110274|NCT01452828|Drug|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
110275|NCT01452828|Drug|TR-701 FA|Two separate infusions of 200 mg
110276|NCT01452828|Drug|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
110277|NCT01452841|Other|Grapefruit|1.5 Rio Red Grapefruit consumed daily for 6 weeks
110278|NCT01452841|Other|Control|Participants followed a diet low in bioactive rich fruits and vegetables and avoided citrus for six weeks
110279|NCT01452867|Device|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
110280|NCT00068783|Drug|imatinib mesylate|Given orally
110547|NCT01450839|Drug|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
111553|NCT01442662|Drug|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
111554|NCT01442675|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
111555|NCT01442688|Drug|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
111556|NCT00067808|Drug|Decitabine|10 mg/m^2 by vein over 1 hour daily for 10 days
111557|NCT01442688|Drug|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
111558|NCT01442701|Other|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
111559|NCT01442714|Drug|Azacitidine|75 mg/m2 SC/IV on d 1-7, IV
111560|NCT01442714|Drug|Lenalidomide|50mg PO given on d 8-28, oral
111561|NCT00068068|Procedure|Chemotherapy|
111562|NCT01445015|Behavioral|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
111563|NCT01445015|Other|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
111564|NCT01445028|Drug|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
111565|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
111566|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
111567|NCT01445054|Drug|111Indium CHX-A DTPA trastuzumab|The 111Indium-trastuzumab will be administered in the Clinical Center, Nuclear Medicine Department intravenously over a 10-15 minute period using an intravenous catheter
111568|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
111832|NCT01478165|Drug|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
112260|NCT00070811|Procedure|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
111339|NCT01447264|Procedure|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
111340|NCT01447277|Procedure|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
111341|NCT01447277|Procedure|Femoral Block only|Performing a preoperative sciatic nerve block only
111342|NCT00068341|Biological|trastuzumab|Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
111343|NCT01449916|Other|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
111344|NCT01449929|Drug|dolutegravir 50 mg OAD|1 x 50 mg tablet OAD
111345|NCT01449929|Drug|darunavir 800mg OAD|2 x 400mg tablets OAD
111346|NCT00001132|Drug|Abacavir sulfate|
111347|NCT00068523|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
111348|NCT01449929|Drug|ritonavir 100mg OAD|1 x 100mg tablet OAD
111349|NCT01449942|Biological|DNAzyme targeting EBV-LMP1 (DZ1)|DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.
The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
111350|NCT01449942|Other|Saline|0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.
The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
111351|NCT01449955|Drug|Rapamycin|Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.
a single dosage of 15mg will be administered during this study.
111352|NCT01449955|Drug|Placebo|Inactive
111353|NCT01449968|Other|home visit|home visit of UMG
111354|NCT01449968|Other|telephone management|telephone management of the situation reported by the patient's GP
111974|NCT00070655|Drug|vitamin K antagonist (warfarin or acenocoumarol) tablets|
111975|NCT01475955|Device|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
111976|NCT01475968|Other|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
111977|NCT01475968|Other|Filtered Air|Filtered Air
111978|NCT01475981|Drug|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
111979|NCT01475994|Other|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
111980|NCT01475994|Other|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
111981|NCT01476007|Drug|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
111982|NCT01476007|Drug|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
112318|NCT01474395|Drug|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
112319|NCT01474395|Drug|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
112320|NCT01474395|Behavioral|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
112321|NCT00070551|Drug|cytarabine|Given IV
112322|NCT01474408|Behavioral|interval training day 1|
112323|NCT01474408|Behavioral|Moderate exercise day 2|
110548|NCT01450839|Drug|Placebo|Matching Placebo tablets and tape
110549|NCT01450852|Behavioral|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
110550|NCT01450865|Drug|flupirtine|Potassium channel opener (SNEPCO)
110551|NCT01450878|Drug|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
110552|NCT01450904|Procedure|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
110553|NCT01450904|Procedure|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
110554|NCT00068588|Drug|capecitabine|Given orally
110555|NCT01450904|Procedure|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
110556|NCT01450930|Drug|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
110557|NCT01450930|Drug|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
110558|NCT01450943|Device|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
110559|NCT01450943|Procedure|debridement, irrigation|debridement, irrigation
110560|NCT01450943|Device|Dermagraft™|Dermagraft™ per company protocol
110561|NCT01450943|Device|Oasis™|Oasis™ per company protocol
110562|NCT01450956|Drug|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
110563|NCT01450956|Other|Control|Patients will receive only oxygen and air through oxygenator
110564|NCT01450982|Drug|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
110565|NCT00068601|Drug|cyclophosphamide|Part of planned chemotherapy regimen
110566|NCT01450995|Drug|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
110567|NCT01450995|Drug|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
111833|NCT01478165|Drug|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
111834|NCT01478178|Drug|VAL-083|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
111835|NCT01478230|Drug|Nicotine|Nicotine 5 mg Inhaler
111836|NCT01478230|Drug|Nicotine|Nicotine 10 mg Inhaler
111837|NCT01478256|Drug|Erythromycin|Topical erythromycin ointment twice a day
111838|NCT01478256|Drug|Besifloxocin|Topical Besifloxocin twice a day
111839|NCT01478282|Drug|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
111840|NCT01471522|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
111841|NCT01471535|Drug|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
111842|NCT01471548|Drug|TKI258|
111843|NCT00070317|Drug|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
111844|NCT01471574|Drug|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
111845|NCT01471574|Drug|Ribavirin|Tablets; oral; for patients weighing <75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing >75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
111846|NCT01471574|Drug|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
111847|NCT01471600|Procedure|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
111848|NCT01471613|Procedure|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
111849|NCT01471613|Drug|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
111850|NCT01471613|Biological|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
111851|NCT01471613|Other|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
111355|NCT01449981|Behavioral|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
111356|NCT01449981|Behavioral|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
111633|NCT01442727|Drug|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
111634|NCT01442727|Drug|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
111635|NCT01442740|Procedure|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
111636|NCT01442753|Behavioral|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
111637|NCT01442766|Drug|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
111638|NCT01442766|Drug|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
111639|NCT00001126|Drug|Cidofovir|
111640|NCT00067808|Drug|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
111641|NCT01442779|Drug|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
111642|NCT01442792|Drug|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
111643|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
111644|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
111645|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
111646|NCT01442805|Behavioral|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
111647|NCT01442805|Behavioral|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
111648|NCT01442818|Drug|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
112324|NCT01474408|Behavioral|Control day 3|
112325|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
112326|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
112327|NCT01474421|Drug|Placebo|Patients will receive placebo once daily orally for 28 days.
112328|NCT01474434|Drug|LCQ908|In Part A of the study subjects will be randomly assigned to one of two treatment sequences; 1) LCQ908 treatment, followed by washout period, followed by placebo or 2) placebo, followed by a washout period, followed by LCQ908 treatment. In Part B of the study, subjects will be randomly assigned to treatment with LCQ908
112329|NCT01474434|Drug|Placebo|In Part A of the study subjects will be randomly assigned to one of two treatment sequences; 1) LCQ908 treatment, followed by washout period, followed by placebo or 2) placebo, followed by a washout period, followed by LCQ908 treatment. In Part B of the study subjects will be randomly assigned to receive placebo
112330|NCT01476605|Procedure|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
112331|NCT01476605|Procedure|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
112332|NCT01476618|Other|No Intervention|No Intervention
111125|NCT01444287|Device|Lotrafilcon A|marketed product
111126|NCT01444287|Other|Spectacles|None - subject used own spectacles
111127|NCT01444300|Drug|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
111128|NCT01444300|Drug|Placebo|placebo pill, bid for 12 weeks
111129|NCT01444313|Device|narafilcon A contact lens|Soft contact lenses with UV protection
111130|NCT01444313|Device|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
111131|NCT01444326|Other|Dairy|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.
During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew).
111132|NCT01444339|Biological|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
111133|NCT01444339|Biological|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
111134|NCT00068042|Drug|Sandostatin LAR|
111135|NCT01444339|Biological|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
110864|NCT01443858|Drug|Nicotine Patch|Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.
Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.
110865|NCT00067977|Drug|anti-hypertensive medications|
110866|NCT01443858|Drug|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
110867|NCT01443871|Other|Aromatherapy|Subject will assigned inhale aromatherapy
110868|NCT01446341|Procedure|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
110869|NCT01446341|Procedure|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
110870|NCT01446406|Device|MONARCA|Monitoring affective symptoms entered by the patient every day.
110871|NCT01446406|Device|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
110872|NCT01446419|Device|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
110873|NCT01446419|Device|Intracept Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
110874|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
110875|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
110876|NCT01446458|Drug|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
110877|NCT01446458|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
110878|NCT00068276|Dietary Supplement|cholecalciferol|
110879|NCT01446484|Biological|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
111852|NCT01471626|Device|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
112183|NCT01478711|Other|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
112184|NCT01478724|Dietary Supplement|Milk proteins fraction|capsules, one per day, 24 months
112185|NCT01478737|Drug|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
112186|NCT01478737|Procedure|Vitrectomy|Vitrectomy only
112187|NCT01478750|Dietary Supplement|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
112188|NCT01478750|Procedure|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
112189|NCT01478776|Dietary Supplement|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
112190|NCT00071110|Procedure|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
112191|NCT01478776|Dietary Supplement|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
112192|NCT01478789|Dietary Supplement|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
112193|NCT01478789|Dietary Supplement|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
112194|NCT01478789|Dietary Supplement|placebo|100g/d yogurt with no added plant sterol
112195|NCT01478802|Device|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
112196|NCT01478802|Device|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
112197|NCT01478815|Behavioral|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
112198|NCT01478815|Other|Standard Care|Standard Care
112199|NCT01478828|Drug|Lovastatin|oral qd varying dose escalations/de-escalations
111649|NCT01442818|Drug|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
111650|NCT01442831|Drug|Human ADME|Oral single dose
111651|NCT00067808|Drug|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
111652|NCT01442844|Device|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
111653|NCT01442857|Radiation|MRI|High resolution MRI of the brachial plexus
111910|NCT01478308|Drug|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
111911|NCT01478308|Drug|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
111912|NCT01478308|Drug|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
111913|NCT01478321|Drug|Temozolomide|Given PO
111914|NCT01478321|Radiation|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
111915|NCT01478321|Biological|bevacizumab|Given IV
111916|NCT01478321|Other|questionnaire administration|Ancillary studies
111917|NCT01478334|Behavioral|high intensity interval training|First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.
Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period.
111918|NCT01478334|Behavioral|Control|First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.
Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.
111919|NCT00071097|Drug|TMC114/rtv|800mg TMC114/100mg rtv once daily
111920|NCT01478347|Biological|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
111136|NCT01444339|Biological|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
111137|NCT01444339|Biological|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
111138|NCT01444339|Biological|Placebo|0.5 mL, intramuscular
111139|NCT01444352|Biological|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
111140|NCT01444352|Biological|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
111141|NCT01444352|Biological|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
111142|NCT01444352|Biological|Placebo|0.5 mL, Intramuscular
111143|NCT01444365|Drug|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
111144|NCT01444365|Drug|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
111145|NCT00068055|Drug|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
111146|NCT01446822|Device|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
110215|NCT01454882|Behavioral|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
110216|NCT01454882|Behavioral|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
110217|NCT00069095|Drug|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
110218|NCT01454895|Behavioral|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
110880|NCT01446484|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
109986|NCT01456715|Biological|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
109987|NCT01458964|Drug|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
109988|NCT01458977|Drug|Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
109989|NCT01458977|Drug|Placebo|Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
109990|NCT00069641|Biological|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
109991|NCT01458990|Drug|Omeprazole|20mg PO BID for 20 days
109992|NCT01459003|Other|beauty care|beauty care performed before each chemo cycle
109993|NCT01459016|Other|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
109994|NCT01459016|Other|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
109995|NCT01459029|Drug|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
109996|NCT01459068|Behavioral|Common Elements Treatment Approach|CETA components include:
Engagement (encouraging participation)
Psychoeducation (introduction)
Anxiety Management Strategies (relaxation)
Behavioral Activation (getting active)
Cognitive Coping/Restructuring (thinking in a different way, part I and part II)
Imaginal Gradual Exposure (talking about difficult memories)
In Vivo Exposure (Live exposure)
Suicide/Homicide/Danger Assessment and Planning (safety)
Screening and Brief Intervention for Alcohol (alcohol intervention)
109997|NCT01459081|Drug|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
109998|NCT01459081|Drug|Placebo|inhaled by mouth, twice daily, for 5 days
109999|NCT01459094|Drug|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
110000|NCT01459094|Drug|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
110001|NCT00069641|Biological|Placebo|Patients will receive weekly infusions of placebo.
112200|NCT01472081|Biological|Nivolumab|
112201|NCT01472081|Biological|Pazopanib|
112202|NCT01472081|Drug|Sunitinib|
112203|NCT01472081|Biological|Ipilimumab|
111285|NCT01442181|Other|Medical therapy|Patients are treated with rhythm and rate control medications.
111286|NCT01442194|Drug|Fingolimod|
111287|NCT01442194|Drug|other disease-modifying therapy|
111288|NCT01442207|Procedure|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
111289|NCT01442207|Procedure|Standard Expectant Management|Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:
Standard management for placenta previa.
Hospital admission for vaginal bleeding/hemorrhage
Antenatal corticosteroids > 24w0d of gestation
Tocolytic therapy per physician's discretion
Magnesium sulfate for neuroprotection
Fetal Heart Rate Monitoring
Avoidance of digital examinations of the cervix
Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM > 34 wks, worsening maternal or fetal condition )
Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound.
111290|NCT01442233|Procedure|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
111291|NCT01442233|Procedure|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
111292|NCT01442246|Drug|Leuprorelin Acetate ((Eligard® )|Leuprorelin Acetate 45mg, one injection every 6 months for 24 months
111293|NCT01442246|Other|Reference arm|Reference arm is only a surveillance
111294|NCT01442259|Drug|AFQ056|
111295|NCT00067743|Drug|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
111296|NCT01442272|Drug|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
111297|NCT01442272|Drug|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
111298|NCT01442272|Drug|Habitual medication|Habitual medication
111299|NCT01442285|Behavioral|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
111921|NCT01478360|Drug|AIN457 (secukinumab)|Secukinumab intravenous injection
111922|NCT01478360|Drug|Placebo|Placebo intravenous injection
111923|NCT01478373|Drug|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
111924|NCT01478386|Other|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
111925|NCT01478386|Device|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
111926|NCT01471691|Drug|ranibizumab 1.0mg|High dose
111927|NCT01471704|Drug|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
112261|NCT01476553|Procedure|Extensive Intraperitoneal Lavage (EIPL)|EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.
Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius).
112262|NCT01476566|Behavioral|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
112263|NCT01476579|Device|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
112264|NCT01476592|Dietary Supplement|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
112265|NCT01476605|Procedure|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
112266|NCT01478971|Drug|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at <11 g/dL.
112267|NCT01478984|Procedure|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
112268|NCT01478984|Procedure|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
110219|NCT01454895|Behavioral|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
110220|NCT01454895|Behavioral|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
110221|NCT01454908|Device|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
110222|NCT01457027|Biological|Inflexal V|Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus
15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
110223|NCT01457040|Drug|TBI/CY/VP-16|CR1 Cohort will receive condition regimen of TBI/CY/VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
110224|NCT01457040|Drug|FA-TBI/CY/VP-16|Non-CR1 Cohort will receive conditioning regimen of FA-TBI/CY/VP-16: Flu: 35mg/m2/d: -10->-6d; AraC: 1g/m2/d, -10d->-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
110225|NCT01457053|Drug|Loop diuretics (furosemide, torsemide, bumetanide)|Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.
Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.
Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety.
110494|NCT01443169|Drug|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
110495|NCT01443169|Drug|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110496|NCT01443169|Drug|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110497|NCT01443169|Drug|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
110498|NCT01443169|Drug|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110002|NCT01459107|Procedure|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
110281|NCT01452867|Device|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
110282|NCT01454921|Behavioral|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
110283|NCT01454934|Drug|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
110284|NCT01454934|Drug|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days
Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days
Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days
Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only).
110285|NCT01454947|Behavioral|Clinical Decision Support: Justification Alerts|Justification Alerts triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (JA).
110286|NCT01454947|Behavioral|Audit and Feedback: Social Norms|Performance feedback that benchmarks providers' own performance to that of their peers (SN, for Social Norms).
110287|NCT01454947|Behavioral|CDS Order Sets: Alternative Prescriptions|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (AP, for Alternative Prescriptions).
110288|NCT00069095|Drug|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
110289|NCT01454960|Behavioral|Clinical Decision Support: Justification Alerts|Justification Alerts triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (JA).
110290|NCT01454960|Behavioral|Audit and Feedback: Social Norms|Performance feedback that benchmarks providers' own performance to that of their peers (SN, for Social Norms).
110291|NCT01454960|Behavioral|CDS Order Sets: Alternative Prescriptions|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (AP, for Alternative Prescriptions).
110292|NCT01454986|Drug|ALXN1007|Single dose, IV
110293|NCT01454986|Other|Placebo|Single dose, IV
110294|NCT01454999|Behavioral|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
110295|NCT01455012|Drug|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
111300|NCT01442298|Procedure|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
111301|NCT01442298|Procedure|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
111302|NCT01444508|Drug|HES 130/04|Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate "SAD".
111569|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
111570|NCT01445080|Drug|Sorafenib|Administered orally BID continuously. 28 days will be considered a cycle
111571|NCT01445106|Drug|Nelfinavir|
111572|NCT00068081|Drug|Capsaicin Dermal Patch|
111573|NCT01445106|Drug|Nelfinavir Mesylate|
111574|NCT01445119|Drug|Enzastaurin (LY317615)|
111575|NCT01445119|Drug|Carboplatin|
111576|NCT01445132|Drug|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
111577|NCT01445171|Device|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
111578|NCT01445197|Biological|Biostate|200 IU/kg administered daily
111579|NCT01445210|Procedure|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
111580|NCT01445210|Procedure|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
111581|NCT01445223|Drug|Lopinavir ritonavir|400mg BD 100mg BD
111582|NCT01445223|Drug|Atazanavir ritonavir|300mg QD 100mg QD
111583|NCT00068094|Drug|Probiotic-containing powder|
111584|NCT01445223|Drug|Efavirenz|600mg QD
111585|NCT01445236|Other|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
111586|NCT01445249|Procedure|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
112269|NCT01478997|Dietary Supplement|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
112270|NCT01478997|Dietary Supplement|Placebo Capsules|Carboxy Methyl Cellulose
112271|NCT01479010|Drug|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
112272|NCT00071188|Drug|ZD6474|
112273|NCT01479023|Drug|64Cu-DOTA-U3-1287|
112274|NCT01479023|Drug|U3-1287 (unlabeled)|
112275|NCT01479036|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
112276|NCT01479036|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
112277|NCT01479049|Drug|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
111357|NCT01449994|Device|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
111358|NCT00068523|Drug|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
111359|NCT01450007|Drug|Ropivacaine|25 ml ropivacaine 0.5%
111360|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (perineural)
111361|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
111362|NCT01450007|Drug|Normal saline|5 ml normal saline (intravenous)
111363|NCT01450007|Drug|Normal saline|0.8 ml normal saline (perineural)
111364|NCT01450020|Other|educational intervention|Receive ACS material
111365|NCT01442311|Other|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
111366|NCT01442311|Other|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
110499|NCT01443169|Drug|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110500|NCT01443169|Drug|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
110501|NCT01443169|Drug|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110502|NCT00067873|Behavioral|Exercise|
110503|NCT01443169|Drug|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
110504|NCT01443169|Drug|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
110505|NCT01443169|Drug|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110506|NCT01443169|Drug|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110507|NCT01443169|Drug|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
110508|NCT01445795|Drug|Placebo QD Fasted|Placebo capsule QD fasted x7 days
110509|NCT01445795|Drug|100 mg INX-08189 QD with ribavirin|100 mg INX-08189 capsule QD with ribavirin for seven days
110510|NCT01445795|Drug|Placebo QD with ribavirin|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
110511|NCT01445795|Drug|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
110512|NCT01445795|Drug|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
110513|NCT01445795|Drug|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
110803|NCT01449058|Drug|BYL719 plus MEK162|BYL719 plus MEK162 administered in this dose escalation study until MTD/RDE is achieved, followed by a dose expansion phase.
110804|NCT01449071|Biological|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
110805|NCT01449071|Biological|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
110806|NCT01449071|Biological|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
110296|NCT01455012|Drug|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
110568|NCT01451008|Device|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
110569|NCT01451021|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
110570|NCT01451034|Procedure|WHYX cancer group|WHYX cancer diagnosed by pathologic report
110571|NCT01443169|Drug|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
110572|NCT01443182|Behavioral|STAIR|Skills Training in Affective and Interpersonal Regulation
110573|NCT01443182|Behavioral|MPE|Modified prolonged exposure (MPE)
110574|NCT01443182|Behavioral|EMDR|Eye movement desensitization and reprocessing
110575|NCT01443195|Drug|Iron preparation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:
Before starting iron supplementation (maximum one week before).
At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).
Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation).
110576|NCT00067899|Drug|Vitamin E with and without Vitamin C|
110577|NCT01443208|Drug|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
110578|NCT01443208|Drug|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
110579|NCT01443208|Drug|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
110580|NCT01443221|Drug|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
110581|NCT01443221|Drug|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
110582|NCT01443234|Other|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
110583|NCT01443234|Other|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
111587|NCT01445249|Procedure|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
111588|NCT01447615|Behavioral|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
111589|NCT01447615|Other|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
111590|NCT01447628|Drug|Saline|intravenous, no active drug
111853|NCT01471639|Drug|intranasal ketorolac|15 mg
111854|NCT00070317|Procedure|Lymph Node Mapping|Undergo lymphatic mapping
111855|NCT01471652|Drug|Nutraceutical supplements|CoEnzyme Q10: oral gel capsule bid
Acetyl L-carnitine: oral capsule bid
Alpha Lipoic Acid: oral tablet qd
Docosahexaenoic acid: oral gel capsule bid
111856|NCT01471652|Drug|Placebo|Capsule form to imitate the following nutraceuticals:
Placebo 1: oral gel capsule bid
Placebo 2: oral capsule bid
Placebo 3: oral tablet qd
Placebo 4: oral gel capsule bid
111857|NCT01471665|Drug|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
111858|NCT01471665|Drug|Placebo|Placebo will be administered once daily for up to 16 days.
111859|NCT01471678|Drug|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
111860|NCT01471678|Drug|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
111861|NCT01471678|Drug|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
111862|NCT01471691|Drug|ranibizumab 0.5mg|Standard dose
111863|NCT01473693|Other|MRI Screening Form, MRI. Demographic / Medical Data|MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.
MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.
Demographic / Medical Data: Administration time: 5 minutes
111864|NCT01473706|Other|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
111367|NCT01442324|Procedure|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
111368|NCT01442337|Drug|ASP8597|one time IV dose
111369|NCT00067756|Drug|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
111370|NCT01442337|Drug|Placebo|one time IV dose
111371|NCT01442363|Drug|BLI-1300 low dose|topical ointment
111372|NCT01442363|Drug|BLI-1300 high dose|topical ointment
111373|NCT01442363|Drug|placebo|topical ointment
111374|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
111375|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
111376|NCT01442376|Drug|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
111377|NCT01442376|Drug|Placebo to Ondansetron|
111378|NCT01442376|Drug|Placebo to Ondansetron|
111654|NCT01442870|Drug|Metformin|Metformin
111655|NCT01442883|Device|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
111656|NCT01442909|Drug|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
111657|NCT01445262|Drug|Levocetirizine|
111658|NCT01445275|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
111659|NCT01445275|Other|Medical Chart Review|Ancillary study
111660|NCT01445275|Other|Study of Socioeconomic and Demographic Variables|Ancillary studies
111661|NCT01445301|Drug|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
111662|NCT01445301|Drug|CLDM 3% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
111663|NCT00068107|Drug|Replagal|enzyme replacement therapy
110807|NCT01449071|Biological|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
110808|NCT01449071|Biological|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
110809|NCT01449084|Procedure|immediate stent removal|The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.
THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE
110810|NCT01449084|Other|Leaving the stent in place|The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.
THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE
110811|NCT01449097|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
110812|NCT00068458|Other|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
110813|NCT01449097|Procedure|The femoral nerve block|US-guided femoral nerve block with ropivacaine
110814|NCT01449097|Procedure|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
110815|NCT01449110|Dietary Supplement|Placebo in primary cardiovascular prevention (PP)|12 months follow-up:
capsule/day of placebo (350 mg maltodextrin) for 6 months
capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months
110816|NCT01449110|Dietary Supplement|Placebo in secondary prevention|12 months follow-up:
capsule/day (350 mg maltodextrin) for 6 months
capsules/day (350 mg + 350 mg maltodextrin) for 6 months
110817|NCT01449110|Dietary Supplement|Grape extract in primary prevention (PP)|12 months follow-up:
capsule/day (350 mg grape extract) for 6 months
capsules/day (350 mg + 350 mg grape extract) for 6 months
110818|NCT01449110|Dietary Supplement|Grape extract in SP|12 months follow-up:
capsule/day (350 mg grape extract) for 6 months
capsules/day (350 mg + 350 mg grape extract) for 6 months
110819|NCT01451411|Drug|Placebo|Intravenous
110820|NCT01451424|Drug|Proellex|vaginal suppository, daily, for 12 weeks
111147|NCT01446835|Device|nelfilcon A contact lens with print|Investigational spherical contact lens
111148|NCT01446835|Device|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
111149|NCT01446848|Dietary Supplement|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
113050|NCT00070304|Biological|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
113051|NCT01471366|Dietary Supplement|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
113052|NCT01471366|Dietary Supplement|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
113053|NCT01471366|Dietary Supplement|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
113054|NCT01471379|Drug|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
113335|NCT01467141|Drug|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
113336|NCT00070174|Procedure|allogeneic bone marrow transplantation|
113337|NCT01467141|Drug|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
113338|NCT01467180|Device|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
113339|NCT01467180|Device|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
113340|NCT01467193|Dietary Supplement|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
113341|NCT01469494|Procedure|SIEA flap breast reconstruction|The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.
The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast.
113342|NCT01469507|Device|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
113343|NCT01469507|Drug|Hyaluronan|3 weekly injections
113344|NCT01469520|Drug|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
113345|NCT01469520|Drug|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
113346|NCT01469520|Drug|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
116497|NCT01488604|Device|Sham Nasal Spray|Sham nasal spray
116745|NCT01479621|Drug|Fluticasone propionate DPI Dose 2|Fluticasone propionate
116746|NCT01479621|Drug|Fluticasone propionate DPI Dose 3|Fluticasone propionate
116747|NCT01479621|Drug|Fluticasone propionate DPI Dose 4|Fluticasone propionate
116748|NCT01479634|Drug|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
116749|NCT01479634|Drug|Study-Provided ART|Study provided drugs:
Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate [TDF] and emtricitabine [FTC]) PLUS
Efavirenz [EFV]
116750|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
116751|NCT00001250|Drug|preoperative dose intense chemotherapy (FLAC/G-CSF)|
116752|NCT00071253|Drug|Olanzapine|
116753|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
116754|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
116755|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
116756|NCT01479647|Drug|PH-797804|Tablet, 24 mg, single dose
116757|NCT01479660|Other|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
116758|NCT01479660|Drug|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
116759|NCT01479673|Dietary Supplement|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
116760|NCT01479686|Procedure|iMRI|3.0TiMRI guided resection in adults with glioma
116761|NCT01479686|Procedure|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
116762|NCT01479699|Dietary Supplement|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
116763|NCT00071266|Drug|Niacin Extended Release and Lovastatin Tablets|
116764|NCT01479712|Procedure|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
113403|NCT01464996|Procedure|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
113404|NCT01464996|Procedure|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
113405|NCT01467193|Other|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
113406|NCT01467206|Behavioral|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
113407|NCT01467206|Behavioral|Standard care|Standard care as it is given to all stoke patients after stroke
113408|NCT01467219|Procedure|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
113409|NCT01467219|Procedure|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
112512|NCT01476956|Other|Observational study|RA patients on standard DMARD therapy
112513|NCT01476969|Device|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
112514|NCT01476982|Device|ClearView Scan|Assessment with ClearView device
112515|NCT01477008|Device|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
112516|NCT01477008|Procedure|Marrow Stimulation|Microfracture or Subchondral Drilling
112517|NCT01477021|Drug|cyclophosphamide|Given IV
112518|NCT01477021|Biological|NY-ESO-1-specific T cells|Given IV
112519|NCT01477021|Other|laboratory biomarker analysis|Correlative studies
112520|NCT00070915|Behavioral|Tai chi|
112521|NCT01477034|Dietary Supplement|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
112522|NCT01477060|Drug|Lapatinib|1250 mg/ die, os
112523|NCT01477060|Drug|Metformin|1500 mg/die, os
112524|NCT01477073|Drug|FSH-GEX™|
112871|NCT01477632|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
112872|NCT01477697|Dietary Supplement|Omega-3|50 mg/kg per day of omega-3 fatty acids
112873|NCT01477697|Dietary Supplement|Placebo|50 mg/kg per day of placebo equivalent
112874|NCT01471067|Drug|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
112875|NCT01471067|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
112876|NCT01471067|Drug|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
112877|NCT01471067|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
112878|NCT01471067|Drug|Rituximab|375 mg/m^2 by vein on Day -10 for B cell malignancy.
112879|NCT01471067|Drug|ATG|1.25 mg/Kg by vein on Day -4.
1.75 mg/Kg by vein on Day -3.
112880|NCT01471067|Drug|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
112881|NCT01471067|Drug|Clofarabine|30 mg/m^2 IV Day -7 to Day -4;
112882|NCT01471067|Radiation|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
112883|NCT00070278|Genetic|mutation analysis|
112884|NCT01471080|Procedure|RFA|using RFA to treat cavernous hemangiomas
112885|NCT01471080|Procedure|hepatectomy|using hepatectomy to treat cavernous hemangiomas
112886|NCT01471093|Drug|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
112887|NCT01471093|Drug|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
112888|NCT01471106|Drug|Dasatinib|Group 1: 40 mg by mouth once a day.
Group 2: 80 mg by mouth once a day.
113161|NCT01466998|Other|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
113162|NCT01467024|Other|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
113467|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
113468|NCT01462864|Behavioral|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
113469|NCT01465009|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
113470|NCT01465009|Drug|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
113471|NCT01465009|Drug|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
113472|NCT01465022|Drug|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
113473|NCT01465022|Drug|Progestin-only pill|.35 mg norethindrone once a day orally
113474|NCT01465035|Biological|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
113475|NCT01465035|Biological|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
113476|NCT01465048|Biological|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
113477|NCT00070109|Other|pharmacological study|Correlative studies
113478|NCT01465048|Biological|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
113479|NCT01465048|Biological|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
113480|NCT01465061|Behavioral|Online support group|Joining online support group
113481|NCT01465074|Drug|Nicotine polacrilex|4 mg
113482|NCT01465074|Drug|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
113483|NCT01465087|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
116765|NCT01479725|Procedure|HBOT|HBOT
116766|NCT01479738|Procedure|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
117079|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
117080|NCT01480219|Drug|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
117081|NCT01480219|Other|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
117082|NCT01480232|Drug|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
117083|NCT01480232|Drug|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
117084|NCT01480232|Drug|NicoDerm CQ Patch (Active)|One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
117085|NCT01480232|Drug|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
117086|NCT01480232|Behavioral|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
117087|NCT01480245|Drug|GSK2402968|6mg/kg/week
117088|NCT01480258|Biological|V419|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age
117089|NCT01480258|Biological|Rotavirus vaccine|Rotarix 1.5 mL oral dose at 2 and 4 months of age (subset 1) or RotaTeq 2 mL oral dose at 2, 4 and 5 months of age (subset 2)
117090|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
117091|NCT01480258|Biological|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age
117092|NCT01480258|Biological|INFANRIX hexa|INFANRIX hexa 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age
117093|NCT01480271|Drug|2 ng GSK2445053|2ng GSK2445053 administered intranasally
117094|NCT01480271|Drug|20ng GSK2445053|20ng GSK2445053 administered intranasally
117095|NCT01480271|Drug|100ng GSK2445053|100ng GSK2445053 administered intranasally
117096|NCT01480271|Drug|200ng GSK2445053|200ng GSK2445053 administered intranasally
112525|NCT01477073|Drug|Drug: Comparator 1|
112526|NCT01477073|Drug|Drug: Comparator 2|
112527|NCT01477073|Drug|Drug: Placebo|
112528|NCT01477073|Drug|FSH-GEX|
112529|NCT01477073|Drug|Placebo|
112530|NCT01477099|Device|Toothbrushing with a manual brush|Toothbrushing with a manual brush
112531|NCT00070915|Behavioral|Mindfulness-based Stress Reduction program|
112532|NCT01477112|Dietary Supplement|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
112533|NCT01477112|Dietary Supplement|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
112534|NCT01477125|Behavioral|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
112535|NCT01477138|Procedure|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
112810|NCT01473173|Drug|Esomeprazole 40mg|
112811|NCT01473199|Device|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
112812|NCT01473225|Other|Calorie information|Nutrition label featuring calorie information will be provided.
112813|NCT01473225|Other|No calorie information|No nutrition label will be provided in this condition.
112814|NCT01473238|Other|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
112815|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
112816|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
112817|NCT00070447|Drug|cyclophosphamide|
112818|NCT01473251|Drug|Lucentis|0.5 mg monthly for 4 months
113163|NCT00070174|Drug|methotrexate|
113164|NCT00070213|Drug|leucovorin calcium|
113165|NCT01469182|Biological|SCH 39641|Rapidly dissolving tablet sublingually once daily
113166|NCT01469182|Drug|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
113167|NCT01469221|Drug|Apaziquone|Apaziquone 4 mg in 40 mL diluent
113168|NCT01469221|Drug|Placebo|Matching placebo in 40mL diluent
113169|NCT01469234|Drug|loratadine|loratadine, one 10 mg tablet, orally
113170|NCT01469234|Drug|fexofenadine|fexofenadine, one 180 mg tablet, orally
113171|NCT01469234|Drug|placebo to loratadine|one tablet, orally
113172|NCT01469234|Drug|placebo to fexofenadine|one tablet, orally
113173|NCT01469247|Radiation|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
113174|NCT01469260|Other|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
113175|NCT00070213|Drug|oxaliplatin|
113176|NCT01469273|Drug|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
113177|NCT01469286|Device|TEA|Electroacupuncture at ST36
113178|NCT01469286|Device|Sham-TEA|Electroacupuncture at sham-points
113179|NCT01469312|Other|modified pasta|50 grams carbohydrate as a single breakfast meal
113180|NCT01469325|Other|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
113181|NCT01469325|Other|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
113182|NCT01469338|Drug|cabazitaxel|Given IV
113183|NCT01469338|Drug|prednisone|Given PO
113184|NCT01469338|Drug|octreotide pamoate|Given IM
113185|NCT01469338|Other|questionnaire administration|Ancillary studies
113484|NCT01465100|Radiation|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
112588|NCT00070564|Drug|cyclophosphamide|Given IV
112589|NCT01474785|Drug|human ghrelin|1 pmol/kg/min of human ghrelin administered by IV two times
112590|NCT01474785|Other|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
112591|NCT01474798|Drug|RA-18C3|For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.
For subjects weighing > 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection.
112592|NCT01474837|Behavioral|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
112593|NCT01474850|Procedure|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
112594|NCT01474863|Drug|High Dose Citrulline|Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
112595|NCT01477151|Drug|Volatile anesthetic|The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.
No IV drug infusions will be permitted until after protamine administration.
112596|NCT01477164|Behavioral|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at ~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
112597|NCT01477164|Behavioral|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
112598|NCT01477164|Behavioral|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
112599|NCT01477177|Device|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
117097|NCT01480271|Drug|400ng GSK2445053|400ng GSK2445053 administered intranasally
117098|NCT01480271|Drug|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
117099|NCT01480271|Drug|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
117100|NCT01480271|Drug|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
116204|NCT01483144|Drug|Sulindac and Placebo|Sulindac [150 mg tablet, one tablet orally once a day] and Placebo [three tablets orally once a day] for 24 months
116205|NCT01483157|Other|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
116206|NCT01485731|Drug|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
116207|NCT01485731|Radiation|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
116208|NCT01485731|Radiation|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
116209|NCT01485731|Procedure|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
116210|NCT01485731|Procedure|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
116211|NCT01485731|Procedure|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
116212|NCT01485731|Procedure|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
116213|NCT01485731|Procedure|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
116214|NCT01485731|Procedure|Proctoscopy|Optional. Pre-Treatment
116215|NCT01485731|Procedure|Cytoscopy|Optional. Pre-Treatment
112819|NCT01473264|Drug|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
112820|NCT01473264|Drug|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
112821|NCT01473264|Drug|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
112822|NCT01473277|Drug|BT-A (Dysport 500U), Triamcinolone acetonide|All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the "time zero" for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment.
112823|NCT01473290|Dietary Supplement|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
112824|NCT01473290|Other|placebo|Given PO
112825|NCT01473303|Biological|ganitumab|Given IV
112826|NCT01473303|Drug|fluorouracil|Given IV
112827|NCT01473303|Drug|irinotecan hydrochloride|Given IV
112828|NCT00070447|Drug|doxorubicin hydrochloride|
112829|NCT01473303|Drug|leucovorin calcium|Given IV
113109|NCT01477996|Procedure|30-gauge|30-gauge needle for IVT
113110|NCT01478009|Dietary Supplement|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
113111|NCT01478009|Dietary Supplement|Placebo|Placebo (3.0g/day) for 12 weeks
113112|NCT01478022|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
113113|NCT01478022|Drug|Ibuprofen|Ibuprofen 200 mg daily, capsules
113114|NCT01478022|Other|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
113115|NCT01478035|Drug|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
112995|NCT01473498|Other|Haemodynamic management|Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.
In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg.
112996|NCT01473511|Behavioral|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
112997|NCT01473524|Drug|Obeticholic Acid (OCA)|5 or 10 mg tablets once daily for 12 months during double-blind phase. 5 - 25 mg once daily for up to 5 years during long term safety evaluation phase.
112998|NCT01473524|Drug|Placebo|One tablet daily for 12 months.
113276|NCT01462409|Device|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
113277|NCT01462409|Device|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
113278|NCT01462422|Drug|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
113279|NCT01462422|Drug|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
113280|NCT01462435|Drug|Diclofenac Test (lower dose)|Capsules
113281|NCT01462435|Drug|Diclofenac Test (upper dose)|Capsules
113282|NCT01462435|Drug|Celecoxib|200 mg Capsules
113283|NCT01462435|Drug|Placebo|Capsules
113284|NCT01462448|Procedure|Blood Draw|Single blood draw of 30 ml after a period of overnight fasting
113285|NCT00069966|Biological|rituximab|
113286|NCT01462474|Drug|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
113287|NCT01462474|Drug|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
113288|NCT01462474|Radiation|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
113289|NCT01462487|Drug|Treatment with zanamivir|Subjects treated with zanamivir
113290|NCT01462500|Drug|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
112600|NCT01477190|Drug|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
112601|NCT00070915|Procedure|Therapeutic massage|
112602|NCT01477190|Drug|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
112603|NCT01477203|Drug|Escitalopram|2-4 weeks, 5-10mg, max 20mg
112889|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
112890|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
112891|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
112892|NCT01471119|Biological|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
112893|NCT01471132|Drug|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
112894|NCT00070278|Procedure|conventional surgery|
112895|NCT01471132|Drug|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
112896|NCT01471145|Drug|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
112897|NCT01471158|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
112898|NCT01473303|Other|placebo|Given IV
112899|NCT01473303|Other|questionnaire administration|Completed on paper
112900|NCT01473316|Drug|GDC-0980|Single oral dose
112901|NCT01473316|Drug|Ketoconazole|Repeating Oral Dose
112902|NCT01473329|Other|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
113347|NCT01469533|Other|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
113348|NCT00070239|Radiation|fludeoxyglucose F 18|Correlative studies
113349|NCT01469533|Other|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
112457|NCT01478880|Procedure|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
112458|NCT01478893|Biological|SEL-068|Sub-cutaneous injection, multiple dose
112459|NCT01478893|Biological|Saline|Sub-cutaneous injection, multiple dose
112460|NCT01478932|Behavioral|diaphragmatic breathing retraining|Experimental group participates in an 8-week breathing retraining intervention that requires 30 minutes a day. Control group receives an 8-week health promotion attention control condition.
112461|NCT01478945|Device|311 nm NB-UVB light|Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.
Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.
Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp.
112462|NCT00000258|Drug|Nitrous oxide 40% and placebo|
112463|NCT00001249|Drug|Yttrium-90 radiolabeled anti-Tac antibody|
112464|NCT00071136|Drug|gemcitabine|
112465|NCT01478958|Dietary Supplement|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
112466|NCT01478958|Dietary Supplement|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
112467|NCT01478958|Dietary Supplement|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
113116|NCT01478035|Drug|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
113117|NCT01478048|Biological|Elotuzumab|Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 & 2: Days 1, 8 & 15; Cycles 3-8: Days 1 & 11; Cycle 9+: Days 1 & 15); Until subject meets criteria for discontinuation of study drug
113118|NCT00071032|Biological|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
113119|NCT01478048|Drug|Bortezomib|Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
113120|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
113121|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 8 mg; (Cycles 1& 2: Days 1, 8, 15; Cycles 3-8: Days 1 &11; Cycles 9+; Days 1 & 15); Until subject meets criteria for discontinuation of study drug
113122|NCT01478048|Drug|Dexamethasone|Solution; IV; 8 mg; (Cycles 1& 2: Days 1, 8, 15; Cycles 3-8: Days 1 &11; Cycles 9+; Days 1 & 15); Until subject meets criteria for discontinuation of study drug
113123|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
113124|NCT01478061|Device|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
113125|NCT01478074|Drug|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC > 1000
113126|NCT01478074|Drug|Cytarabine|2 g/m2 daily from day -6 through -2
113127|NCT01471444|Drug|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
113410|NCT01467219|Procedure|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
113411|NCT00070187|Biological|aldesleukin|Given IV
113412|NCT01467219|Radiation|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
113413|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
113291|NCT01462513|Biological|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
113292|NCT01462513|Biological|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
113293|NCT01462552|Drug|Lapatanib|Prescription of lapatinib (Tykerb)
113294|NCT01462565|Drug|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
113295|NCT01462565|Drug|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
113296|NCT00069966|Drug|cisplatin|
113297|NCT01462578|Drug|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
112397|NCT01472484|Other|BAT 881|2 x 50 g
112398|NCT00070421|Procedure|management of therapy complications|
112399|NCT01472484|Other|586/8|2 x 50 g
112400|NCT01472497|Drug|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
112401|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
112402|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
112403|NCT01472536|Behavioral|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
112404|NCT01474447|Behavioral|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
112405|NCT01474460|Dietary Supplement|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
112406|NCT00070551|Other|pharmacological study|Optional correlative studies
112407|NCT01474460|Drug|none-control group|none. Pts will receive normal doses of warfarin and standard of care follow-up.
112903|NCT01473342|Behavioral|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors & their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting & participation. During the 9th week (Week 17), participants complete one final survey & accelerometer wear.
112904|NCT01473355|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
112905|NCT01473368|Dietary Supplement|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
112906|NCT00070447|Drug|prednisone|
112907|NCT01473368|Drug|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
113186|NCT00001202|Drug|Deslorelin|
113187|NCT00070213|Procedure|quality-of-life assessment|
113188|NCT01469338|Drug|octreotide acetate|Given SC
113189|NCT01469351|Drug|Liraglutide|Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.
Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.
Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.
1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used.
113190|NCT01469351|Drug|non-active study drug|placebo
113191|NCT01462292|Drug|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
113192|NCT01462292|Drug|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
113193|NCT01462292|Drug|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
113194|NCT00069953|Procedure|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
113195|NCT01462305|Device|goLITE|goLITE at 30 minutes per day, within 30 minutes of waking in the morning
113196|NCT01462305|Device|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
113197|NCT01462318|Drug|Probe drug cocktail|The probe drug cocktail consists of 5 mg oral midazolam, 200 mg caffeine,10 mg S-warfarin,10 mg vitamin K, 40 mg omeprazole, 30 mg dextromethorphan
112468|NCT01478971|Drug|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous [IV] or subcutaneous [SC]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of <11 g/dL.
112469|NCT01472549|Drug|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
112470|NCT01472549|Drug|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
112471|NCT01472562|Drug|lenalidomide|Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.
Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.
112472|NCT01472562|Biological|rituximab|Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.
Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52.
112473|NCT01472588|Behavioral|DPP lifestyle intervention-Community Health Coach (CHWs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
112755|NCT01475097|Drug|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
112756|NCT01475110|Drug|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
112757|NCT00070616|Drug|Palifermin 6 x 60 μg/kg/day|
112758|NCT01475123|Drug|Nicorandil|15mg per day
112759|NCT01475136|Drug|LY2140023|Administered orally
112760|NCT01475149|Other|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
112761|NCT01475162|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
112762|NCT01475175|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D) Medtronic Vision 3D™|Market approved Medtronic Vision 3D™ CRT-D implantable device.
112763|NCT01475175|Other|Adaptive CRT (aCRT) Pacing|Adaptive CRT pacing software adjusts how the device paces the heart based on the patient's current heart status.
112764|NCT01475188|Drug|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
113414|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
113415|NCT01467245|Procedure|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
113416|NCT01467245|Procedure|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
113417|NCT01467258|Drug|Amantadine|Single dose
113418|NCT01467284|Behavioral|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
113419|NCT01467284|Behavioral|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
113420|NCT01467297|Drug|ceftidoren|ceftidoren 200 mg bid for 5 days
113421|NCT01467297|Drug|levofloxacin|levofloxacin 500 mg once daily for 7 days
113422|NCT00070187|Biological|filgrastim|Given IV
113423|NCT01467310|Drug|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
113424|NCT01467323|Drug|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
113425|NCT01467323|Drug|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
113426|NCT01467336|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
113427|NCT01467362|Drug|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
113428|NCT01469572|Procedure|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (Liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
113429|NCT01469572|Drug|Everolimus|Given orally every day for the duration of the study
113430|NCT01469585|Drug|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
112536|NCT01479127|Device|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
112537|NCT01479127|Device|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
112408|NCT01474473|Device|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.
CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days
112409|NCT01474473|Device|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.
Placebo is applied on the wound for 10 minutes every 3 to 4 days
112410|NCT01474486|Drug|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
112411|NCT01474499|Drug|Glycerine|
112412|NCT01474499|Drug|Docusate sodium and sorbitol rectal solution|
112413|NCT01474512|Drug|80mg LY2439821 Dosing Regimen|Administered SC
112414|NCT01474512|Drug|Placebo|Administered SC
112702|NCT01477450|Device|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
112703|NCT01477450|Device|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
112704|NCT01470794|Biological|Toca 511|All subjects will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antibiotic 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, subjects will take a course of oral 5-FC. These courses of 5-FC will be repeated cyclically during the 6-month study.
112705|NCT01470807|Device|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
112706|NCT01470820|Other|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
112707|NCT01470833|Procedure|Early weight-bearing|The group allowed early weight-bearing is instructed as follows:
Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.
Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.
Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made.
112708|NCT01470846|Procedure|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
113198|NCT01462318|Biological|BIIB019 (Daclizumab)|150 mg in 1 ml pre-filled syringe (PFS)
113199|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
113200|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
113201|NCT01462331|Other|Sucrose|12g/dose, three times a day
113202|NCT01462344|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
113203|NCT01462344|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
113204|NCT01462344|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
113205|NCT00069953|Radiation|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (> 6 MV) will be used to deliver multiple (> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
113206|NCT01462344|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
113485|NCT01465100|Procedure|Hepatocyte Transplant|Within a maximum of two days after hepatic irradiation,the right or main portal vein will be occluded transiently (60-90 min)to provide a compensatory mitotic signal to donor hepatocytes. Directly following this transient occlusion of the portal vein, donor hepatocytes will be transplanted into the irradiated portion of the recipient's liver. If at 6 months we see an improvement in PHE tolerance but not normalization (i.e. PHE levels from 6 mg/dl to 10 mg/dl) on an unrestricted PHE diet, we will recommend re-transplantation with a goal of complete correction of PKU. Subjects will be re-evaluated every 6 months for re-transplantation.
113486|NCT01465100|Drug|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
113487|NCT01467362|Drug|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
113488|NCT01467362|Drug|desonide 0.1% cream|cream, once a day (in the evening) during flares
113489|NCT01467362|Other|Foaming gel|for the washing and cleaning
113490|NCT01467375|Drug|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
113491|NCT01467388|Procedure|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
113492|NCT00070187|Biological|recombinant interferon gamma|Given IV
113493|NCT01467401|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
112765|NCT00070941|Drug|oral citalopram|20mg or 30mg daily in two divided doses, along with placebo SAM-e.
112766|NCT01477463|Drug|Vitamin D3|4,000 IU oral vitamin D3
112767|NCT01477463|Drug|Vitamin D3|4,000 IU oral vitamin D3
112768|NCT01477476|Drug|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
112769|NCT01477476|Other|Placebo Comparator|A placebo will be given to 7 subjects.
112770|NCT01477489|Drug|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
112771|NCT01477489|Radiation|Standard radiation treatment|Limited to 60 Gy.
112772|NCT01477502|Other|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
112773|NCT01477502|Other|standard treatment without homeopathy|participants receive standard UTI prophylaxis
112774|NCT01477541|Other|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
113055|NCT01471379|Drug|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
113056|NCT01471379|Drug|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
113057|NCT01471379|Drug|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
113058|NCT01471392|Device|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
113059|NCT01471418|Drug|PET/CT with 18-FDG|FDG uptake
113060|NCT01471431|Other|spontaneous breathing trial|The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).
During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia <100 for >15 seconds or oxygen saturation by pulse oximetry <85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met.
113061|NCT00070304|Drug|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
112538|NCT01479153|Procedure|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
112539|NCT00071188|Drug|Carboplatin|
112540|NCT01479179|Drug|AMG 479|Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.
Phase II Starting Dose: Maximum tolerated dose from Phase I.
112541|NCT01479179|Drug|Trastuzumab|Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.
Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle.
112542|NCT01479192|Drug|Fenretinide|100mg (2cps/day) for 5 years
112543|NCT01479192|Other|Placebo|2 cpr/day of matched placebo for 5 years
112544|NCT01479218|Device|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
112545|NCT01479231|Drug|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
112546|NCT01479244|Biological|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
112547|NCT01479244|Biological|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
112548|NCT01479257|Behavioral|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
112549|NCT01479257|Device|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
112550|NCT00071201|Drug|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
112551|NCT01479257|Device|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
112552|NCT01479270|Drug|TAP Block of 0.25% Ropivacaine with 1:200,000 Epinephrine|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
112830|NCT01473303|Drug|oxaliplatin|Given IV
112831|NCT01475188|Other|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
112709|NCT01470846|Procedure|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
112710|NCT01470859|Drug|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
112711|NCT00070278|Drug|paclitaxel|
112712|NCT01470859|Drug|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
112713|NCT01470898|Device|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
112714|NCT01470911|Drug|SB010|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL.
112999|NCT01473537|Drug|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
113000|NCT01473550|Behavioral|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
113001|NCT01473563|Drug|Pemetrexed|Administered intravenously
113002|NCT01473576|Dietary Supplement|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
113003|NCT01473576|Dietary Supplement|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
113004|NCT01475422|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
113005|NCT01475422|Behavioral|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
113006|NCT01475435|Procedure|non- surgical periodontal treatment|scaling and root planning
113494|NCT01467401|Drug|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
113495|NCT01467414|Drug|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
113496|NCT01467427|Drug|NNC-0156-0000-0009|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
113497|NCT01467440|Device|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
113498|NCT01467453|Device|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
113499|NCT01467466|Drug|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
113500|NCT01467466|Drug|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
112604|NCT01477216|Other|ELSA 1-9|Measuring GI and II values for Finnish foods
112605|NCT01477242|Drug|Ondansetron|2mg (5mL) in < 15 kg and 4mg (10mL) in 15kg to 30kg
112606|NCT01477255|Behavioral|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
112607|NCT01477268|Drug|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
112608|NCT01477281|Drug|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
112609|NCT01477281|Drug|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
112610|NCT01477294|Drug|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
112611|NCT01477294|Drug|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
112612|NCT00070928|Drug|valerian|
112613|NCT01477307|Other|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
113062|NCT01471444|Drug|Fludarabine|Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.
Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3.
113063|NCT01471444|Drug|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
113064|NCT00070473|Drug|pemetrexed disodium|
113065|NCT01473589|Drug|Teriparatide|Administered by SC injection
113066|NCT01473589|Drug|Placebo|Administered by SC injection
113067|NCT01473589|Dietary Supplement|Calcium supplementation|Administered orally
113068|NCT01473589|Dietary Supplement|Vitamin D supplementation|Administered orally
113069|NCT01473602|Drug|Teriparatide|Administered by SC injection
113070|NCT01473602|Drug|Placebo|Administered by SC injection
113071|NCT01473602|Dietary Supplement|Calcium supplementation|Administered orally
113072|NCT01473602|Dietary Supplement|Vitamin D supplementation|Administered orally
113073|NCT01473615|Behavioral|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
113350|NCT01469546|Drug|Axitinib (AG-013736)|The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST [Response Evaluation Criteria In Solid Tumors] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
113351|NCT01469559|Drug|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
113352|NCT01469559|Drug|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
113353|NCT01469572|Drug|Pasireotide|Pasireotide is given as an injection.
112832|NCT01475201|Behavioral|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
112833|NCT01475201|Behavioral|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
112834|NCT00070616|Drug|Palifermin 2 x 180 μg/kg/day|
112835|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
112836|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
112837|NCT01475214|Other|Inactive placebo capsule|microcrystalline cellulose
112838|NCT01475227|Drug|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
112839|NCT01475227|Drug|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
112840|NCT01475253|Drug|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
112841|NCT01475253|Other|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
112842|NCT01475253|Procedure|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
112843|NCT01475266|Drug|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
112844|NCT01475266|Drug|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
112845|NCT00070616|Radiation|radiotherapy|
112846|NCT01475279|Drug|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
112847|NCT01475292|Drug|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
112848|NCT01475292|Drug|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
112849|NCT01475292|Drug|Placebo|Placebo administered via a nebuliser once daily for 14 days
113007|NCT01475435|Procedure|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
113008|NCT01475448|Other|Long distance training|Long distance training during four months, 3 times per week
113009|NCT01475448|Other|Walking training|Walking training during four months, three times per week
113010|NCT01475461|Drug|Placebo|double-dummy placebo tablets administered once-daily for 84-days
113011|NCT00070629|Drug|Chemotherapy|A taxane and a platinum compound given on week one of three-week cycles:
Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6
113012|NCT01475461|Drug|PF-04937319 - 3mg|PF-04937319 3mg administered as tablets once-daily for 84-days
113013|NCT01475461|Drug|PF-04937319 - 20mg|PF-04937319 20mg administered as tablets once-daily for 84-days
113014|NCT01475461|Drug|PF-04937319 - 50mg|PF-04937319 50mg administered as tablets once-daily for 84-days
113015|NCT01475461|Drug|PF-04937319 - 100mg|PF-04937319 100mg administered as tablets once-daily for 84-days
113016|NCT01475461|Drug|Sitagliptin - 100mg|Sitagliptin 100mg administered as tablets once-daily for 84-days
113017|NCT01475474|Device|Renew Insert|The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.
113298|NCT01464749|Behavioral|usual care|no specific rehabilitation
113299|NCT01464762|Drug|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
113300|NCT01464775|Other|NBI|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
113301|NCT01464775|Other|White light|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
113302|NCT00070083|Drug|doxorubicin hydrochloride|
113303|NCT01464788|Drug|Argatroban|100 micrograms/kilogram bolus, followed by 1 micrograms/kilogram/minute IV infusion for 48 hours.
113304|NCT01464788|Drug|Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours.
113305|NCT01464801|Dietary Supplement|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
113306|NCT01464801|Dietary Supplement|Placebo|Tablet Placebo 3 times daily for 6 months
112614|NCT01479478|Dietary Supplement|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
112615|NCT01479491|Other|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
112616|NCT00071240|Drug|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
112617|NCT01479504|Drug|nedaplatin and docetaxel|neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
112618|NCT01479504|Drug|cisplatin and docetaxel|neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
112619|NCT01479504|Drug|nedaplatin and docetaxel|neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
112620|NCT01479504|Drug|cisplatin and docetaxel|neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
112621|NCT01479517|Drug|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|Nasal spray with 0.1 mL per spray. Dose = 4 sprays of study drug per subject delivered at 4-minute intervals.
112908|NCT01473368|Drug|Saccharomyces boulardii AND Amoxicillin Clavulanate|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
112909|NCT01473381|Drug|Vilazodone|Vilazodone was supplied as film-coated tablets.
112910|NCT01473381|Drug|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
112911|NCT01473381|Drug|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
112912|NCT01473381|Drug|Citalopram|Citalopram was supplied as encapsulated tablets.
112913|NCT01473394|Drug|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
112914|NCT01473394|Drug|Vilazodone|Vilazodone was supplied as tablets.
112915|NCT01473407|Biological|Epoetin Hospira|Variable dose
112916|NCT01473407|Biological|Epogen (Amgen)|Variable dose
112917|NCT00070447|Drug|vincristine sulfate|
113354|NCT01462591|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
113355|NCT01462604|Other|non-drug intervention educational programme|educational programme
113356|NCT01462617|Drug|GSK2269557|Study Drug
113357|NCT01462617|Drug|GSK2269557 matching placebo|Study Drug
113358|NCT01462630|Drug|pazopanib hydrochloride|Given PO
113359|NCT01462630|Other|laboratory biomarker analysis|Correlative studies
113360|NCT01462630|Procedure|positron emission tomography|Correlative studies
113361|NCT01462630|Procedure|computed tomography|Correlative studies
113362|NCT01462630|Radiation|fludeoxyglucose F 18|Correlative studies
113363|NCT00069966|Drug|cytarabine|
113364|NCT01462643|Drug|LAS41004|once daily, topical ointment, 100 microgram per day
113365|NCT01462656|Drug|Non-EZG containing AED polytherapy|AED polytherapy without EZG
113366|NCT01462656|Drug|EZG containing AED polytherapy|AED polytherapy including EZG
113367|NCT01462656|Drug|Non-EZG AED monotherapy|AED monotherapy without EZG
113368|NCT01462656|Drug|EZG AED monotherapy|Any off-label use of EZG as monotherapy
112474|NCT00070421|Procedure|psychosocial assessment and care|
112475|NCT01472588|Behavioral|DPP Lifestyle intervention--health professionals/(PHCs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
112476|NCT01472588|Other|Self Help|Public education/information booklet on weight management.
112477|NCT01472614|Drug|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
112478|NCT01472627|Procedure|Blood draws|Blood draws
112479|NCT01472640|Drug|liraglutide|1.8 mg sc QOD
112480|NCT01472640|Drug|placebo|1 U sc QOD
113128|NCT01471444|Drug|Thymoglobulin|Both groups who receive a graft from an unrelated donor:
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete.
113129|NCT01471444|Procedure|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
113130|NCT01471444|Drug|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
113131|NCT01471444|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
113132|NCT01471457|Drug|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
113133|NCT01471470|Drug|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
113134|NCT01471483|Behavioral|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
113135|NCT00070304|Drug|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
113136|NCT01471483|Other|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
113137|NCT01471496|Procedure|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
113138|NCT01471509|Other|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
113139|NCT01471522|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
113140|NCT01471522|Procedure|coronary artery bypass graft surgery|Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, "cabbage"). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart.
113307|NCT01464814|Dietary Supplement|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
113308|NCT01464814|Dietary Supplement|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
113309|NCT01464827|Drug|ABT-450|ABT-450 tablets
113310|NCT01464827|Drug|ABT-333|ABT-333 tablets
113311|NCT01464827|Drug|ABT-267|ABT-267 tablets
113312|NCT01464827|Drug|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
113313|NCT00070083|Drug|prednisone|
113314|NCT01464827|Drug|Ritonavir|Ritonavir capsules
113315|NCT01464840|Drug|Azithromycin|500 mg intravenous infused over 1 hour
113316|NCT01464853|Other|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
113317|NCT01464853|Other|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
113318|NCT01464866|Other|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
113319|NCT01464866|Other|Hospital food|Typical hospital food given daily at meals
113320|NCT01464879|Drug|Testosterone (FE 999303)|
113321|NCT01464879|Drug|Testosterone (FE 999303)|
112415|NCT01474525|Device|Home Blood Glucose Telemonitoring System|The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.
Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers.
112416|NCT01474538|Drug|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
112417|NCT00001217|Drug|pre-surgical chemotherapy|
112418|NCT00070551|Other|laboratory biomarker analysis|Optional correlative studies
112419|NCT01474538|Drug|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
112918|NCT01473420|Biological|Epoetin Hospira|Variable dose
112919|NCT01473420|Biological|Epogen Amgen|Variable dose
112920|NCT01473433|Procedure|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
112921|NCT01475331|Drug|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
112922|NCT00001221|Drug|Growth Hormone (Humatrope)|
112923|NCT00070616|Drug|Chemotherapy|
112924|NCT01475331|Drug|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
112925|NCT01475331|Drug|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
112926|NCT01475344|Drug|Human Fibrinogen Concentrate|intravenous infusion over 5 min/vial:
Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg
No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)
Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g
Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
113207|NCT01462357|Biological|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6
113208|NCT01462357|Biological|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gard_2D) or at Day 0, Month 2 and Month 6 (Gard_3D), respectively.
113209|NCT01462357|Drug|placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding
113210|NCT01462370|Drug|Etoricoxib|Etoricoxib 120 mg tablet given orally for one dose.
113211|NCT01462370|Drug|Ibuprofen|Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
113212|NCT01462370|Drug|Placebo to etoricoxib|Placebo to etoricoxib, one tablet.
113213|NCT01462370|Drug|Placebo to ibuprofen|Placebo to ibuprofen, up to four 3-capsule doses.
113214|NCT01462370|Drug|Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg|Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
112481|NCT01472653|Drug|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
112482|NCT01472653|Radiation|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
112483|NCT01472653|Drug|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
112484|NCT01472666|Dietary Supplement|High content of MC-SFA|12 weeks dietary intervention
112485|NCT00070434|Drug|capecitabine|825mg/m2 BID, PO, daily
112486|NCT01472666|Dietary Supplement|Whey|12 weeks dietary intervention
112487|NCT01472666|Dietary Supplement|Low content of MC-SFA|12 weeks dietary intervention
112488|NCT01472666|Dietary Supplement|Casein|12 weeks dietary intervention
112489|NCT01472692|Drug|Febuxostat|80mg PO daily for 8 weeks
112490|NCT01472718|Device|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
112491|NCT01472718|Device|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
112492|NCT01472731|Other|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
112493|NCT01474564|Other|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
112494|NCT01474577|Other|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
112775|NCT01477554|Other|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
112776|NCT00001237|Drug|granulocyte-macrophage colony stimulating factor (GM-CSF)|
112777|NCT00070941|Drug|placebo|oral placebo citalopram and oral placebo SAM-e daily in two divided doses.
113141|NCT01471522|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
113142|NCT01471522|Behavioral|Lifestyle|diet, physical activity, smoking cessation
113431|NCT01469598|Drug|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
113432|NCT01469611|Biological|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
113433|NCT00070239|Other|fluorine F 18 fluorothymidine|Correlative studies
113434|NCT01469624|Drug|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
113435|NCT01469637|Drug|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
113436|NCT01469637|Drug|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
113437|NCT01469650|Dietary Supplement|cholecalciferal|400 IU/day
113438|NCT01469650|Dietary Supplement|cholecalciferol|800 IU/day D3
113439|NCT01469676|Device|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
113440|NCT01469689|Other|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
113441|NCT01469689|Other|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
113442|NCT01469702|Drug|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
113443|NCT01469702|Drug|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
113444|NCT00070239|Procedure|positron emission tomography|Correlative studies
113445|NCT01469702|Drug|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
112420|NCT01474551|Drug|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
112421|NCT01476787|Drug|Rituximab-CHOP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
112422|NCT01476787|Drug|Rituximab-CVP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
112423|NCT01476787|Drug|Rituximab-Bendamustine|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
112424|NCT01476800|Drug|YM178 OCAS|oral
112425|NCT01476800|Drug|Ketoconazole|oral
112426|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
112427|NCT00070863|Behavioral|Individual Cognitive Behavioral Therapy|
112428|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
112429|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
112430|NCT01476813|Drug|Comparator|comparison of different dosages of drug versus comparator
112431|NCT01476839|Biological|basiliximab|Given IV
112432|NCT01476839|Drug|carmustine|Given IV
112433|NCT01476839|Drug|etoposide|Given IV
112434|NCT01476839|Drug|cytarabine|Given IV
112435|NCT01476839|Drug|melphalan|Given IV
112436|NCT01476839|Other|pharmacological study|Correlative studies
112715|NCT01470911|Drug|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
112716|NCT01470937|Drug|Acarbose|acarbose 100 mg PO once daily
112717|NCT01472991|Drug|Placebo|Placebo capsules will be taken once daily for 4 weeks
113215|NCT01464567|Procedure|"T" Tube Spontaneous Breathing Trial|"T" Tube ventilation for 30 minutes
113216|NCT01464567|Procedure|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
113217|NCT01464593|Drug|Lyso-Thermosensitive Liposomal Doxorubicin|Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
113218|NCT01464593|Other|5% Dextrose Solution|Single 30 minute intravenous infusion
113219|NCT01464593|Drug|ThermoDox|ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
113220|NCT01464606|Drug|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
113221|NCT00070083|Biological|rituximab|
113222|NCT01464606|Drug|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
113223|NCT01464606|Drug|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
113224|NCT01464606|Drug|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
113225|NCT01464606|Drug|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
113226|NCT01464619|Other|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
113227|NCT01464619|Other|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
113501|NCT01467466|Drug|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
113502|NCT01467466|Drug|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
113503|NCT00070187|Drug|carmustine|Given IV
113504|NCT01467479|Drug|Telaprevir|Tablet
113505|NCT01467479|Drug|Ribavirin|Tablet
113506|NCT01467479|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
113507|NCT01467479|Drug|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
112778|NCT01477567|Drug|LY3009385|
112779|NCT01477567|Drug|Placebo|
112780|NCT01477580|Biological|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112781|NCT01477580|Biological|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112782|NCT01477580|Biological|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
112783|NCT01477580|Biological|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112784|NCT01477580|Biological|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112785|NCT01477580|Biological|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
112786|NCT01477580|Biological|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
112787|NCT01477580|Biological|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112788|NCT01470937|Drug|Placebo|acarbose placebo
112789|NCT01470950|Procedure|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
112790|NCT01470963|Other|Implementation of referral template|Implementation of referral template at the GP office
112791|NCT01470976|Other|Goal-directed Resuscitation Therapy (GDT)|A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.
The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.
When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.
The final step will be red blood transfusion to reach a hematocrit higher than 28%.
113074|NCT01473628|Drug|Rituximab|375 mg/m2 by vein every week for four consecutive weeks during the radiation treatment.
Maintenance: 375 mg/m2 by vein every 3 months for a total of 2 years.
113075|NCT00070486|Drug|carboplatin|given IV
113076|NCT01473628|Radiation|Radiation|Total dose of 24 to 30 Gy over 12 to 15 treatments.
113077|NCT01473654|Behavioral|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
113446|NCT01469715|Device|GBP CGM|Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active & one mock device simultaneously during hyperglycemic & hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 & 4: Subjects will return to the research center approximately 24 & 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 & 5.
113447|NCT01469728|Procedure|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
113448|NCT01462760|Device|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
112553|NCT01479283|Drug|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.
Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.
Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered.
112554|NCT01472731|Drug|GC1008|5 mg/kg intravenous use
112555|NCT01472744|Behavioral|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
112556|NCT01472744|Behavioral|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
112557|NCT00070434|Drug|fluorouracil|Bolus + IV for 46 hrs on Day 1
112558|NCT01472744|Behavioral|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
112559|NCT01472744|Behavioral|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
112560|NCT01472757|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
112561|NCT01472757|Drug|Placebo|Placebo delivered via a new dry powder inhaler
112562|NCT01472770|Drug|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
112718|NCT00070434|Radiation|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
112719|NCT01473004|Device|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
112720|NCT01473017|Behavioral|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
112721|NCT01473043|Drug|Axitinib|5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
112722|NCT01473056|Drug|JTK-853|Tablets, twice a day for 3 days
112723|NCT01473056|Drug|Dose 2 JTK-853|Tablets, twice a day for 3 days
112724|NCT01473056|Drug|Dose 3 JTK-853|Tablets, three times a day for 3 days
112725|NCT01473056|Drug|Dose 4 JTK-853|Tablets, twice a day for 3 days
112726|NCT01473056|Drug|Placebo|Tablets, twice a day or three times a day for 3 days
112727|NCT01473069|Drug|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
112728|NCT01473069|Drug|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
112729|NCT00070434|Drug|Pyridoxine|50mg TID, PO daily
112730|NCT01473082|Device|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
112731|NCT01473082|Device|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
112732|NCT01473095|Drug|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
112733|NCT01473108|Drug|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
113018|NCT01475487|Procedure|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
113019|NCT01475500|Procedure|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
113508|NCT01467492|Drug|Telaprevir|Tablet
113509|NCT01467492|Drug|Ribavirin|Tablet
113510|NCT01469728|Procedure|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
113511|NCT01469741|Behavioral|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
113512|NCT01469767|Drug|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
113513|NCT01469793|Drug|DMOT4039A|multiple ascending doses
113514|NCT01469806|Device|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
113515|NCT01469819|Drug|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
113516|NCT01469832|Biological|MA09-hRPE|Cohort 1 50,000 cells
Cohort 2 100,000 cells
Cohort 2a Better Vision 100,000 cells
Cohort 3 150,000 cells
Cohort 4 200,000 cells
113517|NCT00070252|Drug|Capecitabine|Given PO
113518|NCT01469845|Device|3% hypertonic saline|4 ml dose to be administered every 6 hours
113519|NCT01469858|Device|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
113520|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
113521|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
113522|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
112622|NCT01479517|Drug|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|Nasal spray with 0.2 mL per spray. Dose = 2 sprays of study drug per subject delivered at 4-minute intervals.
112623|NCT01479517|Drug|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|Nasal spray with 0.2 mL per spray. Dose = 1 spray of study drug per subject.
112624|NCT01479530|Drug|Placebo|Once daily; tablet; orally; 16 weeks
112625|NCT01479530|Drug|Azilect®|1 mg daily; tablet; orally; 16 weeks
112626|NCT01479543|Other|Probiotic CNCM I-4034|Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
113078|NCT01473667|Procedure|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
113079|NCT01473667|Procedure|Local site infiltration|Local site infiltration using 2% lidocaine
113080|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
113081|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
113082|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
113083|NCT01473693|Other|MRI Screening Form, MRI, Demographic / Medical Data form|MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.
Demographic / Medical Data: Administration time: 5 minutes.
113084|NCT01475500|Procedure|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
113085|NCT01475500|Procedure|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
113086|NCT01475500|Procedure|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
113087|NCT01475500|Procedure|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
113088|NCT01475500|Procedure|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
113089|NCT01475500|Procedure|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
113369|NCT01462669|Drug|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
113370|NCT01462669|Drug|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
112563|NCT01472783|Drug|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
112564|NCT01472796|Dietary Supplement|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
112565|NCT01472796|Drug|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
112566|NCT01472809|Drug|ZYGK1|ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.
Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved
112567|NCT01472809|Drug|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
112568|NCT00070434|Drug|irinotecan hydrochloride|IV infusion over 90 min on Day 1
112850|NCT01475305|Drug|MEDI-557|Recombinant humanized immunoglobulin G (IgG)1kappa monoclonal antibody
112851|NCT01475305|Other|Placebo|Placebo
112852|NCT01475318|Drug|mifepristone|200 mg mifepristone on day 1
112853|NCT01475318|Drug|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
112854|NCT01475318|Drug|Misoprostol|misoprostol 800mcg PV on day 3
112855|NCT00070954|Dietary Supplement|ginkgo biloba|EgB 761
112856|NCT01477580|Biological|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112857|NCT01477580|Biological|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112858|NCT01477580|Biological|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112859|NCT01477580|Biological|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
112860|NCT01477580|Biological|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
112861|NCT01477593|Procedure|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
113020|NCT01475500|Procedure|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
113021|NCT01475500|Radiation|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
113022|NCT00070629|Drug|Chemotherapy|A taxane and a platinum compound given on week one of three-week cycles:
Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6
113023|NCT01475500|Other|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
113024|NCT01477853|Other|Placebo to atorvastatin|Placebo to atorvastatin orally daily. Participants not meeting specific goals for low density lipoprotein cholesterol during Phase A will be switched to atorvastatin 80 mg.
113025|NCT00070993|Drug|creatine monohydrate|
113026|NCT01477853|Drug|Metformin|Participant will remain on prestudy dose of metformin (at leat 1500 mg daily) throughout entire study.
113027|NCT01477853|Drug|Glimepiride|Phase A: Glimepiride 1 or 2 mg once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals. Phase B: glimepiride up to 6 mg daily with placebo to sitagliptin and atorvastatin 80 mg daily
113028|NCT01477853|Drug|Placebo to glimepiride|Placebo to glimepiride orally daily
113029|NCT01477866|Dietary Supplement|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
113030|NCT01477866|Other|conventional therapy|conventional therapy for colon-rectal cancer
113031|NCT01477879|Other|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
113032|NCT01477879|Other|placebo (versabase gel only)|versabase gel only
113033|NCT01477892|Drug|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
113034|NCT01477905|Device|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
113035|NCT01477905|Device|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
113036|NCT00071006|Drug|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
112627|NCT00071253|Drug|Divalproex Sodium (Delayed-Release Tablets)|
112628|NCT01479543|Other|Probiotic CNCM I-4035|9x10E9 cfu (colony forming unit) per day during 28 days.
112629|NCT01479543|Other|Probiotic CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
112630|NCT01479543|Other|Probiotics CNCM I-4035 and CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
112631|NCT01479543|Other|Placebo|Placebo capsule for 28 days.
112632|NCT01479556|Drug|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
112633|NCT01479556|Drug|Placebo|150mg BID p.o.
112634|NCT01479569|Procedure|Pericardiocentesis|
112635|NCT01479582|Drug|Access to unlicensed cord blood units|
112636|NCT01479595|Drug|QBX258|QBX258 intravenous infusion every 4 weeks for up to 4 doses total
112637|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
112638|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
112639|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
112640|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
112641|NCT00070434|Drug|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
112642|NCT01472861|Procedure|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
112643|NCT01472861|Other|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
112927|NCT01475344|Drug|Placebo|intravenous infusion over 5 min/vial:
Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg
No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)
Placebo: 1.5 g / 3 g / 4.5 g / 6 g
Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
112928|NCT01475357|Other|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
113371|NCT01462669|Drug|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
113372|NCT01462669|Drug|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
113373|NCT01462695|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
113374|NCT00069966|Drug|methylprednisolone|
113375|NCT01462695|Other|Pharmacological Study|Correlative studies
113376|NCT01462695|Drug|Sunitinib Malate|Given PO
113377|NCT01462708|Drug|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not >10% of 10 mCi limit)of [18F]MK-9470, followed by PET imaging.
113378|NCT01462721|Device|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
113379|NCT01462734|Procedure|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
113380|NCT01462747|Device|KULIST|Twice daily dosing for 8 weeks
113381|NCT01464905|Biological|Placebo|1 mL SQ, every other day for 4 months
113382|NCT01464905|Biological|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
113383|NCT01464918|Device|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
113384|NCT01464931|Drug|Denosumab|Adminstered by subcutaneous injection
113385|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
113386|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
113387|NCT01464944|Drug|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
113388|NCT01464944|Drug|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
113389|NCT01464944|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
112862|NCT01477593|Procedure|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
112863|NCT01477593|Procedure|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
112864|NCT01477606|Drug|Midostaurin|Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.
Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.
Maintenance therapy:
50 mg oral twice daily over one year.
112865|NCT01477606|Drug|Cytarabine|Induction therapy:
200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)
Consolidation therapy:
Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).
Older patients (>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2).
112866|NCT00070954|Other|matched placebo|Inactive look-alike placebo
113143|NCT01466868|Drug|MK2206|Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.
The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms.
113144|NCT01466881|Drug|Alisertib|Given PO
113145|NCT01466881|Other|Laboratory Biomarker Analysis|Correlative studies
113146|NCT01466881|Other|Pharmacological Study|Correlative studies
113147|NCT01466894|Biological|IMM 124-E|Tablets orally twice a day for 24 weeks
113148|NCT01466894|Biological|Placebo|Tablets orally twice daily for 24 weeks
113149|NCT01466907|Other|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
113150|NCT01466907|Other|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
113151|NCT01466933|Behavioral|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
113152|NCT00070174|Drug|gemtuzumab ozogamicin|
113322|NCT01464892|Behavioral|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
113323|NCT01464892|Behavioral|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
113324|NCT00070083|Drug|vincristine sulfate|
113325|NCT01464905|Biological|NU100|0.25 mg SQ, every other day for 12 months
113326|NCT01467115|Biological|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
113327|NCT01467115|Drug|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
113328|NCT01467115|Drug|Erythropoetin|Subcutaneous or intravenous
113329|NCT01467115|Drug|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
113330|NCT01467115|Drug|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
113331|NCT01467115|Drug|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
113332|NCT01467128|Other|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
113333|NCT01467128|Other|No Intervention|Normal hospital pharmaceutical care
112929|NCT01475357|Other|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
112930|NCT01475370|Drug|OCV-501|Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.
After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose.
112931|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
112932|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
112933|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
112934|NCT00070629|Drug|CPG 7909|CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
112935|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
112936|NCT01475396|Behavioral|exercise|
112937|NCT01475409|Biological|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
112938|NCT01477710|Procedure|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
112939|NCT01477710|Procedure|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
112940|NCT01477710|Procedure|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
112941|NCT00070967|Procedure|Acupuncture|
113228|NCT01464632|Device|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
113229|NCT01464645|Device|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
112495|NCT01474590|Drug|Epiduo/Tactuo + doxycycline 200mg|Epiduo gel: topical to the face, once daily in the evening Doxycycline: oral, 2 capsules a day. The capsules should be taken with a glass of water and with food either as a single dose or in two divided doses during the day.
112496|NCT01474590|Drug|Isotretinoin + vehicle gel|Vehicle gel: topical to the face, once daily in the evening Isotretinoin: oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
112497|NCT01474603|Dietary Supplement|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
112498|NCT01474616|Other|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
112499|NCT01474629|Dietary Supplement|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
112500|NCT01474629|Dietary Supplement|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
112501|NCT00070564|Biological|pegfilgrastim|Given IV
112502|NCT01474642|Drug|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
112503|NCT01474642|Drug|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
112504|NCT01474655|Procedure|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
112505|NCT01474668|Drug|GDC-0941|Single oral dose\n \n\n\n\n
112506|NCT01474681|Biological|HSC835|
112507|NCT01474694|Other|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
112508|NCT01474707|Behavioral|Group one|Group 1 will view the knowledge-based video only
112509|NCT01474707|Behavioral|Group two|Group two will view the motivational video only
113153|NCT01466933|Behavioral|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
113154|NCT01466946|Behavioral|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin & Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
113155|NCT01466959|Other|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
113156|NCT01466959|Other|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
113157|NCT01466972|Drug|Pazopanib|Oral, 800mg tablet daily per cycle
113158|NCT01466985|Drug|Doravirine|Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
113159|NCT01466985|Drug|Placebo|Placebo tablets once daily for 7 days.
113160|NCT01466998|Other|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
113449|NCT01462760|Device|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
113450|NCT01462773|Drug|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
113451|NCT01462773|Drug|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
113452|NCT00001188|Procedure|radiation therapy following surgery|
113453|NCT00069966|Drug|pixantrone dimaleate|
113454|NCT01462786|Drug|ATX-101|2 mg/cm2 ATX-101
113334|NCT01467141|Drug|insulin aspart|Injected s.c. (under the skin) three times a day
112437|NCT01476839|Other|laboratory biomarker analysis|Correlative studies
112438|NCT00070876|Behavioral|Mental health communication skills training|
112439|NCT01476839|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic progenitor cell infusion
112440|NCT01476839|Biological|yttrium Y 90-labeled basiliximab|Given IV
112441|NCT01476878|Device|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
112442|NCT01476891|Other|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
112443|NCT01476891|Other|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
112444|NCT01476904|Drug|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine, 2x 0 mcg placebo inhalations, QID, every 4-6 hours
112445|NCT01476904|Drug|Primatene Mist|2x 220 mcg Primatene Mist inhalations, QID, 4-6 times a day
112446|NCT01476904|Drug|Epinephrine inhalation aerosol, HFA|2 inhalations QID, 125 mcg/inhalation
112447|NCT01476904|Drug|epinephrine inhalation aerosol|2 inhalations of 125 mcg QID
112448|NCT01476917|Device|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
112449|NCT00070902|Procedure|Lumbar side-posture spinal adjusting|
112450|NCT01478841|Drug|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
112451|NCT00071136|Drug|pemetrexed|
112452|NCT01478841|Drug|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
112453|NCT01478854|Radiation|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
112454|NCT01478854|Drug|Chemotherapy|Temozolomide
113230|NCT01464658|Procedure|panniculectomy|surgery
113231|NCT01464671|Drug|Bivalirudin|Anticoagulation during percutaneous coronary intervention
113232|NCT00070083|Drug|cyclophosphamide|
113233|NCT01464671|Drug|Heparin|Anticoagulation during percutaneous coronary intervention
113234|NCT01464697|Drug|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
113235|NCT01464697|Drug|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
113236|NCT01464723|Drug|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
113237|NCT01464736|Other|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
113238|NCT01464749|Behavioral|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
113239|NCT01467037|Other|No intervention done|Not applicable because no intervention was done.
113240|NCT01467050|Other|Application of STOPP/START criteria|The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.
Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's.
113241|NCT01467050|Other|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
113242|NCT01467063|Dietary Supplement|Glutamine|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
113523|NCT01469884|Drug|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
113524|NCT01469884|Drug|Cyclosporine|Trough level should be between 100 and 200ng/ml.
112510|NCT01476930|Procedure|cupping and serkangabin syrup|wet cupping serkangabin syrup
112511|NCT01476930|Drug|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
112792|NCT01470976|Other|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
112793|NCT00070278|Genetic|comparative genomic hybridization|
112794|NCT01470989|Biological|canakinumab|Canakinumab 150 mg
112795|NCT01471002|Device|Galil Medical patented 17G Cryoablation Needles|
112796|NCT01471015|Drug|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
112797|NCT01471015|Drug|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
112798|NCT01471015|Drug|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
112799|NCT01471028|Biological|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
112800|NCT01471028|Other|Standard of care (Control)|Control receives standard medical treatment.
112801|NCT01471041|Device|Venous Window Needle Guide|Subcutaneous, extravascular needle guide made of medical-grade titanium
112802|NCT01471054|Drug|Ozurdex|Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:
i.The study eye must have shown initial favorable response to prior Ozurdex implant (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]) ii. Interval since last Ozurdex implant should be > 4 and < 12 months. iii. The study eye must show definite evidence of recurrence of macular edema (>10% increase in central macular thickness with worsening of visual acuity [decrease of BCVA of >1 line not attributable to other causes]).
iv. None of the exclusion criteria for Ozurdex implant must be present.
112803|NCT01471054|Drug|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]). If after extension, the macular edema recurs (>10% increase in central macular thickness with worsening of visual acuity [decrease of BCVA of >1 line not attributable to other causes based on the judgment of the investigators]), then the interval between injections will be reduced to 4 weeks without further attempts to extend the injection interval.
112804|NCT00001209|Drug|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
112805|NCT00070278|Genetic|microarray analysis|
113455|NCT01462799|Behavioral|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
113456|NCT01462799|Behavioral|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
113457|NCT01462812|Drug|Sumatriptan|Sumatriptan 20mg
113458|NCT01462812|Drug|Placebo|Matching placebo
113459|NCT01462825|Dietary Supplement|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
113460|NCT01462825|Dietary Supplement|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
113461|NCT01462838|Biological|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
113462|NCT01462851|Drug|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
113463|NCT01462851|Drug|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
113464|NCT00069966|Procedure|autologous bone marrow transplantation|
113465|NCT01462851|Drug|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
113466|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
112569|NCT01472822|Dietary Supplement|Omija extract.|Omija extract 1.2g/day for 12weeks
112570|NCT01472822|Dietary Supplement|Placebo|Placebo 1.2g/day for 12weeks
112571|NCT01472835|Drug|Midazolam|Used for anxiolysis
112572|NCT01472835|Drug|Fentanyl|Used for analgesia and as a sedative
112573|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
112574|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
112455|NCT01478867|Other|Detection of gluten in feces|Detection of Gluten in Feces
112456|NCT01478880|Procedure|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
112734|NCT01473108|Drug|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
112735|NCT01473108|Drug|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
112736|NCT01473108|Drug|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
112737|NCT01473121|Other|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
112738|NCT01473147|Drug|Exenatide|Exenatide 5 microgram bid sc.
112739|NCT01473147|Drug|Normal saline|Normal saline 2 u bid sc.
112740|NCT00001212|Drug|cyclosporin A|
112741|NCT00070447|Biological|rituximab|
112742|NCT01475006|Drug|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
112743|NCT01475019|Drug|Orlistat|Tablet, 120 mg, three times daily, for six months
112744|NCT01475019|Drug|Sibutramine|Tablet, 10 mg, once daily, for six months
112745|NCT01475019|Behavioral|Diet and physical exercise|Hypocaloric diet and regular physical exercise
112746|NCT00070590|Drug|Bosentan|
112747|NCT01475032|Drug|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
112748|NCT01475032|Drug|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
112749|NCT01475032|Drug|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
112750|NCT01475058|Biological|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
112751|NCT01475071|Drug|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
112752|NCT01475071|Drug|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
113525|NCT01469884|Drug|Tacrolimus|Trough level should be between 5 and 10ng/ml.
113526|NCT01469910|Drug|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
113527|NCT01469910|Drug|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
113528|NCT00070252|Drug|Docetaxel|Given IV
113529|NCT01469923|Drug|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
113530|NCT01469923|Drug|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
113531|NCT01469936|Dietary Supplement|PERMEAPROTECT|Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.
Duration : 5 weeks +/- 1 week.
Dosage :
First Week of intervention : 1/2 stick per day
Second to 5th Week : 1 stick per day
113532|NCT01469936|Dietary Supplement|PLACEBO|Duration : 5 weeks +/- 1 week.
Dosage:
First Week : 1/2 stick per day
Second to 5th Week : 1 stick per day
113533|NCT01469949|Other|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
113534|NCT01462877|Drug|fenofibrate|Fenofibrate Capsule 200mg qd orally
113535|NCT01462890|Biological|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22
113536|NCT01462890|Biological|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 44
113537|NCT01462890|Drug|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
113538|NCT01462890|Drug|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
113539|NCT01462890|Other|specialized pathology review (Germany only)|before randomization
113540|NCT00069966|Procedure|peripheral blood stem cell transplantation|
113541|NCT01462903|Biological|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
113542|NCT01462916|Dietary Supplement|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control [I/C] and control to intervention [C/I] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
112806|NCT01471067|Drug|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
112807|NCT01473160|Device|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
112808|NCT01473160|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
112809|NCT01473173|Drug|CJ-12420|
113090|NCT01475513|Drug|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
113091|NCT01475526|Other|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
113092|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
113093|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
113094|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
113095|NCT01475539|Biological|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
113096|NCT01475552|Drug|Abciximab|Patients, who showed PRU >270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
113097|NCT01475552|Drug|control|Patients,who showed PRU >270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.
Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd
113098|NCT01475578|Drug|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
113099|NCT01475578|Drug|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
113100|NCT01475591|Behavioral|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
113101|NCT01475604|Device|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
113102|NCT01475604|Device|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
113103|NCT01475617|Dietary Supplement|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
112575|NCT01474707|Behavioral|Group three|Group three will view both knowledge-based and motivational videos
112576|NCT01474707|Behavioral|Group four|Group four will view the printed educational pamphlet and will not view either video
112577|NCT00070564|Drug|AC regimen|Given IV
112578|NCT01474720|Drug|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
112579|NCT01474733|Other|educational intervention|series of lectures and workshops on health literacy
112580|NCT01474746|Drug|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
112581|NCT01474746|Drug|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
112582|NCT01474759|Behavioral|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
112583|NCT01474759|Behavioral|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
112584|NCT01474759|Other|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
112585|NCT01474759|Behavioral|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
112586|NCT01474772|Drug|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
112587|NCT01474772|Other|placebo|matching placebo capsules given in 3 divided doses
112867|NCT01477606|Drug|Daunorubicin|Induction therapy:
60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)
112868|NCT01477619|Drug|Tasimelteon|20mg single dose on Day 1
112869|NCT01477632|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
112870|NCT01477632|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
112753|NCT01475084|Device|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
Forceps biopsy will be performed on usual way.
112754|NCT01475097|Drug|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
113037|NCT01477931|Drug|Bupropion extended release|300mg once a daily, PO, 8weeks
113038|NCT01477957|Procedure|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
113039|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
113040|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
113041|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
113042|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
113043|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
113044|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
113045|NCT01471340|Drug|Mometasone Furoate MDI 200 mcg|two inhalations BID
113046|NCT01471340|Drug|Albuterol 90 mcg /salbutamol 100 mcg HFA MDI|use as needed for asthma symptoms
113047|NCT01471340|Drug|Prednisone/prednisolone|Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
113048|NCT01471353|Drug|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
113049|NCT01471366|Dietary Supplement|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
116483|NCT01488513|Drug|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
116484|NCT01488526|Drug|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
116485|NCT01488539|Behavioral|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
116486|NCT01488539|Behavioral|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
116487|NCT01488552|Drug|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
116488|NCT01488552|Drug|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
116489|NCT01488552|Drug|FOLFIRINOX|The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;
Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
116490|NCT01488552|Genetic|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
116491|NCT00072150|Drug|bortezomib|Given IV
116492|NCT01488552|Drug|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
116493|NCT01488552|Drug|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
116494|NCT01488565|Drug|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
116495|NCT01488578|Drug|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
116496|NCT01488604|Device|Polymeric Nasal Spray|Experimental nasal spray
113104|NCT00070642|Drug|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
113105|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
113106|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
113107|NCT00071032|Biological|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
113108|NCT01477996|Procedure|27-gauge|27-gauge needle for IVT
113390|NCT00001191|Drug|Pantoprazole|
113391|NCT00070096|Drug|ixabepilone|
113392|NCT01464957|Behavioral|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
113393|NCT01464970|Procedure|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
113394|NCT01464970|Procedure|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
113395|NCT01464970|Procedure|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
113396|NCT01464970|Procedure|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
113397|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
113398|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
113399|NCT01464983|Drug|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
113400|NCT01464983|Drug|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
113401|NCT01464983|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
113402|NCT00070109|Drug|trabectedin|Given IV
114339|NCT01466452|Drug|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
114340|NCT01466452|Drug|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
114341|NCT00070174|Drug|busulfan|
114342|NCT01466465|Drug|Cholecalciferol|given orally, once daily, before grass pollen season
114343|NCT01466465|Other|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
114344|NCT01466478|Drug|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
114345|NCT01466478|Drug|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
114346|NCT01466478|Drug|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
114347|NCT01466478|Drug|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
114348|NCT01466478|Drug|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
114349|NCT01466478|Drug|Daivonex® ointment|once daily application, 4 weeks
114350|NCT01466478|Drug|Diprosone® ointment|once daily application, 4 weeks
114351|NCT01466491|Drug|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
114691|NCT01526473|Biological|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
114692|NCT01526486|Procedure|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
114693|NCT01528566|Behavioral|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
114694|NCT01528579|Other|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
114695|NCT01528579|Behavioral|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
112685|NCT01477320|Other|Placebo and tube feed|Patients randomized to Placebo group "placebo Comparator" will receive tube feed plus an Placebo.
112686|NCT01477333|Drug|UT-15C SR|Initiated at 0.125 mg BID, titrated as needed.
112687|NCT01477346|Other|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
112688|NCT01477346|Other|Standard care|Continuing standard General Practitioner led care.
112689|NCT01477372|Behavioral|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
112690|NCT01477385|Procedure|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
112691|NCT01477385|Procedure|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
112692|NCT01477385|Procedure|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
112693|NCT00070941|Drug|SAM-e|oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo citalopram.
112694|NCT01477385|Procedure|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
112695|NCT01477385|Procedure|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
112696|NCT01477398|Device|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
112697|NCT01477411|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
112698|NCT01477411|Drug|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
112699|NCT01477424|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
112700|NCT01477424|Drug|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
113667|NCT01465438|Drug|Adalimumab|Adalimumab 40 mg every other week
113668|NCT01467648|Drug|Doripenem|(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.
Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem.
113669|NCT01467661|Drug|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
113670|NCT01467687|Drug|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
113671|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets, sublingual, once daily, at night time for up to 8 weeks.
113672|NCT00070187|Drug|etoposide|Given IV
113673|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets, sublingual, once daily, at night time for up to 8 weeks.
113674|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets, sublingual, once daily, at night time for up to 8 weeks.
113675|NCT01467700|Drug|Placebo|Ramelteon placebo-matching tablets, sublingual, once daily, at night time for up to 8 weeks.
113676|NCT01467713|Drug|Ramelteon SL|Ramelteon SL tablets, sublingual, once every night at bedtime for up to 9 months.
113677|NCT01467713|Drug|Ramelteon SL|Ramelteon SL tablets, sublingual, once every night at bedtime for up to 9 months.
113678|NCT01467713|Drug|Ramelteon SL|Ramelteon SL tablets, sublingual, once every night at bedtime for up to 9 months.
113679|NCT01467713|Drug|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once every night at bedtime for up to 9 months.
113949|NCT01468298|Other|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
113950|NCT01470703|Device|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure <25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level <25 cm H2O and low pressure level ≥10 cm H2O
113951|NCT00070278|Drug|epirubicin hydrochloride|
114620|NCT01528540|Drug|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
114621|NCT01528553|Device|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
114622|NCT01528553|Device|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
114623|NCT01528566|Behavioral|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
114624|NCT01530503|Drug|capecitabine and mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.
Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
114625|NCT01530503|Drug|Capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.
Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
114626|NCT00075972|Behavioral|Mood Management|
114627|NCT01530516|Device|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
114628|NCT01530516|Device|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
113739|NCT01465464|Drug|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
113740|NCT01465464|Drug|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
113741|NCT01465477|Biological|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
113742|NCT01465477|Biological|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
113743|NCT01465490|Behavioral|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
113744|NCT01465503|Drug|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
113745|NCT01465503|Drug|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
114696|NCT01528579|Other|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
114697|NCT01528592|Drug|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
114698|NCT00075738|Drug|leucovorin calcium|
114699|NCT01528605|Dietary Supplement|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
114700|NCT01528605|Dietary Supplement|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
114701|NCT01528605|Dietary Supplement|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
114702|NCT01528605|Dietary Supplement|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
114703|NCT01528605|Dietary Supplement|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
114704|NCT01528605|Dietary Supplement|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
114705|NCT01528618|Drug|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
114706|NCT01528618|Drug|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
114707|NCT01528631|Other|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
114708|NCT01528631|Other|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
114709|NCT00075751|Drug|gemcitabine hydrochloride|Given IV
113808|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
113809|NCT00070018|Drug|Cyclophosphamide|750 mg/m^2
113810|NCT01463371|Drug|Azithromycin|250 mg three times a week during three months
113811|NCT01463384|Drug|Minocycline|50mg, twice daily for 6 months.
113812|NCT01463397|Drug|SAR292833|Pharmaceutical form: capsule
Route of administration: oral
113813|NCT01463397|Drug|placebo|Pharmaceutical form:capsule
Route of administration: oral
112701|NCT01477437|Other|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|The content will be delivered on a password-protected website, as part of the "About Kids Health" interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention.
112983|NCT01471340|Drug|Mometasone Furoate/Formoterol MDI 100/5 mcg|two inhalations twice daily (BID)
112984|NCT01471340|Drug|Mometasone Furoate/Formoterol MDI 200/5 mcg|two inhalations BID
112985|NCT01471340|Drug|Mometasone Furoate MDI 100 mcg|two inhalations BID
112986|NCT01473433|Other|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
112987|NCT01473446|Procedure|Goal directed fluid therapy guided by LiDCOrapid|Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.
Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV <10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding >1000ml. By fall in blood pressure and SVV <10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h.
112988|NCT01473459|Procedure|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
112989|NCT01473459|Procedure|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
112990|NCT01473472|Drug|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
112991|NCT01473472|Drug|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
112992|NCT01473485|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
112993|NCT00070447|Radiation|yttrium Y 90 ibritumomab tiuxetan|
112994|NCT01473498|Other|Haemodynamic management|Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.
In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients.
113952|NCT01470703|Other|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 <80% for >6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
113953|NCT01470716|Drug|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
113954|NCT01470729|Other|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
113955|NCT01470742|Drug|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
113956|NCT01470742|Drug|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
113957|NCT01470755|Drug|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
113958|NCT01470755|Drug|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
113959|NCT01470755|Drug|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
113960|NCT01470755|Drug|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
113961|NCT01470768|Other|Amino Acid-based Formula with high DHA and ARA|
113962|NCT00070278|Drug|gemcitabine hydrochloride|
113963|NCT01470768|Other|Amino Acid-based Formula with lower DHA and ARA|
114215|NCT01461772|Drug|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
114216|NCT01461772|Drug|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
114217|NCT01461785|Biological|Addition of PRP ( platelet rich plasma) to the lipograft|27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).
The lipograft of Group A will be enriched with 3ml of autologous PRP
113746|NCT01465516|Drug|Boceprevir|Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).
Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results
113747|NCT01465529|Drug|OligoG CF-5/20|6% OligoG CF-5/20 in water
113748|NCT01465529|Drug|Saline|0.9% NaCl in water
113749|NCT00070122|Other|laboratory biomarker analysis|Correlative studies
113750|NCT01465555|Behavioral|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
113751|NCT01465568|Drug|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
113752|NCT01465568|Drug|bisphosphonates|continue present bisphosphonate treatment
113753|NCT01467817|Behavioral|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
113754|NCT00001202|Drug|Spironolactone|
113755|NCT00070187|Procedure|autologous bone marrow transplantation|
113756|NCT01467817|Behavioral|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
114009|NCT01468337|Drug|Interferon gamma-1b|Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg
Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.
Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.
Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.
If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes).
114010|NCT01468350|Drug|dalfampridine-ER 10mg|
114011|NCT01468350|Other|Placebo|
114012|NCT01468363|Device|Dry weight adjustment|Dry weight adjustment according to BCM results
114013|NCT01468376|Dietary Supplement|GLU-01|14 day dosing
114014|NCT01468376|Dietary Supplement|GLU-02|14 day dosing
113814|NCT01463423|Procedure|PET Scan|Standard of Care
113815|NCT01463423|Procedure|CT Scan|Standard of Care
113816|NCT01465581|Procedure|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
113817|NCT01465594|Procedure|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
113818|NCT01465594|Procedure|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
113819|NCT01465607|Behavioral|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
113820|NCT01465607|Behavioral|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
113821|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
113822|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
113823|NCT00070135|Biological|filgrastim|Given SC
113824|NCT01465633|Drug|levothyroxine|
113825|NCT01465633|Drug|levothyroxine|
113826|NCT01465646|Drug|levothyroxine|
113827|NCT01465646|Drug|levothyroxine|
113828|NCT01465659|Drug|temozolomide|Given PO
114089|NCT01466127|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
114090|NCT01466127|Drug|Placebo|Matched nasal spray placebo
114091|NCT01466140|Other|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
114092|NCT00070148|Drug|Megestrol Acetate|Megace by mouth for 12 weeks
114494|NCT01462266|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
114495|NCT01462266|Biological|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
114496|NCT01462266|Drug|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
114497|NCT01462279|Drug|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
114498|NCT01462292|Drug|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
114499|NCT01464437|Drug|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
114500|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg BID
113597|NCT01470170|Drug|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
113598|NCT01470170|Device|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
113599|NCT00001208|Other|Botulinum Toxin|
113600|NCT00070252|Drug|Tipifarnib|Given orally (PO)
113601|NCT01470170|Drug|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
113602|NCT01470196|Drug|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
113603|NCT01470196|Drug|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
113604|NCT01470196|Drug|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
113605|NCT01470209|Drug|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
114218|NCT01461785|Procedure|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
114219|NCT01461798|Dietary Supplement|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
114220|NCT01461798|Dietary Supplement|Placebo Yogurt|Yogurt without the active principle
114221|NCT00069940|Biological|sargramostim|
114222|NCT01461798|Dietary Supplement|yogurt|yogurt without plant stanols
114223|NCT01461811|Device|Nelfilcon A toric contact lenses (with comfort additives)|
114224|NCT01461811|Device|Nelfilcon A toric contact lenses|
114225|NCT01461824|Drug|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
114226|NCT01461837|Drug|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
114227|NCT01461850|Procedure|Laparoscopy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
114561|NCT01530464|Drug|Ambrisentan|Drug will be administered as a single dose of 5mg, followed by a 48h washout period
114562|NCT01530464|Drug|Aminophylline plus ambrisentan|Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
114563|NCT01530477|Device|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
114564|NCT01530477|Device|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
114565|NCT01530477|Device|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
114015|NCT01468376|Dietary Supplement|GLU-03|14 day dosing
114016|NCT00070200|Drug|etoposide|
114017|NCT01468376|Dietary Supplement|GLU-04|14 day dosing
114018|NCT01468376|Dietary Supplement|GLU-05|14 day dosing
114019|NCT01468376|Dietary Supplement|GLU-06|14 day dosing
114020|NCT01468389|Drug|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
114021|NCT01468389|Drug|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
114022|NCT01468402|Procedure|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
114023|NCT01461473|Device|Oral Appliance|Participants who are randomized to the Oral Appliance Treatment Group will receive a dental evaluation to determine the optimal setting for the Oral Appliance (OA) device.
114024|NCT00069888|Drug|Docetaxel|
114025|NCT01461486|Device|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
114026|NCT01461486|Device|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
114027|NCT01461499|Drug|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
114274|NCT01468740|Drug|Prednisone|The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
114275|NCT01468753|Procedure|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
114276|NCT01468766|Other|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
114277|NCT01468766|Other|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
114093|NCT01466153|Drug|MEDI-551|MEDI-551 will be administered by Intravenous (IV) infusion. There will an initial cycle and up to 5 subsequent cycles.
114094|NCT01468415|Drug|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
114095|NCT01468441|Drug|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
114096|NCT01468441|Drug|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
114097|NCT01468454|Drug|18 F-DOPA|one time injection of 0.08 - 0.16 mCurie/kg of 18F-DOPA
114098|NCT00070200|Drug|isotretinoin|
114099|NCT01468467|Drug|AC220|Oral Liquid
114100|NCT01468480|Drug|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
114101|NCT01468480|Drug|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
114102|NCT01468480|Drug|MultiCal|application of Multical in forth group as a pulp dressing agent
114103|NCT01468480|Drug|Dycal|application of Dycal in first group as a pulp dressing agent
114104|NCT01468519|Drug|Insulin|Insulin via continuous subcutaneous insulin infusion
114105|NCT01468519|Drug|Insulin|insulin via multiple daily injections
114106|NCT01468532|Drug|docetaxel|Given IV
114107|NCT01468532|Drug|pasireotide|Given IM
114108|NCT01468532|Drug|prednisone|Given PO
114109|NCT00070200|Drug|melphalan|
114110|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
114111|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
114112|NCT01468558|Drug|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
114352|NCT00070174|Drug|cyclophosphamide|
113606|NCT01470209|Drug|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
113607|NCT01470222|Other|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
113608|NCT01470248|Drug|Arsenic Trioxide|Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
113609|NCT01470287|Biological|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
113610|NCT01470300|Other|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit & vegetables, decreased fat, added plain water).
113611|NCT00070265|Drug|oxaliplatin|Given IV
113612|NCT01470313|Drug|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
113891|NCT01463488|Drug|SAR113945|Pharmaceutical form:Injection
Route of administration: Intra-articular
113892|NCT01463488|Drug|placebo|Pharmaceutical form:Injection
Route of administration: Intra-articular
113893|NCT01463501|Other|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
113894|NCT01463501|Other|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
113895|NCT01463514|Procedure|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
113896|NCT01463514|Procedure|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
113897|NCT01463527|Device|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
114566|NCT01530490|Drug|Cabergoline and Hydroxyethyl Starch|0.5mg
114567|NCT01530490|Drug|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
114568|NCT01532739|Behavioral|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
114569|NCT01532765|Procedure|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
114570|NCT01532765|Procedure|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
114571|NCT01532765|Procedure|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
114572|NCT01532804|Drug|bevacizumab, oxaliplatin and 5FU combination|Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.
Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)
114573|NCT00076310|Drug|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
114574|NCT01532804|Drug|Bevacizumab, oxaliplatin and raltitrexed combination|Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.
Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min
114575|NCT01532817|Device|The AlphaCore Device|A single 90 second stimulation to the vagus nerve on the right side of the neck
114576|NCT01532830|Device|GammaCore device|
114577|NCT01532843|Drug|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
113680|NCT01467726|Drug|Velusetrag|Capsules
113681|NCT01467726|Drug|Velusetrag|Capsules
113682|NCT01467726|Drug|Placebo|Capsules
113683|NCT00070187|Drug|melphalan|Given IV
113684|NCT01467739|Device|Ambu ® aScope®|
114278|NCT01468779|Dietary Supplement|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
114279|NCT01468779|Dietary Supplement|Sugar pill|
114280|NCT01468805|Procedure|Cockroach mitigation/extermination|
114281|NCT01468818|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
114282|NCT01468818|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
114283|NCT00070200|Procedure|peripheral blood stem cell transplantation|
114284|NCT01461863|Dietary Supplement|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
114285|NCT01461863|Dietary Supplement|multivitamin|Standard multivitamin
114286|NCT01461876|Drug|antiretroviral therapy|Standard of care antiretroviral therapy
114287|NCT00069940|Biological|telomerase: 540-548 peptide vaccine|
114288|NCT01461889|Other|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
114289|NCT01461889|Other|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
114290|NCT01461915|Drug|Abraxane ( Nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes. Given weekly for 3 weeks followed by one week of rest.
114291|NCT01461915|Drug|Abraxane ( Nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes. Nab-paclitaxel to be given weekly for 3 weeks followed by one week of rest.
114292|NCT01461915|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 over 30 minutes to be administered after the completion of Abraxane administration. Gemcitabine will be given weekly for 3 weeks followed by one week of rest.
114629|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
114630|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
114631|NCT01530529|Drug|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
114632|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
114633|NCT01530542|Drug|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
114353|NCT01468818|Biological|Young TIL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
114354|NCT01468831|Drug|Minocycline|
114355|NCT01468844|Drug|Minocycline|
114356|NCT01468883|Procedure|M|Modified radical mastectomy
114357|NCT01468883|Radiation|X|Excisional biopsy plus radiation
114358|NCT01468896|Biological|Cetuximab|Given IV
114359|NCT01468896|Other|Laboratory Biomarker Analysis|Correlative studies
114360|NCT01468896|Biological|Recombinant Interleukin-12|Given SC
114361|NCT01468909|Other|Laboratory Biomarker Analysis|Correlative studies
114362|NCT01468909|Drug|Paclitaxel|Given IV
114363|NCT00070200|Radiation|radiation therapy|
114364|NCT01468909|Drug|Pazopanib Hydrochloride|Given PO
114365|NCT01468909|Other|Placebo|Given PO
114366|NCT01468922|Drug|Pazopanib|VEGFR inhibitor
114367|NCT01468922|Drug|ARQ 197|MET inhibitor
114368|NCT01468948|Drug|Octanoic Acid|
114369|NCT01468961|Behavioral|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
114370|NCT01468974|Device|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
114371|NCT01468987|Drug|LY2605541|- Administered by subcutaneous injection
114372|NCT01468987|Drug|Insulin Glargine|- Administered by subcutaneous injection
114373|NCT01468987|Drug|Insulin Lispro|- Administered subcutaneously
114374|NCT00070213|Drug|FOLFOX regimen|
114375|NCT01469000|Drug|Pemetrexed|500 mg/m^2, intravenous (in the vein) on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
113898|NCT01463540|Device|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
113899|NCT01463540|Device|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
113900|NCT00070018|Drug|prednisone|100 mg
113901|NCT01465698|Behavioral|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
113902|NCT01465698|Behavioral|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
113903|NCT01465698|Other|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
114154|NCT01463930|Behavioral|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
114155|NCT01463943|Other|Probiotic|
114156|NCT01463943|Other|Probiotic|
114157|NCT01463943|Other|Probiotic|
114158|NCT01463956|Drug|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
114159|NCT01463956|Biological|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
114160|NCT01463956|Drug|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: <65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; >105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
114161|NCT00070031|Drug|edotecarin|
113685|NCT01467739|Device|a conventional reusable fiberscope|
113686|NCT01467752|Procedure|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
113687|NCT01467765|Other|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
113688|NCT01467778|Device|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
113689|NCT01467778|Device|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
113690|NCT01467791|Other|Observation|Observe patients
113691|NCT01467804|Drug|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
113692|NCT01467804|Drug|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
113693|NCT01470521|Biological|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
113694|NCT01470521|Biological|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
113695|NCT01470534|Dietary Supplement|carbohydrate drink|carbohydrate drink
113696|NCT01470534|Procedure|Muscle biopsy|Open muscle biopsy
113697|NCT00070265|Other|laboratory biomarker analysis|Correlative studies
113698|NCT01470534|Procedure|Blood sampling|Venopuncture
113699|NCT01470534|Dietary Supplement|Placebo|
113700|NCT01470560|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
113701|NCT01470560|Behavioral|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
114634|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
114635|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
114636|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
114637|NCT00075972|Drug|Nicotine Replacement therapy|
114638|NCT01530542|Drug|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
114639|NCT01530555|Drug|Rabbit ATG, Thymoglobuline (Genzyme)|Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.
Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months
114640|NCT01530568|Other|Xpert|This arm receives the GeneXpert test
114641|NCT01530568|Other|Smear|This arm receives smear microscopy
114642|NCT01530581|Procedure|G-PB Transplant|G-PB Transplant
114643|NCT01530581|Procedure|G-BM Transplant|G-BM Transplant
114644|NCT01530594|Drug|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
114645|NCT01530594|Drug|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
114646|NCT01530594|Drug|Lenalidomide|Lenalidomide/Low dose Dex (LLD
114647|NCT01530607|Drug|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
114648|NCT00075998|Drug|Interferon gamma-1b ("Actimmune")|200 mcg, SQ, 3x per week
114649|NCT01532895|Drug|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
114650|NCT01532908|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
113757|NCT01467830|Procedure|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
113758|NCT01467843|Behavioral|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
113759|NCT01467843|Behavioral|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
114376|NCT01469000|Drug|Gefitinib|250 mg, orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
114710|NCT01528644|Dietary Supplement|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
114711|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
114712|NCT01530607|Drug|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
114713|NCT01530620|Drug|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
114714|NCT01530620|Drug|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
114715|NCT01530646|Behavioral|Weight loss|-750kcal/d
114716|NCT01530646|Dietary Supplement|Soy|2 x 25g/d SPC
114717|NCT01530646|Dietary Supplement|Whey|2 x 25g/d WPI
114718|NCT01530659|Drug|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
114719|NCT01530672|Device|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
114720|NCT01530685|Dietary Supplement|Glycabiane|2 gelule per day for 4 months
114721|NCT01530685|Dietary Supplement|placebo|2 gelules per day for 4 months
114722|NCT00076011|Drug|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
114723|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
114724|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
114162|NCT01463982|Drug|Oratecan and Capecitabine|Oratecan in combination with Capecitabine
Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5
HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5
Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14
114163|NCT01464008|Drug|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
114164|NCT01464034|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
114165|NCT01464034|Drug|Pomalidomide|PO daily on Days 1-21, every 28 Days
114166|NCT01464034|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
114167|NCT01466153|Drug|Rituximab|Rituximab will be administered at 375 mg/m2 by IV infusion on Day 2 of Cycle 1 and then at 500 mg/m2 on Day 1 of up to 5 subsequent 28-day cycles (90-minute infusion).
114168|NCT01466153|Drug|Bendamustine|Bendamustine will be administered to subjects in each treatment group at 70 mg/m2 by IV infusion on Days 1 and 2 of each 28-day cycle (30-min infusion).
114169|NCT01466166|Biological|pegloticase|pegloticase 8 mg intravenous every 2 weeks
114170|NCT01466179|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
114171|NCT01466192|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
114172|NCT01466192|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
114173|NCT01466192|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
114501|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg BID
114502|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg QD
114503|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg QD
114504|NCT01464437|Drug|AMG 151|Drug: AMG 151 400 mg QD
114505|NCT01464450|Drug|Rivaroxaban|Single 20 mg-dose
114506|NCT01464463|Behavioral|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
114507|NCT01464463|Behavioral|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
114508|NCT00070070|Biological|sargramostim|
113964|NCT01470781|Behavioral|BrainWorks|13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as "directors" for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training.
113965|NCT01470781|Behavioral|Computer Control|Sessions will involve generic computer games administered via the game interface "Sporcle." Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session.
113966|NCT01463553|Procedure|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
113967|NCT01463566|Device|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
113968|NCT01463579|Other|Exercise Programme|Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.
At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home.
113969|NCT01463579|Other|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
113970|NCT01463592|Biological|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
113971|NCT01463592|Drug|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
113972|NCT01463592|Biological|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
113973|NCT01463605|Drug|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
113974|NCT01463631|Drug|LY3007113|Administered orally
113975|NCT01463644|Drug|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
113760|NCT01467856|Procedure|PAP Device Procedure|Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP "Smartcard" for download and interpretation.
Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP > 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic.
113761|NCT01467882|Drug|Triptorelin|Powder and solution for solution for injection
113762|NCT01467908|Device|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
113763|NCT01467921|Drug|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
113764|NCT01467947|Biological|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
113765|NCT01467986|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
113766|NCT00070187|Procedure|bone marrow ablation with stem cell support|
113767|NCT01467986|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
113768|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
113769|NCT01467986|Drug|Temozolomide|Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).
Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
113770|NCT01469975|Drug|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
114028|NCT01461499|Drug|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
114029|NCT01461512|Drug|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
114725|NCT01530711|Drug|Terlipressin and albumin|Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase < 10 mmHg and the creatinine values decrease <25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.
Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day.
114726|NCT01530724|Other|low-fat diet|low-fat diet
114727|NCT01530724|Other|low-carb diet|low-carb diet
113543|NCT01462929|Drug|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
113544|NCT01462929|Drug|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
113545|NCT01462929|Drug|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
113546|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose, twice per day
113547|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose, twice per day
113548|NCT01462942|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
113549|NCT01462942|Drug|Placebo|Inhaled dose-matched placebo, twice per day
113550|NCT01462942|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
113551|NCT00069992|Radiation|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
113552|NCT01462968|Device|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
113553|NCT01462994|Other|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
113554|NCT01463007|Radiation|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
113555|NCT01463007|Other|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
113556|NCT01463020|Behavioral|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
114509|NCT01464463|Behavioral|CBASP|Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.
Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship.
114510|NCT01464476|Drug|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
114511|NCT01464476|Drug|Placebo|Dose-matched placebo. Once daily, oral administration
114512|NCT01464489|Drug|Atropine|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.
Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition
114513|NCT01464489|Drug|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
114514|NCT01464502|Procedure|Standard CRT Implant|
114515|NCT01464502|Procedure|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
114516|NCT01464515|Device|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
114517|NCT01464515|Device|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
114518|NCT01464528|Drug|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
114519|NCT00070083|Biological|oblimersen sodium|
114520|NCT01464541|Procedure|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
114521|NCT01464541|Procedure|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
114522|NCT01464554|Behavioral|Usual care|alcohol and drug education
113613|NCT01470313|Drug|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
113614|NCT01470326|Drug|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
113615|NCT01463020|Other|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
113616|NCT01463033|Drug|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
113617|NCT01463046|Drug|Panobinostat|Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8
Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5
Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8
113976|NCT00070018|Drug|vincristine sulfate|1.4 mg/m^2
114228|NCT01461850|Procedure|Cytoreduction|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
114229|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
114230|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
114231|NCT01464073|Behavioral|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
114232|NCT01464073|Behavioral|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
114233|NCT01464073|Behavioral|Good Medical Practices|Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of "moderate" exercise).
114234|NCT00070057|Drug|celecoxib|Given orally
114235|NCT01464073|Dietary Supplement|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
114236|NCT01464086|Other|whole body MRI|whole body MRI at inclusion, one and two years
114237|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
114238|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
114239|NCT01464112|Drug|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
114240|NCT01464125|Drug|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
114241|NCT01464125|Drug|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
114030|NCT01461512|Drug|Placebo administration|NaCl isotonic
114031|NCT01461525|Procedure|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
114032|NCT01461525|Procedure|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
114033|NCT01461538|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
114034|NCT01461538|Drug|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
114035|NCT00069901|Drug|CT-2103 (poly(L)glutamate-paclitaxel)|
114036|NCT01461538|Drug|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
114037|NCT01461551|Drug|Sevoflurane|anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
114038|NCT01461551|Drug|Propofol|anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
114039|NCT01461551|Drug|combine of sevoflurane and propofol|anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
114040|NCT01461564|Procedure|Colonoscopy|Screening colonoscopy
114041|NCT01461577|Drug|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
114042|NCT01461590|Other|Whole blood|30mls/kg transfused over fours hours
114043|NCT01461590|Other|Whole blood|20mls/kg transfused over four hours
114044|NCT01461603|Dietary Supplement|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
114045|NCT01461603|Dietary Supplement|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
114046|NCT00069901|Drug|carboplatin|
114047|NCT01463683|Biological|1XP HEPTAVAX™-II SC|
114048|NCT01463683|Biological|2XP HEPTAVAX™-II IM|
114293|NCT01461915|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 administered IV over 30 minutes (after the nab-paclitaxel IV administration is complete). Gemcitabine to be administered weekly for 3 weeks followed by one week of rest.
113557|NCT01465100|Other|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases and abdominal ultrasound to assess blood flow to the blood vessels in the liver.
113558|NCT00070122|Drug|oxaliplatin|Given IV
113559|NCT01465100|Behavioral|Psychological Assessment|Subjects may undergo a psychological assessment at least 6 months post-transplant which will include a semi-structure open ended interview as well as the Adaptive Behavior Assessment System-II assessment and Beck Depression Inventory. If subjects undergo these assessments, they will be compared to those obtained pre-transplant to determine whether an improvement is associated with the transplant procedure. In addition, if subjects are experiencing depression, they will be referred for further care.
113560|NCT01465113|Drug|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
112644|NCT01472874|Drug|Once a day Trientine|Trientine at a dosage of ~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
112645|NCT01472887|Drug|SAR3419|Pharmaceutical form:concentrate for solution for infusion
Route of administration: intravenous
112646|NCT01472900|Device|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
112647|NCT01472900|Drug|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
112648|NCT01472913|Drug|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
112649|NCT01472913|Drug|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
112650|NCT01472926|Drug|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
112651|NCT01472926|Drug|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
112652|NCT00070434|Drug|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
112653|NCT01472939|Drug|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
112654|NCT01472939|Drug|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
112655|NCT01472939|Drug|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
112656|NCT01472939|Drug|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
112657|NCT01472965|Drug|ethanol|70% ethanol catheter lock therapy
113618|NCT01463046|Drug|Cytarabine|Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.
Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.
Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.
113619|NCT01463046|Drug|Daunorubicin|Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.
Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.
Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.
113620|NCT00069992|Drug|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
113621|NCT01463059|Biological|Placebo|Placebo solution for injection, administered as subcutaneous injections
113622|NCT01463059|Biological|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
113623|NCT01463059|Biological|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
113624|NCT01463059|Biological|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
113625|NCT01463072|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
113626|NCT01463072|Other|questionnaire administration|Ancillary studies
113627|NCT01463085|Other|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
113628|NCT01463098|Drug|E2006 1.0 mg|1.0 mg, or placebo
113629|NCT01463098|Drug|E2006 2.5 mg|2.5 mg or placebo
113630|NCT01463098|Drug|E2006 5.0 mg|5.0 mg or placebo
113631|NCT00069992|Drug|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
113632|NCT01463098|Drug|E2006 10.0 mg|10.0 mg or placebo
113633|NCT01463098|Drug|E2006 25.0 mg|25.0 mg or placebo
113634|NCT01463098|Drug|E2006 50.0 mg|50.0 mg or placebo
113635|NCT01463098|Drug|E2006 100 mg|100mg or placebo
113904|NCT01465711|Procedure|All abdominal surgical procedures|Laparotomy, Laparoscopy
113905|NCT01465711|Procedure|Intubation|Ventilatory support
113906|NCT01465711|Radiation|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
114242|NCT01464138|Drug|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
114578|NCT01532856|Drug|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
114579|NCT01532856|Drug|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
114580|NCT01532856|Drug|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
114581|NCT01532869|Drug|Placebo|Subcutaneously weekly, Weeks 1-48
114582|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 1-48
114583|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 49-96
114584|NCT00076310|Drug|Cisplatin|75 mg/m^2 IV every 21 days.
114585|NCT01532882|Drug|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
114586|NCT01532882|Drug|Placebo|tablet, PO, 1 per day during 28 days
114587|NCT01526200|Procedure|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
114588|NCT01526213|Drug|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
114589|NCT01526226|Device|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
114590|NCT01526226|Device|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
114591|NCT01526239|Other|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
114592|NCT00075686|Biological|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles
114294|NCT01461915|Drug|ODSH ( 2-O, 3-O Desulfated Heparin)|ODSH IV bolus at 4 mg/kg to be administered in 5 minutes immediately after completion of gemcitabine administration.
ODSH 48-h IV continuous infusion at 0.375 mg/kg/h should be started immediately after the ODSH IV bolus has been administered.
114295|NCT01461915|Drug|ODSH ( 2-O, 3-O Desulfated Heparin)|ODSH IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration.
ODSH 48-h IV continuous infusion at 0.375 mg/kg/h should be started immediately after the ODSH IV bolus has been administered.
114296|NCT01461915|Drug|Abraxane ( nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes will be given weekly for 3 weeks followed by one week of rest.
114297|NCT01461915|Drug|Gemcitabine|Gemcitabine to be administered IV at 1000 mg/m2 over 30 minutes given weekly for 3 weeks followed by one week of rest
114298|NCT00069953|Biological|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients >70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
114299|NCT01461928|Drug|chemotherapy|Induction phase: standard combination chemotherapy, 6 to 8 cycles
114300|NCT01461928|Drug|rituximab [MabThera/Rituxan]|Maintenance II: 1400 mg sc every 8 weeks until disease progression or end of study, whichever occurs first
114301|NCT01461928|Drug|rituximab [MabThera/Rituxan]|Induction therapy: 375 mg/m2 iv in Cycle 1, followed by 1400 mg sc every 3-4 weeks, 7 cycles
114302|NCT01461928|Drug|rituximab [MabThera/Rituxan]|Maintenance I: 1400 mg sc every 8 weeks for 24 months
114303|NCT01461941|Drug|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
114304|NCT01461941|Drug|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
114305|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x7Gy|Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization.
114306|NCT01464190|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
114307|NCT01464190|Drug|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
114308|NCT01464203|Other|CT coronary angiography|CT coronary angiography:
This allows two distinct assessments of the coronary arteries to be made:
coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.
contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries.
112658|NCT01472965|Drug|heparin-saline placebo|heparin-saline placebo catheter lock therapy
112659|NCT01472978|Drug|metronidazole|Metronidazole, 500 mg three times a for 10 days
112660|NCT01472991|Drug|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
112661|NCT01472991|Drug|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
112662|NCT01474863|Drug|Placebo|D5W IV fluids at isovolumetric rate (about 15ml/hr)
112663|NCT01474863|Drug|Low Dose Citrulline|Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
112664|NCT01474889|Device|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
112942|NCT01477723|Other|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
112943|NCT01477736|Drug|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
112944|NCT01477736|Drug|Botulinum toxin A|300 U intradetrusor injection
112945|NCT01477749|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
112946|NCT01477762|Drug|Dexamethasone|0.5 mg, one time administration at 11pm prior to study visit
112947|NCT01477762|Drug|Dexamethasone|One time pill administration, at 11pm prior to the study visit
112948|NCT01477775|Drug|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
112949|NCT01477775|Drug|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
112950|NCT01477801|Drug|CHOLECALCIFEROL|Standard guideline based therapy plus cholecalciferol:
Loading dose 300.000 U then 50.000 U every month for six months
112951|NCT01477801|Drug|PLACEBO|Standard guideline based therapy plus placebo
112952|NCT00070980|Procedure|Massage therapy|
112953|NCT01477814|Behavioral|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
113907|NCT01465724|Procedure|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
113908|NCT01465737|Other|Histologic types|evaluate survival among different histologic types
113909|NCT01465763|Drug|tofacitinib|10 mg oral BID
113910|NCT01465763|Drug|Placebo|Plabebo oral BID
113911|NCT00070135|Drug|busulfan|Given IV
113912|NCT01465776|Other|laboratory biomarker analysis|Correlative studies
113913|NCT01465776|Other|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
113914|NCT01465802|Drug|Dacomitinib Plus Blinded Doxycycline or Placebo|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent PLUS doxycycline or doxycycline placebo BID for 4 weeks
113915|NCT01465802|Drug|Dacomitinib Plus Probiotic Plus Topical Alclometasone cream|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent PLUS Probiotic PLUS topical Alclometasone cream
113916|NCT01465802|Drug|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
113917|NCT01465815|Drug|erlotinib hydrochloride|Given PO
113918|NCT01465815|Drug|linsitinib|Given PO
113919|NCT01465815|Drug|placebo|Given PO
113920|NCT01465815|Radiation|radiation therapy|Undergo radiation therapy
113921|NCT01465815|Procedure|therapeutic conventional surgery|Undergo planned surgery
113922|NCT00070135|Drug|fludarabine phosphate|Given IV
113923|NCT01465815|Other|laboratory biomarker analysis|Correlative studies
113924|NCT01465828|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
113925|NCT01468155|Drug|dabigatran|30 days pre ablation and 90 days post ablation
113926|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
114593|NCT01526265|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
114594|NCT01526265|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
113702|NCT01470573|Procedure|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
113703|NCT01470586|Procedure|Surgery for colorectal cancer|Surgical resection of colorectal cancer
113704|NCT01470599|Drug|CP-690,550|ORAL TABLET, TWICE DAILY
113705|NCT01470599|Drug|CP-690,550|ORAL TABLETS, TWICE DAILY
113706|NCT01470612|Drug|CP-690,550|5 mg tablets, BID, for at least 12 months
113707|NCT01470612|Drug|CP-690,550|10 mg tablets, BID, for at least 12 months
113708|NCT00070278|Drug|cyclophosphamide|
113709|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
113710|NCT01470651|Drug|Armodafinil|50mg - 250mg pills, taken each morning, for 14 weeks
113711|NCT01470651|Drug|Placebo Comparator|Inactive pill, matched to look like active medication
113712|NCT01470664|Drug|FST-100|FST-100
113713|NCT01470664|Drug|FST-100 (Component #1)|FST-100 (Component #1)
113714|NCT01470664|Drug|FST-100 Vehicle|FST-100 Vehicle
113715|NCT01470677|Drug|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
113716|NCT01470690|Drug|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
113717|NCT01470690|Drug|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
113718|NCT00070005|Procedure|conventional surgery|
113719|NCT01463124|Behavioral|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
114651|NCT01532908|Drug|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
114652|NCT01532908|Drug|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
114653|NCT01532934|Behavioral|motivational enhancement therapy|Four 45-minute MET sessions
114654|NCT01532934|Other|standard care|standard care
114655|NCT01532947|Procedure|post placement|placement of an endocanalar post
114656|NCT01532960|Biological|poly-ICLC|poly-ICLC
114657|NCT00076323|Drug|Primaquine|
114658|NCT01532960|Biological|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA & CTA derived breast cancer proteins.
114659|NCT01532960|Biological|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
114660|NCT01532973|Drug|Elbasvir|Elbasvir was administered orally by tablet(s)
114661|NCT01532973|Drug|Placebo|Dose-matched placebo tablets were administered orally.
114662|NCT01532986|Other|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
114663|NCT01532986|Other|Educational handout|To minimize potential bias from participants' awareness of randomization arm assignment, we will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's "Healthwise for Life" handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise.
114664|NCT01532999|Behavioral|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
114665|NCT01532999|Behavioral|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
114666|NCT01533012|Procedure|Pressure difference|Peak inspiratory pressures difference between two lungs
114667|NCT01533025|Procedure|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
114668|NCT00076336|Drug|Telbivudine|600mg/day oral tablet for 104 weeks
112954|NCT01477814|Behavioral|usual care|usual care
112955|NCT01477814|Behavioral|chart reminder, mailed education, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
112956|NCT01477814|Behavioral|chart reminder, mailed education, FIT, telephone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
112957|NCT01477827|Other|None - observational study|
112958|NCT01477840|Drug|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
112959|NCT01477853|Drug|Sitagliptin|Sitagliptin 100 mg orally daily
112960|NCT01477853|Drug|Atorvastatin|Atorvastatin 80 mg orally daily
112961|NCT01477853|Other|Placebo to sitagliptin|Placebo to sitagliptin orally daily
112962|NCT01471158|Drug|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
113243|NCT01467063|Dietary Supplement|Placebo|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
113244|NCT01467076|Drug|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
113245|NCT01467076|Drug|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
113246|NCT01467089|Other|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
114174|NCT01466205|Drug|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
114175|NCT01466205|Drug|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
114176|NCT00070148|Drug|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
114177|NCT01466231|Drug|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
114178|NCT01466244|Biological|cetuximab|
114179|NCT01466244|Drug|cisplatin|
114180|NCT01466244|Genetic|gene expression analysis|
114181|NCT01466244|Genetic|microarray analysis|
114182|NCT01466244|Other|immunohistochemistry staining method|
114183|NCT01466244|Other|laboratory biomarker analysis|
114184|NCT01466257|Biological|cetuximab|
114185|NCT01466257|Drug|cisplatin|
114186|NCT01466257|Genetic|DNA analysis|
114187|NCT00070161|Dietary Supplement|EGb761|
114188|NCT01466257|Genetic|gene expression analysis|
114189|NCT01466257|Genetic|mutation analysis|
114190|NCT01466257|Other|laboratory biomarker analysis|
114191|NCT01466270|Drug|donepezil hydrochloride|Given PO
114192|NCT01466270|Drug|Placebo|Given PO
114193|NCT01466283|Genetic|DNA methylation analysis|
114194|NCT01466283|Genetic|fluorescence in situ hybridization|
114195|NCT01466283|Genetic|gene expression analysis|
114196|NCT01466283|Genetic|reverse transcriptase-polymerase chain reaction|
113720|NCT01463137|Behavioral|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
113721|NCT01463150|Drug|Clopidogrel|Clopidogrel 150mg per day for 15 days
113722|NCT01463150|Drug|Prasugrel|Prasugrel 5mg per day for 15 days
113723|NCT01463163|Drug|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
113724|NCT01463163|Drug|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
113977|NCT01463644|Drug|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
113978|NCT01463657|Device|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
113979|NCT01463657|Device|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
113980|NCT01463670|Drug|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
113981|NCT01463683|Biological|2XP HEPTAVAX™-II SC|
113982|NCT01465828|Drug|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
113983|NCT01465841|Device|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
113984|NCT01465867|Dietary Supplement|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
113985|NCT01465867|Other|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
114669|NCT01526330|Drug|YH14618|C mg/disc
114670|NCT01526330|Drug|Placebo|0mg/disc
113771|NCT01469975|Drug|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
113772|NCT01469975|Drug|OTSA101-DTPA-90Y level 3|Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.
This third dose level evaluation will be based on safety and preliminary efficacy data.
113773|NCT01469988|Drug|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
113774|NCT01470001|Drug|solifenacin|patient will receive solifenacin 5mg daily or placebo daily
113775|NCT00070252|Other|Laboratory Biomarker Analysis|Correlative studies
113776|NCT01470027|Drug|N-acetylcysteine|900mg NAC effervescent tablets
113777|NCT01470027|Drug|Placebo|effervescent tablets
113778|NCT01470040|Drug|discontinuation of aspirin therapy|discontinuation of aspirin therapy
113779|NCT01470040|Drug|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
113780|NCT01470053|Drug|mometasone furoate plus azelastine HCl|
113781|NCT01470053|Drug|mometasone furoate|
113782|NCT01470053|Drug|azelastine HCl|
113783|NCT01470092|Drug|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
113784|NCT01470105|Other|blood sampling, the SF-36 questionnaire|The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.
At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit
113785|NCT01470118|Drug|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
113786|NCT00070252|Other|Pharmacological Study|Correlative studies
113787|NCT01470118|Drug|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
113247|NCT01467115|Radiation|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
113248|NCT01467115|Drug|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
113249|NCT00001197|Drug|Hydroxyurea|
113250|NCT00070174|Drug|mitoxantrone hydrochloride|
113251|NCT01469364|Drug|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
113252|NCT01469364|Procedure|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
113253|NCT01469377|Drug|cariprazine|cariprazine (2-4.5 mg/day) given orally, in capsule form, once daily for 8 weeks
113254|NCT01469377|Drug|cariprazine|cariprazine (1-2 mg/day) given orally, in capsule form, once daily for 8 weeks
113255|NCT01469377|Drug|placebo|Matched placebo given orally, in capsule form, once daily for 8 weeks
113561|NCT01465113|Drug|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
113562|NCT01465113|Drug|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
113563|NCT01465113|Procedure|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
113564|NCT01465113|Drug|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
113565|NCT01465139|Drug|CDX-301|CDX-301, administered in multiple dosages and frequencies depending on arm:
n=3-6 at between 1-75 μg/kg over 5 days
n=3-6 at 25 μg/kg over 7 days
n=3-6 at 25 μg/kg over 10 days
113566|NCT01465152|Drug|metformin|Adminstered orally during the three main meals for 24 weeks
113567|NCT01465152|Drug|repaglinide|Administered orally before the three main meals for 24 weeks
114197|NCT01468610|Drug|desvenlafaxine|50-100 mg daily for 8 weeks
114198|NCT01468623|Other|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
114199|NCT01468623|Other|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
114523|NCT01464554|Behavioral|Project Free Talk|motivational interviewing alcohol and drug program
114524|NCT01466712|Drug|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
114525|NCT01466712|Drug|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
114526|NCT01466725|Drug|CC-930|Cohort 1: 25 mg orally once daily for 4 weeks Cohort 2: 50 mg orally once daily for 4 weeks Cohort 3: 100 mg orally once daily for 6 weeks Cohort 4: 100 mg orally twice daily for 6 weeks
114527|NCT01466725|Drug|Placebo|Placebo
114528|NCT01466738|Biological|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
114529|NCT01466738|Biological|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
114530|NCT01466751|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
114531|NCT01466764|Drug|Anakinra|An injection of Anakinra will be administered 1 hour prior to surgery and again 24 hours following surgery.
114532|NCT01466764|Drug|Normal Saline|An injection of normal saline will be administered 1 hour prior to surgery and again 24 hours following surgery.
114533|NCT01466777|Procedure|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
114534|NCT00070174|Drug|daunorubicin hydrochloride|
114535|NCT01466777|Procedure|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
114536|NCT01466790|Drug|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
114537|NCT01466790|Drug|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
113986|NCT01465867|Other|Selenium + L-Thyroxine (LT4)|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)
113987|NCT01465867|Other|Sugar Pill Placebo + L-Thyroxine (LT4)|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour
+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)
113988|NCT01465880|Other|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
113989|NCT01465893|Drug|Vitamin D|vitamin D ,50000 unit /week
113990|NCT00070135|Drug|methotrexate|Given IV
113991|NCT01465893|Drug|Vitamin D withheld|do not receive anything
114243|NCT01464164|Drug|Sotatercept|Dose escalation study of the drug sotatercept to be given as a subcutaneous injection:
Cohorts of 3 subjects will receive sotatercept every 28 days for up to 4 doses. Starting dose of 0.1 mg/kg (dose level 1). The second and subsequent cohorts may begin after and only after all 3 subjects in the first cohort have completed 28 days following their 4th dose of sotatercept (or last dose if sotatercept is not discontinued for safety reasons) and safety has been determined to proceed. Subsequent dose levels are 0.3 mg/kg (dose level 2) and 0.5 mg/kg (dose level 3).
114244|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x5Gy|Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization
114245|NCT00070057|Procedure|therapeutic conventional surgery|Undergo surgery
114246|NCT01466283|Other|laboratory biomarker analysis|
114247|NCT00070161|Drug|donepezil hydrochloride|
114248|NCT01466296|Device|Chaotic Perturbation|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., "Walk 5 strides forward," or, "Walk to the right side until I ask you to stop." During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session.
114249|NCT01466296|Device|Dummy not active shoes|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., "Walk 5 strides forward," or, "Walk to the right side until I ask you to stop." During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session.
114250|NCT01466296|Device|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
113788|NCT01470118|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
113789|NCT01470131|Drug|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
113790|NCT01470131|Drug|placebo|matching placebo
114049|NCT01463696|Drug|MK-8242|MK-8242 capsules will be administered orally twice a day (BID) on Days 1-6 of Cycle 1 and once in the morning (QD) on Day 7 of a 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, MK-8242 will be administered orally twice a day (BID) on Days 1-7 in a 21-day cycle.
114050|NCT01463709|Device|PulseCure pulse generator and Derm-pulse electrode|PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.
NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure
114051|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
114052|NCT00070018|Radiation|radiation therapy|4000-5000 cGy total
114053|NCT01463735|Dietary Supplement|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
114054|NCT01463748|Other|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
114055|NCT01463748|Other|Placebo|starch
114056|NCT01463761|Device|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
114057|NCT01463774|Drug|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
114058|NCT01463774|Drug|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
114059|NCT01463774|Drug|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
114060|NCT01463787|Procedure|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
114061|NCT01463787|Procedure|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
114062|NCT01463800|Behavioral|Structured exercise training|12 weeks low level ambulatory structured exercise training
114063|NCT00070018|Biological|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
113568|NCT01465178|Dietary Supplement|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
113569|NCT00070122|Drug|leucovorin calcium|Given IV
113570|NCT01465178|Dietary Supplement|Placebo|matching placebo
113571|NCT01465191|Drug|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
113572|NCT01465204|Behavioral|Total Sanitation and Sanitation Marketing|Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes "Community-Led Total Sanitation" (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment.
113573|NCT01465204|Behavioral|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
113574|NCT01467492|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
113575|NCT01467505|Drug|Telaprevir|Tablet
113576|NCT01467505|Drug|Ribavirin|Tablet
113577|NCT01467505|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
113578|NCT00070187|Drug|cyclosporine|Given IV
112665|NCT01474902|Drug|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
112666|NCT00070564|Drug|doxorubicin hydrochloride|Given IV
112667|NCT01474915|Drug|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
112668|NCT01474915|Drug|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
112669|NCT01474915|Drug|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
112670|NCT01474915|Drug|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
112671|NCT01474928|Behavioral|Community video group|Group two viewed the patient role played community video
112672|NCT01474928|Behavioral|knowledge and community videos group|Group three viewed both the knowledge and community videos
114538|NCT01466790|Drug|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
114539|NCT01466803|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
114540|NCT01466803|Drug|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
114541|NCT01466816|Dietary Supplement|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
114542|NCT01466829|Drug|Parathyroid hormone|100 microgram daily. S.c
113636|NCT01463098|Drug|E2006 200 mg|200 mg or placebo
113637|NCT01463098|Drug|zolpidem 10 mg|10 mg
113638|NCT01463098|Drug|zolpidem - matched placebo|Part B only
113639|NCT01463098|Drug|E2006 - matched placebo|(Part A and Part B)
113640|NCT01463111|Drug|Lithium, valproate, lamotrigine|Open label treatment per standard of care for bipolar disorder
113641|NCT01463124|Behavioral|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
113642|NCT01465217|Behavioral|text message medication reminders|daily medication reminders for one month
113643|NCT01465230|Drug|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
113644|NCT01465243|Drug|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
113645|NCT01465256|Drug|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
113646|NCT01465269|Behavioral|Group Interactive Structured Treatment|GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.
113647|NCT01465269|Behavioral|Alternative Intervention|Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.
114251|NCT01466309|Device|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
114252|NCT01466322|Drug|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
114253|NCT01466335|Drug|Ronacaleret (100mg tablet)|100mg tablet
114254|NCT01466335|Drug|Placebo|matching placebo tablet
114255|NCT01466348|Drug|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
114256|NCT01466348|Drug|Paracetamol|Paracetamol 1000 mg
114257|NCT01466361|Drug|Nicotine lower dose|lower dose nicotine lozenge
114258|NCT00001193|Procedure|high dose melphalan and autologous bone marrow transplantation|
114595|NCT01526265|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
114596|NCT01526265|Behavioral|Competitive Deposits (Pari-Mutuel)|Groups (or "cohorts") of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day "0's") near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
114597|NCT01526265|Behavioral|Collaborative Rewards|Groups (or "cohorts") of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day "0's") near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking.
114598|NCT01526278|Drug|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
114599|NCT01526304|Other|no intervention|No intervention, only observational study
114600|NCT01526317|Drug|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
114601|NCT01526330|Drug|YH14618|A mg/disc
114602|NCT01526330|Drug|YH14618|B mg/disc
114603|NCT00075686|Drug|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
114064|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
114065|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
114066|NCT01463813|Dietary Supplement|Placebo|Inactive placebo
114067|NCT01463852|Drug|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
114068|NCT01463865|Drug|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
114309|NCT01464203|Other|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
114310|NCT01464229|Drug|Iloperidone|Iloperidone 1-8 mg for 4 weeks
114311|NCT01464229|Drug|Placebo|Placebo
114312|NCT01464242|Drug|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
114313|NCT01464242|Drug|Placebo|Placebo 400mg orally 3 times a day for 20 days
114314|NCT01464242|Drug|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
114315|NCT00070057|Other|pharmacological study|Correlative studies
114316|NCT01464255|Device|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
114317|NCT01464255|Device|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
114318|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
114319|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
114320|NCT01464281|Drug|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
114321|NCT01464294|Device|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
114322|NCT01464294|Device|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
114323|NCT01464307|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
112673|NCT01474928|Behavioral|Pamphlet group|Group four read an educational pamphlet only
112674|NCT01474928|Behavioral|Knowledge video group|Group one viewed a physician-led knowledge video
112675|NCT01474928|Behavioral|knowledge video|Group one viewed a physician-led knowledge video
112676|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
112677|NCT00070564|Drug|paclitaxel|Given IV
112678|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
112679|NCT01474941|Drug|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
112680|NCT01474967|Drug|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
112681|NCT01474967|Drug|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
112682|NCT01474993|Drug|Sulforaphane-rich Broccoli Sprout Extract|30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing ~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to ~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:
Subjects with body weight less than 101 lbs will receive ~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)
Subjects with body weight 101 lbs to 199 lbs will receive ~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)
Subjects with bidy weight > 199 lbs will receive ~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)
112683|NCT01474993|Drug|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
112684|NCT01477320|Drug|Pantoprazole 40 mg IV daily and tube feed.|Patients randomized to the control group "active Comparator" will receive tube feed plus an Pantoprazole 40 mg IV daily.
112963|NCT01471171|Drug|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
112964|NCT01471171|Drug|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
112965|NCT01471184|Device|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
112966|NCT01471184|Device|Placebo|Placebo Eye Drops/Nasal Spray
112967|NCT01471197|Biological|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
112968|NCT01471197|Biological|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
113648|NCT00070122|Drug|capecitabine|Given orally
113649|NCT01465282|Drug|CT327 0.05%|0.05% CT327 (w/w) ointment
113650|NCT01465282|Drug|CT327 0.1%|0.1% CT327 (w/w) ointment
113651|NCT01465282|Drug|CT327 0.5%|0.5% CT327 (w/w) ointment
113652|NCT01465282|Drug|Placebo|Placebo
113653|NCT01465295|Device|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
113654|NCT01465308|Dietary Supplement|Honey mouthwash|The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
113655|NCT01465308|Other|Normal Saline|Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
113927|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
113928|NCT01468168|Drug|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
113929|NCT01468181|Drug|LY2189265|
113930|NCT01468181|Drug|Sulfonylureas (SU)|SU is a pre-study prescribed dose and is not being provided as part of the trial.
113931|NCT00070200|Drug|cisplatin|
113932|NCT01468181|Drug|Biguanides (BG)|Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
113933|NCT01468181|Drug|alpha-glucosidase inhibitor (a-GI)|a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
113934|NCT01468181|Drug|Thiazolidinedione (TZD)|TZD is a pre-study prescribed dose and is not being provided as part of the trial.
113935|NCT01468181|Drug|Glinides|Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
113936|NCT01468194|Other|Breathing procedure 1|inhalation during one step, exhalation during the next step
113937|NCT01468194|Other|Breathing procedure 2|inhalation and exhalation during one step
113938|NCT01468207|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
113939|NCT01468207|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
113940|NCT01468220|Other|Endurance training|Endurance training three times per week over six weeks
114604|NCT01528423|Procedure|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
114605|NCT01528436|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
114606|NCT01528436|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
114607|NCT00075738|Drug|fluorouracil|
114608|NCT01528436|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
114609|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
114610|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
113725|NCT01463176|Behavioral|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
113726|NCT01463189|Behavioral|painACTION: Arthritis|Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute "booster" sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs.
113727|NCT01463202|Drug|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
113728|NCT01463202|Drug|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
113729|NCT00070005|Procedure|management of therapy complications|
113730|NCT01463215|Drug|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
113731|NCT01463228|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
113732|NCT01463228|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
114324|NCT01464307|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
114325|NCT01464320|Drug|ABT-614|Active
114326|NCT00000258|Drug|Nitrous oxide 20% & placebo|
114327|NCT00001190|Drug|Deslorelin|
114328|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
114329|NCT01466387|Biological|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
114330|NCT00070174|Drug|asparaginase|
114671|NCT01526343|Device|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
114672|NCT01526356|Drug|Placebo|Study cream is applied nightly to the affected areas on the face.
114673|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
114674|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
114675|NCT01526369|Drug|Trastuzumab|
114676|NCT01526369|Drug|Paclitaxel|
114677|NCT01526369|Drug|Lapatinib|
114678|NCT01526382|Device|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
114679|NCT00075699|Drug|cisplatin|
114680|NCT01526382|Procedure|central venous catheter|patients in this arm can receive central venous catheter
114681|NCT01526395|Drug|Propofol|The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be "amnestic," meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week.
114682|NCT01526408|Drug|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
112969|NCT00070278|Procedure|neoadjuvant therapy|
112970|NCT01471210|Drug|Urelumab (BMS-663513)|
112971|NCT01471236|Device|Agili-C Bi-phasic Implant|The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).
The implant will be inserted gently in a pressed fit manner.
112972|NCT01471236|Procedure|mini-arthrotomy|The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator`s final decision. Related treatments during the procedure should be recorded.
Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded.
112973|NCT01471262|Procedure|Right hepatectomy|Right liver resection
112974|NCT01471262|Procedure|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
112975|NCT01471275|Drug|Metformin|250 mg or 500mg three times a day
112976|NCT01471275|Drug|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
112977|NCT01471288|Drug|Carum Cravi|40mg/kg of body weight
112978|NCT01471288|Drug|Placebo|Placebo
112979|NCT01471314|Behavioral|Headache day versus non-headache day|
112980|NCT00070291|Drug|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is > 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
112981|NCT01471327|Biological|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
112982|NCT01471327|Other|Placebo|Saline IV, single dose at Day 1
113256|NCT01469403|Behavioral|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
113257|NCT01469416|Drug|Rosuvastatin|Rosuvastatin 20 mg PO x 1
113258|NCT00070239|Drug|alvocidib|Given IV
113941|NCT01468233|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
113942|NCT00070200|Drug|cyclophosphamide|
113943|NCT01468233|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
113944|NCT01468259|Drug|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
113945|NCT01468272|Drug|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
113946|NCT01468272|Drug|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
113947|NCT01468285|Drug|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
113948|NCT01468285|Other|placebo|placebo tablets b.i.d., six weeks treatment
114200|NCT01468636|Drug|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
114201|NCT01468636|Drug|Placebo|200mg BID x 8 weeks
114202|NCT01468649|Device|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
114203|NCT01468675|Other|risk assessment survey; decision support for providers for prevention based on risk|
114204|NCT01468688|Drug|STI571 + BKM120|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
114205|NCT01468688|Drug|STI571 + BKM120|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
114206|NCT01468688|Drug|STI571 + BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
114207|NCT00070200|Drug|vincristine sulfate|
114208|NCT01468714|Drug|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
114209|NCT01468727|Dietary Supplement|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
113733|NCT01463241|Behavioral|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills [Belief Repair, Action, Solving Problems, Incentives, and Calming]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
113734|NCT01463267|Device|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
113735|NCT01463267|Behavioral|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
113736|NCT01465451|Procedure|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
113737|NCT01465451|Drug|intra-operative 5-FU chemotherapy|5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.
5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A.
113738|NCT00070122|Drug|fluorouracil|Given IV
113992|NCT01465906|Drug|tulobuterol|patch, 2mg, qN, 3 months
113993|NCT01465906|Drug|Tiotropium Bromide|18ug, inhale, qD, 3 months
113994|NCT01465906|Drug|tiotropium bromide|18ug, inhale, qD, 3 months
113995|NCT01465919|Drug|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
113996|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
113997|NCT01465932|Other|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
113998|NCT01465932|Other|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
113999|NCT01465945|Procedure|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
114000|NCT01465945|Procedure|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
114683|NCT01526408|Drug|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
114684|NCT01526421|Other|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
114685|NCT01526447|Procedure|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
114686|NCT01526447|Procedure|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
114687|NCT01526460|Drug|Atorvastatin|80 mg
114688|NCT01526460|Drug|Rosuvastatin|40 mg
114689|NCT01526460|Drug|Placebo|no statin loading dose
114690|NCT00075699|Drug|mitomycin C|
113791|NCT01470144|Drug|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit.
113792|NCT01470157|Drug|Ketamine|5mg/kg as oral suspension
113793|NCT01470157|Drug|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
113794|NCT01463280|Drug|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
113795|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
113796|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
113797|NCT01463293|Dietary Supplement|Placebo|Capsule containing no probiotic once a day
113798|NCT00070018|Biological|rituximab|250 mg/m^2, as part of Zevalin regimen
113799|NCT01463306|Drug|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects <4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
113800|NCT01463319|Other|air insufflation|air insufflation during insertion phase colonoscopy
113801|NCT01463319|Other|warm water irrigation|warm water irrigation during insertion phase colonoscopy
113259|NCT01469416|Drug|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
113260|NCT01469429|Other|placebo|Receive lozenge placebo PO
113261|NCT01469429|Other|laboratory biomarker analysis|Correlative studies
113262|NCT01469429|Other|questionnaire administration|Ancillary studies
113263|NCT01469429|Drug|chemoprevention|Receive LBR lozenge PO
113264|NCT01469429|Drug|chemoprevention|Receive LBR Saliva Substitute PO
113265|NCT01469429|Other|placebo|Receive Saliva Substitute placebo PO
113266|NCT01469442|Procedure|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
113267|NCT01469455|Drug|DT01|DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.
DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions.
113268|NCT01469468|Drug|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
113269|NCT00070239|Other|pharmacological study|Correlative studies
113270|NCT01469468|Drug|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
113271|NCT01469481|Drug|PF-04991532|a single oral dose of [14C]PF-04991532 (450 mg/100 uCi suspension)
113272|NCT01469494|Procedure|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
113273|NCT01462396|Device|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
113274|NCT00069966|Biological|filgrastim|
113275|NCT01462409|Device|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
112375|NCT01479465|Drug|Simtuzumab|Simtuzumab administered intravenously biweekly
112376|NCT01479465|Drug|FOLFIRI|FOLFIRI administered intravenously biweekly
114210|NCT01468727|Dietary Supplement|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
114211|NCT01468740|Drug|Doxorubicin|The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
114212|NCT01468740|Drug|Bleomycin|The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
114213|NCT01468740|Drug|Vinblastine|The four-drug ABVD chemotherapy regimen contains vinblastine
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation
114214|NCT01461772|Radiation|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
114543|NCT01466829|Drug|Placebo|Placebo; saline injection.
114544|NCT01466842|Procedure|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
114545|NCT00070174|Drug|etoposide|
114546|NCT01466855|Drug|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
114547|NCT01530386|Drug|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
114548|NCT00075959|Drug|NXY-059|
114549|NCT01530399|Drug|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
114550|NCT01530399|Drug|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
114551|NCT01530399|Drug|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
114001|NCT00070135|Drug|tacrolimus|Given PO or IV
114002|NCT01468298|Other|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
114003|NCT01468311|Procedure|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
114004|NCT01468311|Drug|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
114005|NCT00070200|Drug|doxorubicin hydrochloride|
114006|NCT01468311|Radiation|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
114007|NCT01468311|Radiation|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of Ca-DTPA followed by BEAM Chemo and Auto stem cell transplant
114008|NCT01468324|Drug|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
114259|NCT00070161|Procedure|cognitive assessment|
114260|NCT01466361|Drug|Nicotine higher dose|higher dose nicotine lozenge
114261|NCT01466361|Drug|Placebo|placebo
114262|NCT01466374|Drug|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
114263|NCT01466374|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
114264|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
114265|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
114266|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
114267|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
114268|NCT01468740|Drug|Dacarbazine|The four-drug ABVD chemotherapy regimen contains dacarbazine
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation
113802|NCT01463332|Drug|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
113803|NCT01463332|Drug|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
113804|NCT01463332|Drug|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
113805|NCT01463345|Other|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 7.5 g/dl. Blood products should be given to maintain Hgb levels >7.5 g/dl.
113806|NCT01463345|Other|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 9.0 g/dl. Blood products should be given to maintain Hgb levels > 9.0 g/dl.
113807|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
114069|NCT01463865|Drug|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
114070|NCT01463878|Dietary Supplement|Glycerna|Diabetes specific formula
114071|NCT01465958|Biological|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
114072|NCT01465958|Biological|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
114073|NCT01465984|Drug|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
114074|NCT01465997|Drug|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
114075|NCT01465997|Drug|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
114076|NCT01466010|Procedure|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
114077|NCT01466036|Drug|Cabozantinib|60 mg QD orally in cycles of 28 days
114078|NCT01466062|Drug|Palivizumab|
112377|NCT01479465|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously biweekly
112378|NCT01479478|Dietary Supplement|Placebo|One placebo capsule daily.
112379|NCT01472380|Drug|efavirenz|600 mg
112380|NCT01472380|Drug|fenofibric acid 105 mg|fenofibric acid 105 mg
112381|NCT01472393|Dietary Supplement|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
112382|NCT01472393|Dietary Supplement|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
112383|NCT01472406|Device|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
112384|NCT01472406|Device|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
112385|NCT01472406|Device|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
112386|NCT00001212|Drug|cyclophosphamide|
112387|NCT00070421|Procedure|complementary or alternative medicine procedure|
112388|NCT01472406|Device|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
112389|NCT01472406|Device|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
112390|NCT01472432|Drug|placebo|Placebo is added to the standard good medical practice.
112391|NCT01472432|Drug|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.
112392|NCT01472445|Drug|Vitamin D3|Vitamin D 10,000 IU/day
112393|NCT01472445|Drug|Vitamin D3|Vitamin D 400 IU/day
112394|NCT01472458|Behavioral|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
112395|NCT01472484|Other|586/8x87 white|2 x 50 g
112396|NCT01472484|Other|586/8x87 brown|2 x 50 g
114552|NCT01530399|Drug|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
114553|NCT01530399|Drug|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
114554|NCT01530399|Drug|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
114555|NCT01530412|Other|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
114556|NCT01530438|Other|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|At T0 and T9 or 12 monts, are performed :
Imaging : fMRI at rest and anatomical MRI
Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...
114557|NCT01530451|Drug|Desmopressin|120mg OD
114558|NCT01530451|Drug|Placebo|one tab OD
114559|NCT00075972|Behavioral|Mood Tolearance|
114560|NCT01530464|Drug|Aminophylline|Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
113656|NCT01465334|Drug|Ofatumumab|1000 mg IV
113657|NCT01465334|Drug|High-Dose Methylprednisolone|1000 mg/m2 IV
113658|NCT01465334|Drug|Alemtuzumab|30 mg subcutaneously
113659|NCT00070122|Biological|bevacizumab|Given IV
113660|NCT01465347|Drug|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
113661|NCT01465373|Drug|Endometrin|100 mg per vagina TID
113662|NCT01465373|Drug|Progesterone in Oil|50 mg IM injection daily
113663|NCT01465386|Drug|bortezomib|Given SC
113664|NCT01465399|Biological|Plasma Rich in Growth Factors PRGF-Endoret|
113665|NCT01465399|Procedure|Conventional closure of the lesion|
113666|NCT01465412|Drug|Preladenant|One 5-mg preladenant tablet, orally, on Day 1.
114269|NCT01468740|Drug|Etoposide|The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
114270|NCT01468740|Drug|Cyclophosphamide|The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
114271|NCT01468740|Drug|Vincristine|The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
114272|NCT00070200|Procedure|conventional surgery|
114273|NCT01468740|Drug|Procarbazine|The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
114611|NCT01528462|Other|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
114612|NCT01528475|Behavioral|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
114613|NCT01528488|Other|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
114614|NCT01528488|Other|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
114615|NCT01528501|Drug|Panobinostat (LBH589)|
114616|NCT01528514|Dietary Supplement|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
114617|NCT01528514|Other|Placebo|Placebo in capsule form, 4 capsules 4 times/day
114618|NCT00075738|Drug|irinotecan hydrochloride|
114619|NCT01528540|Drug|Placebo|This group will include placebo.
114079|NCT01466075|Device|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
114080|NCT01466088|Drug|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
114081|NCT00070135|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
114082|NCT01466088|Drug|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
114083|NCT01466101|Drug|Placebo administration|Administration of placebo
114084|NCT01466101|Drug|Pregabalin administration|Administration of pregabalin
114085|NCT01466114|Drug|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
114086|NCT01466114|Other|Placebo|4 capsules PO QD
114087|NCT01466114|Drug|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
114088|NCT01466114|Other|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
114331|NCT01466387|Biological|Yellow Fever Vaccine|One dose of yellow fever vaccine.
114332|NCT01466387|Biological|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
114333|NCT01466387|Biological|Rabies Vaccine|Three doses of Rabies vaccine.
114334|NCT01466387|Biological|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
114335|NCT01466413|Device|Tropoelastin|Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼" needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43.
114336|NCT01466439|Procedure|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
114337|NCT01466439|Procedure|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
114338|NCT01466452|Drug|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
115095|NCT01534013|Device|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
115096|NCT01534026|Drug|Aspirin|Current dose
115097|NCT01534026|Other|withdrawal of aspirin|Stopping current dose of aspirin
115098|NCT01534039|Device|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
115099|NCT01534039|Device|FormaFlex|Hollister skin barrier for ostomy patients
115100|NCT01534052|Drug|MDV3100|Oral
115101|NCT01534065|Device|Barricaid|Implanted intra-operatively during discectomy
115102|NCT00001383|Drug|PSC 833|
115103|NCT00076492|Drug|CoQ10|
115104|NCT01534078|Drug|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
115105|NCT01534078|Drug|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
115106|NCT01534091|Behavioral|Pedometer with supervision|
115107|NCT01534091|Behavioral|Pedometer without supervision|
115108|NCT01534104|Procedure|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI & DSI, neurological/physical testing & brain MRI showing tumor &/or edema located in or near (<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), &/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately <48 hours before surgery*) fMRI to localize gray matter DTI, DSI & tractography to localize white matter, DSI & updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray &/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (<48 hours after surgery)
115109|NCT01534117|Biological|Platelets|1 unit of platelets
115401|NCT01527695|Drug|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
115402|NCT01527695|Drug|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
115403|NCT01527695|Drug|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
115404|NCT01529515|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
115894|NCT01485120|Device|Blood pressure monitoring with GE Healthcare DASH4000 and Carescape V100|BP readings with marketed cuff with DASH4000 or V100 Patient Monitor and BP readings with Investigational BP cuff and DASH4000 Patient Monitor and V100 Patient Monitor
115895|NCT01485146|Drug|ETC-1002|escalating doses
115896|NCT01485159|Procedure|Spirometry|assessment of lung function by spirometry
115897|NCT01485172|Drug|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
115898|NCT01485172|Drug|placebo monotherapy|placebo as monotherapy in Parkinson's disease
115899|NCT01485185|Drug|Gabapentin lower dose|Repeat, oral dose
115900|NCT01485185|Drug|Donepezil|Repeat, oral dose
115901|NCT01485185|Other|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
115902|NCT00071968|Procedure|neoadjuvant therapy|
115003|NCT01531205|Drug|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
115004|NCT01531205|Drug|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
115005|NCT01531205|Drug|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
115006|NCT01533662|Drug|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
115007|NCT01533662|Drug|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
115008|NCT01533675|Other|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
115009|NCT01533675|Other|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
115010|NCT01533688|Drug|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
115011|NCT00076414|Drug|Acetylcholine|
115461|NCT00073034|Drug|EAA-090|
115462|NCT01498588|Drug|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
115463|NCT01498588|Drug|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
115464|NCT01498601|Other|Enhanced oral care protocol|Changing mouth suction equipment every 24 hours
Mouth assessment every 2-4 hours
Cleansing mouth with toothbrush every 12 hours
Cleansing oral mucosa with oral rinse solution every 2-4 hours
Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours
Suction mouth and throat as needed
Head of the bed elevated to a minimum of 30° during oral care
115465|NCT01498614|Behavioral|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
115466|NCT01527708|Procedure|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
115467|NCT01527721|Procedure|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
115468|NCT01527721|Procedure|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
115469|NCT01527734|Drug|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
115470|NCT01527734|Drug|placebo|1ml once or twice a day for 1 or 2 days.
115471|NCT01527747|Drug|Saxagliptin|5 mg daily
115757|NCT01530152|Procedure|Truwiev PCD laryngoscope|The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.
The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made.
114919|NCT01533389|Drug|Placebo|dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks
114920|NCT01533402|Behavioral|therapist support|Weekly therapist support without CBT-interventions
114921|NCT01533402|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
114922|NCT01533415|Device|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of <1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
114923|NCT01533415|Device|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
114924|NCT01533428|Drug|Capsaicin 8%|Capsaicin 8% transdermal delivery system
114925|NCT00076388|Drug|Gefitinib|
114926|NCT01533428|Drug|Placebo|Placebo Patch
114927|NCT01533441|Dietary Supplement|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
114928|NCT01533454|Other|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
114929|NCT01533467|Device|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
114930|NCT01533480|Drug|Zirgan|0.15% ganciclovir gel(Zirgan)
114931|NCT01533480|Drug|genteal gel|0.3% Hypromellose gel
114932|NCT01526707|Drug|inhaled steroid|inhaled budesonide for 7 days
114933|NCT01526733|Drug|Sham Injection|
114934|NCT01526733|Drug|Recombinant human hyaluronidase PH20|
114935|NCT01526733|Drug|Insulin aspart|
115240|NCT01529398|Other|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
115531|NCT00074711|Drug|Vitamin D|
115532|NCT01516255|Drug|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
115533|NCT01516255|Drug|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
115534|NCT01516255|Procedure|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
115535|NCT01516255|Procedure|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
115536|NCT01516268|Drug|Sufentanyl|As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.
As comparator 1cc normal saline is added to bupivacain in control group for Tap block.
115537|NCT01516294|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
115538|NCT01516307|Biological|OPT-822/OPT-821(30 μg/100 μg) + Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
115539|NCT01516307|Biological|Phosphate Buffer Saline (PBS) + Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
115540|NCT01516333|Other|High GL 107|Three meals a day
115541|NCT01516333|Other|Medium GL 76|Three meals a day
115542|NCT00074724|Procedure|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
115543|NCT01516333|Other|Medium GL 68|Three meals a day
115544|NCT01516333|Other|Low GL 48|Three meals a day
115545|NCT01516346|Drug|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
115012|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
115013|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
115014|NCT01533701|Other|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
115015|NCT01533714|Biological|Olokizumab|Solution for injection with a concentration of Olokizumab of 100 mg/mL Subjects will receive CDP6038 at a dose of 120 mg every two weeks.
This study will continue until approval of the marketing application for the indication of RA in the subject's country or region or until further notice from UCB.
115016|NCT01533727|Drug|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
115017|NCT01533727|Drug|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
115295|NCT01527448|Drug|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
115296|NCT01527474|Drug|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
115297|NCT01527487|Drug|Eribulin|1.4 mg/m2 IV (Days 1 & 8), given short (≤15 minute) IV infusion, per institutional standard
115298|NCT01527487|Drug|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
115299|NCT01527487|Drug|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
115300|NCT00075725|Drug|dexamethasone|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115301|NCT01527500|Drug|LFG316|LFG316 20 mg/0.2 mL solution (in 2 mL vial) for IVT injection,
115302|NCT01527500|Drug|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
115303|NCT01527500|Drug|LFG316 Lower dose|LFG316 20 mg/0.2 mL solution for IVT Injection
115758|NCT01530165|Behavioral|Life style counseling|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat <30 proportion of total energy, saturated fat <10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
115759|NCT01530178|Drug|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
115760|NCT01530204|Procedure|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
115761|NCT00076245|Behavioral|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
115762|NCT01532401|Other|Methylcellulose crystalline|Methylcellulose 37 ml
115763|NCT01532414|Drug|Androxal|oral, capsules, taken one time daily, for 3 months
115764|NCT01532414|Drug|Placebo|Oral capsule taken one time daily for 3 months
115765|NCT01532453|Device|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
115766|NCT01532453|Other|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
115767|NCT01532466|Drug|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
115768|NCT01532518|Drug|Nepadutant|Nepadutant oral solution
115769|NCT01532531|Device|"GEMORE" Multi-Function Electrotherapy Stimulator|The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator ("GEMORE" Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study.
115770|NCT01532544|Drug|Ilomedin and Integrilin|Continuous infusion
115771|NCT01532544|Drug|low molecular weight heparin.|
115772|NCT00001381|Drug|suramin|
115773|NCT00076258|Behavioral|Exercise|
115774|NCT01532570|Drug|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
114864|NCT01526642|Device|Non Invasive Ventilation- Device is: VPAP ST (Resmed, Australia)|NIV during night
114936|NCT01526733|Drug|Insulin lispro|
114937|NCT01526746|Drug|Tasimelteon|20mg capsule, once
115222|NCT01529333|Device|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
115223|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
115224|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
115225|NCT00075829|Procedure|Tandem Autologous Transplant|Transplant plus dexamethasone/thalidomide
115226|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
115227|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
115228|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
115229|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
115230|NCT01529346|Drug|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
115231|NCT01529346|Other|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
115232|NCT01529346|Other|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
115233|NCT01529346|Other|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
115234|NCT01529359|Dietary Supplement|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
115235|NCT01529359|Dietary Supplement|Placebo|Placebo 2 gelules per days for 6 weeks
115236|NCT00075829|Drug|Autologous Transplant Plus Non-Myeloablative Allogeneic Transplant|Transplant
115237|NCT01529372|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
115238|NCT01529385|Device|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
115239|NCT01529385|Device|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
115546|NCT01516346|Drug|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
115824|NCT01530243|Drug|Tolterodine|2 mg daily
115825|NCT01530243|Drug|Tolterodine + Terazosin|2mg daily and 2mg BID
115826|NCT01530256|Biological|ALD518|160 mg IV q 4 weeks for 4 doses
115827|NCT01530256|Biological|ALD518|320 mg IV q 4 weeks for 4 doses
115828|NCT01530256|Biological|ALD518|640 mg IV q 4 weeks for 2 doses
115829|NCT01530269|Drug|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
115830|NCT01530282|Other|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
115831|NCT01530282|Other|Non invasive method|Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
115832|NCT01530295|Drug|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
115833|NCT00075946|Biological|rituximab|Given IV
115834|NCT01530308|Drug|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
115835|NCT01530308|Drug|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
115836|NCT01530321|Other|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
115837|NCT01530321|Other|Light Massage|5 minutes of light pressure massage to the neck and upper back
115838|NCT01530334|Drug|Gefitinib 250mg|Gefitinib 250mg once daily
115839|NCT01530347|Device|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
115840|NCT01530360|Device|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
115841|NCT01530373|Drug|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
115842|NCT01530373|Drug|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
115304|NCT01529398|Other|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
115305|NCT01529398|Other|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
115306|NCT01529411|Drug|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min).
115307|NCT01529411|Other|Undefined (standard care)|All the current interventions used by each institution for the study disease.
115308|NCT01529424|Drug|ISIS apoC-III Rx|Dose 1
115309|NCT01529424|Drug|ISIS apoC-III Rx|Dose 2
115310|NCT00075842|Dietary Supplement|Valeriana officinalis extract|Given orally
115311|NCT01529424|Drug|ISIS apoC-III Rx|Dose 3
115312|NCT01529424|Drug|Placebo|Dose 1
115313|NCT01529424|Drug|Placebo|Dose 2
115314|NCT01529424|Drug|Placebo|Dose 3
115609|NCT00076232|Drug|Acyclovir placebo|Oral tablet taken twice daily
115610|NCT01532232|Drug|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
115611|NCT01532232|Drug|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
114865|NCT01526655|Procedure|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
114866|NCT01526655|Procedure|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
114867|NCT01526668|Behavioral|Follow-up strategy|Comparison of different follow-up strategies
114868|NCT01526668|Behavioral|No contact after discharge|
114869|NCT01526681|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve tissue scaffold at the time of surgery
114870|NCT01526681|Other|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical Control from Established Literature
114871|NCT00075699|Procedure|psychosocial assessment and care|
114872|NCT01526694|Drug|Bendamustine + Dexamethasone + Thalidomide|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
114873|NCT01528761|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
114874|NCT01528761|Other|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
114875|NCT01528774|Other|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
114876|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.01%|AR-13324 Ophthalmic Solution 0.01% q.d.
114877|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.02%|AR-13324 Ophthalmic Solution 0.01% q.d.
114878|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.04%|AR-13324 Ophthalmic Solution 0.04%, q.d.
114879|NCT01528787|Drug|AR-13324 Vehicle Ophthalmic Solution|AR-13324 Vehicle Ophthalmic Solution, q.d.
115036|NCT01527006|Drug|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
115037|NCT01527019|Drug|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
115038|NCT01527019|Drug|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
115039|NCT01527019|Drug|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
115040|NCT01527032|Drug|melphalan, thalidomide and dexamethasone|
115041|NCT01527045|Drug|Atorvastatin Calcium|Given PO
115042|NCT00075712|Procedure|adjuvant therapy|
115043|NCT01527045|Drug|Cyclosporine|Given PO
115044|NCT01527045|Drug|Fludarabine Phosphate|Given IV
115045|NCT01527045|Other|Laboratory Biomarker Analysis|Correlative studies
115046|NCT01527045|Drug|Mycophenolate Mofetil|Given PO or IV
115047|NCT01527045|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
115048|NCT01527045|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
115049|NCT00075803|Drug|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients > 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients < 12 years, intravenous doses will be prepared.
115050|NCT01529047|Behavioral|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
115051|NCT01529060|Drug|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
115052|NCT01529060|Drug|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
115843|NCT01532635|Drug|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
115844|NCT00076284|Drug|GW873140|
115845|NCT01532635|Drug|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
115846|NCT01532635|Biological|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells.
114938|NCT01526746|Drug|Tasimelteon|20mg, once
114939|NCT01526759|Dietary Supplement|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
114940|NCT01526759|Dietary Supplement|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
114941|NCT00075699|Procedure|quality-of-life assessment|
114942|NCT01526772|Procedure|Endoscopy|Transoral endoscopy versus transoral endoscopy
114943|NCT01526785|Drug|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
114944|NCT01526798|Device|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
114945|NCT01526798|Device|Conventional high-flux dialyzer|
114946|NCT01526811|Device|Endurant Stent graft|Endurant Stent graft implantation
114947|NCT01526824|Dietary Supplement|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
114948|NCT01526837|Drug|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
114949|NCT01526850|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
114950|NCT01526850|Drug|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
114951|NCT01526863|Dietary Supplement|HA egg|Daily dose of HA egg or placebo for 6 months
114952|NCT00075712|Drug|carboplatin|
114953|NCT01526876|Drug|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
115405|NCT01529515|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
115406|NCT01529515|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
115407|NCT01529515|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
115408|NCT00001368|Procedure|cytokine and leukocyte activation profile|
115409|NCT00075855|Drug|therapeutic testosterone|
115410|NCT01529515|Drug|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
115411|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
115412|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
115413|NCT01529528|Drug|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
115414|NCT01529541|Drug|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
115415|NCT01529541|Drug|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
115416|NCT01529554|Drug|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
115417|NCT01529554|Drug|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
115418|NCT01529567|Behavioral|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
115419|NCT01529567|Behavioral|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
115420|NCT00075855|Other|placebo|
115699|NCT01525901|Drug|Normal saline|Saline solution will be administered for three months subcutaneously.
115700|NCT01525914|Drug|Dutasteride|dutasteride 0.5mg daily
115701|NCT01525927|Drug|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
114880|NCT01528800|Drug|Vitamin K1|10mg orally three times a week for 12 months
115168|NCT01531465|Other|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
115169|NCT01531465|Other|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
115170|NCT00076063|Biological|LIPO-5|experimental vaccine
115171|NCT01531478|Other|Unique medical visit of the study|The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.
After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia).
115172|NCT01531491|Procedure|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
115173|NCT01531491|Procedure|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
115174|NCT01531504|Device|ViKY UP|laparoscopic-assisted hysterectomy procedure
115175|NCT01533493|Drug|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
115176|NCT01533493|Drug|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
115177|NCT01533493|Drug|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
115178|NCT01533506|Drug|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
115179|NCT00076388|Drug|Docetaxel|
115180|NCT01533519|Drug|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
115181|NCT01533532|Drug|KLH-2109|
115053|NCT01529073|Drug|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
115337|NCT00001379|Drug|Rituxan and EPOCH|For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
115338|NCT00076102|Drug|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
115339|NCT01531712|Radiation|Radiotherapy|50.4 Gy
115340|NCT01531712|Drug|Tarceva|100mg/day
115341|NCT01531712|Drug|Oxaliplatin|100mg/m2 (only in QT)
115342|NCT01531725|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
115343|NCT01531751|Device|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
115344|NCT01531751|Drug|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
115345|NCT01531764|Drug|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 & 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
115346|NCT01531777|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
115347|NCT01531777|Drug|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
115348|NCT01531790|Drug|Carboplatin|d1, AUC 5, i.v.
115349|NCT00076115|Drug|Risperidone|
115350|NCT01531790|Drug|Pemetrexed|d1, 500 mg/m2, i.v.
115351|NCT01531790|Drug|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
115352|NCT01531790|Drug|Centrum|1 tablet/day
115353|NCT01531803|Drug|Kedbumin 25%|Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).
The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin).
115354|NCT01534130|Device|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
114954|NCT01526889|Drug|LFG316|LFG316 administered intravitreally (IVT)
114955|NCT01526889|Drug|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
114956|NCT01526902|Device|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
114957|NCT01526902|Device|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
114958|NCT01526915|Procedure|Bone curettage + PRF|Bone curettage and PRF insertion
114959|NCT01528865|Drug|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
115241|NCT01531517|Drug|Royal Jelly and Panthenol (PedyPhar® Ointment)|the following will be done to each patient depending on the number of the visit:
Assessment of the patient for inclusion/exclusion criteria
Informed consent process
Medical history of the patient
Blood withdrawn for investigation
Drainage of the ulcer if there is a collection
Revascularization as needed and indicated by APSV done at visit 0.
Swab from the ulcer for culture and micro-organism count: on detailed visits only.
Debridement as needed.
Dressing:
Inspection and assessment of the ulcer
Irrigation using 500 ml of saline or as required.
Drying of the ulcer (leave to dry)
Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer
Fix the dressing to the ulcer
115242|NCT01531517|Drug|Panthenol Ointment|the following will be done to each patient depending on the number of the visit:
Assessment of the patient for inclusion/exclusion criteria
Informed consent process
Medical history of the patient
Blood withdrawn for investigation
Drainage of the ulcer if there is a collection
Revascularization as needed and indicated by APSV done at visit 0.
Swab from the ulcer for culture and micro-organism count: on detailed visits only.
Debridement as needed.
Dressing:
Inspection and assessment of the ulcer
Irrigation using 500 ml of saline or as required.
Drying of the ulcer (leave to dry)
Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer
Fix the dressing to the ulcer
115243|NCT01531530|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
115244|NCT01531530|Other|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
115245|NCT01531543|Device|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
115246|NCT01531556|Other|Honey spiked with known concentration of tutin and hyenanchin|Prepared honey will contain 5.1 mg/kg tutin and 23 mg/kg hyenanchin; honey dose will be calculated based on body weight, such that each subject receives 1.8 mcg per kg body weight of tutin.
115247|NCT00076076|Drug|Roflumilast|
115248|NCT01531569|Other|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
115702|NCT01525927|Radiation|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
115703|NCT01525927|Radiation|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
115704|NCT00001353|Drug|Genetically Marked Syngeneic T Lymphocytes|
115705|NCT00075647|Drug|temsirolimus|Given IV
115706|NCT01525940|Device|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
115707|NCT01525953|Drug|Chemotherapy|Chemotherapy according to standard
115708|NCT01525953|Radiation|Radiotherapy|Radiotherapy according to local standard
115709|NCT01525966|Drug|carboplatin|Given IV
115710|NCT01525966|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
115711|NCT01525966|Other|laboratory biomarker analysis|Correlative studies
115712|NCT01525979|Behavioral|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
115713|NCT01525979|Behavioral|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
115714|NCT01525979|Behavioral|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
115715|NCT01525979|Behavioral|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
115716|NCT00075647|Other|laboratory biomarker analysis|Correlative studies
115182|NCT01533532|Drug|KLH-2109|
115183|NCT01533532|Drug|KLH-2109|
115184|NCT01533532|Drug|placebo|
115472|NCT01527760|Drug|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
115473|NCT00075725|Drug|mercaptopurine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115474|NCT01527786|Drug|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
115475|NCT01527812|Procedure|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
115476|NCT01527825|Biological|Trivalent influenza vaccine (seasonal)|Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:
An A/California/7/2009 (H1N1)pdm-like virus
An A/Perth/16/2009 (H3N2)-like virus*
A B/Brisbane/60/2008-like virus * A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season.
115477|NCT01527825|Biological|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
115478|NCT01527838|Biological|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
115479|NCT01527864|Drug|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
115480|NCT01527864|Drug|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
115481|NCT01529606|Other|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
115482|NCT01529606|Procedure|Plasma treatment|plasma treatment after preparation and for caries prevention
115483|NCT01529619|Drug|Rivastigmine transdermal patch|
115484|NCT01529632|Drug|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
115485|NCT01529632|Drug|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
115486|NCT01529632|Drug|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
115487|NCT01529632|Drug|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
115355|NCT01534143|Other|pharmacological study|Correlative studies
115356|NCT00076492|Drug|GPI 1485|
115357|NCT01534143|Drug|tacrolimus|Given IV
115358|NCT01534143|Drug|sirolimus|Given PO
115640|NCT01528033|Other|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
115641|NCT00075725|Drug|prednisone|Given IV or orally
115642|NCT01528046|Drug|Vincristine|Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
115643|NCT01528046|Drug|Irinotecan|Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes
115644|NCT01528046|Drug|Temozolomide|Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5
115645|NCT01528046|Drug|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
115646|NCT01528059|Procedure|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
115647|NCT01528072|Device|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
115648|NCT01528085|Drug|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
115649|NCT01528111|Drug|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
115650|NCT01528111|Drug|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
115651|NCT01528111|Drug|LX7101 Vehicle|Subjects will receive vehicle
115652|NCT00075725|Drug|thioguanine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115653|NCT01528124|Drug|LY3025876|Given as a SC injection
115654|NCT01528124|Drug|Placebo|Given as a SC injection
115655|NCT01528137|Biological|talactoferrin|Given PO
115656|NCT01529827|Drug|methotrexate|Given IV
115657|NCT01529827|Other|laboratory biomarker analysis|Correlative studies
115249|NCT01531582|Drug|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
115250|NCT01531595|Drug|Bevacizumab plus alternating Xelox/Xeliri|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
115251|NCT01531621|Other|Biomarker sampling|Blood samples every 8-12 weeks
115252|NCT01531634|Behavioral|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
115253|NCT01531647|Drug|danoprevir|100 mg q12h Days 8-21
115254|NCT01531647|Drug|raltegravir|400 mg q12h Days 1-4 and 18-21
115255|NCT01531647|Drug|ritonavir|100 mg q12h Days 8-21
115256|NCT01531660|Behavioral|step-up jogging program|
115257|NCT01531673|Drug|VX-661|Tablet, taken once daily (qd)
115547|NCT01527877|Drug|BKM120|Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.
• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed.
115548|NCT01527890|Drug|Fentanyl|intravenous patient-controlled analgesia
115549|NCT01527903|Drug|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
115550|NCT00075725|Drug|methotrexate|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115551|NCT01527903|Drug|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
115552|NCT01527916|Drug|placebo|Placebo Comparator
115553|NCT01527916|Drug|donepezil|Active Comparator
115554|NCT01527916|Drug|ABT-126|low dose, middle dose, high dose
115555|NCT01527929|Drug|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
115556|NCT01527942|Drug|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
114805|NCT01530802|Procedure|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
114806|NCT01530815|Drug|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
114807|NCT01530841|Device|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
114808|NCT01530880|Drug|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL NS IV over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL NS at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
114809|NCT01530880|Drug|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
114810|NCT01530893|Dietary Supplement|Flavanone - supplement|acute single optimal dose
114811|NCT01530893|Other|Flavanone - food|acute single dose
114812|NCT01530893|Other|Flavanone - placebo|acute single dose (flavanone free)
114813|NCT01530893|Dietary Supplement|Isoflavone - supplement|acute single optimal dose
114814|NCT00076024|Drug|Docetaxel|Standard of care drug administration
114815|NCT01530893|Other|Isoflavone - food|acute single optimal dose
114816|NCT01530893|Other|Isoflavone - placebo|acute single dose (isoflavone free)
114817|NCT01530893|Dietary Supplement|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
114818|NCT01530893|Dietary Supplement|Flavan-3-ol - supplement|acute single optimal dose
114819|NCT01530893|Other|Flavan-3-ol - food|acute single optimal dose
114820|NCT01530893|Other|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
114821|NCT01530893|Dietary Supplement|Anthocyanin - supplement|acute single optimal dose
114822|NCT01530893|Other|Anthocyanin - food|acute single optimal dose
115488|NCT00075868|Drug|octreotide acetate|
115489|NCT01529645|Biological|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
115490|NCT01529645|Biological|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
115775|NCT01532583|Other|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
115776|NCT01532596|Behavioral|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
115777|NCT01532609|Behavioral|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
115778|NCT01532622|Dietary Supplement|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
115779|NCT01532622|Other|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
115780|NCT01532635|Radiation|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
115781|NCT01532635|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
115782|NCT01532635|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
115783|NCT01525992|Behavioral|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
115784|NCT01525992|Other|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
115785|NCT01526005|Drug|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
115786|NCT01526005|Drug|Transdermal Placebo Patch|1 patch per day; 8 weeks total
115787|NCT01526018|Behavioral|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
115658|NCT01529827|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
115659|NCT01529827|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
115660|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
115661|NCT00075894|Drug|L-alanosine|
115662|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
115949|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
115950|NCT01482754|Drug|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
115951|NCT01482767|Drug|Pegylated-Interferon Alfa 2b (PEG-IFN)|Week 1 through Week 48: 1.5 mcg/kg SC once a week (based on participant's weight at entry).
115952|NCT01482767|Drug|Ribavirin (RBV)|Week 1 through Week 48: 800-1400 mg orally per day with food (based on participant's weight at entry).
115953|NCT01482767|Drug|Boceprevir (BOC)|Participants will receive 800 mg orally every 8 hours with food at Week 5 through Week 36 or through Week 48.
115954|NCT00071695|Drug|Venlafaxine Extended Release|
115955|NCT01482780|Device|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
115956|NCT01482793|Procedure|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
115957|NCT01485198|Procedure|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
115958|NCT01485198|Drug|Acetaminophen|Acetaminophen (750mg orally TID) administration
115557|NCT01527942|Drug|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
115558|NCT01527955|Other|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
115559|NCT01527968|Drug|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
115560|NCT01527968|Drug|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
115561|NCT00075725|Drug|pegaspargase|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115562|NCT01527968|Drug|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
115563|NCT01527981|Behavioral|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
115564|NCT01527994|Drug|Aprepitant|Aprepitant 125 mg oral tablets
115847|NCT01532648|Drug|Budesonide|One budesonide-MMX® 9 mg tablet plus current oral 5-aminosalicylic acid (5-ASA) regimen daily in the morning after breakfast.
115848|NCT01532648|Drug|Placebo|One tablet indistinguishable from budesonide MMX 9 mg tablet plus current oral 5-aminosalicylic acid (5-ASA) regimen daily in the morning after breakfast.
115849|NCT01532648|Procedure|Procedure/Surgery: Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores.
115850|NCT01532661|Other|observational study|data collected by investigators
115851|NCT01532674|Device|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|ROOT PLANNING PROCEDURE:
The procedure is the same as in the control group
APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :
The photosensitive agent : Formulation Periowave Treatment Kit-2ml
Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.
Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.
All the periodontal pockets will be treated subgingivally
Elimination of the photosensitive by irrigation
114823|NCT01530893|Other|Anthocyanin - placebo|acute single dose (anthocyanin free)
114824|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
115110|NCT01534117|Drug|DDAVP|Desmopressin 0.3mcg/kg IV x 1
115111|NCT01534130|Device|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
115112|NCT01527045|Radiation|Total-Body Irradiation|Undergo TBI
115113|NCT01527058|Drug|68Ga-BNOTA-PRGD2|Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors
Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs
115114|NCT01527084|Procedure|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
115115|NCT01527097|Drug|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
115116|NCT00075712|Procedure|conventional surgery|
115117|NCT01527097|Drug|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
115118|NCT01527110|Drug|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
115119|NCT01527123|Drug|GSK2585823|CLDM1%/BPO3%
115120|NCT01527136|Drug|entolimod|Given IM or SC
115121|NCT01527136|Other|pharmacological study|Correlative studies
115122|NCT01527136|Other|laboratory biomarker analysis|Correlative studies
115123|NCT01527149|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
115124|NCT01527149|Drug|Cyclophosphamide|Given IV
115125|NCT01527149|Drug|Cytarabine|Given IV
115126|NCT01527149|Drug|Dexamethasone|Given IV or PO
115127|NCT00075712|Procedure|neoadjuvant therapy|
115788|NCT01526031|Procedure|1:10,000 bee venom (BV) acupuncture|after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)
1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)
2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)
3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)
4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)
115789|NCT01526031|Procedure|1:30,000 bee venom (BV) acupuncture|after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)
1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)
2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)
3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)
4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)
114881|NCT01528800|Drug|Chrystalline Lactose|10mg orally three times a week for 12 months
114882|NCT00075764|Drug|anastrozole|Given orally
114883|NCT01528813|Device|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
114884|NCT01528813|Drug|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
114885|NCT01528826|Drug|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
114886|NCT01528839|Drug|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
114887|NCT01528839|Drug|Placebo|
114888|NCT01528852|Drug|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
114889|NCT01528852|Drug|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
114890|NCT01528852|Other|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
114891|NCT01528865|Drug|Lamivudine|Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.
Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.
Subjects will be taking drug for 16 weeks.
114892|NCT00076024|Drug|AG-013736 (axitinib)|5mg twice daily [bid] continuous dosing
114893|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
114894|NCT01530919|Other|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
115959|NCT01485211|Drug|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
115960|NCT01485224|Drug|Thalidomide|Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.
Treatment will be continued until one of the following criteria is met:
8 additional weeks of treatment after the achievement of complete response
16 additional weeks of treatment after the achievement of partial response
24 weeks of treatment completed without response
unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks.
115961|NCT01485237|Other|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
115962|NCT01485276|Procedure|DBS Surgery|
115054|NCT01529099|Device|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
115055|NCT01529112|Drug|Lenvatinib|
115056|NCT01529112|Drug|Lenvatinib matched placebo|
115057|NCT01529112|Drug|BSC|
115058|NCT01529125|Drug|zidovudine, lamivudine, nevirapine|
115059|NCT01529138|Drug|Axitinib|Combination treatment with temsirolimus and axitinib
115060|NCT00075803|Drug|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients > 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients > 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age < 12 years.
115061|NCT01529138|Drug|Temsirolimus|Combination treatment with temsirolimus and axitinib
115062|NCT01529151|Other|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
115063|NCT01529151|Other|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
115064|NCT01529164|Drug|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
115852|NCT01532674|Procedure|scaling and root planing|ROOT PLANNING PROCEDURE:
An unique operator ( independent from the explorer) will do the root planing for both the test and control group.
Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.
* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque.
115853|NCT01532687|Drug|Gemcitabine Hydrochloride|Given IV
115854|NCT01532687|Other|Laboratory Biomarker Analysis|Correlative studies
115855|NCT00076310|Drug|Docetaxel|60 mg/m^2 IV repeated every 21 days.
115856|NCT01532687|Drug|Pazopanib Hydrochloride|Given PO
115857|NCT01532687|Other|Placebo|Given PO
115858|NCT01532700|Drug|Ofatumumab with GSK2110183|GSK2110183 125mg OD continuously
Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses
115859|NCT01532713|Procedure|oxygen administration|nasal O2 5L/min via nasal cannula
115860|NCT01532726|Drug|ESL|ESL 400/800/1200 mg tablets once daily
115861|NCT01526096|Drug|Plerixafor|Plerixafor (self-administered shot)prior to the beginning of the stem cell collection. Up to 4 doses of plerixafor may be given.
115862|NCT01526096|Procedure|Apheresis|Stem cell collection begins on day 5 and can last up to 3 days depending on the number collected.
115863|NCT01526096|Drug|Melphalan|Melphalan chemotherapy 100mg/m2 for 2 days after your admission into the hospital for your ASCT procedure.
115864|NCT00075673|Drug|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
114960|NCT00001365|Drug|dextromethorphan|
114961|NCT00075764|Drug|fulvestrant|Given intramuscularly
114962|NCT01528878|Radiation|Stereotactic Radiosurgery using the CyberKnife System.|Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.
The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy.
114963|NCT01528891|Drug|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
115128|NCT01527149|Drug|Doxorubicin Hydrochloride|Given IV
115129|NCT01527149|Other|Laboratory Biomarker Analysis|Correlative studies
115130|NCT01527149|Drug|Methotrexate|Given IV
115131|NCT01527149|Biological|Ofatumumab|Given IV
115132|NCT01527149|Drug|Vincristine Sulfate|Given IV
115421|NCT01529580|Behavioral|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|The intervention has 3 components:
One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.
Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.
Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training.
115422|NCT01529593|Drug|Temsirolimus|Starting dose: 25 mg by vein weekly.
Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled.
115423|NCT01529593|Drug|Metformin|Starting dose: 500 mg titrated over first 3 weeks.
Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled
115424|NCT01531816|Device|Early Rehabilitation intervention|Passive mobility: cycle ergometer
Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention.
115425|NCT01531829|Drug|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
115426|NCT01531829|Drug|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
115427|NCT01531842|Procedure|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
115428|NCT01531855|Other|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
115429|NCT01531868|Other|Video|Video of physician
115430|NCT00076180|Biological|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
115431|NCT01531868|Other|Video|Video of physician
115432|NCT01531868|Other|Video|Video of physician
115433|NCT01531868|Other|Video|Video of physician
115434|NCT01531868|Other|Video|Video of physician
114895|NCT01530958|Behavioral|CKD Registry|Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:
identify patients with CKD
notify PCPs of a patients' CKD status
provide PCP outreach with NKDEP guidelines and patient educational materials
114896|NCT01530958|Behavioral|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
114897|NCT01530958|Behavioral|Usual care|Primary care providers will manage their patients with CKD per usual care.
Patients will receive usual care.
114898|NCT01530971|Drug|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
114899|NCT01530984|Drug|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
115185|NCT01533545|Drug|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
115186|NCT01533545|Drug|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
115187|NCT01533558|Drug|caspofungin|normal dosage for caspofungin, not adapted for the study
115188|NCT01533571|Procedure|Immediate implant placement with simultaneous bone grafting|Flapless surgery is used for surgical implant installation.
Implant is placed in the cingulum position of adjacent teeth incisal edge.
After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.
Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .
Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material.
115189|NCT01533597|Drug|Solifenacin|Solifenacin (5mg, qd, oral)
115190|NCT00076401|Drug|Motexafin gadolinium|
115191|NCT01533597|Drug|Solifenacin plus Tamsulosin|Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
115192|NCT01533610|Procedure|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
115193|NCT01533623|Device|Mandibular Advancement Device|Nightly wearing time
115194|NCT01533649|Behavioral|Andrews/Reiter approach to epilepsy|The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook ("Taking Control of Your Epilepsy") as an on-going step-by-step guideline.
115065|NCT01529164|Drug|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
115066|NCT01529164|Drug|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
115067|NCT01529164|Drug|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
115068|NCT01529177|Drug|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
115069|NCT01531205|Drug|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
115359|NCT01534143|Biological|anti-thymocyte globulin|Given IV
115360|NCT01534143|Drug|fludarabine phosphate|Given IV
115361|NCT01534143|Drug|busulfan|Given IV
115362|NCT01534143|Drug|bortezomib|Given IV
115363|NCT01534143|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
115364|NCT01534143|Other|laboratory biomarker analysis|Correlative studies
115365|NCT01534169|Drug|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
115366|NCT01534182|Drug|Fingolimod|0.5 mg orally once a day
115367|NCT00076518|Drug|Fenofibrate|
115368|NCT01534182|Drug|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
115369|NCT01534182|Drug|Glatiramer acetate (GA)|20 mg subcutaneously once a day
115370|NCT01534195|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
115371|NCT01534195|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
115372|NCT01534208|Drug|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
114964|NCT01528891|Other|Placebo|
114965|NCT01528930|Drug|Amikacin|500 mg, once daily for 2 years
114966|NCT01528943|Drug|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
114967|NCT01528943|Drug|Isotonic saline|same volume as the group that are allocated to prostacycline
114968|NCT01528956|Genetic|DNA methylation analysis|
114969|NCT01528956|Genetic|RNA analysis|
114970|NCT01528956|Genetic|gene expression analysis|
114971|NCT01528956|Genetic|nucleic acid sequencing|
114972|NCT00075777|Drug|valproic acid|250 mg by mouth twice a day
114973|NCT01528956|Genetic|polymorphism analysis|
114974|NCT01528969|Dietary Supplement|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
114975|NCT01528969|Dietary Supplement|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
114976|NCT01528982|Behavioral|Mindfulness|Subjects receive mindfulness training
114977|NCT01528982|Behavioral|Cognition|Subject receive cognitive training
114978|NCT01528995|Device|Medtronic Interstim II-3058|impulse generator
114979|NCT01528995|Procedure|Anal bulking injection|Permacol injection:
four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa
114980|NCT01529008|Drug|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
115258|NCT00076089|Drug|Roflumilast|
115259|NCT01531673|Drug|ivacaftor|Tablet, taken every 12 hours (q12h)
115260|NCT01531673|Drug|VX-661 placebo|Tablet, taken once daily (qd)
115261|NCT01531673|Drug|ivacaftor placebo|Tablet, taken every 12 hours (q12h)
115262|NCT01533805|Other|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
115435|NCT01531868|Other|Video|Video of physician
115436|NCT01531894|Drug|GSK2110183|an oral, low nanomolar pan-AKT kinase inhibitor
115437|NCT01531907|Other|Study visit procedures|Anthropometric measurements to include:
Weight, height, and BMI.
Waist and hip circumference
Triceps skinfold thickness
Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.
115438|NCT01531920|Drug|alcohol + placebo|Part A alcohol + placebo
115439|NCT01531920|Drug|alcohol + perampanel|Part A: alcohol + perampanel
115717|NCT01528137|Other|laboratory biomarker analysis|Correlative studies
115718|NCT01528163|Drug|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
115719|NCT01528163|Drug|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
115720|NCT01528176|Drug|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
115721|NCT01528189|Other|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
115722|NCT01528189|Other|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
115723|NCT01528202|Dietary Supplement|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
115724|NCT00001359|Drug|Penicillin or Placebo|
115725|NCT00075725|Drug|vincristine sulfate|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115726|NCT01528202|Dietary Supplement|Fruit juice cordial|fruit flavoured juice concentrate
115727|NCT01528215|Device|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
115728|NCT01528215|Device|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
115729|NCT01528228|Device|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
115195|NCT01533649|Behavioral|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
115196|NCT01527188|Biological|500IR|500IR sublingual tablet of
115197|NCT01527188|Other|Placebo|Placebo sublingual tablet of
115198|NCT01527201|Procedure|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
115199|NCT01527214|Radiation|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
115200|NCT01527227|Other|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
115201|NCT01527240|Drug|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
115491|NCT01529645|Biological|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
115492|NCT01529645|Biological|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
115493|NCT01529645|Other|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
115494|NCT01529658|Procedure|Renal hypothermia|Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.
When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery.
115495|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
115496|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
115497|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
115498|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
115499|NCT00075868|Other|Placebo|
115500|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension BID
115373|NCT01534221|Device|Biomatrix drug eluting stent|Biomatrix drug eluting stent
115374|NCT01534234|Device|PARADYM RF SONR|SonR CRT Optimization
115375|NCT01534234|Device|PARADYM RF SONR|Echocardiography Optimization
115376|NCT01534247|Drug|CAZ-AVI|Infusion
115377|NCT01534247|Drug|metronidazole|Infusion
115378|NCT00076518|Drug|Fish Oil|
115379|NCT01534247|Drug|CAZ-AVI + metronidazole|Infusion
115380|NCT01534260|Drug|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
115381|NCT01534273|Drug|LY2886721|Administered orally.
115663|NCT01529853|Drug|SAR156597|Pharmaceutical form: solution
Route of administration: subcutaneous
115664|NCT01529853|Drug|Placebo (for SAR156597)|Pharmaceutical form: solution
Route of administration: subcutaneous
115665|NCT01529866|Device|New Abutment Connection implant|New abutment connection implant
115666|NCT01529866|Device|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
115667|NCT01529879|Device|New Abutment Connection implant|New abutment connection implant
115668|NCT01529879|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
115669|NCT01529892|Drug|A single oral 5 mg of duterium labeled methamphetamine|
115670|NCT01529918|Other|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
115671|NCT01529944|Drug|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
115672|NCT00075907|Drug|Efavirenz + 2 NRTIs|
115673|NCT01529944|Drug|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
115674|NCT01529957|Drug|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
115263|NCT01533818|Drug|Amoxicillin|80-100 mg/kg/day in 2 divided doses for 7 days
For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0
115264|NCT01533818|Drug|Sugar Syrup|It will be given 2 times/day for 7 days
115265|NCT01533857|Dietary Supplement|hot water|Hot water and placebo capsule
115266|NCT01533857|Dietary Supplement|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
115267|NCT01533870|Drug|NKTR-118|Oral 25 mg
115268|NCT00076440|Drug|Leuprolide acetate|
115269|NCT01533870|Drug|Rifampin|Oral 600 mg
115270|NCT01533883|Device|Cardioband adjustable band|Cardioband is an adjustable sutureless annuloplasty band designed for mitral valve repair by a transfemoral approach. Cardioband is intended to remodel the annulus by deployment and fixation along the posterior annulus of the mitral valve, in order to correct mitral regurgitation. Adjustment can be performed on a beating heart, to optimize correction of mitral regurgitation.
115271|NCT01533896|Behavioral|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
115272|NCT01533922|Drug|Placebo|placebo matching tiotropium + olodaterol FDC
115273|NCT01533922|Drug|Tiotropium|Tiotropium 5 mcg once daily
115274|NCT01533922|Drug|Olodaterol|Olodaterol 5 mcg once daily
115275|NCT01533922|Drug|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
115276|NCT01533922|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
115277|NCT01533922|Device|Respimat|Respimat inhaler
115278|NCT01533935|Drug|Placebo|placebo matching tiotropium + olodaterol
115279|NCT00076453|Device|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
115565|NCT01527994|Drug|Placebo pill|Placebo oral pill- inactive compound
115566|NCT01528007|Drug|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
115567|NCT01528007|Drug|Placebo|Placebo pill with no active ingredients.
115730|NCT01528241|Drug|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
115731|NCT01528254|Drug|Placebo to vildagliptin|
115732|NCT01528254|Drug|vildagliptin|Patients will be instructed to take one tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
115733|NCT01528254|Drug|Metformin|Metformin should be taken in a twice daily (bid) regimen during or after meals at the same time as vildagliptin.
115734|NCT01528267|Other|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
115735|NCT01528267|Other|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
115736|NCT00075725|Radiation|radiation therapy|Patients undergo radiation therapy periodically during study treatment
115737|NCT01528280|Biological|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
114825|NCT00001379|Biological|Interferon|For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.
114826|NCT01533181|Other|Laboratory Biomarker Analysis|Correlative studies
114827|NCT01533181|Drug|Linsitinib|150 mg given orally (PO) twice a day (BID)
114828|NCT01533181|Other|Pharmacological Study|Correlative studies
114829|NCT01533181|Drug|Topotecan Hydrochloride|1.5 mg/m^2 intravenously (IV) or 2.3 mg/m^2 orally (PO)
114830|NCT01533194|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
114831|NCT01533194|Biological|Wild-type Reovirus|Given IV
114832|NCT01533207|Other|Clinical Observation|Patients followed clinically
114833|NCT00076349|Drug|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
114834|NCT01533207|Drug|Docetaxel|Given IV
114835|NCT01533207|Drug|Doxorubicin Hydrochloride|Given IV
114836|NCT01533207|Biological|Filgrastim|Given subcutaneously (SC)
115501|NCT01529684|Drug|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
115502|NCT01529684|Drug|OSI-906|Part B: oral tablets OSI-906
115503|NCT01531946|Procedure|MRI Scan|Patients will have to spend additional 10min in the scanner.
Additional scan modalities used:
Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.
Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.
An overall 20min scan period.
115504|NCT01531959|Drug|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
115505|NCT01531959|Drug|Placebo|Patients will be randomized to blinded placebo control
115506|NCT01531972|Drug|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
115507|NCT01531972|Drug|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
115508|NCT01531998|Drug|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
115509|NCT01531998|Drug|Bortezomib|Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.
Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8.
115510|NCT00076206|Drug|Placebo|
115790|NCT01526031|Procedure|normal saline injection|after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)
1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)
2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)
3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)
4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)
115791|NCT01526031|Procedure|physiotherapy|Physiotherapy treatment will be provided at each visit after bee venom or saline injection.
transcutaneous electrical nerve stimulation (TENS) for 15 minutes
transcutaneous infrared thermotherapy (TDP) for 15 minutes
manual physical therapy for 15 minutes
simple home exercise program
115792|NCT01526044|Device|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
115793|NCT00075660|Drug|triapine|
115794|NCT01526057|Biological|PF-05280586|1000 mg, IV on days 1 and 15
115795|NCT01526057|Biological|MabThera|1000 mg, IV on days 1 and 15
115796|NCT01526057|Biological|Rituxan|1000 mg, IV on days 1 and 15
115797|NCT01526070|Drug|Intravitreal injection of Aflibercept|
115798|NCT01526083|Other|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
115675|NCT01529983|Procedure|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
115676|NCT01529996|Procedure|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
115677|NCT01530009|Drug|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
115678|NCT01530009|Other|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
115679|NCT01532245|Other|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
115680|NCT01532245|Other|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
115681|NCT01532245|Other|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
114768|NCT01526525|Procedure|sedation|If the patient had sedation score >2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
114769|NCT01526525|Procedure|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
114770|NCT01526525|Drug|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
114771|NCT01526525|Drug|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
114772|NCT01526538|Drug|d-cycloserine|50 mg d-cycloserine
114773|NCT01526538|Drug|sugar pill|placebo
114774|NCT01526551|Other|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
114775|NCT01526551|Other|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
114776|NCT01526564|Drug|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or >4 hours for 8 weeks
114777|NCT01526564|Drug|Placebo|3 t.i.d, two plates per time
114778|NCT00001354|Drug|Interleukin-2/Zidovudine (AZT)|
114779|NCT00075699|Drug|vinorelbine tartrate|
115568|NCT01529697|Behavioral|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
115569|NCT01529710|Drug|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
115570|NCT01529736|Procedure|High torque insertion|Osseotite implant placed with high insertion torque forces
115571|NCT01529736|Procedure|Low torque insertion|Osseotite implant placed with low insertion torque forces
115572|NCT01529749|Drug|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --> oral, 600/200/245 mg, od Losartan --> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
115573|NCT01529749|Drug|EFV/FTC/TDF|600/200/245 mg, od, oral
115574|NCT01529749|Drug|FTC/TDF + MK-0518|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral
115575|NCT00075881|Drug|bortezomib|Given IV
115576|NCT01529749|Drug|FTC/TDF+MK-0518+Losartan|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral Losartan --> -> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
115577|NCT01529775|Device|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
115578|NCT01529775|Device|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
115579|NCT01529788|Drug|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
115580|NCT01529788|Drug|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
115581|NCT01529801|Device|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
115582|NCT01529801|Device|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
115583|NCT01529801|Device|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
115584|NCT01529814|Device|Implant with new abutment connection|New abutment connection implant system
115865|NCT01526096|Procedure|Stem cell re-infusion|Stem cells are thawed and reinfused back into the body via a catheter in the vein.
114837|NCT01533207|Drug|Gemcitabine Hydrochloride|Given IV
114838|NCT01533207|Biological|Pegfilgrastim|Given SC
114839|NCT01533220|Drug|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 05 days
114840|NCT01533220|Drug|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 05 days
114841|NCT01533233|Procedure|thoracoscopic lobectomy and mediastinal lymph node dissection|
114842|NCT01533246|Drug|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
114843|NCT01533246|Other|laboratory biomarker analysis|Correlative studies
114844|NCT00001382|Biological|PROSTVAC|
114845|NCT00076362|Drug|Sandostatin LAR|
114846|NCT01533259|Drug|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
114847|NCT01533272|Drug|Tenofovir, emtricitabine, maraviroc|experimental drug
115133|NCT01527162|Device|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
115134|NCT01527162|Other|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
115135|NCT01527175|Other|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
115136|NCT01527188|Biological|100IR|100IR sublingual tablet of
115137|NCT01527188|Biological|300IR|300IR sublingual tablets of
115138|NCT00075725|Drug|cyclophosphamide|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115139|NCT01529177|Drug|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
115140|NCT01529190|Drug|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
115141|NCT00075816|Biological|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
115142|NCT01529190|Drug|Placebo|placebo
115143|NCT01529203|Drug|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
115799|NCT01526083|Other|Warfarin|Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period
In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.
Duration: single dose
115800|NCT01526096|Drug|G-CSF|G-CSF will be self-administered shot daily for 4 days pre-transplant. Up to 8 doses of G-CSF may be given. G-CSF will also be administered once daily under the skin beginning 5 days after your stem cell infusion until your white blood cell count is high enough
115801|NCT01528293|Other|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
115802|NCT01528306|Biological|HP802-247|Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods
Larger wounds:
(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each
115803|NCT01528306|Other|Placebo|Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods
Larger wounds:
(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each
115804|NCT01528319|Device|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
115805|NCT01528332|Device|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
115806|NCT01528332|Device|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
114900|NCT01530984|Drug|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
114901|NCT01530997|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
114902|NCT01530997|Drug|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
114903|NCT00076024|Drug|Docetaxel|Standard of care drug administration
114904|NCT01530997|Procedure|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
114905|NCT01531010|Device|Ventilation protocol delivered by the SLE5000 ventilator|In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.
In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits.
114780|NCT01526577|Drug|LC23-1306|LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
114781|NCT01526577|Drug|placebo|LC23-1306 placebo
114782|NCT01526577|Drug|Ticagrelor|Ticagrelor 90mg
114783|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
114784|NCT01528644|Dietary Supplement|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
114785|NCT01528657|Other|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
114786|NCT01528657|Other|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
115070|NCT01531205|Drug|Neoadjuvant Treatment - Cabazitaxel|All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.
Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay.
115071|NCT00076050|Dietary Supplement|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
115072|NCT01531218|Drug|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
115073|NCT01531218|Drug|Placebo|
115074|NCT01531244|Biological|dactinomycin|Given via ILI
115075|NCT01531244|Drug|melphalan|Given via ILI
115076|NCT01531244|Biological|Conditionally replicative adenovirus 3/5-delta|Given via ILI
115077|NCT01531283|Drug|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
115078|NCT01531283|Drug|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
115866|NCT01526096|Drug|Basiliximab|Basiliximab (20mg) given by IV infusion (through the vein) 20-30 minutes the day after ASCT.
115867|NCT01526096|Device|CliniMACS CD25 microbeads and cell sorter|The stem cells collected during apheresis will be counted and treated with CD25 microbeads and processed by a special device called a CliniMACs machine which removes the regulatory T cells from you stem cell product.
115868|NCT01526109|Behavioral|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
115869|NCT01526109|Behavioral|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
115870|NCT01526109|Behavioral|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
115871|NCT01526122|Drug|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg & Aspirin 100mg in 1 capsule), PO
115872|NCT01526122|Drug|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets & Aspirin 100mg 2 capsules, PO
115873|NCT01526135|Drug|Arm B : mFolfirinox|Arm B : mFolfirinox every 14 days, 12 cycles, 24 weeks.
mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.
Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.
5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)
115874|NCT01526148|Drug|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels > 0.6mEq/L.
115875|NCT00075673|Drug|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
115876|NCT01526148|Drug|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
115877|NCT01526161|Drug|inhaled fluticasone propionate|100 micrograms
115878|NCT01526161|Drug|salmeterol|50 m
115879|NCT01526161|Drug|Montelukast|Double blind double dummy
115880|NCT01526174|Drug|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
115144|NCT01529203|Device|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
115145|NCT01529216|Device|DIAMOND System|Electrical stimulation to the fundus
115146|NCT01529229|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
115147|NCT01529229|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
115148|NCT01529242|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
115149|NCT01529242|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
115150|NCT01529255|Drug|telbivudine (ROADMAP)|Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
Stopping rules:
The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.
The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.
Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
115440|NCT01531920|Drug|perampanel + alcohol|Part B: perampanel + alcohol
115441|NCT00076206|Drug|CCI-779|
115442|NCT01531920|Drug|placebo + alcohol|Part B: placebo + alcohol
115443|NCT01531933|Drug|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
115444|NCT01531933|Drug|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
115445|NCT01498484|Biological|EBV-specific T-cells|Patients in Group 2 will also receive 3 weekly intravenous infusions of 2 x 106 EBV-specific T-cells/kg recipient weight (+/- 3 days). After the third dose, patients will be observed for at least 3 weeks.
115446|NCT01498497|Drug|EUR-1100|
115447|NCT01498497|Drug|Placebo|
114906|NCT01531036|Device|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
114907|NCT01531049|Drug|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
114908|NCT01531049|Drug|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
114909|NCT01531049|Drug|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
114910|NCT01531049|Other|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
114911|NCT01533324|Drug|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
114912|NCT01533337|Procedure|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
114913|NCT01533363|Procedure|Stapled hemorrhoidopexy|
114914|NCT00076375|Drug|Nanocrystalline silver cream (NPI)|
114915|NCT01533363|Procedure|Milligan Morgan|
114916|NCT01533376|Drug|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
114917|NCT01533376|Drug|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
114918|NCT01533389|Drug|Silodosin|Drug: silodosin dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks
Arms: Placebo
115202|NCT01527240|Drug|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
115203|NCT01527253|Other|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
115204|NCT01527266|Dietary Supplement|Carbohydrate drink|sucrose beverage
115205|NCT01527266|Dietary Supplement|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
115206|NCT00001357|Drug|Interleukin-2|
115207|NCT00075725|Drug|cytarabine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115079|NCT01531283|Drug|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
115080|NCT01531283|Drug|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
115081|NCT01531309|Drug|AGO178|AGO178 is administered as a sublingual tablet.
115082|NCT00076050|Dietary Supplement|Placebo|Placebo soy isoflavones
115083|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
115084|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
115085|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
115086|NCT01531335|Dietary Supplement|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
115087|NCT01531335|Dietary Supplement|Standard care|25 kcal per kg of body weight
115088|NCT01531348|Other|Intravitreal injection of bone marrow-derived mesenchymal stem cells|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
115089|NCT01531361|Drug|Vemurafenib|Dose Escalation Group Starting Dose: 240 mg by mouth twice a day for a 28 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group.
115382|NCT01527513|Drug|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
115383|NCT01527513|Drug|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
115384|NCT01527539|Drug|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
115385|NCT01527552|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
115386|NCT01527565|Drug|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
115387|NCT01527591|Biological|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
115388|NCT01527604|Other|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
115881|NCT01484977|Drug|Lacosamide|50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.
Maximum duration of study drug administration is approximately 23 weeks.
114981|NCT01529008|Drug|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
114982|NCT01529034|Drug|USL261|
114983|NCT01531062|Drug|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
114984|NCT01531062|Dietary Supplement|black sticky rice|300 mg capsule bid, 56 days
114985|NCT01531075|Biological|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
114986|NCT00076037|Biological|HIV CTL MEP administered with RC529-SE adjuvant|
114987|NCT01531075|Biological|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
114988|NCT01531088|Behavioral|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
114989|NCT01531101|Behavioral|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
114990|NCT01531114|Drug|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
114991|NCT01531114|Drug|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
114992|NCT01531140|Drug|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
114993|NCT01531140|Drug|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
114994|NCT01531140|Drug|Sennosides|Sennosides 1tbl/8kg for 2 days
114995|NCT01531153|Drug|Galantamine|8mg or 16mg
114996|NCT01531153|Drug|Placebo|Placebo dose.
114997|NCT00076037|Drug|GM-CSF|
114998|NCT01531166|Drug|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
114999|NCT01531179|Drug|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
115448|NCT01498510|Behavioral|Therapeutic Education System (TES) for chronic pain|an interactive, web-delivered intervention based on principles of cognitive behavior therapy (CBT) designed to train chronic pain patients in self-management skills to reduce pain severity and improve functioning
115449|NCT01498523|Other|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
115450|NCT00073021|Drug|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
115451|NCT01498523|Other|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
115452|NCT01498523|Other|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
115453|NCT01498523|Other|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
115454|NCT01498536|Behavioral|aerobic exercise|3 times per week for 12-weeks
115455|NCT01498549|Drug|Atomoxetine|40mg or 80mg
115456|NCT01498549|Drug|Sugar Pill|Once out of the three days
115738|NCT01528280|Other|No Intervention|No Intervention
115739|NCT01528293|Device|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
115740|NCT01530022|Drug|Lacosamide (LCM)|LCM 300 mg:
LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.
Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.
Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period
115741|NCT01530022|Drug|Carbamazepine Immediate Release (CBZ-IR)|CBZ-IR 600 mg:
CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.
LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.
Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period.
115742|NCT01530035|Other|physical training|training
115743|NCT01530048|Drug|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
115208|NCT01527279|Drug|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
115209|NCT01527279|Drug|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
115210|NCT01527292|Radiation|Stereotactic Radiation Therapy|SRT only
115211|NCT01527292|Radiation|SRT with Vertebral Augmentation Procedure|SRT with VAP
115212|NCT01527305|Drug|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
115213|NCT01527318|Drug|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
115214|NCT01527331|Behavioral|video decision aid|cpr video decision aid
115215|NCT01527357|Biological|Fibrocaps (PRO-0601)|Human fibrinogen and thrombin powder Single application during surgery
115216|NCT01527357|Device|Gelatin sponge|Single application during surgery
115217|NCT01527370|Biological|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
115218|NCT01529281|Dietary Supplement|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with ~300 ml of water.
115219|NCT01529294|Drug|Iloperidone|
115220|NCT01529307|Drug|TAS266|TAS266 IV infusions given weekly
115221|NCT01529320|Drug|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
115511|NCT01531998|Drug|Siltuximab|Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.
Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy.
115512|NCT01531998|Drug|Dexamethasone|Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.
Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week.
115513|NCT01531998|Behavioral|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
115389|NCT00075725|Drug|doxorubicin hydrochloride|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115390|NCT01527604|Other|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
115391|NCT01527617|Other|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
115392|NCT01527617|Other|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
115393|NCT01527630|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
115394|NCT01527643|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
115395|NCT01527656|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
115396|NCT01527669|Drug|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
115397|NCT01527669|Drug|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
115398|NCT01527682|Drug|Latanoprost, Dorzolamide|Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost
115399|NCT01527695|Drug|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
115400|NCT00075725|Drug|leucovorin calcium|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115682|NCT01532258|Behavioral|Go! Foods for You without Weekly MA Support.|Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary "practices" that have been associated with healthy weights.
Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule "activities" on a built in calendar and practice the activity throughout the week.
115683|NCT01532258|Behavioral|Go! Foods for You with Weekly MA Support.|Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary "practices" that have been associated with healthy weights.
In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals.
115684|NCT01532284|Other|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
115685|NCT01532297|Device|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
115000|NCT01531179|Drug|Placebo|Placebo for 3 months
115001|NCT01531192|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
115002|NCT01531192|Drug|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
115280|NCT01533935|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
115281|NCT01533935|Drug|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
115282|NCT01533935|Drug|Tiotropium|tiotropium
115283|NCT01533935|Drug|Olodaterol|Olodaterol 5 mcg once daily
115284|NCT01533935|Device|Respimat|Respimat inhaler
115285|NCT01533948|Drug|axitinib|Given PO
115286|NCT01533948|Other|laboratory biomarker analysis|Correlative studies
115287|NCT01533961|Drug|SCYX-7158|
115288|NCT01533961|Drug|Placebo|
115289|NCT00075725|Drug|daunorubicin hydrochloride|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
115290|NCT01527383|Biological|V212|V212 viral antigen for Herpes Zoster (HZ), 0.5 mL subcutaneous injection per dose, in a 4-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
115291|NCT01527383|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL subcutaneous per dose, in a 4-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
115292|NCT01527409|Behavioral|Tailored health partnership program|When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).
Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.
Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.
The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.
Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement.
115293|NCT01527409|Behavioral|Usual care and health education workshop|While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.
Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group.
115744|NCT00075907|Drug|Lopinavir/Ritonavir + 2 NRTIs|
115745|NCT01530061|Other|Egg Breakfast|Egg, Toast and Jelly
115746|NCT01530061|Other|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
115747|NCT01530074|Procedure|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
115748|NCT01530087|Device|CASTLE barrier|Prototype barrier to be used in place of current two piece device
115749|NCT01530126|Biological|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
115750|NCT01530126|Biological|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
115751|NCT01530126|Biological|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
115752|NCT01530139|Behavioral|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
115753|NCT01530139|Behavioral|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
115754|NCT01530139|Behavioral|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
115755|NCT00075907|Procedure|Therapeutic Drug Monitoring|
115756|NCT01530139|Behavioral|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
114848|NCT01533272|Drug|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
114849|NCT01533285|Biological|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
114850|NCT01533285|Biological|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
114851|NCT01533298|Drug|CombiflexOmega peri|intravenously over 3 days infusion
114852|NCT01533298|Drug|SmofKabiven peripheral|intravenously over 3 days infusion
114853|NCT01526590|Drug|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
115514|NCT01532011|Drug|Erlotinib|Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.
Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group.
115515|NCT01532011|Drug|Pralatrexate|Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.
Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group.
115516|NCT01532024|Other|Microdose of NAP|Delivery of NAP at microdose (<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
115517|NCT01532037|Other|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
115518|NCT01532037|Other|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
115519|NCT01532050|Device|Mandibular Advancement Device ( MAD)|
115520|NCT01532063|Procedure|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
115521|NCT00076219|Procedure|renal replacement therapy|renal replacement therapy
115522|NCT01532076|Procedure|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
115523|NCT01532076|Procedure|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
115524|NCT01532089|Drug|erlotinib|Given PO
115525|NCT01532089|Biological|bevacizumab|Given IV
115526|NCT01516216|Dietary Supplement|Vitamin D|Higher Dose (8000 IU once daily for 2 weeks, followed by 4000 IU once daily)
115527|NCT01516229|Drug|somatropin|Prescription of somatropin at the discretion of the physician
115528|NCT01516242|Other|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
115529|NCT01516255|Drug|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
115530|NCT01516255|Drug|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
115807|NCT01528345|Drug|Dovitinib|Active Dovitinib (in tablet form) will be taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule (i.e patients will take active Dovitinib on Day 1 through Day 5, and will take no medication on Day 6 and Day 7 "rest days").
115808|NCT00075738|Drug|cisplatin|
115686|NCT01532297|Device|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
115687|NCT00076245|Behavioral|Light Therapy|Light therapy will involve exposure to bright light twice a day.
115688|NCT01532310|Drug|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
115689|NCT01532323|Other|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
115690|NCT01532336|Drug|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
115691|NCT01532336|Drug|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
115692|NCT01532349|Drug|Cholecalciferol|Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for > 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
115693|NCT01532362|Drug|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
115694|NCT01532375|Dietary Supplement|Kochujang|Kochujang (32g/day) for 12weeks.
115695|NCT01532375|Dietary Supplement|placebo|placebo(32g/day) for 12weeks
115696|NCT01532388|Behavioral|eScreen|Web based self-monitoring of problematic alcohol and drug use.
115697|NCT01532401|Other|sodium chloride|sodium chloride 500mg
115698|NCT01525901|Drug|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
114787|NCT01528683|Radiation|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
114788|NCT01528696|Device|Dressing Type ( Silverlon)|Patients will be randomized to either receive a standard dressing or a silver dressings. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum.
114789|NCT01528709|Drug|Atorvastatin 80 mg daily|Atorvastatin 80 mg daily for 1 year
114790|NCT01528709|Drug|Atorvastatin 10 mg daily|Atorvastatin 10 mg daily for 1 year
115294|NCT01527422|Drug|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
115585|NCT01529814|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
115586|NCT00075881|Other|laboratory biomarker analysis|Optional correlative studies
115587|NCT01529827|Drug|fludarabine phosphate|Given IV
115588|NCT01529827|Drug|melphalan|Given IV
115589|NCT01529827|Radiation|total-body irradiation|Undergo TBI
115590|NCT01529827|Drug|tacrolimus|Given IV or PO
115591|NCT01529827|Drug|mycophenolate mofetil|Given IV or PO
115592|NCT01532089|Other|laboratory biomarker analysis|Correlative studies
115593|NCT01532102|Drug|AP611074|
115594|NCT01532102|Drug|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
115595|NCT01532115|Drug|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
115596|NCT01532115|Drug|Placebo|single-dose
115597|NCT01532115|Drug|moxifloxacin|400 mg moxifloxacin (single-dose)
115598|NCT00076232|Drug|Acyclovir|400 mg tablet taken orally twice daily
115599|NCT01532128|Drug|rasagiline|1 mg rasagiline (single-dose)
115600|NCT01532128|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
115601|NCT01532141|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
115602|NCT01532141|Drug|Rasagiline|1 mg rasagiline (single-dose)
115603|NCT01532154|Drug|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
114854|NCT01526603|Drug|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
114855|NCT01526603|Biological|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
114856|NCT01526603|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) > 2000/μL for 3 consecutive days.
114857|NCT01526603|Radiation|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring >1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
114858|NCT01526603|Drug|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients >12 kg isotretinoin (accutane) should be administered at 160 mg/m^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
114859|NCT01526603|Drug|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
114860|NCT00075699|Procedure|pain therapy|
114861|NCT01526603|Drug|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
114862|NCT01526616|Drug|Metformin|Metformin 850 mg twice a day for six months
114863|NCT01526616|Drug|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
115151|NCT01529255|Drug|Telbivudine (Standard of Care)|Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
Stopping rules:
The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.
The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.
Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
115152|NCT00075816|Biological|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
115153|NCT01529268|Drug|DR cysteamine bitartrate capsule|600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline
115809|NCT01528345|Drug|Fulvestrant|Fulvestrant (in solution) will be injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
115810|NCT01528371|Drug|Midazolam|Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.
Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.
Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.
10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.
Investigators inject an additional sedative agent and the dental treatment is started.
115811|NCT01528371|Drug|Normal Saline Solution (NSS)|Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.
Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.
Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.
10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.
Investigators inject an additional sedative agent and the dental treatment is started.
115812|NCT01528384|Drug|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
115813|NCT01528397|Procedure|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
115814|NCT01528410|Device|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
115815|NCT01528410|Procedure|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
115816|NCT01530204|Behavioral|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
115817|NCT01530204|Other|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
115818|NCT01530217|Drug|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
115819|NCT01530230|Drug|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
115820|NCT01530243|Drug|Placebo|same as tolterodine and terazosin dose
115821|NCT00001378|Drug|fenretinide|
115822|NCT00075933|Drug|ARQ 501|
115823|NCT01530243|Drug|Terazosine|2 mg BID
114791|NCT00075751|Drug|carboplatin|Given IV
114792|NCT01528722|Drug|Bupivacaine|0.25% 20ml administered intraperitoneal
114793|NCT01528722|Other|Normal saline|sodium chloride 0.9% solution
114794|NCT01528735|Drug|BI 207127 NA|one fix dose
114795|NCT01528735|Drug|peginterferon|per package insert
114796|NCT01528735|Drug|Ribavirin|per weight BID
114797|NCT01528735|Drug|Ribavirin|per weight BID
114798|NCT01528735|Drug|BI 207127 NA|one fix dose
114799|NCT01528735|Drug|BI 201335 NA|high dose
114800|NCT01528735|Drug|BI 201335 NA|low dose
114801|NCT01528735|Drug|peginterferon|per package insert
114802|NCT00075751|Drug|bortezomib|Given IV
114803|NCT01528748|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
114804|NCT01530776|Behavioral|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
115090|NCT01533974|Other|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
115091|NCT00076453|Device|Standard orthotic shoe inserts|Neutral orthotic inserts
115092|NCT01533974|Other|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
115093|NCT01533987|Dietary Supplement|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
115094|NCT01534000|Procedure|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
115604|NCT01532180|Device|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
115605|NCT01532193|Other|Decreased oxygen concentration|The oxygen concentration is decreased during the "in Vitro" embryo culture.
115606|NCT01532206|Other|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
115607|NCT01532219|Behavioral|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
115608|NCT01532219|Behavioral|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
115882|NCT01484990|Drug|Levodopa-Carbidopa|Intestinal Gel
115883|NCT01485003|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
115884|NCT01485029|Procedure|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
115885|NCT01485042|Drug|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
115886|NCT01485055|Drug|Infliximab and Basiliximab|Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.
Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times.
115887|NCT01485068|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
115888|NCT01485081|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
115889|NCT01485094|Drug|GRT6010|Oral solution given once daily.
115890|NCT01485094|Drug|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
115891|NCT00071968|Procedure|conventional surgery|
115892|NCT01485094|Drug|Matching Placebo|Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.
Capsules twice daily on Days 1 to 7. Solution once daily.
115893|NCT01485107|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
115154|NCT01529268|Other|DR cysteamine bitartrate placebo|600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline
115155|NCT01529281|Dietary Supplement|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with ~300 ml of water.
115156|NCT01531361|Drug|Sorafenib|Dose Escalation Group Starting Dose of Sorafenib: 200 mg by mouth twice a day for a 28 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group.
115157|NCT01531361|Drug|Crizotinib|Dose Escalation Group Starting dose of Crizotinib 250 mg by mouth daily for a 28 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group.
115158|NCT01531374|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
115159|NCT00076063|Biological|ALVAC-HIV (vCP1452)|experimental vaccine
115160|NCT01531387|Drug|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
115161|NCT01531400|Other|self-selected music|Investigators played self-selected background music in the music group
115162|NCT01531413|Other|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
115163|NCT01531426|Device|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
115164|NCT01531439|Drug|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
115165|NCT01531439|Drug|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
115166|NCT01531452|Drug|Oxaliplatin|130mg/m2 d1,repeated q21d
115167|NCT01531452|Drug|s1|80mg/m2/d, d1-14,repeated q21d
115457|NCT01498562|Drug|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
115458|NCT01498562|Drug|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
115459|NCT01498575|Behavioral|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
115460|NCT01498588|Drug|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
116143|NCT01485705|Other|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic "optimal or not" of initial medical care is then determined by the independent experts blinded from issue of the care.
116144|NCT01485718|Dietary Supplement|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
116145|NCT01485718|Dietary Supplement|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
116146|NCT01485731|Drug|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
116147|NCT00071994|Drug|gefitinib|Given orally
116148|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
116149|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
116150|NCT01488123|Behavioral|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
116151|NCT01488136|Drug|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
116152|NCT01488136|Drug|Placebo|Lactose Ph capsules (Placebo)
116408|NCT01489033|Biological|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
116409|NCT01489046|Drug|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
116410|NCT01489046|Drug|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
116411|NCT01489046|Drug|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
116412|NCT01489046|Drug|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
116413|NCT01489046|Drug|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
116414|NCT00072189|Other|laboratory biomarker analysis|Correlative studies
116415|NCT01489046|Drug|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
117064|NCT01487317|Drug|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity < 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity < 10, the active treatment will be stopped
117065|NCT01487317|Drug|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity < 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity < 10, the placebo treatment will be stopped
117066|NCT01487330|Device|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
117067|NCT01487343|Behavioral|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
117068|NCT01487356|Other|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
117069|NCT01487369|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
117070|NCT01487382|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
117071|NCT01487395|Drug|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
117072|NCT01487395|Drug|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
117073|NCT01487408|Drug|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
117074|NCT00072085|Biological|gp100 antigen|
117075|NCT01487421|Drug|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
117076|NCT01487421|Drug|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
117077|NCT01487434|Behavioral|Check & Connect|Structured mentoring and case management
117078|NCT01487447|Other|Customized sound|treatment with customized sound therapy
116534|NCT01483651|Drug|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
116857|NCT00071604|Behavioral|Friendly Support Group|
116858|NCT01482143|Drug|AFQ056|
116859|NCT01482156|Drug|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
116860|NCT01482169|Drug|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC) procedure. The first 48 eligible patients enrolled in the study will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. In the event of a serious adverse reaction to adenosine or regadenoson (heart block, bronchospasm, arrhythmias) the protocol will be suspended. Patients who react to either medication will be supported conservatively under close scrutiny. Any adverse reactions will be recorded and reported.
116861|NCT01482195|Genetic|Recombinant Adeno-Associated Virus|Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus
116862|NCT01482221|Drug|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
116863|NCT01482221|Drug|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
116864|NCT01482221|Drug|Placebo|0.9 sodium chloride [normal saline] solution for injection by iv infusion
116865|NCT01482234|Behavioral|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
116866|NCT01482247|Dietary Supplement|L-Arginine|Dietary Supplement
116867|NCT01482247|Dietary Supplement|Placebo Supplement|Dietary Supplement
116868|NCT00071617|Behavioral|Youth-Nominated Support Team|
116869|NCT00071890|Drug|HAART|HAART from week 0 to week 24
116870|NCT01484119|Drug|ACT-129968|daily tablets
116871|NCT01484119|Drug|Placebo|matching placebo tablets and capsules
116345|NCT00071487|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
116346|NCT01481272|Drug|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
116347|NCT01481272|Drug|Leukovorin|15mg, po 24 hours after methotrexate it
116348|NCT01481272|Drug|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC>1.0x109/l
116349|NCT01481311|Device|medical Body Composition Analyzer seca 514/515|Current of 100 µA
116350|NCT01481311|Procedure|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
116351|NCT01481337|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
116352|NCT01481350|Drug|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
116589|NCT01481701|Drug|Oxaliplatin|85 mg/m² / 14days
116590|NCT01481701|Drug|oxaliplatin|oxaliplatin
116591|NCT01481714|Drug|Sodium picosulphate, magnesium oxid and citric acid|A sachet mixed with 250 mL of water at 18:00 pm
A sachet mixed with 250 mL of water at 21:00 pm
A minimum of 4 litres of fluid were recommended throughout the preparation
116592|NCT01481714|Drug|Sodium picosulphate/magnesium oxide and citric acid|The day before the procedure:
- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids
The day of the procedure:
A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.
A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am.
116593|NCT01481727|Device|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (>18mmHg) for at least six hours, nocturnal ventilation.
116594|NCT01481727|Device|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
116595|NCT01481740|Drug|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
116596|NCT00071552|Drug|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
116597|NCT01481740|Drug|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
116598|NCT01481753|Procedure|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
116416|NCT01489046|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
116417|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
116418|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
116419|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
116420|NCT01481363|Behavioral|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
116421|NCT01481389|Dietary Supplement|Theobromine|200 ml drink with added theobromine (no cocoa added)
116422|NCT00071500|Device|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
116423|NCT01481389|Dietary Supplement|Cocoa|200 ml drink with cocoa (no theobromine added)
116424|NCT01481389|Dietary Supplement|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
116425|NCT01481389|Dietary Supplement|Placebo|200 ml drink (no added theobromine or cocoa)
116426|NCT01481402|Drug|Liothyronine|Liothyronine 40 microgram per day
116427|NCT01481402|Drug|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
116671|NCT01489189|Drug|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
116672|NCT00001269|Drug|IL-3|
116673|NCT00072215|Drug|cisplatin|given IV
116674|NCT01489189|Other|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
116675|NCT01489202|Device|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
116676|NCT01489202|Device|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
116677|NCT01489215|Behavioral|"presence"|constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the "checking" method if the child is actively protesting or crying.
115939|NCT01480531|Drug|Clevidipine|Clevidipine administration begins in the ER or ICU
Clevidipine is again administered post op when blood pressure control is required.
Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:
Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.
Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.
Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.
As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)
115940|NCT01480544|Other|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
115941|NCT01480544|Other|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
115942|NCT01480557|Procedure|liquefaction|Cataract extraction surgery type
115943|NCT00071448|Drug|insulin human|
115944|NCT01480557|Procedure|Torsional ip|A type cataract surgery using torsional ip technology
115945|NCT01480583|Drug|GRN1005|550 mg/m2 IV every 3 weeks
115946|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
115947|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
115948|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
116872|NCT01484119|Drug|Cetirizine|daily capsules
116873|NCT01484132|Procedure|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
116874|NCT01484145|Drug|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
116875|NCT01484171|Drug|idarubicin|idarubicin 10-12 mg/m2 for three days
116003|NCT01480622|Drug|TDF tablets|White, almond-shaped, film-coated tablets, one side with the markings "GILEAD" and "4331"
116004|NCT01480648|Drug|BI 144807 Placebo|Placebo that represents BI drug
116005|NCT01480648|Drug|BI 144807|single dose (low to high dose)
116006|NCT00071448|Drug|insulin lispro|
116007|NCT01480661|Drug|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
116008|NCT01480661|Drug|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
116009|NCT01480661|Radiation|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
116010|NCT01480687|Dietary Supplement|DHA-EPA|1800 mg/day
116011|NCT01480687|Drug|Ciprofibrate|100 mg/day
116012|NCT01480700|Other|Nutritional study|subjects consume 2 eggs per day during 4 months
116013|NCT01480713|Drug|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
116014|NCT01480713|Drug|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
116015|NCT01480726|Procedure|Surgery|
116016|NCT01480739|Drug|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
116017|NCT00071448|Drug|insulin aspart|
116018|NCT01480739|Drug|100 mg Placebo|Twice daily for 7 days
116019|NCT01480752|Drug|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
116020|NCT01480752|Drug|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
116599|NCT01481753|Procedure|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
116600|NCT01481766|Dietary Supplement|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
116601|NCT01481766|Dietary Supplement|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
116602|NCT01481766|Behavioral|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
116603|NCT01481779|Drug|Glargine|Administered by SC injection via a pen device.
116604|NCT01481779|Drug|LY2605541|Administered by SC injection with a pen device.
116605|NCT01481779|Drug|Insulin Lispro|Administered by SC injection with a pen device.
116606|NCT01483690|Drug|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
116607|NCT01483690|Drug|Methotrexate|Given intrathecally to all patients the dose defined by age below.
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age
CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35
116927|NCT01480050|Drug|temozolomide|
116928|NCT01480050|Other|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
116929|NCT01480050|Other|pharmacological study|
116930|NCT01480050|Drug|Mibefradil|
116931|NCT01482260|Procedure|Biopsy|Biopsy
116932|NCT01482273|Procedure|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
116933|NCT01482273|Procedure|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
116934|NCT01482286|Drug|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
116935|NCT01482286|Behavioral|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
116678|NCT01481818|Drug|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
116679|NCT00001255|Drug|ADA PBSC|
116680|NCT00071578|Behavioral|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
116681|NCT01481831|Drug|Palonosetron Hydrochloride|0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
116682|NCT01481831|Drug|Palonosetron Hydrochloride|0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
116683|NCT01481844|Drug|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
116684|NCT01481844|Drug|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
116685|NCT01481857|Other|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
116686|NCT01481857|Other|Segmental trunk exercise|Segmental trunk exercise
116687|NCT01481870|Drug|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
116688|NCT01481870|Drug|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
116689|NCT01481883|Drug|Raloxifene Hydrochloride|120mg daily - 1 capsule daily for 12 week trial
116690|NCT01481883|Drug|Placebo|1 capsule daily for 12 week trial
116691|NCT00071578|Behavioral|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
117001|NCT01480154|Drug|Akt Inhibitor MK2206|Given PO
117002|NCT01480154|Drug|Hydroxychloroquine|Given PO
117003|NCT00071396|Drug|Rituximab|375 mg/m^2 IV infusion on day 1, then 500 mg/m^2 on days 8, 15, and 22.
117004|NCT01480154|Other|Laboratory Biomarker Analysis|Correlative studies
117005|NCT01480154|Other|Pharmacological Study|Correlative studies
117006|NCT01480167|Device|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
117007|NCT01480167|Other|Non-operative Management|Conservative Care
116216|NCT00001262|Drug|Copper Histidine|
116217|NCT00071994|Other|laboratory biomarker analysis|Correlative studies
116218|NCT01485731|Procedure|Renal Ultrasound|Optional. Pre-Treatment
116219|NCT01485731|Procedure|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
116220|NCT01485731|Procedure|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
116767|NCT01481948|Behavioral|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
116768|NCT01481961|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
116769|NCT01481974|Drug|Treprostinil|The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.
Treatment phase activities include:
• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design.
116770|NCT01481987|Procedure|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
116771|NCT00071591|Behavioral|Functional Adaptation Skills Training (FAST)|
116772|NCT01482000|Other|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
116773|NCT01482000|Other|usual care|The control group will get the usual care with some additional tests for the study.
116774|NCT01482013|Drug|HPP854|Oral, once a day for 28 days.
116775|NCT01482013|Drug|Placebo|Oral, once a day for 28 days.
116776|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
116777|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
116778|NCT01482039|Procedure|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
116021|NCT01480752|Drug|no injection|inject nothing after inferior alveolar injection and before root canal therapy
116022|NCT01480765|Drug|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
116023|NCT01480765|Drug|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
116024|NCT01480765|Drug|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
116025|NCT01480765|Drug|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
116283|NCT01483196|Procedure|quality-of-life assessment|Ancillary studies
116284|NCT01483196|Procedure|magnetic resonance imaging|Undergo MRI
116285|NCT01483209|Drug|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
116286|NCT01483222|Device|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
116287|NCT01483222|Device|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
116288|NCT01483235|Behavioral|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
116289|NCT01483235|Behavioral|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
116290|NCT01483248|Biological|conventional therapy plus MenSC transplantation|patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.
MenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks.
116291|NCT01483248|Drug|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
116292|NCT00001255|Drug|Transduced Lymphocytes|
116936|NCT01482286|Behavioral|Exercise Training|For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).
The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch.
116937|NCT01482299|Drug|RAD001|RAD001 (everolimus) 10 mg daily, orally without interruption.
1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability.
116938|NCT01482312|Device|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
116939|NCT01482312|Device|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
116940|NCT01482312|Other|Glasses|Glasses per habitual prescription
116941|NCT00071630|Behavioral|Cognitive Behavioral Therapy|
116942|NCT01482325|Device|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
116943|NCT01482338|Drug|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
116085|NCT01488071|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
116086|NCT01488071|Drug|Agomelatine|encapsulated tablets, daily, orally
116087|NCT01488084|Procedure|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
116088|NCT01488084|Procedure|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
116089|NCT01488097|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose A of SBC-102 (sebelipase alfa) and bi-weekly infusions of Dose B or Dose C of SBC-102 (sebelipase alfa)
116090|NCT01488097|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose B of SBC-102 (sebelipase alfa) and bi-weekly infusions of Dose B or Dose C of SBC-102 (sebelipase alfa)
116091|NCT00072137|Biological|Recombinant Fowlpox-TRICOM Vaccine|Given intravesically
116092|NCT01488097|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose C of SBC-102 (sebelipase alfa) and bi-weekly infusions of Dose C of SBC-102 (sebelipase alfa)
116093|NCT01480778|Drug|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
117008|NCT01480180|Drug|turoctocog alfa pegol|Administered i.v.
117009|NCT01480180|Drug|turoctocog alfa pegol|Administered i.v.
117010|NCT01480193|Other|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
117011|NCT01480193|Other|Integrated Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
117012|NCT01480193|Other|Integrated Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
117013|NCT01480206|Other|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
117014|NCT01482377|Drug|RO5479599|Cohorts receiving multiple escalating doses intravenously
117015|NCT01482377|Drug|cetuximab|standard doses
117016|NCT01482377|Drug|erlotinib|standard doses
117017|NCT01482377|Drug|zirconium-89-labeled RO5479599|single dose
117018|NCT00071643|Behavioral|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
117019|NCT01482390|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
117020|NCT01482390|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
117021|NCT01482390|Drug|mericitabine|1000 mg twice daily for 24 weeks
117022|NCT01482390|Drug|mericitabine|1000 mg twice daily for 12 weeks
117023|NCT01482390|Drug|Pegasys|180 microgram subcutaneous once weekly for 24 weeks
116153|NCT01488175|Procedure|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
116154|NCT01488175|Procedure|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
116155|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
116156|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
116779|NCT01482039|Procedure|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
116780|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
116781|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
116782|NCT00071604|Behavioral|Medication Adherence Therapy|
116803|NCT01484093|Other|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
116804|NCT01484106|Other|Fluid Resuscitation|In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is "fluid responsive" (FR).
116805|NCT01484106|Other|Standard of Care|Standard of Care
116806|NCT01486797|Drug|NOX-A12|Pilot Group (NOX-A12 single agent, and combined with BR):
3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.
Expansion Group (NOX-A12 in combination with BR):
Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.
116807|NCT01486810|Drug|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
116808|NCT01486823|Drug|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
116809|NCT01486823|Drug|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
116810|NCT01486849|Drug|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
116811|NCT01486849|Drug|Placebo|Matching placebo tablets BID for 21 days
116812|NCT01486862|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
116293|NCT01485796|Biological|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
116294|NCT01485809|Drug|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
116295|NCT00072007|Biological|filgrastim|filgrastim
116296|NCT01485822|Procedure|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
116297|NCT01485822|Drug|Travoprost 0.004% ophthalmic solution|
116298|NCT01485835|Drug|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
116299|NCT01485835|Drug|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
116535|NCT00071812|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
116536|NCT01483651|Drug|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
116537|NCT01483677|Other|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
116538|NCT01483677|Other|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
116539|NCT01483690|Drug|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
116540|NCT01483690|Drug|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
116541|NCT01483690|Drug|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
116542|NCT01483690|Drug|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
116543|NCT01483690|Drug|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
116544|NCT01486316|Device|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
116094|NCT01480778|Drug|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
116095|NCT00071461|Drug|bosentan|Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight < 40 kg (90 lb): 62.5 mg b.i.d.
116096|NCT01480791|Drug|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
116097|NCT01480791|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
116098|NCT01480804|Other|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
116099|NCT01480817|Drug|Sorafenib|Sorafenib 400mg po bid
116100|NCT01480817|Procedure|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
116101|NCT01480830|Device|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
116102|NCT01480843|Drug|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
116103|NCT01480856|Procedure|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
116353|NCT01481363|Behavioral|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
116354|NCT00071773|Procedure|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
116355|NCT01483261|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
116356|NCT01483274|Biological|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
116157|NCT00072137|Biological|Recombinant Fowlpox GM-CSF Vaccine Adjuvant|Given intravesically
116158|NCT01488201|Drug|Placebo|
116159|NCT01488201|Drug|KHK4827|
116160|NCT01488214|Other|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
116161|NCT01488227|Dietary Supplement|Vitamin D|4000 IU of Vitamin D daily for 6 months
116162|NCT01488227|Dietary Supplement|Placebo|Acts as a control for the Vitamin D intervention
116163|NCT01488240|Procedure|pulsed dye laser|laser energy
116164|NCT01488253|Drug|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
116165|NCT01488253|Drug|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
116166|NCT01488266|Drug|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
116167|NCT01488266|Drug|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
116168|NCT00072137|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy
116169|NCT01480908|Procedure|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
116170|NCT01480908|Procedure|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
116813|NCT01486875|Drug|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
116814|NCT01486888|Drug|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
116815|NCT01486901|Drug|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
116816|NCT00072046|Biological|bevacizumab|10mg/kg IV infusion on Days 1 & 15 of each cycle
116817|NCT01486914|Drug|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
117101|NCT00001251|Drug|Mafosfamide|
117102|NCT00071409|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
117103|NCT01480271|Drug|Placebo|Placebo administered intranasally
117104|NCT01480284|Drug|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
117105|NCT00071643|Other|Placebo|Participants will receive a placebo pill.
117106|NCT01482455|Other|Elevation of FFA during OGTT|0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin "Immuno"®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1
117107|NCT01482455|Other|Elevation of FFA during Clamp|0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin "Immuno"®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1.
117108|NCT01482468|Drug|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
117109|NCT01482468|Drug|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
117110|NCT01482559|Drug|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
117111|NCT01482559|Drug|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
117112|NCT01482572|Procedure|biopsy|percutaneous lung biopsy and aspiration
117113|NCT01482585|Other|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
117114|NCT01482598|Device|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
116545|NCT01486316|Other|Heart Failure Risk Status Diagnostic|The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.
Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: "Low", "Medium", "High", or "Very High".
116546|NCT01486329|Biological|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
116547|NCT01486329|Biological|Placebo|Drink solution
116548|NCT01486342|Radiation|PET-CT scan|PET-CT imaging with [18F]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.
A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames.
116549|NCT00072007|Drug|prednisone|prednisone
116550|NCT01486355|Biological|Measles vaccine|Edmonston-Zagreb measles vaccine
116551|NCT01486368|Drug|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
116876|NCT01484171|Biological|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
116877|NCT01484184|Drug|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
116878|NCT01484197|Drug|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
116879|NCT01484197|Drug|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
116880|NCT00071890|Drug|Treatment interruption|HAART is interrupted from week 24 in both arms
116881|NCT01484197|Drug|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
116882|NCT01484197|Drug|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
116357|NCT01483287|Dietary Supplement|Alpha-Galactosidase|The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.
No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time).
116358|NCT01483300|Drug|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
116359|NCT01483300|Drug|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
116360|NCT01483339|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
116361|NCT01483339|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
116362|NCT01483352|Device|Accu-Chek DiaPort|
116363|NCT01483365|Drug|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
116364|NCT01483378|Other|Choosing to receive the vaccine|
116365|NCT00071773|Procedure|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
116366|NCT01483391|Behavioral|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
116367|NCT01483391|Behavioral|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
116368|NCT01483404|Procedure|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
116608|NCT00071812|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
116609|NCT01483703|Device|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
116610|NCT01483716|Behavioral|Rehabilitation|
116611|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
116428|NCT01481428|Behavioral|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
116429|NCT01481428|Behavioral|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
116430|NCT01481441|Drug|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
116431|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
116432|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
116433|NCT00071513|Behavioral|Coping and Support Training for Transition program|
116434|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
116435|NCT01481454|Biological|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
116436|NCT01481467|Behavioral|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
116437|NCT01481480|Procedure|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
116438|NCT01481480|Procedure|Arthroscopic repair|Arthroscopic repair
116439|NCT01481493|Biological|BT061|subcutaneous administration of the monoclonal antibody BT061
116440|NCT01481493|Biological|Placebo|subcutaneous injection of placebo
116441|NCT01481506|Procedure|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
116442|NCT01481519|Drug|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
116443|NCT01483456|Other|The multidisciplinary prevention program called "IPR" (in French "Identifier, Prévenir, Relever")|The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:
Identification of patient's fall risk,
Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),
"Get up" workshop and morbidity and mortality conferences related to fall cases
117115|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
117116|NCT00001255|Drug|ADA Umbilical Cord Blood Cells|
117117|NCT00071656|Behavioral|Psychosocial (behavioral) Intervention|
117118|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
117119|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
117120|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
117121|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
117122|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
116221|NCT01485744|Drug|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
116222|NCT01485757|Drug|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
116223|NCT01485770|Drug|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
116224|NCT01485770|Drug|Placebo|Placebo to match ADX-N05 to be taken for 2 consecutive weeks during 4 week study treatment period
116225|NCT01485796|Biological|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
116226|NCT01488279|Drug|Dexamethasone|2.5 mg daily x 7 days
116227|NCT01488292|Behavioral|RECAP social skills and reading program|weekly individual and group sessions
116228|NCT01488305|Dietary Supplement|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
116229|NCT01488318|Drug|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
116230|NCT01488318|Drug|Dasatinib|Dasatinib 150 mg po
116231|NCT01488344|Drug|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
116232|NCT01488370|Device|Endotracheal intubation|Endotracheal intubation
116883|NCT01484197|Drug|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
116884|NCT01484210|Drug|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
116885|NCT01484223|Behavioral|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
116886|NCT01484249|Device|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
116887|NCT01484262|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
116888|NCT01484262|Drug|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
116889|NCT01484275|Drug|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
116890|NCT01486953|Drug|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
116026|NCT01482806|Behavioral|CCBT+ISG/Collaborative Care|Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants
These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.
Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference.
116027|NCT01482806|Behavioral|CCBT/Collaborative Care|Guided patient access to the Beating the Blues CCBT program.
This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.
Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference.
116028|NCT01482819|Device|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
116029|NCT01482819|Device|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
116030|NCT01482819|Device|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
116031|NCT01482819|Device|polymacon|contact lenses worn bilaterally for 8-12 hours
116612|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
116613|NCT01483729|Drug|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
116614|NCT01483729|Drug|ritonavir|Test Formulation 1, single oral dose
116615|NCT01483729|Drug|ritonavir|Test Formulation 2, single oral dose
116616|NCT01483729|Drug|ritonavir|Reference Formulation, single oral dose
116617|NCT01483742|Drug|RO5024048|1000 mg orally bid, 24 weeks
116618|NCT01483742|Drug|danoprevir|100 mg orally bid, 24 weeks
116619|NCT00071812|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
116620|NCT01483742|Drug|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
116621|NCT01483742|Drug|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
116622|NCT01483742|Drug|ritonavir|100 mg orally bid, 24 weeks
116623|NCT01483755|Procedure|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
116624|NCT01483755|Procedure|Percutaneaous intervention|Conventional primary percutaneaous intervention
116625|NCT01483768|Procedure|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
116626|NCT01483781|Drug|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
116627|NCT01483781|Drug|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
116944|NCT01482338|Drug|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
116945|NCT01482351|Device|Continuous Positive Airway Pressure [CPAP]|Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
116444|NCT00071799|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
116445|NCT01483469|Drug|RO4917523|orally daily, 14 days
116692|NCT01481896|Device|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
116693|NCT01481909|Drug|Rupatadin|20 mg, 28 days over 60 days
116694|NCT01481922|Device|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
116695|NCT01481922|Device|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
116696|NCT01481935|Other|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
116697|NCT01481935|Other|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
116698|NCT01483820|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
116699|NCT00071838|Drug|Daclizumab|
116700|NCT01483833|Drug|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
116701|NCT01483833|Drug|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
116702|NCT01483846|Drug|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
116703|NCT01483846|Drug|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
116704|NCT01483859|Other|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
116233|NCT01488383|Drug|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
116234|NCT01488383|Drug|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
116235|NCT01488396|Drug|0.05%cyclosporin eye drop|use twice daily for 6 months
116236|NCT00001267|Drug|2',3'-dideoxyinosine|
116237|NCT00072137|Other|Pharmacological Study|Correlative studies
116238|NCT01488409|Drug|Acipimox|250 mg by mouth (PO) three times daily
116239|NCT01488409|Drug|Placebo|0 mg by mouth (PO) three times daily
116240|NCT01488422|Behavioral|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
116241|NCT01488435|Dietary Supplement|Cow's milk|Powdered whole cow's milk
116242|NCT01488435|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
116783|NCT01482065|Device|CPAP (ResMed S9 autoset CPAP)|A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
116784|NCT01482091|Drug|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
116785|NCT01483963|Biological|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
116786|NCT01483963|Other|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
116787|NCT01483976|Other|Oral medical nutritional supplement|orally over a three hour period
116788|NCT01483976|Other|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
116789|NCT01483989|Other|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
116790|NCT01484002|Device|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
116791|NCT01484015|Drug|cefepime hydrochloride|Given IV
116792|NCT01484028|Device|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
116032|NCT01482819|Other|spectacles|habitual spectacles owned by subject, non-specific manufacturer
116033|NCT01482832|Behavioral|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
116034|NCT00071708|Drug|Duloxetine Hydrochloride|
116035|NCT01482845|Drug|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
116036|NCT01482845|Drug|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
116037|NCT01482858|Dietary Supplement|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
116038|NCT01482858|Other|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
116039|NCT01482871|Drug|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
116040|NCT01482871|Drug|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
116041|NCT01482871|Drug|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
116042|NCT01482871|Drug|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
116043|NCT01482884|Drug|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
116044|NCT01482884|Drug|placebo|2 sc injections of every 2 weeks for 12 weeks.
116300|NCT01485835|Drug|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
116301|NCT01485848|Drug|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
116302|NCT01485848|Drug|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
116303|NCT01485861|Drug|GDC-0068|400 mg once daily
116304|NCT01485861|Drug|GDC-0068|200 mg once daily
116305|NCT01485861|Drug|GDC-0068|Repeating oral dose
116946|NCT01482364|Device|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
116947|NCT01482364|Device|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
116948|NCT01484275|Drug|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
116949|NCT00071929|Drug|oxaliplatin|
116950|NCT01484288|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
116951|NCT01484314|Drug|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
116952|NCT01484327|Drug|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
116953|NCT01484340|Drug|Nicotine|The nicotine patch be given in three phases:
2 weeks of patches at enrollment
6 weeks of patches at two-week follow-up visit
2 weeks of patches at two-month follow-up visit
This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg.
116954|NCT01484340|Behavioral|Intensive Counseling|The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
Visit schedule:
Baseline
2-week follow-up (Quit Day)
1-month follow-up
2-month follow-up
3-month follow-up
6-month follow-up
Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.
Participants still smoking at 6-month follow-up will be offered group-assigned intervention again.
116955|NCT01484353|Behavioral|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
116956|NCT01484366|Procedure|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
116957|NCT01484366|Procedure|plating|Surgical plating of both bonforearm fractures
116958|NCT01484379|Procedure|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
116104|NCT01480856|Procedure|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
116105|NCT01480869|Drug|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
116705|NCT01483872|Drug|NAC/Tigecycline/Heparin combination lock solution|
116706|NCT01483872|Drug|Standard anticoagulant (Heparin or Citrate)|
116707|NCT01483885|Device|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
116708|NCT01483885|Device|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
117024|NCT01482390|Drug|Pegasys|180 microgram subcutaneous once weekly for 48 weeks
117025|NCT01482390|Drug|Placebo|Placebo to RO5024048 for 12 weeks (weeks 12-24)
117026|NCT01482390|Drug|telaprevir|750 mg three times daily for 12 weeks
117027|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
117028|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
117029|NCT00071643|Drug|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
117030|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 24 weeks
117031|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 48 weeks
117032|NCT01482403|Drug|boceprevir|800 mg three times a day for 24 weeks
117033|NCT01482403|Drug|boceprevir|800 mg three times a day for 48 weeks
117034|NCT01482403|Drug|mericitabine|1000 mg twice daily for 24 weeks
117035|NCT01482416|Drug|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
117036|NCT01482416|Drug|Placebo|Placebo group will use placebo once/day during 30 days
117037|NCT01482429|Other|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
117038|NCT01482442|Drug|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
116793|NCT01484028|Device|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
116794|NCT01484028|Device|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
116795|NCT00071890|Drug|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
116796|NCT01484041|Drug|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest period in combination with 1 of the following:
Anastrozole 1 mg daily Exemestane 25 mg daily Letrozole 2.5 mg daily
116797|NCT01484041|Drug|Aromatase Inhibitors|The trial will combine dovitinib with an aromatase inhibitor either anastrozole, letrozole, or exemestane
116798|NCT01484054|Device|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
116799|NCT01484054|Device|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
116800|NCT01484067|Device|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
116801|NCT01484080|Drug|BIBF + Paclitaxel|Priming Period:
Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.
One week washout is planned before starting the treatment phase.
Treatment Phase:
Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days).
116802|NCT01484080|Drug|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
116818|NCT01486927|Biological|Recombinant Factor VIII (rFVIII)|In Part 1 of the study, subjects will receive a single infusion of 50 IU/kg of octocog alfa followed by a single infusion of 50 IU/kg CSL627; each infusion will be preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects will receive infusions of CSL627 to prevent or treat bleeding episodes, at a dose and frequency determined by their study doctor (based on the subject's underlying bleeding phenotype).
116819|NCT01486940|Drug|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
116820|NCT01486940|Drug|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
116821|NCT01486940|Drug|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
116822|NCT01486940|Drug|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
116823|NCT01486953|Drug|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
116306|NCT00072007|Biological|rituximab|rituximab
116307|NCT01485861|Drug|GDC-0980|Repeating oral dose
116308|NCT01485861|Drug|abiraterone|Repeating oral dose
116309|NCT01485861|Drug|placebo|Repeating oral dose
116310|NCT01485861|Drug|prednisone|Repeating oral dose
116311|NCT01485874|Drug|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
116312|NCT01485874|Drug|BIBF 1120|Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid
Phase II: MTD orally, bid, day 2 of 28-day cycle
116313|NCT01485887|Drug|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
116314|NCT01485900|Drug|SAR407899A|Pharmaceutical form:capsule
Route of administration: oral
116315|NCT01485913|Other|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
116316|NCT01488656|Dietary Supplement|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
116317|NCT01488669|Procedure|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
116552|NCT01486381|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
116553|NCT01486394|Other|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
116554|NCT01486420|Procedure|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
116106|NCT00071461|Drug|Placebo|Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight < 40 kg (90 lb): 62.5 mg b.i.d.
116107|NCT01480869|Drug|calcium and cholecalciferol|Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:
100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level < 10 ng/mL
100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level < 20 ng/mL
100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level < 30 ng/mL
116108|NCT01480882|Procedure|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
116109|NCT01480882|Device|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
116110|NCT01480895|Behavioral|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
116111|NCT01480908|Procedure|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
116112|NCT01480908|Procedure|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
116113|NCT01482897|Drug|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
116114|NCT01482897|Drug|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
116115|NCT01482910|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
116116|NCT01482910|Drug|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
116117|NCT01482923|Behavioral|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
116118|NCT01482923|Behavioral|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
116369|NCT01483417|Procedure|Single incision Laparoscopic hysterectomy|SILS port
117039|NCT01482442|Drug|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
117040|NCT01484457|Device|Closed-loop session|Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose < 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.
Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched "on" on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.
After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia.
117041|NCT01484470|Biological|StemEx|For patients allocated to StemEx® arm:
Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase
Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase
Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.
Day 1: StemEx® transplantation.
Day 2 to 3 years: Post transplant follow-up.
116171|NCT01480921|Behavioral|Home-based exercise training|Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:
5-10 min warm-up
30 min aerobic interval training (walking or stationary bicycle)
10 min cool-down
Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study.
116172|NCT01480921|Behavioral|Supervised hospital-based exercise training|Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:
5-10 min of warm-up
30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers
10 min of cool down
Exercise will be tracked by the participant in exercise log books.
116173|NCT00071474|Procedure|shamanic healing|
116174|NCT01480947|Drug|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
116175|NCT01480960|Other|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
116176|NCT01480973|Radiation|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
116177|NCT01480986|Drug|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m^2，ivgtt，90min，D1 Cisplatin 50 mg/m^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
116824|NCT01479751|Drug|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
116825|NCT01479751|Drug|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
116826|NCT01479751|Drug|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
116827|NCT01479764|Drug|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
116828|NCT01479764|Drug|Neostigmine|neostigmine, per usual practice
116829|NCT01479764|Drug|Glycopyrrolate|glycopyrrolate per usual practice
116830|NCT01479777|Device|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
116831|NCT00071279|Drug|SR34006 (idraparinux sodium) Injection|
116832|NCT01479790|Device|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
116833|NCT01479803|Procedure|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
116834|NCT01479829|Drug|ESC + CBX|Escitalopram (ESC) 10 mg twice day given orally twice a day plus Celecoxib (CBX) 200 mg twice daily.
115963|NCT01485302|Drug|SAR228810|Pharmaceutical form:solution
Route of administration: intravenous
115964|NCT01485302|Drug|SAR228810|Pharmaceutical form:solution
Route of administration: subcutaneous
115965|NCT00071981|Biological|incomplete Freund's adjuvant|Given by injection
115966|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
115967|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
115968|NCT01485328|Drug|AMARGOL®|per oral solution, 40 mL single dose
115969|NCT01485341|Dietary Supplement|gluten|gluten is administered once a day at 10g/day for 15 days
115970|NCT01485341|Dietary Supplement|rice starch|rice starch is administered once a day at 10 g/day for 15 days
116555|NCT01486420|Procedure|Open surgery|Open A1-pulley release
116556|NCT01486433|Drug|Simvastatin|40 mg (1 tablet) simvastatin once a day
116557|NCT01486433|Drug|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
116558|NCT01486433|Drug|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
116559|NCT01486446|Drug|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
116560|NCT00072007|Drug|vincristine sulfate|vincristine sulfate
116561|NCT01486446|Drug|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
116562|NCT01486459|Drug|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
116563|NCT01486472|Drug|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
116564|NCT01488747|Dietary Supplement|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
116565|NCT01488773|Drug|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
116566|NCT01488773|Drug|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
116567|NCT01488786|Device|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
116568|NCT01488799|Behavioral|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
116569|NCT00072176|Drug|temsirolimus|Given IV
116891|NCT01486966|Drug|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
116892|NCT01486966|Drug|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
116370|NCT01483417|Procedure|Conventional laparoscopic hysterectomy|3-4 conventional ports
116371|NCT01483430|Drug|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
116372|NCT01483430|Drug|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
116373|NCT01483430|Drug|Placebo|1 capsule/day (starch), Duration: 8 weeks
116374|NCT01483443|Procedure|Oophrectomy|Both oophrectomy
116375|NCT01485926|Drug|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
116376|NCT00072007|Drug|CHOP regimen|CHOP regimen
116377|NCT01485926|Drug|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
116378|NCT01485939|Other|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
116379|NCT01485939|Other|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
116380|NCT01485952|Drug|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
116381|NCT01485952|Drug|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
116382|NCT01485952|Drug|Placebo|Once daily administration (immediate release capsule)
116383|NCT01485965|Drug|SEN0014196|100 mg, immediate release tablets, once daily administration
116384|NCT01485978|Drug|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
116385|NCT01485978|Drug|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
116386|NCT01485978|Drug|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
116387|NCT00072007|Drug|cladribine|cladribine
116388|NCT01485991|Drug|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
116178|NCT01481025|Drug|Cimicifuga + Hiperico|1 tablet, 80+450mg/tablet, twice a day for 1-3 months
1 tablet, 80+450mg/tablet, once a day for 3-6 months
116179|NCT01481025|Drug|Cimicifuga Herbarium|2 caps, 80mg/caps, once a day for 1-3 months
1 caps, 80mg/caps, once a day for 3-6 months
116180|NCT01481025|Drug|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
116181|NCT01481051|Drug|Latanoprost-PPDS|Sustained delivery for 12 weeks
116182|NCT01481064|Behavioral|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
116183|NCT01481077|Drug|Latanoprost-PPDS|Sustained release for 12 weeks
116184|NCT00001253|Behavioral|cognitive tests and scales|
116185|NCT01482975|Other|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
116446|NCT01483469|Drug|RO5011232|[11C]-RO5011232 intravenously
116447|NCT01483482|Procedure|Conservative Treatment|Simple Sling
116448|NCT01483482|Procedure|Surgical treatment|Superior Locking plate
116449|NCT01483495|Device|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
116450|NCT01483508|Other|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomer] and procyanidins [dimers to decamers]
116451|NCT01483508|Other|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins [dimers to decamers]
116452|NCT01483508|Other|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomers]
116453|NCT01483521|Other|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
116454|NCT01483534|Device|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
116455|NCT00071799|Other|Physician Choice|Physician Choice was one of three options:
Best supportive care (BSC) alone,
Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or
Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).
All three options included best supportive care
115971|NCT01485354|Device|Sensing glove|Comparing the use of Armeo with grip sensor to use of Armeo with sensing glove
115972|NCT01485354|Device|Grip Sensor|Typical use of Armeo Spring without the use of Sensing Glove.
115973|NCT01485367|Drug|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand & extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand & extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right & left forearms.
115974|NCT01485380|Drug|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
115975|NCT01485393|Drug|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
115976|NCT01487759|Dietary Supplement|Oligofructose enriched inulin|
115977|NCT01487759|Dietary Supplement|Maltodextrin|
115978|NCT01487785|Drug|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
115979|NCT01487798|Drug|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
115980|NCT01487798|Drug|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
115981|NCT01487811|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
116243|NCT01488448|Drug|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
116244|NCT01488448|Drug|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
116245|NCT01488461|Genetic|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
116246|NCT01488474|Procedure|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
116247|NCT01488487|Drug|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
116248|NCT00072137|Other|Laboratory Biomarker Analysis|Correlative studies
116893|NCT00072046|Biological|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
116894|NCT01486966|Drug|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
116895|NCT01486966|Drug|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
116896|NCT01486966|Drug|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
116897|NCT01486979|Drug|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
116898|NCT01486979|Drug|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
116899|NCT01486992|Drug|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
116900|NCT01487018|Procedure|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
116901|NCT01487018|Procedure|Traditional Surgery|To compare with the experamental group.
116902|NCT01487031|Other|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
116903|NCT01487031|Other|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
116904|NCT00072059|Biological|methoxy polyethylene glycol epoetin beta|
116905|NCT01487044|Drug|Macugen (Pegaptanib Sodium)|Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.
Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only.
116906|NCT01487070|Drug|Macugen (Pegaptanib Sodium)|Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.
Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only.
116045|NCT00071721|Drug|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
116628|NCT01483807|Behavioral|Sound Production Treatment|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice
116629|NCT01486485|Drug|heparinized saline priming group|
116630|NCT01486485|Drug|nafamostat infusion after heparinized saline priming|
116631|NCT01486511|Procedure|Liver resection|Hepatectomy including both minor and major.
116632|NCT01486511|Radiation|Computed Tomography|Computed Tomography +/- pulmonary angiography
116633|NCT01486550|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
116634|NCT01486550|Drug|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
116635|NCT01486563|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
116636|NCT00072020|Drug|zoledronic acid|
116637|NCT01486563|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
116638|NCT01486576|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
116639|NCT01486576|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
116640|NCT01486602|Drug|carboplatin|IV
116641|NCT01486602|Drug|paclitaxel|IV
116642|NCT01486602|Radiation|radiation therapy|Defined per the protocol
116643|NCT01486615|Drug|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
116644|NCT01486615|Drug|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
116645|NCT01486615|Drug|(alprax) alprazolam|0.5 mg alprazolam
116646|NCT01486615|Drug|placebo|similar looking placebo tablet
116647|NCT00000259|Drug|15 % Nitrous oxide|
116648|NCT00001266|Drug|Suramin|
116649|NCT00072020|Procedure|adjuvant therapy|
116650|NCT01486628|Drug|ND0612|levodopa and carbidopa solution for subcutaneous administration
116456|NCT01483547|Device|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
116457|NCT01483560|Drug|Metformin|3 years treatment duration
116458|NCT01483560|Drug|Placebo|3 years duration
116459|NCT01483573|Other|neural mobilization|stretch the nerve
116460|NCT01483573|Other|straight leg raise|stretch the hamstring
116461|NCT01483586|Drug|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
116462|NCT01483586|Drug|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
116463|NCT01483599|Drug|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
116464|NCT01486095|Device|Culotte technique with Xience V or Xience Prime stents|NAP
116465|NCT01486108|Procedure|dorsal column stimulator|test different settings of stimulation
116466|NCT00072007|Drug|cyclophosphamide|cyclophosphamide
116709|NCT01483885|Procedure|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
116710|NCT00071851|Biological|VRC-HIVDNA009-00-VP|
116711|NCT01483898|Biological|Ixmyelocel-T|On Day 14, 20 intramuscular injections of either ixmyelocel-T or vehicle control on pre-identified index leg.
116712|NCT01483898|Other|Vehicle Control|On Day 14, 20 intramuscular injections of either ixmyelocel-T or vehicle control on pre-identified index leg.
116713|NCT01483911|Biological|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
116714|NCT01483911|Biological|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
116715|NCT01483924|Drug|Apo805K1|Sequential parallel dose escalation.
116716|NCT01483937|Device|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
116717|NCT01483937|Other|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
116718|NCT01483963|Biological|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
116249|NCT01488487|Drug|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
116250|NCT01488500|Other|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
116251|NCT00071487|Drug|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
116252|NCT01481090|Procedure|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
116253|NCT01481103|Procedure|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
116254|NCT01481116|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
116255|NCT01481116|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
116256|NCT01481116|Drug|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
116257|NCT01481129|Drug|Akt Inhibitor MK2206|Given PO
116258|NCT01481129|Other|Laboratory Biomarker Analysis|Correlative studies
116259|NCT01481129|Other|Pharmacological Study|Correlative studies
116260|NCT01481142|Device|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
116261|NCT01481155|Procedure|ablative CO2 laser therapy|CO2 laser therapy
116498|NCT01488630|Other|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
116499|NCT01488656|Dietary Supplement|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
116500|NCT01481519|Drug|Artificial Tears|artificial tears 1 drop, 4 times per day
116501|NCT00071539|Drug|TP-38|Recombinant chimeric protein
116502|NCT01481532|Drug|Crotoxin|Intra patient dose escalation
116046|NCT01482897|Drug|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
116047|NCT00071981|Biological|melanoma helper peptide vaccine|Given by injection
116048|NCT01485393|Drug|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
116049|NCT01485406|Biological|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
116050|NCT01485406|Biological|Synflorix™|1 dose administered intramuscularly
116051|NCT01485432|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
116052|NCT01485445|Drug|Fluticasone Furoate (200mcg unit strength)|inhalation powder
116053|NCT01485445|Drug|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
116054|NCT01485458|Procedure|Early surgery|Surgery within 24 hours after admission
116055|NCT01485458|Procedure|Delayed surgery|Surgery more than 2 weeks after injury
116056|NCT01485471|Device|Diffuse optical spectroscopy imaging|ear exam imaging
116057|NCT01485484|Device|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
116058|NCT00071981|Biological|multi-epitope melanoma peptide vaccine|Given by injection
116059|NCT01485497|Device|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
116060|NCT01485510|Behavioral|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
116061|NCT01485510|Behavioral|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
116062|NCT01485523|Other|Nasal provocation test|TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called "minute" (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.
116063|NCT01485536|Drug|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
116651|NCT01486628|Drug|Placebo|Saline solution for SC continuous administration
116652|NCT01486641|Procedure|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
116959|NCT01484405|Procedure|posterior approach|Surgical approach for Total Hip Arthroplasty
116960|NCT00071942|Biological|recombinant vaccinia-MUC1 vaccine|Given intradermally
116961|NCT01484405|Procedure|anterolateral approach|anterolateral surgical approach
116962|NCT01484418|Behavioral|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
116963|NCT01484418|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
116964|NCT01484431|Drug|Tadalafil- Tablet|Tadalafil tablets: 2.5 mg and 5 mg, 10 mg, 20 mg and 40 mg (two 20 mg) administered orally, once daily in the heavy weight cohort >=40 kg and middle weight cohort >=25 kg to <40 kg
Drug: Tadalafil - Oral suspension
Tadalafil Oral suspension: 1 mg, 5 mg administered orally, once daily in the light weight cohort <25 kg
116965|NCT01487083|Drug|Pomaglumetad methionil|Administered orally
116966|NCT01487096|Drug|Teriflunomide|film-coated tablet
oral administration
116967|NCT01487096|Drug|Placebo (placebo for teriflunomide)|film-coated tablet
oral administration
116968|NCT01487109|Drug|CTP-499|600 mg tablet twice daily
116969|NCT01487109|Drug|Placebo|Matching placebo tablet
116970|NCT01487122|Radiation|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
116971|NCT01487122|Radiation|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
116972|NCT01487122|Procedure|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
116973|NCT00072072|Drug|celecoxib|
116974|NCT01487135|Drug|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
116975|NCT01487135|Drug|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
116976|NCT01487135|Drug|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
116977|NCT01487161|Drug|FX006|Single intra-articular injection
116719|NCT01483963|Biological|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
116720|NCT01483963|Biological|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
116721|NCT00001256|Drug|prednisone and methotrexate|
116722|NCT00071877|Drug|Replagal|
116723|NCT01486667|Drug|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
116724|NCT01486667|Drug|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
116725|NCT01486680|Procedure|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
117042|NCT01484496|Biological|Placebo|Placebo
117043|NCT01484496|Biological|Belimumab 200 mg SC|Belimumab 200 mg SC
117044|NCT01484496|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
117045|NCT01484522|Biological|FluMist|Administered at the manufacture's recommended dose
117046|NCT00071942|Biological|recombinant vaccinia-TRICOM vaccine|Given intradermally
117047|NCT01484522|Biological|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
117048|NCT01484522|Biological|Fluzone|Vaccine administered at manufacturer's recommended dose
117049|NCT01484535|Procedure|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
116503|NCT01481545|Radiation|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
116504|NCT01481545|Drug|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
116505|NCT01481545|Drug|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
116506|NCT01481545|Drug|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
116507|NCT01481545|Drug|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
116508|NCT01481545|Drug|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
116509|NCT01481558|Device|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
116510|NCT01481571|Device|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
116511|NCT01481584|Dietary Supplement|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
116512|NCT00071539|Drug|TP38|recombinant chimeric protein
116513|NCT01481584|Dietary Supplement|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
116514|NCT01481597|Drug|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
116515|NCT01481597|Drug|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
116835|NCT01479829|Drug|ESC + PBO.|• Escitalopram (ESC) 10 mg twice per day plus Placebo (PBO)administered twice daily.
116836|NCT01479829|Drug|ESC+CBX|• Escitalopram 10 mg given twice day plus Celecoxib 200 mg twice daily.
116837|NCT01479842|Drug|BTK inhibitor PCI-32765|Given PO
116838|NCT01479842|Biological|rituximab|Given IV
116064|NCT01485562|Drug|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
116318|NCT00072163|Drug|temozolomide|Given orally
116319|NCT01488669|Procedure|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
116320|NCT01488682|Procedure|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
116321|NCT01488682|Procedure|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
116322|NCT01488695|Device|GlideScope Groove|GlideScope Groove
116323|NCT01488695|Device|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
116324|NCT01488708|Drug|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies are not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
116325|NCT01488708|Drug|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
116326|NCT01488734|Dietary Supplement|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
116327|NCT01488734|Dietary Supplement|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
116328|NCT01488734|Dietary Supplement|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
116329|NCT00072163|Drug|thalidomide|Given orally
116330|NCT01488734|Dietary Supplement|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
116331|NCT01488734|Drug|Placebo|Placebo for the fortified mushroom arms
116332|NCT01488747|Dietary Supplement|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
116333|NCT01488747|Dietary Supplement|Coromega Nectar|660 mg EPA, 436 mg DHA
116978|NCT01487161|Drug|Commercially available triamcinolone acetonide|Single intra-articular injection
116979|NCT01487174|Drug|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
116980|NCT01487174|Drug|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
116119|NCT01482936|Drug|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
116120|NCT01482949|Drug|AGS-003|Autologous Dendritic Cell Immunotherapy
116121|NCT01482962|Drug|Alisertib|Patients randomized to receive alisertib will be administered an enteric-coated tablet formulation 5×10-mg twice daily orally for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle.
116122|NCT00071721|Drug|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
116123|NCT01482962|Drug|Pralatrexate|Patients randomized to single-agent comparator will be assigned by the investigator to receive ONE of either Pralatrexate,or Romidepsin, or Gemcitabine.
Patients randomized to receive Pralatrexate will be administered the drug at 30mg/m2 as an intravenous (IV) push over 3 to 5 min once weekly for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles should be repeated every 7 weeks
116124|NCT01482962|Drug|Gemcitabine|Patients randomized to single-agent comparator will be assigned by the investigator to receive ONE of either Pralatrexate, or Romidepsin, or Gemcitabine.
Patients randomized to receive Gemcitabine will receive the drug intravenously at 1,000 mg/m2 over 30 minutes on Days 1, 8, and 15 of a 28-day cycle. Cycles should be repeated every 28 days in the absence of disease progression or unacceptable toxicity.
116125|NCT01482962|Drug|Romidepsin|Patients randomized to single-agent comparator will be assigned by the investigator to receive ONE of either Pralatrexate, or Romidepsin, or Gemcitabine.
Patients randomized to receive Romidepsin will be administered the drug intravenously at 14mg/m2 over a 4-hour period on Days 1,8,& 15 of a 28-cycle. Cycles should be repeated every 28 days.
116126|NCT01482975|Other|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
116127|NCT01485614|Drug|Metformin|
116128|NCT01485614|Drug|Placebo to sitagliptin|
116129|NCT01485614|Drug|Placebo to metformin|
116130|NCT01485614|Drug|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin in both Phase A and Phase B. Participants in the placebo arm who require glycemic rescue will receive metformin in Phase A. Participants on background insulin will NOT have their insulin doses up-titrated, but will be rescued with metformin.
117050|NCT01484535|Procedure|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
117051|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
117052|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
117053|NCT01484548|Biological|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
117054|NCT01484561|Drug|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
117055|NCT01484561|Drug|Placebo|Placebo BID orally, approximately 72 days
117056|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
117057|NCT00071942|Other|laboratory biomarker analysis|Correlative studies
117058|NCT01487252|Behavioral|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
117059|NCT01487265|Drug|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
116186|NCT01483001|Drug|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
116187|NCT01483014|Drug|imatinib mesylate|
116188|NCT01483027|Device|TheraSphere|yttrium 90 microspheres
116189|NCT01483040|Device|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
116190|NCT01483053|Drug|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
116191|NCT00071747|Drug|lamotrigine|
116839|NCT01479842|Drug|bendamustine hydrochloride|Given IV
116840|NCT01479842|Other|pharmacogenomic studies|Correlative studies
116841|NCT01479842|Other|pharmacological study|Correlative studies
116842|NCT00071292|Behavioral|stress reduction program|
116843|NCT01479842|Other|laboratory biomarker analysis|Correlative studies
116844|NCT01479868|Drug|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
116845|NCT01479868|Drug|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
116846|NCT01479868|Drug|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
116847|NCT01479881|Drug|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
116848|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
116849|NCT01482091|Drug|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
116850|NCT01482104|Drug|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
116851|NCT01482104|Drug|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
116852|NCT01482117|Drug|Clopidogrel|single oral administration of 300mg of clopidogrel
116853|NCT01482117|Drug|Cilostazol|single oral administration of 100mg cilostazol
116854|NCT01482117|Drug|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
116855|NCT01482130|Behavioral|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
116856|NCT01482130|Behavioral|recommendations|The control group will be encouraged to follow a training program according to recommended exercise guidelines:
Weight bearing activities (walking, jogging or strength training)
30 - 60 minutes, 3 - 5 times each week
A total of 2 - 3 hours each week should be achieved
115982|NCT01487837|Drug|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
116334|NCT01488747|Dietary Supplement|Barlean Swirl|660 mg EPA, 660 mg DHA
116570|NCT01488825|Behavioral|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
116571|NCT01488838|Drug|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
116572|NCT01488838|Radiation|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
116573|NCT01488864|Behavioral|Applied Relaxation (AR)|AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.
During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.
The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation.
116574|NCT01488877|Drug|PF-03882845|3 mg tablet once daily
116575|NCT01488877|Drug|PF-03882845|up to 10 mg tablet once daily
116576|NCT01488877|Drug|PF-03882845|up to 30 mg once daily
116577|NCT01488877|Drug|Spironolactone|spironolactone 25 mg once daily
116578|NCT01488877|Other|placebo|placebo once daily
116579|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
116580|NCT00072176|Other|laboratory biomarker analysis|Correlative studies
116581|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
116582|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
116583|NCT01488890|Biological|Yellow Fever|0.5 mL, Subcutaneous
116584|NCT01481623|Other|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
116585|NCT00071552|Drug|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
116586|NCT01481662|Device|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
116131|NCT01485614|Drug|Glycemic Rescue 2|Participants in the placebo arm who have switched to metformin in Phase B and require glycemic rescue will receive sitagliptin. Participants on background insulin will NOT have their insulin doses up-titrated, but will be rescued with sitagliptin.
116132|NCT01485614|Biological|Glycemic Rescue 3|Participants who require glycemic rescue after Glycemic Rescue 1 or 2, will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
116133|NCT01485627|Behavioral|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
116134|NCT01485640|Drug|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
116389|NCT01485991|Drug|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
116390|NCT01486004|Drug|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
116391|NCT01486004|Drug|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
116392|NCT01486017|Drug|ASP015K|oral
116393|NCT01486043|Drug|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
116394|NCT01486082|Other|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
116395|NCT01486095|Device|AXXESS + Biomatrix Biolimus Eluting stent|NAP
116396|NCT01488929|Drug|TC-5619|
116397|NCT01488929|Drug|Placebo|
116398|NCT01488942|Other|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
116399|NCT01488955|Drug|Ibuprofen|400 mg oral once a day from day 0 for 3 days
116400|NCT01488955|Drug|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
116401|NCT01488968|Radiation|Standard Radiation Treatment|39 radiation treatments
116192|NCT01483053|Drug|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
116193|NCT01483066|Device|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
116194|NCT01483092|Dietary Supplement|inulin|20g/day for 4 weeks
116195|NCT01483092|Dietary Supplement|maltodextrin|20g/day for 4 weeks
116196|NCT01483105|Behavioral|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
116197|NCT01483118|Drug|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
116198|NCT01483118|Dietary Supplement|Placebo|Placebo capsules containing ground cereal.
116199|NCT01483131|Other|Exercise training|12 weeks of resistance training twice a week.
116200|NCT01483131|Other|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
116201|NCT01483144|Drug|Eflornithine plus Sulindac|Eflornithine [250 mg tablet, three tablets (750 mg) orally once a day] and Sulindac [150 mg tablet, one tablet orally once a day] for 24 months
116202|NCT00071760|Drug|GW433908|Fosamprenavir suspension bid
116203|NCT01483144|Drug|Eflornithine and Placebo|Eflornithine [250 mg, three tablets (750 mg) orally once a day] and Placebo [one tablet orally once a day] for 24 months
116467|NCT01486121|Other|Therapy strategy|Sedation & mechanical ventilation
116468|NCT01486134|Procedure|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
116469|NCT01486147|Behavioral|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
116470|NCT01486147|Behavioral|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
116471|NCT01486186|Drug|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
116472|NCT01486186|Drug|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
115983|NCT01487850|Biological|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
115984|NCT01487863|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
115985|NCT00072124|Drug|cisplatin|
115986|NCT01487863|Drug|abiraterone acetate|Abiraterone acetate (1000 mg po QD) is administered in combination with prednisone (5 mg po BD) for a total of 26 weeks.
115987|NCT01487876|Biological|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
115988|NCT01487876|Other|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
115989|NCT01487889|Other|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
115990|NCT01487902|Drug|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
115991|NCT01487902|Drug|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
115992|NCT01487915|Drug|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
115993|NCT01487915|Drug|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
115994|NCT01487928|Dietary Supplement|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
115995|NCT01487954|Dietary Supplement|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
115996|NCT00072124|Drug|dacarbazine|
115997|NCT01487954|Dietary Supplement|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
115998|NCT01480583|Drug|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
115999|NCT01480583|Drug|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
116000|NCT01480596|Biological|Belimumab|10mg/kg IV infusion
116001|NCT01480596|Other|Placebo|placebo IV infusion
116587|NCT01481688|Other|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
116588|NCT01481688|Other|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
116907|NCT01479881|Drug|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
116908|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
116909|NCT01479907|Dietary Supplement|Synbiotics|12 gr in 250 cc of water once daily X 15 days
116910|NCT01479907|Dietary Supplement|Placebo|12 gr in 250 cc of water once daily X 15 days
116911|NCT00071292|Behavioral|meditation|
116912|NCT01479920|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
116913|NCT01479920|Procedure|DCEAS (Hwato®/ Dongbang®)|Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.
Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
116914|NCT01479920|Procedure|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
116915|NCT01479933|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
116916|NCT01479933|Dietary Supplement|Placebo|Inactive placebo
116917|NCT01479933|Dietary Supplement|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
116918|NCT01479946|Drug|Electrochemotherapy|bleomycin together with electroporation
116919|NCT01479959|Device|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
116920|NCT01479972|Biological|VPM1002|Tuberculosis vaccine
116921|NCT01479972|Biological|BCG|commercially available live vaccine BCG
116922|NCT00071331|Drug|Tolvaptan|
116402|NCT01488968|Radiation|Hypofractionated radiation treatment|25 radiation treatments
116403|NCT00072189|Drug|7-hydroxystaurosporine|Given IV
116404|NCT01488981|Other|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
116405|NCT01488981|Device|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
116406|NCT01488994|Biological|Recombinant Factor IX|Participants underwent a pharmacokinetic evaluation with recombinant Factor IX prior to starting a twice weekly prophylactic treatment.
116407|NCT01489020|Biological|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
116653|NCT01486654|Device|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
116654|NCT01486654|Device|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
116655|NCT01486654|Device|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
116656|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
116657|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
116658|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
116659|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
116660|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
116661|NCT00072189|Other|pharmacological study|Correlative studies
116662|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
116663|NCT01489111|Drug|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
116664|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
116473|NCT01486199|Other|Absorptive clearance scan|Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
116474|NCT01486225|Device|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
116475|NCT01486225|Other|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
116476|NCT01486238|Drug|Macugen® pegaptanib sodium|Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.
Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert.
116477|NCT00072007|Drug|doxorubicin hydrochloride|doxorubicin hydrochloride
116478|NCT01486251|Drug|axitinib|Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.
One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles.
116479|NCT01486264|Biological|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
116480|NCT01486277|Drug|JNJ 26481585, 12 mg|Participants will receive JNJ 26481585 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
116481|NCT01486290|Behavioral|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
116482|NCT01486303|Procedure|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
116726|NCT01486680|Procedure|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
116727|NCT00072020|Procedure|neoadjuvant therapy|
116728|NCT01486706|Drug|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
116729|NCT01486706|Drug|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
116730|NCT01486706|Drug|Placebo drugs|will titrate medications similar to the active drug group
116002|NCT01480609|Drug|Retigabine / Ezogabine|
116262|NCT00071487|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
116263|NCT01481155|Procedure|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
116264|NCT01481168|Device|Pacemaker implantation (Medtronic)|DDD+/-R pacing
116265|NCT01481168|Device|Pacemaker implantation (Medtronic)|ODO pacing
116266|NCT01481168|Device|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
116267|NCT01481181|Dietary Supplement|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
116268|NCT01481194|Drug|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
116269|NCT01481194|Drug|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
116270|NCT01481194|Drug|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
116271|NCT01481194|Drug|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
116272|NCT01481194|Drug|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
116273|NCT00071487|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
116274|NCT01483157|Other|high intensity resistance training|twelve weeks of resistance training twice a week
116275|NCT01483170|Drug|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
116276|NCT01483170|Drug|Placebo|Placebo fexinidazole
116277|NCT01483183|Drug|OPC-108459|Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target
Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1
116278|NCT01483183|Drug|Placebo|Placebo dose, 10-minute constant rate IV infusion
116279|NCT01483196|Procedure|ultrasound imaging|Undergo TCD
116923|NCT01479985|Other|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
116924|NCT01479998|Other|standard care|standard care plus nicotine replacement therapy
116925|NCT01479998|Other|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
116926|NCT01480011|Drug|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
116065|NCT01485562|Other|placebo|4 tablets, administered sublingually if the woman experiences a PPH
116066|NCT01485575|Procedure|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
116067|NCT01485588|Drug|hI-con1™|Phase 1: 20µl, 50µl, or 100µl per injection (in the eye) on Day 1 only
116068|NCT01485601|Biological|MT10109|Single dose intramuscular injection MT10109 vs Botox®
116069|NCT00071981|Biological|sargramostim|Given by injection
116070|NCT01485614|Drug|Sitagliptin|
116071|NCT01487954|Radiation|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
116072|NCT01487967|Other|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
116073|NCT01487980|Procedure|Cord clamping|Early vs Delayed
116074|NCT01487993|Drug|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
116075|NCT01487993|Behavioral|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
116076|NCT01488006|Device|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
116077|NCT01488019|Drug|Peforomist-Placebo|Placebo vehicle, 2mL, twice daily
116078|NCT01488019|Drug|Perforomist, nebulization, COPD|Peforomist, 20 mcg/2 mL, twice daily for 52 weeks
116665|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
116666|NCT01489124|Drug|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
116667|NCT01489137|Drug|remifentanil|According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.
For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml.
116668|NCT01489163|Behavioral|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
116669|NCT01489176|Drug|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
116670|NCT01489189|Other|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
116981|NCT01487187|Procedure|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
116982|NCT01487187|Procedure|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
116983|NCT01487200|Drug|FX006|single intra-articular injection
116984|NCT00072072|Drug|erlotinib hydrochloride|
116985|NCT01487200|Drug|commercially available triamcinolone acetonide|single intra-articular injection
116986|NCT01487213|Other|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
116987|NCT01487226|Drug|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks * 6 cycles
116988|NCT01487226|Drug|Cisplatin 50mg/m2|Cisplatin 50mg/m2
Repeat every 3 weeks * 6 cycles
116989|NCT01487239|Drug|[14C]-GDC-0980|100 uCi of [14C]-GDC-0980 in total dose of 10 mg GDC-0980
116990|NCT01480063|Drug|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
116991|NCT01480076|Drug|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
116731|NCT01486719|Procedure|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
116732|NCT01486732|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
116733|NCT01486732|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
116734|NCT01486732|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
116735|NCT01486758|Drug|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
116736|NCT01486771|Drug|Macugen ® (pegaptanib sodium)|Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.
Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.
Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.
All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection.
116737|NCT01486784|Drug|TL32711|
116738|NCT00072033|Drug|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
116739|NCT01479595|Drug|Placebo|Placebo to QBX258 intravenous infusion every 4 weeks up to 4 doses total
116740|NCT00071253|Drug|Divalproex Sodium (Extended-Release Tablets)|
116741|NCT01479608|Procedure|Liver transplantation and liver resection|
116742|NCT01479621|Drug|Placebo|Placebo DPI
116743|NCT01479621|Drug|Flovent Diskus|Flovent Discus 100mcg BID
116744|NCT01479621|Drug|Fluticasone propionate DPI Dose 1|Fluticasone propionate
117060|NCT01487278|Drug|misprostol|600 mcg misoprostol oral
117061|NCT01487278|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
117062|NCT01487304|Drug|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
117063|NCT00072085|Biological|aldesleukin|
116280|NCT01483196|Other|questionnaire administration|Complete neurocognitive questionnaires
116281|NCT00071760|Drug|ritonavir|Ritonavir solution bid
116282|NCT01483196|Procedure|assessment of therapy complications|Undergo TCD
116516|NCT01481597|Drug|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
116517|NCT01481597|Drug|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
116518|NCT01481597|Drug|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
116519|NCT01481610|Drug|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
116520|NCT01481610|Drug|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
116521|NCT01481623|Other|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
116522|NCT01483599|Drug|CNTO 1959 (15 mg)|SC injections
116523|NCT01483599|Drug|CNTO 1959 (50 mg)|SC injections
116524|NCT00071812|Drug|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
116525|NCT01483599|Drug|CNTO 1959 (100 mg)|SC injections
116526|NCT01483599|Drug|CNTO 1959 (200 mg)|SC injections
116527|NCT01483599|Drug|Adalimumab|SC injections
116528|NCT01483599|Drug|Placebo|SC injections
116529|NCT01483612|Behavioral|Interdisciplinary lifestyle intervention|Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.
The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity.
116530|NCT01483625|Drug|tiotropium|18mcg
116531|NCT01483625|Drug|Placebo|placebo
116532|NCT01483638|Drug|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
116533|NCT01483638|Drug|placebo|will be administered orally with the same schedule of axitinib
116079|NCT01488045|Drug|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
116080|NCT00072124|Procedure|conventional surgery|
116081|NCT01488045|Drug|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
116082|NCT01488045|Drug|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
116083|NCT01488058|Other|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
116084|NCT01488058|Other|Waitlist Control|Waitlist will receive iCBT at week 11
116335|NCT01481220|Drug|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
116336|NCT01481233|Drug|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
116337|NCT01481246|Behavioral|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
116338|NCT01481259|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
116339|NCT01481259|Other|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
116340|NCT01481272|Drug|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
116341|NCT01481272|Drug|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
116342|NCT01481272|Drug|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients >/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
116343|NCT01481272|Drug|Mesna|300mg/m2 or 200mg/m2 (patients >/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients >/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
116344|NCT01481272|Drug|Cytarabine|2g/m2 or 0,5-1g/m2 (patients >/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
116992|NCT00071396|Drug|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
116993|NCT01480089|Drug|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
116994|NCT01480089|Other|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
116995|NCT01480102|Drug|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
116996|NCT01480102|Other|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
116997|NCT01480115|Other|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
116998|NCT01480128|Procedure|Single-port|Single-port laparoscopic colon resection
116999|NCT01480128|Procedure|Multi-port|Multi-port laparoscopic colon resection
117000|NCT01480141|Drug|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
116135|NCT01485653|Drug|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
116136|NCT00071981|Biological|tetanus peptide melanoma vaccine|Given by injection
116137|NCT01485666|Other|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
116138|NCT01485679|Other|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
116139|NCT01485692|Drug|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
116140|NCT01485692|Drug|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
116141|NCT01485692|Drug|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
116142|NCT01485692|Drug|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
117978|NCT01502566|Behavioral|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
117979|NCT01502592|Procedure|Cryoablation|OncCore Biopsy (+ Cryo) Date*
Pre- and post- cryo MRI
Core biopsy x ≥3
Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.*
117980|NCT01502592|Biological|Ipilimumab|Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date*
MRI
Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery.
117981|NCT01504542|Biological|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
117982|NCT01504542|Biological|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
117983|NCT01504568|Other|Treatment|Adults: ≥40 kg:250mg every eight hours Children: <40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
118280|NCT01501149|Drug|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
118281|NCT01501149|Drug|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
118282|NCT01501162|Drug|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
118283|NCT01501162|Drug|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
118284|NCT01501175|Other|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
118285|NCT01501188|Other|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
118286|NCT00073411|Drug|placebo|
118287|NCT01501188|Other|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
118288|NCT01501201|Procedure|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
117871|NCT01500564|Device|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
117872|NCT01500564|Device|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
117873|NCT00073593|Drug|Protamine|Per institutional practice. Batches from hospital stock.
117874|NCT01502254|Other|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
117875|NCT01502267|Drug|High dose IVIG and B cell depleting agents|IVIG(2g/kg two times on day 1, 30)
Rituximab(375mg/m2 on day 3)
Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)
117876|NCT01502280|Drug|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
117877|NCT01502280|Drug|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
117878|NCT01502293|Biological|Plasmid INTERLEUKIN-12|Patients will receive intratumoral injection(s) of pIL-12.
117879|NCT01502293|Device|Intratumoral Electroporation|Immediately following intratumoral injection of pIL-12, electroporation will follow by electrical discharge around the tumor site using the OMS system.
117880|NCT01502306|Behavioral|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
117881|NCT01502306|Drug|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
117882|NCT01502306|Behavioral|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
117883|NCT01502319|Behavioral|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
117884|NCT00073619|Behavioral|Cognitive behavior therapy|
117885|NCT01502332|Other|Mechanical ventilation strategy|Intensive Alveolar Recruitment ARM: recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
118170|NCT01498770|Drug|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
117173|NCT01487590|Other|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
117174|NCT01480284|Drug|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
117175|NCT01480297|Drug|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
117176|NCT01480310|Drug|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
117177|NCT01480310|Drug|Placebo|may receive up to 3 subcutaneous doses of placebo
117178|NCT01480323|Drug|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
117179|NCT01480323|Drug|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
117180|NCT01480336|Drug|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
117181|NCT01480336|Drug|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
117182|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
117455|NCT01499940|Drug|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
117456|NCT01499953|Drug|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
117457|NCT01499953|Drug|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
117458|NCT01499966|Procedure|Plaster of Paris/ Tubigrip|After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and "TG" for Tubigrip and "POP" for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks
117459|NCT01499979|Procedure|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
117806|NCT00073593|Drug|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of >300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
117807|NCT01502202|Drug|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
117808|NCT01502202|Drug|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
117809|NCT01502202|Drug|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
117810|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
117811|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
117812|NCT01502228|Drug|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
117813|NCT01502228|Drug|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
117814|NCT01502228|Procedure|Positron Emission Tomography|PET Scan
117815|NCT01502241|Drug|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
117816|NCT01502241|Radiation|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
117817|NCT01504256|Drug|Fluorouracil, leucovorin, oxaliplatin, docetaxel|FLOT; 6 cycles q2w:
Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)
118100|NCT01498731|Behavioral|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
118101|NCT01498744|Drug|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
118102|NCT01498770|Drug|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
118103|NCT00073073|Drug|Exemestane|exemestane 25 mg by mouth (PO) every day for two years calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day x 2 years
117234|NCT01503203|Other|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
117235|NCT01503216|Dietary Supplement|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
117236|NCT01503216|Dietary Supplement|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
117237|NCT01503216|Dietary Supplement|Placebo|Placebo
117238|NCT01503229|Drug|Abiraterone Acetate|Given PO
117239|NCT01503229|Other|Laboratory Biomarker Analysis|Correlative studies
117240|NCT01503229|Other|Pharmacological Study|Correlative studies
117241|NCT01503229|Drug|Prednisone|Given PO
117242|NCT00073697|Drug|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
117243|NCT01503242|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
117244|NCT01503242|Drug|Cyclosporine|Given PO
117245|NCT01503242|Drug|Fludarabine Phosphate|Given IV
117246|NCT01503242|Drug|Mycophenolate Mofetil|Given IV or PO
117247|NCT01503242|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
117248|NCT01503242|Radiation|Total-Body Irradiation|Undergo TBI
117249|NCT01503242|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
117250|NCT01503255|Behavioral|cognitive behavioral group therapy|6 weekly 90-minute group sessions
117251|NCT01503255|Behavioral|health education group|6 weekly 90-minute group sessions
117252|NCT01503268|Device|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
117531|NCT01500018|Drug|TC-5214 Placebo|Single oral dose
117532|NCT01500018|Drug|Ketamine|Single oral dose of 100 mg
117533|NCT01500018|Drug|Phentermine|Single oral dose of 45 mg
118171|NCT01498770|Drug|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
118172|NCT01498783|Drug|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
118173|NCT01498796|Drug|Ketorolac|
118174|NCT01498796|Drug|Normal Saline|
118175|NCT01498809|Drug|Midodrine|Single 10 mg dose
118176|NCT01498822|Drug|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
118177|NCT01498822|Drug|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
118178|NCT01498835|Drug|Sunitinib|Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).
Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual.
118179|NCT01498848|Dietary Supplement|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
118180|NCT00001298|Drug|carboxypeptidase-G2|
118181|NCT00073125|Drug|ABT-510/Thrombospondin-1 mimetic|
118182|NCT01498861|Drug|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
118183|NCT01498861|Drug|Dolutegravir|Dolutegravir is an experimental HIV drug
118184|NCT01498861|Drug|Placebo|Placebo is a tablet with no drug in it
118185|NCT01498874|Drug|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
118186|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
118187|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
118188|NCT01498887|Drug|Fingolimod (FTY720)|Fingolimod will be used in two group of patients with treatment different characteristics at baseline
118189|NCT01498900|Drug|repaglinide|Prescription according to the product labelling at the physicians' discretion
118190|NCT01498913|Drug|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
117460|NCT01499992|Procedure|Standard physical therapy program PLUS aquatic physical therapy|2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
117461|NCT00073242|Drug|T3 repletion|administer T3
117462|NCT01499992|Other|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
117463|NCT01500005|Drug|Baby D3 drops|2000-4000 iu per day
117464|NCT01501734|Device|watch-pat|The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.
The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.
Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea.
117465|NCT01501747|Drug|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
117466|NCT01501747|Drug|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
117749|NCT01504178|Drug|duloxetine|administration during 28 days
117750|NCT01504178|Drug|placebo of duloxetine|administration during 28 days
117751|NCT01504178|Drug|injection of apomorphine|injection performed at D28
117752|NCT01504178|Drug|injection of placebo of apomorphine|performed at D28
117753|NCT01504178|Drug|L-Dopa|performed at D28
117754|NCT01504178|Drug|injection of placebo of L-Dopa|performed at D28
117755|NCT00073762|Drug|DVS-233 SR|
118104|NCT01498770|Drug|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
118105|NCT01498770|Drug|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
118106|NCT01498770|Drug|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
118107|NCT01498770|Drug|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
118108|NCT01498770|Drug|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
118109|NCT01498770|Drug|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
118110|NCT01500850|Drug|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
118111|NCT01500850|Drug|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Insulin glulisine: bolus injections before each main meal
118112|NCT01500863|Drug|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
118113|NCT01500863|Drug|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
118114|NCT01500863|Drug|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
118115|NCT01500863|Drug|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
118116|NCT01500863|Drug|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
118117|NCT01500863|Drug|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
118118|NCT01500876|Radiation|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
117230|NCT01484964|Drug|ASP015K|oral
117231|NCT00071968|Drug|temsirolimus|
117232|NCT01503203|Other|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
117233|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
117534|NCT01500018|Drug|TC-5214|Single oral dose of 8 mg
117535|NCT01500018|Drug|TC-5214|Single oral dose of 16 mg
117536|NCT01500018|Drug|Phentermine|Single oral dose of 90 mg
117537|NCT01500031|Device|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
117538|NCT00073255|Drug|hokt3g1 (ALA-ALA)|
117539|NCT01500044|Procedure|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
117540|NCT01500044|Procedure|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
117541|NCT01500057|Device|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
117542|NCT01500057|Device|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
117543|NCT01500070|Device|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
117544|NCT01500083|Drug|Bendamustine at a dose of 100 mg/m2|Bendamustine will be administered intravenously over 30 minutes.
117545|NCT01500083|Drug|Bendamustine at a dose of 120 mg/m2|Bendamustine will be administered intravenous (i.v.) over 60 minutes.
117546|NCT01500096|Drug|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
117547|NCT01500096|Dietary Supplement|Placebo for American ginseng|Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day
117548|NCT01500109|Drug|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
117549|NCT00073268|Behavioral|Exercise|
117818|NCT01504269|Other|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
117306|NCT01501487|Drug|PTH followed by dose dense AC of FEC|Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,
Followed by 4 cycles of AC or FEC:
AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles
In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel.
117307|NCT01501500|Drug|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
117308|NCT00073489|Drug|OSI-461|
117309|NCT01501500|Drug|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
117310|NCT01501513|Drug|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
117311|NCT01501513|Drug|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
117312|NCT01501513|Drug|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
117313|NCT01501539|Procedure|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
117314|NCT01501539|Procedure|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
117315|NCT01501552|Other|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
117316|NCT01503320|Dietary Supplement|Placebo|Similar appearing nutritional supplement without glutamine.
117317|NCT01503333|Behavioral|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
117318|NCT01503346|Drug|DaHuang GanTsao Tang|Intervention group
2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;
each package was given to each patient four times a day (three time after meal and one time before sleep);
each patient received the usual medication of the hospice ward at the same time;
record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;
record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.
117319|NCT01503359|Dietary Supplement|Sarcosine|Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.
Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months.
117756|NCT01504191|Behavioral|Internet‐based CBT|The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.
A psychologist will communicate with the participants through internal text‐messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc.
117757|NCT01504204|Drug|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
117758|NCT01504204|Drug|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
117759|NCT01504256|Drug|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)
and 7 days after the last catumaxomab infusion
FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)
117760|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
117761|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
117762|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
117763|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
117764|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
117765|NCT01506765|Drug|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
117766|NCT01506778|Device|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
117767|NCT00073957|Drug|liposomal cytarabine|
118045|NCT01500837|Drug|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
118046|NCT01500850|Drug|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
118047|NCT01500850|Drug|human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
human insulin: bolus injections before each main meal
118048|NCT00073385|Drug|Pivanex|
119383|NCT01493700|Procedure|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
119384|NCT01493713|Other|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
119385|NCT01493726|Drug|ALKS 9072, Low dose|IM injection, given monthly
119386|NCT01493726|Drug|ALKS 9072, Med dose|IM injection, given monthly
119387|NCT01493726|Drug|ALKS 9072, High dose|IM injection, given monthly
119388|NCT00001287|Drug|intravenous immunoglobulin (IVIg)|
119389|NCT00072527|Drug|etoposide|IV
119390|NCT01493726|Drug|Placebo|Dosed matched placebo IM injection, given monthly
119391|NCT01495988|Drug|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
119392|NCT01495988|Drug|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
118497|NCT01499316|Procedure|Room Air|Room air breathing
118498|NCT01499355|Biological|BIIB023|Intravenous (IV) Infusion of BIIB023
118499|NCT01499355|Biological|Placebo|Intravenous (IV) Infusion
118500|NCT01499355|Drug|Mycophenolate Mofetil|Mycophenolate mofetil titrated to a target daily dose of 2 g (1 g twice daily)
118501|NCT00073190|Behavioral|Osteoporosis Education|
118502|NCT01499368|Drug|Lafutidine|Lafutidine 20mg/day
118503|NCT01499368|Drug|Famotidine|Famotidine 40mg/day
118504|NCT01499368|Drug|Omeprazole|Omeprazole 20mg/day
118505|NCT01499407|Device|ClearWay RX catheter|
118506|NCT01499407|Drug|Abciximab|
118507|NCT01499420|Biological|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
118508|NCT01499420|Biological|Placebo|Single intravenous doses of normal saline (0.9%)
117819|NCT01504282|Drug|mitomycin-C|
117820|NCT01504282|Drug|Placebo|balanced salt solution (BSS)
117821|NCT01504295|Drug|Metadoxine|Improve Liver Function and Reduce ALcohol Use
117822|NCT01504308|Device|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
117823|NCT00073788|Procedure|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
117824|NCT01504308|Device|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
117825|NCT01504321|Drug|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
117826|NCT01504321|Drug|Placebo|Encapsulated lactose powder
117827|NCT01504334|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
117828|NCT01504334|Drug|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
117829|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
117830|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
117831|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
117832|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
118119|NCT01500889|Procedure|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
118289|NCT01502917|Radiation|Radioactive iodine-labeled monoclonal antibody 8H9|Prior to treatment, children will be pre-medicated with super-saturated potassium iodide (SSKI) and liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-8H9 into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-8H9. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations and PET/CT scans of the brain and other organs. Clinical observations, intensive care unit monitoring, routine blood and interval imaging studies (MRI and PET/CT scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
118290|NCT01502930|Behavioral|IRT|Internet-based IRT with therapist support during 6 weeks
118291|NCT01502930|Behavioral|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
118292|NCT01502943|Drug|Louxiangdan Tongxin granules|TCM treatment:
Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.
Usage:Once 100ml, twice per day after breakfast and supper.
118293|NCT01502943|Drug|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
117398|NCT01501708|Drug|Caspofugin based combination therapy|Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.
All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.
In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.
117399|NCT01501721|Behavioral|Exercise|Home-based exercise program
117400|NCT01501721|Behavioral|Diet|Nutritional counseling aiming to reduce suggar intake
117401|NCT01503515|Drug|caspofungin acetate|Given IV
117402|NCT01503515|Drug|fluconazole|Given IV or PO
117403|NCT01503515|Drug|voriconazole|Given IV or PO
117404|NCT01503515|Other|laboratory biomarker analysis|Optional correlative studies
117405|NCT01503528|Procedure|Spinal anesthesia with periarticular infiltration|Spinal anesthesia with 15 mg of hyperbaric bupivacaine and periarticular infiltration will be given. Postoperatively patients will receive patient controlled analgesia with hydromorphone at a dose of 0.1- 0.3mg with a lock out of 6 minutes for 24 hours. On termination of PCA, they will receive a combination of oxycodone and oxycontin.
Patients will also receive peri-articular infiltration with a mixture of ropivacaine (300mg), ketorolac 30 mg, morphine 10 mg and epinephrine 2.5mcg/mL in 110mL.
118049|NCT01502605|Drug|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
118050|NCT01502618|Behavioral|Focus Group Guide|N/A. Protocol is the focus group
118051|NCT01502631|Drug|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
118052|NCT00073645|Behavioral|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
118053|NCT01502631|Drug|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
118054|NCT01502644|Drug|Oxycodone|up to 120mg daily dosage
118055|NCT01502644|Drug|Morphine|daily dosage up to 90mg immediate release and 180mg extended release.
118056|NCT01502657|Device|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
118057|NCT01502670|Drug|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
118058|NCT01502683|Procedure|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
118059|NCT01502683|Procedure|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
118060|NCT01502683|Procedure|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
118061|NCT01502683|Procedure|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
118062|NCT01502696|Biological|PEG IFN alfa-2b|3µg/kg weekly injections
118063|NCT00073658|Drug|Citalopram|
118064|NCT01502709|Device|Scion Neurostim, LLC, Caloric Vestibular Neurostimulation Device|3 treatments over 1week, caloric vestibular neurostimulation for 7.5 minutes in the right ear
117183|NCT01480362|Device|Negative Pressure Wound Therapy|Used therapy systems:
KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
118509|NCT01499433|Drug|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
118510|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
118511|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
118512|NCT00073203|Drug|R228060|
118513|NCT01499446|Drug|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
118514|NCT01499446|Drug|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
118515|NCT01499459|Genetic|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
118516|NCT01499472|Device|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
118517|NCT01499472|Device|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
118518|NCT01499472|Procedure|standard of care|regular care including debridement and bandaging.
118519|NCT01499485|Drug|Acetazolamide|Daily morning ABGA:
If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of acetazolamide 500 mg .
If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of acetazolamide 500 mg.
If actual bicarbonate <= 26 mmol/L: omit treatment that day.
118794|NCT01495026|Drug|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
118795|NCT00001288|Drug|FDG|
118796|NCT00072566|Other|Laboratory Biomarker Analysis|Correlative studies
118797|NCT01495026|Drug|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
118798|NCT01495026|Drug|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
118799|NCT01495039|Drug|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
118800|NCT01495052|Dietary Supplement|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
118801|NCT01495065|Drug|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
118120|NCT00073385|Drug|Docetaxel|
118121|NCT01500889|Procedure|GroupII: V-Y advancement flap|GroupII: V-Y advancement flap:
The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide.
118122|NCT01500889|Procedure|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
118123|NCT01500902|Other|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
118124|NCT01500902|Other|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
118125|NCT01500915|Drug|Ranibizumab|0,5mg intravitreal ranibizumab
118126|NCT01500928|Device|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
118127|NCT01500941|Dietary Supplement|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
118128|NCT01500941|Other|maltodextrin|sachets
118129|NCT01502761|Drug|Magnesium Sulfate|Intra-arterial
118130|NCT01502774|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
118131|NCT01502774|Drug|Placebo|One single intravenous bolus injection of Placebo
118132|NCT01502774|Procedure|Echocardiography|1 year and 3 years after AMI
118133|NCT00073658|Drug|Risperidone|
118134|NCT01502787|Drug|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
118135|NCT01502787|Drug|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
118136|NCT01502787|Procedure|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
117406|NCT01503528|Procedure|Femoral and sciatic nerve blocks|Continuous femoral (20mL of 0.2% ropivacaine as the initial bolus) and sciatic (10 mL of 0.1% ropivacaine as initial bolus) nerve blocks will be initiated in the preoperatively and continued for 48 hours. This group will receive spinal anesthetic with 15 mg of hyperbaric bupivacaine. This group will not receive peri-articular infiltration. The femoral block will be patient controlled regional analgesia with 0.13%-0.2% ropivacaine, basal rate 5mL/h and patient controlled bolus of 5 mL every hour as needed. The sciatic infusion will be 4mL/hour as continuous infusion. Nurse administered boluses of 10mL of the corresponding solution will be allowed for breakthrough pain. The blocks will be held at 6AM on Postoperative day 2. In the event of inadequate analgesia, and following block discontinuation the patients will receive oxycodone and oxycontin.
117407|NCT01503528|Procedure|Periarticular infusions|3 peri-articular catheters will inserted at the end of surgery following periarticular infiltration and wound infusions will be continued for 48 hrs using elastomeric infusion devices. They will receive spinal anesthetic with 15 mg of hyperbaric bupivacaine. They will receive oxycodone and oxycontin.
This group will also receive peri-articular infiltration with a mixture of ropivacaine (300mg), ketorolac 30 mg, morphine 10 mg and epinephrine 2.5mcg/mL in 110mL.
117408|NCT01503541|Genetic|DNA analysis|
117409|NCT01503541|Genetic|RNA analysis|
117410|NCT00073710|Procedure|42 Ca carbonate absorption via single tracer method|
117411|NCT01503541|Genetic|gene expression analysis|
117412|NCT01503541|Genetic|mutation analysis|
117413|NCT01503541|Genetic|polymerase chain reaction|
117414|NCT01503541|Other|laboratory biomarker analysis|
117695|NCT01506531|Procedure|Primary closure for gastroschisis|primary closure for gastroschisis if possible
117696|NCT01506544|Drug|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
117697|NCT01506557|Dietary Supplement|cholecalciferol|dose 800 IU/day for 6 month
117698|NCT01506557|Dietary Supplement|placebo|oil capsules
117699|NCT00073944|Drug|forodesine hydrochloride|
117700|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10^3 plaque-forming unit [PFU] of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
117701|NCT01500239|Drug|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
117702|NCT01500239|Drug|Metronidazole|500 mg of Metronidazole
117703|NCT01500239|Drug|Meropenem|1 gram of Meropenem
117704|NCT00073307|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
117184|NCT01480362|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
117185|NCT01480375|Device|Navigo system|The NaviGo workstation is used as an adjunct to the ultrasound imaging and biopsy procedures of the prostate gland. When operated in conjunction with the standard equipment in a TRUS guided prostate biopsy procedure, the NaviGo™ software may be used for the following:
To assist the physician by transfer and display of ultrasound images on the workstation screen;
Build display and manipulate a 3D model of the prostate on screen;
Archiving the ultrasound images and the 3D model;
Providing data management solutions;
Tracking, displaying and recording of the biopsy needle trajectory location in real time.
117186|NCT01480388|Drug|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
117187|NCT01480388|Drug|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
117188|NCT01480388|Drug|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
117189|NCT01480388|Drug|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
117190|NCT01480388|Drug|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
117191|NCT01480401|Other|low-sodium diet (1500 mg daily)|
117192|NCT01480414|Biological|4times injection|bone marrow derived mono nuclear stem cell
117193|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
117194|NCT01480414|Biological|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
117195|NCT01480440|Device|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
117196|NCT01480453|Device|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
117197|NCT01482650|Device|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
117198|NCT01482663|Behavioral|Healthy Skin Clinic|The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).
Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.
Finally, a counselling consultation with a nurse, trained within dermatology.
117467|NCT01501760|Drug|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
117468|NCT00073528|Drug|Lapatinib (GW572016)|1500 mg orally once a day
118802|NCT01495065|Drug|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
118803|NCT01495065|Drug|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
118804|NCT01495065|Drug|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
118805|NCT01495065|Drug|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
118806|NCT01495065|Drug|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
118807|NCT00072579|Biological|sargramostim|
118808|NCT01495078|Procedure|Telemonitoring|Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.
Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses.
118809|NCT01495104|Drug|RO4917838|Multiple doses
118810|NCT01497470|Drug|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
118811|NCT01497483|Drug|Pravastatin alone|Pravastatin 40 mg with placebo.
118812|NCT01497483|Drug|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
118813|NCT01497496|Drug|High Dose Methylprednisolone (HDMP)|1000 mg/m^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
119043|NCT01495494|Device|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
119044|NCT01495494|Device|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
119045|NCT01495507|Procedure|MPFL- Reconstruction|
119046|NCT01495520|Drug|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
119047|NCT01495520|Drug|Placebo|os, pill, b.i.d., 30 days
119048|NCT01495533|Device|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
119049|NCT01495533|Device|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
117253|NCT00073697|Behavioral|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
117254|NCT01503268|Procedure|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
117255|NCT01503268|Procedure|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
117256|NCT01503281|Other|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
117257|NCT01503320|Dietary Supplement|Enteral glutamine|Dosage of glutamine: 0.57g/kg, ~ 30g/day= 3sachets
117258|NCT01505569|Drug|Etoposide|Arms A&B: 100 mg/m^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.
Arm C: 400 mg/m^2 daily on days -4, -3, and -2 every 21 days
117259|NCT01505569|Drug|Mesna|Arms A&B: 1.8 g/m^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.
Arm C: 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles
117260|NCT01505569|Biological|G-CSF|Arms A&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (>) 1,000/mm^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3.
Arm C: 10 μg/kg subcutaneously daily beginning 6 hours after completion of ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first.
117261|NCT01505569|Drug|Busulfan|Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6
117262|NCT01505569|Drug|Melphalan|Arm A: 50 mg/m^2 intravenously (IV) over 30 min on Days -4 and -5
117263|NCT01505569|Drug|Thiotepa|Arm A: 250 mg/m^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2
117264|NCT01505569|Biological|Autologous stem cell infusion|Arms A, B & C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
117265|NCT01505569|Radiation|Radiation|Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.
Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive "spot" irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose.
117266|NCT00073879|Procedure|peripheral blood stem cell transplantation|
117267|NCT01505569|Drug|Carboplatin|Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days
117268|NCT01505569|Drug|Paclitaxel|Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
117705|NCT01500252|Device|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
117706|NCT01500252|Device|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
117707|NCT01500265|Biological|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
117708|NCT01500278|Biological|Certolizumab Pegol (CZP)|Active substance: an injectable volume of 1 ml solution for injection CZP
Pharmaceutical form: prefilled syringes CZP
Concentration: 200 mg/ml CZP
Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal.
117709|NCT01500278|Biological|Adalimumab (ADA)|Active substance: an injectable volume of 0.8 ml solution for injection ADA
Pharmaceutical form: prefilled syringes ADA
Concentration: 40 mg/0.8 ml ADA
Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal.
117710|NCT01500278|Drug|Methotrexate (MTX)|Active substance: Methotrexate
Pharmaceutical form: oral tablet
Concentration: 15-25 mg/week
Route of Administration: MTX orally
117711|NCT01500291|Other|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
117712|NCT01500304|Procedure|Minimally invasive inguinal lymph node dissection|
117713|NCT01500317|Drug|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
117714|NCT01500317|Drug|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
117984|NCT01504581|Biological|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
117985|NCT01504581|Biological|HM10660A placebo|Single dose of HM10660A Placebo
117986|NCT01504581|Biological|Pegasys|Single dose of Pegasys 180ug
117987|NCT01504594|Procedure|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
117988|NCT01504607|Procedure|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
117989|NCT01504620|Other|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
117990|NCT00001304|Drug|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
117991|NCT00073827|Drug|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
117469|NCT01501760|Drug|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
117470|NCT01501773|Biological|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
117471|NCT01501786|Drug|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
117472|NCT01501786|Drug|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
117473|NCT01501786|Drug|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
117474|NCT01501799|Drug|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
117475|NCT01501799|Drug|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
117476|NCT01501799|Drug|Placebo (Vehicle Gel)|Vehicle Gel
117477|NCT01501812|Behavioral|Generalization pattern|During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound ("metal scratch") will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones ("neutral" and "aversive") before and after the conditioning, and after extinction phase. The generalization will also be measured by the "generalization curve" that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new
117478|NCT01501825|Device|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
117479|NCT00073528|Drug|Letrozole|2.5 mg orally once a day
117480|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
117481|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
117482|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
117483|NCT01503619|Other|laboratory biomarker analysis|Correlative studies
117484|NCT01503632|Behavioral|behavioral intervention|Receive intervention program
117485|NCT01503632|Drug|mercaptopurine|Given orally
117486|NCT01503632|Procedure|standard follow-up care|Receive usual standard of care
117487|NCT01503632|Behavioral|compliance monitoring|Correlative studies
119050|NCT01495546|Other|Early loading|Patients stepping down immediately after THA
119051|NCT01495546|Other|Late loading|Patients stepping down after three weeks of HTA
119052|NCT00072657|Behavioral|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
119053|NCT01495572|Drug|Fludarabine|25 mg/m^2 IV (in the vein) for 5 days (day -5 to -1)
119054|NCT01495572|Drug|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
119055|NCT01495572|Drug|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
119056|NCT01495572|Drug|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
119057|NCT01498081|Drug|Indacaterol|Indacaterol administered via inhalation
119058|NCT01498081|Drug|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
119059|NCT01498094|Procedure|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
119060|NCT01498094|Other|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
119061|NCT01498107|Behavioral|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
119062|NCT01498120|Drug|Rotigotine|Optimal dose after titration period
0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)
1 patch /day
119393|NCT01496001|Procedure|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
119394|NCT00072735|Procedure|Electrocardiogram|
119395|NCT01496001|Other|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
119396|NCT01496040|Drug|rAAV2/4.hRPE65|One injection in on eye
Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP
Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.
Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP.
119397|NCT01496053|Dietary Supplement|AndoSan|AndoSan 30 ml x 2 for 21 days
119398|NCT01496053|Dietary Supplement|Sugar Extract|Sham comparator
117269|NCT01505569|Procedure|Leukapheresis|Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
117550|NCT01500109|Drug|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
117551|NCT01500109|Drug|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
117552|NCT01501825|Device|five channels Multiway deep Transcranial Magnetic Stimulation|During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.
10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
1 Hz protocol:
1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)
117553|NCT01501864|Behavioral|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
117554|NCT01501877|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
117555|NCT01501877|Behavioral|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
117556|NCT01501890|Drug|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
117557|NCT01501890|Drug|Placebo|0.9% NaCl
117558|NCT01501903|Procedure|Standard|FNA in a single plane
117559|NCT01501903|Procedure|Fanning|FNA in multiple planes
117560|NCT01501916|Dietary Supplement|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
117561|NCT01501916|Dietary Supplement|Placebo|daily intake of placebo
117562|NCT00073541|Drug|EMD 72000|
117563|NCT01501929|Drug|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
117992|NCT01504620|Drug|insulin infusion|i.v. infusion of insulin
117993|NCT01504633|Dietary Supplement|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
117994|NCT01504646|Dietary Supplement|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
117995|NCT01504646|Dietary Supplement|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
117996|NCT01504659|Drug|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
117997|NCT01504659|Drug|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
117998|NCT01504672|Other|Medication review|In the intervention, the pharmacist will evaluate:
Is there an indication for the drug?
Has the drug desired effect?
Is the dose correct and dosing scheme correct?
Side effects, contraindications, inappropriate drugs
Interactions
Treatment time
Cost effectiveness
Adherence to recommendation list
Problems with handling the drugs (for example crushing of the tablets)
Untreated indication
Double medications
Administration of drugs
117999|NCT01506895|Drug|placebo|Placebo to match
118000|NCT01506908|Drug|oral nicotine|oral nicotine replacement product
117123|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
117124|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
117125|NCT01482624|Device|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
117126|NCT01482624|Procedure|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
117127|NCT01482637|Other|CAS|All clients will be asked to complete the CAS instrument.
117128|NCT00071669|Procedure|Acupuncture|
117768|NCT01506791|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
117769|NCT01506804|Other|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
117770|NCT01506817|Procedure|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
117771|NCT01506830|Procedure|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
117772|NCT01506830|Procedure|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
117773|NCT01506843|Biological|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
117774|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
117775|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
117776|NCT01506882|Drug|Levetiracetam (LEV)|Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: LEV 250 mg, LEV 500 mg
Frequency: Twice daily
Route of Administration: Oral use
117777|NCT01506895|Drug|darapladib|Experimental compound 160 mg dose
117778|NCT00001305|Drug|Nutropin|
117779|NCT00073957|Drug|methotrexate|
117780|NCT01500369|Other|sphygmomanometer cuff inflations|: Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this "pre-conditioning" phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes.
117781|NCT01500369|Other|standard of care|Placebo Comparator
117782|NCT01500382|Drug|MK-4618|Tablet, 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
117783|NCT00073320|Drug|Paliperidone Palmitate|
119399|NCT01496092|Drug|Keto Acid|12 tablets per day
119400|NCT01496105|Drug|Lidocaine|
119401|NCT01496105|Drug|saline|
119402|NCT01496118|Drug|carfilzomib and panobinostat|Cohort 1 (Dose Level 4): Carfilzomib Cycle 1: 20 mg/m2 IV D1, 2 / 45 mg/m2 IV D8, 9, 15, 16; Carfilzomib Cycle 2 to progression: 45 mg/m2 IV D 1, 2, 8, 9, 15, 16;
Panobinostat cycle 1: 30 mg D 1, 3, 5, 15, 17, 19; Panobinostat cycle 2 to progression: 30 mg D 1, 3, 5, 15, 17, 19
Cohort 2 (Dose Level 6): Carfilzomib Cycle 1: 20 mg/m2 IV D1, 2 / 56 mg/m2 IV D8, 9, 15, 16; Carfilzomib Cycle 2: 56 mg/m2 IV D 1, 2, 8, 9, 15, 16;
Panobinostat all cycles: 20 mg D 1, 3, 5, 15, 17, 19.
119403|NCT01496131|Radiation|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
119404|NCT01496131|Drug|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
119405|NCT00072748|Drug|EKB-569|
119406|NCT01496131|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
119407|NCT01496131|Drug|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
119408|NCT01496144|Procedure|Manual therapy and active exercises|Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.
Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises
119409|NCT01496144|Procedure|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
119410|NCT01496157|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) [9-11 mCi (333-407 MBq)] of 18F-DCFBC will be injected into the IV line by slow IV push.
119411|NCT01496170|Drug|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
118520|NCT01499485|Drug|Placebo|Daily morning ABGA:
If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of placebo.
If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of placebo.
If actual bicarbonate <= 26 mmol/L: omit treatment that day.
118521|NCT01494636|Drug|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
118522|NCT01494636|Drug|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
117564|NCT01501929|Drug|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
117565|NCT01501929|Drug|Hydrochlorothiazide|During the washout period between the two treatments, subjects will be followed after 2 weeks of drug withdrawal. Hydrochlorothiazide (HCTZ) 25 mg once daily will be started in subjects found to have BP > 140/90 mmHg and continued for a 2 week period. The subjects will return in 2 weeks, and at that time HCTZ will be stopped if started in the earlier visit. The subject will then be switched to the remaining treatment (Nebivolol or Metoprolol).
117833|NCT01506271|Drug|Matching placebo to MK-7655|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
117834|NCT01506284|Procedure|Forced oscillatory technique (FOT) and laser interferometry (LIR).|FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.
LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient.
117835|NCT01506310|Behavioral|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
117836|NCT01506310|Other|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
117837|NCT01506310|Other|Behavioral therapy and exercise|General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.
Written recommendations for physical activity A brief written guide on behavior change
117838|NCT01506323|Behavioral|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
117839|NCT00073931|Procedure|autologous bone marrow transplantation|autologous stem cells given via central catheter
117840|NCT01506323|Behavioral|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
117841|NCT01506336|Drug|masitinib|masitinib 12 mg/kg/day
117842|NCT01506336|Drug|sunitinib|sunitinib 50 mg/day
117843|NCT01506349|Dietary Supplement|gluten|4 grams of gluten.
117129|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
117130|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of high dose of stem cells
117131|NCT01484574|Other|Standard protocol of care|Standard protocol of care alone
117132|NCT01484587|Drug|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
117133|NCT01484587|Drug|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
117134|NCT01484600|Drug|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
117135|NCT01484600|Drug|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
117136|NCT01484613|Device|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
117137|NCT01484626|Drug|Bendamustine|The first group of 3 patients to enter the study will receive a 25 mg/m2 dose of Bendamustine. If this dose is found to be safe, the next 3 patients will receive 50 mg/m2. The dose will continue to increase until the highest safe dose of Bendamustine is found. Bendamustine and Bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and Lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
117138|NCT01484626|Drug|Bortezomib|Bortezomib will be given through a catheter twice a week every 21 days.
117139|NCT00071942|Procedure|quality-of-life assessment|Ancillary studies
117140|NCT01484626|Drug|Lenalidomide|Lenalidomide will be given orally taken as instructed by the physician.
117141|NCT01484626|Drug|Dexamethasone|Dexamethasone will be given orally as instructed by the physician.
117142|NCT01484639|Other|Liberal transfusion triggers|Patients allocated to a "liberal" transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward.
117415|NCT01503554|Behavioral|Combined Social Worker and Pharmacist Program|Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.
Pharmacist will be available to patients should they have any medication-related questions post-discharge
117416|NCT01503554|Behavioral|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
117417|NCT01503567|Other|No treatment given|Subject will only fill out a questionaire
117784|NCT01500382|Drug|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
118065|NCT01502709|Device|Placebo|placebo
118066|NCT01502722|Behavioral|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
118067|NCT01502735|Biological|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
118068|NCT01502735|Biological|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
118069|NCT01502748|Other|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
118070|NCT01504685|Procedure|Banded Laparoscopic Roux-en-Y gastric bypass|A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.
The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively.
118071|NCT01504685|Procedure|Unbanded Laparoscopic Roux- en-Y gastric bypass|A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.
To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively.
118072|NCT01504698|Procedure|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
118073|NCT00073827|Drug|racemic albuterol MDI|racemic albuterol 180 mcg QID
118074|NCT01504698|Procedure|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
118075|NCT01504711|Drug|fosaprepitant dimeglumine|Given IV
118076|NCT01504724|Drug|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
118077|NCT01504737|Other|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
118078|NCT01504737|Other|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
118523|NCT01494636|Drug|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
118524|NCT01494649|Drug|Test Toothpaste|0.454% stannous fluoride toothpaste
118525|NCT01494649|Drug|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
118526|NCT01494662|Drug|HKI-272|240 mg orally, once daily
118527|NCT01494662|Drug|HKI-272|240 mg orally, once daily
118528|NCT00072553|Drug|leucovorin calcium|
118529|NCT01494662|Procedure|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
118530|NCT01494662|Drug|Capecitabine|
118531|NCT01494675|Other|procalcitonin measurement|The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.
The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as " antibiotic discontinuation overruling"
118532|NCT01494688|Drug|RO5509554|Multiple ascending doses
118533|NCT01494688|Drug|RO5509554|Multiple doses
118534|NCT01494688|Drug|paclitaxel|standard chemotherapy
118535|NCT01494701|Drug|ISIS-SMNRx|Single intrathecal injection
118536|NCT01494714|Drug|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
118537|NCT01494714|Drug|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
118538|NCT01494714|Drug|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
118539|NCT00072553|Drug|oxaliplatin|
118814|NCT01497496|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
118815|NCT01497496|Drug|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
117844|NCT01506349|Dietary Supplement|Placebo|
117845|NCT01506362|Drug|BL-7040|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.
BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days.
117846|NCT01506375|Biological|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
117847|NCT01506375|Biological|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
118137|NCT01502787|Procedure|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
118138|NCT01502787|Procedure|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
118139|NCT01502787|Procedure|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
118140|NCT01502787|Drug|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
118141|NCT01502800|Drug|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
118142|NCT01502800|Drug|ARQ 761 Weekly Administration|If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)
You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.
The beginning dose level will be 390 mg/m2.
118143|NCT01502800|Drug|Bi-Weekly Administration of ARQ 761|If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)
You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.
The beginning dose level will be 390 mg/m2.
117418|NCT01503580|Drug|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
117419|NCT01503593|Device|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
117420|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
117421|NCT00073710|Drug|Calcijex|
117422|NCT01505764|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 84 days, at least 1 hour before the first meal of the day.
117423|NCT01505777|Drug|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
117424|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
117425|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
117426|NCT01505777|Drug|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
117427|NCT01505777|Drug|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
117428|NCT01505790|Drug|PRASUGREL|60 mg the first day then 10 mg per day during one month
117429|NCT01505790|Drug|Clopidogrel|600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP <50%. No more than 3 * 600mg of clopidogrel will be authorized in this protocol.
Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least.
117430|NCT01505803|Dietary Supplement|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
117431|NCT01505803|Dietary Supplement|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
117432|NCT00073918|Drug|etoposide|Given IV
117433|NCT01505803|Dietary Supplement|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
117434|NCT01505816|Device|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
117715|NCT00001300|Drug|ifosfamide|
117716|NCT00073307|Drug|Placebo|Placebo
117717|NCT01500317|Drug|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
118079|NCT01504750|Procedure|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
117199|NCT01482689|Dietary Supplement|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
117200|NCT01482689|Dietary Supplement|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
117201|NCT01482702|Behavioral|weight loss intervention|Behavioral weight loss intervention
117202|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
117203|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
117204|NCT01482715|Drug|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
117205|NCT01482728|Drug|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
117206|NCT01482728|Drug|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
117207|NCT00071695|Drug|Duloxetine Hydrochloride|
117208|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
118816|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
118817|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
118818|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
118819|NCT00072904|Drug|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
118820|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
118821|NCT01497509|Drug|No epidural fentanyl or bupivacaine|
118822|NCT01497522|Drug|Vildagliptin|vildagliptin 50 mg twice daily
118823|NCT01497522|Drug|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
118824|NCT01497535|Drug|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
118825|NCT01497535|Drug|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
118826|NCT01497548|Drug|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
118827|NCT01497548|Drug|Placebo|Placebo given on morning (0800) and noon (1200)daily
118828|NCT01497561|Drug|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
118829|NCT01497561|Drug|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
118830|NCT00072904|Drug|Repaglinide|0.5mg tab with meals tid
118831|NCT01497574|Drug|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
119063|NCT01498133|Procedure|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
118144|NCT01504789|Behavioral|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
118145|NCT01504789|Behavioral|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
118146|NCT01504815|Drug|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
118147|NCT01504815|Radiation|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
118148|NCT01504815|Radiation|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
117270|NCT01505582|Other|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
117271|NCT01505582|Other|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
117272|NCT01505595|Other|Proprioceptive training|12 weeks
117273|NCT01505595|Other|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
117274|NCT01505608|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
117275|NCT01505608|Drug|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
117276|NCT01505608|Drug|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
117277|NCT00073892|Drug|PI-88|
117278|NCT01499498|Drug|Sildenafil and Boceprevir|25mg once/800mg three times a day
117279|NCT01499537|Device|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
117280|NCT00073203|Drug|Placebo and Paroxetine|
117281|NCT01499537|Device|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
117282|NCT01499550|Device|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
117718|NCT01500330|Procedure|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
117719|NCT01500330|Procedure|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
117720|NCT01500343|Drug|Saccharomyces boulardii|1 gram per day, during 3 months
117721|NCT01500356|Behavioral|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
117722|NCT01500356|Behavioral|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
117723|NCT01500356|Behavioral|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
117724|NCT01502007|Other|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
117725|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
117726|NCT00073580|Drug|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) >300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
117727|NCT01502020|Drug|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
117728|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
117729|NCT01502033|Device|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
117730|NCT01502046|Drug|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
118001|NCT01506908|Drug|Placebo|no active
117209|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
117210|NCT01484730|Device|Multi-Spectral & Laser Speckle Imaging|Changes in skin tissue and blood flow.
117211|NCT01484743|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
117488|NCT01503632|Other|questionnaire administration|Ancillary studies
117489|NCT01503632|Other|laboratory biomarker analysis|Correlative studies
117490|NCT00073723|Drug|ABI-007|
117491|NCT01503658|Drug|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
117492|NCT01503671|Drug|Atorvastatin|Atorvastatin 40 mg/day
117493|NCT01503684|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
117494|NCT01503723|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
117495|NCT01503736|Drug|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
117496|NCT01503736|Drug|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
117497|NCT01503736|Drug|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
117498|NCT01503749|Drug|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
117499|NCT01503749|Other|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
117500|NCT01503762|Other|Mirror therapy|mirror therapy
117501|NCT00073736|Drug|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
117502|NCT01503762|Other|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
119064|NCT01498159|Behavioral|Pharmacist disease/medication management|
119065|NCT01498159|Behavioral|Pharmacist-patient encounters|
119066|NCT01498159|Behavioral|Pharmacist medication intensification and adherence support|
119067|NCT00001296|Procedure|hyperthermic isolated limb perfusion|
119068|NCT00072982|Drug|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
119069|NCT01498159|Behavioral|Pharmacist communication with primary care physicians|
119070|NCT01498159|Behavioral|Pharmacist documentation in electronic medical record|
119071|NCT01498159|Behavioral|Health promoter-patient encounters in-person or by phone|
119072|NCT01498159|Behavioral|Health promoter medication and lifestyle support|
119073|NCT01498159|Behavioral|Health promoter communication with pharmacists|
119074|NCT01498172|Biological|MAGE-A3 ASCI|5 doses every 3 weeks
119075|NCT01498172|Biological|BCG|1 intravesical dose /week for 6 weeks
119076|NCT01498185|Drug|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
119077|NCT01498185|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
119078|NCT01498198|Procedure|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
119079|NCT00072995|Behavioral|Four Diets Differing in Macronutrient Composition|
119080|NCT01498198|Other|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
119081|NCT00072319|Procedure|adjuvant therapy|
119082|NCT01490762|Drug|Regular Human Insulin|Subcutaneous injection
119083|NCT01490775|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
119084|NCT01490775|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
117283|NCT01499550|Other|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
117284|NCT01499563|Drug|ITI-007|Capsules containing ITI-007 for 28 days
117285|NCT01499563|Drug|Placebo|Capsules containing inactive placebo for 28 days
117286|NCT01499563|Drug|Risperidone|Capsules containing risperidone for 28 days
117287|NCT01499576|Procedure|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
117288|NCT01499589|Procedure|regional anesthesia|regional anesthesia procedure
117289|NCT01499602|Drug|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
117290|NCT01499602|Drug|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
117566|NCT01501929|Drug|DEFINITY®|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with the aid of a Vialmix®, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
117567|NCT01501929|Procedure|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
117568|NCT01501929|Procedure|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
117569|NCT01503814|Other|Simplified cardiovascular disease management|This study is a complex pragmatic trial.The intervention includes a "package" of 4 main established measures for cardiovascular prevention and management:
2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption
2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)
117570|NCT01503827|Radiation|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
117571|NCT01503840|Drug|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
117572|NCT01503840|Drug|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
117573|NCT01503866|Drug|bardoxolone methyl|oral, single dose
118002|NCT01506921|Drug|Racemic ketamine|0.6 mg/kg
118003|NCT01506921|Drug|S-ketamine|0.3 mg/kg
118004|NCT01506934|Drug|linifanib|Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)
Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)
118005|NCT01506947|Drug|Paricalcitol|Paricalcitol will be administered by intravenous route, and will be initiated in patients with a intact parathyroid hormone (iPTH) level >500 pg/mL, and the starting dose will be calculated according to the following formula; paricalcitol (µg) for each dialysis session= intact parathyroid hormone (iPTH) (pg/mL)/120.
118006|NCT01506960|Device|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
118007|NCT01506973|Drug|Hydroxychloroquine (HCQ)|
118008|NCT01506973|Drug|Gemcitabine|
118009|NCT00073957|Radiation|yttrium Y 90 ibritumomab tiuxetan|
118010|NCT01506986|Drug|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
118011|NCT01506986|Drug|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
118012|NCT01506999|Biological|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
118013|NCT01507012|Dietary Supplement|Berry Polyphenols|
118014|NCT01507012|Dietary Supplement|Placebo|Placebo control containing sugar and artificial flavouring.
118015|NCT01507038|Drug|YH14617|1mg once weekly
118016|NCT01507038|Drug|YH14617|1.6mg once weekly
118017|NCT01507038|Drug|YH14617|2mg once biweekly
118018|NCT01507038|Drug|Placebo|Once weekly
118019|NCT01507051|Drug|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
118020|NCT00073970|Drug|celecoxib|400mg, given twice daily
118021|NCT01507051|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
118022|NCT01507051|Drug|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
117503|NCT01503788|Drug|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
117504|NCT01503801|Drug|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
117505|NCT01503801|Device|respiratory support|Routine respiratory support.
117506|NCT01505881|Drug|warfarin 3mg|comparator warfarin
117507|NCT01505894|Drug|BI 409306|High dose film-coated tablet
117508|NCT01505894|Drug|BI 409306 Placebo|Placebo film-coated tablet
117509|NCT01505894|Drug|BI 409306|Low dose film-coated tablet
117510|NCT01505894|Drug|BI 409306|Medium dose film-coated tablet
117785|NCT01500382|Drug|MK-1468 and Tolterodine ER|Co-administration of MK-4618 (Tablet, 100 mg, once daily, for up to 10 days) and Tolterodine ER (Capsule, 4 mg, once daily, for up to 10 days)
117786|NCT01500382|Other|Placebo (MK-4618)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
117787|NCT01500382|Other|Placebo (Tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
117788|NCT01500382|Drug|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
117789|NCT01500395|Procedure|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
117790|NCT01500408|Drug|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
117791|NCT01500408|Drug|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
117792|NCT01500421|Device|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
117793|NCT01500421|Device|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
117794|NCT00073333|Behavioral|Social Skills Training|Social skills training once per week
119412|NCT01496170|Drug|Placebo|Placebo capsules, orally, once per day for 7 days
119413|NCT01489215|Behavioral|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
119414|NCT01489228|Drug|E1224|100 mg tablets
119415|NCT01489228|Drug|Benznidazole|100mg tablets
119416|NCT01489228|Drug|Placebo|tablets
119417|NCT01489241|Procedure|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
119418|NCT01489254|Drug|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
119419|NCT00072215|Drug|ifosfamide|given IV
119420|NCT01489254|Drug|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
119421|NCT01489254|Drug|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
119422|NCT01489267|Other|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10`7 cells).
119423|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
119424|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
119425|NCT01489319|Drug|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
119426|NCT01489319|Drug|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
119427|NCT01489332|Drug|intensified preoperative chemotherapy|capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).
Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery
117574|NCT01503892|Dietary Supplement|Metanx|Metanx- one tablet twice daily for twelve months
117575|NCT00001304|Drug|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
117576|NCT00073736|Drug|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
117577|NCT01503892|Drug|Placebo|Placebo- one tablet twice daily for twelve months.
117578|NCT01503905|Drug|Docetaxel|75mg/m2, iv injection, day1, every 21 days
117579|NCT01503905|Drug|epirubicin|80mg/ m2, iv injection, day1, every 21 days
117580|NCT01503905|Drug|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
117581|NCT01503905|Procedure|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
117582|NCT01503905|Drug|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
117583|NCT01503905|Drug|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
117848|NCT01506388|Device|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
117849|NCT01506388|Drug|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
117850|NCT00073931|Procedure|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
117851|NCT01500434|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
117852|NCT01500473|Drug|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
117853|NCT01500486|Device|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
117854|NCT01500499|Genetic|gene expression analysis|
117855|NCT01500499|Genetic|gene rearrangement analysis|
117856|NCT01500499|Genetic|polymerase chain reaction|
117857|NCT01500499|Genetic|protein analysis|
118023|NCT01507051|Drug|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
117143|NCT01484639|Other|Restrictive transfusion triggers|Patients allocated to a "restrictive" transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively.
117144|NCT01484652|Drug|COV795|2 tablets taken every 12 hours
117145|NCT01484652|Drug|Placebo|2 tablets taken every 12 hours
117146|NCT01484665|Other|PROCASE Decision-Aid|VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled "The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study.
117147|NCT01484691|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
117148|NCT01484717|Behavioral|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
117149|NCT01484717|Drug|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)].
117150|NCT00071955|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
117151|NCT01484717|Behavioral|Telephone counseling|Participants receive brief twice weekly telephone counseling.
117152|NCT01487447|Other|Regular Masker|treatment with white noise
117153|NCT01487460|Drug|TAP311|
117154|NCT01487473|Behavioral|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
117155|NCT01487486|Drug|IVF Antagonist Protocol|Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.
Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle >14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection
hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval.
117156|NCT01487499|Drug|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
117157|NCT01487512|Drug|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
117158|NCT00001267|Drug|zidovudine|
117159|NCT00072085|Biological|incomplete Freund's adjuvant|
117795|NCT01500421|Device|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
117796|NCT01500434|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
117797|NCT01500434|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
117798|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
117799|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
117800|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
117801|NCT01502150|Other|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
118080|NCT01504763|Procedure|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
118081|NCT01504776|Drug|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
118082|NCT01504776|Drug|Bortezomib|
118083|NCT01504789|Behavioral|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
118084|NCT00073827|Drug|Placebo|Placebo MDI QID
118085|NCT01504789|Behavioral|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
118086|NCT01498627|Biological|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
118087|NCT01498627|Other|Data collection|PGRx information system
118088|NCT01498640|Biological|Collagenase clostridium histolyticum|up to three 0.58 mg injections
118089|NCT01498653|Drug|GW685698/GW642444|ICS/LABA
119428|NCT01489345|Drug|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
119429|NCT01489345|Drug|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
118263|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
118264|NCT01499004|Drug|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
118265|NCT01499017|Drug|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
118266|NCT01499017|Drug|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
118267|NCT01499043|Drug|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
118268|NCT01499056|Biological|stem cell injection|intra articular inection of mesenchymal stem cell
118269|NCT01499069|Drug|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .
Duration; 3 or 6 months
118270|NCT01501097|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
118271|NCT01501110|Drug|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
118272|NCT01501123|Drug|Haloperidol|5mg IM
118273|NCT01501123|Drug|Midazolam|
118274|NCT01501136|Other|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
118275|NCT00073411|Drug|escitalopram|
118276|NCT01501136|Other|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
118277|NCT01501136|Other|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
117858|NCT00073333|Behavioral|Exposure Treatment|Exposure once per week
117859|NCT01500499|Genetic|western blotting|
117860|NCT01500499|Other|laboratory biomarker analysis|
117861|NCT01500499|Other|mass spectrometry|
117862|NCT01500512|Other|Clinical Observation|Undergo observation
117863|NCT01500512|Procedure|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node dissection
117864|NCT01500512|Procedure|Therapeutic Conventional Surgery|Undergo surgery
117865|NCT01500512|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
117866|NCT01500512|Radiation|Selective External Radiation Therapy|Undergo radiation therapy
117867|NCT01500538|Drug|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
117868|NCT01500551|Drug|CP-690,550|Dosing Scheme in Patients Completing Index Study A3921103:
CP 690,550 will be administered orally twice daily 12 hours apart, based on body weight as provided below.
Oral tablets will be used for patients weighing ≥30 kg. Oral solution will be used for patients weighing <30 kg.
Body Weight (Dose in tablet [mg BID] or solution [ml BID]):
5-6kg (1mg or 1 ml); 7-9kg (1.5mg or 1.5ml); 10-12kg (2mg or 2ml); 13-15kg (2.5mg or 2.5 ml); 16-19kg (3mg or 3ml); 20-22kg (3.5mg or 3.5ml); 23-26 (4mg or 4 ml); 27-29 kg (4.5mg or 4.5ml); 30 kg (5mg or 5ml).
118149|NCT01504828|Drug|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
118150|NCT01504841|Drug|Etravirine (ETR)|ETR will be administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children will take the specified dose orally twice daily within 30 minutes following a meal. Dose will be decided according to dosing tables in protocol.
118151|NCT01504854|Drug|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
118152|NCT01504854|Drug|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
118153|NCT00073840|Drug|levalbuterol|Levalbuterol 90 ųg QID (manufacturing sites A or B);
Racemic Albuterol 180 ųg QID;
Placebo QID
118154|NCT01504867|Drug|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
118155|NCT01504867|Drug|Lactose powder|Matching Lactulose powder filled capsules will be administered on days 1-7.
117160|NCT01487512|Drug|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
117161|NCT01487512|Drug|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
117435|NCT01505842|Procedure|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
117436|NCT01505842|Procedure|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
117437|NCT01505855|Drug|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
117438|NCT01505868|Drug|Cabazitaxel|25 mg/m² intravenously on Day 1 of each 3 week cycle.
Phase I Starting Dose: 20 mg/m2 intravenously on Day 1 of each 3 week cycle.
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
117439|NCT01505868|Drug|Prednisone|5 mg by mouth twice a day on day 1 of a 3 week cycle.
117440|NCT01505868|Drug|Carboplatin|Phase I Starting Dose: AUC 3 intravenously on Day 1 of each 3 week cycle.
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
117441|NCT01505881|Drug|dabigatran etexilate low dose|active treatment (low)
117442|NCT01505881|Drug|warfarin 5mg|comparator warfarin
117443|NCT00073918|Radiation|iodine I 131 tositumomab|Given IV
117444|NCT01505881|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
117445|NCT01505881|Drug|warfarin 1mg|comparator warfarin
117446|NCT01505881|Drug|dabigatran etexilate high dose|active treatment (high)
117447|NCT01499888|Procedure|Allogeneic Non-Myeloablative Stem Cell Transplantation|Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.
Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion
117448|NCT01499888|Drug|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
117449|NCT01499888|Drug|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
117450|NCT00073242|Behavioral|Dietary modification|Subjects lose 10% of body weight via dietary restriction
118090|NCT01498653|Drug|CCI18781|ICS
118091|NCT01498666|Dietary Supplement|L. reuteri protectis|1 tablet once daily for 4 weeks
118092|NCT00073047|Drug|Daclizumab|
118093|NCT01498666|Dietary Supplement|Placebo tablet|1 tablet once daily for 4 weeks
118094|NCT01498679|Drug|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
118095|NCT01498679|Drug|Placebo|Placebo administered once daily in the evening via a NDPI
118096|NCT01498692|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
118097|NCT01498705|Other|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
118098|NCT01498718|Biological|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
118099|NCT01498718|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
117212|NCT01484756|Dietary Supplement|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
117213|NCT01484756|Dietary Supplement|Placebo|calcium carbonate 500 mg
117214|NCT01484782|Behavioral|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
117215|NCT01484795|Device|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
117216|NCT01484795|Device|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
117217|NCT01484821|Device|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
117218|NCT01484834|Other|Exercise, Educational Intervention|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors
118278|NCT01501136|Other|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
118279|NCT01501136|Radiation|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
117378|NCT01501552|Other|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
117379|NCT01501552|Other|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
117380|NCT01501565|Procedure|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
117381|NCT00073502|Drug|OSI-7904L|
117382|NCT01501591|Drug|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
117383|NCT01501591|Other|Placebo|Matching placebo once on two different days, 72 hours apart.
117384|NCT01501591|Drug|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
117385|NCT01501604|Drug|BKM120|100 MG PO QD in cycles of 28 days
117386|NCT01501617|Biological|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
117387|NCT01501617|Device|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
117388|NCT01501630|Device|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
117389|NCT01501643|Device|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
117390|NCT01501643|Device|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
117391|NCT01501669|Drug|Irinotecan, Capecitabine|Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks
+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks
117392|NCT00000259|Drug|30% Nitrous oxide|
117393|NCT00001302|Drug|PSC 833|
118156|NCT01504893|Procedure|protective ventilation|Low tidal volume, PEEP and recruitment maneuver
118157|NCT01504906|Drug|cyclosporine|Oral tablets, 600 mg , single dose
118158|NCT01504906|Drug|ticagrelor|Oral tablets, 180 mg, single dose
118159|NCT01504919|Behavioral|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
118160|NCT01504919|Behavioral|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
118161|NCT01504919|Behavioral|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
118162|NCT01504919|Drug|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
118163|NCT01504932|Drug|lyophilized black raspberry lozenge|ARM I: Patients will be instructed to begin LBR administration and continue daily for 6 months.
118164|NCT00073853|Procedure|Autologous Incubated Macrophages (cell therapy)|
118165|NCT01498770|Drug|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
118166|NCT01498770|Drug|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
118167|NCT01498770|Drug|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
118168|NCT01498770|Drug|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
118169|NCT00073112|Drug|ABT-751|
117291|NCT00001300|Drug|doxorubicin|
117292|NCT00073216|Biological|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
117293|NCT01499615|Device|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
117294|NCT01499628|Behavioral|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
117295|NCT01499628|Behavioral|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
117296|NCT01499628|Behavioral|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
117451|NCT01499901|Procedure|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
117452|NCT01499901|Procedure|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
117453|NCT01499914|Biological|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
117454|NCT01499927|Other|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
117731|NCT01502046|Drug|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
117732|NCT01502059|Other|Pilates|Pilates training - twice a week (one hour per class) during 90 days
117733|NCT01502072|Drug|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
117734|NCT01502072|Drug|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
117735|NCT01502085|Drug|Vorinostat, Lenalinomide and Dexamethasone|Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21
* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert
Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above
117736|NCT01502098|Procedure|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
117737|NCT00073593|Drug|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) >300 seconds (s).
117738|NCT01502098|Other|Sling|Sling for 4 weeks
117739|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
117740|NCT01504139|Drug|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
117741|NCT01504139|Drug|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
117742|NCT01504152|Behavioral|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
117219|NCT00001261|Drug|Gamma Globulin|
117220|NCT00071955|Biological|sargramostim|
117221|NCT01484847|Drug|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
117222|NCT01484860|Drug|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
117223|NCT01484873|Drug|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
117224|NCT01484886|Other|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
117225|NCT01484886|Other|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
117226|NCT01484912|Drug|STA-2|After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:
STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
117227|NCT01484912|Drug|Placebo|After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:
Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
117228|NCT01484938|Device|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
117229|NCT01484951|Drug|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
117511|NCT01505907|Drug|CXB909|CXB909
117512|NCT01505920|Procedure|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
117513|NCT00073918|Procedure|quality-of-life assessment|Ancillary study
117514|NCT01505920|Procedure|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
117515|NCT01505933|Drug|Dexmedetomidine|Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.
After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate.
117516|NCT01505933|Drug|propofol|Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.
After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.
Image acquisitions will be repeated approximately 5 min after the increase in infusion rate.
117394|NCT00073515|Drug|Alfimeprase|
117395|NCT01501695|Drug|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
117396|NCT01501695|Drug|tiapride|dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.
Total duration:8 weeks.
117397|NCT01501695|Drug|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
117676|NCT01504139|Drug|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
117677|NCT01504139|Drug|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
117678|NCT01506388|Drug|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
117679|NCT01506401|Device|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
117680|NCT01506401|Procedure|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure < or = 35cmH20; Prescribed PEEP/FiO2 chart
117681|NCT01506414|Drug|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
117682|NCT01506427|Radiation|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
117683|NCT01506440|Procedure|cognitive assessment|Given cognitive assessments
117684|NCT01506440|Procedure|quality-of-life assessment|Ancillary studies
117685|NCT01506453|Drug|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
117686|NCT01506453|Drug|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
117687|NCT01506466|Other|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
117688|NCT00073931|Radiation|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with ~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
117297|NCT01499641|Drug|Methylprednisolone|Epidural methylprednisolone 40 mg or none
117298|NCT01499654|Drug|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
117299|NCT01499667|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
117300|NCT01499667|Drug|Placebo|Matching placebo in capsules for oral administration once daily.
117301|NCT01501487|Drug|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
117302|NCT01501487|Drug|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
117303|NCT01501487|Drug|T + trastuzumab followed by CEF + trastuzumab|Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.
Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr
117304|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).
Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
117305|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
117584|NCT01503905|Drug|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
117585|NCT01503905|Radiation|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
117586|NCT01503905|Drug|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
117587|NCT00073736|Drug|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
117588|NCT01503905|Drug|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
117743|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
117744|NCT00073749|Drug|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
117745|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
117746|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
117747|NCT01504165|Drug|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
117748|NCT01504165|Drug|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide > 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
118024|NCT01507064|Drug|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
118025|NCT01500668|Drug|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
118026|NCT00073359|Behavioral|Cognitive Behavioral Therapy|
118027|NCT01500668|Drug|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
118028|NCT01500681|Procedure|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
118029|NCT01500694|Drug|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
118030|NCT01500707|Drug|SCH 900800|SCH 900800, one 20 mg tablet, orally
118031|NCT01500720|Drug|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
118032|NCT01500720|Drug|Topotecan|Topotecan 1.5 mg/m^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
118033|NCT01500733|Drug|PCI 32765|420 mg daily
118034|NCT01500746|Procedure|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
118035|NCT01500746|Other|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
118036|NCT01500772|Drug|Alisporivir|Patients will take two DEB025 200mg capsules twice per day along with a body weight managed dosage of RBV twice per day with an injection of peg/IFN once per week.
117517|NCT01505946|Other|TGA (Thrombin generation Assay)|TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the "most effective". The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period
117518|NCT01505959|Device|CPAP treatment|Usual CPAP treatment
117519|NCT01505959|Device|CPAP treatment|CPAP treatment with telemedicine system
117520|NCT01505972|Other|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
117521|NCT01505972|Other|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
117522|NCT01505985|Dietary Supplement|Oral nutritional Supplement|Specialized nutritional supplement for seniors
117523|NCT01505985|Dietary Supplement|Placebo|placebo product with no specific nutrients
117524|NCT00001305|Other|Growth hormone|
117525|NCT00073918|Procedure|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
117526|NCT01505998|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
117527|NCT01506011|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
117528|NCT01506024|Procedure|Total hip arthroplasty direct lateral approach|
117529|NCT01506024|Procedure|Total hip arthroplasty posterior approach|
117530|NCT01500018|Drug|TC-5214|Single oral dose of 2 mg
117802|NCT01502150|Other|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
117803|NCT01502163|Device|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
117804|NCT01502163|Device|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
117805|NCT01502189|Other|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
117689|NCT01506479|Behavioral|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
117690|NCT01506479|Behavioral|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
117691|NCT01506479|Behavioral|No Intervention|No-exercise control (i.e., usual care);
117692|NCT01506492|Behavioral|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
117693|NCT01506505|Drug|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
117694|NCT01506531|Procedure|silo|silo placed around abdominal contents in gastroschisis patients
117965|NCT01502384|Other|neurological examination|motor and cognitive functions
117966|NCT01502410|Drug|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
117967|NCT01502410|Other|pharmacological study|Optional correlative studies
117968|NCT01502410|Other|laboratory biomarker analysis|Optional correlative studies
117969|NCT01502423|Biological|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
117970|NCT01502449|Behavioral|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
117971|NCT01502449|Other|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
117972|NCT01502488|Procedure|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
117973|NCT00073645|Behavioral|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
117974|NCT01502501|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
117975|NCT01502514|Procedure|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
117976|NCT01502527|Dietary Supplement|Femarelle|Twice daily oral treatment with Femarelle
117977|NCT01502553|Device|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
117589|NCT01503918|Drug|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
117590|NCT01503918|Drug|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
117591|NCT01503944|Drug|18F-AV-133|185 MBq
117592|NCT01503944|Drug|18F-AV-45|185-370 MBq
117593|NCT01506024|Procedure|Total hip arthroplasty, anterior approach|
117594|NCT01506037|Drug|Desloratadine|Desloratadine ODT 5 mg
117595|NCT01506050|Drug|Desloratadine|Desloratadine ODT 5 mg
117596|NCT01506063|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
117597|NCT01506076|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
117598|NCT01506089|Other|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
117599|NCT00073931|Biological|filgrastim|5 µg/kg/day subcutaneously
117600|NCT01506102|Device|Thromboelastography|Thromboelastography during labor and after delivery
117601|NCT01506115|Drug|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
117602|NCT01506128|Other|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
117603|NCT01506141|Drug|Idursulfase-IT|Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD)
117604|NCT01506154|Drug|MRX-7EAT|Once daily application of a patch for 14 days
117869|NCT00073333|Behavioral|Placebo|Placebo
117870|NCT01500551|Drug|CP-690,550|Dosing Scheme in Patients Completing Index Study A3921104:
Body Weight (dose in tablet [mg BID] or solution [mL BID]):
5 - <7 kg (2 mg or 2 ml); 7 - <10kg (2.5 mg or 2.5 mL); 10 - <15kg (3 mg or 3 mL); 15 - < 20kg (3.5 mg or 3.5 mL); 20 - < 25kg (4 mg or 4 mL); 25 - < 40kg (5 mg or 5 mL);
≥ 40kg (5 mg or 5 ml in AM, 10 mg or 10 mL in PM).
Oral solution will be used for subjects weighing <25 kg. Oral tablets will be used for subjects weighing ≥25 kg.
118037|NCT00073372|Drug|Abciximab|
118038|NCT01500785|Drug|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
118039|NCT01500785|Drug|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
118040|NCT01500798|Drug|20 mg bardoxolone methyl|20 mg, oral, once daily
118041|NCT01500798|Drug|Placebo|Oral, once daily
118042|NCT01500811|Biological|cell injection|Intra articular injection of chondrocyte
118043|NCT01500824|Drug|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
118044|NCT01500837|Drug|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
117162|NCT01487512|Drug|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
117163|NCT01487525|Device|Double leg press with partial blood flow restriction|double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
117164|NCT01487525|Other|Double leg press without partial blood flow restriction|double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
117165|NCT01487538|Behavioral|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
117166|NCT01487538|Behavioral|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
117167|NCT01487538|Behavioral|Discussion Boards|forum to exchange information and experiences
117168|NCT01487538|Behavioral|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
117169|NCT01487551|Drug|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
117170|NCT00072098|Biological|adenovirus vector|
117171|NCT01487564|Drug|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
117172|NCT01487577|Drug|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
118961|NCT01495377|Drug|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
118962|NCT00072631|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
118963|NCT01495377|Drug|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
118964|NCT01495377|Drug|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
119298|NCT01493531|Drug|Lesinurad|Tablets, 400 mg QD
119299|NCT01493531|Drug|Placebo|Tablets, Placebo QD
119300|NCT01493531|Drug|Allopurinol|Tablets
119301|NCT01493557|Drug|pantoprazole|40 mg q.a.m, p.o.
119302|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
119303|NCT01493557|Drug|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
119304|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
119305|NCT00072709|Drug|TCH346|
119306|NCT01495884|Drug|non-pegylated liposomal doxorubicon (Myocet™)|
119307|NCT01495884|Drug|Lapatinib (Tyverb™)|
119308|NCT01495897|Device|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
119309|NCT01495897|Device|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
119310|NCT01495910|Drug|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
119311|NCT01495923|Procedure|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
118788|NCT01495026|Drug|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
118789|NCT01495026|Drug|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
118790|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
118791|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
118792|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
118793|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
119024|NCT01492920|Other|Quality-of-Life Assessment|Ancillary studies
119025|NCT01492959|Drug|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
119026|NCT01492972|Radiation|Proton Radiation|Consists of Conformal Proton Radiation Dose:
2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))
119027|NCT00072501|Procedure|magnetic resonance imaging|
119028|NCT01492972|Drug|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
119029|NCT01492985|Biological|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
119030|NCT01492985|Biological|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
119031|NCT01492998|Other|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
119032|NCT01493011|Device|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
119033|NCT01495377|Device|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
119034|NCT01495403|Drug|Hydroxychloroquine|daily dosing
119035|NCT01495429|Procedure|Central venous catheter|Placement of a peripherally inserted central venous catheter
119036|NCT01495429|Procedure|Central venous catheter|Placement of a centrally inserted central venous catheter
118571|NCT01490047|Drug|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
118572|NCT01490047|Drug|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
118573|NCT00072280|Drug|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
118574|NCT01490060|Drug|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
118575|NCT01490060|Drug|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
118576|NCT01490060|Drug|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
118577|NCT01490060|Drug|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
118578|NCT01490060|Drug|Doxorubicin|25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
118579|NCT01490060|Drug|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
118580|NCT01490060|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m^2).
119126|NCT01493193|Other|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
119127|NCT01493193|Other|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
119128|NCT01495585|Drug|Lonafarnib|Commercially approved products used to test the research hypothesis
119129|NCT01495598|Drug|Pomalidomide|5 mg p.o. for 21 of 28 days
119130|NCT01495624|Other|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
119131|NCT01495624|Other|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
118340|NCT01501227|Device|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
118341|NCT01501227|Other|Conventional endotracheal tube|Sham Comparator
118342|NCT01501253|Drug|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
118343|NCT01501253|Drug|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
118344|NCT01501253|Drug|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
118345|NCT00073437|Drug|Infliximab|
118346|NCT01501279|Procedure|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
118347|NCT01501292|Other|Fixation and staining|Fixation and staining by MitiTracker Green FM
118348|NCT01501292|Other|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
118349|NCT01501305|Dietary Supplement|Mineral solution|Rehydration mineral solution
118350|NCT01501305|Dietary Supplement|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
118351|NCT01501318|Behavioral|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
118352|NCT01501318|Behavioral|Personalized feedback report plus education|Persons receive both a brief education session and the personalized feedback report. This is the currently implemented service approach.
118353|NCT01501331|Device|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
118354|NCT01501344|Dietary Supplement|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
118355|NCT01501357|Behavioral|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
118356|NCT00073450|Drug|Farnesyl Protein Transferase Inhibitor|
118357|NCT01501357|Behavioral|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
118358|NCT01501370|Drug|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
118359|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
119312|NCT01495923|Procedure|Sham epidural steroid injection|Injection of saline into the back muscles
119313|NCT01495923|Drug|Gabapentin|Titration of gabapentin to effect
119314|NCT01495923|Drug|Placebo gabapentin|Titration of placebo gabapentin
119315|NCT01495936|Procedure|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
119316|NCT00072722|Drug|CC-4047|
118415|NCT01499251|Drug|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
118416|NCT01499264|Device|MySkin patch|Hydrogel and polyurethane film
118417|NCT01499264|Device|Traditional Dressing|Gauze and Patch
118418|NCT01499277|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
118419|NCT01499277|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
118420|NCT00073177|Drug|Roflumilast|
118421|NCT01499277|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
118422|NCT01499290|Drug|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
118423|NCT01499290|Drug|Metronidazole|500 mg of Metronidazole
118424|NCT01499290|Drug|Meropenem|1 gram of Meropenem
118425|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
118426|NCT01501383|Drug|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
118427|NCT01501383|Drug|Placebo|Matching placebo
118428|NCT01501383|Drug|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
118429|NCT01501396|Drug|Megestrol Acetate|
118430|NCT00073463|Genetic|tgAAVCF|
118431|NCT01501396|Drug|Mirtazapine|
119037|NCT01495442|Device|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
119038|NCT01495442|Device|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
119039|NCT01495468|Biological|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
119040|NCT01495481|Drug|Dexmedetomidine|Dexmedetomidine 1 mcg/kg, Intravenous push
119041|NCT00072657|Behavioral|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
119042|NCT01495481|Drug|Adenosine|stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
119371|NCT01493622|Drug|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
119372|NCT01493622|Drug|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
119373|NCT01493635|Other|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
119374|NCT01493635|Other|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
119375|NCT01493648|Drug|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
119376|NCT01493648|Drug|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
119377|NCT00072527|Drug|cisplatin|IV
119378|NCT01493661|Other|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
119379|NCT01493674|Dietary Supplement|folic acid|two 5-mg tablets of folic acid
119380|NCT01493687|Drug|CD5024|CD5024 1% Cream, once daily
119381|NCT01493687|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
119382|NCT01493700|Procedure|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
119132|NCT01495637|Drug|GM-CSF|GM-CSF is to be administered IV on post-trauma days 1, 2, and 3 at a dose of 30, 62, or 125 mcg/m2 per day.
119133|NCT01495637|Drug|placebo|placebo will be administered on post-trauma days 1, 2, and 3
119134|NCT00072657|Behavioral|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
119135|NCT01495650|Behavioral|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
119136|NCT01495663|Drug|I-131-CLR1404|Description:
Dosimetry: IV, 5 mCi, single dose, 6-day duration
Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year
119137|NCT01495676|Other|Radiation + cisplatin|RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.
Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.
A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.
In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.
In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study.
119138|NCT01495676|Other|Radiation + cisplatin + gemcitabine|Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.
Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.
Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection.
119139|NCT01495689|Behavioral|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
119156|NCT01498445|Drug|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
119157|NCT01498445|Drug|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
119158|NCT01498458|Drug|Pazopanib plus capecitabine|Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:
dose level I: 400 mg
dose level II: 600 mg
dose level III: 800 mg
In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.
Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.
Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.
If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level.
118360|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
118361|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
118644|NCT01497223|Drug|MGCD290|1 Oral Dose Administration
118645|NCT01497236|Dietary Supplement|Dietary Supplement: Nutrition supplement with RUTF or MNP|14 days nutritional supplementation with either
a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients
a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake
a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier
118646|NCT01497249|Dietary Supplement|A dietary fiber (FCHO)|15 g twice per day in beverage
118647|NCT01497249|Dietary Supplement|Placebo|Placebo drink
118648|NCT01497262|Drug|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
118649|NCT00072852|Drug|Irinotecan|
118650|NCT01497275|Drug|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
118651|NCT01497288|Drug|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
118652|NCT01497301|Behavioral|Group Visits|During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the "ABCs to Better Diabetic Care" as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants.
118653|NCT01497314|Other|Low Lactose Infant Formula|Low Lactose Infant Formula
118654|NCT01497327|Drug|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
118655|NCT01497327|Drug|PSI-7977|PSI-7977 400mg QD for seven days
118656|NCT01497340|Other|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
118657|NCT01497340|Other|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
118658|NCT01497353|Procedure|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
118432|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
118433|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
118718|NCT01495013|Drug|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
118719|NCT01495013|Drug|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
118720|NCT00072566|Drug|Cyclophosphamide|Given PO
118721|NCT01495013|Drug|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
118722|NCT01495013|Drug|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
118723|NCT01497353|Procedure|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
118724|NCT00072865|Drug|Pemetrexed|
118725|NCT01497366|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
118726|NCT01497366|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
118727|NCT01497366|Drug|RBV|Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose
Dose of sofosbuvir+RBV group based on baseline weight: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg
Dose of PEG+RBV group: 800 mg
118728|NCT01497379|Procedure|surgical implantation of subretinal device|surgical implantation of subretinal device
118729|NCT01497379|Procedure|surgical implantation of subretinal device|intra-individual implant OFF
118730|NCT01497392|Drug|dovitinib lactate|Given PO
118731|NCT01497392|Drug|gemcitabine hydrochloride|Given IV
118732|NCT01497392|Drug|capecitabine|Given PO
115612|NCT01516346|Drug|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
115613|NCT01516372|Drug|GEn 1200mg|1200 mg of Gen administered as a single dose
115614|NCT01516372|Drug|Gen 6000 mg|6000 mg of Gen administered as a single dose
115615|NCT01516372|Drug|GEn Placebo|Placebo to match GEn Tablets
115616|NCT01516372|Drug|Moxifloxacin Placebo|Placebo to match Moxifloxacin
115617|NCT01516372|Drug|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
115618|NCT00074724|Drug|Modern medical management|Therapies with evidence-based recommendations.
115619|NCT01516411|Behavioral|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
115620|NCT01516424|Drug|Blonanserin|tablet,4mg,b.i.d
115621|NCT01516424|Drug|Risperidone|tablet,2mg,b.i.d,
115622|NCT01516437|Procedure|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
115623|NCT01516437|Procedure|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
115624|NCT01516437|Procedure|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
115625|NCT01516450|Drug|GSK1550188 IV|Single IV dose of belimumab 200 mg
115903|NCT01485185|Other|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
115904|NCT01485185|Drug|Gabapentin higher dose|Repeat, oral dose
115905|NCT01487590|Other|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
115906|NCT01487629|Drug|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
115907|NCT01487629|Drug|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
115908|NCT01487642|Device|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
119159|NCT01498484|Biological|EBV-specific T-cells|Patients in Group 1 will each receive a course of three weekly infusions of EBV-specific T-cells. Each weekly dose will provide 2 x106 T-cells/Kg recipient weight (+/- 3 days) from the donor's EBV-specific T-cell line. After the third dose, patients will be observed for approximately 3 weeks.
119160|NCT01490866|Drug|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
119161|NCT01490866|Drug|Leucovorin|400 mg/m2 Days 1 and 15; IV
119162|NCT01490866|Drug|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
119163|NCT01490879|Drug|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
119164|NCT01490879|Drug|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
119165|NCT01490879|Drug|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
119166|NCT01490879|Drug|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
119167|NCT00072332|Drug|edotecarin|
119168|NCT01490892|Drug|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
119169|NCT01490905|Other|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
119170|NCT01490905|Drug|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
119171|NCT01490905|Drug|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
119172|NCT01490918|Drug|Acarbose|The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively
119173|NCT01490931|Drug|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
118294|NCT01502943|Drug|Chixiangshen Tongxin granules|TCM treatment:
Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.
Usage:Once 100ml, twice per day after breakfast and supper.
118295|NCT00073684|Behavioral|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
118659|NCT01490125|Drug|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
118660|NCT01490125|Drug|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
118661|NCT00072280|Procedure|Conventional Surgery|Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an "envelope" of normal tissue should be undertaken at the initial and/or subsequent resections.
118902|NCT01497665|Drug|GRN1005|650 mg/m2 IV every 3 weeks
118903|NCT01497678|Device|Extracellular Matrix|Extracellular Matrix
118904|NCT01497691|Device|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
118905|NCT01497691|Device|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
118906|NCT01497691|Device|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
118907|NCT01497704|Drug|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
118908|NCT01497717|Drug|Adalimumab (Humira)|Open label pilot trial.
The study includes 3 phases :
Open label treatment period of 24 weeks.
Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.
Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks.
118909|NCT01490554|Procedure|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
118910|NCT01490567|Drug|Donepezil|5 mg/day
118911|NCT01490567|Drug|placebo|placebo 5mg/d
118912|NCT01490580|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
118913|NCT01490580|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
118914|NCT01490593|Behavioral|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
118915|NCT01490606|Other|knee OA project|physical therapy in "OA Knee project", total of 12 sessions, 6 group therapies amd 6 one on one therapy.
118733|NCT01497392|Other|laboratory biomarker analysis|Correlative studies
118734|NCT01497392|Other|enzyme-linked immunosorbent assay|Correlative studies
118735|NCT00001296|Drug|interferon-gamma|
118736|NCT00072865|Drug|Carboplatin|
118737|NCT01497392|Other|pharmacological study|Correlative studies
118738|NCT01497405|Behavioral|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
118965|NCT01497730|Device|Total Knee Replacement|Subjects will receive one of the following total knee implants:
PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices.
118966|NCT00072930|Biological|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
118967|NCT01497743|Drug|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
118968|NCT01497756|Device|CAPP use|Any abdominal pelvic pressure
118969|NCT01497769|Biological|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10^7 pfu and intradermal saline placebo
118970|NCT01497769|Biological|Intradermal MVA85A|Intradermal MVA85A 1 x 10^7 pfu and inhaled aerosol saline placebo
118971|NCT01497782|Other|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
118972|NCT01497808|Drug|Ipilimumab|
118973|NCT01497808|Radiation|Stereotactic Body Radiation Therapy|
118974|NCT01497821|Drug|AMG 172|AMG 172 is an antibody drug conjugate
118975|NCT01497834|Drug|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
118976|NCT01497834|Drug|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
118977|NCT00072943|Drug|anti-Interferon-gamma monoclonal antibody|
115909|NCT01487642|Device|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
115910|NCT01487642|Device|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
115911|NCT01487642|Device|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
115912|NCT00072098|Biological|interleukin-12 gene|
115913|NCT01487668|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
115914|NCT01487694|Drug|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
115915|NCT01487694|Drug|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
115916|NCT01487707|Behavioral|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
115917|NCT01487707|Behavioral|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
115918|NCT01487707|Behavioral|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
115919|NCT01487720|Drug|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
115018|NCT01533740|Drug|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
115019|NCT01533753|Drug|Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
115020|NCT01533753|Drug|Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
118296|NCT01502943|Drug|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
118297|NCT01502943|Drug|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
118298|NCT01502956|Device|InterStim® device|Subjects will be screened to assess eligibility criteria and baseline number of daily urge urinary incontinence episodes. Candidates will be approached for enrollment and will be consented and enrolled into the study. A minimum of a 3-week washout period is required for any subject currently on anticholinergic therapy prior to randomization. Eligible subjects will complete baseline assessments, be randomized and scheduled for either a first stage lead placement (FSLP) InterStim® or Botox A® injection visit. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
118299|NCT01505062|Genetic|UshStat|Single dose, 3 ascending dose cohorts, followed by two maximum tolerated dose cohorts
118300|NCT01505075|Radiation|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
118301|NCT01505088|Drug|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
118302|NCT01505088|Drug|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
118303|NCT01505088|Drug|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
118304|NCT01505088|Drug|Placebo Eyedrops|Placebo Eyedrops
118305|NCT01505101|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
118306|NCT01505101|Behavioral|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
118581|NCT01490060|Drug|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
118582|NCT01490073|Drug|Insertion of nitroglycerin ointment|Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion
118583|NCT01490073|Drug|Insertion of placebo ointment|Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
118584|NCT00072280|Drug|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
118916|NCT01490606|Other|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
118917|NCT01490619|Behavioral|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
118918|NCT01490619|Other|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
118919|NCT00001271|Drug|IgG-RFB4-SMPT-dgA|
118920|NCT00072319|Drug|cyclophosphamide|
119238|NCT01497938|Device|Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Automatic suspension of insulin delivery when glucose is low.
119239|NCT01497938|Device|Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump|No Automatic suspension of insulin delivery when glucose is low.
119240|NCT01497951|Other|Aminolaevulinic acid|Photodynamic therapy
119241|NCT01497951|Other|Methylcellulose Placebo|Methylcellulose
119242|NCT01497964|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
119243|NCT01497977|Drug|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
119244|NCT01497977|Drug|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
119245|NCT01497990|Drug|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
119246|NCT00072982|Drug|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
119247|NCT01498003|Drug|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
119248|NCT01498003|Drug|normal saline solution|same use as tirofiban
119249|NCT01498016|Drug|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
119250|NCT01498029|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
118978|NCT01497860|Drug|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
118979|NCT01497873|Drug|Topotecan|1.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
118980|NCT01497873|Drug|Belotecan|0.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
118981|NCT01497886|Behavioral|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
118982|NCT01497886|Behavioral|Nutrition Education program|The investigators will use what they will refer to as a "usual care" control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for "attention", i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence).
118983|NCT01497899|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally once daily
119317|NCT01495936|Procedure|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
119318|NCT01495949|Drug|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
119319|NCT01495949|Drug|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
119320|NCT01495962|Drug|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
119321|NCT01495962|Drug|Placebo|Placebo (Normal Saline)
119322|NCT01495975|Other|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
119323|NCT01495988|Drug|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
119324|NCT01498211|Procedure|Biopsy|3 mm punch biopsy of the skin at the distal leg.
119325|NCT01498224|Device|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
119326|NCT01498224|Procedure|Sutures|
115021|NCT01533766|Drug|CombiflexOmega|intravenously over 5 days infusion
115022|NCT00076414|Drug|L-NMMA|
115023|NCT01533766|Drug|SmofKabiven|intravenously over 5 days infusion
115024|NCT01533792|Procedure|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
115025|NCT01533792|Procedure|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
115026|NCT01533805|Other|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
115027|NCT01526915|Procedure|Bone curettage alone|Bone curettage without PRF insertion
115028|NCT01526928|Drug|Rociletinib|Phase 1: Rociletinib will be administered in escalating dosages in a period of 21-day cycles
Phase 2: Rociletinib will be administered daily
115029|NCT01526941|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
115030|NCT01526941|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
115031|NCT00075712|Drug|paclitaxel|
115032|NCT01526954|Device|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
115033|NCT01526980|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
115034|NCT01526980|Drug|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
115035|NCT01526980|Drug|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
115315|NCT01529437|Drug|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
115316|NCT01529437|Drug|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
115317|NCT01529450|Drug|LDE225|800-mg (4 200-mg capsules/day) capsule
115318|NCT01529476|Drug|Levofloxacin|levofloxacin 500 mg,QD,7~10 days
118585|NCT01490086|Drug|RP5063|daily
118586|NCT01490086|Drug|placebo|daily
118587|NCT01490086|Drug|RP5063|daily
118588|NCT01490086|Drug|RP5063|daily
118589|NCT01490086|Drug|aripiprazole|daily
118590|NCT01490099|Drug|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
118591|NCT01490112|Drug|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
118592|NCT01490125|Drug|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
118593|NCT01492270|Procedure|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
118594|NCT01492270|Procedure|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
118595|NCT00072449|Biological|rituximab|
118596|NCT01492270|Procedure|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
118597|NCT01492283|Other|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
118598|NCT01492283|Other|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
118599|NCT01492296|Procedure|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
118600|NCT01492296|Procedure|conventional fasting|patients were evaluated after fasting for 8 hours
118601|NCT01492309|Device|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
118602|NCT01492309|Device|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
118850|NCT01490515|Procedure|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
118851|NCT01490515|Other|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
119251|NCT01498029|Device|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
119252|NCT01498068|Drug|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
119253|NCT01498068|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
119254|NCT01498068|Drug|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is < 75kg) or 1200mg (if participant's weight is >= 75kg) per day for 24 or 48 weeks.
119255|NCT01498081|Drug|AZD2115|AZD2115 administered via inhalation
119256|NCT01498081|Drug|Placebo|Placebo administered via inhalation
118362|NCT01502956|Drug|Botox® injection|Subjects will be screened to assess eligibility criteria and baseline number of daily urge urinary incontinence episodes. Candidates will be approached for enrollment and consented and enrolled into the study. A minimum of a 3-week washout period is required for any subject currently on anticholinergic therapy prior to randomization. Eligible subjects will complete baseline assessments, be randomized and scheduled for either a first stage lead placement (FSLP) InterStim® or Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
118363|NCT01502969|Biological|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
118364|NCT01502969|Biological|cell culture medium in absence of virus|Placebo
118365|NCT01502982|Drug|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
118366|NCT01502995|Device|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
118367|NCT01503008|Device|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
118368|NCT01503008|Drug|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
118369|NCT00073684|Behavioral|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
119327|NCT01498237|Device|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
119328|NCT01498237|Procedure|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
119329|NCT01498289|Drug|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, & leucovorin calcium.
119330|NCT01498289|Drug|docetaxel|30 mg/m^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
119331|NCT01498289|Drug|fluorouracil|400 mg/m^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
119332|NCT01498289|Drug|irinotecan hydrochloride|65 mg/m^2, IV over 90 minutes on Days 1 & 8 of every 21 day cycle.
119333|NCT00072995|Behavioral|Diets Low in Saturated Fat|
119334|NCT01498289|Drug|leucovorin calcium|400 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
119335|NCT01498289|Drug|oxaliplatin|85 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
118434|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
118435|NCT01501422|Drug|Estrogen patch|50 microgram estrogen patch weekly
118436|NCT01501422|Drug|Placebo|Placebo patch for 8 weeks
118437|NCT01501435|Drug|CJ-30039|single dose
118438|NCT01501435|Drug|Active Comparator: Greencross Lipidil Supra 160mg|single dose
118439|NCT01501448|Drug|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
118440|NCT01501448|Drug|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
118441|NCT00073476|Drug|traxiprodil (CP-101,606)|
115319|NCT01529476|Drug|Nemonoxacin|Nemonoxacin 500mg,QD,7~10 days
115320|NCT01529489|Other|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
115321|NCT00075842|Other|placebo|Given orally
115322|NCT01529489|Other|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
115323|NCT01529489|Other|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
115324|NCT01529489|Other|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
115325|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
115326|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
115327|NCT01529502|Drug|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
115328|NCT01531673|Drug|VX-661|Tablet, taken every 12 hours (q12h)
115329|NCT01531673|Drug|VX-661 placebo|Tablet, taken every 12 hours (q12h)
115330|NCT01531686|Procedure|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
115331|NCT01531699|Drug|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
115332|NCT01531699|Other|saline control|single application for up to 6 hours
115333|NCT01531699|Drug|Comparator Product|single application for up to 6 hours
115334|NCT01531712|Drug|Gemcitabine|1000mg/m2 / / 40mg/m2
115335|NCT00000120|Drug|Erythromycin Ointment|
115336|NCT00000261|Drug|30% Nitrous oxide|
115626|NCT01516450|Drug|GSK1550188 SC|Single SC dose of belimumab 200mg
115627|NCT01516463|Drug|Collagenase Santyl|Applied topically (2 mm thickness once daily)
118852|NCT00072319|Biological|filgrastim|
118853|NCT01492647|Drug|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
118854|NCT01492647|Drug|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
118855|NCT01492647|Drug|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
118856|NCT01492660|Device|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
118857|NCT01492660|Device|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
118858|NCT01492673|Drug|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
118859|NCT01492686|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
118860|NCT01492686|Drug|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
118861|NCT01492686|Drug|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
118862|NCT01492699|Drug|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
118863|NCT00072488|Procedure|positron emission tomography|
118864|NCT01492712|Drug|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
118865|NCT01492712|Drug|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
118370|NCT01503021|Drug|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
118371|NCT01503021|Other|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
118372|NCT01503047|Dietary Supplement|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
118373|NCT01503047|Dietary Supplement|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
118374|NCT01503060|Behavioral|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
118375|NCT01503060|Behavioral|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
118376|NCT01503060|Drug|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
118377|NCT01503060|Drug|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
118662|NCT01490125|Drug|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
118663|NCT01490125|Drug|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
118664|NCT01490151|Device|TTR controller (Medtronic)|Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
118665|NCT01490177|Drug|Food proteins|Oral ingestion of Food proteins
118666|NCT01490190|Drug|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
118667|NCT01490203|Drug|Gd-EOB-DTPA|Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.
Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.
118668|NCT01490203|Drug|Gd-EOB-DTPA|Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.
Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.
118669|NCT01490203|Procedure|MRI|Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.
Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.
118442|NCT01501461|Procedure|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
118443|NCT01501487|Drug|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
118444|NCT01501487|Drug|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
118445|NCT00073684|Behavioral|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
118446|NCT01503073|Device|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
118447|NCT01503086|Other|computer-assisted cognitive training|Receive computer-assisted cognitive training
118448|NCT01503086|Other|questionnaire administration|Ancillary studies
118449|NCT01503086|Procedure|cognitive assessment|Ancillary studies
118450|NCT01503086|Procedure|psychosocial assessment and care|Ancillary studies
118451|NCT01503086|Procedure|quality-of-life assessment|Ancillary studies
118452|NCT01503112|Other|No intervention, observational study|
118453|NCT01503138|Behavioral|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
118739|NCT01497405|Biological|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
118740|NCT01497431|Dietary Supplement|Selenium|Given PO
118741|NCT01497431|Other|Placebo|Given PO
118742|NCT01497431|Other|Laboratory Biomarker Analysis|Correlative studies
118743|NCT01497431|Other|Pharmacological Study|Correlative studies
118744|NCT01497431|Drug|Methylselenocysteine|Given PO
118745|NCT01497444|Drug|hypoxia-activated prodrug TH-302|
118746|NCT01497444|Drug|sorafenib tosylate|
118747|NCT00072891|Behavioral|telephone counseling|
115628|NCT01516463|Biological|Bacitracin|Applied topically (2 mm thickness) once daily
115629|NCT00074724|Device|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
115630|NCT01516476|Drug|Placebo|Placebo for 12 weeks
115631|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
115632|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
115633|NCT01516476|Drug|liraglutide|liraglutide for 12 weeks
115634|NCT01516489|Behavioral|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
115635|NCT01516489|Behavioral|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
115636|NCT01516502|Other|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
115637|NCT01528020|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
115638|NCT01528020|Behavioral|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
115639|NCT01528033|Device|Vacuum Assisted Closure®|Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.
VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.
Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended.
115920|NCT01487733|Genetic|gene expression analysis|
115921|NCT01487733|Genetic|in situ hybridization|
119174|NCT01490944|Drug|Iron, Folic acid and Cyanocobalamin|Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks
Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks
119175|NCT01490944|Drug|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
119176|NCT01490957|Other|Database|Database
119177|NCT01490970|Other|Database|Database
119178|NCT00072345|Drug|lomustine|
119179|NCT01490983|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
119180|NCT01490983|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
119181|NCT01490996|Drug|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
119182|NCT01490996|Drug|Chemotherapy only|Standard care chemotherapy
119183|NCT01491009|Drug|Remifentanil|IV infusion
119184|NCT01491009|Drug|Midazolam|IV infusion
119185|NCT01491022|Drug|Dalfampridine|10 mg po bid for 4 weeks
119186|NCT01491022|Drug|placebo|placebo
119187|NCT01491035|Drug|Vortioxetine|5 mg tablets for 14 days; orally; once daily
119188|NCT01493193|Other|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
119189|NCT01493206|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
119190|NCT01493232|Other|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
119191|NCT01493245|Drug|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
118670|NCT01490203|Procedure|MRI|Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.
Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.
118671|NCT01490216|Drug|lisdexamfetamine|20mg q.d. to 70mg b.i.d
118672|NCT00072280|Biological|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
118673|NCT01490229|Drug|Ezetimibe|os, 10 mg, once daily, 1 year
118674|NCT01490229|Drug|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
118675|NCT01490255|Drug|Ranolazine|os, 750 mg, twice per day, for 15 days
118676|NCT01490255|Drug|Amlodipine|os, 10 mg, once daily, 15 days
118677|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
118678|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
118679|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
118921|NCT01490632|Drug|Placebo|Administered orally
118922|NCT01490632|Drug|LY3009104|Administered orally
118923|NCT01490658|Drug|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
118924|NCT01490658|Drug|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
118925|NCT01490658|Drug|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
118926|NCT01490671|Drug|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
118927|NCT01490671|Drug|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
118928|NCT01490697|Drug|Mifepristone|1800 mg tablet, single dose on script preparation day
118748|NCT01497457|Procedure|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
118749|NCT01490281|Behavioral|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
118750|NCT01490281|Behavioral|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
118751|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
118752|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
118753|NCT00072280|Biological|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
118754|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
118755|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
118756|NCT01490307|Behavioral|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
118757|NCT01490320|Behavioral|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
118758|NCT01490320|Behavioral|Play Nicely Program|Multimedia program available at www.playnicely.org.
118984|NCT01497899|Drug|E/C/F/TAF Placebo|E/C/F/TAF placebo tablet administered orally once daily
118985|NCT01497899|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
118986|NCT01497899|Drug|E/C/F/TDF Placebo|E/C/F/TDF placebo tablet administered orally once daily
118987|NCT01497912|Drug|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
118988|NCT01490710|Other|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
118989|NCT01490710|Other|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
115922|NCT01487733|Other|immunohistochemistry staining method|
115923|NCT00072111|Biological|anakinra|
115924|NCT01487733|Other|laboratory biomarker analysis|
115925|NCT01480466|Other|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
115926|NCT01480479|Drug|Rindopepimut (CDX-110) with GM-CSF|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.
Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
115927|NCT01480479|Drug|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
115928|NCT01480479|Drug|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
115929|NCT01480492|Drug|Telbivudine|600mg,1/d,one year
115930|NCT01480505|Procedure|Pars plana vitrectomy with gas tamponade|A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.
Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment.
115931|NCT01480518|Genetic|DNA analysis|
115932|NCT00071422|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
115933|NCT01480518|Genetic|comparative genomic hybridization|
115934|NCT01480518|Genetic|gene expression analysis|
115935|NCT01480518|Genetic|mutation analysis|
115936|NCT01480518|Genetic|polymerase chain reaction|
115937|NCT01480518|Genetic|polymorphic microsatellite marker analysis|
115938|NCT01480518|Other|laboratory biomarker analysis|
118832|NCT01490398|Drug|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
119192|NCT01493258|Other|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
119193|NCT01493271|Drug|Placebo|Placebo to RO5093151
118307|NCT01505114|Drug|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
118308|NCT01505114|Drug|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
118309|NCT00073866|Drug|irinotecan hydrochloride|
118310|NCT01505114|Drug|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
118311|NCT01505114|Other|Maraviroc placebo|Once daily from Week 0 through Week 48
118312|NCT01505114|Other|Emtricitabine placebo|Once daily from Week 0 through Week 48
118313|NCT01505114|Other|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
118314|NCT01505127|Drug|TAK-438|
118315|NCT01505127|Drug|Lansoprazole|
118316|NCT01505127|Drug|Amoxicillin|
118317|NCT01505127|Drug|Clarithromycin|
118318|NCT01505140|Other|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
118319|NCT01505153|Biological|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
118320|NCT00073879|Biological|alemtuzumab|
118321|NCT01505166|Biological|Vigil™ Vaccine|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
118929|NCT01490697|Drug|Cycloserine|100 mg capsule, single dose, taken 4 hours prior to script preparation on day 2
118930|NCT01490697|Drug|sugar pill|sugar pill in the same shape and size as the mifepristone and DCS tablets and capsules
118931|NCT00072319|Drug|epirubicin hydrochloride|
118932|NCT01492751|Behavioral|Quality of life assessment and Clinical evaluation|quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.
Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment.
118933|NCT01492751|Procedure|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
119257|NCT00072982|Drug|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
119258|NCT01491035|Drug|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
119259|NCT00072345|Drug|temozolomide|
119260|NCT01491035|Drug|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
119261|NCT01491035|Drug|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
119262|NCT01491048|Procedure|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
119263|NCT01491048|Procedure|No physiotherapy after THA|No physiotherapy after THA
119264|NCT01491061|Drug|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
119265|NCT01491061|Drug|Placebo|os, two doses 12 hours apart prior to PCI
119266|NCT01491074|Drug|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
119267|NCT01491074|Drug|NaCl 0.9% 100 ml|Placebo
118990|NCT01490723|Drug|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
118991|NCT01490723|Drug|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
118992|NCT01490723|Procedure|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
118993|NCT01490723|Drug|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
118994|NCT01490723|Drug|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
118995|NCT01490723|Drug|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
118996|NCT01490723|Drug|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
118997|NCT01490723|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.
For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present.
118998|NCT00072319|Drug|paclitaxel|
118999|NCT01490723|Drug|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
119000|NCT01490723|Drug|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
119001|NCT01490723|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
119336|NCT01498302|Other|diagnostic laboratory biomarker analysis|
119337|NCT01498302|Other|flow cytometry|
119338|NCT01498315|Other|Ultrasound examination|Ultrasound examination following hysterectomy
119339|NCT01498328|Drug|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
118833|NCT01490411|Drug|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
118834|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
118835|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
118836|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
118837|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
118838|NCT01490437|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
118839|NCT01490437|Drug|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
118840|NCT01490437|Drug|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
118841|NCT00072293|Procedure|No axillary lymph node dissection|Therapeutic conventional surgery
118842|NCT01490437|Drug|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
118843|NCT01490450|Biological|Placebo matching BMS-945429|Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
118844|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
118845|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
118846|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
118847|NCT01490476|Drug|RAD001|10 mg per os / day or 05mg per os / day with 12 month
118848|NCT01490489|Other|blood sample and doppler Ultrasound of uterine arteries|36 ml of blood samples (serum and plasma) will be collected
After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch
118849|NCT01490502|Drug|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
118322|NCT01499082|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
118323|NCT01499082|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
118324|NCT00073164|Drug|Divalproex Sodium Extended-Release Tablets|
118325|NCT01499095|Drug|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
118603|NCT01492322|Radiation|TRODAT|Smoker will receive a TRODAT injection
118604|NCT01492335|Behavioral|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
118605|NCT01492335|Behavioral|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
118606|NCT00072462|Drug|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
118607|NCT01492348|Behavioral|STEPS UP|The STEPS UP intervention enhances RESPECT-Mil in several ways:
Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.
Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, & primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.
Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.
Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components.
118608|NCT01492348|Behavioral|OUC|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the "three-component model" where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist.
118609|NCT01492361|Drug|AMR101|Parallel Assignment
118610|NCT01492361|Drug|Placebo|Parallel Assignment
118611|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
119268|NCT01491087|Biological|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
119269|NCT01491100|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
119270|NCT00072345|Drug|thalidomide|
119271|NCT01491113|Drug|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
119272|NCT01491113|Drug|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
119273|NCT01491139|Drug|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
119274|NCT01491139|Drug|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
119275|NCT01491139|Radiation|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
119276|NCT01491152|Device|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
119277|NCT01491165|Procedure|stem cell transplantation through interventional procedures|one time interventional procedures
119278|NCT01491178|Drug|Prazaxa|Dabigatran etexilate
118378|NCT01503060|Drug|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
118379|NCT01503060|Drug|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
118380|NCT01505166|Drug|Placebo|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
118381|NCT01505179|Drug|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
118382|NCT01505179|Drug|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
118383|NCT01505192|Device|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
119340|NCT01498328|Drug|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
119341|NCT01498328|Drug|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
119342|NCT01498354|Procedure|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
119343|NCT01498354|Procedure|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
119344|NCT00073008|Drug|GW572016 (lapatinib)|tyrosine kinase inhibitor
119345|NCT01498367|Procedure|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
119346|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
119347|NCT01491204|Drug|Paclitaxel+HM30181|oral, 3times for 4weeks
119348|NCT01491217|Drug|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
119349|NCT01491243|Drug|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
119350|NCT01491243|Drug|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
119351|NCT01491256|Drug|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
119352|NCT01491256|Drug|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
118454|NCT01503151|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
118455|NCT01503151|Behavioral|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
118456|NCT00001303|Drug|Inhaled Nitric Oxide|
119085|NCT01490788|Drug|TNX-102 2.4 mg, Fasting conditions|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
119086|NCT01490788|Drug|TNX-102 2.4 mg, Fed conditions|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
119087|NCT01490788|Drug|Cyclobenzaprine 5 mg, Fasting conditions|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
119088|NCT01490801|Genetic|DNA analysis|
119089|NCT01490801|Genetic|RNA analysis|
119090|NCT01490801|Genetic|cytogenetic analysis|
119091|NCT01490801|Genetic|in situ hybridization|
119092|NCT00072319|Procedure|neoadjuvant therapy|
119093|NCT01490801|Genetic|mutation analysis|
119094|NCT01490801|Genetic|polymerase chain reaction|
119095|NCT01490801|Genetic|western blotting|
119096|NCT01490801|Other|flow cytometry|
119097|NCT01490801|Other|immunohistochemistry staining method|
119098|NCT01490801|Other|medical chart review|
119099|NCT01490814|Procedure|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
119100|NCT01490814|Procedure|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
119101|NCT01490840|Drug|Physical exercise|Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gymballs. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
119102|NCT01490853|Drug|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
119103|NCT00072332|Drug|cisplatin|
119104|NCT01490866|Drug|Axitinib|5-mg tablets PO BID
118612|NCT01494740|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
118613|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
118614|NCT01494753|Drug|T2345|One drop at 8.00pm.
118615|NCT01494753|Drug|Prostaglandin|One drop at 8.00pm.
118616|NCT01494766|Dietary Supplement|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
118617|NCT00072553|Procedure|adjuvant therapy|
118618|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
118619|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
118620|NCT01494792|Device|In Vitro Diagnositc aid for diagnosis|
118866|NCT01492725|Device|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
118867|NCT01492725|Genetic|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
118868|NCT01492738|Procedure|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
118869|NCT01495104|Drug|valproate|Multiple doses
118870|NCT01495117|Drug|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
118871|NCT01495117|Drug|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
118872|NCT01495130|Procedure|ultrasound imaging|Undergo transrectal ultrasound
118873|NCT01495130|Procedure|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
118874|NCT01495143|Procedure|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
118384|NCT01505218|Drug|Propofol sedation by nurse anaesthestist|Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.
Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.
Propofol sedation by nurse anaesthetists:
118385|NCT01505218|Drug|Patient-controlled propofol sedation|Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.
Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.
Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness.
118386|NCT01505231|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.
118387|NCT01505231|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
118388|NCT01505244|Behavioral|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
118389|NCT00073879|Biological|graft-versus-tumor induction therapy|
118390|NCT01505257|Behavioral|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
118391|NCT01505270|Other|Retrospective case study|Retrospective case study
118392|NCT01505283|Drug|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
118393|NCT01505283|Drug|Sufentanil|epidural administration of sufentanil 10 µg
118394|NCT01505283|Drug|lidocaine|epidural administration of lidocaine 50 mg
118680|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
118681|NCT01492374|Drug|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
118682|NCT01492387|Other|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
118683|NCT01492400|Drug|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
118684|NCT00072462|Drug|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
118685|NCT01492400|Drug|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
118457|NCT00073684|Behavioral|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
118458|NCT01503151|Behavioral|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
118459|NCT01503151|Behavioral|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
118460|NCT01503164|Device|Positive Pressure Therapy (PAP)|Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
118461|NCT01503164|Behavioral|LifeStyle Counseling|Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
118462|NCT01503177|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
118463|NCT01503177|Other|laboratory biomarker analysis|Correlative studies
118464|NCT01503177|Procedure|single photon emission computed tomography|Correlative studies
118465|NCT01503177|Procedure|computed tomography|Correlative studies
118466|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
118467|NCT01503203|Other|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
118468|NCT00073684|Behavioral|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
118469|NCT00001305|Drug|Humatrope|Patients receive a subcutaneous injection.
118470|NCT00073879|Drug|cyclophosphamide|
118471|NCT01505361|Biological|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
118472|NCT01505361|Biological|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
118473|NCT01505374|Procedure|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
118759|NCT01490320|Other|Control Group|Standard care in primary care clinic.
118760|NCT01490333|Dietary Supplement|Vitamin D3|The vitamin D3 will be taken daily.
119105|NCT01490866|Drug|Bevacizumab|5 mg/kg Days 1 and 15; IV
119106|NCT01490866|Drug|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
119430|NCT00072215|Drug|paclitaxel|given IV
119431|NCT01489358|Biological|VRC-CHKVLP059-00-VP|
119432|NCT01489371|Biological|EGEN-001|Given IP
119433|NCT01489371|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
119434|NCT01491373|Device|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
119435|NCT01491373|Device|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
119436|NCT01491386|Device|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
119437|NCT01491386|Device|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
119438|NCT01491399|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
119439|NCT00072384|Drug|liposomal vincristine sulfate|Given IV
119440|NCT01491399|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
119441|NCT01491425|Device|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
119442|NCT01491425|Device|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
119443|NCT01491438|Procedure|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.
Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing
119444|NCT01491438|Procedure|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
119445|NCT01491451|Device|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
119446|NCT01491451|Device|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
118875|NCT01495156|Drug|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.
Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L).
118876|NCT01495156|Drug|Placebo/Adjunctive SGA treatment|All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.
Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA.
118877|NCT00072592|Drug|Rituximab|
118878|NCT01495169|Drug|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
118879|NCT01495182|Other|Dietary fiber|A proprietary fiber will be given to subjects
118880|NCT01495195|Drug|High-dose donepezil|Donepezil titrated to 22.5 mg daily
118881|NCT01495195|Drug|Low-dose donepezil|Donepezil titrated to 10 mg daily
118882|NCT01495195|Drug|Selegiline|Transdermal selegiline, 6 mg daily
118883|NCT01495195|Drug|Placebo|microcrystalline cellulose
119194|NCT00072514|Drug|gemcitabine hydrochloride|Given IV
119195|NCT01493271|Drug|RO5093151|oral doses twice daily for up to 28 days
119196|NCT01493284|Device|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
119197|NCT01493297|Other|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
119198|NCT01493310|Drug|mifepristone|Given orally (by mouth)
Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)
119199|NCT01493310|Drug|placebo|Given orally
119200|NCT01493310|Drug|nab-paclitaxel|Given by intravenous infusion (IV)
Dose of 80 mg/m2
119201|NCT01493323|Behavioral|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
119202|NCT01493323|Behavioral|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
118686|NCT01492413|Behavioral|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
118687|NCT01492426|Drug|BMS-790052 (Daclatasvir)|Film coated Tablet, Oral, 60 mg, Once daily, 24 weeks
118688|NCT01492426|Drug|Telaprevir|Film coated Tablet, Oral, 750 mg, three times daily, 12 weeks
118689|NCT01492426|Drug|Peginterferon alfa-2a|Solution for Injection, Subcutaneous injection, 180 μg, Weekly, 24 or 48 weeks
118690|NCT01492426|Drug|Ribavirin|Film coated Tablet, Oral, 1000 mg or 1200 mg based on weight, twice daily, 24 or 48 weeks
118691|NCT01492439|Behavioral|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
118692|NCT01492439|Behavioral|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
118693|NCT01492452|Other|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
118694|NCT01492465|Drug|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
118695|NCT00072475|Drug|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or > tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
118934|NCT01492751|Radiation|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
118761|NCT01490346|Drug|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
118762|NCT01490359|Behavioral|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
118763|NCT01490359|Behavioral|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
118764|NCT00072293|Procedure|axillary lymph node dissection|Axillary lymph node dissection
118765|NCT01490385|Device|LED Phototherapy|
118766|NCT01492504|Drug|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention [(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)]
118767|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
118768|NCT01492517|Other|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
118769|NCT01492517|Other|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
118770|NCT01492517|Other|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
118771|NCT01492530|Behavioral|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
118772|NCT01492530|Behavioral|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
118773|NCT01492543|Drug|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
118774|NCT01492556|Drug|Etoposide|Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
118775|NCT00072488|Procedure|computed tomography|
119002|NCT01490723|Procedure|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
119447|NCT01491464|Device|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
119448|NCT01491464|Device|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
118540|NCT01494714|Drug|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
118541|NCT01494714|Drug|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
118542|NCT01494727|Drug|CJ Amlodipine/Valsartan 10/160mg|single dose
118543|NCT01494727|Drug|Novartis Exforge 10/160mg|single dose
118544|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
118545|NCT01497015|Behavioral|memory training|10 1-hour sessions over 6-8 weeks
118546|NCT01497015|Behavioral|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
118547|NCT00072839|Drug|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
118548|NCT01497015|Behavioral|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
118549|NCT01497028|Procedure|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
118550|NCT01497041|Drug|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
118551|NCT01497041|Drug|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
118552|NCT01497093|Drug|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
118553|NCT01497093|Drug|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
118554|NCT01497093|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
118555|NCT01497106|Behavioral|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
119203|NCT01493323|Behavioral|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
119204|NCT01493323|Procedure|Cyber ball game|functional neuroimaging
119205|NCT00072514|Drug|carboplatin|Given IV
119206|NCT01493323|Procedure|Iowa Gambling Task|functional neuroimaging
119207|NCT01493323|Procedure|Microcomputer|functional neuroimaging
119208|NCT01493323|Procedure|blood sample|blood sample
119209|NCT01493336|Drug|capecitabine RTD|single oral dose
119210|NCT01493336|Drug|capecitabine [Xeloda]|single oral dose
119211|NCT01493336|Drug|capecitabine [Xeloda]|standard treatment
119212|NCT00072670|Drug|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m^2) weekly as 3-hour infusion or 1.5 mg/m^2 or 1.2 mg/m^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
119213|NCT01495715|Drug|Placebo|
119214|NCT01495728|Procedure|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
119215|NCT01495728|Procedure|Sham Manipulation|Mid and Upper Thoracic Spine
119216|NCT01495754|Other|coffee|Comparison of different amounts of coffee
119217|NCT01495767|Other|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
118326|NCT01499095|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
118327|NCT01499108|Drug|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
118328|NCT01499121|Drug|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop > grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
118935|NCT01492751|Radiation|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
118936|NCT01492790|Procedure|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
118937|NCT00072501|Procedure|breast imaging study|
118938|NCT01492790|Procedure|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
118939|NCT01492803|Dietary Supplement|Probiotics|Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as "generally recognized as safe" (GRAS)
118940|NCT01492803|Dietary Supplement|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
118941|NCT01492816|Behavioral|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
In ATN 105, the C2P intervention is being extended for an additional five years because of the length of time that it takes to achieve changes in community structures and for the community structures to take hold and have an effect on reducing HIV risk in our target population of adolescents and young adults.
118942|NCT01495260|Drug|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
118943|NCT01495260|Drug|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
118944|NCT01495260|Drug|vitamin E|vitamin E, 150-300 mg daily for 2 months
118945|NCT01495273|Procedure|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
118946|NCT01495273|Procedure|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
119279|NCT01491191|Dietary Supplement|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
119280|NCT01491191|Dietary Supplement|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
119281|NCT00001272|Drug|taxol|
119003|NCT01490736|Drug|Lemuteporfin|lemuteporfin topical solution, 1%
119004|NCT01490749|Drug|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
119005|NCT01490749|Drug|XELOX|Patients will receive two cycles of XELOX.
119006|NCT01490749|Drug|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
119007|NCT01490749|Radiation|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
119008|NCT01490762|Drug|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
119009|NCT01492829|Behavioral|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
119010|NCT01492855|Procedure|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
119011|NCT01492855|Behavioral|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
119012|NCT01492881|Drug|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
119013|NCT01492881|Drug|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
119014|NCT01492881|Drug|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
119015|NCT00001282|Drug|Zidovudine (AZT) & Interleukin-2 (IL2)|
119016|NCT00072501|Procedure|comparison of screening methods|
119017|NCT01492894|Drug|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
119018|NCT01492894|Drug|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
119019|NCT01492907|Radiation|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
119020|NCT01492907|Procedure|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
119021|NCT01492920|Dietary Supplement|Acetyl-L-Carnitine Hydrochloride|Given orally
119022|NCT01492920|Other|Placebo|Given orally
118556|NCT01497106|Behavioral|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
118557|NCT01497119|Drug|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
118558|NCT00072839|Drug|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
118559|NCT01497119|Drug|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
119107|NCT01493024|Drug|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent), or placebo, administered 3 times (tid) daily with meals.
119108|NCT01493024|Drug|silicified microcrystalline cellulose|Randomized to mimic escalating doses of experimental drug administered 3 times (tid) daily with meals.
119109|NCT01493037|Device|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
119110|NCT01493050|Drug|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
119111|NCT01493050|Drug|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
119112|NCT00072501|Procedure|radiomammography|
119113|NCT01493076|Device|Primary cannulation/precut sphincterotomie with the Baby-S|At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the "Albaran"-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome.
119114|NCT01493089|Drug|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
119115|NCT01493089|Drug|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
119116|NCT01493102|Drug|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
119117|NCT01493102|Drug|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
119118|NCT01493115|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
119119|NCT01493115|Drug|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
118329|NCT01499134|Drug|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
118330|NCT01499134|Drug|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
118331|NCT01499147|Drug|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
118332|NCT01499147|Drug|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl).
118333|NCT01499160|Drug|letrozole|Drug is are to be taken orally. 2.5 mg once daily
118334|NCT01499160|Drug|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
118335|NCT00073164|Drug|Olanzapine|
118336|NCT01499160|Drug|everolimus|Drug is to be taken orally. 5 mg once daily.
118337|NCT01501201|Drug|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
118338|NCT01501214|Drug|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
118339|NCT01501214|Drug|Normal saline|Normal saline given
118621|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
118622|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
118623|NCT01494805|Other|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
118624|NCT01494818|Device|Hydrogen peroxide-based contact lens care system|
118625|NCT01494818|Device|PHMB-containing contact lens solution|
118626|NCT01494818|Device|Soft contact lenses|Contact lenses identical to habitual prescription worn per usual replacement regimen
119282|NCT01493388|Drug|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
119283|NCT01493401|Procedure|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
119284|NCT01493414|Drug|INC424|All patients enrolled into the study receive INC424 (ruxolitinib). The study drug is provided as 5 mg tablets. Sixty tablets are packaged per bottle. Starting dose is based on baseline platelet counts: 15 mg BID PO with PC 100 - 200,000/μl or 20 mg BID PO with PC > 200,000 μl. After 4 weeks, dose can be increased by 5 mg BID (15 mg BID increased to 20 mg BID or 20 mg BID increased to 25 mg BID) if warranted. No INC424 dose will exceed 25 mg BID PO.
119285|NCT01493427|Drug|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
119286|NCT00072514|Drug|dexamethasone|Given PO
119287|NCT01493440|Drug|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
119288|NCT01493453|Genetic|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
119289|NCT01493479|Drug|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
119290|NCT01493479|Drug|Rituximab|All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.
In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to <= 20% to enter the main treatment phase of the trial.
119291|NCT01493505|Drug|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
119292|NCT01493505|Drug|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
119293|NCT01493505|Drug|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
119294|NCT01493505|Drug|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
119295|NCT01493518|Drug|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
119296|NCT01493531|Drug|Lesinurad|Tablets, 200 mg QD
119297|NCT00072514|Biological|rituximab|Given IV in Group 2 only (CD20-POSITIVE LYMPHOMAS)
118395|NCT01505296|Drug|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
119023|NCT01492920|Other|Questionnaire Administration|Ancillary studies
119353|NCT01491269|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
119354|NCT01491282|Other|Enabling and disabling VNS|No intervention
119355|NCT01491295|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months
119356|NCT01491295|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months Adefovir 10mg QD for 36 months
119357|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
119358|NCT01491308|Other|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
119359|NCT01491321|Procedure|Bee Venom Acupuncture Therapy|Bee Venom 1:20,000 under BVA Increment Protocol
Increment Protocol as
1st week : SC 0.2cc/day, 2days/week
2nd week : SC 0.4cc/day, 2days/week
3rd week : SC 0.8cc/day, 2days/week
119360|NCT01491321|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
119361|NCT01491321|Procedure|Placebo|Normal Saline (0.9% NaCl) under NS Increment Protocol
Increment Protocol as
1st week : SC 0.2cc/day, 2days/week
2nd week : SC 0.4cc/day, 2days/week
3rd week : SC 0.8cc/day, 2days/week
119362|NCT01491360|Procedure|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
119363|NCT01493570|Drug|BI 409306|High dose film-coated tablet
119364|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
119365|NCT01493570|Drug|BI 409306 Placebo|Film-coated tablet
119366|NCT00072527|Drug|carboplatin|IV
119367|NCT01493570|Drug|BI 409306|Medium dose film-coated tablet
119120|NCT01493154|Biological|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
119121|NCT01493154|Drug|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
119122|NCT01493167|Other|limb casting/splinting|ankle and arm cast
119123|NCT00072501|Procedure|ultrasound imaging|
119124|NCT01493180|Drug|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension 2%
119125|NCT01493180|Drug|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution 0.1%
119140|NCT01495689|Behavioral|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
119141|NCT01495702|Drug|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
119142|NCT01495702|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
119143|NCT01495702|Drug|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
119144|NCT01495715|Drug|Idebenone|
119145|NCT01498380|Drug|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease < 20% or blood pressure decrease/increase < 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease >/= 20% or SBP/DBP/MAP decrease or increase >/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
119146|NCT01498393|Device|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
119147|NCT01498406|Dietary Supplement|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
119148|NCT01498419|Drug|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|M (400 mg tablet) Pa (100 mg tablet) Z (1500 mg- 3 500 mg tablets) once daily for 8 weeks
119149|NCT01498419|Drug|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|M (400 mg tablet) Pa (200 mg tablet) Z (1500 mg- 3 500 mg tablets) once daily for 8 weeks in Drug Sensitive Participants
118627|NCT01494831|Behavioral|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
118628|NCT00072553|Procedure|conventional surgery|
118629|NCT01494844|Device|Respiratory monitor patient interface.|Wear each interface for 20 minutes
118630|NCT01494857|Drug|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
118631|NCT01494870|Procedure|PCI|urgent PCI on admission
118632|NCT01494883|Behavioral|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
118633|NCT01494909|Dietary Supplement|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
118634|NCT01494922|Drug|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
118635|NCT01494935|Behavioral|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
118636|NCT01494935|Behavioral|Control diet|Normal fat, normal fat diet
118637|NCT01494948|Other|allergen challenge|nasal challenges with antigen to which they are sensitive to
118638|NCT00072839|Drug|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
118639|NCT01497184|Genetic|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
118640|NCT01497197|Drug|GONAL-f®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen.
118641|NCT01497197|Drug|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
118642|NCT01497197|Biological|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
118643|NCT01497210|Device|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
118884|NCT01495208|Drug|Aflibercept|intravitreal aflibercept injection 2mg
118885|NCT01495221|Drug|Alfilbercept|All patients will receive 2.0 mg intravitreal aflibercept injection.
118886|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
118396|NCT01505296|Procedure|Catheter ablation|Complete PVI
118397|NCT01505309|Device|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
118398|NCT01505335|Device|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
118399|NCT01505348|Other|Overnight fast|Overnight fast from 21:00 h
118400|NCT01499173|Behavioral|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
118401|NCT01499186|Other|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
118402|NCT01499199|Drug|Dolutegravir|50mg Once Daily
118403|NCT01499212|Procedure|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
118404|NCT01499225|Drug|YH14642 500mg Tab|YH14642 500mg per day(once a day)
118405|NCT01499225|Drug|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
118406|NCT01499225|Drug|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
118407|NCT01499225|Drug|INSADOL[Zea mays L. extract] 35mg Tab|[Initiation dose : 4weeks after administraion] INSADOL[Zea mays L. extract] 210mg TAB per day
[Maintain dose : Between 4weeks and 8weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day
[Maintain dose : Between 8weeks and 12weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day
118408|NCT01499225|Drug|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA[Doxycycline hyclate] Cap 40mg per day
118409|NCT00073164|Drug|Risperidone|
118410|NCT01499225|Drug|Placebo|Placebo
118411|NCT01499238|Device|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
118412|NCT01499238|Device|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
118413|NCT01499251|Drug|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
119368|NCT01493596|Drug|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
119369|NCT01493596|Drug|Placebo|An equal volume of water mixed with juice will be administered.
119370|NCT01493609|Behavioral|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
118474|NCT01505374|Procedure|Control Technique|The other leg will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
118475|NCT01505387|Dietary Supplement|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
118476|NCT01505387|Dietary Supplement|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
118477|NCT01505413|Drug|Erlotinib|Erlotinib 100 mg po qd daily
118478|NCT01505413|Drug|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
118479|NCT01505413|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
118480|NCT01505426|Drug|ASP1941|oral
118481|NCT00073879|Drug|fludarabine phosphate|
118482|NCT01505426|Drug|metformin|oral, concomitant use
118483|NCT01505426|Drug|Placebo|oral
118484|NCT01505439|Drug|solifenacin|oral
118485|NCT01505465|Drug|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
118486|NCT01505465|Drug|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
118487|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
118488|NCT01505491|Drug|BI695501|BI 695501 single s.c injection
118489|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
118490|NCT01505504|Drug|mirtazapine|30 mg at bedtime
118491|NCT01505530|Drug|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
119150|NCT01498419|Drug|Drug Sensitive: Rifafour|Rifafour e-275 once daily for 8 weeks in Drug Sensitive participants. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
119151|NCT01498419|Drug|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|M (400 mg tablet) Pa (200 mg tablet) Z (1500 mg- 3 500 mg tablets) once daily for 8 weeks
119152|NCT01498432|Drug|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
119153|NCT01498432|Drug|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
119154|NCT00073021|Drug|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
119155|NCT01498445|Drug|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
119449|NCT01491477|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
119450|NCT00072384|Procedure|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
119451|NCT01491477|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
119452|NCT01491490|Drug|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
119453|NCT01491490|Drug|Placebo|Capsules taken once a day for 6 weeks
119454|NCT01491503|Drug|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
119455|NCT01491503|Drug|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
119456|NCT01493752|Dietary Supplement|beetroot juice|250mls daily beetroot juice
119457|NCT01493765|Other|Simulator training with expert scoring|Residents will be trained using surgical simulation
119458|NCT01493778|Drug|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
119459|NCT01493791|Drug|CDB-2914|
119460|NCT01493817|Other|laboratory biomarker analysis|Correlative studies
119461|NCT01493830|Genetic|fluorescence in situ hybridization|
118887|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
118888|NCT00072605|Drug|VRC-EBODNA012-00-VP|
118889|NCT01495247|Drug|BEZ235 + Paclitaxel|Doses of oral BEZ235 (BID), supplied as 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.
BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts.
118890|NCT01497574|Drug|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
118891|NCT01497587|Drug|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
118892|NCT01497600|Drug|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
118893|NCT01497600|Drug|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
118894|NCT01497613|Behavioral|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
118895|NCT01497613|Behavioral|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
118896|NCT01497626|Drug|Lapatinib and bortezomib|Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.
Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts.
118897|NCT01497639|Device|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
118898|NCT01497639|Device|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
118899|NCT00072930|Biological|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
118900|NCT01497652|Drug|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
118901|NCT01497652|Drug|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
119218|NCT01495780|Behavioral|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
118414|NCT01499251|Drug|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
118696|NCT01492491|Device|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
118697|NCT01494961|Behavioral|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
118698|NCT00072553|Procedure|neoadjuvant therapy|
118699|NCT01494974|Device|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
118700|NCT01494974|Device|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
118701|NCT01494987|Drug|Ranolazine|Ranolazine tablet(s) administered orally
118702|NCT01494987|Drug|Placebo|Placebo to match ranolazine for the duration of the study
118703|NCT01494987|Drug|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
118704|NCT01494987|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
118705|NCT01494987|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
118706|NCT01495000|Drug|denosumab|60mg subcutaneous injection, single dose
118707|NCT01495000|Drug|placebo|placebo subcutaneous injection, single dose
118708|NCT01495013|Drug|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
118709|NCT00072566|Biological|Bevacizumab|Given IV
118710|NCT01495013|Drug|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
118711|NCT01495013|Drug|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
118712|NCT01495013|Drug|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
118713|NCT01495013|Drug|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
118492|NCT00073879|Procedure|allogeneic bone marrow transplantation|
118493|NCT01505530|Drug|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
118494|NCT01505569|Drug|Ifosfamide|Arms A&B: 1.8 g/m^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen
Arm C: 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles
118495|NCT01499303|Drug|Fostamatinib|Phase II Trial to evaluate the efficacy of 200mg fostamatinib
118496|NCT01499316|Procedure|High Flow oxygen|10 minute shigh flow oxygen
118776|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS at sham point
118777|NCT01492569|Other|questionnaire administration|Ancillary studies
118778|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS
118779|NCT01492582|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Given IM
118780|NCT01492582|Other|laboratory biomarker analysis|Correlative studies
118781|NCT01492582|Other|survey administration|Ancillary studies
118782|NCT01492582|Other|medical chart review|Ancillary studies
118783|NCT01492608|Drug|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
118784|NCT01492621|Drug|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
118785|NCT01492634|Other|Prescription of post-dialytic weight based on BCM device|Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).
The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.
Prescription steps will be calculated weekly for all study patients. TAFO < -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO > 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week.
118786|NCT00072488|Procedure|magnetic resonance imaging|
118787|NCT01495013|Drug|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
119462|NCT01493830|Genetic|gene expression analysis|
119463|NCT01493830|Genetic|microarray analysis|
119464|NCT01493830|Genetic|mutation analysis|
119465|NCT00072527|Drug|irinotecan hydrochloride|IV
119466|NCT01493830|Genetic|protein analysis|
119467|NCT01493830|Other|immunohistochemistry staining method|
119468|NCT01493830|Other|laboratory biomarker analysis|
119469|NCT01493830|Other|microscopy|
119470|NCT01493843|Drug|GDC-0941|Repeating oral dose
119471|NCT01493843|Drug|Placebo|Repeating oral dose
119472|NCT01493843|Drug|bevacizumab|Intravenous repeating dose
119473|NCT01493843|Drug|carboplatin|Intravenous repeating dose
118560|NCT01497119|Drug|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
118561|NCT01497132|Drug|Vitamin D3|Oral drops 30000 IU weekly
118562|NCT01497132|Drug|Placebo|Matching placebo
118563|NCT01497145|Drug|KRN321|
118564|NCT01497158|Other|Self-help brochure|Self help brochure given at baseline visit.
118565|NCT01497158|Other|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
118566|NCT01497171|Procedure|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
118567|NCT01497171|Procedure|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
118568|NCT01497184|Procedure|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
118569|NCT01490047|Drug|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
118570|NCT01490047|Drug|Liposomal doxorubicin|Infusion over 60 minutes
119219|NCT01495793|Drug|Rotigotine|Rotigotine transdermal patch:
Dose (size): 0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied.
119220|NCT01495806|Drug|Glucomannan|2 x 5g
119221|NCT01495806|Drug|placebo|glucose 5 g
119222|NCT01495819|Drug|Saline|5cc's of saline give at least once.
119223|NCT00001296|Drug|melphalan|
119224|NCT00072683|Drug|tolvaptan|
119225|NCT01495819|Drug|Nicotine|1.5, 3.0, 4.5, or 6.0 mcg/kg.
119226|NCT01495832|Other|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
119227|NCT01495832|Other|Control Group|The control group will consume comparator foods for 12 weeks.
119228|NCT01495845|Other|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
119229|NCT01495858|Drug|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
119230|NCT01495858|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
119231|NCT01495858|Drug|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
119232|NCT01495871|Dietary Supplement|Amino Acids|15 grams amino acids two times per day for 6 weeks
119233|NCT01495871|Dietary Supplement|Placebo of inert compounds|Placebo two times per day for 6 weeks
119234|NCT01495871|Dietary Supplement|Valine|2.5 grams valine supplementation two times a day for 6 weeks
119235|NCT00072969|Drug|Daclizumab|
119236|NCT01497912|Drug|Placebo|Placebo tablet once daily for 8 weeks
119237|NCT01497925|Drug|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
118714|NCT01495013|Drug|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
118715|NCT01495013|Drug|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
118716|NCT01495013|Drug|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
118717|NCT01495013|Drug|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
118947|NCT01495286|Device|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
118948|NCT01495299|Device|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
118949|NCT01495312|Device|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
118950|NCT01495325|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
118951|NCT00072618|Drug|Exisulind|
118952|NCT01495325|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
118953|NCT01495338|Drug|AC-170 0.17%|1 drop in one eye at one timepoint
118954|NCT01495338|Drug|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
118955|NCT01495338|Drug|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
118956|NCT01495338|Drug|Olopatadine hydrochloride 0.2%|1 drop in one eye at one timepoint
118957|NCT01495338|Drug|Tears Naturale II (vehicle)|1 drop in one eye at one timepoint
118958|NCT01495351|Drug|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
118959|NCT01495364|Biological|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
118960|NCT01495364|Other|placebo|matching placebo
121437|NCT01515176|Drug|Dinaciclib|Given IV
121438|NCT01515176|Other|Laboratory Biomarker Analysis|Correlative studies
121751|NCT01513200|Drug|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
121752|NCT01513200|Drug|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
121753|NCT01513226|Other|Cycled light|lights on at daytime, lights off at nighttime
121754|NCT01513239|Biological|MK-6072|Single infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
121755|NCT01513239|Biological|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
121756|NCT00074438|Drug|methotrexate|Oral or parenteral repeating dose
121757|NCT01513239|Biological|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
121758|NCT01513239|Drug|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
121759|NCT01513252|Behavioral|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
121760|NCT01513265|Other|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
121761|NCT01513278|Drug|APN201|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).
121762|NCT01513278|Drug|Placebo|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).
119903|NCT01521910|Dietary Supplement|low protein diet|An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.
The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.
Supplementation of Calcium of 500mg/day.
Urine albumin losses >= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet.
119904|NCT01521910|Dietary Supplement|normal protein diet|The patients pre-study diet during the whole study period
Patients were also seen by the same doctor during each visit for the whole study period.
119905|NCT01521923|Biological|Certolizumab Pegol + Methotrexate (MTX)|Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.
On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).
CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.
The MTX treatment is to remain between 15-25 mg/week.
119906|NCT01521923|Biological|Placebo + Methotrexate (MTX)|1 syringe of Placebo every 2 Weeks and MTX.
The MTX treatment is to remain between 15-25 mg/week.
119907|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (lower dose)
119908|NCT01521936|Other|pharmacological study|Correlative studies
119909|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (higher dose)
120209|NCT01525004|Drug|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
120210|NCT01525004|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
120211|NCT01525017|Biological|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
120212|NCT01525043|Drug|Naproxen|Naproxen 500mg BID for the first 2 weeks
120213|NCT00075608|Biological|filgrastim|16mcg/kg IV daily beginning three days prior to SCC through last day of SCC
120214|NCT01525043|Drug|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
120215|NCT01525043|Drug|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
120216|NCT01525043|Drug|Naproxen|500mg bid
120217|NCT01525043|Drug|Synera|Topical appication of single patch to elbow for 12hrs/day
120218|NCT01525043|Drug|Synera|Single patch applied to elbow for 4hrs/twice daily
119474|NCT01493843|Drug|paclitaxel|Intravenous repeating dose
119475|NCT01493856|Drug|Cresto|tablet, rosuvastatin 20mg
119476|NCT00072527|Radiation|radiation therapy|
119477|NCT01493856|Drug|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
119478|NCT01493856|Drug|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
119479|NCT01493869|Drug|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
119480|NCT01493882|Drug|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
119481|NCT01493882|Drug|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
119482|NCT01493882|Drug|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
119483|NCT01493882|Drug|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
119484|NCT01496183|Drug|Olanzapine|Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
119485|NCT01496183|Drug|Placebo|Placebo capsule administered orally at bedtime for 14 days
119486|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
119487|NCT00072761|Procedure|transfusion therapy|Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
119488|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
119489|NCT01496209|Biological|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
119490|NCT01496209|Biological|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
119491|NCT01496235|Dietary Supplement|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
119492|NCT01496235|Dietary Supplement|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
119835|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (2 courses): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8.
119836|NCT01497002|Biological|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
120134|NCT01517659|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
120135|NCT01517672|Behavioral|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
120136|NCT01517685|Dietary Supplement|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
120137|NCT01517685|Dietary Supplement|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
120138|NCT01517698|Drug|Placebo|placebo to RO4917523 orally once a day for 12 weeks
120139|NCT01517698|Drug|RO4917523|0.5 mg orally once a day for 12 weeks
120140|NCT01517698|Drug|RO4917523|1.5 mg orally once a day for 12 weeks
120141|NCT00074828|Drug|enoxaparin|
120142|NCT01517711|Drug|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
120143|NCT01517711|Drug|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
120144|NCT01517724|Drug|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
120145|NCT01517750|Device|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
120146|NCT01517750|Device|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
120147|NCT01517763|Device|Conventional CPAP Therapy|HC244 devices without Thermosmart or SensAwake
120441|NCT01522885|Procedure|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
120442|NCT01522898|Procedure|AV nodal ablation|Percutaneous catheter ablation of the AV node.
120443|NCT01522898|Drug|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
120444|NCT01522911|Device|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
119546|NCT01493895|Device|LLLT-808 B-cure laser machine|From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.
All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.
Every treatment will consist of the following steps:
A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.
Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.
The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards.
119547|NCT01493908|Drug|High price|Acetaminophen label as high price
119548|NCT00072540|Drug|celecoxib|
119549|NCT01493908|Drug|Low price|Acetaminophen label as low price
119550|NCT01493908|Drug|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
119551|NCT01493908|Drug|No price|acetaminophen. No price - price issue not introduced to participants.
119552|NCT01493908|Drug|Free of charge|Acetaminophen. participants aware the product is free of charge
119553|NCT01493921|Drug|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
119554|NCT01493921|Drug|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
119555|NCT01493934|Drug|injection of 6-DIG|Unique injection dose of 92.5 MBq
119556|NCT01493947|Drug|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
119557|NCT01493947|Drug|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
120219|NCT01525056|Radiation|ct and mri scans|ct and mri scan preradiation and postradiation
120220|NCT01517802|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
120221|NCT01517802|Drug|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
120222|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:
in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.
in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.
120223|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:
in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.
in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.
120224|NCT01517828|Drug|Sedation by ketamine|Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.
One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.
120512|NCT01520519|Drug|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
120513|NCT01520519|Drug|PCI-32765|420 mg (3 * 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
120514|NCT01520532|Other|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
120515|NCT01520545|Drug|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
120516|NCT01520558|Biological|CNDO-109-AANK Cells|Single dose, infusion
120517|NCT00075231|Drug|Kaletra® (lopinavir/ritonavir)|
120518|NCT01520571|Procedure|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
120519|NCT01520571|Procedure|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
120520|NCT01520584|Dietary Supplement|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
119493|NCT01496248|Dietary Supplement|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
119494|NCT01496261|Drug|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
119763|NCT01489904|Biological|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
119764|NCT00072280|Biological|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose < 1yr 0.025 mg/kg > or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
119765|NCT01489917|Other|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
119766|NCT01489930|Behavioral|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
119767|NCT01489930|Behavioral|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for ~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
119768|NCT01489930|Behavioral|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
119769|NCT01489943|Drug|GSK1605786|
119770|NCT01489956|Biological|Subcutaneous Immucothel|100 ug at day 0 (priming dose) and day 9(booster dose)
119771|NCT01491997|Behavioral|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
119772|NCT01492010|Dietary Supplement|whey protein|25 g whey protein
119773|NCT01492010|Dietary Supplement|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
119774|NCT01492010|Dietary Supplement|whey protein supplemeted with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
119775|NCT00072436|Drug|gemcitabine hydrochloride|Given IV
120148|NCT01517763|Device|Fixed pressure ICON™ without ThermoSmart™|Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
120149|NCT01517763|Device|Auto ICON™ with SensAwake™ and ThermoSmart™|APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
120150|NCT01517776|Drug|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
120151|NCT01517776|Drug|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
120152|NCT00074841|Drug|Azithromycin/Chloroquine|
120427|NCT01520454|Drug|Saline|IV saline at 0.83 mL/kg/hr for six hours
120428|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
120429|NCT01522820|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
120430|NCT01522820|Other|Laboratory Biomarker Analysis|Correlative studies
120431|NCT01522820|Other|Pharmacological Study|Correlative studies
120432|NCT01522820|Drug|Sirolimus|Given PO or PEG
120433|NCT01522846|Drug|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
120434|NCT01522859|Device|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
120435|NCT01522872|Drug|TH-302|
120436|NCT01522872|Drug|TH-302 and Dexamethasone|
120437|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
120438|NCT00075478|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
120439|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
120440|NCT01522885|Device|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
119558|NCT01493960|Drug|Kappaproct|30 mg rectal dose at week 0 and 4
119559|NCT00072540|Procedure|anti-cytokine therapy|
119560|NCT01493960|Drug|Placebo|Rectal dose at week 0 and 4
119561|NCT01493973|Drug|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
119562|NCT01493973|Drug|Placebo|Placebo
119563|NCT01493986|Drug|Ropivacaine|Dosage. Onset time
119564|NCT01493999|Drug|Clopidogrel reloading|Up to three times 600 mg clopidogrel
119565|NCT01493999|Drug|Prasugrel|60 mg prasugrel in patients with HPR
119566|NCT01494012|Radiation|stereotactic body radiation therapy|Undergo SBRT
119837|NCT01489956|Biological|Subcutaneous Immucothel plus Montanide|100 ug SQ Immunoclthel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
119838|NCT01489956|Biological|Oral KLH followed by immunization|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
119839|NCT01489969|Drug|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
119840|NCT01489982|Device|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
119841|NCT00001270|Drug|interleukin-1|
119842|NCT00072280|Drug|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
119843|NCT01489982|Behavioral|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
119844|NCT01489982|Drug|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
119845|NCT01489982|Device|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
119846|NCT01489995|Drug|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
119847|NCT01489995|Drug|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
119848|NCT01489995|Drug|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
120521|NCT01520623|Other|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
120522|NCT01520636|Procedure|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
120523|NCT01522950|Drug|atenolol|25 mg daily or 50 mg daily
120524|NCT00075491|Drug|fenretinide|Given orally
120525|NCT01522950|Drug|placebo|one tablet daily
120526|NCT01522963|Drug|Nicotine lozenge 4 mg|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
120527|NCT01522976|Drug|Azacitidine|Given SC or IV
120528|NCT01522976|Drug|Lenalidomide|Given PO
120529|NCT01522976|Drug|Vorinostat|Given PO
119620|NCT01491802|Drug|GSK573719/GW642444|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
119621|NCT01491802|Drug|GSK573719|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
119622|NCT01491815|Drug|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
119623|NCT01491815|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
119624|NCT01491815|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
119625|NCT01491815|Biological|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.
Methotrexate: 25mg/week
119626|NCT01491828|Device|Kai Strap|Medical device component that vibrates on a subject's neck.
119627|NCT01494012|Procedure|computed tomography|Undergo FDG-PET/CT
119628|NCT01494012|Other|questionnaire administration|Ancillary studies
119629|NCT00072540|Procedure|antiangiogenesis therapy|
119776|NCT01492023|Behavioral|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
119777|NCT01492036|Other|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR), . blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
120069|NCT01519700|Drug|EP2006|Eligible patients will be teated with EP2006
120070|NCT01519700|Drug|Filgrastim|Eligible patients will be teated with Filgrastim
120071|NCT01519713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
120072|NCT00075140|Genetic|Mutation in the gene|
120073|NCT01519726|Drug|Midazolam|
120074|NCT01519739|Device|MediGuide™|MediGuide™ system will be used to guide CRT implants
120075|NCT01519752|Drug|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
120076|NCT01519752|Drug|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
120077|NCT01519752|Drug|Placebo|Placebo applied to affected area once a day for 28 days
120078|NCT01519765|Drug|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
120079|NCT01519765|Drug|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
120080|NCT01519778|Drug|TR701 FA|1 tablet 200 mg once daily
120081|NCT01519791|Biological|Certolizumab Pegol|Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.
Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50.
120082|NCT01522209|Procedure|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
120083|NCT01522209|Device|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
120084|NCT01522209|Radiation|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
120085|NCT00075439|Other|laboratory biomarker analysis|Correlative studies
121384|NCT01508065|Device|Glucometer GM-205|The study procedure consists of two days trial. Each day consists of 4-6 hours, during which, hyper and hypoglycaemic clump will be done. The first day will be used to calibrate the non-invasive Glucometer GM-205 for the specific patient.. The calibration will be done using the hexokinase assay (YSI 2300 STAT Plus ) from the venous. During the second day, hyper and hypo glycemic clump will be done and the results of blood glucose level reading from the non-invasive
121385|NCT01508091|Behavioral|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
121386|NCT01508091|Behavioral|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
121387|NCT01508104|Drug|BEZ235|dose escalation 400mg- 1000mg per day
121696|NCT01515657|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 3 days
121697|NCT00074620|Drug|PEG-hirudin|
121698|NCT01515683|Behavioral|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
121699|NCT01515683|Behavioral|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
121700|NCT01515683|Behavioral|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
121701|NCT01515683|Behavioral|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
121702|NCT01515696|Drug|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
121703|NCT01515696|Drug|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
121704|NCT01515722|Behavioral|Health education intervention (HEI)|<Part 1> Understanding OAB
<Part 2> Behavioral/lifestyle modification
<Part 3> Bladder training
<Part 4> Understanding antimuscarinics
121705|NCT01515748|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
121706|NCT01515748|Drug|OXALIPLATIN (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
121707|NCT01515748|Drug|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + CDHP (Gemeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
121708|NCT00074152|Drug|chemotherapy|Given within 10 weeks after surgery.
121709|NCT01508624|Other|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
119849|NCT01489995|Drug|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
119850|NCT01489995|Drug|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
119851|NCT01490008|Drug|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
119852|NCT01490008|Other|Green Tea|Healthy volunteers in treatment arm 2 will drink "Lipton® Green Limone" in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals
119853|NCT00072280|Drug|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
119854|NCT01490021|Procedure|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
119855|NCT01490021|Procedure|rTMS/Placebo TBS|rTMS/Placebo TBS
119856|NCT01490034|Behavioral|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
120153|NCT01517789|Device|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.
Flash and steady state visual evoked potential are measured during the surgical procedure at different times.
120154|NCT01519791|Other|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
120155|NCT00075166|Procedure|Stereotactic surgery (SRS)|
120156|NCT01519791|Biological|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
120157|NCT01519804|Drug|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
120158|NCT01519804|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
120159|NCT01519804|Drug|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
120160|NCT01519804|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
120161|NCT01519817|Biological|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
121763|NCT01513291|Drug|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
121764|NCT01513291|Drug|Placebo|Placebo, 2 tablets, orally, once daily
121765|NCT01513304|Procedure|Manual therapy|
120891|NCT01516736|Drug|Doxorubicin|
120892|NCT01516736|Drug|Cyclophosphamide|
120893|NCT01516749|Drug|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
120894|NCT01516762|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
120895|NCT01518803|Dietary Supplement|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
120896|NCT01518842|Biological|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
120897|NCT01518855|Drug|Nifedipine (Adalat, BAYA1040)|
120898|NCT01518855|Drug|Amlodipine (Norvasc)|
120899|NCT01518855|Drug|Diovan|
120900|NCT01518881|Drug|TKM-100201|IV Infusion
120901|NCT01518881|Drug|Placebo|IV infusion
120902|NCT00001335|Drug|G-CSF|
120903|NCT00075010|Drug|Valproic acid|20 mg/kg given orally daily for 10 days
120904|NCT01518894|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
120905|NCT01518894|Drug|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
120906|NCT01518894|Drug|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
120907|NCT01518894|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
120086|NCT01522209|Radiation|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
120087|NCT01522222|Procedure|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
120088|NCT01522235|Drug|IVIG|Participants will be randomized to Group A (2 treatments of IVIG and 2 treatments of placebo), or Group B (4 treatments of IVIG). Placebo is 5% albumin. Study treatment with IVIG, at 2.0 gm/kg over 2-5 consecutive days, and then 1.0 gm/kg over 2-5 consecutive days three weeks later. Placebo 5% at equivalent volume.
120374|NCT01525368|Behavioral|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
120375|NCT01525394|Drug|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
120376|NCT01525394|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
120377|NCT01525394|Drug|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
120378|NCT01525407|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
120379|NCT01525407|Drug|Atorvastatin Calcium|Given PO
120380|NCT01525407|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
120381|NCT01525420|Behavioral|Acceptance Therapy (ACT)|ACT
120382|NCT01525420|Other|Cognitive Behavioral Therapy (CBT)|CBT
120383|NCT00075621|Procedure|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
120384|NCT01525433|Behavioral|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
120385|NCT01525433|Behavioral|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
120386|NCT01525446|Radiation|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
120387|NCT01525459|Procedure|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
121710|NCT01508624|Other|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
121711|NCT01508624|Behavioral|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
121712|NCT01508624|Behavioral|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
121713|NCT01508637|Other|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
121714|NCT01508637|Other|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
120839|NCT01521143|Biological|Placebo|Study agent dosing will be administered as an intradermal injection every 4 weeks for the first 3 doses, then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
120840|NCT01521143|Biological|Cvac|Study agent dosing will be administered as an intradermal injection every 4 weeks for the first 3 doses, then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
120841|NCT01521156|Other|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
120842|NCT01521156|Other|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
120843|NCT01521169|Other|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
120844|NCT00075283|Device|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
120845|NCT01521169|Other|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
120846|NCT01521169|Other|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
120847|NCT01521182|Other|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
120848|NCT01521182|Other|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
120849|NCT01521195|Device|Extracorporeal blood flow via ECMO machine|Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.
Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%
120850|NCT01521208|Device|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
120162|NCT01519830|Drug|Iron carboxymaltose (Ferinject)|Intravenous iron
120163|NCT01519830|Drug|Placebo|0.9% NaCl solution
120164|NCT01519843|Device|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
120165|NCT01519843|Device|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
120166|NCT00075166|Procedure|Craniotomy|
120167|NCT01519856|Drug|piribedil (Clarium)|oral tablets, 50 mg
120168|NCT01519869|Drug|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
120169|NCT01519882|Other|Placebo|Placebo patches size equivalent to 4, 6 & 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.
Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day.
120170|NCT01519882|Other|Rotigotine|Rotigotine patches of 4,6 & 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.
Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day.
120171|NCT01519895|Behavioral|Telephone intervention|counseling and education support
120445|NCT01522924|Other|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
120446|NCT01522937|Radiation|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
120447|NCT01522950|Drug|Nebivolol|5 mg daily or 10 mg daily
120448|NCT01525628|Drug|pegylated interferon|HCV treatment
120449|NCT00075634|Drug|cyclophosphamide|Given IV
120450|NCT01525628|Drug|BI 201335|HCV protease inhibitor
120451|NCT01525628|Drug|BI 201335|HCV protease inhibitor
120452|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
120453|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
120908|NCT01518907|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
120909|NCT01518920|Drug|PF-04958242|PF-04958242 0.35 mg oral solution
120910|NCT01518920|Drug|PF-04958242|PF-04958242 0.27 mg oral solution
120911|NCT01518920|Drug|Placebo|Placebo oral solution
120912|NCT01518933|Drug|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
120913|NCT01518933|Drug|Saline|Placebo
121185|NCT01519479|Other|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
121186|NCT01519492|Drug|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
121187|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
121188|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
121189|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
121190|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
121191|NCT01521780|Procedure|MRI|Participants undergo volumetric & diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
121192|NCT01521780|Procedure|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
121193|NCT00075387|Drug|Sodium Thiosulfate|Given IV
121194|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
121195|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
121196|NCT01521793|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
121197|NCT01521806|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to snack foods
121198|NCT01521819|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
120388|NCT01525459|Other|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
120389|NCT01518023|Other|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
120390|NCT00074867|Drug|CP-547,632|
120391|NCT01518036|Drug|somatropin|2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
120392|NCT01518036|Drug|somatropin|4.3 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
120393|NCT01518062|Drug|somatropin|4 IU/m^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
119495|NCT01496261|Drug|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
119496|NCT01496274|Biological|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
119497|NCT01496287|Device|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
119498|NCT00072774|Drug|DVS-233 SR|
119499|NCT01496300|Procedure|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
119500|NCT01496300|Procedure|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
119501|NCT01496313|Drug|300mg vandetanib|Oral blinded tablets taken once daily.
At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment
Dosing with unblinded study treatment can continue until 24 months after patient was randomised.
At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.
119502|NCT01496313|Drug|150mg vandetanib|Oral blinded tablets taken once daily.
At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg
Dosing with unblinded study treatment can continue until 24 months after patient was randomised
At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) [OR 300 reduced to 200mg/day if dose was increased at unblinding.] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.
119503|NCT01496326|Drug|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
119504|NCT01496326|Drug|placebo|2 grams of placebo cream for 14 days
119505|NCT01489371|Other|laboratory biomarker analysis|Correlative studies
120851|NCT01521208|Other|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
120852|NCT01521221|Other|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
120853|NCT01521234|Behavioral|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
120854|NCT01523561|Behavioral|dance group|The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and "become part of the movement" was encouraged.
120855|NCT01523574|Drug|Vitamin E|Vitamin E 400mg PO orally
121126|NCT01524003|Procedure|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
121127|NCT01524016|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
121128|NCT01524042|Procedure|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
121129|NCT01524055|Device|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
121130|NCT00075556|Radiation|radiation therapy|
121131|NCT01524055|Device|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
121132|NCT01524068|Drug|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
121133|NCT01524068|Drug|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
121134|NCT01524081|Drug|Metronidazole, Cefuroxime|administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.
- Cefuroxime in 100ml saline
- Metronidazole in 500ml saline
121135|NCT01524081|Drug|Amoxicillin (+ clavulanic acid) and Fluconazole|Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.
- 2x amoxicillin in 100ml saline
- Fluconazole in 500ml saline
120454|NCT01525628|Drug|BI 201335|HCV protease inhibitor
120455|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
120456|NCT01525628|Drug|ribavirin|HCV treatment
120457|NCT01525628|Drug|ribavirin|HCV treatment
120458|NCT01525628|Drug|ribavirin|HCV treatment
120459|NCT01525628|Drug|pegylated interferon|HCV treatment
120460|NCT00075634|Biological|filgrastim|Given SC
120461|NCT01525628|Drug|ribavirin|HCV treatment
120462|NCT01525628|Drug|caffeine|CYP1A2 probe drug
120463|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
120464|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
120465|NCT01525628|Drug|midazolam|CYP3A probe drug
120466|NCT01525628|Drug|BI 201335|HCV protease inhibitor
120467|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
120468|NCT01525628|Drug|ribavirin|HCV treatment
120469|NCT01525641|Drug|Mirapex LA|Pramipexole Hydrochloride Hydrate
119567|NCT01494012|Procedure|positron emission tomography|Undergo FDG-PET/CT
119568|NCT01496339|Biological|MenSCs transplantation|1×10^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
119569|NCT01496339|Drug|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
119570|NCT01496352|Drug|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
119571|NCT01496352|Drug|Placebo|DFA-02 placebo
119572|NCT00072787|Drug|S-1|
119573|NCT01496365|Drug|DS-5565 tablet|5mg and 10mg tablets
119574|NCT01496365|Drug|pregabalin capsule|75mg and 150mg over-encapsulated
121199|NCT01521819|Drug|Lucentis|Intravitreal injection of Lucentis as needed.
121200|NCT01521832|Drug|SEN0014196|5 mg single oral dose
121201|NCT01521832|Drug|SEN0014196|25 mg single oral dose
121202|NCT01521832|Drug|SEN0014196|75 mg single oral dose
121203|NCT01521832|Drug|SEN0014196|150 mg single oral dose
121204|NCT00075400|Drug|imatinib mesylate|Given PO
121205|NCT01521832|Drug|SEN0014196|300 mg single oral dose
121206|NCT01521832|Drug|SEN0014196|600 mg single oral dose
121207|NCT01521832|Drug|SEN0014196|300 mg single oral dose (females)
121439|NCT01515176|Biological|Ofatumumab|Given IV
121440|NCT01515176|Other|Pharmacological Study|Correlative studies
121441|NCT01515189|Biological|Ipilimumab|
121442|NCT01515202|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
121443|NCT01515202|Drug|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
121444|NCT01515202|Drug|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
121445|NCT01515202|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
121446|NCT01515202|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
121447|NCT00001328|Device|G1TKSVNa.53 Producer Cell Line|
121448|NCT00074581|Drug|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
121449|NCT01515215|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
121450|NCT01515228|Device|Xience Prime|everolimus-eluting stent implantation
121451|NCT01515228|Device|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
121452|NCT01515241|Drug|CER-001|Weekly injection
119506|NCT01489397|Device|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
119507|NCT01489410|Drug|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
119508|NCT01489410|Drug|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
119509|NCT01489423|Genetic|RNA analysis|
119510|NCT01489423|Genetic|in situ hybridization|
119511|NCT01489423|Genetic|polymerase chain reaction|
119512|NCT00072215|Drug|vinblastine|given IV
119513|NCT01489423|Other|enzyme-linked immunosorbent assay|
119514|NCT01489423|Other|flow cytometry|
119778|NCT01492036|Behavioral|Questionnaires|Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.
Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time.
119779|NCT01492049|Behavioral|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
119780|NCT01492049|Behavioral|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
119781|NCT01492049|Behavioral|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
119782|NCT01492062|Device|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
119783|NCT01492075|Drug|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
119784|NCT01492088|Drug|brentuximab vedotin|Brentuximab vedotin will be administered by intravenous (IV) infusion once every 21 days. Each 21-day treatment cycle is composed of 1 day study drug treatment, followed by a monitoring period of 20 days. Patients may receive brentuximab vedotin for up to 16 cycles. Treatment with brentuximab vedotin beyond 16 cycles may be allowed for responding patients after discussion between the investigator and medical monitor. Following the final dose of brentuximab vedotin patients will be monitored for safety for a minimum of 30 days. Patients will be followed for progression-free survival (PFS) and overall survival (OS) every 12 weeks for 12 months after the end of treatment (EOT) visit. Thereafter, assessment for OS will continue every 6 months until the sooner of death or study closure or a maximum of 2 years after enrollment of the last patient.
121136|NCT01524081|Drug|Placebo|Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery
- 100ml saline solution
- 500ml saline solution
121137|NCT01524081|Drug|Placebo|Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery
- 2x 100ml saline solution
- 500ml saline solution
121138|NCT01524094|Drug|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
121139|NCT01524094|Procedure|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
121140|NCT01516983|Drug|icotinib|Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.
Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.
Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.
Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity.
121388|NCT01508104|Drug|Everolimus|dose escalation 2.5 to 5 mg per day
121389|NCT01508117|Drug|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
121390|NCT01508117|Radiation|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
121391|NCT00074074|Biological|infliximab|
121392|NCT01508143|Drug|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
121393|NCT01508143|Drug|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
121394|NCT01508156|Drug|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
121395|NCT01508156|Drug|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
121396|NCT01508169|Device|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
121397|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
121398|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
119575|NCT01496365|Drug|Placebo tablet|
119576|NCT01496365|Drug|placebo capsule|
119577|NCT01496378|Behavioral|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
119578|NCT01496404|Procedure|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
119579|NCT01496404|Procedure|Scalpel|Incising skin (epidermis and dermis) with scalpel.
119580|NCT01496417|Drug|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
119581|NCT01496430|Drug|Placebo|
119582|NCT01496430|Drug|Azilsartan medoxomil|
119583|NCT00072787|Drug|cisplatin|
119584|NCT01496430|Drug|Azilsartan medoxomil|
119585|NCT01496443|Drug|TAK-875 and Glimepiride|
119586|NCT01496456|Device|Resin infiltration|Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
119587|NCT01496456|Behavioral|Caries management|Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and OTC-fluoride supplements
119588|NCT01496469|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
119857|NCT01490034|Behavioral|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
119858|NCT01490034|Behavioral|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
119859|NCT01490034|Behavioral|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
119860|NCT01492101|Drug|Treatment of Physician's Choice (TPC)|One of the following Treatment of Physician Choice will be administered per standard of care:
eribulin ixabepilone vinorelbine gemcitabine paclitaxel docetaxel or nab-paclitaxel
121453|NCT01515254|Behavioral|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
121454|NCT01515293|Procedure|Single Incision Laparoscopic Appendectomy|
121455|NCT01515293|Procedure|Conventional appendectomy|
121456|NCT01515306|Biological|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
121457|NCT01515306|Drug|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
121458|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
121459|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
121460|NCT00074087|Drug|pegylated liposomal doxorubicin hydrochloride|
121766|NCT01513317|Drug|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
121767|NCT00074438|Drug|rituximab|Intravenous repeating dose
121768|NCT01515891|Drug|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
121769|NCT00074646|Drug|CC-8490|
121770|NCT01515904|Behavioral|STOMP Clinic|A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a "key worker" (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions.
121771|NCT01515917|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
121772|NCT01515917|Drug|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
121773|NCT01515917|Other|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
119785|NCT01492101|Drug|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90 minute intravenous (IV) infusion on day 1 of each treatment cycle.
119786|NCT00001280|Drug|itraconazole|
119787|NCT00072436|Drug|alvocidib|Given IV
119788|NCT01494350|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
119789|NCT01494363|Drug|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
119790|NCT01494363|Drug|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
119791|NCT01494363|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
119792|NCT01494363|Drug|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
119793|NCT01494402|Drug|D961S|Oral gelatine capsule
119794|NCT00072540|Procedure|enzyme inhibitor therapy|
119795|NCT01494402|Drug|Esomeprazole|Oral HPMC capsule
120089|NCT01522248|Biological|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
120090|NCT01522261|Other|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
120091|NCT01522261|Other|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
120092|NCT01522274|Behavioral|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
120093|NCT01522274|Behavioral|Health education|Videos
120094|NCT01522287|Behavioral|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
120095|NCT01522300|Other|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
120096|NCT00075452|Drug|gemcitabine hydrochloride|
120097|NCT01522300|Other|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
120098|NCT01522326|Drug|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
121399|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
121400|NCT01510262|Behavioral|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
121401|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
121402|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
121403|NCT01510288|Drug|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
121715|NCT01508637|Drug|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
121716|NCT01508637|Drug|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
121717|NCT01508650|Behavioral|Usual care|Usual care control group
121718|NCT01508650|Behavioral|Rehabilitation intervention|Multi-domain rehabilitation intervention
121719|NCT00074152|Radiation|radiation therapy|Given within 6 months after surgery
121720|NCT01508663|Device|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
121721|NCT01508663|Drug|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
121722|NCT01508676|Drug|Pennsaid|
121723|NCT01508676|Drug|Placebo (2.3% DMSO solution)|
121724|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
119861|NCT01492114|Dietary Supplement|Resveratrol|Subjects in the group "resvetarol first" will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting).
119862|NCT01492114|Dietary Supplement|resveratrol|Subjects in the group "Placebo first" will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting).
119863|NCT01492127|Biological|Blood test|Blood test
119864|NCT01492140|Procedure|Subdermal Injection|Injection of dermal filler
119865|NCT01492140|Device|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
119866|NCT01492153|Drug|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
119867|NCT01492153|Drug|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
119868|NCT01492153|Drug|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
119869|NCT01492166|Drug|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
119870|NCT00072436|Other|pharmacological study|Correlative studies
119871|NCT01492179|Drug|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
119872|NCT01492179|Drug|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
119873|NCT01492179|Drug|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
119874|NCT01492192|Drug|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.
The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions
120172|NCT01519908|Device|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
120173|NCT01519921|Drug|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
120174|NCT01519947|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|50-250 mcg sc according to local label
121774|NCT01515917|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
121775|NCT01515930|Behavioral|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. MI seeks to increase motivation & self-efficacy by altering decisional & self-regulatory balances through eliciting verbalizations that are consistent with change. MI is consistent with psychotherapy research, which indicates empathy, optimism, & congruence are strongly related to outcome. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding monitoring diabetes care.
121776|NCT01515930|Behavioral|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. MI seeks to increase motivation & self-efficacy by altering decisional & self-regulatory balances through eliciting verbalizations that are consistent with change. MI is consistent with psychotherapy research, which indicates empathy, optimism, & congruence are strongly related to outcome. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding diabetes care.
121777|NCT01515930|Behavioral|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
120641|NCT01525615|Device|Respimat inhaler|Respimat inhaler
120642|NCT01525615|Drug|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
120643|NCT01525615|Drug|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
120644|NCT01525615|Device|Respimat inhaler|Respimat inhaler
120645|NCT01525615|Device|Respimat inhaler|Respimat inhaler
120646|NCT00075634|Drug|doxorubicin hydrochloride|Given IV
120647|NCT01525615|Drug|placebo to tiotropium+olodaterol|comparator
120648|NCT01525628|Drug|midazolam|CYP3A probe drug
120649|NCT01525628|Drug|BI 201335|HCV protease inhibitor
120650|NCT01525628|Drug|tenofovir|nucleoside analogue
120651|NCT01525628|Drug|caffeine|CYP1A2 probe drug
120652|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
120099|NCT01522326|Drug|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
120100|NCT01522339|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
120101|NCT01522352|Procedure|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
120102|NCT01522365|Device|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
120103|NCT01522365|Device|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
120104|NCT00075595|Drug|FOLFIRI regimen|
120105|NCT01524731|Drug|Saline|Normal Saline
120106|NCT01524731|Drug|Dexamethasone|4 mg
120107|NCT01524731|Drug|Dexamethasone|8 mg
120108|NCT01524744|Drug|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
120109|NCT01524744|Drug|Adcortyl|triamcinolone acetonide 0.1% in orabase
120110|NCT01524757|Drug|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
120111|NCT01524770|Biological|Dulaglutide|Administered by subcutaneous (SC) injection
120394|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
120395|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface, the second year and finally 8 IU/m^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
120396|NCT01518062|Drug|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
120397|NCT01518075|Other|Spontaneous Breathing|Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.
Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
121725|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
121726|NCT01508702|Drug|lesinurad|Tablets, 400 mg QD
121727|NCT01508702|Drug|Placebo|Tablets, Placebo QD
121728|NCT01508715|Other|Shoulder resistive exercise|Both groups will perform the seated "full can", sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks.
121729|NCT01510795|Drug|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
121730|NCT01510808|Procedure|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
121731|NCT01510821|Other|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
121732|NCT01510821|Other|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
120856|NCT01523574|Drug|Placebo|Placebo, given orally
120857|NCT01523587|Drug|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
120858|NCT01523587|Drug|erlotinib|erlotinib taken once daily
120859|NCT01523600|Behavioral|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
120860|NCT01523600|Behavioral|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
120861|NCT01523613|Device|Glassionomer restoration|High-viscous glassionomer restoration used as posterior dental filling material.
120175|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
120176|NCT01522378|Drug|123 iodine metaiodobenzylguanidine|10 mCi (370 MBq)
120177|NCT01522391|Drug|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
120178|NCT01522391|Drug|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
120179|NCT00075452|Drug|oxaliplatin|
120180|NCT01522404|Drug|Atomoxetine|6 month, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
120181|NCT01522404|Drug|Placebo|At the six-month timepoint, subjects who were taking placebo during the first six months will be placed on active study medication.
120182|NCT01522417|Drug|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
120183|NCT01522417|Drug|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
120184|NCT01522417|Drug|Long Tirofiban|25 ug/kg i.v. bolus followed by a 0.15 ug/kg/min i.v. infusion for 12 to 18 hours post-PCI.
120185|NCT01522430|Procedure|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
120186|NCT01522430|Procedure|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
120187|NCT01522443|Drug|cabozantinib|Tablets taken orally once daily.
120188|NCT01522443|Drug|mitoxantrone|Given by IV once every 3 weeks.
120189|NCT01522443|Drug|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
120190|NCT00075465|Drug|docetaxel|
120191|NCT01522456|Drug|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
120470|NCT01525654|Behavioral|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
120653|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
120654|NCT01525628|Drug|midazolam|CYP3A probe drug
120655|NCT01525628|Drug|caffeine|CYP1A2 probe drug
120656|NCT01518348|Biological|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
120657|NCT01518374|Drug|Florbetapir F 18|370 MBq (10 mCi)
120658|NCT00074971|Drug|Fabrazyme (agalsidase beta)|
120659|NCT01518387|Drug|Lanthanum Carbonate (BAY77-1931)|
120660|NCT01518413|Drug|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
120661|NCT01518413|Drug|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
120662|NCT01518426|Device|EEG Recording (Emotiv)|Record EEG during auditory oddball paradigms:
with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)
with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)
120663|NCT01518439|Device|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
119725|NCT01494337|Procedure|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
119726|NCT01494337|Procedure|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
119727|NCT01496690|Drug|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
119728|NCT01496690|Drug|Pregabalin Placebo Capsules|Parallel to Active Comparator
119729|NCT01496703|Other|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
119730|NCT01496716|Procedure|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
119731|NCT01496729|Procedure|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
119732|NCT01496729|Procedure|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
120398|NCT01518075|Other|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
120399|NCT01518088|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to study foods
120400|NCT01518101|Drug|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
120401|NCT00074893|Device|piezoelectric wrist brace|
120402|NCT01518101|Drug|Liraglutide|1.2 mg once daily by commercially available injection pens
120403|NCT01518101|Drug|Metformin|1000 mg tablets twice daily
120404|NCT01518114|Behavioral|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
120405|NCT01518127|Other|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
120406|NCT01518140|Device|Oxygen Delivery Devices|Participants receive air through VapoTherm for 1 hour, and then on an "as needed" basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask.
120407|NCT01518140|Behavioral|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
120408|NCT01520298|Drug|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
119515|NCT01489423|Other|immunohistochemistry staining method|
119516|NCT01489423|Other|laboratory biomarker analysis|
119517|NCT01489436|Procedure|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
120862|NCT01523626|Other|Total body Computed Tomography.|The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.
The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT.
120863|NCT00001343|Drug|Humatrope|
120864|NCT00075543|Drug|docetaxel|
120865|NCT01523626|Other|Conventional imaging and selective CT scanning.|The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.
Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers.
120866|NCT01523639|Drug|Metformin/Placebo|The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.
Duration of treatment: 24 weeks
120867|NCT01523678|Drug|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
120868|NCT01523678|Drug|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
120869|NCT01523678|Drug|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
121141|NCT01516983|Radiation|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
121142|NCT01516996|Drug|docetaxel and cisplatin|The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT
121143|NCT01516996|Radiation|IMRT|IMRT is administered with chemotherapy from week 7 to week 13
GTV（primary tumor）：68-70Gy/35~38 F，once a day, 5 times per week
CTV（Clinical target）：56-66Gy/30~36f，once a day, 5 times per week
GTV-ln（positive neck region）：66-70Gy/33~36 F，once a day, 5 times per week
CTV-ln（negative neck region）：50-54Gy/28~30F, once a day, 5 times
121144|NCT01516996|Biological|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13~14 weeks
121145|NCT01517009|Drug|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
121146|NCT01517009|Drug|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
121147|NCT00074789|Behavioral|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
120471|NCT00075634|Biological|pegfilgrastim|Given SC
120472|NCT01525667|Biological|150M PLX-PAD|Single course, multiple IM injections
120473|NCT01525667|Biological|300M PLX-PAD|Single course, multiple IM injections
120474|NCT01525667|Biological|Placebo|Single course, multiple IM injections
120475|NCT01525680|Other|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
120476|NCT01525680|Other|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
120477|NCT01518153|Drug|Fludarabine|40 mg/m^2 by vein on Day -6 to -3.
120478|NCT01518153|Drug|Melphalan|140 mg/m^2 by vein on Day -2.
120479|NCT01518153|Drug|Alemtuzumab|50 mg by vein on Day -1.
120480|NCT01518153|Procedure|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
120481|NCT00001335|Drug|Topotecan|
120482|NCT00074906|Drug|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
120483|NCT01518153|Drug|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
120484|NCT01518153|Drug|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
120485|NCT01518153|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
120486|NCT01518153|Procedure|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64.
120487|NCT01518153|Procedure|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64.
120488|NCT01518166|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
120489|NCT01518166|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
120490|NCT01518166|Drug|atorvastatin|One single dose of 40 mg. Tablet
119733|NCT01496742|Drug|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
119734|NCT00072826|Drug|Acetylcholine|
119735|NCT01496742|Drug|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
119736|NCT01496742|Drug|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
119737|NCT01496742|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
119738|NCT01496742|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
119739|NCT01496742|Drug|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
119740|NCT01496755|Drug|Placebo|Single/multiple doses
119741|NCT01496755|Drug|RG7667|Single/multiple ascending doses
119742|NCT01496768|Dietary Supplement|Leucine|7,2 g/day during 3 months
119743|NCT01496768|Dietary Supplement|Alanine|7,2 g/day during 3 months
119744|NCT01496781|Procedure|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
119745|NCT00072839|Drug|ALX-0600|teduglutide
119746|NCT01496781|Procedure|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
120033|NCT01524692|Drug|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
120034|NCT01524705|Drug|"GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]|Glargine-injectable, variable, QD, 6 months Metformin-oral, up to 1000mg, BID, 6 months Exenatide-injectable, 5mcg, BID, 6 months
120035|NCT01524705|Drug|Insulin glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
120036|NCT01524718|Radiation|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
120037|NCT01517451|Radiation|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
120038|NCT01517451|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
119518|NCT01489436|Procedure|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
119519|NCT01489449|Device|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
119520|NCT01489449|Device|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
119521|NCT01489462|Behavioral|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
119522|NCT01489462|Behavioral|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
119523|NCT00072228|Drug|gemcitabine|
119524|NCT01489462|Behavioral|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
119525|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter [mg/mL], i.e. 16 mL) under fasting conditions
119526|NCT01491503|Drug|Montelukast & levocetirizine|Montelukast sodium 10mg & levocetirizine dihydrochloride 5mg PO. Single dose.
119527|NCT01491516|Device|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
119528|NCT01491529|Drug|AFQ056|AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.
Patients will be randomized in two groups by amantadine status.
Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.
Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)
119529|NCT01491529|Drug|Placebo|Placebo for AFQ056 will be supplied as oral tablets.
119796|NCT01494402|Drug|Buffered acetylsalicylic acid|Tablet
119797|NCT01494415|Drug|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
119798|NCT01494415|Drug|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
119799|NCT01494415|Radiation|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
121148|NCT01517009|Drug|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
121149|NCT01517009|Procedure|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
121150|NCT01517022|Drug|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
121151|NCT01517035|Procedure|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
121152|NCT01517074|Drug|Sirolimus|Subconjunctival injection
121153|NCT01517100|Drug|Nabllone|CB Agonist
121154|NCT01517100|Drug|CP-945,598|Cannabinoid Receptor 1 antagonist
121155|NCT01517100|Procedure|Hypoglycemic Clamp|Assesses beta cell response
121156|NCT01517100|Drug|Euglycemic-Hyperinsulinemic Clamp|Measures insulin sensitivity
121157|NCT01517165|Drug|Pioglitazone|
121158|NCT00074789|Behavioral|Attention control/usual care|Participants will receive the usual care for depression.
121159|NCT01517165|Drug|Placebo|
121160|NCT01517178|Device|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
121161|NCT01517178|Device|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
121404|NCT01510301|Device|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;
Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;
Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence.
121405|NCT01510314|Biological|C-reactive protein and procalcitonin dosages|
121406|NCT01510327|Device|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
121407|NCT01510327|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
119589|NCT01496469|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
119590|NCT01496482|Other|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
119591|NCT01496495|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
119592|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
119593|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
119594|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
119595|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
119596|NCT01489501|Procedure|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
119597|NCT01489514|Other|Epicutaneous skin prick testing|Epicutaneous skin prick testing will be performed utilizing the following extracts:
Histamine control purchased from Greer.
Saline control purchased from Greer.
Standard Peanut Extract purchased from Greer.
Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A & T.
Sterile extract prepared from roasted & blanched but untreated peanuts. This is prepared by North Carolina A & T.
Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A & T. This is not classified as a drug and is
Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.
Sterile extracts containing peanuts that have been treated with alcalase
119598|NCT01489527|Biological|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
119599|NCT01489527|Other|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
119600|NCT00072228|Drug|soblidotin|
119601|NCT01489540|Device|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
119602|NCT01489566|Drug|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
119603|NCT01489566|Drug|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
120039|NCT01517464|Genetic|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
120040|NCT01517477|Device|iStent|Implantation of One iStent through a small temporal clear corneal incision.
120041|NCT01517477|Device|iStent|Implantation of Two iStents through a small temporal clear corneal incision
120042|NCT01517477|Device|iStent|Implantation of Three iStents through a small temporal clear corneal incision
120043|NCT01517490|Other|Insulin pump|Insulin pump therapy
120044|NCT01517490|Other|Multiple daily insulin injections|Multiple daily insulin injections
120045|NCT00074815|Behavioral|Instructional cognitive behavioral therapy by a psychiatrist|The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor "best practice" treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy.
120046|NCT01517490|Procedure|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
120047|NCT01517490|Other|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
120048|NCT01517503|Behavioral|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-minute sessions will be provided over 16 weeks, with sessions generally held twice weekly for the first 6 weeks and once weekly for the next 8 weeks.
120333|NCT01520181|Drug|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
120334|NCT01520207|Drug|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
120335|NCT00075192|Drug|leuprolide acetate and bicalutamide|
120336|NCT01520207|Drug|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
120337|NCT01520220|Drug|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
120338|NCT01520233|Genetic|RNA analysis|
120339|NCT01520233|Genetic|gene expression analysis|
120340|NCT01520233|Other|laboratory biomarker analysis|
119800|NCT01494428|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
119801|NCT01494428|Device|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
119802|NCT01494441|Procedure|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
119803|NCT01494441|Device|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
119804|NCT01494441|Device|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
119805|NCT00000259|Drug|0.3 % Sevoflurane|
119806|NCT00001288|Drug|15 O Water|
119807|NCT00072540|Procedure|growth factor antagonist therapy|
119808|NCT01494454|Device|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
119809|NCT01494454|Device|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
119810|NCT01494467|Drug|CD5024|CD5024 1% Cream, once daily
119811|NCT01494467|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
119812|NCT01494480|Procedure|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
119813|NCT01496846|Drug|Articaine local anesthetic|After unsuccessful IANB, proceed to give 1.7cc of either 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection
119814|NCT01496846|Drug|Lidocaine local anesthetic|After unsuccessful IANB, proceed to give 1.7cc 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection
119815|NCT01496859|Device|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
119816|NCT01496911|Drug|Levocetirizine|a single oral dose of 5 mg
120112|NCT01524783|Drug|Everolimus|After randomization, patients will receive everolimus once daily until disease progression, intolerable toxicity, or consent withdrawal
120113|NCT01524783|Drug|Everolimus Placebo|After randomization, patients will receive everolimus placebo once daily until disease progression, intolerable toxicity, or consent withdrawal
121408|NCT01510327|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
121409|NCT00074204|Drug|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
121410|NCT01510340|Behavioral|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
121411|NCT01510353|Device|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
121412|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
121413|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
121414|NCT01512706|Biological|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
121415|NCT01512706|Biological|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
121416|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
121417|NCT01512706|Biological|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
121418|NCT01512706|Biological|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
121419|NCT00074399|Drug|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
121733|NCT01510834|Behavioral|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
121734|NCT01510847|Drug|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
121735|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|250 mg
121736|NCT00074269|Biological|graft-versus-tumor induction therapy|
121737|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|500 mg
119604|NCT01489579|Behavioral|Brief, Structured, Telephone Counseling for Tobacco Cessation as Part of a Cardiovascular Risk Reduction Service|The patients in the BST counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources ("Ready to quit" patient handout)
119875|NCT01492205|Drug|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
119876|NCT01492218|Drug|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
119877|NCT01492257|Other|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
119878|NCT01492270|Procedure|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
119879|NCT01494493|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
119880|NCT01494493|Procedure|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
119881|NCT01494506|Drug|MM-398|Arm A: MM-398 120 mg/m2 IV Q3W
Arm C: MM-398 80mg/m2 IV Q2W
119882|NCT01494506|Drug|5 Fluorouracil|Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks
Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks
119883|NCT01494506|Drug|Leucovorin|Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks
Arm C: Leucovorin 400 mg/m2 IV every 2 weeks
119884|NCT00072553|Drug|celecoxib|
119885|NCT01494519|Procedure|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
119886|NCT01494519|Procedure|Definitive fixation with a locked IM nail or plate|Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.
Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
119887|NCT01494532|Drug|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
120341|NCT01520246|Genetic|gene expression analysis|
120342|NCT01520246|Other|laboratory biomarker analysis|
120343|NCT01520285|Drug|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
120344|NCT01520285|Drug|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
120345|NCT01522651|Drug|Ranolazine placebo|Placebo to match ranolazine administered orally twice daily
120346|NCT00075478|Drug|Fludarabine Phosphate|Given IV
120347|NCT01522651|Drug|Dronedarone placebo|Placebo to match dronedarone administered orally twice daily
120348|NCT01522664|Drug|DEDN6526A|Multiple ascending doses
120349|NCT01522677|Drug|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
120350|NCT01522690|Other|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
120351|NCT01522703|Drug|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
120352|NCT01522703|Drug|Placebo|Alfalfa Sprouts
120353|NCT01522716|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
120354|NCT01522729|Drug|Fentanyl|Single-dose of intrathecal fentanyl [25ug] Duration of fentanyl : 3.5 hours
120355|NCT01522729|Drug|Placebo comparator|placebo [NaCl]
120664|NCT01518439|Device|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
120665|NCT01518439|Device|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
120666|NCT01518439|Device|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
120667|NCT01518439|Other|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
120114|NCT01524796|Other|No intervention. Non-interventional study|No intervention. Non-interventional study
120115|NCT00075595|Drug|fluorouracil|
120116|NCT01524809|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
120117|NCT01524809|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
120118|NCT01524848|Drug|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
120119|NCT01524861|Drug|Placebo|a placebo tablet bis in die for 12 months
120120|NCT01524861|Drug|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
120121|NCT01524861|Drug|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
120122|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
120123|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
120124|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
120125|NCT01524887|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
120126|NCT00075595|Drug|irinotecan hydrochloride|
120127|NCT01524887|Biological|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
120128|NCT01524913|Drug|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
120129|NCT01524913|Drug|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
120130|NCT01524913|Drug|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
120131|NCT01524926|Drug|Crizotinib (PF-02341066)|Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie
120132|NCT01517633|Device|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
120133|NCT01517646|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
120409|NCT00075205|Drug|SR141716 (Rimonabant)|
121738|NCT01510873|Other|HRQOL evaluation|Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.
The Questionnaire properly formatted will be distributed to all participating Centers prior to study start.
121739|NCT01510899|Drug|RO4917838|Single dose of RO4917838
121740|NCT01510899|Drug|RO4917838|Single dose of RO4917838
121741|NCT01510912|Drug|Diclofenac|35 mg bid or tid Capsules
121742|NCT01510938|Dietary Supplement|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
121743|NCT01510938|Dietary Supplement|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
121744|NCT01510951|Drug|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
121745|NCT01510964|Behavioral|prompt-sheet|Prompt sheet is a form on which to write the reply to the following request: "Please indicate the arguments which you want to discuss today with your oncologist" and a written list of possible questions the patient (companion) would like to ask to the oncology.
121746|NCT01510964|Behavioral|control group|Patients and companions of the control group receive a form on which to write their reply to the following request: "Please indicate the arguments which you want to discuss today with your oncologist"
121747|NCT00074269|Biological|therapeutic allogeneic lymphocytes|
121748|NCT01510977|Drug|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
121749|NCT01510977|Drug|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
121750|NCT01513200|Drug|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
120870|NCT01516619|Drug|Romiplostim|Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.
In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8.
120871|NCT01516632|Behavioral|SMS (Stop my Smoking) USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
119888|NCT01494532|Drug|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
119889|NCT01494545|Device|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
119890|NCT01494558|Other|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
119891|NCT01494584|Drug|ezogabine/retigabine|ezogabine dose escalation
119892|NCT01494597|Drug|isavuconazole|oral
120192|NCT01522456|Drug|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
120193|NCT01522469|Drug|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
120194|NCT01522482|Dietary Supplement|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
120195|NCT01522482|Dietary Supplement|Saturated fatty acids and fish oil meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.
The dose of fish oils was equivalent to two portions of oily fish.
120196|NCT01522482|Dietary Supplement|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
120197|NCT01524939|Drug|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
120198|NCT01524952|Device|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
120199|NCT01524965|Procedure|Immediate mobilisation after locking-plate osteosynthesis|Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.
Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management.
120200|NCT01524965|Procedure|Standard mobilisation after locking plate osteosynthesis|Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.
Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management.
120201|NCT01524965|Device|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
120202|NCT00075595|Drug|leucovorin calcium|
120668|NCT01518452|Behavioral|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
120669|NCT00074984|Biological|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
120670|NCT01518452|Behavioral|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
120671|NCT01518465|Drug|dalteparin|Given SC
120672|NCT01518465|Drug|lenalidomide|Given PO
120673|NCT01518465|Drug|dexamethasone|Given PO
120674|NCT01518465|Other|laboratory biomarker analysis|Correlative studies
120675|NCT01518478|Drug|Fluzone® Intradermal (Sanofi Pasteur Inc.)|Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated "split" influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.
Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus.
120676|NCT01518491|Drug|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
120677|NCT01520753|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
120678|NCT01520766|Device|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
120679|NCT01520766|Device|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
119747|NCT01496807|Drug|Sylatron|Sylatron - Once per week for 12 weeks (while receiving Yervoy), given as an injection under the skin. Both groups will receive the SAME dose of Sylatron.
119748|NCT01496807|Drug|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein). The 2 groups will receive DIFFERENT doses of Yervoy as outlined below.
Group 1: Yervoy, 3 milligrams (mg) per kilogram (kg) of body weight, every 3 weeks for 12 weeks (4 times).
Group 2: Yervoy, 10 milligrams (mg) per kilogram (kg) of body weight, every 3 weeks for 12 weeks (4 times).
119749|NCT01496820|Dietary Supplement|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
120410|NCT01520298|Drug|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
120411|NCT01520311|Device|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
120412|NCT01520324|Device|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
120413|NCT01520337|Device|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
120414|NCT01520350|Drug|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
120415|NCT01520350|Drug|placebo|Placebo
120416|NCT01520363|Drug|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
120417|NCT01520363|Drug|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
120418|NCT01520376|Behavioral|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
120419|NCT01520389|Drug|MM-151|MM-151
120420|NCT00075218|Drug|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
120421|NCT01520389|Drug|MM-151 + irinotecan|MM-151 + irinotecan
120422|NCT01520402|Drug|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
120423|NCT01520415|Drug|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
120424|NCT01520415|Drug|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
120425|NCT01520428|Behavioral|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
120872|NCT01516645|Drug|KHK2898|injection
120873|NCT01516658|Device|Hydrogel coil|at least one Hydrogel coil have to use for embolization
120874|NCT01516658|Device|Bare platinum coil|only bare platinum coil have to use for embolization
120875|NCT01516684|Drug|placebo administration|Given topically
120876|NCT00000259|Other|Placebo|
120877|NCT00001333|Drug|topotecan|
120878|NCT00074737|Drug|Idarubicin|standard of care for AML
120879|NCT01516684|Drug|EMLA|Given topically
120880|NCT01516684|Drug|propofol|Given IV
120881|NCT01516684|Drug|fentanyl citrate|Given IV
120882|NCT01516697|Procedure|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
120883|NCT01516697|Procedure|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
120884|NCT01516710|Procedure|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
120885|NCT01516710|Procedure|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
120886|NCT01516723|Device|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
120887|NCT01516736|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
120888|NCT01516736|Drug|Peg-Filgrastim|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
120889|NCT00074737|Drug|Cytarabine|standard of care Ara-C and High dose Ara-C
120890|NCT01516736|Drug|Docetaxel|
121162|NCT01517204|Device|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
121163|NCT01519310|Other|Antibiotic (metronidazole and ciprofloxacin)/probiotic|Antibiotic cocktail/yogurt as follows:
Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks.
120203|NCT01524978|Drug|cetuximab|Escalating doses administered once weekly by intravenous infusion
120204|NCT01524978|Drug|vemurafenib [Zelboraf]|Escalating doses given twice a day starting on Day 2
120205|NCT01524978|Drug|vemurafenib [Zelboraf]|960 mg twice a day until disease progression, unacceptable toxicity, or withdrawal of consent
120206|NCT01524991|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 & 8 (all cycles)
120207|NCT01524991|Drug|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
120208|NCT01524991|Drug|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
120491|NCT01518166|Drug|lisinopril|One single dose of 20 mg. Tablet
120492|NCT01518166|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
120493|NCT00074919|Biological|alglucosidase alfa|20 mg/kg qow
120494|NCT01518166|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
120495|NCT01518166|Drug|griseofulvin|One single dose of 500 mg. Tablet
120496|NCT01518166|Drug|digoxin|One single dose of 1 mg. Tablet
120497|NCT01518179|Device|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
120498|NCT01518179|Other|Routine follow up and treatment|Control
120499|NCT01518192|Drug|doxycycline|100 mg bid; 15 days
120500|NCT01518192|Drug|cefuroxime axetil|500 mg bid; 15 days
120501|NCT01518205|Device|LDL-apheresis|The patient of the Arm "LDL-apheresis" in addition to standard therapy, will undergo a cycle of LDL-apheresis.
LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).
To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used.
120502|NCT01520454|Drug|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
120503|NCT01520454|Dietary Supplement|Water|Water by mouth
120504|NCT01520454|Dietary Supplement|Soybean oil|Soybean oil by mouth at 1.25 g/kg x 2 doses
120505|NCT00001337|Biological|Rituximab|Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
119750|NCT01496820|Dietary Supplement|Placebo|placebo 1500mg/day for 12weeks
119751|NCT01496833|Device|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
119752|NCT01489787|Procedure|HIFU|Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.
Several metastases can be treated in the same patient
119753|NCT00072267|Drug|topotecan hydrochloride|
119754|NCT01489800|Behavioral|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
119755|NCT01489813|Drug|Genistein|30mg of Genistein supplements by mouth three times daily (PO TID).
119756|NCT01489813|Drug|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
119757|NCT01489826|Drug|Dexanabinol|Patients will (initially) be given a slow infusion (IV) of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle
119758|NCT01489839|Other|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
119759|NCT01489852|Drug|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
119760|NCT01489865|Drug|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
119761|NCT01489891|Drug|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
119762|NCT01489891|Drug|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
120049|NCT01517503|Behavioral|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-minute sessions will be provided over 16 weeks, with sessions generally held twice weekly for the first 6 weeks and once weekly for the next 8 weeks.
120050|NCT01517542|Other|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
120426|NCT01520441|Drug|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
119530|NCT01491542|Device|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
119531|NCT00072384|Procedure|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
119532|NCT01491542|Device|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
119533|NCT01491568|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
119534|NCT01491581|Dietary Supplement|food bar|milk based food bar enriched with micronutrients
119535|NCT01491594|Drug|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
119536|NCT01491607|Biological|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
119537|NCT01491620|Device|532 nm KTP laser|Two laser treatment sessions, 6 weeks apart.
119538|NCT01491633|Drug|Dasatinib|140 mg orally, daily in 28 day cycles
119539|NCT01491659|Dietary Supplement|Idoform Plus|orally once daily
119540|NCT01491659|Dietary Supplement|Placebo|orally once daily
119541|NCT01491672|Drug|RAD001|
119542|NCT00072384|Drug|carboplatin|Given IV
119543|NCT01491698|Procedure|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
119544|NCT01491698|Procedure|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
121164|NCT01519323|Drug|vemurafenib|Multiple doses
121165|NCT01519336|Drug|danoprevir|100 mg q12h
121166|NCT00075075|Drug|Infliximab|
121167|NCT01519336|Drug|darunavir|600 mg q12h
121168|NCT01519336|Drug|ritonavir|100 mg q12h
121169|NCT01519349|Biological|rAAV1.CMV.huFollistatin344|First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)
Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)
Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)
121170|NCT01519388|Other|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
121171|NCT01519388|Device|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
121172|NCT01519401|Drug|3 mg drospirenone and 20 µg ethinyl-estradiol|
121173|NCT01519401|Drug|3 mg drospirenone and 30 µg ethinyl-estradiol|
121174|NCT01519414|Other|Laboratory Biomarker Analysis|Optional correlative studies
121175|NCT01519414|Other|Placebo|Given PO
121176|NCT01519414|Drug|Tivantinib|Given PO
121177|NCT00075088|Device|Electrocardiogram (ECG) Intervention|Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing "Incoming ECG from the field" and print out in the ED.
121178|NCT01519427|Drug|Akt inhibitor MK2206|Given PO
121179|NCT01519427|Drug|selumetinib|Given PO
121180|NCT01519427|Other|laboratory biomarker analysis|Correlative studies
121181|NCT01519453|Behavioral|Home Based Asthma Education|4 home and 3 phone sessions with community asthma outreach worker to provide families with asthma education
121182|NCT01519466|Device|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
121183|NCT01519466|Device|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
121184|NCT01519479|Other|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
120506|NCT00075218|Drug|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
120507|NCT01520454|Drug|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours
120508|NCT01520467|Drug|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
120509|NCT01520467|Drug|Placebo|1 placebo tablet /day administered orally for 18 months.
120510|NCT01520493|Other|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
120511|NCT01520506|Device|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
119605|NCT01489579|Behavioral|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
119606|NCT01489592|Drug|curcuma longa|oral administration of 6 grams of curcumin
119607|NCT01489605|Device|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
119608|NCT01489605|Device|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
119609|NCT01491711|Drug|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
119610|NCT01491711|Drug|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
119611|NCT01491737|Drug|Aromatase Inhibitor|1 mg anastrozole or 2.5 mg letrozole orally once daily
119612|NCT01491737|Drug|Induction Chemotherapy|At the investigator's discretion, patients may also receive induction chemotherapy, either docetaxel or paclitaxel.
120051|NCT01517555|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
120052|NCT01517555|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
120053|NCT01517555|Drug|paracetamol|One single dose of 1 g. Tablet
120054|NCT01517568|Drug|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
120055|NCT01517607|Other|Mesalazine|Patient's treated with oral Mesalazine
120056|NCT00074828|Drug|LY517717|
120057|NCT01517620|Drug|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
120058|NCT01519622|Other|Questionnaire|Questionnaire to be distributed among sick elderly in the community
120059|NCT01519635|Drug|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
120060|NCT00001337|Drug|EPOCH|Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.
120061|NCT00075114|Behavioral|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
120062|NCT01519635|Drug|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
120063|NCT01519661|Drug|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
120064|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
120065|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
120066|NCT01519674|Drug|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
120067|NCT01519674|Drug|metformin|Subjects will continue on their pre-trial metformin treatment.
120068|NCT01519687|Drug|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
120356|NCT01522755|Device|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
119545|NCT01493895|Device|standard hoem treatment|All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.
Every treatment will consist of the following steps:
A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.
Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.
119817|NCT00072839|Drug|placebo|placebo solution injected subcutaneously
119818|NCT01496911|Drug|Hydroxyzine|a single oral dose of 50 mg
119819|NCT01496911|Drug|Placebo|a single oral dose
119820|NCT01496924|Other|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
119821|NCT01496937|Drug|GLPG0974|
119822|NCT01496937|Drug|GLPG0974|
119823|NCT01496950|Device|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
119824|NCT01496950|Device|Placebo|10Hz placebo rTMS delivered to the vertex
119825|NCT01496963|Other|Physician standard-of-care according to ESC/ERS Guidelines|Physician standard-of-care
119826|NCT01496976|Drug|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
119827|NCT01496976|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
119828|NCT00072839|Drug|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
119829|NCT01496976|Drug|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
119830|NCT01496989|Biological|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
119831|NCT01496989|Biological|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
119832|NCT01496989|Biological|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
119833|NCT01496989|Biological|Ad35-GRIN/ENV|(2x10^10vp) Delivered intramuscularly by standard needle injection
119834|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
121420|NCT01512706|Biological|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
121421|NCT01512706|Biological|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
121422|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
121423|NCT01512706|Biological|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
121424|NCT01512719|Procedure|POEM|Per Oral Endoscopic Myotomy for achalasia
121425|NCT01512745|Drug|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
121426|NCT01512745|Drug|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
121427|NCT01512758|Drug|Alisertib|Alisertib will be given orally twice daily for 7 consecutive days followed by a 14-day rest period (cycle length = 21 days). If, at the end of 14 days of rest, all alisertib-related toxicities (except alopecia) have not resolved to less than Grade 2, the cycle will be extended to a maximum of 28 days (ie, additional 7-day rest period). Patients will continue to receive repeated cycles of alisertib treatment for as long as their disease has not progressed and they have not experienced unacceptable alisertib-related toxicity.
121428|NCT01512771|Other|CPAP|6 weeks of CPAP
121429|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).
Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:
First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.
Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:
Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms.
121430|NCT00001318|Drug|interferon gamma|
121431|NCT00074399|Drug|Nevirapine placebo|Placebo tablet taken orally daily
121432|NCT01515137|Drug|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
121433|NCT01515137|Drug|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
121434|NCT01515137|Drug|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
121435|NCT01515163|Behavioral|Exercise training|Aerobic exercise training, two times a week
121436|NCT00074581|Drug|Lamivudine|300 mg taken orally once daily
119613|NCT01491737|Drug|pertuzumab|Loading dose of 840 mg intravenously on Day 1 of first treatment cycle, followed by 420 mg on Day 1 of each subsequent 3-weeks cycle. Until disease progression or unacceptable toxicity.
119614|NCT01491737|Drug|trastuzumab|Loading dose of 8 mg/kg intravenously on Day 1 of first treatment cycle, followed by 6 mg/kg on Day 1 of each subsequent treatment 3-weeks cycles. Until disease progression or unacceptable toxicity.
119615|NCT01491750|Behavioral|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
119616|NCT01491750|Behavioral|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
119617|NCT00072384|Drug|etoposide|Given IV
119618|NCT01491763|Drug|Imatinib|600 mg p.o. from day 1 until consolidation
119619|NCT01491789|Device|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
119893|NCT01494597|Drug|cyclosporine|oral
119894|NCT01494610|Drug|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
119895|NCT00072553|Drug|fluorouracil|
119896|NCT01494610|Drug|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
119897|NCT01494623|Device|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
119898|NCT01494636|Drug|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
119899|NCT01521871|Procedure|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
119900|NCT00075400|Other|laboratory biomarker analysis|Correlative studies
119901|NCT01521884|Other|SC anti-TNF|SC anti-TNF
119902|NCT01521897|Biological|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
120357|NCT00075478|Drug|Mycophenolate Mofetil|Given PO
120358|NCT01522768|Drug|Afatinib (BIBW 2992) and trastuzumab|Patients will be treated with afatinib and trastuzumab combination. Patients will receive intravenous trastuzumab 4 mg/kg every 2 weeks (after the initial 6 mg/kg loading dose if at least 4 weeks elapsed since the last dose of trastuzumab) in combination with afatinib 30 mg daily continuously until disease progression, unacceptable toxicity or serious intercurrent illness develops or if patient consent is withdrawn.
120359|NCT01522794|Drug|NOX-H94|single i.v. infusion
120360|NCT01522794|Drug|Placebo solution|single i.v. infusion
120361|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
120362|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
120363|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
120364|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
120365|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
120366|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
120367|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
120368|NCT00001341|Drug|ZD1694 (TOMUDEX)|
120369|NCT00075478|Drug|Cyclosporine|Given PO
120370|NCT01525316|Dietary Supplement|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
120371|NCT01525316|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
120372|NCT00075621|Drug|melphalan|200 mg/kg over 2 days
120373|NCT01525329|Drug|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting ~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
121042|NCT01523925|Behavioral|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
121043|NCT01523925|Behavioral|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
121306|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
121307|NCT01507948|Behavioral|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
121308|NCT00074022|Other|pharmacological study|Correlative studies
121309|NCT01507974|Drug|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
121310|NCT01507974|Drug|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
121311|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
121312|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
121313|NCT01507974|Drug|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
121314|NCT01507974|Drug|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
121315|NCT01508000|Drug|FOLFOX6|5-FU, folinic acid, oxaliplatin
121316|NCT01508000|Biological|Bevacizumab|Targeted therapy
121317|NCT01508000|Biological|Panitumumab|Targeted therapy
121318|NCT01508000|Procedure|Surgery|
121319|NCT00074035|Drug|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
121320|NCT01508013|Behavioral|Appearance-Focused Website Intervention|The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
121321|NCT01508013|Behavioral|Control Website|The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
120838|NCT01521130|Drug|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
121105|NCT01521624|Drug|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
121106|NCT00075387|Drug|Etoposide Phosphate|Given IV
121107|NCT01521637|Procedure|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
121108|NCT01521637|Procedure|Sham-treatment: no NMES|Sham comparator
121109|NCT01521650|Dietary Supplement|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
121110|NCT01521663|Drug|IPX159|
121111|NCT01521663|Drug|Placebo|
121112|NCT01521676|Genetic|molecular alteration|research of molecular alteration
121113|NCT01521689|Drug|Rituximab|Low doses of sub cutaneaous rituximab
121114|NCT01521702|Drug|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
121115|NCT01521702|Procedure|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
121116|NCT01521715|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
121117|NCT00075387|Other|Quality-of-Life Assessment|Ancillary studies
121118|NCT01521728|Other|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
121119|NCT01521728|Other|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
121120|NCT01521728|Other|Stretching/Range-of-Motion|Stretching and range of motion exercise is widely accepted as a "standard of care" for ALS management.
121121|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of extended release capsules
121122|NCT01523977|Drug|Dexrazoxane|300 mg/m2 IV on days 4 and 5
117948|NCT01500603|Device|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
117949|NCT00073346|Behavioral|Cognitive Behavioral Treatment|
117950|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
117951|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
117952|NCT01500629|Device|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
117953|NCT01500629|Device|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
117954|NCT01500642|Biological|Slit One|slit one sublingual immunotherapy 200 stu
117955|NCT01500642|Biological|Slit One|slit one vestibular immunotherapy 200 stu
117956|NCT01500642|Biological|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
117957|NCT01500655|Procedure|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
117958|NCT01500655|Procedure|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
117959|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
117960|NCT01502371|Drug|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
117961|NCT00001303|Drug|Reference Endotoxin|
117962|NCT00073632|Behavioral|Acceptance Based Behavioral Therapy|
121240|NCT01517269|Behavioral|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
121552|NCT01508312|Drug|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
121553|NCT01508325|Drug|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was >=90 mmHg measured every 4 weeks.
121554|NCT01508325|Drug|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
121555|NCT01508338|Dietary Supplement|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
121556|NCT01508338|Dietary Supplement|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
121557|NCT01508338|Dietary Supplement|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
121558|NCT00074139|Drug|docetaxel|
121559|NCT01508338|Dietary Supplement|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning for 12 weeks.
121560|NCT01510535|Drug|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
121561|NCT01510535|Drug|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
121562|NCT01510535|Drug|LBSA0103|at third week LBSA0103(60mg) once in experimental group
121563|NCT01510548|Biological|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
121564|NCT01510561|Drug|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
121565|NCT01510561|Drug|90Y-hPAM4|
121566|NCT01510561|Drug|90Y-hPAM4 + gemcitabine|
121322|NCT01508026|Drug|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
121323|NCT01508026|Drug|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
121324|NCT01508026|Drug|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
121325|NCT01508026|Drug|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
121619|NCT01508377|Behavioral|Exposure for PTSD with cognitive restructuring|The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)
The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.
First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.
Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.
Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document.
121620|NCT01508377|Behavioral|Exposure for PTSD without cognitive restructuring|The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).
The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.
First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.
Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document.
121621|NCT01508390|Radiation|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
121622|NCT01508429|Other|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
121623|NCT01508429|Drug|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
121624|NCT01508455|Drug|Dexmedetomidine|
121625|NCT01508455|Drug|Midazolam|
121626|NCT01508455|Drug|Fentanyl|
121627|NCT00074139|Drug|doxorubicin hydrochloride|
121628|NCT01508455|Drug|Morphine|
121629|NCT01508468|Drug|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
121123|NCT01523990|Drug|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
121124|NCT01523990|Drug|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
121125|NCT01524003|Procedure|cryotherapy|cryotherapy treatment of the uterine cervix
121371|NCT01515072|Other|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
121372|NCT01515085|Procedure|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
121373|NCT01515098|Dietary Supplement|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
121374|NCT01515098|Dietary Supplement|Dextrose Placebo|Placebo developed to closely match blueberry powder.
121375|NCT01515124|Behavioral|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
121376|NCT01515124|Behavioral|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
121377|NCT01508026|Drug|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
121378|NCT01508026|Drug|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
121379|NCT01508026|Drug|Placebo|Dose matched placebo, oral administration
121380|NCT00074048|Drug|BL22|Dosing via IV on Days 1,3, and 5.
121381|NCT01508039|Other|Chitin Micro Particle|The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).
A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)
121382|NCT01508052|Device|sequential compression device|applying sequential compression device during the surgery
121383|NCT01508052|Device|elastic stockings|applying elastic stockings during the surgery
117963|NCT01502371|Drug|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
117964|NCT01502371|Drug|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
118244|NCT01505023|Dietary Supplement|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
118245|NCT01505023|Dietary Supplement|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
118246|NCT01505036|Other|SMARTCARE service|U-Healthcare service
118247|NCT01505049|Drug|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
118248|NCT00073866|Drug|docetaxel|
118249|NCT01498926|Drug|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
118250|NCT00073138|Drug|ABT-751|
118251|NCT01498926|Drug|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
118252|NCT01498939|Drug|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
118253|NCT01498952|Drug|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
118254|NCT01498952|Drug|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
118255|NCT01498978|Biological|ipilimumab|Given IV
118256|NCT01498978|Other|laboratory biomarker analysis|Correlative studies
118257|NCT01498991|Device|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
118258|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
121567|NCT01510574|Drug|Misoprostol|3 x 200mcg tablets of oral misoprostol
121568|NCT00074230|Biological|Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin|Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.
120700|NCT01523236|Drug|Placebo|Nasal Spray
120701|NCT01523249|Device|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
120702|NCT00075504|Drug|triapine|Given IV
120703|NCT01523262|Procedure|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
120704|NCT01523262|Procedure|Normal surgery, with sham intervention without inflating arm cuff|
120705|NCT01523275|Drug|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
120706|NCT01523275|Other|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
120707|NCT01523301|Drug|Rotigotine|Transdermal Patch
Content:
2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)
For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period
For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period
120708|NCT01523301|Drug|Placebo|Transdermal Patch
Size:
10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2
Subjects randomized to placebo received matching placebo patches
120709|NCT01523314|Drug|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
120710|NCT01523314|Other|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
120711|NCT01523327|Other|measuring protein creatinin ratio,serum uric acid|A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.
Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method.
120712|NCT01523353|Behavioral|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
120713|NCT00075504|Drug|gemcitabine|Given IV
121630|NCT01508468|Drug|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
121631|NCT01508494|Drug|Galantamine|16 mg galantamine daily P/O
121632|NCT01508494|Drug|placebo|placebo
121633|NCT01508546|Procedure|axillary dissection|Conservative breast surgery with or without axillary dissection
121634|NCT01508572|Drug|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
121635|NCT01508585|Behavioral|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
120774|NCT01521000|Device|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
120775|NCT01521013|Behavioral|Supported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook.
120776|NCT01521013|Behavioral|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
120777|NCT01521026|Behavioral|Cognitive Training|12-week compensatory cognitive training in group format
120778|NCT01521039|Procedure|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
120779|NCT00075270|Drug|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
120780|NCT01523418|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) & 5 weeks (THR)
120781|NCT01523431|Drug|CPT-11|CPT-11 will be administered according to UGT1A1 genotypes, while the doses of infusional 5-FU/LV will remain the standard dose.
120782|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice|The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and "talking points" designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence.
117320|NCT01503372|Drug|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
117321|NCT01503372|Drug|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
117605|NCT01506193|Biological|PriorixTetra™|One dose administered subcutaneously
117606|NCT01506193|Biological|Meningitec|One dose administered intramuscularly
117607|NCT01506219|Other|Geriatric Medical Intervention|The geriatric medical intervention includes medical history, medication review, physical examination, paramedical clinical assessment, planning and follow-up incl. medication optimization. Medication adjustments and follow-up of the medication changes in the intervention group will be carried out using the STOP / START method by geriatrician.
117608|NCT01506245|Behavioral|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
117609|NCT01506258|Procedure|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
117610|NCT00073931|Biological|sargramostim|250µg/m2/d subcutaneously
117611|NCT01506258|Procedure|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
117612|NCT01506271|Drug|MK-7655 250 mg with imipenem/cilastatin|Participants randomized to receive MK-7655 250 mg will be administered 250 mg doses of MK-7655 IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
117613|NCT01506271|Drug|MK-7655 125 mg with imipenem/cilastatin|Participants randomized to receive MK-7655 125 mg will be administered 125 mg doses of MK-7655 IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
117614|NCT01506271|Drug|imipenem/cilastatin with placebo|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
117615|NCT01500122|Drug|RhuDex|Part 1:
Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose
The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions.
117616|NCT01500135|Drug|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
118259|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
118260|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
118261|NCT00073151|Drug|ABT-751|
118262|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
121208|NCT01521832|Drug|SEN0014196|100 mg multiple oral dose
121209|NCT01521832|Drug|SEN0014196|300 mg multiple oral dose
121210|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose
121211|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose (females)
121212|NCT01521845|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
121213|NCT01521871|Procedure|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
121214|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
121215|NCT00075569|Biological|HspE7|
121216|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
121217|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
121218|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
121219|NCT01524133|Drug|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
121220|NCT01524133|Behavioral|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
121221|NCT01524146|Procedure|Photodynamic Therapy|PDT is a therapeutic approach that specifically targets neoplastic cells.
• PDT involves three components:
Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.
Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis
Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.
Technique:
Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.
Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months.
120714|NCT01523366|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
120715|NCT01523366|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
120716|NCT01523379|Drug|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
120717|NCT01523379|Drug|Placebo|NaCl i.v. two times a day, two days in an row
120718|NCT01523392|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
120974|NCT01516827|Behavioral|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
120975|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
120976|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
120977|NCT01516840|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
120978|NCT01516840|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
120979|NCT01516853|Device|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
120980|NCT01516866|Procedure|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
120981|NCT01516879|Biological|Evolocumab|Administered by subcutaneous injection once a month
120982|NCT01516879|Biological|Placebo|Administered by subcutaneous injection once a month
120983|NCT00074763|Biological|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
120984|NCT01516879|Drug|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
120783|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
120784|NCT00075517|Drug|docetaxel|
120785|NCT01523457|Drug|Folfirinox|Oxaliplatin 85 mg/m2 IV infused over two hours, followed by
Leucovorin 400 mg/m2 IV over two hours
Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)
5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours
120786|NCT01523470|Device|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
121044|NCT01523925|Behavioral|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
121045|NCT01523925|Behavioral|Functional electrical stimulation|
121046|NCT01523938|Behavioral|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
121047|NCT01523964|Other|Testing with EIM|
121048|NCT01523977|Drug|Everolimus|Orally, daily days 1-32 per assigned dose level
121049|NCT01523977|Drug|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
121050|NCT01523977|Drug|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
121051|NCT00075556|Procedure|neoadjuvant therapy|
121052|NCT01523977|Drug|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
121053|NCT01523977|Drug|Doxorubicin|30 mg/m2 IV on days 4 and 5
121054|NCT01516892|Biological|onabotulinumtoxinA|Patients will receive 155 U of onabotulinumtoxinA approximately every 12 weeks for 96 weeks. OnabotulinumtoxinA will be administered as 31 intramuscular injections in 7 head/neck muscle areas.
121055|NCT01516905|Drug|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
121056|NCT01516918|Drug|VX-222|tablet, 400-mg twice daily
117617|NCT01500135|Drug|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
117618|NCT01500148|Device|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
117619|NCT01500161|Drug|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
117620|NCT01500161|Drug|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
117886|NCT01502332|Other|Mechanical ventilation strategy|Moderate alveolar recruitment ARM: recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
117887|NCT01502345|Biological|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
117888|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
117889|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
117890|NCT01502358|Biological|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
117891|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
117892|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
117893|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
117894|NCT00073814|Drug|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
117895|NCT01504373|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
117896|NCT01504386|Procedure|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
117897|NCT01504386|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
117898|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
117899|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
121222|NCT01524159|Dietary Supplement|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
121223|NCT01524159|Dietary Supplement|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
121461|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
121462|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
121463|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
121464|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
121465|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
121466|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
121467|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
121468|NCT01508208|Other|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
121469|NCT01508221|Drug|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
121470|NCT01508221|Dietary Supplement|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
121471|NCT00074100|Drug|amonafide dihydrochloride|
121472|NCT01508247|Biological|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
121473|NCT01508247|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
121474|NCT01508260|Procedure|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
121475|NCT01508260|Drug|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
120985|NCT01516879|Drug|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
120986|NCT01516879|Other|Diet Only|Diet only, no lipid lowering background drug given
120987|NCT01518985|Drug|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
120988|NCT01518985|Drug|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
120989|NCT01518985|Other|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
121241|NCT01517269|Behavioral|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
121242|NCT01517282|Biological|MOR103|Anti-GM-CSF monoclonal antibody
121243|NCT01517282|Other|Placebo|Placebo to anti-GM-CSF monoclonal antibody
121244|NCT01517295|Drug|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
121245|NCT01517308|Drug|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
121246|NCT01517321|Drug|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
121247|NCT01517321|Drug|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
121248|NCT00074802|Behavioral|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
121249|NCT01517334|Drug|Minocycline HCl Microspheres|
121250|NCT01517347|Drug|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
121251|NCT01517360|Drug|Oxytocin|Oxytocin 40 IU, intranasal inhalation
121252|NCT01512433|Procedure|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
121253|NCT01512433|Procedure|Sham acupuncture|The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude."DeQi"was avoided during needling.
121057|NCT01516918|Drug|telaprevir|tablet, 1125-mg twice daily
121058|NCT01516918|Drug|ribavirin|tablet, 1000-mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
121059|NCT01516918|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
121060|NCT01516931|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
121061|NCT00074776|Drug|Lithium|Participants will receive lithium.
121062|NCT01516931|Behavioral|counseling|Placebo monthly by general counseling for 12 months.
121063|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
121064|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
121326|NCT01508026|Drug|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
121327|NCT01510171|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
121328|NCT01510184|Drug|Zevalin (ibritumomab tiuxetan)|Day 1: Rituximab 250 mg/m2 intravenous infusion Days 7-9:Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg. In centers where biodistribution imaging is performed Day 1: Rituximab 250 mg/m2 intravenous infusion followed by In-111-Zevalin 185 MBq (5mCi), Days 3-4: Biodistribution imaging Days 7-9: Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg
121329|NCT01510223|Dietary Supplement|Olive oil|Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).
The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.
High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase.
121330|NCT01510223|Dietary Supplement|Olive oil and fish powder|Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).
The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.
High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase.
117900|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
117901|NCT01504412|Drug|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
117902|NCT01504412|Drug|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
117903|NCT01504438|Device|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
117904|NCT01504438|Device|STAR Total Ankle Replacement|STAR Total Ankle Replacement
117905|NCT00073814|Drug|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
118191|NCT01500967|Other|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
118192|NCT01500967|Other|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
118193|NCT00001300|Drug|mesna|
118194|NCT00073398|Biological|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
118195|NCT01500980|Biological|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
118196|NCT01500980|Drug|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
118197|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
118198|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
118199|NCT01500993|Drug|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
118200|NCT01500993|Drug|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cylce of 5-Fu based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
118201|NCT01501019|Other|Exercise training|"Sjöegren arm": 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.
"Myositis arm": 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.
"Takayasu's arteritis arm": 30-50 minutes of aerobic, twice a week, moderate intensity.
121476|NCT01508273|Behavioral|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
121477|NCT01508273|Behavioral|Website|Website access given that allows participant to track exercise behavior and help to set goals.
121478|NCT01508273|Behavioral|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
121479|NCT01510379|Device|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
121778|NCT01515943|Other|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
121779|NCT01508728|Device|ORTHOSENS orthosis|with active vibration
121780|NCT00074165|Drug|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
121781|NCT01508728|Device|ORTHOSENS orthosis|with placebo vibration
121782|NCT01508741|Dietary Supplement|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
121783|NCT01508741|Dietary Supplement|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
121784|NCT01508754|Procedure|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
121785|NCT01508767|Other|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
121786|NCT01508780|Device|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
121787|NCT01508780|Device|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
121788|NCT01508793|Behavioral|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
121789|NCT01508806|Drug|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
121254|NCT01512446|Drug|Alendronate|70 mg per week
121255|NCT00074321|Other|pharmacological study|Correlative studies
121256|NCT01512446|Drug|Placebo|1 pill per week
121257|NCT01512459|Drug|Venlafaxine|Venlafaxine MR Capsules 150 mg
121258|NCT01512472|Drug|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
121259|NCT01512485|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
121569|NCT01510574|Drug|placebo|3 x placebo tablets resembling misoprostol taken orally
121570|NCT01510587|Behavioral|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
121571|NCT01510587|Behavioral|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
121572|NCT01510600|Genetic|DNA analysis|
121573|NCT01510600|Genetic|polymerase chain reaction|
121574|NCT01510600|Other|laboratory biomarker analysis|
121575|NCT01510600|Other|medical chart review|
121576|NCT01510613|Drug|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
121577|NCT01510626|Dietary Supplement|Food proteins|Food proteins
121578|NCT01510626|Drug|Omalizumab|Drug
121579|NCT00001312|Drug|Vitamin and/or Mineral Supplement|
121580|NCT00074243|Drug|CC-8490|
121331|NCT01510223|Dietary Supplement|Olive oil and macadamia oil|Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).
The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.
High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase.
121332|NCT01510223|Dietary Supplement|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
121333|NCT01510236|Behavioral|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
121334|NCT00074191|Drug|procarbazine hydrochloride|
121636|NCT01508611|Other|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
Anteroposterior toothbrushing technique will be explained to the children.
121637|NCT01508611|Behavioral|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
121638|NCT01510652|Procedure|BiP Group|Implantation of standard Left Ventricular (LV) lead
121639|NCT01510652|Device|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
121640|NCT01510665|Dietary Supplement|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
121641|NCT01510665|Dietary Supplement|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
121642|NCT01510665|Behavioral|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
121643|NCT01510678|Behavioral|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F&Vs is perceived cost of these foods, information regarding lower-cost options for F&Vs will be included in the manual.
121644|NCT01510678|Behavioral|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
118202|NCT01501032|Device|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
118203|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
118204|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
118205|NCT00073411|Drug|duloxetine|
118206|NCT01501058|Behavioral|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
118207|NCT01501058|Behavioral|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
117322|NCT00073697|Other|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
117323|NCT01503385|Drug|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
117324|NCT01503398|Drug|Olanzapine|Olanzapine Tablets, 5 mg
117325|NCT01503424|Drug|Olanzapine|Olanzapine Tablets, 5 mg
117326|NCT01503437|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
117327|NCT01503450|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
117328|NCT01503463|Procedure|Home telemonitoring of patients with CHF|Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.
If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified.
117329|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
117330|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
117331|NCT01503489|Drug|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
117332|NCT01503502|Drug|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
121790|NCT01508819|Other|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
121791|NCT00074165|Drug|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
121792|NCT01508832|Drug|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
121793|NCT01508832|Drug|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
121794|NCT01508845|Dietary Supplement|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
121795|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
121796|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
120914|NCT00075023|Drug|Thalidomide Gel|
120915|NCT01518946|Drug|Midodrine HCl|dose at the subject's current dose level
120916|NCT01518946|Drug|Placebo|single dose of matching placebo
120917|NCT01518959|Drug|Cholecalciferol|180.000 IU monthly
120918|NCT01518959|Drug|oleum neutralicum|Placebo comparator, 9 ml monthly
120919|NCT01518972|Drug|Prazosin|Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg
120920|NCT01518972|Drug|Placebo medication|Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg
120921|NCT01521247|Other|Asthma Transition Program|Asthma Education.
120922|NCT00075335|Drug|AMD3100|
120923|NCT01521260|Procedure|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
120924|NCT01521260|Procedure|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
120925|NCT01521273|Other|Bean varieties|10 x 50 g/ arm
121581|NCT01510639|Biological|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
121582|NCT01512940|Procedure|Laparoscopic Greater Curvature Plication|The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.
Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope.
121583|NCT00074412|Drug|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
121584|NCT01512953|Drug|Lansoprazole|Lansoprazole 30 mg once a day
121585|NCT01512966|Biological|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
120719|NCT01523392|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
120720|NCT01525706|Drug|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL [3mg/ml diluted in normal saline from original concentration of 6mg/mL] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
120721|NCT01525719|Drug|Everolimus|10 mg everolimus
120722|NCT01525732|Procedure|Per Oral Endoscopic Myotomy|
120723|NCT01525745|Radiation|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
120724|NCT01525745|Radiation|External Beam Radiation Therapy|10 consecutive days of standard radiation
120725|NCT00075634|Other|laboratory biomarker analysis|Correlative studies
120726|NCT01525758|Drug|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
120727|NCT01525758|Drug|microcrystalline cellulose|identical number of tablets to active drug groups
120728|NCT01525771|Other|Docetaxel|The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.
Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)
Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days
Cisplatin 60mg/m2 IV (D1) every 21 days
121645|NCT01510678|Behavioral|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
121646|NCT01510704|Drug|APD421|IV
121647|NCT00074269|Biological|anti-thymocyte globulin|
121648|NCT01510704|Drug|Placebo|IV
121649|NCT01510717|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
121650|NCT01510717|Device|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
121651|NCT01510730|Drug|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
121652|NCT01510756|Drug|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
121653|NCT01510769|Drug|Lesinurad|Tablets, 400 mg once daily (QD)
121654|NCT01510769|Drug|Lesinurad|Tablets, 200 mg QD
120787|NCT01523483|Drug|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
120788|NCT01523483|Drug|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
120789|NCT01523496|Drug|Vitamin D3|Vitamin D3, randomized to receive either 18,000 IU per month, 60,000 IU per month or 120,000 IU per month
120790|NCT01523496|Drug|Vitamin D3|Vitamin D3 18,000IU/month; 60,000IU/month; 120,000IU/month
120791|NCT01523509|Device|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
120792|NCT01523522|Other|Myoblast injection|Autologous myoblast injection in the anal sphincter
120793|NCT01523522|Procedure|saline solution injection|saline solution injection in anal sphincter
120794|NCT01523535|Behavioral|repeated cycles of short sleep|- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
120795|NCT00075517|Drug|gemcitabine hydrochloride|
120796|NCT01523548|Drug|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
117333|NCT00073710|Drug|Zemplar|
117334|NCT01503502|Drug|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
117335|NCT01505621|Other|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L[ring-13C6]phenylalanine
117336|NCT01505634|Drug|MK-7655 250 mg|Participants randomized to receive MK-7655 250 mg will be administered a 250 mg dose of MK-7655 IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
117337|NCT01505634|Drug|MK-7655 125 mg|Participants randomized to receive MK-7655 125 mg will be administered a 125 mg dose of MK-7655 IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
117338|NCT01505634|Drug|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
117621|NCT01500161|Drug|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
117622|NCT01500161|Drug|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
117623|NCT00073281|Procedure|Islet transplantation|
117624|NCT01500161|Drug|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
117625|NCT01500161|Drug|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
117626|NCT01500161|Drug|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
117627|NCT01500174|Device|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
117628|NCT01500174|Device|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
117629|NCT01500187|Device|Vanish varnish|5% sodium fluoride varnish with tricalcium phosphate
117630|NCT01500187|Device|Oral B Minute-Gel|Fluoride gel
117631|NCT01500200|Drug|ALKS 5461|Two active tablets, given daily
117632|NCT01500200|Drug|Placebo|Two placebo tablets, given daily
117633|NCT01500213|Drug|Rolapitant|200 mg PO
117634|NCT00073294|Behavioral|diet|
120926|NCT01521286|Other|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
120927|NCT01521299|Drug|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
120928|NCT01521312|Drug|saxagliptin|5mg a day for 11-14 weeks
120929|NCT01521312|Other|placebo pill|one tablet a day for 11-14 weeks
120930|NCT01521325|Drug|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
120931|NCT01521364|Drug|Addition of different doses of clarithromycin.|At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.
At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks.
120932|NCT01521377|Drug|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
120933|NCT00001338|Drug|FLAC chemotherapy with GM-CSF|
120934|NCT00075348|Genetic|mutation analysis|
120935|NCT01521377|Drug|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
121480|NCT01510379|Drug|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
121481|NCT01510379|Drug|IV promethazine 25 mg q 6 hours prn|
121482|NCT01510379|Drug|Elixir promethazine 25 mg q 6 hours prn after discharge|
121483|NCT01510392|Device|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
121484|NCT01510405|Other|Tissue Collection|Tissue sample collection
121485|NCT00074204|Drug|docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
121486|NCT01510431|Drug|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
121487|NCT01510457|Drug|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
120729|NCT01525810|Drug|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention [subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)]
120730|NCT01525823|Drug|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
120731|NCT01525823|Drug|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
120732|NCT01525836|Drug|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 29th day)
120733|NCT01525836|Drug|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
120734|NCT01525849|Device|Balloon Sinus Dilation|Balloon Sinus Dilation
120735|NCT01525849|Procedure|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery
120736|NCT00075634|Other|pharmacological study|Correlative studies
120737|NCT01525862|Device|Sinus Balloon Dilation Tool|transnasal sinus balloon dilation procedure
120990|NCT01518998|Drug|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60/Amlodipine 5mg combination, Fimasartan 60/Amlodipine 10mg combination, Fimasartan 30/Amlodipine 5mg combination, Fimasartan 30/Amlodipine 10mg combination
120991|NCT00075023|Drug|Placebo Gel|
120992|NCT01519011|Drug|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
120993|NCT01519011|Drug|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
120994|NCT01519037|Drug|calcimimetic agent (cinacalcet)|one dose of oral cinacalcet, 60mg
120995|NCT01519037|Drug|placebo|one dose of oral placebo
120996|NCT01519050|Behavioral|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
120997|NCT01519063|Drug|Naltrexone and memantine|Naltrexone 50mg memantine 20mg
120998|NCT01519063|Drug|Naltrexone and Placebo|Naltrexone 50 mg Placebo
120999|NCT01519076|Device|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
120797|NCT01516515|Drug|Vehicle gel|placebo
120798|NCT01516515|Drug|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
120799|NCT01516528|Procedure|Spirometry|Assessment of lung function by spirometry
120800|NCT00074724|Drug|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
120801|NCT01516541|Other|Background care|Guidelines-based medical care
120802|NCT01516541|Drug|Placebo|Matching dalcetrapib placebo orally daily
120803|NCT01516541|Drug|dalcetrapib|600 mg orally daily
120804|NCT01516554|Drug|Testosterone undecanoate|40 mg twice daily
120805|NCT01516554|Drug|placebo|twice daily
120806|NCT01516567|Drug|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
120807|NCT01516580|Drug|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|Prephase (COP) for all groups followed by:
in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses.
121065|NCT01516944|Drug|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
121066|NCT01516957|Drug|AMG 827|140 mg AMG 827 SC (subcutaneous)
121067|NCT01516957|Drug|Placebo|Placebo SC (subcutaneous)
121068|NCT01516957|Drug|AMG 827|280 mg AMG 827 SC (subcutaneous)
121069|NCT01516957|Drug|AMG 827|210 mg AMG 827 SC (subcutaneous)
121070|NCT01516970|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
121071|NCT01516970|Drug|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
121072|NCT00074776|Drug|Lamotrigine|Participants will receive lamotrigine.
121073|NCT01516970|Drug|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
117635|NCT01500213|Drug|Granisetron|10 mcg/kg IV
117636|NCT01500213|Drug|Dexamethasone|20 mg PO and 8 mg PO
117637|NCT01500213|Drug|Placebo|(4 X 0 mg capsules) o mg PO
117638|NCT01500226|Drug|Rolapitant|(4 X 50 mg capsule) 200 mg PO
117639|NCT01500226|Drug|Granisetron|2 mg PO
117640|NCT01500226|Drug|Dexamethasone|20 mg PO
117641|NCT01500226|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
117642|NCT01501929|Procedure|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
117906|NCT01504451|Device|ILR insertion|Insertion of implantable loop recorder
117907|NCT01504451|Procedure|AF ablation|AF ablation
117908|NCT01504464|Biological|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
117909|NCT01504464|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
117910|NCT01504477|Drug|Panitumumab and bortezomib|Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.
117911|NCT01504490|Drug|CS-7017 and Bexarotene|CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.
Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to.
117912|NCT01504503|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
117913|NCT01504503|Drug|Aricept|Aricept 10 mg Tablets
117914|NCT01504516|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
117915|NCT01504516|Drug|Aricept|Aricept 10 mg Tablets
117916|NCT00073814|Drug|Placebo|Placebo MDI QID
117917|NCT01504542|Biological|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
121488|NCT01510457|Drug|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
121489|NCT01510483|Behavioral|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
121490|NCT01510483|Behavioral|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
121491|NCT01510496|Procedure|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
121492|NCT01510496|Procedure|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
121493|NCT01510496|Procedure|Thoracotomy .|Thoracotomy (non laparoscopic).
121494|NCT01510509|Device|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
121495|NCT01510509|Device|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
121496|NCT00074204|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
121515|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
121516|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
121517|NCT01512914|Drug|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
121518|NCT01512914|Drug|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
121519|NCT01515319|Drug|Y242|Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 120 mg Y242 (Part A) Multiple ascending doses at weekly intervals, doses to be determined (Part B)
121520|NCT00074581|Drug|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
121521|NCT01515319|Drug|0.9% saline|Identical volume to that of Y242
121522|NCT01515345|Drug|prasugrel or ticagrelor|prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
121523|NCT01515345|Drug|Clopidogrel|clopidogrel 75mg od for 12 month
121000|NCT01519089|Drug|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
121001|NCT01519089|Drug|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
121002|NCT00075049|Biological|RTS,S with AS02A/AS01B adjuvant|
121003|NCT01519102|Device|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
121004|NCT01519115|Other|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
121005|NCT01519115|Other|usual care|one physical therapy visit in hospital following ACF surgery
121006|NCT01519128|Drug|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
121007|NCT01519128|Drug|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
121008|NCT01519154|Drug|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
121009|NCT01519154|Drug|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
121010|NCT01519167|Drug|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
121260|NCT01512511|Procedure|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
121261|NCT01512524|Other|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
121262|NCT01512537|Radiation|Narrowband UVB|UVB 3 times a week
121263|NCT01512537|Dietary Supplement|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
121264|NCT01512550|Procedure|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
121265|NCT01512550|Procedure|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
121266|NCT00074334|Biological|TGFa-PE38 immunotoxin|
121267|NCT01512550|Device|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
121074|NCT01516970|Drug|NRTIs|The NRTIs (including tenofovir/emtricitabine [Truvada], lamivudine/zidovudine [Combivir]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
121075|NCT01516970|Drug|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
121076|NCT01519167|Drug|Fentanyl|0.5 - 3 mcg/kg IV
121077|NCT00075062|Procedure|Flexible Sigmoidoscopy|
121078|NCT01519193|Behavioral|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
121079|NCT01519206|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
121080|NCT01519219|Radiation|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
121081|NCT01519232|Radiation|Liver Irradiation|Patients already scheduled to undergo radiation treatment
121082|NCT01519245|Drug|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
121335|NCT01510262|Behavioral|Tailored Socio-Contextual Intervention|Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.
Recruit/enroll in the intervention 500 subjects (50% women; African American focus).
After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:
A. The STI strengths-based prevention case management, or B. Standard care.
Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.
Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.
Conduct cost effectiveness analyses of intervention compared to the standard.
121336|NCT01512602|Behavioral|CAMS|CAMS-informed psychotherapy
121337|NCT01512615|Other|Integrated rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
121338|NCT00074334|Procedure|conventional surgery|
121339|NCT01512615|Other|Usual follow-up|Standard follow-up at the participating heart center
121340|NCT01512628|Drug|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
117918|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
117919|NCT01506570|Biological|Placebo|One SC injection at Day 0 and Day 180 of placebo
117920|NCT01506596|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
117921|NCT01506609|Drug|Veliparib|Days 1 through 7 of 28-day cycle (in combination with Temozolomide) or Days 1 through 7 of 21-day cycle (in combination with Carboplatin and Paclitaxel).
117922|NCT01506609|Drug|Temozolomide|Days 1 through 5 of 28-day cycle (in combination with veliparib).
117923|NCT01506609|Drug|Carboplatin|Day 3 of 21-day cycle
117924|NCT01506609|Drug|Paclitaxel|Day 3 of 21-day cycle.
117925|NCT01506609|Drug|Placebo|Placebo comparator for Veliparib days 1 through 7 of 21-day cycle (in combination with carboplatin and/or paclitaxel).
117926|NCT01506622|Drug|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
117927|NCT00073957|Biological|rituximab|
118208|NCT01501071|Device|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
118209|NCT01501084|Drug|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
118210|NCT01501084|Drug|Normal saline .2cc subcutaneous injection|sterile saline injection
118211|NCT00073671|Behavioral|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
118212|NCT01502800|Drug|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)
You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.
The beginning dose level will be 390 mg/m2.
118213|NCT01502813|Drug|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
118214|NCT01502826|Dietary Supplement|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
118215|NCT01502839|Other|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
121524|NCT01515358|Drug|Placebo|Administered orally
121525|NCT01515358|Drug|LY3000328|Administered orally
121526|NCT01515371|Drug|IncobotulinumtoxinA|Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.
For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
121527|NCT01515371|Drug|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
121528|NCT01515384|Drug|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
121529|NCT01515397|Drug|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
121530|NCT01515397|Drug|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
121531|NCT00074581|Drug|Stavudine|Dosage depends on weight
121532|NCT01515410|Drug|DM-1992|72.5mg carbidopa/230mg levodopa
121533|NCT01515410|Drug|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
121534|NCT01515423|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
121535|NCT01515423|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
121797|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
121798|NCT01508858|Drug|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
121799|NCT01508858|Drug|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
121800|NCT01508858|Drug|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
121801|NCT01508871|Other|Observational study, no intervention|No intervention
121802|NCT00074165|Drug|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
121803|NCT01510990|Drug|Gefitinib|gefitinib 250mg/day daily
121804|NCT01511003|Drug|Tacrolimus|oral
121268|NCT01512563|Device|Biliary stent|palliative treatment for malignant patients
121269|NCT01512576|Other|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
121270|NCT01512576|Behavioral|relaxation|1 treatment session of 30 minutes
121271|NCT01512589|Radiation|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
121272|NCT01512589|Radiation|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
121273|NCT01512589|Behavioral|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
121274|NCT01512602|Behavioral|DBT|16 weeks DBT treatment
121275|NCT00074542|Drug|Epanova™ (Omega-3 Free Fatty Acids)|
121276|NCT01514786|Behavioral|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
121277|NCT01514799|Procedure|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
121278|NCT01514812|Drug|YM150|oral - modified release formulation of YM150
121279|NCT01514812|Drug|placebo|oral
121280|NCT01514812|Drug|digoxin|oral
121281|NCT01514825|Drug|YM150|oral
121586|NCT01512979|Drug|metformin|1000 mg to 2000 mg per day
121587|NCT01512979|Drug|linagliptin|5 mg daily
121588|NCT01512979|Drug|metformin placebo|0 to 2 tablets daily
121589|NCT01512979|Drug|metformin placebo|4 tablets daily
121590|NCT01512992|Procedure|Home telehealth|Patients receive tailored intervention according to their clinical complexity.
All patients in the intervention group receive:
Personalised care plan
Education on self-management
Access to a personalized online health folder
Access to Call center
Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).
Patients with LOW complexity additionally receive:
Daily videoconferences for the 1st week after discharge
Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.
Patients with HIGH complexity additionally receive:
Videoconferences for at least 1 month after discharge, scheduled on an individual basis.
Remote monitoring for respiratory parameters.
One monthly phone call from the call centre to promote and assess patient self-management.
121341|NCT01512641|Other|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
121342|NCT01512641|Other|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
121343|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
121344|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
121345|NCT01512667|Drug|MK-0822|1 single, oral dose (50 milligram [mg] tablet) of MK-0822 will be administered on Day 1.
121346|NCT01512680|Behavioral|Education to Functional Insulin Therapy|Intake of Continuous Glucose Monitor for 5 to 7 days
"Functional Insulinotherapy" training during 3 days, blood sampling, autoevaluation and QOL questionnary.
1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes
3 months after the training: Blood sampling, vital signs and data on diabetes
6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days
9 months after the training: Blood sampling, vital signs and data on diabetes
1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days
12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary
121347|NCT01512693|Drug|Single Dose MK-0822|A one-time, single-dose (50 mg tablet) administered orally on Day 1
121348|NCT01512706|Biological|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
121655|NCT01510769|Drug|Placebo|Tablets, Placebo QD
121656|NCT01510769|Drug|Febuxostat|80 mg
121657|NCT01510782|Drug|Placebo to BI 655064|intravenous infusion of escalating doses
121658|NCT00074269|Biological|filgrastim|
121659|NCT01510782|Drug|Placebo to BI 655064|subcutaneous injection of escalating doses
121660|NCT01510782|Drug|BI 655064|intravenous infusion of escalating doses
121661|NCT01510782|Drug|BI 655064|subcutaneous injection of escalating doses
121662|NCT01513044|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
118216|NCT01502878|Dietary Supplement|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
118217|NCT01502878|Dietary Supplement|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
118218|NCT01502878|Dietary Supplement|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
118219|NCT01502891|Other|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
118220|NCT01502904|Device|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
118221|NCT01502904|Device|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
118222|NCT00073671|Other|Usual care|Participants receive usual care
118223|NCT01502904|Drug|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
118224|NCT01502904|Drug|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
117339|NCT01505634|Drug|Placebo to MK-7655|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
117340|NCT01505634|Drug|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
117341|NCT01505647|Biological|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
117342|NCT01505647|Biological|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
117343|NCT01505660|Behavioral|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at ~9 and 12 months after enrollment.
117344|NCT01505673|Drug|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
121805|NCT01511016|Drug|Human recombinant leptin ("metreleptin")|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
121806|NCT01511016|Drug|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
121807|NCT01511029|Drug|Dexpramipexole|300 mg - Oral Tablets
121808|NCT01511029|Drug|Dexpramipexole|600 mg Oral Tablets
121809|NCT01511029|Drug|Dexpramipexole Placebo|Placebo - Oral Tablet
121810|NCT01511029|Drug|Moxifloxacin|400 mg - Oral Tablet
121811|NCT00074269|Drug|cyclosporine|
121812|NCT01511042|Drug|Para-aminohippuric Acid|Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated "PAH".
121813|NCT01511042|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
121814|NCT01511042|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
121815|NCT01511055|Drug|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
121816|NCT01511068|Drug|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
120936|NCT01521377|Drug|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
120937|NCT01521377|Drug|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
120938|NCT01521377|Drug|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
120939|NCT01521377|Drug|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
120940|NCT01521390|Drug|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
120941|NCT01521390|Drug|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
120942|NCT01521390|Drug|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
121591|NCT01513005|Procedure|Laparoscopic Sleeve Gastrectomy|the operative technique consists in few steps:
position of 4 trocars and insertion of a nasogastric tube
dissection and mobilization of the greater curvature of the stomach
preparation of the stomach for division
gastric partition
extraction of the gastric remnant
postoperative surveillance
121592|NCT01513018|Other|high tidal volumes|One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.
Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used.
121593|NCT01513018|Other|low tidal volume|One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.
Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used.
121594|NCT00074425|Drug|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
121595|NCT01513031|Other|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
121596|NCT01513044|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
121597|NCT01515423|Drug|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
121598|NCT01515436|Other|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
121599|NCT01515436|Other|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
120738|NCT01525875|Drug|Magnesium Oxide|Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).
Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).
120739|NCT01525875|Drug|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
120740|NCT01525888|Procedure|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
120741|NCT01518491|Other|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
121663|NCT01513057|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
121664|NCT01513057|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
121665|NCT01513070|Drug|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
121666|NCT01513070|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
121667|NCT01513070|Drug|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
121668|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
121669|NCT01513070|Drug|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
121670|NCT00074425|Drug|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
121671|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
121672|NCT01513083|Drug|trastuzumab emtansine|Multiple intravenous doses
121673|NCT01513096|Drug|itopride|itopride, 10mg, twice per day, for 1 day
121674|NCT01513109|Biological|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
121675|NCT01513122|Drug|Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI
121676|NCT01513122|Drug|Lopinavir /ritonavir + raltegravir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.
121677|NCT01513135|Biological|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
120808|NCT01516580|Drug|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
120809|NCT01516593|Drug|Induction Phase|dd -2 to 1: Methylprednisolone
dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine
dd 2, Rituximab
dd 7, Methotrexate
dd 14, Rituximab
dd 15, Etoposide
dd 21, Methotrexate
dd 29, Rituximab and Doxorubicin
dd 36, Rituximab and VCR
At the end of this induction phase, subsequent treatment will be performed according to the objective response:
pts in CR: consolidation phase followed by bulky site irradiation
pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation
pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation
120810|NCT01516593|Drug|Consolidation Phase (on day +50)|dd 1-2: cytarabine twice a day
dd 3 and 11: rituximab
dd 11-13: leukapheresis for PBPC collection.
117345|NCT00073905|Drug|capecitabine plus gemcitabine|capecitabine plus gemcitabine
117346|NCT01505673|Drug|Saline|Placebo injection of 1.8mg saline once daily for 6-months
117347|NCT01505686|Procedure|MRI scan|MRI scan with a 1,5 T MRI scanner
117348|NCT01505699|Genetic|RNA analysis|
117349|NCT01505699|Genetic|cytogenetic analysis|
117350|NCT01505699|Genetic|microarray analysis|
117351|NCT01505699|Other|laboratory biomarker analysis|
117352|NCT01505712|Genetic|gene expression analysis|
117353|NCT01505712|Other|laboratory biomarker analysis|
117354|NCT01505738|Other|bacterial samples|bacterial samples taken
117355|NCT01505764|Drug|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
117356|NCT00073918|Drug|cyclophosphamide|Given IV
117357|NCT01499693|Drug|Magnesium Pantoprazole 20 mg|oral dose, twice a day
117358|NCT01499693|Drug|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
117359|NCT00073216|Biological|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
117643|NCT01501929|Procedure|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
117644|NCT01501942|Drug|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
117645|NCT01501942|Drug|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
117646|NCT00073554|Drug|Alfimeprase|
117647|NCT01501955|Device|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
120943|NCT01521390|Drug|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
120944|NCT01521390|Drug|Placebo|Placebo, no active ingredient
120945|NCT00075374|Drug|docetaxel|Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.
Patients are followed at 1 month and then every 2-3 months thereafter.
120946|NCT01523691|Behavioral|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
120947|NCT01523691|Behavioral|Control sleep|Regular amounts of sleep across study protocol
120948|NCT01523704|Device|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
120949|NCT01523704|Device|BIOTRONIK Home Monitoring System with In-office Follow-up|
120950|NCT01523730|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
120951|NCT00075543|Drug|oxaliplatin|
120952|NCT01523730|Device|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
120953|NCT01523743|Device|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
121497|NCT01510522|Drug|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
121498|NCT01510522|Drug|Glucophage|Glucophage tablets (metformin hydrochloride in 850mg strengths)
Dosing schedule: > 1.700mg/day for 6 month
121499|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).
Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:
first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.
Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:
Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms.
120742|NCT01518504|Other|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
120743|NCT01518504|Other|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
120744|NCT00074984|Biological|Placebo|1 mg/kg placebo intravenously every 2 weeks
120745|NCT01518517|Drug|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
120746|NCT01518517|Drug|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
120747|NCT01518530|Device|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
120748|NCT01518556|Drug|Idarubicin|In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.
In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days .
120749|NCT01518569|Drug|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
120750|NCT01518569|Drug|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
120751|NCT01518582|Device|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
120752|NCT01518595|Drug|bosentan|pts. will receive bosentan for 3 months
120753|NCT01518595|Drug|Placebo|pts. will receive placebo for 3 months
120754|NCT01518608|Drug|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.
Pentothal 4mg/kg Rocuronium 0.6 mg/kg
120755|NCT00074997|Other|Placebo|Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight
121011|NCT01519167|Drug|Midazolam|0.025 - 2 mg/kg IV
121012|NCT01521403|Drug|Metronidazole|3x500 mg/day for 10 days
121013|NCT01521403|Drug|Placebo|3x1 tablet per day for 10 days
120811|NCT00074737|Drug|cenersen|cenersen with standard of care
120812|NCT01516593|Drug|Intensification phase|One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.
CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);
AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed).
120813|NCT01516593|Drug|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
120814|NCT01516593|Radiation|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
120815|NCT01516606|Drug|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
120816|NCT01518686|Device|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .
The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)
120817|NCT01518699|Drug|Ha44|study drug at low, moderate and high dose single exposure
120818|NCT01518699|Drug|Ha44 Placebo|Ha44 Vehicle Gel without Ha44
120819|NCT00074997|Genetic|OZ1|Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight
120820|NCT01518699|Drug|Moxifloxacin Placebo|Moxifloxacin Placebo
120821|NCT01518699|Drug|Moxifloxacin|moxifloxacin 400mg
120822|NCT01518712|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
121083|NCT01519245|Drug|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
121084|NCT01519258|Device|NAVA ventilation|Mechanical ventilation with the mode NAVA (neurally-adjusted ventilatory support), delivered by the Servoi Mechanical Ventilator (Maquet, Sweden) after the placement of an esophageal catheter. Nava will be titrated before the initiation of data collection to offer the same level of ventilatory assistance as the conventional mode used by the ICU team previous to enrollment in the study.
117648|NCT01501955|Device|Stanmore|Stanmore hip prosthesis
117649|NCT01501968|Drug|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
117650|NCT01501968|Drug|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
117651|NCT01501994|Other|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
117652|NCT01501994|Other|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
117653|NCT01501994|Procedure|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
117654|NCT01502007|Other|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
117655|NCT01503957|Device|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
117928|NCT01506622|Drug|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
117929|NCT01506622|Drug|Administration of saline|Saline will be administered to control group at the end of anesthesia.
117930|NCT01506635|Drug|Timolol|
117931|NCT01506635|Drug|Placebo|artificial tear twice a day
117932|NCT01506661|Drug|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
117933|NCT01506687|Behavioral|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
121500|NCT01512797|Drug|Sitagliptin phosphate|100 mg/day orally
121501|NCT01512797|Other|Placebo|1 Placebo Pill per day
121502|NCT01512810|Procedure|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
121503|NCT01512823|Behavioral|Education|Interactive educational intervention:
4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)
Emailed notes from second session
Telephonic/email follow-up (reminders)
Didactic educational intervention:
- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills
121504|NCT01512836|Behavioral|Case Management|Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:
Formulation and implementation of care plans together with the patient
Monitoring of individual status and care plan effectuation
Overall coordination between health care providers
Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)
Regular telephone consultations and home visits
Promote disease-self management through coaching
121505|NCT01512849|Drug|TA-7284 Low|Low
121506|NCT01512849|Drug|TA-7284 High|High
121507|NCT01512862|Drug|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
121508|NCT01512862|Drug|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
121509|NCT00074412|Drug|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
121510|NCT01512888|Genetic|CL20-4i-EF/a-hyc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
121511|NCT01512888|Drug|Busulfan|Given intravenously (IV).
121512|NCT01512901|Drug|Betamethasone Microsphere (DE-102） Low Dose|
121513|NCT01512901|Drug|Betamethasone Microsphere (DE-102） High Dose|
121514|NCT01512901|Drug|Sham|
121536|NCT01515423|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
121537|NCT01515423|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
121538|NCT01515423|Drug|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
121014|NCT01521416|Other|Data collection|Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.
All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated.
121015|NCT01521442|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
121016|NCT01521442|Behavioral|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
121017|NCT01521455|Drug|HCP0910|250/50, BID for 2 weeks
121018|NCT01521455|Drug|Seretide Diskus|250/50, BID for 2 weeks
121019|NCT01521481|Other|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
121020|NCT01521481|Other|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
121021|NCT01521494|Drug|PA21|
121022|NCT00075387|Drug|Carboplatin|Given IA
121023|NCT01521494|Drug|PA21|
121024|NCT01521494|Drug|PA21|
121025|NCT01521494|Drug|PA21|
121026|NCT01521494|Drug|Placebo|
121027|NCT01521507|Device|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
121028|NCT01521507|Device|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
121029|NCT01521520|Drug|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
121282|NCT01514825|Drug|Placebo|oral
121283|NCT01514838|Drug|ASP1941|oral
121284|NCT01514838|Drug|acarbose|oral
121085|NCT01519258|Other|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
121086|NCT01519271|Drug|Exelon Patch (rivastigmine transdermal system)|The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.
5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )
121087|NCT01519271|Drug|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
121088|NCT00075062|Procedure|Rectal Biopsy|
121089|NCT01519284|Drug|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
121090|NCT01519284|Drug|Entacapone|Entacapone 200 mg
121091|NCT01519284|Drug|Placebo|placebo (four times a day)
121092|NCT01519284|Drug|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
121093|NCT01519284|Drug|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
121094|NCT01519284|Drug|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
121095|NCT01519297|Drug|Irbesartan|150mg orally for one dose
121096|NCT01521559|Procedure|Macular Laser Photocoagulation|
121097|NCT01521559|Drug|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
121098|NCT01521572|Drug|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
121099|NCT01521585|Drug|SEN0014196|50 mg oral once daily tablet
121100|NCT01521585|Drug|SEN0014196|200 mg oral once daily tablet
121101|NCT01521585|Drug|Placebo|oral once daily tablet
121102|NCT01521598|Drug|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
121103|NCT01521598|Drug|Placebo|This is the placebo. Patients will be randomized the placebo.
121104|NCT01521611|Radiation|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
121349|NCT00074373|Other|No intervention; observational|
121350|NCT01512706|Biological|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
117934|NCT01506687|Behavioral|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
117935|NCT01506700|Device|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
117936|NCT01506713|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
117937|NCT01506726|Drug|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
117938|NCT00073957|Drug|cytarabine|
117939|NCT01506726|Drug|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
117940|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
117941|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
117942|NCT01500577|Drug|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
117943|NCT01500577|Drug|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
117944|NCT01500577|Other|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
117945|NCT01500590|Drug|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
117946|NCT01500590|Drug|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
117947|NCT01500603|Device|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
118225|NCT01502904|Drug|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
118226|NCT01502904|Drug|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
118227|NCT01504932|Other|survey administration|Patients will be asked to complete a baseline survey of family history of cancer and tobacco/alcohol and mouthwash usage, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) survey, and a Brief Fatigue Inventory (BFI) survey. They will then receive a logbook (specific for this trial)
121539|NCT01515423|Drug|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
121540|NCT01515423|Drug|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
121541|NCT01515423|Drug|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
121542|NCT00074581|Drug|Tenofovir disoproxil fumarate|300 mg taken orally once daily
121543|NCT01508273|Behavioral|Survey|Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.
Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake.
121544|NCT01508273|Behavioral|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
121545|NCT01508286|Drug|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
121546|NCT00001307|Drug|Oxygen-15 Water|
121547|NCT00074139|Drug|cyclophosphamide|
121548|NCT01508286|Drug|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
121549|NCT01508286|Drug|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
121550|NCT01508299|Procedure|skin test|skin test with the Suspected raw food
121551|NCT01508312|Drug|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
120680|NCT01520792|Drug|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
120681|NCT00075244|Drug|Replagal|
121285|NCT01514838|Drug|Placebo|oral, used only during placebo run-in period
121286|NCT00074581|Drug|Atazanavir|300 mg taken orally once daily
121287|NCT01514851|Drug|Lanthanum carbonate (BAY77-1931)|
121288|NCT01514851|Drug|Calcium carbonate|
121289|NCT01514864|Drug|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
121290|NCT01514877|Drug|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
121291|NCT01514903|Drug|HIP0908|SINGLE DOSE , CROSS OVER
121292|NCT01514903|Drug|viagra|single dose, cross over
121293|NCT01514916|Device|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
121294|NCT01514929|Drug|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
121295|NCT01514929|Drug|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
121296|NCT01514929|Drug|Moxifloxacin|400mg oral pill given once
121297|NCT00074581|Drug|Didanosine|400 mg taken orally once daily
121298|NCT01514929|Drug|Placebo|Placebo oral pill given once
121299|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
121300|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
121301|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
121302|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
121303|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
121304|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
121305|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
121351|NCT01512706|Biological|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
121352|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
121353|NCT01512706|Biological|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
121354|NCT01512706|Biological|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
121355|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
121356|NCT01514955|Radiation|Gold seeds insertion to detect movements at pelvis|
121357|NCT01514955|Radiation|Image guided MRI based RT (IMRT+Brachytherapy)|
121358|NCT01514968|Drug|cyclosporine|Single oral dose
121359|NCT00074581|Drug|Efavirenz|600 mg taken orally once daily
121360|NCT01514968|Drug|danoprevir|Single oral dose
121361|NCT01514968|Drug|ritonavir|Single oral dose
121362|NCT01514981|Drug|AMG 761|Single dose of AMG 761 on study day 1.
121363|NCT01514981|Drug|Placebo|Single dose of placebo on study day 1.
121364|NCT01514994|Device|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
121365|NCT01515007|Drug|Ciprofloxacin|once daily for 28 days on and 28 days off for six cycles
121366|NCT01515020|Drug|vancomycin monotherapy|intravenous therapy by vancomycin
121367|NCT01515020|Drug|daptomycin monotherapy|intravenous therapy by daptomycin
121368|NCT01515033|Other|aerobic exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
121369|NCT01515046|Drug|Gemcitabine with escalating ascorbic acid|Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)
Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)
121370|NCT00074581|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
118228|NCT01504932|Other|laboratory biomarker analysis|Patients will be asked to do blood, urine, and saliva sample and a buccal scrape. These biological samples will be evaluated for the presence of LBR components (as a measure of compliance) and assessment of LBR responsive genes, respectively.
118229|NCT01504932|Other|pharmacological study|Correlative studies
118230|NCT01504945|Other|RBC transfusion|1 bag of packed red blood cells
118231|NCT01504945|Other|Normal saline infusion|500 mL of normal saline infusion
118232|NCT01504958|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).
Sham participants will receive the same study procedures as patients receiving active rTMS.
118233|NCT01504958|Behavioral|NICE Cognitive Training|12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).
A particular cognitive exercise will start 200msec after the termination of each TMS train.
Sham participants receive real cognitive training that follows the same procedures as the active group.
118234|NCT01504971|Other|symptom questionaire|GerdQ questionaire
118235|NCT01504971|Procedure|pH monitoring|24-hour pH monitoring
118236|NCT01504971|Procedure|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
118237|NCT00073866|Drug|celecoxib|
118238|NCT01504971|Drug|rabeprazole|10mg, bid, p.o.
118239|NCT01504984|Drug|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
118240|NCT01504984|Drug|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)
118241|NCT01504997|Device|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
118242|NCT01505010|Procedure|Renal denervation|Renal denervation in the intervention group
118243|NCT01505023|Dietary Supplement|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
117360|NCT01499693|Drug|Placebo|oral dose, once a day (night)
Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group).
117361|NCT01499706|Behavioral|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
120682|NCT01520805|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
120683|NCT01520818|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m^2 will receive BIAsp 50
120684|NCT01520818|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m^2 will receive BIAsp 70
120685|NCT01520818|Drug|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
120686|NCT01520831|Drug|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
120687|NCT01520831|Drug|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
120688|NCT01520831|Drug|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
120689|NCT01520831|Drug|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
120690|NCT01520844|Biological|blood sampling|blood sampling
120691|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
120692|NCT00075257|Drug|DVS-233 SR|
120693|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
120694|NCT01520870|Drug|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
120695|NCT01520896|Drug|NKTR-118|Oral 25 mg
120696|NCT01520896|Drug|Ketoconazole|Oral 400 mg
120697|NCT01520909|Drug|Eltrombopag|Thrombopoietin receptor agonist
120698|NCT01523236|Drug|Mometasone furoate|50 mcg/actuation Nasal Spray
120699|NCT01523236|Drug|Nasonex®|50 mcg/actuation Nasal Spray
120954|NCT01523743|Device|Standard care|The coated intermittent catheter normally used by subject
121600|NCT01515462|Genetic|Autologous CD34 positive cells transduced with WAS encoding lentiviral vector.|The Medicinal Product consists of autologous CD34+ cells collected from the bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding WASP controlled by WAS promoter sequences (w1.6W). Dosage indications: a minimum dose of 2x10^6 CD34+ cells/Kg (maximum 20x10^6 CD34+ cells/Kg) and an optimal dose of 5-10x10^6 CD34+ cells/Kg will be infused i.v.
121601|NCT01515475|Procedure|Glasses|For patients in the glasses group, glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction. If a subject in the observation group has confirmed deterioration, glasses will be prescribed with amount of correction at investigator discretion.
121602|NCT01515488|Other|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
121603|NCT01515488|Other|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
121604|NCT01515501|Procedure|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
121605|NCT01515527|Drug|Cladribine|Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.
Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.
121606|NCT01515527|Drug|Cytarabine|Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.
Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.
121607|NCT00074581|Drug|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
121608|NCT01515527|Drug|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
121609|NCT01515540|Drug|lidocaine|5% lidoderm patch
121610|NCT01515540|Drug|placebo|placebo
121611|NCT01515553|Drug|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
121612|NCT01515566|Drug|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
121613|NCT01515566|Other|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
121614|NCT01515566|Other|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
121615|NCT01515566|Behavioral|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
121616|NCT01515579|Drug|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
121678|NCT01513135|Biological|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
121679|NCT01513148|Device|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
121680|NCT01513161|Drug|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
121681|NCT00074425|Drug|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
121682|NCT01513161|Drug|Placebo|
121683|NCT01513174|Drug|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
121684|NCT01513174|Drug|Gefitinib plus olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
121685|NCT01513187|Drug|Pazopanib + interferon alpha 2A|Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.
Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient
121686|NCT00074607|Drug|Gemcitabine|Schedule
Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).
In the absence of disease progression or DLT, patients may proceed to consolidation.
Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.
Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year.
121687|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
121688|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
121689|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
121690|NCT01515592|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
121691|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin I
121692|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin II
121693|NCT01515644|Other|Powder based infant formula|Powder based infant formula without Inulin
121694|NCT01515657|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 3 days
117362|NCT01499706|Behavioral|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
117363|NCT01499719|Behavioral|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
117364|NCT01499745|Behavioral|Pulmonary Rehabilitation|Exercise Training in Pulmonary Rehabilitation Program:
12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation
117365|NCT01499758|Drug|Atorvastatin|80 Mg tablets
117366|NCT01499771|Drug|Atorvastatin|80 Mg tablets
117367|NCT01499784|Behavioral|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
117368|NCT01499797|Other|The CareWell programme|The CareWell programme contains the following components:
multidisciplinary primary care teams
working with proactive care plans integrating cure, care and welfare
advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)
medication review
case-management
guidelines for consultation of in-hospital geriatric experts
guidelines for transfers from primary care to home-based facilities and hospital and back
practice guidelines for management of common geriatric conditions
117369|NCT01499810|Procedure|Bilateral radiofrequency sympathetic renal denervation|Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
117370|NCT00073242|Drug|Leptin|leptin administration
117371|NCT01499836|Other|PVB|paravertebral block
117372|NCT01499849|Drug|Rolapitant|(4 X 50 mg capsules) 200 mg PO
117373|NCT01499849|Drug|Granisetron|10 mcg/kg IV
117374|NCT01499849|Drug|dexamethasone|20 mg PO and 8 mg PO
117375|NCT01499849|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
117376|NCT01499862|Device|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
117377|NCT01499875|Drug|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
117656|NCT01503957|Device|Saline solution|Nasal spray, 2 sprays in each nostril
117657|NCT01503970|Device|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
120955|NCT01523756|Device|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
120956|NCT01523756|Device|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
120957|NCT01523769|Procedure|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
120958|NCT01523782|Drug|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
120959|NCT01523795|Other|Motion-controlled video gaming|Play of motion-controlled video games for one hour
120960|NCT01523795|Other|Traditional video gaming|Participants played traditional video games for one hour
120961|NCT01523795|Other|Television watching|Participants watched television for one hour
120962|NCT00075556|Drug|capecitabine|
120963|NCT01523808|Drug|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
120964|NCT01523821|Biological|Alpha-1-Proteinase Inhibitor Human|Given IV
120965|NCT01523821|Other|Laboratory Biomarker Analysis|Correlative studies
120966|NCT01523821|Other|Pharmacological Study|Correlative studies
120967|NCT01516775|Other|clear fluid ingestion|drinking of clear fluid in preoperative period
120968|NCT01516788|Other|Phototesting|Single MED dose on Day 2
120969|NCT01516801|Other|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
120970|NCT01516814|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
120971|NCT01516814|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
120972|NCT00074750|Drug|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
120973|NCT01516814|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
121617|NCT01515579|Drug|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
121618|NCT01508364|Drug|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
120756|NCT01518621|Radiation|Radiation|Whole brain radiation
120757|NCT01518621|Drug|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
120758|NCT01518634|Drug|Imipramine treatment|Dosages is 10-75 mg Imipramine/placebo tablets pr. day in a period of 12-19 weeks.
120759|NCT01518634|Drug|Placebo|placebo tablets pr. day in a period of 12-19 weeks.
120760|NCT01518647|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
120761|NCT01518660|Behavioral|Training|Bi-weekly progressive resistance training
120762|NCT01518673|Procedure|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
120763|NCT01520909|Drug|Placebo|Placebo with no active pharmaceutical ingredient
120764|NCT01520922|Biological|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
120765|NCT01520922|Drug|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
120766|NCT01520935|Other|Data collection|The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).
Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed.
120767|NCT01520948|Behavioral|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
120768|NCT00075270|Drug|Paclitaxel|Active Comparator
120769|NCT01520948|Behavioral|Behavioral control|Mirrored star drawing
120770|NCT01520974|Other|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
121695|NCT01515657|Drug|Immediate-Release Aspirin Tablets|325 mg aspirin; once per day for 3 days
120823|NCT01518712|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
120824|NCT01518725|Dietary Supplement|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
120825|NCT01518725|Dietary Supplement|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
120826|NCT01518738|Behavioral|breath attention training|4 week training
120827|NCT01518738|Behavioral|working memory attention training|4 week training
120828|NCT01518764|Dietary Supplement|Red Wine Polyphenols 600mg/day|
120829|NCT01518764|Dietary Supplement|placebo|
120830|NCT00075010|Drug|Decitabine|15 mg/m^2 by vein over 1 hour times 10 days
120831|NCT01518777|Other|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
120832|NCT01518790|Drug|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
120833|NCT01518803|Dietary Supplement|Mediterranean-style breakfast|The experimental meal will be administered early in the morning as breakfast, "Cardioliva" olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
120834|NCT01521052|Device|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
120835|NCT01521065|Device|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
120836|NCT01521078|Behavioral|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
120837|NCT01521117|Drug|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
117658|NCT01503983|Drug|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
117659|NCT01503983|Drug|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
117660|NCT00073736|Drug|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
117661|NCT01503983|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
117662|NCT01503996|Behavioral|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
117663|NCT01504009|Other|Muscle training|12 weeks of strength training 2-3 times/week
117664|NCT01504022|Other|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
117665|NCT01504035|Device|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
117666|NCT01504035|Device|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
117667|NCT01504048|Procedure|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
117668|NCT01504061|Other|Mederma N&I|Topical gel applied three times a day for eight weeks.
117669|NCT01504061|Other|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
117670|NCT01504074|Behavioral|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
117671|NCT00073736|Drug|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
117672|NCT01504126|Drug|Propranolol|20 mg by mouth twice a day for 48-72 hours preoperatively. Resume when participant tolerating oral intake post-operatively until completion of chemotherapy.
117673|NCT01504126|Drug|Chemotherapy|Within 3 weeks of surgery, standard intravenous platinum or taxane chemotherapy (without bevacizumab) over 3-week cycles.
117674|NCT01504126|Procedure|Surgery|Initial tumor reductive surgery.
117675|NCT01504126|Behavioral|Questionnaire|Completion of questionnaires at baseline and after cycles 3 and 6 of chemotherapy.
121224|NCT01524172|Behavioral|Yoga Based Psychotherapy Group|YBMPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
121225|NCT01524172|Behavioral|Standard Mental Health Treatment|Trauma and evidence informed therapy
121226|NCT00075582|Procedure|conventional surgery|Some patients may undergo second-look surgery
121227|NCT01524185|Behavioral|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
121228|NCT01524185|Behavioral|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
121229|NCT01524198|Drug|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
121230|NCT01524198|Drug|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
121231|NCT01517204|Device|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
121232|NCT01517217|Procedure|No girdle|No girdle is used for the first five postoperative days
121233|NCT01517217|Procedure|Girdle|Girdle the first five postoperative days
121234|NCT01517230|Behavioral|Local radio campaign to reduce under-five child mortality|The media campaign is designed by Development Media International. It includes short "spots" and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years.
121235|NCT01517243|Drug|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
121236|NCT01517243|Drug|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
121237|NCT00074802|Drug|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
121238|NCT01517256|Behavioral|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
121239|NCT01517256|Other|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
120771|NCT01520974|Other|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
120772|NCT01520987|Drug|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
120773|NCT01520987|Drug|Placebo|once-daily
121030|NCT01521533|Drug|NOX-A12|Pilot Group (NOX A12 single agent, and combined with VD):
3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.
Expansion Group (NOX A12 in combination with VD):
Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.
121031|NCT01521546|Drug|eplerenone|25mg tablet, once daily by mouth for 12 months
121032|NCT01521546|Drug|placebo|one tablet by mouth daily for 12 months
121033|NCT00075387|Drug|Cyclophosphamide|Given IV
121034|NCT01523834|Drug|Panobinostat|Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).
Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted.
121035|NCT01523847|Drug|MBVD (Myocet+BVD)|MBVD will be scheduled as follows:
Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15
121036|NCT01523860|Drug|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
121037|NCT01523886|Drug|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
121038|NCT01523886|Drug|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
121039|NCT01523899|Device|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
121040|NCT00075556|Procedure|conventional surgery|
121041|NCT01523912|Device|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
123468|NCT01544075|Behavioral|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
123469|NCT01544075|Behavioral|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
123470|NCT01544088|Behavioral|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
123471|NCT00077324|Procedure|surgery|
123472|NCT01544088|Behavioral|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
123473|NCT01544101|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
123717|NCT01544426|Procedure|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
123718|NCT01544426|Procedure|Office hysteroscopy|Office hysteroscopy
123719|NCT01544439|Procedure|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
123720|NCT01544439|Procedure|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
123721|NCT01544452|Procedure|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
123722|NCT01544452|Procedure|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
123723|NCT00077363|Drug|capecitabine|Given PO
123724|NCT01544465|Behavioral|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
123725|NCT01544465|Behavioral|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
123726|NCT01544478|Biological|V501|Human Papillomavirus types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
121925|NCT01513473|Drug|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
121926|NCT01513473|Drug|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
121927|NCT01513486|Behavioral|immobilization|
121928|NCT01513499|Drug|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
121929|NCT01513499|Drug|Placebo|Intranasal Placebo single-dose administration
121930|NCT01513525|Drug|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
121931|NCT01513538|Device|TherapyGuide|Use of TherapyGuide function to help programming the device
121932|NCT01513551|Biological|Pneumococcal Conjugate Vaccine (V114)|Single intramuscular injection of V114 (0.5 mL) on Day 1
121933|NCT01513551|Biological|Pneumococcal Polysaccharide Vaccine|Single intramuscular injection of pneumococcal polysaccharide vaccine (0.5 mL) on Day 1
121934|NCT00001325|Drug|18 FDG|
121935|NCT00074477|Drug|R092670|
121936|NCT01513551|Biological|Pneumococcal 13-Valent Conjugate Vaccine|Single intramuscular injection of pneumococcal 13-valent conjugate vaccine (0.5 mL) on Day 1
121937|NCT01513564|Drug|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
122210|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
122211|NCT01507363|Drug|Placebo|Placebo tablets for 7 days, starting on the day of surgery
122212|NCT01507376|Drug|recombinant hCG|recombinant hCG(250 µg Ovitrell)
122213|NCT01509443|Other|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
122214|NCT01509456|Dietary Supplement|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
122215|NCT01509469|Dietary Supplement|Casein|Ileal infusion of low dose casein (5 gram)
122216|NCT01509469|Dietary Supplement|Casein|Ileal infusion of high dose casein (15 gram)
122217|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
123788|NCT01551628|Drug|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
123789|NCT01551641|Other|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
123790|NCT01551641|Drug|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
123791|NCT01551641|Other|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
123792|NCT01551654|Device|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
124107|NCT01542788|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
124108|NCT00077285|Drug|irinotecan hydrochloride|
124109|NCT01542788|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
124110|NCT01542788|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
124111|NCT01542801|Drug|Norfloxacin|Norfloxacin 400 mg per day
124112|NCT01542801|Drug|ciprofloxacin|Ciprofloxacin 750 mg per week
124113|NCT01542814|Device|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
124114|NCT01535417|Drug|Celebrex|
124115|NCT01535443|Drug|PRO-155 Ophthalmic Solution 0.09 %|PRO-155 Ophthalmic Solution 0.09 % applied twice to day during 10 days..
124116|NCT01535456|Procedure|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
124117|NCT01535469|Drug|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
124118|NCT01535482|Behavioral|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
124119|NCT00076726|Drug|Infliximab|
121846|NCT01516047|Drug|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
121847|NCT01516060|Drug|Efavirenz|400mg qd; 2 x 200mg
121848|NCT01516060|Drug|Efavirenz|600mg qd; 3 x 200mg qd
121849|NCT01516073|Drug|Fluticasone Propionate|FP BID for 12 weeks
121850|NCT01516086|Drug|Fluticasone Propionate (FP)|FP Inhalation BID
121851|NCT01516099|Other|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
122132|NCT01509313|Device|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
122133|NCT00074178|Biological|filgrastim|
122134|NCT01509326|Other|chiropractic treatment|12 sessions over 4 weeks
122135|NCT01509326|Device|Dr. Zaxx pillow|Daily use of an acupressure pillow
122136|NCT01509339|Drug|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
122137|NCT01509352|Procedure|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
122138|NCT01509352|Procedure|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
122139|NCT01509365|Drug|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
122140|NCT01509365|Drug|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
122141|NCT01509391|Drug|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
122142|NCT01509404|Drug|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
122143|NCT01509404|Biological|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
122144|NCT00074178|Biological|pegfilgrastim|
122145|NCT01509404|Drug|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
122146|NCT01509417|Other|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
122443|NCT00074009|Drug|bortezomib|
122444|NCT01507623|Device|Capnography (Phillips MP20 monitor)|In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.
*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures
122445|NCT01507636|Other|Occupational Therapy|Occupational therapy using a special arm function training.
122446|NCT01507636|Other|Physical therapy|Physical therapy for arm force training.
122447|NCT01507649|Behavioral|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
122448|NCT01507662|Behavioral|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
122747|NCT01545011|Other|Inspiratory muscle training|Inspiratory muscle training
122748|NCT01545024|Drug|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
122749|NCT00077389|Procedure|adjuvant therapy|
122750|NCT01545037|Dietary Supplement|Lactobacillus acidophilus and Lactobacillus casei|Each capsule contains of Lactobacillus acidophilus CL1285® + Lactobacillus casei LBC80R® contains50 billion cfu live bacteria. The randomized subjects will consume 2 capsules per day at breakfast.
122751|NCT01545037|Other|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
122752|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
122753|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
122754|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
122755|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
122756|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
122757|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
122758|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
122218|NCT00074178|Drug|cyclophosphamide|
122219|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
122220|NCT01509469|Other|Saline|Ileal infusion with saline (180mL in total)
122221|NCT01509469|Dietary Supplement|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
122222|NCT01509482|Other|blood samples|blood samples to test for primary and secondary outcome measures
122223|NCT01509482|Other|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
122224|NCT01509495|Device|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
122225|NCT01509508|Drug|Immediate ARV treatment initiation with TDF/FTC/EFV|All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.
The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD.
122226|NCT01509508|Other|South African recommendation guided ARV (TDF/FTC/EFV) initiation|HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:
CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms
WHO clinical stage 3 or 4 irrespective of CD4 count
MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD.
122227|NCT01509521|Drug|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
122228|NCT01509521|Drug|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
122229|NCT00074178|Drug|cytarabine|
122230|NCT01509547|Drug|Varenicline|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
122509|NCT01514578|Drug|TRV130A|Intravenous infusion of 1 hour duration
122510|NCT01514578|Drug|Dextrose in Water|Intravenous infusion of 1 hour duration
122511|NCT01514617|Procedure|Diffusion -and perfusion weighted MRI including iv contrast agent injection|MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.
During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.
122512|NCT01514630|Drug|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
124120|NCT01535482|Behavioral|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
124121|NCT01535495|Drug|Propranolol|Propranolol XL 120mg by mouth once daily
124122|NCT01535508|Drug|Liquid Vitamin D|300 IU/Kg/day not to exceed 10,000 IU/day.
124123|NCT01535521|Device|Sleep Position Trainer (SPT)|
124124|NCT01535547|Drug|isavuconazole|oral
124125|NCT01535547|Drug|tacrolimus|oral
124126|NCT01535560|Drug|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
124127|NCT01535560|Drug|AL-60371 Vehicle|Inactive ingredients used as placebo
124128|NCT01535573|Drug|Citalopram|20 mg once per day for 9 weeks
124129|NCT01535573|Drug|Citalopram|40 mg per day for 9 weeks
122985|NCT01552668|Drug|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
122986|NCT01552668|Drug|Placebo|Receive Placebo twice daily
122987|NCT01552681|Biological|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
122988|NCT01545388|Drug|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
122989|NCT01545401|Other|EMPOWER-PAR Intervention|Implementation process is conducted in 3 phases:
I. Phase 1: Formation and training of the CDM team
II. Phase 2: Distributions of the intervention tools
Global CV Risks Self-Management Booklets
CPG to aid clinical decision making
III. Phase 3: Facilitation and support to implement the intervention
122990|NCT01545414|Behavioral|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
122991|NCT01545414|Behavioral|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
122992|NCT01545427|Drug|Imatinib mesylate|200 mg bid for 6 months
122993|NCT01545427|Other|Placebo|Placebo coated to match appearance of Gleevec identically.
122994|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
122995|NCT00077428|Drug|bortezomib|Given IV
122147|NCT01509417|Other|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
122148|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
122149|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
122150|NCT01511510|Drug|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
122151|NCT01511510|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
122152|NCT01511510|Drug|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
122153|NCT01511510|Drug|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
122154|NCT01511510|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
122433|NCT01514500|Drug|NNC0195-0092|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
122434|NCT01514500|Drug|placebo|Single placebo dose administered s.c. (subcutaneously, under the skin)
122435|NCT01514500|Drug|NNC0195-0092|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
122436|NCT01514500|Drug|placebo|Multiple placebo doses administered s.c. (subcutaneously, under the skin)
122437|NCT01514513|Drug|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
122438|NCT01514513|Drug|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
122439|NCT00074490|Drug|Filgrastim|Filgrastim:5 mcg/kg/day SC, day 6 (require ANC & gt; 1000, two values; or ANC & gt; 5000 cells/ul on one occasion)
122440|NCT01514526|Drug|Dovitinib|Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.
The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
122441|NCT01514539|Other|cross-sectional|Monitoring two recently discovered appetite hormones called "ghrelin" and "neuropeptide YY (PYY)." This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity.
122442|NCT01514552|Other|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
122759|NCT01547312|Drug|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
122760|NCT01547312|Procedure|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
122761|NCT01547312|Procedure|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
122762|NCT01547312|Procedure|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
122763|NCT01547312|Drug|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
122764|NCT01547312|Drug|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
122765|NCT01547312|Drug|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
122766|NCT01547312|Procedure|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
122767|NCT01547325|Drug|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
122768|NCT00077558|Drug|triapine|
121852|NCT00074711|Drug|Calcium phosphate|
121853|NCT01516099|Other|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
121854|NCT01516138|Drug|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
121855|NCT01516138|Drug|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
121856|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
121857|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
121858|NCT01516151|Dietary Supplement|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
121859|NCT01516151|Drug|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
121860|NCT01516151|Dietary Supplement|CaPre™|4 capsules of 1 g total per day for 8 weeks.
122513|NCT01514656|Other|CPR Training using the Family and Friends CPR Anytime Video Self Instruction|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
122514|NCT01514656|Other|Implementation of a Hospital-based CPR Training Model|Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
122515|NCT00074529|Drug|MK0677|
122516|NCT01514656|Other|Follow-up prompting to encourage skill retention|Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
122517|NCT01514682|Drug|Anti-inflammatory Combination Therapy|salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening
fluvastatin: target dose 40 mg/day, administered in a single evening dose
combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose
122518|NCT01514682|Drug|Placebo|Non-medication pills; To be taken in morning and evening intervals.
122519|NCT01514695|Drug|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
122520|NCT01514695|Drug|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
122521|NCT01514695|Other|Placebo|One dose of saline (2ml)
122522|NCT01514708|Biological|AdimFlu-S Influenza Vaccine|Suspension for injection
122523|NCT01514721|Drug|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
122524|NCT01514734|Drug|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
122821|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
122822|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
122823|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
122824|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
122825|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
122826|NCT01545076|Biological|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:
0.2 g/kg body weight (low dose arm)
0.4 g/kg body weight (high dose arm)
122996|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
122997|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
122998|NCT01545440|Drug|placebo|subcutaneous dose every 4 weeks
122999|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
123000|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
123001|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
123002|NCT01545453|Drug|placebo|subcutaneous dose every 4 weeks
123003|NCT01545466|Behavioral|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
123004|NCT01545479|Drug|captopril 25mg|renal blood oxygenation after captopril
123005|NCT01545505|Behavioral|Neuropsychological assessment|A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.
A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test.
123006|NCT00077428|Drug|doxorubicin hydrochloride|Given IV
123007|NCT01545518|Drug|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
122079|NCT01511484|Behavioral|Information-only|Selected pages from the British National Health Service (NHS) information booklets ["5 A Day, Just Eat More (fruit & veg)"; pages i, ii, 12-15, 20 & 21] and ["5 A Day, Just Eat More (fruit & veg): What's it all about?"; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions
122080|NCT01511484|Behavioral|Generic appearance intervention|Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.
Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.
Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour.
122081|NCT01511484|Behavioral|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
122082|NCT01511497|Biological|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
122083|NCT01511497|Other|Normal saline|Intravenous, normal saline
123421|NCT01546298|Other|Patch tests|Patch tests for allergic reaction
123422|NCT01546311|Device|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
123423|NCT01546324|Procedure|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
123424|NCT01546350|Genetic|PGD|array CGH after blastocyst biopsy
123425|NCT00077467|Other|laboratory biomarker analysis|Correlative studies
123426|NCT01546350|Procedure|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
123660|NCT01546805|Drug|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
123661|NCT01546805|Drug|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
123662|NCT01546818|Biological|SAV001-H|A whole-killed HIV
123663|NCT01546844|Other|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
123664|NCT01546857|Drug|Placebo|Placebo
123665|NCT01546857|Drug|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
123666|NCT01546883|Drug|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
123667|NCT01546896|Drug|buspirone+alprazolam|day 1~7: buspirone 10mg/d + alprazolam 0.5mg / day 8~28: buspirone 20mg/d + alprazolam 0.5mg / day 29~56: buspirone 20~30mg/d + alprazolam 0.5mg
123668|NCT00077519|Radiation|radiation therapy|
123669|NCT01546896|Drug|alprazolam|0.5mg/d
123670|NCT01546909|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
123671|NCT01549041|Drug|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
123672|NCT01549054|Drug|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
123673|NCT01549054|Drug|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
123674|NCT01549054|Drug|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
121861|NCT01516164|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
121862|NCT01516190|Behavioral|Exercise|Supervised exercise sessions and independent exercise
121863|NCT00074711|Drug|Teriparatide|
121864|NCT01516190|Behavioral|Surgical preparation program|Book, tapes, CD
121865|NCT01516203|Drug|Rifafour|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
121866|NCT01516203|Drug|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
121867|NCT01516216|Drug|FOLFOX + bevacizumab|Given intravenously on Day 1 of every cycle
121868|NCT01516216|Dietary Supplement|Vitamin D|Standard Dose (400 IU once daily)
121869|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
121870|NCT01508884|Drug|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
121871|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
121872|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
122155|NCT01511523|Dietary Supplement|RGMA001|3 capsules administered BID once a day.
122156|NCT01511523|Dietary Supplement|Sugar Pill|Placebo
122157|NCT01511536|Drug|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
122158|NCT01511536|Drug|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
122159|NCT01511536|Drug|Prednisone 5 mg|Route of administration: oral
122160|NCT00074282|Drug|cyclophosphamide|
122161|NCT01511549|Drug|placebo|Pharmaceutical form:injection
Route of administration: intra-articular
122162|NCT01511549|Drug|SAR113945|Pharmaceutical form:injection
Route of administration: intra-articular
122163|NCT01511562|Drug|carmustine|Given IV
123727|NCT01544491|Drug|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
123728|NCT01544491|Drug|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
123729|NCT01544504|Drug|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
123730|NCT01546922|Drug|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
123731|NCT01546935|Drug|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
123732|NCT01546948|Drug|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
124051|NCT01537653|Drug|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
124052|NCT01537653|Drug|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
124053|NCT01537666|Drug|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
124054|NCT01537666|Drug|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
124055|NCT01537679|Behavioral|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
124056|NCT01537679|Behavioral|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
124057|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
124058|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
124059|NCT01537692|Drug|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
124060|NCT01537705|Drug|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
124061|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
124062|NCT01537718|Device|REPLY 200|REPLY 200 pacemaker
122084|NCT00074282|Biological|rituximab|
122085|NCT01513798|Behavioral|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
122086|NCT00074490|Drug|Cyclosporine|Cyclosporine:2 mg/kg/dose every 12 hours on day +7
122087|NCT01513798|Behavioral|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
122088|NCT01513811|Drug|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
122089|NCT01513811|Drug|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
122090|NCT01513811|Drug|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
122091|NCT01513824|Behavioral|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
122092|NCT01513850|Drug|Hepabulin IV|I.V.
122093|NCT01513863|Drug|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
122382|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
122383|NCT01507610|Drug|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
122384|NCT00001305|Drug|GRH|
122385|NCT01509690|Other|Multidisciplinary, intensive and collaborative care|No specific study drugs, devices or procedures are involved.
Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access [arteriovenous (AV) fistula or graft] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications.
123675|NCT01549054|Drug|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
123676|NCT01549080|Drug|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
123677|NCT01549093|Drug|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
123678|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
123999|NCT01540175|Other|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
124000|NCT01540188|Behavioral|Family Intervention to Address Drug Use and HIV in Vietnam|Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.
Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community
124001|NCT01540201|Other|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
124002|NCT01540201|Other|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
124003|NCT01540214|Other|Pre- and postoperative evaluations|At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).
At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).
At time of surgery: additional cystoscopy.
124004|NCT01540227|Drug|Regular Treatment for Syphilis|Drug: Benzathine Penicillin G (Bicillin)
Dose: 2.4 million units
Mode of Administration: intramuscular injection
Duration of Treatment: one dose
Health Canada approved indication: Yes
124005|NCT01540240|Drug|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
124006|NCT01540240|Drug|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
124007|NCT00077129|Drug|carboplatin|
124008|NCT01540253|Drug|PI3K inhibitor BKM120|Given PO
122164|NCT01511562|Drug|cytarabine|Given IV
122165|NCT01511562|Drug|etoposide|Given IV
122166|NCT01511562|Drug|thiotepa|Given IV
122167|NCT01511562|Procedure|stem cell transplant|
122168|NCT01511562|Drug|G-CSF|
122169|NCT01511575|Genetic|RNA analysis|
122170|NCT01511575|Genetic|reverse transcriptase-polymerase chain reaction|
122171|NCT00074282|Drug|lenalidomide|
122172|NCT01511575|Other|laboratory biomarker analysis|
122173|NCT01511627|Drug|General Anesthesia + Spinal anesthesia combined|All patients will receive a preoperative multimodal analgesic regime:
Tylenol® 975mg per os
Naproxen® 500 mg per os
Patients will receive a spinal anesthetic with:
Bupivacaine 0.5% 10 mg
Fentanyl 10ug
Epidural Morphine 150ug
After the spinal, a general anesthetic will be induced using:
Midazolam 1 - 2 mg intravenously
Fentanyl 1 - 2 ug/kg intravenously
Propofol 1-3 mg/kg intravenously
Rocuronium 0.3 - 0.9mg/kg intravenously
followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.
Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.
Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.
Dexamethasone 4mg and Ondansetron 4mg intravenously
Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU).
122174|NCT01513941|Drug|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
122175|NCT01513941|Drug|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
122449|NCT01507688|Behavioral|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
122450|NCT01507701|Drug|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
122451|NCT01507714|Procedure|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
122452|NCT01507727|Drug|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
122453|NCT01507727|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
122454|NCT00074022|Biological|GTI-2040|Given IV
124063|NCT01537731|Procedure|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
124064|NCT01537744|Drug|oral 5-azacitidine in combination with romidepsin|DOSING REGIMEN(S):
Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)
Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15
Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15
Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15
Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15
Level 4d MTD 8mg/m2 days 8, 15, and 22
Each cycle will last 28 days.
Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.
On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.
Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene.
124065|NCT01537757|Drug|MK-8931|Single dose, administered as oral capsules
124066|NCT01537770|Procedure|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
124067|NCT01537770|Procedure|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
123220|NCT01550523|Drug|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
123221|NCT01550523|Device|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
123222|NCT01550536|Behavioral|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
123223|NCT01550549|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
123224|NCT00077948|Drug|Enoximone|Enoximone administered orally
123225|NCT01550562|Device|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
123226|NCT01550575|Device|Non Boston Scientific spinal cord stimulation system|Epidural spinal cord stimulation
122386|NCT01509703|Procedure|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
122387|NCT01509729|Procedure|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
122388|NCT01509729|Procedure|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
122389|NCT00074178|Drug|etoposide phosphate|
122390|NCT01509742|Drug|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
122391|NCT01509742|Drug|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
122392|NCT01509755|Drug|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
122393|NCT01509755|Drug|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
122394|NCT01509755|Drug|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
122395|NCT01509781|Procedure|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
122396|NCT01509781|Procedure|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
122685|NCT00077558|Drug|fludarabine phosphate|
122686|NCT01547299|Drug|Dutasteride|
122687|NCT01549730|Procedure|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
122688|NCT01549743|Drug|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
122689|NCT01549743|Drug|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
122690|NCT01549743|Drug|Celecoxib plus Rebamipide|Celecoxib plus Rebamipide same way as "arm: celecoxib" and "arm: rebamipide"
122691|NCT01549756|Behavioral|bulletin board and teleophone depth interview|qualitative based research
124009|NCT01540253|Drug|docetaxel|Given IV
124010|NCT01542515|Procedure|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a "T" shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors.
124011|NCT01542528|Behavioral|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
124012|NCT01542541|Drug|Rifaximin|550mg BID for 2 days
124013|NCT01542554|Other|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
124014|NCT01542554|Other|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
124015|NCT01542567|Drug|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
124016|NCT00077285|Drug|doxorubicin hydrochloride|
123161|NCT01553175|Other|laboratory biomarker analysis|
123162|NCT01553188|Drug|AMG 386|AMG 386 dose will be calculated using the subject s actual body weight (Kg). Supplied in 240 mg v will be administered as an IV infusion using an intravenous infusion pump given over a 60-minute
123163|NCT01553188|Drug|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
123164|NCT01553188|Drug|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patient s preference.
123165|NCT01553201|Drug|Botuninum toxin A|
123166|NCT01545726|Drug|Placebo|Placebo was supplied as capsules for oral administration.
123167|NCT01545739|Device|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
123168|NCT01545752|Other|teaching by non-interactive CD|teaching book with non-interactive CD
123169|NCT01545752|Other|Interactive CD|Teaching book with interactive CD
123170|NCT00077441|Other|laboratory biomarker analysis|Correlative studies
123171|NCT01545765|Drug|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
122455|NCT01507740|Drug|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
122456|NCT01507740|Drug|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
122457|NCT01507740|Drug|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
122458|NCT01507753|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
122459|NCT01507753|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
122460|NCT01509807|Drug|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
122461|NCT01509833|Drug|rFSH|Administration of rFSH for ovarian stimulation.
122462|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
122463|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
122464|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^8 vp/mL Sf2aWC administered on Day 0
122465|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^9 vp/mL administered on Days 0, 28, and 56
122769|NCT01547325|Drug|placebo hydrogel|placebo hydrogel
122770|NCT01547351|Other|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
122771|NCT01547364|Drug|Saline|Injection of 10 ml of normal saline into the caudal epidural space
122772|NCT01547364|Drug|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
123227|NCT01550575|Device|Boston Scientific Precision Plus spinal cord stimulation system|epidural spinal cord stimulation
123228|NCT01552681|Other|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
123229|NCT01552694|Drug|Sitagliptin|Oral, 100 mg/day for 2 months
123230|NCT01552694|Drug|Placebo|oral, matching placebo daily for 2 months
123231|NCT00078221|Device|Rheopheresis blood filtration|
123232|NCT01552707|Biological|XCEL-MT-OSTEO-ALPHA|Isolation and "ex-vivo" expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion.
123233|NCT01552707|Procedure|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
123234|NCT01552733|Device|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
123235|NCT01552733|Other|Standard of care|Rehabilitation Therapy
123236|NCT01552759|Procedure|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
123237|NCT01552759|Behavioral|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
123474|NCT01544101|Dietary Supplement|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
123475|NCT01544114|Drug|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
123476|NCT01544114|Drug|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
123477|NCT01544114|Drug|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
123478|NCT01544127|Behavioral|Motivational Interviewing to Address Suicidal Ideation (MI-SI)|1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
123479|NCT01544127|Behavioral|Motivational Interviewing to Address Suicidal Ideation (MI-SI)- Revised|1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
123480|NCT01544140|Drug|Midazolam|Oral syrup 7.5 mg, single dose
123481|NCT01544140|Drug|vandetanib|Oral tablets, 800 mg, single dose
123482|NCT00077337|Drug|romidepsin|
122692|NCT00001426|Drug|Paclitaxel|
122693|NCT00077805|Drug|Enoxaparin sodium|
122694|NCT01549769|Drug|Bardoxolone Methyl|Oral, once daily
122695|NCT01549782|Dietary Supplement|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
122696|NCT01549782|Dietary Supplement|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
122697|NCT01549795|Procedure|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
122698|NCT01549795|Radiation|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
122699|NCT01549795|Radiation|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
122700|NCT01549795|Drug|Capecitabine|Capecitabine - administered till liver transplantation
122701|NCT01549795|Procedure|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
122702|NCT01549808|Other|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
122703|NCT01549808|Other|mobilization|sitting, standing and walking
123008|NCT01545531|Drug|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration [13]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
123009|NCT01545557|Device|Hyaluronic acid dermal filler gel|1 injection per indication and 1 touch-up injection if necessary
123010|NCT01545570|Drug|GSK2376497|GSK2376497 Active Comparator
123011|NCT01545570|Drug|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
123172|NCT01545778|Drug|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
123173|NCT01545778|Drug|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
123174|NCT01545791|Drug|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
123175|NCT01545804|Drug|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
123176|NCT01545817|Drug|Pazopanib followed by everolimus|all patients will receive Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
123177|NCT01545830|Dietary Supplement|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
123178|NCT01545843|Behavioral|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
123179|NCT01545843|Drug|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
123180|NCT01545856|Drug|levodopa|levodopa use
123181|NCT00077454|Drug|erlotinib hydrochloride|Given orally (PO)
123427|NCT01548651|Drug|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
123428|NCT01548651|Drug|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
123429|NCT01548664|Other|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
123430|NCT00077649|Drug|Copegus|800mg po bid for 48 weeks
122773|NCT01547377|Dietary Supplement|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
122774|NCT01547377|Other|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
122775|NCT01547390|Drug|Aspirin|
122776|NCT01547390|Drug|placebo|
122777|NCT01547416|Drug|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .
Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.
General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
122778|NCT01549860|Device|MIST Therapy|Non-contact low frequency ultrasound therapy
122779|NCT01549873|Drug|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
122780|NCT01549873|Drug|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
122781|NCT01549886|Drug|Zevalin Regimen|Day 1 - Rituximab 250 mg/m2 intravenous infusion. Day 8 - Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
122782|NCT01549886|Drug|Moxtezafin Gadolinium|Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m2 intravenous infusion.
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.
122783|NCT00077831|Behavioral|neurobehavioral development|observational study of infant and child development
121873|NCT01508884|Biological|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
121874|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
121875|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
121876|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
123483|NCT01546363|Other|Blood draw|phlebotomy
123484|NCT01546376|Radiation|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
123485|NCT01546376|Other|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
123486|NCT01546389|Biological|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
123487|NCT01546389|Drug|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
123488|NCT01546402|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
123489|NCT01546402|Procedure|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
123490|NCT01546415|Drug|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
123491|NCT01546428|Drug|INC280|
123492|NCT00001416|Drug|CEREDASE™|
123733|NCT01546948|Drug|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
123734|NCT01546961|Drug|Chloroquine|Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).
Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2.
123735|NCT01546974|Device|HME filter Twin Star 55, Drager Medical, Germany|
123736|NCT01546974|Device|Heated humidification|
123737|NCT01546987|Drug|bicalutamide|Given orally
123738|NCT00077532|Biological|gp100 antigen|
123739|NCT01546987|Drug|buserelin|Given subcutaneously or intramuscularly
123740|NCT01546987|Drug|flutamide|Given orally
123012|NCT01545583|Drug|LY3016859 IV|Administered IV
123013|NCT01545583|Drug|Placebo IV|Administered IV
123014|NCT01547780|Radiation|PET|
123015|NCT00077610|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms/week iv (starting dose) every 2 weeks
123016|NCT01547806|Drug|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
123017|NCT01547806|Drug|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
123018|NCT01547806|Procedure|Apheresis|The minimum CD34+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
123019|NCT01547897|Drug|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
123020|NCT01547910|Dietary Supplement|Fish Oil|Fish oil given in supplementary dose
123021|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
123022|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
123023|NCT01547949|Dietary Supplement|tart cultivar Montmorency cherry juice|
123024|NCT01547949|Dietary Supplement|placebo cherry fruit drink|
123025|NCT01547962|Device|Gintuit|Gintuit is prepared in a "S" fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture.
123026|NCT00077610|Drug|methoxy polyethylene-glycol epoetin beta [Mircera]|30, 50 or 90 micrograms/week iv (starting dose) every 4 weeks
123027|NCT01547962|Other|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
122094|NCT01513863|Drug|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
122095|NCT01513863|Drug|Placebo|Placebo applied to affected area once a day for 70 days
122096|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
123431|NCT01548664|Other|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
123432|NCT01548677|Drug|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
123433|NCT01548690|Drug|Ornithine phenylacetate|Up to 36 patients will be enrolled into 2 groups [~18 with minimal renal dysfunction (Cohort 1) & ~18 w/ comprised renal function (Cohort 2)] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.
The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.
The remaining 12 patients (~6 Cohort 1 & ~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4).
123434|NCT01548703|Drug|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
123435|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
123436|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
123437|NCT01548729|Procedure|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
123438|NCT01548742|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
123439|NCT01548742|Behavioral|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
123679|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
123680|NCT00077688|Drug|TOCOSOL Paclitaxel|
123681|NCT01549106|Drug|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
123682|NCT01549106|Drug|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
123683|NCT01549119|Biological|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
123684|NCT01549119|Biological|Placebo|Comparison with experimental vaccine
123685|NCT01549145|Device|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
123686|NCT01549158|Drug|torasemide-PR|Single oral dose of torasemide PR 10 mg
121877|NCT01508910|Biological|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
121878|NCT01508910|Biological|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
121879|NCT00074165|Drug|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
121880|NCT01508910|Other|Standard of care|Standard of care for refractory angina
121881|NCT01508923|Drug|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
121882|NCT01508923|Drug|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
121883|NCT01508936|Drug|Reslizumab|Reslizumab will be administered to patients at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
121884|NCT01508936|Drug|Matching Placebo|Matching placebo will be administered every 4 weeks for 16 weeks.
121885|NCT01508949|Drug|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
121886|NCT01508949|Drug|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
121887|NCT01508975|Other|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
121888|NCT01508988|Drug|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
121889|NCT01508988|Drug|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
121890|NCT00074165|Drug|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
121891|NCT01508988|Drug|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
121892|NCT01508988|Drug|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
121893|NCT01508988|Drug|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
121894|NCT01508988|Drug|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
121895|NCT01508988|Drug|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
122176|NCT01513941|Drug|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
122177|NCT01513967|Drug|RPh201, botanical drug product|SC administration at varying doses
123741|NCT01546987|Drug|goserelin acetate|Given subcutaneously or intramuscularly
123742|NCT01546987|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
123743|NCT01546987|Drug|orteronel|Given orally
123744|NCT01546987|Drug|triptorelin|Given subcutaneously or intramuscularly
123745|NCT01547000|Drug|placebo|Administered up to 8 weeks.
123746|NCT01547000|Drug|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
123747|NCT01547026|Behavioral|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
123748|NCT01547052|Behavioral|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
123749|NCT00077532|Biological|incomplete Freund's adjuvant|
123750|NCT01547052|Behavioral|Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
123751|NCT01547078|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
123752|NCT01547078|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
123753|NCT01547091|Biological|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
123754|NCT01547091|Drug|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
124068|NCT01540253|Other|pharmacological study|Correlative studies
124069|NCT01540253|Other|questionnaire administration|Ancillary studies
124070|NCT01540253|Other|laboratory biomarker analysis|Correlative studies
124071|NCT01540266|Procedure|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
124072|NCT01540266|Procedure|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
124073|NCT01540292|Biological|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
122097|NCT00074490|Drug|Etoposide|Etoposide: 50 mg/m2/day CIV, days 1-4
122098|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
122099|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing <30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
122100|NCT01513915|Other|Group cognitive behavioral intervention|A six 2 hour session group cognitive behavioral intervention was done based on FRIENDS program for parents of children with anxiety disorders.
122101|NCT01513928|Drug|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
122102|NCT01513928|Drug|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
122103|NCT01513928|Drug|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
122104|NCT01507064|Procedure|laser ablation (LA)|For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.
When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
122105|NCT01507077|Drug|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
122106|NCT01507077|Drug|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
122107|NCT01507090|Device|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
122108|NCT01507103|Biological|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
122109|NCT01507103|Drug|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
122110|NCT00073983|Biological|filgrastim|filgrastim
122397|NCT01509794|Other|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
123687|NCT01549158|Drug|Furosemide-IR|Single oral dose of furosemide IR 40 mg
123688|NCT01549158|Drug|torasemide-IR|Single oral dose of torasemide IR 10 mg
123689|NCT01549171|Drug|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
123690|NCT01549171|Other|normal saline|Supplement with vehicle only no Iloprost.
123691|NCT00077714|Drug|Paliperidone ER|
123692|NCT01549223|Drug|Oxytocin|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
123693|NCT01551433|Device|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
123694|NCT01551446|Drug|Bardoxolone Methyl|Oral, once daily
123695|NCT01551459|Drug|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
123696|NCT01551459|Drug|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
123697|NCT00078039|Drug|Paliperidone ER|
123698|NCT01551472|Device|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
124017|NCT01542567|Drug|Placebo|Placebo suppositories
124018|NCT01542580|Device|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
124019|NCT01542580|Device|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
124020|NCT01542580|Device|Vanguard DA 360|Dual-articulation device, only cleared in EU
124021|NCT01542593|Device|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.
Measurement results will be compared to measurements performed on CT scan (obtained before surgery).
122178|NCT00074490|Drug|Doxorubicin|Doxorubicin:10 mg/m2/day CIV, days 1-4
122179|NCT01513967|Drug|Placebo|SC administration at varying doses
122180|NCT01513967|Drug|RPh201, botanical extract product|3-month treatment schedule, consisting of bi-weekly SC administration of the study drug followed by a follow up period 3 months post end of the last treatment day
122181|NCT01513967|Drug|Placebo|3-month treatment schedule, consisting of bi-weekly SC administration of the placebo followed by a follow up period 3 months post end of the last treatment day
122182|NCT01513980|Procedure|self-monitoring for patients with severe COPD|Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.
The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients
122183|NCT01513980|Procedure|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
122184|NCT01513993|Procedure|Telemonitoring for patients with Congestive Heart Failure|Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.
The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms.
122185|NCT01514019|Drug|Acebutolol|Acebutolol
122186|NCT01514019|Drug|Placebo|Placebo capsule(Capsules filled up with lactose)
122187|NCT01514032|Procedure|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
122188|NCT01514032|Procedure|Retrograde intrarenal surgery|Retrograde intrarenal surgery
122189|NCT00074490|Drug|Vincristine|Vincristine:0.4 mg/m2/day CIV, days 1-4
122190|NCT01514058|Procedure|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
122191|NCT01514058|Procedure|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
122192|NCT01514071|Behavioral|Pop-up picture|An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will "pop-up" when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either "meets criteria" or "does not meet criteria" in order to close the animated picture window.
122466|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^10 vp/mL administered on Days 0, 28, and 56
124074|NCT01540305|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
124075|NCT01540305|Device|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
124076|NCT00001387|Drug|paclitaxel|
124077|NCT00077129|Drug|paclitaxel|
124078|NCT01540318|Procedure|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
124079|NCT01540331|Device|"model 1000 PNT vacuum controller" (the vacuum device for ocular suction)|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
124080|NCT01540344|Procedure|CRS|complete macroscopic cytoreduction (CC-0/1)
124081|NCT01540344|Drug|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
124082|NCT01540357|Behavioral|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
124083|NCT01540357|Behavioral|Treatment after waiting time|Treatment was performed after completion of the active arm.
124084|NCT01540370|Other|No Treatment|No treatment
124085|NCT01540383|Behavioral|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, >=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
124086|NCT01540383|Behavioral|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
123238|NCT01552759|Behavioral|Test meal|Subjects are presented with an ad libitum buffet meal.
123239|NCT01552772|Drug|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
123240|NCT01552785|Device|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
123241|NCT01552798|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
122398|NCT01509794|Other|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
122399|NCT01509807|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
122400|NCT00001311|Device|heparin-surface modified intraocular lens|
122401|NCT00074178|Drug|methotrexate|
122402|NCT01511965|Other|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
122403|NCT01511978|Drug|3,4-DAP|Subjects will maintain their usual dosage using tablets on their regular personal schedule
122404|NCT01511978|Drug|3,4-DAP Taper to Placebo|Subjects will take decreasing amounts of 3,4-DAP using tablets on their regular personal schedule
122405|NCT01511991|Drug|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
122406|NCT01512004|Drug|Propiverine Hydrochloride|drug of oral capsule
122407|NCT01512004|Drug|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
122408|NCT00074308|Other|pharmacological study|Correlative studies
122409|NCT01512017|Device|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
122410|NCT01512017|Device|Vaseline|External use
122411|NCT01512043|Behavioral|Breathing control|Practice of device guided breathing control twice a day for four weeks.
122412|NCT01512056|Drug|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
122413|NCT01512069|Behavioral|Web-based Health Planner on diet and exercise|URL is closed
The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors.
122704|NCT00077818|Drug|Enoxaparin sodium|
124022|NCT01542606|Device|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
124023|NCT01542619|Biological|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
124024|NCT01542619|Biological|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
124025|NCT01542632|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
124026|NCT01542632|Biological|TDV New Formulation|TDV New Formulation subcutaneous injection
124027|NCT00001399|Drug|Transduced CD34+ Cells|
124028|NCT00077285|Drug|etoposide|
124029|NCT01542632|Drug|Placebo|Placebo subcutaneous injection
124030|NCT01542632|Drug|New Formulation Placebo|New Formulation placebo subcutaneous injection
124031|NCT01542645|Drug|Methadone|Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
124032|NCT01535274|Other|Inspired oxygen fraction / end tidal carbon dioxide|Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:
FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.
FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.
FIO2 100%, PETCO2 30mmHg - beach chair position.
FIO2 100%, PETCO2 45mmHg - beach chair position.
FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.
124033|NCT01535287|Drug|Dexmedetomidine|Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).
All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider.
124034|NCT01535300|Procedure|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
123182|NCT01545869|Procedure|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
123183|NCT01545882|Drug|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
123184|NCT01545908|Other|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
122467|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^11 administered on Days 0, 28, and 56
122468|NCT01509859|Device|PFNA proximal femur nail device (Synthes)|synthes "PFNA" proximal femur nail device
122469|NCT01509859|Device|INTERTAN proximal femur nail device (Smith&Nephew)|Smith&Nephew "INTERTAN" proximal femur nail device
122470|NCT00074191|Drug|cytarabine|
122471|NCT01509872|Behavioral|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
122472|NCT01509872|Behavioral|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
122473|NCT01509898|Device|Water jet|use of water jet for a month
122474|NCT01509911|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
122475|NCT01509911|Drug|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
122476|NCT01509924|Other|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
122477|NCT01509937|Device|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
122478|NCT01509937|Device|Device|participants in control arm will not receive BCM measurement.
122479|NCT01509950|Procedure|Staples|Staples for closure of cesarean section skin incision
122480|NCT01509950|Procedure|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
122481|NCT00074191|Drug|dexamethasone|
122482|NCT01509950|Procedure|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
122483|NCT01512134|Device|Deep Brain Stimulation Device|Deep brain stimulation surgery
123242|NCT00078234|Drug|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
123243|NCT01552798|Drug|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
123244|NCT01552798|Drug|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
123245|NCT01552824|Procedure|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
123246|NCT01552824|Procedure|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
123247|NCT01552837|Drug|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
123248|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
123249|NCT01545947|Drug|CC-223, erlotinib|Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
123250|NCT01545947|Drug|CC-223, oral azacitidine|Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
123251|NCT01545947|Drug|CC-223, oral azacitidine|Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
123252|NCT01545960|Other|not applicable in this study|No actual interventions will be administered for this study.
123493|NCT00077493|Drug|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
123494|NCT01546441|Behavioral|interprofessional assessment|assessment by interprofessional team
122705|NCT01549834|Drug|ABT-126|Low Dose
122706|NCT01549834|Drug|ABT-126|High Dose
122707|NCT01549834|Drug|placebo|Placebo
122708|NCT01549847|Drug|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
122709|NCT01549847|Drug|Placebo|Placebo PO BID
122710|NCT01552070|Other|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
122711|NCT01552083|Other|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
122712|NCT01552096|Drug|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
122713|NCT01552122|Drug|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
122714|NCT01552122|Drug|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
122715|NCT01552122|Other|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
122716|NCT01552122|Dietary Supplement|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
122717|NCT01552122|Dietary Supplement|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
122718|NCT01552122|Other|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
122719|NCT00078182|Drug|Tenofovir DF|
122720|NCT01552148|Other|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
122721|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
122722|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
122723|NCT01552187|Drug|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (<70kg) 48 to 72 hours before surgery till 1 months after surgery
122724|NCT01552187|Drug|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
123185|NCT01545908|Other|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
123186|NCT01545921|Other|Quality Of Life questionnaires completion|Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.
MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.
123187|NCT01545934|Behavioral|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
123188|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
123189|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
123190|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms sc (starting dose) every 4 weeks
123191|NCT01548183|Behavioral|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
123192|NCT01548196|Procedure|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
123193|NCT01548209|Drug|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
123194|NCT01548209|Drug|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
123195|NCT01548235|Drug|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
123196|NCT01548248|Drug|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
123197|NCT01548248|Drug|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
123198|NCT01548261|Procedure|Donating oral mucosal cells|Donating oral mucosal cells
123199|NCT01548274|Drug|Sarpogrelate|Sarpogrelate 300mg/day
123200|NCT01548287|Drug|AZD5213|AZD5213 doseA daily
122484|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|We will include following general anesthesia techniques:
Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.
After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:
Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.
After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.
Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr.
122784|NCT01549899|Behavioral|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi will be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consists of 6-sessions and will include the same efficacious and commonly used modules of CBTi (i.e., sleep education & hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive re-structuring).
122785|NCT01549899|Behavioral|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology. The treatment consists of the same components as the in-person CBTi, but their mode of delivery is considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions is divided into lessons covering different aspects of each of the components. The lessons are presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components are included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits. Patients can print out reviews of each session, instructions for relaxation, and written handouts with accompanying graphics and diagrams for each treatment.
122786|NCT01549925|Other|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
122787|NCT01549925|Device|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
122788|NCT01549938|Dietary Supplement|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
122789|NCT01549938|Dietary Supplement|Placebo|Microcellulose capsule identical in appearance to treatment
122790|NCT01549951|Drug|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
122791|NCT01549964|Drug|TAK-875|TAK-875 tablets
122792|NCT01549964|Drug|Sitagliptin|Sitagliptin tablets
122793|NCT01549964|Drug|Placebo|Placebo-matching tablets
122794|NCT00077844|Drug|Enoxaparin sodium|
122795|NCT01549977|Drug|Febuxostat|Febuxostat tablets
122796|NCT01549977|Drug|Placebo|Febuxostat placebo-matching tablets
122797|NCT01549990|Drug|Sevoflurane|maintenance of general anesthesia with sevoflurane
122798|NCT01549990|Drug|desflurane|maintenance of general anesthesia with desflurane
123495|NCT01546441|Behavioral|usual care|usual care in primary care clinic
123496|NCT01546454|Drug|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
123497|NCT01546454|Drug|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
123498|NCT01546454|Drug|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
123499|NCT01546454|Drug|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
123500|NCT01546467|Behavioral|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
123501|NCT01546493|Procedure|MRI, qCT, motion analysis|MRI scan, quantitative computed tomography(QCT), 3D motion analysis after imaging
123502|NCT01546493|Procedure|MRI, qCT, motion analysis|MRI scan, quantitative computed tomography(QCT), 3D motion analysis after imaging
123503|NCT01546493|Procedure|MRI, qCT, motion analysis|MRI scan, quantitative computed tomography(QCT), 3D motion analysis after imaging
123504|NCT00077649|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
123505|NCT01548781|Behavioral|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
123506|NCT01548794|Procedure|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
123507|NCT01548794|Procedure|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
123508|NCT01548794|Procedure|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
123509|NCT01548807|Drug|Everolimus (RAD001)|
123510|NCT01548833|Device|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
123511|NCT01548833|Device|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
123512|NCT01548833|Device|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
122725|NCT01552200|Procedure|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
121817|NCT01511081|Radiation|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
121818|NCT01511081|Radiation|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
121819|NCT01511094|Procedure|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
121820|NCT01511107|Drug|Amoxicillin-Clavulanate (10 days)|Amoxicillin-clavulanate administered at a dosage of 90/6.4mg/kg/day in 2 divided doses for 10 days.
121821|NCT01511107|Drug|Amoxicillin-Clavulanate 5 days, placebo 5 days|Amoxicillin-clavulanate administered at a dosage of 90/6.4mg/kg/day in 2 divided doses for Days 1-5 followed by placebo in 2 divided doses for Days 6-10.
121822|NCT00074269|Drug|fludarabine phosphate|
121823|NCT01511120|Drug|Tetraspan|
121824|NCT01511120|Drug|acetated Ringer`s solution|
121825|NCT01511133|Procedure|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
121826|NCT01513317|Drug|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
121827|NCT01513317|Drug|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
121828|NCT01513330|Device|SenSura Mio|Ostomy product - 1 piece closed bag
121829|NCT01513330|Device|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
121830|NCT01513343|Behavioral|Parent and child groups focused on self-regulation of eating|
121831|NCT01513356|Drug|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
121832|NCT01513369|Drug|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
121833|NCT01513369|Drug|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
121834|NCT01513382|Procedure|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
123440|NCT01548768|Drug|TNF inhibitors|Patients will receive one of the FDA approved TNF inhibitors at the approved dosage regimen.
Patients will be evaluated during safety visits scheduled every 8 weeks between the 0 and 6 month study visits. At the time of the ﬁrst safety visit medication tolerability and safety will be evaluated. At the time of the second safety visit if joint disease activity is still moderate or high an increase in the dose or frequency of the TNF inhibitor or a switch to treatment to an alternative/equivalent TNF inhibitor will take place ( there are 5 TNF inhibitors approved at the moment).
123441|NCT01550913|Other|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
123442|NCT01550926|Drug|120 mg orlistat|2 X60 mg capsule
123443|NCT01550926|Drug|60 mg orlistat|60 mg orlistat
123444|NCT01550926|Drug|orlistat experimental dose|experimental
123445|NCT01550939|Device|Ophthalmic Biometer|One complete biometry examination
123446|NCT01550965|Biological|Adalimumab|160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg EOW starting at Week 4
123447|NCT01550978|Device|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
123448|NCT01551004|Other|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
123449|NCT00077974|Drug|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
123450|NCT01551004|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
123451|NCT01551030|Drug|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
123452|NCT01551043|Biological|CART-19|
123453|NCT01551056|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
123454|NCT01551056|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
123455|NCT01551069|Drug|hydroxychloroquine (Z0188)|Pharmaceutical form:tablet
Route of administration: oral
123456|NCT01551069|Drug|Placebo|Pharmaceutical form:tablet
Route of administration: oral
123457|NCT01551095|Device|PEGJ tube|The self-propelled PEGJ feeding tube
122799|NCT01552239|Radiation|IMRT/IGRT, Tumor resection, Brachytherapy|All:
Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)
Tumor resection after 4-6 weeks
Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection
122800|NCT01552252|Dietary Supplement|apple juice|unaltered(0% POs-Ca) commercially available apple juice
122801|NCT01552252|Dietary Supplement|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
121896|NCT01511133|Procedure|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
121897|NCT01511146|Drug|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
121898|NCT01511146|Drug|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
121899|NCT01511159|Drug|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
121900|NCT01511159|Drug|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
121901|NCT01511159|Drug|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
121902|NCT01511159|Drug|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
121903|NCT00074269|Drug|melphalan|
121904|NCT01511159|Drug|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
121905|NCT01511159|Drug|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
121906|NCT01511159|Drug|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
121907|NCT01511172|Drug|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
121908|NCT01511172|Drug|metformin|1000 mg daily, administered orally
121909|NCT01511172|Drug|placebo|Metformin placebo administered orally. 1000 mg daily
121910|NCT01511172|Drug|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
121911|NCT01511172|Drug|glimepiride|Individually adjusted dose, administered orally
121912|NCT01511185|Drug|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
123755|NCT01549223|Drug|Oxytocin|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
123756|NCT01549236|Drug|Benznidazole 12,5mg or 100mg|All 80 subjects recruited into the study will receive treatment with:
- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days.
123757|NCT01549249|Device|optical coherence tomography|spectral-domain optical coherence tomography
123758|NCT01549262|Device|Observe embryo development with "Unisense FertiliTech A/S" (EC Certificte DGM - 673)|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
123759|NCT01549262|Device|Observe embryo development|Observe embryo development in the traditional manner
123760|NCT01549288|Behavioral|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
123761|NCT01549288|Other|no dietetic input|continuation of anti-epileptic medication without any dietetic input
123762|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
123763|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
123764|NCT00077727|Drug|Extended-release galantamine hydrobromide|
123765|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
123766|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
123767|NCT01549327|Other|Oncology Interactive Navigator|
123768|NCT01549327|Other|Routine Care|
123769|NCT01549353|Behavioral|gum chewing|
123770|NCT01549366|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
123771|NCT01549366|Device|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
123772|NCT01549379|Radiation|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
123773|NCT01549392|Device|DECT|DECT at tumor progression and 3 months later
123774|NCT01549392|Device|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
122111|NCT01507103|Other|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
122112|NCT01507116|Other|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
122113|NCT01507155|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
122114|NCT01507168|Drug|RO5137382|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
122115|NCT01507168|Drug|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
122116|NCT01507181|Drug|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
122117|NCT01507181|Drug|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
122118|NCT01507194|Drug|Ondansetron|Single IV dose
122119|NCT01507194|Drug|Vestipitant|Single IV dose
122120|NCT01507207|Procedure|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
122121|NCT00073983|Biological|pegfilgrastim|pegfilgrastim
122122|NCT01507220|Drug|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
122123|NCT01509300|Biological|anti-thymocyte globulin|On days -10 to -9
122124|NCT01509300|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
122125|NCT01509300|Radiation|Total body irradiation|2Gy D-6 to D-4
122126|NCT01509300|Drug|Fludarabine|30mg/M2 once daily IV on days -8 to -4
122127|NCT01509300|Drug|cyclophosphamide|60 mg/kg IV on day-3 and -2
122128|NCT01509300|Drug|Tacrolimus|begin on 0
122129|NCT01509300|Drug|Mycophenolate mofetil|begin on 0
123699|NCT01551485|Drug|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
123700|NCT01551485|Drug|Placebo|Pacebo tablet, blinded given on the first night after surgery
123701|NCT01551498|Dietary Supplement|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
123702|NCT01551498|Dietary Supplement|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
123703|NCT01551511|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
123704|NCT01551511|Drug|Placebo|Identical step-up approach to the Namisol arm.
123705|NCT01551524|Biological|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
123706|NCT01551537|Other|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
123707|NCT01551537|Other|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
123708|NCT00078065|Drug|Xcellerated T Cells|
123709|NCT01551550|Procedure|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
123710|NCT01551550|Procedure|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
123711|NCT01551550|Procedure|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
123712|NCT00077363|Drug|tipifarnib|Given PO
123713|NCT01544374|Other|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
123714|NCT01544387|Other|Bed Rest|Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position
Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed
Subjects may have limited bathroom privileges
123715|NCT01544387|Other|Activity|Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed
Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired.
121913|NCT01511185|Drug|placebo|A single dose administered subcutaneously in random order
121914|NCT00074269|Drug|methotrexate|
121915|NCT01511198|Drug|liraglutide|Injected subcutaneously once daily
121916|NCT01511198|Drug|metformin|1000 mg twice daily, administered orally
121917|NCT01511211|Drug|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
122193|NCT01507220|Drug|bupivacaine liposome extended-release injectable suspension|Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed.
122194|NCT01507233|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
122195|NCT01507233|Drug|EXPAREL (bupivacaine liposome injectable suspension)|Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed.
122196|NCT01507246|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
122197|NCT01507246|Drug|EXPAREL (bupivacaine liposome injectable suspension)|Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed.
122198|NCT01507259|Other|cocoa|70% versus 34%
122199|NCT01507272|Drug|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
122200|NCT01507272|Drug|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
122201|NCT01507272|Drug|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
122202|NCT00073983|Drug|docetaxel|docetaxel
123775|NCT00077753|Drug|enoxaparin sodium|
124087|NCT01540396|Behavioral|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
124088|NCT00077142|Drug|TAC-101|Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
124089|NCT01540409|Drug|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. Their are two treatment groups, 30 mg/kg and 50 mg/kg.
124090|NCT01542645|Drug|Fentanyl|Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
124091|NCT01542671|Behavioral|Intervention|Lifestyle Counselor meetings at baseline, 6 months, and 12 months
Structured eating plan
Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.
Monthly Motivational phone calls with Lifestyle Counselor for the first year
4 informational DVDs over the two year period
Feedback on submitted food and exercise journals
124092|NCT01542671|Behavioral|Control|Lifestyle Counselor meetings at baseline, 6 months, and 12 months
Structured eating plan
5 informational NIDDK mailings over the two year period
124093|NCT01542684|Drug|Azacytidine|Starting dose: 40 mg/m^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
124094|NCT01542684|Drug|GM-CSF|250 mcg/m^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
124095|NCT01542697|Drug|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
124096|NCT01542710|Drug|Ganfort|Bimatoprost/Timolol fixed combination
124097|NCT00077285|Drug|ifosfamide|
124098|NCT01542710|Drug|Duotrav|Fixed combination of Travoprost and Timolol
124099|NCT01542723|Drug|LMWH|Each hospital will use a LMWH according to their own preferences.
Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
124100|NCT01542736|Drug|Carboplatin|Administered concurrently with craniospinal radiation.
124101|NCT01542736|Drug|Vincristine|Administered concurrently with craniospinal radiation.
124102|NCT01542736|Radiation|24 Gy|Craniospinal radiation.
124103|NCT01542762|Drug|LMWH|Each hospital will use a LMWH according to their own preferences.
Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
122130|NCT01509300|Drug|Rituximab|375mg/m2 on day +21
122131|NCT01509313|Device|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
122414|NCT01512069|Behavioral|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
122415|NCT01512082|Device|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
122416|NCT01512082|Device|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
122417|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
122418|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
122419|NCT00001317|Drug|interferon-gamma|
122420|NCT00074308|Other|laboratory biomarker analysis|Correlative studies
122421|NCT01512108|Drug|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
122422|NCT01512108|Drug|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
122423|NCT01514409|Dietary Supplement|5-Hydroxytryptophan|Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.
5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia.
122424|NCT01514409|Dietary Supplement|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
122425|NCT01514422|Drug|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
122426|NCT01514435|Device|Electroconvulsive therapy|treatment for major depression
122427|NCT01514435|Device|18-Fluoro-desoxy-glucose positron emission tomography|intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.
It´s a neuroimaging technique.
122428|NCT00074490|Procedure|Allogeneic HSCT|Allogeneic Hematopoietic Stem Cell Transplant
122429|NCT01514448|Drug|Everolimus|Everolimus will be prescribed by the investigator. Everolimus will be used as commercially available tablets of 10 mg strength and 5 mg strength for dose modifications. On the first day of each cycle, patients will receive a prescription of an adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take everolimus exactly as prescribed.
123716|NCT01544413|Procedure|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
124035|NCT01535313|Device|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
124036|NCT01535326|Procedure|air insufflation|insufflate air during the insertion of colonoscopy
124037|NCT01535326|Procedure|water immersion|infuse water during insertion, aspirate water during withdrawal
124038|NCT01535326|Procedure|water exchange|infuse and remove water during insertion phase of colonoscopy
124039|NCT01535352|Behavioral|Mom-Net|The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes" administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration.
124040|NCT01535352|Behavioral|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
124041|NCT01535365|Other|Heat|Application of heat pack to the back or neck sprain.
124042|NCT00076687|Drug|saline|Saline injection at Day 1, Week 12, Week 18
124043|NCT01535365|Other|Cold|Application of ice pack to the back or neck sprain.
124044|NCT01535391|Drug|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
124045|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
124046|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
124047|NCT01535417|Drug|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
122203|NCT01507272|Drug|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
122204|NCT01507285|Drug|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
122205|NCT01507285|Drug|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
122206|NCT01507311|Drug|liraglutide|A single dose injected subcutaneously (under the skin)
122207|NCT01507311|Drug|placebo|A single dose injected subcutaneously (under the skin)
122208|NCT01507337|Drug|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
122209|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
122485|NCT01512160|Drug|PF-04531083|2000 mg oral solution
122486|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
122487|NCT01512160|Drug|PF-04531083|1000 mg oral solution
122488|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
122489|NCT01512160|Drug|Ibuprofen|2 x 200 mg tablets
122490|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
122491|NCT00074321|Drug|irinotecan hydrochloride|Given IV
122492|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
122493|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
122494|NCT01512173|Drug|propranolol gel|Topical administration twice daily
122495|NCT01512173|Drug|Placebo|Topical administration twice daily
122496|NCT01512199|Drug|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
122497|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
122498|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
122499|NCT01512199|Drug|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
124104|NCT01542775|Behavioral|Aerobic Exercise Group|12 weeks Aerobic exercise
124105|NCT01542775|Behavioral|Control Group|maintaining usual activities
124106|NCT01542788|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
123253|NCT00077454|Drug|temozolomide|Given PO
123254|NCT01545973|Other|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
123255|NCT01545986|Behavioral|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
123256|NCT01545999|Other|Brain Stimulation via Transcranial Magnetic Stimulation|PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.
Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task.
123257|NCT01546012|Device|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
123258|NCT01546012|Device|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
123259|NCT01546025|Behavioral|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
123260|NCT01546025|Behavioral|Relaxation training|One hour training in relaxation techniques
123261|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
123262|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
123263|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
123264|NCT00077454|Other|pharmacological study|Correlative studies
123265|NCT01546038|Drug|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
123266|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
122430|NCT01514461|Drug|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
122431|NCT01514461|Drug|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
122432|NCT01514487|Drug|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subcutaneously
122726|NCT01552200|Procedure|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
122727|NCT01552213|Other|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
122728|NCT01552213|Other|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
122729|NCT01552226|Device|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
122730|NCT00001427|Drug|9-aminocamptothecin|
122731|NCT00078195|Biological|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
122732|NCT01552226|Device|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
122733|NCT01544920|Drug|boceprevir|Four 200 mg capsules three times a day orally for a total daily dose of 2400 mg.
122734|NCT01544946|Drug|88% sucrose po|88% sucrose solution (Syrup B.P.)
122735|NCT01544946|Drug|placebo po|sterile water
122736|NCT01544959|Drug|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
122737|NCT01544959|Drug|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
122738|NCT00077389|Drug|doxorubicin hydrochloride|
122739|NCT01544972|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
122740|NCT01544972|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
122741|NCT01544985|Drug|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
124048|NCT01537640|Biological|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
124049|NCT01537640|Biological|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
124050|NCT00076986|Procedure|surgery and wafer placement (1 procedure)|
123201|NCT00077636|Drug|Copegus|400mg po bid for 16 weeks
123202|NCT01548287|Drug|AZD5213|AZD5213 doseB daily
123203|NCT01548287|Drug|AZD5213|AZD5213 doseC daily
123204|NCT01548287|Other|Placebo|Placebo tablet daily
123205|NCT01548326|Drug|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
123206|NCT01548326|Drug|placebo|one Placebo tablet orally per day for 10 days
123207|NCT01548339|Procedure|Laparoscopic cholecystectomy|3 trocars laparoscopic cholecystectomy
123208|NCT01548365|Other|Infusion therapy nursing expert service|The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.
If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.
If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device.
123209|NCT01548378|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
123210|NCT01550471|Drug|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
123211|NCT01550471|Drug|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
123212|NCT00001426|Drug|Cisplatin|
123213|NCT00077935|Drug|Civamide|Cream 0.075%, TID for 52 weeks
123214|NCT01550471|Drug|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
123215|NCT01550471|Drug|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
122500|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
122501|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
122502|NCT00074321|Drug|oxaliplatin|Given IV
122503|NCT01512199|Drug|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
122504|NCT01512212|Procedure|biopsy|fnab
122505|NCT01512225|Drug|Domperidone maleate|domperidone 10 mg orally three times daily for 28 days
122506|NCT01512225|Drug|Domperidone maleate plus placebo|identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
122507|NCT01512238|Other|Pharmaceutical care|Information about medicine, sideeffect, adherence
122508|NCT01514552|Other|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
122802|NCT01552252|Dietary Supplement|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
122803|NCT01552252|Dietary Supplement|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
122804|NCT01552252|Dietary Supplement|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
122805|NCT01552291|Dietary Supplement|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
122806|NCT01552291|Drug|Placebo|30g oral maltodextrin / day for 5 days before surgery
122807|NCT01552304|Other|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
122808|NCT00078195|Biological|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
122809|NCT01552304|Other|Control group|
122810|NCT01552317|Other|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
123267|NCT01548378|Genetic|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
123268|NCT01548378|Genetic|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
123269|NCT00077636|Drug|Copegus|400mg po bid for 24 weeks
123513|NCT01548846|Radiation|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
123514|NCT01548859|Drug|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
123515|NCT00077649|Drug|peginterferon alfa-2a [Pegasys]|270 micrograms sc weekly for 48 weeks
123516|NCT01548859|Drug|Sevoflurane|end tidal concentration of % 0,5-8
123517|NCT01548872|Drug|HTK solution|50 ml/kg bolus in 2 minutes
123518|NCT01548872|Drug|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
123519|NCT01548885|Device|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
123520|NCT01548885|Device|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
123521|NCT01548885|Device|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
123522|NCT01548885|Device|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
123523|NCT01551121|Other|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
123524|NCT01551134|Procedure|Fundoplication|Primary fundoplication
122742|NCT01544985|Drug|placebo po|sterile water
122743|NCT01544998|Drug|Nesiritide|10 ug/kg
122744|NCT01544998|Drug|Tadalafil|5 mg
122745|NCT01544998|Drug|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
122746|NCT01544998|Drug|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
121835|NCT01513395|Behavioral|Interval bladder emptying|Participants randomized to the "Interval" arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time.
121836|NCT00074438|Drug|corticosteroids|Intravenous repeating dose
121837|NCT01513408|Other|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
121838|NCT01513421|Procedure|Percutaneous drainage of intra-abdominal collection|Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.
Procedures perform by a board certified interventional radiologist
121839|NCT01513434|Procedure|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
121840|NCT01513434|Procedure|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
121841|NCT01513434|Procedure|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
121842|NCT01513447|Drug|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
121843|NCT01513460|Drug|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
121844|NCT01516034|Device|Cupola Tattoo Removal device|Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
121845|NCT01516047|Drug|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
123216|NCT01550471|Drug|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
123217|NCT01550484|Drug|18F-AV-133|222 MBq (6 mCi)
123218|NCT01550497|Other|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
123219|NCT01550510|Drug|Vitamin C|3x a week for 9 weeks
123458|NCT01551108|Behavioral|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
123459|NCT01551108|Behavioral|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
123460|NCT00077987|Drug|SU011248|
123461|NCT01544010|Behavioral|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
123462|NCT01544010|Behavioral|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
123463|NCT01544010|Behavioral|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
123464|NCT01544010|Behavioral|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
123465|NCT01544010|Behavioral|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
123466|NCT01544036|Drug|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
123467|NCT01544062|Drug|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
122811|NCT01552330|Drug|Primaquine and Pyronaridine-artesunate|Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period
Primaquine:
- Dosage: 2 tablets
and
Pyronaridine-Artesunate:
- Dosage: 3 tablets
122812|NCT01552330|Drug|Primaquine and Pyronaridine-Artesunate|Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.
Primaquine:
- Dosage: 2 tablets
and
Pyronaridine-Artesunate:
- Dosage: 3 tablets
122813|NCT01552343|Drug|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
122814|NCT01552343|Drug|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
122815|NCT01552356|Other|Laboratory Biomarker Analysis|Correlative studies
122816|NCT01552356|Drug|Pazopanib Hydrochloride|Given PO
122817|NCT01552356|Other|Pharmacological Study|Correlative studies
122818|NCT01552369|Other|Preemptive Therapy|Subjects monitored for CMV viremia with weekly CMV PCR testing. 900 mg of Valganciclovir given twice daily only after a positive CMV PCR test and stopped after PCR is negative for 2 weeks. Dosages may be adjusted for renal dysfunction
122819|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
122820|NCT00077389|Procedure|conventional surgery|
121918|NCT01511211|Drug|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
121919|NCT01511237|Drug|Nevirapine, zidovudine, lamivudine|Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum
Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:
NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake
AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).
3TC syrup 2 mg/kg every 12 hours for four weeks.
121920|NCT01513460|Drug|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
121921|NCT01513460|Drug|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
121922|NCT01513460|Drug|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
121923|NCT00074438|Drug|placebo|Intravenous repeating dose
121924|NCT01513473|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
123525|NCT01551134|Procedure|Fundoplication|Primary fundoplication
123526|NCT01551147|Drug|ONO-6950|200 mg QD for 8 days
123527|NCT01551147|Drug|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
123528|NCT01551147|Drug|Montelukast|10 mg Montelukast QD for 8 days
123529|NCT01551160|Other|Non-technical skills training|This will be delivered as a half-day session by experienced trainers
123530|NCT01551173|Drug|Fluvastatin sodium|Fluvastatin sodium Extended Release Tablets 80mg
123776|NCT01549405|Other|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
123777|NCT01549418|Drug|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
123778|NCT01549418|Drug|Placebo|
123779|NCT01549431|Drug|Panobinostat|Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.
Standard 3+3 design
3 out of 4 weeks
123780|NCT01551589|Radiation|docetaxel and cisplatin concurrent chemoradiotherapy|Drug: Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8
PTV-GTV（primary tumor）：66-70Gy/33~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33~35F，once a day, 5 times per week
123781|NCT01551589|Radiation|docetaxel and cisplatin|Prophylactic Irradiation easier involved lymph node region according to different primary tumor sites For upper site： CTV include Bilateral supraclavicular/1/2/4/7 region node，middle site：CTV include 2/4/7/8 region node；lower site：CTV include 4/5/7/8/16/17/18 node. CTV need include the region where the positive node is in the same time.
Drug: docetaxel and cisplatin The concurrent consists of docetaxel 60-80mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3,repeat every 3 weeks, for 2 cycles.
IMRT IMRT is administered with chemotherapy from week 1 to week 8 PTV-GTV（primary tumor）：66-70Gy/33~35F，once a day, 5 times per week PTV-CTV（Clinical target）：50-56Gy/33~35F，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33~35F，once a day, 5 times per week
123782|NCT01551602|Drug|AK159|transdermal administration of teriparatide acetate
123783|NCT01551602|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
123784|NCT01551602|Drug|Placebo|Multiple administration of placebo AK159
123785|NCT01551615|Drug|Metformin 1000 mg|2 x 500 mg oral tablets
123786|NCT01551615|Drug|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
123787|NCT00078104|Procedure|Extraction of wisdom teeth|
123078|NCT00001410|Drug|Lysodase|
123079|NCT00077428|Other|laboratory biomarker analysis|Correlative studies
123080|NCT01545609|Other|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
123349|NCT01546103|Dietary Supplement|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
123350|NCT01546103|Dietary Supplement|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
123351|NCT00077467|Drug|bortezomib|Given IV
123352|NCT01546116|Drug|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
123353|NCT01546129|Device|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
123354|NCT01546142|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
123355|NCT01546142|Drug|Placebo|Phosphate buffered saline placebo for injection
123356|NCT01548534|Dietary Supplement|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
123357|NCT01548547|Other|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
123358|NCT01548560|Drug|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
123359|NCT01548560|Drug|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
123360|NCT01548573|Drug|DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide)|Dexamethasone 20 mg oral on days 1-4 and 8-11; Cisplatin 10 mg/m2/day on days 1-4 Continuous Infusion (CI); Adriamycin 10 mg/m2/day on days 1-4 CI; Cyclophosphamide 400 mg/m2/day or 600 mg/m2 (if high-risk MM) on days 1-4 CI; Etoposide 40 mg/m2/day on days 1-4 CI.
123361|NCT01548573|Procedure|Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan)|Dexamethasone 20 mg oral on days -4 to -1 and +2 to +5;Velcade 1mg/m2 IV Bolus on days -4, -1, +2, and +5; Thalidomide 100mg/day oral on days -4 to +5; Melphalan 100 mg/m2 on days -4 and -1 (Patients > 70 years of age or with a creatinine > 2.0 mg/dl will receive a reduced dose of Melphalan of 70 mg/m2 on days -4 and -1); Peripheral blood stem cell infusion will be given intravenously on day 0, at least 18 hours after the second dose of melphalan.
123362|NCT01548573|Procedure|Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan)|Dexamethasone 20 mg oral on days -4 to -1, and on day +2 to day +5; Carmustine 300mg/m2 on day -4; Melphalan 140 mg/m2 on day -1 (Patients > 70 years of age or with a creatinine > 2.0 mg/dl may receive Melphalan 100 mg/m2 at the discretion of the treating physician);Velcade 1mg/m2 will be given on days -4, -1, +2, +5; Gemcitabine 1000 mg/m2 on days -4 and -1;Peripheral blood stem cell infusion will be given intravenously on day 0, at least 18 hours after melphalan.
123994|NCT01540123|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
123995|NCT01540123|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
123996|NCT00077116|Radiation|radiation therapy|
123997|NCT01540136|Drug|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
123998|NCT01540136|Drug|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
123140|NCT01550458|Drug|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
123141|NCT01550458|Other|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
123142|NCT01550471|Drug|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
123143|NCT01553084|Drug|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
123144|NCT01553097|Other|Neurocognitive impairment observation|None - observational
123145|NCT01553123|Drug|Ulipristal Acetate|once daily, oral
123146|NCT00078260|Drug|pemetrexed|A: 500 mg/m2, IV, q 21 days until disease progression
B: 900 mg/m2, IV, q 21 days until disease progression
123147|NCT01553123|Drug|Iron|once daily, dried ferrous sulfate
123148|NCT01553136|Drug|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
123149|NCT01553149|Drug|Lenalidomide|Given PO
123150|NCT01553149|Other|Pharmacological Study|Correlative studies
123151|NCT01553162|Genetic|DNA analysis|
123152|NCT01553162|Genetic|RNA analysis|
123153|NCT01553162|Genetic|gene expression analysis|
123154|NCT01553162|Other|laboratory biomarker analysis|
123155|NCT01553175|Genetic|DNA analysis|
119979|NCT01519570|Other|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
119980|NCT01519583|Behavioral|Basic Intervention|Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
119981|NCT00075101|Drug|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
119982|NCT01519583|Behavioral|Enhanced Pedometry|Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
119983|NCT01519583|Behavioral|Control Group|Maintain usual physical activity, and return for follow-up measures.
119984|NCT01519596|Procedure|quality-of-life assessment|Ancillary studies
119985|NCT01519596|Other|counseling intervention|Receive lifestyle-related counseling
119986|NCT01519596|Behavioral|exercise intervention|Undergo physical activity intervention
119987|NCT01519596|Other|educational intervention|Receive educational materials
119988|NCT01519596|Procedure|standard follow-up care|Undergo usual care
119989|NCT01519609|Drug|bowel prep before endoscopy|bowel prep before colonoscopy
119990|NCT01522014|Device|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
120279|NCT01522651|Drug|Dronedarone low dose 2|Dronedarone 150 mg capsule administered orally twice daily
120280|NCT01525056|Radiation|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
120281|NCT01525056|Radiation|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
120282|NCT01525069|Drug|Floxuridine|
120283|NCT01525069|Drug|Dexamethasone|
120284|NCT00075608|Drug|melphalan|140-200 mcg/kg IV over two days
120285|NCT01525069|Drug|Gemcitabine|
123817|NCT01544647|Other|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
123818|NCT01544647|Other|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
123819|NCT01544673|Drug|linezolid|600 mg oral tablet twice daily for 4.5 days
123820|NCT01544673|Drug|Placebo|500 mg oral placebo twice daily for 4.5 days
123821|NCT01544686|Device|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
123822|NCT01544699|Device|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
123823|NCT01547091|Biological|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
123824|NCT01547104|Drug|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
123825|NCT01547104|Drug|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
123826|NCT01547117|Radiation|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called carbon monoxide (CO) rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
123827|NCT01547117|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
123828|NCT00077532|Biological|ipilimumab|
123829|NCT01547117|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
123830|NCT01547117|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
123831|NCT01547130|Drug|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
123832|NCT01547130|Drug|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
123852|NCT01549509|Biological|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
123363|NCT01548573|Drug|Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide)|Dexamethasone 20 mg oral on days 1-4 and days 8-11; Thalidomide 100mg oral on days 1-11; Velcade 1mg/m2 IV Bolus on days 1, 4, 8, 11; Cisplatin 10 mg/m2 on days 1-4 continuous infusion (CI); Adriamycin® 10mg/m2 on days 1-4 CI; Cyclophosphamide 400 mg/m2 on days 1-4 CI; Etoposide 40 mg/m2 on days 1-4 CI.
123364|NCT00077649|Drug|Copegus|600mg po bid for 48 weeks
123594|NCT01548885|Device|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
123595|NCT01548898|Device|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
123596|NCT01548911|Drug|gemtuzumab ozogamicin|Given IV
123597|NCT00001426|Drug|Cyclophosphamide|
123598|NCT00077675|Drug|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
123599|NCT01548911|Other|laboratory biomarker analysis|Correlative studies
123600|NCT01548924|Drug|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
123601|NCT01548924|Drug|Dovitinib + Paclitaxel|Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.
Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.
Each cycle will last for 28 days.
123602|NCT01548937|Drug|I-123 ADAM|This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
123603|NCT01548950|Drug|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
123604|NCT01548963|Procedure|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
123605|NCT01549002|Drug|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
123606|NCT01549002|Drug|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
123156|NCT01553175|Genetic|gene expression analysis|
123157|NCT00078273|Behavioral|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
123158|NCT01553175|Genetic|mutation analysis|
123159|NCT01553175|Genetic|protein expression analysis|
123160|NCT01553175|Other|immunohistochemistry staining method|
123412|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
123413|NCT01546233|Behavioral|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
123414|NCT00077467|Other|pharmacological study|Correlative studies
123415|NCT01546233|Behavioral|standard education|standard education before and after chemotherapy
123416|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
123417|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
123418|NCT01546272|Device|Insorb resorbable staples|Subcutanous suture using resorbable staples
123419|NCT01546272|Device|Monocryl resorbable wire|Subcutanous suture using resorbable wire
123420|NCT01546285|Device|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
120286|NCT01525069|Drug|Oxaliplatin|
120287|NCT01525082|Drug|capecitabine|Given PO
120288|NCT01525082|Drug|temozolomide|Given PO
120289|NCT01525082|Biological|bevacizumab|Given IV
120290|NCT01525108|Behavioral|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
120291|NCT01525108|Other|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
120292|NCT01525121|Other|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
120293|NCT01525134|Device|Alere "Determine" lateral-flow urine lipoarabinomannan assay|lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere
120294|NCT01525134|Device|Alere "Clearview" ELISA urine LAM assay|ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere.
120295|NCT00075608|Procedure|autologous bone marrow transplantation|infusion of previously collected stem cells on Day 0
120296|NCT01525147|Biological|YHB1411-2: Level 2|IV infusion
120297|NCT01525147|Biological|YHB1411-2: Level 3|IV infusion
120298|NCT01525147|Biological|YHB1411-2: Level 4|IV infusion
120299|NCT01525147|Biological|YHB1411-2: Level 5|IV infusion
120300|NCT01525147|Biological|Placebo|IV infusion
120581|NCT01520636|Procedure|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
120582|NCT01520649|Drug|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
120583|NCT01520649|Drug|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
123853|NCT01549522|Behavioral|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
123854|NCT01549522|Behavioral|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
123855|NCT01549535|Device|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
123856|NCT01549548|Drug|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
123857|NCT01549561|Behavioral|Parent Training|16 weeks of parent training led by a trained group facilitator
123858|NCT01549561|Behavioral|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
123859|NCT01549574|Drug|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
123860|NCT00077766|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv (starting dose) every 2 weeks
123861|NCT01549574|Drug|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
123862|NCT01549587|Drug|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
123863|NCT01549587|Device|toothbrush|brush thoroughly twice daily
123864|NCT01549587|Device|dental floss|floss the whole mouth once daily
123865|NCT01549587|Drug|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
123866|NCT01551706|Dietary Supplement|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
123867|NCT00078117|Drug|Buprenorphine|
123868|NCT01551706|Other|Placebo|Placebo
123869|NCT01551719|Behavioral|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
123870|NCT01551732|Behavioral|ACT|10 session manualized cognitive behavioral anger control therapy
123871|NCT01551732|Behavioral|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
123607|NCT01549015|Other|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
123608|NCT01549028|Behavioral|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
123922|NCT01540058|Other|No test Empiric strategy|Empiric strategy
123923|NCT01540071|Drug|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
123924|NCT01542333|Other|immunohistochemistry staining method|
123925|NCT01542333|Other|laboratory biomarker analysis|
123926|NCT01542333|Procedure|spectroscopy|
123927|NCT01542346|Procedure|subcutaneous adaption|
123928|NCT01542359|Other|Yogic practice|breathing, meditation, physical postures
123929|NCT01542359|Other|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
123930|NCT01542372|Biological|Prazosin as first-line agent|Prazosin .5 to 2 mg
123931|NCT01542372|Behavioral|Cognitive Behavioral Therapy for PTSD|This is a culturally sensitive CBT for the treatment of PTSD
123932|NCT00077285|Drug|cyclophosphamide|
123933|NCT01542385|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
123934|NCT01542398|Behavioral|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
123935|NCT01542424|Drug|biphasic insulin aspart 30|Prescribed at the discretion of the physician
123936|NCT01542424|Drug|insulin detemir|Prescribed at the discretion of the physician
123937|NCT01542437|Drug|BIBW 2992|All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.
Not to be compared with any other drug.
123938|NCT01542450|Drug|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
119630|NCT01494012|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
119631|NCT01494025|Behavioral|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
119632|NCT01494038|Drug|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
119633|NCT01494038|Drug|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
119634|NCT01494051|Behavioral|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
119635|NCT01494077|Other|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
119636|NCT01494090|Drug|Rosuvastatin|5 or 20 mg per day during 6 months
119637|NCT01494090|Drug|Placebo|5 or 20 mg per day during 6 months
119638|NCT01494103|Biological|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
119639|NCT01494103|Drug|AP1903|AP1903 will be administered if there is development of Grade 1 or greater GvHD.
Dose: 0.4 mg/kg by IV over 2 hours.
Up to 3 additional doses may be administered if the GvHD does not respond or gets worse.
119910|NCT01521936|Other|laboratory biomarker analysis|Correlative studies
119911|NCT00075413|Drug|arsenic trioxide|
119912|NCT01521949|Drug|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
119913|NCT01521962|Drug|Alogliptin|Alogliptin tablets
119914|NCT01521962|Drug|Insulin|Insulin injection
119915|NCT01521975|Drug|Telbivudine, Adefovir dipivoxil|All patients will take Sebivo 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding ADV.
119916|NCT01521988|Procedure|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
119917|NCT01521988|Procedure|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
120584|NCT01520662|Other|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
120585|NCT01520675|Procedure|surgery|Drainage procedure
120586|NCT00075231|Drug|Combivir® (lamivudine, zidovudine)|
120587|NCT01520675|Procedure|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
120588|NCT01520688|Drug|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
120589|NCT01520688|Drug|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
120590|NCT01520688|Drug|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
120591|NCT01520688|Drug|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
120592|NCT01520688|Drug|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
120593|NCT01520688|Drug|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
120594|NCT01520701|Device|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
120595|NCT01520701|Drug|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
120596|NCT01520714|Device|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
120597|NCT00075231|Drug|Sustiva® (efavirenz)|
120598|NCT01520727|Drug|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
120599|NCT01520727|Drug|Placebo|single-dose
119694|NCT01491880|Behavioral|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
119695|NCT01491880|Behavioral|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
124148|NCT01537796|Behavioral|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
124149|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
124150|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
124151|NCT01537822|Procedure|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
124152|NCT01537822|Procedure|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
124153|NCT01537835|Other|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
124154|NCT01537848|Procedure|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
124155|NCT01537861|Drug|Filgrastim|
124156|NCT01540435|Drug|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
124157|NCT01540448|Procedure|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
123294|NCT01550575|Other|Non-spinal cord stimulation conventional medical management for chronic pain|May include chronic pain medication, interventional pain procedures, spine surgery, etc.
123939|NCT01542450|Drug|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
123940|NCT01542463|Drug|insulin detemir|Prescribed at the discretion of the physician
123941|NCT01542476|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
123942|NCT01542489|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
123943|NCT00077285|Drug|dexrazoxane hydrochloride|
123081|NCT01545635|Drug|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min
Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min
FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.
Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min
123082|NCT01545635|Drug|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 <7mm and/or ExTEM CT>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
123083|NCT01545648|Drug|Denosumab|Formulation of Dosage forms
The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.
Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year
Route of administration: subcutaneous injection
123084|NCT01545661|Procedure|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
123085|NCT01545661|Procedure|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
123086|NCT01545674|Procedure|Blood Draw|Blood will be drawn from the mother and father
123087|NCT01545687|Dietary Supplement|Lactobacillus brevis CD2 lozenge|Dissolved orally
123088|NCT01545687|Other|placebo|Dissolved orally
123089|NCT01545700|Drug|Control-saline|Patients are randomized to receive saline 2 cc
123090|NCT00077441|Drug|bortezomib|Given IV
123091|NCT01545700|Drug|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
119918|NCT01522001|Behavioral|Shared Care model|First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.
Dietary counseling with dietician
Exercise (1 hour, 2 timer pr week for 12 weeks)
Smoking cessation if smoker with educated smoking cessation instructor
Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse
Examination by the patient´s general practitioner 8-12 weeks after discharge.
119919|NCT01522014|Device|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
119920|NCT01524211|Device|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
119921|NCT01524224|Drug|LY2495655|administered intravenously
119922|NCT01524237|Drug|LY2979165|Capsules administered orally
119923|NCT01524237|Drug|LY2140023|Tablets administered orally
119924|NCT01524237|Other|Placebo|Administered orally
119925|NCT01524237|Other|Ketamine|Administered intravenously (IV)
119926|NCT00075582|Drug|dactinomycin|Given IV
119927|NCT01524250|Drug|corticosteroids|1250mg of oral prednisone daily for 3 days
119928|NCT01524250|Drug|corticosteroids|1000mg IV methylprednisolone daily for 3 days
119929|NCT01524289|Drug|Anacetrapib|one 100 mg tablet, orally once daily for 52 weeks
119930|NCT01524289|Drug|Placebo for Anacetrapib|one tablet, orally, once daily for 52 weeks
120225|NCT01517828|Drug|Sedation with Midazolam|Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.
One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.
120226|NCT01517854|Drug|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
120227|NCT01517854|Drug|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
120228|NCT01517867|Behavioral|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
120229|NCT00074841|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
119696|NCT01491893|Biological|PVSRIPO|PVSRIPO will be delivered in a single infusion directly into the tumor via catheter placed at the time of biopsy. The current dose level is dose level minus one (5 x 10^7 TCID50 (tissue culture infectious dose)).
119697|NCT01491906|Behavioral|Text Messaging and Behavior Counseling|Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group "starter" counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring.
119698|NCT01491919|Drug|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
119699|NCT01491932|Drug|AFQ056|AFQ056 will be supplied as oral capsules.
119700|NCT01491945|Device|Ventana Fenestrated Stent Graft System|The Ventana Fenestrated Stent Graft System consists of the following:
bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts
119701|NCT01491958|Drug|atorvastatin|donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.
Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first.
119702|NCT00072410|Radiation|yttrium Y 90 monoclonal antibody Hu3S193|
119703|NCT01491958|Drug|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
119704|NCT01491958|Drug|methotrexate|Day +1, +3, and +6 and +11
119705|NCT01491971|Drug|Degarelix|
119706|NCT01491984|Device|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
119707|NCT01491984|Device|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
119708|NCT01491997|Behavioral|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
119991|NCT01522027|Procedure|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
119992|NCT00001339|Drug|doxorubicin, vincristine, and etoposide with mitotane|
119993|NCT00075426|Drug|arsenic trioxide|
123295|NCT01550588|Device|Device closure|PFO Amplatzer device closure
123296|NCT01550601|Device|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
123297|NCT01550614|Genetic|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
123298|NCT01550627|Other|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
123299|NCT01550627|Other|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
123300|NCT01550640|Drug|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
123301|NCT00077948|Drug|Metoprolol succinate|Metoprolol succinate administered orally
123302|NCT01550653|Drug|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
123303|NCT01550653|Drug|Placebo|
123304|NCT01550666|Behavioral|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
123305|NCT01550705|Drug|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
123306|NCT01550718|Behavioral|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
123307|NCT01550718|Behavioral|ESML-Social (Social Activity Program)|ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a "homework" assignment to be completed prior to the next session.
123308|NCT01550731|Behavioral|PREPARE website|Advance care planning website and materials plus an advance directive.
123309|NCT01550731|Behavioral|Advance directive|The control group will only receive an advance directive.
123310|NCT01550744|Drug|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
123092|NCT01545700|Drug|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
123093|NCT01545700|Drug|Control saline|Patients are randomized to receive saline 2 cc
123094|NCT01545700|Drug|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
123095|NCT01545700|Drug|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
123096|NCT01545726|Drug|QAW039|QAW039 was supplied as capsules for oral administration.
123097|NCT01548040|Device|quadriceps TENS (at a minimal sensory input) using Kneehab XP|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
123098|NCT00077623|Drug|epoetin alfa or beta|iv 3 times weekly, as prescribed
123365|NCT01548573|Drug|Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12)|Velcade 1.0mg/m2 IV Bolus on days 1, 4, 15, 18; Thalidomide 100mg oral daily (Thalidomide may be replaced by Revlimid 10-25mg x21 days or Cytoxan 500mg on days 1 and 15); Dexamethasone 20mg oral on days 1-4 and 15-18
123366|NCT01548573|Drug|Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)|Revlimid 10-15mg x 21 days; Dexamethasone 20mg on days 1, 8, 15, 22
123367|NCT01548586|Device|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
123368|NCT01548599|Other|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
123369|NCT01548612|Drug|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
123370|NCT01548612|Drug|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
123371|NCT01548638|Drug|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.
Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER.
123372|NCT01550757|Behavioral|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
120230|NCT01517867|Behavioral|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
120231|NCT01517880|Drug|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
120232|NCT01517880|Drug|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
120233|NCT01517893|Drug|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
120234|NCT01517893|Drug|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
120235|NCT01517906|Behavioral|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
120236|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
120237|NCT00075179|Drug|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
120238|NCT01519973|Radiation|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
120239|NCT01519986|Dietary Supplement|Vitamin D3|Supplement of vitamin D3
120240|NCT01519986|Dietary Supplement|Placebo|Placebo
120530|NCT01522989|Drug|PD-0332991|Stage 1:
PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10
Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:
Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3
In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
120531|NCT01522989|Drug|5-FU|Stage 1:
PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10
Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:
Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3
In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
119994|NCT01522040|Drug|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
119995|NCT01522040|Drug|Placebo|Simple saline drip, without active drug
119996|NCT01522053|Procedure|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
119997|NCT01522053|Procedure|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
119998|NCT01522066|Procedure|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
119999|NCT01522066|Procedure|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
120000|NCT01522079|Procedure|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
120001|NCT01522092|Drug|escitalopram|5mg-20mg, tablet, od, 12 months
120002|NCT01522105|Drug|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
120003|NCT01522118|Device|ExAblate 2100; InSightec|Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.
MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens
120004|NCT00075439|Drug|gefitinib|Given orally
120005|NCT01522131|Procedure|bioresorbable membrane alonewill be used for regeneration of the periodontium(control)|bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
120006|NCT01522144|Behavioral|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
120007|NCT01522157|Dietary Supplement|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
120008|NCT01522157|Dietary Supplement|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
120009|NCT01522157|Dietary Supplement|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
120301|NCT01525147|Biological|YHB1411-2: level 1|IV infusion
123311|NCT01550744|Drug|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
123833|NCT01547143|Drug|IST and/or alloHCT|1) Patients will be categorized by their initial serum ferritin level.
Mild ( ferritin<3,000 μg/L): close observation
Moderate (ferritin: 3,000-10,000 μg/L):
Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)
continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.
Severe (ferritin>10,000 μg/L):
initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)
continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.
2) AlloHCT for refractory or reactivated cases.
123834|NCT01547156|Device|Intervention group|
123835|NCT01547169|Drug|Placebo Comparator|saline, taken twice per day for a 3 week duration
123836|NCT01547169|Drug|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
123837|NCT01547169|Drug|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
123838|NCT01547182|Behavioral|Caloric restriction|Caloric restriction
123839|NCT00077545|Drug|triapine|Given IV
123840|NCT01547182|Behavioral|Aerobic Training|Walking
123841|NCT01547182|Behavioral|Resistance Training|Lifting weights
123842|NCT01547195|Procedure|swim training|Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.
Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training.
123843|NCT01549431|Drug|Carfilzomib|Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.
Standard 3+3 design
Days 1/2, 8/9 and 15/16 every 4 weeks
123844|NCT01549431|Drug|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
123845|NCT01549444|Other|presence of maternal risk factor for hypertension|
123846|NCT01549457|Other|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
123847|NCT01549470|Biological|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
123848|NCT01549470|Biological|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
123373|NCT01550770|Drug|propofol|peripheral IV of propofol at increasing dose levels
123374|NCT01550783|Other|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
123375|NCT01550783|Other|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
123376|NCT01550783|Other|Questionnaire Administration|Ancillary studies
123377|NCT01550783|Procedure|Screening Method|Undergo standard of care Pap test screening
123378|NCT01550783|Procedure|Screening Method|Undergo home-based HPV screening
123379|NCT01550796|Behavioral|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
123380|NCT01550809|Other|iBolus|Insulin bolus calculated from data obtained through CGM
123381|NCT00077948|Drug|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
123609|NCT00077675|Drug|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
123610|NCT01549041|Drug|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
123611|NCT01551290|Drug|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
123612|NCT00078013|Drug|MCC-135|
123613|NCT01551303|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
123614|NCT01551303|Drug|Placebo|Matched nasal spray placebo
123615|NCT01551316|Drug|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
123616|NCT01551316|Drug|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
123617|NCT01551329|Drug|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
123618|NCT01551355|Behavioral|children - sesame street story book|children - sesame street story book
123619|NCT01551355|Behavioral|children - education imparted by teachers|children - education imparted by teachers
120532|NCT01522989|Drug|Oxaliplatin|Stage 1:
PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10
Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:
Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3
In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
120533|NCT01523002|Drug|Metoprolol and Pyronaridine : artesunate|On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of Pyramax as follows:
55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)
≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)
On Day 10, a 100 mg dose of metoprolol will be coadministered with Pyramax at the above dose.
On Days 98 - 100, subjects will receive Pyramax once daily at the same dose described above.
120534|NCT01523002|Drug|pyronaridine:artesunate|In the first period, subjects will receive 3 days of Pyramax as follows:
55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)
≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate) followed by a 57 day follow-up period. In the second period, subjects will receive 3 days of Pyramax at the dose described above.
120535|NCT00075491|Procedure|therapeutic conventional surgery|Undergo surgery
120536|NCT01523015|Other|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
120537|NCT01523015|Procedure|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
120538|NCT00075608|Procedure|peripheral blood stem cell transplantation|infusion of previously collected stem cells on Day 0
120539|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
120540|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
120541|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
120542|NCT01525212|Drug|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
119640|NCT00072540|Procedure|biological therapy|
119641|NCT01494116|Other|900 mL of 0.9% Normal Saline|The intervention consists of the administration of 900 mL of Normal Saline to the model using the "Disconnection- Reconnection" method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered.
119642|NCT01494155|Drug|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
120302|NCT01525173|Drug|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
120303|NCT01525173|Drug|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
120304|NCT01525173|Drug|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
120305|NCT01525173|Drug|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
120306|NCT01517906|Behavioral|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
120307|NCT01517919|Behavioral|Peer-Led Self-Management|The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step "action-planning" process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.
PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants.
120308|NCT01517932|Drug|dexmedetomidine|In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.
Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.
Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery
120309|NCT01517932|Drug|saline placebo|In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.
Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.
Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery
120310|NCT00074854|Drug|CP-547,632|
120311|NCT01517945|Behavioral|AIM materials and assessments|Part 1 will be used to develop & refine the intervention & assessment materials with 10 participants. We will adapt two previously validated CBM tasks, attention modification & interpretation modification to create two novel AIM programs (designated AIM-Neutral & AIM-Meaning), each of which targets both attention & interpretation biases for fear of breast cancer recurrence. Participants will complete the assessment battery & 1 30-minute session of each version of the intervention (AIM-Neutral & AIM-Meaning) & will provide feedback about the recruitment procedures, stimuli, & assessments. Part 2 will be a proof-of-concept, small scale, single-blind, placebo-controlled RCT of AIM. One hundred eleven participants will be randomized to receive either AIM-Neutral (n=37), AIM-Meaning (n=37), or computer placebo (CP; n=37). The AIM & CP conditions will involve completion of 8 30-minute sessions Participants will be instructed to complete 2 sessions per week for a total of 4 weeks.
120312|NCT01517958|Other|Respiratory Distress Group|Diagnostic lung ultrasound.
120313|NCT01517958|Other|Control Group|Lung ultrasound
120314|NCT01517971|Other|laboratory biomarker analysis|Correlative studies
123849|NCT00077766|Drug|Darbepoetin alfa|iv weekly, every 2 weeks, as prescribed
123850|NCT01549496|Drug|Amlodipine|amlodipine 2.5 mg QD
123851|NCT01549496|Drug|Diltiazem|diltiazem 120 mg qd
123872|NCT01551745|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
123873|NCT01551745|Drug|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
123874|NCT01551758|Drug|FF/VI|FF/VI
123875|NCT01551758|Other|Existing Maintenance Therapy|Existing Maintenance Therapy:
Long acting bronchodilator therapy alone
ICS alone or in combination with a long acting bronchodilator
Triple maintenance therapy
123876|NCT01551771|Drug|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
123877|NCT01551771|Drug|GW824575 matched-placebo|Placebo
123878|NCT00078130|Drug|Buprenorphine/naloxone|
123879|NCT01551797|Drug|Paracetamol 500 mg|Standard Paracetamol formulation
123880|NCT01551797|Drug|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
123881|NCT01551797|Drug|Paracetamol 750 mg|Paracetamol Sustained Release formulation
123882|NCT01551810|Biological|Influenza Virus Vaccine (no Preservative )|Influenza Virus Vaccine(no Preservative) 0.5ml intramuscular injections
123883|NCT01551810|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
123884|NCT01551823|Biological|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
123885|NCT01551823|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
123886|NCT01551836|Drug|Paracetamol formulation 1|formulation 1
123887|NCT01551836|Drug|Paracetamol formulation 2|Formulation 2
123888|NCT01551862|Procedure|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
123620|NCT01551355|Behavioral|teachers - sesame street story books|teachers - sesame street books
123621|NCT01551368|Drug|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
123622|NCT01551368|Drug|Placebo|Identical inactive tablets.
123623|NCT00001426|Drug|G-CSF|
123624|NCT00078026|Drug|Apomine|
123625|NCT01551381|Drug|EV-077|twice daily oral administration
123626|NCT01551381|Drug|Placebo|twice daily oral administration
123627|NCT01551394|Drug|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
123944|NCT01542489|Drug|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
123945|NCT01542489|Drug|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
123946|NCT01542502|Drug|Anakinra|Anakinra 100 mg daily subcutaneous injection
123947|NCT01542502|Drug|Placebo|Placebo daily subcutaneous injection
123948|NCT01535079|Drug|Ibuprofen 25 mg|Single administration
123949|NCT01535079|Drug|Ibuprofen 15 mg|Single administration
123950|NCT01535079|Drug|Strefen|Single administration
123951|NCT01535092|Drug|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
123952|NCT01535092|Drug|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
123953|NCT01535131|Procedure|palatoplasty|procedure to close cleft palate
123954|NCT01535144|Device|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
123955|NCT01535144|Device|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
119643|NCT01494155|Drug|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
119644|NCT01494155|Radiation|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
119645|NCT01494168|Procedure|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
119646|NCT01494194|Other|Air Structuring Protein|A novel food protein preparation
119647|NCT01494194|Other|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
119648|NCT01494207|Behavioral|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
119649|NCT01496508|Device|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
119650|NCT01496521|Drug|Aspirin|100mg qd for 6 months.
119651|NCT00072826|Drug|Oxypurinol|
119652|NCT01496521|Dietary Supplement|Tea Polyphenols|300mg bid for 6 months.
119653|NCT01496534|Drug|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
119654|NCT01496534|Drug|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
119655|NCT01496547|Drug|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
119656|NCT01496573|Other|laboratory biomarker analysis|Correlative studies
119931|NCT01524302|Drug|Ceftaroline|600 mg Q12h
119932|NCT01524302|Drug|Levofloxacin|750 mg QD
119933|NCT01524315|Drug|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
119934|NCT01524315|Drug|Placebo|100 ml normal saline, intravenous, preoperative
120600|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
120601|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
120602|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
120603|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
120604|NCT01523028|Other|Soluble Coffee|Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:
200 mL coffee or
200 mL coffee + 2 bread rolls + honey
200 mL coffee + 1 bread roll + peanut butter
120605|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
120606|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
120607|NCT01523041|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
120608|NCT01523054|Drug|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
120609|NCT01523054|Drug|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
120610|NCT01523067|Drug|Vasomera (PB1046)|Single dose of Vasomera
120611|NCT01523067|Drug|0.9% Sodium Chloride|Placebo injection
120612|NCT00075491|Other|pharmacological study|Correlative studies
120613|NCT01523080|Drug|Acetaminophen|Extended release Gel tabs 650 mg
120614|NCT01523093|Drug|Ondansetron|Orally Disintegrating Tablets 8mg
120615|NCT01523106|Drug|L-carnitine|dietary supplement
120616|NCT01523106|Other|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
120617|NCT01523119|Drug|Ondansetron|Orally Disintegrating Tablets 8 mg
120618|NCT01523145|Behavioral|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
120619|NCT01523145|Other|Control Group|usual follow-up Standard follow-up at the participating heart center
123889|NCT00078143|Behavioral|Behavior Therapy|
123890|NCT01551888|Drug|Aclidinium/Formoterol|Aclidinium/Formoterol 400 μg/12μg fixed-dose combination, one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
123891|NCT00077376|Drug|carboplatin|Given IV
123892|NCT01544712|Procedure|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
123893|NCT01544712|Procedure|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
123028|NCT01547988|Other|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
123029|NCT01548001|Drug|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
123030|NCT01548001|Drug|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
123031|NCT01548014|Dietary Supplement|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
123032|NCT01548027|Procedure|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
123033|NCT01548027|Procedure|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
123034|NCT01548027|Other|No intervention|No intervention
123035|NCT01548040|Device|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
123036|NCT01550276|Other|Manual Therapy|All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal.
123956|NCT01535157|Drug|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
123957|NCT01535170|Dietary Supplement|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17].
123958|NCT00076687|Biological|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
123959|NCT01535183|Drug|Irinotecan combination chemotherapy|Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)
VCR 2㎎/㎡ d0 IV push
Etoposide 100㎎/㎡ d0-d2 IV over 1hr
Carboplatin 450㎎/㎡ d0 IV over 8hrs
Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna
123960|NCT01535196|Drug|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
123961|NCT01535209|Radiation|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
123962|NCT01535209|Radiation|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
123963|NCT01535222|Drug|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
123099|NCT01548053|Other|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
123100|NCT01548066|Drug|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
123101|NCT01548066|Drug|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
123102|NCT01548079|Drug|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
123103|NCT01548092|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
123104|NCT01548105|Other|Blood draw for the study participants|These will include:
Procollagen 1-N propeptide levels (PINP)
Matrix metalloproteinase (MMP9)
Plasma Vitamin C levels
123105|NCT01548118|Biological|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
123106|NCT01548118|Biological|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
119935|NCT01524341|Drug|KAE609|KAE609 was supplied as capsules for oral use.
119936|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
119937|NCT00075582|Drug|cyclophosphamide|Given IV
119938|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
119939|NCT01524367|Drug|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
119940|NCT01524367|Drug|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
119941|NCT01524380|Drug|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
119942|NCT01524380|Drug|Placebo|twice a day, 10 weeks
119943|NCT01524406|Drug|HPP593|Oral, twice a day.
119944|NCT01524406|Drug|Placebo|Oral, twice a day.
119945|NCT01524432|Drug|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
119946|NCT01524432|Drug|Placebo|No drug loaded microcapsules socks
119947|NCT01517360|Other|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
119948|NCT01517360|Behavioral|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
119949|NCT01517373|Drug|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
119950|NCT01517373|Drug|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
119951|NCT01517373|Drug|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
119952|NCT01517373|Drug|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
120620|NCT01523158|Biological|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
120621|NCT01523171|Drug|SAR302503|Pharmaceutical form:capsule
Route of administration: oral
119709|NCT01494220|Device|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
119710|NCT01494233|Drug|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
119711|NCT00072540|Procedure|cancer prevention intervention|
119712|NCT01494233|Drug|Placebo tablet|Matching placebo tablet administered orally
119713|NCT01494246|Other|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
119714|NCT01494259|Drug|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
119715|NCT01494259|Drug|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
119716|NCT01494285|Drug|ARK-E021 5%|Topically applied once daily at bedtime
119717|NCT01494285|Drug|ARK-E021 10%|Topically applied once daily at bedtime
119718|NCT01494285|Drug|Placebo|Topically applied once daily at bedtime
119719|NCT01494311|Drug|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
119720|NCT01494311|Drug|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
119721|NCT01494311|Drug|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
119722|NCT00072540|Procedure|chemoprevention of cancer|
119723|NCT01494311|Drug|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
123037|NCT01550276|Other|Manual Therapy|All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation.
123038|NCT01550276|Other|Placebo control|All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The control group received four sessions of placebo treatment, followed by ten minutes of resting position.
123039|NCT01550289|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
123040|NCT00077883|Drug|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
123312|NCT00077948|Drug|Placebo to match enoximone|Placebo to match match enoximone administered orally
123313|NCT01550744|Drug|Placebo|Form = Injection, route = subcutaneous
123314|NCT01552941|Device|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
123315|NCT01552954|Behavioral|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
123316|NCT01552967|Drug|Capecitabine|Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.
Efficacy will be evaluated every three cycles.
123317|NCT01552980|Drug|S-1 and Oxaliplatin|Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;
Efficacy will be evaluated every three cycles.
123318|NCT01552993|Drug|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
123319|NCT01552993|Drug|sucrose|pacifier and sucrose
123320|NCT01553006|Drug|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
123321|NCT01553019|Radiation|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
123322|NCT01553019|Drug|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
123323|NCT01553032|Drug|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
123107|NCT01548118|Biological|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
123108|NCT01548118|Biological|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
123109|NCT00001422|Drug|fludarabine|
123110|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms sc (starting dose) every 2 weeks
123111|NCT01548131|Behavioral|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
123112|NCT01548144|Drug|Crizotinib (Xalkori)|Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Expansion Groups Starting Dose: MTD from Phase 1.
123113|NCT01548144|Drug|Pazopanib|Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.
Expansion Groups Starting Dose: MTD from Phase 1.
123114|NCT01548144|Drug|Pemetrexed|Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Expansion Groups Starting Dose: MTD from Phase 1.
Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.
Expansion Group Starting Dose: MTD from Phase 1.
123115|NCT01548157|Drug|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
123116|NCT01548170|Drug|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
123117|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
123382|NCT01550809|Other|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
123383|NCT01550822|Other|HEALS|
123384|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
123385|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
123386|NCT01550848|Drug|Abraxane and Gemcitabine|ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15
GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15
123387|NCT01550861|Procedure|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
123388|NCT01550861|Procedure|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
120241|NCT01519999|Behavioral|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
120242|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
120243|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
120244|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
120245|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
120246|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
120247|NCT01520025|Radiation|PET MPI imaging with 18F-Fluorodeoxyglucose|Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.
18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.
Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)
120248|NCT00075179|Procedure|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
120249|NCT01520038|Radiation|Proton therapy|
120250|NCT01520038|Radiation|IMRT|
120251|NCT01520051|Drug|Mepolizumab|3 monthly intravenous infusions of 750 mg
120252|NCT01520051|Drug|Placebo|3 monthly intravenous infusions with saline
120253|NCT01520077|Drug|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
120254|NCT01520103|Drug|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
120255|NCT01522495|Device|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
119724|NCT01494324|Other|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
120010|NCT01522196|Drug|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
120011|NCT01522196|Other|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
120012|NCT01524445|Other|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
120013|NCT00000260|Drug|Nitrous oxide|
120014|NCT00001343|Drug|Oxandrolone|
120015|NCT00075582|Drug|vincristine sulfate|Given IV
120016|NCT01524458|Procedure|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
120017|NCT01524471|Procedure|Per Oral Endoscopic Myotomy|
120018|NCT01524497|Drug|Trazodone|75mg tablet/150 mg tablet
120019|NCT01524497|Drug|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
120020|NCT01524510|Radiation|CT scan|low dose radiation scan without contrast without and with MRA
120021|NCT01524510|Device|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
120022|NCT01524536|Drug|Corticosteroids|
120023|NCT01524575|Drug|gemcitabine and oxaliplatin|gemcitabine 1000mg/m2 IV q2week and oxaliplatin 85mg/m2 IV q2week
120024|NCT01524601|Drug|Rosuvastatin|20 mg rosuvastatin for 4 weeks
120025|NCT01524614|Procedure|nasal mask|nasal mask use instead of face mask
120026|NCT00075582|Radiation|radiation therapy|Undergo radiotherapy
123324|NCT00078247|Drug|Tuberculosis treatment|Tuberculosis treatment
123325|NCT01553032|Radiation|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
123326|NCT01553058|Drug|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
123327|NCT01553058|Drug|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
123328|NCT01553058|Other|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
123329|NCT01553071|Drug|Fenretinide (4-HPR) plus Intravenous Safingol|A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.
Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects.
123548|NCT01544179|Drug|Placebo|Matching placebo as comparator
123549|NCT01544179|Drug|Pemetrexed|Chemotherapy (concomitant therapy)
123550|NCT01544179|Drug|Cisplatin|Chemotherapy (concomitant therapy)
123551|NCT01544192|Drug|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
123552|NCT01544192|Drug|α−tocopherol|2x300 mg α−tocopherol
123553|NCT00001407|Drug|Interferon Gamma|
123554|NCT00077350|Drug|triapine|Given IV
123555|NCT01544192|Drug|Placebo|control group did not receive oral neuroprotective agent
123556|NCT01544192|Drug|Antioxidant formula|2x1 tablet AOF
123557|NCT01544205|Other|fMRI-based neurofeedback|5 sessions lasting one hour each
123558|NCT01544231|Biological|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
123559|NCT01544244|Procedure|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
123560|NCT01544244|Procedure|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
123389|NCT01550874|Behavioral|Motivation|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and get feedback about performance toward goals
123390|NCT01550887|Other|No intervention|No intervention will be performed on this study
123391|NCT01550900|Drug|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
123392|NCT00077961|Drug|CAMPATH (alemtuzumab)|
123393|NCT01550900|Other|Placebo|Placebo tablets by mouth 1 time a day.
123394|NCT01550913|Behavioral|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
123395|NCT01553214|Drug|Filgrastim (G-CSF)|Recombinant G-CSF is available from the Clinical Center pharmacy in colorless glass, single-use vials containing 480 mcg G-CSF in 1.6 mL vials (300 mcg/mL). It is formulated as a sterile, clear, colorless liquid in 10 mm sodium acetate buffer at pH 4.0. The quantitative composition (per mL) is: Recombinant human G-CSF 300 mcg Acetate 0.59 mg Mannitol 50 mg Tween 80TM 0.004% Sodium 0.035 mg Water for injection (qs ad) to 1.0 mL Storage: The intact vials of G-CSF should be stored under refrigeration (2-8 degrees Celsius). Administration: G-CSF is administered subcutaneously, with the entire contents of one 1.6 mL vial given in one injection 12 to 24 hours prior to apheresis.Stability: G-CSF in the intact vial is stable for 36 months when stored in a refrigerator at 2-8 degrees Celsius. A single brief exposure (up to 7 days) to elevated temperatures (& lt; 37 degrees Celsius) does not affect the stability. G-CSF should not be frozen, and vials that have been frozen should not be used.
123396|NCT01553214|Drug|Dexamethasone|Oral dexamethasone is available from the Clinical Center pharmacy as green 4 mg tablets. The tablets contain the following inactive ingredients: lactose monohydrate, magnesium stearate, starch, sucrose, FD& amp; C Green No. 3, FD& amp; C Yellow No. 10, and FD& amp; C Yellow No. 6. They are packaged in unit-dose blister pack strips. Storage: Dexamethasone tablets should be stored at room temperature (20-25 degrees Celsius). Administration: Dexamethasone is administered as two 4-mg tablets 12 hours prior to apheresis (approximately one hour after dinner the evening prior to apheresis). Stability: Dexamethasone is stable for 36 months when stored at room temperature in an unopened blister pack.
123628|NCT01551394|Drug|Ampicillin + gentamicin or cefotaxime + gentamicin|Ampicillin:
Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours
Gentamicin:
Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)
Cefotaxime:
Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days.
123629|NCT01551407|Drug|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
123630|NCT01551420|Device|Advanced upper limb prosthetic device|There are three versions of the advanced upper limb prosthetic device: shoulder configuration (SC, also known as shoulder disarticulation (SD)); humeral configuration (HC also known as transhumeral (TH)) and radial configuration (RC also known as transradial (TR)).
120256|NCT01522495|Device|SPY Imaging|SPY Imaging to assess tissue perfusion
120257|NCT01522508|Procedure|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
120543|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
120544|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
120545|NCT01525225|Drug|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
120546|NCT01525225|Drug|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
120547|NCT01525225|Drug|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
120548|NCT01525225|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
120549|NCT00001344|Drug|dextromethorphan|
120550|NCT00075621|Drug|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
120551|NCT01525225|Drug|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
120552|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 2.5 mg, Single-dose
120553|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 5 mg, Single-dose
120554|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 10 mg, Single-dose
120555|NCT01525264|Behavioral|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
120556|NCT01525290|Drug|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
120557|NCT01525290|Drug|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
120027|NCT01524627|Drug|Varenicline or placebo|Varenicline or placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
120028|NCT01524640|Biological|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
120029|NCT01524640|Biological|Placebo|1.5 ml oral administration on day 0 and day 14
120030|NCT01524653|Drug|Rosuvastatin|20 mg po od
120031|NCT01524653|Drug|Placebo|20 mg po od
120032|NCT01524679|Drug|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
120315|NCT01517984|Drug|Tacrolimus (CNI) Withdrawal|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.
120316|NCT01517984|Drug|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
120317|NCT01517997|Procedure|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
120318|NCT01517997|Procedure|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
120319|NCT01518010|Behavioral|Play game|Participants engage in non-game activity (establish baseline) 7 * 1 hr weekly; play single-player game 7 * 1 hr weekly; play multi-player game 7 * 1 hr weekly.
120320|NCT01520103|Drug|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
120321|NCT01520116|Drug|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
120322|NCT01520116|Drug|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
120323|NCT01520116|Drug|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
120324|NCT00075192|Drug|CP-675,206 and leuprolide acetate and bicalutamide|
120325|NCT01520116|Drug|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
120326|NCT01520116|Drug|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
120327|NCT01520116|Drug|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
123561|NCT01544257|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
123562|NCT01544257|Procedure|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
123563|NCT01544270|Dietary Supplement|Yogurt-like snacks|twice a day 120 g for four weeks
123564|NCT01544283|Drug|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
123565|NCT00077350|Drug|gemcitabine hydrochloride|Given IV
123566|NCT00077493|Procedure|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
123567|NCT01546506|Drug|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
123568|NCT01546519|Drug|Vismodegib|oral repeating dose
123569|NCT01546532|Drug|RLX030|RLX030 as intravenous infusion for 24 hours.
123894|NCT01544725|Drug|Procedural sedation with ketamine-propofol combination|K= Kétamine P= Propofol RSS= Ramsay Sedation Score
At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).
At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).
At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).
At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver).
123895|NCT01544725|Drug|Procedural sedation with ketamine alone|K= Ketamine I= Intralipid placebo
At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).
At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.
At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.
At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver).
123896|NCT01544738|Other|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
123631|NCT01544283|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
123632|NCT01544296|Drug|KHK6188|
123633|NCT01544296|Drug|Placebo|
123634|NCT01544309|Drug|Atorvastatin|Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in the Japan Atherosclerosis Society [JAS] Guidelines [GL] after 3 months, had the atorvastatin [ATV] dose of 20 mg.)
123635|NCT01544309|Drug|Rosuvastatin|Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin [RSV] dose of 10 mg.)
123636|NCT01544322|Drug|ME-344|experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
123637|NCT01544335|Other|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
123638|NCT01544348|Other|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
123639|NCT01544348|Biological|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
123640|NCT01544348|Biological|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
123641|NCT00077350|Other|laboratory biomarker analysis|Correlative studies
123642|NCT01544348|Biological|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
123643|NCT01544348|Biological|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
123964|NCT01535222|Drug|Placebo|Commercially available NaCl
123965|NCT01535235|Drug|Lisinopril|Lisinopril 20mg QD x 24 weeks
123966|NCT01535235|Drug|Placebo|Placebo QD x24wks
123967|NCT01535248|Other|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
120558|NCT01525303|Behavioral|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
120559|NCT01518218|Behavioral|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
120560|NCT01518231|Procedure|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
119657|NCT01496612|Drug|Buspirone|
119658|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
119659|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
119660|NCT01496651|Procedure|Percutaneous coronary intervention|PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.
There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement.
119661|NCT01496651|Procedure|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
119662|NCT00001296|Drug|tumor necrosis factor|
119663|NCT00072826|Drug|L-NMMA|
119664|NCT01496664|Procedure|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
119665|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
119666|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
119667|NCT01489618|Biological|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
119668|NCT01489618|Biological|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
120328|NCT01520116|Drug|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
120329|NCT01520116|Drug|Timoptic|0.5%
120330|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
120331|NCT01520142|Drug|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
120332|NCT01520142|Drug|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
120622|NCT01523184|Drug|Placebo Capsule|This is the placebo capsule
120623|NCT00075491|Other|laboratory biomarker analysis|Correlative studies
120624|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
120625|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
120626|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
120627|NCT01523197|Device|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
120628|NCT01523210|Other|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
120629|NCT01523223|Biological|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
120630|NCT01525511|Drug|A|Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.
Primaquine:
1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)
Dosage: 2 tablets
DHA-PQP:
1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg
Dosage: 3 tablets
120631|NCT01525511|Drug|B|Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.
Primaquine:
1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)
Dosage: 2 tablets
DHA-PQP:
1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg
Dosage: 3 tablets
123897|NCT01544738|Other|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
123898|NCT01544751|Drug|Low dose metformin|500 mg twice a day
123899|NCT01544751|Drug|Metformin|1000 mg twice a day
123900|NCT01544751|Drug|Atorvastatin|20 mg/day
123901|NCT01544764|Other|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
123902|NCT00077376|Other|laboratory biomarker analysis|Correlative studies
123903|NCT01544777|Device|Study IOL|Aspheric IOL for correction of aphakia
123904|NCT01544777|Device|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
123905|NCT01544777|Device|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
123906|NCT01544790|Procedure|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
123041|NCT01550289|Biological|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
123042|NCT01550302|Procedure|Superficial Cervical Plexus Block|At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a "fan" technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site.
123043|NCT01550302|Drug|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
123044|NCT01550315|Procedure|Pulsitile Arterial Tonometry (PAT) Protocol|A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).
RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.
Continuous recording of pulsatile blood volume responses from both hands will be initiated.
After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped.
123968|NCT01535261|Drug|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
123969|NCT00076687|Biological|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
123970|NCT01537484|Procedure|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
123971|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
123972|NCT00076986|Procedure|surgery and catheter placement (2 procedures)|
123973|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
123974|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
123975|NCT01537497|Drug|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
123976|NCT01537510|Behavioral|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
123977|NCT01537523|Procedure|community-care program|community nurse care, physiotherapy
123978|NCT01537536|Drug|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
123979|NCT01537549|Drug|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
123980|NCT01537562|Other|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
123981|NCT01537575|Biological|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
123118|NCT01548170|Drug|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
123119|NCT01550341|Drug|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
119669|NCT00072228|Procedure|chemotherapy|
119670|NCT01489631|Drug|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
119671|NCT01489631|Drug|marcaine|bupivacaine 0,125%
119672|NCT01489631|Drug|sufentanil|sufentanil 1mcg/ml
119673|NCT01489631|Drug|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
119674|NCT01489644|Drug|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
119953|NCT01517373|Drug|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
119954|NCT00001335|Drug|ADR-529|
119955|NCT00074815|Drug|Serotonin reuptake inhibitors management|Participants are maintained on their optimized dose of SRI for OCD symptoms (see "Other Names" section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI.
119956|NCT01517386|Procedure|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
119957|NCT01517399|Drug|tivantinib|three oral 120 mg tablets administered twice a day
119958|NCT01517399|Drug|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
119959|NCT01517399|Drug|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
119960|NCT01517399|Drug|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
119961|NCT01517399|Dietary Supplement|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
119962|NCT01517399|Drug|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
119963|NCT01517399|Drug|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
119964|NCT01517412|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
119965|NCT01517412|Device|Pen auto-injector|
120632|NCT01525524|Device|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
120633|NCT01525537|Drug|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
120634|NCT01525537|Drug|sufentanil|sufentanil was given at standard practise
120635|NCT00075634|Drug|decitabine|Given IV
120636|NCT01525550|Drug|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
120637|NCT01525576|Behavioral|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
120638|NCT01525589|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
120639|NCT01525602|Drug|PLX3397|PLX3397 tablets, 200mg
120640|NCT01525602|Drug|Paclitaxel|Paclitaxel IV
123531|NCT01551186|Dietary Supplement|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
123532|NCT01551199|Behavioral|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
123533|NCT00078000|Drug|SU011248|
123534|NCT01551212|Drug|Everolimus (RAD001) as add-on|
123535|NCT01551212|Drug|tacrolimus group|
123536|NCT01551225|Drug|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
123537|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
123538|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
123539|NCT01551264|Device|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
123045|NCT01550315|Device|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
123046|NCT01550315|Device|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
123047|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
123048|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
123049|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
123050|NCT01552850|Drug|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
123051|NCT00078247|Drug|Abacavir|300 mg tablet taken orally twice daily
123052|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
123053|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
123054|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
123055|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
123056|NCT01552863|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
123330|NCT01553084|Drug|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
123331|NCT01553084|Drug|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
123332|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
123333|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
123120|NCT01550354|Drug|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
123121|NCT01550354|Drug|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
123122|NCT01550354|Drug|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
123123|NCT00077896|Procedure|Direct Current Polarization|
123124|NCT01550367|Drug|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
123125|NCT01550367|Drug|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
123126|NCT01550380|Drug|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
123127|NCT01550393|Genetic|proteomic profiling|
123128|NCT01550393|Other|enzyme-linked immunosorbent assay|
123129|NCT01550393|Other|laboratory biomarker analysis|
123130|NCT01550393|Other|medical chart review|
123131|NCT01550406|Device|Tachocomb|A kind of Mesh:
ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin
123132|NCT01550406|Device|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
123133|NCT01550419|Drug|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
123134|NCT00077922|Drug|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
123135|NCT01550419|Drug|Placebo|The smell and shape of placebo are the same as atorvastatin
123136|NCT01550432|Dietary Supplement|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
123137|NCT01550432|Dietary Supplement|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
123138|NCT01550432|Other|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
123139|NCT01550445|Drug|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
119966|NCT00074815|Behavioral|Cognitive behavioral therapy by a psychologist|CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
119967|NCT01517412|Drug|Metformin|To be kept at stable dose throughout the study
119968|NCT01517438|Behavioral|agitation|agitation score after desflurane anesthesia
119969|NCT01519505|Behavioral|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
119970|NCT00075088|Other|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
120258|NCT01522521|Drug|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
120259|NCT00075465|Drug|epirubicin hydrochloride|
120260|NCT01522521|Drug|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
120261|NCT01522534|Drug|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
120262|NCT01522534|Drug|Morphine|Morphine alone with a placebo nerve block
120263|NCT01522547|Drug|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
120264|NCT01522560|Other|Feedback group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF).
120265|NCT01522560|Other|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
120266|NCT01522573|Procedure|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
120267|NCT01522586|Drug|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
120268|NCT01522586|Drug|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
123540|NCT01551277|Other|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
123541|NCT01551277|Other|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
123542|NCT01551290|Drug|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
123543|NCT01544153|Behavioral|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
123544|NCT01544153|Behavioral|Social Network|Proactive communications from established members of the community ("Integrators") designed to integrate study participants into the online social network on BecomeAnEX.org.
123545|NCT01544153|Behavioral|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
123546|NCT01544166|Drug|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants <2 years of age.
123547|NCT01544179|Drug|Gefitinib|Investigational Drug
123793|NCT01551667|Biological|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
123794|NCT01551667|Biological|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
123795|NCT01551680|Radiation|Radiation combined with iniparib (BSI-201)|Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.
Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.
RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields.
123796|NCT01551693|Drug|STA-9090|200 mg/m^2 IV over 1 hours +/- 15 min, on days 1, 8 15 of 28 day cycle
123797|NCT01544517|Drug|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
123334|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
123335|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
123336|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
123337|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
123338|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
123339|NCT01546051|Drug|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
123340|NCT00077454|Other|laboratory biomarker analysis|Correlative studies
123341|NCT01546051|Drug|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
123342|NCT01546051|Drug|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
123343|NCT01546051|Drug|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
123344|NCT01546064|Device|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
123345|NCT01546064|Device|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
123346|NCT01546077|Procedure|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
123347|NCT01546090|Drug|Alprazolam|preoperative administration of an orally 0.50 mg single dose
123348|NCT01546090|Drug|placebo|placebo capsules were filled with starch
123570|NCT01546532|Drug|Placebo|Intravenous infusion of Placebo over 24 hours
123571|NCT01546558|Drug|Metformin|Metformin 1000 mg bid on Days 1-10
123572|NCT01546558|Drug|Ranolazine|Ranolazine 500 mg bid on Days 6-10
123573|NCT01546571|Biological|POL-103A|POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
123397|NCT00078273|Behavioral|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
123398|NCT01553227|Device|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
123399|NCT01553240|Device|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
123400|NCT01553266|Behavioral|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
123401|NCT01553279|Biological|V419 (PR5I)|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b conjugate [Meningococcal Outer Membrane Protein Complex], and hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2, 3 and 4 months of age
123402|NCT01553279|Biological|Prevenar 13|Pneumococcal conjugate vaccine (13-valent, adsorbed) 0.5 mL intramuscular injection at 2 and 4 months of age
123403|NCT01553279|Biological|NeisVac-C|Meningococcal group C polysaccharide conjugate vaccine adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
123404|NCT01553279|Biological|MENJUGATE|Meningococcal group C conjugate vaccine adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
123405|NCT01553279|Biological|MENITORIX|Haemophilus type b and meningococcal group C conjugate vaccine 0.5 mL intramuscular injection at 12 months of age
123406|NCT01553279|Biological|M-M-RVAXPRO|Measles, mumps, and rubella vaccine (live)
123407|NCT01553292|Device|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
123408|NCT01546155|Radiation|PET imaging|Up to a 120 minute PET scan using [11C]diprenorphine as the radiotracer
123409|NCT01546168|Device|esophageal deviation with IDE device|esophageal deviation during AF ablation
123410|NCT01546194|Other|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
120269|NCT01522599|Other|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
120270|NCT00075478|Procedure|Total-Body Irradiation|Undergo TBI
120271|NCT01522599|Other|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
120272|NCT01522612|Drug|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
120273|NCT01522612|Drug|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
120274|NCT01522612|Drug|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
120275|NCT01522625|Drug|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
120276|NCT01522625|Drug|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
120277|NCT01522651|Drug|Ranolazine|Ranolazine 750 mg tablet administered orally twice daily
120278|NCT01522651|Drug|Dronedarone low dose 1|Dronedarone 225 mg capsule administered orally twice daily
120561|NCT00074932|Biological|Myozyme|20 mg/kg
120562|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
120563|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial);
120564|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
120565|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt.
120566|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
120567|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial)
120568|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
120569|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt
120570|NCT01518244|Drug|Brinzolamide/timolol maleate fixed combination|
120571|NCT01518257|Biological|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
120572|NCT00074958|Biological|Fabrazyme (agalsidase beta)|1 mg/kg every 2 weeks
123798|NCT01544530|Other|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
123799|NCT01544569|Genetic|DNA analysis|
123800|NCT01544569|Genetic|fluorescence in situ hybridization|
123801|NCT00077376|Biological|trastuzumab|Given IV
123802|NCT01544569|Genetic|gene expression analysis|
123803|NCT01544569|Genetic|gene mapping|
123804|NCT01544569|Genetic|microarray analysis|
123805|NCT01544569|Genetic|polymerase chain reaction|
123806|NCT01544569|Genetic|protein expression analysis|
123807|NCT01544569|Other|laboratory biomarker analysis|
123808|NCT01544569|Other|medical chart review|
123809|NCT01544595|Drug|Secukinumab (AIN457)|Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.
123810|NCT01544595|Drug|Placebo|Placebo
123811|NCT01544621|Other|Smoking cessation|Smoking cessation
123812|NCT00077376|Drug|ixabepilone|Given IV
124130|NCT00001384|Drug|Adriamycin|
124131|NCT00076752|Drug|fludarabine phosphate|Conditioning and transplant regimen: 30 mg/m^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
124132|NCT01535573|Drug|Placebo|0 mg per day for 9 weeks
124133|NCT01535586|Device|CPAP versus MAD|Cross over design
124134|NCT01535599|Drug|AL-60371, 0.3% Otic Suspension|
124135|NCT01535599|Other|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
123574|NCT01546571|Biological|POL-103A without API|Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
123575|NCT01546597|Drug|Metformin|Metformin 500 mg bid on Days 1-5
Metformin 850 mg bid on Days 6-10
Metformin 500 mg bid on Days 11-15
Metformin 850 mg bid on Days 16-20
123576|NCT01546597|Drug|Ranolazine|Ranolazine 1000 mg bid on Days 11-15
Ranolazine 1000 mg bid on Days 16-20
123577|NCT00077493|Procedure|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
123578|NCT01546610|Other|insoles intervention|EVA insole with arch support and bar retrocapital
123579|NCT01546610|Other|placebo insole|EVA insole flat
123580|NCT01546623|Drug|TAP-144-SR(6M)|
123581|NCT01546623|Drug|TAP-144-SR(3M)|
123582|NCT01546636|Other|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
123583|NCT01546636|Other|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
123584|NCT01546649|Drug|TAP-144-SR(6M)|
123585|NCT01546649|Drug|TAP-144-SR(3M)|
123586|NCT01546662|Dietary Supplement|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
123587|NCT01546662|Dietary Supplement|Placebo|1/ 2 capsules, twice daily for 12 weeks
123588|NCT00077493|Procedure|monoclonal antibody therapy|administered intravenously over 30 minutes.
123589|NCT01546675|Other|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
123590|NCT01546688|Drug|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
123591|NCT01546688|Drug|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
123592|NCT01546701|Drug|Buprenorphine|2 mg sublingual tablet
123593|NCT01546701|Drug|Morphine|0.1 mg/kg IV morphine
123907|NCT01539876|Procedure|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
123411|NCT01546207|Procedure|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
123644|NCT01544348|Biological|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
123645|NCT01544348|Biological|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
123646|NCT01544348|Biological|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
123647|NCT01544361|Other|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
123648|NCT01544361|Biological|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
123649|NCT01544361|Biological|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
123650|NCT01544361|Biological|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
123651|NCT01544361|Biological|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
123652|NCT01546727|Behavioral|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
123653|NCT01546727|Behavioral|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
123654|NCT01546753|Drug|Walnut Protein Powder|Dosing begins with a one-day walnut oral desensitization protocol. Starting at 0.1 mg protein and increasing every thirty minutes until a maximum dose of 6 mg is reached or until allergic symptoms develop. After the initial escalation day, subjects will continue daily dosing with dosing build-every two weeks to a maximum dose of 1500mg walnut protein at 34 weeks. A daily maintenance dose (1500mg or the highest dose reached by 34 weeks) will be given for 4 weeks followed by 5 gram oral food challenges to walnut and the second tree nut (at 38 weeks), after which the study will be unblinded. Active treatment subjects will continue on maintenance dosing for up to a total of 298 weeks of therapy. Subjects reaching a qualifying specific IgE to walnut and the test tree nut at any early time point will receive a tolerance oral food challenge to the tree nuts on and 4 weeks off therapy. All subjects will have an oral food challenge on and off therapy at 142 weeks and at 298 weeks.
123655|NCT01546753|Drug|Oat Powder (placebo)|Subjects in the placebo group will undergo the same one-day desensitization protocol as the active treatment group, consuming a maximum dose of 6 mg of oat powder (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of oat powder, the dosing build-up will occur every two weeks through dose 24 (1500mg oat flour) at ~34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein double blind, placebo controlled OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment beginning with initial escalation day.
123656|NCT01546766|Device|Pupillometry testing.|
120573|NCT01518257|Drug|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
120574|NCT01518270|Other|No treatment|No treatment will be provided
120575|NCT01518283|Drug|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
120576|NCT01518296|Device|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
120577|NCT01518309|Drug|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
120578|NCT01518322|Device|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
120579|NCT01518335|Procedure|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
120580|NCT01518335|Procedure|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
119675|NCT01489644|Drug|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
119676|NCT01489644|Drug|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
119677|NCT01489670|Drug|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
119678|NCT01489683|Drug|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
119679|NCT01489683|Drug|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
119680|NCT00072267|Drug|7-hydroxystaurosporine|
119681|NCT01489696|Drug|mirabegron|oral
119682|NCT01489696|Drug|tamsulosin|oral
119683|NCT01489709|Drug|Vesicare|oral
124136|NCT01535612|Device|PaQ™ continuous subcutaneous insulin infusion (CSII) device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
124137|NCT01535625|Device|Momo stent|Patients with PCI
124138|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
124139|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
124140|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
124141|NCT01535651|Behavioral|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
124142|NCT01537783|Drug|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
124143|NCT01537783|Drug|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
124144|NCT01537796|Behavioral|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
124145|NCT01537796|Behavioral|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
124146|NCT00001384|Drug|paclitaxel|
124147|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
123270|NCT01548378|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
123271|NCT01548391|Drug|HX-1171|20mg, 200mg, 500mg
123272|NCT01548404|Drug|REGN668/SAR231893|REGN668/SAR231893 for SC dosing will be evaluated in this study.
123273|NCT01548404|Drug|Placebo|Placebo matching REGN668/SAR231893
123274|NCT01548417|Drug|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
123275|NCT01548417|Drug|Sugar Pill|600 mg/day, oral pill, 7 days
123908|NCT01539889|Radiation|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
123909|NCT01539902|Biological|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
123910|NCT01539902|Drug|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
123911|NCT01539915|Drug|BCT194|Topically applied BCT194 cream (0.5%)
123912|NCT01539928|Other|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
123913|NCT01539941|Behavioral|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
123914|NCT01539967|Procedure|Laparoscopic Sleeve Gastrectomy|the operative technique consists in few steps:
position of 4 trocars and insertion of a nasogastric tube
dissection and mobilization of the greater curvature of the stomach
preparation of the stomach for division
gastric partition
extraction of the gastric remnant
postoperative surveillance
123915|NCT01539980|Device|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith&Nephew, London, UK) are applied on the other half of the skin graft donor site
123916|NCT01540006|Other|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
123917|NCT00077116|Procedure|peripheral blood stem cell transplantation|
123918|NCT01540019|Drug|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
123919|NCT01540032|Behavioral|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
123920|NCT01540032|Behavioral|Normal diet|Patients will eat their usual diet.
123921|NCT01540058|Other|Cancer Type ID test|CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).
CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York.
123657|NCT00077519|Drug|tipifarnib|
123658|NCT01546779|Device|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
123659|NCT01546792|Behavioral|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
123982|NCT01537575|Biological|Saline solution|Placebo
123983|NCT00076986|Drug|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
123984|NCT01537588|Other|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
123985|NCT01537588|Other|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
123986|NCT01537601|Procedure|Circumcision|Circumcision
123987|NCT01537601|Other|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
123988|NCT01537614|Drug|COLIMYCINE inhalation|2 MILLION UI
123989|NCT01537614|Drug|COLIMYCINE injectable|2 MILLIONS UI
123990|NCT01537627|Other|Physical training|Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.
Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months.
123991|NCT01537627|Other|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
123992|NCT01540084|Drug|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
123993|NCT01540110|Drug|Neoadjuvant Docetaxel and Cyclophosphamide|5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.
Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.
Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)
5.1.2 Cyclophosphamide
Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.
No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)
119684|NCT01489722|Drug|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
119685|NCT01489761|Device|percutaneous coronary intervention|drug eluting stent implantation
119686|NCT01489774|Drug|Placebo|single and multiple dose
119687|NCT01489774|Drug|CJ-12406|single and multiple dose
119688|NCT01489787|Procedure|HIFU|The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:
One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.
One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient.
119689|NCT01489787|Procedure|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
119690|NCT01491841|Drug|Bendamustine + Rituximab + Pixantrone|Maximum tolerated dose and optimal dose schedule of pixantrone in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
119691|NCT00072384|Biological|filgrastim|Given subcutaneously
119692|NCT01491854|Other|Bloodsampling|Bloodsampling
119693|NCT01491867|Drug|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
119971|NCT01519518|Drug|unfractionated heparin|70 units/kg body weight intravenous
119972|NCT01519518|Drug|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
119973|NCT01519531|Drug|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
119974|NCT01519531|Drug|VIA-3196|Oral, daily dosing for 14 days
119975|NCT01519544|Drug|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
119976|NCT01519544|Drug|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
119977|NCT01519557|Drug|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
119978|NCT01519557|Drug|Placebo|Placebo
123276|NCT01548430|Drug|TTP4000|
123277|NCT01548430|Drug|Placebo|
123278|NCT01548443|Device|Medifoam H dressing|Cover "medifoam H" on the wound for a week.
123279|NCT01548443|Device|Duoderm THIN dressing|Cover "Duoderm THIN" on the wound for a week
123280|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
123281|NCT01548456|Procedure|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
123282|NCT01548456|Procedure|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
123283|NCT01548469|Other|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
123284|NCT01548469|Other|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
123285|NCT01548482|Other|Laboratory Biomarker Analysis|Correlative studies
123286|NCT01548482|Other|Pharmacological Study|Correlative studies
123287|NCT01548482|Drug|Temsirolimus|Given IV
123288|NCT01548482|Biological|Trebananib|Given IV
123289|NCT01548508|Other|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
123290|NCT01548508|Other|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
123291|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
123292|NCT01548521|Drug|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
123293|NCT01548534|Dietary Supplement|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
123813|NCT01544634|Drug|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
123814|NCT01544634|Drug|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
123815|NCT01544634|Drug|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
123816|NCT01544634|Drug|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
123057|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
123058|NCT01552876|Device|etafilcon A|A daily wear contact lens
123059|NCT01552876|Device|nelfilcon A|A daily wear contact lens
123060|NCT01552876|Device|Filcon II 3|a daily disposable
123061|NCT01552889|Behavioral|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
123062|NCT00078247|Drug|Lamivudine|300 mg tablet taken orally daily
123063|NCT01552902|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
123064|NCT01552902|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
123065|NCT01552902|Drug|Placebo|Daily oral dosing in the AM for 6 weeks
123066|NCT01552915|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
123067|NCT01552915|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
123068|NCT01552915|Drug|Placebo|Daily oral dosing in the AM for 8 weeks
123069|NCT01552928|Drug|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
123070|NCT01552928|Drug|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
123071|NCT01552928|Drug|Moxifloxacin|400 mg Moxifloxacin single oral dose
123072|NCT01552928|Drug|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
123073|NCT00001428|Drug|5-fluorouracil|
123074|NCT00078247|Drug|Zidovudine|300 mg tablet taken orally twice daily
123075|NCT01545583|Drug|LY3016859 SC|Administered SC
123076|NCT01545583|Drug|Placebo SC|Administered SC
123077|NCT01545596|Behavioral|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
125527|NCT01584882|Behavioral|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
125528|NCT01584895|Behavioral|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
125529|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
125530|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.
On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding.
125531|NCT01584921|Drug|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
125532|NCT01584934|Drug|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
125533|NCT01584934|Drug|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
125534|NCT01584947|Drug|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
125535|NCT01584947|Drug|Placebo|Placebo lozenge taken three times a day for two weeks
125536|NCT00080860|Procedure|lymphangiography|
125537|NCT01584960|Behavioral|endurance training|2 years of home-based endurance training
125805|NCT01587924|Drug|GSK1278863|tablet
125806|NCT01587924|Drug|rhEPO|injection
125807|NCT01587937|Other|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
125808|NCT01587950|Drug|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
125105|NCT01542073|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
125106|NCT01542086|Procedure|Myocardial SPECT|
125107|NCT01542086|Procedure|64-channel coronary CT angiography (CCTA)|
125108|NCT01542099|Drug|Remifentanil|According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.
For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml.
125109|NCT00077246|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
125110|NCT01542099|Drug|Remifentanil|According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.
For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml.
125111|NCT01542112|Other|PSactive model|The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.
The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention.
125112|NCT01542112|Other|No treatment|Patients in this arm receive the usual routine in the department.
125113|NCT01542125|Drug|Liposomal Lidocaine|4% Liposomal Lidocaine
125114|NCT01542125|Drug|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
125115|NCT01542138|Drug|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
125116|NCT01542138|Drug|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
125117|NCT01542138|Drug|Placebo|Humectant placebo cream
125118|NCT01534793|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
125119|NCT01534806|Drug|Ketorolac|Ketorolac(0.5mg/kg) IV push
125120|NCT01534806|Drug|Placebo|Sodium Chloride 0.9% - 10 mL IV push
125121|NCT00076622|Drug|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
125874|NCT01583283|Drug|Dexamethasone|Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
125875|NCT00080795|Drug|gemcitabine hydrochloride|
125876|NCT01583296|Behavioral|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
125877|NCT01585493|Other|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
125878|NCT01585493|Behavioral|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
125879|NCT01585493|Behavioral|CHANGE|Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.
CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change.
125880|NCT00001498|Drug|paclitaxel|
125881|NCT00080886|Drug|carmustine|
125882|NCT01585506|Other|No treatment given|Patients to complete the "WHO-5 Well-being Index" questionnaire
125883|NCT01585506|Other|No treatment given|Physicians to complete two questionnaires, "Demographic Data and Disease and Treatment Course" and "Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
125884|NCT01585519|Dietary Supplement|High/ Low Epicatechin Apples/ Apple Extract/ Granules|(Group 1) Low Apple Diet (i.e. <1 portion per day) + 2 placebo capsules daily.
(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.
(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.
(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.
(Group 5) Low apple diet + 2 x Apple Extract Capsules daily.
125885|NCT01585558|Drug|Ospemifene (Dose 1)|
125886|NCT01585558|Drug|Ospemifene (Dose 2)|
125887|NCT01585558|Drug|Placebo|
125888|NCT01585584|Drug|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
126130|NCT01586039|Radiation|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
125033|NCT01534689|Device|Erchonia FX-405™ Laser|The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
125034|NCT01534702|Drug|clofarabine, cytarabine, idarubicin|Treatment is stratified according to patients age (< 60 years vs. ≥ 60 years).
Medication:
Patients < 60 years:
idarubicin 7.5 mg/m2 iv, days 1 + 3
cytarabine 750 mg/m2 iv, days 1 to 5
Patients ≥ 60 years:
idarubicine 6 mg/m2 iv, days 1 + 3
cytarabine 750 mg/m2 iv, days 1 to 5
Clofarabine will be given in escalating doses to cohorts of at least three patients:
Clofarabine:
level -1: 15 mg/m2 iv, days 1 to 5
level 1: 20 mg/m2 iv, days 1 to 5
level 2: 25 mg/m2 iv, days 1 to 5
level 3: 30 mg/m2 iv, days 1 to 5
level 4: 35 mg/m2 iv, days 1 to 5
Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1.
125035|NCT01534715|Drug|IMGN529|
125036|NCT01534741|Other|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
125037|NCT01534741|Device|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
125038|NCT01534754|Drug|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
125039|NCT00001383|Drug|paclitaxel|
125040|NCT00076609|Drug|capecitabine|
125041|NCT01534754|Drug|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
125042|NCT01534754|Drug|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
125365|NCT01584609|Device|Penumbra System alone|The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
125366|NCT01584622|Device|CADence System|Non-invasive detection of > or equal to 50% stenosis in any of the major coronary arteries.
125367|NCT01587053|Other|therapeutic education program|
125368|NCT01587066|Drug|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
125369|NCT01587066|Drug|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
125370|NCT00080925|Drug|prednisone|
124464|NCT01543880|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
124465|NCT01543893|Behavioral|Video instruction|Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks
Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm
124466|NCT01536067|Biological|ofatumumab|Given IV
124467|NCT01536067|Drug|bortezomib|Given SC
124468|NCT01536067|Other|laboratory biomarker analysis|Correlative studies
124469|NCT01536093|Other|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
124470|NCT01536093|Other|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
124471|NCT01536106|Other|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
124472|NCT01536106|Other|Placebo control|Intracoronary infusion of autologous peripheral blood.
124473|NCT00076752|Procedure|autologous hematopoietic stem cell transplantation|Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
124474|NCT01536119|Behavioral|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
124475|NCT01536132|Drug|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
124476|NCT01536132|Drug|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
124757|NCT01538979|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
124758|NCT01538979|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
124759|NCT01538992|Device|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
124760|NCT01539018|Drug|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
125122|NCT01534819|Device|Heli-FX EndoAnchor System|Placement of the Aptus Heli-FX™ EndoAnchor System in subjects with previously implanted commercial endografts, for the prevention of graft migration and the treatment of Type Ia endoleak or Aptus Heli-FX EndoAnchor System placed at the time of initial endograft implantation, either to prevent endograft migration and Type Ia endoleak, or to treat Type Ia endoleak evident at the time of implantation.
124209|NCT01537861|Drug|Carfilzomib|
124210|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
124211|NCT01537861|Drug|Dexamethasone|
124212|NCT01537861|Drug|Cyclophosphamide|
124213|NCT01537861|Drug|Thalidomide|
124214|NCT01537861|Drug|Lenalidomide|
124215|NCT01537861|Drug|Pomalidomide|
124216|NCT01537874|Behavioral|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
124217|NCT01537874|Behavioral|Usual best practices|Standard care delivered using informational materials
124218|NCT01537887|Drug|LY2484595|Administered orally once daily for 10 days.
124219|NCT01537887|Drug|Placebo|Administered orally once daily for 10 days.
124220|NCT01537887|Drug|Moxifloxacin|Single dose administered orally.
124221|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
124222|NCT01537900|Drug|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
124223|NCT01537926|Drug|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
124224|NCT01537926|Drug|Placebo|sugar pill manufactured to minic NAC 600mg capsule
124225|NCT01537939|Behavioral|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
124226|NCT01537965|Device|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|Five ultrasounds exams are realised:
elastography with Fibroscan®
ultrasound elastography in supersonic mode with Aixplorer®
ultrasound analysis of the surface liver with QRS software,
quantification of acoustic structure with Aplio XG,
elastography ARFI with Acuson S2000.
126131|NCT01586052|Drug|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
126132|NCT01586065|Device|Continuous Glucose Monitor (CGM)|Use of CGM for 6 months
126133|NCT01586065|Other|Fingerstick BGs only|No CGM - fingerstick BGs only
126134|NCT01586091|Drug|Levocetirizine|levocetirizine 5 mg once daily
126135|NCT01586091|Drug|Fexofenadine|fexofenadine 60 mg twice daily, oral
126136|NCT01586104|Radiation|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
126137|NCT00080899|Other|laboratory biomarker analysis|Correlative studies
126138|NCT01586117|Drug|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
126139|NCT01586130|Other|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
126140|NCT01586143|Drug|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
126141|NCT01586143|Drug|Placebo|
126142|NCT01586156|Drug|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
126143|NCT01586156|Drug|Carvedilol placebo|Placebo taken twice daily for 6 months
126144|NCT01586169|Drug|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
126145|NCT01588535|Drug|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
126146|NCT01588535|Drug|placebo|placebo solution, five drops in affected ear canal each hour as needed
126147|NCT01588548|Drug|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
126148|NCT00081003|Other|physiologic testing|
125371|NCT01587079|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
125372|NCT01587079|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
125373|NCT01587079|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
125374|NCT01587079|Drug|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
125375|NCT01587092|Behavioral|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
125376|NCT01587092|Behavioral|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
125377|NCT01587105|Behavioral|Comprehensive Case Management Service|When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
125378|NCT01587118|Drug|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
125379|NCT01587131|Biological|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
125380|NCT01587144|Drug|Lucanthone|Lucanthone or Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks along with radiation and TMZ during the concomitant phase. In the maintenance phase, lucanthone/placebo will be administered along with TMZ on days 1-5 of a 28-day cycle for 6 cycles.
125381|NCT00001499|Drug|paclitaxel|
125382|NCT00080925|Drug|vincristine sulfate|
124457|NCT00077311|Drug|BNP7787|40 g IV over 30 min Day 1 of each cycle
124458|NCT01543815|Other|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
124459|NCT01543828|Drug|indacaterol|delivered via single-dose dry-powder inhaler
124460|NCT01543828|Drug|placebo|delivered via single-dose dry-powder inhaler
124461|NCT01543854|Drug|RLX030|Intravenous infusion of RLX030 over 20 hrs
124462|NCT01543854|Drug|Placebo|Intravenous infusion of placebo over 20 hours
124463|NCT01543867|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
124761|NCT01539018|Drug|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
124762|NCT00077103|Biological|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
124763|NCT01541345|Procedure|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
124764|NCT01541358|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
124765|NCT00077220|Drug|paclitaxel|
124766|NCT01541358|Procedure|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
124767|NCT01541371|Drug|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
124768|NCT01541384|Device|Vitality GlowCaps|The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.
Note: GlowCaps are a "Class 1" Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval.
124769|NCT01541397|Drug|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
124770|NCT01541410|Device|Vascutek Hybrid Graft|Single Group Assignment
124771|NCT01541436|Device|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
124772|NCT01541462|Other|Weaning|Decrease assistance provided by the ventilator
124773|NCT01541475|Drug|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
125043|NCT01534754|Drug|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
125044|NCT01534780|Procedure|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
125045|NCT01534780|Device|Protack|fixation of mesh with protack
124227|NCT01537978|Other|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
124228|NCT01537991|Radiation|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
124229|NCT01538017|Drug|Xiapex|Collagenase Clostridium Histolyticum
124539|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
124540|NCT00077298|Biological|bevacizumab|Given IV
124541|NCT01543165|Drug|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
124542|NCT01543165|Drug|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
124543|NCT01543165|Drug|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
124544|NCT01543178|Drug|open-label rifaximin|550 mg three times a day (open-label)
124545|NCT01543178|Drug|double-blind placebo|3 times a day (double-blind)
124546|NCT01543178|Drug|double-blind rifaximin|550 mg three times a day (double-blind)
124547|NCT01543191|Drug|PUR118|low dose and high dose for 3 doses, BID
124548|NCT01543204|Drug|etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
124549|NCT01543217|Other|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
124550|NCT01543217|Other|Ususal care|Routine respiratory care.
124551|NCT00077298|Drug|irinotecan hydrochloride|Given IV
124552|NCT01543230|Device|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
124553|NCT01543243|Device|Stochastic resonance whole-body vibration A|Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.
Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
126471|NCT01586624|Drug|Vandetanib, Selumetinib|Dose escalation phase This phase consists of various cohorts, each investigating an increasing dose level of vandetanib and/or selumetinib. Vandetanib steady state dose levels investigated include 100, 200 or 300mg OD. Selumetinib dose levels are 25mg bd, 50mg bd and 75mg bd or 100 and 125mg OD.
All patients in this phase will take the study treatment as follows:
Cycle 1
Vandetanib higher (lead in) dose once daily (2 or 4 days) followed by vandetanib steady state dose once daily (10 or 12 days) followed by vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).
Cycle 1 is 42 days in length.
126472|NCT01586624|Drug|Vandetanib, Selumetinib|Cycle 2 onwards
Vandetanib steady state once daily in combination with selumetinib once/twice daily(28 days).
Cycle 2 and subsequent cycles are 28 days in length. From this phase, we will establish what the maximum tolerated dose (MTD) of the combination treatment is, which can safely be given to patients.
126473|NCT01586624|Drug|Vandetanib, Selumetinib|Expansion cohort (patients with non small cell lung cancer).
All patients will receive the same dose of combination treatment (the MTD established during dose escalation phase). As follows:
All patients in the expansion cohort will take the study treatment in the same way as follows:
Cycle 1
Vandetanib higher dose (lead in) once daily (2 or 4 days) followed by vandetanib steady state dose once daily (10 or 12 days) followed by vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).
Cycle 1 is 42 days in length.
126474|NCT01586624|Drug|Vandetanib, Selumetinib|Cycle 2 onwards •o Vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).
o Cycle 2 and subsequent cycles are 28 days in length. Number of cycles: Patients will be allowed to receive 6 cycles of study treatment. If the patient is still benefiting clinically and experiencing no unacceptable toxicity, then the Investigator can make a request to the Sponsor for continuation of treatment.
126475|NCT01586637|Other|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
126476|NCT01586637|Other|Walking|The group walked twice a week during one hour.
126477|NCT01586650|Other|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
126478|NCT01586650|Other|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
126479|NCT00080925|Drug|cyclosporine|
126480|NCT01586663|Device|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
126481|NCT01586663|Drug|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
126482|NCT01586676|Behavioral|SAU|Supervision-as-usual
126483|NCT01586676|Behavioral|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
126484|NCT01586689|Behavioral|Oxford House|community-based recovery home for participants recovering from substance dependency
126485|NCT01586689|Behavioral|Safe Haven|professionally-staffed treatment facility
125473|NCT00080938|Drug|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
125474|NCT01587287|Device|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
125475|NCT01587313|Drug|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
125476|NCT01587326|Drug|Escitalopram|escitalopram 10 mg/d to 20 mg/d
125477|NCT01587339|Drug|retigabine/ezogabine|oral - all doses
125478|NCT01587339|Drug|lacosamide|oral - all doses
125479|NCT01587339|Drug|zonisamide|oral - all doses
125480|NCT01587339|Drug|pregabalin|oral - all doses
125481|NCT01587339|Drug|eslicarbazepine|oral - all doses
125482|NCT01587352|Other|Laboratory Biomarker Analysis|Correlative studies
125483|NCT01589822|Biological|EVICEL Fibrin Sealant|Intraoperative
125484|NCT01589835|Behavioral|Lifestyle changes|Green prescription with support from facilitator
125485|NCT01589861|Drug|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
125746|NCT01590251|Other|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
125747|NCT01590251|Behavioral|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
125748|NCT01590264|Device|Bimodal rTMS|High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.
DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000
TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000
125749|NCT01590277|Drug|Ethanol|Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil
active ethanol + placebo iomazenil
active ethanol + active iomazenil
placebo ethanol + active iomazenil
125046|NCT01534780|Device|Securestrap|fixation of mesh with Securestrap
125047|NCT01534780|Device|Glubran|fixation of mesh with Glubran
125048|NCT01537042|Drug|Rotigotine|Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.
Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal.
125049|NCT01537042|Drug|Placebo|Transdermal patch; Patches matching to active treatment patches in size and appearance.
Up to 3 weeks of Titration,
2 weeks of Maintenance,
Up to 4 days of Taper Period.
125050|NCT01537055|Drug|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
125051|NCT01537055|Drug|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
125052|NCT01537068|Drug|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
125053|NCT01537068|Drug|Placebo|Matching placebo pills
125054|NCT00001384|Drug|G-CSF|
125055|NCT00076934|Drug|RG2077 (CTLA4-IgG4m)|RG2077
125056|NCT01537081|Drug|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
125057|NCT01537081|Drug|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
125058|NCT01537081|Drug|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
125059|NCT01537094|Dietary Supplement|Placebo|
125060|NCT01537094|Dietary Supplement|Vitamin C 250 mg once daily|
125061|NCT01537094|Dietary Supplement|Vitamin C 1,000 mg once daily|
125062|NCT01537107|Drug|vismodegib|Given PO
125063|NCT01537107|Drug|sirolimus|Given PO
125809|NCT01587950|Drug|Placebo|Sterile Water
125810|NCT00001499|Drug|cisplatin|
125811|NCT00080990|Drug|fluorouracil|Given IV
125812|NCT01587963|Drug|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
125813|NCT01587963|Other|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
125814|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 1-12
125815|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 13-24
125816|NCT01587989|Drug|placebo|methotrexate placebo orally weekly, Weeks 13-24
125817|NCT01587989|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
125818|NCT01588002|Drug|danoprevir|multiple oral doses
125819|NCT01588002|Drug|efavirenz|multiple oral doses
125820|NCT01588002|Drug|ritonavir|multiple oral doses
125821|NCT01588015|Biological|tetanus-CMV fusion peptide vaccine|Given SC
125822|NCT00080990|Drug|oxaliplatin|Given IV
125823|NCT01588015|Other|laboratory biomarker analysis|Correlative studies
125824|NCT01588028|Drug|CH5424802|Oral capsules taken twice daily
125825|NCT01588080|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
125826|NCT01590758|Drug|Topical pexiganan cream 0.8%|14 days of treatment
125827|NCT01590758|Drug|Topical placebo cream|14 days of treatment
126068|NCT01588457|Drug|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
126069|NCT00081003|Other|laboratory biomarker analysis|
126486|NCT01586689|Behavioral|Usual aftercare|control group - participants may or may not seek treatment on their own
125592|NCT01582659|Other|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
125593|NCT01582672|Drug|Standard Treatment|Standard treatment for Renal Cell Carcinoma
125594|NCT00080756|Other|laboratory biomarker analysis|Correlative studies
125595|NCT01582672|Biological|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
125596|NCT01582685|Behavioral|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
125597|NCT01582698|Biological|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
125598|NCT01582711|Behavioral|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
125599|NCT01582711|Behavioral|SMS reminders|Short Message Service (SMS) text reminders
125600|NCT01582711|Drug|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
125601|NCT01582724|Procedure|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
125602|NCT01582737|Drug|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
125603|NCT01582776|Drug|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
125604|NCT01582789|Device|enfilcon A|enfilcon A daily wear soft contact lens
125605|NCT00080782|Drug|Celecoxib|Oral celecoxib twice daily in the absence of disease progression.
125606|NCT01582789|Device|senofilcon A|senofilcon A daily wear soft contact lens
125607|NCT01582815|Drug|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
125608|NCT01585051|Drug|25(OH) vitamin D|300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
125609|NCT01585051|Drug|0.9 % NaCl|1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
125750|NCT01590277|Drug|Iomazenil|Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil
active ethanol + placebo iomazenil
active ethanol + active iomazenil
placebo ethanol + active iomazenil
125751|NCT00081159|Drug|Goserelin acetate|
125752|NCT01590290|Other|financial compensation|financial monetary reimbursement
125753|NCT01590303|Drug|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
125754|NCT01590303|Drug|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
125755|NCT01590316|Device|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
125756|NCT01590329|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
125757|NCT01590342|Drug|Diclofenac|Diclofenac 75 mg, two doses
125758|NCT01590342|Drug|Placebo|Placebo, two doses
125759|NCT01583023|Other|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
125760|NCT01583023|Device|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
125761|NCT01583036|Drug|Digoxin Alone|Single administration of digoxin 0.25mg
125762|NCT01583036|Drug|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
126025|NCT01590615|Drug|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
126026|NCT01583400|Other|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
126027|NCT01583413|Procedure|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
124158|NCT01540448|Procedure|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
124159|NCT01540448|Procedure|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
124160|NCT01540461|Drug|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
124161|NCT01540474|Biological|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
124162|NCT01540474|Biological|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
124163|NCT01540474|Biological|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
124164|NCT01540487|Drug|linagliptin/metformin(high dose)|patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
124165|NCT00077155|Drug|cilengitide|
124166|NCT01540487|Drug|Linagliptin/metformin(low dose)|patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
124167|NCT01540500|Drug|Tasimelteon|5.66 mg dose on Day 1 and Day 8
124168|NCT01540500|Drug|Fluvoxamine|50 mg Dose on Days 2-8
124169|NCT01540513|Drug|NM404|injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging
Other Names:
PET imaging with I-124 NM404
124170|NCT01540513|Drug|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
124171|NCT01542814|Device|2D FFDM|Standard of care screening mammogram.
124172|NCT01542827|Other|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
126070|NCT01588457|Drug|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
126071|NCT01588470|Drug|pioglitazone|45 mg per day for 6 months
126072|NCT01588496|Biological|Evolocumab|Administered by subcutaneous injection
126073|NCT01588496|Drug|Placebo|Administered by subcutaneous injection
126074|NCT01588509|Drug|AMG 785 Dose 1|3 doses
126075|NCT01588509|Drug|AMG 785 Dose 2|3 doses
126076|NCT01588522|Drug|compound 31543 Calcitriol|topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
126077|NCT01590810|Drug|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
126078|NCT01590810|Drug|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
126079|NCT01590810|Drug|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
126080|NCT01590810|Drug|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
126081|NCT01590810|Drug|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
126082|NCT01590823|Drug|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
126083|NCT01590836|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
126084|NCT00081224|Drug|celecoxib|
126085|NCT01590836|Drug|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
126086|NCT01590849|Drug|Contraceptives, Oral, Combined (Yaz®)|After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:
Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).
Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).
Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use.
126087|NCT01590875|Drug|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
125610|NCT01585064|Other|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of < 2.4.
125611|NCT00080860|Procedure|radionuclide imaging|
125889|NCT01585597|Device|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
125890|NCT01585610|Behavioral|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
125891|NCT01585610|Behavioral|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
125892|NCT00080886|Drug|cytarabine|
125893|NCT01585623|Drug|SAR302503|Pharmaceutical form:capsule
Route of administration: oral
125894|NCT01585623|Drug|omeprazol|Pharmaceutical form:capsule
Route of administration: oral
125895|NCT01585623|Drug|metoprolol|Pharmaceutical form:tablet
Route of administration: oral
125896|NCT01588080|Device|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
125897|NCT01588093|Drug|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
125898|NCT01588093|Drug|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
125899|NCT01588132|Drug|Anfibatide|To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.
To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
125900|NCT01588145|Drug|HM61713 (BI 1482694)|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
125901|NCT01588158|Drug|Acetaminophen|325 mg
126028|NCT01583426|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
126029|NCT01583426|Drug|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
126030|NCT00080795|Procedure|conventional surgery|
126031|NCT01583439|Drug|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
126032|NCT01583452|Other|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
126033|NCT01583465|Device|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
126034|NCT01583465|Device|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
126035|NCT01583478|Biological|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
126036|NCT01583491|Procedure|autologous platlet rich fibrin|one dose immediate after surgery
126037|NCT01583491|Procedure|one side in control group|control group insert any things after surgery
126038|NCT01583504|Procedure|Ultrasound guided injection of steroid and local anaesthetic|2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
126356|NCT01581528|Other|cell culture procedure|
126357|NCT01581528|Other|flow cytometry|
126358|NCT00080639|Procedure|study of high risk factors|
126359|NCT01581528|Other|laboratory biomarker analysis|
126360|NCT01581528|Other|metabolic assessment|
124173|NCT01542827|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
124477|NCT01536145|Drug|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
124478|NCT01536158|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
124479|NCT01536158|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
124480|NCT01536171|Other|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
124481|NCT01536184|Behavioral|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
124482|NCT01536197|Procedure|Gastric bypass|Roux-en-Y gastric bypass
124483|NCT01536197|Procedure|Gastric banding|Laparoscopic adjustable gastric banding
124484|NCT00076752|Drug|Diphenhydramine|Conditioning and transplant regimen 25-50 mg orally or intravenously.
124485|NCT01536210|Drug|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
124486|NCT01536210|Drug|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
124487|NCT01538446|Drug|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
124488|NCT01538446|Drug|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
124489|NCT01538446|Device|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
124490|NCT01538459|Drug|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
124491|NCT01538459|Drug|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
124492|NCT01538472|Drug|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
126409|NCT01589107|Behavioral|video decision aid|video decision aid
126410|NCT00081042|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
126411|NCT01589120|Behavioral|Video decision aid|Video decision aid of the goals of care
126412|NCT01589146|Drug|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
126413|NCT01589159|Drug|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
126414|NCT01589159|Drug|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
126415|NCT01589185|Drug|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
126416|NCT01589185|Drug|Placebo|Placebo administered as a single intravenous infusion
126417|NCT01589211|Behavioral|Brief advice|Brief advice of about 10 min accompanied by self-help material
126418|NCT01589211|Behavioral|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
126419|NCT01589211|Behavioral|Standard cessation course|Cessation course over 6 dates. Group setting.
126420|NCT01589237|Drug|LCQ908|
126421|NCT00081055|Biological|autologous expanded mesenchymal stem cells OTI-010|
126422|NCT01589263|Drug|onaBoNT-A + placebo|200 U prostate injection once
Arms: ARM 1: onaBoNT-A + placebo
126423|NCT01589263|Drug|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
126424|NCT01589289|Device|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
126425|NCT01581632|Device|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
126426|NCT01581645|Device|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
126427|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
126428|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
125902|NCT01588158|Drug|Vicodin|Vicodin 5/325 mg
125903|NCT00080990|Drug|leucovorin calcium|Given IV
125904|NCT01588171|Drug|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
126149|NCT01588561|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70 kg or 1.5 mg/70 kg or 2.0mg/70 kg;) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered IV nicotine over 10 seconds without any adverse reactions. The investigators concur with the IRB recommendation that the lower doses (1.0mg/70 kg and 1.5 mg/70 kg) should be administered first and the higher dose (2.0mg/70 kg ) will be administered last.
126150|NCT01588574|Biological|MT10109|Botulinum toxin type A
126151|NCT01588574|Biological|BOTOX(Registered trade mark)|Botulinum toxin type A
126152|NCT01588587|Drug|Sitagliptin|The dosage, frequency and duration for each sitagliptin are variant.
126153|NCT01588587|Drug|Alogliptin|The dosage, frequency and duration for each alogliptin are variant.
126154|NCT01588587|Drug|Vildagliptin|The dosage, frequency and duration for each vildagliptin are variant.
126155|NCT01588600|Other|Dietary Fiber|Fiber added to breakfast
126156|NCT01588626|Drug|AZD6140|tablet
126157|NCT01588639|Drug|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
126158|NCT01588639|Drug|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
126159|NCT00081003|Procedure|breast duct lavage|
126160|NCT01588639|Drug|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
126161|NCT01588678|Drug|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
126162|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
126163|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
126164|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
126361|NCT01581541|Drug|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
126362|NCT01581580|Procedure|Deep Brain Stimulation|
126363|NCT01581593|Biological|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Duration - 12 months
126364|NCT01581619|Radiation|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
126365|NCT01584024|Device|Resin infiltration|Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.
126366|NCT01584024|Device|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
126367|NCT01584050|Dietary Supplement|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
126368|NCT01584050|Dietary Supplement|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
126369|NCT01584050|Dietary Supplement|Placebo|frequency: once daily, duration: 12 weeks
126370|NCT01584063|Behavioral|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
126371|NCT01584076|Drug|Donepezil|Oral Donepezil Daily
Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.
Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds.
126372|NCT01584076|Other|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
126373|NCT01584102|Behavioral|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
126374|NCT00080847|Biological|oblimersen sodium|Given IV
126375|NCT01584102|Behavioral|group fitness classes only|15 weeks biweekly group fitness
125486|NCT01589913|Behavioral|ICD-Forum|The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:
Introduction to participants and online system
Knowledge regarding ICDs
Strategies for behavior change
Psychological models for anxiety and depression
Strategies to cope with avoidance, anxiety and depression
Resume, evaluation, resolution of open questions, goal setting, good bye
124493|NCT01538472|Drug|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
124494|NCT01538472|Drug|Rituxan|250 mg/m2 by vein on Day -21 and on Day -14.
1000 mg/m2 by vein on Days +1 and +8.
124495|NCT01538472|Drug|BCNU|300 mg/m2 by vein on Day -6.
124774|NCT01541475|Drug|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
124775|NCT01541488|Drug|BI 1021958|tablet
124776|NCT00077220|Procedure|adjuvant therapy|
124777|NCT01541488|Drug|BI 1021958|drinking solution / tablet
124778|NCT01541488|Drug|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
124779|NCT01541501|Device|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
124780|NCT01541527|Biological|blood test|One blood test entering in the usual follow-up of the patient
124781|NCT01541540|Behavioral|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
124782|NCT01534273|Drug|Placebo|Administered orally.
124783|NCT01534286|Drug|Theramine|Theramine 2 capsules 3 times per day
124784|NCT01534286|Drug|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
124785|NCT01534299|Device|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
124786|NCT01534312|Drug|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
124787|NCT01534312|Drug|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
126429|NCT00080665|Drug|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
126430|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
125538|NCT01584986|Biological|ACP injections|Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
125539|NCT01584999|Biological|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
125540|NCT01585012|Device|Cervical cap (Focus Touch™ Conception System)|Cervical cap
125541|NCT01585025|Drug|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
125542|NCT01585038|Drug|Efavirenz|600mg orally every evening
125543|NCT01585038|Drug|Rilpivirine|25mg orally once daily
125544|NCT01587352|Drug|Vorinostat|Given PO
125545|NCT00080938|Radiation|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
125546|NCT01587365|Biological|BMS-962476|
125547|NCT01587365|Biological|Placebo matching with BMS-962476|
125548|NCT01587378|Drug|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
125549|NCT01587378|Drug|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
125550|NCT01587391|Drug|Placebo to BI 163538 XX|1 single dose per subject as oral solution
125551|NCT01587391|Drug|BI 163538 XX|1 single dose per subject as oral solution
125552|NCT01587404|Device|THERMOCOOL® SMARTTOUCH™ Catheter|Variable contact force as measured at the catheter tip within the left atrium
125553|NCT01587417|Drug|Placebo to BI 187004 CL|1 single dose per subject as oral solution
125554|NCT01587417|Drug|BI 187004 CL|1 single dose per subject as oral solution
125555|NCT01587430|Drug|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
125556|NCT00080951|Drug|fluorouracil|
126165|NCT01588704|Drug|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
126166|NCT01588717|Drug|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
126167|NCT01588730|Device|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
126487|NCT01586702|Behavioral|Patient centered structured support program|Behavioural: Structured support program
Program with up to 8 outpatient appointments focusing on:
Measurement of risk factors
Assessment of medication intake
Monitoring of antithrombotic therapy
Joint agreement of an individual target plan
Target values for risk factors:
Blood pressure < 140/85 mmHg (<130/80 in diabetics), normal circadian profile
HbA1c <7.5%
Nicotine abstinence
LDL < 100mg/dl (< 70mg/dl in high risk patients)
Physical activity ≥ 30min >2 x / week
Targets for pharmaceutical treatment:
Platelet inhibitors for strokes / TIA of arterial etiology
Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis
Cumarins (INR 2-3) or new oral anticoagulants in AF patients
Statin treatment in patients with LDL >100mg/dl
Intervention strategies:
• According to Motivational Interviewing
126488|NCT01589289|Device|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
126489|NCT01589289|Device|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|TB POC Nucleic Acid Amplification Test: "microPCR handheld device" (Molbio Diagnostics PVT ltd, India)
126490|NCT01589289|Device|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
126491|NCT01589289|Device|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
126492|NCT01589302|Drug|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
126493|NCT01589302|Other|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
126494|NCT01589302|Other|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
126495|NCT00081055|Drug|busulfan|
126496|NCT01589315|Device|focal ECT|FEAST, ECT, unidirectional stimulation
126497|NCT01589328|Other|Early Palliative care integrated with usual oncologic care|Drug: The interventions consisted of the following:
(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education
126498|NCT01589341|Other|laboratory biomarker analysis|Correlative studies
125487|NCT01589926|Procedure|Bi-level positive airway pressure|BLPAP initiated for at least 16 hours per day for a minimum of 48hrs.
125488|NCT01589926|Procedure|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
125489|NCT01589952|Drug|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
125490|NCT01589965|Behavioral|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
125491|NCT01589978|Device|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
125492|NCT01589978|Drug|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
125493|NCT00081094|Procedure|11Carbon-Acetate-PET|
125494|NCT01589978|Drug|P2Y12 antagonist|Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.
Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)
Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)
Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses >100 mg may reduce ticagrelor effectiveness and should be avoided.
Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)
125495|NCT01589991|Drug|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
125496|NCT01590017|Drug|cisplatin|
125497|NCT01590017|Radiation|external beam radiation therapy|
125498|NCT01590030|Procedure|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
125499|NCT01590043|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
125500|NCT01590056|Other|Electrophysiological recording|During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:
listening to nonverbal affect bursts corresponding to emotions
applying a simple go-no-go auditory test
125501|NCT01590069|Drug|Aerosol IL-2|Phase I starting dose: 1 mg in 3 mL volume of nebulized solution daily for 21 days of a 28 day cycle.
Phase II starting dose: Maximum tolerated dose from Phase I.
124788|NCT01534325|Device|SD|The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.
The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.
The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.
The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements.
124789|NCT00076531|Drug|Leuprolide Acetate for Injectable Suspension 22.5 mg|
125064|NCT01537107|Procedure|positron emission tomography|Correlative studies
125065|NCT01537107|Procedure|computed tomography|Correlative studies
125066|NCT00076947|Biological|EnvPro|
125067|NCT01537107|Other|pharmacological study|Correlative studies
125068|NCT01537107|Other|laboratory biomarker analysis|Correlative studies
125069|NCT01537107|Radiation|fludeoxyglucose F 18|Correlative studies
125070|NCT01537120|Drug|Vildagliptin|
125071|NCT01537120|Drug|Placebo|
125072|NCT01537133|Drug|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
125073|NCT01537133|Drug|Placebo|Dry Powder Inhaler: Placebo
125074|NCT01537146|Drug|Ropivacaine|Bolus infusion via catheter/6H for 24H
125075|NCT01539382|Procedure|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow >2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
125076|NCT01539395|Other|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
125077|NCT01539408|Drug|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
125078|NCT01539408|Procedure|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
125557|NCT01587430|Drug|standard dose ARA-C|
125558|NCT01587482|Procedure|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
125559|NCT01587495|Drug|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
125828|NCT01590758|Other|Standard wound care|14 days of treatment
125829|NCT00081172|Radiation|lutetium Lu 177 monoclonal antibody J591|
125830|NCT01590771|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
125831|NCT01590771|Drug|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
125832|NCT01590771|Drug|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
125833|NCT01590771|Drug|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
125834|NCT01590771|Drug|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
125835|NCT01590797|Drug|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
125836|NCT01590797|Drug|Placebo|Matching placebo once daily for 24 weeks
125837|NCT01590797|Biological|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
125838|NCT01590797|Drug|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
125839|NCT01590810|Drug|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
125840|NCT00081211|Biological|PV701|Given intratumorally
125841|NCT01590810|Drug|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
125842|NCT01590810|Drug|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
125843|NCT01590810|Drug|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
126499|NCT01589354|Procedure|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
126500|NCT01589354|Procedure|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
126501|NCT01589354|Device|Ultrasound guided technique|The block will be performed under U/S guidance
126502|NCT01589354|Drug|Ropivacaine|20ml of 0.375% Ropivacaine
125612|NCT01585064|Other|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
125613|NCT01585064|Other|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
125614|NCT01585077|Biological|P. vivax infected mosquito bites|All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
125615|NCT01585090|Other|doing strengthening exercises of pelvic floor muscles|
125616|NCT01585103|Device|Cytosponge - Brushing|Patients with eosinophilic esophagitis will be enrolled. Undergoing clinically indicated endoscopy and biopsy either for initial diagnosis or for monitoring the activity of their disease.
Two hours prior to endoscopy in the patients will be asked to swallow the Cytosponge. Briefly, the capsule and bunched up string are swallowed with water.
The string is held without any tension to allow the capsule to move into the stomach. The patient holds onto the string for five minutes after ingestion to allow the capsule to dissolve in the proximal stomach, where a spherical mesh of 3 cm diameter is released.
The back of the throat is then sprayed with 1% lidocaine and the expanded mesh withdrawn by pulling on the string with the patient's head in an extended position.
Following this, the clinically indicated endoscopy will be performed. Prior to biopsies we will do a brushing of the esophagus.
125617|NCT01585129|Drug|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
125618|NCT01585129|Drug|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
125619|NCT01585142|Other|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
125620|NCT01585155|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
125621|NCT01585168|Drug|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
125763|NCT01583062|Drug|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
125764|NCT01583062|Drug|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
125765|NCT00001498|Drug|5-fluorouracil|
125766|NCT00080795|Biological|filgrastim|
125767|NCT01583075|Procedure|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
125768|NCT01583075|Procedure|single ring pulmonary vein ablation|single ring pulmonary vein ablation
125769|NCT01583088|Device|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
125770|NCT01583088|Device|sham phrenic nerve stimulation|sham phenic nerve stimulation
125771|NCT01583101|Other|Highlight set 1|We will highlight two prompts.
125772|NCT01583101|Other|Highlight Set 2|We will highlight 2 different prompts
125773|NCT01583114|Drug|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
125774|NCT01583114|Drug|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
125775|NCT01583127|Behavioral|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
125776|NCT01583140|Behavioral|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
125777|NCT00080795|Drug|cisplatin|
125778|NCT01583140|Behavioral|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
125779|NCT01585389|Other|immunohistochemistry staining method|
125780|NCT01585389|Other|laboratory biomarker analysis|
125781|NCT01585402|Drug|Etidronate|20mg/kg oral 14days on / 10 weeks off cyclical drug schedule
125079|NCT01539421|Behavioral|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
125080|NCT01539434|Behavioral|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
125081|NCT01539434|Behavioral|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
125082|NCT01539447|Drug|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
125083|NCT01539447|Drug|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
124174|NCT01542866|Device|Health Management Tool (HMT)|utilization of software specific for measuring vision impairment on a mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
124175|NCT01542879|Device|WB-DW-MR scan|
124176|NCT00077285|Drug|vincristine sulfate|
124177|NCT01542892|Other|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
124178|NCT01542892|Dietary Supplement|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
124179|NCT01542905|Dietary Supplement|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
124180|NCT01542905|Other|Placebo|Placebo Capsule (1g/day) for 8 Weeks
124181|NCT01542918|Drug|Lenalidomide|Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.
Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)
Route of administration: Oral
124182|NCT01542918|Drug|Rituximab|Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial
Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)
Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)
124183|NCT01542931|Drug|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
125844|NCT01590810|Drug|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
125845|NCT01590810|Drug|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
125846|NCT01590810|Drug|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
125847|NCT01590810|Drug|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
125848|NCT01590810|Drug|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
125849|NCT01590810|Drug|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
125850|NCT01590810|Drug|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
125851|NCT00081224|Drug|capecitabine|
126088|NCT01590888|Drug|PBT2|250mg capsules administered orally once per day for 26 weeks
126089|NCT01590888|Drug|PBT2|100mg capsules administered orally once per day for 26 weeks
126090|NCT01590888|Drug|Placebo|Matching capsules administered orally once per day for 26 weeks
126091|NCT01590901|Drug|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
126092|NCT01590914|Procedure|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
126093|NCT01590914|Procedure|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
126094|NCT01590940|Procedure|Open inguinal hernia repair with mesh|
126095|NCT00081224|Radiation|radiation therapy|
126096|NCT01590966|Drug|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
126097|NCT00080795|Procedure|neoadjuvant therapy|
126098|NCT01583517|Procedure|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
126099|NCT01583517|Procedure|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
126100|NCT01583517|Procedure|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
125622|NCT00080860|Procedure|sentinel lymph node biopsy|
125623|NCT01585168|Drug|Placebo|Identically appearing sugar pill, given orally
125624|NCT01585181|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
125625|NCT01585181|Biological|Placebo|Approx 2 grams of lactose reconstituted in water
125626|NCT01587586|Biological|Pegasys|48 doses, solution, 48 weeks
125627|NCT01587586|Biological|P1101, 48 doses|48 doses, solution, 48 weeks
125628|NCT01587586|Biological|P1101, 24 doses|24 doses, solution, 48 weeks
125905|NCT01588171|Drug|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
125906|NCT01588184|Drug|bevacizumab [Avastin]|7.5 or 15 mg/kg intravenously every 21 days, or 5 or 10 mg/kg intravenously every 14 days until disease progression or unacceptable toxicity
125907|NCT01588197|Behavioral|MRI Feedback|Real Time fMRI Feedback
125908|NCT01588197|Behavioral|MRI Feedback|Real Time fMRI Feedback
125909|NCT01588210|Other|Sealant application|A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.
All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.
125910|NCT01588210|Other|sealant application|A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.
All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.
125911|NCT01590628|Drug|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
125912|NCT00081159|Procedure|orchiectomy|
125913|NCT01590641|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
125914|NCT01590641|Drug|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
125782|NCT01585402|Procedure|MRI|Visit on day 0 and visit at 36 month
125783|NCT00080873|Other|Placebo|
125784|NCT01585402|Procedure|CT Scan|Baseline visit, and visit on day 0, visit at 12, 24 , 36 months
126039|NCT01583504|Procedure|High volume saline injection|After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
126040|NCT01583504|Behavioral|exercise programme|a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
126041|NCT01585818|Other|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
126042|NCT01585818|Other|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
126043|NCT01585831|Drug|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
126044|NCT01585831|Drug|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
126045|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.
126046|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
126047|NCT01585870|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).
If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort.
126048|NCT01585870|Drug|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
124184|NCT01542944|Drug|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
124185|NCT01542957|Behavioral|Combined Cognitive Behavioral and Dilemma-Focused Therapy|7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.
124186|NCT01542957|Behavioral|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
124187|NCT00077285|Procedure|conventional surgery|
124188|NCT01542970|Dietary Supplement|Placebo|Olive oil
124189|NCT01542970|Dietary Supplement|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
124190|NCT01542970|Dietary Supplement|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
124191|NCT01542970|Dietary Supplement|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
124496|NCT00077051|Drug|cytochlor|
124497|NCT01538472|Drug|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
124498|NCT01538472|Drug|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
124499|NCT01538472|Drug|Melphalan|140 mg/m2 by vein on Day -1.
124500|NCT01538472|Procedure|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
124501|NCT01538472|Drug|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
124502|NCT01538485|Drug|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
124503|NCT01538511|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
124504|NCT01538511|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
124505|NCT01538511|Drug|No treatment given|Control group of non-treated healthy volunteers
126101|NCT01583530|Biological|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
126102|NCT01583530|Biological|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
126103|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
126104|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
126105|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
126106|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
126107|NCT01583543|Drug|Olaparib|400mg PO BID Continuous
126108|NCT00080808|Drug|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
126109|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
126431|NCT01581684|Drug|Placebo|Solution for oral administration
126432|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
126433|NCT01581684|Drug|BI 411034|High dose solution for oral administration
126434|NCT01581697|Dietary Supplement|Oat bran|
126435|NCT01581710|Drug|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
126436|NCT01581710|Drug|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
126437|NCT01581723|Device|Monopolar diathermy|monopolar diathermy
126438|NCT01581723|Device|Bipolar diathermy|bipolar diathermy
126439|NCT01581736|Drug|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
126440|NCT00080665|Drug|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
126441|NCT01581736|Other|Exercise|Single episode of exercise riding a stationary bike.
126442|NCT01581749|Radiation|"TrueBeam" stereotactic body radiosurgery|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
125915|NCT01590654|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
125916|NCT01590654|Drug|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
125917|NCT01590667|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
125918|NCT01590667|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
125919|NCT01590680|Radiation|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
126168|NCT01572181|Drug|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|IV fludarabine (30 mg/m²/day for 5 days)
IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)
Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days).
126169|NCT01572194|Biological|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
126170|NCT01572207|Behavioral|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
126171|NCT01572207|Behavioral|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
126172|NCT01572220|Other|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
126173|NCT01572233|Behavioral|Personalized Physical Activity and Psycho-Education (PPAPE) Program|Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection
The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment.
126174|NCT01572246|Other|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
126175|NCT01572259|Drug|Growth Hormone|
126176|NCT01572259|Other|interruption of the traitment with growth hormone|
126177|NCT01572285|Procedure|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
126178|NCT00001474|Drug|Interleukin-2|
126179|NCT00079742|Drug|Nutropin AQ [somatropin (DNA origin) injection]|
126049|NCT01585883|Behavioral|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
126050|NCT01585896|Other|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, & Steketee, 2007).
126376|NCT01584115|Biological|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
126377|NCT01584115|Biological|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
126378|NCT01584154|Procedure|cryoablation|cryoablation with an 8mm-tip catheter
126379|NCT01584154|Procedure|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
126380|NCT01584167|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
126381|NCT01584167|Device|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
126382|NCT01584180|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
126383|NCT01584180|Device|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
126384|NCT01584193|Procedure|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
126385|NCT00080847|Biological|rituximab|Given IV
126386|NCT01584193|Procedure|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
126387|NCT01586494|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
126388|NCT01586494|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
126389|NCT01586507|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
126390|NCT00080925|Biological|therapeutic allogeneic lymphocytes|
124506|NCT01538537|Drug|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
124507|NCT00077051|Drug|tetrahydrouridine|
124508|NCT01538550|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
124509|NCT01538550|Procedure|iFOBT|Biennial screening with iFOBT
124510|NCT01540877|Procedure|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
124511|NCT01540877|Procedure|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
124512|NCT01540877|Procedure|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
124513|NCT01540877|Procedure|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
124514|NCT01540903|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
124515|NCT01540903|Biological|Saline|Saline
124516|NCT00001396|Device|Paragon Pacemaker|
124517|NCT00077194|Drug|romidepsin|
124790|NCT01534325|Device|Control|The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.
The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance.
124791|NCT01534325|Device|SD|The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.
The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.
The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.
The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements.
124792|NCT01534338|Behavioral|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
126443|NCT01581762|Procedure|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
126444|NCT01581775|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
126445|NCT01581788|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
126446|NCT01581801|Procedure|Gastric Bypass|Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.
An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection.
126447|NCT01581801|Procedure|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
126448|NCT01581814|Drug|Metformin|500 mg of Metformin per 3/die
126449|NCT01584206|Drug|Ezetimibe|10mg ezetimibe/day, at least 4 months
126450|NCT01584232|Drug|LY2189265|
126451|NCT01584232|Drug|Insulin glargine|
126452|NCT01584232|Drug|Sulfonylureas (SU)|
126453|NCT01584232|Drug|Biguanide (BG)|
125560|NCT01587508|Drug|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
125561|NCT01587508|Drug|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
125562|NCT01587508|Drug|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
125563|NCT01587534|Drug|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
125564|NCT01587560|Device|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
125565|NCT01587560|Device|TITAN, Ascension Orthopedics, Inc.|
125566|NCT01587573|Other|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
125567|NCT00080951|Drug|irinotecan hydrochloride|
126180|NCT01572285|Procedure|Sham|Sham procedure using a non-penetrating needle
126181|NCT01572298|Device|allograft alone (MinerOss allograft plus Alloderm GBR membrane)|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
126182|NCT01572298|Device|allograft combined wtih autograft (combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane)|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
126183|NCT01572311|Behavioral|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
126503|NCT01589354|Drug|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
126504|NCT01589367|Drug|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
126505|NCT01589367|Drug|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
126506|NCT00081055|Drug|cyclophosphamide|
126507|NCT01581814|Drug|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
126508|NCT01581814|Drug|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
126509|NCT00080678|Drug|Docetaxel|
126510|NCT01581840|Drug|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
126511|NCT01581840|Drug|Panitumumab|3 or 6 mg/kg (according to dose level)
126512|NCT01581853|Drug|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
126513|NCT01581866|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
126514|NCT01581879|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
126515|NCT01581892|Procedure|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
126391|NCT01586507|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
126392|NCT01586533|Drug|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine [5-ASA], 1.0g N-acetylcysteine [NAC]; 60ml)
126393|NCT01586533|Drug|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine [5-ASA], 60ml)
126394|NCT01586546|Behavioral|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
125502|NCT01582438|Drug|Access program|The recommended dose is 20 mg TID for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
125503|NCT01582451|Drug|LY2605541|Administered once daily at bedtime by SQ injection
125504|NCT01582451|Drug|Insulin glargine|Administered once daily at bedtime by SQ injection
125505|NCT01582477|Drug|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
125506|NCT01582477|Drug|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
125507|NCT01582490|Drug|Instillation - EXPAREL|Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
125508|NCT01582490|Drug|Infiltration - EXPAREL|IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
125509|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
125510|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
125511|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
125512|NCT00080756|Other|active surveillance|Undergo continued surveillance
125513|NCT01582503|Drug|placebo|Subcutaneous repeating dose
125514|NCT01582516|Biological|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
124793|NCT01534338|Behavioral|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
124794|NCT01534351|Drug|Finasteride|Finasteride 5 mg oral tablet taken once daily.
124795|NCT01534351|Drug|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
124796|NCT01534351|Drug|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
124797|NCT01534351|Drug|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
124798|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
124799|NCT01536574|Drug|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
124800|NCT01536587|Drug|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
124801|NCT01536600|Drug|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
124802|NCT01536613|Drug|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
124803|NCT01536626|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
124804|NCT01536639|Drug|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
125084|NCT00077116|Drug|busulfan|
125085|NCT01539460|Procedure|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
125086|NCT01539473|Drug|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
125087|NCT01539473|Drug|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
125088|NCT01539512|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
125089|NCT01539512|Drug|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m^2, and 500 mg/m^2 thereafter
125568|NCT01590069|Procedure|Symptom Assessment|Symptoms (self report), oximetry, and pulmonary function assessed prior to each nebulized dose of IL-2 using remote spirometry and pulse oximetry.
125569|NCT01590082|Drug|Doxycycline|Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
125570|NCT00081107|Drug|epothilone D|
125571|NCT01590082|Drug|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
125572|NCT01590082|Drug|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
125573|NCT01590095|Behavioral|Water quality|Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.
Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age.
125574|NCT01590095|Behavioral|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
125575|NCT01590095|Behavioral|Hand washing|Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.
Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces.
125852|NCT01590810|Drug|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
125853|NCT01590810|Drug|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
125854|NCT01590810|Drug|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
125855|NCT01583153|Other|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
125856|NCT01583153|Other|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
125857|NCT01583166|Drug|Bupivicaine + epinephrine|10ml 0.5% bupivicaine plus 1:200,000 epinephrine
126516|NCT01581905|Procedure|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
126517|NCT01581905|Procedure|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
126518|NCT01581918|Drug|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
126519|NCT01581931|Drug|Linagliptin/metformin|FDC
126520|NCT00080678|Drug|Imatinib Mesylate|
126521|NCT01581931|Drug|Metformin|single tablet Metformin
126522|NCT01581931|Drug|Linagliptin|single tablet Linagliptin
126523|NCT01581944|Drug|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
126524|NCT01581944|Drug|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
125349|NCT01582282|Dietary Supplement|placebo|fiber-free placebo
125350|NCT01584505|Drug|CHF1535 daily dose|CHF1535 daily dose for 14 days
125351|NCT01584518|Drug|Furosemide|Based on clinical standard per clinician
125352|NCT01584531|Drug|rigosertib|Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.
Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.
The patient will fill a diary indicating the day and time of drug intake.
125353|NCT01584544|Drug|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
125354|NCT01584544|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
125355|NCT01584544|Drug|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
125356|NCT01584544|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
125357|NCT01584544|Drug|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
125358|NCT01584557|Drug|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
125515|NCT01582542|Drug|Desmopressin|Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 M"G per day. The rate of improvement of night time urinary incontinence will be measured.
125516|NCT01582555|Drug|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
125517|NCT01582555|Drug|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
125518|NCT01582568|Drug|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
125519|NCT01582581|Behavioral|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
125520|NCT01582581|Behavioral|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
125785|NCT01585402|Procedure|ABI|At baseline and visit 1-7 every 6 months
125786|NCT01585402|Procedure|Treadmill|visit 1-7 every 6 months
125787|NCT01585402|Procedure|Dexa Scan|Visit1, 3, 5, 7 every 12 months
125788|NCT01585402|Procedure|Hand X-ray|Visit1, 3, 5, 7 every 12 months
125789|NCT01585415|Drug|Vemurafenib|Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
125790|NCT01585415|Biological|Young TIL|Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
125791|NCT01585415|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
125792|NCT01585415|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
125793|NCT01585415|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
125794|NCT00080886|Biological|rituximab|
125795|NCT01585428|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
125796|NCT01585428|Drug|Cycolphosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
125090|NCT01539512|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
125091|NCT01539525|Behavioral|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
125092|NCT01539525|Other|Resource brochure|Subjects given a brochure listing relevant recovery resources in the local area.
125093|NCT01539538|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
125094|NCT01539538|Drug|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
125095|NCT00077116|Drug|cyclophosphamide|
125096|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
125097|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
125098|NCT00077233|Drug|oxaliplatin|IV
125099|NCT01542021|Drug|androgen deprivation therapy|
125100|NCT01542034|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
125101|NCT01542034|Drug|Placebo|Phosphate buffered saline placebo for injection
125102|NCT01542047|Drug|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
125103|NCT01542047|Drug|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
125104|NCT01542060|Drug|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
124192|NCT00076752|Drug|cyclophosphamide|Priming regimen: 2000 mg/m^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
124193|NCT01535664|Other|Withdrawal of dalfampridine-ER 10mg|Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)
On drug Day-7 (visit 1) through Day 1 (visit 2)
Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)
On drug Day 15±2 days (visit 5)
124194|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
125858|NCT01583166|Drug|Sodium chloride + epinephrine|10ml 0.9% sodium chloride plus 1:200,000 epinephrine
125859|NCT01583179|Drug|Buprenorphine|added to nerve block, 0.3mg one time peripheral block use
125860|NCT01583192|Procedure|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
125861|NCT01583205|Behavioral|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
125862|NCT01583218|Drug|Betrixaban|Betrixaban 80 mg PO QD for 35 day + 7 days.
Enoxaparin Placebo: Once daily, 6-14 days
125863|NCT01583218|Drug|Enoxaparin|Enoxaparin 40 mg SC QD for 10 ± 4 days.
Betrixaban Placebo: once daily, 35 days
125864|NCT00080795|Drug|doxorubicin hydrochloride|
125865|NCT01583231|Other|Prewash|The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
125866|NCT01583244|Drug|No Intervention (subjects were previously treated with Orencia®)|No Intervention
125867|NCT01583257|Behavioral|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
125868|NCT01583270|Dietary Supplement|Arabinoxylan|Porridge rich in arabinoxylan
125869|NCT01583270|Dietary Supplement|Rye kernel|Porridge made of rye kernels
125870|NCT01583270|Dietary Supplement|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
126110|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
126111|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
126112|NCT01583621|Dietary Supplement|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
126113|NCT01583634|Device|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
126114|NCT01583634|Device|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
126115|NCT01583647|Drug|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
126116|NCT01583647|Drug|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
125359|NCT00080847|Other|laboratory biomarker analysis|Correlative studies
125360|NCT01584557|Drug|placebo or sugar pill|sugar pill
125361|NCT01584570|Drug|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
125362|NCT01584596|Behavioral|Adapted Dietary Guidelines|This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).
The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist.
125363|NCT01584596|Behavioral|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
125364|NCT01584609|Device|Penumbra System with Separator 3D|The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
124435|NCT01540838|Drug|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
124436|NCT00077181|Other|laboratory biomarker analysis|Correlative studies
124437|NCT01540851|Behavioral|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
124438|NCT01540851|Other|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
124439|NCT01540864|Drug|HPP404|Administered orally once daily for 26 weeks
124440|NCT01540864|Drug|Placebo|Administered orally once daily for 26 weeks
124441|NCT01543698|Drug|LGX818|
124442|NCT01543698|Drug|MEK162|
124443|NCT01543698|Drug|LEE011|
124444|NCT01543724|Drug|Lithium|10mg/kg/day for 12 weeks
124445|NCT01543737|Device|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
125797|NCT01585428|Biological|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
125798|NCT01585428|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
125799|NCT01585441|Drug|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
125800|NCT01585441|Drug|Placebo|Capsule with no active ingredients to mimic finasteride
125801|NCT01585480|Behavioral|Weight Gain Prevention Intervention|Behavioral Approaches
Distribution of pedometers
Traffic light labeling in worksite cafeteria and vending machines
Informational & Persuasive Messages
Stair use prompts
Posters, pamphlets, table toppers
Website
Social Approaches
a. Identification and training of influential employees (Peer Helpers) to shape healthy norms
Environmental Changes
Traffic light labeling
1/2 portions at 1/2 price
Walking routes
Introduction of healthier foods
Rearrangement of foods in the cafeteria
Adjusting serving spoon size
125802|NCT01587911|Other|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
125803|NCT01587911|Other|MPI|Preload containing whole milk protein.
125804|NCT01587911|Other|CPI|Preload containing sodium caseinate.
126051|NCT00080886|Procedure|peripheral blood stem cell transplantation|
126052|NCT01585909|Procedure|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
126053|NCT01585922|Procedure|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
126054|NCT01585922|Procedure|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
126055|NCT01585935|Drug|SMOFLIPID|target dose: 3g/kg/d
126056|NCT01585935|Drug|INTRALIPID|target dose: 3g/kg/d
126057|NCT01588379|Other|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
126058|NCT00081003|Other|cytology specimen collection procedure|
126059|NCT01588392|Behavioral|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
124195|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
124196|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
124197|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
124198|NCT01535690|Other|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
124199|NCT01535716|Behavioral|hemodynamic optimization strategy driven by the ECOM|goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) & cardiac index (CI).
goals:
SVV < 11%
IC > 2,2 ml/min/m²
During the anesthesia
124200|NCT01535716|Behavioral|standard management strategy|goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index
Diuresis > 0,5ml/kg/h
Blood pressure , PAM > 65 mmHg
Pulse pressure variation
CVP 8 to 12 cmH20
Visual aspect of the heart
Overload signs During the anesthesia
124201|NCT01535742|Device|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
124202|NCT01535742|Device|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
124203|NCT00076752|Biological|Rituxan (rituximab)|Priming regimen: 375 mg/m^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m^2 intravenous infusion, day -7.
124204|NCT01535742|Device|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
124205|NCT01535742|Device|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
124206|NCT01535755|Device|protocol|In this group, the patients were weaned as the protocol.
124207|NCT01535755|Other|physician's orders|In this group, the patients were weaned as the clinicians' order.
124208|NCT01537861|Drug|Bortezomib|
124518|NCT01540916|Other|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
124519|NCT01540916|Other|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
126117|NCT01583660|Drug|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
126118|NCT01583660|Drug|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
126119|NCT00080808|Drug|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
126120|NCT01583673|Other|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
126121|NCT01585961|Device|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
126122|NCT01585974|Other|No intervention|All dosage, frequency and duration for drugs will be under the decision of the treating physician
126123|NCT01585987|Biological|Ipilimumab|
126124|NCT01585987|Other|Best Supportive care (BSC)|
126125|NCT01586000|Drug|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
126126|NCT00080899|Drug|fenretinide|Given orally
126127|NCT01586000|Drug|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
126128|NCT01586000|Drug|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
126129|NCT01586013|Drug|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
126454|NCT01584245|Other|Amino Acid formula|
126455|NCT01584258|Procedure|Laproscopic Prostatectomy|
126456|NCT01584258|Radiation|Conventionally Fractionated Prostate Radiotherapy|Conventional fractionation delivered to a dose of 78 Gy in 2 Gy fractions.
126457|NCT01584258|Radiation|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
126458|NCT00080847|Drug|cyclophosphamide|Given IV
126459|NCT01584271|Device|Natural Ear Comfort(TM), a botanical ear drops product|Ear Comfort(TM): active ingredients - Thyme essential oil & Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.
Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.
Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.
Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin.
124446|NCT00077311|Drug|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
124447|NCT01543737|Device|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
124448|NCT01543750|Drug|4-Aminopyridine|
124449|NCT01543750|Drug|Placebo|Placebo
124450|NCT01543763|Drug|PZP115891, PCI-24781|PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19
PZP115891: oral, 400 - 800 mg qd 28 days per cycle
124451|NCT01543776|Drug|abiraterone acetate|Given PO
124452|NCT01543789|Procedure|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
124453|NCT01543789|Procedure|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
124454|NCT01543802|Drug|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
124455|NCT01543815|Behavioral|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
124456|NCT01543815|Behavioral|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
124738|NCT01536561|Biological|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|Each patient will undergo two phases of study. The first phase, termed "tracer Study", involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radiommunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three patients per dose level.
124739|NCT01538875|Drug|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
124740|NCT00077077|Drug|capecitabine|
124741|NCT01538888|Procedure|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
124742|NCT01538901|Other|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
124743|NCT01538901|Drug|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
126060|NCT01588392|Behavioral|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
126061|NCT01588405|Drug|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
126062|NCT01588418|Drug|Exenatide or placebo|Exenatide or placebo will be administered in random order, (i.e. first or second before OGTT-PET study) The results obtained after Exenatide injection will be compared with the ones obtained after injection of placebo in the same subject.
126063|NCT01588431|Drug|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
126064|NCT01588444|Device|cortical FDBA|cortical mineralized freeze-dried bone allograft
126065|NCT01588444|Device|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
126066|NCT01588457|Drug|Lithium/Lithium Carbonate|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain LI of ≥0.5mEq/L.
126067|NCT01588457|Drug|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
126395|NCT01586546|Other|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
126396|NCT01586546|Other|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
126397|NCT01586546|Behavioral|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
126398|NCT01586572|Drug|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
126399|NCT01586572|Drug|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
124520|NCT01540942|Dietary Supplement|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;[W=weight（Kg）；H=height（cm）；A=age（year）]
124521|NCT01540942|Other|surgery|bowel resection
124522|NCT01540955|Behavioral|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
124523|NCT01540968|Behavioral|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
124524|NCT01540981|Device|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
124525|NCT01540981|Other|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
124526|NCT01540994|Radiation|radiation therapy|Stereotactic Body Radiation Therapy
124527|NCT01541007|Drug|Cabazitaxel|25 mg/m2 every three weeks
124528|NCT00077207|Drug|carboplatin|Given IV
124529|NCT01541007|Drug|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
124530|NCT01541046|Biological|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
124531|NCT01541046|Biological|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
124532|NCT01541059|Drug|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
124533|NCT01541059|Drug|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
124534|NCT01541072|Drug|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
124535|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
124536|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
124537|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
124538|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
126460|NCT01584284|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
126461|NCT01584297|Drug|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
126462|NCT01584310|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
126463|NCT01584310|Other|No STAMP using|No intervention
126464|NCT01584323|Dietary Supplement|Pomgranate pills|Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before
The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)
126465|NCT01584323|Dietary Supplement|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
126466|NCT01584336|Procedure|LATG|After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy
The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).
The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.
After then, the operator performs the jejunojejunostomy.
126467|NCT01584362|Drug|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
126468|NCT01584362|Drug|placebo|single oral dose of placebo
126469|NCT00080847|Drug|doxorubicin hydrochloride|Given IV
126470|NCT01584362|Drug|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
125576|NCT01590095|Behavioral|Water quality, Sanitation, Hand washing (Combined WASH)|Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age.
Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces.
124744|NCT01538914|Procedure|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
124745|NCT01538914|Procedure|PCA|Postoperative pain is controlled with intravenous PCA.
124746|NCT01538927|Drug|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
124747|NCT01538927|Drug|Suture|Black silk 000
124748|NCT01538940|Biological|Intradermal vaccine|15ug
124749|NCT01538940|Biological|Intramuscular vaccine|15ug
124750|NCT01538953|Other|handwashing|participants received weekly in-home handwashing promotion and soap as needed
124751|NCT00077090|Drug|hyperbaric oxygen|
124752|NCT01538953|Other|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
124753|NCT01538953|Other|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
124754|NCT01538966|Drug|Pegvisomant|
124755|NCT01538966|Drug|Somatostatin Receptor Ligand (SRL)|
124756|NCT01538979|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
125027|NCT01542008|Behavioral|broadly-directed, non-individualized education (EDU)|EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care "control" intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed.
125028|NCT00076609|Drug|PHY906|
125029|NCT01534637|Procedure|management of therapy complications|Receive aprepitant
125030|NCT01534663|Drug|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
125031|NCT01534663|Drug|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
125032|NCT01534676|Biological|Transfusion|1 or 2 unit transfusion of fresh (defined as less than 14 days of storage) packed red blood cells stored in an additive solution vs. 1 or 2 unit transfusion of older (defined as greater than 28 days of storage) packed red blood cells stored in an additive solution.
126400|NCT01586598|Behavioral|sensory retraining protocol|within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day
one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day
three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day
126401|NCT00080925|Drug|cyclophosphamide|
126402|NCT01586611|Drug|5FU, leucovorin, oxaliplatin|Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
126403|NCT01586611|Drug|Gemcitabine|1000 mg/m2 IV weekly for 3 weeks then one week off
126404|NCT01589068|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
126405|NCT01589068|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
126406|NCT01589081|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
126407|NCT01589081|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
126408|NCT01589094|Drug|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
125521|NCT01582607|Drug|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
125522|NCT01582607|Drug|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
125523|NCT00080756|Procedure|quality-of-life assessment|Ancillary studies
125524|NCT01584843|Drug|GSK1358820|IM injection of Botulinum Toxin Type A
125525|NCT00080860|Procedure|conventional surgery|
125526|NCT01584869|Device|capsule endoscopy|
124805|NCT01536652|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
124806|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
124807|NCT01536665|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
124808|NCT01536665|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
124809|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
124810|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
124811|NCT01536691|Drug|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
124812|NCT01536691|Drug|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
124813|NCT01536704|Drug|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
124814|NCT01536704|Drug|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
124815|NCT01536717|Drug|Articaine hydrochloride 2% solution|4 ml/h periosteal wound infusion
duration of 72 h
124816|NCT01536717|Drug|Sodium Chloride|Placebo Sodium chloride 0,9%
124817|NCT00076843|Drug|Hu MiK-Beta-1|
124818|NCT01536730|Behavioral|Homework Intervention Strategy|Participants assigned to intervention will receive a condom "ditty bag" containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention.
124819|NCT01536743|Drug|PD0332991|30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.
PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle).
124820|NCT01539031|Drug|E2020|Subjects in the Group-10 mg:
Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg
124821|NCT01539031|Drug|E2020|Subjects in the Group-23 mg:
Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg
124822|NCT01539044|Drug|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
124823|NCT01539044|Drug|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
125577|NCT01590095|Behavioral|Nutrition|Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.
Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old.
125578|NCT01590095|Behavioral|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation & Hand washing (Combined WASH) Plus the intervention described above for nutrition.
125579|NCT01590108|Drug|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
125580|NCT01590108|Drug|Saline|Saline
125581|NCT00081133|Drug|arsenic trioxide|
125582|NCT01590121|Other|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
125583|NCT01590121|Other|Questionnaire|Flight by aeroplane (previous)
125584|NCT01582607|Drug|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
125585|NCT01582607|Drug|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
125586|NCT01582607|Drug|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
125587|NCT01582607|Drug|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
125588|NCT01582620|Procedure|Telestroke|remote videoconference consultations
125589|NCT01582633|Biological|2012 trivalent influenza vaccine|2012 trivalent influenza vaccine:
influenza A/California/7/2009 (H1N1)
influenza A/Perth/16/2009 (H3N2)
influenza B/Brisbane/60/2008 Single dose.
125590|NCT01582646|Drug|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
125591|NCT01582659|Other|Telephone counseling|2 planned telephone counseling sessions are conducted.
125871|NCT01583270|Dietary Supplement|Semolina|Semoline porridge. control meal.
125872|NCT01583283|Drug|ACY-1215|Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
125873|NCT01583283|Drug|lenalidomide|Dosed on Days 1-21 of a 28 day cycle.
125383|NCT01587144|Drug|Temozolomide (TMZ)|TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment. Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the CTC nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.
125384|NCT01587144|Radiation|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
125385|NCT01587144|Drug|Placebo|Lucanthone or Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks along with radiation and TMZ during the concomitant phase. In the maintenance phase, lucanthone/placebo will be administered along with TMZ on days 1-5 of a 28-day cycle for 6 cycles.
125386|NCT01587157|Procedure|capnography|
125387|NCT01587183|Behavioral|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
125388|NCT01587183|Behavioral|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
125389|NCT00081055|Radiation|radiation therapy|
125390|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
125391|NCT01589666|Drug|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
125392|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
125393|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
125394|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
125395|NCT01589679|Other|standard of care|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
125396|NCT01589679|Device|Metarsal Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
125397|NCT01589692|Procedure|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
125398|NCT01589692|Procedure|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
125399|NCT01589692|Procedure|Percutaneous Pinning|Pinning with any number of Kirschner wires
125400|NCT00081068|Biological|alemtuzumab|
126016|NCT00081159|Drug|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
126017|NCT01590459|Drug|VX-509|50 mg oral tablet
126018|NCT01590459|Drug|VX-509 matching placebo|0 mg oral tablet
126019|NCT01590485|Other|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
126020|NCT01590485|Other|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
126021|NCT01590524|Behavioral|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
126022|NCT01590537|Drug|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
126023|NCT01590537|Device|Copper IUD|Copper device, inserted intrauterine
126024|NCT01590563|Device|IUD|Insertion of a spherical IUD, one year follow-up
126335|NCT01589003|Other|High GI growing up milk|High glycaemic index growing up milk
126336|NCT01589029|Drug|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
126337|NCT01589055|Drug|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
126338|NCT01581398|Drug|Pegasys|sc, qw, 24 weeks.
126339|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
126340|NCT01581398|Drug|Pegasys|sc, qw, 48 weeks.
126341|NCT01581411|Drug|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
126342|NCT01581437|Procedure|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
126343|NCT01581450|Drug|Nitrous Oxide|35%
126344|NCT01581450|Drug|Nitrous Oxide|50%
126345|NCT01581463|Drug|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
121993|NCT01511302|Drug|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
121994|NCT01511315|Drug|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
121995|NCT01511328|Other|HPV testing|Testing for Human Papilloma Virus
121996|NCT01511341|Behavioral|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
121997|NCT01511367|Drug|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
121998|NCT00001312|Drug|Vitamins and Minerals|
121999|NCT00074282|Biological|filgrastim|
122000|NCT01511367|Drug|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
122001|NCT01511367|Drug|Flixotide|50ug 2 puffs twice daily
122002|NCT01511380|Behavioral|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
122003|NCT01513603|Drug|CLAG-M|IV times 5 days
122004|NCT01513603|Drug|CLAG-M|Chemotherapy
122005|NCT01513616|Other|Pulmonary rehabilitation|8-week program, 3 supervised session per week
122006|NCT00074490|Drug|Rituximab|Rituximab:375 mg/m2/day IV, day 1 (for CD20+ patients)
122007|NCT01513616|Other|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
122292|NCT00073983|Genetic|microarray analysis|microarray analysis
122293|NCT01507428|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
122294|NCT01507428|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
122295|NCT01507428|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
122296|NCT01507428|Other|Laboratory Biomarker Analysis|Correlative studies
122949|NCT01550146|Drug|Placebo|iv. Normal Saline 0.1 ml/kg
122950|NCT01550172|Behavioral|Sleep Behavioral Therapy A and NHMS|The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.
Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments.
122951|NCT01550172|Behavioral|Sleep Behavioral Therapy B and NHMS|The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.
Sleep behavioral therapy B uses primarily behavioral adjustments.
122952|NCT01550185|Drug|eltrombopag olamine|Given PO
122953|NCT01550185|Procedure|standard follow-up care|Receive standard care
122954|NCT01550198|Device|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
122955|NCT01550211|Device|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
122956|NCT00077870|Drug|ocrelizumab|
122957|NCT01550224|Drug|Temozolomide|100-200 mg/m2/d oral
122958|NCT01550237|Radiation|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
122959|NCT01550237|Radiation|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
122960|NCT01550250|Behavioral|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
122961|NCT01550250|Behavioral|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
122962|NCT01550276|Other|Manual Therapy|All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas.
122963|NCT01552499|Other|Standard of care|
122059|NCT01509235|Procedure|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
122060|NCT01509261|Drug|Ilaprazole|20mg/Tap, QD
122061|NCT01509261|Drug|Lansoprazole|30mg/Tap, QD
125401|NCT01589692|Procedure|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
125402|NCT01589718|Drug|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
125669|NCT01590212|Other|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
125670|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
125671|NCT01590225|Drug|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 24 weeks.
125672|NCT01582815|Drug|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
125673|NCT01582828|Procedure|Epicardial (surgical) ablation|Pulmonary vein isolation with bipolar clamps and bipolar box lesion
Epicardial atrial appendage closure
125674|NCT01582828|Procedure|Hybrid|Epicardial (surgical) ablation
Pulmonary vein isolation with bipolar clamps and bipolar box lesion
Epicardial atrial appendage closure
Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation
125675|NCT01582841|Procedure|MSI screening test|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
125676|NCT01582854|Drug|Actovegin|Actovegin solution for infusion and Actovegin tablets
125677|NCT01582854|Drug|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
125678|NCT01582867|Device|ARTIS hemodialysis system|Software versions:
Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01
125679|NCT01582880|Drug|Riboflavin|Used to treat donor cornea before implantation
125680|NCT00080782|Drug|Doxorubicin Hydrochloride|By vein (IV) over 30 minutes on days 1, 8, 15, and 22
125681|NCT01582893|Device|HCO1100|Dialysis
125682|NCT01582893|Device|P210H|Dialysis
125683|NCT01582919|Other|Neuroimaging|
125684|NCT01582932|Drug|STF 115469 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
125685|NCT01582932|Drug|Vehicle Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
126346|NCT01581476|Drug|Statin|10mg daily for a minimum period of 2 years
126347|NCT00080639|Other|physiologic testing|
126348|NCT01581476|Drug|Ace Inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
126349|NCT01581476|Drug|Placebo|Participants receive statin placebo and ACEI placebo
126350|NCT01581476|Drug|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
126351|NCT01581489|Procedure|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
126352|NCT01581502|Other|This is an observational study.|This is an observational, not intervention, study.
126353|NCT01581515|Device|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
126354|NCT01581515|Device|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
126355|NCT01581528|Genetic|gene expression analysis|
125464|NCT01587235|Drug|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
125465|NCT01587235|Drug|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
125466|NCT01587248|Device|Harmonic|Dissection with harmonic scalpel
125467|NCT01587248|Procedure|electrocautery|Dissection in modified radical mastectomy
125468|NCT01587261|Drug|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
125469|NCT01587261|Drug|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
125470|NCT01587274|Drug|Naproxen|Naproxen 500mg twice/ day x 10 days
125471|NCT01587274|Drug|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
125472|NCT01587274|Drug|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
122297|NCT01507428|Drug|Paclitaxel|Given IV
122298|NCT01507428|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
122299|NCT01507428|Procedure|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
122300|NCT01507441|Genetic|gene mapping|
122301|NCT01507441|Genetic|microarray analysis|
122302|NCT01507441|Genetic|mutation analysis|
122303|NCT00073983|Other|laboratory biomarker analysis|laboratory biomarker analysis
122304|NCT01507441|Genetic|nucleic acid sequencing|
122305|NCT01507441|Other|laboratory biomarker analysis|
122306|NCT01507454|Drug|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
122307|NCT01507467|Radiation|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
122308|NCT01507467|Radiation|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
122309|NCT01507480|Drug|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
122310|NCT01509573|Behavioral|Family Strengthening Intervention in Rwanda (FSI-R)|Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.
8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material.
122586|NCT01512342|Behavioral|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
122587|NCT01512342|Behavioral|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
122588|NCT01512355|Drug|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
122589|NCT00074321|Other|laboratory biomarker analysis|Correlative studies
122590|NCT01512355|Drug|placebo group|normal saline_02mcg/kg/hr
122062|NCT01509274|Biological|Plasma|3 ml plasma injected once into the plantar fascia
122063|NCT01509274|Biological|Saline|3 ml of saline injected once into the plantar fascia
122064|NCT01509274|Other|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
122065|NCT00074165|Drug|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
122066|NCT01511380|Behavioral|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
122067|NCT01511393|Other|No treatment given|Completion of a questionnaire
122068|NCT01511406|Behavioral|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
122069|NCT01511419|Biological|live attenuated monovalent A/17/mallard/Netherlands/00/95(H7N3) influenza vaccine|two doses given one month apart
122070|NCT01511419|Biological|placebo|manufactured placebo based on allantoic fluid of chicken embryos not inoculated with influenza virus
122071|NCT01511432|Drug|telaprevir formulation A|A single 1125-mg dose administered orally
122072|NCT01511432|Drug|telaprevir Formulation B|A single 1125-mg dose administered orally
122073|NCT00074282|Biological|pegfilgrastim|
122074|NCT01511432|Drug|telaprevir Formulation C|A single 1125-mg dose administered orally
122075|NCT01511432|Drug|telaprevir Formulation D|A single 1125-mg dose administered orally
122076|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
122077|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
122078|NCT01511471|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
122367|NCT01514383|Device|Cyanoacrylate (Octylseal )|surgical adhesive
122368|NCT01514396|Device|Surgiseal|surgical glue
125686|NCT01582945|Drug|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
125687|NCT01582958|Procedure|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
125688|NCT01582958|Other|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
125936|NCT01583335|Behavioral|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
125937|NCT01583348|Procedure|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
125938|NCT01583361|Drug|Oxaliplatin+S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
125939|NCT01583361|Drug|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
125940|NCT00080795|Drug|ifosfamide|
125941|NCT01583374|Drug|Apremilast tablet 20 mg|PDE4-specific inhibitor
125942|NCT01583374|Drug|Apremilast tablet 30 mg BID|PDE4-specific inhibitor
125943|NCT01583374|Drug|Placebo|PDE4-specific inhibitor
125944|NCT01583387|Other|1-Increased water intake regimen|Arm 1-Intervention
125945|NCT01583387|Other|2-Non-modified water intake regimen|Arm 2-Control
125946|NCT01583400|Other|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
125947|NCT01585623|Drug|midazolam|Pharmaceutical form:solution
Route of administration: oral
125948|NCT01585636|Drug|SQ109|Single oral dose
125949|NCT01585649|Drug|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
122827|NCT01545076|Biological|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
122828|NCT01545076|Biological|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
122829|NCT01545089|Other|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
122830|NCT01545089|Other|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
122831|NCT00077389|Procedure|neoadjuvant therapy|
122832|NCT01545141|Drug|Chemokine modulatory regimen|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
122833|NCT01545154|Device|Transperineal Ultrasound|
122834|NCT01545167|Genetic|blood sampling|blood samples obtained to extract biomarkers and dna for analysis
122835|NCT01545167|Other|questionnaire|questionnaire
122836|NCT01545193|Other|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
122837|NCT01545219|Dietary Supplement|Prebiotic|8g/day xylo-oligosaccharide
122838|NCT01545219|Dietary Supplement|Bi-07|10^9 CFU B. lactis / day
122839|NCT01545219|Dietary Supplement|Synbiotic|8g/day xylo-oligosaccharide + 10^9 CFU Bi-07
122840|NCT01545219|Dietary Supplement|Placebo|8g/day maltodextrin
121938|NCT01513564|Drug|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
121939|NCT01513577|Other|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
121940|NCT01513577|Other|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
122591|NCT01512368|Other|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
122592|NCT01512381|Device|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
122593|NCT01512381|Device|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
122594|NCT01512394|Procedure|standard bowel prep|standard bowel prep
122595|NCT01512394|Procedure|no bowel prep|no bowel prep
122596|NCT01512407|Procedure|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
122597|NCT01549587|Device|toothbrush|twice daily brush thoroughly for 2 minutes
122598|NCT01549587|Drug|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
122599|NCT01549587|Device|dental floss|floss the whole mouth once daily
122600|NCT01549600|Dietary Supplement|psyllium|1 level tablespoon (~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
122601|NCT01549600|Dietary Supplement|Microcrystalline Cellulose|1 level tablespoon (~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
122602|NCT00077779|Drug|Adalimumab|
122603|NCT01549613|Drug|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
122604|NCT01549613|Drug|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
122605|NCT01549626|Dietary Supplement|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
122606|NCT01549626|Dietary Supplement|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
122607|NCT01549626|Dietary Supplement|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
122891|NCT01552434|Drug|Cetuximab|Starting dose of Cetuximab loading dose 100 mg/m2, and maintenance dose 75 mg/m2 by vein on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group.
122892|NCT01552447|Other|EpiFix|Dehydrated placental tissue
122893|NCT01552447|Other|Compression Therapy|Compression bandaging
122369|NCT01507506|Radiation|Radiotherapy|Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.
Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,
post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.
122370|NCT01507506|Radiation|Experimental arm|Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed
Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,
post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.
122371|NCT01507519|Device|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
122372|NCT01507532|Other|pharmacokinetic monitoring|pharmacokinetic monitoring
122373|NCT00073983|Other|pharmacokinetic study|pharmacokinetic study
122374|NCT01507545|Drug|MORAb-004|MORAb-004 8mg IV per kg once a week
122375|NCT01507545|Drug|Placebo|Placebo - normal saline IV once a week
122376|NCT01507558|Procedure|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
122377|NCT01507571|Other|Dignity Therapy|Dignity Therapy is a brief psychotherapeutic intervention consisting of:
a tape-recorded session with the patient using the DT question protocol
Transcription of the interview, which is then edited
A session where the edited transcript is returned to the patient who can give it to family members or friends.
If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by.
122378|NCT01507584|Device|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
122379|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
122380|NCT01507597|Drug|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
122381|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
125950|NCT01585662|Procedure|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
125951|NCT01585688|Drug|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
125952|NCT01585701|Biological|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
125953|NCT01585727|Procedure|TME|Total mesorectal excision
125954|NCT00080886|Drug|etoposide|
125955|NCT01585727|Procedure|TME|Total mesorectal excision
126275|NCT01583842|Radiation|124I-MIBG (carrier added)|124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.
Optional 124I-MIBG (carrier added) Administration & PET/CT scan 6 weeks later.
126276|NCT01583855|Procedure|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
126277|NCT01583855|Device|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
126278|NCT01583881|Procedure|renal denervation|Renal denervation
126279|NCT01583920|Radiation|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
126280|NCT01583933|Device|Essix retainer|The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 ", it processed gives a thickness of 0.015" approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake.
126281|NCT01583933|Device|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
126282|NCT00080808|Procedure|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
126283|NCT01583959|Drug|Folic Acid|Folic acid tablets 5 mg
126284|NCT01583959|Drug|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
126285|NCT01583972|Dietary Supplement|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
126286|NCT01583972|Dietary Supplement|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
126287|NCT01583985|Other|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
121941|NCT01513590|Drug|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
121942|NCT01513590|Drug|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued
121943|NCT00074633|Behavioral|Health at Every Size (HAES)|
121944|NCT01515761|Procedure|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
121945|NCT01515761|Procedure|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
121946|NCT01515774|Drug|Mirapex ER|Change Requip or Mirapex to Mirapex ER
121947|NCT01515787|Drug|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m^2 IV over 2 hours on day 1, leucovorin 400 mg/m^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m^2 bolus over 5-15 minutes then 2400 mg/m^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
121948|NCT01515787|Other|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
121949|NCT01515787|Procedure|surgery|low anterior resection with total mesorectal excision
121950|NCT01515787|Procedure|magnetic resonance imaging or endorectal ultrasound|
121951|NCT01515800|Behavioral|Text message reminder|Receive text message
121952|NCT01515813|Drug|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
121953|NCT01515813|Drug|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
121954|NCT00074633|Behavioral|Diet (Traditional, moderate energy restriction)|
122231|NCT01509547|Drug|placebo|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
122894|NCT00078195|Biological|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
122895|NCT01552473|Behavioral|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
122896|NCT01552473|Behavioral|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
122897|NCT01552486|Other|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
122898|NCT01552486|Other|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
122899|NCT01545232|Biological|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
122900|NCT01545258|Other|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
122901|NCT01545271|Drug|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours
122902|NCT01545271|Device|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment)
122903|NCT01545284|Drug|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
122904|NCT01545297|Drug|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
122905|NCT01545297|Drug|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
122906|NCT01545297|Drug|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
122907|NCT01545310|Drug|SLV354|One dose of ABT-354
122008|NCT01513642|Behavioral|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
122666|NCT01547208|Procedure|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
122667|NCT01547208|Procedure|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
122668|NCT01547221|Drug|clotrimazole|single application of 1%clotrimazole ear drop
122669|NCT01547221|Drug|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
122670|NCT01547247|Device|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
122671|NCT01547247|Procedure|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
122672|NCT00000261|Drug|0.2% sevoflurane|
122673|NCT00001421|Drug|methimazole|
122674|NCT00077545|Drug|cisplatin|Given IV
122675|NCT01547260|Drug|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
122676|NCT01547260|Drug|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
122677|NCT01547273|Procedure|bone graft inside socket only|bone graft inside socket only
122678|NCT01547273|Procedure|bone graft inside and outside socket|bone graft inside and outside socket
122679|NCT01547273|Procedure|no bone graft|no bone graft
122680|NCT01547286|Biological|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated PC20-allergen delivered for 5 minutes at tidal breathing, followed by FEV1 at 10-minute intervals until the lowest FEV1 is established. If the %FEV1 fall is < 20%, the next concentration is given, until the FEV1 falls ≥ 20%. When this happens the FEV1 will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum %FEV1 fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
122681|NCT01547286|Radiation|CT imaging, functional PET imaging|Physiology study using CT and PET imaging with Nitrogen-13 (13NN) saline as radiotracer; images obtained during the early and late phases after allergen challenge
122682|NCT01547286|Drug|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's PC20 dose (the dose that causes a 20% fall in FEV1 from baseline).
126288|NCT01583985|Other|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
126289|NCT01583998|Behavioral|e-MBC|antidepressant treatment
126290|NCT01584011|Other|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
126291|NCT01584011|Other|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
126292|NCT01584011|Behavioral|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
126293|NCT00080834|Drug|DJ-927|
126294|NCT01584011|Other|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
125403|NCT01589718|Drug|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
125404|NCT01589744|Device|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
125405|NCT01589757|Other|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
125406|NCT01589757|Other|Low GI diet|Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the "Stop-Light-Method". This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate.
125407|NCT01589783|Other|completion of a questionnaire|Completion of a questionnaire
125408|NCT01589783|Other|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
125409|NCT01589796|Procedure|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
125410|NCT01589809|Drug|nicotinamide|dose-escalation, 2-8 grams, oral
125411|NCT00081094|Procedure|18F-Fluorodeoxyglucose-PET (FDG-PET)|
125412|NCT01582282|Dietary Supplement|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
125413|NCT01582282|Dietary Supplement|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
122232|NCT01509560|Drug|Everolimus|Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.
Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16
122233|NCT01511627|Drug|General Anesthesia (control group)|All patients will receive a preoperative multimodal analgesic regime:
Tylenol® 975mg per os
Naproxen® 500 mg per os
Group I (General anesthetic) patients will receive a general anesthetic :
Midazolam 1 - 2 mg intravenously
Fentanyl 1 - 2 ug/kg intravenously
Propofol 1-3 mg/kg intravenously
Rocuronium 0.3 - 0.9mg/kg intravenously
followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.
Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.
Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.
Dexamethasone 4mg and Ondansetron 4mg intravenously
Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously
Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU).
122234|NCT01511640|Drug|Tiagabine|tiagabine or placebo 2x daily for duration of study
122235|NCT01511666|Device|Prehospital mechanical compression device, intraarrest cooling and in hospital ECLS (LUCAS, Rhinochill, PLS ECMO)|ECLS states for extracorporeal life support.
122236|NCT01511666|Other|Standard care|Standard care as per recent guidelines will be provided.
122237|NCT01511692|Drug|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
122238|NCT01511692|Drug|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
122239|NCT01511692|Drug|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
122240|NCT01511692|Drug|glimepiride|Dose individually adjusted, administered orally for 4 weeks
122241|NCT00074282|Drug|pentostatin|
122242|NCT01511705|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
122243|NCT01511705|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
122244|NCT01511718|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
122245|NCT01511718|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
122246|NCT01511731|Drug|Famotidine|Famotidine Tablets 40 mg
122247|NCT01511731|Drug|Pepcid|40mg tablets
122009|NCT01513655|Device|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
122010|NCT01513668|Drug|Acetaminophen|Extended release Gel tabs 650 mg
122011|NCT01513681|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
122012|NCT01513681|Drug|Lamictal®|Lamictal® 200 mg Tablets
122013|NCT01513694|Procedure|Instrumented posterolateral arthrodesis|Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.
They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.
Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery.
122014|NCT01513720|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
122015|NCT01513720|Drug|Lamictal®|Lamictal® 200 mg Tablets
122016|NCT01513733|Drug|tasquinimod|tasquinimod 0.25 mg continuously
122017|NCT00074490|Drug|Fludarabine|Fludarabine:25 mg/m2/day IV, days 1-4
122018|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
122019|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
122020|NCT01513759|Drug|recombinant tissue plasminogen activator|Patients receive 24 mg of recombinant tissue plasminogen activator delivered via the EkoSonic Endovascular Device.
122021|NCT01513759|Device|EKOS EkoSonic Endovascular System|24 mg of recombinant tissue plasminogen activator delivered through the EkoSonic Endovascular System.
122022|NCT01513759|Drug|Alteplase|Patients receive 24 mg of alteplase delivered via the EkoSonic Endovascular Device
122023|NCT01513772|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
122024|NCT01513772|Drug|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
122025|NCT01513785|Drug|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
122026|NCT01513785|Drug|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
122683|NCT01547299|Drug|Enzalutamide|
122684|NCT01547299|Drug|Leuprolide|
122964|NCT01552499|Other|Applications of EpiFix|
122965|NCT01552512|Dietary Supplement|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
122966|NCT01552512|Other|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
122967|NCT01552538|Device|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
122968|NCT01552551|Behavioral|Assessment and education|PA Healthy Steps program
122969|NCT00078195|Biological|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
122970|NCT01552551|Behavioral|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
122971|NCT01552551|Behavioral|Healthy Steps in Motion|Group exercise program
122972|NCT01552564|Procedure|Index of microvascular resistance|
122973|NCT01552564|Other|Cardiac magnetic resonance|
122974|NCT01552564|Other|Blood markers|
122975|NCT01552590|Drug|Tolvaptan|
122976|NCT01552590|Drug|Placebo|
122977|NCT01552603|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
122978|NCT01552616|Procedure|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
122979|NCT01552629|Drug|QGE031|
122980|NCT00078195|Biological|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
125414|NCT01582295|Drug|Cabozantinib|Starting dose 40 mg daily
125415|NCT01582308|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
125416|NCT01582308|Drug|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
125417|NCT01582308|Drug|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
125418|NCT01582308|Drug|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
125419|NCT01582308|Drug|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
125420|NCT01582321|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
125421|NCT00080756|Drug|therapeutic testosterone|0.275mg/100ul per day as a nasal spray
125689|NCT01582971|Other|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
125690|NCT01582984|Other|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
125691|NCT00080782|Radiation|Strontium chloride Sr 89|IV on day 1
125692|NCT01582997|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
125693|NCT01583010|Device|ANV(R)|Device: Advanced Needle Visualization Technology ®
Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.
Arms: ANV ® Group
125694|NCT01583023|Drug|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
125695|NCT01583023|Device|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
125696|NCT01585194|Drug|Nivolumab|Induction Phase:
1 mg/kg by vein for a total of four doses (week 1, 4, 7, 10). The induction phase continues through week 12.
125697|NCT01585194|Drug|Ipilimumab|Induction Phase:
3 mg/kg by vein for a total of four doses (week 1, 4, 7, 10). The induction phase continues through week 12.
Maintenance Phase:
For patients who have not experienced disease progression or unmanageable toxicity by week 12:
Nivolumab 3 mg/kg by vein every 2 weeks until disease progression or unmanageable toxicity as deemed by the clinical investigator.
122525|NCT01514760|Other|Mobile-based Asthma Action Plan|The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth "rotating" message will be sent twice weekly.
122526|NCT01507753|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
122527|NCT01507766|Drug|early enteral nutrition|The enteral nutrition was started within 48h after admission
122528|NCT01507766|Drug|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
122529|NCT01507779|Biological|IVACFLU|IVACFLU is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose
122530|NCT01507779|Other|PBS (Phosphate buffered saline)|Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
122531|NCT00074022|Drug|docetaxel|Given IV
122532|NCT01507792|Drug|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
122533|NCT01507792|Drug|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
122534|NCT01507805|Device|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5—30 Hz，2．34—6．24 mA，30 min)for 5 consecutive days before surgery
122535|NCT01507805|Device|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5—30 Hz，2．34—6．24 mA，30 min)for 5 consecutive days before surgery
122536|NCT01507818|Device|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0>
122537|NCT01507818|Device|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
122538|NCT01507831|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
122539|NCT01507831|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
122540|NCT01507831|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
122541|NCT01507844|Device|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
122311|NCT01509586|Drug|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
122312|NCT01509599|Procedure|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap during the home-based intervention
122313|NCT01509599|Procedure|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
122314|NCT01509612|Drug|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
122315|NCT01509612|Drug|Placebo homeopathic globules|Homeopathic placebo globules every 2 to 3 months
122316|NCT01509612|Drug|Placebo globules|saccharose globules and dilutions taken orally
122317|NCT00074178|Drug|dexamethasone|
122318|NCT01509638|Drug|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
122319|NCT01509638|Drug|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
122320|NCT01509651|Drug|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
122321|NCT01509664|Behavioral|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
122322|NCT01509677|Drug|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
122323|NCT01509677|Drug|Placebo|tablet, once daily, oral administration in the morning after breakfast
122324|NCT01511796|Other|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
122325|NCT01511809|Drug|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
122981|NCT01552629|Drug|Placebo|
122982|NCT01552629|Drug|Cyclosporine A|
122983|NCT01552642|Behavioral|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
122984|NCT01552655|Radiation|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
125920|NCT01590693|Drug|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
125921|NCT01590719|Drug|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
125922|NCT01590719|Drug|mFOLFOX6|Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 or levofolinic acid 200 mg/m2, 5-fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
125923|NCT00081159|Radiation|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
125924|NCT01590719|Drug|onartuzumab|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment\n
125925|NCT01590732|Drug|Romidepsin|Starting Dose: 8 mg/m2 by vein on Days 1 and 4 of a 14 Day cycle.
125926|NCT01590732|Drug|Ifosfamide|5 gm/m2 by vein on Day 1 of a 14 Day cycle.
125927|NCT01590732|Drug|Mesna|5 gm/m2 by vein given with Ifosfamide over 24 hours on Day 1 of a 14 Day cycle.
2 gm/m2 by vein given over 12 hours starting after completion of ifosfamide plus MESNA on Day 1 of a 14 Day cycle.
125928|NCT01590732|Drug|Carboplatin|mg to equal target area under curve (AUC) by Calvert equation of 5 mg/ml/min with a maximum of 750 mg by vein on Day 1 of a 14 Day cycle.
125929|NCT01590732|Drug|Etoposide|100 mg/m2 by vein on Days 1 - 3 of a 14 Day cycle.
125930|NCT01590745|Device|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
125931|NCT01583296|Behavioral|Cognitive Behavioral Therapy (CBT) and heart rate variability biofeedback|cognitive behavioral therapy and heart rate variability biofeedback
125932|NCT01583309|Procedure|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
125698|NCT01585207|Drug|vigabatrin|3 tablets, bid for 8 weeks
125699|NCT01585220|Device|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
125700|NCT01585233|Drug|ASKP1240|Intravenous
125701|NCT01585233|Drug|Placebo|Intravenous
125702|NCT01585246|Drug|Saw Palmetto|either placebo (soybean oil soft gel) or 1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
125703|NCT00080860|Radiation|technetium Tc 99m sulfur colloid|
125704|NCT01585259|Drug|Anfibatide|Snake venom
125705|NCT01585259|Drug|Placebo|Saline
125706|NCT01585272|Drug|ENA713|
125707|NCT01585285|Procedure|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
125708|NCT01585285|Procedure|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
125956|NCT01585727|Procedure|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
125957|NCT01585740|Drug|0.9% Normal Saline|Crystalloid fluid
125958|NCT01585740|Drug|Ringer's Lactate|Crystalloid fluid
125959|NCT01585753|Drug|NRTI + PI|tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
125960|NCT01585753|Drug|maraviroc + PI|maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
125961|NCT01585753|Drug|maraviroc + NRTI|maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
125962|NCT01585766|Biological|MEDI-551 IV|Associated Dosage Level x 2 MEDI-551 IV
125963|NCT01585766|Biological|MEDI-551 SC|Associated Dosage Level X 1 MEDI-551 SC
125964|NCT01585766|Drug|Placebo IV|Placebo IV x 2
125965|NCT00080886|Drug|melphalan|
122542|NCT00074022|Other|laboratory biomarker analysis|Correlative studies
122543|NCT01507857|Biological|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
122841|NCT01545232|Biological|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
122842|NCT00077402|Drug|fenretinide|
122843|NCT01547416|Drug|no epidural drug administered|Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.
General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
122844|NCT00077584|Drug|Bosentan|
122845|NCT01547429|Device|Artisan Aphakia Intraocular Lens|Implantation of lens to correct refractive error in aphakic eye
122846|NCT01547442|Device|Artisan Aphakia Intraocular Lens|Implantation of an intraocular lens
122847|NCT01547455|Drug|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
122848|NCT01547455|Drug|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
122849|NCT01547468|Procedure|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
122850|NCT01547468|Procedure|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
122851|NCT01547494|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
122852|NCT01547494|Dietary Supplement|mixture of omega3 and vitamins|mixture of omega3 and vitamins
122853|NCT01547507|Device|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
122854|NCT01547520|Drug|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
122855|NCT00077597|Drug|epoetin|3 times a week iv, as prescribed.
122856|NCT01547520|Drug|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
122857|NCT01547546|Drug|GDC-0084|Multiple doses
122858|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
122326|NCT01511822|Drug|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
122327|NCT01511822|Drug|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
122608|NCT01549652|Drug|Ondansetron|Prevention of Physical Dependence: After 1 month of oral morphine therapy, patients will go to the Stanford human opioid physiology lab for opioid withdrawal testing for Visit #1. Patients will be randomized in a double-blind fashion to treatment crossover assignments (placebo vs. 32 mg ondansetron) that will be conducted on 2 separate visits at least 1 week apart. Patients will continue to take oral morphine therapy until both study visits are complete.
Treatment of Opioid Withdrawal: Patients will be randomized into 2 groups: control arm (placebo) or prevention arm (8 mg ondansetron). Patients will go to the Stanford human opioid physiology lab for opioid withdrawal testing for Visit #1. After Visit #1, patients will undergo 1 month of oral morphine therapy. Patients will be instructed to take a treatment pill (placebo vs. ondansetron) with each dose of morphine. Then, patients will return to the Stanford human opioid physiology lab for Visit #2, which will be identical to Visit #1.
122609|NCT01549665|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
122610|NCT01549678|Other|Total contact insole|EVA insole shaped on patient´s foot.
122611|NCT01549678|Other|placebo insole|EVA insole flat
122612|NCT01549691|Drug|Zopiclone|7.5 mg before sleep, the evening before surgery
122613|NCT00077792|Drug|Enoxaparin sodium (XRP4563)|
122614|NCT01549691|Drug|Alprazolam|0.5 mg at awakening, the day of surgery
122615|NCT01549691|Drug|placebo|given night before surgery and at awakening, the day of surgery
122616|NCT01549704|Drug|Ropivacaine|Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).
Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine.
122617|NCT01549704|Drug|Saline|please see intervention description for ropivacaine
122618|NCT01549717|Device|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
122619|NCT01551888|Drug|Formoterol|Formoterol 12 μg, one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
122620|NCT01551901|Device|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
122621|NCT01551914|Device|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
122622|NCT01551914|Device|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
125933|NCT01583309|Procedure|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
125934|NCT01583322|Drug|vargatef|400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).
Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years.
125935|NCT01583322|Drug|placebo|Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).
Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.
The maximum time on monotherapy is 2 years.
126184|NCT01572311|Behavioral|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
126185|NCT01583673|Other|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
126186|NCT01583686|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
126187|NCT01583686|Biological|Anti-mesothelin CAR|Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by IV infusion of anti-mesothelin CAR engineered PBL. On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
126188|NCT01583686|Drug|Cycolphosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
126189|NCT01583686|Drug|Aldesleukin|Aldesleukin (based on total body weight) 72,000 IU/kg IV over a period of 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
126190|NCT01583699|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
126191|NCT01583699|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
126192|NCT01583712|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
126193|NCT01583712|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
125966|NCT01585766|Drug|Placebo SC|Placebo SC x 1
125967|NCT01585779|Device|Contour 3D® or Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
125968|NCT01585792|Drug|TAK-875|
125969|NCT01585792|Drug|TAK-875|
125970|NCT01585792|Drug|Glimepiride|
125971|NCT01585792|Drug|Placebo|
125972|NCT01585805|Drug|Cisplatin|Given IV
125973|NCT01585805|Drug|Gemcitabine Hydrochloride|Given IV
125974|NCT01585805|Other|Laboratory Biomarker Analysis|Correlative studies
125975|NCT01585805|Drug|Veliparib|Given PO
125976|NCT00080886|Procedure|autologous bone marrow transplantation|
125977|NCT01588210|Other|sealant application|A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.
All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary.
125978|NCT01588223|Other|Lipid identification|The lipids are identified using Mass Spectrometry
125979|NCT01588236|Drug|KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
125980|NCT00081003|Genetic|gene expression analysis|
126295|NCT01586325|Drug|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
126296|NCT01586338|Drug|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
126297|NCT00000262|Drug|0.2% sevoflurane|
126298|NCT00001498|Drug|doxorubicin|
126299|NCT00080925|Biological|graft-versus-tumor induction therapy|
126300|NCT01586351|Device|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
126301|NCT01586364|Drug|Ospemifene|
122859|NCT01547559|Drug|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
122860|NCT01547559|Drug|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
122861|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
121955|NCT01515813|Drug|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
121956|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
121957|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
121958|NCT01515839|Dietary Supplement|Multivitamin Supplement intervention|We recommend the following protocol:
2 tablets of a high quality multivitamin BID
2 capsules of omega 3 fish oil BID for a total of 3 grams daily
3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg
Weight loss
121959|NCT01515852|Procedure|general anesthesia in stereotactic biopsy|stereotactic biopsy
121960|NCT01515852|Procedure|local anesthesia in stereotactic biopsy|stereotactic biopsy
121961|NCT01515865|Drug|Midodrine HCl|dose at subject's current dose level
121962|NCT01515865|Drug|Placebo|single dose of matching placebo
121963|NCT01515878|Device|Hemocontrol|Blood Volume Tracking system using biofeedback
121964|NCT01509001|Drug|Metformin|750 to 2500 mg/day, two times a day during 4 months
121965|NCT01509001|Drug|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
121966|NCT01509014|Behavioral|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
121967|NCT01509027|Behavioral|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
121968|NCT01509027|Behavioral|Standard care|standard care
121969|NCT00000259|Drug|0.6% Sevoflurane|
122623|NCT01551940|Drug|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
122624|NCT01551940|Drug|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
122625|NCT01551953|Behavioral|Tai chi|12 week tai chi class
122626|NCT01551953|Behavioral|Mind-body breathing|12 week breathing class
122908|NCT01545323|Genetic|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
122909|NCT00077415|Drug|gemcitabine hydrochloride|
122910|NCT01545336|Drug|Anastrozole|1 mg tablet to be taken 1 time daily
122911|NCT01545336|Drug|Placebo|1 mg tablet to be taken 1 time daily
122912|NCT01545349|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
122913|NCT01545349|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
122914|NCT01545349|Biological|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
122915|NCT01545362|Procedure|Total knee arthroplasty|Total knee arthroplasty
122916|NCT01545375|Biological|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
122917|NCT01545375|Biological|Placebo|4 doses administered intramuscularly
122918|NCT01545375|Biological|Prevnar 13®|4 doses administered intramuscularly
122919|NCT01545375|Biological|PedvaxHIB®|4 doses administered intramuscularly
122920|NCT00077415|Drug|triapine|
122921|NCT01545388|Drug|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
122922|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
122923|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
122924|NCT01547598|Drug|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
126194|NCT00080808|Drug|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
126195|NCT01583725|Procedure|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
126196|NCT01583725|Behavioral|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
126197|NCT01583738|Drug|V0251|single dose
126198|NCT01583738|Drug|placebo|single dose
126199|NCT01583751|Procedure|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
126525|NCT01581957|Other|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
126526|NCT01581957|Other|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
126527|NCT01581970|Drug|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
126528|NCT01581970|Drug|Cetuximab|The initial dose of cetuximab 400 mg/m^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m^2 intravenously (IV) over 60 minutes.
126529|NCT01581983|Behavioral|Internet Mindfulness Meditation|one hour session each week for six weeks
126530|NCT01581983|Behavioral|Individual Mindfulness Meditation|one hour session each week for six weeks
126531|NCT00080743|Drug|gefitinib|250 mg po once daily
126532|NCT01584362|Drug|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
126533|NCT01584362|Drug|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
126534|NCT01584362|Drug|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
126535|NCT01584362|Drug|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
126536|NCT01584375|Other|Flat midline head position|Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.
126537|NCT01584375|Other|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
126302|NCT01586390|Other|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
126303|NCT01586390|Other|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
126304|NCT01586403|Biological|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10^6 TIL 1383I TCR transduced T cells per kg body weight.
126305|NCT01586403|Biological|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10^6 TIL 1383I TCR transduced T cells per kg body weight.
126306|NCT01586403|Biological|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10^7 TIL 1383I TCR transduced T cells per kg body weight.
126307|NCT01586403|Biological|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10^7 TIL 1383I TCR transduced T cells per kg body weight.
126308|NCT01586416|Behavioral|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
126309|NCT01586429|Other|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
126310|NCT00080925|Biological|rituximab|
126311|NCT01586442|Drug|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
126312|NCT01586442|Drug|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
126313|NCT01586455|Drug|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
125422|NCT01582321|Drug|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
125423|NCT01582334|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
125424|NCT01582347|Drug|RBP-6300|8, 16, 24mg daily, for 30 days
125425|NCT01582347|Drug|Placebo|8, 16, 24mg daily, 30 days
121970|NCT00001307|Drug|Capsaicin|
121971|NCT00074165|Drug|Sodium thiosulfate|Dose: 4 hrs post carboplatin = 20gm/m2;
Dose: 8 hrs post carboplatin = 16gm/m2
Infused IV x 2 days
121972|NCT01509027|Behavioral|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
122248|NCT01511744|Biological|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
122249|NCT01511757|Drug|Fluconazole|Fluconazole Tablets, 200 mg
122250|NCT01511757|Drug|Fluconazole|fluconazole 200 mg
122251|NCT01511770|Drug|Fluconazole|Fluconazole Tablets, 200 mg
122252|NCT00074295|Biological|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
122253|NCT01511770|Drug|Fluconazole|Fluconazole 200 mg tablets
122254|NCT01511783|Drug|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
122255|NCT01511783|Drug|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
122256|NCT01514110|Drug|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
122257|NCT01514123|Drug|VGX-100|VGX-100 will be administered by IV infusion once every week
122258|NCT01514123|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
122259|NCT01514136|Device|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
122260|NCT01514149|Drug|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
122261|NCT01514149|Drug|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
122262|NCT01514175|Drug|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
122263|NCT00074490|Drug|Cyclophosphamide|Cyclophosphamide, 750 mg/m2/day IV, day 5
122925|NCT01547598|Drug|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
122926|NCT01547598|Drug|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
122927|NCT01547611|Other|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
122027|NCT01515943|Procedure|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
122028|NCT00001332|Procedure|CHPP with cisplatin|
122029|NCT00074698|Drug|FG-3019|
122030|NCT01515943|Other|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
122031|NCT01515943|Procedure|Placebo yoked prism flippers|Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and "Accommodative Hopping Cards". Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:
Weeks 1-4: View the target through prism flippers
Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers
Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers
122032|NCT01515956|Drug|BMN 110|Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
122033|NCT01515969|Drug|erlotinib hydrochloride|Given PO
122034|NCT01515969|Drug|dovitinib lactate|Given PO
122035|NCT01515982|Behavioral|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
126538|NCT01584388|Drug|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
126539|NCT01584427|Dietary Supplement|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
126540|NCT01584440|Drug|AVP-923 (dextromethorphan/quinidine)|AVP-923 capsules administered twice a day over a 10-week period
126541|NCT00080847|Drug|vincristine sulfate|Given IV
126542|NCT01584440|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
126543|NCT01584453|Drug|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
126544|NCT01584453|Drug|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
125629|NCT01587586|Biological|P1101, 12 doses|12 doses, solution, 48 weeks
125630|NCT01587599|Behavioral|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
125631|NCT01587625|Drug|Syntocinon|
125632|NCT01587638|Drug|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
125633|NCT01587638|Drug|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
125634|NCT01587651|Drug|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
125635|NCT01587651|Drug|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
125636|NCT00080951|Drug|leucovorin calcium|
125637|NCT01587651|Drug|Ticagrelor Maintenance Dose|one 90mg film coated tablet
125638|NCT01587664|Device|NewBreez ILP Implant|NewBreez ILP implant
125639|NCT01587703|Drug|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
125640|NCT01587716|Drug|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
125641|NCT01587716|Other|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
125642|NCT01587716|Drug|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
125426|NCT01582373|Behavioral|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
125427|NCT01582399|Drug|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
125428|NCT01582412|Drug|Isavuconazole|oral
125429|NCT01582412|Drug|digoxin|oral
125430|NCT01582425|Drug|Isavuconazole|oral
125431|NCT01582425|Drug|Methadone|oral
125432|NCT00080756|Procedure|therapeutic conventional surgery|Undergo risk reduction mastectomy
125433|NCT01584635|Procedure|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
125434|NCT01584648|Drug|dabrafenib|dabrafenib 150 mg twice daily
125435|NCT01584648|Drug|dabrafenib plus trametinib placebo|dabrafenib 150 mg twice daily and trametinib placebo
125436|NCT00001498|Procedure|peripheral blood progenitor cell|
125437|NCT00080860|Genetic|microarray analysis|
125438|NCT01584648|Drug|Trametinib|trametinib 2 mg once daily
125439|NCT01584661|Behavioral|Dietary recommendations|
125440|NCT01584674|Device|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
125441|NCT01584687|Biological|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
125442|NCT01584700|Procedure|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
125709|NCT01585298|Drug|FTY720|
125710|NCT01585324|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
125711|NCT01585324|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
122264|NCT01514175|Drug|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
122265|NCT01514188|Drug|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
122266|NCT01514188|Drug|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
122267|NCT01514201|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
122268|NCT01514201|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
122544|NCT01507857|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
122545|NCT01507870|Procedure|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
122546|NCT01507896|Biological|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
122547|NCT01507922|Drug|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
122548|NCT01507922|Drug|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
122549|NCT01509963|Other|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
122550|NCT01509976|Other|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
122551|NCT01510002|Procedure|Total thyroidectomy|Extracapsular total thyroidectomy
122552|NCT01510002|Procedure|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
122553|NCT01510015|Drug|Risperidone|variable dose
122554|NCT01510028|Biological|Recombinant human arylsulfatase A|
122555|NCT01510041|Other|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
122556|NCT01510041|Other|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
122036|NCT01515982|Behavioral|Control Group|All participants were asked not to commence any new exercise regimen.
122037|NCT01515995|Drug|Nebulized magnesium sulfate|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
Versus
15 mg albuterol in 22 ml of normal saline via nebulizer over one hour
122038|NCT01516008|Drug|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
122039|NCT01516008|Drug|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
122040|NCT00074711|Drug|Calcium carbonate|
122328|NCT01511822|Drug|placebo|
122329|NCT01511835|Dietary Supplement|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
122330|NCT01511835|Dietary Supplement|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
122331|NCT00074308|Drug|imatinib mesylate|Given orally
122332|NCT01511835|Drug|Folic Acid|Folic Acid 400mcg; 1 cp/die
122333|NCT01511848|Drug|DFP (ferriprox) and deferasirox (ICL 670)|Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).
Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.
Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.
Other Name: ICL670
122334|NCT01511848|Drug|DFP, DFO|Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.
Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days
122335|NCT01511874|Drug|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
122336|NCT01511887|Drug|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
122337|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
122338|NCT01511900|Drug|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
122339|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
125643|NCT01587716|Other|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
125644|NCT01587729|Drug|Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants|TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
125645|NCT01587742|Drug|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
125646|NCT01587755|Other|TTOP|Patient is taken care of in an intensified, optimised manner
125647|NCT00080951|Drug|oxaliplatin|
125648|NCT01587755|Other|non-TTOP|Standard medical care
125649|NCT01587768|Drug|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides &amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
125650|NCT01587807|Drug|GSK1995057|inhaled dose (volume based on cohort)
126200|NCT01583777|Drug|Belinostat|On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.
After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days.
126201|NCT01583816|Drug|Resiquimod 0.03%|topical application
126202|NCT01583816|Drug|Resiquimod 0.01%|topical application
126203|NCT01583816|Drug|placebo|topical application
126204|NCT01583829|Behavioral|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
126205|NCT00001498|Drug|cyclophosphamide|
126206|NCT00080808|Drug|Sildenafil citrate|Oral sildenafil as needed
126207|NCT01586182|Radiation|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
126208|NCT01586195|Drug|Zelboraf (vemurafenib)|repeating oral dose
126209|NCT01586208|Drug|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
126210|NCT00080912|Radiation|radiation therapy|Given in a single fraction or multiple fractions
125712|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|Cohort 1 will be divided into three sub-groups and will receive:
Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)
Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1
Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations
125713|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + polyICLC|Cohort 2 will be divided into three sub-groups and will receive:
Group 2a: MELITAC 12.1 + polyICLC adjuvant
Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1
Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations
125714|NCT00080873|Drug|Traumeel S|
125715|NCT01585376|Genetic|mutation analysis|
125716|NCT01585376|Genetic|nucleic acid sequencing|
125717|NCT01585376|Other|laboratory biomarker analysis|
125718|NCT01585389|Genetic|gene expression analysis|
125719|NCT01585389|Genetic|genetic linkage analysis|
125720|NCT01585389|Genetic|microarray analysis|
125721|NCT01587807|Drug|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
125722|NCT01587820|Drug|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
125723|NCT01587820|Drug|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
125724|NCT01587833|Drug|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
125725|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
125726|NCT00080977|Biological|aldesleukin|
125727|NCT01587846|Dietary Supplement|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
125981|NCT01588236|Drug|KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
122557|NCT01510080|Behavioral|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
122558|NCT00074191|Drug|lomustine|
122559|NCT01510080|Behavioral|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
122560|NCT01510093|Drug|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
122561|NCT01510106|Drug|Calcium acetate, sevelamer carbonate|per package insert
122562|NCT01510106|Drug|Ferric citrate|6 caplets daily to start. Titrate as needed to up to 12 per day.
122563|NCT01510119|Drug|Hydroxychloroquine|
122862|NCT01547559|Drug|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
122863|NCT01547572|Procedure|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
122864|NCT01547572|Procedure|The control group will receive a leaflet only|The control group will receive a leaflet only
122865|NCT01547585|Other|Standardized soy containing muffin|Standardized muffin containing two levels of soy
122866|NCT00077597|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
122867|NCT01550003|Drug|Certolizumab Pegol (CZP)|CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.
CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.
Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range:
10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);
20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
122868|NCT01550016|Other|Observation|Clinical follow-up and laboratory investigations.
122869|NCT01550029|Behavioral|Counseling/Healthy Lifestyle|A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's "Clearing the Air" guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle.
122870|NCT01550029|Behavioral|Counseling/Managing Mood|A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's "Clearing the Air" guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting.
122340|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
122341|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
122342|NCT00074308|Biological|bevacizumab|Given IV
122343|NCT01511900|Drug|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
122344|NCT01511939|Drug|Pennsaid|Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
122345|NCT01511952|Other|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
122346|NCT01511952|Other|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
122347|NCT01514253|Dietary Supplement|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
122627|NCT01551953|Behavioral|Education|12 week education class
122628|NCT00078156|Behavioral|Behavior Therapy|
122629|NCT01551966|Device|Wireless esophageal capsule endoscopy ( PillCam Eso2)|This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.
During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.
For to asses the tolerance, after they completed both exams, the patients will be asked to answer a "comfort score" questionnaire.
In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy.
122630|NCT01551979|Device|Repetitive Transcranial Magnetic Stimulation|intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.
Sham participants will undergo the same procedures as those in the active rTMS group.
122631|NCT01551992|Procedure|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
122632|NCT01552005|Drug|Saxagliptin|No Intervention
122633|NCT01552018|Drug|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
122634|NCT01552018|Drug|Placebo|Placebo, 1 tablet per day for 3 months.
122635|NCT01552044|Drug|Spironolactone|25mg tablet once a day for 1 month
126211|NCT01586221|Other|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
126212|NCT01586234|Procedure|DSAEK with graft shaping and smoothing|A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea
The tissue on the underside of the cornea (endothelium) will be scraped away
The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea.
126213|NCT01586234|Procedure|Standard DSAEK|A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea
The tissue on the underside of the cornea (endothelium) will be scraped away
The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea.
126214|NCT01586247|Dietary Supplement|Synbiotic|8g/day galacto-oligosaccharide + 10^9 CFU/day B.lactis
126215|NCT01586247|Dietary Supplement|Placebo|8g/day maltodextrin
126216|NCT01586247|Dietary Supplement|Prebiotic|8g/day galacto-oligosaccharide
126217|NCT01586247|Dietary Supplement|Probiotic|10^9 CFU/day B.lactis
126218|NCT01586260|Drug|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
126219|NCT01586273|Device|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
126240|NCT01588795|Drug|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
126241|NCT01588808|Behavioral|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
126242|NCT01588821|Drug|Cabozantinib|60 mg daily by mouth
126243|NCT00001499|Procedure|chest radiotherapy|
126244|NCT00081003|Procedure|study of high risk factors|
126245|NCT01588834|Procedure|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
126246|NCT01588847|Procedure|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
126247|NCT01588847|Procedure|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
125982|NCT01588236|Drug|placebo|3 capsules of placebo tid (morning, midday, and evening)
125983|NCT01588249|Dietary Supplement|Pasteurized maple syrup|
125984|NCT01588249|Dietary Supplement|Placebo|
125985|NCT01588262|Other|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
125986|NCT01588275|Device|mandibular repositioning appliance (MRA) (SomnoDent)|bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
125987|NCT01588275|Procedure|Continuous positive airway pressure (CPAP)|Proper CPAP-pressure will be set for each patient separately.
125988|NCT01588288|Procedure|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
125989|NCT01588301|Behavioral|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
125990|NCT01588301|Behavioral|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
125991|NCT00081003|Genetic|protein expression analysis|
125992|NCT01588314|Drug|Gabapentin|gabapentin 100 mg capsules
125993|NCT01588314|Drug|placebo|compounded placebo capsules
125994|NCT01588340|Procedure|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
125995|NCT01588340|Procedure|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
125996|NCT01588353|Drug|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
125997|NCT01588366|Drug|Placebo|Administered orally
125998|NCT01588366|Drug|LY2409021|Administered orally
125999|NCT01588379|Behavioral|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
126000|NCT01588379|Behavioral|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
126001|NCT01590355|Radiation|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
122871|NCT01550055|Drug|Cetuximab plus Irinotecan Synchronously|Combined with irinotecan 180 mg/m2 every 2 weeks, Cetuximab 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
122872|NCT01550055|Drug|Irinotecan and Cetuximab Subsequently|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, cetuximab 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
122873|NCT00077857|Drug|capecitabine (Xeloda®)|825 mg/m^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
122874|NCT01550081|Other|Rate of perceived exertion|Exercise intensity controlled by Borg scale
122875|NCT01550081|Other|Heart rate monitor|Exercise intensity controlled by heart rate monitors
122876|NCT01550107|Drug|Allopurinol|300mg b.d for 24 weeks
122877|NCT01550107|Drug|Lactose tablets|matched placebo tablets b.d
121973|NCT01509040|Other|Standard Care|Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.
Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.
Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.
Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours.
121974|NCT01509040|Device|Low Volume Hemofiltration|Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.
Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required.
121975|NCT01509040|Device|High Volume Hemofiltration|Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.
Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required.
121976|NCT01509053|Drug|Aripiprazole (Abilify®) IM Depot Injection|400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.
Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014.
121977|NCT01509053|Drug|Oral aripiprazole|Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
121978|NCT01509066|Other|Diet|Dietary approaches for PCOS
121979|NCT01509079|Drug|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
122636|NCT01552044|Drug|Placebo|one tablet once a day for 1 month
122637|NCT01552057|Drug|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
122638|NCT01552057|Drug|Placebo|Placebo taken orally once every day for 15 weeks
122639|NCT00078169|Behavioral|Behavior Therapy|
122640|NCT01552070|Behavioral|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
122641|NCT01544803|Behavioral|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
122642|NCT01544803|Behavioral|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
122643|NCT01544816|Other|Snack Product|control food product
122644|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 1
122645|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 2
122928|NCT01547611|Other|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
122929|NCT01547624|Other|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
122930|NCT01547637|Procedure|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
122931|NCT01547637|Procedure|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
122932|NCT01547650|Other|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
122933|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
122934|NCT00077610|Drug|epoetin alfa or beta|iv 3 times weekly, as prescribed
122935|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
122936|NCT01547689|Biological|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
126248|NCT01588873|Drug|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.
After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.
Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment.
126249|NCT01588899|Device|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
126250|NCT01588912|Drug|Telbivudine|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
126251|NCT01581229|Procedure|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
126252|NCT01581229|Procedure|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
126253|NCT01581242|Drug|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
126254|NCT01581242|Drug|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
126255|NCT01581242|Drug|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
126256|NCT01581281|Drug|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
126545|NCT01584466|Drug|Paliperidone|The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.
Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary.
126546|NCT01584492|Drug|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
126547|NCT01584492|Drug|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
126548|NCT01584492|Drug|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
126549|NCT01584492|Drug|Formoterol + Beclomethasone dipropionate|Formoterol HFA pMDI 6 µg / actuation
Extrafine BDP HFA pMDI 50 µg/actuation
126002|NCT01590355|Procedure|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
126314|NCT01586468|Drug|WF10|0.5 mg/kg B.W.
126315|NCT01586468|Drug|NaCl Solution|NaCl Solution
126316|NCT01586481|Device|SANIDIAB|off-loading shoe
126317|NCT01586481|Device|BAROUK|old shoe
126318|NCT01588912|Drug|Tenofovir|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
126319|NCT01588912|Drug|Entecavir|Maintain the entecavir through the study period
126320|NCT01588925|Device|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
126321|NCT01588925|Drug|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
126322|NCT00081029|Procedure|management of therapy complications|
126323|NCT01588925|Drug|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
126324|NCT01588951|Drug|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
126325|NCT01588951|Drug|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
126326|NCT01588964|Procedure|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
126327|NCT01588990|Drug|FOLFIRI|Irinotecan 180 mg/m2 intravenously on Day 1, leucovorin 400 mg/m2 on Day 1, fluorouracil 400 mg/m2 on Day 1, fluorouracil 2400 mg/m2 intravenous infusion on Day 1 every 2 weeks until 2nd disease progression
126328|NCT01588990|Drug|XELOX|Oxaliplatin 130 mg/m2 intravenously on Day 1, capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of every 3 weeks cycle until 1st disease progression
126329|NCT01588990|Drug|bevacizumab [Avastin]|7.5 mg/kg intravenously on Day 1 of every 3 weeks cycle until 1st disease progression
126330|NCT01588990|Drug|bevacizumab [Avastin]|5.0 mg/kg intravenously on Day 1 every 2 weeks until 2nd disease progression
126331|NCT01588990|Drug|bevacizumab [Avastin]|5.0 mg/kg intravenously on Day 1 every 2 weeks until 1st disease progression
121980|NCT01509079|Drug|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
121981|NCT01509092|Procedure|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling" done immediately after the identification of the macular hole
121982|NCT01511250|Biological|DENVax|live attenuated Dengue vaccine, 0.5 ml dose subcutaneously administered at Day 0 and Day 90
121983|NCT01511250|Biological|Phosphate buffered saline|placebo control
121984|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
121985|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
EGCG, 675 mg/day, oral, for one year.
121986|NCT01511276|Behavioral|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
121987|NCT00074269|Procedure|peripheral blood stem cell transplantation|
122269|NCT01514201|Other|Laboratory Biomarker Analysis|Optional correlative studies
122270|NCT01514201|Other|Pharmacological Study|Correlative studies
122271|NCT01514201|Drug|Temozolomide|Given PO
122272|NCT01514201|Drug|Veliparib|Given PO
122273|NCT01514214|Device|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
122274|NCT00074490|Biological|T-Rapa cell DLI|The dose of Th2 cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 107 Th2/kg; minimum dose will be 1 x 107 Th2/kg).
122275|NCT01514214|Device|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
122276|NCT01514227|Drug|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
122277|NCT01514227|Drug|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
122278|NCT01514240|Drug|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
122937|NCT01547702|Behavioral|Teacher Help for ADHD|Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:
Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology
Session 2: Help establish teacher's role; goal setting; introduce behaviour planning
Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals
Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship
Session 5: Help to use instructional interventions for ADHD
Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours
122938|NCT01547715|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine
122939|NCT01547728|Drug|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
122940|NCT01547741|Drug|Doxorubicin|
122941|NCT01547741|Drug|Cyclophosphamide|
122942|NCT01547741|Drug|Docetaxel|
122943|NCT01547741|Drug|Paclitaxel|
122944|NCT01550133|Behavioral|Not Learned: Non-Nutritive solid to Non-nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
122945|NCT00077857|Drug|docetaxel (Taxotere®)|75 mg/m^2 intravenous on day 1 of each 3 week cycle
122041|NCT01516008|Drug|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
122042|NCT01516021|Dietary Supplement|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
122043|NCT00074165|Drug|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
122044|NCT01509105|Biological|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
122045|NCT01509131|Drug|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
122046|NCT01509131|Drug|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
122047|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
122048|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
126550|NCT01584492|Drug|Placebo (6 inhalations)|Matched placebo via pMDI
126551|NCT01584505|Drug|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
126552|NCT00080847|Drug|prednisone|Given orally
126553|NCT01584505|Drug|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
126554|NCT01586715|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
126555|NCT01586728|Other|Air - oxygen|his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)
nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.
During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%.
126556|NCT00080925|Drug|cytarabine|
126557|NCT01586728|Other|Oxygen - Air|nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.
his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%.
126558|NCT01586741|Procedure|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
126559|NCT01586767|Radiation|Proton radiation therapy|Daily proton radiation therapy
126560|NCT01586767|Radiation|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
126561|NCT01586780|Dietary Supplement|Protein drink|Test drink providing 9g protein
126562|NCT01586780|Dietary Supplement|Reference meal|Control meal
125651|NCT01587807|Procedure|bronchoalveolar lavage|BAL
125652|NCT01587807|Drug|LPS|50 μg
125653|NCT01590134|Dietary Supplement|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
125654|NCT01590134|Drug|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
125655|NCT01590147|Procedure|Yoga therapy|receive YST
125656|NCT01590147|Other|questionnaire administration|Ancillary studies
125657|NCT01590147|Procedure|quality-of-life assessment|Ancillary studies
126332|NCT01588990|Drug|mFOLFOX6|Oxaliplatin 85 mg/m2 intravenously on Day 1, leucovorin 400 mg/m2 intravenously on Day 1, fluorouracil 400 mg/m2 on Day 1, fluorouracil 2400 mg/m2 intravenous infusion on Day 1 every two weeks until 1st disease progression
126333|NCT00081029|Radiation|radiation therapy|
126334|NCT01589003|Other|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
125443|NCT01584713|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
125444|NCT01584726|Drug|Magnesium Sulfate|single dose of magnesium sulfate nebulization
125445|NCT01584739|Drug|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
125446|NCT01584739|Drug|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
125447|NCT01584752|Procedure|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
125448|NCT00080860|Other|immunohistochemistry staining method|
125449|NCT01584765|Drug|Prescription drugs with known hepatotoxicity|14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
125450|NCT01584778|Other|eosinophil cationic protein|Serum eosinophil cationic protein levels
125451|NCT01584791|Drug|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
125452|NCT01584791|Drug|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
125453|NCT01584804|Drug|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
125454|NCT01584804|Drug|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
125455|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
125456|NCT01584830|Drug|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
125457|NCT01584830|Drug|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
125458|NCT01587183|Behavioral|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
125459|NCT01587196|Drug|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
122279|NCT01514240|Drug|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
122280|NCT01514253|Drug|Glucose 25%|1 ml glucose 25%, once
122281|NCT00073983|Drug|gemcitabine hydrochloride|gemcitabine hydrochloride
122282|NCT01507376|Drug|recombinant hCG|recombinant hCG(500 µg Ovitrell)
122283|NCT01507376|Drug|urinary hCG|10,000 IU urinary hCG
122284|NCT01507389|Drug|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
122285|NCT01507402|Drug|REGN1033(SAR391786)|Administration method A
122286|NCT01507402|Drug|REGN1033(SAR391786)|Administration method B
122287|NCT01507402|Drug|Placebo|(inactive substance)
122288|NCT01507428|Other|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
122289|NCT01507428|Drug|Carboplatin|Given IV
122290|NCT01507428|Procedure|Computed Tomography|Undergo FDG PET/CT
122291|NCT01507428|Procedure|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
122564|NCT01510119|Drug|RAD001|
122565|NCT01510132|Drug|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
122566|NCT01510145|Drug|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
122567|NCT01510158|Drug|Lesinurad|Tablets, 200 mg QD
122568|NCT01510158|Drug|Lesinurad|Tablets, 400 mg QD
122569|NCT00074191|Drug|methotrexate|
122570|NCT01510158|Drug|Placebo|Tablets, Placebo QD
122571|NCT01510158|Drug|Allopurinol|
122572|NCT01510171|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
122049|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
122050|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
122051|NCT01509144|Biological|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
122052|NCT01509157|Device|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
122053|NCT01509157|Procedure|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
122054|NCT00074165|Drug|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
122055|NCT01509183|Device|Asthmapolis System|The Asthmapolis system works through the provision of information to patients and their providers. With the Asthmapolis device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Asthmapolis where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
122056|NCT01509196|Drug|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
122057|NCT01509209|Drug|Pseudoephedrine / Levocetirizine|tablet, BID everyday
122058|NCT01509222|Behavioral|Personalized nutrition counseling|
122348|NCT01514253|Other|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
122349|NCT01514266|Drug|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
122350|NCT01514266|Drug|Placebo|
122351|NCT00074490|Procedure|T cell DLI|Th2 Cell Transplantation
122352|NCT01514279|Behavioral|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls.
122353|NCT01514279|Behavioral|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.
It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls.
125658|NCT01590147|Other|laboratory biomarker analysis|Correlative studies
125659|NCT01590147|Other|assessment of therapy complications|Ancillary studies
125660|NCT01590147|Procedure|management of therapy complications|Receive YST or CE
125661|NCT00081133|Drug|imatinib mesylate|
125662|NCT01590147|Other|educational intervention|Receive CE
125663|NCT01590160|Drug|Ganetespib|IV, Using dose from Phase I
125664|NCT01590173|Drug|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
125665|NCT01590173|Drug|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
125666|NCT01590199|Drug|RAD001|
125667|NCT01590199|Drug|SOM230|
125668|NCT01590212|Other|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
126220|NCT01586286|Drug|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
126221|NCT00080925|Biological|filgrastim|
126222|NCT01586286|Drug|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
126223|NCT01586299|Drug|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
126224|NCT01586299|Drug|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
125460|NCT01587222|Drug|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
125461|NCT01587222|Drug|Midodrine|Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.
If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed.
125462|NCT00080925|Procedure|peripheral blood stem cell transplantation|
125463|NCT01587222|Drug|Octreotide|Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.
If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed.
125728|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
125729|NCT01587846|Dietary Supplement|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
125730|NCT01587859|Procedure|laparoscopic surgery|Nissen fundoplication; Collis Gastroplasty.
125731|NCT01587872|Procedure|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
125732|NCT01587885|Drug|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
125733|NCT01587885|Drug|Omeprazole 20 mg|Tablets, orally
125734|NCT01587898|Drug|GSK1278863|Tablet
125735|NCT01587898|Other|Placebo|Tablet
125736|NCT01587911|Other|Whey|Preload containing complete whey protein.
125737|NCT00080990|Drug|alvocidib|Given IV
125738|NCT01587911|Other|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
125739|NCT01587911|Other|Control|Preload control matched for energy to the other 5 preloads.
125740|NCT00081159|Drug|Doxorubicin hydrochloride|Doxorubicin 20 mg/m^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
122573|NCT01512251|Drug|BKM120 Combined with Vemurafenib (PLX4032)|Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)
Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid
Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid
Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid
Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid
Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid
Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D
122574|NCT01512264|Device|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
122575|NCT01512277|Biological|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
122576|NCT01512290|Other|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
122577|NCT01512303|Behavioral|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
122578|NCT00074321|Drug|capecitabine|Given PO
122579|NCT01512303|Behavioral|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
122580|NCT01512316|Drug|d-Cycloserine|250mg, one dose, 2hrs prior to fMRI
122581|NCT01512316|Drug|Lactose pill|one dose, 2hrs prior to fmri
122582|NCT01512316|Genetic|Saliva sample|Buccal cell material will be sampled from all participants on day3
122583|NCT01512316|Other|Functional neuroimaging (fMRI)|
122584|NCT01512329|Behavioral|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
122585|NCT01512329|Behavioral|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
122878|NCT01550133|Behavioral|Learned: Non-nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
122879|NCT01550133|Behavioral|Learned: Nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
122880|NCT01550133|Behavioral|Learned: Nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
122881|NCT01550133|Behavioral|Not Learned: Non-nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
122354|NCT01514292|Device|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
122355|NCT01514318|Device|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
122356|NCT01514331|Other|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
122357|NCT01514331|Other|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
122358|NCT01514344|Drug|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
122359|NCT01514344|Biological|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
122360|NCT01514357|Drug|Nesiritide (BNP)|This arm is designed to determine the optimal dose rage of nesiritide (BNP) to be used in the double blind trial (second arm of the study).
122361|NCT01514357|Drug|Nesiritide (BNP)|The optimal dose rage of nesiritide (BNP) to be used in the double blind trial will be determined in the first dose finding arm.
122362|NCT00001328|Drug|Cytovene (Ganciclovir Sodium)|
122363|NCT00074490|Drug|Prednisone|Prednisone:60 mg/m2/day PO, days 1-5
122364|NCT01514357|Drug|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
122365|NCT01514370|Drug|IFN beta 1 a + curcumin (BCM 95)|IFN beta 1 a (44 mcg TIW) + curcumin (500 mg 2 times a day)
122366|NCT01514370|Drug|IFN beta-1a + placebo|IFN beta-1a 44 mcg TIW + placebo (1 tablet 2 times per day)
122646|NCT01544829|Dietary Supplement|Theobromine|Single dose of theobromine
122647|NCT00077389|Drug|carboplatin|
122648|NCT01544829|Dietary Supplement|Theobromine|Multiple doses of theobromine
122649|NCT01544829|Dietary Supplement|Placebo|Placebo capsules
122650|NCT01544842|Drug|0.1 % tacrolimus ointment|applied topically to oral mucosa
122651|NCT01544842|Drug|0.1 % triamcinolone paste|applied topically to oral mucosa
122652|NCT01544842|Drug|Orabase paste|applied topically to oral mucosa
126225|NCT01586312|Other|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
126226|NCT01586312|Drug|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
126227|NCT01586325|Drug|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
126228|NCT01586325|Drug|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
126229|NCT01586325|Drug|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
126230|NCT01588730|Procedure|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
126231|NCT01588743|Drug|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
126232|NCT00081003|Procedure|endoscopic biopsy|
126233|NCT01588756|Drug|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
126234|NCT01588756|Drug|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
126235|NCT01588769|Biological|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
126236|NCT01588782|Drug|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
126237|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
126238|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
126239|NCT01588795|Procedure|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
126257|NCT01581281|Drug|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period. Dosing of topiramate will be weight-based.
126258|NCT00080626|Procedure|conventional surgery|lumpectomy or mastectomy at end of treatment
126259|NCT01581281|Drug|Placebo|Placebo will be administered twice daily at home during the 8-week titration period.
125741|NCT01590225|Drug|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 24 weeks.
125742|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
125743|NCT01590225|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 48 weeks.
125744|NCT01590225|Drug|Ribavirin|Drug: Ribavirin
The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 48 weeks.
125745|NCT01590238|Biological|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
126003|NCT01590368|Device|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
126004|NCT00081159|Drug|Leuprolide acetate|
126005|NCT01590368|Device|Modified "test" electrode|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
126006|NCT01590394|Device|Large plastic biliary stent|Stent placement for bile duct obstruction.
126007|NCT01590407|Drug|ALS-002200|ALS-002200
126008|NCT01590407|Drug|Placebo|Placebo
126009|NCT01590420|Device|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
126010|NCT01590433|Drug|Exenatide|Subjects will inject 5mcg of exenatide or identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
126011|NCT01590433|Drug|Placebo|Subjects will inject 5mcg of exenatide or identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
126012|NCT01590433|Behavioral|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects may or may not be asked to follow a reduced calorie diet in addition to receiving treatment.
126013|NCT01590446|Drug|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
126014|NCT01590446|Drug|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
126015|NCT00001504|Drug|9-cis-Retinoic Acid|
122882|NCT01550133|Behavioral|Not Learned: Nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
122883|NCT00078195|Biological|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
122884|NCT01552369|Drug|Prophylaxis with Valganciclovir|All subjects in this arm are given 900mg valganciclovir daily for 100 days post transplantation. Dosage may be adjusted for renal dysfunction
122885|NCT01552408|Drug|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
122886|NCT01552408|Procedure|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
122887|NCT01552421|Procedure|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
122888|NCT01552434|Drug|Temsirolimus|Dose Escalation Group: Starting dose of Temsirolimus 5 mg by vein on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group.
122889|NCT01552434|Drug|Bevacizumab|Temsirolimus + Bevacizumab + Cetuximab Group Starting Dose of Bevacizumab: 2.5 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
Temsirolimus + Bevacizumab + Valproic Acid Group and Temsirolimus + Bevacizumab Group Starting Dose of Bevacizumab: 5 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
Dose Expansion Groups Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group.
122890|NCT01552434|Drug|Valproic Acid|Starting dose of Valproic Acid 5 mg/kg rounded to nearest 250 mg by mouth on Days 1 - 7 and 15 - 21 of each 28 day cycle.
Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group
121988|NCT01511276|Behavioral|Combined exercise- + diet-induced weight loss|Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.
Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day.
121989|NCT01511289|Drug|Imatinib|400mg/Tab, QD
121990|NCT01511289|Drug|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
121991|NCT01511302|Drug|RNS60|RNS60, 2ml, nebulized twice daily.
121992|NCT01511302|Drug|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
122653|NCT01544855|Dietary Supplement|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
122654|NCT01544868|Other|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
122655|NCT01544881|Drug|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
122656|NCT01544881|Drug|Rapid Acting Analog|Subcutaneous Injection
122657|NCT01544894|Drug|Raloxifene|60 mg/d for one year
122658|NCT00001409|Drug|Interleukin-2|
122659|NCT00077389|Drug|cisplatin|
122660|NCT01544894|Drug|Strontium ranelate|2 g/d, for one year
122661|NCT01544907|Device|Conventional PTA|Use of conventional balloon for angioplasty only
122662|NCT01544907|Device|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
122663|NCT01544920|Biological|peginterferon alfa-2a|peginterferon alfa-2a vials 180 ug/week subcutaneous
122664|NCT01544920|Drug|ribavirin|ribavirin 1,000 mg/day (body weight <75 kg) or 1200 mg/day (body weight ≥75 kg) orally divided into two daily doses.
122665|NCT01547195|Procedure|Training walk|The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.
The training of walking will last 50 minutes, three times per week for 12 weeks.
At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes.
122946|NCT01550133|Behavioral|Not Learned: Non-nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
122947|NCT01550133|Behavioral|Not Learned: Non-Nutritive solid to Non-Nutritive Solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
122948|NCT01550146|Drug|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
126260|NCT01581307|Drug|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
126261|NCT01581307|Device|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
126262|NCT01581320|Drug|Test group|Once a month, administration of DP-R206 & placebo for 16 weeks
126263|NCT01581320|Drug|Reference group|Once a month, administration of Bonviva & placebo for 16 weeks
126264|NCT01581333|Other|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
126265|NCT01581333|Other|Standard empirical antimicrobial treatment discontinuation|The empirical antimicrobial treatment discontinuation will occur when the patient is:
The neutrophil count is above 500 million per mm3.
126266|NCT01581346|Other|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
126267|NCT01581359|Drug|Triptorelin acetate|Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses
Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses
126268|NCT01581372|Other|Pharmacist care|Pharmacist prescribing, education, drug management
126269|NCT00001498|Drug|methotrexate|
126270|NCT00080626|Procedure|neoadjuvant therapy|treatment prior to definitive breast surgery
126271|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
126272|NCT01583829|Behavioral|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
126273|NCT01583829|Other|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
126274|NCT01583842|Radiation|124I-MIBG (no-carrier added)|124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.
Optional 124I-MIBG (no-carrier added) Administration & PET/CT scan 6 weeks later.
128355|NCT01575925|Drug|2 mg Oral POM + 40 mg Oral DEX|
128356|NCT01575938|Behavioral|HIV prevention intervention|The 6-session HIV prevention intervention curriculum, "LifeSkills," incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into "real-life" situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
128357|NCT01575938|Behavioral|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
128674|NCT01574287|Drug|FACBC|Drug is give intravenously over 2 minutes at time of scan
128675|NCT01574300|Other|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
128676|NCT01574313|Procedure|stellate ganglion block|stellate ganglion block
128677|NCT00080002|Drug|Pegamotecan|
128678|NCT01574313|Drug|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
128679|NCT01574313|Drug|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
128680|NCT01574313|Drug|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
128681|NCT01574326|Drug|sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
128682|NCT01574326|Drug|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
128683|NCT01574339|Device|EndoStim LES Stimulation System|The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.
The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative.
128684|NCT01576393|Behavioral|WHE|12 Women's Health Education Sessions
128685|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
128686|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
128687|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
128688|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
128689|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
126576|NCT01589393|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
126577|NCT01589393|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
126578|NCT01589419|Drug|veliparib|see arm description
126846|NCT01557049|Other|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
126847|NCT01557062|Other|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
126848|NCT01557062|Other|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
126849|NCT01557062|Other|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
126850|NCT01557075|Drug|Atorvastatin (High dose statin treatment)|Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program
Atorvastatin 40 mg daily for 12 months after randomization
126851|NCT01557075|Drug|Pravastatin (High dose statin treatment)|Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program
Pravastatin 20mg daily for 12 months after randomization
126852|NCT00078624|Other|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
126853|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
126854|NCT01559272|Drug|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
126855|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
128746|NCT01581190|Dietary Supplement|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
128747|NCT01581203|Drug|Asunaprevir (ASV)|
128748|NCT01581203|Drug|Daclatasvir (DCV)|
128749|NCT01581203|Drug|Pegylated-interferon alfa 2a (PegIFN)|
128750|NCT01581203|Drug|Ribavirin (RBV)|
128751|NCT00080626|Drug|docetaxel|100 mg per meter-squared, every 14 days for 4 cycles
128752|NCT01581216|Other|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
128753|NCT01581216|Other|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
128754|NCT01581216|Other|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
128755|NCT01574352|Behavioral|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
128756|NCT01574352|Behavioral|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
127866|NCT01561222|Drug|Calcitriol|0.25 ug per day for one year
127867|NCT01561222|Drug|placebo|one pill per day
127868|NCT01561235|Other|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
127869|NCT01561248|Drug|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
127870|NCT01554098|Procedure|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
127871|NCT01554111|Drug|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
128202|NCT01580072|Other|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
128203|NCT01580085|Other|polysomnography|full night supervised laboratory polysomnography
128204|NCT01580098|Other|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
128205|NCT01580098|Other|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
128206|NCT00080522|Drug|zidovudine|
128207|NCT01580111|Biological|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
128208|NCT01580124|Procedure|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
128209|NCT01580124|Procedure|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
128210|NCT01580150|Other|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
128211|NCT01580150|Other|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
128212|NCT01580163|Drug|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
128213|NCT01580163|Drug|Methadone|Oral Solution，1mg/ml
128214|NCT01580163|Drug|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
128215|NCT01580176|Device|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
128216|NCT01580189|Dietary Supplement|Whey protein|18g protein, immediately after training, 9 weeks
128217|NCT00080522|Drug|didanosine|
128218|NCT01580189|Dietary Supplement|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
128466|NCT01580943|Drug|Chlorhexidine|All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer ("Did you feel any side effects caused by mouth rinse?", "If so, what are they?").
128467|NCT01580956|Other|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
128820|NCT01579019|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
128821|NCT01579019|Drug|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
128822|NCT01579019|Drug|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
128823|NCT01579045|Device|senofilcon A|bilateral daily use soft contact lens
128824|NCT01579045|Device|etafilcon A|bilateral daily use soft contact lens
128825|NCT01572324|Drug|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
128826|NCT01572337|Procedure|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
128827|NCT01572337|Other|Standard care|
128828|NCT01572350|Other|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
128829|NCT01572350|Drug|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
128830|NCT00079755|Drug|SGN-30 (anti-CD30 mAb)|
128831|NCT01572350|Drug|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
128832|NCT01572363|Drug|Sildenafil|50 mg once
128833|NCT01572376|Procedure|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
128834|NCT01572389|Behavioral|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
128835|NCT01572389|Behavioral|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
128836|NCT01572402|Other|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
128837|NCT01572402|Other|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
126856|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
126857|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
126858|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
127138|NCT01562301|Drug|Carboplatin|AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
127139|NCT01562301|Drug|Docetaxel|75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
127140|NCT01562301|Drug|Anvirzel|Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.
Expansion Cohort Starting Dose: Maximum tolerated dose from
127141|NCT01562301|Behavioral|Questionnaires|Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
127142|NCT01562314|Drug|GWP42003|1-5 capsules taken twice daily, 10 week treatment period.
127143|NCT01562314|Drug|Placebo|1-5 capsules taken, twice daily. 10 week treatment period.
127144|NCT01562340|Other|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
127145|NCT01562340|Other|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
127146|NCT00079053|Procedure|adjuvant therapy|
127147|NCT01562366|Device|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
127148|NCT01562366|Procedure|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
127149|NCT01562379|Dietary Supplement|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
127150|NCT01562379|Dietary Supplement|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
127151|NCT01555138|Drug|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
127872|NCT01554111|Drug|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
127873|NCT01554111|Drug|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
127874|NCT01554124|Drug|Meropenem|40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).
Treatment duration = 21 ± 7 days
127875|NCT01554137|Other|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
127876|NCT01554137|Other|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
127877|NCT01554150|Behavioral|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
127878|NCT01554163|Drug|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
127879|NCT01554163|Drug|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
127880|NCT00078377|Drug|Placebo|Matching placebo tablets once daily
127881|NCT01554176|Drug|MK-6096|MK-6096, one 10 mg tablet, orally, once daily
128144|NCT00079911|Drug|valacyclovir hydrochloride|
128145|NCT01573377|Drug|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
128146|NCT01573403|Drug|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
128147|NCT01573403|Drug|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
128148|NCT01573403|Drug|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
128149|NCT01573416|Other|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
128468|NCT01580956|Other|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
128469|NCT01580969|Drug|Bevacizumab|This is an open-label, multi-agent design. Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15. Blood pressure, CBC, CMP, and urine protein level, either by UA or urine protein/creatinine ratio will be checked at the beginning of each cycle.
128470|NCT01580969|Drug|Minocycline|Minocycline will be given by mouth twice a day starting at about half of the monotherapy maximal tolerated dose, 100 mg PO BID. Minocycline will be started on the day prior to radiation and continued until progression or intolerance. During the combined radiation, minocycline, and bevacizumab treatment, patients will be seen weekly with a CBC, CMP, and adverse event monitoring.
128471|NCT01580969|Radiation|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
128472|NCT01580995|Drug|Valacyclovir|Valacyclovir 500 mg po bid
128473|NCT01580995|Drug|Placebo|Placebo tablet twice daily
128474|NCT01581008|Other|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
128475|NCT00080613|Procedure|neoadjuvant therapy|
128476|NCT01581008|Behavioral|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
128477|NCT01581021|Device|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
128478|NCT01581021|Device|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
128479|NCT01581034|Drug|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
128480|NCT01581034|Drug|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
128481|NCT01581060|Drug|WX-554|Capsules of WX-554
128818|NCT01579019|Drug|RO5024048|1000 mg po bid, 24 or 26 weeks
128819|NCT01579019|Drug|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
127942|NCT01577485|Dietary Supplement|Probiotics in an pastille|Test group
127943|NCT01577485|Dietary Supplement|Control pastille|Control group
127944|NCT01577511|Biological|Samples and follow up|Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.
Follow-up: disease outcomes assessed at 24 months
127945|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
127946|NCT01577524|Drug|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
127947|NCT01577524|Drug|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
127948|NCT01577537|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
127949|NCT01577537|Drug|Placebo|Vaginal gel, daily for 7 days
127950|NCT01577550|Drug|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
127951|NCT01577550|Drug|Placebo, i.v.|Single i.v. administration of placebo
127952|NCT01577550|Drug|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
127953|NCT01577550|Drug|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
127954|NCT01577550|Drug|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
127955|NCT01577550|Drug|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
127956|NCT00001483|Drug|sertraline (Zoloft)|
127957|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
127958|NCT01577550|Drug|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
127959|NCT01577550|Drug|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
127960|NCT01579643|Procedure|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.
The host cornea bed will be prepared with an excimer laser.
Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed.
127152|NCT01555151|Drug|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
127153|NCT01555151|Device|Concept 1|A single dose dry powder inhaler (SDDPI)
127154|NCT01555151|Device|Twisthaler|A single dose dry powder inhaler (SDDPI)
127155|NCT01555164|Drug|Ranolazine|Ranolazine tablet(s) administered orally
127156|NCT01555164|Drug|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
127157|NCT00078533|Biological|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10^7cells/m2 and the highest will be 1x10^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
127423|NCT01557959|Drug|erlotinib hydrochloride|Given PO
127424|NCT01557959|Other|laboratory biomarker analysis|Optional correlative study
127425|NCT01557959|Genetic|polymorphism analysis|Correlative study
127426|NCT00078767|Drug|Trauma-focused Cognitive Behavioral Therapy plus Sertraline|
127427|NCT01557959|Other|pharmacogenomic studies|Correlative study
127428|NCT01557959|Genetic|genetic linkage analysis|Correlative study
127429|NCT01557959|Drug|docetaxel|Given IV
127430|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
127431|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
127432|NCT01557985|Drug|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
127433|NCT01560429|Procedure|Patient controlled epidural analgesia|CEA infusion rates were set when pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 were achieved in PACU. PCEA parameters were adjusted to allow an equivalent dose per hour. Use of hydromorphone 20 mcg/ml and bupivacaine 1 mg/ml (20 and 1) or hydromorphone 10 mcg/ml and bupivacaine 2 mg/ml (10 and 2) was permitted to achieve pain scores ≤ 3. Rescue boluses of 0.25% bupivacaine of 3 to 5 cc to a maximum of 10 cc were also permitted to achieve pain scores of less than 3 in PACU. Total consumption includes rescue medications as well as any switch in anesthetic concentration.
128150|NCT01573416|Other|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
128151|NCT01573429|Other|deuterated-Bisphenol A (d-BPA)|
128152|NCT01573442|Drug|testosterone|120 mg
128153|NCT01573442|Other|placebo|
128154|NCT01573442|Drug|anastrozole|8 mg
128155|NCT00079924|Drug|teriparatide|
128156|NCT01573468|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
128157|NCT01573468|Drug|Placebo|Placebo orally once on Day 1 of each cycle
128158|NCT01573468|Drug|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
128159|NCT01573481|Other|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
128160|NCT01573481|Other|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min).
128161|NCT01573494|Other|Sampling of blood|7,5 ml of blood
128162|NCT01573507|Other|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
128163|NCT01573520|Other|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
128410|NCT00079950|Drug|Pegamotecan|
128411|NCT01573845|Behavioral|Healthy Eating Campaign|Participants receive a 6-month school-based campaign that includes:
A 22-lesson classroom curriculum
Homework activities that involve the family
Monthly parent newsletters
A food shopping and packing guide for parents
Food demonstrations
A poster contest
School wide announcements
128412|NCT01573858|Other|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
128413|NCT01573858|Other|Acupuncture treatment 2|Needles will be inserted to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
128290|NCT01580254|Drug|Latanoprost RATIOPHARM© latanoprost eyedrops|patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
128291|NCT00080522|Drug|lopinavir/ritonavir|
128292|NCT01580280|Other|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
128293|NCT01580280|Other|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
128294|NCT01580293|Biological|BAY94-9027|Intravenous infusion of BAY94-9027
128295|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (A) for oral administration
128619|NCT01578577|Behavioral|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
128620|NCT01578577|Behavioral|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
128621|NCT00080431|Drug|Daclizumab|
128622|NCT01578590|Dietary Supplement|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
128623|NCT01578603|Dietary Supplement|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
128624|NCT01578603|Dietary Supplement|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
128625|NCT01578629|Other|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
128626|NCT01578629|Other|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
128627|NCT01578642|Device|EndoStim LES Stimulation System|The EndoStim LES Stimulation System comprises three components:
an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer.
128628|NCT01578655|Drug|cabazitaxel, prednisone, custirsen sodium|Following 3 loading doses of custirsen (640 mg IV), cabazitaxel (25mg/m² IV) is administered on a 3-week cycle with weekly custirsen (640 mg IV) and daily prednisone (10 mg PO) until disease progression, unacceptable toxicity, or completion of 10 cycles
128629|NCT01578655|Drug|cabazitaxel, prednisone|Cabazitaxel (25 mg/m² IV) is administered on a 3-week cycle with daily prednisone (10 mg PO) until disease progression, unacceptable toxicity, or completion of 10 cycles
127961|NCT01579643|Procedure|Penetrating Keratoplasty (KP)|A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.
The donor cornea is then sutured where the patient's cornea was.
128219|NCT01580189|Dietary Supplement|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
128220|NCT01580202|Drug|Entecavir|Entecavir 0.5mg daily per os
128221|NCT01580202|Drug|Lamivudine|lamivudine 100mg daily per os
128222|NCT01580215|Device|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
128223|NCT01580228|Drug|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m^2 on Day 1, 10 mg/m^2 on Day 8, and 14 mg/m^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
128224|NCT01580228|Drug|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
128225|NCT01580254|Drug|IOPIZE© Latanoprost eyedrops|patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
128226|NCT01580254|Drug|GALAXIA© Latanoprost eyedrops|patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
128227|NCT01573546|Behavioral|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
128228|NCT00079924|Drug|aldrenodate|
128229|NCT01573546|Behavioral|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
128230|NCT01573546|Other|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
128231|NCT01573572|Drug|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
128690|NCT01576419|Drug|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
128691|NCT00080210|Drug|Puricase|
128692|NCT01576419|Drug|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
128693|NCT01576432|Behavioral|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
127813|NCT01556425|Drug|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
127814|NCT01556425|Behavioral|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
127815|NCT01556425|Other|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
127816|NCT01556438|Biological|LY2127399|Administered IV
127817|NCT01556438|Drug|Bortezomib IV|Administered IV
127818|NCT01556438|Drug|Bortezomib SC|Administered SC
127819|NCT00078559|Drug|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
127820|NCT01556438|Drug|Dexamethasone|Administered orally
127821|NCT01556451|Biological|Zoster Vaccine Live|Zoster vaccine live
127822|NCT01556464|Device|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
127823|NCT01556477|Drug|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
128414|NCT01573858|Other|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
128415|NCT01573858|Other|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
128416|NCT01573871|Other|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
128417|NCT01573910|Drug|Moxifloxacin ophthalmic solution, 0.5%|
128418|NCT01573910|Drug|Ofloxacin ophthalmic solution, 0.3%|
128419|NCT01573923|Biological|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
128420|NCT01573923|Biological|Conventional therapy|Conventional therapy without cell therapy
128421|NCT00079963|Dietary Supplement|Vitamin C|1000 mg/day
128422|NCT00080158|Drug|bupropion|
128423|NCT01576003|Drug|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
128424|NCT01576003|Dietary Supplement|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
128425|NCT01576016|Device|Accent MRI system|Patients implanted with an Accent MRI system will receive 30 minutes of magnetic scan imaging
128426|NCT01576016|Device|Accent MRI system|Patients implanted with an Accent MRI system will wait for one hour without receiving an MRI scan
128427|NCT01576029|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
128428|NCT01576029|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
128757|NCT01574365|Drug|RTA 402|
128758|NCT01574378|Device|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
128759|NCT00080015|Drug|Diflomotecan (BN80915)|
128760|NCT01574378|Device|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
128761|NCT01574391|Device|Epidrum|Epidrum is used
128630|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
128631|NCT01578668|Drug|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
128632|NCT00080444|Drug|aprepitant|aprepitant capsules
128633|NCT01578668|Drug|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
128634|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
127751|NCT01558505|Device|PEB|paclitaxel-eluting balloon angioplasty
127752|NCT01558505|Device|POBA|conventional balloon angioplasty
127753|NCT01558531|Device|DEB|paclitaxel-eluting balloon angioplasty
127754|NCT01558531|Device|POBA|conventional balloon angioplasty
127755|NCT01558544|Procedure|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
127756|NCT01558557|Other|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
127757|NCT01558570|Procedure|Blood Draw|One time blood draw
127758|NCT01558583|Other|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
127759|NCT01558583|Other|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
127760|NCT00078845|Drug|Amifostine|500 mg three times a week.
127761|NCT01558583|Other|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
127762|NCT01558596|Procedure|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
127763|NCT01561001|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
128232|NCT01573585|Behavioral|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
128233|NCT01573585|Behavioral|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
128482|NCT01581073|Drug|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
128483|NCT01581099|Procedure|Digestive Adaptations III surgery|
128484|NCT01581112|Biological|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
128485|NCT01573936|Other|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
128486|NCT01573949|Drug|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
128487|NCT01573975|Drug|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
128488|NCT01573975|Drug|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
128489|NCT01573975|Drug|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
128490|NCT01573988|Other|Increasing eating frequency|The subjects receive the same breakfast with two sequences :
breakfast in one intake at 8:00
breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior
The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.
The administration order is determined by randomized allocation. The wash-out period is one to three weeks.
There are not diet or exercise interventions.
128491|NCT01574001|Behavioral|Antismoking intervention with no early follow-up|an anti-smoking intervention in line with the "5A's" method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke
128492|NCT01574001|Behavioral|Antismoking intervention with minimal early follow-up|Anti-smoking intervention in line with the "5A's" method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke
128493|NCT01574001|Behavioral|Antismoking intervention with intensive early follow-up|an anti-smoking intervention in line with the "5A's" method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke
128494|NCT01574014|Behavioral|CBGT|Cognitive-behavioral group therapy
128495|NCT00079963|Dietary Supplement|Vitamin E|800 IU/day
127824|NCT01556477|Drug|azacitidine + lenalidomide|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks.
127825|NCT01556490|Device|TheraSphere|Yttrium 90 microspheres
127826|NCT01556503|Device|VivaScope System|VivaScope System, Model#s 1500 and 2500
127827|NCT01556529|Procedure|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
127828|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
127829|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
127830|NCT00078559|Drug|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
127831|NCT01556542|Device|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
128082|NCT01575509|Other|Bread product|Brown bread
128083|NCT00080132|Drug|implitapide|
128084|NCT01575509|Other|Bread product|Whole grain bread
128085|NCT01575509|Other|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
128086|NCT01575509|Other|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
128087|NCT01575522|Other|Laboratory Biomarker Analysis|Correlative studies
128088|NCT01575522|Drug|Tivantinib|Given PO
128089|NCT01575535|Genetic|gene expression analysis|
128090|NCT01575535|Other|flow cytometry|
128091|NCT01575535|Other|fluorescence activated cell sorting|
128092|NCT01575535|Other|laboratory biomarker analysis|
128093|NCT01575535|Other|medical chart review|
128094|NCT00080145|Drug|Risperidone|
128762|NCT01574404|Procedure|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
128763|NCT01574417|Dietary Supplement|control margarine|Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.
Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.
128764|NCT01574417|Dietary Supplement|plant stanol-enriched margarine|Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.
Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.
128765|NCT01574430|Procedure|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
128766|NCT01574469|Other|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
128767|NCT01574469|Other|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
128768|NCT01574482|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
128769|NCT01574482|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
128770|NCT00001476|Device|Isolex 300i Magnetic Cell Selector|
128771|NCT00080028|Drug|Motexafin Gadolinium Injection|
128772|NCT01574495|Other|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
128773|NCT01574508|Drug|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
128774|NCT01574508|Drug|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
128775|NCT01574534|Device|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
128776|NCT01574534|Device|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
127882|NCT01554176|Drug|Placebo|Placebo, one tablet, orally, once daily
127883|NCT01554189|Drug|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
127884|NCT01554189|Drug|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
127764|NCT00078988|Procedure|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
127765|NCT01561014|Drug|erlotinib hydrochloride|Given PO
127766|NCT01561014|Drug|oxaliplatin|Given IV
127767|NCT01561014|Drug|fluorouracil|Given IV
127768|NCT01561014|Radiation|radiation therapy|Undergo radiotherapy
127769|NCT01561014|Procedure|conventional surgery|Undergo surgical resection
127770|NCT01561014|Other|immunohistochemistry staining method|Correlative study
127771|NCT01561014|Procedure|positron emission tomography|Correlative study
127772|NCT01561014|Procedure|computed tomography|Correlative study
128030|NCT01577667|Device|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
128031|NCT00080340|Drug|TLK286 (Telcyta) HCl for Injection|
128032|NCT01577680|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
128033|NCT01577680|Drug|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
128034|NCT01577693|Drug|dutasteride|novel dutasteride
128035|NCT01577693|Drug|dutasteride|dutasteride soft gel capsule
128036|NCT01577706|Drug|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
128037|NCT01579760|Drug|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
128038|NCT01579760|Drug|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
128039|NCT01579786|Procedure|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
128040|NCT01579799|Drug|L-lysine|Dose finding study for L-lysine
128496|NCT01574014|Drug|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
128497|NCT01574014|Drug|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
128498|NCT01574027|Drug|Vitamin D3 (cholecalciferol)|One capsule per day for six months
128499|NCT01574027|Drug|Placebo|One capsule per day for six months
128838|NCT01572402|Other|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
128839|NCT01572428|Procedure|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
128840|NCT01572428|Procedure|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
128841|NCT00079768|Drug|Alemtuzumab (Campath)|
128842|NCT01572454|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
128843|NCT01572454|Drug|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
128844|NCT01572467|Genetic|RNA analysis|
128845|NCT01572467|Genetic|gene expression analysis|
128846|NCT01572467|Genetic|mutation analysis|
128847|NCT01572467|Genetic|reverse transcriptase-polymerase chain reaction|
128848|NCT01574560|Behavioral|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
128849|NCT01574560|Behavioral|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
128850|NCT01574573|Behavioral|Self support, group sessions|Self support,group sessions
128851|NCT01574586|Device|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
128852|NCT01574599|Other|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
128853|NCT00080041|Drug|Motexafin Gadolinium Injection|
128095|NCT01575548|Drug|Pazopanib Hydrochloride|Given PO
128096|NCT01575548|Other|Pharmacological Study|Correlative studies
128097|NCT01575548|Other|Placebo|Given PO
128098|NCT01575548|Other|Quality-of-Life Assessment|Ancillary studies
128099|NCT01577706|Drug|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
128100|NCT01577719|Behavioral|Multimedia Lifestyle Improvement|Online Goal setting to improve diet, physical activity or smoking behaviours
regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.
Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks.
128101|NCT01577719|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
128102|NCT01577732|Biological|Infanrix-IPV+Hib™|Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
128103|NCT01577745|Biological|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
128104|NCT00080340|Drug|gefitinib (Iressa)|
128105|NCT01577758|Drug|MLN0264|All patients will receive MLN0264 as a 30-minute infusion on Day 1 of each treatment cycle
128358|NCT01575951|Radiation|MRI-DCE|The treatment follows the standard practice including radiation dose and treatment volumes.
DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.
Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.
MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.
Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week.
128359|NCT01575990|Behavioral|Making A Decision About CRC Screening|Targeted by age and gender with 3 components.
Educational component
Values clarification exercise
Individualized decision making worksheet
The intervention or control condition is administered before the index visit with the patient's provider.
128360|NCT01575990|Behavioral|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
127885|NCT01554202|Behavioral|assessment of memory|
127886|NCT01554202|Biological|circulating tPA dosage|
127887|NCT01554202|Genetic|ApoE4|
127888|NCT01554202|Other|Brain imaging examination MRI and PET examinations|
127889|NCT01554215|Behavioral|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
127890|NCT01554215|Behavioral|Mom Power Attentional Control Group|at home control, weekly mailings
127891|NCT00078390|Drug|S-3304|
127892|NCT01556581|Procedure|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
127893|NCT01556581|Procedure|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
127894|NCT01556594|Drug|glucagon|glucagon solution for injection containing 1 mg of glucagon Single subcutaneous injection
127895|NCT01556594|Drug|Low dose novel formulation|Low dose novel formulation
127896|NCT01556594|Drug|high dose novel formulation|high dose novel formulation
127897|NCT01556594|Drug|Medium dose novel formulation|Medium dose novel formulation
127898|NCT01556607|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
127899|NCT00078572|Drug|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
127900|NCT01556607|Drug|Placebo|
127901|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
127902|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
127903|NCT01556646|Drug|Tolvaptan|15 to 30mg qd titrated to sodium concentration
128041|NCT01579812|Drug|Metformin|Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.
Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy.
128042|NCT01579825|Other|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
128043|NCT01579838|Drug|Eculizumab|PNH and or atypical TTP classical protocols
128044|NCT01579851|Drug|Sugammadex|sugammadex
4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count
2 mg/kg : if there is at least two responses to Train of Four stimulations
128045|NCT01579864|Drug|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
128046|NCT00080522|Drug|stavudine|
128047|NCT01579864|Drug|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
128048|NCT01579877|Dietary Supplement|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
128296|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (B) for oral administration
128297|NCT01580319|Other|physical exercise|150 minutes per week
128298|NCT01580345|Dietary Supplement|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group)from <=20 weeks of gestation until delivery.
128299|NCT01580345|Dietary Supplement|Placebo|400 mg of placebo (corn/soy oil) will be given to the pregnant women from <=20 weeks of gestation until delivery.
128300|NCT01580358|Drug|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
128301|NCT01580358|Drug|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
128302|NCT00080535|Biological|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
128303|NCT01580371|Drug|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
128304|NCT01580397|Drug|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
128305|NCT01580410|Drug|mitomycin C|Given by HIPEC
128854|NCT01574612|Drug|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
128855|NCT01574638|Drug|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
128856|NCT01574651|Drug|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
128857|NCT01574651|Drug|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
128858|NCT01574651|Drug|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
127670|NCT01560871|Behavioral|Low-intensity IMT plus walking|The IMT training is about 15-20 minutes. Both groups will need to come in once a week for 15 to 20 minutes to probably readjust the IMT training intensity on the breathing device.
For the walking program, each participant will be given a pedometer and a heart rate monitor so he/she can track daily step counts and walking heart rate during the study. The walking program will consist of walking every day at an intensity of "hard" to "somewhat hard" on the Rating of Perceived Exertion (RPE) scale. Participants will begin walking at least 15 minutes twice a day for 7 days a week and eventually progress to 45-50 minutes a day by the end of the six weeks.
127671|NCT01560884|Drug|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
127672|NCT00001440|Procedure|Autologous T cells|
127673|NCT00078988|Drug|isotretinoin|Given IV
127674|NCT01560884|Drug|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
127675|NCT01560884|Drug|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
127676|NCT01560884|Drug|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
127677|NCT01560897|Drug|Oral C13|Ingestion of C13 and follow up of the ureogenesis
127678|NCT01560923|Biological|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
127679|NCT01560923|Biological|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
127680|NCT01560923|Other|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
127681|NCT01560949|Drug|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
128361|NCT01578148|Procedure|Noxipoint Therapy|Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:
Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named "Noxipoints").
Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.
Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.
Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age.
128362|NCT00080353|Drug|Montanide ISA 51|
128363|NCT01578148|Procedure|Physical Therapy|The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:
TENS stimulation (45 minutes):
• Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.
Other modalities of PT per the therapist's choice:
Infrared treatment on the pain areas (about 15 minutes)
Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).
Exercise and training:
Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or
Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes
Hot/cold pack to the pain area for about 15 minutes
128364|NCT01578161|Drug|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
128365|NCT01578161|Drug|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
128366|NCT01578174|Drug|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
128367|NCT01578174|Drug|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
128368|NCT01578187|Device|Hair2Go|Treatment with the device once under observation
128369|NCT01578200|Drug|Lanthanum Carbonate|
128370|NCT01578200|Drug|Calcium Carbonate|
128694|NCT01576445|Procedure|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
128695|NCT01576445|Procedure|medial parapatellar approach|medial parapatellar approach
128696|NCT01576458|Drug|ursodeoxycholic acid|450 mg/day for 14 days
128697|NCT01576458|Drug|Placebo|placebo
128698|NCT01576471|Biological|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
128699|NCT01576471|Biological|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
128164|NCT01573533|Biological|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
128165|NCT01575548|Other|Questionnaire Administration|Ancillary studies
128166|NCT01575561|Drug|Lurasidone|Lurasidone 20-80 mg taken orally once daily
128167|NCT01575574|Drug|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
128168|NCT01575587|Drug|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
128169|NCT01575587|Drug|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
128170|NCT01575587|Drug|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
128171|NCT00080145|Behavioral|Behavior Therapy|
128172|NCT01575587|Drug|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
128173|NCT01575600|Other|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
128174|NCT01575613|Drug|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
128175|NCT01575613|Biological|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
128176|NCT01575613|Biological|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
128177|NCT01575613|Biological|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
128178|NCT01575626|Drug|Sevoflurane|All active comparators of this study have the same intervention as mentioned ahead:
First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.
Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).
Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices.
128179|NCT01575639|Drug|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
128306|NCT01580410|Drug|oxaliplatin|Given by HIPEC
128307|NCT01580410|Procedure|therapeutic conventional surgery|Undergo surgery
128308|NCT01580410|Other|quality-of-life assessment|Ancillary studies
128309|NCT01580410|Drug|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
128310|NCT01580423|Drug|aprepitant|125 mg capsule
128311|NCT01580423|Drug|placebo|capsule identical to aprepitant
128312|NCT01580436|Procedure|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
128313|NCT00080574|Procedure|Skin Biopsy|
128314|NCT01580462|Other|Observational study|Study plan - data collecting:
Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded.
128315|NCT01580475|Other|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
128316|NCT01573637|Drug|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
128317|NCT01573663|Drug|Ambroxol and Levodropropizine|Ambroxol HCl 30mg & Levodropropizine 60mg, PO, Single dose
128635|NCT01578681|Procedure|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
128636|NCT01578681|Procedure|Stretching|Patient will be instructed to do muscle stretching of the thorax
128637|NCT01578694|Procedure|MRI|T1 rho MRI
128638|NCT01580813|Drug|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
128639|NCT01580813|Drug|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
128640|NCT01580826|Other|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
127682|NCT01560949|Drug|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
127683|NCT01560949|Drug|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
127684|NCT00078988|Drug|thiotepa|Given IV
127685|NCT01560949|Drug|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
127686|NCT01560949|Radiation|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
127687|NCT01560962|Drug|povidone iodine|
127688|NCT01560962|Drug|Povidone-Iodine|
127689|NCT01560962|Drug|Azithromycin|
127690|NCT01560962|Drug|tobramycin-dexmethasone|
126807|NCT01561586|Drug|Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).
Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.
External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)
126808|NCT01561599|Drug|BB3|Daily intravenous administration of 2mg/kg for 4 days
126809|NCT01561599|Drug|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
126810|NCT01561612|Behavioral|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
126811|NCT01561625|Other|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
126812|NCT01554514|Biological|rituximab|rituximab intravenously 100 mg every week for four doses
126813|NCT01554527|Procedure|CPAP treatment|6 months of treatment with PAP (CPAP or BPAP)
126814|NCT01554527|Other|No CPAP treatment|Children randomized to the comparison group will receive routine care
126815|NCT01554540|Drug|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
126816|NCT01554553|Procedure|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
128700|NCT01576484|Drug|REGN727 (SAR236553)|REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
128701|NCT01576497|Procedure|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
128702|NCT00080223|Drug|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
128703|NCT01576497|Device|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
128704|NCT01576497|Device|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
128705|NCT01578694|Procedure|MRI|T1 rho MRI
128706|NCT01578707|Drug|ofatumumab|The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.
Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)
128707|NCT01578707|Drug|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
128708|NCT01578720|Drug|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
128709|NCT01578733|Dietary Supplement|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
128710|NCT00080444|Drug|ondansetron|ondansetron IV preparation
128711|NCT01578746|Procedure|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
128712|NCT01578746|Procedure|Anterior approach|The use of anterior approach in total hip arthroplasty
128713|NCT01578759|Procedure|Salpingectomy|Removal of the fallopian tubes
127832|NCT01556542|Device|nitinol stent implantation|nitinol stent implantation
127833|NCT01556568|Drug|MEK162|
127834|NCT01558596|Procedure|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
127835|NCT01558622|Drug|dexketoprofen trometamol|50mg intravenous infusion
128180|NCT01575652|Other|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
128181|NCT01575652|Other|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
128429|NCT01576042|Drug|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
128430|NCT01576042|Drug|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
128431|NCT01576042|Device|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
128432|NCT01576068|Other|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
128433|NCT00001482|Drug|Gabapentin (Neurontin® (Registered Trademark))|
128434|NCT00080158|Drug|mirtazapine|
128435|NCT01576081|Device|HEPHAISTOS|HEPHAISTOS unloading orthotic
128436|NCT01576094|Drug|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
128437|NCT01576094|Drug|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
128438|NCT01576107|Other|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
128439|NCT01576107|Other|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
128440|NCT01576120|Other|bowel prep regimen first boost 6 oz. and second boost 3 oz.|Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)
128441|NCT01578278|Drug|Bepotastine besilate-fluticasone propionate|Nasal Spray
128442|NCT01578278|Drug|Placebo Comparator|Nasal Spray
128641|NCT01580839|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
128642|NCT01580839|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
128643|NCT01580852|Procedure|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
128644|NCT01580852|Procedure|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
128645|NCT01580865|Drug|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Tacrolimus will be started in 45 patients at a dosage of 0.05 mg/kg/d divided into 2 daily doses at 12-hour intervals, and the dosage will be titrated to achieve 12-hour trough blood concentrations of 10-20 ng/mL in the first and second month and then 6-8 ng/mL thereafter.
MMF will be initiated in 45 patients at a dose of 750 mg twice daily (for patients > 50 Kg and eGFR > 60 ml/min), and advanced weekly to a maximum dose of 1,000 mg two times daily to achieve or MPA trough level > 3 mg/dL.
All patients will be received concomitant prednisone at a dose of 1 mg/kg/d (maximum 60 mg/d), with tapering by 5 mg/d every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage will be maintained to the end of 24 weeks.
128646|NCT00080613|Procedure|endocrine therapy|
128647|NCT01580878|Drug|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
128648|NCT01580878|Drug|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
128649|NCT01580878|Drug|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
128650|NCT01580891|Drug|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% applied topically once a day for 28 days.
128651|NCT01580891|Drug|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
128652|NCT01580891|Drug|Placebo topical cream|Placebo topical cream applied topically once a day for 28 days.
127773|NCT01561014|Procedure|laboratory biomarker analysis|Correlative study
127774|NCT01561014|Genetic|gene expression analysis|Correlative study
127775|NCT00078988|Procedure|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
127776|NCT01561014|Radiation|fludeoxyglucose F 18|Undergo F18 PET and CT scan
127777|NCT01561027|Drug|CNV1014802|CNV1014802 350mg bid for 21 days Matching placebo
127778|NCT01561040|Dietary Supplement|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
126817|NCT01554566|Dietary Supplement|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
126818|NCT00078455|Drug|ILX651|
126819|NCT01554579|Drug|AF-219|BID
126820|NCT01554579|Drug|Sugar Pill|Placebo
126821|NCT01554592|Drug|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
126822|NCT01554592|Drug|Statin therapy|Participants will continue on stable statin therapy.
126823|NCT01554618|Drug|Exenatide Once Weekly|2 mg exenatide once weekly
126824|NCT01554618|Drug|Placebo|Placebo
126825|NCT01554631|Drug|Acarbose (Glucobay ODT, BAYG5421)|
126826|NCT01554631|Drug|Acarbose (Glucobay, BAYG5421)|
127102|NCT01557374|Drug|Decrease Tocilizumab, Abatacept|The decrease pattern is established on 4 consecutive stages :
IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):
Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop
SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):
Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop
If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.
If DAS 28 > 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage
If DAS 28 > 3,2 : return to previous stage, (relapse according to European expert consensus)
In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study.
127103|NCT01557387|Other|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
127104|NCT01557400|Drug|Ataluren|Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
127105|NCT01557413|Procedure|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
127106|NCT01557413|Procedure|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
127836|NCT01558622|Drug|tramadol hydrochloride|100mg intravenous infusion
127837|NCT01558622|Drug|pethidine hydrochloride|50mg intravenous infusion
127838|NCT01558622|Drug|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
127839|NCT01558622|Drug|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
127840|NCT01558622|Drug|vitamin c|500mg intravenous infusion
127841|NCT01558635|Device|Medtronic Cardioblate CryoFlex|Patients will have their scheduled surgery plus, during the same procedure, their AF will be treated with the Cardioblate CryoFlex Surgical Ablation System to perform the Cox Cryo Maze III procedure. In addition they will receive an implantable monitor.
127842|NCT00078858|Drug|fludarabine phosphate|Given IV
127843|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
127844|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
127845|NCT01558661|Drug|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) > 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
127846|NCT01558674|Drug|MK-7145 2 mg|
127847|NCT01558674|Drug|MK-7145 8 mg|
127848|NCT01558674|Drug|Furosemide|
127849|NCT01558674|Drug|Torsemide|
128106|NCT01577771|Biological|Prevnar13 (manufactured by Pfizer)|PCV13 administered IM in the antero-lateral thigh
128107|NCT01577784|Drug|Pazopanib|800 mg / day of pazopanib in monotherapy.
128443|NCT01578291|Behavioral|Parental information|An informational brochure indicating the study details
128444|NCT00000262|Drug|0.4% Sevoflurane|
128445|NCT00001483|Drug|venlafaxine (Effexor)|
128446|NCT00080392|Drug|DNA Plasmid Vector|
128777|NCT01576510|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
128778|NCT01576523|Biological|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
128779|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
128780|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
128781|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
128782|NCT01576549|Drug|LY2127399|Administered subcutaneously (SC)
128783|NCT01576575|Drug|Buprenorphine|.2 mg IV or 2-4 mg sublingual
128784|NCT01576575|Drug|Rifampin|600 mg orally for 7 days
128785|NCT00080236|Drug|IDN-6556|
128786|NCT01576575|Other|grapefruit juice|8 oz at bedtime and 3oz in the morning.
128787|NCT01576575|Drug|Ketoconazole|400 mg orally for 3-4 days
128788|NCT01576588|Drug|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
128789|NCT01576588|Drug|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
128790|NCT01576614|Behavioral|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
128791|NCT01576627|Dietary Supplement|zinc citrate|10 mg of zinc as either zinc citrate
128792|NCT01576627|Dietary Supplement|Zinc Gluconate|10 mg of zinc as either zinc gluconate
127779|NCT01561053|Biological|Albumin|Human albumin 20%
127780|NCT01561053|Biological|Immune globulin|Intravenous (human) immune globulin 5%
127781|NCT01561066|Procedure|Autologous platelet-rich fibrin glue (PRFG)|Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.
PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings.
127782|NCT01561066|Drug|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
127783|NCT01561079|Drug|Buprenorphine|Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
127784|NCT01561092|Drug|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
127785|NCT01561092|Drug|Placebo|Tablets
127786|NCT00079001|Drug|zoledronic acid|Given IV
127787|NCT01561105|Other|IMPACT|IMPACT is a collaborative care management program for late-life depression
127788|NCT01553942|Drug|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
127789|NCT00078364|Procedure|MRI|
127790|NCT01553942|Radiation|Radiation|Daily, Monday-Friday
127791|NCT01553942|Drug|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
127792|NCT01553942|Drug|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
127793|NCT01553942|Procedure|Surgery|Surgery to remove tumor
128049|NCT01579877|Dietary Supplement|Placebo herbal extract granule|The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
128050|NCT01579890|Drug|Diclofenac|diclofenac topical lotion
128051|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
127107|NCT01559753|Drug|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.
Beta-Lactams:
Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS
Ceftriaxone : 2 g OD during 3 days, then 1 g OD
Cefotaxime : 2 g TDS during 3 days, then 1 g TDS
Aminoglycosides
Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)
Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
127108|NCT01559753|Drug|compare 8 to15 days of antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.
•
Beta-Lactams:
Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS
Ceftriaxone : 2 g OD during 3 days, then 1 g OD
Cefotaxime : 2 g TDS during 3 days, then 1 g TDS
Aminoglycosides
Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)
Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
127109|NCT00078949|Drug|cisplatin|Given IV
127110|NCT01559805|Behavioral|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
127111|NCT01559805|Behavioral|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
127112|NCT01559818|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
127113|NCT01559831|Biological|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
127114|NCT01559844|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
127115|NCT01559844|Drug|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
127387|NCT01562509|Other|Standard intervention|Standard intervention consists of audit&feedback
127388|NCT01562522|Other|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
127389|NCT01562535|Other|Pronation|In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a "click" in the elbow meaning the re-accommodation of the radial head has been accomplished.
127390|NCT01555593|Device|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
127391|NCT01555606|Other|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
127392|NCT01555619|Device|Implantation of a CRT-D System|Implantation of a CRT-D System
128108|NCT01577797|Behavioral|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
128109|NCT01577810|Device|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
128110|NCT01577823|Device|Foley Catheter|
128111|NCT01577849|Drug|Vitamin D3|administration of Vitamin D3 24,000 IU
128112|NCT01577849|Drug|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
128113|NCT01577862|Drug|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
128114|NCT01577862|Drug|Rifampicin|600 mg every 12 hours intravenously
128115|NCT00080353|Drug|IL-2|
128116|NCT01577875|Device|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
128117|NCT01577888|Device|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
128118|NCT01577901|Other|Clearblue Advanced|Pregnancy test
128119|NCT01577914|Drug|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
128120|NCT01577914|Drug|Carvedilol|12.5mg tablet once a day
128121|NCT01577927|Other|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
128122|NCT01577927|Behavioral|PT-assisted home rehabilitation|Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.
Every two weeks, PT phones the patient for an educational reinforcement.
128123|NCT01579929|Drug|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
128124|NCT01579955|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
128793|NCT01576627|Dietary Supplement|Zinc oxide|10 mg of zinc as either zinc oxide
128794|NCT01576640|Drug|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
128795|NCT01576640|Drug|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
128796|NCT00080236|Drug|Placebo|
128797|NCT01576640|Other|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
127904|NCT01556659|Drug|Absence of Acenocoumarol|Dual anti-platelet therapy without the addition of Acenocoumarol.
127905|NCT01556672|Drug|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
127906|NCT01556672|Device|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
127907|NCT01556685|Other|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
127908|NCT01556685|Other|Blood Sample|For evaluation of interferon-related Nab
127909|NCT01556685|Genetic|Blood Sample|genetic evaluation - predisposition to Nab generation
127910|NCT00078572|Drug|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
127911|NCT01556698|Drug|NVN1000 Topical Gel|
127912|NCT01556698|Drug|Topical Gel Vehicle|Placebo
127913|NCT01558687|Other|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
127914|NCT01558700|Drug|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
127915|NCT00078858|Radiation|total-body irradiation|Undergo TBI
127916|NCT01558700|Drug|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
128052|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
128053|NCT01579916|Biological|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
128054|NCT01579916|Other|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
128055|NCT01573234|Device|Gauze and Patch|Traditional Dressing
128056|NCT01573247|Drug|AKN-028|Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.
During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit.
128057|NCT01573260|Other|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
128058|NCT01573260|Other|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
128059|NCT01573273|Drug|Oxytocin|intranasal administration, 40 IUs
128060|NCT01573273|Drug|Saline|intranasal administration, 40 IUs
128061|NCT01573286|Drug|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
128062|NCT01573286|Drug|Glucagon like peptide-2|Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.
Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days.
128063|NCT01573299|Other|Mobilization of stroke patients|In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively "verticalised" and is allowed to sit outside of the bed on the third day after the stroke onset.
128318|NCT00079937|Drug|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
128319|NCT01573663|Drug|Ambroxol|Ambroxol HCl 30mg, PO, single dose
127393|NCT00078559|Drug|Tacrolimus|2mg orally twice daily, on days 1-60
127394|NCT01555632|Drug|atorvastatin calcium|Given PO
127395|NCT01555632|Drug|placebo|Given PO
127396|NCT01555645|Behavioral|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
127397|NCT01555658|Drug|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
127398|NCT01555658|Drug|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200—250 s)
127399|NCT01555671|Drug|Placebo|Bag B (placebo group), containing 10 mL of normal saline solution
127400|NCT01555671|Drug|Meperidine|50 mg meperidine injection intramusculer
127401|NCT01555684|Procedure|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
127402|NCT01555697|Drug|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
127691|NCT01560975|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
127692|NCT01560988|Drug|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
127693|NCT01560988|Drug|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
127694|NCT01553708|Drug|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
127695|NCT01553721|Drug|udenafil|Phase IIa - Udenafil Dose 1, Dose 2(Single dose)
Phase IIb - Udenafil(BID)
127696|NCT01553721|Drug|placebo|Phase IIa - placebo Phase IIb - placebo
128371|NCT01578213|Drug|Imatinib mesylate|Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg
Total dosage per day: 800 mg
Oral use
128372|NCT01578239|Drug|Octreotide LAR|In the experimental arm, 30 mg Octreotide LAR treatment will be given to the patients until the end of study for symptom control purpose, unless the patient progresses or dies.
In the active comparator arm, 60 mg Octreotide LAR treatment will be given to the patients every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies.
128373|NCT00080366|Drug|1-Octanol|
128374|NCT01578239|Drug|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity;
128375|NCT01578252|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
128376|NCT01578252|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
128377|NCT01578265|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
128378|NCT01578265|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
128379|NCT01578278|Drug|Bepotastine besilate formulation|Nasal Spray
128380|NCT01578278|Drug|Fluticasone propionate|Nasal Spray
128381|NCT01580657|Behavioral|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
128382|NCT01580657|Behavioral|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
128383|NCT01580657|Behavioral|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
128384|NCT01580657|Behavioral|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
128385|NCT01580657|Behavioral|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
128386|NCT01580670|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
128387|NCT01580683|Drug|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
127917|NCT01558713|Drug|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
127918|NCT01558713|Drug|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
127919|NCT01558713|Drug|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
127920|NCT01558713|Drug|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
127921|NCT01558713|Drug|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
127922|NCT01558713|Drug|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
128182|NCT00080158|Drug|fluoxetine|
128183|NCT01575665|Device|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
128184|NCT01575678|Drug|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
128185|NCT01575678|Drug|Lactose|blinded capsule 1/day, oral use, for 4 weeks
128186|NCT01575691|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
128187|NCT01577940|Procedure|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
128188|NCT01577940|Procedure|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
128189|NCT01577953|Drug|SB010|Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.
Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.
Dose levels:
Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL).
128190|NCT00080353|Drug|gp100:209-217|
128191|NCT01577953|Drug|Placebo|Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.
Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.
128320|NCT01573663|Drug|Levodropropizine|Levodropropizine 60mg, PO, single dose
128321|NCT01573689|Behavioral|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
128322|NCT01573702|Procedure|Stereostatic Radiosurgery|21 Gy daily for 5 days
128323|NCT01573702|Drug|Erlotinib|150mg once daily
128324|NCT01573715|Drug|NIMBEX|
128325|NCT01573715|Drug|NIMBEX|
128326|NCT01573715|Other|WITHOUT NIMBEX|
128327|NCT01573728|Behavioral|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
128328|NCT01573728|Behavioral|Public Health Exercise|At least 150 minutes at moderate intensity
128329|NCT00001476|Drug|Gene Therapy Method for CGD|
128330|NCT00079937|Drug|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
128331|NCT01573741|Drug|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
128332|NCT01573754|Drug|Hydroxychloroquine|100 mg by mouth twice weekly
128333|NCT01573754|Procedure|Phlebotomy|450 mL every 2 weeks
128334|NCT01573767|Drug|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
128335|NCT01573767|Drug|Placebo|Placebo inhalation powder during treatment period
128336|NCT01573767|Drug|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
128337|NCT01573780|Drug|Smac mimetic TL32711|Given IV
128338|NCT01573780|Drug|gemcitabine hydrochloride|Given IV
128339|NCT01573780|Other|laboratory biomarker analysis|Correlative studies
128340|NCT01573780|Other|pharmacological study|Correlative studies
128341|NCT00079937|Drug|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
127697|NCT01553747|Drug|JNJ-27018966|Oral tablets twice daily
127698|NCT01553747|Other|Placebo Comparator|Oral tablets twice daily
127699|NCT00078338|Drug|Human interferon beta-1a and glatiramer acetate|
127700|NCT01553760|Procedure|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
127701|NCT01553760|Procedure|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
127702|NCT01553773|Drug|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
127703|NCT01553773|Drug|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
127704|NCT01553786|Drug|Lenalidomide|Lenalidomide
127705|NCT01553838|Device|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
127706|NCT01553851|Drug|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
127707|NCT01553877|Dietary Supplement|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
127708|NCT01553877|Dietary Supplement|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
127709|NCT01553877|Dietary Supplement|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
127710|NCT00078351|Procedure|High molecular weight hylan (Synvisc) injection|
127711|NCT01553890|Other|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
127712|NCT01553903|Drug|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
126827|NCT01554644|Device|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
126828|NCT01554644|Device|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
126829|NCT00078468|Drug|PELITREXOL/AG-2037|
128388|NCT00080613|Procedure|aromatase inhibition|
128389|NCT01580683|Other|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
128714|NCT01578772|Drug|Telmisartan|80mg tablets po daily for 6 weeks
128715|NCT01578785|Drug|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
128716|NCT01578785|Drug|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
128717|NCT01578811|Drug|Placebo|Dosage
128718|NCT01578811|Drug|SK-MS10|Dosage
128719|NCT01578811|Drug|SK-MS10|Dosage
128720|NCT01578824|Other|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
128721|NCT00080444|Drug|dexamethasone|dexamethasone tablets
128722|NCT01578837|Dietary Supplement|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
128723|NCT01578837|Dietary Supplement|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
128724|NCT01578850|Drug|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
128725|NCT01578850|Drug|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
128726|NCT01578863|Other|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
128727|NCT01578876|Device|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
128728|NCT01581125|Behavioral|Sleep:wake 1|Sleep and Wake durations for arm 1
128729|NCT00080613|Procedure|surgery|
128730|NCT01581125|Behavioral|Sleep:wake 2|Sleep and Wake durations for arm2
128192|NCT01577966|Drug|Sulfasalazine|Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety
Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA.
128193|NCT01577979|Behavioral|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
128194|NCT01577979|Behavioral|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
128195|NCT01577992|Drug|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
128447|NCT01578291|Behavioral|Play therapy|Play therapy with a child life specialist
128448|NCT01578304|Drug|Imidafenacin|Tablet, 12 weeks twice daily
128449|NCT01578304|Drug|Fesoterodine|Tablet, 12 weeks once daily
128450|NCT01578317|Biological|H5N1 vaccine plus MF59 adjuvant|
128451|NCT01578317|Biological|H5N1 vaccine without adjuvant|
128452|NCT01578330|Drug|Fingolimod|Fingolimod 0.5mg orally once a day without food.
128453|NCT01578343|Drug|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
Consolidation treatment for responders Patients not eligible for transplantation
Vorinostat maintenance up to 6 cycles
200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle
Delay of the start of the next cycle by up to 7 days will be acceptable.
If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation
High-dose chemotherapy followed by autologous stem cell transplantation
128454|NCT01578369|Other|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
128455|NCT01578395|Radiation|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
128653|NCT01580904|Behavioral|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
128654|NCT01580930|Behavioral|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
128655|NCT01580930|Behavioral|sedentary time reduction|participants provided with strategies to decrease sitting
128656|NCT01580930|Behavioral|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
128657|NCT00080613|Procedure|hormone therapy|
128658|NCT01580943|Drug|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
128659|NCT01574157|Drug|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
128660|NCT01574157|Drug|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
128661|NCT01574170|Other|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
128662|NCT01574183|Drug|Vilazodone|up to 40 mg capsule daily
128663|NCT01574183|Drug|Placebo|up to 40 mg capsule daily
128664|NCT01574196|Other|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
128665|NCT01574222|Biological|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
128666|NCT00079989|Drug|tigecycline|
128667|NCT01574235|Biological|Nivestim®|
128668|NCT01574248|Drug|icatibant|Subcutaneous at time 0 and 6 hours
128669|NCT01574248|Other|Placebo|Subcutaneous at time 0 and 6 hours
128670|NCT01574261|Drug|Placebo|Placebo for four months
128671|NCT01574261|Drug|Inositol|Inositol 4g/die for four months
126830|NCT01554657|Other|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
126831|NCT01554657|Other|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
126832|NCT01554670|Procedure|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
126833|NCT01556997|Drug|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
126834|NCT01556997|Drug|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
126835|NCT01556997|Drug|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
126836|NCT01557010|Drug|DWP05195|Tablets, oral administration, 100mg
126837|NCT01557010|Drug|DWP05195|Tablets, oral administration, 200mg
126838|NCT01557010|Drug|DWP05195|Tablets, oral administration, 300mg
126839|NCT01557010|Drug|Control|Tablets, oral administration, Placebo
126840|NCT00001436|Drug|OncoLAR® (Registered Trademark)|
126841|NCT00078624|Other|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
126842|NCT01557023|Drug|barrier methods|
126843|NCT01557023|Drug|barrier methods|
126844|NCT01557036|Device|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
126845|NCT01557049|Other|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
127116|NCT01559857|Drug|Pioglitazone|15mg once daily for 15 days, 30mg once daily for 15 days, 45mg once daily for 60 days
127117|NCT01559857|Drug|Sugar Pill|Placebo
128731|NCT01581138|Drug|VX-222|400 mg tablets twice daily for oral administration
128732|NCT01581138|Drug|telaprevir|1125 mg tablets twice daily for oral administration
128733|NCT01581138|Drug|ribavirin|1000 mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
128734|NCT01581151|Drug|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
127850|NCT01558687|Drug|Drug (including placebo)|Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide.
127851|NCT01561118|Other|Bicycle-Ergometer Training|Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).
In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis.
127852|NCT01561131|Dietary Supplement|Whey protein|45g protein/d; Dosage 3x15g protein daily
127853|NCT01561131|Dietary Supplement|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
127854|NCT01561131|Dietary Supplement|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
127855|NCT01561131|Dietary Supplement|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
127856|NCT01561170|Device|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
127857|NCT01561170|Device|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
127858|NCT01561183|Procedure|Indirect pulp capping (IPC)|Procedure: IPC
The IPC will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
incomplete removal of carious tissue from the cavity walls
indirect pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique
127859|NCT01561183|Procedure|Direct pulp capping (DPC)|Procedure: DPC
The DPC will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
complete removal of carious tissue from the cavity walls result in pulp exposure
preparation of clot-free pulpal mound
direct pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique
127860|NCT00079001|Other|placebo|Given IV
128456|NCT01578395|Radiation|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
128457|NCT00080392|Drug|EW-A-401 DNA Plasmid Vector|
128458|NCT01578395|Other|No radiation exposure|Subjects not undergoing any radiation exposure
128459|NCT01578408|Procedure|Total Hip Arthroplasty|
128460|NCT01578408|Device|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
128461|NCT01578408|Device|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
128462|NCT01578421|Device|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
128463|NCT01578434|Drug|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
128464|NCT01578434|Drug|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
128465|NCT01578434|Drug|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
128798|NCT01576653|Other|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
128799|NCT01576666|Drug|LDE225|
128800|NCT01576666|Drug|BKM120|
128801|NCT01576679|Drug|Cathflo (Alteplase)|
128802|NCT01578889|Biological|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
128803|NCT01578889|Biological|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
128804|NCT01578889|Biological|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10^8 plaque-forming units (PFUs) administered as 5x10^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
128805|NCT01578889|Biological|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
128806|NCT00080444|Drug|placebo to aprepitant|Matching placebo to aprepitant capsules
128672|NCT01574274|Drug|SC-PEG|11 doses Intravenously over one hour
128673|NCT01574274|Drug|Oncaspar|16 doses Intravenously over one hour
127794|NCT01553955|Procedure|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
127795|NCT01553968|Other|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
127796|NCT01553981|Drug|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
127797|NCT01553981|Drug|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
127798|NCT01554007|Other|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
127799|NCT01554020|Dietary Supplement|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
127800|NCT00078377|Drug|Armodafinil|Armodafinil 250 mg once daily in the morning
127801|NCT01554020|Dietary Supplement|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
127802|NCT01554046|Drug|Methylphenidate- Ritalin IR (Immediate Release)|Duration of treatment- 4 weeks. Dosage- up to 3 times/day.
Ages 6-12, up to 25Kg - 35mg maximum per day.
Ages 6-12, above 25Kg - 50mg maximum per day.
Ages 12-65, above 25Kg - 80mg maximum per day.
127803|NCT01554059|Drug|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
127804|NCT01554059|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly * 6 doses 3-4 weeks after radical resection
127805|NCT01554059|Drug|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
127806|NCT01554059|Radiation|Radiotherapy|2GY daily *20次
127807|NCT01554072|Other|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
127808|NCT01554085|Drug|ALS-002158|ALS-002158
127809|NCT01554085|Drug|Placebo|placebo
127118|NCT01559883|Other|no intervention is being made|This is a Non-Interventional Study (NIS)
127119|NCT01559896|Dietary Supplement|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
127120|NCT00078949|Drug|cytarabine|Given IV
127121|NCT01559909|Device|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
127122|NCT01559922|Drug|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
127123|NCT01559922|Device|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
127124|NCT01559935|Drug|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
127125|NCT01559935|Drug|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
127126|NCT01559935|Drug|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
127127|NCT01562249|Other|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
127128|NCT01562249|Other|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
127129|NCT01562275|Drug|GDC-0068|multiple doses
127130|NCT01562275|Drug|GDC-0973|multiple doses
127131|NCT01562288|Genetic|DNA analysis|
127132|NCT01562288|Genetic|gene expression analysis|
127133|NCT01562288|Genetic|polymerase chain reaction|
127134|NCT00001442|Drug|paclitaxel concurrent with radiation therapy|
127135|NCT00079053|Drug|erlotinib hydrochloride|
127136|NCT01562288|Other|enzyme-linked immunosorbent assay|
127137|NCT01562288|Other|laboratory biomarker analysis|
127861|NCT01561183|Procedure|Miniature pulpotomy (MP)|Procedure: MP
The MP will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
complete removal of carious tissue from the cavity walls result in pulp exposure
intentionally removal of pulp horn (≈1 mm)
preparation of clot-free pulpal mound
direct pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique
127862|NCT01561183|Procedure|Full pulpotomy (FP)|Procedure: FP
The FP will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
complete removal of carious tissue from the cavity walls result in pulp exposure
pulpotomy
preparation of clot-free pulpal mound
direct pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique
127863|NCT01561196|Procedure|arterial catheterisation|arterial catheterisation in Arterial Radialis
127864|NCT01561209|Drug|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
127865|NCT01561209|Drug|Placebo|Placebo pill
1 before bedtime
128125|NCT00080522|Drug|lamivudine|
128126|NCT01579968|Drug|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
128127|NCT01579981|Other|Exendin 9-39 (Bachem, Germany)|On two separate experimental days before, 1 wk, and 3 mo after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized.
128128|NCT01579994|Drug|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
128129|NCT01580007|Drug|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
128130|NCT01580007|Drug|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
128131|NCT01580007|Drug|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
128132|NCT01580007|Drug|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
128133|NCT01580020|Biological|RFB002|
128134|NCT01580020|Drug|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone;
128135|NCT01580033|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
128136|NCT00080522|Drug|efavirenz|
128807|NCT01578889|Device|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
128808|NCT01578902|Radiation|Hypofractionated radiotherapy|35Gy/5 fractions/29 days
128809|NCT01578928|Drug|SOM230|
128810|NCT01578941|Other|Diary|Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and "migraine" headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM.
128811|NCT01578954|Drug|Lenalidomide|Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.
Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months
128812|NCT01578967|Drug|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
128813|NCT01578967|Drug|ABVD|Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.
Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.
Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles.
128814|NCT01578980|Device|Outpatient Control-to-Range|Subjects will spend two nights (~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
128815|NCT01579006|Drug|Tocilizumab|
128816|NCT01579019|Drug|RO5024048|1500 mg po bid, 24 or 26 weeks
128817|NCT00080444|Drug|placebo to dexamethasone|Matching placebo to dexamethasone tablets
127923|NCT01558726|Behavioral|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
127924|NCT01558726|Behavioral|Usual Treatment|The usual treatment used for regular patients of CAPSad
127925|NCT01558739|Drug|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
127926|NCT00078858|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
127927|NCT01558752|Device|Total hip replacement with titanium shell and CORAIL stem|Total hip replacement with titanium shell and CORAIL stem
127928|NCT01558752|Device|Total hip replacement with Modular Titanium Femoral Stem (Tri-lock)|Total hip replacement with modular titanium femoral stem (Tri-lock)
127810|NCT01554098|Procedure|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
127811|NCT00078377|Drug|Armodafinil|Armodafinil 150 mg once daily in the morning
127812|NCT01556399|Other|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
128064|NCT01573312|Drug|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
128065|NCT00079898|Procedure|Acupuncture|
128066|NCT01573312|Biological|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
128067|NCT01573338|Drug|Roniciclib (BAY 1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
128068|NCT01573338|Drug|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
128069|NCT01573338|Drug|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
128070|NCT01573338|Drug|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
128071|NCT01573351|Drug|Asunaprevir|
128072|NCT01573351|Drug|Daclatasvir|
128073|NCT01573351|Drug|Peg-interferon Alfa-2a|
128074|NCT01573351|Drug|Ribavirin|
128075|NCT01575418|Radiation|Radiolabeling of study drugs and semen|Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.
Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.
The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing.
128076|NCT01575457|Behavioral|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
127403|NCT01555697|Drug|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
127404|NCT00078559|Procedure|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
127405|NCT01555710|Drug|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
127406|NCT01555710|Drug|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
127407|NCT01555710|Drug|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
127408|NCT01555710|Drug|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
127409|NCT01557842|Device|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
127410|NCT01557868|Device|hylan G-F 20|Three 2 cc injections at weekly intervals
127411|NCT01557868|Device|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
127412|NCT01557881|Device|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center [SCC] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
127413|NCT01557894|Other|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
127414|NCT01557907|Device|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
127415|NCT00078754|Drug|Placebo|Placebo capsules by mouth, up to 8 capsules daily
127416|NCT01557907|Device|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
127417|NCT01557920|Drug|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
127418|NCT01557920|Drug|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
127419|NCT01557933|Other|No interventions will be used|No interventions will be used
127420|NCT01557946|Drug|citalopram|Citalopram tablet taken once daily. Dosage depends on study arm.
128137|NCT01580033|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
128138|NCT01580033|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
128139|NCT01580033|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
128140|NCT01580046|Drug|iodixanol|coronary angiography, 32gI/100ml, 40～60 ml once injection
left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection
128141|NCT01580046|Drug|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
128142|NCT01580072|Other|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
128143|NCT01573377|Drug|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
128390|NCT01580696|Biological|E39 peptide vaccine|100mcg, 500mcg and 1,000mcg of lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine.
128391|NCT01580696|Other|Clinical tracking for disease progression/recurrence|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
128392|NCT01580709|Procedure|Multiple brushings|Seven consecutive brush samples for cytology.
128393|NCT01580709|Procedure|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
128394|NCT01580722|Procedure|early reconstruction|patients underwent < 8 weeks reconstruction after injury
128395|NCT01580722|Procedure|delay reconstruction|patients underwent > 8 weeks reconstruction after injury
128396|NCT01580735|Drug|ARQ 197|ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)
erlotinib: 150 mg qd
128397|NCT01580748|Drug|Roflumilast|500 microgram once daily for 16 weeks
128398|NCT01580761|Behavioral|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
128399|NCT00080613|Procedure|conventional surgery|
128400|NCT01580787|Device|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
127929|NCT01558765|Other|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
127930|NCT01558778|Procedure|management of therapy complications|Undergo mechanical stimulation
127931|NCT01558778|Procedure|musculoskeletal complications management/prevention|Undergo mechanical stimulation
127932|NCT01558791|Other|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
127933|NCT01558804|Other|Identifying group A strep carriers|At study entry and at 14 days: Standard culture for GAS and analysis of mRNA.
127934|NCT01558817|Behavioral|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
127935|NCT01577446|Procedure|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
127936|NCT01577459|Drug|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
127937|NCT01577459|Other|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
127938|NCT01577472|Drug|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
127939|NCT01577472|Drug|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
127940|NCT01577472|Drug|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
127941|NCT01577472|Drug|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
128196|NCT01577992|Procedure|determination of objective and subjective pain threshold|Test without levodopa intake
128197|NCT01578018|Other|Measure DCAM levels in blood|Measure DCAM levels in blood
128198|NCT01578018|Other|DCAM levels in blood|DCAM levels in blood
128199|NCT01578031|Device|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
128200|NCT01578031|Other|Usual Care|Usual care.
128201|NCT00080353|Drug|OKT3|
128077|NCT01575470|Biological|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
128078|NCT01575483|Drug|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
128079|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
128080|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
128081|NCT01575509|Other|Berry product|Sugar infused dried lingonberry
128342|NCT01573780|Procedure|biopsy|Optional correlative studies
128343|NCT01573793|Behavioral|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
128344|NCT01575821|Dietary Supplement|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
128345|NCT01575834|Drug|AMG 785|sub-cutaneous AMG 785 injections for 12 months, followed by sub-cutaneous open-label denosumab injections for another 24 months
128346|NCT01575834|Drug|Placebo|sub-cutaneous placebo injections for 12 months, followed by sub-cutaneous open-label denosumab injections for another 24 months
128347|NCT01575860|Drug|Lenalidomide|
128348|NCT01575873|Drug|Active denosumab with placebo for risedronate|Active denosumab with placebo for risedronate
128349|NCT01575873|Drug|Active risedronate with placebo for denosumab|Active risedronate with placebo for denosumab
128350|NCT00080158|Drug|escitalopram|
128351|NCT01575886|Other|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
128352|NCT01575899|Drug|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
128353|NCT01575899|Drug|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
128354|NCT01575925|Drug|4 mg Oral POM + 40 mg Oral DEX|
127421|NCT01557959|Drug|cisplatin|Given IV
127422|NCT01557959|Biological|pegfilgrastim|Given SC
126563|NCT01586793|Device|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
126564|NCT01586793|Device|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
126565|NCT01586806|Drug|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
126566|NCT01586806|Drug|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
126567|NCT00080925|Drug|doxorubicin hydrochloride|
126568|NCT01586806|Drug|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
126569|NCT01586819|Drug|Botulinum Toxin Type A|The botulinum toxin will be injected into the wrinkles "crow's feet". The injections will take about 10 minutes to complete.
126570|NCT01586819|Procedure|Chemical Facial Peel|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution [a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel [35% Trichloroacetic acid] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
126571|NCT01586845|Drug|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
126572|NCT01586845|Drug|tacrolimus|tacrolimus as per labeled dose
126573|NCT01586858|Other|Observational|Observational study of subjects previously enrolled in the RAVE trial
126574|NCT01589380|Drug|Fimasartan|Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.
Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan.
126575|NCT01589380|Drug|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
128401|NCT01580787|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
128402|NCT01573793|Behavioral|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
128403|NCT01573806|Drug|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
128404|NCT01573806|Drug|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
128405|NCT01573819|Drug|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
128406|NCT01573819|Drug|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
128407|NCT01573832|Other|integrated client care group|receives integrated client care for wound treatment
128408|NCT01573832|Other|usual care|receives usual care for wound treatment
128409|NCT01573845|Behavioral|Healthy Eating + Eco-Friendly Campaign|Participants receive a 6-month school-based campaign that includes:
A 22-lesson classroom curriculum
Homework activities that involve the family
Monthly parent newsletters
A food shopping and packing guide for parents
Food demonstrations
A poster contest
School wide announcements
128735|NCT01581151|Drug|Monthly Ranibizumab|30 days between treatments
128736|NCT01581164|Biological|Influenza vaccine|Influenza vaccine: Injection, post transplant
128737|NCT01581164|Biological|Varicella vaccine|Varicella vaccine: Injection, post transplant
128738|NCT01581177|Drug|Albuterol 25 mcg, Placebo|Albuterol Dry Powder, 25 mcg per inhalation, 1 inhalation followed by 1 inhalation of placebo
128739|NCT01581177|Drug|Albuterol 0.25 mcg|Albuterol Dry Powder Inhalation 0.25 mcg, 2 inhalations
128740|NCT00080626|Biological|pegfilgrastim|6 mg injection on day 1 of each cycle
128741|NCT01581177|Drug|Albuterol 90 mcg, Placebo|Albuterol Dry Powder, 90 mcg per inhalation, 1 inhalation, followed by 1 inhalation of placebo
128742|NCT01581177|Drug|Albuterol, 90 mcg|Albuterol Dry Powder, 90 mcg per inhalation, 2 inhalations
128743|NCT01581177|Drug|Placebo|Two inhalations of placebo
128744|NCT01581177|Drug|Proventil 90 mcg|Proventil, 90 mcg per inhalation, 1 inhalation
128745|NCT01581177|Drug|Proventil 90 mcg|Proventil, 90 mcg per inhalation, 2 inhalations
128237|NCT01573611|Dietary Supplement|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
128238|NCT01573611|Dietary Supplement|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
128239|NCT00079924|Drug|raloxifene|
128240|NCT01573624|Drug|FF/GSK573719|100/15.6
128241|NCT01573624|Drug|FF/GSK573719|100/31.25
128242|NCT01573624|Drug|FF/GSK573719|100/62.5
128243|NCT01573624|Drug|FF/GSK573719|100/125
128244|NCT01573624|Drug|FF/GSK573719|100/250
128245|NCT01573624|Drug|FF|100
128246|NCT01573624|Drug|FF/VI|100/25
128247|NCT01573637|Drug|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
128248|NCT01575691|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
128249|NCT01575691|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
128250|NCT01575704|Other|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
128251|NCT01575704|Other|Mental Training|Memorial/ mental training and relaxation, 5 times per week
128252|NCT01575717|Drug|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
128253|NCT01575717|Drug|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
128254|NCT00080158|Drug|sertraline|
128255|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
128256|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
128257|NCT01575730|Drug|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
127748|NCT00001437|Drug|pentoxifylline|
127749|NCT00078832|Drug|anastrozole|aromatase inhibitor
127750|NCT01558492|Drug|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
128011|NCT01575418|Drug|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
128012|NCT01577550|Drug|Placebo, s.c.|Single s.c. administration of placebo
128013|NCT01577550|Drug|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
128014|NCT01577589|Drug|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
128015|NCT01577589|Drug|Placebo in 50 ml infusion volume|IV infusion
128016|NCT01577589|Drug|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
128017|NCT01577589|Drug|Placebo in 250 ml infusion volume|IV infusion
128018|NCT01577589|Drug|600 mg ceftaroline in 100 ml infusion volume|IV infusion
128019|NCT01577589|Drug|Placebo in 100 ml infusion volume|IV infusion
128020|NCT00080327|Drug|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
128021|NCT01577602|Other|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
128022|NCT01577602|Other|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
128023|NCT01577602|Other|Combined intervention|Combines the printed medication list with the open ended question
128024|NCT01577615|Behavioral|Patterned Experience|The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.
Nonnutritive sucking will be offered to infants.
Blood work will be collected for inflammatory cytokines.
Saliva will be collected for genetic analysis
Saliva will be collected in 10 infant sub study for cortisol pre and post feedings
All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.
Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.
Follow up visits will occur at 2,6and 24 months corrected age.
128025|NCT01577628|Drug|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
124880|NCT01536782|Procedure|Gravity|The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).
Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.
124881|NCT01536782|Device|Pump|The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).
Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.
124882|NCT01536795|Drug|WR279 396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
124883|NCT01536795|Drug|WR 279, 396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
124884|NCT01536808|Other|Cardiac RMI|Cardiac RMI
124885|NCT00076856|Drug|Temozolomide|
124886|NCT01536808|Other|Analysis telomere|Analysis telomere
124887|NCT01536808|Other|Stress test|Stress test
124888|NCT01536808|Other|echocardiography|echocardiography
124889|NCT01536834|Device|Vettel|
125187|NCT01539733|Drug|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
125188|NCT01542151|Other|Time of labor induction|Assigned time of labor induction - morning or evening
125189|NCT01542190|Drug|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
125190|NCT00077259|Drug|epothilone D|
125191|NCT01542216|Behavioral|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
125192|NCT01542216|Behavioral|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
125193|NCT01542229|Behavioral|PE + TAU|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
124678|NCT01538797|Drug|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
124679|NCT01538836|Behavioral|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
124680|NCT01538836|Behavioral|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
124681|NCT01538849|Drug|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
124682|NCT01538849|Drug|YH4808 A mg|1 tablet = YH4808 A mg
124683|NCT01538849|Drug|YH4808 B mg|1 tablet = YH4808 B mg
124684|NCT01538849|Drug|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
124685|NCT01538862|Drug|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
124686|NCT01538875|Drug|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
124687|NCT01541228|Device|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.
Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.
Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval.
124688|NCT01541228|Procedure|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.
Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval.
124689|NCT01541254|Device|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
124690|NCT01541267|Drug|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
124947|NCT01534585|Radiation|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
128500|NCT01574040|Behavioral|Promotion of stair climbing|Application of labels on all UMC elevator doors stating: " If you take the stairs, you will burn 11 times more calories."
128501|NCT01574040|Behavioral|Promotion of a low-salt soup alternative for the 'soup of the day'|Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: "The cream soup contains 30% less salt and contributes to a healthy blood pressure."
128502|NCT01574040|Behavioral|Promotion of a low-fat alternative for the butter croissants|Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: "This croissant contains 30% fewer saturated (unhealthy) fatty acids."
128503|NCT01576120|Other|bowel prep regimen first boost 3 oz. and second boost 6 oz.|Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)
128504|NCT01576133|Behavioral|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
128505|NCT01576133|Behavioral|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
128506|NCT01576146|Drug|KAI-4169 (also known as AMG 416)|KAI-4169 (also known as AMG 416) will be administered as an IV bolus three times each week for 92 weeks at dosages up to 15 mg
128507|NCT00080158|Drug|venlafaxine|
128508|NCT01576159|Other|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
128509|NCT01576159|Other|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
128510|NCT01576159|Other|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
128511|NCT01576172|Drug|Abiraterone Acetate|Given PO
128512|NCT01576172|Other|Laboratory Biomarker Analysis|Correlative studies
128513|NCT01576172|Drug|Prednisone|Given PO
128514|NCT01576172|Drug|Veliparib|Given PO
128515|NCT01576185|Other|laboratory biomarker analysis|Correlative studies
128516|NCT01576185|Drug|quizartinib|Via gavage
128517|NCT01576185|Drug|sorafenib tosylate|Via gavage
128518|NCT00080158|Drug|lithium|
128026|NCT01577654|Drug|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
128027|NCT01577654|Drug|EC145 + Docetaxel|EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +
Docetaxel 75 mg/m2 IV Day 1 q 3 weeks
128028|NCT01577654|Drug|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
128029|NCT01577654|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
128275|NCT01578070|Biological|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
128276|NCT01578070|Biological|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
128277|NCT01578070|Biological|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
128278|NCT01578070|Biological|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
128279|NCT01578070|Biological|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
128280|NCT00080353|Drug|rF-go 100P209|
128281|NCT01578096|Behavioral|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
128282|NCT01578109|Procedure|Bone Marrow Transplantation|Undergo BMT
128283|NCT01578109|Other|Laboratory Biomarker Analysis|Correlative studies
128284|NCT01578109|Other|Pharmacological Study|Correlative studies
128285|NCT01578109|Drug|Sorafenib Tosylate|Given PO
128286|NCT01578122|Device|compression stockings 25mm Hg|Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.
Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
128287|NCT01578122|Device|compression stockings 35 mm Hg|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
128288|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
128289|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire at inclusion in registry
125194|NCT01542229|Behavioral|Treatment As Usual|TAU will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
125195|NCT01542242|Drug|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
125196|NCT01542255|Drug|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
125197|NCT01542255|Drug|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
125198|NCT01542255|Drug|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
125199|NCT01542268|Drug|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
125200|NCT01542268|Drug|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
125201|NCT00077285|Biological|filgrastim|
125202|NCT01542281|Dietary Supplement|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
125203|NCT01542281|Other|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
125204|NCT01542294|Drug|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
125205|NCT01542294|Drug|Oxaliplatin|130mg/m2 d1 repeated every 21 days
125206|NCT01542307|Biological|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
125207|NCT01542307|Biological|Room air|Placebo
124290|NCT01535872|Dietary Supplement|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
124291|NCT01535885|Biological|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-60 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
124292|NCT01535898|Other|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
124948|NCT01534585|Drug|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
124949|NCT01534585|Other|Quality of life|The EORTC QLQ-C30 and H&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
124950|NCT00076570|Drug|Tacrolimus|
124951|NCT01534585|Genetic|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
124952|NCT01534598|Drug|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown be feasible in an expansion cohort of the previous trial.
124953|NCT01534637|Drug|aprepitant|Given PO
124954|NCT01534637|Drug|gemcitabine hydrochloride|Given IV
124955|NCT01534637|Drug|capecitabine|Given PO
124956|NCT01534637|Drug|fluorouracil|Given IV
124957|NCT01534637|Procedure|radiation therapy|Undergo radiation therapy
124958|NCT01534637|Other|questionnaire administration|Ancillary studies
124959|NCT01534637|Procedure|quality-of-life assessment|Ancillary studies
124960|NCT01534637|Procedure|nausea and vomiting therapy|Receive aprepitant
124961|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
124962|NCT00076869|Drug|MK0991, caspofungin acetate|
124963|NCT01536873|Drug|dolutegravir|integrase inhibitor in development
124964|NCT01536886|Drug|LEO 90100|
124965|NCT01536886|Drug|Betamethasone plus calcipotriol|
124966|NCT01536886|Drug|Ointment vehicle|
124967|NCT01536886|Drug|LEO 90100 vehicle|
124968|NCT01536938|Drug|LEO 90100|
125268|NCT01539798|Other|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
128519|NCT01576198|Genetic|DNA analysis|
128520|NCT01576198|Genetic|nucleic acid amplification|
128859|NCT01574651|Drug|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
128860|NCT01574651|Drug|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
128861|NCT01574651|Drug|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
128862|NCT01574664|Device|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
128863|NCT01574690|Device|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
128864|NCT00080054|Drug|Motexafin Gadolinium Injection|
128865|NCT01574690|Procedure|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
128866|NCT01574690|Procedure|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
128867|NCT01574703|Drug|placebo|All dosing to have taken place per study A3051123
128868|NCT01574703|Drug|varenicline tartrate|All dosing to have taken place per study A3051123
128869|NCT01574703|Drug|bupropion hydrochloride|All dosing to have taken place per study A3051123
128870|NCT01574703|Drug|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
128871|NCT01576679|Drug|Saline|
128872|NCT01576692|Biological|Humanized anti-GD2 antibody|A maximum of 6 courses of therapy may be given on the following schedule:
Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy
Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)
Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m^2)/dose, over 4 hours daily
NK Cell dosage: minimum of 0.1 * 10^6 cells/kg; maximum of 400 * 10^6 CD45+ cells/kg, given once
128873|NCT01576692|Drug|Chemotherapy|Chemotherapy may include the following at the dosages shown below:
cyclophosphamide: 400 mg/m^2 IV days 1-5
topotecan: 1.2 mg/m^2 IV days 1-5
temozolomide: 150 mg/m^2 PO at least 1 hour before irinotecan
irinotecan: 50 mg/m^2 IV over 1 hour daily for 5 days
carboplatin (AUC 8-dosing based on GFR), IV day 1 only
ifosfamide: 2 g/m2 IV days 1-3
etoposide: 100 mg/m2 days 1-3
128874|NCT01576692|Other|Cytokines|Cytokines may be given at the following dosages:
interleukin-2: 1 million units/m^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses
GM-CSF: 250 mcg/m^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC >2,000/mm^3
124554|NCT01543243|Device|Stochastic resonance whole-body vibration B|Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.
Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4.
124555|NCT01543256|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell.
124556|NCT01543256|Device|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
124557|NCT01536223|Drug|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
124824|NCT01539057|Drug|Fibrinogen|The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.
Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.
Administration before surgery starts
124825|NCT01539057|Drug|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
124826|NCT01539070|Behavioral|Eating and physical activity counseling|The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.
There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity.
124827|NCT01539083|Drug|Thalidomide|Thalidomide: Type=1, unit=mg, number=100, form=tablet, route=oral use. Oral thalidomide consolidation will be administered for a maximum of 12 months or until disease progression along with Prednisolone: Type=1, unit =mg, number=50, form=tablet, route=oral use. Prednisolone maintenance therapy will be administered on alternate days continued indefinitely or until disease progression.
124828|NCT01539083|Drug|Bortezomib|Type=1, unit=mg/ml, number=2.5, form= Solution for injection, route=Subcutaneous use. Bortezomib will be administered as a single subcutaneous injection at a concentration of 1.3 mg/m2 every 2 weeks for 32 weeks (16 doses) in addition to 100 mg daily oral thalidomide consolidation for a maximum of 12 months or until disease progression and 50 mg oral alternate-day prednisolone maintenance continued indefinitely or until disease progression.
124829|NCT01539083|Drug|Thalidomide|Type=1, unit=mg, number=100, form=tablet, route=oral use. 100 mg daily oral thalidomide consolidation (administered in addition to bortezomib) will be administered for a maximum of 12 months or until disease progression and 50 mg oral alternate-day prednisolone maintenance continued indefinitely or until disease progression.
124830|NCT00077103|Biological|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
124293|NCT01535911|Other|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
124294|NCT01535924|Drug|gemcitabine hydrochloride|Given IV
124295|NCT01538056|Device|Fenestrated Endovascular Graft|Modified endovascular graft with fenestrations to allow for blood flow to vital visceral vessels such as the renal arteries and SMA (Superior Mesenteric Artery).
124296|NCT01538069|Other|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
124297|NCT01538069|Other|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
124298|NCT01538069|Other|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
124299|NCT01538095|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
124300|NCT01538095|Other|Laboratory Biomarker Analysis|Correlative studies
124301|NCT01538095|Other|Pharmacological Study|Correlative studies
124302|NCT01538095|Biological|Trebananib|Given IV
124303|NCT01538108|Device|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
124304|NCT01538108|Procedure|Plain Balloon angioplasty (PBA)|PBA
124305|NCT00077012|Drug|Photodynamic therapy|
124618|NCT01541202|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
124619|NCT01541215|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
125269|NCT00077116|Drug|idarubicin|
125270|NCT01539811|Procedure|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
125271|NCT01539811|Drug|Short course antibiotics|Short course (<2 weeks) of antibiotics will be prescribed
125272|NCT01539811|Drug|Long course antibiotics|Long course (>2 weeks) of antibiotics will be prescribed
125273|NCT01539824|Biological|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
125274|NCT01539824|Radiation|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
125275|NCT01539837|Drug|Deferiprone|20mg/kg/d or 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
125276|NCT01539837|Drug|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
125277|NCT01539850|Device|OMS102|Subjects will receive implanted OMS102 System.
125278|NCT01539863|Other|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
125279|NCT01539863|Other|Treatment as needed|Participants may never receive treatment, there is no upper limit
125280|NCT00077116|Procedure|allogeneic bone marrow transplantation|
125281|NCT01586884|Procedure|Pressure/Conductance Catheter|The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.
The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.
The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point.
125282|NCT01586897|Device|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
125283|NCT01586897|Other|Usual Care|
125284|NCT01586910|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
128875|NCT01576692|Biological|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy & Procedure Manual.
128876|NCT00001483|Drug|buproprion (Wellbutrin)|
127962|NCT01579656|Dietary Supplement|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
127963|NCT01579656|Dietary Supplement|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
127964|NCT01579656|Dietary Supplement|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
127965|NCT01579656|Dietary Supplement|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
127966|NCT00080522|Behavioral|Monitoring by HIV-trained primary care nurses|
127967|NCT01579656|Dietary Supplement|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
127968|NCT01579669|Behavioral|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
127969|NCT01579682|Behavioral|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
127970|NCT01579682|Behavioral|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
127971|NCT01579695|Drug|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
127972|NCT01579708|Behavioral|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
127973|NCT01579721|Procedure|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
127974|NCT01579734|Drug|Tamoxifen|1 tablet, 5 mg / day for 5 years
127975|NCT01579734|Drug|Placebo|1 tablet day for 5 years
124831|NCT01539096|Procedure|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
124832|NCT01539096|Behavioral|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
124833|NCT01541540|Behavioral|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
124834|NCT01541553|Procedure|Cryotherapy|Cryotherapy of all visible AKs (4-8 lesions, "baseline lesions") in the selected treatment area
124835|NCT01541553|Drug|Vehicle|Field treatment with vehicle gel once daily for 3 consecutive days.
124836|NCT01541553|Drug|Ingenol metabute|Field treatment with vehicle gel once daily for 3 consecutive days.
125123|NCT01534819|Procedure|AAA endograft placement|Use of the Aptus Heli-FX EndoAnchor System (Heli-FX) during either primary placement or revision of a previously placed AAA endograft.
125124|NCT01534819|Device|Use of Aptus Heli-FX EndoAnchor System (Heli-FX)|Placement of Heli-FX during revision of a previously placed AAA endograft
125125|NCT01534832|Device|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
125126|NCT01534845|Drug|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
125127|NCT01534858|Device|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
125128|NCT01534871|Behavioral|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
125129|NCT01534884|Biological|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
125130|NCT01534897|Drug|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
125131|NCT01534910|Drug|aged garlic extract|2400 mg a day
124620|NCT01541215|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
124621|NCT01541215|Drug|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
124622|NCT01543464|Drug|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
124623|NCT01543490|Drug|ISV-305|Dexamethasone in DuraSite® twice daily for 2 weeks
124624|NCT01543490|Other|Vehicle|Placebo twice daily for 2 weeks
124625|NCT01543529|Drug|RO4917838|Single dose of RO4917838
124626|NCT01543529|Drug|Placebo to RO4917838|Single dose of placebo to RO4917838
124627|NCT01543529|Other|Alcohol|Standard alcoholic drink
124628|NCT01543542|Radiation|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
124629|NCT00077311|Biological|pegfilgrastim|6 mg sub Q day 2 of each cycle
124630|NCT01543555|Drug|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
124631|NCT01543555|Drug|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
124632|NCT01543568|Drug|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
124633|NCT01543581|Drug|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
124634|NCT01543581|Drug|Placebo|
124635|NCT01543607|Device|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
124636|NCT01543633|Drug|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
124890|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
124891|NCT01536847|Other|Dietary Intervention|300 mL of liquid food product
124892|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
125285|NCT00080925|Drug|etoposide|
124364|NCT01535950|Drug|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
124365|NCT01535976|Drug|Placebo|Placebo Comparator: Placebo
.9 normal saline infusion
124366|NCT01535976|Drug|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
124367|NCT01535989|Drug|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
124368|NCT01535989|Drug|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
124369|NCT01536002|Drug|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
124370|NCT01536015|Drug|Rotigotine|Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours
Dosage and Frequency: One patch every 24 hours
Duration: 10 weeks
124371|NCT00076752|Other|immunologic technique|Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
124372|NCT01536015|Drug|Placebo|Frequency: One patch applied every 24 hours
Duration: 10 weeks
124373|NCT01536028|Drug|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
124374|NCT01536028|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
124375|NCT01536028|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
124376|NCT01536028|Drug|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
124377|NCT01536041|Drug|ONO-6950|200 mg QD, single dose
124378|NCT01536041|Drug|ONO-6950|20 mg QD, single dose
124379|NCT01536041|Drug|Montelukast|10 mg Montelukast, QD single dose
124380|NCT01536041|Drug|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
124381|NCT01536054|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
124382|NCT00076752|Other|laboratory biomarker analysis|Standard human immunology research laboratory ex vivo studies.
127976|NCT01579747|Procedure|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
127977|NCT00001493|Genetic|peripheral blood progenitor cells carrying MDR1|
127978|NCT00080522|Behavioral|Community-based directly observed therapy (DOT)|
127979|NCT01579747|Procedure|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
127980|NCT00079859|Drug|Implitapide|
128521|NCT01576198|Other|diagnostic laboratory biomarker analysis|
128522|NCT01576198|Other|medical chart review|
128523|NCT01576211|Genetic|DNA methylation analysis|
128524|NCT01576211|Genetic|RNA analysis|
128525|NCT01576211|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
128526|NCT01576211|Genetic|gene expression analysis|
128527|NCT01576211|Genetic|nucleic acid sequencing|
128528|NCT01576211|Genetic|polymorphism analysis|
128529|NCT00080158|Behavioral|Cognitive Behavioral Therapy|
128530|NCT01576211|Other|laboratory biomarker analysis|
128531|NCT01578447|Drug|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
128532|NCT01578447|Drug|Intramuscular DMPA|Intramuscular DMPA
128533|NCT00080405|Drug|Bortezomib|
128534|NCT01578460|Device|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
128535|NCT01578460|Device|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
128536|NCT01578473|Drug|Vitamin D2|oral softgel 2000 IU once daily 9 months
128537|NCT01578473|Drug|Vitamin E|oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily
1 softgel of 200 IU daily 9 months
125132|NCT00076622|Drug|No antidepressant medication|Participants assigned to discontinue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
125133|NCT01534910|Drug|placebo|placebo
125134|NCT01534923|Behavioral|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
125135|NCT01534949|Biological|rituximab|375 mg/m2 by intravenous [IV] infusion
125136|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
125137|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
125138|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
125139|NCT01534962|Drug|Placebo|Oral administration, BID; for a maximum of 112 days.
125140|NCT01537146|Drug|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
125141|NCT01537159|Device|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
125142|NCT00076960|Drug|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
124230|NCT01538017|Procedure|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
124231|NCT01538043|Other|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
124232|NCT00077012|Drug|QLT0074|
124233|NCT01540526|Drug|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
124234|NCT01540539|Drug|REGN1154 or placebo|Participants will receive active drug or placebo
124235|NCT01540552|Other|medical chart review|
124236|NCT01540552|Procedure|computed tomography|
124237|NCT01540552|Procedure|computer-aided detection/diagnosis|
124238|NCT00077168|Drug|anastrozole|
124239|NCT01540565|Other|Laboratory Biomarker Analysis|Correlative studies
124893|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
124894|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
124895|NCT01539096|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
124896|NCT01539109|Behavioral|Rehabilitation|Patients will receive training upon tasks of daily living. They will perform these exercises in our laboratory under the supervision of qualified personnel.
124897|NCT01539109|Procedure|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 5 weeks in conjunction with therapy for the affected hand.
124898|NCT01539109|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
124899|NCT01539122|Device|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
124900|NCT01539122|Device|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
124901|NCT01539135|Drug|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
124902|NCT01539161|Device|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
124903|NCT00077103|Drug|cisplatin|cisplatin IV over 30-60 minutes on day 1
124904|NCT01539161|Procedure|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
124905|NCT01539174|Biological|rituximab|Given IV
124906|NCT01539174|Drug|cyclophosphamide|Given IV
124907|NCT01539174|Drug|doxorubicin hydrochloride|Given IV
124908|NCT01539174|Drug|vincristine sulfate|Given IV
124909|NCT01539174|Drug|prednisone|Given PO
125208|NCT01542320|Dietary Supplement|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
124383|NCT01536054|Drug|sirolimus|Given PO
124384|NCT01536054|Other|laboratory biomarker analysis|Correlative studies
124385|NCT01536054|Biological|sargramostim|Given SC
124691|NCT01541280|Drug|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of >15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of >1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
124692|NCT00077220|Drug|carboplatin|
124693|NCT01541280|Other|DLI|Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of >grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.
If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too.
124694|NCT01541293|Drug|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
124695|NCT01541293|Drug|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
124696|NCT01541332|Drug|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
124697|NCT01541332|Drug|Pegylated Liposomal Doxorubicin (PLD)|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle.
124698|NCT01541332|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
124699|NCT01541345|Device|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
124700|NCT01541345|Drug|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
124701|NCT01543893|Behavioral|Personal instruction|Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.
Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm
124702|NCT01543906|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
128538|NCT01578473|Drug|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
128539|NCT01578486|Drug|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
128540|NCT01578499|Drug|Brentuximab Vedotin|Brentuximab vedotin (1.8 mg/kg) will be administered intravenously over approximately 30 minutes once every 21 days and may continue as monotherapy for up to a total of 16 cycles (48 weeks)
128541|NCT01578499|Drug|Methotrexate or Bexarotene|Methotrexate will be administered orally (5 to 50 mg) once weekly. Dose adjustment is guided by patient response and toxicity or Bexarotene will be administered orally (300 mg/m2) once daily with meals.
128542|NCT01578512|Behavioral|Face-to-Face|Face-to-Face behavioral weight loss
128543|NCT01578512|Behavioral|Web-based|Web-based behavioral weight loss
128544|NCT00080418|Drug|Liposome Entrapped Paclitaxel Easy to Use|
128563|NCT01580527|Procedure|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
128564|NCT01580527|Procedure|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
128565|NCT01580553|Drug|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
128566|NCT01580553|Drug|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
128567|NCT01580592|Drug|Omalizumab|150mg, s.c., every 4 weeks
128568|NCT01580592|Drug|Omalizumab|300mg, s.c., every 4 weeks
128569|NCT01580592|Drug|Placebo|Placebo, s.c., every 4 weeks
128570|NCT01580605|Drug|somatropin|Data are extracted from the French National Registry "l'Observatoire National des Prescriptions et Consommations de Médicaments" to where physicians report data about growth hormone treatment
128571|NCT01580618|Drug|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
128572|NCT00001495|Drug|irinotecan (CPT-11)|
128573|NCT00080613|Procedure|adjuvant therapy|
128574|NCT01580618|Drug|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
128575|NCT01580644|Drug|GLPG0187 prodrug|
124240|NCT01540565|Drug|Veliparib|Given PO
124241|NCT01540578|Other|laboratory biomarker analysis|Correlative studies
124242|NCT01540591|Drug|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
124243|NCT01540604|Drug|CRD007|
124244|NCT01540630|Drug|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
124245|NCT01540630|Drug|Placebo|Double-blind placebo comparator for 28 days.
124246|NCT01540643|Device|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
124247|NCT01540656|Device|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.
A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.
124248|NCT01540669|Dietary Supplement|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
124249|NCT00077168|Drug|tamoxifen citrate|
124250|NCT01540669|Dietary Supplement|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
124251|NCT01540669|Dietary Supplement|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
124252|NCT01540669|Dietary Supplement|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
124558|NCT01536223|Drug|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .
And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
124559|NCT01536236|Device|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
124560|NCT01536236|Device|Placebo|Placebo
124561|NCT01536249|Drug|Dexpramipexole|Single Oral Dose
124562|NCT01536249|Drug|Cimetidine plus Dexpramipexole|Multiple Oral Doses
124563|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
124564|NCT01536262|Device|Respimat|Respimat inhaler
125209|NCT01542320|Other|Placebo|Solution without active Lactobacillus reuteri
125210|NCT01542333|Genetic|gene expression analysis|
125211|NCT01542333|Genetic|proteomic profiling|
125212|NCT00077285|Drug|carboplatin|
125213|NCT01542333|Genetic|reverse transcriptase-polymerase chain reaction|
125214|NCT01542333|Genetic|western blotting|
125215|NCT01535001|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
125216|NCT01535001|Behavioral|Information|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.
125217|NCT01535001|Drug|Paracetamol|1 g x 4/day
125218|NCT00076635|Drug|Interferon gamma-1b|200 mcg, SQ, 3x per week
125219|NCT01535001|Drug|Burana|400 mg x 3/day for three weeks
125220|NCT01535001|Drug|Pantoprazole|20mg x 1/day for three weeks
125221|NCT01535001|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
125222|NCT01535001|Behavioral|Patient education|The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, "Lær at leve med kronisk sygdom (Learn to live with chronic illness)" by The National Board of Health, Denmark and "Artrosskolan Spenshult" in Sweden.
125223|NCT01535001|Other|Insoles|The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.
125224|NCT01535014|Drug|Dietressa|Comparison of different dosages (frequency) of drug
125225|NCT01535014|Device|Placebo|Placebo either (2 tablets 3 times daily) or
(1 tablet 6 times daily)
125226|NCT01535027|Drug|teriparatide|teriparatide 20 ug/day, sc.
125227|NCT01535027|Drug|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
125228|NCT01535027|Drug|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
124703|NCT00077324|Genetic|proteomic profiling|
124704|NCT01543919|Drug|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
124705|NCT01543919|Drug|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
124706|NCT01543919|Drug|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
124969|NCT01536938|Drug|Calcipotriol|
124970|NCT01536938|Drug|Betamethasone|
124971|NCT01536951|Drug|LY3009104|administered orally
124972|NCT01536951|Drug|Placebo|Administered orally
124973|NCT00076869|Drug|Comparator: amphotericin B|
124974|NCT01536951|Drug|moxifloxacin|Administered orally
124975|NCT01536964|Drug|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
124976|NCT01536964|Drug|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
124977|NCT01536977|Other|quality-of-life assessment|Ancillary studies
124978|NCT01536977|Other|questionnaire administration|Ancillary studies
124979|NCT01536977|Behavioral|management of therapy complications|Undergo BBT-I
124980|NCT01536977|Behavioral|cognitive assessment|Ancillary studies
124981|NCT01536977|Behavioral|educational intervention|Undergo BBT-I
124982|NCT01537003|Device|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
124983|NCT01537003|Device|Coban 2 layer|Compression bandage
124984|NCT00076869|Drug|Comparator: lipid formulation of amphotericin B and/or azole|
124985|NCT01537016|Device|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
124986|NCT01537016|Device|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
128576|NCT01580657|Behavioral|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
128577|NCT01574040|Behavioral|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
128578|NCT01574066|Procedure|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
128579|NCT01574079|Other|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
128580|NCT00079963|Dietary Supplement|Placebo|
128581|NCT01574079|Other|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
128877|NCT00080262|Drug|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
128878|NCT01576705|Drug|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
128879|NCT01576718|Drug|Fluticasone propionate DPI Dose 1|Fp DPI Dose 1 twice daily
128880|NCT01576718|Drug|Fluticasone propionate DPI Dose 2|Fp DPI Dose 2 twice daily
128881|NCT01576718|Drug|Fluticasone propionate DPI Dose 3|Fp DPI Dose 3 twice daily
128882|NCT01576718|Drug|Fluticasone propionate DPI Dose 4|Fp DPI Dose 4 twice daily
128883|NCT01576718|Other|Placebo DPI|Placebo BID
128884|NCT01576718|Drug|Flovent Diskus 250 mcg|Flovent Diskus 250 mcg twice daily
128885|NCT01576731|Drug|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
128886|NCT01576731|Drug|Tenofovir, Emtricitabine, Raltegravir|Combination drug
128887|NCT01576770|Device|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
124565|NCT00076752|Drug|Mesna|Priming regimen: 600 mg/m^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
124566|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
124567|NCT01536262|Drug|Olodaterol|Olodaterol once daily inhalation
124568|NCT01536262|Device|Respimat|Respimat inhaler
124569|NCT01536262|Device|Respimat|Respimat inhaler
124570|NCT01536275|Other|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
124571|NCT01536288|Drug|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
124572|NCT01536288|Drug|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
124573|NCT01536301|Drug|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
124574|NCT01536301|Drug|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
124575|NCT01536314|Drug|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
124576|NCT00001384|Drug|cyclophosphamide|
124577|NCT00076791|Drug|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
124578|NCT01536314|Drug|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
124579|NCT01536353|Drug|AGSAV301|tablet, q.d.
124837|NCT01541579|Other|Cx601|120 million cells administered by intralesional injection.
124838|NCT00077220|Radiation|radiation therapy|
124839|NCT01541579|Other|Saline solution|24 mL saline solution by intralesional injection
124840|NCT01541592|Other|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of ~1 tablespoon per hour so that the total infusion time will be 6 hours.
124841|NCT01541605|Drug|methylphenidate|tablets for oral use
125229|NCT00076648|Drug|Poly SFH-P Injection|
124306|NCT01538160|Drug|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
124307|NCT01538173|Drug|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
124308|NCT01538173|Drug|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
124309|NCT01538199|Device|Near-infrared radiation via Transcranial LED Therapy|The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.
The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject.
124310|NCT01538199|Device|Sham device|The sham device does not emit near-infrared radiation.
124311|NCT01538225|Drug|Sativex®|THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.
Duration: 2 weeks
124312|NCT01538225|Drug|Placebo|Placebo
Same frequency and dosage form as Sativex.
Duration: 2 weeks
124313|NCT01538238|Drug|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
124314|NCT01538251|Drug|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
124315|NCT01540708|Drug|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
124316|NCT01540708|Drug|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
124317|NCT01540721|Drug|Marketed paracetamol|marketed formulation
124987|NCT01537029|Drug|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
124988|NCT01537029|Drug|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
124989|NCT01539239|Device|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
124990|NCT01539239|Procedure|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
124991|NCT01539252|Procedure|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
124992|NCT01539252|Procedure|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
125286|NCT01586910|Procedure|Surgical Aortic Valve Replacement (SAVR)|
125287|NCT01586910|Device|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
125288|NCT01586923|Biological|RBC transfusion|RBC transfusion of different storage age
125289|NCT01586936|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
125290|NCT01586949|Behavioral|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
125291|NCT01586962|Drug|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
125292|NCT01586975|Drug|Clopidogrel|Clopidogrel 75 mg QD
125293|NCT01586975|Drug|Aspirin 81 mg|Aspirin 81mg QD
125294|NCT01586975|Drug|Aspirin >300 mg|Aspirin >300 mg QD
125295|NCT01586988|Behavioral|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
125296|NCT00080925|Drug|fludarabine phosphate|
125297|NCT01587001|Dietary Supplement|N-acetyl-cysteine|900mg three times daily for 8 weeks
125298|NCT01587001|Drug|Placebo|Matching placebo three times daily for 8 weeks.
125299|NCT01587027|Drug|Aminophylline|Aminophylline dosage form-tablet dosage-500mg
125300|NCT01587027|Drug|Methazolamide|Methazolamide dosage form-tablet dosage-250mg
128888|NCT00080275|Drug|Niacin Extended-Release and simvastatin Tablets|
128889|NCT01576770|Drug|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
128890|NCT01576783|Drug|DHA+AA|200 mg DHA + 200 mg AA per day for 6 months
128891|NCT01576783|Dietary Supplement|Placebo|400 mg corn oil per day for 6 months
128892|NCT01576796|Radiation|Radiotherapy|No additional dose (patients negative F-miso)
Radiation therapy is conducted under standard conditions of conformal radiotherapy:
The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week
With additional dose (patients positive for F-miso)
The dose in the PTVmiso increased until the maximum tolerable radiation by the lung.
128893|NCT01579045|Device|nelfilcon A|bilateral daily use soft contact lens
128894|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lens
128895|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lenses
128896|NCT00001487|Drug|Dehydroepiandrosterone|
128897|NCT00080444|Drug|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
128898|NCT01579058|Drug|bisoprolol|bisoprolol 5mg qd for 4 years
128899|NCT01579058|Drug|placebo|placebo for 4 years
127981|NCT01573013|Dietary Supplement|iron fortified biscuits|control biscuit on a daily basis for 8 months
127982|NCT01573052|Drug|Chlordiazepoxide|25mg qid x 3 days then tapered over 3 days
127983|NCT01573052|Drug|Gabapentin|300mg qid x 3 days then tapered over 3 days
127984|NCT01573065|Behavioral|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
127985|NCT01573078|Behavioral|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
127986|NCT01573091|Procedure|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
127987|NCT01573104|Other|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
124842|NCT01541605|Drug|Placebo|tablets for oral use
124843|NCT01541618|Other|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
124844|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
124845|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
124846|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
124847|NCT01541644|Device|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
124848|NCT01541657|Other|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
124849|NCT00077233|Drug|cetuximab|IV
124850|NCT01541657|Other|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
124851|NCT01541657|Other|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
124852|NCT01541670|Drug|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
124853|NCT01534377|Behavioral|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
125143|NCT01537172|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
125144|NCT01537172|Drug|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
125145|NCT01537185|Other|Placebo|3 cohorts of normal saline injection
124318|NCT01540721|Drug|Experimental paracetamol formulation|Experimental formulation
124319|NCT00077168|Procedure|adjuvant therapy|
124320|NCT01540734|Drug|Marketed paracetamol|Marketed formulation
124637|NCT01543659|Drug|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11−100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
124638|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
124639|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
124640|NCT00077311|Drug|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
124641|NCT01543685|Drug|Indomethacin|40 mg TID capsules
124642|NCT01543685|Drug|Indomethacin|40 mg BID capsules
124643|NCT01543685|Drug|Indomethacin|20 mg TID capsules
124644|NCT01543685|Drug|Celecoxib|200 mg capsules
124645|NCT01543685|Drug|Placebo|Capsules
124646|NCT01536366|Drug|Repaglinide|0.5 mg repaglinide (single-dose)
124647|NCT01536379|Drug|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
124648|NCT01536379|Drug|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
124649|NCT01536392|Drug|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
124650|NCT01536392|Drug|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
124651|NCT01536392|Behavioral|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
124652|NCT00076791|Drug|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
125301|NCT01587027|Drug|Aminophylline and Methazolamide|Aminophylline 500mg orally and Methazolamide 250mg orally
125302|NCT01587040|Drug|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
125303|NCT01587040|Drug|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
125304|NCT01589497|Drug|Moxifloxacin|Participants will be administered one 400 mg tablet orally once a day.
125305|NCT00081055|Drug|methotrexate|
125306|NCT01589510|Drug|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
125307|NCT01589523|Drug|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
125308|NCT01589536|Other|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
124386|NCT01538251|Drug|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
124387|NCT00077025|Drug|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
124388|NCT01538277|Procedure|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
124389|NCT01538277|Other|Standard ablation procedure|Standard ablation procedure
124390|NCT01538316|Dietary Supplement|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
124391|NCT01538316|Dietary Supplement|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
124392|NCT01538316|Dietary Supplement|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
124393|NCT01538329|Drug|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
124394|NCT01538329|Drug|placebo|200mg / day once daily in the morning and at noon - oral administration -
124395|NCT01538342|Other|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
124396|NCT01538342|Other|2 biopsies|
124397|NCT01538342|Other|biopsy|1 biopsy ok healthy skin
127988|NCT01573104|Other|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
127989|NCT01573104|Other|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
127990|NCT01573117|Device|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
127991|NCT00079872|Drug|Pemetrexed|
127992|NCT01573117|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
127993|NCT01573130|Behavioral|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
127994|NCT01573143|Drug|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
127995|NCT01573143|Drug|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
127996|NCT01573156|Drug|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 & 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
127997|NCT01573169|Drug|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
127998|NCT01573169|Other|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
127999|NCT01573182|Biological|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
128545|NCT01578512|Behavioral|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
128546|NCT01578525|Other|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
128547|NCT01578538|Procedure|inguinal hernia repair|strangulated hernias will be repaired surgically
128548|NCT01578551|Drug|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
125146|NCT01537185|Biological|SPWCV+Alum 100 mcg|3 injections 28 days apart
125147|NCT01537185|Biological|SPWCV+Alum 600 mcg|3 injections 28 days apart
125148|NCT01537185|Biological|SPWCV+Alum 300 mcg|3 injections 28 days apart
125149|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
125150|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
125151|NCT01537224|Other|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
125152|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
125153|NCT00076973|Drug|montelukast sodium|Duration of Treatment: 6 months
125154|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
125155|NCT01537250|Drug|Nemonoxacin 3 tablets|oral form,once daily,7~10 days
125156|NCT01537263|Device|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
125157|NCT01537276|Procedure|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
125158|NCT01537289|Device|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
125159|NCT01537289|Device|chest tube (28-French)|inserting chest tube to decompress pneumothorax
125160|NCT01537302|Device|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
125161|NCT01537315|Drug|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
125162|NCT01537315|Other|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
125163|NCT01539551|Other|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
125164|NCT01539564|Drug|Minocycline HCl Microspheres|
124253|NCT01540682|Drug|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
124653|NCT01536392|Behavioral|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
124654|NCT01536405|Biological|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
124655|NCT01536405|Biological|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
124910|NCT01539174|Other|laboratory biomarker analysis|Correlative studies
124911|NCT01539174|Other|pharmacological study|Correlative studies
124912|NCT01539187|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
124913|NCT01539200|Dietary Supplement|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
124914|NCT00077103|Drug|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
124915|NCT01539200|Dietary Supplement|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
124916|NCT01539213|Drug|secukinumab (AIN457)|anti-IL-17 antibody
124917|NCT01539226|Drug|Placebo Vaginal Ring|Vaginal Ring containing 25 mg Dapivirine
124918|NCT01541683|Other|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
124919|NCT01541683|Other|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
124920|NCT01541709|Drug|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
124921|NCT01541735|Drug|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
124922|NCT01541735|Drug|placebo|Placebo 40 mg dose.
124923|NCT01541748|Other|Axis|Coloplast's Axis™ Allograft Dermis consists of solvent-dehydrated, gamma-irradiated, preserved human collagen. It is restricted to homologus use as a soft tissue graft for horizontal and vertical soft tissue augmentation of thickness and length.
124924|NCT01541761|Behavioral|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
124398|NCT00077025|Drug|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
124399|NCT01538355|Other|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
124400|NCT01538355|Other|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
124401|NCT01538355|Other|Control diet|Patients stay on their regular diet.
124402|NCT01538381|Drug|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
124403|NCT01538381|Other|Observation|Observation
124404|NCT01538394|Drug|Varenicline|
124405|NCT01538394|Drug|Nicotine patches|
124406|NCT01538394|Drug|Placebo (nicotine patches)|
124407|NCT01538407|Other|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
124707|NCT01543919|Drug|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
124708|NCT01543919|Drug|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
124709|NCT01543919|Drug|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
124710|NCT01543932|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
124711|NCT01543932|Drug|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
124712|NCT01543932|Drug|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
124713|NCT01543945|Drug|Dexamethasone|4 mg iv before induction for high and extremely high risk
124714|NCT00077324|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
124715|NCT01543945|Drug|Ondansetron|4 mg iv before ended surgery 30 min
128549|NCT01578551|Drug|Carboplatin|Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days
Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy
128550|NCT01578551|Drug|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
128551|NCT01578551|Drug|Metformin|1000 mg twice daily with food.
128552|NCT01578564|Drug|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
128553|NCT01580488|Drug|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
128554|NCT01580488|Drug|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
128555|NCT01580488|Drug|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
128556|NCT01580488|Drug|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
128557|NCT01580488|Drug|Daivonex® ointment|once daily application, 3 weeks
128558|NCT01580488|Drug|Daivonex® ointment vehicle|once daily application, 3 weeks
128559|NCT01580501|Drug|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
128560|NCT01580514|Drug|exenatide BYETTA® (Amylin-Lilly)|After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.
Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.
128561|NCT00080613|Drug|exemestane|
128562|NCT01580514|Drug|Saline|After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.
Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.
128582|NCT01574092|Drug|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
128583|NCT01574118|Behavioral|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
124254|NCT01540682|Drug|Cetuximab|~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
124255|NCT01540682|Radiation|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of ~70 Gy.
124256|NCT01542983|Behavioral|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
124257|NCT01542983|Behavioral|treatment as usual|Standard treatment for fatigue and insomnia
124258|NCT01543009|Other|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
124259|NCT01543022|Device|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
124260|NCT01543022|Procedure|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
124261|NCT01543035|Drug|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
124262|NCT00077285|Radiation|radiation therapy|
124263|NCT01543048|Other|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
124264|NCT01543061|Device|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
124265|NCT01543061|Procedure|No treatment|One month of contact lens wear with no eye drop use
124266|NCT01543061|Device|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
124267|NCT01543074|Dietary Supplement|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
124268|NCT01543074|Dietary Supplement|Garlic oil|1 pill = 30 mg garlic oil/day
124269|NCT01543074|Drug|BSE|2 pills = 200 micromoles of Sulforaphane/day
124270|NCT01543074|Dietary Supplement|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
124271|NCT01543087|Procedure|blood sampling|Blood sample collection at different time points
124925|NCT00077233|Drug|5-FU|IV
124926|NCT01541774|Device|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
124927|NCT01541826|Dietary Supplement|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
124928|NCT01541826|Dietary Supplement|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
125230|NCT01535040|Drug|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
125231|NCT01535040|Drug|placebo|Placebo by mouth through completion of 12 weeks.
125232|NCT01535053|Biological|Dactinomycin|Given IV
125233|NCT01535053|Drug|Leucovorin Calcium|Given PO
125234|NCT01535053|Drug|Methotrexate|Given IV and IM
125235|NCT01535053|Other|Quality-of-Life Assessment|Ancillary studies
125236|NCT01535066|Procedure|acupuncture therapy|Receive acupuncture
125237|NCT01535066|Procedure|sham acupuncture|Receive sham acupuncture
125238|NCT01535079|Drug|Placebo|Single administration
125239|NCT01535079|Drug|Ibuprofen 35 mg|Single administration
125240|NCT00076674|Drug|Intravenous Levodopa|
125241|NCT01537328|Other|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
125242|NCT00076973|Drug|Comparator: placebo|Duration of Treatment: 6 months
125243|NCT01537341|Behavioral|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
125244|NCT01537341|Behavioral|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
125245|NCT01537354|Drug|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
124716|NCT01543945|Drug|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
124717|NCT01543958|Drug|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
124718|NCT01543958|Device|Sevelamer carbonate|
124719|NCT01543971|Drug|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
124720|NCT01543971|Drug|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
124721|NCT01543984|Other|Tailored Physical Activity|Tailored Physical Activity (3*50 min/week in 10 weeks)
124722|NCT01543984|Behavioral|Health Counselling|Health guidance (1,5h)
124723|NCT01543997|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
124724|NCT01543997|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
124725|NCT00077324|Procedure|biopsy|
124993|NCT01539265|Drug|silodosin|
124994|NCT01539265|Drug|silodosin|
124995|NCT01539265|Drug|placebo|
124996|NCT00077103|Drug|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
124997|NCT01539278|Procedure|Adenotonsillectomy|Tonsils and adenoids are surgically removed
124998|NCT01539278|Other|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
124999|NCT01539291|Drug|Idelalisib|Idelalisib 150 mg tablet(s) administered orally twice daily
125000|NCT01539304|Drug|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
125001|NCT01539304|Drug|Placebo|Placebo dry syrup, b.i.d
125002|NCT01539317|Drug|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
125003|NCT01539317|Drug|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
128584|NCT01574118|Behavioral|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
128585|NCT01574118|Behavioral|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
128586|NCT01574118|Behavioral|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
128587|NCT01574118|Behavioral|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
128588|NCT01574118|Behavioral|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
128589|NCT01574118|Behavioral|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
128590|NCT01574118|Behavioral|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
128591|NCT00079976|Drug|Tigecycline|
128592|NCT01574131|Drug|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
128593|NCT01574131|Drug|placebo|pill every day for 6 months
128594|NCT01574144|Device|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
128595|NCT01576224|Device|Removable splint "omni med", Fischer Medical Aps, DK-2800 Lyngby, Denmark|To be removed during training exercises three to five times a day
128596|NCT01576237|Other|blood donation|blood donation with preparative hemapheresis
128597|NCT01576250|Other|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
128598|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
127713|NCT01553903|Drug|Exemestane|Exemestane 25mg/day during 5 years
127714|NCT01553903|Drug|Anastrozole|Anastrozole 1 mg/day during 5 years,
127715|NCT01553903|Drug|Letrozole|Letrozole 2.5 mg/day during 5 years,
124272|NCT01543087|Drug|bivalent rLP2086|
124580|NCT01536353|Drug|Exforge 10/160|Tablet, q.d.
124581|NCT01536366|Drug|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
124582|NCT01538563|Drug|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
124583|NCT01538576|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
124584|NCT01538589|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
124585|NCT01538615|Behavioral|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
124586|NCT01538628|Device|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
124587|NCT01538641|Drug|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
124588|NCT01538654|Procedure|enteral protein tube feeding in obese patients|The intervention is rapresened by a new alternative to treate obese patients by mean of a protein sparing modified fast administered by continous 24 h enteral feeding Vs oral protein sparing modified fast feeding
124589|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
124590|NCT00001386|Drug|PCLUS 3-18 MN|
124591|NCT00077051|Radiation|radiation therapy|
124592|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
124593|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
124594|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
125246|NCT01537354|Drug|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
125247|NCT01537367|Behavioral|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
125248|NCT01537367|Behavioral|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
125249|NCT01537367|Behavioral|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
125250|NCT01537380|Drug|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
125251|NCT01537393|Biological|Cornea tissue transplant|Cornea tissue preserved either 7 or less days or 8 to 14 days.
124321|NCT01540734|Drug|Experimental paracetamol formulation|Experimental formulation
124322|NCT01540747|Dietary Supplement|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
124323|NCT01540747|Dietary Supplement|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
124324|NCT01540760|Drug|MCAF5352A|Multiple ascending doses
124325|NCT01540760|Drug|Placebo|Matching MCAF5352A, multiple doses
124326|NCT01540773|Drug|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
124327|NCT01540773|Drug|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
124328|NCT01540786|Procedure|High resolution urodynamic assessment|
124329|NCT01540786|Procedure|Conventional urodynamic assessment|
124330|NCT00077168|Radiation|radiation therapy|
124331|NCT01540799|Device|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
124332|NCT01540812|Drug|Vincristine in induction|
124333|NCT01540812|Drug|Daunorubicin in induction|
124334|NCT01540812|Drug|Prednisone in induction|
124335|NCT01540812|Drug|Metotrexato in induction|
124336|NCT01540812|Drug|Cytarabine in induction|
125004|NCT01539330|Drug|Voriconazole|At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min
at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min
at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min
at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min
at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po
125005|NCT01539330|Other|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
125006|NCT01539343|Drug|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
125007|NCT00000261|Other|Placebo|No drug (100% oxygen)
125008|NCT00001386|Drug|PCLUS 6.1 MN|
125009|NCT00077103|Radiation|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
125010|NCT01539369|Other|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|Participants were randomly assigned to one of two parallel arms:
Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: "Food Should Be Fun And Healthy". Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided.
125011|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
125309|NCT01589549|Biological|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
125310|NCT01589562|Drug|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
125311|NCT01589562|Drug|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
125312|NCT01589588|Device|Open Hudson Mask|Mask type 1 oxygen
125313|NCT01589588|Device|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
125314|NCT01589588|Device|Mask 3|Mask type 3 oxygen
125315|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 oxygen
125316|NCT00081055|Procedure|peripheral blood stem cell transplantation|
125317|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 placebo
127716|NCT01553916|Drug|Lithium Carbonate|
127717|NCT01553929|Other|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
127718|NCT01553929|Other|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
127719|NCT01553929|Other|control group|no physical training and no cognitive activity
127720|NCT01556204|Procedure|Surgery for endometriosis|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
127721|NCT01556217|Drug|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
127722|NCT01556217|Drug|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
127723|NCT01556230|Procedure|Surgical intervention for CNFA|(non-experimental) standard procedure
127724|NCT01556230|Radiation|Radiotherapy for CNFA|(non-experimental) standard procedure
127725|NCT01556243|Procedure|therapeutic conventional surgery|
127726|NCT01556243|Radiation|whole breast irradiation|
127727|NCT00078559|Drug|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
127728|NCT01556256|Procedure|music therapy|Undergo TMV
127729|NCT01556256|Procedure|music therapy|Undergo TMV+P
127730|NCT01556256|Other|caregiver-related intervention or procedure|Undergo TMV+P
127731|NCT01556256|Other|questionnaire administration|Ancillary studies
127732|NCT01556256|Other|quality-of-life assessment|Ancillary studies
128000|NCT01573208|Device|Custom guides|Symbios custom guides for TKA
128001|NCT01573234|Device|MySkin patch|Hydrogel and polyurethane film
124595|NCT01538680|Drug|Regorafenib (BAY73-4506)|Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):
Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.
Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol
124596|NCT01538693|Drug|escitalopram oxalate|10 mg 4.5 hours prior to testing
124854|NCT00076544|Drug|Ziconotide|
124855|NCT01534377|Behavioral|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
124856|NCT01534390|Device|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
124857|NCT01534403|Biological|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
124858|NCT01534416|Drug|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
124859|NCT01534416|Drug|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
124860|NCT01534429|Procedure|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
124861|NCT01534442|Drug|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
124862|NCT01534442|Drug|Placebo|
124863|NCT01534455|Drug|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
124864|NCT01534455|Drug|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
124865|NCT00076557|Genetic|Adeno-Associated Viral with Human Factor IX|
124866|NCT01534468|Biological|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
124867|NCT01534481|Biological|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
124868|NCT01534481|Dietary Supplement|Preterm Formula|Preterm Formula determined by center practice.
124869|NCT01534494|Drug|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
124337|NCT01540812|Drug|Hydrocortisone in induction|
124338|NCT01543269|Drug|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
124339|NCT01543269|Drug|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
124340|NCT01543282|Device|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
124341|NCT01543321|Drug|Tetrabenazine|Treatment with tetrabenazine consists in:
5-week titration to a maximum dose of 200 mg / day
5 weeks at stable dose
2 weeks in wash-out
The treatment will be blinded for patients and investigators
124342|NCT01543321|Drug|Placebo|Treatment with placebo consists in:
5-week titration to a maximum dose of 200 mg / day
5 weeks at stable dose
2 weeks in wash-out
The treatment will be blinded for patients and investigators
124343|NCT00077298|Other|laboratory biomarker analysis|Correlative studies
124656|NCT01536418|Drug|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
124657|NCT01536418|Drug|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
124658|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
124659|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
124660|NCT01536431|Drug|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
124661|NCT01536444|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
124662|NCT01536470|Other|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
124663|NCT00076804|Behavioral|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
124664|NCT01536470|Other|Ephedryne chorydrate|
125318|NCT01589601|Behavioral|Usual heart failure care + interdisciplinary palliative care|Usual heart failure care + interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
125319|NCT01589614|Drug|PH-797804|Tablet, 6mg, single
125320|NCT01589614|Drug|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
125321|NCT01589627|Device|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
125322|NCT01589640|Other|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
125323|NCT01589640|Other|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
125324|NCT01589640|Other|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
125325|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
125326|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
125327|NCT00001502|Drug|RMP-7 and carboplatin|
125328|NCT01582113|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
125329|NCT01582126|Other|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
124408|NCT01538420|Drug|GLPG0492|Oral solution
124409|NCT00077051|Drug|cisplatin|
124410|NCT01538420|Drug|Placebo|Placebo oral solution
124411|NCT01540812|Drug|Idarubicin in induction-2|
124412|NCT01540812|Drug|Fludarabine in induction-2|
124413|NCT01540812|Drug|Ara-C in induction-2|
124414|NCT00077181|Drug|cytarabine|Given IV
124415|NCT01540812|Drug|G-CSF in induction-2|
128002|NCT00079885|Drug|tigecycline|
128003|NCT01575379|Drug|Allopurinol|The allopurinol dosage will vary from 200 to 400 mg per day based on GFR. Subjects randomized to allopurinol will initially take 100 mg per day for four weeks. After that, they will be switched to 400 mg per day if their GFR is ≥50 ml/min/1.73 m2, 300 mg per day if their GFR is in the 25-50 ml/min/1.73 m2 range, and 200 mg per day if the GFR is in the 15-25 ml/min/1.73 m2 range. Allopurinol will be continued at this dosage throughout the study unless the GFR changes, in which case the dosage will be modified to that appropriate for the new GFR class.Subjects will be given four tablets per day to be taken orally following meals, two in the morning and two in the evening. A dosage of 100 mg will be given as a 100 mg tablet plus three placebo tablets, 200 mg as two 100 mg and two placebo tablets, 300 mg as three 100 mg and one placebo tablet, 400 mg as four 100 mg tablets. Subjects randomized to placebo will be given four placebo tablets.
128004|NCT01575379|Drug|Placebo|Subjects will be given four placebo (inactive) tablets per day to be taken orally following meals, two in the morning and two in the evening.
128005|NCT01575405|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
128006|NCT01575405|Drug|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy) propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
128007|NCT01575405|Drug|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
128008|NCT01575418|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
128009|NCT00080119|Drug|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
128010|NCT01575418|Drug|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy)propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
124870|NCT01534520|Drug|Lidocaine|Intravaginal insertion of 5mL 2% lidocaine gel
124871|NCT01534520|Drug|Placebo|KY Jelly
124872|NCT01534533|Dietary Supplement|Placebo|one gelatine capsule containing starch per day, for 12 months
124873|NCT01534533|Dietary Supplement|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
124874|NCT01534533|Dietary Supplement|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
125165|NCT01539577|Drug|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
125166|NCT01539590|Drug|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
125167|NCT01539590|Drug|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
125168|NCT01539603|Device|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
125169|NCT01539603|Device|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
125170|NCT01539616|Drug|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
125171|NCT01539616|Drug|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
125172|NCT01539616|Drug|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
125173|NCT00077116|Drug|cytarabine|
125174|NCT01539616|Drug|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
125175|NCT01539629|Device|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
125176|NCT01539642|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
125177|NCT01539642|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
125178|NCT01539655|Drug|vandetanib|Oral tablets, 300 mg, single dose
125179|NCT01539655|Drug|omeprazole|Oral capsules, 40 mg, multiple doses
125180|NCT01539655|Drug|ranitidine|Oral tables, 150 mg, multiple doses
124665|NCT01538719|Drug|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
124666|NCT00077064|Drug|captopril|
124667|NCT01538719|Drug|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
124668|NCT01538732|Drug|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
124669|NCT01538745|Drug|Ketamine|0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.
124670|NCT01538745|Drug|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
124671|NCT01538758|Other|Us guided needling|Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.
After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance.
124672|NCT01538758|Other|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
124673|NCT01538771|Drug|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
124929|NCT01541826|Dietary Supplement|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
124930|NCT01541839|Device|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
124931|NCT01541852|Drug|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
124932|NCT01541852|Drug|Placebo|One tablet twice daily
124933|NCT01541865|Device|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
124934|NCT01541891|Drug|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
124935|NCT01541891|Drug|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
124936|NCT00001398|Drug|Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)|
124937|NCT00077233|Drug|irinotecan|IV
124416|NCT01540812|Drug|Dexamethasone in consolidation-1|
124417|NCT01540812|Drug|Vincristrine in consolidation-1|
124418|NCT01540812|Drug|Metotrexato in consolidation-1|
124419|NCT01540812|Drug|PEG-ASP in consolidation-1|
124420|NCT01540812|Drug|Dexamethasone in consolidation-2|
124421|NCT01540812|Drug|ARA-C in consolidation-2|
124422|NCT01540812|Drug|PEG-ASP in consolidation-2|
124423|NCT01540812|Drug|Dexamethasone in consolidation-3|
124424|NCT01540812|Drug|Vincristine in consolidation-3|
124425|NCT00077181|Drug|triapine|Given IV
124426|NCT01540812|Drug|Metotrexato in consolidation-3|
124427|NCT01540812|Drug|PEG-ASP in consolidation-3|
124428|NCT01540812|Procedure|allogeneic HSCT|
124429|NCT01540812|Procedure|Allo HSCT with reduced-intensity conditioning|
124430|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
124431|NCT01540825|Drug|BI 113608|High dose powder for oral solution
124432|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
124433|NCT01540825|Drug|Placebo|Powder for oral solution
124434|NCT01540838|Drug|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
124726|NCT01536483|Drug|Butyrate enemas|Seven enemas
Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)
The study remains blinded for the investigation team through the intervention of a clinical research nurse
According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention
Installation time and retention is setted at 15 minutes
Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C
Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist
128258|NCT01575743|Behavioral|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
128259|NCT01575756|Biological|Octafibrin - (Factor I concentrate)|Single intravenous infusion of 70 mg/kg body weight
128260|NCT01575756|Biological|Haemocomplettan/Riastap (Factor I concentrate)|Single intravenous infusion of 70 mg/kg bodyweight
128261|NCT01575769|Drug|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
128262|NCT01575782|Drug|Chloroquine|Daily intake of Chloroquine during radiotherapy
128263|NCT01575795|Drug|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
128264|NCT01575795|Drug|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
128265|NCT00080158|Drug|citalopram|
128266|NCT01575808|Device|GP1101|Endovascular Device Implantation
128267|NCT01575821|Dietary Supplement|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
128268|NCT01575821|Dietary Supplement|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
128269|NCT01575821|Dietary Supplement|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
128270|NCT01578044|Behavioral|Intervention|Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.
Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.
Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication.
128271|NCT01578057|Drug|tasimelteon|20mg, once
128272|NCT01578057|Drug|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
128273|NCT01578057|Other|Placebo tasimelteon|once
125181|NCT01539681|Drug|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
125182|NCT01539707|Drug|Solifenacin succinate|oral suspension
125183|NCT01539720|Drug|Ulipristal acetate|30 mg tablet
125184|NCT00077116|Drug|gemtuzumab ozogamicin|
125185|NCT01539720|Device|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
125186|NCT01539733|Drug|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
124273|NCT00077298|Biological|cetuximab|Given IV
124274|NCT01543100|Other|blood and bone marrow samples|Specific tests of the study will be realized from :
Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.
Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.
In all cases, no additional sampling will be performed.
124275|NCT01543113|Other|sequencing|sequencing
124276|NCT01543139|Dietary Supplement|Valproate+Cytidine+Creatine|Valproate: 300mg/day, Cytidine: 1g every other day, Creatine: Week0-1: 3g/day Week1-12: 5g/day
124277|NCT01543139|Dietary Supplement|Valproate+Cytidine|Valproate: 300mg/day, Cytidine: 1g every other day
124278|NCT01543139|Drug|Valproate|Valproate: 300mg/day
124279|NCT01535768|Drug|Aqueous Suppressant Eye Drops|Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).
Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).
Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)
124280|NCT01535781|Drug|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
124281|NCT01535781|Drug|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
124282|NCT01535807|Device|CorMatrix extra cellular matrix (ECM)|Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.
No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care.
124938|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
124939|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
124940|NCT01534546|Drug|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
124941|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
124942|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
124943|NCT01534559|Other|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
124944|NCT01534572|Dietary Supplement|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
124945|NCT01534572|Dietary Supplement|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
124946|NCT01534585|Drug|Icotinib|Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.
Phase II:According to the maximum tolerated dose, 50 patients will been recruited.
125252|NCT01537406|Radiation|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
125253|NCT00076986|Drug|IL13-PE38QQR|
125254|NCT01537419|Behavioral|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
125255|NCT01537419|Behavioral|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
125256|NCT01537432|Drug|secukinumab|secukinumab
125257|NCT01537432|Drug|placebo|placebo comparator
124727|NCT01536496|Biological|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
124728|NCT01536496|Biological|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
124729|NCT01536509|Behavioral|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
124730|NCT01536509|Behavioral|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
124731|NCT01536522|Biological|Allergen|Inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation.
124732|NCT01536535|Drug|Mesalamine|Pentasa comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
124733|NCT01536535|Drug|Prednisone|Initiate treatment with prednisone, 1-1.5 mg/kg/day, (maximum 40-60 mg in a single morning dose, either as tablet or liquid equivalent), rounded up to the nearest 5 mg value. This dose will be continued for 2 weeks to assess response.
124734|NCT01536535|Drug|Corticosteroids followed by mesalamine (Pentasa)|500 mg capsules 70-75 mg/kg per day
124735|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
124736|NCT01536548|Procedure|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
124737|NCT01536548|Procedure|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
125012|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
125013|NCT01541904|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
125014|NCT01541917|Behavioral|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
128274|NCT01578057|Drug|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
128599|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
128600|NCT01576276|Radiation|Integrated MR-PET scan|Integrated MR-PET scan using [11C]diprenorphine
128601|NCT01576276|Drug|Ketorolac|3 administrations of ketorolac over course of study
128602|NCT01576276|Drug|Morphine|3 administrations of morphine over course of study
128603|NCT01576289|Other|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
128604|NCT00080184|Procedure|Low Energy Neurofeedback System|
128605|NCT01576302|Behavioral|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
128606|NCT01576302|Behavioral|Muscle relaxation|Progressive passive muscle relaxation
128607|NCT01576315|Drug|Itraconazole/voriconazole|The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
128608|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
128609|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
128610|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
128611|NCT01576341|Drug|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
128612|NCT01576354|Drug|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
128613|NCT01576354|Drug|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
128614|NCT01576367|Biological|ACZ885|
128615|NCT00080197|Drug|E7070|
128616|NCT01576380|Drug|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
128617|NCT01576393|Behavioral|Home-based Family Therapy|12 home-based family therapy sessions
124283|NCT01535820|Drug|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
124284|NCT01535820|Drug|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
124285|NCT00076752|Biological|filgrastim|Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC >500 microliters.
124286|NCT01535833|Procedure|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
124287|NCT01535846|Behavioral|Conscious food tasting intervention|Six weekly 2-hour workshops
124288|NCT01535859|Drug|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
124289|NCT01535859|Drug|Placebo|1 tablet daily for 8 days.
124597|NCT01538693|Drug|Cyproheptadine|8mg 4.5 hours prior to testing
124598|NCT01538693|Drug|sugar pill|4.5 hour prior to testing
124599|NCT01538693|Other|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
124600|NCT01538706|Other|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
124601|NCT01541072|Drug|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils >= 0.5 G/L)
124602|NCT01541085|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
124603|NCT01541085|Drug|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
124604|NCT01541098|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
124605|NCT00077207|Drug|temozolomide|Given orally
124606|NCT01541098|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
124607|NCT01541111|Drug|Magnesiun|75mg pills; each 12h; 12wk
124608|NCT01541124|Drug|Opioid|10 mg/pill, po, each 6h, during 6m
125258|NCT01537458|Procedure|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
125259|NCT01537471|Drug|Placebo|Placebo
125260|NCT01537471|Drug|Meclizine|Meclizine 12.5 mg
125261|NCT01537471|Drug|Meclizine|Meclizine 25 mg
125262|NCT01539746|Procedure|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
125263|NCT01539746|Procedure|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
125264|NCT01539759|Device|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
125265|NCT01539785|Procedure|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
125266|NCT01539785|Procedure|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
125267|NCT01539798|Other|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
124344|NCT01543334|Biological|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
124345|NCT01543347|Drug|Temocillin|Antibiotic treatment
124346|NCT01543360|Procedure|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
124347|NCT01543360|Procedure|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
125015|NCT01541917|Behavioral|Online disease education|The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse "health coach" to discuss the participant's efforts at managing his/her disease.
125016|NCT01541930|Drug|GK567|Once or twice daily, for 14 days, up to 30 g per day
125017|NCT01541943|Drug|Atorvastatin|Once daily, administered orally, 8 week
125018|NCT01541943|Drug|Losartan|Once daily, administered orally, 8 week
125019|NCT00077233|Drug|leucovorin|IV
125020|NCT01541943|Drug|Placebo|Once daily, administered orally, 8 week
125021|NCT01541943|Drug|HL-040XC|Once daily, administered orally, 8 week
125022|NCT01541956|Drug|Metformin|500 mg twice daily
125023|NCT01541956|Drug|vildagliptin|Vildagliptin 50 mg twice daily
125024|NCT01541969|Device|CR Neuromodulation|Ear level device which delivers patterned sound stimulation.
The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour.
125025|NCT01541969|Device|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
125026|NCT01542008|Behavioral|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
125330|NCT01582139|Device|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
125331|NCT01582152|Drug|TPI287|Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
125332|NCT01582152|Drug|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
128618|NCT01576393|Behavioral|office-based family therapy|12 office-based family therapy sessions
127733|NCT01556282|Device|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
127734|NCT01556308|Procedure|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
127735|NCT01556321|Dietary Supplement|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
127736|NCT01556321|Dietary Supplement|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
127737|NCT01556334|Drug|Azithromycin|Azithromycin 1g po
127738|NCT00078559|Drug|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
127739|NCT01556334|Drug|Erythromycin|Erythromycin IV then PO
127740|NCT01556347|Drug|Bortezomib, Thymoglobulin, (rATG), Rituximab, Gamimune N, (IVIG), Plasmapheresis (Multidrug Protocol)|Bortezomib, Thymoglobulin, (rATG), Rituximab, Gamimune N, (IVIG), Plasmapheresis
127741|NCT01556373|Other|NA : non interventional study|NA : non interventional study
127742|NCT01558440|Dietary Supplement|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
127743|NCT01558440|Dietary Supplement|Diluted F-100|300 ml of water is added to 1000 ml of f-100
127744|NCT01558453|Drug|Oxaliplatin|Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.
NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30).
127745|NCT01558466|Drug|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
127746|NCT01558466|Drug|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
127747|NCT01558492|Drug|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
124609|NCT01541137|Drug|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
124610|NCT01541137|Drug|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
124611|NCT01541137|Device|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
124612|NCT01541150|Behavioral|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
124613|NCT01541176|Other|Absence of corticotherapy post-transplantation|No study treatment
124614|NCT01541176|Drug|Corticotherapy post-transplantation|Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :
D1 to D14 : 20 mg/day,
D15 to M1 : 15 mg/day,
M1 to M3 : 10 mg/day,
M3 to M12 : 5 mg/day.
124615|NCT01541189|Drug|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
124616|NCT00077207|Drug|vincristine sulfate|Given IV
124617|NCT01541202|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
124875|NCT01534533|Dietary Supplement|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
124876|NCT00076570|Drug|Sirolimus|
124877|NCT01536756|Other|Exercise Intervention -- Physical Rehabilitation Program|The intervention group will participate in a "Physical Rehabilitation Program" which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise.
124878|NCT01536756|Other|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
124879|NCT01536782|Procedure|Bolus|The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).
Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.
124348|NCT01543373|Device|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
124349|NCT01543373|Device|Bare Metal Stent|Bare metal coronary stent
124350|NCT01543386|Drug|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
124351|NCT01543399|Drug|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
124352|NCT01543399|Drug|Placebo|patients of the placebo group will use placebo one a day for 30 days
124353|NCT01543412|Drug|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
124354|NCT00001402|Device|PET scan|
124355|NCT00077311|Biological|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB < or = 11 g/dL
124356|NCT01543438|Other|Video Prescription (additional education)|receives video prescriptions
124357|NCT01543451|Drug|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
124358|NCT01543451|Drug|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
124359|NCT01535924|Drug|bendamustine hydrochloride|Given IV
124360|NCT00076752|Drug|methylprednisolone|Priming regimen:1000 mg intravenous over 30 minutes, day 1.
124361|NCT01535937|Drug|Ketamine|0.5 mg/kg IV over 40 minutes
124362|NCT01535937|Drug|Midazolam|0.025 mg/kg IV over 40 minutes
124363|NCT01535950|Drug|LFG316|
124674|NCT01538771|Drug|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
124675|NCT01538784|Drug|YF476|Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:
Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth
Groups A & B were dosed alternately, at weekly intervals
124676|NCT01538797|Drug|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
124677|NCT00077077|Drug|DJ-927|
125333|NCT01582165|Drug|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
125334|NCT01582165|Drug|Placebo.|Placebo once daily vs rosuvastatin for 6 months
125335|NCT01582178|Procedure|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
125336|NCT00001498|Drug|leucovorin|
125337|NCT00080756|Biological|therapeutic estradiol|0.35mg/100ul per day as a nasal spray
125338|NCT01582178|Procedure|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
125339|NCT01582191|Drug|Vandetanib|Starting Dose: 100 mg by mouth daily in a 28 day cycle.
125340|NCT01582191|Drug|Everolimus|Starting dose: 2.5 mg by mouth daily of a 28 day cycle.
125341|NCT01582204|Drug|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd & pelvis), 124I-cG250-PET/CT & Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan & 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, & pelvis with contrast after cycles 2, 3, 4 & 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline & week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, & serial blood sampling, following the lst inj of 124I-cG250.
125342|NCT01582230|Drug|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
125343|NCT01582230|Drug|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
125344|NCT01582243|Drug|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
125345|NCT01582269|Drug|LY2157299 monohydrate|Orally administered as tablets
125346|NCT01582269|Drug|Lomustine|Orally administered as capsules
125347|NCT01582269|Drug|Placebo|Orally administered as tablets
125348|NCT00080756|Drug|deslorelin|1mg/100ul per day as a nasal spray
128234|NCT01573598|Drug|Placebo|Matching placebo given orally, once per day
128235|NCT01573598|Drug|Vilazodone|Vilazodone, 20 mg per day, oral administration
128236|NCT01573598|Drug|Vilazodone|Vilazodone, 40 mg once per day, oral administration
130403|NCT01563107|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
130404|NCT01563107|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
130405|NCT01563120|Drug|metformin|metformin up to 2550mg per day.
130406|NCT01563120|Drug|glybenclamide|glybenclamide up to 20mg per day.
130407|NCT01563133|Procedure|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
130408|NCT00079105|Drug|etoposide|
130409|NCT01563133|Device|nCLE|needle-based Confocal Laser Endomicroscopy
130410|NCT01563146|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
130411|NCT01563159|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
130412|NCT01563172|Drug|Fluoride Toothpaste|comparison of different doses of fluoride (1150ppm and 250ppm ) applied for different durations
130413|NCT01563172|Drug|Placebo|fluoride-free toothpaste
130414|NCT01563185|Drug|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
130415|NCT01565616|Other|Biological: Bone Marrow Transplant|The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.
SCHEMA OF CONDITIONING REGIMEN Day Treatment (BU- Busulfan, FLU-Fludarabine, ATG-Rabbit Anti-thymocyte globulin)
Day -8 BU 3.2 mg/ kg/dose IV
Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV
Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV
Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV
Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV
Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV
Day -2 ATG 1.5mg/kg IV
Day -1 Rest
Day 0 Stem cell infusion
GVHD Regimen
Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper
Day 0 Stem cell infusion
Day +1 Methotrexate 7.5 mg/m2 IV
Day +3 Methotrexate 7.5 mg/m2 IV
Day +6 Methotrexate 7.5 mg/m2 IV
Day+11 Methotrexate 7.5 mg/m2 IV
130416|NCT01565629|Behavioral|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
130417|NCT01565642|Behavioral|Goals of care decision support|Decision aid and care plan meeting
130418|NCT01565655|Drug|ASP015K|oral
131181|NCT01601574|Behavioral|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
131182|NCT01601574|Other|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
130046|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
130047|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
130048|NCT01569815|Drug|LCZ696|LCZ696 400 mg once daily
130049|NCT00079469|Behavioral|smoking cessation intervention|
130050|NCT01572025|Drug|Placebo|Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol
: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)
130051|NCT01572038|Drug|pertuzumab|840 mg iv on Day 1 of Cycle 1, followed by 420 mg iv on Day 1 of each subsequent 3-week cycle
130052|NCT01572038|Drug|taxane|docetaxel or paclitaxel or nab-paclitaxel, administered in line with the respective product information
130053|NCT00079677|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
130054|NCT01572038|Drug|trastuzumab [Herceptin]|8 mg/kg iv on Day 1 of Cycle 1, followed by 6 mg/kg iv on Day 1 of each subsequent 3-week cycle, administered in line with the product information
130055|NCT01572051|Behavioral|Educational Course|2 Educational courses
130056|NCT01572051|Behavioral|Phone Calls|Phone Calls
130057|NCT01572051|Behavioral|Printed Material|Printed Material
130058|NCT01572064|Procedure|Blood sample|1 fasted blood sample taken for metabolomics
130059|NCT01572064|Other|MRI Scan|1 single visit for MRI and MRS
130060|NCT01572077|Radiation|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
130061|NCT01572090|Behavioral|Lifestyle Changes|Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.
Dietetic and physical activity counselling with a dietitian.
130062|NCT01572090|Other|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
130737|NCT01604993|Other|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
130738|NCT01605006|Device|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
130739|NCT01605019|Device|CoSeal|3 - 8mls of Coseal
130740|NCT00082862|Drug|gemcitabine hydrochloride|
130741|NCT01605019|Device|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
130742|NCT01605032|Drug|Busulfan|Given IV
130743|NCT01605032|Drug|Melphalan|Given IV
130744|NCT01605032|Drug|Bortezomib|Given IV
130745|NCT01605032|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
130746|NCT01605032|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
130747|NCT01605032|Other|Laboratory Biomarker Analysis|Correlative studies
130748|NCT01605032|Other|Pharmacological Study|Correlative studies
130749|NCT01605045|Other|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
130750|NCT01605045|Other|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
130751|NCT00082862|Procedure|hyperthermia treatment|
130752|NCT01605071|Drug|Estradiol|1 week of transdermal estradiol (0.15mg)
1 week of transdermal placebo
130753|NCT01605084|Drug|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
130754|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|In the placebo group the TENS device had no current output although the power "on" indicator light remained active.
130755|NCT00083057|Drug|paclitaxel|
131116|NCT00082719|Biological|Recombinant Interferon Alfa|In all arms, treatment begins at pre-operative visit and continues until cystoscopy.
Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose.
130252|NCT01565317|Other|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
130253|NCT01565330|Drug|florbetapir F 18|single dose IV injection
130254|NCT01565343|Drug|florbetapir F 18|IV injection, 370MBq (10mCi)
130255|NCT01565356|Drug|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
130256|NCT01565369|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
130257|NCT00079235|Drug|temsirolimus|Given IV
130258|NCT01565382|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
130259|NCT01565395|Drug|Xeomin|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
130260|NCT01565395|Drug|placebo|
130261|NCT01565408|Drug|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
130262|NCT01565408|Drug|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
130263|NCT01567462|Device|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
130264|NCT01567462|Device|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
130265|NCT01567475|Drug|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
130266|NCT01567488|Drug|Everolimus|Everolimus 10mg/day
130267|NCT01567488|Drug|octreotide LAR|30 mg each 28 days
130268|NCT01567501|Drug|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
130556|NCT01570569|Drug|Cocktail|Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
130557|NCT01570569|Drug|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
130558|NCT01570569|Drug|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
130810|NCT01602874|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|Subject with CAP:
IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
130811|NCT01602887|Drug|PD-0332991|isethionate hard capsule, 125 mg, single dose
130812|NCT01602887|Drug|PD-0332991|freebase hard capsule with a "small" particle size, 125 mg, single dose
130813|NCT00082667|Drug|gefitinib|
130814|NCT01605084|Drug|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
130815|NCT01605084|Drug|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
130816|NCT01605084|Drug|Optimized NRTI backbone|tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks
NRTI backbone are:
- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)
The following NRTI combinations are prohibited in this study:
Didanosine + Stavudine
Zidovudine + Stavudine
Lamivudine + Emtricitabine
130817|NCT01605097|Radiation|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
130818|NCT01605110|Drug|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
130819|NCT01605110|Drug|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
130820|NCT01605136|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
130821|NCT01605136|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
130822|NCT00082875|Drug|cilengitide|Given IV
130063|NCT01572090|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy. Dietetic and physical activity counselling with a dietitian.
130064|NCT00079677|Drug|Placebo|Matching placebo tablets once daily
130065|NCT01572090|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. Dietetic and physical activity counselling with a dietitian.
130066|NCT01572103|Dietary Supplement|Coffee|Administration of 4 cups of coffee per day for 1 month
130067|NCT01572103|Dietary Supplement|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
129153|NCT01572779|Device|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
129154|NCT01572779|Device|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
129155|NCT01572792|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose, twice per day
129156|NCT00079820|Biological|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
129157|NCT01572792|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose, twice per day
129158|NCT01572792|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
129159|NCT01572792|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
129160|NCT01572792|Drug|Placebo|Inhaled dose-matched placebo, twice per day
129161|NCT01572805|Drug|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
129162|NCT01572805|Drug|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
129163|NCT01572805|Drug|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
129164|NCT01572818|Procedure|phlebotomy|7 ml/kg without exceeding 500 mL
129165|NCT01572818|Behavioral|dietary and lifestyle counseling|dietary and lifestyle counseling
130756|NCT01607476|Drug|C11 PiB|One time intravenous administration of 8-22 mCi C11 PiB
131042|NCT01603251|Drug|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
131043|NCT01605526|Drug|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
131044|NCT01605526|Drug|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
131045|NCT01605539|Drug|Cannabidiol|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
131046|NCT01605539|Drug|Cannabidiol|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
131047|NCT01605539|Drug|Placebo|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
131048|NCT01605552|Behavioral|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
131049|NCT01605552|Other|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
131050|NCT01605565|Procedure|A nasal brushing|A nasal brushing in every nostril
131051|NCT01605578|Procedure|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
131052|NCT00082914|Biological|denileukin diftitox|
131053|NCT01605591|Procedure|the DLT bending to the right|bending the bronchial lumen of DLT 60~90 degrees in the same side with the tracheal lumen
131054|NCT01605591|Procedure|the DLT bending to the left|bending the bronchial lumen of DLT 60~90 degree opposed to the tracheal lumen
131055|NCT01605604|Behavioral|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
131056|NCT01605617|Drug|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
131057|NCT01605617|Drug|Placebo|PTNS + placebo for 12 weeks
130269|NCT01567501|Drug|Levocetirizine Dihydrochloride|5 mg tablet once in a day
130270|NCT01567514|Procedure|Glass ionomer cement lining|Resin-modified glass ionomer lining
130271|NCT01567527|Drug|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
130539|NCT01568047|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
130540|NCT01568060|Other|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
130541|NCT01568073|Drug|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
130542|NCT01568073|Drug|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
130543|NCT00079378|Drug|decitabine|Given IV
130544|NCT01568073|Drug|Placebo|200 mg
130545|NCT01568073|Drug|Levodopa|
130546|NCT01568073|Drug|Carbidopa|DOPA decarboxylase inhibitor
130547|NCT01568073|Drug|Benserazide|DOPA decarboxylase inhibitor
130548|NCT01568099|Biological|AFFITOPE® PD01A|s.c. injection
130549|NCT01568099|Other|Control|Untreated control
130550|NCT01568112|Drug|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
130551|NCT01568112|Drug|BG00012 placebo|Placebo matching BG00012
130552|NCT01568112|Drug|ASA|325 mg microcoated aspirin (ASA)
130553|NCT01570569|Drug|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
130554|NCT01570569|Drug|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
130555|NCT01570569|Drug|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
130823|NCT01605162|Drug|E7016 plus TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
130824|NCT01605201|Biological|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
130825|NCT01605227|Drug|cabozantinib|Tablets taken orally once-daily
130826|NCT01605227|Drug|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
131117|NCT01603303|Other|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
131118|NCT01603303|Behavioral|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
131119|NCT01603303|Behavioral|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
131120|NCT01603316|Behavioral|Food pantry only arm|Participants will have: 1x per week access to food pantry. 3 and 6 month follow-up Administer study follow-up, Survey, Medical Chart review/extraction, Measure & record patient weight/BMI
131121|NCT01603316|Behavioral|Food pantry + Food voucher arm|Participants will have: 1x per week access to food pantry + 1x per month voucher to buy food *monthly voucher will be $230 *food receipts collected each month 3 and 6 month follow-up, Administer study follow-up Survey, Medical Chart review/extraction, Measure & record patient weight/BMI
131122|NCT01603316|Behavioral|Food pantry + Grocery delivery|Participants will have: 1x per week access to food pantry + 1x per week grocery delivery *weekly grocery delivery will include: 5 lunches & 5 dinners 3 and 6 month follow-up , Administer study follow-up Survey, Medical Chart review/extraction , Measure & record patient weight/BMI. Patients will have the opportunity to request to the study team to cancel a weekly grocery delivery if there are unique circumstances (e.g. patient is away on vacation, delivered food is being stocked piled/unused, unexpected/unspecified food aversions).
131123|NCT01603329|Other|Increasing Medication Adherence through Physician Incentives and Messaging|There are two treatments:
Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.
When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart.
131124|NCT01605656|Behavioral|Questionnaires|Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.
Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.
The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete.
131125|NCT00082927|Drug|ibandronate sodium|
129166|NCT01572831|Other|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (<12,000 and >4,000).
129167|NCT00079833|Drug|Esomeprazole magnesium (Nexium)|
129168|NCT01572844|Device|Fractional Carbon Dioxide (FCO2) Laser (Candela QuadraLase (TM))|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
129169|NCT01572844|Drug|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% STS solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
129170|NCT01572857|Biological|urinary excretion of FLC immunoglobulin|First phase :
Collection of four urine samples daily for 2 days:
Of the 24-hour urine
at 8 AM
at 12 AM
at 4 PM
On each of these urine samples, the following analysis will be performed:
Proteinuria
Albuminuria
Urinary FLC (Freelite ™)
Urine creatinine
Second phase:
Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row.
129444|NCT01571011|Behavioral|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
129445|NCT01571024|Drug|BKM120|BKM120 40 mg, orally, once daily.
129446|NCT01571024|Drug|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
129447|NCT01571037|Drug|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
129448|NCT01571037|Drug|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
129449|NCT01571050|Drug|Purified water|Ingestion of 30 mL of purified water
129450|NCT01571050|Drug|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
129451|NCT01571050|Drug|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
131058|NCT01605617|Procedure|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
130198|NCT01567436|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
130199|NCT00079352|Drug|alvocidib|Given IV
130200|NCT01570010|Other|new norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
130201|NCT00079482|Drug|lestaurtinib|lestaurtinib with induction regimen of MEC
130202|NCT01570023|Behavioral|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
130203|NCT01570036|Drug|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
130204|NCT01570036|Drug|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
130205|NCT01570036|Drug|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
130206|NCT01570049|Drug|Bendamustine|for injection
130207|NCT01570062|Device|HEPA Filter|Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., "placebo" filtration).
130208|NCT01570062|Device|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
130343|NCT01565590|Drug|propofol|5-80 mcg/kg/min
130344|NCT01567631|Procedure|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
130345|NCT00079352|Drug|irinotecan hydrochloride|Given IV
130346|NCT01567644|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
130347|NCT01567657|Drug|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
130348|NCT01567657|Drug|Propofol|50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.
< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved.
130349|NCT01567670|Drug|Naloxone|2 mg x 1-2
130350|NCT01567670|Drug|naloxone placebo|h2o placebo spray
130351|NCT01567683|Drug|Imiquimod (topical use)|
130352|NCT01567709|Drug|Alisertib|Given PO
130353|NCT01567709|Other|Laboratory Biomarker Analysis|Correlative studies
130354|NCT01567709|Other|Pharmacological Study|Correlative studies
130355|NCT01567709|Drug|Vorinostat|Given PO
130356|NCT00001449|Drug|leucovorin|
130357|NCT00079365|Drug|fluorouracil|
130358|NCT01567722|Genetic|DNA analysis|
130359|NCT01567722|Genetic|RNA analysis|
130360|NCT01567722|Genetic|gene expression analysis|
130361|NCT01567722|Genetic|polymorphism analysis|
130362|NCT01567722|Other|biologic sample preservation procedure|
130363|NCT01567722|Other|flow cytometry|
131126|NCT01605656|Behavioral|Focus Groups|Phase I: There will be up to 8 women in each of the 5 focus groups.
Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes.
131127|NCT01605669|Other|Tranthoracic Echocardiogram|
131128|NCT01605669|Other|Cardiac Ascultation Recordings with Electronic stethoscope|
131129|NCT01605682|Dietary Supplement|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
131130|NCT01605708|Drug|REGN846|Dose 1
130272|NCT01567527|Drug|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
130273|NCT00079352|Drug|gemcitabine hydrochloride|Given IV
130274|NCT01567540|Drug|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
130275|NCT01567553|Other|USPIO MRI - Gadolinium MRI|USPIO MRI scanning will be performed at :
baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.
baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,
baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,
baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,
baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.
Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36.
130276|NCT01567566|Other|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
130277|NCT01567592|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
130278|NCT01567605|Drug|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
130279|NCT01567605|Other|Placebo lubricant|Placebo lubricant (no topical anesthetic) 30 mL
130280|NCT01567618|Drug|Docetaxel|Docetaxel 50mg/m2 iv drip, repeat every two weeks;
Efficacy will be evaluated every three cycles.
130281|NCT01567618|Drug|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
130282|NCT01567631|Procedure|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
130419|NCT01565655|Drug|Placebo|oral
130420|NCT01565668|Drug|AC220|oral
130675|NCT01607398|Drug|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
130676|NCT00083057|Drug|gefitinib|
130677|NCT01607398|Drug|Placebo|Placebo inhalation, twice daily, from week0 -12.
130678|NCT01607411|Drug|Fluoride|Fluoride Toothpaste
130679|NCT01607411|Drug|Placebo|Fluoride free toothpaste
130680|NCT01607424|Behavioral|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
130681|NCT01607450|Drug|GLP-1 Low Dose|0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
130682|NCT01607450|Drug|GLP-1 Mid-Range Dose|1.5mmol/kg/min for 12 hours prior to PET study
130683|NCT01607450|Drug|GLP-1 High Dose|4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
130684|NCT01607450|Drug|Saline|Normal saline placebo infusion for 12 hours prior to PET study
130685|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
130686|NCT01600456|Behavioral|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
130687|NCT00082394|Drug|atazanavir|
130688|NCT01600456|Other|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
130689|NCT01600469|Drug|DAOI-B|250-1500 mg/day, oral, for 24 weeks
130690|NCT01600469|Other|Placebo|placebo, oral, for 24 weeks
130691|NCT01600482|Device|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.
130692|NCT01600495|Other|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
130209|NCT01570075|Procedure|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
130210|NCT01570075|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
130478|NCT01570556|Other|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
130479|NCT00079547|Behavioral|low-carbohydrate diet|low-carbohydrate diet
130480|NCT01563198|Behavioral|Comfort Talk|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
130481|NCT01563224|Drug|Baclofen 10mg|Baclofen 10mg single dose po
130482|NCT01563224|Drug|Baclofen 60mg|Baclofen 60mg single dose po
130483|NCT01563224|Drug|placebo|placebo
130484|NCT00079105|Drug|mitoxantrone hydrochloride|
130485|NCT01563237|Device|MIDI Arrow|Implantation of MIDI Arrow
130486|NCT01563250|Device|Point of Care testing|The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.
Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.
All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well.
130487|NCT01563263|Biological|IC43|100 mcg
130488|NCT01563263|Drug|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
130489|NCT01563289|Drug|Ibuprofen|3 times a day
130490|NCT01563289|Drug|Placebo|3 times a day
130491|NCT01563302|Drug|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
130492|NCT01563328|Drug|DTG|50 mg q24h
130493|NCT01563328|Drug|BCV|800 mg q8h
130904|NCT01607827|Procedure|Polyp removal upon insertion and withdrawal|Endoscopic procedures:
All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.
The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back.
130905|NCT01607827|Procedure|Polyp removal upon withdrawal only|Endoscopic procedures:
All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.
The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques.
130906|NCT01607840|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
130907|NCT00001550|Drug|IVIg|
130908|NCT00083083|Drug|cisplatin|
130909|NCT01607853|Drug|Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)|Once daily application, 3 weeks
130910|NCT01607853|Drug|Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)|Once daily application, 3 weeks
130911|NCT01607853|Drug|Daivobet® gel applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
130912|NCT01607853|Drug|Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
130913|NCT01607866|Procedure|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
130914|NCT01607866|Procedure|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
130915|NCT01607879|Drug|Standard of care ADT + (HMB + arginine + glutamine)|1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.
Take one packet twice daily for 3 months
130916|NCT01607879|Other|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
130917|NCT01607892|Drug|KPT-330|
130918|NCT01607905|Drug|KPT-330|Subjects in this study will receive KPT-330 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
130919|NCT00083083|Drug|docetaxel|
130920|NCT01607918|Drug|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
130283|NCT01570127|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
130284|NCT01570127|Procedure|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
130285|NCT01570127|Other|Waiting|No interventions were applied to the patients in this group.
130286|NCT01570140|Behavioral|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
130559|NCT01570582|Drug|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
130560|NCT01570595|Behavioral|Web-Based Tailored Smoking Cessation Intervention|The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The "standard care" group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
130561|NCT01570595|Behavioral|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
130562|NCT01570608|Drug|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
130563|NCT00079560|Drug|dronabinol|dronabinol to prevent development of marijuana withdrawal
130564|NCT01570608|Drug|Verteporfin|Verteporfin photodynamic therapy standard fluence
130565|NCT01570621|Procedure|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
130566|NCT01570634|Drug|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
130567|NCT01570660|Drug|Pioglitazone|12 weeks of pioglitazone treatment
130568|NCT01570673|Behavioral|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
130569|NCT01570673|Behavioral|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
130693|NCT01600508|Other|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
130694|NCT01600521|Drug|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
130695|NCT01600534|Behavioral|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
130988|NCT01608048|Device|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
130989|NCT01608061|Device|DBS-f on|deep brain stimulation of the fornix
130990|NCT01608061|Device|DBS-f off|deep brain stimulation of the fornix turned off
130991|NCT01608074|Procedure|Radical fimbriectomy|Laparoscopic bilateral radical fimbriectomy :
Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)
130992|NCT01608074|Other|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
130993|NCT01608087|Drug|BI 695502|BI 695502 single i.v. infusion
130994|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
130995|NCT00083083|Drug|paclitaxel|
130996|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
130997|NCT01608100|Device|ARCHITECT STAT High Sensitive Troponin I Assay|Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.
Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit.
130998|NCT01608126|Procedure|cervical block|In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.
The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm).
130999|NCT01608139|Drug|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
131000|NCT01601119|Drug|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
130494|NCT01563328|Drug|TVR|750 mg q8h
130495|NCT00079105|Drug|prednisolone|
130496|NCT01563341|Device|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
130497|NCT01563354|Drug|Pasireotide LAR|60 mg i.m. injected once every 28 days
130498|NCT01563354|Drug|Everolimus|10 mg p.o. daily
130499|NCT01563354|Drug|Pasireotide LAR + Everolimus|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
130757|NCT01607476|Drug|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
130758|NCT01607476|Drug|FDG|One time intravenous administration of 10 mCi (+/- 20%) FDG.
130759|NCT01607489|Radiation|Dual-energy computed tomography investigation|1x 20ml Ultravist (370mg J/ml)3-5ml/s,
1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration
130760|NCT01607515|Other|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
130761|NCT01607528|Dietary Supplement|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
130762|NCT01607528|Dietary Supplement|Placebo|A similar looking and tasting powder with no active substances
130763|NCT01607541|Behavioral|BCAP peer-driven intervention (PDI)|The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized "CARE for Prevention" tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation).
130764|NCT01607541|Behavioral|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
130765|NCT01607554|Drug|Irinotecan|180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle
Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician
130766|NCT00083057|Radiation|radiation therapy|
130767|NCT01607580|Drug|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
130768|NCT01607593|Drug|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
130921|NCT01607918|Drug|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
130937|NCT01601093|Drug|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
130938|NCT01601093|Drug|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
130939|NCT01601106|Drug|liposomal prednisolone|Two weekly dosages with 150 mg.
130940|NCT01601106|Drug|Placebo|
130941|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN 1x10^8 will be administered intramuscularly to Group F on day 0 and day 28.
130942|NCT01602991|Procedure|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
130943|NCT01602991|Procedure|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
130944|NCT01603004|Other|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
130945|NCT01603017|Device|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
130946|NCT01603017|Device|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
130947|NCT01603030|Drug|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
130948|NCT00082706|Drug|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
130949|NCT01603030|Drug|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
130950|NCT01603043|Drug|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
130951|NCT01603043|Drug|Sham injection|Mock injection administered as an empty hub without needle
130570|NCT01570686|Drug|Aliskiren|Aliskiren 300 mg once daily
130571|NCT01563393|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
130572|NCT01563393|Other|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
130573|NCT01563406|Other|15 second scrub|Catheter hubs are normally cleansed prior to accessing the central venous line. All catheter hubs in this arm will be scrubbed for 15 seconds.
130574|NCT00079105|Drug|procarbazine hydrochloride|
130575|NCT01563406|Other|5 second scrub|Catheter hubs are normally cleansed prior to accessing the central venous line. All catheter hubs in this arm will be scrubbed for 5 seconds.
130827|NCT01605240|Drug|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
130828|NCT01605240|Drug|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
130829|NCT01605253|Drug|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
130830|NCT01605253|Drug|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
130831|NCT01605279|Drug|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
130832|NCT01605279|Drug|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
130833|NCT01607658|Drug|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
130834|NCT01607658|Drug|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
130835|NCT01607671|Drug|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
131001|NCT01601119|Other|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
131002|NCT01601132|Drug|theophylline|300mg (80mg/15ml elixir)
131003|NCT01601132|Drug|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
131004|NCT01601145|Dietary Supplement|consumption of lozenges|Each subject two lozenges a day for 6 weeks
131005|NCT01601158|Biological|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
130147|NCT01562574|Drug|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
130148|NCT01562587|Drug|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
130149|NCT01562587|Drug|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
130150|NCT01562626|Drug|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
130151|NCT01562626|Drug|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
130152|NCT01562626|Drug|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
130153|NCT01562652|Device|AposTherapy (All Phases of Step-cycle {APOS} system, APOS—Medical and Sports Technologies Ltd. Herzliya, Israel)|
130154|NCT01562678|Drug|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
130155|NCT01562678|Drug|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
130156|NCT00079079|Drug|cisplatin|
130157|NCT01562691|Procedure|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
130158|NCT01562691|Procedure|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
130159|NCT01562691|Procedure|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
130769|NCT01607619|Dietary Supplement|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
130770|NCT01607632|Behavioral|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
130771|NCT01607645|Drug|decitabine|Given IV
130772|NCT01607645|Drug|idarubicin|Given IV
130773|NCT01607645|Drug|cytarabine|Given IV
130774|NCT01607645|Other|laboratory biomarker analysis|Correlative studies
130775|NCT01607658|Drug|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
130776|NCT01607658|Drug|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
130777|NCT00083070|Drug|temozolomide|
131059|NCT01605630|Behavioral|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
131060|NCT01605630|Behavioral|Control|standard of care
131061|NCT01605656|Behavioral|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
131062|NCT01608321|Device|Sham device|Placebo Device that simulates active rTMS treatment
131063|NCT01608334|Drug|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
131064|NCT01608334|Drug|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
131065|NCT01608347|Drug|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
131066|NCT00083083|Genetic|gene expression analysis|
131067|NCT01608347|Drug|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
131068|NCT01608360|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
131069|NCT01608360|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
130952|NCT01603056|Biological|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
130953|NCT01603056|Biological|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
130088|NCT00079183|Other|questionnaire administration|Ancillary studies
130089|NCT01565057|Other|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
130090|NCT01565070|Drug|Biofreeze|Use of Biofreeze ointment
130091|NCT01565070|Other|Placebo|Use of placebo ointment
130092|NCT01565083|Drug|pertuzumab|840 mg iv infusion Day 1 of Cycle 1, followed every 3 weeks by 420 mg iv as separate infusion on Day 1
130093|NCT01565083|Drug|pertuzumab|840 mg iv infusion Day 1 of Cycle 1, followed every 3 weeks by 420 mg iv together with trastuzumab in a single infusion bag on Day 1
130094|NCT01565083|Drug|trastuzumab [Herceptin]|8 mg/kg iv infusion on Day 2 of Cycle 1, followed every 3 weeks by 6 mg/kg iv as separate infusion on Day 1 or 2
130095|NCT01565083|Drug|trastuzumab [Herceptin]|8 mg/kg iv infusion on Day 2 of Cycle 1, followed every 3 weeks by 6 mg/kg iv together with pertuzumab in a single infusion bag on Day 1
130096|NCT01565083|Drug|vinorelbine|25 mg/m2 iv infusion on Days 2 and 9 of Cycle 1, followed by 30-35 mg/m2 on Days 1 and 8 (or Days 2 and 9) of each 3-week cycle
130097|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
130098|NCT01567202|Radiation|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
130099|NCT01567202|Biological|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
130100|NCT01567202|Drug|blank placebo|Saline that has the same appearance with DC vaccine.
130101|NCT01567215|Procedure|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
130102|NCT00079326|Other|laboratory biomarker analysis|Correlative studies
130103|NCT01567215|Drug|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
130104|NCT01567215|Procedure|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
130836|NCT01607684|Device|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
130837|NCT01607697|Behavioral|Mindfulness Training|Mindfulness Training
130838|NCT01607723|Other|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
130839|NCT01607723|Other|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
130840|NCT01607736|Behavioral|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
131131|NCT01605721|Device|XIENCE PRIMETM everolimus-eluting coronary stent|Active prospective registration of patients receiving the following stent
: XIENCE PRIMETM
131132|NCT01605734|Procedure|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
131133|NCT01605734|Drug|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
131134|NCT01605747|Dietary Supplement|Culturelle|one capsule 2x per day per feeding tube
131135|NCT01605747|Dietary Supplement|Placebo|one placebo 2x per day per feeding tube
131136|NCT00082940|Biological|denileukin diftitox|
131137|NCT01605760|Drug|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
131138|NCT01605773|Drug|repaglinide|Dose individually adjusted and conducted according to labeling
131139|NCT01605773|Drug|glyburide|Dose individually adjusted and conducted according to labeling
130160|NCT01562704|Drug|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
130161|NCT01562717|Drug|Ibuprofen|3 times a day
130162|NCT01562717|Drug|Placebo|3 times a day
130163|NCT01562743|Drug|SPM 962|Tansdermal patch
130164|NCT01562756|Other|HVLA-SM|High velocity, low amplitude spinal manipulation
130165|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
130166|NCT00079183|Procedure|quality-of-life assessment|Ancillary studies
130167|NCT01565096|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
130168|NCT01565096|Drug|Glimepiride|Glimepiride at individual dose
130421|NCT00079248|Drug|conjugated estrogens|
130422|NCT01565681|Drug|ASP1240|infusion
130423|NCT01565681|Drug|Placebo|infusion
130424|NCT01565694|Drug|Solifenacin succinate|oral
130425|NCT01565707|Drug|Solifenacin Succinate Suspension|Oral suspension
130426|NCT01565707|Drug|Placebo|Oral suspension
130427|NCT01565707|Behavioral|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
130428|NCT01565720|Drug|Isavuconazole|oral
130429|NCT01565720|Drug|Placebo|oral
130430|NCT01565720|Drug|Moxifloxacin|oral
130431|NCT01565733|Drug|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
130432|NCT00079261|Drug|CHOP regimen|
130433|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
130434|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
131070|NCT01608373|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
131071|NCT01608373|Drug|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
131072|NCT01608373|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
131073|NCT01608386|Procedure|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
131074|NCT01608399|Behavioral|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
131075|NCT01608412|Drug|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
131076|NCT01608412|Drug|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
131077|NCT00083083|Procedure|positron emission tomography|
130211|NCT01570088|Dietary Supplement|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
130212|NCT00079482|Drug|lestaurtinib|lestaurtinib with induction regimen of HiDAC
130213|NCT01570088|Dietary Supplement|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
130214|NCT01570088|Other|Placebo|Placebo contains no folic acids
130215|NCT01570114|Device|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
130216|NCT01570127|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
130217|NCT01562782|Other|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
130218|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
130219|NCT00079079|Drug|gemcitabine hydrochloride|
130220|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
130221|NCT01562795|Drug|corticosteroids|corticosteroids plus artificial tear substitute
130222|NCT01562795|Drug|artificial tear substitute|artificial tear substitute alone
130105|NCT01567228|Other|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
130106|NCT01567241|Other|clinical hypnosis or relaxation music|25 minute tape recording
130107|NCT01567254|Behavioral|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
130108|NCT01567254|Behavioral|music ONLY|music. It will be equal in length to the auditory guided imagery disk
130364|NCT01567722|Other|laboratory biomarker analysis|
130365|NCT01567722|Other|medical chart review|
130366|NCT01567735|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
130367|NCT01567748|Procedure|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
130368|NCT00079365|Drug|gemcitabine hydrochloride|
130369|NCT01567774|Drug|Atorvastatin|os, 20 mg, once per day, for 30 days
130370|NCT01570244|Drug|levonorgestrel|multiple doses
130371|NCT01570244|Drug|BI 201335|multiple doses
130372|NCT01570244|Drug|Ethinylestradiol|multiple doses
130373|NCT01570257|Procedure|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
130374|NCT01570270|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
131140|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.
The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval.
131141|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.
The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval.
131142|NCT01608633|Other|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
131143|NCT00083083|Radiation|radiation therapy|
131144|NCT01608646|Drug|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
131145|NCT01608659|Drug|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
131146|NCT01608672|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
130287|NCT01570166|Procedure|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
130288|NCT01570166|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
130289|NCT00079495|Drug|NBI-5788|
130290|NCT01570179|Drug|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
130291|NCT01570179|Drug|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
130292|NCT01570179|Drug|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
130293|NCT01570179|Drug|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
130294|NCT01570192|Drug|IV meropenem; parenteral aminoglycoside|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr) plus a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h) plus tobramycin nebulization
130435|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
130436|NCT01565759|Drug|Lithium Carbonate|The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.
Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg.
130437|NCT01565772|Radiation|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
130438|NCT01567774|Drug|Rosuvastatin|os, 10 mg, once per day, for 30 days
130439|NCT01567787|Radiation|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
130440|NCT01567787|Radiation|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
130441|NCT01567800|Other|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
130442|NCT01567826|Drug|standard of care lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]
130443|NCT01567826|Drug|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
130696|NCT01600573|Drug|pazopanib in combination with weekly topotecan|Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and
Pazopanib orally once daily continuous dosing in the following dose levels:
Phase I Trial:
Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg
Phase II Trial:
Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary.
130697|NCT01600586|Device|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
130698|NCT00001526|Drug|Daclizumab (Zenapax)|
130699|NCT00082394|Drug|Combivir|
130700|NCT01600599|Drug|Tranexamic Acid|intravenous 1g and topical 1g
130701|NCT01600599|Drug|saline|100mls of topical saline
130702|NCT01600612|Drug|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
130703|NCT01600612|Drug|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
130704|NCT01600612|Drug|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
130705|NCT01600625|Drug|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
130223|NCT01562808|Drug|Aripiprazole|single oral administration of aripiprazole
130224|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
130225|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
130226|NCT01562821|Drug|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
130227|NCT01562834|Drug|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
130228|NCT01562834|Drug|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
130229|NCT01562847|Drug|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
130230|NCT00079092|Drug|procarbazine hydrochloride|
130231|NCT01562860|Procedure|Pronator Teres Release|Surgical release of median nerve compression
130500|NCT01563367|Drug|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
130501|NCT01563367|Drug|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
130502|NCT01563380|Biological|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
130503|NCT01565772|Drug|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
130504|NCT01565772|Drug|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
130505|NCT01565785|Behavioral|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
130506|NCT01565798|Other|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
130375|NCT01570283|Biological|Multi-virus-specific cytotoxic T lymphocytes|The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.
Dose Level One: 5x10^6 mCTLs/m2
Dose Level Two: 1x10^7 mCTLs/m2
Dose Level Three: 2x10^7 mCTLs/m2
There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
130376|NCT01570296|Drug|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
130377|NCT01570309|Drug|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
130378|NCT01570309|Other|Sugar pill|Oral capsule, once a week, 12 weeks
130379|NCT00079521|Procedure|Therapeutic Touch|
130380|NCT01570348|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
130381|NCT01570348|Drug|Cyclophosphamide|Given IV
130633|NCT01568216|Drug|AMG 747|Three dose levels once-daily oral administration
130634|NCT01568216|Drug|Placebo|Once-daily oral administration
130635|NCT01568229|Drug|AMG 747|Three dose levels once-daily oral administration
130636|NCT01568229|Drug|Placebo|Once-daily oral administration
130637|NCT01568242|Device|Phacoemlsification|Transurgical measurement of temperature
130638|NCT01604811|Drug|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
130639|NCT00082836|Radiation|yttrium Y 90 ibritumomab tiuxetan|
130640|NCT01604824|Drug|alirocumab|Randomized, double-blind treatment period may be followed by open-label treatment with alirocumab for all patients if certain criteria are met.
130641|NCT01604824|Drug|placebo|
130642|NCT01604850|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
130643|NCT01604850|Drug|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
130644|NCT01604850|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
130645|NCT01604850|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
130295|NCT01570192|Drug|I.V. Meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
130296|NCT01570205|Drug|XG-102|single intravenous infusion
130297|NCT01570218|Behavioral|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
130298|NCT01570231|Device|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
130299|NCT01570244|Drug|levonorgestrel|multiple doses
130300|NCT00079508|Drug|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
130301|NCT01570244|Drug|Ethinylestradiol|multiple doses
130302|NCT00079092|Drug|thalidomide|
130303|NCT01562925|Dietary Supplement|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
130576|NCT01563406|Drug|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
130577|NCT01563406|Drug|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
130578|NCT01563419|Device|Indicator magnifying window (Izumi Planning Co.)|IZUMI PLANNING CO,.LTD.Tokyo.Japan
Material: Polypropylene with polycarbonate lens
130579|NCT01563432|Drug|Feburic®|80 mg*1 tablet
130580|NCT01563432|Drug|TMX-67|40 mg*2 tablets
130581|NCT01563445|Drug|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
130582|NCT01563445|Drug|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
130583|NCT01563458|Drug|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
130706|NCT01600638|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
130707|NCT01600651|Other|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
130708|NCT01600651|Other|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
130709|NCT01602666|Procedure|therapeutic conventional surgery|Undergo surgery
130710|NCT01602666|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
130711|NCT00082628|Drug|Serostim®[somatropin (rDNA origin) for injection]|
130712|NCT01602666|Radiation|intensity-modulated radiation therapy|Undergo IMRT
130713|NCT01602666|Drug|carboplatin|Given IV
130714|NCT01602666|Drug|etoposide|Given IV
130715|NCT01602666|Drug|ifosfamide|Given IV
130716|NCT01602679|Drug|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
130717|NCT01602679|Drug|Placebo|placebo
130718|NCT01602692|Drug|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
131006|NCT01601158|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
131007|NCT01601184|Drug|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
131008|NCT01601184|Drug|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
131009|NCT01601197|Behavioral|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
131010|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10^7, 5x10^7, 1x10^8, 1x10^8, respectively, on days 0 and day 28.
131011|NCT01601210|Drug|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
131012|NCT01601236|Drug|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups [8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)].
130507|NCT01565811|Procedure|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
130508|NCT00079261|Drug|cyclophosphamide|
130509|NCT01565824|Other|web-based support|
130510|NCT01565837|Drug|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
130511|NCT01565837|Radiation|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
130512|NCT01565850|Drug|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg STR administered orally once daily
130513|NCT01565850|Drug|DRV|DRV 2x400 mg tablets administered orally once daily
130514|NCT01565850|Drug|COBI|COBI 150 mg tablet administered orally once daily
130515|NCT01565850|Drug|FTC/TDF|FTC 200 mg/TDF 300 mg tablet administered orally once daily
130516|NCT01565850|Drug|Placebo to match D/C/F/TAF|Placebo to match D/C/F/TAF administered orally once daily
130517|NCT01565850|Drug|Placebo to match DRV|Placebo to match DRV administered orally once daily
130778|NCT01600664|Behavioral|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
130779|NCT00082407|Drug|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
130780|NCT01600664|Behavioral|Convertible PC|Participants will be using the convertible PC without the interactive computer game
130781|NCT01600677|Device|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
130782|NCT01600677|Other|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
130783|NCT01600690|Other|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
130646|NCT01604863|Drug|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
130647|NCT01604863|Drug|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
130648|NCT01604863|Drug|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
130649|NCT01604876|Device|light therapy 30 min morning and evening, three months|Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.
therapy consists of 30 minutes light exposure in the morning and evening during 3 months.
130650|NCT00082862|Biological|recombinant interferon alfa|
130651|NCT01604876|Device|light therapy 30 min morning and evening, three months|200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).
Therapy consists of 30 minutes light exposure in the morning and evening during 3 months.
130652|NCT01604889|Drug|INCB024360|
130653|NCT01604889|Drug|Placebo|Placebo
130954|NCT01603069|Drug|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
130955|NCT01603069|Drug|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
130956|NCT01603069|Drug|Placebo|Placebo to AZD3241 BID
130957|NCT01603082|Drug|Ticagrelor|180 mg loading dose
130958|NCT01603082|Drug|Clopidogrel|600 mg loading dose
130959|NCT00082706|Drug|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
130960|NCT01603108|Drug|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
130961|NCT01605409|Procedure|Emergency cardiopulmonary bypass under ongoing CPR|Emergency cardiopulmonary bypass under ongoing CPR
Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.
Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT.
130584|NCT01563458|Drug|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
130585|NCT00079105|Drug|vinblastine sulfate|
130586|NCT01563458|Drug|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
130587|NCT01563471|Drug|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
130588|NCT01563471|Drug|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
130589|NCT01563497|Drug|PF-05089771|Oral dispersion TS formulation- fasted
130590|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fasted
130591|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fed
130592|NCT01565889|Drug|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
130593|NCT01565889|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
130594|NCT01565889|Drug|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
130841|NCT01607749|Behavioral|Educational Program|Schools in the intervention group received the educational program "Asthma, Sport and Health", as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.
Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days.
130842|NCT01607749|Other|Usual Asthma Information for teachers|Common asthma information for teachers
130843|NCT00083083|Drug|carboplatin|
130844|NCT01607762|Drug|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
130845|NCT01607762|Drug|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
131013|NCT01601236|Drug|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
131014|NCT01601249|Procedure|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
131015|NCT01601262|Device|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
131016|NCT01601301|Device|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
131017|NCT01601314|Drug|Magnesium Sulfate|At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.
After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started.
131018|NCT01601314|Other|Sodium Chloride|At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.
After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started.
131019|NCT01601327|Drug|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
131020|NCT01601327|Drug|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
131021|NCT01603108|Drug|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
131022|NCT01603121|Drug|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
130169|NCT01565109|Drug|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
130170|NCT01565109|Radiation|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
130171|NCT01565135|Behavioral|Multimodal Vaccine Program|Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:
Patient education regarding the importance of vaccination, including encouragement of vaccination for family members
Practice-based reminder/recall
Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback
130172|NCT01565148|Drug|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
130173|NCT01565148|Drug|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
130784|NCT01600703|Drug|Sitagliptin|100mg po single dose
130785|NCT01600716|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
130786|NCT01600716|Drug|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
130787|NCT01600729|Drug|No Intervention|No intervention.
130788|NCT01600742|Drug|Vorinostat|Run-in phase:
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.
Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.
Randomization phase:
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.
Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.
130789|NCT01600742|Drug|Placebo|Randomization phase:
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.
Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.
130790|NCT00082407|Drug|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
130791|NCT01600755|Biological|AMDC|Cell Treatment
130792|NCT01600768|Drug|Beta-Lactams|infusion time: 30 mins or 1 hr
130793|NCT01600768|Drug|Beta-Lactams|infusion time 4 hrs
130794|NCT01600781|Dietary Supplement|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
130795|NCT01600807|Drug|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
131078|NCT01608425|Procedure|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
131079|NCT01608438|Device|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
131080|NCT01608451|Drug|Cholecalciferol|300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
131081|NCT01608451|Drug|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
130962|NCT01605409|Procedure|Standard ACLS|Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.
Transportation:
Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.
Standard Post resuscitation Management:
After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.
If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible.
130963|NCT01605422|Other|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
130964|NCT01605435|Drug|Ghrelin|The first three participants will receive 2 mcg/kg as a single subcutaneous dose at Visit 3, 5 mcg/kg as a single subcutaneous dose at Visit 4, and 10 mcg/Kg as a single subcutaneous dose at visit 5. There will be 3-10 days between visits. The next three participants will receive either the same dosing at the first three, a regimen that includes an intermediate dose (e.g., 7.5 mcg/kg), or higher (e.g., 12, 15, and 18 mcg/kg) doses.
130965|NCT00082888|Other|Laboratory Biomarker Analysis|Correlative studies
130966|NCT01605448|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
130967|NCT01605461|Drug|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
130968|NCT01605474|Other|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
130969|NCT01605474|Other|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
130109|NCT01567267|Behavioral|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
130110|NCT01567267|Behavioral|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
130111|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
130112|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
130113|NCT00079339|Radiation|radiation therapy|Undergo radiotherapy
130114|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
130115|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
130846|NCT01607762|Drug|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
130847|NCT01607762|Drug|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
130848|NCT01607762|Drug|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
130849|NCT01607775|Device|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
130850|NCT01600820|Other|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
130851|NCT01600820|Other|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
130852|NCT01600859|Drug|E2609|E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg
E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg
According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo
130853|NCT00082433|Drug|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
130854|NCT01600859|Drug|Placebo for E2609|Placebo capsules
According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo
130855|NCT01600885|Drug|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
131147|NCT01608698|Drug|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
131148|NCT01608698|Drug|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
131149|NCT01608711|Biological|AGS-1C4D4|Intravenous Infusion
131150|NCT01608711|Biological|gemcitabine|Intravenous Infusion
131151|NCT01608724|Drug|Saxagliptin|oral, 5 mg once a day (Q.D.)
131152|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
131153|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
130174|NCT01565148|Drug|iCo-007 350 mcg Plus Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
130175|NCT01565148|Drug|Ranibizumab Plus iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
130176|NCT01565161|Behavioral|Home-Based Health Coaching|The 6-month intervention arm consists of 3 components:
In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.
Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.
Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months.
130177|NCT00079222|Drug|itraconazole|
130178|NCT01565161|Behavioral|Mailed materials|We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.
Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's "Positive Parenting Tips for Healthy Child Development", and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials.
130179|NCT01565187|Behavioral|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
130180|NCT01565200|Drug|T-DM1|3.6 mg/kg iv every 3 weeks
130181|NCT01565200|Procedure|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
130182|NCT01565213|Behavioral|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
130444|NCT01567839|Procedure|Mandibular buccal Infiltration injection|
130445|NCT01567852|Drug|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
130446|NCT01567852|Drug|Methohexital|Methohexital (1.5mg/kg) will be given for induction
130447|NCT00079365|Radiation|brachytherapy|
130448|NCT01567865|Biological|JE live attenuated SA 14-14-2 vaccine|
130449|NCT01567891|Biological|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
131082|NCT01608464|Drug|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
131083|NCT00082446|Other|Placebo|Group E will receive sterile saline placebo for injection via scarification on day 112.
131084|NCT01601327|Drug|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
131085|NCT01601340|Drug|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
131086|NCT01601340|Drug|Placebo|Placebo tablets, twice daily for 48 weeks
131087|NCT01601353|Device|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
131088|NCT01601366|Device|LNG-IUS|The study includes 2 treatment groups: Group I "the LNG-IUS group" where they will have a LNG IUS inserted for them
131089|NCT01601366|Drug|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
131090|NCT01601392|Procedure|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
131091|NCT01601392|Procedure|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
131092|NCT01601392|Procedure|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
131093|NCT01601405|Drug|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
131094|NCT00082446|Other|Placebo|Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
131095|NCT01601405|Drug|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
131096|NCT01601418|Drug|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
130232|NCT01562860|Procedure|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
130233|NCT01562860|Procedure|dual compression release|both procedures will be done on the same day
130234|NCT01562860|Procedure|median nerve release only|only the carpal tunnel compression is released
130235|NCT01562873|Drug|Ruxolitinib|Taken orally, twice daily
130116|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
130117|NCT01567306|Biological|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
130118|NCT01567319|Biological|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
130119|NCT01569828|Drug|LCZ696A|
130120|NCT01569828|Drug|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
130121|NCT01569841|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
130122|NCT01569841|Drug|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
130123|NCT01569893|Other|Self-monitoring for patients with Dibetes mellitus|Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.
The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms.
130124|NCT01569906|Radiation|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
130125|NCT01569919|Biological|TroVax®|Dose of 1 x 10^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
130126|NCT01569919|Drug|Pemetrexed|500 mg/m^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
130127|NCT01569919|Drug|Cisplatin|75mg/m^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
130382|NCT01570348|Drug|Fludarabine Phosphate|Given IV
130383|NCT01570348|Other|Laboratory Biomarker Analysis|Correlative studies
130384|NCT01570348|Drug|Mycophenolate Mofetil|Given PO
130385|NCT01570348|Drug|Mycophenolic Acid|Given PO
130386|NCT01570348|Other|Quality-of-Life Assessment|Ancillary studies
130387|NCT01570348|Drug|Tacrolimus|Given IV or PO
130388|NCT01570348|Radiation|Total-Body Irradiation|Undergo TBI
130389|NCT01570361|Device|Catheter Ablation|Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
131154|NCT00001554|Device|intraoperative infrared (IR) neuroimaging|
131155|NCT00083096|Drug|lonafarnib|
131156|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
131157|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
131158|NCT01608737|Drug|BI 201335|BI 201335 once daily low dose for 24 weeks
131159|NCT01608750|Drug|Pantoprazol|40mg/day, oral, 28 days
131160|NCT01608750|Drug|Folic Acid|5 mg/day, oral, 28 days
131161|NCT01608763|Behavioral|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
131162|NCT01608776|Device|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
131163|NCT01608776|Other|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
131164|NCT01608789|Device|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
131165|NCT01608802|Other|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
131166|NCT00083096|Drug|temozolomide|
131167|NCT00082459|Biological|autologous human tumor-derived HSPPC-96|
131168|NCT01601483|Drug|MC-1101|1% Ophthalmic Solution TID
131169|NCT01601483|Drug|MC-1101 Vehicle|Ophthalmic solution, TID
130304|NCT01562925|Dietary Supplement|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
130305|NCT01562938|Drug|Placebo|Placebo
130306|NCT01562938|Drug|MEDI-557|MEDI-557 low-dose
130307|NCT01562938|Drug|MEDI-557|MEDI-557 high-dose
130450|NCT01567904|Drug|Semuloparin sodium|Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)
Subcutaneous injection
130451|NCT01567917|Procedure|CRC surgery|Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)
- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE
130452|NCT01567930|Drug|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
130453|NCT01567943|Behavioral|Contingency Management|Behavioral reinforcement for alcohol abstinence
130454|NCT01567956|Drug|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
130455|NCT01567956|Drug|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
130456|NCT01567969|Behavioral|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
130457|NCT01567969|Behavioral|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
130458|NCT00079365|Radiation|phosphorus P32|
130459|NCT01567982|Device|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
130460|NCT01570387|Drug|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-28
130461|NCT01570387|Drug|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
130719|NCT01602692|Drug|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
130720|NCT01602705|Other|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
130721|NCT01602705|Other|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
130722|NCT00082641|Biological|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
130236|NCT01562886|Drug|Rilpivirine|Rilpivirine 26mg
130237|NCT01562899|Drug|MEK162 + AMG 479|
130238|NCT01562912|Device|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
130239|NCT01562912|Device|Radiofrequency Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
130240|NCT01562925|Dietary Supplement|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
130241|NCT01565213|Behavioral|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
130242|NCT01565213|Behavioral|CAU|Care as usual by the GPs
130243|NCT01565239|Device|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
130244|NCT01565252|Dietary Supplement|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
130245|NCT01565265|Drug|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
130246|NCT00079222|Drug|voriconazole|
130247|NCT01565265|Drug|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
130248|NCT01565278|Drug|Soybean oil (Standard treatment)|1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
130249|NCT01565278|Drug|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
130250|NCT01565291|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
130251|NCT01565304|Behavioral|POWER Through Choices|10-session group-based sexual education curriculum
130518|NCT01565850|Drug|Placebo to match COBI|Placebo to match COBI administered orally once daily
130519|NCT00079261|Drug|doxorubicin hydrochloride|
130520|NCT01565850|Drug|Placebo to match FTC/TDF|Placebo to match FTC/TDF administered orally once daily
130390|NCT00079534|Behavioral|Non-local/distant healing or prayer|
130391|NCT01570361|Drug|Drug Treatment|Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
130392|NCT01570374|Behavioral|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
130393|NCT01563042|Drug|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
130394|NCT01563055|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
130395|NCT00000261|Drug|0.6% sevoflurane|
130396|NCT00001443|Drug|indinavir (MK-0639)|
130397|NCT00079105|Drug|cyclophosphamide|
130398|NCT01563055|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
130399|NCT01563068|Drug|calcipotriene|topical application applied twice a day for 15 days
130400|NCT01563081|Drug|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
130401|NCT01563081|Drug|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
130402|NCT01563107|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
130654|NCT01604889|Drug|ipilimumab|ipilimumab 3 mg/kg IV
130655|NCT01604889|Drug|ipilimumab|Doses to be determined following the completion of Phase I of the study
130656|NCT01604902|Other|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
130657|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
130658|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
130308|NCT01562951|Drug|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
130309|NCT01562951|Drug|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
130310|NCT01562964|Behavioral|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
130311|NCT01562964|Behavioral|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
130312|NCT01562977|Drug|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
130313|NCT00079105|Biological|bleomycin sulfate|
130314|NCT01562990|Drug|Rituximab, CMC544, Gemcitabine and Oxaliplatine|2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.
2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.
130315|NCT01563003|Other|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
130316|NCT01563003|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
130317|NCT01563016|Dietary Supplement|glucose drink|participants will receive a drink rich in glucose
130318|NCT01563029|Drug|Fluticasone Furoate|current asthma medicine
130319|NCT01563029|Drug|Fluticasone Propionate|Fluticasone propionate
130320|NCT01563029|Drug|Placebo|placebo
130595|NCT01565889|Drug|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
130596|NCT01565889|Drug|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
130723|NCT01602705|Other|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
130724|NCT01602718|Other|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
130725|NCT01602731|Device|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
130726|NCT01602744|Other|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
130727|NCT01602757|Drug|Synera|Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat ("no heat patches") and were crossed over during Study Session 3.
130728|NCT01602770|Drug|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
130729|NCT01602783|Other|11C Acetate Imaging|Single scan
130730|NCT01604928|Drug|Placebo|Oral
130731|NCT01604941|Drug|SPD602|50 mg/kg/day orally twice daily for 24 weeks
130732|NCT01604954|Behavioral|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
130733|NCT01604954|Behavioral|Calorie-label|A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement ("The recommended daily caloric intake for an average adult is 2000 calories") will be posted on the containers.
130734|NCT01604954|Behavioral|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
130735|NCT01604980|Dietary Supplement|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
131023|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
131024|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
131025|NCT01603147|Biological|normal saline|saline 225 ml
131026|NCT01603147|Biological|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
130521|NCT01565863|Behavioral|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
130522|NCT01565876|Device|"Minkal"- Auxiliary device to alleviate backload|The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.
Then The participants will undergo heat tolerance test 5 times (in different days).
first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards.
130523|NCT01567995|Drug|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
130524|NCT01567995|Drug|Vehicle (base cream)|Vehicle (base cream)
130525|NCT01568008|Drug|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
130526|NCT01568021|Other|No Intervention|No intervention was administered in this study.
130527|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
130528|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
130529|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
130530|NCT01568034|Drug|Placebo|single-dose
130531|NCT01568034|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
130532|NCT00079365|Radiation|radiation therapy|
130533|NCT01568034|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
130534|NCT01568047|Drug|Placebo|once-daily
130535|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
130536|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
130537|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
130538|NCT01568047|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
130796|NCT01600807|Drug|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
130659|NCT01604928|Drug|YM178|Oral
130660|NCT01604928|Drug|tolterodine|Oral
130661|NCT00082862|Drug|cisplatin|
130662|NCT01607307|Drug|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
130663|NCT01607307|Drug|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
130664|NCT01607320|Drug|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
130665|NCT00083031|Drug|methotrexate|
130666|NCT01607320|Drug|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
130667|NCT01607333|Drug|Lamotrigine use|Lamotrigine prescription during the study period
130668|NCT01607346|Drug|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
130669|NCT01607372|Drug|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
130670|NCT01607372|Device|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
130671|NCT01607372|Other|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
130672|NCT01607385|Drug|GSK2330672|BID, repeat doses
130673|NCT01607385|Drug|Placebo|BID, repeat doses
130674|NCT01607385|Drug|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
130970|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
130971|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
130597|NCT01565889|Drug|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
130598|NCT01565889|Drug|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
130599|NCT00079261|Drug|gemcitabine hydrochloride|
130600|NCT01565889|Drug|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
130601|NCT01565889|Drug|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
130602|NCT01565889|Drug|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
130603|NCT01565889|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
130604|NCT01565902|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
130605|NCT01565915|Device|Perlane-L|Perlane-L Injection in the midface
130606|NCT01565915|Other|Non-treatment|Non-treatment Arm
130607|NCT01565928|Drug|MDV3100|4 x 40 mg capsules, orally, once per day
130608|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
130609|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
130610|NCT00079261|Drug|prednisone|
130611|NCT01565954|Drug|Hydroxycarbamide|Initial dose: 15mg/kg/d. Biological tests every 15 days for 2 months. Visit every two months. HC dose is increased every 2 months by 5mg/kg/d (maximal authorized dose: 30mg/kg/d)until hematological impregnation is reached and without haematological toxicity. Biological tests will be done every month after each dose escalation. Total treatment duration: 16 months.
The same therapeutical schema will be applied for both arms.
130612|NCT01565980|Behavioral|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
130613|NCT01565980|Behavioral|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
130614|NCT01565993|Device|Hemoclip|A rotatable clip-fixing device "Quickclip 2" standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm
130615|NCT01565993|Device|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
131027|NCT01603160|Behavioral|Quality Improvement|There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.
A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized.
131028|NCT01603173|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
131029|NCT01603173|Drug|Quetiapine Fumarate|25 mg tablet once a day
131030|NCT00082706|Drug|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
131031|NCT01603186|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
131032|NCT01603186|Drug|Quetiapine Fumarate|25 mg tablet once a day
131033|NCT01603199|Dietary Supplement|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
131034|NCT01603212|Drug|Vemurafenib|Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.
Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I.
131035|NCT01603212|Drug|IL-2|Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I.
131036|NCT01603212|Drug|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
131037|NCT01603225|Procedure|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
131038|NCT01603238|Drug|[14C]-LC15-0444|A single oral administration of [14C]-LC15-0444 50 mg, containing 4.9 MBq [14C]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
131039|NCT01603251|Drug|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
131040|NCT01603251|Drug|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
131041|NCT00082706|Drug|Gemcitabine|Day: 1 & 5 Dose: 200 mg/m2 (Two doses only)
130183|NCT01567319|Biological|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
130797|NCT01600820|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
130798|NCT01602796|Behavioral|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
130799|NCT01602822|Drug|3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
130800|NCT01602822|Drug|Ritonavir, Atazanavir, Truvada|
130801|NCT00001534|Drug|Losartan|
130802|NCT00082654|Procedure|psychosocial assessment and care|
130803|NCT01602848|Other|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
130804|NCT01602848|Other|usual care|usual care including services for which patients are eligible via fee for service medicaid
130805|NCT01602861|Drug|Spironolactone|One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.
In case of hyperkaliemia (>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo).
130806|NCT01602861|Drug|placebo|
130807|NCT01602874|Drug|Tigecycline|Subject with cIAI:
Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
130808|NCT01602874|Drug|Tigecycline|Subject with CAP:
IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
130809|NCT01602874|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|Subject with cIAI:
Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.
In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given.
131097|NCT01601418|Drug|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
130972|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
130973|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
130974|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
130975|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
130976|NCT00082888|Drug|Tipifarnib|Given PO
130977|NCT01605513|Drug|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
130978|NCT01607957|Drug|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
130979|NCT01607970|Drug|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
130980|NCT01607983|Drug|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
130981|NCT01607996|Procedure|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
130982|NCT01607996|Drug|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
130983|NCT01608009|Drug|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
130984|NCT00083083|Drug|etoposide|
130985|NCT01608022|Drug|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
130986|NCT01608035|Procedure|Sciatic catheter|presurgical sciatic catheter insertion
130987|NCT01608035|Procedure|Stump catheter|intraoperative placed stump catheter
130128|NCT01569919|Dietary Supplement|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
130129|NCT00001457|Drug|Lamivudine|
130130|NCT00079469|Drug|bupropion hydrochloride|
130856|NCT01600885|Drug|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
130857|NCT01600911|Other|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
130858|NCT01600937|Behavioral|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
130859|NCT01600950|Drug|LY2963016|Single 0.3 U/kg dose administered subcutaneously
130860|NCT01600950|Drug|Lantus|Single 0.3 U/kg dose administered subcutaneously
130861|NCT01600963|Drug|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
130862|NCT01600963|Drug|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
130863|NCT01600963|Drug|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
130864|NCT00082433|Drug|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
130865|NCT01600963|Drug|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
130866|NCT01600976|Drug|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
130867|NCT01600989|Other|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
130868|NCT01600989|Other|blood sampling|Blood samples will be taken twice at a 7 day interval
130869|NCT01602887|Drug|PD-0332991|freebase hard capsule with a "large" particle size, 125 mg, single dose
130870|NCT01602887|Drug|PD-0332991|oral solution, 50 mg, single dose
130871|NCT01602900|Drug|GSK356278|Investigational Medicinal Product
130872|NCT01602900|Drug|Rolipram|Challenge Agent
130184|NCT01567319|Biological|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
130185|NCT01567332|Device|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).
6-week interval between two sessions.
130186|NCT01567332|Device|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).
6-week interval between two sessions.
130187|NCT01567345|Device|Implantable pump with continuous flow|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
130188|NCT00079339|Drug|tipifarnib|Given orally
130189|NCT01567345|Device|Implantable pump with programmable flow.|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
130190|NCT01567358|Biological|Infliximab|100mg/vial
130191|NCT01567358|Biological|Infliximab|100mg/vial
130192|NCT01567371|Device|LiDCO rapid monitor|Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
130193|NCT01567384|Drug|OSI-906 and Pemetrexed|Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.
OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1.
130194|NCT01567410|Other|e-learning|Braden scale and pressure ulcer classification
130195|NCT01567410|Other|traditional classroom training|Braden scale and pressure ulcer classification
130196|NCT01567423|Drug|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
130197|NCT01567423|Drug|Coartem®, Novartis|artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:
tab/dose for children 5 to 14.9 kg (total 6 tabs)
tabs/dose for children 15 to 24.9 kg (total 12 tabs)
130462|NCT01570400|Behavioral|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
131098|NCT01601431|Device|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
131099|NCT01601431|Device|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
131100|NCT01601444|Device|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
131101|NCT01601457|Drug|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
131102|NCT01601457|Drug|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
131103|NCT01601470|Drug|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
131104|NCT01601470|Drug|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
131105|NCT00000263|Drug|30% Nitrous oxide|
131106|NCT00001529|Drug|G-CSF|
131107|NCT01603264|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
131108|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
131109|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
131110|NCT01603277|Biological|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
131111|NCT01603277|Other|Placebo|Normal Saline
131112|NCT01603303|Behavioral|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
131113|NCT01603303|Other|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
131114|NCT01603303|Other|Luvena|Use vaginally 2 or 3 times a week.
131115|NCT01603303|Other|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
130131|NCT01569919|Dietary Supplement|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
130132|NCT01569919|Drug|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
130133|NCT01569945|Drug|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
130134|NCT01569945|Drug|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
130135|NCT01569958|Other|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
130136|NCT01569958|Other|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
130137|NCT01569971|Other|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
130138|NCT01569984|Radiation|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
130139|NCT01569997|Other|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
130140|NCT01562535|Other|Supination|The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the "click" and the child is able to move the arm without pain.
130141|NCT01562548|Drug|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
130142|NCT01562548|Drug|Placebo|no active ingredient
130143|NCT01562561|Drug|repaglinide|2 mg at each main meal
130144|NCT01562561|Drug|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
130145|NCT00079079|Drug|carboplatin|
130146|NCT01562574|Drug|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
130873|NCT01602913|Drug|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
130874|NCT01602913|Drug|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
131170|NCT01601496|Device|FUSION™ Vascular Graft|All subjects receive FUSION™ Vascular Graft at baseline implant procedure
131171|NCT01601509|Drug|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
131172|NCT01601509|Drug|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
131173|NCT01601522|Procedure|Peanut protein|500 mg
131174|NCT01601522|Procedure|Oat flour|500 mg Oat flour
131175|NCT01601535|Drug|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
131176|NCT01601535|Drug|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
131177|NCT01601535|Drug|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
131178|NCT00082472|Drug|Doxorubicin HCl Inhalation Solution|
131179|NCT01601548|Behavioral|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
131180|NCT01601561|Drug|Regular human insulin injection|Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.
Humulin R 5 mU/kg/min and a variable infusion of glucose.
130463|NCT01570400|Behavioral|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks.
130464|NCT01570400|Behavioral|Cognitive bias modification training program variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks.
130465|NCT01570413|Procedure|No Pelvic Exam|Will not receive pelvic examination.
130466|NCT01570413|Procedure|Pelvic Examination|Pelvic examination will be performed.
130467|NCT01570452|Procedure|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
130468|NCT00079547|Behavioral|Low-calorie diet|low-calorie diet
130469|NCT01570465|Other|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
130470|NCT01570478|Drug|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
130471|NCT01570478|Drug|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
130472|NCT01570491|Other|ultrasound guided placement spinal block|Anesthesiologist will use ultrasound as a guide for placement of spinal block.
130473|NCT01570491|Other|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
130474|NCT01570504|Drug|Ivermectin|
130475|NCT01570517|Device|IASD System|Implantation of the DC Devices Inc. IASD System
130476|NCT01570530|Procedure|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
130477|NCT01570530|Procedure|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
130736|NCT01604993|Other|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
127332|NCT01557751|Genetic|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
127333|NCT01557764|Drug|lapatinib ditosylate|Given PO
127334|NCT01557764|Biological|trastuzumab|Given IV
127335|NCT01557777|Drug|Navitoclax|QD
127336|NCT01557790|Radiation|Proton Radiation Therapy|
127337|NCT01557816|Drug|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
127338|NCT00078754|Drug|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
127339|NCT01557816|Drug|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
127340|NCT01557829|Device|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
127341|NCT01557829|Device|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
127342|NCT01557842|Drug|Drug Treatment|Class I and III antiarrhythmic drug treatment.
127343|NCT01560221|Drug|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
127344|NCT01560234|Drug|AZD8848|Single dose, oral inhalation (nebuliser solution)
127617|NCT01553643|Drug|placebo|at a rate of 3g two times per day
127618|NCT01553656|Drug|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
127619|NCT01553656|Drug|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
127620|NCT01553669|Behavioral|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
127621|NCT00001430|Procedure|PBSC|
127622|NCT00078325|Drug|Placebo|Matching placebo tablets once daily in the morning
130926|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
130927|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
130928|NCT01601015|Other|placebo treatment|The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The control group received four sessions of placebo treatment, followed by ten minutes of resting position.
130929|NCT01601028|Drug|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
130930|NCT00082446|Biological|Live vaccinia virus vaccine|Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
130931|NCT01601028|Drug|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
130932|NCT01601041|Other|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
130933|NCT01601054|Device|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
130934|NCT01601067|Behavioral|Integrated Prolonged Exposure Therapy|Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
130935|NCT01601067|Behavioral|Seeking Safety|Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
130936|NCT01601093|Drug|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
131204|NCT01603485|Drug|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
131205|NCT01603498|Drug|Dexamethasone|Dexamethasone 8mg
131206|NCT01603498|Drug|Methylprednisolone|Methylprednisolone 40mg
126645|NCT01561300|Other|Nutrition intervention study with a black tea extract|Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.
Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.
Both products will be consumed for 8 days. On measurement days active or control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.
On day 2-7 subjects will consume 3 cups or tea extract or control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added.
126646|NCT01561313|Biological|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
126647|NCT01561326|Behavioral|Cognitive-affective barriers counseling|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
126648|NCT01561326|Behavioral|Cognitive-affective barriers counseling via brochure|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
126649|NCT01561326|Behavioral|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
126920|NCT01554852|Drug|lenalidomide, cyclophosphamide, dexamethasone|Days 1 and 8 cyclophosphamide 500 mg orally
Days 1-21 lenalidomide 25 mg daily orally
Days 1-4 and 15-18 dexamethasone 20 mg daily orally
The cycle is repeated every 28 days.
126921|NCT01557088|Other|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
126922|NCT01557088|Procedure|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
126923|NCT01557101|Procedure|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
126924|NCT01557101|Procedure|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
126925|NCT01557114|Drug|Ipilimumab|Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.
Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy
126926|NCT01557114|Radiation|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
126927|NCT01557127|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
127556|NCT01555918|Drug|Isavuconazole (IV)|intravenous (IV)
127557|NCT01555931|Drug|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
127558|NCT01555957|Drug|intravenous lipid|intravenous given daily for 6 weeks
127559|NCT01555970|Drug|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
127560|NCT01555970|Drug|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
127561|NCT01555983|Drug|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
127562|NCT01555996|Behavioral|Early and Intensive Occupational Therapy|Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.
General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit.
127563|NCT01555996|Behavioral|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
126698|NCT01559090|Drug|MEDI-546|Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
126699|NCT01559090|Drug|MEDI-546|Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
126700|NCT00078858|Other|laboratory biomarker analysis|Correlative studies
126701|NCT01559103|Biological|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
126702|NCT01559103|Biological|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
126703|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
126704|NCT01559116|Drug|tiotropium|low dose
126705|NCT01559116|Drug|olodaterol|one dose only
127623|NCT01553682|Behavioral|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
127624|NCT01553682|Behavioral|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
127625|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
127626|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
127627|NCT01553708|Drug|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
127628|NCT01556048|Behavioral|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, & Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
127629|NCT01556061|Device|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
127630|NCT01556061|Device|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
127631|NCT01556074|Behavioral|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
127632|NCT01556087|Behavioral|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
126770|NCT01556984|Other|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
126771|NCT01559142|Drug|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
126772|NCT01559142|Drug|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
126773|NCT01559168|Device|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
131207|NCT01605786|Other|Rehydragel™ HPA|Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.
Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group.
131208|NCT01605799|Behavioral|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
131209|NCT01605799|Behavioral|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
131210|NCT01605825|Drug|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
131211|NCT01605825|Drug|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
131212|NCT00082966|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
131213|NCT01605851|Device|Closure, Foramen Ovale|
131214|NCT01605864|Drug|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
131215|NCT01605877|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
131216|NCT01605890|Drug|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.
131217|NCT01605903|Drug|Ibuprofen|Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
131218|NCT01605903|Drug|Acetaminophen|During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
131219|NCT01605916|Drug|AZD6244|Tablet Oral bid
131220|NCT01605916|Drug|Docetaxel|IV once every 21 days
130340|NCT01565564|Behavioral|Shared glycaemic control care within the local three-tier's antenatal care network|Individualized dietary and physical activity consultation plus group diabetes education
Self blood glucose monitoring
Insulin therapy if indicated
Self blood glucose monitoring
Insulin therapy institutions if indicated;
130341|NCT01565577|Biological|MenbVac|Blood test
130342|NCT01565590|Drug|Dexmedetomidine|0.2-1.5 mcg/kg/hr
126928|NCT01557140|Drug|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
126929|NCT01557153|Drug|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
126930|NCT01557153|Drug|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
126931|NCT00078637|Drug|E7820|
126932|NCT01557166|Drug|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
126933|NCT01557166|Drug|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
126934|NCT01557179|Device|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
126935|NCT01557179|Device|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
127212|NCT01560052|Drug|Placebo|Matching placebo tablets; All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.
127213|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
127214|NCT01561859|Behavioral|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
127215|NCT01561859|Behavioral|Enriched Supportive Therapy|Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are "enriched" by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis.
126706|NCT01559116|Drug|tiotropium|high dose
126707|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
126708|NCT01559116|Drug|Placebo|placebo matching tiotropium+olodaterol FDC
126709|NCT01559116|Device|Respimat|Respimat inhaler
126710|NCT01559129|Drug|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
126711|NCT00078897|Drug|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
126712|NCT01559129|Drug|Placebo|Placebo
126713|NCT01561378|Drug|Aspart insulin|40 IU of aspart insulin will be administered intranasally using a mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
126714|NCT01561378|Drug|Placebo|200 microliters of normal saline will be administered per nostril using a mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
126715|NCT01561391|Drug|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
126716|NCT01561391|Drug|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
126717|NCT01561391|Other|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
126718|NCT01561391|Drug|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
126992|NCT01554930|Drug|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
126993|NCT01554943|Other|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
126994|NCT01554956|Biological|Human Plasminogen|Eye Drops
126995|NCT01554969|Drug|capecitabine + ganetespib|Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.
Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.
In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily.
126774|NCT01559194|Behavioral|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
126775|NCT01559194|Behavioral|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
126776|NCT01559220|Device|Deep Brain Stimulation|Implanted device
126777|NCT01559233|Device|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
126778|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
126779|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
126780|NCT00001438|Drug|all-trans-retinoic acid with IFN-alpha2a|
126781|NCT00078910|Drug|exisulind|
126782|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
126783|NCT01559259|Drug|Ibuprofen|Two caplets of ibuprofen 200 mg
126784|NCT01559259|Drug|Placebo|Two caplets of placebo
126785|NCT01559272|Drug|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
126786|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
126787|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
126788|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
126789|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
127068|NCT01562106|Procedure|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
127434|NCT01560429|Procedure|Continuous epidural analgesia|The CEA infusion rates were set when pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 were achieved in PACU. PCEA parameters were adjusted to allow an equivalent dose per hour. Use of hydromorphone 20 mcg/ml and bupivacaine 1 mg/ml (20 and 1) or hydromorphone 10 mcg/ml and bupivacaine 2 mg/ml (10 and 2) was permitted to achieve pain scores ≤ 3. Rescue boluses of 0.25% bupivacaine of 3 to 5 cc to a maximum of 10 cc were also permitted to achieve pain scores of less than 3 in PACU. Total consumption includes rescue medications as well as any switch in anesthetic concentration.
127435|NCT01560442|Drug|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
127436|NCT00078975|Drug|gemcitabine hydrochloride|
127437|NCT01560455|Device|single stent|single stent
127438|NCT01560455|Device|two stent|culotte
127439|NCT01560468|Drug|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
127440|NCT01560481|Drug|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
127441|NCT01560481|Drug|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
127442|NCT01560481|Drug|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
126579|NCT01589419|Drug|capecitabine|see arm description
126580|NCT01589419|Radiation|radiation|see arm description
126581|NCT01589432|Drug|ABT-639|two 50 mg oral capsules
126582|NCT01589432|Drug|Placebo|2 placebo capsules
126583|NCT01589432|Drug|Lidocaine|3mg/kg infusion over 30 minutes
126584|NCT00081055|Drug|cyclosporine|
126585|NCT01589445|Drug|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
126586|NCT01589445|Drug|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
126587|NCT01589458|Drug|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
126588|NCT01589471|Drug|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
127216|NCT01561885|Other|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
127217|NCT01561898|Drug|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
127218|NCT01561911|Drug|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
127219|NCT01561924|Drug|activated recombinant human factor VII|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
127220|NCT01561937|Drug|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
127221|NCT00079027|Procedure|hepatic artery embolization|
127222|NCT01561937|Drug|activated recombinant human factor VII|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
127497|NCT01558011|Drug|Capecitabine, Oxaliplatin, Docetaxel|Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.
Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy.
127498|NCT01558050|Dietary Supplement|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
127499|NCT01558063|Drug|Ketamine|Single dose of 0.1 mg/kg of ketamine given intravenously over 40 minutes
127500|NCT00078767|Drug|Trauma-focused Cognitive Behavioral Therapy plus Placebo|
127501|NCT01558063|Drug|Ketamine|Single dose of 0.2 mg/kg of ketamine given intravenously over 40 minutes
127502|NCT01558063|Drug|Ketamine|Single dose of 0.3 mg/kg of ketamine given intravenously over 40 minutes
127503|NCT01558063|Drug|Ketamine|Single dose of 0.4 mg/kg of ketamine given intravenously over 40 minutes
127504|NCT01558063|Drug|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously over 40 minutes
126996|NCT01554982|Drug|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
126997|NCT00078507|Behavioral|Sensory Retraining|Facial Exercises
126998|NCT01554995|Drug|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
126999|NCT01554995|Drug|Linezolid|Linezolid 600 mg (Cohort 9) none
127000|NCT01555008|Drug|LX4211|Subjects will receive LX4211 once daily for 7 days
127001|NCT01555008|Drug|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
127002|NCT01557218|Other|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
127003|NCT00078663|Behavioral|Oral Care|
127004|NCT01557218|Other|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
127005|NCT01557218|Other|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
127006|NCT01557218|Other|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
127007|NCT01557244|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
127008|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
127009|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
127010|NCT01557244|Drug|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
127011|NCT01557244|Drug|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
127272|NCT01560143|Drug|Tigecycline|100 mg IV as a single infusion over 30 minutes
127273|NCT01560182|Genetic|Autologous CD34+ stem cells transduced with ARSA encoding lentiviral vector|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA under the control of the human phosphoglyceratekinase (PGK) promoter. Dose: ≥ 2x10^6 transduced CD34+ cells/Kg (maximum 20x10^6) at bedside for infusion.
127274|NCT00078962|Drug|gemcitabine hydrochloride|Given IV
127275|NCT01560195|Drug|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
127069|NCT01555021|Genetic|Genotyping assays|Patients will be asked for a saliva sample. If the patient is in the Assay-Guided Treatment group (as opposed to the Treatment as Usual group), their saliva will be genotyped. Their psychiatrists will be given the results of the tests and then they will decide which antidepressants to use. The genotyping test is a one-time occurrence that happens at the beginning of the study. Patients who are in the Treatment as Usual group will have their saliva samples stored.
Patients will receive questionnaires to measure their mood, side effects, and symptoms.
Patients will be asked for a blood sample. Those in the AGT group will have the sample processed to see the amount of antidepressant present in their blood. Those in the TAU group will have their blood samples stored for future use.
Patients will be asked to participate in 3 follow-up phone calls to measure their mood.
127070|NCT01555034|Behavioral|movement therapy|exercise, nutrition, movement therapy
127071|NCT01555034|Other|exercise plus nutrition|exercise, nutrition
127072|NCT01555047|Procedure|IUI|intrauterine insemination
127073|NCT01555047|Procedure|IUI|intrauterine insemination
127074|NCT01555060|Dietary Supplement|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
127075|NCT00078507|Behavioral|Opening Exercises|
127076|NCT01555073|Drug|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
127077|NCT01555073|Drug|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
127078|NCT01555073|Drug|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
127079|NCT01555073|Drug|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
127080|NCT01555086|Procedure|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
127081|NCT01555086|Procedure|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
127082|NCT01555099|Drug|AZD5423|oral inhaled
127083|NCT01555099|Drug|Budesonide|oral inhaled
127084|NCT01555099|Drug|Placebo|oral inhaled
127085|NCT01555112|Drug|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
127086|NCT00078520|Biological|IL-2 AND HUMAN CD40 LIGAND PLASMID GENE MODIFIED AUTOLOGOUS TUMOR CELLS|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
126589|NCT01589484|Device|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
126590|NCT01589497|Drug|Rifampicin|Participants with body weight </= 50kg will be administered one 450 mg tablet orally once daily. Participants with body weight >50kg will be administered one 600 mg tablet orally once daily.
126591|NCT01589497|Drug|Isoniazid|Participants will be administered three 100 mg tablets or one 300 mg tablet once daily.
126592|NCT01589497|Drug|Pyrazinamide|Participants with a body weight of 40-55 kg will be administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg will be administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg will be administered four 500 mg tablets orally once daily.
126593|NCT01589497|Drug|Ethambutol|Participants with a body weight of 40-55 kg will be administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg will be administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg will be administered four 400 mg tablets orally once daily.
126594|NCT01581996|Drug|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
126595|NCT01582009|Drug|panobinostat|Given orally
126596|NCT01582009|Drug|everolimus|Given orally
126597|NCT01582009|Other|laboratory biomarker analysis|Correlative studies
126598|NCT01582009|Other|pharmacological study|Correlative studies
126599|NCT01582009|Other|liquid chromatography|Correlative studies
126859|NCT01559285|Drug|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
126860|NCT01559285|Drug|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
126861|NCT01559285|Drug|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
126862|NCT01559298|Drug|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
126863|NCT00078910|Procedure|neoadjuvant therapy|
126864|NCT01559298|Drug|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
127505|NCT01558063|Drug|Saline|Single infusion of saline given intravenously over 40 minutes
127506|NCT01558089|Drug|etanercept|according to SmPC and clinical practice
127507|NCT01558089|Drug|methotrexate|according to SmPC and clinical practice
127508|NCT01558115|Drug|Denosumab|The dose of denosumab is 60 mg every 6 months by subcutaneous injection.
The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.
Group # 1 (35 patients): Receive active drug for year 1 and year 2 of the study
Group #2 (17 patients): Receive placebo for year 1 and active drug for year 2 of the study
127509|NCT01558115|Other|Placebo|The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.
The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.
Group # 1 (35 patients): Receive active drug for year 1 and year 2 of the study
Group #2 (17 patients): Receive placebo for year 1 and active drug for year 2 of the study
127510|NCT01558128|Drug|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
127511|NCT00078793|Drug|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
127512|NCT01558128|Procedure|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
127513|NCT01558141|Other|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
127514|NCT01558141|Other|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
126650|NCT01561352|Drug|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
126651|NCT00079001|Drug|GnRH agonist|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
126652|NCT01561365|Behavioral|Ottawa ankle rules|Ottawa ankle rules implementation
126653|NCT01554228|Other|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
126654|NCT01554241|Dietary Supplement|D3 2000 IU/day|2000 IU/day D3
126655|NCT01554241|Dietary Supplement|D3 4000 IU/day|vitamin D3 4000 IU/day
126656|NCT01554241|Dietary Supplement|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
127276|NCT01560195|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
127277|NCT01560195|Drug|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
127278|NCT01560221|Behavioral|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
127279|NCT01560221|Drug|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
127280|NCT01562132|Drug|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
127281|NCT01562132|Drug|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
127282|NCT01562145|Procedure|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
127283|NCT01562158|Procedure|standard therapy|Standard treatment of bleeding
127284|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
127285|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
127286|NCT00079040|Biological|bevacizumab|Given IV
127287|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
127288|NCT01562158|Drug|placebo|Placebo
127289|NCT01562171|Other|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
127564|NCT00078559|Drug|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
127565|NCT01556009|Drug|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
127566|NCT01556009|Drug|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
127345|NCT01560234|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
127346|NCT01560247|Procedure|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
127347|NCT01560260|Other|Laboratory Biomarker Analysis|Correlative studies
127348|NCT00078962|Other|laboratory biomarker analysis|Correlative studies
127349|NCT01560260|Drug|Linsitinib|Given PO
127350|NCT01560260|Other|Pharmacological Study|Correlative studies
127351|NCT01560273|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
127352|NCT01560286|Biological|rAvPAL-PEG|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
127353|NCT01560299|Drug|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
127354|NCT01560299|Drug|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
127355|NCT01560299|Drug|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
127356|NCT01560312|Device|Renal denervation (Symplicity® Catheter System™)|4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
127357|NCT01560325|Drug|CKD-516 inj.|CKD-516: 3.3~13mg/m2/day
127358|NCT01560351|Device|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
127359|NCT00078962|Other|pharmacological study|Correlative studies
127360|NCT01560364|Other|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
127361|NCT01560377|Device|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
127362|NCT01560390|Drug|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
127363|NCT01560390|Drug|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
126865|NCT01559311|Device|CRT|CRT Implant
126866|NCT01559324|Device|ECT|Bifrontal ECT, low dosage
126867|NCT01559324|Device|ECT|Right unilateral electrode position, high dosage
126868|NCT01559337|Procedure|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
126869|NCT01559350|Procedure|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
126870|NCT01559350|Procedure|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
126871|NCT01559363|Drug|KD019|
126872|NCT01559389|Drug|solifenacin succinate|5 mg daily up to 10 mg daily
126873|NCT01559402|Procedure|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
126874|NCT01561638|Procedure|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
126875|NCT01561638|Procedure|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
126876|NCT01561638|Procedure|Sham|will receive puncture for 4 minutes
126877|NCT01561651|Other|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
126878|NCT01561664|Other|muscle and fat biopsy|muscle and fat biopsy
127158|NCT01555164|Drug|Metformin|Metformin tablet(s) administered orally once daily
127159|NCT01555164|Drug|Placebo to match metformin|Placebo to match metformin for the duration of the study
127160|NCT01555164|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
127161|NCT01555164|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
127162|NCT01555190|Drug|myo-inositol 1500 gr|
127163|NCT01555190|Drug|myo-inositol 2000 gr + folic acid 200 mcg|
126657|NCT01554241|Dietary Supplement|vitamin D3 800 IU/day|vitamin D3 800 IU/day
126658|NCT01554254|Drug|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
126659|NCT01554267|Device|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
126660|NCT01554280|Device|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
126661|NCT01554293|Drug|Matching placebo|Matching Placebo, single dose
126662|NCT01554293|Drug|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
126663|NCT00078403|Drug|Peginterferon alfa-2a|180 mcg PEG-IFN subcutaneously
126664|NCT01554319|Drug|SB010|Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).
Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.
Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL.
126665|NCT01554319|Drug|Placebo (phosphate-buffered saline)|Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).
Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.
126666|NCT01554332|Device|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
126936|NCT01557192|Device|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
126937|NCT01557218|Other|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
126938|NCT01557218|Other|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
126939|NCT01557218|Other|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
126940|NCT01557218|Other|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
127567|NCT01556022|Device|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
127568|NCT01556022|Device|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
127569|NCT01556035|Drug|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
127570|NCT01558154|Other|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
127571|NCT01558154|Device|Transcranial magnetic stimulation|Give magnetic stimulation at head
127572|NCT01558167|Drug|Bendamustine, Rituximab, Lenalidomide|Bendamustine: 50 mg/m2, i.v., day 1+2 Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1
Lenalidomide:
Doselevel 1: Cycle 1-6: 2,5mg p.o., d1-28
Doselevel 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28
Doselevel 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28
Doselevel 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28
Doselevel 5: maximal tolerated dose
127573|NCT01558180|Behavioral|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
127574|NCT01558180|Behavioral|Usual Care|educational handouts on pediatric insomnia
127575|NCT00078806|Drug|Enbrel|Enbrel
127576|NCT01558193|Dietary Supplement|Placebo|Placebo for DHA of identical appearance - based on olive oil
Placebo for vitamins/minerals of identical appearance
127577|NCT01558193|Dietary Supplement|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
127578|NCT01558193|Dietary Supplement|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
127579|NCT01558193|Dietary Supplement|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
127580|NCT01558206|Other|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
126719|NCT01561404|Drug|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
126720|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
127364|NCT01560403|Drug|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
127365|NCT01560416|Drug|Fulvestrant|injection on day 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle
127633|NCT00078559|Drug|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
127634|NCT01556087|Behavioral|Health Education|7 individual sessions with didactic health education information
127635|NCT01556100|Drug|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
127636|NCT01556113|Other|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
127637|NCT01556126|Device|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
127638|NCT01556139|Device|Spirotiger|The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.
The setting is the following:
volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.
increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.
At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step.
127639|NCT01556152|Drug|GRC 17536 (Medium Dose)|1 BD for 28 days
127640|NCT01556152|Drug|GRC 17536 (Low Dose)|1 BD for 28 Days
127641|NCT01556152|Drug|Placebo|Matching Placebo for 28 Days
127642|NCT01556165|Drug|rasagiline|1 mg/day, tablets, once daily, orally
127643|NCT01556165|Drug|placebo|tablets, once daily, orally
127644|NCT00001431|Drug|gemcitabine|
127645|NCT00078559|Drug|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
127646|NCT01556191|Drug|Gefitinib|250 mg per day (oral)
127647|NCT01556191|Drug|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
127648|NCT01556191|Drug|Erlotinib|150 mg per day (oral)
127649|NCT01558297|Behavioral|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
127164|NCT01555203|Behavioral|liveWell: A healthy foundation for life|liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.
In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI.
127165|NCT01555216|Drug|Ropivacaine|5 ml of 0.5% ropivacaine
127166|NCT01555216|Drug|Ropivacaine|3 ml/h of 0.2% ropivacaine with a bolus every two hours
127167|NCT01555229|Device|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
127168|NCT00000261|Drug|0.4% sevoflurane|
127169|NCT00001430|Drug|EPOCH II|
127170|NCT00078546|Biological|EBV specific CTL Infusion|One injection at one of the following dose levels
Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2
127171|NCT01555229|Device|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
127172|NCT01557426|Other|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
127173|NCT01557439|Drug|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
127174|NCT01557452|Drug|Givinostat|oral suspension, 0,75 mg/Kg b.i.d. in fed conditions
127175|NCT01557478|Drug|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
127443|NCT01560481|Drug|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
127444|NCT01560481|Drug|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
127445|NCT01560481|Drug|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
127446|NCT01560481|Drug|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
126941|NCT00078923|Dietary Supplement|soy isoflavones|
126942|NCT01559402|Procedure|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
126943|NCT01559402|Procedure|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
126944|NCT01559415|Other|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
126945|NCT01559415|Other|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
126946|NCT01559428|Dietary Supplement|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
126947|NCT01559428|Dietary Supplement|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
126948|NCT01559428|Dietary Supplement|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
126949|NCT01559441|Dietary Supplement|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
126950|NCT01559441|Dietary Supplement|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
126951|NCT01559454|Drug|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
126952|NCT00078923|Procedure|neoadjuvant therapy|Prostatectomy or Brachytherapy
126953|NCT01559454|Drug|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
127223|NCT01561937|Drug|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
127224|NCT01561950|Drug|activated recombinant human factor VII|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
127225|NCT01555242|Drug|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
126721|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
126722|NCT00079001|Dietary Supplement|Calcium supplement|Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
126723|NCT01561430|Drug|LY2886721|One capsule administered orally once daily
126724|NCT01561430|Drug|Placebo|One capsule administered orally once daily
126725|NCT01561456|Drug|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
126726|NCT01561456|Drug|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
126727|NCT01561469|Drug|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
126728|NCT01561469|Drug|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
126729|NCT01561482|Drug|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
126730|NCT01561482|Drug|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
126731|NCT01561495|Radiation|Proton Therapy|
126732|NCT01554384|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
126733|NCT01554397|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
126734|NCT01554397|Drug|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
126735|NCT00078403|Drug|Ribavirin|One tablet or capsule containing ribavirin 200 mg
126736|NCT01554410|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
127012|NCT01557244|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
127650|NCT01558297|Behavioral|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
127651|NCT01558297|Behavioral|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
127652|NCT01558310|Drug|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
126790|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
126791|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
126792|NCT00078910|Procedure|conventional surgery|
126793|NCT01561508|Drug|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
126794|NCT00079001|Dietary Supplement|Vitamin D|Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
126795|NCT01561508|Dietary Supplement|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
126796|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
126797|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
126798|NCT01561521|Drug|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
126799|NCT01561547|Behavioral|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
126800|NCT01561547|Dietary Supplement|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
126801|NCT01561560|Device|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
126802|NCT01561560|Device|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
126803|NCT01561573|Device|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
127447|NCT00078975|Drug|triapine|
127448|NCT01560494|Other|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
127449|NCT01560507|Drug|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
127450|NCT01560507|Drug|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
127451|NCT01560507|Drug|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
127452|NCT01560520|Behavioral|Physical activity|Observation only
127453|NCT00078286|Drug|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
127454|NCT01553292|Device|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
127455|NCT01553305|Other|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
127456|NCT01553305|Other|Exercise programme|Supervised exercise programme
127457|NCT01553318|Drug|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
127458|NCT01553318|Drug|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
127459|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
127460|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
126600|NCT01582009|Other|mass spectrometry|Correlative studies
126601|NCT01582009|Other|enzyme-linked immunosorbent assay|Correlative studies
126602|NCT01582009|Other|immunohistochemistry staining method|Correlative studies
127226|NCT01555268|Biological|trebananib|Given IV
127227|NCT01555268|Drug|cytarabine|Given SC
127228|NCT01555268|Other|laboratory biomarker analysis|Correlative studies
127229|NCT01555268|Other|pharmacological study|Correlative studies
127230|NCT01555281|Drug|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
127231|NCT01555281|Drug|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
127232|NCT01555281|Drug|Dexamethasone|40 mg (for patients <75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
127233|NCT01555307|Other|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
127234|NCT00078546|Biological|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
127235|NCT01555307|Other|Typical group|Seven typical exercises, 10 times each, 3 times a day
127236|NCT01555320|Drug|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
127237|NCT01555320|Drug|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
127238|NCT01555333|Drug|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
127239|NCT01555372|Device|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
127515|NCT01558154|Drug|Chinese herbs|Chinese herbs special for depression
127516|NCT01558154|Procedure|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
127517|NCT01560533|Behavioral|Interviews|Interviews will be done with patients
127518|NCT01560546|Drug|Testosterone|50 mg/dose/day for 24 weeks
127013|NCT01557244|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
127014|NCT00078689|Drug|Daclizumab|
127015|NCT01557257|Drug|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
127016|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
127017|NCT01557257|Drug|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
127018|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
127019|NCT01557257|Drug|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
127020|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
127021|NCT01557270|Drug|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
127022|NCT01557270|Drug|saline|ropivacaine + saline placebo, single shot perineural application
127023|NCT01557283|Other|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
127024|NCT01557296|Dietary Supplement|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
127025|NCT00078715|Drug|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
127026|NCT00078923|Other|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
127027|NCT01559558|Procedure|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
127028|NCT01559584|Radiation|ultraviolet A (UVA)|0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).
UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions.
127029|NCT01559584|Drug|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
127030|NCT01559597|Biological|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
126804|NCT01561586|Drug|Weekly cisplatin with RT|Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.
Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day
External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)
126805|NCT00001440|Drug|Interleukin-2|
126806|NCT00079014|Drug|triapine|Given IV
127087|NCT01555125|Drug|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
127088|NCT01555125|Drug|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
127089|NCT01555125|Drug|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
127090|NCT01555138|Drug|Indacaterol|Indacaterol is delivered via a SDDPI.
127091|NCT01557296|Radiation|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
127092|NCT01557296|Other|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
127093|NCT01557296|Biological|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
127094|NCT01557322|Biological|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
127095|NCT01557322|Drug|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
127096|NCT01557335|Drug|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
127097|NCT01557335|Drug|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
127098|NCT01557361|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
126603|NCT01582022|Drug|Bupivacaine|local application for 5 minutes
126604|NCT00080743|Drug|tamoxifen citrate|20 mg po once daily
126605|NCT01582022|Drug|normal saline|local application for 5 minutes
126606|NCT01582035|Drug|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
126607|NCT01582035|Drug|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
126608|NCT01582035|Drug|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
126609|NCT01582035|Drug|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
126610|NCT01582035|Drug|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
126611|NCT01582035|Drug|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
126612|NCT01582035|Drug|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
126613|NCT01582048|Drug|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
126614|NCT01582061|Drug|Pasireotide sub-cutaneous formulation|Pasireotide will be administered twice a day until pasireotide is approved and reimbursed for commercial use in each respective country or until 31DEC15, whichever comes first
126615|NCT00080743|Drug|Placebo|One pill po once daily
126616|NCT01582100|Device|Reletex|Neuromodulation device worn on the wrist
126617|NCT01582113|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
126618|NCT01558817|Behavioral|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
126619|NCT01558830|Drug|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
126879|NCT00079014|Drug|doxorubicin hydrochloride|Given IV
127519|NCT01560546|Drug|Placebo|placebo on the skin for 24 weeks
127520|NCT01560559|Procedure|Peroral endoscopic myotomy|An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.
This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips.
127521|NCT01560572|Drug|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
127522|NCT00078988|Biological|filgrastim|Given IV
127523|NCT01560585|Drug|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
127524|NCT01560611|Device|Near infrared spectroscopy|
127525|NCT01560624|Drug|UT-15C (treprostinil diethanolamine)|UT-15C sustained release oral tablets for three times daily administration
127526|NCT01560624|Drug|Placebo|Placebo (sugar pill) for three times daily oral administration
127527|NCT01560637|Drug|UT-15C (treprostinil diethanolamine)|UT-15C sustained release oral tablet for three times daily administration
127528|NCT01560650|Device|CRRT|Difference dose of CRRT
127529|NCT01560663|Drug|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
127530|NCT01560676|Behavioral|HEALTH[e]TEEN|8 lessons over 6-8 weeks
127531|NCT01560676|Behavioral|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
127532|NCT01560689|Drug|Budesonide/formoterol|800 µg/j twice a day, every day
127533|NCT00078988|Drug|carboplatin|Given IV
127534|NCT01560689|Drug|Placebo|Twice a day, every day
126667|NCT01554345|Drug|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
127031|NCT01559610|Other|Intervention Group|The patients were instructed by a nurse
127290|NCT01562171|Other|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
127291|NCT01562184|Device|Sham tDCS device|Sham tDCS
127292|NCT01562184|Device|Soterix tDCS device|Active tDCS
127293|NCT01562197|Drug|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
127294|NCT01562197|Drug|Axitinib plus Lomustine|Lomustine 90mg/m²
127295|NCT01562210|Drug|Olaparib|Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.
The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID.
127296|NCT01562210|Drug|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
127297|NCT00079040|Other|laboratory biomarker analysis|Correlative studies
127298|NCT01562210|Radiation|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
127299|NCT01562223|Other|motexafin gadolinium|
127300|NCT01562249|Other|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
127301|NCT01555424|Dietary Supplement|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
127302|NCT00078559|Drug|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
127303|NCT01555450|Other|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
127304|NCT01555463|Drug|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
127305|NCT01555463|Drug|Vehicle foam|twice daily topical application
127306|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
127099|NCT01557361|Other|Standard RRT initiation|Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:
I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND
II. At least one of the following indications for RRT initiation:
Serum potassium ≥6.0 mmol/L, or
Serum bicarbonate ≤ 10 mmol/L, or
Evidence of severe respiratory failure, based on a PaO2/FiO2 <200 and bilateral infiltrates on the chest x-ray, or
By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization
127100|NCT01557374|Drug|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
127101|NCT00078715|Drug|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
127366|NCT01560416|Drug|Ganetespib|Intravenous, on days 1, 8 and 15 eof each cycle
127367|NCT01562379|Dietary Supplement|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
127368|NCT01562379|Dietary Supplement|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
127369|NCT01562392|Dietary Supplement|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
127370|NCT01562392|Dietary Supplement|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
127371|NCT01562405|Drug|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
127372|NCT01562405|Drug|Lenalidomide|15 to 25 mg days 1-21, given orally
127373|NCT00079066|Biological|cetuximab|
127374|NCT01562405|Drug|Dexamethasone|40 mg days 1,8,15,22; given orally
127375|NCT01562418|Behavioral|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
127376|NCT01562418|Behavioral|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
127377|NCT01562418|Behavioral|control group|general instructions no intervention
127378|NCT01562431|Other|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
127379|NCT01562444|Other|Blood Sampling|Annual blood draws
127380|NCT01562457|Drug|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
126880|NCT01561677|Device|Continuous Positive Airway pressure-RESPIRONICS|obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
126881|NCT01561677|Device|Sham Continuous Positive Airway pressure-RESPIRONICS|inefficient Continuous Positivie Airway pressure
126882|NCT01561690|Drug|ARRY-502, CRTh2 antagonist; oral|multiple dose, single schedule
126883|NCT01561690|Drug|Placebo; oral|matching placebo
126884|NCT01561703|Other|No postoperative antibiotic|Patients will not be given a prescription for postoperative antibiotics
126885|NCT01561703|Drug|Amoxicillin|Generic antibiotic at standard dosage that may be used for 7-10 days following surgery .
126886|NCT01561703|Drug|Amoxicillin/clavulanate potassium|Generic antibiotic given at standard dosage that may be used for 7-10 day after surgery
126887|NCT01561703|Drug|Azithromycin|Generic antibiotic given at standard dosage that may be used for 7-10 day after surgery
126888|NCT01561703|Drug|Cefaclor|Generic antibiotic given at standard dosage that may be used for 7-10 day after surgery
126889|NCT01561703|Drug|Cephalexin|Generic antibiotic given at standard dosage that may be used for 7-10 day after surgery
126890|NCT00079014|Other|laboratory biomarker analysis|Correlative studies
126891|NCT01561703|Drug|Cefdinir|Generic antibiotic given at standard dosage that may be used for 7-10 day after surgery
126892|NCT01561703|Drug|Clindamycin|Generic antibiotic given at standard dosage that may be used for 7-10 day after surgery
126893|NCT01561716|Device|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
126894|NCT01561729|Device|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
126895|NCT01561729|Radiation|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
126896|NCT01561742|Drug|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
126897|NCT01554683|Drug|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
126668|NCT01554358|Behavioral|Lifestyle intervention|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) saturated fat intake <10% of energy consumed, 4) carbohydrate intake 55-65% of energy consumed, 5) fiber intake 20-30g per day, and 6) moderate or vigorous exercise for at least 30 min daily, seven days each week.
126669|NCT01554371|Drug|Eribulin in Combination w/ Cyclophosphamide|Phase Ib Eribulin mesylate (mg/m2)
Level -1: 0.7 day 1, 8
Level 0 (start): 1.1 day 1, 8
Level 1: 1.4 day 1, 8
Cyclophosphamide (mg/ m2) Level -1: 600 day 1
Level 0: 600 day 1
Level 1: 600 day 1
Phase II The dose-expansion will enroll 40 patients with advanced breast cancer
126670|NCT01554384|Procedure|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
126671|NCT01556724|Drug|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
126672|NCT01556737|Dietary Supplement|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
126673|NCT01556737|Dietary Supplement|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
126674|NCT01556763|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
126675|NCT01556763|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
126676|NCT01556763|Drug|Placebo|Matching placebo was administered as one capsule per day for 21 days.
126677|NCT01556763|Drug|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole [10 to 30 mg/day], olanzapine [10 to 20 mg/day], paliperidone [3 to 12 mg/day], or risperidone [2 to 16 mg/day]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
126678|NCT01556776|Drug|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
126679|NCT00078585|Biological|PROSTVAC®-VF/TRICOM™|
126954|NCT01559467|Other|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
127307|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
127308|NCT01555489|Drug|Ascorbic Acid|3x per week
127581|NCT01558206|Other|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
127582|NCT01558219|Drug|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
127583|NCT01558232|Device|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
127584|NCT01558245|Drug|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
127585|NCT01558258|Behavioral|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
127586|NCT00078806|Drug|Placebo|placebo
127587|NCT01558271|Drug|LY2189265|
127588|NCT01558271|Drug|Placebo|
127589|NCT01558271|Drug|Liraglutide|
127590|NCT01558284|Drug|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
127591|NCT01558284|Drug|Placebo|Placebo
127592|NCT01560728|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
127593|NCT01560741|Device|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
127594|NCT01560741|Device|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
127595|NCT01560754|Drug|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
127596|NCT01560767|Drug|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
127381|NCT01562470|Other|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
127382|NCT01562483|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
127383|NCT01562483|Drug|Placebo|Identical to the Namisol arm.
127384|NCT00079066|Procedure|quality-of-life assessment|
127385|NCT01562496|Behavioral|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
127386|NCT01562509|Other|Implementation tools|Professionals receive audit & feedback
Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.
Standardization of diagnostic and evaluative request forms and reports for clinicians.
Supporting material for standardizing the procedure for multidisciplinary meetings.
127653|NCT01558310|Drug|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
127654|NCT00078819|Drug|Enbrel®|0.8 mg/kg (up to an intended dose of 50 mg) once weekly
127655|NCT01558323|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
127656|NCT01558336|Drug|praziquantel|praziquantel 40 mg/kg oral tablets
127657|NCT01558362|Drug|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections.
127658|NCT01558375|Drug|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
127659|NCT01558375|Drug|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
127660|NCT01558388|Drug|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
127661|NCT01558388|Drug|Placebo|One vaginal tablet daily for 10 days.
127662|NCT01558401|Other|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
126898|NCT01554696|Drug|ASP015K|oral
127176|NCT01557478|Drug|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
127177|NCT00078728|Behavioral|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
127178|NCT01557491|Procedure|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
127179|NCT01557491|Procedure|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
127180|NCT01557504|Drug|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metrformin XR 2000 mg).
127181|NCT01557504|Drug|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
127182|NCT01557504|Drug|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
127183|NCT01557504|Drug|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
127184|NCT01557517|Drug|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
127185|NCT01557517|Drug|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
127186|NCT01557543|Other|Cell Therapy|Intramyocardial Injection of BMSCs
127187|NCT01557569|Drug|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
127188|NCT00078728|Behavioral|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
127189|NCT01557569|Drug|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
127190|NCT01557582|Device|Ventripoint Medical System|The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.
Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images.
126955|NCT01559467|Other|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
126956|NCT01559480|Drug|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
126957|NCT01559480|Drug|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
126958|NCT01559506|Device|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
126959|NCT01559519|Drug|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
126960|NCT01559545|Drug|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
126961|NCT01559545|Drug|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
126962|NCT01559545|Drug|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
126963|NCT01561742|Drug|Placebo|EquivalentPlacebo will be given
126964|NCT01561755|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
126965|NCT01561755|Drug|Placebo|Placebo - 2gr/kg over 2 days of saline
126966|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
126967|NCT00079014|Other|pharmacological study|Correlative studies
126968|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
126969|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
126970|NCT01561768|Biological|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
126971|NCT01561768|Biological|cTIV|Preconfigured dose; intramuscular injection, deltoid
126972|NCT01561781|Drug|Digoxin|Oral tablets 0.25mg, single dose
126973|NCT01561781|Drug|Vandetanib|Oral tablets, 300 mg, single dose
127597|NCT01560767|Drug|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
127598|NCT00078988|Drug|etoposide|Given IV
127599|NCT01560780|Drug|Prasugrel|one 10 mg tablet by mouth daily
126737|NCT01554410|Drug|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
126738|NCT01554410|Drug|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
126739|NCT01554423|Other|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
126740|NCT01554423|Behavioral|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
126741|NCT01554423|Behavioral|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
126742|NCT01554436|Behavioral|neuropsychological assessment|The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.
The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test
126743|NCT01554449|Procedure|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
126744|NCT01554449|Procedure|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
126745|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
126746|NCT00001430|Drug|IL-2|
126747|NCT00078442|Drug|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
127663|NCT01558414|Procedure|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
127664|NCT01558414|Procedure|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
127665|NCT00078819|Drug|Placebo|0.8 mg/kg (up to an intended dose of 50 mg) once weekly
127666|NCT01558414|Procedure|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
127667|NCT01558427|Procedure|Surveillance|Active clinical surveillance
127668|NCT01558427|Procedure|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
127669|NCT01558440|Dietary Supplement|Infant Formula|A diet that is being fed to the young infants.
130616|NCT01566006|Drug|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
130617|NCT01568112|Drug|ASA placebo|Placebo matching aspirin
130618|NCT00079378|Drug|valproic acid|Given orally
130619|NCT01568125|Drug|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
130620|NCT01568138|Device|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
130621|NCT01568151|Behavioral|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
130622|NCT01568151|Behavioral|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
130623|NCT01568164|Device|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
130624|NCT01568177|Behavioral|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
127191|NCT01559935|Drug|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
127192|NCT01559935|Drug|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
127461|NCT01553357|Drug|Lenalidomide, dexamethasone|Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.
Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study.
127462|NCT01553370|Other|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
127463|NCT01553370|Other|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
127464|NCT00078286|Drug|Placebo|Dosage ranging from 50 mg to 200 mg once a day
127465|NCT01553383|Device|nasal peep valve "Provent"|application of nasal peep valve vs dental device and cpap
127466|NCT01553422|Other|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
127467|NCT01553422|Other|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
127468|NCT01553435|Drug|Dextromethorphan|The study medicines shall be administered via tube.
127469|NCT01553435|Drug|Placebo|The study medicines shall be administered via tube.
127470|NCT01553448|Genetic|gene expression analysis|
127471|NCT01553448|Genetic|protein expression analysis|
127472|NCT01553448|Other|enzyme-linked immunosorbent assay|
127473|NCT01553448|Other|immunohistochemistry staining method|
127474|NCT01553448|Other|laboratory biomarker analysis|
127475|NCT00078312|Drug|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
127476|NCT01553448|Other|medical chart review|
127477|NCT01555736|Drug|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
127478|NCT01555749|Drug|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
126974|NCT01561794|Drug|Ciprofloxacin (Cipro, BAYQ3939)|(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.
2) Hospital-acquired pneumonia (HAP): For the patient with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.
127240|NCT01555372|Device|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
127241|NCT01555385|Dietary Supplement|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
127242|NCT01555398|Dietary Supplement|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
127243|NCT01555424|Dietary Supplement|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
127244|NCT01557595|Device|Polarized glasses designed to filter out blue light|Participants will be given polarized glasses (yellow "sun"- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written "Instruction Sheet." Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so.
127245|NCT01557608|Procedure|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
127246|NCT01557608|Procedure|Placebo treatment|For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the "ON" position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment.
127247|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
127248|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
126748|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
126749|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
126750|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
126751|NCT01554488|Drug|Inhaled Fluticasone Propionate|Inhaled corticosteroid
126752|NCT01556841|Biological|TroVax®|Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.
127032|NCT01559623|Procedure|retrospective data analysis|retrospective data analysis
127033|NCT01559636|Biological|bivalent oral polio vaccine|vaccine given during immunization campaigns
127034|NCT01559649|Behavioral|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Nurse practitioners with advanced practice skills in stroke and trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
127035|NCT01559662|Dietary Supplement|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
127036|NCT01559675|Drug|Hydrocortisone|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
127037|NCT00078949|Biological|rituximab|Given IV
127038|NCT01559675|Drug|Hydrocortisone|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
127039|NCT01559688|Behavioral|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
127040|NCT01559688|Behavioral|Waitlist|Fitness assessment or career counseling
127041|NCT01559701|Drug|PF-00345439|5-80 mg twice-a-day for 12 months
127042|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
130625|NCT01568177|Other|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
130626|NCT01568177|Other|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
130627|NCT01568177|Other|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
130628|NCT01568177|Procedure|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
130629|NCT00079378|Other|pharmacological study|Correlative studies
130630|NCT01568190|Biological|AVANZ MITE|Immunotherapy Dermatophagoides mix
130631|NCT01568203|Drug|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
130632|NCT01568203|Drug|Placebo|Matching placebo control for AMG 579 at each dose level
130875|NCT01602913|Drug|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
130876|NCT01602926|Procedure|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
130877|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
130878|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
130879|NCT00082667|Procedure|Surgery|
127479|NCT01555749|Drug|placebo|One injection administered subcutaneously (s.c., under the skin)
127480|NCT01555775|Dietary Supplement|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
127481|NCT01555775|Dietary Supplement|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
126620|NCT00078858|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
126621|NCT01558830|Drug|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
126622|NCT01558856|Procedure|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
126623|NCT01558856|Procedure|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
126624|NCT01558869|Drug|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
126625|NCT01558869|Drug|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
126626|NCT01558869|Drug|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
126627|NCT01558882|Device|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
126628|NCT01558895|Radiation|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
126629|NCT01558895|Other|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
126630|NCT01558908|Biological|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
126631|NCT00078858|Drug|cyclosporine|Given PO
126632|NCT01558921|Other|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
126633|NCT01558921|Other|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
127249|NCT01557621|Behavioral|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
127250|NCT01557634|Procedure|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
127535|NCT01560702|Drug|Epinephrine|10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
127536|NCT01560702|Biological|Blood|5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
127537|NCT01560715|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
127538|NCT01553461|Procedure|Cord Blood Transplant|
127539|NCT01553487|Other|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
127540|NCT01553500|Dietary Supplement|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
127541|NCT01553500|Behavioral|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
127542|NCT01553513|Other|[18F]-FDG positron emission computed tomography|Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.
This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.
Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest.
127543|NCT01553513|Procedure|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
127043|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
127044|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
127045|NCT01559740|Drug|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
127046|NCT01561950|Drug|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
127047|NCT01561950|Drug|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
127309|NCT01555515|Procedure|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
127310|NCT01555515|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
127311|NCT01555528|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
127312|NCT01555541|Drug|Ofatumumab|1000 mg IV days 0, 7, 14, 21
127313|NCT00078559|Drug|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
127314|NCT01555541|Drug|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
127315|NCT01555541|Drug|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
127316|NCT01555554|Drug|Propranolol Hydrochloride|Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.
On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).
On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).
On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).
On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).
This will complete the course of propranolol.
127317|NCT01555554|Other|Placebo|The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.
On post operative days #1-13, patients will take one placebo pill (once daily by mouth).
This will complete the course of the placebo.
127318|NCT01555567|Device|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
127319|NCT01555567|Other|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
130880|NCT01602939|Drug|Cladribine and pegylated interpheron alpha-2a|Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.
Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months.
130881|NCT01602952|Drug|Radotinib|50mg, 100mg or 200mg Capsule BID
130882|NCT01602965|Procedure|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
130883|NCT01602965|Procedure|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
130884|NCT00082875|Other|pharmacological study|Correlative studies
130885|NCT01605292|Procedure|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
130886|NCT01605292|Procedure|Palpation|Manual palpation for localizing radial artery for inserting needle.
130887|NCT01605305|Drug|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
131183|NCT01603342|Drug|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
131184|NCT01603342|Drug|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
131185|NCT01603355|Drug|Tocilizumab|Intravenous tocilizumab:
Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks
131186|NCT00082732|Behavioral|behavioral dietary intervention|
131187|NCT01603368|Dietary Supplement|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
131188|NCT01603368|Dietary Supplement|Placebo|Oil drops without Lactobacillus reuteri
131189|NCT01603381|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
131190|NCT01603394|Drug|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
131191|NCT01603407|Drug|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
131192|NCT01603407|Drug|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
126634|NCT01558934|Drug|Lofexidine HCl|Lofexidinne HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
126635|NCT01558947|Drug|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4~6 weeks after surgery.
126636|NCT01558947|Drug|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4~6 weeks after surgery.
126637|NCT01558960|Drug|IVit Melphalan|IVit injections of Melphalan
126899|NCT01554696|Drug|Placebo|oral
126900|NCT01554709|Device|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
126901|NCT01554722|Procedure|Needle placement|In plane versus out of plane needle placement techniques
126902|NCT01554735|Behavioral|Exercise and diet|24 weeks of exercise and diet counselling
126903|NCT01554748|Other|implant fixation with different techniques and designs|implant fixation cemented/uncemented
126904|NCT00078481|Drug|Idebenone|
126905|NCT01554761|Procedure|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
126906|NCT01554761|Device|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
126907|NCT01554787|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
126908|NCT01554787|Other|Placebo|at a rate of 2.8g three times per day
126909|NCT01554800|Drug|ACP-501|A single dose infusion
126910|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
126911|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
126912|NCT01554813|Biological|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
126913|NCT01554826|Biological|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
127544|NCT01553513|Procedure|Intravascular ultrasound and virtual histology|During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.
A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.
Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque.
127545|NCT01553513|Other|Serum biomarkers|A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.
ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers.
127546|NCT01553539|Drug|therapeutic angiotensin-(1-7)|Given SC
126680|NCT01556776|Drug|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
126681|NCT01556789|Biological|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
126682|NCT01556802|Drug|Minocicline|Minocicline 100mg oral twice a day for 5 days
126683|NCT01556802|Drug|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
126684|NCT01556815|Procedure|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
126685|NCT01556815|Other|Sorafenib in combination with TACE|Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.
Procedure: TACE
TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
126686|NCT01558986|Procedure|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
126687|NCT01558999|Drug|High concentration SI-614|1 drop in each eye 4 times a day
126688|NCT01558999|Drug|Low concentration SI-614|1 drop in each eye 4 times a day
126689|NCT00078858|Drug|mycophenolate mofetil|Given PO or IV
127320|NCT01555580|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
127321|NCT01557699|Biological|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
127322|NCT01557699|Biological|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
127323|NCT01557699|Biological|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
127324|NCT01557712|Drug|ketamine venlafaxine|After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:
Intravenous injection on day 0 to 0.5 mg / kg of ketamine
D0 to D5: 75 mg of venlafaxine
D5 to D28: 150 mg per day of venlafaxine
D28 to D42: 150 mg daily of venlafaxine or 225 mg per day of venlafaxine if patient not responder to D28
127600|NCT01560780|Drug|Placebo|placebo similar in appearance to prasugrel
127601|NCT01560793|Biological|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
127602|NCT01560806|Other|Commune Hypertension Management|People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.
Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI
127603|NCT01560819|Drug|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
127604|NCT01560845|Procedure|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
127605|NCT01560845|Procedure|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
127606|NCT01560871|Behavioral|High-intensity IMT plus walking|The IMT intensity will be set at 60% of PImax which will be adjusted weekly and nose clip will be used. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.
For the walking program, each participant will be given a pedometer and a heart rate monitor so he/she can track daily step counts and heart rate during the study. The walking program will consist of walking every day at an intensity of "hard" to "somewhat hard" on the Rating of Perceived Exertion (RPE) scale. Participants will begin walking at least 15 minutes twice a day for 7 days a week and eventually progress to 45-50 minutes a day by the end of the six weeks.
127607|NCT01553591|Drug|JNJ-27018966|Oral tablets twice daily
131193|NCT01603407|Drug|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
131194|NCT01603420|Drug|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
131195|NCT01603420|Drug|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
131196|NCT01603420|Other|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
131197|NCT00082732|Dietary Supplement|dietary intervention|
131198|NCT01603446|Drug|L-Arginine|NOW® L-Arginine powder
131199|NCT01603459|Drug|IncobotulinumtoxinA|Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.
For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection.
131200|NCT01603485|Drug|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
131201|NCT01603485|Drug|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
131202|NCT01603485|Drug|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
131203|NCT01603485|Drug|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
130321|NCT01563042|Drug|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
130322|NCT01565421|Drug|IT-101|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression. (12mg/m2/dose)
130323|NCT01565421|Drug|IT-101|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression. (15mg/m2/dose)
130324|NCT01565421|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
130325|NCT01565434|Other|CR1 impact|
130326|NCT01565460|Other|sample collection|bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
130327|NCT00079235|Other|laboratory biomarker analysis|Correlative studies
130328|NCT01565486|Device|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
126914|NCT01554826|Biological|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
126915|NCT00078494|Drug|EBV-LMP-2|
126916|NCT01554839|Behavioral|"Family of Heroes"|One hour online educational tool
126917|NCT01554839|Behavioral|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
126918|NCT01554852|Drug|lenalidomide, cyclophosphamide, dexamethasone|Days 1 and 8 cyclophosphamide 500 mg orally
Days 1-21 lenalidomide 25 mg daily orally
Days 1-4 and 12-15 dexamethasone 40 mg daily orally
The cycle is repeated every 28 days.
126919|NCT01554852|Drug|thalidomide, cyclophosphamide, dexamethasone|Continuously thalidomide 50 mg hard capsules - initially 100 mg daily orally for 3 weeks, increasing to 200 mg daily orally
Days 1,8,15 (weekly) cyclophosphamide 500 mg orally
Days 1-4 and 12-15 dexamethasone 40 mg daily orally
The cycle is repeated every 21 days
127193|NCT01559935|Drug|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
127194|NCT01559948|Behavioral|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
127195|NCT00078949|Drug|dexamethasone|Given IV
127196|NCT01559948|Device|Sacroiliac joint belt|Those participants randomly assigned to the lumbopelvic stabilization plus belt group will also receive a pelvic compression belt. They will be taught how to don/doff the belt and instructed to wear the belt during all waking hours for the first 4 weeks of the study. The belt should be worn low around the pelvis just above the greater trochanter. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
127197|NCT01559961|Drug|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
127198|NCT01559974|Drug|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
127199|NCT01559974|Drug|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
127200|NCT01559987|Device|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
127201|NCT01559987|Device|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
127202|NCT01559987|Device|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
127203|NCT01560000|Dietary Supplement|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
126690|NCT01558999|Drug|Vehicle|1 drop in each eye 4 times a day
126691|NCT01559012|Drug|Clonidine|transdermal clonidine patch 5 mg q. 5 days
126692|NCT01559025|Drug|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
126693|NCT01559051|Procedure|Adipose-Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 120 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
126694|NCT01559064|Device|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
126695|NCT01559077|Drug|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
126696|NCT01559077|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
126697|NCT01559090|Drug|MEDI-546|Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
126975|NCT01561807|Drug|VX-787|low dose capsule, taken orally for 5 days
126976|NCT01561807|Drug|VX-787|high dose capsule, taken orally for 5 days
126977|NCT01561820|Behavioral|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5[HRmax-HRrest]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
126978|NCT00079027|Drug|doxorubicin hydrochloride|
126979|NCT01561833|Drug|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
126980|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
126981|NCT01554852|Drug|thalidomide, cyclophosphamide, dexamethasone|Continuously thalidomide 50 mg hard capsules; initially 50 mg daily orally for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily orally
Days 1, 8, 15, 22 (weekly) cyclophosphamide 500 mg orally
Days 1-4 and 15-18 dexamethasone 20 mg daily orally
The cycle is repeated every 28 days.
127608|NCT01553591|Drug|Placebo|Oral tablets twice daily
127609|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the first postoperative day
127610|NCT00078325|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
127611|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
127612|NCT01553617|Drug|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
127613|NCT01553617|Drug|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
127614|NCT01553630|Procedure|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
127615|NCT01553630|Procedure|Surgery without bone graft|Plating of fracture without bone graft
127616|NCT01553643|Drug|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
126753|NCT01556841|Biological|Placebo|Matched placebo will be administered as above.
126754|NCT01556867|Other|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
126755|NCT01556867|Other|Cord care with the use of antiseptics|For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.
In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care.
126756|NCT00078598|Drug|Rituximab or Iodine I 131 Tositumomab Therapy|
126757|NCT01556880|Behavioral|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
126758|NCT01556893|Device|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
126759|NCT01556906|Drug|Lomitapide|Oral administration with escalating doses administered once daily
126760|NCT01556919|Procedure|Standard of care endoscopy|standard of care endoscopy
126761|NCT01556932|Drug|ABH gel|Given topically
126762|NCT01556932|Other|placebo|Given topically
130329|NCT01565486|Device|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
130330|NCT01565499|Drug|Nab-paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
130331|NCT01565512|Drug|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
130332|NCT01565512|Drug|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
130333|NCT01565525|Behavioral|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
130334|NCT01565525|Behavioral|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
130335|NCT01565538|Drug|Erlotinib|150 mg Given orally
130336|NCT01565538|Drug|Pemetrexed|500mg/m2 Given IV
130337|NCT01565551|Other|N/A (Observational Study)|No Interventions: Observational Study
130338|NCT00001446|Drug|thalidomide|
130339|NCT00079248|Biological|therapeutic progesterone|
130888|NCT01605318|Drug|IMMU-130|This is a Phase I/II, open-label study of IMMU-130 administered in 21-day treatment cycles, once or twice weekly for 2 consecutive weeks followed by one week of rest to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
130889|NCT01605331|Drug|sustained-release recombinant human GH (SR-rhGH)|
130890|NCT01605344|Drug|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
130891|NCT01605344|Drug|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
127204|NCT01560013|Drug|Naltrexone|Naltrexone, oral 50 mg per day.
127205|NCT01560026|Procedure|surgery|endometrial cancer with or without oophorectomy
127206|NCT00001439|Biological|gp100 human melanoma peptide|
127207|NCT00078949|Drug|gemcitabine hydrochloride|Given IV
127208|NCT01560039|Device|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
127209|NCT01560039|Other|Neurofeedback|EEG neurofeedback based on the primary motor cortex
127210|NCT01560039|Other|Sham neurofeedback|Sham EEG neurofeedback
127211|NCT01560052|Drug|methylprednisolone|oral methylprednisolone or placebo 0.6-0.8mg/kg/day with a maximum 48mg/day x 2 months, tapered by 8mg/day every month to stop within 6-8 months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.
127482|NCT01555788|Device|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
127483|NCT00078559|Drug|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
127484|NCT01555801|Device|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
127485|NCT01555801|Device|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
127486|NCT01555814|Drug|Amisulpride|4-week open label amisulpride treatment
127487|NCT01555827|Other|Ophthalmological examination & Questionnaire|The following examinations will be performed, after pupil dilation:
Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)
Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)
Wide-field colour and autofluorescence imaging (Optomap)
Measure of intra-ocular pressure (pneumotonometer)
The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:
Age, gender
educational level
smoking
cardiovascular diseases, current medications
scores at neuropsychological tests
127488|NCT01555840|Device|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.
It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field." "b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields." c) Conventional gastroscope
127489|NCT01555853|Drug|Abraxane|
127490|NCT01555866|Drug|isavuconazole|IV
126982|NCT01554852|Drug|bortezomib, cyclophosphamide, dexamethasone|Days 1, 4, 8 and 11 bortezomib 1.3 mg/m2 rapid intravenous push
Days 1, 8, 15 cyclophosphamide 500 mg orally
Days 1-2, 4-5, 8-9 and 11-12 dexamethasone 20 mg daily orally
The cycle is repeated every 21 days
126983|NCT01554852|Drug|lenalidomide maintenance|Days 1-21 lenalidomide 10 mg daily orally
The cycle is repeated every 28 days
126984|NCT01554852|Drug|lenalidomide plus vorinostat maintenance|Days 1-21 lenalidomide 10 mg daily orally
Days 1-7 and 15-21 vorinostat 300 mg orally
The cycle is repeated every 28 days
126985|NCT01554865|Dietary Supplement|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
126986|NCT00078507|Behavioral|Sensory Re-training|
126987|NCT01554865|Behavioral|Conventional diet counseling|
126988|NCT01554878|Procedure|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
126989|NCT01554904|Device|Facial-Flex|Oral exercise device
126990|NCT01554917|Drug|Iguratimod|taken orally, 2 tablets/day (bid)
126991|NCT01554930|Drug|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
127251|NCT01557647|Drug|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
127252|NCT00078741|Behavioral|Cognitive Behavioral Therapy (CBT)|
127253|NCT01557647|Drug|Placebo|placebo inhalation solution
127254|NCT01557660|Drug|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
127255|NCT01557673|Dietary Supplement|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
127256|NCT01557673|Dietary Supplement|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
127257|NCT01557686|Behavioral|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
127258|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
127259|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
126763|NCT01556945|Biological|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
126764|NCT01556945|Biological|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
126765|NCT01556945|Other|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
126766|NCT01556945|Other|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
126767|NCT00078611|Drug|Antegren(TM) (natalizumab)|
126768|NCT01556971|Drug|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
126769|NCT01556971|Drug|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
127048|NCT01561963|Drug|Apremilast|Each subject will receive the following 3 treatments in the same fixed sequence during the study (the study days are numbered sequentially across all 3 periods):
A single oral dose of 30 mg apremilast on Day 1 in Period 1;
A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3.
127049|NCT01561963|Drug|Rifampin|A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3.
127050|NCT01561976|Drug|Metformin hydrochloride prolonged release|1000mg in fasting state
127051|NCT01561976|Drug|metformin hydrochloride prolonged release|1000mg in fed state
127052|NCT01561976|Drug|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
127053|NCT00079040|Drug|cisplatin|Given IV
127054|NCT01561989|Dietary Supplement|cholecalciferol|Given PO
127055|NCT01561989|Other|questionnaire administration|Ancillary studies
127056|NCT01561989|Biological|trivalent influenza vaccine|Given IM
127057|NCT01562002|Procedure|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
130892|NCT01605357|Drug|Induced, sustained hypernatremia using hypertonic saline|Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.
Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.
Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.
Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.
Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines
130893|NCT01605357|Drug|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium < 135 mmol/L) is to be corrected at the discretion of the provider.
130894|NCT01605370|Drug|Nebivolol|Nebivolol 2.5 mg once daily
130895|NCT00001542|Drug|fluconazole|
130896|NCT00082875|Other|laboratory biomarker analysis|Correlative studies
130897|NCT01605370|Drug|Metoprolol succinate|Metoprolol succinate 50 mg once daily
130898|NCT01605383|Biological|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
130899|NCT01605383|Procedure|Standard treatment|Isolated core decompression
130900|NCT01605396|Drug|Ridaforolimus|Participants receiving 10 mg PO (orally) QD (daily) of ridaforolimus in the triplet and 30 mg in the doublet may escalate to 20 mg QDx5 and 40 mg QDx5 respectively in the absence of grade 2 or above stomatitis in the initial cycle of treatment.
130901|NCT01605396|Drug|Dalotuzumab|10 mg/kg/week intravenously.
Note: Based upon evaluation of additional data the sponsor may adjust the starting dose of dalotuzumab, which may be changed to 7.5 mg/kg/week.
130902|NCT01605396|Drug|Exemestane|25 mg PO QD
130903|NCT01607775|Device|PMMA-cage|The in-house produced cervical cage will be implanted
130922|NCT01607931|Behavioral|Exercise|1 hour of cycling at 50% of maximum power output
130923|NCT01607957|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
130924|NCT01601002|Drug|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
130925|NCT01601015|Other|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
127491|NCT01555879|Drug|Abatacept|As prescribed by a doctor for patient medical care.
127492|NCT01555892|Biological|LMP, BARF1 & EBNA1 specific CTLs: A|Dose Level 1: 2 x 10^7 cells/ m2; 2 x 10^7 cells/m2
Dose Level 2: 2 x 10^7 cells/m2; 1 x 10^8 cells/m2
Dose Level 3: 1 x 10^8 cells/m2; 2 x 10^8 cells/m2
127493|NCT01555892|Biological|LMP, BARF1 & EBNA1 specific CTLs : B|Dose Level 1: 2 x 10^7 cells/ m2; 2 x 10^7 cells/m2
Dose Level 2: 2 x 10^7 cells/m2; 1 x 10^8 cells/m2
Dose Level 3: 1 x 10^8 cells/m2; 2 x 10^8 cells/m2
127494|NCT00078559|Drug|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
127495|NCT01555905|Device|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
127496|NCT01557998|Behavioral|Point of Care CD4 count and peer case management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <350/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
126638|NCT01558986|Procedure|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
126639|NCT01561261|Other|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
126640|NCT00079001|Drug|androgen deprivation therapy|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
126641|NCT01561274|Drug|2 ml bupivacaine|2 ml bupivacaine
126642|NCT01561274|Drug|1.5 ml bupivicaine.|1.5 ml bupivicaine.
126643|NCT01561287|Procedure|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
126644|NCT01561287|Procedure|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
127260|NCT01560091|Drug|silodosin|8mg PO Qday
127261|NCT01560091|Procedure|Extra-corporeal shock wave lithotripsy|ESWL
127262|NCT01560091|Drug|Tamsulosin|Tamsulosin 0.4mg PO Qday
127263|NCT00078962|Biological|GTI-2040|Given IV
127264|NCT01560104|Drug|Veliparib|
127265|NCT01560104|Drug|Carboplatin|
127266|NCT01560104|Drug|paclitaxel|
127267|NCT01560104|Drug|placebo|
127268|NCT01560117|Drug|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
127269|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
127270|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
127271|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
127547|NCT00078325|Drug|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
127548|NCT01553539|Other|laboratory biomarker analysis|Correlative study
127549|NCT01553565|Procedure|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
127550|NCT01553578|Other|questionnaire administration|Ancillary studies
127551|NCT01553578|Procedure|therapeutic touch|Receive healing touch therapy
127552|NCT01553578|Behavioral|management of therapy complications|Receive healing touch therapy
127553|NCT01553578|Behavioral|management of therapy complications|Receive guided imagery audiotapes
127554|NCT01553578|Procedure|standard follow-up care|Receive standard care
127555|NCT01555918|Drug|Isavuconazole|oral
127058|NCT01562015|Drug|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
127059|NCT01562028|Drug|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
127060|NCT01562028|Drug|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
127061|NCT01562041|Drug|Ranolazine|twice per day for 14 days
127062|NCT01562067|Device|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
127063|NCT01562080|Dietary Supplement|Armolipid Plus|one tablet per day during 12 weeks
127064|NCT00079040|Drug|etoposide|Given IV
127065|NCT01562080|Dietary Supplement|placebo|one tablet per day during 12 weeks
127066|NCT01562093|Drug|corticosteroid nasal spray|fluticasone furuoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
127067|NCT01562093|Drug|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
127325|NCT01557712|Drug|Venlafaxine|After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:
Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)
D0 to D5: 75 mg of venlafaxine
D5 to D28: 150 mg per day of venlafaxine
D28 to D42: 150 mg daily of venlafaxine or 225 mg per day of venlafaxine if patient not responder to D28
127326|NCT00001436|Drug|tamoxifen|
127327|NCT00078754|Drug|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
127328|NCT01557738|Dietary Supplement|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
127329|NCT01557738|Dietary Supplement|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
127330|NCT01557738|Dietary Supplement|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
127331|NCT01557738|Dietary Supplement|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
133256|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
133257|NCT01624116|Drug|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
133258|NCT01624116|Other|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
133259|NCT01624116|Drug|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
133260|NCT00084526|Procedure|ultrasound imaging|
132405|NCT01594385|Biological|Seprafilm|Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:
Two Seprafilm pieces between the liver and the anterior abdominal wall
Four pieces over the exposed bowel surfaces anteriorly
Two slightly staggered pieces of Seprafilm in each colic gutter
Two pieces in the pelvic area.
If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair.
132406|NCT00081588|Drug|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
132407|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
132408|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
132409|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
132410|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
132411|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
132412|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
132413|NCT01594424|Drug|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
132414|NCT01594437|Biological|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
132415|NCT01594437|Biological|Placebo|One or two doses administered by intravenous infusion.
132416|NCT01594450|Biological|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
132417|NCT00081601|Drug|CEP-701|
133136|NCT01591668|Drug|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
133137|NCT01591668|Drug|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
133138|NCT01591681|Device|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
133139|NCT01591707|Behavioral|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
133140|NCT00081276|Other|laboratory biomarker analysis|Correlative studies
133141|NCT01593462|Procedure|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take approximately 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
133142|NCT00081458|Drug|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
133433|NCT01624519|Procedure|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
133434|NCT01624532|Biological|rPA vaccine containing alhydrogel 1.0 mL|rPA vaccine containing alhydrogel 1.0 mL
133435|NCT01624532|Drug|Normal Saline|Normal Saline 0.5mL
133436|NCT01624532|Biological|rPA vaccine containing alhydrogel 0.5 mL|rPA vaccine containing alhydrogel 0.5 mL
133437|NCT01626976|Drug|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
133438|NCT01626976|Drug|Placebo|Solution, single dose
133439|NCT01626976|Drug|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
133440|NCT01626976|Drug|Placebo|suspension, single dose
133441|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
133442|NCT01626976|Drug|Placebo|suspension, single dose
133443|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
132468|NCT01592578|Procedure|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
132469|NCT01592578|Procedure|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
132470|NCT00001507|Drug|Monoclonal Antibody 95-6-22|
132471|NCT00081302|Radiation|radiation therapy|
132736|NCT00081367|Behavioral|Standard care alone|Participants will receive standard care for suicide prevention.
132737|NCT01592981|Drug|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
132738|NCT01592981|Drug|Cyclophosphamide|Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.
Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm.
132739|NCT01592981|Biological|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
132740|NCT01592981|Drug|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
132741|NCT01592994|Behavioral|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
132742|NCT00081731|Procedure|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
132743|NCT01594983|Drug|Placebo of LCQ908|Matching placebo of LCQ908
132744|NCT01594983|Drug|Placebo of fenofibrate|Matching placebo of fenofibrate
132745|NCT01594983|Drug|Placebo of fish oil|Matching placebo of fish oil capsule
132746|NCT01595009|Drug|RAD001|
132747|NCT01595022|Drug|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
132748|NCT01595022|Drug|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
132749|NCT01595022|Drug|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
133061|NCT01593319|Drug|Natrium chloride|Placebo injection of Natrium chloride solution
133062|NCT01593332|Drug|Rituximab|two 500 mg rituximab infusions 2 weeks apart
133063|NCT01593332|Drug|Rituximab|500mg,two times with two weeks interval
133064|NCT01593345|Other|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
133065|NCT01593345|Other|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
133066|NCT01593371|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
133067|NCT01593371|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
133068|NCT00081458|Drug|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
133069|NCT01593397|Drug|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
133369|NCT01626911|Procedure|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
133370|NCT01626911|Other|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
133371|NCT01626924|Drug|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
133372|NCT01626937|Other|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
132543|NCT01598753|Drug|Tramadol|50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.
Minimum accepted dose of 200mg per day
132544|NCT01598753|Drug|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
132545|NCT01598753|Behavioral|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
132546|NCT01598753|Behavioral|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
132547|NCT01598766|Device|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
132548|NCT01598792|Biological|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
132549|NCT01598805|Behavioral|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
132550|NCT01598831|Drug|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
132551|NCT01598831|Drug|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
132552|NCT00082251|Drug|Niacin extended release and simvastatin tablets|
132553|NCT01598844|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
132554|NCT01598857|Drug|Blisibimod|
132555|NCT01598857|Drug|Placebo|
132556|NCT01598870|Other|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
132557|NCT01598883|Drug|Heparin|150 U/kg
132558|NCT01598883|Drug|ATryn|1000 IU
132819|NCT01593020|Drug|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
132820|NCT01593020|Drug|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
132821|NCT01593020|Drug|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
133444|NCT01626976|Drug|Placebo|suspension, single dose
133445|NCT00001569|Drug|5-FU|
133446|NCT00084695|Biological|anti-thymocyte globulin|Given IV
133447|NCT01626976|Drug|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
133448|NCT01626976|Drug|Placebo|suspension, single dose
133449|NCT01626989|Device|BiPAP auto Advanced|Auto Servo Ventilation Device
133450|NCT01626989|Device|BiPAP auto SV4|Auto Servo Ventilation Device
133451|NCT01627002|Biological|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
133452|NCT01627002|Other|Placebo|Subcutaneous
133453|NCT01627015|Other|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
133454|NCT01627015|Other|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
133455|NCT01627028|Procedure|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
133456|NCT01627041|Drug|Cytarabine|Given IV
132612|NCT01596998|Drug|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
132613|NCT00081965|Procedure|acupuncture therapy|
132614|NCT01596998|Other|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
132615|NCT01596998|Other|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
132616|NCT01597011|Procedure|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
132617|NCT01597011|Procedure|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
132750|NCT01595035|Behavioral|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
132751|NCT01595048|Biological|Rituximab|Given IV
132752|NCT01595048|Drug|Prednisone|Given PO or IV
132753|NCT00081744|Drug|Tigecycline|
132754|NCT01595048|Drug|Etoposide|Given IV
132755|NCT01595048|Drug|Doxorubicin Hydrochloride|Given IV
132756|NCT01595048|Drug|Cytarabine|Given IV
132757|NCT01595048|Drug|Vincristine Sulfate|Given IV
132997|NCT01595425|Drug|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
132998|NCT01595425|Drug|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
132999|NCT01595438|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
133000|NCT01595438|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
133001|NCT01595438|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
133002|NCT01595438|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
133003|NCT01595451|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
133004|NCT01595464|Behavioral|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
133005|NCT00081770|Drug|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
133006|NCT01595477|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
133007|NCT01595490|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
133373|NCT01626937|Other|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
133374|NCT00084682|Drug|romidepsin|Given IV
133375|NCT01626963|Procedure|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
133376|NCT01626963|Procedure|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
133377|NCT01619826|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
133378|NCT01619826|Behavioral|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
133379|NCT01619839|Drug|NKTR-181|
133380|NCT01619839|Drug|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
133381|NCT01619852|Drug|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
133382|NCT01619852|Drug|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
133383|NCT01619865|Drug|68Ga-DOTATOC PET/C|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
133384|NCT01619878|Drug|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
133385|NCT00084123|Behavioral|Standard Care|Standard Care
133386|NCT01619891|Dietary Supplement|Vitamin D|100mcg per day
132536|NCT01598714|Device|Podalux shoe|Podalux shoe
132537|NCT01598714|Device|Standard dressing shoe|Standard dressing shoe
132538|NCT01598727|Device|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
132539|NCT01598740|Drug|CLP|Oral administration
132540|NCT00001521|Drug|Deslorelin|
132541|NCT00082238|Drug|Ibuprofen|
132542|NCT01598740|Drug|Spironolactone|oral administration
132822|NCT01593033|Dietary Supplement|Fish oil and Micronutrient Supplementation|0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months
1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months
132823|NCT01593033|Dietary Supplement|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
132824|NCT01593033|Drug|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
132825|NCT01593046|Drug|GSK1265744 Oral|30mg tablet
132826|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
132827|NCT01593046|Drug|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
132828|NCT01593046|Drug|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
132829|NCT00081380|Drug|lithium (mood stabilizer)|
132830|NCT01593046|Drug|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
132831|NCT01593046|Drug|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
132832|NCT01593046|Drug|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
132833|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
132834|NCT01593072|Drug|AVI-7537|Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV
The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.
132835|NCT01593072|Other|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
132836|NCT01595087|Drug|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
132837|NCT01595152|Drug|solifenacin succinate|8 mg once daily for 60 days
132838|NCT01595152|Drug|fesoterodine|8 mg, once daily for 60 dyas
133070|NCT01593410|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
132618|NCT01597024|Other|Breakfast Study|Subjects (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and assess appetite, biomarkers in blood and saliva and complete questionnaires to assess influences on feeding behaviour. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There are two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Subjects will be offered a morning snack buffet to assess ad libitum feeding behaviour. Phase 1 will also include a subgroup of malnourished male and female elderly participants.
132619|NCT01599117|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
132620|NCT01599117|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
132621|NCT01599130|Drug|Entecavir|entecavir 0.5mg per day
132622|NCT01599130|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
132623|NCT01599143|Behavioral|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
132624|NCT01599156|Procedure|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
132625|NCT01599169|Dietary Supplement|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
132626|NCT01599169|Dietary Supplement|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
132886|NCT01591187|Other|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
132887|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
132888|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
132889|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
132890|NCT01591226|Dietary Supplement|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
132891|NCT01591226|Dietary Supplement|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
133008|NCT01595503|Procedure|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
133009|NCT01595503|Procedure|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
133010|NCT01595516|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
133011|NCT01595516|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
133012|NCT01595516|Drug|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
133013|NCT01595529|Drug|Trimethoprim sulfamethoxazole, cefixime, or cephalexin|After five days of active drug, five additional days of one of the following: 1) Oral suspension 200 mg of sulfamethoxazole/40 mg trimethoprim per 5mL. 8 mg/kg/day Trimethoprim in 2 divided doses 2) Reconstituted oral suspension containing 100 mg of cefixime as a trihydrate per 5 mL for small children or 200 mg of cefixime as a trihydrate per 5 mL for large children 3) Reconstituted oral suspension 250mg anhydrous cephalexin per 5mL for small children and two packages of oral suspension of 250mg anhydrous cephalexin per 5mL for large children
133318|NCT01619800|Device|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
133319|NCT00084123|Behavioral|Relaxation Therapy|
133320|NCT01619813|Drug|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
133321|NCT01619813|Drug|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
133322|NCT01621867|Drug|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
133323|NCT01621880|Drug|bevacizumab|Patients receive bevacizumab IV over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
133324|NCT01621880|Drug|Methylprednisolone|Patients receive intravenous steroid over 5 consecutive days. The dosage was decreased gradually. The regimen repeats every other month for up to 4 courses.
133325|NCT01621893|Procedure|Subchondroplasty|the Subchondroplasty procedure for treatment of bony defects associated with bone marrow edema
129436|NCT01568827|Dietary Supplement|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
129437|NCT01568840|Other|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
129438|NCT01568840|Other|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
129439|NCT01568853|Drug|Norepinephrine|Intravenously, 10 ug/min, 24 hours
129440|NCT00079417|Radiation|ruthenium Ru 106|Undergo radioactive therapy
129441|NCT01568853|Procedure|Open abdomen|IAH >=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
129442|NCT01568853|Other|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
129443|NCT01568853|Other|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
129742|NCT01564355|Device|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
129743|NCT00079144|Drug|cyclophosphamide|
129744|NCT01564355|Drug|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
129745|NCT01564368|Procedure|diffusion-weighted magnetic resonance imaging|
129746|NCT01564381|Dietary Supplement|ResA|90mg of resveratrol conjugated with arginine.
129747|NCT01564381|Dietary Supplement|Resveratrol|90mg of resveratrol.
129748|NCT01564381|Dietary Supplement|Placebo|Made up of cellulose.
129749|NCT01564394|Behavioral|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
129750|NCT01564394|Behavioral|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
133071|NCT01593410|Drug|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
133072|NCT01593423|Behavioral|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
133073|NCT01593423|Behavioral|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
133074|NCT01593423|Behavioral|a comparison group|No intervention.
133075|NCT01593436|Behavioral|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
133076|NCT01593449|Behavioral|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
133077|NCT01593462|Procedure|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
133078|NCT00081783|Drug|Xcellerated T Cells|
133079|NCT01595555|Behavioral|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
133080|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
133081|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
133082|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
133083|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
133084|NCT01595581|Drug|Testosterone|8 weeks supraphysiologic dose testosterone enanthate
133085|NCT01595581|Drug|Saline|Placebo for 8 weeks
133086|NCT01595594|Drug|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
132418|NCT01594450|Procedure|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
132419|NCT01594463|Other|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
132420|NCT01594463|Other|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
132421|NCT01594476|Drug|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
132422|NCT01594489|Drug|Aminophylline|200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration
Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure
N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI
132683|NCT01597024|Other|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Subjects will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The subjects will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
132684|NCT01597037|Behavioral|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
132685|NCT01597050|Drug|R932333|R393233 6% (60 mg/g), bid
132686|NCT01597050|Drug|Placebo|Placebo, bid
132687|NCT01597063|Device|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
132688|NCT00081965|Procedure|hot flashes attenuation|
132689|NCT01597076|Dietary Supplement|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas & Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
132690|NCT01597102|Other|No interventions|No intervention is planned in this study
132691|NCT01597115|Procedure|Duplex ultrasonography|
132692|NCT01597128|Device|Flex HD|Flex HD mesh for hernia repair
132693|NCT01597128|Device|Strattice|Strattice mash for hernia repair
133326|NCT01621906|Device|18F-FLT-PET Imaging|All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.
Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.
Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care.
133327|NCT01621906|Device|18F-FLT-PET Imaging|All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.
Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.
Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care.
133328|NCT01621932|Procedure|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
133329|NCT01621932|Procedure|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
133330|NCT00001566|Drug|indinavir sulfate|Oral dose, 350 mg/m^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
133331|NCT00084318|Drug|docetaxel|
133332|NCT01621945|Biological|MenBvac|Blood test
133333|NCT01621958|Behavioral|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
133334|NCT01621958|Behavioral|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
132472|NCT01592604|Device|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
132473|NCT01592604|Device|Below knee walking cast|Below knee walking cast for 4 weeks
132474|NCT01592617|Drug|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
132475|NCT01592630|Drug|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
132476|NCT01592630|Drug|Saline|On-Q pumps containing saline to be attached to TAP catheters
132477|NCT01592643|Device|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
132478|NCT01592656|Radiation|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
132479|NCT01592656|Other|Lung compliance measurement|At baseline
129751|NCT01564407|Drug|ICX‐RHY‐013|Drug Dosing for Cohorts as follows:
Cohorts (N=4)
Safety Cohort 1:
Empty control no injection
Vehicle only (0.5 ml of HypoThermosol solution)
5 million cells / cm² , single administration at Day 0
5 million cells/ cm² , single administration at week 4
5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4
At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.
Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks
129752|NCT01564433|Procedure|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
129753|NCT01564433|Procedure|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
129754|NCT00079144|Drug|fludarabine phosphate|
129755|NCT01566747|Drug|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
129756|NCT00079287|Drug|paclitaxel|
130027|NCT00079456|Other|pharmacological study|Correlative studies
130028|NCT01569672|Behavioral|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
130029|NCT01569672|Behavioral|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
130030|NCT01569685|Drug|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
130031|NCT01569685|Drug|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
130032|NCT01569698|Procedure|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
130033|NCT01569711|Procedure|Deep brain stimulation of nucleus accumbens|Day0 : surgical placement of electrodes
M1 : stimulation of nucleus accumbens
M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)
130034|NCT01569724|Other|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
130035|NCT01569737|Drug|ella|ella, single intake, tablet 30mg
133387|NCT01619904|Procedure|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
133388|NCT01619904|Procedure|Standard Therapy|Following standard protocol during peri-operative period
133389|NCT01619917|Device|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
133390|NCT01619930|Behavioral|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
133391|NCT01619930|Behavioral|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
133392|NCT01619930|Behavioral|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
133393|NCT01619930|Behavioral|Behavioral activation without rationale|A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided ("Activate yourself and feel better!"). Approximately 15 minutes of electronic therapist support will be included per week.
133394|NCT01619943|Other|no intervention|clinical follow up
133395|NCT01619943|Other|no intervention|no intervention
133396|NCT00084136|Drug|Atazanavir|400 mg taken orally daily
133397|NCT01619956|Device|SLA dental implants|Dental implant with surface modification.
133398|NCT01622010|Other|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
133399|NCT01622010|Device|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
133400|NCT00084318|Procedure|adjuvant therapy|
133401|NCT01622023|Procedure|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
132559|NCT01598896|Drug|Dronabinol|Dronabinol titrated to 5 mg three times daily
132694|NCT01597141|Behavioral|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
132695|NCT01597141|Behavioral|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
132696|NCT01597154|Behavioral|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
132697|NCT01597167|Dietary Supplement|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
132698|NCT01597193|Drug|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
132699|NCT00081965|Procedure|management of therapy complications|
132700|NCT01597193|Drug|anastrozole|1 mg/day
132701|NCT01597193|Drug|exemestane|The exemestane dose is 25mg daily.
132702|NCT01597193|Drug|fulvestrant|500 mg every 28 days
132703|NCT01597193|Drug|enzalutamide|160 mg (4 capsules) taken orally daily.
132939|NCT01597505|Drug|CB-183,315|250 mg bid for 10 days
132940|NCT01597505|Drug|oral vancomycin|oral, 125 mg qid for 10 days
132941|NCT01597518|Drug|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
132942|NCT00082069|Biological|Shigella flexneri 2a Invaplex 50|
132943|NCT01597518|Drug|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
132944|NCT01597531|Drug|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
132945|NCT01597531|Drug|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
132946|NCT01597531|Drug|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
132480|NCT01592656|Device|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 > 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
132481|NCT01592669|Procedure|passive leg raising|bilateral PLR was achieved by raising the legs of patient
132482|NCT00081315|Drug|Amifostine|
132483|NCT01592682|Behavioral|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
132484|NCT01592695|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
132485|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
132486|NCT00001509|Drug|IFN-alpha with retinoic acid|
132487|NCT00081614|Drug|Avastin (bevacizumab)|
132488|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
132489|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
132490|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
132491|NCT01594515|Drug|Placebo|Solution for oral administration
132492|NCT01594515|Drug|BI 101550|High dose powder for oral solution
132493|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
132494|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
132758|NCT01595048|Drug|Cyclophosphamide|Given IV
132759|NCT01595048|Drug|Methotrexate|Given IT
132760|NCT01595048|Drug|Methylprednisolone|Given IV
132761|NCT01595048|Drug|Leucovorin Calcium|Given PO
132762|NCT01595048|Drug|Therapeutic Hydrocortisone|Given IT
132763|NCT01595048|Other|Laboratory Biomarker Analysis|Correlative studies
132764|NCT00081757|Drug|Thalidomide|
130036|NCT01569750|Drug|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
130037|NCT01569750|Drug|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
130038|NCT00079456|Other|laboratory biomarker analysis|Correlative studies
130039|NCT01569750|Drug|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
130040|NCT01569750|Drug|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
130041|NCT01569750|Drug|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
130042|NCT01569763|Device|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
130043|NCT01569763|Device|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
130044|NCT01569776|Other|Amino Acid formula|Amino Acid baby formula
130045|NCT01569776|Other|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
132919|NCT01595347|Drug|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
132920|NCT01595347|Other|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
132921|NCT01595360|Drug|Placebo|It is applied directly to the bleeding site after tooth extraction
132922|NCT01595360|Drug|TT-173|It is applied directly to the bleeding site after tooth extraction
132923|NCT01595373|Drug|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
132924|NCT01595373|Drug|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
132925|NCT01595386|Drug|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
132926|NCT01595386|Drug|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
132560|NCT01598896|Drug|Clonidine|Clonidine 0.1 mg twice daily
132561|NCT01598896|Drug|Placebo|One placebo capsule by mouth twice daily
132562|NCT01592695|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
132563|NCT01592695|Behavioral|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
132564|NCT01592695|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
132565|NCT01592695|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
132566|NCT01592695|Drug|Bupropion SR|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
132567|NCT01592695|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
132568|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
132569|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
132570|NCT00081328|Drug|Metformin|capsule, 1000 mg bid
132571|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
132572|NCT01592695|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
132573|NCT01592695|Behavioral|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
132574|NCT01592695|Behavioral|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
132575|NCT01592708|Other|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
132947|NCT01597544|Procedure|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
132948|NCT01597557|Drug|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
132949|NCT01597557|Other|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
132950|NCT01591226|Dietary Supplement|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
132951|NCT00081250|Dietary Supplement|creatine monohydrate|Given orally
132952|NCT01591226|Dietary Supplement|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
132953|NCT01591239|Behavioral|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
132954|NCT01591239|Behavioral|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
133261|NCT01624116|Drug|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
133262|NCT01624116|Drug|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
133263|NCT01624129|Drug|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
133264|NCT01624142|Biological|Evolocumab (AMG145)|every month
133265|NCT01624142|Biological|Evolocumab (AMG145)|every 2 weeks
133266|NCT01624155|Behavioral|Education|EMR referral to teratogen and contraception counseling
133267|NCT01624168|Behavioral|Anxiety Management Education|written materials on management of anxiety for self-study
133268|NCT01624168|Behavioral|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
133269|NCT01624168|Behavioral|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
132765|NCT01595061|Drug|Cisplatin|Given IV
132766|NCT01595061|Drug|Gemcitabine Hydrochloride|Given IV
132767|NCT01595061|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
132768|NCT01595061|Procedure|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
132769|NCT01595074|Other|medical chart review|Correlative studies
132770|NCT01595074|Other|laboratory biomarker analysis|Correlative studies
132771|NCT01597219|Procedure|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
132772|NCT01597219|Procedure|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
132773|NCT01597232|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
132774|NCT00081978|Drug|TMC125|
132775|NCT01597232|Other|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
132776|NCT01597232|Other|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
132777|NCT01597245|Drug|80 mg ixekizumab Dosing Regimen|Administered SC
132778|NCT01597245|Drug|50 mg etanercept|Administered SC
132779|NCT01597245|Drug|Placebo|Administered SC
132780|NCT01597258|Drug|Crizotinib (Xalkori)|XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows. " The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
133014|NCT01595529|Drug|Placebo|After five days of active drug, five days of placebo with the same flavoring as active counterpart. Dosage, dosage form, frequency and duration would be matched to each active counterpart.
133015|NCT01595542|Behavioral|Modified Vaccine Consent Form|Packet of written immunization materials for parents and students which includes the following:
Cover letter
Vaccine promotional flyer
Vaccine information sheets (one for adolescent vaccination and one for other vaccination)
Improved consent form
Note advertising a lottery for free movie tickets for returning the consent form
Self-addressed stamped envelope
132927|NCT01595399|Drug|atropine|Atropine 0.02 mg/kg IV
132928|NCT01595399|Drug|Placebo|an equivalent volume of normal saline to atropine IV
132929|NCT00081770|Biological|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
132930|NCT01595412|Procedure|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
132931|NCT01595412|Procedure|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
132932|NCT01597440|Other|Standard of Care|Standard of Care
132933|NCT01597453|Behavioral|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
132934|NCT01597466|Device|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
132935|NCT01597466|Procedure|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
132936|NCT01597479|Drug|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
132937|NCT01597492|Biological|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Tetanus toxoid and pneumococcal vaccinations are administered on the same day 4 weeks prior to the first dose of belimumab.
132938|NCT01597492|Biological|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Tetanus toxoid and pneumococcal vaccinations are administered on the same day 24 weeks after the first dose of belimumab.
133169|NCT01595802|Device|Nautilus NeuroWave|The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.
In this intervention, patients are recorded using the Nautilus Neurowave device.
133170|NCT01597765|Drug|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
133171|NCT01597778|Biological|Haploidentical Bone Marrow Transplant|The conditioning regimen consists of:
Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1
The GVHD prophylaxis regimen consists of:
Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID beginning Day 5 until Day 35
132839|NCT01595165|Procedure|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
132840|NCT00001512|Drug|Id-KLH Vaccine|
132841|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
132842|NCT01595165|Procedure|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
132843|NCT01595178|Behavioral|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
132844|NCT01595191|Other|Bach music|Infants listened to Bach or Mozart using the compact discs entitled "Baby Bach" and "Baby Mozart" (Baby smart, Nir Zvi, Israel).
132845|NCT01595191|Other|Mozart music|Infants listened to Bach or Mozart using the compact discs entitled "Baby Bach" and "Baby Mozart" (Baby smart, Nir Zvi, Israel).
132846|NCT01595204|Procedure|Diagnostic laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers.
132847|NCT01595217|Device|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
132848|NCT01595230|Procedure|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
132849|NCT01595243|Behavioral|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
132850|NCT01595256|Behavioral|muscular strength|12-week moderate intensity walking program
132851|NCT01595269|Other|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
132852|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
132853|NCT01595282|Drug|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
133270|NCT01624194|Drug|Oxytocin nasal spray|24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.
133271|NCT00084539|Radiation|Radiation therapy|
133272|NCT01624194|Drug|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
133273|NCT01624207|Drug|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
133274|NCT01624207|Drug|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
133275|NCT01624220|Radiation|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
133276|NCT01624220|Radiation|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
133277|NCT01624220|Procedure|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
133278|NCT01624220|Behavioral|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
133279|NCT01624233|Drug|80 mg ixekizumab|Administered SC
133280|NCT01626729|Behavioral|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
133281|NCT00084669|Drug|venlafaxine|
132423|NCT01594489|Drug|Hydration plus N-acetylcisteine|Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure
N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI
132424|NCT01594502|Drug|Dutasteride|0.5 mg daily
132425|NCT01594502|Drug|Placebo|Placebo Comparator
132426|NCT01594515|Drug|BI 1015550|High dose powder for oral solution
132427|NCT01596764|Drug|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
132428|NCT01596764|Drug|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
132429|NCT01596764|Drug|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
133016|NCT01597570|Device|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
133017|NCT01597583|Behavioral|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
133018|NCT01597596|Biological|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
133019|NCT00082082|Drug|Thymalfasin (thymosin alpha-1)|
133020|NCT01597596|Biological|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
133021|NCT01597609|Drug|sibutramine|10 mg, taken orally once per day for 12 weeks
133022|NCT01597609|Other|sibutramine placebo|taken orally once per day for 12 weeks
133023|NCT01597622|Drug|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
133024|NCT01597635|Drug|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
133025|NCT01597635|Drug|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
133026|NCT01597635|Drug|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
133027|NCT01597635|Drug|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
133028|NCT01597635|Drug|Placebo (saline)|Administered intravenously to match intervention
133029|NCT01597648|Drug|Maraviroc|300 mg
133030|NCT00082082|Procedure|Trans arterial chemoembolization (TACE)|
133031|NCT01597648|Drug|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
133032|NCT01597648|Drug|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
133033|NCT01597661|Drug|Exposure to any bupropion during the first trimester|The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.
Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves.
133335|NCT01621971|Drug|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
133172|NCT01597778|Biological|Double Umbilical Cord Blood Transplant|The preparative regimen consists of:
Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.
The GVHD prophylaxis regimen consists of:
Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.
Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID beginning Day -3 until Day 35
133173|NCT01597791|Device|Foley catheter placement|Foley catheter placement after CSE.
133174|NCT01597791|Other|Spontaneous Micturation/ Post Void Residual|the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
133175|NCT01597804|Procedure|Infection Prophylaxis and Management|Undergo preoperative preparation with the "Bathing Bundle"
133176|NCT01597817|Other|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
133177|NCT01597817|Other|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
133178|NCT00082121|Drug|TP10|
133179|NCT01597830|Other|Mobility shoe|flat, specialized shoe
133180|NCT01597830|Other|control shoe|control shoe
133181|NCT01597843|Other|Education|Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
133182|NCT01597856|Behavioral|SBIRT|SBIRT Therapy overview-
Therapist explains purpose of the therapy.
Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.
Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.
Discuss treatment needs, administer screening, provide feedback.
133183|NCT01597869|Device|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
133184|NCT01597895|Drug|Maraviroc|Maraviroc 150 mg BID x 5 days with food
133185|NCT01597895|Drug|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
133492|NCT01622244|Other|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
133493|NCT01622244|Other|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
133494|NCT01622244|Behavioral|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
133087|NCT01595594|Drug|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
133088|NCT01595607|Other|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
133089|NCT00081796|Drug|larotaxel (RPR109881, XRP9881)|
133090|NCT01595620|Other|Thermal|Thermal sensation/pain testing
133091|NCT01595620|Device|Electrical|Electrical sensation/pain testing
133092|NCT01595620|Other|Capsaicin|Intradermal Capsaicin
133093|NCT01595633|Drug|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
133094|NCT01595646|Drug|Saline|Saline, administered intranasally twice per day for a 16 week duration
133095|NCT01595646|Drug|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
133096|NCT01595646|Drug|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
133097|NCT01595659|Behavioral|Passenger effect|Driving with risk accepting or risk averse passenger
133098|NCT01595672|Device|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
133099|NCT01595672|Other|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
133100|NCT00081796|Drug|capecitabine|
133101|NCT01597661|Other|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.
Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves.
133102|NCT01597674|Drug|YF476|There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.
Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments.
133103|NCT01597687|Procedure|Blood collection|1 blood sample will be collected from each subject.
133104|NCT01597687|Other|Data collection|Quality of Life and HE questionnaires.
132430|NCT01596764|Drug|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
132431|NCT01596777|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
132432|NCT01596777|Drug|Loperamide placebo|200 ml apple juice
132433|NCT00081926|Drug|Gleevec|
132434|NCT01596777|Drug|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
132435|NCT01596777|Drug|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
132436|NCT01596777|Drug|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
132437|NCT01596777|Drug|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
132438|NCT01596777|Device|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
132439|NCT01596777|Drug|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
132440|NCT01596790|Other|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
132441|NCT01596803|Procedure|Taking of blood|Taking venous blood samples to analyse oxidant stress
132704|NCT01597193|Drug|exemestane|The exemestane dose is 50 mg daily.
132705|NCT01597206|Device|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
132706|NCT01597206|Other|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
132707|NCT01599481|Behavioral|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
132708|NCT01599481|Behavioral|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
133336|NCT01621971|Drug|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
133337|NCT01621984|Other|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
133338|NCT01621997|Behavioral|operation inspection|Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.
Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months
133339|NCT01622010|Behavioral|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
133340|NCT01624246|Drug|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil [600 mg] plus avibactam [600 mg]) infused over 60 (± 5) minutes.
133341|NCT01624259|Drug|LY2189265|Administered SC
133342|NCT00084552|Radiation|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
133343|NCT01624259|Drug|Liraglutide|Administered SC
133344|NCT01624259|Drug|Metformin|
133345|NCT01624272|Device|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
133346|NCT01624272|Other|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
133347|NCT01624285|Drug|sorafenib tosylate|Given PO
133348|NCT01624285|Other|placebo|Given PO
133349|NCT01624285|Other|laboratory biomarker analysis|Correlative studies
133350|NCT01624298|Behavioral|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
133351|NCT01624311|Other|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
133495|NCT01622257|Device|Cavitation US|The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm^2 adjustable, 60W with 20cm^2 active surface).
133496|NCT01622257|Drug|Metformin|Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
133497|NCT01622257|Other|Cavitation US + Metformin|Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
133498|NCT01622270|Other|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
133499|NCT01622283|Drug|Levocetirizine|Levocetirizine
133500|NCT01622283|Drug|Cetirizine|Cetirizine
133501|NCT00084344|Procedure|breast imaging study|
133502|NCT01622296|Drug|Sodium bicarbonate|8.4% neutralizing solution
133503|NCT01622296|Drug|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
133504|NCT01624532|Biological|rPA vaccine containing alhydrogel 0.3 mL|rPA vaccine containing alhydrogel 0.3 mL
133505|NCT01624545|Other|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
133506|NCT01624558|Device|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
133507|NCT01624571|Drug|LD02GIFRO|comparison of different dosages of drug
133508|NCT00084578|Drug|celecoxib|
133509|NCT01624584|Behavioral|Experimental treatment|six sessions of child anxiety treatment
133510|NCT01624584|Behavioral|Traditional Treatment|six sessions of treatment consistent with current practice
133511|NCT01624597|Behavioral|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
132645|NCT01592773|Drug|Memantine Hydrochloride (HCl)|During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.
During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily.
133105|NCT01597700|Drug|10mg Ezetimibe|1 tablet taken by mouth
133106|NCT01597700|Drug|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
133402|NCT01622049|Device|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
133403|NCT01622062|Biological|Purified Vero cell Rabies Vaccine (PVRV)|0.1 mL, 4 site 'one week' (4-4-4-0-0) Intradermal
133404|NCT01622062|Biological|PVRV + purified Equine Rabies Immunoglobulin (pERIG)|0.1 mL of vaccine, 4 site 'one week' (4-4-4-0-0) administered intradermally + RIG (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
133405|NCT01622062|Biological|PVRV + purified Equine Rabies Immunoglobulin (pERIG)|0.1 mL of vaccine, 4 site 'one week' (4-4-4-0-0) administered intradermally + RIG (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
133406|NCT01622075|Device|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
133407|NCT01622075|Device|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
133408|NCT01622088|Drug|Dexpramipexole|Oral tablet 150 mg given twice daily up to 36 months
133409|NCT01622101|Dietary Supplement|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by >7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
133410|NCT01622114|Other|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
133411|NCT00084318|Radiation|radiation therapy|
133412|NCT01622127|Device|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
133413|NCT01622153|Procedure|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
132709|NCT01599494|Drug|MK-8962|MK-8962 is supplied in a ready-to-use prefilled syringe containing
100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962.
132710|NCT01599494|Drug|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
132711|NCT01599494|Drug|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
132712|NCT01599494|Drug|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
132713|NCT01599494|Drug|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
132714|NCT01599507|Drug|FG-4592|TIW dosing, capsule
132715|NCT01599507|Drug|Placebo|TIW dosing, capsule
132716|NCT00082303|Behavioral|Music Imagery|
132717|NCT01599520|Behavioral|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled "Cómo tratar el estrés durante la quimioterapia." Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques.
132955|NCT01591265|Procedure|compensatory extraction of upper FPMs|Routine clinical care group who will receive standard therapy of extraction of upper FPMs
132956|NCT01591265|Procedure|no compensatory extraction of Upper FPMs|Intervention group: clinical care group who will receive non standard therapy of not extracting the upper FPMs.
132957|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
132958|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
132959|NCT01591291|Drug|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
132960|NCT01591291|Drug|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
132495|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
132496|NCT01594528|Other|pain tests|pain induction with pressure application or ischemia on the arm
132497|NCT01594567|Other|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
132498|NCT00081614|Drug|Tarceva (erlotinib HCl)|
132499|NCT01594580|Other|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
132500|NCT01594580|Other|Non-impregnated scrubs|
132501|NCT01594593|Behavioral|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
132502|NCT01594606|Behavioral|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
132503|NCT01594619|Drug|Naloxegol|Oral 25mg tablet
132504|NCT01594619|Drug|Diltiazem XR|Oral 240mg tablet
132505|NCT01594632|Drug|Jadelle|LNG containing subdermal contraceptive implant
132506|NCT01594632|Drug|Sino-implant (II)|LNG containing subdermal contraceptive implant
132507|NCT01594645|Procedure|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
132508|NCT01594658|Procedure|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
132509|NCT00081627|Drug|CoFactor and 5FU|
132510|NCT01594658|Procedure|conservative|This arm only has medical standard handling (healings performed by the nurse group)
132511|NCT01594671|Drug|Tranexamic Acid|Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
Each dosage: 2 ampoules of 500mg/5 mL/ampoule
132512|NCT01596829|Dietary Supplement|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
132513|NCT01596829|Dietary Supplement|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
132646|NCT01592786|Drug|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
132647|NCT01592799|Procedure|Throat swab and/or nasopharyngeal swab|Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
132648|NCT01592799|Other|Data collection|Log Sheet will be used to collected data on a monthly basis for the following age groups: < 6 months; 6-23 months; 24-59 months; > 5 years.
132649|NCT01592812|Device|electrical muscle stimulation|Duration of the stimulation 20 minutes
132650|NCT01592838|Other|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
132651|NCT00081328|Behavioral|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
132652|NCT01592851|Drug|Stannous Fluoride|dentifrice containing stannous fluoride
132653|NCT01592851|Drug|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
132654|NCT01592864|Drug|Stannous Fluoride|dentifice
132655|NCT01592864|Drug|Sodium Monofluorophosphate|dentifrice
132656|NCT01592890|Drug|RO4917523|[14C]-labeled RO4917523, single oral dose
132657|NCT01592890|Drug|RO4917523|[13C]-labeled RO4917523, single intravenous tracer dose
132658|NCT01592903|Genetic|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.
Sample digestion through controlled enzymes.
Isolated the "Side Population" from leiomyoma cell suspension by Flow cytometry .
Culture of these cells.
Morphological and genetic characterization.
Assessment of pluripotent potential from isolated cells.
Analysis of the degree of functionality.
132659|NCT01594827|Drug|Rifampin|Oral Rifampin by mouth for 28 days
>45 kg: 600 mg by mouth daily
35-45 kg : 450 mg by mouth daily
25-34.9 kg: 300 mg by mouth daily
132660|NCT01594827|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Oral trimethoprim/sulfamethoxazole (DS-160/800)
>45 kg: two DS tablets twice a day by mouth (320/1600)
25-45 kg: one DS tablet twice a day by mouth (160/800)
132661|NCT00081653|Drug|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
132662|NCT01594827|Drug|Doxycycline|If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline
>45 kg: 100 mg by mouth twice a day
35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day
132576|NCT01592721|Biological|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
132577|NCT01592734|Drug|Polyethylene glycol with electrolytes|Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.
Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days.
132578|NCT01592734|Device|Polyethylene glycol|Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children > 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.
Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days.
132579|NCT01594671|Drug|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
132580|NCT01594671|Other|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
132581|NCT01594684|Device|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
132582|NCT01594684|Device|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
132583|NCT01594684|Device|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
132584|NCT01594684|Device|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
132585|NCT01594697|Drug|Metformin|
132586|NCT01594723|Drug|120 mg LY2784544|Administered orally
132587|NCT00081640|Drug|PRO 2000/5 Gel (P)|
132588|NCT01594736|Drug|ORSIRO|due randomization ORSIRO will be implanted
132589|NCT01594736|Device|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
132590|NCT01594749|Drug|Fosaprepitant dimeglumine|
132591|NCT01594749|Drug|Fosaprepitant Placebo|
132592|NCT01594749|Drug|Dexamethasone|
132593|NCT01594749|Drug|Ondansetron|
132594|NCT01594749|Drug|Dexamethasone Placebo|
132595|NCT01594749|Drug|Ondansetron Placebo|
132961|NCT01591304|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
132962|NCT00081250|Other|placebo|Given orally
132963|NCT01591317|Drug|Prasugrel|Tablets orally
132964|NCT01591330|Drug|LY2140023 Monohydrate (Reference)|80 mg tablet administered orally
132965|NCT01591330|Drug|LY2140023 Monohydrate (Test - Low)|80 mg tablet administered orally
132966|NCT01591330|Drug|LY2140023 Monohydrate (Test - Medium)|80 mg tablet administered orally
132967|NCT01591330|Drug|LY2140023 Monohydrate (Test - High)|80 mg tablet administered orally
132968|NCT01591343|Biological|Depigoid® (500 DPP/ml)|Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).
Dose:
Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection
132969|NCT01591356|Drug|siRNA-EphA2-DOPC|Starting dose: 450 ug/m2 by vein twice weekly on Days 1 and 4 of each 3 week cycle.
132970|NCT01591382|Drug|Ketamine|IV ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
132971|NCT01591382|Drug|Placebo|Patients who received placebo were given saline infusions
132972|NCT01591395|Procedure|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
132973|NCT00081263|Other|hydrocortisone/placebo|Given orally
132974|NCT01593202|Behavioral|Dialectical behavior therapy|16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.
The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively.
133282|NCT01626729|Behavioral|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
133283|NCT01626729|Behavioral|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
133284|NCT01626729|Behavioral|No label control group|No label control group
132514|NCT01596842|Drug|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
132515|NCT01596842|Other|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
132781|NCT01597297|Drug|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
132782|NCT01597297|Other|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
132783|NCT01597310|Drug|Warfarin|single doses at specified time periods
132784|NCT01597310|Drug|Dexpramipexole|multiple doses
132785|NCT00001520|Drug|neostigmine|
132786|NCT00082017|Drug|UCN-01 (7-hydroxystaurosporine)|UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days.
UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days.
132787|NCT01597336|Procedure|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
132788|NCT01597336|Procedure|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
132789|NCT01597349|Drug|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
132790|NCT01597362|Procedure|laparoscopy|Trocar access in laparoscopy
132791|NCT01590966|Drug|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
132792|NCT01590979|Drug|Ranolazine|1000mg, two times a day, 12 hour intervals
132793|NCT01590979|Drug|Placebo|two times a day, 12 hour intervals
132794|NCT01590992|Behavioral|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
133186|NCT01597895|Drug|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
133187|NCT01597908|Drug|Dabrafenib|dabrafenib 150 mg twice daily po
133188|NCT01597908|Drug|Vemurafenib|vemurafenib 960 mg twice daily po
133189|NCT00082134|Drug|ILX651|
133190|NCT01597908|Drug|Trametinib|trametinib 2 mg once daily po
133191|NCT01597934|Drug|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
133192|NCT01591720|Behavioral|Tailored Internet-based CBT for depression and anxiety|This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are "prescribed" following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
133193|NCT01591733|Drug|FOLFIRINOX|Four-14 day cycles
133194|NCT01591733|Drug|Capecitabine|Orally, for 10 days
133195|NCT01591733|Radiation|Short Course Radiation|Five or ten days
133196|NCT01591733|Procedure|Surgery|1-4 weeks after completion of capecitabine therapy
133197|NCT01591746|Drug|Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride in the pectoralis major muscle in each operated breast.
133198|NCT01591746|Drug|Sodium Chloride Solution|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast.
133199|NCT01591759|Drug|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
133200|NCT01591759|Drug|Placebo|Placebo arm of single-blind study
133201|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
133202|NCT00081289|Radiation|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
133220|NCT00081471|Drug|darbepoetin alfa|0.45 micrograms/kg sc (starting dose) weekly
132596|NCT01594749|Drug|Rescue Therapy|
132597|NCT01594762|Drug|Topical pexiganan cream 0.8%|14 days of treatment
132598|NCT00081653|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
132854|NCT01597362|Procedure|Laparoscopy|The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.
The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume.
132855|NCT01597362|Procedure|Laparoscopy|Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.
On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field.
132856|NCT01597362|Procedure|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
132857|NCT01597375|Drug|Prasugrel|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
132858|NCT01597388|Drug|AZD2014|Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
132859|NCT01597388|Drug|Fulvestrant|IM monthly after loading dose
132860|NCT00082043|Drug|Dutasteride|
132861|NCT01597401|Drug|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
132862|NCT01597401|Drug|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
132863|NCT01597401|Drug|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
132864|NCT01597401|Drug|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
132865|NCT01597401|Drug|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
132866|NCT01597414|Drug|Pertuzumab + trastuzumab|Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.
Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.
if T-DM1: 3.6 mg/kg IV, every 3 weeks.
133285|NCT01626742|Other|Ready to Drink Flavored Beverage|2 servings a day
133286|NCT01626742|Other|Ready to drink flavored beverage w/ AN 777|2 servings a day
133287|NCT01626755|Procedure|Sciatic name block|Ultrasound-guided sciatic nerve block.
133288|NCT01626781|Device|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
133289|NCT01626781|Other|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
133290|NCT01626794|Biological|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
133291|NCT01626794|Biological|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
133292|NCT00084669|Drug|zolpidem tartrate|
133293|NCT01626794|Biological|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
133294|NCT01626807|Behavioral|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
133295|NCT01626820|Biological|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
133296|NCT01626833|Drug|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
133297|NCT01626833|Biological|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
133298|NCT01626859|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for twelve weeks.
132442|NCT01596803|Dietary Supplement|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
132443|NCT01596803|Dietary Supplement|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
132795|NCT01590992|Behavioral|Relaxation therapy|Progressive muscle relaxation (Jacobson)
132796|NCT01591005|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
132797|NCT01591005|Procedure|endarterectomy|carotid endarterectomy
132798|NCT01591005|Procedure|carotid stenting|percutaneous transluminal angioplasty and stenting
133034|NCT01597661|Drug|Exposure to bupropion alone during the first trimester|The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.
Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves.
133035|NCT01591408|Device|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
133036|NCT01591421|Drug|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
133037|NCT01591421|Drug|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
133038|NCT01591434|Device|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
133039|NCT01591434|Device|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
133040|NCT01591447|Drug|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
133041|NCT01591447|Drug|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
133042|NCT01591460|Drug|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
133043|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
133044|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
133045|NCT00081263|Drug|celecoxib|Given orally
133046|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
133047|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
133048|NCT01591473|Drug|FluMist + Poly I:Poly C12U 50 ug|FluMist 0.2 ml and Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
133221|NCT01593592|Drug|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
133222|NCT01593592|Drug|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
133223|NCT01593592|Drug|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
133224|NCT01593605|Dietary Supplement|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
133225|NCT01593605|Dietary Supplement|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
133226|NCT01593605|Other|Placebo treatment|Placebo - one tablet taken twice a day by mouth
133227|NCT01593618|Behavioral|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
133228|NCT01593618|Other|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
133229|NCT01593631|Dietary Supplement|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
133230|NCT01593631|Dietary Supplement|Acid lactase|capsules containing 9000 FCC of acid lactase
133231|NCT00081471|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg sc (starting dose) once every 2 weeks
133232|NCT01595802|Device|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
133233|NCT01595815|Other|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
133234|NCT01595815|Other|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
133235|NCT01595828|Drug|Pitavastatin|
133236|NCT01595841|Drug|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
133237|NCT00081822|Drug|clofarabine|Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
133238|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
133239|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
132867|NCT01597414|Drug|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
132868|NCT01597427|Drug|Clonidine|Administration of 2 μg/kg of intravenous clonidine
132869|NCT01597427|Drug|Placebo|Injection of placebo solution.
133107|NCT00082095|Drug|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
133108|NCT01597713|Drug|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
133109|NCT01597713|Drug|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
133110|NCT01597713|Drug|placebo|Subjects will receive a single dose of oral placebo within each dose group
133111|NCT01597713|Drug|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
133112|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
133113|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
133114|NCT01597726|Drug|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D&E, repeated once 3 hours after the first dose if needed
133115|NCT01597726|Device|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D&E
133116|NCT01597739|Drug|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
133117|NCT01597739|Drug|Placebo|Form=capsule; route=oral use; twice daily.
133118|NCT00082095|Drug|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
133119|NCT01597752|Biological|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
133120|NCT01597765|Drug|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
133121|NCT01591551|Drug|Natalizumab (Tysabri)|300 mg IV every 4 weeks
132444|NCT00081939|Drug|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m^2. Maintenance year one 1.0mg/m^2 1,4,8,11 q 28 days.
132445|NCT01596803|Dietary Supplement|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
132446|NCT01596816|Radiation|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
132447|NCT01596816|Procedure|Fiducials placement|Placement of intra-prostatic markers for the tracking
132448|NCT01596816|Radiation|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
132449|NCT01599312|Device|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
132450|NCT01599325|Drug|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
132451|NCT00082290|Other|period of quiet time|
132452|NCT01599338|Drug|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
132453|NCT01599351|Radiation|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
132454|NCT01599364|Drug|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
132455|NCT01599377|Drug|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
132456|NCT01599377|Drug|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
132718|NCT01599520|Behavioral|Usual Care Only|Patients will be given the Spanish-language version of "Chemotherapy and You: Support for People with Cancer" ("La quimioterapia y usted: Apoyo para las personas con cancer") published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health.
133049|NCT01591473|Drug|FluMist + Poly I:Poly C12U 200 ug|FluMist 0.2 ml and Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
133050|NCT01591473|Drug|FluMist + Poly I:Poly C12U 500 ug|FluMist 0.2 ml and Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
133051|NCT01591473|Drug|FluMist + Poly I:Poly C12U 1250 ug|FluMist 0.2 ml and Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
133052|NCT01591473|Drug|FluMist + Placebo|FluMist 0.2 ml and Placebo; 3 doses; nasal administration every 28 days
133352|NCT01624311|Other|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
133353|NCT00084565|Drug|estramustine phosphate sodium|
133354|NCT01624337|Drug|DHA-piperaquine|Drug: Dihydroartemisinin piperaquine
40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)
133355|NCT01624337|Drug|placebo|
133356|NCT01624363|Other|Diagnosis of a previously undetected pancreatic cyst|patients identified to have a pancreatic cyst, will need to be followed via imaging studies.
133357|NCT01624376|Drug|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
133358|NCT01624376|Drug|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
133359|NCT01624389|Drug|F18-AV45|This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
133360|NCT01626859|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for twelve weeks.
133361|NCT01626872|Drug|MP-214 low dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
133362|NCT01626872|Drug|MP-214 middle dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
133363|NCT00084669|Procedure|management of therapy complications|
133364|NCT01626872|Drug|MP-214 high dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
133365|NCT01626872|Drug|Risperidone|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
133240|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
133512|NCT01624597|Behavioral|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
133513|NCT01624610|Other|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
133514|NCT01624636|Drug|Placebo|
133515|NCT01624636|Drug|LFG316|
133516|NCT01624636|Drug|LFG316|
133517|NCT01624649|Drug|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
133518|NCT01624649|Drug|Atomoxetine|Form = tablet, route = oral;
133519|NCT00084578|Drug|rosiglitazone maleate|
133520|NCT01624662|Drug|fluticasone propionate|
133521|NCT01624662|Drug|fluticasone propionate|
133522|NCT01624675|Drug|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
133523|NCT01624675|Drug|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
133524|NCT01624688|Procedure|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
133525|NCT01624701|Other|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
133526|NCT01624714|Drug|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
133527|NCT01627080|Other|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
133528|NCT01627093|Other|Chart Review|Both retrospective and prospective patient charts reviewed to determine pretreatment characteristics, time to progression and overall survival of patients.
133122|NCT01591564|Behavioral|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
133123|NCT01591577|Other|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
133414|NCT01624402|Behavioral|Education on Stroke and Depression (ESD)|Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.
Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.
Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.
ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy).
133415|NCT01624402|Behavioral|Ecosystem Focused Therapy (EFT)|EFT offers an action-oriented, new perspective about the subject's recovery;
It provides an adherence enhancement structure;
It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;
It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;
It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities.
133416|NCT01624428|Drug|Varenicline|1 mg bid varenicline titrated over a 2 week period
133417|NCT01624428|Drug|Placebo|1 mg bid placebo titrated over a 2 week period
133418|NCT00084565|Drug|paclitaxel|
133419|NCT01624441|Drug|Dinaciclib|Given IV
133420|NCT01624441|Drug|Epirubicin Hydrochloride|Given IV
133421|NCT01624441|Other|Laboratory Biomarker Analysis|Correlative studies
133422|NCT01624454|Other|Laxabon|4 l PEG solution split dose cleansing
133423|NCT01624454|Other|CitraFleet|Small volume osmotic bowelcleansing
133424|NCT01624467|Biological|Necitumumab|800 mg necitumumab, administered once per week IV
133425|NCT01624480|Drug|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
133426|NCT01624493|Drug|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
132719|NCT01599533|Other|blood samples|
132720|NCT01599559|Other|observation|observation
132721|NCT01599559|Radiation|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
132722|NCT01592929|Radiation|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
132723|NCT01592929|Other|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
132724|NCT01592929|Radiation|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
132725|NCT00081367|Behavioral|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
132726|NCT01592929|Radiation|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
132727|NCT01592929|Other|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
132728|NCT01592942|Device|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
132729|NCT01592942|Device|Progrip|self-gripping mesh
132730|NCT01592942|Device|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
132731|NCT01592955|Device|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
132732|NCT01592968|Radiation|Stereotactic Radiosurgery (SRS)|Dose based on largest diameter lesion as measured on volumetric MRI, as follows: 20-24 Gy for lesions 2 cm or less in size, 16-18 Gy for lesions >2-2.5 cm in size, and 12-16 Gy for lesions >2.5-3.5 cm in size. SRS performed on day 1.
132733|NCT01592968|Radiation|Whole Brain Radiation Therapy (WBRT)|Fractionated radiation delivered to whole brain daily to deliver a dose of 30 Gy in 10 fractions.
132734|NCT01592968|Behavioral|Questionnaires|Three (3) sets of quality of life (QOL) questionnaires completed 1, 4, 6, 9, and 12 months after assigned treatment.
132735|NCT01592968|Behavioral|Cognitive Function Tests|7 cognitive function tests completed 1, 4, 6, 9, and 12 months after assigned treatment.
132975|NCT01593202|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
132976|NCT01593215|Drug|Yohimbine|Yohimbine capsule
133366|NCT01626885|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for four weeks, then flexible dose of MP-214
133367|NCT01626898|Behavioral|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
133368|NCT01626898|Behavioral|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
132516|NCT01596842|Other|cholecalciferol|if baseline 25-hydroxyvitamin D levels are < 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
132517|NCT01596855|Drug|FG-4592|TIW dosing, capsule
132518|NCT00081939|Drug|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
132519|NCT01596855|Drug|Epoetin Alfa|TIW
132520|NCT01596868|Drug|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
132521|NCT01596868|Drug|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
132522|NCT01596894|Drug|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
132523|NCT01596894|Drug|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
132524|NCT01596907|Drug|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
132525|NCT01596907|Drug|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
132526|NCT01596920|Other|Tissue|Allograft Tissue Cellular Repair Matrix
132527|NCT01596920|Other|Control|Non-adherent Dressing
133529|NCT00084695|Drug|cyclophosphamide|Given IV
133530|NCT01627093|Behavioral|Questionnaires|Completion of 5 questionnaires before treatment begins, at each visit during treatment, and again at all follow-up visits. It should take about 30 minutes to complete the questionnaires each time.
132663|NCT01594827|Drug|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
132664|NCT01594827|Drug|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
132665|NCT01594840|Device|Changing chat|Diapers with tips
132666|NCT01594853|Behavioral|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
132667|NCT01594866|Drug|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
132668|NCT01594866|Drug|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
132669|NCT01594879|Device|MIrena(LNG-IUS), oral MPA|General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate
132670|NCT01594892|Radiation|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
132671|NCT01594905|Drug|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
132672|NCT00081731|Drug|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
132673|NCT01594918|Drug|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
132674|NCT01594918|Drug|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
132675|NCT01594918|Drug|Prednisone|5 mg PO BID
132676|NCT01594918|Drug|Pegfilgrastim|6 mg, SC, once every 21 days
132677|NCT01594931|Drug|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1
132678|NCT01594957|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
132679|NCT01594970|Drug|Bimatoprost 0.01%|1 drop in the affected eye(s), administered in the evening for 12 weeks.
133427|NCT01624493|Drug|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
133428|NCT01624493|Drug|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
133429|NCT00001568|Drug|2-Fluoro-2-deoxyglucose|
133430|NCT00084565|Drug|topotecan hydrochloride|
133431|NCT01624493|Drug|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
133432|NCT01624493|Drug|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
132599|NCT01594762|Drug|Topical placebo cream|14 days of treatment
132600|NCT01594762|Other|Standard wound care|14 days of treatment
132601|NCT01594775|Drug|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
132602|NCT01594775|Drug|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
132603|NCT01594801|Device|InsuPad|Use of the InsuPad for at least 3 times a day.
132604|NCT01594814|Procedure|RFA|radiofrequency ablation of slow pathway or accesory pathway
132605|NCT01594827|Drug|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
132606|NCT01594827|Drug|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
132607|NCT01596959|Procedure|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
132608|NCT01596972|Device|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
132977|NCT01593228|Drug|Iniparib (SAR240550/BSI-201)|Pharmaceutical form:Solution
Route of administration: Intravenous
132978|NCT01593228|Drug|Carboplatin|Pharmaceutical form:Solution
Route of administration: Intravenous
132979|NCT01593228|Drug|Doxorubicin HCL liposome injection|Pharmaceutical form:Solution
Route of administration: Intravenous
132980|NCT01593228|Drug|Gemcitabine|Pharmaceutical form:Solution
Route of administration: Intravenous
132981|NCT01593228|Drug|Irinotecan|Pharmaceutical form:Solution
Route of administration: Intravenous
132982|NCT01593228|Drug|Paclitaxel|Pharmaceutical form:Solution
Route of administration: Intravenous
132983|NCT01593228|Drug|Topotecan|Pharmaceutical form:Solution
Route of administration: Intravenous
132984|NCT00081406|Behavioral|Family CBT|
132985|NCT01593241|Drug|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
132986|NCT01593241|Radiation|Involved node RT|Involved node RT
132987|NCT01593254|Drug|Imatinib|
132988|NCT01593254|Drug|Dasatinib|
132989|NCT01593267|Procedure|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
132990|NCT01593267|Procedure|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
132991|NCT01593280|Device|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
132992|NCT01593280|Drug|intrathecal morphine|0.3 mg
132993|NCT01593293|Drug|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
132994|NCT01593293|Drug|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
132995|NCT00081406|Behavioral|Education/Support/Attention|
132996|NCT01593306|Drug|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
132528|NCT01596933|Dietary Supplement|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
132529|NCT00081952|Drug|L-norleucine|
132530|NCT01596933|Dietary Supplement|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
132531|NCT01596946|Behavioral|Contact tracing mode test at clinic|
132532|NCT01596946|Behavioral|Self-sampling at home - Sent Test Kit|
132533|NCT01596959|Procedure|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
132534|NCT01598701|Drug|Placebo|100 mL Normal Saline
132535|NCT01598714|Device|Darco shoe|Darco shoe
132799|NCT01591018|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
132800|NCT00081224|Procedure|surgery|
132801|NCT01591018|Procedure|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
132802|NCT01591031|Drug|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
132803|NCT01591031|Drug|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
132804|NCT01591044|Drug|Placebo|Placebo x 1, 1 puff bid Placebo x 2, 2 puffs bid
132805|NCT01591044|Drug|R940343|R343 1mg, 1 puff bid R343 2mg, 2 puffs bid
132806|NCT01591057|Dietary Supplement|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
132807|NCT01591057|Dietary Supplement|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
132808|NCT01591057|Dietary Supplement|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
132809|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
132810|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
132811|NCT00081237|Drug|OSI-7904L|
132680|NCT01594983|Drug|LCQ908|
132681|NCT01594983|Drug|Fenofibrate|Fenofibrate once daily 12 weeks
132682|NCT01594983|Drug|Fish Oil|Fish Oil once daily for 12 weeks
133203|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
133204|NCT01591785|Drug|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
133205|NCT01591785|Drug|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
133206|NCT01591798|Procedure|Robotic surgery|Robotic assisted rectal resection
133207|NCT01591798|Procedure|Laparoscopic surgery|Laparoscopic assisted rectal resection
133208|NCT01591811|Radiation|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
133209|NCT01591811|Radiation|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
133210|NCT01593527|Drug|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
133211|NCT01593540|Device|metal-free interdental brush|one time per day
133212|NCT01593540|Device|metal-core interdental brush|one time per day
133213|NCT01593553|Other|ECG screening for atrial fibrillation|ECG screening for atrial fibrillation with intermittent ECG recording for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
133214|NCT01593566|Drug|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
133215|NCT01593566|Drug|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
133216|NCT01593579|Behavioral|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine & standing heart rate & blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
132609|NCT01596985|Procedure|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
132610|NCT01596985|Procedure|Cystectomy|Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic "chocolate fluid" evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C).
132611|NCT01596998|Drug|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
132870|NCT01597440|Drug|N-carbamylglutamate|Active NCG & Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).
The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.
This drug will be administered for 7 days after admission or until discharge (whichever is sooner).
132871|NCT00082043|Drug|Placebo oral capsule|
132872|NCT01591096|Drug|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
132873|NCT01591122|Drug|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
132874|NCT01591122|Drug|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
132875|NCT01591135|Drug|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
132876|NCT01591135|Drug|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
132877|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
133299|NCT01626859|Drug|MP-214 middle dose|Patients who meet eligibility criteria will be administered a once daily oral middle dose of MP-214 for twelve weeks.
133300|NCT01619657|Drug|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
133301|NCT01619670|Device|Apligraf|non adhesive layer
133302|NCT01619683|Drug|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
133303|NCT01619683|Drug|Placebo|1 placebo capsule per day, oral
133304|NCT01619696|Procedure|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
133305|NCT01619709|Other|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
133306|NCT01619761|Drug|Lenalidomide|10 mg by mouth on days -8 to -2.
133307|NCT01619761|Drug|Fludarabine monophosphate|40 mg/m2 by vein on days -7 to -4.
133308|NCT00084123|Behavioral|Healing Touch Therapy|
133309|NCT01619761|Drug|Melphalan|140 mg/m2 by vein on day -4.
133310|NCT01619761|Procedure|NK Infusion|The NK cell infusion will be administered intravenously on day -2 over a period of 30 minutes. The NK dose infused will be 5x 106/kg. Remaining cells will be discarded if not needed for laboratory studies.
133311|NCT01619761|Procedure|CB Infusion|On Day 0, the unmanipulated products (smaller cord blood unit and the remnant of the larger unit) will be infused.
133312|NCT01619761|Drug|Tacrolimus|0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no GvHD is present.
133313|NCT01619761|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth Days -3 to Day +100 in the absence of GvHD.
133314|NCT01619761|Drug|Rituximab|375 mg/m2 by vein on day -8 for CD20 positive participants.
133315|NCT01619774|Drug|GSK2118436|Starting dose 150 mg by mouth twice a day.
133316|NCT01619774|Drug|GSK1120212|2 mg by mouth daily.
132812|NCT01591083|Drug|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score >=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score <6 are assigned to the control group.
In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days.
132813|NCT01593007|Other|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
132814|NCT01593007|Other|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
132815|NCT01593020|Drug|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
132816|NCT01593020|Drug|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
132817|NCT01593020|Drug|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
132818|NCT00081380|Drug|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
133053|NCT01591499|Device|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
133054|NCT01591499|Device|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
133055|NCT01591525|Behavioral|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
133056|NCT00081276|Drug|triapine|Given IV
133057|NCT01591525|Behavioral|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
133058|NCT01591525|Behavioral|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
133059|NCT01593306|Drug|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
133060|NCT01593319|Drug|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
133217|NCT01593579|Other|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
133218|NCT01593592|Dietary Supplement|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
133219|NCT01593592|Dietary Supplement|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
133241|NCT01595854|Drug|dabigatran etexilate|low dose dabigatran
133242|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
133243|NCT01595867|Drug|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
133244|NCT01595867|Drug|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
133245|NCT01595867|Drug|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
133246|NCT01595880|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
133247|NCT01595880|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
133248|NCT00001512|Drug|GM-CSF|
133249|NCT00081822|Drug|Ara-C|Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 & 3.
133250|NCT01595893|Drug|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
133251|NCT01595893|Drug|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
133252|NCT01595906|Procedure|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
133253|NCT01595919|Other|Nutritional Intervention|Ad libitum amounts of beverage at a meal
133254|NCT01595932|Dietary Supplement|α-galactosidase|Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:
children < 20kg: 4 drops;
children > 20kg and < 40kg: 8 drops;
children > 40kg: 1 tablet.
133255|NCT01595932|Dietary Supplement|Placebo|Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:
children < 20kg: 4 drops;
children > 20kg and < 40kg: 8 drops;
children > 40kg: 1 tablet.
132878|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
132879|NCT01591148|Drug|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
132880|NCT01591161|Drug|Mapracorat|1 drop of study medication into the study eye QID for 14 days
132881|NCT00001507|Drug|Monoclonal Antibody 3A1|
132882|NCT00081237|Drug|oxaliplatin|
132883|NCT01591161|Drug|Placebo|1 drop of vehicle into the study eye QID for 14 days.
132884|NCT01591187|Other|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
132885|NCT01591187|Other|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
133124|NCT01591590|Other|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
133125|NCT01591590|Other|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
133126|NCT01591590|Other|Blood samples (plasma preparation and CTC)|
133127|NCT01591603|Procedure|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
133128|NCT01591603|Procedure|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
133129|NCT00081276|Drug|cisplatin|Given IV
133130|NCT01591616|Drug|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
133131|NCT01591629|Drug|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
133132|NCT01591629|Drug|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
133133|NCT01591629|Drug|Placebo|Placebo
133134|NCT01591655|Drug|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
133135|NCT01591655|Drug|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
133317|NCT01619800|Device|Blended Sensor Optimization (BSO)|At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:
HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized.
132457|NCT01599390|Other|Data collection|The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.
Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted.
132458|NCT01599403|Procedure|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
132459|NCT01599403|Procedure|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
132460|NCT01599416|Dietary Supplement|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
132461|NCT01599468|Drug|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
132462|NCT00082290|Behavioral|questionaire about pain|
132463|NCT01599468|Drug|saline serum|The Placebo group received normal saline with the same volumes
132464|NCT01592513|Device|BIS monitor|BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).
BIS values between 80-90 represent values corresponding to light/moderate sedation.
BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs.
132465|NCT01592526|Other|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
132466|NCT01592526|Other|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
132467|NCT01592565|Other|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
129348|NCT01568645|Drug|Carvedilol|
129349|NCT01568645|Drug|Imatinib|
129350|NCT01568684|Other|Citalopram|Treatment
129351|NCT01568723|Genetic|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
129352|NCT01570803|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
129353|NCT01570803|Device|Complete SE Stent|same to SMART CONTROL Stent
129354|NCT01570816|Device|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
129355|NCT01570829|Drug|Dietressa|Safety and Efficiency of New Dosage Schedule
129356|NCT01570829|Drug|Placebo|Safety and Efficiency of New Dosage Schedule
129357|NCT01570842|Other|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
129358|NCT01570842|Procedure|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
129359|NCT01570868|Drug|Ponatinib|Starting dose: 30 mg by mouth once daily.
129360|NCT01570894|Drug|Quetiapine Fumarate|25 mg tablet
129361|NCT00079573|Behavioral|Ornish diet (very low fat)|
129362|NCT01570907|Drug|Quetiapine Fumarate|25 mg tablet
129363|NCT01570920|Behavioral|physical training|walking many times a week
129364|NCT01570933|Device|NivNava|Non-invasive Nava ventilation mode on nasal cannula
129365|NCT01570933|Device|Cpap|nasal Cpap on nasal cannula
129661|NCT01564212|Other|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
129662|NCT01564225|Drug|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
130023|NCT01567189|Behavioral|Cardiac rehabilitation|Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.
Health education sessions and relaxation sessions: one per week.
Smoking and diet checking: as recommended by doctor.
130024|NCT01567189|Behavioral|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
130025|NCT01567202|Procedure|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
130026|NCT01567202|Drug|Chemotherapy|Temozolomide(TMZ), 200mg·m^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
129135|NCT01579448|Biological|Shanchol™, oral cholera vaccine|This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.
Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension.
129136|NCT01579448|Biological|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.
Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension.
129137|NCT01579448|Other|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
129138|NCT01579461|Drug|mirabegron|oral
129139|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
129140|NCT01579474|Drug|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
129141|NCT00080496|Drug|Imipenem|
129142|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
129143|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
129144|NCT01579487|Device|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
129818|NCT01564459|Drug|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
129819|NCT01564472|Other|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
129820|NCT01564485|Procedure|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
129821|NCT01564485|Drug|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
129822|NCT01564498|Other|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
129823|NCT01564511|Device|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
129824|NCT01564511|Other|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
128935|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
128936|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
128937|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
128938|NCT00080080|Drug|talabostat (PT-100) tablets|
128939|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
128940|NCT01574729|Drug|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
128941|NCT01574729|Procedure|Surgery|Surgery plus post-surgery chemotherapy
128942|NCT01574742|Drug|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
128943|NCT01574768|Procedure|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
128944|NCT01574781|Procedure|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
128945|NCT01574781|Procedure|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
129587|NCT01566539|Drug|Lorazepam|Dosage and details described in arm
129588|NCT01566552|Drug|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
129589|NCT01566565|Drug|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
129590|NCT01566578|Drug|Human recombinant epidermal growth factor|topical
129591|NCT01566578|Other|Placebo cream|Dermal cream without EGF
129592|NCT01566591|Device|Deep TMS Treatment|24 TMS treatments over 6 weeks .
129593|NCT01566591|Device|Sham Treatment|24 TMS treatments over 6 weeks
129594|NCT01566604|Drug|NVA237|Delivered via a single dose dry powder inhaler
129595|NCT01566604|Drug|Placebo|Delivered via a single dose dry powder inhaler
129596|NCT00079287|Drug|docetaxel|
129597|NCT01566617|Other|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
129598|NCT01566617|Other|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
129599|NCT01566630|Drug|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
129875|NCT00079625|Drug|Th2/Tc2 Cells|
129876|NCT01571453|Drug|Vortioxetine (Lu AA21004)|10 mg/day
129877|NCT01571453|Drug|Venlafaxine extended release|150 mg/day
129878|NCT01571466|Drug|Vaccination|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml
3 immunisations at week 0, 4 and 16
129879|NCT01571466|Drug|Placebo|3 immunisations at week 0, 4 and 16
129880|NCT01571479|Procedure|2- mini-instrument|The patient was positioned in the supine position with the head and right side up.
Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.
A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups.
129881|NCT01571492|Procedure|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
129663|NCT01564238|Other|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
129664|NCT01564238|Other|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
129665|NCT01564251|Drug|GDC-0575|multiple doses
129666|NCT00079144|Biological|therapeutic autologous lymphocytes|
129667|NCT01564251|Drug|gemcitabine|multiple doses
129668|NCT01564264|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
129669|NCT01564277|Drug|rasburicase|Given IV
129670|NCT01564277|Drug|allopurinol|Given PO
129671|NCT01564290|Dietary Supplement|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
129672|NCT01566630|Drug|RLX030|RLX030 1 mg/mL vials
129673|NCT01566643|Drug|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
129674|NCT01566643|Drug|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
129675|NCT01566643|Drug|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
129676|NCT01566656|Drug|total lymphoid irradiation and anti-thymocyte globulin|TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.
ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.
Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.
GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0
129677|NCT01566669|Drug|Parecoxib Sodium|Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
129678|NCT01566669|Drug|Normal saline|Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
129145|NCT01579500|Drug|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
129146|NCT01579500|Drug|normal saline|Subcutaneous injection of normal saline
129147|NCT01579513|Drug|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
129148|NCT01579513|Drug|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
129149|NCT01579526|Drug|FP01|comparison of different dosages
129150|NCT01579539|Drug|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
129151|NCT01579539|Drug|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
129152|NCT00080496|Drug|Cilastatin|
129424|NCT01568762|Drug|VAK694|Intravenous infusion
129425|NCT01568762|Drug|VAK694 placebo|Intravenous infusion
129426|NCT01568762|Drug|QAX576|Intravenous infusion
129427|NCT01568762|Drug|QAX576 placebo|Intravenous infusion
129428|NCT01568775|Drug|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
129429|NCT00079417|Radiation|iodine I 125|Undergo radioactive therapy
129430|NCT01568788|Biological|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
129431|NCT01568788|Biological|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
129432|NCT01568788|Biological|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
129433|NCT01568801|Behavioral|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
129434|NCT01568814|Drug|Low volume PEG|low volume polyethylene glycol 2 liter one time
129435|NCT01568814|Drug|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
128946|NCT01574794|Other|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
128947|NCT01574794|Other|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
128948|NCT01574807|Drug|3% mepivacaine/2% lidocaine with 1:100,000 epinephrine combo|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine compared to an injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
128949|NCT00080080|Drug|Docetaxel|
128950|NCT01574820|Drug|placebo tablet|placebo tablet for 6 months
128951|NCT01574820|Drug|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
128952|NCT01574833|Device|pulsed electromagnetic field|PEMF treatment
128953|NCT01574833|Device|sham|sham treatment
128954|NCT01574859|Other|levothyroxine|titration of T4 according to biochemical values
128955|NCT01574872|Device|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
129219|NCT01579604|Procedure|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
129220|NCT00080509|Drug|KOS-862|
129221|NCT01579617|Behavioral|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
129222|NCT01579617|Behavioral|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
129223|NCT01579630|Drug|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
129224|NCT01579630|Drug|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
129882|NCT01571492|Procedure|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
129883|NCT01571505|Biological|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
129884|NCT01571518|Drug|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
129885|NCT01571518|Drug|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
129886|NCT00001464|Procedure|Oxygen therapy|
129887|NCT00079638|Drug|Niacin|
129888|NCT01571544|Device|Thermal suit|Thermal suit
129889|NCT01571544|Other|Conventional clothing|Conventional clothing
129890|NCT01571557|Drug|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
129891|NCT01571570|Drug|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
129892|NCT01571570|Drug|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
129893|NCT01571570|Drug|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
129894|NCT01571570|Drug|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
129895|NCT01571570|Drug|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
129012|NCT01572688|Drug|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
129013|NCT01572701|Drug|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
129014|NCT01572714|Behavioral|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
129015|NCT00079794|Drug|mistletoe|
129016|NCT01572714|Behavioral|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
129951|NCT01569581|Biological|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
129952|NCT01569581|Biological|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
129953|NCT01569594|Device|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
129954|NCT00079456|Drug|temsirolimus|Given IV
129955|NCT01569607|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
129956|NCT01569607|Device|Sham stimulation|Sham stimulation
129957|NCT01569620|Behavioral|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
129958|NCT01569620|Behavioral|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
129959|NCT01569620|Behavioral|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
129960|NCT01569633|Drug|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
129961|NCT01569633|Drug|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
129962|NCT01569633|Drug|placebo|The dose of sugar water is 1 ml per 8 hours.
129963|NCT01569659|Drug|Lurasidone|80 mg/day for up to 30 weeks
129964|NCT01569659|Drug|Lurasidone|Up to 240 mg/day for up to 30 weeks
129965|NCT01571700|Procedure|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension >5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
129966|NCT01571726|Drug|Fluciclatide|7mCi
129967|NCT00079638|Drug|Ezetimibe|
129968|NCT01571765|Other|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
129452|NCT01571050|Drug|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
129453|NCT00079586|Drug|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
129454|NCT01571050|Drug|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
129455|NCT01571063|Drug|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
129456|NCT01571063|Drug|Placebo|Placebo Tbl. p.o.
129457|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
129458|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
129459|NCT01571076|Other|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
129460|NCT01571076|Other|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
129757|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
129758|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
129759|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
129760|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
129761|NCT01566760|Drug|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
129762|NCT01566773|Drug|PT001 MDI|Administered as two puffs BID for 14 days
129763|NCT01566773|Drug|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
129764|NCT01566773|Drug|PT001 Placebo MDI|
129765|NCT01566786|Drug|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
129766|NCT01566786|Drug|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
129225|NCT01572896|Behavioral|Standard Medical Care and JIA Resource Center|The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA ("JIA Resource Centre") and online assessments.
129226|NCT01572909|Drug|Bendavia (MTP-131)|0.05 mg/kg/hr
129227|NCT01572909|Drug|Placebo|Identically appearing placebo
129228|NCT01572922|Device|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
129229|NCT01572922|Device|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
129230|NCT01572922|Procedure|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
129520|NCT01568905|Other|High level nicotine cigarette|smoke the study cigarette exclusively for one week
129521|NCT01568918|Drug|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
129522|NCT01568918|Other|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
129523|NCT01568931|Drug|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
129524|NCT01568931|Drug|Saline|intracoronary, saline, bolus 1 cc
129525|NCT01568944|Drug|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
129526|NCT01568944|Procedure|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
129527|NCT00079417|Drug|vincristine sulfate|Given IV
129528|NCT01568957|Behavioral|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
129017|NCT01574885|Device|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
129018|NCT01574898|Drug|V0474 - A mg|Single oral administration
129019|NCT00080093|Behavioral|Individual feedback and specially-tailored manuals|Individual feedback and specially-tailored manuals
129020|NCT01574898|Drug|V0474 - B mg|Single oral administration
129021|NCT01574898|Drug|V0474 - C mg|Single oral administration
129022|NCT01574898|Drug|V0018 - B mg|Single oral administration
129023|NCT01574898|Drug|Niquitin® Fresh Mint 4 mg|Single oral administration
129024|NCT01574924|Other|No intervention.|There are no interventions in this observational study.
129025|NCT01574937|Drug|Cabozantinib|28 day cycle
129026|NCT01574937|Drug|Abiraterone|28 day cycle
129027|NCT01574976|Behavioral|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
129028|NCT01574989|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
129029|NCT01574989|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35^2 electrodes.
129030|NCT00080093|Behavioral|General HIV information feedback and the best-available information|General HIV information feedback and the best-available information
129031|NCT01575002|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
129287|NCT01563510|Procedure|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
129288|NCT01563523|Drug|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
129289|NCT01563523|Drug|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
129969|NCT01571778|Behavioral|Hand Hygiene before Donning Non-sterile Gloves|In the "No Intervention" arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
In the Experimental arm, they will be instructed to don gloves without washing their hands as described.
129086|NCT01572740|Drug|insulin|All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
129087|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
129088|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
129089|NCT00079807|Drug|Alpha-Lipoic Acid|
129090|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
129091|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
129092|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
129093|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
129094|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
129095|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
129096|NCT01572766|Other|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
129097|NCT01575054|Drug|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
129098|NCT00080106|Biological|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
129767|NCT00079287|Drug|vinorelbine tartrate|
129768|NCT01566799|Drug|Metformin|metformin 500 mg/day po for 24 weeks.
129769|NCT01566812|Behavioral|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
129770|NCT01566812|Behavioral|Usual care|Usual care applied in the hospital
129771|NCT01566825|Drug|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
129772|NCT01566825|Drug|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
129773|NCT01566838|Drug|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
129774|NCT01566838|Drug|Standard acute pain management|A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.
Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.
The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3.
130068|NCT01572116|Drug|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
130069|NCT01572116|Drug|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
130070|NCT01572129|Drug|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
130071|NCT01572129|Drug|Placebo|Placebo in addition to the chronic daily dose of 75 mg
130072|NCT01572155|Procedure|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
130073|NCT01572155|Procedure|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
130074|NCT01572168|Other|Acupuncture|Eight session of weekly acupuncture
130075|NCT01564914|Biological|Chimeric monoclonal antibody (TRC105) to CD105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
130076|NCT01564927|Device|Electroacupuncture to right LI4 and LI11 (ITO, EX-160)|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
129529|NCT01568970|Behavioral|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
129530|NCT01568970|Behavioral|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
129531|NCT01571102|Behavioral|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
129532|NCT00079599|Drug|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
129533|NCT01571115|Behavioral|Physical Exercise|
129534|NCT01571128|Other|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
129535|NCT01571128|Other|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
129536|NCT01571128|Drug|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
129537|NCT01571128|Behavioral|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
129538|NCT01571141|Device|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
129539|NCT01571167|Drug|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
129825|NCT01564524|Procedure|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
129826|NCT00079157|Biological|incomplete Freund's adjuvant|
129827|NCT01564537|Drug|Ixazomib|Ixazomib capsules
129828|NCT01564537|Drug|Lenalidomide|Lenalidomide capsules
129829|NCT01564537|Drug|Dexamethasone|Dexamethasone tablets
129830|NCT01564537|Drug|Placebo|Ixazomib placebo-matching capsules
129290|NCT00079118|Drug|docetaxel|
129291|NCT01563536|Drug|ABT-267|Tablet
129292|NCT01563536|Drug|ABT-450|Tablet
129293|NCT01563536|Drug|ABT-333|Tablet
129294|NCT01563536|Drug|Ritonavir|Capsule
129295|NCT01563536|Drug|Ribavirin|Tablet
129296|NCT01563562|Drug|Bardoxolone Methyl|Oral, Single dose
129297|NCT01563575|Other|WHO-HPH Recognition Process|Undergo WHO-HPH recognition Process, including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
129298|NCT01563588|Behavioral|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
129299|NCT01563601|Drug|Obatoclax Mesylate, Carboplatine and Etoposide|Obatoclax Mesylate:
30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.
Carboplatin:
Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles
Etoposide:
100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles
129300|NCT01563601|Drug|Carboplatin and Etoposide|Carboplatin:
Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.
Etoposide:
100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles
129301|NCT00079118|Drug|irinotecan hydrochloride|
129302|NCT01563614|Radiation|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
129303|NCT01563614|Drug|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
129304|NCT01563614|Drug|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
129305|NCT01563627|Other|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
129306|NCT01563627|Device|Magnetic Resonance Imaging|
129600|NCT01568983|Dietary Supplement|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
129601|NCT01568983|Dietary Supplement|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
129099|NCT01575080|Device|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
129100|NCT01575093|Other|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
129101|NCT01575106|Device|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
129366|NCT01570946|Behavioral|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
129367|NCT01570959|Drug|Quetiapine Fumarate|300 mg tablet
129368|NCT01570972|Behavioral|Group Cognitive Behavioral Therapy|weekly
129369|NCT01570972|Behavioral|Multifamily Group Psychoeducation|twice monthly
129370|NCT01570985|Drug|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
129371|NCT01570985|Drug|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
129372|NCT00079586|Drug|Heparin|Unfractionated Heparin per institutional practice
129373|NCT01570998|Radiation|Intraoperative radiation therapy (IORT)|The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial.The Intrabeam is FDA approved for use in any part of the body. For breast irradiation, the radiation source is covered by a spherical applicator that is used to uniformly conform the lumpectomy cavity around the radiation source, enabling delivery of an accurately calculated dose to a prescribe depth.
129374|NCT01563640|Other|washing|normal washing of school uniforms, without permethrin insecticide impregnation
129375|NCT01563653|Procedure|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
129376|NCT01563705|Procedure|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
129377|NCT01563705|Procedure|Manual dexterity assessment|Purdue pegboard test
129378|NCT00079131|Biological|oblimersen sodium|Given IV
130077|NCT00079183|Drug|sirolimus|Given PO
130078|NCT01564927|Device|Sham Electroacupuncture to knee caps|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
130079|NCT01564927|Device|Sham electroacupuncture to LI4 and LI11|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
130080|NCT01564979|Drug|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
130081|NCT01564979|Drug|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
130082|NCT01564992|Other|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
130083|NCT01565018|Drug|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
130084|NCT01565018|Drug|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
130085|NCT01565031|Procedure|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
130086|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
130087|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
129171|NCT01572896|Behavioral|Taking Charge: Managing JIA Online|In addition to standard medical care, adolescents in the experimental group will receive the "Taking Charge: Managing JIA Online" Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French.
129172|NCT01575223|Device|NeilMed sinus rinse|High volume saline irrigation
129173|NCT01575223|Device|Salinex|Low volume saline irrigation
129174|NCT01575236|Device|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
129175|NCT01575236|Device|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
129176|NCT00080119|Drug|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
129831|NCT01564550|Drug|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
129832|NCT01564550|Drug|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
129833|NCT01564550|Other|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
129834|NCT01564550|Other|no diet|The subjects will ingest a non-restricted diet prior to the study day.
129835|NCT01566864|Behavioral|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
129836|NCT01566864|Behavioral|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
129837|NCT00079300|Drug|imiquimod|
128956|NCT01574872|Device|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
128957|NCT01574885|Device|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
128958|NCT01576809|Drug|IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin|Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
128959|NCT01576822|Other|This protocol will utilize a sauna as the primary method of detoxification.|This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.
High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).
Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna).
128960|NCT01576848|Dietary Supplement|Protein|Subjects will receive a drink containing 20 gram intrinsically labelled casein.
Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).
129602|NCT01568983|Dietary Supplement|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
129603|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
129604|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
129605|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
129606|NCT01569022|Device|CPAP|CPAP Treatment for 12 weeks
129607|NCT00079417|Radiation|radiation therapy|Undergo radioactive therapy
129608|NCT01569022|Device|MAD|MAD Treatment for 12 weeks
129609|NCT01569035|Drug|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
129610|NCT01569048|Drug|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
129611|NCT01569048|Drug|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
129612|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
129613|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
129614|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
129615|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
129616|NCT01569074|Drug|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
129617|NCT01569074|Drug|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
129618|NCT00079430|Procedure|adjuvant therapy|
129619|NCT01569074|Drug|Placebo|Placebo twice daily for 12 weeks
129620|NCT01569087|Biological|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
129621|NCT01569087|Biological|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
129379|NCT01563718|Drug|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
129380|NCT01563731|Drug|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
129381|NCT01563744|Procedure|EGD-assisted administration of colonoscopy prep|Control group receive standard colonoscopy prep. Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
129382|NCT01563770|Dietary Supplement|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
129383|NCT01563770|Dietary Supplement|Placebo|3 placebo capsules, twice daily for four consecutive weeks
129679|NCT00079287|Drug|gemcitabine hydrochloride|
129680|NCT01566695|Drug|Oral Azacitidine|300mg daily, First 21 days of each 28-day cycle
129681|NCT01566695|Drug|Placebo|Placebo, First 21 days of each 28-day cycle
129682|NCT01566708|Behavioral|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
129683|NCT01566708|Behavioral|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
129684|NCT01566708|Behavioral|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
129685|NCT01566721|Drug|trastuzumab [Herceptin]|600 mg sc by assisted administration using the vial formulation, into thigh, on Day 1 of each 3-week cycle, 18 cycles
129686|NCT01566721|Drug|trastuzumab [Herceptin]|600 mg sc by single-use injection device (SID) and by self-administration in select patients, into thigh, on Day 1 of each 3-week cycle, 18 cycles
129687|NCT01566734|Other|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
129688|NCT01566734|Other|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
129689|NCT01569126|Drug|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
129177|NCT01575262|Behavioral|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
129178|NCT01575262|Behavioral|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
129179|NCT01575275|Drug|aminolevulinic acid|Given PO
129180|NCT01575275|Procedure|therapeutic conventional surgery|Undergo surgery
129181|NCT01575288|Drug|Placebo|100g maltose 1/day
129182|NCT01575288|Drug|High-dose trehalose|100g 1/day
129183|NCT01575301|Drug|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
129184|NCT01575314|Device|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
129185|NCT01575327|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
129186|NCT01575327|Device|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
129187|NCT00001482|Drug|Lamotrigine (Lamictal® (Registered Trademark)|
129188|NCT00080119|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
129189|NCT01575340|Dietary Supplement|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
129190|NCT01575353|Device|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
129461|NCT01571089|Behavioral|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
129462|NCT01571102|Behavioral|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
129463|NCT01563848|Procedure|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
129464|NCT01563861|Genetic|RNA analysis|
128961|NCT01576848|Dietary Supplement|Protein + carbohydrate|subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.
Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).
128962|NCT01576861|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
128963|NCT01576874|Drug|Oxytocin|40 IUs of oxytocin administered intranasally one time
128964|NCT00080288|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
128965|NCT01576874|Drug|placebo|placebo administered intranasally one time
128966|NCT01576887|Drug|Bardoxolone Methyl 20 mg|Oral, once daily
128967|NCT01576887|Drug|Placebo|Oral, once daily
128968|NCT01576900|Behavioral|SyBeMeP (Systemized Behavioural Modification education Program)|Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.
Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)
During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.
After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education.
128969|NCT01576913|Other|Music listening|Listening to tempo music while cycling in an exercise test
128970|NCT01576939|Radiation|intensity modulated radiotherapy treatment|
128971|NCT01576952|Drug|ISV-303|Bromfenac in DuraSite
129231|NCT00001475|Drug|IL-2 plus Anti-TNF or Thalidomide|
129232|NCT00079846|Drug|Implitapide|
129233|NCT01572948|Drug|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
129234|NCT01572948|Drug|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
129235|NCT01572961|Drug|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
129236|NCT01572961|Drug|Placebo|
129237|NCT01572987|Device|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
129896|NCT01571583|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
129897|NCT00079716|Drug|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
129898|NCT01564563|Drug|standard therapy|Standard treatment of bleeding
129899|NCT01564563|Drug|placebo|Placebo
129900|NCT00079157|Biological|sargramostim|
129901|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
129902|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
129903|NCT01564576|Drug|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
129904|NCT01564602|Device|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
129905|NCT01564615|Device|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
129906|NCT01564615|Device|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
129907|NCT01564628|Device|Acoustic recording. *CAD Patch System' Prototype no. 3.0. Manufactured by Acarix A/S, Denmark|
129908|NCT01564641|Device|iDuo G2|single comparator
129909|NCT01564654|Device|iTotal KRS|Total Knee Replacement System
129910|NCT01564667|Behavioral|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
129911|NCT00001445|Biological|HIV-1 Immunogen|
129912|NCT00079157|Biological|telomerase: 540-548 peptide vaccine|
129913|NCT01564680|Other|placebo|normal saline
129914|NCT01564680|Drug|Paracetamol|IV paracetamol infusion
129915|NCT01564680|Drug|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
129690|NCT01569152|Drug|MK-8457 100 mg BID|MK-8457 100 mg dosed orally twice daily.
129691|NCT01569152|Drug|Dose-Matched Placebo|Dose-matched placebo dosed orally.
129692|NCT01569152|Drug|MK-8457 150 mg QD|MK-8457 dosed orally once daily.
129693|NCT00079430|Drug|paclitaxel|Given IV
129694|NCT01569152|Drug|MK-8457 75 mg QD|MK-8457 dosed orally once daily.
129695|NCT01569152|Drug|MK-8457 25 mg QD|MK-8457 25 mg dosed orally once daily.
129696|NCT01569152|Drug|MTX|MTX dosed at the stable dose receive upon study entry.
129697|NCT01569152|Drug|MK-8457 25 mg BID|MK-8457 25 mg dosed orally twice daily
129698|NCT01569165|Procedure|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
129970|NCT01571791|Drug|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
129971|NCT01571791|Drug|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
129972|NCT01571804|Drug|Placebo|to receive two identical placebo capsules 1 hr before surgery
129973|NCT01571804|Drug|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
129974|NCT01571804|Drug|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
129975|NCT01571817|Biological|Isolated Human Pancreatic Islets|
129976|NCT01571843|Other|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
129977|NCT01571843|Other|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
129978|NCT00079638|Drug|Rosuvastatin|
129979|NCT01571856|Drug|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
129980|NCT01571856|Other|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
129981|NCT01571869|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
129465|NCT01563861|Genetic|gene expression analysis|
129466|NCT01563861|Other|immunohistochemistry staining method|
129467|NCT01563861|Other|laboratory biomarker analysis|
129468|NCT00001444|Drug|7-hydroxystaurosporine (UCN-01)|
129469|NCT00079131|Other|laboratory biomarker analysis|Correlative studies
129470|NCT01563887|Behavioral|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
129471|NCT01563887|Behavioral|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
129472|NCT01563900|Device|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
129473|NCT01563900|Device|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
129474|NCT01563913|Drug|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
129475|NCT01563913|Drug|Placebo|Sugar Pill, taken for 1.5 years
129476|NCT01563926|Drug|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
129477|NCT01563939|Drug|Remifentanil|Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.
Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.
129478|NCT01563952|Device|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
129775|NCT01566851|Other|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
129776|NCT01569230|Other|Waiting|No interventions were applied to the patients in this group.
129777|NCT01569243|Other|Text messages|Participants will receive diabetic medical care as usual.
Participants will be given an ActiHealth pedometer to measure daily activity.
In addition, they will be enrolled to receive the study text messages.
129238|NCT01572987|Device|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
129239|NCT01573000|Biological|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
129240|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
129241|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
129242|NCT01573013|Dietary Supplement|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
129243|NCT01568255|Drug|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
129244|NCT01568255|Drug|Placebo|placebo at 50,000IU for 8 weeks
129245|NCT00079378|Other|laboratory biomarker analysis|Correlative studies
129246|NCT01568268|Drug|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
129247|NCT01568268|Drug|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
129248|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
129249|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
129250|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
129251|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
129540|NCT01571167|Drug|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
129541|NCT01571167|Drug|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
129542|NCT01571193|Dietary Supplement|Pomegranate extract|Pomegranate extract
129916|NCT01564706|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
129032|NCT01575015|Device|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
129033|NCT01575015|Procedure|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
129034|NCT01575028|Drug|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
129035|NCT01575028|Drug|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
129036|NCT01575041|Dietary Supplement|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
129037|NCT01575041|Drug|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
129038|NCT01575041|Drug|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
129039|NCT01575054|Biological|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
129040|NCT01576978|Behavioral|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
129041|NCT00080288|Drug|Placebo|Matching placebo tablets once daily
129042|NCT01577004|Dietary Supplement|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
129043|NCT01577017|Drug|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
129044|NCT01577030|Dietary Supplement|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
129045|NCT01577030|Dietary Supplement|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
129046|NCT01577043|Drug|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
129982|NCT01571869|Other|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
129983|NCT01571882|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
129984|NCT01571882|Other|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
129985|NCT01564745|Other|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
129986|NCT01564758|Drug|Linezolid|Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days
Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days
Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days
129987|NCT01564771|Other|Non Intervention|This Is A Non Interventional Study
129988|NCT00079170|Dietary Supplement|garlic|
129989|NCT01564784|Drug|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
129102|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
129103|NCT01575119|Behavioral|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
129104|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
129105|NCT01575119|Behavioral|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
129106|NCT01575145|Behavioral|Quitline facilitation intervention|brief quitline facilitation intervention
129107|NCT01575145|Behavioral|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
129108|NCT01575158|Drug|Citalopram|
129109|NCT00080106|Other|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
129110|NCT01575158|Drug|Clomipramine|
129111|NCT01575158|Drug|placebo|
129778|NCT01569243|Other|Usual care|Participants will receive diabetic medical care as usual.
In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity).
129779|NCT01569256|Drug|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
129780|NCT01569269|Behavioral|Yoga Intervention|The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).
Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.
The conclusion of the session will be comprised of 10 minutes of relaxation.
129781|NCT01569269|Behavioral|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
129782|NCT01569269|Behavioral|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
129783|NCT01569269|Other|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
129784|NCT01569282|Procedure|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
129785|NCT01569282|Procedure|Stent strategy|Biliary and/or enteral stents on demand
129786|NCT00079443|Drug|romidepsin|Given IV
129787|NCT01569295|Drug|Idelalisib|Idelalisib 150 mg administered orally twice daily
129788|NCT01569295|Drug|Rituximab|Rituximab 375 mg/m^2 on Day 1, then 500 mg/m^2 every 28 days administered intravenously for a maximum of 6 infusions
128900|NCT01579071|Procedure|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
129543|NCT00079599|Other|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
129544|NCT01571193|Dietary Supplement|Placebo|Placebo
129545|NCT01571206|Biological|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
129546|NCT01571219|Biological|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
129547|NCT01571232|Drug|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
129548|NCT01571232|Drug|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
129549|NCT01571258|Behavioral|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
129550|NCT01571271|Procedure|Laser Lithotripsy|Laser Lithotripsy
129551|NCT01571284|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: intravenous
129552|NCT01563965|Dietary Supplement|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
129553|NCT01563965|Other|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
129554|NCT01563978|Drug|fostamatinib|fostamatinib 100 mg twice daily
129555|NCT01563978|Drug|placebo|placebo
129556|NCT01563991|Procedure|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
129557|NCT01563991|Procedure|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
129558|NCT01564004|Other|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
129047|NCT01577043|Other|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
129048|NCT01577056|Dietary Supplement|Fish oil capsule|4g Omega capsule for 12 weeks
129049|NCT01577056|Drug|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
129307|NCT01563640|Other|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
129308|NCT01566019|Procedure|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
129309|NCT01566045|Procedure|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
129310|NCT01566045|Procedure|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
129311|NCT01566058|Device|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
129312|NCT00079261|Drug|vincristine sulfate|
129313|NCT01566058|Other|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
129314|NCT01566071|Other|Assessment of drive abilities|
129315|NCT01566084|Drug|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
129316|NCT01566084|Other|placebo|Placebo tablets are administered to maintain the low sodium condition.
129317|NCT01566097|Device|Smoking Cessation Decision Aids|The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.
The decision aids contained the followings, in proper Korean social and cultural context:
Information on the risk of continued smoking and benefits of cessation
Messages that address common misbeliefs regarding smoking cessation services and medications
Information on possible smoking cessation options, their efficacy, side effects, costs, etc.
The choices given in the decisions aid were:
Behavioral only
Nicotine replacement therapy
Bupropion
Varenicline
129318|NCT01566110|Dietary Supplement|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
129319|NCT01566123|Radiation|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
129320|NCT01566123|Radiation|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
129112|NCT01575171|Behavioral|Nudge|Behavioral economics recognizes that individuals often are not fully "rational" in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to "nudge" individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support "nudge" will see the new "optout" prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines.
129113|NCT01575184|Other|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
129114|NCT01575184|Other|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
129115|NCT01575197|Biological|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 & 10 weeks of age, 10 & 14 weeks of age, or 6, 10, & 14 weeks of age, depending on study arm assignment.
129116|NCT01577160|Drug|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
129117|NCT00080301|Drug|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
129118|NCT01577173|Drug|MEHD7945A|1100 mg iv every 2 weeks
129119|NCT01577173|Drug|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
129384|NCT01563783|Procedure|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
129385|NCT01563783|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
129386|NCT01563783|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
129387|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
129388|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
129389|NCT00079131|Other|pharmacological study|Correlative studies
129390|NCT01563822|Biological|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
129391|NCT01563835|Drug|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
129392|NCT01563835|Drug|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
128901|NCT01579084|Drug|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
128902|NCT01579084|Drug|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
128903|NCT01579084|Drug|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
128904|NCT01579084|Drug|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
128905|NCT01579097|Other|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
128906|NCT01579097|Other|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
128907|NCT01579110|Drug|levamisole|Levamisole 2.5mg/kg(every other day) over six months.
Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
128908|NCT00080457|Drug|sitaxsentan sodium|
128909|NCT01579110|Drug|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
128910|NCT01579123|Procedure|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
128911|NCT01579123|Procedure|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
128912|NCT01579136|Behavioral|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
128913|NCT01579149|Drug|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
128914|NCT01579149|Drug|Placebo|Single subcutaneous (SC) dose of placebo
128915|NCT01572467|Other|laboratory biomarker analysis|
128916|NCT01572467|Other|medical chart review|
128917|NCT01572480|Drug|Carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
128918|NCT01572480|Drug|Revlimid|Cycles 1-8: 25 mg/day, days 1 21 every 28 days (exception: lenalidomide is NOT given on cycle 1, day 1) Cycles 9 and beyond: 25 mg/day, days 1 21 every 28 days
129838|NCT01566864|Behavioral|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
129839|NCT01566877|Drug|AVI-7288|Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV
The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.
129840|NCT01566877|Other|Placebo|Normal Saline Solution (NSS)
129841|NCT01566890|Drug|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
129842|NCT01566890|Procedure|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
129843|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
129844|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
129845|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
129846|NCT01566916|Procedure|Total Hip Arthroplasty|
129847|NCT01566929|Dietary Supplement|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
129848|NCT00001449|Drug|fluorodeoxyuridine|
129849|NCT00079300|Procedure|conventional surgery|
129850|NCT01569321|Device|PEM scan with ClearPemSonic|
129851|NCT01569334|Biological|blood samples|
129852|NCT01569347|Other|Interviews|Interviews
129853|NCT01569347|Other|Blood sample|Blood sample
129854|NCT00079443|Biological|rituximab|Given IV
129855|NCT01569347|Other|Hair sample|Hair sample
129321|NCT01566136|Behavioral|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
129322|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
129323|NCT00079274|Drug|irinotecan hydrochloride|Given IV
129324|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
129325|NCT01566162|Drug|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
129622|NCT01569113|Drug|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
129623|NCT01569113|Drug|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
129624|NCT01569126|Drug|LY110140|Administered orally as capsules
129625|NCT01571284|Drug|FOLFIRI|irinotecan, 5-FU and leucovorin
129626|NCT01571297|Drug|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
129627|NCT00079612|Drug|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
129628|NCT01571297|Drug|Placebo|Placebo given subcutaneously for 35 days
129629|NCT01571310|Other|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
129630|NCT01571310|Other|Breakfast|In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
(YesB): The patients in YesB will eat all three mealswill consume three meals:
129631|NCT01571323|Drug|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
129632|NCT01571323|Drug|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
129633|NCT01571323|Drug|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
129634|NCT01571362|Drug|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
129635|NCT01571362|Drug|Placebo|oral placebo, divided into symmetric doses and administered twice daily
129393|NCT01563848|Procedure|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
129394|NCT01563848|Procedure|Implantation of loop recorder|The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events
129395|NCT01566201|Drug|placebo|water for injection
129396|NCT01566214|Behavioral|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
129397|NCT01566227|Other|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
129398|NCT01566240|Drug|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 160mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 & 36.
129399|NCT00079274|Drug|oxaliplatin|Given IV
129400|NCT01566240|Drug|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, & 36.
129401|NCT01566240|Radiation|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
129699|NCT01569178|Procedure|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
129700|NCT01569191|Other|Non-Pharmaceutical Tear Supplement|artificial tear supplement (Hypromellose)
129701|NCT01569191|Device|Eye Gel Mask Blue placed over the closed eyes|Bag fill with temperature retention gel
129702|NCT01569191|Drug|ELESTAT® (epinastine HCl ophthalmic solution) 0.05%|1 drop on single occasion after exposure to grass pollen
129703|NCT01569204|Drug|Etoposide|
129704|NCT00001450|Drug|cisplatin|
129705|NCT00079430|Drug|carboplatin|Given intraperitoneally
129191|NCT01575353|Device|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
129192|NCT01575366|Behavioral|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
129193|NCT01577303|Behavioral|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
129194|NCT01577303|Behavioral|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
129195|NCT01577303|Behavioral|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
129196|NCT01577316|Biological|Seasonal influenza vaccination|2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Victoria/361/2011 (H3N2)-like virus;
a B/Wisconsin/1/2010-like virus.
129197|NCT01577329|Behavioral|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
129198|NCT00080314|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
129199|NCT01577342|Drug|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
129200|NCT01577355|Radiation|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
129856|NCT01569360|Device|Corset|the patients are assigned the use of a custome made corset during daytime
128972|NCT01576952|Other|DuraSite Vehicle|DuraSite Vehicle
128973|NCT01576965|Drug|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
128974|NCT01579162|Device|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:
20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.
40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.
The 3 test visits will be on separate days within a span of 30 days
128975|NCT01579175|Other|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
128976|NCT01579188|Drug|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
128977|NCT01579188|Drug|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
128978|NCT00080470|Device|bion|battery powered microstimulator
128979|NCT01579201|Drug|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
128980|NCT01579214|Other|Cellular Phone Text Message Formats|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
128981|NCT01579227|Device|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
128982|NCT01579227|Dietary Supplement|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
128983|NCT01579227|Device|Tamoxifen Cream|Tamoxifen cream
128984|NCT01579227|Device|Placebo cream|Placebo cream
128985|NCT01579227|Dietary Supplement|placebo capsule|placebo capsule
128986|NCT01579240|Other|Internet exercise program|12 voluntary weekly visits to website
128987|NCT01579279|Drug|ABT-652 6 mg|6 mg capsules
128988|NCT01579279|Drug|ABT-652 12 mg|12 mg capsules
129636|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
129637|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
129638|NCT00079612|Drug|Placebo|2x 400mg tabs daily
129639|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
129640|NCT01571401|Behavioral|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
129917|NCT01564719|Behavioral|Holistic health|The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
129918|NCT01564732|Device|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
129919|NCT01564732|Device|Plicated-LAGB|At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to "tighten" and "cinch up" the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss.
129920|NCT01566942|Drug|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
129921|NCT01566942|Drug|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
129922|NCT01566955|Procedure|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
129923|NCT01566968|Other|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
129924|NCT01566968|Other|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
129925|NCT01566968|Other|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
129926|NCT01566981|Procedure|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
129706|NCT01569204|Drug|Cyclophosphamide|
129707|NCT01569204|Drug|Doxorubicin|
129708|NCT01569204|Drug|Prednisone|
129709|NCT01569204|Drug|Procarbazine|
129710|NCT01569204|Drug|Dexamethasone|
129711|NCT01569204|Drug|Dacarbazine|
129712|NCT01569204|Drug|Brentuximab Vedotin|
129713|NCT01569230|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
129714|NCT01569230|Procedure|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
129715|NCT01569230|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
129716|NCT00079430|Biological|bevacizumab|Given IV
129717|NCT01571583|Drug|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
129718|NCT00079638|Drug|Atorvastatin|
129719|NCT01571583|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day [5 to 6 tablets] based on subject weight), twice daily regimen, for 48 weeks.
129720|NCT01571596|Drug|Biological KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 4 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
129990|NCT01564784|Drug|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m^2/day IV days 1-6 fludarabine30 mg/m^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
129991|NCT01564784|Drug|HIDAC (high dose cytarabine)|cytarabine 3 g/m^2 IV every 12 hours for up to 12 times
129992|NCT01564784|Drug|cytarabine and mitoxantrone|mitoxantrone 12 mg/m^2 IV days 1-3 cytarabine 200 mg/m^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
129993|NCT01564797|Behavioral|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
129201|NCT01577368|Drug|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
129479|NCT01563952|Device|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
129480|NCT00079144|Biological|NY-ESO-1 peptide vaccine|
129481|NCT01563952|Device|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
129482|NCT01563952|Device|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
129483|NCT01566357|Other|Toothpaste|
129484|NCT01566357|Dietary Supplement|Milk|
129485|NCT01566357|Dietary Supplement|Fluoridated Milk|
129486|NCT01566357|Drug|Tooth Mousse|
129487|NCT00079274|Drug|fluorouracil|Given IV
129488|NCT01566357|Drug|MI Paste Plus|
129489|NCT01566357|Drug|Elmex Erosion Protection|
129490|NCT01566370|Drug|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
129491|NCT01566370|Drug|Placebo|placebo
129492|NCT01566383|Procedure|24-hr pH monitoring|Visit 1
The following will be done:
A medical history including review of your current drugs;
Collection of demographic information;
A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;
24-hour pH testing will be done
Visit 2
You will return to the clinic 24 hours after the visit 1 and the following will occur:
The catheter will be removed from your nose; and
You will return the recording device
129493|NCT01566396|Device|A3F|A3F fractional RF treatments for facial wrinkles
129494|NCT01566409|Drug|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
129495|NCT01566409|Other|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
129496|NCT01566422|Drug|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
128989|NCT00080483|Drug|Testosterone plus somatropin|AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
128990|NCT01579279|Drug|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
128991|NCT01579279|Drug|Placebo|Placebo capsules
128992|NCT01579279|Drug|Duloxetine|Duloxetine capsules
129252|NCT01568294|Drug|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
129253|NCT01568307|Drug|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
129254|NCT01568320|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
129255|NCT01568333|Drug|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given at least three cycles.
129256|NCT00079391|Device|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
129257|NCT01568346|Other|MRI|Breast MRI
129258|NCT01568372|Other|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
129259|NCT01568385|Drug|TAK-438|
129260|NCT01568398|Drug|TAK-438|
129261|NCT01568411|Drug|TD-1211|Period 1
129262|NCT01568411|Drug|TD-1211+ itraconazole|Period 2
129263|NCT01568424|Device|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
129264|NCT01568437|Procedure|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
129265|NCT01568437|Other|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
129266|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
129267|NCT00001450|Drug|paclitaxel|
129927|NCT01566994|Behavioral|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
129928|NCT01566994|Behavioral|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
129929|NCT01566994|Behavioral|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
129930|NCT00079313|Drug|Imatinib|
129931|NCT01567007|Behavioral|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
129050|NCT01577082|Drug|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
129051|NCT01577082|Drug|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
129052|NCT00080301|Drug|Ixabepilone + Capecitabine|Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity
Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
129053|NCT01577095|Other|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
129054|NCT01577095|Drug|TZD|Rosiglitazone 8 mg single dose
129055|NCT01577108|Dietary Supplement|GR-1, RC-14|oral taking 2 capsules before sleeping per day for 14 days
129056|NCT01577121|Drug|indomethacin|50 mg / 6 hours during 5 days
129057|NCT01577121|Drug|placebo|50 mg / 6 hours during 5 days
129058|NCT01577134|Behavioral|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
129059|NCT01577134|Behavioral|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
129060|NCT01577134|Behavioral|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
129061|NCT01577147|Other|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
129994|NCT01564810|Drug|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
129995|NCT01564810|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
129996|NCT01564823|Drug|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
129997|NCT01564823|Drug|Metronidazole|Metronidazole 250 mg/8h 3 months
129998|NCT01564823|Drug|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
129999|NCT00079170|Drug|docetaxel|
130000|NCT01564823|Drug|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
130001|NCT01564836|Behavioral|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
130002|NCT01564862|Drug|vortioxetine (Lu AA21004)|Lu AA21004 capsules
130003|NCT01564862|Drug|Duloxetine|Duloxetine capsules
130004|NCT01564862|Drug|Placebo|Placebo matching capsules
130005|NCT01564875|Drug|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
130006|NCT01564875|Drug|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
130007|NCT01564888|Procedure|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
130008|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
130009|NCT00079326|Biological|trastuzumab|Given IV
130010|NCT01567072|Drug|Placebo|Only placebo treatment instead of NSAID painkillers
129120|NCT01577186|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
129121|NCT01577199|Drug|clomiphene citrate with low dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
129497|NCT01566435|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
129498|NCT00079274|Biological|cetuximab|Given IV
129499|NCT01566435|Drug|Cisplatin|
129789|NCT01569295|Drug|Bendamustine|Bendamustine 70 mg/mg^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
129790|NCT01569295|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
129791|NCT01569321|Device|MRI|
129792|NCT01569321|Device|PET-CT scan|
129793|NCT01571882|Other|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
129794|NCT01571895|Drug|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 [CXCL8; formerly interleukin (IL)-8] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
129795|NCT01571908|Drug|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
129796|NCT01571908|Drug|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
129797|NCT00079651|Behavioral|Montessori-based dementia programming|
129798|NCT01571908|Drug|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
129799|NCT01571908|Drug|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
129800|NCT01571921|Dietary Supplement|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
129801|NCT01571947|Other|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
129802|NCT01571960|Biological|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
129803|NCT01571960|Biological|MVA/HIV62B (MVA62B) vaccine|1 x 10^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
129804|NCT01571960|Biological|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
129268|NCT01570699|Genetic|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
129269|NCT01570712|Other|HOUSING FIRST PROGRAM|Realization of a psychosocial organic evaluation and a citizen;
Support in the development and the maintenance of the housing;
Support in the diverse steps (administrative, judicial, financiers, etc.);
Support around addictions / alcohol;
Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)
to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration.
129559|NCT01564017|Biological|Allergovac depot|Depot sterile suspension fpor subcutaneous injection
Increasing concentrations to reach the following maintenance doses:
Group 1: 0.25 SPT
129560|NCT00079144|Biological|aldesleukin|
129561|NCT01564017|Biological|Allergovac depot|Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 2: 0.5 SPT
129562|NCT01564017|Biological|Allergovac depot|Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 3: 1 SPT
129563|NCT01564017|Biological|Allergovac depot|depot sterile suspension for subcutaneous injection
Increasing concentrations to reach the following maintenance doses:
Group 4: 2 SPT
129564|NCT01564017|Biological|Allergovac depot|Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 5: 4 SPT
129565|NCT01564017|Biological|Allergovac depot|Sterile suspension for subcutaneous injection.
Same number of administration as the active groups
129566|NCT01564030|Other|Empty|overnight fast
129567|NCT01564030|Other|Fluid|250mL apple juice
129568|NCT01564030|Other|Solid|breakfast
129569|NCT01564043|Behavioral|website and pedometer|use of pedometer and website
129570|NCT01564056|Drug|HORMONOTHERAPY|Hormonotherapy will be administered during 5 years following chemotherapy when allocated.
(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
129571|NCT00079144|Biological|filgrastim|
129572|NCT01564056|Drug|CHEMOTHERAPY then HORMONOTHERAPY|CHEMOTHERAPY regimen will be chosen amongst the following ones:
i) 4 cycles of TC (docetaxel + cyclophosphamide)
Docetaxel 75 mg/m² IV infusion at hospital every 21 days
Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days
ii) 4 cycles of AC (doxorubicin + cyclophosphamide)
Doxorubicin 60 mg/m² IV infusion at hospital every 21 days
Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days
iii) 4 cycles of MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)
Myocet® 60 mg/m² IV infusion at hospital every 21 days
Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days
HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
129062|NCT01579318|Drug|IL-12 plasmid (pIL-12)|All subjects may receive up to six cycles of treatment consisting of two treatment days, Days 1 and 8, in a 28-day cycle. Patients will receive intratumoral injection of IL-12 plasmid (pIL-12) at a concentration of 0.5 mg/mL and a fixed volume of 0.25 mL per each 1.0 cm diameter of target region. Up to a maximum of 8 fixed volume injections per patient per day depending up on the size of each individual lesion, or affected areas in erythrodermic patients.
129063|NCT01579318|Device|Electroporation|Electroporation of the target lesion will occur using the OncoSec Medical System (OMS). Six pulses at field strengths of (E+) of 1500 V/cm and pulse width of 100 μs at 1-second intervals will be administered to each previously injected region. Up to 8 target regions may be treated on Days 1 and 8 of each cycle. A total of three cycles may be completed at 4-week intervals.
129064|NCT01579331|Device|DCT (PASCAL© Tonometer) IOP and OPA measurement|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.
Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve.
129065|NCT00080483|Drug|testosterone|AndroGel transdermally 5 g a day for two years
129066|NCT01579344|Drug|Radioiodine therapy|Radioiodine therapy with NaI131
129067|NCT01579357|Other|blood samples|Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).
day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min
129326|NCT01566175|Device|Neovac coronary sinus reducer|reducer
129327|NCT01566188|Dietary Supplement|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
129328|NCT01566188|Dietary Supplement|Placebo|6 months of supplementation with placebo
129329|NCT01566201|Drug|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
129330|NCT00079404|Drug|tanespimycin|Given IV
129331|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
129332|NCT01568450|Drug|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
129333|NCT01568476|Procedure|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
129334|NCT01568476|Procedure|Interneural|Sciatic nerve blockade at the site of bifurcation
129335|NCT01568489|Drug|HL-009 Liposomal Gel|a semi-transparent red-color gel and is supplied as a laminated tube
129122|NCT01577199|Drug|Gonal F or Follistim|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
129123|NCT01577212|Radiation|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
129124|NCT01577225|Device|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
129125|NCT01577225|Device|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
129126|NCT01577238|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
129127|NCT01577238|Drug|Placebo|Vaginal gel, daily for 7 days
129128|NCT00080314|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
129129|NCT01577290|Behavioral|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
129130|NCT01577290|Behavioral|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
129131|NCT01577303|Behavioral|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
129132|NCT01577303|Behavioral|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
129133|NCT01577303|Behavioral|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
129134|NCT01579435|Device|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
129402|NCT01566240|Drug|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
129805|NCT01571960|Biological|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
129806|NCT01571973|Procedure|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
129807|NCT01571986|Procedure|Non-invasive ventilation|Non-invasive ventilation
129808|NCT00079664|Behavioral|Tai Chi|
129809|NCT01571999|Drug|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
128919|NCT00079781|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
128920|NCT01572480|Drug|Dexamethasone|20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23 (exception: dexamethasone is NOT given on cycle 1, day 1)
128921|NCT01572493|Biological|rh IL-15|IL-15 IV for first 10 days of each cycle
128922|NCT01572506|Procedure|Biotin RBC survival|
128923|NCT01572519|Drug|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
128924|NCT01572519|Drug|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
128925|NCT01572519|Drug|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
128926|NCT01572519|Drug|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
128927|NCT01572519|Drug|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
128928|NCT01572532|Other|Screening treatment and referral|Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.
Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days.
128929|NCT01572545|Drug|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
129573|NCT01564082|Device|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
129574|NCT00079274|Drug|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
129575|NCT01566487|Drug|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
129576|NCT01566513|Behavioral|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
129857|NCT01569386|Behavioral|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
129858|NCT01569386|Behavioral|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
129859|NCT01569399|Other|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
129860|NCT01569412|Biological|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
129861|NCT01569425|Other|Dietary intervention|High Calorie breakfast and high calorie dinner
129862|NCT01569438|Drug|AF-219|BID
129863|NCT01569438|Drug|Sugar Pill|Placebo
129864|NCT01569451|Drug|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
129865|NCT00079443|Drug|fludarabine phosphate|Given IV
129866|NCT01569451|Drug|Glatiramer Acetate|20 mg injected subcutaneously daily
129867|NCT01569464|Drug|Rotigotine|Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:
Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours
7 weeks (titration plus maintenance)
129868|NCT01569464|Other|Placebo|Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.
Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.
7 weeks (titration plus maintenance)
129336|NCT01568515|Procedure|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention & control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
129337|NCT01568528|Drug|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
129338|NCT01568528|Drug|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
129339|NCT01568541|Drug|Regular toothpastes|One tooth brushing
129340|NCT01568541|Drug|Children's toothpastes|One tooth brushing
129341|NCT00079417|Procedure|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
129342|NCT01568567|Dietary Supplement|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
129343|NCT01568580|Drug|GreenGene|Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus
129344|NCT01568593|Device|T2750|1 drop in each eye 3 to 6 times daily during 84 days
129345|NCT01568593|Device|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
129641|NCT01571414|Drug|PA-824|200-mg tablets once a day
129642|NCT01571414|Drug|Efavirenz (EFV)|600-mg tablets once a day
129643|NCT01571414|Drug|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
129644|NCT01571414|Drug|Rifampin (RIF)|300-mg capsules once a day
129645|NCT01571427|Behavioral|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
129646|NCT01571427|Behavioral|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device
129647|NCT01564095|Drug|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
129403|NCT01566253|Drug|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
129404|NCT01566253|Drug|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
129405|NCT01566266|Drug|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
129406|NCT01566266|Drug|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
129407|NCT01566279|Drug|Everolimus|All patients will receive everolimus 10mg q.d.
129408|NCT01566292|Drug|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
129409|NCT01566305|Dietary Supplement|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
129410|NCT00001449|Drug|gemcitabine|
129411|NCT00079274|Drug|leucovorin calcium|Given IV
129412|NCT01566305|Dietary Supplement|Buttermilk with added egg yolk|Buttermilk with added egg yolk
129413|NCT01566305|Dietary Supplement|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
129414|NCT01566305|Dietary Supplement|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
129415|NCT01566318|Behavioral|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
129416|NCT01566331|Device|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
129417|NCT01566344|Other|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
129418|NCT00079417|Procedure|infrared laser therapy|Laser therapy or "photobiomodulation" is the use of specific wavelength of light (red and near-infrared) to create therapeutic effects
129419|NCT01568749|Drug|Paracetamol|Paracetamol
129420|NCT01568749|Drug|Paracetamol formulation 1|Paracetamol
129421|NCT01568749|Drug|Paracetamol Formulation 2|Paracetamol
129422|NCT01568749|Drug|Paracetamol formulation 3|Paracetamol
128930|NCT00079781|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
128931|NCT01572545|Drug|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
128932|NCT01572558|Procedure|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
128933|NCT01572558|Drug|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
128934|NCT01574716|Drug|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
129202|NCT01577368|Drug|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
129203|NCT01577381|Biological|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
129204|NCT01577381|Biological|Placebo|Intravenous, 11 doses, 30 minute infusion
129205|NCT01577394|Other|oculomotor measurements|The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.
Mean reflexive saccades latency Percentage of express saccades
129206|NCT01577407|Drug|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
129207|NCT01577420|Other|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
129208|NCT01577420|Other|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
129209|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
129210|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
129211|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
129869|NCT01569477|Behavioral|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
129870|NCT01569477|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
129871|NCT01569490|Behavioral|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
129872|NCT01569490|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
129873|NCT01571440|Dietary Supplement|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
129874|NCT01571440|Dietary Supplement|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
128993|NCT01579292|Behavioral|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
128994|NCT01579292|Behavioral|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
128995|NCT01579305|Device|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
128996|NCT01579305|Device|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
128997|NCT01572597|Drug|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
128998|NCT01572597|Drug|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
128999|NCT01572610|Drug|RTA 402|once a day, oral administration
129000|NCT01572623|Drug|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
129001|NCT01572623|Drug|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
129002|NCT01572636|Drug|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
129003|NCT01572649|Drug|Lixisenatide (AVE0010)|Pharmaceutical form:Solution for injection
Route of administration: subcutaneous
129004|NCT00079794|Drug|Iscar|
129648|NCT01564095|Drug|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
129649|NCT01564108|Drug|Ranibizumab|Series of intravitreal injections of Ranibizumab
129650|NCT01564121|Drug|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
129651|NCT01564134|Biological|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
129652|NCT01564147|Other|immediate therapeutic education|Access to the course of immediate therapeutic education
129653|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
129654|NCT01564160|Dietary Supplement|Fish Oil|Source of omega-3 fatty acids.
129655|NCT00079144|Biological|incomplete Freund's adjuvant|
129656|NCT01564160|Dietary Supplement|PCSO-524|Extract of Greenshell Mussel
129657|NCT01564199|Drug|salmeterol / fluticasone propionate|100/1000 μg oral capsule
129658|NCT01564212|Other|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
129659|NCT01564212|Other|laminar airflow with surgical drapes|
129660|NCT01564212|Other|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
129932|NCT01567007|Behavioral|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
129933|NCT01567007|Behavioral|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
129934|NCT01567033|Behavioral|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
129935|NCT01567046|Other|laboratory biomarker analysis|Correlative studies
129423|NCT01568749|Drug|Paracetamol formulation 4|paracetamol
129721|NCT01571609|Other|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.
HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes
Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.
Palmitate tracer:[9,10-3H]-palmitate 0,3 µCi/min. Duration 60 minutes.
129722|NCT01571622|Dietary Supplement|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
129723|NCT01571622|Dietary Supplement|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
129724|NCT01571635|Drug|Dose level 1a|
129725|NCT01571635|Drug|Dose level 1b|
129726|NCT01571635|Drug|Dose level 2|
129727|NCT01571635|Drug|dose level 3|
129728|NCT01571635|Drug|dose level 4|
129729|NCT00079638|Drug|Simvastatin|
129730|NCT01571635|Drug|dose level 5|
129731|NCT01571648|Drug|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
129732|NCT01571661|Drug|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
129733|NCT01571661|Other|Placebo|Placebo
129734|NCT01571674|Procedure|Manipulation + Exercise Group|First 2 sessions
High-velocity, low-amplitude manipulations to the thoracic spine.
Low-velocity mid to end-range mobilizations to the cervical spine.
Active Range of Motion Exercises for the cervicothoracic spine
Final 6 sessions
◦ Evidence based shoulder girdle exercise program
129735|NCT01571674|Procedure|Exercise Group|First 2 sessions
◦ Active Range of Motion Exercises for the cervicothoracic spine
Final 6 sessions
◦ Evidence based shoulder girdle exercise program
129736|NCT01571687|Dietary Supplement|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
129737|NCT01571687|Dietary Supplement|Placebo|Intake of 6 identically appearing tablets daily containing placebo
129738|NCT01564290|Drug|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
129212|NCT01579565|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
129213|NCT01579565|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
129214|NCT01579578|Drug|AZD8931|40 mg, oral dose twice daily
129215|NCT01579578|Drug|Placebo|Placebo, oral dose twice daily
129216|NCT01579578|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
129217|NCT01579591|Other|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
129218|NCT01579591|Other|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
129500|NCT01566435|Drug|Fluorouracil|
129501|NCT01566435|Radiation|Intensity modulated radiation therapy|
129502|NCT01566435|Drug|Cetuximab|
129503|NCT01566435|Procedure|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
129504|NCT01566448|Drug|Ketamine|20mg/5ml swish and spit four times daily
129505|NCT01566461|Device|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
129506|NCT01566461|Device|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
129507|NCT01566474|Drug|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
129508|NCT01566474|Drug|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
129509|NCT01568866|Drug|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
129510|NCT01568866|Drug|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
129005|NCT01572649|Drug|Placebo|Pharmaceutical form:Solution for injection
Route of administration: subcutaneous
129006|NCT01572662|Drug|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
129007|NCT01572662|Drug|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
129008|NCT01572662|Procedure|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
129009|NCT01572662|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
129010|NCT01572662|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
129011|NCT01572662|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
129270|NCT01570712|Other|traditional French services|The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said " about "common law " set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\or the restoring, but this by means of the existing devices
129271|NCT00000262|Drug|30% Nitrous oxide|
129272|NCT00001460|Behavioral|inpatient evaluation and management|
129273|NCT00079573|Behavioral|Atkins diet (extremely low carbohydrate)|
129274|NCT01570725|Behavioral|Virtual reality exposure|The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.
Patients were exposed to the virtual environment for the entire length of the operation.
129275|NCT01570725|Behavioral|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
129276|NCT01570751|Drug|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
129277|NCT01570751|Drug|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
129278|NCT01570764|Drug|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
129936|NCT01567059|Drug|tosedostat|Given PO
129937|NCT01567059|Drug|cytarabine|Given IV
129938|NCT01567059|Drug|decitabine|Given IV
129939|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
129940|NCT01569503|Device|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
129941|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1mg, tid
129942|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
129943|NCT00079443|Other|laboratory biomarker analysis|Correlative studies
129944|NCT01569516|Drug|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
129945|NCT01569516|Drug|Placebo|0mg, tid
129946|NCT01569529|Behavioral|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
129947|NCT01569568|Behavioral|MRI scanning|1H MRS, DTI, FMRI
129948|NCT01569568|Behavioral|Cognitive testing|Neuropsychological testing
129949|NCT01569581|Biological|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
129950|NCT01569581|Biological|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
129068|NCT01579370|Other|Quaternary ammonium|Rooms from which a patient with a target organisms has been discharged (ie, a "seed" room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital.
129069|NCT01579370|Other|Bleach|Rooms from which a patient with a target organisms has been discharged (ie, a "seed" room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital.
129070|NCT01579370|Other|Quaternary ammonium and UV-C light|Rooms from which a patient with a target organisms has been discharged (ie, a "seed" room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room.
129739|NCT01564303|Drug|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
129740|NCT01564329|Drug|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
129741|NCT01564342|Procedure|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
130011|NCT01567085|Drug|Eculizumab|Eculizumab 1200 mg (4 vials) administered intravenously (IV) over 35 to 45 minutes.
Eculizumab 900 mg (3 vials) administered IV over 35 to 45 minutes.
130012|NCT01567098|Procedure|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
130013|NCT01567111|Procedure|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
130014|NCT01567124|Drug|Moxonidine|Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.
At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.
130015|NCT01567124|Drug|Placebo|To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.
The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.
130016|NCT01567124|Drug|Moxonidine|Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.
At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.
130017|NCT01567124|Drug|Placebo|To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.
The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.
130018|NCT01567150|Device|Novel Dressing|Topical wound dressing
130019|NCT01567163|Biological|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
130020|NCT00079326|Drug|ixabepilone|Given IV
130021|NCT01567163|Drug|Docetaxel|docetaxel 75 milligrams/square meter (mg/m^2) intravenous infusion administered on Day 1 of each 3-week cycle
130022|NCT01567176|Biological|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
129511|NCT01568866|Drug|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
129512|NCT01568879|Other|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
129513|NCT01568879|Other|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
129514|NCT01568892|Drug|dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7)
129515|NCT01568892|Drug|dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
129516|NCT00079417|Drug|carboplatin|Given IV
129517|NCT01568892|Drug|Open-label dolutegravir 50mg twice daily|Open label dolutegravir plus optimized background regimen (from Day 8)
129518|NCT01568905|Other|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
129519|NCT01568905|Other|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
129810|NCT01571999|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
129811|NCT01572012|Drug|Ondansetron|Ondansetron solution 4 mg single administration
129812|NCT01572012|Drug|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
129813|NCT01572012|Drug|Zofran ODT|Zofran ODT (8 mg) single administration
129814|NCT01572012|Drug|Ondansetron solution|Ondansetron solution (4 mg) single administration
129815|NCT01572025|Drug|Dehydroepiandrosterone|Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol
: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)
129816|NCT01564446|Other|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
129817|NCT01564459|Drug|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
129279|NCT01570764|Drug|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
129280|NCT01570777|Procedure|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
129281|NCT01570777|Procedure|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
129282|NCT01570790|Drug|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
129283|NCT01570790|Drug|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
129284|NCT00079573|Behavioral|Zone diet (low carbohydrate, high protein)|
129285|NCT01570790|Drug|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
129286|NCT01563510|Procedure|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
129577|NCT01566513|Behavioral|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
129578|NCT01566513|Behavioral|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
129579|NCT01566526|Drug|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
129580|NCT01566539|Drug|Intranasal Oxytocin|Dosage and details described in arm.
129581|NCT01566539|Drug|Intranasal Vasopressin 40 or 20 units|Dosage and details described in arm.
129582|NCT01566539|Drug|Intranasal Vasopressin|Dosage and details described in arm.
129583|NCT01566539|Drug|Intranasal Placebo OT Vehicle|Dosage and details described in arm.
129584|NCT01566539|Drug|Intranasal Placebo Saline|Dosage and details described in arm.
129585|NCT00079287|Drug|carboplatin|
129586|NCT01566539|Drug|Intranasal Placebo AVP Vehicle|Dosage and details described in arm.
129071|NCT01579370|Other|Bleach and UV-C light|Rooms from which a patient with a target organisms has been discharged (ie, a "seed" room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room.
129072|NCT01579383|Biological|ALD403|Single Dose IV infusion on Day 1
129073|NCT01579383|Biological|ALD403|Single Dose subcutaneous injection on Day 1
129074|NCT01579383|Biological|Sumatriptan|Single Dose subcutaneous injection on Day 1
129075|NCT01579396|Device|septeX|12 h septeX CVVH treatment after cardiac surgery
129076|NCT00080496|Drug|Tigecycline|
129077|NCT01579396|Other|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
129078|NCT01579409|Other|PNNS guidelines|Application of PNNS guidelines
129079|NCT01579422|Behavioral|social cognitive training|social cognitive training, 8-10 sessions
129080|NCT01572714|Behavioral|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
129081|NCT01572727|Drug|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week.
129082|NCT01572727|Drug|BKM120 matching placebo|BKM120 matching placebo, daily oral capsules
129083|NCT01572727|Drug|BKM120|BKM120 daily oral capsules
129084|NCT01572740|Drug|liraglutide|Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
129085|NCT01572740|Drug|placebo|Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
129346|NCT01568606|Device|Body Composition Analysis InBody Scale|Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a "monitor-only" mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist.
129347|NCT01568632|Drug|Imetelstat|
135213|NCT01618175|Device|Home oxygen therapy|Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.
During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration.
135214|NCT01618188|Drug|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
135215|NCT01618188|Drug|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
135216|NCT00083967|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
135217|NCT01618214|Drug|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
135218|NCT01618227|Device|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
135465|NCT01616277|Biological|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
135466|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
135467|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
135468|NCT00083785|Device|LED-based light infusion device|
135469|NCT01616277|Drug|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
135470|NCT01609153|Drug|Olanzapine and Amisulpride|Zyprexa:
Coated tablet 5-20 mg milligram(s) per day for 16 weeks
Amisulpride:
Coated tablet 200-800 mg milligram(s)per day for 16 weeks
135471|NCT01609166|Drug|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
135472|NCT01609166|Drug|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
135473|NCT01609179|Drug|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
135474|NCT01609192|Drug|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
135119|NCT01615744|Procedure|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
135120|NCT01615744|Procedure|Non-surgical management|Early active exercises and elevation to decrease swelling
135121|NCT00083681|Drug|G-CSF|
135122|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
135123|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
135124|NCT01615770|Behavioral|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
135125|NCT01615783|Other|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
135126|NCT01615783|Other|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
135127|NCT01615796|Drug|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
135366|NCT01616121|Device|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
135367|NCT01616134|Other|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
135368|NCT01616134|Other|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
135369|NCT01616147|Behavioral|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
135370|NCT01616147|Behavioral|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
135371|NCT01616160|Drug|mometasone furoate|2 sprays/nostril BID
135372|NCT01616173|Drug|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
135373|NCT01616173|Drug|Dexamethasone|8mg/2mL
135571|NCT01609452|Other|Placebo|
135572|NCT00083135|Procedure|autologous bone marrow transplantation|
135573|NCT01609478|Drug|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
135574|NCT01609478|Drug|placebo|placebo delivered via Concept 1 inhaler
135575|NCT01609478|Drug|mometasone furoate|via Twisthaler inhaler
134722|NCT01614990|Drug|Placebo|placebo (Powerade®) daily for 7 days.
134723|NCT01615003|Drug|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
134724|NCT01615003|Drug|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
134725|NCT01615016|Other|Minimally invasive endotracheal surfactant application|What are the planned trial interventions?
MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device
InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).
Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.
Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26
134726|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^9 pfu/2mL administered into each deltoid
134727|NCT01615029|Drug|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
134728|NCT01615029|Drug|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
134729|NCT01615029|Drug|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
134730|NCT01617304|Other|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
134731|NCT00083915|Drug|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
134732|NCT01617317|Drug|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
135055|NCT01618396|Drug|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
135056|NCT01618409|Behavioral|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
135057|NCT00083980|Drug|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
135284|NCT01616043|Procedure|Glyaderm|acellular dermis
135285|NCT01616043|Procedure|STSG|autologous split skin only
135286|NCT01616056|Biological|graft versus host disease prophylaxis/therapy|Wear bandage lenses
135287|NCT01616056|Other|questionnaire administration|Ancillary studies
135288|NCT01618487|Procedure|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
135289|NCT01618513|Drug|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
135290|NCT01618526|Dietary Supplement|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
135291|NCT01618526|Dietary Supplement|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
135292|NCT01618539|Drug|propofol|varying intravenous dosages
135293|NCT01618552|Behavioral|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
135294|NCT01618552|Other|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
135295|NCT01618565|Procedure|Hands-On Training|one-time, 30 minute hands-on training
135296|NCT01618565|Procedure|Demonstration|30 minutes passive training
135297|NCT00083993|Drug|Temsirolimus (CCI-779) for 34 months|
135298|NCT01618578|Procedure|rubber hand illusion|There were three consecutive trials of the RHI:
one control trial: asynchronous condition (3 Min.)
two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)
135641|NCT01609530|Procedure|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
135642|NCT01609530|Procedure|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
135643|NCT00000120|Drug|Silver Nitrate Drops|
135644|NCT00000263|Other|0.25 g/Kg ethanol|
135645|NCT00001561|Drug|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
135646|NCT00083135|Procedure|peripheral blood stem cell transplantation|
135647|NCT01609543|Drug|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
134798|NCT01612676|Drug|FE 202158|
134799|NCT01612689|Device|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
134800|NCT01615029|Drug|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously [injection of a substance into a vein] before the daratumumab infusion and 20 mg orally after daratumumab infusion) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index [BMI] less than [<] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
134801|NCT01615042|Drug|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
134802|NCT01615055|Drug|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
134803|NCT01615055|Drug|Placebo|same as above with pharmacologically inactive tablets
134804|NCT01615081|Other|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
134805|NCT01615107|Device|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
134806|NCT01615107|Drug|PITOCIN|: Oxytocin infusion alone (Standard Protocol
134807|NCT00083616|Biological|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
134808|NCT01615107|Other|double balloonand oxytocin|balloonand oxytocin
134809|NCT01615107|Other|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
135374|NCT00083772|Drug|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
135375|NCT01616173|Drug|Saline|2mL
135376|NCT01616186|Drug|Everolimus and sorafenib|Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing
Everolimus and sorafenib are dosed continuously
(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)
135377|NCT01616186|Drug|Sunitinib monotherapy|Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing
(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)
135378|NCT01608984|Procedure|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
135379|NCT01609010|Drug|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
135380|NCT00083109|Other|Pharmacological Study|Correlative studies
135381|NCT01609010|Drug|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
135382|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
135383|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
135384|NCT01609088|Dietary Supplement|Erythritol-containing beverage|Orange flavored beverage containing erythritol
135695|NCT01616654|Drug|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
135696|NCT01616654|Drug|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
135697|NCT01616654|Drug|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
135698|NCT01616654|Drug|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
135699|NCT01616654|Drug|Vehicle cream|Vehicle cream applied once daily
135700|NCT01616667|Procedure|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
135701|NCT00083824|Drug|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
135702|NCT01616680|Drug|brentuximab vedotin|Given IV
134733|NCT01617317|Drug|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
134734|NCT01617330|Procedure|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
134735|NCT01617343|Behavioral|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.
Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s.
134988|NCT01618136|Drug|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
134989|NCT01618149|Radiation|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
134990|NCT01618162|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
134991|NCT01618162|Drug|placebo|Injected subcutaneously (under the skin) once daily.
134992|NCT01610765|Drug|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
134993|NCT00083252|Drug|talabostat (PT-100) tablets|
134994|NCT01610778|Dietary Supplement|Placebo|
134995|NCT01610778|Dietary Supplement|5-aminolevulinic acid phosphate|
134996|NCT01610791|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
134997|NCT01610817|Other|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
134998|NCT01610856|Drug|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
134999|NCT01610856|Drug|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
135000|NCT01610869|Drug|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
135299|NCT01618591|Drug|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
135300|NCT01618591|Drug|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
135301|NCT01618591|Drug|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
135302|NCT01618591|Drug|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
135303|NCT01618591|Drug|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
135630|NCT01616550|Other|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
135631|NCT01616550|Other|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
135632|NCT01616550|Other|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
135633|NCT01616563|Behavioral|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
135634|NCT01616563|Behavioral|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
135635|NCT01616576|Device|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
135636|NCT01609491|Drug|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
135637|NCT01609491|Drug|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
135638|NCT01609504|Procedure|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
135639|NCT01609504|Procedure|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
135640|NCT01609517|Drug|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
134810|NCT01615107|Procedure|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
134811|NCT01615120|Drug|GTx-758 125 mg|One 125 mg tablet once a day
134812|NCT01615120|Drug|GTx-758 250 mg|two 125 mg tablets once daily
134813|NCT01615146|Other|Platelet Transfusion|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.
Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is < 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded.
134814|NCT01615159|Behavioral|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
134815|NCT01615172|Procedure|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
134816|NCT01615185|Drug|full-dose amisulpride|amisulpride 800mg/d
135058|NCT01618422|Other|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
135059|NCT01618422|Other|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
135060|NCT01618435|Biological|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
135061|NCT01618448|Drug|Tolvaptan|Tolvaptan 15mg once daily
135062|NCT01618448|Drug|Placebo|Placebo
135063|NCT01618461|Behavioral|Drug indication icons|Icons illustrate the purpose of each medication
135064|NCT01618461|Behavioral|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
135065|NCT01618474|Drug|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
135703|NCT01616680|Other|laboratory biomarker analysis|Correlative studies
135704|NCT01616680|Other|pharmacological study|Correlative studies
135705|NCT01616693|Biological|Rotavirus vaccine (Rotarix), oral polio vaccine (Bio-polio), zinc supplement and probiotic supplement (Culturelle)|Oral rotavirus vaccine (Rotarix). 2 doses (1 ml) at 6 and 10 weeks of age.
Oral polio vaccine (Bio-polio). 3 doses (0.1 ml) at 6, 10 and 14 weeks of age.
Oral zinc sulphate syrup or placebo (1mg/ml; 5ml), given weekly starting 1 week pre-rotavirus vaccine dose 1 through 1 week post rotavirus vaccine dose 2.
Oral probiotic, Lactobacillus rhamnosus (Culturelle) or placebo (lx10^9; 20ml), given weekly starting 1 week pre-rotavirus vaccine dose 1 through 1 week post rotavirus vaccine dose 2.
135706|NCT01616719|Device|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
135707|NCT01616732|Drug|Testosterone|TU im
135708|NCT01616732|Drug|placebo|placebo im
135709|NCT01616758|Drug|GTx-024 9mg|
135710|NCT01616771|Device|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
135711|NCT01616771|Device|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
135712|NCT00001564|Drug|IL-2|
135713|NCT00083876|Drug|Thalidomide|
135714|NCT01616771|Device|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
135715|NCT01609647|Drug|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
135716|NCT01609647|Drug|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
135717|NCT01609660|Dietary Supplement|Saccharomyces boulardii|100mg daily for seven days prior to surgery
134875|NCT01612806|Procedure|moist wound therapy|standard of care moist wound therapy
134876|NCT01612832|Drug|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
134877|NCT01612832|Other|Control|pain treatment as customary in the department
134878|NCT01612845|Procedure|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
134879|NCT01612845|Biological|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
135001|NCT01610882|Device|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
135002|NCT01610882|Device|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
135003|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.
Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed.
135004|NCT00083252|Drug|cisplatin|
135237|NCT01611194|Drug|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
135238|NCT01611207|Device|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
135239|NCT01611207|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
135240|NCT01611220|Behavioral|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
135241|NCT01611246|Device|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
135242|NCT01611259|Drug|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
135243|NCT01611298|Biological|Tetanus|Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.
Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).
Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection.
135244|NCT00001563|Biological|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
135245|NCT00083330|Drug|VRC-HIVADV014-00-VP|
131422|NCT01603719|Dietary Supplement|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
131423|NCT01603745|Drug|Zoely|1 pill every day
131424|NCT01603745|Drug|Yasmin|1 pill every day
131425|NCT01603758|Drug|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
131426|NCT00082758|Biological|hu14.18-Interleukin-2 fusion protein|Given IV
131707|NCT01606813|Behavioral|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
131708|NCT01606813|Behavioral|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
131709|NCT01606852|Drug|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
131710|NCT00083018|Other|immunohistochemistry staining method|
131711|NCT01606878|Drug|crizotinib|Given orally
131712|NCT01606878|Drug|cyclophosphamide|Given IV
131713|NCT01606878|Drug|topotecan hydrochloride|Given IV
131714|NCT01606878|Drug|vincristine sulfate|Given IV
131715|NCT01606878|Drug|dexrazoxane hydrochloride|Given IV
131716|NCT01606878|Drug|doxorubicin hydrochloride|Given IV
131717|NCT01606878|Other|pharmacological study|Correlative studies
131718|NCT01606878|Other|laboratory biomarker analysis|Correlative studies
131719|NCT01606878|Other|pharmacogenomic studies|Correlative studies
131720|NCT01606878|Other|questionnaire administration|Ancillary studies
131721|NCT00001545|Device|Cadwell MES-10|
131722|NCT01599975|Drug|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
135066|NCT01618474|Drug|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
135067|NCT01618487|Procedure|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
135068|NCT00083980|Drug|Kava|140 to 280 mg per day
135069|NCT01618487|Procedure|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
135070|NCT01610908|Other|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
135071|NCT01610921|Other|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
135072|NCT01610934|Drug|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
135304|NCT01618604|Procedure|Quantitative Sensory Testing|following the standardized protocol of DFNS
135305|NCT01618604|Procedure|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
135306|NCT01618604|Procedure|Repetition of four QST parameters|warm detection threshold (WDT)
cold detection threshold (CDT)
mechanical detection threshold (MDT)
mechanical pain threshold (MPT)
135307|NCT01618617|Dietary Supplement|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
135308|NCT00001564|Drug|GM-CSF|
135309|NCT00083993|Drug|Letrozole for 34 months|
135310|NCT01611324|Drug|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
135311|NCT01611337|Other|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
135312|NCT01611350|Other|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
135475|NCT01609205|Biological|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
135476|NCT01609218|Drug|LY2140023|80 mg tablet LY2140023 monohydrate, administered orally
135477|NCT01609218|Drug|Aqueous activated charcoal|75 g aqueous activated charcoal, mixed with water and administered orally
135478|NCT00083122|Drug|alvocidib|Given IV
135479|NCT01609231|Drug|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
135480|NCT01609231|Drug|Irinotecan|Irinotecan 180 mg/m^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator, such as with dexamethasone or atropine will follow local, or country-specific standard of care.
135481|NCT01609231|Drug|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m^2 followed by weekly infusions of 250 mg/m^2. Pre-medication at the discretion of the investigator, such as with a histamine receptor antagonist or corticosteroid, will follow local, or country-specific standard of care.
135482|NCT01609244|Device|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
135483|NCT01609244|Device|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
135484|NCT01609257|Biological|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
135788|NCT01616940|Behavioral|Enhanced Peer Intervention|Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:
Introduction and Assessment
HIV Transmission & Viral Life Cycle
Effective Communication and Self-Advocacy
Understanding Lab Values
HIV Medications
Drug Resistance & Adherence, and Understanding & Managing Side Effects
Disclosure and Stigma
Harm & Risk Reduction
Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:
Are any services needed?
Have referrals or appointments been made?
Does patient need accompaniment to a visit?
Connect patient with services as needed.
Appointment reminders.
Overall well-being?
Schedule next peer contact.
135789|NCT01616953|Biological|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
135790|NCT01616953|Procedure|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
135791|NCT01616966|Drug|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
135792|NCT01616966|Drug|propofol|Maintenance of anesthesia with propofol
135793|NCT01616979|Procedure|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
135246|NCT01611311|Drug|BI 409306 BS|Medium dose film-coated tablet
135247|NCT01611311|Drug|BI 409306 BS|High dose film-coated tablet
135248|NCT01611311|Drug|Placebo|Film-coated tablet
135249|NCT01611324|Drug|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
135250|NCT01613495|Drug|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
135576|NCT01611792|Other|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
135577|NCT01611805|Drug|GSK1605786|Opaque Swedish orange body and cap.
135578|NCT01611805|Drug|GSK1605786 Placebo|Opaque Swedish orange body and cap.
135579|NCT01611818|Other|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
135580|NCT01611818|Other|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
135581|NCT01611818|Other|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
135582|NCT01611831|Behavioral|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
135583|NCT01611831|Behavioral|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
135584|NCT01611844|Device|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|2 intradermal injections are performed on each arm/bottom of the subject:
1 intradermal injection of Tuberculin (5UI)
1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right
135585|NCT00083408|Drug|Thalidomide|
131723|NCT01599975|Drug|Matched placebo|2 tablets of matched placebo daily by mouth
131724|NCT00082368|Drug|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
131725|NCT01599988|Dietary Supplement|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
131726|NCT01599988|Dietary Supplement|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
131727|NCT01600001|Drug|KWA-0711|
131728|NCT01600001|Drug|Placebo|
132003|NCT01596140|Drug|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
132004|NCT00081848|Drug|rF-CEA(6D)/TRICOM|
132005|NCT01596140|Drug|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
132006|NCT01596140|Drug|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
132007|NCT01596153|Dietary Supplement|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
132008|NCT01596166|Drug|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
132009|NCT01596166|Drug|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
132010|NCT01596179|Behavioral|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
132011|NCT01596179|Behavioral|Internet access|a netbook computer with internet access is provided to participants on the control arm.
132012|NCT01596192|Other|PETCT|CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).
CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec.
132013|NCT01596205|Behavioral|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
135313|NCT01611350|Other|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
135314|NCT01611350|Other|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
135315|NCT01611363|Drug|ASP1941|Oral
135316|NCT00083343|Drug|MK0991, caspofungin acetate/Duration of Treatment: variable|
135317|NCT01611363|Drug|Placebo|Oral
135318|NCT01611376|Device|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
135319|NCT01611389|Device|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
135320|NCT01611389|Device|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
135321|NCT01611415|Drug|Ipragliflozin|Oral
135322|NCT01611415|Drug|Furosemide|Oral
135323|NCT01611428|Drug|Ipragliflozin|Oral and Intravenous (i.v.)
135324|NCT01611454|Device|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
135648|NCT01609556|Drug|IMGN853|Dose escalation study. Dosing on day 1 of every 21 day cycle.
135649|NCT01609582|Drug|TAK-875|TAK-875 tablets
135650|NCT01609582|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
135651|NCT01609595|Drug|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
135652|NCT01609608|Procedure|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
135653|NCT01609621|Device|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
135654|NCT01609634|Other|Standard infant formula/follow-on formula|Standard infant formula/follow-on formula with added scGOS/lcFOS
135794|NCT01609816|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
135795|NCT00083148|Drug|irinotecan hydrochloride|
135796|NCT01609829|Procedure|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
135797|NCT01609842|Other|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
135798|NCT01609855|Drug|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
135799|NCT01609855|Drug|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
135800|NCT01609868|Dietary Supplement|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
135801|NCT01609868|Dietary Supplement|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
135802|NCT01609881|Drug|Acuvail|Dosing of drug 3 days prior to surgery
135803|NCT01609881|Other|Placebo|Artificial tears qid for 3 days preoperatively
135804|NCT01609894|Dietary Supplement|Individualized fortification of breast milk|Lactose, fat and protein content will be measured prior to breast milk fortification.
Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis.
134939|NCT01612897|Other|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
134940|NCT01612910|Drug|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
134941|NCT01612910|Other|laboratory biomarker analysis|Correlative studies
134942|NCT01612923|Other|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
134943|NCT01612936|Biological|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A "test dose" concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent.
135586|NCT01611844|Device|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|2 intradermal injections are performed on each arm/bottom of the subject:
1 intradermal injection of Tuberculin (5UI)
1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right
135587|NCT01611857|Drug|Tivantinib|Patients with advanced solid tumors will be treated with Tivantinib on Days 1 to 14
135588|NCT01611857|Drug|FOLFOX|This treatment regimen will be repeated on Day 1 of each 14-day (2 week) cycle.
135589|NCT01611870|Device|AVAPS-AE|AVAPS-AE is the experimental ventilation mode of therapy in this study that includes a combination of already cleared therapy attributes.
135590|NCT01611870|Device|AVAPS-AE mode of ventilator therapy|All participants will use the study device in the titrated to the AVAPS-AE mode of ventilator therapy for six weeks of home use.
135591|NCT01611883|Drug|Ezetimibe|10 mg oral dose once daily for 24 weeks
135592|NCT01611883|Drug|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
134736|NCT01617356|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
134737|NCT01617356|Other|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
134738|NCT01617369|Drug|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
134739|NCT01617421|Behavioral|Yoga|
134740|NCT01617434|Drug|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
134741|NCT01617434|Drug|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
134742|NCT00083915|Drug|Adriamycin|20mg/m2 continuous infusion -3 and -2.
134743|NCT01617447|Drug|Placebo of Aripiprazole|administered orally once daily
134744|NCT01617447|Drug|Aripiprazole|Flexibly dose administered orally once daily
134745|NCT01617460|Drug|Aripiprazole|Flexibly dose administered orally once daily
134746|NCT01617473|Procedure|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
134747|NCT01617486|Behavioral|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
132014|NCT01596205|Behavioral|Conventional cognitive training group|Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.
In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil.
132015|NCT00081848|Drug|Recombinant Fowlpox-GM-CSF|
132016|NCT01598064|Dietary Supplement|GK#10|GK#10, 1 pack tid
132017|NCT01598064|Drug|Placebo|Placebo 1 pack tid po
132018|NCT01598077|Drug|LJM716|
132019|NCT01598090|Biological|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
132020|NCT01598090|Biological|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
132021|NCT01598090|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
132303|NCT01592279|Drug|Insulin injections|
132304|NCT01592305|Drug|atazanavir|multiple oral doses
132305|NCT01592305|Drug|danoprevir|multiple oral doses
132306|NCT01592305|Drug|ritonavir|multiple oral doses
132307|NCT00081302|Biological|cetuximab|
132308|NCT01592305|Drug|tenofovir disoproxil fumarate|single oral doses
132309|NCT01592318|Drug|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
132310|NCT01592318|Drug|danoprevir|Reference tablet, single oral dose
132311|NCT01592318|Drug|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
132312|NCT01592318|Drug|ritonavir|Reference tablet, single oral dose
132313|NCT01592331|Drug|Placebo|Single oral dose
132314|NCT01592331|Drug|RO5508887|Single oral dose
132315|NCT01592344|Device|StimRouter - active stimulation|The stimulation program settings for this arm are as follows:
Stim Settings
Waveform: Symmetric or Asymmetric
Phase Duration: 100-250 µsec
Pulse Rate: 50-100 Hz
Intensity: 0-30mA Time Settings
Constant Stim: On
Total Time: 6 hour
135655|NCT01609634|Other|Standard infant formula/follow-on formula|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
135656|NCT01609634|Other|Standard infant formula/follow-on formula|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
135657|NCT00083135|Radiation|iobenguane I 131|
135658|NCT01611896|Other|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
135659|NCT01611909|Drug|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
135660|NCT00083421|Drug|ONO-2506PO|
135661|NCT01611922|Other|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
135662|NCT01611922|Device|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
135663|NCT01611935|Drug|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
135664|NCT01611948|Drug|Aprepitant|125mg/day for 8 weeks
135665|NCT01611948|Drug|Placebo|125mg/d placebo pill for 8 weeks
135666|NCT01611961|Drug|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
135667|NCT01611961|Drug|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
134817|NCT01615198|Drug|Olmesartan|10 mg, 20 mg, 40 mg capsules
134818|NCT00083629|Procedure|PET|
134819|NCT01615198|Drug|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
134820|NCT01615198|Drug|LCZ696|100 mg, 200 mg tablets
134821|NCT01615211|Drug|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
134822|NCT01615211|Drug|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
134944|NCT01612936|Procedure|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
134945|NCT00083538|Drug|Cyclophosphamide|
134946|NCT01612949|Other|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
134947|NCT01612975|Drug|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
134948|NCT01612975|Drug|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
134949|NCT01612988|Drug|BOMP|Day-8 OMB prephase:
Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8
BOMP cycle 1 and 2 :
Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15
BOMP cycle 3 to 6 :
Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3
134950|NCT01613014|Drug|ABT-436|Target dose - 400mg BID
134951|NCT01613014|Drug|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
135485|NCT01609257|Biological|Saline Comparator|2 doses IM 28 days apart
135486|NCT01609270|Device|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
135487|NCT01609283|Biological|autologous mesenchymal stem cells|There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:
Group 1: single intrathecal dose of 1 x 107 cells
Group 2: single intrathecal dose of 5 x 107 cells
Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells
Group 4: single intrathecal dose of 1 x 108 cells
Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells
135488|NCT01609296|Device|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
135489|NCT00083122|Drug|cisplatin/flavopiridol|Given IV
134748|NCT01617499|Behavioral|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
134749|NCT01617512|Device|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
134750|NCT01617525|Other|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
134751|NCT01617538|Drug|atorvastatin|40mg per day,duration for 24 weeks
134752|NCT01610284|Drug|BKM120 Matching placebo|BKM120 matching placebo, daily oral
134753|NCT01610284|Drug|Fulvestrant|Fulvestrant 500mg given intramuscularly at cycle 1 day 1, cycle 1 day 15 and at day 1 at each cycle thereafter
134754|NCT01610284|Drug|BKM120|BKM120 100mg, daily oral capsules
134755|NCT01610297|Drug|ICL670|
134756|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
135005|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|Patients will be instructed to arrive for colonoscopy at or after 10 AM.
Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.
Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed.
135006|NCT01610908|Other|The Schroth exercises treatment|The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.
Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months.
135007|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 1
135008|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 11
135009|NCT01613040|Drug|RO4917838|Multiple daily low doses of RO4917838 for 10 days
135010|NCT01613040|Drug|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
135011|NCT00083538|Drug|Etoposide|
135012|NCT01613040|Drug|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
135013|NCT01613053|Drug|Glivec|800 mg per day
132316|NCT01594281|Procedure|Laser photocoagulation|
132317|NCT01594281|Procedure|Ranibizumab & laser photocoagulation|
132318|NCT00081575|Drug|Tigecycline|
132319|NCT01594294|Device|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
132320|NCT01594294|Device|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
132321|NCT01594294|Device|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
132322|NCT01594294|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
132323|NCT01594294|Device|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
132324|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
132325|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
131427|NCT01603771|Other|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
131428|NCT01603784|Behavioral|Intensive Exercise|Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by "cool-down" activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at ~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max.
131429|NCT01603784|Behavioral|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
131430|NCT01603784|Behavioral|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
134823|NCT01617551|Drug|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
134824|NCT00083915|Drug|Etoposide|80mg/m2 continuous infusion -3 and -2.
134825|NCT01617564|Drug|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
134826|NCT01617564|Other|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
134827|NCT01617577|Drug|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
134828|NCT01617577|Drug|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
134829|NCT01617590|Drug|leflunomide|Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.
Intravenous CTX was administrated once 200-400mg per 3 weeks.
134830|NCT01617590|Drug|methotrexate|MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.
Intravenous CTX was administrated once
134831|NCT01617603|Other|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
134832|NCT01617629|Biological|MUC1 Dendritic Cell Vaccine (Cvac)|The recommended dosing regimen for CAN-003X is every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).
Patients who received more than 3 doses of Cvac in CAN-003 should continue with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)
134833|NCT01617655|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
134834|NCT01617655|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
135073|NCT01610934|Drug|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
135074|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
135490|NCT01611688|Drug|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
135491|NCT01611688|Drug|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
135492|NCT01611688|Drug|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
135493|NCT00083382|Drug|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
135494|NCT01611701|Procedure|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
135495|NCT01611701|Procedure|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.
135496|NCT01611714|Other|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
135497|NCT01611714|Other|Clinical Decision Support|Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the "headache" electronic charting template.
135498|NCT01611727|Drug|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
135512|NCT01614041|Drug|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
135513|NCT01614054|Other|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
135514|NCT01614067|Drug|GnRH antagonist|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
135515|NCT01614093|Drug|Oxytocin|Single dose intranasal oxytocin (24 IU)
135516|NCT01614093|Drug|Placebo|Placebo control
135517|NCT01614106|Behavioral|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
135014|NCT01613066|Procedure|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
135015|NCT01613079|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
135016|NCT01613079|Drug|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
135017|NCT01613092|Drug|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
135018|NCT01613092|Drug|Cefazolin|Preoperative antibiotic
135019|NCT01613105|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
135020|NCT01613118|Drug|RE-021 (Sparsentan)|Oral, once-daily
135021|NCT01613118|Drug|Irbesartan|Oral, once-daily
135022|NCT00083551|Drug|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
135251|NCT01613495|Drug|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
135252|NCT01613508|Procedure|Direct Anterior Approach|
135253|NCT01613508|Procedure|Mini-Posterior Approach|
135254|NCT01613521|Other|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
135255|NCT01613534|Drug|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
135256|NCT01613534|Drug|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
135257|NCT01613547|Drug|Amoxicillin|80 mg/kg/day for 7 days
131431|NCT01603784|Behavioral|Health Education|Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a "homework" assignment.
131432|NCT01603797|Behavioral|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
131433|NCT01603810|Other|OCT|Optical coherence tomography of periocular basal cell carcinoma
131434|NCT01603836|Biological|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
131435|NCT01603849|Radiation|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
131436|NCT01606202|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
131437|NCT01606215|Drug|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
131438|NCT01606215|Drug|Placebo|Placebo
131729|NCT01600014|Drug|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
131730|NCT01600014|Drug|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
131731|NCT01600027|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
131732|NCT01600027|Procedure|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
131733|NCT01600040|Radiation|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
131734|NCT01600053|Drug|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
135075|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
135076|NCT01610960|Device|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
135077|NCT01610960|Device|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
135078|NCT00083278|Drug|MDX-010|
135079|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
135080|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
135081|NCT01610986|Dietary Supplement|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
135082|NCT01610986|Dietary Supplement|Water|Only water intake during training
135083|NCT01610999|Drug|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
135084|NCT01611038|Dietary Supplement|Methylselenocysteine|Methylselenocysteine capsule given daily
135085|NCT01611038|Dietary Supplement|Placebo|Placebo capsule given daily
135086|NCT01611051|Drug|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
135087|NCT01611051|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
135088|NCT01613209|Drug|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
135089|NCT01613209|Drug|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
135090|NCT01613222|Device|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
135091|NCT00083551|Drug|Ara-C|Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).
Start infusion 30 minutes after completion of BCNU on day -5.
135325|NCT01611454|Device|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during fluoroscopy guided interventions.
135518|NCT00083551|Drug|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
135519|NCT01614119|Other|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
135520|NCT01614132|Drug|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
135521|NCT01614132|Radiation|Radiotherapy|Radiotherapy of the partial brain
135522|NCT01614158|Device|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) [Schiefer 2008] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
135523|NCT01614158|Other|D-BCVA|D-BCVA using EDTRS chart
135524|NCT01614158|Other|RAPD|RAPD using swinging flashlight test
135525|NCT01616277|Biological|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
135526|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
135527|NCT01616277|Biological|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
135528|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
135529|NCT01616277|Biological|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
135530|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
135531|NCT01616290|Drug|PRT-201|0.03, 1, or 3 mg single adventitial administration
135532|NCT01616303|Drug|Carboplatin & paclitaxel|Carboplatin (AUC 6, administered intravenously in a single day for 6 cycles every three weeks [21 days])plus paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks [21 days])
135805|NCT01609894|Dietary Supplement|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
135806|NCT00083161|Drug|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
135807|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
135808|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
135258|NCT01613547|Drug|Placebo|7 days
135259|NCT00083551|Drug|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as < 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
135260|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
135261|NCT01613560|Drug|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
135262|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
135263|NCT01613573|Drug|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
135264|NCT01613573|Drug|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
135265|NCT01613586|Drug|ASP3652|Oral
135266|NCT01613586|Drug|Placebo|Oral
135267|NCT01613612|Procedure|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
135593|NCT01611896|Dietary Supplement|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
135594|NCT01614158|Device|IOP|IOP using applanation tonometer
135595|NCT01614158|Device|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
135596|NCT01614158|Other|Fundus photography|Optic disk morphology will be documented by fundus photography
135597|NCT01614171|Biological|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
135598|NCT00083551|Drug|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
135599|NCT01614184|Drug|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
131735|NCT00082368|Drug|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
131736|NCT01600079|Biological|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
131737|NCT01600092|Biological|RotaTeq™ experimental formulation|
131738|NCT01600092|Biological|RotaTeq™ existing formulation|
131739|NCT01600105|Drug|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
131740|NCT01600118|Device|Extracorporeal shockwave therapy|1000 impulses
131741|NCT01600118|Device|No extracorporeal shockwave|0 impulses, acoustic effect
131742|NCT01600131|Behavioral|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
131743|NCT01600131|Other|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
131744|NCT01602328|Biological|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
131745|NCT01602328|Biological|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
131746|NCT01602341|Drug|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
131747|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
132022|NCT00082160|Procedure|Functional Magnetic Resonance Imaging|
132023|NCT01598090|Drug|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
132024|NCT01598103|Drug|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
132025|NCT01598103|Drug|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
132026|NCT01598116|Procedure|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
132027|NCT01598116|Procedure|Urine collection|Bagged urine collection
135326|NCT01611467|Drug|CC-223|20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
135327|NCT00083356|Procedure|Wisdom tooth extraction|
135328|NCT01611467|Drug|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
135329|NCT01611480|Drug|Imiquimod (topical use)|
135330|NCT01611493|Device|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
135331|NCT01611493|Device|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
135332|NCT01611506|Biological|Cetuximab|Induction chemotherapy:
Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter
Followed by:
Cetuximab 250mg/m2 weekly on day 1 during chemoradiation
Postoperative treatment:
3 cycles of Cetuximab 250mg/m2 weekly on day 1
135333|NCT01613612|Procedure|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
135334|NCT01613625|Procedure|Elastography|
135335|NCT00083551|Drug|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
135336|NCT01613638|Other|meconium samples + maternal self-questionnaire|meconium samples + maternal self-questionnaire
135337|NCT01613651|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
135338|NCT01613651|Other|questionnaire administration|Ancillary studies
135339|NCT01613651|Other|intraoperative complication management/prevention|Undergo placement of pelvic drain
135340|NCT01613664|Drug|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
135341|NCT01613664|Other|no tisseel|the surgeon does not applied tissucol during the surgery
135342|NCT01613677|Drug|BKM120|
135343|NCT01613690|Drug|NVA237|NVA237 is administered via a BREEZHALER device
135344|NCT01613703|Drug|ONO-2952|1 mg to 200 mg QD at a single descending dose
135809|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
135810|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
135811|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
135812|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
135813|NCT01609920|Drug|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
135814|NCT01609933|Drug|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
135815|NCT01612143|Drug|setrobuvir|200 mg capsule formulation, single oral dose
135816|NCT01612143|Drug|setrobuvir|200 mg tablet formulation, single oral dose
135817|NCT01612156|Drug|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
135818|NCT01612156|Drug|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
135819|NCT01612169|Behavioral|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
135820|NCT01612169|Behavioral|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
135821|NCT01612182|Other|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
134952|NCT01615328|Device|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
134953|NCT01615354|Drug|Aleglitazar|Multiple oral doses
134954|NCT01615354|Drug|Microgynon®|Multiple oral doses
134955|NCT01615354|Drug|Placebo|Multiple oral doses
135600|NCT01614197|Drug|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
135601|NCT01614197|Drug|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
135602|NCT01614197|Drug|Etoposide phosphate|For patients allergic to etoposide. 100 mg/m2 IV daily x 5 days on days 1-5.
135603|NCT01614197|Drug|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
135604|NCT01614197|Drug|Methotrexate|PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.
Age 1 - 1.99 give 8 mg of methotrexate
Age 2 - 2.99 give10 mg of methotrexate
Age 3 - 8.99 give 12 mg of methotrexate
Age ≥ 9 give 15 mg of methotrexate
PATIENTS WITH CNS 2 or 3 DISEASE
-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.
COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age
135605|NCT01614197|Drug|Hydrocortisone|Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.
COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.
COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age
135606|NCT01614197|Drug|Cytarabine|For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1
Age 1 - 1.99 give 30 mg of Cytarabine
Age 2 - 2.99 give 50mg of Cytarabine
Age ≥ 3 give 70 mg of Cytabine
For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.
COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.
16 mg for patients age 1-1.99
20 mg for patients age 2-2.99
24 mg for patients 3-8.99 years of age
30 mg for patients >9 years of age
135607|NCT01614210|Drug|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
134757|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
134758|NCT00083187|Drug|laromustine|
134759|NCT01610323|Other|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
134760|NCT01610323|Other|Standard Care|
134761|NCT01610336|Drug|INC280|experimental
134762|NCT01610362|Biological|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
132028|NCT01598129|Genetic|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
132029|NCT01598142|Procedure|Team 1|experienced endoscopist with a experienced assistant
132030|NCT01598142|Procedure|Team 2|same experienced endoscopist with a new trained assistant
132031|NCT01598155|Procedure|Group 1 - Supragingival biofilm control|30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):
Scaling, planning and polishing coronary surface;
Education and motivation for oral hygiene and daily supragingival biofilm control by the patient.
132032|NCT01598155|Procedure|Group 2 - Supra- and subgingival biofilm control|30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):
Scaling, planning and polishing of coronary surface;
Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;
Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged.
132033|NCT00082173|Drug|Moxifloxacin|400mg daily for 8 weeks
132034|NCT01598168|Drug|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
132035|NCT01598181|Device|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
132036|NCT01598181|Device|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
132037|NCT01598194|Device|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
132038|NCT01598207|Drug|Marinol|5mg BID, orally for 1 month
132039|NCT01598207|Drug|Placebo|5mg BID, orally for 1 month
132040|NCT01591954|Device|Video Augmentation|Assessment of value of video-based navigation system
132041|NCT01591967|Device|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
132326|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
132327|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
132328|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
132329|NCT00081575|Drug|Levofloxacin|
135345|NCT01613716|Drug|Dexamethasone implant (Ozurdex)|Ozurdex .7 mg injected into the treated eye
135668|NCT01611974|Drug|Maribavir|Tablet for oral administration
135669|NCT01611987|Other|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
135670|NCT01611987|Other|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
135671|NCT00083434|Drug|Epoetin alfa|
135672|NCT01612000|Biological|PanBlok|Intramuscular injection
135673|NCT01612000|Biological|rHA adjuvant|Intramuscular injection
135674|NCT01612013|Drug|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
135675|NCT01614223|Drug|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
135676|NCT01614236|Drug|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
135677|NCT01614236|Drug|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
135678|NCT01614249|Dietary Supplement|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
135679|NCT01614249|Dietary Supplement|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
135680|NCT01614262|Other|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
134956|NCT01615367|Other|Nutrition, Exercise, and Wellness (NEW) psychotherapy|NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
134957|NCT01615367|Drug|Typically consists of at least one FDA-approved mood stabilizer|Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
134958|NCT01615380|Behavioral|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
134959|NCT01615380|Behavioral|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
134960|NCT01615393|Drug|ribavirin [Copegus]|Single oral dose of 400 mg tablets
134961|NCT01615393|Drug|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
134962|NCT00083681|Drug|Dexamethasone|
134963|NCT01615406|Drug|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
134964|NCT01615432|Device|V-PAP III ventilator|
134965|NCT01615432|Device|Stellar 150 ventilator|
134966|NCT01615432|Device|BiPAP vision ventilator|
134967|NCT01615432|Device|V60 ventilator|
134968|NCT01615445|Drug|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
134969|NCT01615445|Drug|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
135499|NCT01611740|Procedure|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|Telemonitoring system prototype developed by INSERM U-642 with analysis of :
the variability of the cardiac cycle duration ;
the variability of respiratory cycle amplitude and duration ;
and their relationships.
135500|NCT01611753|Other|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
134763|NCT01610375|Other|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
134764|NCT01610388|Drug|500mg IV GSK1322322/placebo|500mg IV
134765|NCT01610388|Drug|1000mg oral GSK1322322/placebo|1000mg oral
134766|NCT01610388|Drug|1000mg IV GSK1322322/placebo|1000mg IV
134767|NCT01610388|Drug|1500mg oral GSK1322322/placebo dose|1500mg oral
134768|NCT01610388|Drug|1500mg IV GSK1322322/placebo|1500mg IV
134769|NCT00001561|Drug|GM-CSF|
134770|NCT00083213|Biological|ziv-aflibercept|
134771|NCT01610388|Drug|2000mg IV GSK1322322J/placebo|2000mg IV
134772|NCT01610388|Drug|3000mg IV GSK1322322J/placebo|3000mg IV
134773|NCT01610388|Drug|1000mg IV GSK1322322J/placebo|1000mg IV
134774|NCT01610401|Drug|Metformin|metformin 500 mg three times a day, for 3 days
134775|NCT01610401|Drug|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
134776|NCT01610401|Drug|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
134777|NCT01612507|Drug|Placebo|1 h infusion
134778|NCT01612507|Drug|600 mg Ceftaroline fosamil|2 h infusion
135023|NCT01613131|Drug|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
135024|NCT01613131|Drug|Estradiol|Topical, .06%, Applied once daily for 50 days.
135025|NCT01613131|Drug|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
135026|NCT01613170|Drug|Toviaz, Premarin Vaginal Cream|Toviaz 4mg daily Premarin estrogen cream 1 g per vagina twice weekly
132330|NCT01594320|Biological|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 & Day 21
132331|NCT01594333|Drug|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
132332|NCT01594333|Drug|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
132333|NCT01594346|Drug|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
132334|NCT01594346|Drug|Sugar Pill|
132335|NCT01594359|Other|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
132336|NCT01594359|Other|BEAN|Placebo
132337|NCT01594372|Procedure|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
132338|NCT01594372|Procedure|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
132339|NCT01596673|Drug|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
132340|NCT01596686|Drug|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
132341|NCT01596699|Drug|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
132342|NCT01596699|Drug|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
132343|NCT01596699|Drug|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
132344|NCT01596699|Drug|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
132345|NCT01596712|Drug|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
132346|NCT00001515|Device|virtual bronchoscopy|
132347|NCT00081900|Drug|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m^2, then escalating to 120mg/m^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
131439|NCT01606228|Drug|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
134835|NCT00083915|Drug|Melphalan|200 mg/m2 IV over <20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
134836|NCT01617655|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
134837|NCT01617668|Drug|Paclitaxel + LCL161|
134838|NCT01617668|Drug|paclitaxel|iv 80mg/m2
134839|NCT01617681|Drug|VAL489|Valsartan 3mg/kg oral solution
134840|NCT01617681|Drug|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
134841|NCT01610414|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
134842|NCT01610414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
134843|NCT01610427|Procedure|Blood sample collection|Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
134844|NCT01610440|Biological|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
134845|NCT00083226|Drug|doxorubicin|Given IV
134846|NCT01610453|Procedure|ultrasound examination|transabdominal and transperineal ultrasound examinations
134847|NCT01610466|Procedure|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
134848|NCT01610479|Drug|TAS-114 + S-1|
134849|NCT01610492|Drug|belimumab|10mg/kg administered intravenously
134850|NCT01610505|Device|Medial knee compartment osteoarthritis treatment - surgical|Surgical treatment intended to reduce or eliminate pain and improve the function of a knee affected by medial compartment osteoarthritis.
134851|NCT01610518|Dietary Supplement|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
134852|NCT01610518|Dietary Supplement|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
134853|NCT01610531|Other|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
135501|NCT01611766|Procedure|Secondary Cytoreductive Surgery|Complete Cytoreduction
135502|NCT01611766|Drug|Salvage Chemotherapy|
135503|NCT01611779|Device|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
135504|NCT00083408|Drug|Pamidronate|
135505|NCT01611792|Other|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
135506|NCT01613989|Procedure|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
135507|NCT00083551|Drug|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
135508|NCT01614015|Behavioral|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
135509|NCT01614015|Behavioral|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
135510|NCT01614028|Procedure|Total Hip Arthoplasty|
135511|NCT01614041|Drug|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
135533|NCT01616303|Biological|Carboplatin & paclitaxel & oregovomab|Carboplatin (AUC 6, administered intravenously in a single day for 6 cycles every three weeks [21 days]) plus paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks [21 days]) plus oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
135534|NCT00083785|Device|Light emitting diodes (LED)|
135027|NCT01613183|Drug|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
135028|NCT01613183|Other|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
135029|NCT01613196|Other|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|2 or 3 FDG-PET scans will be performed in all patients : at inclusion*, end of treatment and 6 months after completion of treatment in cases of persistent uptake
*except if already done in the last 15 days.
135030|NCT01615484|Procedure|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
135031|NCT00083681|Drug|Cytoxan|
135032|NCT01615484|Device|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
135033|NCT01615497|Behavioral|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
135034|NCT01615497|Behavioral|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
135035|NCT01615497|Behavioral|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
135036|NCT01615510|Drug|Tapentadol immediate release|100 mg, single administration
135037|NCT01615510|Drug|placebo|placebo, single administration
135038|NCT01615523|Other|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
135268|NCT01615900|Other|Teleconsultation / Standard consultation|Stage 1: randomization. Two arms: teleconsultation and standard consultation
Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.
Stage 3: follow-up (2 years) according to the group:
Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year
Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year
Teleconsultation low risk: same follow-up as "standard consultation low risk" group but all the consultations are teleconsultations
Teleconsultation high risk: same follow-up as "standard consultation high risk" group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)
131440|NCT01606241|Drug|Cyclophosphamide|Given PO
131441|NCT01606241|Other|Laboratory Biomarker Analysis|Correlative studies
131442|NCT01606241|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
131443|NCT01606254|Drug|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
131444|NCT00082979|Procedure|breast duct lavage|
131445|NCT01606267|Other|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
131446|NCT01606293|Behavioral|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
131447|NCT01606306|Drug|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
131448|NCT01606306|Drug|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
131449|NCT01606306|Drug|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
131450|NCT01606319|Drug|Acetaminophen|15 mg/kg every 6 hours as needed
131451|NCT01606319|Drug|Ibuprofen|9.4 mg/kg every 6 hours as needed
131452|NCT01606332|Procedure|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
131453|NCT01606345|Drug|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
131454|NCT01606358|Drug|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
131455|NCT00083005|Drug|docetaxel|
131456|NCT01606371|Drug|Placebo|Administered orally
131457|NCT01606371|Drug|LY2409021|Administered orally
131458|NCT01606384|Drug|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
131459|NCT01606384|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
134854|NCT01610544|Drug|3'-deoxy-3'-18F fluorothymidine (FLT)|
134855|NCT01610544|Other|PET/CT scan|
134856|NCT00083226|Drug|bortezomib|Given IV
135092|NCT01613235|Other|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
135093|NCT01613248|Drug|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
135094|NCT01613248|Drug|Placebo|Single administration of placebo taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
135095|NCT01613248|Drug|Rescue medication|If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,
participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans or other medication not explicitly excluded.
135096|NCT01613261|Drug|TAK-733 and alisertib|TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.
Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle.
135097|NCT01613274|Other|gum chewing|gum chewing three times a day for up to 20 minutes
135098|NCT01613274|Other|no gum chewing|no gum chewing
135099|NCT01613287|Device|TheraSorb® - Ig flex|TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.
5 treatments performed over 5 to 8 consecutive days.
135100|NCT01613300|Drug|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
135101|NCT01613313|Drug|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
135102|NCT00083551|Drug|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
135103|NCT01613326|Drug|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
135104|NCT01613326|Drug|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
135535|NCT01616316|Procedure|subfascial flap|subfacial dissection to thyroid
135536|NCT01616316|Procedure|subplatysmal flap|subplatysmal approach to thyroid
135537|NCT01616342|Device|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
135538|NCT01616355|Other|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
135539|NCT01616368|Behavioral|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
135540|NCT01616381|Drug|Sildenafil|PDE-5 Inhibitor
135541|NCT01616381|Drug|Placebo|Placebo for sildenafil 40mg x 3 daily
135542|NCT01616407|Drug|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
135543|NCT01616407|Drug|Methylphenidate|40 mg per os, single dose
135544|NCT01616407|Drug|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
135545|NCT00083785|Procedure|Photodynamic therapy|
135546|NCT01616420|Other|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
135547|NCT01616433|Behavioral|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
135548|NCT01616433|Behavioral|"10 Keys" to Healthy Aging|"10 Keys" to Healthy Aging. 10 week program, twice a week, 75 minutes per session.
135549|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
135550|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
135551|NCT01609309|Procedure|Laparoscopic gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy.
135552|NCT01609309|Procedure|Open gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience.
135269|NCT01615913|Drug|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
135270|NCT00083720|Biological|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
135271|NCT01615913|Drug|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
135272|NCT01615913|Drug|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
135273|NCT01615939|Drug|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
135274|NCT01615939|Drug|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
135275|NCT01615965|Other|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
135276|NCT01615978|Drug|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
135277|NCT01615978|Drug|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
135278|NCT01615978|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
135279|NCT01615991|Drug|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
135280|NCT01616004|Drug|N2O|
135281|NCT00083759|Drug|natalizumab|
135282|NCT01616004|Drug|Air|sham comparator
135283|NCT01616030|Other|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
135608|NCT01614210|Procedure|Breast cancer surgery|Breast cancer surgery
135609|NCT00083564|Drug|STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)|
131460|NCT01606397|Drug|Placebo|Administered orally (capsule)
131748|NCT01602341|Drug|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
131749|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
131750|NCT01602367|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
131751|NCT01602367|Drug|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
131752|NCT01602367|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
131753|NCT00082576|Drug|Azithromycin/Chloroquine|
131754|NCT01602367|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
131755|NCT01602380|Drug|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
131756|NCT01602380|Drug|arimidex 1mg|oral tablet 1 daily
131757|NCT01602380|Drug|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
131758|NCT01602380|Drug|arimidex dummy|oral tablet 1 daily
131759|NCT01602393|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
131760|NCT01602393|Drug|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
131761|NCT01602393|Drug|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
131762|NCT01602406|Drug|LJM716|
131763|NCT01602406|Drug|Trastuzumab|
131764|NCT00082576|Drug|Mefloquine|
131765|NCT01602419|Other|Patients using wilate as standard of care|Patients with von Willebrand Disease using wilate for a period of 2 years.
131766|NCT01602458|Procedure|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
135105|NCT01613326|Drug|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
135106|NCT01613326|Drug|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
135107|NCT01615614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
135108|NCT01615614|Drug|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
135346|NCT00001564|Drug|EF-1 Peptide|
135347|NCT00083551|Drug|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
135348|NCT01613716|Drug|Ozurdex|
135349|NCT01613729|Drug|Rosuvastatin 5 mg|Rosuvastatin 5 mg
135350|NCT01613729|Drug|Rosuvastatin 10 mg|
135351|NCT01613755|Drug|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
135352|NCT01613755|Drug|Metformin|Metformin 500 mg twice daily for four days
135353|NCT01613768|Drug|eribulin mesylate|Given IV
135354|NCT01613781|Other|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
135355|NCT01613781|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
135356|NCT01613794|Drug|Rosuvastatin|20 mg od
135357|NCT01613807|Drug|Insulin LISPRO|Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
135358|NCT01616056|Procedure|optical coherence tomography|Optional ancillary studies
135359|NCT01616069|Drug|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
135360|NCT01616082|Behavioral|Low Calorie Diet (LCD)|A Diet History Questionnaire will be completed, and the subjects will have dietary counseling and be provided shakes. The low calorie diet will begin, to continue for a period of 8 weeks.
134705|NCT01612455|Behavioral|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
134706|NCT01612468|Drug|Liraglutide|1.8 mg/day subcutaneous
134707|NCT01612468|Drug|Placebo|1.8 mg/day subcutaneous
134708|NCT01612481|Procedure|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
134709|NCT01612481|Procedure|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
134710|NCT01612494|Drug|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
134711|NCT01612494|Other|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
134712|NCT00083525|Drug|WX-UK1 in combination with Capecitabine|
134713|NCT01612507|Drug|600 mg Ceftaroline fosamil|1 h infusion
134714|NCT01614951|Procedure|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
134715|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^8 pfu/2mL administered into each deltoid
134716|NCT01614951|Drug|HTK Custodiol|Pulmoplegia before ECC.
134717|NCT01614951|Other|Standard ECC|ECC after standard procedure
134718|NCT01614964|Drug|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
134719|NCT01614964|Drug|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
134720|NCT01614977|Drug|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
135610|NCT01614223|Procedure|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
135611|NCT01616459|Biological|Synflorix™|Intramuscular injection
135612|NCT01616459|Biological|Prevnar 13™|Intramuscular injection
135613|NCT01616459|Biological|Infanrix hexa™|Intramuscular injection
135614|NCT01616472|Drug|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
135615|NCT01616485|Drug|TA-1790|2 TA-1790 100 mg capsules
135616|NCT00083785|Procedure|Phototherapy|
135617|NCT01616485|Drug|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
135618|NCT01616485|Drug|Placebo|2 placebo capsules for TA-1790 100 mg capsules
135619|NCT01616485|Drug|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
135620|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
135621|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
135622|NCT01616524|Biological|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
135623|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
135624|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
135625|NCT01616524|Drug|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
135626|NCT01616524|Drug|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
135627|NCT00083785|Procedure|Chemotherapy|
135628|NCT01616537|Other|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
135629|NCT01616550|Other|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
131767|NCT01602458|Procedure|Silicone Pressure Garment Therapy (SPGT)|SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.
The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment.
132042|NCT01591980|Drug|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
132043|NCT01591980|Drug|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
132044|NCT01591980|Drug|placebo|Identical placebo capsules will be administered in the same way.
132045|NCT01591993|Procedure|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
132046|NCT00081289|Drug|Irinotecan|50mg/m^2 IV over 1 hour on days 1, 8, 22, and 29
132047|NCT01591993|Procedure|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
132048|NCT01592006|Drug|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
132049|NCT01592006|Drug|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
132050|NCT01592006|Drug|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
132051|NCT01592019|Drug|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
132052|NCT01592019|Device|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
132053|NCT01592019|Drug|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
132054|NCT01592019|Device|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
135361|NCT01616082|Drug|Phentermine|Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
Protection Against Risk:
Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.
Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated.
135362|NCT00001564|Drug|E7 Peptide|
135363|NCT00083759|Drug|placebo|
135364|NCT01616108|Drug|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
135365|NCT01616121|Other|Usual treatment of patients with developing acute heart failure|
135681|NCT01614275|Behavioral|Parent-training Curriculum|The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate "child" will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback.
135682|NCT01614275|Behavioral|Technology-Enhanced Tutor Training|The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate "child" will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback.
135683|NCT01614275|Behavioral|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
135684|NCT00083577|Drug|Thalidomide|
135685|NCT01614275|Behavioral|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
135686|NCT01614288|Procedure|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
134721|NCT01614990|Drug|Macimorelin|Subjects will receive different doses of macimorelin (0.25, 0.5 or 1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
134970|NCT01615458|Behavioral|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
134971|NCT01615471|Behavioral|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
134972|NCT01618019|Dietary Supplement|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
134973|NCT00083941|Biological|TroVax in combination with IL-2|1ml intramuscular injection
134974|NCT01618032|Other|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
134975|NCT01618032|Other|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
134976|NCT01618032|Other|placebo|Manual contact during a period of time similar of teh other interventions
134977|NCT01618045|Dietary Supplement|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
134978|NCT01618058|Drug|No Investigational Product|This study is observational in nature and no investigational product will be used.
Groups: ARV-Treated Participants, ARV-Naive Participants
134979|NCT01618071|Dietary Supplement|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
134980|NCT01618084|Device|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
134981|NCT01618097|Behavioral|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
134982|NCT01618097|Behavioral|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
134983|NCT01618110|Device|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
134984|NCT00083954|Drug|Quetiapine Fumarate|
134985|NCT01618110|Other|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
134986|NCT01618136|Drug|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
134779|NCT01612507|Drug|Placebo|2 h infusion
134780|NCT01612520|Behavioral|telecoaching|The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.
The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).
The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy.
134781|NCT01612546|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
134782|NCT01612546|Other|Laboratory biomarker analysis|Correlative studies
134783|NCT01612546|Other|Pharmacological studies|Correlative studies
134784|NCT01612598|Other|counseling intervention|Undergo PCI
134785|NCT01612598|Procedure|quality-of-life assessment|Ancillary studies
134786|NCT00083538|Drug|Dexamethasone|
134787|NCT01612598|Other|questionnaire administration|Ancillary studies
134788|NCT01612598|Other|educational intervention|Undergo PCI
134789|NCT01612637|Behavioral|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
134790|NCT01612637|Behavioral|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
134791|NCT01612650|Device|tomosynthesis|2 incidences 3D numeric mammography
134792|NCT01612650|Device|2D mammography|2 incidences 2D analogic mammography
134793|NCT01612663|Device|Pain relief by Acupuncture needle at non-specific site|
134794|NCT01612663|Device|Acupuncture needle|
134795|NCT01612663|Device|Acupuncture needle|
132055|NCT01592032|Drug|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
132056|NCT01592032|Drug|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
132057|NCT00081289|Drug|Oxaliplatin|50mg/m^2 IV over 2 hours on days 1, 8, 15, 22, and 29
132058|NCT01593787|Drug|LCZ696|100 mg, 200 mg, 400 mg tablets.
132348|NCT01596712|Drug|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
132349|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
132350|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
132351|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
132352|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
132353|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
132354|NCT01596725|Biological|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
132355|NCT01596738|Drug|Tranexamic Acid|Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction
Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization
132356|NCT01596738|Drug|Saline|Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction
Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization
132357|NCT01596751|Drug|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
132358|NCT00081913|Genetic|Cell Therapy - Autologous CD34 Positive Cells|
132359|NCT01596751|Drug|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
132360|NCT01596764|Drug|Loperamide placebo|200 ml apple juice
132361|NCT01596764|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
135687|NCT01614288|Other|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
135688|NCT01616576|Device|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
135689|NCT01616602|Other|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
135690|NCT00083824|Drug|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
135691|NCT01616602|Other|Standard Position|The traditional left-lateral decubitus position
135692|NCT01616615|Drug|Aspirin|150 mg/day oral use
135693|NCT01616615|Drug|placebo|1 capsule / day oral use
135694|NCT01616628|Behavioral|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
134857|NCT01610557|Drug|Ranibizumab and Bevacizumab|Eyes are randomly assigned to receive a set sequence of monthly eye injections; all eyes receive ranibizumab at some time points and bevacizumab at others during the cross-over study.
134858|NCT01610557|Drug|Bevacizumab|
134859|NCT01610570|Drug|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
134860|NCT01610596|Drug|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
134861|NCT01610596|Drug|Placebo|
134862|NCT01612702|Drug|Dexamethasone|Dexamethasone 10 mg intravenous administration
134863|NCT01612715|Other|Segmental Allergen Challenge|segmental allergen challenge
134864|NCT01612728|Other|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine & Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
134865|NCT01612728|Drug|Women with Arthralgia|
134987|NCT01618136|Drug|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
135219|NCT01618227|Procedure|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
135220|NCT01618240|Other|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
135221|NCT01618240|Other|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
135222|NCT01618253|Drug|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
135223|NCT01618253|Radiation|Conventional fractionation (2 Gy per day) external beam radiation therapy|Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or >10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If >1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.
The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions >10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced.
135224|NCT01618266|Drug|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
135225|NCT01618292|Procedure|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
135226|NCT01618305|Drug|Lamivudine/zidovudine|Participants will receive one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day.
135227|NCT00083980|Drug|Venlafaxine ER|75 to 225 mg daily
135228|NCT01618305|Drug|Efavirenz|Participants will receive one 600 mg tablet of efavirenz each night.
135229|NCT01618305|Drug|Raltegravir|Participants will receive one 400 mg raltegravir tablet twice a day.
135230|NCT01618331|Behavioral|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
135231|NCT01611168|Other|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
135232|NCT01611181|Drug|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
135233|NCT00083304|Other|Supplemental Oxygen|4 L/minute by nasal cannula.
Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days.
134796|NCT01612663|Device|Acupuncture needle|
134797|NCT00083538|Drug|Thalidomide|
135039|NCT01615536|Procedure|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
135040|NCT01615536|Procedure|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
135041|NCT01615549|Procedure|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
135042|NCT00083681|Drug|Etoposide|
135043|NCT01615575|Procedure|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
135044|NCT01615575|Procedure|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
135045|NCT01615588|Dietary Supplement|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
135046|NCT01615601|Drug|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
135047|NCT01615601|Drug|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
135048|NCT01615601|Drug|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
135049|NCT01615601|Drug|Other antiretroviral medications|Given as per Canadian Product Monograph
135050|NCT01618331|Dietary Supplement|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
135051|NCT01618357|Radiation|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
135052|NCT01618357|Procedure|Lumpectomy/Mastectomy|Resection of breast cancer.
135053|NCT01618370|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
135054|NCT01618383|Other|colonoscopy or rectosigmoidoscopy|Usual procedure
132362|NCT01596764|Device|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
132363|NCT01598909|Drug|Arnica|Application of Arnica ointment periorbitally
132364|NCT00082277|Drug|Anastrozole|1mg/Day Oral
132365|NCT01598909|Drug|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
132366|NCT01598922|Behavioral|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
132367|NCT01598935|Other|nutrition|protein-based food
132368|NCT01598948|Drug|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
132369|NCT01598961|Other|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
135201|NCT01615861|Procedure|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
135202|NCT01615861|Device|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
135203|NCT01615874|Drug|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
135204|NCT00083707|Drug|Thalidomide|
135205|NCT01615874|Drug|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
135206|NCT01615874|Drug|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
135207|NCT01615874|Drug|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
135208|NCT01615874|Drug|Montelukast tablets 5 mg (4 mg for children 5 years of age)|Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age
OR
Montelukast chewable tablets 4 mg QD for children 5 years of age
135209|NCT01615874|Drug|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
135210|NCT01615874|Drug|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
135211|NCT01615887|Drug|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
135212|NCT01615887|Drug|placebo|sugar pill
134866|NCT01612741|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
134867|NCT01612754|Behavioral|Noise reduction work place rules|Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of "workplace rules" on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.
Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones.
134868|NCT01612754|Behavioral|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
134869|NCT01612767|Device|PRO-Kinetic Energy Stent|Coronary artery stent implant
134870|NCT00083538|Drug|Cisplatinum|
134871|NCT01612780|Device|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
134872|NCT01612793|Device|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
134873|NCT01612806|Device|PriMatrix|fetal bovine dermal scaffold
134874|NCT01612806|Device|PriMatrix Ag|fetal bovine dermal scaffold with Ag
135109|NCT01615627|Drug|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
135110|NCT00083681|Drug|Cisplatin|
135111|NCT01615627|Drug|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
135112|NCT01615653|Procedure|EUS|EUS Guided Therapy
135113|NCT01615718|Procedure|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
135114|NCT01615718|Procedure|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
135115|NCT01615731|Drug|Mifepristone|200mg Mifepristone orally
135116|NCT01615731|Other|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
135117|NCT01615731|Drug|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
135118|NCT01615731|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op
135234|NCT01611181|Drug|Kräuterblut|40 mg iron, 20 ml twice daily.
135235|NCT01611181|Drug|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
135236|NCT01611194|Drug|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
135553|NCT01609322|Behavioral|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
135554|NCT01609322|Behavioral|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
135555|NCT01609335|Drug|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
135556|NCT01609335|Drug|C-11 PiB|One time intravenous administration of 10-20 mCi
135557|NCT01609348|Drug|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
135558|NCT01609348|Drug|Venlafaxine|225 mg daily for 12 weeks
135559|NCT01609361|Other|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
135560|NCT01609374|Device|M6-C Artificial Cervical Disc|Total disc replacement
135561|NCT00083135|Biological|filgrastim|
135562|NCT01609374|Device|Anterior plate system with corticocancellous allograft bone|Cervical fusion
135563|NCT01609387|Dietary Supplement|Fit For me|
135564|NCT01609387|Dietary Supplement|Davitamon|
135565|NCT01609413|Dietary Supplement|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
135566|NCT01609413|Dietary Supplement|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
135567|NCT01609426|Genetic|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
135568|NCT01609439|Drug|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
135569|NCT01609439|Drug|Placebo|Placebo
135570|NCT01609452|Biological|Blisibimod|
132225|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
132226|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
131345|NCT00082485|Other|Placebo|Placebo
131346|NCT01601743|Behavioral|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
131347|NCT01603602|Drug|Normal Saline (Placebo)|Subjects will receive intramuscular injections of normal saline (placebo) into specified muscles of the upper limb.
131348|NCT01603615|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A into the upper limb muscles and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments. Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/kg) per treatment.
131349|NCT01603628|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb.
131350|NCT01603628|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb.
131351|NCT01603628|Drug|Normal Saline (Placebo)|Subjects will receive intramuscular injections of normal saline (placebo) into specified muscles of the lower limb.
131352|NCT01603641|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments. Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/kg) per treatment.
131353|NCT01603654|Drug|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
131354|NCT01603654|Drug|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
131355|NCT01603667|Drug|PG2|STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.
ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
131356|NCT00082745|Other|Questionnaire Administration|Ancillary studies
131357|NCT01603667|Drug|placebo|STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.
ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
132001|NCT01596114|Other|Stopping treatment with TKI|stopping until loss of MMR
132002|NCT01596127|Drug|Intrathecal Rituximab|Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.
Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I.
132286|NCT01598688|Other|Blood collection immediately after interrupting CSA infusion|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
For peripheral blood collection, venous access will be established with a small gauge needle.
The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL.
132287|NCT01598688|Other|Blood collection five minutes after interrupting CSA infusion|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
For peripheral blood collection, venous access will be established with a small gauge needle.
The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL.
132288|NCT01598701|Drug|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
132289|NCT01592214|Drug|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
132290|NCT01592214|Drug|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
132291|NCT01592227|Drug|Marketed paracetamol|Marketed paracetamol
132292|NCT01592227|Drug|Experimental paracetamol formulation|Experimental paracetamol formulation
132293|NCT01592240|Drug|PBO|Placebo Q28d
132294|NCT01592240|Drug|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
132295|NCT01592240|Drug|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
132296|NCT00081289|Drug|Oxaliplatin|85 mg/m^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
132297|NCT01592240|Drug|PBO|Placebo, Q14d
132298|NCT01592240|Drug|PF-04950615|PF-04950615 50mg, Q14d
131787|NCT01606956|Procedure|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
131788|NCT01606956|Procedure|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
131789|NCT01606969|Drug|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 2% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
131790|NCT01606969|Drug|scalp infiltration solution|1:200000 epinephrine-containing 2% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
131791|NCT01606982|Drug|MDV3100|oral
131792|NCT01606995|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
131793|NCT00083018|Procedure|breast duct lavage|
131794|NCT01607008|Other|MRI imaging|3 total MRI imaging studies:
pre standard radiation treatment
during standard radiation treatment
post standard radiation treatment
131795|NCT01607034|Drug|Dexpramipexole|150 mg single dose
131796|NCT01607060|Drug|Lactulone|Patients will receive lactulone to daily laxation
132078|NCT00081510|Drug|Lonafarnib|
132079|NCT01593969|Dietary Supplement|RUTF/Flax Oil|Ready to Use Therapeutic Food
132080|NCT01593969|Dietary Supplement|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
132081|NCT01596218|Drug|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
132082|NCT01596231|Dietary Supplement|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
132083|NCT01596231|Dietary Supplement|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
132084|NCT01596244|Behavioral|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
131552|NCT01599754|Drug|Placebo|Placebo twice daily
131553|NCT01599767|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
131554|NCT00082342|Device|Phoressor II (IOMED)|sham stimulation
131555|NCT01599793|Drug|cabozantinib|Given PO
131556|NCT01599793|Other|laboratory biomarker analysis|Correlative studies
131557|NCT01599793|Procedure|magnetic resonance imaging|Undergo MRI
131558|NCT01599806|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
131559|NCT01599806|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
131560|NCT01599806|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
131561|NCT01602029|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
131562|NCT01602029|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
131563|NCT00082524|Drug|caspofungin acetate|Duration of Treatment - 7-90 days
131564|NCT01602029|Drug|Placebo|Placebo added to TAU
131565|NCT01602029|Drug|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
131566|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
131567|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
131568|NCT01602068|Drug|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
131569|NCT01602068|Drug|100 mM sodium citrate buffer solution|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
131854|NCT01604655|Procedure|Stress Test|Stress Test
131855|NCT01604681|Dietary Supplement|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
131358|NCT01603680|Procedure|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
131359|NCT01603680|Procedure|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
131627|NCT01599806|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
131628|NCT01599819|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
131629|NCT01599819|Biological|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
131630|NCT01599832|Drug|pazopanib hydrochloride|Given PO
131631|NCT00082342|Device|Phoressor II (IOMED)|real tDCS stimulation
131632|NCT01599832|Other|laboratory biomarker analysis|Correlative studies
131633|NCT01599832|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
131634|NCT01599832|Other|pharmacogenomic studies|Correlative studies
131635|NCT01599858|Drug|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
131636|NCT01599858|Drug|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
131637|NCT01599871|Drug|theophylline|theophylline 100 mg, twice at day
131638|NCT01599871|Other|placebo|Placebo
131639|NCT01599884|Drug|N-acetylcysteine|1800 mg twice daily for 8 weeks
131640|NCT01599884|Drug|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
131641|NCT01599897|Biological|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
131642|NCT00082355|Drug|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
131643|NCT01599897|Biological|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
132299|NCT01592240|Drug|PF-04950615|PF-04950615 100 mg, Q14d
132300|NCT01592240|Drug|PF-04950615|PF-04950615 150mg, Q14d
132301|NCT01592253|Drug|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
132302|NCT01592279|Drug|liraglutide|
131409|NCT00082498|Drug|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
131410|NCT01601808|Drug|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
131411|NCT01601821|Drug|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
131412|NCT01601821|Drug|CsA+MMF+CS|The control arm is the standard local practice (official protocol) in Iran:
Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS.
131413|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
131414|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
131415|NCT01601847|Dietary Supplement|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
131416|NCT01601847|Drug|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
131417|NCT01601860|Other|Use of non-pharmacological|Evaluation of maternal and perinatal outcomes associated with the use of non-pharmacological
131418|NCT01601873|Device|Heparin-bonded vascular access graft|Heparin-bonded graft implantation for hemodialysis vascular access
131419|NCT01601873|Device|Conventional ePTFE hemodialysis graft|non-heparin bonded conventional hemodialysis vascular access graft
131420|NCT00082498|Drug|Placebo|Patients in Group 1 will receive placebo.
131421|NCT01603706|Procedure|Echo guided implantation group|Lead placement according echo strain imaging result
132085|NCT01596257|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
132086|NCT01596257|Device|CliniMACS|
132087|NCT01596270|Drug|SAR245409|Pharmaceutical form: tablet Route of administration: oral
132088|NCT01596283|Procedure|Standard fluid management|The patient will receive standard fluid management
132089|NCT01596283|Device|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
132090|NCT01596296|Device|Transcervical foley catheter|16 French foley catheter insertion
132091|NCT00081848|Drug|Celecoxib|
132092|NCT01596296|Drug|Dinoprostone 10mg|Dinoprostone vaginal insertion
132093|NCT01596309|Dietary Supplement|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
132094|NCT01596335|Drug|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
132095|NCT01596335|Drug|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
132096|NCT01596387|Drug|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
131221|NCT01605929|Procedure|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
131222|NCT01605942|Drug|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
131223|NCT00082979|Genetic|cytogenetic analysis|
131224|NCT01605942|Drug|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
131856|NCT01604681|Dietary Supplement|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
131857|NCT01604694|Procedure|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
131858|NCT01604707|Other|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
131859|NCT01604746|Biological|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
131860|NCT00082836|Biological|rituximab|
131861|NCT01604759|Device|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
131862|NCT01604772|Drug|Akt Inhibitor MK2206|Given PO
131863|NCT01604772|Other|Laboratory Biomarker Analysis|Correlative studies
131864|NCT01604785|Drug|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q15 minutes to a maximum of 5 doses
131865|NCT01604785|Drug|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
131866|NCT01604798|Other|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
131867|NCT01604811|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
131868|NCT01604811|Drug|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
131869|NCT01604811|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
131870|NCT01607112|Biological|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
131871|NCT01607125|Drug|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
131872|NCT01607125|Drug|Placebo|capsules, orally, once daily for 13 to 14 days
131873|NCT00083031|Biological|bevacizumab|
131874|NCT01607151|Other|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
131875|NCT01607151|Other|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
131644|NCT01599910|Other|Scribes|Scribe
131645|NCT01599923|Biological|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
131646|NCT01599936|Biological|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
131647|NCT01599949|Drug|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
131927|NCT01596062|Drug|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
131928|NCT01597934|Drug|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
131929|NCT01597947|Drug|ACHN-975|Intravenous single dose
131930|NCT01597947|Drug|placebo|Intravenous single dose
131931|NCT01597960|Other|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
131932|NCT01597960|Other|Usual care|Those randomised to usual care alone will undergo the series of baseline and follow-up investigations (i.e. before and after their cardiac rehabilitation programme).
131933|NCT01597973|Drug|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
131934|NCT01597973|Drug|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
131935|NCT01597986|Drug|isavuconazole|oral
131936|NCT00001521|Drug|Flutamide and Testolactone|
131937|NCT00082147|Procedure|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
131938|NCT01597986|Drug|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
132892|NCT01593085|Behavioral|interview with a doctor for evaluating suicide risk|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
132893|NCT01593111|Other|Environmental Intervention|Home-based environmental intervention
132894|NCT01593124|Drug|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
132895|NCT01593124|Other|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
132896|NCT00081380|Drug|divalproex (mood stabilizer)|
132897|NCT01593124|Drug|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
132898|NCT01593137|Drug|Liraglutide + metformin|Liraglutide 1.8 mg/day + metformin >1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.
Patients will continue on metformin therapy as they were prescribed before enrolment.
132899|NCT01593137|Drug|Glimepiride + metformin|Glimepiride 4 mg/day + metformin >1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.
Patients will continue on metformin therapy as they were prescribed before enrolment.
132900|NCT01593150|Drug|Pradaxa|Pradaxa for 3 weeks prior to DC
132901|NCT01593150|Procedure|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
132902|NCT01593150|Other|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
133143|NCT01593462|Behavioral|Study Questionnaires|The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.
A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. Answering the questionnaires should take no longer than 10 to 40 minutes to complete.
133144|NCT01593475|Radiation|Induction chemotherapy followed by CCRT|Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy
Radiotherapy
- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively.
131225|NCT01605968|Device|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
131226|NCT01608139|Drug|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
131227|NCT01608139|Drug|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
131228|NCT01608152|Behavioral|Needs Analysis|Focus group discussion lasting about 1½ hours. Several weeks after focus group, return visit to provide opinions on game development.
131229|NCT01608152|Behavioral|Video game|Instructions given at clinic visit on using video game through the internet. Participant asked to play game at home for 3 weeks.
131230|NCT01608152|Behavioral|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
131231|NCT01608165|Procedure|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
131232|NCT00083083|Drug|vinblastine sulfate|
131233|NCT01608165|Procedure|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
131234|NCT01608165|Procedure|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
131235|NCT01608191|Behavioral|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
131236|NCT01608217|Drug|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
131237|NCT01608217|Drug|Placebo|placebo (tablet) three times daily for a period of three weeks.
131238|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
131239|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
131240|NCT01608243|Biological|SLIT tablets of house dust mite allergen extracts|10 dosing days
131494|NCT01602003|Drug|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
131495|NCT01602016|Drug|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
132155|NCT01594047|Drug|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
132156|NCT01594060|Drug|regular insulin|4 shots of regular insulin: 3 before meals and one at bedtime.
132157|NCT01594060|Drug|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
132158|NCT01594086|Dietary Supplement|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
132159|NCT01594099|Radiation|irradiation|EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).
132160|NCT01594099|Drug|Cisplatin|EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).
Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy.
132161|NCT01594099|Drug|liposome paclitaxel|EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).
Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy.
132162|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
132163|NCT00081510|Drug|anastrozole|
132164|NCT01594125|Drug|Nintedanib low dose|twice daily oral dosing
132165|NCT01596465|Other|Self-Study using MP3 Player|Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or "shuffle" files in random order. Each heart sound file was introduced by the narrated phrase "Identify this sound,", followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training.
132166|NCT01596465|Other|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
132167|NCT01596478|Behavioral|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
132168|NCT01596478|Behavioral|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
131939|NCT01597999|Radiation|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
131940|NCT01598012|Drug|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
131941|NCT01598012|Drug|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
131942|NCT01598025|Radiation|total-body irradiation (TBI)|
131943|NCT01598025|Drug|thiotepa|
131944|NCT01598025|Drug|fludarabine phosphate|
132227|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
132228|NCT01594138|Other|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
132229|NCT01594151|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
132230|NCT01594164|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
132231|NCT01594164|Radiation|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
132232|NCT01594177|Drug|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
132233|NCT01594177|Drug|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
132234|NCT00081536|Drug|Aroplatin (Liposomal NDDP) in combination with capecitabine|
132235|NCT01594177|Drug|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
132236|NCT01594177|Drug|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
132237|NCT01594177|Drug|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
132238|NCT01594190|Behavioral|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
132239|NCT01594190|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
132240|NCT01594203|Other|F18-FGD PET/CT|
132241|NCT01594216|Drug|Ruxolitinib|
133145|NCT01593488|Drug|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
133146|NCT01593501|Dietary Supplement|vitamin D3|pharmaceutical grade D3
133147|NCT01593514|Biological|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
133148|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
133149|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
133150|NCT01593514|Biological|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
133151|NCT01593514|Biological|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
133152|NCT01593527|Drug|ACZ885|Canakinumab 150 mg s.c.
133153|NCT00081458|Drug|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
133154|NCT01595685|Drug|Telbivudine|Telbivudine 600 mg Daily Oral
133155|NCT01595685|Drug|Entecavir|Entecavir 0.5 mg Daily Oral
133457|NCT00084695|Drug|busulfan|Given orally
133458|NCT01627041|Drug|Daunorubicin Hydrochloride|Given IV
133459|NCT01627041|Drug|Decitabine|Given IV
133460|NCT01627041|Other|Laboratory Biomarker Analysis|Correlative studies
131496|NCT01602016|Drug|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
131497|NCT01603862|Procedure|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
131498|NCT00082784|Drug|Bortezomib|Given IV
131499|NCT01603875|Biological|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
131500|NCT01603888|Other|no intervention|
131501|NCT01603901|Device|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
131502|NCT01603914|Device|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.
The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.
A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site.
131503|NCT01603927|Device|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
131504|NCT01603940|Drug|Benazepril|Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
131505|NCT01603940|Drug|Losartan|Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
131506|NCT01603979|Biological|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
131507|NCT01604005|Radiation|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
131508|NCT01604031|Biological|B-CLL Vaccine|Patients will receive a fixed dose (2X10^7) of IL-2 secreting B-cells together with (2X10^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
131509|NCT00082784|Drug|Alvocidib Hydrochloride|Given IV
132169|NCT01596478|Behavioral|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
131295|NCT01606007|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
131296|NCT01606007|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
131297|NCT01606020|Other|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
131298|NCT01606020|Other|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
131299|NCT01606033|Other|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
131300|NCT01606033|Other|questionnaire|understanding of the implications of participating in a clinical trial
131301|NCT01606046|Device|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
131302|NCT01606046|Drug|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
131303|NCT01606059|Drug|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
131304|NCT01606059|Drug|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
131305|NCT00082979|Other|cytology specimen collection procedure|
131306|NCT01606072|Drug|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
131307|NCT01606085|Behavioral|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
131308|NCT01606085|Behavioral|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
131309|NCT01606098|Procedure|Surgery of the primary tumour|Surgical resection of the colon tumour
131310|NCT01606098|Drug|Systemic treatment|First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:
5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)
131311|NCT01606111|Drug|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
132242|NCT01594216|Drug|Exemestane|
132243|NCT01594229|Drug|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
132244|NCT01594229|Drug|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
132245|NCT00081549|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
132246|NCT01594229|Drug|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
132247|NCT01594242|Other|Bortezomib|
132248|NCT01594255|Drug|sotrastaurin|
132249|NCT01594255|Drug|sotrastaurin|
132250|NCT01594255|Drug|placebo to sotrastaurin|
131360|NCT01603693|Device|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
131361|NCT01603693|Device|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
131362|NCT01606111|Drug|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
131363|NCT01606124|Drug|defined green tea catechin extract|Given PO
131364|NCT01606124|Other|placebo|Given PO
131365|NCT01606124|Other|questionnaire administration|Ancillary studies
131366|NCT00001545|Device|Magstim Super Rapid Magnetic Stimulator|
131367|NCT00082979|Other|immunohistochemistry staining method|
131368|NCT01606124|Other|laboratory biomarker analysis|Correlative studies
131369|NCT01606137|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
133461|NCT01627041|Other|Pharmacological Study|Correlative studies
133462|NCT01627054|Drug|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
133463|NCT01627067|Drug|Everolimus|10 mg by mouth once daily.
133464|NCT01627067|Drug|Exemestane|25 mg by mouth once daily.
133465|NCT01627067|Drug|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
133466|NCT01619956|Procedure|Osteotome sinus floor elevation|After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a "greenstick" fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre.
133467|NCT01619956|Procedure|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
133468|NCT01619969|Drug|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
133469|NCT01619969|Drug|placebo|Capsules of identical appearance containing starch
133470|NCT01619982|Drug|Cefazolin pre-operative prophylaxis|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery.
133471|NCT01619982|Drug|Vancomycin hydrochloride|Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is > 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is > 8 hours in duration.
133472|NCT01620008|Procedure|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
133473|NCT01620034|Radiation|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
133474|NCT01620047|Drug|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
132627|NCT01599195|Device|AudioDoc|AudioDoc has the capability of recording sounds of blood flow in open or narrowed femoral or carotid arteries simply by placing head of stethoscope against selected vessel
131797|NCT01607073|Drug|Verapamil|Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.
Children will start on a 4 weeks titration period:
Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID
In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study.
131798|NCT01607086|Drug|Cherry lamotrigine ODT|25mg, taken orally on one study visit
131799|NCT01607086|Drug|Cherry Placebo|Taken orally on one study visit
131800|NCT01607099|Procedure|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
131801|NCT01600144|Other|digital mammography|data collection
131802|NCT01600157|Procedure|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
131803|NCT00082381|Drug|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
131804|NCT01600170|Drug|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
131805|NCT01600170|Drug|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
131806|NCT01600183|Device|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
131807|NCT01600183|Procedure|cast|casting of the infant legs
131808|NCT01600196|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
131809|NCT01600222|Drug|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
131810|NCT01600235|Drug|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
131811|NCT01600248|Behavioral|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
131812|NCT01600274|Drug|Ethyinylestradiol Dienogest combination|A: One tablet of Test B: One tablet of Reference
2 x 0.03 mg EE = 0.06 mg EE 2 x 2 mg DNG = 4 mg DNG
132097|NCT01596400|Drug|granisetron transdermal system|patch
132098|NCT01596400|Drug|Granisetron IV|IV
131312|NCT01608464|Drug|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
131313|NCT01608490|Device|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
131314|NCT01608503|Procedure|lung deflation|lung was deflated during respiration cycle
131570|NCT01602081|Device|reinforce soft tissue|reinforce soft tissue
131571|NCT01602107|Other|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
131572|NCT01602120|Drug|FCFD4514S|Repeating intravitreal injection
131573|NCT01602133|Procedure|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
131574|NCT00001533|Drug|cyclosporine|
131575|NCT00082537|Drug|caspofungin acetate|Duration of Treatment: 28-90 days
131576|NCT01602146|Other|ultramarathon running|blood samples before and after ultramarathon
urinary samples before and after ultramarathon
voluntary ant electrically muscular forces measuring before and after ultramarathon
Broadband ultrasound Attenuation before and after ultramarathon
131577|NCT01602159|Procedure|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
131578|NCT01602159|Procedure|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
131579|NCT01602172|Behavioral|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
131580|NCT01602172|Other|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
131581|NCT01602185|Drug|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
131370|NCT01606150|Drug|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
131371|NCT01606150|Drug|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
131372|NCT01606163|Biological|GC1102|Description: GC1102 IV bolus injection during 10~ 30 seconds.
Amount: group1-3ml, group2-5ml, group3-8ml
Subject number: group1-8, group2-8, group3-8
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)
131373|NCT01606163|Other|JW normal saline|Description: Normal saline IV bolus injection through 10~ 30 seconds.
Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.
Subject number: 9
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)
131374|NCT01606176|Drug|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
131375|NCT01606176|Drug|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
131648|NCT01599962|Drug|Cinacalcet|single administration, 90mg
131649|NCT01599962|Drug|Placebo|single administration
131650|NCT01599975|Drug|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
131651|NCT01602185|Drug|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
131652|NCT01602185|Drug|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
131653|NCT01602198|Drug|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
131654|NCT01602198|Drug|Placebo patch|Placebo patch 1/day for 6 months
131655|NCT00082537|Drug|Comparator: AmBisome|Duration of Treatment: 28-90 days
131656|NCT01602211|Other|Internet-Based Intervention|Receive full access to INSPIRE
131657|NCT01602211|Other|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
131658|NCT01602211|Other|Medical Chart Review|Ancillary studies
131659|NCT01602211|Other|Quality-of-Life Assessment|Ancillary studies
132628|NCT01599208|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
132629|NCT00082290|Other|visit with a volunteer|
132630|NCT01599221|Device|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
132631|NCT01599234|Drug|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
132632|NCT01599234|Drug|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
132633|NCT01599260|Other|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
132634|NCT01599273|Drug|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
132635|NCT01599286|Drug|Carbaglu|Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG) The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg. and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube standard of care will prevail when choosing the mode of drug administration.
The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.
132636|NCT01599286|Drug|Placebo|
132637|NCT01599286|Drug|Standard Care Treatment|
132638|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for 12 weeks.
132639|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for 12 weeks.
132640|NCT00081328|Drug|Rosiglitazone|capsule, 4 mg bid
132641|NCT01592747|Drug|Placebo capsules|Patients randomized to the placebo will be dosed once daily for 12 weeks.
132642|NCT01592760|Device|air-Q SP|air-Q SP placement for airway maintenance.
132643|NCT01592760|Device|air-Q|air-Q placement for airway maintenance.
132644|NCT01592760|Device|i-gel|i-gel placement for airway maintenance.
132099|NCT01596413|Drug|Sancuso|granisetron transdermal system
132100|NCT01596413|Drug|IV granisetron|IV
132101|NCT01596426|Drug|Sancuso|granisetron transdermal system
132102|NCT00081861|Drug|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
132103|NCT01596426|Drug|IV granisetron|IV granisetron
132104|NCT01598220|Behavioral|Computer-assisted cognitive remediation therapy|Comparison of two groups:
The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.
The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient.
132105|NCT01598220|Other|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
132106|NCT01598233|Device|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
132107|NCT01598259|Drug|Melatonin|po 1 hour before bedtme
132108|NCT00082186|Drug|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
132109|NCT01598259|Other|placebo|po, 1 hour before bed
132110|NCT01598272|Dietary Supplement|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
132111|NCT01598272|Dietary Supplement|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
132112|NCT01598298|Drug|duloxetine hydrochloride|Given PO
132113|NCT01598298|Other|placebo|Given PO
132114|NCT01598311|Drug|CB-183,315|oral, 250 mg bid for 10 days
132115|NCT01598311|Drug|oral vancomycin|oral, 125 mg qid for 10 days
132116|NCT01598337|Drug|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
132117|NCT01598337|Drug|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
132118|NCT01598337|Drug|Clopidogrel|75 mg orally started 6-8hours before surgery
132119|NCT00082199|Drug|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
131582|NCT01604096|Other|Multifaceted information campaign|Following is the description of the multifaceted intervention:
brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)
posters (same distribution as brochures)
short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies
radio-spots transmitted in local radio stations
advertisements in local newspapers
banners on websites of local newspapers
newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists
training courses in counselling strategies, directed to a subgroup of GPs and paediatricians
131583|NCT01604109|Drug|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
131584|NCT00082784|Other|Pharmacological Study|Correlative studies
131585|NCT01604109|Drug|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
131876|NCT01607164|Behavioral|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
131877|NCT01607177|Behavioral|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
131878|NCT01607203|Drug|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
131879|NCT01607203|Drug|pregnyl|5000 IU SC
131880|NCT01607229|Other|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
131881|NCT01607242|Other|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
131882|NCT01607242|Other|Voice Handicap Index|Subjective Evaluation of Voice disorders
131883|NCT01607242|Other|Swallowing Assesment|Swallowing function questionnaire
131884|NCT00083031|Drug|cyclophosphamide|
131885|NCT01607255|Drug|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
131886|NCT01607255|Procedure|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
131887|NCT01607255|Procedure|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
131660|NCT01602211|Other|Questionnaire Administration|Ancillary studies
131661|NCT01602224|Drug|Placebo|Administered IV
131662|NCT01602224|Drug|Dexamethasone|Administered orally
131663|NCT01602224|Drug|Bortezomib|Administered SQ
131664|NCT01602224|Biological|Tabalumab|Administered IV
131665|NCT01602250|Drug|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
131666|NCT00082563|Drug|Azithromycin/Chloroquine|
131667|NCT01602250|Drug|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
131668|NCT01602263|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
131669|NCT01602276|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
131670|NCT01602289|Biological|LY2875358|Administered IV
131671|NCT01602289|Drug|Erlotinib|Administered orally
131672|NCT01602289|Drug|Gefitinib|Administered orally
131945|NCT01598025|Drug|melphalan|
131946|NCT01598025|Biological|anti-thymocyte globulin|
131947|NCT01598025|Procedure|allogeneic hematopoietic stem cell transplantation|
131948|NCT00082160|Behavioral|Meditation|
131949|NCT01598025|Biological|peripheral blood stem cell transplantation|
131950|NCT01598025|Other|laboratory biomarker analysis|
131951|NCT01598038|Other|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
131952|NCT01598051|Drug|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
131953|NCT01591824|Other|Resonant oscillation|Resonant sustained oscillations are applied in the following areas
general column.
lumbar muscles, and paraspinal muscles,
sacral decompression oscillatory
Opening by lateral vertebral lumbar rhythmic swing.
Balancing and pelvic decompression
Swing-lumbar vertebral rotation.
132903|NCT01593163|Drug|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
132904|NCT01593163|Drug|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
132905|NCT01593176|Procedure|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
132906|NCT01593189|Behavioral|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
132907|NCT00001507|Device|Baxter Isolex 3001 Stem Cell Selection System|
132908|NCT00081406|Behavioral|Individual Child CBT|
132909|NCT01595282|Drug|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
132910|NCT01595295|Other|non interventional|
132911|NCT01595308|Dietary Supplement|Pomegranate juice|Pomegranate juice
132912|NCT01595321|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
132913|NCT01595321|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Vaccine will be administered one day after cyclophosphamide (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
132914|NCT01595321|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first vaccine dose (Arm 2) or within 6-10 weeks of surgery (Arm 1).
132915|NCT01595321|Drug|FOLFIRINOX|FOLFIRINOX will be administered over 6 cycles starting at least 14 days after SBRT (Arms 1 and 2) and at least 28 days after the first vaccine (Arm 2).
132916|NCT01595334|Drug|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (>4.5 mIU/ml) in the study arm
132917|NCT01595334|Drug|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
131241|NCT01608243|Biological|Matching placebo|10 dosing days
131242|NCT01608269|Drug|Abacavir/Lamivudine|one tablet once a day
131243|NCT00083083|Drug|vinorelbine tartrate|
131244|NCT01608282|Behavioral|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
131245|NCT01608295|Drug|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
131246|NCT01608295|Drug|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
131247|NCT01608308|Drug|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
131248|NCT01608308|Drug|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
131249|NCT01608321|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
131250|NCT01601587|Other|A psychoeducational group intervention.|The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:
What is mental health?
Treatment options: orientation about individual and group based treatment modalities.
Former patients experience with their own treatment, self-help and participation.
How to influence and participate actively in the treatment and patient rights.
What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?
131251|NCT01601600|Drug|BYM338|BYM338
131252|NCT01601600|Drug|Placebo|BYM338 Placebo
131253|NCT01601613|Drug|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
131254|NCT01601613|Drug|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
131255|NCT01601626|Drug|Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
131256|NCT00082472|Drug|Docetaxel|
131257|NCT01601626|Drug|Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
131258|NCT01601626|Drug|Raltegravir|400 mg orally twice daily from entry to Week 72.
131888|NCT01607255|Procedure|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
131889|NCT01607268|Procedure|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
131890|NCT01607294|Drug|ETC-1002|ETC-1002 Daily for 4 weeks
131891|NCT01607294|Drug|Placebo|Placebo Daily for 4 weeks
131892|NCT01600326|Procedure|Tenotomy|Subjects randomized to this group will complete a pretreatment pain assessment survey which should take 15 min. to complete. Subjects will also have blood drawn from an arm vein. Follow-up by principal investigator who will contact the subject by telephone or email on day 14 and day 30 to complete the pain assessment survey questionnaire. Subjects will be asked to avoid non steroidal anti inflammatory medications for 2 weeks prior to enrollment. 2 weeks after enrollment in study, subjects will see their referring physician to begin physical therapy.
132170|NCT01596491|Procedure|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
132171|NCT01596504|Drug|lixisenatide (AVE0010)|Pharmaceutical form:solution for injection
Route of administration: subcutaneous
132172|NCT01596504|Drug|liraglutide|Pharmaceutical form:solution for injection
Route of administration: subcutaneous
132173|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight <75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
132174|NCT00081861|Drug|Rituximab|375 mg/m^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
132175|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
132176|NCT01596530|Drug|Drug-AZD8931|Active drug for biological activity
132177|NCT01596530|Drug|Drug-Placebo|Placebo comparator for biological activity comparison
132178|NCT01596543|Other|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
132179|NCT01596556|Drug|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
131954|NCT01591824|Other|column exercise group|paraspinal muscle stretching exercises
postural correction
mobilization exercises thoracic and lumbar
Motor control exercises
131955|NCT01591837|Biological|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
131956|NCT00081289|Drug|Capecitabine 1650 mg/m^2/day|825 mg/m^2 q12 hours (1650 mg/m^2/day) orally 5 days per week during radiotherapy.
131957|NCT01591850|Drug|RO5093151|Single oral dose
131958|NCT01591850|Drug|atazanavir|Multiple oral doses
131959|NCT01591850|Drug|ketoconazole|Multiple oral doses
131960|NCT01591850|Drug|rifampicin|Multiple oral doses
131961|NCT01591850|Drug|ritonavir|Multiple oral doses
131962|NCT01591863|Drug|fidaxomicin|6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.
6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days.
131963|NCT01591876|Other|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
131964|NCT01591876|Other|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
132251|NCT01594255|Drug|Avelox|
132252|NCT01594268|Drug|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
132253|NCT01594281|Drug|Ranibizumab|
132254|NCT01596582|Behavioral|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid The ACNI uses a point based system to stratify patients into low (mean rate of ACN ~3%)versus intermediate/high (~ 8%) risk groups based on responses to 6 items: age, sex (male/female), race/ethnicity (black, other), smoking history (never, <20 years, >20 years), daily alcohol intake (< 2 vs. >/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never).
132918|NCT00081770|Drug|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
133156|NCT01595698|Other|Physical Exercise|The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.
Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.
133157|NCT01595698|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
133158|NCT01595711|Device|Pain Monitor|Measurement of cutaneous conductance
133159|NCT01595724|Drug|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
133160|NCT01595737|Drug|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
133161|NCT01595737|Drug|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
133162|NCT01595750|Drug|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
133163|NCT01595750|Drug|Placebo|Placebo 500 mcg , 12 weeks of treatment
133164|NCT00081809|Drug|autologous human tumor-derived HSPPC-96|
133165|NCT01595763|Other|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
133166|NCT01595776|Other|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
133167|NCT01595789|Drug|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
131259|NCT01601626|Drug|Isoniazid|300 mg orally once daily from entry through Week 24.
131260|NCT01601626|Drug|Pyridoxine|25 mg orally once daily from entry to Week 24.
131510|NCT01604031|Drug|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
131511|NCT01604044|Drug|Meropur 150 a day|one subcutaneous injection a day
131512|NCT01604044|Drug|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
131513|NCT01604057|Drug|ZT-034 Low Dose Nasal Spray|Nasal Spray
131514|NCT01604057|Drug|ZT-034 Mid Dose Nasal Spray|Nasal Spray
131515|NCT01604057|Drug|ZT-034 High Dose Nasal Spray|Nasal Spray
131516|NCT01604057|Drug|Teriparatide|20 mcg subcutaneous daily
131517|NCT01604057|Drug|Placebo|Nasal Spray
131518|NCT01606397|Drug|LY2409021|Administered orally (capsule)
131519|NCT01606410|Other|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
131520|NCT01606423|Drug|Placebo|Administered orally, single dose
131521|NCT01606423|Drug|LY2409021|Administered orally, single dose
131522|NCT01606436|Drug|Pomaglumetad methionil|Administered orally.
131523|NCT00083005|Drug|estramustine phosphate sodium|
131524|NCT01606436|Drug|Matching placebo|Administered orally.
131525|NCT01606436|Drug|Moxifloxacin|Administered orally.
131526|NCT01606449|Procedure|Surgical Therapy|Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.
Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen.
131527|NCT01606462|Drug|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
131528|NCT01606475|Biological|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
131529|NCT01606488|Drug|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
132180|NCT01596556|Other|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
132181|NCT01596569|Device|Repetitive Transcranial Magnetic Stimulation (rTMS), MagStim|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
132182|NCT01596569|Behavioral|Cognitive Intervention|Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.
All participants receive weekly cognitive treatment sessions for 10 weeks.
132183|NCT01598415|Drug|SAR113945|Pharmaceutical form:Injection
Route of administration: Intra-articular
132184|NCT01598415|Drug|placebo|Pharmaceutical form:Injection
Route of administration: Intra-articular
132185|NCT00082199|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks.
132186|NCT01598428|Procedure|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
132187|NCT01598441|Drug|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
132188|NCT01598441|Drug|distilled water|1-2 ml aerosolized distilled water inhalation per session
132189|NCT01598454|Drug|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
131315|NCT01608503|Procedure|lung inflation|lung was inflated during respiratory cycle
131316|NCT01608516|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
131317|NCT00083083|Radiation|fludeoxyglucose F 18|
131318|NCT01608529|Device|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
131319|NCT01608542|Drug|Fostamatinib 100mg|oral tablet
131320|NCT01608542|Drug|Fostamatinib 200mg|oral tablet
131321|NCT01608555|Drug|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
132255|NCT01596608|Device|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
132256|NCT00081874|Drug|RAD001|Phase I: Starting dose 5 mg by mouth daily for 28 days.
Phase II: Maximum Tolerated Dose (MTD) from Phase I.
132257|NCT01596621|Drug|Bendamustine hydrochloride|Bendamustine will be supplied in 20-mL, amber, single-use vials containing 100 mg of bendamustine hydrochloride as a white to off-white lyophilized powder. The drug will be labeled as study drug with the study number and batch number. Patients will be administered bendamustine hydrochloride 120mg/m^2 as a 60-minute infusion, and not more than 120 minutes, on days 1 and 2 of each 21-day treatment cycle for 6 planned cycles or up to 8 total cycles. Dose reductions or modifications may be made as appropriate. Day 1 only of the 21-day cycle may be ±1 day. Day 2 dosing should begin 24 ±4 hours after the start of the day 1 dose.
132258|NCT01596634|Other|questionnaire administration|Ancillary studies
132259|NCT01596634|Procedure|quality-of-life assessment|Ancillary studies
132260|NCT01596634|Other|laboratory biomarker analysis|Correlative studies
132261|NCT01596634|Biological|bovine lactoferrin|Given PO
132262|NCT01596647|Drug|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
132263|NCT01596647|Drug|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
132264|NCT01596647|Drug|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
132265|NCT01596647|Drug|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
132266|NCT01596647|Drug|TKI258|dovitinib, 5 days on / 2 days off dose schedule
132267|NCT00081887|Drug|Clofarabine|Starting dose is 10 mg/m^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
132268|NCT01596660|Drug|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
131376|NCT01606189|Drug|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
131377|NCT01606189|Drug|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
133168|NCT01595789|Drug|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
133475|NCT00084136|Drug|Didanosine (enteric-coated)|400 mg taken orally daily
133476|NCT01620047|Drug|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
133477|NCT01620047|Drug|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
133478|NCT01620060|Drug|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
133479|NCT01620073|Other|HIV counseling and testing|Male partner HIV counseling and testing
133480|NCT01620086|Device|Repetitive Transcranial Magnetic Stimulation (Magstim Rapid2)|Visits 3-14: 12 sessions in random order 4 days of one type of active rTMS, 4 days of a second type, 4 days of either. After completing 1 type of tx, return in approx 3 wks to complete the next type until all 3 are finished. Subjects fill out questionnaires 3 times during the 3-week period.
Electrodes are placed on muscles of thumb on side of body opposite stimulating coil. There will be muscles twitching and brief movements of the coil and a clicking sound during stimulation. Subjects rate and document auditory hallucinations each day. Image of brain activity (fMRI) will be performed on the last day of each week of tx.
The f/up is 2 months after last session. Subjects complete same questionnaires and rating scales as before. The fMRI will also be performed.
133481|NCT01620086|Other|Functional magnetic resonance imaging|Normal subjects do not have schizophrenia and receive fMRIs on Days 6, 29, 54
133482|NCT01622153|Procedure|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
133483|NCT01622166|Behavioral|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
133484|NCT01622179|Procedure|sewed indirectly|The epitenon was repaired and sewed indirectly.
133485|NCT01622179|Procedure|sewed directly|The epitenon was unrepaired and sewed directly.
133486|NCT01622192|Device|Florida Probe automated probe|Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
133487|NCT01622205|Other|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
133488|NCT01622205|Other|Ordinary rehabilitation|Ordinary rehabilitation
131530|NCT01606488|Other|no intervention|
131531|NCT01606514|Behavioral|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
131532|NCT01606527|Drug|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
131813|NCT01600287|Other|IAADS|In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS "error" (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS "error" values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol.
131814|NCT00082381|Drug|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
131815|NCT01600287|Other|Manual propofol administration|In "manual" mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value.
131816|NCT01600300|Device|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
131817|NCT01600300|Device|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
131818|NCT01600313|Dietary Supplement|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
131819|NCT01602471|Drug|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis > 69% will undergo an endarterectomy and will be imaged under PET/CT with [F-18]RGD-K5
131820|NCT01602484|Device|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
131821|NCT01602497|Device|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
131822|NCT01602497|Device|sham rTMS|Patients will undergo ten session of sham rTMS.
131823|NCT01602510|Drug|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
131824|NCT01602510|Drug|Placebo|Placebo
131825|NCT01602523|Drug|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
131826|NCT00082589|Drug|Eplerenone|
131827|NCT01602523|Drug|Placebo|Placebo inhaler once daily 28 days
131322|NCT01608568|Device|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
131323|NCT01608581|Other|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
131324|NCT01608594|Drug|administration of ipilimumab10mg/kg|Ipilimumab IV infusion:
Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery
After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart
Dose continued 12 weeks later for 4 additional doses given 12 weeks apart
Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
131325|NCT01608594|Drug|administration of ipilimumab 3mg/kg + HDI|Ipilimumab IV infusion:
Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery
After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart
Dose continued 12 weeks later for 4 additional doses given 12 weeks apart
Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
131326|NCT01608607|Other|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
131327|NCT01601665|Device|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
131586|NCT01604122|Other|No drug|No drug.
131587|NCT01604122|Other|No drug|No drug.
131588|NCT01604135|Device|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
131589|NCT01604161|Drug|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
131590|NCT01604174|Other|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
131591|NCT01604174|Other|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
131592|NCT01604187|Drug|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
131378|NCT00082979|Other|laboratory biomarker analysis|
131379|NCT01606189|Drug|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
131380|NCT01606202|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
131381|NCT01608802|Other|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
131382|NCT01608815|Biological|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
131383|NCT01608841|Drug|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
131384|NCT01608854|Other|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
131385|NCT01608867|Biological|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
131386|NCT01608880|Drug|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
131387|NCT01608880|Drug|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
131388|NCT01608893|Drug|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
131389|NCT01608893|Drug|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
131390|NCT01608906|Drug|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
131391|NCT00083109|Drug|Fluorouracil|Given IV
131392|NCT01608906|Drug|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
131393|NCT01608919|Other|blood tests|thromboelastogram platelet mapping
131673|NCT01602302|Drug|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
133489|NCT01622218|Behavioral|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
133490|NCT00084344|Drug|4-hydroxytamoxifen|
133491|NCT01622231|Drug|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
132370|NCT01598961|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
132371|NCT01598961|Other|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
132372|NCT01598974|Procedure|Traditional Acupuncture|
132373|NCT01598974|Procedure|Laser Acupuncture|
132374|NCT01598987|Drug|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation.
132375|NCT00082277|Drug|Risedronate Sodium|35mg/week, oral
132376|NCT01599000|Drug|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
132377|NCT01599013|Drug|Vinflunine, Gemcitabine|Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
132378|NCT01599013|Drug|Vinflunine, Carboplatin|Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
132379|NCT01599065|Other|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
132380|NCT01599078|Drug|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
132381|NCT01599078|Drug|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
132382|NCT01599091|Other|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
132383|NCT01599104|Drug|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
132384|NCT01599104|Drug|Olmesartan|Olmesartan 20 mg capsule one daily
131828|NCT01602536|Behavioral|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
131829|NCT01602536|Behavioral|Twitter|Twitter quit-smoking group
131830|NCT01602549|Drug|GSK962040 (25 mg tablet)|25 mg tablet
131831|NCT01602549|Drug|Placebo|matching placebo tablet
132120|NCT01598337|Drug|Prasugrel|10 mg daily as per instructions of investigators
132121|NCT01598350|Device|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
132122|NCT01598363|Drug|Digoxin|Oral, Day 1 and Day 10
132123|NCT01598363|Drug|Rosuvastatin|Oral, Day 1 and Day 10
132124|NCT01598376|Procedure|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
132125|NCT01598376|Procedure|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
132126|NCT01598389|Other|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
132127|NCT01598402|Drug|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
132128|NCT01592032|Drug|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
132129|NCT01592032|Drug|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
132130|NCT01592032|Drug|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
132131|NCT01592045|Biological|ch14.18 -NCI|25 mg/m^2/day IV for four consecutive days
132132|NCT01592045|Biological|ch14.18-UTC|17.5 mg/m^2/day IV for four consecutive days
132133|NCT01592045|Biological|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF will be administered SC at a dose of 250 mcg/m^2/day for 14 days during Courses 1, 3, and 5.
131593|NCT01604187|Drug|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
131594|NCT01604200|Behavioral|focus group|key informant review
131595|NCT00082797|Drug|leucovorin calcium|
131596|NCT01604213|Drug|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
131597|NCT01604213|Drug|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
131598|NCT01604239|Drug|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
131599|NCT01604265|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
131600|NCT01604265|Drug|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
131601|NCT01604278|Drug|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
131602|NCT01604278|Drug|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
131603|NCT01606592|Behavioral|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
131604|NCT01606592|Other|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
131605|NCT00083018|Genetic|cytogenetic analysis|
131606|NCT01606644|Procedure|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
131893|NCT01600326|Drug|Ultrasound guided platelet rich plasma injection|Subjects will have an ultrasound performed and blood drawn from an arm vein. The drawn blood is spun in a centrifuge to separate the blood cells from the fluid, or plasma. The plasma is used for injection into the tendon. Under sterile conditions the subject will be given a local anesthetic, lidocaine. A pain assessment survey will be completed before the procedure. The primary investigator will also contact the subject via telephone or by email on day 14 and day 30 to complete the pain assessment questionnaire. Subject will be asked to avoid any non steroidal anti inflammatory medications for 2 weeks before and 2 weeks after enrollment unless other medical conditions require their use. Subjects will also be asked to see their referring physician two weeks after treatment to begin physical therapy.
131894|NCT01600339|Drug|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
131895|NCT01600365|Drug|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
131674|NCT01602315|Drug|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
131675|NCT01602315|Drug|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
131676|NCT01602315|Biological|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
131677|NCT00082563|Drug|Chloroquine|
131678|NCT01602315|Drug|BYL719 as film-coated (FC) drink suspension|Oral alpha-specific PI3K inhibitor
131679|NCT01604304|Procedure|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
131680|NCT01604304|Procedure|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
131681|NCT01604317|Procedure|Torso bag during resuscitation|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
131682|NCT00082797|Drug|methotrexate|
131683|NCT01604317|Procedure|Partial head covering plastic bag during resuscitation|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
131684|NCT01604330|Drug|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
131685|NCT01604330|Drug|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
131686|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
131687|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
131688|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
131689|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
131690|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
131965|NCT01591889|Drug|Tinidazole|500 mg tablet
132385|NCT01599104|Drug|Placebo|Placebo to LCZ696 or Olmesartan
132386|NCT00082290|Other|massage therapy|
132387|NCT01592344|Device|StimRouter - Control|The stimulation program settings for this arm are as follows:
Stim Settings
Waveform: Symmetric or Asymmetric
Phase Duration: 200 µsec
Pulse Rate: 1 Hz
Intensity: 0 mA Time Settings
Constant Stim: On
Total Time: 6 hour
131461|NCT01599572|Other|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
131462|NCT01599585|Behavioral|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
131463|NCT01599598|Behavioral|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
131464|NCT01599598|Behavioral|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
131465|NCT01599611|Procedure|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
131466|NCT00082316|Drug|Capsaicin Dermal Patch|
131467|NCT01599624|Behavioral|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
131468|NCT01599624|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad & Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
131469|NCT01599624|Behavioral|Wait-list control|Wait-list controls will receive the iPad-based SRTS program after taking two-month assessment. This group will serve as the control group for the baseline and 2 month assessments.
131470|NCT01599637|Drug|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
131471|NCT01599637|Drug|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
132134|NCT01592045|Biological|Aldesleukin (IL-2)|Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m^2/day for the first week and at a dose of 4.5 MIU/m^2/day for the second week during Courses 2 and 4.
132135|NCT01592045|Drug|Isotretinoin|Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:
If weight > 12 kg: 80 mg/m^2/dose twice daily (total daily dose is 160 mg/m^2/day, divided twice daily).
If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily).
132136|NCT01592071|Other|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
132137|NCT01592110|Drug|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
131261|NCT01601626|Drug|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
131262|NCT01601626|Drug|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
131263|NCT01601626|Drug|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
131264|NCT01601626|Drug|Rifampin|Weight-based dose; for weight < 45 kg: 450 mg orally once daily; for weight > 45 kg: 600 mg orally once daily, from entry to week 24.
131265|NCT01601639|Device|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
131266|NCT01601639|Device|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
131267|NCT00082472|Drug|Cisplatin|
131268|NCT01601652|Drug|Omegaven|1 g/kg/d iv infusion over 24h
131269|NCT01601665|Device|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
131270|NCT01601665|Device|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
131271|NCT01603511|Device|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
131272|NCT00001535|Drug|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
131273|NCT00082732|Procedure|therapeutic dietary intervention|
131896|NCT01600365|Drug|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
131897|NCT01600391|Behavioral|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
131898|NCT00082394|Drug|Trizivir|
131899|NCT01600391|Behavioral|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
131900|NCT01600391|Behavioral|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
131901|NCT01600404|Drug|antimuscarinic treatment|
131902|NCT01600430|Dietary Supplement|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
131903|NCT01600430|Dietary Supplement|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
131904|NCT01600430|Dietary Supplement|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
131905|NCT01600443|Device|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
131906|NCT01600443|Device|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
131907|NCT01600443|Device|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
132190|NCT01598467|Procedure|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
132191|NCT01598480|Drug|Flamazine|Silver sulfadiazine cream
132192|NCT01598480|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
132193|NCT01598493|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
132194|NCT01598493|Drug|Flamazine|Silver sulfadiazine cream
131966|NCT01591889|Drug|Tinidazole|500 mg tablet
131967|NCT00001507|Drug|Monoclonal Antibody 95-5-49|
131968|NCT00081289|Drug|Capecitabine 1200 mg/m^2/day|600 mg/m^2 q12 hours(1200 mg/m^2/day) orally 5 days per week during radiotherapy.
131969|NCT01591902|Drug|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
131970|NCT01591902|Drug|Placebo-Control|3.0 mL vials
131971|NCT01591915|Other|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
131972|NCT01591941|Other|Core-PAC|Core position and control movement strategy (Core-PAC):
Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task.
131973|NCT01593631|Dietary Supplement|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
131974|NCT01593631|Dietary Supplement|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
131975|NCT01593631|Dietary Supplement|Placebo|Capsules containing di-calcium-phosphate
131976|NCT01593644|Drug|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
131977|NCT01593657|Other|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
131978|NCT01593657|Other|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
131979|NCT01593657|Procedure|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
131980|NCT01593657|Procedure|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
131981|NCT01593670|Drug|Decitabine|administered intravenous (IV), 10 mg/m^2/day over 1 hour on days 1-5.
131982|NCT01593670|Drug|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
131983|NCT00081484|Drug|epoetin alfa or beta|iv or sc, as prescribed
131472|NCT01599650|Drug|Ranibizumab|
131473|NCT01599650|Procedure|Laser|laser photocoagulation
131474|NCT01599663|Other|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
131768|NCT01604421|Procedure|Thermoregulation with torso-covering plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
131769|NCT01604434|Procedure|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
131770|NCT01604434|Procedure|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
131771|NCT01604447|Procedure|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
131772|NCT01604447|Procedure|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
131773|NCT00001538|Biological|APL 400-003|
131774|NCT00082810|Drug|tipifarnib|Given IV
131775|NCT01604460|Procedure|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
131776|NCT01604460|Procedure|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
131777|NCT01604499|Behavioral|Feedback letters|Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to "all employees" and to the "healthiest employees eaters"
131778|NCT01604499|Behavioral|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
131274|NCT01603524|Other|OMSC Group|The OMSC Group will receive a multi-component intervention which includes:
Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.
Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.
Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).
Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program.
131275|NCT01603524|Behavioral|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
131276|NCT01603550|Other|Sleep Deprivation|Sleep Deprivation
131277|NCT01603550|Other|Energy Restriction|Energy Restriction
131533|NCT01606540|Drug|Tablets Ibumetin and placebo|Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.
Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.
Group C: Placebo tablets 1 week after reposition.
131534|NCT00083005|Drug|thalidomide|
131535|NCT01606540|Drug|Tablets Ibumetin and placebo|Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.
Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.
Group C: Placebo tablets for 1 week after surgery.
131536|NCT01606553|Device|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
131537|NCT01606553|Device|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
131538|NCT01606566|Drug|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
131539|NCT01606579|Drug|PRI-724|PRI-724
131540|NCT01606579|Drug|PRI-724|PRI-724 in combination with dasatinib
131541|NCT01606579|Drug|PRI-724|PRI-724 in combination with low dose ara-C therapy
131542|NCT01606592|Behavioral|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
131543|NCT00082329|Drug|AMD 3100 (Mozobil plerixafor)|Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis
132195|NCT01598506|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
132196|NCT00082212|Biological|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
132197|NCT01598519|Behavioral|suicide intervention|universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.
indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net.
132198|NCT01598532|Device|MedX Health Phototherapy (light and laser therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
132199|NCT01598545|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
132200|NCT01598558|Drug|Cu-64 Rituximab|Up to 14 mCi, iv
132201|NCT01598571|Drug|Fostamatinib|Fostamatinib 50 mg tablet
132202|NCT01598571|Drug|Fostamatinib|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose
132203|NCT01598584|Drug|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
132204|NCT01598584|Drug|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
132205|NCT01592123|Behavioral|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
132206|NCT01592123|Behavioral|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
131328|NCT01601665|Device|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
131329|NCT01601665|Device|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
132269|NCT01596660|Drug|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
132270|NCT01596673|Drug|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|Phase B:
Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.
Phase C:
Eligible subjects will be randomly assigned to 1 of 4 treatment arms:
Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.
Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.
Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet.
132271|NCT01598610|Device|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
132272|NCT01598623|Drug|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
132273|NCT00082225|Biological|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
132274|NCT01598623|Behavioral|Social Skills Training|three times a week for three weeks.
132275|NCT01598623|Behavioral|Placebo + Non Specific Counselling|
132276|NCT01598636|Procedure|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
132277|NCT01598649|Dietary Supplement|Fabricated foods with lupin protein|- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
132278|NCT01598649|Dietary Supplement|Mannitol|- Placebo capsules containing mannitol (four capsules per day)
132279|NCT01598649|Dietary Supplement|Arginine|- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
132280|NCT01598649|Dietary Supplement|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
132281|NCT01598662|Device|Mirena (levonorgestrel-releasing intrauterine system)|The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
132282|NCT01598675|Other|Treadmill belts of dual-belt treadmill respond to encourage symmetric gait|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax
132283|NCT01598675|Other|Treadmill belts of dual-belt treadmill respond to amplify asymmetric gait|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax
132284|NCT00082225|Biological|EBV specific T cells|The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:
2 x 10e7 cells/m2 5 x 10e7 cells/m2
1 x 10e8 cells/m2
131779|NCT01604512|Other|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
131780|NCT01604525|Behavioral|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
132059|NCT01593800|Dietary Supplement|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
132060|NCT01593826|Drug|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
132061|NCT01593826|Drug|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
132062|NCT01593826|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
132063|NCT01593826|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
132064|NCT01593852|Radiation|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
132065|NCT00000262|Other|Placebo|
132066|NCT00001507|Device|Ceprate SC|
132067|NCT00081497|Biological|agalsidase beta|1.0 mg/kg every 2 weeks
132068|NCT01593852|Radiation|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
132069|NCT01593865|Procedure|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
132070|NCT01593865|Procedure|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
132071|NCT01593878|Other|TV|test taken with TV on
132072|NCT01593930|Other|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
131544|NCT01599689|Other|Mirrors Intervention|Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.
To be administered at set times and in a standardised way by ICU nursing and physical therapy teams.
131545|NCT01599702|Drug|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
131546|NCT01599715|Behavioral|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
131547|NCT01599715|Behavioral|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
131548|NCT01599728|Drug|Urocortin 2, Urocortin 3 and Substance P|After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min [15, 50 and 150 ng/min] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) [to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]) will be administered intra-arterially.
Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones.
131832|NCT01602562|Drug|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
131833|NCT01602575|Behavioral|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
131834|NCT01602588|Drug|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
131835|NCT01602588|Radiation|Radiotherapy|Short Course radiotherapy
131836|NCT01602601|Drug|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
131837|NCT00082602|Drug|galantamine ER|
131838|NCT01602601|Drug|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
131839|NCT01602627|Drug|Hsp90 inhibitor AUY922|Given IV
131840|NCT01602627|Other|pharmacological study|Correlative studies
131841|NCT01602627|Other|laboratory biomarker analysis|Correlative studies
131842|NCT01602640|Drug|Morphine infusion|Conventional dose
131843|NCT01602640|Drug|Fentanyl and Midazolam infusion|Conventional dose
131330|NCT01601678|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoluminal submucosal myotomy of the distal esophagus/lower esophageal sphincter for treatment of achalasia(see Inoue et al. Endoscopy 2010) POEM procedure steps: Lavage, entry point 12-14cm above GEJ at the lesser curvature site, Inject 10ml saline with methylene blue, create 2cm entry point, advance endoscope into the submucosa, repeated submucosal injection and dissection of the submucosal tunnel up to 2-3cm into the cardia, dissect the submucosa close to the muscularis with repeated checks endoluminally, after completion of the submucosal tunnel flush with gentamycin, perform myotomy from proximal to distal starting 4-5cm below the entry point down to at least 2cm onto the cardia, after complete myotomy check for mucosal integrity, close the entry point with clips from distal to proximal
131331|NCT01601678|Procedure|Laparoscopic Heller Myotomy (LHM)|laparoscopic myotomy of the lower esophageal sphincter as with standard achalasia therapy: after opening the phren-oesophageal ligament to mobilise distal esophagus distally and proximally, a 1.5- 2cm myotomy at the cardia with an approximately 6-8cm myotomy extension into the distal esophagus is made. As anti reflux procedure, a Dor hemifundoplication is preferred
131332|NCT01601691|Device|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
131333|NCT01601704|Drug|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
131334|NCT00082485|Drug|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
131335|NCT01601704|Drug|PBO|Placebo. Administered in addition to the weight management program.
131336|NCT01601704|Behavioral|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
131337|NCT01601717|Drug|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
131338|NCT01601717|Drug|Placebo|Matching placebo pill administered once per day for 10 days.
131339|NCT01601730|Drug|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
131340|NCT01601730|Drug|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
131341|NCT01601730|Drug|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
131342|NCT01601730|Drug|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
131343|NCT01601743|Behavioral|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
131344|NCT01601743|Behavioral|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
131607|NCT01606657|Procedure|Irrigation|The patient will receive irrigation as a part of their wound care
131608|NCT01606657|Other|No Irrigation|The patient will not receive irrigation as part of their wound care
132285|NCT01598675|Other|No difference in treadmill belt speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax
131394|NCT01608932|Procedure|Telemonitoring for frail patients with chronic diseases|Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.
The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms.
131395|NCT01608945|Drug|Hydrocortisone sodium succinate|100mg/day
131396|NCT01608958|Drug|Oxytocin|10 IU oxytocin in 500 ml infusion
131397|NCT01608958|Drug|Oxytocin|10 IU oxytocin IM injection
131398|NCT01608984|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.
The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
131399|NCT01608984|Procedure|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
131400|NCT01601756|Device|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
131401|NCT01601756|Device|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
131402|NCT01601769|Device|Vitom|Patients treated and diagnosed by vitom
131403|NCT01601769|Device|Colposcopy|a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
Patients treated by colposcopy
131404|NCT01601782|Procedure|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
131405|NCT01601782|Device|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
131406|NCT01601795|Drug|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
131407|NCT01601795|Drug|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
132073|NCT01593930|Other|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
132074|NCT01593930|Other|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
132075|NCT01593930|Other|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
132076|NCT01593943|Behavioral|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
132077|NCT01593956|Behavioral|tDCS|
132388|NCT01592357|Behavioral|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
132389|NCT00081302|Drug|carboplatin|
132390|NCT01592357|Behavioral|Sham Exercise|The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a "sham exercise" condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the "sham exercise" group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks.
132391|NCT01592370|Biological|Nivolumab|
132392|NCT01592370|Biological|Ipilimumab|
132393|NCT01592370|Biological|Lirilumab|
132394|NCT01592383|Drug|erlotinib hydrochloride|Given PO
132395|NCT01592383|Other|laboratory biomarker analysis|Correlative studies
132396|NCT01592396|Biological|Cohort 1|Tralokinumab (CAT‐354) is a human IgG4 anti‐IL‐13 monoclonal antibody that has been shown to potently and specifically neutralize IL‐13 in preclinical models.
132397|NCT01592409|Drug|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
131844|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
131845|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
131846|NCT01604525|Other|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
131847|NCT01604577|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
131848|NCT01604590|Radiation|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
131849|NCT00082823|Biological|ziv-aflibercept|
131850|NCT01604629|Drug|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
131851|NCT01604629|Drug|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
131852|NCT01604642|Other|blood tests and muscular biopsies|blood tests and muscular biopsies
131853|NCT01604655|Procedure|Coronary CT Angiography|CCTA
132138|NCT00081289|Procedure|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
132139|NCT01592110|Other|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
132140|NCT01592110|Drug|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
132141|NCT01592110|Drug|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
132142|NCT01592123|Procedure|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
132143|NCT01592123|Behavioral|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score >5 is considered to be suggestive of significant sleep disturbance.
131609|NCT01606683|Other|Infant formula with GOS, beta-palmitate, acidified milk|Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.
Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.
131610|NCT01606683|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
131611|NCT01606683|Other|No intervention|
131612|NCT01606696|Behavioral|HIIT|Higher intensity interval training.
131613|NCT01606696|Behavioral|Standard intensity non-interval training|Standard intensity non-interval training.
131614|NCT01606709|Drug|GnRH agonist|GnRH agonist 1mg one dose
131615|NCT01606709|Drug|hCG|5,000 IU one dose
131616|NCT00083018|Genetic|proteomic profiling|
131617|NCT01606722|Drug|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
131618|NCT01606735|Drug|IBI-10090|dexamethasone
131619|NCT01606748|Biological|Necitumumab|PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg
Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg
Patients in Cohort 1 will receive necitumumab Process C drug product and patients in Cohort 2 will receive necitumumab Process D drug product
131620|NCT01606748|Drug|Gemcitabine|PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 mg/m2
Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2
131621|NCT01606748|Drug|Cisplatin|PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2
Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2
131622|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
131623|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
131624|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
131625|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
131626|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
131408|NCT01601808|Drug|Placebo|Orally once a day, continuously throughout the study
131691|NCT01604356|Procedure|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device [Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
131692|NCT01604369|Procedure|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
131693|NCT00082810|Drug|fulvestrant|Given intramuscularly
131694|NCT01604382|Drug|General Anesthesia|General Anesthesia as described above
131695|NCT01604382|Drug|Neuraxial anesthesia|Neuraxial anesthesia as described above
131696|NCT01604408|Biological|LY2495655|Administered SQ
131697|NCT01604408|Drug|Placebo|Administered SQ
131698|NCT01604421|Procedure|Thermoregulation without plastic bag|One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
131699|NCT00083018|Other|cytology specimen collection procedure|
131700|NCT01606774|Other|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
131701|NCT01606787|Drug|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
131702|NCT01606787|Other|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
131703|NCT01606800|Drug|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
131704|NCT01606800|Drug|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
131705|NCT01606813|Other|Usual Care|Standard care
132398|NCT01592409|Drug|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
132399|NCT01592422|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
132400|NCT00081302|Drug|paclitaxel|
132401|NCT01592422|Other|Best Supportive Care|Best Supportive Care in the absence of disease progression
132402|NCT01592448|Behavioral|Active Ingredient Icon|Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. "Ac" for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen.
132403|NCT01592500|Drug|MOD-4023|Once weekly subcutaneous injection
132404|NCT01592500|Drug|Somatropin|Once daily subcutaneous injection of Genotropin
131475|NCT01599676|Dietary Supplement|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
131476|NCT01599676|Dietary Supplement|Non essential amino acid|Non essential amino acid supplementation
131477|NCT00001524|Drug|Thalidomide|
131478|NCT01601899|Drug|Stavudine|30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg
131479|NCT01601899|Drug|Stavudine|20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg
131480|NCT01601899|Drug|Tenofovir|300 mg po QD
131481|NCT01601912|Drug|Atomoxetine|40 mg, 1 application
131482|NCT01601912|Drug|Citalopram|20 mg, 1 application
131483|NCT01601925|Other|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
131484|NCT01601938|Dietary Supplement|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
131485|NCT01601938|Dietary Supplement|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
131486|NCT01601951|Other|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
132144|NCT01593969|Dietary Supplement|Standard RUTF|Standard formulation RUTF given according to National Guidelines
132145|NCT01593982|Other|repetitive Transcranial Magnetic Stimulation (rTMS)|20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.
Site: Left Dorsolateral Prefrontal Cortex
132146|NCT01593995|Drug|Epidermal growth factor (EGF) ointment|EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as "no effect"
132147|NCT01594008|Other|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
132148|NCT01594008|Other|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
132149|NCT01594008|Other|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
132150|NCT01594021|Drug|Gelatin 500 mL|intravenous administration
132151|NCT01594021|Drug|Gelatin 50 mL|intravenous administration
132152|NCT00081510|Drug|Placebo|
132153|NCT01594034|Procedure|expired air|collection of expired air from ventilator
132154|NCT01594047|Drug|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
131278|NCT01603563|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
131279|NCT01603563|Behavioral|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
131280|NCT01603576|Device|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
131908|NCT01595945|Procedure|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
131909|NCT01595945|Behavioral|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
131910|NCT01595958|Drug|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
131911|NCT01595958|Procedure|cardio-pulmonary resuscitation|usual care of cardiac arrest
131912|NCT00081835|Drug|NP-016 Vaccine Immune Globulin (IV-VIG)|
131913|NCT01595971|Behavioral|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
131914|NCT01595971|Other|usual care|Received the usual care provided
131915|NCT01595984|Drug|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
131916|NCT01595984|Drug|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
131917|NCT01595997|Drug|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
131918|NCT01596010|Drug|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
131919|NCT01596023|Device|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
131920|NCT01596036|Behavioral|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
131921|NCT01596036|Other|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
131922|NCT01596049|Device|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
131923|NCT00081848|Drug|rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|
131924|NCT01596062|Drug|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
131925|NCT01596062|Drug|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
131926|NCT01596062|Drug|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
131706|NCT01606813|Behavioral|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
131984|NCT01593670|Biological|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
131985|NCT01593670|Other|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
131986|NCT01593683|Behavioral|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
131987|NCT01593696|Biological|Anti-CD19- CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
131988|NCT01593722|Drug|Diethylcarbamazine|8 mg/kg po single dose
131989|NCT01593722|Drug|Ivermectin|200 microgram/kg po single dose
131990|NCT01593735|Drug|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
131991|NCT01593735|Drug|Placebo|Placebo tablets, orally, once daily for 7 days
131992|NCT01593748|Drug|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
131993|NCT01593748|Drug|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
131994|NCT00081484|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
131995|NCT01593761|Drug|CG400549|960mg QD at fed state approx 1 hour after meal
131996|NCT01593774|Drug|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
131997|NCT01593774|Drug|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
131998|NCT01596062|Drug|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
131999|NCT01596075|Drug|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
132000|NCT01596088|Drug|Dexrazoxane|
131487|NCT01601977|Device|Omnilab - AVAPS AE algorithm|Nocturnal NIV via Omnilab device using the AVAPS AE algorithm
131488|NCT00082511|Drug|Prasterone (GL701)|There were 4 arms to the study:
During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study.
131489|NCT01601977|Device|Usual care|usual care
131490|NCT01601990|Drug|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
131491|NCT01601990|Drug|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
131492|NCT01602003|Drug|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
131493|NCT01602003|Drug|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
131781|NCT01604525|Behavioral|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
131782|NCT00083018|Other|laboratory biomarker analysis|
131783|NCT01606891|Behavioral|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
131784|NCT01606904|Behavioral|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
131785|NCT01606917|Other|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
131786|NCT01606930|Behavioral|Patient Primer Tool|The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to "Prime" them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs.
131281|NCT01603589|Procedure|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
131282|NCT01603589|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
131283|NCT01603602|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 3 U per kg of body weight (3 U/kg) into specified muscles of the upper limb.
131284|NCT00082745|Other|Laboratory Biomarker Analysis|Correlative studies
131285|NCT01603602|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb.
131286|NCT01605968|Device|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
131287|NCT01605981|Drug|AMN107|
131288|NCT01605994|Drug|BMS-933043|
131289|NCT01605994|Drug|Placebo matching with BMS-933043|
131290|NCT01605994|Drug|Antacid Buffer Predose Solution|
131291|NCT01606007|Drug|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
131292|NCT01606007|Drug|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
131293|NCT01606007|Drug|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
131294|NCT00082979|Genetic|proteomic profiling|
131549|NCT01599741|Radiation|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
131550|NCT01599741|Radiation|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
131551|NCT01599754|Drug|Axitinib|Axitinib 5 mg twice daily
132207|NCT01592136|Drug|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
132208|NCT01592149|Other|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
132209|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
132210|NCT00081289|Drug|Folinic Acid|400 mg/m^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
132211|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
132212|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
132213|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
132214|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
132215|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
132216|NCT01592162|Drug|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
132217|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
132218|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
132219|NCT01592188|Behavioral|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
132220|NCT01592188|Behavioral|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
132221|NCT00081289|Drug|Fluorouracil|5-fluorouracil bolus 400 mg/m^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
5-fluorouracil infusion 2400 mg/m^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles.
132222|NCT01592201|Drug|Paliperdidone ER|Form = osmotic release oral system, route = oral
132223|NCT01592201|Drug|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
132224|NCT01592214|Other|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
134629|NCT01612351|Drug|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
134630|NCT00083473|Drug|Pivanex|
134631|NCT01612351|Drug|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
134632|NCT01612351|Radiation|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
134633|NCT01612351|Radiation|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
134634|NCT01614782|Drug|MK-5823|MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.
In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.
133754|NCT01622673|Drug|TUMS® Ultra Strength|3 tablets TUMS® Ultra Strength (US) 1000 mg
Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
133755|NCT01622673|Drug|MINTOX® Maximum Strength|20 mL MINTOX® Maximum Strength (MS)
Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
133756|NCT01622686|Behavioral|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
133757|NCT01625052|Device|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
133758|NCT01625078|Device|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
133759|NCT01625091|Drug|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
133760|NCT00084591|Procedure|neoadjuvant therapy|
133761|NCT01625091|Drug|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
137183|NCT01684592|Behavioral|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
137184|NCT01684592|Behavioral|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by ACOG for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
137185|NCT01684605|Drug|NESP 60μg|Administrated NESP 60μg once intravenously
137186|NCT01684605|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
137187|NCT01684618|Procedure|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
137188|NCT01684631|Device|Total Hip arthroplasty|
137189|NCT01684644|Behavioral|New Forest Parenting Programme|
137190|NCT01684644|Behavioral|Treatment as usual|
137191|NCT01684657|Drug|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
137192|NCT01687439|Drug|Endostar|7.5mg/m2, D1-14
137193|NCT01687439|Drug|Vinorelbine|25-30mg/m2, D1,8
137194|NCT01687439|Drug|Cisplatin|25 mg/m2, D1-3
137195|NCT01687439|Radiation|Radiotherapy|
137196|NCT01687452|Biological|Blood samples|
137462|NCT01629537|Procedure|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicane, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicane will be injected and the needle will be removed.
137463|NCT01629537|Procedure|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
137909|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
137910|NCT01630343|Drug|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
137911|NCT01630343|Drug|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
137912|NCT01630356|Behavioral|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
137913|NCT01630356|Device|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
137932|NCT01632930|Other|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
137933|NCT01632943|Device|Symplicity renal denervation system|Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.
A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator.
137934|NCT01632956|Behavioral|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
137935|NCT00085124|Other|laboratory biomarker analysis|Correlative studies
137936|NCT01632956|Behavioral|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
137937|NCT01632969|Behavioral|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
137938|NCT01632982|Behavioral|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
137939|NCT01632982|Behavioral|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
137940|NCT01632982|Behavioral|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
137118|NCT01687309|Drug|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
137119|NCT01687309|Other|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
137120|NCT01687309|Other|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
137121|NCT00089544|Drug|dacarbazine|Given IV
137122|NCT01687335|Other|answering questionnare in differents time of the treatment|
137123|NCT01687348|Drug|lidocaine aguettant|
137124|NCT01687361|Dietary Supplement|branched-chain amino acids (BCAA) supplementation|
137125|NCT01687361|Drug|PLACEBO|
137126|NCT01687374|Drug|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
137392|NCT01629498|Behavioral|Questionnaire|Symptom questionnaire completion before chemoradiation beings, each week during chemoradiation, each week until 16 weeks after chemoradiation is complete, every other week from Week 16 until 12 weeks after chemoradiation is complete, and at follow-up visits. The symptom questionnaire should take about 10 minutes to complete each time.
137393|NCT01629498|Radiation|IMRT + SIB + Chemotherapy|Phase I Starting IMRT Dose: 60 Gy (RBE) in 30 fractions. Phase I Starting SIB Dose: (72 - 84) Gy (RBE).
Fractions given once a day, 5 times a week for six weeks.
Dose level 1 of 66-72 Gy(RBE) in 30 fractions used as the planned dose in the Phase II portion of the trial.
137394|NCT00084838|Drug|dexrazoxane hydrochloride|
137395|NCT01631851|Behavioral|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
137396|NCT01631864|Drug|LCZ696|LCZ696 was provided as 400 mg tablets.
137397|NCT01631864|Drug|amlodipine|amlodipine was provided as 5 mg tablets.
137398|NCT01631864|Drug|Placebo|Matching placebo to LCZ696 and amlodipine.
137399|NCT01631877|Drug|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
137400|NCT01631877|Other|placebo|injection placebo will be given for 5 days along with placebo tablets
137401|NCT00085020|Biological|trastuzumab|
137670|NCT01632384|Behavioral|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
137671|NCT01632397|Behavioral|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
137672|NCT01632397|Behavioral|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
137673|NCT01632423|Drug|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
137674|NCT01632436|Drug|Pixantrone|Experimental Drug
137675|NCT00085098|Drug|etoposide|Given IV over 2 hours
137676|NCT01632449|Drug|Test product|Dimethyl Fumarate (BG00012)
137677|NCT01632449|Drug|Reference product|Dimethyl Fumarate (BG00012)
137678|NCT01632462|Drug|VSL#3|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a "wash-out" period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks.
137679|NCT01632475|Biological|Pneumostem®|A single intratracheal administration
Low Dose Group (3 patients): 1.0 x 10^7 cells/kg, High Dose Group (6 patients): 2 x 10^7 cells/kg
* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study.
137680|NCT01632501|Device|Coronary stent - Tsunami|A coronary angioplasty was done
138007|NCT01630616|Drug|Odanacatib|single oral dose, tablets, 10 or 50 mg
138008|NCT01630616|Drug|Placebo|single oral dose, tablets
138009|NCT01630642|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
138010|NCT01630655|Drug|Torrent's Felodipine Extended-Release Tablets|
138011|NCT01632995|Drug|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
138012|NCT01633008|Behavioral|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
138013|NCT01633047|Other|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
137464|NCT00084838|Drug|doxorubicin hydrochloride|
137465|NCT01629550|Procedure|skin disinfection prior catheter insertion|
137466|NCT01629563|Drug|PGL4001 5 mg|PGL4001 5 mg daily administration
137467|NCT01629563|Drug|PGL4001 10 mg|PGL4001 10mg daily administration
137468|NCT01629576|Other|economic incentive|economic incentive for weight loss
137469|NCT01629576|Other|economic incentive|economic incentive for weight loss
137470|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
137471|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
137472|NCT01629602|Procedure|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
137473|NCT01629615|Drug|BKM120|BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
137474|NCT01631981|Drug|PGL2001 + Primolut-Nor 5|PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.
Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up.
137475|NCT01631981|Drug|Placebo + Primolut-Nor 5|Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.
Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up.
137476|NCT01631994|Drug|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
137477|NCT01632007|Drug|SYR-472|
137478|NCT01632007|Drug|Alogliptin 25 mg|
137479|NCT01632007|Drug|Placebo|
137480|NCT00085059|Drug|boronophenylalanine-fructose complex|
137481|NCT01632020|Drug|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
137735|NCT00084838|Radiation|radiation therapy|
137736|NCT01630083|Drug|IMAB362 800/600 mg/m2|800 mg/m2 loading dose on cycle 1. 600 mg/m2 every 3 weeks.
137737|NCT01630083|Drug|IMAB362 1000 mg/m2|1000 mg/m2 every 3 weeks.
137941|NCT01635803|Drug|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
137942|NCT01635816|Biological|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
137943|NCT01635816|Biological|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
137944|NCT00085293|Radiation|Fludeoxyglucose F 18|Optional correlative studies
137945|NCT01635816|Biological|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
137946|NCT01635816|Biological|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
137947|NCT01635829|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
138231|NCT01628510|Device|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
138232|NCT01628510|Other|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
138233|NCT01628523|Other|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
138234|NCT01628536|Dietary Supplement|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
138235|NCT00084773|Radiation|radiation therapy|
138236|NCT01628549|Drug|50 mg P005672|50 mg P0005672 taken daily for 84 days at doses achieving 0.75 or 1.5 mg/kg daily treatment
138237|NCT01628549|Drug|Placebo|placebo capsule matching 50 mg or 100 mg capsules of P0005672 taken daily for 84 days
138238|NCT01628549|Drug|100 mg P005672|100 mg P0005672 taken daily for 84 days a dose achieving 3.0 mg/kg daily treatment
138239|NCT01628562|Drug|Esmolol|Esmolol 50 mcg/kg/min
138240|NCT01628562|Drug|Remifentanil|Remifentanil 0.5 mcg/kg/min
138241|NCT01628575|Procedure|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
138242|NCT01628588|Drug|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
137402|NCT01631890|Procedure|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
137403|NCT01631890|Procedure|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
137404|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
137405|NCT01631903|Drug|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
137406|NCT01631903|Drug|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
137407|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
137408|NCT01631903|Drug|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
137409|NCT01631916|Drug|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
137662|NCT01632345|Drug|Doravirine|Part 1: doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) tablet or placebo matching doravirine orally every morning with or without food for at least 24 weeks When the doravirine selected dose is determined after all participants reach Week 24, participants on other doses of doravirine will be switched to the selected dose for the remainder of the 96-week study. Part 2: Selected dose of doravirine (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet or placebo matching doravirine orally every morning with or without food for 96 weeks
137663|NCT01632345|Drug|Efavirenz|Efavirenz 600 mg tablet or placebo matching efavirenz orally at bedtime taken without food on an empty stomach for 96 weeks
137664|NCT00085098|Drug|cyclophosphamide|Given IV over 1 hour
137665|NCT01632345|Drug|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning alone or with doravirine or placebo matching doravirine for 96 weeks
137666|NCT01632358|Drug|TAP311 capsules|
137667|NCT01632358|Drug|Placebo|
137668|NCT01632371|Device|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
137669|NCT01632371|Device|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
138014|NCT01633047|Other|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
138015|NCT01633060|Drug|Fulvestrant|Intramuscular fulvestrant 500 mg (cycle 1 days 1 & 15 and once every cycle thereafter)
138016|NCT00085150|Biological|LMB-2 immunotoxin|
138017|NCT01633060|Drug|BKM120|BKM120 100 mg once daily
138018|NCT01633060|Drug|BKM120 matching placebo|BKM120 matching placebo, once daily
138019|NCT01633073|Device|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
138020|NCT01633073|Device|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
138021|NCT01633086|Drug|nitric oxide gel|st gel: sodium nitrites,BID local use X 28 days
nd gel: maleic/ascorbic acids ,BID local use X 28 days
138022|NCT01633086|Drug|placebo gel|placebo gel,BID local use X 28 days
138023|NCT01633099|Drug|Decitabine|Number of Cycles: 4 cycles.
Dose and drug delivery(decitabine):
The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.
If bone marrow blast cells<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle.
If Grade 4 neutropenia（<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle).
138024|NCT01633112|Drug|fingolimod|
138025|NCT01633112|Drug|copaxone|copaxone
137127|NCT01687374|Drug|Placebo|Saline injection daily for 8 weeks.
137128|NCT01687387|Drug|IPH2102 at 0.1 mg/kg|every 3 months
137129|NCT01687387|Drug|IPH2102 at 1 mg/kg|every 4 weeks
137130|NCT01687387|Drug|Placebo (normal saline solution)|every 4 weeks
137131|NCT01687400|Drug|decitabine|
137132|NCT00001705|Drug|GP100 peptide|
137133|NCT00089544|Biological|filgrastim|Given subcutaneously
137738|NCT01630096|Drug|Nu-Lytely|Bowl prep solution.
137739|NCT01630109|Drug|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
137740|NCT01630109|Drug|Placebo|A placebo capsule made to look like the metoclopramide capsule.
137741|NCT01630135|Drug|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
137742|NCT01630135|Drug|Placebo|Placebo, intranasal, 2 weeks
137743|NCT01630148|Drug|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
137744|NCT01632514|Drug|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
137745|NCT01632527|Drug|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
137746|NCT01632540|Drug|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
137747|NCT01632566|Drug|Placebo|Capsules administered orally
137748|NCT01632566|Drug|LY3031207|Administered orally
137749|NCT00085098|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week
137750|NCT01632566|Drug|Celecoxib|Administered orally
137751|NCT01632566|Drug|Simvastatin|Administered orally
137752|NCT01632579|Drug|LY3023703|Administered orally
137753|NCT01632579|Drug|Placebo|Administered orally
137754|NCT01632579|Drug|Celecoxib|Administered orally
137755|NCT01632592|Drug|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
137756|NCT01632592|Drug|Placebo|placebo given by injection 2mg subcutaneously daily
137757|NCT01632605|Drug|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
137758|NCT01632618|Other|Neuromuscular Electrical Stimulation plus Lumbar Stabilization Exercises|
138243|NCT01630954|Procedure|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
138244|NCT01630954|Procedure|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
138245|NCT00084890|Drug|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
138246|NCT01630967|Drug|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
138247|NCT01630980|Other|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
138248|NCT01630993|Other|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
138249|NCT01631006|Device|CPAP|A low or high CPAP pressure is delivered for 20 minutes
137332|NCT01634646|Dietary Supplement|Lyzme5|Dietary Supplement (or placebo):
Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).
Week one:
A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;
Week two:
Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;
Week three through the end of the study:
Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day.
137333|NCT01634659|Device|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
137334|NCT01634659|Device|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
137335|NCT01634685|Radiation|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
137336|NCT01634685|Drug|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
137337|NCT01634685|Drug|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
137338|NCT01634698|Dietary Supplement|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
134571|NCT00083889|Drug|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
134572|NCT01617044|Dietary Supplement|Placebo|Placebo
134573|NCT01617057|Drug|tiludronic acid|400 mg / day for 3 months
134574|NCT01617057|Drug|Placebo|400 mg / day for 3 month
134575|NCT01617070|Drug|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
134576|NCT01617070|Dietary Supplement|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
134577|NCT01617083|Drug|Azithromycin|Antibiotic used to treat infections
134578|NCT01617083|Drug|Placebo|Thickening compound with sugar and flavoring
134579|NCT01617096|Drug|Dapivirine|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
133700|NCT01627613|Drug|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
133701|NCT01627626|Drug|Pilocarpine|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.
subjects were instructed to mouthwash with 10ml of solution for 1 minute.
133702|NCT00084708|Drug|dexamethasone|
133703|NCT01627626|Drug|saline|0.9% saline solution
133704|NCT01627639|Drug|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
133705|NCT01627639|Drug|Placebo|Placebo
133706|NCT01627652|Other|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
133707|NCT01627665|Drug|D->R->C+R|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
133708|NCT01627665|Drug|D->R->C+D|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
133709|NCT01627665|Drug|R->D->C+D|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
133710|NCT01627665|Drug|R->D->C+R|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
133711|NCT01627678|Drug|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
137134|NCT01687413|Radiation|Intensity-modulated radiation therapy (IMRT)|
137135|NCT01687413|Drug|Cisplatin|
137136|NCT01687426|Drug|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
137137|NCT01687426|Drug|Vehicle|1 drop in each eye daily four times a day for 14 days
137138|NCT01679743|Drug|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
137139|NCT01679756|Procedure|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
137140|NCT01679795|Drug|Tibolone|
137141|NCT01679795|Drug|Placebo|
137142|NCT01679821|Other|A questionnaire and a clinical examination|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
137143|NCT00089063|Other|laboratory biomarker analysis|Correlative studies
137144|NCT01679860|Procedure|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|Clin A:
CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).
HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest
Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation.
137410|NCT01631929|Other|One bag|Infusion of dextrose and electrolytes using one bag
137411|NCT01631929|Other|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
137412|NCT00085020|Drug|lapatinib ditosylate|
137413|NCT01631942|Drug|NNC172-2021|Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.
Escalation to next dose level is based on a safety evaluation.
133762|NCT01625117|Behavioral|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
133763|NCT01625130|Dietary Supplement|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
133764|NCT01625130|Dietary Supplement|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
133765|NCT01625143|Other|laboratory biomarker analysis|Correlative studies
133766|NCT01625156|Other|Laboratory Biomarker Analysis|Correlative studies
133767|NCT01625156|Other|Pharmacological Study|Correlative studies
133768|NCT01625156|Drug|Temsirolimus|Given IV
133769|NCT01625156|Drug|Tivantinib|Given PO
133770|NCT01625169|Drug|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
133771|NCT00084591|Radiation|radiation therapy|
133772|NCT01625182|Drug|Fingolimod|
134054|NCT01628263|Other|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
134055|NCT01628276|Behavioral|Cog Rehab|Cognitive rehab for MS patients
134056|NCT01628289|Other|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
134057|NCT01628289|Other|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
134058|NCT00084773|Biological|cetuximab|
134059|NCT01628302|Behavioral|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
134060|NCT01620944|Drug|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
137339|NCT01634711|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
137340|NCT01634724|Drug|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
137341|NCT01634750|Drug|ManNAc|Single dose
137342|NCT00085202|Radiation|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
137343|NCT01634763|Drug|LDK378|
137344|NCT01634776|Dietary Supplement|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
137345|NCT01634776|Dietary Supplement|corn oil|
137346|NCT01637168|Drug|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
137347|NCT01637168|Drug|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
137348|NCT01637181|Procedure|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
137349|NCT01637194|Drug|everolimus|Given PO
137914|NCT01630356|Behavioral|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
137915|NCT01630356|Behavioral|Printed material|The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.
The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency.
137916|NCT01630369|Drug|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
137917|NCT00084864|Other|clinical observation|No intervention before surgery
137918|NCT01630395|Procedure|protective ventilation|low tidal volume and PEEP
137919|NCT01630395|Procedure|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
133712|NCT01627678|Drug|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
133713|NCT00084708|Drug|gefitinib|
133714|NCT01627691|Device|Lotus Valve System|bioprosthetic bovine pericardial aortic valve
delivery system
133715|NCT01627704|Drug|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
133716|NCT01627717|Drug|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
133717|NCT01627717|Drug|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
133718|NCT01627730|Other|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
133719|NCT01627756|Other|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
133720|NCT01627756|Other|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
133996|NCT01623011|Procedure|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
133997|NCT00084422|Drug|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
133998|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
133999|NCT01623024|Drug|Vitamin D|20.000 UI/week for 96 weeks
134000|NCT01623024|Behavioral|Lifestyle counseling|Lifestyle counseling for 96 weeks
134001|NCT01623037|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
134002|NCT01623050|Device|SinuSys Dilation System|Sinuplasty
134003|NCT01623063|Procedure|Hysteroscopy|hysteroscopy with guided biopsies
137414|NCT01631955|Drug|Ciprobay|Ciprobay (250mg, bid, oral)
137415|NCT01631968|Procedure|Cement without antibiotic.|
137416|NCT01631968|Procedure|Cement with erytromycin and colistin.|
137417|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
137418|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
137419|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
137420|NCT01634789|Drug|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
137421|NCT01634802|Other|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
137422|NCT01634802|Other|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
137423|NCT01634815|Procedure|The Edge|measuring blood lactate
137424|NCT00085228|Biological|oblimersen sodium|
137425|NCT01634841|Dietary Supplement|Walnuts|30 to 45g (1 to 1.5 oz) per day of walnuts
137426|NCT01634841|Other|habitual diet|Dietary information will be provided
137427|NCT01634854|Drug|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
137428|NCT01634854|Drug|Intravenous Oxytocin|Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.
Route of administration: intravenous
137429|NCT01634880|Drug|Postoperative Radiotherapy and Panitumumab|The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.
Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses).
137430|NCT01634893|Drug|Sorafenib combined with Hydroxychloroquine|dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.
Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.
Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2.
137681|NCT01635270|Radiation|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
134061|NCT01620970|Drug|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
134062|NCT01620983|Behavioral|Pain Coping Skills Training|
134063|NCT01620983|Behavioral|Arthritis Education|
134064|NCT01620983|Other|Usual Care|
134065|NCT01620996|Behavioral|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
134066|NCT01620996|Behavioral|Motivational Interviewing|Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:
FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism
These mediators/ingredients are delivered by the clinician using the following principles:
Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy
134067|NCT00084227|Drug|Azithromycin/Chloroquine|
134068|NCT01620996|Behavioral|Motivational Enhancement|Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.
The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance
These stages are specific to different behaviours.
134328|NCT01623713|Drug|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
134329|NCT00084487|Drug|becatecarin|Given IV
134330|NCT01626183|Genetic|proteomic profiling|
134331|NCT01626183|Other|laboratory biomarker analysis|
134332|NCT01626196|Other|No intervention|This was an observational study
137920|NCT01630408|Drug|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
137921|NCT01630434|Device|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
137922|NCT01630434|Device|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
137923|NCT01632891|Drug|emtricitabine/tenofovir disoproxil fumarate|Participants will receive one 200 mg/300 mg tablet of emtricitabine/tenofovir disoproxil fumarate orally once daily starting on study day 16 for 15 days.
137924|NCT00085124|Drug|daunorubicin hydrochloride|Given IV
137925|NCT01632891|Drug|trimethoprim/sulfamethoxazole|Participants will receive one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily starting on study day 16 for 15 days.
137926|NCT01632904|Drug|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
137927|NCT01632904|Drug|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
137928|NCT01632904|Drug|HU-placebo|All placebo will be self-administered, and dosing will be the same as with the blinded dose.
When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently.
137929|NCT01632904|Drug|Ruxolitinib-placebo|All placebo will be self-administered, and dosing will be the same as with the blinded dose.
When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently.
137930|NCT01632917|Drug|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
137931|NCT01632917|Drug|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
137948|NCT01635829|Drug|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
137949|NCT01635829|Drug|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
137950|NCT01635855|Device|Belotero®|Hyaluronic acid dermal filler
137951|NCT01635881|Device|Emerge™ 1.20 mm PTCA Dilatation Catheter|The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.
The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures.
134004|NCT01623102|Drug|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
134005|NCT01623102|Drug|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
134006|NCT01623115|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
134007|NCT01623115|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
134008|NCT00084435|Drug|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
134009|NCT01623115|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
134010|NCT01623128|Behavioral|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
134011|NCT01623141|Procedure|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
134012|NCT01623154|Other|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
134275|NCT01619007|Drug|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
134276|NCT00084032|Drug|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
134277|NCT01619020|Dietary Supplement|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
134278|NCT01619033|Drug|BF2.649|single dose 20 mg
134279|NCT01619046|Biological|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate < 10 mL/min
134280|NCT01619046|Biological|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
134281|NCT01619046|Biological|GreenGene™ F|intra-venous infusion,
On-demand safety and efficacy substudy:
minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg
137682|NCT01635270|Radiation|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
137683|NCT01635283|Biological|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
137684|NCT01635283|Other|laboratory biomarker analysis|Correlative studies
137685|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
137686|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
137687|NCT00085254|Other|pharmacological study|Correlative studies
137688|NCT01635296|Drug|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
137689|NCT01635296|Drug|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
137690|NCT01635309|Other|Coronary CT Angiogram|pre-operative coronary CTA
137691|NCT01635322|Device|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
137692|NCT01635335|Behavioral|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
137693|NCT01635348|Behavioral|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
137694|NCT01635348|Behavioral|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
137695|NCT01635361|Other|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
137696|NCT01635374|Procedure|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
137697|NCT01635387|Drug|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
134333|NCT01626209|Drug|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
134334|NCT01626222|Drug|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
134335|NCT01626222|Drug|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
134336|NCT01626261|Device|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
134337|NCT01626274|Device|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
134338|NCT01626287|Other|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
134339|NCT01626287|Other|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
134340|NCT00084643|Drug|capecitabine|Given orally
134341|NCT01626313|Behavioral|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
134342|NCT01626326|Behavioral|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
134635|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^9 pfu /2mL administered in each deltoid
134636|NCT01614782|Other|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
134637|NCT01614795|Biological|cixutumumab|Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).
137952|NCT01635894|Behavioral|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
137953|NCT01635907|Drug|Dovitinib|
137954|NCT01635920|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
137955|NCT00085293|Procedure|Positron emission tomography|Optional correlative studies
137956|NCT01635920|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
137957|NCT01635933|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
137958|NCT01635933|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
137959|NCT01635946|Drug|Isavuconazole|oral
137960|NCT01635946|Drug|atorvastatin|oral
137961|NCT01635972|Drug|Isavuconazole|oral
137962|NCT01635972|Drug|bupropion hydrochloride|oral
137963|NCT01635985|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
137964|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
137965|NCT01638078|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
137966|NCT01638078|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
137967|NCT01638091|Behavioral|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
137968|NCT01638091|Behavioral|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
137066|NCT01682044|Other|flow cytometry|Correlative studies
137067|NCT01682044|Procedure|biopsy|Correlative studies
137068|NCT00089206|Biological|multi-epitope melanoma peptide vaccine|
137069|NCT01682044|Other|immunohistochemistry staining method|Correlative studies
137070|NCT01682044|Genetic|western blotting|Correlative studies
134282|NCT01619046|Biological|GreenGene™ F|intra venous infusion,
Surgical substudy:
Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.
Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level.
134283|NCT01619059|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
134284|NCT01619059|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
134285|NCT01619059|Drug|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
134286|NCT01619059|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
134287|NCT00084045|Procedure|Intrapartum HIV counseling/testing|
134288|NCT01619072|Other|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
134289|NCT01619072|Other|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
134290|NCT01619085|Drug|BIBF 1120|BIBF 1120 BID (twice a day)
134291|NCT01621321|Drug|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
134292|NCT01621321|Drug|Voriconazole|Voriconazole 200 mg BD for 6 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
134580|NCT01617096|Drug|Placebo|Vaginal ring containing no drug substance
134581|NCT01617109|Dietary Supplement|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
134582|NCT00083902|Drug|Thalidomide|
134583|NCT01617109|Other|Placebo|administered as 5 pills daily or as 2 snack bars
134584|NCT01617122|Biological|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
134585|NCT01617135|Drug|CVT-301|
134586|NCT01617135|Drug|Placebo|
134587|NCT01617135|Drug|Sinemet (carbidopa/levodopa)|
138026|NCT01633125|Other|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
138027|NCT00085163|Drug|celecoxib|
138028|NCT01633138|Behavioral|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
138029|NCT01633138|Behavioral|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
138030|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
138031|NCT00001577|Procedure|double isolated limb perfusion with melphalan alone|
138032|NCT00085306|Biological|recombinant interferon beta|recombinant interferon beta
138033|NCT01635985|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
138034|NCT01635985|Drug|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
138035|NCT01635985|Drug|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
138036|NCT01635998|Device|Boston Scientific Vessix Renal Denervation System|Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.
Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts
138037|NCT01636011|Other|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
138038|NCT01636011|Other|Light Touch sham|Light Touch sham
138039|NCT01636024|Drug|AZD7594|Suspension inhaled via Spira nebuliser
138040|NCT01636024|Drug|Placebo to match|Matching placebo inhaled via Spira nebuliser
138041|NCT01636037|Drug|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
138042|NCT01636050|Other|squat exercise training|Intervention may include squat exercise for 8 weeks
138043|NCT00085332|Drug|docetaxel|
138044|NCT01636063|Drug|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
138045|NCT01636063|Drug|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
134638|NCT01614795|Drug|temsirolimus|Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.
134639|NCT01614795|Other|laboratory biomarker analysis|Correlative studies
134640|NCT01614808|Other|laboratory biomarker analysis|Correlative studies
134641|NCT01614821|Drug|PCI-32765|Taken orally, once daily in the morning
134642|NCT01614847|Drug|Artificial tears|At random, subjects will receive hypo-osmolar artificial tear or a control (normal saline).
134643|NCT01614873|Device|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
134644|NCT01614886|Drug|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
134645|NCT01614886|Drug|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
134646|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^7 pfu/2mL administered into each deltoid
134647|NCT01614899|Drug|SM-13496 40mg|once daily orally
134648|NCT01614899|Drug|SM-13496 80mg|once daily orally
134649|NCT01614899|Drug|Placebo|once daily orally
134650|NCT01614912|Drug|SM-13496|40 or 80 mg once daily orally
134651|NCT01614938|Drug|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
134652|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
134653|NCT01614938|Drug|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
134654|NCT01614938|Radiation|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
133773|NCT01625182|Drug|Placebo Comparator|
137071|NCT01682057|Device|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
137072|NCT01682057|Device|ROX Anastomotic Coupler System (ACS)|
137073|NCT01682070|Biological|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
137074|NCT01682070|Biological|Placebo|
137075|NCT01682083|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
137076|NCT01682083|Drug|Trametinib|Each tablet contains 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
137077|NCT01682083|Drug|Placebos|The placebo capsules and tablets contain the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
137078|NCT01682096|Radiation|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
137079|NCT00089206|Biological|sargramostim|
137080|NCT01682096|Procedure|Exercise stress echocardiography|Limited by symptoms
137081|NCT01682109|Drug|Valacyclovir|
137082|NCT01682135|Biological|Ramucirumab|Administered IV.
137083|NCT01682148|Procedure|Current clinical practice technique and high-concentration dilution|The same number and sites of injections/deposits per muscle will be given as pre study. With a Dysport dilution of 300U/mL the volume to be injected will vary in the interval of 0.1 mL to 0.7 mL per muscle.
137084|NCT01682148|Procedure|NMJ targeted technique and low-concentration dilution|A single injection per muscle will be given in the midline of the band of NMJ zones. With a Dysport dilution of 100U/mL the volume to be injected will vary in the interval of 0.4 mL to 2.0 mL per muscle.
137085|NCT01682161|Drug|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
137086|NCT01682174|Other|Control Drink|
137087|NCT01682174|Other|Experimental Drink|
137088|NCT01682187|Drug|LY2157299|Administered orally
137350|NCT01637194|Biological|cetuximab|Given IV
137351|NCT01637194|Other|pharmacological study|Correlative studies
134588|NCT01617135|Drug|CVT-301|
134589|NCT01617161|Radiation|Proton Beam Therapy|5 days per week 8-9 weeks
134590|NCT01617161|Radiation|Intensity Modulated Radiation Therapy|5 times per week 8-9 weeks
134591|NCT01617174|Behavioral|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
134592|NCT01617187|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
134593|NCT00083902|Drug|Dexamethasone|
134594|NCT01617187|Drug|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
134595|NCT01609933|Drug|ABT-267|ABT-267 (tablets)
134596|NCT01609933|Drug|pegylated interferon alpha-2a (pegIFN)|pegylated interferon alpha-2a syringe
134597|NCT00083161|Drug|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
134598|NCT01609933|Drug|Ribavirin (RBV)|Ribavirin (tablets)
134599|NCT01609946|Device|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
134600|NCT01609946|Procedure|Cytology (FNAB) or Surgery|
134601|NCT01609959|Drug|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
133721|NCT01627782|Drug|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
133722|NCT01620333|Drug|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
133723|NCT01620346|Procedure|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
138046|NCT01636076|Drug|QMF149|delivered via Concept1 device
138047|NCT01636076|Drug|Salmeterol|delivered via Accuhaler®
137145|NCT01679860|Drug|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|Clin B:
CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course.
137146|NCT01679873|Other|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
137147|NCT01679886|Radiation|Rubidium PET|Rubidium PET
137148|NCT01679899|Drug|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
137149|NCT01679899|Drug|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
137150|NCT01679912|Other|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
137151|NCT01679938|Behavioral|primary obesity prevention|Training of child care providers.
Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.
Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.
Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention.
137152|NCT01679951|Drug|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
137153|NCT00089219|Biological|IFA|vaccine adjuvant
137154|NCT01682200|Drug|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
137155|NCT01682213|Drug|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
137156|NCT01682226|Device|CliniMACS Fractionation system (Arm A)|7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)
1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF
137157|NCT01682226|Device|CliniMACS Fractionation system (Arm B)|8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3
1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood
1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF
133774|NCT01625195|Dietary Supplement|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
133775|NCT01625195|Dietary Supplement|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide
133776|NCT01625208|Procedure|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
133777|NCT01625208|Procedure|Supraclavicular block|Standard supraclavicular brachial plexus block
133778|NCT01628003|Device|Brain MRI|Brain MRI
133779|NCT01628003|Device|MRI|Physical examination Neuropsychological testing Questionnaires
133780|NCT00084734|Drug|capecitabine|Oral
133781|NCT01628016|Behavioral|a word dot-probe task for training procedure|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition, only assessment for blank control condition.
133782|NCT01628029|Device|Litebook|Either light therapy or placebo light over 30 minutes within 2 hours of waking for 14 days.
133783|NCT01628029|Drug|Melatonin|20 mg by mouth at bed time.
133784|NCT01628029|Drug|Methylphenidate|5 mg by mouth twice daily.
133785|NCT01628029|Drug|Placebo|One placebo capsule orally twice a day before 3 PM, and/or one placebo capsule at bedtime.
133786|NCT01628029|Behavioral|Counseling Sessions|Counseling session with a counselor lasting about 30 minutes, either in person or by phone on Days 8 and 15 only.
133787|NCT01628029|Behavioral|Questionnaires|Symptom and emotional well-being questionnaires completed on Days 1, 3, 8, 15, and 29.
133788|NCT01628029|Behavioral|Study Diaries|Completion of diaries at the end of each day of the 14-day study period, explaining how much light received from Litebook, and a pill diary about medication.
133789|NCT01628042|Drug|MK-4618|MK-4618 tablets, orally, on Day 1
133790|NCT01628055|Biological|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (~3-4 hours depending on weight).
133791|NCT00084734|Drug|cisplatin|IV
137352|NCT00085397|Biological|therapeutic autologous dendritic cells|Given IV
137353|NCT01637194|Other|laboratory biomarker analysis|Correlative studies
137354|NCT01637207|Other|Palpation|Group A: Palpation Group
137355|NCT01637207|Other|Ultrasound|Group B: Ultrasound Group
137356|NCT01637220|Biological|Blood volume collected specifically for this study|case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.
Control patients: 20 ml following neuromuscular blocking drug injection
137357|NCT01637233|Drug|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
137358|NCT01637233|Drug|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
137359|NCT01637233|Drug|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
137360|NCT01637246|Drug|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
137361|NCT01637259|Drug|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
137362|NCT01637259|Drug|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
137363|NCT00085410|Drug|bortezomib|Given IV
137364|NCT01637259|Drug|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
137365|NCT01637272|Drug|SOM230|
137366|NCT01637285|Biological|PF-04856883|Dose A
137367|NCT01637285|Biological|PF-04856883|Dose B
137368|NCT01637285|Biological|PF-04856883|Dose C
137369|NCT01637285|Biological|PF-04856883|Dose D
137370|NCT01637311|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
137371|NCT01637337|Procedure|laparoscopic pyelolithotomy|laparoscopy
137372|NCT01637337|Procedure|percutaneous nephrolithotomy|percutaneous nephrolithotomy
133724|NCT01620346|Procedure|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
133725|NCT01620359|Device|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
133726|NCT01620385|Device|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
133727|NCT01620398|Behavioral|BALANCE|
133728|NCT01620398|Behavioral|Cardioprotective diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
133729|NCT01620411|Other|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
133730|NCT00084149|Drug|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
133731|NCT01620411|Procedure|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
133732|NCT01620424|Drug|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
133733|NCT01620424|Drug|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
133734|NCT01620437|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
133735|NCT01620450|Drug|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
133736|NCT01620463|Drug|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
134013|NCT01625468|Behavioral|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
134014|NCT01625481|Device|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
134015|NCT01625494|Drug|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
137158|NCT01682239|Other|RVAP|In this arm pacemaker leads will be placed in the RV apex.
137159|NCT01682239|Other|RVSP|In this arm pacemaker leads will be placed in the RV septum.
137160|NCT01682265|Other|Stretta procedure|
137161|NCT01682265|Other|Sham procedure|No radiofrequency delivered
137431|NCT01634906|Drug|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
137432|NCT01634919|Device|chronic hepatitis C|acoustic radiation force impulse ultrasonography
137433|NCT01634932|Other|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
137434|NCT01634932|Other|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
137435|NCT00085228|Drug|docetaxel|
137436|NCT01634932|Other|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
137437|NCT01634945|Drug|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
137438|NCT01634945|Dietary Supplement|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
137439|NCT00085423|Biological|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
137440|NCT01637363|Behavioral|Psychoeducation|6 x 2 hours of psychoeducation
137441|NCT01637376|Drug|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
137442|NCT01637389|Other|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
134069|NCT01621009|Drug|Active bupropion + counseling|Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.
Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date.
134070|NCT01621009|Drug|Active bupropion, No counseling|Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.
Counseling: No cessation counseling, only medication checks
134071|NCT01621009|Drug|Placebo medication + counseling|Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.
Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day.
134072|NCT01621009|Drug|Placebo medication, No counseling|Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.
Counseling: No counseling, just medication checks
134073|NCT01621022|Drug|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
134074|NCT01621022|Drug|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
134075|NCT01623167|Drug|Eltrombopag|
134076|NCT01623167|Drug|Horse Anti-Thymocyte Globulin (ATG)|
134077|NCT01623167|Drug|Cyclosporine A (CSA)|
134078|NCT01623180|Device|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
134079|NCT01623180|Device|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
134080|NCT01623193|Other|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
134081|NCT00084435|Drug|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
134082|NCT01623193|Procedure|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
134083|NCT01623206|Drug|Desmopressin|Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.
All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion.
134084|NCT01623219|Behavioral|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
137373|NCT01637350|Procedure|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
137621|NCT00085436|Biological|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
137622|NCT01637701|Procedure|B-TURP|Bipolar transurethral resection of the prostate
137623|NCT01637714|Drug|Multi-strain probiotics|B. longum BORI: 1 x 109
B. bifidum BGN4: 1 x 109
B. lactis AD011: 1 x 109
B. infantis IBS007: 1 x 109
Lactobacillus acidophilus AD031: 1 x 109
three times a day, within 10 minutes after meal, per oral with water
137624|NCT01637714|Drug|Placebo powder|same taste, shape, dosage as experimental drug
three times a day, within 10 minutes after meal, per oral with water
137625|NCT01637753|Drug|Carmustine(BCNU)|Carmustine Sustained Release Implant
137626|NCT01637753|Procedure|Surgery|Routine tumor resection surgery
137627|NCT01637766|Drug|Melphalan (intra-arterial infusion)|Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.
The chemotherapy will be infused via a tiny soft plastic tube (called "microcatheter") at the tumor site over approximately 30 minutes.
The drug of choice is Melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.
We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts.
137628|NCT01637779|Behavioral|Fact sheet|fact sheet about pain management during immunization
137629|NCT01637792|Other|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
137630|NCT01637805|Biological|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
137631|NCT01637818|Procedure|Lichtenstein's operation|
137632|NCT01629745|Other|flow cytometry|
137633|NCT01629745|Other|laboratory biomarker analysis|
137634|NCT01629758|Biological|Denenicokin|
137635|NCT01629758|Biological|Nivolumab|
137636|NCT01629784|Behavioral|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
137637|NCT01629797|Behavioral|Educational script on Acne|An educational script on Acne will be presented by investigator
134016|NCT01625494|Drug|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
134017|NCT01625494|Drug|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
134018|NCT01625494|Drug|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
134019|NCT01625507|Behavioral|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
134020|NCT00084604|Other|laboratory biomarker analysis|Correlative studies
134021|NCT01625520|Drug|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
134022|NCT01625533|Procedure|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
134023|NCT01625533|Procedure|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
134024|NCT01625546|Device|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
134025|NCT01625559|Biological|MA09-hRPE|MA09-hRPE: 50,000 cells
134026|NCT01625572|Procedure|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
134027|NCT01625572|Procedure|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
134028|NCT01625598|Procedure|Photography of the retina|Every subject will undergo photography of the retina in both eyes
134029|NCT01625598|Procedure|Retinal photography|Device
Subjects will have photography of both eyes
134030|NCT01625611|Drug|Naltrexone|Naltrexone 100 mg titrated over one week
134031|NCT00084617|Drug|oxaliplatin|Given IV
134032|NCT01625624|Other|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
134293|NCT01621334|Behavioral|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
137443|NCT01637389|Other|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
137444|NCT01637402|Drug|Abiraterone Acetate|Standard dose: 1,000 mg, once daily, oral administration
Increased dose: 1,000 mg, twice daily, oral administration
137445|NCT01637402|Drug|Prednisone|5 mg, twice daily, oral administration
137698|NCT00085280|Drug|erlotinib hydrochloride|Given orally
137699|NCT01635400|Drug|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
137700|NCT01635413|Behavioral|Exercise Intervention|Undergo strength training classes
137701|NCT01637909|Other|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
137702|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
137703|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
137704|NCT01637935|Drug|Pioglitazone|Pioglitazone tablets.
137705|NCT01637948|Drug|Listerine mouthrinse|For six months
137706|NCT01637948|Drug|Chinese Medicine mouthrinse|six months
137707|NCT00085449|Biological|alemtuzumab|
137708|NCT01637961|Drug|Alisertib|Given PO
137709|NCT01637961|Other|Laboratory Biomarker Analysis|Correlative studies
137710|NCT01637974|Drug|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
134343|NCT01626339|Drug|Intravitreal Ranibizumab|
134344|NCT01626339|Drug|Intravitreal bevacizumab|
134345|NCT01626352|Drug|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m^2 Days 1 and 2 of Cycles 1 through 6 and ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2 through 6(a cycle is defined as 21 days in length).
134346|NCT01626352|Drug|Ofatumumab|Patients will receive as an IV infusion bendamustine 90 mg/m^2 Days 1 and 2 of Cycles 1 through 6 and ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2 through 6(a cycle is defined as 21 days in length).
134347|NCT01619098|Other|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
134348|NCT01619098|Other|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
134349|NCT01619111|Drug|standard chemo- or endocrine therapy|standard chemo- or endocrine therapy:
Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)
Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)
134350|NCT01619111|Drug|standard chemo- or endocrine therapy + Lapatinib|Lapatinib
+ standard chemo- or endocrine therapy:
Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)
Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)
134351|NCT01619137|Drug|water and soap|water and soap for 6-8 hours per day.
134352|NCT01619137|Drug|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
134353|NCT01619150|Drug|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
134354|NCT00084045|Procedure|Postpartum HIV counseling/testing|
134355|NCT01619150|Drug|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
134356|NCT01619163|Drug|Placebo|
134357|NCT01619163|Drug|Prednisolone|low dose, 7.5 mg/day
134358|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
134359|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
137638|NCT01629810|Device|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
137639|NCT01629823|Device|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm H2O, 5H2O or 10H2O. they will be instructed to use the CPAP device every night for 12 weeks. There will be a washout methacholine measurement after a 2 week washout period.
137969|NCT01638104|Drug|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
137970|NCT01638104|Drug|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
137971|NCT01638117|Other|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
137972|NCT01638117|Drug|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
137973|NCT00085449|Drug|fludarabine phosphate|
137974|NCT01638117|Drug|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
137975|NCT01638117|Drug|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
137976|NCT01638117|Other|Saline|Saline, Daily for up to 21 days
137977|NCT01638117|Other|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
137978|NCT01638143|Dietary Supplement|MenaQ7 M-1500 capsules|The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
137979|NCT01638143|Dietary Supplement|Gnosis P-1000 capsules|The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
137980|NCT01638143|Dietary Supplement|Gnosis M-1500 capsules|The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
137981|NCT01638169|Device|adding a heel|walking with and without heels on the gaitrite system
137982|NCT01638182|Dietary Supplement|Placebo|27 participants received for three months 1 placebo capsule per day
137983|NCT01638182|Dietary Supplement|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
137984|NCT00085449|Drug|melphalan|
134294|NCT01621334|Behavioral|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
134295|NCT01621360|Procedure|Arthroscopic hip surgery|Hip arthroscopy
134296|NCT01621360|Other|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
134297|NCT01621373|Drug|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
134298|NCT01621386|Drug|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
134299|NCT00084253|Drug|Atazanavir-Ritonavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD*, Once daily, 96 weeks.
134300|NCT01621386|Drug|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
134301|NCT01621399|Drug|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
134302|NCT01621399|Drug|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
134303|NCT01621425|Other|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
134304|NCT01621425|Other|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
134305|NCT01621425|Other|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
134306|NCT01621451|Drug|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
134307|NCT01621451|Drug|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.
In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
134308|NCT01621464|Device|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
134309|NCT01621477|Drug|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
134310|NCT00084266|Drug|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
137711|NCT01637987|Procedure|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
137712|NCT01637987|Procedure|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
137713|NCT01637987|Procedure|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein & surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
137714|NCT01638000|Drug|Mirabegron|oral tablet
138048|NCT01636089|Drug|bicarbonates|sodium bicarbonates 1,4%
138049|NCT01636089|Drug|saline|sodium chloride 0,9%
138050|NCT01636102|Biological|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
138051|NCT01636128|Drug|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
138052|NCT01636128|Drug|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
138053|NCT01636141|Drug|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
138054|NCT00085345|Drug|arsenic trioxide|
138055|NCT01636141|Drug|Placebo gel|
138056|NCT01636154|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
138057|NCT01638403|Drug|BF2.649|BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).
Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
138058|NCT01638403|Drug|Vigil|Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.
Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
134360|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
134361|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
134655|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
134656|NCT01617187|Drug|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
134657|NCT01617187|Drug|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
134658|NCT01617200|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
134659|NCT01617200|Drug|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
134660|NCT01617200|Drug|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
134661|NCT01617200|Drug|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
134662|NCT01617213|Drug|Melphalan|200 mg/m2/IV
134663|NCT01617213|Drug|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
134664|NCT01617226|Drug|Azacitidine|Azacitidine both arms; 75mg/m^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
134665|NCT00083915|Drug|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
134666|NCT01617226|Drug|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
134667|NCT01617239|Biological|Virosomal influenza vaccine|Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:
15 μg HA antigen of A/California/7/2009 (H1N1)-like virus
15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus
15 μg HA antigen of B/Brisbane/60/2008-like virus
Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)
134668|NCT01617252|Device|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
137985|NCT01638182|Dietary Supplement|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
137986|NCT01638195|Device|Focused Ultrasound|Focused Ultrasound
137987|NCT01638208|Drug|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
137988|NCT01638234|Dietary Supplement|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
137089|NCT01682187|Drug|Lomustine|Administered orally
137090|NCT01684397|Biological|Bevacizumab|Given IV
137091|NCT01684397|Other|Laboratory Biomarker Analysis|Correlative studies
137092|NCT01684397|Drug|Pazopanib Hydrochloride|Given PO
137093|NCT01684397|Other|Pharmacological Study|Correlative studies
137094|NCT01684410|Biological|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
137095|NCT01684410|Biological|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
137096|NCT00089401|Drug|melphalan|
137097|NCT01684410|Biological|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
137098|NCT01684423|Drug|Rivaroxaban (Xarelto, BAY59-7939)|
137099|NCT01684436|Device|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
137100|NCT01684449|Drug|Gemcitabine + Rapamycin|Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.
Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination.
137101|NCT01684462|Biological|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4~8h, commencing within 12 hours of stroke onset
137102|NCT01684462|Drug|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset
134602|NCT01609959|Drug|Valsartan|Valsartan 160 mg per day
134603|NCT01609972|Device|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
134604|NCT01609998|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
134605|NCT01609998|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
134606|NCT01610011|Dietary Supplement|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
134607|NCT01610024|Dietary Supplement|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
134608|NCT00083161|Drug|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
134609|NCT01610037|Drug|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
134610|NCT01610037|Drug|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
134611|NCT01610037|Drug|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
134612|NCT01610050|Drug|LFA102|
134613|NCT01610063|Other|Algorithm|Genetic test results was put through algorithm and provided to physician for guidance prescribing medication.
134614|NCT01610076|Other|Code Status Video|10 minute video about "Code Status"
134615|NCT01610089|Other|stable isotope infusion|Control subjects: [15N2-ureido] arginine (0.69 mg/kg); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of [15N2-ureido] arginine (0.69 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr).
Citrullinemia type 1 subjects,[15N2-ureido] arginine (4.14 mg/kg); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of [15N2-ureido] arginine (4.14 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr).
134616|NCT01612273|Drug|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
134617|NCT01612273|Drug|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
138059|NCT01638403|Drug|palcebo|placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.
placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
138060|NCT01638416|Other|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
138061|NCT01638429|Drug|Neomycin and Rifaximin|Neomycin: 500mg po bid for 10 days Rifaximin: 550mg po tid for 10 days
138062|NCT01638442|Drug|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
138063|NCT00085449|Radiation|radiation therapy|
138064|NCT01638442|Drug|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
138065|NCT01638455|Device|Noninvasive monitoring, blood sampling|Noninvasive monitoring, blood sampling
138066|NCT01638468|Device|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
137162|NCT01682278|Device|Removal of dental amalgam restorations|Patients in the "amalgam cohort" will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient.
137163|NCT01682291|Behavioral|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
137164|NCT00089219|Biological|6MHP|melanoma helper peptides
137165|NCT01682291|Dietary Supplement|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
137166|NCT01682317|Behavioral|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, < 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
137167|NCT01682343|Dietary Supplement|Calcium|Milk-calcium supplement
137168|NCT01682356|Dietary Supplement|Beetroot Juice (BRJ)|double-blind placebo-controlled cross-over study
137169|NCT01682356|Dietary Supplement|placebo|double-blind placebo-controlled cross-over study
137170|NCT01682369|Biological|TIV (Aggripal)|
134669|NCT01617265|Procedure|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
134670|NCT01617265|Procedure|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
137603|NCT01635205|Procedure|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
137604|NCT01635205|Procedure|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
137605|NCT01635218|Drug|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
137606|NCT01635218|Drug|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
137607|NCT00085254|Other|laboratory biomarker analysis|Correlative studies
137608|NCT01635218|Drug|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
137609|NCT01635231|Other|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
137610|NCT01635244|Device|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
137611|NCT01635257|Other|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
137612|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 12
137613|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 6
137614|NCT01637636|Drug|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
137615|NCT01637636|Drug|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
137616|NCT01637662|Drug|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
137617|NCT01637675|Drug|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
137103|NCT01684475|Drug|CJH1 (CLR4001)|
137104|NCT01684488|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
137105|NCT01684488|Other|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
137374|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
137375|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
137376|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)]
137377|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
137378|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
137379|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
137380|NCT01629407|Other|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
137381|NCT01629420|Drug|KLH-2109|
137382|NCT00001572|Drug|Id-KLH Vaccine|
137383|NCT00084838|Drug|cytarabine|
137384|NCT01629420|Drug|KLH-2109|
137385|NCT01629446|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
137386|NCT01629459|Behavioral|Resistance exercise|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home
137387|NCT01629472|Behavioral|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
137388|NCT01629485|Behavioral|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
134618|NCT01612286|Drug|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle *4cycles
134619|NCT00083460|Drug|Dexamethasone|A dose of 20mg for cylces 3-8.
133737|NCT01620463|Drug|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
133738|NCT01620476|Drug|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
133739|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
133740|NCT01622556|Radiation|Total Body Irradiation|150 cGy for 2 days
133741|NCT01622556|Biological|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
133742|NCT01622569|Drug|fluticasone propionate|
133743|NCT01622569|Drug|fluticasone propionate|
133744|NCT01622608|Behavioral|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
133745|NCT01622621|Procedure|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
133746|NCT01622621|Radiation|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
133747|NCT01622634|Behavioral|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
133748|NCT01622634|Other|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
133749|NCT00084396|Drug|letrozole|
133750|NCT01622634|Other|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
133751|NCT01622647|Other|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
137171|NCT01682369|Biological|ATIV (Fluad)|
137172|NCT01682395|Procedure|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
137173|NCT01684540|Other|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
137174|NCT01684540|Drug|Sinupret forte|
137175|NCT01684553|Behavioral|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
137176|NCT01684553|Behavioral|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
137177|NCT01684566|Device|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
137178|NCT01684566|Other|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
137179|NCT01684579|Behavioral|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
137446|NCT01637428|Device|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
137447|NCT01637441|Procedure|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
137448|NCT01637441|Procedure|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
137449|NCT01637454|Drug|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
137450|NCT00001579|Drug|Ethynyluracil|
137451|NCT00085423|Biological|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
137452|NCT01637454|Drug|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
137453|NCT01637467|Other|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
137618|NCT01637675|Drug|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
137619|NCT01637688|Dietary Supplement|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula and a commercial amino acid formula
137620|NCT01637701|Procedure|PkEP|Plasmakinetic enucleation of the prostate
137883|NCT01635790|Drug|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
137884|NCT01635790|Drug|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
137885|NCT01635803|Drug|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
137886|NCT00085436|Biological|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
137887|NCT01637818|Procedure|Mesh Plug Repair|
137888|NCT01637818|Drug|Opiate|Postoperative pain therapy
137889|NCT01637818|Drug|Paracetamol|Postoperative pain therapy
137890|NCT01637818|Drug|non-steroidal anti-inflammatory drug|Postoperative pain therapy
137891|NCT01637831|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
137892|NCT01637844|Drug|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
137893|NCT01637857|Dietary Supplement|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
137894|NCT01637857|Dietary Supplement|oligoantigenic diet|oligoantigenic diet associated to life style counseling
137895|NCT01637870|Device|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
137389|NCT01629485|Behavioral|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
137390|NCT01629485|Behavioral|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
137391|NCT01629498|Radiation|IMPT + SIB + Chemotherapy|Phase I Starting Dose: For all SIBVi dose levels, the dose to the PTV will be kept constant at 60 Gy(RBE) in 30 fractions, which is biologically equivalent to 67 Gy(RBE) delivered in 2 Gy(RBE) fractions. We will start the SIB at the lowest dose level to SIBVi to 72 Gy(RBE) (SIBV72) in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks.
All patients will receive standard concurrent chemotherapy as prescribed by their treating medical oncologist.
Dose level 1 of 66-72 Gy(RBE) in 30 fractions used as the planned dose in the Phase II portion of the trial.
137640|NCT00084838|Drug|temozolomide|
137641|NCT01629849|Drug|Placebo to BI 1021958 qd|tablet
137642|NCT01629849|Drug|BI 1021958 bid|tablets
137643|NCT01629849|Drug|Placebo to BI 1021958 bid|tablets
137644|NCT01629849|Drug|BI 1021958 qd|tablet
137645|NCT01629862|Device|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
137646|NCT01629862|Device|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
137647|NCT01629875|Drug|Generic equivalent of Clostridium Botulinum A Toxin|
137648|NCT01629875|Drug|Botox (Clostridium Botulinum A Toxin)|
137649|NCT01629888|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
137650|NCT01629888|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
137651|NCT00084838|Drug|therapeutic hydrocortisone|
137652|NCT01629901|Device|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
137653|NCT01629914|Behavioral|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
137654|NCT01629953|Other|Group based manualized vocational rehabilitation|Group based manualized vocational rehabilitation
137655|NCT01629953|Other|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
133752|NCT01622660|Drug|Gemcitabine and Pazopanib|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days). Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
133753|NCT01622673|Drug|Raltegravir|Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours
Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
134033|NCT01625624|Other|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
134034|NCT01625637|Behavioral|AAT-experiment|This AAT condition trains kids to avoid cigarettes
134035|NCT01625637|Behavioral|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
134036|NCT01625676|Other|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
134037|NCT01628120|Biological|Epoetin Hospira|Other ESAs may be used as rescue therapy provided they are not long acting.
134038|NCT01628133|Procedure|ultrasound|sonographic evaluation of intestinal blood flow
134039|NCT01628146|Device|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
134040|NCT01628159|Device|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
134041|NCT01628172|Device|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
134042|NCT01628185|Procedure|Repositioning|pain assessment at baseline then following routine care repositioning in bed
134043|NCT01628198|Device|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.
There are 2 devices that can be used---this is optional, based on physician preference:
Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California
or
Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California
134044|NCT01628211|Procedure|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
134045|NCT01628211|Procedure|peritonectomy|for patients with PCI < 20
134046|NCT01628211|Drug|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI < 20
134047|NCT00084747|Drug|bortezomib|
134048|NCT01628211|Drug|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI < 20
137454|NCT01629511|Drug|Busulfan|32 mg/m2 test dose by vein based on actual body weight given between Day -15 and Day -8.
Busulfan administered at dose calculated to achieve a systemic exposure dose of 4000 µMol-min in normal saline over 3 hours by vein every 24 hours on Days -6 to -3, starting one hour after the completion of Clofarabine.
137455|NCT01629511|Drug|Clofarabine|30 mg/m2 diluted in NS to produce a final concentration of 0.4mg/mL by vein on Days -6 through -3.
137456|NCT01629511|Drug|Gemcitabine|Phase I Starting Dose: 275 mg/m2 by vein preceded by a loading dose of 75 mg/m2 administered as a bolus on Days -6 and -4.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I.
137457|NCT01629511|Drug|Thymoglobulin|0.5 mg/kg by vein on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1 for patients receiving a graft from a matched unrelated donor.
137458|NCT01629511|Procedure|Allogeneic Stem Cell Transplantation|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
137459|NCT01629511|Drug|Filgrastim|5 mcg/kg subcutaneously 1 time each day starting 1 week after the transplant until blood cell levels return to normal.
137460|NCT01629511|Drug|Tacrolimus|Starting dose of 0.015 mg/kg by vein as a 24 hour continuous infusion daily beginning on Day -2, adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no GVHD is present.
137461|NCT01629511|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6 and +11 post transplant.
137715|NCT01638000|Drug|Solifenacin succinate|oral tablet
137716|NCT01638013|Drug|ASP015K|oral
137717|NCT01638026|Drug|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
137718|NCT00085449|Drug|cyclosporine|
137719|NCT01638039|Other|Laboratory Tests|Stool, blood, urine and saliva samples
137720|NCT01638052|Drug|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
137721|NCT01629979|Procedure|Grafting with epidermal cells|A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.
Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
137722|NCT01629979|Radiation|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
137896|NCT01637883|Drug|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
137897|NCT00085436|Biological|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
137898|NCT01637896|Device|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
137899|NCT01637896|Device|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
138211|NCT01636440|Device|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
138212|NCT01636453|Device|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
138213|NCT01636466|Drug|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
138214|NCT01636479|Drug|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
138215|NCT00085345|Procedure|chemotherapy|
138216|NCT01636492|Drug|bitopertin|Single oral dose
138217|NCT01636492|Drug|placebo|Single oral dose
138218|NCT01636505|Drug|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
138219|NCT01636505|Drug|gnrh agonist (suprefact)|suprefact 5.5 ml
138220|NCT01628419|Behavioral|Health intervention|physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.
Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects.
138221|NCT01628432|Procedure|conservative hysterectomy I|conservative hysterectomy for benign disease
138222|NCT01628432|Procedure|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
138223|NCT01628445|Drug|liraglutide|liraglutide titrated to 1.8 mg sc daily
138224|NCT00084773|Procedure|neoadjuvant therapy|
138225|NCT01628445|Drug|placebo injection|placebo injected sc daily volume equal to active comparator
137656|NCT01629966|Drug|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
137657|NCT01629966|Drug|Vilazodone|Vilazodone, 20mg, oral administration once per day.
137658|NCT01629966|Drug|Vilazodone|Vilazodone, 40mg, oral administration once per day.
137659|NCT01632319|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
137660|NCT01632332|Biological|HER-2/neu peptide vaccine|Given ID
137661|NCT01632332|Other|laboratory biomarker analysis|Correlative studies
137989|NCT01630473|Procedure|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
137990|NCT01630473|Procedure|Conventional orthodontics|Conventional orthodontic treatment
137991|NCT01630499|Behavioral|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
137992|NCT01630499|Behavioral|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
137993|NCT01630512|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
137994|NCT00084877|Drug|triapine|Given IV
137995|NCT01630512|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
137996|NCT01630525|Other|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
137997|NCT01630525|Other|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
137998|NCT01630525|Other|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
137999|NCT01630538|Drug|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
134049|NCT01628211|Drug|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI < 20
134050|NCT01628211|Drug|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI > 20
134051|NCT01628237|Device|comparison of spinal cord stimulation|
134052|NCT01628250|Procedure|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
134053|NCT01628250|Procedure|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
134311|NCT01623609|Drug|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
134312|NCT01623609|Drug|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
134313|NCT01623622|Drug|HC-58|once or more / week
134314|NCT01623622|Drug|Placebo|once or more / week
134315|NCT01623635|Drug|Ropivacaine|ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion
Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:
each subdiaphragmatic area 3.5 ml + 3.5ml
surgical dissection site 3 ml
diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.
At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections).
134316|NCT01623635|Drug|placebo (normal saline)|ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion
Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:
each subdiaphragmatic area 3.5 ml + 3.5ml
surgical dissection site 3 ml
diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.
At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections).
134317|NCT00001567|Drug|Roferon-A|
134318|NCT00084461|Other|laboratory biomarker analysis|Correlative studies
134319|NCT01623648|Other|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
134320|NCT01623648|Other|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
134321|NCT01623648|Other|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
137723|NCT01629992|Other|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
137724|NCT00084838|Drug|vincristine sulfate|
137725|NCT01630005|Behavioral|talk therapy|Psychotherapy
137726|NCT01630018|Drug|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
137727|NCT01630018|Drug|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
137728|NCT01630044|Device|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
137729|NCT01630057|Drug|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
137730|NCT01630057|Drug|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
137731|NCT01630070|Device|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
137732|NCT01630083|Drug|Epirubicin|50 mg/m2; d 1 q3w for max. 8 cycles
137733|NCT01630083|Drug|Oxaliplatin|130 mg/m2; d 1 q3w for max. 8 cycles
137734|NCT01630083|Drug|Capecitabine|625 mg/m2; p.o. d 1 - d 21 q3w twice daily for max. 8 cycles
138067|NCT01638494|Dietary Supplement|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
138068|NCT01638507|Device|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
138069|NCT01638520|Drug|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
138070|NCT01638520|Drug|Placebo|5ml of Saline
138071|NCT01638533|Other|Pharmacological Study|Correlative studies
138072|NCT01638533|Drug|Romidepsin|Given IV
138226|NCT01628458|Procedure|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
138227|NCT01628471|Drug|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
138228|NCT01628484|Other|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
138229|NCT01628484|Other|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
138230|NCT01628484|Other|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
137314|NCT01631747|Behavioral|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
137315|NCT01631760|Genetic|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
137316|NCT01631773|Genetic|microRNA|Biological samples will be taken from subjects w/ Nasal polyps & AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
137317|NCT01631799|Device|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
137318|NCT01631799|Device|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
137319|NCT00001575|Biological|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
137320|NCT00084981|Other|laboratory biomarker analysis|Correlative studies
137321|NCT01631812|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
137322|NCT01631825|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
137323|NCT01631838|Dietary Supplement|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
137324|NCT01631838|Dietary Supplement|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
138000|NCT01630551|Dietary Supplement|Fishoil supplement|1 capsule per day
138001|NCT01630551|Dietary Supplement|Olive Oil|1 capsule per day
138002|NCT01630564|Drug|Ex vivo Expanded T Cells|Starting Dose 1: 1 * 10e6 T cells/kg infused through central venous catheter (CVC).
138003|NCT01630577|Other|volume of serum salin titated to CVP level|volume of serum salin titated to CVP level
138004|NCT01630590|Drug|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
138005|NCT00084877|Drug|irinotecan hydrochloride|Given IV
138006|NCT01630590|Drug|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
137106|NCT01684514|Device|Confocal laser endomicroscopy|Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an "optical biopsy", which can be compared with a similar microscopic image.
137107|NCT00089401|Procedure|conventional surgery|
137108|NCT01684527|Other|Respiratory secretions obtained|
137109|NCT01687283|Drug|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
137110|NCT00089544|Drug|ifosfamide|Given IV
137111|NCT01687283|Drug|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
137112|NCT01687296|Drug|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
137113|NCT01687296|Drug|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
137114|NCT01687296|Drug|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
137115|NCT01687296|Drug|placebo tablet|placebo soluble tablet, oral ,once daily
137116|NCT01687296|Drug|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
137117|NCT01687309|Drug|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
134322|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
134323|NCT01623687|Device|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
134324|NCT01623687|Device|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
134325|NCT01623687|Device|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
134326|NCT01623687|Device|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson & Johnsson, USA).
134327|NCT01623713|Drug|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
134620|NCT01612299|Drug|Zortress® /Everolimus|Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 &2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.
Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml.
134621|NCT01612312|Procedure|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
134622|NCT01612312|Procedure|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
134623|NCT01612325|Device|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
134624|NCT01612338|Behavioral|Targeted|Targeted letter and booklet
134625|NCT01612338|Behavioral|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
134626|NCT01612351|Drug|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
134627|NCT01612351|Drug|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
134628|NCT01612351|Drug|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
138073|NCT01638546|Other|Laboratory Biomarker Analysis|Correlative studies
138074|NCT00085462|Biological|aldesleukin|
138075|NCT01638546|Other|Placebo|Given PO
138076|NCT01638546|Drug|Temozolomide|Given PO
138077|NCT01638546|Drug|Veliparib|Given PO
138078|NCT01630668|Dietary Supplement|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
138079|NCT01630668|Dietary Supplement|One-a-Day placebo capsule|Once per day, 12 weeks
138080|NCT01630681|Behavioral|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
138081|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
138082|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
138083|NCT00084877|Other|laboratory biomarker analysis|Correlative studies
138084|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
138085|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
137180|NCT01684579|Behavioral|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
137181|NCT01684579|Behavioral|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
137182|NCT00089414|Drug|CDB 2914|Administered during weeks 3, 8 and 14. Drug administered dependent upon arm.
137325|NCT01634555|Drug|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
137326|NCT01634568|Drug|V81444|Single ascending oral doses of V81444 and placebo
Multiple ascending oral doses of V81444 and placebo
137327|NCT01634594|Drug|Group R|
137328|NCT01634594|Drug|Group N|
137329|NCT01634594|Drug|Group D|
137330|NCT01634620|Device|NIOX MINO® Instrument (09-1100)|FeNO measurements will be performed according to the "Perform FeNO Measurement" guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)
137331|NCT00085202|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
137900|NCT01637909|Drug|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
137901|NCT01637909|Dietary Supplement|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
137902|NCT01630278|Drug|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
137903|NCT01630291|Device|Electrode device|Lacrimal gland stimulation
137904|NCT01630304|Behavioral|WelTel SMS service|Weekly text message "Mambo?" ("How are you?") to which participants are required to respond either "Shida" (problem) or "Sawa" (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician.
137905|NCT01630317|Procedure|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
137906|NCT00084864|Drug|dexamethasone|Given orally
137907|NCT01630317|Procedure|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
137908|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
134482|NCT01623947|Dietary Supplement|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
134483|NCT01623947|Dietary Supplement|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
134484|NCT00084513|Drug|imatinib mesylate|
134485|NCT01623947|Dietary Supplement|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
134486|NCT01623973|Other|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
134487|NCT01623986|Device|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
134488|NCT01623986|Device|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
134489|NCT01624012|Device|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
134490|NCT01624012|Device|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
134491|NCT01624025|Other|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
134492|NCT01624038|Drug|Hydroxyurea ,Epiao|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week.
134493|NCT01624038|Drug|hydroxyurea, blood transfusion|Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
134494|NCT01624051|Other|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
134495|NCT00084526|Procedure|computed tomography|
134496|NCT01624051|Other|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
134497|NCT01624064|Drug|Enalapril|2.5-20 mg/day
134498|NCT01624064|Drug|Calcium Supplement|Calcium 2.5-20 mg/day
133993|NCT01620944|Drug|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
133994|NCT01620944|Drug|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
133995|NCT01623011|Procedure|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
134257|NCT01626092|Drug|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
134258|NCT01626092|Drug|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
134259|NCT01626118|Drug|Indomethacin|capsules, 40 mg, TID
134260|NCT01626118|Drug|Indomethacin|capsules, 40 mg, BID
134261|NCT01626118|Drug|Indomethacin|capsules, 20 mg, TID
134262|NCT01626118|Drug|Placebo|capsules
134263|NCT01626131|Behavioral|exercise training|Participants will engage in 3 aerobic and resistance exercise sessions (~60-75 min total per session) weekly for 8 consecutive weeks.
Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.
Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form.
134264|NCT01626131|Behavioral|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
134265|NCT01626170|Other|laboratory biomarker analysis|Correlative studies
134266|NCT01626183|Genetic|RNA analysis|
134267|NCT00000263|Other|0 g/Kg ethanol|
134268|NCT00001569|Drug|Paclitaxel|
134269|NCT00084643|Drug|oxaliplatin|Given IV
135186|NCT01613482|Radiation|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
135187|NCT01613482|Drug|Trastuzumab|Weekly, 2mg/kg of corporal weight
135188|NCT00083551|Drug|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
135189|NCT01613482|Drug|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
135190|NCT01615809|Drug|﻿AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.The administration regimen for each Abelcet® nebulization will be 10 ml (50 mg) twice a week for the first week, and then from the second week onwards it will be 5 ml (25 mg) with a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.
135191|NCT01615822|Drug|OZ439 100mg|OZ439 100mg oral suspension, single dose
135192|NCT01615822|Drug|OZ439 400mg|OZ439 400mg oral suspension, single dose
135193|NCT00083694|Drug|Thalidomide|
135194|NCT01615822|Drug|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
135195|NCT01615822|Drug|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
135196|NCT01615822|Drug|Placebo|
135197|NCT01615835|Other|EnSite NavX System|EnSite NavX system is a 3D Mapping system
135198|NCT01615848|Other|mediterranean diet restricted calorie|1500 k/cal 30% fat
135199|NCT01615848|Other|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
135200|NCT01615848|Other|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
135449|NCT01613989|Procedure|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
135450|NCT01616199|Drug|PX-866|Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.
Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.
Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity.
135451|NCT01616199|Drug|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
133551|NCT01620112|Drug|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
133552|NCT01620112|Drug|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
133553|NCT00084136|Drug|Efavirenz|600 mg taken orally daily
133554|NCT01620112|Drug|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
133555|NCT01620125|Dietary Supplement|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
133556|NCT01620138|Drug|Pasireotide|The patients with NFPA and residual tumor on MRI at least three months after surgery will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for six months; (B) the second one, with cabergoline that will be administered, during the titration period, at an initial dose of 0.5 mg on the first week and afterward will be increased 0.5 mg per week until the dose reaches 3 mg/week, according to drug tolerability by patients. After dose reaches 3.0 mg/week, patients will be maintained at this dose for six months.
The patients with prolactinomas resistant to DA will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day. The patients will be treated for six months.
133557|NCT01620138|Drug|cabergoline|The patients with NFPA and residual tumor on MRI at least three months after surgery will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for six months; (B) the second one, with cabergoline that will be administered, during the titration period, at an initial dose of 0.5 mg on the first week and afterward will be increased 0.5 mg per week until the dose reaches 3 mg/week, according to drug tolerability by patients. After dose reaches 3.0 mg/week, patients will be maintained at this dose for six months.
The patients with prolactinomas resistant to DA will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day. The patients will be treated for six months.
133558|NCT01620151|Procedure|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
133559|NCT01620164|Other|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
133560|NCT01620177|Drug|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
133561|NCT01620177|Drug|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
133562|NCT01620190|Other|Laboratory Biomarker Analysis|Correlative studies
133563|NCT01620190|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
134499|NCT01624077|Biological|Regulatory T cells|Tregs will inject after liver transplantation
133621|NCT00084695|Drug|methylprednisolone|Given IV
133622|NCT01627353|Procedure|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
133623|NCT01627353|Procedure|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case.
133624|NCT01627366|Other|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
133625|NCT01627379|Drug|Cisplatin, 5-FU|Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.
Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
133626|NCT01627379|Drug|Panitumumab|Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.
Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.
Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled.
133627|NCT01627392|Behavioral|Smoking abstinence|6 hour smoking abstinence
133628|NCT00084136|Drug|Emtricitabine|200 mg taken orally daily
133629|NCT01620216|Device|in vitro kinase inhibitor assay|An in vitro kinase inhibitor assay will be used to determine the sensitivity of primary leukemic cells to four kinase inhibitors/drugs.
133630|NCT01620216|Drug|Sunitinib|50 milligrams (mg) orally once daily, with or without food, 4 weeks on treatment
133631|NCT01620216|Drug|Dasatinib|100 mg once daily with possible escalation to 140 mg once daily for 28 days
133632|NCT01620216|Drug|Nilotinib|400 mg twice daily for 28 days
133633|NCT01620216|Drug|Sorafenib|400 mg (2 tablets) orally twice daily without food for 28 days
133634|NCT01620216|Drug|Ponatinib|45 mg dose once per day
133635|NCT01620229|Drug|brentuximab vedotin|Given IV
133636|NCT01620229|Other|laboratory biomarker analysis|Correlative studies
133637|NCT01620229|Other|pharmacological study|Correlative studies
134270|NCT01618955|Device|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
134271|NCT01618968|Drug|MTX|Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)
Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)
Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)
134272|NCT01618981|Procedure|pace make active/inactive cross over|
134273|NCT01618994|Procedure|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
134274|NCT01619007|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
134557|NCT01614717|Device|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
134558|NCT01614730|Device|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
134559|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^8 pfu /2mL administered in each deltoid
134560|NCT01614730|Device|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
134561|NCT01614743|Drug|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
134562|NCT01614743|Drug|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
134563|NCT01614756|Biological|BMS-981164|
134564|NCT01614756|Biological|Placebo matching with BMS-981164|
134565|NCT01614769|Drug|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
134566|NCT01614769|Drug|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
134567|NCT01614769|Drug|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
134568|NCT01614769|Procedure|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
134569|NCT01616992|Drug|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
134570|NCT01617044|Dietary Supplement|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
135452|NCT01616212|Other|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
135453|NCT01616212|Other|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
135454|NCT01616212|Other|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
135455|NCT01616212|Other|Drug Education for adolescents|Drug Education for adolescents
135456|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
135457|NCT00083785|Drug|Talaporfin sodium (LS11)|
135458|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
135459|NCT01616225|Drug|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
135460|NCT01616251|Other|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
135461|NCT01616277|Biological|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
135462|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
135463|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
135464|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
135770|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
135771|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
135772|NCT01614444|Other|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
133845|NCT01625260|Biological|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
133846|NCT00084604|Drug|irinotecan hydrochloride|Given IV
133847|NCT01625260|Drug|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
133848|NCT01625273|Other|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10^8 CFU per day from 28 days to 6 months of infant age
133849|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
133850|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
133851|NCT01625286|Drug|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
133852|NCT01625286|Drug|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
133853|NCT01625299|Dietary Supplement|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
133854|NCT01625299|Dietary Supplement|Placebo|Rice flour 1.0 g/kg/day
133855|NCT01625338|Drug|SOF|SOF 400 mg tablet administered orally once daily
133856|NCT01625338|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
133857|NCT00001569|Drug|Cisplatin|
133858|NCT00084604|Biological|bevacizumab|Given IV
133859|NCT01625338|Drug|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
133860|NCT01625351|Drug|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
133861|NCT01625351|Drug|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
133638|NCT01620242|Drug|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
133639|NCT00084136|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
133640|NCT01620255|Drug|PF-00547659 SC Injection|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
133918|NCT01622959|Procedure|Acupuncture|-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.
The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.
-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%. Treatment failure is defined as VAPS>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion.
133919|NCT01622972|Drug|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
133920|NCT01622998|Drug|NicoDerm Patch|Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period
*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable.
133921|NCT01622998|Drug|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
133922|NCT01625351|Drug|sirolimus|Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)
Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.
133923|NCT01625351|Drug|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
133924|NCT01625351|Drug|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
133925|NCT01625351|Biological|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
133926|NCT01625364|Behavioral|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
133927|NCT01625364|Behavioral|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
133928|NCT01625377|Drug|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
133929|NCT00084604|Drug|cisplatin|Given IV
134880|NCT01612858|Drug|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
134881|NCT00001563|Drug|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
134882|NCT00083538|Drug|Adriamycin|
134883|NCT01612858|Drug|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
134884|NCT01612871|Drug|Tamoxifen, Letrozole , Anastrozole, Exemestane|Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :
Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
134885|NCT01615224|Drug|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
134886|NCT01615237|Behavioral|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
134887|NCT01615237|Behavioral|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
134888|NCT01615237|Behavioral|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
134889|NCT01615250|Biological|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
134890|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
135128|NCT01615796|Drug|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
135129|NCT00083915|Drug|Dexamethasone|40 mg po days 1 - 4 (4 days)
135130|NCT01617824|Drug|Placebo|Placebo tablets for 4 days
135131|NCT01617837|Device|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
135773|NCT01614444|Other|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
135774|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^7 pfu /2mL administered in each deltoid
135775|NCT01614457|Drug|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
135776|NCT01616784|Other|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
135777|NCT01616784|Other|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
135778|NCT01616797|Behavioral|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
135779|NCT01616836|Other|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
135780|NCT01616836|Other|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
135781|NCT01616836|Other|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
135782|NCT01616849|Drug|cisplatin and 5-Fu combined with nimotuzumab|DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.
Nimotuzumab 200mg/d, intravenous infusion every week
135783|NCT01616875|Drug|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
135784|NCT01616888|Device|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
135785|NCT00083889|Drug|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
135786|NCT01616901|Procedure|Spontaneous breathing trial|5 spontaneous breathing trial will be tested by the patients in the same order :
7 cm H2O continuous positive airway pressure
T piece
7 cmH2O of pressure support
0 cmH20 of pressure support
7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure.
135787|NCT01616927|Drug|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
134671|NCT01617278|Device|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
134672|NCT01617278|Device|HD Colon|High definition white light
133862|NCT01627418|Behavioral|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
134138|NCT00084227|Drug|Atovaquone/Proguanil|
134139|NCT01621087|Other|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
134140|NCT01621100|Drug|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
134141|NCT01621113|Drug|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
134142|NCT01621113|Drug|Placebo|Placebo tablet, twice daily, for 10 weeks.
134143|NCT01621126|Device|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
134144|NCT01621139|Procedure|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
134145|NCT01621152|Other|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
134146|NCT01621152|Other|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
134147|NCT01621165|Drug|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
134148|NCT01621165|Drug|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
134149|NCT00084240|Drug|Azithromycin/Chloroquine|
134150|NCT01621178|Drug|Dulaglutide|Administered SQ
133930|NCT01625377|Drug|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
133931|NCT01625390|Drug|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
133932|NCT01625390|Drug|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
133933|NCT01625390|Drug|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
133934|NCT01625403|Drug|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
134206|NCT01618903|Drug|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
134207|NCT00084032|Behavioral|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
134208|NCT01618916|Drug|LY3015014|Administered SQ
134209|NCT01618916|Other|Placebo|Administered SQ
134210|NCT01618929|Drug|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
134211|NCT01618942|Device|pressure algometer|
134212|NCT01621191|Drug|Duloxetine|Administered Orally
134213|NCT01621204|Drug|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) as of 21 days before surgery. Dose may be adjusted based on platelet count monitoring (minimum 25mg; maximum 75mg).
134214|NCT01621204|Drug|IVIG infusion|IVIG infusion (2 g/kg, over 2 days) given 7 (+/-2) days prior to surgery and additional infusions given as needed until 7 days after surgical hemostasis is achieved.
134215|NCT01621217|Drug|Cetuximab|Will be given weekly intravenously during study treatment.
134216|NCT01621217|Drug|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
134217|NCT01621217|Drug|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
134218|NCT01621217|Radiation|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
134219|NCT00084240|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
135132|NCT01617837|Other|Placebo band|Comparison between groups 0-48 hours postoperatively
135133|NCT01617850|Other|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
135134|NCT01617850|Other|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
135135|NCT01617889|Other|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
135136|NCT01617889|Other|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
135137|NCT01617928|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
135138|NCT01617928|Drug|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
135139|NCT01617928|Drug|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
135140|NCT00083928|Drug|Å6 subcutaneous injection|
135141|NCT01617941|Drug|BGG492|
135142|NCT01617941|Drug|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
135143|NCT01617954|Device|MammaPrint|All subjects
135144|NCT01617967|Drug|ALN-TTR02|Ascending doses of ALN-TTR02 administered by intravenous (IV) infusion
135145|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
135385|NCT01609101|Device|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
135386|NCT01609101|Device|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
135387|NCT01609101|Device|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
134673|NCT01617278|Device|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
134674|NCT01617291|Other|Induced therapeutic hypothermia|induced therapeutic hypothermia
134675|NCT01610141|Other|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
134676|NCT01610141|Other|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
134677|NCT01610167|Device|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
134678|NCT00083174|Drug|exemestane|one 25 mg tablet daily in am
134679|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
134680|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
134681|NCT01610180|Drug|Eltrombopag Olamine|Subjects will initiate study medication at an oral dose of 50 mg/day (25 mg/day for East Asians and for patients with grade 1 serum liver tests impairment).
Treatment scheme and dose adjustments:
Initial dose : 50 mg/day for 14 days.
Next doses:
If platelet count <60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).
If platelet count >60000/µL and ≤200000/µL same dose for the next 14 days.
If platelet count >200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.
If platelet count >400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is <150000/µL, reinitiate therapy at a daily dose reduced by 25 mg.
134682|NCT01610193|Procedure|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
134683|NCT01610206|Drug|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
134684|NCT01610206|Drug|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
134685|NCT01610219|Behavioral|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
134686|NCT01610219|Other|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
134151|NCT01621178|Drug|Insulin glargine|Administered SQ
134152|NCT01621178|Drug|Insulin lispro|Administered SQ
134153|NCT01623336|Drug|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
134420|NCT01626430|Dietary Supplement|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
134421|NCT01626430|Dietary Supplement|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
134422|NCT01626443|Dietary Supplement|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
134423|NCT01626443|Dietary Supplement|Folic acid|Folic acid (200 mcg); 2 x die
134424|NCT01626456|Drug|ALKS 9072, Low|IM injection, given monthly
134425|NCT01626456|Drug|ALKS 9072, High|IM injection, given monthly
134426|NCT01626469|Drug|Captopril|25mg Captopril
134427|NCT00084643|Other|laboratory biomarker analysis|Correlative studies
134428|NCT01626469|Drug|placebo|placebo
134429|NCT01626482|Other|Kinesio Taping|The taping consisted of two strips of material in the form of "I" on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12.
134430|NCT01626482|Other|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
134431|NCT01626495|Biological|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
134432|NCT01626521|Other|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
134433|NCT01626534|Drug|Clopidogrel|600mg loading dose then 75mg/day
134434|NCT01626534|Drug|trigagrelor|180 mg loading dose then 90 mg Twice a day
134435|NCT01626560|Drug|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
134436|NCT01626560|Drug|Vancomycin|Vancomycin 1g q12h 10 - 14 days
134220|NCT01621230|Drug|epidural 0.125% bupivacaine with fentanyl 2 mcg/cc infusion|Randomization will occur when the woman reaches 8 cm cervical dilation. Group II will receive a 100mL cassette of fentanyl 10mcg/mL (to be infused at 10mL/hr). Group I will receive a 100mL epidural cassette of 0.125% bupivacaine with fentanyl 2mcg/mL to be infused at 10mL/hr. Both groups will have the same rate of epidural infusion such that the patient, nurse, obstetrician, and anesthesia providers will be blinded to the randomized treatment group.
The patient may request a 5mL bolus from the epidural infusion every 30 minutes if pain relief is inadequate. The study regimen will continue until spontaneous delivery of the infant or until which time operative vaginal delivery or cesarean delivery is planned.
134221|NCT01621230|Drug|fentanyl 10 mcg/cc epidural infusion|Randomization will occur when the woman reaches 8 cm cervical dilation. Group II will receive a 100mL cassette of fentanyl 10mcg/mL (to be infused at 10mL/hr). Group I will receive a 100mL epidural cassette of 0.125% bupivacaine with fentanyl 2mcg/mL to be infused at 10mL/hr.Both groups will have the same rate of epidural infusion such that the patient, nurse, obstetrician, and anesthesia providers will be blinded to the randomized treatment group.
The patient may request a 5mL bolus from the epidural infusion every 30 minutes if pain relief is inadequate. The study regimen will continue until spontaneous delivery of the infant or until which time operative vaginal delivery or cesarean delivery is planned.
134222|NCT01621243|Drug|nab-paclitaxel|nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
134223|NCT01621243|Drug|gemcitabine|gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
134500|NCT01624090|Drug|Mithramycin|30 mg/kg IV over 6 h once daily for 7 days, to be repeated every 28 days (one cycle) until disease progression or unacceptable toxicity
134501|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
134502|NCT01626573|Drug|INCB039110|
134503|NCT00084656|Biological|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
134504|NCT01626573|Drug|INCB039110 Placebo|
134505|NCT01626586|Behavioral|Group Therapy|Self-management Group Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
134506|NCT01626599|Device|ProGuardian|The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.
The investigational system:
is not implantable and no surgical procedure is required for a human subject to use the devices;
is not for use in supporting or sustaining a human life; and
is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.
Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles.
134507|NCT01626612|Procedure|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
134508|NCT01626612|Procedure|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
135388|NCT01609101|Device|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
135389|NCT01609101|Device|King Vision® videolaryngoscope|King Vision® videolaryngoscope
135390|NCT01609101|Device|Venner® videolaryngoscope|Venner® videolaryngoscope
135391|NCT00083109|Drug|Suramin|Given IV
135392|NCT01609101|Device|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
135393|NCT01609127|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
135394|NCT01609127|Drug|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
135395|NCT01609127|Drug|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
135396|NCT01609140|Drug|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
135397|NCT01609140|Drug|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
135398|NCT01609140|Drug|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
135399|NCT01609140|Drug|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
135400|NCT01609140|Drug|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
135401|NCT01609140|Drug|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
135402|NCT00083122|Drug|cisplatin|Given IV
135403|NCT01609153|Drug|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
135404|NCT01609153|Drug|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
135405|NCT01611506|Drug|Capecitabine|Induction chemotherapy:
Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
Postoperative treatment:
Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
135406|NCT01611506|Drug|Cisplatin|Induction chemotherapy:
Cisplatin 80mg/m2 on day 1 of each 21 day cycle
Followed by:
Cisplatin 30mg/m2 weekly on day 1 during chemoradiation
Postoperative treatment:
Cisplatin 80mg/m2 on day 1 of each 21 day cycle
135407|NCT01611545|Genetic|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
133792|NCT01628055|Other|Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).
It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.
The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours.
133793|NCT01628068|Device|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
133794|NCT01628081|Dietary Supplement|Alga Dunaliella Bardawil placebo|Dosage Regimen and Treatment Groups
Daily oral administration of:
Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).
Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).
133795|NCT01628081|Dietary Supplement|Dunaliella Bardawil|Dosage Regimen and Treatment Groups
Daily oral administration of:
Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).
Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).
133796|NCT01628094|Drug|RO5024048|
133797|NCT01628094|Drug|RO5190591|
133798|NCT01628094|Drug|RO5466731|
133799|NCT01628094|Drug|ribavirin [Copegus]|
133800|NCT01628094|Drug|ritonavir|
133801|NCT01628107|Biological|Epoetin Hospira|Rescue therapy including other ESAs (except for long-acting) may be used.
133802|NCT00084734|Drug|docetaxel|IV
133803|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
133804|NCT00084149|Drug|Lopinavir/Ritonavir|antiretroviral therapy
133805|NCT01620476|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
133806|NCT01620489|Drug|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
133807|NCT01620489|Drug|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
133808|NCT01620502|Dietary Supplement|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
133809|NCT01620515|Drug|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
133810|NCT01620515|Drug|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
134437|NCT01619228|Other|Vitamin B3 (Nicotinamide)|The assigned leg will be treated with a solution of Vitamin B3 (nicotinamide) in sterile water once a day for 14 consecutive days in an amount not to exceed 6 milligrams of Vitamin B3 (nicotinamide) per kilogram of body weight per day.
134438|NCT01619241|Other|PET/CT|F-18 FLT PET/CT
134439|NCT01619254|Behavioral|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
134440|NCT01619280|Drug|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
133564|NCT01622309|Dietary Supplement|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
133565|NCT01622309|Other|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
133566|NCT01622322|Drug|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
133567|NCT01622322|Other|oxygen|Subjects will receive Genral anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
133568|NCT01622335|Drug|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
133569|NCT01622335|Other|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
133570|NCT01622348|Drug|IMO-3100|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
133571|NCT01622348|Drug|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
133572|NCT00084344|Procedure|radiomammography|
133573|NCT01622348|Drug|IMO-3100|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
133574|NCT01622361|Drug|Adriamycin+Cyclophosphamide>Docetaxel|Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2
Route: by slow intravenous bolus
Schedule: every 3weeks for 4 cycle
Docetaxel 75mg/m2
Route: intravenous as per local practice
Schedule: every 3weeks for 4 cycle
133575|NCT01622361|Drug|GnRHa with Tamoxifen|Goserelin(GnRHa) 3.6mg
Route: subcutaneously under the abdominal skin
Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)
Tamoxifen 20mg/day
Route: Oral
Schedule: everyday
133576|NCT01622374|Behavioral|Music|Ten minutes of music or silence were applied prior to dental procedures
133577|NCT01622387|Procedure|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
134509|NCT01626625|Drug|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
134510|NCT01626625|Other|autograft taken from iliac crest|patient will be transplanted with autograft
134511|NCT01626638|Procedure|Confocal Micro Endoscopy|
134512|NCT01626651|Drug|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
134513|NCT01626651|Drug|Ketoconazole|Ketoconazole (400 mg [2 x 200 mg] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
134514|NCT00084656|Biological|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
134515|NCT01626664|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
134516|NCT01626664|Drug|investigator's choice (pralatrexate; gemcitabine/oxaliplatin; dexamethasone/cisplatin/cytarabine)|pralatrexate (30 mg/m2 weekly for 3 weeks until progression)
gemcitabine plus oxaliplatin (gemcitabine 1000 mg/m2, oxaliplatin 100 mg/m2 every 2 weeks until progression)
DHAP (dexamethasone 40 mg on day 1-4, cisplatin 100 mg/m2, cytarabine 2000 mg/m2 every 4 weeks until progression)
134517|NCT01626677|Biological|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
133641|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
133642|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
133643|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
133644|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
133645|NCT01620268|Drug|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
133646|NCT01620281|Device|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
133647|NCT01620294|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
133648|NCT01620294|Procedure|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
133649|NCT01620307|Drug|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
133650|NCT00001565|Drug|phenylbutyrate|
135718|NCT01609673|Drug|Everolimus|On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.
In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended.
135719|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
135720|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
135721|NCT01609712|Procedure|Radiofrequency Kyphoplasty|Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.
The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved.
135722|NCT01609725|Device|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
135723|NCT01609725|Device|Oral prophylaxis|One session of supraginigval calculus removal
135724|NCT01609738|Device|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
135725|NCT00083148|Drug|capecitabine|
135726|NCT01609751|Dietary Supplement|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
135727|NCT01609764|Behavioral|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
135728|NCT01609777|Procedure|SBAR|situation, background, assessment, recommendation
135729|NCT01609790|Biological|Bevacizumab|Given IV
135730|NCT01609790|Other|Laboratory Biomarker Analysis|Correlative studies
135731|NCT01609790|Other|Pharmacological Study|Correlative studies
135732|NCT01609790|Other|Placebo|Given IV
135733|NCT01609790|Biological|Trebananib|Given IV
133811|NCT01620528|Drug|Elagolix|Elagolix Dose 1 for 6 month Treatment Period, Elagolix Dose 2 for the 6 month Treatment Period
133812|NCT01620528|Other|placebo|Placebo for 6 Month Treatment Period
134085|NCT01623232|Biological|MAS-1 adjuvant and influenza HA antigen|Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.
Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).
Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.
Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.
134086|NCT01623232|Biological|standard dose, inactivated trivalent influenza vaccine (TIV)|Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.
4. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains.
134087|NCT01623271|Drug|Gabapentin|Titrating standard dosage for 8 weeks.
134088|NCT01623284|Drug|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
134089|NCT01623284|Drug|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of [18-F]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
134090|NCT01623310|Drug|Fluticasone Propionate|Fluticasone Propionate 400 μg
134091|NCT01623323|Drug|Fluticasone Propionate|Fluticasone Propionate 400 μg
134092|NCT00084435|Radiation|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
134093|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
134094|NCT01625676|Other|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
134095|NCT01625689|Biological|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
134096|NCT01625689|Biological|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
134097|NCT01625702|Device|CellSearch® CTC kit|Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).
Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.
Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
133578|NCT01622387|Procedure|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
133579|NCT01622400|Other|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
133580|NCT01622413|Procedure|joimax TESSYS|Transforaminal Endoscopic Surgery System
133581|NCT01622413|Procedure|Microdiscectomy|Standard procedure for disc surgery
133863|NCT01627418|Behavioral|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
133864|NCT01627431|Drug|Acetylsalicylic acid|100 mg once per day
133865|NCT01627431|Drug|Clopidogrel|75 mg once per day
133866|NCT00084695|Radiation|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
133867|NCT01627444|Procedure|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
133868|NCT01627457|Device|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
133869|NCT01627470|Device|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
133870|NCT01627483|Other|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
133871|NCT01627522|Procedure|TURP|Transurthral resection of prostate
133872|NCT01627535|Other|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
133873|NCT01627548|Behavioral|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
133651|NCT00084136|Drug|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
133652|NCT01620320|Other|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
133653|NCT01620333|Drug|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
133654|NCT01622439|Drug|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
133655|NCT01622439|Drug|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
133656|NCT01622439|Drug|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
133657|NCT01622439|Drug|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
133658|NCT01622439|Drug|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
133659|NCT01622439|Drug|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
133660|NCT01622465|Behavioral|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
133935|NCT01625403|Drug|standard of care|standard of care for heart failure
133936|NCT01625416|Behavioral|Case management, information technology/mHealth innovations, psychotherapy, and psychopharmacology.|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the three month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-months.
133937|NCT01625429|Drug|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
133938|NCT01625442|Drug|Saffron tablet|Saffron tablets 100 mg
133939|NCT01625442|Drug|Barberry tablet|Barberry tablets 200 mg
133940|NCT00084604|Procedure|computed tomography|Correlative studies
133941|NCT01625442|Drug|Placebo|Placebo tablets received daily for 45 days
135734|NCT01609803|Other|laboratory biomarker analysis|Correlative studies
134891|NCT00083668|Drug|Paliperidone ER|
134892|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
134893|NCT01615276|Device|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
134894|NCT01615276|Device|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
134895|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
134896|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
134897|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
134898|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
134899|NCT01615302|Procedure|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
134900|NCT01615302|Other|Platelet rich plasma (PRP)|The PRP will be injected into the fistula, after the mucosa advancement flap was created.
For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP.
134901|NCT01615328|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
134902|NCT00001564|Drug|PXFK Peptide|
134903|NCT00083681|Drug|Thalidomide|
134904|NCT01617694|Drug|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
134905|NCT01617694|Drug|Normal Saline|
134906|NCT01617707|Drug|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
134098|NCT01625715|Drug|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
134099|NCT00084617|Drug|irinotecan hydrochloride|Given IV
134100|NCT01625741|Drug|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
134362|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
134363|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
134364|NCT01619176|Procedure|Acupuncture|30 minutes acupuncture every other day for 3 months.
Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20.
134365|NCT00084058|Drug|Lopinavir/ritonavir|
134366|NCT01619189|Biological|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
134367|NCT01619189|Procedure|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
134368|NCT01619202|Behavioral|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
134369|NCT01621477|Drug|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
134370|NCT01621477|Drug|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
134371|NCT01621477|Drug|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
134372|NCT01621477|Drug|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
134373|NCT01621477|Drug|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
134374|NCT01621477|Biological|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
134375|NCT01621477|Drug|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
134376|NCT01621477|Drug|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
134377|NCT01621490|Biological|Nivolumab|
133874|NCT01627561|Biological|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6 in the HPV_2D and HPV_2D CO Groups 3 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0, Month 1 and Month 6 in the HPV_3D Group
133875|NCT01627561|Biological|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Day 0
133876|NCT01627561|Biological|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Month 6
133877|NCT00084708|Dietary Supplement|calcitriol|
133878|NCT01627574|Behavioral|Motivational Intervention|There are 3, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, one week following the initial visit, and at 3 month follow-up.
133879|NCT01627574|Behavioral|Didactic Educational Counseling|There are 3, 30-45 minute didactic sessions designed to provide information on contraception and STI prevention. The first session occurs after enrollment in the study, the second at one week following the initial visit, and the last at 3 month follow-up.
133880|NCT01627587|Drug|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
134154|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
134155|NCT01623349|Drug|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
134156|NCT01623349|Drug|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
134157|NCT01623362|Other|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
134158|NCT01623362|Other|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
134159|NCT01623362|Other|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
134160|NCT01623375|Drug|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
134161|NCT01623375|Drug|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
134162|NCT00084448|Drug|celecoxib|
134163|NCT01623388|Procedure|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
134164|NCT01623401|Drug|TR-701 FA|TR-701 FA 200 mg once daily
133942|NCT01625455|Drug|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
133943|NCT01625455|Drug|Placebo|Placebo will be given orally for a total of 7 days.
133944|NCT01627782|Drug|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
133945|NCT01627795|Drug|Oshadi D and Oshadi R|anti cancer agents
133946|NCT00001570|Drug|PSC 833|
133947|NCT00084721|Drug|celecoxib|
133948|NCT01627821|Device|Jarvik 2000 VAS|Jarvik 2000 LVAD
133949|NCT01627821|Device|HeartMate II|HeartMate II LVAD
133950|NCT01627834|Drug|Ropinirole|
133951|NCT01627847|Drug|Ropinirole|
133952|NCT01627860|Drug|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
133953|NCT01627860|Drug|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
133954|NCT01627873|Drug|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
134224|NCT01621243|Drug|placebo|Placebo will be dosed daily
134225|NCT01621243|Drug|Necuparanib|Necuparanib will be dosed daily
134226|NCT01621256|Drug|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
134227|NCT01621256|Drug|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
134228|NCT01621269|Drug|Fingolimod|
134229|NCT01621282|Other|Education|A 6-month interactive course on critical appraisal
134230|NCT00084253|Drug|Atazanavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
134231|NCT01621282|Other|Conventional|Conventional method/no intervention
135146|NCT01618006|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
135147|NCT01618006|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
135148|NCT01618006|Drug|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
135149|NCT01618019|Dietary Supplement|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
135150|NCT01611051|Drug|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
135151|NCT00083304|Drug|Efaproxiral|75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).
Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days.
135152|NCT01611064|Drug|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
135153|NCT01611064|Drug|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
135154|NCT01611077|Drug|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
135155|NCT01611077|Drug|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
135156|NCT01611077|Drug|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
135157|NCT01611090|Drug|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
135158|NCT01611090|Drug|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
135159|NCT01611090|Drug|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
135160|NCT01611090|Drug|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
135161|NCT01611103|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
135162|NCT00083304|Radiation|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
135163|NCT01611116|Drug|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
134378|NCT01621490|Drug|Ipilimumab|
134379|NCT00084266|Drug|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
134380|NCT01621503|Device|NT-530P|intraocular pressure and central corneal thickness measurement
134381|NCT01621542|Biological|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
134382|NCT01621568|Drug|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
134687|NCT01610232|Device|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
134688|NCT01610232|Other|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
134689|NCT00083187|Drug|hydroxyurea|
134690|NCT01610245|Drug|Nitazoxanide|
134691|NCT01610245|Drug|Oseltamivir|
134692|NCT01610258|Other|Blood and placenta samples|The placenta sample is realised, specially for the study, in surgical unit after the delivery.
The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission.
134693|NCT01610271|Device|Air Barrier System (Nimbic)|ABS is a device that blows a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
134694|NCT01612351|Procedure|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
134695|NCT01612364|Procedure|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
134696|NCT01612377|Drug|Prednisolone-Dipyridamole|Oral, QD
134697|NCT01612377|Drug|Prednisone|Oral QD Prednisone 5mg
134698|NCT01612377|Drug|prednisone|Oral, QD prednisone 7.5mg
134699|NCT01612403|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
134165|NCT01623427|Procedure|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
134166|NCT01623427|Procedure|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
134167|NCT01623440|Drug|Placebo|Pill form, participant dosed one time an hour before fMRI.
134168|NCT01623440|Drug|Naltrexone|50 mg pill given one time, one hour before fMRI
134169|NCT01623453|Biological|Autologous adipose derived stem cells|low dose group: 1x10e7 cells/mL, high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
134170|NCT01623466|Drug|levonorgestrel|transdermal contraceptive delivery system
134171|NCT01623479|Drug|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
134172|NCT01623492|Other|Subjects with diagnosis of Eisenmenger Syndrome|Antibiotic recommendation for SBE prophylaxis and influenza vaccine
Contraception counseling, and recommendations regarding avoidance of pregnancy
Documentation and prescription of the specific medications:
Oxygen
Diuretic
ASA, Anticoagulant
CCB, BB, ACEI, ARB
Iron Supplementation
Allopurinol
PAH specific therapy
134173|NCT00084448|Drug|paclitaxel|
134441|NCT01619319|Other|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
134442|NCT01619319|Other|computer games|computer games that that consist of word puzzles
134443|NCT01619332|Drug|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
134444|NCT00084058|Drug|Saquinavir|
134445|NCT01619332|Drug|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
134446|NCT01619332|Drug|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
134447|NCT01619345|Drug|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
134448|NCT01619371|Device|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
134449|NCT01619384|Behavioral|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
134232|NCT01621308|Other|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
134233|NCT01623505|Drug|Champix|Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.
All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
134234|NCT01623505|Drug|Transdermal Nicoderm patch combined with gum or inhaler|Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the "standard patch treatment", but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.
All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
*Off-label dosage approved by Health Canada via "No Objection" letter.
134235|NCT01623505|Drug|Transdermal Nicoderm patch|Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.
All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
134236|NCT01623518|Biological|ChAdOx1-NP+M1|Dose escalation in a 3+3 study plan;
5 x10^8 vp, 5 x10^9 vp, 2.5 x10^10 vp, 5 x10^10 vp
134237|NCT01623531|Drug|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
134238|NCT01623557|Biological|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
134518|NCT01626677|Procedure|Microfracture|Active control
134519|NCT01626690|Device|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
134520|NCT01626690|Device|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
134521|NCT01626703|Other|Reminding call|
134522|NCT01626716|Other|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
134523|NCT01626729|Behavioral|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
135164|NCT01611116|Drug|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
135408|NCT01611558|Biological|Ipilimumab|
135409|NCT01611571|Drug|Risedronate|weekly risedronate
135410|NCT00083382|Drug|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
135411|NCT01611571|Drug|Teriparatide|daily teriparatide
135412|NCT01611571|Drug|Placebo Teriparatide|daily placebo of teriparatide
135413|NCT01611571|Drug|placebo Risedronate|weekly placebo of Risedronic Acid
135414|NCT01611584|Drug|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
135415|NCT01611597|Other|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
135416|NCT01611610|Other|Functional tests|The ambulant patients will perform
MFM (20 items)
Hammersmith modified module - MHMFS
Timed tests (time to rise from the floor,...)
6 minute walk test
PedsQL - neuromuscular module
135417|NCT01611610|Other|Functional tests|The non-ambulant patients will perform:
MFM (20 items)
Hammersmith modified module - MHMFS
Upper Limb Functional Items
Egen Klassifikation 2 questionnaire - EK2
PedsQL questionnaire - neuromuscular module
135418|NCT01611623|Drug|SNX-5422|Tablets dose every other day; dose escalation based on safety
135419|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils|4 months consumption
135420|NCT01611649|Dietary Supplement|Formula containing plant oils|4 months consumption
135421|NCT00083382|Drug|Thalidomide|All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.
Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)
135422|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
135423|NCT01611662|Drug|gemcitabine hydrochloride|Given IV
135424|NCT01611662|Drug|cisplatin|Given IV
135425|NCT01611662|Procedure|therapeutic conventional surgery|Undergo radical cystectomy
134700|NCT01612416|Device|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
134701|NCT00083486|Drug|epoetin alfa|
134702|NCT01612429|Dietary Supplement|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
134703|NCT01612442|Behavioral|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
134704|NCT01612442|Behavioral|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
133813|NCT01620541|Procedure|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
133814|NCT01620541|Procedure|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
133815|NCT00084175|Behavioral|Behavior Therapy|
133816|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
133817|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
133818|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
133819|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
133820|NCT01620554|Drug|Placebo|1 capsule per week during 2 weeks
133821|NCT01620567|Dietary Supplement|avocado or chickpeas/potatoes|1 avocado/day for 6 months or equivalent calories of chickpeas/potatoes for 6 months
133822|NCT01620580|Behavioral|Self-management|Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.
Week 3
134450|NCT01619397|Device|Xanthan gum coating on a standard natural rubber latex (NRL) condom|
134451|NCT01619410|Biological|Linezolid|Linezolid 600 mg every 12 hours for 7 days
134452|NCT01619410|Biological|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
134453|NCT01619423|Drug|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
134454|NCT01619423|Drug|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
134455|NCT00084071|Drug|Tifacogin|
134456|NCT01619423|Drug|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
134457|NCT01619436|Drug|Clonidine|bolus, clonidine 2 mg/kg IV
134458|NCT01619436|Drug|Ringer lactato|1 ML ringer lactato IV, as placebo
134459|NCT01619449|Procedure|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
134460|NCT01621711|Behavioral|Linkage patient activation intervention|Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist.
133582|NCT01622426|Dietary Supplement|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
133583|NCT00084370|Drug|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
133584|NCT01622426|Dietary Supplement|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
133585|NCT01624714|Drug|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
133586|NCT01624727|Dietary Supplement|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
133587|NCT01624740|Device|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
133588|NCT00084578|Procedure|conventional surgery|
134524|NCT01619462|Biological|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
134525|NCT01619488|Device|Adjustable Gastric Band|Surgical placement of an adjustable gastric band around the upper portion of the stomach.
Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction.
134526|NCT01619527|Drug|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
134527|NCT01619527|Drug|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
134528|NCT01619540|Other|Valsalva maneuver|
134529|NCT01619566|Drug|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
134530|NCT00001564|Drug|CD40 Ligand|
134531|NCT00084084|Drug|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
134532|NCT01619579|Device|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
134533|NCT01619592|Device|webbased education (telemonitoring)|Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. "Timely" will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon.
134534|NCT01619605|Procedure|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
134535|NCT01619618|Genetic|mutation analysis|
134536|NCT01619618|Genetic|polymerase chain reaction|
133661|NCT01622465|Behavioral|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
133662|NCT01622478|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
133663|NCT00084370|Procedure|oophorectomy|
133664|NCT01622478|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
135426|NCT01611662|Other|laboratory biomarker analysis|Correlative studies
135427|NCT01611675|Drug|Vemurafenib|take orally, twice daily
135428|NCT01611675|Drug|Leflunomide|take orally, once daily
135735|NCT01612013|Drug|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
135736|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
135737|NCT01612013|Drug|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
135738|NCT01612013|Drug|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
135739|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
135740|NCT01612026|Procedure|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
135741|NCT01612039|Drug|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
135742|NCT00001563|Biological|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
135743|NCT00083447|Drug|TransMID™|
135744|NCT01612039|Drug|Placebo|Matching placebo tablets
135745|NCT01612052|Drug|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
135746|NCT01612065|Drug|Misoprostol|200 ug
135747|NCT01612065|Drug|Misoprostol|Misoprostol vaginally, 400 ug
133823|NCT01620580|Behavioral|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills & adherence to renal diet and fluid restriction without discussing any intervention with the group.
133824|NCT01622699|Device|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
133825|NCT01622699|Other|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
133826|NCT01622712|Device|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
133827|NCT00001566|Procedure|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
133828|NCT00084396|Procedure|conventional surgery|
134101|NCT01625754|Behavioral|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
134102|NCT01625767|Behavioral|AAT experiment|Smokers and nonsmokers complete AAT experiment
134103|NCT01625780|Procedure|3-layer block|0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the "3-layer" method using a standard 20-gauge block needle.
134104|NCT01625780|Procedure|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
134105|NCT01625793|Drug|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
134106|NCT01625806|Drug|RO4602522|Single oral dose
134107|NCT01625806|Drug|ketoconazole|Multiple oral doses
134108|NCT01625819|Behavioral|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
134109|NCT01625819|Behavioral|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
134110|NCT00084617|Drug|capecitabine|Given orally
133589|NCT01624740|Device|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
133590|NCT01624753|Device|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
133591|NCT01624766|Drug|Everolimus|Starting Dose (Everolimus + Anakinra): Everolimus 5 mg by mouth daily for a 28 day cycle.
Starting Dose (Everolimus + Denosumab): Everolimus 10 mg by mouth daily for a 28 day cycle.
Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalating Group.
133592|NCT01624766|Drug|Anakinra|Starting dose: 100 mg subcutaneously daily for a 28 day cycle.
Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalating Group.
133593|NCT01624766|Drug|Denosumab|Starting dose: 120 mg subcutaneously day 1 of a 28 day cycle.
Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalating Group.
133594|NCT01624779|Drug|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1&2
133595|NCT01624792|Dietary Supplement|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
133596|NCT01624792|Dietary Supplement|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
133597|NCT01624792|Dietary Supplement|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
133598|NCT01624805|Drug|hATG|40 mg/kg by vein on Days 1 - 4.
35 mg/kg by vein on Days 1 - 4 (in patients with MDS age >/= 55).
133599|NCT00084578|Procedure|neoadjuvant therapy|
133881|NCT01627587|Drug|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
133882|NCT01627587|Drug|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
133883|NCT01620593|Drug|Placebo and Castration|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin or placebo, blinded to the patient and the study team.
133884|NCT01620593|Drug|Metformin and Castration|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient500mg tablets of metformin or placebo, blinded to the patient and the study team.
133885|NCT00084188|Behavioral|Behavior Therapy|
133886|NCT01620606|Behavioral|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy & Social Learning
133887|NCT01620606|Behavioral|Education and Support|Education about the GI system, nutrition and food safety
133665|NCT01622478|Procedure|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
133666|NCT01622478|Procedure|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
133667|NCT01622504|Drug|MVP005|2 mg single dose administered intranasally
133668|NCT01622504|Drug|MVP005|4 mg single dose administered intranasally
133669|NCT01622504|Drug|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
133670|NCT01622543|Drug|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
133671|NCT01622543|Drug|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
133672|NCT01622556|Drug|Fludarabine|35 mg/m2 IV/day x 5 days
133673|NCT01622556|Drug|Busulfan|.8 mg/kg IV Q6h x 8 doses
133674|NCT00084383|Biological|GVAX pancreatic cancer vaccine|Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth "booster" vaccination, six months following the fourth vaccination.
133675|NCT01622556|Drug|Thymoglobulin|1.5 mg/kg/day x 3 days
133676|NCT01624935|Behavioral|interpersonal psychotherapy|interpersonal psychotherapy
133677|NCT01624948|Drug|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
133678|NCT00084591|Drug|capecitabine|
133679|NCT01624948|Drug|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
133680|NCT01624961|Biological|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
133955|NCT01627873|Drug|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
133956|NCT01627886|Drug|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
135748|NCT01612078|Drug|Droxidopa|200mg/tab 2tablets, po, three times a week
135749|NCT01612078|Drug|Placebo|200mg/tab, po, three times a week.
135750|NCT01612091|Device|Monitoring Messenger|Monitoring Messenger prototype device
135751|NCT01612091|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
135752|NCT01612104|Behavioral|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
134907|NCT01617707|Drug|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
134908|NCT01617733|Drug|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
134909|NCT00000263|Other|0.5 g/KG ethanol|
134910|NCT00001564|Drug|IL-4|
134911|NCT00083915|Drug|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets >50K.
134912|NCT01617746|Drug|Ambrisentan|5mg od two weeks
134913|NCT01617746|Drug|Bosentan|62.5mg bd two weeks
134914|NCT01617746|Drug|Placebo|bd for two weeks
134915|NCT01617772|Drug|Atorvastatin|Atorvastatin 20 mg
134916|NCT01617772|Drug|L-Carnitine|1000mg L-carnitine
134917|NCT01617772|Drug|Placebo|Identically looking placebo
134918|NCT01617798|Drug|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
134919|NCT01617798|Drug|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
134111|NCT01625819|Behavioral|Health Education|32 1-hour bi-weekly group sessions of health education
134112|NCT01625832|Procedure|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
134113|NCT01625845|Drug|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
134114|NCT01625845|Other|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
134115|NCT01618617|Dietary Supplement|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
134116|NCT01618630|Dietary Supplement|Dietary Supplement: Amino acids for six weeks|Amino acids in drinks between meals for six weeks.
134117|NCT01618630|Dietary Supplement|Placebo|Placebo supplementation as drinks in between meals for six weeks
134118|NCT01618643|Procedure|Acetic acid chromoendoscopy|Prospective observational pilot study.
We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.
We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray.
134383|NCT01621581|Genetic|Convection enhanced delivery/AAV2-GDNF|
134384|NCT01621620|Drug|Yohimbine|
134385|NCT01621633|Drug|LCZ696|
134386|NCT01621646|Other|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
134387|NCT01621659|Behavioral|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
134388|NCT01621672|Drug|Revlimid|10 mg/day in the morning same time each day
134389|NCT01621685|Biological|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
134390|NCT00084279|Drug|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
134391|NCT01621698|Procedure|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
133888|NCT01620619|Other|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
133889|NCT01620619|Procedure|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
133890|NCT01620632|Procedure|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
133891|NCT01620645|Radiation|CT scan and PA chest X-ray|All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.
The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK.
133892|NCT01620658|Device|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material.
133893|NCT01620658|Device|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material.
133894|NCT01620658|Device|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
133895|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
133896|NCT00084201|Drug|Cranberry juice|
133897|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
133898|NCT01620684|Drug|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
133899|NCT01620684|Drug|placebo|placebo capsules
133900|NCT01620697|Procedure|Colorectal surgery|Colorectal surgery
134174|NCT01625845|Behavioral|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
134175|NCT01625871|Drug|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
134176|NCT01625897|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for four weeks, then flexible dose of MP-214
133957|NCT01627899|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
133958|NCT00084721|Drug|irinotecan hydrochloride|
133959|NCT01627912|Other|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink [white wine or red wine or 12.5% ethanol or water]/kg of individual, parallel with a standardized meal.
133960|NCT01627925|Device|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
133961|NCT01627938|Drug|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
133962|NCT01627938|Drug|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
133963|NCT01627951|Other|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
133964|NCT01627951|Other|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
133965|NCT01627951|Other|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
133966|NCT01627977|Other|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
133967|NCT01620736|Drug|Raltegravir|Raltegravir 400 mg po bid
133968|NCT01620749|Radiation|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
133969|NCT00084201|Drug|Amoxicillin|
133970|NCT01620762|Drug|Cat-PAD|1 dose every 4 weeks
133971|NCT01620762|Drug|Placebo|1 dose every 4 weeks
133972|NCT01620775|Procedure|MRI (Magnetic Resonance Imaging)|Subjects will undergo (2) MRI scans to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. The MRI scan will take approximately hour to complete. An MRI will be completed in the morning and one in the afternoon.
133973|NCT01620775|Procedure|MRI|Subjects designated as Healthy volunteers will undergo (2) MRIs that will take approximately 1 hour each to complete. One MRI will be completed in the morning and one in the afternoon.
133974|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg and 1 tablet of Indapamide placebo, a day
134920|NCT01617811|Procedure|epidural anesthesia and analgesia|A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.
Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).
Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed.
134921|NCT01617824|Drug|Linagliptin|Linagliptin 5 mg tablets for 4 days
134922|NCT01610609|Behavioral|Population Health Management Intervention|This intervention includes:
Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and
Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention
134923|NCT01610622|Device|COstatus cardiac output measurement with isotonic saline|Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.
No other interventions are made for the purpose of the study.
134924|NCT01610635|Other|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
135165|NCT01611129|Behavioral|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI & CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
135166|NCT01611142|Biological|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
135167|NCT01611155|Drug|venlafaxine|Given PO
135168|NCT01611155|Drug|placebo|Given PO
135169|NCT01611155|Other|questionnaire administration|Ancillary studies
135170|NCT01611155|Other|quality-of-life assessment|Ancillary studies
135171|NCT01613326|Drug|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
135172|NCT01613339|Other|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Exemple of exercies are weight-balancing in standing and relaxation exercises.
135173|NCT01613352|Other|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
134392|NCT01621698|Procedure|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
134393|NCT01623726|Procedure|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by "Chattanooga Iontophoresis Dual Channel Delivery Device", that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA.
134394|NCT01623739|Procedure|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
134395|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
134396|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
134397|NCT01623778|Drug|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
134398|NCT01623804|Device|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
134399|NCT01623804|Device|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
134400|NCT01623817|Drug|Vancomycin HCL|Loading dose of 30mg/kg via central or peripheral intraveous infusion during 2 or 3 hours.
Maintanance dose of vancomycin is 15mg/kg twice a day or 1g twice a day.
133531|NCT01627106|Drug|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
133532|NCT01627106|Drug|Amiodarone|Administered IV as per product label
133533|NCT01627132|Drug|Dasatinib|100mg QD
133534|NCT01627145|Drug|Solifenacin|Solifenacin 5 mg qd,
133535|NCT01627158|Drug|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
133536|NCT01627158|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler
133537|NCT01627158|Drug|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
133538|NCT01627158|Drug|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
134177|NCT01625897|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for four weeks, then flexible dose of MP-214
134178|NCT01625897|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral dose of risperidone for two weeks, then flexible dose of risperidone
134179|NCT01625910|Behavioral|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
134180|NCT00084630|Drug|imatinib mesylate|Given orally
134181|NCT01625923|Drug|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD < 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
134182|NCT01625936|Drug|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
134183|NCT01625936|Drug|Bevacizumab|
134184|NCT01625949|Procedure|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
134185|NCT01625949|Procedure|coronary dilatation and stenting|coronary dilatation and stenting
134186|NCT01625988|Drug|LY2951742|Administered subcutaneously once every other week for 12 weeks
134187|NCT01625988|Drug|Placebo|Administered subcutaneously once every other week for 12 weeks
134188|NCT01626001|Procedure|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
134189|NCT01626014|Behavioral|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
134190|NCT01626014|Behavioral|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
134461|NCT01621724|Genetic|WT1 TCR-transduced T cells|Two patient cohorts:
Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells
Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells
134462|NCT01621737|Drug|Oxytocin|42 IU BID for six weeks
134463|NCT01621737|Drug|Oxytocin|84 IU BID for six weeks
134464|NCT01621737|Drug|Placebo|Vehicle placebo
134239|NCT01623557|Biological|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
134240|NCT01623557|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
134241|NCT01623570|Drug|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
134242|NCT01623570|Drug|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
134243|NCT00084461|Drug|romidepsin|Given IV
134244|NCT01623583|Other|Enhanced Needle Phobia Intervention|The enhanced intervention will include the standard intervention, with two enhancements:
The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch
Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity.
134245|NCT01623583|Other|Standard Needle Phobia Intervention|The standard intervention will include the following components:
Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.
Basic training on relaxation breathing
Brief video of a patient overcoming needle phobia
Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle
134246|NCT01623596|Drug|Fingolimod|
134247|NCT01623596|Drug|Disease Modifying therapy|
134248|NCT01626053|Other|Control Group|no intervention
134249|NCT01626066|Drug|LUM015|LUM015 assigned dose given once by IV push
134250|NCT01626079|Device|MitraClip System|Percutaneous mitral valve repair using MitraClip System
134251|NCT01626092|Drug|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
134252|NCT01626092|Drug|Clofarabine|A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,
-8, -7, -6, and -5.
134253|NCT01626092|Drug|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
134254|NCT01626092|Radiation|Total Body Irradiation with Marrow Boosting|Dose to total body 200 cGy in single dose
Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border.
134255|NCT01626092|Biological|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
135174|NCT01613365|Drug|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
135175|NCT01613365|Drug|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
135176|NCT01613404|Other|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
135177|NCT00083551|Drug|Cisplatin|Cisplatin* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)
*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) < 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) > 3.0 mg/dl
135178|NCT01613417|Drug|gadoteridol|ProHance 0.1 mmol/kg
135179|NCT01613417|Drug|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
135180|NCT01613430|Behavioral|Coach Training (COACH)|Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a "Things to Remember" diary checkup list, and resources addressing well-known barriers to cancer screening.
135429|NCT00083551|Drug|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
135430|NCT01613807|Drug|Insulin, Long-Acting and Insulin LISPRO|Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
135431|NCT01613820|Drug|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
135432|NCT01613820|Drug|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
135433|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
135434|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
135435|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
135436|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
135437|NCT01613846|Drug|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
135438|NCT01613846|Drug|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
133539|NCT01627171|Drug|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
133540|NCT00084695|Drug|fludarabine phosphate|Given IV
133541|NCT01627171|Drug|Polyethelene Glycol|280g reconstituted in 4 liters of water
133542|NCT01627171|Drug|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
133543|NCT01627184|Device|Dexcom G4 CGM System|
133544|NCT01627197|Procedure|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
133545|NCT01627223|Drug|Lamivudine|Lamivudine 100 mg p.o. q.d.
This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.
133546|NCT01627223|Drug|Entecavir|•Entecavir 0.5 mg p.o. q.d
This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.
133547|NCT01627236|Drug|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
133548|NCT01627249|Drug|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
133549|NCT01620099|Drug|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
133829|NCT01622725|Procedure|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
133830|NCT01622725|Procedure|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
133831|NCT01622764|Radiation|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
133832|NCT01622777|Drug|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
134465|NCT01621750|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
134466|NCT01621763|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
134467|NCT01621776|Drug|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
134468|NCT00084318|Biological|cetuximab|
134469|NCT01621776|Drug|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
134470|NCT01621776|Drug|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
134471|NCT01621789|Other|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
134472|NCT01621802|Biological|Priorix®|Single dose administered subcutaneously (SC) with or without licensed co-administered vaccines, DTaP-IPV and varicella
134473|NCT01621802|Biological|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™)|Single dose administered SC with or without DTaP-IPV and varicella vaccines
134474|NCT01621802|Biological|Kinrix®|Single dose administered SC with varicella vaccine and with either Priorix® or M-M-R®II
134475|NCT01621802|Biological|Varivax®|Single dose administered SC with DTaP-IPV vaccine and with either Priorix® or M-M-R®
134476|NCT01621815|Behavioral|Video Game|Playing various video games: RPG, Race, FPS, Strategy
134477|NCT01621828|Other|video|a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
134478|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
134479|NCT00084318|Drug|cisplatin|
134480|NCT01621854|Drug|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
134481|NCT01621867|Drug|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
133600|NCT01624805|Drug|Cyclosporine|5 mg/kg by mouth daily given in 2 divided doses starting on Day 1 and given for 6 months (180 days).
133601|NCT01624805|Drug|Methylprednisone|1 mg/kg by vein daily for 4 days on Days 1 - 4, to be given prior to the hATG infusion.
134256|NCT00084643|Biological|GTI-2040|Given IV
134537|NCT01619618|Genetic|polymorphism analysis|
134538|NCT01619618|Other|laboratory biomarker analysis|
134539|NCT01619631|Behavioral|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
134540|NCT01619631|Behavioral|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
134541|NCT01619644|Drug|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
134542|NCT00084097|Drug|Omalizumab|
134543|NCT01619644|Drug|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
134544|NCT01619657|Drug|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
134545|NCT01614613|Device|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
134546|NCT01614613|Device|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
134547|NCT01614613|Device|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
134548|NCT00083603|Biological|Empty TBC-FPV|Empty FPV 10^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
134549|NCT01614639|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
134550|NCT01614652|Device|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
134551|NCT01614665|Drug|Prograf®|Oral
134552|NCT01614665|Drug|Advagraf|oral
134553|NCT01614678|Device|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
135439|NCT01613872|Other|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
135440|NCT00083551|Drug|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
135441|NCT01613898|Biological|Blood tests|Blood tests
135442|NCT01613924|Device|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
135443|NCT01613924|Device|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
135444|NCT01613937|Behavioral|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
135445|NCT01613950|Drug|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
135446|NCT01613950|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
135447|NCT01613963|Drug|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
135448|NCT01613976|Drug|Panobinostat|
135753|NCT01612130|Drug|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
135754|NCT00083460|Drug|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
135755|NCT01612130|Drug|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
135756|NCT01614301|Drug|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity
135757|NCT01614314|Other|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
135758|NCT01614314|Other|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
133833|NCT01622777|Drug|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
133834|NCT01622790|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
133835|NCT01622790|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
133836|NCT01622790|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
133837|NCT01622803|Procedure|parallel stent|bilateral parallel stent insertion (right and left side)
133838|NCT01622803|Device|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
133839|NCT00084409|Drug|iloprost|Given orally
133840|NCT01622829|Procedure|"Prescription for Activity" and individual instructions|Structured education. "Prescription for Activity". This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator).
133841|NCT01622829|Other|"Prescription for Activity", without instructions|Prescription with exercise programme. "Prescription for activity". This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week.
133842|NCT01625221|Device|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
133843|NCT01625234|Drug|X-396|Oral, ALK inhibitor
133844|NCT01625247|Procedure|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
134119|NCT01618656|Drug|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
134120|NCT01618656|Drug|Placebo|Sugar pill
134121|NCT01618669|Drug|Regadenoson|Administered as an intravenous (IV) bolus
134122|NCT01618669|Procedure|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
133602|NCT01624805|Drug|Pegfilgrastim|6 mg subcutaneously one time on Day 5 as needed to keep ANC >/= 1.5.
133603|NCT01624805|Drug|Filgrastim|300-480 mcg subcutaneously on Day 5 as needed to keep ANC >/= 1.5.
133604|NCT01624818|Behavioral|Cardiac habilitation program|physical activity three weeks
133605|NCT01624844|Other|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
133606|NCT01624857|Drug|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
133607|NCT01624857|Drug|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
133608|NCT01627249|Drug|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
133609|NCT01627249|Drug|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
133610|NCT00084695|Drug|melphalan|Given IV
133611|NCT01627262|Drug|Mesalamine|3x1000mg mesalamine granules per day
133612|NCT01627262|Drug|Placebo|3x1000mg placebo granules per day
133613|NCT01627275|Biological|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
133614|NCT01627288|Radiation|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
133615|NCT01627301|Device|Device-Guided Breathing using the RESPeRATE device|15 minutes of device-guided breathing daily for 8 weeks
133616|NCT01627314|Biological|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
133617|NCT01627314|Biological|Untreated CB|Cord Blood
133618|NCT01627327|Drug|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
133619|NCT01627327|Drug|tiotropium bromide 18mcg|inhalation powder
133620|NCT01627340|Biological|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
134554|NCT01614678|Device|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
134555|NCT01614691|Drug|SPARC1203|Active
134556|NCT01614691|Drug|Placebo|Placebo
133681|NCT01624974|Drug|MK-1029|MK-1029 150 mg tablets taken once daily (QD)
133682|NCT01624974|Drug|placebo|placebo tablets (matching the MK-1029 150 mg tablets) QD
133683|NCT01624974|Drug|montelukast (ML)|ML 10 mg tablets QD
133684|NCT01624987|Behavioral|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
133685|NCT01624987|Other|Control group|The control group receives no intervention.
133686|NCT01625000|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for six weeks.
133687|NCT01625000|Drug|MP-214 middle dose|Patients who meet eligibility criteria will be administered a once daily oral middle dose of MP-214 for six weeks.
133688|NCT01625000|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for six weeks.
133689|NCT00084591|Procedure|conventional surgery|
133690|NCT01625000|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral dose of risperidone for six weeks.
133691|NCT01625000|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
133692|NCT01625013|Device|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
133693|NCT01625026|Drug|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
133694|NCT01625026|Drug|Placebo|Placebo to obeticholic acid
133695|NCT01625039|Behavioral|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
135759|NCT01614340|Behavioral|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
135760|NCT01614353|Other|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
135761|NCT01614353|Other|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
135762|NCT01614366|Drug|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
135763|NCT00083590|Drug|Huperzine A|
135764|NCT01614366|Drug|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
135765|NCT01614366|Drug|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
135766|NCT01614366|Drug|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
135767|NCT01614392|Behavioral|Lower Extremity high velocity low force Power Training|Lower Extremity high velocity, low force Power Training
135768|NCT01614405|Drug|Truvada and Kaletra|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
135769|NCT01614418|Device|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
134925|NCT01610661|Other|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
134926|NCT01610674|Other|Intervention to improve perioperative diabetes care|A step-wise implementation model is applied:
1) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients.
134927|NCT00083239|Drug|talabostat (PT-100) tablets|
134928|NCT01610674|Other|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals.
134123|NCT01618695|Drug|E2007|Core study:4 mg group:
Week 0 Once daily; 2 mg/day,
Week 1 to Week 18 Once daily 4 mg/day:
8 mg group: Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day,
Week 3 to Week 18 Once daily 8 mg/day:
12 mg group: Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day Extension study 4 mg group: Week 19 to Week 22 Once daily perampanel 4 mg/day, Week 23 Once daily perampanel 6 mg/day, Week 24 Once daily perampanel 8 mg/day, Week 25 Once daily perampanel 10 mg/day,
Week 26 to Week 75 or more Once daily perampanel 12 mg/day:
8 mg group: Week 19 to Week 22 Once daily perampanel 8 mg/day, Week 23 Once daily perampanel 10 mg/day,
Week 24 to Week 75 or more Once daily perampanel 12 mg/day:
12 mg group: Week 19 to Week 75 or more Once daily perampanel 12 mg/day
134124|NCT01618695|Drug|Placebo|Core study:
Week 0 to Week 18 Once daily placebo, Week 19 to Week 22 Once daily placebo
Extension study
Week 19 to Week 22 Once daily placebo:
Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day
134125|NCT00084019|Drug|Atazanavir|
134126|NCT01618708|Device|Synvisc-One (hylan G-F 20)|6-mL intra-articular (IA) injection
134127|NCT01618708|Device|Saline Placebo|6 mL injection of phosphate buffered saline
134128|NCT01618760|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
134129|NCT01618760|Drug|Risperidone|1 mg tablet once a day
134130|NCT01618773|Drug|0.1% adapalene / 2.5% benzoyl peroxide|topical application
134131|NCT01618786|Other|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
134132|NCT01618786|Other|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
134133|NCT01618799|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
134134|NCT01621022|Drug|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
134135|NCT01621074|Dietary Supplement|Sodium bicarbonate|Ergogenic effect
134136|NCT01621074|Dietary Supplement|Placebo|Placebo effect
134137|NCT00001566|Biological|therapeutic autologous dendritic cells|3 syringes containing 1 x 10^6peptide pulsed dendritic cells
134401|NCT01623830|Behavioral|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
133901|NCT01620710|Radiation|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
133902|NCT01620710|Radiation|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
133903|NCT01620723|Other|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
133904|NCT01620723|Other|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
133905|NCT01622829|Other|usual physiotherapy|physiotherapy, treatment as usual
133906|NCT01622855|Behavioral|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
133907|NCT01622868|Other|Laboratory Biomarker Analysis|Correlative studies
133908|NCT01622868|Drug|Lapatinib Ditosylate|Given PO
133909|NCT01622868|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
133910|NCT01622881|Drug|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
133911|NCT01622881|Drug|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
133912|NCT01622920|Other|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
133913|NCT00084409|Other|placebo|Given orally
133914|NCT01622933|Biological|DC Vaccine + IFN|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.
IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks.
133915|NCT01622933|Biological|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
133916|NCT01622946|Drug|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
133917|NCT01622946|Drug|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
134191|NCT00084630|Other|laboratory biomarker analysis|Correlative studies
133696|NCT01625039|Behavioral|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
133697|NCT01627587|Drug|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
133698|NCT01627587|Drug|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
133699|NCT01627613|Drug|AP301|AP301 25 mg powder for reconstitution for solution for inhalation
Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days.
133975|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide1.5mg + Losartan 100mg and 1 tablet of Indapamide placebo, a day
133976|NCT01620788|Drug|Indapamide|1 tablet of Indapamide 1.5mg and 1 tablet of Indapamide+Losartan placebo, a day
133977|NCT01620801|Biological|AAV8-hFIX19|One-time IV vector administration.
133978|NCT01620814|Drug|Dinoprostone|
133979|NCT01620814|Drug|misoprostol|
133980|NCT00084214|Drug|STA-4783|
133981|NCT01620814|Drug|control|
133982|NCT01620827|Other|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
133983|NCT01620827|Other|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
133984|NCT01620840|Drug|Lacosamide 10mg/ml|intravenous administration up to 10 days
133985|NCT01620866|Other|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
133986|NCT01620905|Procedure|Manipulation|Single level cervical spine joint manipulation
133987|NCT01620918|Procedure|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
133988|NCT01620918|Procedure|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
133989|NCT01620931|Drug|RO5469754|Single ascending doses, iv or sc
133990|NCT01620931|Drug|Placebo|Single doses, iv or sc
133991|NCT00084214|Drug|Paclitaxel|
133992|NCT01620944|Drug|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
134929|NCT01610687|Drug|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
134930|NCT01610700|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
134931|NCT01610700|Drug|Placebo|Each actuation of placebo delivered the excipients only.
134932|NCT01610713|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
134933|NCT01610726|Procedure|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
134934|NCT01610739|Drug|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
134935|NCT01610752|Behavioral|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
134936|NCT01610765|Drug|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
134937|NCT01612884|Drug|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
134938|NCT01612884|Drug|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
135181|NCT01613430|Behavioral|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
135182|NCT01613456|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
135183|NCT01613456|Dietary Supplement|Placebo|Capsule with comparable organoleptic properties and weight than the experimental product.
2 capsules/day during 12 weeks
135184|NCT01613469|Drug|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
135185|NCT01613469|Radiation|external beam photon radiation|45 Gy in 25 fractions (1.8Gy per fraction, 5 fractions per week)over 5 weeks.
134402|NCT01623843|Procedure|Arthroscopic osteochondroplasty vs. Arthroscopic lavage|Osteochondroplasty: reshaping the hip ball and socket ("osteoplasty" or "rim trimming"). Lavage: inflammation debris caused from continual friction in the hip is washed out.
134403|NCT00084513|Biological|trastuzumab|
134404|NCT01623856|Other|laboratory biomarker analysis|Correlative studies
134405|NCT01623869|Other|Laboratory Biomarker Analysis|Correlative studies
134406|NCT01623869|Biological|Trebananib|Given IV
134407|NCT01623908|Drug|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
134408|NCT01623921|Drug|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
134409|NCT01623921|Drug|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
134410|NCT01623921|Drug|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
134411|NCT01623921|Drug|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
134412|NCT01626365|Procedure|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
134413|NCT01626365|Procedure|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
134414|NCT01626378|Drug|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
134415|NCT01626378|Drug|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
134416|NCT00084643|Other|pharmacological study|Correlative studies
134417|NCT01626391|Drug|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
134418|NCT01626391|Drug|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
134419|NCT01626417|Device|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
133550|NCT01620112|Drug|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
134192|NCT01626040|Drug|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
134193|NCT01626053|Behavioral|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
134194|NCT01618799|Drug|Lamotrigine|2 x 25 mg tablet once a day
134195|NCT01618812|Procedure|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
134196|NCT00084019|Drug|Ritonavir|
134197|NCT01618825|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
134198|NCT01618825|Drug|Lamotrigine|2 x 25 mg tablet once a day
134199|NCT01618838|Radiation|CyberKnife radiosurgery|Treatment Planning:
Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively.
134200|NCT01618851|Radiation|Radiotherapy with IMRT and CyberKnife Boost|Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.
The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.
For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions.
134201|NCT01618864|Device|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
134202|NCT01618877|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
134203|NCT01618877|Other|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
134204|NCT01618890|Procedure|Hepatic venous pressure gradient measurement|Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.
In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.
In hemodynamic responders (HVPG second measurement< 12 mmHg or >20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up.
134205|NCT01618903|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
136309|NCT01688453|Behavioral|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
136310|NCT01688453|Behavioral|The strengthened care management|The strengthened care management is the addition of the standard care management and of additional interventions.
The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation.
136311|NCT01688466|Drug|Pomalidomide|0.5 mg/day without Dose Escalation and 0.5 mg/day- 2.0 mg/day PO QD(every day) of each 28 day cycle
136601|NCT01681251|Other|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
136602|NCT00089167|Drug|dexamethasone|
136603|NCT01681264|Drug|Guanfacine|Subjects will be randomized into 1 of the following 5 treatment groups:
morphine: placebo
morphine: guanfacine (1mg)
morphine: guanfacine (2mg)
placebo: guanfacine (2mg)
placebo: placebo
To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 12 weeks of drug treatment (combination or placebo).
136604|NCT01681264|Drug|Morphine|Subjects will be randomized into 1 of the following 5 treatment groups:
morphine: placebo
morphine: guanfacine (1mg)
morphine: guanfacine (2mg)
placebo: guanfacine (2mg)
placebo: placebo
To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 12 weeks of drug treatment (combination or placebo).
136605|NCT01681264|Drug|Placebo|Subjects will be randomized into 1 of the following 5 treatment groups:
morphine: placebo
morphine: guanfacine (1mg)
morphine: guanfacine (2mg)
placebo: guanfacine (2mg)
placebo: placebo
To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 12 weeks of drug treatment (combination or placebo).
136606|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
136607|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
136608|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
136609|NCT01681277|Drug|Placebo to BI 113608 PIB qd|powder for oral solution
136610|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
136611|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
136612|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
136613|NCT00089167|Drug|melphalan|
140137|NCT01644097|Other|questionnaire administration|Ancillary studies
140138|NCT00085969|Drug|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
140139|NCT01644097|Procedure|quality-of-life assessment|Ancillary studies
140140|NCT01644097|Dietary Supplement|Bifidobacterium lactis probiotic supplement|Given PO
140141|NCT01644110|Drug|INCB018424/CC-4047|For all patients the starting dose of ruxolitinib in this trial is 10mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.
140142|NCT01644136|Procedure|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
140143|NCT01644136|Procedure|regional lymph node dissection|Undergo pelvic lymph node dissection
140144|NCT01644136|Device|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
140145|NCT01644149|Device|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
140146|NCT01644149|Device|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
140147|NCT01646567|Drug|Calcipotriol|Topical cream, 0.005%
140148|NCT01646580|Drug|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
140149|NCT01646593|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
140150|NCT01646606|Procedure|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
140151|NCT00086255|Drug|Tiagabine|
140152|NCT01646606|Procedure|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
140483|NCT01644617|Drug|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
136674|NCT01689142|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
136675|NCT01689142|Drug|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
136676|NCT01689155|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
136677|NCT01689168|Behavioral|Counseling|Tobacco cessation counseling
136678|NCT01689168|Procedure|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
136679|NCT01689194|Drug|genexolPM + cisplatin|
136680|NCT01689207|Drug|Avibactam (AVI)|PART A: AVI IV infusion
136681|NCT01689207|Drug|Aztreonam (ATM)|PART A: ATM IV infusion
136682|NCT00089661|Drug|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
136981|NCT01681992|Biological|Havrix®|Single dose Intramuscular injection (IM) administered at Visit 1 (Day 0) with either one of two Inv_MMR vaccine lots (Inv_MMR_Min or Inv_MMR_Med) or one of two active control Com_MMR vaccine lots (Com_MMR_L1 and Com_MMR_L2).
136982|NCT01681992|Biological|Prevnar 13® (Pfizer Inc.)|Single dose Intramuscular injection (IM) administered at Visit 1 (Day 0) in subjects enrolled in US with either one of two Inv_MMR vaccine lots (Inv_MMR_Min or Inv_MMR_Med) or one of two active control Com_MMR vaccine lots (Com_MMR_L1 and Com_MMR_L2).
136983|NCT01682005|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
136984|NCT00089206|Biological|incomplete Freund's adjuvant|
136985|NCT01682018|Device|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
136986|NCT01682031|Dietary Supplement|selenomethionine|Given PO
136987|NCT01682031|Other|placebo|Given PO
136988|NCT01682031|Drug|cisplatin|Given IV
136989|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
136990|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
140375|NCT01642212|Drug|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
140376|NCT01642212|Drug|Placebo|
140377|NCT01642238|Drug|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
140378|NCT01642238|Drug|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
140379|NCT01642251|Drug|Cisplatin|Given IV
140380|NCT01642251|Drug|Etoposide|Given IV
140381|NCT01642251|Other|Laboratory Biomarker Analysis|Correlative studies
140382|NCT01642251|Other|Placebo|Given PO
140383|NCT01642251|Other|Quality-of-Life Assessment|Ancillary studies
140384|NCT01642251|Other|Questionnaire Administration|Ancillary studies
140385|NCT00085787|Drug|ARRY-142886, MEK inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
140386|NCT01642251|Drug|Veliparib|Given PO
140387|NCT01642264|Behavioral|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
140407|NCT00086060|Behavioral|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
140408|NCT01644565|Biological|Modified E. coli heat labile enterotoxin LTR192G|
140409|NCT01644578|Procedure|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
140410|NCT01644591|Radiation|SRS|Lesions targeted with 20-24 Gy for 2 cm, 16-18 Gy for >2 to 2.5 cm, and 12-16 Gy for >2.5-3.5 cm on day 1.
140411|NCT01644591|Radiation|WBRT|30 Gy delivered in 10 fractions. WBRT delivered in 10 fractions once daily Monday-thru-Friday (and weekends for inpatients), on days 1 through 10-to-14.
139525|NCT01650961|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
139526|NCT01650974|Device|HFNOT|high flow nasal oxygen therapy
139527|NCT01651000|Drug|CTAP101 30 μg capsules|Subjects will take 1 capsule (CTAP101 30 μg)daily at bedtime for 12 weeks. After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.
139528|NCT00086671|Drug|Placebo|
139529|NCT01651000|Drug|CTAP101 60 μg capsules|After twelve weeks subjects will take 2 capsules (CTAP101 30 μg each capsule) daily at bedtime for 12 weeks.
139530|NCT01651000|Drug|CTAP101 30 μg sugar pill capsule|Subjects will take 1 capsule (placebo)daily at bedtime for 12 weeks. After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.
139531|NCT01651000|Drug|CTAP101 60 μg sugar pill capsules|After twelve weeks subjects will take 2 capsules (1 CTAP101 and 1 placebo capsule) at bedtime for 12 weeks.
139532|NCT01651039|Drug|Panobinostat, Lenalidomide and Dexamethasone|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19. Lenalidomide will be given 25 mg: Days 1-21. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
139533|NCT01653106|Other|questionnaire administration|Participate in PROMS
139534|NCT01653106|Other|pharmacological study|Correlative studies
139535|NCT01653119|Drug|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
139536|NCT01653132|Drug|Xeomin|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
139537|NCT01653132|Drug|Placebo|Placebo
139538|NCT01653145|Other|Diet A|Dietary
139539|NCT01653145|Other|Diet B|Dietary
139540|NCT01653145|Other|Diet C|Dietary
139798|NCT01653613|Genetic|DNA analysis|
139799|NCT01653613|Genetic|fluorescence in situ hybridization|
139800|NCT01653613|Genetic|gene expression analysis|
139801|NCT01653613|Genetic|microarray analysis|
139802|NCT01653613|Genetic|mutation analysis|
140484|NCT00086060|Behavioral|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
140485|NCT01644630|Procedure|Cemented crowns|The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.
- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection.
140486|NCT01644630|Procedure|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
140487|NCT01644643|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
140488|NCT01644643|Drug|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
140489|NCT01644643|Drug|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
140490|NCT01644656|Device|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
140491|NCT01644669|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
140492|NCT01644682|Other|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
140493|NCT01644682|Other|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
140494|NCT01644682|Other|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
140495|NCT01647763|Procedure|Hemorrhoidal artery ligation with rectoanal repair|Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.
In the area with the 3 largest knots a purse string suture will be placed.
140496|NCT01647763|Procedure|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
136991|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
136992|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
136993|NCT01684241|Biological|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
136994|NCT01684267|Device|Robotic Gait Rehabilitation (RGR) Trainer|
136995|NCT00089388|Drug|cilengitide|Given IV
136996|NCT01684280|Genetic|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
136997|NCT01684293|Behavioral|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
136998|NCT01684293|Behavioral|Psychoeducation/games|Psychoeducation/games
136999|NCT01684306|Drug|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
136083|NCT01688076|Procedure|Botulinum Toxin A|Forehead will be injected with Botox.
136084|NCT01688089|Drug|ODM103|
136085|NCT01688089|Drug|Placebo|
136086|NCT01688089|Drug|Entacapone|
136087|NCT01688089|Drug|Levodopa/carbidopa|
136088|NCT01688102|Dietary Supplement|Oral Vitamin D3|50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
136089|NCT01688102|Radiation|Ultraviolet Light|16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
136090|NCT01688115|Procedure|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
136091|NCT00089596|Procedure|Expansion of umbilical cord stem cells|
136092|NCT01680393|Device|Sequential compression device|a sequential compression device will be applied to the legs
140412|NCT01647412|Other|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
140413|NCT01647412|Other|Placebo Growth Hormone|
140414|NCT01647425|Behavioral|physician assessment|Socio-economic conditions and general features: educational level, professional status...
Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...
in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...
Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...
Assessment of current use of cannabis using the Cannabis Abuse Screening Test
Psychiatric assessment using the MINI 5.0
140415|NCT01647438|Behavioral|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
140416|NCT01647438|Other|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
140417|NCT01647451|Drug|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
140418|NCT00086281|Drug|Modafinil (M)|Modafinil Oral Tablets
140419|NCT01647451|Drug|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
140420|NCT01647477|Behavioral|interview|25 minutes of semi directive interview
140421|NCT01647477|Behavioral|questionnaires|questionnaires to answer at baseline 45 minutes
140422|NCT01647490|Procedure|Permanent Cardiac Pacemaker Implantation|
139519|NCT01650896|Other|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
139520|NCT01650922|Procedure|phlebotomy|
139521|NCT01650922|Procedure|biopsy|
139522|NCT01650935|Behavioral|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
139523|NCT01650948|Device|RetnaGene AMD LDT|
139524|NCT01650961|Drug|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
139803|NCT01653613|Genetic|polymorphism analysis|
139804|NCT01653613|Genetic|reverse transcriptase-polymerase chain reaction|
139805|NCT01653613|Other|laboratory biomarker analysis|
139806|NCT00086931|Procedure|neoadjuvant therapy|chemotherapy and radiation prior to surgery
139807|NCT01653626|Other|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
139808|NCT01655836|Procedure|Quality-of-life assessment|Ancillary studies
139809|NCT01655836|Other|Questionnaire administration|Ancillary studies
139810|NCT01655849|Drug|z160|
139811|NCT01655849|Drug|Placebo|
139812|NCT01655862|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
139813|NCT00087074|Drug|temsirolimus|Given IV
139814|NCT01655875|Drug|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
139815|NCT01655888|Drug|Tremelimumab|Tremelimumab is administered as endovenous infusion
139816|NCT01655901|Behavioral|Active video gaming|
139817|NCT01655901|Behavioral|Passive video gaming|
139818|NCT01655901|Behavioral|Resting|
139819|NCT01655914|Drug|Flumazenil|
139820|NCT01655927|Drug|Tranexamic Acid|
139821|NCT01655927|Drug|Placebo: Saline|
139822|NCT01655940|Device|Somanetics cerebral oximeter|Somanetics cerebral oximeter
139823|NCT01655940|Device|CASMED cerebral oximeter|CASMED cerebral oximeter
140070|NCT01646567|Drug|SHP-141C|Topical Cream
140071|NCT01646567|Drug|Placebo to SHP-141C|Placebo Topical Cream
139594|NCT01648621|Behavioral|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
139595|NCT01651052|Procedure|Heart Valve Surgery|Implant of an aortic valve, Model 11000
139596|NCT01651065|Behavioral|Microclinic Diabetes Education Program|The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.
The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors.
139597|NCT01651065|Behavioral|Control|
139598|NCT01651091|Other|Meditation Awareness Training|Psychotherapy Intervention
139599|NCT01651091|Other|Treatment as usual|
139600|NCT01651104|Biological|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
139601|NCT00001622|Procedure|investigate the relationship between in vivo and in vitro vascular responses|
139602|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
139603|NCT01651117|Behavioral|Peer Mentoring|Arm 2: Will receive peer mentoring from diabetic veterans who were once in poor control but are now in good control.
Arm 3: Will receive peer mentoring from former mentees
139604|NCT01651130|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
139605|NCT01651143|Drug|SAR100842|Pharmaceutical form: tablets
Route of administration: oral
139606|NCT01651143|Drug|Placebo (for SAR100842)|Pharmaceutical form: tablets
Route of administration: oral
139607|NCT01651156|Drug|Tolvaptan|oral taken
139608|NCT01651156|Drug|Placebo|
139609|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.
Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity
136093|NCT01680393|Other|TED stockings|TED stockings will be applied to the patients legs during surgery
136094|NCT01680406|Drug|Artemether-lumefantrine combination|
136095|NCT01680406|Drug|Primaquine|
136096|NCT00089115|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
136097|NCT01680406|Drug|Chloroquine|
136098|NCT01680419|Behavioral|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
136099|NCT01680419|Behavioral|PREP|The Army's "PREP for Strong Bonds" program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others.
136100|NCT01680432|Dietary Supplement|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
136101|NCT01680432|Dietary Supplement|Regular Cheese|
136364|NCT01683136|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.
From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks
136365|NCT01683149|Drug|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
136366|NCT00001703|Biological|incomplete Freund's adjuvant|0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
136367|NCT00089453|Procedure|Leukapheresis #2|on day +2
136368|NCT01685775|Procedure|Transvaginal/transumbilical|
136369|NCT01685775|Procedure|Needlescopic with 3 trocars|
136370|NCT01685788|Other|No intervention|
136371|NCT01685801|Drug|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
136262|NCT01680718|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
136263|NCT00089128|Drug|irinotecan hydrochloride|
136264|NCT01680718|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
136265|NCT01680718|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
136266|NCT01680744|Other|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
136267|NCT01680757|Device|LARIAT Suture Delivery Device and Accessories|
136268|NCT01680783|Device|Non invasive ventilation using a helmet hyperbaric device|Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.
If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
136544|NCT01683422|Radiation|Proton, Gemcitabine, Erlotinib, Capecitabine|Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.
Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.
136545|NCT01683422|Radiation|Proton Radiation|
136546|NCT01683435|Other|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
136547|NCT01683461|Behavioral|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
136548|NCT01683461|Behavioral|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
136549|NCT01683474|Device|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
136550|NCT01683487|Procedure|Observation|Observational study only, no intervention.
136551|NCT01686139|Biological|ABMD-MSC|10-20 x 10^6 cells/20mL
140072|NCT01646567|Drug|Betamethasone Valerate|Topical cream, 0.02%
140073|NCT01639469|Behavioral|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
140074|NCT01639469|Behavioral|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
140075|NCT01639495|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
140076|NCT01639508|Drug|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
140077|NCT01639521|Drug|cisplatin|Given IV
140078|NCT01639521|Drug|gemcitabine hydrochloride|Given IV
140079|NCT01639521|Drug|methotrexate|Given IV
140080|NCT00085501|Drug|paclitaxel|Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.
Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1.
140081|NCT01639521|Drug|vinblastine|Given IV
140082|NCT01639521|Drug|doxorubicin hydrochloride|Given IV
140083|NCT01639521|Biological|pegfilgrastim|Given SC
140084|NCT01639521|Other|laboratory biomarker analysis|Correlative studies
140085|NCT01639547|Drug|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
140086|NCT01639560|Drug|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
140087|NCT01639560|Drug|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
140088|NCT01639586|Behavioral|respite platform|Impact of the respite platform patient care on health profit
140089|NCT01639586|Behavioral|Day care|Impact of the day care on health profit of patient
140090|NCT01639586|Behavioral|No access to a respite structure|Control group without access to a respite structure
140091|NCT00085527|Drug|depsipeptide|
140092|NCT01639599|Drug|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
136614|NCT01681277|Drug|BI 113608 PIB qd|powder for oral solution
136615|NCT01681290|Drug|CBX129801|
136616|NCT01681303|Drug|AST-120|
136617|NCT01681316|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
136618|NCT01681316|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
136619|NCT01681316|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
136620|NCT01681329|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
136919|NCT01686867|Device|Improved, ventilated cookstove|An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.
The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial.
136920|NCT01686880|Device|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
136921|NCT01686893|Device|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
136922|NCT01686893|Device|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
136923|NCT00089505|Drug|Tenofovir disoproxil fumarate|300 mg taken orally
136924|NCT01686906|Procedure|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
136925|NCT01686919|Dietary Supplement|milk-free|milk-free diet during 8 preoperative weeks
136926|NCT01686932|Drug|Vildagliptin|vildagliptin 50mg BID for 8 weeks
136927|NCT01686932|Drug|Sitagliptin|sitagliptin 100mg QD for 8 weeks
136928|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
136929|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
136372|NCT01685801|Drug|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
136373|NCT01685814|Drug|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
136374|NCT01685814|Biological|autologous stem cell transplant|
136375|NCT01685814|Biological|allogeneic stem cell transplant|
136376|NCT01685827|Drug|Fexinidazole|
136377|NCT01685827|Drug|Nifurtimox|
136378|NCT00089453|Procedure|Infusion #2|on day +2
136379|NCT01685827|Drug|Eflornithine|
136380|NCT01685840|Other|Usual Care|Usual Care
136381|NCT01685840|Device|Biomarker-guided care NT-proBNP|Device: NT-proBNP
136382|NCT01685853|Drug|Bisacodyl plus PEG-CS|the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime
the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam
136383|NCT01685853|Drug|PEG 4 litres split|the day before colonoscopy: 2 litres of PEG
the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination
136384|NCT01685866|Device|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
136385|NCT01685879|Other|Rice|Rice portion containing 50 g total carbohydrate
136683|NCT01689207|Drug|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
136684|NCT01689207|Drug|Placebo|PART A, PART B, PART C: matching placebo IV infusions
136685|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
136686|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
136687|NCT01689233|Drug|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
136688|NCT01689233|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
136689|NCT01689246|Drug|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
136552|NCT01686152|Drug|Imiquimod Cream, 3.75%|
136553|NCT01686152|Drug|Zyclara®|
136554|NCT01686152|Other|Vehicle of Test Product|
136555|NCT00089479|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
136556|NCT01686165|Drug|belinostat|Given IV
136557|NCT01686165|Biological|rituximab|Given IV
136558|NCT01686165|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
136559|NCT01686178|Behavioral|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
136560|NCT01686204|Other|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
136561|NCT01686204|Other|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
136562|NCT01686217|Drug|ASP015K ER|oral extended release (ER) at three dosing levels
136563|NCT01686217|Drug|ASP015K IR|oral immediate release (IR)
136864|NCT01668953|Other|Whole Blood Injection|The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.
A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.
6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.
Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.
The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations.
136865|NCT01668953|Other|Dry Needle Fenestration|The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.
3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.
A 22-gauge needle will then be placed into the tendon.
15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon.
136866|NCT00088309|Procedure|Neuropsychological testing|
136867|NCT01668953|Other|Sham Injection|The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.
3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.
The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected.
136868|NCT01668966|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
136869|NCT01668979|Device|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
140423|NCT01647516|Drug|RPC1063|
140424|NCT01647516|Drug|placebo|
140425|NCT01647529|Drug|Ganciclovir|Treatment with topical ganciclovir ointment
140426|NCT01647542|Drug|TAK-875|TAK-875 tablets
140427|NCT01647542|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
140428|NCT01647555|Drug|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
140429|NCT00086281|Drug|Placebo (P)|Placebo Oral Solution
140430|NCT01647555|Radiation|Radiotherapy|Curative dose: 66 to 70 Gy
140431|NCT01647581|Device|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
140432|NCT01647581|Device|NO hemoclip placement|No hemoclip placement (placebo / sham)
140433|NCT01647594|Behavioral|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
140434|NCT01640197|Dietary Supplement|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
140435|NCT00085566|Drug|gefitinib|
140436|NCT01640197|Other|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
140437|NCT01640210|Device|JewelPUMP (insulin patch pump)|The study will be proposed during the visit of selection.
Visit of inclusion:
This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.
Patients treated with insulin pump will be instructed to reproduce the same "programming" between their usual pump and the JewelPUMP, they will use in parallel.
Volume infused will be evaluated during a period of basal and bolus with a precision scale.
Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:
Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.
Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump
140438|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
140439|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
140440|NCT01640249|Drug|Placebo|Capsules administered orally
140441|NCT01640249|Drug|LY3006072|Capsules administered orally
136930|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
136931|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
136932|NCT01686945|Drug|placebo|Placebo semaglutide. For oral administration.
136933|NCT01686945|Drug|placebo|Placebo semaglutide with carrier. For oral administration.
136934|NCT00089518|Drug|Valsartan|
136935|NCT01686958|Device|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
136936|NCT01686984|Other|Altered breath|
136937|NCT01686997|Procedure|Roux-en-Y Gastric Bypass|
136938|NCT01687036|Device|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
136939|NCT01687049|Drug|Red yeast rice|
136022|NCT01682551|Drug|Acetalozamide|If the participators have the history of AMS, he/she will be randomized to take "Wu Zhu Yu Tang" plus "placebo of Acetalozamide" or "Acetalozamide" plus "placebo of Wu Zhu Yu Tang".
136023|NCT01682564|Drug|Candemore tablet|Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)
136024|NCT01682564|Drug|Atacand tablet|Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)
136025|NCT01682577|Drug|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
136026|NCT01682577|Drug|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
136027|NCT01682590|Procedure|Renal Remplacement Therapy|Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).
In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.
In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output > 1000ml/24 hr or >2000ml/24hr with diuretics), RRT is not mandatory.
136028|NCT01682603|Drug|Botulinum toxin A|BoNT-A (BOTOX 300U)
136029|NCT00089258|Biological|monoclonal antibody 3F8|
136690|NCT01689246|Drug|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
136691|NCT01689246|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
136692|NCT01681329|Other|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
136693|NCT01681355|Other|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
136694|NCT01681368|Drug|Birinapant (TL32711)|47mg/m^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
136695|NCT00089167|Drug|thalidomide|
136696|NCT01681381|Device|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
136697|NCT01681381|Device|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
136698|NCT01681394|Dietary Supplement|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
136699|NCT01681394|Dietary Supplement|Chocolate cream|
136700|NCT01681420|Behavioral|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
137000|NCT01684306|Drug|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
137001|NCT01684319|Dietary Supplement|Formula milk free of cow's milk protein|
137002|NCT01684319|Dietary Supplement|Placebo|Infant formula milk
137003|NCT01684332|Other|Strawberry Jam|
137004|NCT01684345|Drug|Placebo|Solution for subcutaneous injection
137005|NCT01684345|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
137006|NCT00089401|Drug|isolated perfusion|
136870|NCT01668992|Behavioral|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
136871|NCT01681719|Device|WBV and Resistance|use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.
For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.
For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.
136872|NCT01681719|Device|resistance & sham WBV|used only resistance
For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.
For WBV: used MY3 platform (Power Plate®, MY3, UK)off.
136873|NCT00089193|Biological|incomplete Freund's adjuvant|
136874|NCT01681719|Device|WBV & resistance sham|used really the WBV, but sham for resistance training
For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.
For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.
136875|NCT01681732|Other|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
136876|NCT01681732|Other|Control Standard Care|This is the standard care arm
136877|NCT01681745|Device|Treatment with Cryo-Touch III|
135960|NCT01684930|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
135961|NCT01684943|Drug|insulin analog administration|
135962|NCT01684956|Procedure|Intradermal injection|
135963|NCT01684956|Procedure|Subcutaneous injection|
135964|NCT01684969|Drug|Haloperidol|0.5 mg iv x one dose
135965|NCT01684969|Drug|Placebo|0.5 mg iv , one dose
135966|NCT01684982|Device|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
135967|NCT01684982|Device|sirolimus eluting stent|control arm of a comparison between drug eluting stents
135968|NCT01684995|Behavioral|Brief physician advice|Brief physician advice to quit smoking
140442|NCT01640262|Other|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
139541|NCT01653158|Drug|CP-751,871|CP-751,871 was given intravenously [IV] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.
Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year).
139542|NCT01653158|Drug|Docetaxel|Docetaxel up to 75 mg/m^2 was administered intravenously [IV] on Day 1 of each 3-week dosing cycle.
139543|NCT00086879|Drug|erlotinib hydrochloride|
139544|NCT01653171|Drug|Water (Placebo)|Water 100 mL
139545|NCT01653171|Drug|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
139546|NCT01653171|Drug|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
139547|NCT01653171|Drug|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
139548|NCT01653184|Dietary Supplement|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
139549|NCT01653197|Behavioral|Control|No scratch off element
139550|NCT01653197|Behavioral|Curiosity|The recipient will be prompted to scratch off for answer to question.
139551|NCT01653197|Behavioral|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
139552|NCT01653223|Drug|simvastatin|In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.
In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months.
139553|NCT01653236|Drug|Boceprevir|
139554|NCT00086879|Drug|temozolomide|
139555|NCT01653236|Drug|Peginterferon alfa-2b|
139556|NCT01653236|Drug|ribavirin|
139557|NCT01653249|Biological|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
139558|NCT01653262|Drug|Brivaracetam|
139559|NCT01655446|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
136030|NCT01682616|Drug|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
136031|NCT01682616|Drug|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6.
136032|NCT01682629|Other|Debriefing Script|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.
All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration.
136033|NCT01682629|Other|High Physical Realism Simulation|High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create "high" physical realism (HiR), full simulator functions were activated ("turned on") including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. "Low" physical realism (LoR) groups had the identical simulator but the compressor was "turned off", thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups.
136034|NCT01682642|Drug|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
136035|NCT01682668|Procedure|Bilateral subthalamic stimulation|
136312|NCT01688479|Drug|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
136313|NCT01688479|Drug|Essex® cream (Schering-Plough), aqueous cream without parabens|
136314|NCT01688492|Drug|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson & Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
136315|NCT01688518|Drug|Heated Lidocaine/Tetracaine Patch|
136316|NCT01688518|Drug|5% Lidocaine Patch|
136317|NCT01688531|Drug|CD0271/CD1579, vehicle|
136318|NCT00089609|Biological|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
136319|NCT01688544|Drug|Ilaprazole|Ilaprazole 10 mg for 7 days
136320|NCT01688557|Device|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
137007|NCT01684345|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
137008|NCT01684358|Device|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
137009|NCT01684371|Other|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
137010|NCT01684384|Radiation|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
137011|NCT01687062|Other|FeSO4|
137012|NCT01687062|Other|reduction of phytate|
137013|NCT01687062|Other|NaFeEDTA|
137014|NCT01687075|Device|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
137015|NCT01687101|Drug|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
137016|NCT00089531|Drug|VRC-HIVDNA016-00-VP|
137017|NCT01687114|Other|cranberry juice|27% cranberry juice
137018|NCT01687127|Dietary Supplement|Folic acid|
137019|NCT01687127|Dietary Supplement|5-methyltetrahydrofolate, calcium salt|
137020|NCT01687140|Drug|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
137021|NCT01687140|Drug|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
140056|NCT01646463|Behavioral|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
135969|NCT00089440|Drug|Aripiprazole|
135970|NCT01684995|Drug|nicotine patch|nicotine patch
135971|NCT01684995|Behavioral|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
135972|NCT01685008|Drug|MOR00208 (formerly Xmab 5574)|
135973|NCT01685021|Drug|MOR00208 (formerly Xmab5574)|
135974|NCT01685034|Biological|Allergy immunotherapy ("allergy shots")|
135975|NCT01685060|Drug|LDK378|
135976|NCT01685073|Drug|Zolpidem extended-release|nightly administration of zolpidem extended-release
135977|NCT01687764|Other|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
135978|NCT01687764|Other|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
135979|NCT01687764|Behavioral|Cognitive Behavioral Group Therapy|"FRIENDS for Life" Australian protocol for the treatment of anxiety disorders in children
135980|NCT01687764|Behavioral|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
135981|NCT01687777|Biological|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
136269|NCT01680783|Other|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
136270|NCT01680796|Drug|Dovitinib|Dose Level 0: 200 mg daily
Dose Level 1: 300 mg daily
Dose Level 2: 300 mg daily
Dose Level 3: 400 mg daily
Dose Level 4: 500 mg daily
136271|NCT01680796|Drug|Bortezomib|Dose Level 0: 1.3 mg/m2 IV on days 1 and 8
Dose Level 1: 1.3 mg/m2 IV on days 1 and 8
Dose Level 2: 1.6 mg/m2 IV on days 1 and 8
Dose Level 3: 1.6 mg/m2 IV on days 1 and 8
Dose Level 4: 1.6 mg/m2 IV on days 1 and 8
136272|NCT01680796|Drug|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
136273|NCT01680809|Device|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
136274|NCT00089141|Drug|mycophenolate mofetil|Given orally
139560|NCT01655446|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
139561|NCT00087022|Biological|girentuximab|Given IV
139824|NCT00087074|Other|laboratory biomarker analysis|Optional correlative studies
139825|NCT01655953|Dietary Supplement|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
139826|NCT01655953|Other|Control: high NaCl|7.7 mmol Na/kgBW/d
139827|NCT01655966|Drug|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
139828|NCT01655966|Drug|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
139829|NCT01655979|Dietary Supplement|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
139830|NCT01655979|Other|Control|Bed rest without dietary supplement
139831|NCT01655992|Drug|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
139832|NCT01655992|Drug|S1 generic|40mg／m2 bid four weeks on two weeks off
139833|NCT01656005|Biological|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
139834|NCT01656005|Biological|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
139835|NCT00087087|Drug|pemetrexed disodium|
139836|NCT01656005|Biological|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
139837|NCT01649011|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
139838|NCT00086411|Drug|placebo patch|placebo patch containing no nicotine
139839|NCT01649011|Behavioral|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
139840|NCT01649024|Drug|Tremelimumab|Given IV
139841|NCT01649037|Drug|nor adrenaline and terlipressin|IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.
Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.[ No response defined as MAP < 10, or 4 hr Urine output < 200 ml] with maximum dose upto 3 mg/h.
136321|NCT01688557|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
136322|NCT01688570|Drug|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
136323|NCT01688570|Drug|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
136324|NCT01688570|Drug|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
136325|NCT01688583|Drug|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
136326|NCT01688596|Drug|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
136327|NCT01688609|Drug|lapatinib ditosylate|Given PO
136328|NCT01688609|Drug|paclitaxel|Given IV
136329|NCT00089609|Genetic|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
136330|NCT01680861|Drug|Tacrolimus, Myfortic|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7 days postoperatively - the plan is for corticosteroids to be discontinued by 7 days postoperatively in both groups.
136621|NCT00089297|Radiation|Radiation therapy|Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).
If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
136622|NCT01683500|Device|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
136623|NCT01683513|Drug|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
136624|NCT01683526|Procedure|Direct laryngoscopy|
136625|NCT01683526|Device|Video laryngoscopy (Glidescope)|
136626|NCT01683539|Behavioral|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
140057|NCT01646476|Device|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
140058|NCT01646476|Device|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
140059|NCT01646489|Drug|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
140060|NCT01646489|Drug|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
140061|NCT01646502|Biological|Esp protein|
140062|NCT01646502|Other|Standard wound care|
140063|NCT01646515|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.
Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks
140064|NCT01646515|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
140065|NCT01646528|Procedure|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
140066|NCT00086242|Procedure|quality-of-life assessment|
140067|NCT01646554|Drug|Modified FOLFOX6|
140068|NCT01646554|Biological|Aflibercept|Targeted therapy
140069|NCT01646554|Procedure|Surgery|
140325|NCT01647217|Drug|Terpinen-4-ol|Lid scrub once or twice per day for one month.
140326|NCT01647217|Other|Placebo|Lid scrub once or twice per day for one month
136275|NCT01680809|Device|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
136276|NCT01680835|Device|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat
136277|NCT01680861|Drug|Tacrolimus, Everolimus|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7 days postoperatively - the plan is for corticosteroids to be discontinued by 7 days postoperatively in both groups.
136278|NCT01682889|Dietary Supplement|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
136279|NCT01682889|Dietary Supplement|Placebo|NaCl 0.9% intravenously for 24h
136280|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
136281|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
136282|NCT01682902|Drug|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
136283|NCT01682928|Drug|IV/Oral Hydration and Bedrest|Maternal BP (sitting)
Pulse Pressure
Pulse
Urine Specific Gravity BID
Fetal Heart Rate
Maternal Body Weight US Procedures
AC/EFW
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
AFI (Baseline, day 3, 7 {or Discharge})
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
1 Liter Water PO over 2 hours
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation
Strict I/O's
Vital signs
136564|NCT01686230|Other|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
136565|NCT01686230|Drug|Basic treatment|Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.
We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.
Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
136566|NCT00089479|Drug|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
136567|NCT01686243|Other|epidural needle placement with echogenic 17G touhy needles (Pajunk TouhySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G touhy needles (Pajunk TouhySono)
139842|NCT01649037|Drug|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response [< 25% decrease in s.creatinine] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
139843|NCT01649050|Drug|BGG492|
139844|NCT01649050|Drug|Placebo|
139845|NCT01649089|Procedure|Conization|Undergo cone biopsy
140093|NCT01639599|Drug|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
140094|NCT01639599|Drug|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
140095|NCT01639612|Biological|ALD-451|ALD-451 iv
140096|NCT01639625|Drug|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
140097|NCT01639638|Drug|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
140098|NCT01639651|Other|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
140099|NCT01641718|Drug|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
140100|NCT01641718|Device|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
140101|NCT01641731|Other|Cow's milk|Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.
Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached.
140102|NCT01641744|Behavioral|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
140103|NCT01641744|Behavioral|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
140104|NCT00085735|Drug|vincristine sulfate|Given IV
140105|NCT01641757|Procedure|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
140106|NCT01641770|Other|Nutritional beverage 10003RF|2 sachets per day
140107|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
140108|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
136627|NCT01683539|Behavioral|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
136628|NCT01683552|Drug|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
136629|NCT01683552|Drug|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
136630|NCT01683552|Drug|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
136631|NCT01683565|Drug|LCPUFA oil supplement|2.5mL per day for 90 days
Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)
136632|NCT00089310|Radiation|technetium-99|0.25 mCi in 4 equal doses
136633|NCT01683565|Other|Canola Oil Placebo|2.5mL per day for 90 days
136634|NCT01683578|Other|Variable Ventilation|
136635|NCT01683591|Procedure|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
136636|NCT01683617|Behavioral|Coping skills and relaxation training with new technologies|
136637|NCT01683617|Behavioral|Traditional coping skills and relaxation training|
136638|NCT01683643|Behavioral|SBIRT|Screening, brief intervention, and referral to treatment.
136639|NCT01683643|Behavioral|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
136940|NCT01679379|Procedure|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
136941|NCT01679392|Drug|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
136942|NCT01679405|Drug|BIBW 2992|single arm study
136943|NCT00089063|Biological|gp100 antigen|Given SC
136944|NCT01679418|Device|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
136945|NCT01679418|Other|No-drain after surgery|After surgery, no drain was put
140327|NCT00086281|Drug|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
140328|NCT01647243|Other|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
140329|NCT01647256|Drug|Nikkomycin Z|Capsule, 500 mg, single-dose
140330|NCT01647269|Procedure|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
140331|NCT01647282|Drug|locally-applied minocycline HCl (1 mg)|
140332|NCT01647282|Procedure|scaling and root planing (Sc/RP)|
140333|NCT01647308|Drug|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
140334|NCT01647308|Drug|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
140335|NCT01647321|Behavioral|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
140336|NCT01647321|Behavioral|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
140337|NCT01647334|Radiation|Adaptive radiotherapy|
140338|NCT00086281|Drug|Zolpidem (Z)|Zolpidem 10 mg oral tablets
140339|NCT01647347|Drug|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
140340|NCT01647347|Other|Water|
140341|NCT01647412|Drug|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
140342|NCT01647412|Dietary Supplement|Nutraceutical Combination|
140343|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
140344|NCT01640080|Drug|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
140345|NCT00085553|Drug|Tipifarnib|Given PO
136568|NCT01686243|Other|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
136569|NCT01686256|Drug|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
136570|NCT01686269|Procedure|blood collecting|
136571|NCT01686282|Dietary Supplement|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
136572|NCT01686282|Dietary Supplement|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
136573|NCT01686295|Device|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
136574|NCT01686295|Device|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
136575|NCT01688609|Biological|trastuzumab|Given IV
136576|NCT01688609|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
136577|NCT01688609|Other|pharmacological study|Correlative studies
136578|NCT01688609|Other|laboratory biomarker analysis|Correlative studies
136579|NCT01688622|Behavioral|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
136580|NCT01688635|Drug|LY2963016|Administered subcutaneously
136581|NCT01688635|Drug|US Approved Lantus|Administered subcutaneously
136582|NCT01688648|Drug|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
136878|NCT01681758|Other|IV fluid according to PPV|intravenous fluids
136879|NCT01681758|Other|fluids according to standard care|
136880|NCT01681771|Behavioral|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
136881|NCT01681771|Behavioral|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
140109|NCT01641783|Drug|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
140110|NCT01641796|Drug|WR 279,396|Topical Cream applied to lesion once a day
140111|NCT01641809|Drug|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
140112|NCT01641809|Drug|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
140443|NCT01640275|Drug|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
140444|NCT01640275|Drug|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
140445|NCT01640288|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
140446|NCT00085579|Biological|aldesleukin|
140447|NCT01640288|Other|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
140448|NCT01640301|Biological|Aldesleukin|Given SC
140449|NCT01640301|Other|Laboratory Biomarker Analysis|Correlative studies
140450|NCT01640301|Biological|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
140451|NCT01640314|Biological|Cell derived subunit trivalent nonadjuvanted vaccine|A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
140452|NCT01640327|Biological|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
140453|NCT01640340|Drug|aprepitant|Given by mouth
140454|NCT01640340|Drug|palonosetron hydrochloride|Given IV(intervenous infusion)
140455|NCT01640340|Drug|ondansetron|Given PO
140456|NCT01640340|Drug|dexamethasone|Given PO
140457|NCT00085579|Biological|sargramostim|
140458|NCT01642316|Other|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
136946|NCT01679431|Other|Doppler-echocardiography|
136947|NCT01679431|Radiation|Computed tomography|
136948|NCT01679431|Other|Magnetic resonance imaging|
136949|NCT01679431|Biological|Fasting blood sample|
136950|NCT01679444|Procedure|Magnetic Resonance Spectroscopy|
136951|NCT01679457|Behavioral|ACT-Focused ERP|
136952|NCT01679457|Behavioral|TAU-ERP|
136953|NCT01679470|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
136954|NCT00089063|Biological|MART-1 antigen|Given SC
136955|NCT01679483|Drug|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
136956|NCT01679496|Other|Food items|Food items with different fatty acid composition
136957|NCT01679509|Procedure|Single-port laparoscopic adnexal surgery|
136958|NCT01679509|Procedure|Three-port laparoscopic adnexal surgery|
136959|NCT01679522|Procedure|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
136960|NCT01679522|Procedure|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
136961|NCT01679535|Behavioral|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
136962|NCT01679548|Procedure|Single-port LAVH|
136963|NCT01679548|Procedure|Three-port LAVH|
136036|NCT01682681|Drug|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
136037|NCT01685073|Behavioral|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
136038|NCT01685125|Drug|abiraterone acetate|Given PO
140346|NCT01640093|Drug|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
140659|NCT01645033|Other|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
140660|NCT01647594|Behavioral|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
140661|NCT01647607|Behavioral|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
140662|NCT01647607|Behavioral|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
140663|NCT01647620|Drug|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
140664|NCT01647620|Drug|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
140665|NCT01647633|Other|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
140666|NCT00086294|Drug|Intravenous Levodopa|
140667|NCT01647646|Drug|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
140668|NCT01647659|Drug|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
140669|NCT01647659|Drug|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
140670|NCT01647672|Drug|Abraxane|Abraxane for neoadjuvant chemotherapy
140671|NCT01647685|Drug|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
140672|NCT01647685|Drug|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
140673|NCT01647685|Drug|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
140674|NCT01647698|Behavioral|Adaptive working memory training task|The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.
Adaptive refers to the increase in the number of items that the patient is required to remember.
140675|NCT01647698|Behavioral|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
136882|NCT01681797|Device|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
136883|NCT01681810|Drug|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg TID for 12 weeks
136884|NCT00089193|Biological|multi-epitope melanoma peptide vaccine|
136885|NCT01681823|Dietary Supplement|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
136886|NCT01681836|Drug|Non-radioactive "heavy" 15N-labeled sodium nitrite|15N-labeled sodium nitrite 20 mg once
136887|NCT01681836|Drug|15N-labeled sodium nitrate|15N-labeled sodium nitrate 1,000 mg once
136888|NCT01681849|Drug|Placebo|Following the double blind phase, subjects are treated with open label paroxetine at a variable dosage of 10-40 mg followed by PET imaging of the brain with O-15 radiolabelled water.
136889|NCT01681849|Drug|Paroxetine|Following the double blind phase, subjects are treated with open label paroxetine at a variable dosage of 10-40 mg followed by PET imaging of the brain with O-15 radiolabelled water.
136890|NCT01684059|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
136891|NCT01684072|Biological|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
136892|NCT01684072|Biological|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
136893|NCT01684085|Behavioral|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
136894|NCT01684085|Behavioral|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
136895|NCT01684085|Drug|Lorazepam|Lorazepam 1 mg
136896|NCT01684098|Drug|Tc 99m EC20|
136897|NCT01684111|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
136898|NCT01684111|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
135982|NCT01687777|Biological|OrthADAPT|
135983|NCT01687790|Device|molecular breast imaging (Discovery)|
135984|NCT00089557|Drug|Capsaicin Dermal Patch|
140459|NCT01642316|Other|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
140460|NCT01642342|Other|laboratory biomarker analysis|Correlative studies
140461|NCT01642342|Other|pharmacological study|Correlative studies
140462|NCT01642342|Biological|recombinant albumin fusion protein sEphB4-HSA|Given IV
140463|NCT00085813|Drug|Ispinesib|
140464|NCT01642355|Behavioral|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
139562|NCT01655446|Behavioral|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
139563|NCT01655446|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
139564|NCT01655446|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
139565|NCT01655459|Procedure|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
139566|NCT01655472|Device|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
139567|NCT01655472|Device|imaging follow up: Ultrasonographic examination|
139568|NCT01655485|Other|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
139569|NCT01655498|Device|vaginal bowel control system (LivSure)|
139570|NCT01655511|Drug|Tafamidis|240 mg, solution, single dose
139571|NCT01655511|Drug|Tafamidis|480 mg, solution, single dose
139572|NCT00001629|Drug|Angiotensin II type 1 receptor antagonists|
139573|NCT00087022|Other|placebo|Given IV
136039|NCT01685125|Drug|dasatinib|Given PO
136040|NCT00089453|Drug|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
136041|NCT01685125|Drug|prednisone|Given PO
136042|NCT01685138|Drug|LDK378|Oral LDK378 750 mg once daily
136043|NCT01685151|Drug|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
136044|NCT01685151|Drug|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
136045|NCT01685151|Drug|Placebo|Placebo
136046|NCT01685164|Other|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
136047|NCT01685190|Radiation|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
136048|NCT01685190|Radiation|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
136049|NCT01685203|Drug|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
136050|NCT01685203|Drug|ABT-267|Tablet
136051|NCT00089453|Drug|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
136052|NCT01685203|Drug|Ribavirin (RBV)|Tablet
136053|NCT01685216|Biological|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
136054|NCT01685229|Device|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
136055|NCT01685242|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
136056|NCT01685242|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
136057|NCT01685255|Drug|INCB024360|
140676|NCT01647698|Behavioral|No training|No training during the experiment.
140677|NCT00086294|Drug|ACP-103|
140678|NCT01647711|Drug|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
139760|NCT01648972|Drug|Placebo|
139761|NCT01648985|Other|diabetes in stroke and TIA|
139762|NCT01648998|Drug|Fludrocortisone|single dose 500 mg, capsule
139763|NCT01648998|Drug|Placebo|
139764|NCT01651351|Biological|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
139765|NCT00086710|Drug|Fuzeon|
139766|NCT01651351|Biological|Placebo: Human albumin 2.5%|Intravenous administration
139767|NCT01651364|Drug|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
139768|NCT01651364|Drug|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
139769|NCT01651377|Drug|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
139770|NCT01651377|Drug|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
139771|NCT01651390|Device|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
139772|NCT01651390|Device|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
139773|NCT01651403|Drug|Tenofovir DF|Participants ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).
Participants < 17 kg and participants ≥ 17 kg who are unable to swallow a tablet will receive oral powder containing 40 mg of TDF once daily.
139774|NCT01651403|Drug|Placebo to match TDF|Matching placebo oral tablet / oral powder
Participants ≥ 17 kg will receive one tablet of placebo to match TDF administered orally once daily
Participants < 17 kg and participants ≥ 17 kg who are unable to swallow a tablet will receive placebo to match TDF oral powder once daily
139775|NCT01651416|Drug|Artemether-lumefantrine combination|
135985|NCT01687803|Behavioral|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
135986|NCT01687803|Behavioral|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
135987|NCT01687842|Other|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
135988|NCT01687855|Device|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
135989|NCT01687868|Drug|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
135990|NCT01687881|Other|Chiropractic|Chiropractic Spinal Manipulative Therapy
135991|NCT01687881|Other|Sham Chiropractic|Sham manipulation
135992|NCT01687894|Drug|Vasopressins|Vasopressins propofol vasopressins sevoflurane
135993|NCT01687894|Drug|Placebo|Placebo propofol & placebo sevoflurane
135994|NCT01687894|Drug|propofol|vasopressin propofol & placebo propofol
135995|NCT00089570|Drug|terlipressin|
135996|NCT01687894|Drug|sevoflurane|vasopressins sevoflurane placebo sevoflurane
135997|NCT01687907|Behavioral|Music|
135998|NCT01687920|Drug|BAY94-8862 (1.25mg)|
135999|NCT01687920|Drug|BAY94-8862 (2.5mg)|
136000|NCT01680263|Procedure|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
136001|NCT01680276|Behavioral|PBS based staff training|Please see published study protocol for more information:
http://www.biomedcentral.com/1471-244X/14/219
136002|NCT01680276|Other|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
136003|NCT00089102|Drug|gemcitabine hydrochloride|
139574|NCT01655511|Drug|Tafamidis|TBD dose will be a single dose if < 720 mg or a loading dose followed by additional dose if > 720 mg.
139575|NCT01655524|Drug|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
139576|NCT01655550|Other|Withhold oral contrast|The intervention is to withhold oral contrast
139577|NCT01655563|Drug|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
139578|NCT01655576|Procedure|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
139579|NCT01648582|Drug|Sulfonylureas|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
139846|NCT01649089|Other|Quality-of-Life Assessment|Ancillary studies
139847|NCT01649089|Other|Questionnaire Administration|Ancillary studies
139848|NCT01649089|Procedure|Therapeutic Conventional Surgery|Undergo hysterectomy
139849|NCT00086411|Drug|placebo bupropion|placebo pills
139850|NCT01649089|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
139851|NCT01649102|Device|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|A tunneled cuffed catheter is inserted, randomization between:
Palindroom
Hemoglide Bard
139852|NCT01649115|Other|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
139853|NCT01649141|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
139854|NCT01649154|Procedure|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
139855|NCT01649180|Drug|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
136331|NCT01680874|Dietary Supplement|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
136332|NCT01680874|Dietary Supplement|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
136333|NCT01680887|Drug|Varenicline|
136334|NCT01680887|Drug|Placebo|
136335|NCT01680900|Drug|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
136336|NCT01680900|Drug|placebo capsules|placebo capsules matched to drug capsules.
136337|NCT00001688|Drug|Nevirapine|
136338|NCT00089141|Drug|placebo|Given orally
136339|NCT01680913|Procedure|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
136340|NCT01680913|Procedure|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
136341|NCT01680913|Procedure|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
136342|NCT01680926|Dietary Supplement|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
136343|NCT01680939|Drug|Morphine|0.2-0.5 mg/kg PO q4h
136344|NCT01680939|Drug|Ibuprofen|10mg/kg PO q6hrs
136345|NCT01680952|Drug|A) TEST|Extended Release Tacrolimus (Advagraf®)
① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.
② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.
Sirolimus (Rapamune®):
After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level.
139776|NCT00086723|Biological|recombinant tissue plasminogen activator|
139777|NCT01651416|Drug|Dihydroartemisinin Piperaquine combination|
139778|NCT01651416|Drug|Amodiaquine plus sulphadoxine-pyrimethamine combination|
139779|NCT01651429|Behavioral|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
139780|NCT01651442|Behavioral|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
140347|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
140348|NCT01640093|Drug|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
140349|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
140350|NCT01640106|Dietary Supplement|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
140351|NCT01640106|Dietary Supplement|Placebo|
140352|NCT01640119|Dietary Supplement|Bicarbonate|bicarbonate administration
140353|NCT01640145|Dietary Supplement|Protein|Whey protein intake
140354|NCT01640145|Other|Exercise|Unilateral low intensity exercise
140355|NCT01640158|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
140356|NCT00085566|Drug|everolimus|
140357|NCT01640158|Other|Commercially available computerized training|Commercially available computerized training, up to 65 hours
140358|NCT01640171|Procedure|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
140359|NCT01640171|Drug|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
140360|NCT01640171|Drug|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
140361|NCT01640171|Drug|Acuvail|Anti-inflammatory drop given after treatment
140362|NCT01640171|Drug|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
136284|NCT00089284|Drug|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
136285|NCT01682928|Other|Hydrotherapy|Maternal BP (sitting)
Pulse Pressure
Pulse
Urine Specific Gravity BID
Fetal Heart Rate
Maternal Body Weight US Procedures
AC/EFW
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
o 1 hour +/- 30 minutes after submersion therapy
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
o 1 hour +/- 30 minutes after submersion therapy
AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
1 Liter Water PO over 2 hours
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation
Strict I/O's
Vital signs
HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy
136286|NCT01682941|Dietary Supplement|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
136287|NCT01682941|Dietary Supplement|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
136288|NCT01682954|Behavioral|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
136289|NCT01682980|Other|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
136290|NCT01682980|Other|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
136291|NCT01685606|Biological|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
136292|NCT01685632|Procedure|Surgery with IPCH|surgical debulking and extensive tumoral resection after laparotomy under general anesthesia
7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).
6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH
136293|NCT01685632|Procedure|Without surgery and without IPCH|The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.
7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).
6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH
139856|NCT01649193|Other|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
139857|NCT01649206|Procedure|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
139858|NCT01649219|Behavioral|Exercise|
139859|NCT01651494|Drug|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
139860|NCT01651494|Drug|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
139861|NCT01651520|Drug|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
139862|NCT01651533|Behavioral|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
139863|NCT01651533|Behavioral|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
140113|NCT01641809|Drug|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
140114|NCT01641809|Drug|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
140115|NCT00085735|Radiation|radiation therapy|Given on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47 (weeks 0-6) at different doses.
140116|NCT01641809|Drug|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
140117|NCT01641809|Drug|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
140118|NCT01641809|Drug|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
140119|NCT01641822|Drug|Aztreonam for Inhalation Solution (AZLI)|75 mg (1 ml) of aztreonam, supplied as Aztreonam for Inhalation Solution (AZLI) administered three times a day for 28 days per course.
140120|NCT01641822|Drug|Placebo|Sugar solution for inhalation administered three times a day for 28 days per course.
136346|NCT01680952|Drug|B) CONTROL|Extended Release Tacrolimus (Advagraf®)
: Same as above.
Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid
136640|NCT01683656|Drug|niacin/laropiprant|
136641|NCT01683656|Drug|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
136642|NCT01686308|Procedure|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
136643|NCT01686308|Procedure|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
136644|NCT00089492|Drug|Optimized Background ARVs|As prescribed
136645|NCT01686321|Drug|Bendamustine and subcutaneous rituximab|
136646|NCT01686334|Biological|DC vaccine|Autologous WT1 mRNA-electroporated DCs
136647|NCT01686347|Drug|ropivacaine|
136648|NCT01686360|Behavioral|Decision Aid|
136649|NCT01686373|Device|Activa Dose II Real tDCS|
136650|NCT01686373|Device|Activa Dose II Sham tDCS|
136651|NCT01686386|Drug|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
136652|NCT01686386|Drug|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
136653|NCT01686386|Drug|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
136654|NCT01686399|Behavioral|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
136655|NCT00089492|Drug|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
136656|NCT01686412|Device|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
136657|NCT01686425|Procedure|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
140363|NCT01640184|Procedure|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
140364|NCT01640184|Drug|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
140365|NCT01640184|Procedure|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
140366|NCT01642160|Behavioral|Standard of care|participants will receive education from staff nurses as needed.
140388|NCT01642277|Drug|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
140389|NCT01642303|Other|vodcasting|listening to downloaded vodcasting files
140390|NCT01642303|Other|no intervension|Listen to student book listening files
140391|NCT01644474|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
140392|NCT01644474|Drug|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
140393|NCT01644474|Drug|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
140394|NCT01644487|Device|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
140395|NCT01644487|Device|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
140396|NCT00086047|Behavioral|Education|8 weekly sessions of fibromyalgia education
140397|NCT01644500|Drug|Dulaglutide|Administered SC
140398|NCT01644500|Drug|Glimepiride|Administered orally
140399|NCT01644500|Drug|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
140400|NCT01644500|Drug|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
140401|NCT01644526|Device|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
136294|NCT01685645|Device|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
136583|NCT01688648|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
136584|NCT01688674|Drug|10% dextrose|
136585|NCT00089609|Other|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
136586|NCT01688687|Procedure|Endoscopic submucosal dissection|
136587|NCT01688700|Drug|Nimotuzumab combined with paclitaxel and cisplatin|Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
Cisplatin: 75mg/m2,IV on days 1，22
paclitaxel: 90mg/m2, IV on days 1,8,22,29.
patients will receive radical operation 4-6 weeks after Neoadjuvant therapy.
136588|NCT01688713|Drug|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
136589|NCT01688726|Other|SYSTANE® BALANCE eyedrops|
136590|NCT01688726|Other|Minims® Saline 0.9% eyedrops|
136591|NCT01688739|Drug|AMG 334|6 dose levels of AMG 334/Placebo administered as single doses SC or IV in healthy volunteers and migraine patients.
136592|NCT01688778|Behavioral|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.
Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks.
136593|NCT01688791|Drug|Vintafolide|
136594|NCT01688791|Drug|Carboplatin|
136595|NCT01688791|Drug|Paclitaxel|
136596|NCT00089609|Other|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
136597|NCT01688947|Drug|V116517 50-mg tablets|Taken orally twice daily
136598|NCT01688947|Drug|V116517 30-mg tablets|Taken orally twice daily
136599|NCT00089622|Drug|Intravenous Levodopa|
140121|NCT01643993|Other|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
140122|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
140123|NCT01644006|Procedure|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
140124|NCT01644019|Procedure|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
140125|NCT01644032|Other|Teleconsultation|Teleconsultation between paramedics and an EMS physician
140126|NCT01644045|Device|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
140127|NCT00085969|Drug|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
140128|NCT01644058|Procedure|Immediate loading|
140129|NCT01644071|Drug|cipralex|one time 10 mg, tablet
140130|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
140131|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
140132|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
140465|NCT01642355|Behavioral|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
140466|NCT01642368|Other|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
140467|NCT01642381|Behavioral|Full Motivational Interviewing ("FMI")|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
140468|NCT01642381|Behavioral|Spirit Only Motivational Interviewing ("SOMI")|Empathic and non-directive counselling based on Rogerian psychotherapy model.
140469|NCT01642394|Behavioral|Diabetes Self-Management Program|The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.
Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader.
136658|NCT01686438|Behavioral|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
136659|NCT01686451|Drug|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
136660|NCT01686451|Drug|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
136964|NCT01679561|Drug|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
136965|NCT00089063|Biological|incomplete Freund's adjuvant|Given SC
136966|NCT01679574|Drug|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
136967|NCT01679574|Drug|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
136968|NCT01681862|Behavioral|Personal Health Record|Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications "Your Guide to Lowering Blood Pressure" and "Facts about the DASH Eating Plan."
136969|NCT01681875|Other|very low nicotine content cigarettes|
136970|NCT01681888|Device|Sanger EMG Biofeedback Device|
136971|NCT01681901|Procedure|ultrasound imaging|Undergo ultrasound
136972|NCT01681940|Drug|Lamazym|ERT, i.v. infusions weekly
136973|NCT00089193|Biological|sargramostim|
136974|NCT01681953|Drug|Lamazym|ERT, i.v. infusions weekly
136975|NCT01681953|Drug|Placebo|Infusions weekly
136976|NCT01681966|Drug|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
136977|NCT01681979|Drug|Fluticasone propionate (with and without concurrent salmeterol)|Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.
Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose.
140402|NCT01644539|Dietary Supplement|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
140403|NCT01644539|Dietary Supplement|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
140404|NCT01644539|Dietary Supplement|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
140405|NCT01644565|Biological|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
140406|NCT01644565|Biological|Recombinant fimbrial adhesin dscCfaE|
140679|NCT01647737|Dietary Supplement|MighTeaFlow|4-6 times daily
140680|NCT01647737|Dietary Supplement|Xylitol|4-6 times daily
140681|NCT01647750|Drug|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
140682|NCT01647750|Drug|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
140683|NCT01648309|Other|Neuropsychological testing|This is an observational study
140684|NCT01640678|Procedure|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
140685|NCT01640678|Procedure|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
140686|NCT01640691|Biological|Pandemic Influenza Vaccine (H5N1)|Inactivated whole-virion vaccine
Administration route: Intramuscular Injection
Dosing schedule: 2 injections - at Day 1 and Day 22 separately
Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)
140687|NCT01640704|Behavioral|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
140688|NCT01640730|Drug|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
140689|NCT00001586|Other|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
140690|NCT00085631|Radiation|brachytherapy|Patients undergo brachytherapy for 2-3 days
136600|NCT01681251|Other|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.
Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV.
136899|NCT01684124|Other|conservative O2 therapy|target lower O2 saturation
136900|NCT00001696|Drug|Genistein|
136901|NCT00089362|Other|laboratory biomarker analysis|Correlative studies
136902|NCT01684124|Other|standard care|
136903|NCT01684137|Dietary Supplement|Joalis Bambi Analerg|
136904|NCT01684137|Dietary Supplement|Joalis Bambi Bronchi|
136905|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
136906|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
136907|NCT01684150|Drug|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
136908|NCT01684163|Drug|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
136909|NCT01684163|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
136910|NCT01684163|Drug|Placebo|Intravenous administration of normal saline into arm.
136911|NCT01684176|Behavioral|Complex tailored intervention|
136912|NCT00089362|Other|pharmacological study|Correlative studies
136913|NCT01684176|Behavioral|Usual care|
136914|NCT01684189|Other|Patient registry|Patient registry without study intervention
136915|NCT01684202|Drug|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
136916|NCT01684215|Drug|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
140470|NCT01642407|Drug|Sildenafil|Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
140471|NCT01642433|Drug|Placebo|Placebo capsules, 3x daily
140472|NCT01642433|Drug|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
140473|NCT01642446|Procedure|Precise hepatectomy|Precise hepatectomy
140474|NCT00085826|Drug|Exisulind|
140475|NCT01642446|Other|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
140476|NCT01642459|Other|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
140477|NCT01642459|Other|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
140478|NCT01644591|Behavioral|Cognitive Function Tests|7 cognitive function tests given at baseline and at 1, 4, 6, 9, and 12 months after Day 1 of radiation treatment.
140479|NCT01644591|Behavioral|Questionnaires|3 questionnaires regarding quality of life and symptoms given at baseline and at 1, 4, 6, 9, and 12 months after Day 1 of radiation treatment. It should take about 40 minutes to complete the questionnaires.
140480|NCT01644604|Device|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
140481|NCT01644617|Drug|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
140482|NCT01644617|Drug|MK-8237 6 Development Units (DU)|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
139580|NCT01648595|Drug|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
139581|NCT01648608|Drug|Exemestane|Exemestane for neoadjuvant chemotherapy
139582|NCT00086398|Behavioral|Behavior Therapy|
139583|NCT01648621|Behavioral|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
139584|NCT01648621|Behavioral|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
139585|NCT01648621|Behavioral|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
136978|NCT01681992|Biological|GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762)|Single dose administered subcutaneously (SC) of either Inv_MMR_Min or Inv_MMR_Med depending on group assigned followed by a second SC injection of Inv_MMR_Release about 6 weeks later.
136979|NCT01681992|Biological|Merck &amp; Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live|Single dose administered by SC injection of either Com_MMR_L1 or Com_MMR_L2 depending on group assigned followed by a second dose SC injection of either Com_MMR_L1 or Com_MMR_L2 about 6 weeks later.
136980|NCT01681992|Biological|Varivax® (Merck & Co., Inc.)|Single dose SC injection administered at Visit 1 (Day 0) with either one of two Inv_MMR vaccine lots (Inv_MMR_Min or Inv_MMR_Med) or one of two active control Com_MMR vaccine lots (Com_MMR_L1 and Com_MMR_L2).
136058|NCT01685255|Drug|tamoxifen|
136059|NCT01685268|Drug|AT13387 and abiraterone|Parallel
136060|NCT01685268|Drug|AT13387 alone|Parallel
136061|NCT01685281|Drug|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
136062|NCT00089453|Drug|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period <or= 20 minutes on day -1.
136063|NCT01687920|Drug|BAY94-8862 (5mg)|
136064|NCT01687920|Drug|BAY94-8862 (7.5mg)|
136065|NCT01687920|Drug|BAY94-8862 (10mg)|
136066|NCT01687933|Device|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
136067|NCT01687933|Other|usual care|Women in Control group did not use the glasses.
136068|NCT01687959|Other|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
136069|NCT00089583|Drug|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
136070|NCT01687972|Device|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
136071|NCT01687972|Device|Absorbable sutures|placement of absorbable sutures at cesarean section
136072|NCT01687985|Drug|BLI801 laxative - low dose|BLI801 laxative - oral solution
136073|NCT01687985|Drug|BLI801 laxative - high dose|BLI801 laxative - oral solution
136074|NCT01687998|Drug|Evacetrapib|Administered Orally
140691|NCT01640743|Drug|Tacrolimus + Methylprednisolone|Induction therapy:
Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.
Maintenance therapy:
Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
140692|NCT01640743|Drug|Tacrolimus + Everolimus + Methylprednisolone|Induction therapy:
Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).
Maintenance therapy:
Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
140693|NCT01640756|Device|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
140694|NCT01640769|Procedure|Image guided delivery of cardiac pacing leads.|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm).
140695|NCT01640769|Procedure|Standard delivery of cardiac pacing leads.|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
139781|NCT01651442|Drug|Zolpidem|5mg or 10mg
139782|NCT01651442|Drug|Trazodone|50mg to 150mg
139783|NCT01651442|Behavioral|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
139784|NCT01651468|Dietary Supplement|HEMOFIX|unique complex herbal mixture
139785|NCT01651481|Drug|HCP1102|
139786|NCT01651481|Drug|Singulair and Xyzal|
139787|NCT00086723|Drug|captopril|
139788|NCT01653535|Behavioral|Anti-Social Behavior Prevention Program|The intervention began in 1991 of the 1st grade year and continued through the end of the 10th grade. A central feature of the program during the first school year was a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and occasionally teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In the third and fourth grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. For the 5th and 6th grades, intervention included monthly parent and child groups, and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking and study skills. After each cohort finished 10th grade, the intervention portion of the project was completed.
139789|NCT01653548|Behavioral|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
139790|NCT01653548|Behavioral|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
136917|NCT01686854|Behavioral|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
136918|NCT01686854|Other|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
136004|NCT01680289|Procedure|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
136005|NCT01680289|Procedure|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
136006|NCT01680302|Behavioral|High intensity exercise|
136007|NCT01680302|Behavioral|Moderate intensity exercise|
136008|NCT01680302|Behavioral|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
136009|NCT01680315|Behavioral|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
136010|NCT01680315|Behavioral|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
136011|NCT01680328|Other|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
136012|NCT01680328|Drug|sodium chloride 0.9% solution|Solution for injection.
136013|NCT01680341|Drug|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
136014|NCT00089102|Drug|irinotecan hydrochloride|
136015|NCT01680341|Drug|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
136016|NCT01680354|Procedure|ReLEx|
136017|NCT01680354|Procedure|LASIK|
139586|NCT01648621|Behavioral|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
139587|NCT01648621|Behavioral|Tele-home monitoring|Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.
Inclusion criteria for tele-home monitoring:
a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness [MRC] Class 4 & 5 or modified MRC [mMRC] 3 & 4) f. frequent ED visits (> 2) in last 12 months
5. 12 weeks of clinical stability with no ED visits.
139588|NCT01648621|Behavioral|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
139589|NCT01648621|Behavioral|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
139590|NCT01648621|Behavioral|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
139591|NCT01648621|Behavioral|in-hospital rehabilitation/self-management program|Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:
have had a recent exacerbation, but are now clinically stable;
symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;
have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and
have sufficient motivation to participate.
139592|NCT01648621|Behavioral|Smoking cessation|Referral to a smoking cessation program (as applicable)
139593|NCT00086411|Drug|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
139864|NCT01651546|Behavioral|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
139865|NCT01651572|Drug|Cisatracurium|Cisatracurium (Nimbex):
initial dose: 0.2 mg/kg
maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)
139866|NCT01651572|Drug|Rocuronium|Rocuronium (Esmeron):
initial dose: 0.6 mg/kg
maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)
139867|NCT01651585|Drug|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
139868|NCT01651598|Drug|Placebo to BI 144807|multiple dose (bid)
139869|NCT00086736|Drug|bicalutamide|
136075|NCT01687998|Drug|Placebo|Administered Orally
136076|NCT01688024|Drug|Mitomycin C|
136077|NCT01688024|Drug|Normal saline|
136078|NCT01688037|Drug|NBI-98854|25 mg capsule
136079|NCT01688037|Drug|NBI-98854|50 mg capsule
136080|NCT00089583|Drug|Ritonavir|Ritonavir solution bid
136081|NCT01688037|Drug|Placebo|
136082|NCT01688050|Device|Zenith® TX2® Low Profile Endovascular Graft|Zenith® TX2® Low Profile Endovascular Graft
136347|NCT01682993|Other|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
136348|NCT01682993|Other|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
136349|NCT01683006|Drug|Rocuronium|Continuous application of Rocuronium (0.5 mg/kg body weight/hour).
Bolus application of placebo in case of shivering.
136350|NCT01683006|Drug|Placebo|Continuous application of placebo during therapeutic hypothermia.
Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering.
136351|NCT00089284|Drug|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
136352|NCT01683019|Device|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
136353|NCT01683019|Device|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
136354|NCT01683032|Drug|MPH|a capsule containing 20 mg
136355|NCT01683045|Device|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
136356|NCT01683058|Drug|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
136357|NCT01683071|Drug|EXPAREL|EXPAREL 67 mg, 133 mg, or 266 mg
139791|NCT01653548|Behavioral|Habituation|Participants will habituate to personally-relevant stressor.
139792|NCT01653561|Drug|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
139793|NCT01653574|Drug|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
139794|NCT01653587|Device|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
139795|NCT00086931|Procedure|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
139796|NCT01653600|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
139797|NCT01653600|Device|LifeStent|same to SMART STENT
140367|NCT01642173|Device|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
140368|NCT01642186|Drug|everolimus|
140369|NCT01642186|Drug|letrozole plus leuprolide|
140370|NCT01642186|Drug|combination of everolimus, letrozole and leuprolide|
140371|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
140372|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
140373|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
140374|NCT00085774|Drug|placebo aerosol by HFA|placebo HFA
136018|NCT01680367|Procedure|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
136019|NCT01680367|Procedure|wound care management|Receive native collagen wound dressing
136020|NCT01680367|Other|questionnaire administration|Ancillary studies
136021|NCT01682551|Drug|Chinese Medicine|The participators in this arm will take 2g (powder in capsule) of "Wu Zhu Yu Tang" or placebo orally three times in the first day and one time in the second day.
136295|NCT01685658|Drug|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
136296|NCT01685658|Drug|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
136297|NCT01685671|Drug|NESP 60μg|Administrated NESP 60μg once subcutaneously
136298|NCT00089453|Procedure|Infusion #1|Infusion of donor NK Cells #1 on day 0
136299|NCT01685671|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
136300|NCT01685684|Drug|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
136301|NCT01685684|Drug|Placebo|Placebo, divided into 2 doses, q12h
136302|NCT01685697|Procedure|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
136303|NCT01685697|Procedure|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
136304|NCT01685710|Drug|GTN patch|
136305|NCT01685710|Drug|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
136306|NCT01685723|Behavioral|Counseling group|Subjects in this group will receive treatments in the form of improved risk communication measures. These measures include brief advice by oncologist or oncology nurses, a special design leaflet, face-to-face individualized risk communication counselling by nurse counselor, and follow-up telephone counselling emphasizing on risk communication.
136307|NCT01685723|Behavioral|General supporting|Subjects in this group will receive:
Usual care by oncologist or nurse;
General care and support by nurse counselor (5 minutes);
Generic self-help smoking cessation booklet; and
Multiple telephone follow-ups (up to 8 sessions) to show support and care for patients' disease condition (5 minutes).
136308|NCT01685762|Drug|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
139870|NCT01651598|Drug|BI 144807|multiple dose (bid, low to high dose)
139871|NCT01651611|Behavioral|Motivational interviewing|
139872|NCT01651611|Behavioral|Smoking cessation counseling|
139873|NCT01651611|Behavioral|Navigation to smoking cessation resources|
139874|NCT01651611|Behavioral|Social support|
139875|NCT01651624|Other|Invitation to screening|
139876|NCT01651637|Drug|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
139877|NCT01651650|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
139878|NCT01651663|Drug|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
139879|NCT01651663|Other|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
139880|NCT00086736|Drug|eflornithine|
139881|NCT01651663|Drug|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
139882|NCT01651663|Other|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
139883|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
139884|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
139885|NCT01653652|Dietary Supplement|Probiotic|
139886|NCT01653652|Dietary Supplement|Maltodextrin|
140133|NCT01644097|Dietary Supplement|Lactobacillus plantarum strain 299v|Given PO
140134|NCT01644097|Dietary Supplement|Lactobacillus acidophilus probiotic|Given PO
140135|NCT01644097|Dietary Supplement|placebo|Given PO
140136|NCT01644097|Other|laboratory biomarker analysis|Correlative studies
136358|NCT01683071|Drug|Placebo|Normal saline 20 mL
136359|NCT01683084|Drug|Telmisartan|
136360|NCT01683084|Drug|Placebo|
136361|NCT01683097|Other|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
136362|NCT00089284|Drug|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
136363|NCT01683110|Drug|cabozantinib|
136661|NCT01686464|Drug|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
136662|NCT01686464|Device|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2~3.0 L / min for the same duration during all acupuncture sections.
136663|NCT01686477|Other|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
136664|NCT01686477|Other|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
136665|NCT01686477|Other|Preterm Formula used when there is a shortfall in mother's own milk|
136666|NCT00089492|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
136667|NCT01689116|Drug|Bardoxolone Methyl 80mg|Oral
136668|NCT01689116|Drug|Bardoxolone Methyl Placebo|Oral
136669|NCT01689116|Drug|Moxifloxacin 400mg|Oral
136670|NCT01689116|Drug|Moxifloxacin Placebo|Oral
136671|NCT00089648|Drug|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
136672|NCT01689129|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
136673|NCT01689129|Drug|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
136176|NCT01680523|Radiation|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
136177|NCT01680523|Radiation|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
136178|NCT01680536|Drug|maraviroc|
136179|NCT01680549|Drug|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
136180|NCT01680562|Other|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
136181|NCT00089115|Biological|sargramostim|
136182|NCT01680588|Drug|[18F]NAV4694|
136183|NCT01680601|Procedure|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
136184|NCT01680601|Procedure|Placebo|
136185|NCT01680614|Behavioral|CASI|
136186|NCT01680627|Behavioral|CASI|
136187|NCT01680640|Dietary Supplement|Synbiotic|The synbiotic to be used is fructo-oligosachharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
136188|NCT01680640|Dietary Supplement|Maltodextrin|
136189|NCT01680653|Drug|Mini-glucagon|Mini dose glucagon given for glucose <70 mg/dl at a dose of 1unit/year of age
136190|NCT01680653|Device|Remote monitoring|Provides real-time continuous glucose monitoring
136191|NCT01680653|Dietary Supplement|Carbohydrates and remote monitoring|16 grams of carbohydrate with remote monitoring
136192|NCT00089128|Drug|gemcitabine hydrochloride|
136193|NCT01680653|Dietary Supplement|Carbohydrates No remote monitoring|Carbohydrates for hypoglycemia and no remote monitoring
136194|NCT01680666|Procedure|central line placement|central line placement
136862|NCT01668940|Other|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
136863|NCT01668953|Other|Platelet Rich Plasma (PRP) Injection|The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.
A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.
For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.
Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.
The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations.
135935|NCT01682473|Drug|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
135936|NCT01682486|Device|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
135937|NCT01682486|Procedure|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
135938|NCT01682499|Drug|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
135939|NCT01682512|Drug|BI 695500|
135940|NCT01682512|Drug|BI 695500|
135941|NCT01682512|Drug|rituximab|
135942|NCT01682512|Drug|rituximab|
135943|NCT01682512|Drug|rituximab|
135944|NCT01682525|Other|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
135945|NCT00089258|Biological|beta-glucan|
135946|NCT01682538|Drug|Nitisinone, capsule|
135947|NCT01682538|Drug|Nitisinone, suspension|
135948|NCT01684826|Radiation|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
135949|NCT01684839|Device|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
135950|NCT01684852|Other|Medical device, drug-like|
138153|NCT01628380|Procedure|Cytoreductive Surgery and HIPEC|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).
HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C.
138154|NCT01628380|Procedure|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
138155|NCT01628393|Drug|RPC1063|oral, low dose, daily for 24 weeks
138156|NCT01628393|Drug|placebo|oral, 1 capsule, daily for 24 weeks
138157|NCT01628393|Drug|RPC1063|oral, high dose, daily for 24 weeks
138158|NCT01628406|Procedure|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
137262|NCT01634529|Drug|V158866|Single ascending oral doses of V158866 and Placebo
137263|NCT00085202|Drug|vincristine|Given IV
137264|NCT01634529|Drug|V158866|Multiple ascending oral doses of V158866 and Placebo
137265|NCT01634555|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
137266|NCT01634555|Drug|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
137267|NCT01634555|Drug|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
137268|NCT01637038|Other|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
137269|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).
The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert.
137270|NCT00085397|Biological|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
136393|NCT01685944|Dietary Supplement|Live Pediococcus pentosaceus LP28|
136394|NCT01685944|Dietary Supplement|Heat-killed Pediococcus pentosaceus LP28|
136395|NCT01688947|Drug|Pregabalin capsules|1-2 capsules taken orally twice daily
136396|NCT01688947|Drug|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
136397|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 1
136398|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 2
136399|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 3
136400|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 1
136401|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 2
136402|NCT01688973|Drug|Erlotinib Hydrochloride|Given PO
136403|NCT01688973|Other|Laboratory Biomarker Analysis|Correlative studies
136404|NCT01688973|Drug|Tivantinib|Given PO
136405|NCT00089622|Drug|Lisuride Transdermal System|
136406|NCT01688999|Drug|Cabozantinib|60 mg PO daily each 28 day cycle. Treatment continues until toxicity or disease progression.
136407|NCT01689012|Behavioral|Facial Exercise|
136408|NCT01689025|Drug|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
136409|NCT01689025|Drug|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
136410|NCT01689038|Drug|F17464|Single dose
136701|NCT01681420|Behavioral|Blood Donation|Blood donation without HIV counseling
136702|NCT01681433|Drug|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
136703|NCT01681433|Drug|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
136704|NCT01681433|Drug|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
136195|NCT01680666|Device|Ultrasound|Ultrasound guided central venous access
136196|NCT01680679|Biological|Inactivated Trivalent Influenza Vaccine (TIV)|
136472|NCT01685957|Behavioral|"Ned i vaegt" (NIV)|This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make "normal" danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation.
136473|NCT01685957|Behavioral|"Verdens bedste kur" (VBK)|This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on "new nordic diet" and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals.
136474|NCT01685970|Drug|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
136475|NCT00089466|Drug|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
136476|NCT01685970|Drug|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
136477|NCT01685983|Drug|abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
136478|NCT01685983|Drug|prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
136479|NCT01685996|Drug|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
136480|NCT01685996|Drug|placebo|
136481|NCT01686009|Drug|Intra-nasal ketamine|
136482|NCT01686022|Other|Immunoblot|serum specific IgE binds to grass extract by immunoblot
136483|NCT01686061|Other|No intervention- only one time survey|
136484|NCT01686087|Behavioral|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
136485|NCT01686087|Procedure|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
136486|NCT00089479|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
136487|NCT01686100|Procedure|No touch technique|The vein graft is harvested with its surronding tissues.
135951|NCT01684878|Drug|chemotherapy|Standard chemotherapy (topotecan, paclitaxel, or gemcitabine)
135952|NCT01684878|Drug|pertuzumab|840 mg intravenous loading dose, followed by 420 mg every 3 weeks
135953|NCT01684878|Drug|placebo|Pertuzumab placebo intravenously every 3 weeks
135954|NCT01684891|Drug|RG1662|multiple doses of RG1662
135955|NCT01684904|Radiation|Proton radiation|
135956|NCT01684917|Behavioral|Energy Intake Restriction|12 week energy intake restriction
135957|NCT00001698|Drug|Ketorolac Rinse|
135958|NCT00089427|Drug|Temozolomide with radiation therapy|
135959|NCT01684930|Drug|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
136251|NCT01688401|Drug|Melphalan hydrochloride|Drug administered intra-arterially (injection in the artery).
Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.
Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks.
136252|NCT01688414|Procedure|photoacoustic imaging|Undergo PAI
136253|NCT01688414|Procedure|fluorescence imaging|Undergo fluorescence imaging
136254|NCT01688414|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
136255|NCT01688427|Behavioral|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
136256|NCT01688427|Behavioral|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
136257|NCT00089609|Drug|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
136258|NCT01688440|Other|#1 Respiratory Care Solution|Respiratory care solution.
136259|NCT01680692|Device|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
136260|NCT01680692|Device|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
136261|NCT01680705|Other|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
137271|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).
The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert.
137272|NCT01637064|Drug|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
137273|NCT01637077|Drug|pregabalin|Given PO
137274|NCT01637077|Drug|placebo|Given PO
137275|NCT01637077|Other|questionnaire administration|Ancillary studies
137276|NCT01637090|Drug|Everolimus|The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.
Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.
If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded.
137277|NCT01637103|Behavioral|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
137541|NCT00085423|Drug|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
137542|NCT01637623|Drug|Placebo|Placebo capsule daily for 6 weeks
137543|NCT01629628|Drug|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
137544|NCT00084838|Drug|etoposide|
137545|NCT01629628|Drug|6 Mercaptopurine|6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.
137546|NCT01629654|Behavioral|Health promotion program|A 13 weeks organized program:
One group session about poststroke fatigue involving both patient and relatives
Two personal meetings, involving both patient and relatives
Three telephone meetings, involving only patient
137547|NCT01629667|Biological|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody (MAb)) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
137548|NCT01629667|Biological|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody (MAb)) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
137549|NCT01629667|Other|Placebo|
136705|NCT01681446|Drug|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
136706|NCT00089180|Drug|liposomal T4N5 lotion|Given topically
136707|NCT01681472|Drug|[6R] 5,10-methylenetetrahydrofolate|i.v. bolus injection
136708|NCT01681472|Drug|Levoleucovorin|i.v. bolus injection
136709|NCT01681511|Device|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
136710|NCT01681511|Device|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®* silver alloy coating and BARD® hydrogel.
136711|NCT01681524|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
136712|NCT01681537|Drug|Lenalidomide|
136713|NCT01681537|Drug|Mitoxantrone|
136714|NCT01683669|Other|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
136715|NCT00089323|Procedure|Bone Marrow Aspiration|
136716|NCT01683669|Other|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
136717|NCT01683682|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
136718|NCT01683682|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
136719|NCT01683682|Drug|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
136720|NCT01683695|Drug|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
136721|NCT01683695|Drug|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
137041|NCT01679600|Device|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
137042|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
136488|NCT01686100|Procedure|Conventional technique|The vein graft is stripped from its surrounding tissues.
136489|NCT01686113|Other|NEFA|
136490|NCT01686113|Other|Sucrose|
136491|NCT01686126|Drug|Levonorgestrel|
136784|NCT01648582|Drug|Metformin|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
136785|NCT01681537|Drug|Etoposide|
136786|NCT01681537|Drug|Cytarabine|
136787|NCT01681550|Drug|Incretin-based therapy|
136788|NCT00089180|Other|placebo|Given topically
136789|NCT01681563|Drug|Pentostatin|Lyophilized powder for intravenous administration.
136790|NCT01681563|Drug|Cyclophosphamide|IV
136791|NCT01681563|Drug|Ofatumumab|Liquid concentrate for solution for infusion.
136792|NCT01681576|Drug|Valsartan|Valsartan 320mg tablet once daily
136793|NCT01681576|Drug|LCZ696|LCZ696 400mg tablet once daily
136794|NCT01681589|Device|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
136795|NCT01681589|Device|Control Group|This group will receive Sham TDCS
136796|NCT01681589|Other|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
136797|NCT01681602|Other|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
136798|NCT01681615|Drug|Acetylsalicylate|1-2 drops
136799|NCT00001688|Drug|Stavudine|
136800|NCT00089180|Other|laboratory biomarker analysis|Correlative studies
136801|NCT01681615|Drug|Isotonic NaCl|1 drop
138086|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
138087|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
138088|NCT01630720|Dietary Supplement|vitamin C or D therapy in acutely-hospitalized patients|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
138089|NCT01630733|Drug|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle; Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
138090|NCT01630733|Drug|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
138091|NCT01630746|Drug|TAK-438|
138092|NCT01630746|Drug|TAK-438|
138093|NCT01630759|Device|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
138094|NCT00084877|Other|pharmacological study|Correlative studies
138095|NCT01630759|Other|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
138096|NCT01630772|Other|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
138097|NCT01630772|Other|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
138098|NCT01633164|Behavioral|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
138099|NCT01633164|Other|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
138100|NCT01633177|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
138101|NCT01633177|Drug|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
137550|NCT01629680|Drug|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
137551|NCT01629680|Drug|Placebo|coated tablets identical in number and appearance as the study drug
137552|NCT01629693|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
137553|NCT01629693|Device|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
137554|NCT01629706|Device|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
137555|NCT00084838|Drug|leucovorin calcium|
137556|NCT01629706|Device|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
137557|NCT01629706|Device|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
137558|NCT01629706|Device|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
137559|NCT01629706|Device|Habitual lens care|Lens care per habitual use
137560|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
137561|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
137821|NCT00001572|Drug|QS-21 (Stimulation-QS-21) Drug|
137822|NCT00084838|Drug|Dactinomycin|
137823|NCT01630187|Drug|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
137824|NCT01630187|Drug|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
137825|NCT01630200|Drug|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
137826|NCT01630200|Drug|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
137827|NCT01630213|Dietary Supplement|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
137828|NCT01630213|Dietary Supplement|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
137043|NCT01679613|Drug|Nintedanib|low dose oral administration
137044|NCT01679613|Drug|Ketoconazole|oral administration
137045|NCT00089063|Drug|Montanide ISA 51 VG|Given SC
137046|NCT01679613|Drug|Nintedanib|low dose oral administration
137047|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
137048|NCT01679613|Drug|Ketoconazole|oral administration
137049|NCT01679639|Drug|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
137050|NCT01679639|Drug|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
137051|NCT01679652|Drug|Nebivolol|Tablet i blinded in capsula
137052|NCT01679652|Drug|placebo|
137053|NCT01679665|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
137054|NCT01679665|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
137055|NCT01679678|Device|PolyHeal 2|PolyHeal is a sterile medical device
137056|NCT00089063|Biological|sargramostim|Given SC
137057|NCT01679678|Device|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
137058|NCT01679691|Other|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
137059|NCT01679704|Dietary Supplement|Food products|
137060|NCT01679717|Other|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
137061|NCT01679743|Drug|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
137062|NCT01682031|Radiation|radiation therapy|Undergo radiotherapy
137063|NCT01682031|Procedure|quality-of-life assessment|Ancillary studies
137064|NCT01682044|Biological|pegfilgrastim|Given SC
137065|NCT01682044|Biological|rituximab|Given IV
136802|NCT01681628|Behavioral|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
136803|NCT01681641|Other|A psycho-social intervention|
136804|NCT01681654|Behavioral|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
136805|NCT01681654|Behavioral|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
135875|NCT01687621|Procedure|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
135876|NCT01687634|Behavioral|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
135877|NCT00089544|Procedure|therapeutic conventional surgery|Undergo surgical resection
135878|NCT01687634|Behavioral|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
135879|NCT01687647|Other|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
135880|NCT01687660|Other|acupuncture|apply acupuncture to prevent the migraine attack
135881|NCT01687673|Drug|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
135882|NCT01687673|Drug|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
135883|NCT01687699|Drug|Spironolactone|
135884|NCT01687712|Drug|Gonal-f|225IU subcutaneously, starting at the day of successful down-regulation for the first 6 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
135885|NCT01687712|Drug|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 6 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
138102|NCT01633177|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
138103|NCT01633177|Drug|Fish oil placebo|Fish oil placebo
137197|NCT01687465|Procedure|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
137198|NCT00089544|Radiation|radiation therapy|Undergo radiotherapy
137199|NCT01687465|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
137200|NCT01687478|Drug|Olanzapine|Administered Orally
137201|NCT01687478|Drug|Fluoxetine|Administered Orally
137202|NCT01687478|Drug|Placebo|Administered Orally
137203|NCT01687491|Drug|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
137204|NCT01687491|Drug|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
137205|NCT01687517|Drug|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
137206|NCT01687530|Procedure|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
137207|NCT01687543|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
137208|NCT01687543|Other|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
137209|NCT00089544|Drug|thalidomide|Given orally
137210|NCT01687556|Other|topical EGCG application on acne|two times application of topical EGCG on acne lesion
137211|NCT01687569|Other|Control Cracker Snack|Base cracker snack
137212|NCT01687569|Other|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
137213|NCT01687569|Other|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
137214|NCT01687582|Drug|GLP-1 analog|GLP-1 analog treatment
137829|NCT01630226|Drug|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
137830|NCT01630239|Procedure|Laser ablation|Laser ablation of hepatic tumors
137831|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
137832|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
137833|NCT00084864|Dietary Supplement|calcitriol|Given orally
137834|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
137835|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
137836|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
137837|NCT01630265|Other|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
137838|NCT01630265|Other|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
137839|NCT01630278|Drug|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
137840|NCT00085124|Biological|oblimersen sodium|Given IV
137841|NCT01632735|Behavioral|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
137842|NCT01632748|Device|Neurotech Vital Device|5 minute treatment
138159|NCT01630785|Device|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
138160|NCT01630798|Drug|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
138161|NCT01630811|Drug|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
138162|NCT01630824|Other|Structured education program|structured education program after kidney transplantation
136122|NCT01682733|Device|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
136123|NCT01682746|Drug|Photofrin (porfimer sodium) & photodynamic therapy.|Intravenous (IV) Photofrin
This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity & light precautions for a minimum of 30 days after the infusion.
Photodynamic Therapy (PDT)
After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time.
136124|NCT01682759|Drug|Omarigliptin|
136125|NCT01682759|Drug|Placebo to Omarigliptin|
136126|NCT00089258|Drug|isotretinoin|
136127|NCT01682759|Drug|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
136128|NCT01682759|Drug|Glimepiride Placebo|
136129|NCT01682759|Drug|Metformin|Participants will continue on their stable dose (>=1500 mg/day) of open-label metformin throughout the trial.
136130|NCT01682759|Drug|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
136131|NCT01682772|Drug|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
136132|NCT01682798|Dietary Supplement|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
136133|NCT01682798|Dietary Supplement|Yili "Chang Qing" Pro-ABB yoghurt (Formula 1)|100g of Yili "Chang Qing" Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day.
136134|NCT01685281|Drug|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
136135|NCT01685294|Behavioral|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
136136|NCT01685307|Dietary Supplement|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
135886|NCT01687725|Device|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
135887|NCT01687738|Other|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
135888|NCT00089544|Other|laboratory biomarker analysis|Correlative studies
135889|NCT01687738|Other|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
135890|NCT01687751|Drug|Dexmedetomidine|Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.
The study drug will be started at a rate of 1.0 mL/hr.
The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse
136197|NCT01680679|Biological|Inactivated poliovirus vaccine (IPV), trivalent|
136198|NCT01680692|Drug|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
136199|NCT01682798|Dietary Supplement|Yili "Chang Qing" Pro-ABB yoghurt (Formula 2)|
136200|NCT01682811|Drug|Levulan (5-aminolevulinic acid) uptake.|8 adult subjects will be needed, two subjects for each incubation time point, and one each for negative and positive controls. Multiple lesions for each subject may be treated in order to provide better estimations of fluorescence levels.
Tumors will be incubated with Levulan under occlusion for 3, 6, or 24 hrs. A minimum of three tumors per group on the same subject will be incubated with Levulan or vehicle only for three hours. Tumors will then be excised in the normal manner. A minimum of three untreated control tumors will be excised. Thus there will be three groups of tumors excised per subject. Tumors will be sectioned vertically and checked for PpIX using fluorescence microscopy. Negative controls will now consist of untreated tumors and tumors incubated with vehicle only for 3 hours on the same subjects as the Levulan treated tumors. Positive controls will consist of intralesional injection of saline-dissolved ALA approximately one hour before excision.
136201|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy.|2-18 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 630 nm red light illumination. 630 nm light will be applied for varying periods of time in order to achieve a dose of 25, 50, or 100 J/cm2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
136202|NCT00089271|Drug|alvespimycin hydrochloride|Given IV
136203|NCT01682824|Behavioral|Three-Factor Eating Questionnaire (TFEQ)-R18v2|Completion of TFEQ-R18v2 questionnaire.
136204|NCT01682824|Behavioral|Multifactor Screener|Completion of multifactor screener, a short assessment tool used to evaluate dietary intake of fruits, vegetables, percentage of energy from fat, and fiber.
136205|NCT01682824|Behavioral|Eating Questionnaire-EMA (EQ-EMA)|Completion of Eating Questionnaire-EMA (EQ-EMA).
137215|NCT01687595|Drug|HerpV and QS-21|HerpV (formerly AG-707 rh-Hsc70 Polyvalent Peptide Complex) in combination with adjuvant QS-21.
137216|NCT01687595|Drug|Placebo|phosphate buffered saline.
137217|NCT01687608|Biological|AskBio009|Single dose IV injection
137218|NCT01679951|Drug|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
137482|NCT01632020|Drug|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
137483|NCT01632046|Drug|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
137484|NCT01632072|Dietary Supplement|Nutritional support|Nutritional support and counseling
137485|NCT01632085|Device|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.
Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R.
137486|NCT01632111|Other|Lung function measurement|Spirometry
137487|NCT01632124|Other|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
137488|NCT01632137|Drug|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
137489|NCT01632137|Drug|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
137490|NCT01632150|Biological|Elotuzumab|Powder for solution, 400-mg vials, for infusion
137491|NCT00085098|Biological|filgrastim|Given by infusion or injection
137492|NCT01632150|Biological|Thalidomide|50-mg capsules administered orally
137493|NCT01632150|Biological|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
137494|NCT01632150|Biological|Cyclophosphamide|50-mg tablets administered orally
137495|NCT01632163|Drug|Lixisenatide (AVE0010)|Pharmaceutical form:solution
Route of administration: subcutaneous injection
137496|NCT01632163|Drug|Placebo|Pharmaceutical form:solution
Route of administration: subcutaneous injection
138163|NCT01630837|Other|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
138164|NCT01630850|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
138165|NCT01630850|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
138166|NCT00084890|Drug|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
138167|NCT01630863|Procedure|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
138168|NCT01630876|Procedure|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
138169|NCT01630876|Procedure|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
138170|NCT01630889|Drug|FG-4592|Subjects previously randomized to FG-4592 will receive study medication on the same dosing frequency assigned at the last dose of the previous FibroGen study.
138171|NCT01630902|Drug|Torrent's Felodipine Extended-Release Tablets|
138172|NCT01630915|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
138173|NCT01630928|Procedure|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
137278|NCT01637103|Behavioral|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
137279|NCT01637129|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
137280|NCT01637129|Device|Sham Magnetic Stimulation|Sham Magnetic Stimulation
137281|NCT00085397|Biological|gp100 antigen|Given IV
137282|NCT01637142|Drug|LY2140023|Administered orally.
136137|NCT01685320|Procedure|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
136411|NCT01689051|Other|human glucagon-like peptide 1 (7-36)amide|
136412|NCT01689051|Other|human glucagon-like peptide 1 (9-36)amide|
136413|NCT01689064|Procedure|Stamm Approach|
136414|NCT01689064|Procedure|Posterior Septectomy|
136415|NCT01689077|Other|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
136416|NCT00001713|Drug|Recombinant Tissue Plasminogen Activator|
136417|NCT00089635|Drug|ABX-EGF (panitumumab)|Panitumumab 6 mg/kg every 2 weeks
136418|NCT01689090|Other|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
136419|NCT01689090|Other|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
136420|NCT01689090|Other|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
136421|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
136422|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
136423|NCT01689116|Drug|Bardoxolone Methyl 20mg|Oral
136424|NCT01680965|Drug|Ofatumumab|Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.
Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)
136425|NCT01680978|Drug|aleglitazar|150 mcg orally daily, 6 weeks
136426|NCT00089154|Biological|apolizumab|Given IV
136427|NCT01680978|Drug|placebo|orally daily, 6 weeks
136428|NCT01680991|Drug|RO5072759 [GA101]|multiple doses of RO5072759 [GA101]
136429|NCT01681004|Device|iFuse Implant System|Placement of iFuse implant system via surgery
136430|NCT01681004|Other|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
136206|NCT01682837|Drug|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
136207|NCT01682837|Drug|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
136208|NCT01682837|Drug|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
136209|NCT01682837|Drug|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
136210|NCT01682850|Behavioral|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
136211|NCT01682850|Other|Usual Care|
136212|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
136213|NCT00089271|Other|laboratory biomarker analysis|Correlative studies
136492|NCT01686126|Drug|Metformin|
136493|NCT01688804|Behavioral|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
136494|NCT01688817|Other|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
136495|NCT01688817|Other|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
136496|NCT01688830|Drug|Dabigatran|
136497|NCT01688830|Drug|BI 655075|
136498|NCT01688830|Drug|Placebo|
136499|NCT01688843|Device|INGEVITY lead|
137497|NCT01632176|Behavioral|Real Talk Intervention|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There are 3 booster calls up to six weeks following the intervention.
137498|NCT01634945|Drug|SP/Amodiaquine + FeFum fortified porridge|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
137499|NCT01634945|Dietary Supplement|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
137500|NCT01634945|Other|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
137759|NCT01632644|Other|Survey/Interview|Each group will be surveyed and interviewed.
137760|NCT00001575|Drug|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
137761|NCT00085111|Biological|bevacizumab|Given IV
137762|NCT01632657|Drug|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
137763|NCT01632657|Drug|Placebo|Single injection saline 0.5ml subcutaneously in recovery
137764|NCT01632670|Other|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
137765|NCT01632683|Device|C-MAC|C-MAC arm
137766|NCT01632683|Device|Glidescope|Glidescope arm
137767|NCT01632696|Drug|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
137768|NCT01632709|Drug|Bupivacaine|one injection of 10ml of .25%
137769|NCT01632709|Drug|Placebo|Dry needling
137770|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|ArmA (postoperative arm)
Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2
137771|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|ArmB (perioperative arm)
Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)
Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)
137772|NCT01635413|Behavioral|Exercise Intervention|Undergo tai chi classes
137283|NCT01637142|Drug|14C-LY2140023|Administered IV.
137284|NCT01637142|Drug|14C-LY404039|Administered IV.
137285|NCT01637155|Drug|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
137286|NCT01629264|Device|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
137287|NCT01629264|Device|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
137288|NCT01629264|Other|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
137289|NCT01629277|Device|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
137290|NCT01629277|Device|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
137291|NCT01629290|Device|Dental Varnish (Enamel Pro, Duraphat, Vanish)|3 varnishes with 5% NaF active ingredient and one bland varnish (No NaF)
137292|NCT01629290|Device|Placebo|0.5 mls applied topically to buccal surfaces of teeth
137293|NCT00084838|Drug|cisplatin|
137294|NCT01629303|Procedure|sacral nerve modulation|After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.
Then all the stimulators are switched OFF (both first and second arms) for 15 days.
Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks
137295|NCT01629316|Behavioral|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
137296|NCT01629316|Behavioral|Standard of care - control arm|The control arm is standard of care for each subject.
137562|NCT01629732|Drug|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
137563|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
137564|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
137565|NCT01629732|Drug|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
136431|NCT01681017|Behavioral|HBB/ENC Training and Equipment|See the detailed description section
136432|NCT01681017|Other|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
136433|NCT01681030|Biological|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
136722|NCT01683708|Dietary Supplement|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
136723|NCT01683747|Drug|Tranexamic Acid|
136724|NCT01683747|Drug|Control Intervention (Carrier fluid only)|
136725|NCT01683760|Drug|Fluconazole|Prophylactic fluconazole administration in VLBW infants
136726|NCT00089349|Biological|alemtuzumab|Given IV
136727|NCT01683773|Biological|AERAS-402|Intramuscular needle injection 1x10^11 vp
136728|NCT01683773|Biological|MVA85A|Intradermal needle injection 1x10^8 pfu
136729|NCT01683786|Drug|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day
136730|NCT01683799|Behavioral|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
136731|NCT01683812|Device|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
136732|NCT01683825|Drug|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
136733|NCT01683838|Drug|Fampridine-SR|25mg bid (twice daily)
136734|NCT01683838|Drug|Placebo|Placebo
136735|NCT01683851|Device|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
136736|NCT01683864|Drug|HIPEC with mytomycin and cisplatin|
136737|NCT00089349|Drug|methotrexate|Given IV
136738|NCT01683864|Procedure|Diagnostic laparoscopy one year after gastrectomy|for all 3 arms
136500|NCT01688856|Device|Electrical stimulator|The treatment period will be 13 weeks in duration, divided into two 6-week periods of actual treatment separated by 1 week to do mid-treatment assessments. Thus 12 weeks of actual treatment are provided over a 13 week period. Treatment consists of two components:
Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES groups but not for Cyclic NMES group during these sessions. To ensure that all 3 groups receive an equivalent dose of stimulation, the cyclic NMES group has slightly lengthened stimulated hand opening exercise sessions at home than the CCFES groups.)
Self-administered hand opening exercise performed 10 sessions per week at home using the device.
136501|NCT01688882|Drug|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
136502|NCT01688882|Drug|Placebo|Placebo will be used to control for normal variability in disease severity.
136503|NCT00089609|Other|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
136504|NCT01688908|Procedure|Endoscopy Screening|Upper G.I. endoscopy examination with Lugols Iodine in esophagus
Biopsy at the visually abnormal sites
Pathologic examination of all biopsy tissue specimens
Advise of regular re-examination will be given to participants who are diagnosed of moderate and severe dysplasia.
Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of early upper G.I. carcinomas.
136505|NCT01688921|Biological|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
136506|NCT01688921|Device|Needle-Syringe|
136507|NCT01688921|Device|Stratis needle-free injection device|
136806|NCT01681667|Drug|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
136807|NCT01681680|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
136808|NCT01681693|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
136809|NCT01683877|Procedure|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
136810|NCT01683877|Procedure|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
136811|NCT01683929|Other|glucose|The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.
The participants HR & BP will be monitored throughout the examination + 1 hour after.
In addition, the participants will be asked to complete a- "24 hr food questionnaire".
137773|NCT01635413|Behavioral|Exercise Intervention|Undergo stretching and relaxation classes
137774|NCT01635413|Other|Laboratory Biomarker Analysis|Optional correlative studies
137775|NCT01635426|Drug|Aspirin|Aspirin 75 mg daily for 2 months after meals
137776|NCT01635426|Drug|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
137777|NCT01635439|Drug|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
137778|NCT01635439|Drug|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
137779|NCT01635504|Biological|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
137780|NCT00085280|Other|laboratory biomarker analysis|Correlative studies
138104|NCT01633203|Drug|epirubicin + cisplatin + capecitabine polychemotherapy|EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.
CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.
CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.
Antiemetic therapy:
Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy
Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis
Symptomatic antiemetic therapy with thiethylperazine will be prescribed.
Loperamide will be prescribed in case of diarrhea.
138105|NCT01633216|Biological|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
138106|NCT00085163|Drug|fluorouracil|
138107|NCT01633216|Biological|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
138108|NCT01633216|Biological|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
138109|NCT01633216|Biological|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
138110|NCT01633216|Biological|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
138111|NCT01633229|Procedure|Bone Marrow Stromal Cell Infusion|
138112|NCT01633255|Drug|18F-Fluciclatide|
137566|NCT00084838|Drug|methotrexate|
137567|NCT01629732|Drug|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
137568|NCT01629745|Genetic|gene expression analysis|
137569|NCT01632189|Drug|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
137570|NCT01632202|Device|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
137571|NCT01632202|Device|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
137572|NCT01632215|Drug|Gabapentine|Gabapentine 600 mg 01 dose
137573|NCT00085098|Drug|carboplatin|Given IV over 1 hour
137574|NCT01632215|Other|Sugar pill|Sugar pill 01 dose
137575|NCT01632228|Drug|bevacizumab|Intravenous repeating dose
137576|NCT01632228|Drug|bevacizumab placebo|Intravenous repeating dose
137577|NCT01632228|Drug|onartuzumab|Intravenous repeating dose
137578|NCT01632228|Drug|onartuzumab placebo|Intravenous repeating dose
137579|NCT01632241|Biological|Placebo plus standard therapy|Placebo plus standard therapy
137580|NCT01632241|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
137581|NCT01632241|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
137582|NCT01632280|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes—anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.
In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks.
137843|NCT01632748|Device|Modified Neurotech Vital Device|5 minute stimulation
137844|NCT01632761|Dietary Supplement|Vitamin D3 .|
136739|NCT01686490|Behavioral|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
136740|NCT01686490|Behavioral|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
136741|NCT01686503|Drug|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
135822|NCT01612195|Procedure|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
135823|NCT01612208|Device|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
135824|NCT00083460|Drug|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
135825|NCT01612208|Device|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
135826|NCT01612221|Drug|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
135827|NCT01612221|Other|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
135828|NCT01612234|Dietary Supplement|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
135829|NCT01612247|Drug|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
135830|NCT01612260|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
135831|NCT01612260|Drug|placebo Capsule|4 granules t.i.d. po for 12 weeks
136812|NCT01683929|Other|sweetner|The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.
The participants HR & BP will be monitored throughout the examination + 1 hour after.
In addition, the participants will be asked to complete a- "24 hr food questionnaire".
136813|NCT01683955|Drug|Transexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
136814|NCT01683955|Drug|Placebo|100mL 0.9% sterile saline
136815|NCT01683981|Drug|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
136816|NCT01683994|Drug|Cabozantinib|assigned dose daily or twice a day (depending on dose level)during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
136817|NCT01683994|Drug|Docetaxel|75mg/m2 IV over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
136818|NCT00089349|Drug|mercaptopurine|Given PO
136819|NCT01683994|Drug|Prednisone|5 mg PO twice a day during each 21 day cycle until disease progression or intolerable toxicity.
136820|NCT01684007|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
136821|NCT01684007|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
136822|NCT01684020|Biological|ARTISS human fibrin sealant|
136823|NCT01684033|Device|Opti-Free® PureMoist® MPDS|
136824|NCT01684033|Device|Biotrue™ MPS|
135891|NCT01687751|Drug|Midazolam|Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.
The study drug will be started at a rate of 1.0 mL/hr.
The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse
135892|NCT01680120|Procedure|Continuous spinal anaesthesia|Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.
Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.
Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12).
138113|NCT01633281|Procedure|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
138114|NCT01633294|Drug|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
138115|NCT01633307|Other|Education|Teaching program
138116|NCT01633333|Other|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
138117|NCT00085163|Drug|leucovorin calcium|
138118|NCT01633333|Other|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
138119|NCT01636154|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
138120|NCT01636154|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
138121|NCT01636167|Device|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
138122|NCT01636180|Drug|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
137219|NCT00089076|Biological|ipilimumab|Given IV
137220|NCT01679951|Drug|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
137221|NCT01679951|Drug|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
137222|NCT01679951|Drug|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
137223|NCT01679964|Drug|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
137224|NCT01679977|Device|Vibrational-proprioceptive Resistance Exercise Training|
137225|NCT01679977|Device|Neuromuscular Electrical Stimulation Training|
137226|NCT01679990|Biological|PLX-PAD Low dose|
137845|NCT01632761|Drug|omega-3 fatty acids (fish oil)|
137846|NCT01632761|Dietary Supplement|Vitamin D3 placebo|
137847|NCT01632761|Dietary Supplement|Fish oil placebo|
137848|NCT01632787|Other|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
137849|NCT01632800|Device|High pulsed magnetic fields|Magnetic fields will escalate in strength
137850|NCT01632826|Drug|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
137851|NCT00085124|Drug|cytarabine|Given IV
137852|NCT01632852|Biological|CSL362|CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.
CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362.
137853|NCT01632865|Device|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
137854|NCT01632891|Drug|Lopinavir/ritonavir|Participants will receive two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily starting on study day 1 for 15 days.
137855|NCT01632891|Drug|Emtricitabine/tenofovir disoproxil fumarate|Participants will receive one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily starting on study day 1 for 15 days.
137856|NCT01632891|Drug|Efavirenz|Participants will receive one 600 mg tablet of efavirenz orally once daily starting on study day 1 for 15 days.
137857|NCT01632891|Drug|Nevirapine|If unable to take efavirenz, participants will receive on 200 mg tablet of nevirapine orally once daily starting on study day 1 for 15 days.
137858|NCT01632891|Drug|Efavirenz|Participants will receive one 600 mg tablet of efavirenz orally once daily starting on study day 16 for 15 days.
137859|NCT01632891|Drug|Nevirapine|For those participants unable to take efavirenz and who have not taken nevirapine in Step 1, participants will receive one 200 mg tablet of nevirapine orally once daily starting on study day 16 for 15 days for participants.
137860|NCT01632891|Drug|Nevirapine|Participants unable to take Efavirenz who have taken nevirapine in Step 1 will received one 200 mg tablet or nevirapine orally twice daily starting on study day 16 for 15 days (unless not clinically warranted per discretion of the site investigator (see section 7.0 of study).
135832|NCT01614457|Drug|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
135833|NCT01614470|Drug|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
135834|NCT01614470|Drug|Placebo|oral use, administered twice a day (q12h)
135835|NCT01614483|Other|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
135836|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
135837|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
136138|NCT01685333|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
136139|NCT01685346|Behavioral|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
136140|NCT01685359|Drug|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
136141|NCT01685372|Biological|Fluzone High Dose|
136142|NCT01685372|Biological|Fluzone|
136143|NCT01685385|Other|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
136144|NCT00089453|Drug|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
136145|NCT01685398|Drug|0.5% timolol maleate eye drop|
136146|NCT01685398|Drug|Normal saline|
136147|NCT01685411|Drug|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
136148|NCT01685411|Drug|Keppra|Day -8 (prior to transplant): Per institutional guidelines
136149|NCT01685411|Drug|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
136150|NCT01685411|Drug|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
135893|NCT01680133|Other|Hyperinsulinemic euglycemic clamp|
135894|NCT01680146|Dietary Supplement|PRO+FAT|
135895|NCT01680146|Dietary Supplement|PRO|
135896|NCT01680159|Drug|TA-650|
135897|NCT01680172|Drug|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
135898|NCT01680172|Drug|Placebo|Single dose of liquid placebo solution taken by mouth
135899|NCT00001688|Drug|Ritonavir|
135900|NCT00089089|Other|pharmacological study|Correlative studies
135901|NCT01680185|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
135902|NCT01680185|Drug|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
135903|NCT01680185|Other|Standard of care|all covered above
135904|NCT01680198|Drug|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
135905|NCT01680198|Drug|placebo|
135906|NCT01680211|Dietary Supplement|Salacia bark extract|
135907|NCT01680211|Dietary Supplement|Salacia leaf extract|
135908|NCT01680211|Dietary Supplement|Sesame seed extract|
135909|NCT01680211|Behavioral|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
135910|NCT01680211|Other|Placebo|
135911|NCT00089089|Other|laboratory biomarker analysis|Correlative studies
136214|NCT01682863|Drug|Long acting b2-agonist|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
136215|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
136216|NCT01682863|Drug|Placebo|To mimic QAB149
136217|NCT01682876|Biological|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
137227|NCT01679990|Biological|PLX-PAD high doses|
137228|NCT01679990|Biological|Double Placebo|
137229|NCT01679990|Biological|high dose +Placebo|
137230|NCT00089076|Other|laboratory biomarker analysis|Correlative studies
137231|NCT01680003|Drug|Hepar-P|
137232|NCT01680003|Drug|Placebo for Hepar-P|
137233|NCT01680016|Biological|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
137234|NCT01680016|Biological|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
137235|NCT01680029|Device|PBASE-system 2.0|
137236|NCT01680042|Drug|Phenytoin paste|
137237|NCT01680042|Drug|Placebo|
137238|NCT01680068|Procedure|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
137239|NCT01680081|Other|Adenosine stress dynamic CT perfusion|
137240|NCT01680094|Drug|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
137241|NCT00089089|Drug|decitabine|Given IV
137501|NCT01634958|Biological|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
137502|NCT01634971|Procedure|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
137503|NCT01635010|Procedure|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
137504|NCT01635023|Drug|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
137505|NCT00085254|Drug|cilengitide|Given IV
137506|NCT01635023|Drug|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
138174|NCT01630941|Drug|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
138175|NCT01633359|Drug|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
138176|NCT01633359|Drug|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
138177|NCT01633372|Drug|INCB039110|
138178|NCT01633398|Genetic|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
138179|NCT01633411|Device|Focal Cryoballoon Ablation System - 6 seconds|Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
138180|NCT01633411|Device|Focal Cryoballoon Ablation System - 8 seconds|Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
138181|NCT01633411|Device|CryoBalloon Focal Ablation System - 10 seconds|Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications".
138182|NCT01633437|Drug|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
138183|NCT01633437|Other|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
138184|NCT00085163|Procedure|adjuvant therapy|
138185|NCT01633450|Other|Zinc biofortified rice|1.12 mg zinc per meal
138186|NCT01633450|Other|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
138187|NCT01633476|Drug|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
138188|NCT01633502|Device|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
138189|NCT01633502|Device|Impella cVAD|Control group treated with Impella cVAD for a minimum of 48 hrs.
136151|NCT01685411|Drug|Cyclosporine A|Day -3 (prior to transplant) and will be administered by mouth/intravenously (PO/IV) maintaining a trough level between 200 and 400 ng/mL. Adult initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. Children < 40 kg will be 2.5 mg/kg IV over 2 hours every 8 hours.
136152|NCT01685411|Drug|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (> or = 40 kg) or 15 mg/kg 3 times per day (< 40 kg) for up to 30 days unless no engraftment.
136153|NCT01685411|Biological|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
136154|NCT01688115|Other|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
136155|NCT01688128|Device|Phase I U-SMART (4 wks)|Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
136156|NCT01688128|Other|Washout (2 wks)|2-weeks wash out period in both arms
136434|NCT01681030|Biological|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
136435|NCT01681030|Other|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
136436|NCT01681043|Behavioral|protocol 'Quiet in the room'|Protocol 'Quite in the room' between 10 p.m. and 6 a.m.
nurse nearby
no visits after 10 p.m.
decreased alarm sound in ventilator and monitor
decreased light intensity
no unnecessary conversations around the patient
medication should be limited to max 1-2 times in this time period
no unnecessary therapeutic or diagnostic procedures in this time period
earplugs and sleep masks
136437|NCT00089154|Other|laboratory biomarker analysis|Correlative studies
136438|NCT01681056|Behavioral|Autosuggestion for 30 days|
136439|NCT01681069|Dietary Supplement|IQP-VV-102|
136440|NCT01681069|Other|Placebo|
136441|NCT01681082|Behavioral|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
136442|NCT01681095|Drug|Custodiol HTK|After cross-clamping of the aorta approximately 1-2L of Custodiol-HTK will be infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml may be administered as needed. The cardioplegic solution will be delivered at a temperature of 4°C - 10°C.
136443|NCT01681095|Drug|Cold Blood Cardioplegia|After cross-clamping the aorta, at least 1000mL of a 4:1 mixture of cold blood: cold crystalloid will be administered at a pressure of 300mmHg or less via a twin roller pump. Every 20 minutes an additional > 200mL will be administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution will be delivered at a temperature of 4°C - 8°C.
136444|NCT01681108|Behavioral|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
136218|NCT01685411|Biological|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is >2500 x 10^9/L or per institutional guidelines.
136219|NCT00089453|Drug|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
136220|NCT01685411|Biological|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
136221|NCT01685424|Drug|Etoricoxib|As per routine clinical practice in the United Kingdom
136222|NCT01685437|Biological|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
136223|NCT01685450|Device|Echodia® hand-held equipment|
136224|NCT01685463|Device|Transcranial Magnetic Stimulation|Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.
136225|NCT01685463|Device|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
136226|NCT01685476|Device|Echodia® hand-held equipment|
136227|NCT01685489|Drug|Docetaxel, PSK®|
136228|NCT01685489|Drug|Docetaxel, Placebo|
136229|NCT01685502|Drug|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
136230|NCT00089453|Procedure|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
136231|NCT01685515|Drug|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
136232|NCT01685515|Drug|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
136233|NCT01685528|Behavioral|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
136234|NCT01685541|Other|Maximum After Visit Summary Content|
136235|NCT01685541|Other|Intermediate After Visit Summary Content|
136508|NCT01688934|Drug|V116517 50-mg tablets|Taken orally twice daily
136509|NCT01688934|Drug|V116517 30-mg tablets|Taken orally twice daily
136510|NCT01688934|Drug|Naproxen 500-mg capsules|Taken orally twice daily
137507|NCT01635023|Drug|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
137508|NCT01635023|Drug|AZD6244 Dosing Period 4|Treatment B
137509|NCT01635036|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
137510|NCT01635062|Drug|Calcitriol and Lisinopril|Subjects will receive calcitriol and lisinopril to evaluate their influence on the renin-angiotensin system when compared to placebo.
137511|NCT01635062|Drug|Placebo|Placebo will be given
137512|NCT01635075|Behavioral|Exercise|1-mile treadmill walk
137513|NCT01635075|Behavioral|passive control|20 min inactivity
137514|NCT01635088|Drug|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
137515|NCT01635088|Device|KoKo Spirometry|
137516|NCT00085254|Drug|temozolomide|Given orally
137517|NCT01635088|Drug|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
137518|NCT01635088|Device|Oscillometry|
137519|NCT01635101|Drug|IV Acetaminophen|7.5 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;
10 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;
12.5 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;
15 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours
137520|NCT01635101|Other|Normal Saline as Placebo|
137521|NCT01635114|Dietary Supplement|resveratrol|150 mg resVida per day for 12 weeks
137522|NCT01637467|Other|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
137781|NCT01635530|Drug|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
137782|NCT01635530|Drug|Ceftriaxone|2 g intravenous once a day, three weeks
137783|NCT01635556|Behavioral|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
137784|NCT01635569|Behavioral|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
137785|NCT01635569|Other|Waitlist|Baseline and post-12 sessions
138190|NCT01633515|Procedure|Intralesional cryotherapy|The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.
Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received).
138191|NCT01633528|Drug|Asprin|100 mg
137297|NCT01629329|Drug|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
137298|NCT01629329|Drug|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
137299|NCT01629342|Behavioral|Standardized activities|All patients do each of the following standardized activities over a course of 2 days:
treadmill walking (5 minutes, 1 and 2km/h)
staircase walking (1 floor, normal pace)
cycling with fixed load (5 minutes)
standing up from sitting position and sitting down again (x5)
standing up from supine position
turning from left to right and back while lying in bed
raising outstretched arm 90° (x5, standing position)
eating (5 minutes, sitting position)
drinking a glass of water
sleeping (6 hours)
137300|NCT01629368|Drug|Carbamazepine|Multiple doses of carbamazepine
137301|NCT01629368|Drug|RO4917523|Single dose of RO4917523
137302|NCT01629381|Drug|Rivaroxaban|10 mg os once daily for 1 week
137303|NCT01629381|Drug|placebo|10 mg os once daily for 1 week
137304|NCT00084838|Drug|cyclophosphamide|
137305|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
137306|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
137307|NCT01631682|Behavioral|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
137308|NCT00084981|Other|pharmacological study|Correlative studies
137309|NCT01631682|Drug|Mifepristone|1800mg, 9 tablets
137310|NCT01631682|Drug|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
137311|NCT01631708|Procedure|Erythrocytapheresis|To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.
An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to ~100 ug/L in accordance with current guidelines.
136445|NCT01681121|Drug|ADX-N05|150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
136446|NCT01681121|Drug|Placebo|One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
136447|NCT01683149|Drug|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
136448|NCT01683162|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
136449|NCT01683162|Drug|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
136450|NCT01683162|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
136451|NCT01683175|Drug|Erlotinib|
136452|NCT01683175|Drug|cis-platinum|
136453|NCT01683175|Drug|Vinorelbine|
136454|NCT00001693|Drug|Celecoxib (SC-58635)|
136742|NCT01686529|Procedure|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
136743|NCT01686529|Drug|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
136744|NCT01686542|Procedure|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
136745|NCT01686542|Procedure|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
136746|NCT01686555|Drug|ABT-199|Tablet
136747|NCT01686555|Other|Placebo|Tablet
136748|NCT01686568|Drug|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
136749|NCT00001703|Biological|von Hippel-Lindau peptide vaccine|1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
136750|NCT00089505|Drug|Emtricitabine|200 mg taken orally
136751|NCT01686568|Drug|placebo|
136511|NCT01688934|Drug|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
136512|NCT01681134|Drug|Advagraf®|oral
136513|NCT00089154|Other|pharmacological study|Correlative studies
136514|NCT01681134|Drug|Prograf®|oral
136515|NCT01681147|Behavioral|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
136516|NCT01681147|Behavioral|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
136517|NCT01681160|Other|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
136518|NCT01681160|Other|conventional therapy|patients receive ordinary treatment for diabetic foot
136519|NCT01681173|Dietary Supplement|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
136520|NCT01681173|Dietary Supplement|Placebo|200ml Placebo, BID, over 24 months
136521|NCT01681186|Drug|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
136522|NCT01681186|Drug|LY2940680 Tablet (Test)|Administered orally as a tablet
136523|NCT01681186|Drug|Lanzoprazole|Administered orally as a capsule
136524|NCT00089167|Biological|filgrastim|
136525|NCT01681186|Drug|Placebo Capsule(s)|Administered orally as a capsule(s)
136526|NCT01681199|Drug|Fluvastatin extended release tablet|
136527|NCT01681212|Drug|Ipilimumab|
136528|NCT01681212|Drug|Dacarbazine|
136529|NCT01681225|Other|Esophageal-pressure guided mechanical ventilation|
136530|NCT01681225|Other|High PEEP mechanical ventilation|
136825|NCT01684033|Device|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
137786|NCT01635582|Other|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
137787|NCT01635582|Other|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
137788|NCT01635595|Procedure|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
137789|NCT01635595|Procedure|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
137790|NCT01635608|Drug|Acetaminophen|administration of 500 mg paracetamol
137791|NCT00085293|Drug|Decitabine|Starting dose 6 mg/m^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
137792|NCT01635608|Drug|Talinolol|administration of 50 mg talinolol
137793|NCT01635608|Drug|Amoxicillin|administration of 500 mg amoxicillin
137794|NCT01635608|Other|non-caloric water|administration of 240 ml water
137795|NCT01635608|Other|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
137796|NCT01638234|Dietary Supplement|Placebo|starch pill
137797|NCT01638247|Drug|Tamoxifen|25 mg daily.
137798|NCT01638247|Drug|Tamoxifen and GnRH analogue|25 mg Tamoxifen daily and GnRH analogue:
Goserelin (10.8 mg s.c. after randomisation and after three months) or
Leuprorelin (11.25 mg s.c. after randomisation and after three months).
137799|NCT01638247|Drug|Exemestane and GnRH analogue|25 mg Exemestane daily and GnRH analogue:
Goserelin (10.8 mg s.c. after randomisation and after three months) or
Leuprorelin (11.25 mg s.c. after randomisation and after three months).
137800|NCT01638260|Drug|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
137801|NCT01638260|Behavioral|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
137802|NCT00001579|Drug|Leucovorin|
138123|NCT01636180|Drug|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
138124|NCT01636193|Biological|Oral Rotarix®|2 doses administered orally.
137312|NCT01631708|Procedure|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
137313|NCT01631747|Behavioral|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
137583|NCT01632293|Behavioral|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
137584|NCT00085098|Drug|cisplatin|Given IV over 6 hours
137585|NCT01632306|Drug|LY2090314|LY2090314 administered IV
137586|NCT01632306|Drug|FOLFOX|FOLFOX administered IV
137587|NCT01632306|Drug|Gemcitabine|Gemcitabine administered IV
137588|NCT01632306|Drug|Nab-paclitaxel|Nab-paclitaxel administered IV
137589|NCT01632319|Behavioral|Combined Motivational Interviewing and Cognitive Behavioral Therapy|8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.
In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms
137590|NCT01635114|Dietary Supplement|Placebo|Placebo for 12 weeks
137591|NCT01635127|Drug|Canakinumab|150mg s.c.
137592|NCT01635127|Drug|Placebo|Constituent of canakinumab
137593|NCT01635140|Radiation|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
137594|NCT01635140|Radiation|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
137595|NCT00001576|Drug|Leucovorin|
137596|NCT00085254|Radiation|radiation therapy|Undergo radiotherapy
137597|NCT01635153|Dietary Supplement|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
136752|NCT01686581|Drug|Onabotulinumtoxin A|Onabotulinumtoxin A (BOTOX®) administered according to physician prescription; all treatment decisions lie with the physician.
136753|NCT01686594|Drug|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
136754|NCT01686607|Drug|Parenteral micafungin application|
136755|NCT01686607|Drug|Other parenteral antifungal drugs|
136756|NCT01686620|Drug|BIOD-123|
136757|NCT01686620|Drug|Lispro (Humalog)|
136758|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
136759|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
136760|NCT01648322|Drug|F-627|subcutaneous injection given 1 per chemotherapy.
136761|NCT01648322|Drug|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
136762|NCT01648335|Device|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
135838|NCT01614496|Other|Algorithm for insulin administration|
135839|NCT01614509|Procedure|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
135840|NCT01614509|Procedure|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
135841|NCT00001564|Drug|EF-2 Peptide|
135842|NCT00083603|Biological|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
135843|NCT01614522|Drug|ASLAN001|ASLAN001 500mg BID
136826|NCT01684046|Device|Opti-Free® PureMoist® MPDS|
136827|NCT01684046|Device|RevitaLens MPDS|
136828|NCT01684046|Device|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
136829|NCT00089362|Drug|alvespimycin hydrochloride|Given IV
136830|NCT01686633|Drug|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
136831|NCT00089505|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
136832|NCT01686646|Drug|paracetamol + caffeine|paracetamol with caffeine
136833|NCT01686646|Drug|paracetamol|paracetamol
136834|NCT01686659|Device|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin [SpHb] and Pleth Variability Index [PVI]) to the clinicians in the operating room
136835|NCT01686672|Behavioral|Web Intervention|Behavioral
136836|NCT01686698|Dietary Supplement|VSL#3|VSL#3 is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
136837|NCT01686698|Other|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
136838|NCT01686711|Drug|AD-4833 15 mg|
136839|NCT01686711|Drug|AD-4833 30 mg|
136840|NCT01686711|Drug|Placebo|
136841|NCT01686724|Behavioral|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
136842|NCT00089505|Drug|Lopinavir/Ritonavir|400/100 mg taken orally
136843|NCT01686724|Other|Business As Usual|
136844|NCT01686737|Behavioral|Iyengar Yoga|12 weeks of Iyengar yoga
2 weekly sessions of 60 minutes
136845|NCT01686737|Behavioral|Walking|12 weeks of walking
2 weekly sessions of 60 minutes
136846|NCT01686750|Behavioral|Integrated care centers|
138125|NCT01636193|Other|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
138126|NCT01636206|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: ~1 year
138127|NCT00085345|Drug|ascorbic acid|
138128|NCT01636206|Drug|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: ~1 year
138129|NCT01636245|Biological|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
138130|NCT01636245|Biological|placebo|placebo, two doses, 28 days interval
138131|NCT01636258|Behavioral|Stress Management|Every other week
138132|NCT01636258|Behavioral|Diet|Every other week
138133|NCT01636258|Behavioral|Exercise|Every week
138134|NCT01636258|Behavioral|Culinary education|Every other week
138135|NCT01636271|Drug|darapladib|darapladib enteric coated tablets 160 mg
138136|NCT01636271|Drug|placebo|placebo
138137|NCT01636284|Biological|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
138138|NCT00085345|Drug|melphalan|
138139|NCT01636297|Behavioral|Forced exercise|Exercise on a stationary bicycle 3 times per week for 8 weeks
138140|NCT01636297|Behavioral|Voluntary exercise|Exercise on a stationary bicycle 3 times per week for 8 weeks
138141|NCT01636297|Behavioral|No-exercise/control|No exercise intervention is given. This group serves as a control group.
138142|NCT01636310|Other|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
138143|NCT01628315|Device|MRI|Annual MRIs as part of participation in the ASA study.
138144|NCT01628341|Drug|insulin|Patients will be asked to complete 2 self-assessment questionnaires
137598|NCT01635153|Dietary Supplement|Micronutrient|Dar-vite Multivitamin
137599|NCT01635166|Device|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
137600|NCT01635179|Procedure|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
137601|NCT01635192|Biological|VSL#3|The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.
Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide.
137602|NCT01635192|Biological|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
137861|NCT01635621|Drug|Olokizumab (OKZ)|Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:
OKZ 120 mg every 2 weeks
OKZ 240 mg every 2 weeks
OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0
1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.
137862|NCT01635621|Drug|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
137863|NCT01635634|Other|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
137864|NCT01635647|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 1 x 10^8 pfu heterologous prime-boost immunisation
137865|NCT01635647|Biological|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
137866|NCT01635660|Device|Intubation|Tracheal Intubation with the assigned video laryngoscope
137867|NCT00085293|Radiation|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
137868|NCT01635673|Other|Exercise intervention|Whole body vibration exercise 3 times per week
137869|NCT01635686|Drug|DWP422 25mg|
137870|NCT01635686|Drug|ENBREL 25MG PFS INJ.|
137871|NCT01635712|Drug|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
137872|NCT01635738|Biological|LP GMNL-133 capsule|One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
137873|NCT01635738|Biological|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
135844|NCT01614535|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
135845|NCT01614574|Biological|velaglucerase alfa|60 U/kg every other week intravenous infusion
135846|NCT01614600|Device|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
135847|NCT01614613|Device|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
135848|NCT01614613|Device|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
135849|NCT01614613|Device|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
135850|NCT01684670|Behavioral|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
135851|NCT00089427|Drug|IL13-PE38QQR|
135852|NCT01684683|Drug|Theophylline|Theophylline 0.1 bid
135853|NCT01684683|Drug|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
136157|NCT01688128|Device|Phase II U-SMART (4 wks)|Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
136158|NCT01688141|Other|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
136159|NCT01688154|Dietary Supplement|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
136160|NCT01688154|Other|2 empty capsules|
136161|NCT01688167|Behavioral|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
136162|NCT01688206|Drug|RO5520985|Phase 1, First in Human Study of RO5520985
135912|NCT01680224|Behavioral|Healthy Weight|
135913|NCT01680224|Behavioral|Project Health|
135914|NCT01680224|Behavioral|Placebo Control|Participants will view a video on overweight and obesity
135915|NCT01680237|Behavioral|Cognitive behavior therapy|
135916|NCT01680237|Behavioral|Exposure in-vivo|
135917|NCT01680250|Drug|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
135918|NCT01680263|Device|Kinesiotaping|Use of kinesiotaping on the painful area in the form of "space correction". Kinesiotaping was repeated for 3 weeks with 1week interval
135919|NCT01682395|Procedure|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
135920|NCT01682395|Procedure|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
135921|NCT00089219|Biological|GM-CSF|vaccine adjuvant
135922|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
135923|NCT01682408|Drug|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
135924|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
135925|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
135926|NCT01682408|Drug|Ranitidine|150 mg ranitidine
135927|NCT01682421|Drug|Weak steroid (Flurolon, Allergan)|
135928|NCT01682421|Drug|Potent steroid (Maxidex, Alcon)|
135929|NCT01682434|Procedure|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
135930|NCT01682447|Other|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
135931|NCT01682460|Drug|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
135932|NCT00000268|Drug|Bupropion|
137242|NCT01680107|Drug|d-cycloserine|
137243|NCT01680107|Drug|placebo|
137244|NCT01680107|Behavioral|cognitive-behaviour therapy|
137245|NCT01634360|Drug|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
137246|NCT01634373|Drug|Torrent's Quetiapine Fumarate Tablets|
137247|NCT01634386|Drug|Torrent's Quetiapine Fumarate Tablets|
137248|NCT01634399|Drug|Torrent's Quetiapine Fumarate Tablets|
137249|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
137250|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
137251|NCT01634412|Drug|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
137252|NCT00085202|Drug|cyclophosphamide|Given IV
137253|NCT01634412|Drug|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
137254|NCT01634425|Device|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
137255|NCT01634438|Drug|unfractionated heparin|unfractionated heparin
137256|NCT01634451|Other|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
137257|NCT01634451|Other|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
137258|NCT01634451|Device|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
137259|NCT01634503|Genetic|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
137874|NCT01635738|Biological|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
137875|NCT01635738|Biological|Placebo|Placebo
137876|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
137877|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
137878|NCT00085293|Biological|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
137879|NCT01635751|Drug|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
137880|NCT01635764|Biological|Adalimumab|Prefilled syringe of adalimumab
137881|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 12 weeks
137882|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 8 weeks
138192|NCT01633528|Drug|placebo|100mg
138193|NCT01633541|Drug|AT-101|Patients will receive AT-101 40 mg orally two times a day.
138194|NCT01633541|Drug|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
138195|NCT00001576|Drug|Melphalan|
138196|NCT00085176|Procedure|management of therapy complications|
138197|NCT01633541|Drug|Cisplatin|Cisplatin 100 mg/m2
138198|NCT01636323|Other|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
138199|NCT01636336|Other|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
138200|NCT01636336|Other|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
138201|NCT01636349|Other|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
136163|NCT01688245|Behavioral|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
136164|NCT00001705|Drug|IL-2|
136165|NCT00089609|Drug|Docetaxel|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
136166|NCT01688245|Behavioral|SMS Assessments|Weekly post-weekend drinking outcome assessments
136167|NCT01688258|Procedure|Diagnostic swab|
136168|NCT01688284|Device|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
136169|NCT01688297|Biological|One or two doses of replication incompetent adenovirus given in a tablet|
136170|NCT01688297|Biological|Placebo Tablet|
136171|NCT01688310|Procedure|Gomco Clamp with Tissue Adhesive|According to WHO (2011), the Gomco clamp has "…an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision." Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC.
136172|NCT01688310|Procedure|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
136173|NCT01688323|Other|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
136174|NCT01688336|Drug|FOLFIRINOX|FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:
Oxaliplatin (85 mg/m2)
Leucovorin (400mg/ m2)
Irinotecan (180 mg/m2)
5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours
136175|NCT01680523|Procedure|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
136455|NCT00089297|Biological|Cetuximab|Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.
Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).
Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
136456|NCT01683188|Drug|vemurafenib + HD IL-2|
135933|NCT00001689|Drug|Vincristine|
135934|NCT00089245|Radiation|iodine I 131 monoclonal antibody 8H9|
136236|NCT01685541|Other|Minimum After Visit Summary Content|
136237|NCT01685541|Other|Usual AVS|
136238|NCT01685554|Device|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
136239|NCT01685554|Device|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
136240|NCT01685567|Device|MICHI NPS+f|Cerebral protection with carotid flow reversal
136241|NCT00089453|Drug|Interleukin|2 at 3x10x6 IU on days +1 to 13.
136242|NCT01685580|Device|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
136243|NCT01685593|Device|abdominal binder|
136244|NCT01685593|Other|no binder|
136245|NCT01688349|Other|analyze the role of glucocorticoid in AT distribution.|The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be
to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;
to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance.
136246|NCT00089609|Drug|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
136247|NCT01688362|Biological|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
136248|NCT01688362|Drug|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.
For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site.
136249|NCT01688375|Drug|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
137260|NCT01634516|Behavioral|Dietary support|Face to face intervention plus subsequent telephone support
137261|NCT01634516|Behavioral|No dietary support|No face to face intervention or subsequent telephone support
137523|NCT01637480|Other|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
137524|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
137525|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
137526|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
137527|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
137528|NCT01637532|Drug|tocilizumab and interferon alpha 2-b|During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.
Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg
137529|NCT01637532|Drug|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
137530|NCT00085423|Drug|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
137531|NCT01637545|Drug|Ramosetron|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
G3 - No medication but regular antiemetics injection if the patient want
137532|NCT01637558|Drug|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
137533|NCT01637558|Drug|Nevirapine|
137534|NCT01637558|Drug|Lopinavir/Ritonavir|
137535|NCT01637571|Drug|Dexilant|60mg of Dexilant QD for 12 weeks
137536|NCT01637571|Drug|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
137537|NCT01637584|Drug|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
138202|NCT01636362|Device|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
138203|NCT01636388|Biological|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
138204|NCT00085345|Procedure|chemosensitization/potentiation|
138205|NCT01636401|Drug|aclidinium bromide 400 μg|
138206|NCT01636401|Drug|aclidinium bromide placebo|
138207|NCT01636414|Procedure|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
138208|NCT01636414|Procedure|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
138209|NCT01636414|Procedure|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
138210|NCT01636440|Device|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
137022|NCT01687166|Device|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
137023|NCT01687166|Device|FDA Approved Open-Irrigated Ablation Catheter|
137024|NCT01687179|Drug|sirolimus and hydroxychloroquine|This will be a phase I dose escalation study of the combination of sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and hydroxychloroquine (200 mg or 400 mg) taken orally daily.
137025|NCT01687192|Biological|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
137026|NCT01687205|Drug|1% Tenofovir Gel|
137027|NCT00089544|Drug|doxorubicin hydrochloride|Given IV
137028|NCT01687218|Drug|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
137029|NCT01687218|Drug|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
137030|NCT01687218|Drug|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
137031|NCT01687231|Other|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
137032|NCT01687244|Drug|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
136457|NCT01683201|Procedure|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
136458|NCT01683201|Procedure|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
136459|NCT01683227|Behavioral|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
136460|NCT01683227|Behavioral|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
136461|NCT01683240|Device|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
136462|NCT01683253|Drug|Levodopa/Carbidopa(200mg/50mg)|
136463|NCT01683266|Drug|HOE901-U300 (Insulin glargine new formulation)|
136464|NCT01683266|Drug|Lantus (Insulin glargine)|
136465|NCT01683279|Biological|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
136466|NCT00089297|Drug|Carboplatin|Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.
Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
136467|NCT01683292|Drug|Inhaled VR040|
136468|NCT01683292|Drug|Placebo for VR040|Placebo arm
136469|NCT01683318|Procedure|Thermal Pulsation therapy|
136470|NCT01685944|Dietary Supplement|Placebo|
136471|NCT01685957|Behavioral|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
136763|NCT01648335|Device|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
136764|NCT01648348|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
136765|NCT01648348|Biological|Bevacizumab|Given IV
136766|NCT00086359|Drug|Lopinavir/ritonavir|four pills twice daily
136250|NCT01688388|Procedure|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
136531|NCT01681238|Procedure|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR <100 bpm, Hb> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
136532|NCT01681238|Procedure|Protocol group 1|The goal of this protocol is to ensure MAP> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP <8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
136533|NCT01683331|Drug|Insulin treatment for hyperglycemia|
136534|NCT01683344|Device|PICO|Negative-Pressure Wound Therapy
136535|NCT01683344|Other|Standard Care|Standard care dressings
136536|NCT01683357|Procedure|Hepatectomy|Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.
If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).
Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy.
136537|NCT01683383|Device|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
136538|NCT01683383|Other|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
136539|NCT01683396|Drug|Placebo|Solution for subcutaneous injection
136540|NCT00089297|Drug|Paclitaxel|Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.
Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
137538|NCT01637584|Drug|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
137539|NCT01637623|Drug|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
137540|NCT01637623|Drug|Allopurinol|Allopurinol 300 mg daily for 6 weeks
137803|NCT00085449|Drug|mycophenolate mofetil|
137804|NCT01638273|Drug|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
137805|NCT01638273|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
137806|NCT01638299|Device|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
137807|NCT01638325|Drug|Insulin Lispro|Administered SC
137808|NCT01638325|Drug|BC106 insulin lispro|Administered SC
137809|NCT01638338|Behavioral|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
137810|NCT01638338|Behavioral|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
137811|NCT01638351|Behavioral|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
137812|NCT01638351|Behavioral|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
137813|NCT01638364|Drug|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
137814|NCT00085449|Procedure|peripheral blood stem cell transplantation|
137815|NCT01638364|Drug|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
137816|NCT01638377|Drug|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
137817|NCT01638377|Drug|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
137818|NCT01638390|Device|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
137033|NCT01687257|Drug|SOF|SOF 400 mg tablet administered orally once daily
137034|NCT01687257|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
137035|NCT01687270|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
137036|NCT01687270|Drug|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
137037|NCT01679574|Drug|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
137038|NCT01679587|Drug|BAY85-3934|Four escalated single oral dose steps of BAY85-3934 will be given - step 1 - 40mg (optional), step 2 - 80mg; step 3 - 120mg step 4 - 160mg (optional). Per arm one dose step will be conducted.
137039|NCT01679587|Drug|Placebo|Single oral dose of matching placebo will be given in each treatment step
137040|NCT01679600|Device|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
136102|NCT01680458|Drug|Fluconazole|Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.
Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.
Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.
Absolute doses exceeding 600 mg/day are not recommended.
136103|NCT01680471|Drug|Midazolam 0.03mg/kg|This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
136104|NCT01680471|Drug|Midazolam 0.05mg/kg|This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
136105|NCT01680471|Drug|Placebo|This group will be injected intravenous normal saline five minutes before the end of surgery.
If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
136106|NCT01680484|Dietary Supplement|Bitter chocolate|
136107|NCT00089115|Biological|rituximab|
136108|NCT01680484|Dietary Supplement|Orange juice|
136767|NCT01648348|Other|Laboratory Biomarker Analysis|Correlative studies
136768|NCT01648348|Other|Pharmacological Study|Correlative studies
136769|NCT01648348|Other|Quality-of-Life Assessment|Ancillary studies
136770|NCT01648452|Biological|NT-501 CNTF-releasing implant|20 ng/day released into the eye
136771|NCT01648465|Drug|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
136772|NCT01648478|Other|It is a hyperinsulinemic-euglycemic clamp.|The hyperinsulinemic-euglycemic clamp includes three periods:
A basal period (from T-30 to T0)
The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)
The infusion of glucose at variable rate (so as to maintain euglycemia)
136773|NCT01648491|Procedure|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
136774|NCT01648491|Biological|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
136775|NCT01648504|Other|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
136776|NCT01648517|Drug|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
136777|NCT00086385|Drug|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
136778|NCT01648517|Drug|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
136779|NCT01648530|Other|No Treatment|No Treatment
136780|NCT01648543|Procedure|lumbar sympathetic ganglion block|
136781|NCT01648556|Other|Blood tests and bone marrow biopsy repeated|Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.
The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal.
136782|NCT01648582|Drug|Dulaglutide|Administered SC
136783|NCT01648582|Drug|Insulin glargine|Administered SC per dosing titration schedule
135854|NCT01684696|Behavioral|Virtual experience|
135855|NCT01684696|Behavioral|Videos|
136541|NCT01683396|Drug|gevokizumab|Solution for subcutaneous injection
136542|NCT01683409|Drug|baricitinib|Administered orally
136543|NCT01683409|Drug|Placebo|Administered orally
136847|NCT01686776|Other|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
136848|NCT01686789|Drug|Pegylated interferon alpha-2a|
136849|NCT01686802|Drug|oral morphine|
136850|NCT01686802|Drug|Ibuprofen|
136851|NCT01686828|Drug|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
136852|NCT01686828|Drug|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 3.75g or 5g/d) for 4 weeks
136853|NCT00089505|Drug|Nevirapine|200 mg taken orally
136854|NCT01686828|Drug|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
136855|NCT01686828|Drug|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
136856|NCT01686828|Drug|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
136857|NCT01686841|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
136858|NCT01668927|Drug|Furazolidone|
136859|NCT01668927|Drug|Amoxicillin|
136860|NCT01668940|Other|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
136861|NCT01668940|Other|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
137819|NCT01630161|Behavioral|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
137820|NCT01630161|Behavioral|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
138145|NCT01628354|Drug|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of >5 letters or increase in retinal thickness of >100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
138146|NCT01628367|Procedure|Minimally Traumatic Tooth Extraction|The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.
A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution.
138147|NCT01628367|Device|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
138148|NCT01628367|Biological|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
138149|NCT01628367|Biological|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
138150|NCT01628367|Biological|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
138151|NCT01628367|Drug|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
138152|NCT00084773|Drug|fluorouracil|
136109|NCT01680497|Device|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
136110|NCT01680510|Dietary Supplement|Alga Dunaliella Bardawil|
136111|NCT01680510|Other|Placebo (starch)|
136112|NCT01682694|Dietary Supplement|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
136113|NCT01682694|Dietary Supplement|placebo|
136114|NCT01682707|Procedure|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
136115|NCT00089258|Biological|sargramostim|
136116|NCT01682707|Procedure|track light|
136117|NCT01682720|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
136118|NCT01682720|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
136119|NCT01682720|Drug|Placebo to match SOF|Placebo to match SOF administered orally once daily
136120|NCT01682720|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
136121|NCT01682733|Drug|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
136386|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
136387|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
136388|NCT01685879|Other|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
136389|NCT00089453|Procedure|Auto Graft|on day +14
136390|NCT01685892|Drug|Obinutuzumab|100 mg of obinutuzumab is administered by intravenous infusion on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, 1000 mg on Day 8 and 15 of Cycle 1 and 1000 mg on Day 1 of Cycles 2-6.
136391|NCT01685892|Drug|Venetoclax (GDC-0199; ABT-199)|Multiple doses of venetoclax are administered orally once daily.
136392|NCT01685931|Drug|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
135856|NCT01684709|Behavioral|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
135857|NCT01684722|Dietary Supplement|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
135858|NCT01684722|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
135859|NCT01684722|Dietary Supplement|Vitamin D placebo|Vitamin D3 placebo
135860|NCT01684722|Dietary Supplement|Fish oil placebo|Fish oil placebo
135861|NCT01684748|Drug|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
135862|NCT00089427|Procedure|Surgery for placement|
135863|NCT01684761|Biological|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
135864|NCT01684761|Biological|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
135865|NCT01684774|Drug|Bupivacaine|
135866|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
135867|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
135868|NCT01684800|Drug|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
135869|NCT01684800|Drug|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
135870|NCT01684800|Drug|C: Placebo|1 orally disintegrating tablet every night during study period
135871|NCT01684813|Drug|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
135872|NCT01684813|Drug|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
135873|NCT00089427|Procedure|Radiation therapy|
135874|NCT01684826|Radiation|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
139352|NCT01650584|Drug|Systane|Sterile ophthalmic solution
139353|NCT01650597|Drug|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
139354|NCT01650597|Drug|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
139355|NCT01650597|Drug|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
138382|NCT01636700|Drug|Tramadol 2mg/kg|2mg/kg
138383|NCT01636700|Drug|Saline solution|saline solution- 1 dose
138384|NCT01636713|Drug|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
138385|NCT01636713|Drug|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
138386|NCT01636713|Drug|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
138387|NCT01636726|Drug|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
138388|NCT01636739|Biological|Oral Rotarix®|2 doses administered orally.
138389|NCT00001579|Drug|5-Fluorouracil|
138390|NCT00085358|Biological|bevacizumab|Given IV
138391|NCT01636739|Other|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
138392|NCT01636752|Behavioral|Deprexis|Online self-help with and without e-mail-support
138393|NCT01636765|Drug|No Intervention|No intervention.
138394|NCT01636778|Drug|SB-497115-GR|TPO receptor agonist to increase platelet count
138395|NCT01628718|Behavioral|Cognitive Processing Therapy, cognitive version only (CPT-C)|Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of "non-recovery" in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these "stuck points" and progress toward recovery.
138396|NCT01628731|Drug|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
138397|NCT01628731|Drug|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
141941|NCT01673425|Drug|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
141942|NCT01673438|Drug|aldoxorubicin|
141943|NCT00088803|Genetic|molecular genetic technique|
141944|NCT01673451|Drug|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
141945|NCT01673451|Drug|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
141946|NCT01673490|Drug|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
141947|NCT01673503|Device|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
141948|NCT01673516|Procedure|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
141949|NCT01673516|Device|The HOTMAN® System|Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to "group Co"
141950|NCT01673529|Drug|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
141951|NCT01673529|Drug|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
141952|NCT01673542|Drug|Lidocaine-Prilocaine 5%|
141953|NCT01673542|Drug|DEXERYL|
141954|NCT00088803|Genetic|polymerase chain reaction|
141955|NCT01673555|Drug|GSK1278863|GSK1278863
141956|NCT01673555|Drug|Placebo|Placebo
141957|NCT01676051|Other|Skin culture|Culture swab used to culture skin adjacent to incision
141958|NCT01676064|Drug|ringer lactate solution|
141959|NCT01676064|Other|restrictive fluid regime|
141960|NCT01676103|Dietary Supplement|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
138456|NCT01634022|Procedure|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (−) to GV24.5 (+).
138457|NCT01634048|Dietary Supplement|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
138458|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
138459|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
138770|NCT01656460|Radiation|Stereotactic radiation Arm 1|Dose Levels Dose per Fraction Total Dose
1 8 Gy 16 Gy
138771|NCT00087165|Biological|GTI-2040|
138772|NCT01656460|Radiation|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
138773|NCT01656460|Radiation|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
138774|NCT01656460|Radiation|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
138775|NCT01656473|Other|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
138776|NCT01656473|Other|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
138777|NCT01656486|Radiation|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
138778|NCT01656499|Dietary Supplement|Arabinoxylanoligosaccharides|
138779|NCT01656499|Dietary Supplement|Maltodextrine|
138780|NCT01656512|Drug|zolendronic acid|patients will receive calcium & vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
Initial dose: (0.025) mg /kg
Subsequent doses ( 0.05) mg /kg.
Maximum dose of 4 mg.
138781|NCT01656512|Drug|calcium & vitamin D|patients will receive calcium & vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
138782|NCT00087165|Drug|docetaxel|
138783|NCT01656525|Drug|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
139178|NCT00086580|Biological|FluCAM [Fludara + Campath]|Phase A: Escalating Doses of alemtuzumab (Campath) Alone
Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.
Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.
Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.
Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.
Phase B: FluCAM
Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity.
139179|NCT01650298|Other|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
139180|NCT01650324|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
139181|NCT01650324|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
139182|NCT01650337|Other|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
139183|NCT01650350|Drug|Naltrexone|
139184|NCT01650363|Other|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
139185|NCT01650363|Drug|Homeopathic placebo medication|2-3 mm small spheric suger pils
139186|NCT01650376|Drug|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
139187|NCT01650376|Drug|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
139465|NCT01653080|Procedure|dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
139466|NCT01653093|Procedure|3-Tesla magnetic resonance imaging|Undergo 3T MRI
139467|NCT01653093|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
139468|NCT01653093|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
139469|NCT01653093|Procedure|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
139470|NCT01653106|Procedure|cryotherapy|Receive shaved ice
142475|NCT01672060|Behavioral|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
142476|NCT01672060|Behavioral|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
142477|NCT01672086|Device|Stelkast Surpass Acetabular System implant|
142478|NCT01672099|Dietary Supplement|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
142479|NCT01674387|Other|comprehensive treatment|Other 30 patients (the matched group) receive the comprehensive treatment, including traction and low-frequency therapy. Each treatment 15 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
142480|NCT01674387|Device|electro acupuncture|
142481|NCT01674387|Device|traction|
142482|NCT01674387|Device|low-frequency therapy.|
142483|NCT01674413|Drug|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
142484|NCT01674413|Drug|Adalimumab|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with
PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,
Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is < 167 mcg/gram of stool.
142485|NCT01674413|Drug|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
142486|NCT00000267|Drug|Risperidone|
142487|NCT00001669|Drug|rhIGF-1 (CEP-151)|
142488|NCT00088855|Drug|Bortezomib|Given IV
142489|NCT01674426|Behavioral|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
142722|NCT01672567|Dietary Supplement|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
142723|NCT00088673|Drug|3APS|
141961|NCT01676103|Other|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
142229|NCT01676636|Drug|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
142230|NCT01676636|Drug|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
142231|NCT01676636|Drug|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
142232|NCT01676636|Drug|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
142233|NCT01676649|Biological|Ipilimumab|3 mg/kg
142234|NCT01676649|Drug|Carboplatin|AUC = 6
142235|NCT01676649|Drug|Paclitaxel|175 mg/m2
142236|NCT01676662|Device|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
142237|NCT01676662|Device|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
142238|NCT01676675|Biological|7.5μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
142239|NCT00088946|Other|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
142240|NCT01676675|Biological|15.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
142241|NCT01676675|Biological|30.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
142242|NCT01676675|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 21 days interval
142243|NCT01676701|Drug|Tabalumab Auto-Injector|Administered SC by auto-injector
142244|NCT01676701|Drug|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
142245|NCT01676714|Drug|Dovitinib|
138784|NCT01656525|Drug|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
138785|NCT01656525|Drug|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
138786|NCT01656525|Drug|Placebo|subcutaneous doses every 4 weeks for 24 weeks
138787|NCT01656538|Drug|Paclitaxel|
138788|NCT01649557|Drug|OPC-34712|oral administered once daily
138789|NCT01649570|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
138790|NCT01649583|Device|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
138791|NCT01649596|Device|3M Bair Paws Flex Gown and Bair Paws Model 875 Warmer|
139107|NCT01652365|Behavioral|RDT Training and Subsidy Offered|
139108|NCT01652365|Behavioral|Information/Education Campaign|
139109|NCT00086801|Drug|gemcitabine hydrochloride|given IV
139110|NCT01652378|Drug|ondansetron, lidocaine|Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.
Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion).
139111|NCT01652391|Device|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
139112|NCT01652404|Behavioral|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
139113|NCT01652404|Behavioral|Conventional treatment|The antibiotics duration will be determined by treating physician.
139114|NCT01652417|Drug|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
139115|NCT01652456|Other|Addiction support|one consultation with an addiction specialist
139116|NCT01652469|Drug|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
139117|NCT01652469|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
139118|NCT01652482|Drug|FOLFIRI|Standard FOLFIRI (irinotecan/5-FU/leucovorin) chemotherapy every 2 weeks
139471|NCT00086879|Drug|carmustine|
139472|NCT01655264|Behavioral|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
139473|NCT01655264|Behavioral|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
139474|NCT01655277|Procedure|Ultrasound Guided Adductor Canal Block|
139475|NCT01655277|Procedure|Ultrasound Guided Femoral Nerve Block|
139476|NCT01655290|Other|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
139477|NCT01655303|Drug|Propranolol|
139478|NCT01655303|Drug|Metoprolol|
139479|NCT01655303|Drug|Verapamil|
139480|NCT01655303|Drug|Diltiazem|
139481|NCT01655316|Drug|Verapamil|
139482|NCT00087009|Biological|rituximab|Given IV
139483|NCT01655368|Behavioral|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
142472|NCT01672021|Procedure|PET/MRI|PET/MRI
142473|NCT01672034|Procedure|Laparoscopic gastric bypass surgery|
142474|NCT01672047|Drug|Vitamin D2|25（OH）D level <12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month，
＞116.75nmol/L stopped.
142724|NCT01674790|Behavioral|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
142725|NCT00088881|Drug|prednisone|Given orally
142726|NCT01674790|Behavioral|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
142727|NCT01674803|Device|Orsiro|biodegradable polymer sirolimus eluting stent
142728|NCT01674803|Device|Synergy|biodegradable polymer everolimus eluting stent
142729|NCT01674803|Device|Resolute Integrity|durable polymer zotarolimus-eluting stent
142730|NCT01674816|Device|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.|
142731|NCT01674816|Device|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.|
142732|NCT01674829|Biological|MA09-hRPE|
142733|NCT01674842|Radiation|Radiation Therapy|Once daily, Monday - Friday for six weeks
142734|NCT01674842|Drug|Cisplatin|Intravenously, once weekly for six weeks
142735|NCT01674855|Drug|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
142736|NCT00088881|Drug|cyclophosphamide|Given IV
142737|NCT01674855|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
142738|NCT01674868|Drug|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
142739|NCT01674868|Drug|placebo|subjects will take one pill po daily for 90 days.
142740|NCT01674881|Other|Mindfulness-Based Cognitive Therapy|MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).
Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD.
142741|NCT01674881|Other|Waitlist|Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
142742|NCT01674920|Behavioral|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
142743|NCT01674933|Drug|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
142246|NCT01676740|Drug|Iron Supplement,|Pills to be swallowed
142247|NCT01676740|Drug|Placebo|Daily administration of active drug or placebo
142248|NCT01679210|Behavioral|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
142505|NCT01677221|Device|Acleara Acne Treatment System|
142506|NCT01677247|Drug|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
142507|NCT01677247|Drug|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
142508|NCT00088985|Biological|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
142509|NCT01677260|Drug|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
142510|NCT01677260|Drug|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
142511|NCT01677273|Dietary Supplement|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
142512|NCT01677273|Dietary Supplement|Intact casein|30 g protein/supplement, 4 supplements/visit
142513|NCT01677273|Dietary Supplement|Intact whey protein|30 g protein/supplement, 4 supplements/visit
142514|NCT01677286|Drug|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
142515|NCT01677299|Drug|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
142516|NCT01677299|Drug|EFB0026 (metformin immediate-release)|Active comparator
142517|NCT01677312|Procedure|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
142518|NCT01677312|Procedure|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
142519|NCT01669330|Procedure|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
139119|NCT01652482|Drug|MEHD7945A|1100 mg iv every 2 weeks
139120|NCT00086801|Drug|vinblastine|given IV
139121|NCT01652482|Drug|cetuximab|400 mg/m2 iv loading dose Day 1 Cycle 1, followed by 250 mg/m2 weekly
139122|NCT01652495|Drug|methylprednisolone acetate|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
139123|NCT01652495|Drug|Triamcinolone Acetonide|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
139124|NCT01652508|Behavioral|ACT|Participants in the intervention group will be provided three sessions of ACT for smoking cessation. Initial ACT session will be given at the centre which will take about 15-20 minutes. The two subsequent sessions will be provided by telephone.
139125|NCT01652534|Drug|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
139126|NCT01652534|Drug|Placebo|Sugar Pill
139127|NCT01654666|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
139407|NCT01657396|Procedure|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
139408|NCT01657409|Drug|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
139409|NCT01657409|Drug|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
139410|NCT01657409|Drug|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
139411|NCT01657422|Behavioral|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
139412|NCT01657435|Device|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
139413|NCT01657448|Drug|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
139414|NCT00087217|Drug|paclitaxel|Given IV
138319|NCT01631084|Other|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
138320|NCT01631097|Drug|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
138321|NCT01631110|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
138322|NCT01631123|Other|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
138323|NCT01631123|Other|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
138324|NCT01631136|Drug|Cisplatin|75 mg/m²
138325|NCT01631136|Drug|Pemetrexed|500 mg/m²
138326|NCT01631136|Drug|Cisplatin|80 mg/m²
138327|NCT01631136|Drug|Gemcitabine|1250 mg/m²
138328|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
138329|NCT00084903|Procedure|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
138330|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
138331|NCT01631162|Other|Breath sample in all patients|Breath sample will be collected by a special nylon bag
138332|NCT01631175|Behavioral|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
138333|NCT01631188|Procedure|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
138334|NCT01631188|Procedure|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
138335|NCT01631188|Device|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
138336|NCT01631201|Drug|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
138337|NCT01631201|Drug|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
143069|NCT01665209|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
143070|NCT01665222|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
143071|NCT01665235|Drug|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
143072|NCT01665235|Drug|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
143073|NCT01665235|Drug|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
143074|NCT01665235|Drug|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
143075|NCT01665248|Other|18-F Sodium Fluoride Uptake in Positron emission tomography|
143076|NCT01665274|Drug|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
143077|NCT01667640|Radiation|whole brain irradiation|For whole brain radiation the entire brain, the base of the skull and the meninges are included.
Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.
The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented.
143078|NCT01667653|Dietary Supplement|Probiotic|Probiotic capsule once daily
143079|NCT01667653|Dietary Supplement|Placebo|Placebo capsule once daily
143080|NCT01667666|Drug|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
143081|NCT01667679|Drug|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|
143082|NCT01667679|Drug|OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet|
143083|NCT00001649|Drug|Valaciclovir|
143084|NCT00088179|Drug|pexelizumab in conjunction with CABG|
143085|NCT01667692|Drug|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.[1] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
138398|NCT01628770|Drug|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
138399|NCT01628770|Drug|Ferrous sulphate|200mg twice daily
138400|NCT01628783|Drug|escitalopram 10 mg|orally once daily
138401|NCT00084799|Biological|monoclonal antibody Hu3S193|
138402|NCT01628783|Drug|Placebo|once daily
138403|NCT01628796|Other|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
138710|NCT01649492|Dietary Supplement|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
138711|NCT01649505|Drug|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
138712|NCT01649505|Procedure|breast reconstruction|Undergo sharp dissection technique
138713|NCT01649505|Procedure|breast reconstruction|Undergo electrocoagulation dissection technique
138714|NCT01649531|Procedure|1 Implant|
138715|NCT01649531|Procedure|2 Implants|
138716|NCT01649544|Device|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
138717|NCT01649544|Drug|Amiodarone|
138718|NCT00086502|Drug|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
138719|NCT01651806|Drug|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
138720|NCT01651819|Procedure|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
139415|NCT01657448|Drug|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
139416|NCT01657461|Drug|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|
139417|NCT01657461|Device|Solitaire FR|
139418|NCT01657474|Other|Weekly application of EpiFix plus standard of care|
139419|NCT01657474|Other|Biweekly application of EpiFix plus standard of care|
139420|NCT01657487|Drug|Fluticasone/Salmeterol high dose|
139421|NCT01657500|Other|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
139422|NCT01657500|Other|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
139423|NCT01657513|Drug|subjects will receive either infliximab, adalimumab or etanercept|The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.
The study subjects will receive treatment with one drug only -
infliximab or
adalimumab or
etanercept
The consulting dermatologist decides which drug to use according to official guidelines
139424|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
139425|NCT00087217|Other|laboratory biomarker analysis|Correlative studies
139426|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
138460|NCT01636791|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
138461|NCT01636791|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
138462|NCT01636804|Device|Quicksite|St. Jude Medical produced lead called Quicksite
138463|NCT01636804|Device|Quickflex|St. Jude Medical produced lead called Quickflex
138464|NCT01636817|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
138465|NCT01636817|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
138338|NCT01631214|Drug|Romosozumab|Romosozumab sub-cutaneous injections and placebo alendronate (oral) for 12 months followed by open-label alendronate (oral) for at least another 12 months (until end of study)
138339|NCT01631214|Drug|Alendronate|Oral alendronate and placebo AMG 785 sub-cutaneous injections for 12 months, followed by open-label alendronate, (oral) for at least another 12 months (until end of study)
138655|NCT01634334|Behavioral|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
138656|NCT01634347|Drug|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
138657|NCT01634347|Drug|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
138658|NCT01653860|Behavioral|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
138659|NCT00086944|Drug|ifosfamide|Given IV
138660|NCT01653860|Behavioral|Ordinary group treatment|group treatment 8 weeks (16 hours)
138661|NCT01653886|Other|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
138662|NCT01653886|Other|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
138663|NCT01653886|Other|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
138664|NCT01653899|Drug|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
138665|NCT01653912|Drug|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
138666|NCT01653925|Other|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
143086|NCT01667692|Drug|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
143087|NCT01667718|Drug|Bismuth|Bismuth 220mg b.i.d for 2 weeks
142171|NCT01678937|Procedure|Blood Draw - MMF|Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G
142172|NCT01678937|Procedure|Blood Draw - Rapamycin|Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G
142173|NCT01678963|Drug|Squalamine lactate|Ophthalmic solution 0.2%
142174|NCT01678963|Drug|Vehicle control|Ophthalmic solution vehicle control
142175|NCT01678976|Drug|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
142176|NCT01678976|Drug|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
142177|NCT01679002|Drug|BIA 2-093|
142178|NCT01679002|Drug|Oxcarbazepine|
142179|NCT01679028|Drug|T89 Group A|150mg single dose on day 1
142180|NCT01671384|Drug|Valproate, Levocarnitine|All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:
Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)
The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
142181|NCT01671384|Drug|Placebo|All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:
Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)
The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
142182|NCT01671397|Behavioral|Diet and exercise counseling|Not needed
142183|NCT01671397|Behavioral|Diet, exercise, sleep hygiene counseling|None needed
138721|NCT01651832|Behavioral|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
138722|NCT01651858|Drug|Nurigra Chewable tablet|1 tablet of 100mg, once a day
138723|NCT01651871|Drug|S-555739 Dose 1|
138724|NCT01651871|Drug|S-555739 Dose 2|
138725|NCT01651871|Drug|Cetirizine HCl Dose 1|
138726|NCT01651871|Drug|S-555739 placebo|
138727|NCT01651871|Drug|Cetirizine HCl placebo|
138728|NCT00001623|Procedure|Allogeneic Bone Marrow Transplant|
138729|NCT00086762|Behavioral|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
139043|NCT01654601|Drug|DWCZP|Multiple dose
139044|NCT01654601|Drug|Clozaril|multiple-dose
139045|NCT00086970|Drug|ifosfamide|Given IV
139046|NCT01654627|Device|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
139047|NCT01654627|Device|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
139048|NCT01654640|Drug|Metformin|metformin 500mg p.o. bid for 24 weeks
139049|NCT01654640|Drug|Placebo (for metformin)|placebo 1T bid
139050|NCT01654653|Drug|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
139051|NCT01654653|Drug|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
139052|NCT01656928|Behavioral|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
138466|NCT00085371|Drug|triapine|Given IV
138467|NCT01636830|Device|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
138468|NCT01636843|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
138469|NCT01636843|Drug|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
138470|NCT01636856|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
138471|NCT01636856|Behavioral|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
138472|NCT01636869|Drug|Bupivacaine|20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.
Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block.
138473|NCT01636882|Biological|Coxsackievirus A21|
138474|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
138475|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
138476|NCT01636908|Drug|Sunitinib|50 mg once daily, oral use, 14 days
138477|NCT00085384|Biological|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
138478|NCT01636908|Drug|Sorafenib|400 mg, twice daily, oral use, 14 days
138479|NCT01636908|Drug|Erlotinib|150 mg once daily, oral use, 14 days
138792|NCT01649596|Other|Standard of care - warm blankets|
138793|NCT01649609|Drug|Reduction of standard immunosuppression|Low dose tacrolimus with low dose mycophenolic acid
138794|NCT01649609|Drug|mTOR Substitution|Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
138795|NCT01649622|Drug|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
138796|NCT01649635|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
138797|NCT01649635|Drug|Prednisone|Pharmaceutical form: tablet Route of administration: oral
138667|NCT01653925|Drug|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
138668|NCT01653938|Behavioral|video decision aid|
138669|NCT01653951|Other|nurse-led care management or peer-led self management|
138670|NCT00001626|Drug|Cyclophosphamide & amp; Cyclosporin A|1 hour IV infusion of 50 mg/kg daily for 4 days
138982|NCT01656902|Procedure|Microfracture|
138983|NCT01649921|Other|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
138984|NCT01649934|Behavioral|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
138985|NCT01649934|Behavioral|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
138986|NCT01649947|Drug|Paclitaxel|Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.
Prior to receiving paclitaxel, all patients will receive the following premedication:
Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv < 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)
Diphenydramine 50 mg iv (or equivalent) < 1 hour prior to paclitaxel infusion
Ranitidine 50 mg iv < 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)
138987|NCT00086515|Drug|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
138988|NCT01649947|Drug|Carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
138989|NCT01649947|Drug|Hydroxychloroquine|Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
138990|NCT01649947|Drug|Bevacizumab|Cohort 1 only:
Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles.
138991|NCT01649960|Drug|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
138992|NCT01649986|Behavioral|Non-pharmacologic intervention|Diet and physical exercise
138993|NCT01649986|Drug|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
138994|NCT01649999|Drug|ASP015K|oral
138995|NCT01649999|Drug|Placebo|oral
142184|NCT01671410|Drug|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
142185|NCT01671410|Drug|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
142186|NCT01671423|Drug|Prednisone|See "Prednisone" arm description
142187|NCT01671423|Drug|Placebo|See "Placebo" arm description
142188|NCT01671436|Behavioral|Central Meditation and Imagery Therapy|
142744|NCT01674933|Behavioral|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
142745|NCT01674946|Other|saline|intraduodenal perfusion
142746|NCT01674946|Other|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
142747|NCT00088881|Drug|doxorubicin|Given IV
142748|NCT01674946|Other|oleanolic acid|intraduodenal perfusion
142749|NCT01674946|Dietary Supplement|oleic acid|intraduodenal perfusion
142750|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
142751|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
142752|NCT00088998|Drug|docetaxel|
142753|NCT01677702|Dietary Supplement|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
142754|NCT01677715|Dietary Supplement|Yili "Mei Yi Tian" active lactobacillus drink|100ml of Yili "Mei Yi Tian" active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention
142755|NCT01677715|Dietary Supplement|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
142756|NCT01677741|Drug|Dabrafenib|Dabrafenib is available as 10 mg, 25 mg, 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
142757|NCT01677754|Drug|RO4601522|Dose B, 12 months
142758|NCT01677754|Drug|RO4602522|Dose A, 12 months
139053|NCT01656954|Procedure|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
139054|NCT01656967|Device|AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera|
139055|NCT01656967|Device|LMA Fastrach Single Use|
139056|NCT01656980|Drug|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
139057|NCT01656980|Procedure|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
139058|NCT01657019|Drug|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
139059|NCT01657032|Dietary Supplement|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
139060|NCT01657032|Dietary Supplement|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
139061|NCT00087191|Drug|EF5|Given IV
139062|NCT01657032|Dietary Supplement|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
139356|NCT01650610|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
139357|NCT01650623|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
139358|NCT01650623|Behavioral|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
139359|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
139360|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
139361|NCT00086632|Drug|oregovomab|
138798|NCT00086502|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
138799|NCT01649635|Drug|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
138800|NCT01649635|Drug|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
138801|NCT01649648|Biological|Autologous cord blood|Baby's own umbilical cord blood
138802|NCT01649661|Behavioral|questionnaire|
138803|NCT01649674|Drug|polyethylene glycole (PEG) solution|
138804|NCT01649674|Drug|sodium picosulphate and magnesium citrate solution|
138805|NCT01649687|Biological|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells
138806|NCT01649700|Biological|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.
138807|NCT01649713|Drug|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
138808|NCT01649726|Procedure|Apnea test - control|
138809|NCT00086502|Drug|Metformin|Metformin rescue for patients meeting
pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8
138810|NCT01649726|Procedure|Apnea test - CPAP|
138811|NCT01649739|Drug|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
138812|NCT01649752|Biological|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
138813|NCT01649752|Biological|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
139128|NCT01654666|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
139129|NCT01654666|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
139130|NCT01654679|Device|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
139131|NCT00086970|Drug|O6-benzylguanine|Given IV
138996|NCT01650012|Drug|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
138997|NCT01650012|Drug|Placebo|Placebo
138998|NCT00086515|Drug|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period [Phase A], from Visit 5 (Week 6) to Visit 8 (Week 24)
138999|NCT01650025|Dietary Supplement|VSL#3 active probiotic|
139000|NCT01650038|Other|treatment with faecal transplantation (donor faeces)|faecal transplantation
139001|NCT01650038|Other|treatment with faecal transplantation (own faeces)|faecal transplantation
139295|NCT01652768|Other|Medical and/or Radiation Oncology Appointment Session|The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).
Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):
Administer Patient and Caregiver Follow-up Assessment
Re-assess pain and/or symptom management issues and /or intervention
Provide resources/referrals for any needs identified during the social work follow-up assessment
Provide supportive care.
139296|NCT01652781|Drug|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
139297|NCT01652794|Radiation|stereotactic body radiation therapy|Undergo SBRT
139298|NCT00086996|Drug|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
139299|NCT01655030|Dietary Supplement|creatine monohydrate|
139300|NCT01655030|Dietary Supplement|placebo|
139301|NCT01655043|Drug|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
139302|NCT01655043|Drug|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
139303|NCT01655056|Drug|YM150|oral
139304|NCT01655056|Drug|Placebo|oral
139305|NCT01655069|Drug|Solifenacin succinate|Oral suspension
139306|NCT01655082|Drug|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
139307|NCT01655082|Drug|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
139308|NCT01655095|Drug|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
142759|NCT01677754|Drug|donepezil|stable dose background medication
142760|NCT01677754|Drug|galantamine|stable dose background medication
142761|NCT01677754|Drug|memantine|stable dose background medication in combination with AChEIs
142762|NCT01677754|Drug|placebo|12 months
142763|NCT00001680|Drug|Thalidomide|
142764|NCT00089011|Drug|fludarabine phosphate|Given IV
142765|NCT01677754|Drug|rivastigmine|stable dose background medication
142766|NCT01677780|Drug|RO5045337|Patients will continue on the same formulation, dose and schedule of RO5045337 they were receiving at the time of transitioning from the parent clinical study protocol.
142786|NCT01669941|Drug|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
142787|NCT01669967|Drug|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
142788|NCT01669967|Drug|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
142789|NCT01669980|Drug|Ceftaroline fosamil|Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)
Subjects < 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)
Optional Oral Switch:
PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h
PO clindamycin 13 mg/kg/dose
PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h
142790|NCT01669980|Drug|IV Ceftriaxone and Vancomycin|IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND
IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.
Optional Oral Switch:
PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h
PO clindamycin 13 mg/kg/dose
PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h
142791|NCT01670019|Drug|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
142792|NCT01670019|Drug|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
142793|NCT01670032|Drug|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
142794|NCT00087789|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10^10 vg, CERE-110 1.0 x 10^11 vg, CERE-110 2.0 x 10^11 vg
139362|NCT01650649|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
139363|NCT01650649|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
139364|NCT00086840|Other|laboratory biomarker analysis|Correlative studies
139365|NCT01652794|Drug|carboplatin|Given IV
139366|NCT01652794|Drug|gemcitabine hydrochloride|Given IV
139367|NCT01652794|Other|laboratory biomarker analysis|Optional correlative studies
139368|NCT01652794|Other|pharmacogenomic studies|Optional correlative studies
139369|NCT01652807|Behavioral|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
139370|NCT01652820|Drug|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
139371|NCT01652820|Drug|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
138404|NCT01628809|Behavioral|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
138405|NCT01628822|Behavioral|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
138406|NCT01628822|Behavioral|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
138407|NCT01628835|Behavioral|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
138408|NCT01628835|Behavioral|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
138409|NCT01628848|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
138410|NCT01628848|Drug|Placebo|Placebo transdermal patch
139132|NCT01654679|Other|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
139133|NCT01654692|Drug|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
139134|NCT01654705|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
139135|NCT01654705|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
139136|NCT01654718|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
139137|NCT01654718|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
139138|NCT01654731|Drug|Bezafibrate|
139139|NCT01654731|Drug|placebo|
139140|NCT01654770|Device|video capsule endoscopy|
139141|NCT01654770|Device|double balloon enteroscopy|
139142|NCT00001628|Drug|Angiotensin II type 1 receptor antagonists|
139143|NCT00086983|Drug|becatecarin|Given IV
139144|NCT01654796|Device|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
139145|NCT01654796|Device|Sham LFMS|SHam LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
139146|NCT01654809|Biological|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
139147|NCT01654809|Biological|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
139148|NCT01654809|Biological|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
139149|NCT01654822|Drug|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
139150|NCT01654822|Drug|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
139427|NCT01650662|Drug|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
139309|NCT00086996|Drug|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
139310|NCT01655095|Drug|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
139311|NCT01655095|Drug|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
139312|NCT01655095|Drug|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
139313|NCT01655095|Procedure|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
139314|NCT01655095|Procedure|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
138340|NCT00084916|Drug|temsirolimus|Given IV
138341|NCT01631227|Drug|Eprosartan|Eprosartan 450 mg
138342|NCT01631227|Drug|Eprosartan Mesylate|Eprosartan mesylate 600 mg
138343|NCT01631227|Drug|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
138344|NCT01631227|Drug|Placebo Eprosartan|Placebo Eprosartan
138345|NCT01633775|Procedure|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
138346|NCT01633788|Drug|AGN-195263 Formulation A|1 drop of AGN-195263 Formulation A will be instilled in each eye twice daily.
138347|NCT01633788|Drug|AGN-195263 Formulation B|1 drop of AGN-195263 Formulation B will be instilled in each eye twice daily.
138348|NCT01633788|Drug|AGN-195263 Formulation C|1 drop of AGN-195263 Formulation C will be instilled in each eye twice daily.
138349|NCT01633788|Drug|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
138350|NCT01633801|Device|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
138351|NCT01633801|Device|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
138352|NCT01633814|Drug|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1 plus oral placebo
142795|NCT01664754|Drug|exemestane|Given PO
142796|NCT01664754|Drug|pemetrexed disodium|Given IV
142797|NCT01664754|Drug|carboplatin|Given IV
142798|NCT01664754|Other|laboratory biomarker analysis|Correlative studies
142799|NCT01664754|Other|pharmacological study|Correlative studies
142800|NCT01664754|Other|questionnaire administration|Ancillary studies
142801|NCT01664754|Procedure|quality-of-life assessment|Ancillary studies
142802|NCT01664767|Other|Sulfur Thermal water|
142803|NCT01664767|Other|Placebo|
142804|NCT01664780|Device|ARFI imaging|
143088|NCT01667718|Drug|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
143089|NCT01667718|Drug|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
143090|NCT01667718|Drug|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
143091|NCT01667731|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
143092|NCT01667731|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
143093|NCT01667744|Drug|Citalopram|10 mg/day
143094|NCT01667770|Procedure|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
143095|NCT00088192|Drug|pegaptanib sodium|
143096|NCT01667783|Procedure|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
143097|NCT01667783|Behavioral|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
143098|NCT01667783|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
143099|NCT01659307|Drug|Aspirin 1200mg|Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
138411|NCT01628861|Device|MyRestBreak 1.0|Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message "stand up, take a break" is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days.
138412|NCT00084812|Drug|cisplatin|
138413|NCT01628861|Behavioral|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
138414|NCT01628874|Device|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
138415|NCT01631253|Procedure|Laparoscopic ovarian cyst enucleation|
138416|NCT01631266|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
138417|NCT01631266|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
138418|NCT01631279|Drug|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
138419|NCT01631292|Dietary Supplement|600 IU Vitamin D3|Once daily
138420|NCT01631292|Dietary Supplement|2000 IU Vitamin D3|Once daily
138421|NCT00084916|Other|laboratory biomarker analysis|Correlative studies
138422|NCT01631292|Dietary Supplement|4000 IU Vitamin D3|Once daily
138730|NCT01651884|Device|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
138731|NCT01651884|Device|Transcranial Direct Current Stimulation (Neuroconn)|
138732|NCT01651923|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
138733|NCT01651936|Drug|MK-8457|MK-8457 administered orally at a dose of 200 mg daily.
138734|NCT01651936|Drug|Methotrexate (MTX)|Participants will continue on the stable dose of MTX that they were receiving prior to study entry.
138735|NCT01651936|Drug|Placebo|Matching placebo to MK-8457 administered orally.
139428|NCT01650675|Behavioral|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
139429|NCT01650675|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
139430|NCT01650701|Drug|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
139431|NCT01650701|Drug|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
139432|NCT01650701|Drug|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
139433|NCT01650701|Drug|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
139434|NCT01650701|Drug|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
139435|NCT00086645|Drug|citalopram hydrobromide|10mg/5ml solution
139436|NCT01650714|Other|Full thickness gastric biopsy|
139437|NCT01650714|Procedure|Full thickness gastric biopsy|
139438|NCT01650727|Drug|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m^2 up to a maximum dose of 14 mg/m^2.
139439|NCT01650727|Biological|Rituximab|Rituximab 375 mg/m^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
139440|NCT01650740|Drug|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
139441|NCT01650740|Drug|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
139442|NCT01650740|Other|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
139443|NCT01650753|Dietary Supplement|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10^10 cells/sachet)
139444|NCT01650753|Dietary Supplement|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
138480|NCT01636908|Drug|Everolimus|10 mg once daily, oral use, 14 days
138353|NCT01633814|Drug|Estradiol plus progesterone|transdermal estradiol 100 µg day-1 plus oral progesterone (provera 5 mg)
138354|NCT01633814|Drug|Oral Progesterone|placebo patch plus oral progesterone (provera 5 mg)
138355|NCT00085189|Biological|tyrosinase peptide|Given SC
138356|NCT01633814|Drug|Placebo|placebo patch plus oral placebo.
138357|NCT01633827|Drug|Placebo pill|Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
138358|NCT01633827|Drug|Sedative|Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
138359|NCT01633827|Other|Room air|Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies
138360|NCT01633827|Other|Oxygen|Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
138361|NCT01633840|Other|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
138671|NCT00086944|Drug|carboplatin|Given IV
138672|NCT01653964|Device|Gamma Medica Instruments-LumaGem 3200S|
138673|NCT01653977|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
138674|NCT01656304|Biological|bevacizumab|Given IV
138675|NCT01656304|Other|laboratory biomarker analysis|Correlative studies
138676|NCT01656317|Other|Early multidisciplinary rehabilitation|Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.
The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist.
138677|NCT01656330|Drug|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
138678|NCT01656330|Drug|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
138679|NCT01656330|Drug|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
143100|NCT01659320|Drug|Minocycline|Minocycline 100 mg twice daily for 8 weeks
143101|NCT01659346|Procedure|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
143102|NCT01659346|Drug|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
143103|NCT01659359|Device|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
143104|NCT01659359|Drug|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
143105|NCT00087399|Drug|antidepressant|
143106|NCT01659372|Radiation|low level laser therapy|
143107|NCT01659372|Drug|Naproxen|
143108|NCT01659398|Device|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
143109|NCT01659411|Other|Observational|Yearly clinical visits
142189|NCT00088556|Drug|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
142190|NCT01671449|Drug|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
142191|NCT01671449|Drug|Cisplatin|60 mg/m2/day Day 1
142192|NCT01671449|Drug|Oxaliplatin|130 mg/m2/day Day 1
142193|NCT01671462|Device|BD HPV assay on Viper LT|
142194|NCT01671475|Device|microEEG (Bio-Signal microEEG)|At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2"x2"x1".
142195|NCT01671488|Biological|Advaxis|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu. The drug will be given as an 500ml infusion over 15 minutes.
142196|NCT01671501|Behavioral|Motivational Interviewing|
142197|NCT01671501|Behavioral|Email Feedback|
142198|NCT01671501|Other|Usual Care|
138736|NCT01651949|Biological|9vHPV Vaccine|9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
138737|NCT01651962|Drug|Terbutaline|
138738|NCT01651962|Drug|Fentanyl|
138739|NCT01651962|Drug|0.9% NaCl|
138740|NCT00086762|Behavioral|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
138741|NCT01653977|Other|OPTIMIZED|In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).
The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
138742|NCT01653990|Drug|moxifloxacin|oral dose of 400mg moxifloxacin
138743|NCT01653990|Drug|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
138744|NCT01654003|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
138745|NCT01654003|Other|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
138746|NCT01654016|Drug|Detralex|Detralex 500 mg twice daily for three month prior to surgery
138747|NCT01654029|Behavioral|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
139063|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
139064|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
139065|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
139066|NCT01657058|Dietary Supplement|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
138481|NCT01636908|Drug|Lapatinib|1250 mg once daily, oral use, 14 days
138482|NCT01636908|Drug|Dasatinib|100 mg once daily, oral use, 14 days
138483|NCT01636908|Drug|Pazopanib|800 mg once daily, oral use, 14 days
138484|NCT01628874|Drug|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
138485|NCT01628874|Drug|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
138486|NCT01628887|Other|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
138487|NCT01628900|Other|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
138488|NCT01628900|Other|Care management|Hospital vs home
138489|NCT01628913|Drug|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
138490|NCT01628913|Drug|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
138491|NCT01628926|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
138492|NCT00084812|Drug|safingol|
138493|NCT01628926|Drug|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
138494|NCT01628926|Drug|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
138495|NCT01628939|Other|MRI of the lumbar spine|standard protocol, approximately 30 minutes
138496|NCT01628939|Other|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
138497|NCT01628952|Drug|Transversus Abdominis Plane|PIA coelioscopic
138498|NCT01628952|Drug|Curare|IAP coelioscopic
138499|NCT01628965|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
138500|NCT01628978|Other|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
138501|NCT01628978|Other|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
138680|NCT01656330|Drug|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
138681|NCT01656330|Other|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
138682|NCT01656343|Drug|Calcineurin inhibitors (CNI)|No Intervention
138683|NCT01656343|Drug|Belatacept|No Intervention
138684|NCT00087152|Drug|Capecitabine|1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle
138685|NCT01656356|Biological|Avian Flu Vaccine|
138686|NCT01656356|Biological|Placebo|
138687|NCT01656369|Procedure|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
138688|NCT01656369|Procedure|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
139002|NCT01650051|Drug|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|Deep brown maroon colored, film coated round biconvex tablet debossed 'AN" obve '2' on one side and plain on the other side.
139003|NCT01650051|Drug|Phenazopyridine Hydrochloride Tables, USP 200 mg|Deep brown maroon colored, film coated round biconvex tablet debossed 'AN" obve '2' on one side and plain on the other side.
139004|NCT01650090|Drug|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
139005|NCT01652157|Biological|PANCREAZE|pancreatic enzyme replacement therapy
139006|NCT01652157|Biological|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
139007|NCT01652157|Other|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis patient registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
139008|NCT01652183|Drug|intravenous paracetamol|
139009|NCT01652183|Drug|Placebo|
142199|NCT01671514|Dietary Supplement|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
142200|NCT00088556|Drug|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
142201|NCT01673984|Drug|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 & month 6 (+/- 7 days).
142202|NCT01673984|Drug|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
142203|NCT01673997|Drug|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
142204|NCT00088816|Procedure|conventional surgery|
142205|NCT01674010|Drug|ELND005|
142206|NCT01674010|Drug|Lamotrigine|
142207|NCT01674010|Drug|Valproic acid|
142208|NCT01674010|Drug|Placebo|
142209|NCT01674036|Drug|Genz-682452|Capsules for oral administration.
142210|NCT01674036|Drug|Placebo|Placebo to Genz-682452
142767|NCT01677806|Procedure|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
142768|NCT01677806|Other|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
142769|NCT01677845|Radiation|Radiation|Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;
Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;
Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions.
142770|NCT01677858|Drug|carfilzomib|
142771|NCT01677871|Drug|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
142772|NCT01677871|Drug|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
142773|NCT01677871|Drug|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
142774|NCT01677871|Drug|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
142775|NCT01669863|Procedure|ECMO in non-intubated patients|Use of veno-venous ECMO in non-intubated patients with ARDS
139067|NCT01657058|Dietary Supplement|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
139068|NCT01657058|Dietary Supplement|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
139069|NCT01657058|Dietary Supplement|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
139070|NCT01657058|Dietary Supplement|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
139071|NCT01657071|Drug|YH14659|YH14659 capsule by oral
139072|NCT00087191|Drug|motexafin lutetium|Given IV
139073|NCT01657071|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
139074|NCT01657084|Device|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
139075|NCT01657084|Device|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
139076|NCT01650129|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
139077|NCT01650129|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
139078|NCT01650142|Other|No intervention|No intervention
139079|NCT01650155|Drug|BI 1005273 s.c.|injection
139080|NCT00086528|Drug|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
139081|NCT01650155|Drug|BI 105273 i.v. Placebo|infusion
139082|NCT01650155|Drug|BI 1005273 s.c. Placebo|injection
139372|NCT01652833|Other|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
139373|NCT01652859|Drug|Liposomal Amphotericin B|
138502|NCT01628991|Behavioral|behavioural program|interventional behavioural program
138503|NCT00084825|Drug|Docetaxel|30 mg/m^2 IV on days 1, 8, 15, and 22 every 42 days
138814|NCT01651975|Dietary Supplement|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
138815|NCT01651975|Dietary Supplement|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
138816|NCT01651988|Drug|Ketamina-Propofol Combination|After randomization to the study group, the patients were given:
Procedures < 10 minutes
Ketamine-Propofol Combination KETOFOL 1:1
Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)
Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)
Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)
Ketamine-Propofol Combination KETOFOL 1:2
Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)
Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)
Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)
Procedures > 10 minutes
In addition to the initial bolus, an infusion was started:
KETOFOL 1:1
20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN
KETOFOL 1:2
20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN
Speed infusion:
0,03cc/kg/min
138817|NCT01652001|Drug|Malic Acid|
138818|NCT01652001|Other|Placebo|
138819|NCT01652014|Drug|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
138820|NCT01652014|Drug|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
138821|NCT01652014|Drug|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
138822|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
138823|NCT01652014|Procedure|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
138824|NCT00086762|Behavioral|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
138825|NCT01652014|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
138826|NCT01652014|Radiation|total-body irradiation|Undergo TBI
139010|NCT01652196|Biological|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
139011|NCT01652196|Drug|oxaliplatin|85 mg/m2 IV infused over 2 hours
139012|NCT01652196|Drug|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
139013|NCT01652196|Drug|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
139014|NCT01652196|Other|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
139015|NCT00086775|Drug|fludarabine phosphate|
139016|NCT01652196|Procedure|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
139017|NCT01652196|Radiation|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
139018|NCT01652196|Procedure|PET (positron emission tomography)|Correlative studies
139019|NCT01652209|Biological|Hearticellgram-AMI|
139020|NCT01652222|Other|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
139021|NCT01652222|Other|Socio-educational training only|4 socio-educative training sessions during 8 weeks
139315|NCT01655108|Drug|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
139316|NCT01655108|Drug|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
139317|NCT01655121|Dietary Supplement|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
Each participant will receive nutritional counseling once month during six months.
139318|NCT01655134|Other|Blood simples|
139319|NCT01655134|Other|Capillary punction|
139320|NCT00086996|Procedure|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
142776|NCT01669876|Dietary Supplement|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
142777|NCT01669876|Dietary Supplement|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
142778|NCT01669915|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
142779|NCT01669915|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
142780|NCT01669915|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
142781|NCT01669915|Dietary Supplement|Fish oil placebo|Fish oil placebo
142782|NCT01669928|Drug|Anti-hypertensive Medication -|Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.
Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00).
142783|NCT00088413|Biological|PANVAC-F|A recombinant fowlpox virus vector vaccine containing genes for human CEA, MUC-1, and three co-stimulatory molecules:B7.1, ICAM-1, and LFA-3.
142784|NCT01669941|Drug|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
142785|NCT01669941|Drug|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
142805|NCT00087802|Drug|gemcitabine/Eloxatin (GEMOX)|GEMOX [gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days [3-week cycle]
142806|NCT01664793|Behavioral|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
142807|NCT01664806|Device|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
142808|NCT01664819|Dietary Supplement|Antioxidant|
142809|NCT01664819|Dietary Supplement|Placebo|
142810|NCT01664832|Device|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
142811|NCT01664845|Drug|metformin|metformin 500mg tid
142812|NCT01664845|Drug|pegylated-IFN|pegasys 180 mcg qw
139374|NCT01652859|Drug|AmBisome|
139375|NCT00086866|Biological|D1/3-MAGE-3-His fusion protein|
139376|NCT01652872|Biological|Darbepoetin alfa|Darbepoetin alfa will be presented as single use prefilled syringes. Investigational product will be administered subcutaneously every 4 weeks for the duration of the treatment period.
139377|NCT01652885|Drug|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
139378|NCT01652898|Drug|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
139379|NCT01652898|Drug|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
139380|NCT01652898|Drug|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
139381|NCT01652911|Device|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
139382|NCT01652924|Device|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
139383|NCT01652924|Device|Manual ventilation with facial mask|This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.
The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist.
139384|NCT01652937|Drug|BIIB057|Oral
139385|NCT01652937|Drug|Placebo|Oral
139386|NCT01655147|Drug|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
139387|NCT01655160|Behavioral|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
139388|NCT01655160|Behavioral|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
139389|NCT01655160|Behavioral|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
138423|NCT01631305|Drug|Levothyroxine|3 mcg/kg/day
138424|NCT01631305|Other|Calcium magnesia|Placebo.
138827|NCT01652014|Drug|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
138828|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
138829|NCT01652014|Procedure|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
138830|NCT01652027|Drug|FVIII concentrate|usual treatment as directed by treating physician
139151|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
139152|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
139153|NCT01657240|Drug|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
139154|NCT01657253|Drug|PRO-148|Instill one drop in each eye four times a day (QID), for 60 days
139155|NCT01657253|Drug|Systane|Instill one drop in each eye four times a day (QID), for 60 days
139156|NCT01657266|Drug|PRO-155|instill one drop 2 times a day (BID) for 30 days
139157|NCT01657266|Drug|Nevanac|instill one drop 2 times a day (BID) for 30 days
139158|NCT01657279|Other|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome [i.e. from low (<10%) to high (>50%) expected risk death at 30 days].
139159|NCT01657292|Drug|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
139160|NCT01657292|Device|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
139161|NCT00087204|Other|laboratory biomarker analysis|Correlative studies
139162|NCT01657305|Drug|Oleogel-S10 ointment and non-adhesive wound dressing|One randomly assigned wound half is treated with Oleogel-S10 and non-adhesive wound dressing
139163|NCT01657305|Device|Non-adhesive wound dressing alone|The other wound half is treated with non-adhesive wound dressing alone.
139164|NCT01657318|Other|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
139165|NCT01657331|Drug|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
139166|NCT01657331|Drug|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
139321|NCT01655134|Other|Urine simples|
139322|NCT01655147|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
139323|NCT01657097|Drug|INCS|
139324|NCT01657097|Drug|Placebo|
139325|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
139326|NCT01657123|Other|ergometry|ergometry measurements
139327|NCT01657123|Other|ergometry|Ergometry measurements
139328|NCT01657136|Drug|Ivabradine|comparison of different drugs
139329|NCT01657136|Drug|Beta blocker|comparison of different drugs
139330|NCT00087191|Other|pharmacological study|Correlative studies
139331|NCT01657149|Procedure|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
139332|NCT01657149|Procedure|individual physiotherapy only|individual physiotherapy only
139333|NCT01657162|Drug|Alendronate|Bisphosphonate
139334|NCT01657175|Other|Supportive care|The patients will be randomized to control or supportive care groups.
The control group will be given "care as usual" wich include clinical follow-ups at the surgical department.
The supportive care group get in addition to the clinical follow-ups a supportive care programme including:
Discharge information about surgery and life after surgery together with their relatives.
Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.
Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery
139335|NCT01657188|Device|Cheyne-Stokes respiration by adaptive servoventilation|
139336|NCT01657201|Drug|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
138362|NCT01633840|Other|Elemental E028|Elemental E028 with no added food allergens
138363|NCT01633853|Drug|Vitamin D2|Treatment with Vit D2.
138364|NCT01633853|Drug|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
138365|NCT01633879|Behavioral|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
138366|NCT00085189|Biological|recombinant MAGE-3.1 antigen|Given SC
142813|NCT01664845|Drug|ribavirin|ribavirin 800-1200 mg qd according to BW
142814|NCT01664858|Other|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
142815|NCT01664858|Other|SPECT|SPECT: Single Photon Emission Computed Tomography
142816|NCT00087802|Drug|carboplatin/paclitaxel (CP)|CP [carboplatin/paclitaxel - 21 day cycle]
o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days [3-week cycle]
142817|NCT01664858|Other|CT calcium score|CT calcium score
142818|NCT01664858|Other|CT coronary angiography|CT coronary angiography
142819|NCT01664858|Other|X-Ray coronary angiography|X-Ray coronary angiography
142820|NCT01667146|Other|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
142821|NCT01667159|Behavioral|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
142822|NCT01667159|Behavioral|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
142823|NCT01667172|Device|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
141919|NCT01670864|Behavioral|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
141920|NCT01670877|Drug|Neratinib|
141921|NCT01670877|Drug|Fulvestrant|
141922|NCT01670877|Drug|Trastuzumab|
141923|NCT01670890|Drug|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
141924|NCT01670890|Drug|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
141925|NCT01670916|Dietary Supplement|probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
138425|NCT01631318|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo 3D contrast enhanced ultrasound imaging
138426|NCT01631331|Drug|vismodegib|Given PO
138427|NCT01631331|Procedure|Mohs surgery|Undergo Mohs surgery
138428|NCT01631344|Other|Daily physical activity consultation, Using the "Stage of change" model|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
138429|NCT01631357|Drug|Arm 1: cytokine-induced killer cell + cisplatin + paclitaxel|TP regimen: intravenous infusions; paclitaxel, 135 mg/m2, day 1; intravenous injection cisplatin, 80 mg/m2, day 1; one cycle every month; up to 6 cycles. CIK cells: intravenous infusions; 5-6 × 109 CIK cells, days 14 and 15; one cycle every month; at least 6 cycles.
138430|NCT01631357|Drug|Arm 2: cisplatin + paclitaxel|TP regimen: intravenous infusions; paclitaxel, 135 mg/m2, day 1; intravenous injection cisplatin, 80 mg/m2, day 1; one cycle every month; up to 6 cycles.
138431|NCT01631370|Procedure|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
138432|NCT00084929|Procedure|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
138433|NCT01631383|Drug|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
138434|NCT01631383|Drug|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
138435|NCT01631396|Drug|Sugammadex vs. Neostigmine|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
138436|NCT01633918|Behavioral|Usual health education|Usual health education lessons
138437|NCT01633944|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
138438|NCT01633944|Drug|Placebo|Matching Placebo Buccal Film twice daily
138439|NCT01633957|Other|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
138440|NCT01633957|Other|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
139167|NCT01657331|Drug|Neulasta|(Non-experimental) - standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
139168|NCT01657357|Other|Routine followup|questionnaires
139169|NCT01657370|Drug|MK-1602|Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).
Dosage form is film coated tablet for oral administration.
139170|NCT01657370|Drug|Placebo|Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).
Dosage form is film coated tablet for oral administration.
139445|NCT01650779|Biological|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
139446|NCT00086658|Drug|mepolizumab|
139447|NCT01650792|Drug|Aspirin|
139448|NCT01650805|Drug|ponatinib|45 mg tablet, taken orally once daily
139449|NCT00086866|Biological|SB-AS02B adjuvant|
139450|NCT01652950|Behavioral|Financial incentives|The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
Level 1: <150 fitness points per month - equivalent to < 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month.
139451|NCT01652963|Other|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
139452|NCT01652976|Drug|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
139453|NCT01652976|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
139454|NCT01652989|Behavioral|Weight loss maintenance intervention face-to-face|
139455|NCT01652989|Behavioral|Weight loss maintenance intervention delivered via DVD|
139456|NCT01653002|Other|No intervention|
139457|NCT01653015|Biological|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
138367|NCT01633879|Behavioral|health and success parent and school|Parenting education and school intervention
138368|NCT01633892|Procedure|Fat Grafting|
138369|NCT01633918|Behavioral|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
138370|NCT01636609|Drug|Tosedostat|Phase I: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade >/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.
Phase II: 120 mg by mouth daily. 120 mg by mouth daily during induction (i.e., first 28 days of therapy). After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade >/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.
138371|NCT01636622|Drug|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
138372|NCT01636622|Drug|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
138373|NCT01636622|Drug|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
138374|NCT01636635|Other|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
138375|NCT01636648|Device|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
138376|NCT01636661|Device|tDCS|transcranial direct current stimulation- non-invasive brain stimulation
138377|NCT01636674|Other|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
138378|NCT00085358|Drug|docetaxel|Given IV
138379|NCT01636687|Drug|Placebo|2 injections of placebo to secukinumab 150mg per dose
138380|NCT01636687|Drug|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose will be administered
138381|NCT01636687|Drug|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
138689|NCT01656382|Drug|ABLC|
138690|NCT01656395|Drug|MK-1029 10 mg|Parts I-II: Participants will receive MK-1029 10 mg tablets taken once daily (QD)
138691|NCT01656395|Drug|MK-1029 30 mg|Parts I-II: Participants will receive MK-1029 30 mg tablets QD
141926|NCT01670929|Drug|Progesterone|progesterone either vaginal or rectal rout twice daily
141927|NCT01670942|Other|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
141928|NCT00088517|Drug|[11C]NNC-112|
141929|NCT01670955|Dietary Supplement|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
141930|NCT01670955|Drug|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
141931|NCT01673347|Biological|Meniscal Allograft|Meniscal allograft
141932|NCT00088790|Drug|AZD5438|
141933|NCT01673360|Device|Prolapse (AMS prolapse products)|List of AMS prolapse products
141934|NCT01673360|Device|Urinary Incontinence (Mini Arc Pro)|List of AMS Urinary Incontinence devices
141935|NCT01673373|Device|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
141936|NCT01673386|Drug|Tivozanib Hydrochloride|
141937|NCT01673386|Drug|Sunitinib|
141938|NCT01673399|Drug|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
141939|NCT01673399|Drug|placebo|
142211|NCT01674049|Dietary Supplement|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
142212|NCT01674049|Dietary Supplement|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
142213|NCT01674049|Other|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
142214|NCT01674062|Drug|pertuzumab [Perjeta]|Loading dose 840 mg intravenously on Day 2 of the first cycle. 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
142215|NCT00088816|Procedure|neoadjuvant therapy|
142216|NCT01674062|Drug|Trastuzumab|Intravenous (IV) infusion of 2 milligrams per kilogram (mg/kg) once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
138748|NCT01654042|Other|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
138749|NCT00086944|Drug|etoposide|Given IV
138750|NCT01654068|Radiation|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14Gy single fraction dosing using 6MV photons
138751|NCT01654081|Drug|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
138752|NCT01654094|Device|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
138753|NCT01654094|Other|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
138754|NCT01654107|Behavioral|Persistence Targeted Smoking Cessation|8-weeks of smoking cessation counseling ("Persistence Targeted Smoking Cessation")
138755|NCT01654107|Behavioral|Clearing The Air|8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
138756|NCT01654107|Drug|Nicotine lozenge|12-weeks 4mg nicotine lozenge
138757|NCT01654120|Drug|Liraglutide|SC, 1.8mg,QD, six months to one year
138758|NCT01654120|Drug|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
138759|NCT01654133|Device|Endovascular repair of TAAA using branched stent graft|Repair of thoracoabdominal aortic aneurysms
138760|NCT00086944|Biological|filgrastim|Given SC
138761|NCT01656395|Drug|MK-1029 1 mg or 3 mg|Part II: Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
138762|NCT01656395|Drug|Montelukast 10 mg + MK-1029|Part II: Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
138763|NCT01656408|Drug|MK-8150|
138764|NCT01656408|Drug|Placebo for MK-8150|
138765|NCT01656434|Drug|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
138766|NCT01656434|Drug|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
139458|NCT01653015|Biological|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
139459|NCT01653028|Drug|Alisertib|Given PO
139460|NCT00086866|Biological|SB-AS15 adjuvant|
139461|NCT01653028|Other|Laboratory Biomarker Analysis|Correlative studies
139462|NCT01653041|Drug|Everolimus|
139463|NCT01653054|Procedure|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
139464|NCT01653067|Drug|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
138504|NCT01628991|Device|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
138505|NCT01629004|Other|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
138506|NCT01629004|Other|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
138507|NCT01629056|Procedure|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
138508|NCT01629056|Procedure|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
138509|NCT01629069|Behavioral|Mindfulness based Resilience Training|6 weekly group sessions
138510|NCT01629082|Drug|Clofarabine|
138511|NCT01631409|Other|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
138512|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
138513|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
138514|NCT01631409|Procedure|PCA|Percutaneous coronary angioplasty
138515|NCT01631409|Procedure|CABG|Coronary artery bypass grafting
138692|NCT01656395|Drug|MK-1029 150 mg|Parts I-II: Participants will receive MK-1029 150 mg tablets QD
138693|NCT01656395|Drug|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
138694|NCT01656395|Drug|Placebo|Parts I-II: Participants will receive Placebo tablets QD
138695|NCT00087152|Drug|Imatinib mesylate|400 mg by mouth daily
138696|NCT01649401|Device|Standard nebulizer|Nebulizer sessions for the patients will be administerd using our "standard" nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical.
138697|NCT01649401|Device|PARI LC Sprint Sp nebulizer|Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.
Manufacturer: PARI GmbH Germany
138698|NCT01649427|Drug|Simulect|Induction Therapy: 2x20mg; day 0 and day 4 post Tx
138699|NCT01649427|Drug|Steroids|recommended on Day 14 after transplantation steroid dose is reduced to 5 mg prednisolon or eqivalent. A minimum dose of 5 mg prednisolon or equivalent should be continued until Month 6.
138700|NCT01649427|Drug|Prograf|0.15 mg/KG Transplantation to Month 1: 8 - 12 ng/ml Month 1 to Month 3: 5 - 10 ng/ml Month 3 to Month 6: 5 - 8 ng/ml
138701|NCT01649427|Drug|Tacrolimus Hexal|0.15 mg-Kg Transplantation to Month 1: 8 - 12 ng/ml Month 1 to Month 3: 5 - 10 ng/ml Month 3 to Month 6: 5 - 8 ng/ml
138702|NCT01649453|Device|Pathwork® Tissue of Origin Test|
138703|NCT01649466|Drug|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
138704|NCT01649466|Drug|Protaphane|Protaphane will be used as commercially available injection pens
138705|NCT01649479|Biological|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
138706|NCT00001614|Drug|Chicken type II collagen|
138707|NCT00086502|Drug|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
138708|NCT01649479|Biological|Thrombophilia bloodwork|Bloodwork will be drawn up for:
antithrombin, protein C, protein S
Factor V Leiden polymorphisms (F5 1691A)
prothrombin 20210A gene polymorphism (F2 20210A)
JAK2 617F Mutation
Homocysteine
Factor VIII
138709|NCT01649479|Other|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
142217|NCT01674101|Other|Endurance|Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.
142218|NCT01674101|Other|Strengthening|Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.
142219|NCT01674101|Other|Stretching|Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.
142220|NCT01674101|Other|Home exercise program|All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
142221|NCT01674114|Procedure|TAP block|
142222|NCT01674114|Procedure|control|
142223|NCT01674127|Drug|Methyldopa|
142224|NCT01674127|Drug|Placebo|
142225|NCT01674140|Drug|anastrozole|Given orally
142226|NCT01676623|Behavioral|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
142227|NCT01676623|Behavioral|Mass media campaign|Alive & Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
142228|NCT00088946|Other|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
142490|NCT01674439|Procedure|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
142491|NCT01674439|Procedure|Without supplementation of ADRC|Standard fat graft preparation
142492|NCT01674452|Behavioral|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
142493|NCT01674452|Behavioral|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
138767|NCT01656434|Other|Placebo|tablet
138768|NCT01656434|Drug|ethinylestradiol (EE)|EE 10 μg tablet
138769|NCT01656434|Drug|ferrous fumarate|ferrous fumarate 75 mg tablet
139083|NCT01650155|Drug|BI 1005273 i.v.|infusion
139084|NCT01650181|Drug|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
139085|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
139086|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
139087|NCT01650181|Drug|Metformin|Patients with fatty liver treated with diet, exercise and metformin
139088|NCT01650194|Drug|enzalutamide|oral
139089|NCT01650194|Drug|abiraterone acetate|oral
139090|NCT01650194|Drug|prednisone|oral
139091|NCT00086541|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
139092|NCT01650207|Procedure|acupuncture|All participants were received regular rehabilitation program, and received different interventions.
treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks
139093|NCT01650207|Procedure|TENS|
139094|NCT01650207|Procedure|sham acupuncture|
139095|NCT01650233|Behavioral|Mindfulness-based stress reduction|
139096|NCT01650246|Drug|lesinurad|Tablets, 400 mg QD
139097|NCT01650259|Drug|OAD|OAD except Trazenta tablets
139098|NCT01650259|Drug|Trazenta|Linagliptin
139099|NCT01650272|Drug|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
139100|NCT01650272|Drug|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
139101|NCT01652300|Behavioral|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
138516|NCT01631409|Device|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
138517|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
138518|NCT00084942|Drug|capecitabine|
138519|NCT01631422|Drug|RO4602522|Single radiolabeled dose
138520|NCT01631435|Other|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
138521|NCT01631435|Device|Ileocolonoscopy|Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure
• Ileocolonoscopy with intubation of terminal ileum
138522|NCT01631448|Biological|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
138831|NCT01652040|Procedure|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
138832|NCT01652040|Drug|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
138833|NCT01654146|Drug|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
138834|NCT01654146|Drug|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
138835|NCT01654146|Drug|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
138836|NCT01654146|Drug|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
138837|NCT01654159|Procedure|Monofocal IOL|Monofocal Intraocular lens will be implanted
138838|NCT01654159|Procedure|Multifocal IOL|Multifocal IOL will be implanted
138839|NCT01654159|Procedure|Toric IOL|Toric IOLS will be implanted
138840|NCT01654172|Dietary Supplement|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is ~900mg
138841|NCT01654172|Dietary Supplement|Low Flavanol Cocoa|
138842|NCT01654185|Drug|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
138843|NCT00086944|Biological|pegfilgrastim|Given SC
139022|NCT01652235|Device|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
139023|NCT01652248|Procedure|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
139024|NCT01652261|Drug|ABVD + FDG-PET/CT Scan treatment adaptation|
139025|NCT01652261|Drug|BEACOPPesc|
139026|NCT00086801|Drug|doxorubicin hydrochloride|given IV
139027|NCT01652287|Drug|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
139028|NCT01652287|Other|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
139029|NCT01654484|Drug|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
139030|NCT01654484|Drug|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
139031|NCT01654484|Drug|Placebo|Ophthalmic Solution, QD, 28 days
139032|NCT01654497|Drug|Dexanabinol|Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)
Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.
Dose Level 1: 2 mg/kg
Dose Level 2: 4 mg/kg
Dose Level 3: 8 mg/kg
Dose Level 4: 16 mg/kg
Dose Level 5: 24 mg/kg
Dose Level 6: 28 mg/kg
Dose Level 7: 36 mg/kg
Dose Level 8: 40 mg/kg
Dose Level 9: 44 mg/kg
139033|NCT01654510|Behavioral|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
139034|NCT00086957|Drug|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
139035|NCT01654510|Other|Vocational Services as Usual|
139036|NCT01654523|Device|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
139037|NCT01654536|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
139038|NCT01654536|Drug|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
139039|NCT01654549|Drug|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
139040|NCT01654562|Drug|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
142494|NCT01674465|Biological|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m^2 two-three hours prior to their standard of care biopsy
142495|NCT01674478|Dietary Supplement|Microlipid and fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
142496|NCT01674478|Dietary Supplement|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
142497|NCT01674491|Dietary Supplement|black soy peptide|black soy peptide: 4.5g/day for 8 weeks
142498|NCT01674504|Drug|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
142499|NCT00088855|Other|Laboratory Biomarker Analysis|Correlative studies
142500|NCT01677195|Drug|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
142501|NCT01677195|Drug|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
142502|NCT01677208|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
142503|NCT01677208|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
142504|NCT01677208|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
142824|NCT01667198|Procedure|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
142825|NCT00088140|Drug|IDN-6556|
139102|NCT01652300|Behavioral|no education|women in the control group received no education
139103|NCT01652313|Drug|Rasagiline|1 mg/day, tablets for 7 days, orally
139104|NCT01652326|Drug|Diazepam|
139105|NCT01652339|Drug|Exforge tab. 10/160mg|
139106|NCT01652339|Drug|Lodivixx tab. 5/160mg|
139390|NCT01655160|Behavioral|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
139391|NCT01655173|Behavioral|Cognitive behaviour therapy|The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.
The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session.
139392|NCT01655173|Behavioral|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
139393|NCT01655186|Drug|Bardoxolone Methyl|
139394|NCT00086996|Radiation|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
139395|NCT01655186|Drug|Placebo|
139396|NCT01655199|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
139397|NCT01655212|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
139398|NCT01655225|Drug|LY3023414|Administered orally QD or BID for a 21 day Cycle. Dose of 20 to 600 mg, as determined in Part A.
139399|NCT01655225|Drug|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
139400|NCT01655225|Drug|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
139401|NCT01655225|Drug|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
138844|NCT01654185|Drug|Aromatase Inhibitor|1 tablet per day
138845|NCT01654198|Radiation|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
138846|NCT01654211|Drug|danoprevir|single iv infusion
138847|NCT01654211|Drug|danoprevir|single oral dose
138848|NCT01654211|Drug|placebo|single iv infusion
138849|NCT01654211|Drug|ritonavir|oral doses
138850|NCT01654224|Biological|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
138851|NCT01654224|Biological|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
138852|NCT01654237|Other|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
138853|NCT01654250|Drug|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
138854|NCT00086944|Other|laboratory biomarker analysis|Correlative studies
139171|NCT01657370|Drug|Rescue medication|If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,
participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
139172|NCT00087217|Drug|tanespimycin|Given IV
139173|NCT01657383|Procedure|HPB Surgery|Hepatopancreatico Biliary Surgery
139174|NCT01657396|Procedure|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
139175|NCT01650285|Drug|Cabazitaxel|Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2
139176|NCT00000264|Other|0.7 g/Kg ethanol|
139177|NCT00001615|Drug|Corticosteroid|
139041|NCT01654575|Drug|Methotrexate|Methotrexate 25mg/week for 16 weeks
139042|NCT01654575|Drug|Placebo|Placebo tablets once a week for 16 weeks
139337|NCT01657201|Drug|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
139338|NCT01657214|Drug|SAR125844|Pharmaceutical form:Concentrate for solution
Route of administration: intravenous
139339|NCT01657227|Behavioral|Intervention to patients|Multifaceted intervention consisting of:
Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.
Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.
Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change.
139340|NCT01657227|Behavioral|Intervention to professionals|Multifaceted intervention consisting of:
Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.
Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.
Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional.
139341|NCT00087204|Drug|becatecarin|Given IV
139342|NCT01657227|Other|Usual care|Usual care for T2DM received in primary health care
139343|NCT01657240|Drug|PRO-118|instill one drop in each eye once a day for 21 days
139344|NCT01650532|Behavioral|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
139345|NCT01650532|Behavioral|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
139346|NCT01650545|Drug|liposomal aerosol cyclosporine|inhaled form of immune suppression
139347|NCT01650545|Other|standard immune suppression, oral|conventional drug
139348|NCT01650558|Drug|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
139349|NCT01650558|Drug|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
139350|NCT00086619|Drug|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
139351|NCT01650584|Drug|ISTA Tears|sterile ophthalmic solution
142826|NCT01667198|Behavioral|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
142827|NCT01667211|Drug|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
142828|NCT01667224|Dietary Supplement|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
142829|NCT01667224|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Actiponin.
142830|NCT01667237|Behavioral|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
142831|NCT01667250|Device|GammaCore Active Device|
142832|NCT01667250|Device|GammaCore Sham Device|
142833|NCT01667263|Drug|All-trance retinoid acid|
142834|NCT01667263|Drug|Danazol|
142835|NCT01667289|Radiation|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
142836|NCT00088140|Drug|Placebo|
142837|NCT01667289|Drug|Concurrent chemoradiation|Concurrent chemoradiation
Chemotherapy:
Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy
142838|NCT01658826|Drug|AIC316|oral administration
142839|NCT01658826|Drug|Valacyclovir|oral administration
142840|NCT01658839|Drug|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
141940|NCT01673412|Other|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
139402|NCT01655225|Drug|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
139403|NCT01655238|Other|BMI|Screening guideline to assess body mass index.
139404|NCT01655251|Behavioral|Intervention|
139405|NCT00087009|Biological|beta-glucan|Given orally
139406|NCT01657396|Procedure|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
138441|NCT01633970|Drug|5-FU|Participants will receive 5-FU 400 mg/m^2 IV q2w.
138442|NCT01633970|Drug|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
138443|NCT00085189|Biological|multi-epitope melanoma peptide vaccine|Given SC
138444|NCT01633970|Drug|Bevacizumab|Participants will receive bevacizumab 10 or 15 mg/kg IV q3w.
138445|NCT01633970|Drug|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
138446|NCT01633970|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV q2w.
138447|NCT01633970|Drug|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m^2 IV q1w.
138448|NCT01633970|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV q2w.
138449|NCT01633970|Drug|Paclitaxel|Participants will receive paclitaxel 200 mg/m^2 IV q3w.
138450|NCT01633970|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV q3w.
138451|NCT01633983|Drug|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
138452|NCT01633983|Drug|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
138453|NCT01633996|Procedure|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
138454|NCT00085189|Biological|incomplete Freund's adjuvant|Given SC
138455|NCT01634009|Dietary Supplement|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
139211|NCT00086827|Other|laboratory biomarker analysis|Correlative studies
139212|NCT01652664|Drug|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to < 3 years of age received 0.25%
139213|NCT01652664|Drug|Travoprost Vehicle|Inactive ingredients used to maintain masking
139214|NCT01652677|Procedure|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
139215|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
139216|NCT00086983|Drug|oxaliplatin|Given IV
139217|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
139218|NCT01654835|Other|low blood pressure alert|A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: "A Low Blood Pressure condition has been detected. Consider hemodynamic support."
139219|NCT01654835|Other|standard of care|A Low Blood Pressure condition as specified (SAP <80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
139220|NCT01654861|Drug|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose >90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
139221|NCT01654874|Drug|99mTc-MIP-1404|
139222|NCT01654887|Other|Lung Ultrasound|Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
138250|NCT01631019|Behavioral|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
138251|NCT01631019|Behavioral|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
138252|NCT01631032|Drug|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
138962|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
138963|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
138964|NCT01656811|Drug|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
138965|NCT01656811|Drug|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
138966|NCT01656811|Drug|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
138967|NCT01656811|Drug|Placebo|Placebo 2 actuations QID
138968|NCT01656837|Behavioral|Comprehensive Community Treatment|
138969|NCT00087178|Drug|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
138970|NCT01656837|Behavioral|MST-BSF|
138971|NCT01656850|Other|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
138972|NCT01656850|Other|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
138973|NCT01656863|Other|Questionnaire|
138974|NCT01656876|Behavioral|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
138975|NCT01656876|Other|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
138976|NCT01656876|Behavioral|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
138977|NCT01656889|Biological|HP-802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
138978|NCT01656889|Biological|Vehicle|(fibrinogen solution & thrombin solution without cells)
138979|NCT01656902|Drug|NOVOCART® 3D plus|
138980|NCT00001631|Procedure|Magnetic resonance imaging|
139966|NCT01651767|Drug|Placebo|Form=suspension, route=oral.
139967|NCT01651767|Drug|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
140212|NCT01642030|Drug|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
140213|NCT01644149|Biological|2011-2012 Fluzone trivalent inactivated influenza vaccine|
140214|NCT01644162|Device|iVAPS ventilation|3 months of ventilation on iVAPS mode
140215|NCT00085982|Drug|Metreleptin|
140216|NCT01644175|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
140217|NCT01644175|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
140218|NCT01644175|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
140219|NCT01644188|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
140220|NCT01644188|Drug|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
140221|NCT01644188|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
140222|NCT01644188|Drug|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
140223|NCT01644188|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
140224|NCT01644201|Dietary Supplement|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
140225|NCT01644201|Dietary Supplement|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
140226|NCT00001598|Drug|Dehydroepiandrosterone|
140227|NCT00086021|Procedure|Acupuncture|
140228|NCT01644214|Other|12 week follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 6 weeks, therefore those that are checked every 12 weeks will be considered to be in the intervention group.
139732|NCT01655771|Drug|TD-1211 Dose 2|
139733|NCT01655784|Procedure|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
139734|NCT01655784|Procedure|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
139735|NCT01655797|Behavioral|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
139736|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
139737|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
139738|NCT00087061|Drug|gimatecan|
139739|NCT01655810|Dietary Supplement|Calcium carbonate|500 mg orally twice daily
139740|NCT01655823|Drug|Placebo|Sham treatment acting as control arm
139741|NCT01655823|Drug|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
139742|NCT01655836|Radiation|Brachytherapy|Undergo high dose rate brachytherapy
139743|NCT01655836|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
140022|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
140023|NCT00086489|Drug|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
140024|NCT01649297|Drug|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
140025|NCT01649310|Other|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
140026|NCT01649336|Drug|MEK162, MEK inhibitor; oral|multiple dose, escalating
140027|NCT01649336|Drug|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
140028|NCT01649349|Device|two-piece nasogastric tube|one week period
138253|NCT01631058|Drug|Everolimus|This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.
Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.
Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.
Corticosteroids: as clinical practice.
138254|NCT01631071|Biological|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
138255|NCT01631084|Other|JADE|Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.
Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate.
138256|NCT00001573|Drug|SU101|
138257|NCT00084903|Procedure|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
138258|NCT01633541|Drug|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
138259|NCT01633567|Behavioral|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
138260|NCT01633567|Behavioral|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
138261|NCT01633580|Drug|corifollitropin alfa|long acting FSH
138262|NCT01633593|Drug|Donepezil|5 mg PO a day, during 2 weeks
138263|NCT01633632|Behavioral|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
138573|NCT01636947|Drug|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
138574|NCT01636947|Drug|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
138575|NCT01636947|Drug|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
138576|NCT01636947|Drug|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
138981|NCT00087178|Drug|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
139280|NCT01652690|Drug|Prolia|This is an non-interventional study, therefore Prolia is adminstered as part of routine care and not for purposes of the study.
139281|NCT01652703|Biological|Evolocumab|Administered by subcutaneous injection
139282|NCT01652703|Other|Placebo|Administered by subcutaneous injection
139283|NCT01652716|Drug|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
139284|NCT01652716|Drug|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
139285|NCT01652729|Drug|Exenatide once weekly suspension|
139286|NCT01652729|Drug|Sitagliptin|
139287|NCT00086840|Drug|temsirolimus|Given IV
139288|NCT01652729|Drug|Placebo|Placebo oral capsule once daily
139289|NCT01652742|Drug|BI 135585 XX|one single dose
139290|NCT01652768|Other|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin & Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
139291|NCT01652768|Other|Palliative Care Team|Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).
Introduce the palliative care team concept.
Provide contact information for the palliative care team given
Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)
Offer community resources to patient and caregiver (Appendix B)
Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment
Provide supportive care
139292|NCT01652768|Other|Educational Information Session for Patients and Caregivers|Provide an educational class "Moving Forward: Facing a Brain Tumor Diagnosis" for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.
Intervention (Length of time for class = 2 hours):
Provide an educational class "Moving Forward: Facing a Brain Tumor Diagnosis" for patient and caregiver.
Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.
Provide supportive care.
139293|NCT01652768|Other|Contact every 2 weeks|The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.
(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):
Administer Patient and Caregiver Follow-up Assessment
Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment
Provide resources/referrals for any needs identified during the social work follow-up assessment
Provide supportive care
139294|NCT01652768|Other|Follow-up Surgical Visit Session|The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.
Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):
Administer Patient and Caregiver Follow-up Assessment
Administer Symptom Assessment Tool
Provide pain and/or symptom management intervention
Provide supportive care
140229|NCT01644240|Drug|TD-8954|Intravenous infusion
140230|NCT01644240|Drug|Placebo - saline|Intravenous infusion
140231|NCT01644253|Biological|20 mg/kg TRU-016 + Rituximab|TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses
Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses
140545|NCT01642511|Procedure|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
140546|NCT01642524|Biological|hypertonic saline mixed Dextran|single dose administered intravenously
140547|NCT01642524|Biological|Saline solution|placebo - saline solution
140548|NCT00085839|Drug|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
140549|NCT01642537|Device|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
140550|NCT01642550|Drug|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
140551|NCT00086060|Behavioral|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
140552|NCT01644695|Procedure|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
140553|NCT01644708|Behavioral|Self empowerment|1. Group meeting, introducing the method and the assessment tools
Self-empowerment,
Handing over the "journal",
Questionnaire about emotional states and motivations for losing weight and for change.
The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant "weighs himself" and he notes his weight down in his journal.
140554|NCT01644721|Biological|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
140555|NCT01644734|Drug|Spiriva HandiHaler|
140556|NCT01644747|Device|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
140029|NCT01649362|Other|prefeeding oral stimulation program|The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.
The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day.
140030|NCT01649375|Drug|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
140031|NCT01649375|Drug|Placebo|Placebo
140032|NCT01649375|Drug|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
140033|NCT01649388|Biological|Hematopoietic Stem Cell Transplant|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells.
Monitoring for chimerism will be done at key time points.
140034|NCT00086489|Drug|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
140035|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
140036|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
140037|NCT01643941|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
140038|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
140291|NCT01642147|Procedure|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
140292|NCT01642147|Procedure|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
140293|NCT00000264|Other|0.35 g/Kg ethanol|
140294|NCT00001587|Drug|Melphalan|
140295|NCT00085774|Drug|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
138577|NCT01636947|Drug|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
138578|NCT00085384|Biological|PEG-interferon alfa-2b|Biological/Vaccine: PEG-interferon alfa-2b
Dose 1.5 mg/kg/week given subcutaneously
EG-Intron
138579|NCT01636960|Biological|PegIFN alfa-2b|
138580|NCT01636973|Procedure|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
138581|NCT01636986|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
138582|NCT01636986|Device|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
138583|NCT01636999|Drug|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
138584|NCT01637012|Procedure|Implantation|index angioplasty with ALEX stent implatation
138585|NCT01637025|Device|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
138586|NCT01637025|Device|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
138587|NCT01629082|Drug|Lenalidomide|
138588|NCT01629121|Behavioral|education intervention|The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.
The proper way to fit the bicycle helmet was demonstrated.
138589|NCT01629134|Device|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
138590|NCT00084825|Drug|Imatinib mesylate|600 mg orally daily
138591|NCT01629147|Dietary Supplement|Biogaia|5 drops containing Lactobacillus reuteri Protectis
138900|NCT01649843|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
138901|NCT01649856|Drug|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
139887|NCT01653665|Drug|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
139888|NCT01653665|Drug|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
139889|NCT01653678|Dietary Supplement|Vitamin D-3 (cholecalciferol), 2000 IU|
139890|NCT01653678|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
139891|NCT01653678|Dietary Supplement|Vitamin D placebo|
139892|NCT00086931|Radiation|radiation therapy|once daily 5 days a week for 5.5 weeks
139893|NCT01653678|Drug|Fish oil placebo|
139894|NCT01653691|Procedure|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
139895|NCT01653691|Procedure|Sham|No treatment to one side of subject's scar.
139896|NCT01653704|Behavioral|observational role|observational role in crisis scenario
139897|NCT01653704|Behavioral|active role|active role in managing crisis scenario
139898|NCT01653717|Procedure|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
139899|NCT01653717|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
139900|NCT01653717|Drug|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
139901|NCT01653717|Procedure|T-cell Infusion|25% of genetically modified cells infused by vein on Day 0. On Day +1, remaining T-cell dose infused.
139902|NCT01653730|Device|Eclipse 3 portable oxygen concentrator|
139903|NCT00086944|Biological|oblimersen sodium|Given IV
139904|NCT01653730|Device|EverGo portable oxygen concentrator|
139905|NCT01653730|Device|iGo portable oxygen concentrator|
140557|NCT01644760|Procedure|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
140558|NCT01644773|Drug|Crizotinib|Starting dose level:
Initial Treatment Plan: 130 mg/m^2 per dose
Modified Treatment Plan per Amendment 1.0: 165 mg/m^2 per dose
The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.
The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.
Cycle 1 (28 days): once a day for 28 days
Cycles 2-26 (28 days each): once a day
140559|NCT01644773|Drug|Dasatinib|Starting dose level: 50 mg/m^2 per dose
The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.
The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.
Cycle 1 (28 days): starting on day 3, once a day for 28 days
Cycles 2-26 (28 days each): once a day
139655|NCT01648738|Other|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
139656|NCT01648738|Other|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
139657|NCT01648751|Drug|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
139658|NCT01648751|Drug|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
139659|NCT01648764|Drug|LY2334737|Administered orally
139660|NCT01648777|Device|L bupivacaine|L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml
o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00
139661|NCT01648777|Drug|placebo|Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml
Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00
139662|NCT01648790|Drug|Prasugrel ODT1 - Tablet|Administered orally as tablet.
139663|NCT01648790|Drug|Prasugrel ODT2 - Tablet|Administered orally as tablet.
139664|NCT01648790|Drug|Prasugrel ODT2 - Suspension|Administered orally as suspension.
139665|NCT00086411|Behavioral|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
139666|NCT01651195|Dietary Supplement|Probiotic|
139667|NCT01651195|Other|Placebo|
140296|NCT01642147|Procedure|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
140297|NCT01642160|Behavioral|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
140298|NCT01644292|Other|EPIC WheelS|EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
140299|NCT01644331|Drug|Tolvaptan|Tolvaptan (given at 0, 12, 24 and 48 hours)
140300|NCT01644331|Drug|Placebo|IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)
140301|NCT00086034|Drug|Motexafin gadolinium|
140302|NCT01644344|Other|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
140303|NCT01644344|Other|Xray|
140304|NCT01644357|Other|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
140305|NCT01644370|Drug|HAART|as per Thai HIV Treatment guidelines
140618|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
140619|NCT00085852|Biological|BLVR|10 mL Hydrogel
140620|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
140621|NCT01642615|Drug|Placebo|Dexlansoprazole placebo-matching capsules
140622|NCT01642628|Other|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
138902|NCT01649856|Drug|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
138903|NCT01649856|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
138904|NCT00086515|Drug|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
138905|NCT01649869|Drug|Valcyte (Valganciclovir hydrochloride) Powder for oral solution|Valganciclovir will be administered at 16mg/kg body weight twice daily
138906|NCT01649869|Drug|Placebo|The placebo comparator will be commercially available Simple Syrup as 60-90% sucrose.
138907|NCT01649882|Procedure|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
138908|NCT01649895|Drug|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
138909|NCT01649895|Drug|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
138910|NCT01649921|Drug|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
138911|NCT01652053|Device|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
138912|NCT01652066|Dietary Supplement|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
138913|NCT00086762|Behavioral|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
138914|NCT01652066|Dietary Supplement|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
138915|NCT01652079|Drug|CRLX101|q 14 days
138916|NCT01652092|Drug|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
138917|NCT01652092|Drug|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
138918|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
139906|NCT01653743|Drug|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of >=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
139907|NCT01656005|Biological|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
140153|NCT01646619|Drug|Magnesium Sulphate|10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).
Diluent: Dextrose 5%.
140154|NCT01646619|Drug|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
140155|NCT01646632|Behavioral|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
140156|NCT01646632|Behavioral|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
140157|NCT01646645|Genetic|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
140158|NCT01646671|Drug|LCZ696|LCZ696 200 mg tablet once daily
140159|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
140160|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
140161|NCT01646684|Drug|SOM230|
140162|NCT00086268|Drug|zoledronic acid|
140163|NCT01646697|Other|cytology specimen collection procedure|Undergo cytopathologic sample collection
140164|NCT01646710|Behavioral|Pretesting food based recommendations|
140165|NCT01639651|Other|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
139668|NCT01651208|Behavioral|Motivational Interviewing (MINT)|We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:
a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment.
139669|NCT01651208|Behavioral|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
139670|NCT01651221|Other|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
139671|NCT01651234|Drug|GCC-4401|Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use
single dose
dosage
Cohort 1: 2.5-mg GCC-4401C
Cohort 2: 5.0-mg GCC-4401C
Cohort 3: 10-mg GCC-4401C
Cohort 4: 20-mg GCC-4401C
Cohort 5: 40-mg GCC-4401C
Cohort 6: 80-mg GCC-4401C
139968|NCT01651780|Procedure|Trans-Aortic Valve Replacement|transcatheter aortic valve replacement (TAVR) procedures performed via the transfemoral approach
139969|NCT01651793|Other|Active comparator 1|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
139970|NCT01651793|Other|Active comparator 2|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
139971|NCT01651793|Other|Active comparator 3|Low flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
139972|NCT01651793|Other|Active comparator 4|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
139973|NCT01651793|Other|Inactive comparator|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
139974|NCT01651806|Drug|Tranexamic Acid standard dose|Uniform 1 gram dosing
139975|NCT00086736|Drug|oral bicalutamide placebo|
139976|NCT01651806|Drug|Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
139977|NCT01653743|Drug|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of >=18 mm; not more than 3 follicles each with a mean diameter of >=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
140623|NCT01642641|Procedure|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
140624|NCT01642641|Procedure|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
140625|NCT01642641|Procedure|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
140626|NCT01642654|Other|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
140627|NCT01642654|Other|Educational lectures|Educational lectures
140628|NCT01642667|Drug|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
140629|NCT01642667|Drug|Placebo|
140630|NCT00085878|Drug|SB-485232|
140631|NCT01642680|Other|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
140632|NCT01642680|Other|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
140633|NCT01644864|Drug|placebo|
140634|NCT01644877|Drug|DAS181 dry powder, formulation F02|
140635|NCT00086099|Drug|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
140636|NCT01644877|Drug|Lactose Placebo|
139744|NCT01648829|Drug|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
139745|NCT01648829|Drug|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
139746|NCT01648855|Other|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
139223|NCT01654887|Radiation|Chest X-Ray|Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
139224|NCT01654900|Other|No intervention in this study|
139225|NCT01654913|Device|hemoglobin measurement|Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :
at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),
with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),
with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin).
139226|NCT01654926|Procedure|blood ultrafiltration|
139227|NCT00086983|Other|pharmacological study|Correlative studies
139228|NCT01654939|Drug|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
139229|NCT01654965|Other|Laboratory Biomarker Analysis|Correlative studies
139230|NCT01654965|Biological|Pegfilgrastim|Given SC
139231|NCT01654965|Other|Pharmacological Study|Correlative studies
139232|NCT01654965|Drug|Tivantinib|Given PO
139233|NCT01654965|Drug|Topotecan Hydrochloride|Given IV
139234|NCT01654991|Behavioral|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
139235|NCT01654991|Behavioral|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
139236|NCT01655004|Drug|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
139237|NCT01655017|Procedure|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
139238|NCT01657526|Biological|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
139239|NCT01657539|Dietary Supplement|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
139240|NCT01657539|Dietary Supplement|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
139241|NCT01657552|Drug|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
140166|NCT01639664|Device|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
140167|NCT01639677|Procedure|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
140168|NCT00085540|Drug|romidepsin|Given IV
140169|NCT01639677|Procedure|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
140497|NCT01647776|Other|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
140498|NCT01647776|Procedure|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors [levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression] as markers of risk of developing adenoma.
140499|NCT01647776|Other|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
140500|NCT00086307|Drug|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
140501|NCT01647789|Drug|CFG920|
140502|NCT01647802|Device|Standing attempts with the "Vertic'Easy" Device|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
140503|NCT01647802|Device|Standing attempts with the "Turner" Device|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
140504|NCT01647802|Device|Standing attempts with the "Tina" device|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
140505|NCT01647815|Procedure|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
140506|NCT01647828|Drug|OMP-59R5|OMP-59R5 administered intravenously
140507|NCT01647828|Drug|Gemcitabine|administered intravenously
140508|NCT01647828|Drug|Placebo|administered IV
139978|NCT01653743|Drug|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
139979|NCT01653756|Drug|IPI-145, a PI3K Inhibitor|Active drug
139980|NCT01653756|Drug|Placebo to match IPI-145|
139981|NCT01653782|Behavioral|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
139982|NCT01653782|Behavioral|Self care advice|Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet "The Back book"
139983|NCT01653782|Behavioral|Exercise|Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet "The Back book"
139984|NCT00086944|Biological|rituximab|Given IV
139985|NCT01653795|Device|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
139986|NCT01653795|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
140232|NCT01644253|Biological|10 mg/kg TRU-016 + Rituximab|TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses
Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule
140233|NCT01644253|Biological|TRU-016 20 mg/kg + Obinutuzumab|TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months
Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months
140234|NCT01644253|Biological|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
140235|NCT01646723|Behavioral|Volunteers Adding Life in Dementia (VALID) Program|The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a "Life Story" for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the "Life Story" assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident.
140236|NCT01646736|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
140237|NCT01646736|Drug|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
139747|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
139748|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
139749|NCT01648881|Radiation|TEP-18FDG for every patient after aortic dissection|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
139750|NCT01648894|Procedure|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
139751|NCT01648894|Procedure|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
139752|NCT01648907|Other|Imaging exams|Radiological examinations:
Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front
MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.
Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.
Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.
Biological tests :
Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.
Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.
Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60.
139753|NCT01648920|Device|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
139754|NCT00086411|Behavioral|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
139755|NCT01648933|Radiation|Rubidium PET|Myocardial Perfusion Imaging
139756|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
139757|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
139758|NCT01648959|Other|EEG Recording|
139759|NCT01648972|Drug|Gastrografin|
140039|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
140040|NCT00085969|Drug|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
139242|NCT01657552|Drug|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
139243|NCT01657552|Drug|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
138264|NCT01633632|Behavioral|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
138265|NCT01633645|Drug|Bortezomib|Velcade
138266|NCT01633645|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
138267|NCT00085176|Procedure|psychosocial assessment and care|
138268|NCT01633645|Drug|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
138269|NCT01633658|Dietary Supplement|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
138270|NCT01633658|Dietary Supplement|25(OH)D|a single dose of 625 micrograms of 25(OH)D
138271|NCT01633697|Behavioral|Breathing|Breathing techniques
138272|NCT01633697|Behavioral|Education alone|No special attention to breathing
138273|NCT01633723|Drug|DA-6886|single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)
multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)
138274|NCT01633723|Drug|Placebo of DA-6886|DA-6886 placebo
138275|NCT01633736|Other|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
138276|NCT01633749|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
138277|NCT01633762|Drug|meropenem, gentamicin, vancomycin (together)|4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin "Hospira"), powder for concentrate; gentamycin 40 mg ("Hexamycin®"), solution; meropenem 500 mg (Meropenem "Hospira"), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)
138278|NCT00085189|Biological|gp100 antigen|Given SC
138279|NCT01636518|Procedure|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
138280|NCT01636531|Drug|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
140509|NCT01647828|Drug|Nab-Paclitaxel|administered intravenously
140510|NCT01647854|Procedure|Teleconsultation|Teleconsultation in prehospital emergencies
140511|NCT00086307|Drug|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
140512|NCT01647867|Other|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
140513|NCT01647880|Drug|Verum arm receiving Gilenya®|
139610|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.
Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity.
139611|NCT01651182|Drug|No tranexamic acid|Control
139612|NCT01651182|Drug|Tranexamic Acid|
139613|NCT00086684|Drug|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
139614|NCT01653275|Other|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
139615|NCT01653288|Behavioral|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
139616|NCT01653301|Drug|XELAC RT|Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.
In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost).
140238|NCT01646736|Drug|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
140239|NCT01646749|Dietary Supplement|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
140240|NCT01646762|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
140241|NCT01646762|Other|Laboratory Biomarker Analysis|Correlative studies
140242|NCT01646775|Drug|epidural fentanyl|withold epidural fentanyl
140243|NCT00001601|Procedure|Biopsies|
140244|NCT00086268|Drug|Taxotere|
140245|NCT01646788|Device|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
140246|NCT01646801|Device|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
140247|NCT01646814|Drug|PL2200|PL2200, containing 325 mg aspirin active ingredient
140248|NCT01646814|Drug|Aspirin tablets|325 mg aspirin tablets (USP)
140249|NCT01646827|Drug|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
140560|NCT01644799|Drug|idelalisib|oral
140561|NCT01644799|Drug|lenalidomide|oral
140562|NCT00086086|Drug|Darbepoetin Alfa|
140563|NCT01644812|Behavioral|Aerobic exercise|
140564|NCT01644812|Behavioral|Stretching|
140565|NCT01644825|Drug|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
140566|NCT01644825|Drug|pazopanib|orally, 800 mg orally daily
140567|NCT01644838|Drug|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
140568|NCT01644838|Drug|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
140041|NCT01643941|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
140042|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
140043|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
140044|NCT01643941|Biological|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
140045|NCT01643941|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
140046|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
140047|NCT01643941|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
140048|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
140049|NCT01643941|Procedure|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
140050|NCT01643954|Procedure|robotic radical prostatectomy|robotic assisted surgery
140051|NCT00085969|Drug|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
140052|NCT01643967|Other|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
140053|NCT01643967|Other|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
140054|NCT01643980|Drug|Vaginal micronized progesterone|200 mg vaginal route per day
140055|NCT01643980|Device|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
140306|NCT01644383|Behavioral|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
140307|NCT01644396|Biological|Adalimumab|
138281|NCT01636531|Drug|gantenerumab|Lyophilized formulation (LyoF), single dose sc
138282|NCT01636544|Procedure|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
138592|NCT01629147|Other|Placebo|5 drops
138593|NCT01629173|Procedure|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
138594|NCT01629173|Procedure|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
138595|NCT01629173|Procedure|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
138596|NCT01629173|Procedure|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
138597|NCT01629186|Other|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) <5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) <80 beats/min or oxygen saturation (SpO2) <85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
138598|NCT01629199|Drug|rhEGF(recombinant human Epidermal Growth Factor)|
138599|NCT01629199|Drug|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
138600|NCT01629212|Drug|Tiropramide HCl 100mg|
138601|NCT00084838|Biological|filgrastim|
138602|NCT01629212|Drug|Octylonium bromide 20mg|
138603|NCT01629225|Drug|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
138604|NCT01629251|Device|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
139617|NCT01653301|Drug|XELOX RT|Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;
Oxaliplatin: 130mg/m2, days 1, 19, 38
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost).
139618|NCT01653314|Drug|Megavec|
139619|NCT01653314|Drug|Glivec|
139620|NCT00001626|Drug|Antithymocyte globulin & amp; Cyclosporin A|40 mg/kg daily for 4 days
139621|NCT00086892|Biological|cetuximab|
139622|NCT01653327|Drug|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
139623|NCT01653327|Drug|Placebo|
139624|NCT01653340|Device|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
139908|NCT01656005|Biological|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
139909|NCT01656018|Drug|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
139910|NCT01656031|Drug|clofarabine|
139911|NCT01656031|Drug|cytarabine|
139912|NCT01656044|Procedure|wound care management|Receive SSD
139913|NCT01656044|Procedure|wound care management|Receive NPT
139914|NCT01656057|Drug|Acetaminophen|Acetaminophen dissolved in 50 ml of water
139915|NCT01656057|Drug|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
139916|NCT00087100|Drug|pemetrexed disodium|
139917|NCT01656057|Drug|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
139918|NCT01656057|Other|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
139919|NCT01656057|Other|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
140569|NCT01644851|Behavioral|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
140570|NCT01644864|Drug|0.375% ROPIVACAINE|
140571|NCT01648075|Dietary Supplement|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
140572|NCT01648101|Drug|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
140573|NCT01648101|Drug|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
140574|NCT01648101|Other|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
140575|NCT00086346|Drug|Sirolimus (Rapamune)|
140576|NCT01648114|Other|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
139672|NCT01651234|Drug|GCC-4401C|Capsule, identical in appearance to GCC-4401C, for oral use
single dose
dosage
Cohort 1: 2.5-mg matching placebo
Cohort 2: 5.0-mg matching placebo
Cohort 3: 10-mg matching placebo
Cohort 4: 20-mg matching placebo
Cohort 5: 40-mg matching placebo
Cohort 6: 80-mg matching placebo
139673|NCT01651247|Procedure|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
139674|NCT01651260|Other|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
139675|NCT01651273|Drug|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
139676|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
140308|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
140309|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
140310|NCT01644422|Other|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
140311|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
140312|NCT00086047|Behavioral|Coping Skills Training|8 weekly sessions of behavioral treatment
140313|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
140314|NCT01644448|Other|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
140315|NCT01644448|Other|Standard Therapy|Topical Applications as directed by the investigator
140316|NCT01644461|Other|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
140317|NCT01644474|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
140318|NCT01647165|Drug|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
140319|NCT01647165|Drug|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
140320|NCT01647178|Procedure|TORQ assisted sternal closure|
140321|NCT01647178|Procedure|Conventional closure|
140322|NCT01647191|Behavioral|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
140323|NCT01647191|Behavioral|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
140324|NCT01647204|Other|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
140637|NCT01644890|Drug|NK105|IV, Weekly
140638|NCT01644890|Drug|Paclitaxel|IV, Weekly
138605|NCT01631500|Other|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
138606|NCT01631513|Drug|Nucynta ER|100 to 250 mg every 12 hours
138607|NCT01631526|Dietary Supplement|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
138608|NCT01631539|Device|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
138919|NCT01652092|Biological|Stem Cell Transplantation|Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10^8 nucleated cells/kg recipient weight.
Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be > 5.0 x 10^7 nucleated cells/kg.
138920|NCT01652092|Drug|Fludarabine phosphate 40 mg|40 mg/m^2 IV on days -5 through -2
138921|NCT01652092|Drug|Melphalan|140 mg/m^2 IV on day -3
138922|NCT01652092|Drug|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
138923|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
138924|NCT00086775|Biological|alemtuzumab|
138925|NCT01652092|Drug|Fludarabine phosphate 30 mg|fludarabine 30 mg/m^2 IV on days -8 through -4
138926|NCT01652092|Drug|MESNA|administered as per the standard institutional protocol.
138927|NCT01652105|Dietary Supplement|Standard diet versus standard VLCD (Prodimed)|
138928|NCT01652118|Drug|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
138929|NCT01652118|Drug|Saline|
138930|NCT01652131|Other|Tetrastarch (130/0.4)|
138931|NCT01652144|Drug|AT7519M|
138932|NCT01652157|Biological|CREON|pancreatic enzyme replacement therapy
138933|NCT01652157|Biological|ZENPEP|pancreatic enzyme replacement therapy
138934|NCT01652157|Biological|ULTRESA|pancreatic enzyme replacement therapy
139920|NCT01656070|Drug|oral cholecalciferol 1000000 UI (vitamin D3)|
139921|NCT01656070|Drug|Placebo|
139922|NCT01656096|Device|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
139923|NCT01656096|Other|Sham procedure|
139924|NCT01656109|Drug|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
139925|NCT01656122|Drug|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
139926|NCT01656122|Drug|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
139927|NCT00087113|Drug|pemetrexed disodium|
139928|NCT01656135|Other|Blood drawing for immune monitoring and questionnaires|
139929|NCT01656148|Drug|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
140170|NCT01639690|Genetic|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10^6 untransduced CD34+ cells per kg will be preserved for every patient.
140171|NCT01639703|Other|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
140172|NCT01639729|Drug|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
140173|NCT01639729|Drug|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
140174|NCT01639729|Drug|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
140175|NCT01639729|Drug|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
140176|NCT01639742|Device|New texture round breast implants|Breast implant surgery
140177|NCT01639755|Device|new texture shaped breast implants|breast implant surgery
139677|NCT01651273|Drug|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
139678|NCT01651273|Drug|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
139679|NCT01651273|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
139680|NCT01651286|Procedure|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
139681|NCT01651286|Procedure|full face mask|using a standard full face mask during the induction of general anesthesia.
139682|NCT01651312|Drug|14C-labeled YM178|oral solution (1.85 MBq)
139683|NCT01651325|Drug|Isavuconazole|oral
139684|NCT01651325|Drug|dextromethorphan|oral
139685|NCT01651338|Procedure|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
139686|NCT01653405|Behavioral|Outreach, Education, and Motivational Interviewing|Patients in the bottom 25% of TTR at baseline will receive an outreach message delivered at a routine care visit. The outreach message will inform them that their control is poor and this puts them at risk for bad outcomes. They will be offered an invitation to attend an education session to learn more about how to self-manage warfarin therapy. This session will be delivered by local clinical staff, using materials that we will provide. Finally, we will educate local clinical staff in the use of motivational interviewing (MI) and will provide a manual to help them deliver MI-based care. They will be asked to deliver MI-based care specifically to patients in the intervention group.
139687|NCT01653418|Drug|Bortezomib|
139688|NCT01653418|Drug|Carmustine|
139689|NCT00086892|Drug|carboplatin|
139690|NCT01653418|Drug|Etoposide|
139691|NCT01653418|Drug|Cytarabine|
139692|NCT01653418|Drug|Melphalan|
139987|NCT01653808|Device|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
139988|NCT01653808|Procedure|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
139989|NCT01653808|Procedure|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
139990|NCT01653821|Procedure|Carotid body excision|
140639|NCT01644916|Procedure|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
140640|NCT01644916|Procedure|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
140641|NCT01644929|Procedure|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
140642|NCT01644929|Procedure|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
140643|NCT01644929|Procedure|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
140644|NCT01644942|Other|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
140645|NCT01644955|Drug|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
140646|NCT00086099|Drug|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
140647|NCT01644955|Procedure|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
140648|NCT01644968|Drug|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
140649|NCT01644968|Drug|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
140650|NCT01644968|Drug|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
140651|NCT01644968|Biological|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
140652|NCT01644968|Biological|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
140653|NCT01644968|Biological|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
140654|NCT01644968|Biological|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
140655|NCT01644981|Other|blood sampling|blood sampling
140656|NCT01644994|Drug|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
140657|NCT00001599|Drug|Thalidomide|
140658|NCT00086112|Drug|risperidone oral tablets|
138935|NCT00086775|Biological|rituximab|
138936|NCT01654289|Other|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
138937|NCT01654302|Drug|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
138938|NCT01654302|Drug|Inactive patch|placebo patch applied once for 12 hours
138939|NCT01654315|Device|Myomo Robotic Arm|Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.
139244|NCT01657578|Drug|Omeprazole|administration of Omeprazole
139245|NCT01657591|Drug|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
139246|NCT01657591|Drug|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
139247|NCT00087217|Other|pharmacological study|Correlative studies
139248|NCT01657604|Drug|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
139249|NCT01657604|Drug|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
139250|NCT01657617|Radiation|Boost Stereotactic Body Radiation Therapy|The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:
Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.
Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy.
139251|NCT01657630|Device|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
139252|NCT01657643|Dietary Supplement|Probiotics|
139253|NCT01657643|Dietary Supplement|placebo|
139254|NCT01657656|Dietary Supplement|Vitamin D|
140178|NCT01639768|Drug|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
140179|NCT00085553|Drug|Erlotinib Hydrochloride|Given PO
140180|NCT01639781|Dietary Supplement|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
140181|NCT01639781|Dietary Supplement|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
140182|NCT01639794|Drug|Vesitirim™ (Solifenacin)|Oral
140183|NCT01639807|Drug|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
140184|NCT01639807|Procedure|SLT|Selective Laser Trabeculoplasty
140185|NCT01639820|Procedure|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
140186|NCT01639820|Procedure|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
140187|NCT01639833|Device|Veriset Hemostatic Patch|Topical hemostat
140188|NCT01639833|Device|TachoSil®|Topical Hemostat
140189|NCT01641848|Device|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
140190|NCT01641861|Device|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
140514|NCT01640366|Device|PICO|Single-use negative pressure wound therapy system
140515|NCT01640379|Behavioral|Technology Enhanced Community Health Nursing|Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)
Enhanced community health nursing visit on day 3-5, includes DEBI STI/HIV prevention component (Sister to Sister Teen)
140516|NCT01640392|Behavioral|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
140517|NCT01640405|Drug|modified FOLFOX6 + bevacizumab|Bevacizumab 5 mg/kg iv, day 1, followed by
Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by
5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:
LV 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
140518|NCT01640405|Drug|FOLFOXIRI + Bevacizumab|Bevacizumab 5 mg/kg iv, followed by
Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by
Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by
LV 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
139991|NCT01653834|Biological|Harvesting and reinfusion of autologous lymphocytes|collect lymphocytes prior to pts starting RT/chemo and put them back after pt completes RT
139992|NCT01653847|Drug|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
139993|NCT01653847|Drug|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is < 3 ng/mL, or reduced if the trough level is > 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
139994|NCT01656187|Drug|Placebo|Inactive ingredient matching the active medication in appearance
139995|NCT01656200|Biological|Live attenuated Japanese encephalitis vaccine SA14-14-2|Live attenuated Japanese encephalitis vaccine SA14-14-2
139996|NCT01656213|Device|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
139997|NCT01656226|Device|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
139998|NCT01656226|Other|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
139999|NCT00001630|Device|Isolex 300i|
140000|NCT00087126|Drug|topotecan hydrochloride|
140001|NCT01656239|Drug|fedovapagon 1 mg|
140002|NCT01656239|Drug|fedovapagon 2 mg|
140003|NCT01656239|Drug|fedovapagon 4 mg|
140004|NCT01656239|Drug|Placebo ( sugar pill)|
140250|NCT01646840|Drug|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
140251|NCT01646840|Drug|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
139484|NCT01655368|Behavioral|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
139485|NCT01655381|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks
139486|NCT01655407|Drug|Autologous Engineered Skin Substitute|The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.
ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.
139487|NCT01655407|Drug|Split-Thickness Autograft (AG)|The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.
The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin.
139488|NCT01655420|Procedure|LASIK|Laser eye surgery
139489|NCT01655433|Device|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
139490|NCT01655433|Other|No Hypothermia Treatment|
139491|NCT00001633|Procedure|Coronary magnetic resonance angiography imaging|
139492|NCT00087256|Drug|Celecoxib|
139493|NCT01657721|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
139494|NCT01657734|Other|MR imaging|MR imaging
139495|NCT01657747|Other|Whole body diffusion-weighted MRI|MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.
During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.
During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines.
139496|NCT01657760|Drug|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
139497|NCT01657773|Other|Ultrasound examination and Colonoscopy examination|
139255|NCT01657669|Drug|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
139256|NCT01657682|Drug|Crenolanib besylate|Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.
Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.
139257|NCT01657708|Other|Shared Decision Making|
139258|NCT00000264|Other|0 g/Kg ethanol|
139259|NCT01650415|Drug|Placebo erythropoietin|twice a week for 1 month
139260|NCT01650428|Biological|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
139261|NCT01650428|Drug|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
138283|NCT01636557|Drug|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
138284|NCT01636557|Drug|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
138285|NCT00085358|Drug|carboplatin|Given intraperitoneally
138286|NCT01636557|Drug|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
138287|NCT01636557|Drug|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
138288|NCT01636557|Drug|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
138289|NCT01636557|Drug|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
138290|NCT01636570|Drug|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
138291|NCT01636570|Drug|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
138292|NCT01636583|Device|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
138293|NCT01636583|Device|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
140519|NCT01640418|Device|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
140520|NCT01640431|Other|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
140521|NCT01640444|Drug|FOLFIRI + bevacizumab|Bevacizumab 5 mg/kg iv, followed by
Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
140522|NCT01640444|Drug|FOLFIRI + cetuximab|Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly
FOLFIRI:
Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle).
140523|NCT01640457|Drug|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
140524|NCT00085579|Procedure|adjuvant therapy|
140525|NCT01640457|Device|NOVOCART® Disc basic|ADCT (Media with no active cell component)
140526|NCT01640470|Device|Assistive Technology Provision and Tune-Up Intervention|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.
The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist.
140527|NCT01640470|Device|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
139625|NCT01653353|Behavioral|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
139626|NCT01653366|Behavioral|Physical Activity Goal Setting|Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the "Exercise and Breast Cancer" digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them.
139627|NCT01653379|Drug|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
139628|NCT01653392|Biological|Observational Intervention|This is an observational study, therefore no interventions are specified.
139629|NCT01655602|Procedure|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
140252|NCT01646853|Radiation|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
140253|NCT01646853|Drug|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
140254|NCT01647152|Drug|Ustekinumab|
140255|NCT00086268|Drug|Carboplatin|
140256|NCT01647165|Drug|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
140257|NCT01639846|Drug|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
140258|NCT00001586|Drug|Fludarabine phosphate|Fludara
140259|NCT00085553|Other|Laboratory Biomarker Analysis|Correlative studies
140260|NCT01639846|Drug|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
140261|NCT01639859|Other|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
140262|NCT01639872|Drug|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
140263|NCT01639872|Drug|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
140264|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
140265|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
140266|NCT01639885|Biological|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
140267|NCT01639898|Drug|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
140268|NCT01639898|Drug|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
140269|NCT01639911|Drug|Alisertib|Alisertib at the assigned (10, 20, 40 or 50 mg) dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
140270|NCT00085553|Other|Pharmacological Study|Correlative studies
139498|NCT01657786|Dietary Supplement|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
138523|NCT01631474|Drug|CB-03-01|Topical cream, applied once a day
138524|NCT01631474|Drug|Vehicle|Topical cream, applied once or twice a day
138525|NCT01631474|Drug|CB-03-01|Topical cream, applied twice a day
138526|NCT01631487|Drug|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
138527|NCT01631487|Drug|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
138528|NCT01631487|Drug|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
138529|NCT00084942|Drug|gemcitabine hydrochloride|
138530|NCT01631487|Drug|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
138531|NCT01631500|Behavioral|Conventional treatment|Conventional treatment
138532|NCT01631500|Other|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
138533|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
138534|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
138535|NCT01634087|Drug|INCB039110|INCB039110 administered orally
138536|NCT01634087|Drug|Placebo|Placebo administered orally
138537|NCT01634100|Drug|Probenecid|Probenecid
138538|NCT00085189|Drug|Montanide ISA 51 VG|Given SC
138539|NCT01634100|Drug|Rifampicin|Rifampicin
138540|NCT01634100|Drug|Empagliflozin|BI Drug
138541|NCT01634100|Drug|Empagliflozin|BI Drug
138542|NCT01634100|Drug|Rifampicin|Rifampicin
138294|NCT01636583|Other|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
138295|NCT01636596|Drug|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
138296|NCT00085358|Drug|paclitaxel|Given IV or intraperitoneally
138297|NCT01636609|Drug|Cytarabine|Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.
Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.
138298|NCT01636609|Drug|5-Azacytidine|Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.
Phase II (Randomized) Starting dose of 5-azacytidine: Maximum tolerated dose from Phase I.
138299|NCT01628601|Drug|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
138300|NCT01628614|Other|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
138609|NCT01631539|Drug|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
138610|NCT01631539|Drug|5 FU|every 2 weeks IV
138611|NCT01631539|Drug|Irinotecan|every 4 weeks chemoembolization
138612|NCT00084981|Drug|decitabine|Given IV
138613|NCT01631552|Drug|IMMU-132|IMMU-132 is administered on days 1 & 8 of 3 week treatment cycles. Up to 8 cycles will be given.
138614|NCT01631565|Behavioral|active comparator|Standard of care. Usual care given to the patients. Treatment, follow-up.
138615|NCT01631565|Behavioral|Early palliative care|Early allocation to palliative care. Nutritional status evaluation, patient and care-taker psychoeducation, depression and anxiety evaluation.
138616|NCT01631578|Procedure|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
138617|NCT01631604|Device|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
138618|NCT01631604|Drug|Muscle/nerve injection|Injection to muscle or nerve
138619|NCT01631604|Procedure|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
139630|NCT01655602|Procedure|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
139631|NCT01655602|Procedure|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
139632|NCT01655615|Behavioral|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
139633|NCT01655628|Drug|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
139634|NCT00087035|Drug|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
139635|NCT01655628|Drug|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
139930|NCT01656161|Drug|Triptorelin embonate 22.5 mg|
139931|NCT01656174|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
139932|NCT01656187|Drug|Memantine|Memantine is a noncompetitive NMDA receptor antagonist used to help treat Alzheimer's disease.
139933|NCT01649232|Device|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
139934|NCT00086450|Procedure|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
140577|NCT01648127|Drug|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
140578|NCT01648140|Drug|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
140579|NCT01648140|Drug|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
140580|NCT01648140|Drug|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
140581|NCT01648140|Drug|Ribavirin|200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with "200" on 1 side and the logo "3RP" on the other side
140582|NCT01648140|Drug|Telaprevir|375 mg film-coated tablet
140583|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
140584|NCT01648153|Other|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
140585|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
140586|NCT00086346|Drug|Cyclosporine or Tacrolimus|
140587|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
140588|NCT01648179|Drug|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
140589|NCT01640496|Other|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
140590|NCT01640509|Radiation|treated by synchrotron radiation|treated by synchrotron radiation
140591|NCT01640522|Other|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
140592|NCT01640522|Other|Enhanced usual Care|
140593|NCT01640535|Drug|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
140594|NCT00085631|Drug|cisplatin|Given IV
140595|NCT01640535|Drug|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
140596|NCT01640535|Drug|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
138543|NCT01634100|Drug|Probenecid|Probenecid
138544|NCT01634100|Drug|Empagliflozin (BI 10773)|BI Drug
138545|NCT01634113|Drug|tiotropium-bromide|IMP
138546|NCT01634113|Drug|tiotropium-bromide|IMP
138547|NCT01634113|Drug|placebo|placebo matching tiotropium
138855|NCT01654250|Drug|Placebo|Placebo
138856|NCT01654263|Biological|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
138857|NCT01654276|Drug|Febuxostat|One 40 mg tablet once a day for 6 months
138858|NCT01654289|Other|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation "retreat" on a weekend day at the end of week 6 will allow participants to practice their skills.
138859|NCT01656538|Drug|Reolysin|
138860|NCT01656551|Drug|Gemcitabine|
138861|NCT01656551|Drug|Pemetrexed|500 mg/m2 day 1 every 3 weeks
138862|NCT01656551|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks
138863|NCT01656577|Drug|Pexacerfont|
138864|NCT00087165|Drug|prednisone|
138865|NCT01656590|Other|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age & gender
500 cc Formula - Nutren Replete with Fiber overnight [8 hours] via gastrostomy tube
Conditioning Exercise once daily
138866|NCT01656603|Biological|unlicensed CBU|infusion of unlicensed cord blood units
138867|NCT01656616|Drug|Cyanide antidote administration|
138868|NCT01656629|Drug|Teriparatide|20 mcg subq daily for 3 months
138869|NCT01656629|Drug|Alendronate|70 mg weekly for 3 months
138870|NCT01656629|Dietary Supplement|calcium and vitamin D|
138620|NCT01631604|Other|Physical therapy treatment|
138621|NCT01631617|Drug|Trimethoprim/sulfamethoxazole (TMP/SMZ)|800/160 orally every 12 hours for 14 days
138622|NCT01631617|Drug|Cephalexin|500 mg orally every 8 hours for 14 days
138623|NCT00084981|Drug|valproic acid|Given PO
138624|NCT01631617|Drug|Doxycycline|20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
138625|NCT01631617|Other|Sodium hypochlorite|6 % dilute bleach
138626|NCT01631630|Drug|Pioglitazone|15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
138627|NCT01631630|Drug|Placebo|
138628|NCT01631643|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
138629|NCT01631656|Drug|Azelaic acid|15% gel, twice daily, 6 weeks
138630|NCT01631656|Device|Nd:Yag laser|Treatment with Nd:Yag laser of half the face, once at Week 2.
138631|NCT01631669|Drug|Celecoxib|200 mg Q 12 hours orally
138632|NCT01631682|Drug|Propranolol|40mg single pill
138940|NCT01654328|Drug|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
138941|NCT01654328|Drug|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
138942|NCT00086957|Biological|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
138943|NCT01654341|Behavioral|Exercise, dietary and educational program|
138944|NCT01654354|Drug|NEOVIST 370 INJ.(Iopromide 768.86mg)|
138945|NCT01654354|Drug|Ultravist 370 INJ.(Iopromide 768.86mg)|
138946|NCT01654367|Drug|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
138947|NCT01654380|Drug|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 U/mL
138948|NCT01654380|Other|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 mL glass vial
139935|NCT01649245|Drug|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
139936|NCT01649258|Drug|granisetron transdermal system|Given granisetron transdermal system patch
139937|NCT01649258|Drug|fosaprepitant dimeglumine|Given IV
139938|NCT01649258|Other|laboratory biomarker analysis|Correlative studies
139939|NCT01649271|Drug|Herceptin|3-weekly
139940|NCT01649271|Drug|afatinib|at MTD level
139941|NCT01649271|Drug|trastuzumab|3-weekly
139942|NCT01649271|Drug|Herceptin|weekly
139943|NCT01649271|Drug|afatinib|at MTD level
139944|NCT01649271|Drug|afatinib|escalating dose
139945|NCT00086450|Device|Percutaneous Coronary Intervention|For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.
The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery.
139946|NCT01649284|Drug|afatinib|40, 30, and 20 mg film-coated tablets
139947|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
139948|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
140191|NCT01641861|Procedure|Conventional method|caries removal by using rotary instrument.
140192|NCT01641874|Procedure|Exercise|Directional specific exercise
140193|NCT01641874|Procedure|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
140194|NCT00085748|Drug|paliperidone ER|
140195|NCT01641887|Other|Decision Aid|Patients will use a decision aid administered on a computer.
140196|NCT01641900|Drug|eszopiclone|3 mg of eszopiclone for two consecutive nights
140597|NCT01640561|Behavioral|MISC|The Mediational Interventions for Sensitizing Caregivers
139693|NCT01653418|Procedure|Stem cell infusion|
139694|NCT01653431|Device|Transcranial direct current stimulation|
139695|NCT01653444|Biological|GC1119, 0.5mg/kg|biweekly, 0.5mg/kg IV infusion
139696|NCT01653444|Biological|GC1119, 1.0mg/kg|biweekly, 1.0mg/kg IV infusion
139697|NCT01653457|Drug|Memantine|Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From 4th week up to 24th week: 20 mg daily
139698|NCT01653457|Drug|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
139699|NCT01653470|Drug|Paclitaxel|
139700|NCT00086931|Drug|capecitabine|oral dose escalating, twice daily.
139701|NCT01653470|Drug|5-Fluorouracil (5FU)|
139702|NCT01653470|Drug|Carboplatin|
139703|NCT01653470|Drug|Leucovorin|
139704|NCT01653470|Drug|Irinotecan|
139705|NCT01653470|Drug|Paclitaxel|
139706|NCT01653470|Drug|BMS-906024|
139707|NCT01653483|Drug|GSK573719|Novel Dry-Powder Inhaler
139708|NCT01653483|Drug|GSK573719matched-placebo|Novel Dry-Powder Inhaler
139709|NCT01653496|Procedure|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
139710|NCT01653509|Device|Acyclovir patch|Patch containing acyclovir
139711|NCT00086931|Drug|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
139712|NCT01653509|Device|Placebo patch|Patch without acyclovir
139713|NCT01653522|Drug|Triptan|
139714|NCT01653522|Drug|Doxycycline|
139715|NCT01655680|Drug|Placebo|Placebo
138871|NCT01656642|Drug|Atezolizumab|Intravenous administration, fixed at either 15 or 20 milligram per kilogram (mg/kg) every 3 weeks (q3w), or a fixed dose of either 1200 mg q3w, or 800 mg every 2 weeks (q2w), depending on the arm/cohort. Participants currently in Cohorts 2 and 3 still receiving atezolizumab (MPDL3280A) therapy (and any participants enrolled after updated formulation availability) will be switched to receive a fixed dose of 1200 mg or 800 mg of atezolizumab formulation.
138872|NCT01656642|Drug|Cobimetinib|Oral repeating dose
138873|NCT01656642|Drug|Vemurafenib|Oral repeating dose, depending on arm/cohort
138874|NCT01656668|Drug|BC1036|
138875|NCT00087178|Drug|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
139188|NCT01650376|Drug|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
139189|NCT00086580|Biological|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
139190|NCT01650389|Biological|MVA85A|
139191|NCT01650389|Biological|Candin|
139192|NCT01650389|Biological|BCG Vaccine SSI|All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.
Infants who test positive by HIV PCR will not receive BCG vaccination.
139193|NCT01650402|Drug|ACE inhibitor, calcium channel blocker|Daily, doses range depending on subject's response
139194|NCT01650415|Drug|Erythropoietin|twice a week for 1 month
139195|NCT01652547|Drug|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
139196|NCT01652547|Drug|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
139197|NCT01652560|Drug|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
138949|NCT01654393|Other|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
138950|NCT01654406|Device|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
138951|NCT01654406|Device|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
138952|NCT01654419|Device|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
138953|NCT00086957|Drug|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
138954|NCT01654419|Device|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
138955|NCT01654432|Other|Paravertebral Blocks (PVB)|
138956|NCT01654445|Drug|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
138957|NCT01654458|Behavioral|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
138958|NCT01654484|Drug|DE-117|Ophthalmic Solution, QD, 28 Days
138959|NCT01656772|Device|Vdrive Lasso navigation|Remote robotic Lasso navigation
138960|NCT01656772|Procedure|Manual Lasso navigation|Manually maneuver a Lasso catheter
139262|NCT01650428|Drug|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
139263|NCT01650428|Drug|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
139264|NCT00086593|Drug|lamotrigine|
139265|NCT01650441|Drug|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
139266|NCT01650441|Radiation|CT thorax|CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.
The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose.
139267|NCT01650454|Other|2 night polysomnography|Polysomnography
140197|NCT01641900|Drug|placebo|placebo capsule for two consecutive nights
140198|NCT01641913|Other|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
140199|NCT01641926|Biological|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
140200|NCT01641926|Biological|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
140201|NCT01641939|Drug|taxane|Standard taxane (docetaxel or paclitaxel) according to investigator choice
140202|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg every 3 weeks
140203|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg once a week
140204|NCT01641965|Device|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 < 45 mmHg and improve symptoms.
140205|NCT00085761|Drug|Capsaicin Dermal Patch|
140206|NCT01641991|Biological|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
140207|NCT01641991|Biological|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
140208|NCT01642004|Biological|Nivolumab|
140209|NCT01642004|Drug|Docetaxel|
140210|NCT01642017|Drug|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
140211|NCT01642030|Drug|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
140528|NCT01640483|Other|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
140529|NCT01640496|Drug|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
139716|NCT00087035|Drug|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
139717|NCT01655693|Drug|Doxorubicin|
139718|NCT01655693|Drug|Doxorubicin|
139719|NCT01655693|Drug|Best Standard of Care|
140005|NCT01656252|Drug|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.
Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag.
140006|NCT01656252|Drug|Phase II- Sequence A|Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.
Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.
Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.
Additional chemotherapy may be administered at the investigators discretion without eltrombopag.
140007|NCT01656252|Drug|Phase II- Sequence B|Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.
Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.
Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.
Additional chemotherapy may be administered at the investigators discretion without eltrombopag.
140008|NCT01656265|Drug|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
140009|NCT01656278|Procedure|Magnetic resonance imaging (MRI)|Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one physically swollen joint and DAS28>3.2 AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)
140010|NCT01656278|Other|Conventional biochemical and clinical examinations|Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one clinically swollen joint and DAS28>3.2
140011|NCT00087139|Drug|ixabepilone|Given IV
140012|NCT00086463|Drug|Iloprost or placebo|
140013|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
140014|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
140015|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
140016|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
139198|NCT01652573|Drug|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
139199|NCT00001624|Drug|Insulin|
139200|NCT00086827|Drug|romidepsin|Given IV
139201|NCT01652573|Drug|Saline Nasal Spray Placebo|
139202|NCT01652586|Drug|dexmedetomidine-remifentanil|
139203|NCT01652586|Drug|midazolam-remifentanil|
139204|NCT01652599|Drug|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
139205|NCT01652612|Other|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
139499|NCT01657799|Drug|Veliparib|High dose veliparib given continuously throughout the entire course of WBRT. One treatment of 3.0 Gy WBRT will be given daily 5 days per week (10 fractions) for a total of 30.0 Gy.
139500|NCT01657799|Drug|Veliparib|Low dose veliparib given continuously throughout the entire course of WBRT. One treatment of 3.0 Gy WBRT will be given daily 5 days per week (10 fractions) for a total of 30.0 Gy.
139501|NCT01657799|Drug|Placebo|Placebo given continuously throughout the entire course of WBRT. One treatment of 3.0 Gy WBRT will be given daily 5 days per week (10 fractions) for a total of 30.0 Gy.
139502|NCT01657812|Drug|dexmedetomidine|Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.
Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery.
139503|NCT00087256|Other|placebo|
139504|NCT01657825|Drug|Isavuconazole|oral
139505|NCT01657825|Drug|Warfarin|oral
139506|NCT01657838|Drug|Isavuconazole|oral
139507|NCT01657838|Drug|Ketoconazole|oral
139508|NCT01657851|Drug|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
139509|NCT01650805|Drug|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
139510|NCT01650818|Other|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
139268|NCT01650454|Other|battery of neuropsychological tests|
139269|NCT01650454|Other|virtual reality test|
139270|NCT01650454|Other|subjective evaluation of sleep and somnolence|
139271|NCT01650480|Other|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
139272|NCT01650493|Device|Clinpro 5000|Dentrifice containing 950ppm fluoride
139273|NCT01650493|Device|MI Paste Plus|Dentrifice containing 950ppm fluoride
139274|NCT01650493|Device|Tom's of Maine|Dentrifice that is fluoride free
139275|NCT00086606|Drug|Xolair (omalizumab)|
139276|NCT01650506|Drug|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
139277|NCT01650506|Drug|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
139278|NCT01650519|Drug|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
139279|NCT01650519|Drug|IV ketorolac|30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) administered intravenously over no less than 15 seconds
138301|NCT01628627|Device|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly ~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
138302|NCT00001570|Drug|vinblastine|
138303|NCT00084786|Drug|docetaxel|
138304|NCT01628627|Device|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
138305|NCT01628640|Other|Laboratory Biomarker Analysis|Correlative studies
140530|NCT01642472|Drug|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
140531|NCT01642485|Drug|Moxifloxacin 400 mg fasted|Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.
This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies.
140532|NCT01642485|Other|FDA breakfast|Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.
140533|NCT01642485|Other|Continental breakfast|High carbohydrate breakfast (>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.
140534|NCT01642485|Drug|Moxifloxacin 400 mg fed|Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
140535|NCT01642485|Procedure|Insulin Clamp|A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.
140536|NCT01642485|Drug|Placebo|Comparison of different meals effect on Moxifloxacin PK profile
140537|NCT00085839|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
140538|NCT01642498|Device|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
140539|NCT01642511|Radiation|99mTc-labeled Sulfur Colloid|Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5~1.0 mCi/0.5mL) in the tumor quadrant.
140540|NCT01642511|Radiation|99mTc-labeled Sulfur Colloid|Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
140541|NCT01642511|Procedure|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
140542|NCT01642511|Drug|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
140543|NCT01642511|Device|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
140544|NCT01642511|Procedure|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
139636|NCT01655641|Drug|Tranexamic acid|Drug: Tranexamic acid
1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.
Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
140017|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
140018|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
140019|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
140020|NCT01649297|Drug|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
140021|NCT01649297|Drug|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
140271|NCT01639911|Drug|Pazopanib|Pazopanib at the assigned dose (400, 600 or 800 mg) by mouth (PO) once a day beginning on day 10 of the 1st cycle and continuing daily for the duration of study treatment.
140272|NCT01640002|Drug|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
140273|NCT01640002|Drug|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
140274|NCT01640015|Other|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
140275|NCT01640041|Device|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
140276|NCT01640054|Drug|Fostamatinib|Fostamatinib 100mg once daily
140277|NCT01640067|Biological|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
140278|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
140279|NCT01642030|Drug|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
140280|NCT01642056|Drug|EPI-743|
140281|NCT01642069|Other|laboratory biomarker analysis|Correlative studies
140282|NCT00085774|Drug|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
140283|NCT01642082|Biological|Dalantercept|Given SC
140284|NCT01642082|Other|Laboratory Biomarker Analysis|Correlative studies
140285|NCT01642095|Other|laboratory biomarker analysis|Correlative studies
139511|NCT01650818|Other|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
139512|NCT01650831|Device|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
139513|NCT01650844|Other|School-Based Telemedicine Enhanced Asthma Management|
139514|NCT01650844|Other|Enhanced Usual Care|
139515|NCT01650870|Drug|Crystalline Lactulose|
139516|NCT01650883|Dietary Supplement|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
139517|NCT00086671|Drug|ABT-874/Human monoclonal antibody against IL-12|
139518|NCT01650883|Dietary Supplement|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
138548|NCT01634126|Behavioral|1 FIT kit|Patient receives 1 FIT
138549|NCT00085189|Drug|agatolimod sodium|Given SC
138550|NCT01634126|Behavioral|2 FIT kit|Patient receives 2 FIT kits
138551|NCT01634139|Drug|Tiotropium low dose QD|2 actuations once daily in the evening
138552|NCT01634139|Drug|Tiotropium high dose QD|2 actuations once daily in the evening
138553|NCT01634139|Drug|Placebo|2 actuations once daily in the evening
138554|NCT01634152|Drug|Placebo|2 actuations once daily in the evening
138555|NCT01634152|Drug|Tiotropium low dose mcg|2 actuations once daily in the evening
138556|NCT01634152|Drug|Tiotropium high dose|2 actuations once daily in the evening
138557|NCT01634165|Drug|LY2963016|Administered subcutaneously
138558|NCT01634165|Drug|Lantus|Administered subcutaneously
138559|NCT01634178|Drug|Apremilast|One oral dose of 30 mg apremilast under fasted conditions
138560|NCT00085189|Other|laboratory biomarker analysis|Correlative studies
138561|NCT01634178|Drug|Apremilast|one oral dose of 30 mg apremilast after a high-fat meal
138306|NCT01628640|Other|Pharmacological Study|Correlative studies
138307|NCT01628640|Biological|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
138308|NCT01628653|Device|U-SMART|4-weeks' training
138309|NCT01628666|Drug|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
138310|NCT01628666|Drug|Conventional|Cefazolin preoperative
138311|NCT01628679|Behavioral|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
138312|NCT01628692|Drug|Daclatasvir|Tablets, oral, 30 mg, once daily
138313|NCT01628692|Drug|Simeprevir|Capsule, oral, 150 mg, once daily
138314|NCT00084786|Drug|gefitinib|
138315|NCT01628692|Drug|Ribavirin|Tablets, oral, 500-600 mg, twice daily
138316|NCT01628705|Other|Nutritional intervention|The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.
The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat <7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber).
138317|NCT01628705|Dietary Supplement|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
138318|NCT01628718|Behavioral|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
138633|NCT01634204|Other|KiloCoach|Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.
Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted.
138634|NCT01634204|Other|Control|Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.
Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months.
139637|NCT01655641|Other|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
139638|NCT01655654|Behavioral|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
139639|NCT01655654|Behavioral|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
139640|NCT01655654|Other|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
139641|NCT01655680|Drug|ABT-126|ABT-126 Middle Dose
139642|NCT01655680|Drug|ABT-126|ABT-126 Low Dose
139643|NCT01655680|Drug|ABT-126|ABT-126 High Dose
139644|NCT01648621|Behavioral|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
139645|NCT01648634|Drug|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is>60kg)
139646|NCT01648634|Drug|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is>60kg)
139647|NCT01648660|Dietary Supplement|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
139648|NCT01648686|Procedure|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
139649|NCT01648699|Drug|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
139650|NCT01648712|Device|Balance surface, Carmeda heparin-coated surface|This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.
139651|NCT01648725|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
139652|NCT01648725|Procedure|usual care|Standard care before induction of anesthesia
139653|NCT00001605|Biological|Nontypeable Haemophilus influenzae|
139654|NCT00086411|Drug|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
140286|NCT01642108|Drug|Sitagliptin|50 mg once per day
140287|NCT01642121|Other|laboratory biomarker analysis|Correlative studies
140288|NCT01642134|Drug|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
140289|NCT01642147|Device|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI－DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
140290|NCT01642147|Procedure|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
140598|NCT01640561|Behavioral|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by an NGO operating in Uganda called UCOBAC (Uganda Community Based Association for Child Welfare) with support from UNICEF.
140599|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
140600|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
140601|NCT01640574|Drug|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
140602|NCT01640574|Drug|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
140603|NCT01640587|Drug|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
140604|NCT01640587|Drug|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
140605|NCT00085631|Procedure|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
140606|NCT01640626|Other|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
140607|NCT01640639|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
140608|NCT01640639|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
138562|NCT01634191|Drug|Apremilast|One oral 30 mg dose of apremilast
138563|NCT01636908|Drug|Vemurafenib|960 mg twice daily, oral use, 15-21 days
138564|NCT01636908|Procedure|tumor biopsy|
138565|NCT01636908|Procedure|skin biopsy (optional)|
138566|NCT01636921|Drug|Sorafenib|200 mg orally twice daily (Maximum Tolerated Dose from Phase I of study) until disease progression.
138567|NCT00085384|Drug|PEG-interferon alfa-2b|Biological/Vaccine: PEG-interferon alfa-2b
Dose 1.25 mg/kg/week given subcutaneously
138568|NCT01636921|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
138569|NCT01636934|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
138570|NCT01636934|Other|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
138571|NCT01636934|Behavioral|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
138572|NCT01636947|Drug|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
138876|NCT01656681|Dietary Supplement|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
138877|NCT01656681|Dietary Supplement|Placebo|Placebo tablet
138878|NCT01656694|Device|DePuy Sigma HP Partial Knee|
138879|NCT01656707|Behavioral|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
138880|NCT01656707|Behavioral|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
138881|NCT01656720|Drug|1R, 2S-methoxamine hydrochloride|
138882|NCT01656720|Drug|Placebo|
138883|NCT01656733|Drug|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper Placebo Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
138884|NCT01656746|Procedure|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
138885|NCT01656759|Drug|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
138635|NCT01634217|Biological|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
138636|NCT01634230|Drug|OCR-002|daily dose: 10g infused over 24 hour
138637|NCT01634243|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
138638|NCT01634256|Dietary Supplement|Placebo|Placebo(3.0g/day)
138639|NCT01634256|Dietary Supplement|Fermented turmeric|Fermented turmeric(3.0g/day)
138640|NCT01634269|Device|MDT-2111 TAVI 23 mm|Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
138641|NCT00000264|Drug|30% Nitrous oxide|
138642|NCT00001576|Drug|Floxuridine|
138643|NCT00085202|Biological|filgrastim|Given subcutaneously
138644|NCT01634282|Drug|OPC-262|Orally administered once daily
138645|NCT01634295|Drug|CKD-828 2.5/40mg|Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.
With the others investigation product placebo 4 tabs QD 2 weeks.
138646|NCT01634295|Drug|CKD-828 5/40mg|Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.
With the others investigation product placebo 4 tabs QD 2 weeks.
138647|NCT01634295|Drug|CKD-828 5/80mg|Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.
With the others investigation product placebo 4 tabs QD 6 weeks.
138648|NCT01634295|Drug|S-amlodipine 2.5mg|S-amlodipine 2.5mg QD 4 weeks
With the others investigation product placebo 4 tabs QD 4 weeks.
138649|NCT01634295|Drug|S-amlodipine 5mg|S-amlodipine 2.5mg QD 6weeks
With the others investigation product placebo 4 tabs QD 6 weeks.
138650|NCT01634308|Drug|Novosis(bongros/BMP-2)|
138651|NCT01634308|Drug|Bio-oss|
138652|NCT01634321|Drug|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
138653|NCT01634334|Behavioral|Real-Time Intervention|Lights and Sound Brief Coaching
138654|NCT00085202|Drug|cisplatin|Given IV
138961|NCT01656785|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
139949|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
139950|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
139951|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
139952|NCT01649297|Drug|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
139953|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
139954|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
139955|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
139956|NCT01651676|Other|VQ11 validation|Two visits per patient are planned: V1 and V2.
For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)
LABD treatment consist in β 2 agonists or anticholinergic drug.
139957|NCT01651702|Device|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
139958|NCT01651702|Device|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
139959|NCT01651715|Drug|TAO1, oral homeopathic antibodies|TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).
The investigational product will be taken for 7 days as follow:
Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.
Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).
139960|NCT01651728|Drug|Simvastatin|Tablet 20 mg once daily for 30 days
139961|NCT01651728|Drug|Placebo|daily for 30 days
139962|NCT01651741|Dietary Supplement|Seaweed and Duolac7S|Seaweed and probiotics is composed of seaweed and Duolac7S.
Seaweed:
Form: brown granule
Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)
Duration: 4 weeks of treatment period
Duolac7S:
The probiotics, Duolac7S, consist of 7 bacteria.
Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.
Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (30 min after morning and evening meal)
Duration: 4 weeks of treatment period
139963|NCT01651741|Dietary Supplement|Seaweed and Duolac7S-P|Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).
Seaweed:
Form: brown granule
Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)
Duration: 4 weeks of treatment period
Duolac7S-P:
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
139964|NCT00086736|Drug|oral eflornithine placebo|
139965|NCT01651754|Biological|Seasonal influenza vaccination|single dose of influenza vaccination
140609|NCT01640652|Biological|MenPF-1.|A new vaccine against meningococcal disease.
140610|NCT01640665|Drug|Sorafenib, Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
140611|NCT01642550|Drug|Placebo|
140612|NCT01642563|Procedure|Platelet transfusion|One dose of pathogen reduced platelets
140613|NCT01642563|Procedure|Platelet transfusion|One dose of standard platelets
140614|NCT01642576|Behavioral|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
140615|NCT01642589|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
140616|NCT01642589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
140617|NCT01642602|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
139720|NCT01655706|Drug|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
139721|NCT01655706|Drug|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
139722|NCT01655719|Drug|Pioglitazone|
139723|NCT01655732|Procedure|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
139724|NCT01655745|Procedure|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
139725|NCT01655758|Drug|0.5% timolol|
139726|NCT01655758|Drug|timolol-dorzolamide fixed combination|
139727|NCT00087048|Drug|topotecan hydrochloride|
139728|NCT01655758|Drug|Latanoprost|
139729|NCT01655758|Drug|Travoprost|
139730|NCT01655758|Drug|Bimatoprost|
139731|NCT01655771|Drug|TD-1211 Dose 1|
138886|NCT00087178|Drug|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
138887|NCT01649765|Drug|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
138888|NCT01649765|Other|placebo|Normal Saline 250 ml
138889|NCT01649778|Drug|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
138890|NCT01649791|Drug|lenalidomide|Given orally
138891|NCT01649791|Other|laboratory biomarker analysis|Correlative study
138892|NCT01649791|Procedure|lymph node biopsy|Correlative study
138893|NCT00086515|Drug|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
138894|NCT01649791|Procedure|bone marrow aspiration|Correlative study
138895|NCT01649791|Other|pharmacological study|Correlative study
138896|NCT01649791|Other|flow cytometry|Correlative study
138897|NCT01649804|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
138898|NCT01649830|Radiation|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
138899|NCT01649830|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
139206|NCT01652625|Drug|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
139207|NCT01652625|Drug|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
139208|NCT01652638|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
139209|NCT01652651|Behavioral|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
139210|NCT01652664|Drug|Travoprost 0.004% PQ ophthalmic solution|
141355|NCT01641588|Behavioral|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
141356|NCT00085735|Drug|cyclophosphamide|Given IV
141357|NCT01641601|Device|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
141358|NCT01641614|Procedure|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
141359|NCT01641614|Procedure|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
141360|NCT01641627|Procedure|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
141361|NCT01641640|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
141362|NCT01641640|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
141363|NCT01641640|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
141364|NCT01641653|Other|Normal saline|Normal saline 2cc. one dose prior to OR
141365|NCT01641653|Drug|Midazolam|1-2.5 mg
141366|NCT01641666|Drug|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
141367|NCT00085735|Drug|lomustine|Given orally
141368|NCT01641666|Drug|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
141369|NCT01641666|Drug|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
141370|NCT01641692|Drug|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
141678|NCT01675557|Dietary Supplement|Placebo|a single oral dose of placebo
145292|NCT00095212|Drug|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
145293|NCT01745523|Procedure|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
145294|NCT01745523|Procedure|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
145295|NCT01745536|Procedure|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
145296|NCT01745536|Procedure|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
145297|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
145319|NCT01748110|Behavioral|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up weekly with a health counselor to verify progress.
145320|NCT01748110|Behavioral|TRIMM|text message intervention.
145321|NCT01748123|Drug|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
145322|NCT01748123|Drug|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
145323|NCT01748136|Device|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
145324|NCT01740531|Biological|S-303 Treated Red Blood Cells (RBCs)|
145325|NCT01740531|Biological|Conventional, untreated Red Blood Cells|
145326|NCT00094783|Procedure|MRI|
145327|NCT01740544|Other|Cathodal tDCS|Cathodal tDCS applied over the right PPC
145328|NCT01740544|Other|Sham tDCS|Sham tDCS applied over the right PPC
145329|NCT01740557|Drug|Cytoxan|60 mg/kg/day by vein on Days -7 and -6.
145330|NCT01740557|Drug|Mesna|60 mg/kg by vein on Days -7 and -6.
145331|NCT01740557|Drug|Fludarabine monophosphate|25 mg/m2 by vein on Days -5 to -1.
145332|NCT01740557|Procedure|T cell Infusion|Participants receive up to 1.5x10^11 T cells by vein (including both CXCR2 and NGFR transduced TIL) on Day 0.
141741|NCT01670578|Biological|PRP|
141742|NCT01670578|Device|Hyaluronic acid|
141743|NCT01670591|Behavioral|PS - Prevention in School|
141744|NCT01670604|Drug|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
141745|NCT01673074|Drug|(PDT) Photodynamic therapy|photosensitizer
141746|NCT01673087|Drug|Metyrapone|750 mcg, oral, administered twice, 3.5 hours apart
141747|NCT01673087|Drug|Dexamethasone|Administered twice:
1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration.
141748|NCT01673087|Drug|Cortrosyn|250 mcg, IV, bolus, in the afternoon.
141749|NCT01673087|Drug|Corticorelin ovine triflutate|100 mcg, IV, over 30 seconds, in the afternoon.
141750|NCT01673100|Behavioral|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
141751|NCT01673113|Device|Zeltiq CoolSculpting device|This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the "love handles."
141752|NCT00088764|Behavioral|Arthritis education|8 sessions of learning about rheumatoid arthritis
141753|NCT01673126|Device|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
141754|NCT01673126|Device|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
141755|NCT01673139|Behavioral|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
141756|NCT01673139|Behavioral|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
140853|NCT01648244|Other|Computer-Assisted Decision Support|The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either "accept" or "reject" the recommendation by the software.Providers with their patients are block randomized into CADS or "Usual Care" for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting "usual care" will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year.
141206|NCT01641393|Drug|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
141207|NCT01641393|Drug|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
141208|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
141209|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with "NTX".
141210|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is >5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is <5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
141211|NCT01641419|Drug|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
141212|NCT01641419|Drug|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
141213|NCT00085722|Other|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
141214|NCT01641419|Drug|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
141215|NCT01641432|Behavioral|Tonic and Phasic Attention Training|The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).
Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes.
141492|NCT00001676|Drug|SQ Fludarabine|
141493|NCT00088881|Radiation|radiation therapy|Undergo radiotherapy
141820|NCT01670643|Behavioral|Video camera magnifier|reading with video camera magnifier
141821|NCT01670656|Drug|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 μg NOMAC and 300 μg E2 intravaginal ring for two 28-day cycles
141822|NCT01670656|Drug|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 μg ENG and 300 μg E2, intravaginally for two 28-day cycles
141823|NCT01670656|Drug|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
141824|NCT01670656|Drug|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
141825|NCT01670669|Drug|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
141826|NCT01670682|Procedure|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
141827|NCT00088504|Drug|Merimepodib|
141828|NCT01670682|Procedure|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
141829|NCT01670682|Device|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
141830|NCT01670708|Behavioral|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
141831|NCT01670708|Behavioral|Probation as Usual|Probation officer supervises following standard protocols.
141832|NCT01670721|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
141833|NCT01670721|Drug|irinotecan|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
141834|NCT01670721|Drug|fluorouracil|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
141835|NCT01670721|Drug|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
141836|NCT01670734|Drug|alirocumab SAR236553 (REGN727)|alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)
Pharmaceutical form:Solution for injection Route of administration: subcutaneous
141837|NCT01670747|Radiation|Chest computed tomography|
141838|NCT00088504|Drug|PEG-Interferon-alpha 2a (Pegasys®)|
145333|NCT01740557|Drug|IL-2|720,000 IU/kg by vein every 8-16 hours for up to 15 doses on Days 1 to 5.
145334|NCT01740557|Other|Questionnaire|Questionnaire completion about health and quality of life one (1) time a year for up to 15 years. Questionnaire should take about 15 minutes to complete.
145335|NCT01740570|Drug|Cabazitaxel|Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.
Phase II: Maximum tolerated dose from Phase I.
145336|NCT01740583|Device|percutaneous annuloplasty|plication of the mitral valve annulus
145337|NCT00094796|Procedure|Exercise cardiopulmonary metabolic testing|
145338|NCT01740596|Device|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
145339|NCT01740609|Drug|Placebo|Placebo
145642|NCT01743807|Drug|GNKG168|GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.
145643|NCT01743820|Drug|dihydroartemisinin-piperaquine|
145644|NCT01743820|Drug|0.125 mg/kg Primaquine|
145645|NCT00095082|Drug|insulin aspart|
145646|NCT01743820|Drug|0.5 mg/kg Primaquine|
145647|NCT01743820|Drug|0.25 mg/kg Primaquine|
145648|NCT01743820|Drug|0.0625 mg/kg Primaquine|
145649|NCT01746082|Biological|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects >/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
145650|NCT01746095|Drug|Vancomycin inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
145651|NCT01746095|Drug|Placebo inhalation powder|
140854|NCT01648257|Drug|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
140855|NCT01648257|Drug|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
140856|NCT01648257|Drug|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
140857|NCT01648270|Drug|buprenorphine|Session 1 Intravenous buprenorphine: 0.2 mg infused over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3intravenous buprenorphine 0.2 mg infused over 1 hr beginning 1 hr after starting cyclosporine.
Session 4 Sublingual buprenorphine: 2 mg
140858|NCT01648270|Drug|Cyclosporine|Session 3 Cyclosporine (2.5mg/kg/hr infused over 2 hr) Subjects then take oral cyclosporine 4.5 mg/kg twice daily, until session 4, continue oral cyclosporine 4.5 mg/kg twice daily for 5 days
140859|NCT00086359|Drug|Lamivudine/zidovudine|one pill twice daily
140860|NCT01648283|Drug|racemic methadone HC1|IV racemic Methadone HC1 6 mg oral d5-methadon HC1 11 mg
140861|NCT01648283|Drug|Oral deuterated racemic methadone HCl,|11 mg capsule once
140862|NCT01648296|Drug|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
140863|NCT00085644|Biological|placebo|Placebo every other week, subcutaneous
140864|NCT01641042|Biological|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
140865|NCT01641055|Dietary Supplement|Salmon peptide|5g salmon peptide per day for 8wk.
140866|NCT01641055|Dietary Supplement|Herring peptide|5g herring peptide per day for 8wk.
140867|NCT01641055|Dietary Supplement|Cod protein|5g cod protein per day for 8wk.
140868|NCT01641055|Dietary Supplement|Milk protein|5g milk protein per day for 8wk.
140869|NCT01641068|Procedure|Functional Magnetic Resonance Imaging|Undergo Functional Neuroimaging
140870|NCT01641068|Other|Cognitive Training Intervention|Participate in memory and thinking skills workshop
140871|NCT01641068|Other|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition.
140872|NCT01641068|Other|Memory Intervention|Participate in memory and thinking skills workshop
141494|NCT01675193|Behavioral|Omission of population-based child vision screening visits at 6-9 and 14-24 months|
141495|NCT01675206|Dietary Supplement|Vitamin K2 supplementation|
141496|NCT01675219|Procedure|white light TUR-BT|traditional transurethral bladder tumor resection
141497|NCT01675219|Procedure|blue light TUR-BT|photodynamic transurethral bladder tumor resection
141498|NCT01675219|Drug|optimized MMC|six weekly optimized mitomycin-C instillations
141499|NCT01675219|Drug|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
141500|NCT01675232|Other|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
141501|NCT01675232|Other|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
141502|NCT01675245|Drug|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
141503|NCT01675258|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
141504|NCT00088881|Procedure|positron emission tomography|Undergo PET scans
141505|NCT01675271|Other|individual exercise|individual exercise and dietary prescription
141506|NCT01675271|Other|general exercise|general exercise counselling
141507|NCT01675284|Biological|AT-301|Inactivated H5N1 Influenza Virion Vaccine
141508|NCT01675297|Drug|Risedronate/Cholecalciferol combination|once a week
141509|NCT01675297|Drug|Risedronate|once a week
141510|NCT01675310|Drug|medical nutrition therapy + metformin|
141511|NCT01675310|Behavioral|Medical nutrition therapy|medical nutrition therapy
141512|NCT01675349|Biological|Prick test Chenopodium album allergen extract|This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
141513|NCT01675362|Drug|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
141839|NCT01670760|Device|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
141840|NCT01670773|Drug|CAT-1004|
140925|NCT01645761|Drug|Endonase|PPI- based triple therapy with endonase
140926|NCT01638559|Other|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
140927|NCT01638585|Drug|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
140928|NCT01638598|Drug|matching placebo|matching placebo in each dose level
140929|NCT01638598|Drug|Test drug|BI 1021958
140930|NCT01638598|Drug|matching placebo|matching placebo in each dose level
140931|NCT01638598|Drug|Test drug|BI 1021958
140932|NCT01638598|Drug|Test drug|BI 1021958
140933|NCT00085462|Biological|filgrastim|
140934|NCT01638598|Drug|Test drug|BI 1021958
140935|NCT01638598|Drug|Test drug|BI 1021958
140936|NCT01638598|Drug|matching placebo|matching placebo in each dose level
140937|NCT01638598|Drug|matching placebo|matching placebo in each dose level
140938|NCT01638598|Drug|matching placebo|matching placebo in each dose level
140939|NCT01638611|Drug|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
140940|NCT01638611|Drug|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
140941|NCT01638624|Drug|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
140942|NCT01638624|Drug|Placebo|
140943|NCT01638637|Device|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
140944|NCT00085462|Biological|gp100-fowlpox vaccine|
145652|NCT01746108|Biological|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
145653|NCT01746121|Genetic|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
145654|NCT01746147|Other|No intervention and study treatment|
145655|NCT00095277|Drug|Darbepoetin Alfa|
145656|NCT01746160|Drug|C1 Implant|Patients treated with dental implants.
145657|NCT01746173|Drug|Cyclophosphamide|Intravenous, on Day 1, 3 or 6 cycles
145658|NCT01746173|Drug|Doxorubicin|Intravenously, on Day 1, 3 or 6 cycles
145659|NCT01746173|Drug|Vincristine|Intravenously, on Day 1, 3 or 6 cycles
145660|NCT01746173|Drug|Etoposide|Intravenously or orally, Day 1,2 and 3, 3 or 6 cycles
145661|NCT01746173|Drug|Prednisone|Taken orally, days 1-5
145662|NCT01746173|Drug|Filgrastim|Subcutaneous daily injection for 5-7 days
144672|NCT01741974|Dietary Supplement|Karinat|
144673|NCT01741974|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
144674|NCT00094887|Drug|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
144675|NCT01741987|Other|Optive ®|instilation of 1 drop each eye 4 times per day
144676|NCT01741987|Other|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
144677|NCT01742000|Dietary Supplement|Karinat|
144678|NCT01742000|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
144679|NCT01742013|Drug|GCJBP Laennec Inj.|Test drug
144680|NCT01742013|Drug|Placebo|Comparator
144681|NCT01742026|Procedure|Aspergillus PCR technique|Aspergillus DNA PCR technique
144682|NCT01742026|Procedure|Aspergillus AGA technique|Aspergillus AGA technique
144683|NCT01742052|Drug|MT-1303-Low|
141145|NCT01643486|Other|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
141146|NCT01643499|Drug|oxaliplatin|Given IV
141147|NCT01643499|Drug|irinotecan hydrochloride|Given IV
141148|NCT01643499|Drug|leucovorin calcium|Given IV
141149|NCT01643499|Drug|fluorouracil|Given IV
141150|NCT01643499|Other|laboratory biomarker analysis|Correlative studies
141151|NCT01643525|Device|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
141152|NCT01643538|Behavioral|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
141153|NCT00085943|Drug|Abacavir/Lamivudine|
141154|NCT01643538|Behavioral|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
141155|NCT01643538|Behavioral|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
141156|NCT01646073|Biological|Adalimumab|adalimumab eow
141157|NCT01646073|Biological|placebo|placebo
141158|NCT01646086|Behavioral|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
141159|NCT01646099|Behavioral|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
141030|NCT01641211|Other|Nutrition video|Children in this group will watch a 2-minute nutrition video.
141308|NCT01643759|Drug|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
141309|NCT01643772|Drug|OxyNorm® Capsules (Oxycodone Hydrochloride)|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
141310|NCT01643785|Drug|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
141311|NCT01643798|Procedure|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
141312|NCT01643798|Procedure|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
141313|NCT01643811|Procedure|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
141314|NCT01643811|Procedure|Endoscopic submucosal dissection|endoscopic submucosal dissection
141315|NCT01643824|Radiation|Proton Beam Therapy|- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%
- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV
141316|NCT01643837|Other|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
141317|NCT01646333|Behavioral|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
141318|NCT01646333|Behavioral|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
141319|NCT01646346|Radiation|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
140945|NCT01638650|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
140946|NCT01638650|Drug|ritonavir|100 mg bid orally, Days 1-14
140947|NCT01638650|Drug|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
140948|NCT01638663|Drug|Tolvaptan|15 mg pr day for 1 day
141216|NCT01641432|Behavioral|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
141217|NCT01643538|Behavioral|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
141218|NCT01643577|Procedure|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
141219|NCT01643577|Procedure|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
141220|NCT01643590|Biological|JVS-100 15 mg dose Injection|Intramyocardial Injection
141221|NCT01643590|Biological|Placebo Injection|Intramyocardial Injection
141222|NCT01643590|Biological|JVS-100 30 mg dose injection|Intramyocardial Injection
141223|NCT01643603|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
141224|NCT01643603|Other|laboratory biomarker analysis|Correlative studies
141225|NCT00001596|Drug|Placebo|Placebo (3 pills), three times daily.
141226|NCT00085943|Drug|Fosamprenavir|
141227|NCT01643616|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
141228|NCT01643616|Drug|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
141229|NCT01643616|Drug|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
141230|NCT01643616|Drug|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
141231|NCT01643616|Device|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
141679|NCT01675570|Drug|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
141680|NCT01675570|Drug|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
141681|NCT01675596|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
141682|NCT01675609|Drug|Placebo|1 drop in each eye daily for up to 35 days
141683|NCT01675609|Drug|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
141684|NCT01675622|Drug|Oxycodone|dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
141685|NCT00088894|Other|laboratory biomarker analysis|Correlative studies
141686|NCT01675622|Drug|Morphine|Morphine tablets 10mg and 20mg, oral every 4-6 hours
141687|NCT01675635|Drug|OxyNorm Capsules|dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
141688|NCT01675635|Other|Morphine tablet|dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
141689|NCT01675648|Drug|Lofexidine|
141690|NCT01675648|Drug|Diazepam|
141691|NCT01675648|Drug|Placebo for Lofexidine|
141692|NCT01675648|Drug|Placebo for Diazepam|
141693|NCT01675661|Drug|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
141694|NCT01675661|Drug|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
141695|NCT01675674|Other|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
141696|NCT00088894|Other|pharmacogenomic studies|Correlative studies
141697|NCT01675687|Behavioral|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
141698|NCT01675700|Drug|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
141160|NCT01646125|Drug|AUY922|AUY922 will be given i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment
141161|NCT01646125|Drug|Docetaxel|Docetaxel will be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
141431|NCT01677949|Biological|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
141432|NCT01677962|Biological|Poly-ICLC|
141433|NCT01677962|Biological|dendritic cell|
141434|NCT01677975|Procedure|FNA (fine needle aspiration)|
141435|NCT01677988|Drug|Neo-adjuvant Chemotherapy|Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.
Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)
Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.
Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation.
141436|NCT01677988|Radiation|Chemoradiation|Chemoradiation may be administered at selected approved CTN sites.
Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.
Unresectable → Off study. Subsequent treatment per patient's primary MD.
Resectable → Continue to Registration #3 for Surgical Resection
141437|NCT01677988|Procedure|Surgical Resection|Meets criteria for resectable* →pancreaticoduodenectomy (POD)
At time of resection, snap frozen tumor specimen sent for correlative biomarker studies
141438|NCT01678001|Drug|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
141439|NCT00089011|Drug|tacrolimus|Given IV or PO
141440|NCT01678014|Procedure|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
141441|NCT01678014|Procedure|Capsulotomy|
141442|NCT00088413|Drug|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant DNA technology in yeast (Saccharomyces cerevisiae). It is a commercially available drug administered subcutaneously.
141443|NCT01670032|Drug|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
141444|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
141445|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
141320|NCT01646359|Device|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
141616|NCT01678287|Drug|Placebo|oral
141617|NCT00089011|Other|laboratory biomarker analysis|Correlative studies
141618|NCT01678313|Drug|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
141619|NCT01678313|Drug|Doxazosin 4 mg every day (QD)|Control group
141620|NCT01678326|Procedure|EUS-Rendezvous or direct intervention|
141621|NCT01678326|Procedure|Advanced ERCP Biliary Access Techniques|
141622|NCT01678352|Biological|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
141623|NCT01678352|Drug|Imiquimod|Cohort 1 Cohort 2 Cohort 3
141624|NCT01678365|Drug|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
141625|NCT01678378|Behavioral|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
141626|NCT01678391|Procedure|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
141627|NCT01678404|Drug|131I-rituximab|
141628|NCT00089024|Drug|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 & 2; Repeat one 3-week cycle starting day 22
141629|NCT01678417|Drug|131I-rituximab|
141630|NCT01678430|Drug|Ofatumumab|
141631|NCT01678430|Drug|Chlorambucil|
141632|NCT01670305|Procedure|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
141633|NCT01670305|Procedure|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
141232|NCT01643616|Device|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
141233|NCT01643629|Biological|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
141234|NCT01643629|Other|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
141235|NCT01643642|Other|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
141236|NCT01643642|Other|Treatment As Usual|Other: Treatment As Usual
141514|NCT01678027|Drug|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
141515|NCT01678027|Drug|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
141516|NCT01678053|Drug|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
141517|NCT01678053|Drug|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
141518|NCT01678066|Device|Bilateral cardiac output|
141519|NCT01678079|Dietary Supplement|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
141520|NCT01678079|Dietary Supplement|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
141521|NCT01678092|Biological|omalizumab|
141522|NCT00089011|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
141523|NCT01678105|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal
141524|NCT01678118|Behavioral|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder & to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs & barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
141699|NCT01675713|Behavioral|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
140794|NCT00001596|Drug|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
140795|NCT00085904|Drug|SB-485232|
140796|NCT01642836|Behavioral|Health and Nutrition Education|Enhanced standard care/health and nutrition education intervention:
notification of primary care providers about metabolic measures and blood pressure
state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and "Family Fun Nights"
140797|NCT01642849|Dietary Supplement|high protein diet|6 months on HP diet
140798|NCT01642849|Dietary Supplement|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
140799|NCT01642862|Drug|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
140800|NCT01642875|Other|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
140801|NCT01642875|Other|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
140802|NCT01642888|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
140803|NCT01642888|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
140804|NCT01642901|Drug|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
140805|NCT01642901|Drug|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
140806|NCT00085917|Drug|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
140807|NCT01642914|Drug|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
140808|NCT01642914|Drug|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
140809|NCT01642914|Drug|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
141446|NCT01670071|Drug|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
141447|NCT01670071|Drug|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
141448|NCT01670084|Drug|nilotinib|Given PO
141449|NCT01670084|Biological|rituximab|Given IV
141757|NCT01673139|Behavioral|Control|Given information on recommendations for physical activity.
141758|NCT01673152|Dietary Supplement|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
141759|NCT01673152|Dietary Supplement|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
141760|NCT01673165|Other|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
141761|NCT01673165|Other|Specialized Formula|Infants will receive our standard of care - specialized formula
141762|NCT01673178|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
141763|NCT00088764|Behavioral|Health behavior writing|4 sessions of writing about various health behaviors
141764|NCT01673178|Drug|25 mg PF-05231023|25 mg IV once a week for 4 weeks
141765|NCT01673178|Drug|50 mg PF-05231023|50 mg IV once a week for 4 weeks
141766|NCT01673178|Drug|100 mg PF-05231023|100 mg IV once a week for 4 weeks
141767|NCT01673178|Drug|150 mg PF-05231023|150 mg IV once a week for 4 weeks
141768|NCT01673191|Drug|Dexamethasone intravitreal implant|
141769|NCT01675739|Drug|polyethylene glycol (PEG)|No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.
SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS
141770|NCT01675765|Biological|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
141771|NCT01675765|Biological|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
141772|NCT01675778|Drug|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
141773|NCT01675791|Biological|ALK tree AIT 0.5 DU|
141634|NCT01670305|Procedure|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
141635|NCT01670318|Device|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
140729|NCT01645098|Drug|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
140730|NCT01645098|Drug|Dexmedetomidine|0.5 mcg/kg/hr IV
140731|NCT01645111|Drug|Clevidipine|
140732|NCT01645124|Drug|Hydroxyurea|
140733|NCT01645124|Procedure|Phlebotomy|
140734|NCT01645137|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
140735|NCT01645137|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
140736|NCT01645150|Behavioral|Progressive strength training|12 weeks of supervised progressive strength training
140737|NCT01645163|Behavioral|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
140738|NCT00086138|Drug|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
140739|NCT01645176|Drug|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
140740|NCT01645189|Biological|Hunterase|once weekly, 0.5mg/kg IV infusion
140741|NCT01645202|Procedure|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
140742|NCT01645215|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
140743|NCT01647880|Drug|Active Comparator receiving Extavia®|
140744|NCT01647893|Drug|CTB-001|IV bolus or IV infusion
140745|NCT01647919|Dietary Supplement|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
140746|NCT01647919|Dietary Supplement|Placebo|4 capsules of placebo identical to cogniVida™ once a day
140747|NCT01647932|Drug|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; >50ml/min 25mg daily, 20-50ml/min 50mg daily amd <20ml/min 100mg daily.
141525|NCT01678131|Drug|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
141526|NCT01678131|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
141527|NCT01678131|Biological|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
141528|NCT01678131|Procedure|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
141529|NCT01678131|Drug|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
141530|NCT01678131|Procedure|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
141841|NCT01673191|Drug|Steroid plus NSAID eye drop combination therapy|
141842|NCT01673204|Drug|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
141843|NCT01673204|Drug|Placebo|
141844|NCT01673217|Drug|decitabine|Given IV
141845|NCT01673217|Biological|NY-ESO-1 peptide vaccine|Given SC
141846|NCT00088777|Behavioral|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
141847|NCT01673217|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
141848|NCT01673217|Biological|sargramostim|Given SC
141849|NCT01673217|Biological|incomplete Freund's adjuvant|Given SC
141850|NCT01673217|Other|immunohistochemistry staining method|Correlative studies
141851|NCT01673217|Other|liquid chromatography|Correlative studies
141852|NCT01673217|Other|mass spectrometry|Correlative studies
141853|NCT01673217|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
141854|NCT01673217|Other|laboratory biomarker analysis|Correlative studies
141855|NCT01673217|Genetic|DNA methylation analysis|Correlative studies
140810|NCT01642940|Drug|Prasugrel|Prasugrel 10mg/day
140811|NCT01642940|Drug|Ticagrelor|Ticagrelor 90mg twice a day
141091|NCT01646047|Dietary Supplement|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
141092|NCT01646047|Dietary Supplement|multi-component dietary supplement|placebo capsules
141093|NCT00001601|Procedure|Electrocardiogram|
141094|NCT00086203|Drug|Talabostat mesylate (PT-100) tablets|
141095|NCT01646060|Device|CM-1500|Blood Volume Monitor
141096|NCT01638858|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
141097|NCT01638871|Behavioral|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
141098|NCT00085462|Drug|cyclophosphamide|
141099|NCT01638884|Behavioral|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
141100|NCT01638884|Other|Structural MRI|to compare differences between each populations
141101|NCT01638884|Other|Functional MRI|to compare differences between each populations
141102|NCT01638884|Other|Virtual reality / Memory assessment|to compare differences between each populations
141103|NCT01638910|Drug|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
141104|NCT01638923|Drug|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
141105|NCT01638923|Drug|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
141106|NCT01638936|Drug|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
141107|NCT01638949|Behavioral|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
141774|NCT00088894|Other|pharmacological study|Correlative studies
141775|NCT01675791|Biological|ALK tree AIT 1 DU|
141776|NCT01675791|Biological|ALK tree AIT 2 DU|
141777|NCT01675791|Biological|ALK tree AIT 4 DU|
141778|NCT01675791|Biological|ALK tree AIT 7 DU|
141779|NCT01675791|Biological|ALK tree AIT 12 DU|
141780|NCT01675791|Biological|ALK tree AIT Placebo|
140873|NCT01641068|Other|Quality-of-Life Assessment|Ancillary studies
140874|NCT00085696|Drug|VELCADE and rituximab|
140875|NCT01641068|Other|Questionnaire Administration|Ancillary studies
140876|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, low dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
140877|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI 6 mcg, twice a day for 14 days|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
140878|NCT01641081|Drug|Foradil Aerolizer, low dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
140879|NCT01641081|Drug|Foradil Aerolizer, high dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
140880|NCT01641081|Drug|Placebo|Placebo in the Pressair for 14 days
140881|NCT01641107|Drug|Ponatinib|Treatment:
Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion.
140882|NCT01641120|Drug|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
140883|NCT01641133|Biological|Synflorix™ (3-Dose)|3 doses administered intramuscularly
140884|NCT01641133|Biological|Synflorix™ (2-Dose)|2 doses administered intramuscularly
140885|NCT00085709|Drug|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses >/= 28 days apart
140748|NCT01647932|Drug|Placebo|Placebo according to clearance of creatinine; >50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd <20ml/min 2 pills daily.
140749|NCT01647945|Drug|Placebo|placebo pill
140750|NCT01647945|Drug|FK506 level < 2 ng/ml|FK506 goal trough blood level < 2 ng/ml
140751|NCT00001601|Procedure|Diagnostic imaging|
140752|NCT00086320|Drug|Paliperidone ER|
141031|NCT01641224|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
141032|NCT01641224|Device|Atractylodes|Atractylodes (~10-15g)
141033|NCT00085709|Drug|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
141034|NCT01641224|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
141035|NCT01641224|Device|Tangerine Peel|Tangerine Peel (~10g)
141036|NCT01641224|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
141037|NCT01641224|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
141038|NCT01641224|Drug|Radix curcumae|Radix curcumae (~10g)
141039|NCT01641224|Drug|Fingered citron|Fingered citron (~10g)
141040|NCT01641224|Drug|Tuckahoe|Tuckahoe (15g)
141041|NCT01641224|Drug|Placebo|Placebo is blindly given to patients.
141042|NCT01641237|Drug|sodium fluoride|fluoride as sodium fluoride
141043|NCT01641237|Drug|no added fluoride in a silica base|no added fluoride
141044|NCT00085709|Drug|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
141045|NCT01641250|Drug|RO5429083|Multiple escalating doses
141046|NCT01641250|Drug|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
141047|NCT01641263|Behavioral|Sleep Education|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
141856|NCT01673217|Other|enzyme-linked immunosorbent assay|Correlative studies
141857|NCT00088777|Behavioral|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
141858|NCT01673230|Procedure|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
141859|NCT01673243|Other|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
141860|NCT01673256|Device|SJM Confirm ICM|
141861|NCT01673269|Other|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
141862|NCT01673295|Drug|RTX infusions|RTX + Standard of Care
140949|NCT01638663|Drug|Placebo|1 tablet Unikalk 1 pr day for 1 day
140950|NCT01638676|Drug|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
140951|NCT01638676|Drug|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
140952|NCT01638689|Drug|Escitalopram|20 mg p.o.
140953|NCT01638702|Other|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
140954|NCT01641133|Biological|Prevenar 13 ™ (2-Dose)|2 doses administered intramuscularly
140955|NCT01641146|Behavioral|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
141108|NCT01638949|Biological|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
141109|NCT00085462|Drug|fludarabine phosphate|
141110|NCT01638949|Genetic|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
141371|NCT01641692|Procedure|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
141372|NCT01641692|Drug|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
141373|NCT01643837|Other|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
141374|NCT00085969|Drug|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
141375|NCT01643850|Drug|MCS110|Patients will receive up to 4 doses of MCS110 (10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
141376|NCT01643850|Drug|Placebo|Participants will receive a single dose of NaCl on day 1
141377|NCT01643876|Behavioral|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
141378|NCT01643889|Drug|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
141379|NCT01643889|Drug|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
141380|NCT01643889|Drug|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
141381|NCT01643889|Drug|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
141382|NCT01643902|Drug|rt-PA|IV rt-PA 0.9 mg/kg minimum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target foor to needle time of 60 minutes or less from ED arrival.
141383|NCT01643915|Behavioral|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
140886|NCT01641133|Biological|Synflorix™ (Single Dose)|1 dose administered intramuscularly
140887|NCT01641133|Biological|Prevenar 13 ™ (Single Dose)|1 dose administered intramuscularly
140888|NCT01642966|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
140889|NCT01642979|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
140890|NCT01642979|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
140891|NCT00085917|Drug|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
140892|NCT01642979|Drug|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
141162|NCT01646125|Drug|Pemetrexed|Pemetrexed will be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
141163|NCT01646138|Biological|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
141164|NCT01646151|Drug|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
141165|NCT00086203|Drug|Rituximab|
141166|NCT01646177|Drug|Placebo|Administered SC
141167|NCT01646177|Drug|50 mg etanercept|Administered SC
141168|NCT01646177|Drug|80 mg ixekizumab|Administered SC
141169|NCT01646190|Dietary Supplement|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
141170|NCT01646190|Procedure|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
141171|NCT01646190|Behavioral|Fasting state after midnight|No preoperative glucose load
141172|NCT01646190|Behavioral|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
141173|NCT01646190|Behavioral|urinary catheter removal|at POD 1
141174|NCT01646190|Behavioral|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
141175|NCT01646190|Behavioral|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
141048|NCT01641263|Behavioral|Cognitve Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
141049|NCT01641276|Device|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
141050|NCT01643239|Other|Hospital-based mCIT|the mCIT group with individualized intervention
141051|NCT01643239|Other|Hospital-based TR|OT or PT or therapist-based training
141052|NCT01643252|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
141321|NCT01646359|Device|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
141322|NCT01646372|Other|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
141323|NCT01646372|Other|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
141324|NCT00086242|Other|counseling intervention|
141325|NCT01646385|Drug|etanercept|use as per routine clinical practice
141326|NCT01646385|Drug|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
141327|NCT01646398|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
141328|NCT01646398|Biological|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
141329|NCT01646437|Drug|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
141330|NCT01646437|Drug|enteric coated aspirin|75 mg daily
141331|NCT01646437|Drug|cholecalciferol|60,000 IU monthly
141332|NCT01646437|Drug|Placebo|Matching Placebo
141333|NCT01646450|Drug|Icotinib|Icotinib: 125mg, oral administration, three times per day.
140956|NCT01641146|Behavioral|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
140957|NCT01641159|Drug|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
140958|NCT01641159|Drug|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
140959|NCT01641172|Procedure|Dexa scan|the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year.
140960|NCT01641172|Procedure|audiogram|the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year.
140961|NCT01641172|Procedure|measurement of heart rate variability and baroreflex sensitivity|the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year.
140962|NCT00085709|Other|observation|No treatment given
141237|NCT00085956|Drug|Arzoxifene|
141238|NCT01643655|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
141239|NCT01643668|Drug|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
141240|NCT01643668|Drug|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
141241|NCT01643668|Procedure|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
141242|NCT01646203|Biological|IMC-TR1|Administered intravenously
141243|NCT01646216|Behavioral|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
141384|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
141385|NCT00085969|Drug|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
141386|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
141700|NCT01675726|Other|questionary on quality of life|
141701|NCT01675739|Behavioral|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
141702|NCT01678430|Drug|Bendamustine|
141703|NCT01678443|Biological|indium In 111 anti-CD45 monoclonal antibody BC8|Given IV
141704|NCT01678443|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
141705|NCT01678443|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
141706|NCT01678469|Other|blood sample|
141707|NCT01678482|Device|light based device for treatment of acne|
141708|NCT01678495|Other|Sulfur hexafluoride + ultrasounds|
141709|NCT00089024|Drug|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 & 2; Repeat one 3-week cycle starting day 22
141710|NCT01678495|Drug|Recombinant tissue plasminogen activator|
141711|NCT01678521|Procedure|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
141712|NCT01678534|Drug|Allogenic mesenchymal stem cells from adipose tissue|
141713|NCT01678534|Drug|Placebo|
141714|NCT01678547|Device|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
141715|NCT01678547|Device|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
141176|NCT00086216|Drug|Atiprimod|Oral, once a day, 14 days on 14 days off
141177|NCT01646190|Behavioral|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), >4h out of bed on POD1, >6h on POD2, complete at POD3
141178|NCT01646190|Other|Preanesthetic medication|Preanesthetic oral medication before surgery
141179|NCT01639001|Drug|Crizotinib|250 mg two times daily [BID], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
141180|NCT01639001|Drug|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
141181|NCT01639001|Drug|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
141450|NCT01670084|Drug|cyclophosphamide|Given IV
141451|NCT01670084|Drug|doxorubicin hydrochloride|Given IV
141452|NCT01670084|Drug|vincristine sulfate|Given IV
141453|NCT00088452|Drug|ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
141454|NCT01670084|Drug|methotrexate|Given IV or IT
141455|NCT01670084|Drug|cytarabine|Given IV or IT
141456|NCT01670084|Drug|prednisone|Given PO
141457|NCT01670084|Drug|mesna|Given IV
141458|NCT01670084|Drug|dexamethasone|Given IV or PO
141459|NCT01670084|Drug|leucovorin calcium|Given IV
141460|NCT01670097|Drug|Dexamethasone|Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.
Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days.
141461|NCT01670097|Drug|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
141462|NCT01670097|Behavioral|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
141334|NCT01646463|Behavioral|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
141335|NCT00086242|Procedure|psychosocial assessment and care|
141336|NCT01639339|Drug|Standard therapy|The standard therapies allowed in this study are:
- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy
OR
- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy
141337|NCT01639352|Biological|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
141636|NCT01670331|Behavioral|Psychological preparation|Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.
Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.
Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur.
141637|NCT01670344|Procedure|Treatment with investigational method (virtual implant positioning system)|
141638|NCT01670344|Procedure|Treatment with surgical standard of care|
141639|NCT00088478|Drug|Intramuscular Olanzapine Depot|
141640|NCT01670357|Drug|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
141641|NCT01670357|Drug|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
141642|NCT01670357|Drug|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
141643|NCT01670370|Drug|R-GemOx|Rituximab Gemcitabine Oxaliplatin
141644|NCT01670370|Drug|GemOx|Gemcitabine oxaliplatin
141645|NCT01670409|Radiation|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
141646|NCT01670409|Drug|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
141244|NCT01646229|Other|Polymyxin-B hemoperfusion|
141245|NCT01646229|Other|Control|
141246|NCT01646242|Procedure|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
141247|NCT01646242|Procedure|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
141248|NCT01646255|Drug|Rotigotine|Transdermal Patch
Content:
4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)
For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period
141249|NCT01646255|Drug|Placebo Patch|Transdermal Patch
Size:
20 cm^2, 30 cm^2, 40 cm^2
Subjects randomized to placebo received matching placebo patches
141250|NCT00086229|Drug|Glucosamine|
141251|NCT01646255|Drug|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release [in combination with benserazide or carbidopa]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
141252|NCT01646268|Drug|Rotigotine|Transdermal Patch
Content:
2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)
For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period
141253|NCT01646268|Drug|Placebo Patch|Transdermal Patch
Size:
10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2
Subjects randomized to placebo will receive matching placebo patches
141254|NCT01646281|Drug|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
141531|NCT01678144|Device|Mitral valve repair using Medentia Annuloplasty Ring|
141532|NCT01678183|Behavioral|Monthly Financial Incentive|A cash payment.
141533|NCT00089011|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
141534|NCT01670123|Behavioral|Personalized Real-Time Intervention for Stabilizing Mood|Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
141535|NCT01670136|Drug|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
141536|NCT01670149|Drug|Rifaximin|Tablets
141537|NCT01670149|Drug|Placebo|Tablets
141716|NCT01678547|Other|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
141717|NCT01678560|Device|Monitoring every 3 months by face-to-face visits|
141718|NCT01678560|Device|Frequent remote monitoring|
141719|NCT01678573|Drug|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
141720|NCT00089024|Drug|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
141721|NCT01678573|Drug|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
140812|NCT01642953|Dietary Supplement|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
140813|NCT01642966|Drug|Prasugrel|Prasugrel 10mg/day for 15 days
140814|NCT01645228|Radiation|coronary calcium score measurement|
140815|NCT01645228|Biological|high sensitivity C reactive protein measurement|
140816|NCT01645228|Procedure|ankle brachial index measurement|
140817|NCT01645241|Drug|gonadotropins plus GnRH antagonists|
140818|NCT01645241|Drug|ganirelix|
140819|NCT01645254|Drug|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
140820|NCT00086138|Drug|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
140821|NCT01645267|Procedure|Hydroxyapatite|Use of artifical bonegraft material
140822|NCT01645280|Drug|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
140823|NCT01645280|Drug|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
140824|NCT01645280|Drug|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
141463|NCT01670097|Device|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
141464|NCT00088452|Drug|lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
141465|NCT01670097|Other|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
141466|NCT01670110|Drug|Pasireotide LAR|Injectible, 60mg per month
141467|NCT01670110|Drug|Placebo|To be injected once per month
141468|NCT01672580|Behavioral|exposure to vitamin use|"Seed" individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village
141469|NCT01672580|Behavioral|exposure to water chlorination|"Seed" individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village
141470|NCT01672580|Behavioral|high in-degree|"Seed" individuals for starting intervention are chosen on the basis of high (social network) in-degree
141471|NCT01672580|Behavioral|nominated by random|"Seed" individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual
141781|NCT01675804|Other|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
141782|NCT01675804|Drug|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
141783|NCT01675804|Other|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
141784|NCT01675830|Device|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
141785|NCT00088907|Drug|docetaxel|Given IV
141786|NCT01675843|Procedure|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
141787|NCT01675856|Other|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
141788|NCT01675856|Other|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
141789|NCT01675869|Behavioral|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
141647|NCT01670435|Drug|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
141648|NCT01670448|Procedure|PECBLOCK under echoguidance|Performance of block under echography
141649|NCT01670461|Behavioral|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
141650|NCT00088478|Drug|Placebo|
141651|NCT00088738|Drug|[18F] SPA-RQ|
141652|NCT01672853|Biological|Simtuzumab|
141653|NCT01672853|Biological|Placebo|
141654|NCT01672866|Biological|Simtuzumab|Simtuzumab administered by subcutaneous injection weekly
141655|NCT01672866|Biological|Placebo|Placebo to match simtuzumab administered by subcutaneous injection weekly
140753|NCT01647945|Drug|FK506 level 2-3 ng/ml|FK506 goal trough blood level 2-3 ng/ml
140754|NCT01647945|Drug|FK506 level 3-5 ng/ml|FK506 goal trough blood level 3-5 ng/ml
140755|NCT01647958|Device|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication
140756|NCT01647971|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
140757|NCT01647984|Dietary Supplement|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
140758|NCT01647984|Dietary Supplement|placebo|
140759|NCT01647997|Other|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
140760|NCT01648010|Device|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
140761|NCT01648010|Device|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
140762|NCT01648023|Device|LC Bead with Gem-Cis|
140763|NCT00086333|Drug|SGN-15, Docetaxel|
141538|NCT01670162|Drug|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
141539|NCT01670175|Drug|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
141540|NCT01670188|Device|Pneumatic SCD - VenaFlow System (DJO Global)|
141541|NCT00088452|Drug|valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
141542|NCT01670201|Device|Mepilex Transfer Ag|Silver dressing
141543|NCT01670214|Procedure|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
141544|NCT01670227|Behavioral|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
141545|NCT01670240|Drug|Adalimumab|
141546|NCT01670240|Drug|Placebo|
141547|NCT01670253|Behavioral|Group 1|6 hour fast from all solid foods and milk beverages
2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)
Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like.
141548|NCT01670266|Drug|ONO-9054|
141549|NCT01670266|Drug|Placebo|
141550|NCT01670279|Drug|Brexpiprazole|up to 3mg oral dose once daily
141863|NCT01673295|Other|Standard of Care|Standard of Care only
141864|NCT01673308|Drug|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
141865|NCT01673321|Other|Dietary intervention|All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
141866|NCT01673334|Device|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
141867|NCT01675882|Biological|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
140825|NCT01645280|Drug|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
140826|NCT01645280|Drug|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
140827|NCT01645293|Genetic|Genetically modified T cells # 1138|
140828|NCT01645306|Drug|Revacept|single intravenous injection
140829|NCT01645306|Drug|Placebo|single intravenous injection
140830|NCT01645332|Drug|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
140831|NCT00086164|Drug|edifoligide (E2F Decoy)|
140832|NCT01645332|Drug|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
141111|NCT01638949|Other|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
141112|NCT01638962|Drug|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
141113|NCT01638962|Other|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
141114|NCT01638975|Behavioral|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
141115|NCT01638988|Drug|Metformin|cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day
to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy
141116|NCT01638988|Drug|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
141117|NCT01641289|Drug|Paracetamol|>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate <50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
141118|NCT01641289|Drug|No Paracetamol|No paracetamol + Intravenous Artesunate
If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.
141119|NCT01641315|Biological|rabies vaccine|Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.
Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.
Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0.
141790|NCT01675869|Behavioral|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
141791|NCT01675882|Biological|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
141792|NCT01675882|Biological|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
141793|NCT01675882|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
141794|NCT01678599|Drug|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients > 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
141795|NCT01678612|Other|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
141796|NCT01678625|Device|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
141797|NCT01678638|Procedure|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
141798|NCT01678638|Procedure|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed between 55-60 weeks post-menstrual age.
140893|NCT01643005|Behavioral|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
140894|NCT01643005|Behavioral|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
140895|NCT01643018|Procedure|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
140896|NCT01643018|Procedure|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
140897|NCT01643031|Drug|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
140898|NCT01643031|Drug|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
140764|NCT01648023|Drug|Gemcitabine and Cisplatin|
140765|NCT01648036|Drug|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
140766|NCT01648036|Drug|Dalteparin|Dose 5000 IU, subcutaneous, daily
140767|NCT01648049|Behavioral|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein & Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, & Dick, 1995).
140768|NCT01648049|Behavioral|Treatment as usual|Standard Care - Treatment as usual
140769|NCT01648062|Behavioral|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
140770|NCT01640821|Behavioral|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
140771|NCT00085631|Radiation|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
140772|NCT01640834|Drug|LY2409021|Administered orally
141053|NCT01643252|Drug|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
141054|NCT01643265|Dietary Supplement|Whey Milk Protein|20 grams of Whey Milk Protein
141055|NCT01643265|Dietary Supplement|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
141056|NCT01643278|Drug|Dasatinib|Given PO
141057|NCT01643278|Biological|Ipilimumab|Given IV
141058|NCT01643278|Other|Laboratory Biomarker Analysis|Correlative studies
141059|NCT00085943|Drug|KALETRA|
141060|NCT01643278|Other|Pharmacological Study|Correlative studies
141061|NCT01643291|Procedure|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
141062|NCT01643304|Behavioral|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
141868|NCT01675895|Drug|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
141869|NCT00088907|Other|placebo|Given orally
141870|NCT01675895|Drug|levobupivacaine Spinal anesthesia|spinal anesthesia
141871|NCT01675908|Procedure|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
141872|NCT01675908|Procedure|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
141873|NCT01675921|Other|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
141874|NCT01675934|Procedure|Retroflexion with the adult colonoscope.|
141875|NCT01675934|Procedure|Retroflexion with the pediatric colonoscope.|
141876|NCT01675947|Drug|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
141877|NCT01675947|Drug|Lidocaine|Lidocaine 2%
141878|NCT01675960|Drug|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
141879|NCT01675960|Drug|placebo|
141880|NCT00001677|Drug|Methotrexate|
141881|NCT00088907|Drug|gefitinib|Given orally
141882|NCT01675973|Drug|RANEXA|500mg BID up to 1000mg BID
141883|NCT01675986|Drug|hydroxyzine|75 mg
141884|NCT01675986|Drug|Pregabalin|150 mg
144958|NCT01742494|Procedure|Water-jet POEM|Water-jet assisted POEM procedure was performed
144959|NCT00094978|Drug|Flavopiridol (alvocidib)|
144960|NCT01742494|Procedure|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
141120|NCT01641328|Behavioral|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
141121|NCT01641328|Behavioral|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
141122|NCT00085722|Procedure|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
141123|NCT01641341|Drug|Bifidobacterium infantis|once a day for seven to eight weeks
141124|NCT01641341|Drug|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
141125|NCT01641341|Drug|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
141126|NCT01641341|Drug|Placebo|Placebo capsule will not contain active treatment ingredients.
141127|NCT01641354|Procedure|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
141387|NCT01643928|Biological|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion [IV] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
141388|NCT01643928|Biological|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
141389|NCT01643928|Biological|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
141390|NCT01643941|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
141391|NCT01674959|Radiation|concurrent chemoradiation|postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks).
141392|NCT01674972|Other|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
141393|NCT01674985|Biological|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
141394|NCT01675011|Device|Embozene® Microspheres|
141395|NCT01675011|Device|Embosphere®|
140899|NCT01643044|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
140900|NCT01643044|Behavioral|Computer-delivered, brief intervention on alcohol use|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
140901|NCT01643057|Device|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
140902|NCT00085930|Biological|14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) w/o lymphodepletion|CTLs: 2x10e7 cells/m2
140903|NCT01643070|Drug|Capecitabine, Oxaliplatin|Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.
140904|NCT01643070|Radiation|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
140905|NCT01643083|Drug|Rifaximin|Rifaximin 400mg tid for 2 wk
140906|NCT01643083|Drug|Placebo|Placebo for 2 week
140907|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
140908|NCT01645436|Other|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
141182|NCT00001586|Biological|Rituximab|Rituxan
141183|NCT00085475|Drug|imatinib mesylate|
141184|NCT01639014|Drug|F2695|75 mg OD in 2 capsules
141185|NCT01639014|Drug|placebo|2 capsules
141186|NCT01639027|Drug|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
141187|NCT01639027|Drug|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
141188|NCT01639040|Drug|REGN668 (SAR231893)|A total of 4 doses will be administered
141189|NCT01639040|Other|Placebo|A total of 4 doses will be administered
141190|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
141063|NCT01643330|Genetic|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10^13 DNase Resistant Particles (DRP) MYDICAR
141064|NCT01643330|Genetic|Placebo|Single intracoronary infusion
141065|NCT01643356|Behavioral|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
141066|NCT01643369|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
141067|NCT01643369|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
141068|NCT01643369|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
141069|NCT01643382|Drug|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
141070|NCT00085943|Drug|EPIVIR|
141071|NCT01643382|Drug|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
141072|NCT01643395|Other|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
141073|NCT01643395|Other|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
141338|NCT00085501|Drug|cetuximab|Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.
Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14.
141339|NCT01639378|Procedure|Renal Denervation|Symplicity Catheter System
141340|NCT01639391|Procedure|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
141341|NCT01639404|Procedure|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
141342|NCT01639404|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
141343|NCT01639430|Other|rectal, tympanal and temporal artery thermometry|Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.
Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well.
144961|NCT01742507|Device|Resolute Integrity Stent|Resolute Integrity Stent
144962|NCT01742507|Device|Biomatrix stent|Biomatrix stent
144963|NCT01742520|Drug|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
144964|NCT01742520|Drug|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
144965|NCT01742533|Biological|human umbilical cord mesenchymal stem cells|
144966|NCT01742533|Biological|hUCMSCs and hCBMNCs|
144967|NCT01742533|Biological|human cord blood mononuclear cells|
144968|NCT01742533|Drug|Hormone Replacement Therapy|
144969|NCT01742546|Device|Therapeutic ultrasound combine TENS|Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.
The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius).
144970|NCT00094991|Drug|Muraglitazar|
144971|NCT01742559|Procedure|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman & Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
144972|NCT01742559|Procedure|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
144973|NCT01742572|Behavioral|Diet|Change in dietary intake
144974|NCT01742585|Drug|ASP1585|oral
144975|NCT01742585|Drug|placebo|oral
145255|NCT00095043|Drug|MK0928, gaboxadol|
145256|NCT01742936|Other|Hospital Laboratory|
145257|NCT01742949|Device|Heated humidification (ThermoSmart)|
141396|NCT01675024|Drug|Rotigotine, Period 1|Formulation: transdermal
Dosage: 2 mg / 24 hours once at Day 2
Frequency: once every 24 hours
Duration: from Day 1 to Day 3
141397|NCT01675024|Drug|Rotigotine, Period 2|Formulation: transdermal
Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12
Frequency: once every 24 hours
Duration: from Day 1 to Day 3
141398|NCT01675037|Other|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
141399|NCT00088881|Drug|vincristine|Given IV
141400|NCT01675050|Drug|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
141401|NCT01675050|Drug|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
141402|NCT01675063|Device|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
141403|NCT01675076|Drug|Dabigatran|NOAC
141404|NCT01675076|Drug|Rivaroxaban|NOAC
141405|NCT01675076|Drug|Apixaban|NOAC
141722|NCT01678573|Drug|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
141723|NCT01678586|Other|Acupuncture or Sham Acupuncture|Acupuncture is when the needles go into the skin. Sham acupuncture is when the needles do not go into the skin. We will compare results between the two acupuncture therapy groups.
141724|NCT01678586|Other|Gabapentin or Placebo|Gabapentin is a commonly prescribed drug used to treat neuropathic pain. The placebo will be used to mimic side effects common to gabapentin. The two medication treatment groups' results will be compared to each other.
141725|NCT01670461|Behavioral|Standard of Care (SOC) Control|Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy: " … regarding advance directives … to honor each non-minor patient's wishes … to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions." Upon admission if they do not have an advance directive, they should be given the "Advance Directive Information Booklet" and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record.
141726|NCT01670474|Drug|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
141191|NCT01639066|Drug|Entecavir|Entecavir 1 mg daily Oral
141192|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
141193|NCT01639079|Behavioral|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
141194|NCT00085475|Procedure|conventional surgery|
141195|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
141196|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
141197|NCT01639092|Drug|Entecavir|Entecavir 1 mg daily Oral
141198|NCT01639105|Procedure|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
141199|NCT01639131|Drug|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
141200|NCT01639131|Drug|Docetaxel|docetaxel 70mg/m2 on day 8 of each 21 day cycle
141201|NCT01639131|Drug|Filgrastim or Pegfilgrastim|filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle
141202|NCT01639144|Biological|PRP and PPP|Autogenous PRP and PPP
141203|NCT01639157|Drug|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
141204|NCT01641367|Other|SOC adherence versus SOC+CPI adherence|not participating in the adherence randomization; OR
randomized to SOC adherence; OR
randomized to SOC+CPI adherence.
141472|NCT01672593|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
141473|NCT01672593|Drug|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
141474|NCT01672593|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
141475|NCT01672593|Procedure|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
141476|NCT01672606|Drug|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
141344|NCT01639443|Other|Predictive no-show overbooking|During intervention period, every Veteran scheduled for an upper endoscopy will be offered "fast-track" offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot.
141345|NCT01639456|Biological|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
141346|NCT01639456|Biological|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
141347|NCT01639456|Device|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
141348|NCT01639456|Device|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
141349|NCT00085501|Drug|carboplatin|Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2
Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1
141350|NCT01639456|Drug|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
141351|NCT01639456|Drug|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
141352|NCT01639456|Drug|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
141656|NCT01672879|Biological|Simtuzumab|Simtuzumab administered by intravenous infusion over 30 minutes every 2 weeks
141657|NCT01672879|Biological|Placebo|Placebo to match simtuzumab administered by intravenous infusion over 30 minutes every 2 weeks
141658|NCT01672892|Radiation|3-dimensional conformal radiation therapy|Undergo radiation therapy
141659|NCT01672892|Radiation|intensity-modulated radiation therapy|Undergo radiation therapy
141660|NCT01672905|Other|laboratory biomarker analysis|
141661|NCT01672931|Other|Oocyte Measurement|
141662|NCT00001666|Device|Cadwell High-Speed Magnetoelectric Stimulator|
141663|NCT00088764|Behavioral|Coping skills training|8 sessions of pain and stress coping skills training
145258|NCT01742962|Procedure|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
145259|NCT01742975|Device|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
145260|NCT01742988|Drug|CUDC-907|CUDC-907 administered orally with meals.
145261|NCT01743001|Drug|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
145262|NCT01743001|Drug|Placebo|Macitentan-matching placebo oral tablet once daily
145263|NCT01743014|Drug|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
145264|NCT01743014|Drug|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
145265|NCT01743027|Drug|AL-4943A ophthalmic solution|
145266|NCT00095043|Drug|Comparator: placebo|
145267|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
145268|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.1%|
145269|NCT01743027|Drug|AL-4943A ophthalmic solution vehicle|
145270|NCT01743053|Device|Standard Care plus ReCell|
145271|NCT01743053|Other|Standard Care|
145272|NCT01743066|Dietary Supplement|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
145273|NCT01743079|Drug|Telbivudine|LdT 600mg QD
145274|NCT01743079|Drug|Lamivudine|LAM 100mg QD
145275|NCT01743092|Behavioral|Webinar|Some clients will receive a webinar as part of their treatment.
145276|NCT01743092|Behavioral|Tutuorial workbook|A work book about their addiciton
145277|NCT00095056|Drug|sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
145278|NCT01743105|Procedure|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
141727|NCT01670474|Drug|rt-PA|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
141728|NCT01670487|Device|Vapocoolant|Topical stream of 4 to 10 seconds duration to skin
141729|NCT01670487|Device|Sterile water|Topical intervention of sterile water stream 4 to 10 seconds to skin.
141730|NCT01670500|Drug|Cisplatin|administered intravenously every 3 weeks for 4 doses
141731|NCT01670500|Drug|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
141732|NCT01670500|Drug|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
141733|NCT01670513|Drug|IDP-118 Low Strength|8 weeks
141734|NCT01670513|Drug|IDP-118 High Strength|8 weeks
141735|NCT00088491|Drug|Intramuscular Olanzapine Depot|
141736|NCT01670526|Drug|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
141737|NCT01670539|Device|HomMed Telemonitor|A "HomMed Telemonitor" wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses.
140833|NCT01645332|Other|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
140834|NCT01645345|Device|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
140835|NCT01645358|Device|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
140836|NCT01645358|Device|Total Face mask (Respironics)|The total face mask is the "classical" interface for NIV delivery
140837|NCT01645384|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
140838|NCT01645410|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
140839|NCT01645423|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
141477|NCT01672619|Procedure|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
141478|NCT00088686|Drug|Capsaicin (Intramucosal Injection)|
141479|NCT01672632|Other|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
141480|NCT01672645|Biological|NIC7-001|Intramuscular, multiple dose
141481|NCT01672645|Biological|NIC7-003|Intramuscular, multiple dose
141482|NCT01672645|Biological|Saline|Saline (0.9% sodium chloride)
141483|NCT01672658|Device|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
141484|NCT01672658|Other|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
141485|NCT01672671|Drug|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
141486|NCT01672684|Procedure|support group therapy|Complete at-home group video calling support sessions
141487|NCT01672684|Other|educational intervention|Receive an educational workbook journal
141488|NCT01675167|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
141489|NCT01675167|Drug|Placebo|Matching Placebo Buccal Film twice daily
141490|NCT01675180|Other|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
141491|NCT01675180|Other|Control|No intervention
141799|NCT01678651|Procedure|Stimulation with human FSH|Human FSH
141800|NCT00001683|Drug|COL-3|
141801|NCT00089024|Drug|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
141802|NCT01678651|Procedure|Stimulation with recombinant FSH|Recombinant FSH
141803|NCT01678664|Drug|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
141804|NCT01678664|Device|embolization|2 sessions embolization with spheric particles
141664|NCT01672944|Other|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
141665|NCT01672944|Other|NCI-developed educational materials|Participants will be asked to view the English biobanking educational Brochure entitled "Providing your Tissue for Research: What you need to Know", or Spanish brochure entitled "Lo que usted debe saber antes de dar sus tejidos para investigación médica."
141666|NCT01672983|Drug|ABT-450/ritonavir, ABT-267|ABT-450 (tablet) dosed with ritonavir (capsule), and ABT-267 (tablet)
141667|NCT01672996|Drug|Ioforminol 160 mgI/mL|Given as s single administration to the subject
141668|NCT01672996|Drug|Ioforminol 200 mgI/mL|Given as a single administration to the subject
141669|NCT01672996|Drug|Iopamidol 300 mgI/mL|Given as a single administration to the subject
141670|NCT01673009|Drug|Gleevec|Gleevec® will be dosed orally 440 mg/m2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
141671|NCT01673022|Drug|IC Green|IC Green
141672|NCT01673035|Behavioral|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
141673|NCT01673035|Behavioral|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
141674|NCT00088764|Behavioral|Written emotional disclosure|4 sessions of writing about stress
141675|NCT01673048|Procedure|3-Nail-ESIN in femoral shaft fractures|
141676|NCT01673061|Drug|Lidocaine|See associated Arm Description
141677|NCT01673061|Drug|Vapocoolant|See associated Arm Description
140773|NCT01640834|Drug|Placebo|Administered orally
140774|NCT01640847|Drug|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
140775|NCT01640873|Drug|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (quaque die, q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
140776|NCT01640873|Drug|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
140777|NCT01640899|Device|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
145617|NCT01741142|Drug|Escitalopram|Subjects receiving escitalopram
145618|NCT01741142|Drug|Placebo|Subject receiving placebo
145619|NCT01743651|Drug|Placebo|arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
145620|NCT01743664|Behavioral|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
145621|NCT01743664|Behavioral|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
145622|NCT00001839|Drug|Antithymocyte globulin|
145623|NCT00095082|Drug|insulin detemir|
145624|NCT01743677|Drug|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
145625|NCT01743677|Drug|Placebo|Single dose placebo tablets (5 tablets)
145626|NCT01743677|Drug|Moxifloxacin|Single dose Avelox 400 mg tablet
145627|NCT01743690|Biological|Probiotic lactobacilli reuteri|
145628|NCT01743690|Drug|Nystatin|
145629|NCT01743690|Drug|fluocinolone|
145630|NCT01743703|Other|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
145631|NCT01743729|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5.0%
145632|NCT01743729|Drug|Placebo|Placebo for Lifitegrast Ophthalmic Solution 5.0%
145633|NCT01743742|Drug|Vitamin E, Vitamin C|
145634|NCT00095082|Drug|insulin glargine|
145635|NCT01743755|Drug|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
145636|NCT01743755|Drug|Placebo|Placebo tablet, once daily for four consecutive days
145637|NCT01743768|Drug|SB010|Treatment group (n=19), receiving the active drug substance.
145638|NCT01743768|Drug|Placebo|Treatment group (n=19), receiving placebo.
145639|NCT01743781|Behavioral|video|view a 10-minute informational video about comprehensive eye examination
140840|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
140841|NCT01648179|Drug|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
140842|NCT01648192|Drug|Losmapimod for single dose|Film coated white tablet
140843|NCT01648192|Drug|Losmapimod for repeat dose|Film coated white tablet
140844|NCT01648205|Drug|Placebo|Matching Placebo will be given
140845|NCT01648205|Drug|Ranolazine|Patients will receive ranolazine 1000mg bid or matching placebo
140846|NCT01648218|Drug|Neutral protamine hagedorn (NPH) insulin|
140847|NCT01648218|Drug|Regular human insulin or Insulin Aspart|
140848|NCT00086359|Drug|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
140849|NCT01648218|Drug|Insulin glargine|
140850|NCT01648231|Drug|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
140851|NCT01648231|Drug|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
140852|NCT01648231|Drug|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
141128|NCT01641367|Drug|Darunavir|Participants will be administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (must be taken with Ritonavir 100 mg twice a day [200 mg per day])
141129|NCT01641367|Drug|Etravirine|Patients will be administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
141130|NCT01641367|Drug|Emtricitabine/tenofovir disoproxil fumarate|Patients will be administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
141131|NCT01641367|Drug|Raltegravir|Participants will be administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
141132|NCT01641367|Drug|Second line ART regimens are usually based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r are the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC are the most frequent NRTI backbones. Cohort A will not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
141133|NCT00001587|Procedure|Isolated hepatic portal and arterial perfusion|
141805|NCT01678664|Drug|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
141806|NCT01678677|Biological|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141807|NCT01678677|Biological|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141808|NCT01678677|Biological|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141809|NCT01678677|Biological|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141810|NCT01678677|Biological|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141811|NCT01678677|Biological|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141812|NCT00089024|Procedure|adjuvant therapy|Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.
If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy.
141813|NCT01678677|Biological|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141814|NCT01678677|Biological|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
141815|NCT01670604|Drug|Tetraspan, B. Braun, Melsungen, Germany|
141816|NCT00088491|Drug|Oral Olanzapine|
141817|NCT01670617|Other|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
141818|NCT01670630|Procedure|Sheathed speculum examination|
141819|NCT01670630|Procedure|Standard speculum examination|
140909|NCT01645449|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
140910|NCT00086177|Drug|8% progesterone vaginal gel|Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
140911|NCT01645475|Drug|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
140778|NCT01640912|Drug|RXI-109|Single intradermal injection of RXI-109 at incision sites
140779|NCT01640912|Drug|Placebo|Single intradermal injection of placebo at incision sites
140780|NCT01640925|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
140781|NCT01640925|Other|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
140782|NCT00085644|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
140783|NCT01640951|Drug|AIN457|
140784|NCT01640964|Drug|Terlipressin acetate|IV bolus injection
140785|NCT01640964|Drug|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
140786|NCT01640977|Procedure|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
140787|NCT01640977|Procedure|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
140788|NCT01640990|Drug|Saline|30mins run-in period
140789|NCT01640990|Drug|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
140790|NCT01640990|Drug|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
140791|NCT01641016|Drug|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
140792|NCT01641029|Other|No intervention|There is no intervention
140793|NCT01642836|Behavioral|MMM|a theory-based community team sports program designed specifically for overweight and obese children,
a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and
a primary care provider behavioral counseling intervention linked to the community and home interventions.
141074|NCT01643408|Drug|asparaginase Erwinia chrysanthemi|
141075|NCT01645904|Behavioral|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
141076|NCT01645904|Behavioral|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
145640|NCT01743794|Drug|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
145641|NCT01743794|Drug|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
144652|NCT01749384|Biological|Bevacizumab|Given IV
144653|NCT01749384|Other|Laboratory Biomarker Analysis|Correlative studies
144654|NCT01749384|Other|Pharmacological Study|Correlative studies
144655|NCT01749384|Drug|Tivantinib|Given PO
144656|NCT01749397|Drug|Floxuridine|Given IP
144657|NCT01749397|Other|Laboratory Biomarker Analysis|Correlative studies
144658|NCT01749397|Other|Pharmacological Study|Correlative studies
144659|NCT01749397|Drug|Veliparib|Given IV
144660|NCT00095628|Other|pharmacological study|Correlative studies
144661|NCT01749410|Biological|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
144662|NCT01749423|Biological|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
144663|NCT01749436|Other|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
144664|NCT01749449|Other|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
144665|NCT01749475|Drug|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
144666|NCT01749475|Other|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
144667|NCT01749488|Other|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
144668|NCT01749501|Drug|Rocuronium|0.6 mg/Kg once
144669|NCT01749501|Other|Placebo|Normal saline same amt as 0.6mg/kg of study drug
141134|NCT00085722|Procedure|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
141135|NCT01641367|Drug|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a patient will indeed receive the same regimen that patients are getting in Cohorts B and C if that is the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there will be no further drug options beyond the available study drugs).
141136|NCT01643421|Other|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
141137|NCT01643434|Drug|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
141138|NCT01643434|Drug|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
141139|NCT01643447|Drug|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
141140|NCT01643447|Drug|Diammonium glycyrrhizinate|
141141|NCT01643460|Procedure|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size & amount of fluid aspirated from the cyst.
141142|NCT00085943|Drug|Ziagen|
141143|NCT01643473|Behavioral|Adherence Intervention|Patients randomized to the AI group will participate in 9 sessions with bilingual Health Coaches who will utilize a culturally tailored adherence checklist to identify patient's specific medication adherence barriers. Based on the patient's responses, the Health Coach will then engage in targeted patient-centered counseling to assist patients in developing individualized self-monitoring strategies to overcome these barriers and improve adherence behaviors.
141144|NCT01643486|Other|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
141406|NCT01675089|Drug|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
141407|NCT01675115|Drug|BNG-1|BNG-1 3 grams TID for 4 weeks
141408|NCT01675115|Drug|Aspirin|Aspirin 100 mg QD for 4 weeks
141409|NCT01675128|Drug|ISIS 183750|
141410|NCT00088881|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
141411|NCT01675128|Drug|Irinotecan|
141412|NCT01675141|Drug|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
140912|NCT01645566|Behavioral|instruction|instructions about focusing on relevant task elements by posing two task-focusing questions ("what is the patient's condition?", "what immediate action is needed?") when feeling overwhelmed by stress (intervention-group)
140913|NCT01645696|Device|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
140914|NCT01645696|Device|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
140915|NCT01645696|Device|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
140916|NCT01645709|Drug|Verapamil|
140917|NCT01645709|Drug|Placebo|
140918|NCT01645722|Procedure|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
140919|NCT01645735|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
140920|NCT01645735|Drug|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
140921|NCT00086177|Drug|Placebo Vaginal Gel|Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
140922|NCT01645748|Drug|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
140923|NCT01645748|Drug|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
140924|NCT01645748|Drug|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
141205|NCT01641380|Behavioral|Text Messaging Intervention|Online enrollment in the Compliance for Life® (CFL) system through iReminder)
Welcome Message 24 hrs after enrollment
Appointment Reminder prior to 3 month injection cycles
Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder
6.Call for missed appointment or no reply to appointment reminder (or other text message)
141077|NCT01645904|Behavioral|Audiotaped Interview|Group 2: Patients provide feedback regarding initial version of My Family Garden website.
Group 3: Patients provide feedback regarding final version of My Family Garden website.
141078|NCT01645904|Behavioral|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
141079|NCT01645917|Device|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
141080|NCT01645930|Drug|IXAZOMIB|Patients will receive Oral IXAZOMIB (4.0 mg) on Days 1, 8, and 15; lenalidomide (25 mg) on Days 1 through 21; and dexamethasone (40mg) on Days 1, 8, 15, and 22.
141081|NCT01645943|Procedure|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
141082|NCT00086190|Other|placebo|an inactive substance
141083|NCT01645995|Dietary Supplement|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
141084|NCT01645995|Dietary Supplement|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
141085|NCT01646008|Other|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
141086|NCT01646008|Other|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
141087|NCT01646021|Drug|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
141088|NCT01646021|Drug|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
141089|NCT01646034|Drug|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
141090|NCT01646034|Drug|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide
previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel
previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine
141353|NCT01641549|Drug|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
141354|NCT01641575|Drug|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
144670|NCT01741948|Drug|Hormonal contraceptive|The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.
First appointment (before initiation of HCs):
Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.
3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:
Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).
FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy.
144671|NCT01741961|Procedure|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
145279|NCT01745380|Drug|Placebo|
145280|NCT01745393|Behavioral|Clinic Quality Improvement + Behavioral Counseling|
145281|NCT00095212|Drug|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
145282|NCT01745393|Behavioral|Clinic Quality Improvement + Attention Control|
145283|NCT01745432|Device|ADBLOCK|Laparoscopic surgery
145284|NCT01745445|Other|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
145285|NCT01745458|Drug|SB-659032|
145286|NCT01745458|Drug|Placebo|Matched placebo
145287|NCT01745484|Other|SPECT-based treatment plan|SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.
The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated
145288|NCT01745497|Drug|Ferrous sulfate|3mg/kg liquid
145289|NCT01745497|Drug|Placebo|Equivalent volume of liquid with similar color and taste.
145290|NCT01745510|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
145291|NCT01745510|Dietary Supplement|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
141413|NCT01675154|Drug|SLx-4090 placebo|
141414|NCT01675154|Drug|Orlistat Placebo|
141415|NCT01675154|Drug|Orlistat|
141416|NCT01675154|Drug|Slx-4090|
141417|NCT00089011|Radiation|total-body irradiation|Undergo radiotherapy
141418|NCT01677884|Drug|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
141419|NCT01677884|Drug|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
141420|NCT01677884|Drug|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
141421|NCT01677897|Drug|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
141422|NCT01677910|Drug|Telotristat etiprate tablets (250 mg)|
141423|NCT01677910|Drug|Placebo tablets|One placebo tablet administered three times daily
141424|NCT01677923|Drug|Metformin|Metformin 500 mg BID for 12 months
141425|NCT01677936|Other|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
141426|NCT01677936|Other|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
141427|NCT01677949|Drug|Clofarabine|Days 1-5: Clofarabine 30 mg/m^2 for 0-30 years of age or 20 mg/m^2 for > 30 years of age intravenously (IV) over 2 hours
141428|NCT00089011|Drug|mycophenolate mofetil|Given IV or PO
141429|NCT01677949|Drug|Etoposide|Days 1-5: Etoposide 100mg/m^2 IV over 2 hours
141430|NCT01677949|Drug|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m^2 as a 30-60 minute infusion
141738|NCT01670552|Drug|Nimesulide + Pantoprazole|1 tablet each 12 hours for 7 days
141739|NCT01670552|Drug|Nimesulide|1 tablet each 12 hours for 7 days
141740|NCT01670565|Drug|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
142460|NCT00088595|Drug|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
142461|NCT01671917|Other|Educational and exercise program|4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement
4 (twice a week) sessions of an exercise programme lasting 1 hour
142462|NCT01671917|Other|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
142463|NCT01671943|Device|Ice-Sense3TM|Ice-Sense Cryoprobe
142464|NCT01671956|Biological|Bertilimumab|
142465|NCT01671956|Biological|Placebo|
142466|NCT01671969|Other|very low calorie diet|medically supervised diet
142467|NCT01671982|Other|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to <50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
142468|NCT01671995|Procedure|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
142469|NCT01671995|Procedure|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
142470|NCT01672008|Drug|NOX-100|
142471|NCT00088608|Drug|SOM230 s.c.|
142709|NCT01672502|Behavioral|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
142710|NCT01672502|Other|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
140712|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
140713|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
140714|NCT01642797|Device|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
140715|NCT01642797|Device|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
140716|NCT01642810|Behavioral|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
140717|NCT01642810|Other|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
140718|NCT01645033|Other|Treatment as Usual (TAU)|This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:
Teaching about the treatment program
Teaching important ideas about sexual behaviors risks
Increasing knowledge about specific sexually transmitted diseases
Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]
140719|NCT01645046|Drug|Coenzyme A|Coenzyme A 200mg per day.
140720|NCT01645046|Drug|Coenzyme A|Coenzyme A 400mg per day.
140721|NCT01645046|Drug|Placebo|Capsule without coenzyme A.
140722|NCT01645072|Other|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI <55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
140723|NCT01645072|Other|Control group|The ongoing anti epileptic drug treatment will be continued without change.
140724|NCT01645085|Drug|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
140725|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
140726|NCT01645085|Drug|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
140727|NCT00086125|Drug|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
140728|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
142916|NCT01667341|Biological|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
142917|NCT01667354|Behavioral|Academic Detailing|The intervention design is based on "academic detailing," an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations.
142918|NCT01667367|Drug|RG1662|Single oral dose
142919|NCT00088153|Drug|Physiologic Estrogen/progesterone|Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
142920|NCT01667367|Drug|placebo|Single oral dose
142921|NCT01667393|Device|IDEV SUPERA Stent|
142922|NCT01667393|Device|Percutaneous Transluminal Angioplasty|
142025|NCT01671189|Other|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
142026|NCT00001662|Drug|CX516 (Ampalex)|
142027|NCT00088530|Drug|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
142028|NCT01671228|Other|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
142029|NCT01671228|Other|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
142030|NCT01673568|Device|ETO garments|patients wearing abdominal binder for 7 days postoperatively
142031|NCT01673581|Other|Survey|
142032|NCT01673594|Drug|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
142033|NCT01673594|Drug|Naltrexone|Subjects randomized to the "active" double-blind group will receive Naltrexone HCl
142034|NCT01673607|Procedure|Biopsie liver|
142035|NCT01673620|Drug|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
142036|NCT01673620|Drug|Placebo|Matching placebo tablet administered once daily
142645|NCT01672476|Drug|Fimasartan|Fimasartan 30mg
142646|NCT01674634|Biological|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent [0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride])
142647|NCT01674647|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
142648|NCT01674647|Drug|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
142649|NCT00088868|Drug|alvespimycin hydrochloride|
142650|NCT01674686|Drug|Sarpogrelate|Sarpogrelate 100mg twice a day
142651|NCT01674686|Drug|Atorvastatin|Atorvastatin 80mg daily
142652|NCT01674699|Device|EXCOR Pediatric|Ventricular Assist Device
142653|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
142654|NCT01674712|Drug|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
142655|NCT01674712|Drug|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
142975|NCT01665001|Other|Treatment strategy: induction, consolidation, HSCT, maintenance|Patients <55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD <0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.
Patients >55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.
Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT.
142976|NCT01665014|Radiation|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
142977|NCT01665027|Procedure|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).
Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections.
142978|NCT01665027|Procedure|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
142711|NCT01672502|Other|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
142712|NCT00088660|Biological|PANVAC™-VF|
142713|NCT01672515|Device|RIPC group|
142714|NCT01672515|Device|Control group|
142715|NCT01672528|Other|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
142716|NCT01672528|Other|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
142717|NCT01672541|Behavioral|Dating Matters Comprehensive Approach|The Dating Matters Comprehensive Approach includes:
6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)
142718|NCT01672541|Behavioral|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
142719|NCT01672554|Drug|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
142720|NCT01672567|Dietary Supplement|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
142721|NCT01672567|Dietary Supplement|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
143049|NCT01662167|Drug|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
143050|NCT01662167|Drug|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
141012|NCT01638754|Procedure|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
141013|NCT01638767|Drug|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
141014|NCT01638767|Drug|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
141015|NCT01638780|Dietary Supplement|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
141016|NCT01638780|Dietary Supplement|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
141017|NCT00085462|Biological|therapeutic tumor infiltrating lymphocytes|
141018|NCT01638793|Device|Microcap (Oridion, Needham, MA, USA)|
141019|NCT01638793|Device|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
141020|NCT01638806|Procedure|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
141021|NCT01638819|Biological|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
141022|NCT01638819|Biological|Placebo|Saline
141023|NCT01638832|Device|Transient Elastography (FibroScan), Echosens, Paris, France|
141024|NCT01638832|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
141025|NCT01638845|Procedure|continuous perineural catheter|continuous perineural catheter
141026|NCT01641172|Behavioral|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
141027|NCT01641185|Procedure|radiation|radiation with protons or carbon ions
141028|NCT01641198|Procedure|Dental implants|Each of 58 subjects received 3 types of screw parallel wall mandibular implants (Branemark, Swede-Vent and Screw-Vent) at 5 different sites for a total of 290 implants.
141029|NCT01641211|Behavioral|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
142037|NCT01673646|Drug|SOM230LAR|Intramuscular administration of pasireotide LAR will be repeated every month (1 month = 28 days) for 12 months in core phase. It is permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 > ULN. In the event of any problem with tolerability, it is permitted to reduce the next lower dosage level at any time.
142038|NCT00088803|Genetic|polymorphism analysis|
142039|NCT01673659|Drug|Mometasone furoate|
142040|NCT01673659|Drug|Nasonex Nasal Spray|
142041|NCT01673659|Drug|Placebo nasal spray|
142042|NCT01673672|Biological|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
142043|NCT01673672|Biological|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
142044|NCT01673685|Device|Portable Oxygen|
142045|NCT01673698|Device|ReShape Duo balloon|
142046|NCT01673698|Other|Diet counseling|
142306|NCT01674218|Drug|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
142307|NCT01674218|Other|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
142308|NCT01674231|Other|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
142309|NCT01674231|Other|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
142310|NCT00088829|Procedure|biopsy|All subjects will have a biopsy to collect tissue
142311|NCT01674244|Behavioral|Integrative Exercise|
142312|NCT01674244|Behavioral|Monitor Only Waitlist|
142313|NCT01676753|Drug|Dinaciclib & paclitaxel treatment|Weekly dinaciclib in combination with weekly paclitaxel
142314|NCT01676779|Biological|Dendritic cell therapy|Dendritic cell therapy IV and ID
142315|NCT00088959|Drug|erlotinib hydrochloride|Given orally
142979|NCT01665040|Device|Neurostimulation device implantation|Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.
Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan.
142980|NCT01665053|Device|PROMUS Element Plus|A drug eluting coronary stent system
142981|NCT00087815|Procedure|cognitive assessment|
142982|NCT01665053|Device|SYNERGY|A drug eluting coronary stent system
142983|NCT01665066|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
142984|NCT01665066|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
142985|NCT01665066|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
142986|NCT01665066|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
142987|NCT01665066|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
142988|NCT01667510|Dietary Supplement|Cardio Mato (tomato extracted lycopene)|Soft gel capsule for oral use
142989|NCT01667510|Dietary Supplement|Placebo|Soft gel capsule without test material
142990|NCT01667523|Dietary Supplement|Capsaicin|1.5 mg capsaicin administered intraduodenally
142991|NCT01667523|Dietary Supplement|Cinnamaldehyde|70 mg per intervention administered intraduodenally
142106|NCT01671267|Behavioral|Strength training|
142107|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
142108|NCT01671267|Behavioral|Ergonomic|
142109|NCT01671280|Drug|Azithromycin IV|The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.
The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
143051|NCT01665079|Drug|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 > 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
143052|NCT01665092|Drug|Levo-Carnitine|
143053|NCT01665092|Drug|placebo|
143054|NCT01665105|Device|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
143055|NCT00087815|Procedure|magnetic resonance imaging|
143056|NCT01665118|Device|Trusculpt (Radio Frequency) Device|
143057|NCT01665131|Device|Cameron Health S-ICD SQ-RX|
143058|NCT01665144|Drug|BAF312|Patients will be randomized to receive BAF312. BAF312 will be provided in a dose titration from 0.25 mg to a 2 mg dose.
143059|NCT01665144|Drug|Placebo|Placebo
143060|NCT01665157|Dietary Supplement|Enimaclin®|Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.
The duration of study is one day before colonoscopy.
143061|NCT01665157|Other|Self-controlled diet|Self-controlled low residue diet.
143062|NCT01665157|Drug|2L PEG-ELS|Normal volume of PEG-ELS
143063|NCT01665157|Drug|low volume 1.5L PEG-ELS|Low volume PEG-ELS
143064|NCT01665170|Drug|Passiflora incarnata|3 x 1 tablet per day for 3 days
143065|NCT01665170|Drug|Placebo|3 x 1 ablet per day for 3 days
143066|NCT00087815|Procedure|positron emission tomography|
143067|NCT01665183|Drug|ADI-PEG 20|
143068|NCT01665196|Drug|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
141885|NCT01675986|Drug|Lactose|4 g
141886|NCT01675999|Other|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
142520|NCT01669343|Drug|Letrozole|Active Comparator Arm receives 2.5 mg letrozole and Experimental Arm receives 5.0 mg letrozole
142521|NCT00088374|Drug|[15-O] H2O|[15-0] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
142522|NCT01669356|Other|Parenteral supplement with enteral nutrition for patients after esophagectomy|
142523|NCT01669356|Other|Enteral Nutrition alone for patients after esophagectomy|
142841|NCT01658852|Drug|metronidazole|
142842|NCT01658852|Drug|Placebo|
142843|NCT01658878|Biological|Nivolumab|
142844|NCT01658878|Drug|Sorafenib|
142845|NCT01658878|Drug|Ipilimumab|
142846|NCT01658891|Drug|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
142847|NCT00087360|Procedure|evaluation of cancer risk factors|
142848|NCT01658891|Drug|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
142849|NCT01658904|Drug|Carfilzomib|
142850|NCT01658904|Drug|Melphalan|
142851|NCT01658904|Drug|Filgrastim|
142852|NCT01658930|Procedure|Radical Hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
142853|NCT01658930|Procedure|Simple hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
142854|NCT01658943|Drug|Akt Inhibitor MK2206|Given PO
142855|NCT01658943|Drug|Fluorouracil|Given IV
142856|NCT01658943|Drug|Oxaliplatin|Given IV
142316|NCT01676792|Drug|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon & before bed time. Medication should be reapply after bathing or cleaning.
142317|NCT01676818|Drug|eribulin mesylate|Given IV
142318|NCT01676831|Drug|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
142319|NCT01676831|Drug|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
142320|NCT01676844|Drug|Oral thin film therapy (Potassium acid phosphate oral thin films)|Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.
Place a single OTF on the tongue, inside cheek or palate and allow to dissolve.
142321|NCT01676844|Drug|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
142322|NCT01676870|Behavioral|1x4 aerobic interval training|endurance training as walking/running "uphill" 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down.
142576|NCT01674621|Drug|BA058 Transdermal (100 mcg)|BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months
142577|NCT01674621|Drug|BA058 Transdermal (150 mcg)|BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months
142578|NCT01674621|Drug|BA058 Injection (80 mcg)|BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months
142579|NCT00088985|Biological|trastuzumab|4 mg/kg intravenously, every 14 days
142580|NCT01677325|Drug|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
142581|NCT01677338|Drug|13C-uracil|Visit 2: Day 15+-4, perform the Breath Test and Scintigraphy with Semi solid Test Meal containing 100 mg of 13C-uracil and 500 uCi
142582|NCT01677338|Drug|99mTc sulfur colloid|
142583|NCT01677351|Drug|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
142584|NCT01677351|Drug|placebo|
142585|NCT01677364|Drug|Oxytocin|Arm - Induction of labour
142586|NCT01677377|Drug|Risperidone|2mg, 3mg, and 4mg oral and 60mg, 90mg, and 120mg subcutaneous injection
142110|NCT01671293|Behavioral|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer & waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
142111|NCT01671293|Other|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
142112|NCT01671319|Drug|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
142113|NCT01671332|Drug|Docetaxel|IV over 60 minutes, 75 mg/m2
142114|NCT01671332|Drug|Suramin|IV over 30 minutes
142115|NCT01671332|Drug|Docetaxel|IV over 60 minutes. 56 mg/m2
142116|NCT01671345|Behavioral|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
142117|NCT01671345|Behavioral|Control|Attention control
142118|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
142119|NCT01671371|Other|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
142120|NCT01673776|Device|PulsioFlex® Monitoring|goal directed therapy according to PulsioFlex- measurements
femoral catheter
extended perioperative monitoring
nutritional supplementation, (if necessary)
142388|NCT01674257|Radiation|18F-Flurodeoxyglucose PET/CT scan|
142389|NCT01674270|Drug|Degarelix|
142390|NCT01674270|Drug|Casodex|
142391|NCT01674270|Drug|LHRH Agonist|
142392|NCT01674283|Drug|Glucagon|
142393|NCT01674283|Drug|placebo|
142394|NCT00088829|Procedure|neoadjuvant therapy|paclitaxel is given neoadjuvantly
142395|NCT01674309|Drug|FOLFORINOX|INTRAVENOUS administration
141887|NCT01675999|Other|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
141888|NCT01675999|Other|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
141889|NCT01676025|Procedure|PRA|
141890|NCT01676025|Procedure|LA|
141891|NCT01676038|Procedure|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
141892|NCT00088933|Drug|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
141893|NCT01676038|Procedure|Conventional Total Knee Arthroplasty|Conventional technique.
141894|NCT01678820|Drug|Sitagliptin|Sitagliptin 100 mg tablet
141895|NCT01678820|Drug|Simvastatin|Simvastatin 40 mg tablet
141896|NCT01678820|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
141897|NCT01678820|Drug|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
141898|NCT01678820|Drug|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
141899|NCT01678820|Drug|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of >= 1500 mg for at least 12 weeks prior to randomization and during the study
141900|NCT01678820|Drug|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
141901|NCT01678846|Behavioral|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
141902|NCT01678872|Drug|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
141903|NCT01678885|Behavioral|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
142857|NCT01658943|Drug|Selumetinib|Given PO
142858|NCT00087373|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
142859|NCT01658956|Drug|GCSF administration on days 8 and 12 after chemotherapy|
142860|NCT01658982|Other|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
142861|NCT01658995|Drug|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days
142862|NCT01658995|Drug|Placebo|Placebo, one capsule orally twice daily for 10 days
142863|NCT01659008|Drug|Estradiol|
141962|NCT01676116|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
141963|NCT01676116|Drug|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
141964|NCT01676116|Drug|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
141965|NCT01676129|Procedure|Nocipoint Therapy|
141966|NCT00088933|Drug|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
141967|NCT01676129|Procedure|Physical Therapy|
141968|NCT01676181|Procedure|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
141969|NCT01676181|Procedure|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
141970|NCT01676194|Other|Intra-arterial administration of DC BeadsR|
141971|NCT01676207|Procedure|Coronary Angiography with collateral flow measurements|Diagnostic coronary angiography and LV angiography
Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate
Right and left IMA CFI during a 1-minute ostial vessel occlusion
Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.
IMA angiography (left and right) during distal IMA and coronary occlusion.
142587|NCT01677390|Drug|SGN-75|1-2 mg/kg IV every 21 days
142588|NCT01677390|Drug|everolimus|10 mg PO daily
142589|NCT01677403|Drug|Tobramycin|Nebulised 80mg twice daily
142590|NCT00088985|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
142591|NCT01677403|Drug|Saline|Nebulised 5mls 0.9% Saline twice daily
142592|NCT01677429|Device|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
142593|NCT01677429|Device|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
142594|NCT01677429|Behavioral|Cognitive Behavioral Therapy|For the treatment of panic disorder
142595|NCT01677442|Procedure|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
142596|NCT01677442|Procedure|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
142597|NCT01677455|Drug|ganetespib|Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
142598|NCT01677468|Procedure|Intermediate embolization|TACE with substasis using gelfoam
142599|NCT01677468|Procedure|Complete embolization|TACE with complete embolization using gelfoam
142923|NCT01667406|Drug|kisspeptin|kisspeptin doses between 1.6 and 12.8 nmol/kg subcutaneously
142924|NCT01667419|Drug|Placebo|Participants will receive oral film-coated tablets matched to vemurafenib twice daily for 52 weeks.
142925|NCT01667419|Drug|Vemurafenib|Participants will receive oral vemurafenib 960 mg twice daily for 52 weeks.
142926|NCT01667432|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
142927|NCT01667445|Drug|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
142928|NCT01667445|Drug|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
142929|NCT01667471|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
142396|NCT01674322|Drug|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
142397|NCT01674335|Behavioral|Operant Learning|The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased "activity-rest" cycling approach (Fordyce, 1976).
This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months.
142398|NCT01674335|Behavioral|Energy Conservation|The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).
This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months.
142399|NCT01674348|Drug|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
142400|NCT01674348|Drug|Placebo|Placebo
142401|NCT01674361|Drug|bitopertin|30 mg (Arm A) or 10 mg (Arm B) orally daily, 16 weeks
142402|NCT01674361|Drug|placebo|orally daily, 16 weeks
142403|NCT01674374|Other|placebo|Given PO
142404|NCT01674374|Procedure|quality-of-life assessment|Ancillary studies
142405|NCT00088829|Drug|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
142406|NCT01674374|Other|questionnaire administration|Ancillary studies
142407|NCT01674374|Drug|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
142656|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
142657|NCT01674712|Drug|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
142658|NCT01674725|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
142659|NCT01674725|Drug|Ribavirin|Tablet
142660|NCT00088881|Biological|rituximab|Given IV
142661|NCT01674738|Drug|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
140963|NCT01641172|Procedure|Glucose tolerance assessment|Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year.
140964|NCT01641172|Dietary Supplement|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
140965|NCT01641172|Behavioral|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
140966|NCT01643096|Other|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
140967|NCT01643109|Other|Casting & CIMT|A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol ("Hand2Hand" developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies.
140968|NCT01643122|Other|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
140969|NCT01643122|Other|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
140970|NCT01643135|Drug|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
140971|NCT00085943|Drug|LEXIVA (GW433908)|
140972|NCT01643135|Drug|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
140973|NCT01643161|Behavioral|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
140974|NCT01643161|Behavioral|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
141972|NCT01676207|Procedure|Coronary Angiography with collateral flow measurements|Diagnostic coronary angiography and LV angiography
Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate
Right and left IMA CFI during a 1-minute ostial vessel occlusion
Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.
IMA angiography (left and right) during distal IMA and coronary occlusion.
141973|NCT01676220|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
141974|NCT01676220|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
141975|NCT01676233|Drug|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
141976|NCT01676233|Drug|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
141977|NCT00089037|Drug|sirolimus|
141978|NCT01679028|Drug|Placebo Group A|150mg single dose
142249|NCT01679236|Behavioral|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
142250|NCT01679236|Behavioral|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
142251|NCT00089050|Drug|gemtuzumab ozogamicin|
142252|NCT01679262|Device|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
142253|NCT01679275|Other|measuring cerebral oxygenation|
142254|NCT01679288|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
142255|NCT01679314|Device|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
142256|NCT01679327|Drug|Oxaliplatin|
142930|NCT00088153|Other|Placebo|Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
142931|NCT01667484|Drug|Adderall XR 5mg|
142932|NCT01667484|Drug|Adderall XR 10 mg|
142933|NCT01667484|Drug|Placebo|
142934|NCT01667497|Drug|Fampridine SR|
142935|NCT01667497|Drug|Placebo|
142936|NCT01659021|Drug|Ofatumumab|Ofatumumab administered intravenously weekly (300 mg on Day 1; thereafter 1000 mg for Part A and 2000 mg for Part B)
142937|NCT01659034|Drug|Thienopyridine for 3 months|
142938|NCT01659047|Drug|GS-1101|150 mg taken twice daily by mouth
142939|NCT00087373|Other|laboratory biomarker analysis|Correlative studies
142940|NCT01659060|Other|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
142941|NCT01659060|Other|Placebo Chocolate|Placebo intervention
142942|NCT01659073|Procedure|Caloric Vestibular Stimulation|
142943|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
142944|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
142047|NCT01673698|Other|Exercise counseling|
142048|NCT01673711|Radiation|deuterated phenanthrene tetraol|Given PO
142049|NCT00001666|Device|Magpro High-Speed Magnetoelectric Stimulator|
142050|NCT00088816|Drug|cisplatin|
142051|NCT01673711|Other|pharmacological study|Correlative studies
142052|NCT01673711|Other|laboratory biomarker analysis|Correlative studies
142053|NCT01673724|Drug|pramipexole|pramipexole
142662|NCT01674738|Drug|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
142663|NCT01674738|Drug|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
142664|NCT01674751|Other|Pre-ordering program|During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, "smart receipt" upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time.
142665|NCT01674764|Procedure|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
142666|NCT01674764|Procedure|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
142667|NCT01674777|Drug|ASP1941|oral
142668|NCT01674790|Behavioral|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
142669|NCT01674790|Behavioral|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
142670|NCT01677533|Other|Panel Management Support|PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
142671|NCT01677533|Other|Education|The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
142672|NCT01677546|Device|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
142992|NCT01667523|Dietary Supplement|Placebo|Physiological saline
142993|NCT00088166|Drug|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
142994|NCT01667536|Drug|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
142995|NCT01667549|Other|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
140975|NCT01643187|Dietary Supplement|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
140976|NCT01643187|Dietary Supplement|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
141255|NCT01646281|Drug|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
141256|NCT01646294|Drug|YM178 modified release (OCAS)|oral
141257|NCT01646294|Drug|YM178 immediate release (IR)|oral
141258|NCT01646307|Drug|Atorvastatin|
141259|NCT01646307|Drug|Rosuvastatin|
141260|NCT01646320|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
141261|NCT00086229|Drug|Chondroitin|
141262|NCT01646320|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
141263|NCT01646320|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
141264|NCT01646320|Drug|Metformin immediate release (IR)|Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
141265|NCT01639157|Drug|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
141266|NCT00085488|Biological|autologous tumor cell vaccine|
141267|NCT01639170|Radiation|chest radiograph|All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.
All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.
The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the
141268|NCT01639183|Device|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
141269|NCT01639183|Other|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
141270|NCT01639196|Other|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
142257|NCT01679327|Drug|Xeloda|
142258|NCT01679327|Drug|Calcium folinate (CF)|
142259|NCT01679327|Drug|5-FU|
142260|NCT01679327|Drug|Bevacizumab|
142261|NCT01679340|Drug|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
142262|NCT00001685|Biological|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
142263|NCT00089063|Biological|tyrosinase peptide|Given SC
142264|NCT01679340|Drug|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
142265|NCT01679340|Drug|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
142266|NCT01679353|Drug|caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
142267|NCT01679353|Drug|normal saline 0.5ml|
142268|NCT01679366|Drug|Placebo|1 tablet 2 times daily
142524|NCT01669369|Drug|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
142525|NCT01669369|Drug|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
142526|NCT01669382|Device|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
142527|NCT01669395|Other|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
142528|NCT01669395|Other|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
142529|NCT01669408|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
142054|NCT01673724|Drug|Bromocriptine|bromocriptine
142055|NCT01673737|Drug|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
142056|NCT01673737|Drug|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
142057|NCT01673750|Other|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
142058|NCT01673763|Device|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
142059|NCT00088933|Drug|docetaxel|Given IV
142060|NCT01676246|Drug|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
142061|NCT01676246|Drug|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
142062|NCT01676246|Drug|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
142063|NCT01676246|Procedure|induce delayed onset of muscle soreness (DOMS)|The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from "no pain" to "intolerable pain" with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly.
142064|NCT01676246|Procedure|electric pain measurement|The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).
During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min.
142065|NCT01676259|Drug|siG12D LODER|The implantation of siG12D LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
142323|NCT01676870|Behavioral|4x4 aerobic interval training|endurance training as walking/running "uphill" 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down.
142324|NCT01676870|Behavioral|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
142325|NCT01676883|Device|Bioelectric impedance|removal of calluses and corns by pedicure
142326|NCT00001677|Drug|Fludarabine|
142996|NCT01667562|Drug|erlotinib [Tarceva]|Daily oral doses of 150 mg administered until disease progression or unacceptable toxicity
142997|NCT01667575|Drug|Esomeprazole|antisecretary drug of the quadruple therapy
142998|NCT01667575|Drug|Amoxicillin|antibiotic of the quadruple therapy
142999|NCT01667575|Drug|Clarithromycin|antibiotic of the quadruple therapy
143000|NCT01667575|Drug|Bismuth Potassium Citrate|one of a component of a quadruple therapy
143001|NCT01667575|Other|long duration (14 day)|
143002|NCT01667601|Other|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
143003|NCT01667601|Behavioral|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
143004|NCT00088166|Drug|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
143005|NCT01667601|Behavioral|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
143006|NCT01667614|Drug|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
143007|NCT01667627|Dietary Supplement|Bio-25|Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.
Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus.
143008|NCT01667640|Radiation|sector irradiation|Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.
A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.
Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.
Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.
Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported.
143009|NCT01659151|Drug|Lymphodepletion|The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more "space" for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion.
142121|NCT01673789|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
141271|NCT01639196|Other|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
141272|NCT01639209|Procedure|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
141273|NCT01639209|Procedure|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
141274|NCT01639222|Drug|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
141275|NCT01639222|Other|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
141551|NCT01670279|Drug|Placebo|
141552|NCT00001658|Drug|Amoxicillin|
141553|NCT00088465|Drug|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
141554|NCT01670292|Other|HVLA-SM|High Velocity Low Amplitude Spinal Manipulation
141555|NCT01670305|Procedure|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
141556|NCT01670305|Procedure|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
141557|NCT01672697|Behavioral|Physical Therapy (PT) and Behavioral Therapy (BT)|Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.
Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment.
141558|NCT00088699|Drug|Ketamine|
141559|NCT01672710|Other|Hubbard detoxification program|A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
141560|NCT01672723|Drug|Naltrexone|
141561|NCT01672736|Drug|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
141562|NCT01672749|Device|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
142530|NCT01669421|Drug|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
142531|NCT01669434|Drug|Take ACE-I|
142532|NCT00001656|Drug|Clozapine|tablet; 12.5-900mg/day; 8 weeks
142533|NCT00088374|Drug|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
142534|NCT01669434|Drug|Hold ACE-I|These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery.
142535|NCT01669447|Biological|ranibizumab|Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.
To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.
Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment.
142536|NCT01669460|Other|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
142537|NCT01672099|Dietary Supplement|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
142538|NCT01672112|Drug|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
142539|NCT01672112|Drug|Codeine|Oral Codeine 60mg 6hrly/prn
142864|NCT01659008|Drug|Lysteda|
142865|NCT01659021|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
142866|NCT01661712|Device|Sham stimulation (SOSATS device, MORGAN Innovation&Technology ltd., Petersfield, UK)|The patient will undergo a sleep study with sham transcutaneous electrical stimulation. The setup will be identical to the intervention, but a blinded mode in the software application will stop triggering electrical current despite indicating on the monitor that stimulation is being applied.
142867|NCT01661725|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
142868|NCT01661738|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2~6 years of age), early youth (7~15 years of age) and adult (16~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
142327|NCT00088959|Drug|celecoxib|Given orally
142328|NCT01676883|Device|Air displacement plethysmography|
142329|NCT01676896|Behavioral|Asthma in-school class|
142330|NCT01676896|Behavioral|Asthma Day Camp|
142331|NCT01676896|Behavioral|Health Promotion in-school class|
142332|NCT01676909|Behavioral|Living Well|Living Well will be implemented as a 12 session small-group intervention (4-8 persons). Groups will meet weekly for 75 minutes for three months (12 sessions). There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
142333|NCT01676909|Behavioral|Health Focused support and education|The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition. Each of the 12 sessions will follow a basic structure that includes a review of the material presented in the previous session, new education content and discussion.
142334|NCT01676935|Drug|ABT-126|See arm description
142335|NCT01669018|Procedure|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
142336|NCT01669018|Procedure|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
142337|NCT01669031|Other|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
142338|NCT01669044|Drug|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
142339|NCT01669044|Drug|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
142340|NCT01669070|Drug|FF, 50 mcg|Novel dry powder inhaler
142341|NCT00088309|Procedure|Electrocardiogram|
142342|NCT01669070|Drug|FF, 100 mcg|Novel dry powder inhaler
142600|NCT01677507|Drug|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
142601|NCT00088998|Biological|bevacizumab|
142122|NCT00088816|Drug|tegafur-gimeracil-oteracil potassium|
142123|NCT01673802|Radiation|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
142124|NCT01673815|Other|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
142125|NCT01673828|Drug|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
142126|NCT01673828|Drug|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
142127|NCT01673841|Procedure|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
142128|NCT01673854|Drug|Ipilimumab|
142129|NCT01673854|Biological|Vemurafenib|
142130|NCT01673867|Biological|Nivolumab|
142131|NCT01673867|Drug|Docetaxel|
142132|NCT01673880|Drug|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
142133|NCT00088816|Procedure|adjuvant therapy|
142134|NCT01673893|Device|ClearWay™ Rx catheter|
142135|NCT01673906|Drug|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
142136|NCT01673919|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
142137|NCT01673932|Biological|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
142138|NCT01673932|Procedure|surgery|
142408|NCT01674387|Device|acupuncture|30 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
141563|NCT01672749|Device|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
141564|NCT01672762|Drug|ASP1941|oral
141565|NCT01672775|Drug|AGS-16C3F|intravenous (IV) infusion
141566|NCT01672788|Drug|Empagliflozin|empagliflozin tablets and metformin tablet
141567|NCT01672788|Drug|Empagliflozin + Metformin|fixed dose combination tablet (low)
141568|NCT01672788|Drug|Metformin|empagliflozin tablets and metformin tablet
141569|NCT00088699|Drug|Riluzole|
141570|NCT01672788|Drug|Metformin|empagliflozin tablet and metformin tablet
141904|NCT00089024|Radiation|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
141905|NCT01678885|Other|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
141906|NCT01678885|Device|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
141907|NCT01678885|Behavioral|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
141908|NCT01678898|Drug|PRX-102|
141909|NCT01670773|Drug|Salsalate + DHA|
141910|NCT01670773|Drug|Placebo|
141911|NCT01670786|Procedure|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
141912|NCT01670799|Drug|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
142869|NCT01661751|Biological|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
142870|NCT01661751|Biological|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
142871|NCT01661764|Drug|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
142872|NCT01661764|Drug|Oleic Acid|Placebo
142873|NCT01661777|Drug|Nasal steroid|
142874|NCT01661777|Procedure|Myringotomy tube placement|
142875|NCT00087581|Drug|Cyclosporine or tacrolimus|Standard, as prescribed
142876|NCT01661777|Drug|Diuretic|
142877|NCT01661777|Drug|Antihistamine|
142878|NCT01661777|Behavioral|Low salt diet|
142879|NCT01661790|Drug|Bevacizumab|Bevacizumab300mg&Cispltin30mg by intrapleural administration of each 2 week
142880|NCT01661790|Drug|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
142881|NCT01661816|Behavioral|interview|psychological, emotional, family and social parameters
142882|NCT01661842|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
142883|NCT01661842|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
141979|NCT01679028|Drug|Placebo Group B|300mg single dose
141980|NCT01679028|Drug|T89 Group B|300mg single dose
141981|NCT01679028|Drug|Placebo Group C|225mg bid
141982|NCT01679028|Drug|T89 Group C|225mg bid
141983|NCT01679041|Drug|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
141984|NCT01679041|Drug|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
142602|NCT01677533|Other|Data|The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
142603|NCT01669473|Other|EHR Based Strategy to promote Safe and Appropriate Drug Use|The printed tools presented in the intervention include:
Medication Review: a consolidated list of the medications a patient is currently taking.
Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.
Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen
142604|NCT01669486|Other|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
142605|NCT01669499|Drug|Dexamethasone acetate|
142606|NCT01669499|Drug|Placebo|
142607|NCT01669512|Biological|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
142608|NCT01669512|Biological|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
142609|NCT01669512|Biological|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
142610|NCT00088387|Drug|Divalproex|
142611|NCT01669538|Drug|Galantamine|
142612|NCT01669538|Drug|Placebo|
142613|NCT01669564|Other|Will use HIT patient feedback to activate patients.|After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.
Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL.
142614|NCT01669564|Other|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
142615|NCT01669577|Procedure|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
142616|NCT01669603|Drug|Bifidobacterium lactis Bl-04|The study product will be a 2*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
142945|NCT01659086|Biological|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
142409|NCT01676948|Drug|ACZ885|
142410|NCT01676948|Drug|Canakinumab|
142411|NCT01676948|Drug|Canakinumab|Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.
Canakinumab-naïve patients
142412|NCT00088959|Other|laboratory biomarker analysis|Correlative studies
142413|NCT01676948|Drug|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
142414|NCT01676961|Biological|romiplostim|Given SC
142415|NCT01676987|Drug|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
142416|NCT01676987|Drug|Budesonide|Delivered dry powder inhaler for 12 weeks.
142417|NCT01677013|Other|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
142418|NCT01677039|Drug|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
142419|NCT01677039|Drug|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
142420|NCT01677039|Drug|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
142421|NCT01677065|Drug|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
142422|NCT01677065|Drug|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
142423|NCT00088972|Drug|celecoxib|Given orally
142424|NCT01677078|Device|Neuronavigation system|Neuronavigation
142425|NCT01677078|Device|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
142426|NCT01677091|Other|Cervical vibration|Vibration of neck muscles during 10 minutes
142427|NCT01677091|Other|Prism adaptation|Prism adaptation during 10 minutes
142428|NCT01677091|Other|Conventional rehabilitation|conventional rehabilitation
142429|NCT01677104|Drug|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
141913|NCT01670812|Drug|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
141914|NCT01670825|Procedure|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
141915|NCT01670825|Drug|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
141916|NCT01670851|Device|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
141917|NCT00088504|Drug|Ribavirin (Copegus®)|
141918|NCT01670864|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
140977|NCT01643200|Device|Zotarolimus-Eluting Peripheral Stent System|Various lengths and diameters of the Zotarolimus-Eluting Peripheral Stent System
140978|NCT01643213|Device|Non Boston Scientific SCS Trial Therapy|No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
140979|NCT01643213|Device|BSC approved SCS Trial Therapy w/ OMG|No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
140980|NCT01643226|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
140981|NCT01643226|Drug|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
140982|NCT00085943|Drug|Ritonavir|
140983|NCT01643239|Other|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
140984|NCT01645774|Procedure|10s injections duration|10s injections duration
140985|NCT01645774|Procedure|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
140986|NCT01645774|Procedure|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
140987|NCT01645774|Procedure|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
141985|NCT01679041|Drug|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
141986|NCT01679067|Procedure|colonoscopy with endoscopic biopsies|
141987|NCT01679080|Drug|Zoledronic acid|antiresorptive
141988|NCT00089037|Drug|tacrolimus|
141989|NCT01679080|Drug|Teriparatide|anabolic
141990|NCT01679080|Drug|placebo zoledronic acid|
141991|NCT01679080|Drug|placebo teriparatide|
141992|NCT01679093|Drug|ondansetron|ondansetron: 4 mg intraveinous administration afer the induction of anesthesia.
141993|NCT01679093|Drug|Droperidol|droperidol: 1.25 mg intraveinous administration after the induction of anesthesia.
141994|NCT01679093|Drug|Dexamethasone|dexametasone: 4 mg intraveinous administration after the induction of anesthesia.
141995|NCT01679106|Other|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
141996|NCT01679106|Other|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
141997|NCT01679119|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
141998|NCT01679119|Drug|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
141999|NCT00089050|Drug|cyclosporine|
142000|NCT01679119|Drug|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
142001|NCT01679119|Drug|Rituximab|Rituximab 375mg/m2 IV given day 1
142002|NCT01679119|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
142003|NCT01679119|Drug|Gemcitabine|Gemcitabine 1g/m2 IV given day 1 and day 8
142269|NCT01679366|Drug|Probiotics|1 tablet twice daily
142270|NCT01679379|Procedure|Absorbable suture group|Skin is closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture]
142271|NCT01671514|Other|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
142946|NCT01659099|Other|PET driven strategy for consolidation phase treatment|PET scan evaluation is done after 2 and 4 cycles during the induction phase.
According to a based on ΔSUVmaxPET0-2 and ΔSUVmaxPET0-4 judgment, consolidation treatment will be adaptated:
If ΔSUVmaxPET0-2≤66%, PET 2 is positive; if ΔSUVmaxPET0-2>66%, PET 2 is negative
If ΔSUVmaxPET0-4≤70%, PET 4 is positive; if ΔSUVmaxPET0-4>70%, PET 4 is negative
According to the PET2/4 result, treatment during the consolidation phase will be adaptated as following:
PET2-/PET4-: fast responders: patient will received consolidation treatment GA101-(CHOP or ACVBP)or rituximab -(CHOP or ACVBP)
PET2+/PET 4-: slow responders: patient will received autologous stem cell transplant
PET2- or PET2+/PET4+: patient will withdraw the study and treated according to local practice.
142947|NCT01659112|Other|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
142948|NCT01659112|Other|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
142949|NCT01659125|Behavioral|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
142950|NCT00087386|Drug|tanespimycin|Given IV
142951|NCT01659138|Drug|SAR339658|Pharmaceutical form:solution Route of administration: intravenous
142952|NCT01659138|Other|Placebo|Pharmaceutical form:solution Route of administration: intravenous
142953|NCT01659151|Drug|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
142954|NCT01659151|Procedure|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
142955|NCT01659151|Drug|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
142956|NCT01661881|Drug|Bendamustine|Cycles 1-3, Intravenously over 30-60 minutes, Days 1 and 2 of each cycle
142957|NCT01661881|Drug|Cytarabine|Cycles 4-6, Intravenously every 12 hours on days 1 an d2 of each cycle
142958|NCT01661894|Device|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
142959|NCT01661907|Procedure|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.5%-0.75% ropivacaine during surgery. Patient controlled epidural analgesia will be provided after surgery.
142673|NCT01677546|Device|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
142674|NCT01677559|Drug|MLN8237|
142675|NCT01677559|Drug|nab-Paclitaxel|
142676|NCT01677572|Drug|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to 14 additional doses.
142677|NCT01677572|Drug|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at Aducanumab doses for up to 14 additional doses.
142678|NCT01677598|Drug|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
142679|NCT00088998|Drug|capecitabine|
142680|NCT01677611|Drug|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
142681|NCT01677611|Drug|Placebo|
142682|NCT01677624|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
142683|NCT01677650|Drug|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
142684|NCT01677676|Biological|FP-01.1|IM injection
142685|NCT01677676|Biological|FP-01.1-Adjuvant|IM injection
142686|NCT01677689|Drug|Apomivir®|Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
142687|NCT01677689|Drug|Placebo|Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
142688|NCT01669707|Drug|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
142689|NCT01669707|Drug|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
140988|NCT01645787|Drug|4-aminopyridine|10 mg/twice daily
140989|NCT01645787|Drug|Placebo|Crossover study involving one trial with sugar pill (placebo)
140990|NCT00086190|Drug|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
140991|NCT01645800|Drug|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
140992|NCT01645800|Drug|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
140993|NCT01645826|Drug|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
140994|NCT01645826|Drug|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
140995|NCT01645839|Drug|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
141276|NCT01639248|Drug|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
141277|NCT00085488|Biological|therapeutic autologous dendritic cells|
141278|NCT01639261|Drug|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever >38,5 dose increase: 50µg/m² BSA three times/week
141279|NCT01639274|Other|COPD prevalence|Determine prevalence of COPD
141280|NCT01639300|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
141281|NCT01639300|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
141282|NCT01639326|Drug|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
141283|NCT01639326|Drug|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
141284|NCT01639339|Biological|Placebo plus standard therapy|Placebo plus standard therapy
141285|NCT01639339|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
141286|NCT01641445|Drug|Topiramate|Topiramate (200 mg daily)
142272|NCT01671527|Procedure|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
142273|NCT01671540|Device|intrapulmonary percussive ventilation|
142274|NCT01671540|Other|standard treatment|breathing control exercises
142275|NCT01671553|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
142276|NCT01671566|Behavioral|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
142277|NCT01671579|Procedure|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
142278|NCT01671579|Procedure|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
142279|NCT01671592|Biological|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
142280|NCT01671631|Other|Measurement of intracoronary pressure|
142281|NCT00088556|Drug|paclitaxel|200 mg/m² Once every 3 weeks
142282|NCT01671670|Other|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
142283|NCT01671670|Other|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
142540|NCT00001663|Device|Magstim Super Rapid Stimulator|
142541|NCT00088621|Drug|Lurasidone 80mg tablet|
142066|NCT01676259|Drug|Gemcitabine or FOLFIRINOX|Gemcitabine or FOLFIRINOX
142067|NCT01676285|Drug|Metoprolol succinate|
142068|NCT01676285|Drug|placebo|
142069|NCT01676298|Device|Spartan FRX CYP2C19 Test System|
142070|NCT00088933|Drug|sargramostim|Given subcutaneously
142071|NCT01676311|Drug|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
142072|NCT01676311|Drug|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
142073|NCT01676337|Other|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
142074|NCT01676350|Procedure|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
142075|NCT01676363|Drug|Diflunisal|Open-label diflunisal 500 mg twice daily for 4 weeks
142076|NCT01676376|Device|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
142077|NCT01676376|Other|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
142078|NCT01676389|Other|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
142079|NCT01678677|Drug|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
142080|NCT01678690|Drug|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
142081|NCT01678703|Device|Laminaria, MedGyn Products, Inc. USA.|Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
142082|NCT01678703|Drug|Misoprostol|Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
142083|NCT01678716|Behavioral|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
142084|NCT01678716|Dietary Supplement|Micronutrient powders|In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name "Pushtikona" in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others.
142690|NCT01669720|Drug|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
143010|NCT01659164|Behavioral|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
143011|NCT01659177|Drug|LY2140023|Administered orally
143012|NCT01659190|Other|Oiled-limestone liniment|
143013|NCT01659203|Radiation|IG-IMPT|Daily, Monday-Friday for about 6 weeks
143014|NCT00087386|Other|laboratory biomarker analysis|Correlative studies
143015|NCT01659203|Radiation|IG IMRT|Daily, Monday-Friday for about 6 weeks
143016|NCT01659242|Drug|Methotrexate plus sulfasalazine|ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))
SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.
MTX:Kept at the highest optimal dose.
143017|NCT01659242|Drug|Leflunomide|ARM 2:Leflunomide(LEF)
LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.
Methotrexate:Off
143018|NCT01659255|Drug|ONO-4059|ONO-4059 QD or BID. Start dose is 20mg.
143019|NCT01659268|Other|Simulation class|The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.
The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation.
143020|NCT01659268|Other|Exhibition-dialogued class|The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.
Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes.
143021|NCT01659281|Drug|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
143022|NCT01659281|Drug|Artesunate|4 mg/kg/day for 3 days
143023|NCT01659281|Drug|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
143024|NCT01659281|Drug|Mefloquine|8 mg/kg daily for 3 days
143025|NCT00001644|Drug|Indinavir|
143026|NCT00087399|Drug|gabapentin|
143027|NCT01659294|Behavioral|Nurse Case Management|
143028|NCT01659294|Behavioral|standard diabetologist care|routine care by diabetologist & team
141287|NCT01641445|Drug|Placebo|Non-active sugar pill
141288|NCT01641458|Other|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G>A, c.1679T>G, HapB3/c.1129-5923C>G and c.2846A>T).
141289|NCT01641458|Other|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
141290|NCT01641471|Device|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current. The 4 electrodes will be focused on the posterior aspect of the knee during the immediate postoperative period and lasting through discharge from the hospital. Once the patient is discharged, he/she will be instructed to use the device as he/she would like, whether it is a continuation of the posterior placement of the electrodes, or a more traditional anterior criss-cross positioning. Patients will be instructed to use the device for 2 hours on, followed by 30 minutes off, as needed. Amount of TENS usage and average intensity used will be recorded. An assessment of blinding will be conducted at the conclusion of the study by asking patients what treatment arm they think that they received.
141571|NCT01672788|Drug|Empagliflozin + Metformin|fixed dose combination tablet (low)
141572|NCT01672788|Drug|Empagliflozin|empagliflozin tablet and metformin tablet
141573|NCT01672801|Drug|Placebo|oral administration
141574|NCT01672801|Drug|Nimodipine|oral administration
141575|NCT01672814|Drug|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
141576|NCT01672814|Device|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
141577|NCT01672827|Drug|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
141578|NCT01672840|Dietary Supplement|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
141579|NCT01672840|Dietary Supplement|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
141580|NCT01675362|Drug|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
142542|NCT01672125|Other|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
142543|NCT01672138|Procedure|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum
142544|NCT01672138|Procedure|CFAE ablation|Catheter ablation of CFAEs
142545|NCT01672138|Procedure|Isolation of non-PV triggers|Catheter ablation of triggers originating from extra-PV sites
142546|NCT01672151|Drug|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
142547|NCT01672177|Behavioral|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
142548|NCT01672190|Other|Yoga Therapy Program|
142549|NCT01672216|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
142550|NCT01672216|Device|EMG-biofeedback alone|
142551|NCT01672229|Drug|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
142552|NCT00088634|Drug|Lurasidone|80 mg AM dosing once daily
142553|NCT01672242|Device|High-flow nasal cannula oxygen|Graded levels of HFNC will be applied and end-expiratory lung volumes measured by respiratory inductive plethysmography
142554|NCT01672242|Device|Facial CPAP|Graded levels of CPAP will be applied by face mask and end-expiratory lung volumes measured by respiratory inductive plethysmography
142555|NCT01672255|Drug|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
142556|NCT01672255|Drug|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
142557|NCT01672268|Other|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
142558|NCT01672281|Other|vibrox- vs. resistance training|Comparison between two exercise interventions
142559|NCT01672294|Other|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
142560|NCT01672294|Other|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
142085|NCT01678716|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
142343|NCT01669070|Drug|FF, 200 mcg|Novel dry powder inhaler
142344|NCT01669070|Drug|FF, 250 mcg|Intravenous
142345|NCT01669083|Drug|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
142346|NCT01669083|Drug|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
142347|NCT01669083|Drug|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
142348|NCT01669083|Drug|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
142349|NCT01669096|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
142350|NCT01669109|Behavioral|Hatha yoga|
142351|NCT01669122|Drug|nicotine|4 mg nicotine lozenge experimental
142352|NCT00088309|Procedure|Echocardiogram|
142353|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|
142354|NCT01669148|Device|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
142355|NCT01669148|Device|standard mammography|
142356|NCT01669161|Device|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
142357|NCT01669161|Other|Rehab Only|Rehabilitation without device implant and VNS
142358|NCT01669174|Drug|Placebo|
142359|NCT01669174|Drug|BYM338|BYM338
142360|NCT01669187|Other|Education brochure|
142361|NCT01671748|Device|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
142362|NCT01671748|Other|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
143029|NCT01659307|Drug|Aspirin 75mg|Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
142139|NCT01673945|Device|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
142140|NCT01673958|Other|Exercise|Comparison between stair descending and stair ascending training
142141|NCT01676389|Other|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
142142|NCT01676402|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
142143|NCT00088946|Dietary Supplement|Polyphenon E|4-200mg capsules PO daily for 12 months
142144|NCT01676402|Biological|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
142145|NCT01676415|Drug|Prednisone|Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily
If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead
Antihistamines if an appropriate history of atopy is obtained
Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days
Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study
142146|NCT01676415|Drug|Topical mometasone|Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily
If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead
Antihistamines if an appropriate history of atopy is obtained
Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study.
142147|NCT01676428|Radiation|Radiotherapy|The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.
For lesions <5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart.
142148|NCT01676441|Procedure|Mesenchymal stem cell transplantation|
142149|NCT01676480|Behavioral|Endurance training|12 weeks of endurance training 3 times per week
142150|NCT01676493|Drug|Codeine|
142151|NCT01676506|Drug|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
141581|NCT00088894|Drug|gemcitabine hydrochloride|Given IV
141582|NCT01675362|Drug|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
141583|NCT01675362|Drug|Placebo|They will receive placebo
141584|NCT01675375|Device|Eye Shield|one application following refractive surgery
141585|NCT01675388|Other|Hypothermia|Hypothermia to 33.5 deg C
141586|NCT01675401|Other|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
141587|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
141588|NCT01675414|Other|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
141589|NCT01675427|Other|Interleukin 28B testing|Blood sampling for ILB28 genotyping
141590|NCT01675440|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
141591|NCT01675453|Drug|7.2% NaCl plus 6% hydroxyethyl starch 200/0.5|
141592|NCT00088894|Biological|bevacizumab|Given IV
140696|NCT01640782|Drug|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by
Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by
5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.
After 3 weeks from last infusion:
Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by
Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles.
140697|NCT01640782|Drug|Leucovorin, 5-Fluorouracil|Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by
5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations.
140698|NCT01640808|Drug|NIK-333(peretinoin)|600mg (8 x 75mg tablets) orally, twice a day, continuously until recurrence of HCC, the patient's death, or termination or discontinuation of the entire study.
140699|NCT01640808|Drug|Placebo|600mg (8 x 75mg tablets) orally, twice a day, continuously until recurrence of HCC, the patient's death, or termination or discontinuation of the entire study.
140700|NCT01642693|Radiation|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
142884|NCT01661855|Drug|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
142885|NCT01661855|Drug|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
142886|NCT00001644|Drug|Nevirapine|
142887|NCT00087581|Drug|mycophenolate mofetil [CellCept]|Concentration-controlled
142888|NCT01661868|Drug|Olaparib|Tablet formulation will be used.
142889|NCT01661881|Drug|Rituximab|Cycles 1-6, Intravenously, Day 1 of each cycle
142890|NCT01664871|Device|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
142891|NCT01664897|Drug|Erlotinib|Starting dose: 150 mg by mouth once daily in a 28-day cycle.
142892|NCT01664910|Drug|CMC-544|0.6, 1.2 or 1.8 mg/m2 (dose is based on actual body weight) by vein on Day -13.
142893|NCT01664910|Drug|Fludarabine|30 mg/m2 by vein on Days -5, -4 and -3.
142894|NCT01664910|Drug|Bendamustine|130 mg/m2 by vein on Days -5, -4 and -3.
142895|NCT01664910|Drug|Rituximab|375 mg/m2 by vein (based on actual body weight) on Day -6, Day +1 and +8 for patients with CD20+ disease.
142896|NCT01664910|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation on Day 0.
142897|NCT00087815|Drug|dexamethasone|
142898|NCT01664910|Drug|Thymoglobulin|1 mg/kg (based on actual body weight) by vein patients receiving a matched unrelated donor (MUD) on Days -2 and -1.
142899|NCT01664910|Drug|Tacrolimus|0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion on Day -2, daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after Day +90 if no graft versus host disease (GVHD) is present.
142900|NCT01664910|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, and +6 for all patients. Patients receiving an unrelated graft will also be given Methotrexate on Day +11 after the transplant.
142901|NCT01664910|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7 for patients receiving related and MUD. G-CSF will continue until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
142902|NCT01664923|Drug|Enzalutamide|160 mg, daily, by mouth.
142363|NCT01671774|Drug|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
142364|NCT01671774|Drug|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
142365|NCT00088569|Drug|0-15 Water|
142366|NCT01671774|Drug|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
142617|NCT01669603|Drug|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
142618|NCT01669629|Device|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
142619|NCT01669629|Device|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
142620|NCT01669642|Drug|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
142621|NCT00088387|Drug|Lithium|
142622|NCT01669668|Procedure|radiofrequency ablation|Undergo RFA
142623|NCT01669668|Procedure|laparoscopy|Undergo laparoscopic ultrasound
142624|NCT01669694|Other|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
142625|NCT01672307|Drug|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
142626|NCT01672307|Drug|Placebo|Placebo is applied twice daily to the other eyebrow.
142627|NCT00088634|Drug|Placebo|Matching Placebo to 40mg lurasidone tablets
142628|NCT01672333|Drug|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
142629|NCT01672346|Procedure|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
142630|NCT01672359|Dietary Supplement|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
142631|NCT01672359|Dietary Supplement|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
142632|NCT01672359|Dietary Supplement|Placebo|
142152|NCT01676506|Procedure|Ranibizumab Injection|
142153|NCT01676519|Procedure|PCI|percutaneous coronary intervention
142154|NCT00088946|Drug|erlotinib hydrochloride|100 mg PO daily for 12 months
142155|NCT01676532|Other|Pediatric Health Initiative|
142430|NCT01677104|Drug|Placebo|
142431|NCT01677143|Drug|Bupivacaine 5mg/ml|5 ml in trocar area
142432|NCT01677169|Dietary Supplement|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
142433|NCT01677169|Dietary Supplement|Placebo|
142434|NCT00088972|Other|placebo|Given orally
142435|NCT01677182|Drug|Ramelteon|Ramelteon tablets for sublingual administration
142436|NCT01677182|Drug|Placebo|Ramelteon placebo-matching tablets for sublingual administration
142437|NCT01669187|Other|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
142438|NCT01669200|Other|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
142439|NCT00088374|Drug|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
142440|NCT01669200|Other|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
142441|NCT01669213|Drug|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
142442|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
142443|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
142444|NCT01669213|Drug|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
142445|NCT01669226|Drug|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
140701|NCT01642693|Other|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
140702|NCT01642719|Behavioral|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
140703|NCT01642719|Behavioral|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
140704|NCT01642732|Other|Everolimus, lupron, bicalutamide, and radiation|Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.
Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).
Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.
Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.
Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study.
140705|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
140706|NCT01642745|Drug|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
140707|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
140708|NCT00085891|Drug|Quetiapine Fumarate|
140709|NCT01642758|Drug|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
140710|NCT01642771|Drug|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
140996|NCT01645852|Dietary Supplement|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
140997|NCT01645865|Behavioral|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
140998|NCT01645865|Behavioral|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
140999|NCT01645878|Behavioral|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
141000|NCT01645878|Behavioral|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
142903|NCT01664923|Drug|Bicalutamide|50 mg, daily, by mouth
142004|NCT01679132|Device|Neo Baroreflex Activation Therapy System|
142005|NCT01679158|Device|Using The IOP system from USGI to place suture anchors|Sutures are placed in the distal body in one of three randomized techniques:
"A" = reduction in "ring" opening to antrum using plications "B" = continuous horizontal row, running from distal body into proximal antrum "C" = Control. Current V shape as Control
142006|NCT01679197|Drug|Metreleptin|
142007|NCT01670981|Biological|ixmyelocel-T|12-20 transendocardial NOGA® -guided injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
142008|NCT01670981|Other|Vehicle Control|12-20 transendocardial NOGA® -guided injections of 0.4 mL of vehicle control per injection into the left ventricle.
142009|NCT01670994|Biological|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
142010|NCT01671020|Drug|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
142011|NCT01671020|Drug|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
142012|NCT01671033|Behavioral|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
142013|NCT01671033|Behavioral|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
142014|NCT01671072|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
142015|NCT00088530|Drug|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
142016|NCT01671072|Drug|Normal Saline|Sodium chloride 0.9%, 3.5ml
142017|NCT01671085|Drug|LY3015014|Administered SQ
142018|NCT01671085|Drug|Placebo|Administered SQ
142019|NCT01671111|Drug|SSP-004184AQ|Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or "active" form)
142020|NCT01671124|Other|Soline capsule|
142021|NCT01671137|Other|Lactobacillus Rhamnosus Strain GG|Lactobacillus Rhamnosus Strain GG
142022|NCT01671150|Drug|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
142633|NCT01672372|Dietary Supplement|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
142634|NCT01672372|Dietary Supplement|Placebo Max Stress B|
142635|NCT01672385|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
142960|NCT01661907|Procedure|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
142961|NCT01661920|Other|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
142962|NCT01661920|Other|Control group|Those antibiotic duration treatments which are not modified by their doctors.
142963|NCT01661933|Biological|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
142964|NCT00087581|Drug|mycophenolate mofetil [CellCept]|1g po bid
142965|NCT01661933|Biological|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
142966|NCT01661946|Drug|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
142967|NCT01661946|Drug|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
142968|NCT01661972|Drug|Capecitabine and aflibercept|A standard 3+3 dose escalation format will be used. Since each agent is well tolerated as monotherapy and in combination with other chemotherapy regimens, we will start at capecitabine 850mg/m2 to be given days 1-14 and off days 15-21. The dose will then be escalated to 1000mg/m2, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks. Both agents will be administered on a 21-day cycle. Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single-arm, Phase II portion for expanded safety, response and biomarker data.
142969|NCT01661985|Drug|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
142446|NCT01669226|Drug|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
142447|NCT01669239|Drug|Liposomal Doxorubicin|Six cycles of:
Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks
Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks
Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks
Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks
142448|NCT01669252|Drug|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
142449|NCT01669278|Device|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
142691|NCT01669733|Other|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
142692|NCT01669733|Other|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
142693|NCT01669746|Biological|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
142694|NCT01669772|Drug|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
142695|NCT00088400|Drug|TransMID|
142696|NCT01669772|Drug|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
142697|NCT01669785|Device|Group C|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
142698|NCT01669785|Device|Group A|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
142699|NCT01669785|Device|Group B|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
142700|NCT01669798|Drug|BIBF 1120|PO 200mg BID
142701|NCT01669811|Drug|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
142702|NCT01669811|Drug|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
142703|NCT01669824|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
141001|NCT00086190|Drug|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
141002|NCT01645878|Behavioral|routin breast feeding education|
141003|NCT01645891|Device|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
141004|NCT01645891|Device|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
141005|NCT01638715|Drug|Remicade|- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
141006|NCT00085462|Biological|therapeutic autologous lymphocytes|
141007|NCT01638715|Drug|Orencia|- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
141008|NCT01638715|Drug|Ro-Actemra|- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
141009|NCT01638715|Drug|Mabthera|- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.
Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
141010|NCT01638741|Behavioral|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
141011|NCT01638754|Procedure|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
141291|NCT01641471|Device|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation (even though screen shows 0-60 milliamps of output current). The 4 electrodes will be focused on the posterior aspect of the knee during the immediate postoperative period and lasting through discharge from the hospital. Once the patient is discharged, he/she will be instructed to use the device as he/she would like, whether it is a continuation of the posterior placement of the electrodes, or a more traditional anterior criss-cross positioning. Patients will be instructed to use the device for 2 hours on, followed by 30 minutes off, as needed. Amount of TENS usage and average intensity "used" will be recorded. An assessment of blinding will be conducted at the conclusion of the study by asking patients what treatment arm they think that they received.
141292|NCT01641484|Procedure|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
142023|NCT01671163|Procedure|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
142024|NCT01671176|Device|4.5 mm bone anchored implant|Measure implant stability with Osstell ISQ
142284|NCT01671696|Other|Cardiac MRI|Cardiac MRI
142285|NCT01671709|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
142286|NCT01671722|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
142287|NCT01671735|Other|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
142288|NCT00088829|Drug|paclitaxel|subjects will receive paclitaxel neoadjuvantly
142289|NCT01674140|Drug|everolimus|Given PO
142290|NCT01674140|Drug|exemestane|Given orally
142291|NCT01674140|Drug|goserelin acetate|Given subcutaneously or intramuscularly
142292|NCT01674140|Drug|letrozole|Given orally
142293|NCT01674140|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
142294|NCT01674140|Drug|tamoxifen citrate|Given PO
142295|NCT01674140|Other|placebo|Given PO
142296|NCT01674153|Procedure|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
142297|NCT01674166|Drug|prucalopride|single dose 0.03 mg/kg prucalopride open label
142298|NCT01674192|Drug|prucalopride|single dose of 2 mg prucalopride
142299|NCT00088829|Genetic|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
142300|NCT01674205|Biological|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
142301|NCT01674205|Biological|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
142302|NCT01674205|Biological|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
142970|NCT01661985|Drug|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
142971|NCT01661985|Drug|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
142972|NCT01664988|Behavioral|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
142973|NCT01664988|Behavioral|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
142974|NCT01664988|Other|control (routine care)|received routine care of clinic or health center and use drugs if necessary
142086|NCT01678742|Dietary Supplement|High-protein diet|The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.
A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea.
142087|NCT00089024|Procedure|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 [negative margins] or R1 [positive microscopic margins]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
142088|NCT01678742|Dietary Supplement|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
142089|NCT01678755|Drug|ABT-126|ABT-126 Low Dose
142090|NCT01678755|Drug|ABT-126|ABT-126 High Dose
142091|NCT01678755|Drug|Placebo|Placebo
142092|NCT01678794|Drug|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
142093|NCT01678794|Drug|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
142094|NCT01678807|Biological|MK-8237 6 DU|
142095|NCT01678807|Biological|MK-8237 12 DU|
142096|NCT01678807|Biological|Placebo|
142097|NCT01678820|Drug|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
142704|NCT01669837|Device|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
142705|NCT01669850|Device|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
142706|NCT00088413|Biological|PANVAC-V|A recombinant vaccinia virus vector vaccine containing genes for human CEA, MUC-1 and three co-stimulatory molecules: B7.1, ICAM-1, and LFA-3.
142707|NCT01669850|Procedure|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
142708|NCT01669863|Device|ECMO|Use of veno-venous ECMO in non-intubated patients with ARDS
143030|NCT01659307|Drug|Lactose powder|Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
143031|NCT01662011|Device|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
143032|NCT01662011|Device|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
143033|NCT01662024|Device|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
143034|NCT00087594|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
143035|NCT01662037|Drug|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
143036|NCT01662050|Drug|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
143037|NCT01662063|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w
143038|NCT01662076|Other|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
143039|NCT01662089|Drug|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
143040|NCT01662089|Drug|Placebo drug supplement|Placebo drug instead of Zinc supplement
143041|NCT01662102|Drug|Zevalin|Group A: Response consolidation with a single dose of 90Y-ibritumomab tiuxetan (Zevalin®) 0.4 mCi/Kg - Maximum dose: 32 mCi given with 2 doses of rituximab followed by observation for 24 months;
141293|NCT00085735|Drug|cisplatin|Given IV
141294|NCT01641497|Radiation|3D conformational radiation|25 * 1.8 Gy in 5 weeks (=45 Gy)
141295|NCT01641497|Radiation|IMRT|25 * 1.8 Gy in 5 weeks (=45 Gy)
141296|NCT01641510|Drug|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
141297|NCT01641510|Drug|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
141298|NCT01641523|Device|CustomBone Service|customized hydroxyapatite cranial prosthesis
141299|NCT01641536|Genetic|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
141300|NCT01641549|Procedure|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
141301|NCT01643681|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
141302|NCT01643694|Behavioral|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
141303|NCT01643707|Behavioral|Evidence based guidelines and tools|Education, guidelines, tools
141304|NCT01643733|Device|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
141305|NCT01643746|Device|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
141306|NCT01643746|Device|Life Stent|
141307|NCT00085956|Drug|Placebo|
141593|NCT01675453|Drug|0.9% NaCl|
141594|NCT01675466|Procedure|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
141595|NCT01675466|Procedure|General anaesthesia|
141596|NCT01675466|Device|Laparoscopic instruments|
142303|NCT01674205|Biological|Vaccine placebo (Leibovitz-15 [L-15])|
142304|NCT01674205|Biological|Vaccine placebo (FluMist®)|
142305|NCT01674218|Drug|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
142561|NCT01674517|Drug|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
142562|NCT01674530|Drug|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
142563|NCT01674530|Drug|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
142564|NCT01674530|Drug|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
142565|NCT01674543|Other|Resistance Training|The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.
Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.
142566|NCT01674543|Other|Concurrent Training|The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.
A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.
142567|NCT01674543|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
142568|NCT01674556|Drug|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
142569|NCT01674569|Drug|X-82 oral|Dose escalation with oral X-82 until unacceptable toxicity develops
142570|NCT01674569|Drug|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
142571|NCT00088855|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
142098|NCT00089024|Procedure|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
142099|NCT01671228|Other|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
142100|NCT01671241|Device|Polyethylene wrap|
142101|NCT01671241|Device|Polyethylene wrap|
142102|NCT01671254|Dietary Supplement|FishOil|
142103|NCT01671254|Dietary Supplement|CBE75|
142104|NCT01671254|Dietary Supplement|CBE150|
142105|NCT01671254|Dietary Supplement|placebo|
142367|NCT01671774|Drug|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
142368|NCT01671787|Drug|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
142369|NCT01671787|Drug|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
142370|NCT01671800|Drug|Botulinum Type B|
142371|NCT01671800|Drug|Placebo|
142372|NCT01671813|Drug|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
142373|NCT01671839|Device|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
142374|NCT01671852|Drug|Mometasone furoate nasal spray|Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.
For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
142375|NCT01671852|Drug|Placebo|
142376|NCT00088582|Drug|Pasireotide (SOM230), Octreotide (Sandostatin)|
142377|NCT01671878|Other|Reference Glucose|
143042|NCT01662102|Drug|Rituximab|Group B: Response maintenance with 375 mg/m^2 of rituximab every 8 weeks for 24 months (12 infusions)
143043|NCT01662115|Drug|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
143044|NCT01662115|Other|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
143045|NCT00087594|Drug|ribavirin|1000/1200mg (< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
143046|NCT01662128|Drug|Xeloda|Xeloda as Adjuvant Therapy
143047|NCT01662154|Device|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
143048|NCT01662154|Device|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
142156|NCT01676558|Drug|131I-rituximab|
142157|NCT01676571|Drug|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
142158|NCT01676584|Drug|RO6811135|single ascending doses sc
142159|NCT01676584|Drug|placebo|single doses sc
142160|NCT01676597|Drug|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
142161|NCT01676597|Drug|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
142162|NCT01676623|Behavioral|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
142163|NCT01678911|Drug|Gralise|Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of "wash-out" before repeating the above procedure for the other arm of the study (placebo or medication).
142164|NCT01678924|Drug|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
142165|NCT01678924|Drug|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
141597|NCT01675479|Device|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
141598|NCT01675492|Device|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
141599|NCT01675518|Drug|ASP7991|oral
141600|NCT01675518|Drug|Placebo|oral
141601|NCT01675531|Drug|Targin|Single arm for Targin
141602|NCT01675544|Procedure|Electrocardiogram|EKG voltage changes between admission and discharge
141603|NCT00088894|Other|placebo|Given IV
141604|NCT01675544|Procedure|Six minute walk test|
141605|NCT01675557|Dietary Supplement|Vitamin D3|a single oral dose of vitamin D3
141606|NCT01675557|Dietary Supplement|Vitamin D2|a single oral dose of vitamin D2
141607|NCT01678183|Behavioral|Final Financial Incentive|One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
141608|NCT01678196|Behavioral|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
141609|NCT01678196|Other|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
141610|NCT01678209|Other|fMRI scans|Control Group: will receive initial evaluation, and 2 fMRI scans each 6-8 weeks apart
141611|NCT01678209|Drug|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks, and fMRI postscan.
141612|NCT01678209|Drug|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate for 6-8 weeks, and fMRI scan post treatment.
141613|NCT01678235|Drug|Insulin glulisine|
141614|NCT01678235|Drug|Insulin aspart|
141615|NCT01678287|Drug|ASP1941|oral
140711|NCT01642771|Drug|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
142572|NCT01674582|Other|MRI, neuropsychological evaluation, blood sampling|MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.
Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years.
142573|NCT01674595|Biological|AVANZ olea|Immunotherapy Olea europaea
142574|NCT01674621|Drug|BA058 Placebo|BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months
142575|NCT01674621|Drug|BA058 Transdermal (50 mcg)|BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months
142904|NCT01664936|Radiation|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
142905|NCT01664949|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
142906|NCT01664949|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
142907|NCT01664975|Drug|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
142908|NCT00087815|Drug|hyperbaric oxygen|
142909|NCT01664975|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
142910|NCT01667302|Drug|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
142911|NCT01667315|Drug|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
142912|NCT01667328|Procedure|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
142913|NCT01667328|Procedure|Standard of care|Control group will receive standard of care with no massage therapy
142914|NCT01667341|Biological|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
142915|NCT01667341|Biological|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
142378|NCT01671878|Other|Test Food 1 (Cereal)|
142379|NCT01671878|Other|Test Food 2 (Biscuit)|
142380|NCT01671891|Radiation|radiation therapy|45-55Gy
142381|NCT01671891|Drug|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
142382|NCT01671904|Drug|Bendamustine|90 mg/m^2 of bendamustine administered by intravenous infusion on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
142383|NCT01671904|Drug|Bendamustine|70 mg/m^2 of bendamustine administered by intravenous infusion on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
142384|NCT01671904|Drug|Obinutuzumab|100 mg of obinutuzumab administered by intravenous infusion on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
142385|NCT01671904|Drug|Rituximab|375 mg/m^2 of rituximab administered by intravenous infusion on Day 1 of Cycle 1 and 500 mg/m^2 administered on Day 1 of Cycles 2-6.
142386|NCT01674257|Other|USPIO (ferumoxytol)-enhanced MRI scan|Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.
142387|NCT01674257|Radiation|18f-Fluoride PET/CT scan|
142636|NCT01672398|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
142637|NCT01672424|Other|Ice Chips|11 ounces of ice chips given to the laboring parturient
142638|NCT00088647|Drug|MST-997|
142639|NCT01672424|Other|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
142640|NCT01672437|Other|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
142641|NCT01672450|Drug|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
142642|NCT01672463|Drug|OKN-007|Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.
Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.
142643|NCT01672476|Drug|Placebo|Placebo
142644|NCT01672476|Drug|Valsartan|Valsartan 80mg
142166|NCT01678937|Procedure|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
142167|NCT01678937|Procedure|Blood Draw from Control Subjects|Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G
142168|NCT01678937|Procedure|Blood Draw - CyA|Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G
142169|NCT00089037|Drug|methotrexate|
142170|NCT01678937|Procedure|Blood Draw - Tacrolimus|Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G
142450|NCT00088374|Drug|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
142451|NCT01669291|Drug|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
142452|NCT01669291|Drug|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
142453|NCT01669291|Drug|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
142454|NCT01669304|Drug|Verapamil|
142455|NCT01669304|Drug|Sertraline|
142456|NCT01669317|Other|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
142457|NCT01669317|Other|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
142458|NCT01669330|Procedure|Nissen fundoplication|Laparoscopic Nissen fundoplication
142459|NCT01671904|Drug|Venetoclax (ABT-199; GDC-0199)|Multiple doses of venetoclax administered orally once daily.
144221|NCT01661660|Other|observationnal|Observation during a physical exercise
144222|NCT01661673|Drug|EVP-0962|Arms: 1,2,3,4
144223|NCT01661673|Drug|Placebo|Arm 5
144224|NCT01661686|Device|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
144225|NCT01661686|Device|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
144226|NCT00087581|Drug|Cyclosporine or tacrolimus|Reduced
144227|NCT01661712|Device|Transcutaneous electrical stimulation (SOSATS device, MORGAN Innovation&Technology ltd., Petersfield, UK)|The SOSATS unit is a first generation sleep apnoea research device which is programmed and controlled by an external PC or laptop via a visual interface.
It stimulates the pharyngeal dilator muscles in order to reduce sleep apnoea.
144228|NCT01664598|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
144229|NCT01664611|Procedure|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
144230|NCT01664611|Procedure|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
144231|NCT01664624|Drug|Roflumilast|Roflumilast tablets
144232|NCT01664624|Drug|Alogliptin|Alogliptin tablets
143265|NCT01668225|Procedure|Blood test|Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.
Taking the follicular fluid during the oocyte collection day
143266|NCT01668264|Procedure|Echocardiograph|
143267|NCT01668264|Procedure|Magnetic Resonance Imaging (MRI)|
143268|NCT01668277|Drug|7.2% NaCl|
143269|NCT00088231|Drug|PTK 787 (vatalanib)|For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.
Starting dose: 250 mg by mouth every day for a 28 day cycle.
143270|NCT01668277|Drug|0.9% NaCl|
143271|NCT01668303|Behavioral|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
143964|NCT01666678|Drug|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
143965|NCT01666678|Drug|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
143966|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
143967|NCT01666691|Drug|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
143968|NCT01666691|Drug|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
143969|NCT01666704|Drug|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
143970|NCT01666704|Drug|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
143971|NCT01666704|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
143972|NCT01666730|Drug|metformin hydrochloride|Given PO
143973|NCT01666730|Drug|oxaliplatin|Given IV
143974|NCT00088075|Drug|Risperidone|
143975|NCT01666730|Drug|leucovorin calcium|Given IV
143976|NCT01666730|Drug|fluorouracil|Given IV
143977|NCT01666730|Other|laboratory biomarker analysis|Correlative studies
143978|NCT01666743|Drug|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
143979|NCT01666756|Dietary Supplement|Chinese herbal formulation PHY906|Given PO
143980|NCT01666756|Drug|sorafenib tosylate|Given PO
143981|NCT01666756|Other|laboratory biomarker analysis|Correlative studies
143982|NCT01666756|Other|pharmacological study|Correlative studies
143983|NCT01666769|Drug|Micafungin|4 mg/kg/day
143984|NCT01666769|Drug|Micafungin|8 mg/kg/day
144295|NCT01748851|Drug|XELOX|capecitabine 1000mg/m2 bid po D1-D14
144296|NCT01748851|Drug|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
145379|NCT01745614|Drug|Nimesulide 100 mg tablets|Test product
145380|NCT01745627|Device|755nm Alex laser|
145381|NCT01745640|Drug|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
145382|NCT00095225|Drug|Tarceva (erlotinib HCl)|
145383|NCT01745640|Drug|Dexamethasone|40mg (if patient <75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
144414|NCT01741610|Biological|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
144415|NCT00094861|Radiation|Radiotherapy|
144416|NCT01744002|Other|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
144417|NCT01744015|Behavioral|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
144418|NCT01744015|Other|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
144419|NCT01744028|Device|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
144420|NCT01744028|Other|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
144421|NCT00095121|Drug|Placebo (PLB)|Matching placebo
144422|NCT01744041|Behavioral|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
144423|NCT01744041|Other|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
145087|NCT01744977|Behavioral|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
145088|NCT01744990|Other|Oral food challenges to multiple nuts|
145089|NCT01745003|Procedure|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes—anode and cathode. We will be using this device to investigate fibromyalgia.
145090|NCT01745016|Dietary Supplement|Placebo|
145091|NCT01745016|Dietary Supplement|Beta-alanine|
145092|NCT01745029|Device|Motilis-3D-transit|
145093|NCT00095186|Drug|Recombinant Human Lactoferrin|
145436|NCT01743274|Procedure|OCT|Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.
OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution.
145437|NCT00095056|Drug|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
145438|NCT01743287|Drug|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
145439|NCT01743287|Drug|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
145440|NCT01743300|Drug|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
145441|NCT01743300|Drug|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
145442|NCT01743300|Other|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
145443|NCT01743300|Other|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
145444|NCT01743326|Procedure|Radio Frequency Denervation|
145445|NCT01743326|Procedure|Local Anesthesia|
144855|NCT01742299|Drug|STI571|STI571 (imatinib mesylate)
144856|NCT01742312|Radiation|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
144857|NCT01742312|Procedure|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
144858|NCT01742312|Other|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
144859|NCT01742325|Behavioral|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
144860|NCT01742338|Drug|Low Dose Corticosteroids|
144861|NCT01742338|Drug|High Dose Corticosteroids|
144862|NCT01742351|Behavioral|Guided internet-based cognitive behavior therapy|
144863|NCT00094965|Drug|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
144864|NCT01742364|Device|Bioject ID Pen|
144865|NCT01742364|Device|Needle and syringe|
144866|NCT01742377|Procedure|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
144867|NCT01742377|Procedure|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
144868|NCT01742377|Procedure|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
144869|NCT01742390|Drug|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
144870|NCT01742390|Drug|risperidone or paliperidone|
145158|NCT01750463|Other|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
145159|NCT01750476|Drug|Mirena|
145160|NCT00001857|Drug|BG9588|
145161|NCT00095693|Radiation|fludeoxyglucose F 18|Correlative studies
145162|NCT01750476|Drug|Oral contraception|
144634|NCT01746875|Drug|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
144635|NCT00095368|Drug|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
144636|NCT01746901|Drug|Placebo|Placebo solution + Placebo ALO-02 (intact)
144637|NCT01746901|Drug|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
144638|NCT01746901|Drug|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
144639|NCT01746901|Drug|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
144640|NCT01746901|Drug|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
144641|NCT01746901|Drug|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
144642|NCT01746927|Other|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
144643|NCT01746940|Drug|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
144644|NCT01746940|Drug|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
144645|NCT01749319|Drug|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
144646|NCT01749319|Drug|Intervenous baclofen|
144647|NCT01749332|Other|Perihepatic Phlebotomy|
144648|NCT01749358|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
144649|NCT00095628|Other|laboratory biomarker analysis|Correlative studies
144650|NCT01749358|Behavioral|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
144651|NCT01749371|Drug|Vitamin E (dl-Alpha Tocopheryl)|
144939|NCT01749592|Device|cochlear implant|Surgical implantation of a cochlear implant device
143751|NCT01663428|Other|Sup-ER Splint|
143752|NCT01663428|Other|Currently accepted treatment|
143753|NCT01663441|Drug|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
143754|NCT01663441|Drug|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
143755|NCT01663441|Drug|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
143756|NCT01663441|Drug|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
144078|NCT01666860|Procedure|Anterior Lumbar Interbody Fusion procedure|
144079|NCT01666873|Procedure|patients that undergo a total knee prosthesis|
144080|NCT01666886|Device|Mandibular Advancement Device (MAD)|
144081|NCT00001647|Procedure|White blood cell infusion|
144082|NCT00088088|Drug|Carboplatin|
144083|NCT01666899|Procedure|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
144084|NCT01666912|Drug|Contraceptive implant|
144085|NCT01666925|Biological|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu
144086|NCT01666925|Biological|Rabies vaccine|2 x 2.5IU Verorab
144087|NCT01666938|Other|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
144088|NCT01666938|Other|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
144089|NCT01666951|Drug|LCP-Tacro tablets|Tacrolimus
144090|NCT01666951|Drug|Prograf|Tacrolimus
144091|NCT01666964|Other|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
144092|NCT01666977|Drug|Arm A|Placebo + Pemetrexed + Carboplatin
144093|NCT00088088|Drug|STA 4783|
143509|NCT01666015|Other|EXERCISE (EX)|This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.
The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games).
143510|NCT01666015|Other|Standard Care|This group will be under standard care without any EX intervention.
143511|NCT01666028|Device|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
143512|NCT01666028|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
143513|NCT01666041|Drug|placebo|
143514|NCT01666041|Drug|fenofibrate/omega|
143515|NCT00087958|Drug|XRP9881|
143516|NCT01666041|Drug|fenofibrate|
143517|NCT01666054|Other|PSV|Pressure Support Ventilation will be used until patient is extubated
143518|NCT01666054|Other|PAV|Proportional Assist Ventilation will be used until patient is extubated.
143519|NCT01666067|Drug|placebo|
143818|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
143819|NCT01658202|Drug|V0116 transdermal patch (Test treatment )|
143820|NCT01660685|Behavioral|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
143821|NCT01660698|Dietary Supplement|Maltodextrin|maltodextrin powder
143822|NCT01660698|Dietary Supplement|Probiotic|probiotic blended in maltodextrin powder
143823|NCT01660711|Drug|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
143824|NCT01660711|Drug|Leucovorin|400 mg/m2 by IV infusion over 2 hours
143825|NCT01660711|Drug|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
143272|NCT01668303|Behavioral|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
143273|NCT01668316|Behavioral|Weight loss|Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.
Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.
Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.
Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work.
143274|NCT01659671|Procedure|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
143275|NCT01659684|Biological|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
143276|NCT00087425|Drug|bryostatin 1|
143277|NCT01659697|Behavioral|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
143278|NCT01659723|Drug|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
143279|NCT01659736|Device|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
143280|NCT01659749|Behavioral|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
143579|NCT01663233|Drug|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
143580|NCT01663233|Drug|Placebo|Matching placebo to LCZ696
143581|NCT01663246|Procedure|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
144297|NCT01748864|Drug|Etarfolatide (EC20)|
144298|NCT01748877|Drug|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
144299|NCT01748877|Drug|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
144300|NCT01741311|Behavioral|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
144301|NCT01741311|Behavioral|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
144302|NCT01741324|Dietary Supplement|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
144303|NCT01741324|Dietary Supplement|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
144304|NCT01741337|Procedure|Adaptive servo-ventilation post-operative treatment for 6 months|
144305|NCT00094835|Drug|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
144306|NCT01741350|Behavioral|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
144307|NCT01741350|Behavioral|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
144308|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
144309|NCT01741363|Other|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
144310|NCT01741363|Other|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
144311|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
144312|NCT01741363|Other|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
144313|NCT01741376|Drug|Progesterone|Progesterone 200 mg twice daily
144314|NCT01741376|Drug|Placebo|
144424|NCT01744054|Device|PET/MR|
144425|NCT01744067|Drug|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
144426|NCT01744067|Drug|Placebo|Placebo capsules 3 times a day (oral administration)
144427|NCT01744080|Other|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
144428|NCT01744080|Other|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
144429|NCT01744093|Drug|Doxycycline|100 mg BID for six months
144713|NCT01744509|Device|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
144714|NCT01746940|Drug|Placebo Topical Solution|Placebo Topical Solution
144715|NCT00095381|Drug|forodesine hydrochloride (BCX-1777)|
144716|NCT01746979|Drug|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
144717|NCT01746979|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
144718|NCT01746979|Drug|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
144719|NCT01746992|Drug|Cyclophosphamide 750mg/m2|day 1 in both arms
144720|NCT01746992|Drug|Vincristine 1.4mg/m2|day 1
144721|NCT01746992|Drug|Doxorubicin 50mg/m2|day 1
144722|NCT01746992|Drug|prednisone 60mg/m2|day1-day5
144723|NCT01746992|Drug|ifosfamide 2000mg/m2|day 22-day 24
144724|NCT01746992|Drug|pirarubicin 50mg/m2|day 1
144725|NCT01746992|Drug|pirarubicin 25mg/m2|day 22
144726|NCT00095394|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
145446|NCT01743339|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
145447|NCT01743339|Behavioral|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
145448|NCT00095056|Drug|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
145449|NCT01743365|Drug|Cisplatin-5FU-Afatinib|
145450|NCT01743378|Procedure|TAP Block Ropivacaine 0,75 %|
145451|NCT01743378|Procedure|TAP Block Saline 0,9 %|
145452|NCT01743391|Procedure|Office-hysteroscopy with biopsy|
145453|NCT01743404|Dietary Supplement|Inflaminat|
144494|NCT01741701|Drug|Oxaloacetate (OAA)|
144495|NCT01741701|Drug|Placebo|
144496|NCT01741714|Other|Sham chiropractic manipulative therapy|Sham manipulation
144497|NCT01741714|Other|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
144498|NCT01741727|Drug|ABT-414|ABT-414 will be administered by intravenous infusion.
144499|NCT01741753|Drug|BKM120|Orally, every morning
144500|NCT01741753|Drug|Abiraterone|Orally, 1000 mg, every morning
144501|NCT01741753|Drug|Prednisone|Orally, 5 mg, every morning
144502|NCT01741766|Other|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
144503|NCT00094861|Drug|Carboplatin|
145163|NCT01742715|Other|PEEP by Best oxygenation|Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.
Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
145164|NCT00001835|Drug|Oxaliplatin|
145165|NCT00095017|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
145166|NCT01742715|Other|PEEP by Best Compliance|In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.
Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed.
145167|NCT01742715|Other|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
145168|NCT01742741|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
145169|NCT01742754|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
145170|NCT01742767|Drug|Cisplatinum|
145171|NCT01742767|Drug|Pemetrexed|
145172|NCT01742780|Procedure|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
145173|NCT01742793|Drug|lenalidomide (Revlimid) and romidepsin (Istodax)|
145174|NCT01742806|Device|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
145511|NCT01740908|Other|Hyperbaric Oxygen Treatment|Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.
All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days.
145512|NCT01740921|Drug|Liraglutide|Administered once daily
145513|NCT01740921|Other|diet|reduction of caloric intake to promote weight loss
144940|NCT01749605|Drug|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
144941|NCT01749605|Drug|ciprofloxacin 250 mg BID x 3 days|
144942|NCT00095641|Procedure|adjuvant therapy|
144943|NCT01749618|Behavioral|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
144944|NCT01749657|Device|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
144945|NCT01749709|Behavioral|Music listening|
144946|NCT01749722|Device|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
144947|NCT01749735|Device|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
144948|NCT01749735|Device|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
144949|NCT01749735|Device|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
144950|NCT01749748|Procedure|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
144951|NCT01749761|Other|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
144952|NCT01749761|Other|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
144953|NCT00001854|Drug|Ribavirin|
144954|NCT00095641|Procedure|chemotherapy|
144955|NCT01742468|Dietary Supplement|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
144956|NCT01742468|Dietary Supplement|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
144094|NCT01666977|Drug|Arm B|AMG 386 Dose 1 + Pemetrexed + Carboplatin
144095|NCT01666977|Drug|Arm C|AMG 386 dose 2 + Carboplatin + Pemetrexed
144096|NCT01666990|Drug|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
144097|NCT01658514|Drug|Met DR|metformin delayed-release tablets
144098|NCT01658514|Drug|Met XR|metformin extended-release tablets
144099|NCT01658514|Drug|Placebo|
144100|NCT01658527|Drug|Orteronel|Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
Upon progression, patient may stay on study medication until the initiation of a new therapy
143129|NCT01662219|Other|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
143130|NCT01662232|Dietary Supplement|Green tea beverage|
143131|NCT01662232|Dietary Supplement|Green tea extract|
143132|NCT01662232|Dietary Supplement|EGCG|
143133|NCT01662232|Other|Placebo|
143134|NCT01662258|Device|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
143135|NCT01662284|Drug|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
143136|NCT01662297|Drug|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
143137|NCT00087607|Drug|PEG-Intron|1.5 micrograms/kg sc weekly
143138|NCT01662297|Drug|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
143139|NCT01662310|Drug|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
143140|NCT01662310|Drug|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
143141|NCT01662323|Behavioral|GP's treating HF according the dutch guidelines|
143826|NCT01660711|Drug|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
143827|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
143828|NCT01660724|Procedure|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
143829|NCT01660724|Procedure|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
143830|NCT01660750|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
143831|NCT01660750|Drug|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
143832|NCT01660750|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
143833|NCT01660763|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
143834|NCT01660763|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
143835|NCT01660789|Behavioral|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
143836|NCT01660802|Drug|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
143837|NCT01660802|Other|Sham|Sham administered in the study eye on Day 1.
143838|NCT00087516|Drug|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
144159|NCT01664585|Behavioral|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
144160|NCT01664585|Behavioral|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
144161|NCT01666990|Drug|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
144162|NCT01667029|Drug|Sulfasalazine|
143582|NCT01663259|Drug|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
143583|NCT01666080|Drug|Busulfan|0.4 mg/kg (0.5 mg/kg if <4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
143584|NCT01666080|Drug|Fludarabine|40 mg/m^2 intravenously (IV) over 1 hour on days -6 through -2.
143585|NCT01666080|Radiation|Total body irradiation|200 cGy on Day -1
143586|NCT01666080|Biological|Stem cell transplant|stem cell infusion on day 0
143587|NCT00087984|Biological|MB-002|Dendritic Cell Immunotherapy
143588|NCT01666080|Drug|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
143589|NCT01666093|Procedure|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
143590|NCT01666119|Drug|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
143591|NCT01666132|Other|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
143592|NCT01666132|Other|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
143593|NCT01666132|Other|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
143594|NCT01666145|Device|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
143897|NCT01658280|Device|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
143898|NCT01658293|Behavioral|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
143899|NCT01658293|Behavioral|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
144004|NCT01658488|Other|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
144005|NCT01658488|Other|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
144006|NCT01658501|Drug|50 mg PB1023|
144007|NCT01658501|Drug|70 mg PB1023|
144008|NCT01658501|Drug|100 mg PB1023|
144315|NCT01741389|Drug|Melatonin ("Circadin")|
144316|NCT00094848|Drug|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
144317|NCT01741402|Device|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
144318|NCT01741402|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
144319|NCT01741415|Behavioral|Skills for Improving Distress Intolerance|
144320|NCT01741428|Behavioral|Intervention (INT1)|The course Program at the Feiring Heart Clinic will:
Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)
144321|NCT01741441|Procedure|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
144322|NCT01743833|Other|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
144323|NCT01743833|Other|Scapular High Velocity, Low Amplitude Thrust Maneuver|
144324|NCT01743859|Drug|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
144325|NCT01743859|Drug|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
144326|NCT01743859|Other|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
144727|NCT01746992|Drug|Etoposide phosphate 100mg/m2|day 22-day 24
144728|NCT01746992|Drug|methotrexate 1500mg/m2|day 43
144729|NCT01747018|Biological|Platelet-rich Plasma|
144730|NCT01747031|Device|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization——A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
144731|NCT01747044|Drug|Milnacipran|100mg/day
144732|NCT01747044|Drug|Placebo|
144996|NCT01744951|Behavioral|ADAPT|ADAPT consists of the following modules/sessions:
Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)
144997|NCT01744964|Drug|Apomorphine|1.5 mg apomorphine
144998|NCT01747447|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
144999|NCT01747447|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
145000|NCT01747486|Biological|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
145001|NCT01747499|Drug|Azacitidine|
145002|NCT01747512|Drug|C-PERT|Patients with thyroid and Head and Neck cancer
145003|NCT01747512|Drug|G-PERT|Patients with thyroid and Head and Neck cancer
145004|NCT01747525|Device|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
145005|NCT01747538|Drug|Placebo|Solution for subcutaneous injection
145006|NCT01747538|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
145007|NCT00001849|Drug|Pentetreotide|
145008|NCT00095433|Drug|rhuFab V2 (ranibizumab)|
145009|NCT01747538|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
145010|NCT01747551|Drug|Oxaliplatin|
144504|NCT01741779|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
144505|NCT01741779|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
144506|NCT01741779|Other|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
144507|NCT01744145|Other|Interventional 40-60|This group will receive the intervention aged 40-60
144508|NCT01744145|Other|Interventional 60 and above|This group will receive the intervention aged 60 and above.
144509|NCT01744158|Other|No intervention applicable|Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:
differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)
measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording
measurement of severity of spasticity using the modified Ashworth score
description of presence of chorea or athetosis
classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)
classification of fine motor abilities using the manual ability classification system (MACS)
collection of demographic data and associated medical history
144510|NCT01744171|Biological|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
144511|NCT01744171|Other|Laboratory Biomarker Analysis|Correlative studies
144792|NCT00095147|Drug|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
144793|NCT01744548|Behavioral|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
144794|NCT01744561|Behavioral|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
144795|NCT01744574|Other|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
145514|NCT00094809|Drug|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
145515|NCT01740921|Drug|Aspirin|300mg of Aspirin per day
145516|NCT01740934|Other|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
145517|NCT01740934|Other|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
145518|NCT01740947|Drug|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
145519|NCT01740960|Drug|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
145520|NCT01743430|Other|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
145521|NCT01743443|Other|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
145522|NCT01743456|Other|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
145523|NCT00095069|Drug|MK0928, gaboxadol / Duration of Treatment - 1 year|
145524|NCT01743469|Drug|Tasquinimod|
145525|NCT01743482|Drug|Pazopanib|
145526|NCT01743495|Behavioral|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
145527|NCT01743508|Procedure|Misoprostol treatment by midwife|Misoprostol treatment by midwife
145528|NCT01743521|Drug|TPV/PEG-IFN/RBV|Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.
Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg).
Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.
144579|NCT01749293|Drug|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
144580|NCT01749306|Biological|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
144957|NCT01742481|Behavioral|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
145233|NCT01740414|Drug|MN-166 (formerly AV411)|in one study arm, 50mg MN-166 BID are administered daily for 20 days
145234|NCT01740414|Drug|placebo|In the placebo arm, the patients receive placebo for 20 days
145235|NCT01740427|Drug|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
145236|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
145237|NCT01740427|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
145238|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
145239|NCT01740440|Device|BMR Face|BMR Face used in accordance with manufacturer IFU
145240|NCT01740453|Drug|ropivacaine 2 mg/ml|single
145241|NCT00001832|Drug|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
145242|NCT00094770|Drug|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
145243|NCT01740479|Procedure|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
145244|NCT01740492|Drug|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
145245|NCT01740492|Drug|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
145246|NCT01740492|Other|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
145247|NCT01740505|Behavioral|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
145248|NCT01740505|Behavioral|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
145249|NCT01740505|Behavioral|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
145250|NCT01740518|Drug|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
143142|NCT01662349|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
143143|NCT01662362|Device|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
143144|NCT01662375|Other|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
143145|NCT01662388|Device|Separation ring|Separation ring placed along with automatrix band
143146|NCT00087815|Procedure|quality-of-life assessment|
143147|NCT01665274|Drug|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
143148|NCT01665274|Procedure|D2 resection|D2 resection
143149|NCT01665326|Other|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
143439|NCT01668030|Drug|Collagenase versus Bacitracin|Person is their own control. Ointments randomly applied to either side of face.
143440|NCT01668043|Drug|Antibody UB-421|UB-421 is administered by intravenous infusion
143441|NCT01668056|Drug|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
143442|NCT01668056|Procedure|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
143443|NCT01668056|Other|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
143444|NCT00088218|Drug|Ara-C|20 mg/m^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
143445|NCT01668069|Drug|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
143446|NCT01668069|Drug|Doxylamine and pyridoxine|Pyridoxine 25mg and doxylamine 12.5mg to be taken orally every 8 hours for 5 days.
143447|NCT01668082|Procedure|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
144163|NCT01667029|Drug|placebo|
144164|NCT01667068|Other|Comprehensive non invasive cardiovascular examination|Anamnesis with the participian
File recherche,Physical examination
Documentation of the carciovascular and antiretroviral medical therapy
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
Measuring of the arterial media thickness
Exercise Montreal Cognitive Assesment test
Exercise the Grooved Pegboard test
Blood collection
Questionnaire to quality of life and health economics
144165|NCT01667081|Drug|Grazoprevir|Grazoprevir was not administered to participants in the course of this study.
144166|NCT01667094|Drug|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
144167|NCT01667094|Drug|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
144168|NCT00088101|Drug|STA-5312|
144169|NCT01667094|Drug|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
144170|NCT01667094|Drug|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
144171|NCT01667094|Drug|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
144172|NCT01667094|Drug|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
144173|NCT01667094|Drug|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
144174|NCT01667094|Drug|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
144175|NCT01667094|Drug|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
144176|NCT01667094|Drug|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
144177|NCT01667107|Drug|Posaconazole|
143203|NCT01659645|Drug|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
143204|NCT01659658|Drug|IXAZOMIB|IXAZOMIB capsules
143205|NCT01659658|Drug|Dexamethasone|Dexamethasone tablets
143206|NCT01659658|Drug|Melphalan|Melphalan tablets
143207|NCT01659658|Drug|Cyclophosphamide|Cyclophosphamide tablets
143208|NCT01659658|Drug|Thalidomide|Thalidomide capsules
143900|NCT00087295|Drug|Depsipeptide|Depsipeptide wil be given 13 mg/m^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
143901|NCT01658306|Procedure|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
143902|NCT01658306|Procedure|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
143903|NCT01658319|Drug|fludarabine phosphate|Given IV
143904|NCT01658319|Drug|methoxyamine|Given IV
143905|NCT01658319|Other|laboratory biomarker analysis|Correlative studies
143906|NCT01658319|Other|pharmacological study|Correlative studies
143907|NCT01658319|Genetic|western blotting|Correlative studies
143908|NCT01658319|Other|mass spectrometry|Correlative studies
143909|NCT01660867|Drug|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
143910|NCT01660893|Drug|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
143911|NCT01660893|Drug|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
143912|NCT01660893|Drug|Placebo|3 unilateral intranasal sprays per dose
143913|NCT00001644|Drug|Lamivudine|
143914|NCT00087529|Drug|placebo|Intravenous repeating dose
143915|NCT01660906|Drug|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
143916|NCT01660919|Drug|placebo|
143917|NCT01660919|Drug|rosuvastatin|
144233|NCT01664624|Drug|Exenatide|Exenatide solution
144234|NCT00087763|Drug|Macugen ™ (pegaptanib sodium injection)|
144235|NCT01664624|Drug|Placebo to roflumilast|Placebo-matching roflumilast tablets
144327|NCT01743872|Procedure|iOCT|Arterial access will performed by the operating surgeon. An aortic and infrainguinal angiogram using the standard method of intravenous iodinated contrast under digital subtraction fluoroscopy will be conducted in the usual manner according to the vascular surgeon. A 54 mm section of Superficial Femoral Artery will be chosen for study imaging. An intervention sheath or injection catheter will be placed just proximal to the area of interest. An 0.014" wire will be passed distal to the area of interest. The patient will then undergo OCT of this 54mm section with each of the three mediums below using a continuous flushing method through injection catheter. All OCT imaging will be collected at a rate of 25mm/sec. In the event of a subsequent procedure, OCT imaging will again be performed.
144328|NCT01743885|Drug|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
144329|NCT00095095|Device|Lumbar Interbody Fusion|
144330|NCT01743885|Drug|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
144331|NCT01743898|Drug|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
144332|NCT01743898|Other|no anticoagulation|
143355|NCT01668693|Other|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
143356|NCT01668719|Biological|elotuzumab|Given IV
143357|NCT01668719|Drug|bortezomib|Given subcutaneously or IV
143358|NCT01659866|Drug|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
143359|NCT01659866|Drug|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
143360|NCT00087451|Drug|AP23573|ridaforolimus
143361|NCT01659866|Drug|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
143362|NCT01659866|Drug|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
143363|NCT01659866|Drug|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
143364|NCT01659866|Drug|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
143365|NCT01659866|Drug|aztreonam|500 mg intramuscularly 2 hours before the procedure
143366|NCT01659866|Drug|imipenem|500 mg intramuscularly 2 hours before the procedure
143367|NCT01659866|Drug|ceftriaxone|2000 mg intravenously 1 hour before the procedure
143368|NCT01659866|Drug|gentamicin|2 mg/kg intravenously 1 hour before the procedure
145011|NCT01747551|Drug|Folinic Acid|
145012|NCT01747551|Drug|5-Fluorouracil|
145013|NCT01747551|Drug|Ziv-aflibercept|
145014|NCT01747551|Drug|Ziv-aflibercept Placebo|
145015|NCT01747564|Drug|YM178 (mirabegron)|oral
145016|NCT01747577|Drug|Solifenacin Succinate|Oral
145017|NCT01747577|Drug|Placebo|Oral
145018|NCT01747590|Drug|Zolpidem|
145019|NCT00095446|Drug|insulin aspart|
145020|NCT01747590|Drug|Alprazolam|
145384|NCT01745653|Device|Low level laser therapy|
145385|NCT01745653|Procedure|sham procedure|
145386|NCT01745666|Other|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
145387|NCT01745666|Other|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
145388|NCT01745679|Drug|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
145389|NCT01745692|Device|Mechanical thrombectomy|
145390|NCT01745692|Drug|Intravenous rtPA|All patients receive IV alteplase
145391|NCT01745705|Other|Cervical Spine Manipulation|
145392|NCT01745705|Other|Manual Contact|
145393|NCT00095238|Drug|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
145394|NCT01745718|Other|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
145395|NCT01745731|Other|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
144796|NCT01744574|Drug|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
144797|NCT01744574|Other|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
144798|NCT01744587|Other|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
144799|NCT01744587|Dietary Supplement|Placebo|Placebo qd (2# bid) for 3 years
144800|NCT01744600|Behavioral|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
144801|NCT01744626|Drug|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
144802|NCT01744626|Drug|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
144803|NCT00095147|Drug|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
144804|NCT01744639|Behavioral|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
144805|NCT01744652|Drug|Crizotinib|Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.
Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group.
144806|NCT01747070|Other|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
144807|NCT01747070|Other|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
144808|NCT00095394|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
145094|NCT01745042|Other|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
145095|NCT01745055|Drug|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
145096|NCT01745055|Drug|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
145097|NCT01745068|Other|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
144581|NCT01749306|Other|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
144582|NCT01741792|Drug|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
144583|NCT01741805|Other|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
144584|NCT01741818|Other|Measuring IVC collapsibility index by bedside ultrasonography|
144585|NCT01741831|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
144586|NCT01741844|Drug|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
144587|NCT01741857|Biological|human umbilical cord derived MSC transplantation for SLE|
144588|NCT01741870|Dietary Supplement|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
144589|NCT00094874|Procedure|Acupuncture|
144590|NCT01741883|Behavioral|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
144591|NCT01741883|Behavioral|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
144592|NCT01741896|Procedure|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
144593|NCT01741909|Behavioral|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
144871|NCT01742403|Radiation|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
144872|NCT01742416|Procedure|Ultrasound|Arterial cannulation facilitated by ultrasound.
145251|NCT01742910|Procedure|intraocular lens implantation|
145252|NCT01742923|Behavioral|Complex tailored intervention|
145253|NCT01742923|Behavioral|Usual care|
145254|NCT01742936|Device|CoaguChek|
145596|NCT01740986|Drug|SA09012 High dose|Tablet, b.i.d
145597|NCT01740986|Drug|Placebo|Tablet, b.i.d
145598|NCT01740999|Procedure|silicone arthroplasty|silicone arthroplasty
145599|NCT00094822|Other|PI Discretion|PI Discretion
145600|NCT01740999|Procedure|arthrodesis|arthrodesis
145601|NCT01741012|Drug|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
145602|NCT01741025|Device|iFuse Implant System|Placement of iFuse implant system via surgery
145603|NCT01741025|Other|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
145604|NCT01741038|Biological|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
145605|NCT01741038|Procedure|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
145606|NCT01741038|Other|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
145607|NCT01741051|Device|HEPA Filter|
145608|NCT01741077|Dietary Supplement|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
145609|NCT01741090|Biological|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
145610|NCT00094835|Biological|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
145611|NCT01741103|Drug|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
143448|NCT01668095|Other|Laboratory Biomarker Analysis|Correlative studies
143449|NCT01668121|Drug|Symbicort Turbohaler|
143450|NCT01668121|Drug|Budesonide/formoterol Easyhaler|
143451|NCT01668134|Radiation|Stereotactic radiation|
143452|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
143453|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
143454|NCT01659996|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
143455|NCT01660009|Other|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
143456|NCT00001644|Drug|Zidovudine|
143457|NCT00087464|Drug|Tenofovir disoproxil fumarate|
143458|NCT01660022|Drug|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
143757|NCT01663454|Behavioral|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
143758|NCT01663467|Drug|Ginkgo biloba|
143759|NCT00087672|Drug|CC-5013|10 mg orally (2 capsules) daily
143760|NCT01663467|Behavioral|modified tinnitus retraining therapy (TRT)|
143761|NCT01663493|Procedure|Cytologist present|
143762|NCT01663519|Other|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
143763|NCT01663519|Other|Prefabricated insoles|Prefabricated insoles
143764|NCT01663519|Other|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
143765|NCT01663532|Drug|Aripiprazole IM Depot|
143766|NCT01663532|Drug|Placebo|Matching Placebo
143209|NCT01659658|Drug|Lenalidomide|Lenalidomide capsules
143210|NCT01662388|Device|automatrix band|band placed with a tightening device
143211|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
143212|NCT00087607|Drug|Rebetol|1000/1200mg/day po
143213|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
143214|NCT01662414|Dietary Supplement|Whey protein|1 sachect (10 g) 2times/ day
143215|NCT01662414|Dietary Supplement|Soy protein|1 sachect (10g) 2times/day
143216|NCT01662427|Other|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
143217|NCT01662440|Biological|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
143218|NCT01662440|Biological|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
143219|NCT01662440|Other|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
143220|NCT01662466|Drug|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
143221|NCT01662466|Dietary Supplement|DHEA|DHEA 25mg tid
143222|NCT01662466|Drug|Placebo|Carrier cream without added testosterone in the identical type of pump
143223|NCT00087607|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
143224|NCT01662492|Biological|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
143225|NCT01662492|Biological|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
143520|NCT01666067|Drug|vytorin|
143521|NCT01666067|Drug|simvastatin|
143522|NCT01668342|Behavioral|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
143523|NCT01668355|Other|Patient Aligned Care Team (PACT)|A integrated healthcare model to coordinate and address physical health needs. The PACT model to be implemented here will be specially designed for individuals with serious mental illness.
144236|NCT01664624|Drug|Placebo to alogliptin|Placebo-matching alogliptin tablets
144237|NCT01664637|Drug|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
144238|NCT01664637|Drug|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
144239|NCT01664650|Dietary Supplement|Genistein|
144240|NCT01664650|Dietary Supplement|Placebo|
144241|NCT01664663|Radiation|Standard radiochemotherapy to 68 Gy|
144242|NCT01664663|Radiation|Dose escalated radiochemotherapy up to 84 Gy|
144243|NCT01664676|Drug|Liraglutide|
144244|NCT01664676|Drug|Placebo-liraglutide|
144245|NCT00001644|Procedure|Leukapheresis|
144246|NCT00087776|Drug|Chemotherapy|
144247|NCT01664689|Procedure|Microcoaxial Phacoemulsification|
144248|NCT01664702|Dietary Supplement|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
144249|NCT01664702|Dietary Supplement|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
144250|NCT01664715|Behavioral|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
144251|NCT01664715|Behavioral|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
144252|NCT01664715|Behavioral|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
144253|NCT01664728|Drug|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
144254|NCT01664728|Drug|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
144255|NCT01664741|Drug|Nicotine patch - transdermal|
144256|NCT01664741|Drug|placebo|
143281|NCT01659762|Biological|autologous mesenchymal stromal cell|
143683|NCT01666236|Other|Triple Therapy|The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.
After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections
143684|NCT01666249|Biological|Immunoglobulin Anti-RhD|KamRho-D (Immunoglobulin Anti-RhD): single dose (300mcg/2mL), via intramuscular, up to 72h after delivery.
143685|NCT01666249|Biological|Rhophylac|Single dose (300 mcg/2 mL), via intramuscular, up to 72h after delivery.
143686|NCT01666262|Biological|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
143687|NCT01666262|Other|Placebo:Stabilizer|5% sucrose
143688|NCT01666301|Drug|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
143689|NCT01666314|Drug|orteronel 200mg/300mg|Patients will be randomized to receive orteronel 200 mg BID or orteronel 300 mg BID
Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg BID continuously throughout the study.
143690|NCT01666314|Drug|orteronel 200mg/400mg|Patients will be randomized to receive orteronel 200 mg BID or orteronel 400 mg BID.
Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg BID continuously throughout the study.
143691|NCT00088010|Drug|Placebo|oral, tablet, once a day for 36 months
143692|NCT01666314|Drug|Placebo|Patients will be randomized to receive placebo (Cycle 1 only).
Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg BID continuously throughout the study.
144009|NCT01658501|Drug|Placebo (0.9% Sodium Chloride)|
144010|NCT01658501|Drug|Victoza®|
144011|NCT00001637|Procedure|Blood cell transplantation|
144012|NCT00087334|Drug|oxaliplatin|
144013|NCT01658501|Other|Diet and Exercise|
144014|NCT01658501|Drug|Metformin|
144015|NCT01658501|Drug|Sulfonylurea|
144016|NCT01658501|Drug|Metformin and Sulfonylurea|
145396|NCT01745744|Other|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
145397|NCT01745757|Drug|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
145398|NCT01745757|Drug|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
145399|NCT01748149|Drug|Vemurafenib|Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg BID. Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.
Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery.
145400|NCT01748162|Drug|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
145401|NCT00095511|Drug|aripiprazole|
144430|NCT01744093|Drug|Placebo (sugar pill)|100 mg BID for six months
144431|NCT01744106|Drug|pseudoephedrine hydrochloride 30 mg tablets|
144432|NCT00095121|Drug|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
144433|NCT01744106|Drug|Placebo tablets|
144434|NCT01744119|Device|Vascutek Anaconda™ Stent Graft System|
144435|NCT01744132|Behavioral|Aim 3: Contract|
144436|NCT01746472|Behavioral|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
144437|NCT01746472|Behavioral|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
144438|NCT00095316|Drug|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
144439|NCT01746472|Behavioral|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
144440|NCT01746472|Behavioral|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
144441|NCT01746485|Drug|UT-15C|
145098|NCT01745081|Drug|20% mannitol bolus administration|
145099|NCT01745081|Drug|Hypertonic saline 3% bolus administration|
145100|NCT01745094|Drug|mirabegron|oral
145101|NCT01745094|Drug|solifenacin|oral
145102|NCT01745107|Radiation|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
145103|NCT01745120|Genetic|LentiGlobin® BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin® BB305 lentiviral vector.
145104|NCT00095199|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
145105|NCT01745133|Drug|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
145106|NCT01745133|Drug|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
145107|NCT01745133|Drug|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
145108|NCT01745146|Behavioral|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
145109|NCT01745146|Behavioral|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
145110|NCT01745159|Drug|tacrolimus|
145111|NCT01747642|Drug|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
145112|NCT00095459|Drug|Bevacizumab|
145113|NCT01747668|Dietary Supplement|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
145454|NCT01743404|Drug|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
145455|NCT01743417|Behavioral|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
145456|NCT01745770|Drug|Mesalazine - TID 1000 mg|
144873|NCT01742416|Procedure|Palpation Method|Arterial cannulation by palpation method.
144874|NCT00094978|Drug|Depsipeptide|
144875|NCT01742429|Drug|Proton pump inhibitor|
144876|NCT01742429|Drug|Bismuth subsalicylate|
144877|NCT01742429|Drug|Metronidazole|antibiotic
144878|NCT01742429|Drug|Tetracycline|antibiotic
144879|NCT01742429|Drug|Amoxicillin|antibiotic
144880|NCT01742429|Drug|Levofloxacin|antibiotic
144881|NCT01744652|Drug|Dasatinib|Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.
Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle.
144882|NCT01744665|Drug|AMN107|Nilotinib will be provided by the sponsor as the study drug. Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
144883|NCT01744678|Behavioral|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
144884|NCT01744678|Behavioral|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
144885|NCT01744691|Drug|PCI-32765|All subjects will receive PCI-32765 420 mg (3 x 140-mg capsules) orally once daily.
144886|NCT01744704|Drug|rhNGF 0.5 µg/mL Sentinel|
144887|NCT01744704|Drug|rhNGF 5 µg/mL Sentinel|
144888|NCT01744704|Drug|rhNGF 20 µg/mL Sentinel|
144889|NCT00095160|Drug|852A|
144890|NCT01744704|Drug|rhNGF 20 µg/mL Part A|
144891|NCT01744704|Drug|rhNGF 60 µg/mL Part A|
144892|NCT01744704|Drug|rhNGF 180 µg/mL Part A|
144893|NCT01744704|Drug|rhNGF 20 µg/mL Part B|
144894|NCT01744704|Drug|rhNGF 20 µg/mL Part B cohort 0M|
144895|NCT01744704|Drug|rhNGF 60 µg/mL Part B|
145612|NCT01741103|Drug|Placebo|Take one by mouth daily for 12 weeks
145613|NCT01741116|Drug|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
145614|NCT01741129|Device|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
145615|NCT01741129|Device|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
145616|NCT01741142|Drug|ABT-436|Subjects receiving ABT-436
144353|NCT01746381|Device|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
144354|NCT01746394|Behavioral|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
144355|NCT01746394|Behavioral|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
144356|NCT01746420|Drug|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
144357|NCT01746433|Other|Sitting up|The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.
The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.
The investigator then gives instructions on how to use the randomized device (correct hand placement).
The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient.
144358|NCT01746446|Other|Care team|
144359|NCT01746459|Other|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
144360|NCT01746459|Other|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
143767|NCT01663558|Drug|imiquimod|
143768|NCT01663558|Procedure|ablative|
143769|NCT01663584|Procedure|Blood draw|
143770|NCT00087685|Drug|RAD001|10 mg by mouth Daily
143771|NCT01663610|Behavioral|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
143772|NCT01663623|Biological|Placebo|Placebo
143773|NCT01663623|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg
143774|NCT01663623|Drug|Azathioprine|Azathioprine
143775|NCT01663649|Behavioral|Deprexis|web-based treatment program for depression
143776|NCT01663649|Behavioral|Wait-list|the wait-list group receives Deprexis after 6 month
143777|NCT01666405|Device|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
143778|NCT00088023|Drug|PT-523 for Injection|
143779|NCT01666418|Drug|Pazopanib/Paclitaxel|
143780|NCT01666431|Drug|Lapatinib|
144101|NCT01658527|Drug|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
144102|NCT01658553|Drug|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
144103|NCT00087347|Drug|ferumoxytol|
144104|NCT01658579|Drug|HOE901-U300 (new formulation of insulin glargine)|
144105|NCT01658579|Drug|Lantus (insulin glargine)|
144106|NCT01658592|Other|Deep brain stimulation|Stimulator setting is ON
144107|NCT01658592|Other|Placebo|Stimulator setting is OFF
143524|NCT01668368|Other|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
143525|NCT01668381|Procedure|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
143526|NCT01668394|Behavioral|Learning and coping strategy|
143527|NCT01668407|Device|Robot-assisted walking (G-EO-System End Effector lower limb Robot)|A group A (GA) of subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
143528|NCT00088270|Drug|OSI-7904L|
143529|NCT01668407|Procedure|Inpatient rehabilitation|A group B (CG) of subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks.
143530|NCT01668420|Other|thermal stimulation|hot and cold/warm and cool pads applying.
143531|NCT01668433|Drug|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
143532|NCT01668446|Drug|Sildenafil|sildenafil tablets(50 mg) daily
143533|NCT01668446|Drug|estradiol valerat|
143534|NCT01668459|Drug|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
143535|NCT01668459|Other|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
143536|NCT01668485|Procedure|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg−1·min−1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
143537|NCT01668498|Drug|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
143839|NCT01660815|Drug|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
143840|NCT01660828|Other|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
143282|NCT01659775|Drug|Sancuso patch|Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.
Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy.
143283|NCT01659775|Drug|Zofran inj.+Zofran tab.|Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.
Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5.
143284|NCT01659788|Dietary Supplement|Coenzyme Q10 concomitant treatment|
143285|NCT01659788|Dietary Supplement|Placebo|
143286|NCT01659801|Device|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
143287|NCT00087438|Radiation|stereotactic body radiation therapy|
143288|NCT01659827|Other|Marcaine|Injection of 2cc of Marcaine
143289|NCT01659827|Other|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
143290|NCT01659827|Other|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
143291|NCT01659827|Other|Saline|Injection of 1.25cc of Saline
143292|NCT01659840|Radiation|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
143293|NCT01659840|Radiation|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
143294|NCT01659853|Drug|CD07805/47 gel 0.5%/CD07805/47 Vehicle|To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.
During each treatment period (baseline to Day 15):
CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily
143295|NCT01659853|Drug|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
143296|NCT01662570|Behavioral|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
143297|NCT00087620|Drug|XELODA [capecitabine]|
143298|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
143299|NCT01662583|Other|Text Message|
143369|NCT01659866|Drug|amikacin|5 mg/kg intravenously 1 hour before the procedure
143370|NCT01659866|Drug|aztreonam|2000 mg intravenously 1 hour before the procedure
143371|NCT00087464|Drug|Emtricitabine|
143372|NCT01659866|Drug|imipenem|1000 mg intravenously 1 hour before the procedure
143373|NCT01659879|Behavioral|Multimedia information|
143374|NCT01659879|Behavioral|verbal information|
143375|NCT01659892|Drug|Montelukast|5 mg Chewable Tablet
143376|NCT01659892|Drug|Singulair|5 mg Chewable Tablet
143377|NCT01659905|Drug|Montelukast|Chewable Tablet
143378|NCT01659905|Drug|Singulair|5 mg Chewable Tablet
143379|NCT01659918|Drug|Montelukast|
143380|NCT01659918|Drug|Singulair|
143674|NCT01663363|Device|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
143675|NCT01663376|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 ~3x10e8 cells
143676|NCT01663389|Drug|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
143677|NCT01663389|Drug|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
143678|NCT01663402|Drug|alirocumab|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
143679|NCT01666223|Drug|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
143680|NCT00088010|Drug|Arzoxifene|20mg, oral, tablet, once a day for 36 months
143681|NCT01666223|Other|saline|100 ml saline
143682|NCT01666223|Drug|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
144442|NCT01746498|Procedure|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
144443|NCT01746498|Procedure|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
144444|NCT01746498|Procedure|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
144445|NCT01746511|Procedure|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
144446|NCT01746511|Drug|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
144447|NCT01746524|Device|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
144448|NCT01746550|Device|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
144449|NCT00095316|Other|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
144733|NCT01747057|Behavioral|Dynamic-parameters-guided fluid management|● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation* and with sinus rhythm.
PPV >12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ [(PPmax+PPmin)/2] x100 (during 5 respiratory cycles)
SVV > 12% (15). SVV: Stroke volume variation
A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.
Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV < 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP>12).
● Non-preload responsive patients (defined as PPV or SVV < 12%) will resume the same protocol as responders when fluid response parameters are negative.
144734|NCT01747057|Behavioral|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (> 65mmHg) or CVP > 12mmHg. If CVP reaches > 12 mmHg and MAP remains < 65mmHg, norepinephrine should be started to reach MAP > 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output < 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
144735|NCT01749774|Behavioral|Physical activity counseling|
144736|NCT01749787|Drug|PRTX-100 at 1.5 mcg/kg|
144737|NCT01749787|Drug|PRTX-100 at 3.0 mcg/kg|
144738|NCT01749787|Drug|PRTX-100 at 6.0 mcg/kg|
144739|NCT01749787|Drug|PRTX-100 at 12.0 mcg/kg|
145457|NCT01745770|Drug|Mesalazine - TID 2x 500 mg|
145458|NCT01745783|Other|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
145459|NCT01745783|Other|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
145460|NCT01745809|Procedure|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
145461|NCT00095238|Drug|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
145462|NCT01745822|Drug|tenofovir disoproxil fumarate|administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
145463|NCT01745822|Drug|placebo|administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
145464|NCT01745835|Drug|2L Coolprep®|* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
145465|NCT01745835|Drug|1L Coolprep® and Bisacodyl|Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)
* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) * composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg
145466|NCT01745848|Drug|Roflumilast|
145467|NCT01745861|Dietary Supplement|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
145468|NCT01745861|Dietary Supplement|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
145469|NCT01745887|Drug|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
145470|NCT01745913|Device|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
145471|NCT01745913|Drug|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
144512|NCT01744184|Drug|Entonox|Entonox arm
144513|NCT01744184|Drug|Midazolam|up to 5mg midazolam as appropriate
145175|NCT01742832|Drug|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
145176|NCT00095030|Drug|muraglitazar|
145177|NCT01742832|Drug|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
145178|NCT01742845|Other|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
145179|NCT01742845|Other|landmark based superfical ropivacaine 4.75 mg/ml injection|
145180|NCT01742884|Other|Thealoz|Instillation of 1 drop of Thealoz
145181|NCT01742884|Other|Vehicle|1 drop of the vehicle will be instillated in the eye
145182|NCT01742897|Drug|TTS-fentanyl|
145183|NCT01745172|Procedure|Carotid body excision|This surgery does not involve any study drug or investigational device.
The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation.
145184|NCT01745211|Device|755nm Alexandrite Laser|755nm Alexandrite laser with modified and standard handpiece
145185|NCT01745224|Device|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
145186|NCT01745224|Device|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
145187|NCT00000276|Drug|Bupropion|
145188|NCT00001842|Drug|Granulocyte colony-stimulating factor|
145189|NCT00095199|Biological|Cetuximab|Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
145190|NCT01745250|Device|Emervel Lips|Lip treatment of both upper and lower lip
145191|NCT01745250|Device|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
145192|NCT01745263|Drug|Vitamin D3|2000 IU/d
145193|NCT01745263|Drug|Omega 3 fatty acids|Ratio EPA:DHA = 1:2
1 g/d
145194|NCT01745263|Procedure|Strength Home Exercise|
144361|NCT01748890|Device|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
144362|NCT01748903|Device|Target 360°, 2D Coils, Nano Coils|
144363|NCT01748916|Other|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
144364|NCT00095589|Genetic|microarray analysis|
144365|NCT01748916|Other|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
144366|NCT01748916|Other|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
144367|NCT01748929|Drug|Albendazole|
143381|NCT01659931|Drug|Montelukast|10 mg Tablet
143382|NCT00087464|Drug|Nevirapine|
143383|NCT01659931|Drug|Singulair|10 mg Tablet
143384|NCT01659944|Drug|Eliglustat|Capsules for oral administration
143385|NCT01659944|Drug|Metoprolol|Tablets for oral administration
143386|NCT01659957|Behavioral|Group Couples Counseling|
143387|NCT01659957|Behavioral|One-on-One Couples Counseling|
143388|NCT01659983|Procedure|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
143389|NCT01662752|Drug|Indocyanine green|Please see arm description
143390|NCT01662765|Procedure|Surgery|modified umbilectomy
143391|NCT01662765|Other|conservative|this treatment will include conservative procedures under local anesthesia for patient comfort.
143392|NCT00001644|Procedure|Blood testing|
143393|NCT00087633|Drug|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
143394|NCT01662778|Drug|Fluticasone Propionate 50 micrograms|Drug: Fluticasone Propionate Dose 50 micrograms (total dose), Monodisperse aerosol with two differemt particle size of drug (1.5, 6.0 microns) generated by Spinning Top Aerosol Generator (STAG)
144108|NCT01658605|Drug|GSK1605786|500 mg twice daily administered orally
144109|NCT01658605|Other|Placebo|500 mg twice daily administered orally
144110|NCT01658618|Biological|HP802-247|
144111|NCT01658631|Device|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
144112|NCT01658644|Other|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
144113|NCT01658657|Drug|Hydrochlorothiazide|
144114|NCT00087347|Procedure|magnetic resonance imaging|
144115|NCT01658657|Drug|Lisinopril|
144116|NCT01658657|Drug|Amlodipine|
144117|NCT01658657|Drug|metoprolol|
144118|NCT01658657|Drug|lisinopril/hydrochlorothiazide|This is a combination pill
144119|NCT01658670|Behavioral|Standard Care Exercise Group|The SC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
144120|NCT01658670|Behavioral|HEART Camp Exercise Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive cognitive-behavioral strtegies that address the intervention components of knowledge, attitudes, self-efficacy, behavioral self-management skills and social support.
144121|NCT01661283|Drug|bevacizumab|10 mg/kg dose every 14 days
144122|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
143150|NCT01665339|Other|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
143151|NCT01665339|Other|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
143152|NCT01665352|Drug|TTP054|Administered orally once daily for 12 weeks.
143153|NCT01665352|Drug|Placebo|Administered orally once daily for 12 weeks.
143841|NCT01660841|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
143842|NCT01660854|Biological|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
143843|NCT01660854|Drug|Malarone treatment|Three days: 4 tablets 250/100mg per day
143844|NCT01660867|Drug|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
143845|NCT01663662|Drug|Tolvaptan|
143846|NCT01663662|Drug|placebo|
143847|NCT01663675|Genetic|karyotype|
143848|NCT01663701|Other|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
143849|NCT00001644|Procedure|Lymph node biospy|
143850|NCT00087698|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
143851|NCT01663701|Other|Usual care|Patients are managed according to admitting doctors' orders
143852|NCT01663714|Biological|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
143853|NCT01663727|Drug|Bevacizumab [Avastin]|Intravenous repeating dose
143854|NCT01663727|Drug|Paclitaxel|Intravenous repeating dose
143855|NCT01663727|Drug|Placebo|Intravenous repeating dose
143856|NCT01663753|Device|18F-FDG-PET|
143857|NCT01663766|Drug|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
143858|NCT01663779|Procedure|Ultrasound guided radial artery catheterization.|Radial artery catheters will be placed with the assistance of bedside ultrasound.
143859|NCT01663779|Procedure|Blind insertion of radial artery catheterization|Radial artery catheters will be placed by the palpation technique only.
143860|NCT01663792|Other|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
143861|NCT00087698|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
143300|NCT01662583|Other|Written reminder|
143595|NCT01666158|Behavioral|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
143596|NCT01666171|Drug|metformin hydrochloride|
143597|NCT01666171|Other|clinical observation|
143598|NCT00000266|Drug|Flupenthixol|
143599|NCT00001646|Drug|Amphotericin B|
143600|NCT00087997|Drug|STA-4783|
143601|NCT01666171|Other|diagnostic laboratory biomarker analysis|
143602|NCT01666171|Other|imaging biomarker analysis|
143603|NCT01666171|Other|medical chart review|
143604|NCT01666171|Procedure|digital mammography|
143605|NCT01666197|Drug|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
143606|NCT01666197|Drug|placebo|placebo
143607|NCT01666210|Drug|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
143608|NCT01666210|Drug|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
143609|NCT01666223|Drug|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
143610|NCT01668719|Drug|dexamethasone|Given orally or IV
143611|NCT01668719|Drug|lenalidomide|Given orally
143612|NCT01668745|Biological|Early measles vaccine|
143613|NCT01668784|Biological|Nivolumab|
143614|NCT01668784|Drug|Everolimus|
143615|NCT01668797|Drug|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
143616|NCT00088309|Procedure|Eye exam|
143335|NCT01668537|Biological|FD formulation of IMVAMUNE®|
143336|NCT01668550|Drug|AZD0424|AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.
Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date.
143337|NCT01668563|Procedure|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
143338|NCT01668563|Procedure|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
143339|NCT01668602|Other|Fast walking and FES|Fast treadmill walking with electrical stimulation delivered to the ankle dorsi- and plantar-flexor muscles
143340|NCT01668602|Other|Fast treadmill walking|Fast treadmill walking without electrical stimulation
143341|NCT00088283|Drug|pegaptanib sodium|
143342|NCT01668615|Drug|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
143343|NCT01668641|Drug|GLPG0634|
143344|NCT01668641|Drug|Placebo|
143345|NCT01668654|Drug|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
143346|NCT01668667|Drug|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
143347|NCT01668667|Drug|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
143348|NCT01668667|Drug|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
143349|NCT01668667|Drug|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
143350|NCT01668680|Drug|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
143351|NCT01668693|Other|ERA (Endometrial Receptivity Array)|The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group "Receptive" or "Non Receptive" and to predict the number of days of Progesterone administration necesary to obtain the "Receptive" prediction.
143352|NCT00001656|Drug|Olanzapine|tablet; 5-20mg/day; 8 weeks
144740|NCT01749787|Drug|PRTX-100 at 240 mcg|
144741|NCT01749787|Drug|Placebo|Placebo administered via infusion once per week for 5 weeks
144742|NCT01749787|Drug|PRTX-100 at 420 mcg|
144743|NCT01749800|Device|GVS|
144744|NCT01749800|Device|Sham GVS|
144745|NCT00095654|Drug|Ramipril|
144746|NCT01749800|Device|Armeo Spring|
144747|NCT01749800|Other|Computer-based attention games|
144748|NCT01749826|Drug|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
144749|NCT01749852|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
144750|NCT01749852|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
144751|NCT01749865|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
144752|NCT01749878|Drug|REGN1500|
145021|NCT01747590|Drug|Caffeine|
145022|NCT01747590|Other|Placebo|
145023|NCT01747603|Other|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
145024|NCT01747616|Device|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
145025|NCT01747616|Other|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
145026|NCT01747629|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
145027|NCT01747629|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
145028|NCT01747642|Dietary Supplement|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
145029|NCT01749956|Radiation|Radiation|
144514|NCT00095121|Drug|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration >= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained >= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
144515|NCT01744197|Device|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
144516|NCT01744223|Biological|BPX-501 and AP1903|Patients will receive BPX-501 Donor T cells genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene after the stem cell graft infusion is complete, but not more than 72 hours after completion of the stem cell allograft infusion.
AP1903: Dimerizer drug administered (per intravenous infusion ) in those subjects who present with severe GvHD (Grades III and IV) as well as those subjects with Grade I and II who progress or do not respond to corticosteroid therapy within 4 days.
144517|NCT01744236|Drug|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
144518|NCT01744236|Drug|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
144519|NCT01744236|Drug|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
144520|NCT01744236|Drug|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
144521|NCT01744236|Drug|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
144522|NCT01744236|Drug|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
144523|NCT01744236|Drug|L-NMMA|
144524|NCT01744249|Drug|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
144525|NCT00095134|Drug|risperidone|
144526|NCT01746615|Device|Dynamic Vessel Analyzer|retinal vessel diameter & oxygen saturation
144527|NCT00095329|Biological|Sirolimus|
144528|NCT01746615|Other|Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)|retinal blood velocity
144529|NCT01746628|Procedure|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
144530|NCT01746641|Drug|Remifentanil|
145195|NCT01745263|Procedure|Flexibility Home Exercise|
145196|NCT01745276|Device|Biphosfonate|External pins coated by biphosfonate.
145529|NCT01743547|Other|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
145530|NCT01743560|Drug|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer will be treated with oral RAD001 at a dose of 10mg daily and oral exemestane 25mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until the last patient enrolled has completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
145531|NCT01743560|Drug|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer will be treated with oral RAD001 at a dose of 10mg daily and oral exemestane 25mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until the last patient enrolled has completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
145532|NCT01743573|Other|yoga|
145533|NCT01743586|Other|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
145534|NCT00095069|Drug|Comparator: placebo / Duration of Treatment -1 year|
145535|NCT01743612|Procedure|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
145536|NCT01743612|Procedure|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
145537|NCT01743625|Drug|COV155|COV155 tablets
145538|NCT01743625|Drug|placebo|
145539|NCT01743638|Procedure|MR-Guided Laser Ablation|
145540|NCT01743651|Drug|arbaclofen|10 mg, 15 mg or 20 mg arbaclofen ER tablets administered orally 2 times per day
145541|NCT01743651|Drug|baclofen|20 mg, 30 mg or 40 mg baclofen administered orally 4 times per day
145542|NCT01745913|Procedure|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of > 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
145543|NCT01745913|Procedure|Haplo-Identical Cord Transplantation|If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a "conditioning regimen" prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen.
143395|NCT01662778|Drug|Inhaled, Metered dose inhaler, 250 micrograms dose (total dose)|Inhaled, Metered dose inhaler, 250 micrograms dose (total dose), delivered via spacer
143396|NCT01662778|Drug|Placebo monodisperse aerosol dose|Solvent only delivered, no drug
143397|NCT01662791|Drug|Rifaximin|All individuals in the weight loss group (i.e., only the Case group) will be offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects will receive antibiotic treatment. The patient will be contacted by phone 1 month after treatment at which time the presence of GI symptoms will be determined and inquiry made about any adverse effects related to rifaximin use. GI symptoms, quality of life, weight measurement and breath testing will be repeated at a 3 month study visit.
143398|NCT01662804|Drug|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
143399|NCT01662817|Behavioral|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
143400|NCT01662817|Behavioral|Control|PCP manages depression in the usual way for six months
143693|NCT01666327|Drug|MT-1303|
143694|NCT01666340|Other|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
143695|NCT01666340|Other|Exercise intervention|High intensity exercise
143696|NCT01666353|Radiation|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
143697|NCT01666366|Procedure|Coronary artery bypass grafting|
143698|NCT01666379|Drug|Fentanyl|
143699|NCT01666392|Dietary Supplement|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
143700|NCT01666392|Dietary Supplement|Placebo|Placebo
143701|NCT01657851|Drug|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
143702|NCT01657851|Drug|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
143703|NCT01657864|Drug|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
143154|NCT01665365|Procedure|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
143155|NCT01665378|Dietary Supplement|Multiple Micronutrient|There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.
Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150
143156|NCT01665378|Dietary Supplement|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
143157|NCT00001646|Drug|Voriconazole|
143158|NCT00087828|Drug|Cranberry juice cocktail|
143159|NCT01665378|Dietary Supplement|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
143160|NCT01665391|Drug|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
143161|NCT01665391|Drug|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
143162|NCT01665391|Drug|Placebo|Placebo administered to match active treatment group
143163|NCT01665404|Drug|Fluvoxamine|Multiple doses of fluvoxamine
143164|NCT01665404|Drug|RO4917523|Single dose of RO4917523
143165|NCT01665417|Drug|Experimental|Icotinib: 125mg, oral administration, three times per day.
143166|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
143167|NCT01667796|Dietary Supplement|Vitamin D3|
143459|NCT01660022|Drug|Placebo|Placebo
143460|NCT01660022|Drug|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
143461|NCT01660022|Drug|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
143462|NCT01660022|Drug|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
144178|NCT01667107|Drug|Calogen®|
144179|NCT00088114|Drug|STA-4783/paclitaxel|
144180|NCT01667120|Drug|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
144181|NCT01667120|Drug|placebo|
144182|NCT01667133|Drug|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
144183|NCT01667133|Drug|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
144184|NCT01667146|Other|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH > 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
144185|NCT01658683|Behavioral|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
144186|NCT01658696|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu heterologous prime-boost immunisation
144187|NCT01658696|Biological|Rabies vaccine|2 x 2.5IU Verorab
144188|NCT01658722|Drug|Bapineuzumab|
144189|NCT00087360|Other|counseling intervention|
144190|NCT01658735|Device|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
144191|NCT01658735|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
144192|NCT01658735|Device|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
143226|NCT01662492|Drug|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
143227|NCT01662505|Drug|Volasertib|Patient to receive volasertib
143617|NCT01668797|Drug|Placebo|Placebo comparator for 52 weeks
143618|NCT01668823|Drug|HPPH|Given IV
143619|NCT01668823|Drug|photodynamic therapy|Undergo photodynamic therapy with HPPH
143918|NCT01660932|Drug|placebo|
143919|NCT01660932|Drug|omega|
143920|NCT01660945|Drug|placebo|
143921|NCT01660945|Drug|vytorin|
143922|NCT01660958|Dietary Supplement|Micronutrient Intervention|The formulation of the mutiple micronutrient products was determined by considering the level of MN deficiency among young children in India, the Indian RDA for each MN by age, and data from efficacy trials on the dose of MN required for changes in cognition. The MN formulations were produced by a certified company in India and include: Iron, Vitamin A,Vitamin C,Folic Acid,Zinc, Vitamin B12 Vitamin B2.
143923|NCT01660958|Behavioral|Early Learning|In the preschool phase, we will recruit 12 Anganwadi Centers (Preschools). They will be scored to determine their quality (in terms of early stimulation and learning opportunities) using the Indian modified Early Childhood Environment Rating Scale (ECERS) and then randomized by quality rating into MN intervention or placebo
143924|NCT01660971|Drug|Dasatinib|Given PO
143925|NCT00087529|Drug|rituximab|Intravenous repeating dose
143926|NCT01660971|Drug|Erlotinib Hydrochloride|Given PO
143927|NCT01660971|Drug|Gemcitabine Hydrochloride|Given IV
143928|NCT01660997|Drug|MLN9708|
143929|NCT01660997|Drug|Dexamethasone|
143930|NCT01661062|Other|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
143931|NCT01661088|Drug|FOLFIRINOX|Starting dose levels as following:
Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1.
143932|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
143353|NCT00088296|Procedure|Blood Draw|
143354|NCT01668693|Other|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
143660|NCT01660464|Behavioral|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
143661|NCT01660477|Drug|Isavuconazole|oral
143662|NCT01663259|Radiation|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
143663|NCT01663272|Drug|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
143664|NCT01663272|Drug|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
143665|NCT01663285|Drug|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
143666|NCT01663298|Procedure|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
143667|NCT01663311|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
143668|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
143669|NCT01663311|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
143670|NCT01663324|Device|rTMS intervention 1|Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.
Arms: single site rTMS
143671|NCT01663324|Device|rTMS intervention 2|Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).
Arms: multisite rTMS
145030|NCT01749956|Drug|Aflibercept|
145031|NCT01749956|Procedure|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
145032|NCT01749956|Drug|FOLFOX6|
145033|NCT00095667|Drug|lapatinib ditosylate|Given orally
145034|NCT01749969|Drug|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
145035|NCT01749969|Drug|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
145036|NCT01749969|Drug|SAR650984|Pharmaceutical form:solution Route of administration: intravenous
145037|NCT01749982|Other|Placebo|
145038|NCT01749982|Drug|Choline bitartrate|
145039|NCT01749982|Drug|Betaine|
145040|NCT01749982|Drug|Choline bitartrate + Betaine|
145041|NCT01750008|Procedure|Global Fibroid Ablation|
145042|NCT01750008|Procedure|Myomectomy|
145043|NCT01750021|Dietary Supplement|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
145044|NCT00095667|Other|laboratory biomarker analysis|Correlative studies
145045|NCT01750021|Dietary Supplement|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
145402|NCT01748175|Drug|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
145403|NCT01748188|Procedure|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
145404|NCT01748188|Procedure|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
145405|NCT01748188|Procedure|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
145406|NCT01748188|Procedure|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
144809|NCT01747070|Other|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
144810|NCT01747070|Other|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
144811|NCT01747083|Drug|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
144812|NCT01747096|Drug|68-Ga-DOTANOC|
144813|NCT01747109|Device|PREOXYFLOW|Patients randomized in "PREOXYFLOW" group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction
144814|NCT01747109|Procedure|STANDARD FACE MASK|Patients randomized in "STANDARD FACE MASK" group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)
144815|NCT01747122|Device|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
144816|NCT01747122|Device|Epidural|
144817|NCT01747135|Drug|2-hydroxypropyl-beta-cyclodextrin|
144818|NCT01747148|Drug|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
144819|NCT00095420|Behavioral|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
144820|NCT01747161|Drug|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
144821|NCT01747161|Drug|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
144822|NCT01747174|Drug|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
144823|NCT01747174|Drug|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
144824|NCT01747174|Procedure|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
144825|NCT01747200|Procedure|Sham rTMS|
144826|NCT01747200|Procedure|Bilateral rTMS at same frequency and in phase|
145544|NCT01745926|Device|MECHANICAL CHEST COMPRESSION|
145545|NCT01745939|Other|Lumbar Manipulation|Manual therapy intervention
145546|NCT01745939|Other|Sham manipulation|Manual therapy intervention
145547|NCT01745952|Device|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
144594|NCT01741922|Drug|ASA evening&placebo morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
144595|NCT01741922|Drug|Acetylsalicylic morning&placebo evening|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
144596|NCT01744249|Drug|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
144597|NCT01744249|Drug|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
144598|NCT01744262|Drug|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5~4 µg/mL and remifentanil effect site concentration 2~5 ng/mL.
144599|NCT01744262|Drug|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5~2.0 % and remifentanil effect site concentration 2~5 ng/mL.
144600|NCT01744275|Dietary Supplement|Omega 3 fatty acids|
144601|NCT01744275|Dietary Supplement|corn oil|Placebo
144602|NCT01744288|Drug|Ticagrelor|Oral single loading dose 180ng
144603|NCT01744288|Drug|Clopidogrel|Oral single loading dose 600mg
144604|NCT01744288|Drug|ASA|81mg once daily from day -2 up to platelet transfusion
144605|NCT01744301|Drug|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
143704|NCT01657877|Drug|Calcium sodium phosphosilicate|CSP high percentage weight by weight
143705|NCT01657877|Drug|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
143706|NCT00087269|Drug|erlotinib hydrochloride|Given orally
143707|NCT01657877|Drug|Placebo|No CSP and no fluoride
143708|NCT01657890|Drug|isavuconazole|oral
143709|NCT01657903|Drug|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
143710|NCT01657903|Drug|Potassium nitrate|All study treatments contain 5% w/w KNO3.
143711|NCT01657929|Biological|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
143712|NCT01657929|Biological|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
143713|NCT01657929|Biological|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
143714|NCT01657929|Biological|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
143715|NCT01657942|Device|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
144032|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
144033|NCT01661231|Device|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
144034|NCT01661244|Drug|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
144035|NCT01661244|Drug|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
144036|NCT01661244|Drug|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
144037|NCT01661244|Drug|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
144038|NCT01661257|Drug|Infliximab|
144039|NCT01661270|Drug|Aflibercept|Pharmaceutical form:Concentrate for Solution for infusion Route of administration: Intravenous
144040|NCT01661270|Drug|Placebo|Pharmaceutical form:Concentrate for Solution for infusion Route of administration: Intravenous
143463|NCT01660022|Drug|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
143464|NCT01660022|Drug|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
143465|NCT01660048|Procedure|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
143466|NCT01660048|Procedure|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
143467|NCT01660074|Other|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
143468|NCT00087477|Drug|Pivanex|
143469|NCT01660087|Device|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
143470|NCT01660100|Procedure|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
143471|NCT01660100|Procedure|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
143472|NCT01662908|Drug|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg QD for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
143473|NCT01662908|Drug|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
143474|NCT01662908|Drug|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
143475|NCT01662921|Drug|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
143476|NCT01662921|Drug|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
143781|NCT01666444|Drug|pegylated liposomal doxorubicin (PLD)|
143782|NCT01666444|Drug|VTX-2337|TLR8 Agonist
143228|NCT01662518|Device|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
143229|NCT01662531|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
143230|NCT01662544|Procedure|Oxygen delivery|
143231|NCT01662557|Behavioral|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
143232|NCT01662557|Other|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
143233|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
143234|NCT01665430|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
143235|NCT00087841|Behavioral|Self-hypnotic relaxation|
143236|NCT01665469|Dietary Supplement|Tomato extracted lycopene|
143237|NCT01665469|Dietary Supplement|Placebo|
143238|NCT01665482|Other|A 2000 kcal test meal|
143239|NCT01665482|Other|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
143240|NCT01665495|Procedure|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return<30 ml.
143241|NCT01665508|Drug|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
143242|NCT01665521|Other|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
143243|NCT01665534|Behavioral|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
143244|NCT01665547|Drug|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
143245|NCT01665573|Drug|Delta-9-THC|Acquisition of conditioning Administration of drug Extinction of conditioning
143246|NCT00087854|Drug|Amonafide L-malate (drug)|
143933|NCT01663844|Behavioral|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
143934|NCT01663857|Drug|LY2228820|Administered Orally
143935|NCT00087711|Drug|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
143936|NCT01663857|Drug|Carboplatin|Administered IV
144257|NCT01746212|Procedure|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
144258|NCT01746212|Biological|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
144259|NCT01746212|Device|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
144260|NCT01746225|Drug|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
144261|NCT00095290|Drug|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
144262|NCT01746238|Drug|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
144263|NCT01746238|Drug|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
144264|NCT01746238|Radiation|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
144265|NCT01746251|Drug|Afatinib|
144266|NCT01746264|Dietary Supplement|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
144267|NCT01746277|Drug|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
144268|NCT01746277|Drug|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
143672|NCT01663337|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
143673|NCT01663337|Behavioral|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
143985|NCT00088088|Drug|Paclitaxel|
143986|NCT01666769|Drug|Micafungin|Standard of care Dosing
143987|NCT01658319|Genetic|DNA analysis|Correlative studies
143988|NCT01658332|Other|blood samples|3 tubes (15 ml)
143989|NCT00087334|Drug|capecitabine|
143990|NCT01658358|Drug|Lapatinib|dose level I, II 1000mg po daily
dose level III, IV 1250mg po daily
143991|NCT01658358|Drug|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
143992|NCT01658384|Other|Observational Cognitive assessments|Observational
143993|NCT01658384|Other|noninterventional, cognitive testing in tysabri treated patients|noninterventional, cognitive testing in Tysabri treated patients
143994|NCT01658397|Behavioral|Fasting|Ten day fast
143995|NCT01658410|Drug|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
143996|NCT01658410|Drug|NaCl|NaCl, Route: intracoronary
143997|NCT01658436|Drug|BEZ235|
143998|NCT01658449|Other|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
143999|NCT01658449|Other|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
144000|NCT00087334|Drug|gefitinib|
144001|NCT01658462|Drug|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
144002|NCT01658462|Drug|Nintedanib|200 mg x 2 per os daily from D2*
*No Nintedanib on days when docetaxel is administered
144003|NCT01658462|Drug|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
145407|NCT01748188|Procedure|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
145408|NCT01748201|Procedure|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
145409|NCT01748227|Behavioral|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
145410|NCT01748240|Drug|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
145411|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
145412|NCT00095524|Drug|Aripiprazole|
145413|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
145414|NCT01748266|Other|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
145415|NCT01748279|Drug|Atorvastatin|
145416|NCT01748279|Drug|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
145417|NCT01748279|Drug|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
145418|NCT01748292|Drug|0.5mg ranibizumab|The subject receives drug at every visit.
145419|NCT01740622|Other|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
144450|NCT01746563|Drug|Ranibizumab|Intravitreal injection
144451|NCT01746563|Procedure|Laser therapy|Laser therapy
144452|NCT01746576|Other|Use of impedance threshold device during spontaneous ventilation|
144453|NCT01746589|Device|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
144454|NCT01746602|Drug|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
144455|NCT01746602|Drug|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
144827|NCT01747200|Procedure|Bilateral rTMS at different frequencies|
144828|NCT01747200|Procedure|Bilateral rTMSat same frequency and out of phase|
145114|NCT01747668|Dietary Supplement|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
145115|NCT01747681|Procedure|Microfracture|
145116|NCT01747694|Behavioral|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
145117|NCT01747707|Drug|Docetaxel|
145118|NCT01747707|Drug|Cisplatin|
145119|NCT01747707|Drug|S-1|
145120|NCT01747720|Dietary Supplement|Vitamin D3|Given orally
145121|NCT01747720|Dietary Supplement|Placebo|
145122|NCT01747733|Device|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
145123|NCT00095459|Drug|BAY 43-9006|
145124|NCT01747746|Drug|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
145125|NCT01747746|Drug|Warfarin and Enoxaparin|Historical Control
145126|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|
145127|NCT01747772|Device|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score from liver biopsy.
145128|NCT01747785|Other|Cardiac rehabilitation|
145129|NCT01747785|Other|Myocardial deformation imaging|
145130|NCT01747798|Drug|auranofin|Given PO
145131|NCT01747798|Other|laboratory biomarker analysis|Correlative studies
145132|NCT01747811|Device|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
144606|NCT00095147|Drug|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
144607|NCT01744314|Drug|Indomethacin and Pantoprazole|
144608|NCT01744314|Drug|microcrystalline cellulose powder tablets|
144609|NCT01744340|Drug|Head and neck|Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter
Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
144896|NCT01744704|Drug|rhNGF 180 µg/mL Part B|
144897|NCT01744704|Drug|Placebo Part A|
144898|NCT01744704|Drug|Placebo Part B|
144899|NCT01744717|Other|Pain measurement|Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.
The procedures to be studied are the following:
TURNING / POSITIONING (moving side to side or up or down in bed)
ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)
NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)
144900|NCT00095173|Drug|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
144901|NCT01744730|Drug|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
144902|NCT01744743|Procedure|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
144903|NCT01744756|Drug|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
144904|NCT01744782|Drug|RP103 Q12H|
144905|NCT01747200|Procedure|rTMS over TP8|
144906|NCT00095420|Behavioral|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
144907|NCT01747200|Procedure|rTMS over TP7|
144908|NCT01747213|Drug|BNC|
144909|NCT01747226|Other|Fluoride rinse|rinse with 15 ml for 1 minute
144910|NCT01747226|Other|Halita|rinsing with 15 ml for 1 minute
144041|NCT01661283|Drug|everolimus|10 mg tablet once daily
144042|NCT00087711|Drug|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
144043|NCT01664039|Drug|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
144044|NCT01664039|Drug|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
144045|NCT01664052|Device|ESS505 (BAY1454033)|
144046|NCT01664052|Device|ESS305 (Essure, BAY1454032)|
144047|NCT01664052|Device|ESS505-A (Essure, BAY1454033)|
144048|NCT01664065|Drug|200 mg Ceftaroline fosamil|1 h infusion
144049|NCT01664065|Drug|600 mg Ceftaroline fosamil|1 h infusion
144050|NCT01664078|Device|Endovascular AAA repair|
144051|NCT01664091|Radiation|Radiation Therapy|Given Monday through Friday over 5-7 weeks
144052|NCT01664130|Radiation|stereotactic body radiation therapy|Undergo SBRT
144053|NCT00087724|Drug|FK962|
144054|NCT01664130|Procedure|quality-of-life assessment|Ancillary studies
144055|NCT01664130|Other|laboratory biomarker analysis|Correlative studies
144056|NCT01664143|Drug|Placebo|Multiple doses of placebo
144368|NCT01748942|Procedure|Transoral Robotic Surgery|Undergo TORS
144369|NCT01748942|Drug|Dexamethasone|Given IV
144370|NCT01748942|Drug|Dexamethasone|Given PO
144371|NCT01748942|Other|Placebo|Given PO
144372|NCT01748942|Procedure|Quality-of-Life Assessment|Ancillary studies
144373|NCT01748942|Other|Questionnaire Administration|Ancillary studies
144374|NCT01748955|Drug|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
143783|NCT01666444|Drug|Placebo|
143784|NCT01666457|Other|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
143785|NCT01666470|Other|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
143786|NCT01666483|Procedure|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
143787|NCT01666483|Procedure|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
143788|NCT01666496|Behavioral|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
143789|NCT00088036|Drug|Olanzapine|
143790|NCT01666496|Behavioral|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
143791|NCT01666509|Device|Rossoseq™|
143792|NCT01666509|Device|Placebo|
143793|NCT01666522|Drug|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
143794|NCT01666522|Other|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
143795|NCT01666535|Biological|Influenza vaccination|
143796|NCT01666561|Other|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
143797|NCT01658046|Other|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
143538|NCT01668498|Drug|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
143539|NCT00088270|Drug|5-Fluorouracil/Leucovorin|
143540|NCT01668511|Biological|ABT-981|Injection
143541|NCT01668511|Biological|Placebo|Placebo Injection
143542|NCT01668524|Drug|ATS907|Single dose of each of three increasing concentrations
143543|NCT01660126|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
143544|NCT01660126|Drug|Placebo|
143545|NCT01660152|Other|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
143546|NCT01660152|Procedure|management of therapy complications|Receive VED
143547|NCT01660152|Procedure|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
143548|NCT01660191|Drug|Statin|Pitavastatin 4mg, Atorvastatin 20mg, or rosuvastatin 5mg, once daily by mouth for 12 weeks
143549|NCT01660204|Other|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
143550|NCT00087490|Drug|linezolid|
143551|NCT01660217|Other|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
143552|NCT01660230|Biological|3K3A-APC, diluted in 0.9% sodium chloride in water|
143553|NCT01660230|Drug|0.9% NaCl in water|
143554|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
143555|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
144269|NCT01746290|Other|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
144270|NCT01746303|Dietary Supplement|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
144271|NCT01746303|Dietary Supplement|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
144272|NCT00095303|Behavioral|Brief Strategic Family Therapy (BSFT)|BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 "booster" sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school).
144273|NCT01746303|Other|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
143301|NCT01662609|Procedure|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
143302|NCT01662622|Drug|Sevoflurane|The design of experiment is referred to the "Dixon up-and-down" method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted.
143303|NCT01662648|Drug|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
143304|NCT01662661|Drug|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
143305|NCT01662661|Drug|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
143306|NCT01662674|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
143307|NCT01662674|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
143308|NCT00087633|Drug|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
143309|NCT01662687|Drug|Sancuso patch|Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.
Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy.
143310|NCT01662687|Drug|Kytril inj.+Kytril tab.|Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.
Active Comparator arm:
Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).
Kytril tab. 1mg: administered twice a day by orally at Day 2~4.
144684|NCT01742052|Drug|MT-1303-Middle|
144685|NCT00001832|Procedure|Apheresis|
144686|NCT00094887|Drug|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
144687|NCT01742052|Drug|MT-1303-High|
144688|NCT01742052|Drug|Placebo|
144689|NCT01742065|Other|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
144690|NCT01742078|Drug|LY2541546 - IV|Administered IV
144691|NCT01742078|Drug|LY2541546 - SC|Administered SC
144692|NCT01742078|Drug|Placebo|Administered IV or SC
144693|NCT01742091|Drug|LY2541546 - SC|Administered SC
144694|NCT01742091|Drug|LY2541546 - IV|Administered IV
144695|NCT01742091|Drug|Placebo - SC|Administered SC
144696|NCT00095147|Drug|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
145298|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
145299|NCT01745562|Drug|Alprazolam 0.5 mg|Reference product
145300|NCT01745562|Drug|Alprazolam 0.5 mg|Test product
145301|NCT01745575|Drug|Alprazolam 2mg tablets|Reference product
145302|NCT01747954|Other|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
145303|NCT01747954|Other|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
145304|NCT00095498|Drug|placebo|placebo subcutaneous injection
144456|NCT01746602|Device|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
144457|NCT01746602|Device|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
144458|NCT01746602|Device|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
144459|NCT01749046|Drug|Remegal|Remegal 1500 mg for 12 weeks
144460|NCT01749072|Drug|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
144461|NCT01749072|Drug|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
144462|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
144463|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
144464|NCT01749098|Drug|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
144465|NCT01749098|Drug|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
144466|NCT01749098|Drug|Placebo|Placebo capsule orally administered on Days 1 - 5
144467|NCT01749098|Drug|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
144468|NCT01749111|Drug|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
144469|NCT00095589|Other|laboratory biomarker analysis|
144470|NCT01749111|Drug|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
144753|NCT01749878|Drug|placebo|
144754|NCT01749891|Drug|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
144755|NCT01749904|Drug|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
144756|NCT00095654|Drug|Rosiglitazone|
145133|NCT01747837|Device|Boston Scientific Vessix Renal Denervation System|Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.
Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts
145134|NCT00095472|Drug|L-NMMA|
145135|NCT01747850|Behavioral|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
145472|NCT00095251|Drug|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
145473|NCT01745913|Drug|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
145474|NCT01745913|Drug|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
145475|NCT01748305|Behavioral|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
145476|NCT01748318|Drug|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
145477|NCT01748318|Drug|Bactrim DS|Bactrim DS
145478|NCT01748331|Other|Fluid restriction|Patients will be randomized to strict fluid restriction < 1 L/day versus moderate fluid restriction < 2.5 L/day
145479|NCT00001849|Drug|18-F-fluorodeoxyglucose|
145480|NCT00095537|Drug|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
145481|NCT01748344|Drug|Cetirizine|10mg tablets
145482|NCT01748344|Drug|High dose ONO-4053|Experimental
145483|NCT01748344|Drug|Low dose ONO-4053|Experimental
145484|NCT01748344|Drug|Placebo|None active
145485|NCT01748370|Drug|Vitamin D supplementation in hypogonadal men|
145486|NCT01748370|Drug|Vitamin D supplementation in eugonadal men|
144911|NCT01747226|Other|Meridol Halitosis|rinsing with 15 ml for 1 minute
144912|NCT01747226|Other|Water|rinsing with 15ml for 1 minute
144913|NCT01747239|Drug|Cabazitaxel|25 mg/m2 IV every three weeks
144914|NCT01747252|Dietary Supplement|RGC|
144915|NCT01747252|Dietary Supplement|RGC|
144916|NCT01747252|Dietary Supplement|Resveratrol|The equivalent of 150 mg resveratrol
144917|NCT00095420|Behavioral|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
145197|NCT01745302|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
145198|NCT01745302|Drug|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
145199|NCT01745315|Device|Advanced bipolar devices|
145200|NCT00095199|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
145201|NCT01745328|Drug|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
145202|NCT01745328|Drug|TCM|Subject is treated with TCM for 4 weeks.
145203|NCT01745328|Drug|LVX-AMX|treatment with placebo from 2 to 4 weeks.
145204|NCT01745354|Drug|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
145205|NCT01745354|Radiation|Local Radiation|
145206|NCT01745367|Drug|Tivozanib Hydrochloride|
145207|NCT01745367|Drug|paclitaxel|
145208|NCT01745380|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|
144375|NCT00001849|Drug|(18F)-L-3,4-dihydroxyophenylalanine (18F-DOPA)|
144376|NCT00095589|Genetic|microsatellite instability analysis|
144377|NCT01748955|Drug|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
144378|NCT01748981|Other|Physical training|Physical training three times a week for 20 week including endurance and strength training compare to the "as usual" group as controls
144379|NCT01748981|Other|As usual|Controls, not training
144380|NCT01748994|Drug|Pioglitazone|30mg per day for four months
144381|NCT01748994|Drug|Placebo|
144382|NCT01749020|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
144383|NCT01749020|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
144384|NCT01749033|Other|Group 1 Classic|Active Comparator: Group 1 classic
Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual.
144385|NCT01749033|Other|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA from the manufacturer.
144386|NCT01749033|Other|Group 3 ELLIA|Group 3 (ELLIA): Using the ELLIA technique
144387|NCT00095589|Other|cytology specimen collection procedure|
144388|NCT01741454|Drug|Tamsulosin|0.4 mg by mouth once per day.
144389|NCT01741454|Drug|Tolterodine ER|4 mg by mouth once a day.
144390|NCT01741467|Behavioral|RT-CGM|Dexcom Seven+
143401|NCT01662856|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
143402|NCT01662856|Procedure|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
143403|NCT01662869|Drug|Onartuzumab|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
143404|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 72 weeks
143405|NCT01662869|Drug|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
144123|NCT01661296|Other|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
144124|NCT01661296|Drug|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
144125|NCT01661309|Dietary Supplement|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
144126|NCT01661309|Dietary Supplement|Methylcobalamin|Aimed at reducing plasma tHcy.
144127|NCT01661322|Drug|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
144128|NCT01661335|Drug|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
144129|NCT01661335|Drug|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
144130|NCT01661361|Procedure|blood levels|
144131|NCT01661400|Drug|Metronomic Cyclophosphamide|
144132|NCT01661400|Drug|Thalidomide|
144133|NCT00087555|Drug|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
144134|NCT01661426|Behavioral|Low-Carbohydrate or Low-Fat Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
144135|NCT01661439|Drug|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
144136|NCT01661452|Other|Referral to counseling services if desired|
144137|NCT01661478|Other|Training on motivational interviewing|
144138|NCT01661504|Behavioral|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
143556|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
143557|NCT01660243|Drug|Placebo|Placebo (2capsules) once daily for 8 weeks
143862|NCT01663792|Other|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
143863|NCT01663792|Other|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
143864|NCT01663805|Drug|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
143865|NCT01663818|Device|Tack-It Endovascular Stapler|
143866|NCT01663831|Other|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
143867|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
143868|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
143869|NCT01666561|Other|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
143870|NCT01666561|Other|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
143871|NCT01666574|Other|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
143872|NCT00088049|Drug|Olanzapine|
143873|NCT01666574|Other|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
143874|NCT01666587|Dietary Supplement|Antioxidant|
143875|NCT01666587|Drug|Prostaglandin inhibitor (Ibuprophen)|
143876|NCT01666600|Drug|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
143311|NCT01662700|Drug|Artesunate|
143312|NCT01662700|Drug|Chloroquine|
143313|NCT01662713|Device|OFDI|
143314|NCT01662726|Drug|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
143315|NCT01662739|Behavioral|Questionnaire|
143316|NCT01665638|Drug|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
143317|NCT01665638|Drug|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
143620|NCT01668823|Procedure|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
143621|NCT01668836|Drug|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
143622|NCT01668836|Behavioral|Caloric restriction|Diet of 1000kcal per day for 30 days
143623|NCT01668849|Dietary Supplement|Grape extract|Grape extract self-administered by mouth daily for 35 days
143624|NCT01668849|Drug|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
143625|NCT01668862|Biological|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
143626|NCT01668862|Drug|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
143627|NCT00088309|Procedure|Oral exam|
143628|NCT01668875|Other|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
143629|NCT01668875|Other|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
143630|NCT01668901|Drug|warfarin|
143631|NCT01668901|Drug|aspirin|
143632|NCT01668914|Procedure|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
145305|NCT01747967|Other|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
145306|NCT01747980|Drug|PRX-112|Single dose level, four doses per cohort
145307|NCT01747993|Drug|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
145308|NCT01747993|Drug|Placebo|(1 tablet / day for 6 days)
145309|NCT01748006|Other|Standard of care therapy for severe decompensated heart failure|
145310|NCT01748019|Drug|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
145311|NCT01748032|Behavioral|Cognitive training|20 minutes/day for 5 sequential working days
145312|NCT01748045|Drug|inhaled nitric oxide|
145313|NCT01748045|Drug|Placebo Comparator - nitrogen gas|
145314|NCT01748058|Behavioral|Exercise based on active video gaming|
145315|NCT00095498|Drug|denosumab|For subcutaneous injection
145316|NCT01748084|Drug|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
145317|NCT01748084|Drug|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
145318|NCT01748097|Drug|sodium bicarbonate 4.2%|
145340|NCT01740609|Biological|PF-06342674 Dose A|Single SC Dose
145341|NCT01740609|Biological|PF-06342674 Dose B|Single SC Dose
145342|NCT01740609|Biological|PF-06342674 Dose C|Single SC Dose
145343|NCT01740609|Biological|PF-06342674 Dose D|Single SC Dose
145344|NCT01740609|Biological|PF-06342674 Dose E|Single SC Dose
145345|NCT01740609|Biological|PF-06342674 Dose F|Single IV Dose
145346|NCT01740609|Biological|PF-06342674 Dose G|Single SC Dose
145347|NCT01740609|Biological|PF-06342674 Dose H|Single IV Dose
145348|NCT00094796|Procedure|Skeletal muscle biopsy|
144757|NCT01749904|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
144758|NCT01749904|Drug|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
144759|NCT01749917|Other|Exercise program|Exercise program An exercise program including proprioceptive and balance activities during 6 weeks, 3 times per week is conducted by a physical therapist in patients with parkinson.
A brief intervention with a plaster of resistance is also developed according to a protocol of exercises. It takes 20 minutes. After the intervention, grip strength, pressure pain measure, dexterity and neurodynamics.
144760|NCT01749930|Drug|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
144761|NCT01749930|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening.
144762|NCT01749930|Drug|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
144763|NCT01742091|Drug|Placebo - IV|Administered IV
144764|NCT00094900|Drug|IL-1 Trap|
144765|NCT01742117|Drug|Clopidogrel|Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.
144766|NCT01742117|Drug|Ticagrelor|Subjects will receive Ticagrelor, one 90 mg tablet twice per day by mouth.
144767|NCT01742117|Genetic|Retrospective Genotype testing|Mayo Clinic will use ABI TaqMan assay of three variants in the CYP2C10 gene: *2, *3 and *17
144768|NCT01742117|Genetic|Prospective Genotype testing|Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene: *2, *3 and *17
144769|NCT01742130|Drug|sodium bicarbonate solution|
144770|NCT01742130|Drug|Isotonic saline|
144771|NCT01742143|Behavioral|The Integrated Cancer Care Access Network (ICCAN)|Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.
144772|NCT01742143|Behavioral|Usual and Customary Group (U&C)|Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed.
145046|NCT01750034|Procedure|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
145047|NCT01750034|Procedure|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
145487|NCT01748370|Drug|Placebo hypogonadal|
145488|NCT01748370|Drug|Placebo eugonadal|
145489|NCT01748383|Procedure|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
145490|NCT01748383|Procedure|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
144531|NCT01746641|Drug|Propofol|
144532|NCT01746654|Drug|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
144533|NCT01746654|Drug|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
144534|NCT01746654|Drug|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
144535|NCT01746654|Drug|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
144536|NCT01746667|Behavioral|Exposure in vivo|
144537|NCT01746667|Behavioral|Virtual Reality Exposure Therapy|
144538|NCT00095342|Drug|TMI-005|
144539|NCT01746680|Drug|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0~week4, 2mg for week4~week8, 3mg for week8~week24 with MTX ≤20mg/week
144540|NCT01746693|Device|Dynamic Vessel Analyzer|retinal vessel diameter, retinal oxygen saturation
144541|NCT01746693|Other|Laser Doppler Velocimetry|retinal blood flow velocity, retinal blood flow
144542|NCT01746693|Device|7-Tesla MRI|High resolution functional and anatomical imaging of the visual pathway
144543|NCT01746693|Other|Pattern electroretinography|inner retinal function
144544|NCT01746693|Other|Fourier domain optical coherence tomography|Blood flow in retina.
144545|NCT01746706|Device|PET amyloid tracer (Florbetapir F18 AV45 F18|
144546|NCT01746719|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
145209|NCT01747850|Drug|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
145210|NCT01747850|Drug|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
145211|NCT01747863|Other|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at </= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
145212|NCT01747876|Drug|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
145548|NCT01745952|Device|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
145549|NCT01745952|Device|sham rTMS coil (figure-of-eight)|Magstim placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
145550|NCT00095251|Drug|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
145551|NCT01745965|Drug|T-DM1|
145552|NCT01745965|Drug|Trastuzumab|
145553|NCT01745978|Procedure|Precut papillotomy|
145554|NCT01745991|Device|CoSeal spray|
145555|NCT01746004|Drug|[^14C]-LY2157299|[^14C]-LY2157299 monohydrate administered as oral solution
145556|NCT01746017|Drug|Placebo|Administered orally as capsules
145557|NCT01746017|Drug|LY2922470|Administered orally as capsules
145558|NCT01746043|Drug|Armodafinil|150 mg by mouth once a day for 6 weeks.
145559|NCT01746043|Other|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
145560|NCT01746043|Drug|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
145561|NCT00001842|Drug|Dexamethasone|
143406|NCT01662869|Drug|mFOLFOX6|Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 (or as deemed appropriate per investigator),or levofolinic acid 200 mg/m2 (or as deemed appropriate per investigator), 5-fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
143407|NCT01662882|Drug|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
143408|NCT01662895|Drug|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
143409|NCT01662895|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
143410|NCT01665781|Drug|Erythropoietin|
143411|NCT01665794|Drug|pomalidomide|Given PO
143412|NCT01665794|Drug|carfilzomib|Given IV
143413|NCT01665794|Drug|dexamethasone|Given PO or IV
143414|NCT01665807|Biological|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
143415|NCT01665807|Biological|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
143416|NCT00087880|Drug|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
143417|NCT01665820|Device|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
143418|NCT01665846|Drug|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
143419|NCT01665872|Behavioral|Cognitive-Behavioral Group Therapy|CBT Group
143420|NCT01665885|Device|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
143716|NCT01657942|Device|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound
143717|NCT00087269|Procedure|therapeutic endoscopic surgery|Undergo surgical resection
143718|NCT01657955|Drug|Bendamustine Hydrochloride Injection|
143719|NCT01657955|Drug|Chlorambucil|
144139|NCT01661517|Behavioral|Motivational interviewing and referral to treatment|
144140|NCT01661530|Dietary Supplement|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
143168|NCT01667809|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
143169|NCT01667809|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
143170|NCT01667822|Behavioral|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
143171|NCT01667822|Behavioral|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
143172|NCT01667835|Behavioral|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
143173|NCT01667848|Device|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
143174|NCT00088205|Drug|enzastaurin|500 mg, oral, daily, up to six 28 day cycles
143175|NCT01667848|Device|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
143176|NCT01667874|Drug|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
143177|NCT01667900|Drug|Dulaglutide|
143178|NCT01667900|Drug|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
143179|NCT01667913|Other|6 minutes walking test|
143180|NCT01667926|Drug|Ketamine|ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
143181|NCT01667926|Drug|Placebo|
143877|NCT01666600|Radiation|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
143878|NCT01666613|Drug|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
143879|NCT01666613|Drug|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
144193|NCT01658748|Device|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
144194|NCT01658748|Device|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
144195|NCT01658761|Procedure|vitrectomy|Surgery
144196|NCT01658774|Drug|Albendazole|Single 400mg dose
144197|NCT01658774|Dietary Supplement|Vitamin C|500 mg Vitamin C
144198|NCT01658787|Device|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
144199|NCT01658800|Biological|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
144200|NCT00087360|Other|physiologic testing|
144201|NCT01658813|Drug|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
144202|NCT01661543|Dietary Supplement|Beans|90g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
144203|NCT01661543|Dietary Supplement|Control (rice)|90g of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group.
144204|NCT00087568|Drug|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
144205|NCT01661543|Dietary Supplement|Peas|90 grams of peas will be consumed 5 out of 7 days per week
143633|NCT01668914|Radiation|99mTc-SC|Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
143634|NCT01668914|Device|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
143635|NCT01668914|Device|LSG|lymphoscintigraphy was performed 0.5~1.0 hour before surgery
143636|NCT01668927|Drug|Proton Pump Inhibitor|
143637|NCT01668927|Drug|Bismuth|
143638|NCT00088309|Procedure|CT scan|
143639|NCT01668927|Drug|Metronidazole|
143640|NCT01668927|Drug|Tetracycline|
143937|NCT01663857|Drug|Placebo|Administered Orally
143938|NCT01663857|Drug|Gemcitabine|Administered IV
143939|NCT01663870|Behavioral|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
143940|NCT01663870|Behavioral|Focus Group Session|Focus group session taking 60-90 minutes.
143941|NCT01663870|Other|Website Session|10-15 minute session with the HealthATM website.
143942|NCT01663870|Behavioral|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
143943|NCT01663883|Other|Isometric exercise|use of a handgrip for 3x2 minutes
143944|NCT01663909|Behavioral|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
143945|NCT01663922|Drug|Boceprevir|Boceprevir as Victrelis(r) 200mg capsules
143946|NCT00087711|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
143947|NCT01663922|Drug|St John's Wort|Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
143948|NCT01663935|Drug|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
143949|NCT01663961|Drug|YM178 OCAS|oral
143950|NCT01663961|Drug|Digoxin|oral
145349|NCT01740609|Biological|PF-06342674 Dose I|Single SC Dose
145350|NCT01740609|Biological|PF-06342674 Dose J|Single IV Dose
145351|NCT01743105|Procedure|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
145352|NCT01743118|Drug|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
145353|NCT01743118|Drug|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
145354|NCT01743118|Drug|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
145355|NCT01743131|Drug|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
145356|NCT01743131|Drug|placebo|
145357|NCT01743144|Drug|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
145358|NCT01743144|Drug|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
145359|NCT01743157|Drug|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, & 4)
145360|NCT00095056|Drug|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
144391|NCT01741480|Other|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system developed at Washington University.
144392|NCT01741480|Other|routine care|
144393|NCT00094861|Drug|Palifermin|
144394|NCT01741493|Drug|ABT-494|Oral administration of ABT-494 capsules
144395|NCT01741493|Drug|Placebo|Oral administration of placebo capsules
144396|NCT01741493|Drug|Tofacitinib|Oral administration
145048|NCT01750060|Drug|Fentanyl|
145049|NCT01750060|Drug|Naltrexone|
145050|NCT01750073|Drug|paclitaxel|Given IV
145051|NCT01750073|Drug|cyclophosphamide|Given IV
145052|NCT01750073|Biological|trastuzumab|Given IV
145053|NCT01750073|Procedure|therapeutic conventional surgery|Undergo mastectomy or breast conserving surgery
145054|NCT01750073|Radiation|radiation therapy|Undergo RT
145055|NCT00095680|Drug|SCIO-469|two 30-mg capsules three times daily
145056|NCT01750073|Drug|doxorubicin hydrochloride|Given IV
145057|NCT01750073|Other|laboratory biomarker analysis|Correlative studies
145058|NCT01750086|Drug|Teriparatide 40-mcg subcutaneous injection|
145059|NCT01750099|Procedure|Combined Spinal-epidural|See arm description
145060|NCT01750099|Procedure|Continuous Lumbar epidural|See arm description
145061|NCT01742598|Device|Portico Transapical Aortic Valve System|
145062|NCT01742611|Drug|ASP1585|oral
145063|NCT01742624|Drug|Advagraf|oral
145064|NCT01742624|Drug|Prograf|oral
145065|NCT01742624|Drug|Corticosteroid|oral
145066|NCT00095004|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
145067|NCT01742624|Drug|Mycophenolate mofetil|oral
145068|NCT01742637|Drug|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
145069|NCT01742637|Drug|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
145070|NCT01742637|Drug|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
145071|NCT01742650|Procedure|Syndesmosis fixation|
144547|NCT01746719|Drug|Etodolac|500 mg tablet once a day
144548|NCT01746732|Drug|Ortho-Cyclen|Oral administration
144549|NCT00001848|Drug|Raloxifene|
144550|NCT00095355|Drug|Lithium|
144551|NCT01746732|Drug|Evacetrapib|Oral administration
144552|NCT01746745|Drug|[C14]-LY2940680|Administered as solution by mouth
144553|NCT01746758|Behavioral|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
144554|NCT01746771|Drug|HM781-36B(Poziotinib)|QD*2weeks/3weeks
144829|NCT01750112|Device|Macrolane VRF20|Injection treatment with Macrolane VRF20
144830|NCT01750125|Device|measure ascending aortic blood flow with pulse wave Doppler|
144831|NCT01750138|Drug|Glutamine|
144832|NCT01750138|Drug|Dextrose powder|
144833|NCT01750151|Dietary Supplement|Glucose Beverage|
144834|NCT00095680|Drug|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
144835|NCT01750151|Behavioral|Video Game Playing|
144836|NCT01750151|Dietary Supplement|Control Beverage|
144837|NCT01750177|Behavioral|Television Viewing before mealtime|
144838|NCT01750177|Behavioral|Video Game Playing|
144839|NCT01750177|Behavioral|Computer Use|
144840|NCT01750177|Behavioral|Sitting quietly|
144841|NCT01750190|Drug|FG-4592|Oral
144842|NCT01750190|Drug|Placebo|Oral
144843|NCT01750203|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
145562|NCT00095264|Drug|Darbepoetin Alfa|
145563|NCT01746043|Behavioral|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
145564|NCT01746056|Device|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
145565|NCT01746069|Behavioral|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
145566|NCT01746069|Behavioral|health advice|routine clinical practice
145567|NCT01748448|Drug|arachides oleum raffinatum|
145568|NCT00095550|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
145569|NCT01748461|Behavioral|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
145570|NCT01748461|Behavioral|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
145571|NCT01748474|Procedure|Supplemental oxygen via a mask|
144610|NCT01744340|Drug|Colon- Closed as of May 2014|Eribulin Mesylate:
1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
144611|NCT01744353|Drug|FOLFOX-A|Three patients will be accrued to level 1. If no dose limiting toxicities (defined in section 5.2) are observed after two cycles of treatment, then accrual to level 2 will proceed. This procedure will continue until level 3 provided that the MTD has not been reached. If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If dose level 1 is not tolerable then dose level -1 will be investigated.Once the MTD is found, the Principal Investigator will determine which dose should be assessed futher and an additional 10 patients will be treated.
144612|NCT01744366|Drug|Degarelix|
144613|NCT01744366|Drug|Goserelin|
144614|NCT01744379|Drug|Lesinurad|
144615|NCT01744379|Drug|Placebo|
144616|NCT01744392|Behavioral|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
144617|NCT00001839|Drug|Cyclosporine|
144618|NCT01746771|Drug|Paclitaxel|175mg/m2
143720|NCT01657981|Drug|YM150|14C-labeled YM150, oral solution
143721|NCT01657994|Other|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
143722|NCT01658007|Drug|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
143723|NCT01658020|Drug|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
143724|NCT01658020|Drug|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
143725|NCT01658033|Drug|Avastin + mFOLFOX6|mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；
Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w
143726|NCT01660477|Drug|Lopinavir/ritonavir|oral
143727|NCT01660490|Procedure|ORIF|Open reduction internal fixation of the proximal femur
143728|NCT01660503|Dietary Supplement|0 grams SCF|Given in snack foods (muffins and flavored beverage)
143729|NCT01660503|Dietary Supplement|10 grams SCF|Given in snack foods (muffins and flavored beverage)
143730|NCT01660503|Dietary Supplement|20 grams SCF|Given in snack foods (muffins and flavored beverage)
143731|NCT01660529|Biological|hTERT|
143732|NCT01660542|Drug|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
143733|NCT00087516|Drug|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
143734|NCT01660581|Biological|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
143735|NCT01660581|Biological|Placebo|
143736|NCT01660594|Other|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
143737|NCT01660607|Biological|Conventional T cells (Tcon) and Regulatory T cells (Treg)|A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg
144057|NCT01664143|Drug|RO5508887|Multiple doses of RO5508887
143182|NCT01667939|Behavioral|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
143477|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 48 weeks
143478|NCT01662921|Drug|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
143479|NCT01662934|Device|I RUNE|
143480|NCT01662934|Device|sham|
143481|NCT01662947|Device|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
143482|NCT01662947|Device|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
143483|NCT01662960|Behavioral|Visual feedback therapy #1|A home based therapy involving modification of visual feedback.
143484|NCT01662960|Behavioral|Visual feedback therapy #2|A home based therapy involving modification of visual feedback.
143485|NCT01662973|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1*10E6 UC-MSC/kg body weight for 12 weeks.
143486|NCT01662973|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
143487|NCT01662986|Drug|tiotropium bromide|18 mcg QD
143488|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
143489|NCT01662986|Drug|Placebo|QD
143490|NCT01662999|Drug|Saxagliptin|
143491|NCT01662999|Drug|Dapagliflozin|
143492|NCT01663012|Drug|Etirinotecan pegol|
143493|NCT01663025|Behavioral|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
143494|NCT01663038|Drug|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
144206|NCT01661556|Drug|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
144207|NCT01661556|Drug|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
144208|NCT01661569|Other|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
143247|NCT01665573|Drug|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
143248|NCT01665573|Drug|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
143249|NCT01665586|Drug|dexmedetomidine|Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water
dexmedetomidine 0.2~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration
143250|NCT01665599|Drug|Testosterone gel (FE 999303)|The testosterone gel is delivered using an applicator
143251|NCT01665612|Device|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
143252|NCT01665625|Procedure|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
143253|NCT01665638|Drug|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
143254|NCT01665638|Drug|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
143255|NCT01668147|Drug|[11c] desmethyl-loperamide (dLop)|intravenous administration of 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging
143256|NCT01668147|Drug|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 10-14 mCi of [11C]dLop with PET/CT imaging
143257|NCT01668147|Drug|Efavirenz|Pretreatment with oral efavirenz for 14 days followed by intravenous administration of 10-14 mCi of [11C]dLop with PET/CT imaging
143258|NCT00088231|Drug|Imatinib Mesylate (Gleevec)|600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.
400 mg by mouth every day (for AMM) for a 28 day cycle.
143259|NCT01668160|Procedure|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
143951|NCT01663987|Drug|tiotropium bromide|18 mcg QD
143952|NCT01663987|Drug|Placebo|QD
143953|NCT01664000|Drug|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
143954|NCT01664013|Drug|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
143955|NCT01664026|Behavioral|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
143956|NCT01664026|Behavioral|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
143957|NCT01666652|Other|Phosphate buffered saline|
143958|NCT01666652|Biological|1 µg TDENV-PIV with Alum adjuvant|
143959|NCT01666652|Biological|1 µg TDENV-PIV with AS01E1 adjuvant|
144274|NCT01746303|Other|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
144275|NCT01746329|Other|Tea|Oral intake of tea containing 75 grams of glucose
144276|NCT01746329|Other|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
144277|NCT01748773|Drug|Oxaliplatin|100 mg/m2 iv on Day 1, 3 cycles
144278|NCT01748773|Radiation|Radiation|Total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 22 (+/- 3 days) of Cycle 3
144279|NCT01748773|Drug|capecitabine|850 mg/m2 orally bid, Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy
144280|NCT01748773|Drug|trastuzumab [Herceptin]|8 mg/kg iv on Day 1 Cycle 1, 6 mg/kg iv on Day 1 of each following 3-week cycle, 12 months
144281|NCT00095576|Drug|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
144282|NCT01748786|Behavioral|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
144283|NCT01748786|Other|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
144397|NCT01741506|Drug|Dalteparin (Fragmin®)|
144398|NCT01741519|Drug|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
144399|NCT01741519|Drug|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
144400|NCT01741532|Drug|Deferiprone oral solution|Deferiprone oral solution will be given twice daily for 18 months. Dose will be escalated every 6 weeks starting at 5mg/kg, and increasing to 10mg/kg and finally 15 mg/kg.
144401|NCT01741532|Drug|Placebo oral solution|Placebo oral solution will be given twice daily for 18 months. Dose will be escalated every 6 weeks starting at 5mg/kg, and increasing to 10mg/kg and finally 15 mg/kg.
144402|NCT01741545|Biological|Pegylated-Interferon-lambda|
144403|NCT01741545|Drug|Ribavirin|
144404|NCT00094861|Drug|Placebo|
144405|NCT01741545|Drug|Daclatasvir|
144406|NCT01741558|Drug|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
144407|NCT01741558|Drug|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
144408|NCT01741571|Device|EBUS guided FNA with and without suction|Device/procedure: lymph node tissue collection using needle with and without suction applied.
Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied.
144409|NCT01741584|Behavioral|stationary bike exercise|
144410|NCT01741584|Behavioral|aerobic|
144411|NCT01741597|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
144412|NCT01741597|Other|pharmacological study|Correlative studies
144413|NCT01741597|Biological|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
144697|NCT01744418|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
145420|NCT01740635|Device|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
145421|NCT01740648|Drug|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
145422|NCT01740648|Drug|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
145423|NCT01740648|Radiation|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
145424|NCT01740661|Other|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
145425|NCT01740661|Other|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
145426|NCT01740674|Other|Electronic data collection|
145427|NCT00094796|Procedure|Brachial artery reactivity testing|
145428|NCT01740687|Device|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
145429|NCT01740687|Procedure|NovaSure|Nova Sure Endometrial Ablation
145430|NCT01740700|Device|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
145431|NCT01740713|Drug|Deferiprone|deferiprone liquid oral solution (80 mg/ml)
145432|NCT01740726|Behavioral|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
145433|NCT01740726|Drug|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
144844|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 1|Frequency Setting 1
144845|NCT00095693|Drug|sorafenib tosylate|Given PO
144846|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 2|Frequency Setting 2
144847|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 3|Frequency Setting 3
144848|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 4|Frequency Setting 4
144849|NCT01750242|Device|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
144850|NCT01750255|Other|Pharmaceutical Care|Patients and their families will be provided with verbal and written information and education about mental health and bipolar disorder. Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
145136|NCT01750268|Drug|Placebo|Placebo comparator
145137|NCT01750281|Drug|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
145138|NCT00095693|Other|laboratory biomarker analysis|Correlative studies
145139|NCT01750281|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
145140|NCT01750281|Drug|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
145141|NCT01750281|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
145142|NCT01750294|Drug|Chlorthalidone|
145143|NCT01750307|Dietary Supplement|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
145144|NCT01750307|Dietary Supplement|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
145145|NCT01750346|Drug|Topical acetyl hexapeptide-8|
145146|NCT01750359|Drug|curcumin|500 mg/day for 6 week
145147|NCT01750385|Drug|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
144619|NCT01746771|Drug|Trastuzumab|8mg/kg
144620|NCT01746784|Drug|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
144621|NCT01746784|Drug|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
144622|NCT01746810|Radiation|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
144623|NCT01746823|Drug|Cyclosporins|
144624|NCT00095355|Drug|Divalproex|
144625|NCT01746836|Drug|Ponatinib|Starting dose of Ponatinib: 30 mg by mouth once daily.
144626|NCT01746849|Biological|Palifermin|
144627|NCT01746849|Biological|Lupron|
144628|NCT01746849|Procedure|peripheral blood stem cell transplantation|
144629|NCT01746849|Radiation|Total-Body Irradiation (TBI)|
144630|NCT01746849|Drug|Thiotepa|
144631|NCT01746849|Drug|Cyclophosphamide|
144918|NCT01747278|Drug|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
144919|NCT01747304|Device|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
144920|NCT01747317|Device|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization——A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
144921|NCT01747330|Drug|Pancreatin|Doses of Pancreatin <2500 lipase u/kg/feed or <4000 lipase U/g fat/intake or <10000 lipase U/kg/day given orally are used
144922|NCT01747343|Behavioral|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
144923|NCT01747356|Device|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
144924|NCT01747382|Procedure|Renal denervation|
144925|NCT01747395|Other|Exercise training|The heart failure patients are subjected to differents protocols of physical training
144058|NCT01664156|Drug|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
144059|NCT01664156|Drug|Placebo|
144060|NCT01664169|Other|enzyme-linked immunosorbent assay|
144061|NCT01664169|Other|laboratory biomarker analysis|
144062|NCT01664182|Biological|Bevacizumab|Given IV
144063|NCT01664182|Other|Laboratory Biomarker Analysis|Correlative studies
144064|NCT00087737|Drug|DVS-233 SR|
144065|NCT01664182|Drug|Pazopanib Hydrochloride|Given PO
144066|NCT01664182|Other|Pharmacological Study|Correlative studies
144067|NCT01664182|Drug|Sorafenib Tosylate|Given PO
144068|NCT01664182|Drug|Sunitinib Malate|Given PO
144069|NCT01664182|Biological|Trebananib|Given IV
144070|NCT01664195|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
144071|NCT01664221|Drug|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
144072|NCT01666782|Biological|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
144073|NCT01666782|Biological|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
144074|NCT01666808|Drug|FACBC|FACBC is given intravenously prior to PET scan
144075|NCT01666808|Radiation|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
144076|NCT01666821|Other|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
143495|NCT01663038|Drug|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
143496|NCT01663038|Drug|Aspirin|
143497|NCT01663051|Device|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
143498|NCT01665950|Drug|Simvastatin|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
143798|NCT01658046|Other|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
143799|NCT00087269|Other|laboratory biomarker analysis|Correlative studies
143800|NCT01658046|Other|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
143801|NCT01658059|Other|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
143802|NCT01658059|Other|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
143803|NCT01658072|Procedure|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
143804|NCT01658072|Procedure|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
143805|NCT01658085|Device|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
143806|NCT01658085|Device|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
143807|NCT01658098|Behavioral|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
143808|NCT01658111|Device|Robot Group|The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).
The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well.
143809|NCT01658111|Procedure|Traditional physiotherapy|Active or passive exercises.
143810|NCT00087282|Drug|alvocidib|
143260|NCT01668173|Drug|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
143261|NCT01668186|Genetic|Next-generation panel|Molecular testing will be offered to participants whose mutations have not been found. Molecular testing will be done with a next-generation panel of 75 genes on a research basis. Genetic counselling services are available to participants.
143262|NCT01668186|Other|Consultation in Ophthalmology|Participants seen in consultation will have an OCT (optical coherence tomography) eye exam and FAF (fundus autofluorescence) photography.
143263|NCT01668199|Drug|TZP-101|
143264|NCT01668212|Procedure|Doppler ultrasound|Doppler Ultrasound
143558|NCT01660256|Drug|OPC-12759|Instillation, 4 times/day for 4 weeks
143559|NCT01660256|Drug|Placebo|
143560|NCT01660295|Drug|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
143561|NCT00087490|Drug|vancomycin|
143562|NCT01660295|Drug|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
143563|NCT01660295|Drug|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
143564|NCT01660295|Drug|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
143565|NCT01660321|Drug|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
143566|NCT01663064|Device|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
143567|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
143568|NCT01663077|Drug|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
143569|NCT01663090|Drug|Ferumoxytol|
143570|NCT01663103|Drug|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
143571|NCT01663103|Drug|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
144284|NCT01748799|Drug|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
144285|NCT01748799|Drug|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
144286|NCT01748812|Drug|Osteomalacia|
144287|NCT01748825|Drug|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK- 1775 selectively enhanced chemotherapy-induced death of cells deficient in p53 signaling.
144288|NCT01748838|Drug|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
144289|NCT01748838|Other|Mannitol|excipient blended with CTX-4430 in capsules
144290|NCT01748838|Drug|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
144291|NCT01748838|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
144292|NCT00095589|Genetic|loss of heterozygosity analysis|
144293|NCT01748838|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
144294|NCT01748838|Other|Mannitol|excipient blended with CTX-4430
143318|NCT00087867|Drug|SCIO-469|two 30-mg capsules three times daily
143319|NCT01665651|Drug|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
143320|NCT01665651|Drug|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
143321|NCT01665651|Drug|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
143322|NCT01665651|Drug|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
143323|NCT01665664|Other|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
143324|NCT01665677|Drug|Atorvastatin calcium|40 mg PO daily
144698|NCT01744444|Drug|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
144699|NCT01744444|Drug|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
144700|NCT01744457|Device|Measurement of tear film osmolarity with the TearLab® instrument|
144701|NCT01744457|Other|Schirmer I test|
144702|NCT01744457|Other|Tear break up time|
144703|NCT01744457|Device|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
144704|NCT01744457|Other|Ocular Surface Disease Index|
144705|NCT01744470|Drug|Tacrolimus targeted half-dose|
144706|NCT01744470|Drug|Tacrolimus targeted plain dose|
144707|NCT00095147|Drug|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
144708|NCT01744483|Device|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
144709|NCT01744483|Device|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
144710|NCT01744483|Device|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
144711|NCT01744496|Drug|Rotigotine|Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
144712|NCT01744496|Drug|Placebo|Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
145434|NCT01740752|Behavioral|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
145435|NCT01740752|Behavioral|CBT|weekly manualized higher "dose" of individual CBT
144471|NCT01749124|Device|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
144472|NCT01749137|Drug|RM-493|
144473|NCT01749137|Drug|Placebo|
144474|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
144475|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
144476|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
144477|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
144478|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
144479|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
144480|NCT00095589|Procedure|computed tomography|
144481|NCT01749163|Biological|Saline|
144482|NCT01741623|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
144483|NCT01741623|Drug|Bisoprolol|10 mg tablet once a day
144484|NCT01741636|Other|educational intervention|Undergo Survivorship Care Planning
144485|NCT01741636|Other|questionnaire administration|Ancillary studies
144486|NCT01741636|Procedure|quality-of-life assessment|Ancillary studies
144487|NCT01741649|Procedure|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
144488|NCT01741649|Procedure|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
144489|NCT01741662|Other|neuropsychological evaluation|
145148|NCT01750385|Drug|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
145149|NCT00095693|Other|pharmacological study|Correlative studies
145150|NCT01750398|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
145151|NCT01750398|Drug|Goserelin|Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an "LHRH agonist."
145152|NCT01750398|Drug|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
145153|NCT01750424|Procedure|Autologous Fat Grafting|
145154|NCT01750437|Drug|YH1885L(Revaprazan)|
145155|NCT01750437|Drug|Esomeprazole 20mg|
145156|NCT01750437|Drug|placebo|
145157|NCT01750463|Other|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
145491|NCT00095550|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
145492|NCT01748383|Procedure|stenting of IRA|The only stent implantation
145493|NCT01748396|Drug|Calcitriol|
145494|NCT01748396|Drug|Calcium Carbonate|
145495|NCT01748409|Other|Biopsies of peripheral autonomic nervous system|
145496|NCT01748409|Other|Autonomic dysfunction questionnaires|
145497|NCT01748409|Other|Electrophysiological tests|
145498|NCT01748422|Drug|Qutenza|Transdermal patch
145499|NCT01748435|Drug|Qutenza|Single treatment with Qutenza
145500|NCT01748448|Drug|Vitamin D|prospective interventional randomized double blind placebo controlled trail
clinical setting (tertiary university hospital)
investigator driven, no pharmaceutical sponsor
cutaneous malignant melanoma patients
add- on study (placebo or vitamin D) on top of optimal standard care
1:1 inclusion ratio (placebo:Vitamin D)
randomisation after informed consent and screening
144926|NCT01747408|Drug|Human Albumin|25% human albumin given in four escalating doses:
Group 1: .625g/kg infused over 3hrs daily X 7day
Group 2: 1.25g/kg infused over 3hrs daily X 7day
Group 3: 1.875g/kg infused over 3hrs daily X 7day
Group 4: 2.5g/kg infused over 3hrs daily X 7day
144927|NCT01747447|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
144928|NCT00095420|Behavioral|Usual training|Participants will receive the usual training offered in their local school districts.
144929|NCT01747447|Drug|Fish oil placebo|Fish oil placebo
144930|NCT01749514|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
144931|NCT00095641|Drug|capecitabine|
144932|NCT01749527|Behavioral|minimal activity|Pad test with minimal activity
144933|NCT01749540|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
144934|NCT01749553|Other|Sleeper Stretch|Posterior shoulder stretch technique
144935|NCT01749566|Drug|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
144936|NCT01749579|Drug|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
144937|NCT01749579|Drug|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
144938|NCT01749579|Drug|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
145213|NCT01747889|Device|electronic chest drainage system|Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.
On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients
145214|NCT01747902|Procedure|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
145215|NCT01747902|Procedure|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
145216|NCT01747915|Drug|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
144077|NCT01666847|Procedure|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
143110|NCT01659424|Radiation|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
143111|NCT01659437|Drug|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
143112|NCT01659437|Drug|Streptomycin intramuscular injection|daily intramuscular drug injection
143113|NCT01659450|Other|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
143114|NCT01659450|Other|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
143115|NCT01659450|Other|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
143116|NCT00087412|Drug|erlotinib hydrochloride|Given orally
143117|NCT01659463|Other|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
143118|NCT01659463|Behavioral|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
143119|NCT01659476|Other|Methacholine(MCh) Challenge Testing|Visit 1: High-dose methacholine challenge test
Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine.
143120|NCT01659476|Other|Methacholine(MCh) Challenge Testing|Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.
Visit 2: Subjects will perform the opposite protocol, based on their first visit:
143121|NCT01662180|Drug|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
143122|NCT01662193|Dietary Supplement|vitamin D3 supplement|
143123|NCT01662193|Dietary Supplement|calcium supplement|
143124|NCT01662193|Dietary Supplement|vitamin D3 and calcium supplement|
143125|NCT01662193|Dietary Supplement|placebo|
143811|NCT01658124|Drug|Tranexamic Acid|
143812|NCT01658124|Drug|Placebo|
143813|NCT01658137|Other|Prudent Diet|This intervention lasts 2 weeks (14 days).
143814|NCT01658137|Other|Typical Western Diet|This intervention lasts 2 weeks (14 days).
143815|NCT01658150|Drug|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
143816|NCT01658176|Drug|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
143817|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
144141|NCT01661530|Dietary Supplement|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
144142|NCT01664234|Other|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
144143|NCT01664234|Other|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
144144|NCT01664247|Drug|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
144145|NCT00087737|Drug|Venlafaxine ER|
144146|NCT01664247|Drug|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
144147|NCT01664247|Drug|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
144148|NCT01664260|Drug|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
144149|NCT01664260|Drug|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
144150|NCT01664273|Drug|Plasmid AMEP|Cohorts of 3 patients will received increasing doses of plasmid AMEP:
50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.
Injection volume will remain constant at 200 μL.
Once-only treatment and intra-individual dose escalation will therefore not occur.
144151|NCT01664507|Drug|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
144152|NCT01664507|Drug|low dose epinephrine|low dose epineprhine : 0.05mg/kg + normal saline
143572|NCT01663116|Genetic|Stem cells|first cohort: 1 million stem cells/kg administered at days 1, 8 and 15
second cohort: 2 million stem cells / kg administered at days 1, 8 and 15
third cohort: 4 million stem cells / kg administered at days 1, 8 and 15
143573|NCT01663116|Genetic|Placebo|first cohort: 20 ml administered at days 1, 8 and 15
second cohort: 40 ml administered at days 1, 8 and 15
third cohort: 80 ml administered at days 1, 8 and 15
143574|NCT01663155|Device|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
143575|NCT01663168|Drug|Rifabutin|
143576|NCT01663194|Procedure|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
143577|NCT01663233|Drug|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
143578|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
143880|NCT01666613|Drug|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
143881|NCT01666613|Drug|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
143882|NCT01666626|Procedure|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
143883|NCT00088049|Drug|Aripiprazole|
143884|NCT01666639|Behavioral|Behavioral Medical Rehabilitation plus behavioral exercise therapy|The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An "Behavioral Exercise Therapy" (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity.
143885|NCT01666639|Behavioral|Usual Behavioral Medical Rehabilitation|The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more "traditional" concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each.
143886|NCT01666652|Biological|4 µg TDENV-PIV with Alum adjuvant|
143887|NCT01666652|Biological|1 µg TDENV-PIV with AS03B1 adjuvant|
143888|NCT01658202|Drug|Nicotine transdermal patch (Reference Treatment )|
143325|NCT01665690|Other|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
143326|NCT01665690|Behavioral|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
143327|NCT01665703|Procedure|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
143328|NCT01665742|Dietary Supplement|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks
AND
4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks
in conjunction with a weight management programme
143329|NCT00087867|Drug|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
143330|NCT01665742|Dietary Supplement|Placebo supplement|1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks
AND
4 x film-coated placebo tablets daily for 8 weeks
in conjunction with a weight management programme
143331|NCT01665755|Device|Upstroke Compression Defibrillation|
143332|NCT01665755|Device|Precompression Defibrillation|
143333|NCT01665768|Drug|Everolimus and Rituximab|Everolimus: The initial dose of everolimus will be 5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL Rituximab: 375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
143334|NCT01668537|Biological|LF formulation of IMVAMUNE®|
143641|NCT01660334|Drug|Voriconazole|Voriconazole Intravenous Solution 200 mg:
Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.
Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:
administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.
Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.
However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.
In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.
Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
143642|NCT01660347|Biological|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
143643|NCT01660347|Biological|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
144976|NCT01744795|Other|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
144977|NCT01744808|Drug|EB-1020 IR|Immediate release
144978|NCT01744808|Drug|EB-1020 SR1|sustained release
144979|NCT01744808|Drug|EB-1020 SR2|Sustained release
144980|NCT01744808|Drug|EB-1020 SR3|Sustained release
144981|NCT01744808|Other|Placebo|Placebo formulation
144982|NCT00095173|Drug|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
144983|NCT01744821|Dietary Supplement|Arm A: Vitamin D3 Group|
144984|NCT01744821|Dietary Supplement|Placebo|
144985|NCT01744847|Device|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
144986|NCT01744873|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
144987|NCT01744873|Drug|Bisoprolol|10 mg tablet once a day
144988|NCT01744886|Procedure|maintain oxygenation during one lung ventilation|All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.
If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung.
144989|NCT01744899|Other|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
144990|NCT01744912|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
144991|NCT01744912|Drug|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
144992|NCT01744925|Drug|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
144993|NCT00095173|Drug|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing < 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing > 100 kg, monthly
144490|NCT01741675|Behavioral|Questionnaire and monetary incentive|
144491|NCT01741675|Behavioral|Questionnaire only|
144492|NCT00094861|Drug|Paclitaxel|
144493|NCT01741688|Other|No intervention|No intervention was administered in this study
144773|NCT01742169|Behavioral|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
144774|NCT01742182|Other|Light exposure|
144775|NCT00094926|Drug|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
144776|NCT01742195|Procedure|Oral EBUS insertion|
144777|NCT01742195|Procedure|Nasal EBUS insertion|
144778|NCT01742208|Drug|LX4211|Subjects will receive LX4211 once daily for 29 days
144779|NCT01742208|Drug|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 29 days
144780|NCT01742208|Drug|LX4211|Subjects will receive LX4211 once daily for 29 days; pioneer subjects will complete dosing prior to dosing any other study subjects.
144781|NCT01742221|Biological|HemaMax|Placebo
144782|NCT01742234|Procedure|Organ Donation|People in this study will donate either a lung or kidney
144783|NCT01742247|Other|Physiogel|Application of moisturizer on laser-treated area
144784|NCT01742247|Other|Moisturizer|Application of moisturizer on laser-treated area
144785|NCT01742260|Procedure|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
144786|NCT00094926|Drug|placebo|matching placebo IM injections every 2wks for 52wks
144787|NCT01742273|Drug|Vitamin K1|Vitamin K1 to slow vascular calcification
144788|NCT01744522|Procedure|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
145501|NCT01740765|Other|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
145502|NCT01740791|Drug|GS-5816|3 days of monotherapy of GS-5816
145503|NCT00094809|Drug|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
145504|NCT01740817|Drug|Intralipid 20%|30 ml/h for 48 h
145505|NCT01740817|Drug|Saline|30 ml/h for 48 h
145506|NCT01740830|Device|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
145507|NCT01740843|Device|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
145508|NCT01740856|Other|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
145509|NCT01740856|Other|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
145510|NCT01740869|Other|Stem cells|
144555|NCT01749163|Biological|GIP|
144556|NCT01749163|Biological|GLP-1|
144557|NCT01749176|Behavioral|SMS texting intervention|
144558|NCT01749176|Behavioral|Control-Usual Care|
144559|NCT01749189|Dietary Supplement|Blend|22 grams of protein/day
144560|NCT01749189|Dietary Supplement|Whey|22 grams of protein/day
144561|NCT01749189|Dietary Supplement|Placebo|22 grams of carbohydrate/day
144562|NCT01749202|Dietary Supplement|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
144563|NCT01749202|Dietary Supplement|EPA softgels|3 x 500 mg softgel capsules/day
145217|NCT01747915|Drug|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
145218|NCT00095472|Drug|Sodium Nitrite|
145219|NCT01747915|Drug|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
145220|NCT01747928|Other|dual-chamber syringe|dual-chamber syringe for mock injection
145221|NCT01747941|Drug|PF-06305591|single dose, solution
145222|NCT01747941|Drug|Placebo|matching placebo
145223|NCT01747941|Drug|PF-06305591|single dose, solution
145224|NCT01747941|Drug|Placebo|matching placebo
145225|NCT01747941|Drug|PF-06305591|single dose, solution
145226|NCT01747941|Drug|Placebo|matching placebo
145227|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
145228|NCT01740375|Procedure|esophagectomy|esophagectomy
145229|NCT01740388|Drug|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
145230|NCT00094770|Drug|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
145231|NCT01740388|Drug|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
145232|NCT01740401|Drug|Cyclophosphamide, Ipilimumab|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimuab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
145572|NCT01748487|Drug|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
145573|NCT01748500|Drug|Pantoprazole|
145574|NCT01748513|Other|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
145575|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
145576|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
143126|NCT00087607|Drug|Copegus|1000/1200mg/day po
143127|NCT01662206|Dietary Supplement|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
143128|NCT01662206|Dietary Supplement|Placebo|2 capsules daily containing 348.25 mg of potato starch
143421|NCT01665885|Device|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
143422|NCT01665898|Procedure|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
143423|NCT01665898|Procedure|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
143424|NCT01665911|Drug|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
143425|NCT01665911|Drug|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
143426|NCT01665911|Drug|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
143427|NCT00087945|Drug|Abacavir sulfate|
143428|NCT01665911|Drug|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
143429|NCT01665911|Other|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
143430|NCT01665924|Drug|GLPG0634 100mg capsule once a day for 10 days|
143431|NCT01665937|Drug|STA-9090|IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.
During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen.
143432|NCT01667952|Genetic|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
143433|NCT00088218|Drug|Clofarabine|1-hour IV infusion 30 mg/m^2 daily times 5 days (Days 1-5)
143434|NCT01667952|Other|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
144153|NCT01664520|Drug|Dexmedetomidine infusion|Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.
Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments
144154|NCT01664533|Drug|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
144155|NCT01664546|Procedure|Trophectoderm biopsy|
144156|NCT00087750|Drug|Quetiapine|
144157|NCT01664559|Drug|Ketorolac|Ketorolac 30mg intramuscular injection, 1cc volume
144158|NCT01664559|Drug|Normal Saline|Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
143183|NCT01667952|Genetic|Family History Questionnaire (FHQ)|Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the "You" in the questionnaire refers to their child.
143184|NCT01659502|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
143185|NCT01659515|Drug|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
143186|NCT01659541|Device|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
143187|NCT01659541|Procedure|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
143188|NCT01659554|Drug|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
143189|NCT01659554|Drug|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
143190|NCT00087412|Other|laboratory biomarker analysis|Correlative studies
143191|NCT01659580|Drug|T89 high dose|225mg bid
143889|NCT00087282|Drug|irinotecan hydrochloride|
143890|NCT01658215|Drug|V0116 transdermal patch (Test treatment )|
143891|NCT01658215|Drug|Nicotine transdermal patch (Reference treatment )|
143892|NCT01658228|Drug|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
143893|NCT01658228|Drug|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
143894|NCT01658241|Drug|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
143895|NCT01658254|Other|survey by email|The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject "Posting basic results". The controlled group will receive no intervention.
143896|NCT01658267|Other|nutritional supplement|2 servings per day
144209|NCT01661582|Other|CT/PET Myocardial Perfusion Imaging using O-15 water|
144210|NCT01661582|Other|Coronary blood flow measured by doppler echocardiography|
144211|NCT01661595|Drug|Sildenafil|50 mg/day for 4 weeks
144212|NCT01661595|Drug|tadalafil|10 mg/day for 4 weeks.
144213|NCT01661595|Drug|Placebo|Placebo 1 capsule per day for four weeks.
144214|NCT01661608|Device|Using the EOS for gastric restriction|
144215|NCT00087568|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
144216|NCT01661621|Drug|Detrusitol 4 mg QD|Group 1
144217|NCT01661621|Drug|Doxazosin 4 mg QD|Group 2
144218|NCT01661634|Drug|Ularitide|
144219|NCT01661634|Drug|Placebo|
144220|NCT01661647|Device|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
143644|NCT01660347|Procedure|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
143645|NCT01660360|Biological|Tanibirumab|
143646|NCT01660373|Drug|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
143647|NCT00087503|Drug|Edotecarin|
143648|NCT01660373|Drug|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
143649|NCT01660386|Drug|Sitagliptin|100mg po once
143650|NCT01660386|Drug|Saxagliptin|5mg po once
143651|NCT01660386|Drug|Glimepiride|2mg po once
143652|NCT01660386|Drug|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
143653|NCT01660399|Drug|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
143654|NCT01660399|Drug|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
143655|NCT01660412|Drug|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40.
143656|NCT01660412|Drug|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
143657|NCT01660425|Behavioral|Enhancement with psychosocial intervention|
143658|NCT00087516|Drug|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
143659|NCT01660451|Drug|Copanlisib (BAY80-6946)|BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.
Part B: The individual dose will be 60 mg per infusion from Cycle 1 on.
143960|NCT01666665|Drug|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
143961|NCT01666665|Drug|Sugar pill|Sugar pill up to 3 times per day for 12 months
143962|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
143963|NCT00088062|Drug|STA-5326|
144994|NCT01744925|Drug|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
144995|NCT01744938|Procedure|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
145361|NCT01743170|Other|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
145362|NCT01743183|Device|Threshold|The load adjustment was done weekly by a single examiner.
145363|NCT01743222|Genetic|eASC|First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.
Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells.
145364|NCT01743222|Drug|Placebo|First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node
Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node
145365|NCT01743235|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
145366|NCT01743235|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
145367|NCT01743235|Drug|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
145368|NCT01743261|Other|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
145369|NCT01743261|Other|usual care|specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.
the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty
145370|NCT01745575|Drug|Alprazolam 2 mg tablets|Test product
145371|NCT00095225|Drug|Avastin (bevacizumab)|
145372|NCT01745588|Drug|Pomalidomide|
145373|NCT01745588|Procedure|stem cell|
145374|NCT01745588|Drug|Dexamethasone|
145375|NCT01745588|Drug|Clarithromycin|
145376|NCT01745601|Drug|escitalopram 10 mg|Reference product
145377|NCT01745601|Drug|escitalopram 10 mg|Test product
145378|NCT01745614|Drug|Nimesulide 100 mg tablets|Reference product
144789|NCT01744535|Behavioral|"My Meal Mate" (smartphone application)|A smartphone application called "My Meal Mate" (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message.
144790|NCT01744535|Behavioral|Paper food diary|The paper food diary is provided by a commerical slimming organisation called "Weight Loss Resources". The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity.
144791|NCT01744535|Behavioral|Online food diary|The online food diary is provided by a commerical slimming organisation called "Weight Loss Resources". The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity.
145072|NCT01742663|Drug|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
145073|NCT01742663|Drug|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
145074|NCT01742663|Drug|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
145075|NCT01742676|Drug|ADVAGRAF|oral
145076|NCT01742676|Drug|PROGRAF|oral
145077|NCT00095004|Drug|Comparator: placebo / Duration of Treatment: 1 day|
145078|NCT01742689|Drug|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
145079|NCT01742689|Drug|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
145080|NCT01742689|Drug|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
145081|NCT01742702|Drug|Nitroglycerin 0.25 mg (single dose)|Single dose of sublingual nitroglycerin to examine acute haemodynamic effects
145082|NCT01742702|Drug|Salbutamol 400 µg (single dose)|Single dose of inhaled salbutamol to examine acute haemodynamic effects
145083|NCT01742702|Drug|L-arginine (10 min infusion)|L-arginine infusion 10 mg/kg/min for 10 minutes to examine acute haemodynamic effects
145084|NCT01742702|Dietary Supplement|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention
145085|NCT01742702|Dietary Supplement|Small milk casein-derived polypeptides (yoghurt, 12 weeks daily)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention
145086|NCT01742702|Drug|Bisoprolol (5mg daily for 3 weeks)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions.
144564|NCT00095589|Procedure|cystoscopy|
144565|NCT01749202|Other|Sunflower Oil Food|3 servings/day
144566|NCT01749202|Other|SDA soybean Oil Food|3 servings/day
144567|NCT01749215|Drug|Topiramate|
144568|NCT01749215|Drug|placebo|
144569|NCT01749228|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
144570|NCT01749228|Drug|Etodolac|500 mg tablet once a day
144571|NCT01749241|Drug|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
144572|NCT01749241|Drug|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
144573|NCT01749267|Procedure|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
144574|NCT01749293|Procedure|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
144575|NCT00095628|Drug|ispinesib|Given IV
144576|NCT01749293|Drug|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
144577|NCT01749293|Drug|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
144578|NCT01749293|Radiation|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
144851|NCT01750255|Other|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
144852|NCT01750268|Behavioral|Medical Management Counseling|Brief alcohol and medication counseling
144853|NCT01750268|Drug|Topiramate|Experimental medication
144854|NCT01742286|Drug|LDK378|LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via NG/G tube
145577|NCT01748539|Drug|KHK4827|
145578|NCT01748539|Drug|Placebo|
145579|NCT00095550|Drug|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
145580|NCT01748552|Drug|Placebo|Administered orally as capsules
145581|NCT01748552|Drug|LY2922083|Administered orally as capsules
145582|NCT01748578|Drug|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
145583|NCT01748578|Drug|EBI-005-1 Placebo|
145584|NCT01748604|Other|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
145585|NCT01748604|Device|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
145586|NCT01748604|Other|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
145587|NCT01748604|Device|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
145588|NCT01748617|Other|Controlled diet|1 week of controlled diet
145589|NCT01748630|Drug|dexmedetomidine|
145590|NCT00095563|Drug|lapatinib ditosylate|Given orally
145591|NCT01748630|Drug|Midazolam|
145592|NCT01748630|Drug|fentanyl|
145593|NCT01748643|Drug|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio > 0.9.
145594|NCT01740960|Drug|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
145595|NCT01740986|Drug|SA09012 Low dose|Tablet, b.i.d
144632|NCT01746862|Drug|Saizen®|Saizen® (Recombinant-human growth hormone [r-hGH]) will be administered subcutaneously as 6 days per week at a weight based dose of 0.067 mg/kg/day for 12 months in Saizen® treatment group and for 6 months in control group.
144633|NCT01746875|Drug|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
143435|NCT01667965|Behavioral|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
143436|NCT01667978|Drug|Norethindrone acetate|
143437|NCT01668004|Biological|Golimumab|Golimumab 50 mg subcutaneously once monthly.
143438|NCT01668017|Drug|Pimasertib|Pimasertib will be supplied as 15 and 30 mg hard gelatin capsules. Pimasertib will be taken orally twice a day continuously. Treatment will be administered in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject, whichever comes first.
143738|NCT01660620|Drug|Betaxolol|
143739|NCT01660620|Drug|topical betaxolol|given topically
143740|NCT01660633|Drug|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
143741|NCT01660646|Behavioral|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
143742|NCT01660659|Device|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
143743|NCT01660672|Drug|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
143744|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
143745|NCT01660685|Behavioral|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
143746|NCT01660685|Behavioral|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
143747|NCT01660685|Behavioral|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
143748|NCT00087659|Drug|zoledronic acid|
143749|NCT01663402|Drug|placebo|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
143750|NCT01663415|Drug|Enzalutamide|oral
143192|NCT01659580|Drug|T89 Low dose|150mg bid
143193|NCT01659580|Drug|Sanqi+Bingpian|225 mg bid
143194|NCT01659580|Drug|Placebo|225mg bid
143195|NCT01659593|Other|procog|3 to 5 people group program
143196|NCT01659593|Other|Placebo|
143197|NCT01659606|Biological|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV x 5 doses
143198|NCT01659606|Drug|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
143199|NCT01659606|Drug|Cyclosporins|Starting Day -2 beginning at 1.5 mg/kg IV twice per day, infused over 2 hours, titrated to maintain a serum trough level of 150 -200 ng/ml. CSA will be administered for a minimum of 6 months and then tapered over 10 weeks.
143200|NCT01659606|Drug|Mycophenolate mofetil|15 mg/kg IV three times a day from day 0 to day +53
143201|NCT00087425|Biological|rituximab|
143202|NCT01659619|Drug|Erythromycin|125mg in normal saline single use infusion for 5 min.
143499|NCT01665950|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
143500|NCT01665963|Device|TopClosure(c) System|
143501|NCT01665963|Device|Pressure Bandage|
143502|NCT01665976|Drug|RO4917838|film coated tablet, single dose
143503|NCT01665976|Drug|RO4917838|oral suspension, single dose
143504|NCT00087945|Drug|Abacavir sulfate, lamivudine, and zidovudine|
143505|NCT01665976|Drug|RO4927838|hard gelatin capsule, single dose
143506|NCT01665989|Behavioral|Group Lifestyle Program|
143507|NCT01665989|Behavioral|Usual Care|Visits with a dietitian at nutrition services at MGH
143508|NCT01666002|Device|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
163758|NCT01821898|Drug|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
163759|NCT01821898|Other|Elimination diet|This group will receive an elimination diet
163760|NCT01821911|Biological|Zagreb2-1-1|Injection on day 0、7、21
163761|NCT01821911|Biological|Essen|Injection on day 0、3、7、14、28
163762|NCT01821937|Drug|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
163763|NCT01821937|Drug|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
163764|NCT01821950|Behavioral|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
163765|NCT01821963|Drug|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
163766|NCT01821963|Drug|Ribavirin|Starting dose: 1,000 mg by mouth daily.
163767|NCT01821963|Drug|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
163768|NCT01814514|Drug|Timolol-trusopt|
163769|NCT01814514|Drug|placebo|
163770|NCT01814527|Dietary Supplement|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
163771|NCT01814527|Drug|Placebo|5 capsules that are identical to the treatment.
164049|NCT01817530|Drug|Estradiol/norethindrone acetate, E2/NETA|E2/NETA Dose 1
164050|NCT01817530|Drug|Estradiol/norethindrone acetate|E2/NETA Dose 2
164051|NCT01817543|Device|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
164052|NCT01817556|Drug|Stillen Tab.|
164053|NCT01817556|Drug|Mucosta Tab.|
164054|NCT01817582|Drug|Lotemax Gel + Restasis|
164055|NCT01817582|Drug|Lotemax Gel|
164056|NCT01817582|Drug|Restasis|
163441|NCT01819077|Procedure|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
163442|NCT01819090|Device|Elysee 150 ventilator|
163443|NCT01819090|Device|Elysee 150 ventilator with a ventilation switch control|
163444|NCT01819129|Drug|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
163445|NCT01819129|Drug|insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
163446|NCT01819129|Drug|insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
163447|NCT01819142|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
163448|NCT01819155|Biological|Adjuvanted seasonal trivalent inactivated influenza vaccine|
163449|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
163450|NCT01819155|Biological|Seasonal trivalent inactivated influenza vaccine|
163451|NCT01819155|Biological|Saline (bacteriostatic 0.9% sodium chloride for injection)|
163452|NCT01819194|Device|Senofilcon A, 38% water|
163453|NCT01821625|Drug|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
163454|NCT01821651|Device|HeartNavigator|Procedure with software
163455|NCT01821651|Device|EchoNav|Procedure with software
163456|NCT00102388|Drug|vildagliptin|
163457|NCT01821651|Other|Control-Group EN|Procedure without software
163458|NCT01821651|Other|Control-group HN|Procedure without software
163459|NCT01821664|Device|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
163460|NCT01821677|Drug|Low Dose Danazol|
163461|NCT01821677|Drug|Placebo|
167843|NCT01856764|Drug|0.5% Roflumilast Cream|Roflumilast 0.5% cream
167844|NCT00105885|Procedure|telephone care|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
167845|NCT01856764|Drug|Vehicle Cream|Roflumilast formulation vehicle
167846|NCT01856777|Device|Semi-quantitative panel test|
167847|NCT01856777|Device|High sensitivity urine pregnancy test|
167848|NCT01856790|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
167849|NCT01856790|Drug|liraglutide|Liraglutide is a long-acting analog of human GLP-1 that works as a GLP-1 receptor agonist
167850|NCT01856803|Drug|anti thymoglobulin|
168152|NCT01859611|Device|TriActive+ RF|Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special "skin contact identification" system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts.
168153|NCT01859624|Drug|Albuterol|Albuterol 4 mg
168154|NCT00106275|Behavioral|Mindfulness Based Stress Reduction|
168155|NCT01859637|Drug|Eligible patients will be treated with Zarzio®/Filgrastim HEXAL®|
168156|NCT01859650|Other|MR and CT imaging|
168157|NCT01859689|Radiation|brachytherapy|Undergo image-guided HDR brachytherapy
168158|NCT01859689|Radiation|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
168159|NCT01859689|Other|laboratory biomarker analysis|Correlative studies
168160|NCT01859702|Drug|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
168161|NCT01859715|Drug|Oxycodone|Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.
168162|NCT01859715|Drug|Hydrocodone|Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.
168163|NCT01859715|Drug|Ondansetron|Subjects given ondansetron for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
167540|NCT01861106|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
167541|NCT01861106|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
167542|NCT01861106|Drug|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
167543|NCT01853982|Drug|Piperacillin/Tazobactam|
167544|NCT01853995|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
167545|NCT00105521|Drug|Sarizotan HC1|
167546|NCT01854008|Other|rehabilitation more the urban circuit|included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called "A PEU, FEM SALUT! Itineraris urbans per Mataró" http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
167547|NCT01854008|Other|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
167548|NCT01854021|Procedure|intravenous anesthesia|intravenous anesthesia
167549|NCT01854021|Procedure|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
167550|NCT01854021|Procedure|inhalational anesthesia|inhalational anesthesia
167551|NCT01854034|Drug|AUY922|AUY922 administered intravenously once a week at 70mg/m2
167552|NCT01854047|Drug|Dupilumab|Pharmaceutical form: solution
Route of administration: subcutaneous
167553|NCT01854047|Drug|placebo|Pharmaceutical form: solution
Route of administration: subcutaneous
167851|NCT01856816|Other|Meal Pattern Treatment A|In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich "chef's salad" ingredients were distributed equally between meals.
167852|NCT01856816|Other|Meal Pattern Treatment B|In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich "chef's salad" ingredients were distributed equally between meals.
167853|NCT01856816|Other|Meal Pattern Treatment C|In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich "chef's salad" ingredients were distributed equally between meals.
167854|NCT01856829|Dietary Supplement|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
167220|NCT01830686|Other|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
167221|NCT01830686|Other|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
167222|NCT01830699|Drug|Rilonacept|160 mg intra-bursal once
167223|NCT01830699|Drug|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
167224|NCT01830712|Drug|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
167225|NCT00103285|Drug|leucovorin calcium|Given PO
167226|NCT01830738|Procedure|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
167227|NCT01822951|Drug|Cerebrolysin|Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.
Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.
167228|NCT01822951|Drug|Donepezil|5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.
Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.
167229|NCT01822964|Device|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
167230|NCT01822964|Device|Placebo - current clinical practice, no cooling|
167231|NCT01822977|Drug|omeprazole|
167232|NCT01823003|Radiation|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall > 1 cm, tumour size < 2 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
167233|NCT01823003|Radiation|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall > 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
167234|NCT00102583|Drug|Subconjunctival Cyclosporine Implant|
166919|NCT01827553|Radiation|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
166920|NCT01827553|Drug|Chemotherapy, gemcitabine|5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d
166921|NCT01827553|Drug|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
166922|NCT00103051|Drug|cisplatin|
166923|NCT01827566|Other|gluten|
166924|NCT01827566|Other|gluten free flour|
166925|NCT01827579|Biological|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
166926|NCT01827592|Drug|Elobixibat 10 mg|Elobixibat 10 mg/day
166927|NCT01827592|Drug|Elobixibat 5 mg|Elobixibat 5 mg/day
166928|NCT01827592|Drug|Placebo|Placebo
166929|NCT01827605|Other|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
166930|NCT01827605|Drug|BEAM|BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution
from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr
day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr
day 0
UReinfusion of autologous stem cells following this rules:
Patient collecting ≥6x106 CD34+ cells/kg use >4x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;
Patient collecting 4-6x106 CD34+ cells/kg use >2x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;
Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.
day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC > 1500/mmc
166931|NCT01827618|Drug|Rapamycin|
166932|NCT01830023|Device|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
166933|NCT01830049|Other|Take blood|
166934|NCT01830062|Other|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
166935|NCT01830062|Other|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
166936|NCT01830075|Behavioral|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
172397|NCT01874782|Device|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
172398|NCT01874795|Device|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
172399|NCT01874795|Device|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
172400|NCT01874821|Device|Dynasplint|Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or "Experimental" group will add this therapy to their standard of care regimen
172401|NCT00107887|Drug|INH preventive therapy|Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
172402|NCT01874821|Other|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
172696|NCT01880814|Behavioral|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
172697|NCT01880827|Procedure|Roux-en-Y|Subjects in the intervention group will be divided into two consecutive surgical groups, and operated at the Department of Surgery at Turku University Hospital (Kiinamyllynkatu 4-8, Turku). During surgery, Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) is performed using standard laparoscopic techniques. In RYGB procedure large part of the ventricle, duodenum, and proximal jejunum (ad 1.5 meters from pylorus) is bypassed. "New" stomach pouch is anastomosed into the "new" proximal jejunum, and remaining larger portion of the stomach, duodenum, and jejunum are reattached to the distal part of the jejunum for the secretion of pancreatic, gastrointestinal, and biliary juice. In SG a notable amount of ventricle is removed to create a stomach pouch which effectively restricts the amount of food feasible to ingest. After the surgery, subjects are controlled in hospital ward for approximately three days.
172698|NCT00108368|Drug|Risperidone|
172699|NCT01880827|Drug|GIP-infusion|Blood flow and volume during infusion
172700|NCT01880827|Drug|GLP-1|Blood flow and volume during infusion
172701|NCT01880827|Drug|MMS|Blood flow and volume after meal solution
172702|NCT01880827|Procedure|Sleeve gastrectomy|
172703|NCT01880840|Drug|205.5 mcg of azelastine hydrochloride|nasal spray
172704|NCT01880840|Drug|137 mcg of azelastine hydrochloride|nasal spray
172705|NCT01880853|Other|mammography|participants were screened by mammography alone every year
172095|NCT01882374|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
172096|NCT01882387|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
172097|NCT01882400|Drug|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
172098|NCT01882413|Other|No intervention|No intervention
172099|NCT01882426|Other|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
172100|NCT01882426|Other|Usual Care|usual step care practice
172101|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
172102|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 6 months
172103|NCT00108524|Behavioral|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
172104|NCT01882439|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
172105|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
172106|NCT01882439|Other|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
172403|NCT01874834|Other|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
172404|NCT01874847|Dietary Supplement|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
172405|NCT01874847|Dietary Supplement|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
172406|NCT01874860|Drug|Doxycycline|Doxycycline capsule, 100 mg, taken twice daily
172407|NCT01877499|Other|Optimization of HDF key parameters|First, patients actually receiving standard dialysis will be switched to post-dilution HDF.
Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.
Precisely, the following 3 parameters will successively be increased towards a maximal target:
Treatment time (up to 4 hours per session);
Blood flow rate (up to 400 mL/min;
Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).
Maximal values for these parameters will be those achieved within pre-specified safety limits.
172408|NCT01877512|Drug|Change in daily dosage of Growth Hormone|
172409|NCT01877525|Procedure|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
171787|NCT01879241|Drug|Rasagiline|
171788|NCT01879241|Drug|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
171789|NCT01879254|Device|Deep Brain Stimulation|
171790|NCT01879267|Behavioral|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
171791|NCT01879280|Procedure|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
171792|NCT01879280|Procedure|Osteoplastic craniotomy|In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an "osteoplastic craniotomy"). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity.
171793|NCT01879293|Drug|Metformin|
171794|NCT01879293|Drug|placebo|
171795|NCT01879319|Biological|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
171796|NCT00108264|Biological|Tumor RNA transfected dendritic cells|
171797|NCT01879319|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
171798|NCT01879332|Drug|Placebo|Matching placebo tablets for oral administration
171799|NCT01879332|Drug|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
171800|NCT01879332|Drug|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
171801|NCT01879345|Drug|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
172107|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 3 months
172108|NCT01882452|Behavioral|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
171159|NCT00112736|Other|pharmacological study|Correlative studies
171160|NCT01927315|Drug|Placebo|Oral Placebo tablets once daily
171161|NCT01927328|Drug|Iron isomaltoside 1000|
171465|NCT01922778|Procedure|Endometrial Biopsy|Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.
For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter.
171466|NCT01922791|Dietary Supplement|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
171467|NCT01922804|Dietary Supplement|K2 vitamin|K2 vitamin tablet
171468|NCT01922804|Dietary Supplement|Placebo|Placebo tablets
171469|NCT00112502|Drug|Celecoxib|400 mg orally twice a day continuous dosing
171470|NCT01922817|Drug|Saxagliptin|5mg saxagliptin
171471|NCT01922830|Dietary Supplement|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
171472|NCT01922830|Dietary Supplement|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
171473|NCT01922843|Drug|DP001 softgel capsules|
171474|NCT01922856|Biological|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
171475|NCT01922856|Other|No Intervention|Controls only receive challenge
171476|NCT01922869|Dietary Supplement|Flavonoids|
171477|NCT01922882|Behavioral|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
171478|NCT01922895|Dietary Supplement|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
171479|NCT01922895|Drug|Placebo for Probiotic|Capsule manufactured without active ingredients.
171480|NCT00112502|Drug|Isotretinoin|40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.
167050|NCT01822691|Drug|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
167051|NCT01822704|Device|Low intensity whole body vibration|
167052|NCT01822704|Device|High intensity whole body vibration|
167053|NCT01822704|Behavioral|Leg exercises|
167054|NCT01822717|Behavioral|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
167367|NCT01853761|Device|Exercise after|Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.
30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.
167368|NCT01853761|Device|Exercise at same time|Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.
30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.
167369|NCT01853761|Device|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
167370|NCT01853761|Device|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
167371|NCT01853761|Device|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
167372|NCT01856010|Other|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
167373|NCT01856010|Other|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
167374|NCT01856023|Drug|High Dose Interleukin-2|
167375|NCT01856023|Drug|Ipilimumab|
167376|NCT01856036|Procedure|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
167377|NCT01856049|Other|Collection of umbilical cord blood|
166732|NCT01827228|Other|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
166733|NCT01827228|Other|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
166734|NCT00103012|Drug|Panax ginseng|Panax ginseng 500 mg twice daily
166735|NCT01827228|Behavioral|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
166736|NCT01829633|Procedure|Physiotherapy|Shoulder physiotherapy with exercises
166737|NCT01829646|Other|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
166738|NCT01829646|Other|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
166739|NCT01829646|Other|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
166740|NCT01829659|Drug|Ticagrelor|
166741|NCT01829672|Radiation|Dual-energy computed tomography investigation|1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.
1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration
166742|NCT00103246|Drug|silicon phthalocyanine 4|Patients receive topical silicon phthalocyanine 4 (Pc 4). One hour later, patients undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 patients receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
167055|NCT00102505|Drug|Motexafin Gadolinium Injection|
167056|NCT01822717|Behavioral|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
167057|NCT01822730|Drug|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
167058|NCT01822730|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
167059|NCT01822743|Procedure|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
167060|NCT01822743|Procedure|sham comparator|
167061|NCT01822756|Drug|ruxolitinib|
167062|NCT01822756|Drug|gemcitabine|Other names: Gemzar®
166430|NCT01824030|Device|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
166431|NCT01824043|Drug|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
166432|NCT01824056|Drug|18F-FDG|During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
166433|NCT01824069|Other|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
166434|NCT01824082|Drug|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
166435|NCT01824095|Dietary Supplement|Dietary supplement|
166436|NCT01824108|Procedure|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
166437|NCT00102700|Drug|ARQ 501 in combination with gemcitabine|
166438|NCT01826591|Behavioral|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
166439|NCT01826604|Device|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used. Other hand-held retractors that are deemed necessary to the surgery by the physician will also be used.
166440|NCT01826604|Other|Control- Conventional hand-held retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
166441|NCT01826630|Other|CLn BodyWash|Comparing two washes to determine change in bacterial load.
166442|NCT00102960|Drug|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
166443|NCT01826630|Other|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
165541|NCT01840189|Other|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
165542|NCT01840189|Other|Solu-cortef|Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
This part of the study will take 2 months.
165543|NCT00104299|Drug|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m^2 infusions once weekly for 4 week
165544|NCT01840228|Drug|Micronized progesterone suppository|
165545|NCT01840241|Drug|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
165828|NCT01833533|Drug|Placebo for Ribavirin|Capsule
165829|NCT01833546|Drug|TH-302 monotherapy|TH-302 will be administered weekly at a dose ranging from 240-480 milligram per square meter (mg/m^2) as intravenous infusion over 30 or 60 minutes on Day 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
165830|NCT01833546|Drug|TH-302|TH-302 will be administered weekly at a dose of either 240 or 340 mg/m^2 as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle, until evidence of progressive disease, intolerable toxicity or subject withdrawal.
165831|NCT01833546|Drug|Gemcitabine|Gemcitabine will be administered weekly at a dose of 1000 mg/m^2 as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle, until evidence of progressive disease, intolerable toxicity or subject withdrawal.
165832|NCT01833559|Dietary Supplement|Dietary control|
165833|NCT01833559|Drug|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
165834|NCT01833572|Drug|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
165835|NCT01833585|Biological|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
165836|NCT01833598|Procedure|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
165837|NCT01833598|Procedure|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
165838|NCT01828138|Dietary Supplement|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
165839|NCT01828138|Dietary Supplement|Placebo|Placebo are given in 5 days
164942|NCT01834482|Dietary Supplement|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
164943|NCT01834495|Device|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
164944|NCT01834495|Device|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
164945|NCT01834508|Drug|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
164946|NCT00103558|Drug|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
164947|NCT01834521|Other|Web-based screening and tailored support|
164948|NCT01834534|Behavioral|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
164949|NCT01836757|Drug|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
164950|NCT01836757|Drug|Placebo|
164951|NCT01836783|Other|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
165249|NCT01837303|Procedure|Pap smear|A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.
These slides will be processed so that they may be reviewed by a single board certified pathologist.
There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo.
165250|NCT01837316|Drug|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
165251|NCT01837316|Drug|Placebo|First strip: Inhalation powder of lactose
165252|NCT01837329|Drug|Tetrathiomolybdate|Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.
Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.
Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.
Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.
Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles.
165253|NCT01837342|Procedure|Surgical reserction|
165254|NCT01837342|Other|Radiological percutaneous drainage and washing drainage|
164361|NCT01820637|Device|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
164362|NCT01820650|Device|iTotal G2 CR Knee Replacement System|Total Knee replacement
164363|NCT01820663|Other|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
164364|NCT00102271|Drug|Sodium Nitrite|
164365|NCT01820663|Other|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
164366|NCT01820676|Device|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
164367|NCT01820689|Other|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
164368|NCT01820702|Other|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at ~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against ~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
164369|NCT01820715|Drug|600㎍ of DA-3030 Injection|
164370|NCT01820715|Drug|Placebo|
164371|NCT01820728|Drug|DA-3801 Injection|
164372|NCT01820728|Drug|Gonal-F®|
164672|NCT01833936|Device|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
164673|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
164674|NCT01833949|Procedure|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
164675|NCT01833949|Procedure|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
164057|NCT00101985|Drug|talnetant|
164058|NCT01817595|Other|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
164059|NCT01817595|Other|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
164060|NCT01817621|Behavioral|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
164061|NCT01817621|Behavioral|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
164062|NCT01817634|Dietary Supplement|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
164063|NCT01817634|Dietary Supplement|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
164064|NCT01817634|Dietary Supplement|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
164065|NCT01817634|Dietary Supplement|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
164066|NCT01817647|Procedure|Colorectal surgery|
164067|NCT01817660|Procedure|Open repair of popliteal artery|
164068|NCT01820117|Other|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
164373|NCT01813084|Drug|RV1729 single dose|Safety and tolerability of single escalating doses
164374|NCT01813084|Drug|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
164375|NCT01813084|Drug|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
164376|NCT01813084|Drug|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
164377|NCT01813110|Drug|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
164378|NCT01813110|Drug|Placebo|
163772|NCT01814540|Dietary Supplement|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
163773|NCT01814540|Dietary Supplement|Placebo Glucose Polymer|
163774|NCT00101647|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
163775|NCT01814553|Drug|afatinib|Daily treatment starting 40 mg per day
163776|NCT01814553|Drug|loperamide|Follow cohort assignment and diarrhea management guidelines
163777|NCT01814579|Device|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
163778|NCT01814579|Device|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
163779|NCT01814592|Procedure|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
163780|NCT01814592|Procedure|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
163781|NCT01814605|Procedure|Infragluteal space group|Sciatic Nerve Block "Infragluteal group": Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.
The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
163782|NCT01814605|Procedure|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
163783|NCT01814618|Drug|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
163784|NCT01814631|Other|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
163785|NCT00101660|Drug|Dasatinib|Tablets; oral; 70 mg BID, depending on response
163786|NCT01814631|Other|image quality and resolution|image quality and resolution will be viewed on the EU-me2
168164|NCT01862120|Drug|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
168165|NCT01862120|Drug|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
168166|NCT01862133|Other|Patient preferences|Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
168167|NCT01862146|Procedure|smoke expose|
168168|NCT01862159|Procedure|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
168169|NCT01862172|Other|Additional MRI|
168170|NCT01862185|Other|semi-quantitative procalcitonin|
168171|NCT01862198|Device|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
168172|NCT01862211|Other|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
168173|NCT01862224|Drug|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
163462|NCT01821690|Drug|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
163463|NCT01821690|Drug|Placebo|
163464|NCT01821703|Drug|LY3045697|Administered as oral solution
163465|NCT01821703|Drug|Placebo|Administered as oral solution
163466|NCT01821703|Drug|Spironolactone|Administered as capsule
163467|NCT00002000|Drug|Acyclovir|
163468|NCT00102388|Drug|Gliclazide|
163469|NCT01821703|Drug|Placebo|Administered as capsule
163470|NCT01821716|Biological|Prick test Dermatophagoides pteronyssinus allergen extract|This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
163471|NCT01821729|Drug|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
167855|NCT00105898|Procedure|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
167856|NCT01856829|Other|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
167857|NCT01856842|Procedure|Angiography and embolotherapy|
167858|NCT01856855|Radiation|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
167859|NCT01856868|Drug|(-)-epicatechin|
167860|NCT01856881|Drug|AMG 876|Ascending multiple doses of study drug administered SC
167861|NCT01856907|Drug|Sitagliptin-Metformin|Experimental -DPP-4 inhibitor- oral medication
167862|NCT01856907|Drug|Metformin|Biguanide- insulin sensitizer
167863|NCT00106210|Behavioral|Early intervention blending several treatment approaches|Early intervention blending several different treatment approaches
167864|NCT01859013|Other|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
167865|NCT01859026|Drug|MEK162|Treatment as outlined in study arms.
167866|NCT01859026|Drug|Erlotinib|Treatment as outlined in study arms.
167867|NCT01859039|Biological|Administration of Live attenuated influenza vaccine|
167868|NCT01859052|Other|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
167869|NCT01859052|Other|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
168174|NCT00106535|Drug|Placebo|IV/month
168175|NCT01862224|Drug|Placebo|Matching placebo once daily (Week 0 to Week 12).
168176|NCT01862224|Drug|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
168177|NCT01862237|Other|Intervention|blood collection
Completion of a pre-operative cardiac MRI.
Completion of a coronary angiography examination
Completion during the surgery d'une myocardial biopsy,
Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year
Completion of a cardiac MRI 1 year after surgery.
167554|NCT01854047|Drug|Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) therapy|Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol at stable dose, oral inhalation
167555|NCT01854073|Drug|Hyoscine butyl bromide|
167556|NCT00002030|Drug|Pentamidine isethionate|
167557|NCT00105534|Drug|AzaSite|1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected
eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
167558|NCT01854073|Drug|Normal saline|
167559|NCT01854086|Other|Questionnaires about compliance and persistence with bisphosphonates treatment|
167560|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 1.
167561|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 2.
167562|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m^2 x 21 days) with group 3.
167563|NCT01854125|Biological|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
167564|NCT01854125|Biological|autologous bone marrow msenchymal stem cells transplantation|
167565|NCT01856270|Drug|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
167566|NCT01856283|Drug|Nilotinib 300mg BID|Nilotinib
167567|NCT01856296|Procedure|Biopsy|
167568|NCT01856309|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
167569|NCT00000292|Procedure|Cocaine|
167570|NCT00002033|Drug|Zidovudine|
166937|NCT01830088|Behavioral|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
167235|NCT01823003|Radiation|50Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall < 1 cm, tumour size < 5 cm and distance to main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
167236|NCT01823003|Radiation|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size < 5 cm and distance to the main bronchus < 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
167237|NCT01823016|Drug|Placebo|Placebo tablet, taken once daily
167238|NCT01823016|Drug|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
167239|NCT01823029|Drug|erythropoietin|
167240|NCT01823029|Drug|enteral nutrition.|
167241|NCT01823029|Drug|injection of iron|
167242|NCT01823042|Drug|azathioprine+enteral nutrition|
167243|NCT01823042|Drug|Azathioprine|
167244|NCT01823055|Procedure|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
167245|NCT01825408|Drug|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
167246|NCT01825421|Other|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
167247|NCT01825434|Dietary Supplement|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
167248|NCT01825447|Drug|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
167249|NCT00002002|Drug|Sulfamethoxazole|
167250|NCT00102856|Drug|Pramipexole|
167251|NCT01825447|Drug|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
172706|NCT01880853|Other|ultrasound|participants were screened by ultrasound alone every year
172707|NCT01880853|Other|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
172708|NCT01880866|Drug|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
172709|NCT00108368|Drug|Olanzapine|
172710|NCT01880879|Device|helios stent|the group with helios stent implanted
172711|NCT01880892|Procedure|Cricopharyngeal myotomy|Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
172712|NCT01880892|Device|Restech's Dx-pH Probe|This is not an intervention, but a newer device that measure the pH of the nasopharynx and detects laryngopharyngeal reflux. We will perform 24 hour tests with this device to see if there is an increase in laryngopharyngeal reflux follow cricopharyngeal myotomy.
172713|NCT01880905|Procedure|Measure of uteroovarian ligament length during gynecological surgery|
173024|NCT01875913|Behavioral|Standard Message|Participants will receive email messages that contain "standard" language encouraging them to complete their VHRs (health review that can be completed online).
173025|NCT01875926|Biological|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
173026|NCT01875926|Biological|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
173027|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,8 application)
173028|NCT01875926|Biological|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
173029|NCT01875939|Drug|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
173030|NCT01875939|Drug|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
173031|NCT01875952|Drug|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
173032|NCT01875978|Dietary Supplement|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
173033|NCT01875991|Drug|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
172410|NCT01877538|Other|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand [11C]donepezil
172411|NCT01877551|Drug|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
172412|NCT01877551|Other|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
172413|NCT01877564|Drug|Metformin|
172414|NCT01877577|Dietary Supplement|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
172415|NCT01877590|Drug|alpha-lipoic acid|
172416|NCT00108082|Drug|lisinopril|Comparator
172417|NCT01877616|Other|diagnostic test|Polysomnography
172418|NCT01877616|Other|Diagnostic test|overnight polysomnography
172419|NCT01877629|Drug|ACT-129968 500 mg Tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
172420|NCT01877629|Drug|ACT-129968 250 mg Capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
172421|NCT01877642|Drug|ADASUVE 10 mg|
172422|NCT01877642|Drug|Lorazepam 2 mg IM|
172714|NCT01872754|Drug|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
172715|NCT01872754|Drug|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2.5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
172716|NCT00107588|Behavioral|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
172717|NCT01872780|Drug|Rosiglitazone|single oral administration of 4mg of rosiglitazone
172718|NCT01872780|Genetic|CYP2C8 genotype|CYP2C8*11.
172719|NCT01872806|Radiation|a dialing smartphone will be placed on the chest and the ear|
172109|NCT01882452|Behavioral|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
172110|NCT01874288|Drug|10.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
172111|NCT01874301|Other|High quantity probiotic|The intervention type is food product
172112|NCT01874301|Other|Low quantity probiotic|The intervention type is food product
172113|NCT01874301|Other|placebo|
172114|NCT01874314|Drug|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
172115|NCT01874314|Other|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
172116|NCT01874314|Drug|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
172117|NCT01874327|Behavioral|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
172118|NCT01874327|Behavioral|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
172119|NCT00107796|Drug|Modafinil|
172120|NCT01874340|Drug|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
172121|NCT01874340|Drug|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
172122|NCT01874353|Drug|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
172423|NCT01877642|Drug|Staccato Placebo|Inhaler with no drug in it to mimic the ADASUVE inhaler
172424|NCT01877642|Drug|Placebo IM|placebo IM solution to mimic lorazepam 2 mg IM
172425|NCT01877655|Biological|ASP0113|intramuscular injection
171481|NCT01922908|Biological|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
171482|NCT01922908|Biological|Placebo Comparator|Normal saline
171483|NCT01922921|Biological|HER-2/neu Intracellular Domain Protein|Given ID
171484|NCT01922921|Other|Laboratory Biomarker Analysis|Correlative studies
171485|NCT01922921|Biological|Pertuzumab|Given per standard of care
171802|NCT01879345|Drug|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
171803|NCT01879345|Drug|Placebo|placebo tablets
171804|NCT01881776|Procedure|ISB|In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.
For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter.
171805|NCT01881789|Drug|Oprozomib|Subjects will receive Oprozomib extended release (ER) Tablets (hereafter referred to as oprozomib) administered orally, once daily on 1, 2, 8, 9, 15,16, 22 and 23 of 28-day cycles
171806|NCT01881789|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg on Days 1-21 of 28 day cycles
171807|NCT01881789|Drug|Dexamethasone|Subjects will receive dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28 day cycles
171808|NCT01881789|Drug|Cyclophosphamide|Subjects will receive cyclophophamide 300 mg/m2 on Days 1, 8 and 15 of 28 day cycles
171809|NCT01881815|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
171810|NCT01881828|Drug|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
171811|NCT01881828|Other|oral placebo|
171812|NCT00108446|Drug|naloxone|
171813|NCT01881841|Behavioral|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
171814|NCT01881867|Biological|Glycosylated Recombinant Human Interleukin-7|Given SC
171815|NCT01881867|Other|Laboratory Biomarker Analysis|Correlative studies
167378|NCT01856062|Drug|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
167379|NCT00105768|Behavioral|Advisor-Teller Money Management-Substance Abuse Counselling|
167380|NCT01856062|Drug|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
167381|NCT01856088|Device|Inspiron Stent|stent implantation
167382|NCT01856088|Device|Biomatrix Flex Stent|stent implantation
167383|NCT01856101|Drug|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
167702|NCT00106184|Drug|Placebo|Treatment Group A: placebo infusion at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1
167703|NCT01858831|Drug|Atovaquone|Atovaquone
167704|NCT01858844|Other|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
167705|NCT01858870|Drug|lacosamide|routine clinical practice
167706|NCT01858883|Drug|INCB039110|
167707|NCT01858883|Drug|Gemcitabine|
167708|NCT01858883|Drug|nab-paclitaxel|
167709|NCT01858883|Drug|filgrastim|
167710|NCT01858896|Drug|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
167711|NCT01858896|Other|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
167712|NCT01858909|Drug|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
167713|NCT00106197|Drug|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
167714|NCT01861366|Other|A one year multifaceted implementation strategy|
167063|NCT01822756|Drug|nab-paclitaxel|Other names: Abraxane®
167064|NCT01822756|Drug|filgrastim|
167065|NCT01822769|Other|Cardiopulmonary rehabilitation|See Arm Description
167066|NCT00102518|Drug|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
167067|NCT01822769|Other|Standard of care|See Arm Description
167068|NCT01825044|Drug|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
167069|NCT01825057|Behavioral|See One|
167070|NCT01825057|Behavioral|Do One|
167071|NCT01825057|Behavioral|Order One|
167072|NCT01825070|Dietary Supplement|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
167073|NCT01825083|Drug|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
167074|NCT01825083|Drug|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
167075|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
167076|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
167077|NCT00102804|Other|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
167384|NCT01856114|Drug|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
167385|NCT01856114|Other|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
167386|NCT01856114|Behavioral|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
167387|NCT01856127|Drug|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
166444|NCT01826656|Procedure|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
166743|NCT01829685|Drug|Entecavir, Adefovir|
166744|NCT01829698|Drug|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
166745|NCT01829698|Drug|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
166746|NCT01829711|Drug|moxetumomab pasudotox|
166747|NCT01829711|Drug|IV Bag Protectant for Moxetumomab pasudotox|
166748|NCT01829750|Genetic|Cardiac progenitor cell infusion|(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group
(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1.
166749|NCT01829763|Drug|injection botox|
166750|NCT01829776|Behavioral|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
166751|NCT01829789|Behavioral|Group Community Reinforcement Training for Parents|
166752|NCT01829789|Behavioral|Individual Community Reinforcement Training for Parents|
166753|NCT00103259|Drug|bortezomib|Given IV
166754|NCT01829802|Drug|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
166755|NCT01829802|Drug|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
166756|NCT01829802|Drug|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
166757|NCT00102440|Drug|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
166758|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
166759|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers earned independent of cocaine use
166760|NCT01822340|Drug|HM10560A|Once weekly HM10560A
166761|NCT01822340|Drug|Genotropin|Once daily Genotropin
165840|NCT01828151|Device|Noninvasive ventilation mask|
165841|NCT01828164|Device|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
165842|NCT01828164|Device|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
165843|NCT01828177|Drug|PDI-320|
165844|NCT01828177|Drug|PDI-320 Monad #1|
165845|NCT01828177|Drug|PDI-320 Monad #2|
165846|NCT00103103|Drug|leucovorin calcium|
165847|NCT01828177|Drug|Vehicle|
166137|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
166138|NCT00103298|Drug|isolated perfusion|
166139|NCT01831284|Procedure|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
166140|NCT01831297|Device|measurement of blood pressure|measurement of pulse wave velocity
166141|NCT01831310|Dietary Supplement|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
166142|NCT01831310|Dietary Supplement|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
166143|NCT01831310|Dietary Supplement|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
166144|NCT01831310|Dietary Supplement|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
166145|NCT01831323|Dietary Supplement|VSL#3|VSL#3
165255|NCT01837355|Dietary Supplement|Lactobacillus rhamnosus|
165256|NCT01837355|Dietary Supplement|Placebo|
165257|NCT01837368|Other|observational research|It is a observational research, no intervention are performed
165258|NCT00002013|Drug|Zidovudine|
165259|NCT00103857|Drug|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
165260|NCT01837381|Procedure|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol [absolute alcohol], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
165261|NCT01837394|Procedure|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
165262|NCT01837394|Procedure|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
165263|NCT01837394|Drug|Paracetamol|
165264|NCT01839799|Drug|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
165265|NCT01839799|Drug|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
165266|NCT01839799|Radiation|Chemoradiation|
165546|NCT01840241|Drug|normal saline|
165547|NCT01840254|Drug|dexmedetomidine|
165548|NCT01840254|Drug|normal saline|
165549|NCT01840267|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
165550|NCT01840306|Other|Biomarker Analysis|
165551|NCT01840332|Drug|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is < 30 after 4 weeks the study continues up to 6 weeks.
165552|NCT01840345|Drug|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
164676|NCT01833975|Biological|Transplantation of Autologous stem cell [MNCs] .|Intra thecal transplantation of Autologous stem cell [MNCs],100millions per dose in 3 divided doses at interval of 10 days.
164677|NCT01833988|Device|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
164678|NCT01833988|Other|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
164679|NCT01834014|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164680|NCT01834014|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164681|NCT01834014|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164682|NCT01834014|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164683|NCT01834014|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164684|NCT00103506|Drug|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
164685|NCT01834014|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164686|NCT01834027|Behavioral|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
164687|NCT01834027|Behavioral|No music|In this group no music will be played in PACU
164688|NCT01834040|Other|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
164689|NCT01834053|Biological|autologous Stem Cell|Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
164952|NCT01836783|Other|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
164953|NCT01836796|Dietary Supplement|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
164954|NCT01836796|Dietary Supplement|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
164379|NCT00101439|Drug|ezetimibe|Duration of Treatment: 56 days
164380|NCT01813123|Behavioral|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
164381|NCT01813136|Drug|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
164382|NCT01813136|Drug|Intermittent pazopanib (Arm B)|Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.
This sequential scheme will be maintained until the patient experiences "on-treatment" progression
164383|NCT01813149|Drug|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
164384|NCT01813149|Other|punch biopsy|
164385|NCT01813162|Drug|Tenofovir 1% gel|
164386|NCT01813162|Drug|Vaginal product|
164387|NCT01813175|Other|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
164388|NCT01813175|Other|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
164389|NCT01813175|Other|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
164390|NCT00101439|Drug|Comparator: placebo|Duration of Treatment: 56 days
164391|NCT01813188|Procedure|ABM seeded onto a porous TCP and DBM|cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.
Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)
164392|NCT01813188|Procedure|autologous bone graft|autologous bone graft
164690|NCT01836393|Drug|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
164691|NCT01836406|Drug|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
163787|NCT01814644|Behavioral|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
163788|NCT01817153|Drug|hydrocortison hemisuccinate|
164069|NCT01820117|Procedure|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
164070|NCT00102206|Drug|Tenofovir disoproxil fumarate|
164071|NCT01820117|Other|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
164072|NCT01820117|Other|Sleep Assessment|A subset of survivor group participants will complete a full sleep assessment consisting of overnight polysomnography (PSG) and multiple sleep latency test (MSLT). This is standard testing used to diagnose sleep disorders.
164073|NCT01820130|Device|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
164074|NCT01820143|Drug|Ilaprazole|
164075|NCT01820143|Drug|Esomeprazole|
164076|NCT01820156|Device|Home Respiratory Polygraphy|
164077|NCT01820156|Device|Standard Polysomnography|
164078|NCT01820169|Device|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
164079|NCT01820182|Device|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
164080|NCT01820195|Drug|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
164081|NCT00102206|Drug|Zidovudine|
164082|NCT01820195|Drug|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
164083|NCT01820195|Drug|Placebo group|The patients in this group will be received both oral placebo and IV placebo
164084|NCT01820208|Drug|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
164085|NCT01820208|Drug|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
163472|NCT01821729|Drug|Losartan|Taken orally every day during Phase I for all 8 cycles
163473|NCT01821729|Radiation|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
163474|NCT01821742|Other|Ultrasound cardiac output measurement|
163475|NCT01821755|Behavioral|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
163476|NCT01821768|Procedure|Sentinel Lymph Node Biopsy|
163477|NCT01821781|Drug|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
163478|NCT01821794|Drug|Peginterferon and Tenofovir|
163479|NCT00102401|Behavioral|Internet-based Dyspnea Self-Management Program|
163480|NCT01814046|Biological|Young TIL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
163481|NCT01814059|Drug|sirolimus|
163482|NCT01814072|Behavioral|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
163789|NCT01817153|Drug|placebo followed by hydrocortisone hemisuccinate|
163790|NCT01817166|Drug|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
163791|NCT01817166|Drug|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
163792|NCT01817166|Other|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
163793|NCT01817166|Biological|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
163794|NCT01817166|Biological|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
163795|NCT01817166|Biological|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
163796|NCT01817179|Other|FES neuroprosthesis to dorsiflexors on affected leg|
168178|NCT01862250|Drug|Clonidine (Duraclon®)|Clonidine at dosing intervals that may be every 4, 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.
10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration
20% drop in HR from the infant's baseline, sustained for ≥30 min after administration
HR ≤70/min, sustained for ≥30 min after administration
168179|NCT01862263|Drug|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
168180|NCT01862263|Drug|Insulin|Long- acting human insulin analog indicated to improve glycemic control
168181|NCT01862263|Drug|Placebo|Matching placebo of vildagliptin
168182|NCT01862289|Other|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
168183|NCT01862302|Drug|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
168184|NCT01862302|Drug|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
168185|NCT00002038|Drug|Fluconazole|
168186|NCT00106535|Drug|Methotrexate|10-25 mg/week
168187|NCT01862315|Drug|Floxuridine (FUDR)|
168188|NCT01862315|Drug|dexamethasone|
168189|NCT01855048|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
168190|NCT01855048|Other|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
168191|NCT01855061|Procedure|Biopsy|Histological biopsy of the "index lesion" (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity.
168192|NCT01855061|Procedure|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
168193|NCT01855061|Procedure|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
163483|NCT01814072|Behavioral|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
163484|NCT01814072|Behavioral|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
163485|NCT01814072|Behavioral|Text Messages|Participants will receive regular text messages
167571|NCT00105807|Behavioral|participation in art and music activities|
167870|NCT01859052|Other|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
167871|NCT01859065|Behavioral|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
167872|NCT01859065|Behavioral|Routine|Routine anticipatory guidance (control)
167873|NCT01859078|Drug|Baricitinib|Administered orally
167874|NCT00002035|Drug|Zidovudine|
167875|NCT00106223|Behavioral|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
167876|NCT01859078|Drug|Digoxin|Administered orally
167877|NCT01859091|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
167878|NCT01859104|Behavioral|Use of smartphone app|
167879|NCT01859117|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
167880|NCT01859117|Biological|10 x 10^6 cells|10 x 10^6 cells administered on Study Days 1 and 8
167881|NCT01859117|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
167882|NCT01859117|Biological|100 x 10^6 cells|100 x 10^6 cells administered on Study Days 1 and 8
167883|NCT01859130|Device|Zimmer Persona Total Knee System|
167884|NCT01859143|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
167885|NCT01859143|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
167886|NCT00106236|Behavioral|exercise|
167887|NCT01861977|Behavioral|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
167252|NCT01825447|Drug|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
167253|NCT01825460|Other|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
167254|NCT01825460|Other|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
167572|NCT01856309|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
167573|NCT01856309|Drug|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
167574|NCT01856322|Drug|Sulindac|one tablet 150mg twice daily
167575|NCT01856322|Drug|Placebo|One tablet twice daily
167576|NCT01856322|Other|Validate assays and shipping methods|
167577|NCT01856335|Other|Patient Education|
167578|NCT01856335|Other|exercise: increase physical activity/goal setting|
167579|NCT01856348|Drug|Vitamin D|
167580|NCT01856361|Drug|Ramipril|Angiotensin Converting Enzyme Inhibitor
167581|NCT01856361|Drug|Placebo|Placebo pill that will match the treatment pill
167582|NCT00105820|Procedure|System level depression care quality improvement|
167583|NCT01856374|Device|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
167584|NCT01856374|Device|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
167585|NCT01856374|Drug|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
167586|NCT01856374|Drug|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
167587|NCT01856387|Biological|high neutrophil to lymphocyte ratio|
173034|NCT01875991|Drug|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
173035|NCT01876004|Drug|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
173036|NCT01876004|Drug|Placebo|Prescribed Placebo IM (intramuscularly), single dose
173037|NCT01876017|Biological|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
173038|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,8 application)
173039|NCT01876030|Device|FES|
173040|NCT01876043|Drug|plitidepsin|
173041|NCT01876056|Behavioral|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
173042|NCT01876069|Device|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
173043|NCT01876069|Device|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
173330|NCT01899495|Other|High sodium diet and low sodium diet|Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
173331|NCT01899508|Procedure|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
173332|NCT01899508|Device|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
173333|NCT01899521|Procedure|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
173334|NCT01899521|Dietary Supplement|Zinc sulfate 220 mg once daily|
173335|NCT01899521|Dietary Supplement|S-adenosylmethionine 400 mg twice daily|
173336|NCT00110110|Biological|filgrastim|Given after chemo cycle for 7 days or until neutrophil counts return to normal.
173337|NCT01899534|Other|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
172720|NCT01872819|Other|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
172721|NCT01872819|Drug|chemotherapy|Patients receive 1 of 160 possible interventions
172722|NCT01872819|Biological|biological therapy|Patients receive 1 of 160 possible interventions
172723|NCT01872832|Drug|RDEA3170 and Placebo|
172724|NCT01872845|Drug|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
172725|NCT01872845|Drug|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
172726|NCT01872858|Drug|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
172727|NCT00107588|Behavioral|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
172728|NCT01872858|Drug|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
172729|NCT01872871|Drug|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
172730|NCT01872871|Drug|Topical anaesthetic drop with placebo|
172731|NCT01872884|Drug|Sevorane Remifentanil|
172732|NCT01872884|Drug|Remifentanil|
172733|NCT01872897|Drug|Sodium Alginate Double Action Tablets|Four tablets as a single dose
172734|NCT01872897|Drug|Placebo|4 tablets as a single dose
172735|NCT01872910|Drug|Placebo|Administered orally
172736|NCT01872910|Drug|LY3023703|Administered orally
173044|NCT01878643|Drug|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
173045|NCT01878643|Drug|Placebo|normal saline administered to patient via nebulization
173046|NCT01878656|Drug|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
173047|NCT01878656|Drug|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
172426|NCT01877655|Drug|Placebo|intramuscular injection
172427|NCT00108095|Drug|intravenous ondansetron|
172428|NCT01877668|Drug|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
172429|NCT01877668|Drug|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
172430|NCT01877668|Drug|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
172431|NCT00108355|Drug|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
172432|NCT01880372|Dietary Supplement|Alpha Lipoic Acid|Same as Arm description
172433|NCT01880385|Biological|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
172434|NCT01880385|Drug|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
172435|NCT01880385|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
172436|NCT01880385|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
172437|NCT01880385|Drug|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
172438|NCT01880385|Biological|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
172439|NCT01880398|Other|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
172440|NCT01880411|Biological|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
172441|NCT01880424|Drug|Placebo|matching Placebo Capsules, Oral, once daily
172442|NCT00108355|Drug|Midodrine|Midodrine oral tablet at 10 mg three times a day.
172443|NCT01880424|Drug|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
172444|NCT01880437|Drug|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
172445|NCT01880437|Drug|vismodegib|Cohorts 1 and 2: 150 mg orally daily
172737|NCT01872910|Drug|Celecoxib|Administered orally
171816|NCT01881880|Device|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
171817|NCT01881893|Behavioral|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
171818|NCT01881906|Other|Usual care|
171819|NCT01881906|Other|Exercise|
171820|NCT01881919|Dietary Supplement|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
171821|NCT01881919|Dietary Supplement|Control|Address: Fagron GmbH&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
172123|NCT01874353|Drug|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
172124|NCT01874366|Drug|P11187|Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)
Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.
Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval.
172125|NCT01874366|Drug|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo
In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo
172126|NCT01874379|Other|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
172127|NCT01874379|Other|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
172128|NCT01874379|Other|Standard of Care|Normal Procedures, no complementary medicine intervention.
172129|NCT01874392|Drug|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
172130|NCT00107809|Drug|Modafinil|
172131|NCT01876927|Other|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
172132|NCT01876940|Device|air-Q, followed by fiberoptic intubation|
172133|NCT01876940|Device|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
172134|NCT01876953|Drug|cytarabine|Given IV
167715|NCT01861366|Other|A three hour lecture about the guidelines|
167716|NCT01861379|Procedure|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
167717|NCT01861392|Procedure|sensorio-motor training|
167718|NCT01861405|Behavioral|neuropsychological testing and quality of life assessments|
167719|NCT01861405|Radiation|Standard of Care WBRT or SRS|
167720|NCT01861405|Device|Functional magnetic resonance imaging|
167721|NCT01861418|Other|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
168012|NCT01854788|Other|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
168013|NCT00002031|Drug|Dinitrochlorobenzene|
168014|NCT00105599|Procedure|FairCare System|
168015|NCT01854788|Other|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
168016|NCT01854788|Other|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
168017|NCT01854801|Other|Individual medical Care|Individual medical care in occupational and environmental diseases centers
168018|NCT01854801|Other|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
168019|NCT01854814|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
168020|NCT01854814|Drug|Losartan|Maximum tolerated labeled dose of Losartan
167388|NCT01856127|Drug|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
167389|NCT01856140|Biological|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
167390|NCT00105781|Behavioral|Exercise counseling|
167391|NCT01856153|Dietary Supplement|Before meal|
167392|NCT01856153|Dietary Supplement|With Meal|
167393|NCT01856153|Dietary Supplement|After meal|
167394|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
167395|NCT01858402|Drug|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
167396|NCT01858402|Drug|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
167397|NCT01858415|Device|TriPollar|
167398|NCT01858428|Device|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
167399|NCT01858428|Device|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
167400|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
167401|NCT01858441|Drug|Abiraterone Acetate|
167402|NCT01858454|Procedure|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
167403|NCT01858454|Procedure|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere [Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.].
167722|NCT00106431|Drug|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
166762|NCT01822353|Dietary Supplement|Dietary supplement|Milk, egg or nut oral immunotherapy
166763|NCT01822366|Behavioral|Trauma-focused Cognitive Behavioral Therapy|
166764|NCT01822379|Procedure|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
166765|NCT01822392|Behavioral|Online Parent Management Training (Interactive)|
167078|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
167079|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
167080|NCT01825122|Drug|Nadolol|
167081|NCT01825122|Drug|Placebo|
167082|NCT01825135|Device|Neuromuscular electrical stimulation|
167083|NCT01825135|Device|sham stimulation|sham stimulation will be applied to the quadriceps
167084|NCT01825148|Other|radiolabeled Exendin|
167085|NCT01825174|Behavioral|Ball games program|twice a week different ball games 90min
167086|NCT01825174|Behavioral|Nutrition counseling|9 units of 90min each of nutrition counseling
167087|NCT01825187|Device|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
167088|NCT00102817|Drug|somatropin|
167089|NCT01825187|Device|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
167090|NCT01825187|Other|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
167091|NCT01825200|Biological|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
167092|NCT01825200|Biological|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
167093|NCT01827722|Drug|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
166146|NCT01831323|Drug|Rifaximin|Rifaximin
166147|NCT01831323|Drug|Mesalazine|Mesalazine
166148|NCT01831323|Dietary Supplement|Psyllium|psyllium
166149|NCT00103298|Drug|leucovorin calcium|
166150|NCT01831362|Behavioral|Mindfulness-Based Cognitive Therapy|
166151|NCT01831362|Behavioral|Focused Awareness (FA)|
166152|NCT01831362|Behavioral|Open- Monitoring|
166153|NCT01823458|Behavioral|Lottery Insurance|
166154|NCT00102635|Drug|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
166155|NCT01823458|Behavioral|Standard Lottery|
166445|NCT01826656|Radiation|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
166446|NCT01826656|Radiation|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
166447|NCT01826656|Radiation|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
166448|NCT01826669|Procedure|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
166449|NCT01826682|Other|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
166450|NCT01826682|Other|Medical treatment|Standard medical treatment without physiotherapy.
166451|NCT01826695|Other|Neurodynamic technique group|Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.
The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks.
166452|NCT01826695|Other|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
165553|NCT01840358|Other|Observation of hypoglycemias frequency 3 days before and after pump initiation|
165554|NCT00104299|Drug|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
165555|NCT01840371|Drug|Conventional sedation|Propofol Meperidine : 25 mg IV just before procedure
IV bolus of 1 mg/kg for sedation induction,
Infusion of 60 mcg/min/kg for maintenance of sedation
Additional bolus dose of 10mg as needed for adequate sedation
165556|NCT01840371|Drug|Experimental sedation|Fentanyl
IV bolus of 1 µg/kg for sedation induction
Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol
IV bolus of 0.4 mg/kg for sedation induction
Infusion of 30 µg/min/kg for maintenance of sedation
Additional bolus dose of 10mg as needed for adequate depth of sedation
165557|NCT01840384|Dietary Supplement|Multi-micronutrients|
165558|NCT01840384|Dietary Supplement|Maltodextrin and Lactose|
165559|NCT01840410|Drug|Ranibizumab|Ranibizumab 0.5 mg is administered intravitreally to the patient
165560|NCT01840410|Other|Sham control|The sham vial will not contain active drug (empty sterile vial). The sham injection is an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
165561|NCT01840423|Drug|ODM-104|ODM-104
165562|NCT01840423|Drug|Placebo|Placebo
165563|NCT01832961|Device|flutter-sham exercises|30 minutes of flutter-sham exercises
165564|NCT01832974|Drug|IL-13-PE|IL-13-PE intravenous infusion
165565|NCT01832987|Drug|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
165566|NCT00103389|Drug|PI-88|
165567|NCT01833000|Device|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
165848|NCT01828190|Other|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
165849|NCT01828203|Drug|Minocycline|
165850|NCT01828203|Drug|Placebo|
165851|NCT01828203|Procedure|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
164955|NCT00103805|Drug|levodopa|
164956|NCT01836809|Drug|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
164957|NCT01836809|Drug|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
164958|NCT01836822|Procedure|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
164959|NCT01836822|Procedure|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
164960|NCT01836822|Procedure|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
164961|NCT01836822|Procedure|Bronchoalveolar lavage (BAL)|
164962|NCT01836822|Procedure|Endobronchial forceps biopsy|
164963|NCT01836835|Other|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
164964|NCT01836835|Other|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
164965|NCT01836848|Procedure|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
164966|NCT00103818|Drug|gaboxadol|Duration of Treatment: 3 months
164967|NCT01836861|Drug|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
164968|NCT01836874|Drug|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
164969|NCT01836887|Dietary Supplement|Very low polyphenol fruit based drink (control)|
164970|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
164971|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
165267|NCT01839812|Drug|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
165268|NCT01839825|Device|QuietCare|
165269|NCT01839838|Radiation|Proton Therapy|
164692|NCT01836419|Procedure|classic LMA insertion|
164693|NCT01836432|Drug|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 22, 36, 50, and 64 for Arm 1A. FOLFIRINOX given on days 1, 15, 29, 43 and 57 for Arm 2A.
For arms 1B and 2B patients with disease progression at day 71-80 evaluation will receive FOLFIRINOX as noted above on a biweekly basis.
For arms 1A and 2A patients with stable disease after surgical resection will continue to receive FOLFIRINOX as noted above on a biweekly basis.
For arms 1B and 2B patients deemed ineligible for surgical resection with noted disease progression will be given FOLFIRINOX as noted above on a biweekly basis.
164694|NCT00103753|Drug|deferiprone|
164695|NCT01836432|Biological|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Arm 1 (1A and 1B) only: Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection on days 1, 8, 15, 29, 43 and 57.
Patients receiving chemoradiation with HAPa will receive HAPa on days 1 and 15 of the 5.5 week 5-FU chemoradiation cycle.
Patients receiving continuation or salvage FOLFIRINOX with HAPa will receive HAPa biweekly, 7 days offset from the administration of FOLFIRNOX for up to 18 doses total.
Patients receiving adjuvant gemcitabine therapy with HAPa will receive HAPa on days 1 and 15 of each cycle for 5 cycles for up to 18 doses total.
Patients receiving continuation or salvage gemcitabine/nab-paclitaxel with HAPa will receive HAPa on days 8 and 22 (of each cycle) for up to 18 doses total.
164696|NCT01836432|Radiation|5-FU Chemoradiation|All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
164697|NCT01836432|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
All Arms: Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles for all arms after surgical resection.
Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.
Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.
164698|NCT01836432|Drug|Capecitabine|All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive capecitabine in place of 5-FU during radiation. Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
164699|NCT01836432|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes (followed by Gemcitabine)
Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.
Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.
164972|NCT01839201|Other|control|No psychological intervention
164973|NCT01839201|Other|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
164086|NCT01820221|Procedure|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
164087|NCT01820234|Other|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
164088|NCT01820234|Other|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
164089|NCT01820247|Drug|enteral nutrition|
164393|NCT01813201|Drug|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
164394|NCT01813201|Drug|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
164395|NCT01813214|Drug|Vemurafenib|
164396|NCT01815697|Device|Enhanced external counterpulsation(EECP)|Enhanced external counterpulsation(EECP) is used in cardiovascular and cerebrovascular diseases，which has the ability to improve the microcirculation
164397|NCT01815710|Other|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
164398|NCT01815710|Other|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
164399|NCT01815723|Drug|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
164400|NCT01815723|Drug|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
164401|NCT01815723|Drug|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
164402|NCT01815723|Drug|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
164403|NCT00001996|Drug|Pentamidine isethionate|
164404|NCT00101790|Drug|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
164405|NCT01815736|Drug|E/C/F/TAF|Single-tablet regimen of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (E/C/F/TAF) administered orally once daily
163797|NCT01817192|Drug|Adjuvant Chemotherapy|
163798|NCT00101920|Drug|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
163799|NCT01817192|Other|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for stage I lung cancer
163800|NCT01817192|Other|Pervenio™ Lung RS Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of early stage non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as high-risk will be randomized to either adjuvant chemotherapy or observation.
163801|NCT01817205|Procedure|TACE with Hyperthermia Treatment|
163802|NCT01817218|Drug|Platelet Rich Plasma|
163803|NCT01817218|Device|Osakidetza protocol|Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in "Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza", 2011).
The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice.
163804|NCT01817244|Other|care management|6-month care management
163805|NCT01817257|Drug|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
163806|NCT01817270|Biological|Live Attenuated Varicella Vaccine|
163807|NCT01817283|Drug|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
164090|NCT01820247|Drug|Tripterygium glycosides|
164091|NCT01820260|Drug|Ingenol mebutate gel|
164092|NCT00001999|Drug|Ganciclovir|
164093|NCT01812603|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
164094|NCT01812616|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
163486|NCT01814072|Behavioral|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
163487|NCT00101582|Drug|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m^2 on Days 1, 22, and 43.
163488|NCT01814072|Behavioral|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
163489|NCT01814085|Drug|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
163490|NCT01814098|Drug|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
163491|NCT01814111|Procedure|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
163492|NCT01814124|Other|Manual therapy plus exercise|
163493|NCT01814124|Other|Advice and home exercise|
163494|NCT01814137|Drug|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
163495|NCT01814137|Drug|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
163496|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
163497|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
163498|NCT00001995|Drug|Rifabutin|
163499|NCT00101582|Radiation|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
163500|NCT01814163|Drug|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
163501|NCT01814176|Device|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
163502|NCT01814189|Drug|Sumatriptan+Promethazine (SPr)|
163808|NCT01817283|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
163809|NCT00000286|Drug|Nefazodone|
167888|NCT01861977|Behavioral|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
167889|NCT01861990|Drug|Valproic Acid|All participants enrolled on valproic acid arm.
168194|NCT01855061|Procedure|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
168195|NCT01855074|Drug|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
168196|NCT01855100|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
168197|NCT01855126|Other|Blue light|On week 6, half of the subjects will be given light masks that deliver blue light before the estimated CBTmin and the other half will be exposed to red light under identical conditions - placebo control. On week 9, the ones who experienced blue light on week 6 will experience the red light, while the ones who experienced the red light on week 6 will experience the blue light on week 9. If subjects awaken while the mask is on, they will be instructed to try to fall asleep again or to stay in bed with their eyes closed. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
168198|NCT01855126|Other|Red light|On week 6, half of the subjects will be given light masks that deliver blue light before the estimated CBTmin and the other half will be exposed to red light under identical conditions - placebo control. On week 9, the ones who experienced blue light on week 6 will experience the red light, while the ones who experienced the red light on week 6 will experience the blue light on week 9. If subjects awaken while the mask is on, they will be instructed to try to fall asleep again or to stay in bed with their eyes closed. The light mask will always be turned on 120 min before estimated CBTmin; it is expected that blue light exposure will delay the timing of the CBTmin.
168199|NCT00105651|Behavioral|Combined nursing invention|
168200|NCT01855139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
168201|NCT01855152|Other|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
168202|NCT01855152|Other|Treatment as usual|Treatment delivered as usual in the care home
168203|NCT01855165|Behavioral|Advice on DDIs|
168204|NCT01855178|Device|Emfit Movement Monitor|Factory settings
168205|NCT01855204|Radiation|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
168206|NCT01855217|Drug|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
168207|NCT01855217|Drug|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
167588|NCT01856387|Other|normal neutrophil-to Lymphocyte ratio|
167589|NCT01858662|Drug|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
167590|NCT01858662|Drug|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
167591|NCT01858662|Drug|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
167592|NCT01858662|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
167890|NCT01862003|Drug|AZD8931|20, 40, 80 or 160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
167891|NCT01862003|Drug|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
167892|NCT01862003|Drug|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
167893|NCT01862003|Drug|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
167894|NCT01862003|Drug|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
167895|NCT01862016|Procedure|APRV|Pressure ventilation mode allowing early spontaneous breathing
167896|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
167897|NCT01862016|Biological|arterial blood gas measurement each morning|
167898|NCT01862029|Drug|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
167899|NCT01862042|Other|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
167900|NCT01862068|Other|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
167901|NCT01862068|Other|Blood sample|Blood sample will be performed at inclusion from all healthy patients
167902|NCT01862081|Drug|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
167903|NCT01862081|Drug|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
173338|NCT01899547|Procedure|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
173339|NCT01899547|Procedure|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
173340|NCT01899560|Procedure|Measure lung and chest wall elastance with esophageal catheter|Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated [9]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.
A low flow pressure/volume curve from 0 to 40 cmH2O will be performed.
173341|NCT01899560|Other|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
173342|NCT01899573|Device|GDS Accucinch®|Percutaneous intervention for the treatment of functional mitral regurgitation
173343|NCT01899586|Other|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
173344|NCT01899586|Other|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
173345|NCT01899599|Drug|PankoMab-GEX|start dose 500mg at C0D1 maintenance dose 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.
168540|NCT01855750|Drug|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
168541|NCT01855750|Drug|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
168542|NCT01855750|Drug|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
168543|NCT01855750|Drug|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
168544|NCT01855750|Drug|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
168545|NCT01855750|Drug|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
168546|NCT01855763|Drug|Metformin|
168547|NCT01855763|Drug|Insulin|
168548|NCT00105729|Behavioral|Intensive referral to 12-step self-help groups|
168549|NCT01855776|Device|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
173048|NCT00108212|Behavioral|Diet|
173049|NCT01878669|Drug|N-acetyl cysteine|
173050|NCT01878669|Drug|Saline|
173051|NCT01878695|Drug|IV/oral n-acetylcysteine|
173052|NCT01878708|Drug|PEG-L-asparaginase|
173053|NCT01878708|Drug|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
173054|NCT01878721|Radiation|PET/CT|positron emission tomography/computed tomography
173055|NCT01878734|Dietary Supplement|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
173056|NCT01878747|Behavioral|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
173057|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.
173058|NCT01878786|Drug|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
173059|NCT00108225|Other|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
173346|NCT01899599|Drug|Placebo|start dose matching 500mg at C0D1 maintenance dose matching 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.
173347|NCT00002078|Drug|Interferon alfa-n3|
173348|NCT00110110|Drug|carboplatin|Given at 28 mg/kg/dose.
173349|NCT01901757|Drug|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
173350|NCT01901757|Drug|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
172738|NCT00107601|Drug|Insulin|
172739|NCT01872923|Drug|Amphinex|Photosensitiser
172740|NCT01872923|Drug|Bleomycin|Anticancer agent
172741|NCT01872923|Device|Laser|Laser that emits red light at 652 nm.
172742|NCT01875328|Other|Telemedicine|Post stroke follow up in home using telemedicine.
172743|NCT01875328|Other|Clinic|Post stroke clinic group follow up
172744|NCT01875341|Device|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
172745|NCT01875341|Device|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
172746|NCT01875354|Dietary Supplement|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
172747|NCT01875354|Dietary Supplement|Placebo and Low Fat Eating Plan|
172748|NCT01875367|Drug|Trastuzumab subcutaneous inyection vial|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
172749|NCT01875367|Device|Trastuzumab subcutaneous device administration|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
172750|NCT01875380|Drug|Regorafenib|
172751|NCT01875393|Drug|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
172752|NCT00107952|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
172753|NCT01875406|Other|diagnostic exercises|
172754|NCT01875419|Device|Transcranial direct current stimulation (tDCS)|Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.
Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between.
172135|NCT01876953|Drug|idarubicin|Given IV
172136|NCT01876953|Drug|dasatinib|Given PO
172137|NCT01876953|Other|laboratory biomarker analysis|Correlative studies
172138|NCT01876966|Drug|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
172139|NCT00108030|Procedure|"Usual" physiotherapy care|
172140|NCT01876966|Drug|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
172141|NCT01876966|Drug|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets [20/120 mg] at 0, 8, 24, 36, 48, and 60 hours)
172142|NCT01876979|Device|IMF Screws|stainless steel screws placed in bone
172143|NCT01876979|Device|Erich Arch Bars|Surgical braces wired around teeth
172446|NCT01880450|Behavioral|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
172447|NCT01880450|Behavioral|TEEN|Control condition the promote communication, decision-making skills etc.
172448|NCT01880463|Drug|Omega-3 fatty acids (fish oil)|
172449|NCT01880463|Dietary Supplement|Vitamin D3|
172450|NCT01880463|Dietary Supplement|Vitamin D3 placebo|
172451|NCT01880463|Drug|Fish oil placebo|
172452|NCT01880476|Other|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
172453|NCT00108355|Drug|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
172454|NCT01882829|Drug|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
172455|NCT01882842|Procedure|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
168021|NCT01854827|Drug|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
168022|NCT01854853|Behavioral|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
168023|NCT01854853|Behavioral|Health Promotion|Health promotion intervention
168024|NCT01857063|Drug|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
168025|NCT01857076|Procedure|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
168026|NCT01857076|Procedure|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
168027|NCT01857076|Other|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
168028|NCT00002033|Drug|AS-101|
168029|NCT00105911|Behavioral|Cognitive Behavioral Therapy|
168030|NCT01857089|Device|Orthotest CE|Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.
Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.
Pressure measurement
163326|NCT01816360|Other|Yogatherapy|Yogatherapy respiratory exercises.
163327|NCT01816373|Device|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
163328|NCT01816386|Other|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
163329|NCT01816386|Other|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
163330|NCT01816399|Procedure|Routine coronary angiography|
163331|NCT01816412|Device|MD02-LDCB Paclitaxel coated balloon catheter|
167723|NCT01861418|Other|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
167724|NCT01861431|Behavioral|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
167725|NCT01861431|Behavioral|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
167726|NCT01861457|Other|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
167727|NCT01861457|Other|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
167728|NCT01861496|Drug|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8 and possibly day 15
167729|NCT01861509|Drug|BP-C1|
167730|NCT01861522|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
167731|NCT01861522|Drug|Placebo|Two Placebo tablets will be taken orally twice a day
167732|NCT01861535|Drug|Imiquimod|
167733|NCT00002037|Drug|Trifluridine|
167734|NCT01854294|Drug|GM604|GM604 treated group subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
167735|NCT01854307|Procedure|Pneumoperitoneum and SVV/PPV|
167736|NCT01854320|Behavioral|Acceptance-based treatment|
167737|NCT01854320|Behavioral|Standard behavioral treatment|
167738|NCT01854333|Other|ADOS module 1-4 or ADI-R|
168031|NCT01857102|Device|Etafilcon A|Soft contact lens to be worn in a daily wear modality for one week
168032|NCT01857102|Device|Etafilcon A Astigmatism|Soft contact lens to be worn by participants in a daily wear modality for one week.
168033|NCT01857115|Drug|Carfilzomib|
167094|NCT01827735|Drug|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
167095|NCT00002003|Drug|Etoposide|
167096|NCT00103051|Procedure|conventional surgery|
167097|NCT01827748|Device|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
167098|NCT01827748|Device|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
167404|NCT01858467|Device|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
167405|NCT01858467|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
167406|NCT01858480|Drug|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
167407|NCT01858480|Other|Placebo|Placebo dosage form designed to mock active.
167408|NCT01858493|Behavioral|Continence promotion group education workshop|Interactive group education workshop promoting continence
167409|NCT01858493|Behavioral|Sham health lecture|Interactive group education workshop about general health
167410|NCT01858506|Procedure|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
167411|NCT00002034|Drug|Ganciclovir|
167412|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
167413|NCT01858506|Procedure|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
167414|NCT01858519|Biological|pancrelipase|pancreatic enzyme replacement therapy
167415|NCT01858532|Drug|Atrasentan|Oral daily low dose for 48 months.
167416|NCT01858532|Drug|Placebo|Oral daily dosing for 48 months.
167417|NCT01858545|Device|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
167418|NCT01858545|Device|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
167419|NCT01860729|Drug|Anacetrapib|
166453|NCT00102960|Drug|Nevirapine|Second Line Regimen: 150 - 200 mg/m^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
166454|NCT01826708|Biological|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
166455|NCT01826721|Other|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
166456|NCT01826747|Drug|crinone (progesterone 8%, vaginal application)|
166457|NCT01829178|Drug|Placebo|placebo tablets: 420 mg in 3 divided dose
166458|NCT01829178|Drug|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
166459|NCT01829191|Device|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
166460|NCT01829191|Device|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
166461|NCT01829217|Drug|Sunitinib|
166462|NCT01829230|Device|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
166766|NCT01822392|Behavioral|Online Parent Management Training (Recorded)|
166767|NCT01822405|Drug|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
166768|NCT00102453|Drug|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
166769|NCT01822405|Other|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.
Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment.
166770|NCT01822418|Drug|agomelatine|n.a.
166771|NCT01822431|Radiation|metaiodobenzylguanidine scintigraphy|
166772|NCT01822444|Other|Biomarker analysis|
166773|NCT01822457|Device|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
166774|NCT01822483|Drug|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
165852|NCT01828203|Procedure|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
165853|NCT01828216|Device|Embletta|The EmblettaTM PDS is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an anpea-hyponea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
165854|NCT01828216|Device|conventional PSG|conventional type I sleep study according to ASSM
165855|NCT01828229|Behavioral|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
165856|NCT01828229|Behavioral|inactivity|inactivity for 2 weeks
165857|NCT00103116|Biological|therapeutic autologous dendritic cells|Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.
Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.
165858|NCT01828229|Behavioral|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
165859|NCT01828229|Behavioral|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
165860|NCT01828229|Behavioral|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
165861|NCT01828242|Behavioral|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
165862|NCT01830738|Procedure|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
165863|NCT01830751|Other|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
165864|NCT01830764|Drug|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
165865|NCT01830777|Drug|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
165866|NCT01830777|Drug|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
166156|NCT01823471|Other|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
166157|NCT01823484|Device|AN 69 ST hemofilter|
166158|NCT01823484|Device|AN 69 hemofilter|
165270|NCT00002014|Drug|Didanosine|
165271|NCT00104234|Drug|Placebo/rhASB|
165272|NCT01839851|Drug|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
165273|NCT01839851|Drug|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
165274|NCT01839864|Behavioral|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
165275|NCT01839877|Drug|HIA DEBIRI + systemic FOLFOX|
165276|NCT01839890|Device|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
165277|NCT01839890|Device|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
165278|NCT01839903|Other|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
165279|NCT01839903|Other|Care as usual|Care as usual in the ED will be tracked
165280|NCT01839916|Biological|therapeutic allogeneic lymphocytes|Given IV
165281|NCT01839916|Other|laboratory biomarker analysis|Correlative studies
165282|NCT00104247|Drug|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
165283|NCT01839929|Drug|Prograf|oral
165284|NCT01839929|Drug|Advagraf|oral
165285|NCT01839942|Procedure|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
165286|NCT01839942|Procedure|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
165287|NCT01839955|Drug|erlotinib hydrochloride|Dose Escalation Group:
Begins day 1: given 150mg daily, orally
Extension Group:
Begins Day 1: 150mg daily, orally
165288|NCT01842503|Drug|inactive ingredients capsule|3 capsules tid on 3 days cycle
165568|NCT01833013|Other|live birth date and quality of life assessment|
164974|NCT01839201|Other|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
164975|NCT00104130|Drug|KOS-862|
164976|NCT01839214|Drug|VB-201 160mg|
164977|NCT01839214|Drug|Placebo|
164978|NCT01839227|Other|Neurologic and neuropsychologic tests|Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.
Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.
Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.
There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery.
164979|NCT01839240|Drug|azacitidine|Given IV or SC
164980|NCT01839240|Drug|cytarabine|Given IV
164981|NCT01839240|Drug|mitoxantrone hydrochloride|Given IV
164982|NCT01839240|Other|laboratory biomarker analysis|Correlative studies
164983|NCT01839253|Drug|b-blocker(Atenolol)|
164984|NCT01839253|Drug|ACE inhibitor(Enapril)|
164985|NCT01839253|Other|control|
164986|NCT00104143|Drug|A4I Antagonist|
164987|NCT01839279|Drug|Tizanidine|
164988|NCT01839279|Drug|Placebo|
164989|NCT01839279|Drug|Moxifloxacin|
164990|NCT01839292|Device|uncovered D-type stent insertion|
164991|NCT01839292|Device|double-layered ComVi stent insertion|
164992|NCT01839305|Other|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
164993|NCT01839318|Device|Nelfilcon A contact lenses|
164994|NCT01839318|Device|Omafilcon A contact lenses|
164406|NCT01815736|Drug|E/C/F/TDF|Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (E/C/F/TDF) tablets administered orally once daily
164407|NCT01815736|Drug|EFV/FTC/TDF|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF) tablets administered orally once daily
164408|NCT01815736|Drug|RTV|Ritonavir (RTV) 100 mg tablets administered orally once daily
164409|NCT01815736|Drug|ATV|Atazanavir (ATV) 300 mg capsules administered orally once daily
164410|NCT01815736|Drug|FTC/TDF|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) tablets administered orally once daily
164411|NCT01815736|Drug|COBI|Cobicistat (COBI) 150 mg tablets administered orally once daily
164700|NCT01836445|Behavioral|Keep It Up!|
164701|NCT01836445|Behavioral|HIV Knowledge Control|
164702|NCT01838811|Behavioral|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
164703|NCT01838824|Behavioral|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
164704|NCT00104052|Drug|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
164705|NCT01838850|Drug|CS8635 20/5/12.5mg and placebo|Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.
Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.
Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day.
164706|NCT01838850|Drug|Olmetec® Plus 20/12.5mg and placebo|Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.
Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.
Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day.
164707|NCT01838863|Biological|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
164708|NCT01838863|Drug|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
164095|NCT01812616|Drug|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs & Cosmetics (FD&C)certified color additives; FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
164096|NCT00001993|Drug|Zidovudine|
164097|NCT00101387|Other|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
164098|NCT01812629|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
164099|NCT01812642|Drug|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
164100|NCT01812642|Other|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
164101|NCT01812655|Device|Virtual Reality|
164102|NCT01812655|Other|Passive Distraction|
164103|NCT01812668|Drug|cabozantinib-s-malate|Given PO
164104|NCT01812668|Radiation|fluorine F 18 d-FMAU|Undergo 18F PET/FMAU PET scan
164105|NCT01812668|Procedure|positron emission tomography|Undergo 18F PET/FMAU PET scan
164106|NCT01812668|Other|pharmacological study|Correlative studies
164107|NCT01812668|Other|laboratory biomarker analysis|Correlative studies
164108|NCT00101387|Other|Lumbar PENS|As above
164109|NCT01812694|Behavioral|Controlling Gestational Weight Gain|Behavioral weight control
164110|NCT01812707|Drug|Alirocumab|Two SC injections in the abdomen only
164111|NCT01812707|Drug|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only
Route of administration: subcutaneous injection (1 mL) in the abdomen
164412|NCT01815749|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
164413|NCT01815749|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
164414|NCT01815749|Other|laboratory biomarker analysis|Correlative studies
164415|NCT00101803|Drug|vildagliptin|
163810|NCT01819714|Other|Multi-sensory supportive care|The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.
The impact of this multisensory strategy will be evaluated using a before-after design.
163811|NCT01819727|Drug|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction).
After the Induction Period, subjects will enter the Titration Period (Week 5 up to Week 32) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 28 weeks (accounts for dose interruptions due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose. A maintenance dose will be administered for 4 weeks.
163812|NCT01819740|Other|determine the levels of the "HEM" substance in seminal plasma|
163813|NCT01819753|Procedure|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
163814|NCT01819779|Drug|Exforge tab. 10/160mg|
163815|NCT01819779|Drug|Lodivixx tab. 5/160mg|
163816|NCT00102206|Drug|Abacavir sulfate|
163817|NCT01819792|Other|Multiplex respiratory viral PCR|
163818|NCT01819805|Drug|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
163819|NCT01819818|Drug|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
163820|NCT01819831|Radiation|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
163821|NCT01819831|Procedure|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
163822|NCT01819844|Device|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose > 2 u/kg).
168208|NCT01855217|Drug|Placebo|0,9% NaCl
168209|NCT01855230|Drug|ASM-024|ASM-024 b.i.d for 14 days
168210|NCT01857414|Procedure|Remote Ischaemic Conditioning|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflate to 200 mmHg for 5 minutes followed by 5 minutes of deflations. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes).In recruiting centres where randomisation occurs at the hospital or in cases with short transportation time, the RIC protocol will continue during PCI until successful or until immediately before reperfusion.
163503|NCT01816594|Drug|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
163504|NCT01816594|Drug|Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
163505|NCT01816607|Procedure|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
163506|NCT01816620|Drug|Lenalidomide, Dexamethasone|12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.
For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.
All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle.
163507|NCT01816633|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
163508|NCT01816646|Drug|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
163509|NCT01816646|Drug|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
163510|NCT00101894|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
163511|NCT01816659|Drug|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
163512|NCT01816672|Device|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
163513|NCT01816672|Other|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
163514|NCT01816685|Device|CPAP|
163515|NCT01816698|Drug|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
167904|NCT01862081|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
167905|NCT01862120|Drug|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
167906|NCT01862120|Drug|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
167907|NCT00106535|Drug|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
167908|NCT01854632|Biological|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
167909|NCT01854632|Biological|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
168211|NCT01857453|Drug|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
168212|NCT01857453|Drug|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
168213|NCT01857453|Radiation|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
168214|NCT01857466|Procedure|Floseal|
168215|NCT01857466|Procedure|Bipolar coagulation|
168216|NCT00105989|Drug|Duloxetine|
168217|NCT01857479|Drug|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
168218|NCT01857479|Drug|Inhaled amphotericin|Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].
The first dose will be administered under direct supervision.
168219|NCT01857492|Device|tDCS|
168220|NCT01857492|Behavioral|Meditation|Both Active and SHAM groups will receive Meditation.
168550|NCT01855776|Behavioral|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
168551|NCT01855776|Behavioral|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
168552|NCT01855776|Other|Usual Care|The "usual care" programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating.
168553|NCT01855789|Drug|methotrexate|stable oral dose, 24 or 52 weeks
168554|NCT01855789|Drug|placebo|methotrexate placebo orally, Weeks 24 to 52
168555|NCT01855789|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc QW or Q2W, 51 weeks
168556|NCT01855828|Drug|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
168557|NCT01855828|Drug|Trastuzumab|For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).
For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total).
168558|NCT01855828|Drug|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
168559|NCT00105742|Procedure|Diagnosis|
168560|NCT01855828|Drug|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
168561|NCT01855828|Drug|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
168857|NCT01843842|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
168858|NCT01843842|Drug|Placebo|Safety and Efficiency of liquid dosage form
168859|NCT01843855|Drug|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
168860|NCT01843855|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
168861|NCT01843868|Drug|Standard anti-emetics in conjunction with R-CHOP|
168862|NCT01843881|Drug|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
168863|NCT01843881|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
168864|NCT01843894|Biological|RU-101|Recombinant human serum albumin
168865|NCT00104676|Drug|cisplatin|At least one course administered
173351|NCT01901770|Other|educational intervention|Receive HPV vaccination educational materials
173352|NCT01901770|Other|educational intervention|Receive influenza vaccination educational materials
173353|NCT01901783|Procedure|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
173354|NCT01901783|Procedure|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
173355|NCT01901796|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
173356|NCT00110305|Drug|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
173357|NCT01901809|Drug|Furosemide|
173358|NCT01901809|Drug|Dopamine|
173359|NCT01901822|Procedure|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
173360|NCT01901822|Procedure|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
173361|NCT01901835|Procedure|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
173362|NCT01901835|Other|survey administration|Ancillary studies
173363|NCT01901835|Procedure|quality-of-life assessment|Ancillary studies
173364|NCT01901848|Behavioral|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
173365|NCT01901848|Drug|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
168562|NCT01857934|Radiation|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
168563|NCT01857934|Biological|GM-CSF|Given subcutaneously (SQ)
168564|NCT01857934|Biological|G-CSF|Given subcutaneously (SQ)
168565|NCT01857934|Drug|mesna|Given IV
172755|NCT01875419|Behavioral|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
173060|NCT01878786|Drug|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
173061|NCT01878786|Drug|Mycophenolate mofetil (MMF/MPA)|Control Drug
173062|NCT01878799|Drug|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
173063|NCT00110071|Procedure|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
173064|NCT01898936|Device|Only photodynamic therapy|After curettage/debulking, the BCC is incubated with MAL cream (Metvix® cream, Galderma, France), occluded for three hours under a plastic film and illuminated with red light-emitting diode light (LED) at 632 nm at a dosage of 37 J/cm2 (Aktilite®, Galderma, Oslo, Norway).
173065|NCT01898949|Other|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
173066|NCT01898962|Procedure|Complete Surgical Removal|
173067|NCT01898962|Radiation|Stereotactic Radiosurgery|
173068|NCT01898962|Radiation|Ablative external beam radiation dose|
173069|NCT01898962|Procedure|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
173070|NCT01898962|Radiation|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
173071|NCT01898975|Other|500ml fluid loading|Fluid loading to evaluate fluid responsiveness
173072|NCT01899001|Behavioral|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
163644|NCT01821469|Behavioral|psychoeducation|Bipolar disorders are educated to learn about their pathology
163645|NCT01821482|Biological|Dendritic and Cytokine-induced Killer Cells|
163646|NCT01821495|Biological|DC-CIK|
163933|NCT01814839|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
163934|NCT01814852|Device|Shockwave system|
163935|NCT01814852|Device|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
163936|NCT01814865|Drug|Abiraterone Acetate|1000 mg PO OD x 2 weeks
163937|NCT00101686|Drug|FOLFIRI + bevacizumab|Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.
I m m e d i a t e l y f o l l o w e d b y :
5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks
Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.
I m m e d i a t e l y f o l l o w e d b y :
5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID [two times a day] oral Every 2 weeks
163938|NCT01814865|Drug|Prednisone|5 mg PO OD x 2 weeks
163939|NCT01814865|Drug|Aromatase Inhibitor|1 mg PO OD x 2 weeks
163940|NCT01814878|Drug|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl [75 mg]/acetaminophen [650 mg]) will be administered at 0, 12, 24 and 36 hours
163941|NCT01814878|Drug|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl [37.5 mg]/acetaminophen [325 mg]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
163942|NCT01814891|Other|Orange maize feeding|This group was fed orange maize.
163943|NCT01814891|Other|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
163944|NCT01814891|Other|Oil only|This group received a small amount of plain oil without vitamin A.
163945|NCT01814904|Drug|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
163946|NCT01814904|Drug|colestilan-M|BSAeq 6 g/day
163947|NCT01814904|Drug|colestilan-H|BSAeq 9 g/day
163948|NCT00001996|Drug|Atovaquone|
163332|NCT01816412|Procedure|Standard Uncoated Balloon Angioplasty Catheter|
163333|NCT00101868|Other|Usual care discharge process|Handwritten
163334|NCT01816425|Device|Thermoplastic partial denture|
163335|NCT01816425|Device|CoCr partial denture|
163336|NCT01816451|Other|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
163337|NCT01816464|Biological|Trivalent Influenza Vaccine|The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.
The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe.
163338|NCT01816477|Device|ON-Q soaker catheter system|
163339|NCT01816477|Device|Epidural (ropivicaine .25%)|
163340|NCT01816490|Drug|Intravenous Silibinin (iSIL)|
163647|NCT01821495|Biological|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
163648|NCT01821508|Other|Clinical Treatment|metabolic surgery for diabetes and weight control
163649|NCT01821508|Procedure|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
163650|NCT01821521|Drug|AGSPT_L20|
163651|NCT01821521|Drug|Pantoloc 40mg|
163652|NCT01821534|Other|No Intervention|No treatment (intervention) was administered.
163653|NCT01821547|Drug|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
163654|NCT00102362|Behavioral|Behavior Therapy|
163655|NCT01821560|Drug|Baclofen|
163656|NCT01821560|Drug|placebo|
168034|NCT01857115|Drug|Cyclophosphamide|
168035|NCT01857115|Drug|Dexamethasone|
168036|NCT01857128|Device|Drawtex dressing|
168037|NCT01857128|Device|Negative Pressure Wound Therapy|
168038|NCT01857141|Drug|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
168039|NCT01857141|Drug|normal saline|patients in the control groups received the equivalent volume of normal saline.
168040|NCT00105937|Drug|OraVescent fentanyl citrate|
168041|NCT01857154|Dietary Supplement|Micronized Calcium Carbonate|Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.
Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.
168042|NCT01857154|Dietary Supplement|Non-Micronized Calcium Carbonate|Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.
Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate.
168043|NCT01857154|Dietary Supplement|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
168044|NCT01857167|Dietary Supplement|Fish Oil Supplementation|
168045|NCT01857167|Dietary Supplement|Flaxseed Oil Supplementation|
168046|NCT01857167|Dietary Supplement|placebo|
168047|NCT01857180|Other|Curriculum|
168048|NCT01857193|Drug|LEE011|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
168049|NCT01859338|Procedure|computed tomography|Undergo fan beam computed tomography
168050|NCT01859351|Drug|WX-037|
168051|NCT01859351|Drug|WX-554|
168052|NCT01859377|Drug|V0498 - A mg|Single oromucosal administration
168053|NCT01859377|Drug|Ibuprofen|Single oral administration
167420|NCT01860729|Drug|Placebo|
167421|NCT00106366|Drug|insulin aspart|
167422|NCT01860742|Drug|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
167423|NCT01860742|Drug|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
167424|NCT01860755|Other|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
167425|NCT01860755|Other|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
167739|NCT01854346|Behavioral|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
167740|NCT01854359|Drug|Idebenone|
167741|NCT00105547|Drug|MPC-7869|Oral BID dosing
167742|NCT01854372|Drug|R-HCVAD and R-MC|
167743|NCT01854385|Drug|Sumatriptan 100 mg|
167744|NCT01854398|Device|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
167745|NCT01854398|Device|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
167746|NCT01854411|Other|analgesic measure|ibuprofen and ketoprofen measured into breast milk
167747|NCT01854424|Other|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
167748|NCT01854437|Drug|Mg Oxide|250 mg orally for 4 weeks
166775|NCT01822483|Drug|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg*h ml-1.
166776|NCT01822496|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D CRT
166777|NCT01822496|Drug|Carboplatin|Given IV
166778|NCT01822496|Drug|Cisplatin|Given IV
166779|NCT00102466|Drug|vildagliptin|
166780|NCT01822496|Drug|Crizotinib|Given PO
166781|NCT01822496|Drug|Erlotinib Hydrochloride|Given PO
166782|NCT01822496|Drug|Etoposide|Given IV
166783|NCT01822496|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
166784|NCT01824654|Other|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
166785|NCT01824654|Other|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
167099|NCT01827761|Behavioral|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
167100|NCT01827774|Device|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
167101|NCT01827787|Drug|Eribulin|Intravenously on Day 1 and 8 of each cycle
167102|NCT01827800|Behavioral|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
166159|NCT01823497|Drug|Morphine|Morphine will be used to control pain post-surgery.
166160|NCT01823510|Drug|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
166161|NCT01823510|Drug|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
166162|NCT01823523|Drug|Cefazolin, Cephalexin, Clindamycin|
166163|NCT01823536|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
166164|NCT01823549|Other|questionnaire administration|Ancillary studies
166165|NCT00102635|Drug|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
166166|NCT01823562|Drug|lyophilized black raspberry confection|Given PO
166167|NCT01823562|Other|laboratory biomarker analysis|Correlative studies
166168|NCT01823562|Dietary Supplement|dietary intervention|Follow a low polyphenol diet
166169|NCT01823562|Dietary Supplement|dietary intervention|Follow a low ellagitannin diet
166170|NCT01823562|Procedure|quality-of-life assessment|Ancillary studies
166171|NCT01823562|Other|questionnaire administration|Ancillary studies
166172|NCT01823575|Device|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
166173|NCT01823575|Device|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
166174|NCT01823588|Behavioral|Nurse-led reminder through email.|Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.
Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.
166463|NCT01829243|Drug|Milnacipran|
166464|NCT00002005|Drug|CD4 Antigens|
166465|NCT00103194|Drug|lapatinib ditosylate|Given PO
165569|NCT01833026|Device|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
165570|NCT01833026|Drug|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
165571|NCT01833039|Drug|Ibrutinib|Ibrutinib
165572|NCT01833052|Device|TAVI (Medtronic CoreValve)|
165573|NCT01833052|Device|Claret-Filter|
165574|NCT01833065|Drug|Elobixibat 10 mg/day|Elobixibat 10 mg/day
165575|NCT01833065|Drug|Elobixibat 5 mg/day|Elobixibat 5 mg/day
165576|NCT01833065|Drug|Placebo|Placebo
165577|NCT00103389|Drug|docetaxel|
165578|NCT01833078|Drug|ghrelin|ghrelin administration subcutaneously for 7 days
165579|NCT01833091|Other|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand & arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
165580|NCT01833104|Behavioral|Presence - Perspective - Affective.|PRESENCE:
Goal is to cultivate attentional skills and interoceptive body awareness through meditation on breath and the so-called "body scan".
PERSPECTIVE:
It focuses on the cognitive aspects of compassion; learn to take perspectives on thoughts, on their sense of self, and on other people; observe more macroscopic dynamics within oneself, that is, your inner "parts", "roles", or "self-aspects"; do not fully identify with them and remaining aware of their transiency; strengthen the ability to detach from one's own perspective and take the perspectives of other people, trying to understand their thoughts, motives, and feelings.
AFFECTIVE:
Cultivate emotional and motivational aspects of compassion; cultivate a sense of benevolence, love, and care, "opening the heart" for oneself and others; work with obstacles, such as fear, anger or sadness ("emotion acceptance"); pro-social motivations as an alley towards loving and benevolent feelings and as a consequence of them.
165581|NCT01833104|Behavioral|Presence - Affective - Perspective.|As specified above the order is interchanged between two groups.
165582|NCT01833104|Behavioral|Affective only|AFFECTIVE:
Cultivate emotional and motivational aspects of compassion; cultivate a sense of benevolence, love, and care, "opening the heart" for oneself and others; work with obstacles, such as fear, anger or sadness ("emotion acceptance"); pro-social motivations as an alley towards loving and benevolent feelings and as a consequence of them.
165583|NCT01833117|Other|FID 119515A|topical ocular drops
165584|NCT01835444|Other|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
165289|NCT01842516|Drug|LCB01-0371 800mg|LCB0-0371 800mg
165290|NCT01842516|Drug|LCB01-0371 1200mg|LCB01-0371 1200mg
165291|NCT01842516|Drug|Placebo|Placebo
165292|NCT01842529|Biological|botulinum toxin injection|
165293|NCT01842529|Biological|0.9% normal saline injection|
165294|NCT01842529|Device|Implantable loop recorder|
165295|NCT00104572|Drug|Androgel (Testosterone Gel)|1 mg tablet for 12 months
165296|NCT01842542|Device|NeuroStar Transcranial Magnetic Stimulation (TMS)|Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.
3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician.
165297|NCT01842555|Other|Registry|Registry
165298|NCT01842581|Drug|Rifaximin|
165299|NCT01842581|Drug|Rifaximin and Lactulose|
165300|NCT01842594|Drug|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .
Each treatment cycle is 28 days.
165301|NCT01842607|Biological|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
165302|NCT01842620|Drug|Metformin|Oral antidiabetic agent
165303|NCT01842633|Drug|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
165304|NCT01842633|Drug|Ibuprofen|Caplets containing 200 mg of ibuprofen
165305|NCT01842633|Other|Placebo|Matching placebo caplets
165306|NCT00104572|Drug|Anastrozole (Aromatase Inhibitor)|
165307|NCT01842646|Drug|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
165308|NCT01842659|Genetic|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
164709|NCT01838876|Drug|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/d; patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
164710|NCT01838889|Behavioral|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
164711|NCT01838902|Drug|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
164712|NCT01838902|Drug|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
164713|NCT01838902|Drug|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
164714|NCT01838902|Drug|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
164715|NCT00104065|Drug|CG53135-05, velafermin|
164995|NCT01839318|Device|Etafilcon A contact lenses|
164996|NCT01839331|Drug|Low Dose Ampion|4 mL Ampion
164997|NCT00104156|Procedure|External Qigong therapy|
164998|NCT01839331|Drug|High Dose Ampion|10 mL Ampion 10mL
164999|NCT01839331|Drug|Placebo Low Dose 4 mL|4 mL Placebo
165000|NCT01839331|Drug|Placebo 10 mL|Placebo 10 mL
165001|NCT01842269|Drug|Mycophenolate Mofetil 250mg|
165002|NCT01842282|Drug|Amlexanox|
165003|NCT01842295|Other|Blood and sperm samples|Blood and sperm samples will be done in each visit
165004|NCT00104546|Procedure|Acupuncture point injection of vitamin K|
165005|NCT01842308|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
165006|NCT01842308|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
165007|NCT01842308|Drug|Carfilzomib|Given IV
165008|NCT01842308|Other|Laboratory Biomarker Analysis|Correlative studies
165009|NCT01842308|Drug|Melphalan|Given IV
164416|NCT01815762|Other|Active arm|In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.
If the patient does not tolerate the intervention (as described above), he will continue the study in the "medication arm", where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication.
164417|NCT01818024|Drug|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
164418|NCT01818024|Drug|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
164419|NCT01818024|Drug|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
164420|NCT00102024|Drug|Unconjugated IDEC-159|
164421|NCT01818024|Drug|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
164422|NCT01818024|Drug|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
164423|NCT01818024|Drug|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
164424|NCT01818024|Drug|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
164425|NCT01818037|Procedure|Cataract surgery|
164426|NCT01818050|Other|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
164427|NCT01818063|Drug|Paclitaxel|Given IV
164428|NCT01818063|Drug|Carboplatin|Given IV
164429|NCT01818063|Drug|Doxorubicin|Given IV
164430|NCT01818063|Drug|Cyclophosphamide|Given IV
164431|NCT00102024|Drug|111In-IDEC-159|
164432|NCT01818063|Drug|Veliparib|Given PO
164433|NCT01818076|Drug|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
164434|NCT01818089|Device|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
164716|NCT01838915|Dietary Supplement|Prebiotics+Glutamine|Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.
Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function.
164112|NCT01812707|Drug|Atorvastatin|Orally once daily at a stable dose of 5 to 20 mg as background therapy
Route of administration: oral administration in the evening
164113|NCT01812720|Drug|carfilzomib|Given IV
164114|NCT01812720|Drug|dexamethasone|Given PO
164115|NCT01812720|Other|laboratory biomarker analysis|Correlative studies
164116|NCT01812746|Drug|BIND-014|
164117|NCT01812759|Drug|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
164118|NCT01812759|Drug|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
164119|NCT01815125|Drug|PLacebo|placebo
164120|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
164121|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
164122|NCT01815164|Behavioral|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
164123|NCT01815164|Behavioral|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
164124|NCT01815177|Device|Arthroscopic transosseous fixation|
164125|NCT01815177|Device|Suture anchors|
164126|NCT00101712|Drug|vildagliptin|
164127|NCT01815203|Drug|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
164128|NCT01815203|Drug|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
164129|NCT01815216|Procedure|Bariatric surgery|Gastric bypass surgery
164130|NCT01815216|Behavioral|Brain activity in resting state|Measure of activity in brain networks during resting state
164131|NCT01815216|Behavioral|Memory performance|Assess concentration in 2D-location task (i.e. "memory game")
164132|NCT01815229|Procedure|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
164133|NCT01815242|Drug|nab-Paclitaxel|
163516|NCT01816698|Drug|Placebo|Placebo: 1 package once a day after meals, 12 weeks
163517|NCT01816750|Device|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
163518|NCT01816763|Behavioral|NRS pain now|Eligible patients will be randomly assigned to complete a patient-reported 'NRS now' on a kiosk prior to making contact with a nursing staff vital signs screener.
163519|NCT01816763|Behavioral|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a kiosk prior to making contact with a nursing staff vital signs screener.
163520|NCT01816776|Device|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
163823|NCT01819857|Drug|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
163824|NCT01819857|Drug|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
163825|NCT01819857|Drug|Zofran 8 mg|intravenous administration of 8 mg ondansetron
163826|NCT01819870|Drug|Dilatrend SR capsule 32mg|1 capsule, oral, once daily, 7days
over the period I&II(crossover)
163827|NCT00102206|Drug|Emtricitabine|
163828|NCT01822197|Device|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
163829|NCT01822210|Drug|Botox|injection by gastroscopy (100 Allergen units)
163830|NCT01822223|Device|Dental implant-abutments|At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a & 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.
Sub-groups 1-b & 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.
The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration.
163831|NCT01822236|Other|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
163832|NCT01822236|Other|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
163833|NCT01822249|Drug|EPI-743|
163834|NCT00102440|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
163835|NCT01822262|Procedure|minimally invasive cholecystolithotomy with gallbladder reservation|
168221|NCT01857518|Other|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|Visit V1: Diagnostic and clinical assessments
Visit V2: psycho-behavioral assessment and neuroimaging
Visit V3: Diagnostic and clinical assessments
Visit V4: psycho-behavioral assessment and neuroimaging
168222|NCT01857531|Drug|Ganaxolone|Pre-Quit Period:
Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.
Post-Quit Period:
Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three.
168223|NCT01857531|Drug|Nicotine Patch|Pre-Quit Period:
Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.
Post-Quit Period:
Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week).
168224|NCT01857544|Drug|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
168225|NCT01857557|Other|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
168226|NCT01857570|Radiation|Volume Computed Tomography of the wrist and carpus|
168227|NCT00105989|Drug|placebo|
163521|NCT00101894|Biological|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
163522|NCT01816776|Device|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
163523|NCT01816789|Drug|rFSH|
163524|NCT01819194|Other|No contact lens wear|
163525|NCT01819207|Other|blood test by thromboelastography|
163526|NCT01819220|Drug|amlodipine/valsartan|This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.
Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.
When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
163527|NCT01819220|Drug|hydrochlorothiazide/telmisartan|When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.
When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
163528|NCT01819233|Behavioral|Behavioral dietary intervention|Receive caloric restricted dietary intervention
163529|NCT01819233|Procedure|Therapeutic conventional surgery|Undergo definitive lumpectomy
168866|NCT01843907|Behavioral|Empowerment|To give patients the necessary resources to take care of their own health
168867|NCT01843907|Other|Conversation with nurse|To find out, if the nurse, using her ....
168868|NCT01843920|Drug|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
168869|NCT01843920|Drug|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
168870|NCT01843933|Device|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
168871|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 6
168872|NCT01843972|Drug|BI 691751|oral solution
168873|NCT01843972|Drug|Placebo|placebo solution
168874|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 2
168875|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 5
168876|NCT00104676|Drug|etoposide|At least one course administered
168877|NCT01843972|Drug|BI 691751|1 tablet
168878|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 3
168879|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 4
168880|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 7
168881|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 1
169168|NCT01849497|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
169169|NCT01849510|Radiation|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT & hfSRT
169170|NCT00105040|Other|Placebo (PB)|Oral tablets and oral solution
169171|NCT01849510|Radiation|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
169172|NCT01849523|Behavioral|Web-based information and support|
169173|NCT01849536|Device|SENSIMED Triggerfish®|
168566|NCT00106067|Behavioral|coping and communication support (CCS) intervention|Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.
The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families.
168567|NCT01857934|Drug|levetiracetam|Given IV
168568|NCT01857934|Biological|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
168569|NCT01857934|Drug|Isotretinoin|Given orally (PO)
168570|NCT01857947|Other|AECOPD Mr proADM|
168571|NCT01857960|Behavioral|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
168572|NCT01857973|Device|OCL/HCL system|The Overnight Closed Loop System is an investigational device intended for closed loop control of blood glucose during the night.
168573|NCT01857986|Device|AnapnoGuard 100 control unit|
168574|NCT01857999|Drug|Losartan|
168575|NCT01857999|Drug|Placebo|
168576|NCT01858012|Behavioral|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks
168577|NCT00106080|Behavioral|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
168578|NCT01858025|Radiation|Pencil Beam scanning Radiation|
168579|NCT01858025|Drug|5-fluorouracil|
168580|NCT01858025|Drug|Mitomycin-C|
168581|NCT01858038|Device|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
168582|NCT01858051|Dietary Supplement|Cholecalciferol|
168583|NCT01858051|Dietary Supplement|Placebo|
168584|NCT01858064|Drug|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
168882|NCT01846299|Other|Sham control|The sham vial will not contain active drug (empty sterile vial). The sham injection is an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
173073|NCT01899001|Behavioral|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
173074|NCT00110071|Radiation|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
173075|NCT01899014|Drug|18F-choline PET-CT imaging|18F-choline PET-CT imaging
173366|NCT01901848|Drug|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
173367|NCT00110305|Drug|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
173368|NCT01901848|Behavioral|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
173369|NCT01901848|Behavioral|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
173370|NCT01901861|Drug|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
173371|NCT01901861|Drug|Placebo|Placebo is given before meal ingestion
173372|NCT01894399|Drug|HM61713 (BI 1482694)|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
173373|NCT01894412|Biological|Etanercept (Enbrel)|
173374|NCT01894412|Biological|HD203|
173375|NCT01894438|Behavioral|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
173376|NCT01894438|Behavioral|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
173377|NCT01894451|Drug|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
163949|NCT00101686|Drug|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV *over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID [two times a day] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID [two times a day] continues daily without interruption Every 3 weeks
163950|NCT01814904|Drug|CBPB|
163951|NCT01814917|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
163952|NCT01814917|Drug|CBPB|
164247|NCT01817842|Behavioral|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
164248|NCT01817842|Behavioral|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
164249|NCT01817842|Behavioral|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
164250|NCT01817855|Drug|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
164251|NCT01817855|Drug|Placebo to match|Multiple doses inhaled placebo via a nebulizer
164252|NCT01817868|Other|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
164253|NCT01820377|Behavioral|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
164254|NCT01820403|Other|portion size kcal of box lunch|
164255|NCT01820416|Radiation|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
164256|NCT01820442|Drug|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
163657|NCT01821573|Drug|botulinum toxin type A|Experimental arm group:
150 Units in rectus femoris ( 3 ml and 3 points)
70 units in medial gastrocnemius (1.4 ml and 1 point)
70 units in lateral gastrocnemius ( 1.4 ml and 1 point)
60 units in soleus ( 1.2 ml and 3 points)
163658|NCT01821573|Drug|injection of NaCl 0.9%|Placebo comparator group: injection of NaCl 0.9%:
3 ml of NaCl 0.9% in rectus femoris in 3 points
1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point
1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point
1.2 ml of NaCl 0.9% in soleus in 3 points
163659|NCT01821586|Other|Modified ORS-1|
163660|NCT01821586|Other|Modified ORS-2 (ReSoMal)|
163661|NCT01821586|Other|Modified ORS-3 (Benefibre)|
163662|NCT01821599|Other|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
163663|NCT01821599|Other|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
163664|NCT01821612|Drug|oxaliplatin|IV
163665|NCT00102375|Drug|Topotecan|
163666|NCT01821612|Drug|irinotecan hydrochloride|IV
163667|NCT01821612|Drug|leucovorin calcium|IV
163668|NCT01821612|Drug|5-fluorouracil|IV
163669|NCT01821612|Drug|capecitabine|PO
163670|NCT01821612|Radiation|radiation|
163671|NCT01821612|Procedure|surgery|pancreaticoduodenectomy
163953|NCT01817400|Dietary Supplement|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
163954|NCT01817400|Drug|Aspirin|
163955|NCT01817400|Drug|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
163341|NCT01818791|Behavioral|Making Proud Choices AND Getting To Outcomes|In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten "steps" that must be addressed and provides practitioners with the guidance necessary to address those steps with quality—i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors.
163342|NCT00102102|Drug|[18F]SPA-RQ|
163343|NCT01818804|Dietary Supplement|n-3PUFA|
163344|NCT01818804|Dietary Supplement|olive oil|
163345|NCT01818843|Other|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
163346|NCT01818856|Drug|Ritonavir withdrawal, atazanavir 200 mg/12h|
163347|NCT01818856|Drug|Telaprevir interactions|
163348|NCT01818869|Drug|AZD8848|Multiple doses inhaled IMP via a nebulizer
163349|NCT01818869|Drug|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
163350|NCT01818882|Other|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
163351|NCT01818882|Device|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
163352|NCT01818908|Drug|DA-EPOCH|DA-EPOCH regimen
163353|NCT00102115|Drug|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
163354|NCT01818921|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
163355|NCT01818921|Drug|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
163356|NCT01818921|Drug|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
163357|NCT01818934|Procedure|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
163358|NCT01818960|Procedure|IRA-PCI|IRA only PCI at the time of Primary PCI
163359|NCT01818960|Procedure|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
167749|NCT01854450|Other|Asymmetrical Lateral Decubitus|After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).
Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position
167750|NCT01854450|Other|control|usual obstetrical care
167751|NCT01854463|Drug|Vitamin D3|2000IU per day
167752|NCT00105560|Radiation|radiation therapy|Radiation therapy with proton beam to standard doses
167753|NCT01854463|Drug|placebo|elemental calcium 200mg per day per 24 weeks
167754|NCT01854476|Device|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
167755|NCT01854489|Drug|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days [Phase 1 ]
167756|NCT01856634|Drug|50 mg Delamanid|50 mg BID for 10 days
167757|NCT01856634|Drug|25 mg Pediatric Formulation Delamanid|25 mg pediatric formulation BID for 10 days
168054|NCT01859390|Drug|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
168055|NCT01859390|Dietary Supplement|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
168056|NCT01859403|Genetic|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
168057|NCT01859416|Dietary Supplement|Oral nutritional supplement|
168058|NCT01859429|Other|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
168059|NCT00106262|Drug|Velcade (bortezomib)|
168060|NCT01859442|Procedure|Structured responsive interval exercise training programme|
168061|NCT01859442|Other|Sham group|NO intervention in this group, only standard care (no exercise programme)
168062|NCT01859455|Drug|LGT209 50 mg|Active experimental drug
168063|NCT01859455|Drug|LGT209 300 mg|Active experimental drug
168064|NCT01859455|Drug|Placebo|Placebo comparator
167103|NCT01827813|Procedure|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
167104|NCT01827813|Procedure|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
167105|NCT01827813|Procedure|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
167106|NCT01827826|Behavioral|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
167107|NCT00103051|Procedure|neoadjuvant therapy|
167108|NCT01830400|Drug|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
167109|NCT00103285|Drug|cytarabine|Given IV or SC
167110|NCT01830439|Drug|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
167426|NCT01860781|Drug|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
167427|NCT01860794|Drug|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
167428|NCT01860807|Drug|Ibudilast|
167429|NCT01860807|Drug|Placebo|
167430|NCT01860820|Device|Geko device|
166466|NCT01829243|Drug|Placebo|
166467|NCT01829256|Behavioral|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
166468|NCT01829282|Behavioral|Risk Reduction|
166469|NCT01829295|Drug|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg BID orally. After two weeks, the dose will be increased to 1.5 g BID.
166470|NCT01829295|Drug|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
166471|NCT01829295|Drug|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
166472|NCT01829308|Behavioral|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
166473|NCT01829308|Behavioral|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
166474|NCT01829321|Drug|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
166475|NCT01829321|Drug|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
166476|NCT00103194|Other|laboratory biomarker analysis|Correlative studies
166477|NCT01829334|Other|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
166478|NCT01829334|Other|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
166479|NCT01829334|Other|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
166480|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
166481|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
166482|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
166786|NCT01824667|Dietary Supplement|B-GOS|
165867|NCT01830777|Drug|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
165868|NCT01830777|Drug|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
165869|NCT01830790|Drug|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
165870|NCT01830816|Drug|ixazomib (MLN9708)|
165871|NCT00103285|Drug|mercaptopurine|Given PO
165872|NCT01830829|Drug|Jalyn|study drug
165873|NCT01830829|Drug|Placebo|Placebo
165874|NCT01830842|Drug|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
165875|NCT01830842|Drug|Placebo|nonsmokers will be measured following placebo administration
165876|NCT01830842|Other|satiety|smokers will be measured in a smoking satiated condition
165877|NCT01830842|Other|abstinence|smokers will be measured following 24-hours of smoking abstinence
165878|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
165879|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
165880|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
165881|NCT01830855|Biological|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
165882|NCT00002006|Drug|Sargramostim|
165883|NCT00103285|Drug|cyclophosphamide|Given IV
165884|NCT01830855|Biological|Saline|0.5 mL dose of sterile normal saline for injection.
165885|NCT01830868|Drug|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
165886|NCT01830881|Drug|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
165887|NCT01830881|Drug|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
165888|NCT01830881|Other|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
165309|NCT01842672|Drug|Clofarabine|Dose Escalation of Clofarabine
165310|NCT01842672|Drug|Mitoxantrone|
165585|NCT01835457|Drug|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects.
165586|NCT00103675|Procedure|Acupuncture|
165587|NCT01835457|Behavioral|Concentration/meditation|A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
165588|NCT01835470|Drug|Abatacept|
165589|NCT01835496|Drug|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
165590|NCT01835509|Behavioral|Intervention, Camp plus reunions|
165591|NCT01835535|Device|TIVUS|
165592|NCT01835548|Drug|NT0102|One or two tablets once daily
165593|NCT01835548|Drug|Placebo|One or two tablets once daily
165594|NCT01835561|Drug|Pomalidomide|Single oral dose of 4‐mg capsule
165595|NCT01835561|Drug|Pomalidomide|4-mg capsule
165596|NCT01835574|Behavioral|Contingency Cash Transfer|
165597|NCT00103701|Drug|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
165598|NCT01835574|Behavioral|Contingency Cash Transfer|Active amphetamine substance users will be enrolled into a 16-week Contingency Cash Transfer intervention designed to reduce use of amphetamine.
165599|NCT01835587|Drug|Oral Azacitidine|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary MTD is identified.
165600|NCT01835600|Other|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
165601|NCT01835613|Other|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
165602|NCT01835626|Drug|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
165010|NCT01842321|Drug|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
165011|NCT01842334|Behavioral|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
165012|NCT01842334|Drug|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
165013|NCT01842347|Other|Fecal microbiota|
165014|NCT01842360|Biological|Placebo|The subjects will receive daily dose of placebo during 12 months
165015|NCT00104559|Behavioral|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
165016|NCT01842360|Biological|MV130|The subjects will receive daily dose of MV130 during 12 months
165017|NCT01842373|Drug|LMX4|
165018|NCT01842373|Drug|BLT|
165019|NCT01842386|Drug|Rituximab/Rituxan|Rituximab is a genetically engineered chimeric murine/human monoclonal antibody targeting the CD20 antigen expressed on the surface of normal and malignant B cells. It is an FDA-approved drug for the treatment of rheumatoid arthritis and non-Hodgkin's Lymphoma. We have received permission from the FDA to use rituximab for this study.
165311|NCT01842685|Procedure|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
165312|NCT01842698|Device|ultrasoundguided paravertebral catheter|
165313|NCT00002010|Drug|Fluconazole|
165314|NCT00103610|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
165315|NCT01835054|Other|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
165316|NCT01835054|Other|Holter ECG|Observational Study using Imaging and Biomarkers
165317|NCT01835067|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
165318|NCT01835067|Drug|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
164717|NCT01838915|Dietary Supplement|Placebo|Maltodextrin, 20 g.
164718|NCT01838928|Drug|Bupivacaine|
164719|NCT01838941|Drug|Betaine|
164720|NCT01838954|Device|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
164721|NCT01841489|Drug|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
164722|NCT01841489|Drug|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
164723|NCT01841489|Drug|Treatment G|1600 mg GS-9973 (Reference formulation)
164724|NCT01841489|Drug|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
164725|NCT00002016|Drug|Sevirumab|
164726|NCT00104429|Drug|GW873140|
164727|NCT01841489|Drug|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
164728|NCT01841489|Drug|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
164729|NCT01841502|Drug|Paroxetine|paroxetine 20 mg once daily
164730|NCT01841502|Drug|telaprevir|telaprevir 1125 mg twice daily
164731|NCT01841515|Drug|Desmopressin administration|
164732|NCT01841528|Other|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
164733|NCT01841528|Other|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
164734|NCT01841541|Behavioral|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
164735|NCT01841554|Device|Cardioband|
164134|NCT01815242|Drug|Gemcitabine|
164135|NCT01815242|Drug|Carboplatin|
164136|NCT01815255|Drug|tenofovir (TDF)|
164435|NCT01818102|Device|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
164436|NCT01818102|Device|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
164437|NCT01818115|Device|Hydrus Implant|
164438|NCT01818115|Procedure|IOL placement|
164439|NCT01818128|Device|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
164440|NCT01818128|Device|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
164441|NCT01818141|Drug|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
164442|NCT00102024|Drug|90Y-IDEC-159|
164443|NCT01818141|Drug|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
164444|NCT01818154|Other|LED phototherapy|
164445|NCT01838265|Procedure|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
164446|NCT01838265|Behavioral|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
164447|NCT01838265|Behavioral|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
164448|NCT01838265|Behavioral|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
164449|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
164450|NCT01838265|Procedure|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
164451|NCT01838265|Procedure|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
163836|NCT01822262|Procedure|laparoscopic cholecystectomy|
163837|NCT01822275|Drug|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
163838|NCT01822275|Radiation|Radiation therapy|
163839|NCT01822288|Drug|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
163840|NCT01822288|Drug|Estradiol & medroxyprogesterone acetate|Estradiol & medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
164137|NCT00101712|Drug|Vildagliptin Placebo|
164138|NCT01815268|Biological|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
164139|NCT01815268|Biological|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
164140|NCT01815268|Biological|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
164141|NCT01815268|Biological|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
164142|NCT01815281|Device|Foot Mechanical Stimulation (GONDOLA)|
164143|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
164144|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
164145|NCT01815307|Drug|Gemcitabine|1000mg/m2, day 1 every 2 weeks
164146|NCT01815307|Drug|S-1|80mg/m2/day, day 1-28, every 6 weeks
164147|NCT01815320|Procedure|Contrast-enhanced ultrasound (CE-US)|
164148|NCT00101725|Drug|crofelemer|
164149|NCT00101998|Drug|alvimopan|
164150|NCT01817660|Procedure|Endovascular repair of popliteal artery|
164151|NCT01817673|Dietary Supplement|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
164152|NCT01817673|Dietary Supplement|placebo|
163530|NCT01819233|Radiation|Radiation therapy|Undergo radiation therapy
163531|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
163532|NCT01819233|Other|Counseling intervention|Receive dietary counseling
163533|NCT01819233|Procedure|Quality-of-life assessment|Ancillary studies
163534|NCT01819246|Procedure|Aphersis Treatment Arm|
163535|NCT01819246|Other|Control Arm|
163536|NCT01819259|Drug|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
163537|NCT01819259|Drug|Placebo|
163538|NCT01819272|Drug|Met DR|metformin delayed-release tablets
163539|NCT01819272|Drug|Met XR|metformin extended-release tablets
163540|NCT01819285|Procedure|Immediate Orchiectomy or depot LHRH|
163841|NCT01822301|Procedure|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
163842|NCT01822314|Drug|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
163843|NCT01822314|Drug|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
163844|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
163845|NCT01814644|Behavioral|Standard Care|Individual assessment, lifestyle counseling
169174|NCT01849549|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
169175|NCT01849549|Other|MRI|Anatomical, diffusion, and/or functional MRI
169176|NCT01849562|Drug|Sovaprevir|NS3/4A protease inhibitor
169177|NCT01849562|Drug|ACH-3102|NS5A inhibitor
169178|NCT01849562|Drug|RBV|
169179|NCT01849562|Drug|Placebo|
169180|NCT01849575|Behavioral|Information vs no information about carotid ultrasound results on asymptomatic atherosclerosis|
169181|NCT00105053|Biological|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
169182|NCT01849588|Drug|Sorafenib|
169183|NCT01849601|Device|percutaneous transluminal angioplasty balloon catheter|
169184|NCT01849614|Other|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
169185|NCT01849627|Behavioral|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
169186|NCT01849627|Behavioral|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
169470|NCT01844960|Procedure|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
169471|NCT01844960|Procedure|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
169472|NCT00104728|Drug|ZD1839|
169473|NCT01844973|Drug|M518101|Proper quantity twice a day
169474|NCT01844973|Drug|Vehicle|Proper quantity twice a day
168883|NCT01846299|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL is administered intravitreally to the patient
168884|NCT01846312|Other|No treatment given|The participants will not receive any treatment.
168885|NCT01846325|Dietary Supplement|vitamin E|
168886|NCT01846325|Dietary Supplement|DHA|
168887|NCT01846325|Other|placebo|
168888|NCT01846338|Dietary Supplement|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
168889|NCT01846364|Dietary Supplement|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
168890|NCT00104858|Biological|Rituximab|Given IV
168891|NCT01846377|Behavioral|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
168892|NCT01846390|Drug|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
168893|NCT01846390|Drug|Dexamethasone|40 mg D1 - D4
168894|NCT01846390|Drug|Cisplatin|75 mg/m2 D1
168895|NCT01846390|Drug|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
168896|NCT01846403|Device|Semi-quantitative urine pregnancy test|
168897|NCT01846416|Drug|Atezolizumab|1200 mg intravenously on Day 1 of 21-day cycles until disease progression
168898|NCT01846429|Drug|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
168899|NCT01846442|Drug|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
168900|NCT01846442|Drug|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
168901|NCT00104858|Radiation|Total-Body Irradiation|Undergo TBI
173378|NCT01894451|Procedure|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
173379|NCT01894451|Procedure|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
173380|NCT00109837|Drug|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
168585|NCT01858077|Device|ABSORB BVS™|Bioresorbable scaffold
168586|NCT01858077|Device|XIENCE™|Drug eluting metallic stent
168587|NCT01858090|Drug|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
168588|NCT01860352|Dietary Supplement|Fish OIl|
168589|NCT01860365|Other|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
168590|NCT01860365|Other|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
168591|NCT01860378|Other|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
168592|NCT01860378|Other|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
168593|NCT01860391|Device|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
168594|NCT01860404|Drug|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
168595|NCT01860404|Drug|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
168596|NCT01860417|Biological|Allogenic Mesenchymal Stromal Cells|
168597|NCT01860417|Drug|Mepivacaine|
164257|NCT01820442|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
164258|NCT00102232|Procedure|supplementation with phosphatidylcholine|
164259|NCT01820455|Drug|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
164260|NCT01820455|Drug|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
164261|NCT01820468|Behavioral|Adapted critical time intervention team|
164262|NCT01820481|Drug|WIN-901X dose level 1|100mg Bid, PO, 12weeks
164263|NCT01820481|Drug|WIN-901X dose level 2|200mg Bid, PO, 12weeks
164264|NCT01820481|Drug|WIN-901X dose level 3|300mg Bid, PO, 12weeks
164581|NCT01841346|Procedure|Procedure: PCI|
164582|NCT01841359|Drug|Pramlintide|See description above (arm description).
164583|NCT01841372|Other|Second Life|Second Life is an online virtual reality environment.
164584|NCT01841372|Behavioral|Group Phone Conference Call|
164585|NCT01841385|Other|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
164586|NCT00104416|Drug|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
164587|NCT01841398|Behavioral|Multimedia Lifestyle Improvement|Goal setting to improve diet, physical activity or smoking behaviours
Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.
164588|NCT01841398|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
164589|NCT01833806|Device|ExAblate MRgFUS|Focused Ultrasound Ablation
164590|NCT01833819|Drug|Dexmedetomidine and lidocaine|
164591|NCT01833819|Drug|Remifentanil|
164592|NCT01833832|Drug|Cisplatin|Patients who are successfully debulked will then undergo HIPEC with cisplatin.
164593|NCT01833832|Procedure|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a CC of 0 or 1.
163956|NCT01817413|Procedure|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
163957|NCT00101946|Drug|683699|
163958|NCT01817413|Procedure|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
163959|NCT01817426|Drug|Infliximab|
163960|NCT01817426|Other|Placebo|
163961|NCT01817439|Drug|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
163962|NCT01817452|Drug|Trastuzumab|
163963|NCT01817452|Drug|Pertuzumab|
163964|NCT01817452|Drug|Paclitaxel|
163965|NCT01817465|Drug|Motilitone ®|
163966|NCT01817465|Drug|Pantoline®|
163967|NCT01817465|Drug|Motilitone® and Pantoline®|
163968|NCT00101959|Drug|Rebif|
163969|NCT01817478|Other|microbiologic sample|
163970|NCT01817491|Other|American Heart Association Diet|
163971|NCT01817491|Other|Reduced Fat Vegan Diet|
163972|NCT01817504|Procedure|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
164265|NCT01820481|Drug|Placebo|Bid, PO, 12weeks
164266|NCT01820494|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
164267|NCT01820507|Device|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
164268|NCT01820507|Device|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
164269|NCT00102258|Drug|Growth Hormone Therapy|
163360|NCT01818973|Drug|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
163361|NCT01818973|Drug|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
163672|NCT01821612|Drug|gemcitabine hydrochloride|IV
163673|NCT01814371|Other|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
163674|NCT01814371|Behavioral|Hygiene Protocol|Follow key hygiene tips:
Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.
Use liquid(pour or pump) soaps instead of bar soaps.
Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.
Do not share personal care items such as razors, brushes, or deodorant.
Wash all sheets and towels in hot water. Wash sheets every week.
Use towels and wash cloths only once before washing and do not share.
163675|NCT01814384|Device|prosthesis GMK ® without the ancillary MyKnee ® LBS|
163676|NCT01814384|Device|Matched patient cutting blocks MyKnee ® LBS|
163677|NCT01814397|Drug|Anastrozole|1 mg orally daily
163678|NCT01814397|Drug|exemestane|25 mg orally daily
163679|NCT01814397|Drug|letrozole|2.5 mg orally daily
163680|NCT01814410|Drug|Intravenous Ethanol|
163681|NCT01814410|Drug|Intravenous Nicotine|
163682|NCT00101621|Drug|M40403|
163683|NCT01814410|Drug|Intravenous Placebo|
163684|NCT01814423|Drug|Chloroquine-base 50 mg|
163685|NCT01814423|Drug|Chloroquine-base 70 mg|
163686|NCT01814436|Device|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and apical tissue in the patients with immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
163687|NCT01814449|Other|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
163688|NCT01814449|Drug|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
163689|NCT01814462|Device|6 months CPAP|
168065|NCT01859455|Drug|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
168066|NCT01859468|Dietary Supplement|Amorphous calcium carbonate|
168067|NCT01859481|Drug|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
168068|NCT01859481|Drug|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
168069|NCT01859481|Drug|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
168070|NCT00106262|Drug|Irinotecan|
168071|NCT01861821|Device|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
163362|NCT01818973|Drug|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
163363|NCT01818973|Radiation|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
163364|NCT00102128|Drug|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
163365|NCT01821274|Drug|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
163366|NCT01821274|Drug|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
163367|NCT00102336|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
163368|NCT01821274|Drug|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
163369|NCT01821287|Other|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
163370|NCT01821313|Other|Moderate exercise|
163371|NCT01821313|Other|High Intensity Interval Exercise|
167431|NCT01860833|Drug|Ibuprofen|time of treatment 14 days
167432|NCT00106379|Drug|Truvada (tenofovir DF + emtricitabine)|
167433|NCT01860833|Drug|Celecoxib|time of treatment 14 days
167434|NCT01860833|Drug|Diclofenac|time of treatment 14 days
167435|NCT01860859|Procedure|Closure of the hysterotomy at the time of primary cesarean|
167436|NCT01860898|Other|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
167437|NCT01860911|Drug|Insulin|
167438|NCT01860911|Drug|NG-monomethyl-L-arginine|
167439|NCT01860924|Behavioral|exercise|vigorous intensity exercise
167440|NCT01860924|Behavioral|health education|education
167441|NCT01860937|Procedure|leukapheresis or collection of PBMCs|
167442|NCT01860937|Drug|cyclophosphamide based chemotherapy regimens|
167443|NCT00106379|Drug|Emtriva (emtricitabine)|
167444|NCT01860937|Biological|modified T cells|
167445|NCT01860950|Device|Transcranial Direct Current Stimulation|20 milliamps of current for 20 minutes
167446|NCT01853761|Device|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
167447|NCT01853774|Behavioral|Tailored navigation|
167448|NCT01853787|Drug|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
167449|NCT01853787|Drug|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
167758|NCT01856634|Drug|(Dose to be determined) Pediatric Formulation Delamanid|(Dose to be determined) pediatric formulation BID for 10 days
167759|NCT01856634|Drug|Optimized Background Regimen (OBR)|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
166787|NCT01824667|Dietary Supplement|Maltodextrin|
166788|NCT00102765|Drug|fluticasone propionate/salmeterol powder|
166789|NCT01824680|Behavioral|Physical activity|There is two sequences, one before and one after the physical activity program. Each sequence contains one "rest" session and one "exercise" session
166790|NCT01824693|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
166791|NCT01824693|Drug|Busulfan|Given IV
166792|NCT01824693|Drug|Cyclophosphamide|Given IV
166793|NCT01824693|Drug|Fludarabine Phosphate|Given IV
166794|NCT01824693|Other|Laboratory Biomarker Analysis|Correlative studies
166795|NCT01824693|Drug|Melphalan|Given IV
166796|NCT01824693|Drug|Mycophenolate Mofetil|Given IV or PO
166797|NCT01824693|Other|Pharmacological Study|Correlative studies
166798|NCT01824693|Drug|Tacrolimus|Given IV or PO
166799|NCT00000288|Drug|Cotinine fumarate|
166800|NCT00002002|Drug|Trimethoprim|
166801|NCT00102765|Drug|fluticasone propionate powder|
166802|NCT01824706|Procedure|craniectomy|craniectomy
166803|NCT01824745|Other|educational intervention|Receive the SCP-BCS template booklet
166804|NCT01824745|Other|counseling intervention|Receive counseling sessions with a patient navigator
166805|NCT01824745|Procedure|standard follow-up care|Receive standard follow-up care
166806|NCT01824745|Procedure|quality-of-life assessment|Ancillary studies
166807|NCT01824745|Other|questionnaire administration|Ancillary studies
166808|NCT01824758|Drug|Lidocaine|Group L lidocaine (1.5 mg/kg), (rocuronium) (0.05mg/kg).
166809|NCT01824758|Drug|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
166810|NCT01824758|Drug|rocuronium|0.05 mg/kg rocuronium
166175|NCT01826032|Other|Standard care for OSA|sleep higiene and dietary counseling
166176|NCT01826045|Drug|Poly-gamma Glutamic Acid|
166177|NCT01826045|Drug|Placebo|
166178|NCT01826058|Radiation|Stereotactic body radiation therapy|
166179|NCT01826071|Other|Static Stretch|
166180|NCT01826071|Other|Active Elongation|
166181|NCT01826097|Device|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
166182|NCT01826110|Drug|[11C]PIB|Approximately 15 mCI [11C]PIB IV x1
166183|NCT00102934|Drug|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
166184|NCT01826123|Device|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
166185|NCT01826123|Device|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
166186|NCT01826136|Device|Acapella device|
166187|NCT01826149|Drug|propofol|Propofol dosage titration to achieve effect site concnetration 1.0 ng/ml, 2.0 ng/ml and 3.0 ng/ml using target controlled infusion
166188|NCT01826162|Other|acetate or placebo infusion|
166189|NCT01826175|Drug|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
166190|NCT01826175|Drug|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
166191|NCT01826175|Device|Optical Coherence Tomography|
166192|NCT01826188|Drug|THC 5 mg/ml and CBD 50 mg/ml.|
166193|NCT01826201|Drug|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
166194|NCT00002002|Drug|Leucovorin calcium|
166195|NCT00102947|Drug|daptomycin (up to 14 days)|
166196|NCT01826201|Drug|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
165603|NCT01835626|Radiation|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
165604|NCT01835639|Dietary Supplement|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
165605|NCT01835652|Other|Active Exercise|
165889|NCT00102596|Drug|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
165890|NCT01823068|Drug|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
165891|NCT01823081|Drug|Intravitreal injection of bevacizumab (Avastin)|
165892|NCT01823081|Drug|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
165893|NCT01823107|Device|Meso BioMatrix Device|
165894|NCT01823120|Other|Supportive and interactive text messages|
165895|NCT01823133|Drug|gemigliptin only|gemigliptin 50mg qd on day 1~7
165896|NCT01823133|Drug|rosuvastatin only|rosuvastatin 20mg qd on day 1~7
165897|NCT01823133|Drug|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1~7
165898|NCT01823146|Drug|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
165899|NCT01823146|Drug|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
165900|NCT00002001|Drug|Zalcitabine|
165901|NCT00102609|Drug|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
165902|NCT01823159|Drug|retigabine|Single oral administration of a 400 mg tablet.
165903|NCT01823159|Drug|placebo|Single oral administration of a tablet
165904|NCT01823172|Procedure|Methylene blue dye injection of sentinel lymph node|
165319|NCT01835067|Drug|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
165320|NCT01835093|Drug|Tipepidine Hibenzate|
165321|NCT01835106|Procedure|Epidural catheter is used postoperatively|
165322|NCT01835106|Procedure|Fascia iliaca compartment catheter is used postoperatively|
165323|NCT01835119|Drug|gum|gum
165324|NCT01835132|Device|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
165325|NCT00103610|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
165326|NCT01835145|Drug|Cabozantinib S-malate|Given PO
165327|NCT01835145|Drug|Dacarbazine|Given IV
165328|NCT01835145|Other|Laboratory Biomarker Analysis|Correlative studies
165329|NCT01835145|Drug|Temozolomide|Given PO
165330|NCT01835158|Drug|Cabozantinib S-malate|Given PO
165606|NCT01835652|Other|Passive Exercise|
165607|NCT01835665|Drug|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
165608|NCT00103714|Drug|denufosol tetrasodium (INS37217)|
165609|NCT01837862|Drug|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
165610|NCT01837875|Behavioral|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
165020|NCT01842399|Dietary Supplement|Resveratrol|Dietary Supplement
165021|NCT01842399|Drug|Placebo|2x/day orally
165022|NCT01842412|Behavioral|exercise|one bout of exercise training
165023|NCT01842438|Behavioral|Behavioral: psychosexual intervention|
165024|NCT01842451|Drug|VX-135|
165025|NCT01842451|Drug|Daclatasvir|
165026|NCT00104559|Behavioral|Standard paper consent form|Standard paper consent form
165027|NCT01842464|Procedure|Anterior Sacro-Spinous|Anterior Sacro-Spinous
165028|NCT01842477|Procedure|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
165029|NCT01842503|Drug|GET 73|300 mg tid on 3 days cycle
165030|NCT01834547|Drug|Drugs use: methylphenidate|40 mg tablets
165031|NCT01834547|Drug|Drug use: modafinil|40 mg tablets
165032|NCT01834547|Drug|caffeine|400 mg
165033|NCT01834547|Drug|placebo|placebo
165034|NCT01834573|Behavioral|physical exercise|10 weeks physical exercise; three times a week
165035|NCT01834586|Drug|Anesthetic Topical Adhesive Synera|For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.
For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week
165036|NCT01834599|Device|cerebral oximetry|tissue saturation measurement in pregnant women
165037|NCT01834612|Device|CM1500|blood volume monitor
165038|NCT00103571|Drug|Olanzapine|
165039|NCT01834625|Procedure|Shunt surgery|
165040|NCT01834638|Drug|ABT-126|capsule(s)
165041|NCT01834651|Drug|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
164452|NCT01838265|Procedure|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
164453|NCT01838265|Procedure|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
164736|NCT01841567|Device|Mepilex border post. op|
164737|NCT00104429|Drug|Combivir|
164738|NCT01841567|Device|Mepilex border post op|
164739|NCT01841593|Drug|Raltegravir|Isentress 400mg tablet taken twice daily
164740|NCT01841593|Drug|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
164741|NCT01841606|Drug|Ondansetron|Time of administration of drug
164742|NCT01841619|Drug|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in <25% subjects, the subjects will be re-treated by the standard protocol.
164743|NCT01841632|Drug|MultiStem|
164744|NCT01834066|Biological|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
164745|NCT01834079|Biological|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
164746|NCT01834092|Other|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
164747|NCT01834105|Drug|Liuwei Dihuang Pills|
164748|NCT01834118|Procedure|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
164749|NCT00103519|Drug|DITPA (3,5-diiodothyropropionic acid)|
164750|NCT01834131|Behavioral|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
164751|NCT01834144|Other|Exercise Training|
164752|NCT01834170|Drug|Gemcitabine|Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.
The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist
164153|NCT01817686|Other|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
164154|NCT01817686|Other|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
164454|NCT01838278|Behavioral|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
164455|NCT01838304|Device|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
164456|NCT01838304|Device|Monitoring|Manual recording of drug doses determined by CRNA
164457|NCT01838317|Drug|Pioglitazone|
164458|NCT01838330|Dietary Supplement|psyllium|
164459|NCT01838343|Other|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
164460|NCT00103948|Drug|Aricept|
164461|NCT01838369|Drug|BI-505|
164462|NCT01838382|Device|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
164463|NCT01838395|Drug|Ara-C|IV
164464|NCT01838395|Drug|BL-8040|SC
164465|NCT01838408|Other|Ez2go Complete|EZ2Go Complete
164466|NCT01838408|Other|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
164467|NCT01838434|Drug|lenalidomide|given PO
164468|NCT01838434|Drug|idelalisib|given PO
163846|NCT01814657|Drug|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
163847|NCT01814657|Drug|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
163848|NCT01814670|Biological|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
163849|NCT01814683|Drug|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
163850|NCT01814683|Drug|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
163851|NCT01814683|Drug|Placebo|14 days placebo.
163852|NCT01814696|Device|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
163853|NCT00101673|Drug|vildagliptin|
163854|NCT01814709|Drug|GDC-0032|Oral doses of GDC-0032
163855|NCT01814709|Drug|Itraconazole|Oral doses of Itraconazole
163856|NCT01814709|Drug|Rifampin|Oral doses of Rifampin
163857|NCT01814735|Other|Brown rice|
163858|NCT01814735|Other|White rice|
163859|NCT01814748|Drug|MK-3102|MK-3102 25 mg capsule administered orally once weekly
164155|NCT01817686|Other|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
164156|NCT01817699|Other|High Hb target|25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.
Dose and interval will be adjusted according to hemoglobin level and its target.
164157|NCT01817699|Dietary Supplement|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
164158|NCT01817712|Behavioral|Individual Placement & Support|IPS uses an integrated "place-train" approach to help people obtain and maintain community-based competitive employment in their chosen occupation.
169475|NCT01844986|Drug|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
169476|NCT01844999|Behavioral|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
169477|NCT01844999|Behavioral|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
169478|NCT01845012|Other|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
169479|NCT01845025|Drug|Formoterol|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
169480|NCT01845025|Drug|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
169481|NCT01845025|Drug|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
169482|NCT01845025|Drug|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
169483|NCT00104741|Drug|flutamide|
169484|NCT01845025|Drug|Placebo|Placebo to formoterol one inhalation twice daily via dry powder inhaler
169485|NCT01847378|Procedure|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
169486|NCT01847391|Drug|GS-6615|GS-6615 tablet(s) administered orally once daily
169487|NCT00104910|Biological|Cetuximab|Given IV
169488|NCT01847391|Drug|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
169489|NCT01847404|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
169781|NCT01850524|Drug|Placebo + Lenalidomide + Dexamethasone|Patients will receive single oral dose of Placebo on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progression
169782|NCT01850537|Device|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
169187|NCT01852149|Device|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
169188|NCT01852162|Drug|Dabigatran|Dabigatran 150mg
169189|NCT01852162|Drug|Placebo|Matching placebo tablets
169190|NCT00105248|Behavioral|patient-centered communication training|
169191|NCT01852175|Drug|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
169192|NCT01852175|Drug|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
169193|NCT01852188|Other|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
169194|NCT01852201|Device|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
169195|NCT01852214|Drug|Prasugrel|Patients randomized to prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
169196|NCT01852214|Drug|Ticagrelor|Patients randomized to ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
169197|NCT01852253|Procedure|2% chlorhexidine|
169198|NCT01852253|Procedure|0.12% chlorhexidine|
169199|NCT01852266|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
169200|NCT01852266|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
169201|NCT00105287|Drug|OraVescent fentanyl (OVF)|
169202|NCT01852279|Device|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
169203|NCT01852279|Device|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
169204|NCT01852292|Drug|Paclitaxel|
169205|NCT01852292|Drug|Buparlisib|
168598|NCT00106340|Drug|Vildagliptin matching placebo|
168599|NCT01860430|Drug|Cetuximab/IMRT Plus Ipilimumab|Cetuximab/IMRT Plus Ipilimumab (14 Week Regimen) IMRT, Weeks 2-8: 70-74.0 Gy with 2.0 Gy daily fractions delivered in 7-7.5 weeks Cetuximab, Weeks 1-8 Week 1: 400 mg/m2 Weeks 2-8 (concurrent with IMRT): 250 mg/m2/week Ipilimumab, Weeks 5, 8, 11, 14 Ipilimumab dose will be determined by cohort (1, 3, 6, or 10 mg/kg)
168600|NCT01860443|Other|Telepsychiatry collaborative program|The intervention includes:
Online training for the health staff
Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression
Online supervision in a web platform by specialists
Telephone monitoring
168601|NCT01860443|Other|Usual care|Online training for the health staff
Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression
168602|NCT01860456|Drug|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
168603|NCT01860469|Procedure|vancomycin-soaked mesh|
168604|NCT01860469|Procedure|plain mesh|
168902|NCT01846442|Drug|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
168903|NCT01846442|Drug|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
168904|NCT01846455|Drug|2.0mg Buprenorphine/0.5mg Naloxone|Each participant will receive a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
168905|NCT00105001|Drug|Tacrolimus|Given IV or PO
168906|NCT01848990|Drug|Insulin lispro|
168907|NCT01848990|Drug|Insulin aspart|
168908|NCT01848990|Drug|Insulin glulisine|
168909|NCT01849003|Drug|GS-6615|GS-6615 tablet(s) administered orally
168910|NCT01849016|Drug|N-Acetylcysteine|
168911|NCT01849016|Drug|Placebo|
168912|NCT01849029|Behavioral|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
168913|NCT01849042|Drug|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
164594|NCT01833845|Drug|Ribavirin|weight-based doses (1000 mg/day administered BID [twice daily] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects > 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
164595|NCT01833845|Drug|Hydroxychloroquine|subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
164596|NCT01833858|Drug|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
164597|NCT01833858|Drug|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
164598|NCT01833871|Other|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
164599|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
164857|NCT01834352|Drug|Walnut Protein Flour|The initial day escalation begins with a dose of 0.1 mg of walnut protein. The dose is then increased and administered every thirty minutes until a maximum dose of 6 mg is reached or until allergic symptoms develop. After the initial escalation day, subjects begin the build-up phase in which the dose is increased every two weeks to a maximum dose of 1500mg walnut protein at 34 weeks. After 34 weeks of build-up, the subject begins the maintenance phase in which daily dose (1500mg or the highest dose reached by 34 weeks) is taken for 4 weeks followed by a 5 gram protein oral food challenge to walnut and a 5 gram protein oral food challenge to the second tree nut (at 38 weeks). Then the study will be unblinded. Active treatment subjects will continue on the 1500mg walnut protein daily dose for a maximum of 33 months.
164858|NCT01836614|Drug|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
164859|NCT01836627|Other|Hyperinsufflation therapy|15 minutes twice a day of hyperinsufflation with Cough Assist® device
164860|NCT01836653|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164861|NCT01836653|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164862|NCT01836653|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164863|NCT00103792|Drug|mycophenolate mofetil|2000 mg mycophenolate per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
164270|NCT01820520|Drug|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
164271|NCT01820533|Other|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
164272|NCT01820559|Drug|Placebo|Tablets
164273|NCT01820559|Drug|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
164274|NCT01820559|Drug|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
164275|NCT00101400|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
164276|NCT01812954|Drug|Acitretin|
164277|NCT01812954|Drug|Infliximab|
164278|NCT01812954|Drug|etanercept|
164279|NCT01812954|Drug|Adalimumab|
164280|NCT01812954|Drug|Ustekinumab|
164281|NCT01812967|Dietary Supplement|Milk Fat|
164282|NCT01812967|Dietary Supplement|Milk Protein|
164283|NCT01812967|Dietary Supplement|Lactose|
164284|NCT01812967|Other|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
164285|NCT01812967|Dietary Supplement|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
164286|NCT00101413|Drug|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles [Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
164287|NCT01812980|Biological|Trivalent Inactivated Influenza Vaccine|WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.
164600|NCT01833871|Other|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
164601|NCT01833884|Other|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
163690|NCT01814475|Drug|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
163691|NCT01814475|Drug|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
163973|NCT01817504|Procedure|Progressive reduction of immunosuppression|Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.
In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group.
163974|NCT01817517|Device|Medtronic Activa Deep Brain Stimulation System|
163975|NCT01817530|Other|Placebo|Placebo for 6 Month Treatment Period
163976|NCT01820026|Drug|Vancomycin|Second line therapy
163977|NCT01820026|Drug|azithromycin|Second line therapy
163978|NCT00102206|Drug|Lopinavir/ritonavir|
163979|NCT01820026|Drug|Cefotaxime|Standard antibiotic therapy
163980|NCT01820026|Drug|Amoxicillin|Standard therapy
163981|NCT01820039|Other|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
163982|NCT01820052|Drug|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
163983|NCT01820052|Drug|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
163984|NCT01820065|Procedure|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
163985|NCT01820078|Drug|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
163986|NCT01820078|Other|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
163987|NCT01820091|Drug|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
163988|NCT01820091|Drug|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
163989|NCT00102206|Drug|Saquinavir|
163372|NCT01821352|Device|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
163373|NCT01821352|Device|Placebo Laser|Emits light that has no therapeutic effect
163374|NCT01821378|Drug|Lurasidone|Lurasidone 20 mg once daily
163375|NCT01821378|Drug|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
163376|NCT01821378|Drug|Placebo|Once Daily
163377|NCT01821391|Drug|NDL-PDT|Metvix natural daylight photodynamic therapy
163378|NCT00102336|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
163379|NCT01821391|Drug|c-PDT|Metvix conventional photodynamic therapy
163380|NCT01821391|Drug|placebo c-PDT|Metvix placebo conventional photodynamic therapy
163381|NCT01821404|Drug|Atorvastatin|Capsules including 80 mg of atorvastatin
163382|NCT01821404|Drug|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
163383|NCT01821417|Device|Microtextured dental implant treatment|Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
163692|NCT01814488|Procedure|allogeneic transplant|Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.
The conditioning regimen in standard use is:
Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;
Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;
Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.
Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if <40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice.
163693|NCT00101634|Drug|Paliperidone palmitate|
163694|NCT01814501|Biological|panitumumab|Given IV
163695|NCT01814501|Drug|irinotecan hydrochloride|Given IV
163696|NCT01814501|Drug|fluorouracil|Given IV
163697|NCT01814501|Drug|leucovorin calcium|Given IV
163698|NCT01816984|Biological|cetuximab|Given IV
163699|NCT01816984|Other|laboratory biomarker analysis|Correlative studies
167760|NCT01856647|Procedure|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (~3 ml) will be obtained from the lower abdomen following local anesthesia.
167761|NCT01856660|Behavioral|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to > 40 min per day, 5 times/week.
167762|NCT01856660|Behavioral|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
167763|NCT01856673|Behavioral|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
167764|NCT00105872|Behavioral|Cognitive-Behavioral Therapy|
167765|NCT01856673|Behavioral|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
167766|NCT01856673|Other|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
167767|NCT01856686|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
167768|NCT01856686|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
167769|NCT01856712|Drug|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
168072|NCT01861834|Drug|Omegaven 10%|Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.
Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN
166811|NCT01824758|Drug|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
166812|NCT00102778|Drug|GW873140|
167111|NCT01830439|Drug|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
167112|NCT01830452|Procedure|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
167113|NCT01830465|Drug|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
167114|NCT01830465|Drug|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
167115|NCT01830478|Drug|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
167116|NCT01830478|Drug|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
167117|NCT01830491|Drug|Clopidogrel|
167118|NCT01830491|Drug|aspirin 100mg|
167119|NCT01830504|Drug|BKM120|BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.
A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment.
167120|NCT00103285|Drug|dexamethasone|Given IV or PO
167121|NCT01830517|Drug|Amlodipine, Losartan|
167122|NCT01830530|Drug|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
167123|NCT01830530|Drug|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
167124|NCT01830530|Drug|placebo|two tablets daily in the morning
167125|NCT01830543|Drug|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
167126|NCT01830543|Drug|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
167127|NCT01830543|Drug|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
166197|NCT01826214|Drug|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
166483|NCT01831479|Drug|Rosuvastatin|Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
166484|NCT01831479|Drug|Olmesartan|Single administration of olmesartan 40mg tablet QD for 7 consecutive days
166485|NCT01831479|Drug|Rosuvastatin and olmesartan|Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
166486|NCT00103311|Drug|ispinesib|Given IV
166487|NCT01831492|Device|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
166488|NCT01831492|Device|cellulose|given for 14 weeks
166489|NCT01831505|Drug|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
166490|NCT01831518|Device|CRT Implant|
166491|NCT01831518|Device|Body Surface ECG Mapping|
166492|NCT01831531|Drug|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA >1.6 m2) p.o bid d1-28
166493|NCT01831531|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
166494|NCT01831544|Device|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
166495|NCT01831557|Other|Blood samples will be taken for gene sequencing|
166496|NCT01831570|Other|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
166497|NCT00002007|Drug|Zidovudine|
166498|NCT00103311|Other|laboratory biomarker analysis|Correlative studies
166499|NCT01831583|Device|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
166500|NCT01831583|Device|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
166501|NCT01831596|Device|ciSNaP|
165905|NCT01823185|Drug|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
165906|NCT01823185|Drug|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
165907|NCT01823198|Drug|Busulfan|32 mg/m2 test dose based on actual body weight given by vein within 2 weeks of the preparative regimen.
Busulfan adjusted dose determined to achieve a systemic exposure represented by an average daily AUC of 6000 µMol-min ± 5% on Day -13 to Day -10. Patients over age 60 and/or with performance status =2 receive and AUC of 4000 microM x min for each dose. If it is not feasible to perform the pharmacokinetic studies, Busulfan dose of 130 mg/m2 administered (100 mg/m2 for age over 60 or PS=2).
PK-guided daily high-dose Busulfan dose(s) started immediately upon completion of the daily fludarabine doses.
166198|NCT01826227|Procedure|Positron Emission Tomography|
166199|NCT01826227|Radiation|18F-Fluoro-2-deoxy-D-lucose|
166200|NCT01826227|Procedure|Cytoreductive surgery|
166201|NCT01826240|Behavioral|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
166202|NCT01828697|Drug|Low dose dalteparin|Fixed low dose dalteparin:
< 100 kg: 5000 IU subcutaneously once-daily
100 kg and above: 7500 IU subcutaneously once-daily
166203|NCT01828697|Drug|Intermediate dose dalteparin|Intermediate weight-adjusted dose dalteparin:
< 50 kg: 7500 IU subcutaneously once-daily, or;
50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;
70 kg to < 100 kg: 12500 IU subcutaneously once-daily, or;
100 kg or above: 15000 IU subcutaneously once-daily.
166204|NCT01828697|Drug|Fixed low dose tinzaparin|Fixed low dose tinzaparin:
< 100 kg: 3500 IU subcutaneously once-daily
100 kg and above: 4500 IU subcutaneously once-daily
166205|NCT01828697|Drug|Intermediate dose tinzaparin|Intermediate weight-adjusted dose tinzaparin:
< 50 kg: 4500 IU subcutaneously once-daily, or;
50 kg to < 70 kg: 7000 IU subcutaneously once-daily, or;
70 kg to < 100 kg: 10000 IU subcutaneously once-daily, or;
100 kg or above: 12000 IU subcutaneously once-daily.
166206|NCT01828710|Dietary Supplement|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
166207|NCT01828710|Dietary Supplement|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
166208|NCT01828710|Dietary Supplement|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
166209|NCT00103168|Drug|imatinib mesylate|
166210|NCT01828723|Biological|SVF|
165611|NCT01837875|Behavioral|Mail-delivered arthritis kit|The Arthritis Self-Management Tool Kit contains 1) a "Self Test" to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets.
165612|NCT01837875|Behavioral|Support group|Interested participants will be referred to the "Lupus: Listening and Learning Group", a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved.
165613|NCT01837875|Behavioral|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
165614|NCT01837888|Device|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
165615|NCT00103922|Drug|cilomilast|
165616|NCT01837901|Device|transcorneal electrostimulation|OkuStim is used to determine the phosphene threshold, and then to administer electrostimulation
165617|NCT01837914|Procedure|Maxillary expansion|
165618|NCT01837914|Procedure|Adenotonsillectomy|
165619|NCT01837927|Drug|NVA237|Once daily for 52 weeks
165908|NCT01823198|Drug|Fludarabine|40 mg/m2 by vein dosed per actual body weight/actual body surface area on Day -13 to Day -10.
165909|NCT01823198|Procedure|Alloreactive NK infusion|Alloreactive NK cell infusion given by vein on Day -8 at one of 4 dose levels based on the number of NK cells (CD3-,CD 56+ cells)/kg recipient body weight. Dose levels are: 106, 107, 3 x 107, 108.
165910|NCT01823198|Drug|Interleukin-2|0.5 million units subcutaneously on Day -8 to Day -4.
165911|NCT01825616|Dietary Supplement|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
165042|NCT01834664|Biological|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell [MNCs ]Per dose at the interval
165331|NCT01835158|Other|Laboratory Biomarker Analysis|Correlative studies
165332|NCT01835158|Drug|Sunitinib Malate|Given PO
165333|NCT01835171|Drug|Cisplatin|Given IV
165334|NCT01835171|Radiation|External Beam Radiation Therapy|Undergo EBRT
165335|NCT01835171|Radiation|Internal Radiation Therapy|Undergo HDR or LDR brachytherapy
165336|NCT00103623|Drug|Plenaxis|
165337|NCT01835171|Other|Laboratory Biomarker Analysis|Optional correlative studies
165338|NCT01837394|Drug|Morphine|5 mg as needed
165339|NCT01837394|Drug|Ondansetron|4 mg i.v. as needed in the PACU
165340|NCT01837394|Drug|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
165341|NCT01837407|Procedure|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
165342|NCT01837420|Drug|VB-201 80mg|
165343|NCT01837420|Drug|VB-201 160mg|
165344|NCT00103857|Drug|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
165345|NCT01837420|Drug|Placebo|
165346|NCT01837433|Drug|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
165347|NCT01837433|Drug|Prednisone 6 weeks|Guidelines recommend
165348|NCT01837446|Drug|2% morphine solution|
165349|NCT01837446|Drug|Magnesium aluminum hydroxide|
165350|NCT01837446|Drug|2% viscous lidocaine|
165351|NCT01837446|Drug|Diphenhydramine|
164753|NCT01834183|Drug|Tivozanib|
164754|NCT01834183|Drug|Gemcitabine|
164755|NCT01834196|Device|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
164756|NCT01834209|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
164757|NCT01834209|Drug|Prednisone or prednisolone|5 mg tablet taken orally once daily
165043|NCT01834703|Procedure|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
165044|NCT01834703|Procedure|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
165045|NCT01834716|Behavioral|Aerobic vs. Non-Aerobic exercise|
165046|NCT01834729|Drug|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
165047|NCT01834729|Other|Placebo|placebo capsule identical to the study drug
165048|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
165049|NCT00103571|Drug|Aripiprazole|
165050|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
165051|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
165052|NCT01836900|Device|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
164469|NCT01841034|Drug|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
164470|NCT01841047|Radiation|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
164471|NCT01841060|Procedure|Radiofrequency|Radiofrequency
164472|NCT01841073|Dietary Supplement|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
164473|NCT01841073|Dietary Supplement|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
164758|NCT01834222|Biological|Non-intervention|Non-intervention
164759|NCT01834235|Drug|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
164760|NCT00103519|Drug|Placebo|Placebo
164761|NCT01834235|Drug|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
164762|NCT01834235|Drug|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
164763|NCT01834248|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
164764|NCT01834248|Drug|Decitabine|Given IV
164765|NCT01834248|Other|Laboratory Biomarker Analysis|Correlative studies
164766|NCT01834248|Drug|Poly ICLC|Given SC
164767|NCT01834261|Drug|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
164768|NCT01834261|Drug|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
164769|NCT01836458|Drug|KAE609|patients will receive KAE609 single dose of different dose level in each cohort.
164159|NCT01817712|Behavioral|VA Transitional Work Program|The long-standing approach to vocational rehabilitation in VHA and state programs is the "train-place" or "stepwise" model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role.
164160|NCT00101998|Drug|placebo|
164161|NCT01817725|Biological|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) will be administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months or until HBsAg clearance. The dosage will be 20μg in those <= 20 years old and 40μg in those > 20 years old.
164162|NCT01817738|Biological|CV9104|Intradermal injection of CV9104
164163|NCT01817738|Biological|Placebo|Intradermal injection of placebo
164164|NCT01817751|Drug|sorafenib tosylate|Given PO
164165|NCT01817751|Drug|valproic acid|Given PO
164166|NCT01817751|Drug|sildenafil citrate|Given PO
164167|NCT01817764|Drug|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
164168|NCT00102219|Drug|Pemetrexed|
164169|NCT01820260|Drug|placebo|
164170|NCT01820286|Behavioral|Positive psychology intervention|
164171|NCT01820286|Behavioral|Recollection intervention|
164172|NCT01820299|Drug|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
164173|NCT01820299|Drug|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
164174|NCT01820312|Radiation|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
164474|NCT01841073|Dietary Supplement|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
164475|NCT00104390|Biological|Grass MATA MPL|
164476|NCT01841073|Dietary Supplement|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
164477|NCT01841073|Dietary Supplement|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.
169783|NCT01850550|Behavioral|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
169784|NCT00105157|Drug|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
169785|NCT01850563|Other|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
169786|NCT01850576|Behavioral|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
169787|NCT01850589|Other|Aggressive Therapy|Pharmacotherapy adjuncts offered at no cost are as follows:
Chantix (varenicline) GlaxoSmithKline,
Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline.
169788|NCT01850602|Drug|PA21|
169789|NCT01850602|Drug|Sevelamer hydrochloride|
169790|NCT01850615|Drug|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
169791|NCT01850615|Drug|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
169792|NCT01850628|Drug|Paclitaxel|
169793|NCT01850628|Biological|trastuzumab|
169794|NCT01850628|Biological|pertuzumab|
169795|NCT00105157|Drug|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
169796|NCT01850641|Drug|PA21|
169797|NCT01850654|Genetic|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
169798|NCT01843062|Drug|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
169799|NCT01843075|Drug|Liraglutide|Daily subcutaneous injection
169800|NCT01843075|Drug|Placebo|Daily subcutaneous injection
170093|NCT01845987|Drug|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
170094|NCT01845987|Drug|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
169206|NCT01852292|Drug|Buparlisib Placebo|
169490|NCT01847404|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
169491|NCT01847404|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
169492|NCT01847404|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
169493|NCT01847417|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
169494|NCT01847417|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
169495|NCT01847417|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
169496|NCT01847417|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
169497|NCT01847430|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
169498|NCT00104910|Drug|Cisplatin|Given IV
169499|NCT01847443|Drug|Nicotine (2 mg)|2 mg nicotine gum in two formulations
169500|NCT01847443|Drug|Nicotine (4 mg)|4 mg nicotine gum in two formulations
169501|NCT01847456|Drug|human insulin as nasal spray|
169502|NCT01847456|Drug|Placebo|
169503|NCT01847469|Behavioral|Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|
169504|NCT01847469|Drug|Zonisamide|
169505|NCT01847469|Drug|Placebo|
169506|NCT01847482|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
169507|NCT01847495|Drug|Irinotecan|40mg/m2 x 3-5 days
168914|NCT01849042|Drug|donepezil|
168915|NCT01849055|Drug|Placebo|Administered orally
168916|NCT00105001|Drug|Mycophenolate Mofetil|Given PO
168917|NCT01849055|Drug|LY3023703|Administered orally
168918|NCT01849055|Drug|Celecoxib|Administered orally
168919|NCT01849068|Drug|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
168920|NCT01849068|Drug|Placebo|Placebo for 12 weeks
168921|NCT01849081|Device|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
168922|NCT01849081|Behavioral|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
168923|NCT01849094|Drug|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
168924|NCT01849094|Drug|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
169207|NCT01852305|Other|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI>30) or moderate sleep apnea (AHI>15 to <30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI>5 to <15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
169208|NCT01852305|Device|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
169209|NCT01844466|Procedure|Physiotherapy and speech therapy|
169210|NCT00104702|Procedure|adjuvant therapy|
169211|NCT01844479|Device|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
169212|NCT01844479|Other|Standard innersole|
164864|NCT01836653|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164865|NCT01836653|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164866|NCT01836653|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
164867|NCT01836679|Drug|Chidamide|Given orally
164868|NCT01836679|Drug|Paclitaxel|Given IV
164869|NCT01836679|Drug|Carboplatin|Given IV
164870|NCT01836679|Drug|Placebo|Given orally
164871|NCT01836692|Radiation|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
164872|NCT01836705|Drug|SAR302503 (TG101348)|Pharmaceutical form:capsule
Route of administration: oral
164873|NCT01836705|Drug|Placebo SAR302503|Pharmaceutical form:capsule
Route of administration: oral
164874|NCT00103792|Drug|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
165161|NCT01837251|Drug|PLD|
165162|NCT01837251|Biological|Bevacizumab|
165163|NCT01837264|Device|Magellan®|
165164|NCT01837277|Drug|Use of Raltegravir-based regimens|Use of Raltegravir-based regimens: patients will receive a Raltegravir-based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
165165|NCT01837277|Drug|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
165166|NCT01837290|Drug|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
165167|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.
Ci-Ca protocole for MultiFiltrate® CRRT machine :
4% trisodium citrate solution
Calcium chloride solution (100 mmol/L)
Dialysate flow rate: 35 ml/kg/h
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3
Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.
Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.
Blood flow adapted to the acid-base status
164602|NCT01833897|Drug|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
164603|NCT01833897|Drug|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
164604|NCT01833897|Drug|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
164605|NCT01833910|Other|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
164606|NCT01836198|Drug|LY2409021|Administered orally
164607|NCT01836198|Drug|Gemfibrozil|Administered orally
164608|NCT01836198|Drug|Ketoconazole|Administered orally
164609|NCT01836198|Drug|Clarithromycin|Administered orally
164610|NCT01836211|Other|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
164611|NCT01836211|Other|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
164612|NCT01836224|Drug|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) >65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
164613|NCT00103740|Drug|Placebo to risedronate|oral capsules
164614|NCT01836224|Drug|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65
164615|NCT01836237|Device|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
164616|NCT01836276|Drug|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
163990|NCT01820104|Drug|lansoprazole, 30 mg per day for 6 days|
163991|NCT01820117|Other|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
163992|NCT01820117|Other|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
164288|NCT01812993|Device|Non-invasive ventilatory treatment with auto-BPAP|
164289|NCT01813006|Drug|Omega-3|
164290|NCT01813006|Drug|placebo|
164291|NCT01813019|Drug|AFQ056|mGluR5 antagonist
164292|NCT01813019|Drug|Placebo|Matched placebo
164293|NCT01813032|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
164294|NCT01813032|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
164295|NCT01813045|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
164296|NCT01813045|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
164297|NCT00101426|Drug|ranirestat, (AS-3201)|
164298|NCT01813045|Radiation|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
164299|NCT01813058|Drug|Tranexamic Acid|Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:
placebo i.e. saline 0.9% (intravenous injection)
intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery.
164300|NCT01813058|Drug|Placebo|Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:
Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or
TXA as previously described.
164301|NCT01813071|Biological|WRSS1|
164302|NCT01815450|Drug|BLI1100 - modified formulation|BLI1100 topical cream
164303|NCT01815450|Drug|Placebo|Placebo topical cream
163700|NCT00101907|Biological|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
163701|NCT01816984|Other|questionnaire administration|Ancillary studies
163702|NCT01816997|Drug|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
163703|NCT01816997|Drug|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
163704|NCT01816997|Drug|Control|placebo
163705|NCT01817010|Behavioral|Multi-Component Rehabilitation (CMC)|
163706|NCT01817010|Behavioral|Control (CON)|
163707|NCT01817023|Radiation|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
163708|NCT01817023|Drug|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
163709|NCT01817036|Dietary Supplement|Placebo|placebo
163710|NCT01817036|Dietary Supplement|Vitamin D|400 IU vitamin D per pill
163711|NCT00101907|Drug|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m^2.
163712|NCT01817049|Behavioral|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
163993|NCT01820117|Other|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
163994|NCT01820117|Other|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
163995|NCT01820117|Other|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
163996|NCT01820117|Other|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
168073|NCT01861847|Drug|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
168074|NCT01861847|Drug|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
168075|NCT01861860|Device|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
168076|NCT01861873|Other|measuring liver function by 18-FDGal PET/CT|
168077|NCT01861886|Device|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
168078|NCT00106522|Drug|Placebo|iv every 4 weeks
168079|NCT01861899|Device|SI-LOK|Sacro-iliac joint fusion
168080|NCT01861912|Device|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities
168081|NCT01861912|Drug|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
168082|NCT01861912|Drug|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
168083|NCT01861912|Drug|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
168084|NCT01861938|Biological|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
168085|NCT01861951|Drug|Pazopanib|
168086|NCT01861951|Drug|Doxorubicin|
168087|NCT01861964|Dietary Supplement|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
168088|NCT01861964|Dietary Supplement|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
168089|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
168090|NCT01861964|Dietary Supplement|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
167128|NCT01830543|Drug|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
167129|NCT01830543|Drug|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
167130|NCT01830543|Drug|clopidogrel|One 75 mg tablet once daily for up to twelve months
167131|NCT01822782|Biological|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
167450|NCT00105495|Drug|Desferal (deferoxamine)|
167451|NCT01853800|Drug|Rivaroxaban (Xarelto, BAY59-7939)|
167452|NCT01853813|Drug|Bevacizumab and FOLFIRI|The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.
After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.
Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity
167453|NCT01853826|Drug|afatinib|Patients will receive afatinib once daily
167454|NCT01853852|Drug|GR181413A/AT1001 solution|Powder for reconstitution
167455|NCT01853852|Drug|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
167456|NCT01853852|Other|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
167457|NCT01853852|Drug|Placebo capsule|Solution matched
167458|NCT01853865|Other|Instruction in self-referral|
167459|NCT01853878|Biological|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
167460|NCT01853878|Biological|Placebo|Intramuscular administration
167461|NCT00105508|Drug|Sarizotan HC1|
167462|NCT01853904|Procedure|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
167463|NCT01853904|Procedure|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
167464|NCT01853917|Other|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
166502|NCT01831622|Drug|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
166503|NCT01831622|Drug|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
166504|NCT01831635|Other|Methodological pens|Randomisation of branded pen, non-branded pen and no pen
166813|NCT01827241|Other|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
166814|NCT01827254|Other|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
166815|NCT01827267|Drug|neratinib|240 mg orally, once daily with food, continuously in 21 day cycles
166816|NCT01827267|Drug|temsirolimus|8 mg or 15 mg weekly by IV infusion
166817|NCT01827280|Drug|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
166818|NCT01827293|Drug|Promethazine|
166819|NCT01827293|Drug|Lorazepam|
166820|NCT01827306|Drug|Biofreeze|
166821|NCT01827332|Drug|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
166822|NCT00103025|Drug|Sodium Nitrite|
166823|NCT01827332|Drug|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
166824|NCT01827345|Dietary Supplement|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
166825|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
166826|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
166827|NCT01827371|Biological|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
166828|NCT01827384|Drug|Temozolomide|
166829|NCT01827384|Drug|Everolimus|
166211|NCT01828736|Biological|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
166212|NCT01828736|Drug|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
166213|NCT01828736|Drug|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
166214|NCT01828736|Drug|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
166215|NCT01828762|Biological|DC-TC+GM-CSF|
166216|NCT01828775|Other|palliative care|Receive early PCI
166217|NCT01828775|Other|palliative care|Receive delayed PCI
166218|NCT01828775|Procedure|quality-of-life assessment|Ancillary studies
166219|NCT01828775|Other|survey administration|Ancillary studies
166505|NCT01831635|Other|Methodological compensation|Randomisation of a £10 monetary reimbursement for expenses on completion of the study
166506|NCT01824108|Procedure|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
166507|NCT01824121|Biological|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
166508|NCT01824134|Other|Klean & Klear The Dandy Day Corp|
166509|NCT01824134|Other|The Skin Gel Herbal Answers, Inc|
166510|NCT01824160|Device|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
166511|NCT01824173|Other|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
166512|NCT01824173|Other|Aerobic exercise|Moderate intensity for 45 minutes
166513|NCT01824186|Procedure|SILC|Underwent single-incision laparoscopic cholecystectomy
166514|NCT01824186|Procedure|LC|Underwent conventional 4-port laparoscopic cholecystectomy
165912|NCT01825616|Other|Placebo|Mushroom powder without vitamin D2
165913|NCT01825629|Other|Multidisciplinary therapy|Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.
Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.
Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks.
165914|NCT01825629|Other|Placebo|
165915|NCT01825642|Procedure|nerve-sparing radical prostatectomy|
165916|NCT01825642|Procedure|seminal vesicle-sparing radical prostatectomy|
165917|NCT01825655|Drug|Cetirizine|
165918|NCT01825655|Drug|Placebo or sugar pill|
165919|NCT01825668|Other|Plant Sterols|
165920|NCT01825668|Other|High cholesterol|
165921|NCT00102882|Drug|fluticasone propionate/salmeterol|
165922|NCT01825668|Other|Placebo|
165923|NCT01825681|Behavioral|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
165924|NCT01825694|Behavioral|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
165925|NCT01825707|Drug|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg (oral) on day1
165926|NCT01825720|Drug|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
165927|NCT01825720|Drug|normal saline group|same rate of normal saline
166220|NCT00103168|Procedure|adjuvant therapy|
166221|NCT01828788|Drug|Ropivacaine|
166222|NCT01828788|Drug|placebo|
166223|NCT01828801|Device|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
165352|NCT01837472|Drug|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
165620|NCT01837927|Drug|Tiotropium Respimat®|Once daily for 52 weeks
165621|NCT01837940|Dietary Supplement|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
165622|NCT01837940|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
165623|NCT01840423|Drug|Entacapone|entacapone + levodopa/carbidopa
165624|NCT01840423|Drug|levodopa/carbidopa|entacapone + levodopa/carbidopa
165625|NCT00104299|Drug|Azathioprine|2 mg/kg/day orally for months 4-6
165626|NCT01840436|Device|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
165627|NCT01840436|Device|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
165628|NCT01840449|Drug|Somatuline Autogel® 60, 90 or 120 mg|
165629|NCT01840488|Drug|Irosustat (BN83495)|Three parts (A, B & C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.
Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression.
165630|NCT01840501|Drug|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
165631|NCT01840501|Drug|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
165632|NCT01840501|Drug|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
165633|NCT01840501|Drug|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
165634|NCT01840540|Drug|Arterial infusion of autologous mesenchymal stem cells|
165635|NCT01840553|Drug|oral sodium phosphate tablets|
165636|NCT00104299|Drug|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
165053|NCT01836926|Procedure|Open intersphincteric resection|laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum
Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.
laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description
intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
165054|NCT01836926|Device|laparoscopic intersphincteric resection|laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
165055|NCT01836939|Drug|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
165056|NCT01836939|Drug|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
165057|NCT00103818|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
165353|NCT01837472|Drug|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
165354|NCT01837485|Drug|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
165355|NCT00103857|Drug|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
165356|NCT01837485|Drug|Placebo|Placebo pill was applied 3 times a day for 3 months
165357|NCT01837498|Drug|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
165358|NCT01837498|Drug|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
165359|NCT01837511|Other|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
165360|NCT01839955|Drug|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 [starting dose]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
164770|NCT01836471|Drug|QAW039|QAW039 for 12 weeks plus Placebo for 2 weeks
164771|NCT01836471|Drug|Placebo|Placebo for 14 weeks
164772|NCT00103766|Drug|Alteplase|
164773|NCT01836471|Drug|Inhaled corticosteroid (ICS)|ICS for 12 weeks plus Placebo for 2 weeks
164774|NCT01836497|Device|SD01 ICD lead|
164775|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
164776|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
164777|NCT01836523|Drug|liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 2 weeks followed by 1.2 mg for 50 weeks as an add-on to their pre-trial insulin treatment. Administered subcutaneously (s.c., under the skin) once daily.
165058|NCT01836965|Behavioral|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
165059|NCT01836978|Other|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
165060|NCT01836991|Procedure|surgery|
165061|NCT01837004|Behavioral|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
165062|NCT01837017|Behavioral|Home-based Exercise|This is a control group with no intervention
165063|NCT01837030|Drug|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
165064|NCT01837030|Procedure|Capsule Endoscopy|GIVEN capsule
165065|NCT01837043|Drug|Belatacept|
165066|NCT01837043|Drug|Calcineurin Inhibitor|
165067|NCT01837069|Drug|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
165068|NCT00103831|Drug|Oral Taxane|
165069|NCT01837069|Drug|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
164478|NCT01841073|Dietary Supplement|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.
164479|NCT01841086|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
164480|NCT01841086|Drug|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
164481|NCT01841099|Drug|Mesalamine|Mesalamine granules
164482|NCT01841099|Drug|Placebo granules|Provided by Ferring Pharma
164483|NCT01841112|Drug|BI 409306|tablet
164484|NCT01841112|Drug|BI 409306|tablet
164485|NCT01841112|Drug|BI 409306|tablet
164486|NCT00104403|Drug|GW679769|
164487|NCT01841112|Drug|BI 409306|tablet
164488|NCT01841112|Drug|placebo|placebo tablet
164489|NCT01841112|Drug|placebo|placebo tablet
164490|NCT01841112|Drug|BI 409306|tablet
164491|NCT01841125|Drug|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
164492|NCT01841125|Drug|Placebo|placebo 15mg, QD(once a day), Oral medication
164493|NCT01841151|Behavioral|SCP training|
164494|NCT01841151|Behavioral|Live Z-score training|
164495|NCT00103467|Biological|rPA102 Vaccine|
164496|NCT01833611|Drug|Entecavir|entecavir 0.5mg qd
164497|NCT01833611|Drug|placebo|placebo qd
164498|NCT01833624|Dietary Supplement|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
164499|NCT01833624|Dietary Supplement|Sondalis® HP|
170744|NCT01924039|Other|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
170745|NCT01924052|Drug|CGRP|Calcitonin-gene-related-peptide (CGRP)
170095|NCT01846000|Procedure|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
170096|NCT01846013|Behavioral|Stand|Stand at least half of the workday at work.
170097|NCT01846013|Behavioral|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
170098|NCT01846013|Behavioral|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
170099|NCT00104819|Biological|sargramostim|
170100|NCT01846026|Drug|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
170101|NCT01846026|Drug|placebo|
170102|NCT01846039|Device|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
170103|NCT01846078|Device|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
170104|NCT01846091|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given IT
170105|NCT01846091|Other|laboratory biomarker analysis|Correlative studies
170106|NCT01846104|Biological|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
170107|NCT01846117|Dietary Supplement|secoisolariciresinol diglucoside, vitamin D, whey powder|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
170108|NCT01846130|Dietary Supplement|Leucine|
170109|NCT01846130|Behavioral|Exercise|
170110|NCT00002021|Drug|Foscarnet sodium|
170111|NCT00104845|Biological|human gp100 plasmid DNA vaccine|
170112|NCT01846130|Dietary Supplement|Whey protein|
170113|NCT01848470|Drug|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
170114|NCT01848470|Drug|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
169508|NCT01847495|Radiation|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
169509|NCT01849991|Biological|Lactobacillus reuteri|Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.
The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily.
169801|NCT01843088|Drug|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
169802|NCT01843088|Drug|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
169803|NCT00002018|Drug|Interferon alfa-n3|
169804|NCT00104598|Behavioral|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
169805|NCT01843101|Device|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
169806|NCT01843114|Device|FDOCT|Measurement of retinal blood velocities
169807|NCT01843114|Other|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
169808|NCT01843127|Drug|Ranolazine|
169809|NCT01843127|Drug|Placebo|
169810|NCT01843127|Drug|Exenatide|
169811|NCT01843153|Drug|Ropivacaine|
169812|NCT01843166|Drug|Premarin vaginal cream|2g at bedtime twice weekly
169813|NCT01843166|Drug|Placebo cream|2g at bedtime twice weekly
169814|NCT01843179|Drug|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
169815|NCT00104611|Device|Repetitive Transcranial Magnetic Stimulation|
169816|NCT01843179|Drug|Sulindac|Taken orally twice per day at home for 12 months
169817|NCT01843192|Device|Endocutter|
169213|NCT01844492|Behavioral|The PARTNER Intervention|In general terms, the PARTNER intervention gives 1) new leadership responsibilities and advanced communication training to the local nurse leaders and social work members of the ICU team and 2) makes systems-level changes to reliably achieve desired care practices. One PARTNER interventionist is assigned as the "main support" for each family, and, through detailed hand-offs and introductions, the ICU's other interventionists fill in when needed. The interdisciplinary intervention 1) gives new responsibilities and advanced communication skills training to existing ICU staff (local nurse leaders and social work members of the ICU team); 2) changes care "defaults" to ensure frequent clinician-family meetings; 3) adds protocolized, nurse-administered coaching and emotional support of surrogates before and during clinician-family meetings, and 4) increases use of palliative care services for patients with a poor prognosis.
169214|NCT01844492|Other|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
169215|NCT01844505|Biological|Nivolumab|
169216|NCT01844505|Biological|Ipilimumab|
169217|NCT01844505|Biological|Placebo for Nivolumab|
169218|NCT01844505|Biological|Placebo for Ipilimumab|
169219|NCT01844518|Biological|Abatacept|
169220|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
169221|NCT00104702|Procedure|conventional surgery|
169222|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
169223|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
169510|NCT01849991|Biological|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
169511|NCT01850004|Drug|Dasatinib|
169512|NCT01850017|Drug|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
169513|NCT01850030|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
169514|NCT01850030|Drug|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
169515|NCT00105079|Drug|Ritonavir|100 mg po bid
169516|NCT01850030|Drug|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
169517|NCT01850030|Drug|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
165168|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.
Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.
Standard dialysate for CRRT : Prismasol® K2 solution
Dialysate flow rate: 35 ml/kg/h
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of
165169|NCT01839591|Device|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
165170|NCT01839604|Drug|AZD9150|Intravenous infusion over 3 hours.
165171|NCT01839617|Dietary Supplement|Early parenteral nutrition|
165172|NCT01839617|Dietary Supplement|Late parenteral nutrition|
165173|NCT01839630|Drug|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
165174|NCT01839643|Drug|Meloxicam vaginal ring|
165175|NCT00104182|Drug|insulin NPH|
165176|NCT01839656|Drug|IONIS-SMNRx|Single intrathecal injection for each dose
165177|NCT01839669|Device|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
165178|NCT01839669|Procedure|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
165179|NCT01839669|Device|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
165180|NCT01839695|Device|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
165465|NCT01840137|Other|Exercise|Treadmill and muscle exercises.
165466|NCT01840150|Procedure|breath test|Undergo NA-NOSE breath test
165467|NCT01840150|Other|laboratory biomarker analysis|Correlative studies
165468|NCT01840163|Other|Static version of CanSORT tool|
165469|NCT01840163|Other|CanSORT Online Tool|
165470|NCT01832792|Other|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
165471|NCT01832792|Other|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
164875|NCT01836705|Drug|Panolosetron|Pharmaceutical form:solution
Route of administration: intravenous
164876|NCT01836731|Behavioral|Classic Intervention|The standard "classic" approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones.
164877|NCT01836731|Behavioral|Minimum Intervention|The "lite" trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers.
164878|NCT01836744|Device|Survival rate dental implant (OsseoSpeed™)|
164879|NCT01839110|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
164880|NCT01839123|Device|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
164881|NCT01839123|Device|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
164882|NCT01839136|Procedure|Intrauterine transfer of gametes|
164883|NCT01839136|Procedure|Intrauterine transfer of embryos|
164884|NCT00104104|Drug|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
164885|NCT01839149|Drug|TI-001|TI-001 is intranasal oxytocin administered at 15 to 60 IU per dose.
164886|NCT01839149|Drug|Placebo|
164887|NCT01839162|Procedure|Coronary angiography|Diagnostic coronary angiography
164888|NCT01839162|Procedure|PCI|Percutaneous coronary intervention
164889|NCT01839162|Procedure|Right approach|Right transradial access
164890|NCT01839162|Procedure|Left approach|Left transradial access
164891|NCT01839175|Biological|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
164892|NCT01839175|Biological|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
164304|NCT01815476|Radiation|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
164305|NCT01815502|Drug|Dobutamine|Patients will receive a dobutamine infusion during catheterization.
164306|NCT01815515|Drug|18F-DCFBC|
164307|NCT01815528|Drug|Catumaxomab|Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:
10 µg on day 0
20 µg on day 3
50 µg on day 7
150 µg on day 10
164617|NCT01836289|Drug|High-dose Cyclophosphamide|
164618|NCT01836302|Other|Observation|
164619|NCT01836315|Other|Observational Study|
164620|NCT01836328|Drug|Parenteral /oral methadone ratio 1:2|See "arm/group descriptions"
164621|NCT01836328|Drug|Parenteral /oral methadone ratio 1:1.2|See "arm/group descriptions"
164622|NCT01836341|Drug|Afatinib|
164623|NCT01836341|Drug|Cisplatin|
164624|NCT00103740|Drug|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
164625|NCT01836341|Drug|Carboplatin|
164626|NCT01836341|Drug|Pemetrexed|
164627|NCT01836341|Radiation|Radiation therapy|
164628|NCT01836354|Behavioral|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
164629|NCT01836367|Drug|Ingenol Mebutate 0.015%|Picato
164630|NCT01836380|Behavioral|Exercise Training|
163997|NCT01820117|Other|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
163998|NCT01812382|Drug|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
163999|NCT01812395|Device|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
164000|NCT01812395|Procedure|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
164001|NCT01812421|Other|Hypertension Health Education Protocol (HHEP)|
164002|NCT00101361|Drug|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
164003|NCT01812434|Drug|Sildenafil|20mg three time daily for 28 days
164004|NCT01812434|Drug|Placebo|20 mg three times daily for 28 days
164005|NCT01812447|Device|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
164006|NCT01812447|Other|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
164007|NCT01812460|Other|Intervention-training-group|As descriped in Arm Description
164008|NCT01812473|Other|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
164009|NCT01812486|Radiation|dose de escalation|
164010|NCT01812486|Radiation|standard dose|
164308|NCT01815541|Drug|teicoplanin|
164309|NCT01815580|Drug|Atripla or Stribild|Antiretroviral therapy
164310|NCT00101751|Behavioral|dietary regimen|
164311|NCT01815593|Device|Enhanced external counterpulsation(EECP)|Enhanced external counterpulsation is mainly used in Cardiovascular and cerebrovascular diseases,which can improve the microcirculation.
164312|NCT01815606|Procedure|biopsy with 19 gauge needle|biopsy with 19 gauge needle
164313|NCT01815606|Procedure|biopsy with 25 gauge needle|biopsy with 25 gauge needle
163384|NCT01821417|Device|Dental implant treatment|Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
163385|NCT01821430|Drug|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
163386|NCT01821430|Drug|Placebo|Placebo group will follow the same titration as the pregabalin group
163387|NCT01821443|Other|Stereotactic radiosurgery (SRS)|Dose & prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% [maximum=100%]), as defined by target delineation on the imaging studies.
The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL).
163388|NCT01821456|Drug|Antiinfectives|To analyze to efficacy of (novel) drug therapies
163389|NCT01813903|Behavioral|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
163390|NCT01813916|Other|proteomic analysis|
163391|NCT01813929|Drug|Metformin|Six week intervention: study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
163392|NCT01813929|Drug|Placebo|Six-week intervention: Placebo will be given in a forced uptitration with 500 mg once daily for one week, twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
163393|NCT01813955|Drug|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
163394|NCT00101582|Drug|Placebo|
163395|NCT01813968|Procedure|Ischemic postconditioning|
163396|NCT01813981|Dietary Supplement|Low roast coffee|Instant coffee
163397|NCT01813981|Dietary Supplement|High roast coffee|Instant coffee
163398|NCT01813981|Dietary Supplement|Control (Caffeine dissolved in water)|Caffeine dissolved in water
163399|NCT01813994|Drug|Arm1: Statin|Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.
Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
167465|NCT01853930|Behavioral|PAECT (Platform for Administering Eye movement Control Training).|The PAECT meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
167466|NCT01853956|Drug|Alprazolam 0.25 mg|Reference product
167467|NCT01853956|Drug|Alprazolam 0.25 mg|Test product
167468|NCT01853969|Other|Typing assessment|
167469|NCT01853982|Drug|Ceftolozane/Tazobactam|
167470|NCT01856166|Device|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
167770|NCT01858922|Drug|ABVE-PC|Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 & Day 2
Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8
Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 & 8 (Max dose 2.8mg)
Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of </=0.4mg/ml in NS on Day 1, 2 & 3
Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable
Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1
167771|NCT01858922|Drug|DECA|Dexamethasone (D):
10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.
Etoposide (E):
100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine*
Cytarabine (A):
3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide*
*Mix together in NS at an etoposide concentration of </=0.4 mg/ml
Dexamethasone eyedrops:
2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.
Cisplatin (C):
90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion.
167772|NCT01858935|Drug|ND-L02-s0201 Injection|Single IV infusion.
167773|NCT01858935|Drug|Placebo|Single IV infusion.
167774|NCT01858948|Drug|Omega|Omega-3 supplements
167775|NCT01858948|Drug|Placebo|Similar in shape and color to Omega supplements
167776|NCT01858948|Drug|Quetiapine fumarate|Patients will be started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
167777|NCT01858961|Drug|BI 201335|Once a day
167778|NCT01858961|Drug|ribavirin|Twice a day
167779|NCT01858961|Drug|BI 207127|Twice a day
167780|NCT00106210|Behavioral|Early intervention blending several tx approaches, w/ focus|Early intervention blending several different treatment approaches, with a focus on certain skills
167781|NCT01858961|Drug|Telaprevir|Three times a day
166830|NCT01827384|Drug|Carboplatin|
166831|NCT01827384|Drug|Trametinib DMSO|
166832|NCT01827384|Drug|ABT-888|
166833|NCT00103025|Drug|Sodium Nitrite Injection|
166834|NCT01827384|Drug|MK-1775|
166835|NCT01827397|Biological|EN41-UGR7C HIV vaccine|
166836|NCT01827397|Biological|NaCl|
167132|NCT01822795|Procedure|Lung volume reduction coïl treatment|
167133|NCT01822795|Other|Regular medical treatment|
167134|NCT01822808|Drug|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
167135|NCT01822808|Drug|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
167136|NCT01822821|Drug|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
167137|NCT01822821|Drug|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
167138|NCT01822860|Drug|Chlorthalidone 12.5 mg|
167139|NCT01822860|Drug|Hydrochlorothiazide 25 mg|
167140|NCT00102531|Drug|SLIT Cisplatin|
167141|NCT01822860|Drug|Placebo|
167142|NCT01822886|Drug|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 d.1,8, 15 for 6 cycles + Gemcitabine 800 mg/m2 d.1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 d. 1, 15 to PD.
167143|NCT01822899|Drug|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
167144|NCT01822899|Drug|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
167145|NCT01822899|Drug|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
166515|NCT01824199|Drug|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
166516|NCT00102713|Drug|Divalproex Sodium (Depakote Sprinkle Capsules)|
166517|NCT01824225|Drug|Aflibercept|
166518|NCT01824238|Drug|Anacetrapib|
166519|NCT01824238|Drug|Placebo for anacetrapib|
166520|NCT01824251|Drug|NPB-01|
166521|NCT01824264|Drug|LIK066|Experimental treatment doses
166522|NCT01824264|Drug|Sitagliptin|Active comparator treatment dose
166523|NCT01824264|Drug|Placebo|Placebo comparator dose
166524|NCT01824277|Other|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
166837|NCT01827410|Procedure|Ventral hernia repair|
166838|NCT01827423|Device|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
166839|NCT01827436|Behavioral|Conventional physical therapy|
166840|NCT01827436|Behavioral|Asymmetrical gait training|
166841|NCT01829815|Behavioral|Parents Make the Difference|The intervention, entitled "Parents Make the Difference," will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children.
166842|NCT01829828|Behavioral|No intervention|This is an observational study with no investigational drug administered.
166843|NCT01829841|Drug|Famitinib|Famitinib 25 mg p.o. qd
166844|NCT01829841|Drug|Sunitinib|Sunitinib 50 mg p.o. qd
166845|NCT01829867|Drug|sNN0031|
166224|NCT01828827|Drug|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
166225|NCT01828840|Drug|epidural morphine via PCEA|
166226|NCT01828840|Drug|epidural fentanyl via PCEA|
166227|NCT01828840|Drug|epidural methadone via PCEA|
166228|NCT01828840|Drug|intravenous morphine via PCA|
166229|NCT01831375|Behavioral|Speak Up|
166230|NCT01831375|Behavioral|Get connected|Participants will learn to be connected with social resources in the community.
166231|NCT01831388|Other|breathing techniques|During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:
- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance.
166232|NCT01831388|Behavioral|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
166233|NCT01831401|Procedure|Operating table position 0° head down (Horizontal)|
166234|NCT01831401|Procedure|Operating table position 7° head down.|
166235|NCT01831401|Procedure|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
166236|NCT00103298|Drug|melphalan|
166237|NCT01831401|Device|Standard straight acetabular component introducer without alignment guide.|
166238|NCT01831401|Device|Modified 35° acetabular component introducer.|
166239|NCT01831401|Device|Inclinometer-assisted acetabular component introducer.|
166240|NCT01831414|Other|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
166525|NCT01824290|Drug|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
165637|NCT01840553|Drug|polyethylene glycol|
165638|NCT01840566|Drug|Carmustine|
165639|NCT01840566|Drug|Etoposide|
165640|NCT01840566|Drug|Cytarabine|
165641|NCT01840566|Drug|Melphalan|
165642|NCT01840566|Biological|Pegfilgrastim|
165928|NCT01825733|Drug|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
165929|NCT01825733|Drug|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
165930|NCT01825746|Other|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
165931|NCT01828242|Other|Control group following conventional approach|Control group following conventional approach
165932|NCT01828255|Device|SENSIMED Triggerfish®|
165933|NCT01828281|Device|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
165934|NCT01828294|Drug|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
165935|NCT01828307|Behavioral|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
165936|NCT01828307|Behavioral|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
165937|NCT00103142|Biological|falimarev|Given subcutaneously and intradermally
165938|NCT01828307|Behavioral|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
165939|NCT01828320|Behavioral|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
165361|NCT01839955|Other|laboratory biomarker analysis|Correlative studies
165362|NCT01839955|Other|pharmacological study|Correlative studies
165363|NCT01839955|Drug|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
165364|NCT01839968|Other|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
165365|NCT00104260|Drug|sapropterin dihydrochloride|
165366|NCT01839981|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
165367|NCT01839994|Radiation|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
165643|NCT01840566|Biological|19-28z T CELLS|
165644|NCT01840566|Procedure|Autologous Stem Cell Transplantation|
165645|NCT01840579|Biological|Pembrolizumab|
165646|NCT01840579|Drug|Cisplatin|
165647|NCT00104299|Drug|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
165648|NCT01840579|Drug|Pemetrexed|
165649|NCT01840579|Drug|Carboplatin|
165650|NCT01840579|Drug|Paclitaxel|
165651|NCT01840592|Drug|Sorafenib|
165652|NCT01833117|Other|Blink® Tears|topical ocular drops
165653|NCT01833130|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
165654|NCT01833130|Drug|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
165655|NCT01833143|Drug|Bortezomib|
165656|NCT00103402|Drug|Alfuzosin|
165070|NCT01837069|Drug|Atorvastatin|80mg PO QD at preadmission testing
165071|NCT01837069|Behavioral|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
165072|NCT01837082|Drug|ferric carboxymaltose|
165073|NCT01837082|Drug|Placebo|
165074|NCT01839344|Dietary Supplement|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
165075|NCT01839344|Drug|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
165076|NCT01839344|Drug|placebo|An oral single dose of a solid, colored empty capsule.
165077|NCT01839357|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
165078|NCT01839370|Device|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
165079|NCT01839383|Other|different dialysate calcium concentration|
165368|NCT01839994|Radiation|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
165369|NCT01839994|Drug|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
165370|NCT01840007|Drug|Metformin Group|The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.
Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken.
165371|NCT01840020|Procedure|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
165372|NCT01840020|Procedure|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
170746|NCT01924065|Procedure|Cardioversion|Electrical or medical cardioversion and spontaneous sinus rhythm return
170747|NCT01924065|Drug|warfarin|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
170748|NCT01924078|Drug|Capecitabine|metronomic use: capecitabine 500mg/tid
170749|NCT01924078|Drug|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
170750|NCT00112567|Radiation|radiation therapy|
170751|NCT01924091|Drug|Dapivirine gel|
170752|NCT01924091|Drug|Dapivirine film|
170753|NCT01924104|Drug|Low molecular weight heparin|2500 mIU/day, subcutaneously
170754|NCT01924104|Drug|Low dose aspirin|75 mg/day, orally
170755|NCT01924104|Drug|Heparin & aspirin|Aspirin (70 mg/day, orally) & heparin (40 mg/day, subcutaneously)
170756|NCT01924104|Other|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
170757|NCT01924117|Other|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
170758|NCT01924130|Other|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
170759|NCT01924130|Behavioral|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
170760|NCT01924130|Behavioral|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
170761|NCT00112580|Biological|ipilimumab|
170762|NCT01924130|Behavioral|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
170763|NCT01924143|Drug|TD-9855|radiolabeled (100 µCi [14C]-Labeled) TD-9855 (20 mg)
170764|NCT01924156|Biological|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
170765|NCT01926392|Drug|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
170766|NCT01926405|Procedure|saliva collection|collection of saliva
170429|NCT00112840|Drug|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
170430|NCT01928576|Drug|Entinostat|
170431|NCT01928576|Drug|Nivolumab|
170432|NCT01928589|Radiation|PBI|270 cGy x15
170433|NCT01928589|Other|PBI with chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
170434|NCT01928602|Behavioral|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, & adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
170435|NCT01928602|Behavioral|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
170436|NCT01928615|Drug|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
170437|NCT01928615|Drug|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
170438|NCT01928615|Drug|Chemotherapy|Standard chemotherapy for early breast cancer.
170439|NCT01928628|Drug|Lercanidipine 10mg|
170440|NCT00112853|Drug|tipifarnib|Given orally
170441|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg|
170442|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg|
170443|NCT01928628|Drug|Lercanidipin 10mg Placebo|
170444|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg Placebo|
170445|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg Placebo|
170446|NCT01928654|Device|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
170447|NCT01928654|Device|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
170448|NCT01928667|Other|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
169818|NCT01843205|Drug|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
169819|NCT01843218|Other|Evaluation of erectile dysfunction|Register R / P and self-administered questionnaire IIEF-5
169820|NCT01843231|Device|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
169821|NCT01843231|Other|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
170115|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
170116|NCT01848470|Drug|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
170117|NCT00104988|Drug|temozolomide|75 mg/m^2/day PO daily for 6 weeks followed by a 2-week break
170118|NCT01848470|Drug|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
170119|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
170120|NCT01848483|Behavioral|AIDS EPC Package plus MI|Motivational Interviewing: In MI session #1, the nurse will set the agenda & ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 & 4, the nurse will also introduce advance care planning.
EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic & conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation & coordination of care.
170121|NCT01848483|Other|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts ART, an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
170122|NCT01848496|Procedure|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
170123|NCT01848509|Device|With teletransmission|Teletransmission of alerts
170124|NCT01848535|Dietary Supplement|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
170125|NCT01848535|Dietary Supplement|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
169518|NCT01850056|Device|drug eluting balloon catheter (trade name: Orchid)|
169519|NCT01850056|Device|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
169520|NCT01850082|Procedure|Vein Harvesting Procedures|Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
169521|NCT01850095|Drug|treatment azelaic acid (azelan)|treatment for 6 months
169522|NCT01850095|Drug|dorspirenone/ethynil estradiol|
169523|NCT01850108|Drug|Thymoglobulin|Day 9 - 0.5 mg/kg IV before BMT
Days 8 & 7 - 2mg/kg IV before BMT
169524|NCT01850108|Drug|Fludarabine|On Days -6 to -2 before BMT, 30 mg/m2/day IV
169525|NCT01850108|Drug|Cyclophosphamide (CTX)|Days 6 & 5 before BMT, 14.5 mg/kg IV; 50 mg/kg each day on 3rd & 4th day after BMT
169526|NCT00105092|Drug|Enzastaurin HCL|
169527|NCT01850108|Drug|Mesna|Days 3 & 4 after BMT: 40 mg/kg IV
169528|NCT01850108|Drug|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
169529|NCT01850108|Drug|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
169530|NCT01850108|Procedure|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
169822|NCT01845454|Device|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
169823|NCT01845480|Behavioral|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
169824|NCT01845493|Dietary Supplement|Alpha Sprout Homogenate|Alpha Sprout Homogenate
169825|NCT01845493|Dietary Supplement|Sulforaphane Homogenate|Active
165472|NCT01832792|Other|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
165473|NCT01832805|Other|Theta burst stimulation.|In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
165474|NCT01832818|Device|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
165475|NCT01832844|Procedure|Group " with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
165476|NCT00103376|Drug|goserelin acetate|
165477|NCT01832844|Procedure|Group " without scan "|
165478|NCT01832857|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
165479|NCT01832870|Drug|sipuleucel-T|
165480|NCT01832870|Drug|ipilimumab|
165481|NCT01832883|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
165482|NCT01832896|Drug|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
165483|NCT01832909|Other|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
165484|NCT01832909|Other|Control Diet|Controlled diet without walnuts.
165773|NCT01836016|Drug|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
165774|NCT00103740|Drug|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
165775|NCT01836016|Drug|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
164893|NCT01839175|Biological|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
164894|NCT01839175|Biological|RotaTeq|2 mL oral administration at 2, 3 and 4 months
165181|NCT01839708|Behavioral|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
165182|NCT01839721|Drug|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
165183|NCT01839721|Other|placebo|
165184|NCT01839734|Drug|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
165185|NCT01839747|Procedure|PET-MRI|Imaging
165186|NCT00104234|Drug|N-acetylgalactosamine 4-sulfatase|
165187|NCT01839747|Procedure|PET-CT|Imaging
165188|NCT01839773|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
165189|NCT01839773|Drug|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
165190|NCT01839799|Drug|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
165191|NCT01842126|Biological|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
165192|NCT01842126|Biological|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
165193|NCT01842126|Drug|Placebo IV|Ascending Doses intravenous (IV) of Placebo
165194|NCT01842126|Drug|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
165195|NCT01842139|Biological|basiliximab|Given IV
165196|NCT01842139|Biological|WT1 126-134 peptide vaccine|Given SC
165197|NCT01842139|Drug|Montanide ISA 51 VG|Given SC
165198|NCT00104520|Drug|Placebo two times a day (BID)/three times a day (TID)|
165199|NCT01842139|Drug|poly ICLC|Given SC
165200|NCT01842139|Other|laboratory biomarker analysis|Correlative studies
164631|NCT01838616|Drug|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
164632|NCT01838642|Drug|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
164633|NCT01838655|Drug|Nitisinone (NTBC)|
164634|NCT00104013|Drug|xaliproden (SR57746A)|
164635|NCT01838668|Drug|Placebo|Placebo orally twice a day
164636|NCT01838668|Drug|dimethyl fumarate|dimethyl fumarate 120 mg capsules
164637|NCT01838681|Drug|Placebo|Once daily, tablets, orally
164638|NCT01838681|Drug|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
164639|NCT01838694|Biological|Ala-Cpn10|
164640|NCT01838694|Drug|Placebo|
164895|NCT00104117|Drug|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
164896|NCT01839175|Biological|Nimenrix|0.5 mL intramuscular injection at 12 months
164897|NCT01839175|Biological|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
164898|NCT01839188|Biological|PR5I (V419)|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b conjugate [Meningococcal Outer Membrane Protein Complex], and hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
164899|NCT01839188|Biological|Pediacel|Adsorbed diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae type b conjugate vaccine 0.5 mL intramuscular injection at 4 months of age
164900|NCT01839188|Biological|NeisVac-C|Meningococcal group C polysaccharide conjugate vaccine adsorbed 0.5 mL intramuscular injection at 2 and 4 months of age
164901|NCT01839188|Biological|RotaTeq|Human-bovine rotavirus reassortants (live) vaccine 2mL oral administration at 2, 4 and 6 month
164902|NCT01839188|Biological|Prevenar 13|Pneumococcal conjugate vaccine (13-valent, adsorbed) 0.5 mL intramuscular injection at 2 and 4 months of age
164314|NCT01815619|Other|on-site pathologist|on-site pathologist will read the slide during the procedure to render a diagnosis
164315|NCT01815619|Other|off-site pathologist|Cell block will be sent to an off-site pathologist for evaluation
164316|NCT01815632|Other|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
164317|NCT01815632|Other|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
164318|NCT01815645|Behavioral|Standard treatment plus Contingence Management|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
164319|NCT01815645|Behavioral|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
164320|NCT01815658|Device|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
164321|NCT00101764|Drug|Triamcinolone Acetonide|
164322|NCT01815671|Procedure|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
164323|NCT01815684|Drug|ASP3652|Oral
164324|NCT01815684|Drug|Placebo|Oral
164325|NCT01817894|Drug|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
164326|NCT01817907|Drug|Placebo pill|Subjects will receive a sugar pill during the placebo arm
164327|NCT01817907|Drug|Trazodone|Subjects will receive trazodone during one of their treatment arm studies
164328|NCT00001997|Drug|Didanosine|
164329|NCT00102011|Procedure|screening colonoscopy|Patients undergo baseline screening colonoscopy
164330|NCT01817920|Behavioral|integrated multidisciplinary fall prevention program|
164641|NCT01838707|Drug|0.125% Bupivacaine HCL @ 4-5 ml/h|
164642|NCT01838707|Drug|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
164643|NCT01838707|Drug|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
164644|NCT01838720|Procedure|zero ischemia laparoscopic RFA assisted TE|
163400|NCT01813994|Drug|Arm2: Placebo|Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.
Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
163713|NCT01817049|Behavioral|placebo attention control|
163714|NCT01817075|Drug|Chlorhexidine Gluconate|Given CGH cleansing
163715|NCT01817075|Procedure|Wound Care Management|Given control cleansing
163716|NCT01817075|Other|Questionnaire Administration|Ancillary studies
163717|NCT01817075|Other|Laboratory Biomarker Analysis|Correlative studies
163718|NCT01817088|Procedure|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
163719|NCT01817088|Procedure|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
163720|NCT01817101|Dietary Supplement|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
163721|NCT01817114|Device|Auto Remote Ischemic Conditioning (AutoRIC) device|
163722|NCT00101907|Drug|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m^2.
163723|NCT01819519|Behavioral|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q&A.
163724|NCT01819532|Procedure|Milking group|The umbilical cord will be "milked" toward the neonate four times prior to clamping the umbilical cord.
163725|NCT01819532|Procedure|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
163726|NCT01819558|Biological|recwt1-A10+AS01B|
163727|NCT01819571|Drug|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
167782|NCT01858961|Drug|ribavirin|Twice a day
167783|NCT01858961|Drug|Pegylated Interferon|Once a week
167784|NCT01858987|Procedure|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
167785|NCT01858987|Procedure|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
167786|NCT01858987|Device|Ligasure|
167787|NCT01858987|Other|vascular staple|
167788|NCT01859000|Other|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
168091|NCT01854866|Other|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
168092|NCT00105612|Device|Memory and Organizational Aid|
168093|NCT01854892|Other|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
168094|NCT01854892|Other|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
168095|NCT01854892|Other|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
168096|NCT01854905|Other|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
168097|NCT01854918|Biological|evolocumab (AMG 145) and standard of care|evolocumab (AMG 145) is a fully human monoclonal antibody against PCSK9. Standard of care therapy is per local practice; this could include prescribed therapies and/or dietary/exercise regimes
168098|NCT01854918|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
168099|NCT01854931|Behavioral|Tai Ji Quan|single aim intervention
168100|NCT01854944|Drug|Brexpiprazole 1mg to 4mg|
168101|NCT01854957|Biological|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
168102|NCT01854970|Drug|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
167146|NCT01822899|Drug|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
167147|NCT01822912|Other|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
167148|NCT01822912|Other|Heart Failure Usual Care|Subjects will receive standard of care.
167149|NCT01822925|Drug|DA-9801 300mg|300 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
167150|NCT01822925|Drug|DA-9801 600mg|600 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
167151|NCT00102557|Drug|Hydroxychloroquine|
167152|NCT01822925|Drug|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
167153|NCT01822925|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
167471|NCT01856166|Device|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
167472|NCT01856166|Drug|Levobupivacaine|
167473|NCT01856166|Drug|Sufentanil|
167474|NCT01856179|Dietary Supplement|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
167475|NCT01856192|Drug|Cyclophosphamide|Given IV
167476|NCT01856192|Drug|Doxorubicin Hydrochloride|Given IV
167477|NCT00105794|Procedure|Psychiatric Advance Directives intervention|
167478|NCT01856192|Other|Laboratory Biomarker Analysis|Correlative studies
167479|NCT01856192|Drug|Lenalidomide|Given PO
167480|NCT01856192|Drug|Prednisone|Given PO
167481|NCT01856192|Biological|Rituximab|Given IV
167482|NCT01856192|Drug|Vincristine Sulfate|Given IV
167483|NCT01856205|Drug|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.
Placebo group received 0.9% saline intravenous at similar rate.
167484|NCT01856218|Drug|UX003|
166846|NCT01829893|Drug|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
166847|NCT01829893|Drug|GL2701 capsule|oral medication with 240 mL water
166848|NCT00103259|Drug|irinotecan hydrochloride|Given IV
166849|NCT01829906|Behavioral|Multidisciplinary outpatient programme|
166850|NCT01829906|Behavioral|Inpatient lifestyle programme|
166851|NCT01829919|Drug|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
166852|NCT01829932|Dietary Supplement|Factor Altered Diet|
166853|NCT01829958|Drug|rituximab|
166854|NCT01829958|Drug|prednisone|
166855|NCT01829958|Behavioral|Geriatric Assessment|
166856|NCT01829971|Drug|MRX34|micro RNA therapy
166857|NCT01829984|Other|Verbal and Written Instruction|Pre-teaching Evaluation: Patient
Pre-teaching Evaluation: Caregiver
o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.
Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.
167154|NCT01822938|Other|incentive program for physical activity|
167155|NCT01825213|Device|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
167156|NCT01825226|Other|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
167157|NCT01825239|Other|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
167158|NCT01825252|Behavioral|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
167159|NCT01825252|Behavioral|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
167160|NCT01825265|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
167161|NCT00102830|Drug|AMG 386|
166526|NCT01824290|Drug|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
166527|NCT00102726|Drug|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
166528|NCT01826760|Other|Using training and testing groups to construct ANN based on laboratory tests|
166529|NCT01826773|Drug|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
166530|NCT01826786|Drug|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
166531|NCT01826786|Drug|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
166532|NCT01826812|Other|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
166533|NCT01826812|Other|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
166534|NCT01826825|Behavioral|Cognitive Screen|Cognitive Screen
166535|NCT00102960|Drug|Zidovudine|First Line Regimen: 240 mg/m^2 taken orally twice daily
166536|NCT01826825|Behavioral|Mini-Cog|Cognitive Screen
166537|NCT01826838|Drug|Dasatinib|
166538|NCT01826851|Drug|Exparel|Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.
Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU.
166539|NCT01826851|Drug|Placebo|Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.
Post-surgical pain management will be the same as for the Exparel group.
166540|NCT01826864|Biological|sargramostim|Given SC
166541|NCT01826864|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
166542|NCT01826864|Other|laboratory biomarker analysis|Correlative studies
166543|NCT01826864|Other|hypertonic saline|Given SC
166544|NCT01826877|Biological|AdGMCAIX-transduced autologous dendritic cells|Given ID
166545|NCT01826877|Biological|therapeutic autologous dendritic cells|Given ID
165940|NCT01828320|Behavioral|Psychoeducation|
165941|NCT01828333|Other|No intervention|No intervention
165942|NCT01828346|Drug|TL32711|Dose escalation part: (Drug escalation dose levels)
Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)
Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)
Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)
Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR
Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)
165943|NCT01828346|Drug|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
165944|NCT01828359|Drug|Amosartan® tab|comparison of different combination of anti-hypertension drug
165945|NCT01828359|Drug|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
166241|NCT01831414|Other|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
166242|NCT01831427|Drug|GS-5745|GS-5745 administered by intravenous infusion or subcutaneous injection
166243|NCT01831427|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered by intravenous infusion
166244|NCT01831440|Behavioral|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
166245|NCT01831440|Drug|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
166246|NCT01831453|Drug|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
166247|NCT00103298|Drug|oxaliplatin|
166248|NCT01831453|Drug|placebo|soft gelatinous capsules filled with isopropylmyristate oil
166249|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
166250|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
166251|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
166252|NCT01823601|Behavioral|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
166253|NCT00102648|Drug|Sarasar|Starting dose 100 mg by mouth twice a day, with water, for 7 consecutive days (days 8 through 14 and days 22 through 28). Cycle is 28 days.
165657|NCT01833143|Drug|Acyclovir|
165658|NCT01833156|Device|MoistureMeterD|measuring erythema size and the dielectric constant values
165659|NCT01833169|Drug|BKM120|BKM120 100 mg (oral gelatine capsules) will be administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
165660|NCT01833182|Other|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
165661|NCT01833182|Other|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
165662|NCT01833208|Other|Laboratory Biomarker Analysis|Correlative studies
165663|NCT01833208|Radiation|Radiation Therapy|Undergo single-fraction radiation therapy
165946|NCT01828372|Other|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
165947|NCT01828385|Drug|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
165948|NCT00103142|Biological|inalimarev|Given subcutaneously and intradermally
165949|NCT01828385|Drug|Saline|Saline + rocuronium + sugammadex
165950|NCT01828398|Device|real-tDCS + UE robot-assisted therapy|
165951|NCT01828398|Device|sham-tDCS + UE robot-assisted therapy|
165952|NCT01828411|Device|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
165953|NCT01828411|Device|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
165954|NCT01828437|Drug|Pyridoxine plus prednisolone|
165955|NCT01828437|Drug|Prednisolone|
165956|NCT01830881|Drug|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
165373|NCT01840033|Device|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
165374|NCT01832584|Dietary Supplement|RGC|
165375|NCT01832584|Dietary Supplement|Placebo|
165376|NCT01832610|Device|HVAD® System|
165377|NCT01832623|Other|Exploration of Vitamin D roles|Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound
Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside
165378|NCT01832636|Dietary Supplement|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
165379|NCT01832649|Behavioral|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
165380|NCT01832649|Behavioral|Health education|Supervised groups 2 times per week during 8 weeks.
165381|NCT01832662|Other|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
165382|NCT01832662|Other|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
165383|NCT00103376|Drug|bortezomib|
165664|NCT01833221|Drug|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
165665|NCT01833234|Other|Interviews and questionnaires|
165666|NCT01833247|Other|Measurement of lactic acid with a seizure|
165667|NCT00103415|Behavioral|Endurance training|
165668|NCT01833260|Behavioral|Music|
165669|NCT01833273|Drug|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
165670|NCT01833286|Procedure|TACE+RFA|TACE first, followed by RFA within 2 months
165671|NCT01833286|Procedure|re-resection|repeat hepatectomy for recurrent small HCC
171077|NCT00112879|Procedure|drug resistance inhibition|
171078|NCT01929551|Other|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
171079|NCT01929551|Other|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
171080|NCT01929551|Other|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
171081|NCT01929551|Other|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
171082|NCT01929564|Other|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
171083|NCT01929564|Other|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
171084|NCT01929577|Drug|ASP015K|oral tablet
171085|NCT01929590|Drug|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
171086|NCT01929590|Drug|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
171087|NCT01929590|Drug|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
171088|NCT00002103|Drug|Trimetrexate glucuronate|
171089|NCT00112879|Procedure|growth factor antagonist therapy|
171090|NCT01929603|Procedure|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
171091|NCT01929603|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
171092|NCT01929603|Drug|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
171093|NCT01929616|Drug|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
171094|NCT01929629|Drug|Part A|Single ascending doses
171095|NCT01929629|Drug|Part B|Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
171096|NCT01929642|Drug|Sirolimus|
170449|NCT01930916|Other|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
170450|NCT01930929|Procedure|Bariatric surgery|
170767|NCT01926418|Behavioral|Planning tasks|Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.
Executive function training aims to improve planning ability and therefore aims to increase condom use planning.
170768|NCT00112697|Drug|fluorouracil|
170769|NCT01926431|Other|Exercise|
170770|NCT01926431|Other|Rest|
170771|NCT01926444|Drug|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
170772|NCT01926457|Other|Treatment of Prediabetes|Standardized treatment of prediabetes per California Diabetes and Pregnancy Program "Sweet Success"
diabetes education
blood glucose monitoring
medications as needed per California Diabetes and Pregnancy established protocol
growth ultrasounds
antenatal testing
170773|NCT01926470|Procedure|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
170774|NCT01926470|Procedure|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
170775|NCT01926483|Other|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
170776|NCT01926496|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
170777|NCT01926496|Drug|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
170778|NCT01926509|Drug|MK-8892|
170779|NCT00112697|Radiation|radiation therapy|
170780|NCT01926509|Drug|Placebo for MK-8892|
170781|NCT01926522|Device|Technological Rehabilitation|The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.
Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.
The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions.
170782|NCT01926522|Other|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
170126|NCT01848548|Procedure|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
170127|NCT01848574|Other|standardized multifaceted information procedure to improve patients' comprehension|
170128|NCT00104988|Drug|thalidomide|200 mg/day PO daily
170129|NCT01848587|Other|acupuncture|
170130|NCT01848587|Other|usual care|
170131|NCT01848600|Behavioral|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
170132|NCT01848613|Drug|Vinorelbine|
170451|NCT01930942|Radiation|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
170452|NCT01930955|Drug|Amoxicillin|β-lactam antibiotics
170453|NCT01930968|Device|Microbubble contrast agent|A bubble test (intravenous small amount of Definity injected with cardiac echo) will be performed in the cardiology imaging suite in order to ensure that the patient does not have a right to left shunt. After that, Definity® (the microbubble contrast agent) will be administered as a slow IV bolus followed by a normal saline 10cc flush. The ultrasonographer will continue the ocular B scan during administration of Definity®. Vital signs will be obtained and documented at 30 minutes after administration of the last dose of Definity® and as the patient's condition warrants.
170454|NCT01931007|Drug|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
170455|NCT01931007|Drug|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
170456|NCT01931020|Drug|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
170457|NCT00112996|Other|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
170458|NCT01931020|Drug|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
169826|NCT01845506|Device|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
169827|NCT01845506|Device|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
169828|NCT01845519|Behavioral|Tailored Email|Participants will receive tailored emails.
169829|NCT01845519|Behavioral|Targeted Email|Participants will receive targeted emails.
169830|NCT00104780|Biological|incomplete Freund's adjuvant|
169831|NCT01845532|Drug|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25~0.5% lidocaine, 0.125% bupivacaine)
169832|NCT01845532|Drug|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
169833|NCT01845545|Other|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
169834|NCT01845558|Drug|Wobenzym® plus|
169835|NCT01845558|Other|Placebo|
169836|NCT01845584|Drug|NPB-01|
169837|NCT01845597|Procedure|MAKOplasty® medial UKA|A robot guided medical Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
169838|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
170133|NCT01928108|Behavioral|Android Application|The Android application "water my body" will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week.
170134|NCT01928108|Device|iPhone cellular|
170135|NCT01928108|Device|Android cellular|
170136|NCT01928121|Other|Care provided by AF expert program|
170137|NCT01928134|Dietary Supplement|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
165776|NCT01836016|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
165777|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
165778|NCT01838083|Drug|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
165779|NCT01838096|Device|THA using 4th generation CoC|
165780|NCT01838109|Dietary Supplement|oral nutritional supplement|
165781|NCT01838135|Device|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
165782|NCT01838161|Behavioral|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
165783|NCT01838161|Behavioral|Part III|•video educational
165784|NCT01838174|Drug|ACTHAR Gel (ACTH)|15 days of daily injections
165785|NCT01838174|Drug|IV steroids with oral taper|3 days of intravenous methylprednisolone followed by 11 days of oral taper
165786|NCT01838187|Radiation|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
165787|NCT01838200|Biological|Bacillus Calmette-Guérin (BCG) vaccine|Bacillus Calmette-Guérin (BCG) is a living attenuated strain of Mycobacterium bovis that stimulates cell-mediated immunity by producing a localized and self-limiting infection. BCG is used worldwide for vaccination against tuberculosis. BCG is an immunostimulating agent that has been also shown to have anti-tumour activity in several clinical studies. The exact mechanism of action is not well known, but study data suggest that active non-specific immune responses are induced. It is probable that BCG invokes a local inflammatory response involving a variety of immune cells, such as macrophages, natural killer cells and T cells
165788|NCT00002013|Drug|AS-101|
165789|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
166079|NCT01823354|Other|Medical consultation|open questions
166080|NCT01823367|Behavioral|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
165201|NCT01842165|Drug|intravenous injection of 177Lu-octreotate|an intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution will be performed
165202|NCT01842178|Procedure|scratching|Endometrial Injury
Done between 18-24 days prior to embryo transfer cycle.
Using transfer catheter.
Introduction of the same to the uterine fundus.
Systematic scrapping of the four uterine walls, lengthwise.
Performed by a skilled doctor.
Subsequent ultrasound control.
165203|NCT01842191|Dietary Supplement|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
165485|NCT01832922|Drug|Bendamustine|
165486|NCT01832922|Drug|Rituximab|
165487|NCT00103376|Drug|leuprolide acetate|
165488|NCT01832935|Drug|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
165489|NCT01832935|Drug|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
165490|NCT01832948|Drug|Endostar|
165491|NCT01832948|Drug|Oxaliplatin|
165492|NCT01832948|Drug|Folinic acid|
165493|NCT01832948|Drug|5-FU|
165494|NCT01832961|Device|flutter valve exercises|30 minutes of flutter exercises
165495|NCT01835262|Drug|Morphine|Morphine: 0.1 mg /kg given as IVP
165496|NCT01835262|Drug|Ketamine|Ketamine:0.3 mg/given as IVP
165497|NCT01835275|Behavioral|Enhanced Audio|
165498|NCT01835275|Behavioral|Audio|
165499|NCT00103662|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
165500|NCT01835288|Drug|arsenic trioxide|Given IV
165501|NCT01835288|Other|laboratory biomarker analysis|Correlative studies
164903|NCT01841970|Device|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
164904|NCT01841983|Other|Be Well Work Well|The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.
Overall intervention objectives:
Motivate individual staff members to engage in targeted health and safety behavior changes;
build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;
facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and
promote co-worker and supervisor support for targeted health and safety behaviors.
164905|NCT01841996|Drug|ME1111 solution|Once a day for 28 days
164906|NCT01841996|Drug|Vehicle Solution|Once a day for 28 days
164907|NCT01842009|Device|High Definition transcranial Direct Current Stimulation|
164908|NCT01842022|Dietary Supplement|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
164909|NCT01842022|Dietary Supplement|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
164910|NCT01842022|Dietary Supplement|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
164911|NCT01842035|Drug|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
165204|NCT01842191|Dietary Supplement|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
165205|NCT01842204|Device|Magnetic field therapy device|Therapy device for 1 week.
165206|NCT01842204|Device|Non magnetic field therapy device.|Non-active device for 1 week.
165207|NCT01842217|Procedure|FES-PET|
165208|NCT01842230|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day
Atorvastatin 40mg: 1 tablet, oral, once daily, 2days
over the period I & II(cross-over)
165209|NCT00002017|Drug|Interleukin-2, Polyethylene Glycolated|
165210|NCT00104533|Device|Magnets|
165211|NCT01842230|Drug|Telmisartan 80mg and S-amlodipine 5mg|Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day
over the period I & II(cross-over)
165212|NCT01842243|Procedure|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
164645|NCT00104052|Biological|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
164646|NCT01838720|Procedure|ischemia|conventional laparoscopic partial nephrectomy
164647|NCT01838733|Other|Observational study|
164648|NCT01838772|Drug|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
164649|NCT01838785|Drug|18F-DTBZ AV-133|
164650|NCT01838798|Other|Baseline activities|Initial consent procedures and baseline data collection.
164651|NCT01838798|Other|Clinical interview with a psychologist|Clinical interview with a psychologist.
This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:
An inventory of peritraumatic distress symptoms
A questionnaire on peritraumatic dissociative experiences
An assessment of related, potential impacts
The HADS questionnaire
164652|NCT01838798|Other|Telephone interview 2 months after ICU discharge|At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:
Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ
An assessment of psychological trauma
An assessment of potential impacts
164653|NCT01838798|Other|Clinical interview with a psychologist|At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:
assess cognitive functions
evaluate clinical symptoms of depression
assess quality of life
assess symptoms of post traumatic stress
164654|NCT01841411|Drug|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
164655|NCT01841411|Drug|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
164656|NCT01841411|Drug|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
164912|NCT00104507|Drug|APD356|
164913|NCT01842048|Other|Hyperthermia|
164914|NCT01842048|Radiation|External-beam radiotherapy|
163728|NCT01819597|Procedure|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
163729|NCT01819610|Drug|SPRIX|
163730|NCT01819623|Other|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
163731|NCT00102167|Drug|gaboxadol|Duration of Treatment -1 day
164011|NCT01812512|Behavioral|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
164012|NCT01812525|Drug|NaCl 3%|NaCl 3%: 4ml QID
164013|NCT00101374|Drug|Leflunomide|
164014|NCT01812525|Other|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
164015|NCT01812538|Drug|DIC075V|Four single dose treatments:
Placebo (normal saline)
Moxifloxacin (positive control)
DIC075V 37.5 mg
DIC075V 75 mg
All subjects receive each of the 4 treatments.
164016|NCT01812551|Drug|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
164017|NCT01812551|Drug|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
164018|NCT01812564|Biological|Platelet Poor Plasma (PPP)|
164019|NCT01812564|Biological|Platelet Rich Plasma (PRP)|
164020|NCT01812590|Behavioral|Exercise|
164021|NCT01814930|Behavioral|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
164022|NCT01814956|Drug|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
168103|NCT00105612|Behavioral|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
168104|NCT01854996|Drug|PF-05089771|450mg
168105|NCT01854996|Drug|PF-05089771|450mg
168106|NCT01854996|Drug|PF-05089771|450mg
168107|NCT01855009|Dietary Supplement|MannaBears|Subjects will be administered 4 MannaBears daily
168108|NCT01855009|Dietary Supplement|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
168109|NCT01855009|Dietary Supplement|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
168110|NCT01855009|Dietary Supplement|Vitamin D3|Subjects will be administered 800 IU vitamin D3
163401|NCT01814007|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
163402|NCT01814020|Drug|MOB015B|
163403|NCT01814033|Other|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
163404|NCT01814033|Other|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
163405|NCT00101582|Drug|palifermin|
163406|NCT01814046|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
163407|NCT01814046|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
163408|NCT01814046|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
163409|NCT01816503|Drug|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
163410|NCT01816516|Behavioral|Healthy Babies|Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).
The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects.
167485|NCT01856231|Behavioral|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
167486|NCT01856244|Behavioral|treadmill walking|
167487|NCT01856244|Device|Treadmill|
167488|NCT00105807|Behavioral|participation in low intensity exercise|
167489|NCT01856257|Biological|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
167490|NCT01856257|Biological|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
167491|NCT01856257|Drug|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
167492|NCT01856257|Biological|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
167789|NCT01859000|Other|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
167790|NCT01859013|Drug|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
167791|NCT01861665|Drug|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
167792|NCT01861665|Drug|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
167793|NCT01861678|Procedure|High tie of IMA|Conventional technique
167794|NCT01861678|Procedure|Low tie of IMA|Technique for preserving left colic arterial perfusion
167795|NCT01861691|Procedure|Open surgery|Conventional technique
167796|NCT01861691|Procedure|Laparoscopic surgery|New minimum invasive technique
167797|NCT01861704|Device|Lyric|Extended wear hearing instrument
167798|NCT01861704|Device|Lyric2|Extended wear hearing instrument
167799|NCT00106509|Drug|tolevamer potassium-sodium (GT267-004)|
167162|NCT01825265|Drug|RAD001|30 mg orally on Days 1 and 8.
167163|NCT01825265|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
167164|NCT01825278|Device|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
167165|NCT01825291|Procedure|CPAP treatment|
167166|NCT01825304|Device|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
167167|NCT01825317|Device|NeuroAD|synchronized TMS+COGNITIVE TRAINING
167168|NCT01825317|Device|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
167169|NCT01825330|Device|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
167170|NCT01825330|Device|sham|
167171|NCT01825356|Procedure|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
167172|NCT00102843|Procedure|supplementation with folic acid and betaine|
167173|NCT01825356|Procedure|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
167174|NCT01825369|Drug|IV L-carnitine|See arm description
167493|NCT01856257|Drug|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
167494|NCT01856257|Drug|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
167495|NCT01858558|Biological|aMIL|Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
167496|NCT01858558|Drug|No aMIL|Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
166858|NCT01829984|Other|Verbal and Written Plus Simulation|Post-injection Evaluation: Patient
Post-injection Evaluation: Caregiver
o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).
Nurse Evaluation: Control
Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study.
166859|NCT00103259|Other|laboratory biomarker analysis|Optional correlative studies
166860|NCT01829997|Device|nanOss Bioactive 3D BVF|nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
166861|NCT01830010|Drug|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
166862|NCT01830010|Drug|Study Part 2: KRP203 lower dose|
166863|NCT01830010|Drug|Study Part 2: KRP203 higher dose|
166864|NCT01822496|Other|Laboratory Biomarker Analysis|Correlative studies
166865|NCT01822496|Drug|Paclitaxel|Given IV
166866|NCT01822509|Biological|Ipilimumab|Given IV
166867|NCT01822509|Other|Laboratory Biomarker Analysis|Correlative studies
166868|NCT01822509|Biological|Nivolumab|Given IV
166869|NCT01822522|Drug|Cabozantinib S-malate|Given PO
166870|NCT00002001|Drug|Zidovudine|
166871|NCT00102466|Drug|Gliclazide|
166872|NCT01822522|Other|Laboratory Biomarker Analysis|Correlative studies
166873|NCT01822522|Other|Pharmacological Study|Correlative studies
166874|NCT01822535|Drug|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
166875|NCT01822548|Drug|Vildagliptin|100 mg daily
166876|NCT01822548|Drug|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
166877|NCT01822561|Drug|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
166254|NCT01823601|Behavioral|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
166255|NCT01823627|Procedure|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
166256|NCT01823640|Other|placebo|
166257|NCT01823640|Other|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
166258|NCT01823653|Device|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
166259|NCT01823679|Drug|capecitabine|Given PO
166260|NCT01823679|Other|laboratory biomarker analysis|Correlative studies
166546|NCT00102973|Drug|TLK286 in Combination with Carboplatin|Experimental Arm
166547|NCT01826877|Other|laboratory biomarker analysis|Correlative studies
166548|NCT01826890|Other|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
166549|NCT01826916|Drug|DX-88 (ecallantide)|solution for injection 10 mg/mL
166550|NCT01826929|Other|Therapeutic education|
166551|NCT01826942|Device|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
166552|NCT01826942|Device|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
166553|NCT01829334|Other|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
166554|NCT01829347|Biological|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
166555|NCT01829347|Other|Standard of Care treatment|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.)
166556|NCT01829360|Behavioral|Treatment (interactive book reading, dialogic reading, shared book reading)|In Study 1, children are randomized to one of four treatment conditions, determining whether they will hear the treated words either 12, 24, 36, or 48 times during treatment. In Study 2, one of the intensities from Study 1 will be tested more extensively by examining how best to achieve the adequate intensity. Specifically, is it better to hear the word more often in the book or to read the book more times? In the treatment condition, words are randomized to more repetitions in the book or to more repetitions of reading the same book to address this question.
165957|NCT01830894|Device|MRI|3 MRI on different times during the study for each arm.
165958|NCT01830907|Dietary Supplement|carbohydrates|
165959|NCT01830907|Dietary Supplement|vitamins|
165960|NCT01830920|Drug|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
165961|NCT00103285|Drug|thioguanine|Given PO
165962|NCT01830920|Drug|Placebo|A normal saline solution identical in appearance to the active drug solution
165963|NCT01830933|Other|BreastCARE|Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
165964|NCT01830946|Other|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
165965|NCT01830946|Other|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
166261|NCT01823692|Other|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
166262|NCT01823705|Device|Exilis Implantable Gastric Electrical Stimulation (GES)|
166263|NCT01823718|Biological|Injection of allogenic CTL EBV specific|
166264|NCT00102648|Drug|Temodar|150 mg/m^2 by mouth once a day, after fasting one hour, for 7 consecutive days (days 1 through 7 and days 15 through 21). Cycle is 28 days.
166265|NCT01823744|Dietary Supplement|micronutrient supplementation|
166266|NCT01823757|Other|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
165672|NCT01833299|Procedure|TACE-Sorafenib group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
165673|NCT01833299|Procedure|TACE|
165674|NCT01835678|Drug|Linagliptin|orally 5 mg/d for 4 weeks
165675|NCT01835678|Drug|Placebo|orally once a day for 4 weeks
165676|NCT01835691|Dietary Supplement|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
165677|NCT01835691|Dietary Supplement|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
165678|NCT01835704|Other|Radio-frequency dennervation of facet joint|
165679|NCT01835704|Other|Diagnostic nerve-blocks performed under direct x-ray vision|
165680|NCT01835730|Drug|PE0139 Injection|
165681|NCT01835730|Drug|Placebo|
165682|NCT01835743|Device|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
165683|NCT01835743|Device|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
165684|NCT00002011|Drug|Methoxsalen|
165685|NCT00103727|Drug|Talnetant|talnetant
165966|NCT01830946|Other|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
165967|NCT01830959|Drug|Roflumilast|Roflumilast
165968|NCT01830959|Drug|Placebo|Placebo one a day
165969|NCT01830972|Drug|SA-ER tablets and SA-IR capsules|
165970|NCT01830985|Drug|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
165971|NCT01831011|Drug|mildronate injection|
165972|NCT00103285|Drug|vincristine sulfate|Given IV
171097|NCT01929642|Drug|Everolimus|
171098|NCT01912768|Device|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
171406|NCT01925131|Drug|prednisone|Given PO
171407|NCT01925131|Biological|inotuzumab ozogamicin|Given IV
171408|NCT00112645|Drug|melphalan|
171409|NCT01925131|Other|laboratory biomarker analysis|Correlative studies
171410|NCT01925144|Drug|Baricitinib|Administered orally
171411|NCT01925144|Drug|Omeprazole|Administered orally
171412|NCT01925157|Biological|LY3090106 - SQ|Administered SQ.
171413|NCT01925157|Biological|LY3090106 - IV|Administered IV.
171414|NCT01925157|Biological|Placebo - SQ|Administered SQ.
171415|NCT01925170|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
171416|NCT01925170|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
171417|NCT01925170|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
171418|NCT01925183|Drug|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
171419|NCT00000123|Device|Polymethyl Methacrylate Contact Lenses|
171420|NCT00000301|Drug|Amantadine|
171421|NCT00002100|Drug|Curdlan sulfate|
171422|NCT00112645|Drug|methotrexate|
171423|NCT01925183|Drug|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients <75kg; orally
171424|NCT01927744|Other|Placebo|150 mg by mouth daily continuously until the day before surgery.
170783|NCT01926535|Procedure|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
170784|NCT01926535|Device|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
170785|NCT01926548|Drug|CJ Imatinib mesylate tablet|
171099|NCT01912768|Device|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
171100|NCT01912781|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
171101|NCT00111592|Procedure|current usual care|current usual care
171102|NCT01912781|Device|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
171103|NCT01912781|Device|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
171104|NCT01912794|Other|Sensory Intervention|full sensory information, whose participants will practice balancing tasks without constraint sensory body;
sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;
control, whose participants will exercise activities involving cognitive and upper limbs.
171105|NCT01912807|Drug|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
171106|NCT01912807|Drug|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
171107|NCT01912820|Dietary Supplement|green tea extract|Given PO
171108|NCT01912820|Drug|quercetin|Given PO
171109|NCT01912820|Other|placebo|Given PO
171110|NCT01912820|Procedure|therapeutic conventional surgery|Undergo prostatectomy
171111|NCT01912820|Other|laboratory biomarker analysis|Correlative studies
171112|NCT00111592|Procedure|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
170459|NCT01931033|Drug|Intranasal Oxytocin|
170460|NCT01931046|Drug|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
170461|NCT01931059|Drug|Risperidone|
170462|NCT01931072|Behavioral|High-intensity interval training|Interval training 3 times a week for 8 weeks
170463|NCT01931072|Behavioral|Moderate training|Moderate training 3 times a week for 8 weeks
170464|NCT01931085|Drug|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
170465|NCT01931098|Drug|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
170466|NCT01931098|Drug|pazopanib|600 mg orally, daily until progression, up to one year.
170467|NCT01931124|Behavioral|High Intensity Training|
170786|NCT01926548|Drug|Gleevec film-coated tablet 2 x 100mg|
170787|NCT00112879|Drug|ascorbic acid|
170788|NCT01929031|Drug|Ibuprofen and caffeine|FDC tablet, multiple doses at stage 2¿ 1 and multiple doses at stage 2
170789|NCT01929044|Drug|654-II (anisodamine)|10mg injection
170790|NCT01929044|Drug|Buscopan® (hyoscine butylbromide)|20mg injection
170791|NCT01929057|Procedure|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
170792|NCT01929057|Procedure|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
170793|NCT01929070|Drug|HCP1007|
170794|NCT01929070|Drug|Omarco and Crestor|
170795|NCT01929083|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
170796|NCT01929083|Drug|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
170797|NCT01929083|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
170798|NCT00112879|Drug|dexamethasone|
170138|NCT01928134|Dietary Supplement|Vit K2+CaCO3|
170139|NCT01928147|Drug|PPI-383|
170140|NCT01928147|Drug|Placebo|
170141|NCT01928160|Drug|pemetrexed disodium|Given IV
170142|NCT01928160|Drug|carboplatin|Given IV
170143|NCT00112827|Biological|filgrastim|Given IV
170144|NCT01928160|Drug|cisplatin|Given IV
170145|NCT01928160|Drug|erlotinib hydrochloride|Given PO
170146|NCT01928160|Other|laboratory biomarker analysis|Correlative studies
170147|NCT01928173|Behavioral|Abbreviated cognitive behavioral therapy|see arm description
170148|NCT01928173|Behavioral|Sleep education/sleep hygiene|see arm description
170149|NCT01928186|Drug|Fluorothymidine F-18|Undergo FLT PET
170150|NCT01928186|Procedure|Positron Emission Tomography|Undergo FLT PET
170151|NCT01928186|Other|Laboratory Biomarker Analysis|Correlative studies
170152|NCT01928199|Drug|Sitagliptin|
170153|NCT01928199|Drug|Placebo|
170154|NCT00112827|Genetic|fluorescence in situ hybridization|Correlative studies
170155|NCT01928212|Device|Optical coherence tomography|
170156|NCT01928225|Biological|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
170157|NCT01928238|Device|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
170158|NCT01928238|Device|Noninvasive pressure support ventilation (NPSV)|
170468|NCT00113009|Drug|VLTS-934|
170469|NCT01923571|Other|intraoperative BGC measure|
170470|NCT01923584|Drug|EPI-743 400mg|
170471|NCT00112554|Drug|cytarabine|Given IV
166081|NCT01823380|Procedure|Blood test|Blood test
166082|NCT01823393|Drug|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
166083|NCT01823393|Drug|NaCl|valvuloplasty is performed without heparin (placebo injection)
166084|NCT01823406|Procedure|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
166085|NCT01823406|Procedure|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
166086|NCT01823445|Other|Xylitol disk|
166087|NCT00102908|Drug|Zoledronate|Zoledronate infusion
166088|NCT01825902|Procedure|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
166089|NCT01825902|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
166090|NCT01825902|Other|laboratory biomarker analysis|Correlative studies
166091|NCT01825915|Procedure|Laparoscopic Hysterectomy|
166092|NCT01825915|Procedure|Laparoscopic Supracervical Hysterectomy|
166093|NCT01825928|Drug|Paliperidone|Paliperidone group,6mg/pill,6-12mg/day non-forced titration method,last 12weeks
166094|NCT01825928|Drug|placebo|placebo group,6mg/pill,6-12mg/day non-forced titration method,last 12 weeks
166095|NCT01825941|Drug|metoclopramide|10 milligrams, administered intravenously over 15 minutes
166096|NCT01825941|Drug|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
166097|NCT01825941|Drug|placebo|
166098|NCT00102908|Drug|Zoledronate placebo|Zoledronate placebo infusion
166099|NCT01825954|Device|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
166100|NCT01825967|Other|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
166101|NCT01825980|Drug|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
165502|NCT01835314|Drug|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
165503|NCT01835340|Device|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
165504|NCT01835353|Drug|Prasugrel 100mg loading dose|
165505|NCT01835353|Drug|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
165506|NCT01835379|Device|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
165507|NCT01835379|Other|Standard|
165508|NCT01835392|Procedure|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
165790|NCT01838200|Drug|Ipilimumab|Ipilimumab is a human CTLA-4-blocking antibody, designed to suppress the CTLA-4 inhibition of T cells. Ipilimumab is marketed by Bristol-Myers-Squibb under the name Yervoy® and was first approved by the FDA and TGA in 2011 for the treatment of unresectable or metastatic melanoma
165791|NCT01838226|Behavioral|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
165792|NCT01838239|Dietary Supplement|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
165793|NCT01838252|Procedure|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
165794|NCT01838252|Procedure|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
165795|NCT01838265|Procedure|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
165796|NCT01840813|Drug|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
165797|NCT01840813|Drug|Normal saline|It is a placebo group
165798|NCT01840826|Other|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
165799|NCT01840839|Device|brain stimulation|
165800|NCT01840839|Device|Sham Stimulation|
165801|NCT00104364|Drug|MK0731|
165213|NCT01842243|Procedure|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
165214|NCT01842243|Device|Pacemaker|MR conditional Pacemaker implanted in all study patients
165215|NCT01842256|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),
oral intake, once in a period
over the period Ⅰ&Ⅱ(crossover)
165216|NCT01842256|Drug|atorvastatin 40mg|1 Tablet (atorvastatin 40mg),
oral intake, once in a period
over the period Ⅰ&Ⅱ(crossover)
165217|NCT01842269|Drug|Mycophenolate Mofetil 500mg|
165218|NCT01834911|Drug|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
165219|NCT01834924|Other|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
165220|NCT01834937|Device|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
165221|NCT01834950|Other|Blood test|
165222|NCT01834963|Drug|Interferon Alfa、Fluorouracil|Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha
Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks
Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks
165223|NCT00103597|Drug|Domperidone|
165224|NCT01834963|Drug|Cisplatin、Fluorouracil|Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)
Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks
Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks
165509|NCT01835392|Other|Control|Sham placement of blood pressure cuff without inflation
165510|NCT00103662|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
165511|NCT01835405|Device|LiquiBand Flex|
165512|NCT01835405|Device|Dermabond Advanced|
165513|NCT01835405|Device|Sutures (Prolene)|
164915|NCT01842061|Behavioral|Active Living Program|
164916|NCT01842061|Behavioral|Education|
164917|NCT01842074|Drug|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
164918|NCT01842087|Other|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
164919|NCT01842087|Other|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
164920|NCT01842100|Drug|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
164921|NCT01842100|Other|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
164922|NCT01842113|Drug|Rifaximin|Rifaximin 550mg by mouth twice a day
164923|NCT00104520|Drug|AZLI 75 mg two times a day (BID)/three times a day (TID)|
164924|NCT01842113|Drug|Lactulose|Lactulose 30ml by mouth three times a day
164925|NCT01842113|Drug|Lactulose Placebo|Lactulose Placebo 30ml three times a day
164926|NCT01842113|Drug|Rifaximin Placebo|Rifaximin Placebo twice a day
164927|NCT01834352|Drug|Oat flour|The initial day escalation begins with a dose of 0.1 mg of oat flour. The dose is then increased and administered every thirty minutes until a maximum dose of 6 mg is reached or until allergic symptoms develop. After the initial escalation day, subjects begin the build-up phase in which the dose is increased every two weeks to a maximum dose of 1500mg oat flour at 34 weeks. After 34 weeks of build-up, the subject begins the maintenance phase in which daily dose (1500mg or the highest dose reached by 34 weeks) is taken for 4 weeks followed by a 5 gram protein oral food challenge to walnut and a 5 gram protein oral food challenge to the second tree nut (at 38 weeks). Then the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment beginning with the initial escalation day, build-up and maintenance.
164928|NCT01834365|Other|Structured education|Formatted education about hypertension
164929|NCT01834365|Other|Checklist|
164930|NCT01834365|Other|Without structure education with checklist|
164931|NCT01834378|Behavioral|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
164932|NCT01834378|Behavioral|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
165225|NCT01834989|Drug|Insulin-like growth factor I|
164023|NCT01814956|Drug|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
164024|NCT01814969|Radiation|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
164025|NCT01814969|Radiation|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
164026|NCT01814982|Drug|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
164027|NCT01814995|Behavioral|Nutrition/Physical Activity Intervention|Please see Arm description.
164331|NCT01817933|Behavioral|physical therapy|
164332|NCT01817946|Other|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
164333|NCT01817959|Drug|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.
164334|NCT01817959|Drug|Placebo|Continuous infusion at a volume/rate matching active treatment.
164335|NCT01817972|Biological|Certolizumab pegol|Subcutaneous injection
164336|NCT01817972|Drug|Azathioprine|50mg tablets
164337|NCT01817985|Drug|GS-5816|
164338|NCT01817998|Other|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
164339|NCT01818011|Drug|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
164340|NCT00102011|Procedure|standard follow-up care|Standard care
164341|NCT01818011|Drug|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
164342|NCT01818011|Drug|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
164343|NCT01818011|Drug|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
163411|NCT01816516|Behavioral|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
163412|NCT00001997|Drug|Interleukin-2, Polyethylene Glycolated|
163413|NCT00101881|Device|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
163414|NCT01816529|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
163415|NCT01816529|Drug|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
163416|NCT01816529|Drug|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
163417|NCT01816529|Drug|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
163418|NCT01816542|Other|patch tests on healthy skin|Patches will be placed on healthy skin.
163732|NCT01819636|Other|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
163733|NCT01819649|Dietary Supplement|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
163734|NCT01819662|Other|Enhanced standard management|Echocardiogram followed by letter to GP about results.
163735|NCT01819662|Other|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
163736|NCT01819662|Other|Standard management|Usual care
163737|NCT01819675|Device|Low frequency rTMS|
163738|NCT01819675|Device|High frequency rTMS|
163739|NCT01819675|Device|Sham rTMS|
163740|NCT01819688|Procedure|laparoscopic liver resection|
163741|NCT01819701|Dietary Supplement|LC-1000|L-carnitine 1000 mg /d
163742|NCT00102193|Device|Adacolumn Apheresis System|
163743|NCT01819701|Dietary Supplement|LC-2000|L-carnitine: 2000 mg/d
167800|NCT01861717|Drug|lanreotide|Somatuline Depot 90 mg deep subcutaneous injecton every 4 weeks X 3 doses
167801|NCT01861730|Biological|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
167802|NCT01861730|Biological|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
167803|NCT01861743|Other|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
167804|NCT01861743|Other|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
167805|NCT01861756|Other|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
167806|NCT01861769|Other|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
168111|NCT01855022|Behavioral|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
168112|NCT01855035|Other|prolonged ECG monitoring|10-day Holter ECG measurement
168113|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
168114|NCT00105638|Behavioral|educational program, by telephone|
168115|NCT01857193|Drug|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
168116|NCT01857193|Drug|Everolimus|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
168117|NCT00105950|Drug|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
168118|NCT01857206|Biological|Mammalian cell based flu vaccine|
168119|NCT01857206|Biological|Egg based flu vaccine|
167497|NCT01858571|Drug|Low dose chemotherapy|Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.
Cycle A
Daily oral Thalidomide (at 3mg/kg)
Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
Daily oral Etoposide (50 mg/m2/d)
Cycle B
Daily oral Thalidomide (at 3mg/kg)
Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days
167498|NCT01858584|Drug|Gastrotuss|Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.
dosage:
Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional
Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day
167499|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
167500|NCT01858584|Dietary Supplement|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
167501|NCT01858610|Drug|Irbeasartan/hydrochlorothiazide|
167502|NCT01858610|Drug|Irbesartan|
167503|NCT01858610|Drug|Hydrochlorothiazide|
167504|NCT01858623|Drug|Losartan/hydrochlorothiazide|
167505|NCT01858623|Drug|Losartan|
167506|NCT01858623|Drug|Hydrochlorothiazide|
167507|NCT01858636|Device|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
167508|NCT01858649|Procedure|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
167807|NCT01861769|Other|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
167808|NCT01861782|Other|Dead Sea Solar and Water Treatment|
167809|NCT01861782|Other|Sulfur Pool & Medicinal Mud|
167810|NCT00106522|Drug|Methotrexate|10-25mg weekly
167811|NCT01861795|Other|Preterm Neonates|Preterm Neonates
166878|NCT01822574|Procedure|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
167175|NCT01825382|Device|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
167176|NCT01825395|Drug|3, 4-Diaminopyridine|
167177|NCT01825408|Drug|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
167178|NCT01825408|Drug|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
167179|NCT01827839|Biological|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
167180|NCT01827865|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
167181|NCT01827865|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
167182|NCT01827878|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
167183|NCT01827878|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
167184|NCT01827891|Procedure|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
167185|NCT01827904|Device|Transcranial ExAblate|
167186|NCT01827904|Device|Sham Transcranial ExAblate|
167187|NCT01827917|Biological|rabies vaccine|Injection on day 0、7、21
167188|NCT01827930|Drug|Imatinib Mesylate|Imatinib Mesylate LMC
167189|NCT00103090|Drug|Fenretinide|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
167190|NCT01827943|Drug|TORISEL|Temsirolimus
167191|NCT01827956|Other|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
167192|NCT01827969|Procedure|ablathermy focused ultrasound|ablathermy focused ultrasound
166557|NCT01829373|Biological|vaccine 1650-G|
166558|NCT01829386|Other|Non heme iron levels on MRI|MRI examinations of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage. Each MRI will take up to 1 hour to complete and will be done on day 3, day 7, day 10, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan, and some will be performed solely for research.
166559|NCT01829399|Drug|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
166560|NCT00103207|Biological|cetuximab|
166561|NCT01829399|Drug|Normal Saline|
166562|NCT01829412|Other|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
166879|NCT01822574|Procedure|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
166880|NCT01822574|Procedure|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
166881|NCT01822587|Drug|Propranolol, 40 mg|
166882|NCT00102466|Drug|Metformin|
166883|NCT01822587|Drug|Propranolol, 80 mg|
166884|NCT01822587|Drug|Placebo|
166885|NCT01822600|Drug|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring GmbH, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels < 25 g/L.
166886|NCT01824771|Other|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
166887|NCT01824810|Procedure|Intramuscular Stimulation|Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of "twirling" the needles to enhance the grasping response in the muscle.
166267|NCT01823770|Drug|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
166268|NCT01823770|Drug|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
166269|NCT01823783|Other|Muscle biopsy|Muscle biopsy
166270|NCT01823796|Other|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
166271|NCT01823796|Other|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
166272|NCT01823809|Device|adenosine stress Cardiac Magnetic Resonance Imaging|
166273|NCT01823822|Dietary Supplement|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
166274|NCT01826253|Drug|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
166275|NCT01826266|Drug|PER977, Placebo|
166276|NCT01826279|Dietary Supplement|Resveratrol|500mg 3 times daily for 1 month
166277|NCT01826279|Other|Placebo|1 placebo tablet 3 times daily for 1 month
166278|NCT00102960|Drug|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
166279|NCT01826305|Procedure|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
166563|NCT01829425|Drug|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
166564|NCT01829425|Behavioral|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
165973|NCT01831011|Drug|cinepazide maleate injection|
165974|NCT01831011|Drug|aspirin|
165975|NCT01831024|Device|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
165976|NCT01831037|Other|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).
165977|NCT01823198|Drug|Thymoglobulin|0.5 mg/kg by vein on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
165978|NCT00102609|Drug|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
165979|NCT01823198|Procedure|Stem Cell Infusion|Peripheral blood progenitor cells infused on Day 0 or on arrival of the unrelated donor cells.
165980|NCT01823198|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
165981|NCT01823198|Drug|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted with a goal to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after Day +90 if no GvHD is present.
165982|NCT01823198|Drug|Methotrexate|5 mg/m2 administered intravenously on Days 1, 3, 6 and 11 post transplant.
165983|NCT01823224|Drug|2 capsules Oral Tylenol 2000 mg and IV "salt water"|
165984|NCT01823224|Drug|IV tylenol 1000mg and 2 oral capsule "sugar pills"|
165985|NCT01823237|Device|Transcranial Magnetic Stimulation|
165986|NCT01823250|Behavioral|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
166280|NCT01826305|Procedure|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
171425|NCT01927744|Behavioral|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
171426|NCT01927744|Behavioral|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
171427|NCT01927744|Drug|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
171737|NCT01873651|Device|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
171738|NCT01873664|Behavioral|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
171739|NCT01873677|Drug|M518101|
171740|NCT01873677|Drug|Vehicle|
171741|NCT01873690|Drug|Ciprofloxacin|Once, 400 mg IV
171742|NCT00107705|Biological|Tree MATA MPL|
171743|NCT01873690|Drug|Placebo|5% Dextrose in water
171744|NCT01873703|Drug|pracinostat|Histone deacetylase inhibitor (HDACi)
171745|NCT01873703|Drug|Placebo|Placebo
171746|NCT01873703|Drug|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
171747|NCT01873716|Drug|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
171748|NCT01873729|Drug|Naltrexone|Adults with ADHD
171749|NCT01873742|Other|STIC feedback system|This condition includes the use of the STIC feedback system.
171750|NCT01873755|Behavioral|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
171751|NCT01873768|Drug|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
171752|NCT01873768|Drug|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
171753|NCT00107718|Drug|SB-485232|
171113|NCT01912846|Behavioral|Interactive advance care planning|The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.
Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.
Facilitating EOL care discussions throughout the dying process.
A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP.
171114|NCT01912846|Behavioral|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
171115|NCT01912859|Behavioral|Nutrition/physical activity intervention|Nutrition/physical activity intervention
171116|NCT01912872|Drug|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
171428|NCT01927757|Biological|etanercept|Etanercept is a protein containing extracellular domains of 2 TNF receptors. It is able to bind both TNF alpha and TNF beta and thus acts primarily by binding and neutralizing both soluble and cell-bound TNF alpha. TNF alpha is a naturally occurring cytokine that is involved with normal inflammatory and immune responses. Elevated levels of TNF are found in involved tissues and fluids of rheumatoid arthritis patients. Etanercept inhibits TNF alpha activity.
171429|NCT01927835|Biological|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
171430|NCT01927835|Biological|NYVAC-HIV-PT1 vaccine|≥ 5x10^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10^8 PFU/ml; administered IM
171431|NCT01927835|Biological|NYVAC-HIV-PT4 vaccine|≥ 5x10^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10^7 PFU/ml; administered IM
171432|NCT01927835|Biological|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
171433|NCT01927835|Biological|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
171434|NCT00112775|Drug|imatinib mesylate|
171435|NCT01927848|Dietary Supplement|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
171436|NCT01927848|Dietary Supplement|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
171437|NCT01927861|Drug|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
171438|NCT01927874|Procedure|Infiltration|injection of local anesthetic, associated with general anesthesia
170799|NCT01929096|Drug|Compound Edaravone Injection|
170800|NCT01929096|Drug|Edaravone Injection|
170801|NCT01929109|Drug|LY2409021|Administered orally
170802|NCT01929122|Dietary Supplement|Placebo-Control Meals and Snacks|
170803|NCT01929122|Dietary Supplement|Cooked Navy Bean Powder Meals and Snacks|
170804|NCT01929122|Dietary Supplement|Rice Bran Meals and Snacks|
170805|NCT01929135|Drug|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
170806|NCT01929135|Drug|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
170807|NCT01929148|Procedure|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
170808|NCT01929148|Procedure|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
170809|NCT00112879|Drug|thalidomide|
171117|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
171118|NCT01924637|Drug|Faster-acting insulin aspart|A single dose will be administered subcutaneously (under the skin) in the abdomen.
Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.
171119|NCT00112619|Drug|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
171120|NCT01924637|Drug|insulin aspart|A single dose will be administered subcutaneously (under the skin)) in the abdomen.
Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.
171121|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
171122|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
171123|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
171124|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
171125|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
170472|NCT01923584|Drug|EPI-743 200mg|
170473|NCT01923597|Drug|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
170474|NCT01923610|Biological|Experimental|Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16
170475|NCT01923623|Drug|Ropivacaine block|
170476|NCT01923636|Other|Standardized test report|Clinical, radiological and laboratory (virological and immunological) standardized reports
170477|NCT01923649|Drug|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
170478|NCT01923649|Drug|Placebo|Placebo for somatuline slow release 90 mg
170479|NCT01923662|Device|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
170480|NCT01923675|Other|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
170481|NCT01923675|Other|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
170482|NCT00112554|Drug|laromustine|Given IV
170483|NCT01923675|Other|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
170484|NCT01923675|Other|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
170485|NCT01923688|Other|Informatics Alert/Nurse/physician responders|
170486|NCT01923701|Behavioral|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
170810|NCT01929161|Drug|Oxytocin|24 International Units
170811|NCT01929161|Drug|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
166395|NCT01829113|Drug|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1.
Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. OGX-427 will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle. A maximum of four treatment cycles will be administered.
Patients with objective response or stable disease after four cycles of therapy will move on to a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1). Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression.
166396|NCT01829113|Drug|Placebo|Three loading doses of placebo will be administered IV Days -9 to -1.
Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. Placebo will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle. A maximum of four treatment cycles will be administered.
Patients with objective response or stable disease after four cycles of therapy will move on to a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1). Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression.
166397|NCT00103181|Radiation|MammoSite or other single-entry intracavitary device|
166398|NCT01829152|Device|CHM|
166399|NCT01829165|Device|rTMS Treatment|MRI-compatible TMS stimulator
166400|NCT01829178|Drug|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
166401|NCT01832025|Procedure|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
166402|NCT00103350|Drug|TG100-115|
166403|NCT01832025|Procedure|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
166404|NCT01832038|Drug|Lacosamide|Strength: Lacosamide (LCM) 50 mg, LCM 100 mg
Formulation: Tablet
Frequency: twice daily during the study period (until the date of approval)
At the completion of EP0008 [NCT01710657], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day.
166405|NCT01832051|Drug|89Zr-trastuzumab injection|
166406|NCT01832064|Behavioral|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
166407|NCT01832077|Device|90 D|rural doctors exam eye fundus by 90 D
166408|NCT01832077|Device|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
166409|NCT01832103|Drug|MK-7145|
165802|NCT01840865|Device|brain stimulation|oscillating direct current brain stimulation
165803|NCT01840865|Device|no stimulation|sham Stimulation
165804|NCT01840891|Behavioral|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
165805|NCT01840943|Drug|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
165806|NCT01840943|Drug|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
165807|NCT01840956|Biological|HAVG|HAVG is implanted into patients' arm.
165808|NCT01840982|Dietary Supplement|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
166102|NCT01825980|Drug|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
166103|NCT01825980|Drug|Placebo|Placebo
166104|NCT01825993|Drug|L-BUPIVACAINE ; MORPHINE|
166105|NCT01825993|Drug|MORPHINE|
166106|NCT01826006|Device|Excimer laser|
166107|NCT01826006|Device|Manual Thrombus Aspiration|
166108|NCT01826019|Other|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
166109|NCT00102921|Drug|CCX282-B|
166110|NCT01826019|Other|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
166111|NCT01826032|Device|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
165514|NCT01835418|Drug|Amlodipine|crossover comparison of amlodipine vs lisinopril
165515|NCT01835431|Drug|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
165516|NCT01835431|Drug|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
165517|NCT01835431|Drug|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
165518|NCT01835431|Drug|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
165519|NCT01837719|Drug|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
165520|NCT01837732|Other|Relational Touch|Relational touch 15 mn " relational touch", hand touch (neck, face and head)
165521|NCT01837732|Other|Relational:|Relational: 10 mn verbal patient's centered exchanges
165522|NCT01837745|Drug|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
165523|NCT01837745|Drug|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
165524|NCT00103870|Procedure|Electrodermal stimulation|
165525|NCT01837745|Other|Follow up|10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation
2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)
3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4
4 years (+/- 2 months) after randomization: a serum Tg/LT4
5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4
165526|NCT01837771|Device|Diaphragmatic stimulation|
165527|NCT01837784|Other|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
165809|NCT01840982|Dietary Supplement|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
165810|NCT01840982|Dietary Supplement|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
165811|NCT01840982|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
165812|NCT00104377|Biological|Grass MATA MPL|
165226|NCT01835002|Device|Electrostimulation|
165227|NCT01835015|Drug|CLG561|Administered by intravitreal injection, Day 1
165228|NCT01835028|Other|Echocardiography|Observational Study using Imaging and Biomarkers
165229|NCT01835028|Other|Computed tomography|Observational Study using Imaging and Biomarkers
165230|NCT01835028|Other|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
165231|NCT01835028|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
165232|NCT01835028|Other|Stress echocardiography|Observational Study using Imaging and Biomarkers
165233|NCT01835041|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
165234|NCT00103597|Behavioral|Conservative Measures for Orthostatic Hypotension|
165235|NCT01835041|Drug|oxaliplatin|Given IV
165236|NCT01835041|Drug|leucovorin calcium|Given IV
165237|NCT01835041|Drug|irinotecan hydrochloride|Given IV
165238|NCT01835041|Drug|fluorouracil|Given IV
165239|NCT01835041|Other|laboratory biomarker analysis|Correlative studies
165240|NCT01835054|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
165241|NCT01835054|Genetic|DNA collection|Observational Study using Imaging and Biomarkers
165242|NCT01835054|Other|Echocardiography|Observational Study using Imaging and Biomarkers
165243|NCT01835054|Other|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
165244|NCT01835054|Other|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
165245|NCT01837290|Drug|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
165246|NCT01837290|Drug|saline infusion|Saline infusion to facilitate blinding
164344|NCT01818011|Drug|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
164345|NCT01818011|Drug|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
164346|NCT01818011|Drug|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
164347|NCT01818024|Drug|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
164348|NCT01820572|Drug|Belatacept|
164349|NCT01820572|Drug|Tacrolimus|
164350|NCT01820572|Drug|Cyclosporine|
164351|NCT01820585|Drug|Placebo|Tablets
164657|NCT01841424|Behavioral|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
164658|NCT01841437|Device|iStent|
164659|NCT01841450|Device|iStent|Implantation of one iStent in conjunction with cataract surgery
164660|NCT01841450|Procedure|Cataract surgery|Cataract surgery alone
164661|NCT01841463|Drug|P1446A-05|- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
164662|NCT00104416|Drug|Placebo|Placebo control
163744|NCT01819701|Dietary Supplement|Q10-150|Coenzyme Q10: 150 mg/d
163745|NCT01819701|Dietary Supplement|Q10-300|Coenzyme Q10: 300 mg/d
163746|NCT01819701|Other|Placebo|
163747|NCT01821820|Other|Pistachios|
163748|NCT01821833|Dietary Supplement|Omega-3 fatty acid|Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.
Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).
Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA).
163749|NCT01821833|Dietary Supplement|Placebo|Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.
Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)
163750|NCT01821833|Drug|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
163751|NCT01821846|Drug|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
163752|NCT01821859|Drug|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
163753|NCT01821859|Drug|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
164028|NCT00101686|Drug|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID [two times a day](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
164029|NCT01815008|Drug|Clopidogrel|Clopidogrel 75 mg daily
164030|NCT01815008|Drug|Aspirin|Aspirin 81 mg daily
164031|NCT01815021|Dietary Supplement|amorphous calcium carbonate|
164032|NCT01815021|Dietary Supplement|crystalline calcium supplements|
164033|NCT01815047|Dietary Supplement|Vitamin D3 Supplementation|
164034|NCT01815073|Biological|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
164035|NCT01815073|Biological|Live Attenuated Varicella Vaccine|
164036|NCT01815073|Biological|live attenuated JE vaccine|
168120|NCT01857219|Radiation|fMRI|
168121|NCT01857232|Drug|Ondansetron, dexamethasone, fosaprepitant|
168122|NCT01857232|Drug|Placebo|
168123|NCT01857245|Other|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
168124|NCT01857258|Dietary Supplement|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
168125|NCT01857271|Drug|Erlotinib Hydrochloride|Given PO
168126|NCT01857271|Procedure|Therapeutic Conventional Surgery|Undergo thoracotomy
168127|NCT01857271|Other|Laboratory Biomarker Analysis|Correlative studies
168128|NCT00105963|Behavioral|Education about infant crying|
168129|NCT01857284|Drug|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
168130|NCT01857284|Drug|Ursodeoxycholic Acid Capsules|250mg.tid.po
168131|NCT01857297|Biological|Enzira® vaccine|
168132|NCT01857310|Dietary Supplement|5 mg folic acid and 30 mg elemental zinc|
168133|NCT01857310|Drug|Placebo Comparator: Placebo|
163419|NCT01816555|Dietary Supplement|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
163420|NCT01816568|Procedure|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
163421|NCT01816568|Procedure|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
163422|NCT01816581|Drug|Targin|
163423|NCT01816581|Drug|Oxynorm|
163424|NCT00101894|Drug|FOLFOX-4|The FOLFOX-4 regimen will be administered every 2 weeks as follows:
Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed
163425|NCT01816581|Drug|Morphine|
167812|NCT01861808|Other|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
167813|NCT01861821|Device|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
167814|NCT01854489|Drug|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
167815|NCT01854489|Drug|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
167816|NCT01854502|Behavioral|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
167817|NCT01854502|Behavioral|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
167818|NCT01854515|Drug|Budesonide|
167819|NCT01854515|Drug|Dexamethasone acetate|
167820|NCT01854528|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
167821|NCT00105573|Behavioral|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
167822|NCT01854528|Drug|Ribavirin|Tablet
167823|NCT01854528|Drug|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
167824|NCT01854528|Drug|Telaprevir|Film-coated tablet
167825|NCT01854554|Radiation|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
167826|NCT01854554|Radiation|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
167827|NCT01854554|Behavioral|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
167828|NCT01854554|Behavioral|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
168134|NCT01857323|Drug|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
168135|NCT01857336|Other|infusion of G-CSF mobilized peripheral harvest|
168136|NCT01857349|Other|Chlora Prep|Surgical Scrub skin preparation
167193|NCT01827982|Drug|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
167194|NCT01827982|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
167195|NCT01827982|Drug|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
167196|NCT01827982|Drug|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
167509|NCT01858649|Drug|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
167510|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
167511|NCT01858649|Drug|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
167512|NCT01858649|Drug|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
167513|NCT01858649|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
167514|NCT01858662|Procedure|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
167515|NCT01860950|Device|Transcranial Direct current Stimulation|20 milliamps of current for 20 minutes
167516|NCT01860963|Procedure|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
167517|NCT01860976|Drug|Abatacept|
167518|NCT01860976|Drug|Placebo matching with Abatacept|
167519|NCT01860989|Drug|KAE609|KAE609 75mg single dose
167520|NCT01860989|Drug|KAE609|KAE609 150mg single dose
167521|NCT01860989|Drug|KAE609|KAE609 225mg single dose
167522|NCT01860989|Drug|KAE609|KAE609 300mg single dose
167523|NCT00106379|Drug|Viread (tenofovir DF)|
167524|NCT01861002|Drug|Azacitidine|Dose assigned at study entry. Azacytidine will be given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
166888|NCT01824810|Procedure|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
166889|NCT01824810|Procedure|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
166890|NCT01824810|Procedure|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
166891|NCT01824823|Drug|afatinib|Given PO
166892|NCT01824823|Other|placebo|Given PO
166893|NCT01824823|Other|laboratory biomarker analysis|Correlative studies
167197|NCT01827982|Drug|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
167198|NCT01827982|Drug|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
167199|NCT01827982|Drug|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
167200|NCT00103090|Drug|Lonafarnib|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
167201|NCT01827982|Drug|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
167202|NCT01827982|Drug|Placebo|Matching placebo will be given as a single oral dose.
167203|NCT00103285|Drug|pegaspargase|Given IM
167204|NCT01830543|Drug|prasugrel|One 10 mg tablet once daily for up to twelve months
167205|NCT01830543|Drug|ticagrelor|One 90 mg tablet twice daily for up to twelve months
167206|NCT01830556|Drug|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
166565|NCT01829438|Behavioral|Listening to fast music|
166566|NCT01829438|Behavioral|Listening to preferred music|
166567|NCT01829438|Behavioral|Listening to slow music|
166568|NCT01829451|Other|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
166569|NCT01829464|Drug|Placebo|TAK-875 placebo-matching tablets
166570|NCT01829464|Drug|TAK-875|TAK-875 tablets
166571|NCT00103220|Drug|SJG-136|Given IV
166572|NCT01831830|Behavioral|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
166573|NCT00103337|Drug|cilengitide|Given IV
166574|NCT01831843|Device|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
166575|NCT01831843|Device|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
166576|NCT01831843|Device|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
166577|NCT01831856|Drug|1g of F373280|Oral administration, one capsule each evening with dinner.
166578|NCT01831856|Drug|Placebo|Oral administration, one capsule each evening with dinner.
166579|NCT01831869|Drug|L-thyroxine|
166580|NCT01831895|Device|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
166581|NCT01831908|Other|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
166894|NCT01824836|Drug|anastrozole|Given PO
166895|NCT01824836|Other|questionnaire administration|Ancillary studies
166896|NCT00102778|Drug|Kaletra (lopinavir/ritonavir)|
166897|NCT01824836|Other|laboratory biomarker analysis|Correlative studies
166281|NCT01826318|Behavioral|Stress coping|Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud ("what is the patient's condition?", "what immediate action is needed?") to overcome the negative consequences of feeling overwhelmed by stress.
166282|NCT01826331|Behavioral|Incentives for Participation|Participants will receive three smoking cessation programs
166283|NCT01826331|Behavioral|Incentives for Cessation|Participants will have access to a smoking cessation program
166284|NCT01826370|Drug|Linagliptin|tablet
166285|NCT01826383|Behavioral|Active-Video|This group will watch an active-video with pain management strategies for parents
166286|NCT01826383|Behavioral|Placebo Video|This group will watch a placebo-video describing immunization generally.
166287|NCT01826396|Drug|Irinotecan|Comparison of standard and high dose irinotecan
166288|NCT01826409|Dietary Supplement|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
166289|NCT00102960|Drug|Didanosine|Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
166290|NCT01826409|Dietary Supplement|Placebo|Placebo 2.7g/day for 4 weeks
166291|NCT01826422|Dietary Supplement|EPA and DHA|Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U.
166292|NCT01826422|Dietary Supplement|Placebo Comparator: Sunflower oil|The placebo capsules will also contain sunflower oil. Each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg.
166293|NCT01828866|Behavioral|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
166294|NCT01828866|Behavioral|Community Reinforcement Approach|CRA is based on behavioural therapy principles:
Functional analysis
Communication skills
Problem-solving skills
Sobriety sampling
Social networking
Refusal of substances
Reinforcing activities
Relapse management
Medication monitoring
166295|NCT00103181|Radiation|3-dimensional conformal accelerated partial breast irradiation|
166296|NCT01828879|Drug|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
171754|NCT01876290|Drug|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
171755|NCT01876290|Drug|Placebo|Placebo
171756|NCT01876303|Other|laboratory biomarker analysis|Correlative studies
171757|NCT00107978|Drug|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
171758|NCT01876303|Other|questionnaire administration|Ancillary studies
171759|NCT01876316|Drug|Moxifloxacin|single oral administration of 400mg of moxifloxacin
172075|NCT01879709|Behavioral|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
172076|NCT00108316|Drug|Fluoxetine (Liquid Prozac)|
172077|NCT01879722|Drug|TAK-063|TAK-063 tablets
172078|NCT01879722|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
172079|NCT01879735|Drug|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
172080|NCT01879735|Drug|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
172081|NCT01879748|Drug|Rasagiline|Each subject will be enrolled into 1 of 4 cohorts:
cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
Each subject will then be randomly assigned to 1 of the following groups:
rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)
placebo (8 Japanese and 8 Caucasian subjects)
172082|NCT01879748|Drug|Placebo|Each subject will be enrolled into 1 of 4 cohorts:
cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
Each subject will then be randomly assigned to 1 of the following groups:
rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)
placebo (8 Japanese and 8 Caucasian subjects)
172083|NCT01879774|Other|Neuropsychological and motoric tests|Evaluation before and after therapy of hyponatremia
Neuropsychological tests
Mini Mental Status Test
Dem-Tect
Rey-Osterrieth Complex Figure Test
Trailmaking Test
Beck Depression Inventory
d2-R (optional)
Motoric tests
modified UPDRS (Unified Parkinson Disease Rating Scale) Part III
Timed-up-and-go Test
Halstead Fingertapping Test
AIMS (Abnormal involuntary movement scale)
EEG
171439|NCT01927874|Procedure|Spinal block|injection of anesthetic
171440|NCT01927874|Drug|Bupivacaine|10ml 0.5% bupivacaine.
171441|NCT01927874|Drug|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
171442|NCT01927887|Drug|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
171443|NCT01930188|Drug|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
171444|NCT00112918|Drug|Capecitabine|Film-coated tablets
171445|NCT01930188|Drug|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
171760|NCT01876316|Drug|Placebo|single oral administration of 400mg of placebo
171761|NCT01876342|Procedure|open repair|2-0 sutures
171762|NCT01876342|Procedure|endoscopic TEP repair|mesh
171763|NCT01876355|Drug|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
171764|NCT01876355|Drug|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
171765|NCT01876368|Drug|LCZ696|
171766|NCT01876368|Drug|Olmesartan|
171767|NCT01876368|Drug|Placebo of LCZ696|
171768|NCT00107991|Drug|etanercept|etanercept 50 mg/week subcutaneous injection
171769|NCT01876368|Drug|Placebo of Olmesartan|
171770|NCT01876381|Drug|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
171771|NCT01876394|Other|Coconut Oil|Shake with 50 g Coconut oil
171772|NCT01876394|Other|Canola Oil|Shake with 50 g Canola oil
171126|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
171127|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
171128|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
171129|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
171130|NCT00112632|Drug|imatinib mesylate|
171131|NCT01924689|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
171132|NCT01924702|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
171133|NCT01924702|Device|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
171134|NCT01924715|Behavioral|ISTDP|An emotion focused brief psychotherapy format.
171135|NCT01924728|Device|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
171136|NCT01924728|Device|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
171137|NCT01924741|Procedure|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
171446|NCT01930188|Drug|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
171447|NCT01930201|Procedure|Caudal epidural block|
171448|NCT01930201|Other|General anesthesia|
171449|NCT01930227|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
171450|NCT01930227|Other|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
171451|NCT01930240|Drug|TRIA-662|
171452|NCT01930253|Drug|Bortezomib|
171453|NCT01930266|Dietary Supplement|Experimental|
171454|NCT01930266|Behavioral|Active comparator|
170812|NCT01929161|Behavioral|Lovingkindness Meditation|
170813|NCT01929161|Behavioral|Mindfulness Meditation|
170814|NCT01929187|Drug|Phytonail|
170815|NCT01929187|Drug|Loceryl|
170816|NCT01931319|Drug|Intravenous baclofen|
170817|NCT01931332|Procedure|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
170818|NCT01931332|Procedure|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
170819|NCT01931345|Behavioral|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
170820|NCT01931345|Behavioral|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
170821|NCT01931358|Biological|ALVAC-HIV|1 mL intramuscular injection containing 10^6 CCID50/dose
170822|NCT01931358|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
170823|NCT01931358|Biological|ALVAC-HIV Placebo|1 mL per injection
170824|NCT01931358|Biological|AIDSVAX B/E Placebo|1 mL per injection
170825|NCT00113048|Drug|CAMPATH (alemtuzumab)|
170826|NCT01931371|Procedure|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
170827|NCT01931371|Procedure|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
170828|NCT01931384|Drug|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
170829|NCT01931384|Drug|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
170830|NCT01931410|Drug|Misoprostol|
170831|NCT01931423|Behavioral|Placental cord drainage|
170832|NCT01931436|Drug|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
166410|NCT01832116|Drug|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
166701|NCT01824589|Device|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
166702|NCT01824602|Drug|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
166703|NCT00102752|Drug|Gemcitabine|
166704|NCT01824602|Drug|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
166705|NCT01824602|Drug|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
166706|NCT01824602|Drug|Placebo|Placebo sugar pills
166707|NCT01824615|Drug|Sunitinib|37.5mg everyday from D1-D28
166708|NCT01824641|Device|Eliminate aspiration catheter|Eliminate aspiration catheter
166709|NCT01824641|Procedure|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
166710|NCT01827111|Behavioral|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
166711|NCT01827124|Drug|Carbetocin|
166712|NCT00103012|Drug|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
166713|NCT01827124|Drug|oxytocin|
166714|NCT01827137|Biological|WT1 Analog Peptide Vaccine|
166715|NCT01827137|Biological|Sargramostim (GM-CSF)|
166716|NCT01827137|Drug|lenalidomide|Optional lenalidomide maintenance starting 3-months post auto SCT
166717|NCT01827150|Drug|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
166718|NCT01827163|Drug|Paclitaxel|
166719|NCT01827163|Drug|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
166720|NCT01827163|Drug|Lapatinib|
166112|NCT01828606|Device|coban lite system|All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment
According to protocol the materials are applied to the whole leg and the measuring devices are put in place
166113|NCT01828619|Procedure|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
166114|NCT01828632|Procedure|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
166115|NCT00103155|Procedure|conventional surgery|
166116|NCT01828645|Dietary Supplement|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
166117|NCT01828658|Other|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
166411|NCT01832129|Drug|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
166412|NCT01832129|Drug|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
166413|NCT00103363|Other|cytology specimen collection procedure|
166414|NCT01832155|Behavioral|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
166415|NCT01832155|Behavioral|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
166416|NCT01832168|Procedure|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
166417|NCT01832168|Other|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
166418|NCT01832168|Other|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
166419|NCT01832194|Drug|Botox|
165813|NCT01840995|Procedure|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
165814|NCT01841008|Drug|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
165815|NCT01841008|Drug|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
165816|NCT01841021|Drug|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
165817|NCT01833442|Behavioral|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
165818|NCT01833455|Drug|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
165819|NCT01833455|Drug|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
165820|NCT01833481|Radiation|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
165821|NCT01833494|Drug|PA21|
165822|NCT01833507|Behavioral|Self-Exercise|Behavioral Goal Setting
165823|NCT01833507|Behavioral|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
165824|NCT01833520|Drug|Ra-223 Dichloride|Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.
Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.
165825|NCT01833533|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
165826|NCT01833533|Drug|Ribavirin|Capsule
165827|NCT00103454|Drug|GW685698X|
166118|NCT01828671|Other|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
166119|NCT01828671|Other|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
165247|NCT00103857|Drug|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
165248|NCT01837290|Drug|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
165528|NCT01837797|Drug|Placebo|Once daily, tablets, orally
165529|NCT01837797|Drug|Brexpiprazole 1 mg|once daily dose, tablets, orally
165530|NCT01837797|Drug|Brexpiprazole 3 mg|once daily dose, tablets, orally
165531|NCT01837810|Drug|Ibuprofen|800mg every 8 hours as needed for pain
165532|NCT01837823|Drug|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
165533|NCT01837836|Behavioral|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
165534|NCT01837862|Drug|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
165535|NCT00103870|Procedure|Music listening task|
165536|NCT01837862|Drug|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients < 12kg: 0.05 mg/kg; for patient > 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
165537|NCT01837862|Drug|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
165538|NCT01837862|Drug|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
165539|NCT01837862|Drug|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
165540|NCT01840176|Procedure|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
164663|NCT01841463|Drug|Vemurafenib (Zelboraf®)|In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.
In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle
Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
164664|NCT01841476|Drug|POL6326|
164665|NCT01841489|Drug|Treatment A|1600 mg GS-9973 (Formulation 1)
164666|NCT01841489|Drug|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
164667|NCT01841489|Drug|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
164668|NCT01841489|Drug|Treatment D|1600 mg GS-9973 (Formulation 2)
164669|NCT01833910|Other|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
164670|NCT01833923|Drug|anlotinib|oral medicine.
164671|NCT01833936|Device|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
164933|NCT01834404|Drug|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
164934|NCT01834404|Drug|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
164935|NCT00103545|Biological|ACA 125|
164936|NCT01834417|Device|TexiMat|
164937|NCT01834430|Dietary Supplement|enteral nutrition|
164938|NCT01834443|Device|Direct current galvanic vestibular stimulation|
164939|NCT01834456|Other|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
164940|NCT01834469|Drug|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
164941|NCT01834482|Dietary Supplement|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
164037|NCT01815086|Biological|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
164038|NCT01815099|Device|NeuroStar TMS|Treatment will entail twice weekly TMS sessions for 5 weeks.
164039|NCT00101686|Drug|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID [two times a day] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
164040|NCT01815112|Other|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
164041|NCT01815112|Other|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
164042|NCT01815125|Drug|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
164043|NCT01817530|Drug|Elagolix|Elagolix Dose 1 for 6 Month treatment Period
164044|NCT01817530|Drug|Estradiol/norethindrone acetate, E2/NETA|E2/NETA Dose 1
164045|NCT01817530|Drug|Estradiol/norethindrone acetate, E2/NETA Dose 2|E2/NETA Dose 2
164046|NCT00101972|Biological|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
164047|NCT01817530|Other|Placebo|Placebo for 6 Month Treatment Period
164048|NCT01817530|Drug|Elagolix|Elagolix Dose 2 for 6 Month Treatment Period
164352|NCT01820585|Drug|ESL 400 mg|tablets
164353|NCT00102271|Drug|Oxypurinol|
164354|NCT01820585|Drug|ESL 800 mg|tablets
164355|NCT01820585|Drug|ESL 1200 mg|tablets
164356|NCT01820598|Device|Multisite NMES training during 6 weeks|
164357|NCT01820611|Device|Arcos Revision Stem System|Revision Hip System
164358|NCT01820624|Drug|tretinoin|Given PO
164359|NCT01820624|Drug|lithium carbonate|Given PO
164360|NCT01820624|Other|laboratory biomarker analysis|Correlative studies
163426|NCT01816594|Drug|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 will be administered orally 100 mg/day.
163427|NCT01816594|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
163428|NCT01818973|Procedure|surgery|Total Mesorectal Excision (TME)
163429|NCT01818986|Drug|Sipuleucel-T|
163430|NCT01818986|Radiation|Stereotactic Ablative Body Radiation|
163431|NCT01818999|Drug|IXABEPILONE|injection
163432|NCT01818999|Radiation|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
163433|NCT01819012|Drug|Isoflurane|Isoflurane dosage titration Comparisons of the effect of the 10 min-inhalation of each concentration of isoflurane, 1.0 MAC, 1.5 MAC and 2.0 MAC (T1, T2 and T3, respectively) to determine the changes in following parameters
TDI of lateral mitral annulus at systole (S'), early filling (E') and atrial contraction (A')
transmitral flow Doppler at early filling (E'), atrial contraction (A'), deceleration time
LV-ejection fraction (EF)
bispectral index (BIS)
phenylephrine-infusion rate
pressure derived hemodymic parameters
163434|NCT01819025|Behavioral|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
163435|NCT01819025|Behavioral|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
163436|NCT01819038|Procedure|continuous renal replacement therapy|
163437|NCT01819051|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
163438|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
163754|NCT01821872|Drug|Administration of paracetamol|Administration of 1g intravenous paracetamol
163755|NCT01821885|Behavioral|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
163756|NCT01821885|Behavioral|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
163757|NCT00102401|Behavioral|Face-to-face Dyspnea Self-Management Program|
168137|NCT01857349|Other|Dura Prep|Surgical Scrub skin preparation
168138|NCT01857362|Drug|Nitisinone 20 mg|Nitisinone 20 mg capsules
168139|NCT00105976|Drug|MM-093|
168140|NCT01857362|Drug|Nitisinone 10 mg|Nitisinone 10 mg capsules
168141|NCT01857375|Device|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
168142|NCT01857388|Behavioral|ParentCorps|
168143|NCT01857401|Other|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
168144|NCT01859507|Drug|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
168145|NCT01859520|Procedure|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
168146|NCT01859533|Device|Neopuff|Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
168147|NCT01859546|Behavioral|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
168148|NCT01859559|Procedure|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
168149|NCT01859559|Procedure|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
168150|NCT01859585|Drug|Parecoxib|Parecoxib 40 mg intravenous
168151|NCT01859585|Drug|Ketorolac|Ketorolac 30 mg intravenous
163439|NCT01819064|Drug|Atropine|intravenous atropine in low doses does not cause bradycardia
163440|NCT01819064|Drug|Atropine|IV dose at 5 mcg/kg
167525|NCT01861002|Drug|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
167526|NCT01861002|Drug|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
167527|NCT01861015|Drug|Epinephrine|
167528|NCT01861015|Drug|Vasopressin|
167529|NCT01861041|Drug|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
167530|NCT01861041|Drug|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
167531|NCT01861054|Drug|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
167829|NCT01854567|Biological|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
167830|NCT01854567|Biological|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
167831|NCT01854593|Drug|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
167832|NCT00105573|Behavioral|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
167833|NCT01854593|Procedure|Vitrectomy|vitrectomy of 25 gauge system.
167834|NCT01854593|Device|Sham injection|Sham injection one day before vitrectomy
167835|NCT01854606|Drug|AEB071|a Protein Kinase C Inhibitor
167836|NCT01854606|Drug|Everolimus|mTOR inhibitor
167837|NCT01854619|Device|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
167838|NCT01854619|Device|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
167839|NCT01856725|Procedure|Hemodynamic measurements for CRT device programming|
167840|NCT01856725|Device|CRT device implant with MultiPoint Pacing|
167841|NCT01856738|Drug|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
167842|NCT01856738|Drug|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
167207|NCT01830569|Behavioral|The EBMeDS system|The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.
The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group.
167208|NCT01830569|Other|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
167209|NCT01830582|Procedure|Advanced MR Imaging|
167210|NCT01830595|Drug|Recombinant Lactoferrin|
167211|NCT01830595|Drug|Placebo|
167212|NCT01830621|Drug|BBI608|
167213|NCT01830621|Drug|Placebo|
167214|NCT00103285|Drug|methotrexate|Given IM or IT
167215|NCT01830621|Other|Best Supportive Care|
167216|NCT01830634|Behavioral|Theraband with strengthening and stretching exercise|
167217|NCT01830660|Drug|Hetrombopag Olamine Tablets|
167218|NCT01830660|Drug|placebo|
167532|NCT01861067|Procedure|LESS-TLH|
167533|NCT01861067|Procedure|LESS-LAVH|
167534|NCT00106392|Drug|Tacrolimus|oral
167535|NCT01861093|Procedure|Cord Blood Units|Transplant
167536|NCT01861106|Procedure|Allogeneic HSC|Stem cell transplant
167537|NCT01861106|Drug|Busulfan Test dose|0.8 mg/kg IV infusion over 2 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
167538|NCT01861106|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
167539|NCT01861106|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing)
166898|NCT01824836|Other|pharmacogenomic studies|Correlative studies
166899|NCT01824849|Procedure|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
166900|NCT01824849|Procedure|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
166901|NCT01824875|Drug|temozolomide|Given PO
166902|NCT01824875|Drug|capecitabine|Given PO
166903|NCT01824875|Other|laboratory biomarker analysis|Correlative studies
166904|NCT01824888|Drug|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
166905|NCT01824888|Drug|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
166906|NCT01824901|Drug|docetaxel|Given IV
166907|NCT00102791|Drug|ICA-17043|
166908|NCT01827449|Device|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
166909|NCT01827462|Biological|Trivalent inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine
166910|NCT01827475|Drug|Ibuprofen|single dose
166911|NCT00103038|Drug|ferumoxytol|Dose: 4 mg Fe/kg
166912|NCT01827475|Drug|Acetaminophen|single dose
166913|NCT01827475|Drug|Ibuprofen-acetaminophen combination|single dose
166914|NCT01827501|Device|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
166915|NCT01827540|Drug|Cenicriviroc|
166916|NCT01827540|Drug|Dolutegravir|
166917|NCT01827540|Drug|Midazolam|
166918|NCT01827553|Drug|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)
167219|NCT01830686|Other|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
166582|NCT01831921|Behavioral|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
166583|NCT01831921|Behavioral|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
166584|NCT00103337|Other|laboratory biomarker analysis|Correlative studies
166585|NCT01831934|Biological|Intramuscular seasonal trivalent inactivated influenza vaccine|FDA-licensed seasonal influenza vaccine
166586|NCT01831947|Biological|Ranibizumab|
166587|NCT01831960|Drug|cortexolone 17α-propionate|
166588|NCT01831973|Drug|Lipotecan|
166589|NCT01831986|Dietary Supplement|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
166590|NCT01831986|Other|Placebo|Caps
166591|NCT01831999|Behavioral|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
166592|NCT01832012|Other|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
166593|NCT01832012|Other|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
166594|NCT01824303|Drug|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
166595|NCT01824303|Other|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
166596|NCT01824329|Procedure|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
166597|NCT01824329|Procedure|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
166598|NCT01824342|Biological|Denosumab|Administered by subcutaneous injection
166599|NCT01824355|Device|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
172084|NCT01879787|Other|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
172085|NCT01879800|Behavioral|Acceptance and Commitment Therapy plus Illness Management|
172086|NCT01879813|Dietary Supplement|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
172087|NCT00108329|Behavioral|Weight Loss|
172088|NCT01879813|Dietary Supplement|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
172386|NCT01882621|Drug|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
172387|NCT01874730|Other|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
172388|NCT01874730|Drug|Volulyte® (6% HES 130/0.4 in balanced solution)|For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.
For the ERS Group:
GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg.
172389|NCT01874730|Other|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
172390|NCT00107874|Drug|misoprostol|
172391|NCT01874743|Drug|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
172392|NCT01874756|Drug|LY500307 150mg|LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
172393|NCT01874756|Drug|LY500307 75mg|LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
172394|NCT01874756|Drug|Placebo|6 placebo capsules daily for 8 weeks
172395|NCT01874769|Other|Blood collection|5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.
10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen
5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria.
172396|NCT01874769|Other|Skin biopsies|A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.
During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients
171773|NCT01876394|Other|Grapeseed Oil|Shake with 50 g Grapeseed oil
171774|NCT01876394|Other|Chia Oil|Shake with 50 g Chia oil
171775|NCT01876394|Other|Butter|Shake with 50 g Butter
171776|NCT01876407|Device|Low intensity laser for oral mucositis|
171777|NCT01876407|Device|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
171778|NCT01876420|Device|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
171779|NCT00108004|Drug|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
171780|NCT01876433|Drug|Mirabegron|
171781|NCT01879189|Behavioral|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
172089|NCT01879826|Device|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
172090|NCT01879826|Device|Aculaser applied to sham points|The patient will receive aculaser, performed by licensed acupuncturist, to "sham" acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
172091|NCT01882348|Behavioral|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)—including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
172092|NCT00108524|Drug|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
172093|NCT01882361|Drug|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
172094|NCT01882361|Drug|placebo comparator|this placebo has no specific pharmacological activity
171455|NCT00112918|Drug|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
171456|NCT01930279|Other|Blood withdrawal|Blood withdrawal
171457|NCT01930292|Drug|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
171458|NCT01930292|Drug|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
171459|NCT01930292|Drug|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
171460|NCT01930292|Drug|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
171461|NCT01930318|Drug|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
171462|NCT01930331|Drug|artemisinin/naphthoquine|Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).
The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).
171463|NCT01930331|Drug|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
171464|NCT01930344|Device|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
171782|NCT01879202|Drug|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
171783|NCT01879202|Drug|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
171784|NCT01879215|Procedure|Intramedullary nailing of the tibia|Standard care surgery
171785|NCT00108251|Drug|Placebo|matching placebo
171786|NCT01879228|Drug|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
171138|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
171139|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
171140|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
171141|NCT00112632|Procedure|conventional surgery|
171142|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
171143|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
171144|NCT01927224|Drug|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
171145|NCT01927237|Other|HLR|
171146|NCT01927237|Other|EHR|
171147|NCT01927250|Behavioral|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
171148|NCT00112736|Other|laboratory biomarker analysis|Correlative studies
171149|NCT01927263|Biological|NI-071|100mg/vial
171150|NCT01927263|Biological|Infliximab|100mg/vial
171151|NCT01927276|Other|Gluten Free Flour|
171152|NCT01927276|Other|Wheat Flour|
171153|NCT01927289|Procedure|Proximal Brachial Plexus vs Distal Forearm Block|Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.
Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
171154|NCT01927302|Behavioral|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
171155|NCT01927302|Behavioral|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
171156|NCT01927302|Behavioral|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
171157|NCT01927302|Behavioral|No Treatment|No treatment will be administered.
171158|NCT01927315|Drug|Fenofibrate 145 mg|Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.
166721|NCT01827163|Drug|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
166722|NCT01827176|Other|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
166723|NCT00103012|Drug|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
167034|NCT01830322|Drug|Any non-gemcitabine chemotherapies or best supportive care|
167035|NCT01830335|Drug|Indomethacin|
167036|NCT01830335|Drug|Placebo|
167037|NCT01830348|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
167038|NCT01830348|Drug|placebo vehicle gel|
167039|NCT01830361|Drug|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
167040|NCT01830387|Device|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
167041|NCT01830387|Other|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
167042|NCT01822652|Genetic|iC9-GD2 T Cell Lymphocytes-fresh cells|subjects who will receive a fresh T cell product:
Dose Level 1 = 1.5 x 10^8
Dose Level 2 = 2 x 10^8
Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
167043|NCT01822665|Drug|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
167044|NCT00102492|Drug|GW679769|
167045|NCT01822665|Drug|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
167046|NCT01822665|Other|Placebo|Placebo tablets
167047|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
167048|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
167049|NCT01822678|Drug|Placebo|Placebo
166420|NCT01832207|Device|Transcutaneous electrical nerve stimulation|
166421|NCT01832207|Device|Placebo transcutaneous electrical nerve stimulation|
166422|NCT01823978|Biological|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
166423|NCT01823991|Drug|VitaBlue™|Self administration of nutritional supplement COGNUTRIN for 3 months.
The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
166424|NCT01823991|Other|Placebo|Self administration of placebo for 3 months.
Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people.
166425|NCT01823991|Drug|Lovaza®|Self administration of nutritional supplement COGNUTRIN for 3 months.
The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
166426|NCT00102687|Drug|azacitidine|Azacitidine is administered subcutaneously
Total of 18 cycles on treatment or early discontinuation.
166427|NCT01824004|Drug|S-1|
166428|NCT01824017|Other|Blood Draw|
166724|NCT01827189|Other|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
166725|NCT01827202|Other|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
166726|NCT01827202|Drug|Aliskiren|
166727|NCT01827202|Drug|Candesartan|
166728|NCT01827215|Behavioral|Intervention (VPA)|Intervention participants will have access to the Virtual Patient Advocate system for a period of 12 months. They will be encouraged to log on at least once a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
166729|NCT01827228|Other|Assays|May vary across sites
166730|NCT01827228|Other|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
166731|NCT01827228|Other|Social network and venue tracing|This is described in Arms 1 and 2
166120|NCT01828671|Other|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
166121|NCT01828671|Other|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
166122|NCT01828671|Other|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
166123|NCT01828684|Other|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
166124|NCT01828684|Other|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
166125|NCT01828697|Drug|Low dose nadroparin|Fixed low dose nadroparin:
< 100 kg: 2850 IU subcutaneously once-daily
100 kg and above: 3800 IU subcutaneously once-daily
166126|NCT00103155|Procedure|radiofrequency ablation|
166127|NCT01828697|Drug|Intermediate dose nadroparin|Intermediate weight-adjusted dose nadroparin:
< 50 kg: 3800 IU subcutaneously once-daily;
50 to < 70 kg: 5700 IU subcutaneously once-daily;
70 to < 100 kg: 7600 IU subcutaneously once-daily;
100 kg or above: 9500 IU subcutaneously once-daily.
166128|NCT01828697|Drug|Low dose enoxaparin|Fixed low dose enoxaparin:
< 100 kg: 40 mg subcutaneously once-daily
100 kg and above: 60 mg subcutaneously once-daily
166129|NCT01828697|Drug|Intermediate dose enoxaparin|Intermediate weight-adjusted dose enoxaparin:
< 50 kg: 60 mg subcutaneously once-daily, or;
50 kg to < 70 kg: 80 mg subcutaneously once-daily, or;
70 kg to < 100 kg: 100 mg subcutaneously once-daily, or;
100 kg or above: 120 mg subcutaneously once-daily.
166130|NCT01831232|Drug|pravastatin sodium|Given PO
166131|NCT01831232|Drug|idarubicin|Given IV
166132|NCT01831232|Drug|cytarabine|Given IV
166133|NCT01831232|Other|laboratory biomarker analysis|Correlative studies
166134|NCT01831258|Device|SensAwake On|
166135|NCT01831258|Device|SensAwake Off|
166136|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
166429|NCT01824030|Device|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
151687|NCT01726764|Drug|Metformin|
151688|NCT01726777|Dietary Supplement|Control|Normal cheddar cheese
151689|NCT01726777|Dietary Supplement|Vitamin D|Vitamin D3 supplemented cheddar cheese
151690|NCT01726803|Other|Early Physical Therapy|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
151691|NCT01726803|Other|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
151692|NCT01726816|Drug|Probucol 250mg/day|Probucol 250mg + Placebo
151693|NCT01726816|Drug|Probucol 500mg/day|Probucol 500mg + Placebo
151694|NCT01726816|Drug|Placebo|Probucol matching placebo
151695|NCT01726829|Device|MD-Logic Artificial Pancreas (MDLAP) system|
151696|NCT00093483|Drug|arsenic trioxide|IV over 1 hour on day 1
151697|NCT01726829|Procedure|sensor augmented pump therapy|
151698|NCT01726842|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
151699|NCT01726855|Procedure|vascularized finger dorsal fascial flap|
151700|NCT01726868|Device|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
151701|NCT01729481|Drug|Erlotinib|100mg, once per day
151702|NCT01729481|Drug|Oxaliplatin|85mg/m², q2weeks
151703|NCT01729481|Drug|Folinic Acid|400 mg/m², q2weeks
151704|NCT00000274|Drug|Flupenthixol|
151705|NCT00001827|Biological|aldesleukin|
151706|NCT00093639|Drug|everolimus|
151707|NCT01729481|Drug|Irinotecan|180 mg/m², q2weeks
150803|NCT01739920|Other|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
151194|NCT01733472|Drug|GA-arm, remifentanil|Remifentanil and propofol will be delivered intravenously via TCI pumps according to the "Marsh" and "Minto" algorithm
151195|NCT01733472|Drug|placebo|
151196|NCT01733485|Drug|Aspirin|500 mg/8 h for 5 days
151197|NCT01733485|Drug|Indomethacin|25 mg/8 h for 5 days
151198|NCT01733524|Behavioral|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
151199|NCT01733524|Behavioral|Picture of a fish|Participants will receive a picture of a betta fish.
151470|NCT01736072|Procedure|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
151471|NCT01736085|Behavioral|Telephone counseling|Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
151472|NCT01736085|Behavioral|Voucher|Subjects will receive a voucher for nicotine patches.
Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
151473|NCT01738529|Device|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
151474|NCT01738542|Drug|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
151475|NCT01738542|Drug|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
151476|NCT01738542|Drug|Statins|
151477|NCT01738542|Drug|Antihypertensive therapy|
151478|NCT01738555|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
151479|NCT01738555|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
150947|NCT01735175|Drug|Peg-Filgrastim|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
150948|NCT01735201|Drug|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
150949|NCT01735201|Drug|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
150950|NCT01735201|Drug|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
150951|NCT01735201|Drug|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
150952|NCT01735214|Drug|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
150953|NCT01735227|Drug|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
150954|NCT00094133|Procedure|hot flashes attenuation|
150955|NCT01737541|Drug|Placebo|
150956|NCT01737554|Other|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
151257|NCT00093743|Radiation|total-body irradiation|Undergo TBI
151258|NCT01730950|Radiation|proton beam radiation therapy|Undergo proton beam RT
151259|NCT01730976|Dietary Supplement|Vitamin D 2,000 I.U.|
151260|NCT01730989|Dietary Supplement|Estromineral Serena Plus|
151261|NCT01730989|Dietary Supplement|Estromineral|
151262|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.01%|
151263|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.02%|
151264|NCT01731002|Drug|Latanoprost ophthalmic solution|
151605|NCT01726608|Procedure|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
151912|NCT01729845|Drug|Decitabine|Given IV
151913|NCT01729845|Drug|Etoposide|Given IV
151914|NCT01721811|Other|Hyperoxia|
151915|NCT01721811|Other|Glucose|
151916|NCT01721824|Behavioral|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
151917|NCT01721850|Other|control formula|commercial stage 1 infant formula
151918|NCT01721850|Other|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
151919|NCT01721850|Other|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
151920|NCT01721863|Other|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
151921|NCT01721876|Drug|placebo|comparator
151922|NCT01721876|Drug|volasertib|'Investigational Medicinal Product
151923|NCT01721876|Drug|low dose cytarabine|background medication
151924|NCT00092963|Drug|Comparator: placebo / Duration of Treatment: 1 day|
151925|NCT01721876|Drug|low dose cytarabine|background medication
151926|NCT01721889|Radiation|Radiostereometric Analysis|The radiostereometric (RSA) patient exam (flexion and extension RSA images) presents additional radiation exposure to the patient above standard of care (additional radiographs). Assuming 120kV, using three protocols (two loaded and one unloaded) per RSA exam results in a typical effective dose of approximately 2.04mSv per exam(single lumbar spine RSA at 120kV yields 0.68mSv,). HBI recommends using 140kV for lumbar spine RSA and has conducted simulations to estimate the effective dose using higher kV settings. 140kV reduces the effective dose from 0.68mSv per spine RSA to 0.2mSV, resulting in a total effective dose per RSA exam of 0.6mSv. In comparison, the estimated effective dose for a single standard lumbar spine x-ray is 1.2mSv. This additional radiation exposure is considered to be minimal risk in consideration of the number of planar x-rays the patient will undergo as part of standard care, as well as average background radiation received by humans per year (3.1mSv).
151927|NCT01721902|Device|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
151928|NCT01721902|Other|Carrier Solution|Intra-myocardial injection of carrier solution
155461|NCT01750892|Behavioral|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
155462|NCT01750892|Behavioral|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
155463|NCT01750892|Other|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
154535|NCT00096278|Drug|fluorouracil|Given IV
154536|NCT01760005|Drug|Gantenerumab|225 mg subcutaneously every 4 weeks
154537|NCT01760005|Drug|Solanezumab|400 mg intravenous infusion every 4 weeks
154538|NCT01760005|Drug|Matching Placebo (Gantenerumab)|subcutaneous injection of placebo every 4 weeks
154539|NCT01760005|Drug|Matching Placebo (Solanezumab)|intravenous infusion of placebo every 4 weeks
154540|NCT01760018|Drug|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
154541|NCT01760018|Drug|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
154542|NCT01760031|Other|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
154543|NCT01760044|Device|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
154544|NCT01760057|Behavioral|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
154545|NCT01760057|Behavioral|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
154546|NCT00096278|Biological|bevacizumab|Given IV
154547|NCT01760070|Device|Hybrid knife|Use Hybrid knife in ESD procedure
154548|NCT01760070|Device|IT knife|Use IT knife in ESD procedure.
154549|NCT01760083|Device|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
155159|NCT01760850|Other|questionnaire administration|Ancillary studies
155160|NCT01760863|Other|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
155161|NCT01760876|Device|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
155162|NCT01760889|Drug|SPD489 low dose range (40mg, 80mg, and 100mg)|Capsule, dose titration,
40 mg capsule once-daily for 1 week; then
80 mg capsule once-daily for 4 weeks; then,
100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;
if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks
155163|NCT00096356|Dietary Supplement|CoQ10 & Vitamin E|
155164|NCT01752569|Drug|Selumetinib|The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.
For phase I there were 4 potential dosing levels:
Level -1 - 50mg once daily (od) (50mg daily total)
Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)
Level 2 - 75mg bd (150mg daily total)
Level 3 - 100mg bd (200mg daily total)
Phase I has been completed and identified 75mg bd as the recommended phase II dose.
Phase II has begun and is utilising a dose of 75mg bd of selumetinib.
155529|NCT01759277|Drug|Experimental: Adductor Canal perineural local anesthetic infusion|The experimental group will receive an adductor canal catheter and block under ultrasound guidance with the final position of catheter between the femoral artery and nerve. Normal saline up to 10ml will be injected if necessary for hydro-dissection via the needle. The catheter will then be threaded 3-5cm past the needle tip and its location will be confirmed by a 30ml bolus of lidocaine 2% via the catheter under ultrasound visualization. The control group will receive a standardized general anesthetic with inhaled volatile anesthesia in nitrous oxide and oxygen or bupivacaine spinal anesthetic.
155530|NCT01759290|Device|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
155531|NCT01759303|Drug|pazopanib|For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.
For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.
155532|NCT01759316|Other|heliox|heliox or oxygen is used in the two groups respectively
155533|NCT01759329|Dietary Supplement|test coffee|test coffee with higher alkyl pyridine content
155534|NCT01759329|Dietary Supplement|control coffee|control coffee with regular alkyl pyridine content
155535|NCT01759342|Behavioral|Aerobic exercise|
155536|NCT01759342|Behavioral|Resistance exercise|
155537|NCT01759342|Behavioral|Flexibility and postural exercise|
154962|NCT01758185|Biological|Aleph influenza vaccine|0.5ml intramuscular
154963|NCT01758198|Biological|Abatacept|
154964|NCT01758198|Drug|Placebo matching with Abatacept|
154965|NCT00096174|Biological|cetuximab C225|400 mg/m^2 IV over 120 minutes on Day 1, 250 mg/m^2 IV over 60 minutes on Day 8, then weekly
154966|NCT01758198|Drug|Methotrexate|
154967|NCT01758211|Procedure|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
154968|NCT01760889|Drug|SPD489 high dose range (120mg, 140mg and 160mg)|Capsule, dose titration,
40 mg capsule once-daily for 1 week; then
80 mg capsule once daily for 1 week; then
120 mg capsule once-daily for 1 week, then,
140 mg capsule once-daily for 2 weeks, then
160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;
if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks
154969|NCT01760889|Drug|Placebo|One capsule a day for 26 weeks
154970|NCT01760902|Behavioral|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
154971|NCT01760941|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
154972|NCT01760941|Other|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
154973|NCT01760941|Other|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
154974|NCT01760954|Drug|Elagolix|Two different doses with matching placebo in 2 different arms daily over a 6 month treatment period
154975|NCT01760967|Drug|Dexmedetomidine|intervention to administer dexmedetomidine or not
155232|NCT00096200|Drug|Sorafenib Tosylate|Given orally
155233|NCT01758549|Other|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
155234|NCT01758562|Device|Caphosol|
155235|NCT01758588|Drug|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
155236|NCT01758601|Other|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
154741|NCT01754623|Other|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
154742|NCT01754623|Procedure|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
154743|NCT01754623|Drug|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
154744|NCT01754636|Other|No intervention|
154745|NCT01754649|Drug|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
154746|NCT01754662|Dietary Supplement|Soy protein|2 bars daily for 8 weeks.
154747|NCT01754662|Dietary Supplement|Isoflavones|2 bars daily for 8 weeks.
154748|NCT01754662|Dietary Supplement|Cocoa|2 bars daily for 8 weeks.
154749|NCT00095979|Drug|ixabepilone|Given IV
154750|NCT01754662|Dietary Supplement|Placebo|
154751|NCT01754675|Behavioral|Soccer|Watching the soccer match at the time that the favorite team is playing
154752|NCT01754675|Behavioral|Movie|Watching a movie at the time that the favorite team is playing
154753|NCT01754688|Other|Bilirubin Induced Neurologic Dysfunction II score|
154754|NCT01754701|Dietary Supplement|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
154755|NCT01754701|Dietary Supplement|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
154756|NCT01754714|Drug|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
155036|NCT01758211|Procedure|conventional resection|conventional resection in AVM patients
155037|NCT01758224|Other|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
154197|NCT01769105|Device|Lipiflow|Patients receive a single Lipiflow-treatment
154198|NCT01769105|Behavioral|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
154199|NCT01769118|Drug|Caffeine|Caffeine will be given according to departmental protocol
154200|NCT01769144|Device|Acticoat Absorbent|wound dressing
154201|NCT01769144|Device|BCT|wound dressing
154202|NCT01769157|Drug|L-carnitine|
154203|NCT01769157|Drug|Placebo|
154204|NCT01769170|Drug|Brincidofovir (CMX001)|
154205|NCT01769183|Drug|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
154206|NCT00097266|Drug|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
154207|NCT01769196|Drug|Simtuzumab (GS-6624)|Simtuzumab (GS-6624) 125 mg/mL single-dose vials administered subcutaneously weekly
154208|NCT01769196|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab single-dose vials administered subcutaneously weekly
154209|NCT01769209|Drug|bortezomib|Given SC
154210|NCT01769209|Drug|doxorubicin hydrochloride|Given IV
154211|NCT01769209|Drug|pegaspargase|Given IV or IM
154212|NCT01769209|Drug|vincristine sulfate|Given IV
154213|NCT01769209|Drug|dexamethasone|Given PO
154214|NCT01769209|Drug|cytarabine|Given IT
154215|NCT01769209|Drug|methotrexate|Given IT
154216|NCT01769222|Biological|ipilimumab|Given intratumorally
154217|NCT00097279|Drug|biphasic insulin aspart|
153650|NCT01768195|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.
In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis.
153651|NCT01768208|Drug|Saxagliptin|
153652|NCT01768221|Behavioral|Caregiver Intervention|Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.
The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.
In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist.
153653|NCT01768234|Other|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
153654|NCT01768247|Drug|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
153655|NCT01768260|Device|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
153970|NCT01761513|Drug|YH4808|Group3
adminitration of YH4808 dose2, bid for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of Nexium tab 40mg, bid for 2weeks
153971|NCT01761513|Drug|YH4808|Group 4
adminitration of Nexium tab 40mg, bid for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of YH4808 dose2, bid for 2weeks
153972|NCT01761526|Drug|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
153973|NCT01761539|Other|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
153974|NCT01761539|Other|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
153975|NCT01761552|Drug|Sugammadex Reversal|
153976|NCT00096382|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggyback daily over 15-20 minutes for 5 days
153977|NCT01761552|Drug|Atropine/Neostigmine|
153978|NCT01763905|Drug|Placebo to Ezetimibe|Tablet for oral administration
153979|NCT01763918|Biological|Evolocumab|Administered by subcutaneous injection
153980|NCT01763918|Drug|Placebo|Administered by subcutaneous injection
153981|NCT01763931|Drug|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
148448|NCT01712880|Procedure|one stage exchange|
148449|NCT01712893|Drug|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
148450|NCT01712893|Drug|chemotherapy (Anthrocyclin combined with or followed by Taxanes)|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should Switch to use Zoladex 3.6mg once a month after chemotherapy up to 2-3 years,all patients will receive Tamoxifen after chemotherapy
148451|NCT01712906|Biological|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
148452|NCT01712906|Biological|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
148453|NCT00092170|Drug|MK0826, ertapenem sodium|
148454|NCT01712906|Biological|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
148455|NCT01712906|Biological|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
148456|NCT01712906|Biological|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
148457|NCT01712919|Radiation|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
148757|NCT01708603|Drug|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
148758|NCT01708603|Drug|placebo|Placebo administered SC
148759|NCT01708616|Drug|RO5285119|multiple doses
148760|NCT01708616|Drug|RO5285119 placebo|multiple doses
148761|NCT01708616|Drug|risperidone|single dose
148762|NCT01708616|Drug|risperidone placebo|single dose
148763|NCT01708629|Drug|210 mg brodalumab|210 mg brodalumab administered SC
148764|NCT01708629|Drug|140 mg brodalumab|140 mg brodalumab administered SC
148765|NCT01708629|Drug|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
148766|NCT01708629|Drug|placebo|placebo administered SC
152259|NCT01727843|Other|placebo|applied topically to surgical site in OR.
152260|NCT01727856|Device|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
152261|NCT01727869|Drug|REGN1400|
152262|NCT01727869|Drug|Erlotinib|
152263|NCT01727869|Drug|Cetuximab|
152264|NCT01727882|Behavioral|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
152265|NCT00001812|Drug|Nystatin|
152266|NCT01730066|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.
Patients randomized 1:1 between groups
152267|NCT01730118|Biological|Autologous Ad HER2 dendritic cell vaccine|Autologous AdHER2 tranduced dendtitic cell vaccine manufactured under GMP conditions from cryopreserved patient monocytes here at hte NIH CC DTM. Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8 and 24 of the study.
152268|NCT00001827|Biological|incomplete Freund's adjuvant|
152269|NCT00093678|Drug|celecoxib|
152270|NCT01730157|Biological|ipilimumab|Given IV
152271|NCT01730157|Radiation|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
152272|NCT01730157|Other|laboratory biomarker analysis|Correlative studies
152273|NCT01730183|Other|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
152274|NCT01730196|Behavioral|Fit Body and Soul|
152275|NCT01730196|Behavioral|Wellness Education|
152885|NCT01723735|Drug|ezetimibe placebo|Pharmaceutical form:capsule Route of administration: oral
152886|NCT00093158|Drug|Angiomax (bivalirudin) anticoagulant|
152887|NCT01723735|Drug|fenofibrate|Pharmaceutical form:tablet Route of administration: oral
152034|NCT01724736|Drug|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
152035|NCT01724736|Drug|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
152036|NCT01724762|Other|Nursing Orientation|Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information
Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath
152037|NCT01724788|Drug|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
152038|NCT01724788|Drug|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
152039|NCT00093249|Drug|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
152040|NCT01724801|Radiation|whole brain radiation(WBI)|WBI : 30GY /10fractions/2weeks
152041|NCT01724801|Drug|Icotinib|Icotinib 125mg tid
152042|NCT01724814|Drug|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
152043|NCT01724814|Drug|Placebo|Singe dose SC administration of Placebo
152044|NCT01724827|Device|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
152045|NCT01724827|Device|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
152046|NCT01724840|Procedure|GraftJacket|Interposition with GraftJacket
152047|NCT01724840|Procedure|Tendon Interposition|Tendon Interposition with the FCR tendon
152048|NCT01724853|Procedure|Surgery|Resection suspension interposition arthroplasty or Arthrodesis
152049|NCT01724853|Other|Conservative|Injection
152050|NCT00093249|Drug|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
152051|NCT01724866|Drug|HM10460A (45 μg/kg)|Single-dose subcutaneous injection
152052|NCT01724866|Drug|HM10460A (135 μg/kg)|Single-dose subcutaneous injection
152709|NCT01725854|Behavioral|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
152710|NCT01725867|Other|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
152711|NCT01725867|Device|oral appliance|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
152712|NCT00093379|Drug|Capecitabine|825 mg/m^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
153064|NCT01762644|Drug|Oral Cyclosporine and Oral Omeprazole|
153065|NCT01762644|Drug|Oral Omeprazole|
153066|NCT01762657|Drug|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
153067|NCT01762657|Drug|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
153068|NCT01762670|Drug|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
153069|NCT01762670|Drug|Metronidazole|500 mg twice daily for 7 days
153070|NCT00096460|Drug|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
153071|NCT01762683|Other|Myometrium biopsy and blood samples|The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.
The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study.
153072|NCT01762696|Behavioral|MET|Motivational Enhancement Therapy only
153073|NCT01762696|Behavioral|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
153074|NCT01762709|Procedure|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
153075|NCT00096616|Drug|Combivent® CFC MDI|
152498|NCT01723059|Drug|Standard Triple Therapy|for 10 days
152499|NCT01723059|Drug|Sequential Therapy|total 10 days
152500|NCT01723072|Biological|Omalizumab|Humanized monoclonal antibody against human IgE
152501|NCT01723072|Drug|Placebo|Placebo to omalizumab
152502|NCT01723098|Behavioral|Exercise group|Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
152503|NCT01723124|Procedure|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
152504|NCT00001790|Drug|FK463|
152505|NCT00093093|Drug|Viramidine|
152778|NCT01723527|Behavioral|Employment-based drug abstinence reinforcement|
152779|NCT01723540|Procedure|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
152780|NCT01723553|Drug|C-11 PiB|One time intravenous administration of ~740 megabecquerel (MBq) of [N-methyl-C-11]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
152781|NCT01723579|Drug|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
152782|NCT01723579|Drug|Estradiol (E2)|Daily release of 1.5 mg
152783|NCT01723592|Dietary Supplement|Probiotics|oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains
152784|NCT01723592|Dietary Supplement|Oral lactose placebo|
152785|NCT01723605|Procedure|insitu repair|closure of the uterine incision while the uterus initu
152786|NCT01723605|Procedure|exteriorisation of the uterus|uterine closure while the uterus is exteriorised
152787|NCT01723618|Drug|CRD007|
152788|NCT00093145|Drug|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
152789|NCT01723631|Device|Trap Myelin Test|
151957|NCT01727180|Other|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
151958|NCT01727193|Drug|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
151959|NCT01727193|Drug|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
151960|NCT01727206|Drug|Tocilizumab|
151961|NCT01727245|Other|Obese|gastric bypass
151962|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
151963|NCT00093509|Drug|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
151964|NCT01727258|Device|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
151965|NCT01727258|Drug|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
151966|NCT01727258|Drug|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
151967|NCT01727271|Drug|Tenofovir|
151968|NCT01727271|Biological|Pegylated interferon alpha-2b|
151969|NCT01727284|Procedure|MR-guided cryoablation|
151970|NCT01727297|Device|REVEAL Implantable cardiac monitor|
151971|NCT01727336|Drug|Dalantercept and axitinib|
151037|NCT01735357|Dietary Supplement|EPA-rich triacylglycerol oil|
151038|NCT01735357|Dietary Supplement|Placebo - olive oil (BP specification)|
151039|NCT01735357|Dietary Supplement|DHA-rich triacylglycerol oil|
151040|NCT01735370|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
151041|NCT01735370|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
151042|NCT01735383|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
150804|NCT01739933|Drug|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS II study steering committee.
150805|NCT01739933|Drug|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS II study steering committee.
150806|NCT00094731|Procedure|Memory Training|
150807|NCT01739972|Drug|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
150808|NCT01739972|Drug|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
150809|NCT01739985|Drug|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
150810|NCT01739985|Drug|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
150811|NCT01739998|Dietary Supplement|functional oil|
150812|NCT01739998|Dietary Supplement|Placebo|
150813|NCT01740011|Procedure|Laparoscopic surgery|
150814|NCT01740024|Biological|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
150815|NCT01740037|Other|Specialized AF Clinic|
150816|NCT01740037|Other|Usual Care|
150817|NCT00094744|Device|Eye patch|adhesive eye patch used to cover the sound eye
150818|NCT01740050|Dietary Supplement|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
150819|NCT01740050|Procedure|RYGB|
150820|NCT01740050|Procedure|LAGB|
150821|NCT01740063|Drug|DAS181-F02 formulation|
151480|NCT01738568|Behavioral|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at ~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
151481|NCT01738568|Behavioral|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
151482|NCT01738581|Device|Repetitive Transcranial Magnetic Stimulation (Magstim)|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
151483|NCT00094575|Procedure|Standard Open Repair|Standard Open Repair
151484|NCT01738581|Behavioral|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
151485|NCT01738594|Drug|carfilzomib|Given IV
151486|NCT01738594|Drug|romidepsin|Given IV
151765|NCT01724307|Procedure|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
151766|NCT01724320|Drug|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
151767|NCT01724346|Other|Arm A - Post-Chlorambucil Therapy Follow-up|Patients remain in this Arm for continue follow-up until PD, unacceptable toxicity, or other reason for treatment discontinuation. All patients in this Arm have completed Chlorambucil therapy.
151768|NCT00093210|Drug|rFIX-R|
151769|NCT01726881|Device|Thermal stimulation|Stimulation using a Thermal Sensory Analyzer:
TSA 2001, Madock ltd., Ramat yishay, Israel.
151770|NCT01726881|Device|Mechanical stimulation|Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
151771|NCT01726881|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|A portable stimulator designed to Physical treatment of pain. TENS- Cefar rehab X2. Chattanooga group-A DJO Company.USA.
151772|NCT01726894|Device|Irreversible Electroporation|
151773|NCT01726907|Device|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
151265|NCT01731015|Drug|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
151266|NCT01731028|Drug|Somatropin|Somatropin powder and solvent for solution for injection
151267|NCT01731041|Drug|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
151268|NCT00001827|Biological|p53 peptide vaccine|
151269|NCT00093743|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
151270|NCT01731041|Drug|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
151271|NCT01731067|Drug|Cocktail probe drugs|
151272|NCT01731093|Drug|AT-001|
151273|NCT01731093|Drug|Placebo|
151274|NCT01731119|Drug|Latuda©|All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
151275|NCT01731132|Drug|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
151276|NCT01731145|Device|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
151277|NCT01731158|Drug|Avastin in combination with Roferon-A|
151278|NCT01731158|Drug|Afinitor|
151540|NCT01729247|Device|NIOX MINO® Instrument (09-1100)|
151541|NCT01729260|Drug|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
151542|NCT00093613|Other|pharmacological study|Correlative studies
151543|NCT01729273|Other|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
151544|NCT01729286|Device|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
151929|NCT01721915|Drug|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
151930|NCT01721915|Drug|Placebo|
151931|NCT01721928|Device|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
155055|NCT00096174|Radiation|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d * 7 weeks (35 fractions)
155056|NCT01758315|Other|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
155057|NCT01761266|Drug|Lenvatinib|Lenvatinib: 12 mg (or 8 mg) once daily (QD) oral dosing
155058|NCT01761266|Drug|Sorafenib|Sorafenib: 400 mg twice daily (BID) oral dosing
155059|NCT00096382|Biological|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count >1x10^9/1.
155060|NCT01761279|Procedure|High definition white light endoscopy|
155061|NCT01761292|Drug|Givinostat|
155062|NCT01761305|Procedure|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
155063|NCT01761305|Behavioral|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
155064|NCT01761305|Other|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
155065|NCT01761318|Drug|Liraglutide|Preparation and labelling of Investigational Medicinal Product:
Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
154550|NCT01760096|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
154551|NCT01760096|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
154552|NCT01760096|Drug|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
154553|NCT01760109|Drug|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
154554|NCT01760122|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
154555|NCT01760122|Drug|Pegasys|sc, qw, 48 weeks.
154556|NCT01760135|Dietary Supplement|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
154557|NCT01751555|Drug|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
154814|NCT01751997|Drug|Transplants from family-mismatched/haploidentical donors|Reduced-intensity conditioning
Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)
Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m^2)
Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)
ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)
GVHD prophylaxis
Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)
Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11
154815|NCT00095823|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
154816|NCT01752010|Other|Traditional Chinese Acupuncture|Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being "blocked." Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic.
154817|NCT01752010|Device|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
154818|NCT01754740|Drug|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
155538|NCT01759342|Behavioral|Balance exercise|
155539|NCT00096226|Drug|Consolidation Paclitaxel|
155540|NCT01759355|Procedure|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
155541|NCT01750905|Drug|Placebo|Vehicle (D5W) SQ
155542|NCT01750918|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
155543|NCT01750918|Drug|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
155544|NCT01750918|Drug|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
155545|NCT01750918|Drug|5-fluorouracil|5-fluorouracil-based chemotherapy
155546|NCT01750931|Drug|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH &amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
154612|NCT01757392|Biological|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
154613|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
154614|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
154615|NCT01757418|Drug|Immune Globulin Intravenous|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
154616|NCT01757418|Drug|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
154617|NCT00096291|Other|Doxorubicin followed by Paclitaxel|Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:
Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin
154618|NCT01760135|Dietary Supplement|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
154619|NCT01760148|Drug|interferon alpha 2b|Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.
Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.
155237|NCT01758601|Other|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
155238|NCT01758614|Procedure|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
155239|NCT01758614|Drug|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
155240|NCT01761084|Behavioral|Exercise and behaviour change strategies|cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day
postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)
perform muscle strengthening and balance training exercises ≥ 3 days a week
the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day.
155241|NCT00096369|Drug|tamoxifen citrate|
155242|NCT01761097|Device|Endocuff attachment|Endocuff
155243|NCT01761110|Behavioral|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
155244|NCT01761123|Biological|VXA-A1.1|
155245|NCT01761136|Biological|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
155246|NCT01761136|Biological|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
155247|NCT01761149|Drug|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
155248|NCT01761162|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
155249|NCT01761162|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
155250|NCT01761175|Procedure|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
155612|NCT01756430|Drug|Carvedilol SR 32mg, QD|Carvedilol SR 32mg QD for 4 weeks
With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
155613|NCT01759368|Device|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
155038|NCT01758224|Other|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
155039|NCT01758237|Device|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
155040|NCT01758237|Procedure|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
155041|NCT01758250|Other|Acoustic Radiation Force Impulse (ARFI)|
155042|NCT01758250|Other|Laser Doppler Flowmetry (LDF)|
155043|NCT01758250|Other|Laser Doppler Perfusion Imaging (LDI)|
155044|NCT00096174|Drug|cisplatin|75 mg/m^2 IV over 30-60 minutes starting day 15 every 3 weeks * 3 (Days 1, 22, and 43 of radiation therapy (RT))
155045|NCT01758250|Other|Optical Coherence Tomography (OCT)|
155046|NCT01758250|Other|Orthogonal Polarization Spectral Imaging (OPSI)|
155047|NCT01758250|Other|Nail fold video capillaroscopy (NVC)|
155048|NCT01758263|Drug|Metoprolol|Metoprolol, oral administration
155049|NCT01758263|Drug|Nebivolol|Nebivolol, oral administration
155050|NCT01758302|Behavioral|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
155051|NCT01758302|Behavioral|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
155052|NCT01758302|Other|Cookies|Participants are asked to taste test chocolate chip cookies
155053|NCT01758302|Other|Vegetables|Participants are asked to taste test raw celery or radishes
155054|NCT01758302|Behavioral|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
155317|NCT01758614|Drug|Clopidogrel|
155318|NCT01758627|Drug|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
154218|NCT01761994|Drug|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
154219|NCT01762020|Device|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
153255|NCT01764997|Drug|Adalimumab|Pharmaceutical form:solution Route of administration: subcutaneous
153256|NCT01764997|Drug|Methotrexate|Dispensed according to local practice.
153257|NCT01765010|Drug|Calcitriol|
153258|NCT01765010|Drug|Alfacalcidol|
153259|NCT01765010|Drug|Cholecalciferol|
153260|NCT01765010|Drug|Placebo|
153261|NCT01765023|Drug|Period I : atorvastatin, Period II : atorvastatin and metformin|
153262|NCT01765023|Drug|Period I : metformin, Period II : atorvastatin and metformin|
153263|NCT01765036|Drug|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
153264|NCT00096668|Drug|TOCOSOL(R) Paclitaxel|
153265|NCT01765088|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
153266|NCT01765088|Drug|α-IFN|3mIU (3million) D1，3，5
153267|NCT01765101|Other|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
153268|NCT01765101|Other|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
153269|NCT01765114|Drug|PEG-Formulation|
153270|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with Lambert Eaton myasthenic syndrome (LEMS)
153271|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
153982|NCT01763944|Behavioral|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
153983|NCT00096551|Drug|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
153984|NCT01763957|Behavioral|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
153985|NCT01763957|Behavioral|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
153986|NCT01763970|Radiation|SBRT|800 delivered in 5 fractions every day to total dose of 4000
153987|NCT01763983|Behavioral|Cognitive Behavioural Therapy|CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.
Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study.
153988|NCT01763983|Behavioral|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
154278|NCT01766882|Behavioral|Lower sodium intervention|1. Lower sodium intervention:
Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximatel >180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.
Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants.
154279|NCT01766882|Other|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
154280|NCT01766895|Other|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
154281|NCT01769222|Radiation|radiation therapy|Undergo local radiation therapy
154282|NCT01769222|Other|laboratory biomarker analysis|Correlative studies
154283|NCT01769235|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
148767|NCT00091715|Drug|placebo|placebo for 6 months followed by an open-label period
148768|NCT01708642|Drug|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
148769|NCT01708642|Drug|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
148770|NCT01708655|Other|Sweat Evaporimeter measurement|The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.
intracutaneous injection of 0.2 ml of atropine
Stimulation and inhibition of sweating in an adjoining "test" area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:
Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.
intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion
intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .
The procedure would take about 45 minutes.
148771|NCT01708668|Procedure|Epidural analgesia|
148772|NCT01708668|Procedure|Combined spinal-epidural analgesia|
148773|NCT01708668|Procedure|Continuous epidural infusion|
148774|NCT01700946|Drug|dexamethasone|given intravenously or orally
148775|NCT01700946|Drug|vincristine sulfate|given intravenously
148776|NCT01700946|Biological|rituximab|given intravenously
148777|NCT01700946|Drug|clofarabine|given intravenously
148778|NCT01700946|Drug|cyclophosphamide|given intravenously
148779|NCT00091026|Biological|cetuximab|Given IV
148780|NCT01700946|Drug|etoposide|given intravenously
149091|NCT01704001|Drug|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
149092|NCT01704027|Radiation|Simultaneous integrated boost intensity-modulated arctherapy|Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :
Pelvis : 55,5 Gy (1,85 Gy/fr)
Seminal vesicles : 66 Gy (2,2 Gy/fr)
Prostate : 72 Gy (2,4 Gy/fr)
149093|NCT00091182|Drug|oxaliplatin|Given IV
149094|NCT01704027|Drug|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
149095|NCT01704040|Drug|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
149096|NCT01704040|Drug|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
152888|NCT01723748|Drug|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
152889|NCT01723774|Drug|PD0332991|
152890|NCT01723774|Drug|Anastrozole|
152891|NCT01723774|Drug|Goserelin|
152892|NCT01723774|Procedure|Surgery (standard of care)|-Breast and axillary lymph node surgery
152893|NCT01723774|Procedure|Tumor biopsy|
152894|NCT01726140|Procedure|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be >200, the patient will stop the treatment.
152895|NCT01726140|Procedure|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be >200, the patient will stop the treatment.
152896|NCT00001806|Other|Genetic Education and Counseling|Individual Education and Counlseing
152897|NCT00093405|Drug|tanespimycin|
152898|NCT01726153|Behavioral|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
152899|NCT01726166|Procedure|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
152900|NCT01726166|Procedure|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
152901|NCT01726179|Device|Icon infiltration|Patients and their guardians will be instructed to use dental floss to remove dental biofilm in both proximal sites once a day and to brush teeth with fluorated toothpaste twice a day. Besides that, test lesion will be infiltrated with a low viscosity resin (Icon, DMG, Hamburg, Germany). The test lesions will be treated using Icon (DMG, Hamburg, Germany) following the instruction for use.
A sub-sample with children with indication for a composite restoration in at least one proximal surface will be selected for the analysis of dental anxiety and stress.
152918|NCT01729078|Dietary Supplement|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
152919|NCT01729091|Drug|Lenalidomide|10 mg by mouth daily Day -8 to Day -2.
152053|NCT01724866|Drug|HM10460A (270 μg/kg)|Single-dose subcutaneous injection
152336|NCT01727882|Behavioral|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
152337|NCT01727895|Dietary Supplement|Beta-glucan (Glucan #300®)|
152338|NCT01727908|Other|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
152339|NCT01727921|Device|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
152340|NCT01727921|Device|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
152341|NCT01727934|Drug|Miravirsen sodium|Subcutaneous injection
152342|NCT01727947|Other|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied > 13% of nuclear area) in each sample will be assessed.
152343|NCT01727960|Behavioral|Education and posture correction|a lecture concerning the fine posture for health and exercises
152344|NCT01727973|Drug|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
152345|NCT01727986|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
152346|NCT00093522|Procedure|conventional surgery|
152347|NCT01728025|Drug|Ranolazine|
152348|NCT01728038|Behavioral|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
152349|NCT01728051|Drug|Melphalan|
152350|NCT01728051|Device|Percutaneous Hepatic Perfusion|
152351|NCT01728064|Drug|Placebo|Placebo capsules
152352|NCT01728064|Drug|EPI-743 400 mg|
152353|NCT01728064|Drug|EPI-743 200 mg|
152354|NCT01728077|Drug|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
152355|NCT01728090|Other|hand sanitizer|alcohol-based, hydroalcoholic gel
152356|NCT01728103|Device|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
153076|NCT01764750|Drug|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
153077|NCT01764776|Drug|LDE225|LDE225
153078|NCT01764789|Other|questionnaire administration|Ancillary studies
153079|NCT01764789|Procedure|quality-of-life assessment|Patients will participate in a quality life assessment.
153080|NCT01764789|Procedure|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
153081|NCT01764789|Behavioral|behavioral intervention|Participate in multi-component biobehavioral intervention
153082|NCT01764789|Other|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
153083|NCT01764789|Other|educational intervention|Participate in multi-component biobehavioral intervention
152118|NCT01722266|Drug|Liraglutide|Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.
Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards.
152119|NCT01722266|Drug|Placebo|Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.
Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards.
152120|NCT01722279|Procedure|Bariatric surgery|
152121|NCT01722292|Drug|LY2940680|Administered orally
152122|NCT01722292|Drug|Carboplatin|Administered IV
152123|NCT01722292|Drug|Etoposide|Administered IV
152124|NCT01722292|Drug|Placebo|Administered orally
152125|NCT01722305|Drug|Dexamethasone|Given PO
152126|NCT01722305|Other|Laboratory Biomarker Analysis|Optional correlative studies
152127|NCT01722305|Other|Pharmacological Study|Optional correlative studies
152128|NCT01724866|Drug|Pegfilgrastim 6mg|Single-dose subcutaneous injection, per manufacturer's Prescribing Information
152129|NCT01724879|Drug|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
152790|NCT01723644|Other|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
152791|NCT01723644|Other|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
152792|NCT01725945|Behavioral|Dietary Approaches to Stop Hypertension dietary pattern|The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
152793|NCT01725958|Dietary Supplement|Nutritional supplement and protein shakes|
152794|NCT01725997|Procedure|hook plate|Surgery with hook plate followed by physiotherapy
153141|NCT01762709|Procedure|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
153142|NCT01762709|Procedure|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
153143|NCT01762722|Device|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
153144|NCT01762735|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
153145|NCT01762735|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
153146|NCT01762748|Drug|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
153147|NCT00096460|Drug|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
151043|NCT01735383|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
151044|NCT01735396|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
151045|NCT00094146|Drug|Sandostatin LAR Depot|
151046|NCT01735409|Drug|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
151047|NCT01735409|Drug|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
151048|NCT01735409|Drug|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
151049|NCT01737723|Device|Neurokeeper stroke detector|Monitoring stroke patients
151050|NCT01737736|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
151051|NCT01737749|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
151052|NCT00094497|Drug|Cisplatin|
151053|NCT01737762|Biological|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
151054|NCT01737762|Biological|Vehicle|
151055|NCT01737775|Procedure|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
151056|NCT01737788|Procedure|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
151057|NCT01737801|Procedure|Lung function test|Lung function test.
151058|NCT01737814|Drug|Saline|
151059|NCT01737814|Drug|MST-188|
151060|NCT01737827|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
151350|NCT01731275|Drug|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
151351|NCT00093743|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
150822|NCT00093821|Other|pharmacological study|Correlative studies
151122|NCT01735422|Drug|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
151123|NCT01735422|Drug|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
151124|NCT01735435|Other|Indirect Calorimetry|The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes.
151125|NCT01735448|Other|Focus group|Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.
The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.
We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research.
151126|NCT01735448|Other|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
151127|NCT01735448|Other|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
151128|NCT00094159|Drug|SNS-595|
151129|NCT01735461|Dietary Supplement|Calcium Carbonate|There is a regimen for dietary supplement intake that will be provided to study participants.
151130|NCT01735474|Other|Manual technique|A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.
The manual technique includes:
stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles.
151131|NCT01735474|Other|Placebo|Usual care
151132|NCT01735487|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
151774|NCT01726907|Device|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson & Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
151775|NCT00093483|Drug|cytarabine|IV over 1 hour every 12 hours on days 1-6
151776|NCT01726920|Drug|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
151777|NCT01726920|Drug|naratriptan|Tablets containing naratriptan 2,5 mg
151778|NCT01726920|Drug|naproxen|Tablets containing naproxen 500 mg
151779|NCT01726933|Drug|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
151780|NCT01726933|Drug|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
151781|NCT01726933|Drug|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
151782|NCT01726946|Drug|VX-135|12 weeks of VX-135
151783|NCT01726946|Drug|ribavirin|12 weeks of ribavirin
150880|NCT01737489|Behavioral|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
150881|NCT01737502|Drug|Auranofin|Given PO
150882|NCT00094484|Drug|Cinacalcet HCl|
150883|NCT01737502|Drug|Sirolimus|Given PO
150884|NCT01737502|Other|Laboratory Biomarker Analysis|Correlative studies
150885|NCT01737502|Other|Pharmacological Study|Correlative studies
150886|NCT01737515|Other|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
150887|NCT01737528|Procedure|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
150888|NCT01737541|Drug|Fluoxetine|
151545|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
151546|NCT01729299|Drug|Exendin (9-39)|
151547|NCT01729299|Drug|acyl ghrelin|
151548|NCT01729299|Drug|saline|
151549|NCT01729325|Behavioral|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
151550|NCT01729338|Drug|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles [10,12,14, etc.]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
151551|NCT01729338|Drug|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
151552|NCT01721135|Drug|GSK2190915 200mg|Film coated oral tablet
151553|NCT01721135|Drug|moxifloxacin 400mg|Film coated oral tablet
151554|NCT01721135|Drug|moxifloxacin placebo|Film coated oral tablet
151555|NCT01721135|Drug|GSK2190915 placebo|Film coated oral tablet
151556|NCT01721148|Drug|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
151557|NCT01721161|Biological|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
151558|NCT01721161|Drug|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
151846|NCT01724398|Other|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
151847|NCT01724398|Other|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
155066|NCT01761318|Drug|Liraglutide - Placebo|Preparation and labelling of Investigational Medicinal Product:
Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
155341|NCT01758861|Drug|EPO group|
155342|NCT00096226|Drug|Induction Paclitaxel|
155343|NCT01758861|Drug|Placebo|
155344|NCT01758874|Procedure|phlebotomy|repeated phlebotomy for 4 weeks
155345|NCT01750476|Drug|Depo-Provera|
155346|NCT01750489|Device|non-invasive ventilation (NIV)|
155347|NCT01750515|Device|Acupuncture|
155348|NCT01750541|Drug|Haloperidol|
155349|NCT01750541|Drug|Valproate|
155350|NCT01750554|Other|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
155351|NCT01750567|Drug|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
155352|NCT01750580|Drug|Lirilumab|
155353|NCT01750580|Drug|Ipilimumab|
155354|NCT00095693|Procedure|positron emission tomography|Correlative studies
155355|NCT01750593|Procedure|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
155356|NCT01750632|Procedure|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anaestesia.
155357|NCT01750645|Drug|Intradetrusor Injection of Type-A Botulinum Toxin|
155358|NCT01750645|Other|Other interventions analyzed according to protocol|Placebo
Different dosage of Type-A Botulinum Toxin injected
Anticholinergic drugs
155359|NCT01750684|Drug|AC105|
155360|NCT01750684|Other|Placebo|
154819|NCT01754753|Other|Telephone Friendship groups|
154820|NCT01754766|Drug|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
154821|NCT01754766|Other|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
154822|NCT01754779|Drug|Placebo|Matching placebo for both aims.
154823|NCT01754779|Dietary Supplement|Citric Acid|
154824|NCT01754779|Dietary Supplement|Potassium Citrate|
154825|NCT01754779|Drug|Indapamide|Aim 2
154826|NCT01754792|Dietary Supplement|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
154827|NCT01754805|Drug|ASP015K|oral
154828|NCT00096005|Drug|tanespimycin|Given IV
155084|NCT01752530|Other|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
155085|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
155086|NCT00095862|Drug|cyclophosphamide|
155087|NCT01752543|Drug|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
155088|NCT01752543|Drug|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
155089|NCT01752556|Procedure|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
155090|NCT01752556|Procedure|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
155091|NCT01755286|Drug|Placebo|Single intratympanic injection
155092|NCT01755286|Drug|Sham|Simulated single intratympanic injection
155093|NCT01755299|Other|Regular "5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
155094|NCT01755299|Other|Decaf "5-hour Energy"|Commercially available "5-Hour Energy Decaf" product in the amount that is packaged (1.93 fl. oz.)
154620|NCT01760161|Drug|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
154621|NCT01760161|Drug|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
154622|NCT01760174|Drug|Ropivacaine bolus in transversus abdominis plane catheter|Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.
In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours.
154623|NCT01760174|Drug|Bupivacain-infusion in epidural catheter|Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.
In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours
154624|NCT01760187|Drug|lomitapide|
154625|NCT01760213|Other|CBT delivered via Internet|
154626|NCT01760226|Drug|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|Day 1: Rituximab IV
Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.
Day 5: cyclophosphamide will be given in a vein
Days 1-5: prednisone given by mouth twice a day
G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved.
154627|NCT01760226|Drug|Methotrexate|CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.
CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.
DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:
2+ extranodal sites
elevated LDH,
MYC rearrangement OR
bone or marrow disease.
ALL OTHERS receive IT MTX cycles 3-6.
154893|NCT01760746|Other|Injection of Avastin / Lucentis, sampling aqueous humour|Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.
On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .
Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays.
154894|NCT01752010|Device|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
154895|NCT01752023|Drug|Arm A|Experimental Arm
154896|NCT01752023|Drug|Arm B|Active Comparator
155614|NCT01759381|Device|Negative pressure wound therapy (NPWT)|
155615|NCT01759394|Drug|Avatrombopag maleate 40 mg|Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:
Fed, Fed, Fasted; or
Fed, Fasted, Fed; or
Fasted, Fed, Fed
During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.
During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.
Randomization Phase consists of three single-dose treatment periods:
Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval.
155616|NCT01759407|Drug|Ropivicaine|
155617|NCT01759420|Drug|Ondansetron|4mg of intravenous ondansetron
155618|NCT01759446|Drug|Hydrocodone/Acetaminophen|
155619|NCT01759459|Drug|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
155620|NCT01759459|Drug|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
155621|NCT01759459|Drug|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
155622|NCT00096239|Drug|CP-547,632|
155623|NCT01759485|Drug|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
155624|NCT01759485|Drug|placebo|
155625|NCT01759498|Dietary Supplement|HYDRO|
155626|NCT01759498|Dietary Supplement|ACTIVE|
155627|NCT01759498|Dietary Supplement|HYDRO 2|
155628|NCT01759511|Drug|Simtuzumab|Simtuzumab 125 mg/mL administered subcutaneously
155629|NCT01759524|Drug|Bupivacaine|
155630|NCT01759524|Drug|Lidocaine|
154680|NCT01757509|Other|Intervention group|Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.
Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling.
155319|NCT01758640|Drug|Warfarin|Low dose warfarin of 5mg or less per day
155320|NCT00096213|Procedure|conventional surgery|surgery
155321|NCT01758640|Drug|phenindione|Phenindione of 100mg or less per day
155322|NCT01758653|Other|No study intervention|There is no study-related intervention.
155323|NCT01758666|Drug|Methotrexate,Calcium folinate|
155324|NCT01758679|Biological|Licartin and CIK|Licartin and CIK
155325|NCT01758718|Procedure|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
155326|NCT01758731|Drug|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
155327|NCT01758731|Drug|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
155328|NCT01758731|Radiation|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
155329|NCT01758744|Drug|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
155330|NCT01758757|Procedure|Vitrectomy|
155331|NCT00096226|Drug|Induction Carboplatin|
155332|NCT01758783|Drug|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
155333|NCT01758796|Procedure|Non-operative treatment|6 weeks in a cast. 4 weeks with partial weight bearing and last 2 weeks weight bearing as tolerated.
155334|NCT01758796|Procedure|Operative treatment|Open reduction and osteosynthesis with semi-tubular plate and cortical screws.
155335|NCT01758809|Procedure|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
155336|NCT01758809|Procedure|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
155337|NCT01758822|Other|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
155338|NCT01758835|Other|Splint 3 weeks|
155339|NCT01758835|Other|Cast 3 weeks|
155340|NCT01758835|Other|Cast 6 weeks|
153272|NCT01765153|Behavioral|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
153273|NCT01765153|Behavioral|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
153274|NCT01765166|Behavioral|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
153275|NCT01767506|Other|Surveillance and treatment with azithromycin of newcomer and traveler families|The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
153579|NCT01770925|Device|n-BiPAP|The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.
The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water).
153580|NCT01770925|Device|NIPPV|The NIPPV group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water).
153581|NCT00097383|Drug|ALIMTA plus Epirubicin|
153582|NCT01770938|Device|Effective light-emitting diode therapy|
153583|NCT01770938|Device|Placebo light-emitting diode therapy|
153584|NCT01770964|Drug|Pregabalin|
153585|NCT01770964|Drug|placebo|
153586|NCT01770964|Behavioral|Training Type A|
153587|NCT01770964|Behavioral|Training Type B|
153588|NCT01770977|Device|Light-emitting diode therapy|
153589|NCT01770977|Device|Placebo light-emitting diode therapy|
153590|NCT01770990|Behavioral|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
153591|NCT01770990|Behavioral|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
153592|NCT00097396|Biological|rF1V vaccine|
154284|NCT01769235|Drug|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
154285|NCT01769235|Drug|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
154286|NCT01769248|Device|Fine needle aspiration|Fine needle aspiration
154287|NCT01769248|Device|Fine needle biopsy|FNB
154288|NCT01769261|Other|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
154289|NCT01769261|Other|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
154290|NCT01769261|Other|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
154291|NCT00097279|Drug|pioglitazone|
154292|NCT01769274|Drug|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
154293|NCT01769274|Drug|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
154294|NCT01769300|Behavioral|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
153337|NCT01762969|Other|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
153338|NCT01762982|Drug|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
153339|NCT01762982|Drug|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
153340|NCT00096460|Procedure|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
153341|NCT01762982|Drug|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
153342|NCT01762982|Other|Empty Finn Chamber|Empty Finn Chamber
153343|NCT01762995|Drug|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
149097|NCT01704040|Drug|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
149098|NCT01704040|Drug|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
149099|NCT01704040|Other|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
149100|NCT01704066|Other|Training and education|
149101|NCT01704079|Drug|CTAP101 30 μg capsules|Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks. After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.
149102|NCT01704079|Drug|CTAP101 60 μg capsules|Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks. After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.
149103|NCT01704079|Drug|CTAP101 30 μg sugar pill capsule|Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks. After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.
149104|NCT00001748|Procedure|Peripheral blood progenitor cell transplant|
149105|NCT00091195|Drug|romidepsin|
149106|NCT01704079|Drug|CTAP101 60 μg sugar pill capsules|Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks. After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.
149107|NCT01704092|Drug|Dexmedetomidine|
149108|NCT01704105|Behavioral|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
149109|NCT01706432|Other|laboratory biomarker analysis|Correlative studies
149421|NCT01709292|Other|Post Surgery - Group B|Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
149422|NCT01709305|Drug|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily
149423|NCT01709305|Drug|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD)
149424|NCT01709305|Drug|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose)
149425|NCT00091845|Drug|AVI-4020 Injection|
152920|NCT00093600|Drug|midostaurin|
152921|NCT01729091|Drug|Melphalan|200 mg/m^2 by vein on Day -7.
152922|NCT01729091|Procedure|NK Cell Infusion|Natural Killer (NK) cell infusion on Day -5.
MTD (NK) Group: Once maximum tolerated dose level reached, 12 additional patients enrolled at the MTD and given IL-2.
152923|NCT01729091|Procedure|Stem Cell Infusion|Autologous stem cell infusion minimum cell dose of 2 e6 cells/kg on Day 0.
152924|NCT01729091|Drug|G-CSF|5 mcg/kg/day subcutaneously on Day 0, and continuing until evidence of an absolute neutrophil count (ANC) of 0.5 x 109/L per 3 consecutive days.
152925|NCT01729104|Drug|Carfilzomib|Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.
Phase II Starting Dose: MTD from Phase I.
152926|NCT01729104|Drug|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
152927|NCT01729104|Drug|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given weekly for 4 weeks every 6 months.
152928|NCT01729117|Other|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
152929|NCT01729117|Other|Standard Care|Standard Care only
152930|NCT01729130|Procedure|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
152931|NCT00093613|Drug|sorafenib tosylate|Given PO
152932|NCT00092846|Behavioral|Self-Management System|
152933|NCT01720901|Drug|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
152934|NCT01720940|Drug|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
152935|NCT01720940|Drug|intermittent vancomycin infusion|
152936|NCT01720953|Other|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
152937|NCT01720966|Procedure|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
151972|NCT01727336|Drug|Placebo and axitinib|
151973|NCT01727349|Other|HbA1c measurement|
152357|NCT00093548|Biological|alpha fetoprotein adenoviral vector vaccine|
152358|NCT01728116|Device|EndoBarrier|
152359|NCT01728116|Procedure|Sham Procedure|
152631|NCT01728480|Other|laboratory biomarker analysis|Correlative studies
152632|NCT01728506|Behavioral|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
152633|NCT01728519|Drug|AllerT SC|AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
152634|NCT00093587|Drug|cyclophosphamide|
152635|NCT01728519|Drug|AllerT ID|AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
152636|NCT01728519|Drug|Placebo SC|Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
152637|NCT01728519|Drug|Placebo ID|Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
152638|NCT01728532|Device|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
152639|NCT01728532|Device|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
152640|NCT01728558|Other|Early goal Directed Sedation|
152641|NCT01728558|Other|Standard care sedation|
152642|NCT01728571|Dietary Supplement|Vitamin D|
152643|NCT01728571|Dietary Supplement|fish oil|
152644|NCT01728571|Dietary Supplement|Vitamin D placebo|
152645|NCT00093587|Drug|cyclosporine|
152646|NCT01728571|Dietary Supplement|Fish oil placebo|
152647|NCT01728584|Drug|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
152648|NCT01728584|Other|Insufflation|Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.
Standard insufflation pressure - a starting pressure of 12 mmHg will be used.
Low insufflation pressure - a starting pressure of 8 mmHg will be used.
152130|NCT01724892|Drug|Dexamethasone|
152131|NCT01724892|Drug|Loteprednol etabonate|
152132|NCT01724905|Dietary Supplement|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
152133|NCT01724905|Dietary Supplement|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
152134|NCT01724918|Drug|Lacosamide|
152135|NCT00093262|Drug|clevidipine|
152136|NCT01724931|Drug|LD-aminopterin|
152137|NCT01724931|Drug|placebo|
152422|NCT00093327|Procedure|Acupuncture|
152423|NCT01725477|Drug|methylene blue|
152424|NCT01725477|Drug|metheylne blue with normal saline|
152425|NCT01725490|Drug|metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
152426|NCT01725503|Dietary Supplement|Creatine and Amino Acid supplement|
152427|NCT01725516|Procedure|Myofascial release technique|
152428|NCT01725529|Drug|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
152429|NCT01725529|Drug|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms [μg] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
152430|NCT01725529|Drug|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is < 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
152431|NCT01725529|Drug|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
152432|NCT01725542|Drug|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
152433|NCT00093353|Drug|cefixime|
152434|NCT01725555|Drug|Fasted treatment: AXL1717|
153148|NCT01762761|Drug|eltrombopag|TPO-R agonist
153149|NCT01762761|Drug|placebo|placebo
153150|NCT01762774|Drug|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
153151|NCT01762774|Drug|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
153152|NCT01762787|Drug|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
153153|NCT01762787|Drug|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
153154|NCT01762787|Drug|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
153155|NCT01762787|Drug|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
153156|NCT01762787|Drug|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
153157|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
152191|NCT01729949|Dietary Supplement|Placebo Treatment Beverage|without active components
152192|NCT00093015|Drug|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
152193|NCT01722305|Drug|Pomalidomide|Given PO
152194|NCT01722318|Drug|Plecanatide|
152195|NCT01722318|Drug|Placebo|
152196|NCT01722331|Drug|MK-3222 200 mg|
152197|NCT01722331|Drug|MK-3222 100 mg|
152198|NCT01722331|Drug|Matching Placebo|
152199|NCT01722344|Behavioral|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
151352|NCT01731275|Drug|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
151353|NCT01731301|Drug|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
151354|NCT01731301|Drug|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
151355|NCT01731301|Drug|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
151356|NCT00093912|Drug|clevidipine|
151357|NCT01733797|Device|Wooden spatula|Lollipop sticks placed between incisors
151358|NCT01733797|Device|Therabite|Hand held device placed in mouth that exercises the jaw
151359|NCT01733810|Other|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
151360|NCT01733823|Radiation|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
151361|NCT01733836|Drug|Metformin|
151362|NCT01733836|Drug|placebo|
151363|NCT01733849|Other|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
151364|NCT01733849|Other|Data collection|Log books
151365|NCT01733862|Other|Data collection|Data sheet. Data will be collected and is planned to be analysed at the following time points:
Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016.
151366|NCT01733875|Drug|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
151623|NCT01729442|Other|Shear-wave ultrasound elastography (SWUE)|
151624|NCT01729455|Biological|BENLYSTA|As prescribed.
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus.
151133|NCT01735487|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
151134|NCT01735487|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
151416|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
151417|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
151418|NCT01731340|Dietary Supplement|Calcium Citrate|750mg
151419|NCT01731340|Other|Low Dietary Calcium|450 mg
151420|NCT01731340|Other|High Dietary Calcium|1200 mg
151421|NCT00093743|Drug|mycophenolate mofetil|Given PO or IV
151422|NCT01731366|Other|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
151423|NCT01731366|Other|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
151424|NCT01731379|Procedure|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
151425|NCT01731392|Dietary Supplement|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
151426|NCT01731392|Dietary Supplement|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
151427|NCT01731392|Dietary Supplement|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
151428|NCT01731418|Behavioral|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, & Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
151429|NCT01731418|Other|Treatment-as-usual|
151430|NCT01731431|Other|Insulin|
151431|NCT01731431|Drug|Glyburide|
151432|NCT00093756|Radiation|3-dimensional conformal radiation therapy|
150889|NCT01739699|Drug|Acetaminophen|
150890|NCT01739699|Drug|Placebo|
150891|NCT01739712|Behavioral|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
150892|NCT01739725|Device|Stent insertion|The patient will receive the helical stent
150893|NCT01739738|Device|Ureteral Stent|patients who need to receive stent as per standard of care
150894|NCT00094718|Biological|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
150895|NCT01739751|Device|pedometers|portable device that estimate the number of steps walked daily
150896|NCT01739764|Drug|vemurafenib|960 mg orally BID or, if the dose was reduced in an antecedent protocol, the dose of the last visit of the antecedent study (minimum 480 mg orally BID)
150897|NCT01739777|Biological|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
150898|NCT01739777|Other|Controls|Autologous Serum will administrated as placebo
150899|NCT01739790|Drug|N-Acetylcysteine|1800 mg twice daily for 8 weeks
150900|NCT01739790|Drug|Identical Placebo manufactured to mimic appearance of intervention drug with identical frequency and duration|
151200|NCT01733537|Other|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
151201|NCT01733537|Behavioral|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
151202|NCT00001827|Procedure|in vitro-treated peripheral blood stem cell transplantation|
151203|NCT00093886|Drug|clevidipine|
151204|NCT01733550|Device|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
151205|NCT01733550|Device|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
151206|NCT01733550|Device|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
151207|NCT01733563|Procedure|Soft drink consumption|
151208|NCT01733576|Device|HD-tDCS|
151848|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m^2 ABI-007, administered IV, administered after placement of denovo stent(s).
151849|NCT01724398|Other|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
151850|NCT01724411|Other|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
151851|NCT01724424|Drug|Melatonin|20 mg oral single dose
151852|NCT01724424|Drug|Melatonin|30 mg oral single dose
151853|NCT01724424|Drug|Melatonin|50mg oral single dose
151854|NCT01724424|Drug|Melatonin|100mg oral single dose
151855|NCT01724437|Device|catheter based pulmonary vein isolation|catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
151856|NCT01724450|Drug|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
151857|NCT01724450|Drug|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
151858|NCT01724463|Other|Severe Sepsis Management Bundle|Management Bundle includes:
Securing Intravenous Access
Obtaining Blood Culture
Antibiotic Administration
Goal Directed Fluid Bolus Therapy
Oxygen Administration
Measuring Serum Lactate Levels
151859|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|
151860|NCT01724476|Drug|folate with B12|
151861|NCT01724476|Drug|placebo|
151862|NCT01724489|Drug|Growth hormone|
151863|NCT01726998|Other|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
151864|NCT01727011|Radiation|IPAS|
151865|NCT01727024|Drug|Tiotropium|Tiotropium via Spiriva Respimat® device once a day
151866|NCT01727024|Drug|Indacaterol|Indacaterol via Onbrize Breezhaler® device once a day
151867|NCT01727037|Procedure|Bronchoscopic intrabullous autologous blood instillation|
150957|NCT01737567|Other|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
155361|NCT01750697|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv on Days 1, 8, 15 and 22
155362|NCT01750723|Drug|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
155363|NCT01750736|Other|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
155364|NCT01750736|Other|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
155709|NCT01759628|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
155710|NCT01759641|Device|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
155711|NCT00001886|Procedure|Real time 3-dimensional stress echocardiography|
155712|NCT00096265|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
155713|NCT01759654|Biological|AdimFlu-V|
155714|NCT01759667|Other|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
155715|NCT01759680|Device|Vibrosphère device|Vertical Sinusoidal vibration
155716|NCT01759693|Procedure|Blood sampling|Blood sampling
155717|NCT01759706|Behavioral|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
155718|NCT01759706|Procedure|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
155719|NCT01759706|Drug|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
155720|NCT01759706|Other|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
155095|NCT01755299|Other|Compounded concentrated caffeine liquid|Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular "5-hour Energy"
155096|NCT01755299|Other|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
155097|NCT00096044|Drug|lenalidomide|Oral
155098|NCT01755312|Device|Medication reminder|Medication reminder
155099|NCT01755325|Drug|Compound realgar natural indigo Tablet|Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.
imatinib,0.4g,qd
155100|NCT01755325|Drug|placebo|
155101|NCT01755338|Drug|Methylprednisolone|Methylprednisolone 15mg/kg
155102|NCT01755338|Drug|Placebo|Placebo
155103|NCT01755364|Biological|AdimFlu-V|
155104|NCT01755377|Drug|Benznidazole|
155105|NCT01755390|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
155106|NCT01755403|Drug|Benznidazole|
155464|NCT00095719|Drug|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
155465|NCT01750905|Drug|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
155466|NCT01753115|Biological|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
155467|NCT01753115|Drug|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
155468|NCT01753128|Drug|imipramine|
155469|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation|
155470|NCT00095888|Other|laboratory biomarker analysis|Correlative studies
155471|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
155472|NCT01753154|Drug|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
154897|NCT01752036|Radiation|Stereotactic Radiotherapy (SRS)|600 cGy x 5 fractions
154898|NCT01752049|Drug|Topical timolol maleate|Topical timolol maleate 0.5% drops
Applied twice daily for 12 weeks (84 days) or until disappearance of lesions
Study drops will be applied to 4 cutaneous telangiectasias per patient (timolol drops for 3 telangiectasia per patient and placebo drops to 1 telangiectasia per patient).
154899|NCT01752049|Drug|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient.
154900|NCT01752075|Drug|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
154901|NCT01752127|Procedure|percutaneous coronary intervention using drug eluting stent|1. Intracoronary stenting
The procedure could be conducted via brachial, radial or femoral approaches.
There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.
When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.
Direct stenting or bifurcation stenting is allowed.
Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator.
154902|NCT00001862|Drug|Enbrel|
154903|NCT00095823|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
154904|NCT01752140|Procedure|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
154905|NCT01752140|Procedure|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
154906|NCT01752153|Drug|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
155165|NCT01752582|Device|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
155166|NCT01752582|Device|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
155167|NCT01752595|Behavioral|Preference Based Rhythmic Auditory Stimulation Music|Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned "background" sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most.
155168|NCT01752595|Other|Preference Based Music Intervention|
154681|NCT01757535|Drug|300 mg Oral Azacitidine|Maintenance therapy
154682|NCT01757535|Drug|Placebo|
154683|NCT01757548|Procedure|open operation|high ligation of spermatic vein by open operation
154684|NCT01757548|Procedure|microsurgery|high ligation of spermatic vein by microsurgery
154685|NCT01757561|Procedure|propofol|use total intravenous anesthesia with propofol
154686|NCT01757561|Procedure|sevoflurane|use inhalation anesthesia with sevoflurane
154687|NCT00096148|Drug|cytarabine|Given IV
154688|NCT01757574|Drug|Alemtuzumab infusion|
154689|NCT01757587|Drug|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
154690|NCT01757587|Drug|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
154691|NCT01757600|Other|Microperimetry|
154692|NCT01757613|Drug|AK 3012|cutaneous use twice a day
154693|NCT01757626|Biological|Hu3F8 With GM-CSF|One cycle consists of treatment with hu3F8 for 3 days (day 1, 3 and 5). GM-CSF is started 5 days in advance of each hu3F8 cycle at 250 mcg/m^2/day (day -4 to day 0), and at 500 mcg/m^2/day x 5 days (day 1 to day 5). Cycles are 5 days. Cycles are repeated at 2-4 week intervals between first days of hu3F8, through 4 cycles. Patients who complete 4 cycles of treatment without complications or disease progression have the option of continuing treatment for up to 24 months from their first dose of hu3F8.
154694|NCT01757639|Biological|Ipilimumab|Given IV
154695|NCT01757639|Other|Laboratory Biomarker Analysis|Correlative studies
154696|NCT01757665|Device|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
154697|NCT01757678|Device|Measured FFR|Fractional Flow Reserve
154698|NCT00096148|Biological|bevacizumab|Given IV
154699|NCT01760226|Drug|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
154700|NCT01760226|Drug|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
154976|NCT01760980|Drug|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
155688|NCT01756495|Drug|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
155689|NCT01756495|Drug|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
155690|NCT01756495|Drug|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
155691|NCT01756495|Drug|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
155692|NCT01756508|Drug|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
155693|NCT01756521|Drug|Moxifloxacin|
155694|NCT01756534|Device|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
155695|NCT00096135|Drug|cyclophosphamide|IV over 15-30 minutes
155696|NCT01756547|Drug|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
155697|NCT01756547|Drug|Placebo|
155698|NCT01756560|Drug|dexamethsone|
155699|NCT01756560|Drug|Bupivacaine|
155700|NCT01756573|Drug|Dexamthsone|
155701|NCT01756573|Drug|Bupivacaine|
155702|NCT01759576|Drug|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
155703|NCT01759589|Drug|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
155704|NCT01759589|Drug|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
155705|NCT01759589|Drug|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
155706|NCT01759602|Drug|C1-esterase inhibitor (Cinryze)|
153593|NCT01771003|Device|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
153594|NCT01771042|Other|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
153595|NCT01771055|Procedure|Galactose|Galactose dripped into the abdomen after surgery
153596|NCT01771055|Procedure|Standard surgical methods|
153597|NCT01771068|Behavioral|Triple P Positive Parenting Program Discussion Group "Dealing with Disobedience"|
153598|NCT01771081|Drug|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
153599|NCT01771094|Behavioral|Effect of sweetness of the beverage in thirst sensation|Effect of sweetness of the beverage in thirst sensation:
The participants will drink Water (control group),"High Sucralose" - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and "Low Sucralose" - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
153909|NCT01766167|Drug|MP-424|High
153910|NCT01766167|Drug|MP-424|Multiple
153911|NCT01766180|Drug|Fruitflow-II|150 mg/day for 3 months, orally
153912|NCT01766180|Drug|resVida|150 mg/day for 3 months, orally
153913|NCT01766193|Procedure|vaginal delivery|
153914|NCT01766193|Procedure|forceps extraction|vaginal delivery by forceps extraction
153915|NCT00096837|Drug|Motexafin Gadolinium Injection|
153916|NCT01766193|Procedure|vacuum extraction|vaginal delivery by vacuum extraction
153917|NCT01766193|Procedure|cesarean section|
153918|NCT01766206|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
153919|NCT01766219|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
153920|NCT01766245|Drug|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
153921|NCT01766258|Drug|ODM-101 65mg Carbidopa|
153344|NCT01762995|Drug|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
153345|NCT00001894|Procedure|pacemaker implantation|
153346|NCT00096694|Device|Levonorgestrel-releasing intrauterine device (IUD)|
153347|NCT01765179|Drug|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
153348|NCT01765192|Drug|Roflumilast|Roflumilast was supplied in tablets.
153349|NCT01765192|Drug|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
153350|NCT01765192|Drug|Montelukast|Montelukast was supplied in tablets.
153351|NCT01765205|Device|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
153352|NCT01765218|Drug|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
153353|NCT01765218|Drug|Placebo|A placebo identical in appearance to the active agent (topiramate)
153354|NCT01765231|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
153355|NCT01765231|Drug|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
153356|NCT01765244|Other|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors and biomaterials
153656|NCT01768260|Drug|Aspirin|Standard drug therapy
153657|NCT01768273|Drug|Midazolam|
153658|NCT01768273|Drug|PA-824|
153659|NCT00097110|Drug|Vitamin C and E|
153660|NCT01768286|Drug|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
153661|NCT01768286|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
149426|NCT01709305|Drug|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily)
149427|NCT01709305|Drug|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily)
149428|NCT01709305|Drug|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose)
149429|NCT01709318|Drug|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
149430|NCT01709318|Drug|Etonogestrel (ENG)|Daily release of 75, 100, or 125 μg
149431|NCT01709318|Drug|Ethinyl estradiol (EE)|Daily release of 15 μg
149432|NCT01709318|Drug|Estradiol (E2)|Daily release of 300 μg
149433|NCT01709331|Drug|MK-8962|MK-8962, 150 μg corifollitropin alfa per 0.5 mL subcutaneous (SC) injection, once every 2 weeks for 52 weeks
149434|NCT01709331|Drug|hCG|hCG, 1500-3000 international units (IU), SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and in combination with MK-8962 for 52 weeks (combined treatment phase)
149435|NCT01709344|Behavioral|PS-OT|
149436|NCT00091858|Drug|Darbepoetin Alfa|6.75 mcg/kg Q4W
149437|NCT01709344|Other|Usual care|Supportive and rehabilitation services available at DHMC
149438|NCT01709357|Other|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
149439|NCT01709357|Other|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
148458|NCT01712919|Drug|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
148459|NCT01712919|Biological|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
148460|NCT01712945|Drug|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
151974|NCT00093509|Drug|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
151975|NCT01727349|Other|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
151976|NCT01727362|Other|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
151977|NCT01727362|Other|Usual care|Patients of this group receive usual care only
151978|NCT01727375|Other|Circadian light|Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.
Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation.
151979|NCT01727388|Procedure|lateral decubitus|
151980|NCT01727388|Procedure|supine decubitus|
151981|NCT01729988|Procedure|Carotid body excision|This surgery does not involve any study drug or investigational device.
The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation.
151982|NCT01730001|Procedure|Early Intubation|
151983|NCT01730001|Procedure|Late intubation|
151984|NCT00093665|Drug|fluorouracil|
151985|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
151986|NCT01730014|Drug|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
151987|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
151988|NCT01730014|Drug|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
151989|NCT01730014|Drug|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
152276|NCT01730209|Drug|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
152649|NCT01728584|Drug|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
152650|NCT01728610|Dietary Supplement|Probiotic (Active high)|Higher dose of probiotic supplement
152651|NCT01728610|Dietary Supplement|Probiotic (Active low)|Lower dose of probiotic supplement
152652|NCT01728610|Dietary Supplement|Placebo|Placebo
153002|NCT01726452|Drug|Cisplatin|60mg/m2 on day 1 of each cycle only (i.e. every 21 days).
153003|NCT01726452|Drug|5 Flourouracil/ Capecitabine|5 Flourouracil(200 mg/m2/Day)as a continuous intravenous infusion every day for 21 days/3 weeks, Capecitabine (625 mg/m2 twice daily orally)for 21 days/3 weeks. The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator. 5 Flourouracil/ Capecitabine are given daily for the duration of each cycle (i.e. for 9 weeks pre-surgery and for 9 weeks post-surgery).
153004|NCT01726452|Radiation|(41.4 Gy/23 fractions)|patient will receive 5 weeks of radiation therapy (41.4 Gy/23 fractions).
153005|NCT01767155|Drug|doxorubicin|60 mg/m2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
153006|NCT01767168|Other|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
153007|NCT01767181|Other|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
153008|NCT01767181|Other|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
153009|NCT01767194|Biological|Dinutuximab|Given IV
153010|NCT00096967|Drug|Avastin (bevacizumab)|
153011|NCT01767194|Drug|Irinotecan Hydrochloride|Given IV
153012|NCT01767194|Other|Laboratory Biomarker Analysis|Optional correlative studies
153013|NCT01767194|Biological|Sargramostim|Given SC or IV
153014|NCT01767194|Drug|Temozolomide|Given PO
153015|NCT01767194|Drug|Temsirolimus|Given IV
153016|NCT01767207|Other|screening for psychological disorders|screening for psychological disorders
153017|NCT01767207|Behavioral|screening for psychological disorders|screening for psychological disorders
152435|NCT01725555|Drug|Fed treatment: AXL1717|
152436|NCT01725568|Device|BioMonitor|Implantable cardiac monitor
152437|NCT01728142|Device|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
152438|NCT01728142|Other|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
152439|NCT01728155|Drug|chemotherapy|
152440|NCT01728181|Drug|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
152441|NCT01728181|Drug|Erlotinib|150 mg/day for 28 day cycle. No rest period.
152442|NCT01728181|Other|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
152443|NCT00093548|Biological|alpha fetoprotein plasmid DNA vaccine|
152713|NCT01725880|Other|Observation|
152714|NCT01725906|Drug|empirical therapy|Nexium (esomeprazole), 40mg, bid, 14 days, plus
Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus
Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs
Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
152715|NCT01725906|Drug|Genotypic resistance guided therapy|Nexium (esomeprazole), 40mg, bid, 14 days, plus
Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus
Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs
Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
152716|NCT01725919|Behavioral|CI therapy|constraint induced movement therapy
152717|NCT01725932|Behavioral|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
152718|NCT01728636|Drug|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
152200|NCT01722344|Behavioral|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
152201|NCT01722357|Behavioral|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
152202|NCT01722357|Behavioral|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
152203|NCT00093028|Drug|CC-5013 (Revlimid™)|N/A Study Complete
152204|NCT01722370|Drug|Oxygen|
152205|NCT01722370|Drug|Medical air equivalent|
152206|NCT01722396|Dietary Supplement|Vitamin D|
152207|NCT01722409|Drug|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
152208|NCT01722409|Drug|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
152209|NCT01722422|Drug|oxygen and saline|
152210|NCT01722435|Drug|Opiate Substitution Treatment|
152211|NCT01722448|Dietary Supplement|Choline|4 capsules with 480 mg choline per day
152506|NCT01723150|Drug|Ciprofloxacin|
152507|NCT01723150|Drug|Ceftriaxone|
152508|NCT01723150|Drug|Trimethoprim/sulfamethoxazole|
152509|NCT01723150|Drug|Ertapenem|
152510|NCT01725581|Procedure|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
152511|NCT01725594|Drug|CAT 2003|
152512|NCT01725594|Drug|Placebo|
152513|NCT01725607|Drug|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
151625|NCT01729455|Other|SLE treatment|As prescribed.
At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated.
151626|NCT01729468|Drug|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
151627|NCT01729468|Drug|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
151628|NCT01729481|Drug|Gemcitabine|1000 mg/m² iv weekly
151629|NCT01721304|Other|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
151630|NCT01721317|Drug|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
151631|NCT00092885|Drug|Comparator: placebo|
151632|NCT01721317|Drug|Placebo|Matching placebo will be available
151633|NCT01721330|Drug|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
151634|NCT01721330|Drug|Placebo|Placebo twice a day for 6 weeks
151635|NCT01721343|Behavioral|telephone-based intervention|Undergo telephonic monitoring
151636|NCT01721343|Other|case management|Participate in an individualized conditioning program with an RCM
151637|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
151638|NCT01721343|Procedure|physical therapy|Participate in an individualized conditioning program with an RCM
151639|NCT01721343|Other|questionnaire administration|Ancillary studies
151640|NCT01721343|Procedure|quality-of-life assessment|Ancillary studies
151641|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care
151642|NCT00092898|Drug|MK0653, ezetimibe|
151643|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care
151644|NCT01721343|Other|educational intervention|Participate in an individualized conditioning program with an RCM
151645|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM
151433|NCT01731444|Drug|Phenylephrine|
151434|NCT01731457|Drug|etanercept|adding appropriate dose of etanercept to the perfusion fluid
151435|NCT01731470|Biological|Liposomes|Intravesical instillation of liposomes.
151436|NCT01731496|Other|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
151708|NCT01729481|Drug|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
151709|NCT01729494|Drug|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
151710|NCT01729494|Drug|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
151711|NCT01729494|Drug|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
151712|NCT01729494|Drug|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
151713|NCT01729494|Drug|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
151714|NCT01729494|Drug|early cessation of steroids|Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:
Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids
151715|NCT01729507|Other|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
151209|NCT01733589|Drug|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
151210|NCT01733602|Device|transcranial direct current stimulation|
151211|NCT01733654|Biological|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
151212|NCT01735487|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
151213|NCT01735513|Device|Intra-aortic embolic protection management system; Embol-X|The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients "embolic showers" which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream.
151214|NCT01735539|Dietary Supplement|15g EAA bolus|Oral; in aqueous solution
151215|NCT00094172|Drug|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
151216|NCT01735539|Dietary Supplement|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
151217|NCT01735539|Dietary Supplement|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
151218|NCT01735591|Dietary Supplement|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
151487|NCT01738594|Other|laboratory biomarker analysis|Correlative studies
151488|NCT01738607|Dietary Supplement|Psyllium|
151489|NCT01738607|Dietary Supplement|Gum Arabic|Gum acacia dietary fiber
151490|NCT01738607|Dietary Supplement|carboxymethylcellulose|dietary fiber
151491|NCT01738607|Dietary Supplement|Placebo|
151492|NCT01738620|Behavioral|psychological counseling|
151493|NCT01738620|Behavioral|prevention of sleep disorders in ICU|
151494|NCT00094614|Drug|Atropine|
151495|NCT01738633|Behavioral|nutritional counseling|
150958|NCT01737567|Other|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
150959|NCT00094497|Drug|Etoposide|
150960|NCT01737580|Drug|resiquimod|
150961|NCT01737580|Drug|placebo gel|
150962|NCT01737593|Drug|Acetaminophen|
150963|NCT01737606|Device|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
150964|NCT01737619|Procedure|PET/CT Scan|PET/CT scan before surgery and sentinel lymph node mapping procedure.
150965|NCT01737619|Procedure|Sentinel Lymph Node Mapping|Blue dye, a radioactive colloid, and/or an indocyanine green (IC-Green) dye injected into cervix during surgery.
150966|NCT01737632|Behavioral|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
150967|NCT01737632|Behavioral|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
150968|NCT01737658|Other|Exercise Program|Exercise Program for Obese Adolescents
150969|NCT01737671|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
150970|NCT00094497|Drug|Doxorubicin|
150971|NCT01737671|Drug|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
150972|NCT01737671|Drug|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
150973|NCT01737684|Drug|MK-4618|50 mg tablet, oral
150974|NCT01737697|Drug|Zirconium silicate (acute phase)|
150975|NCT01737697|Drug|Zirconium silicate (subacute phase)|
150976|NCT01737710|Biological|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
155721|NCT01759706|Drug|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
155722|NCT01759706|Drug|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
155723|NCT01751113|Drug|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
155724|NCT01751113|Drug|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
155725|NCT01751113|Drug|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
155726|NCT00095745|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
154757|NCT01754714|Drug|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
154758|NCT01754714|Drug|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
154759|NCT01754740|Drug|Uréia|The subjects were randomly divided into two groups:
1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months.
154760|NCT00001864|Device|Patch|
154761|NCT00095992|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
154762|NCT01757691|Drug|Fingolimod 0.5mg/daily|
154763|NCT01757691|Drug|Placebo|
154764|NCT01757704|Procedure|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
154765|NCT01757704|Procedure|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
154766|NCT01757717|Radiation|Ir-192 high dose rate (HDR)|Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
154767|NCT01757756|Drug|Pf-05175157|200-mg administered twice daily for 14 days
155473|NCT01753154|Drug|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
155474|NCT01753167|Drug|Placebo|repeating doses of matching placebo to RG7667
155475|NCT01753167|Drug|RG7667|repeating doses of RG7667
155476|NCT01753180|Biological|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
155477|NCT01753180|Drug|saline|Local intra-coronary administration of saline at or into the CTO
155478|NCT01753193|Biological|MEDI-546|MEDI-546, IV q4wks for 104 weeks
155479|NCT01753219|Procedure|Onstep|
155480|NCT01753219|Procedure|Lichtenstein|
155481|NCT00095888|Other|pharmacological study|Correlative studies
155482|NCT01753232|Device|DALI-adsorber|Recording of treatment data. No extra interventional treatment
155483|NCT01753232|Device|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
155484|NCT01753271|Other|thoracic mobilization & shoulder mobilization & exercise|
155485|NCT01753271|Other|shoulder mobilization & exercise|
154558|NCT01751568|Drug|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) twice daily.
154559|NCT01751581|Behavioral|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
154560|NCT01751581|Behavioral|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
154561|NCT01751594|Behavioral|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
154562|NCT01751594|Behavioral|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
155169|NCT01752608|Behavioral|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
155170|NCT00095875|Drug|carboplatin|Given IV
155171|NCT01752634|Drug|Secukinumab (AIN457)|Secukinumab (AIN457)
155172|NCT01752634|Drug|Placebo|Placebo PFS for s.c. administration.
155173|NCT01752647|Procedure|Low dose computed tomography|Low dose computed tomography scan
155174|NCT01752660|Behavioral|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
155175|NCT01752660|Behavioral|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
155176|NCT01752673|Other|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
155177|NCT01752673|Other|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
155178|NCT01752686|Drug|carboplatin|carboplatin as adjuvant chemotherapy
155179|NCT01752699|Drug|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
155180|NCT01752699|Drug|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
155181|NCT00095875|Drug|cisplatin|Given IV
155182|NCT01752712|Drug|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
155183|NCT00001865|Drug|Daclizumab|
155547|NCT01750931|Drug|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
155548|NCT01750944|Procedure|Ankle first|Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).
A 15 minute walking test (WT) is performed.
BBP-LR and BPA-LR are re-measured.
2 hours of rest.
BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.
WT is reperformed.
BBP-LR and BPT-LR are re-measured.
154977|NCT01760980|Drug|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
154978|NCT00096356|Dietary Supplement|Placebo & Vitamin E|
154979|NCT01760993|Drug|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
154980|NCT01761006|Device|NIOX MINO®|
154981|NCT01761019|Drug|Taclonex Topical Suspension|topical medication for psoriasis
154982|NCT01761032|Device|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
154983|NCT01761045|Dietary Supplement|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
154984|NCT01761045|Dietary Supplement|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
154985|NCT01761045|Dietary Supplement|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
154986|NCT01761071|Drug|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
154987|NCT01761071|Drug|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
154988|NCT01752192|Device|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
154989|NCT01752205|Drug|Paclitaxel|45mg/m2/w,total 6 weeks
154990|NCT01752205|Drug|Erlotinib|150mg/d,days 1-42,total 6 weeks
154991|NCT01752205|Radiation|Radiation therapy|
154992|NCT01752218|Device|arcuate incision|
155707|NCT01759615|Other|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
155708|NCT01759615|Other|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
154474|NCT01751490|Other|physiotherapy|physiotherapy
154475|NCT01751490|Procedure|shoulder stabilisation surgery|arthroscopic stabilisation surgery
154476|NCT01751503|Procedure|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
154477|NCT01751503|Procedure|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
154478|NCT01751529|Procedure|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
154479|NCT00095784|Drug|Decitabine|Given SC
154480|NCT01751529|Drug|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
154481|NCT01751542|Behavioral|Mindfulness + Residential Treatment|
154482|NCT01751542|Behavioral|Residential treatment alone|
154483|NCT01754090|Behavioral|Online multi session follow-up|An online multi session follow-up program (i.e., "Balance"). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group).
154484|NCT01754103|Other|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
154485|NCT01754116|Drug|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
154486|NCT01754116|Drug|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
154487|NCT01754116|Drug|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
153922|NCT01766258|Drug|ODM-101 105mg Carbidopa|
153923|NCT01766258|Drug|Stalevo|
153924|NCT01766271|Behavioral|Health Coaching|biweekly health coaching for 5 months
153925|NCT01766271|Genetic|9p21|Genetic testing results of 9p21
153926|NCT00096850|Drug|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
153927|NCT01766271|Other|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
153928|NCT01766284|Device|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
153929|NCT01766297|Radiation|Proton Radiotherapy|
153930|NCT01766310|Drug|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
153931|NCT01766310|Drug|placebo|sugar tablet manufactured to mimic folic acid tablet
153932|NCT01766323|Drug|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
154220|NCT01762033|Drug|ASONEP|Intravenous infusion
154221|NCT01762046|Drug|Glipizide|
154222|NCT00096395|Other|laboratory biomarker analysis|Correlative studies
154223|NCT01762046|Drug|Metformin|
154224|NCT01762046|Other|Oral Glucose Tolerance Test|
154225|NCT01762059|Device|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
154226|NCT01762059|Other|Usual care|
154227|NCT01762072|Dietary Supplement|Fish oil|
154228|NCT01762072|Dietary Supplement|vitaminB12|
154229|NCT01762085|Procedure|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
148702|NCT01703221|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
148703|NCT01703221|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 50 mg tablet administered orally once daily
148704|NCT01703234|Drug|Ramipril|ramipril 10 mg/day during 3 months
148705|NCT01703247|Procedure|Pulmonary vein isolation|
148706|NCT01703247|Procedure|Ganglionated plexi ablation|
148707|NCT01703247|Procedure|Linear Lesion Ablation|
148708|NCT01703260|Drug|Roflumilast|Roflumilast dose
148709|NCT01703260|Drug|Pioglitazone|Pioglitazone dose
148710|NCT01703260|Drug|Placebo|Pioglitazone placebo-matching dose
148711|NCT01703260|Drug|Placebo|Roflumilast placebo-matching dose
148712|NCT00091143|Biological|incomplete Freund's adjuvant|
148713|NCT01703273|Behavioral|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
148714|NCT01703273|Behavioral|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
148715|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
148716|NCT01703286|Drug|Linagliptin|given once daily for 28 days
149028|NCT00091442|Drug|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
149029|NCT01706380|Behavioral|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
149030|NCT01706380|Behavioral|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
149031|NCT01706393|Dietary Supplement|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
148461|NCT01712945|Drug|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
148462|NCT01712984|Biological|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
148463|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
148464|NCT00092170|Drug|Comparator: Ticarcillin/Clavulanate|
148465|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
148466|NCT01712997|Drug|Iloprost|
148467|NCT01712997|Drug|Bosentan|
148468|NCT01713010|Other|Predictive indexes of weaning from mechanical ventilation|
148469|NCT01713023|Dietary Supplement|Glucose|The same described in Arm description
148470|NCT01715285|Drug|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
148471|NCT01715285|Drug|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
148472|NCT01715285|Other|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
148473|NCT01715285|Drug|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
148474|NCT01715285|Drug|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
148475|NCT00092339|Drug|Comparator: valdecoxib, placebo|
148476|NCT01715298|Drug|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
148477|NCT01715298|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
148781|NCT01700946|Biological|aldesleukin|given subcutaneously
148782|NCT01700946|Drug|pegaspargase|given intravenously
148783|NCT01700946|Drug|methotrexate|given intrathecally or intravenously
152277|NCT01730209|Drug|Placebo|
152278|NCT01730222|Drug|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
152279|NCT01730222|Drug|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
152280|NCT00093678|Procedure|anticachectic therapy|
152281|NCT01730222|Drug|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
152282|NCT01730222|Drug|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
152283|NCT01730235|Other|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
152284|NCT01730248|Drug|INC424|5 mg tablets administered orally twice daily
152285|NCT01730248|Drug|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
152286|NCT01730261|Behavioral|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
152287|NCT01730287|Drug|Control|The teeth in this group restored only by filling material,without liner application.
152288|NCT01722487|Drug|PCI-32765|PCI-32765 will be supplied as hard gelatin 140-mg capsules for oral (PO) administration.PCI-32765 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. PCI-32765 will be dispensed to patients in bottles at each visit.
152289|NCT01722487|Drug|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration.Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
152290|NCT01722513|Drug|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
152291|NCT01722526|Drug|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
152292|NCT01722539|Drug|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
153018|NCT01767220|Procedure|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
153019|NCT01767220|Procedure|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
153020|NCT01767233|Procedure|ERCP and pancreatic stenting|
152054|NCT01727401|Drug|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
152055|NCT01727414|Drug|OROS-Methylphenidate|capsule; dosages - 18mg, 27mg, 36mg, 54 mg; frequency - each AM; duration - one week for each dose, with each child receiving 3 doses [children < 25 kg receive 18mg, 27mg, 36mg; children > or = to 25kg get 18mg, 36mg, 54mg]
152056|NCT01727414|Drug|Placebo|capsule, frequency - each AM, duration - 1 week
152057|NCT01727427|Drug|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
152058|NCT00093509|Procedure|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
152059|NCT01727453|Drug|warfarin|Warfarin in anticoagulant dose
152060|NCT01727453|Drug|Bemiparina|Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer.
152061|NCT01727466|Behavioral|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
152062|NCT01727479|Other|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
152063|NCT01727479|Other|Placebo|
152064|NCT01727492|Drug|Antioxidantia|
152719|NCT01728649|Other|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermogaurd XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 43cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
152720|NCT00001818|Drug|Hydroxyurea|
152721|NCT00093587|Procedure|allogeneic bone marrow transplantation|
152722|NCT01728662|Procedure|ELVR Procedure|Lung Volume Reduction Procedure
152723|NCT01728675|Other|Exercise|Participants will perform two isokinetic eccentric exercise bouts
152724|NCT01728688|Other|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
152725|NCT01728688|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
152726|NCT01728701|Biological|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
152727|NCT01728701|Biological|Normal Saline (NS)|Normal saline
152728|NCT01728727|Other|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
152729|NCT01728727|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
153084|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in enhanced standard care
153085|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in psychological intervention
153086|NCT00096616|Drug|Albuterol HFA MDI|
153087|NCT01764815|Device|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
153088|NCT01764828|Drug|Refametinib (BAY86-9766)|
153089|NCT01764828|Drug|Gemcitabine|
153090|NCT01764841|Drug|Ciprofloxacin DPI (BAYQ3939)|
153091|NCT01764841|Drug|Placebo|
153092|NCT01764854|Drug|AZD1722|doses between 5 and 90 mg may be administered based on tolerability
152514|NCT01725607|Procedure|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
152515|NCT01725620|Drug|LBEC0101 (Etanercept 25mg)|
152516|NCT01725620|Drug|Enbrel (Etanercept 25mg)|
152517|NCT00093353|Drug|irinotecan hydrochloride|
152518|NCT01725633|Behavioral|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
152519|NCT01725633|Behavioral|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
152520|NCT01725633|Other|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
152521|NCT01725633|Other|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
152522|NCT01725646|Drug|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
152523|NCT01725646|Drug|Placebo|Subjects in placebo group will take this drug
152524|NCT01725659|Other|Motor Learning|training of the hemiplegic upper limb with motor learning
152525|NCT01725659|Other|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
152526|NCT01725659|Other|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
152795|NCT01725997|Other|Physiotherapy|Patients will be following a program specific for AC joint dislocations
152796|NCT01726010|Device|22-G Procore Needle|
152797|NCT00093379|Drug|Oxaliplatin|50 mg/m^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
152798|NCT01726023|Drug|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
152799|NCT01726023|Drug|metronidazole|Metronidazole 500mg/100ml solution for infusion
152800|NCT01726023|Drug|Meropenem|Meropenem powder for solution for infusion 1000mg
152801|NCT01726036|Device|Gomco Circumcision Clamp|
150748|NCT01732718|Drug|Placebo for atorvastatin|Inactive substance in tablet form made to mimic atorvastatin 40mg tablet
150749|NCT01732731|Other|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
150750|NCT01732744|Other|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
150751|NCT01732744|Other|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
150752|NCT01732744|Other|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
150753|NCT00001827|Biological|therapeutic autologous dendritic cells|
150754|NCT01734876|Behavioral|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
150755|NCT01734876|Behavioral|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
150756|NCT01734889|Drug|Nitisinone|Oral suspension
150757|NCT00094081|Drug|cisplatin|
150758|NCT01734902|Drug|Hyoscine butylbromide|sugar coated tablets for oral administration
150759|NCT01734902|Drug|Hyoscine butylbromide|drops for oral administration
150760|NCT01734915|Device|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
150761|NCT01734928|Drug|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
150762|NCT01734928|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
151716|NCT01729507|Behavioral|standardised behavioural therapy|The standardised behavioural therapy will be performed according to the certified "Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.
1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session.
151717|NCT00093639|Drug|imatinib mesylate|
151718|NCT01721434|Drug|Levosimendan|
151719|NCT01721434|Drug|Placebo|Similar coloured placebo
151720|NCT01721447|Drug|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
150823|NCT01732744|Other|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
150824|NCT01732757|Drug|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
150825|NCT01732757|Drug|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
150826|NCT01732757|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
150827|NCT01732770|Biological|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
150828|NCT01732770|Drug|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
150829|NCT01732770|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
150830|NCT01732770|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
150831|NCT01732783|Other|Observational|Observational of the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer
150832|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
150833|NCT00093821|Other|laboratory biomarker analysis|Correlative studies
150834|NCT01732796|Drug|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
150835|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
151496|NCT01738633|Behavioral|respirology counseling|
151497|NCT01738646|Drug|Vorinostat|
151498|NCT01738646|Drug|Bevacizumab|
151499|NCT01738659|Dietary Supplement|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
151500|NCT01738672|Drug|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
151501|NCT01731522|Behavioral|EF condition|
151502|NCT01731548|Radiation|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
151503|NCT01731561|Drug|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
151504|NCT01731561|Drug|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
151505|NCT00093756|Drug|bortezomib|Given IV
151506|NCT01731574|Drug|dapivirine|
151507|NCT01731574|Drug|miconazole|
151508|NCT01731587|Other|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
151509|NCT01731587|Drug|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
151784|NCT01726985|Other|Parameter Based Clinical Disposition|Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:
NT-ProBNP reduction of > 23% from peak value during admission
Fluid Reduction of > 1.3L (orders for I/O q8h required)
Serum Sodium of > 135 mmol/L the day of planned discharge
151785|NCT01726998|Other|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
151786|NCT00001810|Drug|Voriconazole|
151787|NCT00093483|Drug|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
151279|NCT01733667|Device|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
151280|NCT01733667|Device|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
151281|NCT00093886|Drug|nitroglycerin|
151282|NCT01733680|Drug|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
151283|NCT01733680|Behavioral|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
151284|NCT01733693|Drug|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
151285|NCT01733693|Drug|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
151286|NCT01733706|Device|No nicotine electronic cigarette|The e-cigarette "T-FUMOTM" is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine.
151287|NCT01733706|Other|Standard counseling|standard counseling
151288|NCT01733719|Procedure|ER plus RFA|
151289|NCT01733719|Procedure|ER plus APC|2 litres/minute, 70 watts
151290|NCT01733732|Other|SYSTANE® BALANCE Lubricant Eye Drops|
151291|NCT01733732|Other|SYSTANE® Gel|
151292|NCT00093899|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
151293|NCT01733745|Other|SYSTANE® Lid Wipes|Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
151294|NCT01733745|Other|SYSTANE® BALANCE|Lubricant Eye Drops
151295|NCT01733745|Dietary Supplement|SYSTANE® Vitamins|
151296|NCT01733745|Other|Microfiber towels (as warm compresses, with or without saline eye drops)|
154768|NCT01757756|Drug|placebo|placebo administered twice daily for 14 days
154769|NCT01757756|Drug|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
154770|NCT01757769|Drug|Silodosin|8 mg daily for 24 weeks
154771|NCT01757782|Drug|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be <10% of previous value and SpO2 was not increasing >5 of previous value) and blood pressure remained stable
154772|NCT00096148|Other|laboratory biomarker analysis|Correlative studies
154773|NCT01757782|Drug|Placebo (distilled water)|
155365|NCT00095693|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
155366|NCT01750749|Biological|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
155367|NCT01750762|Drug|Lenalidomide|
155368|NCT01750775|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
155369|NCT01750775|Drug|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
155370|NCT01750788|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
155371|NCT01752894|Device|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
155372|NCT01752894|Drug|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (>6%) at 3months OCT follow up after stent implantation.
155373|NCT01752894|Drug|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
155374|NCT01752907|Other|General Education DVD|A general chemotherapy side effects education DVD
155375|NCT01752907|Other|Bone Pain Education DVD|
154563|NCT01751620|Behavioral|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
154564|NCT00095784|Other|Laboratory Biomarker Analysis|Correlative studies
154565|NCT01751620|Behavioral|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
154566|NCT01751633|Procedure|Surgical|
154567|NCT01751633|Procedure|Conservative treatment|
154568|NCT01751646|Dietary Supplement|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
154569|NCT01751646|Dietary Supplement|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
154570|NCT01751672|Behavioral|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
154571|NCT01751672|Behavioral|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
154572|NCT01751685|Behavioral|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
154573|NCT01751685|Other|Control|monthly educational lectures on various topics
154829|NCT01754805|Drug|Methotrexate|oral
154830|NCT01754818|Drug|Bendavia 10mg|
154831|NCT01754818|Drug|Bendavia 50mg|
154832|NCT01754818|Drug|Bendavia 100mg|
154833|NCT01754818|Drug|Placebo|
154834|NCT01754831|Device|Fluoride varnish|Topical application of fluoride varnish on present teeth
154835|NCT01754844|Drug|AZD7624|Single dose inhaled IMP via a nebulizer
154836|NCT01754844|Drug|Placebo to match|Single dose inhaled Placebo via a nebulizer
154837|NCT01754857|Drug|Bendamustine Hydrochloride|Given IV
155549|NCT01750944|Procedure|Toe first|Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).
A 15 minute walking test (WT) is performed.
BBP-LR and BPT-LR are re-measured.
2 hours of rest.
BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.
WT is reperformed.
BBP-LR and BPA-LR are re-measured.
155550|NCT00095719|Drug|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
155551|NCT01750957|Drug|Placebo|orally daily, 12 weeks
155552|NCT01750957|Drug|RO4917523|Dose A orally daily, 12 weeks
155553|NCT01750957|Drug|RO4917523|Dose B orally daily, 12 weeks
155554|NCT01750970|Other|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
155555|NCT01750983|Drug|Ipilimumab|Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.
Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group.
155556|NCT01750983|Drug|Lenalidomide|Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.
Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group.
155557|NCT01750996|Behavioral|Strongest Families|Behavioural intervention
155558|NCT01751009|Dietary Supplement|Vitamin A supplements|Sprinkles with Vitamin A
155559|NCT01751009|Dietary Supplement|Sprinkles without Vitamin A|Active comparator
155560|NCT01751022|Device|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead
155561|NCT01753362|Drug|placebo|
155562|NCT01753375|Dietary Supplement|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
155563|NCT01753375|Dietary Supplement|Placebo|Placebo to be given orally on weekly basis
155564|NCT01753388|Device|Liberty Stent|
155565|NCT01753401|Drug|Acthar|Acthar given SC (40 U daily or 80 U every other day) for Weeks 1-4 and tapered for Weeks 5-8
155566|NCT01753401|Drug|Placebo for Acthar|Placebo contains the same inactive ingredients as H.P. Acthar Gel with the API. Placebo is given SC for 6 months in equal volume as the Acthar comparator.
154628|NCT00096291|Other|Paclitaxel followed by Doxorubicin|Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:
Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin
155251|NCT01761175|Procedure|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
155252|NCT00000278|Drug|Disulfiram|
155253|NCT00001889|Procedure|Stress echocardiography with dobutamine|
155254|NCT00096382|Biological|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
155255|NCT01761188|Procedure|Ablation|electrophysiology substrate mapping is the critical difference between both groups
155256|NCT01761201|Drug|Levofloxacin|Levofloxacin
155257|NCT01761201|Drug|Isoniazid|300 mg/day for 9 months beginning after transplantation, when the "liver function is stable" and not before 3 months nor after 6 months.
155258|NCT01761214|Drug|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
155259|NCT01761214|Drug|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
155260|NCT01761227|Drug|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
155261|NCT01761227|Drug|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
155262|NCT01761240|Drug|MORAb-066|
155263|NCT01752712|Drug|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
155264|NCT01752725|Device|BiCision®|
155265|NCT01752725|Device|Ultracision® Har-monic Scalpel(Ethicon)|
155266|NCT01752764|Other|Test product: Salad with a high dosage fat|
155267|NCT01752764|Other|Control product: Salad with low dosage fat|
155268|NCT01752777|Behavioral|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
155269|NCT01752777|Behavioral|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
154488|NCT01754116|Drug|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
154489|NCT01754116|Drug|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
154490|NCT01754155|Radiation|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
154491|NCT00095940|Other|pharmacological study|Correlative studies
153528|NCT01763268|Biological|Trivivac vaccine|Trivalent MMR vaccine
153529|NCT01763281|Drug|CRH|
153530|NCT01763281|Drug|Placebo|
153531|NCT01763294|Device|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
153532|NCT01763294|Device|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
153533|NCT01763294|Device|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
153534|NCT01763294|Device|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
153535|NCT01763294|Device|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
153536|NCT01765530|Device|ETT cleaning maneuver|The ETT cleaning maneuver will be performed through the endOclear device. This is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.
We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period.
153537|NCT01765543|Drug|rifampin|multiple doses of rifampin in Period B and C
154230|NCT01762124|Device|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
154231|NCT01762137|Procedure|Flow Diversion|Endovascular flow diverter placement
154232|NCT01762137|Procedure|Coiling|Endovascular coil placement
154233|NCT00096408|Procedure|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
154234|NCT01762150|Drug|Sorafenib|Sorafenib 400mg BID by oral until progressed;
154235|NCT01762150|Drug|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30~60min on Day 1 and 8,for 4 cycles;
154236|NCT01762150|Drug|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
154237|NCT01762163|Drug|Qizhitongluo Capsule|
154238|NCT01762163|Drug|Naoxintong Capsule|
154239|NCT01762163|Drug|Aspirin Enteric-coated Tablets|
154240|NCT01762163|Behavioral|the routine recovery training|
154241|NCT01762163|Drug|placebo|
154242|NCT01762176|Procedure|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
154243|NCT01762176|Procedure|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
153276|NCT01767519|Biological|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
153277|NCT01767519|Drug|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
153278|NCT01767519|Drug|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
153279|NCT01767519|Drug|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
153280|NCT01767532|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
153281|NCT01767532|Drug|Cephalexin 125 mg/5ml|Test product 20 ml
153282|NCT01767545|Drug|Dexamethasone implant|
149032|NCT01706393|Dietary Supplement|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
149033|NCT01706406|Behavioral|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
149034|NCT01706419|Dietary Supplement|Fortified rice cold extruded kernel|
149035|NCT01706419|Dietary Supplement|fortified rice warm extruded kernel|
149036|NCT01706419|Dietary Supplement|fortiified rice hot extruded kernel|
149037|NCT01706432|Radiation|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
149038|NCT01708941|Other|Laboratory Biomarker Analysis|Correlative studies
149039|NCT01708941|Biological|Recombinant Interferon Alfa-2b|Given IV or SC
149040|NCT01708954|Drug|Cabozantinib S-malate|Given PO
149041|NCT01708954|Drug|Erlotinib Hydrochloride|Given PO
149042|NCT01708954|Other|Laboratory Biomarker Analysis|Correlative studies
149043|NCT01708967|Procedure|pretreatment method for transnasal endoscopy|Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).
Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity.
149044|NCT01708980|Other|Six different strength training exercises|Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.
The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
149360|NCT01701882|Drug|tenofovir/emtricitabine/rilpivirine|
149361|NCT01701921|Drug|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
149362|NCT01701921|Drug|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
149363|NCT01701921|Drug|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
149364|NCT01701934|Drug|Roflumilast|500 mcg, oral, once daily for 6 months
148784|NCT01700946|Drug|mercaptopurine|given orally
148785|NCT01700946|Drug|cytarabine|given intrathecally or intravenously
148786|NCT01700946|Drug|mitoxantrone|given intravenously
148787|NCT01700946|Drug|teniposide|given intravenously
148788|NCT01700946|Drug|vinblastine|given intravenously
148789|NCT01700946|Biological|natural killer cell infusion|undergo allogeneic natural killer cell infusion
148790|NCT00091026|Drug|gemcitabine hydrochloride|Given IV
148791|NCT01700946|Other|laboratory biomarker analysis|correlative studies
148792|NCT01700946|Drug|therapeutic hydrocortisone|given intrathecally
148793|NCT01700946|Procedure|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
148794|NCT01700959|Drug|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
148795|NCT01700959|Drug|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
148796|NCT01700972|Procedure|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
148797|NCT01700985|Drug|122-0551|Applied twice daily for two weeks
148798|NCT01700985|Drug|Vehicle|Applied twice daily for two weeks
148799|NCT01700998|Drug|Magnesium|
148800|NCT01700998|Drug|Placebo|
148801|NCT00091026|Biological|bevacizumab|Given IV
148802|NCT01701011|Behavioral|Coping intervention|Positive reappraisal coping intervention
148803|NCT01701024|Drug|ACYC|
148804|NCT01701024|Drug|ACYC vehicle|
148805|NCT01703351|Drug|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
152573|NCT01720329|Other|probiotic placebo|Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
152574|NCT01720342|Procedure|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
152575|NCT01720394|Device|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
152576|NCT01720394|Drug|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
152577|NCT00092781|Drug|MK0663, etoricoxib|
152578|NCT01720407|Drug|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
152579|NCT01720407|Drug|vehicle + surgery|vehicle (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
152580|NCT01720420|Device|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
152581|NCT01720433|Procedure|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
152582|NCT01720446|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
152583|NCT01720446|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
152584|NCT01723163|Behavioral|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
152585|NCT01723163|Behavioral|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
152586|NCT01723176|Procedure|Echocardiography|
152587|NCT01723202|Drug|dabrafenib|150 mg orally twice daily given orally
152588|NCT01723202|Drug|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
152065|NCT01727505|Device|volume guarantee ventilation|The study will consist of two arms. In one arm, a 24-hour period during which the infant receives conventional mechanical ventilation and a second 24 hour period during which the infant receives volume guarantee ventilation.
In the other Arm, a 24-hour period during which the infant receives volume guarantee ventilation and a second 24 hour period during which the infant receives conventional mechanical ventilation.
These two arms will be assigned at random. Both conventional and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).
During the 24 hour period of conventional ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.
During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study.
152066|NCT01727531|Drug|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
152067|NCT01727544|Procedure|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
152068|NCT01727557|Procedure|regional anesthesia|Regional anesthesia will be compared to local anesthesia
152069|NCT00093509|Radiation|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of > 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
152360|NCT01728129|Device|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
152361|NCT01728129|Other|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
152362|NCT01730495|Drug|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
152363|NCT01730521|Behavioral|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
152364|NCT01730534|Drug|Dapagliflozin 10 mg|Oral dose (od)
152365|NCT01730534|Drug|Placebo tablet|Oral dose (od)
152366|NCT01730547|Biological|Autologous mesenchymal stem cells|
152367|NCT01730560|Other|Treatment A|The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.
The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.
Each treatment phase has the same pattern:
two visits in pre-tests evaluation (V1 and V2),
one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),
two visits after treatment (V4 at one week and V5 at one month).
153093|NCT01764867|Drug|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
153094|NCT01764867|Drug|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
153095|NCT01764867|Other|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
153096|NCT01764867|Other|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
153097|NCT00096629|Biological|human prostate-specific membrane antigen plasmid DNA vaccine|
153098|NCT01764867|Drug|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153099|NCT01764867|Drug|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153100|NCT01764867|Drug|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153101|NCT01767285|Drug|Etonogestrel implant|This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
153102|NCT01767298|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
153103|NCT01767298|Drug|Valsartan|Valsartan alone
153104|NCT01767298|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
153105|NCT00096993|Drug|Placebo|Placebo was provided as a single-use formulation for infusion.
152138|NCT01724944|Procedure|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
152139|NCT01724957|Procedure|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
152140|NCT01724970|Device|ProSeal|Patients will be ventilated with PLMA
152141|NCT01724970|Device|Supreme LMA|Patients will be ventilated with SLMA
152802|NCT01726036|Device|Mogen Circumcision Clamp|
152803|NCT01726049|Drug|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
152804|NCT01726049|Drug|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
152805|NCT01726062|Behavioral|Motivational Interviewing plus Incentives|Two hospital-based, face-to-face MI+ sessions
Two home-based MI+ sessions
Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge
152806|NCT01726062|Behavioral|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
152807|NCT01726075|Drug|COLIRIOBCN070660|One drop per eye twice a day during 24 months
152808|NCT00093379|Radiation|Radiation Therapy (XRT)|Undergo radiotherapy* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. *Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
152809|NCT01726075|Drug|Placebo|One drop per eye twice a day during 24 months
152810|NCT01726075|Drug|Brimonidine|One drop per eye twice a day during 24 months
152811|NCT01726088|Drug|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
152812|NCT01726114|Device|Non-invasive Optical Glucose Monitor™|Test device
152813|NCT01726114|Device|YSI blood glucose analyzer|Reference device
152814|NCT01726127|Other|Broccoli and Brussels Sprouts|
152815|NCT01726127|Dietary Supplement|Cruciferous Complete|
152816|NCT01726127|Other|Placebo|
152817|NCT00093587|Radiation|radiation therapy|
152818|NCT01728805|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
153158|NCT00096460|Radiation|Chemotherapy or Radiation therapy|Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.
Radiation - administered at a rate of < 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.
Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC > 500/mm3 x 3 days.
153159|NCT01762800|Drug|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
150763|NCT01734928|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [>75 years old] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
151061|NCT01737840|Drug|Pantoprazole|33 patients
151062|NCT01737840|Drug|Ranitidine|33 patients
151063|NCT00094497|Drug|Streptozotocin|
151064|NCT01737853|Drug|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
151065|NCT01737853|Drug|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
151066|NCT01737866|Drug|AMG 423|omecamtiv mecarbil
151067|NCT01737879|Drug|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
151068|NCT01737879|Drug|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
151069|NCT01737892|Drug|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
151070|NCT01737892|Drug|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
151071|NCT01737905|Drug|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
151072|NCT01737905|Drug|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
151073|NCT01737918|Procedure|TOT|
151074|NCT00094497|Drug|Mitotane|
151075|NCT01737918|Drug|solifenacin|
151076|NCT01720082|Procedure|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
150836|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
150837|NCT01732796|Drug|BI 201335 (Faldaprevir)|24 weeks of BI 201335
150838|NCT01732796|Drug|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
150839|NCT01732796|Drug|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
150840|NCT01732796|Drug|Faldaprevir (BI 201335)|24 weeks of 201335
150841|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
150842|NCT01732809|Drug|group A|isovolumetric (0.02 mL) doses of 2 units of ABO injected on one side of the forehead and 2 units of ONA injected on the contralateral side
150843|NCT01732809|Drug|group B|Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.
151135|NCT01735487|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
151136|NCT01737931|Drug|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
151137|NCT01737931|Drug|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
151138|NCT01737944|Drug|Methotrexate (MTX)|Vibex MTX Device
151139|NCT01737957|Device|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
151140|NCT01737957|Device|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
151141|NCT01737983|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10^10 colony-forming units) for 6 months.
151142|NCT01737983|Dietary Supplement|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
151143|NCT01737996|Drug|BI 207127|tablets, oral administration
151144|NCT01737996|Drug|BI 207127 + faldaprevir|fixed dose combination
151145|NCT00094523|Drug|fosamprenavir|
151146|NCT01737996|Drug|BI 207127|tablets, oral administration
151788|NCT01729520|Other|Knee extension strength training|Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for
Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for
151789|NCT01729533|Other|ICSI|ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
151790|NCT01729533|Other|IMSI|Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei ([1] smooth, [2] symmetric, and [3] oval configuration) and [4] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies <4% of the nuclear area) are selected for injection.
151791|NCT01729546|Device|7 Blood glucose monitoring systems|
151792|NCT01729559|Drug|5000 Units unfractionated Heparin Q 8 hours|Venous thromboembolic prophylaxis medication
151793|NCT01729559|Drug|30mg enoxaparin Q12 hours|Venous thromboembolic prophylaxis
151794|NCT01729572|Other|Tele-medicine monitoring of medication adherence|
151795|NCT01729585|Procedure|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
151796|NCT01729598|Drug|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
151797|NCT01729598|Drug|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
151798|NCT00093652|Drug|gefitinib|
151799|NCT01729650|Behavioral|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
150901|NCT01739803|Behavioral|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
151297|NCT01733758|Drug|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
151298|NCT01733758|Drug|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
151559|NCT01721174|Procedure|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
151560|NCT00092885|Drug|MK0476, montelukast sodium|
151561|NCT01721174|Procedure|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
151562|NCT01721200|Other|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
151563|NCT01721200|Other|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
151564|NCT01721213|Drug|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
151565|NCT01721226|Device|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
151566|NCT01721226|Other|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
151567|NCT01721239|Other|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
151568|NCT01721291|Drug|SALBUTAMOL|In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.
In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY.
151569|NCT01723943|Other|laboratory biomarker analysis|Correlative studies
155376|NCT01752920|Drug|ARQ 087|Subjects in this study will receive ARQ 087 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg every other day (QOD) and will escalate until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
155377|NCT01752933|Drug|SGI-110|SGI-110 will be administered by subcutaneously on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
155378|NCT01752959|Drug|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
155379|NCT00095888|Drug|triapine|Given IV
155380|NCT01752959|Drug|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
155381|NCT01752972|Dietary Supplement|Spirulina|10 g/day orally for 12 weeks
155382|NCT01752985|Drug|BMS-813160|
155383|NCT01752985|Drug|Placebo matching with BMS-813160|
155384|NCT01752998|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|
155385|NCT01752998|Behavioral|Health Education|
155411|NCT01755936|Other|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
155412|NCT01755936|Other|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
155413|NCT01755936|Other|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
155414|NCT01755949|Drug|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
155415|NCT01755949|Drug|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
155416|NCT00096096|Drug|tacrolimus|
155417|NCT01755962|Other|Glycemic Load|
155418|NCT01755962|Other|Resistance Training|
155419|NCT01755975|Drug|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
155420|NCT01755975|Drug|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
154838|NCT01754857|Drug|Rituximab|Given IV
154839|NCT00096005|Drug|bortezomib|Given IV
154840|NCT01754857|Drug|Lenalidomid|Given PO
154841|NCT01754870|Drug|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
154842|NCT01754883|Drug|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
154843|NCT01754896|Other|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
154844|NCT01754896|Other|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
154845|NCT01754896|Other|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
154846|NCT01757847|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), an empirically-supported intervention that is being rolled out nationally by the VA, has been effective in reducing distress, increasing quality of life, and improving other indices of health in a wide range of conditions from depression to diabetes. The investigator's preliminary findings suggest that a brief ACT-based group intervention for patients with overweight or obesity can substantially reduce binge eating and distress, and improve functioning.
154847|NCT00001873|Device|Isolex 300i plus MoAbs|
154848|NCT00096161|Drug|Cyclosporine|Given PO
155107|NCT01755416|Device|Closed loop with enlite sensors, insulin, liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take 1.2mg of Liraglutide subcutaneoulsy before dinner on Day 1.
155108|NCT00096057|Biological|monoclonal antibody HuHMFG1|
155109|NCT01755416|Device|Closed loop with enlite sensors, insulin|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
155110|NCT01755442|Other|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
155111|NCT01755442|Drug|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
155112|NCT01755455|Drug|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
155113|NCT01755455|Drug|Placebo|Matching placebo capsule
155114|NCT01755468|Drug|Intermittent insulin therapy|
154629|NCT01760226|Drug|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
154630|NCT01760226|Drug|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
154631|NCT01760226|Drug|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
154632|NCT01760226|Drug|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
154633|NCT01760226|Drug|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
154634|NCT01751698|Behavioral|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
154635|NCT00095797|Drug|R(+)XK469|Given IV
154636|NCT01751698|Behavioral|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
154637|NCT01751724|Drug|Caffeine citrate|Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.
Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.
After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.
Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.
154638|NCT01751724|Other|Normal saline|Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).
Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.
After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.
Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.
154639|NCT01751737|Procedure|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
154907|NCT01752153|Drug|Silymarin (Legalon)|
155631|NCT01759537|Device|Ankylos dental endosseous implants-sub-crestal|Implants placed subcrestally
155632|NCT01759537|Device|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
155633|NCT00096265|Drug|erlotinib hydrochloride|Given orally
155634|NCT01759563|Device|nasopharyngeal targeted brain cooling|
155635|NCT00095732|Drug|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
155636|NCT01751035|Behavioral|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
155637|NCT01751035|Behavioral|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
155638|NCT01751048|Biological|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
155639|NCT01751048|Biological|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
155640|NCT01751048|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
155641|NCT01751048|Drug|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
155642|NCT01751061|Behavioral|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
155643|NCT01751061|Other|Usual care|usual ICU care
155644|NCT01751074|Drug|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
155645|NCT01751074|Drug|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
153538|NCT01765543|Drug|vemurafenib|single dose of vemurafenib in Period A and C
153539|NCT01765556|Drug|ketoconazole|multiple doses of ketoconazole in Period B and C
153540|NCT01765556|Drug|vemurafenib|single dose of vemurafenib in Period A and C
153541|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
153542|NCT01765569|Drug|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
153543|NCT01765569|Drug|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
153848|NCT01768585|Drug|Ivabradine|Please see description of Intervention Arm
153849|NCT01768585|Drug|Placebo|
153850|NCT01768598|Other|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
153851|NCT01768598|Other|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
153852|NCT01768598|Other|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
153853|NCT00097214|Drug|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
153854|NCT01768598|Other|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
153855|NCT01768624|Procedure|dialysis, kidney transplant|
153856|NCT01768637|Drug|Aspirin|Aspirin 81 mg by mouth daily
153857|NCT01768637|Drug|Clopidogrel|Clopidogrel 75 mg by mouth once daily
153858|NCT01768650|Behavioral|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
153859|NCT01771107|Drug|Brentuximab Vedotin|Given IV
153860|NCT01771107|Drug|Dacarbazine|Given IV
153861|NCT01771107|Drug|Doxorubicin Hydrochloride|Given IV
153283|NCT00097032|Drug|risperidone; quetiapine|
153284|NCT01767545|Drug|Bevacizumab|
153285|NCT01767558|Other|Ablation / MRI|All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.
MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit.
153286|NCT01767571|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
153287|NCT01767571|Drug|Cephalexin 250mg/5ml|Test product 10 ml
153288|NCT01767584|Drug|Cephalexin 1g tablets|Reference product
153289|NCT01767584|Drug|Cephalexin 1g tablets|Test product
153290|NCT01767597|Other|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
153291|NCT01767597|Other|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
153292|NCT01767610|Drug|micronized fenofibrate 160mg|
153293|NCT01767610|Drug|pitavastatin Ca 2mg|
153294|NCT00097045|Drug|omega interferon|
153295|NCT01767610|Drug|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
153296|NCT01767623|Drug|vemurafenib|960 mg BID
153297|NCT01767623|Drug|vemurafenib|720 mg BID
153298|NCT01767636|Drug|Pazopanib Hydrochloride|Given PO
153299|NCT01767649|Other|Caesarean|Collection of tissues and blood
153600|NCT00096486|Drug|everolimus|
153601|NCT01763307|Drug|RECONVAL CREAM|
153602|NCT01763307|Drug|PLACEBO|
153603|NCT01763320|Procedure|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
153604|NCT01763320|Drug|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
149365|NCT01701934|Drug|Placebo|One placebo pill daily, for 6 months
149366|NCT01701947|Biological|Hemoleven|Replacement therapy
149367|NCT01701973|Drug|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
149368|NCT01701973|Drug|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
149369|NCT00091091|Other|medical chart review|
149370|NCT01701973|Drug|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
149371|NCT01701973|Drug|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
149372|NCT01701973|Drug|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
149373|NCT01704417|Drug|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
149374|NCT01704417|Drug|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
149375|NCT01704430|Dietary Supplement|Glutamine|Enteric L-Glutamine
149376|NCT01704430|Dietary Supplement|Maltodextrin|Enteric Maltodextrin
149377|NCT01704443|Behavioral|Group Psychoeducational Treatment|The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)
149378|NCT01704443|Other|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
148405|NCT01715259|Drug|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
148406|NCT01715259|Drug|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
148407|NCT01715272|Device|TF037|
148408|NCT01715272|Drug|Fleet enema|
149110|NCT00091442|Drug|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
149111|NCT01706432|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
149112|NCT01706445|Other|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
149113|NCT01706458|Biological|sipuleucel-T|Given IV
149114|NCT01706458|Biological|DNA Vaccine|Given ID
149115|NCT01706471|Drug|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up >3 ng/mL. Steroid dose follows local protocol.
149116|NCT01706471|Drug|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
149117|NCT01706484|Drug|BNO 1016|comparison of different dosages of drug and placebo
149118|NCT01706497|Device|Cerebral tissue oxygen saturation monitoring, blinded|
149119|NCT01706510|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
149120|NCT01706510|Drug|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
149121|NCT00091468|Drug|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
149122|NCT01706523|Drug|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
149123|NCT01706536|Drug|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
149124|NCT01706536|Drug|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
149125|NCT01706536|Drug|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
149126|NCT01706536|Drug|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
149127|NCT01706536|Drug|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
149128|NCT01706562|Drug|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
149129|NCT01706575|Drug|nucleos(t)ide analogues|Adenovir, entecavir, lamivudine or tenofovir
152589|NCT01723202|Other|Correlative Studies|Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)
BRAF mutation studies in circulating plasma DNA (all study patients)
Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)
Assess predictors of response (Archival tumor block/unstained slides in all study patients)
Pharmacokinetic studies (First 10 pts enrolled on each arm)
Pharmacogenomics studies (All study patients)
152590|NCT00093093|Drug|Ribavirin|
152938|NCT01720992|Other|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
152939|NCT01721005|Other|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
152940|NCT01721018|Biological|HSV1716 Intra-pleural delivery|
152941|NCT01721031|Procedure|DPNB|Patients receive DPNB 30min before extubation at the end of operation
152942|NCT01721031|Drug|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
152943|NCT00092859|Drug|MK0557|
152944|NCT01721044|Drug|Placebo|Administered orally
152945|NCT01721044|Drug|Baricitinib|Administered orally
152946|NCT01721057|Drug|Placebo|Administered orally
152947|NCT01721057|Drug|Baricitinib|Administered orally
152948|NCT01721070|Drug|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
152949|NCT01721070|Drug|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
152950|NCT01721083|Procedure|Procedure: Z-track|Subject received immunization by z-track
152951|NCT01721083|Procedure|Procedure: Bunch|Subject receives immunization by bunch method.
152952|NCT01721096|Device|XIENCE PRIME - Long Length (LL)|Long Length
152953|NCT01721096|Device|XIENCE PRIME - Core Length|Core Length
152954|NCT00092872|Drug|MK0557|
152368|NCT01730560|Other|Treatment B|Placebo treatment using the same computer-based training task, but including only the ramp phase.
Each treatment phase has the same pattern:
two visits in pre-tests evaluation (V1 and V2),
one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),
two visits after treatment (V4 at one week and V5 at one month).
152369|NCT01730573|Procedure|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
152370|NCT01730573|Procedure|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
152371|NCT00093704|Drug|bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
152372|NCT01730586|Drug|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
152373|NCT01730599|Other|neurological exam|motor and cognitive functions
152374|NCT01730612|Drug|TF2 - 68 Ga-IMP-288:|ImmunoTEP
152375|NCT01730625|Behavioral|Cognitive behavioral therapy for anxiety|
152376|NCT01730625|Behavioral|Attention Bias Modification Treatment|
152377|NCT01730638|Drug|• TF2 and 68 Ga-IMP-288|
152653|NCT01728623|Drug|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
152654|NCT01720446|Drug|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment.
Administered subcutaneously (s.c., under the skin).
152655|NCT01720459|Dietary Supplement|Micronized trans-resveratrol|
152656|NCT01720459|Dietary Supplement|Placebo|
152657|NCT01720472|Genetic|Biomarker studies|
152658|NCT00092781|Drug|Comparator: celecoxib|
152659|NCT01720485|Drug|Desloratadine + Prednisolone|1 tablet 3 times a day
152660|NCT01720485|Drug|Dexchlorpheniramine + Betamethasone|1 tablet 3 times a day
152661|NCT01720498|Drug|remifentanil|The effect site concentration of remifentanil
152662|NCT01720511|Dietary Supplement|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
152142|NCT01724983|Drug|ketamine|
152143|NCT01724983|Drug|fentanyl|
152144|NCT01724996|Other|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
152145|NCT01725009|Drug|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam|Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days
152146|NCT00093262|Drug|placebo|
152147|NCT01725022|Other|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
152148|NCT01725048|Drug|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
152149|NCT01725048|Drug|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
152150|NCT01727583|Dietary Supplement|meal intake|Intake of meals characterized by lipid composition
152151|NCT01727583|Dietary Supplement|Placebo|
152152|NCT01727596|Other|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
152153|NCT01727609|Dietary Supplement|Milk feed (breast milk or formula milk)|
152154|NCT01727622|Drug|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
152155|NCT01727622|Other|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
152444|NCT01728194|Drug|Escitalopram|20 mg target dose for 12 weeks
152445|NCT01728207|Drug|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
152446|NCT01728220|Drug|Inhaled NO|
152447|NCT01728220|Other|Placebo|Nitrogen gas
152448|NCT01728233|Drug|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
153160|NCT01764867|Drug|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153161|NCT01764867|Drug|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153162|NCT01764867|Drug|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153163|NCT01764867|Drug|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153164|NCT01764867|Drug|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153165|NCT01764867|Drug|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153166|NCT01764867|Drug|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153167|NCT00096629|Biological|mouse prostate-specific membrane antigen plasmid DNA vaccine|
153168|NCT01764867|Drug|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
153169|NCT01764880|Drug|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
153170|NCT01764893|Other|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
153171|NCT01764893|Other|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
153172|NCT01764906|Device|Novosis|
153173|NCT01764906|Procedure|Iliac crest bone graft|
153174|NCT01764919|Radiation|[124I]FIAU|A single intravenous injection of 5 mCi[124I]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
153175|NCT01764932|Procedure|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
153176|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
152212|NCT01722448|Dietary Supplement|Placebo|
152213|NCT01722461|Device|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
151077|NCT01720082|Procedure|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
151078|NCT01720095|Drug|Niaspan|
151079|NCT01720108|Drug|rivaroxaban and ASA|
151367|NCT00093912|Drug|sodium nitroprusside|
151368|NCT01733875|Drug|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
151369|NCT01733875|Drug|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
151370|NCT01733875|Drug|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
151371|NCT01733875|Drug|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
151372|NCT01733875|Drug|Placebo|A single dose of placebo will be administered orally once a day.
151373|NCT01733875|Drug|CC-220|CC-220 4 mg will be administered orally once a day
151374|NCT01733875|Drug|CC-220|CC-220 6 mg will be administered orally once a day
151375|NCT01733875|Drug|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
151376|NCT01733888|Device|Office Bleaching with 35 % Hydrogen Peroxide|In this group before starting the procedure the teeth intended to be treated will be cleaned with pumice and after that cheek retractors will be placed and exposed lip surface will be covered with petroleum gel. Thereafter, teeth will be dried and gingival Barrier will be applied to both arches, slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds . Once the gingival barrier will be cured then homogeneous mixing of the powder and liquid will be done in powder pot, followed by application of thick layer of gel to all teeth undergoing treatment. The gel will be then left in place for 8 minutes and after that the gel will be removed using a surgical aspirator tip.
151377|NCT01733888|Device|Icon Infiltration|In this group after taking pre-operative photographs the fluorosed tooth will be isolated using rubber dam and the Resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. For this purpose, after rubber dam application tooth surface will be dried using cotton rolls and air syringe. Icon Etchant will be applied and left for 2 minutes followed by rinsing and air drying for 30 sec. After complete etching, Drying agent (99% ethanol), as supplied in the Icon kit. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds followed by cleaning of the surface with pumice and rubber polishing cup and rinsing with water for 30 sec. After application, patient will be instructed neither to eat nor brush their teeth for 45 minutes.
151378|NCT01735864|Drug|Indirubin 50 μg/g|Dosage form: Ointment
Dose(s): Each gram of ointment contains 50 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
151147|NCT01738009|Other|Induction of flow limitation|
151148|NCT01738022|Other|Administration of gas mixtures|
151149|NCT01738035|Drug|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
151150|NCT01738035|Other|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
151151|NCT01738048|Procedure|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
151152|NCT01738061|Behavioral|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
151153|NCT01738074|Biological|trivalent rotavirus genetic reassortment vaccine|
151154|NCT01738074|Biological|Placebo|
151155|NCT01738087|Drug|NEXThaler 100/6 mcg DPI|
151437|NCT01731496|Other|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
151438|NCT01731509|Other|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
151439|NCT00093925|Drug|clevidipine|
151440|NCT01733888|Device|Icon Infiltration twice|In this group application of the resin infiltration shall be done similar to the procedure as explained for intervention "Icon infiltration", but the resin infiltrant shall be applied twice.
151441|NCT01733888|Device|Bleaching+Icon Infiltration|In this group vital bleaching will be done using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia), as explained in intervention "bleaching"; followed by wash over period of 20 days. After 20 days the patient will be recalled and on the day of appointment initially a new preoperative photograph shall be taken, then the fluorosed tooth will be isolated using rubber dam and the Resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions, similar to intervention "Icon Infiltration". For this group a postoperative photograph shall be taken after the application of RI and then the circle of post-operative recall shall be counted from here, that is, 1week, 1 month and 6 months respectively.
151442|NCT01733901|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
150902|NCT01739816|Behavioral|Medication review|Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.
The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.
As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.
150903|NCT01739829|Device|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
150904|NCT01739829|Device|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
150905|NCT00094718|Biological|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
150906|NCT01739842|Dietary Supplement|Kudzu extract|
150907|NCT01739855|Drug|Calciferol, calcium carbonate|
150908|NCT01739868|Other|Biopsies of muscular and fat tissue|3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:
1 visit the first year (inclusion visit)
1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes
1 intermediary visit (in 3 years) or activated by the following conditions:
Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)
Normalization of the glycemia (fasting blood glucose < 1 g/l)
150909|NCT01739881|Device|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
150910|NCT01732822|Drug|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
150911|NCT01732835|Device|HAART 300 Annuloplasty Ring|
150912|NCT01732848|Drug|BMS-986094/INX-08189|
150913|NCT01732848|Drug|Placebo matching BMS-986094/INX-08189|
150914|NCT01732861|Drug|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
150915|NCT01732861|Drug|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
150916|NCT01732874|Drug|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
150917|NCT01732874|Drug|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
151219|NCT01735591|Dietary Supplement|Probiotic|Capsules with 3x10^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
151570|NCT01723956|Procedure|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
151571|NCT01723956|Procedure|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
151868|NCT01727050|Device|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
151869|NCT01727050|Device|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
151870|NCT01727063|Procedure|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
151871|NCT01727076|Other|Laboratory Biomarker Analysis|Correlative studies
151872|NCT01727076|Other|Pharmacological Study|Correlative studies
151873|NCT00093496|Drug|gemcitabine hydrochloride|Given IV
151874|NCT01727076|Biological|Recombinant Human Interleukin-15|Given SC
151875|NCT01727089|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
151876|NCT01727089|Biological|Bevacizumab|Given IV
151877|NCT01727089|Other|Laboratory Biomarker Analysis|Correlative studies
151878|NCT01727089|Other|Pharmacological Study|Correlative studies
151879|NCT01727115|Other|Infant Formula Feeding|Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.
If the challenge is positive: The children continue the assigned formula
If the challenge is negative: A Follow up formula is given
(Nan pro2) if child > 6 months
(Nan pro1) if child < 6 months
151880|NCT01727128|Drug|BKM120|
151881|NCT01727141|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
151882|NCT01727141|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
151883|NCT01727141|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
151884|NCT00093496|Drug|tanespimycin|Given IV
151885|NCT01727141|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
155421|NCT01755988|Other|Educational website (in addition to usual care).|
155422|NCT01755988|Other|Website and interactive platform with telemonitoring.|
155423|NCT01756001|Device|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
155424|NCT01756001|Behavioral|Daily email, text message, or phone call reminders|
155425|NCT01756001|Behavioral|Paid for adherence|
155426|NCT01758900|Device|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
155427|NCT01758900|Device|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
155428|NCT01758913|Drug|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
155429|NCT01758965|Other|PPI|monotherapy of PPI
155430|NCT01758965|Other|H2RA and surgicel|combination therapy of H2RA and surgicel
155727|NCT01751126|Drug|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
155728|NCT01751126|Drug|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
155729|NCT01751139|Procedure|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
155730|NCT01751139|Other|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
155731|NCT01751152|Drug|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
155732|NCT01751152|Drug|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
155115|NCT01755468|Drug|Continuous metformin|
155116|NCT01755481|Other|Probiotic|
155117|NCT01755481|Other|Whey protein concentrate|
155118|NCT01755494|Drug|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
155119|NCT01758328|Drug|busulfan|
155120|NCT01758328|Drug|melphalan|
155121|NCT01758328|Drug|fludarabine|
155122|NCT01758328|Biological|anti-thymocyte globulin (ATG)|
155123|NCT01758328|Procedure|a T cell depleted stem cell transplant|
155124|NCT01758341|Procedure|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
155125|NCT01758341|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
155126|NCT01758341|Device|HabibTM EndoHPB catheter|Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention "endoscopic radiofrequency ablation")
155127|NCT01758354|Other|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
155128|NCT00096187|Drug|pemetrexed disodium|
155486|NCT01753297|Drug|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
155487|NCT01753310|Drug|Dysport|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
155488|NCT01753310|Drug|Placebo|Up to 2mL
155489|NCT01753323|Drug|KAF156|KAF156 was supplied as tablets for oral use.
155490|NCT01753336|Drug|Dysport|Dysport (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
155491|NCT01753349|Drug|BoNT-A injections, 3-4 times yearly|
155492|NCT00095901|Drug|capecitabine|
155493|NCT01753362|Drug|liraglutide|
154908|NCT01752179|Procedure|kinesio Tape : Width 5cm ,Length 35cm Y shape|In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.
Taping method include :
stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.
puts the base of tape over the contralateral of sacrum with no tension.
attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.
attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.
This is an origin to insertion application.
154909|NCT01754896|Other|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
154910|NCT01754909|Drug|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
154911|NCT01754909|Drug|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
154912|NCT01754935|Drug|VX-509|50 mg oral tablet
154913|NCT00096005|Other|laboratory biomarker analysis|Correlative studies
154914|NCT01754935|Drug|VX-509 matching placebo|0 mg oral tablet
154915|NCT01754961|Drug|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
154916|NCT01754961|Drug|Placebo|Placebo given orally on Day 1
154917|NCT01754974|Biological|Peginterferon Lambda-1a|
154918|NCT01754974|Drug|Ribavirin|
154919|NCT01754974|Biological|Peginterferon alfa-2a|
154920|NCT01754987|Drug|Ascorbic Acid + Sorafenib|
154921|NCT01754987|Drug|Sorafenib alone|
154922|NCT01755000|Procedure|USCOM scan|
154923|NCT01755000|Procedure|Fluid Bolus|
154924|NCT00096018|Drug|fludarabine phosphate|Given IV
154925|NCT01755013|Procedure|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
154926|NCT01755026|Drug|cefazolin|2 gram dose for pre-operative prophylaxis
154927|NCT01755026|Drug|cefazolin|4 gram dose for pre-operative prophylaxis
154928|NCT01755078|Drug|Sevelamer HCl|Non-metal phosphate binder
155646|NCT00095732|Drug|Placebo|Administered orally in either Size 2 or Size 5 capsules
154701|NCT01760239|Behavioral|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
154702|NCT01760252|Drug|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
154703|NCT01760278|Drug|recombinant Follicle Stimulating Hormone (rFSH)|There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.
On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study.
154704|NCT00096304|Drug|docetaxel|
154705|NCT01760291|Device|WATCHMAN LAA Closure Technology|
154706|NCT01760304|Drug|Budesonide / Formoterol|Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).
After 45 minutes , the above measurements will be repeated.
154707|NCT01760304|Drug|Placebo|Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).
After 45 minutes , the above measurements will be repeated.
154708|NCT01760317|Procedure|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
154709|NCT01760330|Drug|IV acetaminophen|
154710|NCT01760330|Drug|Placebo|
154711|NCT01760343|Biological|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
154712|NCT01760343|Biological|CSL830|CSL830 is a formulation of Berinert.
154713|NCT01760382|Device|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
154714|NCT01760408|Other|all patients on Home Parenteral Nutrition|
154715|NCT00001889|Procedure|Myocardial contrast echocardiography|
154716|NCT00096304|Drug|epirubicin hydrochloride|
153862|NCT00097409|Drug|Ispinesib|
153863|NCT01771107|Other|Laboratory Biomarker Analysis|Correlative studies
153864|NCT01771107|Other|Pharmacological Study|Correlative studies
153865|NCT01771107|Drug|Vinblastine|Given IV
153866|NCT01771120|Other|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
153867|NCT01771133|Behavioral|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
154155|NCT01764334|Device|Fractional flow reserve|Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014") with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed.
154156|NCT01764347|Procedure|therapeutic conventional surgery|Undergo robotic radical prostatectomy
154157|NCT01764347|Procedure|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
154158|NCT01764347|Procedure|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
154159|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
154160|NCT01764373|Other|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
154161|NCT00096590|Other|laboratory biomarker analysis|
154162|NCT01764386|Drug|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
154163|NCT01764386|Behavioral|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
154164|NCT01764386|Behavioral|Usual Care|Usual Care is a self-directed lifestyle intervention program
153605|NCT01763333|Drug|BI 1026706 Placebo|Placebo to BI 1026706
153606|NCT01763333|Drug|BI 1026706|different dose formulations
153607|NCT01763333|Drug|BI 1026706|single dose (low to high dose)
153608|NCT01763346|Drug|Metformin|metformin 1000 mg bid
153609|NCT01763346|Device|gastric banding|LAP-BAND
153610|NCT01763385|Drug|Erlotinib|
153611|NCT00096486|Drug|gefitinib|
153612|NCT01763385|Radiation|concurrent brain radiotherapy|
153613|NCT01763385|Radiation|secondary brain radiotherapy|
153614|NCT01763424|Drug|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
153615|NCT01763424|Drug|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
153616|NCT01763437|Drug|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
153617|NCT01763450|Drug|bevacizumab plus chemotherapy|Bevacizumab:
7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;
Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;
Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:
Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;
153618|NCT01763463|Drug|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
153933|NCT01766323|Drug|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
153934|NCT01768650|Behavioral|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
148409|NCT01717898|Drug|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
148410|NCT01717911|Drug|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
148411|NCT01717911|Drug|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
148412|NCT01717911|Drug|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
148413|NCT01717924|Procedure|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
148414|NCT01717924|Procedure|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
148415|NCT01717937|Procedure|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
148416|NCT00092573|Drug|Comparator: fenofibrate monotherapy|
148417|NCT01717950|Biological|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
148418|NCT01717950|Biological|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
148419|NCT01717963|Drug|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
148420|NCT01717963|Drug|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
148717|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
148718|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
148719|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
149130|NCT01706575|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
149131|NCT01706588|Drug|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
149440|NCT01701986|Drug|Gemcitabine|Phase I Starting dose of Gemcitabine: 75 mg/m2/ loading dose by vein targeting the desired steady state concentration of 20 µmolar on Day -6 and Day -4. This will be immediately followed by an infusion at a fixed rate of 10 mg/m2/min over varying lengths of time per study cohort.
Phase II Starting dose of Gemcitabine: Maximum tolerated dose (MTD) from Phase I.
149441|NCT01701986|Drug|Clofarabine|Phase I and Phase II dose of Clofarabine: 40 mg/m2 by vein on Days -6 to -3.
149442|NCT01701986|Drug|Busulfan|Phase I and Phase II dose of Busulfan: Test dose of 32 mg/m2 by vein as an outpatient between Day -15 and Day -8, or on Day -9 as an inpatient.
Busulfan 4000 µMol-min by vein four consecutive days (Days -6 to -3), starting immediately after the completion of clofarabine. If not feasible to perform pharmacokinetic monitoring, patients receive fixed dose of 100 mg/m2/day for 4 days, which is expected to yield a median daily AUC of 4,000 µMol.min-1.
149443|NCT01701986|Procedure|Stem Cell Infusion|Stem cell infusion on Day 0.
149444|NCT01701986|Drug|Anti-Thymocyte Globulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1 for patients receiving a graft from a matched unrelated donor.
149445|NCT01701986|Drug|Rituximab|375 mg/m2 by vein on Day -14 and Day -7 and then on Day +1 and Day +8 for patients with CD20+ disease.
149446|NCT01701986|Drug|Filgrastim|5 mcg/kg/day subcutaneously starting on Day +7 until blood cell levels return to normal.
149447|NCT00091091|Other|questionnaire administration|
149448|NCT01701986|Drug|Tacrolimus|0.015 mg/kg by vein beginning on Day -2, as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) is present.
149449|NCT01701986|Drug|Mycophenolate Mofetil|1,000 mg by vein three times a day on Day 0 after cell infusion and will be changed to oral dosing (1:1 conversion) when tolerated.
149450|NCT01701999|Biological|rBV A/B|rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
149451|NCT01702012|Dietary Supplement|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
149452|NCT01702012|Behavioral|Group-Based Lifestyle Intervention|
149453|NCT01702025|Drug|Placebo|Yellow corn meal in gel capsules
152955|NCT01721109|Drug|EVG/COBI/FTC/TDF|Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EVG/COBI/FTC/TDF) single-tablet regiment (STR) administered orally once daily with food
152956|NCT01721135|Drug|GSK2190915 100mg|Film coated oral tablet
152957|NCT01723800|Drug|PI3K inhibitor BKM120|Given PO
152958|NCT01723800|Drug|pemetrexed disodium|Given IV
152959|NCT01723800|Drug|carboplatin|Given IV
151990|NCT01730014|Drug|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
151991|NCT01730027|Drug|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
151992|NCT01730027|Drug|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
151993|NCT01730027|Drug|montelukast|montelukast for 12 weeks
151994|NCT01730040|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
151995|NCT00093665|Radiation|radiation therapy|
151996|NCT01730040|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
151997|NCT01730040|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
151998|NCT01730040|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
151999|NCT01730040|Drug|Placebo|Placebo for alirocumab and ezetimibe.
152000|NCT01730053|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
152001|NCT01730053|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
152002|NCT01730053|Drug|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
152003|NCT01730053|Drug|Placebo|Placebo for alirocumab and ezetimibe.
152004|NCT01721941|Drug|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
152005|NCT01721954|Drug|FOLFOX6m|
152006|NCT01721954|Device|SIR-Spheres microspheres|
152663|NCT01720511|Dietary Supplement|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
152664|NCT01720524|Drug|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
152665|NCT01720524|Drug|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
152666|NCT01720537|Biological|PF-05335810 Dose A|Single SC Injection
152667|NCT01720537|Biological|PF-05335810 Dose B|Single Subcutaneous Injection(s)
152668|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
152669|NCT00092807|Drug|MK0653, ezetimibe|
152670|NCT01720537|Biological|PF-05335810 Dose B|Single Intravenous Infusion
152671|NCT01720537|Biological|Placebo|Single Intravenous Infusion
152672|NCT01720537|Biological|PF-04950615 Dose A|Single Subcutaneous Injection(s)
152673|NCT01720537|Biological|PF-04950615 Dose A|Single Intravenous Infusion
152674|NCT01720537|Biological|PF-05335810 Dose C|Single Subcutaneous Injection(s)
152675|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
152676|NCT01720537|Biological|PF-05335810 Dose C|Single Intravenous Infusion
153021|NCT00096980|Drug|Raptiva (efalizumab)|
153022|NCT01767246|Other|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
153023|NCT01767246|Other|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
153024|NCT01767259|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
153025|NCT01767259|Drug|Valsartan|Valsartan alone
153026|NCT01767259|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
153027|NCT01767272|Drug|fexofenadine|fexofenadine brand name
152449|NCT01728246|Drug|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
152450|NCT01728246|Drug|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
152451|NCT01728259|Drug|pomalidomide|Given PO
152452|NCT01728259|Drug|bortezomib|Given IV
152453|NCT01728259|Drug|dexamethasone|Given PO
152454|NCT00093548|Biological|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
152455|NCT01728259|Other|Laboratory Biomarker Analysis|Correlative studies
152456|NCT01728272|Drug|blood concentration of metoprolol|measure blood concentration of metoprolol
152457|NCT01728285|Device|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
152458|NCT01728298|Biological|SLITone ULTRA HDM immunotherapy|
152459|NCT01728311|Drug|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
152460|NCT01728324|Drug|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
152461|NCT01728324|Drug|Ribavirin: 24-week treatment|24 weeks of active treatment
152462|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
152463|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
152464|NCT01709656|Drug|"celecoxib", "Celebrex®"|non-steroid anti-inflammatory drugs (NSAID):"celecoxib", "Celebrex®" 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up
152465|NCT01709682|Drug|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
152730|NCT01728740|Drug|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
152731|NCT01728740|Drug|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
152732|NCT00093587|Procedure|peripheral blood stem cell transplantation|
152733|NCT01728740|Drug|Metformin|Metformin 500mg, oral, single dose
152214|NCT00093028|Drug|bortezomib|N/A Study Complete
152215|NCT01722461|Device|Sham treatment|Ulthera System delivering no ultrasound energy
152216|NCT01722474|Device|ASI Device|
152217|NCT01725074|Behavioral|Case Management "CM CHD"|Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:
Biweekly/monthly telephone consultations or home visits
Identification of health or personal problems of the patient
Monitoring of medical parameters
Coordination of contact with health care providers if necessary
Support to the patient related to health status and environmental changes
Promote disease-self management through coaching
Counseling, that is focused on emotional support and active listening
152218|NCT01725074|Behavioral|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
152219|NCT01725087|Drug|Matching Placebo|
152220|NCT01725087|Drug|Low Dose GRT6005|
152221|NCT01725087|Drug|Medium Dose GRT6005|
152222|NCT01725087|Drug|High Dose GRT6005|
152223|NCT01725087|Drug|Tapentadol|
152224|NCT00093275|Drug|HP184|
152225|NCT01725100|Drug|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
152226|NCT01725100|Drug|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
152227|NCT01725113|Drug|Calcitriol|3 times weekly
152228|NCT01725113|Drug|Paricalcitol|3 times weekly
152229|NCT01725126|Drug|GSK2890457|Provided as powder and capsule.
152230|NCT01725126|Drug|Metformin|Tablet
Part A: Single doses on Day 1 and Day 42 orally
Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed
Part C: Subject continues usual metformin dose throughout study
152231|NCT01725126|Drug|Placebo|Provided as powder and Capsule.
152232|NCT01725126|Drug|Liraglutide|Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg
Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only
152233|NCT01725139|Drug|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
151379|NCT01735864|Drug|Indirubin 10 μg/g|Dosage form: Ointment
Dose(s): Each gram of ointment contains 10 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
151380|NCT01735877|Other|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
151381|NCT01735877|Other|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
151646|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM
151647|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
151648|NCT01721382|Drug|Sitagliptin|
151649|NCT01721395|Dietary Supplement|Agave Syrup|
151650|NCT01721408|Drug|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
151651|NCT01721408|Drug|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
151652|NCT01721421|Other|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
151653|NCT00000273|Drug|opiates|prescription opioids
151654|NCT00001785|Drug|Recombinant human interferon beta-1a|
151655|NCT00092898|Drug|Comparator: placebo|
151656|NCT01721421|Other|Standard treatment time|
151657|NCT01724034|Other|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
151658|NCT01724047|Behavioral|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
151443|NCT01733901|Procedure|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
151444|NCT01733914|Procedure|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
151445|NCT01733914|Other|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
151446|NCT01733927|Device|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
151447|NCT01733940|Device|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
151448|NCT01733940|Device|Application of a dressing without clorhexidine gluconate|
151449|NCT01733953|Drug|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
151450|NCT00093925|Drug|nicardipine|
151721|NCT01721460|Drug|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
151722|NCT01721486|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR in study group only.
151723|NCT01721486|Drug|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
151724|NCT01721499|Behavioral|Nutritional Counseling|weekly group and individual skills training to improve self control and decrease stress.
151725|NCT01721499|Behavioral|Mindfulness Intervention|
151726|NCT01721512|Other|Breastfeeding|
151727|NCT00092911|Drug|DVS-233 SR|
151728|NCT01721512|Other|Infant formula|
151220|NCT01735604|Biological|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
151221|NCT01735604|Other|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
151222|NCT01735617|Drug|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
151223|NCT01735630|Drug|ELND005|
151224|NCT01735630|Drug|Placebo|
151225|NCT01735643|Device|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
151226|NCT00094172|Drug|Placebo|tablet form
151227|NCT01735643|Other|waiting|waiting for 12 weeks
151228|NCT01735656|Device|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
151229|NCT01735669|Drug|Remifentanil|
151230|NCT01735669|Drug|Nitrous Oxide|
151231|NCT01735682|Device|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
151232|NCT01735682|Behavioral|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
151233|NCT01735682|Behavioral|Control|The control treatment involves exercises of the upper limbs.
151234|NCT01735708|Behavioral|HIVPASS|
151235|NCT01738087|Drug|NEXThaler placebo|Placebo comparator
151236|NCT01738100|Drug|Ticagrelor|
151237|NCT01738100|Drug|Clopidogrel|
151238|NCT01738100|Drug|Morphine Sulfate|
151239|NCT01738100|Drug|Saline|
151240|NCT01738113|Other|Open Kinetic Chain exercise|Hamstrings strengthening exercise
Quadriceps strengthening exercise
Hamstrings stretch
Hip extensors and abductors strengthening
Calf-muscles stretching
Strength exercise of ankle dorsiflexors & plantar flexors
151886|NCT01727154|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
151887|NCT01727167|Drug|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
151888|NCT01727167|Other|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
151889|NCT01729728|Drug|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
151890|NCT01729741|Procedure|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
150977|NCT01737710|Biological|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
150978|NCT01740219|Behavioral|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
150979|NCT01740232|Procedure|trephination|Artroscopic meniskal repair with trephination.
150980|NCT01740232|Procedure|Normal meniscal repair|Artroscopic meniskal repair without trephination.
150981|NCT01740245|Device|Chlorhexidine vaginal suppositories|
150982|NCT01740245|Device|Polyhexamethylene biguanide vaginal suppositories|
150983|NCT00094757|Drug|Comparator: placebo|placebo oral tablet once daily during Phase A (Weeks 0-18)
150984|NCT01740258|Radiation|Radiation Therapy|
150985|NCT01740258|Drug|Temozolomide|
150986|NCT01740258|Drug|Bevacizumab|
150987|NCT01740271|Drug|Epirubicin|
150988|NCT01740284|Drug|Grazax + Aerius|
150989|NCT01740284|Drug|Grazax + placebo|
150990|NCT01740297|Drug|Talimogene laherparepvec plus ipilimumab|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter. Ipilimumab administered intravenously on Day 1 of Week 6, Week 9, Week 12, and Week 15 for a total of 4 infusions. Subjects will be treated wtih talimogene laherparepvec until complete response, all injectable tumors have disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurs first.
155733|NCT01751165|Biological|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
155734|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
155735|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
155736|NCT01751204|Dietary Supplement|Calcium tablet|
155737|NCT00095758|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
155738|NCT01751204|Dietary Supplement|Calcium ion water (250mg)|
155739|NCT01751204|Dietary Supplement|Calcium ion water (125mg)|
155740|NCT01751217|Behavioral|Functional Family Tx|
155741|NCT01751217|Behavioral|Services as Usual|
155742|NCT01751230|Behavioral|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
155743|NCT01753739|Drug|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
155744|NCT01753739|Drug|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
154774|NCT01757795|Drug|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
154775|NCT01757795|Drug|Placebo|
154776|NCT01757808|Drug|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
154777|NCT01757808|Drug|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
154778|NCT01757821|Device|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
154779|NCT01757821|Device|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
155494|NCT01756027|Device|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
155495|NCT00096109|Drug|tanespimycin|Given IV
155496|NCT01756027|Device|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
155497|NCT01756040|Drug|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
155498|NCT01756053|Drug|ABT-089|Selective neuronal nicotinic receptor agonist.
155499|NCT01756053|Drug|Placebo|Matched placebo capsules supplied by study drug supplier.
155500|NCT01756066|Behavioral|Different levels of cost sharing|
155501|NCT01756079|Drug|boceprevir|
155502|NCT01756079|Biological|PegIFN-2b|
155503|NCT01756079|Drug|RBV|
155504|NCT01756092|Procedure|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
155505|NCT01756105|Drug|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
155506|NCT00096109|Other|laboratory biomarker analysis|Correlative studies
155507|NCT01756105|Drug|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
154574|NCT01754298|Procedure|Retro-articular drilling|Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.
Use a 0.045 K-wire for drilling.
Minimum of 8 wire passes per square centimeter with no maximum number of wire passes.
154575|NCT01754298|Procedure|Trans-articular drilling|Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)
Use a 0.045 K-wire for drilling
A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter
154576|NCT01754324|Drug|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
154929|NCT01755078|Drug|Calcium-based phosphate binder|
155184|NCT00096070|Radiation|radiation therapy|Undergo radiation therapy
155185|NCT01755494|Drug|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
155186|NCT01755494|Drug|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
155187|NCT01755494|Drug|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
155188|NCT01755494|Drug|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
155189|NCT01755507|Drug|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
155190|NCT01755507|Drug|Placebo|
155191|NCT01755520|Drug|Ticagrelor|90mg twice daily dose
155192|NCT01755520|Drug|Aspirin|Aspirin 100mg once daily
155193|NCT01755520|Drug|Placebo - Ticagrelor|Placebo
155194|NCT01755520|Drug|Placebo - Aspirin|Placebo
155195|NCT00096070|Drug|oxaliplatin|Given IV
155196|NCT01755533|Other|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
155197|NCT01755533|Other|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
155198|NCT01755546|Drug|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
155199|NCT01755559|Drug|Artesunate-amodiaquine|antimalarial ACT
155200|NCT01755559|Drug|Dihydroartemisinin-piperaquine|antimalarial ACT
155201|NCT01755559|Drug|Artemether-lumefantrine|antimalarial ACT
155202|NCT01755572|Drug|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
155203|NCT01755572|Drug|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
155204|NCT01755598|Biological|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
154717|NCT01760421|Drug|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
154718|NCT01760434|Other|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
154993|NCT00095836|Drug|gefitinib|Taken orally once a day
154994|NCT01752231|Drug|MultiHance|
154995|NCT01752231|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI using new pulse sequences
154996|NCT01752244|Dietary Supplement|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
154997|NCT01752244|Dietary Supplement|Alfacalcidol|Alfacalcidol
154998|NCT01752257|Drug|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
154999|NCT01752270|Drug|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
155000|NCT01752270|Drug|Diane-35 pretreatment|
155001|NCT01752283|Procedure|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
155002|NCT01752283|Procedure|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
155003|NCT01752322|Drug|Lidocaine 5% medicated plaster|
155004|NCT00095862|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|
155005|NCT01752322|Drug|Placebo plaster|
155006|NCT01752335|Other|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
155007|NCT01752348|Other|Endotoxin, US standard reference E.coli|
155008|NCT01752361|Device|Motilis-3D transit|
155009|NCT01752400|Drug|AUY922|
155010|NCT01752413|Dietary Supplement|Ferrous gluconate 325mg|Participants with low ferritin (<30 micrograms/L (males) or <20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
155011|NCT01752413|Behavioral|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
154165|NCT01766674|Behavioral|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
154166|NCT01766687|Dietary Supplement|Hydration|
154167|NCT01766700|Behavioral|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
154168|NCT01766700|Behavioral|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
154169|NCT01766713|Drug|Ezetimibe|
154170|NCT01766739|Biological|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
154171|NCT01766752|Device|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
154172|NCT00001895|Drug|FDG|
154173|NCT00096863|Other|Placebo|
154492|NCT01754181|Drug|Insulin|the intervention is applied only at the dose of insulin
154493|NCT01754194|Procedure|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
154494|NCT01754194|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
154495|NCT01754207|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
154496|NCT01754207|Device|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
154497|NCT01754220|Drug|Montelukast|Montelukast is a leukotriene receptor antagonist
154498|NCT01754233|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
154499|NCT01754246|Device|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
154500|NCT01754259|Drug|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor.
154501|NCT01754259|Drug|Placebo Pill|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor.
154502|NCT00095940|Procedure|positron emission tomography|Correlative studies
153935|NCT01768663|Drug|Lumacaftor|tablet, 200mg taken every 12 hours
153936|NCT01768663|Drug|Ivacaftor|tablet, 250mg taken every 12 hours
153937|NCT01768663|Drug|Ciprofloxacin|750 mg taken every 12 hours
153938|NCT01768663|Drug|Itraconazole|200mg taken once daily
153939|NCT00097214|Biological|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
153940|NCT01768663|Drug|Rifampin|600mg taken once daily
153941|NCT01768676|Drug|avanafil|100 mg
153942|NCT01768676|Drug|Placebo|
153943|NCT01768689|Behavioral|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
153944|NCT01768689|Behavioral|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
153945|NCT01768689|Behavioral|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
153946|NCT01768702|Biological|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
153947|NCT01768702|Biological|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
153948|NCT01768728|Procedure|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
153949|NCT01768728|Procedure|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
153950|NCT00097227|Biological|Cetuximab|(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.
A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.
153951|NCT01768741|Procedure|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
153952|NCT01768741|Procedure|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
154244|NCT00001890|Drug|Estrogen therapy|
154245|NCT01764399|Behavioral|Care4U|
154246|NCT01764425|Drug|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
148720|NCT01703286|Drug|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
148721|NCT01703312|Drug|QGE031|Drug administered by subcutaneous injection
148722|NCT01703312|Drug|omalizumab|Drug administered by subcutaneous injection
148723|NCT00091143|Biological|keyhole limpet hemocyanin|
148724|NCT01703312|Drug|placebo|Drug administered by subcutaneous injection
148725|NCT01703325|Drug|0.1% triamcinolone , 0.05% clobetasol propionate ointment|Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C
Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection
Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months
Group C: Controlled group
148726|NCT01705899|Drug|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
148727|NCT01705912|Other|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
148728|NCT01705912|Other|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
148729|NCT01705938|Drug|SP-333|
148730|NCT01705951|Other|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
148731|NCT01705951|Biological|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
148732|NCT01705964|Drug|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
148733|NCT00091377|Drug|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
149045|NCT01708993|Drug|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
149454|NCT01702025|Drug|Aminophylline|National Drug Code (NDC) 0143-1020-01
149455|NCT01702025|Drug|Methazolamide|NDC 0781-1072-01
149456|NCT01702025|Drug|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
149457|NCT01702038|Drug|Rituximab|1000 mg administered intravenously
149458|NCT00091091|Procedure|management of therapy complications|
152548|NCT01728389|Procedure|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
152549|NCT01728402|Procedure|blood draw, bone marrow procedure, or tissue biopsy|
152550|NCT01728415|Other|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
152551|NCT01728441|Device|Paclitaxel Eluting Stent|
152552|NCT01728441|Device|Paclitaxel Eluting Balloon|
152553|NCT01728454|Drug|Placebo|
152554|NCT01728454|Drug|Proellex 6 mg|
152555|NCT00093587|Drug|busulfan|
152556|NCT01728454|Drug|Proellex 12 mg|
152557|NCT01728467|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
152558|NCT01728467|Drug|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
152559|NCT01728480|Drug|entolimod|Given SC
152560|NCT01720264|Drug|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
152561|NCT01720277|Biological|HD Fluzone Vaccine|
152562|NCT01720277|Biological|SD Fluzone Vaccine|
152563|NCT01720290|Drug|repaglinide|Dose individually adjusted
152564|NCT01720290|Drug|metformin|Dose individually adjusted
152565|NCT01720290|Drug|metformin|Dose at 1000 mg/day
152007|NCT01721967|Drug|Ranolazine|
152008|NCT01721980|Drug|GLPG0974|
152009|NCT01721980|Drug|Placebo|
152010|NCT01721993|Drug|T121|
152011|NCT01721993|Drug|Zoledronic acid|
152012|NCT01722006|Behavioral|Pairing condition|
152013|NCT01722006|Behavioral|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
152014|NCT00092989|Drug|montelukast sodium|Duration of Treatment: 1 dose
152293|NCT01722539|Drug|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
152294|NCT01722539|Drug|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
152295|NCT01722539|Drug|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
152296|NCT00093041|Drug|Zalutumumab|Weekly infusion
152297|NCT01722552|Behavioral|adherence feedback|
152298|NCT01722565|Procedure|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
152299|NCT01722578|Drug|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
152300|NCT01722578|Drug|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
152301|NCT01722591|Device|Cardiapex device|Cardiapex percutaneous transapical access and closure system
152302|NCT01722604|Drug|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
152303|NCT01722604|Drug|Azopt 1%|Azopt 1%, RLD
152304|NCT01722617|Other|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
152305|NCT01722630|Drug|Dopamine|
153028|NCT01769456|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
153029|NCT01769469|Drug|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
153030|NCT00097305|Behavioral|Standardized Massage Therapy|
153031|NCT01769482|Drug|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
153032|NCT01769482|Drug|placebo|
153033|NCT01769495|Other|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
153034|NCT01769508|Drug|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
153035|NCT01769508|Drug|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
153036|NCT01769508|Drug|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
153037|NCT01769508|Radiation|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
153038|NCT01769521|Device|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
153039|NCT01769547|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
153040|NCT01769560|Behavioral|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
153041|NCT00001905|Drug|Interferon gamma|
153042|NCT00097318|Drug|Interferon beta-1a|
152070|NCT01727557|Procedure|local anesthesia|Regional anesthesia will be compared to local anesthesia
152071|NCT01727570|Dietary Supplement|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
152072|NCT01730287|Drug|Calcium Hydroxide|Calcium Hydroxide paste applied.
152073|NCT01730287|Drug|Mineral Trioxide Aggregate(MTA)|MTA applied .
152074|NCT01730287|Drug|CEM cement|CEM cement applied .
152075|NCT00093678|Procedure|nutritional support|
152734|NCT01728753|Drug|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
152735|NCT01728753|Drug|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
152736|NCT01728753|Drug|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
152737|NCT01728753|Drug|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
152738|NCT01728766|Other|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at >37 weeks by and birth weight <2500 g
152739|NCT01728766|Other|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at >37 weeks and birth weight >2800 g
152740|NCT01728779|Drug|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
152741|NCT01728779|Radiation|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
152742|NCT01728792|Biological|DENVax|DENVax is a live attenuated Dengue vaccine
152743|NCT01720537|Biological|PF-05335810 Dose D|Single Intravenous Infusion
152744|NCT01720537|Biological|Placebo|Single Intravenous Infusion
152745|NCT01720550|Drug|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
152746|NCT01720550|Drug|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
152747|NCT01720563|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
152748|NCT01720563|Drug|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
152749|NCT01720563|Procedure|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
152750|NCT01720576|Drug|REGN1033 (SAR391786)|
152751|NCT00001784|Drug|Mexiletine|
152752|NCT00092820|Drug|MK0653, ezetimibe|
152753|NCT01720576|Drug|Placebo|
153106|NCT01767311|Drug|BAN2401 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
152527|NCT01725672|Drug|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152528|NCT00093353|Drug|temozolomide|
152529|NCT01725672|Drug|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152530|NCT01725672|Drug|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152531|NCT01725672|Drug|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152532|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
152533|NCT00093561|Dietary Supplement|lycopene|
152534|NCT01728324|Drug|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
152535|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
152536|NCT01728324|Drug|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
152537|NCT01728324|Drug|Faldaprevir: 16-week treatment|16 weeks of active treatment
152538|NCT01728324|Drug|Ribavirin: 16-week treatment|16 weeks of active treatment
152539|NCT01728324|Drug|RBV: 24-week treatment|24 weeks of active treatment
152540|NCT01728324|Drug|BI 207127: 16-week treatment|16 weeks of active treatment
152541|NCT01728337|Drug|Dysport|Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
152542|NCT01728337|Drug|Xeomin|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
152543|NCT01728350|Behavioral|HOPE - Helping Others through Purpose and Engagement|
152544|NCT00093587|Biological|anti-thymocyte globulin|
152545|NCT01728363|Drug|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
151659|NCT01724047|Behavioral|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
151660|NCT01724073|Dietary Supplement|Leafy vegetable-fish sauce|
151661|NCT01724073|Dietary Supplement|Leafy vegetable-fish/liver sauce|
151662|NCT01724073|Dietary Supplement|Misola|
151663|NCT01724086|Drug|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
150764|NCT01734941|Drug|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
150765|NCT01734941|Drug|Placebo|
150766|NCT01734954|Procedure|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
150767|NCT01734954|Procedure|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
150768|NCT00001830|Drug|Th2 Cells|
150769|NCT00094081|Procedure|Radiation Therapy|
150770|NCT01734954|Drug|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
150771|NCT01734954|Device|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
150772|NCT01734954|Device|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
150773|NCT01734954|Drug|supplemental oxygen|supplemental oxygen during the block and/or during surgery
150774|NCT01734954|Drug|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
150775|NCT01734954|Drug|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
151729|NCT01721525|Drug|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
151730|NCT01721538|Other|Weight reduction program|
151731|NCT01721538|Other|Lecture on healthy nutrition|
151732|NCT01721551|Other|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
151733|NCT01721564|Drug|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
151734|NCT01721577|Drug|AXL1717|IGF-1 receptor inhibitor
151735|NCT01721590|Drug|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
151736|NCT01721590|Drug|placebo|3 capsules/time，3times/day for 1 year
151737|NCT01721603|Drug|Dabrafenib|150mg capsule by mouth twice daily
151738|NCT00092924|Drug|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
151739|NCT01721603|Procedure|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
151740|NCT01721616|Drug|Azithromycin|
151741|NCT01721616|Drug|Cefazolin|
151742|NCT01721629|Procedure|Sudden wean of nasal CPAP|
150844|NCT00093834|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
150845|NCT01732822|Drug|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
150846|NCT01734954|Procedure|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
151510|NCT01731600|Drug|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
151511|NCT01731613|Dietary Supplement|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
151512|NCT01731639|Other|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form > 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
151513|NCT01731652|Drug|TMX-101|
151514|NCT01731678|Procedure|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
151515|NCT01731691|Biological|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
151516|NCT00093756|Drug|paclitaxel|Given IV
151517|NCT01731704|Radiation|Stereotactic radiosurgery (SRS)|
151518|NCT01731704|Radiation|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
151519|NCT01726452|Drug|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine given IV half an hour before commencing Paclitaxel.Once the Paclitaxel infusion is completed NACL 0.9%,100 ml will be infused IV over half an hour.After this infusion is completed Ondansetron or its equivalent diluted in 100mls NACL 0.9% will be given IV over half an hour on Days 1, 8, 15, 22 and 29.
151520|NCT01726452|Drug|Carboplatin|Dose determined as per calculation,infused on Days 1, 8, 15, 22 and 29.
151521|NCT01726465|Drug|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
150991|NCT01740297|Drug|Ipilimumab|Ipilimumab administered intravenously on Day 1 of Week 1, 4, 7, and 10 for a total of 4 infusions.
150992|NCT01740310|Behavioral|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
150993|NCT01740323|Drug|Placebo|daily placebo for 6 weeks
150994|NCT00094757|Drug|Comparator: pioglitazone|pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
150995|NCT01740323|Drug|Curcumin|500 mg BID
151299|NCT01733758|Drug|Placebo|Albiglutide matching placebo will be available as a pen injector
151300|NCT01733758|Drug|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
151301|NCT01733771|Other|CAM treatments|CAM treatments last 10-30 minutes
151302|NCT01733784|Other|Induced central apneas|
151303|NCT01735708|Other|Health Education|
151304|NCT01735721|Procedure|Open Sinus Lift|A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).
The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material.
151305|NCT00001832|Drug|gp100:209-217 (210M)|gp100 = gp100:209‑217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209‑217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
151306|NCT00094250|Behavioral|Resistance and Aerobic Training|
151307|NCT01735734|Device|Air cooling to CM site|
151308|NCT01735747|Radiation|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
154780|NCT01757821|Device|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
154781|NCT01757834|Device|SWUS Elastography|
154782|NCT01760447|Drug|Placebo to Sitagliptin + Metformin XR|Matching placebo to Sitagliptin + Metformin XR fixed-dose combination tablet administered with a meal, preferably in the evening
154783|NCT01760447|Drug|Metformin XR|Metformin XR tablet (500 mg, 1000 mg) administered with a meal, preferably in the evening
154784|NCT01760447|Drug|Placebo to metformin XR|Matching placebo to metformin XR tablet administered with a meal, preferably in the evening
154785|NCT01760447|Drug|Insulin glargine|The insulin regimen and dosing will be at the discretion of the investigator (based on locally accepted, national, or international guidelines for the indication and use of insulin glargine). When thresholds for rescue are met, participants who are not on background insulin will initiate insulin glargine.
154786|NCT01760447|Biological|Background insulin|Participants who enter the study on background insulin will continue on the same dose and formulation of insulin throughout the study. When thresholds for rescue are met, participants who have entered the study on background insulin will uptitrate their background insulin dose.
154787|NCT01760460|Drug|Anacetrapib|
154788|NCT01760460|Drug|Placebo for anacetrapib|
154789|NCT00096317|Drug|ixabepilone|
154790|NCT01760473|Drug|Buprenorphine/naloxone|administered intranasally
154791|NCT01760473|Drug|Buprenorphine|administered intranasally
154792|NCT01760473|Drug|Naloxone|negative control
154793|NCT01760473|Drug|Placebo|neutral control
154794|NCT01760473|Drug|Heroin|positive control
154795|NCT01760486|Behavioral|Shape Up Rhode Island|
155386|NCT01753024|Dietary Supplement|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
155387|NCT01753037|Dietary Supplement|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
155388|NCT01753037|Other|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
155389|NCT01753050|Device|Stroke volume monitoring|Pulse contour stroke volume monitoring
155390|NCT00000277|Drug|Mazindol|
154577|NCT01754337|Other|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
154578|NCT01754350|Dietary Supplement|calorie-restricted ketogenic diet and transient fasting|On day 1-3 and day 7-9, restriction of carbohydrates to < 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by "Tavarlin".
154579|NCT01754350|Dietary Supplement|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
154580|NCT01754363|Device|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
154581|NCT00095940|Procedure|magnetic resonance imaging|Correlative studies
154582|NCT01754376|Drug|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
154583|NCT01754376|Drug|Vemurafenib|Tablets given twice daily.
154584|NCT01754389|Drug|Tacrolimus|
154585|NCT01754389|Drug|Methotrexate|
154586|NCT01754389|Drug|Bortezomib|
154587|NCT01754389|Drug|Sirolimus|
154588|NCT01754402|Drug|Bendamustine|Bendamustine will be administered intravenously over one hour on day 1, every 28 days for 12 cycles.
154589|NCT01754402|Drug|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
154590|NCT01754402|Drug|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
154591|NCT01754415|Device|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
155205|NCT01755598|Biological|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
155206|NCT00096070|Drug|fluorouracil|Given IV
155207|NCT01755611|Drug|Minocycline 100mg|Test product
155567|NCT01753414|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
155568|NCT01753414|Procedure|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
155569|NCT01753440|Procedure|Intramyocardial implantation of allogeneic mesenchymal stem cells|Intramyocardial implantation of allogeneic mesenchymal stem cells
155570|NCT00095914|Drug|paclitaxel|
155571|NCT01753453|Drug|Plerixafor|240mcg/kg, solution, subcutaneous injection
155572|NCT01753453|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
155573|NCT01753466|Dietary Supplement|Hydration|
155574|NCT01753479|Other|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
155575|NCT01753492|Device|Ologen|
155576|NCT01753505|Other|64-slice Multidetector coronary CT angiography|
155577|NCT01753518|Device|Subcuticular suture|subcuticular Monocryl suture closure
155578|NCT01753518|Device|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
155579|NCT01753531|Device|Flu Symptoms|
155580|NCT01753557|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
155581|NCT00095914|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
155582|NCT01753557|Drug|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
155583|NCT01753557|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
155584|NCT01753570|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
155585|NCT01753570|Drug|RBV|RBV: 600 - 1000 mg/day based on body weight for 48 weeks
155012|NCT01752426|Other|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
155013|NCT01755143|Device|Pacemaker System|
155014|NCT01755156|Drug|MK-3102|MK-3102 25 mg capsule administered orally once weekly (preferably on the same day of each week)
155015|NCT01755156|Drug|Matching placebo to MK-3102|Matching placebo to MK-3102 capsule administered orally once weekly (preferably on the same day of each week)
155270|NCT01752790|Drug|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
155271|NCT01752790|Drug|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
155272|NCT00095875|Drug|docetaxel|Given IV
155273|NCT01752803|Dietary Supplement|Probiotic|mix probiotic
155274|NCT01752803|Dietary Supplement|Placebo|placebo
155275|NCT01752816|Behavioral|exercise training|
155276|NCT01752842|Drug|Fenofibrate|
155277|NCT01752842|Drug|Placebo for fenofibrate|
155278|NCT01752855|Biological|New formulation adalimumab|New formulation adalimumab 40 mg every other week
155279|NCT01752868|Dietary Supplement|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
155280|NCT01752881|Biological|Influenza vaccine (split virion, inactivated)|AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013
Dosage: 0.5mL/per syringe
Administration route: Intramuscular Injection, once
155281|NCT01752881|Biological|AdimFlu-S|
155282|NCT01752894|Device|Angio-guided PCI with EES or BES|Angio-guided intervention
155283|NCT00095875|Drug|fluorouracil|Given IV
154503|NCT01754285|Drug|LF-PB and Placebo|
154504|NCT01754285|Drug|Placebo|
154505|NCT01754285|Drug|LF-PB|
154506|NCT01757145|Drug|Eltrombopag|From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.
If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).
If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count >50,000/microliter will be reached again).
154507|NCT01757158|Radiation|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
154508|NCT01757171|Drug|Cabazitaxel|20mg IV over 1 hour every 3 weeks
154509|NCT01757184|Drug|SBC-102 [sebelipase alfa] (1 mg/kg)|
154510|NCT01757184|Drug|Placebo|
154511|NCT01757197|Drug|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
153544|NCT01765582|Drug|5-fluorouracil|iv every 2 weeks, 4-6 months induction followed by maintenance therapy
153545|NCT01765582|Drug|bevacizumab [Avastin]|5 mg/kg iv every 2 weeks, 4-6 months induction, followed by 5 mg/kg iv every 2 weeks or 7.5 mg/kg iv every 3 weeks maintenance therapy, and 2.5 mg/kg/week reinduction after disease progression
153546|NCT01765582|Drug|capecitabine [Xeloda]|1000 or 850 mg/kg orally b.i.d. Day 1-14, repeated every 3 weeks, maintenance phase
153547|NCT01765582|Drug|fluoropyrimidine-based chemotherapy|reinduction therapy after disease progression
153548|NCT01765582|Drug|irinotecan|iv every 2 weeks (Arm A) or iv 2 x 2 weeks cycles alternating months (Arm B), 4-6 months induction
153549|NCT01765582|Drug|leucovorin|iv every 2 weeks, 4-6 months induction followed by maintenance therapy
153550|NCT01765582|Drug|oxaliplatin|iv every 2 weeks (Arm C) or 2 x 2 week cycles alternating months (Arm B), 4-6 months induction
153551|NCT01765595|Other|DDI+|
153552|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
154247|NCT01764438|Procedure|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
154248|NCT01764451|Drug|Simvastatin|
154249|NCT01764464|Drug|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
154250|NCT01764464|Drug|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
154251|NCT01764477|Drug|PRI-724|Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)
PRI-724:
Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)
154252|NCT00001893|Drug|TNFR:Fc|
154253|NCT00096590|Other|physiologic testing|
154254|NCT01764529|Other|Natural history data collection|Collection of detailed medical history, brain MRI, and neurological and physical examination.
154255|NCT01764542|Procedure|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
154256|NCT01764555|Drug|acetaminophen 2 g|
154257|NCT01764568|Behavioral|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz & Woodward 2007a; Moritz & Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8‐module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
154258|NCT01764568|Behavioral|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
154259|NCT01764581|Procedure|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
154260|NCT01764594|Biological|CDP7657|CDP7657 100 mg/ ml solution
30 mg/ kg initial dose
15 mg/ kg every other week
10 weeks
153300|NCT01767649|Other|Vaginal delivery|Collection of tissues and blood
149046|NCT00091806|Drug|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
149047|NCT01708993|Drug|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
149048|NCT01708993|Drug|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
149049|NCT01708993|Drug|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
149050|NCT01709006|Radiation|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
149051|NCT01709019|Biological|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
149052|NCT01709019|Biological|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
149053|NCT01709019|Biological|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
149054|NCT01709019|Biological|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
149055|NCT01709019|Biological|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
149056|NCT01709032|Drug|Deferasirox and deferiprone|
149057|NCT00091806|Drug|Panitumumab|9 mg/kg once every 3 weeks
149058|NCT01709045|Other|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
149059|NCT01709045|Radiation|Dual-Energy Computed Tomography (DECT)|
149060|NCT01701349|Drug|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
149061|NCT01701362|Drug|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
149062|NCT01701362|Drug|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
149063|NCT01701375|Drug|PD 0332991|• PD 0332991 will be given orally days 1,2,3
149064|NCT00091039|Drug|carboplatin|
149065|NCT01701388|Device|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
152566|NCT00092768|Drug|Comparator: celecoxib|
152567|NCT01720303|Drug|repaglinide|2 mg (tablets) before each main meal
152568|NCT01720303|Drug|isophane human insulin|Injection s.c. (under the skin) at bedtime
152569|NCT01720303|Drug|insulin|Injection s.c. (under the skin) twice daily
152570|NCT01720316|Drug|glycine powder|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
152571|NCT01720316|Drug|placebo|
152572|NCT01720329|Dietary Supplement|Probiotics|Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
152843|NCT01720654|Behavioral|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
152844|NCT01720667|Drug|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
152845|NCT01720667|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg)following EEG confirmation of seizure activity load.
152846|NCT00092833|Drug|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
152847|NCT01720680|Radiation|Low dose multislice CT thorax|All patients will have 2 low dose multi-slice CT's at visit 2: one CT "pre-dose" and one CT 1 to 3 hours "post-dose".
152848|NCT01720680|Device|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
152849|NCT01720693|Procedure|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
152850|NCT01720706|Device|RFA Loosely wound thermal coil|This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.
This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode.
152851|NCT01720719|Drug|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
152852|NCT01720719|Drug|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
152853|NCT01720732|Behavioral|Lifeline NET|Short Version of Narrative Exposure Therapy
152854|NCT01720771|Dietary Supplement|probiotic tablet|Intake of one probiotic lozenge tablet per day
152855|NCT01720771|Dietary Supplement|sugar pill|one tablet daily
152306|NCT01722643|Behavioral|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
152307|NCT00093054|Drug|Cranberry juice|TID dosage for UTI treatment
152308|NCT01725178|Behavioral|Cognitive and Physical training|Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.
Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management.
152309|NCT01725191|Other|Laboratory Biomarker Analysis|Correlative studies
152310|NCT01725191|Other|Pharmacological Study|Correlative studies
152591|NCT01723215|Behavioral|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
152592|NCT01723215|Behavioral|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
152593|NCT01723215|Behavioral|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
152594|NCT01723228|Drug|Rasagiline|
152595|NCT01723228|Drug|Placebo|
152596|NCT01723241|Drug|XAF5, concentration A|
152597|NCT01723241|Drug|XAF5, concentration B|
152598|NCT01723241|Drug|XAF5, concentration C|
152599|NCT01723241|Drug|Placebo|
152600|NCT01723254|Biological|IGE-1|Intramuscular, multiple dose
152601|NCT00093093|Drug|pegylated interferon alfa-2a|
152602|NCT01723254|Biological|IGE-2|Intramuscular, multiple dose
152603|NCT01723254|Biological|Saline|Saline (0.9% sodium chloride)
152604|NCT01723267|Other|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
152076|NCT01730313|Drug|Pyridoxine|
152077|NCT01730313|Drug|Sodium Valproate|
152078|NCT01730313|Drug|Phenytoin|
152079|NCT01730313|Drug|Placebo|
152080|NCT01730326|Drug|Paracetamol|1000 mg
152081|NCT01730326|Drug|Dexketoprofen|50 mg
152082|NCT01730339|Drug|PF-06473871|Single dose administered by injection four different times
152083|NCT01730339|Drug|PF-06473871|Single dose administered by injection three different times
152084|NCT01730352|Drug|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
152085|NCT01730365|Procedure|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
152086|NCT00093678|Procedure|pain therapy|
152087|NCT01730378|Biological|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
152088|NCT01730378|Biological|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
152089|NCT01730391|Other|Data collection|Collection of demographic data and vaccination history
152090|NCT01730391|Other|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
152091|NCT01730404|Drug|CHF6001 DPI|
152092|NCT01730404|Drug|Roflumilast|
152093|NCT01730404|Drug|Placebo|
152378|NCT01730651|Radiation|Tomotherapy|IMRT boost of gross LNs
Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)
Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)
152379|NCT01730664|Drug|ertapenem|single dose of 1000mg ertapenem IV
152380|NCT01730677|Drug|Lapatinib|lapatinib 1000mg, once daily
153107|NCT01767311|Drug|BAN2401 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
153108|NCT01767311|Drug|BAN2401 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
153109|NCT01767311|Drug|BAN2401 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as a 60 minute i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
153110|NCT01767311|Drug|BAN2401 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as a 60 minute i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
153111|NCT01767324|Device|FLUGEN 101.2 microneedle-based delivery device|
153112|NCT01767337|Device|FLUGEN 101.2 microneedle-based delivery device|
153113|NCT01767350|Procedure|Blood withdrawal for DNA|Single withdrawal of 8 ml whole blood for DNA analysis, during a "standard" blood collection as part of standard clinical follow up.
153114|NCT01767363|Other|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
153115|NCT01767363|Other|Alpha-blockers|Use of alpha-blockers over the study period.
153116|NCT00096993|Drug|Gemcitabine|Gemcitabine was provided as a solution for infusion.
153117|NCT01767376|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
153118|NCT01767376|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
153119|NCT01767389|Other|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
153120|NCT01767389|Other|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
153121|NCT01767389|Other|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
153122|NCT01767402|Biological|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
153123|NCT01767402|Biological|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
153124|NCT01769664|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
152546|NCT01728376|Drug|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes
152547|NCT01728376|Drug|Comparator (Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin)|Administered per standard of care
152819|NCT01728805|Drug|Vorinostat|
152820|NCT01728818|Drug|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
152821|NCT01728818|Drug|Afatinib|40mg flat dose, po, once daily
152822|NCT01728818|Drug|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
152823|NCT01728857|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
152824|NCT01728870|Other|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
152825|NCT01728870|Other|Exclusive Enteral Nutrition (Modulen)|
152826|NCT01728883|Device|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
152827|NCT01728896|Other|Patient-controlled oral refeeding|
152828|NCT00093600|Drug|cytarabine|
152829|NCT01728909|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
152830|NCT01728909|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
152831|NCT01728922|Dietary Supplement|5000IU vitamin D|Vigantol Oil
152832|NCT01728922|Dietary Supplement|10000IU vitamin D|Vigantol Oil
152833|NCT01728922|Other|Placebo|Placebo Oil
152834|NCT01728935|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
152835|NCT01728948|Drug|Sorafenib( Nexavar, BAY43-9006)|treatment(including dose, duration, modification) decided by the investigator
152836|NCT01728961|Drug|Artemether/Lumefantrine (AL)|
152837|NCT01728974|Other|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
152838|NCT01728987|Drug|cholecalciferol|as in arm description
150776|NCT01737190|Other|PEEP guided by Esophageal pressure + Recruitment maneuver|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.
A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed.
150777|NCT01737203|Drug|Viagra|50 mg tablet on Day 1 of each period
150778|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
150779|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
150780|NCT01737216|Drug|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
150781|NCT01737216|Drug|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
151080|NCT01720121|Other|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
151081|NCT00092755|Drug|Comparators: ibuprofen and placebo|
151082|NCT01720147|Drug|Quercetin (dietary supplement)|Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.
151083|NCT01720160|Device|Barostim Neo system|Patients will be implanted with the Neo system.
151084|NCT01720173|Biological|Dalantercept|Given SC
151085|NCT01720173|Other|Laboratory Biomarker Analysis|Correlative studies
151086|NCT01720186|Device|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
151087|NCT01720199|Other|Diario della Salute (DDS)|DDS is composed by
tools for children and their parents on health and social and emotional well-being issues:
a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),
a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);
five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers.
151088|NCT01720212|Drug|YM178|oral
151089|NCT01720225|Drug|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
150847|NCT01734967|Device|needle based CLE|EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:
The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.
nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).
Image data will be stored digitally for offline analysis.
150848|NCT01734967|Procedure|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
150849|NCT01734980|Procedure|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
150850|NCT00094094|Drug|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
150851|NCT01734993|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, 104 weeks
150852|NCT01735006|Biological|HPV Vaccine|3 doses at month 0,1 and 6
150853|NCT01735006|Biological|HEV vaccine|3 doses at month 0,1 and 6
150854|NCT01735019|Drug|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
150855|NCT01735045|Device|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
150856|NCT01735045|Device|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
150857|NCT01735058|Drug|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
150858|NCT01735058|Drug|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
150859|NCT01735071|Drug|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
151156|NCT00001832|Drug|MART-1:26-35(27L)|MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
151157|NCT00094536|Procedure|HerOption Endometrial Cryoablation Therapy|
151522|NCT01726465|Drug|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°−110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
151800|NCT01729663|Biological|CSF470 vaccine, BCG, Molgramostim|
151801|NCT01729663|Drug|interferon alpha 2b|
151802|NCT01729676|Drug|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
151803|NCT01729689|Other|counseling intervention|Undergo cognitive behavioral therapy
151804|NCT01729689|Other|questionnaire administration|Ancillary studies
151805|NCT01729689|Procedure|quality-of-life assessment|Ancillary studies
151806|NCT01729702|Other|blood sample collection|
151807|NCT01729715|Behavioral|Internet|
151808|NCT01729715|Behavioral|DVD|
151809|NCT00093652|Drug|oxaliplatin|
151810|NCT01721642|Device|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
151811|NCT01721655|Drug|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
151812|NCT01721655|Drug|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
151813|NCT01721668|Behavioral|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
151814|NCT01721668|Behavioral|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
151815|NCT00092937|Drug|Busulfan|
151816|NCT01721681|Biological|FACTOR X|
151817|NCT01721694|Drug|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
151309|NCT01735747|Drug|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
151310|NCT01735747|Drug|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
151311|NCT01735747|Drug|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
151312|NCT01735786|Device|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
151313|NCT01735812|Device|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
151314|NCT01735825|Device|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
151315|NCT01735825|Device|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
151316|NCT01735825|Device|paclitaxel-coated balloon catheter with hydrophilic coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter with hydrophilic coating
151572|NCT01723969|Genetic|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
151573|NCT01723982|Drug|Barusiban (FE 200440)|
151574|NCT01723982|Drug|Placebo Comparator|
151575|NCT01723995|Radiation|low-level laser on nipples|The LASER HAND WL device, manufactured by MM Optics.
151576|NCT01724008|Drug|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
151577|NCT01724008|Drug|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
151578|NCT01724021|Drug|CHOP|standard chemotherapy
151579|NCT00093197|Drug|KAI-9803 for Injection|0.5 mg
151580|NCT01724021|Drug|CVP|standard chemotherapy
151581|NCT01724021|Drug|bendamustine|standard chemotherapy
151582|NCT01724021|Drug|rituximab [MabThera/Rituxan]|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
151583|NCT01724021|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 IV, Day 1 Cycles 1-4
155391|NCT00001863|Drug|Leflunomide|
155392|NCT00095888|Drug|gemcitabine hydrochloride|Given IV
155393|NCT01753063|Behavioral|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
155394|NCT01753063|Behavioral|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
155395|NCT01753076|Drug|Ozanezumab|Ozanezumab injection solution
155396|NCT01753076|Drug|Placebo|Normal saline (0.9% sodium chloride) infusion
155397|NCT01753089|Biological|WDVAX|
155398|NCT01753102|Drug|Estradiol|one tablet will be inserted daily for 14 days
155399|NCT01755871|Drug|Fingolimod|0,5mg Fingolimod once a day
155400|NCT01755884|Dietary Supplement|Wheat oral immunotherapy|Cooked spaghetti
155401|NCT01755897|Procedure|radical hysterectomy + pelvic lymph node dissection|
155402|NCT01755897|Drug|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
155403|NCT01755897|Drug|Cisplatin|75 mg/m(2) IV on day 2 and 3
155404|NCT01755897|Drug|Cisplatin|35 mg/m(2) IV once a week
155405|NCT00096096|Drug|mycophenolate mofetil|
155406|NCT01755897|Radiation|Pelvic RT|IMRT
155407|NCT01755910|Other|Left thoracic paravertebral block|
155408|NCT01755910|Other|Right thoracic paravertebral block|
155409|NCT01755923|Drug|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
155410|NCT01755923|Drug|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
155431|NCT01758978|Drug|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
154849|NCT01757847|Behavioral|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
154850|NCT01757860|Drug|CARD-024|Comparison of different dosages of drug
154851|NCT01757860|Other|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
154852|NCT01757873|Drug|Z160|
154853|NCT01757873|Drug|Placebo|
154854|NCT01757886|Other|Biomarkers to analyze both intracoronary thrombi as blood|
154855|NCT01757899|Drug|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
154856|NCT01757899|Drug|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
154857|NCT01757912|Procedure|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
154858|NCT01757925|Behavioral|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
154859|NCT00096161|Drug|Mycophenolate Mofetil|Given PO
154860|NCT01757925|Other|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
154861|NCT01757938|Procedure|Shang Ring Guided Circumcision|
154862|NCT01757938|Procedure|Forceps Guided Circumcision|
154863|NCT01757951|Procedure|Talocrural joint is stable after fixation of medial malleolus. Patient is then randomized|
154864|NCT01757964|Biological|Bacteriotherapy|
154865|NCT01757977|Device|double lumen endotracheal tube placement and use|
155586|NCT01753570|Drug|IFN beta|IFN: 600 MIU/day, 6 days/week for initial 4 weeks following to 3 days/week
155587|NCT01753583|Device|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
155588|NCT01753583|Other|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
155589|NCT01756248|Drug|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
155590|NCT01756261|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
154640|NCT01751750|Other|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
154641|NCT01751763|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
154642|NCT01751776|Drug|BI 655064 medium dose|Medium dose
154643|NCT01751776|Drug|BI 655064 high dose|High dose
154644|NCT01751776|Drug|BI 655064 high dose|High dose
154645|NCT01751776|Drug|Placebo|Placebo
154646|NCT00095797|Other|pharmacological study|Correlative studies
154647|NCT01751776|Drug|BI 655064 low dose|Low dose
154648|NCT01751776|Drug|Placebo|Placebo
154649|NCT01751776|Drug|BI 655064 medium dose|Medium dose
154650|NCT01751789|Behavioral|Linkage|
154651|NCT01751789|Other|Treatment as Usual|
154652|NCT01754467|Behavioral|NEAT!|A total of 10 participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
154653|NCT01754480|Biological|Fibrin Sealant (FS) Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
154654|NCT01754480|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
155284|NCT01752894|Device|OCT-guided PCI with EES or BES|OCT-guided intervention
155285|NCT01752894|Device|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
155286|NCT01755663|Drug|Ivabradine and Metoprolol|
155287|NCT01755676|Drug|Orlistat 60 mg|1 tablet 3 times a day
155288|NCT01755676|Other|Placebo|1 tablet 3 times a day
155289|NCT01755689|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
155290|NCT00096070|Drug|gemcitabine hydrochloride|Given IV
155647|NCT01751087|Other|Mifepristone|oral mifepristone 200 mg on Day 1.
155648|NCT01751087|Drug|misoprostol|buccal misoprostol 400 mcg on Day 2
155649|NCT01751087|Device|Osmotic dilators|osmotic dilators on Day 1
155650|NCT01751087|Other|placebo|placebo for mifepristone, on day 1
155651|NCT01751087|Other|placebo|placebo for misoprostol, on day 2
155652|NCT01751100|Behavioral|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
155653|NCT01751100|Behavioral|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
155654|NCT01753596|Device|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
155655|NCT01753596|Other|Physiological Sodium Chloride solution (0,9%)|Placebo
155656|NCT01753609|Device|Tulip capsule|swallowing Tulip capsule for up to 29 days
155657|NCT00095927|Drug|amifostine trihydrate|Given subcutaneously
155658|NCT01753622|Behavioral|Exercise group|Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
155659|NCT01753635|Device|supraglottic airway placement and use|
155660|NCT01753648|Device|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
153553|NCT01765608|Drug|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
153554|NCT01765608|Drug|Placebo|
153555|NCT01765608|Device|nCPAP|
153556|NCT01765621|Other|DDI+ System and Pharmacogenetic Data|
153557|NCT01765634|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) each week, four times for a cycle.
153558|NCT01765634|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
153559|NCT01765647|Other|AGY|AGY is a natural health product produced in egg yolks
153560|NCT01768000|Behavioral|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
153561|NCT01768013|Drug|LEO 90105|Once daily for four weeks
153562|NCT01768039|Drug|Vitamin D|
153563|NCT01768039|Drug|Placebo|
153564|NCT01768052|Device|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
153868|NCT01771146|Drug|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
153869|NCT01771159|Device|TBC|The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor [bladder] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.
After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder.
153870|NCT01771185|Procedure|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
153871|NCT01771185|Drug|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
153872|NCT01771198|Drug|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
153301|NCT01767662|Procedure|manipulation|home programme
153302|NCT01769911|Drug|O6-benzylguanine|Given IV
153303|NCT01769911|Procedure|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
153304|NCT01769911|Procedure|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
153305|NCT01769911|Other|laboratory biomarker analysis|Correlative studies
153306|NCT00097344|Drug|Aromatase inhibition|
153307|NCT01769924|Other|Nephrectomy|
153308|NCT01769937|Drug|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
153309|NCT01769950|Other|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
153310|NCT01769963|Other|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
153311|NCT01769976|Other|Periodic fasting|
153312|NCT01769976|Other|Energy restriction|
153313|NCT01769976|Other|Energy balance diet|
153314|NCT01769989|Procedure|Electrodermabrasion|
153315|NCT01769989|Procedure|Dermabrasion|
153316|NCT01770002|Procedure|Everted suture technique|
153317|NCT00097344|Drug|Estrogen receptor blocker|
153318|NCT01770002|Procedure|Non-everted suture technique|
153319|NCT01770015|Procedure|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
153320|NCT01770015|Procedure|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
153321|NCT01770015|Procedure|endotracheal aspiration|fungi and bacteria endotracheal aspiration
149066|NCT01701401|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
149379|NCT01704456|Behavioral|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
149380|NCT01704456|Behavioral|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
149381|NCT00091260|Drug|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
149382|NCT01704469|Procedure|The local anesthetic injection|
149383|NCT01704482|Drug|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
149384|NCT01704482|Drug|placebo|
149385|NCT01704495|Drug|AZD5069|AZD5069 oral capsules self-administered twice daily.
149386|NCT01704495|Drug|Placebo|Placebo oral capsules self-administered twice daily.
149387|NCT01704508|Drug|Artemether-lumefantrine|
149388|NCT01704508|Drug|Dihydroartemisinin-piperaquine|
149389|NCT01704521|Drug|PegInterferon|
149390|NCT01704521|Drug|Ribavirin|
149391|NCT01704521|Drug|Telaprevir|
149392|NCT00091273|Biological|incomplete Freund's adjuvant|
149393|NCT01704534|Drug|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
149394|NCT01706874|Other|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
149395|NCT01706887|Other|Diet Amiloride|only arm of the trial
149396|NCT01706900|Other|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
152856|NCT01720784|Dietary Supplement|Alginate dietary fiber|
152857|NCT00092846|Drug|MK0803, lovastatin|
152858|NCT01720784|Dietary Supplement|Placebo|
152859|NCT01720797|Device|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
152860|NCT01720797|Drug|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
152861|NCT01720797|Other|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
152862|NCT01720823|Device|home polysomnography (GETEMED)|
152863|NCT01720823|Device|standard polysomnography (BRAINNET II)|
153198|NCT01767467|Biological|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
153199|NCT01767467|Drug|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
153200|NCT01767480|Device|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
153201|NCT00097019|Drug|bevacizumab|
153202|NCT01767480|Behavioral|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
153203|NCT01767493|Drug|[18F]Florbetapir and PET imaging|Subjects will have a baseline scan and second scan within 1 month following the baseline PET scan
153204|NCT01769768|Drug|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
153205|NCT01769781|Drug|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
153206|NCT01769781|Drug|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
152605|NCT01723267|Other|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
152606|NCT01723280|Drug|Oxygen|During and 2 hrs after surgery
152607|NCT01723293|Behavioral|Exercise group|The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.
Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training.
152608|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152609|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152610|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152960|NCT00093171|Drug|rFIX|
152961|NCT01723800|Other|laboratory biomarker analysis|Correlative studies
152962|NCT01723800|Other|pharmacological study|Correlative studies
152963|NCT01723800|Procedure|quality-of-life assessment|Ancillary studies
152964|NCT01723813|Biological|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
152965|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
152966|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
152967|NCT01723826|Drug|crenezumab|dosing frequency, dose level and route of administration as assigned to after the Week 73 visit of study ABE4869g or ABE4955g
152968|NCT01723839|Drug|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
152969|NCT01723852|Dietary Supplement|Vitamin D at 30 ug/day|
152381|NCT01730677|Drug|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
152382|NCT00093730|Drug|BMS-59926|
152383|NCT01730716|Device|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
152384|NCT01730729|Drug|cabergoline|Given orally
152385|NCT01722643|Behavioral|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment—quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
152386|NCT01722656|Drug|Aflibercept|
152387|NCT01722669|Drug|isoquercetin or quercetin|
152388|NCT01722682|Biological|Human pancreatic islet transplantation|
152389|NCT01722695|Other|Dialyzer comparison|Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).
The order of dialyzers used will be randomly assigned to the patient at randomization.
152390|NCT01722708|Drug|Clindamycin|Oral clindamycin 300 Milligrams*2/Day for a week
152391|NCT01722708|Drug|Metronidazole|Oral metronidazole 500 Milligrams*2/Day for a week
152392|NCT01722734|Behavioral|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
152393|NCT01722747|Behavioral|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)|A 7-month intervention was conducted over one academic year & included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
152394|NCT01722760|Procedure|measurements|
152395|NCT00093054|Dietary Supplement|Placebo cranberry juice|TID placebo dosage to match active comparator
152396|NCT01722773|Device|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
152677|NCT01720537|Biological|Placebo|Single Intravenous Infusion
152678|NCT01720537|Biological|PF-04950615|Single Subcutaneous Injection(s)
153125|NCT00097331|Drug|SB683699|
152156|NCT01727622|Procedure|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
152157|NCT01727635|Other|body-mind-spirit group therapy|8-session therapy
152158|NCT00093522|Biological|autologous tumor cell vaccine|
152159|NCT01727648|Behavioral|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
152160|NCT01727648|Behavioral|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
152161|NCT01727648|Behavioral|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
152162|NCT01727648|Behavioral|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
152163|NCT01727661|Behavioral|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
152164|NCT01727661|Behavioral|lung function testing|spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.
single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds.
152165|NCT01727661|Behavioral|quality of life|assessing quality of life using short-forum 36 (questionnaire)
152166|NCT01729845|Other|Laboratory Biomarker Analysis|Correlative studies
152167|NCT01729845|Drug|Mitoxantrone Hydrochloride|Given IV
152839|NCT00093600|Drug|daunorubicin hydrochloride|
152840|NCT01728987|Drug|placebo|capsule looking identical to the cholecalciferol capsule
152841|NCT01729000|Other|Gloves|All staff must wear gloves for subjects that are in the experimental group.
152842|NCT01729026|Other|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
153177|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
153178|NCT00096642|Behavioral|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
153179|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
153180|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
153181|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
153182|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
153183|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
153184|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
153185|NCT01764971|Other|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
153186|NCT01767402|Biological|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
153187|NCT01767415|Drug|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
153188|NCT01767428|Drug|Paracetamol|500 mg immediate release paracetamol formulations
153189|NCT00001895|Drug|NH(3)|
153190|NCT00096993|Drug|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
153191|NCT01767441|Procedure|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
153192|NCT01767441|Procedure|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
151090|NCT01720225|Drug|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
151091|NCT01720238|Drug|Entecavir|0.5mg qd
151092|NCT00092768|Drug|MK0663, etoricoxib|
151093|NCT01720238|Drug|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
151094|NCT01720251|Drug|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
151095|NCT01720251|Drug|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
151096|NCT01733173|Procedure|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
151097|NCT01733186|Biological|CARTISTEM®|
151098|NCT01733199|Other|questionnaires|Summons of patients and filling questionnaire.
151099|NCT01733212|Drug|Ginger|
151100|NCT01733238|Drug|PNT2258|
151382|NCT01735890|Drug|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
151383|NCT01735903|Procedure|Arm A - Non-Diabetic, Gait and Balance|Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University.
Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet.
151384|NCT00094276|Behavioral|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
151385|NCT01735916|Device|CRT-P Implant|The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.
The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.
Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care.
151386|NCT01735916|Device|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
151387|NCT01735929|Procedure|Neck Liposuction and Ultrasound Treatment|
151158|NCT01738087|Drug|Flixotide Accuhaler 500 mcg|Active comparator
151159|NCT01738087|Drug|NEXThaler 200/6 mcg DPI|
151160|NCT01730742|Behavioral|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
151161|NCT01730742|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
151162|NCT01730742|Procedure|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
151163|NCT01730755|Drug|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
151164|NCT01730768|Drug|AQW051|
151165|NCT01730768|Drug|Placebo|
151166|NCT01730781|Radiation|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
151167|NCT01730794|Other|NAVA ventilation|Neurally adjusted ventilatory assist
151168|NCT00093743|Drug|fludarabine phosphate|Given IV
151169|NCT01730794|Other|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
151170|NCT01730833|Biological|pertuzumab|Given IV
151171|NCT01730833|Biological|trastuzumab|Given IV
151172|NCT01730833|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
151173|NCT01730833|Other|laboratory biomarker analysis|Optional correlative studies
151174|NCT01730846|Drug|Doxazosin|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
151175|NCT01730846|Drug|Placebo|Placebo
151176|NCT01730859|Other|Balance exercise and ankle taping|Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.
Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week.
151451|NCT01733953|Drug|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
151818|NCT01721694|Drug|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
151819|NCT01721707|Drug|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
151820|NCT01721707|Drug|Latanoprost|1 drop in each eye, 1x/day, at 9PM
151821|NCT01721733|Drug|Placebo|
151822|NCT01721733|Drug|EPI-743 15 mg/kg|
150918|NCT01732887|Other|Cognitive fitness training|Computer-based training of basic cognitive functions. It has activities under two headings,
General training applications
Memory training applications
Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval.
150919|NCT00093834|Drug|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
150920|NCT01732900|Other|Morphology|Embryos selected for transfer will be based upon morphology alone.
150921|NCT01732900|Other|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
150922|NCT01732913|Drug|Idelalisib|Idelalisib tablet(s) administered orally
150923|NCT01732913|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
150924|NCT01732913|Drug|Placebo to match idelalisib|Placebo to match idelalisib tablet(s) administered orally
150925|NCT01732926|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
150926|NCT01732926|Drug|Rituximab|Rituximab 375 mg/m^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
150927|NCT01732926|Drug|Bendamustine|Bendamustine 90 mg/m^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
150928|NCT01732926|Drug|Placebo to match idelalisib|Placebo to match idelalisib tablet administered orally twice daily
150929|NCT01732965|Other|Phototherapy|
150930|NCT00093834|Drug|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
150931|NCT01732965|Other|Phototherapy and Photochemotherapy|
151584|NCT01724021|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
151585|NCT01724021|Drug|rituximab [MabThera/Rituxan]|1400 mg SC, Day 1 Cycles 5-8
151586|NCT01724034|Other|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
151587|NCT01724034|Other|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
151588|NCT01724034|Other|Pulmonary Interstitial Syndrome|If lung ultrasound shows "B pattern" - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial.
151589|NCT01724034|Other|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
151590|NCT00093197|Drug|KAI-9803 for Injection|1.25 mg
151591|NCT01724034|Other|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
151891|NCT01729754|Drug|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC
151892|NCT01729754|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC
151893|NCT01729754|Drug|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
151894|NCT01729754|Drug|Etanercept Placebo|Matching placebo to etanercept administered SC
151895|NCT01729754|Drug|Etanercept 50 mg|Etanercept 50 mg administered SC
151896|NCT01729767|Drug|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
155432|NCT01758991|Device|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
155433|NCT01759004|Other|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
155434|NCT00096226|Procedure|Resection|
155435|NCT01759030|Drug|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
155436|NCT01759043|Procedure|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
155437|NCT01759043|Procedure|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
155438|NCT01759056|Drug|AVX 470|active comparator
155439|NCT01759056|Drug|Placebo|
155440|NCT01759069|Procedure|Surgical treatment with microscope|
155441|NCT01759095|Device|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
155442|NCT01759108|Drug|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
155443|NCT01759121|Radiation|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
155444|NCT01759121|Radiation|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
155445|NCT00096226|Drug|Consolidation Carboplatin|
155446|NCT01759134|Other|Post discharge formula|Babies will be given either materna sensitive or similac neosure
155447|NCT01759147|Procedure|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
154512|NCT01757223|Biological|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
154513|NCT01757223|Biological|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
154514|NCT00096135|Drug|pegaspargase|intramuscularly (IM)
154866|NCT01760577|Drug|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
155129|NCT01758367|Drug|Deciatbine(DAC)|
155130|NCT01758380|Drug|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
155131|NCT01758380|Drug|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
155132|NCT01758380|Drug|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
155133|NCT01758380|Drug|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
155134|NCT01758380|Drug|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
155135|NCT01758393|Drug|Prednisone|
155136|NCT01758406|Biological|Intracoronary injection|stem cell transplantation
155137|NCT01758406|Biological|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
155138|NCT01758419|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
155139|NCT00096200|Drug|Carboplatin|Given IV
155140|NCT01758432|Biological|PRT064445|
155141|NCT01758432|Biological|Placebo|
155142|NCT01758445|Radiation|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol & physician.
155143|NCT01760759|Drug|antiretroviral therapy|Patients receive antiretroviral therapy.
155144|NCT01760759|Behavioral|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
155145|NCT01760759|Behavioral|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
154655|NCT01754493|Drug|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
154656|NCT01754506|Dietary Supplement|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
154657|NCT01754519|Procedure|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
154658|NCT01754519|Radiation|Radiation Therapy|Undergo SFRT
154659|NCT01754519|Other|Laboratory Biomarker Analysis|Correlative studies
154660|NCT01754519|Other|Quality-of-Life Assessment|Ancillary studies
154661|NCT00095966|Drug|sorafenib tosylate|Given orally
154930|NCT01755091|Drug|Dronabinol|
154931|NCT01755091|Drug|Placebo (for Dronabinol)|
154932|NCT01755104|Dietary Supplement|Stablor|
154933|NCT01755104|Dietary Supplement|Placebo|
154934|NCT01755117|Other|Sciatic, femoral, obturator nerve blocks|
154935|NCT00096018|Drug|thalidomide|Orally
154936|NCT01755117|Other|Sciatic nerve block, posterior lumbar plexus block|
154937|NCT01755130|Procedure|LOUIS-3D Imaging Procedure|LOUIS-3D imaging procedure either on the same day or within 10 days of a regular scheduled visit for a mammogram, ultrasound, magnetic resonance imaging (MRI) scan, or any other breast imaging procedure, between 1 and 7 days before scheduled biopsy. Results of the LOUIS-3D imaging scans compared with results of other imaging scan(s). Entire LOUIS-3D procedure should take about 30 minutes to complete.
154938|NCT01755143|Other|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
154939|NCT01757990|Dietary Supplement|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
154940|NCT01758029|Drug|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
154941|NCT01758042|Procedure|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
154942|NCT01758055|Biological|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
155661|NCT01753648|Other|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
155662|NCT01753648|Other|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
155663|NCT01753661|Behavioral|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
155664|NCT01753661|Behavioral|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
154719|NCT01760447|Drug|Sitagliptin + Metformin XR FDC|Sitagliptin + Metformin XR fixed-dose combination tablet (sitagliptin/metformin: 50/500 mg, 50/1000 mg) administered with a meal, preferably in the evening
154720|NCT01751802|Drug|Ecopipam|Antagonist of the dopamine D1 receptor
154721|NCT01751802|Drug|Placebo|Placebo for Ecopipam
154722|NCT01751815|Procedure|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
154723|NCT01751815|Procedure|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
154724|NCT01751828|Drug|Sertraline|
154725|NCT00095797|Other|laboratory biomarker analysis|Optional correlative studies
154726|NCT01751854|Drug|SSRI|SSRI alone or with training
154727|NCT01751854|Drug|Placebo|Placebo alone or with training
154728|NCT01751867|Drug|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
154729|NCT01751867|Drug|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
154730|NCT01751880|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
153873|NCT00097422|Drug|OPT-80|
153874|NCT01771211|Device|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
153875|NCT01771224|Dietary Supplement|Palmitoleic acid|Palmitoleic acid and 5-ASA
153876|NCT01771237|Behavioral|Group-based intervention - Experimental|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
153877|NCT01771237|Behavioral|Group-based intervention - Control|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
153878|NCT01771250|Biological|LY2605541|Daily doses administered SQ.
153879|NCT01771250|Biological|Insulin Glargine|Daily doses administered SQ.
153880|NCT01763801|Device|P-Max|tip placement in correspondence to the P-Max on the ECG
153881|NCT01763801|Device|P-Submax|tip placement in correspondence to the P-Submax on the ECG
153882|NCT01763814|Procedure|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
153883|NCT01763814|Procedure|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
153884|NCT01763814|Procedure|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
153885|NCT01763827|Biological|Evolocumab|Administered by subcutaneous injection
153886|NCT01763827|Drug|Ezetimibe|Administered orally once a day
154174|NCT01766765|Procedure|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
154175|NCT01766765|Other|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
154176|NCT01766778|Drug|Vildagliptin|Vildagliptin 50mg capsule
154177|NCT01766778|Drug|Metformin|Metformin maximum tolerance dose
154178|NCT01766791|Other|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM
153322|NCT01770041|Other|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
153619|NCT01763463|Drug|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
153620|NCT01763476|Procedure|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
153621|NCT01763476|Procedure|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
153622|NCT01765660|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
153623|NCT01765660|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
153624|NCT01765673|Device|Passy Muir Swallowing Self-Trainer|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
153625|NCT00096759|Behavioral|Tai Chi Chih|
153626|NCT01765686|Device|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
153627|NCT01765686|Device|Ligasure Small Jaw (Covidien, USA)|
153628|NCT01765699|Device|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
153629|NCT01765712|Procedure|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
153630|NCT01765712|Biological|Platelet Rich Plasma|
153631|NCT01765725|Behavioral|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
153632|NCT01765738|Device|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
153633|NCT01765751|Procedure|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
149397|NCT01706900|Other|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
149398|NCT01706913|Other|Dermatology consult|
149399|NCT01706926|Drug|Mavrilimumab or placebo subcutaneous Injection|GM-CSFR alpha inhibitor
148421|NCT01717976|Behavioral|DISPO ED|primary care based nurse telephone support
148422|NCT01718002|Behavioral|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
148423|NCT01718028|Other|Propylene glycol 0.6% ocular emulsion|
148424|NCT01718028|Other|Sodium chloride 0.9% saline solution|
148425|NCT01718041|Drug|Experimental: VRS-317|Active treatment arm
148426|NCT00091962|Behavioral|Counseling|Counseling program
148427|NCT01710280|Dietary Supplement|High-fat meal containing native palm olein|
148428|NCT01710280|Dietary Supplement|High-fat meal containing interesterified palm olein|
148429|NCT01710293|Behavioral|Electronic Communication to Providers|In the first step of the intervention, we will automatically query the patient record database daily to identify possible lost to follow-up events in a pre-specified time period, using the computerized method developed in the first phase of the study. We will capture on a "near-real time" basis patients whose abnormal test results were not followed by an appropriate action. The output data containing the list of patients who have not been followed-up with after receiving abnormal test results will be transmitted to our communication engine.
The second step of the intervention will be electronic communication of surveillance data to the providers. The precise strategies for this communication will be informed by Phase 2 of the stud
148430|NCT01710306|Behavioral|Phase 2|Nurse care manager interventions with shared decision making compared to outreach as usual OEF/OIF/OND outreach.
148431|NCT01710319|Other|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
148432|NCT01710332|Drug|Intravitreal Aflibercept Injection|GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).
GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).
148433|NCT01710345|Drug|Sufentanil NanoTab 20 mcg|
148434|NCT01710345|Drug|Sufentanil NanoTab 30 mcg|
148435|NCT01710345|Drug|Placebo NanoTab|
153207|NCT01769794|Drug|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
153208|NCT01769794|Drug|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
153209|NCT01769794|Drug|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
153210|NCT00097344|Drug|Toremifene|
153211|NCT01769807|Device|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
153212|NCT01769820|Drug|Dexamethasone|studies 1&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
153213|NCT01769820|Drug|placebo|
153214|NCT01769833|Drug|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
152234|NCT01725139|Drug|Placebo|Matching placebo will be available
152235|NCT00093288|Drug|bupropion XL|
152236|NCT01725152|Drug|Ganaxolone|oral suspension, given in 3 divided doses
152237|NCT01725152|Drug|Placebo|oral suspension, given in 3 divided doses
152238|NCT01725165|Other|No LCT|No surgery or radiation therapy right after induction chemotherapy. Patients receive either systemic therapy (i.e. chemotherapy) or observation. The care received will depend on discretion of doctor.
152239|NCT01725165|Other|LCT|Patients receive local consolidation therapy (LCT) after induction chemotherapy. LCT is radiation, surgery, or both. If assigned to the LCT group, study doctor will decide if patient has radiation alone, surgery alone, or radiation combined with surgery.
Radiation therapy delivered using external beam radiation, with either 2D/conventional techniques, three-dimensional conformal therapy, intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS) or proton beam therapy (PBT), at discretion of treating radiation oncologist.
Surgical control of primary and metastatic sites of disease may include control of either or both sites of disease as determined by multidisciplinary group (medical oncologist, radiation oncologist, and surgeon).
152240|NCT01727687|Behavioral|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
152241|NCT01727700|Drug|Aripiprazole|Once-daily, tablet
152242|NCT01727700|Drug|Placebo|
152243|NCT00093522|Biological|keyhole limpet hemocyanin|
152970|NCT01723852|Dietary Supplement|Vitamin D at 10 ug/day|
152971|NCT00001797|Drug|Recombinant human interleukin-10|
152972|NCT00093184|Drug|Angiomax (bivalirudin) anticoagulant|
152973|NCT01723891|Drug|Surfolase capsule|
152974|NCT01723891|Drug|HT-002-01|
152975|NCT01723904|Drug|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
152976|NCT01723917|Dietary Supplement|PhytoSERM tablet|
152977|NCT01723917|Dietary Supplement|placebo|
152978|NCT01723943|Other|educational intervention|Receive the "What's Happening to the Woman I Love?" booklet
152979|NCT01723943|Other|counseling intervention|Undergo Helping Her Heal educational counseling program
152980|NCT01723943|Other|educational intervention|Undergo Helping Her Heal educational counseling program
152981|NCT01723943|Other|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
152015|NCT01722019|Device|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
152016|NCT01722019|Device|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
152017|NCT01722032|Other|Childhood Obesity|
152018|NCT01722045|Drug|Intravitreal Aflibercept Injection (IAI)|
152019|NCT01722058|Drug|Peptide application|
152020|NCT01722071|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
152021|NCT01722071|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
152679|NCT01720537|Biological|PF-05335810 Dose D|Single Subcutaneous Injection(s)
152680|NCT00092807|Drug|Comparator: placebo|
152681|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
152682|NCT01720537|Biological|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
152683|NCT01723306|Genetic|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
152684|NCT01723319|Device|HBLPADD coil deep TMS|20 daily deep TMS treatment
152685|NCT01723319|Device|Sham|inactive treatment
152686|NCT01723332|Behavioral|Educational|The first interaction will happen at study enrolment and will be educational in nature.
Following the session, the nurse will follow up with the participant to discuss any questions.
152687|NCT00093119|Drug|ABI-007|
152688|NCT01723332|Behavioral|Self management|The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.
Following the session, the nurse will follow up with the participant to discuss any questions.
152689|NCT01723345|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
152690|NCT01723358|Device|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
152691|NCT01723371|Drug|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
152692|NCT01723384|Drug|Intermittent Oral Naltrexone|
152693|NCT01723384|Drug|Placebo|
152694|NCT01723397|Device|Nasaleze Spray device|
152695|NCT01723397|Device|Placebo|
152696|NCT01723410|Behavioral|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
152168|NCT01729858|Device|Ceramic-Ceramic|Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.
Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline.
152466|NCT01709682|Procedure|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
152467|NCT01709682|Procedure|ILR implantation|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events.
152468|NCT01709695|Drug|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
152469|NCT00091923|Device|Eye patch|
152470|NCT01709695|Drug|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
152471|NCT01709708|Drug|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
152472|NCT01709708|Drug|Saline|
152473|NCT01709721|Drug|Hydromorphone Hydrochloride|Subjects who meet criteria for randomization, will be randomized in a 1:1 ratio to either the active arm or control arm.
152474|NCT01709721|Drug|Hydromorphone Hydrochloride|Active Control Based on Dose Reduction
152475|NCT01709734|Drug|galeterone|
152476|NCT01709747|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
152477|NCT01709760|Drug|Methotrexate|Methotrexate 15-25 mg/week
152478|NCT01709760|Drug|ENIA11|ENIA11 25 mg, sc twice weekly
152479|NCT01709760|Drug|Placebo|Placebo, sc twice weekly
152480|NCT00001758|Drug|Abacavir|
152481|NCT00091923|Device|Spectacles|
152482|NCT01709773|Procedure|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
153193|NCT01767441|Procedure|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
153194|NCT01767441|Other|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
153195|NCT01767454|Drug|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
153196|NCT01767454|Drug|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
153197|NCT01767454|Drug|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
151932|NCT01721941|Drug|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
151933|NCT01721941|Drug|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
151934|NCT01721941|Drug|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
151935|NCT00092976|Drug|ReFacto|
151936|NCT01724489|Drug|Placebo|
151937|NCT01724502|Behavioral|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
151938|NCT01724515|Other|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
151939|NCT01724528|Drug|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
151940|NCT01724528|Drug|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
151941|NCT01724554|Drug|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
151942|NCT01724567|Other|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
151943|NCT00001805|Drug|Rituximab|
151944|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
151388|NCT01735929|Procedure|Sham Treatment|
151389|NCT01735942|Drug|Ingenol mebutate|
151390|NCT01735942|Procedure|cryotherapy|
151391|NCT01735955|Drug|AMN107|AMN107 (nilotinib)
151392|NCT01735968|Drug|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
151393|NCT01735981|Other|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
151394|NCT01735981|Other|hand-held video game|hand-held video games
151395|NCT00094289|Drug|Disulfiram|
151396|NCT01735994|Behavioral|Healthy Weight|Eating Disorder Prevention Program for Athletes
151397|NCT01738360|Drug|Arsenic trioxide|The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.
The course of study is as follows :
Pre-inclusion between D-35 and D-15
Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.
A telephone contact between D32 and D34
A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180
151664|NCT01724086|Drug|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
151665|NCT01724086|Drug|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
151666|NCT00093197|Drug|KAI-9803 for Injection|5 mg
151667|NCT01724086|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
151668|NCT01724086|Drug|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
151669|NCT01724086|Drug|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
151452|NCT01733966|Drug|Secnidazole, ciprofloxacine|2g of microgranules of secnidazole. a single dose per day during 3 days.
1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)
151453|NCT01733966|Drug|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
151454|NCT01733979|Dietary Supplement|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
151455|NCT01733979|Dietary Supplement|Placebo|Placebo (1g/day)
151456|NCT01735994|Other|Brochure|Brochure on the Female athlete triad
151457|NCT01736007|Device|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
151458|NCT01736007|Device|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
151459|NCT01736020|Drug|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
151460|NCT01736020|Drug|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
151461|NCT01736020|Drug|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
151462|NCT01736020|Drug|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
151463|NCT01736033|Drug|Tamsulosin|1 tablet(0.2mg) orally q.d.
151464|NCT01736033|Drug|Finasteride|1 tablet(5mg) orally q.d.
151465|NCT00094302|Drug|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
151466|NCT01736033|Drug|Placebo|1 tablet(0.2mg) orally q.d.
151467|NCT01736046|Radiation|CT Enterography|Diagnostic CT Enterography Scan (CTE)
Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease.
151468|NCT01736059|Drug|CD34+ bone marrow stem cells intravitreal|
151469|NCT01736072|Procedure|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
150932|NCT01732978|Behavioral|Crying record|Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.
Listening tests:
Tests will be conducted playbacks with the father and mother separately, and with a staff
150933|NCT01735084|Biological|Prevenar13|The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.
Active ingredients
Each 0.5 mL dose contains:
2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg).
150934|NCT01735084|Biological|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
150935|NCT01735097|Dietary Supplement|Vitamin E|Vitamin E (200 mg, soft capsule)
151241|NCT01738113|Other|Closed kinetic chain exercise|Foot sliding from sitting
Seated Toe Raises
Hamstrings and quadriceps co-contraction from sitting
Bridging exercise
Sitting-to-standing
Side-to side, forward and backwards weight shifting
Lunge exercise
Squatting exercise
Standing Toe Raises
Standing Hamstrings Stretch
151242|NCT01738139|Drug|Ipilimumab|Dose Escalation Group Starting Dose: 1 mg/kg by vein on day 15. The first study cycle is 35 days. Each cycle after that is 21 days.
Dose Expansion Group Starting Dose: MTD from Dose Escalation Group.
151243|NCT00094549|Drug|olanzapine|
151244|NCT01738139|Drug|Imatinib Mesylate|Dose Escalation Group Starting Dose: 400 mg by mouth once per day for 35 days. The first study cycle is 35 days. Each cycle after that is 21 days.
Dose Expansion Group Starting Dose: MTD from Dose Escalation Group.
151245|NCT01738152|Other|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
151246|NCT01738152|Behavioral|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the NP for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires (Appendix II-Follow-Up and Appendix IV) and moisturizer diaries (Appendix III) will be completed and collected during the NP follow-up appointments.
151247|NCT01738165|Device|KineSpring System|The KineSpring System is designed to treat pain and loss of function secondary to medial knee OA by absorbing joint overload.
151248|NCT01738178|Drug|Caffeine|
151897|NCT01729767|Drug|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
151898|NCT01729780|Device|EEG-NF|
151899|NCT00093652|Procedure|conventional surgery|
151900|NCT01729793|Dietary Supplement|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
151901|NCT01729793|Other|Placebo|Capsule containing microcrystalline cellulose
151902|NCT01729806|Biological|Ipilimumab|Given IV
151903|NCT01729806|Other|Laboratory Biomarker Analysis|Correlative studies
151904|NCT01729806|Biological|Rituximab|Given IV
151905|NCT01729819|Drug|Tolterodine tartrate extended release capsules|
151906|NCT01729819|Drug|Desmopressin orally disintegrating tablets|
151907|NCT01729819|Drug|Placebo orally disintegrating tablets|
151908|NCT01729832|Procedure|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
151909|NCT01729832|Procedure|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
151910|NCT00093652|Procedure|neoadjuvant therapy|
151911|NCT01729845|Drug|Cytarabine|Given IV
150996|NCT01740336|Drug|GDC-0941|orally daily for 5 consecutive days each week, followed by 2 days during which GDC-0941 is not administered (5/7-day schedule)
150997|NCT01740336|Drug|Placebo|matching GDC-0941 placebo orally, 5/7-day schedule
150998|NCT01740336|Drug|paclitaxel|90 mg/m2 IV weekly for 3 out of 4 weeks in every 28-day cycle
150999|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
151000|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
151001|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
154515|NCT01757236|Drug|VANCOMYCIN|
154516|NCT01757236|Drug|CEFTRIAXONE|
154517|NCT01757236|Drug|CLINDAMYCIN|
154518|NCT01757236|Drug|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
154519|NCT01757236|Drug|FLUOROQUINOLONE|
154520|NCT01757236|Drug|LINEZOLID|
154521|NCT01757236|Drug|RIFAMPIN|
154522|NCT01757249|Drug|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
154523|NCT01757262|Drug|90 mg Ticagrelor|Morning and Evening dose for 5 days
154524|NCT01757262|Drug|75mg Clopidogrel|Morning dose for 5 days
154525|NCT00096135|Drug|therapeutic hydrocortisone|
154526|NCT01757275|Drug|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
154527|NCT01757275|Drug|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
154528|NCT01757275|Drug|Esomeprazole Mg|40 mg tablet once daily for 27 days
154529|NCT01757288|Drug|NAB-PACLITAXEL|
154530|NCT01757288|Drug|PACLITAXEL|
154531|NCT01757301|Other|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
154532|NCT01759979|Procedure|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
154533|NCT01759979|Procedure|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
154534|NCT01759992|Device|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
154796|NCT01760486|Behavioral|Shape Up Rhode Island + Professional Coach + Incentives|
155146|NCT01760772|Drug|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
155147|NCT01760772|Drug|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
155148|NCT01760772|Other|saline|Constant infusion
155508|NCT01756118|Drug|BEZ235|A minimum of 3 dose levels
155509|NCT01756131|Drug|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
155510|NCT01756131|Other|Placebo to match injectable suspension|placebo
155511|NCT01756144|Device|rhBMP-2|
155512|NCT01756157|Biological|CINRYZE with rHuPH20|
155513|NCT01756170|Drug|paclitaxel|
155514|NCT01756170|Drug|cisplatin|
155515|NCT01756170|Radiation|Radiotherapy|
155516|NCT01756183|Drug|S-1 + Paclitaxel Chemotherapy|Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1
155517|NCT00001866|Procedure|horizontal muscles of the eye will be cut and then reattached in the same position|
155518|NCT00096122|Drug|cytarabine|Given IV
155519|NCT01756196|Drug|Spinal Steroid Injection|Steroid Injection
155520|NCT01759160|Procedure|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
155521|NCT01759160|Procedure|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
155522|NCT01759199|Procedure|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
155523|NCT01759212|Biological|Allogeneic stem cells implantation|
155524|NCT01759238|Drug|Capecitabine|825mg/m2 per os bid
155525|NCT01759238|Drug|Bevacizumab|7.5 mg/kg
155526|NCT01759238|Radiation|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
154943|NCT00096161|Drug|Pentostatin|Given IV
154944|NCT01758068|Procedure|Coconut Oil Application|Coconut oil - 4 ml
154945|NCT01758081|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
154946|NCT01758081|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
154947|NCT01758081|Dietary Supplement|Vitamin D3 placebo|
154948|NCT01758081|Dietary Supplement|fish oil placebo|
154949|NCT01758094|Drug|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
154950|NCT01758107|Other|Withdraw cyclosporine|
154951|NCT01758120|Drug|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)
154952|NCT01758120|Drug|Prednisone alone|prednisone alone: prednisone(0.5mg/kg/day*6 months)
155208|NCT01755611|Drug|Minocycline 100mg|Reference product
155209|NCT01755624|Device|NovoTTF-100A device|
155210|NCT01755624|Other|Best Standard of Care|
155211|NCT01755637|Drug|Albendazole|Albendazole tablets 400 mg
155212|NCT01755650|Radiation|18F FPM|
155213|NCT01758458|Biological|Aldesleukin|Given SC
155214|NCT01758458|Other|Laboratory Biomarker Analysis|Correlative studies
155215|NCT01758458|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
155216|NCT01758458|Radiation|Radiation Therapy|Undergo radiation therapy
155217|NCT01758458|Biological|Recombinant Interferon Beta|Given intralesionally
155218|NCT01758471|Drug|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
155219|NCT01758471|Drug|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
155220|NCT00096200|Drug|Paclitaxel|Given IV
154731|NCT01751893|Drug|Henna|
154732|NCT01751893|Drug|Placebo|
154733|NCT01751906|Device|Absorb BVS|Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
154734|NCT01751906|Device|XIENCE|Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
154735|NCT01751919|Drug|Imatinib mesylate tablet 400 mg, 1 Tablet|
155016|NCT01755156|Drug|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
155017|NCT01755156|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
155018|NCT01755156|Drug|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
155019|NCT01755156|Drug|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
155020|NCT00096031|Biological|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
155021|NCT01755169|Drug|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
155022|NCT01755182|Drug|approved pharmacologic therapy|
155023|NCT01755182|Procedure|TAE|after randomization, and after 3 months
155024|NCT01755195|Drug|Cabozantinib|Cabozantinib inhibits multiple RTKs implicated in tumor growth, metastasis, and angiogenesis, and targets primarily MET and VEGFR2.
155025|NCT01755208|Procedure|light-scattering spectroscopy|Undergo light-scattering spectroscopy
154179|NCT01766791|Other|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - < 75 1RM
154180|NCT01766791|Other|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM and Protein Supplementation
154181|NCT01766791|Other|Control|control group, no intervention, maintenance of physical activity
154182|NCT01766804|Dietary Supplement|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
154183|NCT01766804|Dietary Supplement|placebo|
154184|NCT00096902|Procedure|Tilt table test|
154185|NCT01766817|Drug|BMS-986020|
154186|NCT01766817|Drug|Placebo matching with BMS-986020|
154187|NCT01766830|Device|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
154188|NCT01766830|Device|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
154189|NCT01769053|Other|Variable Ventilation|
154190|NCT01769066|Drug|Sequential Gefitinib With Pemetrexed/Platinum|
154191|NCT01769066|Drug|Pemetrexed/Platinum|
154192|NCT01769079|Drug|Nitrate|Two arms: placebo and nitrate
154193|NCT01769079|Drug|Placebo|
154194|NCT01769092|Dietary Supplement|Fish Oil|Daily dose of fish oil standardized to contain 3g/day of DHA. The daily dose is divided; capsules are taken with meals for a period of 6 months.
154195|NCT00097266|Drug|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
154196|NCT01769092|Other|Safflower Oil|Daily dose of 8g/day of safflower oil taken in divided doses as capsules and consumed with meals
153236|NCT01762839|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
153237|NCT00096460|Drug|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
153634|NCT01765764|Drug|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
153635|NCT01765764|Drug|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
153636|NCT00096759|Behavioral|Relaxation training|
153953|NCT01768754|Behavioral|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
153954|NCT01768767|Drug|Placebo|
153955|NCT01768767|Drug|Ketamine|
153956|NCT01768767|Drug|Ketamine/Lithium|
153957|NCT01761383|Other|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
153958|NCT01761396|Behavioral|CBT|
153959|NCT01761396|Behavioral|UC|
153960|NCT01761435|Biological|Influenza vaccine|Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :
A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.
The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline.
153961|NCT01761448|Device|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
153962|NCT01761448|Device|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
153963|NCT01761448|Device|Control group training without Guided Exercise system at home|
153964|NCT01761461|Drug|TS-1, oxaliplatin|
153965|NCT00096382|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
148436|NCT01710358|Drug|Placebo|Baricitinib placebo administered orally. Adalimumab placebo administered SC.
148437|NCT00091962|Drug|Pharmacotherapy|Medication to treat depression
148438|NCT01710358|Drug|Adalimumab|Administered SC
148439|NCT01710358|Drug|Baricitinib|Administered orally
148440|NCT01710371|Drug|18F-AV-133|296 MBq (8 mCi)
148734|NCT01705964|Other|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
148735|NCT01705977|Biological|Placebo plus standard therapy|Placebo plus standard therapy
148736|NCT01705977|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
148737|NCT01705977|Other|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
148738|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
148739|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
148740|NCT01705990|Biological|Ad35-GRIN (0.5mL)|(1x10^10 vp) Delivered intramuscularly by standard syringe and needle injection
148741|NCT01706016|Procedure|Thermic destruction of tissue by Laser using the Novilase device|
148742|NCT01706042|Other|legume meal|
148743|NCT01706042|Other|white bread|
148744|NCT00091377|Drug|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
148745|NCT01706055|Biological|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
148746|NCT01708538|Drug|CXL|corneal crosslinking
148747|NCT01708551|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
148748|NCT01708564|Biological|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
148749|NCT01708577|Device|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
152244|NCT01727713|Drug|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
152245|NCT01727726|Drug|Brexpiprazole|tablet/capsule
152246|NCT01727726|Drug|Seroquel XR|tablet/capsule
152247|NCT01727726|Drug|Placebo|tablet/capsule
152248|NCT01727739|Device|Linvatec PLLA+TCP|Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
152249|NCT01727739|Device|Linvatec PLLA|Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
152250|NCT01727752|Procedure|Decompression|
152251|NCT01727765|Other|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
152252|NCT01727778|Biological|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
152253|NCT01727791|Drug|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
152254|NCT00093522|Biological|therapeutic autologous dendritic cells|
152864|NCT01720836|Biological|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
152865|NCT01720849|Drug|Fampyra|The will be given as per normal patient treatment plan
152866|NCT01720875|Drug|Vorinostat Velcade Dexamethasone|
152867|NCT01720888|Other|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
152868|NCT01723657|Drug|Ara-C|Intermediate dose during induction phase to remission.
High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20.
152869|NCT01723657|Other|Autologous peripheral blood stem cell transplantation.|In patients with favorable cytogenetics with a Leukocyte index above 20.
Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor.
152870|NCT01723657|Other|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
152022|NCT01722084|Behavioral|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were "driving" the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process.
152023|NCT01722097|Drug|Rocuronium|
152024|NCT01722097|Drug|placebo|
152025|NCT00092989|Drug|placebo|Duration of Treatment: 1 dose
152026|NCT01722110|Drug|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
152027|NCT01722110|Drug|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
152028|NCT01722123|Other|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
152029|NCT01722136|Behavioral|Low Dosage|Exercise dose of 8kcal/kg/week
152030|NCT01724684|Other|Usual care|
152031|NCT01724697|Other|BMSC transplantation|Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.
152032|NCT01724697|Other|conventional treatment & antivrial treatment|Participants will recieve conventional treatment and antivrial treatment.
152033|NCT01724723|Drug|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
152311|NCT01725191|Drug|Tivantinib|Given PO
152312|NCT01725204|Drug|Dasatinib + PegIFN|
152313|NCT01725217|Biological|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
152314|NCT00093301|Drug|Levosimendan|
152315|NCT01725230|Drug|Fostamatinib|100-mg tablet
152316|NCT01725230|Drug|Rosuvastatin|20-mg tablet
152317|NCT01725230|Drug|Simvastatin|40-mg tablet
153043|NCT01769573|Biological|RG-HRV16|A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
153044|NCT01769573|Drug|Placebo|The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
153045|NCT01769586|Drug|Diphenhydramine|
153046|NCT01769586|Drug|Midazolam|
153047|NCT01769612|Other|No Intervention|
153048|NCT01769625|Drug|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
153049|NCT01769638|Drug|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
153050|NCT01769638|Drug|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
153051|NCT01769651|Other|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
153052|NCT01762540|Drug|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
153053|NCT01762540|Drug|Calcium Supplement|Placebo
153054|NCT01762553|Behavioral|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
153055|NCT01762566|Dietary Supplement|wheat|wheat is administered blindly versus placebo in capsules once
153056|NCT01762566|Dietary Supplement|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
153057|NCT01762579|Dietary Supplement|wheat flour|wheat flour is administered three times per day for 15 days
153058|NCT01762579|Dietary Supplement|Xylose|Xylose will be administered three times per day for 15 days
153059|NCT00096447|Drug|lapatinib ditosylate|
153060|NCT01762592|Drug|Iodine (124I) Girentuximab|
153061|NCT01762605|Other|Supportive Care|
152483|NCT01709799|Behavioral|Exercise|Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:
(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate
Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.
Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data.
152484|NCT01720251|Drug|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
152754|NCT01720589|Dietary Supplement|Melt (test oil)|
152755|NCT01720589|Dietary Supplement|Corn oil (control)|
152756|NCT01720602|Drug|vorinostat|Given PO
152757|NCT01720602|Drug|anastrozole|Given PO
152758|NCT01720602|Drug|letrozole|Given PO
152759|NCT01720602|Drug|exemestane|Given PO
152760|NCT01720602|Procedure|positron emission tomography|Correlative studies
152761|NCT01720602|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
152762|NCT01720602|Radiation|fludeoxyglucose F 18|Correlative studies
152763|NCT00092820|Drug|Comparator: placebo|
152764|NCT01720602|Other|laboratory biomarker analysis|Correlative studies
152765|NCT01720615|Drug|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
152766|NCT01720615|Drug|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
152767|NCT01720628|Other|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
152768|NCT01720641|Behavioral|Internet|Referral and user instructions for Peru section of www.inspot.org partner notification website
152769|NCT01720641|Behavioral|Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
152770|NCT01720641|Behavioral|Internet and Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
152771|NCT01723501|Drug|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
152772|NCT01723501|Drug|sterile water|Sterile water wipes (placebo)
151945|NCT01724567|Other|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
151946|NCT01724580|Drug|Baricitinib|Administered orally
151947|NCT01724606|Radiation|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
151948|NCT01724606|Drug|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
151949|NCT01724619|Drug|[F-18] fluorinated dihydrotestosterone (FDHT)|
151020|NCT01733134|Drug|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
151021|NCT00093847|Drug|Placebo|Placebo to be taken daily for 6 weeks
151022|NCT01733147|Drug|Omega-3 free fatty acids|Baseline assessment: Measure waist and hip circumference, height, weight. Complete Gastroesophageal Reflux Questionnaire (GERQ). Blood draw for serum free fatty acid (FFA) profile. Clinical baseline blood draw: INR, LDL, AST and ALT. Single slice CT of abdomen. Endoscopy performed with biopsies, brushings, and mucosal impedance testing. Randomized to ω3 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects and reinforce compliance. Repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a blood draw as outlined at baseline, and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the GERQ.
151023|NCT01733147|Drug|Placebo|Baseline assessment: Measure waist and hip circumference, height, weight. Complete Gastroesophageal Reflux Questionnaire (GERQ). Blood draw for serum free fatty acid (FFA) profile. Clinical baseline blood draw: INR, LDL, AST and ALT. Single slice CT of abdomen. Endoscopy performed with biopsies, brushings, and mucosal impedance testing. Randomized to ω3 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects and reinforce compliance. Repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a blood draw as outlined at baseline, and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the GERQ.
151024|NCT01735227|Drug|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
151025|NCT01735240|Drug|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
151026|NCT01735240|Drug|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
151027|NCT01735253|Procedure|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
151670|NCT01724099|Drug|Euiiyin-tang|Korean medicinal herbal drug
151671|NCT01724099|Drug|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
151672|NCT01724112|Drug|LY2940094|Administered orally
151673|NCT01724112|Drug|Placebo|Administered orally
151674|NCT01724125|Other|personal electronic medical record|
151675|NCT01726660|Device|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
151676|NCT01726673|Device|Transcranial Direct Current Stimulation (tDCS)|
151677|NCT01726673|Device|Placebo sham|
151678|NCT01726686|Drug|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
151679|NCT01726686|Drug|Placebo|
151680|NCT01726712|Other|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
151681|NCT01726725|Drug|desflurane|
151682|NCT01726738|Drug|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
150782|NCT01737229|Device|Application of Biodentine™ (RD94), dentin substitute|
150783|NCT01737255|Other|Whole body MRI|Individuals will undergo whole body and brain MRI
150784|NCT01737255|Other|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
150785|NCT00000275|Drug|Flupenthixol|
150786|NCT00001832|Drug|IL-2|125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.
720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.
150787|NCT00094458|Biological|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
150788|NCT01737268|Drug|FK949E|oral
150789|NCT01737281|Behavioral|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
151743|NCT01721629|Procedure|Gradual wean of nasal CPAP|
151744|NCT01724138|Drug|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
151745|NCT01724164|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
151746|NCT00093197|Drug|Placebo|
151747|NCT01724164|Behavioral|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
151748|NCT01724164|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
151749|NCT01724164|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
151750|NCT01724164|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
151751|NCT01724177|Drug|Lenalidomide|25 mg of Lenalidomide administered orally once daily
151752|NCT01724190|Drug|Vitamin D|
151753|NCT01724190|Drug|Placebo|
151754|NCT01724203|Dietary Supplement|Lactobacillus rhamnosus|
151755|NCT01724203|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
151756|NCT01724203|Dietary Supplement|Placebo|
151757|NCT00093210|Drug|rFIX|
151758|NCT01724216|Device|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
151759|NCT01724229|Drug|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
151760|NCT01724242|Drug|Vaginal DHEA|
151761|NCT01724255|Other|questionnaire|
151762|NCT01724268|Drug|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
151249|NCT01738178|Drug|Placebo|
151250|NCT01738191|Drug|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
151251|NCT01738191|Drug|Placebo|
151252|NCT01738217|Procedure|Fluobeam|
151253|NCT01730937|Radiation|stereotactic body radiation therapy|Undergo SBRT
151254|NCT01730950|Biological|bevacizumab|Given IV
151255|NCT01730950|Radiation|intensity-modulated radiation therapy|Undergo IMRT
151256|NCT01730950|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
151523|NCT01726478|Drug|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
151524|NCT01726478|Drug|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
151525|NCT01726504|Device|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
151526|NCT00093457|Drug|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
151527|NCT01726504|Device|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
151528|NCT01726517|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
151529|NCT01726517|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
151530|NCT01726530|Drug|transdermal fentanyl patch (50 mcg/hour)|
151531|NCT01726530|Drug|Placebo|
151002|NCT01732991|Device|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
151003|NCT01733004|Drug|MM-141|
151004|NCT01733017|Behavioral|Sodium reduction|Teaching and skill building to reduce dietary sodium
151005|NCT01733017|Dietary Supplement|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
151006|NCT01733030|Drug|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
151007|NCT01733030|Drug|Seromycin|
151008|NCT01733043|Drug|Dexmedetomidine|
151009|NCT01733043|Drug|Placebo|
151010|NCT00093847|Drug|S-adenosyl methione (SAMe)|Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
151011|NCT01733056|Biological|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
151012|NCT01733069|Device|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
151013|NCT01733095|Drug|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
151014|NCT01733108|Drug|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
151015|NCT01733108|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
151016|NCT01733121|Drug|NBI-98854|25 mg capsule
151017|NCT01733121|Drug|NBI-98854|50 mg capsule
151018|NCT01733121|Drug|Placebo|
151019|NCT01733134|Drug|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
151317|NCT00094276|Behavioral|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
151318|NCT01735851|Drug|Thoracic epidural analgesia|
151319|NCT01735851|Procedure|Bilateral Paravertebral block|
154797|NCT01760486|Behavioral|Shape Up Rhode Island + Peer Coach + Incentives|
154798|NCT01760499|Drug|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
154799|NCT01760499|Procedure|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
154800|NCT00096317|Drug|ketoconazole|
154801|NCT01760512|Procedure|Gastric bypass|Gastric bypass
154802|NCT01760525|Drug|CGM097|Patients treated with CGM097
154803|NCT01760538|Behavioral|Exercise training|exercise training
154804|NCT01760538|Behavioral|usual care|received usual medical care after heart transplantation
154805|NCT01760564|Drug|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
154806|NCT01760577|Drug|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
154807|NCT01751945|Behavioral|EmONC package|The EmONC package consists of:
Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.
Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.
Community mobilisation
154808|NCT01751958|Radiation|Epidural steroid injection|Epidural steroid injection
154809|NCT01751971|Drug|Inspired oxygen (40%)|Supplemental oxygen at approximately 40% e.g. via Pink venturi mask
154810|NCT01751971|Other|Sham|Medical air with 21% oxygen e.g. via Pink venturi mask
154811|NCT01751984|Drug|ETC-1002|Weeks 1-2, 60 mg/day; Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
154812|NCT01751984|Drug|Placebo|Placebo once daily for 8 weeks
154813|NCT01751997|Drug|Transplants from 8/8-matched Unrelated donors|Myeloablative conditioning
Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)
Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)
Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)
Reduced-intensity conditioning; older patients (age > 55 years) and/or patients with comorbidities
Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m^2)
Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)
Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)
ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)
GVHD prophylaxis
Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)
Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11
155527|NCT01759277|Drug|Active comparator: Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve catheter and block under ultrasound guidance with the final position of catheter posterior to the femoral nerve and lateral to the femoral artery. Normal saline up to 10ml will be injected if necessary for hydro-dissection via the needle. The catheter will then be threaded 3-5cm past the needle tip and its location will be confirmed by a 30ml bolus of lidocaine 2% via the catheter under ultrasound visualization. The control group will receive a standardized general anesthetic with inhaled volatile anesthesia in nitrous oxide and oxygen or bupivacaine spinal anesthetic.
155528|NCT00096226|Radiation|Radiation Therapy|
154592|NCT00095953|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
154593|NCT01754454|Biological|Human Umbilical Cord Derived MSC|1×10^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
154594|NCT01757301|Other|Comprehensive Symptom Management (CSM)|This arm couples ASM with care management by a nurse-physician team, thus testing "combined" therapy vs. "monotherapy" (ASM only).
154595|NCT01757314|Behavioral|ultrasound technique|instruction in the ultrasound technique
154596|NCT01757314|Other|palpation technique|placement of a line via palpation technique
154597|NCT01757327|Drug|Erismodegib|
154598|NCT00096135|Drug|vincristine sulfate|given IV
154599|NCT01757327|Drug|Placebo|
154600|NCT01757340|Behavioral|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
154601|NCT01757340|Behavioral|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
154602|NCT01757353|Behavioral|BASICS motivational interview|
154603|NCT01757353|Behavioral|BASICS plus normative enhancement motivational interview|
154604|NCT01757353|Behavioral|Self-directed: Information only|
154605|NCT01757366|Drug|Ginsenoside Rg3 plus First-line Chemotherapy|Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression
XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
154606|NCT01757366|Drug|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
154607|NCT01757379|Dietary Supplement|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
155221|NCT01758484|Other|palliative care|Undergo supportive care intervention
155222|NCT01758484|Other|questionnaire administration|Ancillary studies
155223|NCT01758484|Procedure|quality-of-life assessment|Ancillary studies
155224|NCT01758497|Procedure|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
155225|NCT01758497|Procedure|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
155226|NCT01758510|Genetic|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10^6 cells/kg, 0.5 X 10^6 cells/kg, 1 X 10^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10^6 cells/kg dose cohort.
155227|NCT01758523|Drug|Dutasteride|
155228|NCT01758523|Drug|sugar pill|
155229|NCT01758536|Drug|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
155230|NCT01758549|Other|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
155231|NCT00001877|Drug|Pentoxifylline|
155591|NCT01756274|Device|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
155592|NCT01756274|Device|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
155593|NCT01756274|Device|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
155594|NCT01756287|Other|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
155595|NCT01756300|Device|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
155596|NCT01756313|Procedure|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
155597|NCT01756326|Drug|PREOB® Implantation|
155026|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|All subjects will have a pH probe placed at their initial clinic visit and will have the probe removed 24 hours later. They will start on PPI medication (as per the standard of care) after probe removal. Subjects will have a follow up clinic visit 8-12 weeks after the initial visit. At the follow up visit, all subjects will have the option of a second probe placement to assess the effects of PPI therapy on reflux events.
155027|NCT01755234|Drug|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
155028|NCT01755234|Drug|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
155029|NCT01755247|Drug|Topical Gel Vehicle|
155030|NCT01755247|Drug|8% NVN1000 Topical Gel|
155031|NCT00096044|Biological|rituximab|IV
155032|NCT01755247|Drug|8% NVN1000 Topical Gel and moisturizer|
155033|NCT01755260|Other|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
155034|NCT01755273|Procedure|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
155035|NCT01755286|Drug|OTO-201|Single intra-operative injection
155291|NCT01755689|Biological|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
155292|NCT01755689|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
155293|NCT01755702|Drug|Placebo|Placebo
155294|NCT01755702|Drug|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
155295|NCT01755702|Drug|ibuprofen marketed formulation|ibuprofen marketed formulation
155296|NCT01755702|Drug|Paracetamol marketed formulation|Paracetamol marketed formulation
155297|NCT01755715|Procedure|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
155298|NCT01755728|Drug|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
155299|NCT01755728|Drug|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
155300|NCT01755728|Procedure|Closure of PDA|Open surgery for closure of PDA
153238|NCT01762839|Drug|Placebo|IV placebo will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
153239|NCT01762839|Drug|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a 400 mg moxifloxacin tablet and will not receive a placebo infusion.
153240|NCT01762852|Drug|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
153241|NCT01762852|Drug|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
153242|NCT01762878|Drug|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
153243|NCT01762878|Drug|Placebo|Dry powder for oral inhalation once daily using DIKUS device
153244|NCT01762891|Drug|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
153245|NCT01762891|Drug|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
153246|NCT01762891|Drug|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
153247|NCT01762891|Drug|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
153248|NCT00001891|Procedure|Myocardial contrast echocardiography|
153249|NCT00096460|Procedure|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
153250|NCT01764971|Other|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
153251|NCT01764984|Device|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
153252|NCT01764997|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
153253|NCT00096655|Drug|Infliximab|
153254|NCT01764997|Drug|Etanercept|Pharmaceutical form:solution Route of administration: subcutaneous
153565|NCT01768065|Device|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
153566|NCT01768065|Device|placebo sham|
153966|NCT01761487|Device|Gentamicin and polymyxin E|
153967|NCT01761500|Other|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
153968|NCT01761513|Drug|YH4808|Group1
adminitration of YH4808 dose1, bid for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of YH4808 dose2, qd for 2weeks
153969|NCT01761513|Drug|YH4808|Group2
adminitration of YH4808 dose2, qd for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of YH4808 dose1, bid for 2weeks
154261|NCT01764594|Other|Placebo|Placebo comparator
154262|NCT01764607|Drug|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
154263|NCT01764620|Other|Elastic taping applied with tension|
154264|NCT01766830|Device|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
154265|NCT01766830|Device|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
154266|NCT01766830|Device|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
154267|NCT01766830|Device|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
154268|NCT01766830|Device|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
154269|NCT01766830|Device|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
154270|NCT00096915|Drug|Darbepoetin Alfa|QM administration for 32 weeks, allowable doses:
15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg
154271|NCT01766830|Device|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
154272|NCT01766830|Device|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
148750|NCT01708590|Drug|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
148751|NCT01708590|Drug|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
148752|NCT01708590|Drug|placebo|Placebo administered subcutaneous (SC)
148753|NCT01708603|Drug|210 mg brodalumab|210 mg brodalumab administered SC
148754|NCT01708603|Drug|140 mg brodalumab|140 mg brodalumab administered SC
148755|NCT00001753|Procedure|Magnetic resonance imaging|
148756|NCT00091715|Drug|bosentan|65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
149067|NCT01701401|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
149068|NCT01701414|Drug|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
149069|NCT01701414|Drug|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
149070|NCT01701440|Device|Biofusionary Bebe|
149071|NCT01701453|Drug|clopidogrel|
149072|NCT01701466|Other|Aveeno cream|Twice a day
149073|NCT01701466|Other|Flamazine cream|Twice a day, when there is dry desquamation
149074|NCT01701466|Other|NeoVIDERM cream|Three times a day
149075|NCT00091039|Drug|paclitaxel|
149076|NCT01701479|Drug|ch14.18/CHO|
149077|NCT01701479|Drug|Aldesleukin|
149078|NCT01701479|Drug|Isotretinoin|
149079|NCT01701492|Other|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
149080|NCT01701492|Other|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
152871|NCT01723657|Drug|G-CSF|Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.
Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L.
152872|NCT01723657|Other|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
152873|NCT01723657|Other|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
152874|NCT01723670|Drug|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
152875|NCT00093145|Drug|Herceptin®|Administered by IV infusion
152876|NCT01723670|Drug|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
152877|NCT01723670|Drug|Placebo|oral tablet,once a day for 24 months
152878|NCT01723683|Drug|Surfactant|
152879|NCT01723696|Dietary Supplement|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
152880|NCT01723696|Dietary Supplement|Placebo tablet+prenatal vitamin|
152881|NCT01723722|Drug|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
152882|NCT01723722|Drug|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
152883|NCT01723735|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: subcutaneous
152884|NCT01723735|Drug|ezetimibe|Pharmaceutical form:overencapsulated tablet Route of administration: oral
152902|NCT01726179|Device|control|Patients and their guardians will be instructed to use dental floss to remove dental biofilm in both proximal sites once a day and to brush teeth with fluoridated toothpaste twice a day.
A sub-sample with children with indication for a composite restoration in at least one proximal surface will be selected for the analysis of dental anxiety and stress.
152903|NCT01726192|Procedure|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
152904|NCT01726192|Procedure|Placement of a femoral neurostimulating catheter|
152905|NCT01726205|Drug|Pregabalin and normal saline infusion, PRG|
152906|NCT01726205|Drug|Pregabalin and ropivacaine 02% infusion|
152907|NCT01726205|Drug|Placebo drug, normal saline infusion|
152318|NCT01725243|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
152319|NCT01725256|Drug|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
152320|NCT01725269|Drug|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
152321|NCT01725282|Drug|quetiapine extended release (XR)|Extended release tablets
152322|NCT01725282|Drug|Placebo|matching tablets
152323|NCT01725295|Other|NST|A form of physical therapy
152324|NCT01725295|Other|Hydrotherapy|
152325|NCT00093301|Drug|Dobutamine|
152326|NCT01725308|Drug|FK949E|Oral
152327|NCT01725308|Drug|Placebo|Oral
152328|NCT01725321|Other|Narrow band imaging|Colonoscopy with new narrow band imaging
152329|NCT01725334|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
152330|NCT01725360|Drug|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
152331|NCT01725399|Other|Apple Juice|
152332|NCT01725399|Other|Water|
152333|NCT01725412|Dietary Supplement|Thiamine 300mg PO once daily|
152334|NCT01725412|Dietary Supplement|placebo|
152335|NCT00093522|Drug|fludarabine phosphate|
152611|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
152612|NCT01725685|Drug|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
152613|NCT01725685|Drug|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
153062|NCT01762605|Procedure|Cast|
153063|NCT01762618|Behavioral|Cognitive Behavioral Therapy Group|Therapy Groups
152094|NCT01730417|Drug|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
152095|NCT01730456|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
152096|NCT01730469|Drug|AT1001 150 mg|AT1001 150mg is available as a capsule
152097|NCT00093678|Procedure|supportive care/therapy|
152098|NCT01730482|Drug|[14C] AT1001|150 mg of [14C] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
152099|NCT01722136|Behavioral|High Dosage|Exercise dose of 14kcal/kg/week
152100|NCT01722149|Genetic|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
152101|NCT01722162|Drug|Bevacizumab|
152102|NCT01722162|Drug|Capecitabine|
152103|NCT01722162|Drug|Levocetirizine|
152104|NCT01722175|Procedure|ALPPS surgery|
152105|NCT00001789|Drug|BG9588|
152106|NCT00093002|Drug|Fulvestrant|250 mg & 500 mg intramuscular injection
152107|NCT01722175|Procedure|PVO surgery|
152108|NCT01722201|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
152109|NCT01722201|Drug|Risperidone|1 mg tablet once a day
152110|NCT01722214|Biological|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
152111|NCT01722214|Other|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
152112|NCT01722227|Drug|Liraglutide|
152113|NCT01722227|Drug|Placebo|
152773|NCT01723514|Drug|AMG 334|3 dose levels of AMG 334 administered as multiple SC doses in healthy subjects and migraine patients.
152774|NCT01723514|Drug|Placebo|3 dose levels of Placebo administered as multiple SC doses in healthy subjects and migraine patients.
152775|NCT01723527|Drug|Methadone|Clinic-Based Methadone Maintenance Treatment
152776|NCT01723527|Drug|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
152777|NCT00093145|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
153126|NCT01769664|Drug|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
153127|NCT01769664|Drug|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
153128|NCT01769677|Drug|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
153129|NCT01769690|Other|DBS stimulator setting alteration|2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator "on" at the subject's stable, clinically effective settings and one with the stimulator "off." the order of the "off" and "on" nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the "on" setting, participants may be able to tell when the DBS is "OFF." In the second phase, the first sleep study night will be with the stimulator "OFF". The order of the "HIGH", and "LOW" frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.
Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy
153130|NCT01769690|Other|virtual reality simulator|This virtual pedestrian environment is a measure of "real-world" street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test.
153131|NCT01769703|Drug|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
153132|NCT01769716|Procedure|Umbilical Cord Blood administration|
153133|NCT01769729|Behavioral|PEPP|
153134|NCT01769729|Behavioral|Care management|
153135|NCT01769742|Behavioral|Early mobility bundle|
153136|NCT00097344|Drug|Atamestane|
151028|NCT01735266|Other|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
151029|NCT01735266|Other|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
151030|NCT01735279|Drug|fish oil|
151031|NCT01735292|Device|Automatic Respiration Transfer System- Timer|
151032|NCT01735318|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
151033|NCT01735318|Drug|Lisinopril|40 mg tablet once a day
151034|NCT00094133|Procedure|hypnotherapy|
151035|NCT01735344|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
151036|NCT01735344|Drug|Lisinopril|40 mg tablet once a day
151333|NCT01738308|Procedure|Healing Touch Sham Treatment|The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the "high heart" area. This will continue until parents are called to the bedside
151334|NCT00094549|Drug|placebo|
151335|NCT01738321|Other|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
151336|NCT01738334|Behavioral|Active comparator (meditation) with healthy subjects|The control group with healthy subjects that was participate in meditation ("active" control group)
151337|NCT01738334|Behavioral|Meditation|In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and "active" controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1.
151338|NCT01738347|Drug|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
151339|NCT01731158|Drug|Sutent, Nexavar or Votrient|TKI
151340|NCT00093743|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
151341|NCT01731171|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
150790|NCT01737281|Behavioral|Usual care|Usual smoking cessation care from VA clinical staff.
150791|NCT01737294|Drug|Qutenza exposure|Cutaneous patch
150792|NCT01737307|Drug|Fluoride varnish|Fluoride Varnish (NaF 5%)
150793|NCT01737307|Other|Oral Hygiene|Oral hygiene followed.
150794|NCT01737307|Drug|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
150795|NCT01737320|Drug|short-course antibiotic treatment|On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:
Intervention group - antibiotic treatment stopped on day 7
Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines.
150796|NCT01737320|Drug|accepted prolonged antibiotic treatment|
150797|NCT01737346|Drug|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
150798|NCT00094458|Other|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
150799|NCT01737359|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
150800|NCT01739894|Drug|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
150801|NCT01739907|Other|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
150802|NCT01739920|Other|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
151101|NCT01733277|Other|Magnetic Resonance Imaging (MRI)|All participants from both arms will be subjected to MRI
151102|NCT01733290|Drug|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
151103|NCT01733290|Drug|Normal saline instillation|Normal saline instillation
151104|NCT00093860|Drug|Propranolol|
151105|NCT01733303|Behavioral|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
151763|NCT01724268|Drug|Anti TNF + Meth|
151764|NCT01724281|Other|No intervention, only follow up|
150860|NCT01735071|Drug|bevacizumab, trabectedin and carboplatin|Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.
Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.
Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.
From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days
150861|NCT00094107|Drug|Axitinib [AG-013736]|VEGFR [vascular endothelial growth factor Receptor] and PDGFR [Platelet-Derived Growth Factor Receptor] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
150862|NCT01737359|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
150863|NCT01737359|Drug|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
150864|NCT01737385|Procedure|Measurement with O2C|Measurement of microcirculation using O2C light probes.
150865|NCT01737398|Drug|IONIS-TTR Rx|300 mg IONIS-TTR Rx administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.
150866|NCT01737398|Drug|Placebo|Placebo administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.
150867|NCT01737411|Drug|solifenacin|
150868|NCT01737411|Procedure|cesa/vasa|surgical repair of USL
150869|NCT01737424|Drug|LC28-0126|LC28-0126
150870|NCT01737424|Drug|Placebo|Placebo
150871|NCT00094458|Drug|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
150872|NCT01737437|Drug|group C|0.9% normal saline was applied to trachea and laryngoscope blade
150873|NCT01737437|Drug|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
150874|NCT01737437|Drug|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
150875|NCT01737437|Drug|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
150876|NCT01737450|Drug|BKM120|
151532|NCT01729143|Other|24-hour energy expenditure and substrate utilization|Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at elast 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
151533|NCT01729156|Drug|Metformin|
151534|NCT01729156|Drug|Placebo|
151535|NCT01729195|Procedure|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
151536|NCT01729208|Device|Dual Focus Soft Contact Lens|
151537|NCT01729208|Device|Single Vision Soft Contact Lens|
151538|NCT01729234|Dietary Supplement|Nitrate|Dietary Supplement
151539|NCT01729234|Dietary Supplement|Placebo|Dietary Supplement
151823|NCT01721733|Drug|EPI-743 5 mg/kg|
151824|NCT01721746|Biological|BMS-936558|
151825|NCT01721746|Drug|Dacarbazine|
151826|NCT00092950|Behavioral|Physical activity|
151827|NCT01721746|Drug|Carboplatin|
151828|NCT01721746|Drug|Paclitaxel|
151829|NCT01721759|Drug|Nivolumab|
151830|NCT01721772|Biological|BMS-936558 (Nivolumab)|
151831|NCT01721772|Biological|Placebo matching BMS-936558 (Nivolumab)|
151832|NCT01721772|Drug|Dacarbazine|
151833|NCT01721772|Drug|Placebo matching Dacarbazine|
151834|NCT01721785|Drug|Gadofosveset trisodium|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
151835|NCT01721798|Device|Mirena levonorgestrel IUD|Intrauterine contraception system
151836|NCT01721798|Device|Copper T-380a IUD|intrauterine contraception system
151320|NCT01735864|Drug|Indirubin 200μg/g|Dosage form: Ointment
Dose(s): Each gram of ointment containing 200 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
151321|NCT01735864|Drug|Indirubin 100 μg/g|Dosage form: Ointment
Dose(s): Each gram of ointment contains 100 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
151322|NCT01738243|Drug|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
151323|NCT00094549|Drug|divalproex sodium|
151324|NCT01738243|Drug|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
151325|NCT01738256|Behavioral|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
151326|NCT01738256|Behavioral|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
151327|NCT01738256|Behavioral|No intervention|No intervention
151328|NCT01738282|Drug|Baclofen|
151329|NCT01738282|Drug|Placebo (for baclofen)|
151330|NCT01738295|Drug|Donepezil administration|
151331|NCT01738295|Drug|Placebo administration|
151332|NCT01738308|Procedure|Healing Touch|When enter PACU + usual standard of care.
The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the "high heart" area. The practitioner will hold this position until they feel a deep connection and "quieting" within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,
155067|NCT01761331|Other|Acupuncture|Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
155068|NCT01761344|Other|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
155069|NCT01761357|Other|answering to questionnaires of quality of live|
155070|NCT00096382|Biological|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
155071|NCT01761370|Procedure|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
155072|NCT01761370|Procedure|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
155073|NCT01752426|Drug|PCI-32765|420 mg orally once daily.
155074|NCT01752439|Device|Anodal transcranial direct current stimulation|
155075|NCT00095862|Biological|recombinant interferon alfa|
155076|NCT01752439|Device|Sham transcranial direct current stimulation|
155077|NCT01752465|Behavioral|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
155078|NCT01752465|Behavioral|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
155079|NCT01752491|Drug|Ascorbate|Intravenous infusion of high-dose ascorbate
155080|NCT01752491|Drug|Temozolomide|Oral chemotherapeutic
155081|NCT01752491|Radiation|Radiation therapy|
154608|NCT01757379|Dietary Supplement|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
154609|NCT00096135|Radiation|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
154610|NCT01757379|Dietary Supplement|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
154611|NCT01757379|Dietary Supplement|Inulin|15 g of inulin dissolved in 200 ml of water
154867|NCT01760590|Procedure|Manual Manipulation|A grade 5 thrust to the thoracic spine
154868|NCT01760590|Procedure|Mobilization|A grade 1-4 mobilization directed at thoracic spine
154869|NCT01760603|Procedure|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
154870|NCT00096330|Dietary Supplement|dietary intervention|oral folic acid supplementation once daily on days 57-84
154871|NCT01760616|Drug|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
154872|NCT01760629|Device|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
154873|NCT01760642|Drug|Midazolam|Midazolam 3 mg IV
154874|NCT01760642|Drug|Ketoconazole|ketoconazole 400 mg PO
154875|NCT01760642|Drug|Rifampicin|Rifampicin 600 mg PO
154876|NCT01760655|Drug|Fludarabine phosphate|Given IV
154877|NCT01760655|Drug|Thiotepa|Given IV
154878|NCT01760655|Radiation|Total body irradiation|Undergo TBI
154879|NCT01760655|Biological|Therapeutic allogeneic lymphocytes|Undergo donor lymphocyte infusion
154880|NCT01760655|Drug|Cyclophosphamide|Given IV
154881|NCT00096330|Dietary Supplement|folic acid|oral folic acid supplementation once daily on days 1-56.
154882|NCT01760655|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo allogeneic PBSCT
154883|NCT01760655|Procedure|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
155598|NCT00096122|Drug|idarubicin|Given IV
155599|NCT01756326|Procedure|Bone Autograft|
155600|NCT01756339|Drug|Solithromycin|
155601|NCT01756339|Drug|Moxifloxacin|
155602|NCT01756339|Other|Placebo to match solithromycin|
155603|NCT01756352|Drug|18F-FET|Radiotracer, surrogate marker for protein synthesis
155604|NCT01756365|Procedure|surgical transplantation of CECA|
155605|NCT01756378|Procedure|joint mobilization with movement|
155606|NCT01756378|Procedure|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
155607|NCT01756404|Drug|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
155608|NCT01756404|Drug|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
155609|NCT00096122|Drug|tipifarnib|Given orally
155610|NCT01756417|Drug|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
155611|NCT01756417|Drug|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
154662|NCT01754532|Biological|Hair Sample|Analysis of hair cortisol levels
154663|NCT01754545|Drug|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
154664|NCT01754545|Drug|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
154665|NCT01754558|Procedure|Ajust system|The use of Ajust system for stress incontinence
154666|NCT01754558|Procedure|TVT/TVT-O|sling surgery
154667|NCT01754571|Behavioral|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
154668|NCT01754597|Drug|Peptide Natriurétique de type B|Peptide Natriurétique de type B
155301|NCT00096083|Drug|isolated perfusion|
155302|NCT01755741|Drug|vaginal ring|
155303|NCT01755754|Drug|vaginal ring|
155304|NCT01755767|Drug|Tivantinib|The tivantinib dosage of 120 mg administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 240 mg.
155305|NCT01755767|Drug|Placebo|The control arm will receive matching placebo tablets, once in the morning and once in the evening, with food, continuously.
155306|NCT01755780|Other|Left interscalene block|
155307|NCT01755780|Other|Right interscalene block|
155308|NCT01755819|Device|Biocomposite interference screw|
155309|NCT01755819|Device|Extracortical ACL Tightrope fixation|
155310|NCT01755832|Procedure|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
155311|NCT01755845|Drug|paclitaxel|
155312|NCT00096083|Drug|melphalan|
155313|NCT01755845|Drug|cisplatin|
155314|NCT01755845|Radiation|radiotherapy|
155315|NCT01755858|Drug|Bendavia|
155316|NCT01755858|Drug|Placebo|
155665|NCT01753661|Behavioral|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
155666|NCT01753674|Dietary Supplement|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
155667|NCT01753674|Dietary Supplement|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
155668|NCT00095927|Drug|carboplatin|Given IV
155669|NCT01753687|Other|Ocular scattering of the tear film|
155670|NCT01753687|Other|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
155671|NCT01753687|Other|Measurement of tear film osmolarity|
153567|NCT01768078|Procedure|Intravitreal injection of Betamethasone + antibiotics|
153568|NCT01768078|Procedure|Intravitreal injection of antibiotics|
153569|NCT00097084|Drug|insulin aspart|
153570|NCT01768091|Procedure|POEM|Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.
Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.
(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)
153571|NCT01768091|Procedure|Pneumatic dilation|A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.
(N Engl J Med 2011;364:1807-16.)
153572|NCT01768104|Procedure|ESTD|A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).
Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.
Dissection was done along the margin of the tumor.
After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.
Endoclips were used to close the entry of the submucosal tunnel.
(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)
153573|NCT01768104|Procedure|VATS|General anesthesia with double lumen intubation.
Three to four cameras or working ports are placed over the chest wall.
After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.
The mass is exposed after the overlying muscle is split longitudinally.
The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.
The muscle layer is re-approximated and a chest tube is place through one of the ports.
(Luh et al. World Journal of Surgical Oncology 2012, 10:52)
153574|NCT01768117|Biological|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
153575|NCT01768143|Behavioral|unexperienced endoscopy nurses|
153576|NCT01768143|Behavioral|Experienced endoscopy nurses|
153577|NCT01768156|Other|Experimental arm|Serum samples are collected:
at time of diagnosis of recurrence (before 1st chemotherapy)
during each cycle of chemotherapy
after the end of chemotherapy
every 3 month until treatment failure (3-6 samples)
stop at the progression or after 18 months post chemotherapy
153578|NCT01770925|Device|N-CPAP|The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.
CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.
If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed.
153887|NCT01763827|Biological|Placebo to Evolocumab|Administered by subcutaneous injection
153888|NCT00096525|Drug|lenalidomide|
154273|NCT01766843|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
154274|NCT01766843|Drug|Seretide Diskus|2 inhalations as a single dose
154275|NCT01766843|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
154276|NCT01766843|Drug|SF Easyhaler|2 inhalations as a single dose
154277|NCT01766856|Other|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
153323|NCT01770054|Other|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
153324|NCT01770067|Drug|CITA-RNPT|
153325|NCT01770080|Drug|Euminz®|3 to 5 time topical use of study drug.
153326|NCT01770080|Drug|Placebo|3 to 5 time topical use of study drug.
153327|NCT01770093|Other|Questionnaire|
153328|NCT00097344|Procedure|Hormone therapy|
153329|NCT01770106|Drug|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
153330|NCT01762904|Other|Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.
153331|NCT01762904|Other|Preparing skin's areas to be tested with two antiseptics and two controls|All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
153332|NCT01762930|Drug|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
153333|NCT01762943|Drug|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
149081|NCT01701505|Drug|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
149082|NCT01701505|Drug|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
149083|NCT01701505|Drug|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
149084|NCT01701518|Drug|Ozurdex|biodegradable 0.7mg dexamethasone implant
149085|NCT01701531|Drug|RBCPF|
149086|NCT00091039|Radiation|radiation therapy|
149087|NCT01701544|Device|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
149088|NCT01703949|Other|laboratory biomarker analysis|Correlative studies
149089|NCT01703975|Other|Training in pairs (Dyad training)|
149090|NCT01703988|Drug|ISIS-SMNRx|Single intrathecal injection for each dose
149400|NCT01706939|Radiation|Reduced Dose Radiation|Reduced Dose Radiation (5600 cGy) dose radiotherapy with weekly Carboplatin
149401|NCT01706939|Radiation|Standard Dose Radiation|Standard Dose Radiation (7000 cGy) dose radiotherapy with carboplatin
149402|NCT01706952|Drug|Cocaine|
149403|NCT00001752|Drug|L-arginine|
149404|NCT00091572|Drug|Temozolomide|oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days ("7 days on / 7 days off" continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
149405|NCT01706952|Drug|Adrenaline|
149406|NCT01706965|Drug|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
149407|NCT01706965|Drug|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
149408|NCT01706978|Procedure|Bone Trephination|
149409|NCT01706978|Procedure|Soft Tissue Trephination|
149410|NCT01706991|Device|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
149411|NCT01707004|Drug|decitabine|Given IV
152908|NCT00093418|Drug|tipifarnib|Given orally
152909|NCT01726244|Behavioral|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
152910|NCT01726257|Device|Nellix System|
152911|NCT01726270|Drug|tamsulosin|0.4 mg
152912|NCT01726283|Device|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
152913|NCT01729039|Behavioral|standard balance rehabilitation|All subjects will perform balance and gait exercises in addition to the eye movement exercises and will be provided a written HEP consisting of balance and gait exercises designed to improve postural stability and mobility with progressively more challenging tasks. Balance exercises will include maintaining stability in standing with vision and somatosensory cues altered, dynamic weight shifting and performing ankle, hip and step strategies. Gait activities will include negotiating uneven terrains and obstacles, gait with slow head turns focusing on objects, varied speed (speeding up and slowing down), and unpredictable starts and stops. Walking for endurance will be included in the HEP. Each participant will receive a customized balance and gait HEP based on identified impairments and will be progressed according to ability and level of assistance at home as is standard in PT.
152914|NCT01729039|Behavioral|gaze stability|Vestibular adaptation and substitution exercises were designed originally based on the error signals (retinal slip) that induce changes in gain in the vestibular system and will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. Substitution exercises specifically attempt to facilitate use of alternative strategies, rather than teaching the specific strategies. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
152915|NCT01729039|Behavioral|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
152916|NCT01729052|Device|Acupuncture|
152917|NCT01729065|Other|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
153215|NCT01769833|Drug|Nucleosides|
153216|NCT01769846|Other|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 5 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 20 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position. In sedated patients, cycling was performed in a passive manner for 20 consecutive minutes at a ﬁxed pedaling rate of 20 cycles/min.
153217|NCT01769872|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
153218|NCT01769885|Drug|tivozanib|Given PO
152614|NCT01725685|Drug|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
152615|NCT00093366|Biological|etanercept|
152616|NCT01725698|Drug|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
152617|NCT01725711|Device|OPRA Implant System|
152618|NCT01725724|Procedure|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
152619|NCT01725724|Procedure|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
152620|NCT01725737|Drug|GlyTI-M|
152621|NCT01725737|Drug|Placebo|Placebo Comparator: starch
152622|NCT01725750|Device|Bright White Light (BWL)|Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18" from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.
152623|NCT01725750|Device|Dim Red Light (DRL)|A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18" from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.
152624|NCT01725763|Other|Cardiac MRI|
152625|NCT01725776|Drug|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
152626|NCT00093366|Drug|arsenic trioxide|
152627|NCT01725789|Drug|Ferinject®|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
Note, Ferinject® should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight <50kg, administration of Ferinject® should be limited to 500mg at baseline . All patients with a serum ferritin value <15ng/mL and Hb<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(Study group: Ferinject®500mg, Control Group:Placebo)
152628|NCT01728480|Radiation|intensity-modulated radiation therapy|Undergo IMRT
152629|NCT01728480|Drug|cisplatin|Given IV
152630|NCT01728480|Other|pharmacological study|Correlative studies
152982|NCT01723943|Other|questionnaire administration|Ancillary studies
152983|NCT00093197|Drug|KAI-9803 for Injection|0.05 mg
152114|NCT01722240|Drug|Liraglutide 1.2mg|
152115|NCT01722240|Drug|Placebo|
152116|NCT01722253|Procedure|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
152117|NCT00093015|Drug|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
152397|NCT01722799|Device|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
152398|NCT01722799|Device|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
152399|NCT01722812|Drug|Cromoglicate|Twice daily topical treatment for 14 days
152400|NCT01722812|Drug|Placebo|Twice daily topical treatment for 14 days
152401|NCT01722825|Drug|LY2157299|Administered orally.
152402|NCT01722838|Behavioral|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
152403|NCT01722864|Drug|COV155|COV155 tablets
152404|NCT01722877|Device|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
152405|NCT01722916|Drug|Hyaluronidase|
152406|NCT00093067|Drug|daptomycin|
152407|NCT01722929|Device|Sensor on surgery side|
152408|NCT01722929|Device|Sensor on non-surgery side|
152409|NCT01725425|Other|Control|The control is designed to determine average mood.
152410|NCT00001806|Other|Genetic Education and Counseling|Group Education and Counseling
152411|NCT00093314|Drug|HuMax-CD20|
152412|NCT01725425|Other|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
152413|NCT01725425|Other|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
152414|NCT01725425|Other|Mixed Portions|The purpose is to determine if a change in mood will occur.
152415|NCT01725438|Other|sample blood|
153137|NCT01769755|Biological|PDA001|Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.
Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.
Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.
153138|NCT01769755|Drug|Vehicle Controlled Placebo|Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
153139|NCT01769768|Drug|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
153140|NCT01769768|Drug|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
152169|NCT01729858|Device|Metal-Ceramic|Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.
Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline.
152170|NCT01729871|Drug|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
152171|NCT01729871|Drug|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
152172|NCT01729884|Biological|HER-2/neu peptide vaccine|Given ID
152173|NCT00093652|Radiation|radiation therapy|
152174|NCT01729884|Other|laboratory biomarker analysis|Correlative studies
152175|NCT01729897|Drug|Etomidate|
152176|NCT01729897|Drug|Fentanyl|
152177|NCT01729897|Drug|Propofol|
152178|NCT01729910|Behavioral|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
152179|NCT01729910|Behavioral|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
152180|NCT01729923|Drug|Capecitabine|Given PO
152181|NCT01729923|Drug|Celecoxib|Given PO
152182|NCT01729923|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
151342|NCT01731171|Dietary Supplement|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
151343|NCT01731184|Drug|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
151344|NCT01731197|Dietary Supplement|Dry-Blended Beverage|
151345|NCT01731210|Device|implantation of the new LV lead: NANO system.|
151346|NCT01731223|Behavioral|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
151347|NCT01731236|Other|Antibiotic/Probiotic|Antibiotic cocktail(Ciprofloxacin, Flagyl, Vancomycin, Neomycin)/yogurt as follows:
Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks; Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks;
151348|NCT01731249|Biological|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
151349|NCT01731249|Biological|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
151606|NCT01726621|Device|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
151607|NCT01726634|Other|Elastic Tapping|
151608|NCT00093470|Drug|Tipifarnib|Given PO
151609|NCT01729338|Drug|Revlimid|Lenalidomide (odd cycles [9,11,13, etc.]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.
Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately.
151610|NCT00093626|Other|Laboratory Biomarker Analysis|Correlative studies
151611|NCT01729364|Drug|crystalloid|
151612|NCT01729364|Drug|colloid|
151613|NCT01729377|Other|Interview|
151106|NCT01733316|Drug|RP103 Q12H|
151107|NCT01733316|Drug|Cystagon Q6H|
151108|NCT01733329|Drug|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
151109|NCT01733329|Drug|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
151110|NCT01733342|Device|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
151111|NCT01733342|Procedure|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
151112|NCT01733342|Device|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
151113|NCT01733355|Radiation|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
151114|NCT01733394|Drug|Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand"|
151115|NCT00093873|Drug|Anti-angiogenesis|Anti-angiogenesis
151116|NCT01733394|Drug|lamotrigine|
151117|NCT01733407|Drug|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
151118|NCT01733407|Drug|placebo|400mg/kg/d divided TID for year 1 only.
151119|NCT01733420|Drug|Biodentine pulpotomy|
151120|NCT01733420|Drug|White MTA pulpotomy|
151121|NCT01735422|Drug|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
151398|NCT01738373|Drug|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
151399|NCT01738399|Dietary Supplement|Coffee|
151400|NCT01738399|Dietary Supplement|Placebo|
151401|NCT01738412|Device|Neurokeeper stroke detector|Monitoring stroke patients
151402|NCT01738425|Drug|GIC-1001; 125 mg oral tablets|Single ascending doses (SAD) from 125 mg to 1000 mg;
Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days
150877|NCT01737463|Procedure|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
150878|NCT01737476|Procedure|Transcranial Magnetic Stimulation. PFC|
150879|NCT01737489|Behavioral|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
151177|NCT01730872|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
151178|NCT01730872|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
151179|NCT00093743|Drug|cyclosporine|Given IV or PO
151180|NCT01730885|Other|Comparison of different Blood Glucose Meters|
151181|NCT01730898|Other|Study product containing lutein|delivered in capsule form
151182|NCT01730898|Other|Study product containing lutein|delivered in capsule form
151183|NCT01730911|Other|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
151184|NCT01730924|Procedure|Pulmonary vein isolation using contact force sensing catheter|
151185|NCT01730937|Drug|sorafenib tosylate|Given PO
151186|NCT01733420|Drug|Tempophore pulpotomy|
151187|NCT01733433|Procedure|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
151188|NCT01733446|Other|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
151189|NCT01733459|Drug|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
151190|NCT01733459|Drug|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
151191|NCT00093873|Drug|AMG 706|Anti-angiogenesis
151192|NCT01733459|Drug|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
151193|NCT01733459|Drug|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
151837|NCT00092963|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
151838|NCT01724346|Drug|Arm B - PCI-32765|PCI-32765 will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. PCI-32765 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. PCI-32765 will be dispensed to patients in bottles at every other visit.
151839|NCT01724346|Drug|Second-line PCI-32765|For patients who experienced PD before other Second-line treatment are eligible to receive PCI-32765.
151840|NCT01724346|Drug|Alternative Anticancer Treatment|Specific therapy and treatment regimen are at the investigator's discretion.
151841|NCT01724359|Drug|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
151842|NCT01724372|Drug|Antidepressant|
151843|NCT01724372|Drug|Antipsychotic|
151844|NCT01724385|Drug|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
151845|NCT01724398|Other|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
150936|NCT01735097|Dietary Supplement|Nigella sativa|Nigella sativa (200 mg, soft capsule)
150937|NCT01735097|Dietary Supplement|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
150938|NCT01735110|Procedure|transfemoral intervention (TFI)|
150939|NCT01735110|Procedure|Transradial intervention|
150940|NCT01735123|Dietary Supplement|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
150941|NCT01735136|Dietary Supplement|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
150942|NCT01735136|Dietary Supplement|Placebo|Placebo (10g/day)
150943|NCT00094120|Drug|MSI-1256F (Squalamine Lactate)|
150944|NCT01735149|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
150945|NCT01735149|Dietary Supplement|Placebo|Placebo (34.5g/day)
150946|NCT01735175|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
151592|NCT01726543|Procedure|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
151593|NCT01726543|Procedure|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
151594|NCT01726556|Device|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
151595|NCT01726556|Device|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
151596|NCT01726569|Behavioral|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
151597|NCT00093470|Procedure|Clinical Observation|Undergo observation
151598|NCT01726569|Other|traditional counseling|Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
151599|NCT01726582|Drug|Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
151600|NCT01726582|Drug|standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatmetn will be standard FOLFIRINOX chemotherapy regimen.
151601|NCT01726582|Drug|Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
151602|NCT01726582|Other|No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
151603|NCT01726582|Drug|Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
151604|NCT01726582|Radiation|Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
155082|NCT01752504|Behavioral|Community Mobilization|The C2P community mobilization intervention begins, as described in this protocol, with a series of approximately four capacity building meetings with community partners to establish the coalitions and to build their capacity for strategic planning around structural change. This will be followed by launching the coalition's strategic planning with the identification of SCOs that the coalitions work to achieve. SCOs are new or modified policies, programs, practices, laws or changes to the built environment. The mobilization effort will include continual development of the coalitions' infrastructure and capacity for identifying and achieving relevant SCOs to influence risk, regular review of strategic plans and SCOs, and the development of new SCOs to achieve. Our primary study objective is to determine if the achievement of community-identified SCOs result in reduced individual risk as indicated by venue-based anonymous surveys with at-risk youth.
155083|NCT01752517|Drug|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
155448|NCT01750801|Drug|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
155449|NCT01750801|Drug|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
155450|NCT01750814|Biological|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
155451|NCT01750814|Biological|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
155452|NCT01750827|Drug|SB659032|single dose
155453|NCT00095706|Drug|Bevacizumab (drug), Herceptin (drug)|
155454|NCT01750853|Drug|LY3045697|Administered orally
155455|NCT01750853|Drug|Placebo|Administered orally
155456|NCT01750866|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
155457|NCT01750866|Drug|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
155458|NCT01750866|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
155459|NCT01750879|Drug|Peanut Flour|Peanut Flour
155460|NCT01750879|Drug|Oat Flour|Oat Flour
154884|NCT01760655|Drug|Tacrolimus|Given IV
154885|NCT01760655|Drug|Mycophenolate mofetil|Given IV
154886|NCT01760681|Device|H- Coil DTMS|20 daily deep rTMS treatments
154887|NCT01760681|Device|Sham|
154888|NCT01760694|Other|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
154889|NCT01760707|Behavioral|exercise training|
154890|NCT01760707|Behavioral|usual care|
154891|NCT01760720|Behavioral|MMT CARE|
154892|NCT00096343|Drug|carboplatin|
155149|NCT01760785|Drug|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
155150|NCT01760785|Drug|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
155151|NCT01760798|Drug|Teriparatide|
155152|NCT00096343|Drug|paclitaxel|
155153|NCT01760811|Drug|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
155154|NCT01760824|Drug|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
155155|NCT01760824|Drug|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
155156|NCT01760837|Other|Baked milk products to cow's milk allergic patients|
155157|NCT01760850|Other|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
155158|NCT01760850|Other|educational intervention|Engage in an educational information session for diabetes
154669|NCT01754610|Behavioral|Strengthening Family Coping Resources (SFCR)|Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.
Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based.
154670|NCT01754623|Drug|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
154671|NCT01754623|Drug|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
154672|NCT00095966|Drug|gemcitabine hydrochloride|Given IV
154673|NCT01757431|Drug|Eculizumab|
154674|NCT01757444|Device|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
154675|NCT01757444|Device|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
154676|NCT00096148|Drug|idarubicin|Given IV
154677|NCT01757457|Drug|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
154678|NCT01757457|Drug|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
154679|NCT01757496|Device|Cough Assist|
154953|NCT01758133|Behavioral|Exposure to medical clown activities|
154954|NCT00096161|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
154955|NCT01758146|Drug|Tamoxifen|20 mg once daily for 5 years
154956|NCT01758146|Drug|Letrozole|Letroz, Femara, Letronat
154957|NCT01758159|Dietary Supplement|Iron supplementation|
154958|NCT01758159|Other|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
154959|NCT01758172|Drug|6% hydroxyethyl starch 130/0.4|
154960|NCT01758172|Drug|Albumin|
154961|NCT01758185|Biological|recombinant hepatitis b vaccine|0.5ml intramuscular
155672|NCT01753700|Dietary Supplement|UHT treated milk|
155673|NCT01753713|Drug|dovitinib|Given PO
155674|NCT01753713|Other|laboratory biomarker analysis|Correlative studies
155675|NCT01753726|Other|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
155676|NCT01753726|Other|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
155677|NCT01756430|Drug|Carvedilol SR 64mg, QD|Carvedilol SR 64mg QD for 4 weeks
With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
155678|NCT01756430|Drug|Carvedilol IR 25mg, QD|Carvedilol IR 25mg QD for 4 weeks
With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks.
155679|NCT01756430|Drug|Carvedilol IR 25mg, BID|Carvedilol IR 25mg BID for 4 weeks
With the others investigation product placebo 2 capsules QD for 4 weeks.
155680|NCT01756443|Drug|2% lidocaine/adrenaline and 0.5% bupivacaine|
155681|NCT01756456|Drug|rhNGF 10 µg/ml eye drops solution|rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only
155682|NCT01756456|Drug|rhNGF 20 µg/ml eye drops solution|rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only
155683|NCT01756456|Drug|Placebo|Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only.
155684|NCT00096135|Biological|filgrastim|given subcutaneously (SC)
155685|NCT01756469|Behavioral|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
155686|NCT01756482|Drug|GS-5806|GS-5806, powder for oral solution
155687|NCT01756482|Drug|Placebo|
154736|NCT00095810|Drug|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
154737|NCT01751919|Drug|Glivec film-coated tablet 100 mg, 4 Tablets|
154738|NCT01751932|Device|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
154739|NCT01754623|Drug|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
154740|NCT01754623|Radiation|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
153889|NCT01763827|Other|Placebo to Ezetimibe|Administered orally once daily
153890|NCT01763840|Drug|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
153891|NCT01763853|Drug|4% albumin|
153892|NCT01763866|Biological|Evolocumab|Administered by subcutaneous injection
153893|NCT01763866|Drug|Ezetimibe|Administered orally once a day
153894|NCT01763866|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
153895|NCT01763866|Drug|Placebo to Ezetimibe|Administered orally once a day
153896|NCT01763866|Drug|Atorvastatin|Administered orally once a day
153897|NCT01763866|Drug|Rosuvastatin|Administered orally once a day
153898|NCT01763866|Drug|Simvastatin|Administered orally once a day
153899|NCT00096538|Drug|valganciclovir|
153900|NCT01763879|Other|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
153901|NCT01763879|Other|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
153902|NCT01763905|Biological|Evolocumab|Subcutaneous injection
153903|NCT01763905|Drug|Placebo to Evolocumab|Subcutaneous injection
153904|NCT01763905|Drug|Ezetimibe|Tablet for oral administration
153905|NCT01766141|Other|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
153906|NCT01766154|Drug|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
153907|NCT01766167|Drug|MP-424|Low
153908|NCT01766167|Drug|MP-424|Middle
153334|NCT01762943|Drug|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
153335|NCT01762943|Drug|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
153336|NCT01762956|Other|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
153637|NCT01765777|Procedure|Osteopathic Manipulative Medicine|
153638|NCT01765777|Procedure|Phototherapy|
153639|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Dosing every 2 weeks
Intravenous injection
153640|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Dosing weekly
Intravenous injection
153641|NCT01765803|Drug|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
153642|NCT01765816|Behavioral|high intensity interval training|
153643|NCT01765816|Behavioral|moderate intensity training|
153644|NCT01765829|Drug|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
153645|NCT01768169|Dietary Supplement|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
153646|NCT01768182|Dietary Supplement|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
153647|NCT00001901|Drug|Etanercept|
153648|NCT00097097|Procedure|Neonatal Resuscitation|
153649|NCT01768182|Other|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
149412|NCT01707004|Drug|fludarabine phosphate|Given IV
149413|NCT01707004|Drug|busulfan|Given IV
149414|NCT01707004|Drug|cyclophosphamide|Given IV
149415|NCT00091572|Drug|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
149416|NCT01707004|Drug|tacrolimus|Given PO or IV
149417|NCT01707004|Drug|mycophenolate mofetil|Given PO
149418|NCT01707004|Biological|filgrastim|Given SC
149419|NCT01707004|Radiation|total-body irradiation|Undergo total-body irradiation
149420|NCT01709292|Drug|Vemurafenib (Post Surgery) - Group A + C|Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.
Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B.
148441|NCT01710371|Drug|10% Arginine Hydrochloride-R-Gene 10|
148442|NCT01710384|Drug|betamethasone|
148443|NCT01710397|Other|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
148444|NCT01710410|Device|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
148445|NCT01710410|Device|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
148446|NCT01710423|Behavioral|Peer mentoring intervention ('Cooking with Friends')|'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.
The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.
The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children.
148447|NCT01712880|Procedure|open debridement with modular exchange|
153219|NCT01769885|Procedure|therapeutic conventional surgery|Undergo nephrectomy
153220|NCT01769898|Drug|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
153221|NCT00097344|Drug|Letrozole|
153222|NCT01769898|Drug|Theophylline|Theophylline 0.1 Q12H
153223|NCT01769898|Drug|Placebo|Placebo for theophylline 0.1 Q12H
153224|NCT01769911|Drug|carmustine|Given IV
153225|NCT01769911|Drug|cytarabine|Given IV
153226|NCT01769911|Drug|melphalan|Given IV
153227|NCT01769911|Drug|etoposide|Given IV
153228|NCT01762800|Drug|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
153229|NCT01762800|Drug|tiotropium bromide placebo|Placebo, Once daily(morning)
153230|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
153231|NCT01762813|Procedure|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
153232|NCT01762826|Dietary Supplement|Myo-inositol|Dietary control plus Myo-inositol
153233|NCT01762826|Dietary Supplement|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
153234|NCT01762826|Dietary Supplement|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
153235|NCT01762826|Dietary Supplement|Placebo|Dietary control plus folic acid 400 mcg daily
152255|NCT01727804|Other|Laser in caries prevention|
152256|NCT01727817|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
152257|NCT01727830|Other|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
152258|NCT01727843|Drug|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
152984|NCT01726283|Drug|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
152985|NCT01726296|Other|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
152986|NCT01726296|Other|medical chart review|Complete patient medical chart audit
152987|NCT01726335|Drug|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
152988|NCT01726348|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
152989|NCT01726361|Behavioral|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
152990|NCT00093444|Drug|lyso-thermosensitive liposomal doxorubicin|
152991|NCT01726361|Behavioral|Treatment as usual|Other kinds of out of home placement
152992|NCT01726374|Drug|BEP(500)|One cycle of BEP(500):
Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
152993|NCT01726387|Behavioral|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
152994|NCT01726387|Behavioral|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
152995|NCT01726400|Drug|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
152996|NCT01726400|Drug|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
152997|NCT01726413|Drug|GRC 17356|
152998|NCT01726413|Drug|Matching Placebo|
152999|NCT01726426|Dietary Supplement|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
153000|NCT01726452|Drug|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
153001|NCT00093444|Procedure|radiofrequency ablation|
152416|NCT01725451|Drug|Testosterone|Administered topically to axillae
152417|NCT01725451|Other|Deodorant Spray|Administered topically to axillae
152418|NCT01725451|Other|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
152419|NCT01725451|Other|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
152420|NCT01725464|Device|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
152421|NCT01725477|Drug|methylen blue &normal saline|Washing after dye injection
152697|NCT01723410|Other|Writing about places, objects|
152698|NCT00093132|Drug|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
152699|NCT01723436|Other|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
152700|NCT01723475|Biological|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
152701|NCT01723475|Biological|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
152702|NCT01723488|Radiation|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
152703|NCT01725789|Drug|normal saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
152704|NCT01725802|Drug|levodopa and carbidopa solution for SC administration|
152705|NCT01725802|Drug|Placebo|
152706|NCT01725815|Behavioral|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
152707|NCT01725828|Device|Ultrasongraphy|Using the Ultrasound to determine the location of the CTM.
152708|NCT01725828|Other|Palpation|Using digital Palpation to identify cricothyoid membrane
152183|NCT01729923|Other|Laboratory Biomarker Analysis|Correlative studies
152184|NCT00093665|Drug|cisplatin|
152185|NCT01729923|Other|Quality-of-Life Assessment|Ancillary studies
152186|NCT01729923|Radiation|Radiation Therapy|Undergo radiation therapy
152187|NCT01729923|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
152188|NCT01729923|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
152189|NCT01729936|Behavioral|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
152190|NCT01729949|Dietary Supplement|Active Treatment Beverage|Strawberry and Blackcurrent extract
152485|NCT01722942|Procedure|ICD implantation|ventricular ICD implantation
152486|NCT01722942|Drug|amiodarone hydrochloride|
152487|NCT01722955|Other|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
152488|NCT01722955|Other|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
152489|NCT01722968|Drug|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
152490|NCT01722968|Drug|Paclitaxel|80mg/m2 iv weekly
152491|NCT01722981|Procedure|Percutaneous tracheostomy|Three methods of percutaneous tracheostomy
152492|NCT01722994|Device|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
152493|NCT00093080|Drug|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
152494|NCT01722994|Device|Chromic Gut Sterile absorbable Suture (Ethicon)|
152495|NCT01723007|Other|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
152496|NCT01723020|Drug|AMG 232|Given an an oral tablet in escalating doses.
152497|NCT01723046|Device|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
151614|NCT01729390|Other|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
151615|NCT01729403|Drug|aleglitazar|150 mcg orally daily, 16 weeks
151616|NCT01729403|Drug|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
151617|NCT01729403|Drug|placebo|orally daily, 16 weeks
151618|NCT01729416|Other|Water Exchange Colonoscopy|We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.
We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.
On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn.
151619|NCT01729416|Other|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
151620|NCT01729429|Behavioral|HPV brochure, recall, reminders|HPV-vaccine specific brochure mailed before clinic visit
Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine
Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses
151621|NCT00093626|Drug|Sorafenib Tosylate|Given orally
151622|NCT01729429|Behavioral|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
151950|NCT01724632|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
151951|NCT01724645|Dietary Supplement|Korean traditional diets|The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.
The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.
151952|NCT01724645|Dietary Supplement|Control group|Told to " eat as usal diets".
151953|NCT01724658|Drug|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
151954|NCT01724658|Drug|placebo|placebo orally twice a week with progynova 1 mg oral daily
151955|NCT00093236|Procedure|Periodontal therapy|comprehensive periodontal treatment
151956|NCT01724684|Other|Telehealth program|
151403|NCT00094562|Drug|Fish oil supplement|
151404|NCT01738425|Drug|GIC-1001 matching placebo|Single ascending doses (SAD) [equivalent to active arm, 125 mg to 1000 mg]
Multiple ascending doses, TID over 7 successive days [equivalent to the active arm, 125 mg to 500 mg]
151405|NCT01738438|Drug|XL184|
151406|NCT01738451|Drug|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
151407|NCT01738451|Drug|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
151408|NCT01738477|Biological|Boostrix|Single dose intramuscular administration.
151409|NCT01738490|Device|Bone anchored hearing implant|
151410|NCT01738503|Drug|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and will be given on alternate sides of the participant's abdomen.
151411|NCT01738503|Drug|Subutex|Participants were inducted and stabilized (over a 14-day period) on SUBUTEX. Tablets are placed under the tongue until dissolved.
151412|NCT01738516|Procedure|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
151413|NCT01738516|Procedure|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
151414|NCT00094575|Procedure|Endovascular Repair|Endovascular Repair
151415|NCT01731314|Behavioral|Learning and Memory of Pain|
151683|NCT01726751|Device|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
151684|NCT01726751|Device|Spinal cord nerve stimulation|
151685|NCT00093483|Biological|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
151686|NCT01726764|Other|St John's Wort|
158204|NCT01776606|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
158205|NCT00098020|Procedure|DEXA Scan|
158206|NCT01776606|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
158207|NCT01776619|Drug|PF-06305591|14 day repeated 20mg BID doses
158208|NCT01776619|Drug|Placebo|14 day repeated BID doses
158209|NCT01776619|Drug|PF-06305591|14 day repeated 80mg BID doses
158210|NCT01776619|Drug|Placebo|14 day repeated BID doses
158211|NCT01776619|Drug|PF-06305591|14 day repeated 40mg BID doses
158212|NCT01776619|Drug|Placebo|14 day repeated BID doses
158213|NCT01776619|Drug|PF-06305591|14 day repeated BID doses
158214|NCT01776619|Drug|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
158215|NCT01776632|Behavioral|Physical activity|Promotoras provide appraisal support and negotiate behavior change goals with individual participants; provide instrumental support by organizing and leading physical activity classes within the churches and nearby church community; and advocate for church and neighborhood environmental changes that support increased moderate-to-vigorous physical activity.
158216|NCT00098020|Procedure|X-rays|
158217|NCT01776632|Behavioral|Cancer prevention|Promotoras provide workshop series on cancer prevention and control within the churches and nearby church community.
158218|NCT01776645|Behavioral|Compassion Cultivation Training Course|
158219|NCT01776658|Drug|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
158220|NCT01776658|Drug|Placebo|Ocular topical administration of placebo for 10 consecutive days
158221|NCT01776671|Drug|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
158222|NCT01776684|Drug|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
158223|NCT01776697|Drug|pelubiprofen (30mg) tablet IR|
158224|NCT01779609|Drug|Placebo|
158225|NCT01779609|Behavioral|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
157660|NCT01778699|Dietary Supplement|lozenges|The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.
The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study).
157661|NCT01778712|Behavioral|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
157662|NCT01778738|Procedure|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
157663|NCT01781377|Drug|PLACEBO|SALINE INFUSION
157982|NCT01781715|Device|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
157983|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 5 Gy x 5 (over 1-2 weeks)*
157984|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 6.6 Gy x 5 (over 1-2 weeks)*
157985|NCT01781741|Procedure|therapeutic lymphadenectomy|Undergo TEMLA
157986|NCT01773408|Drug|RO5503781 SDP|recommended phase 2 dose, new optimized formulation
157987|NCT01773408|Drug|anthracycline|anthracycline per standard clinical practice
157988|NCT00097734|Drug|ertapenem|
157989|NCT01773408|Drug|cytarabine|1000 mg/m2 iv daily for 6 days each cycle
157990|NCT01773421|Drug|E7820|FOOD EFFECT STUDY:
Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8.
157991|NCT01773421|Drug|E7820|MTD DETERMINATION FOR BID DOSING SCHEDULE
The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation,the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID.
157992|NCT01773434|Drug|MORAb-004|MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.
Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).
Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1.
157993|NCT01773447|Procedure|Set-back suture|
157994|NCT01773447|Procedure|Vertical mattress suture|
157379|NCT01778049|Drug|BI 10773|Empagliflozin active
157380|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
157381|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
157382|NCT01778049|Drug|BI 10773|Empagliflozin active
157383|NCT00098163|Biological|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
157384|NCT01778049|Drug|BI 10773|Empagliflozin active
157385|NCT01778049|Drug|BI 10773|Empagliflozin active
157386|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
157387|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
157388|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
157389|NCT01778049|Drug|BI 10773|Empagliflozin active
157686|NCT01781572|Drug|LEE011 and MEK162|Once the MTD(s)/RP2D have been determined for each tested dose schedule, the phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination.
157687|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily and LEE011 will be administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).
157688|NCT01772940|Drug|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
157689|NCT01772940|Drug|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
157690|NCT01772940|Drug|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
157691|NCT01772940|Drug|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
157692|NCT01772953|Drug|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
157693|NCT00001917|Drug|O15|
157694|NCT00097669|Dietary Supplement|Vitamin B6|25mg
157695|NCT01772966|Procedure|Spinal manipulation|
157104|NCT01805596|Drug|clopidogrel|
157105|NCT01805596|Drug|Ticagrelor|
157106|NCT01805609|Behavioral|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture & discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff & that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
157107|NCT01805609|Behavioral|questionnaires|
157108|NCT01805622|Behavioral|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
157109|NCT01805635|Other|No intervention|No intervention
157110|NCT01805648|Drug|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10^9/L～100×10^9/L.
157111|NCT00100854|Drug|erlotinib hydrochloride|Given orally
157112|NCT01805661|Procedure|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
157410|NCT01780909|Drug|Paromomycin Sulfate Fed State|
157411|NCT01780909|Drug|Paromomycin Sulfate w/ domperidone|
157412|NCT01780909|Drug|Paromomycin Sulfate w/ loperamide HCl|
157413|NCT01780922|Other|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
157414|NCT01780922|Other|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
157415|NCT01780922|Other|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
157416|NCT01780935|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
156843|NCT01792635|Drug|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
156844|NCT01792648|Other|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
156845|NCT01792648|Other|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
156846|NCT01792648|Other|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
156847|NCT01792661|Other|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
156848|NCT01792661|Other|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
156849|NCT01792661|Other|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
156850|NCT00099437|Drug|Fulvestrant|intramuscular injection
156851|NCT01805115|Drug|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
156852|NCT01805115|Drug|Control|The control group was not given any cervical priming agents or placebo.
156853|NCT01805128|Other|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
156854|NCT01805128|Other|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
156855|NCT01805128|Other|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
156856|NCT01805154|Device|Cardiac Resynchronization Therapy|
156857|NCT01805167|Other|Electrophysiological study of the interindividual variability of vocal performance|
156858|NCT00100828|Drug|irinotecan hydrochloride|
156859|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
163876|NCT01817322|Drug|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
163877|NCT01817335|Procedure|psychosocial assessment and care|Participate in psycho-educational program
164175|NCT01820325|Drug|BKM120|
164176|NCT01820325|Drug|placebo|Placebo + Carboplatin + Paclitaxel
164177|NCT01820325|Drug|Carboplatin|
164178|NCT01820325|Drug|Paclitaxel|
164179|NCT00102219|Drug|Doxorubicin|
164180|NCT01820338|Behavioral|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
164181|NCT01820338|Behavioral|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
164182|NCT01820338|Other|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains & carbohydrates. Topics will also include use of vitamin & mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
164183|NCT01820351|Other|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
164184|NCT01820364|Drug|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
164185|NCT00101387|Other|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
163577|NCT01814267|Other|conventional|conventional group: iterative diabetes physicians consultations at hospital
1 consultation at inclusion time, week 0
1 consultation 2 weeks after inclusion, week 2
1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period
1 consultation to validate that the wound is well-healed
163578|NCT00101595|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
163579|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
163878|NCT01817335|Other|educational intervention|Participate in psycho-educational program
163879|NCT01817335|Other|communication skills training|Participate in psycho-educational program
163880|NCT01817335|Other|questionnaire administration|Ancillary studies
163881|NCT00101933|Device|Medtronic DBS Therapy for epilepsy|Stimulation Off
163882|NCT01817348|Procedure|Lidocaine group|Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle
Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine.
163883|NCT01817348|Other|Physiotherapy (PT)|- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
163884|NCT01817374|Drug|Definity (Perflutren Lipid Microspheres)|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
163885|NCT01817387|Behavioral|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
163886|NCT01817387|Behavioral|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
163887|NCT01817400|Other|Microdialysis|Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two "control" probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One "experimental" probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second "control" probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.
163888|NCT01819870|Drug|Dilatrend IR tablet 25mg|1 tablet, oral, once daily, 7days
over the period I&II(crossover)
163889|NCT01819896|Drug|Pacemaker and defibrillator|
168282|NCT01855243|Drug|Glargine|
168283|NCT01855243|Drug|glulisine|
168284|NCT01855256|Drug|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
168285|NCT01855256|Drug|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
168286|NCT01855269|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
168287|NCT01855269|Dietary Supplement|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
168288|NCT01855269|Dietary Supplement|placebo sterile water|
168289|NCT00105664|Procedure|Group interventions|
168290|NCT01855282|Behavioral|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
163580|NCT01814293|Device|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
163581|NCT01814306|Device|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
163582|NCT01814306|Device|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
163583|NCT01814319|Drug|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
163584|NCT01814319|Drug|Placebo|Matching placebo oral twice daily
163585|NCT01814332|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
163586|NCT01814332|Drug|Placebo|Placebo compound treatment for comparison with IP
163587|NCT01814358|Dietary Supplement|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
163588|NCT01814358|Dietary Supplement|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
167976|NCT00106249|Device|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
167977|NCT00106496|Drug|Protopic|topical
167978|NCT01861535|Procedure|Surgery|
167979|NCT01861561|Drug|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
167980|NCT01861561|Drug|High-dose intravenous cyclophosphamide|Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:
the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose
167981|NCT01861574|Device|Real TMS: Active Comparator|2 ( 20 minute) sessions of TMS
167982|NCT01861574|Device|Sham TMS: Sham Comparator|102 seconds of sham or active tms.
167983|NCT01861574|Device|Transcranial Magnetic Stimulation|1-2 seconds of TMS either of Sham or Active.
167984|NCT01861587|Device|tDCS|20 minutes of either real or sham stimulation
167985|NCT01861600|Other|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
167986|NCT01861600|Other|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
167987|NCT01861600|Other|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
167988|NCT00106496|Drug|Corticosteroid|topical
167989|NCT01861600|Other|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
167990|NCT01861600|Other|Human Milk|Human Milk
167991|NCT01861613|Biological|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
167992|NCT01861626|Drug|V0057 - A mg|Single oral administration
168291|NCT01855295|Dietary Supplement|Protein Supplement|During the treatment phase, in addition to the protein supplementation if any that the participant was on, supervised supplementation on each dialysis session was provided. Each participant received 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
168292|NCT01855308|Procedure|Single site robotic chole|Cholecystectomy via the daVinci single site platform.
167685|NCT01856621|Drug|Seretide Diskus|2 inhalations as a single dose
167686|NCT01856621|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
167687|NCT00105859|Behavioral|Education and Counseling|
167688|NCT01856621|Drug|SF Easyhaler|2 inhalations as a single dose
167689|NCT01856634|Drug|100 mg Delamanid|100 mg BID for 10 days
167690|NCT01858753|Biological|placebo sterile saline|
167691|NCT00106184|Drug|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
167692|NCT01858766|Drug|SOF|SOF 400 mg tablet administered orally once daily
167693|NCT01858766|Drug|GS-5816|GS-5816 tablet administered orally once daily
167694|NCT01858766|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
167695|NCT01858779|Behavioral|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
167696|NCT01858779|Device|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
167697|NCT01858792|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
167698|NCT01858792|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
167699|NCT01858792|Other|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
167700|NCT01858805|Procedure|esophagectomy|
167701|NCT01858831|Drug|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
167993|NCT01861626|Drug|Isotretinoin|Single oral administration
167994|NCT01861639|Device|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
167995|NCT01861639|Device|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
153407|NCT01770197|Drug|IV rt-PA|IV rt-PA treatment
153408|NCT01770210|Drug|Patients on atorvastatin treatment|Statins Therapy
153409|NCT01770223|Drug|boceprevir|
153410|NCT01770223|Biological|PegIFN-2b|
153411|NCT01770223|Drug|RBV|
153412|NCT01770236|Drug|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
153413|NCT01770249|Procedure|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
153414|NCT00097344|Procedure|Antiestrogen therapy|
153415|NCT01770288|Other|Anaerobic wingate test|
153416|NCT01770301|Drug|Paclitaxel|
153417|NCT01770301|Drug|Bevacizumab|
153418|NCT01770314|Behavioral|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
153419|NCT01762995|Drug|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
153420|NCT01763008|Drug|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
153718|NCT01765881|Drug|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route all 4 hours
153719|NCT01765881|Drug|Dinoprostone|administration of one sustained released capsule of 10 milligrams by intravaginal route
153720|NCT01765894|Other|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
153721|NCT01765907|Device|HIFU|
153722|NCT01765920|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
153723|NCT01765920|Drug|Placebo|Safety and Efficiency of liquid dosage form
154117|NCT01769027|Drug|Sertraline+Antibiotic (penicillin/azithromycin)|12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.
Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
154417|NCT01762514|Drug|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
154418|NCT01762514|Drug|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
154419|NCT01762527|Radiation|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
154420|NCT01756950|Biological|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
154421|NCT01756950|Biological|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
154422|NCT01756950|Biological|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
154423|NCT01756950|Biological|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
154424|NCT01756950|Biological|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
154425|NCT01756950|Biological|Placebo|administered as a single 2-hour intravenous infusion
154426|NCT01756976|Device|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
154427|NCT01756989|Drug|Thalidomide, etoposide, celecoxib|Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.
Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day.
154428|NCT01757002|Behavioral|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
154429|NCT01757002|Behavioral|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
154430|NCT00001870|Drug|Acetylcholine|
154431|NCT00096135|Drug|mercaptopurine|oral
154432|NCT01757015|Drug|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
154433|NCT01757015|Drug|Placebo to NVA237|Placebo to NVA237
157154|NCT01810588|Drug|Rabbit ATG (rATG)|Administer 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
157155|NCT01810601|Drug|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
157156|NCT00101192|Biological|cetuximab|
157157|NCT01810614|Other|ADPKD Diet|Diet specifically designed for people with ADPKD
157158|NCT01803165|Procedure|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
157159|NCT01803178|Dietary Supplement|Plant Sterols|
157160|NCT01803178|Dietary Supplement|Placebo Product|
157161|NCT01803191|Drug|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
157162|NCT01803191|Drug|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
157471|NCT00001926|Device|Cadwell rTMS|
157472|NCT00098202|Drug|Zinc|
157473|NCT01778127|Behavioral|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
157474|NCT01778140|Other|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
157475|NCT01778140|Other|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
157476|NCT01778153|Behavioral|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
157477|NCT01778166|Drug|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
157478|NCT01778166|Drug|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
156905|NCT01810289|Behavioral|START|INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level < 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.
This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design.
156906|NCT01810302|Drug|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
156907|NCT01810302|Drug|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
156908|NCT01810315|Drug|TFV 1% gel|
156909|NCT01810315|Drug|Estradiol vaginal cream|
156910|NCT01810328|Other|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
156911|NCT00101153|Drug|daunorubicin hydrochloride|
156912|NCT01810328|Other|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
156913|NCT01810354|Drug|Cefazolin|
156914|NCT01810367|Drug|ABX Combined With Cisplatin|
156915|NCT01810367|Drug|Gemcitabine Combined With Cisplatin|
156916|NCT01810380|Drug|Placebo|Once daily as tablets and capsules, orally
156917|NCT01810380|Drug|Brexpiprazole|Up to 4 mg/day, once daily, tablets, orally
156918|NCT01810380|Drug|Quetiapine extended release|Up to 800 mg/day, once daily, encapsulated tablets, orally
156919|NCT01810393|Drug|trastuzumab [Herceptin]|600 mg/5mL SC, Cycles 1-3 or 4-6, and Cycles 7-18
156920|NCT01810393|Drug|trastuzumab [Herceptin]|6 mg IV, Cycles 4-6 or 1-3
157186|NCT01805752|Other|integrated mother-infant care|
157187|NCT01805752|Other|Prominent role for influential family members (male partners) in collaboration with CHWs|
157188|NCT01805765|Drug|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
156309|NCT01804192|Other|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
156310|NCT01804205|Drug|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
156311|NCT01804218|Drug|Nadolol|
156619|NCT01807312|Device|Placebo|
156620|NCT01809613|Procedure|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
156621|NCT01809626|Drug|Zolpidem|
156622|NCT00101140|Drug|thiotepa|
156623|NCT01809626|Other|Placebo|
156624|NCT01809639|Drug|Progesterone|
156625|NCT01809652|Other|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
156626|NCT01809665|Device|ICD/CRT-P therapy|
156627|NCT01809665|Other|MRI|
156628|NCT01809678|Behavioral|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
156629|NCT01809678|Behavioral|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
156630|NCT01809678|Other|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
156631|NCT01809691|Drug|TAK-700|300 mg, PO, twice daily
156632|NCT01809691|Drug|Bicalutamide|50 mg, PO, q daily
156633|NCT00000285|Drug|Phenytoin|
156634|NCT00001990|Drug|Atovaquone|
156635|NCT00101140|Procedure|biological therapy|
156021|NCT01811043|Behavioral|Supportive Dialogue|
156022|NCT01811056|Drug|Mifepristone|Mifepristone use outside of the center
156023|NCT01811069|Procedure|Head up|30˚ reverse trendelenburg body position
156024|NCT01811082|Drug|Coenzyme A|Coenzyme A 400mg per day.
156025|NCT01811082|Drug|Pantethine|Pantethine 600mg per day.
156026|NCT01803555|Drug|Budesonide/Formoterol SPIROMAX®|
156027|NCT01803555|Drug|SYMBICORT® TURBOHALER®|
156028|NCT01803568|Other|Exercise|12 weeks of exercise; 4 times pr week
156029|NCT01803581|Other|X92001327|
156030|NCT01803581|Other|RID shampoo|
156031|NCT01803594|Dietary Supplement|Krill Oil|Neptune Krill Oil Gold
156032|NCT00100698|Drug|placebo|placebo subcutaneously once a day, 18 months
156033|NCT01803594|Dietary Supplement|Lutein|Jarrow Formulas
156034|NCT01803594|Dietary Supplement|Nicotinic acid|Natures Way
156035|NCT01803594|Dietary Supplement|Dairy phospholipids|PC700 manufactured by Fonterra
156036|NCT01803594|Other|Control|Control shake without dietary supplements
156037|NCT01803607|Drug|odanacatib|odanacatib 50 mg oral tablet
156333|NCT01806753|Procedure|Intermittent midazolam/propofol injection controlled by endoscopist|In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.
First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.
When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).
If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected.
156334|NCT01806753|Procedure|Continuous propofol infusion with opioid administration|In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.
First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.
Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.
When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.
If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min.
156335|NCT01806766|Procedure|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
158226|NCT01779622|Other|Mixed meal|Ingestion of mixed meal
156060|NCT01806168|Device|rTMS|Magstim Super Rapid-2
156061|NCT01806181|Other|Exercise|
156062|NCT01806194|Behavioral|Lifestyle Counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers
156063|NCT01806194|Behavioral|Educational Control Arm|16 mailings of diabetes educational materials but no regular contact with community health workers
156064|NCT01806207|Device|Durolane injection|
156065|NCT01806207|Other|Saline injection|
156066|NCT00100906|Drug|IL-2|Immunotherapy with interleukin-2
156067|NCT01806220|Procedure|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
156068|NCT01806220|Procedure|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
156069|NCT01806233|Procedure|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
156070|NCT01806233|Procedure|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
156071|NCT01806246|Behavioral|integrative rehabilitation program|
156072|NCT01806259|Drug|Ketorolac 30 mg IV|
156073|NCT01806272|Drug|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
156074|NCT01806272|Drug|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
156075|NCT01806298|Drug|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to the local product label instructions on locally approved product labeling.
156076|NCT01806311|Drug|Candesartan32mg|
156077|NCT00100906|Drug|ATRA|
156078|NCT01806311|Drug|Amlodipine10mg|
157995|NCT01773460|Drug|Everolimus|Everolimus is given beyond progress (comparison with placebo)
157996|NCT01773460|Drug|Everolimus-placebo|Everolimus-placebo
157997|NCT01773473|Drug|Insulin Lispro Mix25|Administered SC
157998|NCT01773473|Drug|Insulin Lispro Mix50|Administered SC
157999|NCT00097747|Drug|Placebo|
158000|NCT01773486|Drug|Hesperidin|Citrus polyphenol, hesperidin
158001|NCT01773486|Drug|Placebo|Placebo matching hesperidin
158002|NCT01773512|Drug|Rosuvastatin|All patients will be using rosuvastatin 40 mg
158003|NCT01773538|Drug|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
155772|NCT01753908|Other|Laboratory Biomarker Analysis|Correlative studies
155773|NCT01753908|Other|Pharmacological Study|Urinary ITCs and metabolites measured
155774|NCT01756586|Drug|Dexamethasone|
155775|NCT01756586|Drug|Bupivacaine|Control
155776|NCT01756599|Biological|blood samples|
155777|NCT01756638|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
155778|NCT00096135|Drug|cytarabine|IV over 3 hours twice daily
155779|NCT01756638|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
155780|NCT01756651|Drug|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
155781|NCT01756664|Other|Sunscreen|
155782|NCT01756664|Other|Vaseline|
155783|NCT01756703|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
155784|NCT01756703|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
155785|NCT01756703|Drug|Placebo|Placebo for 8 weeks
157696|NCT01772979|Drug|Trabectedin|
157697|NCT01772992|Behavioral|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
157698|NCT01773005|Drug|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
157699|NCT01773005|Drug|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
157700|NCT01773018|Drug|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
157701|NCT01773044|Drug|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
157702|NCT01773044|Drug|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
157703|NCT01773044|Drug|Placebo (for alcalinized lidocaine)|
157704|NCT01773057|Other|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
157705|NCT00097669|Dietary Supplement|Vitamin B12|500ug
158023|NCT01776216|Other|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
158024|NCT01776229|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
158025|NCT00097981|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
158026|NCT01776255|Behavioral|Healthy Children, Strong Families|Healthy Children, Strong Families is a series of 13 "lessons" mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year.
158027|NCT01776255|Behavioral|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
157417|NCT01780948|Drug|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
157418|NCT00098488|Biological|rituximab|Given IV
157419|NCT01772524|Drug|Placebo|
157420|NCT01772537|Drug|Propofol|Intravenous anesthetic
157421|NCT01772537|Drug|isoflurane|
157422|NCT01772550|Device|20GA BD Nexiva Diffusics|The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.
If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.
157423|NCT01772550|Device|18GA Conventional Catheter|The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.
If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.
157424|NCT00097630|Procedure|SBT: Spontaneous Breathing Trial|
157425|NCT01772563|Drug|volasertib|cycle in 21 days
157426|NCT01772563|Drug|itraconazole|over 18 days
157427|NCT01772576|Device|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
157428|NCT01772589|Procedure|New saw blade|
157429|NCT01772589|Procedure|Reprocessed saw blade|
157430|NCT01772615|Drug|Ciprofloxacin|Antibiotic
157431|NCT01772615|Dietary Supplement|E. coli Nissle|Probiotic
157728|NCT01775631|Biological|Rituximab|
157729|NCT00097916|Drug|memantine HCl|
157730|NCT01775657|Device|Thopaz (Digital drainage)|
157731|NCT01775657|Device|Pleur Evac (Analogue drainage)|
157732|NCT01775670|Device|Off-the-shelf splint|Subjects will use an off-the-shelf splint
157733|NCT01775670|Device|OT Splint|Subjects will use a splint custom-made by MGH Occupational Therapists.
157131|NCT01808196|Drug|Losartan Potassium|The medication dosage for Losartan will change throughout this study slowly increasing to a larger amount. You will start the study drug at a low dose. It will be increased at Visit 3/Week 4, unless you have certain side effects. The dose of study drug will be increased depending on your weight and how well you tolerate each dose and will not exceed 100mg of study drug. It may be increased or decreased during the study if there are any side effects.
157132|NCT01808209|Device|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
157133|NCT01808209|Device|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
157134|NCT00101088|Drug|temsirolimus|Given IV
157135|NCT01808222|Drug|FACBC|
157136|NCT01808235|Behavioral|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
157137|NCT01808248|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
157138|NCT01808248|Drug|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
157139|NCT01810510|Procedure|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
157140|NCT01810523|Behavioral|Narrative|Narrative form as described above.
157141|NCT01810523|Behavioral|Control|Blank piece of paper
157142|NCT01810536|Device|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
157143|NCT01810536|Device|Venturi mask|
157144|NCT01810549|Drug|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
157145|NCT00101179|Drug|Entinostat|Given orally
157146|NCT01810549|Drug|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
164186|NCT01812759|Other|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
164187|NCT01812772|Device|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
164188|NCT01812772|Device|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
164500|NCT01833637|Other|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
164501|NCT01833650|Dietary Supplement|thymus honey mouthwash|
164502|NCT01833663|Drug|Solifenacin Succinate Tablets|
164503|NCT01833663|Drug|Estrogen|
164504|NCT01833676|Drug|Sevoflurane|
164505|NCT01833676|Drug|Desflurane|
164506|NCT00103493|Behavioral|Motivational interviewing|
164507|NCT01833689|Dietary Supplement|food consumption|Reference food The reference food is 50 g glucose powder dissolved in 250ml water
Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.
Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk.
164508|NCT01833715|Drug|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
164509|NCT01833715|Drug|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
164510|NCT01833715|Drug|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
164511|NCT01833728|Drug|nefopam-propacetamol combination|Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.
In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
164512|NCT01833728|Drug|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
164513|NCT01833741|Drug|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
163890|NCT01819909|Procedure|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
163891|NCT01819909|Procedure|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
163892|NCT01819922|Drug|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
163893|NCT01819922|Drug|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
163894|NCT01819935|Drug|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
164189|NCT01812798|Other|Double Blind Placebo Controlled Food Challenge|All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.
For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.
Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour
0.1 0.25 0.5 0.75
1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000
For "Placebo" arm, participants will be fed increasing amounts of food matrix without peanut flour.
164190|NCT01812824|Behavioral|Intervention (Virtual Patient Advocate)|Intervention (Virtual Patient Advocate) participants will have access to the "Gabby" system for 6 months. There is no required "dose" or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week.
164191|NCT01812837|Device|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
164192|NCT01812837|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
164193|NCT01812837|Radiation|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
164194|NCT01812863|Procedure|Supraclavicular nerve block|Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.
If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels.
164195|NCT01812889|Drug|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
164196|NCT00101387|Other|Control PENS + exercise|as above
164197|NCT01812889|Drug|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
164198|NCT01812902|Procedure|Radical Prostatectomy|
163589|NCT00101608|Drug|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
163590|NCT01814371|Drug|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
163591|NCT01816789|Drug|buserelin|
163592|NCT01816802|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
163593|NCT01816815|Drug|BAY1002670|
163594|NCT01816815|Drug|Placebo|
163595|NCT01816828|Behavioral|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
163596|NCT01816828|Other|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
163597|NCT01816841|Procedure|fluorescence imaging|Undergo DVFE
163598|NCT01816841|Procedure|biopsy|Undergo scalpel biopsy
163599|NCT00101894|Drug|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
163895|NCT01819935|Drug|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
163896|NCT01819948|Dietary Supplement|PhytoMed™|
163897|NCT01819961|Drug|MCT/LCT and fish oil|
163898|NCT00102206|Drug|Lamivudine|
163899|NCT01819961|Drug|MCT/LCT|
163900|NCT01819974|Other|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
163901|NCT01819987|Behavioral|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
168293|NCT01855321|Drug|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
168294|NCT01855321|Drug|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
168295|NCT01855334|Drug|Spironolactone|
168296|NCT01855334|Dietary Supplement|L-arginine|
168297|NCT01855334|Drug|Placebo|
168298|NCT01855347|Device|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
168299|NCT01855360|Drug|Tauroursodeoxycholic Acid and Doxycycline|
168300|NCT00105664|Procedure|Facilitated consultation|
168301|NCT01857583|Drug|15mg DU-176b|
168302|NCT01857583|Drug|30mg DU-176b|
168303|NCT01857583|Drug|Fondaparinux|
168304|NCT01857596|Drug|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
168305|NCT01857609|Drug|Metformin|
168306|NCT01857609|Drug|Metformin and Pantoprazole|
168307|NCT01857609|Drug|Metformin and Rabeprazole|
168308|NCT01857622|Drug|DU-176b 15mg|oral DU-176b 15mg once daily
168309|NCT01857622|Drug|DU-176b 30mg|oral DU-176b 30mg once daily
168310|NCT01857622|Drug|DU-176b 60mg|oral DU-176b 60mg once daily
168311|NCT00106002|Drug|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
168312|NCT01857648|Other|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
168313|NCT01857661|Device|sound generator|hearing aid with an integrated sound generator
163600|NCT01816841|Procedure|examination|Undergo COE
167996|NCT01861639|Device|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
167997|NCT01861639|Device|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2*-weighted echo-planar imaging sequence
167998|NCT01861639|Device|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
167999|NCT00106496|Drug|placebo|topical
168000|NCT01861639|Device|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
168001|NCT01861652|Device|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
168002|NCT00105599|Behavioral|End of life care coordination|
168003|NCT01854710|Drug|Placebo (for moxifloxacin)|placebo capsule to mimic moxifloxacin 400 mg
168004|NCT01854723|Drug|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
168005|NCT01854723|Drug|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
168006|NCT01854736|Drug|Grazax|GRAZAX
168007|NCT01854736|Other|Placebo|Placebo
168008|NCT01854749|Drug|S1 combined with cisplatin|
168009|NCT01854762|Drug|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
168010|NCT01854762|Drug|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg coformulated with rtv 50 mg, 2 pills BID
168011|NCT01854775|Drug|E/C/F/TAF|E/C/F/TAF tablets contain 150 mg of elvitegravir (EVG), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of tenofovir alafenamide (TAF; as 11.2 mg of TAF fumarate)
163308|NCT01813838|Drug|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.
In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.
In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d
153724|NCT01765933|Dietary Supplement|DMAA|no placebo
153725|NCT01765946|Drug|Metformin|Metformin tablets 500 mg tris in die (tid)
153726|NCT00001894|Procedure|percutaneous transluminal septal ablation (PTSA)|
153727|NCT00096785|Drug|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
153728|NCT01765946|Drug|placebo|
153729|NCT01765959|Other|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
153730|NCT01765959|Other|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:
Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future
153731|NCT01765972|Device|etafilcon A with print|
153732|NCT01765972|Device|etafilcon A with print w Lacreon|
153733|NCT01765972|Device|etafilcon A with Lacreon|
153734|NCT01765972|Device|No Contact Lenses|
153735|NCT01765985|Device|PSORIAMED|V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.
V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.
V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs.
153736|NCT01768338|Drug|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
153737|NCT01768351|Drug|Paricalcitol|Zemplar cp 1 mcg/day per os
154047|NCT01761617|Behavioral|Yoga class once per week|The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., "Listening to the Wisdom of the Body," "Engaging your Power"). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio.
154434|NCT01757054|Dietary Supplement|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
154435|NCT01757067|Device|PVC ablation|This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
154436|NCT01757080|Other|Cardiorespiratory performance assessment with ergospirometry test|
154437|NCT01757080|Other|Biochemical analysis|
153482|NCT01767948|Drug|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
153483|NCT01767961|Procedure|diagnostic imaging|Undergo MBS
153484|NCT01767961|Other|questionnaire administration|Correlative studies
153485|NCT01767961|Procedure|quality-of-life assessment|Correlative studies
153486|NCT01767987|Drug|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
153487|NCT00097084|Drug|insulin glargine|
153488|NCT01767987|Drug|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
153489|NCT01770483|Drug|Ribavirin|ribazole
153490|NCT01770496|Behavioral|Childhood vaccination reminder / recall notification|
153491|NCT01770509|Device|NMBM|Daily application of NMBM in addition to compression therapy
153492|NCT01770509|Other|Compression garments|Compression garments
153493|NCT01770548|Genetic|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
153494|NCT01770548|Genetic|DNA collection|DNA collection
153495|NCT01770548|Other|Auditory evoked potentials|auditory evoked potentials
153496|NCT00097357|Drug|Warfarin|Tablets, Oral, QD, 12 +/- 2 days
153497|NCT01770561|Device|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
153498|NCT01770574|Device|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
153499|NCT01770574|Procedure|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
157479|NCT01778179|Drug|Tri-luma|Pre-procedure phase (From Baseline up to Week 2)treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.
Post-procedure phase (From week 2 up to Week 13 - Visit )
- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.
157480|NCT01778192|Drug|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
157481|NCT01778192|Drug|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
157482|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
157483|NCT01780948|Drug|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
157484|NCT01780974|Drug|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
157485|NCT01780987|Drug|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
157486|NCT01780987|Drug|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
157487|NCT01780987|Drug|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
157488|NCT01781000|Behavioral|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
157793|NCT00097695|Drug|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
157794|NCT01773122|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
157795|NCT01773122|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
157796|NCT01773135|Other|collection of blood sample and tocolysis adminstration|investigators will abtain a blood sample from all patient to measure the serum level of ACTH.
all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.
After delivery, investigators devide the pateints into 2 groups (full term delivery & preterm delivery) and investigators compare between these 2 groups by level of hormone.
157797|NCT01773148|Device|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
157798|NCT01773161|Procedure|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
157189|NCT01805765|Drug|Placebo|Containing 2% of Qing'E pills
157190|NCT01805791|Drug|HMPL-004 tablet|
157191|NCT01805791|Drug|Placebo|Placebo tablets will be used in the placebo arm of the study.
157192|NCT01805804|Drug|placebo/valsartan|
157193|NCT01805817|Drug|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
157194|NCT01805817|Device|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
157195|NCT00100880|Drug|lenalidomide|Given PO
157196|NCT01805817|Device|levonorgestrel-releasing system|intrauterine device
157197|NCT01805830|Drug|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
157198|NCT01805830|Drug|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
157199|NCT01805843|Other|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
157200|NCT01805856|Drug|PIPC piperacillin sodium|
157201|NCT01805856|Drug|CEZ, cefazolin sodium|
157202|NCT01805869|Other|Third Molar Removal|Third Molar Removal
157203|NCT01805882|Drug|Fixed Dose GS-7977/GS-5885|
157204|NCT01805882|Drug|FDC with GS-9451|
157205|NCT01805882|Drug|FDC with GS-9669|
157206|NCT00100880|Procedure|perfusion-weighted magnetic resonance imaging|Correlative studies
157207|NCT01805895|Drug|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
157208|NCT01805908|Other|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
157209|NCT01805921|Biological|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10^10 vp
157210|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10^8 pfu
156636|NCT01809717|Other|Weight Lifting Exercises|
156637|NCT01809743|Drug|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
156638|NCT01809743|Drug|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
156639|NCT01809743|Drug|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
156640|NCT01809743|Drug|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
156944|NCT01802918|Drug|Ritonavir|100mg tablets once daily for 12 days
156945|NCT01802931|Drug|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
156946|NCT01802931|Drug|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
156947|NCT01802944|Device|Intranasal Insulin|
156948|NCT01805297|Other|Standard Vitrectomy|Surgical intervention
156949|NCT01805310|Other|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
156950|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
156951|NCT01805323|Drug|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
156952|NCT00100841|Biological|bevacizumab|Given IV
156953|NCT01805336|Other|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
156954|NCT01805336|Other|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
156955|NCT01805336|Other|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
156336|NCT01806766|Procedure|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
156337|NCT01806779|Drug|Chantix|
156338|NCT01806779|Drug|Zyban|
156339|NCT01806779|Drug|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
156340|NCT00100971|Drug|therapeutic autologous dendritic cells|
156341|NCT01806792|Drug|risedronate combine|
156342|NCT01806792|Drug|Risedronate|
156343|NCT01806792|Drug|Placebo(for Risedronate)|
156344|NCT01806792|Drug|Placebo(for risedronate combine)|
156345|NCT01806805|Drug|zonegran|
156346|NCT01809132|Drug|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
156347|NCT01809132|Drug|Pentoxifylline|Pentoxifylline, generic
156348|NCT01809132|Drug|Zinc Sulfate|Zinc Sulfate, nutritional supplement
156349|NCT01809132|Drug|Methylprednisolone|Methylprednisolone, corticosteroid
156350|NCT01809145|Other|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
156351|NCT01809158|Drug|minocycline|
156352|NCT01809158|Drug|placebo|
156353|NCT01809171|Drug|Vitamin D3|ampoule
156354|NCT00101127|Biological|filgrastim|
156355|NCT01809171|Drug|Placebo|ampoule
156661|NCT01811953|Drug|Empagliflozin|low dose of Empagliflozin oral administration
156662|NCT01811953|Drug|Empagliflozin/Metformin|low dose of Empagliflozin
156663|NCT01811953|Drug|Metformin|oral administration
156664|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
156079|NCT01806324|Drug|HL040XC|single dose
156080|NCT01808677|Other|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
156081|NCT01808690|Drug|Metformin|
156376|NCT01811628|Behavioral|Interview|Audio-recorded interview that will last about 1 hour.
156377|NCT01811641|Other|season, dietary intake|
156378|NCT00101296|Drug|tipifarnib|Given orally
156379|NCT01811654|Device|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
156380|NCT01811667|Drug|Sirolimus|
156381|NCT01811680|Device|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
156382|NCT01811693|Drug|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
156383|NCT01811693|Drug|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
156384|NCT01811693|Drug|Glycerly Trinitrate|0.4 mg sublingual single metered spray
156385|NCT01811706|Drug|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
156386|NCT01811706|Drug|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
156387|NCT01811719|Behavioral|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
156388|NCT01811719|Behavioral|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
156389|NCT00101296|Other|pharmacological study|Correlative studies
156390|NCT01811732|Drug|Delafloxacin|Delafloxacin
156391|NCT01811732|Drug|Vancomycin|Vancomycin
156392|NCT01811732|Drug|Aztreonam|Aztreonam
155786|NCT01756716|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
155787|NCT01756716|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
155788|NCT01756716|Drug|Placebo|Placebo for 8 weeks
155789|NCT00096135|Drug|daunorubicin hydrochloride|IV over 15 minutes
155790|NCT01756729|Device|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
155791|NCT01756742|Other|Respiratory physiotherapy|The respiratory physiotherapy intervention included:
Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)
Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry.
155792|NCT01756742|Other|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
155793|NCT01756755|Device|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
155794|NCT01756768|Radiation|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of [14C]-PD-0332991.
155795|NCT01756781|Drug|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
156096|NCT01811095|Other|Training|Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a "completed score") on two non-consecutive attempts. For the "Suturing skills (SymbionixTM): Horizontal suturing defect" task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score.
156097|NCT01811121|Drug|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
156098|NCT01811121|Drug|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
156099|NCT00101244|Other|pharmacological study|Correlative studies
156100|NCT01811134|Device|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
156101|NCT01811134|Device|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
156102|NCT01811147|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) for 24 months
156103|NCT01811160|Drug|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
158028|NCT01776268|Other|Oral priming|Intervention:Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated. Infants randomized to receive formula/donor milk OP will receive an identical volume of oral formula/donor milk with the start of OP matched by post-natal age.
158029|NCT01776268|Other|No oral priming|no intervention
158030|NCT01779245|Dietary Supplement|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
158031|NCT01779245|Dietary Supplement|Placebo|
158032|NCT01779258|Drug|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
158033|NCT01779258|Device|Atopiclair®|1 application in the morning, in the afternoon and in the evening
158034|NCT01779258|Drug|Locatop@|During the Run-In period:
1 application in the morning and in the evening during a maximum of 21 days
158035|NCT01779258|Drug|Locapred@|During the 3 months study treatment:
1 application in the evening in case of flare "
158036|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
158037|NCT01779271|Drug|Pelubiprofen|
158038|NCT01779271|Drug|Loxoprofen|
158039|NCT01779284|Drug|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
155819|NCT01759810|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
155820|NCT01759823|Biological|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
155821|NCT01759823|Other|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
155822|NCT01751243|Other|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
157734|NCT01775709|Device|PE tube with Duckbill Valve|PE tube with Duckbill Valve
157735|NCT01775722|Device|port wine stain|port wine stain
157736|NCT01775735|Device|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
157737|NCT01775748|Other|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
157738|NCT01775748|Other|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
157739|NCT01778738|Procedure|Sleeve gastrecomy|Vertical sleeve gastrectomy
157740|NCT01778738|Procedure|Bastric bypass|Gastric bypass surgery
157741|NCT01778751|Behavioral|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
157742|NCT01778777|Device|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
157743|NCT01778790|Device|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude
Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude
157744|NCT01778803|Drug|defactinib (VS-6063)|
157745|NCT01778803|Drug|Paclitaxel|
157746|NCT00098293|Drug|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
157747|NCT01778829|Procedure|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
157748|NCT01778829|Procedure|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
157749|NCT01778842|Drug|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
157750|NCT01778842|Drug|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
158059|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
157446|NCT01775150|Other|health education|Health education via text messaging
157447|NCT00097851|Drug|docetaxel|
157448|NCT01775176|Drug|Metformin|
157449|NCT01775176|Behavioral|Exercise|
157450|NCT01775176|Behavioral|Dietary Restriction|
157451|NCT01775189|Drug|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
157452|NCT01775189|Drug|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
157453|NCT01775189|Drug|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
157454|NCT01775189|Drug|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
157455|NCT01775215|Radiation|Cardiac I123-MIBG Scintigraphy|
157456|NCT01775215|Other|Cardiac MRI|
157457|NCT01775215|Other|Stress and rest Echocardiogram|
157458|NCT00097851|Drug|PI-88|
157459|NCT01775215|Other|High Sensitivity Troponin I|
157460|NCT01775215|Other|Brain Natriuretic Peptide|
157461|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
157462|NCT01778088|Drug|I-131-CLR1404 Injection|
157463|NCT01778101|Drug|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
157464|NCT01778114|Dietary Supplement|Vitamin D2 in orange juice|1000 IU dose
157465|NCT01778114|Dietary Supplement|Vitamin D3 in orange juice|1000 IU
157466|NCT01778114|Dietary Supplement|Vitamin D2|capsule, 1000 IU
157467|NCT01778114|Dietary Supplement|Vitamin D3|capsule, 1000 IU
157468|NCT01778114|Other|Placebo|Placebo
157469|NCT01778127|Behavioral|Activity Monitor|Measurement of physical activity.
164514|NCT01833754|Drug|Romosozumab|Subcutaneous, Single Dose, Single Dose Level
164515|NCT01833767|Drug|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
164516|NCT01833793|Drug|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
164517|NCT00103493|Behavioral|Targeted DVD-based educational program|
164778|NCT01836523|Drug|placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 2 weeks followed by 1.2 mg for 50 weeks as an add-on to their pre-trial insulin treatment. Administered subcutaneously (s.c., under the skin) once daily.
164779|NCT01836523|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment or liraglutide placebo will receive, in addition to their pre-trial insulin treatment, 0.6 mg for 2 weeks followed by 1.2 mg for 2 weeks. After 4 weeks of liraglutide treatment or liraglutide placebo, subjects will receive 1.8 mg for 48 weeks. Administered subcutaneously (s.c., under the skin) once daily.
164780|NCT01836523|Drug|placebo|Subjects randomised to 1.8 mg liraglutide treatment or liraglutide placebo will receive, in addition to their pre-trial insulin treatment, 0.6 mg for 2 weeks followed by 1.2 mg for 2 weeks. After 4 weeks of liraglutide treatment or liraglutide placebo, subjects will receive 1.8 mg for 48 weeks. Administered subcutaneously (s.c., under the skin) once daily.
164781|NCT01836536|Drug|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
164782|NCT01836549|Drug|imetelstat sodium|Given IV
164783|NCT00002012|Drug|Interferon alfa-n3|
164784|NCT00103779|Drug|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
164785|NCT01836562|Biological|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
164786|NCT01836575|Drug|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment [dexamethasone + vitamin B12 + folic acid, as per pemetrexed label] + Antiemetic therapy at investigator's discretion.
164787|NCT01836575|Drug|Carboplatin|Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle].
164788|NCT01836588|Procedure|conventional cervix biopsy|Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.
For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions.
164789|NCT01836601|Behavioral|Family-centered nighttime communication bundle|
164790|NCT01838967|Drug|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
164199|NCT01812915|Device|Tapered cuff endotracheal tube|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube or Mallinckrodt TaperGuard(TM) endotracheal tube
164200|NCT01812928|Drug|Diclofenac|
164201|NCT01812941|Other|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
164202|NCT01812941|Other|healthy volunteers: blood collection|blood collected at designated time intervals
164203|NCT01812941|Other|Burn: blood collection|blood collected at designated time intervals
164204|NCT01812954|Drug|Methotrexate|
164205|NCT01812954|Drug|Cyclosporins|
164206|NCT01812954|Drug|fumaric acid|
164207|NCT01815320|Device|SonoVue|
164518|NCT01836016|Drug|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
164519|NCT01836016|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
164520|NCT01836016|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
164521|NCT01836016|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
164522|NCT01836016|Drug|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
164523|NCT01836029|Drug|VTX-2337|TLR8 Agonist
164524|NCT01836029|Drug|Carboplatin|
164525|NCT01836029|Drug|Cisplatin|
164526|NCT00103740|Drug|placebo to zoledronic acid|5 mL of sterile water for infusion
164527|NCT01836029|Drug|5-fluorouracil|
164528|NCT01836029|Drug|Placebo|
163902|NCT01819987|Behavioral|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
163903|NCT01820000|Procedure|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
163904|NCT01820013|Device|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
163905|NCT01820013|Device|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
163906|NCT01820026|Drug|Imipenem|second line therapy
163907|NCT01812252|Drug|Idarubicin|Given IV
163908|NCT01812252|Other|Quality-of-Life Assessment|Ancillary studies
163909|NCT01812265|Drug|PF-06305591|single Dose
163910|NCT01812265|Drug|PF-06305591|single Dose
163911|NCT01812265|Drug|Placebo|Single Dose
163912|NCT01812278|Behavioral|ACT|
163913|NCT00101348|Other|laboratory biomarker analysis|Correlative studies
163914|NCT01812278|Behavioral|CBT|
164208|NCT01815333|Drug|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
164209|NCT01815333|Procedure|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
164210|NCT01815346|Procedure|Acupuncture|One group receives acupuncture 2 times a week for 6 weeks.
One group receives acupuncture 3 times a week for 4 weeks.
Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
164211|NCT01815346|Behavioral|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
164212|NCT01815346|Other|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
163601|NCT01816841|Procedure|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
163602|NCT01816854|Device|Stenting|
163603|NCT01816867|Device|Intramesh T1 implantation|
163604|NCT01816893|Drug|Eplerenone|
163605|NCT01816893|Drug|Placebo|
163606|NCT01816906|Device|Footwear :PU|One group of patients will receive "Footwear" with PU insoles
163607|NCT01816906|Device|Footwear: MCP|One group of patients will receive footwear with MCP insoles
163608|NCT01816919|Other|collecting breath samples|
163609|NCT01816932|Procedure|Home Visit|The intervention is the location of the insertion visit.
163610|NCT00101907|Drug|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
163611|NCT01816945|Behavioral|MOMBA web-based application|Web-based, interactive, social network application.
163612|NCT01816958|Other|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
163613|NCT01816971|Drug|dexamethasone|Given IV or PO
163614|NCT01816971|Drug|carfilzomib|Given IV
163615|NCT01816971|Drug|lenalidomide|Given PO
163616|NCT01816971|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
163617|NCT01816971|Other|laboratory biomarker analysis|Correlative studies
163618|NCT01816984|Drug|PI3K inhibitor BKM120|Given PO
163619|NCT01819311|Behavioral|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
163620|NCT01819324|Behavioral|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
163621|NCT01819324|Behavioral|Standardized Lifestyle Management|SLM material (every other week for 4 months)
163622|NCT01819350|Other|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
163309|NCT01813838|Drug|ACADESINE 210mg/kg/d|3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.
In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.
In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d
163310|NCT01813838|Drug|ACADESINE 315mg/kg/d|3 patients will be included at the dose of 315mg/kg/d.
In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.
In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d
163311|NCT01813851|Device|Exercise training in addition to nutritional support|
163312|NCT01813864|Behavioral|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
163313|NCT00101569|Drug|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
163314|NCT01813877|Drug|FDOPA PET/CT|
163315|NCT01813890|Drug|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
163316|NCT01813890|Drug|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
163317|NCT01813890|Drug|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
163318|NCT01813903|Behavioral|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
163319|NCT01816321|Drug|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
163320|NCT01816334|Drug|methylprednisolone|
163321|NCT01816334|Drug|Ketoprofen|
163322|NCT00101868|Device|Discharge communication software|Computerized physician order entry software used by discharging physician
163323|NCT01816334|Drug|Sodium Chloride|
163324|NCT01816347|Procedure|Routine PCI|
163325|NCT01816360|Other|Olfactory aromatherapy|Inhalation of essential oils.
154048|NCT01761617|Behavioral|Yoga class twice per week|The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., "Listening to the Wisdom of the Body," "Engaging your Power"). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio.
154049|NCT01761643|Device|SoC + iTab|Text messaging reminders to improve adherence to PrEP
154050|NCT00096382|Radiation|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
154051|NCT01761656|Drug|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
154052|NCT01761656|Drug|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
154053|NCT01761669|Drug|Vitamin D|
154054|NCT01761682|Other|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
154055|NCT01761695|Other|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
154056|NCT01761708|Procedure|primary ventral hernia repair with mesh|
154057|NCT01761734|Behavioral|text message|
154058|NCT01761747|Drug|ponatinib|
154059|NCT01761760|Behavioral|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
154060|NCT01761773|Drug|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
154061|NCT00096395|Drug|gemcitabine hydrochloride|Given IV
154062|NCT01764035|Behavioral|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
154352|NCT01767012|Device|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
153500|NCT01770587|Behavioral|Behavioral Insomnia Treatment|
153501|NCT01770600|Other|placebo|placebo pill administered daily for 5 days
153502|NCT01770600|Drug|Riperidone|1 mg risperidone administered orally for 5 days
153503|NCT01770613|Biological|Stem cells|Allogeneic mesenchymal stem cells
153504|NCT01770626|Other|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
153505|NCT01770639|Procedure|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
153803|NCT01763762|Behavioral|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
153804|NCT01763775|Device|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
153805|NCT01763775|Device|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
153806|NCT01763788|Drug|Necitumumab|Administered IV
153807|NCT00096512|Other|laboratory biomarker analysis|Correlative studies
153808|NCT01763788|Drug|Gemcitabine|Administered IV
153809|NCT01763788|Drug|Cisplatin|Administered IV
153810|NCT01765985|Device|PLACEBO|V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.
V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.
V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs.
153811|NCT01765998|Drug|Probiotic|Clinical evaluation according to the Crohn's activity scale
153812|NCT00096798|Drug|Ethyl-eicosapentanoic acid (ethyl-EPA)|
153813|NCT01765998|Drug|Placebo|
153814|NCT01766011|Other|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
153815|NCT01766024|Drug|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
157799|NCT01773174|Drug|dabigatran etexilate|age & weight adjusted equivalent of adult dose
157800|NCT01773187|Drug|Pacritinib|
157801|NCT01773187|Drug|Best Available Therapy|
157802|NCT01773213|Procedure|Ice-water-test|
157803|NCT01773226|Device|Autologous Protein Solution "APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
157804|NCT00097695|Drug|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
157805|NCT01773239|Behavioral|TARA computer-based exercises|
157806|NCT01773252|Device|Flow Detection System|
157807|NCT01773278|Drug|Antioxidants|Patients will be prescribed the drug AquADEKS at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings.
157808|NCT01773278|Drug|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels > 100 mg/dl if possible
157809|NCT01773291|Other|acupuncture|acupuncture on GV26 and 12 Well points
157810|NCT01773291|Other|laser acupuncture|laser acupuncture on GV26 and 12 Well points
157811|NCT01773291|Other|control|sham laser acupuncture
157812|NCT01775761|Drug|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
158116|NCT01776424|Drug|Pantoprazole|Subjects who are not on a PPI (proton pump inhibitor) will also be randomized to pantoprazole or pantoprazole placebo
158117|NCT01776437|Drug|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
158118|NCT01776450|Device|Endovascular AAA repair|
158119|NCT01776463|Drug|Z-360|
158120|NCT01776463|Drug|placebo|
158121|NCT01776476|Drug|Glutamine|Glutamine dipeptide 0.5 gm/kg/day will be administered as a continuous infusion over 24 hours for up to 7 days or ICU discharge, whichever comes first.
158122|NCT00098020|Procedure|Kidney needle biopsy|
157508|NCT01772641|Other|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
157509|NCT01772641|Other|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
157510|NCT01772641|Other|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
157511|NCT01772654|Device|Arterial Spin Labeled (ASL) MRI sequence|The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.
This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence.
157512|NCT01772667|Procedure|Inpatient Rehabilitation|Rehabilitation program in "Schoen Klinik Berchtesgadener Land"
157513|NCT01772680|Dietary Supplement|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
157514|NCT01772693|Device|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
157515|NCT01772693|Device|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
157516|NCT00097643|Behavioral|health promotion|
157517|NCT01772706|Procedure|low level laser therapy|
157518|NCT01772706|Procedure|placebo (laser low level energy nonfunctional)|
157519|NCT01772719|Drug|Simvastatin and zoledronic acid|Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.
Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
157520|NCT01772732|Drug|Simotinib Hydrochloride|
157521|NCT01772745|Procedure|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
157522|NCT01772745|Procedure|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
157523|NCT01772758|Drug|BH4|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects will receive an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
157524|NCT01772758|Dietary Supplement|Vitamin C, 1000mg|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
157525|NCT01772758|Dietary Supplement|Vitamin E, 600IU|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
156956|NCT01805336|Other|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
156957|NCT01805336|Other|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
156958|NCT01805349|Radiation|Hand X-rays|Hand X-rays to assess the digital arthrosis
156959|NCT01805362|Other|Randomization that determine the time of treatment|
156960|NCT01805375|Drug|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
156961|NCT01805388|Drug|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
156962|NCT01805388|Procedure|Control Non-Study Drug Group|Endodontic RTC with no study drug
156963|NCT00100841|Drug|oxaliplatin|Given IV
157229|NCT01808417|Procedure|Near Infrared Imaging (NIR) for lymphatic mapping|
157230|NCT00101101|Drug|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
157231|NCT01808430|Procedure|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
157232|NCT01808443|Other|Cryotherapy|up to a maximum of four treatments every 21-28 days
157233|NCT01808443|Other|laser|up to a maximum of four treatments every 21-28 days
157234|NCT01810627|Radiation|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
157235|NCT01810640|Procedure|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
157236|NCT01810653|Drug|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
157237|NCT01810653|Drug|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
156665|NCT01811953|Drug|Empagliflozin|medium dose oral administration
156666|NCT00101309|Biological|therapeutic autologous lymphocytes|
156667|NCT01811953|Drug|Metformin|oral administration
156668|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
156669|NCT01811966|Other|Volume|
156670|NCT01811966|Other|Control|
156671|NCT01811979|Dietary Supplement|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
156672|NCT01804803|Procedure|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made "hot" for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS).
156673|NCT01804803|Procedure|Use of regular glucometer|
156674|NCT01804816|Procedure|Acupuncture|Standardized acupuncture administration for 10 sessions.
156675|NCT01804829|Biological|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
156676|NCT01804842|Drug|EFB0027|Comparison of dosing regimens to assess effect on glucose and PK
156677|NCT00100802|Radiation|radiation therapy|
156678|NCT01804855|Behavioral|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
156679|NCT01804855|Device|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
156680|NCT01804868|Other|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
156985|NCT01807884|Other|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
156986|NCT00101062|Drug|letrozole|
156393|NCT01811732|Drug|Placebo|Placebo
156394|NCT01811745|Behavioral|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
156395|NCT01804283|Device|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
156396|NCT01804283|Device|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
156703|NCT01807442|Other|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
156704|NCT01807455|Device|Restylane Vital Lidocaine|
156705|NCT01807468|Procedure|haploidentical stem cell transplantation and NK cell therapy|
156706|NCT01807481|Drug|Mircera|Once Monthly Mircera
156707|NCT01807494|Device|Total hip replacement components|All patients will receive the same implants
156708|NCT01807507|Device|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
156709|NCT01807520|Biological|secukinumab 150 mg|Study treatment is provided in pre-filled 1 mL syringes containing either secukinumab 150 mg or placebo secukinumab. Dosing consists of one secukinumab s.c. injection plus one placebo s.c. injection and takes place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients receive two placebo injections at Weeks 17, 18 and 19. Patients self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
156710|NCT01807520|Biological|secukinumab 300 mg|Study treatment is provided in pre-filled 1 mL syringes containing either secukinumab 150 mg or placebo secukinumab. Dosing consists of two secukinumab s.c. injections and takes place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients receive two placebo injections at Weeks 17, 18 and 19. Patients self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
156711|NCT01807520|Biological|Placebo|Study treatment is provided in pre-filled 1 mL syringes containing either secukinumab 150 mg or placebo secukinumab. Dosing consists of two placebo s.c. injections weekly for five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Weeks 8 and 12. At Week 16, placebo patients are randomly assigned to receive either secukinumab 150 mg or secukinumab 300 mg once weekly for five weeks (at Weeks 16, 17, 18, 19 and 20), then once every four weeks, starting at Week 24 until Week 128 inclusive. Patients self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
156712|NCT01809808|Procedure|Surgery for acromegaly|(non-experimental) standard procedure
156104|NCT01811160|Drug|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
156105|NCT01811173|Other|Nurse-physician comprehensive care|Components of the intervention include:
Complete assessment of the patient's and family's needs conducted by the nurse.
Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.
"Multimorbid care plan" integrating all care aspects.
"Action Plan" for patients, supporting self management
Proactive monitoring according to the plan.
156106|NCT01811186|Drug|oxycodone/naloxone|oral tablets
156107|NCT01811212|Drug|Cabozantinib S-malate|Given PO
156108|NCT01811212|Other|Laboratory Biomarker Analysis|Correlative studies
156109|NCT01811225|Drug|Low dose progesterone|The "low" dose progesterone is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM).
156110|NCT00001992|Biological|rgp120/HIV-1IIIB|
156111|NCT00101257|Biological|therapeutic autologous lymphocytes|
156112|NCT01811225|Drug|High dose progesterone|The "high" progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM).
156113|NCT01811238|Drug|Oxycodone/Naloxone|8 weeks treatment with Oxycodone/Naloxone
156114|NCT01811251|Drug|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
156415|NCT01804413|Drug|Regular insulin|0.1-0.15 units/kg
156416|NCT01806805|Drug|placebo|
156417|NCT01806818|Drug|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
156418|NCT01806831|Device|"Biocellulose Mask", Farhorm®"|
156419|NCT01806857|Drug|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
156420|NCT01806857|Drug|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
156421|NCT00100971|Procedure|tumor cell-derivative vaccine therapy|
156422|NCT01806870|Dietary Supplement|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
156423|NCT01806883|Behavioral|WII Rehabilitation|30 patients will receive "Wii" rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects.
156424|NCT01806883|Behavioral|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
155823|NCT01751243|Other|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
155824|NCT01751256|Device|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
155825|NCT01751269|Drug|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
155826|NCT01751269|Drug|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
155827|NCT00001860|Drug|Sandostatin LAR Depot versus transsphenoidal surgery|
155828|NCT00095758|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
155829|NCT01751282|Genetic|Stem Cell|
155830|NCT01751295|Drug|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
155831|NCT01751308|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
155832|NCT01751321|Drug|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
155833|NCT01751334|Device|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
155834|NCT01751334|Device|total knee arthroplasty|Fixed Total Knee Arthroplasty
155835|NCT01751347|Drug|Bupivacaine|Local anesthetics
155836|NCT01751347|Drug|Lidocaine|Local anesthetics
155837|NCT01751360|Drug|SYR-472|
156131|NCT01803880|Device|Mechanical Debridement (Mechanical Shaver)|mechanical shaver that removes areas of damaged tissue
156132|NCT01803880|Device|Radiofrequency-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
156133|NCT01803919|Device|Silver Alloy-Coated Urinary Catheters|
156134|NCT01803919|Device|Conventional Urinary Catheter|
156135|NCT01803932|Behavioral|Male-focused group violence prevention intervention|
156136|NCT01803945|Drug|AVE8112|
158060|NCT01781962|Other|No Treatment|No Treatment was given in this study.
158061|NCT01781975|Drug|Imatinib Mesylate|
158062|NCT01781975|Drug|Placebo (For imatinib mesylate)|
158063|NCT01781988|Drug|carboplatin, gemcitabine , pametrexed|A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.
B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression.
158064|NCT01782001|Dietary Supplement|vitamin A|vitamin A with placebo
158065|NCT00098605|Other|laboratory biomarker analysis|Correlative studies
158066|NCT01782001|Dietary Supplement|vitamin A and zinc|combination of vitamin A and zinc supplements
158067|NCT01782014|Procedure|colonoscopy|colonoscopy using different methods of insufflation
158068|NCT01782027|Drug|3H-cholesterol bound to albumin|up to 100 uCi of [3H]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
158069|NCT01782040|Other|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
158070|NCT01782053|Behavioral|Picture warning|Warning contains picture proposed for each text statement by FDA
158071|NCT01782053|Behavioral|Control|
158072|NCT01782066|Biological|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
158073|NCT01782079|Dietary Supplement|L. brevis|
158074|NCT01782092|Other|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
158075|NCT01782105|Behavioral|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
158076|NCT00098605|Procedure|quality-of-life assessment|Ancillary studies
158077|NCT01773616|Drug|Methyl prednisolone|
155859|NCT01754064|Device|Cardiac Rhythm Management device|
157470|NCT01778127|Behavioral|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
157773|NCT01781806|Drug|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in CrCl to <50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min, Truvada will be discontinued.
157774|NCT01781819|Procedure|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
157775|NCT01781832|Device|ARFI-Derived Shear Wave Velocities|An ultrasound based scan using acoustic radiation force impulse-derived shear wave velocities to obtain images of the urinary bladder. The research ultrasound scan will take approximately 10 to 15 minutes to complete.
157776|NCT00098579|Drug|doxorubicin hydrochloride|Given IV
157777|NCT01781845|Procedure|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
157778|NCT01781871|Biological|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
157779|NCT01781871|Biological|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
157780|NCT01781884|Drug|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
157781|NCT01781884|Drug|Placebo|
157782|NCT01781897|Device|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
157783|NCT01781897|Drug|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
157784|NCT01781910|Dietary Supplement|Branched Chain Amino Acid drink supplement|
157785|NCT01781910|Dietary Supplement|Placebo|
157786|NCT01781923|Behavioral|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
157787|NCT00098605|Drug|lapatinib ditosylate|Given orally
157788|NCT01781923|Behavioral|Small group social skills training|Meet once per week for duration of 40 weeks.
164791|NCT01838967|Drug|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
164792|NCT01838967|Drug|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
164793|NCT01838967|Drug|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
164794|NCT01838967|Drug|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
164795|NCT00104078|Drug|MYO-029|
164796|NCT01838967|Drug|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
165080|NCT01839396|Device|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
165081|NCT00104169|Drug|Epoetin Alfa|
165082|NCT01839409|Behavioral|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
165083|NCT01839422|Behavioral|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
165084|NCT01839422|Other|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
165085|NCT01839435|Procedure|outpatient surgery|
165086|NCT01839448|Biological|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
165087|NCT01839474|Device|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
165088|NCT01839487|Drug|PEGPH20+nab-paclitaxel+gemcitabine|PEGPH20 3ug/kg + nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2. PEGPH20 given IV x2/week for Cycle 1 and weekly for Cycle 2 and beyond. Nab-paclitaxel and gemcitabine given IV x1/week for 3 weeks for all cycles.
165089|NCT01839487|Drug|nab-paclitaxel + gemcitabine|nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 given IV x1/week 3/4 weeks per cycle
165090|NCT01839526|Drug|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
165091|NCT01839539|Biological|dendritic and cytokine-induced killer cells|
164529|NCT01836068|Drug|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
164530|NCT01836081|Other|Volume expansion|
164531|NCT01836094|Drug|Methylene Blue (USP grade, 280mg oral)|
164532|NCT01836094|Drug|Placebo|oral, one time
164533|NCT01836120|Drug|Raltitrexed plus Docetaxel|Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d
1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)
164534|NCT01836120|Drug|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
164535|NCT01836146|Device|EnligHTN™ Renal Artery Ablation Catheter|
164536|NCT01836159|Other|iPad Intervention|Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total "dose" received. Patients may receive outpatient rehabilitation as required as part of usual care.
The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:
Popping a stationary balloon
Popping a moving balloon
Popping a pair of stationary balloons
Popping a pair of moving balloons
Stretching a balloon to pop
Balloon/Text distraction test
164537|NCT00103740|Drug|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
164797|NCT01838980|Device|Motus GI Clean-Up Device|
164798|NCT01838993|Drug|Lidocaine inhalation|Lidocaine inhalation before intubation
164799|NCT01838993|Drug|Placebo|
164800|NCT01839006|Procedure|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
164801|NCT01839019|Drug|ODM-102|Single dose escalation
164802|NCT01839019|Drug|Placebo for ODM-102|Single dose escalation
164803|NCT01839032|Drug|Vinorelbine cisplatin radiotherapy|During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.
Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy).
164804|NCT01839058|Other|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
164213|NCT01815359|Procedure|Cytoreductive Surgery|Optimal Surgical Debulking
164214|NCT01815359|Drug|HIPEC with Mitomycin-C|
164215|NCT01815359|Drug|EPIC with FUDR and Leucovorin|
164216|NCT01815372|Procedure|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
164217|NCT00101738|Drug|Myfortic|
164218|NCT01815372|Procedure|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
164219|NCT01815398|Behavioral|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
164220|NCT01815398|Behavioral|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
164221|NCT01815411|Dietary Supplement|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
164222|NCT01815424|Drug|placebo|placebo BID for 16 weeks and then re-randomized into active groups
164223|NCT01815424|Drug|CP-690,550|CP-690,550 5mg BID for 52 weeks
164224|NCT01815424|Drug|CP-690,550|CP-690,550 10mg BID for 52 weeks
164225|NCT01815437|Dietary Supplement|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
164226|NCT01815437|Dietary Supplement|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
164538|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
164539|NCT01836172|Drug|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
164540|NCT01836185|Drug|Evacetrapib|
164541|NCT01838447|Dietary Supplement|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
164542|NCT01838460|Drug|sublingual nicotine tablets|6 mg = 3 tablets
163623|NCT01819350|Other|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
163915|NCT01812291|Behavioral|Step 1: Diabetes-Specific CBT (5 group sessions)|Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').
Includes:
Diabetes problem analysis/ definition
Diabetes problem solving intervention
Cognitive restructuring of diabetes problems
Activation of personal and social resources
Goal definition and agreement
163916|NCT01812291|Behavioral|Step 2: Depression-Specific CBT (6 single sessions)|Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).
Includes:
Functional explanatory model of depression
Cognitive restructuring of negative thoughts
Practice of alternative beneficial thoughts
Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity.
163917|NCT01812291|Behavioral|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
163918|NCT01812291|Behavioral|Standard Diabetes Education|Standard diabetes education and professional care.
Includes:
Health care and specific topics (e. g. blood pressure)
Diabetes complications
Healthy and unhealthy foods, cooking recommendations and recipes
Foot care: exercises, care and control, injuries, and diabetic neuropathy
Sports, activities and exercise
Social aspects of living with diabetes
163919|NCT01812304|Other|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
163920|NCT01812304|Other|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
163921|NCT01812317|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
163922|NCT01812317|Procedure|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
163923|NCT01812330|Drug|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
163924|NCT00101361|Drug|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
163925|NCT01812330|Drug|Ticagrelor|90mg Bid
163926|NCT01812343|Other|Exercise test|
163927|NCT01812356|Device|Cryomaze procedure using Nitrous oxide|
163928|NCT01812356|Device|Cryomaze procedure using Argon|
163929|NCT01812369|Drug|GEMCITABINE CISPLATINE|
163930|NCT01812369|Drug|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
163624|NCT01819363|Procedure|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
163625|NCT01819376|Other|Facebook Status Update|
163626|NCT01819389|Drug|Imatinib and Nilotinib|
163627|NCT01819402|Drug|Pioglitazone vs Glimepiride|
163628|NCT00102141|Drug|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
163629|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
163630|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
163631|NCT01819428|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
163632|NCT01819441|Drug|Azelnidipine|8mg or 16mg
163633|NCT01819441|Drug|Perindopril|4mg or 8mg
163634|NCT01819441|Drug|hydrochlorothiazide|12.5mg or 25mg
163635|NCT01819454|Device|pH monitoring (Restech)|see in "detail description of the study" part of the protocol
163636|NCT01819467|Device|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
163637|NCT01819480|Procedure|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
163638|NCT01819493|Behavioral|Lifestyle Intervention|Family-based group lifestyle intervention
163639|NCT00001999|Drug|Globulin, Immune|
163640|NCT00102154|Drug|MK0928, gaboxadol / Duration of Treatment: 10 months|
163641|NCT01819493|Behavioral|Standard Family-Based intervention|Comparison intervention
163642|NCT01819506|Behavioral|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
163643|NCT00102349|Behavioral|Behavior Therapy|
154353|NCT01767012|Device|Polylens EC-Y10-PAL (uncoated)|
154354|NCT01767025|Drug|Oxytocin|
154355|NCT01767025|Drug|Sea water|
154356|NCT01767038|Procedure|OCT Spectralis|
154357|NCT00096954|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of > 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
154358|NCT01767038|Procedure|microperimetry|
154359|NCT01767064|Other|Posted commitment letter|
154360|NCT01767077|Dietary Supplement|Butter oil|Daily intake of 40 g butter oil
154361|NCT01767077|Dietary Supplement|Cream|Daily intake of 100 g cream (40%)
154362|NCT01767090|Drug|ASP1707|Oral
154363|NCT01767090|Drug|Placebo|Oral
154364|NCT01767090|Drug|Leuprorelin acetate|subcutaneous
154365|NCT01767103|Drug|Ferriprox®|
154366|NCT01767116|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
154367|NCT01767116|Drug|Ribavirin|Capsule
154368|NCT00096954|Drug|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
154369|NCT01767116|Drug|Placebo for ribavirin|Capsule
154370|NCT01767129|Drug|AVP-923-45|One capsule twice daily for 14 days
154371|NCT01767129|Drug|Placebo|One capsule twice daily for 14 days
154372|NCT01767142|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
154373|NCT01767155|Drug|AEZS-108 / zoptarelin doxorubicin|267 mg/m2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
153816|NCT01766037|Device|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
153817|NCT01766037|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
153818|NCT01766050|Drug|Caffeine|
153819|NCT01766050|Drug|Losartan|
153820|NCT01766050|Drug|Omeprazole|
153821|NCT01766050|Drug|Dextromethorphan|
153822|NCT01766050|Drug|Midazolam|
153823|NCT00096811|Drug|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
153824|NCT01766050|Biological|Belatacept|
154118|NCT00097266|Drug|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
154119|NCT01769027|Drug|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
154120|NCT01769027|Biological|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
154121|NCT01769040|Drug|Rifaximin|550 mg two times daily for 28 days
154122|NCT01769040|Drug|placebo|
154123|NCT01761786|Genetic|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with *1/*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (*2 or *3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
154124|NCT01761799|Behavioral|P3 Vaccine Promotion Package.|"P3" stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a "vaccine champion" within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients.
154125|NCT01761812|Other|MRI with gadofosveset and MR elastography|
154126|NCT01761825|Drug|ivabradine|
154127|NCT01761838|Other|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
158123|NCT01779414|Other|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
158124|NCT01779427|Behavioral|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
158125|NCT00098332|Drug|forodesine hydrochloride|
158126|NCT01779440|Behavioral|Electronic Decision Support System|
158127|NCT01779453|Drug|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
158128|NCT01779453|Drug|Placebo|Placebo once daily for 8 weeks
158129|NCT01779453|Drug|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
158130|NCT01779466|Drug|Desmopressin|
158131|NCT01779466|Drug|Placebo (not active)|
158132|NCT01779479|Drug|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
158133|NCT01779479|Drug|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
158134|NCT01779492|Drug|GL2907|once a day
158135|NCT01779492|Drug|Oxycontine CR 10mg|twice a day
158136|NCT00098345|Drug|ZD6474 (vandetanib)|oral once daily tablet
158137|NCT01779505|Biological|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
155914|NCT01810809|Drug|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
155915|NCT01810848|Device|Hylan G-F 20|Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint ("intra-articular") for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
155916|NCT01810848|Other|Control|Control is puncture of the skin at the site of the knee.
155917|NCT01810861|Other|serotype distribution|This is a non-interventional study.
157526|NCT01772758|Dietary Supplement|Alpha Lipoic Acid, 600mg|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
157831|NCT01775904|Drug|LY2886721 ODT|Administered orally.
157832|NCT01775930|Drug|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
157833|NCT01778959|Device|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
157834|NCT01778959|Device|standard OVD|use of a standard cohesive OVD during cataract surgery
157835|NCT01778959|Device|OVD|use of a highly cohesive OVD during cataract surgery
157836|NCT01778972|Other|Otago home exercise programme|Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.
The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist.
157837|NCT00098293|Drug|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
157838|NCT01778972|Other|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
157839|NCT01778985|Drug|Premarin|
157840|NCT01778985|Other|Placebo|
157841|NCT01778998|Procedure|MICS-group|Micro incision cataract surgery is done
157842|NCT01778998|Procedure|SICS-group|small incision cataract surgery is done
157843|NCT01778998|Procedure|SICS pre-cut|Small incision cataract surgery with pre-cut is done
157844|NCT01778998|Procedure|SICS stab-incision|Small incision cataract surgery with stab-incision is done
157845|NCT01779024|Drug|Ghrelin|
157846|NCT01779024|Drug|Placebo|
157847|NCT01779024|Procedure|fMRI|
157848|NCT00098306|Drug|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
157849|NCT01779024|Drug|Alcohol|
157850|NCT01779050|Drug|Doxorubicin|
157238|NCT01810666|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
157239|NCT01810679|Device|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
157240|NCT01810692|Device|Group1:Spiriva® Respimat®|COPD patients using Respimat®
157241|NCT01810692|Device|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
157242|NCT01810705|Drug|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
157243|NCT00101192|Drug|cisplatin|
157244|NCT01810718|Drug|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond >600 or <200mg/die The MTD will be used for phase II
157245|NCT01810731|Biological|Quadrivalent Inactivated Influenza Vaccine (QIV)|
157246|NCT01810731|Biological|Inactivated Polio Vaccine|
157545|NCT01775358|Drug|Placebo 0.015 mg/kg|
157546|NCT01775358|Drug|Placebo 0.05mg/kg|
157547|NCT00097877|Drug|insulin glargine|
157548|NCT01775358|Drug|Placebo 0.15mg/kg|
157549|NCT01775371|Procedure|Patient controlled analgesia|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
157550|NCT00098215|Behavioral|Pediatric residency training on tobacco|
157551|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
157552|NCT01778205|Other|Observational|
156987|NCT01807897|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
156988|NCT01807897|Device|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
156989|NCT01807897|Behavioral|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
156990|NCT01807910|Drug|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
156991|NCT01807923|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
156992|NCT01807923|Drug|Ivacaftor|Film-coated tablet
156993|NCT01807923|Drug|Placebo|Matching placebo tablet
156994|NCT01807936|Procedure|Lymphadenectomy|
156995|NCT01807949|Drug|Placebo|Matching placebo tablet
156996|NCT01810406|Procedure|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
156997|NCT00101153|Drug|tipifarnib|
156998|NCT01810406|Procedure|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
156999|NCT01810419|Device|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
157000|NCT01810419|Device|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
157001|NCT01810432|Drug|Evacetrapib|Administered orally
157002|NCT01810432|Other|High-fat Meal|Administered orally, at breakfast.
157003|NCT01810458|Device|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
157004|NCT01810458|Procedure|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
157005|NCT01810458|Procedure|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
157268|NCT01803347|Drug|◦Drug: ASCs. + fibrin glue|Experimental group
156713|NCT01809808|Drug|Medications for acromegaly|(non-experimental) standard procedure
156714|NCT01809821|Behavioral|Online Sleep Education|
156715|NCT01809834|Device|Etafilcon A|
156716|NCT01809834|Device|Stenfilcon A|
156717|NCT01809847|Drug|Ofatumumab|Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy.
157017|NCT01802957|Other|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
157018|NCT01802957|Other|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
157019|NCT01802957|Other|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
157020|NCT01802957|Other|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
157021|NCT01802970|Drug|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
157022|NCT01802996|Drug|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
157023|NCT01803009|Behavioral|Patient views NCI CRC RAT|
157024|NCT01803009|Behavioral|View presentation regarding current chance of having an advanced adenoma|
156425|NCT01806896|Drug|PF-02545920|Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.
Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Treatment for 28 days.
156426|NCT01806896|Drug|Placebo|- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Dosing for 28 days.
156427|NCT01806896|Drug|PF-02545920|5mg dose
Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Dosing for 28 days.
156428|NCT01806896|Drug|Placebo|Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Dosing for 28 days.
156429|NCT01806909|Biological|Ad4-H5-Vtn|
156430|NCT01806922|Behavioral|Yoga|
156431|NCT01806935|Device|DC086|
156432|NCT00100984|Drug|FUZEON [enfuvirtide]|
156433|NCT01806935|Device|Placebo|
156434|NCT01806948|Drug|Ramosetron|
156435|NCT01806974|Other|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
156737|NCT01812122|Drug|Vildagliptin|
156738|NCT01812135|Biological|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
156739|NCT01812148|Procedure|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
156740|NCT01812161|Other|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
156741|NCT00101348|Biological|cetuximab|Given IV
156742|NCT01812161|Other|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of <5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
156137|NCT01803945|Drug|Placebo|
156138|NCT00100737|Drug|rituximab|
156139|NCT01806324|Drug|Losartan + Atorvastatin|Single dose
156140|NCT01806337|Drug|Alemtuzumab|Consolidation after CHOP induction
156141|NCT01806350|Other|questionnaire administration|Ancillary studies
156142|NCT01806350|Procedure|standard follow-up care|Receive usual care
156143|NCT01806350|Other|educational intervention|Undergo PFMT
156144|NCT01806363|Drug|Telmisartan 80mg|
156145|NCT01806363|Drug|Chlorthalidone 25mg|
156146|NCT01806376|Drug|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
156147|NCT00100932|Drug|E7389 28 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
156148|NCT01806415|Drug|Fenobam|Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
156149|NCT01806415|Drug|Placebo|Oral administration of placebo or lactose 150 mg
156150|NCT01806441|Other|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
156151|NCT01806441|Other|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
156152|NCT01806454|Drug|calcium|
156153|NCT01806480|Behavioral|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
156456|NCT01809340|Drug|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
156457|NCT01809353|Drug|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
156458|NCT01809353|Other|Placebo|Single matching intravenous dose
156459|NCT01809366|Procedure|seminal plasma insemination|
155860|NCT01754077|Behavioral|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
155861|NCT01754077|Behavioral|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
155862|NCT01754077|Behavioral|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
155863|NCT00095940|Other|laboratory biomarker analysis|Correlative studies
155864|NCT01754090|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
155865|NCT01754090|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
155866|NCT01756807|Device|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
155867|NCT01756820|Procedure|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
155868|NCT01756820|Procedure|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
155869|NCT01756833|Drug|Doxycycline|
155870|NCT01756833|Drug|Placebo|
155871|NCT01756846|Other|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
156167|NCT01808885|Drug|olesoxime (TRO19622)|olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.
Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit).
157789|NCT01773096|Drug|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
157790|NCT01773109|Drug|Etirinotecan pegol (NKTR-102)|
157791|NCT01773122|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
157792|NCT01773122|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
165686|NCT01835756|Device|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
165687|NCT01835756|Device|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
165688|NCT01835782|Drug|L-Serine|
165689|NCT01835795|Device|Radial Extracorporeal Shock Wave|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 10 to 15 hertz frequency, 2 to 4 bar pressure
165690|NCT01835795|Device|Placebo|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 10 to 15 hertz frequency, 2 to 4 bar pressure
165691|NCT01835808|Device|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
165692|NCT01835821|Device|prosthetic crowns|prosthetic crowns
165693|NCT01835834|Procedure|zirconia bridge restoration|
165694|NCT01835847|Drug|Tipepidine Hibenzate|
165695|NCT01835860|Procedure|Prostate artery embolization|
165696|NCT00103727|Other|placebo|Placebo Comparator
165697|NCT01835873|Other|Lactated Ringer's|
165698|NCT01835873|Other|HES 130/0.42|Balanced colloid solution
165699|NCT01835886|Other|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
165700|NCT01835899|Drug|Placebo|Placebo to BI 1015550
165092|NCT00104182|Drug|insulin detemir|
165093|NCT01839552|Drug|Fentanyl Citrate Nasal Spray (FCNS)|
165094|NCT01839565|Device|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
165095|NCT01841788|Device|Marketed Thermal Adhesion Patch|
165096|NCT01841801|Device|Thermal Adhesive Patch|
165097|NCT01841801|Device|Marketed Thermal Adhesive Patch|
165098|NCT01841814|Radiation|Bone densitometry.|
165099|NCT01841827|Drug|Cilostazol|
165100|NCT01841827|Drug|Placebo|
165384|NCT01832662|Other|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
165385|NCT01832675|Drug|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
165386|NCT01832675|Drug|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
165387|NCT01832688|Other|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
165388|NCT01832701|Other|Coffee|coffee versus placebo
165389|NCT01832701|Other|Placebo comparator|maltodextrine with caffeine
165390|NCT01832727|Drug|Oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 or on Days 1, 2, 8, and 9 of the 14-day treatment cycle.
165391|NCT01832727|Drug|Dexamethasone|Dexamethasone 20 mg will be taken on Days 1, 2, 8, and 9
165392|NCT01832740|Device|brain stimulation|oscillating direct current brain stimulation
165393|NCT01832740|Device|SHAM|no stimulation
165394|NCT00103376|Drug|flutamide|
165395|NCT01832753|Drug|Levothyroxine|
165396|NCT01832766|Drug|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
165397|NCT01832766|Other|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
164805|NCT01839071|Procedure|biopsy|
164806|NCT00002014|Drug|Zidovudine|
164807|NCT00104091|Drug|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
164808|NCT01839084|Drug|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
164809|NCT01839084|Drug|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
164810|NCT01839097|Drug|Belinostat|Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:
Cohort 1: belinostat 1000 mg/m2 IV on Day 1
Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2
Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3
Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4
Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5
164811|NCT01839097|Drug|CHOP|Cyclophosphamide - 750 mg/m2 - IV - Day 1
Vincristine - 1.4 mg/m2 - IV - Day 1
Doxorubicin - 50mg/m2 - IV - Day 1
Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat.
164812|NCT01839110|Drug|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
164813|NCT01841645|Dietary Supplement|CLA depletion-repletion|
164814|NCT01841658|Dietary Supplement|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
165101|NCT01841840|Other|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
165102|NCT01841840|Other|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
165103|NCT01841853|Behavioral|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
165104|NCT00104481|Behavioral|cognitive behavior therapy|
165105|NCT01841866|Other|LMA removal|
164543|NCT00103961|Behavioral|Questionnaire|A behavioral questionnaire will occur at Week 8
164544|NCT01838460|Other|Smokeless tobacco|Swedish type moist snuff
164545|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
164546|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
164547|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
164548|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
164549|NCT01838486|Procedure|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
164550|NCT01838499|Biological|MEDI8968|SC injection at baseline, Week 4 and Week 8
164551|NCT01838499|Biological|Saline|SC injection at baseline, Week 4 and Week 8
164552|NCT01838538|Drug|Bevacizumab|
164553|NCT01838538|Drug|TC:paclitaxel + carboplatin|
164554|NCT00103974|Biological|BHT-3009-01|
164555|NCT01838551|Drug|COR-003|
164556|NCT01838564|Other|Routine Data collection|Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.
Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST.
164557|NCT01838564|Other|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
164558|NCT01838590|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
164815|NCT01841671|Biological|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
164816|NCT01841671|Biological|bOPV|As indicated
164817|NCT00104442|Drug|Rivastigmine|
163931|NCT01814826|Drug|MLN4924 and azacitidine|MLN4924 (IV) and azacitidine (IV) in AML patients to determine maximum tolerated dose (MTD) on a 28-day cycle:
Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles
MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles
Both agents given on Days 1, 3, and 5 of Cycle 1 and all subsequent cycles
163932|NCT01814839|Drug|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
164227|NCT01815437|Dietary Supplement|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
164228|NCT00101751|Drug|biphasic insulin aspart|
164229|NCT01815437|Dietary Supplement|Mushroom Extract|Same quantity of mushroom extract in a capsule
164230|NCT01815450|Drug|BLI1100|BLI1100 topical cream
164231|NCT01817764|Drug|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
164232|NCT01817764|Drug|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
164233|NCT01817777|Drug|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
164234|NCT00102011|Procedure|annual screening|Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
164235|NCT01817777|Drug|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
164236|NCT01817790|Drug|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
164237|NCT01817790|Drug|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
164238|NCT01817803|Drug|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
164239|NCT01817803|Drug|metolazone/no spironolactone|metolazone (add 2.5mg qod)
164240|NCT01817803|Drug|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
164241|NCT01817803|Drug|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
164242|NCT01817816|Procedure|Botox_A|
164243|NCT01817816|Procedure|Botox_B|
153662|NCT01768299|Drug|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
153663|NCT01768299|Drug|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
153664|NCT01768312|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
153665|NCT01768325|Device|EUS-TCB needle (QuickCore) standard of care|The number of needle passes requiring to acquire adequate specimen were tallied.
Length of core tissue obtained
Diagnostic contribution of immunohistochemical staining
Rates of complications
153666|NCT01768325|Device|EUS-Guided biopsy needle (ProCore)|The number of needle passes requiring to acquire adequate specimen were tallied.
Length of core tissue obtained
Diagnostic contribution of immunohistochemical staining
Rates of complications
153667|NCT01770327|Behavioral|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
153668|NCT01770340|Biological|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
153669|NCT01770340|Procedure|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
153670|NCT01770353|Drug|Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at 1mL/sec, given once. MM-398 80 mg/m2 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
153671|NCT01770366|Device|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
153672|NCT01770366|Device|Usual Care|
153673|NCT00001906|Biological|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
153674|NCT00097357|Drug|Apixaban|Tablets, Oral, 12 +/- 2 days
153675|NCT01770379|Biological|Secukinumab (AIN457)|Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17)
153989|NCT01763996|Drug|Febuxostat|Capsules
153990|NCT01763996|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
153991|NCT01764009|Biological|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
154374|NCT01769352|Drug|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
153421|NCT01763021|Drug|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
153422|NCT01763021|Drug|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
153423|NCT01763034|Procedure|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
153424|NCT01763060|Radiation|CT scan|
153425|NCT00096460|Drug|Rituximab maintenance therapy|Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:
Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT
153426|NCT01763060|Behavioral|Cognitive function|
153427|NCT01763060|Radiation|MRI|
153428|NCT01763086|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
153429|NCT01763099|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
153430|NCT01763099|Biological|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
153431|NCT01763112|Device|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
153432|NCT01763125|Other|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
153433|NCT01763138|Behavioral|oral health education|oral health education in the form of a pictorial pamphlet.
153434|NCT01763138|Behavioral|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
153435|NCT01763151|Device|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
154128|NCT01761838|Other|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
154129|NCT01761838|Other|Low back pain participants without SMT|No treatment
154130|NCT01761864|Behavioral|academic detailing intervention|
154131|NCT01761877|Drug|Sulindac|
154132|NCT01761890|Behavioral|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
154133|NCT00096395|Drug|sorafenib tosylate|Given orally
154134|NCT01761916|Drug|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
154135|NCT01761916|Drug|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
154438|NCT01757093|Device|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
154439|NCT01757093|Device|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
154440|NCT01757106|Drug|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
154441|NCT01757106|Drug|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
154442|NCT00096135|Drug|methotrexate|intramuscularly (IM)
154443|NCT01757119|Drug|Tardyferon 80 mg|Oral administration (2 tablets)
154444|NCT01757132|Device|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
154445|NCT01759823|Biological|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
154446|NCT00096278|Drug|oxaliplatin|Given IV
154447|NCT01759836|Drug|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
155918|NCT01810874|Procedure|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
155919|NCT01810874|Procedure|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
155920|NCT00101205|Drug|etoposide|Given IV
155921|NCT01810887|Drug|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
155922|NCT01810887|Drug|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
155923|NCT01810900|Device|Protescal|
155924|NCT01810913|Drug|cisplatin|Given IV
155925|NCT01810913|Drug|docetaxel|Given IV
155926|NCT01810913|Biological|cetuximab|Given IV
155927|NCT01810913|Other|laboratory biomarker analysis|Correlative studies
155928|NCT01810913|Procedure|quality-of-life assessment|Ancillary studies
155929|NCT01810913|Radiation|intensity-modulated radiation therapy|Undergo IMRT
155930|NCT01810926|Biological|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
155931|NCT00101231|Drug|alvocidib|Given IV
155932|NCT01810926|Drug|Rituximab|single infusion of200 mg/m2 on day -1
155933|NCT01810926|Drug|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
155934|NCT01810926|Drug|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
155935|NCT01810926|Drug|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
155936|NCT01810926|Drug|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
156229|NCT01806571|Other|Pharmacological Study|Correlative studies
156230|NCT01806584|Biological|SRM003|One time implant (3 SRM003 pieces) on surgery day.
157851|NCT01779050|Biological|Trastuzumab|
157852|NCT01779050|Drug|Cyclophosphamide|
157853|NCT01779050|Drug|Paclitaxel|
157854|NCT01779050|Drug|Epirubicin|
158250|NCT01779830|Drug|Placebo - Capsules|Administered orally as capsules.
158251|NCT01779830|Drug|Placebo - Tablets|Administered orally as tablets.
158252|NCT01771263|Device|iControl-RP|
158253|NCT01771276|Device|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
158254|NCT01771289|Drug|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
158255|NCT01771289|Radiation|Radiation|chemoradiation
158256|NCT00001909|Drug|Soluble recombinantly produced IL-4R|
158257|NCT00097435|Drug|Albuferon|
158258|NCT01771302|Device|Bio-Oss|It is a bone substitute of bovine origin
158259|NCT01771302|Device|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
158260|NCT01771315|Behavioral|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
158261|NCT01771328|Drug|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
158262|NCT01771328|Drug|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
158263|NCT01771341|Device|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
158264|NCT01771341|Device|MAQUET SERVOi ventilator|Pressure Support
158265|NCT01771354|Biological|Engerix B Vaccine|
158266|NCT01771354|Biological|Placebo|
157553|NCT01778218|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
157554|NCT01778231|Dietary Supplement|Nutrof Total|Antioxidant and trace element supplement
157555|NCT01778231|Dietary Supplement|Placebo|
157556|NCT01778244|Drug|metformin|1000mg/day for 24 weeks
157557|NCT01778257|Dietary Supplement|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
157558|NCT01778257|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Mate extracts.
157559|NCT01778270|Device|Body Bioimpedance Sensor|
157560|NCT01778283|Biological|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
157561|NCT00098228|Drug|QAB149|
157562|NCT01778296|Device|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
157563|NCT01778309|Dietary Supplement|n-acetylcysteine supplementation|n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise
placebo administration: 500 mL orally, daily for eight days following exercise
157564|NCT01778322|Procedure|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
157565|NCT01778335|Procedure|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
157566|NCT01778348|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
157880|NCT01782261|Drug|Saxagliptin|once daily tablet
157881|NCT01782274|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
157882|NCT01782274|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
157883|NCT01782287|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
157884|NCT00098618|Drug|sorafenib tosylate|Given orally
157885|NCT01782287|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
157269|NCT01803347|Drug|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
157270|NCT01803360|Drug|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
157271|NCT01803373|Drug|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
157272|NCT00100672|Drug|LErafAON-ETU|
157273|NCT01803373|Drug|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
157274|NCT01803373|Drug|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
157275|NCT01803386|Device|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
157276|NCT01803399|Drug|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
157277|NCT01803399|Drug|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
157278|NCT01803399|Drug|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
157279|NCT01777672|Device|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
157280|NCT01777672|Device|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
157281|NCT01777685|Drug|Sulpiride|
157282|NCT01777711|Behavioral|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
157283|NCT01777711|Behavioral|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
157284|NCT00098124|Drug|milnacipran hydrochloride|
157025|NCT01805466|Device|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
157026|NCT01805466|Device|Conventional CPB|conventional miniature cardiopulmonary bypass technique
157027|NCT01805479|Other|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
157028|NCT00100841|Drug|leucovorin calcium|Given IV
157029|NCT01805479|Other|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
157307|NCT01780662|Drug|Brentuximab Vedotin|Given IV
157308|NCT01780662|Drug|Gemcitabine Hydrochloride|Given IV
157309|NCT01780662|Other|Laboratory Biomarker Analysis|Optional correlative studies (Part B only)
157310|NCT01780675|Radiation|Radiation Prophylactic Cranial Irradiation|
157311|NCT01780675|Radiation|Radiation Hippocampal Avoidance PCI|
157312|NCT01780688|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
157313|NCT01780688|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
157314|NCT00001931|Drug|N-0923|
157315|NCT00098475|Drug|Lenalidomide|Given PO
157316|NCT01780701|Procedure|Magnetic Resonance Spectroscopy Imaging with rectal probe|
157317|NCT01780714|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
157318|NCT01780714|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
157319|NCT01780727|Procedure|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
157320|NCT01780740|Drug|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
156743|NCT01812174|Device|17 or 23 mm valve (On-X )|Heart valve replacement surgery
156744|NCT01812187|Behavioral|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
156745|NCT01812200|Drug|Dabigatran, Ticagrelor, ASA|
156746|NCT01812200|Drug|Rivaroxaban, Ticagrelor, ASA|
156747|NCT01812200|Drug|Phenprocoumon, Ticagrelor, ASA|
156748|NCT01812213|Drug|[18F]NAV4694|
156749|NCT01812239|Drug|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
156750|NCT01812239|Procedure|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
156751|NCT01812239|Drug|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
156752|NCT00101348|Biological|bevacizumab|Given IV
156753|NCT01812252|Drug|Azacitidine|Given IV or SC
156754|NCT01812252|Drug|Cytarabine|Given IV
156755|NCT01812252|Drug|Daunorubicin Hydrochloride|Given IV
156756|NCT01812252|Drug|Decitabine|Given IV or SC
156757|NCT01804972|Other|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
157045|NCT01807962|Drug|Sterile saline|Placebo = 5ml of sterile saline solution
157046|NCT01807975|Other|Forced oscillation|
157047|NCT01807988|Behavioral|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
157048|NCT01808014|Drug|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
156460|NCT01809379|Drug|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
156461|NCT01809392|Drug|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
156462|NCT01811979|Dietary Supplement|Steril water|steril water plus topical anesthetics
156463|NCT01811992|Biological|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.
Radiation and chemotherapy will be administered as per standard of care.
156464|NCT01812005|Drug|alisertib|Given PO
156465|NCT01812005|Biological|rituximab|Given IV
156466|NCT01812005|Other|laboratory biomarker analysis|Laboratory correlative studies will be performed
156467|NCT00101335|Drug|celecoxib|
156468|NCT01812018|Drug|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
156469|NCT01812018|Drug|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
156470|NCT01812018|Drug|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
156471|NCT01812031|Other|medical imaging|After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.
Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.
Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations.
156472|NCT01812044|Drug|subtenons anesthetic - preservative-free bupivacaine 0.75%|
156473|NCT01812044|Drug|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
156474|NCT01812044|Drug|topical control - 0.5 cc of Hypromellose 0.3% gel|
156778|NCT01805115|Drug|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
156168|NCT00101101|Drug|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
156169|NCT01808885|Drug|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
156170|NCT01808898|Procedure|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
156171|NCT01808911|Drug|Steroid + cyclophosphamide|
156172|NCT01808911|Drug|Steroid + rituximab|
156173|NCT01808924|Other|Exercise training protocol|Participants will complete a progressive 6-month exercise-training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include both stationary cycling and rowing, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55).
Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using Keiser pneumatic-powered machines (total days of exercise will still be 4 to 5)
156174|NCT01808924|Other|Dietary|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (<30% of calories from fat) diet will be used as part of the weight loss intervention. Particular efforts will be made to maintain the recommended daily protein, vitamin and mineral intake. The weight loss program will be administered individually to subjects so that the registered dietician will meet with each subject weekly to provide dietary prescription and record body weight. In order to eliminate the confounding effects of acute caloric restriction on insulin sensitivity, the dietician will keep subjects weight stable during the last two weeks.
156175|NCT01811303|Other|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose in 200 ml water if added 40 mg D-fagomine
156176|NCT01811316|Other|Probiotics|
156177|NCT01811329|Dietary Supplement|Dairy fat|
156178|NCT01811329|Dietary Supplement|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
156179|NCT01811329|Dietary Supplement|Palm fat|
156180|NCT00101270|Drug|irinotecan hydrochloride|Given IV
156181|NCT01811329|Dietary Supplement|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
156182|NCT01811355|Drug|Mexiletine|Sodium channel blocker
156183|NCT01811355|Drug|Placebo|Placebo
156184|NCT01811368|Biological|rituximab|Given IV
165701|NCT01837953|Behavioral|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
165702|NCT01837953|Behavioral|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
165703|NCT01837966|Other|Lavender oil|2 drops for aromatherapy
165987|NCT01823250|Behavioral|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
165988|NCT01823250|Behavioral|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
165989|NCT00102609|Drug|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
165990|NCT01823250|Behavioral|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
165991|NCT01823263|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
165992|NCT01823263|Procedure|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
165993|NCT01823263|Procedure|Interference task|30-minute interference task
165994|NCT01823263|Behavioral|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
165995|NCT01823263|Behavioral|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
165996|NCT01823263|Behavioral|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
165398|NCT01832779|Other|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
165399|NCT01835171|Drug|Triapine|Given IV
165400|NCT01835184|Drug|cabozantinib-s-malate|Given PO
165401|NCT01835184|Drug|vemurafenib|Given PO
165402|NCT01835184|Other|laboratory biomarker analysis|Correlative studies
165403|NCT01835184|Other|pharmacological study|Correlative studies
165404|NCT01835197|Drug|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
165405|NCT01835197|Drug|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
165704|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
165705|NCT01837966|Other|Placebo|2 drops unscented mineral oil for aromatherapy
165706|NCT01837979|Procedure|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
165707|NCT01837992|Drug|Primaquine|
165708|NCT01837992|Drug|delayed primaquine|
165709|NCT01838005|Behavioral|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
165710|NCT01838031|Other|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
165711|NCT01838044|Drug|pregabalin and celecoxib|During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.
All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
165106|NCT01841879|Behavioral|Intervention Program|Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.
Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.
Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced.
165107|NCT01841879|Behavioral|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
165108|NCT01841892|Behavioral|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
165109|NCT01841905|Other|Observational Study|Observational Study
165110|NCT01841918|Biological|Avian Flu Vaccine|
165111|NCT01841931|Drug|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
165112|NCT01841944|Drug|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
165113|NCT01841944|Other|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
165114|NCT01841957|Procedure|ISBCS|same-day cataract surgery
165115|NCT00104494|Drug|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
165116|NCT01841957|Procedure|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
165117|NCT01834742|Drug|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
165406|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
165407|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
165408|NCT00103636|Procedure|Extending peripheral intravenous (IV) cannula dwell times|
165409|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
165410|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
165411|NCT01835197|Drug|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
164818|NCT01841671|Biological|mOPV type 2|Administered at 28 weeks of age to all study participants
164819|NCT01841671|Biological|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
164820|NCT01841684|Drug|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
164821|NCT01841684|Drug|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
164822|NCT01841697|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
164823|NCT01841697|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
164824|NCT01841697|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
164825|NCT01841697|Drug|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
164826|NCT01841697|Drug|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
164827|NCT01841697|Drug|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
164828|NCT00104455|Drug|activated recombinant human factor VII|
164829|NCT01841723|Drug|Ibrutinib|Given PO
164830|NCT01841723|Other|Laboratory Biomarker Analysis|Correlative studies
164831|NCT01841723|Other|Pharmacological Study|Correlative studies
164832|NCT01841736|Other|Laboratory Biomarker Analysis|Correlative studies
164833|NCT01841736|Drug|Pazopanib Hydrochloride|Given PO
164834|NCT01841736|Other|Placebo|Given PO
164835|NCT01841736|Other|Quality-of-Life Assessment|Ancillary studies
164836|NCT01841749|Procedure|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
164837|NCT01841762|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
164838|NCT01841775|Drug|interferon α 2b + ribavirin|interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks
ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks
165118|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
164244|NCT01817829|Drug|paracetamol|500 mg oral tablet
164245|NCT00102011|Procedure|fecal occult blood test|Participants undergo a baseline fecal occult blood test (FOBT)
164246|NCT01817829|Drug|placebo|
164559|NCT01838590|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
164560|NCT01838603|Other|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
164561|NCT01838616|Drug|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
164562|NCT01841151|Behavioral|WM training|
164563|NCT01841164|Drug|Montelukast|
164564|NCT00104403|Drug|Dexamethasone|
164565|NCT01841164|Drug|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
164566|NCT01841164|Other|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
164567|NCT01841177|Drug|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
164568|NCT01841216|Device|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
164569|NCT01841242|Drug|alcoholic povidone iodine|
164570|NCT01841242|Drug|alcoholic chlorhexidine|
164571|NCT01841255|Device|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
164572|NCT01841255|Device|facemask|
164573|NCT01841281|Drug|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
164574|NCT01841281|Drug|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
164575|NCT00104403|Drug|Ondansetron Hydrochloride|
153992|NCT01764022|Drug|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
153993|NCT01764022|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
153994|NCT00096551|Drug|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
153995|NCT01764035|Behavioral|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
153996|NCT01766336|Drug|Group 1 ELND005|
153997|NCT01766336|Drug|Group 2 ELND005|
153998|NCT01766349|Behavioral|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
153999|NCT00096850|Drug|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
154000|NCT01766362|Procedure|PRPC using Pascal laser|
154001|NCT01766375|Drug|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
154002|NCT01766401|Drug|Placebo|
154003|NCT01766401|Drug|Vilazadone|Viibryd
154004|NCT01766414|Drug|C1-esterase inhibitor|intravenously
154005|NCT01766414|Drug|Endotoxin|intravenously
154006|NCT01766440|Drug|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
154007|NCT01766453|Behavioral|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
154008|NCT01766453|Behavioral|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
154009|NCT01766466|Drug|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
154295|NCT01769313|Device|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
153436|NCT00096460|Drug|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
153437|NCT01763151|Procedure|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
153738|NCT01768351|Drug|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
153739|NCT00097123|Drug|Misoprostol|
153740|NCT01768364|Drug|Trimetoprim-Sulfa (Bactrim)|
153741|NCT01768364|Other|No antibiotics|
153742|NCT01768377|Drug|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
153743|NCT01768377|Drug|Fentanyl|Fentanyl 2 microgram/Kg BW IV
153744|NCT01768377|Drug|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
153745|NCT01768390|Other|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
153746|NCT01768390|Other|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
153747|NCT01768429|Behavioral|Fatty fish|
153748|NCT01768429|Behavioral|Lean Fish|
153749|NCT01768429|Behavioral|Alpha-linolenic acid|
153750|NCT00097149|Procedure|Systematic pediatric care|
153751|NCT01768429|Behavioral|Control|
153752|NCT01768455|Drug|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
153753|NCT01768455|Drug|Glimepiride|Glimepiride 4mg (qd) on Day1
153754|NCT01768468|Drug|LAYLA tablet|1 tablet twice a day
153755|NCT01768468|Drug|JOINS tablet|1 tablet at each time, 3 times a day
153756|NCT01768481|Drug|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
153757|NCT01768481|Drug|sugar pill|placebo controlled arm receives similarly looking placebo.
154448|NCT01759849|Drug|CSL 311|CSL311 is a humanized monoclonal antibody targeting the common beta chain receptor to IL-3, IL-5 and GM-CSF, which is present on select leukocytes including eosinophils.
154449|NCT01759862|Drug|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
154450|NCT01759862|Other|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
154451|NCT01759862|Drug|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
154452|NCT01759875|Drug|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
154453|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
154454|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
154455|NCT01759888|Drug|18F-DTBZ|Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
154456|NCT01759901|Procedure|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
153506|NCT01770652|Drug|Deferiprone|Oral iron chelator
153507|NCT00097357|Drug|Enoxaparin Placebo|Injection, SQ, BID, 12 +/- 2 days
153508|NCT01770678|Other|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
153509|NCT01770691|Device|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
153510|NCT01770717|Other|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
153511|NCT01770730|Device|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
153512|NCT01770743|Biological|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
153513|NCT01770743|Biological|BioThrax|
153514|NCT01770756|Behavioral|Self-Care Training|
156231|NCT01806584|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
156232|NCT01806597|Biological|secukinumab 150 mg|Study treatment will be provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consists of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients will also receive two placebo injections at Weeks 17, 18 and 19. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
156233|NCT00001984|Drug|Alemtuzumab and DSG|Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
156234|NCT00100945|Drug|gefitinib|
156235|NCT01806597|Biological|secukinumab 300 mg|Study treatment will be provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consists of two secukinumab 150 mg s.c. injections and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients will also receive two placebo injections at Weeks 17, 18 and 19. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
156236|NCT01806597|Biological|Placebo|Placebo will be provided in 1 mL pre-filled syringes. Each dosing consists of two s.c. injections and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders will continue on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders will end their participation in the study while ppIGA non-responders will be re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
156237|NCT01806610|Drug|BPS804|Single dose BPS804 administration.
156238|NCT01806610|Drug|Placebo|Single dose placebo administration.
156239|NCT01806623|Drug|Fluconazole|Single oral dose of 150mg Fluconazole
156240|NCT01806636|Device|PneumRx Coil System|
156241|NCT01806649|Drug|BKM120|
156242|NCT01806662|Drug|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
156243|NCT01806662|Other|Placebo|Injection of placebo
156244|NCT01806675|Radiation|fludeoxyglucose F 18|Undergo 18F FDG PET/CT
156245|NCT00100958|Drug|indole-3-carbinol|
158267|NCT01771367|Biological|Fluad|
158268|NCT00097435|Drug|Ribavirin|
158269|NCT01771367|Biological|Agrippal|
158270|NCT01771367|Biological|Placebo|
158271|NCT01771393|Device|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
158272|NCT01771393|Device|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
155954|NCT01803529|Other|heat-pack with massage|
155955|NCT01803529|Other|heat-pack only|
155956|NCT01803542|Radiation|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
155957|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10^7 pfu
155958|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10^9 vp
155959|NCT01805934|Drug|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
155960|NCT01805934|Drug|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
155961|NCT00100880|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
155962|NCT01805947|Behavioral|Lifestyle Modification|Lifestyle Modification
155963|NCT01805960|Biological|Canakinumab|
155964|NCT01805960|Biological|Placebo|
155965|NCT01805973|Behavioral|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
155966|NCT01805999|Dietary Supplement|7 g Ispaghula|
155967|NCT01805999|Dietary Supplement|7 g placebo|
155968|NCT01805999|Dietary Supplement|3.5g Ispaghula + 3.5 g placebo|
155969|NCT01806012|Device|Sealing tissue with the Enseal device|
157886|NCT01782300|Biological|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
157887|NCT01782300|Biological|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
157888|NCT01782313|Drug|tivozanib|Given PO
157889|NCT01782313|Other|laboratory biomarker analysis|Correlative studies
157890|NCT01782326|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
157891|NCT01773304|Other|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
157892|NCT01773317|Other|Perturbation|all subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
157893|NCT01773330|Procedure|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
157894|NCT00097708|Drug|experimental anti-anxiety drug|
157895|NCT01773330|Dietary Supplement|Gatorade|The patient will be given Gatorade to drink at various times during the study.
157896|NCT01773330|Other|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
157897|NCT01773330|Other|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
157898|NCT01773330|Procedure|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
157899|NCT01773330|Procedure|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
158138|NCT01779518|Drug|Sofosbuvir|
158139|NCT01779518|Drug|Ribavirin|
158140|NCT01779518|Drug|Pegylated Interferon|
158141|NCT01779544|Other|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
157285|NCT01777724|Behavioral|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
157585|NCT01781286|Behavioral|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
157586|NCT01781299|Device|AlloDerm RTU|
157587|NCT01781299|Device|SurgiMend PRS|
157588|NCT01781312|Dietary Supplement|ProTectis|
157589|NCT01781312|Dietary Supplement|Gastrus|
157590|NCT01781325|Device|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
157591|NCT01781338|Other|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
157592|NCT00098527|Drug|romidepsin|Given IV
157593|NCT01781351|Other|Taping the ankle|
157594|NCT01781364|Behavioral|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
157595|NCT01781377|Drug|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
157596|NCT01781377|Drug|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
157597|NCT01772784|Other|Phenolic acids|Phenolic acids
157598|NCT01772797|Drug|LDK378|LDK378 is a capsule to be taken daily by mouth.
157599|NCT01772797|Drug|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
157600|NCT01772810|Device|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
157601|NCT01772823|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
157321|NCT01780740|Drug|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
157322|NCT01780753|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
157323|NCT01780779|Other|MRI|MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.
The MR findings will not have any impact on the treatment.
157324|NCT01780792|Other|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
157325|NCT01772368|Drug|FS Spiromax|Fluticasone/Salmeterol Spiromax is an inhalation driven, multi-dose dry powder inhaler (DPI) containing salmeterol xinafoate with a fixed dose (100 mcg) of fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. The inhaler contains 60 actuations, with a target per-inhalation dose of 6.25, 12.5, 25, or 50 mcg of salmeterol xinafoate, each with 100 mcg of fluticasone propionate.
157326|NCT01772368|Drug|Fluticasone propionate Spiromax|This inhaler will be provided in a device identical in appearance to FS Spiromax. It is an inhalation driven, multiple-dose, dry powder inhaler (MDPI) containing 100 or 50 mcg of fluticasone propionate per inhalation dispersed in a lactose monohydrate excipient and contained within a reservoir.
157622|NCT01775436|Behavioral|FAmily-CEntered Advance Care Planning|Two-60 to 90 minute sessions scheduled one week apart.
Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.
Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have.
157623|NCT01775436|Behavioral|Healthy Living Control|Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.
Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention.
157624|NCT01775449|Behavioral|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
157625|NCT01775462|Drug|EDI200|3 or 10 mg/kg of EDI200
157626|NCT01775475|Drug|cyclophosphamide|Given IV
157627|NCT01775475|Drug|doxorubicin hydrochloride|Given IV
157628|NCT01775475|Drug|vincristine sulfate|Given IV
157629|NCT01775475|Drug|prednisone|Given PO
157630|NCT01775475|Drug|lomustine|Given PO
157631|NCT01775475|Drug|etoposide|Given PO
157632|NCT00001923|Procedure|Transcranial magnetic stimulation|
157049|NCT01808040|Drug|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
157050|NCT01808053|Device|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
157051|NCT01808066|Device|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
157052|NCT01808079|Other|laboratory biomarker analysis|Correlative studies
157053|NCT00101075|Drug|oxaliplatin|
157054|NCT01808092|Drug|ceftazidime-avibactam|2000mg ceftazidime plus 500mg avibactam
157055|NCT01808092|Drug|meropenem|1000mg of Meropenem
157056|NCT01808105|Other|Control Formula|Feeding ad libitum
157057|NCT01808105|Other|Experimental Formula 1|Feeding ad libitum
157058|NCT01808105|Other|Experimental Formula 2|Feeding ad libitum
157059|NCT01808105|Other|Human Milk|Feeding ad libitum
157060|NCT01808118|Biological|adalimumab|40 mg every other week
157061|NCT01808118|Biological|Placebo|every other week
157062|NCT01808131|Drug|Lesinurad|Tablets, 200 mg QD
157063|NCT01808131|Drug|Lesinurad|Tablets, 400 mg QD
157347|NCT01774864|Drug|Placebo|
157348|NCT01774877|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
157349|NCT01774877|Drug|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
157350|NCT01774903|Drug|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
156779|NCT01807533|Other|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
156780|NCT00101010|Drug|Prednisone|40 mg/m^2 oral days 1 - 5.
156781|NCT01807546|Drug|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
156782|NCT01807559|Device|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
156783|NCT01807585|Device|VenaSeal Sapheon Closure System (VSCS)|
156784|NCT01807585|Device|ClosureFast Radiofrequency Ablation (RFA)|
156785|NCT01807598|Drug|brentuximab vedotin|Brentuximab vedotin is an antibody with a covalently attached toxin. The antibody portion targets the protein CD30 on the surface of cells, and the toxin acts against those cells.
156786|NCT01807611|Radiation|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
156787|NCT01807611|Drug|Fludarabine|Given IV.
156788|NCT01807611|Drug|Cyclophosphamide|Given IV.
156789|NCT01807611|Drug|Thiotepa|Given IV.
156790|NCT01807611|Drug|Melphalan|Given IV.
156791|NCT00101010|Drug|Vincristine Sulfate|2 mg IV, day 1
156792|NCT01807611|Biological|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
156793|NCT01807611|Biological|TC-NK Infusion|Participants receive infusions of TC-NK.
156794|NCT01807611|Biological|G-CSF|Participants receive G-CSF subcutaneously or intravenously.
Donors receive G-CSF subcutaneously during cell mobilization.
156795|NCT01807611|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
156496|NCT01804582|Other|Family Navigator consultation|Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:
(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan.
156497|NCT01804595|Other|Sunscreen|
156498|NCT00100802|Drug|lomustine|Capsule
156499|NCT01804595|Behavioral|Text-Message Reminders|
156500|NCT01804595|Other|Sunscreen and Text Message Reminders|
156501|NCT01804595|Behavioral|Education|
156502|NCT01804608|Other|Strength|
156503|NCT01804608|Other|Sensorimotor|
156504|NCT01804621|Behavioral|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
156505|NCT01807013|Procedure|ultrasound, liver elastometry, minilaparoscopy|conventional high-end ultrasound technique,
small access laparoscopy with fine laparoscopes
Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity.
156506|NCT01807026|Drug|LY2886721|Administered orally
156507|NCT01807026|Drug|Placebo|Administered orally
156508|NCT01807039|Procedure|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
156509|NCT01807052|Other|laboratory biomarker analysis|Correlative studies
156510|NCT00100997|Drug|tanespimycin|
156511|NCT01807065|Biological|sipuleucel-T|Given IV
156512|NCT01807065|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
156513|NCT01807065|Other|laboratory biomarker analysis|Correlative studies
156514|NCT01807078|Drug|Ezetimibe|10 mg p.d. of ezetimibe
156515|NCT01807078|Dietary Supplement|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
165997|NCT01823276|Other|Tyrosine-Containing Bar|
165998|NCT01825759|Drug|danshen dripping pill|
165999|NCT00102882|Drug|salmeterol xinafoate|
166000|NCT01825785|Drug|Treatment Interval 1|Dose every 2 weeks
166001|NCT01825785|Drug|Treatment Interval 2|Dose every 4 weeks
166002|NCT01825798|Drug|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
166297|NCT01828892|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
166298|NCT01828892|Procedure|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
166299|NCT01828892|Drug|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
166300|NCT01828892|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
166301|NCT01828905|Device|CERAMENT™/BONE VOID FILLER|ceramic bone void filler
166302|NCT01828905|Procedure|Autologous cancellous bone graft|autologous cancellous bone graft
166303|NCT01828918|Genetic|microRNAs|
166304|NCT01828931|Behavioral|Lifestyle Intervention|
166305|NCT01828931|Other|Usual Care|
166306|NCT00103181|Radiation|brachytherapy|
166307|NCT01828944|Dietary Supplement|olive oil|
166308|NCT01828957|Biological|Pneumostem®|
166309|NCT01828957|Other|Normal Saline|
165712|NCT01838044|Drug|Placebo and celecoxib|Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.
All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
165713|NCT01838057|Device|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
165714|NCT01838057|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
165715|NCT01840592|Drug|Doxorubicin|
165716|NCT01840605|Drug|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
165717|NCT01840605|Drug|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
165718|NCT01840618|Device|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
166003|NCT01825798|Drug|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
166004|NCT01825811|Biological|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10^6 cells mixed with fibrin-glue
166005|NCT01825811|Biological|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10^6 cells mixed with fibrin-glue
166006|NCT01825824|Radiation|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
166007|NCT01825837|Drug|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
166008|NCT01825837|Drug|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
166009|NCT01825837|Drug|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
165412|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
165413|NCT01835197|Drug|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
165414|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
165415|NCT01835223|Other|Laboratory Biomarker Analysis|Correlative studies
165416|NCT01835223|Other|Pharmacological Study|Correlative studies
165417|NCT01835223|Drug|Tivozanib|Given PO
165418|NCT01835236|Drug|Trastuzumab|First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.
- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.
165419|NCT00103649|Drug|xaliproden (SR57746A)|
165420|NCT01835236|Drug|Pertuzumab|First administration (loading dose) 840 mg i.v. infusion over 60 min.
- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.
165421|NCT01835236|Drug|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
165422|NCT01835236|Drug|Vinorelbine|First administration: Day 1 and 8 25 mg/m2 i.v. infusion
then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion
165423|NCT01835236|Drug|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
165424|NCT01835249|Other|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP <120 mmHg.
165425|NCT01835249|Other|Standard BP arm|Participants in the Standard BP arm have a goal of SBP <140 mmHg.
165426|NCT01837524|Behavioral|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
165719|NCT01840631|Behavioral|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
165720|NCT01840644|Other|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
165721|NCT00000290|Drug|Cocaine|
165722|NCT00002015|Drug|Ganciclovir|
165723|NCT00104338|Drug|FK778|
165119|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
165120|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
165121|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
165122|NCT01834755|Other|Evaluation of psychological phenotype|
165123|NCT01834768|Drug|Eplerenone|
165124|NCT01834781|Device|Pulsed electromagnetic fields|
165125|NCT00103584|Biological|LC16m8 Smallpox Vaccine|
165126|NCT01834781|Device|w/o pulsed electromagnetic fields|
165127|NCT01834794|Behavioral|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
165128|NCT01834820|Drug|Epinephrine and Dexamethasone|
165129|NCT01834820|Drug|Hypertonic Saline|
165130|NCT01834820|Drug|Normal Saline|
165131|NCT01834833|Other|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
165132|NCT01834846|Procedure|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
165133|NCT01834846|Procedure|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
165134|NCT01834859|Behavioral|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
165135|NCT01834859|Behavioral|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
165136|NCT00103597|Drug|Fludrocortisone|
165137|NCT01834872|Device|Amigo|
165138|NCT01834872|Device|Manual ablation|
164576|NCT01841294|Drug|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
164577|NCT01841294|Drug|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
164578|NCT01841307|Drug|Cromolyn Sodium|
164579|NCT01841320|Other|Integrated methadone and antiretroviral therapy (iMART) clinic|
164580|NCT01841333|Drug|Hedgehog inhibitor PF-04449913|Given orally
164839|NCT00104468|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
164840|NCT01841788|Device|Thermal Adhesion Patch|
164841|NCT01834274|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
164842|NCT01834274|Drug|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
164843|NCT00002009|Drug|Sargramostim|
164844|NCT00103532|Behavioral|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
164845|NCT01834274|Drug|Sitagliptin|Sitagliptin tablets
164846|NCT01834274|Drug|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
164847|NCT01834274|Drug|Metformin|Metformin tablets
164848|NCT01834287|Behavioral|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
164849|NCT01834287|Behavioral|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
164850|NCT01834300|Behavioral|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
164851|NCT01834300|Behavioral|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
154296|NCT01769313|Device|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
154297|NCT01769326|Other|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
154298|NCT01769326|Device|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
154299|NCT01769326|Other|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
154300|NCT01769326|Device|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
154301|NCT01769339|Drug|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
154302|NCT00097279|Drug|metformin|
154303|NCT00096408|Procedure|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
154304|NCT01762189|Procedure|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
154305|NCT01762202|Drug|Cyclophosphamide|
154306|NCT01762202|Drug|Fludarabine|
154307|NCT01762202|Drug|Ofatumumab|
154308|NCT01762215|Behavioral|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
154309|NCT01762228|Device|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
154310|NCT01762228|Dietary Supplement|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
154311|NCT01762241|Behavioral|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
153758|NCT01768507|Dietary Supplement|Resveratrol|5 g (10 capsules) as single oral dose on day 1
153759|NCT01768520|Drug|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex
evening : 1 tab. of active Entelon 150mg
153760|NCT01768520|Drug|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex
evening : 1 tab. of placebo Entelon 150mg
153761|NCT00097162|Procedure|Anodal stimulation|
153762|NCT01768520|Drug|Placebo|morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex
evening : 1 tab. of placebo Entelon 150mg
154063|NCT01764048|Drug|Fix protocol|Please see arm description
154064|NCT01764048|Drug|medications following demand protocol|Please see arm description
154065|NCT01764074|Behavioral|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
154066|NCT01764087|Drug|KX2-391 and Paclitaxel|A treatment cycle in phase I will consist of 28 days, according to the following schedule:
KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated
A treatment cycle in phase II will consist of 28 days, according to the following schedule:
KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
154067|NCT01764100|Genetic|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
154068|NCT01764113|Behavioral|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
154069|NCT01764113|Behavioral|Standard dietary counselling|
154070|NCT01764126|Drug|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
154071|NCT00096551|Drug|Recombinant Fowlpox-GM-CSF|
154072|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
154073|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
154074|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
153515|NCT01770769|Device|Hemi - arthroplasty|cemented hemi - arthroplasty
153516|NCT01763164|Drug|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
153517|NCT01763164|Drug|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
153518|NCT01763177|Other|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
153519|NCT01763190|Drug|SAR302503|Pharmaceutical form:capsule
Route of administration: oral
153520|NCT01763203|Behavioral|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
153521|NCT01763203|Behavioral|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
153522|NCT01763216|Other|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
153523|NCT01763216|Other|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
153524|NCT01763229|Procedure|transthoracic echocardiography|
153525|NCT00096473|Drug|Donepezil hydrochloride|
153526|NCT01763242|Other|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
153527|NCT01763255|Biological|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
153825|NCT01766063|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
153826|NCT01766076|Other|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
153827|NCT01766076|Drug|Placebo|PBMC collected for immune activation assays using flowcytometry
153828|NCT01766089|Drug|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
153829|NCT01766089|Drug|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
153830|NCT01766102|Procedure|Intra-operative Mammography|The patient's breast specimen will be imagine in the operating room in an intra-operative imaging device - Biovision SN #30042
156556|NCT01811784|Behavioral|Ask people not to drink raw sap|
156557|NCT00101296|Other|laboratory biomarker analysis|Correlative studies
156558|NCT01811784|Behavioral|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
156559|NCT01811784|Other|No Intervention|
156560|NCT01811784|Other|No Intervention|
156561|NCT01811797|Device|Low Intensity Shockwave by Renova|
156562|NCT01811797|Device|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
156563|NCT01811810|Radiation|Radiation therapy (XRT)|
156564|NCT01811810|Other|Androgen Deprivation Therapy (ADT)|
156565|NCT01811810|Other|Chemotherapy|
156566|NCT01811823|Biological|Trivalent Inactivated Influenza Vaccine|The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.
The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:
A/California/7/2009 (H1N1)pdm-like virus
A/Victoria/361/2011 (H3N2)-like virus
B/Wisconsin/1/2010-like virus. (Yamagata lineage)
156567|NCT01811836|Dietary Supplement|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
156568|NCT00101309|Biological|aldesleukin|
156569|NCT01811849|Drug|Insulin LISPRO|
156570|NCT01811849|Drug|Insulin LISPRO|
156571|NCT01811849|Drug|Insulin LISPRO|
156572|NCT01804634|Drug|Cyclophosphamide|preparative regimen
156573|NCT01804634|Drug|Fludarabine|
156574|NCT01804634|Radiation|low dose total body irradiation|
156575|NCT01804634|Drug|Melphalan|
155970|NCT01806012|Procedure|Conventional supracervical hysterectomy|
155971|NCT01806025|Other|no intervention|
155972|NCT00100880|Other|laboratory biomarker analysis|Correlative studies
155973|NCT01806038|Other|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
155974|NCT01806038|Other|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
156270|NCT01809093|Biological|Blood draw|3-4 tablespoons of blood will be drawn, one time.
156271|NCT01809106|Drug|Morphine|60 mg /24 ore
156272|NCT01809106|Drug|Fentanyl|25 microg/h
156273|NCT01809106|Drug|Buprenorphine|35 microg/h
156274|NCT00101114|Other|laboratory biomarker analysis|Optional correlative studies
156275|NCT01809106|Drug|Oxycodone|40 mg /24 ore
156276|NCT01809119|Procedure|Partial nephrectomy|
156277|NCT01811407|Behavioral|Walking program|
156278|NCT01811420|Procedure|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
156279|NCT01811420|Procedure|Conventional method|Dental caries removal using rotatory instrument
156280|NCT01811446|Device|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
156281|NCT01811459|Drug|Quetiapine|PO
156282|NCT01811459|Drug|Haloperidol|IV
156283|NCT01811459|Drug|Placebo|PO or IV
156284|NCT01811472|Drug|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
156285|NCT01811472|Drug|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
158142|NCT01779544|Other|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
158143|NCT01779557|Drug|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
158144|NCT01779557|Drug|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
158145|NCT01779570|Drug|Macrolide treatment|
158146|NCT01779596|Drug|Bosentan|
158147|NCT00098358|Drug|Zileuton|
158148|NCT01779596|Drug|Placebo|
158149|NCT01779609|Drug|Bosentan|
158150|NCT01782326|Drug|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
158151|NCT01782339|Drug|Combination Chemotherapy|4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 3 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2
*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.
NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle.
158152|NCT01782352|Drug|Omega-3 fatty acids (fish oil)|
158153|NCT01782352|Dietary Supplement|Vitamin D3|
158154|NCT00098618|Biological|recombinant interferon alfa|Given orally
158155|NCT01782352|Dietary Supplement|Vitamin D3 placebo|
158156|NCT01782352|Dietary Supplement|Fish oil placebo|
158157|NCT01782365|Device|SHAM stimulation|no stimulation
158158|NCT01782365|Device|0,75 Hz stimulation|
158159|NCT01782378|Device|Photomedex Helmet, with Near-Infrared Light-Emitting Diodes (LEDs), Sham Helmet is identical but has power output of 0.|The LED helmet from Photomedex, Horsham, PA will be used. 18 LED pods are in the helmet. Each LED pod: Pod size: 4.5 x 4.8 cm, 21.6 cm2 Power output: 665.3 mW Power density: 30.8 mW/cm2 20 NIR diodes, 830 nm
155997|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 2|Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.
Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs.
157602|NCT01772823|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
157603|NCT01772823|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
157604|NCT01772836|Drug|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
157919|NCT01775995|Behavioral|Meditation-CBT Intervention + Usual Care|The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.
Control participants will be offered the intervention after completing the study.
All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
157920|NCT01775995|Other|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
157921|NCT01776008|Drug|Akt Inhibitor MK2206|Given PO
157922|NCT01776008|Drug|Anastrozole|Given PO
157923|NCT01776008|Drug|Goserelin Acetate|Given SC
157924|NCT01776008|Other|Laboratory Biomarker Analysis|Correlative studies
157925|NCT01776008|Procedure|Neoadjuvant Therapy|Given before standard-care surgery
157926|NCT01776008|Other|Pharmacological Study|Correlative studies
157927|NCT00097968|Drug|everolimus|
157928|NCT01776008|Procedure|Therapeutic Conventional Surgery|Undergo standard-care surgery
157929|NCT01776021|Other|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
157930|NCT01776021|Other|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
157931|NCT01776034|Behavioral|SystemCHANGE Group Lifestyle counseling|
157932|NCT01776034|Behavioral|Phone Lifestyle Counseling|
157933|NCT01776047|Drug|Exforge®|
157934|NCT01776047|Drug|G-0081|
157633|NCT00097890|Drug|Replagal|
157634|NCT01775475|Drug|cyclophosphamide|Given PO
157635|NCT01775475|Drug|procarbazine hydrochloride|Given PO
157636|NCT01775475|Other|laboratory biomarker analysis|Correlative studies
157637|NCT01775488|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
157638|NCT01778400|Procedure|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
157639|NCT01778413|Drug|ATRIPLA|
157640|NCT01778439|Drug|OMP-52M51|
157641|NCT01778452|Procedure|endometrial biopsy|endometrial biopsy
157642|NCT01778465|Behavioral|Low salicylate diet|
157961|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily and LEE011 will be administered once daily for 2 weeks followed by a 1 week break (21-day cycle).
157962|NCT01781585|Procedure|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
157963|NCT01781598|Device|Total knee arthroplasty (TKA) (Smith &Nephew®)|
157964|NCT00001933|Drug|Nefiracetam|
157965|NCT00098540|Other|laboratory biomarker analysis|Correlative studies
157966|NCT01781611|Drug|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
157967|NCT01781611|Drug|81mg aspirin|half a tablet twice daily for 24 weeks
157968|NCT01781624|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
157969|NCT01781637|Drug|Omalizumab|subcutaneous injection
157970|NCT01781637|Drug|placebo|subcutaneous injection
157971|NCT01781650|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
157351|NCT01774916|Genetic|blood samples|
157352|NCT01774929|Drug|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
157353|NCT01774942|Other|All teeth out, full dentures, dental implants, blood draw|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
157354|NCT00097838|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
157355|NCT01774968|Drug|Human Regular U-500 Insulin|
157356|NCT01774981|Drug|Placebo|Administered IV
157357|NCT01774981|Drug|LY3016859|Administered IV
157358|NCT01774994|Other|stable isotope infusion for measurement of metabolism|
157359|NCT01775007|Device|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
157360|NCT01775020|Dietary Supplement|L-arginine|
157361|NCT01775033|Other|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
157362|NCT01775046|Device|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
157363|NCT01775059|Device|Integrated sensor and infusion set.|
157364|NCT01775072|Genetic|molecular profiling of tumors|All Patients (MSK & non-MSK) Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational "next-generation" profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies.
157664|NCT01781390|Other|12.5 M Mesenchymal Precursor Cells (MPC)|
157665|NCT01781390|Other|Placebo|
157666|NCT01781390|Other|25M Mesenchymal Precursor Cells (MPC)|
157667|NCT01781403|Drug|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
157076|NCT01810510|Procedure|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
157077|NCT00100646|Behavioral|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
157078|NCT01803035|Drug|LTX-109 1 %|
157079|NCT01803035|Drug|LTX-109 2 %|
157080|NCT01803035|Drug|Placebo gel|
157081|NCT01803061|Behavioral|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
157082|NCT01803074|Drug|BMS-955176|
157083|NCT01803074|Drug|Placebo matching with BMS-955176|
157084|NCT01803074|Drug|Atazanavir|
157085|NCT01803074|Drug|Ritonavir|
157086|NCT01803074|Drug|Tenofovir|
157087|NCT01803074|Drug|Emtricitabine|
157088|NCT00100646|Drug|Lamivudine|300 mg tablet taken orally daily
157089|NCT01803087|Drug|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
157090|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
157091|NCT01803087|Drug|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
157092|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) (CTR)|
157093|NCT01803100|Other|No intervention|There is no intervention in this trial
157094|NCT01803113|Device|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
157095|NCT01803139|Device|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
157096|NCT01803152|Biological|Dendritic Cells Vaccine|Subjects will begin to receive Dendritic Cells vaccination alone, approximately 2 weeks after pheresis and continue weekly for a total of four vaccinations.
156516|NCT01807091|Drug|Chemotherapy|Receive outpatient induction chemotherapy
156517|NCT01807104|Procedure|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
156818|NCT01810159|Other|Education and Resources|
156819|NCT00101140|Procedure|radiation therapy|
156820|NCT01810172|Device|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
156821|NCT01810172|Device|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
156822|NCT01810185|Drug|Low dose naltrexone|4.5 mg daily for 12 weeeks
156823|NCT01810185|Drug|Placebo|
156824|NCT01810198|Procedure|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
156825|NCT01810198|Procedure|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
156826|NCT01810211|Other|Horizontal Adduction Stretch and Pendulums|
156827|NCT01792557|Procedure|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
156828|NCT00099385|Behavioral|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg & Kusche) curriculum.
156829|NCT01792557|Procedure|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
156830|NCT01792557|Procedure|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
156831|NCT01792570|Drug|RPV + DRV/r|Switch to dual HAART
156832|NCT01792570|Drug|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
156833|NCT01792583|Drug|Modafinil/armodafinil|
156834|NCT01792596|Other|Pasta with protein|Pasta with Protein
156835|NCT01792596|Other|Pasta with Fiber|Pasta with Fiber
156836|NCT01792596|Other|Pasta|Pasta
156837|NCT01792609|Procedure|Maximum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
166310|NCT01828970|Drug|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
166311|NCT01828983|Behavioral|Telephone support groups|
166312|NCT01828983|Other|Education webinars|
166313|NCT01828996|Device|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
166314|NCT01828996|Device|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
166315|NCT01831635|Other|Methodological trolley tokens|Trolley tokens to be randomly assigned to half of cases and General Practice controls.
166316|NCT01831648|Other|Blood sample|
166317|NCT01831661|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
166600|NCT01824368|Procedure|Extracorporeal Photopheresis Procedure (FEC)|The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.
1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.
Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex.
166601|NCT01824381|Procedure|Place amniotic membrane in large wounds|After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.
The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.
We will place a new membrane weekly to a maximum of 6 times.
166602|NCT01824381|Procedure|Obtaining and Cryopreservation of amniotic membrane|
166603|NCT01824381|Drug|amniotic membrane|
166604|NCT00102726|Other|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
166605|NCT01824394|Device|nMARQ Navigation Catheters|
166606|NCT01824394|Device|NaviStar ThermoCool Catheters|
166607|NCT01824407|Device|Electrohydraulic-generated shock wave|
166608|NCT01824407|Device|Sham device plus standard of care|
166010|NCT00102895|Drug|CP-724,714|
166011|NCT01825837|Drug|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
166012|NCT01825850|Drug|Gemigliptin|
166013|NCT01825850|Drug|Irbesartan|
166014|NCT01825863|Drug|Ropivacaine|
166015|NCT01825863|Drug|Saline 9%|
166016|NCT01825876|Drug|Evacetrapib|Oral administration
166017|NCT01825876|Drug|Warfarin|Oral administration
166018|NCT01825889|Drug|Evacetrapib|Administered orally
166019|NCT01825902|Other|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
166020|NCT01825902|Radiation|fludeoxyglucose F 18|Undergo 18F-FDG PET
166021|NCT01828463|Drug|Nitisinone|doses 1, 2, 4 & 8 mg plus no treatment arm
166022|NCT01828476|Drug|Abiraterone|ARM A and ARM B
166023|NCT01828476|Drug|ABT-263|ARM A and ARM B
166318|NCT00103324|Drug|lapatinib ditosylate|Given orally
166319|NCT01831661|Drug|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
166320|NCT01831674|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
166321|NCT01831674|Drug|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
166322|NCT01831687|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
166323|NCT01831687|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
166324|NCT01831700|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
166325|NCT01831700|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
166326|NCT01831726|Drug|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
165724|NCT01840670|Drug|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
165725|NCT01840683|Device|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
165726|NCT01840696|Drug|Regadenoson|Vasodilator stress testing
165727|NCT01840709|Behavioral|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
165728|NCT01840722|Other|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
165729|NCT01840735|Drug|GS-5737|
165730|NCT01840735|Drug|Placebo|
165731|NCT01840761|Drug|herbal drug|
165732|NCT01840761|Drug|placebo|
165733|NCT01840774|Drug|Low-dose pain medication (Ketalar) and saline placebo|
165734|NCT00104351|Drug|VX-680 (an Aurora Kinase Inhibitor)|24 hr CIV infusion at rising dose levels of 2, 4, 8, 16, 32 and 64 mg/m2/hour; 5-day continuous infusion every 21 days.
165735|NCT01840787|Device|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
165736|NCT01840787|Device|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
165737|NCT01840787|Device|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
165738|NCT01840800|Drug|Ropivacaine|
165739|NCT01840800|Drug|placebo|
166024|NCT00002004|Drug|CD4 Antigens|
166025|NCT00103142|Biological|sargramostim|Given subcutaneously
166026|NCT01828476|Drug|Hydroxychloroquine|ARM B
166027|NCT01828489|Drug|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
166028|NCT01828489|Drug|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
165139|NCT01834885|Drug|QVA149|QVA149 via inhaler twice a day
165427|NCT01837524|Behavioral|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
165428|NCT01837550|Behavioral|Intervention group|The intervention group is going to have access to a book and to a prepared compendium about communication strategies via the Internet and will receive weekly topic-based reading instructions related to the different chapters of the book or the compendium. The group will also have access to online and telephone support and access to an online discussion forum where new discussion topics will be posted each week. The project leader will evaluate the weekly data via the Internet.
165429|NCT01837550|Behavioral|Control group|The control group will only have access to the book's content via the Internet and will be asked to read and evaluate the content.
165430|NCT01837576|Drug|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
165431|NCT01837589|Other|QCT|
165432|NCT00103857|Drug|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
165433|NCT01837589|Other|DXA|
165434|NCT01837602|Biological|cMet RNA CAR T cells|
165435|NCT01837615|Device|Photopill treatment|
165436|NCT01837628|Drug|Lidocaine Gel|
165437|NCT01837628|Drug|Paraffin Oil|
165438|NCT01837641|Biological|LY3002813-IV|Administered IV
165439|NCT01837641|Biological|LY3002183-SC|Administered SC
165440|NCT01837641|Drug|Placebo-IV|Administered IV
165441|NCT01837654|Behavioral|Performing Plantarflexion during urodynamic test|
165442|NCT01837667|Drug|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
165443|NCT00103857|Drug|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
164852|NCT01834326|Biological|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|The EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
164853|NCT01834326|Biological|POM (Palatal oral mucosa)|
164854|NCT01834339|Biological|AlloDerm|
164855|NCT00103532|Behavioral|Standard care|Participants will receive standard care plus referrals at three months post-baseline
164856|NCT01834339|Biological|EVPOME|
165140|NCT01834885|Drug|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
165141|NCT01834898|Drug|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
165142|NCT01837095|Drug|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
165143|NCT01837108|Drug|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
165144|NCT01837108|Drug|Placebo|
165145|NCT01837121|Other|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 1 day before there appointment,to remind them the exact time and address of the revisit appointment.
165146|NCT01837134|Device|telemedical (TM) group|telemedical devices (weighing machine and step counter)
165147|NCT00103844|Drug|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
165148|NCT01837134|Behavioral|telemedical coaching (TMC) group|care calls once per week for 12 weeks
165149|NCT01837147|Behavioral|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
165150|NCT01837147|Behavioral|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
165151|NCT01837160|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
165152|NCT01837160|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
165153|NCT01837160|Procedure|Echocardiogram|Echocardiography.
165154|NCT01837160|Radiation|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
153357|NCT00096707|Drug|2-deoxy-D-glucose (2DG)|
153358|NCT01765257|Drug|AZILECT®|
153359|NCT01765257|Drug|Placebo|
153360|NCT01765270|Drug|Saxagliptin|one 5-mg saxagliptin tablet daily
153361|NCT01765270|Drug|Placebo|5mg placebo tablet daily
153362|NCT01765283|Biological|HepaStem|
153363|NCT01765296|Drug|CG100649|2 mg capsule
153364|NCT01765296|Drug|Celecoxib|200 mg capsule
153365|NCT01765296|Drug|Placebo|Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
153366|NCT01765309|Procedure|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
153367|NCT01765322|Device|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
153368|NCT00096720|Drug|levodopa|
153369|NCT01765335|Device|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
153370|NCT01767662|Procedure|No intervention|observation
153371|NCT01767675|Procedure|Secondary Cytoreductive Surgery|
153372|NCT01767675|Drug|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
153373|NCT00097045|Drug|Ribavirin|
153374|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|5 cycles
153375|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|6 cycles
153376|NCT01767688|Drug|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
153377|NCT01767701|Drug|Raltegravir|400mg twice daily for 3 months
153378|NCT01767714|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
154075|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
154076|NCT01764139|Procedure|Blood sampling|
154077|NCT01764152|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
154078|NCT01764165|Other|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
154079|NCT01764165|Other|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
154080|NCT01764178|Drug|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
154081|NCT01764178|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
154082|NCT00096590|Other|coagulation study|
154375|NCT01769365|Drug|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
154376|NCT01769365|Drug|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
154377|NCT01769365|Drug|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
154378|NCT01769378|Drug|Placebo|Administered SQ
154379|NCT01769378|Drug|Dulaglutide|Administered SQ
154380|NCT01769378|Drug|Glimepiride|Administered PO
154381|NCT01769391|Drug|Necitumumab|Administered IV
154382|NCT01769391|Drug|Paclitaxel|Administered IV
154383|NCT01769391|Drug|Carboplatin|Administered IV
154384|NCT00097305|Behavioral|Body-Oriented Therapy|
154385|NCT01769404|Biological|LY2605541|Daily dose administered subcutaneously
154386|NCT01769404|Biological|Insulin Glargine|Daily dose administered subcutaneously
154387|NCT01769417|Drug|Placebo|Placebo
154388|NCT01769417|Drug|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
153831|NCT01766102|Procedure|Standard Mammography|There is not an added device associated with this arm.
153832|NCT01766115|Drug|Telaprevir|HCV Protease Inhibitor
153833|NCT01766128|Drug|Zonisamide|The first arm will be treated by zonisamide and the second one will only receive placebo
153834|NCT00096824|Behavioral|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
153835|NCT01768559|Drug|lixisenatide (AVE0010)|Pharmaceutical form:solution for injection (disposable self injector)
Route of administration: subcutaneous injection
153836|NCT01768559|Drug|insulin glulisine (HMR1964)|Pharmaceutical form:solution for injection (disposable self injector)
Route of administration: subcutaneous injection
153837|NCT01768559|Drug|Insulin Glargine|Doses to be adjusted to maintain a fasting SMPG between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
153838|NCT01768559|Drug|Metformin|If previously taken Metformin to be continued at stable dose ( ≥1.5 g/day) throughout the study
153839|NCT01768572|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
153840|NCT01768572|Drug|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
153841|NCT01768572|Drug|hydroxychloroquine|Dispensed according to local practice.
153842|NCT00097188|Drug|rituximab|
153843|NCT01768572|Drug|methotrexate|Dispensed according to local practice.
153844|NCT01768572|Drug|sulfasalazine|Dispensed according to local practice.
153845|NCT01768572|Drug|leflunomide|Dispensed according to local practice.
153846|NCT01768572|Drug|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
153847|NCT01768572|Drug|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
154136|NCT01761929|Radiation|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
154137|NCT01761942|Dietary Supplement|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
154138|NCT01761955|Other|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
156576|NCT00100802|Drug|temozolomide|Capsule
156577|NCT01804634|Drug|Sirolimus|
156881|NCT01807663|Device|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
156882|NCT01807676|Device|ET View Double Lumen Tube|
156883|NCT01807676|Device|conventional Double Lumen Tube|
156884|NCT01807702|Drug|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
156885|NCT01807715|Other|survey|Survey before procedure to obtain demographic information and contraceptive information
156886|NCT01807728|Other|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
156887|NCT01807728|Other|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
156888|NCT01807741|Drug|Asenapine|Available in 5 and 10 mg.
156889|NCT01807741|Drug|Placebo|
156890|NCT00101036|Other|laboratory biomarker analysis|Correlative studies
156891|NCT01807754|Procedure|Imaging modalities for breast cancer screening|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. You will be seated and your breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
156892|NCT01807754|Procedure|Imaging modalities for breast cancer screening|The subject will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the subject's chest to allow the computer to record ultrasound blood flow in your breast. The low intensity laser light will be focused on the targeted area of the breast.
156893|NCT01807767|Drug|Everolimus, Myfortic and Tacrolimus|Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).
Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.
Myfortic 360-720 mg BID
156894|NCT01807767|Drug|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
156895|NCT01807780|Other|biological monitoring|
156896|NCT01807793|Behavioral|Psychoeducation|
156897|NCT01810211|Other|Modified Sleeper Stretch and Pendulum|
156286|NCT01811485|Drug|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
156287|NCT00101283|Drug|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
156288|NCT01811485|Drug|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
156289|NCT01811485|Drug|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
156290|NCT01811498|Drug|Bevacizumab|
156291|NCT01811511|Dietary Supplement|Chungkookjang|
156292|NCT01811511|Dietary Supplement|Placebo|
156293|NCT01811537|Device|Artificial Chordae|
156294|NCT01811550|Other|Glycemic Control|
156295|NCT01811563|Device|Zimmer|
156597|NCT01807182|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
156598|NCT01807195|Other|contrast medium usage|
156599|NCT01807208|Other|Educational Tool|A personalized health goal education and reminder tool, with 3 parts: "report card" showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician.
156600|NCT01807221|Drug|Finerenone (BAY94-8862)|
156601|NCT01807221|Drug|Placebo|
156602|NCT01807221|Drug|Inspra (eplerenone)|
156603|NCT01807234|Drug|SPRIX|Single dose of Sprix nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
156604|NCT01807234|Drug|Sumatriptan|Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
156605|NCT01807234|Drug|Placebo|SPRIX placebo one spray in each nostril and Sumatriptan placebo one nasal spray.
156606|NCT00101010|Biological|Rituximab|375 mg/m^2 intravenous piggy back (IVPB) on day 1, administered 1st
156607|NCT01807247|Procedure|Intensive lower limbs muscles strengthening|
155998|NCT01808651|Drug|Fluoxetine|Administered orally
155999|NCT01808664|Behavioral|Standardized Patient Instructor Intervention|In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.
During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques.
156000|NCT01808664|Behavioral|Control|In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control "information sharing" will be about one-third the SPI intervention to enhance patient-centeredness.
156001|NCT00101101|Drug|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
156002|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
156003|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
156004|NCT01810939|Drug|Patiromer|
156005|NCT01810939|Drug|Placebo|
156006|NCT01810952|Drug|Active Comparator: Glargine/Lispro insulin|In both protocols glargine dose will be increased by 10% if the fasting glucose value is 141-200 mg/dL and by 20% if the fasting glucose value is more than 200 mg/dL, and decreased by 10% if the fasting FSG is 70-89 mg/dL and by 20% if the fasting FSG is less than 70 mg/dL.
If the patient had an outpatient regimen which includes a total daily dose of insulin (TDI) that exceeds 0.4 unit/kg/day, then the same TDI will be continued with 50% given as glargine once daily if the dose is between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units; and 50% given as lispro divided between three meals. The patient will still be randomly assigned to either one of the two protocols as described previously.
156007|NCT00101244|Drug|ispinesib|Given IV
156008|NCT01810952|Drug|Glargine/Lispro/NPH insulin arm|The G/L/N Protocol will include 0.2 unit/kg/day as insulin glargine daily if the dose is between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units; plus 0.2 unit/kg/day as lispro divided between three meals for all the insulin-naïve patients. A "coverage" dose of 0.1 unit/kg/day of NPH for each 10 mg of prednisone or its equivalent will be given twice daily with the administration of the glucocorticoid. The maximum starting "coverage" dose will be 0.4 units/kg per day.
156009|NCT01810965|Procedure|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
156010|NCT01810978|Dietary Supplement|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
156312|NCT00100750|Other|Laboratory Biomarker Analysis|Correlative studies
157935|NCT01776060|Other|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
157936|NCT01776073|Behavioral|Patient Navigation|
157937|NCT01779076|Procedure|100% oxygen|
157938|NCT01779089|Drug|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
157939|NCT01779089|Drug|placebo|
157940|NCT01779102|Biological|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
158182|NCT01773798|Drug|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
158183|NCT01773798|Drug|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
158184|NCT01773811|Behavioral|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
158185|NCT01773811|Behavioral|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
158186|NCT01773824|Behavioral|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
158187|NCT01773824|Behavioral|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
158188|NCT01773837|Drug|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
158189|NCT01773850|Device|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
158190|NCT00097760|Drug|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
158191|NCT01773876|Drug|Micafungin|MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%
infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis
158192|NCT01773876|Drug|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
157972|NCT01781650|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
157973|NCT01781650|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
157974|NCT01781663|Device|KAM2904 Face Cream|
157975|NCT01781663|Device|KAM3008 Body Lotion|
157976|NCT00098553|Drug|everolimus|
157977|NCT01781663|Other|petrolatum-based moisturizer|
157978|NCT01781689|Procedure|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
157979|NCT01781689|Other|Rehabilitation programs|include occupational therapy and physical therapy
157980|NCT01781702|Drug|Pelubiprofen 30 mg|
157981|NCT01781702|Drug|Celebrex 200 mg|
155745|NCT00095927|Drug|paclitaxel|Given IV
155746|NCT01753752|Drug|Chitosan- N- Acetylcysteine eye drops|
155747|NCT01753752|Drug|Placebo|
155748|NCT01753765|Device|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
155749|NCT01753778|Device|Cryo-Touch III Device|Treatment with Cryo-Touch III
155750|NCT01753791|Drug|80 mg PF-06473871|80 mg of PF-06473871 or placebo
155751|NCT01753791|Drug|160 mg PF-06473871|160 mg of PF-06473871 or placebo
155752|NCT01753791|Drug|320 mg PF-06473871|320 mg of PF-06473871 or placebo
155753|NCT01753791|Drug|480 mg PF-06473871|480 mg of PF-06473871 or placebo
155754|NCT01753804|Other|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
157668|NCT01781429|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
157669|NCT00098527|Other|laboratory biomarker analysis|Correlative studies
157670|NCT01781442|Drug|Temsirolimus|The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.
Treatment will continue until disease progression or unacceptable toxicity.
The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity.
157671|NCT01781455|Drug|BBI503|
157672|NCT01781468|Drug|armodafinil 150 mg|given orally
157673|NCT01781468|Other|Placebo|given orally
157674|NCT01781468|Drug|armodafinil 250 mg|given orally
157675|NCT01781494|Procedure|Immobilization followed by protected range of motion|
157676|NCT01781494|Procedure|Immediate range of motion|
157677|NCT01781507|Drug|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
157678|NCT01781507|Drug|Placebo|This placebo ( sugar pill) will provide the negative control for this study
157679|NCT01781520|Other|S-1 plus DC-CIK|
157680|NCT00098540|Drug|sorafenib tosylate|Given orally
157681|NCT01781533|Procedure|algorithm|
157682|NCT01781546|Procedure|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is >20mm or stent malapposition is suspected).
157683|NCT01781546|Procedure|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length >20mm or stent malapposition is suspected).
157684|NCT01781559|Dietary Supplement|phenolic acid|phenolic acid
157685|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily on a continuous dosing schedule. LEE011 will be administered orally once daily for 21 days followed by a 1 week break (28-day cycle).
158004|NCT01773538|Dietary Supplement|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
157097|NCT01803152|Biological|Lysate of Tumor|After completion of DC vaccination course, lysate of tumor will be administered during weeks 8, 12, 16, and 28. Lysate dose will be up to 1.5 mg of tumor lysate, divided into 4 equal doses. All lysate will be injected into one arm intradermally in alternating arms/thigh
157390|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
157391|NCT01778062|Drug|Indacaterol|Indacaterol 150µg once daily oral inhalation
157392|NCT01778062|Drug|Control|Placebo once daily oral inhalation
157393|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
157394|NCT00098202|Drug|Low phytic acid maize|
157395|NCT01780818|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
157396|NCT00098475|Drug|Thalidomide|Given PO
157397|NCT01780818|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
157398|NCT01780818|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
157399|NCT01780831|Drug|Raltegravir|RAL will be given as oral granules for suspension. Dose may be modified after ongoing PK and safety analyses.
157400|NCT01780844|Drug|ASKP1240|intravenous infusion
157401|NCT01780844|Drug|Tacrolimus|intravenous or oral
157402|NCT01780844|Drug|Mycophenolate Mofetil (MMF)|intravenous or oral
157403|NCT01780844|Drug|Basiliximab|intravenous
157404|NCT01780844|Drug|Corticosteroids|intravenous or oral
157405|NCT01780870|Dietary Supplement|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
156838|NCT01792609|Procedure|Minimum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
156839|NCT00099424|Behavioral|High-intensity exercise training|
156840|NCT01792622|Other|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
157113|NCT01805661|Procedure|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
157114|NCT01805674|Dietary Supplement|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
157115|NCT01805687|Drug|Zileuton extended release|
157116|NCT01805700|Other|Caffeine enhanced energy drink|Comparison of different energy drinks
157117|NCT01805700|Other|Glucose drink|Glucose drink (containing 84mg glucose alone)
157118|NCT01805726|Drug|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
157119|NCT01805726|Drug|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
157120|NCT01805726|Drug|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
157121|NCT01805752|Other|Task-shifting to lower-cadre providers at PMTCT sites|
157122|NCT00001989|Drug|Trichosanthin|
157123|NCT00101088|Drug|imatinib mesylate|Given orally
157124|NCT01808144|Drug|lesinurad|Tablets, 400 mg once daily (QD)
157125|NCT01808144|Drug|lesinurad|Tablets, 200 mg QD
157126|NCT01808157|Drug|CT327 ointment|
157127|NCT01808157|Drug|placebo|
166609|NCT01824420|Drug|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
166610|NCT01824420|Drug|Detrusitol 4mg QD|Control group
166611|NCT01824433|Drug|venlafaxine,fluoxetine|venlafaxine 75-225mg qd fluoxetine 20-60mg qd
166612|NCT01824446|Drug|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
166613|NCT01824459|Drug|S-1|S-1：40~60mg bid，d1~14 q3W
166614|NCT01824459|Drug|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
166615|NCT00102739|Drug|SB497115|
166616|NCT01824459|Drug|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
166617|NCT01824472|Device|CPAP|Treatment for sleep apnea
166618|NCT01826968|Procedure|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
166619|NCT01826981|Drug|LDV/SOF FDC|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet administered orally once daily
166938|NCT00002006|Drug|Zidovudine|
166939|NCT00103272|Drug|tanespimycin|Given IV
166940|NCT01830088|Behavioral|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
166941|NCT01830101|Drug|TMZ plus concurrent re-irradiation|
166942|NCT01830101|Drug|Temozolomide|low-dose temozolomide daily for one year
166943|NCT01830114|Behavioral|Web app|The Checkup and Choices web application
166944|NCT01830127|Drug|Ribavirin|24 Weeks
166945|NCT01830127|Drug|BI 207127 high dose|24 Weeks
166946|NCT01830127|Drug|Faldaprevir|24 Weeks
166947|NCT01830127|Drug|Ribavirin|24 Weeks
166948|NCT01830127|Drug|BI 207127 low dose|24 Weeks
166327|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
166328|NCT01831765|Drug|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
166329|NCT00103324|Other|laboratory biomarker analysis|Correlative studies
166330|NCT01831765|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
166331|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal dosing is defined as injecting 20 minutes after the start of the meal.
166332|NCT01831791|Drug|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
166333|NCT01831804|Drug|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
166334|NCT01831804|Drug|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
166335|NCT01831817|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
166336|NCT01831817|Drug|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
166337|NCT01831817|Drug|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
166338|NCT01831817|Drug|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
166620|NCT01826981|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
166621|NCT01826981|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
166622|NCT00102973|Drug|Doxorubicin HCl Liposome Injection|Active Comparator
166623|NCT01826981|Drug|PEG|Peginterferon alfa-2b (PEG) 180 µg administered subcutaneously once weekly
166624|NCT01826981|Drug|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
166625|NCT01826981|Drug|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
166626|NCT01826994|Device|heart type fatty acid binding protein testing|
166627|NCT01827007|Other|Volume expansion with gelofusine|
166029|NCT01828502|Behavioral|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
166030|NCT01828502|Behavioral|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
166031|NCT01828515|Drug|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
166032|NCT01828515|Drug|Placebo|
166033|NCT01828528|Procedure|Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG).|Surgery includes intraoperative Tru-Cut liver biopsy.
166034|NCT01828528|Other|Low carbohydrate diet|Low carbohydrates diet, starting 3 weeks before surgery, providing daily amount of: 60g Carbohydrates, 1400 Kilo-Calories and 130g protein.
166035|NCT01828541|Behavioral|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
166036|NCT00103142|Biological|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
166037|NCT01828541|Other|Standard of Care|
166038|NCT01828554|Drug|Xeloda|Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using "Ideal Body Weight" to calculate dosage. Cycle 1, Day 8-No drug.
Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.
Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage.
166039|NCT01828567|Behavioral|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to PACT, and a follow-up call one month later to assess the progress of the prevention plan.
166040|NCT01828580|Device|active laparoscope positioner (AutoLap)|
166041|NCT01828593|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
166042|NCT01828593|Other|Placebo|
166339|NCT01823822|Dietary Supplement|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
166340|NCT00102661|Drug|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
166341|NCT01823835|Drug|GDC-0810|Oral administration, continuous daily dosing regimen per protocol dose escalation and expansion stages
165444|NCT01837667|Drug|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
165445|NCT01837680|Drug|Insulin|
165446|NCT01837693|Procedure|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
165740|NCT01833312|Device|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
165741|NCT01833312|Drug|Buspirone|anti-shivering treatment
165742|NCT01833312|Drug|Pethidine|anti-shivering treatment
165743|NCT01833325|Radiation|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
165744|NCT00103415|Behavioral|Weight-lifting training|
165745|NCT01833338|Device|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
165746|NCT01833351|Drug|IV Vitamin C|We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.
If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.
165747|NCT01833351|Drug|IV Vitamin C|There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.
Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.
165748|NCT01833364|Procedure|Implantation of the Peripheral Nerve Graft|The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.
The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility.
165749|NCT01833377|Dietary Supplement|caraway sample|
165750|NCT01833377|Dietary Supplement|placebo|
165155|NCT01837160|Procedure|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
165156|NCT01837199|Drug|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
165157|NCT01837238|Dietary Supplement|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
165158|NCT00103844|Drug|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
165159|NCT01837238|Dietary Supplement|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
165160|NCT01837251|Drug|Carboplatin|
165447|NCT01837719|Drug|Atazanavir|300-mg capsule
165448|NCT01837719|Drug|Cobicistat|150-mg tablet
165449|NCT01840033|Device|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
165450|NCT01840046|Drug|Interleukin-2|The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:
5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.
The dosage is as follows:
S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5).
165451|NCT00104273|Drug|Rasagiline|
165452|NCT01840059|Device|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
165453|NCT01840072|Other|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
165454|NCT01840085|Drug|0.03% DSC127 topical gel|
165455|NCT01840098|Dietary Supplement|low leucine content drink|
165456|NCT01840098|Dietary Supplement|high leucine content drink|
165457|NCT01840098|Dietary Supplement|low leucine + HMB drink|
153379|NCT01767714|Drug|Plerixafor|0.24 mg/kg/day subcutaneous injection
153380|NCT01767714|Drug|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
153381|NCT01767727|Procedure|Soft tissue coverage|The dorsal homodigital island flaps are used for reconstruction of multiple finger defects
153676|NCT01770379|Biological|Placebo|
153677|NCT01770392|Drug|Nintedanib|single dose administration
153678|NCT01770392|Drug|Rifampicin|single dose once daily for 7 days
153679|NCT01770392|Drug|Nintedanib|single dose administration
153680|NCT01770405|Device|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
153681|NCT01770418|Radiation|Radiation Concurrent Chemotherapy|RADIATION: Proton Radiotherapy Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE)per fraction x 24 fractions
Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE)per fraction x 20 fractions
Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE)per fraction x 17 fractions
Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE)per fraction x 15 fractions
CONCURRENT CHEMOTHERAPY:
Paclitaxel and Carboplatin or Cisplatin and Etoposide Paclitaxel at a dose of 45 mg/m2 and carboplatin at a dose of AUC 2 mg/min/ml(a total of 3-5 weekly doses) OR cisplatin 50mg/m2 days 1, 8, 29, and 36 and etoposide 50mg/m2 days 1-5, 29-33.
Adjuvant chemotherapy is optional .
153682|NCT01770431|Drug|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
153683|NCT01770444|Other|Low-dose Cardiac CT protocol|A cardiac CT protocol modified for reduction of radiation exposure
Prospective gating
Range: dedicated imaging (below carina to heart base)
153684|NCT01770444|Other|Conventional cardiac CT protocol|Conventional CCTA protocol
Retrospective gating with tube current modulation
Range: dedicated imaging (below carina to heart base)
153685|NCT00097357|Drug|Enoxaparin|Injection, SQ, Q12H, 12 +/- 2 days
153686|NCT01770470|Dietary Supplement|Chitosan|The product chitosan is contained in a chewing gum formulation
153687|NCT01770483|Drug|nitazoxanide|nitazoxanide 500mg twice daily
153688|NCT01770483|Drug|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
153689|NCT00096499|Drug|ispinesib|Given IV
153690|NCT01763489|Behavioral|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
153691|NCT01763502|Other|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
154389|NCT01769443|Drug|bortezomib|Bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
154390|NCT01769443|Procedure|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
154391|NCT01769456|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
154392|NCT01769456|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
153438|NCT01765348|Behavioral|Syntax treatment via sentence-combining method|Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.
Treatments are conduced by school-speech therapist once two weeks for 8 sessions.
153439|NCT01765348|Behavioral|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
153440|NCT01765374|Device|ESAOTE MyLab60|US evaluation at different time points
153441|NCT01765374|Drug|Rituximab|
153442|NCT01765387|Behavioral|Spa session|
153443|NCT01765400|Drug|Prasugrel 10 mg daily x 2 weeks|
153444|NCT01765400|Drug|Clopidogrel 75 mg daily x 2 weeks|
153445|NCT01765413|Biological|Varicella-zoster virus|
153446|NCT01765413|Biological|Yellow Fever Vaccine|
153447|NCT00096720|Drug|Mirapex (pramipexole)|
153448|NCT01765413|Biological|Placebo|
153449|NCT01765426|Biological|DENVax|low dose given intradermally
154139|NCT01761968|Drug|Givinostat|Patients will continue at their last tolerable dose and treatment schedule of Givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
If patients previously received Givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination.
154140|NCT01764191|Other|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
154141|NCT01764204|Drug|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
154142|NCT01764230|Drug|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
154143|NCT01764243|Drug|MT-4666|low dose, high dose
154144|NCT01764243|Drug|Placebo|
154145|NCT01764256|Biological|P2-VP8 subunit rotavirus vaccine|
154146|NCT01764269|Other|text message surveillance for fever|
154147|NCT01764282|Behavioral|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
154148|NCT01764295|Drug|DWJ1276|
154149|NCT01764295|Drug|Olmesartan|
154150|NCT00096590|Other|immunoenzyme technique|
154151|NCT01764295|Drug|Rosuvastatin|
154152|NCT01764295|Drug|Placebo|
154153|NCT01764308|Dietary Supplement|Omega-3|1200mg twice a day for 24 weeks
154154|NCT01764308|Dietary Supplement|Placebo|4 tablets twice a day for 24 weeks
154457|NCT00096278|Drug|leucovorin calcium|Given IV
154458|NCT01759914|Drug|Potent topical steroid|
154459|NCT01759914|Drug|Superpotent topical steroid|
156898|NCT01810224|Procedure|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
156899|NCT01810237|Drug|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
156900|NCT00101153|Drug|cytarabine|
157163|NCT01803204|Other|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
157164|NCT01803217|Other|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
157165|NCT01803230|Dietary Supplement|creatine supplementation|creatine supplementation
157166|NCT00100646|Drug|Stavudine|Dosage dependent on weight
157167|NCT01803230|Dietary Supplement|Placebo|
157168|NCT01803243|Other|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
157169|NCT01803243|Other|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
157170|NCT01803243|Other|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
157171|NCT01803269|Drug|topotecan hydrochloride|Given IV
157172|NCT01803269|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
157173|NCT01803282|Drug|GS-5745|GS-5745 administered intravenously
157174|NCT01803282|Drug|Gemcitabine|Gemcitabine administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
157175|NCT01803282|Drug|Nab-paclitaxel|Nab-paclitaxel administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
157176|NCT01803282|Drug|Carboplatin|Carboplatin administered intravenously on Day 1 of each 21-day treatment cycle
157177|NCT00001968|Drug|Ritonavir|
157178|NCT00100646|Biological|Rabies de novo antigen|Vaccine injected intramuscularly
157179|NCT01803282|Drug|Pemetrexed|Pemetrexed administered intravenously on Day 1 of each 21-day treatment cycle
157180|NCT01803282|Drug|Leucovorin|Leucovorin administered intravenously on Days 1 and 15 of each 28-day treatment cycle
156608|NCT01807260|Procedure|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
156609|NCT01807273|Other|Walking test|
156610|NCT01807286|Drug|Pomalidomide|Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.
Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I.
156611|NCT01807286|Drug|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
156612|NCT01807286|Drug|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
156613|NCT01807286|Behavioral|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
156614|NCT01807299|Dietary Supplement|Omega 3|
156615|NCT01807299|Other|Physical Training|
156616|NCT01807312|Device|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
156617|NCT00001986|Drug|1-Octanol|
156618|NCT00101010|Drug|Cyclophosphamide|750 mg/m^2 IVPB on day 1
156921|NCT01802762|Device|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
156922|NCT01802775|Drug|edoxaban|
156923|NCT01802775|Drug|Clopidogrel|75mg tablet
156924|NCT01802775|Drug|Aspirin|
156925|NCT01802788|Device|St Jude Medical Portico replacement aortic valve|
156926|NCT01802788|Procedure|Transcatheter Aortic Valve Implant|
156927|NCT01802801|Other|embryo development|intra- and inter-observator analysis
156928|NCT00100620|Drug|Zoledronic Acid|
156929|NCT01802814|Drug|SR-A + Epratuzumab|
156930|NCT01802814|Drug|SR-B + Epratuzumab|
156313|NCT01804218|Drug|Placebo|
156314|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
156315|NCT01804244|Drug|TMC278|1 25-mg tablet [27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
156316|NCT01804257|Device|Digital Health Feedback System|
156317|NCT01804270|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
156318|NCT01804283|Procedure|ischemic postconditioning|multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult
Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest.
156319|NCT01804283|Procedure|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
156320|NCT01806675|Procedure|positron emission tomography|Undergo 18F FPPRGD2 PET/CT or PET/MRI
156321|NCT01806675|Procedure|computed tomography|Undergo 18F FPPRGD2 PET/CT or PET/MRI
156322|NCT01806675|Procedure|positron emission tomography|Undergo 18F FDG PET/CT
156323|NCT01806675|Procedure|computed tomography|Undergo 18F FDG PET/CT
156324|NCT01806675|Other|laboratory biomarker analysis|Correlative studies
156325|NCT01806688|Other|snack|
156326|NCT01806701|Behavioral|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
156327|NCT01806714|Other|Text-based reminder for recommended HPV vaccine or well care visit|
156328|NCT01806714|Other|Non-specific text-based reminder (general health tip)|
156329|NCT00100971|Drug|autologous tumor cell vaccine|
156330|NCT01806727|Behavioral|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
156331|NCT01806727|Behavioral|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
158193|NCT01773889|Drug|Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a|
158194|NCT01773902|Dietary Supplement|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
158195|NCT01776476|Other|Placebo|normal saline of equivalent volume to the experimental drug infusion administered as a continuous infusion over 24 hours for up to 7 days or ICU discharge, whichever comes first
158196|NCT01776476|Procedure|Surgery|
158197|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
158198|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
158199|NCT01776528|Biological|NGM282|
158200|NCT01776528|Biological|Placebo|
158201|NCT01776541|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
156038|NCT01803607|Other|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
156039|NCT01803633|Other|Cheddar cheese|Tillamook medium cheddar cheese brand
156040|NCT01803633|Other|Vegan cheese|Daiya brand vegan cheese
156041|NCT01803646|Drug|AM-101|AM-101 gel for intratympanic injection
156042|NCT01803646|Drug|Placebo|Placebo gel for intratympanic injection
156043|NCT00100711|Drug|Motexafin Gadolinium|
156044|NCT01803659|Dietary Supplement|b-carotene|
156045|NCT01803659|Dietary Supplement|retinyl palmitate|
156046|NCT01803659|Dietary Supplement|placebo|
156047|NCT01803672|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
156048|NCT01803672|Behavioral|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
156049|NCT01803698|Behavioral|Training in the use of IOM charts|
155755|NCT01753830|Device|Durolane|
155756|NCT00095927|Radiation|radiation therapy|Given once daily for 4 weeks and then twice daily for 2 weeks.
155757|NCT01753830|Device|PBS|
155758|NCT01753843|Procedure|early cord clamping|early ( <20 seconds)
155759|NCT01753843|Procedure|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
155760|NCT01753856|Drug|Teriparatide|Administered SC
155761|NCT01753856|Drug|Denosumab|Administered SC
155762|NCT01753856|Drug|Demeclocycline|Administered orally
155763|NCT01753856|Drug|Tetracycline|Administered orally
155764|NCT01753856|Drug|Calcium Supplement|Administered orally
155765|NCT01753856|Drug|Vitamin D|Administered orally
155766|NCT01753869|Procedure|Airways clearance and Hypertonic saline inhalation|
155767|NCT00001864|Drug|Atropine|
155768|NCT00095940|Drug|lapatinib ditosylate|Given orally
155769|NCT01753882|Drug|Lexapro|Agent + training vs Placebo + training
155770|NCT01753882|Drug|Placebo|Agent + training vs Placebo + training
155771|NCT01753908|Drug|Broccoli Sprout Extract|Given PO
156082|NCT01808690|Drug|Placebo|
156083|NCT01808703|Device|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
156084|NCT01808703|Procedure|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
156085|NCT01808716|Device|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
158005|NCT01773538|Other|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
158006|NCT01773551|Other|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
158007|NCT01773590|Other|Rhinovirus Infection|
158008|NCT01773603|Device|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
158009|NCT01773616|Drug|Oral prednisolone|
158010|NCT00097747|Drug|peginesatide|
158011|NCT01773616|Drug|Rituximab|
158012|NCT01773616|Drug|Mycophenolate mofetil|
158013|NCT01776086|Behavioral|Neurological testing|
158014|NCT00097981|Drug|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
158015|NCT01776099|Dietary Supplement|Dietary supplement (4 arms, 2 active, 2 placebo)|
158016|NCT01776112|Other|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
158017|NCT01776112|Other|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
158018|NCT01776125|Other|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
158019|NCT01776138|Other|Collect Blood and Survey Instruments|
158020|NCT01776190|Device|UVA1 radiation treatment|
158021|NCT01776203|Drug|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
158022|NCT01776216|Other|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
157406|NCT01780883|Drug|melatonin|
157407|NCT00098488|Drug|tanespimycin|Given IV
157408|NCT01780883|Drug|Placebo|Placebo tablets of Circadin®
157409|NCT01780909|Drug|Paromomycin Sulfate Fasted State|
157706|NCT01773070|Drug|ABT-450/ritonavir|Drug is not administered -- this study is follow-up for subjects previously receiving the drug.
157707|NCT01773070|Drug|ABT-333|Drug is not administered -- this study is follow-up for subjects previously receiving the drug.
157708|NCT01773070|Drug|ABT-267|Drug is not administered -- this study is follow-up for subjects previously receiving the drug.
157709|NCT01773083|Drug|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
157710|NCT01773083|Drug|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
157711|NCT01773096|Drug|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
157712|NCT01775501|Drug|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
157713|NCT01775501|Drug|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
157714|NCT01775501|Drug|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
157715|NCT01775501|Drug|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
157716|NCT01775527|Other|blood test|
157717|NCT01775540|Drug|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
157718|NCT00097903|Drug|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
157719|NCT01775540|Drug|Saline solution|Saline solution,1 drop used QID for 4 weeks
157720|NCT01775540|Drug|Maxidex|Eyedrop-1 drop QID for 4 weeks
157721|NCT01775553|Drug|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
157128|NCT01808170|Procedure|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
157129|NCT01808170|Procedure|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
157130|NCT01808183|Device|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
157432|NCT01772628|Behavioral|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
157433|NCT01772628|Behavioral|STI/HIV prevention education|For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing "youth friendly" Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration.
157434|NCT01772628|Behavioral|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
157435|NCT00097643|Behavioral|exercise|
157436|NCT01772628|Behavioral|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
157437|NCT01775072|Genetic|Clinical Germline Analysis|Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the "ACMG list").
166949|NCT01830127|Drug|Faldaprevir|24 Weeks
166950|NCT00103272|Drug|bortezomib|Given IV
166951|NCT01830140|Drug|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
166952|NCT01830140|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
166953|NCT01830153|Drug|RAD001|
166954|NCT01830166|Radiation|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
166955|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
166956|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
166957|NCT01830205|Drug|Daclatasvir|
166958|NCT01830218|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
166959|NCT01830231|Drug|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
166960|NCT01822600|Drug|Omeprazole|After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca AB, Södertälje, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.
After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.
After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up.
167255|NCT01825473|Drug|Erythromycin|
167256|NCT01825473|Device|Multi-channel intra-luminal impedance (MII) pH monitoring|
167257|NCT01825473|Drug|Placebo (D5W)|
167258|NCT01825486|Behavioral|accidental falls|
167259|NCT01825499|Other|Registry|
167260|NCT01825512|Drug|Deferiprone|Deferiprone 80 mg/mL oral solution
167261|NCT00102856|Drug|Rivastigmine|
167262|NCT01825512|Drug|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
167263|NCT01825525|Device|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
166628|NCT01827020|Drug|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
166629|NCT01827020|Drug|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
166630|NCT01827020|Drug|Saline|12 mL saline (0.9% isotonic solution)
166631|NCT01827033|Behavioral|meditation training|
166632|NCT01827046|Drug|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
166633|NCT00002003|Drug|Mitoxantrone hydrochloride|
166634|NCT00102986|Drug|Lopinavir/ritonavir|
166635|NCT01827059|Drug|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
166636|NCT01827059|Drug|Placebo|
166637|NCT01827072|Drug|NPB-01|
166638|NCT01827085|Device|Conventional Macintosh laryngoscope|
166639|NCT01827085|Device|Stortz videolaryngoscope|
166640|NCT01827098|Procedure|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
166641|NCT01827111|Drug|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
166642|NCT01827111|Drug|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
166643|NCT01829464|Drug|TAK-875|TAK-875 tablets
166961|NCT01822613|Drug|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
166962|NCT01822613|Drug|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
166963|NCT01822613|Drug|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
166964|NCT01822613|Drug|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
166342|NCT01823848|Drug|Sodium phosphate enema|Rectally administered medication to treat constipation
166343|NCT01823848|Drug|Normal saline enema|Rectally administered medication to treat constipation
166344|NCT01823848|Drug|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
166345|NCT01823861|Behavioral|Mobile phone-based intervention|Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
166346|NCT01823874|Procedure|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
166347|NCT01823887|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
166348|NCT01823900|Drug|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
166349|NCT01823900|Drug|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
166350|NCT01823913|Drug|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
166351|NCT00002001|Drug|Didanosine|
166352|NCT00102674|Drug|cangrelor|
166353|NCT01823913|Drug|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
166354|NCT01823926|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
166355|NCT01823926|Device|Jet nebulizer|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a "T" piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min.
166356|NCT01823926|Device|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
166644|NCT01829477|Drug|TAK-875|TAK-875 50 mg tablets
166645|NCT01829477|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
166646|NCT01829477|Drug|Glimepiride|Glimepiride tablet.
165751|NCT01833390|Drug|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
165752|NCT01833403|Device|Hyperinsulinemic-euglycemic clamp|Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery
165753|NCT01833403|Drug|Glucose|
166043|NCT01828606|Device|coban 2 system|All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment
According to protocol the materials are applied to the whole leg and the measuring devices are put in place
166044|NCT01831037|Other|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
166045|NCT01831050|Biological|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
166046|NCT01831050|Biological|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
166047|NCT01831050|Biological|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
166048|NCT01831050|Biological|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
166049|NCT01831050|Biological|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
166050|NCT00103298|Drug|FOLFOX regimen|
166051|NCT01831050|Biological|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India [SII]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
166052|NCT01831063|Behavioral|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
166053|NCT01831076|Drug|Exemestane|Given PO
165458|NCT01840098|Dietary Supplement|Control/carbohydrate|
165459|NCT01840098|Behavioral|36 hour fasting|
165460|NCT01840111|Behavioral|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
165461|NCT01840111|Behavioral|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
165462|NCT00104286|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
165463|NCT01840124|Procedure|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
165464|NCT01840137|Other|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
165754|NCT01833442|Behavioral|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
165755|NCT00002008|Drug|Sargramostim|
165756|NCT00103428|Biological|CG7870|
165757|NCT01835899|Drug|BI 1015550|medium dose 1 powder for oral solution
165758|NCT01835899|Drug|BI 1015550|medium dose 2 powder for oral solution
165759|NCT01835899|Drug|BI1015550|low dose 2 powder for oral solution
165760|NCT01835899|Drug|BI 1015550|low dose 1 powder for oral solution
165761|NCT01835912|Other|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
165762|NCT01835925|Genetic|Tissue specimen|
165763|NCT00103727|Other|risperidone|Active Comparator
165764|NCT01835938|Drug|1- Erlotinib|Erlotinib 50 mg tablet by mouth every day for 14 days,
Erlotinib 100 mg tablet by mouth every day for 14 days,
Erlotinib 150 mg tablet by mouth every day for 14 days,
165765|NCT01835938|Drug|placebo|Placebo 50 mg tablet by mouth every day for 14 days,
Placebo 100 mg tablet by mouth every day for 14 days,
Placebo 150 mg tablet by mouth every day for 14 days,
165766|NCT01835951|Other|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
153692|NCT01763502|Other|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
153693|NCT01763515|Procedure|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
153694|NCT01763528|Other|nutrition intervention|high protein diet
153695|NCT01763541|Drug|leuprolide acetate|Given to both arms to induce hypogonadism
153696|NCT01763541|Drug|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
154010|NCT00096850|Drug|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
154011|NCT01766466|Drug|Ticagrelor|Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion
Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.
154012|NCT01766479|Radiation|CT colonography|
154013|NCT01766492|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
154014|NCT01766505|Drug|Candemore tablet|Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.
dosage is depends on the sitting blood pressure.
154015|NCT01766505|Drug|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
154016|NCT01766518|Drug|Mycophenolate mofetil|MY-REPT capsule 500~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
154017|NCT01766531|Device|body bioelectrical impedance|
154018|NCT01766544|Other|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
154019|NCT01766544|Other|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
154020|NCT01768780|Device|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.
A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.
For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle.
153450|NCT01765426|Device|PharmaJet Injector|
153451|NCT01765439|Dietary Supplement|VSL#3|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
153452|NCT01765452|Drug|Closone|75mg/100mg, 8weeks, PO
153453|NCT01765452|Drug|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
153454|NCT01765465|Drug|Rowachol|
153455|NCT01765465|Drug|Placebo|
153456|NCT01765478|Drug|HM71224 single ascending dose|
153457|NCT01765478|Drug|HM71224 food effect|
153458|NCT00096720|Procedure|[123I]ß-CIT and SPECT imaging|
153459|NCT01765478|Drug|HM71224 Multiple ascending dose|
153460|NCT01765491|Other|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
153461|NCT01765491|Other|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
153763|NCT01768546|Behavioral|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
153764|NCT01768546|Behavioral|Interactive tracking and problem solving web portal|
153765|NCT01770769|Device|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
153766|NCT01770782|Procedure|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
153767|NCT00097357|Drug|Apixaban Placebo|Tablets, Oral, BID, 12 +/- 2 days
153768|NCT01770782|Other|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
153769|NCT01770795|Drug|Genexol-PM/Gemcitabine|
153770|NCT01770808|Dietary Supplement|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
154460|NCT01759927|Behavioral|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
154461|NCT01759940|Drug|ropivacaine 0,375%|
154462|NCT01759940|Drug|ropivacaine 0,75%|
154463|NCT01759953|Other|Game|InsuOnline game, on the web, in the player´s own time and rhythm
154464|NCT01759953|Other|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
154465|NCT01751438|Other|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
154466|NCT01751438|Other|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
154467|NCT01751438|Behavioral|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
154468|NCT00095771|Radiation|radiation therapy|
154469|NCT01751438|Other|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
154470|NCT01751451|Drug|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
154471|NCT01751451|Drug|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
154472|NCT01751451|Drug|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
154473|NCT01751464|Behavioral|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
157181|NCT01803282|Drug|Oxaliplatin|Oxaliplatin administered intravenously on Days 1 and 15 of each 28-day treatment cycle
157182|NCT01803282|Drug|5-FU|5-FU administered intravenously on Days 1 and 15 of each 28-day treatment cycle
157183|NCT00001972|Drug|15 O Water|
157184|NCT00100854|Drug|fulvestrant|Given intramuscularly
157185|NCT01805752|Other|POC CD4+ cell count testing|
157489|NCT01781000|Behavioral|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
157490|NCT01781000|Behavioral|Treatment as usual|standard treatment protocol of schizophrenia ward
157491|NCT01781013|Other|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
157492|NCT01781026|Drug|Vemurafenib|Single arm trial
157493|NCT00098501|Drug|pelitinib|
157494|NCT01781052|Drug|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
157495|NCT01781065|Device|transcranial direct current stimulation|
157496|NCT01781078|Radiation|MRI|The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
157497|NCT01781078|Device|ImageReady System implant|Pacemaker and lead(s) implant
157498|NCT01781091|Device|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
157499|NCT01781091|Device|Conventionals Modes|
157500|NCT01781104|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
157501|NCT01781104|Drug|Placebo|Placebo delivered subcutaneously once daily for 14 days.
157502|NCT01781117|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
156931|NCT01802840|Dietary Supplement|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
156932|NCT01802853|Drug|RO6811135|Single subcutaneous dose
156933|NCT01802853|Drug|RO6811135|Single intravenous dose
156934|NCT01802866|Drug|ACU-4429|Take orally once daily for 24 months
156935|NCT01802866|Drug|Placebo|Take orally once daily for 24 months
156936|NCT01802879|Drug|Panobinostat|single agent panobinostat starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications are at the discretion of the investigator based on guidance provided in the protocol and IB.
156937|NCT01802892|Drug|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
156938|NCT01802892|Drug|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
156939|NCT00100633|Drug|CpG7909 oligodeoxynucleotides (ODN)|
156940|NCT01802892|Drug|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
156941|NCT01802905|Genetic|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
156942|NCT01802918|Drug|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
156943|NCT01802918|Drug|Placebo|Visually matching GSK2838232
157211|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10^10 vp
157212|NCT01805921|Biological|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10^9 vp
157213|NCT01808248|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
157214|NCT01808261|Drug|GSK249320 100/mg|clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial)
157215|NCT01808261|Drug|Placebo|Placebo is a clear, colorless
157216|NCT01808274|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
156332|NCT01806740|Drug|Meglumine Gadoterate|DCE-MRI is a method to measure the evaluated response
156641|NCT01809743|Drug|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
156642|NCT01809756|Other|Caphosol|Caphosol 4 times a day
156643|NCT01809769|Biological|Mesenchymal progenitor cells|Biological: Adipose tissue derived mesenchymal progentior cells administrated for intra-articular use
156644|NCT01809795|Other|Blueberry Smoothie|
156645|NCT01809795|Other|Sham Smoothie|
156646|NCT00101140|Procedure|bone marrow ablation with stem cell support|
156647|NCT01811862|Procedure|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
156648|NCT01811862|Procedure|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
156649|NCT01811875|Biological|Optivate 500IU|
156650|NCT01811888|Behavioral|Quantitative sensory testing (QST)|
156651|NCT01811901|Other|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
156652|NCT01811914|Other|intraoperative TTE|
156653|NCT01811927|Device|PRO-Kinetic Energy Stent|Bare-metal stent
156654|NCT00001993|Drug|Butyldeoxynojirimycin|
156655|NCT00101309|Biological|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
156656|NCT01811940|Drug|Adderall-ER|MAS-ER 60mg/day
156657|NCT01811940|Drug|Topiramate|Topiramate 100 mg bid.
156050|NCT01803711|Drug|Desvenlafaxine|
156051|NCT01803711|Dietary Supplement|Omega 3 Fatty acids|
156052|NCT01803711|Drug|Placebo (for Omega 3 fatty acid supplement)|
156053|NCT01803737|Behavioral|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
156054|NCT00100724|Biological|rPA102|
156055|NCT00100893|Dietary Supplement|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
156056|NCT01806129|Other|questionnaire administration|Ancillary studies
156057|NCT01806129|Procedure|quality-of-life assessment|Ancillary studies
156058|NCT01806142|Other|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
156059|NCT01806142|Other|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
156356|NCT01809184|Drug|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
156357|NCT01809184|Drug|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
156358|NCT01809184|Drug|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
156359|NCT01809197|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
156360|NCT01809197|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
156361|NCT01809197|Device|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
156362|NCT01809197|Device|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
156363|NCT01809210|Drug|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
156086|NCT01808742|Device|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
156087|NCT01808755|Dietary Supplement|D Mannose|1 gr. every 8 hours
156088|NCT01808755|Drug|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
156089|NCT01808768|Drug|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
156090|NCT00101101|Biological|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
156091|NCT01808781|Other|Exercises plus walking program|Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become "somewhat active" or "active" by the end of the 8-week intervention.
156092|NCT01808781|Other|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
156093|NCT01808794|Device|Mucograft|Mucograft Collagen Matrix
156094|NCT01808794|Device|Dynamatrix|Dynamatrix
156095|NCT01808820|Biological|Dendritic Cell Vaccine|Subjects will begin to receive DC vaccination alone, when recovered from pheresis and continue weekly for a total of four vaccinations. The vaccination with loaded DC will be given in the clinic as an intradermal injection in the upper arms. DC will be delivered with each vaccination in 6 separate syringes (3 syringe injections per arm within the area of approximately the size of a silver dollar spaced approximately equally) alternating between anterior and posterior deltoid. For subjects who are missing limbs (e.g., arms), the injection sites will be rotated between the arms and thighs (alternating anterior and lateral thigh) with anterior and posterior deltoid. For subjects who do not have an accessible deltoid, both legs will be used. All injections with DC or lysate will be done after topical treatment with imiquimod to the site of injection the day prior to injection, which will then be applied for two nights after the injection to the sites.
156397|NCT01804296|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
156398|NCT00100776|Drug|Olanzapine|
156399|NCT01804309|Procedure|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
155796|NCT01756781|Drug|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
155797|NCT01756781|Drug|Midazolam|Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
Treatment A includes a single 2 mg oral dose of midazolam alone.
155798|NCT01756781|Drug|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
155799|NCT01756794|Procedure|Liver transplantation|
155800|NCT00096135|Drug|dexamethasone|oral twice daily
155801|NCT00096265|Radiation|stereotactic radiosurgery|Patients undergo surgery after radiation therapy
155802|NCT01759706|Behavioral|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
155803|NCT01759706|Drug|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
155804|NCT01759719|Device|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
155805|NCT01759732|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -4
155806|NCT01759732|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
155807|NCT01759732|Biological|anti-thymocyte globulin|
155808|NCT01759732|Biological|filgrastim|
155809|NCT01759732|Radiation|Total body irradiation|200 cGy per day on D-5 & -4
155810|NCT01759732|Procedure|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
155811|NCT01759758|Other|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
155812|NCT00096265|Drug|temozolomide|Given orally
155813|NCT01759758|Other|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
155814|NCT01759771|Drug|Vitamin D3|4,000 IU of VD3 for at least one year
155815|NCT01759771|Drug|Placebo|Placebo for at least one year
155816|NCT01759784|Biological|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
157722|NCT01775579|Drug|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
157723|NCT01775592|Drug|Arterakin (DHA-PPQ)|
157724|NCT01775605|Drug|Synera|Synera Pain Patch
157725|NCT01775618|Biological|BAY94-9027|Prophylaxis treatment 25-60 IU/kg at least 1x/week.
157726|NCT01775618|Biological|BAY94-9027|Prophylaxis treatment 25-60 IU/kg 2x/week for 12 weeks.
157727|NCT01775631|Biological|Urelumab|
158040|NCT01779284|Drug|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
158041|NCT01779323|Other|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
158042|NCT01779336|Drug|PL225B|Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.
This 21 day administration will define a treatment cycle.
Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified.
158043|NCT01779349|Device|Dynamic Urine Vibration "Holter"|each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration "Holter" and then urodynamically by pressure flow study
158044|NCT01779362|Drug|Metformin|Titrated to 1000 mg BID
158045|NCT01779362|Drug|Liraglutide|Titrated to 1.8 mg/day
158046|NCT01779362|Drug|Glargine|Titrated to target fasting glucose <90 mg/dl
158047|NCT00098319|Drug|Folic acid (0.4mg vs. 4.0mg)|
158048|NCT01779362|Drug|Placebo|Matching to metformin 1000 mg BI
158049|NCT01779375|Drug|Metformin|
158050|NCT01779375|Drug|Glargine|
158051|NCT01779388|Procedure|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
158052|NCT01779401|Drug|Clopidogrel 75mg|
158053|NCT01779401|Drug|Clopidogrel 150mg|
158054|NCT01779401|Drug|Aspirin 100mg|
158055|NCT01779401|Drug|Cilostazol 100mg|
157438|NCT01775085|Behavioral|manualized group intervention|MCG-BCS manual outlines 8, 90-minute modules: 1) Concepts & Sources of Meaning; 2) Identity, Cancer Survivorship, & Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present & Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity & Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, & Humor; and 8) Transitions: Reflections & Hopes for the Future.
157439|NCT01775085|Behavioral|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
157440|NCT01775098|Drug|allopurinol|
157441|NCT01775111|Behavioral|Cognitive Training|
157442|NCT01775111|Behavioral|Strength Training|
157443|NCT01775111|Dietary Supplement|FortiFit|
157444|NCT01775124|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
157445|NCT01775137|Drug|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
157751|NCT01778855|Other|IV t-PA and normothermia|
157752|NCT01778855|Device|IV-tPA and hypothermia|
157753|NCT01778881|Other|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
157754|NCT01778881|Other|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
157755|NCT01778881|Other|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
157756|NCT01778881|Other|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
157757|NCT00098293|Drug|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
157758|NCT01778907|Other|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
157759|NCT01778920|Drug|EC17|
157760|NCT01778933|Drug|EC17|
167264|NCT01825551|Drug|Granulocyte Colony Stimulating Factor|
167265|NCT01825551|Drug|Placebo|
167266|NCT01825577|Drug|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
167267|NCT01825590|Other|Dialysate and serum sodium concentration aligned|
167268|NCT01825603|Drug|ADH-1|Given IV
167269|NCT01825603|Drug|cisplatin|Given IV
167270|NCT01825603|Drug|gemcitabine hydrochloride|Given IV
167271|NCT01825603|Other|laboratory biomarker analysis|Correlative studies
167272|NCT00102869|Drug|levodopa|100mg levodopa per day over 10 days/ treatment phase
167273|NCT01827995|Other|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
167274|NCT01827995|Other|Routine assessment|Follow up in the clinic
167275|NCT01828021|Biological|Margetuximab|Anti-HER2 monoclonal antibody
167276|NCT01828034|Drug|Gemcitabine|
167277|NCT01828034|Drug|Cisplatin|
167593|NCT01858662|Drug|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
167594|NCT01858675|Other|Biomarkers, red blood cells and plasma assessment|
167595|NCT00106158|Biological|protein vaccination|
167596|NCT01858688|Device|Multiparametric MRI|an MRI of the prostate will be performed
167597|NCT01858688|Procedure|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
167598|NCT01858701|Device|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
166965|NCT01822613|Drug|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
166966|NCT01822626|Behavioral|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
166967|NCT00102479|Drug|Aripiprazole|
166968|NCT01822639|Drug|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
166969|NCT01822639|Drug|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
166970|NCT01822639|Drug|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
166971|NCT01822652|Genetic|iC9-GD2 T Cell Lymphocytes-frozen cells|Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.
Subjects will receive one of the following dose levels (cells/m2):
Dose Level 1 = 1 x 10^7
Dose Level 2 = 1 x 10^8
Dose Level 3 = 2 x 10^8
Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
166972|NCT01822652|Genetic|iC9-GD2 T Cell Lymphocytes-fresh cells|For subjects who will receive a fresh T cell product:
Dose Level 1 = 1 x 10^8
Dose Level 2 = 1.5 x 10^8
Dose Level 3 = 2 x 10^8
Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
166973|NCT01822652|Drug|Cyclophosphamide|Cyclophosphamide (500 mg/m2/day x 2 days, for patients <12 kg = 16.7 mg/kg/day x 2 days)
166974|NCT01822652|Drug|Fludarabine|Fludarabine (30 mg/m2/day x 3 days, for patients <12 kg = 1 mg/kg/day x 3 days)
166975|NCT01822652|Drug|pembrolizumab|pembrolizumab (2 mg/kg on Day -1 and on Day 21).
166976|NCT01824901|Drug|AZD4547|Given PO
167278|NCT01828034|Drug|MEK162|
167279|NCT01828047|Device|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
167280|NCT01828060|Dietary Supplement|Jobelyn™|Sorghum bicolor leaf sheath extract
167281|NCT00103103|Drug|bortezomib|
166647|NCT01829490|Biological|ChAdOx1 85A|Intramuscular injection
166648|NCT01829490|Biological|MVA85A|Intramuscular injection
166649|NCT01829503|Drug|decitabine and cytarabine|
166650|NCT01829503|Other|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
166651|NCT01829516|Drug|Oxytocin|
166652|NCT01829516|Drug|Placebo|
166653|NCT00103233|Biological|trastuzumab|
166654|NCT01829529|Drug|Amoxicillin|Amoxicillin
166655|NCT01829542|Dietary Supplement|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
166656|NCT01829542|Dietary Supplement|Control|Macro- and micro-nutrient matched control in water
166657|NCT01829555|Behavioral|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
166658|NCT01829568|Drug|Ibrutinib|Given PO
166659|NCT01829568|Other|Laboratory Biomarker Analysis|Correlative studies
166660|NCT01829568|Drug|Lenalidomide|Given PO
166661|NCT01829568|Other|Pharmacological Study|Correlative studies
166662|NCT01829568|Biological|Rituximab|Given PO
166663|NCT01829581|Other|no intervention, only descriptive data analysis|
166664|NCT00103233|Drug|vinorelbine tartrate|
166665|NCT01829594|Other|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
166666|NCT01829607|Other|Functional electrical stimulation of peripheral muscles|
166054|NCT01831089|Drug|PM01183 + paclitaxel +/- bevacizumab|PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion
paclitaxel: 6 mg/ml concentrate for solution for infusion
bevacizumab: 25 mg/ml concentrate for solution for infusion
Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients
166055|NCT01831102|Other|none- observational study|
166056|NCT01831128|Device|ASV Treatment|
166057|NCT01831154|Drug|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
166058|NCT01831154|Drug|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
166357|NCT01823939|Drug|iOWH032|Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.
Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032.
166358|NCT01823965|Drug|ranibizumab|
166359|NCT01826435|Behavioral|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
166360|NCT01826448|Drug|PLX3397|
166361|NCT01826448|Drug|vemurafenib|
166362|NCT01826461|Drug|PDI-192|
166363|NCT01826461|Drug|Vehicle|
166364|NCT01826474|Drug|PRO045, 0.15 mg/kg/week|Subcutaneous injection
166365|NCT01826474|Drug|PRO045, 1.0 mg/kg/week|Subcutaneous injection
166366|NCT00102960|Drug|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
166367|NCT01826474|Drug|PRO045, 3.0 mg/kg/week|Subcutaneous injection
166368|NCT01826474|Drug|PRO045, 6.0 mg/kg/week|Subcutaneous injection
166369|NCT01826474|Drug|PRO045, 9.0 mg/kg/week|Subcutaneous injection
165767|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
165768|NCT01835964|Procedure|Glucose Variability Observation|On the morning of ~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
165769|NCT01835977|Device|Irreversible Electroporation (Nanoknife)|
165770|NCT01835990|Device|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
165771|NCT01835990|Device|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
165772|NCT01836003|Other|Tokafatso programmatic intervention|Tokafatso programmatic intervention:
SMS-based platform for delivery of CD4 test results
Participatory educational session for clinic staff
Loan program for HIV and CD4 testing supplies
Facilitation of tracing of HAART-eligible pregnant women
166059|NCT01831154|Drug|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
166060|NCT01831167|Other|dynamic light|
166061|NCT00103298|Drug|fluorouracil|
166062|NCT01831193|Drug|Curcumin|
166063|NCT01831206|Procedure|Collagen cross-linking|Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.
Standard treatment arm will receive only standard medication.
166064|NCT01823276|Other|Placebo Bar|
166065|NCT01823289|Drug|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
166066|NCT00102622|Biological|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
166067|NCT01823302|Dietary Supplement|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
166068|NCT01823302|Other|nutritional counseling|nutritional counseling
166069|NCT01823315|Drug|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
166070|NCT01823315|Drug|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h)
154021|NCT01768793|Behavioral|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
154022|NCT01768793|Behavioral|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
154023|NCT01768806|Behavioral|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
154024|NCT00097227|Drug|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
154025|NCT01768806|Behavioral|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
154312|NCT01762254|Procedure|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
154313|NCT01762254|Procedure|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
154314|NCT00096421|Behavioral|Tight control of blood glucose levels|
154315|NCT01762267|Other|nutrition intervention|DASH diet control diet
154316|NCT01762280|Drug|Famitinib Malate Capsule|
154317|NCT01762293|Drug|Famitinib|Famitinib 25 mg p.o. qd
154318|NCT01762306|Drug|Diclofenac Potassium|
154319|NCT01762306|Drug|Folic Acid|
154320|NCT01762319|Drug|Misoprostol|
154321|NCT01762319|Drug|Vitamin B6|
154322|NCT01762332|Drug|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
154323|NCT01762332|Drug|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
153771|NCT01770808|Dietary Supplement|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
153772|NCT01770808|Dietary Supplement|Placebo|Subjects swallowed 4 capsules/day for six weeks.
153773|NCT01770821|Other|Dietary supplement and/or physical training|
153774|NCT01770860|Device|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
153775|NCT01770860|Device|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
153776|NCT01770860|Device|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
153777|NCT01770860|Device|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
153778|NCT00097370|Drug|mepolizumab|Study Drug
153779|NCT01770873|Behavioral|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
153780|NCT01770886|Drug|UE2343|Oral capsule
153781|NCT01770886|Drug|Placebo|Oral capsule
153782|NCT01770899|Drug|Montelukast|
154083|NCT01766557|Other|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
154084|NCT00096863|Drug|Ziprasidone|
154085|NCT01766557|Other|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
158092|NCT01773772|Drug|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those or = to 42 kg.
158093|NCT01776281|Behavioral|Kangaroo Mother Care|
158094|NCT01776281|Behavioral|Standard Care|
158095|NCT01776307|Drug|BBI608|BBI608 is administered at 500 mg po bid continuously.
158096|NCT01776307|Drug|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
158097|NCT01776307|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
158098|NCT01776307|Drug|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
158099|NCT00097981|Drug|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
158100|NCT01776320|Drug|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
158101|NCT01776333|Behavioral|video decision aid|
158102|NCT01776359|Dietary Supplement|High Protein|2.4g/kg of protein
158103|NCT01776359|Dietary Supplement|Low Protein|1.2g/kg of protein
158104|NCT01776372|Device|Medela Thopaz Thoracic Drainage System|
158105|NCT01776372|Device|Atrium Express Dry Seal Chest Drain|
158106|NCT01776385|Other|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
158107|NCT01776385|Other|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
158108|NCT01776411|Drug|forodesine hydrochloride|
158109|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 2.5 mg twice daily, tablet
158110|NCT00001925|Drug|Alcohol|
158111|NCT00098007|Drug|Everolimus (Certican)|
158112|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5.0 mg twice daily, tablet
158113|NCT01776424|Drug|Aspirin|Aspirin 100 mg once daily, tablet
157503|NCT01781117|Device|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
157504|NCT00098501|Drug|temsirolimus|Given PO
157505|NCT01781130|Procedure|Steroid injection|
157506|NCT01781143|Device|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
157507|NCT01772641|Other|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
157813|NCT00097929|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
157814|NCT01775761|Drug|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
157815|NCT01775761|Drug|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
157816|NCT01775774|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
157817|NCT01775787|Other|Nicotine with Tobacco Flavor|Randomly assigned to 18mg of nicotine with tobacco flavor for 7 to 10 days and then switched to other flavor for an additional 7 to 10 days.
157818|NCT01775787|Other|Nicotine with Tobacco and Menthol Flavor|Randomly assigned to 18mg of nicotine with tobacco and menthol flavor for 7 to 10 days and then switched to other flavor for an additional 7 to 10 days.
157819|NCT01775800|Other|Treatment modification|
157820|NCT01775813|Drug|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
157821|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
157822|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
157823|NCT01775852|Behavioral|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
157217|NCT01808287|Device|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
157218|NCT01808300|Drug|Pregabalin 300mg, Thioctic acid 600mg|A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days
B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days
C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B
157219|NCT00101088|Other|laboratory biomarker analysis|Correlative studies
157220|NCT01808313|Drug|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
157221|NCT01808326|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
157222|NCT01808339|Drug|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
157223|NCT01808339|Drug|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
157224|NCT01808352|Drug|FTC/TDF|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
157225|NCT01808365|Procedure|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
157226|NCT01808365|Other|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
157227|NCT01808378|Drug|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
157228|NCT01808404|Behavioral|Web-Based Guided Self-Help|The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based "lessons" in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness.
157527|NCT00097656|Other|multi-center, randomized, controled periodontal therapy|periodontal therapy
157528|NCT01775228|Behavioral|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
157529|NCT01775267|Procedure|Associating liver partition and portal vein ligation for staged hepatectomy|
157530|NCT01775267|Procedure|Portal vein embolization or ligation|
157531|NCT01775280|Radiation|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
156658|NCT01811940|Other|Placebo|Placebo
156659|NCT01811953|Drug|Empagliflozin|medium dose oral administration
156660|NCT01811953|Drug|Metformin|oral administration
156964|NCT01805401|Device|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
156965|NCT01805414|Other|Modified Carbohydrate Breakfast|
156966|NCT01805414|Other|Control Breakfast|
156967|NCT01805440|Drug|Uridine|Uridine is the active treatment in this clinical trial.
156968|NCT01805440|Drug|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
156969|NCT01805453|Drug|Losartan|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg*2/day until the halting for any reason
156970|NCT01805453|Drug|Placebo|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
156971|NCT01807806|Behavioral|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
156972|NCT01807819|Other|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
156973|NCT01807832|Other|capsaicin challenge|
156974|NCT01807845|Dietary Supplement|enriched skimmilk with VD|enriched skimmilk with VD
156975|NCT00101062|Drug|celecoxib|
156976|NCT01807845|Dietary Supplement|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
156977|NCT01807845|Dietary Supplement|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
156978|NCT01807858|Dietary Supplement|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
156979|NCT01807858|Dietary Supplement|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
156980|NCT01807858|Other|Maltodextrin|Maltodextrin
156981|NCT01807858|Dietary Supplement|İnulin|900 mg inulin per day will be given
156364|NCT01809210|Drug|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
156365|NCT00101127|Biological|pegfilgrastim|
156366|NCT01809210|Drug|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
156367|NCT01809210|Drug|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
156368|NCT01809210|Drug|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
156369|NCT01809223|Drug|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
156370|NCT01809223|Drug|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
156371|NCT01809223|Other|sham injection|sham intravitreal injection per month, fixed injection
156372|NCT01811602|Other|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
156373|NCT01811615|Other|alcohol-free experimental mouth rinse|
156374|NCT01811615|Other|alcohol-containing mouth rinsing|
156375|NCT01811628|Behavioral|Questionnaire|Questionnaire completion taking about 10-15 minutes.
156681|NCT01804868|Other|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
156682|NCT01804881|Behavioral|Lifestyle counseling|Six week program to address problematic eating
156683|NCT01804907|Behavioral|Cognitive Behavioral Therapy|
156684|NCT01804907|Behavioral|Behavioral Modification|
156685|NCT01804920|Dietary Supplement|D-serine|
156686|NCT01804933|Drug|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
156687|NCT01804946|Drug|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
156688|NCT00001968|Drug|Lamivudine|
156400|NCT01804322|Other|Standardized educational plan|The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:
The cause and nature of the adverse event and/or drug interaction
The tolerability profile of each drug present in the schedule
The clinical manifestations associated with the current drug interactions
Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule
The reasons for and the potential benefits of the suggested treatment change
An encouragement to withdraw any potentially interfering or contraindicated drug
156401|NCT01804322|Other|usual care|usual care according to the participating Epilepsy Centers
156402|NCT01804335|Drug|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
156403|NCT01804348|Device|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
156404|NCT01804361|Drug|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
156405|NCT01804361|Drug|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
156406|NCT01804374|Drug|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
156407|NCT01804374|Drug|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
156408|NCT01804387|Drug|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
156409|NCT00100789|Drug|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
156410|NCT01804387|Drug|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
156411|NCT01804400|Drug|QAW039|
156412|NCT01804400|Drug|Montelukast|
156413|NCT01804400|Drug|Placebo|
156414|NCT01804413|Drug|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
156718|NCT01809860|Drug|isavuconazole|Oral
156719|NCT01809860|Drug|sirolimus|Oral
156720|NCT01809873|Behavioral|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
155817|NCT01759797|Biological|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
155818|NCT01759810|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
156115|NCT01811264|Behavioral|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
156116|NCT01811277|Drug|SOX sequential S-1|4-6 cycles SOX followed by S-1 monotherapy until disease progression
S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
156117|NCT01803737|Behavioral|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
156118|NCT01803750|Behavioral|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
156119|NCT01803763|Drug|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
156120|NCT01803763|Drug|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
156121|NCT01803776|Behavioral|lifestyle counseling|Lifestyle intervention is based on Finnish exercise and nutrition recommendations. The children and their parents in the intervention group undergo intensive individual family-based exercise and diet intervention. They meet an exercise specialist and an authorized nutritionist, who give detailed and individualized instructions on health promoting physical activity and nutrition at months 0, 1.5, 3, 6, 12, 18, and 24 with a specific topic at each visit. After the 2-year intensive intervention period the intervention continues with yearly physical activity and dietary counseling sessions. Group-based exercise and cooking clubs are part of intervention.
156122|NCT01803789|Device|Single Kirschner Wire|
156123|NCT01803789|Device|Double Kirschner Wire|
156124|NCT01803802|Behavioral|Expressive writing|Five sessions of 30 minutes of expressive writing
156125|NCT01803828|Drug|Tadalafil|5 mg/die (1 capsule)
156126|NCT01803828|Drug|Placebo|Placebo 5mg/die (1 capsule)
158056|NCT01781936|Drug|Fluocinolone Acetonide|
158057|NCT01781949|Other|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
158058|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS <30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
155838|NCT01751373|Behavioral|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
155839|NCT00095771|Drug|arsenic trioxide|
155840|NCT01751373|Behavioral|Standard Therapy|
155841|NCT01751386|Drug|Baclofen|
155842|NCT01751386|Other|Placebo|
155843|NCT01751399|Drug|LY2605541|Administered once as single SC dose
155844|NCT01751412|Radiation|Proton Radiation|
155845|NCT01751425|Drug|Ruxolitinib|Phase I Dose Escalation Group: Ruxolitinib starting dose level 5 mg orally, twice daily.
Phase II Dose Expansion Group: Ruxolitinib starting dose level MTD from Phase I.
155846|NCT01751425|Drug|TKI|Phase I Dose Escalation Group and Phase II Dose Expansion Group: Patients continue receiving commercially available TKIs (IM, NIL or DAS) at dose they had been receiving during the last 6 months.
155847|NCT01753908|Other|Placebo|Given PO
155848|NCT01753921|Device|Nautilus Neurowave System™ (NNS)|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
155849|NCT01753921|Device|Cognitive testing|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
155850|NCT01753921|Device|MRI|MRI study of the brain will be performed at t=3months.
155851|NCT01753947|Other|Deliberate Practice|
157761|NCT01778946|Drug|Low Dose Nicotine (7mg)|
157762|NCT01778946|Drug|Moderate Dose Nicotine (14mg)|
157763|NCT01778959|Device|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
157764|NCT01781741|Radiation|stereotactic radiosurgery|Undergo SBRT
157765|NCT00098579|Drug|alvocidib|Given IV
157766|NCT01781741|Other|quality-of-life assessment|Ancillary studies
157767|NCT01781754|Procedure|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
157768|NCT01781780|Behavioral|General Nutrition Recommendations|
157769|NCT01781780|Behavioral|Breakfast Recommendation|
157770|NCT01781780|Behavioral|No Breakfast Recommendation|
157771|NCT01781793|Other|Room air (21% oxygen)|humidified room air will be inspired
157772|NCT01781793|Other|Hyperoxia (60% oxygen)|humidified hyperoxia (60% oxygen) will be inspired
158078|NCT01773629|Other|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
158079|NCT01773629|Other|Control|Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a "perinatal depression champion" for a timely formal diagnostic interview.
158080|NCT01773642|Behavioral|Cognitive behavioral intervention to support pediatric HIV disclosure|
158081|NCT01773655|Other|tumor specimens|All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).
Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome.
158082|NCT01773668|Device|Integrated sensor and infusion set.|
167599|NCT01858701|Device|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
167600|NCT01858714|Behavioral|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
167601|NCT01858714|Behavioral|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
167602|NCT01858714|Behavioral|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
167603|NCT01858727|Other|forced air warming group|30 minutes before the preoperative will use forced air warming
167604|NCT01858727|Other|control group resistive heating|do not heating group
167605|NCT01858740|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
167606|NCT00106171|Drug|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
167607|NCT01858740|Drug|Fludarabine Phosphate|Given IV
167608|NCT01858740|Other|Laboratory Biomarker Analysis|Correlative studies
167609|NCT01858740|Drug|Methotrexate|Given IV
167610|NCT01858740|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
167611|NCT01858740|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
167612|NCT01858740|Drug|Tacrolimus|Given IV or PO
167613|NCT01858740|Drug|Thiotepa|Given IV
167614|NCT01858740|Radiation|Total-Body Irradiation|Undergo TBI
167615|NCT01858753|Biological|Autologous fibroblasts|
167616|NCT01861119|Drug|Silicone gel Kelo-cort™;|
167910|NCT01854645|Drug|GFF MDI|GFF MDI administered as two puffs BID
167911|NCT01854645|Drug|GP MDI|GP MDI administered as two puffs BID
167912|NCT00105573|Behavioral|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
167913|NCT01854645|Drug|FF MDI|FF MDI administered as two puffs BID
167282|NCT01828060|Dietary Supplement|Placebo|Placebo capsules
167283|NCT01828073|Drug|Raltegravir|No study-specific drugs will be given to women or infants during this study. Women will be receiving RAL for clinical indications outside of the study.
167284|NCT01828086|Biological|CJM112|Monoclonal antibody
167285|NCT01828086|Biological|Secukinumab|Monoclonal antibody
167286|NCT01828086|Other|Placebo|Liquid for subcutaneous injection without active drug.
167287|NCT01828099|Drug|LDK378|Oral LDK378 750 mg once daily
167288|NCT01828099|Drug|Pemetrexed + cisplatin or pemetrexed + carboplatin|Pemetrexed 500 mg/m² plus cisplatin 75 mg/m² every 21 days for 4 cycles followed by pemetrexed 500 mg/m² every 21 days or pemetrexed 500 mg/m² plus carboplatin AUC 5-6 every 21 days for 4 cycles followed by pemetrexed 500 mg/m² every 21 days
167289|NCT01828112|Drug|LDK378|Oral LDK378 750 mg once daily
167290|NCT01828112|Drug|pemetrexed|pemetrexed is 500 mg/m2 IV every 21 days
167291|NCT01828112|Drug|docetaxel|docetaxel is 75 mg/m2 every 21 days
167292|NCT00103103|Drug|fluorouracil|
167293|NCT01828125|Procedure|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-[6,6-2H2] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-[6,6-2H2] glucose. A third catheter will be inserted for sampling. D-[6,6-2H2] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
167294|NCT01828125|Drug|Glucagon|
167295|NCT01858207|Procedure|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
167296|NCT01858207|Drug|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
167297|NCT01858233|Behavioral|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
167617|NCT01861119|Drug|Onion extract gel Contractubex™|
167618|NCT00106392|Drug|Placebo|oral
166977|NCT01824914|Device|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
166978|NCT01824927|Procedure|First eye (FE)|Phacoemulsification cataract extraction surgery
166979|NCT01824927|Procedure|Second eye (SE)|Phacoemulsification cataract extraction surgery
166980|NCT01824927|Drug|Steroids eye drops|Use steroids eye drops to decrease the pain.
166981|NCT01824940|Behavioral|Standard care|Standard Care:
Exclusive breastfeeding promotion for all infants, birth to 6 months
Strengthened PMTCT (prevention of mother to child transmission of HIV) services
Strengthened Village Health Worker system
166982|NCT01824940|Other|WASH|WASH:
Standard care interventions
Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space
Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths.
166983|NCT01824940|Dietary Supplement|Nutrition|IYCF:
Standard care interventions
Provide 20 g/d Nutributter from 6-18 months
Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness.
166984|NCT01824940|Other|WASH and Nutrition|Sanitation/Hygiene AND Nutrition:
Standard care interventions
All WASH interventions
All IYCF interventions
166985|NCT01824979|Device|CPAP mask ( Pilairo)|
166986|NCT00102804|Drug|Pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV) administration, every (q) 21 days, until disease progression
166987|NCT01824979|Procedure|Other CPAP mask|
166988|NCT01824992|Drug|Yallaferon®|
166989|NCT01825018|Behavioral|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
166990|NCT01825018|Behavioral|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
166991|NCT01825031|Drug|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
166992|NCT01825031|Drug|Fluconazole|100mg once daily for 12 weeks
166993|NCT01825031|Drug|Azithromycin|500mg once daily for 5 days
166370|NCT01826474|Drug|PRO045, selected dose|Subcutaneous injection
166371|NCT01826487|Drug|Ataluren|
166372|NCT01826487|Drug|Placebo|
166373|NCT01826500|Other|blood test|blood test
166374|NCT01826513|Device|Modified AutoSet algorithm|An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
166375|NCT01826526|Device|TauroSept®|5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.
The duration of TauroSept® administration in this trial will be 12 months.
166376|NCT01826539|Procedure|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
166377|NCT00102960|Drug|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
166667|NCT01829620|Behavioral|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
166668|NCT01829620|Behavioral|CCVT+TAU|Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, & 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.
Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures.
166669|NCT01832233|Procedure|Symplicity Renal Denervation System|Symplicity Renal Denervation System consists of two main components: the Symplicity Catheter; and the Symplicity Radio Frequency Generator.The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
166670|NCT01832259|Drug|Pazopanib|Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
166671|NCT00103363|Other|physiologic testing|
166672|NCT01832259|Other|Placebo|Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
166673|NCT01832272|Procedure|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
166674|NCT01832285|Drug|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
166675|NCT01832298|Drug|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
166071|NCT01823315|Biological|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
166072|NCT01823328|Drug|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
166073|NCT01823328|Drug|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
166074|NCT01823341|Device|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
166075|NCT01823354|Other|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
166076|NCT01823354|Other|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
166077|NCT00102622|Drug|Paclitaxel|80 mg/m^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
166078|NCT01823354|Other|Assessment of executive functions|Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility "reactive"), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing).
166378|NCT01826552|Device|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
166379|NCT01826552|Device|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
166380|NCT01826565|Procedure|Rotational technique|90 degree rotation
166381|NCT01826578|Procedure|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
166382|NCT01826591|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
166383|NCT01826591|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
166384|NCT01829009|Other|Resistance Exercise Group|An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.
Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24
166385|NCT01829022|Procedure|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
166386|NCT00103181|Radiation|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
154324|NCT00096590|Procedure|study of high risk factors|
154325|NCT01764620|Other|Elastic taping applied without tension|
154326|NCT01764620|Other|Fatigue protocol|
154327|NCT01764633|Biological|Evolocumab (AMG 145)|Evolocumab (AMG 145)
154328|NCT01764633|Other|Placebo|Placebo
154329|NCT01764633|Drug|Effective statin therapy|Effective statin therapy defined as greater than or equal to atorvastatin 20 mg or an equivalent statin
154330|NCT01764646|Radiation|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
154331|NCT01764646|Radiation|Volumetric modulated arc therapy|Highly conformational dose distribution
154332|NCT01764646|Radiation|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
154333|NCT01764672|Drug|Methylphenidate|Oral dose 40mg (2 x 20mg)
154334|NCT01764672|Other|Placebo|Oral intake of 2 placebo tablets
153382|NCT01767740|Device|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
153383|NCT01767740|Device|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
153384|NCT00097071|Drug|insulin lispro|
153385|NCT01767753|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
153386|NCT01767766|Drug|TGR-1202|TGR-1202 Daily Oral Dose
153387|NCT01767792|Drug|Bevacizumab|Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising "clinical benefit") will transition to maintenance therapy with bevacizumab.
During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance).
153388|NCT01767805|Procedure|Standard incubator|
153389|NCT01767805|Procedure|Mini incubator|
153390|NCT01767805|Procedure|5% oxygen|
153391|NCT01767805|Procedure|20% oxygen|
154086|NCT01766570|Other|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
154087|NCT01766570|Other|Placebo|
154088|NCT01766583|Drug|CC-292 + lenalidomide|CC-292 + lenalidomide
154089|NCT01766596|Procedure|Optical Coherence Tomography|
154090|NCT01766609|Drug|Triamcinolone Acetonide|
154091|NCT01766622|Drug|[18F]-CP18|7mCi, IV (in the vein) at baseline
154092|NCT01766622|Procedure|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third [18F]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
154093|NCT01766648|Device|Far Cortical locking screw fixation|Standard locking screw fixation
154094|NCT01766648|Device|Standard locking screw fixation|
154095|NCT00096863|Drug|Haloperidol|
154096|NCT01766661|Procedure|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
154097|NCT01766661|Procedure|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
154393|NCT01762332|Other|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
154394|NCT00096421|Behavioral|Conventional control of glucose levels|
154395|NCT01762345|Device|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter & Gamble
154396|NCT01762358|Other|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
154397|NCT01762358|Other|Physiotherapy|Twelve times standardized Physiotherapy
154398|NCT01762371|Other|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
158114|NCT01776424|Drug|Aspirin placebo|Placebo(1), matching Aspirin tablets
158115|NCT01776424|Drug|Rivaroxaban placebo|Placebo(2), matching Rivaroxaban tablets
155895|NCT00101101|Drug|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
155896|NCT01808482|Drug|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
155897|NCT01808495|Drug|Mitomycin C|
155898|NCT01808508|Device|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
155899|NCT01808508|Device|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
155900|NCT01808521|Drug|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
155901|NCT01808534|Drug|palifosfamide|Given IV
155902|NCT01808547|Drug|ISV-303|
155903|NCT01808547|Other|DuraSite Vehicle|
155904|NCT01808560|Device|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
155905|NCT01808560|Device|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
155906|NCT00101101|Drug|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
155907|NCT01808573|Drug|neratinib|240 mg orally, once daily with food, continuously in 21 day cycles
155908|NCT01808573|Drug|capecitabine|1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal. Taken on days 1 to 14 of each 21 day cycle.
155909|NCT01808573|Drug|lapatinib|1250 mg orally, once daily, continuously in 21 day cycles
155910|NCT01810796|Drug|Ranolazine|Ranolazine versus placebo
157824|NCT00097942|Drug|memantine HCl|
157825|NCT01775865|Drug|Salsalate|
157826|NCT01775865|Drug|Placebo (for salsalate)|
157827|NCT01775878|Device|Telemonitoring Device|Telemonitoring device was installed in patients' homes
157828|NCT01775891|Drug|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
157829|NCT01775891|Drug|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
157830|NCT01775904|Drug|LY2886721 Capsule|Administered orally.
158227|NCT01779635|Device|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
158228|NCT01779635|Device|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
158229|NCT01779648|Device|DVT-3000|
158230|NCT01779648|Device|SCD Express|
158231|NCT01779661|Other|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
158232|NCT00098371|Drug|alvocidib|
158233|NCT01779661|Other|Infant Massage|Infant Massage
158234|NCT01779687|Drug|raltegravir|Raltegravir 400 mg BID for 7 days
158235|NCT01779687|Drug|Atorvastatin|Atorvastatin 20 mg QD for 7 days
158236|NCT01779700|Drug|Fingolimod|0.5mg each day of 8 week cycle
158237|NCT01779700|Drug|placebo|1 tablet each day of 8 week cycle
158238|NCT01779713|Genetic|Case-control transcriptomic study|No intervention
158239|NCT01779726|Radiation|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
157532|NCT01775293|Device|Non-absorbable polypropylene mesh|2 step procedures
first step is insertion of Non-absorbable polypropylene mesh under the facial skin
second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step
157533|NCT01775319|Dietary Supplement|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
157534|NCT01775319|Dietary Supplement|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
157535|NCT01775319|Dietary Supplement|Placebo|
157536|NCT00097877|Drug|biphasic insulin aspart|
157537|NCT01775332|Other|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
157538|NCT01775345|Procedure|Isotonic exercises|20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.
Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR.
157539|NCT01775345|Procedure|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
157540|NCT01775345|Procedure|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
157541|NCT01775345|Procedure|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
157542|NCT01775358|Drug|ALRN-5281 0.015 mg/kg|
157543|NCT01775358|Drug|ALRN-5281 0.05 mg/kg|
157544|NCT01775358|Drug|ALRN-5281 0.15 mg/kg|
157855|NCT01779050|Drug|Docetaxel|
157856|NCT01779050|Drug|Carboplatin|
157857|NCT01779050|Drug|Fluorouracil|
157858|NCT01779063|Behavioral|web based multimedia intervention|cognitive therapy based web intervention
157859|NCT00001929|Drug|Eliprodil|
156982|NCT01807871|Drug|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
156983|NCT01807871|Drug|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
156984|NCT01807884|Procedure|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
157247|NCT01810731|Biological|Double Dose QIV|
157248|NCT01810744|Other|capillaroscopy|
157249|NCT01810744|Other|blood pressure measurement|
157250|NCT01810757|Radiation|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
157251|NCT01810757|Radiation|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
157252|NCT01810770|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
157253|NCT01810783|Drug|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
157254|NCT00101205|Drug|oxaliplatin|Given IV
157255|NCT01803282|Drug|Bevacizumab|Bevacizumab administered intravenously on Days 1 and 15 of each 28-day treatment cycle
157256|NCT01803282|Drug|Irinotecan|Irinotecan administered intravenously on Days 1 and 15 of each 28-day treatment cycle
157257|NCT01803282|Drug|Paclitaxel|Paclitaxel administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
157258|NCT01803295|Device|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
157259|NCT01803295|Other|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
157260|NCT01803295|Device|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
157261|NCT00100659|Drug|Pegylated Interferon/ribavirin|
156689|NCT00100815|Biological|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
156690|NCT01804946|Drug|Oseltamivir|Safety and Efficiency in treatment of Influenza
156691|NCT01804959|Dietary Supplement|VSL#3 probiotics|
156692|NCT01804972|Other|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
156693|NCT01807325|Procedure|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
156694|NCT01807377|Drug|PF-05175157|200 mg tablet administered twice per day for 14 days
156695|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
156696|NCT01807377|Other|Placebo|Placebo administered twice per day for 14 days
156697|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
156698|NCT01807403|Procedure|Deep brain stimulation|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
156699|NCT01807416|Procedure|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
156700|NCT01807429|Drug|Ketamine-midazolam|Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
156701|NCT01807429|Drug|Morphine|morphine 0.05 mg/kg
156702|NCT00101010|Drug|Pegylated liposomal doxorubicin hydrochloride|40 mg/m^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
157006|NCT01810458|Procedure|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
157007|NCT01810458|Other|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
157008|NCT00101166|Biological|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
157009|NCT01810458|Procedure|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
156721|NCT01809886|Drug|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
156722|NCT00101140|Procedure|chemotherapy|
156723|NCT01809886|Drug|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
156724|NCT01809899|Behavioral|consent procedure|Enhanced consent entails a more detailed consent process
156725|NCT01809912|Drug|Recombinant human apolipoprotein(a) Kringle V|
156726|NCT01809925|Dietary Supplement|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
156727|NCT01809925|Dietary Supplement|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
156728|NCT01809938|Other|Black tea|300ml of tea without milk
156729|NCT01809938|Other|Tea with milk|250ml of black tea with 50ml of full fat milk
156730|NCT01809964|Biological|ANT-1401|
156731|NCT01809964|Biological|Vehicle|
156732|NCT01809977|Procedure|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
156733|NCT00101140|Procedure|non-specific immune-modulator therapy|
156734|NCT01809977|Procedure|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
156735|NCT01812109|Device|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes ~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
156736|NCT01812122|Drug|Glimepiride|
156127|NCT00100737|Drug|interleukin-2|
156128|NCT01803841|Procedure|Transradial coronary angiography and intervention|
156129|NCT01803841|Procedure|Transfemoral coronary angiography and intervention|
156130|NCT01803867|Drug|rHIgM22|Administered via IV infusion
156436|NCT01806987|Behavioral|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
156437|NCT01807000|Drug|Radiolabeled Prucalopride Succinate|A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
156438|NCT01809236|Biological|Conbercept|intravitreal injection of 0.5 mg Conbercept
156439|NCT01809262|Drug|single dose of 5 mcg|solution for inhalation
156440|NCT01809262|Drug|single dose of placebo|solution for inhalation
156441|NCT01809262|Drug|single dose of 40 mcg|solution for inhalation
156442|NCT00101127|Drug|docetaxel|
156443|NCT01809262|Drug|single dose of 20 mcg|solution for inhalation
156444|NCT01809262|Drug|single dose of 2 mcg|solution for inhalation
156445|NCT01809262|Drug|single dose of 10 mcg|solution for inhalation
156446|NCT01809275|Drug|QBECO|
156447|NCT01809275|Drug|Placebo|
156448|NCT01809301|Drug|Niaspan|
156449|NCT01809301|Drug|TRIA-662|
156450|NCT01809327|Drug|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
156451|NCT01809327|Drug|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
155852|NCT00095940|Procedure|therapeutic conventional surgery|Undergo surgery
155853|NCT01753986|Behavioral|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
155854|NCT01753986|Behavioral|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
155855|NCT01753999|Device|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
155856|NCT01753999|Device|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
155857|NCT01754012|Dietary Supplement|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
155858|NCT01754051|Device|PC 400 coils|
156154|NCT01806506|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
156155|NCT01806506|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
156156|NCT01806519|Behavioral|Motor control intervention of head posture|The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.
The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage
156157|NCT01806545|Biological|SRM003|One time implant (2 SRM003 pieces) on surgery day.
156158|NCT00100932|Drug|E7389 21 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1 and 8 of a 21 day cycle.
156159|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
156160|NCT01806558|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
156161|NCT01806571|Drug|Cytarabine|Given IV
156162|NCT01806571|Drug|Daunorubicin Hydrochloride|Given IV
158083|NCT01773681|Drug|Cimzia|For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.
After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen.
158084|NCT01773681|Device|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
158085|NCT00097760|Drug|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
158086|NCT01773681|Device|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
158087|NCT01773694|Behavioral|Early Water Exposure|The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing.
158088|NCT01773707|Drug|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
158089|NCT01773707|Drug|Placebo|Saline given as 30 minute IV infusion
158090|NCT01773746|Other|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
158091|NCT01773759|Behavioral|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
155872|NCT01756846|Other|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
155873|NCT01756859|Procedure|MRI Scan|
155874|NCT01756872|Procedure|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
155875|NCT01756885|Drug|Varenicline|
155876|NCT00096135|Drug|etoposide|IV over 1 hour
155877|NCT01756885|Drug|Placebo|
155878|NCT01756885|Behavioral|Smoking Cessation Counseling|
167914|NCT01854645|Drug|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
167915|NCT01854645|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID
167916|NCT01854658|Drug|GFF MDI (PT003)|GFF MDI administered as two puffs BID
167917|NCT01854658|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
167918|NCT01854658|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
167919|NCT01854658|Drug|Placebo|
167920|NCT01854671|Other|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
167921|NCT01854684|Drug|Temoporfin|Given IV
167922|NCT01854684|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
167923|NCT00105586|Drug|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
167924|NCT01854684|Drug|Photodynamic Therapy|Undergo intraoperative PDT
167925|NCT01854684|Other|Laboratory Biomarker Analysis|Correlative studies
167926|NCT01854684|Other|Pharmacological Study|Correlative studies
167927|NCT01854697|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
167928|NCT01854697|Drug|Ribavirin|Tablet
167929|NCT01854697|Drug|Telaprevir|Film-coated tablet
167930|NCT01854697|Drug|Pegylated Interferon alpha 2-alpha (PegIFN)|Pre-filled syringe
167931|NCT01854710|Drug|ADASUVE 10 mg 2 doses 2 hours apart|inhaled loxapine
167932|NCT01854710|Drug|Oral moxifloxacin 400 mg|
168228|NCT01859728|Drug|Irinotecan|Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics.
168229|NCT00106288|Drug|Micafungin|IV
167619|NCT01861145|Device|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
167620|NCT01861145|Drug|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
167621|NCT01861158|Behavioral|Parenting Wisely|Computer-based, online, interactive parenting intervention
167622|NCT01861171|Dietary Supplement|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
167623|NCT01861197|Drug|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
167624|NCT01861210|Behavioral|Couples Voluntary HIV Counseling and Testing|
167625|NCT01861210|Behavioral|Individual Counseling and Testing|
167626|NCT01861223|Drug|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
167627|NCT01861236|Drug|Firmagon® (degarelix)|Monthly subcutaneous injections
167628|NCT01861249|Drug|SAR339658|Pharmaceutical form:Solution Route of administration: Intravenous
167629|NCT00106405|Drug|Memantine HCl|
167630|NCT01861262|Device|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
167631|NCT01861301|Other|Laboratory Biomarker Analysis|Correlative studies
167632|NCT01861301|Drug|Tivantinib|Given PO
167633|NCT01861314|Drug|Bortezomib|Given SC
167634|NCT01861314|Drug|Decitabine|Given IV
167635|NCT01861314|Other|Laboratory Biomarker Analysis|Correlative studies
167636|NCT01861314|Other|Pharmacological Study|Correlative studies
167637|NCT01861314|Drug|Sorafenib Tosylate|Given PO
167638|NCT01861327|Drug|CO2|carbon dioxide (CO2) as arterial contrast media
166994|NCT01825031|Drug|Albendazole|a single dose 400mg
166995|NCT01825031|Drug|Isoniazid|300mg taken immediately in combination with cotrimoxazole
167298|NCT01858246|Device|Bonebridge|
167299|NCT01858246|Device|Bone Anchored Hearing Aid|
167300|NCT01858272|Drug|H5.020CMV.PDGF-b and limb compression bandage|
167301|NCT01858298|Other|Conservative treatment: pulpectomy and composite resin crown|
167302|NCT01858298|Other|Non-conservative treatment: Tooth extraction|
167303|NCT00106132|Drug|Triamcinolone Acetonide|
167304|NCT01858311|Dietary Supplement|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
167305|NCT01858311|Other|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
167306|NCT01858324|Other|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
167307|NCT01858337|Other|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
167308|NCT01858337|Other|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
167309|NCT01858337|Other|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
167310|NCT01858337|Other|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
167311|NCT01858350|Other|Active Music Therapy|
167312|NCT01858350|Other|Passive Music Therapy|
167313|NCT01858350|Other|Distraction Therapy|
167314|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
167315|NCT01858363|Device|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
167316|NCT01858363|Device|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
166676|NCT01832311|Drug|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
166677|NCT01832337|Procedure|Limb remote ischemic preconditioning (LRIP)|Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
166678|NCT01832350|Drug|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
166679|NCT01832363|Drug|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
166680|NCT01832363|Other|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
166996|NCT01825031|Dietary Supplement|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
166997|NCT00102804|Drug|Placebo|IV administration, q 21 days
166998|NCT01825044|Drug|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
166999|NCT01827631|Drug|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
167000|NCT00103051|Drug|gefitinib|
167001|NCT01827644|Drug|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
167002|NCT01827644|Drug|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
167003|NCT01827644|Drug|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
167004|NCT01827644|Drug|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
167005|NCT01827644|Drug|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
166387|NCT01829035|Other|Conventional Transarterial Chemoembolization (cTACE)|Concurrent use of the following material/drug is defined as cTACE in this trial.
Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil
Anti-tumor drug:
Unapproved drug/embolization material from each regulatory agency should not be used.
To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed
166388|NCT01829048|Drug|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
166389|NCT01829048|Drug|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
166390|NCT01829048|Drug|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
166391|NCT01829048|Drug|Placebo|Placebo Q12h
166392|NCT01829087|Drug|Botox|
166393|NCT01829087|Drug|placebo|
166394|NCT01829100|Behavioral|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
166681|NCT01832376|Procedure|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
166682|NCT00103363|Procedure|annual screening|
166683|NCT01832389|Device|PiCCO|
166684|NCT01824472|Behavioral|CBT|Treatment for insomnia
166685|NCT01824472|Device|sham CPAP|Placebo for sleep apnea
166686|NCT01824472|Behavioral|CC|Placebo (sham) for insomnia
166687|NCT01824485|Drug|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
166688|NCT01824485|Drug|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
166689|NCT01824498|Other|Low Fat diet|Low fat diet = 20% fat
153392|NCT01767831|Behavioral|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
153393|NCT01767844|Dietary Supplement|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
153394|NCT01770106|Drug|Alendronate|Alendronate 70mg once weekly
153395|NCT01770119|Biological|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
153396|NCT01770132|Drug|porfimer sodium|Given IV
153397|NCT01770132|Procedure|endoscopic ultrasonography|Undergo EUS-PDT
153398|NCT01770132|Procedure|photodynamic therapy|Undergo EUS-PDT
153399|NCT01770132|Drug|gemcitabine hydrochloride|Given IV
153400|NCT01770145|Drug|APOKYN|Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' "best on" UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes).
153697|NCT01763554|Drug|Lu-177 DOTA-TATE|Radiopharmaceutical solution for IV injection containing DOTA-TATE labeled with Lutetium-177. Standard dose is 5.5 GBq given as a single injection once every 8 to 12 weeks for 4 doses, followed by maintenance doses of 5.5 GBq every 6 months.
153698|NCT01763580|Drug|Tacrolimus|Oral
153699|NCT01763580|Drug|Prednisolone|Oral
153700|NCT00096499|Other|pharmacological study|Correlative studies
153701|NCT01763606|Drug|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
153702|NCT01763606|Drug|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
153703|NCT01763619|Device|Freedom Cervical Disc|
153704|NCT01763632|Device|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
153705|NCT01763645|Drug|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
154399|NCT01762384|Procedure|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
154400|NCT01762384|Procedure|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
154401|NCT01762384|Device|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
154402|NCT01762397|Drug|PMK-S005|
154403|NCT01762410|Drug|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
154404|NCT01762423|Device|Active Device (IVIVI SofPulse)|
154405|NCT00096434|Drug|sorafenib tosylate|Given orally
154406|NCT01762423|Device|Sham Device|
154407|NCT01762436|Drug|bisoprolol|
154408|NCT01762436|Drug|atenolol|
154409|NCT01762449|Other|Followup survey|
154410|NCT01762462|Drug|SAR302503|Pharmaceutical form:capsule
Route of administration: oral
154411|NCT01762475|Drug|Sildenafil|
154412|NCT01762488|Procedure|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
154413|NCT01762488|Procedure|Renal angiography|Renal angiography by femoral access
154414|NCT01762501|Drug|Azilsartan|Azilsartan 20mg/day
154415|NCT01762501|Drug|Amlodipine|Amlodipine 5mg/day
154416|NCT00096434|Other|laboratory biomarker analysis|Correlative studies
153462|NCT01765517|Dietary Supplement|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
153463|NCT01765517|Dietary Supplement|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
153464|NCT01767844|Dietary Supplement|Placebo|
153465|NCT00097071|Drug|insulin aspart|
155911|NCT01810809|Procedure|articular lavage with saline injection|Patients will receive articular lavage with saline injection
155912|NCT01810809|Drug|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
155913|NCT01810809|Drug|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
156208|NCT01803984|Other|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
156209|NCT01803997|Behavioral|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
156210|NCT01804010|Drug|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
156211|NCT01804023|Other|HEC placebo gel applicators|Participants will handle, but not insert, 4 applicators containing HEC placebo gel.
Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators.
156212|NCT01804036|Drug|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
156213|NCT00001968|Drug|Abacavir|
156214|NCT00100750|Drug|Gemcitabine Hydrochloride|Given IV
156215|NCT01804036|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
156216|NCT01804049|Drug|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
156217|NCT01804049|Drug|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
156218|NCT01804075|Drug|Methadone, Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
156219|NCT01804088|Device|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
156220|NCT01804101|Other|Laboratory Biomarker Analysis|Correlative studies
156221|NCT01804101|Drug|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
156222|NCT01804114|Procedure|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
156223|NCT01804114|Procedure|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
158240|NCT01779726|Radiation|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
158241|NCT01779739|Procedure|Perineorrhaphy|Procedure to build up the vaginal opening
158242|NCT01779765|Dietary Supplement|PHGG|
158243|NCT00098384|Drug|rifaximin|
158244|NCT01779765|Dietary Supplement|Maltodextrin|
158245|NCT01779791|Drug|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
158246|NCT01779804|Procedure|OFAR|OFAR
158247|NCT01779817|Behavioral|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
158248|NCT01779830|Drug|LY2624803 - Capsules|Administered orally as capsules.
158249|NCT01779830|Drug|Zolpidem - Tablets|Administered orally as tablets.
155937|NCT01803399|Drug|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
155938|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
155939|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
155940|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
155941|NCT00100685|Drug|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
155942|NCT01803425|Other|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
155943|NCT01803438|Device|cryoballoon ablation system|
155944|NCT01803438|Drug|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
157860|NCT00098306|Drug|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
157861|NCT01779063|Other|educational booklet|patient education booklet
157862|NCT01779076|Procedure|30% oxygen|
157863|NCT01782105|Behavioral|Control group|Evaluation of nutritional and physcial activity habits
157864|NCT01782118|Dietary Supplement|Lactobacillus GG|
157865|NCT01782131|Drug|Posaconazole|
157866|NCT01782131|Drug|Voriconazole|
157867|NCT01782144|Other|NutriSystem portion-controlled pre-packaged meals|
157868|NCT01782170|Drug|Iocide Oral Rinse|
157869|NCT01782170|Drug|Placebo|
157870|NCT01782183|Device|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
157871|NCT01782196|Device|Enhanced one piece drainable pouch with Type A mouldable adhesive|
157872|NCT01782196|Device|Enhanced one piece drainable pouch with Type B mouldable adhesive|
157873|NCT00098605|Other|questionnaire administration|Ancillary studies
157874|NCT01782222|Drug|Rotigotine|Rotigotine, transdermal patches:
10 cm^2 (2 mg / 24 hours); 20 cm^2 (4 mg / 24 hours); 30 cm^2 (6 mg / 24 hours); 40 cm^2 (8 mg / 24 hours)
The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)
157875|NCT01782222|Other|Placebo|Placebo, matching transdermal patches
Duration: up to 21 weeks (including de-escalation)
157876|NCT01782235|Drug|Tocilizumab|
157877|NCT01782235|Drug|Placebo|
157878|NCT01782248|Other|Questionnary and IRM|
157879|NCT01782261|Drug|Liraglutide|once daily subcutaneous injection
158273|NCT01771406|Drug|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
158274|NCT01771406|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
157262|NCT01803308|Drug|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
157263|NCT01803308|Drug|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
157264|NCT01803308|Drug|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
157265|NCT01803321|Drug|rilonacept (IL-1 Trap)|
157266|NCT01803321|Other|Placebo|
157267|NCT01803334|Other|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
157567|NCT01778348|Device|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
157568|NCT01778374|Other|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
157569|NCT01778374|Other|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
157570|NCT01778387|Procedure|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
157571|NCT01778400|Procedure|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
157572|NCT00098241|Drug|Certican|
157573|NCT01781169|Dietary Supplement|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
157574|NCT01781208|Device|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scan using an ultrasound-based acoustic radiation force impulse will be used to image the liver. This is non-invasive and will take approximately 5 to 10 minutes to complete.
157575|NCT01781221|Device|Alpha-Bio's GRAFT Natural Bovine Bone|
157576|NCT01781221|Device|Bio-Oss xenograft|
157577|NCT01781234|Drug|Intranasal Insulin|
157578|NCT01781234|Drug|Placebo|
157010|NCT01810458|Drug|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
157011|NCT01810458|Drug|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
157012|NCT01802957|Other|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
157013|NCT01802957|Other|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
157014|NCT00100633|Biological|Hepatitis B virus vaccine|
157015|NCT01802957|Other|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
157016|NCT01802957|Other|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
157286|NCT01777737|Drug|Cotrimoxazole|24 weeks of treatment
157287|NCT01777737|Drug|Placebo|Identical capsules to cotrimoxazole
157288|NCT01777750|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
157289|NCT01777763|Drug|Posaconazole 200 mg|
157290|NCT01777763|Drug|Posaconazole 300 mg|
157291|NCT01777776|Drug|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
157292|NCT01777776|Drug|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
157030|NCT01805492|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
157031|NCT01805505|Procedure|Transvaginal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound
157032|NCT01805505|Procedure|Transabdominal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
157033|NCT01805518|Dietary Supplement|Scelectium Tortuosum|One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.
The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d.
157034|NCT01805531|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
157035|NCT01805544|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
157036|NCT01805557|Drug|R-DHAP|Rituximab 375 mg/sqm iv day 0 or 1
Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion
Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3
Dexamethasone 40 mg day 1-4
Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)
Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy
157037|NCT01805557|Drug|BR-DHAP|Rituximab 375 mg/sqm iv day 0 or 1
Bortezomib SC 1.5 mg/sqm day 1, day 4
Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion
Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3
Dexamethasone 40 mg day 1-4
Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)
Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days.
157038|NCT01805570|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
157039|NCT00100841|Drug|fluorouracil|Given IV
157040|NCT01805570|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
157041|NCT01807949|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
157042|NCT00101075|Drug|capecitabine|
157043|NCT01807949|Drug|Ivacaftor|Film-coated tablet
156452|NCT01809327|Drug|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
156453|NCT00101127|Drug|gemcitabine hydrochloride|
156454|NCT01809340|Drug|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
156455|NCT01809340|Drug|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
156758|NCT01804985|Drug|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
156759|NCT01804985|Drug|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
156760|NCT01804985|Drug|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
156761|NCT01804998|Procedure|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
156762|NCT01804998|Procedure|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
156763|NCT01805011|Other|minimum 4 months of breastfeeding|
156764|NCT00100815|Drug|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
156765|NCT01805024|Drug|Omigapil|
156766|NCT01805037|Drug|brentuximab vedotin|Given IV
156767|NCT01805037|Biological|rituximab|Given IV
156768|NCT01805037|Other|laboratory biomarker analysis|Correlative studies
156769|NCT01805050|Procedure|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
156770|NCT01805063|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
156163|NCT01808820|Biological|Tumor Lysate|After completion of DC vaccination course, lysate of tumor will be administered during weeks 8, 12, 16, and 28. Lysate dose will be 1.5 mg of tumor lysate, divided into 2 syringes with a total volume of 0.4 mL per injection. If there is not enough lysate to produce 1.5 mg per dose, then the remaining lysate will be divided into four equal aliquots. All lysate will be injected into one (1) arm intradermally in alternating arms/thigh as above within an area of approximately the size of a silver dollar spaced approximately equally. Lysate will be injected from one syringe for each administration. Clinical examination after study treatment ends will be required every three (3) months + 14 days.
156164|NCT01808820|Other|Imiquimod|Subjects will self-apply imiquimod one night before and each night for two nights after the scheduled administration of DC or lysate. Investigator will instruct the subject to apply a thin layer of imiquimod on the selected area (approximately the area of a silver dollar) of both arms,or thigh. Subjects are advised to rinse the selected area with water (where imiquimod is applied) the morning after application. Subjects will be given a medication diary when supplied with imiquimod in which they will record both the time of application of the imiquimod, and the time of rinse of the imiquimod.
156165|NCT01808820|Procedure|Leukapheresis|Patients enrolled in the study will undergo a leukapheresis procedure performed to collect peripheral blood mononuclear cells. Leukapheresis will be performed using a continuous flow blood cell separator (COBE Spectra, Caridian BCT, Lakewood, CO). This instrument relies on density gradient centrifugation to collect mononuclear cells from the apheresis patients. Leukapheresis is typically performed through a central venous catheter (a catheter inserted into one of the larger veins in the body) or through a peripheral intravenous catheter that may be placed the day of the procedure. An anticoagulant is added to circulate blood to prevent clotting during the procedure. In this study, leukapheresis will be performed to collect 1.5 x 10^9 mononuclear cells. Each procedure may take 3-5 hours.
156166|NCT01808859|Device|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
156475|NCT01812044|Drug|subtenons control - 0.5 cc of Normal Saline|
156476|NCT01812057|Drug|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
156477|NCT01812057|Drug|Placebo|Sodium Chloride 0.9% -5 ml
156478|NCT00101348|Drug|erlotinib hydrochloride|Given orally
156479|NCT01812070|Behavioral|ACT|
156480|NCT01812070|Behavioral|CBT|
156481|NCT01812096|Other|Subcutaneous bortezomib|
156482|NCT01812096|Other|Intravenous bortezomib|
156483|NCT01804452|Other|Observational Study|
156484|NCT01804465|Drug|SipT Treatment|All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.
SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion.
156485|NCT01804465|Drug|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
156486|NCT01804478|Behavioral|Mild pneumatic compression|
155879|NCT01756898|Drug|ASB17061|Oral administration of ASB17061 taken once daily for 28 consecutive days.
155880|NCT01756898|Drug|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
155881|NCT01756911|Device|MFM|Implantation of the MFM
155882|NCT01756924|Drug|CEM-102|
155883|NCT01756924|Drug|IV or Oral standard of care antibiotics|
155884|NCT01756924|Drug|Rifampin|
155885|NCT01756937|Drug|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
155886|NCT01756937|Drug|Placebo|1 capsule once daily for 24 weeks
155887|NCT00096135|Drug|leucovorin calcium|rescue IV over 24 hours
155888|NCT01808456|Biological|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
155889|NCT01808456|Biological|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
155890|NCT01808469|Biological|Monoclonal antibody|
155891|NCT01808482|Drug|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
155892|NCT01808482|Drug|Part A: matching placebo|Matching placebo
155893|NCT01808482|Drug|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
155894|NCT01808482|Drug|Part B: matching placebo|Matching placebo
156185|NCT01811368|Biological|ibritumomab tiuxetan|Given IV
156186|NCT01811368|Biological|anti-thymocyte globulin|Given IV
156187|NCT01811368|Radiation|total nodal irradiation|Undergo TLI
156188|NCT01811368|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
156189|NCT01811368|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
156190|NCT01811368|Drug|cyclosporine|Given PO or IV
168230|NCT01859728|Drug|Cisplatin|Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics.
168231|NCT01859728|Drug|Cisplatin|Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.
Given in association with standard hydration and anti-emetics.
168232|NCT01859728|Drug|Gemcitabine|Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics.
168233|NCT01859741|Drug|OMP-59R5|OMP-59R5 administered intravenously
168234|NCT01859741|Drug|Etoposide|administered intravenously
168235|NCT01859741|Drug|Placebo|administered IV
168236|NCT01859741|Drug|Cisplatin or Carboplatin|administered intravenously
168237|NCT01859754|Biological|Octagam 5%|Intravenous immunoglobulin 5%
168238|NCT01859754|Biological|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
168239|NCT01859767|Drug|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
168240|NCT00106288|Drug|Liposomal Amphotericin B|IV
168241|NCT01859780|Other|Visual distractor|
168242|NCT01859793|Drug|sitagliptin|100 mg pill, administered once/day orally
168243|NCT01859793|Drug|Placebo|
168244|NCT01859806|Procedure|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
168245|NCT01859806|Procedure|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
168246|NCT01859819|Drug|Rituximab|
168247|NCT01859819|Drug|IT Cytarabine|
168248|NCT01859832|Other|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
163541|NCT01819285|Procedure|Delayed Orchiectomy or depot LHRH|
167639|NCT01861327|Drug|Iodine contrast media|Iodine as arterial contrast media
167933|NCT01854710|Drug|Staccato Placebo 2 doses 2 hours apart|Inhaler with no drug in it to mimic the ADASUVE inhaler
167934|NCT01856907|Drug|Placebo pill|Will evaluate effect of lifestyle and diet only
167935|NCT01856920|Biological|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
167936|NCT01856933|Drug|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
167937|NCT00105898|Procedure|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
167938|NCT01856946|Dietary Supplement|4,000 IU vitamin D3|
167939|NCT01856959|Drug|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
167940|NCT01856959|Drug|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
167941|NCT01856959|Drug|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
167942|NCT01856972|Procedure|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
167943|NCT01856972|Procedure|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
167944|NCT01856972|Other|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
167945|NCT01856985|Drug|Misoprostol|
167946|NCT01856985|Drug|Mifepristone|
167947|NCT01856998|Drug|Propofol|
167317|NCT01858376|Dietary Supplement|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
167318|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
167319|NCT01860573|Drug|Amino acids|
167640|NCT00106418|Drug|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
167641|NCT01861340|Drug|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
167642|NCT01861353|Other|Cranberry-lingonberry juice|
167643|NCT01854138|Device|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
167644|NCT01854151|Other|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
167645|NCT01854164|Dietary Supplement|HGE (hydrolyzed ginseng extract)|
167646|NCT00105534|Other|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
167647|NCT01854164|Dietary Supplement|Placebo|
167648|NCT01854177|Drug|Aprepitant|
167649|NCT01854177|Drug|placebo|
167650|NCT01854190|Device|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
167651|NCT01854203|Drug|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
167006|NCT01827644|Drug|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
167007|NCT01827657|Drug|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
167008|NCT01827670|Drug|Stannous fluoride|Test dentifrice containing 0.454% SnF
167009|NCT01827670|Drug|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate [1000 parts per million (ppm) fluoride]
167010|NCT01827683|Other|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
167011|NCT00103051|Drug|gemcitabine hydrochloride|
167012|NCT01827696|Dietary Supplement|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
167013|NCT01827709|Other|A polymerase chain reaction -based hypoxia classifier|Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.
These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET.
167014|NCT01827709|Other|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
167320|NCT01860586|Drug|Bevacizumab|.005 mL of Bevacizumab will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
167321|NCT01860599|Behavioral|Exercise|150 minutes of moderate exercise per week
167322|NCT01860599|Behavioral|Without exercise|Pre-study activity level (i.e. no exercise)
167323|NCT01860612|Device|Artificial Iris (CustomFlex)|
167324|NCT01860625|Drug|Donepezil patch|
167325|NCT00106366|Drug|insulin detemir|
167326|NCT01860625|Drug|placebo|
167327|NCT01860638|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg IV every 2 weeks, followed by 15 mg/kg IV every 3 weeks until disease progression (PD1).
167328|NCT01860638|Drug|Lomustine|Lomustine will be administered orally at a dose of 90 milligrams per meter square (mg/m^2; may be increased to 110 mg/m^2) once every 6 weeks.
167329|NCT01860638|Drug|Placebo|Post-PD1: Bevacizumab placebo will be administered IV every 2 weeks.
166690|NCT01824498|Other|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
166691|NCT01824498|Other|High Fat Diet|High Fat Diet = 40% fat
166692|NCT00102752|Drug|Glufosfamide|
166693|NCT01824511|Behavioral|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
166694|NCT01824524|Drug|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
166695|NCT01824537|Biological|HPV vaccine, Gardasil|Once recruited, both individuals in a couple will be randomized independently to Gardasil or placebo (Havrix).
166696|NCT01824537|Biological|Hepatitis A vaccine|Provided by GSK.
166697|NCT01824550|Other|home-based exercise training condition|Home based endurance exercise training
166698|NCT01824563|Other|Observational study|
166699|NCT01824576|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
166700|NCT01824589|Device|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
167015|NCT01827709|Other|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
167016|NCT01827709|Other|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
167017|NCT01827709|Other|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
167018|NCT01827722|Drug|Ozurdex|Intravitreal injection of Ozurdex
167019|NCT01827722|Drug|Ranibizumab|Intravitreal Injection of Ranibizumab
167020|NCT01830231|Drug|Vinflunine|Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:
320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of
280 mg/m2 in patients aged >75 - ≤80 years or with PS 1 or prior pelvic radiation,
250 mg/m2 in patients aged >80 years.
167021|NCT00103285|Drug|doxorubicin hydrochloride|Given IV or IT
153706|NCT01763645|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
153707|NCT01763645|Drug|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
153708|NCT01763658|Drug|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
153709|NCT01763658|Other|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
153710|NCT01763671|Drug|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
153711|NCT00096499|Other|laboratory biomarker analysis|Correlative studies
153712|NCT01763671|Drug|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
153713|NCT01765829|Drug|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
153714|NCT01765842|Biological|Rituximab|Only one cycle of rituximab will be administered in this arm.
153715|NCT00096785|Drug|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
153716|NCT01765855|Drug|Betrixaban single oral dose|
153717|NCT01765868|Drug|Betrixaban|Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
154026|NCT01768819|Behavioral|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
154027|NCT01768832|Behavioral|Treadmill|
154028|NCT01768832|Behavioral|Tango|
154029|NCT01768832|Behavioral|Stretching|
154030|NCT01768845|Genetic|umbilical cord transplant (UCB)|Infusion will occur after preparative regimen in one or two UCB unit(s). If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis.
154031|NCT01768884|Drug|Nitric Oxide|
154032|NCT01768884|Drug|Placebo|
153466|NCT01767857|Drug|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
153467|NCT01767857|Drug|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
153468|NCT01767870|Procedure|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
153469|NCT01767870|Procedure|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
153470|NCT01767883|Other|Facilitated Clinical Decision Support|The primary care practices in this arm will receive:
CKD decision support algorithms added to their Clinical Decision Support
System Academic detailing concerning the rationale for the algorithms
On-going mentoring and practice facilitation
Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference.
153471|NCT01767883|Other|Clinical Decision Support Only|CKD decision support algorithms added to their Clinical Decision Support
System Academic detailing concerning the rationale for the algorithms
153472|NCT01767896|Biological|ASP7374|subcutaneous (sc)
153473|NCT01767896|Biological|approved egg-derived TIV|subcutaneous (sc)
153474|NCT01767909|Drug|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
153475|NCT01767909|Drug|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
153476|NCT00097084|Drug|insulin detemir|
153477|NCT01767922|Dietary Supplement|Extramel 10 mg - 140 UI SOD|Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.
Each volunteer was seen for the 3 visits:
visit V1, so-called inclusion visit (D0),
visit V2 at 28 days, tolerance of +/- 3 days, (D28) and
visit V3 at 84 days, tolerance of +/- 3 days, (D84).
153478|NCT01767922|Dietary Supplement|Placebo - Excipient only|
153479|NCT01767935|Procedure|cryosurgery|Undergo cryosurgery
153480|NCT01767935|Radiation|radiation therapy|Undergo radiation therapy
153481|NCT01767935|Procedure|quality-of-life assessment|Ancillary studies
153783|NCT01770899|Drug|Placebo|Gelatin capsule given every 24 hours
153784|NCT01770912|Drug|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
156224|NCT01804127|Drug|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
156225|NCT00100750|Drug|Tipifarnib|Given PO
156226|NCT01804153|Drug|Adipose-derived expanded stem cells|Intralesional application ASC
156227|NCT01806571|Other|Laboratory Biomarker Analysis|Correlative studies
156228|NCT01806571|Drug|Nilotinib|Given PO
156538|NCT01809483|Device|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
156539|NCT01809483|Device|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
156540|NCT01809496|Behavioral|Informational Counseling|
156541|NCT01809496|Behavioral|Patient Centered Counseling|
156542|NCT01809509|Procedure|Endometrial biopsy|
156543|NCT00101140|Drug|fludarabine phosphate|
156544|NCT01809522|Procedure|Posterior reconstruction of the rhabdosphincter|
156545|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
156546|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
156547|NCT01809548|Other|Early intervention group|solid food will be introduced between week 10 and 12
156548|NCT01809548|Other|Late intervention group|solid food is introduced between 16-18th week of gestation corrected for prematurity
156549|NCT01809561|Procedure|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
156550|NCT01809587|Device|IQP-PO-101|
156551|NCT01809600|Other|No intervention (observational study)|
155945|NCT01803451|Drug|exendin-(9-39)|hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
155946|NCT01803451|Drug|exendin -(9-39)|2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
155947|NCT01803464|Other|Botox plus low-magnitude vibration|Half of the children who receive Botox treatment will be randomly assigned to receive a high-frequency, low magnitude vibration treatment. The other half of the children who receive Botox treatment and are randomly assigned to the Botox-only group will be offered the vibration treatment at the end of the study.
155948|NCT01803464|Drug|Botox|Children will not receive vibration treatment. Children in the Botox-only group will be offered vibration treatment at the end of the study.
155949|NCT01803477|Drug|once daily for two consecutive days (Picato)|
155950|NCT01803503|Drug|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
155951|NCT01803503|Drug|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
155952|NCT00100698|Drug|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
155953|NCT01803516|Behavioral|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
156246|NCT01806675|Radiation|2-fluoropropionyl-labeled pegylated dimeric RGD peptide|Undergo 18F FPPRGD2 PET/CT or PET/MRI
156247|NCT01808924|Other|Educational control.|Subjects in the control arm will require special attention for compliance. This will involve frequent (biweekly) educational sessions, including topics such as medications. We will in part model this program on what we have developed and implemented for the LIFE study, a large, multi-center randomized controlled exercise trial in older adults (57; 58). The primary purpose to ensure compliance is not to equate their contact time or exposure time to the exercise group, but rather to increase the chance to detect differences in the outcomes between the control group and treatment groups. At the end of the 6 months these participants will be offered a structured weight loss and exercise program, which should greatly aid in recruitment and adherence.
156248|NCT01808937|Other|Morphea|
156249|NCT01808950|Drug|0.06% Resiquimod Gel - A|
156250|NCT01808950|Drug|0.06% Resiquimod Gel - B|
156251|NCT00001989|Drug|Zidovudine|
156252|NCT00101114|Drug|sorafenib tosylate|Given PO
156253|NCT01808950|Drug|0.06% Resiquimod Gel - C|
158275|NCT01771419|Device|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
158276|NCT01771419|Device|Cannulotome CT-25mm Cook Medical|
158277|NCT01771432|Drug|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
158278|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
158279|NCT01773902|Dietary Supplement|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
158280|NCT01773902|Dietary Supplement|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
158281|NCT01773928|Biological|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
158282|NCT01773928|Biological|VCIV manufactured with the current manufacturing process (VCIV current)|
158283|NCT01773928|Biological|Fluzone®, licensed trivalent influenza vaccine (TIV)|
158284|NCT01773954|Drug|Intravitreal Aflibercept Injection More|Increased time between visits
158285|NCT00097773|Drug|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
158286|NCT01773954|Drug|Intravitreal Aflibercept Injection Less|Reduced time between visits
158287|NCT01773967|Drug|LGG|LGG 10^10 cfu PO BID X 5 days
158288|NCT01773967|Drug|micro-crystalline cellulose|1 capsule PO bid x 5 days
158289|NCT01773980|Other|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
158290|NCT01773980|Other|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
158291|NCT01773993|Drug|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
158292|NCT01774006|Other|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
158293|NCT01774019|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
157579|NCT01781247|Behavioral|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
157580|NCT01781247|Behavioral|Control intervention|The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to "trauma" will be completely avoided.
157581|NCT00098514|Drug|talotrexin ammonium|
157582|NCT01781273|Other|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
157583|NCT01781273|Other|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
157584|NCT01781286|Behavioral|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
157900|NCT01773343|Procedure|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
157901|NCT01773356|Dietary Supplement|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
157902|NCT01773369|Behavioral|Early leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity.
157903|NCT01773369|Behavioral|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur ~3 months after recruitment.
157904|NCT01773382|Behavioral|weight reduction|Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)
Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.
Daily body weight measurement.
Record food diary
157905|NCT00097721|Drug|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
157906|NCT01773395|Biological|GVAX|
157907|NCT01773395|Biological|Placebo Vaccine|
157908|NCT01773395|Procedure|Allogeneic Hematopoietic Stem Cell Transplant|
157909|NCT01773395|Drug|Busulfan|
157910|NCT01773395|Drug|Fludarabine|
157293|NCT01777815|Device|NeoChord DS1000 Artificial Chordae Delivery System|
157294|NCT01777841|Other|Electronic Care plan delivery|
157295|NCT00098137|Drug|Olmesartan|
157296|NCT01777841|Other|Standard care|
157297|NCT01777854|Drug|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
157298|NCT01777893|Behavioral|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
157299|NCT01777893|Behavioral|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
157300|NCT01780610|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
157301|NCT01780623|Device|Bright white light|
157302|NCT01780623|Device|Dim red light|
157303|NCT00098475|Other|Laboratory Biomarker Analysis|Optional correlative studies
157304|NCT01780636|Drug|botulinum toxin|
157305|NCT01780649|Procedure|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
157306|NCT01780649|Procedure|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
157605|NCT01772836|Drug|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
157606|NCT01772836|Drug|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
157607|NCT00097669|Other|folic acid|2 mg
157044|NCT01807962|Drug|rapidocain and bethametsaone|lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine
bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)
157327|NCT01772368|Drug|Advair Diskus|Each inhalation consists of a dry powder formulation of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate in a lactose excipient.
157328|NCT01772381|Drug|Dexamethasone|Long acting corticosteroid
157329|NCT00097604|Dietary Supplement|Valerian root extract|Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
157330|NCT01772394|Behavioral|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
157331|NCT01772394|Behavioral|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
157332|NCT01772420|Drug|Eltrombopag Olamine|Given PO
157333|NCT01772420|Other|Laboratory Biomarker Analysis|Correlative studies
157334|NCT01772420|Drug|Lenalidomide|Given PO
157335|NCT01772433|Dietary Supplement|Olive oil|Phonophoresis with Olive oil for 10 day, daily
157336|NCT01772433|Drug|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
157337|NCT01772446|Behavioral|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
157338|NCT01772472|Drug|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
157339|NCT01772472|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
157340|NCT00097630|Procedure|SAT: Spontaneous Awakening Trial|
157341|NCT01772485|Behavioral|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
157342|NCT01772485|Behavioral|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
157343|NCT01772498|Behavioral|heart rate variability biofeedback|
156771|NCT01805063|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
156772|NCT01805076|Procedure|Breast surgery|
156773|NCT01805076|Procedure|Magnetic resonance imaging|
156774|NCT01805076|Procedure|Mammography|
156775|NCT00100815|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
156776|NCT01805089|Drug|Melatonin 3 mg|Melatonin vs. Placebo
156777|NCT01805115|Drug|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
157064|NCT01810458|Drug|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
157065|NCT01810458|Drug|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
157066|NCT01810458|Drug|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
157067|NCT01810458|Drug|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
157068|NCT01810458|Drug|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
156487|NCT00100789|Drug|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
156488|NCT01804491|Other|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
156489|NCT01804504|Behavioral|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
156490|NCT01804530|Drug|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
156491|NCT01804530|Drug|Gemcitabine|Gemcitabine IV
156492|NCT01804530|Drug|nab-Paclitaxel|nab-Paclitaxel IV
156493|NCT01804543|Drug|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
156494|NCT01804556|Procedure|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 ~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
156495|NCT01804569|Other|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
156796|NCT01807611|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
156797|NCT01807611|Drug|Mycophen0late mofetil|Given intravenously or orally.
156798|NCT01807624|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl
156799|NCT01809990|Behavioral|Internet-delivered Cognitive Behavior Therapy|
156800|NCT01810003|Dietary Supplement|High DHA|10 week supplementation period
156801|NCT01810003|Dietary Supplement|High EPA|10 week supplementation period
156802|NCT01810003|Dietary Supplement|Placebo|10 week supplementation period
156803|NCT01810016|Biological|Ipilimumab|
156804|NCT01810016|Biological|NY-ESO-1 Protein Vaccine|
156191|NCT00101270|Drug|oxaliplatin|Given IV
156192|NCT01811368|Drug|mycophenolate mofetil|Given PO or IV
156193|NCT01811368|Other|laboratory biomarker analysis|Correlative studies
156194|NCT01811381|Drug|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
156195|NCT01811381|Behavioral|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home.
156196|NCT01811381|Behavioral|non aerobic yoga|Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.
Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home.
156197|NCT01811381|Dietary Supplement|Placebo|Subjects will take 4 capsules x BID of placebo
156198|NCT01811394|Radiation|protons|Treatment is performed using 16 x 4 GyE protons
156199|NCT01811394|Radiation|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
156200|NCT01811407|Behavioral|Precommitment announcement|
156201|NCT01811407|Behavioral|Results announcement|
156202|NCT00101283|Drug|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
156203|NCT01803958|Radiation|partial breast irradiation|
156204|NCT01803958|Radiation|whole breast irradiation|
156205|NCT01803971|Other|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
156206|NCT01803984|Device|MRI|
156207|NCT01803984|Device|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
156518|NCT01807104|Procedure|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
156519|NCT01807117|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
156520|NCT01807117|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
156521|NCT00101010|Biological|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
163542|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
163543|NCT01819311|Behavioral|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
163544|NCT00102414|Drug|Gemcitabine|
163545|NCT01821976|Procedure|Ertl Procedure|
163546|NCT01821976|Procedure|Burgess Procedure|
163547|NCT01821989|Dietary Supplement|Lactoferrin|dose of 100 mg/day
163548|NCT01821989|Dietary Supplement|Lactoferrin|dose of 150 mg/kg/ twice daily
163549|NCT01821989|Dietary Supplement|Placebo|in form of distilled water
163550|NCT01822002|Procedure|Canalith repositioning maneuver|
163551|NCT01822015|Drug|Sirolimus|Given PO
163552|NCT01822015|Drug|Idarubicin|Given IV
163553|NCT01822015|Drug|Cytarabine|Given IV
163554|NCT01822028|Drug|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
163555|NCT00102427|Behavioral|Telephone-based collaborative care management|
163556|NCT01822028|Drug|Treatment B|Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).
Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
163557|NCT01822041|Drug|ARN-509|Single oral dose of 240 mg ARN-509
163558|NCT01822080|Drug|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
163559|NCT01822080|Drug|Placebo|Matching placebo once daily by mouth
163560|NCT01822093|Biological|Cytovir-ADV|A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results > 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.
This is a feasibility/pilot study and has no control group
163561|NCT01822106|Other|Placebo|
167948|NCT00105898|Procedure|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
167949|NCT01856998|Drug|Diprivan|
167950|NCT01857011|Drug|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
168249|NCT01859845|Other|Smartphone|Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the "three-poin checklist of dermoscopy". The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research.
168250|NCT01859858|Dietary Supplement|curcumin|
168251|NCT00106301|Drug|FK228 (romidepsin)|Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
168252|NCT01842724|Procedure|Motec total wrist arthroplasty|
168253|NCT01842724|Procedure|Remotion total wrist arthroplasty|
168254|NCT01842737|Procedure|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
168255|NCT01842737|Procedure|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
168256|NCT00104572|Drug|Placebo tablet|Daily for 12 months
168257|NCT01842750|Device|Endorectal Balloon insertion|
168258|NCT01842789|Device|Acessa Procedure|Acessa Procedure
168259|NCT01842802|Device|Diode Laser|Diode Laser for treatment of subcutaneous fat
168260|NCT01842802|Device|YAG laser|YAG laser for treatment of subcutaneous fat
168261|NCT01842815|Device|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwante, non cosmetic, tattoos.
168262|NCT01842828|Other|Standard care plus electronic cigarettes|
168263|NCT01842828|Behavioral|Standard care|
167652|NCT01854203|Drug|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
167653|NCT01854216|Drug|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
167654|NCT01854216|Drug|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
167655|NCT01854216|Drug|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
167656|NCT01854229|Device|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE-study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
167951|NCT01857011|Drug|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
167952|NCT01857024|Drug|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
167953|NCT01857037|Other|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
167954|NCT01857063|Drug|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
167955|NCT01859169|Procedure|Photodynamic therapy|﻿Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
167956|NCT01859182|Drug|selumetinib|Given PO
167957|NCT01859182|Drug|Akt inhibitor MK2206|Given PO
167958|NCT01859182|Other|laboratory biomarker analysis|Correlative studies
167959|NCT01859182|Other|pharmacogenomic studies|Correlative studies
167960|NCT01859182|Procedure|quality-of-life assessment|Ancillary studies
167961|NCT01859221|Radiation|SBRT/SHRT|SBRT/SHRT
167962|NCT01859234|Drug|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
167963|NCT01859247|Device|rTMS|
167330|NCT01860638|Radiation|Radiotherapy|Radiotherapy wil be administered as standard first-line treatment.
167331|NCT01860638|Drug|SOC|Post-PD1: SOC agent indicated for use in 3rd- and subsequent lines of treatment at the Investigator's discretion.
167332|NCT01860638|Drug|Temozolomide|Temozolomide will be adminsistered daily at standard doses orally.
167333|NCT01860651|Behavioral|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
167334|NCT01860664|Drug|hydrocortisone ophthalmic ointment 0.5%|Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID
Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.
Study medication dosing details:
0.05 grams hydrocortisone per gram of combination product
each application equal to 1/20th of a gram
total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone
total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone
Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone
167335|NCT01860664|Drug|placebo|
167336|NCT00002036|Drug|Anti-HIV Immune Serum Globulin (Human)|
167337|NCT00106366|Drug|insulin glargine|
167338|NCT01860677|Device|Fisher Wallace Cranial Stimulator|
167339|NCT01860690|Drug|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
167340|NCT01860703|Drug|Deferiprone|Ferriprox 500 mg tablets
167341|NCT01860703|Drug|deferiprone matching placebo tablets|deferiprone matching placebo tablets
167657|NCT00105547|Drug|MPC-7869|oral 800 mg BID
167658|NCT01854242|Other|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
167659|NCT01854255|Drug|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
167660|NCT01854268|Drug|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
167661|NCT01856413|Drug|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
167662|NCT01856426|Drug|EDP239|
167663|NCT01856426|Drug|Placebo|
167022|NCT01830244|Drug|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
167023|NCT01830257|Other|sending message|Sending the suggestive short message
167024|NCT01830270|Drug|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
167025|NCT01830270|Drug|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
167026|NCT01830270|Drug|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
167027|NCT01830270|Procedure|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
167028|NCT01830283|Biological|varicella vaccine|The providers would get varicella vaccine
167029|NCT01830296|Drug|Remifentanil+morphine|Morphine, Remifentanil+Morphine
167030|NCT01830309|Drug|CJ-12420 200mg|Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition
Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition
167031|NCT01830322|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
167032|NCT00103285|Radiation|3-dimensional conformal radiation therapy|Some patients undergo cranial radiotherapy
167033|NCT01830322|Drug|Gemcitabine|
167342|NCT01860703|Drug|moxifloxacin|Active control
167343|NCT01860703|Drug|placebo|moxifloxacin-matching placebo
167344|NCT01860716|Drug|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
167345|NCT01860716|Drug|Placebo|
167346|NCT01853631|Biological|CD19 Specific CAR T Cells|Group 1: CD19.CAR/28137ζ at 1×10^6 cells/m^2 and CD19.CAR/28ζ at 1×10^6 cells/m^2
Group 2: CD19.CAR/28137ζ at 5×10^6 cells/m^2 and CD19.CAR/28ζ at 5×10^6 cells/m^2
Group 3: CD19.CAR/28137ζ at 2×10^7 cells/m^2 and CD19.CAR/28ζ at 2×10^7 cells/m^2
167347|NCT01853644|Drug|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
167348|NCT01853657|Other|Virological monitoring|
154033|NCT01768897|Drug|CPI-613|Given IV
154034|NCT01768897|Drug|cytarabine|Given IV
154035|NCT00000122|Drug|5-Fluorouracil|
154036|NCT00000279|Drug|Clonidine|
154037|NCT00001903|Drug|RSV Polyclonal Immunoglobulin|
154038|NCT00097227|Drug|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
154039|NCT01768897|Drug|mitoxantrone hydrochloride|Given IV
154040|NCT01768897|Other|laboratory biomarker analysis|Optional correlative studies
154041|NCT01761565|Drug|Single dose of SUF NT 15 mcg|
154042|NCT01761565|Drug|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
154043|NCT01761578|Device|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
154044|NCT01761591|Device|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
154045|NCT01761591|Device|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
154046|NCT01761604|Device|Nasal ganglion block for TN|
154335|NCT00096603|Drug|Raptiva (efalizumab)|
154336|NCT01764685|Drug|Topiramate|Max therapeutic dose of 150mg/day
154337|NCT01764685|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
154338|NCT01764685|Drug|Placebo|Placebo
154339|NCT01764698|Behavioral|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
153785|NCT01770912|Drug|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
153786|NCT01763671|Drug|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
153787|NCT01763684|Device|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
153788|NCT01763684|Procedure|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
153789|NCT01763697|Behavioral|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
153790|NCT01763697|Behavioral|Recorded meal|
153791|NCT01763710|Drug|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
153792|NCT01763710|Drug|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
153793|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
153794|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
153795|NCT00001891|Procedure|Dobutamine echocardiography|
153796|NCT00096512|Drug|sorafenib tosylate|Given orally
153797|NCT01763723|Device|IPL-home use device|A light based home use device for hair removal
153798|NCT01763736|Behavioral|Music|playlist per patient preference
153799|NCT01763749|Drug|Closone|Closone 75mg/100mg, 4weeks, PO
153800|NCT01763749|Drug|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
153801|NCT01763762|Behavioral|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
153802|NCT01763762|Behavioral|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
156552|NCT01811745|Behavioral|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
156553|NCT01811758|Behavioral|Culturally Specific CBT|
156554|NCT01811758|Behavioral|Standard CBT|
156555|NCT01811771|Biological|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
156860|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
156861|NCT01805193|Other|Computed tomography myocardial perfusion imaging|
156862|NCT01805193|Other|Oxygen 15 labelled water positron emission tomography|
156863|NCT01805206|Other|Assessment of urinary iFABP|
156864|NCT01805206|Other|Administration of enteral feedings|
156865|NCT01805219|Other|GPS and accelerometer recording (s) during exercises|
156866|NCT01805232|Drug|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
156867|NCT01805232|Drug|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
156868|NCT01805245|Behavioral|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
156869|NCT00100841|Biological|cetuximab|Given IV
156870|NCT01805258|Drug|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
156871|NCT01805258|Drug|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
156872|NCT01805271|Drug|Everolimus|(10mg/day, i.e. 2 tablets/day)
156873|NCT01805271|Drug|Placebo|
156254|NCT01808976|Other|Problem Solving Therapy|
156255|NCT01808976|Behavioral|Evolution|
156256|NCT01808976|Behavioral|Baisc health push|
156257|NCT01808989|Other|Exercise oxymetry|
156258|NCT01809002|Biological|Processed Nerve Allograft (human)|
156259|NCT01809002|Device|Collagen Nerve Cuff|Bovine collagen based nerve cuff
156260|NCT01809028|Procedure|EUS FNA with 2 passes|biopsy with 2 passes
156261|NCT01809028|Procedure|EUS FNA with 4 passes|biopsy with 4 passes
156262|NCT01809041|Drug|Sevoflurane|
156263|NCT00101114|Biological|recombinant interferon alfa-2b|Given SC
156264|NCT01809041|Drug|propofol|
156265|NCT01809041|Drug|remifentanil|
156266|NCT01809054|Drug|Arixtra|
156267|NCT01809054|Device|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
156268|NCT01809054|Drug|Aspirin|
156269|NCT01809067|Other|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
156578|NCT01804647|Other|No study treatments administered - blood draws only|
156579|NCT01804660|Other|No study treatments administered|
156580|NCT01804673|Drug|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
156581|NCT01804686|Drug|PCI-32765 (Ibrutinib)|PCI-32765 (Ibrutinib) will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent PCI-32765 clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
156582|NCT01804712|Drug|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
156583|NCT01804738|Other|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
155975|NCT01806051|Drug|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
155976|NCT01806064|Drug|TRC105 and Axitinib|
155977|NCT01806077|Drug|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
155978|NCT01806090|Drug|clopidogrel|continue clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
155979|NCT01806090|Drug|clopidogrel|Stop clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
155980|NCT01806103|Behavioral|Antimicrobial Stewardship Bundle|Guidelines, Education, Audit and Feedback
155981|NCT01806116|Drug|decitabine|
155982|NCT01806129|Other|educational intervention|Undergo reproductive health program
155983|NCT01808573|Drug|capecitabine|2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal. Taken on days 1 to 14 of each 21 day cycle.
155984|NCT01808586|Procedure|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
155985|NCT01808586|Procedure|Dexamethasone|4mg/mL
155986|NCT01808586|Procedure|Intramuscular Lidocaine|2%
155987|NCT01808586|Behavioral|Home Exercise|Standardized home exercise program
155988|NCT01808599|Drug|Chlorambucil|
155989|NCT01808599|Drug|Rituximab i.v.|
155990|NCT00101101|Drug|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
155991|NCT01808599|Drug|Rituximab s.c.|
155992|NCT01808612|Drug|Fluoxetine|
155993|NCT01808612|Drug|Placebo|
155994|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
155995|NCT01808638|Drug|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
157911|NCT01773395|Drug|Tacrolimus|
157912|NCT01773395|Drug|Methotrexate|
157913|NCT01773408|Drug|RO5503781 MDP|multiple escalating doses, current formulation
157914|NCT01775969|Other|Text Message|A text message with instructions is sent to the patient
157915|NCT01775969|Other|Voicemail|A voicemail with instructions is sent to the patient
157916|NCT00097955|Drug|aliskiren|
157917|NCT01775982|Other|Psychiatric evaluation|This evaluation is carried out in several stages:
Assessment of cognitive functioning;
Interview with a relative;
Interview with caregivers;
Evaluation of the presence of delirium according to DSM-IV criteria;
Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;
Reports of adverse events.
A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment.
157918|NCT01775982|Other|Geriatric evaluation|This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.
CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.
A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment.
158160|NCT01782378|Device|Intranasal LED device, Sham intranasal device appears identical but has power output of 0.|Red and Near-infrared LED devices will be used.
Power output: 6.5 mW
Power density: 7.6 mW/cm2
Wavelength: 633 and 810 nm
158161|NCT01782391|Device|Stimulation|
158162|NCT01782391|Device|SHAM|no stimulation
158163|NCT01782404|Device|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
158164|NCT01782417|Behavioral|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
158165|NCT00001934|Drug|Zenapax|
158166|NCT00098618|Other|laboratory biomarker analysis|Correlative studies
158167|NCT01782430|Procedure|- standard oxygenation|
158168|NCT01782443|Drug|Ziv-aflibercept|
158169|NCT01782456|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
158170|NCT01782482|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
157608|NCT01772849|Behavioral|Intervention group|The intervention components includes (real time sequence):
An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.
Appointment of two classmates as "ambassadors" Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors
157609|NCT01772862|Behavioral|Intervention group|The intervention components includes (real time sequence):
An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.
Appointment of two classmates as "ambassadors". An individualized physical training program combining supervised and non-supervised training 3-5 times per week.
Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors
157610|NCT01772875|Procedure|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
157611|NCT01772901|Other|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
157612|NCT01772927|Dietary Supplement|Parenteral Nutrition|Protein and energy intakes
157613|NCT01775371|Procedure|Usual Care|Usual opioid analgesia determined by the provider
157614|NCT01775384|Dietary Supplement|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
157615|NCT01775384|Dietary Supplement|Placebo|
157616|NCT01775397|Drug|Fidaxomicin|capsule
157617|NCT01775397|Drug|Vancomycin|capsule
157618|NCT01775397|Drug|Placebo|Capsule
157619|NCT01775410|Device|Wolverine System to perform atherectomy|
157620|NCT01775423|Drug|BBI608|
157621|NCT00097890|Drug|Replagal (Agalsidase Alfa)|
157941|NCT01779102|Biological|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
157942|NCT01779102|Biological|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
157943|NCT01779128|Procedure|PET-CT|
157344|NCT01772511|Behavioral|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
157345|NCT01772524|Biological|ALD403|
157346|NCT01774864|Drug|DA-8159 (Udenafil)|
157643|NCT01778517|Other|Group Psychotherapy|
157644|NCT01778517|Other|Cognitive behavior therapy based on self help|
157645|NCT01778530|Drug|TRC105|Intravenous infusion.
157646|NCT01778556|Biological|Metreleptin|Recombinant analog of the human hormone, leptin
157647|NCT01778621|Device|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
157648|NCT00098254|Drug|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
157649|NCT01778634|Drug|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
157650|NCT01778634|Drug|Placebo (for azithromycin)|
157651|NCT01778647|Dietary Supplement|Stimulants plus Lovaza (drug)|Patients randomized to Stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. COnners and CGI scales filled out by PArents, teachers and Evaluators on each visit
157652|NCT01778647|Drug|Stimulants plus Placebo (instead of Lovaza)|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
157653|NCT01778660|Other|Type of Counselling (Mnemonic)|
157654|NCT01778660|Other|Standard|
157655|NCT01778673|Procedure|Cast immobilization|
157656|NCT01778686|Drug|Citalopram and Pindolol|Citalopram: selective serotonin reuptake inhibitor
Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist
157657|NCT01778686|Other|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
157658|NCT01778686|Dietary Supplement|Acute tryptophan depletion|
157659|NCT00098280|Drug|Eculizumab|
157069|NCT01810471|Device|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
157070|NCT01810484|Device|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
157071|NCT00001991|Drug|Atovaquone|
157072|NCT00101179|Drug|Azacitidine|Given SC
157073|NCT01810484|Device|Ultherapy® treatment and CO2 laser treatment|Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;
CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
157074|NCT01810484|Device|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
157075|NCT01810497|Procedure|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
157365|NCT00097838|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
157366|NCT01777893|Behavioral|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
157367|NCT01777893|Behavioral|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
157368|NCT01777919|Drug|Temozolomide|
157369|NCT01777919|Drug|Disulfiram|
157370|NCT01777919|Drug|Copper|
157371|NCT01777997|Drug|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|
157372|NCT00098163|Biological|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
157373|NCT01778010|Drug|Modafinil|Modafinil (300 mg) administration for 3 weeks
157374|NCT01778010|Drug|Modafinil|Modafinil (300 mg/day) for 3 weeks
157375|NCT01778023|Drug|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
157376|NCT01778049|Drug|BI 10773|Empagliflozin active
157377|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
157378|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
156805|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine|
156806|NCT01810029|Behavioral|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
156807|NCT01810042|Drug|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
156808|NCT00101140|Procedure|peripheral blood stem cell transplantation|
156809|NCT01810068|Procedure|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
156810|NCT01810068|Procedure|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
156811|NCT01810068|Procedure|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
156812|NCT01810068|Procedure|Diagnostic cystoscopy|Cysto-urethroscopy
156813|NCT01810094|Device|Fracture Fixation|Thoracolumbar Fracture Fixation
156814|NCT01810107|Procedure|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
156815|NCT01810120|Biological|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
156816|NCT01810146|Other|Digestive functions investigations|
156817|NCT01810159|Other|Integrated collaborative care|
157098|NCT01803152|Drug|Gemcitabine|After surgery and leukapheresis is completed and subject is cleared, gemcitabine 1000 mg/m2 IV wil be administered weekly x 3 followed by a week rest.
157099|NCT00100646|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
157100|NCT01803152|Other|Imiquimod|Subjects will self-apply imiquimod one night before and each night for two nights after the scheduled administration of DC or lysate. Investigator will instruct the subject to apply a thin layer of imiquimod on the selected area (approximately the area of a silver dollar) of both arms,or thigh. Subjects are advised to rinse the selected area with water (where imiquimod is applied) the morning after application. Subjects will be given a medication diary when supplied with imiquimod in which they will record both the time of application of the imiquimod, and the time of rinse of the imiquimod.
157101|NCT01803152|Procedure|Leukapheresis|Blood draw post-surgery via central venous catheter to obtain peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained.
157102|NCT01805583|Other|Acceptance and Commitment Therapy (ACT)|
157103|NCT01805583|Other|workplace intervention (WPI)|
156522|NCT01807117|Procedure|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
156523|NCT01807117|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
156524|NCT01807130|Other|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
156525|NCT01807130|Other|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
156526|NCT01807143|Other|laboratory biomarker analysis|Correlative studies
156527|NCT01807156|Drug|Tivozanib|Oral medication given daily. No placebo.
156528|NCT01807169|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
156529|NCT01807182|Biological|Aldesleukin|Given IV
156530|NCT01809431|Behavioral|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
156531|NCT01809444|Drug|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
156532|NCT00101140|Drug|anti-thymocyte globulin|
156533|NCT01809444|Drug|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
156534|NCT01809457|Other|educational poster|educational poster for dental trauma
156535|NCT01809470|Behavioral|FIFA2013|Playing FIFA2013 for 1 hour
156536|NCT01809470|Behavioral|Call of Duty|Playing Call of Duty for 1 hour
156537|NCT01809470|Behavioral|Watching TV|Watching TV for 1 hour
156841|NCT01792622|Other|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
156842|NCT01792635|Drug|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
163562|NCT01822119|Device|Baha Attract System|
163860|NCT01814748|Drug|Placebo to MK-3102|Matching placebo to MK-3102 25 mg capsule administered orally once weekly
163861|NCT01814748|Drug|Metformin|Participants exceeding pre-specified glycemic thresholds during the double-blind treatment period will receive rescue therapy with open-label metformin.
163862|NCT01814761|Drug|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
163863|NCT01814774|Other|No Intervention|No treatment (intervention) was administered.
163864|NCT00101686|Drug|Modified Bolus 5-FU/LV with Irinotecan|Day 1 & 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID [two times a day] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
163865|NCT01814787|Other|CHICA Type 2 Diabetes Module|Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI > 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
163866|NCT01814800|Biological|RI-002|
163867|NCT01814813|Biological|HSPPC-96|intradermal infusion
163868|NCT01814813|Drug|bevacizumab|intravenous
163869|NCT00001997|Drug|Zidovudine|
163870|NCT00101933|Device|Medtronic DBS Therapy for epilepsy|Stimulation On
163871|NCT01817283|Drug|placebo|Placebo pills produced the same as Triptolide wilfordii.
163872|NCT01817296|Procedure|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
163873|NCT01817309|Other|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
163874|NCT01817322|Drug|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
163875|NCT01817322|Drug|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
168264|NCT01842841|Drug|velaglucerase alfa|15-60 U/kg, EOW
168265|NCT01842893|Drug|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
168266|NCT01842906|Device|Theravent|nasal EPAP device
168267|NCT00104572|Drug|Placebo gel|Daily for 12 months
168268|NCT01842906|Device|Control|Sham device without EPAP
163563|NCT01822132|Drug|Extended release naltrexone|
163564|NCT01822132|Drug|Placebo|
163565|NCT01822145|Device|ICD|
163566|NCT00102440|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
163567|NCT01822158|Other|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
163568|NCT01822171|Other|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
163569|NCT01822171|Other|Home medication if needed|Patient will be provided with medication to take home, when needed.
163570|NCT01822171|Other|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
163571|NCT01814202|Other|PTM202|
163572|NCT01814202|Other|Placebo|
163573|NCT01814215|Behavioral|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
163574|NCT01814228|Procedure|transcatheter ablation of ganglionated plexi in right atrium|
163575|NCT01814241|Drug|Peanut protein|Subject will take varying amounts of peanut protein starting with a small amount and building up over time to larger amounts.
163576|NCT01814267|Other|telemedicine|Intervention group: care and follow-up through telemedicine (e-consultations)
1 hospital consultation at inclusion time, week 0
then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.
1 hospital consultation to validate that the wound is well-healed
167964|NCT01859260|Device|CPAP/autopap|
167965|NCT00106249|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
167966|NCT01859273|Behavioral|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
167967|NCT01859286|Other|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
167968|NCT01859312|Drug|Hydrocortisone (Solucortef)|
167969|NCT01859312|Device|Insulin pump (Medtronic)|
168269|NCT01842919|Other|Kinesthetics tests|
168270|NCT01842919|Other|Psychological questionnaires|
168271|NCT01842919|Other|structural Magnetic ResonanceImaging (MRI)|
168272|NCT01842932|Drug|Phloroglucin|Premedication of colonoscopy
168273|NCT01842932|Drug|Cimetropium bromide|Premedication of colonoscopy
168274|NCT01842932|Procedure|Colonoscopy|Diagnostic examination of colon
168275|NCT01842932|Drug|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
168276|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
168277|NCT01852864|Drug|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
168278|NCT00105664|Procedure|Collaborative care model|
168279|NCT01855230|Drug|Placebo|Placebo b.i.d. for 14 days
168280|NCT01855243|Drug|regular insulin|
168281|NCT01855243|Drug|70/30 insulin|
167664|NCT01856439|Drug|ProSavin|Long term follow up of patients who received ProSavin in a previous study
167665|NCT00105833|Behavioral|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
167666|NCT01856452|Device|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
167667|NCT01856452|Device|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
167668|NCT01856478|Drug|methotrexate|intravenous bolus injection, once weekly
167669|NCT01856478|Drug|afatinib|oral intake, once daily
167670|NCT01856491|Device|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
167671|NCT01856517|Drug|Clonidine|
167672|NCT01856517|Drug|Placebo|
167673|NCT01856530|Drug|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
167674|NCT01856530|Drug|Placebo|Matched placebo nasal spray
167675|NCT01856543|Other|Eucerin|
167676|NCT00105846|Procedure|Home care telemedicine|
167677|NCT01856543|Other|Mometasone Furoate 0.1%|
167678|NCT01856556|Drug|NRX-1074|Single IV or PO administration
167679|NCT01856556|Drug|Placebo|Single IV or PO placebo administration
167970|NCT01859325|Biological|rVSV|Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene
167971|NCT01859325|Biological|IL-12 pDNA adjuvant|plasmid DNA containing human IL-12 gene
167972|NCT01859325|Biological|HIV-Mag pDNA|plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins
167973|NCT01859325|Drug|Placebo|
167974|NCT01859338|Procedure|cone-beam computed tomography|Undergo CBCT
167975|NCT01859338|Procedure|magnetic resonance imaging|Undergo MRI
167349|NCT01853670|Radiation|concurrent chemo + IGRT|
167350|NCT01853670|Radiation|neoadjuvant chemo + IGRT|
167351|NCT01853683|Procedure|Conservative Management|
167352|NCT01853683|Procedure|Operative Management|
167353|NCT01853696|Drug|loteprednol etabonate|
167354|NCT00105482|Behavioral|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
167355|NCT01853696|Drug|prednisolone acetate 1%|
167356|NCT01853709|Behavioral|Education|
167357|NCT01853709|Other|Fiber free diet|
167358|NCT01853709|Dietary Supplement|Adjuvants|
167359|NCT01853709|Drug|Polyethylene glycol (PEG)|
167360|NCT01853709|Drug|Bisacodyl|
167361|NCT01853722|Drug|DCN01|Three serial applications per periocular region.
167362|NCT01853722|Drug|Unisol|Three serial applications per periocular region.
167363|NCT01853748|Drug|Trastuzumab|
167364|NCT01853748|Drug|Paclitaxel|
167365|NCT00105495|Drug|Ferriprox (deferiprone)|
167366|NCT01853748|Drug|Trastuzumab emtansine|
167680|NCT01856569|Other|no intervention|in real life of drug,dosage,frequency and duration
167681|NCT01856582|Biological|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
167682|NCT01856595|Drug|PF-06291874|The dosing schedule is 5, 15, 50 and 150 mg QD for 14 days for the first 4 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days. Doses for part A cohort 5 and Part B cohorts 2 and 3 are TBD QD for 28 days.
167683|NCT01856595|Drug|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1-4 and Part B cohort 1) or 28 days (Part A cohort 5 and Part B cohorts 2 and 3).
167684|NCT01856621|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
154340|NCT01764698|Behavioral|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
154341|NCT01764711|Drug|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
154342|NCT01764724|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
154343|NCT01764737|Drug|VX15/2503|single dose intravenous administration
154344|NCT01764737|Drug|Placebo|single dose intravenous administration
154345|NCT01764750|Drug|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
154346|NCT00096941|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
154347|NCT01766908|Other|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
154348|NCT01766921|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
154349|NCT01766947|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
154350|NCT01766960|Other|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
154351|NCT01766960|Drug|Morphine|Five milligrams of intravenous morphine will be administered.
153401|NCT01770145|Drug|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
153402|NCT01770145|Drug|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duratoin of the APOKYN Initiation Period and APOKYN Treatment Period.
153403|NCT00097344|Procedure|Endocrine therapy|
153404|NCT01770171|Drug|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
153405|NCT01770171|Drug|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
153406|NCT01770184|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
154098|NCT01766661|Procedure|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
154099|NCT01768897|Other|pharmacological study|Correlative studies
154100|NCT01768910|Other|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
154101|NCT01768910|Other|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
154102|NCT01768910|Other|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
154103|NCT01768910|Other|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
154104|NCT01768923|Procedure|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score [SDAI] <3.3)
154105|NCT01768923|Procedure|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28<2.6) (minimal disease activity group)
154106|NCT01768949|Device|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
154107|NCT00097253|Behavioral|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
154108|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel|Vaginal
154109|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|
154110|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|
154111|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel - Vaginal|
154112|NCT01768975|Drug|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
154113|NCT01768975|Other|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
154114|NCT01768988|Drug|Placebo|
154115|NCT01768988|Drug|Pregabalin|Treatment during 90 days with pregabalin.
154116|NCT01769001|Drug|PRX-102|Comparison of different doses of drug
156874|NCT01805284|Drug|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
156875|NCT01805297|Drug|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
156876|NCT01807637|Device|transcranial direct current stim|tDCS will be applied using a Life-Tech®, Iontophor PM Deluxe constant current stimulator with carbon rubber electrodes encased in saline (0.9% NaCl) soaked sponges that measure 5 x 5 cm (25cm2) for the anode and 5x7 for the cathode (35cm2). The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere. The cathodal electrode will be placed over the contralateral supraorbital region.
156877|NCT01807650|Drug|Oleogel-S10 ointment and non-adhesive wound dressing|One randomly assigned wound half is treated with Oleogel-S10 and non-adhesive wound dressing
156878|NCT01807650|Device|Non-adhesive wound dressing alone|The other wound half is treated with non-adhesive wound dressing alone.
156879|NCT00101036|Drug|lapatinib ditosylate|Given PO
156880|NCT01807663|Device|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
157147|NCT01810562|Other|Specific treatment in addition to standard stroke care|Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.
Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.
Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.
Scrolling with spiked ball over the same area as brushing for two minutes evenly.
Firm pressure for two minutes evenly in the same area.
157148|NCT01810575|Drug|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
157149|NCT01810575|Drug|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
157150|NCT01810575|Drug|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
157151|NCT01810588|Device|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
157152|NCT01810588|Drug|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
157153|NCT01810588|Drug|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
156584|NCT01804738|Other|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
156585|NCT01804777|Drug|Amiloride|Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.
On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet.
156586|NCT01804777|Drug|HCTZ|HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.
On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet
156587|NCT00100802|Procedure|adjuvant therapy|
156588|NCT01804790|Drug|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles:oxaliplatin: 85 mg/m2 in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m2 simultaneously in 2 hours at D1 during the irinotecan infusion 5FU : 2400 mg/m2 continuous infusion during 48 hours (1200 mg/m2 at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800mg/m2 bid 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on ypTNM and center choice.
156589|NCT01804790|Radiation|Radiotherapy 50Gy|5 radiations per week of 2 Gy for 5 weeks
156590|NCT01804790|Drug|Capecitabine|1600mg/m2 (800mg/m2 twice daily) for 5 weeks
156591|NCT01804790|Procedure|TME surgery|
156592|NCT01804790|Drug|mFolfox6 or capecitabine|oxaliplatine 85mg/m2 (day 1 of cycle; perfusion in 2h), folinic acid 400mg/m2 (day 1 of cycle perfusion in 2h), 5-fluorouracil (bolus 4OOmg/m2 in 10min and 2400mg/m2 perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500mg/m2/day (Each cycle consists of 1250mg/m2 twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
156593|NCT01807182|Drug|Cyclophosphamide|Given IV
156594|NCT01807182|Drug|Fludarabine Phosphate|Given IV
156595|NCT00101010|Biological|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
156596|NCT01807182|Other|Laboratory Biomarker Analysis|Correlative studies
156901|NCT01810250|Device|Endurant Stent Graft|
156902|NCT01810263|Dietary Supplement|high protein supplement|Dietary Supplement: high protein supplement
156903|NCT01810276|Other|Saline|400 mL of Saline will be given intravenously over 2 hours once
156904|NCT01810276|Other|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
155996|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 1|Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.
Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs.
156296|NCT01811563|Device|Stryker|
156297|NCT01811576|Drug|TV-1106|
156298|NCT00101283|Drug|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
156299|NCT01811576|Drug|Recombinant human growth hormone|Subcutaneous once daily
156300|NCT01811589|Device|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
156301|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
156302|NCT01811602|Other|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
156303|NCT01804166|Biological|Collection of samples|There is no study-related therapeutic intervention and this protocol will not restrict or introduce any therapeutic interventions, including medications.
156304|NCT01804179|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
156305|NCT01804179|Other|Standard Intervention (SI) Educational Materials|"Screen for Life" brochure
156306|NCT01804179|Other|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
156307|NCT01804179|Other|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
156308|NCT01804179|Other|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
158171|NCT01782482|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
158172|NCT01782495|Drug|ABT-450/r/ABT-267|tablet
158173|NCT01782495|Drug|ABT-333|tablet
158174|NCT01782495|Drug|ribavirin (RBV)|tablet
158175|NCT01773772|Drug|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
158176|NCT01773785|Drug|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
158177|NCT01773798|Drug|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
158178|NCT00001917|Drug|[F-18] FP-TZTP|
158179|NCT00097760|Drug|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
158180|NCT01773798|Drug|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
158181|NCT01773798|Drug|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
156011|NCT01810978|Dietary Supplement|Maltodextrin|same amount of maltodextrin per day will be given as placebo
156012|NCT01810991|Device|Nd:YAG Laser|Nd:YAG 1440nm Laser
156013|NCT01811004|Device|miraDry|miraDry
156014|NCT01811004|Device|Nd:YAG Laser|Nd:YAG 1440 nm Laser
156015|NCT01811004|Device|Botox®|Botox®
156016|NCT01811017|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
156017|NCT01811030|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
156018|NCT00101244|Other|laboratory biomarker analysis|Correlative studies
156019|NCT01811043|Behavioral|Guided Meditation|
156020|NCT01811043|Behavioral|Music|
157944|NCT01779128|Procedure|MR-PET|
157945|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
157946|NCT01779167|Drug|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 & 27)
157947|NCT01779167|Drug|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 & 28). Lenalidomide will be initiated at a starting dose of 5 mg.
157948|NCT01779167|Drug|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
157949|NCT01779193|Dietary Supplement|lactic acid bacteria|oral lactobacillus capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
157950|NCT01779193|Dietary Supplement|cranberry|oral cranberry capsule, one pill daily
157951|NCT01779193|Dietary Supplement|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
157952|NCT01779206|Drug|Epirubicin|
157953|NCT01779206|Drug|Cyclophosphamide|
157954|NCT01779206|Drug|Docetaxel|
157955|NCT01779206|Drug|Paclitaxel|
157956|NCT00098306|Drug|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
157957|NCT01779219|Device|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
157958|NCT01779219|Device|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
157959|NCT01779232|Drug|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
157960|NCT01779232|Drug|placebo|administered daily like the active comparator
158202|NCT01776554|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
158203|NCT01776567|Device|Everolimus eluting stents|
146758|NCT01689519|Drug|Cobimetinib|Cobimetinib was supplied as tablets.
146759|NCT01689532|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
145802|NCT00090025|Drug|5-Fluorouracil Plus Leucovorin|5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
145803|NCT01692821|Drug|100% oxygen breathing|100% oxygen breathing - 30 minutes
145804|NCT01692821|Drug|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
145805|NCT01692821|Drug|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
145806|NCT01692834|Drug|Sandimmune® Injection|
145807|NCT01692834|Drug|NeuroSTAT®|
145808|NCT01695824|Drug|Warfarin|Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for "Watchman group"
All patients in "Warfarin group" continued to receive Warfarin during hole study period with IMR from II to III.
145809|NCT01695837|Behavioral|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
145810|NCT00090246|Drug|Comparator: ondansetron IV|
145811|NCT01695850|Drug|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
145812|NCT01695850|Drug|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
145813|NCT01695850|Drug|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
145814|NCT01695863|Drug|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
145815|NCT01695876|Drug|AMG 357|Oral administration available in varying dose strength.
145816|NCT01695876|Drug|Placebo|Matching placebo to AMG 357 containing no active drug
145817|NCT01695902|Drug|Levosert-20|
145818|NCT01695902|Drug|Mirena|
145819|NCT01695915|Procedure|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
146513|NCT01691560|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
146514|NCT01691560|Drug|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
146515|NCT01691560|Drug|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
146516|NCT01694082|Behavioral|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
146517|NCT01694082|Behavioral|Brief brochure and assessment control|
146518|NCT01694108|Biological|BCG-vaccine (SSI)|
146519|NCT01694121|Behavioral|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
146520|NCT00090129|Drug|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
146521|NCT01694121|Behavioral|Comparison|general health intervention for men, not inclusive of HIV or relationship health
146811|NCT01697605|Drug|BGJ398|
146812|NCT01697618|Drug|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
146813|NCT01697618|Drug|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
146814|NCT01697631|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
146815|NCT01697631|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
146816|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
146817|NCT01697644|Drug|somatropin|6 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
146818|NCT01697657|Drug|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
150348|NCT01739088|Other|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
150349|NCT00094666|Drug|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
150350|NCT01739088|Other|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
150351|NCT01739101|Behavioral|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
150352|NCT01739114|Procedure|"IPPV group"|Infants randomized into the "IPPV group" will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided.
150353|NCT01739114|Procedure|SI group|Infants randomized into the "SI group" will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided
150354|NCT01739127|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
150355|NCT01739127|Drug|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
150356|NCT01739140|Behavioral|Yoga|
150357|NCT01739153|Other|Dietary intervention: CHEESE (High cheese intake)|
150358|NCT01739153|Other|Dietary intervention: MEAT (High Meat intake)|
150359|NCT01739153|Other|Dietary intervention: CARB (High Carbohydrate intake)|
150713|NCT01737177|Drug|Bendamustine, Lenalidomide, Rituximab|INDUCTION PHASE (COURSE 1-4)
Bendamustine: 70 mg/m2 on day 2 and 3 every 28
Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course
Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8
CONSOLIDATION PHASE (courses 5-6)
Patients in CR and PR at the end of the induction phase
Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.
Rituximab: 375 mg/m2 on day 1 every 28 days
MAINTENANCE PHASE (courses 7-24)
Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)
- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days
150714|NCT01740063|Drug|DAS181-F04 formulation|
150715|NCT01740063|Drug|Placebo|
149832|NCT01705041|Device|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
149833|NCT01705067|Device|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
150101|NCT01703117|Drug|Riluzole|24 subjects between the ages of 60-85 will receive study drug.
150102|NCT01703117|Drug|Placebo|24 subjects between the ages of 60-85 will receive placebo
150103|NCT01703130|Procedure|Dose of of ropivacaine 0.75% used in block procedure|
150104|NCT00091130|Other|laboratory biomarker analysis|Correlative studies
150105|NCT01703143|Procedure|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
150106|NCT01703156|Procedure|Stress Test|
150107|NCT01703156|Procedure|No Stress Test|
150108|NCT01703169|Drug|Eltrombopag|Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
150109|NCT01703195|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
150110|NCT01703195|Procedure|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
150111|NCT01703208|Drug|Omarigliptin|
150112|NCT01703208|Drug|Placebo|
150113|NCT01703221|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
150114|NCT01703221|Drug|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
150115|NCT00001741|Drug|Losartan|
150116|NCT00091338|Biological|gp100 antigen|
150117|NCT01705509|Drug|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
149595|NCT01699776|Drug|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
149596|NCT01699789|Other|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
149597|NCT01699789|Behavioral|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
149598|NCT01699789|Behavioral|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
149599|NCT00090844|Drug|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
149600|NCT01699802|Other|Inhaled anaesthetic agent|
149601|NCT01699815|Drug|Acetaminophen|
149602|NCT01699828|Drug|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
149603|NCT01699828|Drug|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
149604|NCT01699854|Drug|capsaicin patch (qutenza)|
149605|NCT01699854|Drug|Placebo|
149606|NCT01699867|Device|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
149607|NCT01699893|Other|unique arm|blood, nasal swab, skin biopsy, stool samples
149608|NCT01699906|Other|Diet regimen to induce weight loss|Diet regimen to induce weight loss
149896|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
149897|NCT01702688|Drug|Para-aminohippuric Acid|Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated "PAH".
149898|NCT01702688|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
150265|NCT01738945|Drug|Amlodipine|10 mg/day for 12 weeks
150611|NCT01736982|Drug|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)],|
150612|NCT01736982|Behavioral|Breath sample monitoring|
150613|NCT01736995|Behavioral|Functional Family Therapy|
150614|NCT01736995|Behavioral|Motivational Enhancement Tx/Cognitive Behavioral Tx|
150615|NCT01736995|Behavioral|Contingency Management|
150616|NCT01737008|Drug|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
150617|NCT00094432|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
150618|NCT01737008|Radiation|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
150619|NCT01737008|Drug|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
150620|NCT01737021|Other|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
150621|NCT01737034|Other|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
150622|NCT01737060|Device|Reverse total shoulder arthroplasty|
150623|NCT01739491|Drug|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
150624|NCT01739504|Procedure|Autologous AD-MSC harvesting through Liposuction for Intra-articular Injection|Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-MSC can be obtained in large quantities after processing of adipose tissue in the laboratory.
Adipose tissue is washed, centrifuged to remove tumescent fluids, oil, and cellular debris to isolate AD-MSC.
AD-MSC to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.
AD-MSC are evaluated to verify viability and number of total cells to determine quality control of the fresh product.
Cells will be re-suspended in autologous Platelet Rich Plasma (PRP) from the patient's blood sample to augment natural regenerative pathways.
Patient's AD-MSC combined with PRP are used for direct intra-articular injection after processing.
150625|NCT01739517|Drug|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
150053|NCT01708213|Device|Aline HA|Implantable dermal filler
150054|NCT01708226|Behavioral|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
150055|NCT00091676|Biological|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
150056|NCT01708239|Other|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
150057|NCT01708252|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
150058|NCT01708265|Other|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
150059|NCT01708265|Procedure|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
150321|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
150322|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
150323|NCT01736475|Biological|PEGylated Recombinant Factor VIII|On-demand treatment
150324|NCT01736488|Drug|Fimasartan|Fimasartan 60mg
150325|NCT01736488|Drug|Atenolol|Atenolol 50mg
150326|NCT01736501|Other|Genetics education at baseline|
150327|NCT01736501|Other|Hypothetical genomic scenarios at follow-up|
150328|NCT01736514|Drug|febuxostat|oral
150329|NCT01736514|Drug|Allopurinol|oral
150330|NCT01736527|Drug|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
150331|NCT00001832|Drug|Montanide ISA-51|MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
150332|NCT00094367|Drug|Abacavir/Lamivudine|
150333|NCT01736540|Device|MRI scan|All patients will be subjected to the non-invasive hepatic and cardiac MRI test to measure iron overload.
148219|NCT01717612|Drug|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
148220|NCT01717612|Drug|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
148221|NCT01717625|Drug|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
148222|NCT01717638|Biological|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
148223|NCT01717638|Biological|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
148224|NCT01717664|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
148225|NCT01717677|Procedure|radical prostatectomy|
148226|NCT00092547|Biological|Comparator: Placebo|0.5 mL intramuscular injection of placebo
148227|NCT01717677|Radiation|percutaneous radiation therapy|
148228|NCT01717677|Radiation|permanent seed implantation|
148229|NCT01717677|Procedure|Active Surveillance|
148230|NCT01717690|Drug|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
148231|NCT01717703|Dietary Supplement|Water|
148232|NCT01717703|Dietary Supplement|Fruit drink|
148233|NCT01717703|Dietary Supplement|Cola|
148234|NCT01717703|Dietary Supplement|1% chocolate milk|
148235|NCT01717716|Dietary Supplement|water with Sucralose|
148236|NCT01717716|Dietary Supplement|water with HFCS|
148542|NCT01710553|Other|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
148543|NCT01713023|Dietary Supplement|Fructose|The same described in Arm description
149250|NCT01701700|Procedure|optical aids|
149251|NCT01701713|Device|DKI ED2011|
149252|NCT01701713|Device|Sham-TDCS|
149253|NCT01701726|Other|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
149254|NCT01701739|Drug|aleglitazar|Multiple doses of aleglitazar
149255|NCT01701739|Drug|digoxin|Single dose of digoxin
149256|NCT01701752|Biological|FP-01.1 + Placebo|
149257|NCT00091078|Biological|oblimersen sodium|Given IV
149258|NCT01701752|Biological|FP-01.1 + TIV|
149259|NCT01701752|Biological|FP-01.1-Adjuvant + Placebo|
149260|NCT01701752|Biological|FP-01.1-Adjuvant + TIV|
149261|NCT01701752|Biological|Adjuvant + TIV|
149262|NCT01701752|Biological|Placebo + TIV|
149263|NCT01701752|Biological|FP-01.1|
149264|NCT01701752|Biological|FP-01.1-Adjuvant|
149265|NCT01701752|Other|Placebo|
149266|NCT01701778|Drug|Caudal Dexmedetomidine|Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg
Intravenous: 10 ml normal saline
149267|NCT01701778|Drug|Intravenous Dexmedetomidine|Caudal: Levobupivacaine 0.25% 1ml/kg
Intravenous: dexmedetomidine 1µg/kg
149268|NCT00091078|Drug|imatinib mesylate|Given orally
149269|NCT01701778|Drug|Placebo|Caudal: Levobupivacaine 0.25% 1ml/kg
Intravenous: 10 ml normal saline
149270|NCT01704261|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
148301|NCT01715025|Drug|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
148690|NCT01700881|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
148691|NCT01700881|Other|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
148692|NCT01700894|Behavioral|Walking Program + Motivational Interviewing Calls|
148693|NCT01700894|Behavioral|Walking Program + Automated Calls|
148694|NCT01700894|Behavioral|Walking Program|
148695|NCT00090987|Drug|imatinib mesylate|400 mg orally once a day for up to 6 months.
149005|NCT01703884|Drug|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
149006|NCT01703897|Device|Manometry and Impedance analysis|
149007|NCT01703910|Drug|Arm A chemotherapy|
149008|NCT00091169|Other|placebo|Given orally
149009|NCT01703910|Drug|arm B chemotherapy|
149010|NCT01703923|Drug|FP01|
149011|NCT01703923|Drug|placebo|
149012|NCT01703936|Other|Agricultural and life skills training program|
149013|NCT01703949|Drug|brentuximab vedotin|Given IV
149014|NCT01706341|Drug|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
149015|NCT00000271|Drug|Desipramine|
149016|NCT00001750|Drug|Stemgen|
149017|NCT00091429|Drug|Ranolazine|
149018|NCT01706341|Drug|acetate Ringer's solution containing no glucose|
149019|NCT01706341|Drug|acetate Ringer's solution containing 1% glucose|
149020|NCT01706354|Procedure|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
147866|NCT01719276|Other|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
147867|NCT01719289|Behavioral|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
147868|NCT01719302|Drug|Gemcitabine|1500 mg/m^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
147869|NCT01719302|Drug|Docetaxel|50 mg/m^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
147870|NCT01711658|Drug|Cisplatin|100 mg/m2 on days 8 and 29
147871|NCT01711658|Drug|placebo|1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 3 months
147872|NCT01711658|Drug|Lapatinib|1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 3 months
147873|NCT01711671|Drug|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
147874|NCT00092079|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
147875|NCT01711671|Drug|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
147876|NCT01711671|Drug|Standard of Care|Current approved standard of care
146936|NCT01689870|Drug|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
146937|NCT01689870|Drug|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
146938|NCT01689883|Device|Armeo Spring|Upper extremity robotic device for rehabilitation
146939|NCT01689883|Device|Stochastic Resonance Stimulation|Device that produces sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
146940|NCT01689896|Drug|Testosterone Gel|
146941|NCT01689896|Drug|Placebo Gel|
146942|NCT01689909|Drug|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
146943|NCT01689909|Drug|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
147572|NCT01719081|Procedure|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
147573|NCT01719107|Dietary Supplement|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
147574|NCT01719107|Dietary Supplement|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
147575|NCT01719120|Behavioral|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
147576|NCT01719133|Drug|placebo|saline solution
147577|NCT00092690|Drug|MK0653A, ezetimibe (+) simvastatin|
147578|NCT01719133|Drug|Histamine|positive control
147579|NCT01719133|Drug|AllerT1|synthetic peptide T1
147580|NCT01719133|Drug|AllerT2|synthetic peptide T2
147581|NCT01719133|Drug|AllerT3|synthetic peptide T3
147582|NCT01719133|Drug|AllerT4|synthetic peptide T4
147583|NCT01711359|Drug|Folic Acid|Administered orally every day
147584|NCT00092027|Drug|Comparator: placebo / Duration of Treatment: 6 months|
147585|NCT01711372|Device|Groundskeeper|A game created to be played on Sifteo Cubes to be used as a diagnostic aid for ADHD.
147586|NCT01711385|Behavioral|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
147587|NCT01711398|Drug|Drug|
147934|NCT01717235|Drug|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
147935|NCT01717248|Drug|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
147360|NCT00092638|Drug|Comparator: ezetimibe, placebo|
147361|NCT01718730|Device|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
147362|NCT01718730|Device|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
147363|NCT01718743|Drug|Lenalidomide|Starting dose: 10 mg by mouth every day in a 28 day cycle.
147364|NCT01718743|Drug|MLN9708|3 mg by mouth on days 1, 8, 15 in a 28 day cycle.
147365|NCT01718743|Radiation|Questionnaires|Questionnaire completion on Day 1 of Cycle 1, 2 and beyond.
147366|NCT01718756|Drug|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
147367|NCT01718756|Drug|Continuous infusion|The "continuous infusion" group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery
147368|NCT01718756|Drug|Scheduled|The "scheduled" group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia.
147369|NCT01718769|Other|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
147370|NCT01718782|Device|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
147371|NCT00092651|Drug|MK0653A, ezetimibe (+) simvastatin|
147372|NCT01718782|Device|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
147373|NCT01718795|Device|Bag-valve mask or laryngeal tube ventilation|Interventions are either "Bag-valve mask (BVM)" or "Laryngeal tube (LT)" ventilation during CPR
147374|NCT01718808|Drug|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
147375|NCT01718808|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
147376|NCT01718834|Biological|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
147377|NCT01718834|Biological|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
148108|NCT01714713|Drug|EVP-6124|Arm 1, 2
148109|NCT01714726|Drug|MEDI2070|1 iv infusion on Week 0 and Week 4
148110|NCT01714726|Drug|placebo|1 iv infusion on Week 0 and Week 4
147142|NCT01695447|Procedure|duct-to-mucosa|
147143|NCT01695447|Procedure|invagination|
147144|NCT01695447|Device|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
147145|NCT01695460|Drug|D3 Vitamin ®|Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.
All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast.
147146|NCT00090233|Biological|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
147147|NCT01695460|Drug|Placebo|
147148|NCT01695473|Drug|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
147149|NCT01695525|Other|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
147150|NCT01695538|Other|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
147151|NCT01695551|Other|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
147152|NCT01695564|Device|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
147153|NCT01695564|Device|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
147154|NCT01695577|Other|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
147155|NCT01695577|Other|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
146287|NCT01699282|Behavioral|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
146288|NCT01699295|Behavioral|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
146289|NCT01699295|Behavioral|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
146290|NCT01699308|Drug|Genotropin (somatropin)|
146291|NCT01699321|Behavioral|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
146292|NCT01699321|Other|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
146293|NCT01699334|Behavioral|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
146294|NCT01699334|Other|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
146295|NCT01699347|Drug|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
146296|NCT01699360|Drug|Cyclosporine A, Tacrolimus, Sirolimus|
146297|NCT00090753|Drug|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
146298|NCT01699373|Procedure|Ultrasound scan|Pre-procedural ultrasound scan was performed
146299|NCT01699386|Other|Control Study Formula|feed as lib
146300|NCT01699386|Other|Experimental Study Formula|feed as lib
146592|NCT01691703|Device|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
146593|NCT01691716|Drug|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
146594|NCT01694225|Other|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
146595|NCT01694238|Procedure|Cruciate incision|
146047|NCT01690676|Dietary Supplement|Epicatechin|
146048|NCT01690676|Dietary Supplement|Microcrystalline cellulose|
146049|NCT01690689|Device|Implant surgery|surgery
146050|NCT01690702|Drug|Epirubicin|
146051|NCT01690702|Drug|nab-Paclitaxel|
146052|NCT01690702|Drug|Cyclophosphamide|
146053|NCT01690702|Drug|Docetaxel|
146054|NCT01690728|Behavioral|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
146055|NCT01690741|Drug|Nerofe|Nerofe administered intravenously 3x/week
146056|NCT01690754|Other|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
146057|NCT00089843|Drug|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
146058|NCT01690767|Drug|2% lidocaine gel|Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
146059|NCT01690767|Drug|Health Care Lubricating Jelly|Non-medicinal lubrication gel
146060|NCT01690780|Drug|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
146061|NCT01690780|Drug|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
146062|NCT01693211|Device|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
146063|NCT01693224|Device|Alere "Determine" lateral-flow urine lipoarabinomannan assay|lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere
146064|NCT01693224|Device|Alere "Clearview" ELISA urine LAM assay|ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere.
146359|NCT00090363|Drug|Placebo|
145820|NCT01695928|Device|Extracorporeal shockwave therapy|1000 impulses
145821|NCT00090259|Drug|Losartan 50 mg|50-mg losartan oral tablet
145822|NCT01695928|Device|ESWT placebo|0 impulses, acoustic effect
145823|NCT01695941|Drug|Alisertib|Given PO
145824|NCT01695941|Drug|Bortezomib|Given SC
146124|NCT01698918|Drug|Letrozole|1st line study treatment: Letrozole will be self administered as a daily dose of 2.5mg continuously from study day 1 until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day, consistently with or without food. Everolimus and letrozole tablets should be taken together.
146125|NCT01698918|Drug|Exemestane|2nd Line Study Treatment: If patients progress on everolimus + letrozole, patients will be offered everolimus + exemestane. Exemestane will be self administered as a daily dose of 25mg taken orally continuously until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day after a meal. Everolimus and exemestane tablets should be taken together.
146126|NCT01690819|Procedure|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
146127|NCT01690819|Procedure|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
146128|NCT01690832|Drug|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
146129|NCT01690832|Drug|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
146130|NCT01690845|Device|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
146131|NCT01690858|Other|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
146132|NCT00089843|Drug|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
146133|NCT01690871|Drug|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
146134|NCT01690884|Drug|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
146819|NCT00090493|Biological|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
146820|NCT01697657|Drug|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
146821|NCT01697657|Drug|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
146822|NCT01697670|Drug|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
146823|NCT01697683|Drug|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
146824|NCT01697683|Drug|Placebo|
146825|NCT01689558|Drug|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
146826|NCT01689571|Drug|CHF6001|
146827|NCT00089700|Drug|TNX-355|
145887|NCT00090038|Drug|rituximab|Dose, schedule,and duration specified in protocol
145888|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
145889|NCT01692912|Other|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28<2.6
145890|NCT01692925|Drug|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
145891|NCT01692925|Drug|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
145892|NCT01692951|Other|blood sample|We will obtain daily blood samples from cancer patients enrolled under Specific Aim 1 while they remain hospitalized, and an additional sample one week after surgery.
145893|NCT01692977|Other|neuropsychological assessment|
150716|NCT01740076|Other|soy nuts|
150717|NCT01740089|Drug|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
150718|NCT01740089|Drug|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
150719|NCT01740089|Drug|Ribavirin|800-1400 mg/day orally
150720|NCT00094757|Drug|Comparator: sitagliptin 100 mg|sitagliptin 100 mg oral tablet once daily for 54 weeks
150721|NCT01740102|Procedure|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
150722|NCT01740128|Device|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
150723|NCT01740128|Other|Multimodal training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
150724|NCT01740141|Procedure|Plexus brachialis block|
150725|NCT01740154|Procedure|transcranial magnetic stimulation|Undergo TMS
150726|NCT01740154|Procedure|electromyography|Undergo EMG
150727|NCT01740154|Other|survey administration|Ancillary studies
150728|NCT01740154|Drug|sunitinib malate|Given PO
150729|NCT01740167|Behavioral|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
150730|NCT01740180|Other|Data entry|This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.
These data are extracted from patient records by each participating center and collected in an e-CRF.
150731|NCT00094757|Drug|Comparator: sitagliptin 200 mg|sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
149748|NCT01707420|Drug|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
149749|NCT00091611|Drug|Mesna|
149750|NCT01707420|Drug|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
149751|NCT01707433|Other|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
150118|NCT01705535|Behavioral|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
150119|NCT01705535|Other|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
150120|NCT01705535|Behavioral|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
150121|NCT01705548|Radiation|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
150465|NCT01732185|Genetic|Patient|Blood and histological samples will be done at day of the inclusion.
150466|NCT01732198|Biological|NU300|
150467|NCT01732198|Biological|ActHIB|
150468|NCT01732198|Biological|Prevnar 13|
150469|NCT01732211|Biological|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
150470|NCT01732211|Other|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
150471|NCT00093795|Drug|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
150472|NCT01732224|Drug|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
150473|NCT01732224|Drug|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
150474|NCT01732237|Drug|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
150475|NCT01732237|Drug|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
150476|NCT01732237|Drug|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
150477|NCT01732250|Drug|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
150478|NCT01732250|Drug|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
150479|NCT01732263|Drug|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
149899|NCT01702701|Drug|Montelukast|montelukast 10mg po pill q day for 12 weeks
149900|NCT01702701|Drug|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
149901|NCT00091104|Procedure|in vitro-treated peripheral blood stem cell transplantation|
149902|NCT01702714|Drug|RO5083945|multiple ascending doses
149903|NCT01702714|Drug|cisplatin|up to 6 cycles
149904|NCT01702714|Drug|gemcitabine|up to 6 cycles
149905|NCT01702714|Drug|carboplatin|up to 6 cycles
149906|NCT01702714|Drug|paclitaxel|up to 6 cycles
149907|NCT01702727|Device|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
149908|NCT01702727|Device|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
149909|NCT01702727|Device|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
149910|NCT01702740|Drug|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
149911|NCT01702740|Drug|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
149912|NCT00091104|Radiation|total-body irradiation|
149913|NCT01702740|Drug|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
149914|NCT01702740|Drug|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
149915|NCT01702753|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
149916|NCT01702766|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
149917|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
150187|NCT01738867|Drug|Placebo|Matching placebo capsules to GSK1521498 or NTX
150188|NCT01731717|Behavioral|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
150189|NCT01731717|Behavioral|Bibliotherapy|Patient works with self-help book "Selbsthilfe bei Depressionen" (Görlitz, 2010) under general physician's supervision.
150626|NCT01739530|Biological|Repaircell|allogenic differentiated adipocyte
150627|NCT00094705|Biological|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
150628|NCT01739543|Device|Hem-Avert|Application of Hem-Avert
149667|NCT01707329|Drug|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
149668|NCT01707342|Drug|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
149669|NCT00091611|Drug|Fludarabine|
149670|NCT01707355|Behavioral|intervention - poster|
149671|NCT01707368|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
149672|NCT01707381|Drug|BOL-303259-X|Topical ophthalmic solution
149673|NCT01707381|Drug|Timolol maleate|Topical ophthalmic solution
149674|NCT01707394|Drug|Apixaban|
149675|NCT01707407|Drug|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
149676|NCT01707407|Drug|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
149677|NCT01707407|Drug|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
149678|NCT01707407|Drug|Carbamazepine|100 mg Carbamazepine tablet administered orally once in the evening on Day 1
100 mg Carbamazepine tablet administered orally twice daily on Days 2-3
200 mg Carbamazepine tablet administered orally twice daily on Days 4-11
149679|NCT01699958|Behavioral|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
149680|NCT01699971|Procedure|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
149681|NCT01699971|Procedure|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
149682|NCT01699971|Procedure|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
149683|NCT01699997|Drug|Oxytocin|Intranasal spray with 40 IU of OXT
149684|NCT01699997|Drug|Placebo|Intranasal spray with placebo solution
150334|NCT01736566|Other|Experimental: "Standard of Care" + Whole Genome Sequencing (Genome Report)|Doctors and their patients will receive a Genome Report and a Family History Report.
There will be two sections of the Genome Report:
The General Genome Report, which will include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.
The Cardiac Risk Supplement, which will contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.
150335|NCT01736566|Other|Placebo Comparator: "Standard of Care" Only|Doctors and their patients will receive a Family History report only
150336|NCT01736579|Drug|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
150337|NCT01736592|Drug|SAR422459|
150338|NCT01736605|Procedure|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
150339|NCT01736605|Procedure|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
150340|NCT01736618|Device|S-ICD System|
150341|NCT01736631|Behavioral|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark & Wells (Clark & Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
150695|NCT01734863|Radiation|External Beam Radiotherapy|
150696|NCT01737073|Behavioral|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
150697|NCT01737073|Behavioral|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
150698|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tip and usual clinical care
150699|NCT01737086|Dietary Supplement|Lactobacillus reuteri DSM 17938 and zinc sulphate|
150700|NCT01737086|Dietary Supplement|placebo|
150701|NCT00094432|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
150702|NCT01737099|Dietary Supplement|DHA-O|
150703|NCT01737099|Dietary Supplement|Fish oil|
150704|NCT01737099|Dietary Supplement|Placebo|
148544|NCT01713036|Drug|Pimasertib|Unlabeled pimasertib, 60 milligram (mg), will be administered as oral capsules in the morning of Day 1 of Part A of the study (21-day treatment period). After 1 hour, the intravenous tracer dose of [14C] pimasertib (2 microgram [mcg] equaling 9 kilobecquerel [kBq]) will be administered as a bolus injection on Day 1. From Days 3-21, 60 mg unlabeled pimasertib oral capsules will be administered twice a day except on Day 8, on which 60 mg unlabeled pimasertib capsules spiked with 2.6 megabecquerel (MBq) of [14C] pimasertib will be administered orally in morning followed by an evening dose of 60 mg pimasertib as unlabeled pimasertib oral capsules. Unlabeled pimasertib, 60 mg will be administered as oral capsule twice a day in Part B of the study, that is, cycles of 21 days duration until disease progression, unacceptable toxicity, withdrawal by subject, lost to follow up, or death.
148545|NCT01713049|Drug|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
148546|NCT01713062|Device|Vitelene|THA
148547|NCT01713062|Device|XLPE|THA
148548|NCT00092183|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
148549|NCT01713088|Other|Multisystemic therapy|
148550|NCT01713088|Other|YOT (usual services)|
148551|NCT01713101|Drug|Early intravenous tranexamic acid administration|Initial history taking and physical examination --> enrollment --> 1g bolus over 10 minutes followed slow infusion over 8 hours.
148552|NCT01713101|Drug|placebo|
148553|NCT01713114|Other|Acute measures of satiety and food intake at next meal|
148554|NCT01713127|Drug|remifentanil infusion|
148555|NCT01713127|Drug|Placebo|
148556|NCT01713140|Other|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
148557|NCT01713153|Drug|Misoprostol|600 mcg misoprostol oral
148558|NCT01713153|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
148559|NCT00092183|Drug|Comparator: ondansetron / Duration of Treatment: 3 days|
148560|NCT01713166|Drug|plasmalyte solution|plasmalyte solution
148860|NCT01708785|Behavioral|16 treatment sessions|Subjects will receive 16 sessions of cue exposure treatment.
148302|NCT01715038|Dietary Supplement|LNS-PLW|Dietary supplement: Lipid-based nutrient supplement
Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)
Daily dose of LNS-PLW will be 20 g, packaged in one sachet
148303|NCT01715038|Dietary Supplement|LNS-Child|Dietary supplement: Lipid-based nutrient supplement
Lipid-based nutrient supplement for infants and young children (LNS-Child)
Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets
148304|NCT01715038|Dietary Supplement|MNP|Dietary supplement: Micronutrient powder
Micronutrient powder for infants and young children (MNP)
The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet.
148305|NCT01715038|Dietary Supplement|IFA|Dietary supplement: Iron and folic acid nutrient supplement
Iron-folic acid tablets for pregnant and lactating women
Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid
148306|NCT00092326|Drug|MK0966, rofecoxib|
148307|NCT01715051|Drug|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
148308|NCT01715051|Behavioral|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
148309|NCT01715051|Drug|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
148310|NCT01715064|Behavioral|Exercise|1 hour of moderate-intensity exercise
148311|NCT01717729|Radiation|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
148312|NCT01717742|Drug|tPA|Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
148313|NCT01717742|Drug|DNase|Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
148314|NCT01717742|Other|Placebo|Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (>10 kg)
148315|NCT01717755|Other|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
149021|NCT01706354|Procedure|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
149022|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
149023|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
149024|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
149025|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
149026|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
149027|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
149338|NCT01709084|Drug|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
149339|NCT01709110|Drug|Teriparatide|Administered SC
149340|NCT01709110|Drug|Risedronate|Administered orally
149341|NCT01709110|Drug|Placebo|Teriparatide arm placebo administered orally.
Risedronate arm placebo administered SC.
149342|NCT00001757|Drug|Voriconazole|
149343|NCT00091819|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
149344|NCT01709110|Drug|Calcium|Administered orally
149345|NCT01709110|Drug|Vitamin D|Administered orally
149346|NCT01709123|Drug|chromium niacinate|200ug or 500ug supplementation in pill form
149347|NCT01709123|Drug|placebo|Placebo pill for chromium niacinate
149348|NCT01701778|Drug|sevoflurane|Induction and maintain anaesthesia
149349|NCT01701791|Other|Computerized Decision Support System|
149350|NCT01701804|Drug|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
146944|NCT00089752|Device|Continuous Positive Airway Pressure (CPAP)|CPAP device used at night
146945|NCT01689922|Other|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
146946|NCT01689935|Drug|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
146947|NCT01689935|Device|Red light only|Red Light therapy
146948|NCT01689935|Device|Blue light only|Blue light only
146949|NCT01689948|Behavioral|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
146950|NCT01692184|Drug|100 mg AVL-292|
146951|NCT01692184|Drug|200 mg AVL-292|
146952|NCT01692184|Drug|350 mg AVL-292|
146953|NCT01692184|Drug|Placebo capsules|
146954|NCT01692197|Drug|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
146955|NCT01692197|Drug|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
146956|NCT01692197|Drug|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age <60 years) or Days 9 - 11 (age > 60 years).
146957|NCT00089973|Drug|Ispinesib|
146958|NCT01692197|Drug|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
147221|NCT01710735|Procedure|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
147222|NCT01710748|Device|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
147223|NCT01710748|Device|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
147224|NCT01710761|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
147225|NCT01710761|Dietary Supplement|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
147226|NCT01710774|Procedure|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
147936|NCT01717261|Radiation|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
147937|NCT00092521|Biological|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
147938|NCT01719575|Drug|Placebo|
147939|NCT01719588|Drug|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
147940|NCT00092716|Drug|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
147941|NCT01719601|Drug|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
147942|NCT01719614|Drug|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
147943|NCT01719614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
147944|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 300mg
147945|NCT01719627|Drug|TVD 300/200 QD|TVD 300/200 QD during 7 days
147946|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 600mg
147947|NCT01719640|Biological|infusion of MSCs|
147948|NCT01719653|Drug|MiraLAX|MiraLAX consumed as described in each arm.
147949|NCT01719653|Other|Gatorade|Gatorade consumed as described in each arm.
147950|NCT01719653|Drug|MoviPrep|MoviPrep consumed as described in each arm.
147951|NCT00092729|Drug|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
147952|NCT01719653|Drug|SUPREP|SUPREP consumed as described in each arm.
147011|NCT01698047|Other|Case Management|See Case Management description
147378|NCT01718847|Drug|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
147651|NCT01716780|Other|Intervention|Patients allocated to the "intervention group" will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care
147652|NCT00092456|Biological|Placebo|Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10
weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
147653|NCT01719302|Drug|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
147654|NCT01719315|Other|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
147655|NCT01719328|Behavioral|Vinyasa yoga|
147656|NCT00092703|Drug|Comparator: Diclofenac sodium|
147657|NCT01719354|Other|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
147658|NCT01719354|Other|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
147659|NCT01719367|Drug|Atenolol|
147660|NCT01719380|Drug|LGX818|
147661|NCT01719380|Drug|Cetuximab|
147662|NCT01719380|Drug|BYL719|
147663|NCT01719406|Behavioral|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
147664|NCT01719419|Drug|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
147665|NCT01719419|Drug|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
147666|NCT01719458|Drug|(S,S)-[11C]MRB|PET radioligand
147667|NCT00092716|Drug|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
147668|NCT01719497|Drug|[C-11]OMAR|PET radioligand
147156|NCT01695590|Drug|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
147157|NCT00001723|Drug|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
147158|NCT01715623|Biological|a blood sample|Dosage of Ig
147159|NCT01715636|Drug|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
147436|NCT01716273|Other|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
147437|NCT01716273|Other|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
147438|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (~207,000 plaque-forming units [PFU]/0.65-mL dose)
147439|NCT01716286|Dietary Supplement|low fat vs. essence yoghurt|
147440|NCT01716299|Other|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
147441|NCT01716299|Other|application of a confirmation test|use of rapid confirmation test
147442|NCT01716312|Drug|Omalizumab|First dose will be 600 mg SQ (under the skin) infusion and subsequent doses will be 300 mg SQ infusion every 4 weeks.
147443|NCT01716325|Other|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
147444|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
147445|NCT01716338|Drug|Glyburide|
147446|NCT01716338|Drug|Placebo|
147447|NCT01716351|Behavioral|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
147448|NCT01716364|Biological|Anti-LeY- scFv-CD28-ζ vector,.|
147449|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (~58,000 plaque-forming units [PFU]/0.65-mL dose)
147450|NCT01716377|Drug|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
146596|NCT01694238|Procedure|Circular incision|
146597|NCT01694238|Other|Mesh enforced cruciate incision|
146598|NCT00090142|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
146599|NCT01694264|Drug|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
146600|NCT01694264|Drug|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
146601|NCT01694277|Drug|Masitinib|12 mg/kg/day
146602|NCT01694277|Drug|Sunitinib|50 mg/day
146603|NCT01694290|Other|Chemical Cold Pack|
146604|NCT01694303|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
146605|NCT01694316|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
146606|NCT01694355|Drug|Vitamin D|
146607|NCT01694394|Device|Implantable Cardiac Monitor (Confirm(R)ICM model 2102)|
146608|NCT01694407|Drug|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
146609|NCT00090155|Drug|MK0869, aprepitant|
146610|NCT01694407|Drug|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
146611|NCT01694407|Drug|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
146612|NCT01694407|Drug|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
145663|NCT01746173|Drug|Plerixafor|daily subcutaneous injections for 0-2 days
145664|NCT01746173|Procedure|Stem Cell Collection|Leukapheresis used to collect stem cells from peripheral blood
145665|NCT01746173|Drug|Palifermin|Daily intravenous infusion
145666|NCT00095290|Drug|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
146360|NCT01696877|Drug|GVAX|GVAX is GM-CSF-secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
146361|NCT01696890|Device|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
146362|NCT01696890|Device|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
146363|NCT01696903|Procedure|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
146364|NCT01696916|Procedure|6-minute walking test|submaximum exercise test
146365|NCT01696929|Drug|Tocilizumab|Therapeutic/Pharmacologic Class of Drug:
Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.
Type of Dosage Form:
Concentrate for solution for infusion.
Route of Administration:
Intravenous (i.v.) infusion.
146366|NCT01696942|Drug|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
146367|NCT01696942|Drug|Mesalamine|mesalamine 800 mg orally three times daily
146368|NCT01696955|Biological|Cetuximab|Given IV
146369|NCT01696955|Other|Laboratory Biomarker Analysis|Correlative studies
146370|NCT00090363|Drug|ZD4054 10 mg|10mg oral tablet once daily
146371|NCT01696955|Drug|Tivantinib|Given PO
146372|NCT01696968|Procedure|Radiography|Undergo a chest x-ray
146373|NCT01696968|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
146374|NCT01696981|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
146375|NCT01696981|Procedure|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
146376|NCT00090766|Drug|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
146377|NCT01699646|Device|Neoventa S 21 ST-ANalysis of fetal heart|Application of "gold-trace" scalp electrode
146378|NCT01699646|Procedure|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
146379|NCT01699659|Other|allergen immunotherapy|allergy shots
146135|NCT01690897|Behavioral|Mindfulness-based treatment|The MIND Study treatment consists of eight 2-hour long weekly group psychoeducational sessions combining education, cognitive and behavioural theory, and mindfulness skills.
146136|NCT01690910|Device|Rifton Gait Trainer|
146137|NCT01690910|Device|Front Wheeled Walker|
146138|NCT01690923|Device|Nasal mask|Nasal mask (Mirage Activa, Micro, FX)
146139|NCT01690923|Device|Pillows mask|Nasal pillows mask (Swift FX)
146140|NCT01690936|Dietary Supplement|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
146438|NCT01694043|Other|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
146439|NCT01694056|Other|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
146440|NCT01694056|Other|Control diet|4 weeks high mixed protein diet (20 en%)
146441|NCT01694069|Drug|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
146442|NCT01696994|Other|Laboratory Biomarker Analysis|Correlative studies
146443|NCT01696994|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
146444|NCT01696994|Procedure|Ultrasonography|Undergo TVU
146445|NCT01697007|Biological|HIVIS DNA vaccine|
146446|NCT01697007|Device|Zetajet|
146447|NCT00090376|Drug|GPI 1485|
146448|NCT01697007|Device|Derma Vax Electroporation|
146449|NCT01697007|Biological|Modified Vaccinia Ankara (MVA-CDMR)|
146450|NCT01697020|Drug|Mercaptopurine 20mg/ml oral suspension|50mg
146451|NCT01697020|Drug|Mercaptopurine 50mg tablet|50mg
145894|NCT01692990|Dietary Supplement|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
145895|NCT01693003|Drug|Indacaterol|150 µg d.o. during the first 3 weeks
145896|NCT01693003|Drug|Tiotropium|150 µg d.o. during 3 weeks
145897|NCT01693016|Device|non-invasive measurement of Hb|
145898|NCT00090051|Drug|Rituximab|Intravenous repeating dose
145899|NCT01693016|Procedure|taking blood samples|
145900|NCT01693029|Drug|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
145901|NCT01693029|Drug|US-licensed epoetin alfa|Solution for subcutaneous injection.
145902|NCT01693042|Biological|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (> 3 months) infarct area
145903|NCT01693055|Device|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
145904|NCT01693068|Drug|Pimasertib|Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will be continued until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever comes first.
145905|NCT01695993|Other|Version 1 handout|The Version 1 handout has less information concerning the acupressure bands than the Version 2 handout.
145906|NCT01695993|Behavioral|Version 1 MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
145907|NCT01695993|Other|Version 2 handout|The Version 2 handout has more information concerning the acupressure bands than the Version 1 handout.
146200|NCT01698970|Other|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
146201|NCT01698970|Other|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
146202|NCT01698996|Procedure|Packing vs No Packing|
146203|NCT01699009|Other|Plant based diet|
146204|NCT01699009|Other|an unrestricted diet|
149752|NCT01707446|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
149753|NCT01707446|Other|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of < 75% from baseline is reached for > 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
149754|NCT01707472|Biological|Simtuzumab|Subjects will receive simtuzumab 700 mg intravenously bi-weekly over 24 weeks, for a total of 12 infusions.
149755|NCT01707485|Drug|amoxicillin|dosed 75-100 mg/kg/day (standardized dosing)
149756|NCT01707498|Procedure|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
149757|NCT01707498|Procedure|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
149758|NCT01707524|Procedure|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
149759|NCT01707537|Biological|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
149760|NCT00091624|Drug|CC-5013|
149761|NCT01707563|Procedure|skin punch biopsy and molecular biology|
149762|NCT01707563|Other|fibroblast culture and molecular biology|
149763|NCT01707576|Behavioral|consultation 10 days later|new depression screening
149764|NCT01707589|Device|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
149765|NCT01707602|Biological|INTANZA® 15|intradermal vaccination
149766|NCT01707602|Biological|Vaxigrip®|Intramuscular vaccination
149767|NCT01707602|Biological|INTANZA® 15 T|transcutaneous vaccination
149768|NCT01707615|Drug|GSPE|GSPE 240 mg/day (120mg bid)
150360|NCT00094666|Drug|Comparator: placebo / Duration of Treatment - 6 weeks|
150361|NCT01731938|Biological|Fibrin Sealant (FS) Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
150480|NCT01732276|Drug|gefitinib|
150481|NCT01732289|Genetic|genes|Draw blood for genetic screening
150482|NCT00093795|Drug|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
150483|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
150484|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
150485|NCT01734473|Dietary Supplement|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
150486|NCT01734486|Drug|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
150487|NCT01734486|Drug|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
149536|NCT01702181|Drug|Tacrolimus|0.1% concentration of tacrolimus.
149537|NCT01702181|Drug|Placebo|
149538|NCT01702194|Drug|TD-1211 IV [C14]|
149539|NCT01702194|Drug|TD-1211 PO [C14]|
149540|NCT01702207|Drug|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
149541|NCT01702207|Drug|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
149542|NCT01702220|Behavioral|CBT|6-12 sessions of CBT in person or over the phone
149543|NCT01702220|Other|ECC|6 biweekly sessions of ECC over the telephone
149544|NCT00091104|Biological|aldesleukin|
149545|NCT01702233|Drug|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
149546|NCT01702233|Drug|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
149547|NCT01702233|Drug|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
149548|NCT01702246|Drug|Simvastatin|40 mg, orally, once daily for 3 months
150190|NCT01731717|Behavioral|Online self-help|Patient works with online self-help program "Deprexis" under general physician's supervision.
150191|NCT01731717|Behavioral|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
150192|NCT01731717|Procedure|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
150193|NCT01731717|Behavioral|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
150194|NCT01731717|Other|Control group: treatment as usual|treatment as usual
150195|NCT01731730|Drug|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
150196|NCT00093756|Drug|carboplatin|Given IV
150197|NCT01731730|Drug|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
150198|NCT01731730|Drug|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
150199|NCT01731743|Device|AT LISA tri 839MP|
150200|NCT01731756|Other|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
150201|NCT01731756|Drug|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
150202|NCT01731756|Other|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
150203|NCT01731769|Procedure|vacuum assisted closure in experimental arm|
150204|NCT01731769|Procedure|Axillary dissection|
150205|NCT01731782|Drug|bupivacaine|
150206|NCT01731782|Drug|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
150547|NCT01739465|Procedure|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
150548|NCT01739465|Procedure|Photodynamic therapy (PDT)|Photodynamic therapy
150549|NCT01739478|Other|Packing of abscess cavity|
149685|NCT01700010|Drug|Lapatinib and Paclitaxel|Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.
Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol.
149980|NCT01700530|Drug|Statin|Statins (40mg/day)for 12 weeks
149981|NCT01700530|Other|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
149982|NCT01700530|Other|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
149983|NCT00090909|Drug|gemcitabine hydrochloride|
149984|NCT01700543|Procedure|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
149985|NCT01700556|Other|Case Manager|The following support will be provided by a case manager:
At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.
Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.
Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity).
149986|NCT01700556|Other|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
149987|NCT01700556|Other|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
149988|NCT01700556|Other|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
149989|NCT01702805|Procedure|Restricted red cell transfusion|
149990|NCT01702831|Drug|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
150705|NCT01737112|Drug|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
150706|NCT01737125|Radiation|Magnetic Resonance Imaging (MRI)|spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences
MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)
150707|NCT01737138|Procedure|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
150708|NCT01737138|Drug|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
150709|NCT01737151|Radiation|stereotactic body radiation therapy|Undergo SBRT
150710|NCT01737151|Radiation|four fraction split-course SBRT|four fraction split-course SBRT
150711|NCT01737164|Behavioral|Aerobic Exercise|
150712|NCT00094445|Drug|Curcumin|8 gm per day
149459|NCT01702064|Drug|Nilotinib|Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.
Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose.
149460|NCT01702064|Drug|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
149461|NCT01704560|Other|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
149462|NCT01704573|Drug|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|The study will be performed using an Investigational New Drug (IND) Application for the 2-[18F]FA radioligand. The 2-[18F]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-[18F]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.
2-[18F]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-[18F]FA from the FDA.
148861|NCT01708785|Behavioral|Single foods|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
148862|NCT01708785|Behavioral|Multiple foods|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
148863|NCT01708785|Behavioral|Daily sessions|Subjects will receive 8 or 16 daily cue exposure treatment sessions.
148864|NCT01708785|Behavioral|Weekly sessions|Subjects will receive 8 or 16 weekly cue exposure treatment sessions.
148865|NCT01708785|Behavioral|Partial reinforcement - Yes|Subjects will be asked to taste the food during cue exposure treatment.
148866|NCT01708785|Behavioral|Partial reinforcement - No|Subjects will NOT be asked to taste the food during cue exposure treatment.
148867|NCT01708785|Behavioral|Single context|Subjects will be exposed to foods in a single context during cue exposure treatment.
148868|NCT01701037|Drug|dabrafenib|150 mg given PO
148869|NCT01701037|Drug|trametinib|2 mg given PO
148870|NCT01701037|Other|laboratory biomarker analysis|Correlative studies
148871|NCT01701050|Other|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
148872|NCT01701063|Drug|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
148873|NCT01701063|Drug|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
148874|NCT01701063|Drug|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
148875|NCT00091026|Drug|erlotinib hydrochloride|Given orally
148876|NCT01701076|Drug|Bendamustine|Induction treatment phase (cycle 1-6):
Bendamustine 75 mg/m2 i.v day 1 and 2
Lenalidomide 25 mg p.o. day 1-21
Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia
Maintenance treatment phase (cycles 7-18):
Lenalidomide 25 mg p.o. day 1-21
Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
148877|NCT01701089|Drug|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
148878|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for 14 days
148879|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for up to 17 days
148880|NCT01701102|Procedure|Mepivacaine plus fentanyl|Mepivacaine (24 - 37.5 mg) and fentanyl (10 µg)
148316|NCT01717768|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
148613|NCT01710579|Procedure|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
148614|NCT00091988|Behavioral|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
148615|NCT01710592|Drug|Epirubicin|
148616|NCT01710592|Drug|Oxaliplatin|
148617|NCT01710592|Drug|Capecitabine|
148618|NCT01710592|Drug|Docetaxel|
148619|NCT01710605|Biological|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
148620|NCT01710631|Drug|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
148621|NCT01710631|Drug|placebo|placebo
148622|NCT01710644|Drug|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
148623|NCT01710644|Drug|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
148624|NCT01710657|Drug|Lacosamide 50 mg|Active Substance: Lacosamide
Pharmaceutical Form: Film-coated tablet
Concentration: 50 mg
Route of Administration: Oral use
148625|NCT00091988|Behavioral|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
148626|NCT01710657|Drug|Lacosamide 100 mg|Active Substance: Lacosamide
Pharmaceutical Form: Film-coated tablet
Concentration: 100 mg
Route of Administration: Oral use
148627|NCT01705691|Drug|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
149351|NCT01701804|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
149352|NCT01701804|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10~20 acupoints once a week for 16 weeks.
149353|NCT01701804|Procedure|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
149354|NCT01701817|Other|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
149355|NCT01701843|Drug|Cromoglicate|Twice daily topical treatment for 14 days
149356|NCT01701843|Drug|Placebo|Twice daily topical treatment for 14 days
149357|NCT00001736|Drug|Cysteamine|
149358|NCT00091078|Other|laboratory biomarker analysis|Correlative studies
149359|NCT01701856|Drug|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
148384|NCT01712867|Other|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
148385|NCT01715077|Drug|Ipilimumab at 3 mg/kg dose|
148386|NCT01715090|Device|Web-based insulin titration|
148387|NCT01715103|Procedure|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
148388|NCT01715116|Device|Enhanced ICD programming|VT monitor: > 166/min
fVT: > 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.
VF: > 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals
SVT/VT discrimination is turned on, high rate time out is "OFF"
SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min
SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min
T wave-oversensing and lead noise discrimination is turned on in all devices.
148389|NCT01715129|Drug|Triptorelin Pamoate 11.25mg|
148390|NCT01715142|Drug|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
148391|NCT00001765|Device|Baxter isolex 300i|
148392|NCT00092326|Drug|Comparator: oxycodone with acetaminophen, placebo|
147227|NCT00092014|Drug|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
147228|NCT01713231|Dietary Supplement|standard-dose vitamin D (400IU per day)|
147229|NCT01713231|Dietary Supplement|high-dose vitamin D (2000 IU per day)|
147230|NCT01713244|Procedure|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
147231|NCT01713244|Procedure|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
147232|NCT00092196|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
147233|NCT01713257|Dietary Supplement|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
147234|NCT01713257|Dietary Supplement|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
147235|NCT01713270|Procedure|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
147236|NCT01713270|Drug|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
147237|NCT01713270|Procedure|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
147238|NCT01713283|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
147502|NCT01711359|Drug|Placebo|Baricitinib placebo administered orally once daily. MTX placebo administered orally once weekly.
147503|NCT01713595|Drug|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
147504|NCT01713608|Drug|OZ439|OZ439 x mg once daily for 3 days with milk
147505|NCT01713621|Drug|OZ439|OZ439 is a novel synthetic trioxolane antimalarial agent
147506|NCT01713634|Other|Preflight|4-d controlled diet sessions will occur twice before flight.
147012|NCT01689961|Behavioral|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
147013|NCT01689974|Drug|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
147014|NCT01689974|Other|Radiation Therapy and Ipilimumab|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
147015|NCT01689987|Drug|Cyclophosphamide|Given IV
147016|NCT01689987|Drug|Dexamethasone|Given PO
147017|NCT00089752|Device|Sham CPAP device|Sham CPAP device used at night
147018|NCT01689987|Drug|Hydroxychloroquine|Given PO
147019|NCT01689987|Other|Laboratory Biomarker Analysis|Correlative studies
147020|NCT01689987|Other|Pharmacological Study|Correlative studies
147021|NCT01689987|Drug|Sirolimus|Given PO
147022|NCT01690000|Drug|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
147023|NCT01690026|Behavioral|Motivation interviewing based brief intervention|
147024|NCT01690026|Behavioral|Standard Intervention|
147025|NCT01690039|Drug|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
147026|NCT01690052|Drug|Cevimeline|Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated "cevimeline first, then pilocarpine" and "pilocarpine first, then cevimeline". Each sequence was evaluated for 4 weeks with one week "washout" period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day.
147027|NCT01690052|Drug|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
147028|NCT00089765|Drug|Ranibizumab|
147029|NCT01690065|Drug|Nilotinib+AD induction|• Post-remission consolidation chemotherapy
4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).
Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation
147303|NCT01710826|Biological|Placebo|Placebo capsules matching the Genz-682452 capsules.
148022|NCT01717300|Drug|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
148023|NCT01717300|Drug|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
148024|NCT01717300|Drug|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
148025|NCT01717313|Drug|MK-3102|MK-3102 25 mg capsule administered orally once a week.
148026|NCT01717313|Drug|Placebo to MK-3012|Placebo to MK-3102 capsule administered orally once a week
148027|NCT00092521|Biological|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
148028|NCT01717313|Drug|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the MK-3102 treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
148029|NCT01717313|Drug|Placebo to metformin|During Phase B of the study, participants in the MK-3102 treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
148030|NCT01717313|Drug|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic therapy
148031|NCT01717326|Drug|Grazoprevir|100 mg tablet orally QD
148032|NCT01717326|Drug|Elbasvir|Part A: 20 or 50 mg capsule orally QD Part B: 50 mg capsule orally QD
148033|NCT01717326|Drug|Placebo|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
148034|NCT01717326|Drug|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
148035|NCT01717339|Other|Sleep Study|
148036|NCT01717352|Behavioral|Weight Loss Education|
148037|NCT01717352|Behavioral|Sleep and Eating Routine|
148038|NCT00092534|Biological|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|Duration of Treatment: 6 months
148039|NCT01717391|Radiation|Bone marrow sparing IMRT radiation therapy|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
148040|NCT01719900|Dietary Supplement|Control|Control biscuit with no yellow pea hull fibre.
147451|NCT01718873|Drug|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
147452|NCT01718873|Drug|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
147453|NCT01718886|Device|Obalon Gastric Balloon|
147454|NCT01718899|Biological|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
147455|NCT01718912|Drug|metronidazole-nystatin oral rinse|
147456|NCT01718938|Drug|velusetrag dose 1|
147733|NCT01716806|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
147734|NCT01716806|Drug|bendamustine|70 mg/m2 by IV infusion on Days 1 and 2 of 3-week cycle
147735|NCT01716806|Drug|dacarbazine|375 mg/m2 every 3 weeks by IV infusion
147736|NCT01716819|Other|Urine sample|dosages on one spot and 24h collection
147737|NCT01716819|Other|Blood sample|dosages
147738|NCT01716819|Other|Assessment of sleep apnea syndrome|
147739|NCT00001768|Drug|Intravenous immunoglobulin|
147740|NCT00092469|Biological|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
147741|NCT01716819|Other|Electrocardiogram|
147742|NCT01716819|Other|Glucose tolerance test|
147743|NCT01716819|Other|Echocardiography|
147744|NCT01716819|Other|cardiac and abdominal magnetic resonance imaging|
147745|NCT01716819|Other|Ambulatory blood pressure monitoring|
147746|NCT01716819|Other|Echotracking|
147747|NCT01716819|Other|Pulse wave velocity|
147748|NCT01716819|Other|Composition of body mass by Dual x-ray absorptiometry|
145667|NCT01746173|Drug|Gemcitabine|intravenous infusion for 2 days
145668|NCT01746173|Drug|Busulfan|intravenous infusion for 4 days
145669|NCT01746173|Drug|Melphalan|intravenous infusion for 2 days
145670|NCT01746173|Procedure|Stem Cell Transplant|Reinfusion of stored peripheral blood stem cells
145671|NCT01746199|Drug|cotrimoxazole daily prophylaxis|
145672|NCT01746199|Drug|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
145673|NCT01748643|Drug|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is > 0.9.
145674|NCT01748656|Device|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
145675|NCT01748656|Device|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
145676|NCT01748669|Dietary Supplement|Garlic oil|Oral administration
145677|NCT01748682|Other|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
145678|NCT01748695|Drug|V158866|
145679|NCT01748695|Drug|Placebo|
145680|NCT00095563|Other|laboratory biomarker analysis|Correlative studies
145681|NCT01748708|Device|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
145682|NCT01748708|Device|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
145683|NCT01748721|Biological|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
145684|NCT01748721|Other|pharmacological study|Correlative studies
145980|NCT01693185|Drug|Midazolam|bolus injection
145981|NCT00090051|Drug|Cyclophosphamide|Intravenous repeating dose
146380|NCT01699672|Other|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
146674|NCT01691768|Drug|1% tenofovir gel|Participants will be randomized to receive 1% tenofovir gel through either:
Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or
The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm).
146675|NCT00089921|Drug|SCIO-469|60 mg capsule three times daily for 12 weeks
146676|NCT01691781|Drug|captopril|At the initial visit, each subject will receive a single dose of captopril, with blood measurements before and 1-2 hours, after the dose.
146677|NCT01691781|Drug|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
146678|NCT01691794|Drug|Atazanavir|
146679|NCT01691794|Drug|Ritonavir|
146680|NCT01691807|Drug|ofatumumab|treatment for NHL
146681|NCT01691807|Drug|bendamustine|treatment for NHL
146682|NCT01691820|Procedure|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
146683|NCT01691820|Procedure|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
146684|NCT01691820|Procedure|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
146685|NCT01691833|Dietary Supplement|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
146686|NCT00089921|Drug|SCIO-469|30 mg capsule three times daily for 12 weeks
146687|NCT01691833|Dietary Supplement|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
146688|NCT01691846|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
146689|NCT01691846|Drug|placebo|oral doses once a day for 26 weeks
146690|NCT01691859|Drug|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
146691|NCT01691872|Drug|Retigabine|Retigabine
146692|NCT01691885|Drug|Fluticasone Furoate|100mcg Once daily
146693|NCT01691885|Drug|Vilanterol|25mcg Once daily
146452|NCT01697046|Drug|Truvada and Isentress|Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.
Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days.
146453|NCT01697059|Drug|Piperacillin + Amoxicillin|
146454|NCT01697072|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
146455|NCT01697072|Other|Placebo|Placebo
146456|NCT01697072|Drug|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
146457|NCT01697072|Drug|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
146458|NCT00090389|Procedure|Chinese Acupuncture|
146459|NCT01697072|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine.
146760|NCT01689532|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
146761|NCT01689532|Drug|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
146762|NCT01689545|Behavioral|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
146763|NCT01689545|Behavioral|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
146764|NCT01689545|Behavioral|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
146765|NCT01689545|Behavioral|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
146766|NCT01691898|Drug|Obinutuzumab|Obinutuzumab 1000 mg intravenous infusion administered on Day 1, 8, 15 of first 21-Day cycle and Day 1 of subsequent 21-Day cycles for up to 8 cycles.
146767|NCT01691898|Drug|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 milligram per kilogram body weight (mg/kg) intravenous infusion administered on Day 1 of 21-day cycles for 6 months or 1 year.
146205|NCT01699022|Drug|Injection Cyclofem|Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.
Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection.
146206|NCT01699048|Procedure|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
146207|NCT01699048|Procedure|PCI|Multi-vessel PCI with DES
146208|NCT00090701|Drug|AG2037|
146209|NCT01699048|Procedure|CABG|Coronary artery bypass graft (CABG) treatment
146210|NCT01699061|Drug|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
146211|NCT01699061|Drug|Placebo|Placebo tablet administered with a meal twice a day on Day 1
146212|NCT01699074|Dietary Supplement|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
146213|NCT01699074|Dietary Supplement|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
146214|NCT01699074|Dietary Supplement|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
146215|NCT01690988|Drug|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
146216|NCT01690988|Drug|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
146217|NCT01690988|Drug|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
146218|NCT01691001|Drug|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
146219|NCT01691001|Drug|normal saline|
146220|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
146221|NCT00089856|Biological|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
146522|NCT01694134|Drug|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
146523|NCT01694134|Drug|Lidocaine|
150362|NCT01731938|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
150363|NCT01731951|Drug|Imetelstat|Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
150364|NCT00001827|Biological|sargramostim|
150365|NCT00093782|Other|laboratory biomarker analysis|Correlative studies
150366|NCT01731964|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
150367|NCT01731964|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
150368|NCT01731977|Behavioral|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
150369|NCT01731990|Drug|ACZ885|
150370|NCT01731990|Drug|Placebo|Matching placebo of CACZ88%M
150371|NCT01732003|Dietary Supplement|Omega-3 Complete|
150372|NCT01732003|Dietary Supplement|Placebo Pill|
150373|NCT01732016|Other|Normobaric hypoxia chamber|
150374|NCT01732029|Other|Normobaric hypoxia chamber|
150375|NCT01732055|Behavioral|Partner-Assisted Interpersonal Psychotherapy|
150376|NCT00093795|Drug|Cyclophosphamide|Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
150377|NCT01732055|Other|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
150378|NCT01732068|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
150379|NCT01732068|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
150401|NCT01734421|Device|Cell phone Aplication for Smarth Phone|
149549|NCT01702259|Device|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
149550|NCT01702259|Device|Placebo device|Inactive Erchonia GLS.
149551|NCT01702272|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
149552|NCT01704664|Dietary Supplement|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
149553|NCT01704664|Drug|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
149834|NCT01705080|Device|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
149835|NCT01705093|Dietary Supplement|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
149836|NCT01705093|Dietary Supplement|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
149837|NCT01705106|Drug|capecitabine|Given PO
149838|NCT01705106|Drug|celecoxib|Given PO
149839|NCT01705106|Other|pharmacological study|Correlative studies
149840|NCT01705106|Other|laboratory biomarker analysis|Correlative studies
149841|NCT01705106|Other|pharmacogenomic studies|Correlative studies
149842|NCT00091312|Drug|irinotecan hydrochloride|
149843|NCT01705119|Other|Standing|
149844|NCT01705145|Drug|Ivacaftor|
150550|NCT01739478|Other|External dressing|Application of external dressing whilst abscess cavity heals
150551|NCT01732302|Other|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
150552|NCT01732315|Behavioral|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
150553|NCT01732328|Dietary Supplement|Calcium plus vitamin D|
150554|NCT01732341|Device|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
150555|NCT01732341|Device|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
150556|NCT01732367|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
150557|NCT01732367|Drug|Tenofovir|Tenofovir 300mg QD for 96 weeks
150558|NCT01732380|Drug|Raltitrexed|
150559|NCT01732380|Drug|Oxaliplatin|
150560|NCT01732380|Radiation|Radiotherapy|
150561|NCT00093795|Drug|Doxorubicin|Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles
150562|NCT01732393|Drug|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
150563|NCT01732393|Drug|Placebo|
150564|NCT01732419|Behavioral|Home-based training|Home-based exercise training for cardiac patients.
150565|NCT01732419|Behavioral|Centre-based training|Usual exercise training in an outpatient setting.
150566|NCT01732445|Drug|ruxolitinib phosphate|Given PO
150567|NCT01732445|Drug|danazol|Given PO
150568|NCT01732445|Other|quality-of-life assessment|Ancillary studies
149991|NCT00091117|Drug|bortezomib|Given IV
149992|NCT01702831|Drug|Melphalan|I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as "Option 1" dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as "Option 2"
149993|NCT01702831|Drug|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
149994|NCT01702844|Drug|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
150266|NCT01738958|Biological|L. retueri|two tablets a day for 6 weeks
150267|NCT01738958|Biological|Placebo|
150268|NCT01738971|Other|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
150269|NCT01738971|Other|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
150270|NCT01738984|Behavioral|MomZing Web Program|Online web platform that is accessed via a television connected to internet
150271|NCT01738984|Behavioral|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
150272|NCT01738997|Device|Dilation 10 sec|
150273|NCT01738997|Device|Dilation 2 min|
150274|NCT00094653|Biological|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
150275|NCT01739023|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
150276|NCT01739036|Biological|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
150277|NCT01739036|Biological|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
150278|NCT01731808|Behavioral|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
149463|NCT01704586|Radiation|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
149464|NCT01704586|Radiation|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
149465|NCT01704599|Drug|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
149466|NCT01704612|Drug|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
149467|NCT01704625|Procedure|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
149468|NCT01704625|Procedure|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
149469|NCT01704638|Drug|fluvoxamine|
149470|NCT00091273|Biological|ovarian cancer peptide vaccine|
149471|NCT01704638|Drug|Digoxin|
149472|NCT01704651|Drug|Alvimopan|Perioperative administration of oral alvimopan
149473|NCT01704651|Drug|Placebo|Perioperative administration of placebo
148478|NCT01715311|Drug|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
148479|NCT01715311|Drug|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
148480|NCT01715311|Drug|Tiotropium|Tiotropium capsules for inhalation once daily
148481|NCT01715311|Drug|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
148482|NCT01715324|Drug|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
148483|NCT01715337|Other|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
148484|NCT01715350|Drug|PM012|The drug will be taken with water within 30 minutes after breakfast and supper.
650mg/1 tablet, PO, 12weeks
148485|NCT01715350|Drug|Placebo|The drug will be taken with water within 30 minutes after breakfast and supper.
650mg/1 tablet, PO, 12weeks
148486|NCT00092352|Drug|MK0966, rofecoxib|
149186|NCT01704209|Procedure|Vehicle|
149187|NCT01704235|Other|Demographic Form and Semi-Structured Interview Guide|The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.
A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team.
149188|NCT01704248|Device|Eye Drop Guide technique|Wash the hands.
Shake and then uncap the bottle.
Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.
Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.
Then place the upper lip down to cover the whole orbital rim area.
Tilt the head back if seated or standing.
Insert the bottle in the device all the way. Hold the bottle gently.
Look upward.
Squeeze the bottle one drop at a time until feel one drop instilled into the eye.
Close the eye 2-3 minutes.
For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward.
149189|NCT01704248|Behavioral|Routine self-instillation technique|Wash the hands.
Shake and then uncap the bottle.
Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.
Lie down or tilt the head back if seated or standing.
Using the other hand, pull the lower lid down.
Hold the bottle over the eye and look up.
Squeeze the bottle one drop at a time until feel one drop instilled into the eye.
Close the eye 2-3 minutes.
For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye.
149190|NCT01706627|Drug|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
149191|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
149192|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - medium|
149193|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
149194|NCT01706653|Dietary Supplement|Very low polyphenol fruit based drink (control)|
149195|NCT01706666|Drug|bortezomib|Given SC
149196|NCT01706666|Drug|cyclophosphamide|Given PO
149197|NCT01706666|Drug|lenalidomide|Given PO
149198|NCT00091481|Drug|Zemplar|
149199|NCT01706666|Other|laboratory biomarker analysis|Correlative studies
149200|NCT01706666|Drug|dexamethasone|Given PO
149201|NCT01706666|Procedure|quality-of-life assessment|Ancillary studies
149202|NCT01706679|Drug|ATX-101 (10 mg/ml)|
149203|NCT01706679|Drug|ATX-101 (20 mg/ml)|
148628|NCT01705691|Drug|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
148629|NCT01705691|Drug|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
148630|NCT01705691|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
148935|NCT01708837|Drug|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
148936|NCT01708850|Drug|Rivaroxaban|All specified in arm description. One arm study.
148937|NCT01708876|Drug|Artesunate-mefloquine|
148938|NCT01708876|Drug|Chloroquine|
148939|NCT01708876|Drug|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
148940|NCT01708889|Biological|BMS-914143 (Peginterferon Lambda-1a)|
148941|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
148942|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
148943|NCT00091793|Drug|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
148944|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
148945|NCT01708902|Drug|Metformin 500mg|Metformin 500mg BID
148946|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
148947|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
148948|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
148949|NCT01708902|Drug|Metformin 1000mg|Metformin 1000mg BID
148950|NCT01708915|Drug|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
148951|NCT01708915|Drug|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
148952|NCT01708915|Drug|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
148393|NCT01715142|Drug|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
148394|NCT01715168|Drug|DOXIL/CAELYX|
148395|NCT01715168|Drug|ATI-0918|
148396|NCT01715181|Other|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
148397|NCT01715194|Device|Telemedicine intervention|
148398|NCT01715207|Drug|Aliskiren|
148399|NCT01715207|Drug|Atenolol|
148400|NCT01715220|Drug|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
148401|NCT01715233|Drug|mDCF|Modified Dose Docetaxel, Ciplatin, and 5FU.
148402|NCT01715233|Drug|mDCF|Modified Dose of Docetaxel, Cisplatin, and 5FU.
148403|NCT00092339|Drug|MK0966, rofecoxib|
148404|NCT01715246|Other|Infant Formula|
148696|NCT01700907|Drug|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
148697|NCT01700907|Drug|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
148698|NCT01700920|Procedure|bone marrow aspirate|
148699|NCT01700933|Other|High-Dosage Exercise Therapy|Structure of the exercise program done three times per week, for eight weeks:
5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)
148700|NCT01700933|Other|Low-Dosage Exercise Therapy|Structure of the exercise program done three times per week, for eight weeks:
5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)
148701|NCT00091143|Biological|gp100 antigen|
147507|NCT00092222|Drug|Rituximab|Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
147508|NCT01713634|Other|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
147509|NCT01713647|Drug|Amlodipin, losartan, HCTZ|
147510|NCT01713660|Device|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
147511|NCT01713673|Drug|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
147512|NCT01713673|Drug|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
147513|NCT01713686|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
147514|NCT01713699|Procedure|lumbar puncture|
147515|NCT01713712|Behavioral|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
147516|NCT01713725|Biological|Omalizumab|Two injections will be administered the first two weeks
The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks
147517|NCT01713725|Biological|Placebo|Two injections will be administered the first two weeks
The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks
147518|NCT00092222|Drug|Zidovudine|Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
147519|NCT01713738|Drug|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
147520|NCT01713751|Other|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
147521|NCT01713751|Other|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene [Prolene®]
147522|NCT01713764|Behavioral|Low Carbohydrate Diet|
147877|NCT01711684|Drug|Diphenylcyclopropenone (DPCP)|Topical application of study drug
147878|NCT01711697|Radiation|stereotactic body radiation therapy|Undergo SBRT
147879|NCT01711697|Drug|carboplatin|
147880|NCT01711697|Drug|paclitaxel|
147304|NCT01710839|Drug|0.5mg Ranibizumab|intravitreal injections
147305|NCT01710839|Procedure|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
147306|NCT00092014|Drug|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
147307|NCT01710852|Drug|ISIS CRP Rx|
147308|NCT01710852|Drug|Placebo|
147309|NCT01710865|Other|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
147310|NCT01710865|Other|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
147311|NCT01710878|Device|Intergard Synergy Graft|
147312|NCT01710891|Procedure|CMAC videolaryngoscope|patients are intubated using the CMAC video laryngoscope
147313|NCT01710891|Procedure|Direct Laryngoscopy|Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
147314|NCT01710904|Drug|Targinact® (oxycodone/naloxone)|
147315|NCT01710917|Drug|Targinact® (oxycodon/naloxon)|
147316|NCT01710930|Other|Study of predictive factors|Phase 1 : Inclusion of patients (V0) :
In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.
Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.
Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9).
147317|NCT00092014|Dietary Supplement|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
147318|NCT01710943|Behavioral|Web-based Cognitive Behavioral Treatment|Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 "core modules" of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week.
147319|NCT01713361|Drug|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). [Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.]
148041|NCT01719913|Other|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
148042|NCT01719913|Other|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
147085|NCT01698164|Drug|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
147086|NCT01698164|Drug|Ximingting Tablet|Participants are given phytoestrogen.
147087|NCT01698164|Drug|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
147088|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
147089|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
147090|NCT01698190|Procedure|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
147091|NCT01698203|Drug|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
147092|NCT01698203|Drug|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
147093|NCT01698203|Drug|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
147094|NCT00090545|Drug|BAY 43-9006|400 mg BAY 43-9006 orally twice daily in 28 day cycles.
147095|NCT01690117|Behavioral|DeREACH-program|The intervention program "Resources to Enhance Alzheimer`s Caregivers Health -second step" (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers
147096|NCT01690130|Device|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
147097|NCT01690130|Device|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
147749|NCT01716832|Behavioral|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
147750|NCT01716858|Dietary Supplement|Sulforaphane-rich Broccoli Sprout Extract|
147751|NCT00092482|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
147752|NCT01716871|Device|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
147753|NCT01716871|Device|cryotherapy with Cold pack® or ice-cubes pack|Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.
The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group.
147754|NCT01716897|Drug|E2609|
147755|NCT01719718|Procedure|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
148111|NCT01714726|Drug|MEDI2070|1 sc injection of every 4 weeks for 100 weeks, starting at Week 12; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
148112|NCT01714739|Drug|Lirilumab|KIR = Killer-cell Immunoglobulin-like Receptors
148113|NCT00092300|Drug|MK0966, rofecoxib|
148114|NCT01714739|Drug|Nivolumab|
148115|NCT01714752|Procedure|measure of left ventricular and diastolic pressure at exercise|
148116|NCT01714765|Drug|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
148117|NCT01714765|Drug|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
148118|NCT01717404|Drug|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
148119|NCT01717456|Other|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
148120|NCT01717456|Dietary Supplement|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
145982|NCT01693185|Drug|Meperidine|bolus injection for 30 sec 1.0 mg/kg
145983|NCT01693185|Drug|placebo (for remifentanil)|normal saline mimic diluted remifentanil
145984|NCT01693185|Drug|placebo (for midazolam)|normal saline mimic to midazolam injection
145985|NCT01693185|Drug|placebo (for meperidine)|normal saline mimic meperidine injection
145986|NCT01693198|Procedure|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
145987|NCT01693211|Device|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
145988|NCT01696110|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
145989|NCT01696110|Drug|heparin|heparin monotherapy
145990|NCT01696110|Drug|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
145991|NCT01696123|Drug|MLC601|It was described
145992|NCT01696136|Device|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
145993|NCT01696149|Device|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
145994|NCT01696162|Other|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
145995|NCT00090285|Biological|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Duration of Treatment: 6 months
145996|NCT01696162|Other|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
145997|NCT01696162|Other|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
145998|NCT01696188|Device|interscalene nerve catheter|
145999|NCT01696201|Behavioral|Exercise group|Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
146694|NCT01694485|Biological|AMG 181|Investigational Product AMG 181 is a monoclonal antibody that binds the human alpha-4-beta-7 heterodimer.
146695|NCT01694485|Other|Placebo|Placebo Control
146696|NCT01694498|Drug|A: Desmopressin 25 µg|
146697|NCT01694498|Drug|B. Desmopressin 50 µg|
145739|NCT01698242|Behavioral|Enhanced Education|The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.
PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.
Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month.
145740|NCT01698255|Behavioral|ENGAGE|
145741|NCT01698255|Behavioral|Standard of Care Psychotherapy|
145742|NCT01698268|Procedure|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
145743|NCT01698268|Procedure|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
145744|NCT01698281|Drug|Zoptarelin doxorubicin|
145745|NCT01698281|Drug|paclitaxel|
145746|NCT01698281|Drug|nab-paclitaxel|
145747|NCT01698281|Drug|eribulin|
145748|NCT00090558|Drug|nitroglycerin|
145749|NCT01698281|Drug|pegylated liposomal doxorubicin|
145750|NCT01698281|Drug|vinorelbine|
145751|NCT01698281|Drug|gemcitabine|
145752|NCT01698281|Drug|capecitabine|
145753|NCT01698294|Other|Clinical Observation|Participants maintain usual diet and undergo clinical observation
145754|NCT01698294|Dietary Supplement|Flaxseed|Given PO
145755|NCT01698294|Other|Laboratory Biomarker Analysis|Correlative studies
146768|NCT01691898|Drug|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 milligram per kilogram body weight (mg/kg) intravenous infusion administered on Day 1 of 21-day cycles for up to 6-8 cycles or 1 year.
146769|NCT00089921|Drug|Placebo|2 capsules three times daily and one tablet daily
146770|NCT01691898|Drug|Rituximab|Rituximab 375 milligram per square meter (mg/m^2) intravenous infusion administered on Day 1 of 21-day cycles for 1 year.
146771|NCT01691911|Procedure|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
146772|NCT01691924|Drug|PBF-509|
146773|NCT01691924|Drug|Placebo|
146774|NCT01691937|Procedure|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
146775|NCT01691937|Procedure|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
145825|NCT01695941|Other|Laboratory Biomarker Analysis|Correlative studies
145826|NCT01695941|Biological|Rituximab|Given IV
145827|NCT01695954|Drug|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
145828|NCT01695954|Drug|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
145829|NCT01695954|Drug|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
145830|NCT01695954|Drug|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
145831|NCT01695967|Procedure|turbinate cauterization|
145832|NCT00090259|Drug|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
145833|NCT01695980|Procedure|ETT with non modified retractor|adenotonsillectomy
145834|NCT01695980|Other|LMA with modified retractor|LMA with modified retractor
146524|NCT01694147|Device|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
146525|NCT01694160|Drug|Paricalcitol|
146526|NCT01694160|Drug|Placebo|
146527|NCT01694173|Other|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
146528|NCT01694173|Other|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
146529|NCT01694173|Other|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
146530|NCT01694173|Other|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
146531|NCT00090142|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
146532|NCT01694186|Drug|FAI insert|
146533|NCT01694186|Drug|Sham injection|
146534|NCT01694199|Device|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
146535|NCT01694199|Device|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
146536|NCT01694212|Drug|Perioperative Diclofenac eye-drops administration|
146537|NCT01694212|Drug|placebo|
146538|NCT01697137|Behavioral|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
146539|NCT00001725|Drug|Dextromethorphan|
146540|NCT00090402|Dietary Supplement|Fish Oil|Fish oil concentrate (daily dose 3 grams containing 675 milligrams docosahexanoic acid and 975 milligrams eicosapentanoic acid) taken for 12 months.
146828|NCT01689571|Drug|Placebo|
150402|NCT00093990|Procedure|Tipifarnib;Zarnestra; R115777|
150403|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
150404|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
150405|NCT01734447|Drug|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
150406|NCT01734473|Dietary Supplement|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
150407|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
150408|NCT01736644|Device|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
150409|NCT00094380|Drug|CTLA4-IgG4m (RG2077)|
150410|NCT01736644|Device|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
150411|NCT01736657|Device|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
150412|NCT01736670|Drug|Triamcinolone Acetonide spray|
150413|NCT01736670|Drug|Triamcinolone acetonide cream|
150414|NCT01736670|Drug|Alcohol spray|
150415|NCT01736683|Drug|Sotatercept|Sotatercept 0.1 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
150416|NCT01736683|Drug|Sotatercept|Sotatercept 0.3 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
150417|NCT01736683|Drug|Sotatercept|Sotatercept 0.5 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
150418|NCT01736683|Drug|Sotatercept|Sotatercept 1.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
150419|NCT01736683|Drug|Sotatercept|Sotatercept 1.5 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
150420|NCT00094380|Drug|Cyclophosphamide|
150421|NCT01736683|Drug|Sotatercept|Sotatercept 2.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
150422|NCT01736696|Drug|tofacitinib|5 mg BID For 13 days and once on Day 14
149845|NCT01705158|Drug|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
149846|NCT01705184|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
149847|NCT01705184|Drug|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
149848|NCT01705184|Drug|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
149849|NCT01707641|Dietary Supplement|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
149850|NCT01707641|Other|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
149851|NCT01707654|Device|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
149852|NCT01707667|Drug|prucalopride|One 2 mg tablet orally administered on Day 1
149853|NCT01707667|Drug|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
149854|NCT01707693|Behavioral|Lifestyle Physical Activity Intervention|Behavioral counseling
149855|NCT01707693|Behavioral|Information / Attention Comparison|Information and attention comparison
150122|NCT01705574|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally with food once daily
150123|NCT01705574|Drug|RTV|RTV 100 mg tablet administered orally with food once daily
150124|NCT01705574|Drug|ATV|ATV 300 mg capsule administered orally with food once daily
150125|NCT01705574|Drug|FTC/TDF|FTC/TDF (200/300 mg) tablet administered orally with food once daily
150126|NCT01705574|Drug|E/C/F/TDF Placebo|E/C/F/TDF placebo tablet administered orally with food once daily
150127|NCT00091338|Biological|incomplete Freund's adjuvant|
150128|NCT01705574|Drug|RTV Placebo|RTV placebo tablet administered orally with food once daily
150129|NCT01705574|Drug|ATV Placebo|ATV placebo capsule administered orally with food once daily
150130|NCT01705574|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally with food once daily
149609|NCT01699919|Drug|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
149610|NCT00090857|Drug|letrozole|
149611|NCT01699932|Drug|Glimepiride+metformin (Amaryl M®) - HOE4900|Pharmaceutical form:tablet
Route of administration: oral
149612|NCT01699945|Other|This is an observational study being conducted as a substudy of antoher trial.|
149613|NCT01702285|Drug|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
149614|NCT01702298|Drug|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
149615|NCT01702298|Drug|Metformin|Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
149616|NCT00091104|Biological|filgrastim|
149617|NCT01702311|Drug|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
149618|NCT01702324|Drug|DD-25|A topical DD-25 cream at 0.025% concentration.
149619|NCT01702337|Other|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
149620|NCT01702350|Drug|GSK2251052|Oral formulation of an an antibacterial
149621|NCT01702363|Drug|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
149622|NCT01702376|Drug|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
149623|NCT01702376|Drug|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
149624|NCT01702376|Drug|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
149625|NCT01702376|Drug|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
149626|NCT01702389|Drug|Remifentanil|
149627|NCT00091104|Biological|incomplete Freund's adjuvant|
150279|NCT01731821|Procedure|pancreaticojejunostomy|Nonstented stump closed pancreaticojejunostomy:
Close the pancreatic stump with interrupted inverting sutures around the "papillary-like" pancreatic duct.
A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the "papillary-like" pancreatic duct by placing 4-6 sutures from the "periductal" parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.
Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with "Duct-to-Mucosa" pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.
150280|NCT01731834|Other|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
150281|NCT01731847|Procedure|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
150629|NCT01739556|Drug|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
150630|NCT01739569|Other|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
150631|NCT01739582|Drug|Androxal|
150632|NCT01739595|Drug|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
150633|NCT01739595|Drug|Placebo|Oral capsule taken one time daily for 3 months
150634|NCT01739608|Other|Invitation to screening|Invitation to screening
150635|NCT01739621|Drug|Proellex 12 mg|
150636|NCT01739621|Drug|Proellex 24 mg|
150637|NCT01739634|Drug|CASAD|CASAD is provided in 500mg capsules.
150638|NCT00001832|Drug|Fludarabine|5x25 mg/m^2 intravenous
150639|NCT00094705|Biological|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
150640|NCT01739647|Drug|AZD3293|Oral solution
150641|NCT01739647|Drug|Placebo|Oral solution
150642|NCT01739660|Drug|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
150643|NCT01739673|Other|Ultraviolet-A and riboflavin|
148487|NCT01715363|Drug|Oxaliplatin|
148488|NCT01715363|Drug|Folinic Acid|
148489|NCT01715363|Drug|Fluorouracile|
148490|NCT01715389|Other|MyAsthma Patient Portal|Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.
Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms.
148491|NCT01715402|Procedure|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
148492|NCT01715415|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
148493|NCT01715415|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
148494|NCT01718054|Dietary Supplement|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
148495|NCT00092586|Drug|MK0653, ezetimibe|
148496|NCT01718054|Dietary Supplement|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
148497|NCT01718054|Drug|Chloroquine|
148498|NCT01718067|Device|VAKÜM system|15 minutes, twice a day.
148806|NCT01703351|Drug|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
148807|NCT01703364|Drug|Lenalidomide|Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs
Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days
Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days
148808|NCT01703390|Drug|FOLFIRI + Cetuximab|
148809|NCT01703390|Drug|modifiedFOLFOX6 + Cetuximab|
148810|NCT01703455|Drug|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
148811|NCT01703468|Drug|Oxcarbazepine|
149204|NCT01706679|Drug|Moxifloxacin (400 mg)|
149205|NCT01706679|Drug|Placebo vehicle (PBS)|
148237|NCT00092560|Drug|MK0653, ezetimibe|
148238|NCT01717716|Dietary Supplement|water with glucose|
148239|NCT01717716|Dietary Supplement|water with sucrose|
148240|NCT01717729|Procedure|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
148241|NCT01709955|Dietary Supplement|Glucomannan|750 MG of Glucomannan in capsule form
148242|NCT01709955|Other|Placebo|750 mg of Cellulose powder in a capsule form
148243|NCT01709968|Drug|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
148244|NCT01709968|Drug|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
148245|NCT01709981|Drug|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
148246|NCT01709981|Drug|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
148247|NCT00091936|Drug|Lamivudine|
148248|NCT01709994|Drug|Aspirin|100 mg/day of aspirin
148249|NCT01710007|Drug|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
148250|NCT01710007|Drug|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
148251|NCT01710020|Drug|CP-690,550|CP-690,550 10 mg oral powder for constitution
148252|NCT01710033|Drug|Placebo|Placebo tables twice daily (BID) for 28 days
148253|NCT01710033|Drug|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
148254|NCT01710033|Drug|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
148255|NCT01710033|Drug|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
148953|NCT01708915|Drug|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
148954|NCT00091793|Drug|Placebo|Placebo given at day 1, month 6, month 12 and month 18
148955|NCT01708928|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
148956|NCT01708941|Biological|Ipilimumab|Given IV
149271|NCT01704261|Drug|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
149272|NCT01704261|Drug|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
149273|NCT00091247|Drug|tetracycline hydrochloride|
149274|NCT01704261|Drug|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
149275|NCT01704274|Other|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
149276|NCT01704274|Other|High Dose GTN 0.057 mg/hr|High Dose GTN
149277|NCT01704274|Other|Placebo|Placebo
149278|NCT01704287|Drug|Pembrolizumab|Pembrolizumab, intravenously (IV) at a dose assigned at randomization
149279|NCT01704287|Drug|Carboplatin|Carboplatin per institutional standard.
149280|NCT01704287|Drug|Paclitaxel|Paclitaxel per institutional standard.
149281|NCT01704287|Drug|Dacarbazine|Dacarbazine per institutional standard.
149282|NCT01704287|Drug|Temozolomide|Temozolomide per institutional standard.
149283|NCT01704313|Procedure|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
149284|NCT00091247|Other|placebo|
149285|NCT01704313|Procedure|Continuous|Continuous suturing technique used for the anastomosis
149286|NCT01704339|Drug|QUTENZA|Single treatment with topical capsaicin 8%
149287|NCT01704352|Behavioral|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
149288|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
144017|NCT01661088|Radiation|Intensity-modulated radiotherapy (IMRT)|The prescribed dose will be 50.0Gy in 2.0Gy per fraction. Heterogeneity of -5% to +10% is permitted provided that normal-tissue constraints are met. The minimal PTV dose is dictated by the normal-tissue constraints. A maximal PTV dose of up to +10% is permitted provided that normal-tissue constraints are met. The mean PTV dose should be as close as possible to 50 Gy.
144018|NCT01661088|Drug|Gemcitabine during Radiation Therapy|Gemcitabine 1000mg/m2 infused over 100 minutes on days 1, 8, 22, and 29 during the 5-week course of radiation treatment.
144019|NCT01661088|Drug|Gemcitabine following Radiation Therapy|Two cycles (infusions) of gemcitabine alone are intended to be given, the first 21 to 28 days following completion of combined modality treatment.
A cycle of treatment is 14 days. A cycle of treatment may begin when ANC ≥ 1,000/mm3, platelets ≥ 100,000/ mm3 and all other treatment related toxicity has resolved to ≤ grade 1.
144020|NCT01661101|Drug|Dabigatran|Dabigatran 110 mg taken twice daily
144021|NCT00087542|Drug|ACP-103|
144022|NCT01661101|Drug|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
144023|NCT01661101|Drug|Omeprazole|Omeprazole 20 mg capsule taken once daily
144024|NCT01661101|Drug|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
144025|NCT01661114|Drug|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
144026|NCT01661140|Drug|methotrexate|Stable or tapering oral weekly doses
144027|NCT01661140|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 56 weeks
144028|NCT01661166|Drug|Fesoterodine|4 mg
144029|NCT01661179|Drug|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
144030|NCT01661192|Drug|AAT( Alpha 1 Antitrypsin)|
144031|NCT01661205|Device|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
144333|NCT01743911|Other|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
144334|NCT01743911|Drug|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
144335|NCT01743924|Other|raw broccoli|To eat this plant material
144336|NCT01743937|Procedure|Coronary occlusion with balloon inflation|
144337|NCT01743950|Drug|Bevacizumab|10mg/kg every 2weeks.
147881|NCT01711697|Radiation|radiation therapy|Undergo radiation therapy
147882|NCT01711710|Device|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.
Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction.
147883|NCT01711723|Drug|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
147884|NCT01711736|Biological|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
147885|NCT00092092|Drug|Montelukast chewable tablets|Montelukast sodium 5 mg chewable tablets
147886|NCT01711736|Biological|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
147887|NCT01711749|Drug|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
147888|NCT01711749|Drug|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
147889|NCT01711762|Drug|GDC-0973|Single oral dose of [14C]-GDC-0973
147890|NCT01711775|Drug|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
147891|NCT01711788|Procedure|Intrabone infusion of umbilical cord blood stem cells|
147892|NCT01711801|Drug|Placebo|Single ascending dose
147893|NCT01711801|Drug|RO5545965|Single ascending dose
147894|NCT01711801|Drug|RO5545965|Single dose, in fed and fasted state
147895|NCT01711814|Drug|ASP015K|oral
147896|NCT01714271|Behavioral|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
146959|NCT01692210|Drug|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
147320|NCT01713374|Procedure|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
147588|NCT01711411|Device|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
147589|NCT01711424|Drug|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
147590|NCT01711437|Device|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
147591|NCT01711437|Device|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
147592|NCT01711437|Device|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
147593|NCT01711437|Device|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
147594|NCT01711450|Procedure|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
147595|NCT00092040|Drug|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
147596|NCT01711450|Procedure|Control sham procedure|Injection of Normal saline into the paravertebral space
147597|NCT01711463|Drug|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
147598|NCT01711463|Drug|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
147599|NCT01711476|Behavioral|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
147600|NCT00092222|Drug|Liposomal Doxorubicin|21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
147601|NCT01713790|Device|Leg press|training program over 10 weeks, three times a week.
147602|NCT01713803|Drug|Buprenorphine and naloxone|
147098|NCT01690143|Drug|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
147099|NCT01690143|Drug|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
147100|NCT00089778|Drug|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
147379|NCT01718873|Drug|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
147380|NCT01718873|Drug|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
147381|NCT01718873|Drug|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
147382|NCT00092651|Drug|Comparators: simvastatin and ezetimibe|
147383|NCT01710956|Radiation|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
147384|NCT01710969|Behavioral|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
147385|NCT01710969|Behavioral|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
147386|NCT01710982|Drug|TZP-101|
147387|NCT01710982|Other|Placebo|
147388|NCT01710995|Drug|Zegerid|
147389|NCT01710995|Drug|Losec|
147390|NCT01711008|Dietary Supplement|Cereal|
147391|NCT01711008|Dietary Supplement|No breakfast|
147392|NCT00092014|Dietary Supplement|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
147393|NCT01711021|Drug|d-Amphetamine Transdermal System|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
147394|NCT01711021|Drug|Placebo patch|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
148121|NCT01717456|Drug|Laxatives or anti-diarrheals|Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.
Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed.
148122|NCT01717456|Behavioral|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
148123|NCT01717456|Behavioral|Tips on how to prevent fecal incontinence|Examples of behavioral tips are "Walk, don't run to the toilet" and "Squeeze before you lift objects or sneeze".
148124|NCT01717456|Behavioral|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
148125|NCT01717456|Other|Protective pads or garments|
148126|NCT01717469|Device|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
148127|NCT00092534|Biological|Matching Placebo|Matching Placebo to Quadrivalent Human Papillomavirus Vaccine
148128|NCT01717469|Device|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
148129|NCT01717482|Drug|Metformin|
147160|NCT01715649|Behavioral|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
147161|NCT00092365|Drug|Comparator: celecoxib, placebo|
147162|NCT01715662|Device|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
147163|NCT01715662|Device|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
147164|NCT01715675|Dietary Supplement|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
147165|NCT01715675|Dietary Supplement|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
146301|NCT01699399|Procedure|water immersion|
146302|NCT01699399|Procedure|water exchange|
146303|NCT01699399|Procedure|air insufflation|
146304|NCT01699412|Drug|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
146305|NCT01699412|Drug|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
146306|NCT01699425|Device|Ajust sling|
146307|NCT01691157|Other|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
146308|NCT01691170|Other|Stretching Hamstring|
146309|NCT01691170|Other|Quadriceps Strengthening|
146310|NCT01691209|Device|Phoenix (BAY81-2996)|Topical formulation applied to the skin
146311|NCT00089869|Drug|olanzapine|
146312|NCT01691209|Drug|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
146313|NCT01691222|Device|Double lumen endotracheal tube tracheostomy|Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.
The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature.
146314|NCT01691235|Device|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
146315|NCT01691248|Drug|fidaxomicin|Fidaxomicin 200 mg tablet once daily from the start of conditioning or at the time of fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any fluoroquinolone antibiotic regimen (whichever occurs later).
Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
146316|NCT01691248|Drug|placebo|
145756|NCT01698307|Other|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
145757|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
145758|NCT01698320|Drug|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
145759|NCT01690247|Drug|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
146065|NCT01693224|Device|Cepheid Xpert MTB/Rif assay|
146066|NCT00090064|Drug|3,4-methylenedioxymethamphetamine (MDMA)|125 mg and 62.5 mg MDMA
146067|NCT01693237|Other|Group psychotherapy|20 sessions of systemic and narrative group therapy
146068|NCT01693237|Other|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
146069|NCT01693250|Device|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
146070|NCT01693250|Device|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
146071|NCT01693263|Other|brachiocephalic fistula (BCF)|We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
146072|NCT01693276|Drug|Gemcitabine|gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.
Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks.
146073|NCT01693276|Drug|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
146074|NCT01693276|Radiation|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
146075|NCT01693289|Drug|metformin plus letrozole|
146076|NCT01693289|Procedure|ovarian drilling|
146077|NCT00090064|Drug|lactose (placebo|two capsules placebo matched in weight with MDMA capsules
146078|NCT01693302|Other|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
145835|NCT01695993|Device|Acupressure bands|Bilateral acupressure wrist bands (Sea-Band International, England), given to patients in trial Arms 2 and 3, are widely available and inexpensive (under $6.00 a pair).
145836|NCT00090584|Drug|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
145837|NCT01698320|Drug|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
145838|NCT01698333|Drug|122-0551|Applied twice daily for 2 weeks
145839|NCT01698346|Biological|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
145840|NCT01698372|Device|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
145841|NCT01698385|Other|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
145842|NCT01698398|Device|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
145843|NCT01698437|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
145844|NCT01698450|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
145845|NCT01698463|Other|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|The intervention was delivered in two visits and two follow-up phone calls.
Physician identifies that the patient is at risk of falls or fractures
Visit one: individualized exercise prescription by a physiotherapist.
Visit two: motivational interviewing (behavioural counselling) by kinesiologist
Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
146141|NCT01690949|Drug|PUR118|inhaled PUR118, BID
146142|NCT01690962|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
146143|NCT00089843|Drug|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
146144|NCT01690962|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
146145|NCT01690975|Drug|Placebo|Placebo - single dose at start of each treatment period
146146|NCT01690975|Drug|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
146147|NCT01690975|Drug|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
146148|NCT01693367|Device|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
146829|NCT01689584|Genetic|salivary kit|The saliva samples will be made of selected related (DNA).
146830|NCT01689597|Drug|Morphine|Comparison of different dosages of drug
146831|NCT01689597|Drug|Placebo|
146832|NCT01689623|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
146833|NCT01689623|Drug|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
146834|NCT01689623|Drug|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
146835|NCT01689636|Drug|Tc 99m EC20|
146836|NCT01689649|Drug|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
146837|NCT01689662|Drug|Tc 99m EC20|
146838|NCT00089713|Drug|alagebrium chloride (ALT-711)|
146839|NCT01689675|Behavioral|Computer based pain management|
146840|NCT01689701|Dietary Supplement|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
146841|NCT01689701|Dietary Supplement|Placebo|Placebo(1.3g/d)
146842|NCT01689714|Drug|Tc 99m EC20|
146843|NCT01689727|Drug|Technetium Tc 99m EC20|
146844|NCT01689740|Drug|Active placebo dose MDMA|Initial dose of 25 mg MDMA administered orally at the start of each of two separate psychotherapy sessions scheduled three to five weeks apart possibly followed by a supplemental dose of 12.5 mg MDMA 1.5 to 2.5 hours later.
146845|NCT01689740|Drug|Full dose MDMA|Initial dose of 125 mg MDMA administered orally at the start of each of two psychotherapy sessions scheduled three to five weeks apart. In each case, it may be followed 1.5 to 2.5 hours later with 62.5 mg MDMA.
146846|NCT01689740|Drug|125 mg MDMA (open label)|Initial dose of MDMA administered orally at the start of each of two psychotherapy sessions, supplement administered 1.5 go 2.5 hours later.
146847|NCT01689753|Device|TEGO connector®|
146848|NCT01689753|Drug|Trisodium citrate|
146849|NCT00089726|Biological|CG8123|
146850|NCT01689766|Drug|Technetium Tc 99m EC20|
150423|NCT01736696|Drug|tofacitinib|10 mg BID for 13 days and once on Day 14*
150732|NCT01740193|Procedure|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
150733|NCT01740193|Procedure|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
150734|NCT01740206|Drug|Amphetamine and/or methylphenidate|Patients are instructed to take their stimulant medication the day of surgery.
150735|NCT01740206|Other|Hold stimulant medication|Patients are instructed to hold their stimulant medication the day of surgery.
150736|NCT01740219|Behavioral|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
150737|NCT01732640|Radiation|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
150738|NCT01732653|Other|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
150739|NCT01732653|Other|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
150740|NCT01732666|Drug|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
150741|NCT01732666|Drug|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
150742|NCT00093821|Drug|tanespimycin|Given IV
150743|NCT01732666|Drug|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
150744|NCT01732679|Other|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
150745|NCT01732692|Drug|MOVIPREP|MOVIPREP solution
150131|NCT01705574|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally with food once daily
150132|NCT01705587|Drug|teriparatide|20 microgram once-daily subcutaneous injection
150133|NCT01705600|Behavioral|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
150134|NCT01705639|Drug|Melatonin|All subjects receive the same dose of melatonin
150135|NCT01705652|Drug|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
150136|NCT01705678|Dietary Supplement|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
150137|NCT01705678|Dietary Supplement|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
150138|NCT00091338|Biological|recombinant interleukin-7|
150139|NCT01736085|Drug|Nicotine patches|Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
150140|NCT01736098|Other|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
150141|NCT01736111|Behavioral|one way text|
150142|NCT00094302|Drug|Placebo|Placebo of spironolactone
150143|NCT01736111|Behavioral|Personal feedback|
150488|NCT00094003|Drug|NS-9 [Poly I: Poly C]|
150489|NCT01734499|Behavioral|Coping Class|A 4-hour structured program which will be offered once a month as the "Coping Class" by a certified facilitator of "The Change Cycle." The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include "Change Moves Me" Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an "act as if" philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in.
149628|NCT01702402|Behavioral|Educational and Behavior Change intervention|Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.
Promote discussion and acceptance of post-partum family planning methods among key household members.
Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.
Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM.
149918|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
149919|NCT01702792|Biological|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
149920|NCT01702805|Procedure|Liberal Cell Transfusion|
149921|NCT01705197|Drug|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
149922|NCT01705223|Biological|DNA vaccine|4mg/dose, three doses at week 0,4,8
149923|NCT01705223|Biological|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
149924|NCT01705223|Biological|rTV boost|at week 16
149925|NCT00091312|Drug|leucovorin calcium|
149926|NCT01705223|Biological|rTV boost|at week 24
149927|NCT01705223|Biological|rTV boost|at week 32
149928|NCT01705236|Other|longitudinal assessment|OTC assessments
149929|NCT01705249|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
149930|NCT01705275|Drug|ONO-8539|ONO-8539
149931|NCT01705275|Other|Placebo|Identical to ONO-8539 tablet but without active ingedient
149932|NCT01705288|Procedure|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
150644|NCT01739686|Other|CASA Intervention|CASA Intervention
The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:
A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.
A social worker provides structured counseling targeting adjustment to illness and depression if present.
A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.
Most of the nurse and social worker visits are by phone.
150645|NCT01732497|Device|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
150646|NCT01732510|Drug|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
150647|NCT01732510|Drug|Placebo|Placebo administered intravenously every 2 weeks for a period of 12 weeks.
150648|NCT01732536|Drug|S8 sinus implant|
150649|NCT01732536|Drug|continued nasal steroid spray|
150650|NCT01732549|Drug|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
150651|NCT00093808|Drug|capecitabine|
149686|NCT01700036|Drug|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
149687|NCT00090870|Biological|PEG-interferon alfa-2b|
149688|NCT01700049|Drug|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
149689|NCT01700062|Dietary Supplement|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
149690|NCT01700075|Drug|Conventional treatment|Lipidlowering: "Atorvastatin" (Liprimar) - 40mg per day. Antihypertensive: "Diroton" (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and "Ditiazem" (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.
Antihyperglycemic drugs: biguanides "Metformin" - 0.5 g two or tree times per day, or "Exenatide" - 5-10 µg per day.
Anti-inflammatory: "TromboACC" (acetylsalicylate acid) up to 2 g per day and/or "Clopidogrel" (thienopyridine class antiplatelet agent) - 75mg per day.
149691|NCT01700075|Dietary Supplement|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
149692|NCT01700114|Device|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
149693|NCT01700127|Other|Breastfeeding|breastfeeding encouraged versus withheld
148812|NCT01703481|Drug|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
148813|NCT00091143|Drug|fludarabine phosphate|
148814|NCT01703481|Drug|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
148815|NCT01703481|Drug|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
148816|NCT01703481|Drug|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
148817|NCT01703494|Biological|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
148818|NCT01703494|Biological|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
148819|NCT01703507|Drug|Ipilimumab|Given IV
148820|NCT01703507|Radiation|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
148821|NCT01703507|Radiation|Stereotactic Radiosurgery (SRS)|Undergo SRS
148822|NCT01703533|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
148823|NCT01703533|Drug|Placebo|Strawberry flavored solution and Water for Injection
149132|NCT00091468|Drug|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
149133|NCT01706627|Drug|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
149134|NCT01706627|Drug|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
149135|NCT01709136|Drug|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the PCTRC , and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
148256|NCT01710046|Drug|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
148257|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
148258|NCT00091936|Drug|Standard TB treatment|
148259|NCT01710046|Drug|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
148561|NCT01713166|Drug|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
148562|NCT01713179|Drug|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
148563|NCT01713218|Drug|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
148564|NCT01713218|Drug|Vismodegib|150 mg capsule, oral, once daily
148565|NCT01713218|Procedure|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
148566|NCT01715415|Drug|Placebo for ABT-450/r/ABT-267|Tablet
148567|NCT01715415|Drug|Placebo for ABT-333|Tablet
148568|NCT01715415|Drug|Placebo for ribavirin|Capsule
148569|NCT00092352|Drug|Comparator: celecoxib, placebo|
148570|NCT01715441|Drug|Sorafenib and irinotecan combination|
148571|NCT01715441|Drug|Sorafenib monotherapy|
148572|NCT01715441|Drug|Irinotecan monotherapy|
148573|NCT01715480|Dietary Supplement|Broccosprouts® (Brassica Protection Products LLC) homogenate|In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.
In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks.
148574|NCT01715493|Drug|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
148575|NCT01715493|Drug|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
149289|NCT01704365|Biological|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
149290|NCT01704365|Biological|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
149291|NCT01704365|Biological|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
149292|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
149293|NCT01704365|Biological|Placebo|0.5mL IM Injection
149294|NCT01704378|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
148317|NCT01717781|Procedure|Thunderbeat technology|
148318|NCT00092560|Drug|Comparator: fenofibrate monotherapy|
148319|NCT01717781|Procedure|Standard bipolar electrosurgery|
148320|NCT01717794|Procedure|Thunderbeat technology|
148321|NCT01717794|Procedure|Standard bipolar electrosurgery|
148322|NCT01717807|Other|C11-Erlotinib PET/CT|
148323|NCT01717820|Dietary Supplement|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
148324|NCT01717833|Procedure|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
148325|NCT01717833|Procedure|Sham|Sham sessions of neuromuscular electrical stimulation
148326|NCT01717846|Drug|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
148327|NCT01717846|Other|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
148328|NCT01717859|Drug|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 > 3.2, dosage will be escalated to 8 mg/kg.
148329|NCT00092573|Drug|MK0653, ezetimibe|
148330|NCT01717872|Device|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades while lifting or not lifting the epiglottis
144338|NCT01743950|Radiation|PRDR|daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions
144339|NCT01743963|Behavioral|Decision support|Clinical pharmacists mediated computerized decision support
144340|NCT00095108|Drug|Recombinant Human Interleukin-21|
144341|NCT01743963|Behavioral|Usual Care|clinicians typical apporach for GID monitering
144342|NCT01743976|Drug|Donepezil|donepezil 5 mg once daily for 6 weeks
144343|NCT01743976|Drug|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
144344|NCT01743989|Drug|Nilotinib|Nilotinib will be provided to patients for at least 24 or 36months. (depending if nilotinib re-initiation is necessary- nilotinib will be provided during nilotinib re-initiation phase)
144345|NCT01744002|Other|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
144346|NCT01746329|Other|Placebo|Oral intake of 75 grams of glucose in water
144347|NCT01746342|Device|Effective continuous positive airway pressure (CPAP)|
144348|NCT01746342|Device|Sham continuous positive airway pressure (CPAP)|
144349|NCT01746355|Procedure|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
144350|NCT01746368|Other|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
144351|NCT01746368|Other|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
144352|NCT00095303|Behavioral|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
147478|NCT01711190|Procedure|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
147479|NCT01711203|Other|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
147480|NCT01711203|Other|General Strengthening|General abdominal and lower quarter musculature strengthening
146960|NCT01692223|Behavioral|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety & Depression Scale (HADS), revised Impact of Events Scale (IES-R), & a questionnaire about their health behaviors, to establish baseline distress levels & health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider & discuss resultant therapeutic & management recommendations for the participants & their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
146961|NCT01692249|Other|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
146962|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
146963|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
146964|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
146965|NCT01692275|Other|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
146966|NCT01692275|Other|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
146967|NCT01695096|Other|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
146968|NCT01695096|Other|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
146969|NCT01695109|Drug|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
146970|NCT01695109|Drug|Placebo|0.9% NaCl, 0.2 ml
146971|NCT00090207|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
147603|NCT01713829|Other|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
147604|NCT01713829|Other|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
147605|NCT01713842|Drug|TCZ|Tocilizumab at week 0, 4 and 8.
147953|NCT01719666|Procedure|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
147954|NCT01719666|Procedure|conventional surgery|conventional surgery: MPFL reconstruction
147955|NCT01719679|Behavioral|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
147956|NCT01719692|Drug|Rituximab|
147957|NCT01719705|Drug|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
147958|NCT01719705|Drug|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
147959|NCT01719705|Drug|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
147960|NCT01719718|Procedure|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
147961|NCT00092092|Drug|Budesonide inhaler|Budesonide 200 mcg inhalation powder
147962|NCT01711827|Drug|Isavuconazole|oral
147963|NCT01711827|Drug|Prednisone|oral
147964|NCT01711853|Drug|Dabigatran Etexilate|Dabigatran Etexilate 75mg twice daily
147965|NCT01711866|Drug|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
147966|NCT01711879|Drug|Aflibercept|Details covered in arm description
147967|NCT01711892|Behavioral|Soccer training|
147968|NCT01711905|Dietary Supplement|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
147969|NCT01711918|Drug|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
147970|NCT01711931|Device|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
147971|NCT01711931|Device|Implantation of everolimus-eluting stents|
147395|NCT01711034|Drug|OPB-111077|Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.
Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles.
147396|NCT01711047|Procedure|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
147397|NCT01711047|Procedure|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
147398|NCT01711060|Drug|oxytocin|
147399|NCT01711060|Procedure|balloon catheter|
147669|NCT01719510|Other|Samples|At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.
For both groups:
one swab for GBS detection by real-time PCR
the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.
For all women included will be achieved in the delivery room:
To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.
A sampling of umbilical cord blood.
Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.
For mothers, the collection of 3-5 ml of milk when breastfeeding.
147670|NCT01719523|Drug|EPI-743|
147671|NCT01719536|Drug|Icotinib|Icotinib: 125 mg is administered orally three times per day.
147672|NCT01719536|Drug|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
147673|NCT01719549|Drug|Dovitinib|Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule
Study drug: TKI258 capsule
Dose: 500mg p.o. qd
Every 3 weeks
147674|NCT01719562|Procedure|magnetic resonance imaging|Undergo MRI scans
147675|NCT01719575|Drug|Motilitone|
147676|NCT01711476|Other|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
147677|NCT01711489|Drug|isavuconazole|oral
147678|NCT01711489|Drug|Mycophenolate mofetil|oral
147679|NCT01711515|Drug|Cisplatin|Given IV
147680|NCT01711515|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
147681|NCT01711515|Radiation|Internal Radiation Therapy|Undergo intracavitary brachytherapy
147682|NCT00092040|Drug|Comparator: risedronate / Duration of Intervention: 12 mo|
147166|NCT01715688|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
147167|NCT01715688|Drug|Saline|Administration of saline in the endotracheal tube cuff
147168|NCT01715701|Procedure|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
147169|NCT01715701|Procedure|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
147170|NCT01715701|Procedure|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
147171|NCT01715714|Drug|Statin Recapture Therapy|Given 12h and 2h before CABG
147172|NCT00092378|Drug|MK0966, rofecoxib|
147173|NCT01715714|Drug|Placebo|Given 12h and 2h before CABG.
147174|NCT01715740|Drug|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
147175|NCT01715740|Drug|Placebo|
147176|NCT01715753|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
147177|NCT01715753|Behavioral|Diet counseling and group education lessons|Individual and group diet counseling to achieve a >10% weight loss
147178|NCT01715779|Drug|Eltrombopag|Eltrombopag exposure
147457|NCT01718938|Drug|velusetrag dose 2|
147458|NCT01718938|Drug|velusetrag dose 3|
147459|NCT01718938|Drug|placebo|
147460|NCT01718951|Drug|golimumab|golimumab
147461|NCT00092664|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
147462|NCT01718951|Drug|Pamidronate|pamidronate
147463|NCT01718964|Drug|Cortisol 20 mg|
147464|NCT01718964|Drug|Mannitol|Mannitol used as placebo
146317|NCT01691261|Biological|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
146318|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, single, 1 day
146613|NCT01694420|Drug|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
146614|NCT01694433|Drug|Calcipotriene|1g daily BID
146615|NCT01694433|Drug|Placebo|1g daily BID
146616|NCT01694446|Other|Intraduodenal glucose or fructose|
146617|NCT01694459|Drug|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
146618|NCT01694459|Drug|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
146619|NCT01694472|Biological|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
146620|NCT00090155|Drug|Comparator: ondansetron IV|
146621|NCT01697293|Drug|Doxorubicin Hydrochloride|Given IV
146622|NCT01697293|Other|Laboratory Biomarker Analysis|Correlative studies
146623|NCT01697293|Drug|Paclitaxel|Given IV
146624|NCT01697293|Procedure|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
146625|NCT01697293|Drug|Triciribine Phosphate|Given IV
146626|NCT01697306|Drug|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
146627|NCT01697306|Drug|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
146628|NCT01697319|Drug|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
146629|NCT00090402|Other|Placebo|Soybean oil 3 grams a day and placebo lipoic acid 600 milligrams a day taken for 12 months.
146079|NCT01693315|Drug|AMA0076|
146080|NCT01693315|Drug|Placebo|
146081|NCT01693328|Drug|PecFent® (fentanyl) nasal spray|
146082|NCT01693341|Other|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
146083|NCT01693354|Device|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
146084|NCT01693354|Device|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
146381|NCT01699685|Drug|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
146382|NCT01699685|Drug|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
146383|NCT01699685|Drug|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
146384|NCT01699698|Other|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
146385|NCT01699711|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
146386|NCT01699724|Drug|JZoloft|50 mg tablet on Day 1 of each period
146387|NCT00090779|Drug|Emtricitabine/ tenofovir disoproxil fumarate|once daily
146388|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
146389|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
146390|NCT01699737|Drug|JTT-851|
146391|NCT01699737|Drug|Glimepiride|Encapsulated Glimepiride tablets
146392|NCT01699737|Drug|Placebo for Active|
146393|NCT01699737|Drug|Placebo for comparator|
146394|NCT01699750|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
146395|NCT01699750|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
146149|NCT01693367|Device|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
146150|NCT01693380|Biological|Influenza vaccine|Influenza vaccine: schoolchidren in the experimental group received IM administered:
From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.
9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.
146151|NCT00090064|Behavioral|Psychotherapy|Psychotherapy provided by a team of two co-therapists
146152|NCT01693380|Biological|Control vaccine|Schoolchildren from 6 to 8 years of age:
- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered.
146153|NCT01693393|Drug|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
146154|NCT01693419|Drug|GES (Gemcitabine, Erlotinib, S-1)|Treatment will be delivered as a 3-week cycle.
Gemcitabine 1000 mg/m² IV on day 1, 8
Erlotinib 100 mg/day PO on day 1
S-1 60 mg/m²/day PO on day 1-14
146155|NCT01693432|Drug|DS (docetaxel+S-1)|Treatment will be delivered as a 3-week cycle.
Docetaxel 60 mg/m²IV on day 1
S-1 80 mg/m2/day PO on day 1-14
146156|NCT01693445|Drug|OIS (Oxaliplatin, Irinotecan, S-1)|Dose level 1 treatment will be delivered as a 2-week cycle as bellows;
Oxaliplatin 85 mg/m²IV on day 1
Irinotecan 120 mg/m² IV on day 1
S-1 60 mg/m2/day PO on day 1-7
Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.
146157|NCT01693458|Behavioral|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
146460|NCT01697085|Dietary Supplement|Sea buckthorn oil|
146461|NCT01697085|Dietary Supplement|Placebo oil|
146462|NCT01697098|Drug|Dexamethasone 24 hours|
146463|NCT01697098|Drug|Dexamethasone 12|
146464|NCT01697111|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
146465|NCT01697111|Drug|Placebo|One tablet (no active ingredient) / day and one tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day, for the first 24 weeks and the later 28 weeks, respectively
146466|NCT01697111|Drug|Dienogest|Dienogest 1mg twice a day (bid)
146851|NCT01689779|Drug|100, 000 IU cholecalciferol|
145908|NCT01695993|Behavioral|Version 2 MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. The MP3 (for subjects randomized to Arm 3) has some additional information in it regarding relaxation.
145909|NCT01696019|Other|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
145910|NCT01696019|Other|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
145911|NCT01696019|Other|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
145912|NCT00090272|Drug|MK0826, ertapenem sodium|
145913|NCT01696019|Other|Contact and testing only|
145914|NCT01696032|Drug|SGI-110 and carboplatin|
145915|NCT01696032|Drug|Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)|Investigator may choose to treat with either topotecan, pegylated liposomal doxorubicin, or paclitaxel
145916|NCT01696045|Biological|Ipilimumab|
145917|NCT01696058|Drug|Tiotropium|marketed product
145918|NCT01696058|Drug|Placebo matching Olodaterol|one dose
145919|NCT01696058|Drug|Tiotropium|marketed product
145920|NCT01696058|Drug|Olodaterol|one dose
145921|NCT01696071|Drug|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
145922|NCT01696071|Drug|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
145923|NCT00090272|Drug|Comparator: cefotetan|
145924|NCT01696084|Drug|CPX-351|
150746|NCT01732705|Behavioral|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
150747|NCT01732718|Drug|Atorvastatin|Subjects will receive either: 1)atorvastatin for 6 weeks, followed by a 4-week washout period, then receive the other intervention (placebo)for 6 weeks; or 2) the other intervention (placebo) for 6 weeks, washout for 4 weeks, then atorvastatin for 6 weeks.
149769|NCT01707615|Other|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
149770|NCT01707628|Biological|influenza vaccination with influenza vaccine|
149771|NCT00001752|Drug|Estrogen|
149772|NCT00091637|Drug|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
149773|NCT01700153|Other|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
149774|NCT00090870|Biological|sargramostim|
149775|NCT01700166|Biological|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
149776|NCT01700179|Drug|ACH-0143102|
149777|NCT01700179|Drug|Ribavirin|
149778|NCT01700192|Biological|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
149779|NCT01700192|Biological|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually once
daily
149780|NCT01700192|Drug|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine preferred dose of 0.30 mg administered intramuscularly as needed for rescue medication
149781|NCT01700192|Drug|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication
149782|NCT01700192|Drug|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication
149783|NCT01700192|Drug|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication
149784|NCT01700205|Other|Type of Formula|infant formula
149785|NCT00090870|Drug|thalidomide|
149786|NCT01700218|Other|telemonitoring|
150490|NCT01734499|Behavioral|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
150491|NCT01734499|Behavioral|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
150492|NCT01734512|Drug|Everolimus|Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.
150493|NCT01734525|Drug|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
150494|NCT01734538|Dietary Supplement|Omega-3 Complete|
150495|NCT01734538|Dietary Supplement|Placebo capsule|
150496|NCT01734551|Drug|Morphine|Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.
Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is <0.1mg/kg/day, may discontinue.
150497|NCT01734551|Drug|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
150498|NCT01734564|Biological|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
150499|NCT00094016|Drug|beclomethasone dipropionate|
150500|NCT01734564|Radiation|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
150501|NCT01736748|Behavioral|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
150502|NCT01736761|Drug|Darunavir, Ritonavir and Rilpivirine|
150503|NCT01736774|Other|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
149554|NCT01704677|Procedure|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
149933|NCT01705288|Drug|intravenous narcotics|given for pain management after surgery per physician orders
149934|NCT01705288|Drug|standard anesthesia|inhalant or intravenous during surgery
149935|NCT01705288|Drug|regional anesthesia|given by spinal or epidural infusion
149936|NCT00091312|Procedure|adjuvant therapy|
149937|NCT01705288|Drug|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
150207|NCT00093769|Drug|bortezomib + rituximab|Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Patients in either arm may crossover to the other arm if treatment is found to be ineffective.
150208|NCT01731795|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
150209|NCT01733979|Dietary Supplement|Heme-Iron|Heme-Iron (1g/day)
150210|NCT01733979|Dietary Supplement|Organic Iron|Organic Iron (1g/day)
150211|NCT01733992|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
150212|NCT01733992|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
150213|NCT01733992|Drug|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
150214|NCT00093938|Drug|Cranberry juice|
150215|NCT01733992|Drug|Placebo|Placebo, single and multiple ascending dose
150216|NCT01734005|Dietary Supplement|Red Ginseng|Red Ginseng (1.4g/day)
150217|NCT01734005|Dietary Supplement|Placebo|Placebo (1.4g/day)
150218|NCT01734044|Drug|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
150219|NCT01734044|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
149694|NCT01700140|Drug|SyB D-0701|Study drug patches [Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
149695|NCT01700140|Drug|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
149696|NCT01700153|Other|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
149697|NCT01702428|Biological|Havrix®|Single dose administered intramuscularly (IM) in the anterolateral region of the right thigh at Visit 1 (Day 0), with either one of the three Inv_MMR vaccine lots or one of the two active control Com_MMR vaccine lots.
149698|NCT01702428|Biological|Prevnar 13® (Pfizer Inc.)|Single dose administered IM in the anterolateral region of the left thigh at Visit 1 (Day 0), with either one of the three Inv_MMR vaccine lots or one of the two active control Com_MMR vaccine lots in the US only.
149699|NCT01702441|Drug|Subcutaneous AKB-9778|
149700|NCT00091104|Biological|therapeutic autologous lymphocytes|
149701|NCT01702454|Biological|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
149702|NCT01702467|Drug|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
149995|NCT01702857|Biological|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
149996|NCT01702857|Biological|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
149997|NCT01702857|Other|Phosphate buffered saline|
149998|NCT01702857|Biological|1 µg TDENV-PIV with Alum adjuvant|
149999|NCT01702857|Biological|1 µg TDENV-PIV with AS01E adjuvant|
150000|NCT01702870|Procedure|Magnetic Resonance Imaging|
150001|NCT01702883|Other|Internet Survey|prompt to complete internet survey
150002|NCT00091117|Other|pharmacological study|Correlative studies
150003|NCT01702896|Drug|Interleukin-2|Interleukin-2
150004|NCT01702909|Drug|Interleukin-2|Interleukin-2
149136|NCT01709149|Drug|CK-2017357|
149137|NCT01709149|Other|Placebo tablets|
149138|NCT01709162|Biological|Ipilimumab|
149139|NCT01709162|Drug|Chemotherapy|
149140|NCT01709175|Behavioral|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
149141|NCT00091832|Biological|Denosumab|Denosumab administered by subcutaneous injection
149142|NCT01709188|Behavioral|Musical Dual Task Training|
149143|NCT01709188|Behavioral|Walking and Talking|
149144|NCT01709201|Behavioral|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
149145|NCT01709214|Drug|Cebranopadol (GRT6005) Low-Dose Range|
149146|NCT01709214|Drug|Cebranopadol (GRT6005) High-Dose Range|
149147|NCT01709214|Drug|Placebo|
149148|NCT01709214|Drug|Oxycodone CR|
149149|NCT01709227|Drug|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
149150|NCT01709227|Procedure|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
149151|NCT01709240|Device|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
149474|NCT01704664|Dietary Supplement|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
148576|NCT01715506|Behavioral|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months.
148577|NCT01715506|Other|Educational intervention|Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
148578|NCT01715519|Drug|Treatment (Viibryd)|
148579|NCT01715532|Drug|Huachansu|
148580|NCT00092365|Drug|MK0966, rofecoxib|
148581|NCT01715532|Other|TACE|
148881|NCT01701115|Procedure|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|Anesthetic volume:
Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL
148882|NCT01701115|Procedure|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|Anesthetic volume:
Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL
148883|NCT01701115|Drug|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
148884|NCT01701115|Drug|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
148885|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
148886|NCT00001735|Procedure|Gene therapy|
148887|NCT00091039|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|
148888|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
148889|NCT01703559|Drug|Phentolamine mesylate ophthalmic solution|Ophthalmic solution, one drop each eye x 15 days
148890|NCT01703572|Drug|OMP-52M51|
148891|NCT01703598|Device|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
148892|NCT01703598|Procedure|DBS surgery|Placement of DBS electrodes
148331|NCT01717898|Drug|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
148332|NCT01717898|Drug|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
148333|NCT01710072|Drug|aspirin|
148334|NCT01710085|Device|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
148335|NCT01710098|Drug|Degarelix|subcutaneous injection
148336|NCT01710111|Device|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
148337|NCT00091949|Drug|pioglitazone|a thiazolidinedione drug
148338|NCT01710124|Other|Financial incentives|
148631|NCT01705743|Drug|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
148632|NCT01705743|Drug|Sevoflurane|100% oxygen+ Sevoflurane
148633|NCT01705756|Drug|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
148634|NCT01705769|Other|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
148635|NCT01705769|Other|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
148636|NCT01705769|Other|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
148637|NCT00091351|Procedure|conventional surgery|
148638|NCT01705782|Biological|E. coli endotoxin, US standard|
148639|NCT01705795|Drug|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
148640|NCT01705795|Drug|Placebo|Nacl four times over four months
148641|NCT01705808|Drug|Protein C concentrate|
148642|NCT01705821|Device|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
147481|NCT00092014|Drug|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
147482|NCT01711229|Drug|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
147483|NCT01711229|Drug|oral acetaminophen|oral acetaminophen will be given preoperatively
147484|NCT01711242|Drug|Capecitabine|
147485|NCT01711242|Drug|Oxaliplatin|
147486|NCT01711242|Radiation|Radiotherapy|
147487|NCT01711281|Device|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
147488|NCT01711294|Device|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
147489|NCT01711294|Device|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
147490|NCT01711294|Device|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
147491|NCT01711307|Procedure|operative|
147492|NCT00001758|Drug|Efavirenz|
147493|NCT00092027|Drug|MK0217, alendronate sodium/Duration of Treatment: 6 months|
147494|NCT01711307|Procedure|non-operative|casting within 48 hrs
147495|NCT01711320|Drug|Placebo|
147496|NCT01711320|Drug|Omeprazole|
147497|NCT01711333|Drug|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
147498|NCT01711346|Biological|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
147499|NCT01711346|Biological|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
147500|NCT01711359|Drug|Baricitinib|Administered orally
147501|NCT01711359|Drug|Methotrexate|Administered orally
147239|NCT01713283|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
147240|NCT01713296|Drug|Pazopanib|
147241|NCT01713309|Drug|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
147242|NCT01713322|Behavioral|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
147243|NCT00092209|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium|
147244|NCT01713322|Behavioral|No pain management education|Control - parents receive general information about childhood immunization.
147245|NCT01713348|Device|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
147246|NCT01713348|Device|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
147247|NCT01713361|Drug|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
147248|NCT01713361|Drug|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
147249|NCT01715805|Drug|Cariprazine|Patients who meet eligibility will have 1-2 week screening period followed by blind placebo, followed by 8 week double blind treatment period on cariprazine with Antidepressant Therapy (ADT) or placebo with ADT for inadequate responders and ADT with single blind placebo for responders, followed by a 1-week safety follow-up period
147250|NCT01715805|Drug|Placebo|Patients who meet eligibility will have 1-2 week screening period followed by blind placebo, followed by 8 week double blind treatment period on placebo with Antidepressant Therapy (ADT) for inadequate responders and ADT with single blind placebo for responders, followed by a 1-week safety follow-up period
147251|NCT01715818|Drug|Placebo|matching aleglitazar placebo tablet orally daily
147252|NCT00092378|Drug|Comparator: diclofenac sodium, placebo|
147253|NCT01715818|Drug|aleglitazar|150 mcg orally daily
147254|NCT01715831|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
147255|NCT01715844|Dietary Supplement|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
147256|NCT01715870|Behavioral|Life style and food habits questionnaire|
147257|NCT01715883|Drug|Sodium Nitrite|Same as the details in Arm Description.
147972|NCT00001761|Drug|Interleukin-10|
147973|NCT00092092|Drug|Placebo to montelukast chewable tablets|Placebo chewable tablets
147974|NCT01711931|Device|Implantation of biolimus-eluting stents|
147975|NCT01711944|Behavioral|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
147030|NCT01690091|Drug|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
Titration:
500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)
147031|NCT01690091|Drug|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
147032|NCT01690104|Drug|Rifampicin|
147033|NCT01690104|Drug|Placebo|
147034|NCT01692288|Behavioral|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
147035|NCT00089986|Drug|Intravenous GR270773- Phospholipid Emulsion|
147036|NCT01692301|Drug|LCZ696|Investigational drug
147037|NCT01692301|Drug|Olmesartan|Comparator Drug
147038|NCT01692301|Drug|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
147039|NCT01692301|Drug|Olmesartan matching placebo|Olmesartan matching placebo capsule
147040|NCT01692301|Drug|amlodipine|amlodipine 2.5 mg or 5 mg tablets
147041|NCT01692301|Drug|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
147042|NCT01692314|Other|Resistance training|
147043|NCT01692327|Dietary Supplement|High fat meal|
147044|NCT01692340|Other|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
147045|NCT01692353|Other|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
147046|NCT00089986|Other|Placebo|
147683|NCT01711515|Biological|Ipilimumab|Given IV
147684|NCT01711515|Other|Laboratory Biomarker Analysis|Correlative studies
147685|NCT01711528|Drug|Bortezomib|Given SC
147686|NCT01711528|Drug|Dexamethasone|Given PO
147687|NCT01711528|Drug|Dinaciclib|Given IV
147688|NCT01711528|Other|Laboratory Biomarker Analysis|Correlative studies
147689|NCT01711541|Drug|Carboplatin|Given IV
147690|NCT01711541|Drug|Cisplatin|Given IV
147691|NCT01711541|Drug|Fluorouracil|Given IV
148043|NCT01719926|Drug|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
148044|NCT01719952|Drug|Carbetocin|IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
148045|NCT01719952|Drug|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
148046|NCT00092742|Drug|Comparator: Diclofenac sodium|
148047|NCT01719965|Other|Interviews and Focus Group Discussions|
148048|NCT01719978|Drug|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
148049|NCT01719978|Procedure|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
148050|NCT01719978|Drug|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
148051|NCT01719978|Drug|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
148052|NCT01719991|Other|Nurse case management and self-management support|Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.
Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease.
148053|NCT01720004|Other|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
147465|NCT01718977|Other|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
147466|NCT01718977|Other|Arm Cycle Ergometry Training|Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.
The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session.
147467|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
147468|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
147469|NCT01719003|Drug|Empagliflozin low dose qd|Empagliflozin low dose once daily
147470|NCT01719003|Drug|Empagliflozin high dose qd|Empagliflozin high dose once daily
147471|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
147472|NCT00092677|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
147473|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
147474|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
147475|NCT01711125|Drug|Placebo|Placebo 3 matched tabs/day
147476|NCT01711177|Drug|placebo|Placebo
147477|NCT01711177|Drug|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
147756|NCT00092729|Drug|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
147757|NCT01719731|Behavioral|Education|This group will receive the psychoeducation
147758|NCT01719731|Behavioral|Non-Education|This group will not receive the psychoeducation
147759|NCT01719744|Drug|ENMD-2076|
147760|NCT01719757|Drug|Oxycodone/Naloxone|Twice daily
146630|NCT01697332|Drug|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
146631|NCT01697345|Drug|Testosterone|
146632|NCT01697358|Device|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
146633|NCT01697358|Drug|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
145685|NCT01748721|Other|laboratory biomarker analysis|Optional correlative studies
145686|NCT01748734|Procedure|quality-of-life assessment|Ancillary studies
145687|NCT01748734|Other|questionnaire administration|Ancillary studies
145688|NCT01748734|Other|counseling intervention|Undergo cognitive behavioral therapy
145689|NCT01748734|Behavioral|behavioral intervention|Undergo cognitive behavioral therapy
145690|NCT01748747|Drug|Montanide ISA 51 VG|Given SC
145691|NCT00095576|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 adenovirus genomes [ad-vg]/dose).
This dose is equivalent to 3x10^10 vp/dose used in study V520-016.
145692|NCT01748747|Biological|MART-1 antigen|Given SC
145693|NCT01748747|Other|laboratory biomarker analysis|Correlative studies
145694|NCT01748747|Biological|Gag:267-274 peptide vaccine|Given SC
145695|NCT01748747|Drug|resiquimod|Applied topically
145696|NCT01748760|Behavioral|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
145697|NCT01748760|Other|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
145698|NCT01741155|Drug|SPI-1620 & Docetaxel|Single Arm & Randomized Part:
On Day 1, the patient will receive standard docetaxel premedication followed by SPI-1620 11 μg/m2 administered intravenously over one minute. Patients will receive docetaxel 10 (±2) minutes following the infusion of SPI-1620. Docetaxel dose is 75 mg/m2 infusion. Patients will continue to receive SPI-1620 plus docetaxel once every 3 weeks until disease progression or intolerable toxicity. Overall 27 patients will be enrolled in the Single Arm Part. If 6 or more responses are observed in this group then the Randomized Part will be initiated. About 100 patient in the experimental arm will receive SPI-1620 & Docetaxel
146396|NCT01699750|Device|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
146397|NCT01699750|Device|BIOTRUE®|Contact lens care system, Phase 2
146398|NCT00090779|Drug|Lopinavir/Ritonavir|twice daily
146399|NCT01699750|Device|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
146400|NCT01699750|Device|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
146401|NCT01699763|Device|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
146402|NCT01691326|Biological|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
146403|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
146698|NCT01694498|Drug|Placebo|
146699|NCT01694511|Procedure|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
146700|NCT01694511|Procedure|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
146701|NCT01694537|Drug|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
146702|NCT01694537|Drug|placebo|Placebo is made with same size and shape with study drug.
146703|NCT01694563|Device|Synergy Ablation System|Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:
Coronary Artery Bypass Grafting (CABG)
Mitral valve repair or replacement
Aortic valve repair or replacement
Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria.
146704|NCT00090168|Drug|MK0653A , ezetimibe (+) simvastatin|
146705|NCT01694576|Drug|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
146706|NCT01694589|Drug|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
146707|NCT01694602|Biological|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
146708|NCT01694615|Procedure|Cryoprobe biopsy|
146467|NCT01697124|Behavioral|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
146468|NCT01699074|Dietary Supplement|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
146469|NCT01699074|Dietary Supplement|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
146470|NCT01699100|Other|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
146471|NCT01699113|Drug|YF476|Subjects will be randomised to once daily treatment by mouth for 6 weeks with:
YF476 100 mg; or
rabeprazole 20 mg; or
a combination of YF476 100 mg and rabeprazole 20 mg.
146472|NCT00090714|Genetic|pVGI.1(VEGF2)|
146473|NCT01699113|Drug|Rabeprazole|Subjects will be randomised to once daily treatment by mouth for 6 weeks with:
YF476 100 mg; or
rabeprazole 20 mg; or
a combination of YF476 100 mg and rabeprazole 20 mg.
146474|NCT01699126|Device|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
146475|NCT01699126|Drug|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
146476|NCT01699139|Device|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
146477|NCT01699139|Device|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
146478|NCT01699152|Drug|TG02 citrate|TG02 citrate capsules
146479|NCT01699165|Device|Nasal filter|Active nasal filter
146776|NCT01691937|Procedure|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
145925|NCT01696084|Drug|7+3 (cytarabine and daunorubicin)|
145926|NCT01696097|Behavioral|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
146222|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
146223|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
146224|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
146225|NCT01691027|Behavioral|Practice tracing objects and printing with a stylus on a tablet computer|Subjects will have three training modules on a tablet computer: scotoma awareness, line and curve tracing, and video games. The order of modules will be different for different groups of subjects. Training on a module will cease when the subject reaches a performance criterion. Retinal assessments will occur after each training module completion.
146226|NCT01691040|Drug|NOX-H94|intravenous injection
146227|NCT01691040|Drug|Placebo solution|intravenous injection
146228|NCT01691053|Drug|Spironolactone|50mg once daily
146229|NCT01691066|Behavioral|Infant Toddler Years PRT|
146230|NCT01691079|Drug|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
146231|NCT01691079|Drug|Placebo|Inhaled placebo administered before exercise.
146232|NCT00089856|Drug|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
146233|NCT01691092|Drug|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
146234|NCT01691105|Other|Academic Detailing + Integrated Tobacco Order Set|Physician will have access to:
NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
146235|NCT01691118|Drug|Fimasartan|
146236|NCT01691118|Drug|Antihypertensive treatment|
146237|NCT01691131|Other|Exercise training|Comparison of high intensity exercise training on land versus water.
146238|NCT01691157|Other|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
146239|NCT01693523|Behavioral|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
149787|NCT01700218|Other|control|
149788|NCT01700231|Procedure|Liver resection|Liver resection of patient with neoplastic hepatic tumors
149789|NCT01700244|Device|Pacemaker implant|
149790|NCT01700257|Radiation|CT scan & Early CDT Lung test|
149791|NCT01700257|Other|CT scan & Early CDT Lung test|
149792|NCT01700270|Drug|dovitinib (TKI258)|
150380|NCT01732068|Drug|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
150381|NCT01732094|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
150382|NCT01732094|Drug|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
150383|NCT01732094|Drug|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
150384|NCT01734291|Behavioral|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
150385|NCT01734304|Biological|DC vaccination for postremission therapy in AML|.DC vaccination
150386|NCT01734317|Device|Mepilex Transfer Ag|A soft silicone wound contact layer.
150387|NCT01734330|Behavioral|Cognitive behavioral therapy in group|
150388|NCT01734330|Drug|Nicotine replacement|
150389|NCT01734343|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
150390|NCT01734343|Device|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
150391|NCT00093977|Drug|darbepoetin alfa SF|Frequency of dosing depends on frequency at randomization:
rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL
150392|NCT01734356|Other|Skin biopsies|
150393|NCT01734382|Drug|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants less than [<] 30 kg) or 8 mg/kg (for participants </=30 kg) Q2W/Q3W/Q4W.
149555|NCT01704677|Behavioral|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
149556|NCT01704690|Drug|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
149557|NCT00091273|Biological|sargramostim|
149558|NCT01704690|Drug|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
149559|NCT01704690|Drug|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
149560|NCT01704703|Drug|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
149561|NCT01704703|Drug|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
149562|NCT01704716|Drug|Vincristine|given during Rapid COJEC and modified N7 therapy
149563|NCT01704716|Drug|Aldesleukin|
149564|NCT01704716|Drug|ch14.18/CHO|
149565|NCT01704716|Drug|Carboplatin|
149566|NCT01704716|Drug|Etoposide|
149567|NCT01704716|Drug|Cisplatin|
149568|NCT00091273|Biological|tetanus toxoid helper peptide|
149569|NCT01704716|Drug|Cyclophosphamide|
149570|NCT01704716|Drug|Doxorubicin|
149571|NCT01704716|Drug|G-CSF|
149572|NCT01707095|Other|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
149573|NCT00091611|Drug|IL-2 (interleukin-2)|
149574|NCT01707095|Other|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
149575|NCT01707108|Device|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
150220|NCT01734057|Drug|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day)
150221|NCT01734057|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
150222|NCT01734070|Other|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
150223|NCT01734083|Device|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
150224|NCT01734083|Behavioral|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
150569|NCT01732445|Other|questionnaire administration|Ancillary studies
150570|NCT01732458|Drug|Aprepitant|
150571|NCT01732458|Drug|Placebo to match aprepitant|
150572|NCT00093808|Biological|trastuzumab|
150573|NCT01732458|Drug|Ondansetron|
150574|NCT01732458|Drug|Placebo to match ondansetron|
150575|NCT01732471|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
150576|NCT01732484|Procedure|intraocular lens implantation|
150577|NCT01734577|Procedure|Dry needling|Sterile monofilament needles
150578|NCT01734577|Procedure|Sham needling|Applicator tubes from the sterile monofilament needles
150579|NCT01734590|Dietary Supplement|Carbohydrate based food mix 1|Carbohydrate based food
150580|NCT01734590|Dietary Supplement|Carbohydrate based food mix 2|Carbohydrate based food
150581|NCT01734590|Dietary Supplement|Control carbohydrate based food|Carbohydrate based food
150005|NCT01702961|Drug|Melphalan|Given on Day -1
Melphalan is administered according to the current SOP.
150006|NCT01702961|Drug|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
150007|NCT01702961|Drug|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
150008|NCT01702961|Drug|BCNU|BCNU 300 mg/m2 IV given on Day -6
150009|NCT01702961|Drug|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
150010|NCT01702961|Drug|Stem Cells|Stem cells given on Day 0
150011|NCT01702974|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
150012|NCT01702974|Drug|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
150013|NCT00091130|Biological|HspE7|Given SC
150014|NCT01702987|Dietary Supplement|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
150015|NCT01702987|Dietary Supplement|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
150016|NCT01705366|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
150017|NCT00091325|Dietary Supplement|defined green tea catechin extract|
150018|NCT01705366|Procedure|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
150282|NCT01731860|Device|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
150283|NCT01731886|Procedure|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2, and will undergo autologous peripheral blood stem cell transplantation on day 0. Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
150284|NCT01731886|Drug|Lenalidomide|ARM A Administered orally at a dose 25 mg daily on days 1-21 of each cycle. ARM B Administered orally at a dose 25 mg daily on days 1-21 of each cycle for 8 cycles. After cycle four, subjects will have peripheral stem cell collection. The final four cycles of lenalidomide and dexamethasone will be started within 4 weeks after stem cell collection.
150285|NCT01731886|Drug|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
149475|NCT01704664|Drug|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
149476|NCT01707004|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
149477|NCT01707004|Other|laboratory biomarker analysis|Correlative studies
149478|NCT01707017|Other|Strength training|
149479|NCT01707030|Other|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
149480|NCT01707030|Other|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
149481|NCT01707043|Drug|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
149482|NCT00091585|Drug|SNS-595|
149483|NCT01707056|Other|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
149484|NCT01707056|Other|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
149485|NCT01707056|Other|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
149486|NCT01707056|Other|Water|Taking Synthroid with water for a period of 6 weeks.
149487|NCT01707069|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.
Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals.
149488|NCT01707082|Drug|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
149489|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
149490|NCT01707082|Drug|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
149491|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
149492|NCT01707082|Drug|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
149493|NCT00091598|Drug|Ambrisentan|
148499|NCT01718067|Other|conventional manual ELTGOL technique|20 minutes twice a day
148893|NCT01703611|Other|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
148894|NCT01703611|Other|Usual Nutrition Care|Usual nutrition care in India
148895|NCT01703624|Drug|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
148896|NCT01703637|Drug|Sitagliptin|before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy
before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy
148897|NCT01703637|Drug|Vildagliptin|before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy
before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy
148898|NCT00091156|Drug|gefitinib|
149206|NCT01706692|Biological|Adalimumab|all dosages, frequencies and durations prescribed
149207|NCT01706692|Biological|Etanercept|all dosages, frequencies and durations prescribed
149208|NCT01706692|Biological|Infliximab|all dosages, frequencies and durations prescribed
149209|NCT00091507|Drug|GIK|Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
149210|NCT01706692|Biological|Ustekinumab|all dosages, frequencies and durations prescribed
149211|NCT01706692|Drug|Cyclosporine A|all dosages, frequencies and durations prescribed
149212|NCT01706692|Drug|Fumaric acids|all dosages, frequencies and durations prescribed
149213|NCT01706692|Drug|Methotrexate|all dosages, frequencies and durations prescribed
149214|NCT01706692|Drug|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
149215|NCT01706705|Device|Intracavitary Applicator Placement|MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
149216|NCT01706705|Other|Computed Tomography (CT)|CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
149217|NCT01706705|Other|Magnetic Resonance Imaging (MRI)|MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
149218|NCT01706718|Dietary Supplement|Bread|
148643|NCT01705821|Procedure|Removal of pituitary tumor using modified curette|
148644|NCT01705847|Drug|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
148645|NCT01705860|Biological|Santyl|
148646|NCT01705886|Procedure|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
148647|NCT01705886|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
148648|NCT00091351|Radiation|radiation therapy|
148649|NCT01705886|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
148650|NCT01705886|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
148651|NCT01705886|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
148957|NCT01701128|Other|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
148958|NCT01701154|Other|respiratory muscle strength training|
148959|NCT01701180|Drug|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
148960|NCT01701180|Drug|Placebo|
148961|NCT01701193|Drug|Amino Acid|Dipeptide
148962|NCT01701193|Drug|Saline|Placebo Comparator
148963|NCT01701206|Behavioral|HIV knowledge Intervention|
148964|NCT01701219|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
148965|NCT01701232|Biological|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
148966|NCT00091039|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
147781|NCT01719887|Procedure|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
147782|NCT01719887|Other|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
147783|NCT01719900|Dietary Supplement|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
147784|NCT01711580|Other|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
147785|NCT01711580|Other|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
147786|NCT01711580|Other|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
147787|NCT01711580|Other|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
147788|NCT01711580|Other|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
147789|NCT01711580|Other|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
147790|NCT01711580|Other|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
147791|NCT01711593|Biological|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshhold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
147792|NCT00092066|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
147793|NCT01711593|Procedure|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
147794|NCT01711619|Device|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
147795|NCT01711619|Other|Optimized Medical Management|Optimized medical management
147258|NCT01715896|Biological|Mavrilimumab or golimumab alternating with placebo subcutaneous injection|GM-CSR alpha inhibitor or TNF alpha Inhibitor alternating with placebo
147259|NCT01715909|Drug|oseltamivir [Tamiflu]|standard dose orally daily, 5-20 days
147260|NCT01715909|Drug|oseltamivir [Tamiflu]|triple standard dose orally daily, 5-20 days
147523|NCT01713764|Behavioral|American Diabetes Association Diet|
147524|NCT01713764|Behavioral|Mindfulness and Positive Affect Skills|
147525|NCT01713777|Drug|Lamotrigine Generic "A"|
147526|NCT01713777|Drug|Lamotrigine generic "B"|
147527|NCT01713790|Device|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
147528|NCT01713790|Device|Exergame|training program over 10 weeks, three times a week.
147529|NCT01716390|Dietary Supplement|Drink that contains plant stanols|
147530|NCT01716390|Dietary Supplement|Placebo drink|
147531|NCT01716403|Biological|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
147532|NCT01716416|Drug|Pazopanib|
147533|NCT01716416|Drug|Cetuximab|
147534|NCT01716429|Behavioral|Vegan diet|Vegan dietary approaches for weight loss
147535|NCT01716429|Behavioral|Low calorie diet|Reduced calorie diet for weight loss
147536|NCT01716442|Drug|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
147537|NCT01716442|Drug|Placebo|
147538|NCT00092430|Biological|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
147539|NCT01716455|Drug|SSP-004184|
147540|NCT01716481|Other|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
147541|NCT01716507|Procedure|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
147047|NCT01692366|Drug|SAR302503|Pharmaceutical form:Capsule
Route of administration: oral
147048|NCT01692379|Device|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
147049|NCT01692379|Other|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
147050|NCT01692405|Device|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
147321|NCT01713374|Other|no intervention|control visit
147322|NCT01713374|Procedure|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
147323|NCT01713374|Procedure|Cold pressure test|A hand will be placed in ice-cold water.
147324|NCT00092209|Drug|Comparator: placebo, losartan, hydrochlorothiazide|
147325|NCT01713387|Drug|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
147326|NCT01713400|Drug|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
147327|NCT01713400|Drug|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
147328|NCT01713400|Drug|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
147329|NCT01713400|Drug|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
147330|NCT01713413|Device|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
147331|NCT01713413|Device|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
147332|NCT01713426|Drug|Qutenza|Cutaneous patch
147333|NCT01713426|Drug|Pregabalin|Oral capsule
148054|NCT01720017|Other|Preclinical Manikin Training|During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.
148055|NCT01720017|Other|Inservice Training|Inservice training will include review of a product information handout and a video demonstration.
148056|NCT01720030|Drug|Levosimendan|Verum therapy
148057|NCT00092755|Drug|MK0663, etoricoxib|
148058|NCT01720030|Drug|Conventional therapy|Placebo therapy to safeguard blinding
148059|NCT01720043|Drug|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
148060|NCT01720056|Drug|Verapamil|
148061|NCT01720056|Drug|Kenalog 10|
148062|NCT01720069|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
148063|NCT01712087|Device|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
147101|NCT01690169|Drug|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
147102|NCT01690169|Drug|placebo|A single dose of oral placebo administered.
147103|NCT01690182|Dietary Supplement|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
147104|NCT01690182|Dietary Supplement|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
147105|NCT01690182|Dietary Supplement|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
147106|NCT01690195|Drug|ABT-126|See arm description
147107|NCT01690208|Other|EMERALD|Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.
These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule.
147108|NCT01690208|Other|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment & explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
147109|NCT01690221|Drug|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
147761|NCT01719770|Drug|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
147762|NCT01719770|Other|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
147763|NCT01719783|Biological|LAIV H5N2|
147764|NCT01719796|Procedure|Regional analgesia infusion|
147765|NCT01719822|Device|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
147766|NCT01719835|Drug|Cyclophosphamide|750mg/m2 IV every 21 days
147767|NCT00092729|Drug|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
147768|NCT01719835|Drug|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
147769|NCT01719835|Drug|Doxorubicin|50mg/m2 IV every 21 days
147770|NCT01719835|Drug|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
147771|NCT01719835|Drug|Prednisolone|40mg/m2 oral Days 1-5 every 21 days
147772|NCT01719835|Drug|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
147773|NCT01719835|Drug|Cisplatin|100mg/m2 IV Day 15 every 28 days
147774|NCT01719848|Other|Measurements of parameters related with physical examinations for difficult airway prediction|
147775|NCT01719861|Drug|desipramine|
147776|NCT01719874|Biological|TCN-032|
147777|NCT01719874|Biological|Placebo (saline)|
147778|NCT00001783|Drug|0-15 Water|
147779|NCT00092742|Drug|MK0663, etoricoxib|
147780|NCT01719887|Device|Conservative treatment|Conservative treatment with functional brace applied after 7 days of initial treatment with prefabricated cork splint.
148130|NCT01717482|Other|Placebo Comparator|Standard of Care Observation
148131|NCT01717508|Behavioral|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
145699|NCT01741155|Drug|Docetaxel|Randomized Part-Control Arm (100 patient):
On Day 1 the patient will receive standard docetaxel premedication followed by docetaxel 75 mg/m2 by infusion over 1 hour. Patients will continue to receive docetaxel once every 3 weeks until disease progression or intolerable toxicity.
145700|NCT00094835|Drug|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
145701|NCT01741168|Other|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
145702|NCT01741168|Other|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
145703|NCT01741181|Drug|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
145704|NCT01741181|Drug|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
146000|NCT01696214|Drug|fluticasone and salmeterol|Drug: Fluticasone/salmeterol Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
146001|NCT01696214|Drug|Leukotriene receptor antagonist|Participants will be assigned to Leukotriene receptor antagonist once a day for 24 weeks.
146002|NCT01696214|Drug|Theophylline|Participants will be assigned to Theophylline once a day for 24 weeks
146003|NCT01696214|Drug|Tiotropium|Participants will be assigned to Tiotropium 18 ug once a day for 24 weeks.
146004|NCT01696227|Drug|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
146005|NCT01696240|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
146006|NCT00090285|Biological|Comparator: placebo (unspecified)|Duration of Treatment: 6 months
146007|NCT01696240|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
146008|NCT01696266|Other|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
146009|NCT01696279|Drug|Lanthanum carbonate|Subjects will receive Lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided equally between three meals.
146010|NCT01698658|Procedure|magnetic resonance imaging|Undergo MRI of the breast
146011|NCT01698671|Device|InterGard Synergy Vascular Graft|
146709|NCT01694615|Procedure|Forceps Biopsy|
146710|NCT01694628|Behavioral|CLIMB (COPD Lifestyle, Mood, and Behavior)|
146711|NCT01694641|Other|observation of embryo development by time lapse embryo monitoring versus standard once a day embryo evaluation|
146712|NCT01694667|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
146713|NCT01694680|Dietary Supplement|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
146714|NCT01694680|Dietary Supplement|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
146715|NCT00001723|Drug|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
146716|NCT00090168|Drug|Comparator: atorvastatin|
146717|NCT01694693|Drug|Orencia|No Intervention
146718|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
145760|NCT01690247|Drug|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
145761|NCT01690260|Drug|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
145762|NCT01690260|Procedure|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
145763|NCT01690273|Other|stretching exercise|30 minutes, twice a week
145764|NCT01690286|Drug|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
145765|NCT01690286|Drug|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
145766|NCT01690286|Drug|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
145767|NCT00089778|Other|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
145768|NCT01690286|Drug|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
145769|NCT01690299|Drug|Apremilast tablet/pill 30 mg|Apremilast tablet/pill 30 mg tablet orally twice a day
146777|NCT01691963|Device|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.
The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.
Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.
The glottic view will be scored in both positions using the Cormack and Lehane classification system.
After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position.
146778|NCT01691976|Drug|Oestrogen Patches|
146779|NCT01691976|Drug|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
146780|NCT00001716|Drug|Nitroglycerin|
146781|NCT00089921|Drug|SCIO-469|100 mg tablet once daily for 12 weeks
146782|NCT01691989|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
146783|NCT01691989|Drug|placebo|oral doses once a day for 26 weeks
146784|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
146785|NCT01694706|Drug|omeprazole|medium dose of omeprazole
146786|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
146787|NCT01694719|Behavioral|Brief Behavioral Activation Treatment for Depression|
146788|NCT01694719|Behavioral|Cognitive Control Training|
146789|NCT01694732|Drug|Varenicline|
146790|NCT01694732|Drug|placebo|
146791|NCT01694771|Drug|Tiotropium|Marketed dose
146792|NCT00090168|Drug|Duration of Treatment: 6 weeks|
146793|NCT01694771|Drug|Placebo matching Olodaterol|One dose
146794|NCT01694771|Drug|Olodaterol|One dose
146795|NCT01694771|Drug|Tiotropium|Marketed dose
145846|NCT01698476|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
145847|NCT00090584|Behavioral|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
146240|NCT01693536|Behavioral|Lifestyle counselling|as in Arm Description
146241|NCT01693549|Drug|Cabazitaxel|
146242|NCT01693562|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21, or 28 days.
146541|NCT01697150|Device|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
146542|NCT01697189|Behavioral|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
146543|NCT01697215|Other|AirWave|
146544|NCT01697228|Dietary Supplement|Vitamin D|
146545|NCT01697241|Other|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
146546|NCT01697241|Other|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
146547|NCT01697267|Biological|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
146548|NCT01697267|Drug|Azathioprine|Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.
The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.
If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%.
146549|NCT01697280|Behavioral|Vaccine promotion messages|The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:
Vaccines can save a child's life
Children who are immunized on time are less likely to become ill
Unimmunized children can become disabled for life
Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings.
146550|NCT01697280|Other|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
146551|NCT00090402|Dietary Supplement|Fish Oil and Lipoic acid|Fish oil concentrate(daily dose 3 grams containing 675 milligrams docosahexanoic acid and 975 milligrams eicosapentanoic acid) plus lipoic acid (daily dose 600 milligrams)taken for 12 months
150394|NCT01734395|Drug|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
150395|NCT01734408|Biological|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
150396|NCT01734408|Biological|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
150397|NCT01734408|Biological|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
150398|NCT01734408|Biological|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
150399|NCT01734408|Biological|0/0.5ml placebo|0/0.5ml placebo
150400|NCT01734421|Other|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
150424|NCT01736696|Drug|tofacitinib|20 mg BID for 13 days and once on Day 14
150425|NCT01736696|Drug|tofacitinib|30 mg BID for 13 days and once on Day 14
150426|NCT01736696|Drug|tofacitinib|60 mg tablet once a day (QD) for 14 days
150427|NCT01736696|Drug|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
150428|NCT01736709|Biological|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
150429|NCT01736722|Device|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
150430|NCT01736735|Drug|CLP|
150431|NCT00094406|Procedure|Bronchoscopy|
150432|NCT01736735|Drug|placebo|
150433|NCT01736748|Behavioral|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
149856|NCT01707706|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
149857|NCT01707732|Drug|Enoxaparin|Administration of Enoxaparin
149858|NCT01707745|Procedure|Intravitreal Bevacizumab|
149859|NCT00091637|Drug|Placebo infusion|bolus infusion over a 10 minute period once
149860|NCT01707771|Procedure|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
149861|NCT01707771|Behavioral|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
149862|NCT01707810|Procedure|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
149863|NCT01707810|Procedure|conventional method|
149864|NCT01707823|Drug|acetylsalicylic acid|Given PO
149865|NCT01707823|Other|laboratory biomarker analysis|Correlative studies
149866|NCT01707849|Drug|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
149867|NCT01707849|Drug|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
149868|NCT01707875|Other|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
149869|NCT01707888|Procedure|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
149870|NCT00091650|Drug|Olanzapine|
149871|NCT01707901|Drug|ONO-8539|Treatment
149872|NCT01707901|Other|Placebo|Placebo
149873|NCT01707914|Dietary Supplement|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
149874|NCT01707914|Dietary Supplement|placebo|
150582|NCT01734603|Procedure|experimental rehabilitation program|Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.
Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.
Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .
Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% .
150583|NCT01734603|Procedure|conventional rehabilitation program|Duration of the training 40 minutes (time excluding rest and warm up)
Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.
Increase :
Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible.
150584|NCT01734616|Behavioral|Old Exercise|
150585|NCT01734616|Dietary Supplement|Old Acute Cocoa|
150586|NCT00094029|Drug|Sutent|Sutent, 25, 37.5, or 50 mg daily
150587|NCT01734616|Dietary Supplement|Old 7 Day Cocoa|
150588|NCT01734668|Device|In Vitro Diagnostic device to aid in diagnosis|
149629|NCT01702402|Other|Comparison Group|A comparison area received standard government health services.
149630|NCT01702415|Drug|Zoledronic acid|Single dose, intravenous solution 5mg
149631|NCT01702415|Drug|Placebo|
149632|NCT01702428|Biological|GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762)|Single dose administered subcutaneously (SC) in the tricep region of the left arm at Visit 1 (Day 0).
149633|NCT01702428|Biological|Merck &amp; Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine|Single dose administered SC in the tricep region of the left arm at Visit 1 (Day 0).
149634|NCT01702428|Biological|Varivax® (Merck & Co., Inc.)|Single dose administered SC in the tricep region of the right arm at Visit 1 (Day 0), with either one of the three Inv_MMR vaccine lots or one of the two active control Com_MMR vaccine lots.
149635|NCT01704716|Drug|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
149636|NCT01704716|Drug|Melphalan|
149637|NCT01704729|Procedure|group1|Non-cycloplegic self-refraction +conventional glasses
149638|NCT01704729|Procedure|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
150286|NCT01731886|Procedure|Stem Cell Mobilization|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously with mesna at a total of 2.4 gm/m2 intravenously or orally divided over 3 doses. Subjects then will receive mobilization using daily filgrastim (G-CSF) at 10 mcg/kg subcutaneously starting 24 hours after cyclophosphamide is completed and until stem cell collection. The use of AMD3100 (Plerixafor) is permitted. Peripheral stem cell collection will be performed at marrow recovery, usually when WBC is >2500 x 109 cells/liter; platelet count is >20 x 103/mm3.
150287|NCT00093782|Drug|temsirolimus|Given IV
150288|NCT01731899|Drug|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
150289|NCT01731912|Drug|Degarelix|Given SC
150290|NCT01731912|Radiation|External Beam Radiation Therapy|Undergo standard EBRT
150291|NCT01731912|Other|Laboratory Biomarker Analysis|Correlative studies
150292|NCT01731925|Drug|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
150293|NCT01731925|Drug|Placebo (for sunitinib)|
150294|NCT01731925|Drug|Sunitinib|Sunitinib 37.5 mg daily
150295|NCT01734148|Behavioral|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
150296|NCT01734161|Drug|Dexamethasone|
150297|NCT01734161|Drug|Placebo|
150298|NCT01734174|Procedure|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
150652|NCT01732549|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
150653|NCT01732562|Other|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
150654|NCT01732575|Behavioral|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
148500|NCT01718093|Drug|Sitagliptin|up to 50 mg twice a day
148501|NCT01718093|Drug|Metformin|up to 1000 mg twice a day
148502|NCT01718093|Drug|Sitagliptin + Metformin|up to 50/1000 mg twice a day
148503|NCT01718106|Device|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
148504|NCT01718119|Drug|r-hCG|r-hCG(250mcg) injection subcutaneously
148505|NCT01718145|Drug|Daclatasvir|
148506|NCT00092586|Drug|Comparator: statins|
148507|NCT01718145|Drug|Asunaprevir|
148508|NCT01718145|Drug|Ribavirin|
148509|NCT01718145|Biological|pegIFNα-2b|
148510|NCT01718145|Drug|Telaprevir|
148511|NCT01718158|Biological|Peginterferon Lambda-1a|
148512|NCT01718158|Biological|Peginterferon Alfa-2a|
148513|NCT01718158|Drug|Ribavirin|
148514|NCT01718158|Drug|Daclatasvir|
148515|NCT01718158|Drug|Telaprevir|
148516|NCT01718184|Procedure|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
148517|NCT00092599|Drug|MK0653, ezetimibe|
148518|NCT01718184|Procedure|Sulcoflex intraocular lens implantation|
148519|NCT01718210|Drug|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
148520|NCT01718210|Drug|CONTROL|group of controls treated with a standard IVF medium
148521|NCT01718223|Drug|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
148522|NCT01718223|Procedure|therapeutic conventional surgery|Undergo surgical resection
148523|NCT01718223|Other|laboratory biomarker analysis|Correlative studies
149219|NCT01709357|Other|Ischemic compression technique|The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was "moderate but bearable", a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to "no pain" and 10 do "unbearable pain"). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds.
149220|NCT01709357|Other|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
149221|NCT01709370|Drug|Letrozole, PD 0332991|
149222|NCT01709383|Device|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
149223|NCT01709383|Device|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
149224|NCT01709396|Radiation|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
149225|NCT01709409|Drug|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
148260|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
148261|NCT01710059|Behavioral|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
148262|NCT01710059|Behavioral|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
148263|NCT01710059|Behavioral|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
148264|NCT01710059|Behavioral|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
148265|NCT01712490|Drug|bleomycin|Bleomycin: 10 units/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
148266|NCT00092131|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
148267|NCT01712490|Drug|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
148268|NCT01712490|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
148967|NCT01701245|Device|GammaCore|vagal stimulation
148968|NCT01701258|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
148969|NCT01701258|Drug|Placebo|single-dose placebo capsule
148970|NCT01701271|Other|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
148971|NCT01701284|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
148972|NCT01701297|Drug|cotrimoxazole|
148973|NCT01701297|Drug|VSL#3 active|
148974|NCT01701297|Drug|VSL#3 placebo|
148975|NCT01701310|Drug|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
148976|NCT01701310|Drug|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
148977|NCT00091039|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
148978|NCT01701323|Drug|Cytarabine|Given IV
148979|NCT01701323|Procedure|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
149295|NCT00091260|Drug|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
149296|NCT01704404|Drug|TD-4208|
149297|NCT01704404|Drug|Placebo|
149298|NCT01706731|Behavioral|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
149299|NCT00091507|Drug|Placebo|Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
149300|NCT01706731|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
149301|NCT01706744|Other|Intermediate care unit|
149302|NCT01706744|Other|Local health care 1|
149303|NCT01706744|Other|Local health care 2|
148150|NCT01709851|Device|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
148151|NCT01709864|Drug|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
148152|NCT01709864|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
148153|NCT01709877|Procedure|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
148154|NCT01709890|Device|YO2(R) catheter|
148155|NCT01709903|Drug|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
148156|NCT01709903|Drug|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
148157|NCT01709903|Drug|Placebo to QVA149|Placebo to QVA149 with SDDPI
148158|NCT00091936|Drug|Efavirenz|
148159|NCT01709903|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
148160|NCT01709929|Drug|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
148161|NCT01709942|Drug|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
148162|NCT01709942|Drug|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were >300pg/ml
148163|NCT01712308|Drug|Sotatercept|Higher dose group: 1.0 mg/kg dose subcutaneously on Day 1 every 3 weeks.
Lower dose group: 0.75 mg/kg dose subcutaneously on Day 1 every 3 weeks.
148164|NCT01712321|Drug|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
148165|NCT01712321|Drug|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
148166|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
148167|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
148168|NCT01712360|Drug|NAFT500 (pediatric)|Applied to both feet and groin area
148169|NCT01712360|Drug|NAFT600 (pediatric)|Applied to both feet only
148170|NCT01712360|Drug|NAFT500 (adult)|Applied to both feet and groin area
147542|NCT01716520|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
147543|NCT01716520|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
147544|NCT01716520|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
147545|NCT01716533|Procedure|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
147546|NCT01716533|Other|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
147897|NCT01714271|Behavioral|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
147898|NCT01714284|Behavioral|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
147899|NCT01714284|Behavioral|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
147900|NCT01714297|Drug|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
147901|NCT01714310|Drug|lisdexamfetamine|Titration and open label treatment for 12 week study.
147902|NCT01714310|Drug|Placebo|
147903|NCT01714310|Drug|fluoxetine|
147904|NCT00001765|Device|Nexell Isolex with T-cell Depletion|
147905|NCT00092222|Drug|Prednisone|Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
147906|NCT01714323|Behavioral|Extended Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free & Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
147907|NCT01714323|Behavioral|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
147334|NCT01713439|Biological|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10^7/kg, 10^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10^4/kg and rising to 10^7/kg (10^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be <1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
147335|NCT00092222|Drug|Etoposide|Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
147336|NCT01716000|Behavioral|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
147337|NCT00001766|Drug|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
147338|NCT00092391|Biological|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
147606|NCT01713855|Biological|Inactivated Trivalent Influenza vaccine|
147607|NCT01713868|Behavioral|Safe Sleep Nursery Education|Nursery-based program for safe sleep
147608|NCT01713868|Behavioral|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
147609|NCT01713868|Behavioral|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
147610|NCT01713868|Behavioral|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
147611|NCT00092222|Drug|Bortezomib|1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
147612|NCT01713894|Other|Decision Aid|
147613|NCT01713894|Other|Standard|
147614|NCT01713907|Device|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
147615|NCT01713920|Drug|SEVIKAR|
147616|NCT01713933|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
147617|NCT01713946|Drug|RAD001|
147618|NCT01713946|Drug|Placebo|
147619|NCT01713959|Device|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
147110|NCT01690221|Drug|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
147111|NCT00089778|Drug|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
147112|NCT01690234|Procedure|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
147113|NCT01690234|Procedure|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
147114|NCT01692470|Drug|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
147115|NCT01692483|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
147116|NCT01692483|Drug|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
147117|NCT01692496|Drug|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
147118|NCT01692522|Procedure|Intubation|visualized blind intubation
147119|NCT01692535|Procedure|Intubation|Intubation with one of the six videolaryngoscopes
147400|NCT01711073|Drug|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
147401|NCT01711086|Device|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
147402|NCT01711086|Device|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
147403|NCT00092014|Drug|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
147404|NCT01711099|Device|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
147405|NCT01711112|Drug|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
147406|NCT01711125|Drug|Baclofen 30mg/day|30mg/day 10 mg t.i.d
147407|NCT01711125|Drug|Baclofen 75mg/day|75mg/day 25 mg t.i.d
148132|NCT01717534|Dietary Supplement|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
148133|NCT01717547|Behavioral|Yoga-based treatment|
148134|NCT01717560|Other|Collaborative, multidisciplinary, integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management.
148135|NCT01717573|Procedure|Deferred stenting|
148136|NCT01717573|Procedure|Conventional treatment|
148137|NCT01717586|Drug|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into two cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg.
148138|NCT00001776|Device|Cadwell Rapid Rate Magnetic Stimulator|
148139|NCT01709799|Behavioral|Exergames|Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.
Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:
THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate
Polar Heart Rate monitors are used to measure THR and save resulting data.
148140|NCT01709799|Behavioral|Cognitive Training|Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.
INSIGHT Assessments are done at baseline, the start of each training week and at week 28.
148141|NCT01709812|Other|individualized patient support program|individualized patient support with compliance supporting tools
148142|NCT01709812|Other|Standard care|
148143|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
148144|NCT01709825|Dietary Supplement|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
148145|NCT01709825|Dietary Supplement|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
148146|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
148147|NCT00091936|Drug|Didanosine|
148148|NCT01709838|Drug|ICL670 deferasirox|deferasirox
148149|NCT01709851|Device|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
146012|NCT01698684|Drug|Placebo|One dose 15 minutes before attempting intercourse
146013|NCT01698684|Drug|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
146014|NCT01698684|Drug|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
146015|NCT01698697|Drug|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
146016|NCT01698710|Drug|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
146017|NCT01698723|Drug|Ribavirin|
146018|NCT01698723|Drug|Placebo|
146019|NCT01698736|Device|Membrane filtration|Membrane filtration (Polysulfone)
146020|NCT00090623|Drug|rhuFab V2 (ranibizumab)|
146021|NCT01698736|Device|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
146319|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, twice a day, 14 days
146320|NCT01691274|Drug|PF-04895162|Tablets, to be decided, twice a day, 14 days
146321|NCT01691274|Drug|Placebo|Tablets, twice a day, 14 days
146322|NCT00001716|Drug|Nitric Oxide|
146323|NCT00089869|Drug|atomoxetine|
146324|NCT01691287|Behavioral|Michael Method|
146325|NCT01691300|Other|ACT PET/CT|Old tracer but new indication
146326|NCT01691313|Drug|Vanoxerine|single oral dose
146327|NCT01691313|Drug|Placebo|single oral dose
146328|NCT01691326|Biological|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
146329|NCT00090103|Drug|dutasteride 0.5mg once daily for 4 years|combination or single agent
146330|NCT01693692|Drug|TD-9855 Group 2|
146331|NCT01693692|Drug|Placebo|
145770|NCT01690299|Drug|Etanercept 50 mg|Etanercept 50 mg evaluator/subject-blinded subcutaneous once weekly injection
145771|NCT01690299|Drug|Placebo tablet|Placebo tablets twice a day
145772|NCT01690299|Drug|Placebo injection (saline)|once weekly evaluator/subject-blinded subcutaneous saline (placebo) injections (1 mL x 2 injections SC)
145773|NCT01690312|Dietary Supplement|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
145774|NCT01690312|Dietary Supplement|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
145775|NCT01690325|Drug|Docetaxel|
145776|NCT01690325|Drug|Trastuzumab|
145777|NCT01690325|Drug|Bevacizumab|
145778|NCT00089791|Drug|placebo|Placebo administered by subcutaneous injection
145779|NCT01690325|Drug|Epirubicin|
145780|NCT01690325|Drug|Cyclophosphamid|
145781|NCT01690338|Drug|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
145782|NCT01690338|Drug|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
146085|NCT01696279|Drug|Calcium carbonate|Subjects will receive Calcium carbonate orally at a total daily dose taken by the subject prior to starting the study or equivalent. For new subjects, dosing will be based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500mg is reached.
146086|NCT01696305|Device|Hyalobarrier|
146087|NCT01696305|Device|Guardix-SG|
146088|NCT01696318|Behavioral|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
146089|NCT01696331|Behavioral|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
146090|NCT01696344|Procedure|PVAI|
146091|NCT01696344|Procedure|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
145848|NCT01698476|Drug|Placebo tablets|
145849|NCT01698528|Device|Tablet Computer|
145850|NCT01698541|Drug|Tacrolimus|Tested generic
145851|NCT01698541|Drug|Tacrolimus|Original formulation used as comparator
145852|NCT01698554|Drug|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
145853|NCT01698554|Drug|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
145854|NCT01698554|Drug|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
145855|NCT01698554|Drug|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
145856|NCT01698567|Drug|Antithrombin III|ATIII will be dosed using the formula recommended by the manufacturer:
(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
145857|NCT01690351|Drug|PF-05089771|Capsules TS formulation- fasted
145858|NCT01690364|Other|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
145859|NCT01690364|Other|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
145860|NCT01690377|Biological|PDC or myDC|PDC or myDC; first patient 0.3 * 10E6 PDC; second and third 1 * 10E6 PDC; fourth and fifth 3 * 10E6 PDC.
145861|NCT00089791|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection
145862|NCT01690390|Drug|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
145863|NCT01690390|Drug|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
145864|NCT01690403|Drug|rifapentine (M000473)|Pharmaceutical form:tablet
Route of administration: oral
145865|NCT01690403|Drug|EFZ EMT TDF|Pharmaceutical form:tablet
Route of administration: oral
145866|NCT01690416|Procedure|Traditional palpation technique|
146552|NCT01697280|Other|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
146553|NCT01697293|Drug|Cyclophosphamide|Given IV
146554|NCT01699425|Device|Classical transobturator sling|Control group
146852|NCT01689779|Drug|Placebo|sugar pill
146853|NCT01692002|Dietary Supplement|Sodium propionate|Sodium propionate capsule or tablet
146854|NCT01692002|Dietary Supplement|Sodium Chloride|Placebo capsule or tablet
146855|NCT01692002|Procedure|Oral glucose tolerance test|
146856|NCT01692002|Procedure|Intravenous glucose tolerance test.|
146857|NCT01692015|Other|Questionnaire on dietary history|
146858|NCT01692015|Other|Questionnaire on nosebleed severity|
146859|NCT01692015|Other|One week food diary generated by weighing foods|
146860|NCT01692015|Procedure|Blood tests for full blood count, albumin, and indices of nutritional status|
146861|NCT00089947|Drug|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
146862|NCT01692041|Drug|ivy leaves dry extract|5 ml twice daily po
146863|NCT01692041|Drug|Placebo|5 ml per os twice daily
146864|NCT01692080|Behavioral|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
146865|NCT01692093|Dietary Supplement|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
146866|NCT01692093|Dietary Supplement|Placebo|Placebo
146867|NCT01692106|Procedure|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
150434|NCT01739166|Other|Practice-tailored intervention to increase rates of targeted services|Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.
During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed.
150435|NCT01739179|Procedure|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
150436|NCT01739179|Procedure|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
150437|NCT01739192|Drug|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
150438|NCT01739205|Behavioral|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
150439|NCT01739218|Drug|Carboplatin|AUC 5 mg/mL/min iv every 3 weeks, Day 1 of Cycles 1-8
149494|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
149495|NCT01707082|Drug|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
149496|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
149497|NCT01707082|Drug|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
149498|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
149499|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
149500|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
149501|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
149502|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
149503|NCT01709513|Drug|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
149504|NCT01709513|Drug|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
149875|NCT01700309|Behavioral|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
149876|NCT01700322|Procedure|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
150144|NCT01736124|Other|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
150145|NCT01736124|Other|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
150146|NCT01736137|Other|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
150147|NCT01736150|Drug|Placebo|Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.
If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals.
150148|NCT01736150|Drug|Sevelamer carbonate|Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.
If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals.
150149|NCT01736163|Drug|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
150150|NCT01736163|Drug|131I|28 mCi or ≥ 1.036 GBq.
150151|NCT01736163|Other|Thyroid Hormone Withdrawal|Stop taking hormone therapy
150152|NCT01736176|Drug|Levodopa-Carbidopa Intestinal Gel|Dose levels will be individually optimized. Should be kept within a range of 0.5-10 ml/hour (10-200 mg levodopa/hour) and is usually 2-6 ml/hour (40-120 mg levodopa/hour).
150153|NCT00094315|Drug|Cocaine (IV)|
150154|NCT01736202|Biological|fat orally|Oral ingestion of palm oil or canola oil at timepoint zero
150155|NCT01736215|Drug|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
150156|NCT01736228|Device|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
150157|NCT01736241|Drug|LY3053102|Administered SQ
150158|NCT01736241|Drug|Placebo|Administered SQ
149639|NCT01704729|Procedure|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
149640|NCT01704729|Procedure|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
149641|NCT01704755|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
149642|NCT00001749|Drug|Antithymocyte globulin|
149643|NCT00091273|Procedure|adjuvant therapy|
149644|NCT01704755|Drug|Ribavirin (RBV)|Capsule
149645|NCT01704768|Behavioral|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
149646|NCT01704768|Behavioral|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
149938|NCT01705301|Device|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
149939|NCT01705314|Dietary Supplement|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
149940|NCT01705314|Dietary Supplement|placebo|7mls of placebo drops per week for 8 months.
149941|NCT01705340|Drug|Akt inhibitor MK2206|Given PO
149942|NCT01705340|Biological|trastuzumab|Given IV
149943|NCT01705340|Drug|lapatinib ditosylate|Given PO
149944|NCT01705340|Other|laboratory biomarker analysis|Optional correlative studies
149945|NCT01705366|Procedure|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
149946|NCT01707940|Drug|Ketoconazole|Ketoconazole 400 mg / day
150655|NCT01732588|Drug|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
150656|NCT01732588|Drug|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
150657|NCT01732588|Drug|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
150658|NCT01732601|Behavioral|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
150659|NCT01732601|Behavioral|Standard Care|Treatment at step-down facilities
150660|NCT01732614|Procedure|Topcon Endpoint Management laser|
150661|NCT01732627|Biological|MenACYW Conjugate Vaccine|0.5 mL, Intramuscular
150662|NCT00093808|Drug|vinorelbine tartrate|
150663|NCT01732627|Biological|Meningococcal Polysaccharide Vaccine Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous
150664|NCT01732640|Drug|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
150665|NCT01732640|Drug|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
150666|NCT01732640|Drug|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
150667|NCT01732640|Drug|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
150668|NCT01734759|Drug|Taste Test|Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.
Medications to be sampled and the corresponding dose of the test dose are:
Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg
Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg
Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg
Steroids: prednisolone 1.5 mg, prednisone 0.5 mg
H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg
149703|NCT01702467|Drug|Placebo|Matching placebo capsules.
149704|NCT01702480|Drug|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
148524|NCT01710449|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
148824|NCT00091143|Procedure|peripheral blood stem cell transplantation|
148825|NCT01703546|Procedure|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band & Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
148826|NCT01706081|Procedure|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
148827|NCT01706081|Procedure|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
148828|NCT01706094|Other|Head Position|Head position during the first 48 hours from admission of patients with acute ischemic stroke.
This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients.
148829|NCT01706120|Drug|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
148830|NCT01706120|Drug|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
148831|NCT01706120|Drug|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
148832|NCT01706133|Other|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
148833|NCT01706146|Drug|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
148834|NCT01706159|Drug|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
148835|NCT00091390|Radiation|HDR brachytherapy boost|Brachytherapy could be performed before or after the external beam radiotherapy. The overall treatment course (external beam radiotherapy and brachytherapy) was limited to no longer than 8 weeks. 19 Gy in two fractions was to be given only to the clinical target volume (CTV). The first HDR treatment was to be delivered on the day of the catheter placement. The second treatment was to be delivered within 24 hours after the first treatment, but no less than 6 hours between implants.
148269|NCT01712503|Device|Phacoemulsfication cataract surgery and intra-ocular lens implant|
148270|NCT01712516|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
148271|NCT01712516|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
148272|NCT01712516|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
148273|NCT01712516|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
148274|NCT01712529|Behavioral|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
148275|NCT01712555|Procedure|autologous fat grafting with PRP to anophthalmic orbits|
148276|NCT01712568|Drug|Test Product (Ropinirole)|one Tablet at "0" hour
148277|NCT00092144|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
148278|NCT01712568|Drug|Reference Product (REQUIP )|one Tablet at "0" hour
148582|NCT01715571|Device|Viberect|Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual/erotic thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.
Men will record device use and intercourse attempts after device use in a diary.
148583|NCT01715584|Other|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
148584|NCT01715597|Drug|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
148585|NCT01715610|Drug|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
148586|NCT01715610|Drug|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
148587|NCT01715610|Drug|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
148588|NCT01718223|Drug|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
149304|NCT01706757|Device|go-cart|conducts exercises with the help of a go-cart
149305|NCT01706770|Device|enfilcon A|The Test device is a contact lens manufactured by CooperVision, Inc.
149306|NCT01706770|Device|galyfilcon A|The Control device is a contact lens manufactured by Johnson & Johnson Vision Care.
149307|NCT01706783|Drug|NNC0195-0092|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 in an escalating order
149308|NCT01706783|Drug|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
149309|NCT01706796|Drug|PF-06273340|Oral solution, single dose, fasted
149310|NCT00091520|Drug|Nesiritide|
149311|NCT01706796|Drug|PF-06273340|Immediate Release Tablet, single dose, fasted
149312|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
149313|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
149314|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
149315|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
149316|NCT01706809|Other|blood sampels from vena rectalis superior and vena cubiti|
149317|NCT01706822|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
148339|NCT01710137|Drug|Varenicline|
148340|NCT01710137|Drug|Placebo|
148341|NCT01710137|Behavioral|Smoking Cessation Counseling|
148342|NCT01710150|Procedure|CTI ablation alone|
148343|NCT01710150|Procedure|CTI ablation and Pulmonary vein isolation (PVI)|
148344|NCT01710163|Drug|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
148345|NCT01710163|Drug|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
148171|NCT00092118|Drug|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
148172|NCT01712360|Drug|NAFT600 (adult)|Applied to both feet
147179|NCT01715792|Other|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
147180|NCT01718353|Drug|prednisone|Pharmaceutical form: tablet Route of administration: oral
147181|NCT01718366|Drug|Deferasirox, Vitamin D and Azacitidine|
147182|NCT01718379|Drug|Lenalidomide|Lenalidomide:10 mg per day during 21 days
147183|NCT01718379|Drug|Epoetin beta|Epoetin beta: 60,000 Units/week.
147184|NCT01718392|Behavioral|Training|
147185|NCT01718405|Other|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
147186|NCT00092612|Drug|Comparator: ezetimibe, placebo|
147187|NCT01718405|Genetic|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
147188|NCT01718418|Other|test meal|
147189|NCT01718418|Other|reference|
147190|NCT01718431|Other|test meal|
147191|NCT01718431|Other|reference meal|
147192|NCT01718444|Drug|Progestin|
147193|NCT01718444|Drug|Clomiphene Citrate|
147194|NCT01718457|Device|Endobarrier|
147195|NCT01718470|Procedure|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
147196|NCT01718470|Procedure|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
147197|NCT00092625|Drug|MK0653, ezetimibe|
147908|NCT01714336|Drug|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
147909|NCT01714349|Procedure|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
147910|NCT01714375|Device|QuietDose Device|The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise "dose", as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss.
147911|NCT01714388|Drug|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
146972|NCT01695122|Drug|Valproic Acid|
146973|NCT01695135|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
146974|NCT01695135|Drug|Placebo|Placebo (4 tablets) taken orally once daily
146975|NCT01695135|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
146976|NCT01695148|Dietary Supplement|β-Carotene Biofortified Maize Flour|
146977|NCT01695148|Dietary Supplement|White Maize Flour|
146978|NCT01695174|Drug|Xifaxan|
146979|NCT01695187|Drug|NB-001 (0.3%)|Topical administration at least five times throughout the day
146980|NCT01695187|Drug|Placebo|
146981|NCT01695200|Dietary Supplement|Omega-3 fatty acids|
146982|NCT00090207|Drug|Comparator: ondansetron / Duration of Treatment: 4 days|
146983|NCT01695213|Procedure|uncemented total hip arthroplasty|
146984|NCT01695226|Drug|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
146985|NCT01695226|Drug|Placebo|pre-operative placebo twice daily for two to three weeks
146986|NCT01695239|Drug|ixekizumab|Administered SC
146987|NCT01695239|Drug|Placebo|Administered SC
146988|NCT01695239|Drug|Adalimumab|Administered SC
147620|NCT01713959|Device|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
147621|NCT01713972|Drug|dabrafenib|Given PO
147622|NCT00092222|Drug|Valganciclovir|Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
147623|NCT01713972|Drug|pazopanib hydrochloride|Given PO
147624|NCT01713972|Other|Correlative studies|Pharmacokinetic studies:
Blood draw for various time points:
Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12
Pharmacogenomic studies: Blood draw on Cycle 1 Day 1
Tumor genotyping: Archival tumor blocks or unstained slides
BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression
147625|NCT01713985|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
147626|NCT01713985|Device|Thermage|Radiofrequency treatment focusing radiofrequency energy
147627|NCT01716611|Drug|Tolvaptan|15 - 60 mg/day for 28 days
147628|NCT01716611|Drug|placebo|
147976|NCT01711957|Procedure|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
147977|NCT01711970|Drug|Paclitaxel|
147978|NCT01712009|Drug|Naproxen|
147979|NCT01712009|Drug|Loratadine|
147980|NCT01712009|Biological|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
147981|NCT01712009|Drug|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
147982|NCT01712048|Procedure|Submucosal Injection EMR|Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a "safety cushion" for resection. EMR is then performed with a standard snare.
147983|NCT01712048|Procedure|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
147984|NCT00092092|Drug|Placebo to budesonide inhaler|Placebo inhalation powder
147985|NCT01712061|Drug|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
147408|NCT01713452|Procedure|Purse string closure|An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.
Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.
Diameter of the skin defect should then be measured.
A postoperative photo will then be taken.
147409|NCT01713452|Procedure|Primary closure|An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.
Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (<1.5cm). No subcutaneous drains will be placed.
Length of the incision should be measured in centimeters.
A postoperative photo will then be taken.
147410|NCT01713465|Other|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
147411|NCT01713478|Other|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
147412|NCT01713504|Biological|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
147413|NCT01713517|Other|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
147414|NCT01713517|Device|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
147415|NCT01713530|Drug|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
147692|NCT01711541|Drug|Hydroxyurea|Given PO
147693|NCT00092053|Drug|Placebo|tablets
147694|NCT01711541|Drug|Paclitaxel|Given IV
147695|NCT01711541|Other|Placebo|Given PO
147696|NCT01711541|Radiation|Radiation Therapy|Undergo radiation therapy
147697|NCT01711541|Drug|Veliparib|Given PO
147698|NCT01711554|Biological|Dinutuximab|Given IV
147699|NCT01711554|Drug|Isotretinoin|Given PO
147700|NCT01711554|Other|Laboratory Biomarker Analysis|Correlative studies
146893|NCT01695005|Drug|LY3039478|Administered orally
146894|NCT01695031|Behavioral|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
146895|NCT00090194|Biological|Immune Globulin Intravenous (Human), 10%|
146896|NCT01695031|Behavioral|Generic web-based education|Generic, web-based asthma education
146897|NCT01695044|Drug|PSMA ADC|PSMA ADC administered IV
146898|NCT01695057|Drug|vorinostat|Given PO
146899|NCT01695057|Procedure|therapeutic conventional surgery|Undergo surgery
146900|NCT01695057|Other|laboratory biomarker analysis|Correlative studies
146901|NCT01695070|Drug|Melatonin|4mg prolonged release melatonin oral tablets twice daily
146902|NCT01697696|Drug|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
146903|NCT01697696|Drug|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
146904|NCT01697696|Drug|Placebo|Placebo to match QAB149
146905|NCT01697709|Drug|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
146906|NCT01697709|Drug|Placebo|
146907|NCT00090493|Biological|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
146908|NCT01697722|Drug|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
146909|NCT01697722|Drug|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
146910|NCT01697735|Drug|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
146911|NCT01697735|Drug|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
146912|NCT01697761|Other|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
146332|NCT01693705|Procedure|Tracheostomy|
146333|NCT01693718|Drug|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
146334|NCT01693718|Drug|5- Fluorouracil|Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.
Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy.
146335|NCT01693718|Drug|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output > 100 cc/ hour.
146336|NCT01693770|Procedure|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
146337|NCT01693783|Biological|Ipilimumab|Given IV
146338|NCT01693783|Other|Laboratory Biomarker Analysis|Correlative studies
146339|NCT01693796|Other|blood and urine samples ; Echography|
146340|NCT00090103|Drug|tamsulosin 0.4mg once daily for 4 years|combination agent
146341|NCT01693809|Drug|Caffeine|
146634|NCT01697371|Radiation|Proton|All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.
Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments
146635|NCT01697371|Radiation|Proton Radiation|
146636|NCT01697384|Drug|histrelin acetate|52 week implant
146637|NCT01697410|Drug|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
146638|NCT01697410|Drug|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
146639|NCT01697423|Drug|platelet-rich plasma|
146640|NCT00090415|Behavioral|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
146641|NCT01697423|Drug|durolane|
146642|NCT01697436|Drug|ribavirin [Copegus]|tablet under fed condition
146643|NCT01697436|Drug|ribavirin [Copegus]|tablet under fasted condition
146092|NCT00090298|Drug|MK0653A, ezetimibe (+) simvastatin|
146093|NCT01696357|Device|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
146094|NCT01696370|Drug|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
146095|NCT01696370|Other|Placebo capsule|one capsule three times per day for 3 months
146096|NCT01696383|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
146097|NCT01696396|Drug|AMG 181|Investigational Product. AMG 181 is a monoclonal antibody that binds the human alpha-4-beta-7 heterodimer
146098|NCT01696396|Other|Placebo|Placebo control
146099|NCT01696409|Dietary Supplement|400 IU vitamin D3|Take 400 IU once/day for 2 months
146100|NCT01696409|Dietary Supplement|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
146101|NCT01696422|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
146102|NCT01696422|Biological|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
146103|NCT00001724|Drug|Flurbiprofen|
146104|NCT00090298|Drug|Comparator: Rosuvastatin|
146105|NCT01696422|Other|Placebo|Route:subcutaneous
146404|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
146405|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
146406|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
146407|NCT00089869|Drug|placebo|
146408|NCT01691352|Procedure|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
146158|NCT01693484|Drug|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
146159|NCT01693497|Behavioral|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
146160|NCT01693497|Behavioral|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
146161|NCT01693510|Behavioral|Exercise and Nutrition Intervention|
146162|NCT00090077|Drug|GW695634|
146163|NCT01693523|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day).
146164|NCT01693523|Other|Placebo|Matching placebo capsules by mouth twice a day.
146165|NCT01696448|Dietary Supplement|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
146166|NCT01696448|Other|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
146167|NCT01696461|Drug|Plerixafor|
146168|NCT01696474|Drug|Bortezomib|
146169|NCT01696487|Dietary Supplement|High oral Fructose challenge (150g per day for 28 days)|
146170|NCT00090311|Drug|quetiapine fumarate|
146171|NCT01696500|Drug|Intravenous immunoglobulin|
146172|NCT01696513|Procedure|Suction|
146173|NCT01696513|Procedure|Subcision|
146174|NCT01696526|Other|vitamin D fortified fish|fish containing vitamin D3
146175|NCT01696526|Other|conventional fish|fish containing low concentrations of vitamin D3
146176|NCT01696539|Behavioral|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
146868|NCT01692119|Behavioral|Regular, pharmacy based intervention|Regular, pharmacy-based intervention conducted in cooperation with the treating physician:
Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.
Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician.
146869|NCT01692132|Drug|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
146870|NCT01692145|Drug|KCT-0809|
146871|NCT01692145|Drug|Placebo|
145927|NCT01698567|Drug|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
145928|NCT00090610|Drug|Docetaxel|For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin
For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin
145929|NCT01698580|Other|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
145930|NCT01698580|Other|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
145931|NCT01698580|Other|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
145932|NCT01698580|Other|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
149505|NCT01709526|Behavioral|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
149506|NCT01709539|Procedure|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
149507|NCT01709552|Behavioral|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
149508|NCT00091897|Drug|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
149509|NCT01709552|Behavioral|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
149510|NCT01709578|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
149511|NCT01709578|Other|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
149512|NCT01709578|Drug|hydroxychloroquine|Dispensed according to the local practice.
149513|NCT01709578|Drug|methotrexate|Dispensed according to the local practice.
149514|NCT01709578|Drug|sulfasalazine|Dispensed according to the local practice.
149793|NCT01700270|Drug|fluvoxamine|perpetrator drug; 7 days of dosing
149794|NCT01700283|Behavioral|exercise education and walking program|12-week moderate intensity walking program
149795|NCT01700296|Behavioral|Best care|"Best Care": subjects are randomly assigned to the "Best care" regardless MRC class and severity of symptoms through:
10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)
Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters.
149796|NCT00090896|Biological|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
149797|NCT00001737|Drug|Cyclosporin A Implant|
149798|NCT00091104|Drug|cyclophosphamide|
149799|NCT01702558|Drug|trastuzumab emtansine [Kadcyla]|3.6 mg/kg intravenously every 3 weeks
150159|NCT01736254|Drug|Evacetrapib|Oral administration
150160|NCT01736254|Drug|Gemfibrozil|Oral administration
150161|NCT01736267|Device|Nucleus 24 Auditory Brainstem Implant (ABI)|Nucleus 24 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
150162|NCT01738685|Behavioral|Behavioral Intervention.|
150163|NCT01738685|Other|Nutritional Education.|
150164|NCT01738698|Drug|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
150504|NCT01736774|Other|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
150505|NCT01736787|Dietary Supplement|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
150506|NCT01736787|Dietary Supplement|Placebo|Placebo (1g/day)
150507|NCT01736800|Drug|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
150508|NCT01736800|Drug|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
150509|NCT00094406|Procedure|Bronchoalveolar lavage|
150510|NCT01736813|Drug|Maraviroc|Twelve patients with 300 mg/bid
150511|NCT01736826|Biological|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
150512|NCT01736826|Biological|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 & 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
150513|NCT01736826|Biological|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
150514|NCT01736852|Device|CRB|Labor induction using the CRB and Pitocin
149947|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
149948|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
149949|NCT01707953|Drug|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
149950|NCT01707953|Drug|Placebo|Placebo capsule to mimic midodrine
149951|NCT01707966|Drug|Orteronel|
149952|NCT00091650|Drug|placebo|
149953|NCT01707966|Drug|Placebo|
149954|NCT01707992|Drug|Laquinimod 0.6 mg|
149955|NCT01707992|Drug|Matching Placebo|
149956|NCT01707992|Drug|Laquinimod 1.2 mg|
149957|NCT01708005|Drug|Lecitone®Se-Vitamin D3|Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.
Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
149958|NCT01708005|Drug|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
150225|NCT00093951|Drug|SGS742|
150226|NCT01734096|Other|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
150227|NCT01734096|Drug|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo
150228|NCT01734109|Device|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
150229|NCT01734135|Other|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
150230|NCT01736332|Drug|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
150231|NCT01736332|Other|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
150232|NCT00094328|Drug|Bicalutamide|oral
149705|NCT01702480|Drug|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
149706|NCT01702493|Drug|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
149707|NCT01702493|Drug|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
149708|NCT01702493|Drug|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
149709|NCT01702493|Drug|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
149710|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
149711|NCT00091104|Biological|therapeutic tumor infiltrating lymphocytes|
149712|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
149713|NCT01702506|Drug|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
149714|NCT01702506|Drug|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
149715|NCT01702506|Drug|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
149716|NCT01702519|Drug|nicotine|nicotine transdermal patch
149717|NCT01702532|Drug|Nicotine|Comparison of different dosage forms of nicotine
149718|NCT01702558|Drug|capecitabine|650-750 mg/m2 twice daily
149719|NCT01702558|Drug|capecitabine|Dosed at maximum tolerated dose (MTD) established in Phase I
149720|NCT01702558|Drug|trastuzumab emtansine [Kadcyla]|3.6 mg/kg intravenously every 3 weeks until disease progression, intolerable toxicity, withdrawal of consent
149721|NCT01702558|Drug|trastuzumab emtansine [Kadcyla]|2.4 mg/kg intravenously every 3 weeks until disease progression, intolerable toxicity, withdrawal of consent
149722|NCT01704807|Device|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
149723|NCT01704820|Procedure|Retroflexion in the right colon|
149724|NCT01704833|Behavioral|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
148836|NCT01706159|Drug|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
148837|NCT01706172|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
148838|NCT01706172|Other|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
149152|NCT00091832|Drug|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
149153|NCT01709253|Radiation|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
149154|NCT01709266|Dietary Supplement|Probiotics|
149155|NCT01709266|Dietary Supplement|Placebo|
149156|NCT01709279|Biological|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
149157|NCT01709292|Drug|Vemurafenib (All Groups)|960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
149158|NCT01701557|Other|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
149159|NCT01701557|Other|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
149160|NCT01701570|Behavioral|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
149161|NCT01701570|Other|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
149162|NCT01701583|Drug|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
149163|NCT01701596|Procedure|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
149164|NCT01701596|Procedure|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
149165|NCT01701609|Behavioral|Cognitive Remediation Therapy|
149166|NCT01701622|Drug|febuxostat|If baseline allopurinol dose < 300 mg daily, will initiate febuxostat 40 mg daily.
If baseline allopurinol dose > 300 mg daily, will initiate febuxostat 80 mg daily.
Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks.
148589|NCT01718236|Drug|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
148590|NCT01718236|Drug|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
148591|NCT01718249|Other|Implantable neurostimulation system|
148592|NCT00092599|Drug|Comparator: ezetimibe, placebo|
148593|NCT01718288|Drug|iloprost|The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).
For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.
The 4 groups:
1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment
B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment
A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment
2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment
148899|NCT01703637|Drug|Saxagliptin|before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy
before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy
148900|NCT01703650|Drug|iopromide|iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.
In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.
iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight[BW] <50kg) or 35 mL (50kg ≤BW <70kg) or 40 mL (70 kg≤BW <90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).
Injection rate is as follows; 6.0mL/sec if BW is <50kg, 7.0 mL/sec if BW is 50kg≤and <70kg, 8.0 mL/sec if BW is 70≤and<90kg and 9.0mL/sec if BW is 90kg≤.
148901|NCT01703650|Procedure|CT|Perfusion CT will be performed by using a 320 channel MDCT
Patients are requested for fasting for at least 8 hours before CT scan.
Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.
Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.
During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.
ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose.
148902|NCT01703663|Device|EPAP|
148903|NCT01703689|Behavioral|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
148904|NCT01703689|Behavioral|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
148346|NCT01710176|Drug|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
148347|NCT01710176|Drug|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
148348|NCT00091949|Drug|placebo|an inactive substance
148349|NCT01710176|Drug|trabectedin 1.3 mg/m2|
148350|NCT01710176|Drug|high-dose ifosfamide 14 g/m2, given in in 14 days|
148351|NCT01710176|Drug|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
148352|NCT01710176|Drug|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
148353|NCT01710189|Drug|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
148354|NCT01710202|Drug|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
148355|NCT01710215|Other|FIT Screening Strategy|Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).
Two "live" phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.
Centralized processes to promote guideline-based follow up.
148356|NCT01710215|Other|Colon Screening Strategy|Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.
Two "live" phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.
Centralized processes to promote guideline-based follow up.
148357|NCT01710228|Drug|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
148358|NCT01710254|Drug|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
148359|NCT01712724|Other|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
148360|NCT01712737|Other|Dietary intervention|
148652|NCT01708317|Behavioral|ACASI|Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
148653|NCT01708330|Drug|Lidocaine|2% Lidocaine gel
148654|NCT00091689|Drug|852A|
148655|NCT01708330|Drug|Placebo gel|odorless, colorless gel will be used as a placebo
147198|NCT01718483|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
147199|NCT01718483|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
147200|NCT01718496|Drug|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
147201|NCT01718496|Drug|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
147796|NCT01711632|Drug|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
147797|NCT01711645|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
147798|NCT01711658|Radiation|Intensity Modulated Radiation Therapy (IMRT)|70 Gy in 2 Gy fractions
147799|NCT01714141|Behavioral|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
147800|NCT01714141|Behavioral|Asthma education active control|
147801|NCT01714154|Drug|danoprevir|100 mg orally every 12 hours
147802|NCT01714154|Drug|ritonavir|100 mg orally every 12 hours
147803|NCT01714154|Drug|setrobuvir|200 mg orally every 12 hours
147804|NCT01714167|Genetic|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
147805|NCT00092222|Drug|Cyclophosphamide|Cyclophosphamide: if CD4 & lt; 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 (Bullet) 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
147806|NCT01714193|Drug|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
147807|NCT01714193|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
147808|NCT01714206|Drug|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
146989|NCT01695252|Other|MEMOS|Patient informed clinical outcomes supervision
146990|NCT01695265|Device|Feel Breathe, restriction device ventilatory nasal in COPD|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subjet was required to perform three identical submaximal exercises with intensity at 65% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET
146991|NCT01695278|Behavioral|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
146992|NCT01695291|Drug|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
146993|NCT01697878|Procedure|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
147261|NCT01715922|Drug|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
147262|NCT01715922|Drug|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
147263|NCT00092391|Biological|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
147264|NCT01715922|Procedure|lumbar punctures|lumbar punctures to control intracranial pressure
147265|NCT01715935|Drug|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
147266|NCT01715948|Device|CROS hearing aid|BAHA users will be fitted with the CROS hearing aid for a two-week trial period. Their hearing abilities with the CROS hearing aid will be compared to their hearing abilities with their BAHA over a two-week period.
147267|NCT01715961|Procedure|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
147268|NCT01715974|Drug|G-CSF group|60 micrograms/day of G-CSF from the day of embryo transfer through the day of beta HCG test
147269|NCT01715974|Drug|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
147270|NCT01715987|Drug|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
147271|NCT01715987|Drug|Entecavir|0.5mg oral daily for two years.
147272|NCT01716000|Other|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
147986|NCT01712061|Drug|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
147987|NCT01712074|Drug|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
147988|NCT01712074|Other|Placebo|Placebo QD
147989|NCT01714401|Drug|Ventolin 5mg|20 min nebulization of 5 mg of salbutamol
147990|NCT01714401|Drug|Atrovent 0.5mg|20 min nebulization of 0.5 mg of ipratropium bromide
147991|NCT01714414|Drug|FZD|
147992|NCT00092222|Drug|Sirolimus|Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
147993|NCT01714414|Drug|3TC|
147994|NCT01714414|Drug|EFV|
147995|NCT01714414|Drug|AZT|
147996|NCT01714427|Drug|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
147997|NCT01714427|Drug|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
147998|NCT01714466|Drug|NER1006|
147999|NCT01714466|Drug|MOVIPREP|
147051|NCT01692405|Procedure|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
147052|NCT01692418|Drug|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
147053|NCT01692418|Drug|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
147054|NCT01692431|Dietary Supplement|EPA|High fat meal containing EPA
147055|NCT01692431|Dietary Supplement|DHA|High fat meal containing DHA
147056|NCT01692431|Dietary Supplement|Placebo|High fat meal containing negligible EPA/DHA content
147057|NCT00089999|Drug|Lapatinib|
147058|NCT01692457|Drug|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
147701|NCT01711554|Drug|Lenalidomide|Given PO
147702|NCT01711554|Other|Pharmacological Study|Correlative studies
147703|NCT01711567|Drug|tenofovir|tenofovir 300 mg qd
147704|NCT00092053|Drug|ibandronate|50 mg tablets
147705|NCT01711567|Drug|entecavir|entecavir 0.5 mg qd
147706|NCT01711580|Other|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
147707|NCT01713998|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
147708|NCT01714011|Drug|Ziprasidone|Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.
Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours.
147709|NCT01714011|Drug|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
147710|NCT01714024|Device|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
148064|NCT01712100|Drug|Irbesartan|
148065|NCT01712100|Drug|Avapro|
148066|NCT01712113|Drug|Irbesartan|
148067|NCT01712113|Drug|Avapro|
148068|NCT01712126|Drug|Irbesartan and Hydrochlorothiazide|
148069|NCT00092105|Drug|MK0476, montelukast sodium|
148070|NCT01712126|Drug|Avalide|
148071|NCT01712139|Drug|Irbesartan and Hydrochlorothiazide|
146913|NCT01697761|Other|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
145939|NCT00090610|Drug|Carboplatin|Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.
Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel
145940|NCT01690507|Drug|Granulocyte colony-stimulating factor|
145941|NCT00000121|Device|Prisms in Eyeglasses|
145942|NCT00000269|Drug|Pergolide|
145943|NCT00001713|Drug|Warfarin|
145944|NCT00089804|Drug|abetimus sodium (LJP 394)|900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
145945|NCT01690507|Other|HLA haploidentical mononuclear cells infusion|
145946|NCT01690520|Drug|Cyclophosphamide|Given IV
145947|NCT01690520|Drug|Cyclosporine|Given IV or PO
145948|NCT01690520|Procedure|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit unmanipulated umbilical cord blood transplant
145949|NCT01690520|Procedure|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
145950|NCT01690520|Drug|Fludarabine Phosphate|Given IV
145951|NCT01690520|Other|Laboratory Biomarker Analysis|Correlative studies
145952|NCT01690520|Drug|Mycophenolate Mofetil|Given IV or PO
145953|NCT01690520|Radiation|Total-Body Irradiation|Undergo TBI
145954|NCT01690520|Procedure|Umbilical Cord Blood Transplantation|Undergo single-unit unmanipulated umbilical cord blood transplant
145955|NCT00089804|Drug|Phosphate-buffered saline|A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
145956|NCT01690533|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
145957|NCT01690546|Drug|very low dose naltrexone|On days 1-4, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 to 8 mg, progressively decreasing to 2 mg on Days 1-4 and very low dose naltrexone at 0.25 mg on Days 1-3, 2.5 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
146644|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fed condition
146645|NCT01689259|Drug|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
146646|NCT00089661|Drug|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
146647|NCT01689259|Drug|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
146648|NCT01689259|Drug|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
146649|NCT01689259|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
146650|NCT01689272|Procedure|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
146651|NCT01689285|Drug|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
146652|NCT01689285|Drug|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
146653|NCT01689298|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
146654|NCT01689298|Drug|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
145705|NCT01741194|Drug|AC-1204|AC-1204 taken once daily, by mouth
145706|NCT01741194|Drug|Placebo|Placebo taken once daily, by mouth
145707|NCT01741207|Drug|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
145708|NCT01741233|Genetic|VitDgen|
145709|NCT01741259|Drug|Meperidine|
145710|NCT01741272|Procedure|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
145711|NCT00001832|Biological|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count > 1.0 x10^9/L x 3 days or > 5.0 x10^9/L.
145712|NCT00094835|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 administered by IV infusion over 3 hours.
145713|NCT01741272|Procedure|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
146409|NCT01691352|Procedure|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
146410|NCT01691365|Dietary Supplement|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
146411|NCT01691365|Drug|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
146412|NCT01691378|Other|Window to Hope|Psychotherapy - Group
146413|NCT01691378|Other|Waitlist Control|Psychotherapy - Group
146414|NCT01691391|Behavioral|pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles|Patients will be treated with cetuximab. For pharmacodynamic purposes PET-imaging with 89Zr-labelled cetuximab will be performed. In addition, two [18F-]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin biopsies for pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles, respectively.
146415|NCT01691404|Dietary Supplement|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
146416|NCT01691404|Dietary Supplement|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
146417|NCT01691404|Dietary Supplement|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
146418|NCT00089882|Procedure|APOE Genetic susceptibility testing|
146419|NCT01691417|Device|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
146420|NCT01691430|Dietary Supplement|2 cranberry capsules|Two 36mg cranberry capsules all qhs
146421|NCT01691430|Dietary Supplement|Placebo|Two 36mg placebo capsules all qhs
146422|NCT01691443|Procedure|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
146719|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fasted condition
146720|NCT01697475|Behavioral|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
146721|NCT01697501|Other|Interleukin 28B testing|Blood sampling for IL28B genotyping
146722|NCT01697514|Drug|LY2940680|Capsule administered orally.
146723|NCT01697514|Drug|LY2940680|Powder administered orally (may be sprinkled on soft food).
146177|NCT01696539|Other|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
146178|NCT01696552|Procedure|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
146480|NCT01699165|Device|Placebo nasal filter|Placebo nasal filter
146481|NCT01699178|Drug|Oral testosterone undecanoate|
146482|NCT01699178|Drug|Transdermal testosterone gel (AndroGel)|
146483|NCT00090727|Drug|AQ4N|
146484|NCT01699191|Dietary Supplement|Probiotic|
146485|NCT01699191|Dietary Supplement|Placebo|
146486|NCT01699204|Dietary Supplement|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
146487|NCT01699204|Other|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
146488|NCT01699204|Other|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
146489|NCT01699230|Dietary Supplement|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
146490|NCT01699256|Behavioral|Guideline implementation as usual|Newsletters and Invitation to Meetings
146491|NCT01691469|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
146492|NCT01691482|Drug|Albuterol/salbutamol|Albuterol/salbutamol (daily)
146493|NCT01691482|Drug|Ipratropium|Ipratropium (daily)
146494|NCT01691495|Drug|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
146495|NCT01691508|Drug|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
146496|NCT00089895|Drug|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG [coronary artery bypass graft]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
146497|NCT01691508|Drug|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
145933|NCT01698580|Other|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
145934|NCT01698593|Drug|Bupivacaine 0.5%|
145935|NCT01698593|Drug|Bupivacaine 0.5% + Epinephrine (1:200,000)|
145936|NCT01698606|Behavioral|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
145937|NCT01698645|Drug|PecFent® (fentanyl) nasal spray|
145938|NCT01698658|Other|ultrasound tomography|Undergo ultrasound tomography using SoftVue
146243|NCT01693575|Device|Pupil expansion with APX 100 device|Patients with small pupils (<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
146244|NCT01693588|Other|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
146245|NCT01693601|Drug|Panobinostat|PO TIW QOW or PO TIW QW
146246|NCT01693601|Drug|Ruxolitinib|PO BID x 28 days
146247|NCT00090090|Drug|Elsamitrucin|
146248|NCT01693614|Drug|BKM120|100 mg once a day
146249|NCT01693627|Device|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
146250|NCT01693627|Device|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
146251|NCT01693627|Device|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
149800|NCT01702571|Drug|Kadcyla (trastuzumab emtansine)|3.6 mg/kg intravenously every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression
149801|NCT01702584|Procedure|stent assisted embolization|stent assisted embolization and anti-thrombotic management
149802|NCT01702597|Device|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
149803|NCT01702597|Other|Physiotherapy|Patients will receive a standardized physical therapy.
149804|NCT01702610|Radiation|IMRT Technique|
149805|NCT01702610|Radiation|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
149806|NCT01702610|Radiation|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
149807|NCT01702610|Drug|Temozolomide and Accelerated Hypofractionation RT|
149808|NCT01702623|Drug|Oxcarbazepine|
149809|NCT00091104|Drug|fludarabine phosphate|
149810|NCT01702636|Drug|Tranexamic Acid|
149811|NCT01702636|Drug|Placebo|
149812|NCT01702649|Drug|RPX2003 (Biapenem)|Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.
Single dose followed by multiple dose, three times a day.
149813|NCT01702649|Drug|Placebo|Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.
Single dose followed by multiple dose, three times a day.
150078|NCT01700725|Other|Nasal Irrigation - Saline|Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup ("neti pot"), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot.
150079|NCT01700725|Drug|Nasal Irrigation - Xylitol|Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup ("neti pot"), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot.
150080|NCT00090961|Other|supervised exercise program|
150081|NCT01700738|Procedure|gastric ring surgery|
150515|NCT01736852|Drug|Pitocin|Labor induction using Pitocin alone
150516|NCT01736865|Drug|Cholecalciferol|
150517|NCT01736865|Drug|Placebo|
150518|NCT01736878|Drug|Sorafenib|
150519|NCT01736891|Drug|Rasagiline|Tablets, qd
150520|NCT00094406|Drug|Endotoxin|
150521|NCT01736891|Drug|Placebo|Tablets, qd
150522|NCT01736904|Drug|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
150523|NCT01736904|Drug|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
149576|NCT01707134|Drug|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
149577|NCT01707134|Drug|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
149578|NCT01707134|Drug|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
149579|NCT01707147|Drug|Trajenta tablet|Linagliptin
149580|NCT01707160|Drug|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
149581|NCT01707160|Drug|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
149582|NCT01707173|Behavioral|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
149583|NCT01707173|Behavioral|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
149584|NCT00091611|Drug|OKT3|
149585|NCT01707199|Drug|Artesunate + Sulphadoxine-pyrimethamine|AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.
One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date.
149586|NCT01707212|Behavioral|Pain management education|Education about pain management during infant immunization
150233|NCT01736345|Genetic|Genetic Providers|Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.
150234|NCT01736345|Other|Visual Aids|Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.
150235|NCT01736345|Other|Post-Disclosure Asessments|Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.
150236|NCT01736345|Other|In-person Clinical Follow-Up|Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner
150237|NCT01736345|Other|6 Month and 12 Month Assessments|At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
150238|NCT01736358|Drug|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
150239|NCT01736358|Drug|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
150240|NCT01736371|Drug|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
150241|NCT01736371|Drug|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
150242|NCT01736371|Drug|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
150243|NCT00094328|Drug|Anastrozole|oral
150244|NCT01736384|Procedure|Gastric bypass or cholecystectomy|
150589|NCT01734681|Drug|G-202|
150590|NCT01734694|Drug|Vancomycin|Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;
Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;
150591|NCT01734694|Drug|Ceftaroline|Dose based on package insert labeling
CrCL > 50 mL/min: 600 mg IV q12h
CrCL 31-50 mL/min: 400 mg q12h
CrCL 15-30 mL/min: 300 mg q12h
CrCL < 15mL/min: 200 mg q12h;
150592|NCT01734694|Drug|Daptomycin|Dose based on renal function and literature dosing recommendations
CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h
CrCL < 30 mL/min: 6 - 10 mg/kg IV q48h
150593|NCT01734694|Drug|Linezolid|600 mg IV/PO q12h
150594|NCT01734707|Dietary Supplement|Allicor|
150019|NCT01705366|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
150020|NCT01705366|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
150021|NCT01705366|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
150022|NCT01705379|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
150023|NCT01705392|Drug|Bevacizumab|Bevacizumab 10 mg/kg q3w
150024|NCT01705392|Drug|Propranolol|Propranolol 80 mg x 1
150025|NCT01705392|Drug|Enalapril|Enalapril 5 mg x 1
150026|NCT01705392|Drug|Dacarbazine|dacarbazine 1000 mg/m2 q3w
150027|NCT01705405|Device|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
150028|NCT00091338|Biological|MART-1 antigen|
150029|NCT01705431|Behavioral|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
150030|NCT01705444|Device|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
150031|NCT01705457|Drug|Dietary Supplement: vitamin A|25000 IU/day vitamin A for 6 months
1 Cap/Day
1 cap placebo/day for 6 month
150032|NCT01705457|Drug|placebo|
150033|NCT01705470|Drug|furosemide|
150034|NCT01705470|Drug|placebo normal saline|
150035|NCT01705483|Drug|ASP9853|oral
150036|NCT01705483|Drug|Docetaxel|intravenous (IV)
150037|NCT01705483|Drug|Paclitaxel|Taxol
149167|NCT00091052|Biological|sargramostim|
149168|NCT01701635|Behavioral|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
149169|NCT01701635|Behavioral|Enhanced usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
149170|NCT01701648|Other|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
148194|NCT01714791|Other|Osteopathic treatment|Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:
Structural High Velocity Low Amplitude-techniques.
Muscle Energy Techniques.
General osteopathic mobilisations.
Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.
Fascia techniques.
Soft tissue- and connective tissue techniques.
Neurovisceral and neurolymphatic reflex techniques.
Fluidal techniques (lymphatic manipulative techniques,...).
Visceral manipulations.
Neurocranial and viscerocranial techniques.
148195|NCT01714804|Device|Accell Evo3 Prospective Use|
148196|NCT01714817|Biological|BMS-188667|
148197|NCT01714817|Drug|Mycophenolate mofetil|
148198|NCT00092300|Drug|Comparator: valdecoxib|
148199|NCT01714817|Drug|Prednisone|
148200|NCT01714817|Biological|Placebo matching with BMS-188667|
148201|NCT01714830|Device|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
148202|NCT01714830|Device|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
148203|NCT01714843|Drug|ASP0456|oral
148204|NCT01714843|Drug|placebo|oral
148205|NCT01714856|Drug|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
148206|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
148207|NCT01714882|Behavioral|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
148905|NCT01703702|Drug|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
148906|NCT01703715|Device|The Hydrant|The Hydrant is a new form of "drinking system" that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant.
148907|NCT01706224|Procedure|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
148908|NCT01706224|Other|Data collection|Electronic Case Report Forms (eCRF)
148909|NCT00091390|Radiation|radiation therapy|1.8 Gy given five times per week for a total dose of 45 Gy.
148910|NCT01706224|Other|Data collection|Questionnaires, active questioning.
148911|NCT01706237|Device|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
148912|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
148913|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
148914|NCT01706250|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
148915|NCT01706250|Other|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
149226|NCT00091858|Drug|Placebo|Placebo Q4W
149227|NCT01709409|Drug|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
149228|NCT01709422|Drug|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
149229|NCT01709422|Drug|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
149230|NCT01709422|Drug|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
149231|NCT01709435|Drug|Cabozantinib S-malate|Given PO
149232|NCT01709435|Other|Laboratory Biomarker Analysis|Correlative studies
149233|NCT01709435|Other|Pharmacological Study|Correlative studies
149234|NCT01709474|Drug|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
148656|NCT01708343|Procedure|DIMMST|
148657|NCT01708356|Behavioral|Cycling on a residential route|
148658|NCT01708369|Drug|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
148659|NCT01708369|Drug|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
148660|NCT01708369|Drug|Oseltamivir|Oseltamivir 150 mg orally
148661|NCT01708369|Drug|Aspirin|Aspirin 650 mg orally will be given
148662|NCT01708382|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
148663|NCT01708408|Genetic|Biomarker studies|
148664|NCT01708434|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
148665|NCT00091702|Biological|Cold-adapted live attenuated influenza vaccine (FluMist)|
148666|NCT01708447|Drug|L.M.X.4.® cream|A lidocaine topical anesthetic cream
148667|NCT01708447|Other|A placebo cream|Placebo cream containing no anesthetic properties.
148668|NCT01708447|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
148669|NCT01708460|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
148670|NCT01708473|Drug|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
148671|NCT01708473|Drug|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
148672|NCT01708473|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
148673|NCT01708499|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
148674|NCT01708512|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
148980|NCT01701323|Biological|Filgrastim|Given SC or IV
148981|NCT01701323|Drug|Fludarabine Phosphate|Given IV
148982|NCT01701336|Biological|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
147809|NCT01714206|Drug|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
147810|NCT01714206|Drug|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
147811|NCT01714219|Procedure|Posterior reconstruction|
147812|NCT01714232|Device|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
147813|NCT01714232|Device|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
147834|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
147835|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
147836|NCT01717040|Drug|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
147837|NCT00092508|Drug|OPC-6535|
147838|NCT01717040|Drug|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
147839|NCT01717053|Drug|Abiraterone acetate|1000 mg orally once a day for 6 months.
147840|NCT01717053|Drug|Androgen deprivation|LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
147841|NCT01717053|Radiation|Radiation Therapy|Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
147842|NCT01717053|Drug|Prednisone|5 mg tablet once daily for 6 months.
147843|NCT01717066|Drug|the ginsenoside Rg3|
147844|NCT01717066|Drug|Placebo|
147845|NCT01717079|Procedure|Sham rTMS|120 pulses 0.2Hz
147846|NCT01719133|Drug|AllerT5|synthetic peptide T5
147847|NCT01719133|Drug|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
147848|NCT01719133|Drug|mix of AllerT4-T5|mix T4-T5
147273|NCT01718561|Procedure|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
147274|NCT00092625|Drug|Comparator: ezetimibe, placebo|
147275|NCT01718574|Other|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
147276|NCT01718587|Procedure|stem cell transplantation through interventional procedure|interventional procedure once
147277|NCT01718587|Drug|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
147278|NCT01718600|Behavioral|Neuropsychological testing|
147279|NCT01718613|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
147280|NCT01718613|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
147547|NCT01716546|Drug|Pazopanib|
147548|NCT01716572|Drug|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
147549|NCT00092443|Biological|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
147550|NCT01716572|Procedure|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
147551|NCT01716585|Drug|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
147552|NCT01716585|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
147553|NCT01716585|Drug|Placebo for ABT-450/r/ABT-267|Tablet
147554|NCT01716585|Drug|Placebo for ABT-333|Tablet
147555|NCT01716585|Drug|Placebo for ribavirin|Capsule
147556|NCT01716598|Device|IPS System|TLD Therapy will be achieved bronchoscopically.
147557|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
147558|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
147059|NCT00090220|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Gardasil intramuscular injection in three 0.5 mL doses over 6 months.
147060|NCT01695291|Other|Placebo|A placebo pill will be administered BID for 12 weeks.
147061|NCT01695304|Other|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
147062|NCT01695317|Drug|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
147063|NCT01695330|Drug|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
147064|NCT01695343|Biological|KB001-A|
147065|NCT01695343|Drug|Placebo Comparator|
147066|NCT01695356|Drug|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
147067|NCT01695356|Drug|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
147068|NCT01695369|Device|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
147069|NCT01695369|Device|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
147070|NCT00090220|Biological|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
147339|NCT01716013|Device|BondEase|topical skin adhesive
147340|NCT01716013|Procedure|CWCD|traditional closure methods of sutures, staples or adhesive strips
147341|NCT01716026|Drug|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
147342|NCT01716039|Drug|MTX 12.5|once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).
Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab
147343|NCT01716039|Drug|MTX 25|once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).
Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab
147344|NCT01716039|Drug|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
148072|NCT01712139|Drug|Avalide|
148073|NCT01712165|Dietary Supplement|ANMUM Materna|
148074|NCT01712165|Dietary Supplement|Control (milk powder)|
148075|NCT01712178|Biological|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
148076|NCT01712178|Biological|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
148077|NCT01712191|Device|NUsurface Meniscus Implant|
148078|NCT01712204|Drug|Placebo|Placebo Capsule BID for 16 Weeks
148079|NCT01712204|Drug|AC-201|AC-201 50mg Capsule BID for 16 Weeks
148080|NCT00092105|Drug|Comparator: placebo|
148081|NCT01712204|Drug|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
148082|NCT01712217|Drug|AT13387|HSP90 inhibitor
148083|NCT01712217|Drug|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
148084|NCT01712230|Drug|GnRH agonist|Drug: leuprolide acetate
Other Names:
Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months
148085|NCT01712230|Behavioral|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
148086|NCT01712230|Drug|Placebo|Placebo
148087|NCT01712243|Other|Light|
148088|NCT01712256|Biological|Vacc-4x|Two re-boost immunisations with adjuvant and vacc-4x, one at week 1 and one at week 3.
148089|NCT01712269|Procedure|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
147120|NCT01692548|Other|Neurofeedback|
147121|NCT01692574|Behavioral|Behavior Modification for Weight Loss|
147122|NCT01692574|Behavioral|Alternative Approach to Weight Loss|
147123|NCT00090012|Drug|Olanzapine|
147124|NCT01692574|Behavioral|Cognitive-Behavior Therapy for Depression|
145958|NCT01690546|Drug|extended release naltrexone|On days 1-4, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 to 8 mg, progressively decreasing to 2 mg on Days 1-4 and very low dose naltrexone at 0.25 mg on Days 1-3, 2.5 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
145959|NCT01690546|Drug|buprenorphine/naloxone|On days 1-4, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 to 8 mg, progressively decreasing to 2 mg on Days 1-4 and very low dose naltrexone at 0.25 mg on Days 1-3, 2.5 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
146260|NCT01696669|Drug|Chemotherapy|Vincristine, 2 mg/m^2 IV bolus, day 1.
Doxorubicin: 75 mg/m^2 per cycle, or 25 mg/m^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).
Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.
Cyclophosphamide: 2100 mg/m^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.
MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.
G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm^3/L.
Ifosfamide: 1800 mg/m^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m^2 total maximum dose).
Window phase in high-risk patients (21-days cycle):
Gemcitabine: 1000 mg/m^2 IV, 90 minutes on day 1 and 8.
Docetaxel 100 mg/m^2, 2-3 hour infusion on day 8.
146261|NCT01696669|Procedure|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
146262|NCT01696669|Radiation|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
146263|NCT01696682|Procedure|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
146264|NCT01696682|Procedure|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
146265|NCT01696708|Other|31-Phosphorus RMN Spectroscopy|
146266|NCT01696721|Other|No intervention|
146267|NCT01696734|Drug|Domperidone|Starting Dose: 10 mg by mouth 3 times a day.
146268|NCT01696734|Behavioral|Questionnaires|Questionnaire completion at baseline, 8 weeks after drug, 6 months, then every 6 months.
146269|NCT00090337|Procedure|standard follow-up care|Patients undergo standard care
146270|NCT01696734|Other|Phone Calls|At 2 weeks and 4 weeks(± 3 days) of treatment, the physician will contact the patient via telephone to assess whether or not a dosage increase is warranted.
146271|NCT01696760|Drug|acetylsalicylic acid|325 mg twice a day
146272|NCT01696760|Drug|enoxaparin|40 mg once daily
146273|NCT01696760|Device|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
146274|NCT01696773|Other|Tangerine tomato juice|Post-prandial feeding study
145714|NCT01741285|Drug|Beclomethasone (QVAR)|Small particle treatment
145715|NCT01741285|Drug|Beclomethasone (Clenil)|Course particle beclomethasone
145716|NCT01741285|Drug|Fluticasone|Course particle treatment
145717|NCT01741298|Behavioral|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
145718|NCT00090233|Biological|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
145719|NCT01695603|Device|Intellivent|Two hours of ventilation will be delivered with the Intellivent automated mode and will be compared to two hours during usual controlled ventilation.
145720|NCT01695616|Drug|Placebo|
145721|NCT01695616|Drug|Active drug|
145722|NCT01695668|Drug|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
145723|NCT01695668|Drug|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
145724|NCT01695681|Other|Gluten-free diet|Dietary advice by clinical dietitian
145725|NCT01695694|Behavioral|supporting positive and healthy relationships|
146022|NCT01698749|Drug|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
146023|NCT01698762|Other|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
146024|NCT01698762|Other|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
146025|NCT01698762|Behavioral|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
146026|NCT01698775|Drug|MK-3102|Participants with moderate renal insufficiency will receive one MK-3102 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one MK-3102 12.5 mg capsule orally once a week
146027|NCT01698775|Drug|Placebo to MK-3102|Matching placebo to MK-3102 capsule administered orally once a week
146724|NCT01697527|Biological|aldesleukin|Given SC
146725|NCT00090428|Behavioral|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
146726|NCT01697527|Drug|fludarabine phosphate|Given IV
146727|NCT01697527|Drug|cyclophosphamide|Given IV
146728|NCT01697527|Other|laboratory biomarker analysis|Correlative studies
146729|NCT01697527|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
146730|NCT01697527|Biological|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
146731|NCT01697527|Radiation|fludeoxyglucose F 18|Undergo PET scan using [18F] FDG tracer
146732|NCT01697527|Procedure|positron emission tomography|Undergo fludeoxyglucose F18 PET
146733|NCT01697553|Other|home automation pack coupled to teleassistance service|
146734|NCT01697553|Other|Home without automation pack coupled to teleassistance service|
146735|NCT01697566|Drug|Metformin|Participants gradually increase the dose of metformin by mouth as listed below:
Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day
After week 4, participant continues to take 2 capsules of metformin 2 times each day.
Each capsule is 425 mg.
146736|NCT00090428|Behavioral|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
146737|NCT01697566|Other|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
146738|NCT01697566|Procedure|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
146739|NCT01697566|Behavioral|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
145783|NCT01690338|Drug|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
145784|NCT01690351|Drug|PF-05089771|Oral dispersion TS formulation- fasted
145785|NCT01692730|Behavioral|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
146498|NCT01691508|Drug|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
146499|NCT01691521|Drug|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
146500|NCT01691521|Drug|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
146501|NCT01691521|Drug|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
146796|NCT01694784|Behavioral|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
146797|NCT01694784|Behavioral|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
146798|NCT01694784|Behavioral|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
146799|NCT01694784|Behavioral|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
146800|NCT01694797|Drug|Metoprolol Succinate|
146801|NCT01694810|Drug|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
146802|NCT01694810|Drug|4% NVN1000 Topical Gel|4% NVN 1000 4% Topical Gel applied once daily 4 weeks
146803|NCT00090181|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
146804|NCT01694810|Drug|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
146805|NCT01694810|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
146806|NCT01697579|Drug|Ondansetron|Administered IV
146252|NCT01693627|Device|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
146253|NCT01693640|Drug|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
146254|NCT01693653|Drug|Tocilizumab|
146255|NCT01693666|Behavioral|Lifestyle intervention|To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.
To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.
To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group.
146256|NCT01693679|Drug|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
146257|NCT01693692|Drug|TD-9855 Group 1|
146258|NCT00001720|Drug|Alendronate|
146259|NCT01696656|Drug|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
146555|NCT00090753|Drug|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
146556|NCT01699438|Drug|Mesalazine|2400 mg q.d. for 8 weeks
146557|NCT01699438|Drug|Placebo|3 tablets q.d. for 8 weeks
146558|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
146559|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
146560|NCT01699464|Drug|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
146561|NCT01699477|Device|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
146562|NCT01699490|Drug|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
146563|NCT01699490|Drug|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
146564|NCT01699503|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
150082|NCT01700738|Other|nutritional help|
150083|NCT01700751|Drug|brentuximab vedotin|
150084|NCT01700777|Other|"HABIT-ILE"|90 h of training with "HABIT-ILE", in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards).
150085|NCT01702987|Drug|statin|statin was given for 1 month to 21 patients
150086|NCT01703000|Device|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
150087|NCT01703039|Drug|Riluzole|
150088|NCT01703039|Drug|Sertraline|
150089|NCT01703039|Other|placebo|
150090|NCT01703052|Drug|CHF 6001 SD or placebo|Dry Powder Inhaler
150091|NCT01703052|Drug|CHF 6001 MD or placebo|Dry Powder Inhaler
150092|NCT01703065|Drug|cabozantinib-s-malate|Given PO
150093|NCT00091130|Other|placebo|Given SC
150094|NCT01703065|Other|laboratory biomarker analysis|Correlative studies
150095|NCT01703078|Drug|Ingenol once daily for two consecutive days|
150096|NCT01703091|Drug|Ramucirumab|Administered IV
150097|NCT01703091|Drug|Placebo|Administered IV
150098|NCT01703091|Drug|Docetaxel|Administered IV
150099|NCT01703104|Drug|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
150100|NCT01703104|Dietary Supplement|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
150440|NCT01739218|Drug|bevacizumab [Avastin]|15 mg/kg iv every 3 weeks, Day 1 of Cycles 1-3
150441|NCT01739218|Drug|bevacizumab [Avastin]|15 mg/kg iv every 3 weeks, Day 1 of Cycles 6-26
150442|NCT01739218|Drug|paclitaxel|175 mg/m2 iv every 3 weeks, Day 1 of Cycles 1-4, and 175 mg/m2 every 3 weeks or 80 mg/m2 weekly Cycles 5-8
150443|NCT01739231|Biological|ACE527|~10^10 cfu ACE527 administered on Days 0, 28, and 56
149587|NCT01707212|Behavioral|No pain management education|Control - no education about pain management during infant immunization
149588|NCT01707225|Drug|Octreotide LAR Depot|The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
149589|NCT01707238|Device|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
149590|NCT01707238|Device|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
149591|NCT01707251|Drug|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
149877|NCT01700322|Drug|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
149878|NCT01700322|Drug|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
149879|NCT01700322|Drug|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
149880|NCT01700335|Drug|SyB L-1101|SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1,200 mg/day or 1,800 mg/day.
The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.
The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied.
149881|NCT01700348|Device|Airflosser|Use of Philips Airflosser
149882|NCT01700348|Device|Manual Floss|Active Comparator
149883|NCT01700387|Drug|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
149884|NCT01700387|Drug|Topiramate|Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:
Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.
149885|NCT00090909|Drug|cisplatin|
150595|NCT01734707|Drug|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
150596|NCT01734733|Other|NTCELL|
150597|NCT00094042|Drug|Iron Supplement, 120mg|
150598|NCT01734746|Procedure|blue dye and radioactive tracer|
150599|NCT01736917|Drug|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
150600|NCT01736917|Drug|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
150601|NCT01736917|Drug|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
150602|NCT01736930|Device|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
150603|NCT01736943|Drug|Bortezomib|Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
150604|NCT01736943|Drug|Doxil|Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
150605|NCT01736956|Procedure|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
150606|NCT00094406|Drug|Carbon Monoxide|
150607|NCT01736969|Device|RD047-023|Experimental hydrogel
150608|NCT01736969|Device|Predicate Device|
150609|NCT01736982|Behavioral|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
150610|NCT01736982|Behavioral|Standard smoking cessation counseling|
149647|NCT01704781|Drug|Part A: lenalidomide dose escalation|Dose escalation (3+3 design) Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is nontolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013) and Vacc-4x/GM-CSF.
149648|NCT01704781|Drug|Part B: lenalidomide|Part B continue with lenalidomide MTD found in Part A in combination with Vacc-4x.
149649|NCT01704781|Drug|Part B: lenalidomide placebo|Part B continue with placebo in combination with Vacc-4x.
149650|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
150038|NCT01705496|Radiation|[124I]FIAU|This is a single dose study of 5 mCi [124I]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after [124I]FIAU injection.
150299|NCT01734174|Procedure|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
150300|NCT01734174|Procedure|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
150301|NCT00093964|Drug|EMD 121974|500 mg EMD 121974 IV (in the vein) twice weekly on Days 1 and 4 during a 4-week cycle for a total of 8 infusions per cycle.
Cycles will be repeated without pause until disease progression or unacceptable toxicity develops
150302|NCT01734187|Dietary Supplement|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
150303|NCT01734187|Dietary Supplement|Placebo|Placebo (30g/day)
150304|NCT01734200|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
150305|NCT01734200|Dietary Supplement|Placebo|Placebo (1.5g/day)
150306|NCT01734213|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
150307|NCT01734213|Dietary Supplement|Placebo|Placebo (1.5g/day)
150308|NCT01734226|Dietary Supplement|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
150309|NCT01734226|Dietary Supplement|Placebo|Placebo (3.94g/day)
150310|NCT01734239|Biological|Pneumovax™ 23|Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
150311|NCT01734252|Drug|Argatroban|Start: Argatroban dose [µg/kg x min] = 2.06 - 0.03 x SAPS II until maximum: 10 µg/kg/min
150312|NCT00001830|Drug|Th2 cells in allo HSCTT|
150313|NCT00093964|Drug|EMD 121974|2000 mg EMD 121974 IV (in the vein) twice weekly on Days 1 and 4 during a 4-week cycle for a total of 8 infusions per cycle.
Cycles will be repeated without pause until disease progression or unacceptable toxicity develops.
150314|NCT01734265|Drug|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
150315|NCT01734265|Drug|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
150316|NCT01734278|Other|No intervention|This is a non-interventional study.
148208|NCT01714882|Behavioral|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
148209|NCT00092313|Drug|MK0966, rofecoxib|
148210|NCT01714895|Other|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
148211|NCT01714895|Other|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
148212|NCT01714908|Other|Erlotinib w Concurrent Radiotherapy|
148213|NCT01714908|Other|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
148525|NCT00091962|Behavioral|Usual Care|Usual care for depression
148526|NCT01710462|Drug|Pantoprazole + Domperidone|
148527|NCT01710462|Drug|Pantozol®|
148528|NCT01710488|Drug|Levofloxacin 1 tablet 500 mg once a day|Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:
Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.
148529|NCT01710488|Drug|Prulifloxacin 1 tablet 600 mg once a day|Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:
Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.
148530|NCT01710501|Drug|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
148531|NCT01710501|Biological|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
148532|NCT01710501|Drug|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
148533|NCT01710501|Drug|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
148534|NCT01710514|Drug|FE 999913 vaginal tablet|
148535|NCT01710527|Drug|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
149235|NCT01709474|Drug|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
149236|NCT01709487|Procedure|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
149237|NCT00091897|Drug|Rituximab|
149238|NCT01709500|Drug|LMT (atorvastatin, simvastatin, or rosuvastatin)|
149239|NCT01709500|Drug|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
149240|NCT01709500|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
149241|NCT01709513|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets.
149242|NCT01709513|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet.
149243|NCT01701674|Drug|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
149244|NCT01701674|Drug|Cyclophosphamide as Part of Lymphodepletion|
149245|NCT01701674|Drug|Fludarabine as Part of Lymphodepletion|
149246|NCT00091052|Radiation|radiation therapy|
148279|NCT01712581|Other|Magnetic Resonance Imaging|
148280|NCT01712594|Device|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
148281|NCT01712607|Other|Preoperative Warm-Up training|Preoperative Warm-Up training
148282|NCT01712620|Drug|Spironolactone|Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
148283|NCT01712620|Drug|Placebo|Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
148284|NCT01712646|Drug|Intranasal Oxytocin|
148285|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Patient may continue to receive treatment until PD.
148286|NCT01712685|Drug|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
148983|NCT01701349|Drug|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
148984|NCT01703728|Other|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
148985|NCT01703741|Drug|Testosterone Gel|Testosterone Gel delivered using an applicator
148986|NCT00091156|Procedure|adjuvant therapy|
148987|NCT01703754|Genetic|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
148988|NCT01703754|Drug|Palifosfamide|Small molecule chemotherapy, IV administration
148989|NCT01703767|Behavioral|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
148990|NCT01703793|Drug|Test Product 49778|
148991|NCT01703793|Drug|Test Product 10156|
148992|NCT01703793|Drug|Vehicle (placebo)|
148993|NCT01703819|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
148994|NCT01703819|Other|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
148995|NCT01703832|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
148996|NCT01703845|Drug|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
148997|NCT00091169|Dietary Supplement|levocarnitine|Given orally
148998|NCT01703845|Drug|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
148999|NCT01703858|Drug|BI 113608 PIB|powder for oral solution
149000|NCT01703858|Drug|BI 113608|conventional tablet formulation
149001|NCT01703858|Drug|BI 113608|conventional tablet formulation
149002|NCT01703858|Drug|BI 113608|conventional tablet formulation
149003|NCT01703858|Drug|pantoprazole 40 mg STADA|film-coated tablet
149004|NCT01703858|Drug|BI 113608|conventional tablet formulation
149318|NCT01706835|Drug|aldoxorubicin|
147849|NCT01719146|Other|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
147850|NCT01719159|Drug|Rituximab|
147851|NCT00092690|Drug|Comparator: atorvastatin|
147852|NCT01719172|Device|Veriset™ Hemostatic Patch|Topical Hemostat
147853|NCT01719185|Drug|Phentermine and B12|
147854|NCT01719185|Drug|Phentermine|
147855|NCT01719224|Procedure|elevated body position|
147856|NCT01719224|Procedure|supine body position|
147857|NCT01719237|Drug|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
148173|NCT01712373|Drug|Ginseng|it is kind of drug
148174|NCT01712373|Drug|Placebo|it is placebo
148175|NCT01712386|Dietary Supplement|Beetroot|
148176|NCT01712386|Dietary Supplement|Beetroot placebo|
148177|NCT01712399|Biological|mavrilimumab subcutaneous Injection|GM-CSFR alpha inhibitor
148178|NCT01712412|Drug|IW-9179|
148179|NCT01712412|Drug|Placebo|
148180|NCT01712425|Biological|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
148181|NCT01712425|Biological|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
148182|NCT00092131|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
148183|NCT01712438|Biological|Human cl rhFVIII|
148184|NCT01712451|Drug|salmeterol xinafoate, fluticasone propionate|LIPO-102
148185|NCT01712451|Drug|Placebo|Placebo
148186|NCT01712451|Drug|salmeterol xinafoate|Salmeterol
147559|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
147560|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
147561|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
147562|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
147563|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
147564|NCT01719016|Procedure|Cardiac PET, Coronary catheterization|Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:
N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress
Lexiscan - stress agent for PET scan
Patients would also undergo Coronary catheterization including the following drug administration and device usage:
Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).
Adenosine - stress agent during catheterization, 140 ug/Kg/min
147565|NCT00001781|Drug|CGP 77116|
147566|NCT00092677|Drug|Comparator: Placebo|matching Placebo
147567|NCT01719029|Other|Low-Carbohydrate/Higher Fat Diet|
147568|NCT01719029|Other|High Carbohydrate/Low fat diet|
147569|NCT01719042|Drug|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
147912|NCT01714401|Drug|ventolin 2.5mg|20 min nebulization of 2.5 mg of salbutamol
147913|NCT01717079|Procedure|rTMS|120 pulses 0.2Hz
147914|NCT01717118|Biological|Bivalent Vaccines|
147915|NCT00092508|Drug|Asacol®|
147916|NCT01717118|Biological|Tetravalent Vaccine|
147917|NCT01717131|Procedure|Surgery for standard axillary node dissection|
147918|NCT01717131|Other|No axillary lymph node dissection|No surgery on axillary lymph node
147919|NCT01717144|Behavioral|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
147920|NCT01717157|Drug|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
147921|NCT01717157|Drug|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
147345|NCT01716052|Drug|placebo|Lactulose
147346|NCT01716052|Drug|Ibuprofen|
147347|NCT01716091|Procedure|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
147348|NCT01716104|Drug|Afalaza|Safety and Efficiency
147349|NCT00092404|Biological|measles, mumps, and rubella virus vaccine live|
147350|NCT01716104|Drug|Placebo|Safety and Efficiency
147351|NCT01716117|Device|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
147352|NCT01716143|Procedure|radiofrequency catheter ablation|
147353|NCT01716156|Drug|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
147354|NCT01716156|Drug|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
147355|NCT01716169|Device|Helicoll|Helicoll Collagen I Wound Dressing
147356|NCT01716169|Device|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
147357|NCT01716195|Other|6 weeks of Radiotherapy|If tumor does not significantly shrink after initial chemotherapy
147358|NCT01716195|Other|5 weeks of Radiotherapy|If tumor shrinks after initial chemotherapy
147359|NCT01716208|Drug|Ofatumumab + Fresh Frozen Plasma|
147629|NCT01716624|Drug|Oxybutynin|standard oral therapy
147630|NCT00092443|Biological|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
147631|NCT01716624|Drug|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
147632|NCT01716637|Biological|Etanercept|
147633|NCT01716637|Dietary Supplement|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
147125|NCT01692574|Behavioral|Depression Support and Education|
147126|NCT01692587|Other|Protein restrictive diet|To begin a reduced protein diet
147127|NCT01692626|Drug|Pimecrolimus|Pimecrolimus 1% topical cream twice daily for four weeks.
147128|NCT01692652|Drug|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
147129|NCT01692652|Other|warm compress only group|
147130|NCT01692678|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
147131|NCT01692678|Drug|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
147132|NCT01692691|Drug|Dacarbazine|Dacarbazine IV - Day 1
147133|NCT01692691|Drug|Carmustine|Carmustine IV- Day 2
147134|NCT00090012|Drug|Quetiapine|
147135|NCT01692691|Drug|Neulasta|Neulasta SC - Day 3
147136|NCT01692704|Drug|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.
Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.
Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications.
147137|NCT01692717|Drug|Atorvastatin|10 mg
147138|NCT01692717|Drug|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
147139|NCT01692717|Drug|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
147140|NCT01695421|Procedure|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
147141|NCT01695434|Other|MRI|All subjects will undergo a MRI.
147416|NCT01713530|Drug|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
147417|NCT01713530|Drug|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
146275|NCT01696773|Other|Red tomato juice|Post-prandial feeding study
146276|NCT01696786|Procedure|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
146277|NCT01696799|Drug|Econazole Nitrate|
146278|NCT01696799|Drug|placebo|
146279|NCT01696812|Procedure|electrode position|
146280|NCT00090363|Drug|ZD4054 15 mg|15 mg oral tablet once daily
146575|NCT01699607|Drug|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
146576|NCT01699620|Procedure|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
146577|NCT00001730|Drug|Thyrogen|
146578|NCT01691560|Drug|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
146579|NCT01691612|Biological|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
146580|NCT00089908|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
146581|NCT01691625|Other|concurrent chemoradiotherapy plus DC-CIK immunotherapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.
DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period.
146582|NCT01691625|Other|Concurrent chemoradiation only|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.
146583|NCT01691651|Procedure|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
146584|NCT01691651|Drug|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
146585|NCT01691664|Radiation|Only radiation therapy|Patients only radiation therapy after surgery
146028|NCT01698775|Drug|Glipizide|Participants may receive open-label glipizide as rescue therapy during Phase A (up to Week 24) of the study. During Phase B of the study (after Week 24), participants who did not receive insulin or open-label glipizide rescue therapy during Phase A will receive glipizide 2.5 mg or 5 mg capsule or matching placebo as blinded therapy at a starting dose of 2.5 mg once daily in the morning prior to the morning meal and electively titrated up to a maximum of 20 mg/day based on glycemic control.
146029|NCT01698775|Drug|Placebo to glipizide|Matching placebo to glipizide
146030|NCT01698775|Biological|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
146031|NCT00000270|Drug|Cocaine|
146032|NCT00001729|Drug|Ribavirin|
146033|NCT00090649|Drug|DVS-233 SR|
146034|NCT01698788|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
146035|NCT00089830|Drug|MSI-1256F (Squalamine Lactate)|
146036|NCT01690598|Drug|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
146037|NCT01690611|Procedure|Treadmill Walking|Individuals will walk at a "comfortable speed" on a treadmill without holding on to the hand rails.
146038|NCT01690611|Other|Visual Feedback|Real time feedback regarding body motion while walking.
146039|NCT01690624|Drug|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
146040|NCT01690637|Drug|Oseltamivir phosphate suspension|
146041|NCT01690637|Drug|Placebo|
146042|NCT01690650|Drug|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
146342|NCT01693822|Drug|Axitinib|Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.
Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.
Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.
Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
146343|NCT01693874|Behavioral|MBSR|Mindfulness-Based Stress Reduction
146344|NCT01693874|Behavioral|control (health education)|health education
145786|NCT01692730|Behavioral|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
145787|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
145788|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
145789|NCT01692756|Drug|Kenalog or placebo|
145790|NCT00090025|Drug|becatecarin|Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
145791|NCT01692756|Drug|Kenalog then Placebo|
145792|NCT01692756|Drug|Kenalog|
145793|NCT01692756|Drug|Placebo|
145794|NCT01692769|Drug|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
145795|NCT01692769|Drug|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
145796|NCT01692782|Drug|SEP-225289|SEP-225289 4mg once daily
145797|NCT01692782|Drug|SEP-225289|SEP-225289 8mg once daily
145798|NCT01692782|Drug|Placebo|Placebo once daily
145799|NCT01692808|Drug|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
145800|NCT01692808|Drug|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
145801|NCT00001718|Device|Electropalatography|
146106|NCT01696435|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
146107|NCT01696435|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
146108|NCT01696435|Dietary Supplement|Fish oil placebo|Fish oil placebo
146807|NCT01697579|Drug|Fosaprepitant 5 mg/kg|Administered IV as a single dose
146808|NCT00090480|Biological|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
146809|NCT01697592|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
146810|NCT01697592|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
145867|NCT01690416|Procedure|Ultrasound DNTP|
145868|NCT01690429|Device|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
145869|NCT01690442|Behavioral|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
145870|NCT01690442|Behavioral|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
145871|NCT01690468|Drug|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
145872|NCT00089804|Drug|abetimus sodium (LJP 394) and/or placebo solution|300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
145873|NCT01690468|Drug|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
145874|NCT01690468|Drug|Ondansetron|Ondansetron 8-16 mg IV or by mouth (PO) 30 minutes prior to administration of chemotherapy.
145875|NCT01690468|Drug|Dexamethasone|Dexamethasone 10-20 mg IV or PO 30 minutes prior to drug administration.
145876|NCT01690468|Drug|Granisetron|Granisetron 10 mcg/kg IV (or 2 mg PO) 30 minutes prior to chemotherapy.
145877|NCT01690494|Behavioral|PACT|Couple-based behavioral HIV/STI preventive intervention
145878|NCT01690494|Behavioral|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
145879|NCT01690507|Drug|Decitabine|20 mg/m²/day for 5 days
146565|NCT01699529|Device|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
146566|NCT00090753|Drug|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
146567|NCT01699542|Device|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
146568|NCT01699542|Device|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
146569|NCT01699555|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
146570|NCT01699555|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
146571|NCT01699568|Device|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
146572|NCT01699581|Dietary Supplement|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
146573|NCT01699594|Drug|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
146574|NCT01699594|Drug|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
146872|NCT00089960|Drug|AMG 706|AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
146873|NCT01692158|Drug|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
146874|NCT01692171|Drug|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
146875|NCT01692184|Drug|50 mg AVL-292|
146876|NCT01694823|Drug|CS-ACI|Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:
Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）
146877|NCT01694836|Biological|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
146878|NCT01694849|Drug|GFT505 80mg|
146879|NCT01694849|Drug|GFT505 120mg|
150444|NCT00094679|Device|Eye patch|adhesive patch to cover the sound eye
150445|NCT01739231|Biological|ACE527 + dmLT|~10^10 cfu ACE527 + 25 ug dmLT administered on Days 0, 28, and 56
150446|NCT01739244|Drug|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
150447|NCT01739244|Drug|Placebo|Ocular topical administration of placebo for 14 consecutive days
150448|NCT01739257|Behavioral|Medical Lecture|
150449|NCT01739257|Behavioral|Dramatic Reading|
150450|NCT01739270|Procedure|supraclavicular brachial plexus block|
150451|NCT01739283|Other|GIP|
150452|NCT01739283|Other|GLP-1|
150453|NCT01739283|Other|Saline|
150454|NCT01739296|Other|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
150455|NCT00094692|Device|Eye patch|
150456|NCT01739296|Other|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
150457|NCT01732107|Drug|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
150458|NCT01732120|Procedure|Off-clamp partial nephrectomy|
150459|NCT01732133|Device|Nexfin|
150460|NCT00093795|Drug|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
150461|NCT01732146|Drug|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
150462|NCT01732146|Drug|Placebo|
150463|NCT01732159|Other|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
150464|NCT01732172|Other|Sperm sample|Sperm sample
149515|NCT01709578|Drug|leflunomide|Dispensed according to the local practice.
149516|NCT01709591|Behavioral|Prenatal education|
149886|NCT01700387|Drug|Placebo|Subjects randomized to the onabotulinumtoxinA + placebo group will receive:
Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.
149887|NCT01700400|Drug|Everolimus|
149888|NCT01700400|Drug|Pemetrexed|
149889|NCT01700400|Drug|Carboplatin|
149890|NCT01700400|Drug|Bevacizumab|
149891|NCT01700413|Drug|Idarubicin|
149892|NCT01700426|Drug|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
149893|NCT01700426|Other|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
149894|NCT01700439|Device|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
149895|NCT01702675|Drug|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
150165|NCT01738698|Drug|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
150166|NCT00094627|Drug|gaboxadol|Duration of Treatment - 6 weeks
150167|NCT01738698|Drug|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
150168|NCT01738698|Drug|Placebo|Oral administration once-daily for 12 weeks
150169|NCT01738711|Behavioral|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
150170|NCT01738724|Drug|Dienogest|Dienogest 2mg pills daily during 6 months
150171|NCT01738724|Drug|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
150172|NCT01738724|Drug|Desogestrel|Desogestrel 75mcg pills daily during six months
150173|NCT01738737|Device|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
150174|NCT01738737|Other|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
149651|NCT01704794|Drug|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
149652|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
149653|NCT01704807|Device|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
149654|NCT00091286|Biological|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
149655|NCT01707251|Drug|Saline|Placebo control
149656|NCT01707264|Drug|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
149657|NCT01707277|Other|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
149658|NCT00091611|Drug|Cyclophosphamide|
149659|NCT01707277|Other|Usual care|Usual pahramacological treatment
149660|NCT01707290|Drug|ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
149661|NCT01707303|Other|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
149662|NCT01707303|Other|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
149663|NCT01707316|Drug|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
149664|NCT01707316|Drug|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
149665|NCT01707316|Other|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
149666|NCT01707329|Drug|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
149959|NCT01708018|Procedure|WATSU|WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.
The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's "energy-flow" in the so called "meridians" (energy-channels) of Traditional Chinese Medicine. These "meridians" are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.
During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4).
150317|NCT01736449|Drug|Bevacizumab|
150318|NCT01736462|Drug|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
150319|NCT01736475|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
150320|NCT00094341|Drug|Etanercept|
150669|NCT01734772|Drug|dabigatran etexilate|multiple doses of dabigatran
150670|NCT01734772|Drug|dabigatran etexilate|medium dose dabigatran
150671|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
150672|NCT01734772|Drug|ticagrelor|multiple doses of ticagrelor
150673|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
150674|NCT01734772|Drug|dabigatran etexilate|single dose of dabigatran
150675|NCT01734785|Drug|Linagliptin|tablet
150676|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
150677|NCT00094055|Drug|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
150678|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
150679|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
150680|NCT01734785|Drug|Empaglifozin placebo + Linagliptin placebo|Matching Empaglifozin + Linagliptin low dose
150681|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
150682|NCT01734798|Radiation|Radiation|
150683|NCT01734798|Drug|gemcitabine and cisplatin|
150684|NCT01734798|Other|Radiotherapy and Drug|
150685|NCT01734811|Biological|Biological vaccine|Daily dose
150686|NCT01734824|Drug|Denosumab|sc RANKL-inhibitor
150687|NCT01734824|Drug|Teriparatide|daily subcutaneous injection of teriparatide
150688|NCT00094081|Drug|tirapazamine (SR259075)|
148536|NCT00001758|Drug|Amprenavir|
148537|NCT00091975|Drug|Zemplar Capsule|
148538|NCT01710527|Drug|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
148539|NCT01710540|Other|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
148540|NCT01710540|Other|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
148541|NCT01710553|Other|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
148839|NCT01706185|Other|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
148840|NCT01706198|Drug|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
148841|NCT01706198|Drug|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
148842|NCT01706211|Drug|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
148843|NCT01706211|Drug|Placebo|
148844|NCT01708668|Procedure|Intermittent epidural bolus|
148845|NCT01708681|Dietary Supplement|Lean seafood|
148846|NCT01708681|Dietary Supplement|Meat, egg, milk|
148847|NCT01708694|Dietary Supplement|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
148848|NCT00091728|Drug|Depo Medroxyprogesterone acetate|
148849|NCT01708694|Dietary Supplement|Amylopectin|The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the "placebo") for 3 months.
148287|NCT01712685|Procedure|PET/CT|
148288|NCT00092144|Drug|Comparator: placebo / Duration of Treatment: 4 weeks|
148289|NCT01712711|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
148290|NCT01714960|Drug|MRZ-99030 eye drops 5mg/mL|
148291|NCT01714960|Drug|MRZ-99030 eye drops 20mg/mL|
148292|NCT01714960|Drug|Placebo to MRZ-99030 eye drops|
148293|NCT01714973|Biological|ACCS|Patients will receive ACCS spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ACCS and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
148294|NCT01714986|Behavioral|Affect School|
148295|NCT00092313|Drug|Comparator: oxycodone and acetaminophen|
148296|NCT01714986|Behavioral|Body Awareness Therapy|
148297|NCT01714999|Procedure|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
148298|NCT01714999|Procedure|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
148299|NCT01715012|Biological|ACCS|ACCS is applied daily by spray to burn wound and skin graft donor site
148300|NCT01715012|Drug|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
148594|NCT01718288|Drug|Standard Treatment (aspirin.....),|The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.
correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids
148595|NCT01718301|Drug|boceprevir|
148596|NCT01718301|Drug|Ribavirin|
148597|NCT01718301|Drug|Peginterferon alfa-2a|
148598|NCT01718301|Drug|Peginterferon alfa-2b|
148599|NCT01718314|Drug|Sublingual Misoprostol|
149319|NCT01706848|Other|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
149320|NCT01706848|Other|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
149321|NCT00091559|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
149322|NCT01706861|Device|Celotres|Celotres following surgical removal of earlobe keloid.
149323|NCT01709045|Other|Ultrasound|
149324|NCT01709045|Other|Transcranial doppler|
149325|NCT01709058|Drug|Intramuscular/paravertebral injections of Oxygen-Ozone|Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called "silent discharge". Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL
149326|NCT01709058|Other|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
149327|NCT01709071|Drug|IPV|
149328|NCT01709071|Drug|Low dose Sabin-IPV|
149329|NCT01709071|Drug|Low dose adjuvanted Sabin-IPV|
149330|NCT01709071|Drug|Middle dose Sabin-IPV|
149331|NCT00091819|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
149332|NCT01709071|Drug|Middle dose adjuvanted Sabin-IPV|
149333|NCT01709071|Drug|High dose Sabin-IPV|
149334|NCT01709071|Drug|High dose adjuvanted Sabin-IPV|
149335|NCT01709084|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
149336|NCT01709084|Drug|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
148187|NCT01712464|Drug|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
148188|NCT01712477|Drug|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
148189|NCT01712477|Drug|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
148190|NCT01712490|Drug|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle
148191|NCT01712490|Drug|doxorubicin|Doxorubicin: 25 mg/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
148192|NCT01714778|Other|e-Cigarette|
148193|NCT01714791|Other|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
147202|NCT01718509|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
147203|NCT01718509|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
147204|NCT01718535|Device|Spartan FRX CYP2C19 Test System|
147205|NCT01718548|Dietary Supplement|Cordyceps Sinensis (CS) and Lingzhi|
147206|NCT01718548|Dietary Supplement|Tea and Flour|Placebo
147207|NCT01710657|Drug|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
147208|NCT01710670|Drug|Brivaracetam|Strength: 200 mg (4 x 50 mg)
Form: oral tablet
Frequency: single dose
Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.
147209|NCT01710670|Other|Ethanol|Form: intravenous infusion
Frequency: continuous infusion
Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.
147210|NCT01710670|Other|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
147211|NCT01710670|Other|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
147922|NCT01717157|Drug|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
147923|NCT01717157|Drug|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
147924|NCT01717157|Drug|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
147925|NCT01717170|Drug|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
147926|NCT00092521|Biological|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
147927|NCT01717183|Device|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
147928|NCT01717183|Device|Placebo URGO 310 3113 dressing|
147929|NCT01717196|Other|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
147930|NCT01717209|Drug|Nitric Oxide|inhaled nitric oxide
147931|NCT01717209|Drug|Prostacyclin|inhaled prostacyclin
147932|NCT01717222|Drug|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
147933|NCT01717222|Drug|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
146994|NCT01697878|Procedure|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
146995|NCT01697891|Device|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
146996|NCT01697904|Procedure|Titration of oxygen during newborn resuscitation in delivery room|
146997|NCT00001728|Drug|Fosamax (Alendronate)|
146998|NCT00090519|Drug|ruboxistaurin|32 mg QD oral for up to 36 months
146999|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
147634|NCT01716663|Device|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
147635|NCT01716676|Other|Telemedicine CPAP monitoring (webpage and televisit)|
147636|NCT01716676|Other|Standard CPAP monitoring|
147637|NCT01716689|Drug|oral cyclophosphamide|50mg daily
147638|NCT01716702|Behavioral|Couples Prostate Cancer Support Group|The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.
In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).
In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).
147639|NCT01716715|Drug|Cabozantinib S-malate|Given PO
147640|NCT01716715|Other|Laboratory Biomarker Analysis|Correlative studies
147641|NCT00092456|Biological|rotavirus vaccine, live, oral, pentavalent|Three oral doses (~8.81 X 10^7 IU/Dose for Lot 1; ~8.01 X 10^7 IU/Dose for Lot 2; and ~6.91 X 10^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
147642|NCT01716715|Drug|Paclitaxel|Given IV
147643|NCT01716728|Other|enzyme analysis|
147644|NCT01716741|Other|Enzyme analysis|
147645|NCT01716754|Drug|QGE031|
147646|NCT01716754|Drug|Omalizumab|
147647|NCT01716754|Drug|Placebo to QGE031|
147648|NCT01716754|Drug|Placebo to omalizumab|
147649|NCT01716767|Other|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
147650|NCT01716767|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
148000|NCT01714479|Other|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
148001|NCT01714479|Other|Placebo|
148002|NCT01714492|Device|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
147418|NCT00000272|Drug|Risperidone|
147419|NCT00001764|Drug|Mycophenolate Mofetil|
147420|NCT00092222|Drug|Interferon-alpha|Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
147421|NCT01713543|Other|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
147422|NCT01713556|Drug|Propranolol|
147423|NCT01713556|Other|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
147424|NCT01713556|Drug|placebo|
147425|NCT01713569|Device|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
147426|NCT01713582|Drug|OTX015/MK-8628|OTX015/MK-8628 10 mg, 20 mg or 40 mg capsules
147427|NCT00092404|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
147428|NCT01716221|Drug|bupropion & Citalopram|
147429|NCT01716221|Drug|Bupropion & Placebo|
147430|NCT01716221|Drug|Placebo & Citalopram|
147431|NCT01716221|Drug|Placebo & Placebo|
147432|NCT01716234|Drug|Posaconazole oral suspension|Posaconazole administered orally in 2 or 3 divided doses to participants stratified by age group
147433|NCT01716247|Other|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
147434|NCT01716260|Drug|Chloroquine|
147435|NCT01716260|Drug|Primaquine|
147711|NCT01714024|Device|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
146586|NCT01691664|Other|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
146587|NCT01691677|Drug|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
146588|NCT01691677|Drug|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
146589|NCT01691690|Drug|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg) administered to evaluate the opioid-sparing effect and pain score reduction in pediatric patients undergoing tonsillectomy or adenotonsillectomy procedures. In addition, Morphine will be used in this arm to manage pain as in the placebo arm of the study.
146590|NCT01691690|Drug|Morphine (hydromorphone)|Saline placebo will be infused intraoperatively, and morphine (0.1 mg/kg) will be added to manage pain prior to intubation.
146591|NCT00089908|Biological|Placebo|Placebo for rDEN1delta30
146914|NCT01697787|Drug|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
146915|NCT01697787|Drug|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
146916|NCT01697800|Drug|Tadalafil|
146917|NCT01697800|Drug|Placebo|
146918|NCT00090506|Behavioral|Yoga|
146919|NCT01697826|Drug|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
146920|NCT01697826|Drug|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
146921|NCT01697852|Other|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
146922|NCT01697852|Other|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
146923|NCT01697865|Procedure|Transfer group|
146924|NCT01697865|Procedure|Control group|
146925|NCT01689792|Drug|MOVIPREP|
146926|NCT01689792|Drug|CitraFleet|
146345|NCT01693900|Procedure|Pre-operative Ultrasound FICB Group|25 subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication, in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves
146346|NCT01693900|Procedure|Intra-operative FICB Group|25 subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
146347|NCT01693913|Behavioral|cognitive behavioral exercise and nutrition over|
146348|NCT01693913|Behavioral|nutrition and exercise education|
146349|NCT01693926|Behavioral|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
146350|NCT01693926|Behavioral|placebo|
146351|NCT01696825|Drug|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
146352|NCT01696838|Other|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
146353|NCT01696838|Other|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
146354|NCT01696851|Other|tests and questionnaires|lung test, depression and self-efficasy questionnaires and Functional testing.
146355|NCT01696864|Device|Hand tutor rehabilitation device|A rehabilitation device for the hand
146356|NCT01696864|Device|Arm tutor rehabilitation device|A rehabilitation device for the arm
146357|NCT01696877|Drug|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
146358|NCT01696877|Drug|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
146655|NCT01689311|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
146656|NCT01689311|Drug|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
146657|NCT00089674|Drug|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
146109|NCT01696435|Dietary Supplement|Vitamin D placebo|Vitamin D placebo
146110|NCT01698801|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
146111|NCT01698801|Drug|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
146112|NCT01698814|Drug|AL-4943A Ophthalmic Solution|
146113|NCT01698814|Drug|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
146114|NCT01698827|Other|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
146115|NCT01698840|Dietary Supplement|Vitamin D|
146116|NCT01698840|Dietary Supplement|Placebo|
146117|NCT01698866|Biological|Vaccin GenHevac B Pasteur|
146118|NCT01698879|Drug|Mylotarg|Cohort 1 (20 evaluable patients):
GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine (cytosine arabinoside): 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours after the administration of GO.
Cohort 2 (20 evaluable patients):
G-CSF: 150 mcg/m^2, SC, days 0 to 7, to begin 12 to 18 hours before treatment with Gemtuzumab. GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1.
Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine (cytosine arabinoside): 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO.
146119|NCT00090675|Drug|ZD1839|
146120|NCT01698892|Drug|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
146121|NCT01698892|Drug|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
146122|NCT01698905|Drug|nilotinib|Nilotinib will be labeled as AMN107 and supplied as 150 mg and/or 200 mg hard gelatin capsule. Nilotinib will not be dosed by weight or body surface area. Nilotinib will be administered orally at 300 mg twice daily (BID) or 400 mg BID, at approximately 12 hour intervals, and must not be taken with food. The capsules should be swallowed whole with water. No food should be consumed for at least 2 hours before the dose is taken and no additional food should be consumed for at least one hour after the dose is taken. Patients who were previously treated with 400 mg BID, and required subsequent permanent dose reduction to 400 mg QD will be allowed to enter this study on the same dose, 400 mg once daily.
146123|NCT01698918|Drug|Everolimus|Everolimus will be self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously from study day 1 until progression of disease, unacceptable toxicity or withdrawal of consent. Everolimus should be taken at the same time every day. Everolimus tablets should be swallowed whole with a glass of water once daily, either consistently with food or consistently without food. Tablets should not be chewed or crushed.
146423|NCT01691456|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
146424|NCT00090116|Drug|Neramexane|
145880|NCT01690507|Drug|Cytarabine|
145881|NCT01690507|Drug|aclacinomycin|
145882|NCT01692860|Other|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
145883|NCT01692873|Procedure|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
145884|NCT01692886|Biological|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
145885|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
145886|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
146179|NCT01696552|Procedure|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
146180|NCT01696565|Drug|PG2|Injectable
146181|NCT00090324|Drug|quetiapine fumarate tablets|
146182|NCT01696578|Behavioral|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
146183|NCT01696591|Biological|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
146184|NCT01696604|Drug|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
146185|NCT01696604|Drug|Placebo|Matching placebo capsules will be available.
146186|NCT01696617|Drug|Aripiprazole 6-week group|
146187|NCT01696617|Drug|Aripiprazole 8-week group|
146188|NCT01696630|Drug|Xenon|
146189|NCT01696630|Drug|Desflurane|
146190|NCT01696643|Drug|CB-5945|
146191|NCT01696643|Drug|Placebo|
146192|NCT00090337|Procedure|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
146880|NCT01694849|Drug|Placebo|
146881|NCT01694862|Procedure|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
146882|NCT01694875|Device|APTIMA HPV Assay|In Vitro Diagnostics Assay
146883|NCT01694888|Other|lecture|Teaching documentation skill using lecture method
146884|NCT00090181|Drug|Comparator: diclofenac / Duration of Treatment: 4 weeks|
146885|NCT01694914|Procedure|corneal graft|
146886|NCT01694927|Procedure|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
146887|NCT01694966|Drug|Methylene Blue MMX®|
146888|NCT01694966|Drug|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
146889|NCT01694979|Other|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
146890|NCT01694979|Other|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
146891|NCT01694979|Other|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
146892|NCT01694992|Other|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
150060|NCT01708278|Drug|Quercetin|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take Placebo containing 350 mg of vitamin C and 10 mg niacin or one of the two doses of quercetin twice a day for 4 weeks
150061|NCT01708291|Behavioral|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
150062|NCT01708291|Behavioral|only pre and post evaluation measures|
150063|NCT01708304|Behavioral|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
150064|NCT01700569|Drug|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
149517|NCT01709604|Procedure|CVVH|Ultrafiltration at 35ml/h/Kg
149518|NCT01709604|Procedure|Standardized therapy regimens|Standardized therapy regimens included the followings:
Remove all contaminated clothing
Gastric lavage
Receive activated charcoal as quickly as possible
Hemoperfusion with activated charcoal(160g)
Immunosuppression with methylprednisolone
Antioxidants (glutathione,1.2 gram iv twice a day)
Supportive care
149519|NCT00091910|Drug|Epoetin alfa|
149520|NCT01709617|Dietary Supplement|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
149521|NCT01709630|Drug|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
149522|NCT01709643|Dietary Supplement|High fat breakfast|The HF breakfast will consist of sausage rolls ("saucijzenbroodjes"), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands).
149523|NCT01709643|Dietary Supplement|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
149524|NCT01709656|Biological|MSC|human mesenchymal stem cells,1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.
a total of 24 weeks for follow up.
149525|NCT01702077|Procedure|Neurofeedback|
149526|NCT01702077|Procedure|Sham feedback|
149527|NCT01702090|Drug|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
149528|NCT01702103|Drug|Mometasone furoate|
149529|NCT01702116|Procedure|extralevator APR|Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more "cylindrical" specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive.
149530|NCT01702116|Procedure|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
149531|NCT01702129|Drug|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
149532|NCT01702155|Drug|DFP-10917|
149533|NCT00091104|Biological|MART-1:27-35 peptide vaccine|
149534|NCT01702168|Other|Provider training: Cognitive Processing Therapy (CPT)|
149535|NCT01702181|Drug|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
150175|NCT01738737|Device|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
150176|NCT01738750|Other|Cost Information Included|
150177|NCT00094627|Drug|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
150178|NCT01738763|Dietary Supplement|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
150179|NCT01738802|Dietary Supplement|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
150180|NCT01738802|Drug|Placebo|This group will take a placebo.
150181|NCT01738815|Drug|Valproic Acid|500 mg orally, once daily for up to 30 days
150182|NCT01738841|Biological|Priorix-Tetra™|Single dose, subcutaneous injection
150183|NCT01738841|Other|Safety data collection|Recording of adverse events, using diary cards
150184|NCT01738854|Procedure|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
150185|NCT01738867|Drug|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
150186|NCT01738867|Drug|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
150524|NCT01739309|Drug|LY2835219|Administered orally
150525|NCT01739322|Biological|Prick test Platanus acerifolia allergen extract|This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
150526|NCT01739335|Drug|Mifepristone (600 mg/day) or placebo (sugar pill)|600 mg/day mifepristone or placebo (sugar pill) for one week
150527|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
150528|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
150529|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
149960|NCT01708031|Other|physiological signals|
149961|NCT01708044|Drug|Pramlintide acetate|
149962|NCT01708044|Other|Placebo|Placebo Comparator
149963|NCT00091663|Drug|Tarceva (erlotinib HCl)|
149964|NCT01708057|Drug|AZD8683|AZD8683 administered via inhalation
149965|NCT01708057|Drug|Placebo|Placebo administered via inhalation
149966|NCT01708057|Drug|Tiotropium|Tiotropium administered via inhalation
149967|NCT01708070|Behavioral|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
149968|NCT01708096|Dietary Supplement|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
149969|NCT01708096|Dietary Supplement|Normal diet|normal diet 2 weeks before gastric by-pass
149970|NCT01700478|Drug|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
149971|NCT00001731|Drug|Cyclosporin A|
149972|NCT00090909|Drug|dexamethasone|
149973|NCT01700478|Drug|Vasopressin|Vasopressin was used in all patients during surgery.
149974|NCT01700491|Drug|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
149975|NCT01700491|Drug|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
149976|NCT01700504|Drug|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
149977|NCT01700517|Other|Spinal anesthesia|spinal anesthesia
149978|NCT01700517|Other|Femoral nerve block|Femoral nerve block
149979|NCT01700517|Other|sciatic nerves block|sciatic nerves block
150245|NCT01736397|Drug|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
150689|NCT01734824|Drug|Placebo Denosumab|one subcutaneous injection denosumab placebo
150690|NCT01734824|Drug|Placebo Teriparatide|daily subcutaneous placebo injection
150691|NCT01734837|Device|DS-Ligature Clip|
150692|NCT01734850|Drug|Busulfan|Intravenous busulfan
150693|NCT01734850|Biological|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
150694|NCT01734850|Biological|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
149725|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
149726|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
149727|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
149728|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
149729|NCT01704859|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
149730|NCT01704859|Dietary Supplement|Fish oil placebo|Fish oil placebo
149731|NCT01704859|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
149732|NCT00091299|Drug|warfarin|
149733|NCT01704859|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
149734|NCT01704872|Drug|ch14.18/CHO|
149735|NCT01704885|Behavioral|Play Intervention|
149736|NCT01704885|Other|Questionnaires|
149737|NCT01704898|Drug|Efavirenz 600 Test-Stocrin 600 Reference|
149738|NCT01704898|Drug|Stocrin 600 Reference-Efavirenz 600 Test|
149739|NCT01704911|Procedure|Transradial Coronary Intervention|
149740|NCT01704911|Procedure|Transfemoral Coronary Intervention|
149741|NCT01704911|Device|Coronary Stent System|Any kind of coronary stent system
148850|NCT01708707|Drug|Buprenorphine|The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.
Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days.
148851|NCT01708707|Drug|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
148852|NCT01708720|Drug|IPV|
148853|NCT01708720|Drug|Sabin-IPV|
148854|NCT01708720|Drug|Adjuvanted Sabin-IPV|
148855|NCT01708733|Drug|KSY|Chinese herbal formula
148856|NCT01708785|Behavioral|8 treatment sessions|Subjects will receive 8 sessions of cue exposure treatment.
148857|NCT01708785|Behavioral|Cue exposure treatment (clinical trial)|This version of the cue exposure treatment that will be provided in the clinical trial context will consist of the optimized components of the treatment as determined by the results of the experimental phase of this study.
148858|NCT01708785|Behavioral|Family-based Behavioral Treatment (FBT)|This is the current gold standard treatment for behavioral weight loss that will be used to compare to the cue exposure treatment.
148859|NCT00091728|Drug|Combined oral contraceptives|
149171|NCT01701661|Procedure|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
149172|NCT01701661|Other|conservative treatment|Compression stockings class II
149173|NCT01701674|Drug|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participant's will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
149174|NCT01701674|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging [MRI] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
148600|NCT01718314|Drug|Lidocaine pump spray|
148601|NCT01718314|Drug|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
148602|NCT01718314|Drug|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
148603|NCT00001777|Drug|Sertraline|
148604|NCT00092612|Drug|MK0653, ezetimibe|
148605|NCT01718327|Drug|Sunitinib|sunitinib dose :37.5mg/day
148606|NCT01718340|Drug|Metformin|metformin tablet 500mg three time per day
148607|NCT01718353|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
148608|NCT01718353|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
148609|NCT01710566|Drug|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
148610|NCT01710566|Drug|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
148611|NCT01710579|Procedure|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
148612|NCT01710579|Procedure|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
148916|NCT01706250|Other|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
148917|NCT01706250|Other|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
148918|NCT01706263|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
148919|NCT01706263|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
148920|NCT00091416|Biological|VRC-HIVADV014-00-VP|
148921|NCT01706263|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
149337|NCT01709084|Drug|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
148361|NCT01712763|Drug|degarelix|50 women will be treated with degarlix 80 mg, in only one administration covering three months
148362|NCT01712763|Drug|goserelin|50 women will be treated with decapeptyl 3.6 every month for three months
148363|NCT01712776|Device|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
148364|NCT01712789|Drug|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
148365|NCT01712789|Drug|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
148366|NCT01712802|Other|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
148367|NCT01712802|Other|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
148368|NCT00001763|Drug|Interleukin-12|
148369|NCT00092157|Drug|MK0733, simvastatin|
148370|NCT01712802|Other|Saline|work as control for Denture Adhesives: Cream and Powder
148371|NCT01712815|Other|laboratory biomarker analysis|Correlative studies
148372|NCT01712815|Other|pharmacological study|Correlative studies
148373|NCT01712815|Other|questionnaire administration|Ancillary studies
148374|NCT01712815|Radiation|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
148375|NCT01712815|Procedure|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
148376|NCT01712828|Drug|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
148377|NCT01712828|Drug|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
148378|NCT01712828|Drug|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
148379|NCT01712828|Drug|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
147212|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid
147213|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid.
147214|NCT01710696|Drug|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
147215|NCT01710696|Drug|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
147216|NCT00092001|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
147217|NCT01710709|Drug|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
147218|NCT01710722|Drug|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
147219|NCT01710722|Drug|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
147220|NCT01710722|Drug|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
147814|NCT01714232|Device|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
147815|NCT01714232|Device|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
147816|NCT00092222|Drug|Filgrastim (G-CSF)|Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
147817|NCT01714232|Device|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
147818|NCT01714258|Procedure|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
147819|NCT01716910|Dietary Supplement|Combination of Lactobacillus acidophilus NCFM and cellobiose|
147820|NCT01716923|Biological|S-303 Red Blood Cells (RBCs) - Test|
147821|NCT01716923|Biological|Conventional, untreated red blood cells (RBCs) - Control|
147000|NCT01697930|Drug|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of [18F] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the [18F] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
147001|NCT01697943|Procedure|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
147002|NCT01697956|Drug|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
147003|NCT01697956|Drug|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
147004|NCT01697969|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
147005|NCT01697982|Behavioral|Living with Hope Program|The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an "About Me Collection."
147006|NCT01697982|Behavioral|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
147007|NCT01698008|Device|Diabetes Doctor|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
147008|NCT01698034|Behavioral|Volunteering|Weekly volunteering with elementary school children in after school programs
147009|NCT00090519|Drug|placebo|QD oral for up to 36 months
147010|NCT01698047|Behavioral|Resiliency Class|See Arm Description
147281|NCT01718626|Drug|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
147282|NCT01718626|Drug|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
147283|NCT01718639|Device|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
147284|NCT01718639|Device|IQP-LH-101 liquid|Oral medical device in the form of a liquid
148003|NCT00092274|Drug|HuMax-CD20|
148004|NCT01714505|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
148005|NCT01714531|Behavioral|Telephone-Based Goal Management Training|
148006|NCT01714531|Behavioral|Telephone-Based Attention-Control|
148007|NCT01714544|Drug|Cloderm Cream|
148008|NCT01714557|Drug|Piperacillin|4.0g q8h 3-5 days
148009|NCT01714557|Drug|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
148010|NCT01714570|Drug|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
148011|NCT01714570|Drug|Imipenem|0.5g q6h, 5-10 days
148012|NCT01714596|Other|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
148013|NCT01714609|Drug|Placebo|Placebo Comparator: Placebo
148014|NCT00092287|Drug|lanreotide Autogel (somatostatin analogue)|
148015|NCT01714609|Drug|Sorafenib|Sorafenib, 400 mg twice daily
148016|NCT01714622|Procedure|subtotal gastrectomy with gastroduodenostomy|
148017|NCT01717274|Procedure|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
148018|NCT01717287|Drug|Raltegravir Film-coated Tablet|
148019|NCT01717287|Drug|Raltegravir Chewable Tablet|
148020|NCT01717287|Drug|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
148021|NCT01717300|Drug|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
147071|NCT01695382|Behavioral|Navigation|As per Arm description
147712|NCT01714037|Drug|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
147713|NCT00092222|Drug|Doxorubicin|10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
147714|NCT01714037|Drug|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
147715|NCT01714037|Drug|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
147716|NCT01714037|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
147717|NCT01714037|Drug|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
147718|NCT01714050|Behavioral|Cognitive-Behavioral Therapy (CBT)|
147719|NCT01714050|Device|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
147720|NCT01714076|Other|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
147721|NCT01714089|Drug|RNS60 125 ml|
147722|NCT01714089|Drug|RNS60 250 ml|
147723|NCT01714089|Drug|Interferon beta 1a|
147724|NCT00092222|Drug|Vincristine|0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
147725|NCT01714102|Dietary Supplement|Placebo|Placebo manufactured to mimic resveratrol tablet
147726|NCT01714102|Dietary Supplement|Resveratrol|Resveratrol PO BID for 30 days
147727|NCT01714115|Drug|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
147728|NCT01714128|Drug|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
147729|NCT01716793|Drug|Ara-C|Intermediate dose during induction phase to remission.
High-dose during consolidation phase in patients with favorable cytogenetics.
147730|NCT01716793|Other|Autologous transplantation|In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.
In patients with other cytogenetics without HLA-Identical sibling.
147731|NCT01716793|Other|Allogeneic HLA-identical sibling transplantation|Patients without favorable or normal karyotype(and one course to CR).
Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics.
147732|NCT01716793|Other|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
146927|NCT01689818|Other|exercise training|exercise training program which included aerobic exercise for 3 times per week.
146928|NCT01689831|Biological|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
146929|NCT01689831|Biological|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
146930|NCT01689844|Behavioral|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
146931|NCT01689844|Behavioral|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
146932|NCT00001713|Drug|Heparin|
146933|NCT00089726|Drug|Cyclophosphamide|
146934|NCT01689857|Device|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
146935|NCT01689857|Device|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
145960|NCT01690559|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
145961|NCT01690572|Device|Paclitaxel coated balloon catheter|Dilatation of the target lesion
145962|NCT01690572|Device|uncoated balloon catheter "sprinter legend"|Dilatation of the target lesion
145963|NCT01690585|Drug|Ferinject 1000 mg|
145964|NCT01690585|Drug|Sodium chlorure 0,9 %|
145965|NCT01690598|Drug|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
145966|NCT01693068|Drug|Dacarbazine|Dacarbazine will be administered intravenously at dose of 1000 mg per square meter of body surface area on Day 1 of each 21-days cycle. Treatment will be continued until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever comes first.
Eligible subjects with documented tumor progression on dacarbazine will be offered to switch to pimasertib treatment at the end of the treatment.
145967|NCT01693081|Drug|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
145968|NCT01693081|Drug|placebo|
146658|NCT01689311|Drug|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
146659|NCT01689311|Drug|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
146660|NCT01689324|Biological|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
146661|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
146662|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
146663|NCT01689337|Drug|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
146664|NCT01689350|Genetic|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
146665|NCT01689363|Drug|Hyaluronidase Intradermal Injection|Intradermal injection of the study drug (2 injections) One injection with a positive control and one with a negative control
146666|NCT01689376|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
146667|NCT01691716|Behavioral|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
146668|NCT01691729|Device|Ostomy accessory|Wearing each of the devices for 10 days each
146669|NCT01691742|Drug|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
146670|NCT01691742|Drug|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
146671|NCT01691742|Drug|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
146672|NCT01691755|Drug|Placebo|oral doses once a day for 26 weeks
146673|NCT01691755|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
145726|NCT01695694|Behavioral|community support group|
145727|NCT01695707|Drug|Pioglitazone|see Arm Description
145728|NCT01695707|Drug|Placebo (for pioglitazone)|see Arm Description
146425|NCT01693939|Device|FS200 Femtosecond Laser|
146426|NCT01693952|Biological|blood draw|
146427|NCT01693965|Other|sputum samples|
146428|NCT01693978|Behavioral|Prolonged Exposure Therapy|Prolonged Exposure Therapy is considered the "gold standard" treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, & Rothbaum, 2007).
146429|NCT01693978|Behavioral|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
146430|NCT01693991|Behavioral|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
146431|NCT01693991|Behavioral|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
146432|NCT01694004|Procedure|Placement of naso-duodenal tube and infusions|
146433|NCT01694017|Drug|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
146434|NCT01694017|Drug|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
146435|NCT00090129|Drug|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
146436|NCT01694030|Other|Attachment security priming|
146437|NCT01694043|Other|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
146193|NCT01698918|Drug|Alcohol-free dexamethasone mouth rinse|At the onset of symptoms suggestive of stomatitis patients must contact the study site. Upon confirmation of stomatitis at the site, patients in countries where the alcohol-free 0.5mg/5ml dexamethasone oral solution is commercially available will be randomly assigned to take either dexamethasone 0.5 mg/5ml mouth rinse or the standard of care used to treat stomatitis at the patient's center. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day. Patients will be instructed to swish and expectorate the mouth rinse. Patients will also be instructed to fill out the Oral Stomatitis Daily Questionnaire (OSDQ) at home every day until the patient recovers. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day.Patients will be instructed to swish and expectorate the mouth rinse.
146194|NCT01698931|Drug|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
146195|NCT01698931|Drug|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
146196|NCT01698931|Drug|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
146197|NCT00090688|Biological|meCS6 + LT(R192G)|
146198|NCT01698944|Drug|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
146199|NCT01698957|Other|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
146502|NCT01691521|Drug|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
146503|NCT01691534|Drug|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
146504|NCT01691534|Drug|PA-824 (PA)|PA-824 200mg Days 1-14
146505|NCT01691534|Drug|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
146506|NCT01691534|Drug|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
146507|NCT00089895|Drug|Placebo|intravenous; delivery to match eptifibatide to maintain blind
146508|NCT01691534|Drug|Rifafour|Rifafour e-275 mg dosed by weight
146509|NCT01691547|Drug|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
146510|NCT01691547|Drug|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
146511|NCT01691547|Drug|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
146512|NCT01691547|Drug|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
150065|NCT01700569|Drug|folinic acid at pharmacological dose is the escalated drug|
150066|NCT01700569|Radiation|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
150067|NCT01700595|Procedure|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
150068|NCT01700608|Drug|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
150069|NCT00090961|Other|educational intervention|
150070|NCT01700621|Biological|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
150071|NCT01700621|Biological|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
150072|NCT01700647|Other|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
150073|NCT01700647|Other|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
150074|NCT01700673|Drug|5-azacitidine and sargramostim|5-azacitidine will be administered days 1-5 of a 28 day cycle. sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
150075|NCT01700686|Other|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
150076|NCT01700712|Dietary Supplement|Probiotic Lactobacilli reuteri|
150077|NCT01700712|Dietary Supplement|Placebo|
150342|NCT01739036|Biological|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
150343|NCT01739036|Biological|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
150344|NCT01739036|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
150345|NCT01739049|Drug|Liraglutide|liraglutide
150346|NCT01739049|Behavioral|Diet and Exercise|diet and exercise
150347|NCT01739062|Genetic|Genetic risk assessment|
149814|NCT01702662|Device|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
149815|NCT01702675|Drug|ACH15 50 mg|ACH15 50mg capsule
149816|NCT01702675|Drug|ACH15 250 mg|ACH15 250mg capsule
149817|NCT01702675|Drug|ACH15 500mg|ACH15 500 mg capsule
149818|NCT01702675|Drug|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
149819|NCT01702675|Drug|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
149820|NCT00091104|Procedure|autologous hematopoietic stem cell transplantation|
149821|NCT01702675|Drug|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
149822|NCT01702675|Drug|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
149823|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
149824|NCT01702675|Drug|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
149825|NCT01704989|Procedure|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
149826|NCT01704989|Drug|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation.
149827|NCT01705002|Drug|Promitil|
149828|NCT01705002|Drug|Capecitabine|
149829|NCT01705015|Behavioral|direct feedback about exercise|
149830|NCT01705015|Behavioral|PLacebo|UCFit plus encouraged exercise
149831|NCT00091312|Drug|fluorouracil|
150530|NCT01739348|Drug|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
150531|NCT01739348|Drug|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
150532|NCT01739361|Drug|Acetaminophen|
150533|NCT00094692|Device|spectacles|
150534|NCT01739361|Drug|placebo|
150535|NCT01739374|Other|reduced mesh implants|mesh for pelvic floor reinforcement
150536|NCT01739387|Device|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
150537|NCT01739400|Drug|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
150538|NCT01739413|Procedure|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
150539|NCT01739426|Device|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
150540|NCT01739439|Drug|gemcitabine hydrochloride|Given IV
150541|NCT01739439|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
150542|NCT01739439|Radiation|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
150543|NCT01739439|Radiation|radiosurgery|Undergo radiosurgery boost
150544|NCT00094692|Drug|atropine|
150545|NCT01739439|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
150546|NCT01739465|Procedure|Self expanding metallic stent (SEMS)|Self expanding metallic stent
149592|NCT01699763|Device|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
149593|NCT01699763|Device|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
149594|NCT01699776|Drug|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
150246|NCT01736410|Drug|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
150247|NCT01736423|Drug|YM060|oral
150248|NCT01736436|Drug|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
150249|NCT01736436|Procedure|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
150250|NCT01736436|Procedure|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
150251|NCT00001832|Biological|Abl cells|Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10^9‑10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
150252|NCT00094640|Drug|Intramuscular Olanzapine Depot|
150253|NCT01738880|Drug|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
150254|NCT01738880|Drug|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
150255|NCT01738893|Drug|Gabapentin 300 mg|Test product
150256|NCT01738893|Drug|Gabapentin 300 mg|Reference product
150257|NCT01738906|Other|Orange juice|
150258|NCT01738906|Other|maltodextrin|
150259|NCT01738906|Other|Vodka|
150260|NCT01738906|Other|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
150261|NCT01738906|Other|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
150262|NCT01738919|Procedure|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
150263|NCT00094653|Drug|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous [iv] infusion over 90 minutes), every 3 weeks for 4 doses
150264|NCT01738919|Procedure|Operative treatment with extension block technique|
149742|NCT01704924|Device|Prevena|Device will be applied at end of procedure over closed incision
149743|NCT00091312|Drug|FOLFIRI regimen|
149744|NCT01704937|Drug|Fecal Microbiota Transplant (FMT)|Reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube
149745|NCT01704963|Drug|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
149746|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
149747|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
150039|NCT00001749|Drug|Cyclosporine|
150040|NCT01708109|Other|no measures taken to clear bile ductus|biliary calculus remain
150041|NCT01708109|Procedure|clearance of bile ductus|biliary calculus removed at surgery
150042|NCT01708122|Drug|Fentanyl|100 mcg in 1 mL intranasal spray
150043|NCT01708122|Drug|saline|Sodium Chloride 0.9% intranasal spray
150044|NCT00091676|Biological|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
150045|NCT01708135|Behavioral|Use of smartphone app|
150046|NCT01708148|Dietary Supplement|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
150047|NCT01708148|Other|Placebo|control group would receive a oral lactose placebo
150048|NCT01708161|Drug|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
150049|NCT01708161|Drug|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
150050|NCT01708174|Drug|LDE225|
150051|NCT01708187|Biological|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
150052|NCT01708200|Other|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
149175|NCT01704105|Behavioral|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.
Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
149176|NCT01704105|Behavioral|Handwashing|Hardware: Handwashing "dual tippy tap" stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.
Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces.
149177|NCT01704105|Dietary Supplement|Nutrition|Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.
Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old.
149178|NCT01704118|Device|I-gel|Supraglottic airway device
149179|NCT01704118|Device|ProSeal Laryngeal mask|Supraglottic airway device
149180|NCT01704157|Device|Cryo-Touch III|Study treatment at Day 0.
149181|NCT01704170|Device|Kona Externally Focused Ultrasound Therapy|
149182|NCT00091234|Drug|gemtuzumab ozogamicin|
149183|NCT01704196|Drug|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
149184|NCT01704196|Drug|Placebo|
149185|NCT01704209|Drug|Fibroblast Treatment|
148214|NCT01714947|Drug|alisertib|
148215|NCT00092547|Biological|V501|0.5 mL intramuscular injection of V501
148216|NCT01717586|Drug|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
148217|NCT01717599|Drug|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
148218|NCT01717599|Drug|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
148922|NCT01706302|Other|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD [recently re-named Clinical Practice Research Datalink (CPRD)], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
148923|NCT01706315|Drug|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
148924|NCT01706315|Drug|Placebo|Matching placebo will be available
148925|NCT01706328|Drug|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
148926|NCT01706328|Drug|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
148927|NCT01706328|Drug|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
148928|NCT01706328|Drug|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
148929|NCT01706328|Drug|Salbutamol as needed|Salbutamol inhalation powder
148930|NCT01708785|Behavioral|Multiple contexts|Subjects will be exposed to foods in multiple contexts during cue exposure treatment.
148931|NCT01708798|Drug|Eplerenone|
148932|NCT00091741|Drug|Etanercept (Enbrel)|
148933|NCT01708824|Behavioral|Dietary|Dietary intervention to meet the target of
<5 servings of red/processed meat weekly; <2 servings would be processed meat
2 servings of refined grains daily
148934|NCT01708824|Behavioral|Physical activity|Physical activity intervention with the following targets:
General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);
Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)
149247|NCT01701674|Drug|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
149248|NCT01701674|Biological|Adoptive Cell Therapy with TIL|
149249|NCT01701700|Procedure|portable electronic magnifier|
148380|NCT00092157|Drug|Comparator: simvastatin|
148381|NCT01712854|Drug|Budesonide + inhaler|budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg
148382|NCT01712854|Drug|Budesonide|budesonide 80 mcg
148383|NCT01712867|Other|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
148675|NCT01708525|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
148676|NCT00091702|Biological|Inactivated influenza vaccine (IAIV)|
148677|NCT01708525|Other|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
148678|NCT01700790|Drug|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
148679|NCT01700803|Drug|Povidone Iodine 10% vand cesarean section wound infections|
148680|NCT01700803|Drug|Povidone Iodine 7.5% vand cesarean section wound infections|
148681|NCT01700816|Device|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
148682|NCT01700816|Device|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
148683|NCT01700829|Drug|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
148684|NCT00090974|Procedure|quality-of-life assessment|
148685|NCT01700829|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
148686|NCT01700855|Procedure|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
148687|NCT01700855|Procedure|Electroacupuncture|Electrodes are applied to bilateral "Hegu(L14)" acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate.
148688|NCT01700868|Other|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
148689|NCT01700868|Other|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
147822|NCT01716949|Radiation|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
147823|NCT01716949|Procedure|Hyperthermia|10 sessions, therapeutic time 60 min
147824|NCT01716949|Drug|5-Fluorouracil|250 mg/m^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
147825|NCT01716949|Drug|Capecitabine|1650 mg/m^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
147826|NCT00092495|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
147827|NCT01716949|Drug|Oxaliplatin|50 mg/m^2/d as 2-hour bolus infusion on d2, 9, 23, 30
147828|NCT01716962|Other|Infusion of 6% tetrastarch for a total of 500 ml|
147829|NCT01716975|Drug|EVP-6124|Arms 1, 2
147830|NCT01716975|Drug|Placebo|Arm 3
147831|NCT01717014|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
147832|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
147833|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
147858|NCT01719237|Drug|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
147859|NCT01719250|Drug|Buparlisib|Given PO
147860|NCT01719250|Other|Laboratory Biomarker Analysis|Correlative studies
147861|NCT01719250|Other|Questionnaire Administration|Ancillary studies
147862|NCT00092703|Drug|MK0663, etoricoxib|
147863|NCT01719263|Device|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
147864|NCT01719263|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
147865|NCT01719276|Other|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
147285|NCT00092638|Drug|MK0653, ezetimibe|
147286|NCT01718639|Other|Placebo|
147287|NCT01718652|Drug|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
147288|NCT01718652|Drug|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
147289|NCT01718678|Drug|Melatonin|it is kind of drug
147290|NCT01718678|Drug|Placebo|It is Placebo
147291|NCT01718691|Drug|SyB L-0501|A dose of 90 mg/m2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
147292|NCT01718691|Drug|rituximab|A dose of 375 mg/m2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
147293|NCT01718704|Device|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
147294|NCT01718717|Other|Thoracic Epidural Analgesia (TEA)|
147295|NCT01718717|Other|TEA followed by Intravenous morphine|
147296|NCT01710787|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
147297|NCT01710787|Drug|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
147298|NCT01710787|Drug|Placebo|3 unilateral intranasal sprays per dose
147299|NCT01710800|Drug|Esomeprazole|
147300|NCT01710800|Drug|placebo|
147301|NCT01710813|Biological|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
147302|NCT01710826|Biological|Genz-682452|Capsules for oral administration.
147570|NCT01719042|Dietary Supplement|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
147571|NCT01719055|Device|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
147072|NCT01695421|Procedure|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
147073|NCT01695421|Procedure|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
147074|NCT01695421|Procedure|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
147075|NCT01698060|Biological|ND1.1|
147076|NCT01698073|Behavioral|mCOL|
147077|NCT01698073|Other|AS+|
147078|NCT01698086|Other|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
147079|NCT01698112|Dietary Supplement|Flaxseed High Dose|26 gram flaxseed intervention
147080|NCT01698112|Dietary Supplement|Flaxseed Low Dose|13 grams flaxseed
147081|NCT01698125|Procedure|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
147082|NCT01698138|Drug|Onabotulinumtoxin A|30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, "Allergan") in 30 ml of NaCl 0.9 %.
147083|NCT00090532|Drug|AG-013,958|
147084|NCT01698138|Drug|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
148090|NCT01712282|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
148091|NCT00092118|Drug|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
148092|NCT01712295|Drug|17% Salicylate with ethyl pyruvate|
148093|NCT01712295|Drug|Salicylates|
148094|NCT01714622|Procedure|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
148095|NCT01714622|Procedure|total gastrectomy with Rou-en-Y esophagojejunostomy|
148096|NCT01714635|Device|Tecnis Multifocal Intraocular Lens|
148097|NCT01714635|Device|Monofocal Intraocular Lens|
148098|NCT01714648|Drug|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
148099|NCT01714661|Drug|EVP-6124|Arms 1, 2
148100|NCT01714661|Drug|Placebo|Arm 3
148101|NCT01714674|Dietary Supplement|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
148102|NCT00092287|Drug|Sandostatin long acting release (LAR) Depot (somatostatin analogue)|
148103|NCT01714674|Dietary Supplement|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
148104|NCT01714687|Device|balloon sinus dilation|
148105|NCT01714687|Other|medical therapy|
148106|NCT01714700|Behavioral|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
148107|NCT01714700|Behavioral|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
145969|NCT01693094|Behavioral|Decision Aid|Cohort I will be managed with a decision aid (henceforth "DA"), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them.
145970|NCT00090051|Drug|Fludarabine Phosphate|Intravenous repeating dose
145971|NCT01693120|Device|Medtronic Phased RF Ablation System|Phased RF ablation
145972|NCT01693133|Other|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
145973|NCT01693133|Other|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
145974|NCT01693146|Device|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
145975|NCT01693146|Device|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
145976|NCT01693159|Device|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
145977|NCT01693159|Other|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
145978|NCT01693172|Behavioral|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
145979|NCT01693185|Drug|Remifentanil|continuous infusion 0.4 mcg/kg/min
146281|NCT01696825|Drug|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
146282|NCT01696825|Drug|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
146283|NCT01699256|Behavioral|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
146284|NCT01699269|Other|peritumoral glial cell infiltration|
146285|NCT01699282|Behavioral|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
146286|NCT00090753|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
145729|NCT00090246|Drug|MK0869, aprepitant|
145730|NCT01695720|Procedure|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam [the system itself] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
145731|NCT01695733|Biological|trivalent influenza vaccine|
145732|NCT01695759|Drug|Epoetin Alfa|The drug will be administered subcutaneously and the initial dose is 50 IU / kg. This dose will be administrated twice/week, totaling 100 U / kg / week.
145733|NCT01695772|Drug|5-FU based doublet chemotherapy|standard 5-FU based doublet chemotherapy
145734|NCT01695772|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
145735|NCT01695798|Biological|Injectable polio vaccine and Bivalent oral polio vaccine|One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.
There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone
145736|NCT01695824|Device|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
145737|NCT01695824|Procedure|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
145738|NCT01698242|Behavioral|Enhanced Training|PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.
Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up).
146043|NCT01690663|Drug|Bupivacaine 0.25%|
146044|NCT01690663|Drug|Dexamethasone|
146045|NCT01690663|Drug|normal saline|placebo
146046|NCT00089843|Drug|Testosterone|Testosterone patch 150mcg daily
146740|NCT01697566|Behavioral|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
146741|NCT01697579|Drug|Fosaprepitant 150 mg|Administered IV as a single dose
146742|NCT01697579|Drug|Fosaprepitant 60 mg|Administered IV as a single dose
146743|NCT01697579|Drug|Fosaprepitant 20 mg|Administered IV as a single dose
146744|NCT01697579|Drug|Placebo Fosaprepitant|Administered IV as a single dose
146745|NCT01689402|Device|MRI Scan with the specified sequences below:|Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.
Susceptibility weighted imaging (SWI)
Chemical Shift Imaging (CSI) multivoxel spectroscopi
Post contrast 3D box reconstruction
146746|NCT00089674|Drug|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
146747|NCT01689441|Drug|Calcitriol|
146748|NCT01689441|Drug|Placebo|
146749|NCT01689467|Dietary Supplement|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
146750|NCT01689467|Dietary Supplement|Placebo|Placebo (1g/day)
146751|NCT01689480|Other|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
146752|NCT01689493|Behavioral|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
146753|NCT01689506|Drug|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
146754|NCT01689506|Drug|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
146755|NCT01689519|Drug|Placebo|Placebo was supplied as tablets.
146756|NCT01689519|Drug|Vemurafenib|Vemurafenib was supplied as tablets.
146757|NCT00089687|Drug|GBR 12909|
183871|NCT02559635|Procedure|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
183872|NCT02559635|Drug|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
183873|NCT02559648|Drug|Denosumab|Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.
The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated.
183874|NCT00002507|Drug|porfiromycin|
183875|NCT00186277|Drug|Taxotere|Calculated per patient
183876|NCT02559648|Drug|Placebo|Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.
The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated.
183877|NCT02559661|Other|Training on a virtual simulator in eye surgery|
183878|NCT02559674|Biological|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
183879|NCT02559674|Biological|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
183880|NCT02561871|Drug|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
183881|NCT02561884|Drug|Olostar Tab.|
183882|NCT02561884|Drug|Co-administration of Olmetec and Crestor|
183883|NCT02561897|Drug|Edoxaban|
184186|NCT02554994|Other|Multifactorial intervention|There are six components of intervention in this study.
For all participants: group exercise.
For selected participants:
Nutritional supplement(commercial liquid formula will be provided every day).
Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.
At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).
domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it).
183585|NCT00187044|Biological|PolyEnv1 vaccine|administered subcutaneously as 10*7 pfu in 0.8 mL
183586|NCT02566005|Device|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
183587|NCT02566005|Device|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
183588|NCT02566018|Procedure|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
183589|NCT02566018|Procedure|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
183590|NCT02566031|Drug|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
183591|NCT02566031|Drug|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
183592|NCT02566044|Drug|QBW276|
183593|NCT02566044|Other|Placebo|
183594|NCT02566057|Biological|PGx testing guided treatment (PGT)|Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
183595|NCT02566070|Other|Continuous Gastric Feeding|
183596|NCT00187057|Drug|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
183597|NCT02566070|Other|Bolus Gastric Feeding|
183598|NCT02566083|Device|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
183599|NCT02566083|Device|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
183600|NCT02566096|Drug|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
183601|NCT02566109|Other|Fast MRI and Questionnaires|The Self-Reported questionnaires are a collection of well-validated, brief, fee-free instruments assessing key patient reported outcomes related to this study. For this study, we are using the short forms for quality of life. The total administration time for these questionnaires is 5 minutes.
Self-Report questionnaires will be obtained monthly. As part of this study, an additional measurement of ultrasensitive Troponin I will be collected at 2-months, as well as, a Fast MRI and 3D ECHO.
187843|NCT01955291|Device|Reinforced Feedback in Virtual Environment (RFVE)|The patients allocated to RFVE group, will be treated using the "Virtual Reality Rehabilitation System" (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task.
187844|NCT01957774|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
187845|NCT01957774|Drug|Placebo|
187846|NCT01957787|Device|Cryoablation|All patients will receive cryoablation of up to 6 metastatic lung tumors.
187847|NCT01957800|Behavioral|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
187848|NCT01957800|Behavioral|Usual Care|Participants will record their weight and complete surveys online.
187849|NCT01957813|Behavioral|Lifestyle Counseling|Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.
Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation
187850|NCT01957813|Other|Standard Health Services|Peer education and health services
188127|NCT01991002|Behavioral|14/21 diet|Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.
The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group.
188128|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
188129|NCT00118534|Behavioral|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
188130|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
188131|NCT01991054|Dietary Supplement|vitamin D3|
188132|NCT01991067|Biological|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
188133|NCT01991080|Behavioral|biofeedback|Patients will go through biofeedback sessions
188134|NCT01991080|Drug|Wheatgerm juice|Patient will drink wheatgerm juice
187549|NCT01963013|Device|Non-returning catheter valve|
187550|NCT00116168|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
187551|NCT01963013|Device|Conventional urine bag|
187552|NCT01963026|Other|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module [17] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. [17]. Intervention B will be called 'ToCUEST variability' in the present project.
187553|NCT01963026|Other|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
187554|NCT01963039|Device|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
187555|NCT01963039|Procedure|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
187556|NCT01963052|Drug|AGS15E|intravenous (IV) infusion
187557|NCT01963078|Drug|Oxytocin|
187558|NCT01963078|Drug|Saline|
187559|NCT01963091|Drug|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
187851|NCT01957826|Other|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
187852|NCT00115609|Drug|emtricitabine|one pill of 200mg once a day
187853|NCT01957826|Other|placebo intervention|placebo administration
187854|NCT01957839|Drug|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
187251|NCT02545192|Device|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
187252|NCT02545205|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).
187253|NCT00184691|Drug|somatropin|
187254|NCT02545205|Other|Conventional gait training|The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
187255|NCT02545218|Procedure|Perineorraphy|Surgery for improperly healed perineal tear
187256|NCT01970072|Drug|Remimazolam Tosylate|
187257|NCT01970072|Drug|Midazolam|
187258|NCT01970098|Drug|KPS-0373, High dose|
187259|NCT01970098|Drug|KPS-0373, Low dose|
187260|NCT01970098|Drug|Placebo|
187261|NCT00117000|Drug|testosterone undecanoate|
187262|NCT01970111|Drug|KPS-0373, High dose|
187263|NCT01970111|Drug|KPS-0373, Low dose|
187264|NCT01970124|Drug|KPS-0373, High dose|
187265|NCT01970124|Drug|KPS-0373, Low dose|
187266|NCT01970137|Drug|KPS-0373, High dose|
187267|NCT01970137|Drug|KPS-0373, Low dose|
187268|NCT01970150|Device|rTMS real|
187269|NCT01970163|Other|DermACELL|Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
187270|NCT01970163|Other|GraftJacket|Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
186656|NCT02558543|Drug|Stromal Vascular fraction|
186657|NCT02558543|Drug|Ringer lactate|
186658|NCT00186108|Drug|Oral Triamcinalone|
186945|NCT02551692|Drug|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
186946|NCT02553772|Drug|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
186947|NCT02553772|Drug|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
186948|NCT00002504|Biological|aldesleukin|
186949|NCT00185510|Drug|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
186950|NCT02553785|Device|Revivent TC|
186951|NCT02553798|Drug|DRM04 Topical Wipes|DRM04 Topical Wipes
186952|NCT02553811|Other|accuracy diagnostic|effectiveness of clinical examination, ultrasound and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
186953|NCT02553824|Drug|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
186954|NCT02553824|Drug|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
186955|NCT02553837|Biological|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
186956|NCT02553863|Procedure|Acupuncture|Acupuncture for 30min [twice weekly for 8 weeks]
186957|NCT02553863|Procedure|Standard care|Standard care
186958|NCT02553889|Drug|ISIS 416858|subcutaneous injection
186959|NCT02553889|Drug|Placebo|subcutaneous injection
186960|NCT00185510|Drug|Placebo|2 days a week Vehicle (Advabase)
186362|NCT02564887|Device|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
186363|NCT02564900|Drug|DS-8201a|
186364|NCT02564913|Other|clinical evaluation|
186365|NCT02564926|Drug|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
186659|NCT02558556|Device|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
186660|NCT02558556|Other|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
186661|NCT02558569|Drug|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
186662|NCT02558569|Other|NSS|Clear intravenous fluid looks alike local anesthetic.
186663|NCT02558582|Behavioral|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
186664|NCT02560701|Other|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
186665|NCT02560714|Device|SImmetry Sacroiliac Fusion System|SImmetry
The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.
The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.
186666|NCT02560727|Device|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
186667|NCT02560727|Device|colonoscope|FMT via colonoscope is the most common approach.
186668|NCT02560740|Dietary Supplement|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
186669|NCT02560740|Dietary Supplement|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
186670|NCT00186472|Behavioral|Brief Cognitive Behavioral Treatment|
186070|NCT02569294|Behavioral|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
186071|NCT02569307|Drug|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
186072|NCT02571361|Drug|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
186073|NCT02571374|Dietary Supplement|symbiotic group|this group received sachets of symbiotic
186074|NCT02571374|Dietary Supplement|placebo group|this group received placebo
186075|NCT02571387|Behavioral|Mindfulness-based intervention|
186076|NCT00187577|Drug|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
186077|NCT02571387|Behavioral|Sham meditation|
186078|NCT02571400|Other|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics >90 days post-surgery
186079|NCT02571413|Other|score before teaching|score the check-point of correct INCS usage before teaching
186080|NCT02571413|Other|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
186081|NCT02571413|Other|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
186082|NCT02571426|Drug|Sevoflurane|anesthetic agent
186083|NCT02571426|Drug|propofol|anesthetic agent
186084|NCT02571439|Procedure|Surgical TAP block|surgeon administered TAP block
186366|NCT02564926|Drug|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
186367|NCT02564939|Drug|ramelteon|double-blind RCT
186368|NCT02564939|Drug|Placebo|double-blind RCT
186369|NCT02564952|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
185786|NCT00002498|Drug|cyclophosphamide|
185787|NCT00183963|Drug|Fulvestrant|250mg
185788|NCT02539849|Dietary Supplement|FOS|
185789|NCT02539849|Drug|Adalimumab|
185790|NCT02539862|Other|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
185791|NCT02539862|Other|psychoeducation|the psychoeducation is delivered by a doctor
185792|NCT02539875|Behavioral|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
185793|NCT02539888|Device|Goggle Balloon|To determine if goggle balloon can help in patients who have very redundant colons. It is a randomized trial, and one arm will undergo colonoscopy with a standard instrument using water immersion, and the other arm will have water immersion plus the goggle balloon.
185794|NCT02539901|Behavioral|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
185795|NCT02539901|Behavioral|Free hearing test categorization|Free hearing test categorization evaluation
185796|NCT02539901|Behavioral|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
185797|NCT02539901|Behavioral|psychomotor infancy development scale|
185798|NCT00183963|Drug|Fulvestrant|500 mg IM
185799|NCT02539901|Behavioral|NEPSY (two domains: "memory and learning" and "attention and executive functions").|NEPSY evaluation
185800|NCT02539914|Other|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
185801|NCT00002498|Drug|mitoxantrone hydrochloride|
185802|NCT00184262|Behavioral|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
185803|NCT02542254|Drug|Ipratropium matched placebo|Placebo pMDI
185804|NCT02542254|Drug|RPL554 matched placebo|Nebulised placebo
185805|NCT02542267|Device|Gore VIABAHN Endoprosthesis|
186085|NCT02571439|Procedure|Conventional TAP block|Anesthesiologist administered TAP block
185240|NCT02555644|Drug|Cisplatin|Administered IV
185241|NCT02555644|Drug|Cetuximab|Administered IV
185511|NCT02548767|Other|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
185512|NCT02548767|Other|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
185513|NCT02548780|Device|Chemoembolization|First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.
Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver.
185514|NCT02548780|Other|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
185515|NCT02548793|Other|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
185516|NCT02548793|Other|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
185517|NCT02548806|Drug|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
185518|NCT02548806|Drug|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
185519|NCT02548806|Drug|Catapres 100μg|Catapres tablet 100μg, single dose
185520|NCT00185042|Drug|Pactimibe, CS-505|
185521|NCT02548819|Other|MRI|
185522|NCT02548832|Drug|Berberine|Berberine capsules, 500 mg 3 times daily with the first bite of each meal
185523|NCT02548832|Drug|Bezafibrate|Bezafibrate capsules, 200 mg 2 times daily with the first bite of each meal
185524|NCT02548832|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
186763|NCT02569645|Drug|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
186764|NCT02569658|Drug|Tranexamic Acid|
187067|NCT02565160|Device|Prosthetic Joint|
187068|NCT02565173|Drug|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
187069|NCT02565173|Drug|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
187070|NCT02565173|Drug|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
187071|NCT02565173|Drug|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
187072|NCT02565173|Drug|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
187073|NCT02565186|Drug|lasmiditan 100 mg|oral tablet
187074|NCT02565186|Drug|lasmiditan 200 mg|oral tablet
187075|NCT00186940|Drug|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
187076|NCT02565199|Device|rTMS over Premotor Cortex (Contralateral Hemisphere)|Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator
187077|NCT02565199|Device|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator
187078|NCT02565199|Device|rTMS (Control 1)|Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 400 milliseconds after the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator
187079|NCT02565199|Device|rTMS (Control 2)|Location of rTMS: somatosensory cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator
187080|NCT02565199|Device|rTMS (Control 3)|Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil
187081|NCT02565199|Other|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
187082|NCT02565212|Drug|Montelukast,mometazon froat|
186477|NCT02540096|Other|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
186478|NCT02540109|Device|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
186479|NCT02540109|Device|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
186480|NCT02540122|Device|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
186481|NCT02540122|Device|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
186482|NCT02540122|Device|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
186483|NCT02540122|Device|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
186484|NCT02540135|Other|flourescein|
186485|NCT02540135|Other|intraoperative MRI|
186765|NCT02571673|Behavioral|Assessments|Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial.
186766|NCT02571686|Device|Surveyor S4|
186767|NCT02571699|Other|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
186768|NCT02571712|Drug|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
186769|NCT02571725|Drug|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
186770|NCT02571725|Drug|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
186771|NCT02571738|Biological|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
186772|NCT00187629|Behavioral|dietary phosphorus|varying amts dietary phosphorus
186184|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
186185|NCT02546960|Biological|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
186186|NCT02546960|Drug|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
186187|NCT00184873|Behavioral|Health Counseling|
186188|NCT02546986|Drug|CC-486|Each cycle will be 21 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
186189|NCT02546986|Drug|Pembrolizumab|Each cycle will be 21 days. Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
186190|NCT02546986|Drug|Placebo|Each cycle will be 21 days. Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
186191|NCT02546999|Drug|botox|The agent will be given only once at point zero in the time scheme for the project.
186192|NCT02546999|Drug|placebo|The agent will be given only once at point zero in the time scheme for the project.
186486|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
186487|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device for 3 consecutive days during week1 and 1 day during week 2.
186488|NCT02542553|Procedure|Bilateral BAL|
186489|NCT00184327|Behavioral|Diagnostic assessment - child and adolescent psychiatry|
186490|NCT02542566|Procedure|Physiotherapy rehabilitation|Physiotherapy rehabilitation
186491|NCT02542579|Genetic|16S rRNA pyrosequencing analysis|For H. pylori identification and genotyping, VAI-F(5'-ATGGAAATACAACAAACACAC-3') and VAI-R(5'-CTGCTTGAATGCGCCAAAC-3') will be used. For vacuolating cytotoxin A (vacA) s1/s2, VAG-F (5'-CAATCTGTCCAATCAAGCGAG-3') and VAG-R(5'-GCGTCAAAATAATTCCAAGG-3') will be used, and for cytotoxin-associated gene A (cagA), cag5c-F(5'-GTTGATAACGCTGTCGCTTC-3') and cag3c-R(5'-GGGTTGTAT GATATTTTCCATAA-3') will be used.
186492|NCT02542592|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
186493|NCT02542592|Drug|Isotonic Sodium Chloride|Placebo
186494|NCT02542605|Drug|AMG 334|AMG 334 Investigational Product
185600|NCT02555852|Drug|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
185601|NCT02555852|Drug|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
185602|NCT02555852|Drug|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
185603|NCT02557932|Drug|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
185604|NCT02557932|Drug|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
185605|NCT02557945|Drug|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
185606|NCT00186030|Behavioral|HIV Skills-based Prevention|
185607|NCT02557945|Drug|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
185608|NCT02557958|Drug|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
185609|NCT02557958|Drug|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
185610|NCT02557971|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
185611|NCT02557984|Drug|Placebo|Placebo Pill
185612|NCT02557984|Drug|Amisulpride|400 mg Amisulpride
185613|NCT02557984|Drug|Naltrexone|50 mg Naltrexone
185906|NCT00185198|Drug|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
185907|NCT02551198|Drug|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]
185908|NCT02551211|Procedure|blood drawn|blood drawn
185909|NCT02551211|Procedure|surgical resection of cancer|
185910|NCT02551224|Other|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
185022|NCT02570984|Drug|Placebo|placebo comparator arm, injection similar to active
185023|NCT02570997|Drug|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
185024|NCT00187525|Drug|Memantine|
185025|NCT02570997|Drug|Placebo|Matching placebo administered.
185026|NCT02571010|Other|Standard Medical treatment|Standard treatment with drugs and usual rehabilitation
185027|NCT02571010|Device|Vibrotactile stimulation|Rehabilitation by vibrotactile stimulation at medical center
185028|NCT02571010|Device|Sham Stimulation with Vibradol device switched off|Sham Rehabilitation at medical center but with Vibradol device switched off
185029|NCT02571023|Procedure|microscope surgery|
185030|NCT02571023|Procedure|neuroendoscope surgery|
185031|NCT02571036|Drug|DCC-2618|10 mg and 50 mg formulated tablets
185032|NCT02571049|Drug|Strength A of DFN-11|
185033|NCT02571049|Drug|Strength B of DFN-11|
185034|NCT02571062|Drug|Fexinidazole|
185035|NCT00187538|Behavioral|Dietary|dietary
185036|NCT02571075|Other|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
185037|NCT02571088|Other|Training Program|Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
185323|NCT02564419|Device|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
184473|NCT02548455|Device|Left Ventricular Lead|
184474|NCT02548468|Drug|Fludarabine|Given IV
184475|NCT02548468|Radiation|Total-Body Irradiation|Undergo TBI
184476|NCT02548468|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
184477|NCT02548468|Drug|Cyclophosphamide|Given IV
184478|NCT02548468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
184479|NCT02548468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
184480|NCT00185003|Drug|endotoxin|
184481|NCT02548468|Drug|Mycophenolate mofetil|Given IV
184482|NCT02548468|Drug|Tacrolimus|Given IV
184483|NCT02548481|Other|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
184484|NCT02548494|Drug|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
184485|NCT02548494|Drug|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
184486|NCT02548494|Other|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
184487|NCT02550483|Other|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
184771|NCT02541916|Other|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy & LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
184772|NCT02541929|Dietary Supplement|Docosahexaenoic acid|
184773|NCT02541942|Other|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
184774|NCT02541955|Drug|Acthar|Injections will be self administered
184187|NCT02554994|Other|Usual care|Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.
According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS).
184188|NCT02555007|Drug|Vinorelbine|
184189|NCT02555020|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
184190|NCT02555020|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
184191|NCT02555020|Dietary Supplement|Allocated to MN NPO group,|Patients received NPO from MN.
184192|NCT00185640|Drug|mycophenolate mofetil|15 mg/kg BID or Q 8 hours
184193|NCT02555033|Other|Resistance training|traditional resistance training
184194|NCT02555033|Other|Instability resistance training|training under unstable conditions
184195|NCT02555046|Procedure|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
184196|NCT02555059|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
184197|NCT02555072|Biological|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
184198|NCT02555085|Biological|BIIB063|Single ascending IV dose
184199|NCT02555085|Other|Placebo|Single dose
184200|NCT02555111|Drug|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
184201|NCT02555124|Drug|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
184202|NCT02555124|Drug|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
184203|NCT02557334|Dietary Supplement|High Dose Strawberry Powder|40 g freeze dried strawberry powder
184204|NCT02557334|Dietary Supplement|Placebo Powder|40 g color and taste matched placebo powder
183602|NCT02568189|Device|SonoSite Maxx Series Ultrasound System|Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
183884|NCT00186628|Drug|Cixutumumab|10 mg/kg, IV
183885|NCT02561897|Drug|Warfarin|
183886|NCT02561910|Device|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
183887|NCT02561923|Drug|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
183888|NCT02561923|Drug|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
183889|NCT02561923|Drug|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 [international units] IU/min) on Day 4.
183890|NCT02561923|Drug|Saline|Saline [Kcentra saline control or TXA saline control] on Day 4.
183891|NCT02561936|Drug|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
183892|NCT02561936|Drug|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10*2.5 mg tablets.
183893|NCT02561936|Drug|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10*2.5 mg tablets.
183894|NCT02561936|Drug|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
183895|NCT00186628|Drug|Paclitaxel|80 mg/m2, IV
183896|NCT02561936|Dietary Supplement|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter [mL]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) [189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins]).
183897|NCT02561949|Behavioral|YRI (Youth Readiness Intervention)|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
188135|NCT01991106|Behavioral|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
188136|NCT01991106|Behavioral|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
188137|NCT01991106|Dietary Supplement|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
188138|NCT01991119|Drug|Propafenone|
188139|NCT01991119|Drug|Dronedarone|
188140|NCT00118534|Behavioral|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
188141|NCT01991132|Other|MediView 2.0 software|
188142|NCT01991145|Procedure|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
188143|NCT01953133|Behavioral|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
188144|NCT01953159|Other|Blood Collection|
188145|NCT01953159|Other|Patient Questionnaires|
188146|NCT01953172|Dietary Supplement|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
188147|NCT01953172|Other|Placebo|Placebo
188148|NCT01953185|Other|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone & Russo, 2006).
183603|NCT02568202|Other|No treatment given|This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.
There will be no treatment.
183604|NCT02568215|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
183605|NCT02568215|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
183606|NCT02568228|Dietary Supplement|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
183607|NCT02568228|Other|Lean and fatty fish|The fish group will be open labeled.
183608|NCT00187135|Drug|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
187855|NCT01957852|Other|FloSeal|
187856|NCT01957865|Device|SMS reminders, real-time adherence monitoring|SMS reminders will be sent to intervention arm A and B to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
187857|NCT01957878|Biological|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
187858|NCT01957878|Biological|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
187859|NCT01957904|Device|ArterX Surgical Sealant|
187860|NCT01957917|Other|NAC (Nutritional Assessment and Counseling)|
187861|NCT01957917|Other|Cash Transfer|
187862|NCT01957917|Other|Food Assistance|
187863|NCT00115622|Drug|fluticasone furoate|
187864|NCT01957930|Other|Intensified conventional insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
187865|NCT01957930|Drug|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
187866|NCT01957943|Dietary Supplement|SMOFLipid|
187867|NCT01957943|Dietary Supplement|equilevant volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
187868|NCT01957956|Other|Laboratory Biomarker Analysis|Correlative studies
187869|NCT01960309|Other|Minimal invasive cardiac imaging|Coronary CT angiography (CCTA)
Coronary magnetic resonance imaging (CMR)
Echocardiography
187870|NCT01960322|Behavioral|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
187871|NCT01960335|Dietary Supplement|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
187271|NCT01970163|Other|Conventional Care Dressings|Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:
If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.
Hydrogels can also be used if the wound is in need of moisture.
For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.
A secondary dressing may be desired to add either loft or cushion.
187560|NCT01963091|Drug|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
187561|NCT00116168|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
187562|NCT01965210|Other|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
187563|NCT01965210|Other|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
187564|NCT00116441|Biological|Therapeutic Cellular Vaccine, GM-CSF Producing|
187565|NCT01965210|Other|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
187566|NCT01965210|Other|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
187567|NCT01965210|Other|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
187568|NCT01965223|Radiation|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
187569|NCT01965223|Radiation|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
187570|NCT01965236|Dietary Supplement|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
187571|NCT01965236|Dietary Supplement|Placebo|
187572|NCT01965249|Device|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HRT48mm
187573|NCT01965249|Device|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
187574|NCT01965262|Device|Hema-copolymer Lens|Hema-copolymer lens pair or the Etafilcon A lens pair
186961|NCT02553902|Device|Sleep position trainer|
186962|NCT02553902|Device|Mandibular advancement device|
186963|NCT02553902|Device|Continuous positive airway pressure|
186964|NCT02553915|Other|Placebo|Soybean oil placebo
186965|NCT02553915|Drug|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
187272|NCT00117013|Drug|Fluorine-19-Fluoroded Xyglucose|
187273|NCT01970176|Drug|Tadalafil|
187274|NCT01970176|Drug|Placebo|
187275|NCT01970202|Drug|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
187276|NCT01970202|Drug|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
187277|NCT01970202|Other|Control|no treatment
187278|NCT01970215|Drug|TA-8995|
187279|NCT01970215|Drug|Atorvastatin|
187280|NCT01970215|Drug|Rosuvastatin|
187281|NCT01970215|Drug|TA-8995 0mg (placebo)|
187282|NCT01970215|Drug|Placebo Statin|
187283|NCT00117013|Drug|Topotecan|
187284|NCT01970228|Other|68Ga PET/CT imaging|Single-day study of the two PET tracers
187285|NCT01970228|Other|18F-FDG PET/CT imaging|
187286|NCT01972672|Drug|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
187287|NCT01972685|Procedure|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchail vs. VATS biopsy
187288|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
187289|NCT01972685|Procedure|Transbronchial Biopsy|
187290|NCT01972685|Procedure|VATS biopsy|
186671|NCT02560753|Drug|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
186672|NCT02560766|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
186673|NCT02560766|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
186674|NCT02560766|Drug|Placebo|Placebo once daily
186675|NCT02560779|Drug|TRC105|Bi-weekly TRC105 will be given with standard-dose sorafenib.
186676|NCT02560779|Drug|Sorafenib|Bi-weekly TRC105 will be given with standard-dose sorafenib.
186966|NCT02553915|Drug|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
186967|NCT02553915|Drug|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
186968|NCT02553928|Drug|Memantine (once daily)|
186969|NCT02553928|Drug|Memantine (twice daily)|
186970|NCT02553941|Drug|Azacitidine|Given intravenous or subcutaneous
186971|NCT00185523|Procedure|Allogeneic hematopoietic cell transplantation|
186972|NCT02553941|Drug|Ibrutinib|Given by mouth once daily
186973|NCT02556268|Drug|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
186974|NCT02556268|Drug|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
186975|NCT02556268|Drug|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
186976|NCT02556268|Drug|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
186977|NCT02556268|Drug|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
186978|NCT02556281|Biological|Blood sampling|Blood sampling is done for patient with colorectal cancer
186370|NCT02564965|Device|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
186371|NCT00186901|Other|Placebo|Placebo
186372|NCT02564965|Device|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
186373|NCT02564978|Drug|Minocycline|Capsule for oral administration
186374|NCT02564978|Other|Placebo|Capsule for oral administration
186375|NCT02567071|Other|clean swab|After planned C-section birth, newborns will suck on clean swab.
186376|NCT02567084|Device|CERAMENT™ /BONE VOID FILLER|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
186377|NCT02567097|Behavioral|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
186378|NCT02567123|Behavioral|Experimental|
186379|NCT02567149|Drug|Cidofovir|Cidofovir
186380|NCT02567175|Drug|Domperidone|
186381|NCT02567188|Other|MIRCERA|
186382|NCT02567201|Other|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
186383|NCT00187096|Drug|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
186384|NCT02567201|Other|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
186385|NCT02567214|Drug|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
186677|NCT02560792|Behavioral|Positive Affect Condition|Participants read: "Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
186086|NCT02571439|Drug|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
186087|NCT00187577|Drug|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
186088|NCT02571452|Behavioral|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
186089|NCT02571452|Behavioral|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
186090|NCT02571465|Other|Passive leg raising test and fluid challenge|
186091|NCT02571478|Behavioral|Marriage Checkup|The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strateiges or resources for the couple to consider pursuing.
186092|NCT02571491|Drug|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
186093|NCT02571491|Other|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
186094|NCT00188032|Procedure|Computer-Assisted diagnostic Decision Support|
186095|NCT02573701|Behavioral|"Psychosocial treatment"|Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: "psychosocial treatment" included "psychoeducation" "social skills" "healthy life style habits" "exercise in group"
186096|NCT02573701|Drug|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
186097|NCT02573714|Drug|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
186098|NCT02573714|Drug|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
185525|NCT02548832|Drug|Placebo|Placebo capsules, 200 mg 2 times daily with the first bite of each meal
185526|NCT02548858|Procedure|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal reconstructive procedure for pelvic organ prolapse.
185527|NCT02548858|Procedure|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal reconstructive procedure for pelvic organ prolapse.
185806|NCT02542280|Procedure|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
185807|NCT02542280|Procedure|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
185808|NCT02542280|Drug|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
185809|NCT02542293|Biological|MEDI4736+Tremelimumab|
185810|NCT02542293|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
185811|NCT02542293|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
185812|NCT02542293|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
185813|NCT00184301|Behavioral|inpatient treatment|inpatient treatment during 1 year
185814|NCT02542293|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
185815|NCT02542293|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
185816|NCT02542306|Drug|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
185817|NCT02542319|Dietary Supplement|Mablet 360 mg|
185818|NCT02542319|Dietary Supplement|Placebo|
185819|NCT02542332|Other|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
185820|NCT02542345|Procedure|magnetic resonance imaging|
185821|NCT02542371|Other|Arterial Imaging|
187083|NCT02565225|Behavioral|RheumaLive App use|
187084|NCT02565238|Device|BioMonitor 2|Implantation of BioMonitor 2
187085|NCT02565251|Device|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
187086|NCT00002509|Drug|carboplatin|
187395|NCT01983241|Biological|Alpha1-proteinase inhibitor (human), modified process (Alpha-1 MP)|
187396|NCT01983241|Other|0.9% Sodium Chloride for Injection, USP|
187397|NCT01983254|Behavioral|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
187398|NCT01983254|Other|education program|web-based, ICU-specific education program
187399|NCT00118222|Drug|porfimer sodium|All patients receive porfimer sodium IV.
187400|NCT01985451|Drug|Temozolomide|Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
187401|NCT01985464|Biological|Umbilical cord mesenchymal stem cells|
187402|NCT01985477|Drug|Lenalidomide|Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.
Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.
Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.
Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment.
187403|NCT01985477|Drug|Dexamethasone|Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.
Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.
Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22.
187404|NCT01985477|Drug|All-Trans Retinoic Acid (ATRA)|Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.
Phase II Group A: ATRA starting dose: MTD from Phase I.
Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.
Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.
Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days.
187405|NCT01985490|Procedure|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
187406|NCT01985516|Other|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
187407|NCT01985516|Other|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
187408|NCT01985529|Other|Exercise|
186773|NCT02571738|Other|Control|Standard of Care
186774|NCT02571751|Device|UNIGEL Silicone Gel-Filled Breast Implant|
186775|NCT02571764|Other|Nutritional Oats Cookie|
186776|NCT02571777|Drug|QVM149|
186777|NCT02571777|Drug|QVM149|
186778|NCT02571777|Drug|QMF149|
186779|NCT02571777|Drug|QMF149|
186780|NCT02571777|Drug|salmeterol/fluticasone|
186781|NCT02571790|Behavioral|Relaxation optimized virtual reality|
186782|NCT02571790|Behavioral|Classical relaxation (without Virtual Reality)|
186783|NCT00187655|Drug|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
186784|NCT02571803|Behavioral|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
186785|NCT02571803|Other|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
186786|NCT02571816|Drug|ASP2215|oral
187087|NCT00186953|Drug|Optison|Intervention description:
Based on recommendation by the FDA, we began with a dose of 0.125ml/m^2 and escalated at 0.15 ml/m^2 increments, to 0.275 ml/m^2 and 0.425ml/m^2 and 0.500ml/m^2. We will now continue to escalate the dose of Optison at 0.300ml/m^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer.
187088|NCT02567383|Drug|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
187089|NCT02567383|Drug|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
187090|NCT00187109|Drug|Recombinant Human Thrombopoietin|
187091|NCT02567396|Other|Laboratory Biomarker Analysis|Correlative studies
187092|NCT02567396|Other|Pharmacological Study|Correlative studies
187093|NCT02567396|Drug|Talazoparib|Given PO
187094|NCT02567409|Drug|ATR Kinase Inhibitor VX-970|Given IV
186495|NCT02542605|Drug|Placebo|Placebo Comparator
186496|NCT02542605|Drug|PACAP-38 Challenge Agent|PACAP-38 challenge agent
186497|NCT02542618|Behavioral|Inquiry Based Stress Reduction (IBSR)|
186498|NCT02542618|Behavioral|Cognitive Behavioral Therapy (CBT)|
186499|NCT02542631|Device|Bolus Insulin Patch (Calibra Finesse)|
186500|NCT00184340|Device|eTherapy|secured e-mail system between patient and therapist
186501|NCT02542631|Device|Insulin Pen (Novo-Nordisk FlexPen®)|
186502|NCT02542644|Device|Ultrahigh resolution Spectral Domain OCT|The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.
A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
186503|NCT02542657|Drug|Clarithromycin|Given PO
186504|NCT02542657|Drug|Dexamethasone|Given PO
186505|NCT02542657|Drug|Ixazomib Citrate|Given PO
186506|NCT02542657|Drug|Pomalidomide|Given PO
186787|NCT02571829|Drug|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
186788|NCT02571842|Drug|Intravenous Rituximab|- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
186789|NCT02571842|Drug|ACEI/ARB and corticosteroids|ACEI or ARB will be prescribed as high as tolerable dose.
Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks
186790|NCT02573948|Other|no intervention is assessed|
186791|NCT02573961|Device|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
186792|NCT00188058|Device|Setting of positive end-expiratory pressure|
186793|NCT02573961|Behavioral|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
186794|NCT02573961|Behavioral|low caloric diet|Tailored balanced low caloric diet
185911|NCT02551237|Radiation|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
185912|NCT02551237|Drug|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
185913|NCT02551237|Radiation|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
185914|NCT02551250|Other|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
185915|NCT02553434|Device|Pigtail catheter|Insertion of pigtail catheter
185916|NCT02553447|Dietary Supplement|Cholecalciferol|Given PO
185917|NCT02553447|Other|Laboratory Biomarker Analysis|Correlative studies
185918|NCT02553460|Drug|ITMHA|Given intrathecally (IT).
185919|NCT02553460|Drug|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
185920|NCT02553460|Drug|Mitoxantrone|Given IV.
185921|NCT00185419|Drug|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
185922|NCT02553460|Drug|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
185923|NCT02553460|Drug|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
185924|NCT02553460|Drug|Bortezomib|Given IV.
185925|NCT02553460|Drug|Vorinostat|Taken PO or NG.
185926|NCT02553460|Drug|Cyclophosphamide|Given IV.
185927|NCT02553460|Drug|Mercaptopurine|Given PO or NG.
185928|NCT02553460|Drug|Methotrexate|Given IV.
185929|NCT02553460|Drug|Leucovorin Calcium|Leucovorin rescue PO or IV.
186193|NCT02547012|Drug|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
186194|NCT02547012|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
186195|NCT02547025|Drug|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
185324|NCT02564445|Behavioral|Gamification|All participants will be entered with their teammate into a game that includes points and levels
185325|NCT00002509|Biological|filgrastim|
185326|NCT00186888|Drug|Vincristine + Carboplatin + Etoposide|Stratum B patients that do not respond to window receive 6 courses of this combination.
Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
185327|NCT02564445|Behavioral|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
185328|NCT02564445|Behavioral|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
185329|NCT02564445|Behavioral|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
185330|NCT02564458|Behavioral|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
185331|NCT02564471|Drug|Chloroquine|FDA approve dosing schedule
185332|NCT02564471|Drug|Atovaquone and Proguanil|FDA approve dosing schedule
185333|NCT02564471|Drug|Doxycycline|FDA approve dosing schedule
185334|NCT02564471|Biological|Rabies Vaccine|FDA approve dosing schedule
185335|NCT02564497|Biological|Process E Belatacept|
185336|NCT02564497|Biological|Process C Belatacept|
185337|NCT02566707|Drug|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
185338|NCT02566720|Drug|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
185614|NCT02557997|Other|Blood tube bottom analyses|
185615|NCT02558010|Drug|Methadone|perioperative IV methadone to be given
184775|NCT02544126|Device|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
184776|NCT02544126|Behavioral|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
184777|NCT02544139|Other|Chagas Detect Plus|
184778|NCT02544152|Drug|Lubiprostone|8 mcg administered orally twice daily (BID)
184779|NCT02544152|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
184780|NCT02544165|Dietary Supplement|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
184781|NCT00184600|Drug|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
184782|NCT02544165|Other|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
184783|NCT02544165|Other|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
184784|NCT02544178|Radiation|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
184785|NCT02544191|Drug|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
184786|NCT02544204|Biological|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
185038|NCT02571101|Drug|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
185039|NCT02571101|Drug|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
185040|NCT02571101|Drug|Condencia|Contains chlomipramine HCl 15mg.
185041|NCT02571101|Drug|CDFR0812-Placebo|Placebo tablet of CDFR0812.
184488|NCT02550483|Other|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
184489|NCT02550496|Device|Dermoscopy|
184490|NCT02550509|Device|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
184491|NCT02550509|Device|elastography|elastography to patient with stoke
184492|NCT00185172|Other|placebo|Placebo oral tablets for 2 weeks
184493|NCT02550522|Device|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
184494|NCT02550535|Genetic|Gene-modified WT1 TCR-transduced T cells intravenous infusion|
184495|NCT02550548|Drug|GIP infusion|after establishing a hyperglycemic clamp (at 2 mM above fasting levels) GIP will be infused
184496|NCT02550548|Drug|GLP-1 infusion|after establishing a hyperglycemic clamp (at 2 mM above fasting levels) GLP-1 will be infused
184497|NCT02550548|Drug|Ex-9 infusion|after establishing a hyperglycemic clamp (at 2 mM above fasting levels) Ex-9 will be infused
184498|NCT02550561|Device|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
184499|NCT02550574|Procedure|Wound Closure with 2-octylcyanoacrylate|
184500|NCT02550574|Procedure|Wound Closure with 5-0 Vicryl Sutures|
184501|NCT02550587|Behavioral|satisfaction|anesthesia satisfaction rates
184502|NCT02550600|Procedure|iLA activve treatment|iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.
Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.
iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow).
184503|NCT00185172|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
184787|NCT02544204|Biological|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
183898|NCT02561949|Other|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
183899|NCT02561962|Drug|AMG 224|AMG 224 will be given on Day 1 once every 3 weeks with dose ranging from 30 mg to 190 mg.
183900|NCT02563938|Drug|AK001|Given parenterally.
183901|NCT00186875|Procedure|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
184205|NCT02557347|Behavioral|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
184206|NCT02557360|Dietary Supplement|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
184207|NCT02557373|Dietary Supplement|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
184208|NCT02557373|Dietary Supplement|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
184209|NCT02557386|Drug|Levobupivacaine|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
184210|NCT02557386|Drug|Levobupivacaine|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
184211|NCT02557386|Drug|Levobupivacaine|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
184212|NCT00185900|Drug|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
184213|NCT02557386|Drug|Levobupivacaine|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
184214|NCT02557386|Drug|Levobupivacaine|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
184215|NCT02557386|Drug|Levobupivacaine|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
184216|NCT02557399|Drug|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
184217|NCT02557399|Drug|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
184218|NCT02557399|Drug|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
183609|NCT02568228|Dietary Supplement|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
183610|NCT02568241|Other|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
183611|NCT02568254|Device|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
183612|NCT02568254|Device|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
183613|NCT02568254|Device|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
183614|NCT02568267|Drug|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
183615|NCT02568280|Drug|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
183616|NCT02568280|Drug|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
183617|NCT02568293|Other|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
183618|NCT02568293|Other|Saline|Saline is used as a control.
183619|NCT00187135|Drug|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
183620|NCT02568306|Drug|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose [SD] or multiple dose [MD] with daily dosing.
183621|NCT02568306|Drug|placebo|Administered subcutaneously (s.c., under the skin) single dose [SD]) or multiple dose [MD] with daily dosing.
183622|NCT02568319|Drug|LIPO-202|
183902|NCT02563938|Drug|Placebo|
183903|NCT02563951|Drug|GNS Spray 0.5mg|
183904|NCT02563951|Drug|GNS Spray 1.0mg|
183905|NCT02563951|Drug|GNS Spray 2.0mg|
183906|NCT02563951|Drug|Kytril 1mg (IV injection)|
183907|NCT02563951|Drug|Kytril 1mg (Tablet)|
188149|NCT01953185|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
188150|NCT01953198|Other|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
188151|NCT01953211|Drug|combined oral contraceptives|
188152|NCT00115063|Other|Intensive Medical Combination Therapy for Obesity|Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a "Treatment Toolbox".
188153|NCT01953224|Behavioral|Game-based intervention|Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, "Zombies, Run!" encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic "zombie chases" encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback.
188154|NCT01953224|Device|Smartphone|
188155|NCT01953237|Behavioral|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
188156|NCT01953237|Device|Smartphone|
188157|NCT01953263|Other|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
188158|NCT01953276|Device|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
188159|NCT01953302|Procedure|modified "open mesh technique"|We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
188160|NCT01953315|Biological|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
188161|NCT01953328|Drug|Atorvastatin|Administered orally once a day
188162|NCT01953328|Biological|Evolocumab|Administered by subcutaneous injection
187575|NCT00116454|Drug|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
187576|NCT01965262|Device|etafilcon A Lens|Hema-copolymer lens pair or the Etafilcon A lens pair
187577|NCT01965275|Drug|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
187578|NCT01965288|Device|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
187872|NCT01960335|Dietary Supplement|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
187873|NCT01960335|Other|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
187874|NCT01960348|Drug|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
187875|NCT00115843|Device|Mobile Cardiac Outpatient Telemetry|
187876|NCT01960348|Drug|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
187877|NCT01960361|Device|ICE dental implant|ICE- Implant Classical Esthetic implant
187878|NCT01960374|Drug|Selumetinib|1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
187879|NCT01960387|Drug|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
187880|NCT01960387|Drug|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
187881|NCT01960400|Device|tDCS|both groups will receive the GMI treatments which will be performed using software and well-established procedures (www.noigroup.com). For its part, the tDCS will be applied for 5 consecutive days during the first 2 weeks of phase 1 and once a week during the 4 other weeks. The anodic (positive) stimulation over the motor cortex (M1) contralateral of the affected limb is sought to modulate cortical excitability and promote pain inhibition and cortical reorganization.
187882|NCT01960413|Drug|Montelukast added to Hydroxyurea|
187883|NCT01960413|Drug|Placebo added to Hydroxyurea|
187884|NCT01960426|Other|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
187291|NCT01972698|Other|Self-directed and simulation-assisted training|All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).
Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.
A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.
Participant will have access to an ultrasound simulator.
Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.
An investigator will supervise the sessions but will not interfere with the self-learning process.
- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm).
187292|NCT01972698|Other|Traditional apprenticeship training|All participants will attend an half-day ultrasound introductory course.
Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).
Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer.
187579|NCT01965288|Device|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
187580|NCT01965301|Drug|BP1.5375 suspension|single oral dose
187581|NCT01965301|Drug|Diphenhydramine|single oral dose of Diphenhydramine 50mg
187582|NCT01965301|Drug|Placebo|Single oral dose
187583|NCT01967537|Drug|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
187584|NCT01967537|Procedure|Radio-guided surgery|Using 68Gallium DOTATATE
187585|NCT01967550|Drug|diclofenac diethylamine, DDEA 2.32% gel|
187586|NCT01967550|Drug|Placebo|
187587|NCT00116714|Drug|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
187588|NCT01967576|Drug|Axitinib (AG-013736)|Axitinib will be given as self-administered oral doses at the initial level of 5 mg every 12 hours continuously in a 28-day cycle. All patients will be evaluated for dose escalation beginning at week 4. In addition to the starting dose level of 5 mg every 12 hours, two additional levels (7 and 10 mg on every-12-hour schedules) will be considered. An interval of at least 4 weeks must elapse between any dose escalations.
187589|NCT01967589|Drug|NNC0113-0987|Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
187590|NCT01967589|Drug|placebo|Once-daily doses for oral administration
187591|NCT01967628|Dietary Supplement|Vitamin D3 (cholecalciferol)|
186979|NCT02556294|Behavioral|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
186980|NCT02556294|Behavioral|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
186981|NCT02556307|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
186982|NCT00185744|Radiation|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
186983|NCT02556307|Drug|Ribavirin|Ribavirin according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
186984|NCT02556320|Drug|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
186985|NCT02556320|Biological|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
187293|NCT01972711|Drug|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
187294|NCT01972711|Drug|Amisulpride|Amisulpride as a single oral dose of 400 mg
187295|NCT01972711|Drug|Placebo|single oral dose placebo
187296|NCT01972724|Drug|Pioglitazone|Pioglitazone tablets
187297|NCT01972737|Biological|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
187298|NCT01972750|Drug|Dovitinib|daily oral intake of capsule
187299|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
187300|NCT01972763|Drug|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
187301|NCT01972776|Drug|QBM076|Supplied in 25 mg and 75 mg capsules
187302|NCT01972776|Drug|Placebo|Matching placebo capsules
187303|NCT01972789|Drug|Ranibizumab|Ranibizumab solution for injection is commercially supplied in vials with each vial containing ranibizumab in the concentration of 10 mg/ml (0.5 mg/0.05 ml, corresponding to a 0.5 mg dose level). It will be prescribed and administered by the investigator or designee.
186678|NCT02560792|Behavioral|Negative Affect Condition|Participants read: "Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
186679|NCT02560792|Behavioral|Control Condition|Participants receive no information about affective response
186680|NCT02560805|Procedure|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
186681|NCT00186485|Device|MagStim|
186682|NCT02562833|Device|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
186683|NCT00186784|Procedure|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
186684|NCT02562833|Device|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
186685|NCT02562846|Other|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
186686|NCT02562859|Drug|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
186687|NCT02562859|Drug|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
186688|NCT02562872|Drug|DSM265|DSM265 400 mg single oral dose
186689|NCT02562872|Drug|Placebo|Placebo to match DSM265, single oral dose
186690|NCT02562872|Biological|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
186691|NCT02562872|Biological|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
186692|NCT02562885|Device|Acoustic pulses|Acoustic pulses applied during NREM sleep slow waves "Up-phase" or "Down-phase". The acoustic stimulus will be delivered by speakers with a volume of about 50 dB.
186099|NCT02573714|Other|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
186386|NCT02567214|Drug|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
186387|NCT02567227|Other|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
186388|NCT02567227|Other|Active Control|Computer, multimedia and group based health education programs.
186389|NCT02567240|Other|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
186390|NCT02567253|Procedure|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
186391|NCT02567253|Drug|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
186392|NCT02567253|Drug|IPEC with Cisplatin (120mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (120mg/m²), during 90min
186393|NCT02567253|Drug|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
186394|NCT00187096|Procedure|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
186395|NCT02567253|Drug|HIPEC with Cisplatin (120mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (120mg/m²), during 90min
186396|NCT02569307|Drug|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
186397|NCT02569307|Drug|Placebo|Placebo added to TAU
186398|NCT02569307|Drug|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
186399|NCT02569320|Drug|Dexamethasone|Given PO
186400|NCT02569320|Drug|HDAC Inhibitor AR-42|Given PO
186401|NCT02569320|Other|Laboratory Biomarker Analysis|Correlative studies
186402|NCT02569320|Drug|Pomalidomide|Given PO
186403|NCT00187265|Device|Cardiac Resynchronization Therapy|
185822|NCT02542384|Drug|CR845 IV 1 mcg/kg|CR845 IV 1 mcg/kg will be administered as an IV bolus one hour prior to anesthetic induction for surgery, again within 30 minutes of the patient being considered stable in the post operative recovery room, then 2 hours following that Baseline dose. Subsequent dosing will be administered at 6, 12 and 18 hours after the Baseline dose.
Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.
185823|NCT02542384|Drug|CR845 IV 2 mcg/kg|CR845 IV 2 mcg/kg will be administered as an IV bolus one hour prior to anesthetic induction for surgery, again within 30 minutes of the patient being considered stable in the post operative recovery room, then 2 hours following that Baseline dose. Subsequent dosing will be administered at 6, 12 and 18 hours after the Baseline dose.
Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.
Saline infusion (IV 0.45%) for fluid replenishment will be provided.
185824|NCT00184301|Behavioral|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
185825|NCT02544516|Other|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
186100|NCT02573714|Other|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
186101|NCT02573714|Other|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
186102|NCT02573727|Drug|Nor adrenaline + albumin|
186103|NCT02573727|Drug|Terlipressin + albumin|
186104|NCT02573740|Drug|ABT-957|
186105|NCT00188032|Procedure|written diagnostic guidelines|
186106|NCT02573740|Other|Placebo|
186107|NCT02573753|Behavioral|Sleep restriction|
186108|NCT02573766|Procedure|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
186109|NCT02573766|Procedure|Electroencephalogram|Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.
Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
186110|NCT02573766|Behavioral|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
186111|NCT02573766|Behavioral|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
187409|NCT01985542|Drug|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
187410|NCT00118222|Procedure|adjuvant therapy|All patients receive porfimer sodium IV.
187411|NCT01985555|Drug|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
187412|NCT01985568|Behavioral|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
187689|NCT01980498|Drug|Physician choice-Usual care (PC-UC)|The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.
If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice.
187690|NCT00117884|Drug|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
187691|NCT01980524|Drug|acipimox|
187692|NCT01980537|Procedure|Magnetic wire navigation|
187693|NCT01980537|Procedure|Conventional wire navigation|
187694|NCT01980550|Drug|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
187695|NCT01980563|Procedure|ultrasound|
187696|NCT01980563|Procedure|combined monitoring|
187697|NCT01980589|Drug|Carfilzomib|Carfilzomib will be administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16. On Days 1 and 2 of Cycle 1, all subjects will receive carfilzomib at 20 mg/m2.
187698|NCT01980589|Drug|Cyclophosphamide|Cyclophosphamide will be administered orally (PO) at the dose of 300 mg/m2 on Days 1, 8, and 15.
187699|NCT01980589|Drug|Dexamethasone|Dexamethasone will be administered PO or IV at 40 mg on Days 1, 8, 15, and 22.
187700|NCT01980602|Procedure|Supervised Exercise program|
187701|NCT00117897|Drug|pegfilgrastim|
187095|NCT02567409|Drug|Cisplatin|Given IV
187096|NCT02567409|Drug|Gemcitabine Hydrochloride|Given IV
187097|NCT02567409|Other|Laboratory Biomarker Analysis|Correlative studies
187098|NCT02567422|Drug|ATR Kinase Inhibitor VX-970|Given IV
187099|NCT02567422|Drug|Cisplatin|Given IV
187100|NCT02567422|Other|Laboratory Biomarker Analysis|Correlative studies
187101|NCT00002509|Drug|mesna|
187102|NCT00187122|Drug|Vincristine|See Detailed Description section for description of treatment plan.
187103|NCT02567422|Radiation|Radiation Therapy|Undergo radiation therapy
187104|NCT02567435|Drug|Cyclophosphamide|Given IV
187105|NCT02567435|Biological|Dactinomycin|Given IV
187106|NCT02567435|Drug|Irinotecan Hydrochloride|Given IV
187107|NCT02567435|Other|Laboratory Biomarker Analysis|Correlative studies
187108|NCT02567435|Other|Quality-of-Life Assessment|Ancillary studies
187109|NCT02567435|Other|Questionnaire Administration|Ancillary studies
187110|NCT02567435|Radiation|Radiation Therapy|Undergo RT
187111|NCT02567435|Drug|Temsirolimus|Given IV
187112|NCT02567435|Drug|Vincristine Sulfate|Given IV
187413|NCT01985568|Behavioral|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
187414|NCT01985581|Drug|Guanfacine extended release|
187415|NCT01985581|Drug|Placebo|
187416|NCT01985594|Drug|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
186795|NCT02573974|Other|Samples|Blood samples, muscle biopsy and sample of hair
186796|NCT02573987|Drug|Equimolar Mix of Oxygen and Nitrogen Monoxide|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
186797|NCT02573987|Drug|Lidocaïn|standart strategy by local injection anesthesy
186798|NCT02574000|Other|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
186799|NCT02574000|Other|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
186800|NCT02574013|Device|Endoractor®|Endoscopic sponge for retraction of small intestine
186801|NCT02574026|Behavioral|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
186802|NCT02574039|Dietary Supplement|Oat bran|66g oat bran made up in 350ml skimmed milk
186803|NCT00188071|Drug|paracetamol|
186804|NCT02574039|Dietary Supplement|refined grain|refined grain product and 350ml skimmed milk
186805|NCT02574052|Behavioral|participants' food choices|just recorded the participants' food choices in the school cafeteria
186806|NCT02574052|Behavioral|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
186807|NCT02574052|Behavioral|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
186808|NCT02574065|Drug|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
187113|NCT00187122|Procedure|Radiation Therapy|See Detailed Description section for description of treatment plan.
187114|NCT02567448|Other|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
187115|NCT02567461|Drug|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
187116|NCT02567461|Drug|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
186196|NCT02547025|Drug|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
186197|NCT02547025|Drug|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
186198|NCT00184886|Drug|Methotrexate 15 mg/week for 12 weeks|
186199|NCT02547038|Drug|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
186200|NCT00185055|Drug|Valsartan|
186201|NCT02549040|Drug|MK-1439 film coated tablet|A single MK-1439 film coated tablet, administered orally at the start of Period 2
186202|NCT02549040|Drug|MK-1439 NF|A single MK-1439 NF, administered orally at the start of Periods 1, 3, 4, and 5.
186203|NCT02549053|Procedure|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
186204|NCT02549053|Procedure|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
186205|NCT02549066|Procedure|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 5 minutes of steady conditions at each level, measurements will be made.
186206|NCT02549079|Other|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
186207|NCT02549092|Drug|ABT-SLV187|Dose levels will be individually optimized.
186208|NCT02549105|Drug|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
186209|NCT02549105|Drug|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
186210|NCT02549118|Drug|Tenoxicam|
186211|NCT00185068|Drug|Olmesartan medoxomil|
186212|NCT02549118|Drug|Pethidine|
186213|NCT02549131|Procedure|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
186507|NCT02542670|Genetic|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
186508|NCT02542683|Other|structured physical activity program|a structured modest physical activity program
185616|NCT02558010|Other|Normal Saline|control arm
185617|NCT00186043|Drug|Quetiapine/Seroquel|Quetiapine/Seroquel
185618|NCT02558010|Drug|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia pump.
185619|NCT02558023|Drug|Urapidil|Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.
The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.
Maximum dose of 30 mg.h-1.
185620|NCT02558023|Drug|Nicardipine|Nicardipine : IV
1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.
Maximum dose of 6 mg.h-1
185621|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
185622|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
185623|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
185624|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
185625|NCT02558049|Other|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
185626|NCT02560233|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
185627|NCT02560259|Other|Physiotherapy|Physiotherapy
185628|NCT02560259|Other|Conservative treatment|Conservative treatment
185629|NCT02560272|Biological|Minhai-HIB|0.5ml, intramuscular
185630|NCT02560272|Biological|Act-HIB®|0.5ml, intramuscular
185631|NCT02560298|Drug|Capecitabine|
185632|NCT02560298|Drug|Carboplatin|Given IV
185633|NCT02560298|Drug|Cisplatin|Given IV
185634|NCT02560298|Drug|Fluorouracil|Given IV
185635|NCT00002507|Radiation|brachytherapy|
185042|NCT02573233|Drug|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
185043|NCT02573246|Behavioral|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
185044|NCT02573246|Device|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
185045|NCT02573246|Device|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
185046|NCT02573259|Drug|PF-06801591|IV every 21 days
185047|NCT02573272|Drug|eslicarbacepine|
185048|NCT02573285|Procedure|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
185049|NCT02573285|Procedure|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
185050|NCT02573298|Device|ice|local ice application for 30 minutes
185051|NCT02573298|Device|cold gas|local cold gas application for 2 minutes
185052|NCT00187941|Drug|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
185053|NCT02573311|Drug|tamsulosin hydrochloride|
185054|NCT02573324|Drug|ABT-414|intravenous infusion
185055|NCT02573324|Radiation|Radiation|
185056|NCT02573324|Drug|Temozolomide|oral
185057|NCT02573324|Drug|Placebo for ABT-414|intravenous infusion
185058|NCT02573337|Device|Emervel Classic Lidocaine|Treatment of wrinkles and folds
185059|NCT02573337|Device|Emervel Deep Lidocaine|Treatment of wrinkles and folds
185060|NCT02573350|Drug|Delamanid|Delamanid was administered orally as 50-mg tablets.
185339|NCT02566720|Procedure|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
184788|NCT02544217|Drug|KH176|
184789|NCT02544217|Drug|placebo|
184790|NCT02544243|Drug|Vinorelbine|
184791|NCT02544243|Drug|Gemcitabine|
184792|NCT00184600|Drug|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
184793|NCT02544243|Drug|Cisplatin|
184794|NCT02544256|Procedure|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
184795|NCT02544269|Procedure|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
184796|NCT02546440|Drug|dimethylfumarate|dose escalation from 30 mg/d to 720 mg/d over 9 weeks following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until unacceptable side effects occur
184797|NCT02546453|Biological|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
184798|NCT02546453|Biological|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
184799|NCT02546466|Procedure|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
184800|NCT02546466|Procedure|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
184801|NCT02546466|Behavioral|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
184802|NCT00184821|Drug|adenosine|
184219|NCT02557412|Device|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
184220|NCT02557412|Behavioral|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
184221|NCT02557412|Other|Conventional treatment|Hygiene and diet recommendations on sleep
184222|NCT02557425|Other|No intervention in PROTECT|
184223|NCT00002506|Biological|recombinant interferon alfa|
184224|NCT00185939|Drug|Augmentin|
184504|NCT02550600|Procedure|Control group|The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.
There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group.
184505|NCT02552758|Biological|omega-3 fatty acid|omega-3 fatty acid
184506|NCT00185354|Drug|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
184507|NCT02552758|Biological|placebo|placebo
184508|NCT02552758|Device|positron emission tomography (PET)|
184509|NCT02552771|Procedure|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
184510|NCT02552771|Procedure|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
184511|NCT02552784|Behavioral|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
184512|NCT02552797|Behavioral|Shared Decision Making tool|
184513|NCT02552810|Procedure|Dental implant placement|Using a surgical stent, patients received one implant in the anterior or premolar region of the maxilla.
184514|NCT02552810|Procedure|Second stage surgery|After 3 months of healing, a minimally invasive flap for the second surgery procedure was performed.
183908|NCT02563977|Device|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
183909|NCT02563990|Procedure|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
183910|NCT02563990|Procedure|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
183911|NCT02563990|Drug|High Pressure Injection|Ropivacaine 0.2% injection at greater than 20 psi injection pressure
183912|NCT00186875|Procedure|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
183913|NCT02563990|Drug|Low Pressure Injection|Ropivacaine 0.2% injection at less than 15 psi injection pressure
183914|NCT02564003|Drug|Oxycodone|oxycodone 0,1 mg/kg iv
183915|NCT02564016|Drug|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
183916|NCT02564016|Other|Capped Epidural|epidural will be capped with no saline infusion.
183917|NCT02564029|Drug|PF-06372865|Single dose
183918|NCT02564029|Drug|Placebo|Placebo for PF-06372865 and placebo for lorazepam
183919|NCT02564029|Drug|Lorazepam|2 mg single oral dose
183920|NCT02564042|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
183921|NCT02564042|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
183922|NCT02564042|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
183923|NCT00186888|Procedure|Enucleation|Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.
For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye.
183924|NCT02564055|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
184225|NCT02557438|Procedure|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
184226|NCT02557438|Procedure|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
188163|NCT01955291|Other|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
183623|NCT02568319|Drug|Placebo|
183624|NCT02570451|Other|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
183625|NCT00187434|Device|Infant Flow System|
183626|NCT02570451|Other|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
183627|NCT02570451|Other|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
183628|NCT02570451|Other|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
183629|NCT02570451|Other|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
183630|NCT02570451|Other|Grip Strength|Measured using the JAMAR dynamometer
183631|NCT02570464|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
183632|NCT02570464|Biological|Blood drawn|Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
183633|NCT02570477|Procedure|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
183634|NCT02570477|Drug|Vancomycin|125mg Vancomycin four times per day
183635|NCT02570490|Drug|sodium fusidate|
183636|NCT00187434|Device|Bubble CPAP|
183637|NCT02570490|Drug|linezolid|
183638|NCT02570503|Drug|Ropivacaine|Ropivacaine (5mg/ml)-50ml
183639|NCT02570503|Drug|Ketorolac|ketorolac (30mg/ml)- 1 ml
183640|NCT02570503|Drug|Clonidine|clonidine (0.1mg/ml)- 0.8ml
187885|NCT01960426|Other|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
187886|NCT00115856|Procedure|Intravascular MRI|Arterial imaging of atherosclerosis
187887|NCT01960452|Behavioral|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
187888|NCT01960465|Device|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
187889|NCT01960478|Biological|(for each intervention)|
187890|NCT01960478|Other|Blood test|
188164|NCT01955304|Drug|fruquintinib|Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
188165|NCT01955317|Behavioral|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
188166|NCT01955317|Behavioral|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
188167|NCT01955330|Procedure|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
188168|NCT01955356|Procedure|Scratching|Endometrial biopsy
188169|NCT01955382|Drug|Actidose Aqua|Actidose Aqua (oAC)(Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
188170|NCT00115349|Drug|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
188171|NCT01955382|Drug|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
188172|NCT01955382|Drug|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer s directions.
187592|NCT01967628|Dietary Supplement|Placebo Sugar Pill|
187593|NCT01967641|Drug|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
187594|NCT01967654|Other|Technical Assistance, training and clinical reminders|
187595|NCT01967654|Other|Referral to Community Health Worker|
187596|NCT01967667|Dietary Supplement|Liposomal glutathione|Escalating dose steps
187597|NCT01967667|Dietary Supplement|Placebo|escalating dose steps
187598|NCT00116727|Drug|ENBREL®|50 mg/wk SC
187891|NCT01963104|Procedure|Automated hearing test|Subjects will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187892|NCT01963104|Procedure|Pure-tone Screener test|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187893|NCT01963104|Procedure|Digits-in-noise test|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187894|NCT01963104|Procedure|No screening test|This group of subjects will not receive a screening test. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187895|NCT01963104|Procedure|Automated hearing test/Motivation video|Subjects will take an automated hearing test that presents tones at different pitches and volumes.Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187304|NCT01972828|Drug|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
187305|NCT01972828|Drug|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
187306|NCT01974973|Procedure|Autologous bone marrow mononuclear cell transplantation in patients with autism|
187307|NCT01974986|Other|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
187308|NCT01974986|Other|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
187309|NCT01974986|Other|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
187310|NCT01975012|Drug|Rilpivirine|For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules [2.5 mg/g]) each day with a meal.
For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.
For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available.
187311|NCT01975025|Procedure|Short daily dialysis for 2 weeks|
187312|NCT01975051|Drug|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
187599|NCT01967680|Procedure|Non-sedation for intubated, mechanically ventilated patients|
187600|NCT01967680|Procedure|Controlgroup, sedation with daily wake-up trial|
187601|NCT01967693|Procedure|Retrospective analysis of data|Retrospective data analysis
187602|NCT01967706|Other|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
187603|NCT01967706|Other|mCC|Single use of subject's own menthol conventional cigarette (mCC)
187604|NCT01967706|Other|NRT|Single administration of 2 mg gum (Nicorette ® 2mg)
187605|NCT01967719|Other|THS 2.2|Single use of THS 2.2 Menthol
187606|NCT01967719|Other|mCC|Single use of subject's own mCC
187607|NCT01970241|Drug|NPH|NPH given per study table based on steroid dose and patient weight in kg.
186986|NCT02556333|Drug|Emtricitabine 200mg/tenofovir alafenamide 25 mg (F/TAF)|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
186987|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
186988|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
186989|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
186990|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
186991|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
186992|NCT02556372|Drug|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation
186993|NCT02558582|Behavioral|respiratory and exercise therapy with supplemental oxygen|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights.
186994|NCT02558595|Dietary Supplement|Niacinamide|
186995|NCT02558595|Other|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
186996|NCT02558608|Procedure|DIPL|dissection of the inferior pulmonary ligament
186997|NCT02558608|Procedure|WR|wedge resection of the lung bleb
186998|NCT00186121|Drug|Anastrozole (Arimidex)|
186999|NCT02558608|Procedure|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
187000|NCT02558621|Device|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
187001|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation ON|
187002|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation OFF|
187003|NCT02558647|Behavioral|CBT for insomnia SHUTi|
187004|NCT02558647|Behavioral|passive patient education/sleep hygiene|
186404|NCT02569333|Other|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
186405|NCT02569346|Drug|Triumeq|Single-dose Triumeq as a whole tablet
186406|NCT02569346|Drug|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
186693|NCT02562898|Drug|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
186694|NCT00186797|Procedure|Allogeneic stem cell transplant|
186695|NCT02562898|Drug|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
186696|NCT02562898|Drug|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
186697|NCT02562911|Procedure|Data collection|Clinical examination
Complete pelvic ultrasound abdominal ultrasound
Bone age: X-ray
biological examination
Lung function assessed by the Maximum Volume Expired
Brasfield radiological score (if available)
186698|NCT02562924|Device|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
186699|NCT02562924|Drug|Budesonide|Topical steroid
186700|NCT02562924|Drug|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
186701|NCT02562924|Drug|Prednisone|Post-operatively, 40 mg daily for 7 days
186702|NCT02562924|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
186703|NCT02562924|Drug|nasal saline spray|saline nasal mist every hour while awake
186704|NCT02562937|Behavioral|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
186705|NCT00186797|Drug|Fludarabine, Cyclophosphamide|
186706|NCT02565017|Behavioral|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 13-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
186707|NCT02565056|Other|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
186708|NCT02565069|Device|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
186112|NCT02573779|Other|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
186113|NCT02573805|Device|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
186114|NCT02539914|Other|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
186115|NCT02539940|Device|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
186116|NCT02539953|Device|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
186117|NCT02539966|Device|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
186118|NCT02539979|Drug|Paracetamol|
186119|NCT02539992|Device|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
186120|NCT02539992|Device|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
186407|NCT02569346|Drug|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
186408|NCT02569359|Dietary Supplement|shea nut oil extract|
186409|NCT02569359|Other|Placebo|
186410|NCT02569372|Biological|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
186411|NCT02569385|Other|Spontaneous breathing trial|
186412|NCT02569398|Drug|JNJ-54861911, 5 mg|Two JNJ-54861911, 5 milligram (mg) tablets orally once daily up to 54 months.
186413|NCT02569398|Drug|JNJ-54861911, 25 mg|One JNJ-54861911, 25 mg tablet and one matching placebo tablet orally once daily up to 54 months.
186414|NCT00187278|Device|Biventricular Pacing|Biventricular Pacemaker implant
186415|NCT02569398|Drug|Placebo|Two matching placebo tablets orally once daily up to 54 months
186416|NCT02569411|Other|Financial Incentive|money
186417|NCT02569424|Behavioral|Patient's position|Supine or Trendelenburg strict -20°)
186418|NCT02569437|Drug|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
187702|NCT01980615|Drug|Inhaled BGF (PT010) Dose 1|
187703|NCT01980615|Drug|Inhaled BGF (PT010) Dose 2|
187704|NCT01980615|Drug|Inhaled BGF (PT010) Dose 3|
187705|NCT01980615|Drug|Inhaled GFF (PT003)|
187706|NCT01980615|Drug|Inhaled Symbicort Dose 1|
187707|NCT01980615|Drug|Inhaled Symbicort Dose 2|
187708|NCT00118053|Procedure|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
187709|NCT01983267|Drug|cannabis|use of cannabis oil or cigarets
187710|NCT01983280|Other|Healing Touch|
187994|NCT01975259|Drug|Hyperglycemic clamp with placebo infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).
After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving.
187995|NCT01975259|Other|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
187996|NCT01975259|Other|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
187997|NCT01975259|Other|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
187998|NCT01975259|Device|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid & every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
187999|NCT01975272|Drug|Ferinject|
188000|NCT00117572|Drug|docetaxel|75 mg/m2 on day 1
188001|NCT01975272|Drug|Ferrous fumarate|
188002|NCT01975272|Drug|Placebo for ferrous fumarate|
188003|NCT01975272|Drug|Placebo for ferinject|
187417|NCT01985594|Drug|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
187418|NCT00118352|Biological|alemtuzumab|Given IV
187419|NCT01988103|Drug|Apremilast|30 mg tablet twice a day for 68 weeks
187420|NCT01988103|Drug|Placebo|Placebo tablet twice a day for 16 weeks
187421|NCT01988116|Drug|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
187422|NCT01988116|Drug|Placebo|
187423|NCT01988129|Other|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
187424|NCT01988142|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
187425|NCT01988155|Other|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
187426|NCT01988155|Other|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
187711|NCT01983293|Other|QLV based implant strategy|
187712|NCT01983293|Other|Standard of care implant strategy|
187713|NCT01983306|Drug|SP-333 1 mg|Tablet
187714|NCT01983306|Drug|SP-333 3 mg|Tablet
187715|NCT01983306|Drug|SP-333 6 mg|Tablet
187117|NCT02569658|Drug|Placebo|
187118|NCT02569671|Device|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
187119|NCT00187304|Device|Aortic valve replacement|
187120|NCT02569671|Device|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
187121|NCT02569684|Dietary Supplement|Prebiotic fibers: oligofructose and inulin|
187122|NCT02569684|Dietary Supplement|Maltodextrin|
187123|NCT02569697|Other|HEC Placebo gel|
187124|NCT02569697|Other|Placebo Intravaginal Ring|
187125|NCT02569697|Other|Placebo Vaginal Film|
187126|NCT02569697|Other|Placebo Vaginal Insert|
187127|NCT02569710|Drug|AL-335|
187128|NCT02569710|Drug|ACH-3102|
187129|NCT02569710|Drug|Simeprevir|
187130|NCT00187317|Behavioral|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
187131|NCT02569723|Drug|Carbon C 14 Oxaliplatin|Intravenous infusion
187132|NCT02569723|Drug|Oxaliplatin|Intravenous infusion
187133|NCT02569749|Other|Berlin and Epworth questionaries|
187134|NCT02569749|Other|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
187135|NCT02569749|Other|Night polygraph / Polysomnography|
187136|NCT02569762|Other|Sucralose-Aspartame|Sucralose or aspartame
187427|NCT01988168|Procedure|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
187428|NCT01988168|Procedure|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
186509|NCT02542696|Drug|APL-130277|Used to treat up to 5 "OFF" episodes per day
186510|NCT02542709|Device|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
186511|NCT00184366|Drug|efalizumab|efalizumab
186512|NCT02544841|Behavioral|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
186513|NCT00184652|Drug|somatropin|
186514|NCT02544841|Behavioral|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
186515|NCT02544854|Drug|Propofol|Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:
First 15 minutes: 15 mg/kg/min
16 to 30 minutes: 13 mg/kg/min
31 to 60 minutes: 11 mg/kg/min
61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.
Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:
5, 15 and 25 minutes of starting infusion,
1, 3, 5, 7, 9 and 12 minutes of bolus and,
5, 25, 60 and 120 minutes of infusion ended.
186516|NCT02544867|Behavioral|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
186517|NCT02544880|Drug|Tadalafil|Tadalafil or placebo will be administered once daily orally (po) for 19 days in conjunction with the first vaccination course (pre-surgery). Thereafter, Tadalafil or placebo will be administered for 14 days in conjunction with each subsequent vaccination course (Courses 2, 3 and 4), except for the last vaccination at which no Tadalafil will be administered (Course 5).
The dose range of Tadalafil will be normalized to the patient's body weight, as follows:
Weight (lb) --> Daily oral dose of Tadalafil (mg)
≤ 140 lbs --> 10 mg
>140 lbs and ≤ 230 lbs --> 15 mg
>230 lbs --> 20 mg
186518|NCT02544880|Biological|Anti-MUC1 Vaccine|The Anti-MUC1 vaccine or placebo will be administered on Day 7 of Course 1, Day 10 of Courses 2, 3 and 4, and on Day 1 (of 1) of Course 5 (5-7 months after Course 4, day 10 and 11-13 months after Surgery).
The anti-MUC1 vaccine will be administered intramuscularly (IM) in the right upper limb of each patient.
186519|NCT02544880|Biological|Anti-Influenza Vaccine|The Anti-Influenza vaccine (Flublok®) or placebo will be administered on Day 7 of Course 1, Day 10 of Courses 2, 3 and 4, and Day 1 (of 1) of Course 5 (5-7 months after Course 4, day 10 and 11-13 months after Surgery).
The anti-influenza vaccine will be administered intramuscularly (IM) in the left upper limb of each patient.
186520|NCT02544880|Other|Tadalafil Placebo|Placebo for Tadalafil.
186521|NCT02544880|Other|Vaccine Placebo|Placebo for Anti-MUC1 and Anti-Influenza vaccines.
185930|NCT02553460|Drug|Cytarabine|Given IV.
185931|NCT02553460|Drug|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
185932|NCT00185419|Drug|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
185933|NCT02553460|Drug|Vincristine|Given IV.
185934|NCT02553473|Drug|Doxycycline|
185935|NCT02553473|Drug|Placebo|
185936|NCT02553486|Other|quality of life evaluation|
185937|NCT02553499|Biological|MK-1248|
185938|NCT02553499|Biological|pembrolizumab|
185939|NCT02553512|Other|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
185940|NCT02553525|Procedure|Tremor Neurostimulator|Neurostimulation will be delivered for approximately 1 min. Postural tremor will be measured after stimulation is turned on. There will be approximately 1 min of stimulation off between trials. Pre-trial baseline tremor measurement will be recorded prior to each of the stimulation cycles. Local field potentials (LFPs) will be recorded throughout both on and off periods between two (non-stimulated) contacts on the implanted brain lead used for stimulation. Postural tremor will be measured using an accelerometer taped to the back of the hand with the wrist extended, and quantified by calculating the total signal power between 2-20Hz of the power spectrum of the time series of tremor. Tremor amplitude recorded by accelerometry correlates well with clinical tremor rating scales.
185941|NCT02555852|Drug|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
185942|NCT02555852|Drug|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
185943|NCT00185705|Drug|Telmisartan|
185944|NCT02555852|Drug|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
185945|NCT02555852|Drug|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
185946|NCT02555852|Drug|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
185947|NCT02555852|Drug|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
185948|NCT02555852|Drug|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
185340|NCT02566733|Drug|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
185341|NCT02566733|Drug|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
185342|NCT02566746|Device|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
185343|NCT02566746|Drug|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde
185344|NCT02566759|Drug|TAK-831|TAK-831 oral suspension.
185345|NCT00187083|Drug|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
185346|NCT02566759|Drug|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
185347|NCT02566772|Drug|TAS3681|TAS3681 will be provided as 25 mg and 100 mg tablets to be administered QD orally for 28 days, at least 1 hour before or 2 hours after a meal. Number of cycles: approximately 6 or until discontinuation criteria is met.
185348|NCT02566785|Other|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
185349|NCT02566798|Drug|Extract of grape and olive|Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.
Blood samples and synovial fluid are performed on D0 and D7
185350|NCT02566798|Drug|Lactose|Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.
Blood samples and synovial fluid are performed on D0 and D7
185351|NCT02566811|Procedure|Abdominal surgery|
185352|NCT02566811|Procedure|Lymphadenectomy|
185353|NCT02566824|Behavioral|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 14 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 14 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
185354|NCT02566824|Behavioral|Supportive Group Therapy|This will be administered in groups of 10 participants in 14 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
184803|NCT02546492|Drug|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
185061|NCT02573363|Drug|Cytarabine|Given per standard of care
185062|NCT02573363|Drug|Mitoxantrone Hydrochloride|Given per standard of care
185063|NCT00187967|Device|pumps used for cardiopulmonary bypass|
185064|NCT02573363|Drug|Selinexor|Given PO
185065|NCT02573376|Behavioral|Directly Observed Therapy|
185066|NCT02573376|Behavioral|Wirelessly Observed Therapy|
185067|NCT02573389|Device|Boston Scientific or Cook pancreatic duct stents|Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
185068|NCT02539446|Behavioral|stable condition|
185069|NCT02539446|Behavioral|unstable condition|
185070|NCT02539446|Behavioral|attentional focus|
185071|NCT00183924|Drug|Carboplatin|
185072|NCT02539459|Drug|Everolimus|10 mg tablets
185073|NCT02539472|Other|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
185074|NCT02539485|Other|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
185075|NCT02539498|Device|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
185076|NCT02539511|Drug|CI-581a|
185077|NCT02539511|Drug|CI-581b|
185078|NCT02539511|Behavioral|Motivational Enhancement Therapy (MET)|
185079|NCT02539524|Other|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
185080|NCT02539524|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
184515|NCT02552810|Procedure|Abutment connection|Abutments were randomly allocated to control (subjected only to the usually adopted steam cleaning) and test groups (subjected to plasma of argon cleaning).
184516|NCT02552810|Device|Steam cleaning|Control group abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 MPa.
184517|NCT00185354|Drug|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
184518|NCT02552810|Device|Plasma of Argon|Test group abutments underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
184519|NCT02552823|Other|Group1|
184520|NCT02552823|Other|Group2|
184521|NCT02552836|Behavioral|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
184522|NCT02552836|Behavioral|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
184804|NCT02546505|Other|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
184805|NCT02546505|Other|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
184806|NCT02546518|Device|Moniri Otovent|Please see Arm Description.
184807|NCT02546518|Device|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
184808|NCT02546531|Biological|Defactinib|
184809|NCT02546531|Biological|Pembrolizumab|
184810|NCT02546531|Drug|Gemcitabine|
184811|NCT02546544|Drug|Linsitinib|
184812|NCT02546557|Procedure|Coronary Artery Bypass Graft surgery|
184813|NCT00002499|Drug|prednisone|
184814|NCT00184834|Behavioral|quality of life|
184815|NCT02546570|Drug|Oxytocin|See arm/group descriptions for dosage amount and procedure.
184816|NCT02546570|Drug|Placebo|See arm/group descriptions for dosage amount and procedure.
184227|NCT02559674|Biological|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
184228|NCT02559687|Biological|pembrolizumab|
184229|NCT02559700|Behavioral|Brain training programme|An online package of brain training programmes
184230|NCT02559713|Drug|Vedolizumab|Vedolizumab intravenous infusion
184231|NCT02559726|Procedure|Echocardiography (TEE)|
184232|NCT02559726|Procedure|Magnetic resonance imaging (MRI) with gadolinium enhancement|
184233|NCT00186290|Procedure|ablative allogeneic hematopoietic cell transplantation|
184234|NCT02559726|Procedure|Magnetic resonance imaging (MRI) without gadolinium enhancement|
184235|NCT02559726|Procedure|3D electrocardiographic mapping (ECM)|
184236|NCT02559752|Other|NIH Toolbox Cognitive Battery|For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.
For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning.
184237|NCT02559752|Device|Proton Beam Radiation Therapy|
184238|NCT02559778|Drug|bortezomib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
184239|NCT02559778|Drug|crizotinib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
184240|NCT02559778|Drug|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
184241|NCT02559778|Drug|lapatinib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
184242|NCT02559778|Drug|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
184523|NCT02552849|Other|No intervention|
183641|NCT02570503|Drug|Epinephrine|epinephrine (1mg/ml)-1ml
183642|NCT02570503|Drug|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
183643|NCT02570516|Procedure|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
183644|NCT02570529|Drug|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
183925|NCT02564055|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
183926|NCT02564055|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
183927|NCT02566122|Other|measurements|
183928|NCT02566135|Device|Tracheal Intubation|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
183929|NCT02566135|Device|Tracheal Intubation|Following general anaesthesia C-LMA was inserted. Aftre proper placement ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
183930|NCT02566187|Drug|Fimasartan/Atorvastatin Combination Tablet|
183931|NCT02566187|Drug|Fimasartan|
183932|NCT00187057|Drug|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
183933|NCT02566187|Drug|Atorvastatin|
183934|NCT02566213|Other|Parabolic flight|
183935|NCT02566213|Other|Motor skills measurements|the kinematics measurements of the right hand with a motion analysis system;
the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;
the measurement of position of the moved object with an inductive position encoder.
183936|NCT02566226|Drug|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
183937|NCT02566226|Drug|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
188173|NCT01955395|Behavioral|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
188174|NCT01955408|Other|Questionnaires, anticholinergic treatment, urodynamic study|
188175|NCT01955421|Drug|Erlotinib 100mg qd|
188176|NCT01955421|Drug|Gefitinib 250mg qd|
188177|NCT01955434|Drug|Cyclophosphamide|Given PO
188178|NCT01955434|Other|Laboratory Biomarker Analysis|Correlative studies
188179|NCT01955434|Other|Pharmacological Study|Correlative studies
188180|NCT01957956|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
183645|NCT02570529|Drug|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
183646|NCT02570542|Procedure|leukapheresis|
183647|NCT00187447|Drug|indomethacin (two different dosing regimens)|
183648|NCT02570542|Drug|Plerixafor|
183649|NCT02570542|Drug|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1
183650|NCT02572791|Behavioral|Household cleaning|
183651|NCT02572804|Device|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
183652|NCT02572804|Device|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
183653|NCT02572817|Biological|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 250-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
187896|NCT01963104|Procedure|Pure-tone Screener/Motivation video|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187897|NCT01963104|Procedure|Digits-in-noise test/Motivational video|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187898|NCT01963104|Procedure|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
187899|NCT01963117|Radiation|Combined hyperthermia and radiation therapy|
187900|NCT01963143|Biological|Gammaplex (5%)|
188181|NCT01957956|Drug|Temozolomide|Given PO
188182|NCT01957969|Device|Sacral Nerve Stimulation|
188183|NCT01957995|Drug|nanosomal docetaxel lipid suspension|Given IV
188184|NCT01957995|Other|pharmacological study|Correlative studies
188185|NCT00002122|Drug|Rifabutin|
188186|NCT00115635|Drug|docetaxel|
188187|NCT01958008|Drug|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
188188|NCT01958008|Drug|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
188189|NCT01958008|Drug|BI 113608 high dose b.i.d.|Film-coated tablet
188190|NCT01958008|Drug|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
188191|NCT01958008|Drug|BI 113608 low dose b.i.d.|Film-coated tablet
188192|NCT01958008|Drug|BI 113608 medium dose b.i.d.|Film-coated tablet
188193|NCT01958021|Drug|LEE011|
187608|NCT01970241|Drug|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
187609|NCT01970254|Other|HBV screening tests|Three (3) hepatitis B virus (HBV) infection tests: HBsAg, anti-HBc, and anti-HBs
187610|NCT01970254|Behavioral|HBV risk assessment survey|Estimated time to complete the HBV risk assessment tool is 5 minutes.
187611|NCT01970267|Procedure|Laser Ablation of Floaters|
187612|NCT01970267|Procedure|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
187613|NCT01970280|Drug|Enoxaparin|
187614|NCT01970293|Other|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
187615|NCT00117026|Drug|Placebo|Placebo for benfotiamine
187616|NCT01970306|Device|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
187617|NCT01970332|Procedure|Revascularization Surgery|
187618|NCT01970332|Other|Supervised exercise therapy|
187619|NCT01970345|Drug|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
187620|NCT01970345|Drug|Placebo/saline|Placebo
187621|NCT01970358|Biological|Poly-ICLC|
187901|NCT00116168|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
187902|NCT01963143|Biological|Gammaplex 10|
187903|NCT01965314|Other|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
187005|NCT02558660|Behavioral|Education|Educational intervention about an existing SNAP healthy food incentive program
187006|NCT02558660|Behavioral|voucher|$10 voucher to spend on produce at farmers markets
187313|NCT01975064|Drug|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
187314|NCT00117520|Drug|Caffeine|
187315|NCT01975064|Drug|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
187316|NCT01975077|Drug|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
187317|NCT01975090|Device|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
187318|NCT01975103|Procedure|Topcon Endpoint Management|
187319|NCT01975116|Drug|azurin-derived cell-penetrating peptide p28|Given IV
187320|NCT01975129|Drug|Vagitocin|
187321|NCT01975142|Drug|Trastuzumab - Emtansine|
187322|NCT01975155|Other|food questionnaire|
187323|NCT01975155|Other|Urinary mycotoxin test|
187324|NCT01975168|Device|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
187325|NCT00117533|Drug|pegylated IFN alfa-2b plus ribavirin|
187326|NCT01975181|Behavioral|Diet|In receiving recommendations for a Mediterranean-style diet, subjects are encouraged to get protein predominantly from fish and legumes, fat from olive oil or other sources high in omega-3 oils, to eat whole grains and complex carbohydrates while avoiding highly processed foods. Subjects are also coached on portion control, stress-eating and snacking, aiming for adequate water intake, and eating meals including breakfast with regularity.
187327|NCT01975181|Behavioral|Exercise|After assessing safety of exercise with a supervised, graded exercise tolerance test, subjects are given a prescription for exercise with activities tailored to their preferences and physical limitations aiming for at least 150 minutes of continuous aerobic exercise per week.
187328|NCT01975181|Behavioral|Stress Management|In supervised coaching sessions and with assigned homework behaviors, subjects learn to use a "tension tamer" with visualized imagery, deep breathing, and progressive muscle relaxation to live with lower levels of stress.
187329|NCT01977664|Other|no intervention|
186709|NCT02565082|Other|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
186710|NCT02565082|Other|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
186711|NCT02565082|Other|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
186712|NCT02565082|Other|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
187007|NCT02558673|Other|TMAO dietary precursors|
187008|NCT02558673|Other|Control (or active comparator)|
187009|NCT00186121|Drug|Goserelin (Zoladex)|
187010|NCT02558686|Other|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
187011|NCT02558686|Other|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
187012|NCT02558686|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
187013|NCT02558699|Procedure|physician's personal experience|
187014|NCT02558699|Procedure|Virtual rotor mapping|
187015|NCT02558712|Other|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
187016|NCT02558725|Drug|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
187017|NCT02558738|Device|ear spray|
187018|NCT02558751|Biological|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
187019|NCT02560805|Behavioral|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
187020|NCT02560805|Procedure|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
187021|NCT02560805|Procedure|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (~0-1°C) up to the wrist for 1 minute.
158497|NCT01771848|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
158498|NCT01771861|Other|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
158499|NCT01771874|Drug|MDMA|125 mg per os, single dose
158500|NCT00097474|Drug|Melatonin|
158792|NCT01793701|Procedure|Intracavitary brachytherapy|Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes
158793|NCT01793701|Drug|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
158794|NCT01793727|Device|Glidescope videolaryngoscope|
158795|NCT01793740|Behavioral|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
158796|NCT01793753|Drug|Propofol|
158797|NCT01793766|Device|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
158798|NCT01793766|Device|Sham modulation|
158799|NCT01793779|Procedure|cold water immersion|
158800|NCT01793779|Dietary Supplement|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
158801|NCT01793779|Dietary Supplement|Placebo|
158802|NCT00000282|Drug|Pemoline|
158803|NCT00001956|Procedure|Tissue biopsy|
158804|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
158805|NCT01793792|Device|LVIS™ and LVIS™ Jr|
158806|NCT01793818|Biological|Tat Oyi|Three injections in the arm
158807|NCT01793831|Procedure|FMT|Standard FMT, once
158808|NCT01793831|Drug|5-ASA, Prednisone, Azathioprine or Remicade|
188004|NCT01975285|Drug|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
188005|NCT01975285|Drug|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
188006|NCT01975298|Drug|Laquinimod|Oral Administration
188007|NCT01975298|Drug|Avonex®|Interferon β1A 30 μg/0.5mL administered Intra Muscular
188008|NCT01975311|Other|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
188009|NCT01975311|Other|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
188010|NCT01977885|Behavioral|Exercise|Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or ~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
188317|NCT01970553|Drug|Gemcitabine|1000 mg vial, powder for injectable solution
188318|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
188319|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
188320|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
188321|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
188322|NCT01970579|Device|Paclitaxel coated balloon|Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD
Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)
Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)
If two treatment balloons are necessary overlap between the balloon must be 10 mm
Inflation pressure 7-10 atm
Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting
188323|NCT00117078|Drug|Aranesp®|
188324|NCT01970579|Device|uncoated PTA catheter|Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD
Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)
Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)
If two treatment balloons are necessary overlap between the balloon must be 10 mm
Inflation pressure 7-10 atm
Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting.
187716|NCT01983306|Drug|Placebo|Tablet
187717|NCT01983319|Device|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
187718|NCT01983319|Device|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
187719|NCT00118066|Dietary Supplement|calcitriol|Given orally
187720|NCT01983319|Behavioral|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
187721|NCT01983345|Procedure|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
187722|NCT01983358|Drug|JPI-289|PARP-1 inhibitor
187723|NCT01983358|Other|Placebo|Placebo
187724|NCT01983371|Drug|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
187725|NCT01983371|Other|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
187726|NCT01983384|Other|Anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
187727|NCT01983397|Other|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
187728|NCT01983397|Other|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
187729|NCT01983410|Behavioral|The risk assessment questionnaire|
187730|NCT00118066|Procedure|observation|No initial intervention
187731|NCT01983410|Other|Blood specimens|
187732|NCT01983410|Other|tumor tissue samples will be requested|
188011|NCT01977898|Drug|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
187429|NCT00118352|Radiation|total-body irradiation|Undergo low-dose TBI
187430|NCT01988181|Device|BVM-UF biofeedback|The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
187431|NCT01988181|Device|Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)|For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
187432|NCT01990573|Drug|Group 1- 0.4mg/kg IV methadone HCl|Group I will receive 0.4mg/kg IV methadone HCl
187433|NCT01990573|Drug|Group 2 - 0.5mg/kg IV methadon HCI|Group II will receive 0.5mg/kg IV methadone HCl.
187434|NCT01990573|Other|Group 3 - control no methadone|The control group will not receive methadone.
187435|NCT01990586|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
187436|NCT01990599|Other|Nasopharyngeal Tube|
187437|NCT01990612|Procedure|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score < 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
187438|NCT01990625|Device|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
187439|NCT01990638|Other|exercise capacity test|
187440|NCT01990664|Device|senofilcon A|
187441|NCT01990664|Device|senofilcon A for Astigmatism|
187442|NCT00118495|Drug|Non-prescription Zestra(TM): patented formulation|
187443|NCT01990677|Drug|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
187444|NCT01990677|Drug|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
187733|NCT01985607|Dietary Supplement|new extensively hydrolysed formula|
187734|NCT01985607|Dietary Supplement|Extensively hydrolysed formula|
186809|NCT02574065|Other|The placebo consists of an identical formulation without L. reuteri DSM 17938|
186810|NCT02574078|Drug|Nivolumab|
186811|NCT02574078|Drug|Bevacizumab|
186812|NCT02574078|Drug|Pemetrexed|
186813|NCT02574078|Other|Palliative radiation|
186814|NCT00188071|Drug|ketoprofen|
186815|NCT02574078|Drug|nab-Paclitaxel|
186816|NCT02574078|Drug|Paclitaxel|
186817|NCT02574078|Drug|Docetaxel|
186818|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation device for 3 consecutive days during week1 and 1 day during week 2.
186819|NCT02540161|Drug|Sym004|Sym004 will be dosed at 18 mg/kg intravenously every two weeks.
186820|NCT02540174|Procedure|integrated addiction treatment program|At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.
At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.
The first addiction consultation will be carried out directly in the cancer treatment unit, and integrated to the overall cancer treatment program. This first addiction consultation will concern :
For patients with lung cancer: tobacco and addiction or harmful use of alcohol according to classical criteria
For patients with upper aerodigestive tract cancer: tobacco and any use of alcohol
186821|NCT02540174|Procedure|standard of care|The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :
At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.
At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption
186822|NCT02540187|Other|blood specimen|
186823|NCT02540200|Device|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
186824|NCT02540200|Procedure|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
186825|NCT02540213|Device|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
185949|NCT02555852|Drug|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
186214|NCT02549144|Dietary Supplement|Low versus high fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day.
186215|NCT02549157|Procedure|Pelvic Floor Muscle Training|
186216|NCT02549170|Biological|HYQVIA|Dosing regimen for HYQVIA/HyQvia will be the same as the participant's pre-randomization monthly equivalent IgG dose when administered every 2, 3, or 4 weeks.
186217|NCT02549170|Biological|0.25% albumin placebo solution with rHuPH20|Dosing regimen for placebo treatment will be the same as the participant's pre-randomization monthly equivalent IgG infusion volume when administered every 2, 3, or 4 weeks.
186218|NCT02549170|Biological|IGIV|IGIV treatment will consist of an induction dose of 2 g/kg, followed by maintenance infusions at the same monthly dose as the participant's pre-randomization IgG dose, every 3 weeks.
186219|NCT02549183|Device|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
186220|NCT02549196|Drug|CPC-201|
186221|NCT02549209|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
186222|NCT00185068|Drug|Olmesartan medoxomil/hydrochlorothiazide|
186223|NCT02549209|Drug|Paclitaxel|For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.
Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion.
186224|NCT02551250|Other|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
186225|NCT02551263|Drug|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
186226|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
186227|NCT02551276|Drug|Salbutamol|
186228|NCT02551276|Drug|Placebo|
186229|NCT02551276|Other|Resistance training|
186230|NCT02551289|Other|Gluten free diet|Patients will follow a gluten free diet
186231|NCT02551302|Device|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
185636|NCT00186407|Procedure|high dose chemo then auto hematopoietic cell transplant|
185637|NCT02560298|Other|Laboratory Biomarker Analysis|Correlative studies
185638|NCT02560298|Drug|Paclitaxel|Given IV
185639|NCT02560298|Other|Quality-of-Life Assessment|Ancillary studies
185640|NCT02560311|Other|observation|
185641|NCT02560324|Drug|Ramelteon|
185642|NCT02560324|Drug|Placebo|
185643|NCT02560337|Drug|Cabazitaxel|
185644|NCT02560337|Drug|Tocotrienol|
185645|NCT02560350|Other|no intervention|no intervention
185646|NCT02560363|Drug|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
185647|NCT00186420|Drug|Taxotere|
185648|NCT02560363|Drug|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
185649|NCT02560363|Drug|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
185650|NCT02560363|Drug|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
185651|NCT02560376|Drug|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
185652|NCT02560389|Drug|Placebo|Sugar pill packaged to resemble levodopa
185653|NCT02560389|Drug|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
185654|NCT02560415|Device|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
185655|NCT02560415|Behavioral|Comparator|Treatment as usual
185656|NCT02560428|Behavioral|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
185657|NCT02562378|Drug|Trastuzumab and non-pegylated liposomal doxorubicin|Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
185081|NCT02539537|Drug|Gemcitabine|
185082|NCT00183937|Drug|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
185083|NCT02539537|Drug|Folinic Acid|
185084|NCT02539537|Drug|5-Fluoro-uracil|
185355|NCT02568917|Procedure|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
185356|NCT02568943|Drug|Panobinostat|Panobinostat (PAN [LBH589]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
185357|NCT02568956|Biological|umbilical cord mesenchymal stem cells|
185358|NCT02568969|Device|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
185359|NCT00187213|Device|Cardiac Resynchronization Therapy|
185360|NCT02568982|Other|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
185361|NCT02568995|Drug|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
185362|NCT02569008|Drug|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
185363|NCT02569021|Device|Biphasic DBS stimulation|The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.
Current best/optimized DBS setting (considered "baseline")
DBS off for 30 minutes as a washout period
Biphasic pulse stimulation mode (assessment at 0.5hr)
Biphasic pulse stimulation mode (assessment at 1hr)
Biphasic pulse stimulation mode (assessment at 2hr)
Biphasic pulse stimulation mode (assessment at 3hr)
185364|NCT02569021|Other|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
185365|NCT02569021|Other|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
185366|NCT02569021|Device|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
184817|NCT02548494|Other|Correction of Fluid Loss|Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:
Administer 1-3 L during the first hour.
Administer 1 L during the second hour.
Administer 1 L during the following 2 hours
Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings
184818|NCT02548507|Other|observational study, no intervention|
184819|NCT02548520|Other|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
184820|NCT02548533|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
184821|NCT00185003|Drug|Potassium channel blockers: TEA, Quinin, Tolbutamide|
184822|NCT02548533|Drug|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
184823|NCT02548533|Drug|EMLA cream|Topical application 2 hours prior to the treatment.
184824|NCT02548546|Device|ECHO|Imaging
184825|NCT02548546|Device|ECG-gated MRA|Imaging
184826|NCT02548559|Drug|Cannabidiol|Cannabidiol; total daily dose of 28.08mg.
185085|NCT02539537|Drug|Oxaliplatin|
185086|NCT02539537|Drug|Irinotecan|
185087|NCT02539537|Drug|L-folinic|
185088|NCT02539550|Drug|Placebo|Placebo
185089|NCT02539550|Drug|PF-06266047|PF-06266047
185090|NCT02539563|Device|peanut shaped birthing ball|peanut ball will be utilized
185091|NCT02539576|Drug|ABC/DTG/3TC FDC tablet|ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with "572 Trı" on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally.
185092|NCT02539589|Behavioral|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
185093|NCT00183937|Drug|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
185094|NCT00184236|Behavioral|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
184524|NCT02552862|Drug|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
184525|NCT02552862|Drug|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
184526|NCT02552875|Other|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
184527|NCT02552875|Other|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
184528|NCT00185640|Drug|g-csf|16 mcg/kg; SQ
184529|NCT02555124|Drug|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
184530|NCT02555124|Drug|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
184531|NCT02555137|Other|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
184532|NCT02555150|Drug|PRC-063|Oral extended-release capsule
184533|NCT02555150|Drug|lisdexamfetamine dimesylate|Oral capsule
184534|NCT02555150|Drug|Placebo|Oral placebo capsule
184535|NCT02555163|Device|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
184536|NCT02555163|Device|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
184537|NCT02555176|Dietary Supplement|Dietary intervention|Follow a low-carbohydrate diet
184538|NCT02555189|Drug|Enzalutamide|Given PO
184539|NCT00185653|Procedure|Autologous followed by non-myeloablative allogeneic transplantation|
184540|NCT02555189|Drug|Ribociclib|Given PO
184541|NCT02555215|Drug|dimethyl fumarate|administered orally
184542|NCT02555228|Drug|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
184543|NCT02555228|Other|Water|5mls of water is given at least 30 minutes before the gastroscopy.
183938|NCT02566239|Other|Share activity data with care team|Share participant in-home activity data with retirement community care team.
183939|NCT02566252|Drug|PUL-042 Inhalation Solution|PUL-042
183940|NCT02566252|Drug|Cromolyn Sodium|Pre-treatment
183941|NCT02566252|Drug|Albuterol sulfate|Pre-treatment
183942|NCT02566265|Biological|Fluzone High Dose Vaccine|
183943|NCT00187057|Drug|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
183944|NCT02566265|Biological|Standard of care/Placebo|
184243|NCT02559778|Drug|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
184244|NCT00186303|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
184245|NCT02559778|Drug|DFMO|DFMO will be given for 2 years as maintenance to all subjects completing immunotherapy.
184246|NCT02559791|Biological|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
184247|NCT02559791|Drug|Placebo|Matching placebo once monthly for 2 months
184248|NCT02561975|Other|Double pulmonary diffusing|Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.
With the expired air, some parameters will be assessed:
Alveolar volume (VA)
Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)
Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc
184249|NCT02561988|Drug|BLU-285|
184250|NCT02562001|Device|HD tDCS active|active HD-tDCS (Soterix Medical, New York, EUA) during 20 minutes before Lokomat and ARMEO Spring
184251|NCT02562001|Device|HD tDCS placebo|placebo HD-tDCS (Soterix Medical, New York, EUA) during 20 minutes before Lokomat and ARMEO Spring
184252|NCT02562014|Other|Glucose|75g glucose
184253|NCT02562014|Other|Inulin|75g glucose plus 24g inulin
184254|NCT00186641|Procedure|high dose chemo and auto hematopoietic cell transplant|
184255|NCT02562014|Other|Resistant Starch|75g glucose plus 28.2g resistant starch
183654|NCT02572817|Biological|Low-titer (control) anti-influenza plasma|Human plasma (FFP or FP24, 250-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
183655|NCT02572830|Behavioral|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
183656|NCT02572830|Behavioral|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
183657|NCT02572843|Drug|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
183658|NCT02572856|Device|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 4 Professional CGM sensor and calibrate the sensor during preanesthesia visit. Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Calibrate sensor at least every 12 hours. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
183659|NCT02572869|Other|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
183660|NCT00187876|Procedure|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
183945|NCT02566278|Other|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
183946|NCT02566291|Device|Success|Success rate and time for insertion
183947|NCT02566304|Drug|Fludarabine|Given IV
183948|NCT02566304|Radiation|Total-Body Irradiation|Undergo TBI
183949|NCT02568332|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
183950|NCT02568332|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
183951|NCT02568345|Drug|sugammadex ED90|The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.
In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.
183952|NCT02568358|Other|Experimental Intervention: DNA-based testing of BAL fluid|DNA based testing needs 4.5 hours lab time in addition to standard testing
188194|NCT01958021|Drug|Letrozole|
188195|NCT01958021|Drug|LEE011 Placebo|
188196|NCT01958034|Dietary Supplement|Bilberry extract|
188197|NCT00115635|Drug|gemcitabine|
188198|NCT01958047|Drug|ASP3652|Oral
188199|NCT01958060|Drug|BI 1034020|intravenous part
188200|NCT01958060|Drug|Placebo to BI 1034020|intravenous part
188201|NCT01958073|Drug|Conjugated Estrogen Vaginal Cream|
188202|NCT01958073|Drug|Estradiol Ring|
188203|NCT01958086|Device|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. Key features include sterile, single use electrodes that provide access to a localized population of individual cells. The Neural Communication system is primarily composed of two NeuroPort Arrays. The main component of the NeuroPort Array is an array comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and has a platinum tip that is 100-200 microns in length. The Patient Pedestal is made from titanium and is 19 mm wide at the skin interface.
188204|NCT01958099|Behavioral|Education|
188205|NCT01958112|Drug|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
183661|NCT02572869|Behavioral|questionnaires|The participating patients will be asked to complete three questionnaires:
(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes.
183662|NCT02572882|Dietary Supplement|p-inulin|12 week self-administered treatment phase
183663|NCT02572895|Dietary Supplement|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
183664|NCT02572908|Other|Sourdough wheat bread|
183665|NCT02501837|Drug|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
187904|NCT01965314|Other|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
187905|NCT01965327|Drug|Interferon Gamma-1b|Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.
All doses will be administered via subcutaneous injection.
187906|NCT00116467|Biological|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
187907|NCT01965340|Other|Systematic Therapeutic Drug Monitoring for the intervention group|
187908|NCT01965353|Drug|Panobinostat|- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
187909|NCT01965353|Drug|Dexamethasone|Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
187910|NCT01965353|Drug|Lenalidomide|Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
187911|NCT01965353|Drug|Bortezomib|Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
187912|NCT01965366|Behavioral|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
187913|NCT01965366|Drug|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
187914|NCT01965379|Other|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
187915|NCT01965379|Other|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
188206|NCT01958112|Drug|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
188207|NCT01958125|Device|gammaCore|Vagal stimulation
188208|NCT00115648|Drug|Nevirapine|Oral NVP daily dosage
188209|NCT01960491|Device|Device Closure of Atrial Septal Defect|Device Closure of Atrial Septal Defect by "Carag Bioresorbable Septal Occluder"
188210|NCT01960504|Device|Percutaneous Coronary Intervention (DREAMS) stenting|
187330|NCT01977677|Radiation|radiation therapy|Undergo radiation therapy
187331|NCT01977677|Drug|temozolomide|Given PO
187332|NCT01977677|Drug|plerixafor|Given IV
187333|NCT01977677|Other|laboratory biomarker analysis|Correlative studies
187334|NCT01977677|Other|pharmacological study|Correlative studies
187622|NCT01970358|Biological|Peptides|
187623|NCT01970371|Drug|plazomicin|intravenous repeating doses
187624|NCT01970371|Drug|colistin|intravenous repeating doses
187625|NCT01970371|Drug|meropenem|intravenous repeating doses
187626|NCT00117026|Drug|Benfotiamine|300mg/day
187627|NCT01970371|Drug|tigecycline|intravenous repeating doses
187628|NCT01970371|Drug|antibiotic of Investigator's choice|repeating doses
187629|NCT01970384|Device|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
187630|NCT01970384|Device|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
187631|NCT01970397|Device|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
187632|NCT01972841|Drug|Solifenacin Succinate|Oral tablet
187633|NCT01972841|Drug|Mirabegron|Oral tablet
187634|NCT01972841|Drug|Placebo|Oral tablet
187635|NCT01972854|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL System at 30mW/cm2 intensity for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off, for a total radiant exposure of 7.2 J /cm2.
187636|NCT00002137|Drug|Tecogalan sodium|
187637|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
187022|NCT02560805|Drug|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
187023|NCT02560805|Drug|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
187024|NCT02560805|Drug|Losartan|Subjects will receive Losartan 25 mg once a day orally up to 12 weeks
187025|NCT02560805|Drug|Atenolol|Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
187026|NCT02560818|Other|collection of a blood sample and breast tissue|a blood sample and a breast tissue sample will be collected in healthy women during their breast reduction surgery
187027|NCT02560818|Other|use of a previous blood collection for patients|
187335|NCT01977690|Device|Clavicle Brace|
187336|NCT00117689|Drug|Corticosteroid|For a minimum of 3 months
187337|NCT01977703|Other|Ultra Conservative ICD Programming|
187338|NCT01977703|Other|Traditional ICD Programming|
187339|NCT01977729|Drug|Sertraline|Medication will be administered daily using a "fixed-flexible strategy" beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20.
187340|NCT01977729|Behavioral|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
187341|NCT01977742|Other|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
187342|NCT01977742|Other|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
187343|NCT01977755|Drug|danegaptide|
187344|NCT01977755|Drug|Placebo|
187345|NCT01977768|Biological|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
187346|NCT01977768|Biological|Placebo|
158809|NCT01793857|Other|Data collection|Paper questionnaire
158810|NCT01793870|Drug|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
158811|NCT01795911|Drug|Ribasphere|
158812|NCT01795911|Drug|Daclatasvir|
158813|NCT01795924|Drug|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
158814|NCT01795937|Drug|Itraconazole|twice daily
158815|NCT01795937|Drug|Atorvastatin|single dose
159122|NCT00100139|Drug|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
159123|NCT01798849|Drug|MK-8892|
159124|NCT01798849|Drug|Placebo for MK-8892|
159125|NCT01798862|Procedure|Endometrial injury by hysteroscopy or pipelle sampling|
159126|NCT01798862|Procedure|Proceed to COH directly|
159127|NCT01798875|Drug|oral metformin|
159128|NCT01798875|Drug|oral contraceptive|
159129|NCT01798888|Procedure|Implantation of Deep Brain Stimulation|
159130|NCT01798901|Drug|HDAC inhibitor AR-42|Given PO
159131|NCT01798901|Drug|decitabine|Given IV
159132|NCT01798901|Other|laboratory biomarker analysis|Correlative studies
159133|NCT00100139|Drug|Paclitaxel for injection (Taxol)|
159134|NCT01798901|Other|pharmacological study|Correlative studies
159135|NCT01798914|Drug|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
159136|NCT01798927|Device|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
159137|NCT01798940|Drug|Torrent's Pioglitazone|
159138|NCT01798966|Device|SENSIMED Triggerfish|
188325|NCT01970592|Behavioral|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
188326|NCT01970605|Procedure|Surgical reconstruction|In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.
Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.
Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible.
188327|NCT01970618|Drug|RV1162 single dose|Safety and tolerability of single escalating doses
188328|NCT01973127|Other|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
188329|NCT01973127|Other|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
188330|NCT01973140|Drug|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
183765|NCT02548208|Device|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
183766|NCT02548221|Device|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
183767|NCT02550197|Biological|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
183768|NCT02550210|Device|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
183769|NCT00185133|Drug|Amlodipine|
183770|NCT02550223|Procedure|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
183771|NCT02550249|Drug|Nivolumab|Intravenous administration of nivolumab
183772|NCT02550262|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
188012|NCT01977898|Drug|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
188013|NCT01977911|Other|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
188014|NCT01977924|Dietary Supplement|one month polyphenols supplementation (600mg)|
188015|NCT00117702|Drug|Tacrolimus|day 0-100, then taper
188016|NCT01977924|Dietary Supplement|placebo (microcrystalline cellulose)|
188017|NCT01977937|Drug|Gabapentin|
188018|NCT01977937|Drug|Simple Syrup|
188019|NCT01977976|Procedure|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
188020|NCT01977989|Drug|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
188021|NCT01978002|Behavioral|Pain sensitivity testing|
188022|NCT01978002|Behavioral|Urodynamic testing|
188023|NCT01978015|Drug|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
188024|NCT01978015|Drug|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
188025|NCT01978015|Drug|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
188026|NCT00117702|Drug|Everolimus|day 0-56
188027|NCT01980628|Drug|ibrutinib|
188331|NCT01973140|Drug|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
188332|NCT00117351|Drug|VELCADE|
187735|NCT01985620|Behavioral|Educational intervention|
187736|NCT00118222|Procedure|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
187737|NCT01985633|Biological|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
187738|NCT01985633|Biological|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
187739|NCT01985646|Procedure|surgery treatment|one staged pull-through left-colectomy
187740|NCT01985646|Behavioral|anal dilation|anal dilation
187741|NCT01985646|Behavioral|colonic lavage|colonic lavage
187742|NCT01985646|Drug|oral probiotic|oral probiotic
187743|NCT01985672|Procedure|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
187744|NCT01985685|Drug|Thiamine|200 mg IV thiamine
187745|NCT01985698|Procedure|robotic-assist resection.|robotic-assist resection.
187746|NCT01985698|Procedure|Laparoscopic resection|Laparoscopic resection
187747|NCT00118235|Drug|cisplatin|Given IV
187748|NCT01985698|Procedure|Open Abdominoperineal Resection|Open Abdominoperineal Resection
187749|NCT01985711|Device|web-based collaborative care|Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
Secondly, usual diabetes outpatient care for 6 months.
187750|NCT01985711|Other|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
187751|NCT01985711|Behavioral|usual diabetes outpatient care|
187752|NCT01985724|Drug|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
187753|NCT01985724|Drug|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
186826|NCT02540226|Drug|Intravenous tranexamic acid|
186827|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
187137|NCT02569762|Other|Aspartame-Sucralose|Aspartame or sucralose
187138|NCT02569775|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
187139|NCT02569788|Radiation|CIRT arm|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
187140|NCT02569801|Drug|Fulvestrant|500 mg of fulvestrant administered as two intramuscular injections
187141|NCT00187317|Other|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
187142|NCT02569801|Drug|GDC-0810|600 mg of GDC-0810 administered orally once daily
187143|NCT02569814|Drug|Fimasartan/Amlodipine/Rosuvastatin|
187144|NCT02569814|Drug|Fimasartan/Amlodipine|
187145|NCT02569814|Drug|Rosuvastatin|
187146|NCT02571855|Drug|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
187147|NCT02571855|Drug|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
187148|NCT02571855|Drug|Placebo|Placebo capsules matching the ACT-541468 formulations
187149|NCT02571868|Device|Optimization CRT-D|
187150|NCT00187681|Drug|Metformin|2 doses of Metformin Day 1 1000mg, Day 2 850 mg
187151|NCT02571881|Procedure|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
187152|NCT02571881|Drug|Oxycodone|
187153|NCT02571881|Drug|oxycodone-naloxone|
187154|NCT02571894|Other|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
187155|NCT02571907|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices into each subject: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
186232|NCT02551302|Device|CD HORIZON BalanC™ Medtronic|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:
CD HORIZON BalanC™ Medtronic
186233|NCT02551328|Drug|sevofluorane|Continuous infusion of sevofluorane
186234|NCT02551341|Procedure|higher PEEP ventilation|
186522|NCT02544880|Procedure|Peripheral Blood Collection|Approximately 50 mL (PBMC and Sera) collected prior to planned (initial) Tadalafil/Placebo administration (or ≤ 21-days prior to intended surgery), on day of intended Surgery, On day 10 (day of the vaccination) of Course 2, 3, 4 and 5, two weeks after Course 4, two weeks after Course 5.
186523|NCT02544880|Procedure|DTH Skin Test|Delayed-type hypersensitivity (DTH) skin testing for candida antigen and MUC1 will be performed prior to planned (initial) Tadalafil/Placebo administration (or ≤ 21-days prior to intended Surgery), on the day of surgery, and two weeks after Course 4 for patients receiving study therapy.
186524|NCT00184665|Drug|insulin detemir|
186525|NCT02544880|Procedure|Tumor-specimen collection|Tumor-specimen collection from surgical resection of recurrent/second primary tumor, after Course 1 of Tadalafil/Placebo administration
186526|NCT02544893|Drug|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
186527|NCT02544893|Drug|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
186528|NCT02547038|Drug|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
186529|NCT02547051|Other|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
186530|NCT02547064|Procedure|Glidescope guided intubation|
186531|NCT02547064|Device|GlideScope®|
186532|NCT02547077|Procedure|Wound Closure with 2-octylcyanoacrylate|
186533|NCT02547077|Procedure|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
186534|NCT02547090|Procedure|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
186535|NCT02547103|Other|Chlorhexidine gluconate-soaked cloths|
186536|NCT02547103|Other|Normal saline|
186537|NCT00184899|Drug|Intravenous infusion of Intralipid/heparin|
185658|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions)|
185659|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
185950|NCT02555852|Drug|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
185951|NCT02555852|Drug|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
185952|NCT02555852|Drug|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
185953|NCT02555878|Drug|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
185954|NCT00185731|Drug|Atorvastatin|80 mg orally once daily
185955|NCT02555878|Drug|Placebo|Placebo tablet will be administered orally once daily for 180 days.
185956|NCT02555917|Procedure|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
185957|NCT02555930|Other|No Intervention|No intervention - observational only
185958|NCT02555943|Drug|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
185959|NCT02555943|Drug|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
185960|NCT02555943|Drug|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
185961|NCT02555943|Drug|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
185962|NCT02555943|Drug|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
185963|NCT02558062|Other|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
185367|NCT02569021|Device|Trigno wireless system|The Trigno system measure muscle contractions.
185368|NCT02569021|Other|GaitRite walking assessment.|GaitRite records a patients gait pattern.
185369|NCT02569034|Other|Functional Magnetic Resonance Imaging|Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward "wanting" and reward "liking" using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia.
185370|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
185660|NCT02562417|Drug|Normal saline|
185661|NCT00002508|Drug|etoposide|
185662|NCT00186732|Procedure|Subcuticular Suture|
185663|NCT02562417|Drug|IV dexamethasone|
185664|NCT02562430|Drug|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
185665|NCT02562430|Drug|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
185666|NCT02562443|Drug|rigosertib|Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).
185667|NCT02562443|Drug|Any approved or standard-of-care therapy|Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
185668|NCT02562456|Procedure|ART with Fuji IX|Occlusal and occlusal-proximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
185669|NCT02562456|Procedure|Restoration with Filtek Z-350 composite resin|Occlusal and occlusal-proximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
185670|NCT02562469|Other|ACTIVATE|A home-based computerized brain training intervention for youth.
185671|NCT02562482|Biological|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins. The vaccine is filled in a single dose glass vial at 40+/- 10mcg/mL.
185672|NCT02562482|Other|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine
185095|NCT02541968|Behavioral|Cognitive-behavioral therapy (face-to-face)|
185096|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy|With therapist support
185097|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy without therapist support|
185098|NCT02541994|Device|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
185099|NCT02541994|Device|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
185100|NCT02542007|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
185101|NCT02542007|Device|sirolimus-eluting stent system|
185102|NCT02542033|Other|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
185371|NCT02569034|Other|Effort-Expenditure for Rewards Task|Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward "wanting", in contrast to commonly used anhedonia questionnaires, which focus on reward "liking." This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations.
185372|NCT02571101|Drug|Condencia-Placebo|Placebo tablet of Condencia
185373|NCT02571114|Dietary Supplement|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
185374|NCT02571114|Dietary Supplement|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
185375|NCT02571114|Dietary Supplement|Control 1|White bread (serving size = 25 g available carbohydrate)
185376|NCT00187551|Other|Interruption of enfuvirtide|treatment interruption
185377|NCT02571114|Dietary Supplement|Control 2|White bread (serving size = 25 g available carbohydrate)
184544|NCT02555241|Behavioral|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
184827|NCT02548572|Device|Transcorneal Electrical Stimulation using Okustim device|The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the "OkuEl®" electrodes, which are held in place via the "OkuSpex®" frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device).
184828|NCT02548585|Drug|MEDI0382|MEDI0382 administered subcutaneously
184829|NCT02548585|Drug|Placebo|Placebo administered subcutaneously
184830|NCT02548598|Procedure|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
184831|NCT02548611|Drug|Prasugrel|see arm description
184832|NCT00002501|Biological|filgrastim|
184833|NCT00185003|Drug|L-NMMA|
184834|NCT02548611|Drug|Clopidogrel|see arm description
184835|NCT02548624|Device|Zephyr BioPatch|The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.
The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station.
184836|NCT02548637|Procedure|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
184837|NCT02548650|Drug|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
184838|NCT02550613|Device|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
184839|NCT02550639|Other|BIOMARKER- elispot test|ELISPOT TEST
184840|NCT02550652|Drug|Mycophenolate Mofetil|
184841|NCT02550652|Drug|Obinutuzumab|Participants will receive obinutuzumab 1000 milligram (mg) intravenous (IV) infusion on Day 1, 15, 168, and 182 along with MMF at a starting dose of 500 mg/day administered orally in 2 or 3 divided doses. MMF dose will be up titrated based on tolerability to a maximum dose of 2.5 gram/day (g/day).
184256|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|30 quality of life questions for the participant to answer
The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)
The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
184257|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|13 quality of life questions for the participant to answer
The answers range from 1 (Not at All) to 4 (Very Much)
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
184258|NCT02562027|Behavioral|Modified Medical Research Council|Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
184259|NCT02562027|Behavioral|EQ-5D|5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day
The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
184545|NCT02555241|Behavioral|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
184546|NCT02555241|Behavioral|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
184547|NCT02555254|Procedure|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
184548|NCT02555254|Procedure|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
184549|NCT02555280|Device|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
184550|NCT00002505|Biological|filgrastim|
184551|NCT00185666|Procedure|Stereotactic radiosurgery|
184552|NCT02555280|Procedure|Decompression|Decompression alone
184553|NCT02555293|Drug|XIFAXAN® (Rifaximin)|
184554|NCT02555306|Drug|DE-122|DE-122 Injectable Solution
184555|NCT02557451|Other|Surgery|
184556|NCT02557451|Other|Intravitreal injections of gas|
184557|NCT02557451|Procedure|injections of an antiangiogenic|
184558|NCT02557464|Behavioral|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
183953|NCT02568397|Drug|Dabigatran etexilate|Administered orally
183954|NCT02568397|Drug|AZD3293|Administered orally
183955|NCT00187135|Drug|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
183956|NCT02568410|Procedure|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
183957|NCT02568423|Drug|LY3074828 - IV|Administered IV
183958|NCT02568423|Drug|LY3074828 - SC|Administered SC
183959|NCT02568423|Drug|Placebo - IV|Administered IV
183960|NCT02568423|Drug|Placebo - SC|Administered SC
183961|NCT02568436|Radiation|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
183962|NCT02568449|Drug|Nintedanib|Given PO
183963|NCT02568462|Device|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
184260|NCT02562027|Behavioral|Center for Epidemiological Studies Depression Scale|20 quality of life questions for the participant to answer
Answers range from "Rarely or none of the time" to "Most or all of the time"
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
184261|NCT02562027|Behavioral|Medical Outcomes Study Social Support Survey|19 quality of life questions for the participant to answer
Answers from from 1 (None of the time) to 5 (All of the time)
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
184262|NCT02562040|Procedure|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to Information about healthy sleep habits for children, a nasal saline spray, and appropriate clinical referrals for management of co-morbidities.
184263|NCT02562040|Behavioral|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children, a nasal saline spray, and appropriate clinical referrals for management of co-morbidities.
184264|NCT02562053|Drug|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
184265|NCT00186654|Procedure|Acupuncture|
184266|NCT02564068|Drug|Oxytocin|1. To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. Ten subjects that have recently undergone a standard "in the sleep-lab" diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment.
183666|NCT02501850|Drug|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
183667|NCT02501850|Drug|metformin|Treatment with metformin and/or sulphonilurea
183668|NCT02501863|Drug|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
183669|NCT02501863|Drug|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
183670|NCT02501876|Other|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
183671|NCT00178971|Drug|adjunctive treatment with buspirone|buspirone 15-30 mg qd
183672|NCT02501889|Behavioral|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
183673|NCT02501889|Behavioral|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
183674|NCT02501902|Drug|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
183675|NCT02501902|Drug|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
183964|NCT02568475|Behavioral|Provision of "Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
183965|NCT02568488|Drug|Metformin|850 mg orally twice daily for 6 months
183966|NCT00187148|Biological|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
183967|NCT02568501|Behavioral|Daily feedback|Daily feedback on glucose levels from wireless glucometers
183968|NCT02568501|Behavioral|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
188211|NCT01960517|Device|ACS Catheter|
188212|NCT01960530|Drug|Infacort|
188213|NCT01960530|Drug|Hydrocortisone Tablet|
188214|NCT01960530|Drug|i.v. Hydrocortisone Injection|
188215|NCT00115869|Behavioral|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
188216|NCT01960530|Other|Dexamethasone|
188217|NCT01960543|Drug|fentanyl 15 microg|
188218|NCT01960543|Drug|Bupivacaine 7 mg|
188219|NCT01960543|Drug|Bupivacaine 9 mg|
188220|NCT01960543|Drug|Levobupivacaine 7 mg|
188221|NCT01960543|Drug|Levobupivacaine 9 mg|
188222|NCT01960556|Other|Simulation Training|Simulation training provided to one group
188223|NCT01960569|Drug|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
188224|NCT01960569|Other|Placebo assigned to arm 2|
188225|NCT01960582|Behavioral|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
188226|NCT00115882|Behavioral|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
188227|NCT01960595|Procedure|IV fentanyl PCA|
188228|NCT01960595|Procedure|local bupivacaine infiltration and post-OP IV fentanyl PCA|
188229|NCT01960595|Procedure|Nerve Blocks and post-OP IV fentanyl PCA|
188230|NCT01960608|Other|24_hours_urine_sodium|
183676|NCT02501915|Device|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
187638|NCT01972854|Drug|placebo: 0.0% riboflavin opthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by irradiation with the KXL System at 30mW/cm2 intensity for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off, for a total radiant exposure of 7.2 J /cm2.
187639|NCT01972867|Device|NanoKnife Procedure|Under general anesthesia and with paralytic on board, patients will have monopolar probes inserted bracketing the tumor. A total of 90 electrical pulses will be delivered to irreversibly electroporate the tissue.
187640|NCT01972880|Drug|ASP1941|Oral
187641|NCT01972893|Drug|ZYD1|Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.
Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.
Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
187916|NCT01965392|Other|Health education intervention|'Health education intervention'
187917|NCT00002128|Drug|Adefovir dipivoxil|
187918|NCT00116480|Drug|Misoprostol|600 mcg of sublingual misoprostol
187919|NCT01965405|Drug|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
187920|NCT01965405|Behavioral|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
187921|NCT01967719|Other|NNS|Single administration of 1 mg of nicotine
187922|NCT01967732|Other|THS 2.2|Single use of THS 2.2
187923|NCT00002131|Drug|Vesnarinone|
187924|NCT00116740|Drug|APD356|
187925|NCT01967732|Other|CC|Single use of subject's own CC
187926|NCT01967732|Other|NNS|Single administration of 1 mg of nicotine
187927|NCT01967745|Procedure|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
187928|NCT01967745|Procedure|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
187929|NCT01967758|Biological|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10^7cfu
187930|NCT01967758|Biological|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10^8cfu
187931|NCT01967758|Biological|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10^9cfu
187347|NCT00002141|Drug|Abacavir sulfate|
187348|NCT00117689|Drug|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
187349|NCT01977781|Drug|Tacrolimus|
187350|NCT01977781|Drug|Methylprednisolone Sodium Succinate|
187351|NCT01977794|Drug|Bisoprolol/Amlodipine (Bisoprolol sub-group A)|Bisoprolol/Amlodipine fixed dose combination (FDC) tablet will be orally administered as an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 5mg/10mg after Visit 2 and are controlled at visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.
187352|NCT01980303|Drug|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
187353|NCT01980316|Drug|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
187642|NCT01972893|Drug|Placebo|Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.
Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.
Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
187643|NCT01972906|Device|moxibustion|apply moxibustion according to traditional Chinese medicine
187644|NCT01972906|Drug|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
187645|NCT01972919|Radiation|Radiation Therapy|Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction.
187646|NCT01972919|Drug|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg 1m2 IV weekly x 6 doses. Capecitabine 825 mg/mm2 po bid Monday-Friday on days of radiation use 500mg tablets.
187647|NCT01972932|Dietary Supplement|Bio-K®|2 ARMS STUDY
Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
187648|NCT00117325|Drug|GW685698X|
187649|NCT01972932|Dietary Supplement|Placebo|lacebo Comparator: 2 capsules orally (or via nasogastric tube) Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
187650|NCT01972945|Procedure|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
159139|NCT01798979|Drug|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
159140|NCT01798979|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
159141|NCT01798992|Drug|Carvedilol|
159142|NCT01798992|Drug|Metoprolol succinate|
159143|NCT01798992|Drug|Metoprolol succinate + doxazosin|
159144|NCT00100152|Drug|MK0752, (Notch Inhibitor)|
159145|NCT01799005|Dietary Supplement|Flavanol (410 mg)|
159146|NCT01799005|Dietary Supplement|Control (no flavanols)|
159147|NCT01799031|Other|internet-based intervention|Receive access to the WISE web-based educational intervention
159439|NCT01794780|Drug|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
159440|NCT00099632|Drug|single dose Nevirapine|one 200 mg tablet taken orally
159441|NCT01794780|Drug|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
159442|NCT01794780|Drug|theophylline based treatment|theophylline based treatment
159443|NCT01794793|Drug|Pasireotide|Pasireotide subcutaneous or Long Acting Release
159444|NCT01794806|Procedure|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
159445|NCT01794806|Procedure|Tooth extraction|Minimally traumatic single-rooted tooth extraction
159446|NCT01794819|Device|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
159447|NCT01794845|Drug|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Mondays.
159448|NCT01794845|Drug|Taxotere|Taxotere : 20 mg/m2 IV once a week on Mondays on weeks 2 to 7 in 500 cc ½ normal saline solution (NSS) or D5W over 60 minutes. Additional intravenous fluids pre- or post-Taxotere can be administered as necessary.
159449|NCT01794845|Radiation|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction BID at least 6 hours apart on Tuesday and Wednesday of weeks 2 to 7 for a total dose of 12 Gy.
183773|NCT02550262|Drug|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
183774|NCT02550262|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
183775|NCT02550275|Behavioral|neuropsychological test|
183776|NCT02550275|Radiation|MRI|
183777|NCT02550288|Drug|Ezetimibe 10 mg|
183778|NCT02550288|Drug|Atorvastatin 10 mg|
183779|NCT02550288|Drug|Placebo for Ezetimibe 10 mg tablet|
183780|NCT00185146|Drug|Pactimibe|
183781|NCT02550288|Drug|Placebo for Atorvastatin 10 mg capsule|
183782|NCT02550288|Behavioral|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
183783|NCT02550301|Other|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
183784|NCT02550314|Drug|fiblast,gelatin sponge,fibrin glue|
183785|NCT02550327|Drug|Nab-paclitaxel|125 mg/m2
183786|NCT02550327|Drug|Gemcitabine|1000 mg/m2
184079|NCT02543892|Biological|Placebo|Normal Saline
184080|NCT00184574|Drug|metformin|
184081|NCT02543905|Procedure|Prostate MRI and Biopsy|All men will undergo a MRI and prostate biopsy
184082|NCT02543918|Drug|Ixekizumab|Administered by SQ injection
184083|NCT02543918|Drug|Boostrix®|Administered by IM injection
184084|NCT02543918|Drug|Pneumovax®23|Administered by IM injection
184085|NCT02546102|Biological|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
184086|NCT02546102|Biological|Placebo|
184087|NCT02546115|Device|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
188333|NCT01973153|Behavioral|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
188334|NCT01973153|Behavioral|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
188335|NCT01973153|Behavioral|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
188336|NCT01973166|Device|Picosecond Q-switched Laser Treatment|
188337|NCT01973166|Device|Nanosecond Q-switched Laser Treatment|
188338|NCT01973179|Radiation|Radiation therapy|Radiation therapy with protons
188339|NCT01973205|Drug|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
188340|NCT01973205|Drug|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
188341|NCT01973218|Biological|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
188342|NCT01973218|Biological|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
188343|NCT00117364|Drug|SACCHACHITIN patch|
188344|NCT01973218|Biological|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
188345|NCT01973231|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
188346|NCT01975324|Drug|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
188347|NCT00117572|Drug|cisplatin|75 mg/m2 on day 1
188348|NCT01975324|Drug|Placebo|placebo (sugar pill) twice a day for two weeks
188349|NCT01975337|Drug|DEB025|Single oral dose of alisporivir 400 mg administered within 2 hours after dialysis
183787|NCT02550327|Drug|Cisplatin|25 mg/m2
188028|NCT01980641|Behavioral|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
188029|NCT01980641|Device|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
188030|NCT01980654|Drug|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
188031|NCT00117897|Drug|Filgrastim|
188032|NCT01980654|Drug|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
188033|NCT01980667|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
188034|NCT01980667|Drug|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
188035|NCT01980680|Drug|hCG|
188036|NCT01980680|Drug|Progesterone and Estradiol|
188037|NCT01980693|Device|SonicBone ultrasound|The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
188038|NCT01980706|Drug|Baclofen|Baclofen is a GABA-B agonist
188039|NCT01980706|Drug|Placebo|Pill containing no pharmacologically active substance.
188040|NCT01980732|Drug|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
188041|NCT01980745|Drug|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
188042|NCT00117910|Drug|pegfilgrastim|
188043|NCT01980745|Drug|Placebo|
188044|NCT01980758|Procedure|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
188045|NCT01980771|Behavioral|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
187156|NCT02571933|Other|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
187157|NCT02571933|Other|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
187158|NCT02571933|Other|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
187445|NCT01990690|Drug|anti oxidant omega 3|Soft gelatineous capsule (Sedico medical company) each capsule contains:
Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.
Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).
Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
187446|NCT01990703|Drug|Levonorgestrel IUD|Timing of IUD insertion
187447|NCT01990716|Other|Colonic Biopsy|Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.
The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.
Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.
For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time.
187448|NCT01990729|Dietary Supplement|ARTRA|ARTRA (glucosamine and chondroitin sulfate)
187449|NCT01990742|Behavioral|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
187450|NCT01990755|Behavioral|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
187451|NCT01990755|Other|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
187452|NCT01990755|Drug|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
187453|NCT01993108|Drug|Placebo|All study participants will receive one dose of any three of the following drug compounds 1 hour before fMRI scan and task performance: 40mgs of methylphenidate, 40mgs of naltrexone, or a placebo. There are a total of three scans per participant, therefore all participants will receive one dose of all three drug compounds for any given scan during their participation in the study
187454|NCT00118794|Drug|Chlorproguanil-dapsone (Lapdap)|
187455|NCT01993121|Other|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
187456|NCT01993134|Procedure|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
186538|NCT02547103|Other|mupirocin ointment|
186539|NCT02547116|Drug|Rifampin|
186540|NCT02547129|Device|Static Antibiotic Spacers surgical implant|Joint spacer for treatment of joint infection
186541|NCT02547129|Device|Articulating Antibiotic Spacer surgical implant|Joint spacer for treatment of joint infection
186542|NCT02547142|Other|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
186828|NCT02540226|Drug|Topical tranexamic acid|
186829|NCT02540226|Drug|Intravenous saline|
186830|NCT02540226|Drug|Topical saline|
186831|NCT02540239|Drug|2L PEG|
186832|NCT02540239|Drug|2L PEG+simethicone|
186833|NCT02540252|Other|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
186834|NCT02540265|Drug|N1539|
186835|NCT02540265|Drug|Intravenous Placebo|
186836|NCT02540278|Behavioral|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
186837|NCT02542709|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
186838|NCT02542722|Behavioral|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
186839|NCT02542722|Behavioral|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
186840|NCT02542748|Drug|Norepinephrine|norepinephrine injection
186841|NCT02542748|Drug|Ephedrine|Ephedrine injection
186842|NCT02542761|Device|Fiberglass composite foot|The intervention is a glass based composite.
185964|NCT02558075|Behavioral|MoodLifters Sessions|This program consists of 12 different sessions with a different topic for each session. These sessions will occur once a week for 12 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
185965|NCT00186056|Drug|Mifepristone|
185966|NCT02558088|Drug|Salmeterol|
186235|NCT02551354|Device|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
186236|NCT02551367|Drug|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
186237|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
186238|NCT02551367|Drug|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
186239|NCT02551367|Drug|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
186240|NCT02551380|Drug|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
186241|NCT02551393|Behavioral|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
186242|NCT02551406|Device|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
186243|NCT02551419|Dietary Supplement|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
186244|NCT02551419|Dietary Supplement|placebo|
186245|NCT02551432|Drug|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
186246|NCT02551445|Behavioral|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
185673|NCT00186732|Procedure|Surgical Staples|
185674|NCT02562495|Device|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
185675|NCT02562508|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
185676|NCT02562508|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
185677|NCT02562521|Behavioral|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
185678|NCT02562521|Drug|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
185967|NCT02558101|Behavioral|Control invitation materials|In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:
a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes
an invitation letter with a pre-scheduled appointment plus the same information booklet
a reminder re-invitation letter for those who miss their appointment without cancelling
185968|NCT02558101|Behavioral|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
185969|NCT02558114|Drug|Ribavirin|
185970|NCT02558127|Genetic|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
185971|NCT02558140|Biological|RO6874813 (Part I)|A single low dose of 0.5 mg/kg will be administered by intravenous infusion in a 7-day run-in period (Cycle 0). Dose escalation will start with 1 participant per dose level until evidence of Common Terminology Criteria for Adverse Events (CTCA) >= G2 toxicity or dose level of 5 mg/kg is reached (whatever comes first). For all further cohorts (>=5mg/kg) a minimum of 3 participants will be used. The first participant at each dose level will receive a single dose of RO6874813 and must have completed at least the first 5 days of Cycle 1 (Days 1-5) without dose-limiting toxicity (DLT) before the next participants within this cohort are treated simultaneously at this dose level.
185972|NCT02558140|Biological|RO6874813 (Part II)|Recommended Phase II dose (RP2D) will be administered by intravenous infusion at dosing schedule as defined in Part I.
185973|NCT02558140|Biological|RO6874813 (Part III)|Recommended Phase II dose (RP2D) will be administered by intravenous infusion at dosing schedule as defined in Part I
185974|NCT02558153|Device|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
185378|NCT02571127|Drug|Hidra1|Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.
Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.
Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient.
185379|NCT02571140|Drug|Teriparatide|subcutaneous standard injection
185380|NCT02571140|Drug|Oral PTH (1-34)|Different optimization of API
185381|NCT02571153|Drug|Ketamine 0.4 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
185382|NCT02571153|Drug|Normal saline|Intravenous normal saline 0.9% 5 mL
185383|NCT02571153|Drug|Ketamine 0.2 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
185384|NCT02571166|Biological|HSV529|Live, Replication-defective HSV-2 virus
185385|NCT02571166|Drug|Valacyclovir|500 mg orally, once daily for 4 weeks
185386|NCT02571179|Drug|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
185387|NCT00187551|Other|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
185388|NCT02571192|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
185389|NCT02571192|Radiation|5.95 μCi RAD|
185390|NCT02571205|Drug|Sustanon (testosterone)|Standard incremental regimen of Sustanon
185679|NCT00186888|Drug|Vincristine + Cyclophosphamide + Doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: < 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin < 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
185680|NCT02564523|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)
185681|NCT02564523|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units)
185682|NCT02564523|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline
185683|NCT02564536|Drug|Pacritinib|
185684|NCT02564536|Drug|Decitabine|
184842|NCT02550652|Drug|Placebo|Participants will receive placebo matched to obinutuzumab IV infusion on Day 1, 15, 168, and 182 along with MMF at a starting dose of 500 mg/day administered orally in 2 or 3 divided doses. MMF dose will be up titrated based on tolerability to a maximum dose of 2.5 g/day.
184843|NCT02550665|Drug|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
185103|NCT02542033|Other|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
185104|NCT02542046|Drug|Barium|Administration of barium oral contrast agent prior to CT scan
185105|NCT00184236|Behavioral|Aerobic intervention training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
185106|NCT02542046|Drug|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
185107|NCT02542046|Drug|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
185108|NCT02542059|Radiation|68Ga-exendin PET/CT|68Ga-exendin PET/CT
185109|NCT02542072|Device|comfilcon A - contact lenses|
185110|NCT02542072|Device|samfilcon A - contact lenses|
185111|NCT02542085|Procedure|Laparoscopic repair|operative method
185112|NCT02542085|Procedure|Hybrid repair|operative method
185113|NCT02544269|Procedure|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
185114|NCT02544282|Drug|Levobupivacaine|Pecs II Block
185115|NCT02544282|Drug|NaCl 0.9%|Placebo Pecs II block
185116|NCT02544282|Drug|Sevoflurane|General Anesthesia
185117|NCT02544282|Drug|Propofol|General Anesthesia
185118|NCT02544282|Drug|Sufentanil|General Anesthesia
185119|NCT02544282|Drug|Atracurium|General Anesthesia
184559|NCT02557464|Behavioral|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
184560|NCT02557477|Dietary Supplement|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
184561|NCT02557477|Dietary Supplement|Placebo|Three placebo capsules twice daily
184562|NCT02557490|Drug|oxaliplatin and raltitrexed|TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.
Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)
184563|NCT00185952|Drug|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
184564|NCT02557503|Drug|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
184844|NCT02550678|Biological|ASN-002|ASN‐002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon‐gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
184845|NCT02550691|Procedure|blood sampling|A blood sample will be taken on subject carrying specific genotype
184846|NCT02550704|Procedure|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
184847|NCT00185172|Drug|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
184848|NCT02550717|Drug|Acetylsalicylic Acid (Asprin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
184849|NCT02550717|Drug|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
184850|NCT02550730|Behavioral|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
184851|NCT02550730|Other|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
184852|NCT02550743|Drug|BYL719|
184853|NCT02550743|Drug|Capecitabine|
184854|NCT02550743|Radiation|Radiation|
184267|NCT02564081|Other|Static Stretching lower limb|
184268|NCT02564081|Other|Static stretching Cervical|
184269|NCT02564094|Drug|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
184270|NCT02564107|Drug|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
184271|NCT02564133|Device|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
184272|NCT02564146|Drug|nab-paclitaxel and gemcitabine|Induction treatment:
3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Continouous treatment after randomization:
Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
184273|NCT00186888|Drug|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
184565|NCT02557516|Drug|IPH2201|During phase 1b, patients receive IPH2201, IV, at the dose of 1, 2, 4 or 10 mg/kg, every 2 weeks during 2 cycles as a single agent and every 2 weeks during 26 cycles, combined with ibrutinib 420 mg, orally, once daily.
During phase 2a, patients receive IPH2201 at the dose recommended upon completion of phase 1b portion, IV, every 2 weeks during 28 cycles, combined with ibrutinib 420 mg orally, once daily, from the first cycle.
184566|NCT02557529|Behavioral|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
184567|NCT02557529|Behavioral|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
184568|NCT02557529|Behavioral|Diet diary|Weekly diet diary during the 12-weeks intervention
184569|NCT02557542|Other|One Stop Vein Clinic|Same day diagnosis and treatment
184570|NCT02557542|Device|Radiofrequency ablation|Venous ablation
184571|NCT02557542|Device|Endovenous laser ablation|Venous ablation
184572|NCT02557542|Drug|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
184573|NCT02557555|Other|educational information|patients will receive pamphlet on labor analgesia options.
183969|NCT02568514|Device|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
183970|NCT02568527|Device|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
183971|NCT02568553|Biological|Blinatumomab|Given IV
183972|NCT02568553|Other|Laboratory Biomarker Analysis|Correlative studies
183973|NCT02570542|Procedure|Autologous Stem Cell Transplantation|
183974|NCT02570568|Device|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
183975|NCT02570568|Device|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
183976|NCT02570568|Procedure|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
183977|NCT02570581|Other|Jelly with:Paracetamol|A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses ("verrines") randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.
The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.
The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.
Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions.
183978|NCT02570581|Other|Jelly with Furosemide|
183979|NCT02570581|Other|Jelly with Levothyroxine sodium salt|
183980|NCT02570581|Other|Jelly with Memantine|
184274|NCT02564146|Drug|gemcitabine mono and nab-paclitaxel and gemcitabine|Induction treatment:
3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Continouous treatment after randomization:
Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.
Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.
Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
184275|NCT02564159|Other|Measure of quadriceps diameter and albumin/prealbumin levels|Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ; collection of albumin and prealbumin levels
183677|NCT02501928|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
183678|NCT02501928|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
183679|NCT02501928|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
183680|NCT02501928|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
183681|NCT02501941|Drug|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
183682|NCT00178971|Drug|placebo|placebo
183683|NCT02501954|Drug|Cisplatin|Given IV
183684|NCT02501954|Drug|Carboplatin|Given IV
183685|NCT02501954|Drug|Paclitaxel|Given IV
183686|NCT02541331|Biological|PLACEBO|Matched tablets without any active substance.
183687|NCT02541344|Device|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
183688|NCT02541344|Device|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
183689|NCT02541344|Device|Placebo|Placebo group will take 4 placebo tablets.
The placebo is designed to be identical to IQP-VV-102.
183690|NCT02541357|Behavioral|relaxation program|relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises
1 week program, one introductory session and daily home practice
183691|NCT02541357|Behavioral|surgery education|intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery
1 single unit in the week before the surgery
183692|NCT02541370|Biological|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
183693|NCT02541383|Drug|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
183694|NCT00184145|Other|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
187932|NCT01967758|Drug|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623.
187933|NCT01967771|Drug|DTG|DTG will be supplied as 50 mg tablet to be administered orally
187934|NCT01967771|Drug|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
187935|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
187936|NCT01967784|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
188231|NCT01960621|Drug|cyclodextrin|intravenous
188232|NCT01960647|Device|Percutaneous transluminal angioplasty with uncoated balloon|
188233|NCT01960647|Device|Percutaneous transluminal angioplasty with Paclitaxel balloon|
188234|NCT01960660|Dietary Supplement|Omega-3 Fatty Acids|
188235|NCT01960673|Device|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
188236|NCT01960673|Device|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
188237|NCT01963156|Behavioral|Prescription synchronization|Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the "index "medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.
Randomization will occur within strata of whether patients are enrolled in the "ReadyFill@Mail" program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point.
188238|NCT01963169|Behavioral|TO-BoneHealth Program (Bone Power Program)|The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
188239|NCT01963169|Behavioral|TO-BoneHealth Plus Program (Bone Power Plus Program)|This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
188240|NCT01963182|Drug|Irinotecan|
188241|NCT01963195|Drug|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
187651|NCT01972945|Procedure|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
187652|NCT01975181|Behavioral|Sleep Improvement|After evaluation of treatment of sleep pathologies such as obstructive sleep apnea and periodic limb movement disorder, subjects are taught to employ "tension tamer" techniques and pursue daily exercise to improve sleep latency and sleep continuity.
187653|NCT01975194|Drug|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
187654|NCT01975207|Behavioral|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
187655|NCT01975207|Behavioral|Internet Intervention|One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed "MoodGYM" (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice
187656|NCT01975207|Behavioral|Depression Treatment Pathway|There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as "a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes." A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family.
187937|NCT01967797|Behavioral|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
187938|NCT01967810|Drug|ANG1005|ANG1005 at a starting dose of 650 mg/m2 by intravenous infusion once every 3 weeks
187939|NCT01967810|Drug|Bevacizumab|For patients enrolled in the bevacizumab-refractory in recurrent GBM (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
187940|NCT01967823|Biological|Anti-NY ESO-1 mTCR PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 mTCR PBL and high dose aldesleukin. On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
187941|NCT01967823|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
187942|NCT01970397|Device|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
187943|NCT01970410|Drug|teriflunomide|14 mg oral teriflunomide daily
159450|NCT01794858|Other|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
159451|NCT00099645|Drug|Mifepristone|
159452|NCT01794884|Drug|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
159453|NCT01794884|Drug|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
159454|NCT01796938|Drug|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
159455|NCT00099944|Drug|Glimepiride|Glimepiride 4 mg qd
159456|NCT01796951|Drug|Aspirin 325 mg daily|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
159738|NCT01800201|Behavioral|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use the GlowCaps, a remote monitoring and reminder pill bottle; (2) will be assigned an engagement advisor from the study team; (3) asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence; and (5) will determine their preferences for Way to Health platform communication methods during the study.
159739|NCT01800227|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
159740|NCT01800240|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
159741|NCT01800253|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
159742|NCT01800253|Procedure|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
159743|NCT00100308|Drug|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
159744|NCT01800253|Procedure|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
159745|NCT01800253|Procedure|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
184088|NCT00184821|Procedure|Ischemic preconditioning|
184089|NCT02546115|Other|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
184090|NCT02546128|Device|Extra-Corporeal Shockwave Therapy (ESWT)|The use of ESWT from a commercially available machine at approved settings already in routine clinical use
184091|NCT02546128|Other|structured rehabilitation programme|a structured and standardised rehabilitation programme specific to the tendon in question - already in routine clinical use
184092|NCT02546141|Other|skimmed milk (UHT)|
184093|NCT02546141|Other|skimmed milk (pasteurized)|
184094|NCT02546141|Other|skimmed yoghurt|
184095|NCT02546141|Other|full-fat milk (UHT)|
184096|NCT02546141|Other|non-homogenized full-fat milk (pasteurized)|
184097|NCT02546141|Other|full-fat cheese (semi-matured)|
184098|NCT02546141|Other|whey protein|
184099|NCT00184821|Procedure|Forearm ischemic exercise|
184100|NCT02546141|Other|micellar casein|
184101|NCT02546154|Drug|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
184102|NCT02546167|Biological|CART-BCMA|
184103|NCT02546180|Other|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
184393|NCT02539277|Drug|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
184394|NCT02539277|Drug|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
184395|NCT02539277|Drug|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
184396|NCT00183911|Procedure|Surgery|
184397|NCT02539290|Behavioral|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
184398|NCT02539290|Procedure|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
183788|NCT02550327|Drug|Anakinra|100 mg
183789|NCT02550340|Other|acute alcohol intake|Smart phone based ECG recording
183790|NCT02550353|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
183791|NCT00185159|Drug|Olmesartan medoxomil|tablets
183792|NCT02552394|Drug|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
183793|NCT02552407|Device|Allocation of treatment to Manual Aspiration Thrombectomy|
183794|NCT02552433|Dietary Supplement|protein intake assessment and optimisation|
183795|NCT02552459|Drug|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
183796|NCT02552459|Drug|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
183797|NCT00185315|Drug|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
183798|NCT02552459|Drug|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
183799|NCT02552459|Drug|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
183800|NCT02552485|Other|No intervention was applied, because it is an observational study|
183801|NCT02552498|Procedure|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
183802|NCT02552524|Device|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
183803|NCT02552524|Device|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
183804|NCT02552537|Drug|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
183805|NCT02552537|Drug|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
188046|NCT01980771|Behavioral|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
188047|NCT01980810|Drug|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
188350|NCT01975337|Drug|DEB025|Single oral dose of alisporivir 400 mg
188351|NCT01975363|Dietary Supplement|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
188352|NCT01975363|Other|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
188353|NCT01975363|Other|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
188354|NCT01975363|Other|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
188355|NCT01975376|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
188356|NCT01975376|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
188357|NCT01975389|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
188358|NCT00117572|Drug|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
188359|NCT01975389|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
188360|NCT01975428|Device|Withings Blood Pressure monitor|Home blood pressure monitor. Participants will measure their blood pressure 2 times per day up to 3 times per week.
188361|NCT01975428|Device|iBG Star Blood Glucose Monitor|Participants will measure their blood glucose up to 4 times per day, every day.
188362|NCT01975428|Device|Alive Cor Portable ECG mopnitor|Portable electrocardiogram. Subjects will monitor their cardiac rhythms only when they have symptoms.
188363|NCT01975428|Behavioral|Diese Management Program|
188364|NCT01975441|Drug|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
188365|NCT01975441|Drug|Albendazole|Albendazole 400mg
187457|NCT01993134|Procedure|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
187458|NCT01993147|Drug|Methylphenidate|20mgs of methlyphenidate or placebo to be administered one hour before fMRI and task performance.
187459|NCT01993147|Drug|Placebo|20mgs of methylphenidate or a placebo to be administered one hour before fMRI and task performance.
187460|NCT01993160|Drug|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
187461|NCT01993160|Radiation|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
187754|NCT01985724|Drug|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
187755|NCT01985724|Drug|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
187756|NCT01985724|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
187757|NCT01985737|Other|Sample collection|
187758|NCT01988194|Device|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
187759|NCT01988207|Behavioral|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
187760|NCT01988207|Behavioral|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
187761|NCT01988220|Other|sensory retraining|
187762|NCT01988220|Other|repeated sensory input|sensory stimulation without attentive learning focus
187763|NCT01988233|Behavioral|BAILAMOS© Dance Program|
187764|NCT01988233|Behavioral|Health Education Control Group|
187765|NCT01988246|Drug|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
187766|NCT00118352|Drug|fludarabine phosphate|Given IV
186843|NCT02542774|Other|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
186844|NCT02542787|Drug|VSN16R|Small molecule
186845|NCT02542787|Other|Placebo|dummy tablet
186846|NCT02542800|Behavioral|Episodic memory task|
186847|NCT00184379|Behavioral|Psychoeducation|Structured disorder-related educational program for relatives
186848|NCT02542800|Device|fMRI|
186849|NCT02542813|Drug|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
187159|NCT02571946|Radiation|Proton beam therapy|
187160|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
187161|NCT00187707|Drug|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
187162|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
187163|NCT02571972|Drug|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
187164|NCT02571985|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation System|Zenith® Branch Endovascular Graft-Iliac Bifurcation (Branch Graft) with the ConnectSX™
187165|NCT02571998|Drug|Omiganan (CLS001) Topical Gel|
187166|NCT02571998|Drug|Vehicle Topical Gel|
187167|NCT02572011|Other|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
187168|NCT02572024|Device|BAT|Baroreflex activation therapy device ON
187169|NCT02572024|Other|Placebo|Baroreflex activation therapy device OFF
187170|NCT02572050|Procedure|Robotic Distal Gastrectomy with D2 LND)|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
187171|NCT02574078|Drug|Gemcitabine|
187172|NCT02574078|Drug|Erlotinib|
186247|NCT02553525|Procedure|Bradykinesia Neurostimulator|Subjects will perform a two-finger tapping task several times during neurostimulation for approximately 20s at a time in which they alternately press the two buttons of a computer mouse with index and middle fingers as rapidly as possible. There will be approximately 4 min of neurostimulation off between trials, and the subject will repeat the task several times during the neurostimulation off periods. LFPs will be recorded throughout both on and off periods. Measurements from the finger-tapping task include the average rate and the coefficient of variation of the tap durations. The correlation between the regularity of finger tapping and the modified UPDRS motor sub-score allows translation of these quantitative results to estimated changes in clinical scores.
186248|NCT02553525|Device|Neurostimulator|All subjects will have a neurotransmitter for deep brain stimulation (DBS) with conventional implantable pulse generator (IPG) which can only generate regular, fixed-frequency pulse trains. During normal treatment, when the battery of the IPG is depleted, the IPG, which is implanted underneath the skin of the chest beneath the collarbone, is surgically replaced. The subjects will be recruited from a group of patients who have opted to have surgery to replace their IPG and will be randomized to receive different frequency pulse trains. The frequency pulse trains will either consist of the Tremor Neurostimulation Protocol or the Bradykinesia Neurostimulation Protocol.
186249|NCT00185445|Drug|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
186543|NCT02547155|Procedure|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
186544|NCT02547155|Procedure|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
186545|NCT02547168|Device|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
186546|NCT02547181|Behavioral|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
186547|NCT02547181|Behavioral|Splint|fibreglass splint
186548|NCT00000372|Drug|D-cycloserine|
186549|NCT00002499|Drug|vincristine sulfate|
186550|NCT00184899|Drug|Intravenous infusion of Glycerol/heparin|
186551|NCT02547220|Biological|Cinryze®|7 doses of study drug over 13 days
186552|NCT02547220|Drug|Placebo|7 doses of placebo over 13 days
186553|NCT02547233|Drug|LEO 43204 gel|
186554|NCT02547233|Drug|Vehicle gel|
186555|NCT02547246|Device|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
186556|NCT02549209|Drug|Carboplatin|For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.
Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes.
185975|NCT02558153|Device|standard PTA|Percutaneous angioplasty performed with a standard balloon
185976|NCT00002506|Drug|isotretinoin|
185977|NCT00186069|Drug|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
185978|NCT02558192|Dietary Supplement|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
185979|NCT02558192|Dietary Supplement|PLACEBO|1 vials q12 for 15 days
185980|NCT02560441|Other|chemotherapy followed by radiotherapy|
185981|NCT00186446|Drug|bupropion|
185982|NCT02560441|Other|radiotherapy followed by chemotherapy|
185983|NCT02560441|Drug|IPGDP regimen chemotherapy|
186250|NCT02553538|Behavioral|Patient Navigation|Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
186251|NCT02553551|Drug|Vitamin C|During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.
After discharge, no additional vitamin C pill was given.
186252|NCT02553551|Drug|Placebo|During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.
After discharge, no additional capsule was given.
186253|NCT02553564|Other|Checklist driven clinical encounter after hospital discharge|Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:
The participants's hospital course will be reviewed and their clinical recovery and stability assessed.
Determination of the participants's estimated dry weight (EDW).
The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.
Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.
Write new dialysis orders.
Dialysis Access- review access and determine any changes required in treatment
186254|NCT02553603|Drug|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
186255|NCT02553616|Behavioral|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
186256|NCT02553629|Drug|Rocuronium|
186257|NCT02553642|Drug|Nivolumab|
186258|NCT02553642|Drug|Nivolumab plus Ipilimumab|
185685|NCT02564549|Procedure|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
185686|NCT02564549|Procedure|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
185687|NCT02564562|Drug|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + [14C] PF-06463922
185688|NCT02564575|Biological|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
185689|NCT02564588|Drug|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
185690|NCT00186888|Drug|Vincristine+Carboplatin+Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
185691|NCT02564588|Drug|Placebo|Placebo once daily
185692|NCT02564601|Behavioral|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
185693|NCT02564601|Behavioral|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
185694|NCT02564614|Drug|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
185695|NCT02564627|Procedure|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
185696|NCT02564627|Procedure|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
185697|NCT02564627|Dietary Supplement|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
185698|NCT02564640|Device|videolaryngoscope|patients intubated by using the videolaryngoscope
185984|NCT02560454|Behavioral|Cogmed|Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.
Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.
Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance`s
185120|NCT00184600|Drug|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
185121|NCT02544282|Drug|Paracetamol|Pain Relief
185122|NCT02544282|Drug|Tramadol|Pain Relief
185123|NCT02544282|Drug|Piritramide|Pain Relief
185124|NCT02544295|Behavioral|Clinical interview|
185125|NCT02544295|Behavioral|Virtual reality task|
185391|NCT02571218|Device|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
185392|NCT02571218|Device|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
185393|NCT02571231|Device|HFV + and - VG|High frequency ventilation with and without volume guarantuee
185394|NCT02573402|Device|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
185395|NCT02573402|Device|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
185396|NCT02573415|Procedure|Uterus Transplant|transplant of a deceased donor uterus.
185397|NCT02573441|Behavioral|Jump Math|Jump Math is a workbook based program aimed at improving math skills
185398|NCT02573441|Behavioral|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
185399|NCT02573441|Behavioral|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
185400|NCT00187993|Drug|Growth hormone|
185401|NCT02573454|Behavioral|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
185402|NCT02573467|Drug|Bimagrumab|
185403|NCT02573467|Drug|Placebo|
184855|NCT02550756|Drug|CTNX-4975|
184856|NCT02550769|Procedure|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
184857|NCT02550769|Procedure|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
184858|NCT00185367|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
184859|NCT02552888|Drug|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
184860|NCT02552888|Dietary Supplement|Isoquercetin|Isoquercetin 225 mg by mouth once per day
184861|NCT02552888|Other|placebos|placebos
185126|NCT02544308|Drug|Lenalidomide|Experimental Arm
185127|NCT02544308|Drug|Dexamethasone|Experimental Arm
185128|NCT02544308|Other|No further treatment|Comparator Arm
185129|NCT02544321|Drug|Bromocriptine|
185130|NCT02544321|Other|Placebo|
185131|NCT00184613|Device|pump|
185132|NCT02544334|Procedure|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
185133|NCT02544334|Other|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
185134|NCT02544334|Other|Saliva Collection|All participants will have a saliva collection.
185135|NCT02544347|Other|gingival crevicular fluid|gingival crevicular fluid was collected
185136|NCT02544347|Other|non-surgical periodontal treatment|scaling and root planing were performed
185137|NCT02544360|Behavioral|Photoaging mobile app promoting poster campaign.|Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a "selfie").
184574|NCT00185965|Drug|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
184575|NCT02557568|Other|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
184576|NCT02559804|Other|survival and late effects|survival and late effects
184577|NCT02559817|Drug|Linaclotide Dose A|
184578|NCT02559817|Drug|Linaclotide Dose B|
184579|NCT02559817|Drug|Linaclotide Dose C|
184580|NCT02559817|Drug|Linaclotide Approved Adult Dose|
184581|NCT02559817|Drug|Matching Placebo|
184582|NCT02559830|Genetic|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10^6 transduced CD34+ cells/Kg (maximum 20x10^6) at bedside for infusion.
184583|NCT00186303|Procedure|ablative allogeneic hematopoietic cell transplant|
184584|NCT02559843|Dietary Supplement|pomegranate juice|
184862|NCT02552901|Drug|0.1 mg/kg ICG Dose|least efficacious dose
184863|NCT02552901|Drug|0.5 mg/kg ICG dose|per package insert
184864|NCT02552914|Device|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
184865|NCT02552927|Device|Chest shield with aluminum foil (CALF)|
184866|NCT02552927|Device|SHIELD|
184867|NCT02552940|Drug|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
184868|NCT02552953|Drug|CYC065|
184869|NCT00185367|Drug|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
184870|NCT02552966|Device|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
184871|NCT02552979|Other|atopic patch test|
184276|NCT02564172|Device|CMS group|Conus medullaris stimulation with pentapolar surgical lead includes:
Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)
Test phase of 10 days according to HAS("Haute Autorité de Santé") recommendation
If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.
If test phase negative, the lead is removed.
Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.
(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect).
184277|NCT02564172|Other|OMM group|Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:
at effective dose, and minimal effective dose on the basis of adverse events and contraindications
as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.
Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.
Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated.
184278|NCT02564185|Other|Usual practice|
184279|NCT02566304|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
184280|NCT02566304|Drug|Cyclophosphamide|Given IV
184281|NCT02566304|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
184282|NCT02566304|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
184283|NCT02566304|Drug|Tacrolimus|Given PO
184284|NCT00187057|Drug|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
184285|NCT02566304|Drug|Mycophenolate mofetil|Given IV
184286|NCT02566317|Device|Sit-Stand workstation|Installation of a sit-stand desk at work
184287|NCT02566317|Behavioral|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
184288|NCT02566330|Device|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
184585|NCT02559843|Behavioral|lifestyle modification|
184586|NCT02559856|Drug|Apixaban|
184587|NCT02559856|Drug|Rivaroxaban|
184588|NCT02559869|Drug|[18F] GE-180|PET Tracer Ligand
184589|NCT02559895|Drug|ALD403|
183981|NCT00187460|Behavioral|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
183982|NCT02570581|Other|Jelly with Zopiclone|
183983|NCT02570581|Other|Jelly with Alprazolam|
183984|NCT02570581|Other|Jelly with Oxazepam|
183985|NCT02570581|Other|Jelly with Donepezil|
183986|NCT02570581|Other|Jelly with Clopidogrel|
183987|NCT02570581|Other|Jelly with Ramipril|
183988|NCT02570581|Other|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
183989|NCT02570581|Other|Plain jelly control|
183990|NCT02570581|Other|Apple compote Paracetamol|
183991|NCT02570581|Other|Apple compote Furosemide|
183992|NCT00187473|Procedure|liver biopsy|Liver biopsy every 5 years
183993|NCT02570581|Other|Apple compote Levothyroxine sodium salt|
183994|NCT02570581|Other|Apple compote Memantine|
183995|NCT02570581|Other|Apple compote Zopiclone|
183996|NCT02570581|Other|Apple compote Alprazolam|
183997|NCT02570581|Other|Apple compote Oxazepam|
183998|NCT02570581|Other|Apple compote Donepezil|
183999|NCT02572908|Other|Regular yeast baked toast bread|
184000|NCT02572908|Other|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
184001|NCT02572921|Behavioral|Positive Psychotherapy|The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:
positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the "full life".
188242|NCT01963208|Drug|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
188243|NCT01963208|Drug|Placebo|placebo
188244|NCT01963221|Radiation|fludeoxyglucose(18f)|
188245|NCT01963221|Other|blood sample|
188246|NCT00116168|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
188247|NCT01963221|Other|cardiac and aortic magnetic resonance imaging|
188248|NCT01963221|Other|carotid femoral pulse wave velocity|
188249|NCT01963221|Radiation|positron emission tomography|
183695|NCT02541383|Drug|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
183696|NCT02541383|Drug|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
183697|NCT02541396|Drug|Wafermine|35 or 70 mg ketamine in a sublingual wafer
183698|NCT02541396|Drug|Oxycodone|5 mg oxycodone capsule
183699|NCT02541396|Drug|Placebo|Placebo capsule or placebo wafer
183700|NCT02541409|Drug|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
183701|NCT02541409|Drug|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
183702|NCT02541409|Drug|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
183703|NCT02541422|Dietary Supplement|N Acetyl Cysteine|
183704|NCT02541422|Other|placebo|
183705|NCT00002498|Drug|methotrexate|
183706|NCT00184158|Procedure|decompression|Conservative, simple decompression and nerve transfer
183707|NCT02541448|Device|SurgiQuest AIRSEAL® Insufflation System (AIS)|The SurgiQuest AirSeal Optical Trocar & Cannula System with integrated Insufflator DPIS 2000 (the "DPIS 2000 System") is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization.
187944|NCT01970423|Device|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
187945|NCT01970423|Device|conventional right ventricular stimulation|
187946|NCT01970436|Other|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
187947|NCT00117039|Drug|Aranesp®|
187948|NCT01970449|Biological|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
187949|NCT01970449|Biological|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
187950|NCT01970449|Biological|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
187951|NCT01970449|Biological|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
187952|NCT01970449|Biological|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
188250|NCT01963221|Radiation|computed tomography|
188251|NCT01963260|Drug|MK-8723|MK-8723 administered as a single IV infusion.
188252|NCT01963260|Drug|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion.
188253|NCT01963273|Procedure|Video Assisted Ablation of Pilonidal Sinus|
188254|NCT01963286|Device|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
188255|NCT01963299|Drug|5 ml Ropivacaine 10% + physiological saline|
188256|NCT01963299|Drug|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
188257|NCT00002125|Drug|Foscarnet sodium|
188258|NCT01965405|Behavioral|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
188259|NCT01965405|Behavioral|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
159746|NCT01800253|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
159747|NCT01800266|Behavioral|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
159748|NCT01800279|Other|Physiotherapy Protocol|Kinesitherapy
Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.
Tongue in the palate for all applied exercises.
Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).
Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.
Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid.
159749|NCT01800279|Other|Deontology Therapy|For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):
Impression of the maxilla with chromatic alginate "Phase plus" (Zhermack ©, Rovigo, Italy).
Emptying working models in plaster-stone type IV "Elite Rock" (Zhermack ©, Rovigo, Italy).
Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate "The Machine" Dentaflux ©, Ripoll, Madrid.
159750|NCT01792752|Behavioral|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
160035|NCT01795716|Drug|Glivec|Single and multiple oral Glivec 400mg qd
160036|NCT01795729|Device|Stent|Coronary revascularization
160037|NCT01795729|Drug|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
160038|NCT01795742|Device|Human-Powered Nebulizer|
160039|NCT01795755|Behavioral|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
160040|NCT01795755|Behavioral|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
160041|NCT00099801|Drug|FTY720|
160042|NCT01795768|Drug|AZD 4547|
160043|NCT01795794|Drug|omeprazole|
160044|NCT01795820|Drug|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
184399|NCT02539290|Procedure|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
184400|NCT02539290|Behavioral|Sexual intercourse|Sexual intercourse within 12 hours after intervention
184401|NCT02541643|Drug|Elotuzumab|Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.
A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:
H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent
H2 blocker: ranitidine (50mg IV) or equivalent
acetaminophen (650-1000mg PO)
184402|NCT02541656|Procedure|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
184403|NCT02541669|Drug|TAK-491|TAK-491 tablets
184404|NCT02541682|Other|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
184405|NCT02541695|Biological|E. coli strain E1392-75-2A|At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.
At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
184406|NCT02541708|Drug|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
184407|NCT00184171|Drug|Fiber|Fiber for control
184408|NCT02541708|Drug|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
184696|NCT02570841|Drug|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
184697|NCT02570841|Drug|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
184698|NCT02570854|Biological|CSJ137|Subjects will be dosed with 0.001 mg/kg to 0.1 mg/kg once over 30-60 minutes via intravenous infusion.
183806|NCT02552550|Procedure|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
184104|NCT02546180|Other|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
184105|NCT02546193|Device|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
184106|NCT02546193|Drug|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
184107|NCT02546206|Dietary Supplement|Probiotic Yoghurt|Probiotic yoghurt consumption
184108|NCT02546206|Dietary Supplement|Natural Yoghurt|Natural yoghurt consumption
184109|NCT02546219|Other|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
184110|NCT00184821|Procedure|Annexin A5 scintigraphy|
184111|NCT02548234|Other|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 0.5 hours/day, 5 days/week.
184112|NCT02548234|Other|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 0.5 hours/day, 5 days/week.
184113|NCT02548247|Dietary Supplement|Orafti® Inulin|Dietary fiber
184114|NCT02548247|Dietary Supplement|Placebo|Maltodextrin
184115|NCT02548260|Device|Syndactyly without compression|three week relative immobilization by syndactyly
184116|NCT02548260|Device|Syndactyly with compression|three week relative immobilization by syndactyly and compression
184117|NCT02548260|Device|Rigid splint without compression|three week rigid immobilization by splint
184118|NCT00184977|Drug|fluticasone propionate|
184119|NCT02548260|Device|Rigid splint with compression|three week rigid immobilization by splint and compression
184120|NCT02548286|Drug|Candesartan 8mg|PO, 1day or 22day
184121|NCT02548286|Drug|Amlodipine 5mg|PO, 1day or 22day
188366|NCT01975441|Drug|Ivermectin|Ivermectin 200 mcg/kg
188367|NCT01975454|Drug|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
188368|NCT01975454|Drug|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
183807|NCT02552563|Behavioral|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
183808|NCT00185328|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
183809|NCT02552576|Biological|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
183810|NCT02552589|Other|Amine fluoride|toothpaste
183811|NCT02552589|Other|Placebo|toothpaste
183812|NCT02552602|Dietary Supplement|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
183813|NCT02554851|Drug|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
183814|NCT02554851|Other|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
183815|NCT02554864|Drug|lidocaine|Local anesthetic
183816|NCT02554864|Drug|ropivacaine|Local anesthetic
183817|NCT02554877|Drug|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
183818|NCT02554877|Drug|Placebo|oral tablet
183819|NCT02554890|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
187767|NCT01988246|Drug|Sham|Sham injection. No actual injection. No medication is used.
187768|NCT01988259|Procedure|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
187769|NCT01988259|Procedure|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
187770|NCT01988259|Procedure|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
187771|NCT01988259|Procedure|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
187772|NCT01988272|Device|SPECT/CT imaging|Patients will undergo scanning on the above system.
187773|NCT01988298|Drug|Ibuprofen|Ibuprofen 400 mg each 8 hours
187774|NCT01988298|Drug|Acetaminophen|Control group
188048|NCT01980810|Drug|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
188049|NCT01980823|Drug|Metformin|Metformin is an oral diabetes medicine that helps control blood sugar levels.
Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes.
188050|NCT01983423|Device|Endometrial Biopsy|An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
188051|NCT01983436|Other|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
188052|NCT01983449|Drug|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
188053|NCT01983462|Drug|Clonidine|
188054|NCT01983462|Drug|Hydrochlorothiazide|
188055|NCT01983462|Drug|Placebo|
188056|NCT01983475|Drug|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
187173|NCT02574078|Drug|Crizotinib|
187174|NCT02574078|Drug|Carboplatin|
187175|NCT02574091|Drug|1% icotinib hydrochloride cream|Topical administration for twice daily
187176|NCT02574091|Drug|2% icotinib hydrochloride cream|Topical administration for twice daily.
187177|NCT02574091|Drug|Placebo|Topical administration for twice daily.
187178|NCT00188071|Drug|ketoprofen + paracetamol|
187179|NCT02574104|Other|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
187462|NCT01993160|Radiation|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
187463|NCT01993173|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
187464|NCT01993173|Biological|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
187465|NCT00118794|Drug|Lumefantrine-artemether (Coartemether )|
187466|NCT01993173|Biological|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
187467|NCT01993186|Drug|UX007 (triheptanoin)|Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. UX007 is manufactured by chemical synthesis from glycerol and heptanoic acid. UX007 (triheptanoin) is a liquid, intended for oral (PO) administration.
187468|NCT01993186|Drug|Placebo Oil|
187469|NCT01993199|Procedure|deep biopsy via ESD technique|
187470|NCT01993212|Drug|Androxal 12.5 mg or 25 mg|
187471|NCT01993212|Drug|AndroGel 1.62%|
187472|NCT01993212|Drug|Placebo Capsules|
187473|NCT01993212|Drug|Placebo Gel|
187474|NCT01993225|Drug|Androxal 12.5 mg/25 mg|
187475|NCT01993225|Drug|Placebo Capsules|
187476|NCT00118807|Drug|Amodiaquine plus artesunate (AQ/AS)|
186557|NCT02549222|Other|Standard of Care|
186558|NCT02549235|Other|Ultrasound|Routine ultrasound assessment
186559|NCT02549248|Other|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
186560|NCT02549248|Other|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
186561|NCT02549248|Other|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
186562|NCT02549248|Other|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
186563|NCT02549248|Other|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
186564|NCT02549261|Drug|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
186565|NCT00185068|Drug|Hydrochlorothiazide|
186850|NCT02542813|Drug|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
186851|NCT02542813|Drug|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
186852|NCT02542813|Drug|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
186853|NCT02542813|Drug|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
186854|NCT02542813|Drug|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
186855|NCT02542826|Other|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
186856|NCT02542839|Device|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
186857|NCT02542839|Device|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
186858|NCT00184392|Procedure|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
186859|NCT02544893|Drug|serum physiologic|21 ml serum physiologic is applied paravertebral space
186259|NCT02553655|Procedure|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
186260|NCT00185458|Drug|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
186261|NCT02555982|Drug|BOTOX ® 200 Unités|Patients eligible for inclusion will be randomized to one of the two groups:
Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
186262|NCT02555982|Drug|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
186263|NCT00185744|Radiation|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
186264|NCT02555995|Device|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
186566|NCT02549261|Drug|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
186567|NCT02549261|Drug|Etoposide|Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.
the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.
186568|NCT02549261|Radiation|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
186569|NCT02549274|Other|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
186570|NCT02549274|Other|physiotherapy|14 physiotherapy sessions (2 by week)
186571|NCT02549287|Behavioral|SafeCare|An evidence-based home visiting program
186572|NCT02549287|Behavioral|Supportive Case Management|Child welfare services as usual
186573|NCT02549300|Other|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
186574|NCT02549313|Procedure|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
185985|NCT02560454|Behavioral|Presco|Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.
Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.
The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances.
185986|NCT02560467|Drug|Echo and myocardial contrast echocardiography perfusion imaging|Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.
Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses.
185987|NCT02560480|Device|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
185988|NCT02560493|Behavioral|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
185989|NCT02560506|Device|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
185990|NCT02560519|Drug|Albumin solution|Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.
During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 4000 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 4000 mL are needed for volume replacement therapy.The volume replacement therapy is not protocolled but will be based on the clinical decision.
185991|NCT02560519|Drug|Ringers acetate solution|The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.
During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 4000 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 4000 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not protocolled but will be based on the clinical decision.
185992|NCT00186446|Drug|nicotine patch|
185993|NCT02560532|Drug|Clazosentan|Concentrated solution for intravenous injection
185994|NCT02560545|Drug|Cannabis oil|Cannabis oil 20% THC
185995|NCT02562521|Drug|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
186265|NCT02556008|Drug|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
186266|NCT02556021|Drug|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
185404|NCT02573480|Behavioral|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
185405|NCT02573493|Drug|nab-Paclitaxel|
185406|NCT02573493|Drug|Cisplatin|
185407|NCT02573493|Biological|Cetuximab|
185408|NCT02573493|Radiation|Intensity-Modulated Radiation Therapy|
185409|NCT02573506|Drug|consolidation chemotherapy of AP or DP after CCRT|pemetrexed(500mg/㎡) and nedaplatin(75mg/㎡) in non-squamous lung cancer or docetaxel(60mg/㎡) and nedaplatin(75mg/㎡) in squamous lung cancer
185699|NCT02564640|Device|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
185700|NCT02564653|Behavioral|Technical Assistance, training and clinical reminders|Technical Assistance, training and clinical reminders (TTC)
185701|NCT00186888|Procedure|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
185702|NCT02566824|Drug|Treatment as Usual - medication + community services|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
185703|NCT00187083|Drug|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
185704|NCT02566824|Drug|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
185705|NCT02566837|Procedure|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
185138|NCT02544373|Other|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
185139|NCT02544386|Procedure|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
185140|NCT02544399|Other|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
185141|NCT02544412|Behavioral|novel mindfulness-based well-being training|
185142|NCT00002499|Drug|daunorubicin hydrochloride|
185143|NCT02546583|Drug|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
185144|NCT02546583|Drug|IV Chlorothiazide|
185145|NCT02546596|Device|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
185146|NCT02546609|Drug|Sildenafil 0.5|0.5 mg of sildenafil BID
185147|NCT02546609|Drug|Sildenafil 1.0|1.0 mg of sildenafil BID
185148|NCT02546609|Drug|Metformin|500 mg Metformin BID
185149|NCT02546609|Drug|Leucine|550 mg Leucine BID
185150|NCT02546609|Drug|Placebo|Placebo
185410|NCT02573506|Radiation|chest radiation|split-course chest radiation at 51Gy/17f and 15Gy/5f
185411|NCT00188006|Device|heparin-coated cardiopulmonary bypass|
185412|NCT02573506|Drug|weekly DP concurrent with chest radiation|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
185413|NCT02573519|Radiation|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) [11C]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
185414|NCT02539589|Behavioral|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
185415|NCT02539602|Behavioral|The Need to Know students received the N2K curriculum as described previously|
185416|NCT02539615|Device|ForeCYTE Breast Aspirator|
184872|NCT02552992|Behavioral|Yoga|
184873|NCT02552992|Behavioral|Self-Directed Mind-Body Program|
184874|NCT02553005|Procedure|Acupuncture|
184875|NCT02553018|Drug|Methotrexate|
184876|NCT02553031|Device|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
184877|NCT02553044|Dietary Supplement|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
184878|NCT02553057|Device|mechanical ventilation|
184879|NCT02553070|Other|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
184880|NCT00002503|Radiation|strontium chloride Sr 89|
184881|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
184882|NCT02553083|Drug|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
184883|NCT02553083|Drug|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
184884|NCT02553083|Drug|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
185151|NCT00184847|Drug|acetylcholine|
185152|NCT02546622|Biological|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|
185153|NCT02546622|Biological|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|
185154|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
185155|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
185156|NCT02546648|Drug|Tranexamic Acid|
185157|NCT02546648|Drug|Tranexamic Acid Placebo|
185158|NCT02546648|Drug|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
184590|NCT02559895|Drug|Placebo|
184591|NCT02559908|Device|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
184592|NCT02559921|Biological|rhRIG（20 IU/kg）|
184593|NCT02559921|Biological|rhRIG（40 IU/kg）|
184594|NCT00186316|Biological|Idiotype-pulsed allogeneic dendritic cells|
184595|NCT02559921|Biological|HRIG（20 IU/kg）|
184596|NCT02559921|Biological|rhRIG（20 IU/kg） and vaccine|
184597|NCT02559921|Biological|rhRIG（40 IU/kg） and vaccine|
184598|NCT02559921|Biological|HRIG（20 IU/kg） and vaccine|
184599|NCT02559921|Biological|placebo and vaccine|
184600|NCT02559934|Drug|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
184601|NCT02559947|Drug|Vortioxetine|Vortioxetine is a novel antidepressant with hypothetical multimodal mechanism of action. It is thought to work through a combination of multiple pharmacological modes of action: 5-HT reuptake inhibition, 5-HT3 and 5-HT7 receptor antagonism, 5-HT1A receptor agonism, and 5-HT1B receptor partial agonism [43]. In vivo nonclinical studies have demonstrated that vortioxetine enhances levels of the neurotransmitters 5-HT, NE, DA, acetylcholine and histamine in specific areas of the brain [43]. These affinities are all considered to be of clinical relevance and involved in the mechanism of action at therapeutic doses.
184602|NCT02559960|Drug|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
184603|NCT02559973|Drug|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
184604|NCT02562053|Drug|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
184605|NCT02562053|Drug|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
184606|NCT02562053|Drug|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
184885|NCT02555319|Device|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
184886|NCT02555332|Other|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
184002|NCT02572921|Behavioral|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
184289|NCT02566356|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
184290|NCT02566356|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
184291|NCT02566369|Drug|CD5789 50μg/g cream|CD5789 50µg/g cream applied once daily for 12 weeks.
184292|NCT02566369|Drug|Placebo cream|Placebo cream applied once daily for 12 weeks
184293|NCT02566382|Procedure|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
184294|NCT02566395|Radiation|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
184295|NCT00187057|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
184296|NCT02566395|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
184297|NCT02566395|Biological|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
184298|NCT02566395|Biological|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
184299|NCT02566408|Other|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
184300|NCT02566408|Other|Survey Questions|Complete survey
184301|NCT02566421|Other|Laboratory Biomarker Analysis|Correlative studies
184302|NCT02566421|Other|Quality-of-Life Assessment|Ancillary studies
184303|NCT02566421|Other|Targeted Therapy|Receive treatment based on genomic sequencing
184304|NCT02566434|Dietary Supplement|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
184305|NCT02568553|Drug|Lenalidomide|Given PO
184306|NCT02568566|Other|Laboratory Biomarker Analysis|Correlative studies
184307|NCT02568566|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
183708|NCT02541461|Procedure|Laparoscopic gastrectomy|Patient enrolled will undergo either a laparoscopic gastrectomy with Billoth 1 anastomosis or Roux-en-Y anastomosis
183709|NCT02543671|Other|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
183710|NCT00002499|Drug|cytarabine|
183711|NCT00184548|Drug|placebo|placebo
183712|NCT02543684|Other|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
183713|NCT02543684|Other|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
183714|NCT02543684|Other|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
183715|NCT02543684|Other|oral glucose load|glucose load providing 50g of carbohydrates
184003|NCT02572947|Drug|Dolutegravir|
184004|NCT02572960|Drug|Valsartan|2 weeks of Valsartan 80 mg per day
184005|NCT00187876|Procedure|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
184006|NCT02572960|Drug|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
184007|NCT02572960|Dietary Supplement|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
184008|NCT02572960|Dietary Supplement|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
184009|NCT02572973|Other|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
184010|NCT02572986|Drug|Permethrin|
184011|NCT02572999|Procedure|Not applicable (observational design)|
184012|NCT02573012|Drug|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
184013|NCT02573012|Drug|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
188260|NCT01965405|Behavioral|No additional treatment|No additional treatment will be given.
188261|NCT01965405|Behavioral|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
188262|NCT01965405|Behavioral|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
188263|NCT01965418|Drug|Fufang Biejia Ruangan Tablet|
188264|NCT01965418|Drug|Placebo|
188265|NCT01965431|Drug|BI 207127|Medium dose oral administration
188266|NCT00116493|Dietary Supplement|Iron-folic acid and mebendazole|100 mg iron for pregnant women, 25 mg iron for children
1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children
188267|NCT01965431|Drug|BI 207127 placebo|
188268|NCT01965431|Drug|Faldaprevir placebo|
188269|NCT01965431|Drug|Faldaprevir|Medium dose oral administration
188270|NCT01965431|Drug|Moxifloxacin (Avalox®)|
188271|NCT01965470|Other|Combination Prevention|
188272|NCT01965470|Other|Enhanced Care|
183716|NCT02543697|Radiation|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
183717|NCT02543710|Procedure|Biomarker (ER/PR) guided lymphadenectomy|Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).
Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.
Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.
Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up.
160045|NCT01795820|Drug|no loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.
In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor.
160046|NCT01795833|Other|Short text messages|In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
160047|NCT01795846|Other|Allergen specific immunotherapy and placebo injections|
160048|NCT01795859|Drug|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
160049|NCT01795859|Drug|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
160050|NCT01795872|Procedure|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
160051|NCT01795885|Behavioral|16 and Pregnant|Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show "16 and Pregnant" once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show.
160052|NCT00099814|Procedure|Two different loop designs which deliver distinctive forces|
160053|NCT01795898|Drug|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
160336|NCT01783704|Behavioral|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
160337|NCT01783717|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
160338|NCT01783743|Other|TT Training Program and Recognition Card|The intervention is an additional training program on trichiasis recognition and a TT recognition card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
160339|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
160340|NCT01783756|Drug|lapatinib ditosylate|Given PO
160341|NCT01783756|Drug|everolimus|Given PO
184699|NCT02570880|Other|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products — Determination of the glycaemic index (GI) and recommendation for food classification
184700|NCT02570893|Radiation|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
184701|NCT02570893|Radiation|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
184702|NCT02570893|Drug|Paclitaxel and carboplatin|
184703|NCT00002510|Drug|etoposide|
184704|NCT00187499|Drug|Inhaled fluticasone 500 ug BID for 8 weeks|
184705|NCT02570906|Device|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
184706|NCT02570919|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
184707|NCT02570919|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
184708|NCT02573155|Drug|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
184709|NCT02573155|Drug|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
184710|NCT02573155|Drug|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
184711|NCT02573155|Drug|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
184712|NCT02573155|Drug|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
184713|NCT02573168|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
184122|NCT02548286|Drug|CKD-330 8/5mg|PO, 1day or 22day
184123|NCT02548299|Other|Nutrition Education|Nutrition classes will be led by a registered dietician.
184124|NCT02548299|Other|Cooking Lecture|
184125|NCT02548299|Other|Cooking Demo|
184409|NCT02541721|Device|LabiaStick#01|This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.
The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area.
184410|NCT02541734|Drug|Gelofusine|Infusion of gelofusine
184411|NCT02541734|Radiation|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
184412|NCT02541734|Drug|Placebo|
184413|NCT02541747|Behavioral|massage|massage
184414|NCT02541760|Drug|Monteleukast|4 ml monteleukast daily for one month
184415|NCT02541760|Drug|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
184416|NCT02541773|Device|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
184417|NCT02541786|Drug|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
184418|NCT00184197|Drug|Botulinum toxin|
184419|NCT02543931|Drug|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
184420|NCT02543931|Drug|placebo|Placebo capsules containing inert ingredients
184421|NCT02543944|Drug|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detox and transition to depot naltrexone.
184422|NCT02543944|Drug|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
184423|NCT02543944|Drug|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
184424|NCT02543944|Drug|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
184425|NCT00184587|Drug|candesartan cilexetil|
183820|NCT02554890|Drug|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
183821|NCT02554890|Drug|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
183822|NCT02554890|Drug|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
183823|NCT00185640|Drug|cyclosporine|3-5 mg/kg BID; IV or oral
184126|NCT02548299|Other|Hands-on Cooking|
184127|NCT02548299|Other|e-Coaching|
184128|NCT02548312|Other|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
184129|NCT00184990|Drug|Aminoguanidine|
184130|NCT02548325|Other|Not apply|None. Just registration epidemiology dates
184131|NCT02548338|Procedure|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
184132|NCT02548351|Drug|Obeticholic Acid|
184133|NCT02548351|Drug|Placebo|
184134|NCT02548364|Drug|Calcifediol|calcifediol treatment
184135|NCT02548364|Drug|Placebo|placebo control group
184136|NCT02548377|Procedure|Remote ischemic preconditioning|
184137|NCT02548377|Procedure|Sham|
184138|NCT02550353|Procedure|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
184139|NCT02550379|Behavioral|Intervention|Emotion Recognition Training
184140|NCT02550379|Other|Placebo|Placebo Training
184141|NCT02550392|Behavioral|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
188057|NCT01983475|Drug|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
188058|NCT00118092|Drug|tanespimycin|Given IV
188059|NCT01983501|Drug|ONT-380|Phase 1b dose escalation: 21-day cycles of ONT-380 (administered twice per day, orally) and T-DM1 (administered intravenously once every 21 days) until disease progression or unacceptable toxicity.
188060|NCT01983501|Drug|T-DM1|Phase 1b dose escalation: 21-day cycles of ONT-380 (administered twice per day, orally) and T-DM1 (administered intravenously once every 21 days) until disease progression or unacceptable toxicity.
188061|NCT01983514|Drug|8IU intranasal oxytocin|
188062|NCT01983514|Drug|24 IU intranasal oxytocin|
188063|NCT01983514|Drug|1 IU intravenous oxytocin|
188064|NCT01983514|Drug|Placebo|
188065|NCT01983527|Procedure|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
188369|NCT01978015|Drug|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
188370|NCT01978028|Drug|ferric carboxymaltose|
188371|NCT01978028|Drug|placebo|
188372|NCT01978041|Other|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
188373|NCT01978041|Other|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
188374|NCT01978041|Other|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
188375|NCT01978041|Other|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
188376|NCT01978041|Other|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
188377|NCT01978041|Other|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
187477|NCT01993225|Drug|AndroGel 1.62%|
187478|NCT01993225|Drug|Placebo Gel|
187479|NCT01955083|Device|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
187480|NCT01955096|Procedure|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
187481|NCT01955096|Procedure|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
187775|NCT01988311|Drug|psilocybin|dose manipulation as described in the protocol
187776|NCT01988324|Other|FDHT-PET scan|
187777|NCT00118352|Drug|cyclosporine|Given PO or IV
187778|NCT01988324|Other|FES-PET scan|
187779|NCT01988324|Other|CT-scan|
187780|NCT01988324|Other|Bone scintigraphy|
187781|NCT01988324|Other|Tumor biopsy|
187782|NCT00118508|Drug|risedronate (including placebo)|risedronate 35mg weekly
187783|NCT01990755|Dietary Supplement|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
187784|NCT01990755|Drug|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
187785|NCT01990768|Drug|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
187786|NCT01990768|Drug|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
187787|NCT01990768|Drug|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
186860|NCT02544906|Drug|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
186861|NCT02544906|Drug|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
186862|NCT02544919|Drug|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
186863|NCT02544932|Drug|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
186864|NCT02544932|Drug|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
186865|NCT02544932|Drug|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
186866|NCT00184665|Drug|insulin NPH|
186867|NCT02544945|Other|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
186868|NCT02544945|Other|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
187180|NCT02574117|Procedure|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
187181|NCT02574130|Drug|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
187182|NCT02574130|Drug|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
187183|NCT02574156|Drug|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
187184|NCT02574169|Other|alveolar recruitment maneuvers group 1|Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.
The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.
The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.
The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM.
187185|NCT02574169|Other|alveolar recruitment maneuvers group 2|Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.
The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.
The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.
The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM.
186575|NCT02549326|Dietary Supplement|vitamin D|
186576|NCT00002501|Drug|cyclophosphamide|
186577|NCT00185081|Drug|Indium labeled IMP-205xm734|
186578|NCT02549326|Dietary Supplement|Placebo|
186579|NCT02549339|Drug|LEO 43204 gel|
186580|NCT02549339|Drug|Vehicle gel|
186581|NCT02549352|Drug|LEO43204 gel|
186582|NCT02551458|Other|Systematic surgery|
186583|NCT00185224|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
186584|NCT02551458|Other|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
186585|NCT02551471|Other|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|This experiment will consist of an inter-country reading of patients' pelvic MRIs, "blind" to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries.
186586|NCT02551471|Other|MDT (Multidisciplinary team) meeting observation|3 per centre with "real" patient cases and "theoretical" patient cases (blinded pelvic MRI re-reading).
186869|NCT02544958|Device|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
186870|NCT02544971|Behavioral|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
186871|NCT02544971|Other|Control|Treatment as usual
186872|NCT02544984|Drug|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
186873|NCT02544984|Drug|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
186874|NCT02544997|Drug|Poziotinib|12mg P.O. for 2wks q21days
186267|NCT02556021|Drug|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
186268|NCT02556021|Drug|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
186269|NCT02556034|Other|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
186270|NCT02556047|Device|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N&S
186271|NCT02556060|Drug|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
186272|NCT02556060|Drug|Placebo|Same dosing schedule as study drug
186273|NCT02556073|Other|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
186274|NCT00002505|Biological|recombinant interferon gamma|
186275|NCT00185744|Procedure|Lumpectomy|
186276|NCT02556073|Drug|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
186277|NCT02556086|Drug|Daclatasvir|
186278|NCT02556086|Drug|Sofosbuvir|
186279|NCT02556099|Drug|Hydroxyurea|drug to be administered
186280|NCT02556112|Behavioral|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
186281|NCT02558205|Radiation|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
186282|NCT02558205|Radiation|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
185706|NCT02566837|Procedure|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
185707|NCT02566850|Device|Ekso|powered lower extremity exoskeleton
185708|NCT02566863|Drug|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
185709|NCT02566876|Drug|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
185710|NCT02566889|Drug|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
185711|NCT02566902|Device|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
185996|NCT02562521|Behavioral|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
185997|NCT02562534|Device|MRI compatible ElectroCardioGraph|MRI with ECG control for personnes with healthy heart or heart diseases
185998|NCT02562547|Device|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
185999|NCT02562560|Behavioral|Neuropsychological tests|
186000|NCT00186745|Drug|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
186001|NCT02562560|Device|Cerebral imaging (MRI, PET-FDG)|
186002|NCT02562573|Drug|PBI4050|
186003|NCT02562586|Device|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
186004|NCT02562599|Drug|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
186005|NCT02562599|Radiation|Intensity-modulated radiotherapy (IMRT)|
185417|NCT02539628|Drug|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
185418|NCT02539641|Radiation|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
185419|NCT02539641|Other|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
185420|NCT02539654|Drug|EXE844 Sterile Otic Suspension, 0.3%|
185421|NCT02539654|Procedure|Tympanostomy Tube Insertion|
185422|NCT02539680|Procedure|endoscopy|duodenal biopsies
185423|NCT02539693|Drug|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
185424|NCT00183950|Drug|Noscapine|
185425|NCT02539693|Drug|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
185426|NCT02539693|Drug|Lidocaine|3 ml lidocaine 1% is injected at each block site
185427|NCT02539693|Procedure|Pilonidal sinus|Removal of pilonidal sinus
185428|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
185429|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
185712|NCT02566902|Device|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
185713|NCT02566902|Drug|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
185714|NCT00187083|Drug|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
185715|NCT02566902|Procedure|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
185716|NCT02566902|Procedure|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
185717|NCT02569047|Procedure|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
185159|NCT02546661|Drug|AZD4547|AZD4547 Monotherapy
185160|NCT02546661|Drug|AZD4547 + MEDI4736|AZD4547 in combination with MEDI4736
185161|NCT02546674|Drug|Nilotinib|Nilotinib will be prescribed by the investigator according to the patient's medical need.
185162|NCT00184847|Procedure|twenty minutes of forearm ischemia|
185163|NCT02546687|Other|Venous blood sampling|The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the "ABL800 FLEX blood gas analyzer" as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood.
185164|NCT02546700|Drug|Lebrikizumab|
185165|NCT02546700|Drug|Placebo|
185166|NCT02546713|Other|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
185167|NCT02546713|Other|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
185168|NCT02548650|Drug|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
185169|NCT02548650|Drug|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
185430|NCT02539719|Drug|SC-003|
185431|NCT02539745|Other|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
185432|NCT02539745|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
185433|NCT02539758|Other|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
185434|NCT02539758|Device|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
185435|NCT00183963|Drug|Tamoxifen|20mg
184887|NCT02555358|Drug|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
184888|NCT02555358|Drug|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
184889|NCT02555371|Biological|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
184890|NCT02555371|Drug|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
184891|NCT02555384|Other|crowded drawing task|
184892|NCT00185679|Device|CliniMACS System|The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer
184893|NCT02555384|Other|uncrowded drawing task|
184894|NCT02555397|Biological|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
184895|NCT02555410|Device|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
184896|NCT02555423|Drug|Local anaesthetic - chirocaine|
184897|NCT02555449|Drug|[¹⁴C]-LY3202626|Administered as solution by mouth
184898|NCT02555462|Device|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
184899|NCT02555475|Other|community based hepatitis C care and treatment|
184900|NCT02555488|Device|diode laser|MB and diode
184901|NCT02555488|Device|diode laser|diode laser
184902|NCT02555488|Drug|Methylene blue|Methylene blue and diode laser was used
184903|NCT00185692|Procedure|non-myeloablative hematopoietic cell transplantation|Total lymphoid irradiation and anti-thymocyte globulin. Infusion of the donor graft Post-transplant immunosuppression with cyclosporin and mycophenolate mofetil.
185170|NCT02548663|Other|Sport therapy|Frequency: 60 min three times/week
20 min: aerobic training on bicycle ergometer.
20 min: strength training at 60% of maximal load.
20 min: proprioception and stretching exercises.
185171|NCT02548663|Other|Osteopathic treatment|Frequency: 60 min weekly
184308|NCT02568579|Procedure|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
184309|NCT00187161|Drug|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
184310|NCT02568592|Dietary Supplement|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
184311|NCT02568592|Dietary Supplement|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
184607|NCT02562066|Drug|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
184608|NCT02562066|Drug|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
184609|NCT02562079|Biological|Blood samples|biological features of the standard follow-up
2 more blood tube for the biological collection (serum and PBMC)
184610|NCT02562079|Biological|Biopsy|Skin biopsies
184611|NCT02562092|Behavioral|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
184612|NCT02562092|Behavioral|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
184613|NCT02562105|Procedure|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
184614|NCT00186654|Procedure|Perinatal massage|
184615|NCT02562118|Drug|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
184616|NCT02562144|Drug|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
184617|NCT02562144|Drug|Placebo|Cutaneous placebo before intravenous cannulation.
184618|NCT02562157|Device|NOTES gastroenteric anastomosis|
184619|NCT02562170|Device|TiLoop Bra|
184014|NCT02573012|Biological|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
184015|NCT02573025|Drug|PEG-IFN alfa-2a BA-free formulation|Single injection of 180 ug PEG-IFN alfa-2a BA-free formulation, administered subcutaneously via prefilled syringe
184016|NCT00187889|Drug|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
184017|NCT02573025|Drug|PEG-IFN alfa-2a market formulation|Single injection of 180 ug PEG-IFN alfa-2a market formulation, administered subcutaneously via prefilled syringe
184018|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
184019|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
184312|NCT02568592|Dietary Supplement|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM, with an additional 30% extra energy coming from fat.
184313|NCT02568605|Dietary Supplement|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
184314|NCT02568605|Dietary Supplement|Placebo|Maltodextrin
184315|NCT02568605|Behavioral|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
184316|NCT02568618|Genetic|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
184317|NCT02568631|Other|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
184318|NCT02568631|Other|control video game|The patients will play 6 sessions of one hour with the control video game
184319|NCT02568644|Dietary Supplement|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerois).
184320|NCT00187174|Drug|Everolimus|The drug is given orally in 28 day courses.
184321|NCT02568644|Other|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
183718|NCT02543710|Drug|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.
During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression.
183719|NCT02543723|Behavioral|Nurse Coach Intervention|Participants randomized to the intervention 2 group will receive the MEMS, plus a tailored nurse coach component. Participants will receive a 60-minute session conducted by the nurse coach. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). MEMS feedback will be used to show Participants their own medication-taking behavior via the MEMS Report, to correct any misperceptions of actual adherence and to identify problem areas. The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
183720|NCT02543723|Behavioral|MEMs Intervention|Participants will be advised to only open their pill bottles when they take their medications. Participants will also be given a MEMS diary to record unscheduled cap openings, such as those to refill the bottle, so that those unscheduled events unrelated to adherence can be removed from analysis. Participants will meet with the nurse coach during their regularly scheduled monthly oncology visits where the MEMS data will be collected. During this monthly meeting, participants in the intervention 1 group will receive feedback of their medication-taking behavior via a MEMS report.
183721|NCT02543736|Device|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
183722|NCT00184561|Drug|biphasic insulin aspart|
183723|NCT02543749|Biological|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
183724|NCT02545920|Other|no intervention|observational study
183725|NCT02545933|Drug|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
183726|NCT02545933|Drug|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
183727|NCT02545933|Drug|Aspirin|Aspirin will be administered at the dose of 81mg once daily
184020|NCT02539056|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
184021|NCT02539069|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
184022|NCT02539082|Device|Regenseal|Regenseal, collagen, injection in the defect area
184023|NCT02539082|Drug|normal saline|placebo, normal saline, injection in the defect area
160342|NCT01783756|Drug|capecitabine|Given PO
160343|NCT01783756|Other|laboratory biomarker analysis|Correlative studies
160344|NCT01783769|Behavioral|"Low O.R. Traffic"|"Low OR Traffic" protocol will restrict personnel movement thru the operating room to a "bare minimum" of personnel traffic.
160345|NCT01783782|Behavioral|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
160346|NCT01783782|Drug|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
160347|NCT01783782|Drug|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
160348|NCT01783795|Genetic|Genetic Analysis|
160349|NCT01783808|Other|Supplemental oxygen|Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.
In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used.
160350|NCT01786070|Drug|placebo|
160351|NCT01786083|Behavioral|Application of Problem Solving Technique|
160352|NCT01786096|Drug|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
160353|NCT01786109|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
160354|NCT01786109|Drug|Placebo|Placebo will match study drug; taken as one dose orally with water.
160355|NCT00098839|Drug|dexrazoxane hydrochloride|Given IV
160650|NCT01789632|Procedure|Group B Whole Blood Injection|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a needle will then be placed into the tendon followed by 10-12 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites. Autologous whole blood will be drawn from the patient's unaffected arm using a butterfly needle and a portion of this blood will be placed into the common extensor tendon, and the remaining platelet rich plasma will be sent for analysis of platelet, white blood and red blood count concentrations.
160651|NCT01789632|Procedure|Group C Dry Needle tendon fenestration|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow. Autologous whole blood will be drawn from the patient's unaffected arm, using a butterfly needle and discarded. The superficial subcutaneous soft tissue will be re-entered however, the tendon itself will not be entered and nothing will be injected.
160652|NCT01789632|Procedure|Group D No injection|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow. Autologous whole blood will be drawn from the patient's unaffected arm using a butterfly needle. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected.
184970|NCT02564315|Drug|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke >10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke <=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
184971|NCT02564328|Genetic|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
184972|NCT02564341|Behavioral|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
184973|NCT00186888|Drug|Vincristine + Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml*hr, daily for 5 consecutive days, infused over 30 minutes.
184974|NCT02564341|Behavioral|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
184975|NCT02564341|Behavioral|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
184976|NCT02564354|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
184977|NCT02564367|Drug|S-1|18 cycles S-1, orally administered twice daily D1-14, q 3 wks
S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks
184978|NCT02566590|Dietary Supplement|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
184979|NCT02566590|Dietary Supplement|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
184980|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
184981|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
184982|NCT00187070|Radiation|Radiation Therapy|See Detailed Description section for details of treatment interventions.
184426|NCT02543944|Drug|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
184427|NCT02543944|Drug|Placebo|Microcrystalline cellulose
184428|NCT02543957|Procedure|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
184429|NCT02543983|Drug|Ketamine|non-competitive N-methyl-D-aspartate receptor antagonist
184714|NCT02573168|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
184715|NCT02573168|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
184716|NCT02573181|Biological|V114|V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F in each 0.5 mL dose
184717|NCT00187915|Drug|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
184718|NCT02573181|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5 mL dose.
184719|NCT02573194|Dietary Supplement|Breakfasts varying in protein source content on appetite|In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
184720|NCT02573220|Biological|Cetuximab|Given IV
184721|NCT02573220|Drug|Fluorouracil|Given IV
184722|NCT02573220|Drug|Irinotecan Hydrochloride|Given IV
184723|NCT02573220|Drug|Leucovorin Calcium|Given IV
184724|NCT02573233|Drug|dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
184725|NCT02573233|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
184726|NCT02573233|Drug|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
184727|NCT02573233|Drug|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
184142|NCT02550405|Behavioral|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
184143|NCT02550418|Drug|Budesonide|
184144|NCT02550444|Drug|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
184430|NCT02544035|Other|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category; one targeted to the age group just below and one from the age group just above the target toy.
184431|NCT02544035|Other|Play Partner (Either parent or friend)|For children ages 6 months-5 years, each child will first play alone then play with parent. For children ages 6-12 years, each child will first play alone then play with a friend.
184432|NCT02544061|Biological|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
184433|NCT02544074|Behavioral|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
184434|NCT02544087|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
184435|NCT02544087|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
184436|NCT00184587|Drug|placebo|
184437|NCT02544087|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
184438|NCT02544100|Other|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
184439|NCT02544113|Drug|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
184440|NCT02544113|Drug|Placebo|Normal transplant immunosupression
184441|NCT02546232|Drug|Carboplatin|Chemotherapy
184442|NCT02546232|Drug|Paclitaxel|Chemotherapy
184443|NCT02546245|Behavioral|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
188378|NCT01978054|Other|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
188379|NCT00117715|Procedure|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
188380|NCT01978067|Procedure|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
188381|NCT01978080|Device|Kinesia HomeView|
188382|NCT01978093|Biological|Hib-MenCY-TT vaccine (GSK792014)|4 doses administered intramuscularly (IM) in the right upper thigh at Day 0, Month 2, Month 4 and Month 10-13.
188383|NCT01978093|Biological|Pediarix®|3 doses administered IM in the left upper thigh in HibCY Group at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper thigh at Month 4 in PedHIB Group.
188384|NCT01978093|Biological|Rotarix®|2 doses administered orally at Day 0 and Month 2.
183824|NCT02554903|Drug|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
183825|NCT02554903|Drug|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
183826|NCT02554916|Behavioral|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
183827|NCT02554916|Behavioral|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
183828|NCT02554916|Other|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
183829|NCT02554916|Device|Dual-Belt Treadmill|
183830|NCT02554929|Behavioral|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
183831|NCT02554929|Behavioral|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
183832|NCT02554942|Drug|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
187788|NCT01990781|Drug|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
187789|NCT01990781|Drug|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
187790|NCT01990781|Drug|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
187791|NCT01990781|Drug|N: Normal saline (placebo)|Normal saline: 2ml
187792|NCT01990807|Drug|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
187793|NCT00118521|Procedure|Foot Orthotics|
187794|NCT01990820|Device|Acclarent Relieva Balloon Sinuplasty|A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.
Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.
188066|NCT01983527|Drug|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
188067|NCT01983540|Biological|DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study
188068|NCT01983540|Biological|DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.
188069|NCT00002146|Drug|Foscarnet sodium|
188070|NCT00118092|Other|laboratory biomarker analysis|Correlative studies
188071|NCT00002149|Drug|Clavulanate potassium|
188072|NCT00118235|Drug|irinotecan hydrochloride|Given IV
188073|NCT01985750|Drug|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
188074|NCT01985750|Drug|placebo|Other Names:
comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception
250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation
188075|NCT01985763|Drug|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
188076|NCT01985776|Procedure|Exercise intervention|Functional stabilisation exercise for the trunk.
187186|NCT02574182|Radiation|Brain MRI|Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.
Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.
The GAITRite is a carpet for recording the walking operating parameters
187187|NCT02574208|Procedure|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
187188|NCT02574208|Procedure|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
187189|NCT00188084|Procedure|DNA Index|
187190|NCT02574221|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
187191|NCT02574221|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
187192|NCT02540291|Drug|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
187193|NCT00184028|Drug|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
187482|NCT01955109|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
187483|NCT01955122|Device|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device).
187484|NCT01955135|Drug|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
187485|NCT01955135|Drug|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
187486|NCT01955135|Drug|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
187487|NCT00115336|Drug|Intravenous Ketorolac|Intravenous ketorolac
187488|NCT01955161|Drug|Placebo|Once daily, matching placebo capsules, orally
187489|NCT01955161|Drug|Lu AE58054|Once daily, encapsulated tablets, orally
187490|NCT01955174|Drug|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
187491|NCT01955174|Other|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
186875|NCT02545010|Drug|Paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.
Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.
Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician.
186876|NCT02545010|Radiation|LDWART (Low Dose Whole Abdominal Radiation Therapy)|LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a "chemosensitizer". LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator.
186877|NCT00184665|Drug|insulin aspart|
186878|NCT02545023|Other|Quality-of-Life Assessment|Complete an in-person one-on-one interview
186879|NCT02545023|Other|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
186880|NCT02547246|Device|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
186881|NCT02547259|Procedure|pain words test|words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the "D" key on the keyboard if they feel that they have not learned this word.
186882|NCT02547259|Procedure|negative words test|words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the "D" key on the keyboard if they feel that they have not learned this word.
186883|NCT02547272|Procedure|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
187194|NCT02540304|Behavioral|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
187195|NCT02540317|Behavioral|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
187196|NCT02540330|Drug|Fulvestrant|
187197|NCT02540343|Other|questionnaires|fill out all questionnaires twice
186587|NCT02551471|Other|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
186588|NCT02551484|Device|Measurements using NIRS|
186589|NCT02551484|Device|TCPO2 measurements|
186590|NCT02551484|Other|2-minute walk test|
186591|NCT02551497|Drug|raxatrigine|
186592|NCT02551510|Procedure|Suture|Skin incision closure with standard subcuticular technique
186593|NCT02551510|Device|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n‐Butyl‐2‐Cyanoacrylate Monomer)
186594|NCT00185224|Drug|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
186595|NCT02551523|Drug|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
186596|NCT02551523|Drug|Standard of care combinational antiretroviral therapy|
186597|NCT02551536|Drug|Montelukast|
186598|NCT02551536|Drug|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
186599|NCT02551536|Drug|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
186600|NCT02551549|Drug|CD101 IV|antifungal
186601|NCT02551549|Drug|Placebo|Normal saline
186602|NCT02551562|Other|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
186603|NCT02551575|Drug|Treatment of MTX and HCQ|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
186604|NCT02551575|Drug|Treatment of TCM|Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks.
186006|NCT02562612|Drug|SM-88|SM-88 single dose
186007|NCT02562625|Drug|Pembrolizumab|Powder solution for infusion
186008|NCT02562625|Radiation|Radiotherapy|24Gy
186009|NCT02562638|Other|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
186010|NCT02562651|Drug|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
186011|NCT00186758|Device|Transcranial Magnetic Stimulation (TMS)|Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.
Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -
186012|NCT02562651|Other|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
186013|NCT02562664|Drug|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
186014|NCT02562664|Drug|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
186015|NCT02562664|Drug|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
186016|NCT02562677|Device|Transcutaneous Trigeminal Nerve Stimulation|
186283|NCT02558218|Drug|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
186284|NCT02558218|Drug|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
186285|NCT02558231|Drug|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
186286|NCT02558231|Drug|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
186287|NCT02558231|Drug|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
186288|NCT02558257|Behavioral|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation. Research nurse/assistant contacts participant within 1 week +/- 4 days of initial consultation and conducts the survey over the phone.
186289|NCT00186069|Other|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
186290|NCT02558270|Drug|Dapagliflozin|
186291|NCT02558270|Drug|Placebo|
185718|NCT02569047|Procedure|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
185719|NCT02569060|Other|Testing and Monitoring of Blood Glucose Levels|Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
185720|NCT02569060|Other|Primary care coordination|Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
185721|NCT02569060|Other|Diabetes-appropriate food packages|Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
185722|NCT02569060|Behavioral|Diabetes self-management education|Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
185723|NCT02569073|Drug|Dronabinol|Dronabinol 5 mg, every other night, orally
185724|NCT02569073|Drug|Placebo|Placebo--no drug
185725|NCT02569086|Other|Blood draw|
185726|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
185727|NCT02569099|Other|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
185728|NCT02569112|Device|Venus Legacy|Venus Legacy is a multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse). RF technology works by exciting fat molecules 2-3 million times per second to achieve desired heating effects on fat. RF has been shown to increase the production new collagen and other cell enhancing biological molecules. PEMF delivered in synergy with RF assists in the creation of FGF-2 (fibroblast growth factors 2), TNF-α (tumour necrosis factor-a) and TGF-β (transforming growth factor-b) increasing fibroblasts. Varipulse technology increases the movement of fluids in the lymphatic system and manually stimulates fibroblasts.
186017|NCT02562690|Other|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
186018|NCT02564653|Behavioral|TTC+Referral to Community Health Worker|TTC+ referral to a VHW for additional counseling and follow-up
186019|NCT02564666|Other|telephone counseling|regular telephone counseling for compliance and advese event
186020|NCT02564679|Procedure|Laparoscopic Sleeve gastrectomy (LSG)|These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.
They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.
At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated.
185436|NCT02539758|Device|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
185437|NCT02539771|Other|Polysomnography and blood sample|Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms " Diurnal VOC " and " Slightly symptomatic "
185438|NCT02542098|Drug|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
185439|NCT02542111|Drug|Bortezomib|Bortezomib IV
185440|NCT02542111|Drug|Gemcitabine|Gemcitabine IV
185441|NCT00184249|Procedure|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
185442|NCT02542111|Drug|Dexamethasone|Dexamethasone IV
185443|NCT02542111|Drug|Cisplatin|Cisplatin IV
185444|NCT02542124|Biological|NM-IL-12|The TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
185445|NCT02542137|Radiation|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
185446|NCT02542137|Drug|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
185447|NCT02542150|Drug|acetate|acetate infusion, saline infusion, fMRI scan
185448|NCT02542150|Drug|alcohol|a "jello shot" containing alcohol, a jello shot containing no alcohol, fMRI scan.
185449|NCT02542176|Other|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
185450|NCT02542176|Other|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
185451|NCT02542202|Other|Laboratory Biomarker Analysis|Correlative studies
185729|NCT02569112|Device|CoolSculpt|Cryolipolysis has been developed and commercialized to non-invasively reduce subcutaneous fat. The cryolipolysis technology utilizes the sensitivity of fat cells to cold injury in order to selectively eliminate subcutaneous fat tissue without affecting the skin or other surrounding tissues. Cryolipolysis technology enables a non-invasive alternative for subcutaneous fat reduction through cellular apoptosis.
185730|NCT02569125|Drug|Everolimus|4.5 mg/m² daily
185731|NCT02569138|Device|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
185732|NCT02569138|Device|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
185172|NCT02548676|Device|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
185173|NCT02548702|Behavioral|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
185174|NCT00185016|Behavioral|a training to improve recognition of partner abuse.|
185175|NCT02548715|Drug|Levothyroxine|
185176|NCT02548715|Drug|Placebo|
185177|NCT02548728|Drug|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
185178|NCT02548728|Drug|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
185179|NCT02548741|Drug|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy & David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
185180|NCT02548741|Drug|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
185181|NCT02548741|Other|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
185182|NCT02548741|Other|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
185183|NCT02548754|Device|Salustim tragus stimulation device|
185184|NCT00185185|Drug|Olmesartan medoxomil|
185452|NCT00184262|Behavioral|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
184620|NCT02562170|Device|Protexa|
184621|NCT02562183|Drug|kallikrein|Using kallikrein
184622|NCT02562196|Device|tdcs|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
184623|NCT02562209|Dietary Supplement|PACER Diet|Pacer diet to be followed for 8 weeks
184904|NCT02555501|Other|PDT + Low level laser|Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).
From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
184905|NCT02555501|Radiation|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
184906|NCT02557581|Other|No training|
184907|NCT02557581|Other|Endurance training|
184908|NCT02557581|Other|Resistance Training|
184909|NCT02557581|Drug|Terbutaline|
184910|NCT02557581|Drug|Clenbuterol|
184911|NCT02557581|Drug|Placebo|
184912|NCT02557594|Drug|Viread 300mg|single dose administration after 10hr fasting
184913|NCT02557594|Drug|DA-2802 319mg|single dose administration after 10hr fasting
184914|NCT02557607|Device|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
184915|NCT00185978|Behavioral|diet, physical activity, reduced sedentary behavior|
184916|NCT02557620|Drug|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
184322|NCT02568644|Drug|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
184323|NCT02568657|Device|Celox group|
184324|NCT02568657|Device|Bakri Balloon|
184325|NCT02568670|Other|clinical signs|to remove the peripheral venous catheter according clinical signs
184326|NCT02568683|Drug|ENTO|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
184327|NCT02568683|Drug|VCR|VCR administered intravenously
184328|NCT02568683|Drug|Rituximab|Rituximab administered intravenously
184329|NCT02570581|Other|Apple compote Clopidogrel|
184330|NCT02570581|Other|Apple compote Ramipril|
184331|NCT02570581|Other|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
184332|NCT02570581|Other|Plain apple compote control|
184624|NCT02564185|Other|Education program|
184625|NCT02564198|Drug|Ramucirumab|Administered IV
184626|NCT02564211|Drug|Ipragliflozin|
184627|NCT02564211|Drug|Sitagliptin|Background medication
184628|NCT02564224|Procedure|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
184629|NCT00186888|Procedure|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
184630|NCT02564224|Procedure|Conventional Wound Closure|Procedure: Conventional Wound Closure
184631|NCT02564224|Device|prolene|
184632|NCT02564237|Biological|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
184633|NCT02564237|Biological|Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
184024|NCT00183898|Drug|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
184025|NCT02539095|Device|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
184026|NCT02539095|Device|Normal saline|Supplementation of fluid and electrolytes (sodium or chlorine deficiency)
Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity.
184027|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
184028|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
184029|NCT02539121|Device|Acupuncture|Acupuncture needles
184030|NCT02539134|Drug|TAK-935|TAK-935 oral solution
184031|NCT02539134|Drug|Placebo|TAK-935 placebo-matching oral solution
184032|NCT02539147|Biological|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
184033|NCT02539160|Drug|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
184034|NCT02539173|Other|Ultrasound scan|Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.
It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes.
184035|NCT00002498|Drug|CMF regimen|
184036|NCT02541474|Other|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
184333|NCT00187486|Drug|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
184334|NCT02570594|Other|questionary|
184335|NCT02570607|Biological|BNP dosage|
184336|NCT02570620|Device|Ultrasonography of the cervix|
160653|NCT01789645|Other|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
160654|NCT01789645|Procedure|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
160655|NCT01789658|Other|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
160656|NCT00099086|Radiation|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
160657|NCT01789671|Behavioral|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
160658|NCT01792011|Device|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
160659|NCT01792024|Procedure|laser interstitial thermal therapy|
160660|NCT01792024|Procedure|magnetic resonance imaging|Undergo MR-guided LITT
160661|NCT01792024|Procedure|quality-of-life assessment|Ancillary studies
160662|NCT01792037|Drug|Etomidate|
160663|NCT01792037|Drug|Midazolam|
160664|NCT01792037|Drug|methylprednisolone|
160665|NCT01792050|Drug|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
160666|NCT01792050|Other|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
185843|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
185844|NCT02546856|Other|HF nurse up-titration|Up-titration of Beta-Blocker (BB) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 European Society of Cardiology (ESC) HF guidelines with cardiologist prescription and support
185845|NCT02546856|Other|HF nurse up-titration|Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support
184983|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
185264|NCT02557867|Drug|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
185265|NCT02557880|Behavioral|Sleep Application Diary|Tool used to document sleep hygiene.
185266|NCT02557880|Behavioral|Treatment As Usual|Sleep hygiene counseling
185267|NCT02557893|Behavioral|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
185268|NCT00186017|Drug|Olanzapine/Zyprexa|
185269|NCT02557893|Other|Education|Bimonthly pregnancy education classes
185270|NCT02557893|Other|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
185271|NCT02557906|Procedure|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
185272|NCT02557906|Procedure|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
185273|NCT02557906|Procedure|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
185274|NCT02557919|Other|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
185275|NCT02557919|Other|Usual Best Practice|.5 day training on tobacco control and emerging products.
185276|NCT02560077|Other|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
185277|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
185278|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
185279|NCT02560090|Behavioral|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
185280|NCT02560090|Behavioral|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
184728|NCT00187928|Drug|Topiramate|
184729|NCT02539303|Drug|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
184730|NCT02539316|Drug|Smoflipid|
184731|NCT02539316|Drug|Médialipides|
184732|NCT02539329|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
184984|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
184985|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
184986|NCT02566616|Device|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
184987|NCT02566629|Other|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
184988|NCT02566642|Other|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
184989|NCT02566655|Biological|Fucosylated MSC for Osteoporosis|Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).
Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.
184990|NCT02566668|Other|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
184991|NCT02566681|Biological|MSC construct for Osteonecrosis|30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).
Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.
The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures.
184992|NCT02566694|Procedure|Implant|orthopaedic implant
184993|NCT00002509|Drug|etoposide|
184994|NCT00187083|Drug|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
184444|NCT02546245|Behavioral|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
184445|NCT02546258|Device|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
184446|NCT02546271|Behavioral|GPS|
184447|NCT02546284|Drug|KB003, Monoclonal Antibody|
184448|NCT02546297|Drug|Symbicort|drug are used for six months，and then exchanged in the 7th month
184449|NCT02546297|Drug|Tiotropium Bromide|drug are used for six months，and then exchanged in the 7th month
184450|NCT02546310|Drug|HTL0009936|
184451|NCT00184821|Drug|Diazoxide|
184452|NCT02546310|Drug|HTL0009936 matching placebo|
184733|NCT02539342|Drug|Caphosol|Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:
Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.
o Participants may increase the use to 6 times per day if you have symptoms of mucositis.
Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.
For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.
For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.
Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.
Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed
184734|NCT02539342|Drug|Biotene|• Use 5 to 10 mL of Biotene to swish and spit
o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab.
184735|NCT00183924|Drug|Estramustine|
184736|NCT02539355|Other|Diet A|12-week diet
184737|NCT02539355|Other|Diet B|12-week Diet
184738|NCT02539368|Drug|Inflectra (infliximab)|
184739|NCT02539381|Procedure|Formal Perimetry (Goldman or Octopus visual Field)|
184740|NCT02539381|Procedure|Albert's visual inattention test|
184741|NCT02539381|Procedure|Star cancellation visual inattention test|
184742|NCT02539381|Procedure|Visual field assessment to confrontation|
183833|NCT02554955|Drug|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
183834|NCT00185874|Biological|autologous dendritic cells|
183835|NCT02557165|Procedure|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
183836|NCT02557178|Device|COPD Activity Monitor|A custom activity monitor capable.
183837|NCT02557178|Behavioral|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
183838|NCT02557191|Other|Observational study|
183839|NCT02557204|Procedure|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
183840|NCT02557204|Procedure|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
183841|NCT02557204|Procedure|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
183842|NCT02557204|Procedure|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
183843|NCT02557217|Drug|NP202|Active
184145|NCT02550444|Drug|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
184146|NCT02550444|Drug|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
184147|NCT02550457|Other|Functional elastic tape|Application of Kinesio Taping with tension in the erector spine muscles.
184148|NCT00185159|Drug|Placebo Tablets|Tablets
184149|NCT02550457|Other|Placebo functional elastic tape|Application of Kinesio Taping without tension in the erector spine muscles.
184150|NCT02550470|Device|Carbon Dioxide Absorbents|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
188077|NCT01985776|Procedure|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
188078|NCT01985789|Drug|Diphenhydramine|
188079|NCT01985789|Drug|cetirizine|
188080|NCT01985789|Drug|desloratadine|
188081|NCT01985789|Drug|placebo|
188082|NCT01985802|Other|Pacing|
188083|NCT00118235|Biological|bevacizumab|Given IV
188084|NCT01985815|Device|VC/VS stimulation|
188085|NCT01985828|Radiation|CyberKnife|
188086|NCT01985828|Other|Androgen Deprivation Therapy (ADT)|
188087|NCT01985828|Radiation|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
188088|NCT01985841|Drug|Bevacizumb|Avastin
188089|NCT01985841|Drug|5-Fluorouracil|5-FU
183547|NCT02561780|Behavioral|eLearning Follow-up|An online mental health education module that students access individually
183548|NCT02561793|Drug|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
183549|NCT02561793|Drug|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
183550|NCT02561806|Drug|Ixekizumab|Administered SC
183551|NCT02561806|Drug|Ustekinumab|Administered SC
183552|NCT02561832|Drug|Olaparib|tablets taken orally twice daily
183553|NCT02561832|Drug|Carboplatin|intravenous injections on day one of each cycle
183554|NCT00186628|Procedure|nonmyeloablative allogeneic hematopoietic cell transplant|TLI is administered ten times in 80cGy fractions on day -11 through day -7 and day -4 through day -1. TLI is administered from a 6 MeV linear accelerator (photon beam).
183555|NCT02561832|Drug|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
183556|NCT02561832|Drug|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
187492|NCT01955187|Drug|TACROLIMUS|Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
187493|NCT01955187|Drug|RITUXIMAB|A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
187494|NCT01955187|Drug|METHYLPREDNISOLONE|Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
187495|NCT01955187|Drug|CYCLOPHOSPHAMIDE|Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
187496|NCT01955200|Drug|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
187497|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
187498|NCT01957579|Drug|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
187499|NCT00115596|Procedure|Formal Curriculum; Low-Fidelity Simulation|
187500|NCT01957592|Other|No treatment given|Patients will fill out a questionnaire by interview.
187795|NCT01990820|Procedure|Adenoidectomy + Maxillary Sinus Irrigation|A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.
Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.
After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home.
187796|NCT01990846|Drug|Flufirvitide 3|
187797|NCT01990846|Drug|Placebo for Flufirvitide-3|
187798|NCT01990859|Biological|Ipilimumab|
187799|NCT01990872|Dietary Supplement|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
187800|NCT01990872|Dietary Supplement|Placebo|Placebo (0 micrograms vitamin D3/day)
187801|NCT01990885|Device|BL-7010|
187802|NCT01990885|Device|Placebo|
187803|NCT01990898|Drug|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
187198|NCT02540356|Biological|BAX69 Single-Route Arm|Intraperitoneal (IP) only
187199|NCT02540356|Biological|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
187200|NCT02540369|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
187201|NCT02540382|Device|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
187202|NCT02540382|Device|bare stent|A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.
The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.
The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.
It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions.
187203|NCT02540395|Drug|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
187204|NCT00184028|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
187205|NCT02540395|Drug|MMF (mycophenolate mofetil) (for Group B)|MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.
Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.
From day 8 on, patients will not receive MMF.
187206|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group B)|At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).
Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed.
187207|NCT02542839|Other|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
187501|NCT01957631|Drug|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
187502|NCT01957631|Biological|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
187503|NCT01957644|Drug|Azacitidine|
186605|NCT02553655|Procedure|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
186884|NCT02547285|Other|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
186885|NCT00184912|Drug|caffeine|
186886|NCT02547298|Procedure|Hydrodistension|Patients who are already scheduled to have a gynecologic, urologic or uro-gynecologic procedure involving cystoscopy if consented will have hydrodistension performed
186887|NCT02547298|Device|Cystoscopy|
186888|NCT02547311|Behavioral|Team Clinic|
186889|NCT02547324|Radiation|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
186890|NCT02547324|Radiation|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
186891|NCT02547350|Drug|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
186892|NCT02547363|Drug|LEO 43204 gel|
186893|NCT02547363|Drug|Vehicle gel|
186894|NCT02547389|Behavioral|Community support group|
186895|NCT02547389|Other|Printed material Supported|
186896|NCT00184912|Drug|Technetium-TC99m-labeled Annexin A5|
186897|NCT02547402|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
186898|NCT02547402|Drug|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
186899|NCT02547402|Drug|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
186900|NCT02547415|Other|questionnaires and psychological testing|Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.
Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:
Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires
Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview.
186901|NCT02547428|Drug|CTN SR|Participants will receive CTN SR tablets in a 100-mg dose strength, designed for twice-daily (BID) oral (PO) administration.
186292|NCT02558283|Device|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
186293|NCT02558283|Device|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
186294|NCT02558296|Drug|Bexagliflozin|20 mg, tablet
186295|NCT02558296|Drug|Placebo|20 mg tablet to match active comparator
186296|NCT02558322|Other|Primary medical care|All study participants receive primary care as usual in the respective region
186297|NCT02558348|Drug|AL3818|Administered orally
186298|NCT02558361|Drug|Treatment with Apremilast|Apremilast (Otezla®) is a Federal Drug Administration (FDA)-approved treatment for psoriatic arthritis and psoriasis. Although there are a lot of data demonstrating how apremilast works in the laboratory, there are very few demonstrating how it works in the actual target organ, i.e. the skin or synovial (joint) tissue in patients with psoriasis and psoriatic arthritis.
186299|NCT02558374|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop placebo (morning) both eyes
1 drop active (evening) both eyes
186300|NCT00186082|Drug|Cefotetan or Cefoxitin vs placebo|Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.
Normal Saline, 100 ml intravenously for placebo arm.
186301|NCT02558374|Drug|Timolol Maleate Ophthalmic Solution|1 drop twice daily (morning/evening) both eyes
186302|NCT02558387|Drug|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
186303|NCT02558400|Drug|PG324 Ophthalmic Solution|1 drop daily (evening) both eyes
186606|NCT02553655|Procedure|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
186607|NCT02553668|Drug|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
186608|NCT02553668|Device|Facemask|
186609|NCT02553681|Device|roflufocon D contact lenses|HPT treated rigid contact lenses
186610|NCT02553681|Device|RGP contact lenses made from roflufocon D|
186611|NCT02553694|Other|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
186612|NCT02553694|Other|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
186021|NCT02564679|Behavioral|Lifestyle Intervention|These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.
They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment.
186022|NCT02564705|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|
186023|NCT02564705|Procedure|Posterior Fusion|Posterolateral Fusion (PLF)
Posterior Lumbar Interbody Fusion (PLIF)
Transforaminal Lumbar Interbody Fusion (TLIF)
186024|NCT02564718|Drug|Rivaroxaban(Xarelto,BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venour thromboembolism (VTE) with 20 mg once daily.
186025|NCT02564744|Drug|IMGN529 with rituxan every 3 weeks|treatment of DLBCL and other NHL patients with the drug IMGN529 with rituxan every 3 weeks
186026|NCT02564783|Other|No intervention|No intervention
186027|NCT02564796|Drug|Epoetin Alfa|
186028|NCT00186888|Other|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is > 2,000/mL in one occasion after the expected nadir.
186029|NCT02564796|Drug|Saline|
186030|NCT02564809|Behavioral|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
186031|NCT02564809|Behavioral|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
186304|NCT02558400|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily (evening) both eyes
186305|NCT02558400|Drug|Latanoprost Ophthalmic Solution|1 drop daily (evening) both eyes
186306|NCT02560558|Drug|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
186307|NCT02560571|Device|ultrasound|
186308|NCT02560571|Other|blood test|
185733|NCT02569151|Device|HBP & CBP measurement using systo 130 mmHg|
185734|NCT02569190|Device|Walkbot|Robot assisted gait training
185735|NCT02569203|Dietary Supplement|standard enteral nutrition|standard enteral nutrition
185736|NCT02571244|Behavioral|Motivational Interview plus text message|After discharge the experimental group will receive extended care including a counseling session and text messages. The session will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills, with the goal of helping the participant build and implement a quit plan. The focus will then shift to increasing motivation to make quit attempt, including confidence building, medication use, and cessation planning.The session will last approximately 30 minutes. Participants in the experimental arm will be offered up to 30 text messages to help the patient implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory.
185737|NCT02571257|Drug|Gemcabene|1-300 mg tablet, QD, 56 days
185738|NCT02571257|Drug|Gemcabene|3-300 mg tablets, QD, 56 days
185739|NCT02571257|Drug|Placebo|
185740|NCT00187564|Drug|controlled-release oral alpha-lipoic acid|
185741|NCT02571270|Other|Combined aerobic and resistance physical training program|
185742|NCT02571283|Drug|Cocktail|Administered as a single dose injection.
185743|NCT02571283|Drug|Exparel|Administered 20 minutes+ before additional medications.
185744|NCT02571283|Drug|Marcaine|Administered 20 minutes or more after Exparel is administered.
185745|NCT02571296|Drug|micronized progesterone|Oral
185746|NCT02571296|Drug|Placebo|Oral
185747|NCT02571309|Device|Asthmatuner|Asthmatuner is an app for self-management of asthma.
185748|NCT02571322|Device|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
186032|NCT02564809|Behavioral|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
186033|NCT02564822|Procedure|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
185453|NCT02542202|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
185454|NCT02542215|Drug|Cobiprostone|
185455|NCT02542215|Drug|Placebo|matching placebo
185456|NCT02542228|Other|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
185457|NCT02542241|Drug|Sodium Chloride [3%]|Subjects in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc / hour rate, the medicine will be administered by a infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
185458|NCT02542241|Drug|Sodium Chloride [0.9%]|Subjects in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc / hour rate, the medicine will be administered by a infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
185459|NCT02542254|Drug|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
185460|NCT02542254|Drug|Ipratropium|40 micrograms ipratropium administered using a pMDI
185461|NCT02542254|Drug|RPL554|6 mg RPL554 administered using a nebuliser
185462|NCT02542254|Drug|Salbutamol matched placebo|Placebo pMDI
185463|NCT00184613|Drug|insulin glargine|
185464|NCT02544425|Drug|etoposide|100 mg/m2 + 5% DW 500 mL MIV over 90 mins D1-3
185465|NCT02544425|Drug|Ifosfamide|1.2g/m2 + 5% DW 100 mL MIV over 1 hr D1-3
185466|NCT02544425|Drug|Dexamethasone|40mg/day PO or IV D1-3
185467|NCT02544425|Drug|L-asparaginase|4000IU/m2 IM D8, 10, 12, 14, 16, 18, 20
185468|NCT02544425|Drug|Etoposide|Peripheral blood stem cell mobilization:Etoposide 375mg/m2 D1-2 + G-CSF (10 ug/kg) injection
185469|NCT02544425|Drug|Busulfan|Conditioning regimen for autologous stem cell transplantation:
Busulfan 3.2 mg/kg D -8, -7, -6
185470|NCT02544425|Drug|Melphalan|Conditioning regimen for autologous stem cell transplantation:
Melphalan 70 mg/m2 D -3, -2
185471|NCT02544425|Drug|Etoposide|Conditioning regimen for autologous stem cell transplantation:
Etoposide 400 mg/m2 D -5, -4
184917|NCT02557620|Drug|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
184918|NCT02557633|Biological|Grass MATA MPL 10200|
184919|NCT02557633|Biological|Grass MATA MPL 18200|
184920|NCT02557633|Biological|Placebo|
184921|NCT02557646|Biological|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
184922|NCT02557646|Drug|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
184923|NCT02557659|Device|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
184924|NCT02557672|Drug|Prothrombin complex concentrate (Human)|PCC (Kcentra)
185185|NCT02550782|Drug|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
185186|NCT02550782|Drug|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
185187|NCT02550795|Drug|Dexmedetomidine|administration of dexmedetomidine only
185188|NCT02550795|Drug|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
185189|NCT02550795|Drug|Control|administration of normal saline
185190|NCT02550821|Device|Triaxial accelerometer|Participants will use triaxial accelerometer for 7 days
185191|NCT02550834|Other|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
185192|NCT02550847|Device|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
185193|NCT02550860|Drug|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
185194|NCT02550860|Drug|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
185195|NCT00002502|Drug|cyclophosphamide|
185196|NCT00185185|Drug|Atenolol|
185197|NCT02550873|Biological|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
184634|NCT02564263|Biological|pembrolizumab|
184635|NCT02564263|Drug|paclitaxel|
184636|NCT02564263|Drug|docetaxel|
184637|NCT02564263|Drug|irinotecan|
184638|NCT02564276|Procedure|Sentinel lymph node biopsy|
184639|NCT02564302|Device|MUSE Headband|MUSE Headband will help patients with mindfulness.
184640|NCT00186888|Radiation|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
184641|NCT02564315|Drug|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
184642|NCT02564315|Behavioral|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
184925|NCT02557672|Biological|Fresh frozen plasma (FFP)|FFP
184926|NCT00185991|Drug|gentamicin|Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).
Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours).
184927|NCT02557685|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
184928|NCT02557698|Other|Balneum oil bath|
184929|NCT02557711|Device|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
184930|NCT02557724|Procedure|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
184931|NCT02557724|Procedure|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
184932|NCT02557737|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
184337|NCT02570633|Other|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
184338|NCT02570633|Other|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
184339|NCT02570646|Behavioral|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
184340|NCT02570659|Behavioral|Information Video|A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
184341|NCT02570672|Drug|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
184342|NCT02570672|Drug|Placebo|Subjects will randomized to placebo will receive placebo
184343|NCT02570685|Behavioral|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
184344|NCT00187486|Drug|Temodar|Temodar 200 mg/m^2/day x 5 days every 28 days
184345|NCT02570685|Behavioral|Reflective-Behavioral Gratitude|Participants were given the following identical instructions as the reflective journal in addition to this "At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
184346|NCT02570685|Behavioral|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
184347|NCT02570711|Drug|ACP-196 and Nab-paclitaxel and gemcitabine|
184348|NCT02570711|Drug|Nab-paclitaxel and gemcitabine|
184349|NCT02570724|Drug|injection of HES " Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
184350|NCT02570724|Biological|blood patch|
184643|NCT02564315|Behavioral|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
184644|NCT02564315|Behavioral|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
185846|NCT02546856|Other|HF nurse up-titration|Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support
185847|NCT02546856|Other|HF nurse up-titration|Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support
185848|NCT00184847|Drug|caffeine|
185849|NCT02546856|Other|HF cardiologist up-titration|Up-titration of Beta-Blocker (BB) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines
185850|NCT02546856|Other|HF cardiologist up-titration|Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines
185851|NCT02546856|Other|HF cardiologist up-titration|Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines
185852|NCT02546856|Other|HF cardiologist up-titration|Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure " De Novo" EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines
185853|NCT02546869|Drug|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
185854|NCT02546869|Device|Prefilled Syringes|
185855|NCT02546882|Biological|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
185856|NCT02546882|Drug|saline|1 ml saline was injected for 1 cm2 area.
185857|NCT02546895|Other|chart review|The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.
Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time.
185858|NCT02546908|Other|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
185859|NCT00184860|Procedure|PET-scan, MRI-scan|
185860|NCT02546921|Drug|MOv18 IgE|The allocated dose of MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for six weeks.
186137|NCT02542384|Drug|Placebo IV|Placebo IV will be administered as an IV bolus one hour prior to anesthetic induction for surgery, again within 30 minutes of the patient being considered stable in the post operative recovery room, then 2 hours following that Baseline dose. Subsequent dosing will be administered at 6, 12 and 18 hours after the Baseline dose.
Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.
Saline infusion (IV 0.45%) for fluid replenishment will be provided.
185281|NCT02560090|Behavioral|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
185282|NCT02560103|Other|Transmeridian travel across multiple time zones|
185550|NCT02551068|Other|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
185551|NCT02551094|Drug|colchicine|0.5 mg tablet taken once a day
185552|NCT02551094|Drug|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
185553|NCT02553226|Drug|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
185554|NCT02553239|Device|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
185555|NCT02553252|Other|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
185556|NCT02553265|Drug|Carbidopa|A reversible competitive inhibitor of dihydroxyphenylalanine (DOPA) decarboxylase that prevents dopamine formation outside the brain. By forming a series of strong but ultimately reversible bonds with the enzyme's co-factor pyridoxine, carbidopa prevents the binding of DOPA and inhibits dopamine production and downstream catecholamine synthesis.
185557|NCT02553265|Other|Placebo|A placebo (or dummy pill) containing an inert substance, in capsule form that does not contain an active drug ingredient.
185558|NCT02553278|Device|VelaShape device|VelaShape device are non invasive for fat reduction.
185559|NCT02553278|Device|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
185560|NCT02553291|Behavioral|SystemCHANGE|
185561|NCT02553291|Behavioral|Control|
185562|NCT00185393|Biological|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
185563|NCT02553317|Biological|caplacizumab|
185564|NCT02553317|Biological|placebo|
185565|NCT02553330|Drug|Placebo Cream|
185566|NCT02553330|Drug|INCB018424 Phosphate Cream|
184995|NCT02566707|Drug|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
184996|NCT02566707|Drug|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
184997|NCT00000372|Drug|Placebo|
184998|NCT00002509|Procedure|peripheral blood stem cell transplantation|
184999|NCT00187200|Device|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
185283|NCT02560129|Other|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
185284|NCT00186381|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
185285|NCT02560155|Drug|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
185286|NCT02560155|Drug|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
185287|NCT02560168|Device|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
185288|NCT02560168|Device|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
185289|NCT02560168|Device|Transthoracic Echocardiography|
185290|NCT02560181|Radiation|HDR brachytherapy|Whole gland salvage
185291|NCT02560194|Procedure|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
185292|NCT02560194|Other|Fecal occult blood test|Test for hemoglobin in faeces
185293|NCT02560207|Drug|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
185294|NCT02560220|Biological|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
185295|NCT00186394|Procedure|ablative allogeneic hematopoietic cell transplantation|
185296|NCT02560233|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
184743|NCT02539381|Procedure|Visual inattention assessment to bilateral stimuli|
184744|NCT02539381|Device|Digital tumbling E visual accuity assessment|
184745|NCT02539381|Device|Digital visual field assessment|
184746|NCT00183924|Drug|Docetaxel|
184747|NCT02539381|Device|Digital line crossing assessment|
184748|NCT02539381|Device|Digital shape cancellation assessment|
184749|NCT02539394|Drug|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
184750|NCT02539394|Other|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
184751|NCT02539407|Other|Pharmacokinetics|
184752|NCT02539420|Device|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
184753|NCT02539433|Procedure|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
185000|NCT02568826|Drug|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
185001|NCT02568839|Drug|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
185002|NCT02568839|Drug|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
185003|NCT02568852|Procedure|Combined anaesthesia|10 mmHg pressure, laparoscopic cholecystectomy under combined spinal epidural anaesthesia
185004|NCT02568852|Procedure|General anaesthesia|10 mmHg pressure, laparoscopic cholecystectomy under general anesthesia
185005|NCT02568865|Other|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
185006|NCT02568865|Other|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
184151|NCT02550470|Device|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
184152|NCT02550470|Drug|Sevoflurane|
184153|NCT02550483|Other|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
184154|NCT02552602|Dietary Supplement|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
184155|NCT02552602|Dietary Supplement|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
184156|NCT02552615|Other|body awareness therapy|
184157|NCT02552615|Other|core stabilization exercises|
184158|NCT02552615|Other|traditional exercises|
184159|NCT02552628|Device|Medtronic, Activa® PC "on"|
184160|NCT00185341|Drug|CCR1-Antagonist (BAY86-5047, ZK811752, SH T 04268H)|Given orally in a dose of 600 mg three times daily over 12 weeks
184161|NCT02552628|Device|Medtronic, Activa® PC "off"|
184162|NCT02552641|Other|Food effect|
184163|NCT02552641|Drug|Esomeprazole|
184164|NCT02552641|Drug|Amoxicillin|
184453|NCT02546323|Drug|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
184454|NCT02546323|Drug|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
184455|NCT02546336|Device|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
184456|NCT02546349|Drug|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
183557|NCT02561845|Drug|rosuvastatin|5mg, 10mg, 20mg
183558|NCT02561858|Other|acid load test|
183559|NCT02561871|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 in Group 2.
183560|NCT02561871|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 85 in Group 2.
183561|NCT02563847|Dietary Supplement|0.52 g L-Tryptophan|
183562|NCT02563847|Dietary Supplement|1.56 g L-Tryptophan|
183563|NCT02563847|Dietary Supplement|1.56 g L-Leucine|
183564|NCT02563847|Dietary Supplement|50 g Xylitol|
183565|NCT02563847|Dietary Supplement|75 g Erythritol|
183566|NCT02563847|Dietary Supplement|75 g Glucose|
183567|NCT02563847|Dietary Supplement|300 mL tap water|
183568|NCT02563847|Other|50 mg 13C-sodium acetate|
183569|NCT02563860|Drug|Lovastatin|dose escallating
183844|NCT02557217|Other|Placebo|Placebo
183845|NCT00185887|Drug|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
183846|NCT02557269|Drug|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
183847|NCT02557269|Drug|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
183848|NCT02557269|Drug|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
183849|NCT02557269|Drug|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
183850|NCT02557269|Other|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
183851|NCT02557269|Drug|Bilastine 20 mg|1 tablet per os - as needed
187804|NCT01993238|Device|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
187805|NCT01993238|Drug|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
187806|NCT01993251|Drug|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
187807|NCT01993251|Drug|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
187808|NCT01993251|Drug|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
187809|NCT01993251|Drug|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
187810|NCT01993264|Other|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
187811|NCT01993277|Device|Nexalin Brain Stimulator|
187812|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
187813|NCT01993277|Device|Fischer Wallace Stimulator|
187814|NCT01993277|Device|David Delight Stimulator|
187815|NCT01993277|Behavioral|Relaxation Therapy|
187816|NCT01993290|Drug|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
188090|NCT01985841|Drug|Epirubicin|Farmorubicin
188091|NCT01985841|Drug|Cyclophosphamide|Endoxan
188092|NCT01985841|Drug|Docetaxel|Taxotere
188093|NCT01985854|Drug|Propofol|
188094|NCT00118235|Other|laboratory biomarker analysis|Correlative studies
188095|NCT01985854|Drug|Desflurane|
188096|NCT01985867|Dietary Supplement|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10^8 CFU, twice daily, orally for 4 weeks)
188097|NCT01985867|Dietary Supplement|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
188098|NCT01985893|Drug|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
187504|NCT01957644|Drug|Volasertib|
187505|NCT01957657|Drug|BI 207127|oral administration
187506|NCT01957657|Drug|faldaprevir|oral administration
187507|NCT01957657|Drug|BI 207127|oral administration
187508|NCT01957657|Drug|BI 207127|oral administration
187509|NCT01957657|Drug|BI 207127|oral administration
187510|NCT00115609|Drug|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
187511|NCT01957657|Drug|faldaprevir|oral administration
187512|NCT01957657|Drug|faldaprevir|oral administration
187513|NCT01957657|Drug|faldaprevir|oral administration
187514|NCT01957670|Device|Lacrima medical Prototypes|
187515|NCT01957683|Device|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
187516|NCT01957709|Other|Laboratory Biomarker Analysis|Correlative studies
187517|NCT01957709|Biological|Recombinant Interferon Gamma|Given SC
187518|NCT01957722|Procedure|microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
187519|NCT01957722|Biological|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
187520|NCT01957735|Drug|BP31510 monotherapy|
187521|NCT00115609|Drug|tenofovir DF|300mg once a day
187522|NCT01957735|Drug|BP31510 in combination with chemotherapy|
187523|NCT01957748|Behavioral|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
187524|NCT01960140|Drug|Baricitinib|Administered orally
187817|NCT01993316|Device|Mitsar 201 neurofeedback|
187818|NCT01993329|Drug|AF219 50 mg|
187819|NCT01993329|Drug|AF219 300 mg|
186902|NCT02549352|Drug|Vehicle gel|
186903|NCT02549365|Drug|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
186904|NCT02549365|Procedure|Surveillance (nasal swabbing) during influenza season|
186905|NCT02549378|Device|confocal microscopy|microvessel diameter measured by confocal microscopy
187208|NCT02542839|Other|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
187209|NCT02542839|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
187210|NCT02542839|Procedure|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
187211|NCT02542852|Drug|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
187212|NCT02542865|Dietary Supplement|Test Product|MMN fortified beverage powder.
187213|NCT02542865|Dietary Supplement|Control|Isocaloric beverage powder without micronutrient fortification.
187214|NCT02542878|Device|Foam roller|A bout of 60 seconds of myofascial release with foam roller
187215|NCT02542891|Other|Blended CBT|
187216|NCT02542891|Other|Treatment as Usual (TAU)|
187217|NCT00184431|Behavioral|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
187218|NCT02542904|Procedure|mesenteric excision|
187219|NCT02542917|Device|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
187220|NCT02542930|Radiation|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
187221|NCT02542930|Drug|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
187222|NCT02542943|Device|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
186613|NCT02553694|Other|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
186614|NCT02553694|Other|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
186615|NCT00185484|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
186616|NCT02553707|Drug|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
186617|NCT02553720|Other|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
186618|NCT02553720|Other|conventional management|conventional management
186619|NCT02553733|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
186620|NCT02553733|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
186621|NCT02553746|Device|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
186622|NCT02553746|Procedure|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
186906|NCT02549391|Drug|KHK7580|Oral administration
186907|NCT02549391|Drug|KRN1493|Oral administration
186908|NCT00185094|Drug|Olmesartan medoxomil|
186909|NCT02549404|Drug|KHK7580|Oral administration
186910|NCT02549417|Drug|KHK7580|Oral administration
186911|NCT02549430|Drug|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
186912|NCT02549430|Drug|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
186309|NCT02560584|Drug|Hexaminolevulinate hydrochloride|Instillation in bladder
186310|NCT02560584|Device|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
186311|NCT02560597|Procedure|repetitive transcranial magnetic stimulation|Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.
In absence of effect, rTMS is given on 5 consecutive days at most.
186312|NCT02560610|Drug|OC000459|
186313|NCT02560610|Drug|Placebo|
186314|NCT00186446|Behavioral|smoking cessation|
186315|NCT02560623|Device|Sponge capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
186316|NCT02560636|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
186317|NCT02560636|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
186318|NCT02560649|Drug|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
186319|NCT02560649|Drug|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
186320|NCT02560649|Drug|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
186321|NCT02560649|Drug|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
186322|NCT02560649|Drug|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
186323|NCT02560649|Drug|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
186324|NCT02560649|Drug|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
186325|NCT00186459|Behavioral|Hypocaloric diet of varying macronutrient composition|
186326|NCT02560649|Drug|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
186623|NCT02553759|Other|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
186624|NCT02556112|Behavioral|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
186034|NCT02566915|Device|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
186035|NCT02566928|Drug|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
186036|NCT02566928|Other|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
186037|NCT02566928|Behavioral|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
186038|NCT02566941|Device|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
186039|NCT02566954|Other|3D measurement of the lower limb by EOS|The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.
3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)
186040|NCT02566967|Drug|tofacitinib|oral tofacitinib will be taken 2 times daily
186041|NCT02566993|Drug|Lurbinectedin (PM01183)|
186042|NCT00187083|Drug|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
186043|NCT02566993|Drug|Doxorubicin|
186044|NCT02566993|Drug|Topotecan|
186045|NCT02567006|Behavioral|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
186046|NCT02567006|Other|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
186047|NCT02567019|Other|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
186048|NCT02567032|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
186049|NCT02567032|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
185472|NCT02544438|Drug|Astarabine|Cohort # Astarabine Dose Number of Patients
0.5 gr/m2 (0.3 age>50) 3
1.5 gr/m2(0.8age>50) 3
3.0 gr/m2(1.5 age>50) 3
4.5 gr/m2(2.3 age>50) 6 Total number of patients: 15
De-escalation:
0.3 gr/m2(0.2 age>50) 6
185749|NCT02571322|Other|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
185750|NCT02571335|Behavioral|Intensive Training|Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.
Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.
Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.
Week 3 Same as week 2.
185751|NCT00187577|Drug|Latanoprost (Xalatan)|
185752|NCT02571335|Behavioral|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
185753|NCT02571348|Procedure|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
185754|NCT02571361|Drug|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
185755|NCT02571361|Drug|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
185756|NCT02571361|Drug|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
185757|NCT02571361|Drug|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
185758|NCT02573519|Device|3D-Transit|3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit in healthy subjects and diabetic patients. The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:
A wireless electromagnetic capsule to be swallowed by the subject
A portable detector plate comprising four sensors worn in a belt around the waist
Specific software for visualizing and analyzing data
185759|NCT02573519|Drug|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
185760|NCT02573545|Device|Planning@IFE and Standard@IFE Software|
185761|NCT02573545|Device|MR Syngo (Numaris/4) software|
185762|NCT02573558|Drug|Dexmedetomidine|
185763|NCT02573558|Drug|Propofol|
185198|NCT02550873|Other|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
185199|NCT02550886|Other|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
185200|NCT02550899|Procedure|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
185201|NCT02550899|Procedure|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
185202|NCT02550899|Procedure|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
185203|NCT02550912|Drug|Vitamin D3|vitamin D drops for paediatrics
185204|NCT02550912|Other|Placebo|glucose syrup with same taste and color to vitamin D3 drops
185205|NCT02550925|Behavioral|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
185473|NCT02544451|Drug|Ivacaftor|
185474|NCT00184613|Drug|insulin aspart|
185475|NCT02544451|Drug|Lumacaftor|
185476|NCT02544464|Drug|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
185477|NCT02544464|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
185478|NCT02544477|Device|High-flow Nasal Cannula Oxygen (HFNC)|
185479|NCT02544477|Device|Conventional oxygen treatment|
185480|NCT02544503|Device|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at 1 month visit and 6 month visit.
185481|NCT02544503|Device|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain.Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at 1 month and 6 month visit.
184933|NCT02559973|Drug|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
184934|NCT00186329|Drug|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
184935|NCT02559986|Other|telephone interview|telephone interview about their care received during the first year of life and associated events
184936|NCT02559999|Other|Painful tonic stimuli|
184937|NCT02559999|Other|non-painful stimuli|
184938|NCT02560012|Drug|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
184939|NCT02560012|Drug|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
184940|NCT02560012|Drug|Sorafenib|400 mg (2 tablets) orally twice daily without food
184941|NCT02560012|Drug|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
184942|NCT02560012|Drug|Everolimus|10 mg orally once daily with or without food
184943|NCT02560012|Drug|Axitinib|5 mg orally twice daily
184944|NCT02560025|Drug|Alisertib|
184945|NCT00186342|Procedure|ablative allogeneic hematopoietic cell transplantation|
184946|NCT02560025|Drug|Cytarabine|
185206|NCT02550925|Behavioral|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
185207|NCT00185185|Drug|Hydrochlorothiazide|tablets
185208|NCT02553083|Drug|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
185209|NCT02553083|Drug|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
185210|NCT02553083|Drug|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
185211|NCT02553096|Device|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
184645|NCT02566447|Device|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
184646|NCT00187070|Drug|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
184647|NCT02566460|Other|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
184648|NCT02566486|Device|Reciprocating system|Different root canal instrumentation systems
184649|NCT02566486|Device|Rotational system|Different root canal instrumentation systems
184650|NCT02566499|Device|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
184651|NCT02566512|Other|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
184652|NCT02566512|Other|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
184653|NCT02566525|Device|CytoSorb|Cytosorb device use during cardiopulmonary bypass
184654|NCT02566551|Procedure|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
184655|NCT02566551|Device|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
184656|NCT02566551|Procedure|TURP|Bipolar transurethral resection of the prostate
184657|NCT00187070|Procedure|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
184658|NCT02566551|Device|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
184659|NCT02566564|Drug|Lopain|intra-articular injection
184947|NCT02560025|Drug|Idarubicin|
184948|NCT02560025|Drug|Daunorubicin|Can be used in place of idarubicin
186138|NCT02542397|Genetic|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
186139|NCT02542410|Drug|Cabergoline|
186140|NCT02542410|Drug|Norethindrone acetate|
186141|NCT02542423|Other|Endocan blood test samples|
186142|NCT02542436|Other|No intervention|No intervention administered in this study
186143|NCT02542449|Dietary Supplement|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
186144|NCT02542449|Dietary Supplement|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
186145|NCT02542462|Drug|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
186146|NCT00184327|Behavioral|Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment
186147|NCT02542462|Drug|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
186148|NCT02542462|Drug|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
186149|NCT02542462|Drug|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
186150|NCT02542475|Device|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (< 100x) than those used in ECT and rTMS.
186151|NCT02542488|Other|STOPBANG Questionnaire|8 question screening tool comprised of the following questions:
S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI >35 kg/m2? A: Are you >50 years old? N: Is your neck circumference >40cm? G: Is your gender male?
186152|NCT02542488|Procedure|Overnight pulse oximetry|All participants will be given a pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
186153|NCT02542514|Drug|Ibrutinib|p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
186154|NCT02542527|Procedure|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
186448|NCT02573831|Drug|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
185567|NCT02553343|Biological|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
185568|NCT02553343|Biological|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
185569|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
185570|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
185571|NCT02553356|Drug|PT2385|
185861|NCT02546934|Drug|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
185862|NCT02546934|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
185863|NCT02548871|Behavioral|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
185864|NCT02548884|Procedure|Biliary cannulation|
185865|NCT02548897|Device|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
185866|NCT00185055|Drug|Olmesartan medoxomil|
185867|NCT02548897|Other|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
185868|NCT02548910|Procedure|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
185869|NCT02548910|Device|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
185870|NCT02548923|Drug|Dexmedetomidine|comparison to propofol
185871|NCT02548936|Drug|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
185872|NCT02548962|Drug|Ibrutinib|
185873|NCT02548962|Drug|Pomalidomide|
185297|NCT02562222|Procedure|sham tDCS|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
185298|NCT02562235|Drug|Riociguat (Adempas, BAY63-2521)|The individual optimal (maintenance) dose is to be determined based on patients' monitoring of systolic blood pressure, well-being and clinical status.
185299|NCT02562248|Other|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
185572|NCT02553369|Other|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
185573|NCT00185393|Other|no treatment|no treatment
185574|NCT02553382|Dietary Supplement|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
185575|NCT02553382|Dietary Supplement|Positive Control|Oat bran blend and wheat bran capsules
185576|NCT02553408|Device|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
185577|NCT02553421|Device|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
185578|NCT02555696|Drug|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
185579|NCT02555709|Drug|VTP-43742|VTP-43742 administered as an oral capsule once daily
185580|NCT02555709|Drug|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
185581|NCT02555709|Drug|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
185582|NCT02555735|Drug|Standard of care chemotherapy|FOLFIRINOX or Gemcitabine + nab-paclitaxel
185583|NCT00185692|Drug|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO
185584|NCT02555748|Drug|Pazopanib|
185585|NCT02555748|Drug|Sunitinib|
185007|NCT02568865|Other|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
185008|NCT02568865|Other|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
185009|NCT02568878|Drug|Creatine monohydrate|
185010|NCT00187200|Device|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
185011|NCT02568891|Dietary Supplement|Probiotic|multispecies probiotic
185012|NCT02568891|Dietary Supplement|Placebo|matrix
185013|NCT02568904|Dietary Supplement|Probiotic|Multispecies Probiotic
185014|NCT02568904|Dietary Supplement|Placebo|matrix
185015|NCT02568904|Dietary Supplement|Alcohol|every participant will drink vodka at a dose of 2g/kg bodyweight
185016|NCT02568917|Procedure|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
185300|NCT02562248|Other|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
185301|NCT00186680|Procedure|high dose chemo then auto hematopoietic cell transplant|
185302|NCT02562274|Dietary Supplement|Placebo|Subjects are received placebo treatments once daily for 8 weeks
185303|NCT02562274|Dietary Supplement|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
185304|NCT02562274|Dietary Supplement|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
185305|NCT02562287|Drug|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
185306|NCT02562287|Drug|Risperidone|Risperidone, in a flexible dosage
185307|NCT02562287|Drug|Olanzapine|Olanzapine, flexible dosage
185308|NCT02562287|Drug|Quetiapine|Quetiapine, flexible dosage
185309|NCT02562300|Drug|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
184457|NCT02546362|Device|Cefaly|
184458|NCT02546375|Drug|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
184459|NCT02546388|Drug|Indium-111 Pentreotide|
184460|NCT02546401|Drug|Insulin Aspart|Injection of Insulin Aspart before or after meals
184461|NCT02546414|Other|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
184462|NCT00184821|Drug|glibenclamide|
184463|NCT02546427|Radiation|Helical TomoTherapy (HT)|
184464|NCT02546427|Radiation|CyberKnife SBRT|
184465|NCT02546427|Radiation|Permanent Prostate Implant (PPI)|
184466|NCT02546427|Radiation|HDR brachytherapy|
184467|NCT02548390|Drug|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
184468|NCT02548403|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
184469|NCT00184990|Drug|endotoxin|
184470|NCT02548403|Drug|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
184754|NCT02541786|Drug|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
184755|NCT02541799|Procedure|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
184756|NCT02541799|Procedure|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
184757|NCT02541812|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
184758|NCT02541825|Device|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
183852|NCT02557269|Drug|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
183853|NCT02557282|Other|Retrospective CTP cases processed with Carestream software.|Retrospective CTP cases were processed using Carestream software and compared to the predicate device software.
183854|NCT02557321|Drug|PV-10|PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
183855|NCT02557321|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
183856|NCT00185900|Drug|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
183857|NCT02557334|Dietary Supplement|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
183858|NCT02559570|Drug|Linaclotide Approved Adult Dose|
183859|NCT02559570|Drug|Matching Placebo|
183860|NCT02559583|Other|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
183861|NCT02559583|Other|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
183862|NCT02559583|Other|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
183863|NCT00186277|Drug|Oxaliplatin|Calculated per patient
183864|NCT02559609|Behavioral|contingency management for alcohol abstinence|Participants will earn chances to win prizes for each negative breath alcohol recording provided.
184165|NCT02552641|Drug|Clarythromycin|
184166|NCT02552654|Behavioral|Stress Film|Film scene with severe physical and sexual violence.
184167|NCT02552654|Drug|Hydrocortisone|10mg
184168|NCT02552654|Drug|Placebo|
184169|NCT02552667|Drug|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
184170|NCT02552667|Drug|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
184171|NCT00185341|Drug|Placebo|Placebo
184172|NCT02552680|Other|Exercise|Physical Exercise
188099|NCT01985906|Procedure|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
188100|NCT01988337|Device|Icon resin Infiltration|One tooth will randomly receive the infiltrating resin (Icon) while the other will receive a placebo. Teeth will be isolated with a rubber dam, the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured with S 10 curing light (3M ESPE, St Paul, MN). Output from the curing light will be measured and recorded weekly. The Icon infiltrating resin will be polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
188101|NCT01988337|Other|mock|Teeth will be isolated with a rubber dam, the tooth surface cleaned with non-fluoride prophylactic paste and pumice. Syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with the solutions having the same consistency and color as the Icon material. The placebo material will be applied following the manufacturer's instructions and light cured with an S 10 curing light (3M ESPE, St Paul, MN). Output from the curing light will be measured and recorded weekly. The placebo material and the Icon infiltrating resin will be polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN).
188102|NCT01988363|Procedure|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
188103|NCT01988376|Device|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
188104|NCT01988376|Device|Conventional Pap smear|Conventional Pap smear
188105|NCT01988389|Dietary Supplement|whole apples (WA)|
188106|NCT00118352|Drug|mycophenolate mofetil|Given PO
188107|NCT01988389|Dietary Supplement|apple juice (AJ)|
183570|NCT02563873|Device|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
183571|NCT00186875|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
183572|NCT02563886|Other|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
183573|NCT02563886|Other|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
187820|NCT01993329|Drug|Placebo (for AF219)|sugar pill manufactured to mimic AF219 50 mg and 300 mg tablets
187821|NCT01993342|Other|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
187822|NCT01993342|Other|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
187823|NCT00002155|Drug|Lamivudine|
187824|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
187825|NCT01993355|Other|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
187826|NCT01993355|Other|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
187827|NCT01993355|Behavioral|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
187828|NCT01993368|Other|flow cytometry|These populations will be identified by different combinations of antibodies to identify:
T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).
Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)
Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)
187829|NCT00115336|Drug|Ibuprofen|Ibuprofen, taken orally
187830|NCT01955200|Drug|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
187831|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
187832|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
187833|NCT01955213|Drug|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
187834|NCT01955226|Other|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
187835|NCT01955226|Other|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
187836|NCT01955239|Radiation|Intensity-modulated Radiotherapy|
188108|NCT01988402|Drug|allopurinol|
187223|NCT02542943|Device|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
187224|NCT02542943|Other|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
187225|NCT02542943|Drug|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
187226|NCT02542956|Drug|Exparel|receive Exparel by injection
187227|NCT02542956|Drug|Marcaine|receive Marcaine in a pain pump
187228|NCT00002499|Drug|asparaginase|
187229|NCT00184444|Behavioral|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
187525|NCT01960140|Drug|Simvastatin|Administered orally
187526|NCT01960153|Drug|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
187527|NCT01960153|Drug|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
187528|NCT01960166|Behavioral|Active Distraction|iPad will be used as active distraction
187529|NCT01960166|Behavioral|Passive Distraction|child will watch TV as passive distraction
187530|NCT01960179|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
187531|NCT00115830|Drug|Atorvastatin|
187532|NCT01960192|Drug|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
187533|NCT01960192|Drug|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
187534|NCT01960205|Drug|Saxagliptin|5mg a day for 6 months
187535|NCT01960205|Drug|saxagliptin|2.5 mg a day for 6 months
187536|NCT01960205|Drug|metformin|500mg three times a day for 6 months
187537|NCT01960205|Other|lifestyle intervention|lifestyle intervention for 6 months
187538|NCT01960231|Other|OGTT|
186913|NCT02549430|Drug|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
186914|NCT02549430|Drug|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
186915|NCT02549430|Drug|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
186916|NCT02549443|Dietary Supplement|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
186917|NCT02549456|Procedure|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
186918|NCT02549456|Procedure|Laparoendoscopic resection|Endoscopic phase: Transanal endoscopic operation (TEO) proctoscope is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.
Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed.
186919|NCT00185094|Drug|Losartan potassium|
186920|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
186921|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
186922|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
186923|NCT02549469|Drug|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
186924|NCT02549482|Other|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
186925|NCT02549508|Device|SensAwake On|The comfort feature 'SensAwake' will be turned on
186926|NCT02549508|Device|SensAwake Off|The comfort feature 'SensAwake' will be turned off
187230|NCT02542956|Drug|Marcaine|receive Marcaine by injection
187231|NCT02542969|Drug|Simvastatin|
187232|NCT02542969|Drug|Rosuvastatin|
187233|NCT02545036|Other|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
186625|NCT02556112|Behavioral|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
186626|NCT02556125|Device|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
186627|NCT02556138|Device|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
186628|NCT02556151|Procedure|Repetitive magnetic stimulation|Six sessions of weekly therapy with 1, 5 or 15 Hz magnetic stimulations of the lumbar and sacral regions.
186629|NCT00185744|Radiation|Whole Breast Radiotherapy|six and a half week treatment
186630|NCT02556164|Procedure|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
186631|NCT02556164|Other|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
186632|NCT02556177|Procedure|MRI|MRI scanning
186633|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg OD (once-daily)
186634|NCT02556203|Drug|Acetylsalicylic acid|75 - 100 mg OD (for first 90 days only in arm 1)
186635|NCT02556203|Drug|Clopidogrel|75 mg OD for first 90 days
186636|NCT02556229|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
186637|NCT02556242|Other|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
186638|NCT02556242|Other|Generalised Indoor residual spraying|IRS is carried out as normally practiced
186927|NCT00002502|Drug|cytarabine|
186928|NCT00185237|Drug|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
186327|NCT02560662|Behavioral|Physical exercise|Preoperative intervention - takes place from randomization until surgery (4 weeks +/-1 w):
• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.
Postoperative intervention - takes place from discharge from the hospital until 4 weeks (+/- 1 w) postoperatively:
• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.
Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call.
186328|NCT02560688|Drug|DS-1040b|20 mg single 12-hour intravenous infusion
186329|NCT02560688|Drug|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
186330|NCT02562703|Device|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
186331|NCT02562716|Drug|Fluorouracil|Given IV
186332|NCT02562716|Drug|Gemcitabine Hydrochloride|Given IV
186333|NCT02562716|Drug|Irinotecan Hydrochloride|Given IV
186334|NCT00186771|Device|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
186335|NCT02562716|Drug|Oxaliplatin|Given IV
186336|NCT02562716|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
186337|NCT02562716|Procedure|Pancreatectomy|Undergo pancreatectomy
186338|NCT02562729|Procedure|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
186339|NCT02562742|Drug|SOF|SOF 400 mg tablets administered orally once daily
186340|NCT02562742|Drug|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
186341|NCT02562755|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
186342|NCT02562755|Drug|Sorafenib|Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.
Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.
Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease.
186343|NCT02562768|Drug|LY3154207|Administered orally
185764|NCT02573571|Other|Development of biomarkers|Blood sampling
185765|NCT02573597|Drug|Bupivacaine|Continuous or bolus administration
185766|NCT00188019|Procedure|diagnosis methods|
186050|NCT02567045|Procedure|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
186051|NCT02567045|Procedure|colonoscopy with sedation|One-time Colonoscopy with sedation.
186052|NCT02567058|Device|Ultrasound exam|Ultrasound exam with :
2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I
1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II
1 succession of 3 measures for group III
186053|NCT00187083|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
186054|NCT02567058|Behavioral|IPAQ questionnaire|IPAQ questionnaire
186055|NCT02567071|Other|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
186056|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
186057|NCT00187239|Device|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
186058|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
186059|NCT02569216|Device|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
186060|NCT02569229|Other|Diagnostics for glucose tolerance with 3 different methods.|A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).
An oral glucose tolerance test done within the 7 day period of CGMS.
Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS.
186061|NCT02569242|Drug|ONO-4538|
186062|NCT02569242|Drug|Docetaxel/Paclitaxel|
186063|NCT02569255|Procedure|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
186064|NCT02569268|Other|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
185482|NCT02544503|Device|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain.Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at 1 month and 6 month visit.
185483|NCT02544503|Device|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at 1 month and 6 month visit.
185484|NCT02544516|Other|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
185485|NCT00184626|Drug|biphasic insulin aspart|
185486|NCT02546726|Behavioral|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
185487|NCT02546726|Behavioral|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
185488|NCT02546739|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
185489|NCT02546752|Other|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
185767|NCT02573597|Drug|Sufentanil|Continuous or bolus administration
185768|NCT02573610|Drug|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
185769|NCT02573610|Drug|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
185770|NCT02573649|Device|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
185771|NCT02573649|Device|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
185772|NCT02573662|Biological|Blood and Urine sampling|Blood and Urine Sampling
185773|NCT02573662|Radiation|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
185212|NCT02553122|Drug|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
185213|NCT02553135|Genetic|Injection of AAV2-REP1 (10e11 vg)|Single Group: single arm study
185214|NCT02553148|Other|Need for children's palliative care|Need for children's palliative care
185215|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
185216|NCT02553161|Drug|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
185217|NCT02553161|Behavioral|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
185218|NCT02553187|Drug|Kanglaite Injection|200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.
Subjects will be treated for 4 courses (12 weeks).
185219|NCT02553200|Device|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
185220|NCT02553200|Device|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
185221|NCT02553200|Device|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
185222|NCT02553213|Other|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
185223|NCT02553213|Other|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
185490|NCT02546765|Drug|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
185491|NCT00184847|Procedure|three 5-minute periods of forearm ischemia|
185492|NCT02546765|Drug|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
185493|NCT02546765|Drug|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
185494|NCT02546765|Drug|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
184949|NCT02560038|Drug|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
184950|NCT02560038|Drug|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
184951|NCT02560038|Drug|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
184952|NCT02560051|Drug|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
184953|NCT02560051|Drug|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
184954|NCT02560051|Drug|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
184955|NCT02560051|Drug|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
184956|NCT00186355|Procedure|high dose chemo then auto hematopoietic cell transplant|
184957|NCT02560051|Drug|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
184958|NCT02560064|Procedure|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
184959|NCT02562209|Other|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
184960|NCT00186667|Procedure|high dose chemotherapy and autologous hematopoietic cell transplant|
184961|NCT02562222|Procedure|anodal tDCS on M1|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
184962|NCT02562222|Procedure|cathodal tDCS on M1|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
186449|NCT02573844|Drug|Proklama|
186450|NCT02573857|Drug|DSM265|Oral suspension from bulk powder
186451|NCT02573857|Drug|OZ439|Oral suspension from powder in a bottle
186452|NCT02573870|Drug|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
186453|NCT02573870|Drug|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
186454|NCT02573870|Drug|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
186455|NCT02573883|Device|Radiofrequency Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center, and include 3 sessions, 4 weeks apart.
186456|NCT02573883|Drug|Clobetasol Propionate 0.5% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
186457|NCT02573896|Drug|Ch14.18|17.5 mg/m2/day of Ch.14.18 will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
186458|NCT00188045|Drug|Propranolol - Spironolactone|
186459|NCT02573896|Biological|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
186460|NCT02573896|Drug|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
186461|NCT02573909|Drug|Oxycodone|
186462|NCT02573922|Drug|oxycodone-naloxone|
186463|NCT02573922|Drug|Oxycodone|
186464|NCT02573935|Drug|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
186465|NCT02573935|Drug|Placebo|Placebo tablet twice daily for 63 days
186466|NCT02573935|Drug|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
185874|NCT02548962|Drug|Dexamethasone|
185875|NCT02548962|Drug|Placebo|
185876|NCT02548975|Drug|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
185877|NCT00185055|Drug|Irbesartan|
185878|NCT02548975|Other|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
185879|NCT02548988|Other|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
185880|NCT02549001|Drug|P-3058 10%|
185881|NCT02549001|Drug|vehicle of P-3058 10%|
186155|NCT02542540|Other|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
186156|NCT02544685|Dietary Supplement|Probio-Fix Inum|Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration
Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin
186157|NCT02544685|Dietary Supplement|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
186158|NCT02544685|Other|Placebo|Same dosage regimen as active drugs
186159|NCT00184626|Drug|metformin|
186160|NCT02544698|Biological|One dose of PCV13a vaccine|
186161|NCT02544698|Biological|One dose of PCV13a vaccine|
186162|NCT02544698|Biological|three doses of PCV13a vaccine|
186163|NCT02544698|Biological|three doses of PCV13a vaccine|
186164|NCT02544711|Device|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
186165|NCT02544711|Procedure|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
186166|NCT02544724|Biological|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
185586|NCT02555761|Drug|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
185587|NCT02555774|Behavioral|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
185588|NCT02555774|Behavioral|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
185589|NCT02555787|Drug|Advagraf|oral
185590|NCT02555800|Drug|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
185591|NCT02555800|Drug|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
185882|NCT02549001|Drug|amorolfine 5%|
185883|NCT02549014|Drug|MK-1064|Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
185884|NCT02549014|Drug|Placebo|Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
185885|NCT02549027|Drug|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
185886|NCT02549027|Drug|MK-6096|Oral MK-6096 tablets (5 mg strength)
185887|NCT02549027|Drug|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
185888|NCT02551107|Device|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
185889|NCT02551133|Drug|dexamethasone|1 hour before surgery
185890|NCT02551146|Device|A Locator with retention elements|Insertion of GC Pilier locator abutments with retention elements
185891|NCT02551146|Device|B Locator without retention elements|Insertion of GC Pilier locator abutments without retention elements
185892|NCT02551159|Biological|MEDI4736|Anti-PD-L1 antibody
185893|NCT02551159|Biological|Tremelimumab|Anti-CTLA-4 Antibody
185894|NCT02551159|Biological|MEDI4736+Tremelimumab|
185310|NCT02562300|Drug|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
185311|NCT02562313|Drug|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
185312|NCT00186706|Drug|Selenium|
185313|NCT02562313|Drug|Humalog®|Humalog® bolus infusion followed by test meal intake
185314|NCT02562326|Drug|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
185315|NCT02562326|Drug|Humalog®|Injection immediately before the start of the individualised standard meal
185316|NCT02562339|Behavioral|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
185317|NCT02562352|Other|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
185318|NCT02562365|Drug|Etoposide, Cyclophosphamide, Carboplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
185319|NCT02564367|Drug|S-1|9 cycles S-1, orally administered twice daily D1-28, q 6 wks
S-1 starting dose: 2 x 30 mg/ m^2 BSA, D1-28, q 6 wks First dose reduction: 2 x 25 mg/ m^2 BSA, D1-28, q 6 wks Second dose reduction: 2 x 20 mg/ m^2 BSA, D1-28, q 6 wks
185320|NCT02564380|Drug|Pembrolizumab|
185321|NCT02564380|Drug|Placebo|
185322|NCT02564406|Device|LOW FLOW EXTRACORPOREAL CO2 REMOVAL PLUS NIV|
185592|NCT02555800|Other|Placebo|Saline solution
185593|NCT02555813|Drug|Abraxane|Abraxane By IV infusion on Days 1, 8, and 15 until progression or toxicity
185594|NCT00185692|Drug|G-CSF|16 mcg/kg, SQ
185595|NCT02555813|Drug|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8 and 15 until disease progression or toxicity
185596|NCT02555826|Drug|Apremilast|
185597|NCT02555839|Drug|Pomalidomide|4mg capsules on Days 1 through 21 of a 28 day cycle
185598|NCT02555839|Drug|Dexamethasone|40mg by mouth on Days 1, 8, 15, 22 of a 28 day cycle
185599|NCT02555852|Drug|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
184759|NCT02541825|Device|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
184760|NCT02541838|Other|Muscle power|
184761|NCT02541838|Other|balance perturbation|
184762|NCT02541838|Other|aerobic exercise|
184763|NCT02541864|Drug|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg bid , bismuth subcitrate 120 mg qid., tetracycline 500 mg qid, and metronidazole 250 mg qid for 14 days
184764|NCT00184223|Behavioral|Motivational Interviewing|
184765|NCT02541864|Drug|Hybrid therapy|a dual therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid for 7 days, followed by a quadruple therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for a further 7 days
184766|NCT02541877|Device|Down sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
184767|NCT02541877|Device|Standard sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
184768|NCT02541877|Device|Standard sizing valve in TAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
184769|NCT02541890|Behavioral|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
184770|NCT02541903|Drug|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
185017|NCT02570932|Biological|Autologous Mesenchymal Bone Marrow Cell|Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.
Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration
185018|NCT02570945|Procedure|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
185019|NCT02570958|Drug|Indocyanine Green|After microcoil inserted into lung nodule, the radiologist will inject 2.5 mg of ICG dye in 1cc of human serum albumin endobronchially adjacent to the lung nodule.
185020|NCT02570971|Drug|Mannitol|
185021|NCT02570984|Drug|Omalizumab|anti-ige injection
184173|NCT02552680|Other|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
184174|NCT02552680|Other|Brochure|Manual/brochure containing information about general health
184175|NCT02552693|Other|Enhanced training, supervision and support|The intervention includes the following activities:
Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities.
184176|NCT02552706|Dietary Supplement|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
184177|NCT02552706|Dietary Supplement|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
184178|NCT02552732|Device|NHF with Oxygen using myAIRVO™ 2|NHF will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
184179|NCT02552732|Device|NHF without Oxygen using myAIRVO™ 2|NHF will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C. Participants can also increase/decrease the flow rate (up to 30L/min or down to 20L/min).
184180|NCT02552745|Drug|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
184181|NCT00185640|Drug|Thymoglobulin|7.5-10 mg/kg; IV
184182|NCT02554955|Drug|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
184183|NCT02554955|Drug|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
184184|NCT02554968|Other|Questionnaires|
184185|NCT02554981|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
184471|NCT02548416|Procedure|Positive end-expiratory pressure|Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.
As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI>25) in the intervention group.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
184472|NCT02548416|Procedure|Control group, zero PEEP|Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
183574|NCT02563899|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
183575|NCT02563899|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
183576|NCT02563912|Other|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
183577|NCT02563912|Other|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
183578|NCT02563925|Radiation|Brain radiotherapy or Stereotactic Radiosurgery|
183579|NCT02563925|Drug|Tremelimumab|
183580|NCT02563925|Drug|HER2 directed therapy|
183581|NCT02565979|Dietary Supplement|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
183582|NCT02565979|Dietary Supplement|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
183583|NCT02565992|Biological|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
183584|NCT02565992|Drug|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
183865|NCT02559609|Behavioral|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
183866|NCT02559609|Behavioral|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
183867|NCT02559622|Drug|Secukinumab|300 mg secukinumab
183868|NCT02559622|Other|Placebo|Placebo followed by 300 mg secukinumab
183869|NCT02559622|Other|Placebo|Placebo followed by 150 mg secukinumab
183870|NCT02559622|Drug|Secukinumab|150 mg secukinumab
188109|NCT01988402|Drug|Placebo (sugar pill)|
188110|NCT01988415|Device|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
188111|NCT01988428|Drug|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
188112|NCT01988467|Other|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
188113|NCT01988480|Procedure|Image-guided surgery|Placement on residual bone around the implant
188114|NCT01988480|Procedure|Sinus lift surgery|Allograft bone
188115|NCT01988493|Drug|MSC2156119J|MSC2156119J will be administered at a total dose range of 300-500 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or subject withdrawal. Dose adjustment will be done as per investigator's discretion based upon individual subject's tolerability.
188116|NCT01988493|Drug|Sorafenib|Sorafenib will be administered at a dose of 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or subject withdrawal. Dose adjustment will be as per investigator's discretion based upon clinical circumstance, taking references to the description in the package insert.
188117|NCT00118352|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
188118|NCT00118521|Procedure|Physiotherapy|
188119|NCT01990911|Device|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
188120|NCT01990911|Drug|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
188121|NCT01990924|Radiation|15 FPS|X-ray pictures
188122|NCT01990924|Radiation|7.5 FPS|X-ray pictures
188123|NCT01990937|Drug|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
188124|NCT01990950|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
188125|NCT01990976|Device|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
188126|NCT01990976|Procedure|Biopsy|biopsy of the vastus lateralis muscle
187539|NCT01960257|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
187540|NCT01960257|Other|SOC DOT|
187541|NCT01960270|Device|Device: INTERSTIM II|A second stimulator is implanted on controlateral site
187542|NCT00115830|Drug|Rosuvastatin|
187543|NCT01960283|Drug|Methotrexate (Novatrex ®) + anti-H1|Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.
After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.
For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group.
187544|NCT01960283|Drug|Placebo + anti-H1|Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.
For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group.
187837|NCT01955252|Drug|Azithromycin|Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).
Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.
Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.
For all subjects, follow-up examination will be performed at 6, and 12 months
187838|NCT01955265|Behavioral|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
187839|NCT01955265|Behavioral|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
187840|NCT00115349|Drug|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
187841|NCT01955278|Device|Definitive end colostomy with mesh|In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.
187842|NCT01955278|Other|Conventional definitive end colostomy|
187234|NCT02545049|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
187235|NCT02545049|Drug|Placebo|Matching placebo to be taken orally, once daily.
187236|NCT02545062|Other|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
187237|NCT02545075|Drug|Ipilimumab|
187238|NCT02545075|Drug|Dacarbazine|
187239|NCT02545088|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
187240|NCT02545088|Other|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
187241|NCT00002499|Drug|dexamethasone|
187242|NCT00184678|Drug|somatropin|
187243|NCT02545088|Other|2nd control group|The 2nd control group will not receive an intervention.
187244|NCT02545114|Drug|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
187245|NCT02545127|Drug|merotocin|
187246|NCT02545127|Drug|placebo|
187247|NCT02545140|Other|No intervention|
187248|NCT02545153|Drug|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
187249|NCT02545153|Drug|Control|No fibrin sealant applied
187250|NCT02545179|Other|web-based daily care training|12 week interactive web based caring training education
187545|NCT01960296|Drug|Clopidogrel|Continue home dose of clopidogrel into surgery
187546|NCT01960296|Drug|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
187547|NCT01962987|Drug|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
187548|NCT01962987|Other|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
186929|NCT02551575|Drug|Integrative Medicine|Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks.
186930|NCT02551588|Procedure|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
186931|NCT02551601|Other|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
186932|NCT02551614|Procedure|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
186933|NCT02551614|Procedure|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
186934|NCT02551614|Procedure|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
186935|NCT02551627|Dietary Supplement|Test Product|MMN fortified beverage powder.
186936|NCT02551627|Dietary Supplement|Control|Isocaloric beverage powder without micronutrient fortification.
186937|NCT02551640|Other|FeatForward App (on study smartphone)|The FeatForward mobile app will have the following features:
Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.
Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.
Community: Users in later stages of change able to encourage and motivate one another through groups.
Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.
Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.
Social Support: Those using the FeatForward app will also have access to a Facebook group.
186938|NCT02551653|Drug|[11C]-GSK2256098 500 MBq|[11C]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
186939|NCT00185237|Drug|Placebo|Placebo patch
186940|NCT02551666|Other|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
186941|NCT02551666|Other|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
186942|NCT02551679|Biological|Angiogenic Cell Precursors|injection of Angiogenic Cell Precursors
186943|NCT02551679|Other|cell culture medium|injection of cell culture medium
186944|NCT02551692|Drug|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
186344|NCT02562768|Drug|Placebo|Administered orally
186345|NCT00186771|Device|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
186639|NCT02556255|Device|CathiTM Atherectomy Hybrid Catheter|Percutaneous Transluminal Atherectomy (PTA) catheter for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD)
186640|NCT00185744|Radiation|Intracavitary Brachytherapy|5 day treatment
186641|NCT02556268|Drug|Riociguat (ADEMPAS)|0.5 mg, Oral (fasted conditions), 1 single dose
186642|NCT02558413|Drug|BTA-C585 oral capsules|BTA-C585; Single ascending doses from 50 mg to 800 mg
186643|NCT02558413|Drug|BTA-C585 matching placebo|Single ascending doses to match 50 to 800 mg BTA-C585 capsules
186644|NCT02558426|Procedure|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
186645|NCT02558439|Drug|CNTX-4975|
186646|NCT02558439|Other|Placebo|
186647|NCT00186095|Procedure|autologous followed by nonmyeloablative allogeneic transplant|
186648|NCT02558452|Drug|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
186649|NCT02558465|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
186650|NCT02558478|Genetic|blood sampling|
186651|NCT02558491|Device|Decision Support System|The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:
An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data
An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.
186652|NCT02558504|Procedure|Oesophagectomy|
186653|NCT02558504|Device|Radiofrequency ablation|
186654|NCT02558517|Drug|prednisone discontinuation|randomization
186655|NCT02558530|Other|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
186065|NCT02569281|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
186066|NCT02569281|Other|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
186346|NCT02562781|Drug|Oxygen|Oxygen in sufficient quantity to maintain SpO2 > 98%
186347|NCT02562781|Other|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
186348|NCT02562794|Behavioral|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
186349|NCT02562807|Drug|TAS-303 18mg single-dose|
186350|NCT02562807|Drug|Placebo 18mg single-dose|
186351|NCT02562807|Drug|TAS-303 9mg single-dose|
186352|NCT02562807|Drug|Placebo 9mg single-dose|
186353|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Ketamine
186354|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Normal Saline
186355|NCT02564835|Other|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
186356|NCT02564835|Other|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
186357|NCT02564848|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
186358|NCT02564861|Drug|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
186359|NCT02564861|Drug|placebo|placebo matching DS-1971a suspension
186360|NCT00186901|Drug|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
186361|NCT02564874|Other|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
185774|NCT02573662|Biological|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
185775|NCT02573688|Behavioral|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
185776|NCT02573701|Drug|Guideline treatment (Risperidone, administered orally)|Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: "psychosocial treatment" included "psychoeducation" "social skills" "healthy life style habits" "exercise in group"
185777|NCT02539784|Device|Kit for Spinal Cord Stimulator System " SCS Systems " : PRECISION® System|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
185778|NCT02539797|Device|tDCS|comparing anodal, cathodal, and sham tDCS
185779|NCT02539810|Device|Renal artery Angioplasty plus stenting.|renal artery stenting
185780|NCT02539810|Drug|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is < 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
185781|NCT02539823|Drug|CBD 400 mg|Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
185782|NCT02539823|Drug|CBD 800 mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
186067|NCT02569294|Behavioral|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
186068|NCT00187252|Device|Atrial Overdrive Pacing|Pacemaker/ ICD implant
186069|NCT02569294|Behavioral|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
185495|NCT02546778|Device|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
185496|NCT02546791|Drug|Dasatinib|
185497|NCT02546804|Procedure|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
185498|NCT02546804|Procedure|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
185499|NCT02546804|Procedure|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
185500|NCT02546830|Device|FreeO2 v2.2|Automatic adjustment of oxygen through the "Free O2" device.
"FreeO2" device in mode medical data collecting(SpO2,EtCO2...).
185501|NCT02546830|Device|FreeO2 v2.2|Manual adjustment of oxygen without the assistance of the "FreeO2" device.
Only "FreeO2" device in mode medical data collecting(SpO2,EtCO2...).
185502|NCT00184847|Drug|adenosine|
185503|NCT02546843|Drug|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
185504|NCT02546843|Drug|Cisatracurium|cisatracurium 0.15mg/kg intravenously
185505|NCT02546843|Drug|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
185506|NCT02546843|Drug|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
185507|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
185508|NCT02548767|Other|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
185509|NCT00185029|Procedure|Ferumoxtran-10 enhanced MRI (MRL)|
185510|NCT02548767|Other|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
185783|NCT02539823|Drug|Control (placebo)|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
185784|NCT02539836|Dietary Supplement|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
185785|NCT00000371|Drug|Placebo|50 mg/day of placebo by mouth
185224|NCT02553213|Other|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
185225|NCT02553213|Other|easy digestible diet|
185226|NCT00185380|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
185227|NCT02553226|Drug|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
185228|NCT02555540|Biological|Boostrix|Randomised assignment
185229|NCT02555540|Biological|Placebo (Saline)|Randomised assignment
185230|NCT02555553|Behavioral|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
185231|NCT02555566|Procedure|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
185232|NCT02555566|Procedure|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
185233|NCT02555579|Behavioral|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
185234|NCT02555592|Procedure|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2~4 weeks after adjuvant chemotherapy.
185235|NCT02555605|Drug|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg−1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg−1•h−1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg−1•h−1. In addition, propofol 0.5 mg.kg−1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
185236|NCT00185692|Drug|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV
185237|NCT02555618|Biological|TAK-850|TAK-850 vaccine
185238|NCT02555631|Behavioral|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
185239|NCT02555644|Drug|LY2606368|Administered IV
186467|NCT02540070|Drug|Ropivacaine|
186748|NCT02569489|Drug|Paclitaxel|
186749|NCT02569502|Drug|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
186750|NCT02569515|Drug|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
186751|NCT02569541|Drug|sodium fusidate|
186752|NCT02569554|Drug|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
186753|NCT02569554|Drug|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
186754|NCT02569567|Procedure|Smart-Shear Wave(SSW) imaging|All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.
The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.
Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement.
186755|NCT00002510|Biological|filgrastim|
186756|NCT00187291|Device|T-Wave Alternans test|
186757|NCT02569567|Procedure|Transient elastography(TE)|Using the M probe in patients with BMI <30 kg/m2.
Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.
Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results.
186758|NCT02569580|Device|Topically|use the "No More" medical device as anti lice treatment
186759|NCT02569593|Dietary Supplement|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
186760|NCT02569619|Behavioral|Activity Intervention|
186761|NCT02569619|Behavioral|Healthy Diet Intervention|
186762|NCT02569632|Biological|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
186167|NCT02544737|Drug|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
186168|NCT02544750|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
186169|NCT02544763|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
186170|NCT00184639|Drug|insulin detemir|
186171|NCT02544763|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
186172|NCT02544776|Drug|Clomifene citrate ( clomid 50 mg )|
186173|NCT02544776|Drug|Amlodipine|
186174|NCT02544789|Drug|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
186468|NCT02540070|Drug|epinephrine|
186469|NCT02540070|Drug|morphine|
186470|NCT02540070|Drug|Ketorolac|
186471|NCT02540070|Drug|Dexmedetomidine|
186472|NCT02540070|Drug|saline|
186473|NCT02540083|Device|Digital Breast Tomosynthesis|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
186474|NCT02540083|Device|Full-Field Digital Mammogram|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
186475|NCT00184002|Drug|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.
Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.
Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).
Prednisone 100 mg po days 1-5.
Cycle 2 until study completion
Doxil 40 mg/m2 iv day 1
Rituxan 375 mg/m2 iv day 1
Cyclophosphamide 750 mg/m2 iv day 1
Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)
Prednisone 100 mg po days 1-5
1 cycle = 21 days.
Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles.
186476|NCT02540096|Other|Mental practice|The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) "Physical Practice" (2) "Familiarization" (3) "Memory" (4) "Relaxation" (5) "Repeat" and (6) "post-practice mental relaxation". After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups).
185895|NCT00185198|Drug|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
185896|NCT02551159|Drug|Cetuximab|Monoclonal Antibody
185897|NCT02551159|Drug|5-fluorouracil (5FU)|Chemotherapy Agent
185898|NCT02551159|Drug|Cisplatin|Chemotherapy agent
185899|NCT02551159|Drug|Carboplatin|Chemotherapy Agent
185900|NCT02551172|Drug|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
185901|NCT02551172|Drug|HGP0816|Rosuvastatin
185902|NCT02551172|Drug|Placebo of HCP1105|Soybean Oil
185903|NCT02551172|Drug|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
185904|NCT02551185|Drug|ACY-241|
185905|NCT02551198|Drug|HAPREP®|Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)
: : PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]
186175|NCT02544802|Drug|Adipose-Derived Mesenchymal Stem Cells|
186176|NCT02544815|Drug|Digoxin|Digoxin 0.25 mg pills
186177|NCT02544815|Drug|Placebo|Placebo pills
186178|NCT02544828|Drug|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
186179|NCT02544828|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
186180|NCT02546947|Other|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
186181|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
186182|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
186183|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
177278|NCT01913561|Device|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
177279|NCT01913574|Device|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
177280|NCT00111644|Drug|Ceftriaxone|1000mg iv daily
177281|NCT01913574|Procedure|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
177282|NCT01913587|Device|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
177283|NCT01913587|Procedure|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
177284|NCT01913600|Device|Resolute Integrity Stent|Drug eluting stent (DES)
177285|NCT01913613|Device|IASD|IASD device implantation
177286|NCT01913626|Behavioral|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
177287|NCT01913639|Drug|Regorafenib|
177288|NCT01913639|Drug|5-Fluorouracil|
177289|NCT01913639|Drug|Leucovorin|
177290|NCT01913639|Drug|Oxaliplatin|
177291|NCT00111644|Drug|beta-lactam|750mg iv q 23h for 3-14 days
177292|NCT01913652|Drug|Cabazitaxel|
177293|NCT01913652|Drug|Prolonged infusional ifosfamide|
177294|NCT01913665|Other|B.lactis|
177295|NCT01913665|Other|Inulin|
177296|NCT01913665|Other|B.Lactis +Inulin|
177297|NCT01913665|Other|Placebo|
177298|NCT01913678|Other|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
176714|NCT01915082|Drug|Ora-Plus|Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):
Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
176715|NCT01915095|Procedure|High frequency non-invasive repetitive transcranial magnetic stimulation|Stimulation with magnetic pulses using transcranial magnetic stimulation and electrical stimulation of a peripheral nerve in the arm
176716|NCT01915095|Procedure|Sham rTMS over control brain area|rTMS stimulation with magnetic pulses using transcranial magnetic stimulation and electrical stimulation applied over the dorsolateral prefrontal cortex or at the leg representation of the primary motor cortex
176717|NCT01917578|Device|Pathologic Large Tissue Selected Table|Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.
Each piece of breast tissues by cutting with the table has 3mm thickness.
176979|NCT01920269|Drug|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
176980|NCT01920269|Device|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
176981|NCT01920282|Drug|Nebivolol|
176982|NCT01920282|Other|Lifestyle Modification|
176983|NCT01920282|Other|Nebivolol plus Lifestyle Modification|
176984|NCT01920295|Device|Cryoballoon ablation|
176985|NCT01920321|Procedure|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
176986|NCT01920334|Drug|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
176987|NCT01920334|Drug|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
176988|NCT01920360|Other|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
176989|NCT00112255|Behavioral|Practice nurse-led partner notification|
176414|NCT01921647|Drug|Amoxicillin|
176415|NCT01921647|Drug|clarithromycin|
176416|NCT01921673|Drug|Dovitinib and docetaxel|In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off
In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used.
176417|NCT01921686|Other|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
176418|NCT01921699|Procedure|taking blood samples from healthy people|
176419|NCT01921712|Drug|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
176420|NCT01921712|Drug|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
176421|NCT00112411|Drug|Bronchodilator|
176422|NCT01921712|Drug|Active comparator|Randomized single dose of inhaled active comparator product
176423|NCT01921725|Device|hydrophilic-based dressing (KoCarbonTM)|"BCT" Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes.
176718|NCT01917578|Device|Leica TP1020|Procedure:
Alcohol 70 % 1h
Alcohol 80 % 1h
Alcohol 85 % 1h
Alcohol 90 % 1h
Alcohol 95 % 1h
Alcohol Ⅰ 100 % 1h
Alcohol Ⅱ 100 % 1h
Xylene Ⅰ 2h
Xylene Ⅱ 2h
Xylene Ⅲ 2h
Paraffin 6h
Paraffin 6h
176719|NCT01917578|Device|Pathologic Large Tissue Embedded Table|The table is made of brass .It is applying for a chinese patent.
The table can simultaneously embed 8 piece of breast tissues.
176720|NCT01917578|Device|Leica SM2000 R|Each of paraffin section has 4 um thickness.
176721|NCT01917578|Procedure|HE Stain|Procedure:
Xylene Ⅰ 60℃ 15-20 minutes
Xylene Ⅱ 60℃ 15-20 minutes
Alcohol 100% Ⅰ 3-5 minutes
Alcohol 100% Ⅱ 3-5 minutes
Alcohol 95% Ⅱ 3-5 minutes
Alcohol 90% Ⅱ 3-5 minutes
Wash in running tap water for 3 minutes
Hematoxylin 5-10 minutes
Wash in running tap water for 3 minutes
Differentiate in 1% acid alcohol for 30 seconds
Wash in running tap water for 1 minute
Bluing in 0.2% ammonia water for 30-60 seconds
Wash in running tap water for 3 minutes
Counterstain in eosin Y solution for 30-60 seconds
Wash in running tap water for 1 minute
Alcohol 90% Ⅱ 2-3 minutes
Alcohol 95% Ⅱ 2-3 minutes
Alcohol 100% Ⅱ 3-5 minutes
Alcohol 100% Ⅱ 3-5 minutes
Xylene Ⅲ 5-10 minutes
Xylene Ⅳ 5-10 minutes
Mounting with neutral resin
176722|NCT01917578|Device|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
176723|NCT01917578|Device|Epson V600|Each slice that has been microscopically outlined is scanned by Epson V600.
Every image by scanning should be saved as JPG.
176112|NCT01916499|Other|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
176113|NCT01916525|Behavioral|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
176114|NCT01916564|Other|Split-dose|2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy
Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy
1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
176115|NCT01916564|Other|Same-morning whole-dose|2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy
Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy
2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
176116|NCT01916577|Drug|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
176117|NCT01918631|Drug|Entecavir|
176118|NCT01918644|Radiation|stereotactic body radiation therapy|Undergo SBRT
176119|NCT01918644|Drug|capecitabine|Given PO
176120|NCT00112151|Drug|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
176121|NCT01918644|Procedure|therapeutic conventional surgery|Undergo definitive surgery
176122|NCT01918644|Procedure|magnetic resonance imaging|Optional correlative studies
176123|NCT01918644|Other|laboratory biomarker analysis|Optional correlative studies
176124|NCT01918657|Drug|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
176424|NCT01921738|Drug|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
176425|NCT01921738|Drug|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
176426|NCT01921738|Drug|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
176427|NCT01921738|Drug|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
175475|NCT00109551|Drug|zinc sulphate dietary supplement|
175476|NCT01890746|Drug|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects > 60 years: daunorubicin dose is adjusted to 60mg /m2.
175771|NCT01883726|Device|Grayson's presurgical nasoalveolar molding|Grayson NAM
175772|NCT01883726|Device|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
175773|NCT00108628|Behavioral|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
175774|NCT01883739|Other|Parental Presence at Handover Rounds|
175775|NCT01883752|Procedure|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
175776|NCT01886196|Behavioral|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
175777|NCT00108901|Behavioral|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of >150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
175778|NCT01886209|Drug|Prednisone|
175779|NCT01886209|Drug|VX-509|
175780|NCT01886209|Drug|Methylprednisolone|
175781|NCT01886222|Other|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
175782|NCT01886222|Other|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
175783|NCT01886235|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
175784|NCT01886235|Drug|Fluorescein Sodium Injection|Given IV
175785|NCT01886235|Other|Laboratory Biomarker Analysis|Correlative studies
175786|NCT01886235|Procedure|Therapeutic Conventional Surgery|Undergo surgery
175787|NCT01886248|Drug|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
175788|NCT00108914|Drug|GW685698X|
175168|NCT01887509|Procedure|Rectoscopy|Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.
Both healthy and tumor tissue will be examined.
175169|NCT01887509|Procedure|EUS|Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.
175170|NCT01887509|Procedure|Biopsy and resection|Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE
Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.
Biopsies will be harvested in both healthy and tumor tissue as well.
175171|NCT01887522|Drug|Vinblastine + Nilotinib|Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28
175172|NCT00109122|Biological|zoster vaccine live (Oka/Merck)|
175477|NCT01890746|Drug|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
175478|NCT01890746|Drug|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of IP will be increased to 300 mg if platelet counts are <100 Gi/L. IP continues until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) will be used and after 7 days, the dose of IP will be increased to 150 mg if platelet counts are <100 Gi/L
175479|NCT01890746|Drug|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given will be matching 300 mg Eltrombopag if platelet counts are <100 Gi/L. Placebo continues until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily will be used and after 7 days, the placebo matching 150 mg Eltrombopag will be given if platelet counts are <100 Gi/L.
175480|NCT01890759|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
175481|NCT01890772|Drug|Telaprevir|
175482|NCT01890772|Drug|Peginterferon alfa-2a|
175483|NCT01890772|Drug|Ribavirin|
175484|NCT01890772|Dietary Supplement|Vitamin D|
175485|NCT01890785|Drug|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
175486|NCT00109551|Drug|iron sulphate-folic acid dietary supplement|
174877|NCT00109707|Drug|Nilotinib|
174878|NCT01892293|Drug|Treatment with NY-ESO-1c259-modified T cells|An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given.
174879|NCT01892306|Behavioral|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
174880|NCT01884545|Behavioral|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
174881|NCT01884558|Drug|isavuconazole|oral
174882|NCT01884558|Drug|metformin|oral
174883|NCT01884571|Drug|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
174884|NCT01884571|Drug|Methylprednisolone|125 mg, IV (in the vein) on day 1.
174885|NCT01884571|Drug|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
175173|NCT01887522|Drug|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
175174|NCT01887535|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
175175|NCT01887535|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
175176|NCT01887535|Drug|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
175177|NCT01887535|Drug|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
175178|NCT01887535|Drug|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
175179|NCT01887535|Drug|Placebo|Matching placebo will be administered as an oral suspension formulation.
175180|NCT01887548|Other|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
175181|NCT01887561|Drug|dasatinib|
175182|NCT01887574|Other|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
174587|NCT01889303|Drug|DC|Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.
chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles.
174588|NCT01889303|Drug|concurrent chemoradiotherapy with 5-FU/CF|FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.
Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles.
174589|NCT01889303|Radiation|adjuvant radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
174590|NCT01889316|Device|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
174591|NCT01889316|Device|AN24|
174592|NCT01889329|Dietary Supplement|RUTF-1|Made from local food ingredients
174593|NCT00109369|Other|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
174594|NCT01889329|Dietary Supplement|RUTF-2|Made from local food ingredients
174595|NCT01889329|Dietary Supplement|Plumpynut|Commercially made from peanut paste
174596|NCT01889342|Behavioral|Metacognitive therapy|
174597|NCT01889342|Behavioral|Cognitive behavioral therapy|
174598|NCT01889355|Device|AgaMatrix Blood Glucose Monitor|
174599|NCT01889368|Dietary Supplement|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
174886|NCT01884571|Drug|Tacrolimus|1-5 mg PO, BID (twice a day) days 2-180.
174887|NCT01884571|Drug|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
174888|NCT01884584|Drug|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
174889|NCT01884597|Drug|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
174282|NCT01893580|Behavioral|Experimental: 1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:
Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.
Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM.
174283|NCT01893580|Behavioral|Experimental: 2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:
Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.
Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM.
174284|NCT01893580|Behavioral|Experimental: 3. Experimental|Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:
Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM.
174285|NCT01893580|Behavioral|Other: 4. Usual care|Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM.
174286|NCT01893593|Other|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
174287|NCT01893593|Other|Control|Guideline summary and data feedback from a baseline medical record review
174288|NCT00109824|Drug|valproic acid|Given PO
174289|NCT01893606|Drug|N-acetyl-D-glucosamine|
174290|NCT01893606|Drug|placebo|
174291|NCT01893632|Drug|gabapentin|
174292|NCT01893632|Drug|Placebo|
174293|NCT01893645|Device|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
174294|NCT01893658|Drug|Omalizumab|
174295|NCT01893658|Drug|Prednisone|
163253|NCT01816243|Drug|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
158501|NCT01771874|Drug|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
158502|NCT01771874|Drug|Placebo|per os
158503|NCT01771887|Behavioral|education program|education program in 6 hours and monitoring phone every 15 days
158504|NCT01771900|Behavioral|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
158505|NCT01771900|Behavioral|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
158506|NCT01771913|Genetic|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
158507|NCT01771913|Genetic|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
158508|NCT01771926|Other|potatoes|Daily intake of assigned treatment for 8 weeks
158509|NCT01771926|Other|other carbohydrate|Daily intake of assigned treatment for 8 weeks
158510|NCT01771939|Procedure|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
158511|NCT00097500|Drug|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
158512|NCT01771939|Procedure|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
158513|NCT01771952|Device|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
158514|NCT01771952|Other|Sham Treatment|A single needle stick without arthrocentesis or injection.
158515|NCT01774474|Drug|Bromfenac|
158516|NCT01774474|Drug|Dexamethasone|
174651|NCT01886716|Behavioral|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
174652|NCT01886729|Other|transcranial direct current stimulation (tDCS)|
174653|NCT01886742|Drug|Cefazolin|
174654|NCT01886742|Drug|Cefazolin|
174655|NCT01886755|Dietary Supplement|ORS rehydration solution|
174656|NCT01886755|Dietary Supplement|placebo|
174657|NCT00109031|Drug|palifermin|Administered as one daily intravenous bolus.
174658|NCT01889368|Dietary Supplement|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
174659|NCT01889381|Drug|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
174660|NCT01889394|Procedure|secondary wound healing|secondary wound healing
174661|NCT01889394|Procedure|primary wound closure using a limberg flap|primary wound closure using a limberg flap
174662|NCT00109382|Drug|Aspirin|
174663|NCT01889407|Drug|Idarubicin|8 mg/m2, iv drip on days 1-3
174664|NCT01889420|Drug|Combination therapy|Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.
Cycles will span 28 days. Dosage schedules will be:
Everolimus daily for 28 days of a 28 day cycle;
Pomalidomide daily for 21 days of a 28 day cycle
Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle.
174665|NCT01889433|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
174666|NCT01889433|Drug|Pegasys|180 µg subcutaneously, once a week
174667|NCT01889446|Dietary Supplement|Calcium propionate|
174668|NCT01889472|Device|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
174058|NCT00110045|Drug|caspofungin acetate|
174059|NCT01898195|Behavioral|Text Message|Text messages will be developed twice daily for three months
174060|NCT01898195|Behavioral|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
174061|NCT01898208|Device|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
174062|NCT01898208|Behavioral|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
174369|NCT01901172|Drug|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
174370|NCT01901172|Drug|RO5503781|Single doses Days 1 and 11
174371|NCT01901172|Drug|posaconazole|Multiple doses Days 8-14
174372|NCT01901185|Drug|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
174373|NCT01901198|Biological|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
174374|NCT01901198|Biological|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
174375|NCT01901211|Other|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
174376|NCT01901224|Drug|Metformin 1000 mg|
174377|NCT00110227|Behavioral|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
174378|NCT01901224|Drug|Placebo|
174379|NCT01893684|Behavioral|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
173744|NCT01902160|Other|Laboratory Biomarker Analysis|Correlative studies
173745|NCT01902160|Drug|Temsirolimus|Given IV
173746|NCT01902173|Drug|Akt Inhibitor GSK2141795|Given PO
173747|NCT01902173|Drug|Dabrafenib|Given PO
173748|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
173749|NCT01895062|Device|Airway Management System (AMS)|The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.
The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway.
173750|NCT01895075|Drug|Inhaled budesonide|Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
173751|NCT01895075|Drug|Normal saline|2 ml normal saline by inhalation
173752|NCT01895088|Device|AcuFocus Corneal Inlay 7000PDT|
173753|NCT01895101|Drug|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
174063|NCT01898208|Other|Bacterial culture|This test identifies the pathogen responsible for an infection.
174064|NCT01898208|Other|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
174065|NCT01898221|Drug|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a ~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
174066|NCT01898221|Procedure|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
174067|NCT01898234|Device|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
174068|NCT01898234|Device|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
174069|NCT00110058|Biological|recombinant interferon alfa|
174070|NCT01898234|Device|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
173428|NCT01899703|Drug|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
173429|NCT01899703|Drug|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
173430|NCT01899716|Other|Exercise|
173431|NCT01899729|Drug|IMO-8400|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
173432|NCT01899729|Drug|IMO-8400|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
173433|NCT01899729|Drug|IMO-8400|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
173434|NCT01899729|Drug|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
173435|NCT01899742|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
173436|NCT00110110|Drug|etoposide|Given at 12 mg/kg/dose
173437|NCT01899742|Drug|Tiotropium 18 mcg|Inhalation Powder
173438|NCT01899755|Drug|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
173439|NCT01901887|Drug|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
173440|NCT01901887|Drug|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
173441|NCT01901900|Biological|Secukinumab (AIN457)|Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
173442|NCT01901913|Device|MD-bolus calculator for pre-meal bolus|
173443|NCT01901913|Device|No MD-bolus calculator for pre-meal bolus|
173754|NCT00109837|Drug|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
173755|NCT01895101|Drug|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
173756|NCT01895127|Drug|Eculizumab|
177912|NCT01912625|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
177913|NCT01912625|Other|Laboratory Biomarker Analysis|Correlative studies
177914|NCT01912625|Drug|Paclitaxel|Given IV
177915|NCT01904786|Drug|placebo|
177916|NCT01904799|Other|Cognitive Assessment test|
177917|NCT01904812|Other|Questionnaire about quality of life and satisfaction|
177918|NCT01904864|Drug|elemental iron (NovaFerrum®)|
178206|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
178207|NCT01907854|Drug|placebo|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily
178208|NCT01907867|Drug|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
178209|NCT01907880|Drug|Pamidronate|90mg IV once every 4 weeks for 3 cycles
178210|NCT00110942|Drug|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
178211|NCT01907880|Drug|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
178212|NCT01907880|Drug|placebo|
178213|NCT01907893|Behavioral|Trauma Collaborative Care Plus Treatment as Usual|
178214|NCT01907906|Device|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
178215|NCT01907932|Device|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
178216|NCT01907945|Behavioral|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
178217|NCT01907945|Behavioral|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
178218|NCT01907984|Drug|Diclofenac|
177580|NCT01909388|Radiation|MRI-TRUS fusion guided real time HDR|
177581|NCT01909401|Drug|boceprevir|
177582|NCT01909414|Biological|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
177583|NCT01909414|Biological|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10^8 TCID50 dose IM.
177584|NCT01909414|Biological|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
177585|NCT01909414|Biological|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
177586|NCT01909427|Drug|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
177587|NCT00111124|Drug|Enbrel®|
177588|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
177589|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
177590|NCT01909427|Drug|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
177591|NCT01909427|Drug|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
177592|NCT01909427|Drug|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
177593|NCT01909427|Drug|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
177594|NCT01909440|Behavioral|exercise intervention|Receive whole body RT
177595|NCT01909440|Dietary Supplement|nutritional supplementation|Given whey protein supplementation PO
177919|NCT01904864|Drug|elemental iron (Ferrous Sulfate)|
177920|NCT01904877|Behavioral|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
177921|NCT01904890|Behavioral|CRC Prevention and Screening Education|Refer to Arm Description
177922|NCT01904890|Behavioral|Nutrition Education|Refer to Arm Description
177923|NCT01904903|Drug|Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine|
177596|NCT01911650|Other|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
177597|NCT01911650|Other|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
177598|NCT00002089|Drug|Azithromycin|
177599|NCT00111423|Drug|Pegsunercept (PEG sTNF-RI)|
177600|NCT01911650|Other|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
177601|NCT01911663|Dietary Supplement|KRG|500 mg Korea red ginseng (KRG)
177602|NCT01911663|Dietary Supplement|Placebo|500 mg placebo
177603|NCT01911676|Drug|PF-03463275|
177604|NCT01911676|Drug|Placebo|
177605|NCT01911702|Other|Standard fluidic resuscitation.|Goals:
arterial pressure mean ≥ 65 mmHg or equal to the pre-operative
diuretic rhythm ≥ 1 ml / Kg / h
venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%
BE> - 3
Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg.
177606|NCT01911702|Other|Volemic small treatment|Goals of the treatment:
arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values
diuretic rhythm ≥ 0.5 ml / kg / h
venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG
BE> - 5
PVC goal not necessary
To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be > 10-15 ml / kg / h an infusion of furosemide should be initiated
177607|NCT01911715|Drug|MDV3100|Oral
177608|NCT01911728|Drug|MDV3100|Oral
177609|NCT01911728|Drug|Pioglitazone|Oral
177610|NCT00111436|Drug|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
177611|NCT01911728|Drug|Warfarin|Oral
177612|NCT01911728|Drug|Omeprazole|Oral
177613|NCT01911728|Drug|Midazolam|Oral
177614|NCT01911741|Drug|MDV3100|Oral
177615|NCT01911754|Biological|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
176990|NCT01920360|Other|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
176991|NCT01920360|Other|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
176992|NCT01920373|Drug|Group A (corticosteroid injection group)|
176993|NCT01920373|Biological|Group B (platelet rich plasma injection group)|
176994|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
176995|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
177299|NCT01913678|Other|Complete diet|The participants will be given all dietary items in their diet with no additional products.
177300|NCT01913678|Other|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
177301|NCT01913691|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
177302|NCT00111644|Drug|beta-lactam|1500mg iv q 12h for 3-14 days
177303|NCT01909024|Procedure|Coil embolisation|transjugular coil embolisation of pelvic veins
177304|NCT01909024|Procedure|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
177305|NCT01909037|Dietary Supplement|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
177306|NCT01909063|Dietary Supplement|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
177307|NCT01909063|Dietary Supplement|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
177308|NCT01909063|Dietary Supplement|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
177309|NCT01909076|Behavioral|Electronic decision support tools|Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function "PEG"), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate.
177310|NCT00111046|Drug|Ibuprofen|
176724|NCT01917578|Device|MRI|Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.
Measurement of tumor size refers to WHO standards.
The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction.
176725|NCT01917578|Procedure|Three-Dimensional Reconstruction|A.Pathological images three-dimensional reconstruction:
Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.
Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.
Observe the shrinkage modes in three-dimensional space.
According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.
According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.
B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction
176726|NCT00112047|Drug|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
176727|NCT01917578|Device|Mammography|Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.
Measurement of tumor size and calcification extent refers to WHO standards.
Calcification extent is not only measured in mammography image but also under microscope.
176728|NCT01917578|Drug|TAC,TC,TA,CAF,CEF|TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)
TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)
TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)
CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
176996|NCT01920399|Drug|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
176997|NCT01920399|Drug|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
176998|NCT01920412|Device|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
176999|NCT01913015|Drug|abiraterone acetate|Given PO
177000|NCT01913015|Dietary Supplement|dietary intervention|Receive low fat breakfast
177001|NCT01913015|Dietary Supplement|dietary intervention|Receive high fat breakfast
177002|NCT01913015|Other|pharmacological study|Correlative studies
177003|NCT01913015|Other|questionnaire administration|Ancillary studies
177004|NCT01913015|Other|laboratory biomarker analysis|Correlative studies
177005|NCT01913028|Drug|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
177006|NCT00002091|Drug|Pentoxifylline|
176428|NCT01921751|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
176429|NCT01921751|Drug|Capecitabine|Given PO
176430|NCT01921751|Drug|Gemcitabine Hydrochloride|Given IV
176431|NCT01914601|Device|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
176432|NCT01914627|Drug|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
176433|NCT01914627|Drug|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
176434|NCT00111748|Drug|Velcade, Thalidomide, Dexamethasone|Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14
This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit.
176435|NCT01914653|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
176436|NCT01914666|Drug|Duloxetine|Administered orally
176437|NCT01914679|Device|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
176438|NCT01914692|Drug|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
176439|NCT01914705|Procedure|Landmark Procedure|Using Landmarks to guide SCVC placement
176440|NCT01914705|Procedure|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
176441|NCT01914718|Drug|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
175789|NCT01886274|Device|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
175790|NCT01886287|Drug|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
175791|NCT01886313|Drug|Civamide Nasal Spray|
175792|NCT01886313|Drug|Placebo|
176125|NCT01918657|Drug|walnut powder|escalating doses of walnut powder
176126|NCT01918670|Procedure|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
176127|NCT01918683|Radiation|TACE transarterial chemoembolization|
176128|NCT01918683|Radiation|stereotatic body radiotherapy (SBRT)|
176129|NCT01918696|Behavioral|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
176130|NCT01918696|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
176131|NCT00112151|Drug|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
176132|NCT01918696|Behavioral|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
176133|NCT01918709|Drug|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
176134|NCT01918709|Drug|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
176135|NCT01918709|Drug|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
176136|NCT01918709|Drug|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
176137|NCT01918709|Drug|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
176138|NCT01918709|Drug|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
176139|NCT01918722|Drug|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
175487|NCT01883141|Device|MultiSpot pacing|Subjects will receive pacing from one right ventriclar lead and one left ventricular catheter/lead with multiple LV pacing spots
175488|NCT01883141|Device|MultiVein pacing|Subjects will receive pacing from one right ventriclar lead and two left ventricular catheter/lead(s)
175489|NCT01883141|Device|Standard biventricular pacing|Subjects will receive standard biventricular pacing from one right ventriclar lead and one left ventricular catheter/lead
175490|NCT01883167|Drug|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
175491|NCT01883167|Drug|Febuxostat 40 mg|Febuxostat 40 mg qd
175492|NCT00108602|Drug|acetazolamide|
175493|NCT01883167|Drug|placebo|placebo qd
175494|NCT01883180|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
175495|NCT01883193|Dietary Supplement|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
175793|NCT01886326|Other|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
175794|NCT01886339|Other|SNIF test (Sniff Nasal Inspiratory Force)|
175795|NCT01886352|Drug|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
175796|NCT01886352|Drug|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
175797|NCT01886352|Drug|Intraperitoneal atomization of levobupivacaine.|Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:
Each subdiaphragmatic area 0.05 ml/kg
Dome of abdomen then settling onto bowel 0.05 ml/kg
Surgical dissection site 0.05 ml/kg
At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg.
175798|NCT01886365|Device|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
175799|NCT01888575|Drug|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
175800|NCT01888588|Drug|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
175183|NCT00109122|Biological|Comparator: placebo (unspecified)|
175184|NCT01887587|Drug|MLN9708|
175185|NCT01890239|Other|Care Programme for the Last Days of Life|The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
175186|NCT01890252|Device|Hyper CL|The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
175187|NCT00109473|Drug|cortecosteroid|As prescribed by the referring gastroenterologist
175188|NCT01890252|Drug|saline solution|saline solution of 5% NaCl
175189|NCT01890265|Drug|FG-3019|Study Drug, FG-3019, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
175190|NCT01890265|Drug|Placebo|Sterile, clear aqueous solution, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
175191|NCT01890278|Radiation|Whole Brain IMRT|
175192|NCT01890278|Radiation|Conventional Whole Brain RT|
175496|NCT01883219|Drug|TKI|Imatinib will be given for patients without BCR/ABL mutations with a dose of 400mg/d or 600mg/d. The second-generation TKI will be given for those with mutations(except for mutation of T315I). The therapy will be suspended if patient peripheral blood absolute neutrophil counts (ANC) is <0.5×10^9/L and or platelet count is <2.0×10^9/L. Donor Lymphocyte Infusion(1.0×10^8/kg) will be given for patients with mutation of T315I.
175497|NCT01883232|Device|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
175498|NCT01883232|Device|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
175499|NCT01883245|Device|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
175500|NCT01883245|Device|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
175501|NCT01883258|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
175502|NCT01883258|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
174890|NCT00108745|Other|Clinical Observation|Undergo observation
174891|NCT01884597|Drug|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
174892|NCT01884623|Drug|Cetuximab|
174893|NCT01884623|Drug|Methotrexate|
174894|NCT01884636|Drug|isavuconazole|oral
174895|NCT01884636|Drug|methotrexate|oral
174896|NCT01884662|Behavioral|Virtual walking|As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs "walking"; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking.
174897|NCT01884662|Behavioral|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
174898|NCT01884675|Drug|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
174899|NCT01884675|Drug|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
174900|NCT01884688|Drug|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
174901|NCT00108745|Other|Laboratory Biomarker Analysis|Correlative studies
174902|NCT01884701|Device|ENABLER-P Catheter System|
174903|NCT01884714|Other|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
174904|NCT01884727|Dietary Supplement|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
174905|NCT01887080|Other|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
175193|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
175194|NCT01890317|Procedure|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
175195|NCT01890330|Other|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
174600|NCT01891708|Other|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
174601|NCT01891721|Behavioral|Brain Fitness Program (BFP)|This computerized "bottom-up" cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session.
174602|NCT01891721|Behavioral|Cognitive Package (Cogpack)|This computerized "top-down" cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises.
174603|NCT01891721|Behavioral|Commercial Computer Games (Sporcle)|Sporcle computer games will be used as a "placebo" treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of "training" per week over 12 weeks, for a total of 36 hours.
174604|NCT01891734|Other|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of PST (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from PST to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person PST or the Moving Forward website. The phone content matches PST. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
174605|NCT01891734|Other|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of PST (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
174606|NCT01891747|Drug|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I & phase II)
174607|NCT01891747|Drug|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I & Phase II)
174608|NCT01891747|Dietary Supplement|Vitamin C|250 mg vitamin C once a day (oral) - Phase I & Phase II
174609|NCT00109616|Behavioral|Cleansing of umbilical cord with 4% chlorhexidine|
174610|NCT01891760|Device|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
174611|NCT01891760|Device|Profore|Four-layer compression bandaging therapy.
158517|NCT01774474|Drug|Bevacizumab|
158518|NCT01774474|Drug|Triamcinolone Acetonide|
158816|NCT01795937|Drug|Faldaprevir|once daily
158817|NCT01795937|Drug|Rosuvastatin|single dose
158818|NCT01795937|Drug|Faldaprevir|once daily
158819|NCT00099827|Behavioral|Education|Individuals will receive information about depression
158820|NCT01795950|Drug|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
158821|NCT01795963|Behavioral|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
158822|NCT01795963|Behavioral|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
158823|NCT01795976|Genetic|NY-ESO-1 T cells|
158824|NCT01795976|Drug|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
158825|NCT01795976|Drug|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
158826|NCT01795976|Biological|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
158827|NCT01795989|Device|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
158828|NCT01796002|Drug|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
158829|NCT01796002|Drug|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
158830|NCT00099840|Procedure|Procalcitonin guided antibiotic therapy|
174669|NCT01889498|Drug|Acetazolamide|Acetazolamide twice a day, at 12 hour intervals:
250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery
One tablet to take two hours before surgery
500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours.
174953|NCT00109733|Biological|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
174954|NCT01892540|Procedure|positron emission tomography/computed tomography|Undergo PET/CT
174955|NCT01892540|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
174956|NCT01892540|Device|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
174957|NCT01892540|Radiation|gadopentetate dimeglumine|Undergo DTPA-PET/MRI
174958|NCT01892540|Other|questionnaire administration|Ancillary studies
174959|NCT01892553|Device|tDCS|Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit
Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min
Cathodal tDCS: Intensity of 1.25 mA during 15 min
Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)
174960|NCT01892566|Other|mHealth Intervention|See arm description
174961|NCT01884727|Dietary Supplement|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
174962|NCT01884740|Drug|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 m/m2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
174963|NCT01884792|Other|Sitting OGTT|
174964|NCT01884792|Other|Standing OGTT|
174965|NCT01884792|Other|Sitting CGM|
174966|NCT01884792|Other|Standing CGM|
174967|NCT01884805|Device|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
174968|NCT00108745|Drug|Paclitaxel|Given IV
174969|NCT01884818|Other|Manipulation vs. TNS thoracic pain|
174380|NCT01893684|Behavioral|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
174381|NCT00109824|Other|pharmacological study|Correlative studies
174382|NCT01893697|Other|HRCT scan in a specific postural position|HRCT Scan taken in supine and lateral position
174383|NCT01893710|Procedure|biopsy sampling|Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.
Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.
174670|NCT01889511|Behavioral|Intervention group - texts|Patients will be instructed to respond to the text message by sending a text stating if the oral agent was "taken". If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes.
174671|NCT01889524|Other|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
174672|NCT01889524|Other|Jet nebulizer|The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a "T" piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
174673|NCT00109382|Drug|Clopidogrel|
174674|NCT01891786|Behavioral|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
174675|NCT01891786|Behavioral|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
174676|NCT01891799|Other|Option B+|Using one low toxicity triple ARV regimen [(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)] for all women, rather than adapting regimens by CD4+
Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART
Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women
174677|NCT01891812|Drug|Nitrous oxide 50%|
174071|NCT01898234|Device|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
174072|NCT01898247|Other|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
174073|NCT01898260|Device|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
174074|NCT01898260|Device|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
174075|NCT01898273|Drug|I-124-CLR1404|single-dose, intravenous
174076|NCT01898286|Drug|DiaPep277|
174077|NCT01900730|Drug|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
174078|NCT01900730|Drug|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
174079|NCT01900730|Behavioral|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
174080|NCT01900730|Behavioral|Pill Diary|Patient given a pill diary to record the time each dose taken.
174384|NCT01893723|Procedure|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
174385|NCT01893723|Procedure|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
174386|NCT01893736|Other|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
174387|NCT01893736|Other|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
173757|NCT01895127|Biological|Immunoglobulin|
173758|NCT01895127|Procedure|Plasmapheresis|
173759|NCT01895140|Device|Renal denervation device|
173760|NCT01895166|Procedure|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
173761|NCT01895166|Procedure|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
173762|NCT01895179|Other|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
173763|NCT01895179|Other|Grazing|Grazing involves eating meals spread out over the course of the day.
173764|NCT01895192|Other|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
173765|NCT00109850|Biological|cetuximab|400mg/m^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m^2 maintenance dose, IV over 60 min, Days 8 & 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
173766|NCT01895205|Drug|Iron isomaltoside 1000|
173767|NCT01895205|Drug|Red blood cell transfusion|
173768|NCT01895218|Drug|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
173769|NCT01895218|Other|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
173770|NCT01895231|Drug|Iron isomaltoside 1000 (Monofer®)|
173771|NCT01895231|Drug|Placebo|
173772|NCT01897649|Dietary Supplement|GLUCIDEX 21|15g/day GLUCIDEX 21
173773|NCT01897662|Dietary Supplement|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
173774|NCT01897662|Dietary Supplement|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
174081|NCT01900730|Behavioral|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
178219|NCT01907984|Drug|Midazolam|
178220|NCT01907997|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
178221|NCT00110942|Other|Placebo|SC placebo injection Q4W for 3 doses
178222|NCT01907997|Drug|normal saline infusion|In group C, the patients receive same volume of normal saline
178223|NCT01908010|Drug|ABT-354|ABT-354 Low Dose
178224|NCT01908010|Drug|ABT-354|ABT-354 High Dose
178225|NCT01908010|Drug|Placebo|Placebo
178226|NCT01908023|Behavioral|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
173444|NCT01901926|Procedure|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
173445|NCT00110305|Drug|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
173446|NCT01901939|Other|exercise|daily tailored low level pedaling exercise at bedside
173447|NCT01901952|Behavioral|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
173448|NCT01901952|Behavioral|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
173449|NCT01901965|Behavioral|Neuromuscular electrical stimulation|
173450|NCT01901965|Behavioral|eccentric training|
173451|NCT01901978|Behavioral|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
173452|NCT01901991|Procedure|Radioactive seed localization (RSL)|
173453|NCT01901991|Procedure|Wire-guided localization (WGL)|
173454|NCT01902004|Drug|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
177924|NCT00110617|Drug|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
177925|NCT01904916|Procedure|Histological biopsy procedure|
177926|NCT01904929|Other|Walk-tests|Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.
This series of test will be repeated 72 hours later for the study reproducibility.
It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of " modified Bruce " in moderation of portable VO2.
177927|NCT01904981|Drug|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
177928|NCT01904981|Drug|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
177929|NCT01904994|Procedure|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HTC (HIV testing and counseling) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
177930|NCT01904994|Procedure|Accelerated ART (antiretroviral therapy) Initiation|Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing.
2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting
177931|NCT01904994|Behavioral|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
177932|NCT01904994|Behavioral|Cellular Appointment Reminders and Follow-Up|SMS (short messaging service) appointment reminders for follow-up appointments.
Telephone call within 7 days of missed appointment for all patients.
177933|NCT01904994|Other|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the FI will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
178227|NCT01910363|Drug|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
178228|NCT01910363|Drug|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
178229|NCT01910389|Drug|Tadalafil|
178230|NCT01910389|Drug|Placebo for tadalafil|
177616|NCT01911767|Drug|dimethyl fumarate|Provided under routine clinical care
177617|NCT01911767|Drug|Peginterferon beta-1a|Provided under routine clinical care
177934|NCT01907412|Behavioral|Family Foundations Coparenting Program|Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.
Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.
Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff.
177935|NCT01907425|Other|Blood samples|
177936|NCT01907464|Other|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
177937|NCT01907464|Other|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
177938|NCT01907464|Other|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
177939|NCT01907464|Other|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
177940|NCT01907477|Other|Samples taken at the clinical hematology unit|
177941|NCT01907490|Drug|Ha44 Gel|
177942|NCT00110890|Drug|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
177943|NCT01907503|Procedure|Evaluation of the balance of force platform|
177944|NCT01907516|Device|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
177945|NCT01907516|Behavioral|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
177946|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
177947|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
177948|NCT01907542|Procedure|stapled skin closure|as above
177311|NCT01909076|Behavioral|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
177312|NCT01909076|Behavioral|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
177313|NCT01909076|Behavioral|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
177618|NCT01911780|Drug|placebo|placebo matching amlodipine capsule
177619|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
177620|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
177621|NCT00111449|Drug|Etanercept|
177622|NCT01911780|Drug|amlodipine|capsule
177623|NCT01904253|Drug|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
177624|NCT01904266|Procedure|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
177625|NCT01904266|Procedure|GA + sham block|Injection of 1 cc saline subcutaneously
177626|NCT01904279|Drug|tocilizumab [RoActemra/Actemra]|Subcutaneous doses every 2 or 3 weeks for 52 weeks
177627|NCT01904292|Drug|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
177628|NCT01904318|Drug|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
177629|NCT01904318|Drug|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
177630|NCT01904318|Drug|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
177007|NCT00111605|Biological|CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)|A 1 mL intramuscular injection in the deltoid
177008|NCT01913028|Drug|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
177009|NCT01913054|Drug|Fentanyl Injection|
177010|NCT01913054|Drug|Etomidate Fat Emulsion Injection|
177011|NCT01913054|Drug|Propofol Injection|
177012|NCT01913067|Drug|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
177013|NCT01913067|Procedure|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
177014|NCT01913080|Other|Health Log|The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:
Personal information and emergency contact(s)
Physician names and contact information
Insurance information
Medications, vitamins and supplements
Surgeries
Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.
The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed.
177314|NCT01909076|Behavioral|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
177315|NCT01911247|Drug|Metformin|Metformin 850 mg once daily
177316|NCT00111345|Drug|AI|AI
177317|NCT01911260|Dietary Supplement|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
177318|NCT01911260|Other|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
177319|NCT01911273|Drug|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
176729|NCT01917578|Drug|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.
TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)
AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)
TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)
TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.
CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)
176730|NCT01919840|Procedure|Group ROTEM|10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.
If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected.
176731|NCT01919840|Other|Group C|10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.
If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result.
176732|NCT01919853|Behavioral|Mindfulness-Based Stress Reduction|
176733|NCT00112229|Biological|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
176734|NCT01919853|Behavioral|Attention Control|
176735|NCT01919866|Other|Transplantation of CD3/CD19 depleted stem cells|
176736|NCT01919879|Drug|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
176737|NCT01919879|Drug|Cetuximab|Cetuximab administered intravenously
176738|NCT01919892|Drug|Lithium|
176739|NCT01919905|Dietary Supplement|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
176740|NCT01919918|Drug|Metabolite Soup|
176741|NCT01919944|Drug|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
176742|NCT01919944|Drug|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
176743|NCT01919957|Other|No intervention|
176744|NCT00112242|Biological|Montanide + Melan-A analogue peptide|1 ml Montanide+ 500 mcg Melan-A analog peptide
176745|NCT01919970|Other|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
176140|NCT01918722|Drug|placebo|placebo herbal medicine, one dose,bid, for 10 days
176141|NCT01921179|Behavioral|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
176142|NCT01921192|Drug|Folic Acid, vit B6 and B12|
176143|NCT01921192|Drug|Placebo|
176144|NCT01921205|Drug|Lacosamide|Subjects <30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)
Subjects ≥30 kg to <50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)
Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)
176442|NCT01914731|Drug|Fecal Microbiota Transplant|Reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile - infected recipient via frozen capsule
176443|NCT01914744|Drug|Entecavir|entecavir 0.5 mg/day PO
176444|NCT01914744|Drug|Lamivudine|lamivudine 100 mg/day PO
176445|NCT00002093|Drug|Daunorubicin (liposomal)|
176446|NCT00111761|Drug|Irinotecan|Part 1: 125 mg/m^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m^2 IV infusion every other week until disease progression or unable to tolerate.
176447|NCT01914757|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
176448|NCT01914757|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
176449|NCT01914757|Biological|Benralizumab (adolescent patients in the EU)|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
176450|NCT01917058|Drug|Abatacept|This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.
Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
176451|NCT01917058|Drug|placebo|
176452|NCT01917071|Other|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
175801|NCT01888627|Other|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
175802|NCT01888640|Device|TENS|TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS
175803|NCT01888653|Behavioral|Attention Bias Modification Treatment|ABMT is designed to implicitly modify patients' biased threat attendance via computerized training protocols. Recent meta analysis of 10 eligible RCTs (N=467) concluded that ABMT produced significantly greater reduction in anxiety symptoms than control training, with a medium effect size (d=.61, p<.001).11
175804|NCT01888653|Behavioral|Attention Bias Modification Treatment|Attention Bias Modification Treatment (ABMT) is a novel 4-week, intervention designed to normalize attention bias to threat and reduce symptoms of anxiety. This neuroscience-informed treatment grew from research linking attention biases to neurocognitive perturbations in PTSD. Currently available treatments, such as cognitive behavioral therapy, may fail to address anxiety-related deficits in rapidly deployed processes instantiated in subcortical circuitries.ABMT was designed to at least partially address such rapidly-deployed processed through repetitive, computer based training methods, methods previously shown to alter implicit and dynamic neural processes.
175805|NCT01888679|Procedure|Head movement|Head movement in extension, flexion, right and left rotation
175806|NCT01888718|Drug|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
175807|NCT00109291|Drug|Placebo|
175808|NCT01888731|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
176145|NCT01921205|Other|Placebo|Subjects <30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)
Subjects ≥30 kg to <50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)
Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)
176146|NCT01921218|Drug|belatacept (Nulojix)|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
176147|NCT01921218|Drug|Calcineurin inhibitor therapy|upon enrollment, wean calcineurin inhibitor to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
176148|NCT01921218|Drug|mycophenolate mofetil|continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
176149|NCT01921218|Drug|prednisone|begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
176150|NCT01921231|Drug|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
175503|NCT00108615|Drug|Metformin|
175504|NCT01883271|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
175505|NCT01883271|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
175506|NCT01885832|Biological|Autologous adipose tissue stromal vascular fraction|
175507|NCT01885845|Device|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
175508|NCT01885845|Other|Indirect weight assesment of blood loss|Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml.
175509|NCT00108836|Drug|XBD173|
175510|NCT01885858|Behavioral|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
175809|NCT01888744|Drug|GnRH agonist|
175810|NCT01888744|Drug|GnRH antagonist|
175811|NCT01888744|Drug|hP-hMG|
175812|NCT01888744|Drug|Human chorionic gonadotropin|induction of final oocyte maturation
175813|NCT01888744|Drug|Progesterone|
175814|NCT01888757|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
175815|NCT01888783|Other|Tactile acuity measured by 2PD and the GOT|For a detailed description of the methods see "outcome measures"
175816|NCT01888796|Drug|Linagliptin|
175817|NCT01888796|Drug|placebo|
175196|NCT01890330|Other|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
175197|NCT01890343|Drug|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
175198|NCT00002070|Drug|Sargramostim|
175199|NCT00109486|Drug|GW685698X|
175200|NCT01890343|Drug|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
175201|NCT01890356|Device|Transcranial electrical stimulation|
175202|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
175203|NCT01890369|Dietary Supplement|3g Leucine|Dissolved in 250ml water.
175204|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
175205|NCT01890382|Dietary Supplement|Whey protein|20 g twice a day (morning and evening)
175206|NCT01890382|Dietary Supplement|whey plus creatine|whey protein combined with creatine (20 g and 2,5 twice a day, respectively)
175207|NCT01890382|Dietary Supplement|leucine supplementation|7,5 g/d three times per day
175208|NCT01890382|Dietary Supplement|soy protein|40 g twice a day
175209|NCT01892579|Behavioral|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
175210|NCT01892579|Other|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
174612|NCT01891773|Behavioral|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
174906|NCT01887093|Behavioral|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
174907|NCT01887106|Drug|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
174908|NCT01887106|Drug|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
174909|NCT01887106|Drug|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
174910|NCT01887106|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
174911|NCT00109044|Drug|Escitalopram|
174912|NCT01887119|Drug|Eplerenone|
174913|NCT01887119|Other|Placebo|Eplerenone-matched placebo
174914|NCT01887132|Drug|Donepezil|
174915|NCT01887132|Drug|Placebo|
174916|NCT01887145|Procedure|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
174917|NCT01887145|Procedure|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
174918|NCT01887158|Drug|Polyethylene glycol|
174919|NCT01887158|Drug|Bisacodyl|
174920|NCT01887171|Drug|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
174921|NCT01887184|Drug|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranassaly
174922|NCT00109057|Drug|Avastin (bevacizumab)|
158831|NCT01796015|Other|ONSD ultrasound|Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).
For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.
At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.
As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned.
158832|NCT01796028|Drug|METFORMIN|
158833|NCT01796028|Drug|Placebo|
158834|NCT01798264|Drug|ITCA 650 (exenatide in DUROS)|
159148|NCT01801683|Other|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
159149|NCT01801696|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
159150|NCT01801696|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
159151|NCT01801709|Genetic|intracerebral administration of AAVrh.10cuARSA|
159152|NCT01801735|Drug|Meloxicam Test Capsules|
159153|NCT01801748|Dietary Supplement|oral wheat challenge|
159154|NCT01801774|Drug|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
159155|NCT01801774|Drug|Placebo|
159156|NCT01801787|Device|tDCS|active vs. sham tDCS left hemisphere
159157|NCT01801800|Procedure|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
159158|NCT00000284|Drug|Cotinine fumarate|
159159|NCT00001967|Drug|HAART|
174970|NCT01884831|Biological|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
174971|NCT01884844|Drug|Vitamin D3, Cholecalciferol|
174972|NCT01884844|Drug|Placebo|
174973|NCT01884857|Drug|Metoprolol Succinate ER Tablets 50 mg|1* 50 mg tablet once a day
175269|NCT01887704|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
175270|NCT01887704|Device|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
175271|NCT01887704|Device|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
175272|NCT01890395|Other|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
175273|NCT00109499|Drug|AdGVPEDF.11D|
175274|NCT01890408|Drug|wound infusion ropivacaine|Laparotomy Hepatic surgery :
Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours.
175275|NCT01890421|Drug|Gadobutrol (Gadovist, BAY86-4875)|
175276|NCT01890434|Drug|Gadobutrol (Gadovist, BAY86-4875)|
175277|NCT01890447|Other|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
175278|NCT01890473|Drug|Abatacept|
175279|NCT01890499|Dietary Supplement|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
175280|NCT01890538|Drug|Administration of 100 mg dimenhydrinate intravenous|
175281|NCT01890538|Drug|2 g piracetam intravenous|
175282|NCT01890551|Other|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
175283|NCT01890564|Other|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
175284|NCT00109512|Drug|NBI-56418 (GnRH antagonist)|
175285|NCT01890564|Other|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
174678|NCT01891825|Procedure|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
174679|NCT01891825|Procedure|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
174680|NCT01891838|Procedure|Volume controlled ventilation|
174681|NCT00109629|Drug|VRC-HIVDNA016-00-VP|
174682|NCT01891838|Procedure|Pressure-controlled ventilation|
174683|NCT01891851|Drug|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
174684|NCT01891851|Drug|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
174685|NCT01891864|Drug|GP2015 Etanercept|
174974|NCT01884857|Drug|'TOPROL-XL®' ER Tablets 50 mg|1 * 50 mg tablet per day
174975|NCT01884870|Procedure|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
174976|NCT01884883|Device|PROTEOR Internal unicompartmental knee brace|
174977|NCT01884896|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
174978|NCT01884896|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
174979|NCT00108745|Drug|Paclitaxel Poliglumex|Given IV
174980|NCT01884909|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
174981|NCT01884909|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
174982|NCT01884922|Drug|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
174983|NCT01887223|Procedure|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
174984|NCT01887223|Drug|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
174388|NCT01893749|Behavioral|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
174389|NCT01893762|Biological|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
174390|NCT01893762|Biological|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
174391|NCT01893775|Biological|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
174392|NCT01896349|Drug|Clomipramine|
174393|NCT01896349|Drug|nortriptyline|
174394|NCT01896349|Drug|trazodone|
174395|NCT01896349|Drug|Mirtazapine|
174396|NCT01896349|Drug|sulpiride|
174397|NCT01896388|Drug|Ifenprodil Tartrate|
174398|NCT00109954|Radiation|brachytherapy|
174399|NCT01896388|Drug|Placebo|
174400|NCT01896401|Device|InSeal's Vascular Closure Device|
174401|NCT01896414|Dietary Supplement|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
174686|NCT01891864|Drug|Enbrel ® Etanercept|
174687|NCT01891890|Drug|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
174688|NCT01891890|Drug|levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
174689|NCT01891890|Drug|lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
174690|NCT01891916|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
174082|NCT01900743|Drug|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
174083|NCT01900743|Drug|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
174084|NCT00110201|Drug|Nesiritide|
174085|NCT01900756|Behavioral|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
174086|NCT01900769|Drug|Blood Volume Dilution|
174087|NCT01900782|Biological|Intervention A|Prefilled syringe.
174088|NCT01900782|Biological|Intervention B|Prefilled syringe.
174089|NCT01900782|Biological|Placebo|Prefilled syringe to match experimental drug and active comparator.
174090|NCT01900795|Drug|V117957|V117957 4.5 mg suspension taken orally after surgery.
174091|NCT01900795|Drug|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
174092|NCT01900795|Drug|Placebo|Placebo taken orally after surgery.
174093|NCT01900808|Device|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
174094|NCT01900808|Device|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
174095|NCT00110214|Drug|docetaxel|Given IV
174096|NCT01900808|Device|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
174097|NCT01900834|Other|No treatment given|The participants will not receive any treatment
174098|NCT01900847|Drug|Ketamine|0.3mg/kg ketamine
174099|NCT01900847|Drug|Morphine|Dosage of morphine determined by treating physician
174100|NCT01900847|Drug|placebo|saline of same volume as appropriate weight based dose of ketamine
174101|NCT01900860|Dietary Supplement|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
174102|NCT01893307|Radiation|Intensity-Modulated X-Ray Therapy (IMRT)|Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
Treating physician evaluate each patient for possible chemotherapy.
173455|NCT01902004|Drug|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
173456|NCT00110305|Drug|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
173457|NCT01902004|Drug|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
173458|NCT01902017|Drug|Ketotifen|5 mg PO bid
173459|NCT01902017|Drug|Placebo|5 mg placebo PO bid
173460|NCT01902056|Procedure|One layer allograft|The acellular dermal matrix was placed on the facial surface.
173461|NCT01902056|Procedure|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
173462|NCT01894516|Drug|GLPG0634|
173463|NCT00109837|Drug|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
173464|NCT01894516|Drug|Placebo|
173465|NCT01894542|Dietary Supplement|Water soluble cod protein|6g protein per day for 8wk
173775|NCT00110019|Other|Placebo|Given PO
173776|NCT01897675|Procedure|Incision and Drainage with wick placement|
173777|NCT01897675|Procedure|Abscess drainage with loop placement|
173778|NCT01897688|Biological|Islet Cell Transplant|
173779|NCT01897701|Biological|Monovalent Avian Influenza VLP (H7N9)|
173780|NCT01897701|Biological|Adjuvant 1|
173781|NCT01897701|Biological|Placebo|
173782|NCT01897714|Drug|Melflufen|
173783|NCT01897714|Drug|Dexamethasone|
173784|NCT01897727|Drug|Spironolactone|
173785|NCT01897727|Drug|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
173786|NCT00110019|Drug|Sorafenib Tosylate|Given PO
178231|NCT01910402|Drug|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
178232|NCT01910402|Drug|Atazanavir|Atazanavir capsule 300 mg
178233|NCT00111241|Drug|aromatase inhibitors (letrozole, anastrozole)|
178234|NCT01910402|Drug|Ritonavir|Ritonavir tablet 100 mg
178235|NCT01910402|Drug|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
178236|NCT01910415|Drug|Lumacaftor|
178237|NCT01910415|Drug|Lumacaftor Placebo|
178238|NCT01910415|Drug|Ivacaftor|
178239|NCT01910415|Drug|Ivacaftor Placebo|
178240|NCT01910415|Drug|moxifloxacin hydrochloride|
178241|NCT01910428|Drug|L-asparaginase encapsulated in RBC|50 IU/kg IV
100 IU/kg IV
150 IU/kg IV
178242|NCT01910441|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
178243|NCT01910441|Drug|Glimepiride|Glimepiride 1-6 mg once daily
178244|NCT00111254|Procedure|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
178245|NCT01910441|Drug|Metformin|Metformin (1000-1500 mg daily)
178246|NCT01910454|Behavioral|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
173466|NCT01894542|Dietary Supplement|Non-water soluble cod protein|6 g protein per day for 8 wk
173467|NCT01894542|Dietary Supplement|Intact cod protein|6 g protein per day for 8wk
173468|NCT01894542|Dietary Supplement|Control|
173469|NCT01894555|Drug|Aspirin|81 mg daily for 4 weeks
177949|NCT01907542|Procedure|monocryl skin suture|as above
177950|NCT01907581|Other|Quality of life questionnaires|
177951|NCT01907594|Drug|D-cycloserine|
177952|NCT01907594|Drug|Nicotine Replacement Therapy (patch)|
178247|NCT01910454|Behavioral|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
178248|NCT01893008|Other|Inspiratory Muscle Training (IMT)|The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.
Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.
Training will be started after the chemoradiation period (if applicable).
178249|NCT01893034|Procedure|Arthroscopic treatment of femoroacetabular impingement|
178250|NCT01893034|Other|Physiotherapy and activity modification|
178251|NCT01893047|Behavioral|live music|live harp music
178252|NCT01893047|Behavioral|recorded music|recorded harp music
178253|NCT01893060|Drug|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
178254|NCT01893060|Drug|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
178255|NCT01893060|Drug|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
178256|NCT01893060|Other|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
178257|NCT00109785|Radiation|fludeoxyglucose F 18|
178258|NCT01893073|Behavioral|Mindful walking program|
178259|NCT01893086|Procedure|LH alone|LH, laparoscopic hysterectomy
177631|NCT01904318|Drug|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
177632|NCT00110539|Behavioral|Complementary and alternative medicine education|
177633|NCT01904318|Drug|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
177634|NCT01904318|Drug|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
177635|NCT01904318|Drug|Placebo|Placebo single dose administration
177636|NCT01904344|Device|Sensor testing and validation|
177637|NCT01904357|Drug|Cefazolin|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.Blood samples for determination of PK of cefazolin will be drawn at the following times: 15 minutes before the start of infusion (baseline), at the end of infusion, 15 and 30 minutes and 1 hour, 2 hours, 3 hours, 6 hours, and 8 hours after the end of the infusion for a total of nine blood samples
177638|NCT01904383|Drug|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
177639|NCT01904396|Drug|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
177640|NCT01904409|Drug|Placebo|
177641|NCT01904409|Drug|Rifaximin SSD 40 mg IR tablet|
177953|NCT00110890|Other|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
177954|NCT01907594|Behavioral|Smoking Cue Exposure|
177955|NCT01907594|Behavioral|Progressive Muscle Relaxation|
177956|NCT01907594|Drug|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
177957|NCT01909882|Other|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
177958|NCT01909895|Other|Anger Induction|The participant will be asked to undergo a validated anger induction task.
177959|NCT00111176|Procedure|Surgical|Surgical endovascular repair
177320|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
177321|NCT01911273|Other|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
177322|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
177323|NCT01911286|Procedure|Apnea test - Standard|
177324|NCT01911286|Procedure|Apnea test - CPAP|
177325|NCT01911299|Dietary Supplement|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
177326|NCT01911299|Dietary Supplement|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
177327|NCT00111358|Behavioral|Lifestyle Modification|
177328|NCT01911312|Device|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
177329|NCT01911312|Device|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
177330|NCT01911325|Drug|Buparlisib|
177331|NCT01911325|Drug|Buparlisib matching placebo|
177642|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet|
177643|NCT00110552|Drug|Salvia officinalis (sage)|oral dosage
177644|NCT01904409|Drug|Rifaximin SSD 40 mg SER tablet|
177645|NCT01904409|Drug|Rifaximin SSD 80 mg SER tablet|
177646|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet|
177647|NCT01904422|Procedure|conventional periodontal treatment|
177648|NCT01904435|Drug|Chemotherapy/Radiation|
177649|NCT01904448|Device|Auditory Brainstem Implantation in Children|
177650|NCT01904461|Device|Vacuum device|
177651|NCT01904461|Procedure|Conventional surgery|
176746|NCT01919970|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
177015|NCT01913106|Drug|HSV-tk +Valacyclovir in Combination with Brachytherapy|The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or "vehicle" to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein.
177016|NCT01913119|Drug|Romidepsin|Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.
Dose and administration: 4-hour infusion of 14 mg/m2
177017|NCT01913132|Device|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
177018|NCT00111605|Biological|Sodium chloride injection (0.9%)|All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.
Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273.
177019|NCT01915667|Drug|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
177020|NCT01915667|Drug|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
177021|NCT01915693|Radiation|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
177022|NCT01915706|Procedure|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
177023|NCT00111839|Drug|Pemetrexed|pemetrexed 500mg per metre squared given i.v. (into the vein) every 3 weeks until progression of disease or unacceptable toxicity
177024|NCT01915719|Procedure|Early non invasive ventilation|
177025|NCT01915719|Procedure|Oxygen therapy only|
177026|NCT01915732|Drug|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
177027|NCT01915732|Drug|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
176453|NCT01917084|Other|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
176454|NCT01917097|Drug|Dexmedetomidine|
176455|NCT01917110|Device|omafilcon A|
176456|NCT01917110|Device|Spectacle|
176457|NCT01917123|Drug|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
176458|NCT01917136|Drug|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
176459|NCT01917136|Drug|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
176460|NCT00112008|Drug|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
176747|NCT01919996|Drug|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
176748|NCT01920009|Behavioral|Pharmacist counselling session with a motivational interview|The intervention:
The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.
The intervention group consultation:
Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation "Express empathy, develop discrepancy, role with resistance, support self efficacy".
The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour "in this case would be adherence to life saving medication"
176749|NCT01920022|Drug|Mifepristone|Day one of medical abortion
176750|NCT01920022|Drug|etonorgestrel|
176751|NCT01922063|Behavioral|Sham neck massage|20x 30 minutes sessions of neck massage
176752|NCT00112437|Drug|MK0822|MK0822 50 mg, once weekly for 24 months
176753|NCT01922076|Other|Laboratory Biomarker Analysis|Correlative studies
176754|NCT01922076|Other|Pharmacological Study|Correlative studies
176755|NCT01922076|Radiation|Radiation Therapy|Undergo radiation therapy
176756|NCT01922076|Drug|WEE1 Inhibitor AZD1775|Given PO
176151|NCT00112346|Drug|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
176152|NCT01921231|Drug|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
176153|NCT01921244|Other|Decision Aid|Parents will receive an intervention modified from the previously published tool called "Autism: Should My Child Take Medicine for Challenging Behavior?" This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters.
176154|NCT01921257|Drug|Cat-PAD|
176155|NCT01921257|Drug|Placebo|
176156|NCT01921270|Drug|AbobotulinumtoxinA|Medication will be reconstituted at 1.5 cc of normal saline for every 300 units of abobotulinumtoxinA, then injected.
176157|NCT01914055|Device|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
176158|NCT01914055|Device|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
176159|NCT01914068|Other|Supervised exercise in hospital|
176160|NCT01914081|Other|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
176461|NCT01917136|Other|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
176462|NCT01917149|Drug|Benazepril|
176463|NCT01917149|Drug|Valsartan|
176464|NCT01917149|Drug|Metoprolol|
176465|NCT01917162|Device|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
176466|NCT01917162|Device|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
176467|NCT01917188|Behavioral|Full simulation and education|
176468|NCT01917188|Behavioral|See simulation room, usual education|
175818|NCT00002068|Drug|Amphotericin B|
175819|NCT00109291|Drug|peginesatide|
175820|NCT01888809|Behavioral|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
175821|NCT01888809|Behavioral|Screening and referral|
175822|NCT01888822|Drug|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
175823|NCT01891331|Drug|VT-1161 (oral)|
175824|NCT00109590|Drug|Nevirapine|single-dose at the onset of labor
175825|NCT01891331|Drug|Fluconazole (oral)|
175826|NCT01891344|Drug|Oral rucaparib|600 mg BID
175827|NCT01891357|Procedure|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
175828|NCT01891357|Drug|Paclitaxel|
175829|NCT01891357|Drug|lapatinib|
175830|NCT01891357|Drug|trastuzumab|
175831|NCT01891396|Device|Hyaluronic Acid and TH|
175832|NCT01891396|Device|Hyaluronic Acid|
175833|NCT01891396|Device|Saline|Saline placebo packaged to look identical to comparator syringes.
175834|NCT01891409|Device|Male circumcision using the Shang Ring device|
175835|NCT00109590|Drug|Zidovudine|twice daily
176161|NCT01914081|Other|Placebo|
176162|NCT01914094|Behavioral|Prehab|
176163|NCT00111696|Biological|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
176164|NCT01914107|Procedure|real-time monitoring and instruction of cancer pain|as description in arm
176165|NCT01914107|Procedure|standard cancer pain care|as description in arm
176166|NCT01914133|Drug|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
175511|NCT01885858|Behavioral|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
175512|NCT01885871|Device|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
175513|NCT01885884|Behavioral|Embedded Supportive Care|
175514|NCT01885897|Biological|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
175515|NCT01885910|Drug|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
175516|NCT01885910|Drug|Aczone 5% gel|Aczone 5% gel twice daily
175517|NCT01885923|Device|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
175518|NCT01885936|Drug|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
175519|NCT01885936|Drug|Placebo|
175520|NCT00002065|Drug|Disulfiram|
175521|NCT00108849|Drug|estradiol, 10 mcg|
175522|NCT01885949|Drug|Tivozanib|Oral
175523|NCT01885949|Drug|Enzalutamide|oral
175524|NCT01885962|Behavioral|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
175525|NCT01885988|Drug|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
175526|NCT01885988|Drug|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
175527|NCT00109213|Procedure|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
175528|NCT01888055|Device|transcranial direct current stimulation|
175529|NCT01888055|Device|sham stimulation|
175530|NCT01888081|Drug|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
174923|NCT01887197|Other|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
174924|NCT01887197|Drug|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
174925|NCT01887197|Drug|mannitol inhalation powder|mannitol inhalation powder
175211|NCT01892592|Behavioral|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
175212|NCT00109733|Biological|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
175213|NCT01892605|Behavioral|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
175214|NCT01892618|Drug|Prevenar 13|13-valent pneumococcal conjugated vaccine
175215|NCT01892618|Drug|Pneumovax|23-valent pneumococcal polysaccharide vaccine
175216|NCT01892631|Other|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
175217|NCT01892631|Other|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
175218|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
175219|NCT01892644|Other|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
175220|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
175221|NCT01892657|Drug|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
175222|NCT01892670|Other|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
175223|NCT00109746|Dietary Supplement|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
175224|NCT01892683|Drug|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
175225|NCT01892696|Device|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
159160|NCT00100542|Behavioral|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
159161|NCT01801813|Other|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
159162|NCT01801826|Device|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
159163|NCT01801852|Biological|NKT cells|
159164|NCT01801865|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan
159165|NCT01801878|Biological|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
159166|NCT01801878|Biological|Normal saline|Normal saline inject to the half of irradiated breast
159457|NCT01796951|Drug|Celecoxib 200 mg BID|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
159458|NCT01796964|Drug|ESBA1008 solution|For intravitreal (IVT) injection
159459|NCT01796964|Drug|Aflibercept|For intravitreal (IVT) injection
159460|NCT01796977|Device|OxyGenesys Dissolved Oxygen Dressing|
159461|NCT01796977|Device|Standard Gauze Dressing|
159462|NCT01796990|Behavioral|ACT|The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.
The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity.
159463|NCT01796990|Behavioral|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
159464|NCT01797003|Other|High tibial osteotomy|
159465|NCT01797029|Biological|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
159466|NCT00099944|Drug|LAF237 placebo|
175286|NCT01890564|Other|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
175287|NCT01890577|Drug|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
175288|NCT01890590|Device|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
175289|NCT01890603|Other|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
175592|NCT01883401|Dietary Supplement|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
175593|NCT01883401|Dietary Supplement|Dietary fiber|4g or 8g dietary fiber blended in water
175594|NCT01886001|Drug|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
175595|NCT01886001|Drug|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
175596|NCT01886001|Drug|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
175597|NCT01886001|Other|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
175598|NCT01886014|Drug|Oxytocin|
175599|NCT00108862|Other|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
175600|NCT01886014|Other|placebo|
175601|NCT01886027|Behavioral|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
175602|NCT01886027|Behavioral|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
175603|NCT01886053|Drug|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
175604|NCT01886053|Drug|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
174985|NCT01887236|Behavioral|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
174986|NCT01887236|Behavioral|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
174987|NCT01887249|Drug|Clarithromycin|
174988|NCT00109070|Drug|Avastin (bevacizumab)|
174989|NCT01887249|Drug|metronidazole|
174990|NCT01887249|Drug|esomeprazole|
174991|NCT01887262|Device|BCM-guided fluid management|
174992|NCT01887262|Procedure|Fluid management based on the clinical information alone|
174993|NCT01887275|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
175290|NCT01890603|Other|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
175291|NCT01890616|Device|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
175292|NCT01890629|Drug|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
175293|NCT01890642|Device|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
175294|NCT01890642|Other|Pain Ease Spray|Cold Spray used to anesthetize the skin
175295|NCT00109512|Drug|placebo|
175296|NCT01890642|Drug|1% buffered lidocaine|Lidocaine placed using Jet Injection
175297|NCT01892813|Behavioral|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
175298|NCT01892813|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
175299|NCT01892813|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
174691|NCT01891929|Behavioral|RECOS (COgnitive REmediation for Schizophrenia)|Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.
After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).
In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
174692|NCT00002071|Drug|Epoetin alfa|
174693|NCT00109629|Drug|VRC-HIVADV014-00|
174694|NCT01884259|Biological|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
174695|NCT01884259|Radiation|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
174696|NCT00002064|Drug|Pyrimethamine|
174697|NCT00108732|Drug|Bicalutamide|Given orally
174698|NCT01884272|Drug|lesinurad 400 mg|
174699|NCT01884272|Drug|naproxen 250 mg|
174700|NCT01884272|Drug|indomethacin 25 mg|
174701|NCT01884285|Drug|AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
174702|NCT01884285|Drug|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
174703|NCT01884285|Drug|Part C: Abiraterone acetate in combination with AZD8186|AZD8186 dose from Part A with Abiraterone acetate (with prednisone) with approved labelled dose.
174704|NCT01884285|Drug|Part D1: AZD2014 combination with AZD8186|Part D1 dose & schedule finding
174705|NCT01884285|Drug|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion
174994|NCT01887275|Drug|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
174995|NCT01887288|Drug|Capecitabine|650 mg/m^2 PO b.i.d.
174996|NCT01887288|Drug|Digoxin|0.25 mg once daily
174997|NCT01887301|Drug|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
174402|NCT01896414|Dietary Supplement|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
174403|NCT01896427|Drug|21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione|single dose of dexamethasone (8mg) will injected
174404|NCT01896440|Drug|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
174405|NCT01896453|Procedure|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
174406|NCT01896453|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
174407|NCT01896466|Device|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
174408|NCT01896466|Behavioral|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
174409|NCT00109954|Radiation|yttrium Y 90 glass microspheres|
174410|NCT01896479|Drug|Cabozantinib (XL184) 140 mg|
174411|NCT01896479|Drug|Cabozantinib (XL184) 60 mg|
174412|NCT01896479|Drug|Placebo tablet|
174413|NCT01896479|Drug|Placebo capsule|
174414|NCT01896492|Drug|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
174415|NCT01896505|Drug|KCP-330|
174416|NCT01896518|Drug|Nicotine polacrilex|
174417|NCT01896518|Drug|Tobacco lozenge|
174418|NCT01896531|Drug|GDC-0068|Participants will receive GDC-0068, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
174419|NCT01896531|Drug|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
174420|NCT01898806|Drug|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
173787|NCT01897740|Drug|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
173788|NCT01897753|Drug|growth hormone|36 months
173789|NCT01897766|Drug|Somatropin|0.23 mg to 0.48 mg/kg/week
173790|NCT01897779|Drug|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
173791|NCT01897779|Drug|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
173792|NCT01897779|Drug|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
173793|NCT01897779|Drug|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
173794|NCT01897792|Dietary Supplement|Vitamin C|
173795|NCT01897792|Dietary Supplement|Vitamin E|
173796|NCT01897792|Dietary Supplement|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
173797|NCT00110032|Drug|EF5|Given IV
174103|NCT01893307|Radiation|Intensity-Modulated Proton Beam Therapy (IMPT)|Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
Treating physician evaluate each patient for possible chemotherapy.
174104|NCT01893307|Procedure|Modified barium swallow (MBS)|Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.
174105|NCT01893307|Behavioral|Questionnaires|Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy.
174106|NCT01893320|Drug|Vosaroxin|Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.
Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I.
174107|NCT00109811|Biological|PSA:154-163(155L) peptide vaccine|Given subcutaneously
174108|NCT01893320|Drug|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
173470|NCT01894568|Drug|LY2605541|Administered SC using a prefilled pen.
173471|NCT01894568|Drug|Insulin Glargine|Administered SC using a prefilled pen
173472|NCT01894581|Dietary Supplement|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
173473|NCT01894581|Drug|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
173474|NCT00109837|Drug|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
173475|NCT01894594|Drug|Sodium Bicarbonate|
173476|NCT01894607|Procedure|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
173477|NCT01894607|Drug|DEFINITY|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.
Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.
173478|NCT01894607|Behavioral|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
173479|NCT01894620|Device|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
173480|NCT01894620|Device|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
173481|NCT01894633|Drug|Chloroquine|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
173482|NCT01894646|Radiation|Positron Emission Tomagraphy (PET) Imaging|
173483|NCT01894659|Other|24% oral sucrose|
173484|NCT01894659|Other|30% oral glucose|
173485|NCT00109837|Drug|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
173486|NCT01894672|Drug|LGX818|
173798|NCT01897792|Drug|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
178260|NCT01893086|Procedure|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
178261|NCT01893099|Drug|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
178262|NCT01893099|Device|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
178263|NCT01893112|Behavioral|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training & Education Center for health).
178264|NCT01893112|Behavioral|Breast Cancer Screening|
173487|NCT01894685|Drug|Mesalazine|Mesalazine 3 grams, once daily for six months
173488|NCT01897181|Device|Hearing aids|Using hearing aids for 12 months
173489|NCT01897207|Biological|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
173490|NCT00110006|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
173491|NCT01897233|Drug|Lumacaftor|
173492|NCT01897233|Drug|Ivacaftor|
173493|NCT01897246|Procedure|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
173494|NCT01897246|Procedure|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
173495|NCT01897259|Drug|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
173496|NCT01897259|Behavioral|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
173497|NCT01897259|Drug|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
173498|NCT01897259|Drug|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
173499|NCT01897272|Behavioral|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
173500|NCT01897285|Device|AQUACEL® foam adhesive dressing|
177960|NCT01909895|Other|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
177961|NCT01909895|Other|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
177962|NCT01909895|Other|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
177963|NCT01909908|Device|ECM|ECM in saline applied to wound
177964|NCT01909908|Biological|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
177965|NCT01909908|Device|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
177966|NCT01909934|Drug|brentuximab vedotin|Brentuximab vedotin will be administered as a single intravenous (IV) infusion over 30 minutes on Day 1 of each 3 week cycle for up to a maximum of 16 cycles and should be administered for a minimum of 8 cycles for patients who achieve stable disease or better.
177967|NCT01909947|Other|Cardiorespiratory signal acquisition|Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:
A 60-minute period while the infant receives any mode of conventional mechanical ventilation
A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant
177968|NCT01909960|Other|Flow imaging|Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.
Clinical examination consists in Larson's score and MMSE
178265|NCT01893125|Drug|CNV2197944|
178266|NCT01893125|Drug|Placebo|
178267|NCT01893138|Biological|Roll-in|Placebo control is the vehicle solution used for the study product, AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
178268|NCT00109785|Radiation|iodine I 124 iododeoxyuridine|
178269|NCT01893138|Other|Placebo|Placebo control is the vehicle solution used for the study product.
178270|NCT01893138|Biological|AMDC for USR|AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
178271|NCT01893151|Drug|Iguratimod|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
178272|NCT01905462|Biological|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
177652|NCT01907087|Biological|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
177653|NCT00110851|Drug|metformin|
177654|NCT01907100|Drug|Nintedanib|triple kinase inhibitor
177655|NCT01907100|Drug|Pemetrexed|backbone chemo
177656|NCT01907100|Drug|Cisplatin|backbone chemo
177657|NCT01907100|Drug|Cisplatin|backbone chemo
177658|NCT01907100|Drug|Pemetrexed|backbone chemo
177659|NCT01907100|Drug|Placebo|Nitedanib matching placebo
177660|NCT01907113|Drug|BI 10773|oral administration
177661|NCT01907113|Drug|BI 10773|oral administration
177662|NCT01907113|Drug|BI 10773|oral administration
177663|NCT01907113|Drug|BI 10773|oral administration
177664|NCT00110851|Drug|PN2034|
177665|NCT01907113|Drug|BI 10773|oral administration
177666|NCT01907126|Behavioral|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
177969|NCT01909973|Behavioral|MedLink System|Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.
The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status.
177970|NCT00111189|Drug|Placebo|Placebo every 4 wk up to 24 mo
177971|NCT01909986|Drug|[14C]ONO-4053|Single dose [14C]ONO-4053
177972|NCT01911949|Drug|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
177973|NCT01911962|Procedure|transvaginal laparoscopic surgery|
177974|NCT01911975|Drug|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
177028|NCT01915745|Other|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
177029|NCT01915758|Drug|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
177030|NCT01915758|Drug|vehicle gel|vehicle gel
177031|NCT01915771|Drug|lomitapide|20 mg dose
177332|NCT01911325|Drug|Docetaxel|
177333|NCT01911338|Device|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
177334|NCT01911338|Device|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
177335|NCT01911351|Drug|Nitrous Oxide|
177336|NCT01911364|Drug|BDP/FF/GB|
177337|NCT01911364|Drug|Tiotropium|
177338|NCT00111358|Other|No lifestyle modification|
177339|NCT01911364|Drug|BDP/FF + Tiotropium|
177340|NCT00110461|Drug|placebo|Placebo tablet
177341|NCT01903850|Device|spray cryotherapy|spray cryotherapy
177342|NCT01903863|Biological|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
177343|NCT01903876|Behavioral|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
177344|NCT01903876|Behavioral|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
177345|NCT01903889|Other|clinic based intervention|counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
176757|NCT01922089|Drug|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
176758|NCT01922102|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
176759|NCT01922102|Drug|Rranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
176760|NCT01922102|Drug|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
176761|NCT01922115|Drug|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
176762|NCT01922115|Drug|Placebo|
176763|NCT00112437|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
176764|NCT01922128|Drug|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
176765|NCT01922141|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
176766|NCT01922141|Drug|Amlodipine|Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
177032|NCT01915784|Device|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
177033|NCT01915784|Device|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
177034|NCT00111839|Drug|Matuzumab + Pemetrexed|matuzumab 800mg given i.v. every week plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity
177035|NCT01915797|Other|blood and tumor samples|all tumor pathology associated with anomaly of development
177036|NCT01915810|Behavioral|Questionnaires|Questionnaire completion on Weeks 3, 2, and 1 before quitting smoking, on quit day, and weeks 1, 2, 3, 4, and 8 after quitting smoking.
177037|NCT01915810|Behavioral|Phone Counseling|Patients receive counseling about quitting smoking over the phone about 1 - 2 weeks before scheduled quit day.
177038|NCT01915810|Other|Breath Test|Breath test administered to check for tobacco consumption weeks 3, 2, and 1 before quitting smoking, on quit day, and weeks 1, 2, 3, 4, and 8 after quitting smoking.
177039|NCT01915810|Other|Walking Program|Group 2 start a walking program 2 weeks before their quit day and finish it 2 weeks after their quit day. Participants walk about 150 minutes (about 2 ½ hours) a week.
Group 3 start a walking program on their quit day and finish it 4 weeks after their quit day. Participants walk about 150 minutes (about 2 ½ hours) a week.
177040|NCT01915810|Drug|Nicotine Patch|6-week supply of the nicotine patch given to participants. Patch dosage congruent with pre-quit smoking rate and will taper over time.
176469|NCT01917201|Procedure|IVUS-guided group|The randomization on groups was completed in accordance with stents to be implanted: "Xience Prime"/"Xience V", "Promus Element", "Resolute Integrity", "Biomatrix Flex", "Nobori", "Orsiro". In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used.
176470|NCT01919281|Behavioral|interval training|
176471|NCT01919294|Drug|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
176472|NCT01919307|Device|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
176473|NCT01919320|Device|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
176474|NCT01919320|Device|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
176475|NCT01919346|Drug|Eculizumab|
176476|NCT01919346|Drug|Normal Saline|
176477|NCT00002096|Drug|Zidovudine|
176478|NCT00112216|Biological|Mage-A10 peptide|
176479|NCT01919359|Dietary Supplement|Multizyme Cellular Vitality Cyruta Plus SHEP|
176480|NCT01919372|Device|Telemedic assistance with a technological system|
176767|NCT01922141|Drug|Ramipril|Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
176768|NCT01922141|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
176769|NCT01922154|Drug|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
176770|NCT01922167|Dietary Supplement|Leucine|
176771|NCT01922167|Dietary Supplement|Alanine|
176167|NCT01914133|Drug|Placebo|Placebo given prior to meal the standardized meal
176168|NCT01914146|Other|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
176169|NCT01914146|Other|No Insulin|Study session will occur prior to initiation of insulin therapy.
176170|NCT01914159|Drug|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
176171|NCT01914185|Other|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
176172|NCT01914198|Other|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
176173|NCT01914211|Drug|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
176174|NCT00111709|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
176175|NCT01914211|Procedure|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If > 5Kg draw 20% of circulating blood volume without PRBC replacement)
176176|NCT01914224|Behavioral|dietary education of low sodium and high potassium consumption|
176177|NCT01914224|Behavioral|dietary education of low sodium consumption only|
176178|NCT01914237|Device|Castor Stent Graft|Endovascular Repair of Aortic Dissection
176179|NCT01916590|Drug|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
176180|NCT01916590|Drug|placebo|
176181|NCT01916603|Behavioral|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
176481|NCT01919372|Other|Standard care|
176482|NCT01919385|Device|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
176483|NCT01919398|Drug|LY2940680|Administered orally
175531|NCT01888081|Radiation|Ionizing Radiation|
175532|NCT01888094|Other|Ultrasound-guided cannulation and examination|
175836|NCT01891435|Drug|Oral paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
175837|NCT01891435|Drug|Intravenous paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
175838|NCT01891435|Drug|Intramuscular diclofenac|after giving medicine temperature is checked every 30 minutes for 2 hours
175839|NCT01891448|Other|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
175840|NCT01891448|Other|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
175841|NCT01891461|Drug|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
175842|NCT01891474|Device|U-health care|voice inception technique based U-healthcare service
175843|NCT01891487|Drug|Track A|Bimatoprost 0.03% solution applied to eyebrow
175844|NCT01891487|Drug|Track B|Refresh Tears applied to eyebrows
175845|NCT01891500|Drug|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
175846|NCT00109603|Drug|Tenofovir disoproxil fumarate|
175847|NCT01891500|Drug|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
175848|NCT01891500|Drug|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
175849|NCT01883765|Behavioral|Neurofeedback active|
175850|NCT01883765|Behavioral|Neurofeedback sham|
175851|NCT01883765|Behavioral|Metacognitive Training|
175852|NCT01883791|Behavioral|SBIRT|See above Arm description.
175226|NCT01892709|Drug|Hydromorphone|
175227|NCT01885312|Behavioral|Adaptive Tailored Intervention|
175228|NCT01885312|Behavioral|Consequence-based Intervention|
175229|NCT01885312|Behavioral|Tailored, not adaptive, based Intervention|
175230|NCT01885312|Other|Assessment only|
175533|NCT01888107|Drug|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
175534|NCT01888107|Drug|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
175535|NCT01888107|Drug|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
175536|NCT01888120|Drug|Ziconotide|
175537|NCT01888133|Behavioral|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
175538|NCT00109213|Procedure|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
175539|NCT01888133|Behavioral|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
175540|NCT01888146|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
175541|NCT01888159|Procedure|Bilateral Salpingectomy|
175542|NCT01888159|Procedure|Tubal sterilization with bipolar energy|
175543|NCT01888172|Behavioral|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
175544|NCT01888172|Device|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
175545|NCT01888172|Behavioral|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
175546|NCT01888198|Behavioral|(EORTC QLQ-C30) questionnaire|
175547|NCT01888198|Behavioral|EuroQol EQ-5D 7-item questionnaire|
176245|NCT01921361|Drug|sodium chloride|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
176246|NCT00112359|Drug|Placebo three times a day (TID)|
176247|NCT01921374|Biological|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
176248|NCT01921374|Biological|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
176249|NCT01921374|Biological|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
176250|NCT01914250|Drug|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
176251|NCT01914263|Biological|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10^9 cord blood-derived cytokine indued killer cells.
176252|NCT01914289|Procedure|Resection|
176253|NCT01914289|Radiation|Radiotherapy|
176254|NCT01914302|Device|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
176255|NCT01914302|Device|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
176256|NCT00111709|Drug|Comparator: placebo / Duration of Treatment - 1 day|
176257|NCT01914302|Device|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
176258|NCT01914302|Device|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
176259|NCT01914302|Device|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
176260|NCT01914302|Device|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
176261|NCT01914302|Device|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
176262|NCT01914302|Device|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
175605|NCT01886053|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
175606|NCT01886066|Biological|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. The ICG will be administered in solution (1.25mg/ml) as four 1ml injections into the cervix (superficial and deep) at 3 and 9 o'clock.
175607|NCT01886079|Drug|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
175608|NCT01886079|Drug|Saline|0.4 mcg/kg/h, IV
175609|NCT01886092|Device|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
175935|NCT01918436|Behavioral|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
175936|NCT01918436|Other|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
175937|NCT01918449|Other|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
175938|NCT01918475|Drug|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
175939|NCT01918475|Drug|Placebo|1ml of NaCl 0.9% is administered intravenously
175940|NCT00112138|Drug|gabapentin|
175941|NCT01918488|Dietary Supplement|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
175942|NCT01918488|Drug|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
175943|NCT01920867|Procedure|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
175944|NCT01920880|Other|Quantitative Sensory Testing analysis|
175945|NCT00002096|Drug|Ganciclovir|
175946|NCT00112307|Procedure|Brachytherapy|
175947|NCT01920893|Drug|Dupilumab|Pharmaceutical form: solution in glass vials
Route of administration: subcutaneous
175948|NCT01920893|Drug|Placebo (for dupilumab)|Pharmaceutical form: solution in glass vials
Route of administration: subcutaneous
175300|NCT01892813|Behavioral|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
175301|NCT01892813|Behavioral|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
175302|NCT01892826|Drug|hCG|5000IU
175303|NCT01892839|Other|low dialysate flow, smaller dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.
175304|NCT01892839|Other|high dialysate flow, larger dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
175305|NCT00109772|Drug|Placebo|Two placebo capsules taken one time per day
175306|NCT01892852|Procedure|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
175307|NCT01892865|Other|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
175308|NCT01892865|Other|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
175610|NCT00108862|Other|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
175611|NCT01886092|Device|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
175612|NCT01888237|Drug|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
175613|NCT01888250|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
175614|NCT01888263|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
174998|NCT01887314|Dietary Supplement|Standardized Ginger extract|
174999|NCT00000296|Drug|Cotinine fumarate|
175000|NCT00002067|Drug|Megestrol acetate|
175001|NCT00109083|Drug|RWJ-333369|
175002|NCT01887327|Drug|stannsoporfin|
175003|NCT01887327|Drug|Placebo|
175004|NCT01887340|Drug|Carboplatin|- carboplatine: Dose (mg) = AUC x (GFR + 25)
GFR : glomérulaire filtration (ml/min)
AUC : area under curve (mg/ml x min)
175005|NCT01887340|Drug|Etoposide|100 mg/m2 D1 to D5
175006|NCT01887340|Drug|Cisplatin|20 mg/m2 de D1 to D5
175007|NCT01887353|Drug|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
175008|NCT01887353|Drug|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
175009|NCT01889992|Other|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
175010|NCT01889992|Drug|M-TOR Immunosuppression|Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).
Sirolimus dosage based on blood levels.
175011|NCT01889992|Procedure|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
175012|NCT01889992|Genetic|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
175013|NCT01889992|Other|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
175014|NCT01890005|Drug|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
175309|NCT01892878|Procedure|VerteLoc|Single Arm
175310|NCT01892891|Drug|VBY-036|Cathepsin S inhibitor
174421|NCT01898806|Drug|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
174422|NCT01898819|Drug|Dexmedetomidine|
174706|NCT01884298|Drug|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
174707|NCT01884298|Drug|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
174708|NCT00108732|Drug|Goserelin Acetate|Given SC
174709|NCT01884311|Biological|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
174710|NCT01884324|Other|Early Delivery|This will be a randomized clinical investigation. The subjects will be allocated into "early" and "late" delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion.
174711|NCT01884337|Drug|Apixaban|
174712|NCT01884350|Drug|Apixaban|
174713|NCT01884363|Other|Once ounce per day of walnuts|
174714|NCT01884376|Device|Neuromaix|
174715|NCT01884389|Other|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
174716|NCT01884402|Drug|Peginterferon alfa-2a|Treatment as usual clinical practice
174717|NCT01884402|Drug|Ribavirin|Treatment as usual clinical practice
174718|NCT01886768|Device|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
174719|NCT01886768|Device|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
174720|NCT01886781|Drug|Lactobacillus plantarum 299v|two capsules of 5 X 10 ^9 c.f.u each
174721|NCT01886781|Drug|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
174109|NCT01893333|Procedure|Nerve sparing radical hysterectomy|Nerve sparing radical hysterectomy
sparing hypogastric nerve
sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
174110|NCT01893346|Drug|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
174111|NCT01893359|Drug|riboflavin ophthalmic solution, 0% dextran|
174112|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
174113|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
174114|NCT01893359|Procedure|Laser-assisted in situ keratomileusis|
174115|NCT01893372|Drug|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
174116|NCT01893372|Drug|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
174117|NCT01893385|Drug|Vitamin D (drug)|
174118|NCT00109811|Biological|incomplete Freund's adjuvant|Given subcutaneously
174119|NCT01893398|Other|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
174120|NCT01893411|Drug|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
174121|NCT01893411|Drug|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
174423|NCT01898819|Drug|saline|
174424|NCT01898845|Drug|LEE011|
174425|NCT01898858|Device|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
174426|NCT01898858|Device|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
174427|NCT01898858|Device|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
174428|NCT01898871|Dietary Supplement|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
173799|NCT01900314|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
173800|NCT01900327|Radiation|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
173801|NCT01900327|Drug|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
173802|NCT01900327|Procedure|Surgery|Upfront pancreato-duodenectomy
173803|NCT00110136|Drug|St. John's Wort|St. John's Wort 300mg tablet three times per day
173804|NCT01900327|Drug|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
173805|NCT01900340|Dietary Supplement|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
173806|NCT01900340|Drug|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
173807|NCT01900340|Dietary Supplement|Saline|IV saline infusion and intraduodenal administration of nutrients
173808|NCT01900340|Drug|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
173809|NCT01900353|Other|brushing methods|
173810|NCT01900366|Procedure|Fat Biopsy|Fat biopsy
173811|NCT01900379|Procedure|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
173812|NCT01900379|Other|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
173813|NCT01900392|Behavioral|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
173814|NCT00002079|Drug|Butyldeoxynojirimycin|
173815|NCT00110149|Biological|rituximab|
173816|NCT01900405|Drug|Dexmedetomidine|
173817|NCT01900418|Behavioral|Walk with Ease|An evidence-based walking program
173818|NCT01900431|Drug|Sarilumab SAR153191/REGN88|Pharmaceutical form:Prefilled syringes Route of administration: subcutaneous
173501|NCT00110006|Procedure|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat ^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
173502|NCT01897298|Behavioral|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
173503|NCT01897311|Device|transcutaneous electrical nerve stimulation|
173504|NCT01897324|Drug|Growth hormone (Norditropin, Novo nordisk)|
173505|NCT01897337|Drug|Aprepitant|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
173506|NCT01897337|Drug|placebo|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
173507|NCT01897350|Other|Cardiac magnetic resonance imaging|
173820|NCT01900431|Drug|Methotrexate|Pharmaceutical form:solution Route of administration: intravenous
173821|NCT01900431|Drug|Folic/folinic acid|Pharmaceutical form:tablet Route of administration: oral
173822|NCT01900431|Other|Sarilumab (SAR153191/REGN88) placebo|Pharmaceutical form:Prefilled syringes Route of administration: subcutaneous
173823|NCT01900444|Biological|IMOJEV®: Live Attenuated Japanese Encephalitis Chimeric Virus|0.5 mL, Subcutaneous
173824|NCT01900457|Other|electromyography|
173825|NCT01900457|Other|electroencephalography|
173826|NCT01902355|Procedure|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
173827|NCT01902355|Procedure|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
173828|NCT00110344|Drug|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
173829|NCT01902368|Other|gluten free diet|
173830|NCT01902381|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
178273|NCT01905475|Drug|POL6326|
178274|NCT01905475|Drug|Placebo|
178275|NCT00110695|Drug|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. [or if given with trastuzumab 75 mg/m2 IV over 15 min.]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
178276|NCT01905501|Drug|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
178277|NCT01905501|Drug|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
178278|NCT01905514|Device|internet mobile application|
178279|NCT01905527|Other|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
178280|NCT01905527|Other|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
178281|NCT01905527|Other|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
178282|NCT01905540|Drug|SSP-004184AQ|Magnesium salt
178283|NCT01905540|Drug|SSP-004184SS|Disodium salt
178284|NCT01905553|Drug|SSP-004184SS|Disodium salt
178285|NCT01905566|Drug|Clopidogrel|75mg once a day
178286|NCT00110708|Drug|Oralgam (human immunoglobulin)|
173508|NCT01897363|Other|Infants with Prader-Willi Syndrome|Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
173509|NCT01897376|Procedure|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
173510|NCT01897376|Procedure|vertical skin incision|vertical skin incision at time of cesarean section
173511|NCT01897389|Drug|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
173512|NCT01899755|Drug|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
177975|NCT01911975|Drug|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
177976|NCT01912001|Other|Telephone follow-up|
177977|NCT01912001|Other|Sympton Assessment|
177978|NCT01912014|Behavioral|Psychosocial support and counselling|
177979|NCT00111488|Device|Flex 4 and Generator|
177980|NCT01912027|Procedure|Open Latarjet technique|
177981|NCT01912027|Procedure|Arthroscopic Latarjet techniques|
177982|NCT01912040|Drug|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
177983|NCT01912053|Radiation|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
177984|NCT01912066|Drug|Stillen|
177985|NCT01912066|Drug|Cytotec (reference drug)|
177986|NCT01912066|Drug|NSAID (Aceclofenac)|
177987|NCT01912092|Device|Askina Calgitrol paste|
177988|NCT01912105|Device|Airway medix closed suction system|
177989|NCT01912105|Device|standard closed suctioning systems|
177990|NCT00111501|Behavioral|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
177991|NCT01912118|Drug|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
178287|NCT01905566|Drug|Ticagrelor|90mg twice a day
178288|NCT01905579|Procedure|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
178289|NCT01905592|Drug|niraparib|Until progression or unacceptable toxicity develops
178290|NCT01905592|Drug|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies
178291|NCT01905605|Drug|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
178292|NCT01905605|Drug|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
177346|NCT01903889|Other|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
177347|NCT01903902|Device|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length < 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
177348|NCT01903928|Biological|ASP0113|injection
177349|NCT01903941|Behavioral|Aerobic Exercise|
177350|NCT01903941|Behavioral|Only Counseling|
177351|NCT00110474|Drug|Glucosamine sulfate|
177667|NCT01907126|Behavioral|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
177668|NCT01907139|Behavioral|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
177669|NCT01907139|Behavioral|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
177670|NCT01909440|Procedure|quality-of-life assessment|Ancillary studies
177671|NCT01909440|Other|questionnaire administration|Ancillary studies
177672|NCT00111137|Drug|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
177673|NCT01909440|Other|pharmacological study|Correlative studies
177674|NCT01909440|Other|laboratory biomarker analysis|Correlative studies
177041|NCT01915810|Behavioral|Audio Recorded Focus Group|Participants take part in a final audio recorded focus group 8 weeks after quitting smoking.
177042|NCT01915823|Drug|azelastine hydrochloride and fluticasone propionate|
177043|NCT01918033|Drug|Placebo|Matching placebo to desloratadine 5 mg tablets
177044|NCT01918059|Procedure|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
177045|NCT01918059|Procedure|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
177046|NCT01918059|Procedure|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
177047|NCT01918072|Other|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
177048|NCT01918085|Other|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
177049|NCT01918085|Other|Strata strip|An adhesive strip made of the Strata adhesive
177352|NCT01903954|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
177353|NCT01903954|Drug|placebo|Orally b.i.d.
177354|NCT01903954|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
177355|NCT01903954|Drug|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
177356|NCT01903980|Other|No intervention. It is a retrospective study|No intervention. It is a retrospective study
177357|NCT01903993|Drug|Atezolizumab|Participants will receive Atezolizumab 1200 mg IV infusion every 3 weeks until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
177358|NCT01903993|Drug|Docetaxel|Participants will receive Docetaxel 75 mg/m^2 intravenous infusion (IV) every 3 weeks until disease progression per standard RECIST v1.1 or unacceptable toxicity.
177359|NCT01904006|Other|Group culture|The embryos will be cultured in groups of 5 embryos per medium drop. The culture will be performed inside a MINC incubator, at a low oxygen tension (5%).
176772|NCT01922180|Radiation|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
176773|NCT01922193|Drug|Highly Purified Urofollitropin|for injection
176774|NCT00002098|Drug|Lentinan|
176775|NCT01915108|Drug|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
176776|NCT01915121|Behavioral|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
176777|NCT01915121|Behavioral|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
176778|NCT01915134|Drug|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
176779|NCT01915134|Drug|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
176780|NCT01915147|Drug|OXN PR followed by OxyPR tablets|
176781|NCT01915147|Drug|OxyPR followed by OXN PR tablets|
176782|NCT00111787|Drug|Paclitaxel|
177050|NCT01918098|Drug|Oxycodone/naloxone prolonged release tablets|
177051|NCT00112086|Drug|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
177052|NCT01918111|Procedure|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
177053|NCT01918111|Drug|adenosine infusion treatment|Continue hypertensive medication
176484|NCT01919411|Drug|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
176485|NCT01919411|Drug|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
176486|NCT01919424|Drug|Methacholine Chloride|Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system
Low risk - commonly used to diagnose asthma
176487|NCT01919424|Device|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
176488|NCT01919424|Device|The English-Wright nebulizer|Continuous-mode nebuilzer, designed to operate continuously with tidal breathing
Roxon Medi-Tech, Montreal, PQ, Canada
176489|NCT00112216|Biological|SB AS-2 adjuvant|
176490|NCT01919437|Device|Web-Enabled Cognitive Neuropsychological Evaluation System|
176491|NCT01919450|Drug|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
176492|NCT01919450|Radiation|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
176493|NCT01921868|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
176494|NCT01921881|Other|St John's wort|
176495|NCT01921894|Dietary Supplement|Cholecalciferol|
176496|NCT01921907|Drug|AD17137 topical treatment|
176497|NCT01921907|Drug|Placebo|
176498|NCT01921920|Drug|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
176499|NCT01921933|Device|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
176500|NCT01921946|Drug|Fimasartan|
176501|NCT01921946|Drug|Rosuvastatin|
176502|NCT01921959|Behavioral|Intervention|Postpartum women are randomized to intervention or control group
176783|NCT01915160|Behavioral|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
176784|NCT01915160|Behavioral|TF-CBT|Treatment as usual.
175853|NCT01883791|Behavioral|Health Education|See Arm Description.
175854|NCT01883804|Drug|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
175855|NCT01883817|Drug|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
175856|NCT01883817|Drug|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
176182|NCT00111917|Drug|Infliximab|anti-TNF
176183|NCT01916616|Behavioral|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
176184|NCT01916629|Drug|Photocil for Psoriasis|Photocil for Psoriasis
176185|NCT01916629|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
176186|NCT01916642|Drug|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
176187|NCT01916642|Drug|Lidocaine 1.5mg/kg|same as other
176188|NCT01916642|Drug|Lidocaine 2mg/kg|same as other
176189|NCT01916642|Drug|Lidocaine 2.5mg/kg|same as other
176190|NCT01916655|Behavioral|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
176191|NCT01916655|Behavioral|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
176192|NCT01916655|Behavioral|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
176193|NCT00111930|Drug|DHEA|
176194|NCT01916681|Device|Cervical Foley & Misoprostol|A cervical foley combined with misoprostol will be used to induce the patient.
176195|NCT01916681|Drug|Misoprostol Alone|Misoprostol will be used alone to induce the patient
176196|NCT01916681|Device|Cervical Foley Alone|A cervical foley alone will be used to induce the patient
176197|NCT01916681|Device|Cervical Foley & Pitocin|A cervical foley combined with pitocin will be used to induce the patient
175548|NCT01888211|Dietary Supplement|Omega 3 fatty acid supplementation|2 grams Omacor daily
175549|NCT00109226|Drug|Avastin (Bevacizumab)|
175550|NCT01888211|Dietary Supplement|Olive Oil|2 grams olive oil daily
175551|NCT01888224|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
175552|NCT01888237|Drug|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
175553|NCT01890798|Drug|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
175554|NCT01890811|Dietary Supplement|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
175857|NCT00108628|Behavioral|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
175858|NCT01883830|Device|gaming therapy (Xbox)|
175859|NCT01883830|Device|Dynamic balance platform (Biodex)|
175860|NCT01883843|Device|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
175861|NCT01883843|Device|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
175862|NCT01883856|Device|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
175863|NCT01883856|Device|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
175864|NCT01883869|Drug|ticagrelor|
175865|NCT01883869|Drug|placebo|placebo
175866|NCT01883882|Behavioral|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
176559|NCT01917331|Drug|Beclometasone/Formoterol|
176560|NCT01917344|Other|MRI|
176561|NCT01917357|Biological|Quinvaxem in Uniject|
176562|NCT01917357|Biological|Quinvaxem in single dose vials|
176563|NCT01919463|Behavioral|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
176564|NCT01919463|Device|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
176565|NCT01919476|Other|Bagel|
176566|NCT01919476|Other|Cream Cheese|
176567|NCT01919476|Other|Almond Butter|
176568|NCT01919489|Drug|Liraglutide + OADs|Liraglutide subcutaneously daily
176569|NCT01919489|Drug|Glargine + OADs|Glargine once daily subcutaneously
176570|NCT00112216|Biological|Montanide adjuvant|
176571|NCT01919502|Device|Semi-quantitative urine pregnancy test|
176572|NCT01919515|Device|ZR Crown|This is an esthetic primary molar crown.
176573|NCT01919515|Device|Stainless Steel Crown|This is a conventional stainless steel crown.
176574|NCT01919528|Procedure|ultrasound|catheterization of the axillary vein under ultrasound guidance
176575|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
176576|NCT01919541|Device|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
176577|NCT01919541|Device|hyperinsulinemic euglycemic hyperaminoacid clamp|
176578|NCT01919541|Dietary Supplement|whey protein supplementation|
176579|NCT01919541|Other|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
175949|NCT01920893|Drug|Mometasone furoate nasal spray|Pharmaceutical form: suspension in bottle
Route of administration: intranasal
175950|NCT01920906|Procedure|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
175951|NCT01920919|Drug|Dexamethasone|
175952|NCT01920919|Drug|Placebo|
175953|NCT01920932|Drug|brentuximab vedotin|Given intravenously (IV).
175954|NCT01920932|Drug|etoposide|Given IV.
175955|NCT01920932|Drug|prednisone|Given orally (PO).
175956|NCT01920932|Drug|doxorubicin|Given IV.
176263|NCT01914315|Behavioral|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
176264|NCT01914315|Other|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
176265|NCT01914341|Other|Music|Live music played on the pentatonically tuned children's harp
176266|NCT01914367|Biological|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
176267|NCT00111722|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
176268|NCT01914367|Biological|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
176269|NCT01914380|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
176270|NCT01916733|Drug|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
175615|NCT01888276|Other|evaluation of word generation and of motivation|Each subject will realize twice each test during 2 sessions with one hour in between :
During the session 1 :
The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.
The test of Stroop that assesses selective attention
During the session 2:
The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.
The task of the casino (Iowa Gambling Test)
The task of landing
The test of Stroop
175616|NCT01888289|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
175617|NCT01888302|Drug|Cisplatin|Given IV
175618|NCT01888302|Drug|Gemcitabine Hydrochloride|Given IV
175619|NCT00109239|Drug|rhuMAb VEGF (Bevacizumab)|
175620|NCT01888302|Other|Quality-of-Life Assessment|Ancillary studies
175621|NCT01888302|Drug|Sirolimus|Given PO
175622|NCT01888315|Device|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
175623|NCT01888315|Device|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
175624|NCT01888315|Device|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
175625|NCT01888315|Device|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
175626|NCT01888328|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
175627|NCT01888341|Drug|Isotretinoin|Isotretinoin Capsules,20 mg
175628|NCT01888354|Drug|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
175629|NCT01888367|Drug|DFA-02 Antibiotic Gel|
175957|NCT00112320|Procedure|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
175958|NCT01920932|Drug|cyclophosphamide|Given IV.
175959|NCT01920932|Drug|Dacarbazine(R)|Given IV.
175960|NCT01920932|Drug|filgrastim|Given subcutaneously (SQ) as clinically indicated.
175961|NCT01920932|Other|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
175311|NCT01892904|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
175312|NCT01892930|Radiation|stereotactic body radiation therapy|Undergo SBRT
175313|NCT01892930|Procedure|therapeutic conventional surgery|Undergo partial or radical nephrectomy
175314|NCT01892930|Other|laboratory biomarker analysis|Correlative studies
175315|NCT01892982|Behavioral|Problem Solving Education tailored to NICU|
175316|NCT00109785|Procedure|positron emission tomography|
175317|NCT01892995|Drug|Ketamine|
175318|NCT01885416|Other|consumption of test meal based on dairy products|
175319|NCT01885416|Other|consumption of high fat test meal without dairy products|
175320|NCT01885416|Other|consumption of high fat test meal with dairy products|
175321|NCT01885429|Dietary Supplement|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
175322|NCT01885429|Dietary Supplement|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
175323|NCT01885429|Dietary Supplement|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
175324|NCT01885429|Dietary Supplement|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
175325|NCT01885429|Dietary Supplement|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
175326|NCT00108797|Drug|Feiba VH|
175327|NCT01885442|Device|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
175328|NCT01885455|Other|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
175329|NCT01885455|Other|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
174722|NCT01886781|Other|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
174723|NCT01886781|Other|Wash - out period|Wash - out period following treatment phase of eight weeks
174724|NCT01886794|Drug|Topical Vaginal Estrogen Cream/placebo|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
175015|NCT00109408|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
175016|NCT01890005|Drug|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
175017|NCT01890018|Behavioral|Electronic Pill Bottle tracking|All 5 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
175018|NCT01890018|Behavioral|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
175019|NCT01890018|Behavioral|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
175020|NCT01890018|Behavioral|Medication schedule alarms|1 arm will have the visual and audial reminder alerts activated on the Glowcaps to alarm when scheduled to take their statin medication.
175021|NCT01890031|Other|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
175022|NCT01890031|Other|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
175023|NCT01890057|Drug|Sugammadex|The dose of sugammadex
175024|NCT01890070|Dietary Supplement|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
175025|NCT01890070|Dietary Supplement|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
175026|NCT00109421|Behavioral|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
175027|NCT01890070|Dietary Supplement|Red wine|Italian Organic Red Wine
175028|NCT01890070|Dietary Supplement|Olive Oil|Italian Organic Olive Oil
175029|NCT01890070|Dietary Supplement|Wild mixed greens|Italian organic wild mixed greens
175030|NCT01890070|Dietary Supplement|Chestnut|Italian Organic Chestnut
174429|NCT00110071|Drug|fludarabine phosphate|Given IV
174430|NCT01898884|Drug|VP 20629|
174431|NCT01898884|Drug|Placebo|
174432|NCT01898897|Procedure|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
174433|NCT01898897|Procedure|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
174434|NCT01898910|Procedure|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
174435|NCT01898910|Procedure|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
174436|NCT01898910|Drug|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
174437|NCT01898923|Drug|WH-1 ointment|
174438|NCT01898923|Other|Aquacel® Hydrofiber® dressing|
174439|NCT01898936|Procedure|Pretreatment with CO2 laser before photodynamic therapy|The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.
The laser settings will be as follows:
The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.
The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours.
174725|NCT01886807|Device|TrueView PCD Video Laryngoscope|
174726|NCT01886820|Drug|[18F]NAV4694|
174727|NCT01886859|Drug|Ibrutinib|Given PO
174728|NCT00109031|Radiation|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
174729|NCT01886859|Other|Laboratory Biomarker Analysis|Correlative studies
174730|NCT01886859|Drug|Lenalidomide|Given PO
173819|NCT01900431|Drug|Prednisone|Pharmaceutical form:tablet Route of administration: oral
174122|NCT01893411|Drug|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
174123|NCT01895790|Device|Pancreatic Duct Stent Placement|
174124|NCT00109889|Procedure|positron emission tomography|positron emission tomography (PET)
174125|NCT01895816|Dietary Supplement|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus & ZINGIBER OFFICINALE & Onion & Ocimum basilicum & Cinnamomum zelanicum & Citrullus lanatus & Citrullus vulgaris & Daucus carota
174126|NCT01895829|Procedure|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
174127|NCT01895829|Drug|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
174128|NCT01895842|Drug|Ruxolitinib|Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.
Starting dose level for Part 2: Maximum tolerated dose from Part 1.
174129|NCT01895855|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
174130|NCT01895855|Biological|placebo|
174131|NCT01895868|Other|Simulation-based ultrasound training|
174132|NCT01895881|Drug|Estradiol|
174133|NCT01895881|Drug|Placebo|
174134|NCT01895894|Drug|Mycophenolate mofetil|Mycophenolate mofetil 25~33mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
174135|NCT00002075|Drug|Flucytosine|
174136|NCT00109928|Drug|cisplatin|
174137|NCT01895920|Other|Blood sample|
174138|NCT01895933|Device|5ml surgishield|in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site
merocel in the inflated state maintained for 36~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site
174139|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
173831|NCT01902394|Other|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
173832|NCT01902394|Other|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
173833|NCT01902433|Procedure|Astym|
173834|NCT01902446|Drug|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
173835|NCT01902459|Biological|EVARREST™ Fibrin Sealant Patch|
173836|NCT01902459|Other|Standard of Care|
173837|NCT01902485|Other|Timing of Contraceptive Initiation in Medical Abortion|
173838|NCT01902498|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
173839|NCT00000298|Drug|Buprenorphine/naloxone|
174143|NCT01895972|Drug|Latanoprostene bunod|
174144|NCT01895985|Drug|Latanoprostene bunod|
174145|NCT01895998|Drug|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
174146|NCT01896011|Biological|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
174147|NCT00109928|Drug|etoposide|
174148|NCT01896011|Other|Placebo|Placebo 20 mcg injection pen
174149|NCT01898299|Device|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
174150|NCT01898299|Device|Sham tDCS|Sham (inactive) tDCS treatment
174151|NCT01898312|Drug|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
174152|NCT00110058|Biological|therapeutic allogeneic lymphocytes|
174153|NCT01898325|Device|Fibroscan|Fibroscan
174154|NCT01898338|Drug|Fosfomycin 2gr/6h iv|
173513|NCT01899755|Drug|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
173514|NCT01899768|Drug|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
173515|NCT01899768|Drug|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
173516|NCT01899781|Drug|Antibiotic-Cefamezin|
173517|NCT01899794|Procedure|TVT-O/Oxytrol|
173518|NCT01899794|Device|TVT-O|
173519|NCT01899794|Drug|Oxytrol|
173520|NCT00110110|Drug|vincristine sulfate|Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
173521|NCT01899807|Device|OssDsign AB|
173522|NCT01899820|Drug|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
173523|NCT01899820|Drug|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
173524|NCT01899833|Radiation|99mTc-ECDG|An injection of 99mTC-ECDG with a target amount of 25 mCi with no more than 250 micrograms of ECDG will be administered by IV push under medically observed conditions.
173525|NCT01899846|Drug|Hydroxyprogesterone caproate 250 mg/ml|
173526|NCT01899859|Drug|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
173527|NCT01899859|Drug|Placebo|GR-MD-02 Placebo
173528|NCT01899872|Behavioral|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
173529|NCT01899872|Behavioral|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
173840|NCT00002081|Drug|Zidovudine|
173841|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
173842|NCT01902498|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
173843|NCT01902498|Drug|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
178293|NCT01905618|Behavioral|Web-based curriculum on tobacco dependence treatment|The University of Massachusetts Medical School's web-based course, "Basic Skills for Working with Smokers" was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play.
178294|NCT01908049|Dietary Supplement|Probiotic.|
178295|NCT01908049|Dietary Supplement|Placebo|
178296|NCT01908062|Drug|Extended Release Naltrexone|
178297|NCT01908062|Other|Treatment As usual|
178298|NCT01908075|Drug|FP/SAL|
178299|NCT00110955|Drug|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
178300|NCT01908075|Drug|BDP/FOR|
178301|NCT01908088|Biological|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
178302|NCT01908101|Drug|Eribulin Mesylate|Given IV
178303|NCT01908101|Other|Laboratory Biomarker Analysis|Correlative studies
178304|NCT01908114|Behavioral|Enhanced Community mobilization|
178305|NCT01908114|Biological|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
178306|NCT01908127|Behavioral|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
178307|NCT01908127|Behavioral|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
173530|NCT01899885|Procedure|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|optimized course: Intervention before, during and after abdominal surgery.
Focus on fast track with multimodal standardized intervention:
standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)
GDT-LiDCO fluid management pre-, per- and postoperative
Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score
Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively
173531|NCT00110110|Procedure|cryosurgery|Local application of extreme cold to destroy residual tumor.
177675|NCT01909453|Drug|LGX818|LGX818- Orally 100mg and 50mg capsules
177676|NCT01909453|Drug|MEK162|MEK162- Orally 15 mg tablets
177677|NCT01909453|Drug|vemurafenib|Tablets in bottles or blisters 240mg
177678|NCT01909466|Drug|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
177679|NCT01909479|Drug|MOD-4023|Individualized once weekly dose of MOD-4023
177680|NCT01909479|Other|Placebo|Once weekly administration of placebo
177681|NCT01909492|Procedure|Blood Draw|Patients will provide a serum sample for research.
177682|NCT01909492|Procedure|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
177992|NCT01912118|Drug|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
177993|NCT01912131|Behavioral|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
177994|NCT01912131|Behavioral|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
177995|NCT01912131|Behavioral|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences,
177996|NCT01912131|Behavioral|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
177997|NCT01912144|Other|Coffee|
177998|NCT01905007|Device|Defibrillation testing|Defibrillation testing at initial ICD implantation
177999|NCT00110617|Drug|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
178000|NCT01905020|Other|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
178001|NCT01905020|Other|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
177360|NCT01904006|Other|Standard culture|The embryos will be cultured individually (each embryo in one medium drop). The culture will be performed inside an Heraeus incubator, at an atmospheric oxygen tension (20%).
177361|NCT01904032|Drug|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
177362|NCT00110799|Drug|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
177363|NCT01906554|Other|Egg Dose|Different quantities of eggs
177364|NCT01906580|Drug|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
177365|NCT01906580|Drug|Entecavir|0.5mg,oral administration every day
177366|NCT01906606|Behavioral|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
177367|NCT01906632|Biological|DC-CIK Immunotherapy|
177368|NCT01906645|Other|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
177369|NCT01906658|Drug|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
177370|NCT01906671|Drug|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
177371|NCT01906671|Drug|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
177683|NCT00002086|Drug|Interferon alfa-n1|
177684|NCT00111137|Drug|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
177685|NCT01909544|Other|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
177686|NCT01909557|Drug|Acetyl-L-carnitine|
177687|NCT01909557|Drug|placebo|
177688|NCT01909570|Procedure|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
177689|NCT01909570|Procedure|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
177054|NCT01918124|Radiation|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
177055|NCT01918124|Drug|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
177056|NCT01918124|Drug|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
177057|NCT01918124|Drug|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
177058|NCT01918137|Dietary Supplement|chocolate bar|
177059|NCT01918137|Dietary Supplement|Porridge|
177060|NCT01918150|Device|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
177061|NCT01918150|Device|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
177062|NCT00112099|Procedure|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
177063|NCT01920425|Device|Kinesia HomeView|Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
177064|NCT00112255|Behavioral|Referral to specialist genitourinary clinic|
177065|NCT01920425|Other|Hand-written diary|Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
177066|NCT01920438|Procedure|Percutaneous Endoscopic Gastrostomy|PEG
177067|NCT01920438|Procedure|Radiologically-guided insertion of Gastrostomy|RIG
177068|NCT01920451|Behavioral|Cognitive-Behavioral Therapy for Insomnia (CBTI)|See arm description.
177372|NCT01906684|Drug|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
177373|NCT00002084|Drug|Acyclovir|
177374|NCT00110799|Other|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
176785|NCT01915173|Drug|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
176786|NCT01915173|Drug|Placebo|Lactose tablets
176787|NCT01915173|Behavioral|Expanded Interview|
176788|NCT01915173|Behavioral|Standard Interview|
176789|NCT01915186|Dietary Supplement|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
176790|NCT01915199|Other|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
176791|NCT01915212|Biological|HSV529|This is a replication-defective HSV-2 vaccine. 20 subjects in each of 3 study groups will be injected with vaccine or placebo in a 3:1 ratio as Day 0, Day 30, and Day 180.
176792|NCT01915264|Drug|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
176793|NCT00111800|Drug|GW0823093|
176794|NCT01915277|Drug|Dexmedetomidine|
176795|NCT01917591|Device|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
176796|NCT01917591|Device|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
176797|NCT01917604|Procedure|open exposure|the open surgical methods of exposing the canine is compared with control
176798|NCT01917604|Procedure|closed exposure|closed exposure is compared with control
176799|NCT01917617|Drug|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|Short hydration via oral rehydration solution (OS-1)
Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively.
176800|NCT01917617|Drug|Gemcitabine , Cisplatin|Standard hydration via intravenous infusion
Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more.
176801|NCT01917630|Drug|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
176802|NCT00112047|Drug|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
176803|NCT01917630|Drug|placebo|
176804|NCT01917656|Drug|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
176198|NCT01916694|Device|Blue tooth enabled glucose meter with smart phone application|
176199|NCT01916694|Behavioral|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
176200|NCT01916707|Drug|Dosing of enoxaparin for VTE prophylaxis|
176201|NCT01916720|Drug|SB-480848 40 mg|Study Drug
176202|NCT01916720|Drug|SB-480848 80 mg|Study Drug
176203|NCT01916720|Drug|Placebo|Study Drug
176204|NCT00111943|Drug|1% tenofovir gel|
176503|NCT00112437|Drug|MK0822|MK0822 10 mg, once weekly for 24 months
176504|NCT01921972|Drug|Galantamine CR|24 mg/day with dose-titration over twelve weeks
176505|NCT01921972|Drug|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
176506|NCT01921972|Drug|Placebo|Placebo will be similar in appearance to Memantine
176507|NCT01921985|Drug|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
176508|NCT01921985|Drug|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
176509|NCT01921998|Procedure|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
176510|NCT01922011|Drug|Daptomycin|
176511|NCT01922011|Drug|Vancomycin (or equivalent)|
176512|NCT01922011|Drug|Nafcillin (or equivalent)|
176513|NCT01922024|Device|LRT55 Testing|Testing on the Unyvero LRT55
176514|NCT00112437|Drug|MK0822|MK0822 25 mg, once weekly for 24 months
176515|NCT01922050|Drug|LEO 43204 Formulation 1|
176516|NCT01922050|Drug|LEO 43204 Formulation 2|
176517|NCT01922050|Drug|LEO 43204 Formulation 1 Dose X|
176518|NCT01922050|Drug|LEO 43204 Formulation 1 Dose Y|
175867|NCT01883895|Device|Forgioni-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study.
175868|NCT00108654|Drug|VRC-HIVADV014-00-VP|
175869|NCT00108927|Behavioral|TRANSLATE|
175870|NCT01886365|Other|Conventional therapy with a fixed insulin dosing scheme|Routine care
175871|NCT01886378|Drug|UX007|
160667|NCT01792050|Drug|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
160668|NCT00001956|Procedure|Blood draw|
160669|NCT00099346|Drug|MK0457, VX-680 (Aurora Kinase Inhibitor)|
160670|NCT01792050|Drug|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
160671|NCT01792063|Drug|Sevoflurane|
160672|NCT01792063|Drug|Sevoflurane|
160673|NCT01792089|Other|fat+protein meal|cream+ whey protein
160674|NCT01792089|Other|Fat + protein + fructose meal|cream+ whey protein + fructose
160675|NCT01792089|Other|Fat+protein+fructose+glucose meal|Cream + whey protein + glucose:fructose mixture
160676|NCT01792102|Drug|Carfilzomib and Dexamethasone|Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.
Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16.
160677|NCT01792115|Drug|Vitamin E 200 IU/d|Supplement-low dose; Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open-label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
160678|NCT01792115|Drug|Vitamin E 400 IU/d|Supplement-intermediate dose; Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open-label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
176580|NCT01919554|Biological|SLIT tablets of HDM allergen extracts|
176581|NCT00112229|Biological|group 1|Melan-A analog peptide + CpG + Montanide
176859|NCT01915303|Drug|Pasireotide with or without cabergoline|The trial consists of Pasireotide-untreated patients will start pasireotide 0.6mg twice a day for 8 weeks. If biochemical control is not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose will be increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline will be added and patients will begin combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline wlil be increased to 1.0mg once a day. Patients can also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients will continue with the combination treatment for 8 weeks. If biochemical control is not achieved by the end of the 8 week period, the dose of cabergoline will be increased to 1mg once a day.
176860|NCT01915316|Other|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
176861|NCT01915329|Device|RSS (repetitive sensory stimulation)|RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.
In case of the sham-stimulation no pulses are transmitted.
176862|NCT01915329|Device|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
176863|NCT01915342|Device|Focal muscular vibration|
176864|NCT01915355|Device|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
176865|NCT01915368|Behavioral|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
176866|NCT01915368|Behavioral|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
176867|NCT01915368|Behavioral|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
176868|NCT00111813|Drug|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
176869|NCT01915381|Other|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
176870|NCT01915433|Other|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
176271|NCT01916746|Procedure|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
176272|NCT01916759|Drug|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
176273|NCT01916772|Other|no interventions|no interventions
176274|NCT01916785|Drug|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
176275|NCT01916798|Drug|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up & another dose at the day of embryo Transfer.
176582|NCT01919593|Drug|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
176583|NCT01919593|Drug|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
176584|NCT01919606|Drug|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
176585|NCT01919619|Drug|Lenalidomide|If creatinine clearance greater than 60 mL/min starting dose of Lenalidomide: 10 mg by mouth daily for 21 days (followed by 7 rest days).
If creatinine clearance 30 to 60 mL/min starting dose of Lenalidomide: 5 mg by mouth daily for 21 days (followed by 7 rest days),
176586|NCT01919619|Drug|Ipilimumab|3 mg/kg by vein on Day 1 of Cycles 2 and 4.
176587|NCT01921517|Device|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
176588|NCT01921517|Device|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
176589|NCT01921530|Procedure|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
176590|NCT01921530|Procedure|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
176591|NCT01921543|Device|ITP Stimulation|Model 7428 Kinetra® Neurostimulator
Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead
Model 3387 DBSTM Brain Lead
Model 7482-51 Extension
Model 7482-66 Extension
Model 7482-95 Extension
Model 7436 AccessTM Therapy Controller
Model 3628 Dual Screener TM
Model 8840 N'Vision
175962|NCT01920932|Radiation|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
175963|NCT01920945|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
175964|NCT01920958|Other|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and sealing of surgical wound.
175965|NCT01920971|Radiation|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
175966|NCT01920984|Drug|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
175967|NCT01921010|Drug|NIaspan|See Arm Description
175968|NCT01913704|Device|NatroxTM Device|The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.
The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks.
175969|NCT01913717|Radiation|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
175970|NCT01913730|Drug|Bortezomib|
175971|NCT01913730|Drug|Dexamethasone|
175972|NCT01913756|Dietary Supplement|Gamalost (Norwegian traditional cheese)|
175973|NCT01913756|Dietary Supplement|Gouda-type cheese|
176276|NCT01916824|Drug|Antidepressant|
176277|NCT01916837|Other|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
176278|NCT01916837|Other|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
176279|NCT01916837|Procedure|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
176280|NCT00111956|Drug|Etanercept|
175330|NCT01885481|Drug|Dexamethasone|epidural steroid injection using dexamethasone
175630|NCT00109252|Drug|Raptiva (efalizumab)|
175631|NCT01888367|Drug|DFA-02 Placebo Gel|
175632|NCT01888380|Procedure|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
175633|NCT01888380|Procedure|Conventional autopsy|
175634|NCT01888393|Drug|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
175635|NCT01888406|Behavioral|Guided Self-Help|
175636|NCT01888406|Behavioral|Pure Self-Help|
175637|NCT01888419|Other|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
175638|NCT01888432|Drug|Everolimus + reduced tacrolimus|Everolimus will be initiated at Week 4 post transplantation. The dose will be adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus will be reduced to 3-5 ng/mL.
175639|NCT01890980|Biological|Montanide adjuvant + GM-CSF|Treatment of 6 injections over 12 weeks, administered on weeks 0, 2, 4, 6, 8, and 10. All receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination and may be self administered with appropriate instruction. Participants keep a logbook noting the time and placement of the injection, and will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide which will be administered by a nurse (not self-administered) subcutaneously to the same anatomical site as the GM-CSF as marked by the patient or treating healthcare professional by a permanent marker pen.
175640|NCT01890993|Drug|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
175641|NCT01891006|Device|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
175642|NCT01891006|Other|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
175643|NCT01891019|Drug|Thalidomide oral|Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.
175644|NCT01891045|Behavioral|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
175645|NCT01891045|Behavioral|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
175646|NCT01891058|Device|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
175031|NCT01892722|Drug|Interferon beta-1a i.m. injections|Administration once weekly via i.m. injections. Double-dummy masking is required to blind formulations: Patients in the interferon beta-1a i.m. arm will also take daily placebo capsules matched in appearance to the fingolimod active capsules.
175032|NCT01892722|Drug|Fingolimod oral capsules|Administration orally once daily. Double-dummy masking is required to blind formulations: Patients in the fingolimod arm will also take weekly placebo i.m. injections (syringes matched in appearance to the active interferon beta-1a i.m. syringes).
175033|NCT01892722|Drug|Placebo oral capsule|Placebo capsule required for double-dummy masking to blind formulations: Patients in interferon beta-1a i.m. arm will also receive daily oral placebo capsules matched in appearance to the fingolimod active capsules.
175034|NCT01892722|Drug|Placebo i.m. injection|Placebo i.m. injection required for double-dummy masking to blind formulations: Patients in the fingolimod arm will also take weekly placebo i.m. injections (syringes matched in appearance to the active interferon beta-1a i.m. syringes).
175331|NCT01885481|Drug|Betamethasone|epidural steroid injection using betamethasone
175332|NCT01885507|Other|Pass recommendations on ventilation factors and extubation|the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)
extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough
175333|NCT01885520|Dietary Supplement|fasting condition|eperisone SR tablet 75mg administrated under fasting
175334|NCT01885520|Dietary Supplement|fed condition|eperisone SR tablet 75mg administrated fed condition
175335|NCT01885546|Device|AgaMatrix Blood Glucose Monitor|
175336|NCT01885559|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
175337|NCT00108810|Drug|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
175338|NCT01885559|Drug|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
175339|NCT01885559|Drug|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
175340|NCT01885572|Device|TiLOOP Bra|Titaniferously coated polypropylene mesh
175341|NCT01887704|Device|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
175342|NCT01887717|Device|TheraSphere|Treatment with TheraSphere
175343|NCT01887717|Drug|Sorafenib|standard of care therapy for treatment of advanced hepatocellular carcinoma
175344|NCT01887730|Behavioral|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
174731|NCT01886859|Other|Pharmacological Study|Correlative studies
174732|NCT01886872|Drug|Bendamustine Hydrochloride|Given IV
174733|NCT01886872|Drug|Ibrutinib|Given PO
174734|NCT01886872|Other|Laboratory Biomarker Analysis|Correlative studies
174735|NCT01886872|Other|Quality-of-Life Assessment|Ancillary studies
174736|NCT01886872|Biological|Rituximab|Given IV
174737|NCT01886885|Behavioral|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
174738|NCT01886898|Other|Infant formula|infant formula
174739|NCT00109031|Drug|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
174740|NCT01886898|Other|Breastfeeding|
174741|NCT01886911|Other|Attention Training Intervention Game|
174742|NCT01886911|Other|Prosocial Training Intervention Game|
174743|NCT01889524|Other|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
174744|NCT01889537|Behavioral|Virtual Reality|The patient will receive virtual reality during a burn care procedure
174745|NCT01889550|Behavioral|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
175035|NCT01892748|Drug|Cholecalciferol|
175036|NCT01892748|Drug|Placebo|
175037|NCT01892761|Drug|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
175038|NCT00002072|Drug|Epoetin alfa|
174140|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
174141|NCT01895959|Drug|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
174142|NCT01895959|Device|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
174440|NCT01901237|Behavioral|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
174441|NCT01901250|Dietary Supplement|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
174442|NCT01901250|Dietary Supplement|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
174443|NCT01901250|Behavioral|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
174444|NCT01901250|Device|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
174445|NCT01901250|Device|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
174446|NCT01901263|Behavioral|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
174447|NCT01901276|Drug|Omeprazole 40 mg bid|As above.
174448|NCT01901289|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
174449|NCT00110240|Drug|vildagliptin|
174450|NCT01901302|Drug|CB-5945|
174451|NCT01901302|Drug|Placebo|
174452|NCT01901315|Procedure|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
174155|NCT01898338|Drug|Daptomycin 10mg/kg/24h iv|
174156|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.
The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.
The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded.
174157|NCT01898364|Drug|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
174158|NCT01898377|Drug|Imatinib mesylate, Mycophenolate mofetil|
174159|NCT01898390|Procedure|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
174160|NCT01898403|Drug|indocyanine green solution|Given peri-tumoral and intradermally
174161|NCT01898403|Drug|isosulfan blue|Given peri-tumoral and intradermally
174162|NCT01898403|Procedure|lymph node mapping|Undergo lymph node mapping
174163|NCT00110058|Drug|cyclosporine|
174164|NCT01898403|Procedure|sentinel lymph node biopsy|Undergo SNLB
174459|NCT01901354|Other|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
174460|NCT00110253|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
174461|NCT01901367|Dietary Supplement|nutritional intervention|Receive nutritional intervention
174462|NCT00109824|Other|laboratory biomarker analysis|Correlative studies
174463|NCT01893788|Drug|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
174464|NCT01893788|Drug|Eplerenone|50 to 100 mg daily for 48 weeks
174465|NCT01893801|Drug|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
174466|NCT01893801|Drug|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
173844|NCT01902511|Drug|G-CSF+Erythropoetin|
173845|NCT01902511|Drug|G-CSF|
173846|NCT01902524|Drug|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
173847|NCT01902537|Drug|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
173848|NCT01895244|Drug|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
173849|NCT01895257|Device|HAI-90Y radioembolization (SIR-spheres injection)|Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.
Hepatic Angiogram
Liver-Lung Break-Through Nuclear Scan
173850|NCT01895257|Drug|systemic chemotherapy LV5FU2|Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.
Cycle 1 onwards:
Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure.
173851|NCT01895270|Drug|Isradipine|Isradipine extended release formulation
173852|NCT00109850|Drug|cisplatin|30mg/m^2, bolus intravenous (IV), on Days 1 & 8 of each cycle.
173853|NCT01895270|Drug|Placebo|Placebo will consist of microcrystalline cellulose.
173854|NCT01895283|Behavioral|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
173855|NCT01895296|Drug|Pasireotide|somatostatin analogue pasireotide
173856|NCT01895296|Drug|Placebo|placebo s.c.
173857|NCT01895309|Drug|Enbrel (etanercept)|
173858|NCT01895309|Drug|SB4 (proposed biosimilar to etanercept)|
173859|NCT01895322|Drug|OPC-41061|
173860|NCT01895335|Drug|TERIFLUNOMIDE HMR1726|Pharmaceutical form:film-coated tablet Route of administration: oral
174165|NCT01898416|Drug|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.
Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given.
173532|NCT01899898|Other|Simplified Modified Atkins Diet|Modified Atkins diet with the following modifications:
Pictorial representation of various food items and exchange lists will be provided.
Instead of weights, we will provide standardized measures
We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures
We will formulate recipes and diets based on locally available and culturally acceptable foods.
We will develop a parent instruction manual.
We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.
We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes.
173533|NCT01899898|Drug|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
173534|NCT01899911|Device|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
173535|NCT01902173|Other|Laboratory Biomarker Analysis|Correlative studies
173536|NCT01902173|Other|Pharmacological Study|Correlative studies
173537|NCT00110318|Procedure|Corticosteroid injections|
173538|NCT01902173|Drug|Trametinib|Given PO
173539|NCT01902186|Drug|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
173540|NCT01902186|Drug|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
173541|NCT01902199|Behavioral|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
173542|NCT01902212|Other|Oral Nutritional Supplement|
173543|NCT01902225|Drug|Istodax|
173544|NCT01902225|Drug|Doxil|
173545|NCT01902238|Procedure|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
173546|NCT01902251|Drug|Enzalutamide tablet|Oral
173861|NCT01895348|Drug|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
178002|NCT01905046|Drug|metformin hydrochloride|given PO
178003|NCT01905046|Other|placebo|given PO
178004|NCT01905059|Drug|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)
178005|NCT01905059|Drug|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
178006|NCT01905072|Other|Education Home Visits|Intervention will include educational home visits on:
Growth monitoring and feedback
Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.
Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.
Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.
Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby.
178007|NCT01905085|Device|No intervention|
178308|NCT01908127|Drug|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
178309|NCT01908127|Procedure|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
178310|NCT00002086|Drug|Zidovudine|
178311|NCT00110955|Drug|Placebo|Q3W dosing of placebo
178312|NCT01908140|Drug|Aclidinium Bromide / Formoterol Fumarate|
178313|NCT01908140|Drug|Salmeterol / Fluticasone|
178314|NCT01908166|Procedure|ultrasound elasticity imaging|Undergo ultrasound elastography
178315|NCT01908192|Drug|NaBen® (Sodium Benzoate)|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo). The Study Treatment will also include Sodium Benzoate alongside the other ingredients in the Control Treatment (Placebo).
178316|NCT01908192|Drug|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient, Sodium Benzoate.
178317|NCT01908205|Drug|Intranasal Oxytocin|
178318|NCT01908205|Drug|Placebo|
178319|NCT01908244|Other|Music|Pentatonic music
178320|NCT01908257|Drug|lesinurad 400 mg|
177690|NCT01909583|Other|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
177691|NCT01909596|Other|Without orthoses|Condition control
177692|NCT01909596|Device|6° lateral wedge insoles|Insoles with a lateral inclination set at 6°
177693|NCT01909596|Device|10° lateral wedge insoles|Insoles with a lateral inclination set at 10°
177694|NCT01909596|Device|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
177695|NCT00111150|Drug|Tenofovir Disoproxil Fumarate 300 mg daily|
177696|NCT01909596|Device|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
177697|NCT01909596|Device|7° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 7°
177698|NCT01911793|Device|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
177699|NCT01911806|Device|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
177700|NCT01911806|Procedure|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
177701|NCT01911819|Procedure|Sinus augmentation|
177702|NCT01911819|Drug|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
177703|NCT01911819|Drug|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
177704|NCT01911819|Drug|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
178008|NCT01905098|Other|Sauna Detoxification Protocol|All study participants will actively undergo sauna intervention sessions.
The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.
On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment.
178009|NCT01905098|Other|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
178010|NCT00110630|Behavioral|10-week smoking cessation group therapy combined with NicoDerm CQ|
177375|NCT01906697|Procedure|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
177376|NCT01906697|Procedure|middle turbinate resection|middle turbinate resection
177377|NCT01906697|Procedure|middle turbinate medialization|middle turbinate medialization
177378|NCT01906710|Other|integrated medicines management|PITH includes the following interventions:
A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge
177379|NCT01906723|Device|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
177380|NCT01906749|Drug|Colchicine|0.5mg once daily orally
177381|NCT01906749|Drug|Placebo|
177382|NCT01906762|Drug|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
177383|NCT01909089|Drug|Spinal administration of chloroprocaine.|In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.
Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:
effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.
Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally.
177384|NCT01909102|Behavioral|ACT-based intervention|
177385|NCT01909102|Behavioral|usual care|
177386|NCT01909115|Dietary Supplement|Vitamin D3|
177387|NCT01909128|Dietary Supplement|fermented milk|fermented milk with Lactobacillus CBA-L74
177388|NCT01909128|Dietary Supplement|fermented rice|fermented rice wit Lactobacillus CBA-L74
177389|NCT00111046|Drug|Tramadol|
177705|NCT01911832|Procedure|esophagojejunostomy after total gastrectomy|
177706|NCT01911832|Procedure|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
177707|NCT00111462|Drug|Darbepoetin alfa|
177069|NCT01920477|Biological|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.6 mL (60mg) of concentration 100 mg/mL drug product
177070|NCT01920477|Biological|Placebo|Placebo to match the active doses will consist of normal saline (sterile, pyrogen-free 0.9% NaCl) filled to 0.6 mL in prefilled glass syringes with staked needle, stopper, and plunger.
177071|NCT01920490|Device|GUILT-INCREASE-CORRELATION|This uses a novel software "FRIEND" created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner
177072|NCT01920490|Device|GUILT-STABILIZE-CORRELATION|This uses a novel software "FRIEND" created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner
177073|NCT01920503|Drug|Doxorubicin|Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
177074|NCT01920516|Drug|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
177075|NCT00112268|Behavioral|QuitLink (office support system for quit line referral)|
177076|NCT01920529|Other|aerobic exercise|Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
177077|NCT01920542|Drug|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
177078|NCT01920542|Drug|no dexmedetomidine|no administration of dexmedetomidine on control group
177079|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
177080|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
177081|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
177082|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
177083|NCT01920555|Drug|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
177084|NCT01920568|Biological|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
177085|NCT01920568|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance <=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
177086|NCT00112281|Drug|Tilarginine Acetate Injection intravenous infusion|
176519|NCT01922050|Drug|LEO 43204 Formulation 2 Dose XX|
176520|NCT01922050|Drug|LEO 43204 Formulation 2 Dose YY|
176521|NCT01922050|Drug|Placebo Formulation 1|
176522|NCT01922050|Drug|Placebo Formulation 2|
176523|NCT01922063|Behavioral|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
176524|NCT01914770|Drug|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
176805|NCT01917656|Drug|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
176806|NCT01917656|Drug|sulfonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
176807|NCT01917682|Procedure|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
176808|NCT01917695|Drug|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
176809|NCT01917695|Radiation|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
176810|NCT01917695|Radiation|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
176811|NCT01917695|Procedure|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
176812|NCT01917708|Drug|4 doses of abatacept|4 doses of abatacept received on days -1, +5, +14 and +28.
176813|NCT00112047|Drug|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
176814|NCT01917708|Drug|6 doses of abatacept|6 doses of abatacept received on days -1, +5, +14, +28, +56, and +84.
176815|NCT01917721|Drug|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 14 days besides receiveing standard care: IVIG and/or Remicade.
176816|NCT01917721|Drug|Standard care|Standard medical care will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
160679|NCT01792115|Drug|Vitamin E 800 IU/d|Supplement High Dose; Subjects randomized to vitamin E 800 IU/day for 24 weeks; invited to optional extension of open-label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
160680|NCT00099359|Drug|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) > 2000 grams 8 mg PO BID if BW < 2000 grams
160681|NCT01784237|Procedure|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
160970|NCT01787383|Drug|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
160971|NCT01787383|Drug|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
160972|NCT01787396|Drug|Gemigliptin 50mg|
160973|NCT01787396|Drug|Placebo(Metformin)|
160974|NCT01787396|Drug|Metformin|
160975|NCT01787396|Drug|Placebo(Gemigliptin)|
160976|NCT00098917|Procedure|conventional surgery|
160977|NCT01787409|Dietary Supplement|Cholecalciferol|Given PO
160978|NCT01787409|Other|Laboratory Biomarker Analysis|Correlative studies
160979|NCT01787409|Other|Placebo|Given PO
160980|NCT01787422|Other|Traditional versus Telemedicine office visit|
160981|NCT01787435|Drug|Risk of asthma in offspring|Exposure to PPI or H2RA, respectively during pregnancy
No exposure to acid suppressing drugs during pregnancy
160982|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
160983|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
160984|NCT01787448|Drug|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
176871|NCT01915433|Other|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
176872|NCT01915459|Biological|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
177155|NCT01918254|Drug|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m^2 intravenously.
177156|NCT01918254|Drug|Pertuzumab|Participants will receive pertuzumab at a dose of 840 mg intravenously initial dose (except for extension phase 2) followed by 420 mg intravenously every 3 weeks.
177157|NCT01918254|Drug|RO5479599|Participants will receive escalating doses of RO5479599 starting at a dose of 1000 mg to determine safe dose.
177158|NCT01918280|Procedure|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
177159|NCT01918293|Device|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
177160|NCT01918306|Drug|cisplatin|In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.
In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
177161|NCT01920568|Drug|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
177162|NCT01920568|Drug|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
177163|NCT01920594|Drug|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
177164|NCT01920594|Drug|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
177165|NCT01920607|Device|magnetic anal sphincter|
177166|NCT01920607|Device|sacral nerve stimulation|
177167|NCT01920620|Behavioral|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
177168|NCT01920620|Behavioral|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
176592|NCT01921543|Device|CI/BNST stimulation|Model 7428 Kinetra® Neurostimulator
Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead
Model 3387 DBSTM Brain Lead
Model 7482-51 Extension
Model 7482-66 Extension
Model 7482-95 Extension
Model 7436 AccessTM Therapy Controller
Model 3628 Dual Screener TM
Model 8840 N'Vision
176593|NCT01921543|Device|No stimulation|
176594|NCT01921556|Behavioral|active comparator, QualiCCare education|Physicians randomized into the intervention group get a "QualiCCare" training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support.
176595|NCT00002097|Drug|Nystatin|
176596|NCT00112385|Drug|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
176597|NCT01921569|Behavioral|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
176598|NCT01921569|Other|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
176599|NCT01921569|Other|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
176873|NCT01915459|Biological|Botulinum toxin type A(Botox®)|
176874|NCT01915472|Drug|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
176875|NCT01917747|Behavioral|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
176876|NCT01917747|Behavioral|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
176877|NCT01917773|Drug|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
176878|NCT01917773|Drug|Bisacodyl|
176879|NCT01917786|Device|ECG|
176880|NCT01917799|Drug|Aspirin|75mg tab of LDA once daily for 7 months
176281|NCT01916850|Drug|LX4211 400 mg|
176282|NCT01916850|Drug|LX4211 800 mg|
176283|NCT01916850|Drug|LX4211 Placebo|
176284|NCT01916863|Drug|LX4211 400 mg|
176285|NCT01916863|Drug|canagliflozin 300 mg|
176286|NCT01916863|Drug|LX4211 Placebo|
176287|NCT01916876|Other|Integrated medical follow-up package|At discharge, patients will receive a discharge plan by their attending caregiver.
On day 3 they will be contacted telephonically to:
i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance
Reminders via SMS to attend there OPD appointment(s)
Medical out-patient review at 2-weeks and 6 weeks if required
Medical telephonic "hot-line" for advice
176288|NCT01916889|Other|RACY test|
176289|NCT01918904|Drug|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
176290|NCT01918904|Drug|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
176291|NCT01918917|Drug|Levobupivacaine|intraarticular
176292|NCT01918917|Drug|Dexmedetomidine|intraarticular 1 ml (100 mcg)
176293|NCT01918917|Drug|Morphine|intravenously, patient-controlled analgesia
176294|NCT01918930|Biological|MGA271|MGA271 anti-B7-H3 monoclonal antibody
176295|NCT01918943|Device|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
176296|NCT01918956|Biological|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
176297|NCT01918995|Drug|Regadenoson|Intravenous (IV)
176298|NCT00112190|Drug|itopride|100 mg three times daily
176299|NCT01918995|Drug|Placebo|Intravenous (IV)
176600|NCT01921582|Drug|Methylphenidate|Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.
Intervention will consist of medication as well as components of "Med-Plus" treatment (e.g., medication management, general support, and compliance enhancement strategies).
176601|NCT01921582|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavior Therapy will include three phases:
Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;
Phase 2 aims to reduce food intake and restructure eating-related cognitions;
Phase 3 focuses upon relapse prevention
175647|NCT01891071|Procedure|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
175648|NCT00002070|Drug|Ganciclovir|
175649|NCT00109577|Drug|Placebo|nutritional supplement
175974|NCT01913769|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
175975|NCT01913795|Other|integrated pest management|integrated pest management and environmental strategy
175976|NCT01913795|Other|air purifier|air purifiers
175977|NCT01913795|Other|Sham air purifier|sham air purifiers
175978|NCT00111657|Biological|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
175979|NCT01913808|Drug|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
175980|NCT01913808|Drug|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
175981|NCT01913834|Drug|Forsteo|Subcutaneous administration 20 micrograms
175982|NCT01913834|Drug|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
175983|NCT01913847|Drug|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
175984|NCT01913847|Drug|Placebo|Oral placebo TID for 12 weeks
175985|NCT01913860|Behavioral|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
175986|NCT01913873|Other|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
175987|NCT01913886|Procedure|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
175988|NCT01913899|Other|Occupational/ physical therapy|
175345|NCT01887730|Behavioral|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
175346|NCT00109161|Drug|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
175347|NCT01887730|Behavioral|Control|
175348|NCT01887743|Drug|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
175349|NCT01887756|Device|Tele Rehabilitation|
175350|NCT01887782|Device|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
175351|NCT01887782|Device|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
175352|NCT01887795|Drug|Erlotinib|
175353|NCT01887795|Drug|WBRT|
175650|NCT01891084|Drug|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
175651|NCT01891084|Drug|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
175652|NCT01891084|Drug|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
175653|NCT01891097|Procedure|Acupuncture plus auricular acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours.
175654|NCT01891097|Procedure|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
175655|NCT01891110|Procedure|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
175656|NCT01883414|Device|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
175039|NCT00109759|Biological|RagweedMATAMPL|
175040|NCT01892774|Procedure|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
175041|NCT01892787|Drug|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
175042|NCT01892787|Drug|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
175043|NCT01892800|Procedure|Lung resection|
175044|NCT01892813|Drug|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175045|NCT01892813|Drug|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175046|NCT01892813|Drug|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175047|NCT01892813|Drug|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175048|NCT01892813|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175049|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175050|NCT00109772|Drug|lenalidomide|Two 5 mg capsules taken one time per day
175051|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175052|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
175053|NCT01884922|Drug|Vinblastine|Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.
Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation.
175054|NCT01884935|Biological|Natalizumab|As specified in the treatment arm
175354|NCT01887808|Other|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
175355|NCT01887821|Drug|Chloroquine|
174453|NCT01901315|Procedure|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
174454|NCT01901328|Drug|CB-5945|
174455|NCT01901328|Drug|Placebo|
174456|NCT01901341|Drug|CB-5945|
174457|NCT01901341|Drug|Placebo|
174458|NCT01901354|Other|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
174746|NCT01889550|Behavioral|Access to the website www.ouh.dk|Access to the usual information from the hospital website
174747|NCT01889563|Other|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
174748|NCT01889576|Dietary Supplement|Magnesium Oxide|
174749|NCT01889589|Other|Surveillance|
174750|NCT01889602|Drug|Topiramate|Topiramate: 100 mg, 150 mg or 200 mg, po, 1x
174751|NCT01889602|Drug|Lorazepam|Lorazepam: 2mg, po, 1x
174752|NCT01889602|Other|Placebo|
174753|NCT00002069|Drug|Ditiocarb sodium|
174754|NCT00109382|Drug|Simvastatin|
174755|NCT01889615|Other|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
174756|NCT01889628|Dietary Supplement|Liquid-based Nutritional Formulae and liquid glucose|
174757|NCT01889654|Other|Venous blood sampling|
174758|NCT01889667|Drug|ORMD-0801 Dose # 1|Oral Insulin Formulation
174759|NCT01889667|Drug|ORMD-0801 Dose # 2|Oral Insulin Formulation
174760|NCT01889667|Drug|Placebo|Oil Capsules
174761|NCT01889680|Drug|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
174467|NCT01893801|Drug|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
174468|NCT01893814|Dietary Supplement|Probiotics|
174469|NCT01893814|Dietary Supplement|Control|
174470|NCT01893827|Drug|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
174471|NCT01893827|Drug|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
174472|NCT01893840|Device|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
174473|NCT00109837|Biological|filgrastim|As needed per physician discretion
174474|NCT01893853|Other|Exercise Intervention|Exercise intervention trials will consist of a steady-state bout of exercise at ~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
174475|NCT01893866|Drug|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
174476|NCT01893866|Drug|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
174477|NCT01893879|Other|placebo|Given PO
174478|NCT01893879|Drug|study drug|Given PO
174479|NCT01893879|Other|laboratory biomarker analysis|Correlative studies
174480|NCT01893892|Dietary Supplement|levocarnitine|Given PO
174481|NCT01893892|Other|placebo|Given PO
174482|NCT01893892|Other|questionnaire administration|Ancillary studies
174767|NCT01891929|Behavioral|TAU (Treatment As Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
174768|NCT01891942|Procedure|twitch by magstim|
174769|NCT01891955|Behavioral|Healthy diet A|Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called "healthy diet with grains and dairy"). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.
174166|NCT01898429|Device|SCC DBS|Deep Brain Stimulator
174167|NCT01898442|Drug|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
174168|NCT01898442|Drug|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
174169|NCT01898442|Drug|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
174170|NCT01898455|Device|RhinoChill intranasal cooling|The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
174171|NCT01898468|Procedure|Pericostal Closure Technique|
174172|NCT01900873|Device|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
174173|NCT01900873|Device|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
174174|NCT01900886|Other|Peginterferon alfa-2a|Treatment as usual clinical practice
174175|NCT01900886|Drug|Ribavirin|Treatment as usual clinical practice
174176|NCT00110214|Other|placebo|Given IV
174177|NCT01900899|Procedure|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
174178|NCT01900912|Other|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
174179|NCT01900925|Procedure|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
174483|NCT01893905|Drug|CS+SG|Chondroitin sulfate+glucosamine sulfate orallly administered once a day for 24 weeks.
173862|NCT01895348|Drug|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
173863|NCT00109850|Drug|irinotecan hydrochloride|65mg/m^2, intravenous (IV) over 30 min, on Days 1 & 8 of each cycle.
173864|NCT01895348|Drug|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
173865|NCT01895361|Drug|SelG1|
173866|NCT01895361|Drug|Placebo|
173867|NCT01895374|Procedure|laser treatments|
173868|NCT01895374|Other|amniotic membrane application|
173869|NCT01895374|Device|hydrocolloid application|
173870|NCT01895387|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
173871|NCT01897805|Drug|Heart-protecting Musk Pill|
173872|NCT01897805|Drug|Placebo|
173873|NCT01897818|Device|communication system P300 Speller|
173874|NCT01897831|Drug|xin te mie|durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
173875|NCT01897844|Drug|ITF2984 (100, 2000, 3000 mcg bid)|
173876|NCT01897844|Drug|Placebo|
173877|NCT01897857|Device|duplex Doppler ultrasonography|
173878|NCT01897870|Behavioral|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
173879|NCT01897896|Drug|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
173880|NCT00110032|Procedure|conventional surgery|Undergo surgery
178321|NCT01908257|Drug|ranitidine 150 mg|
178322|NCT01910467|Device|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
178323|NCT01910467|Device|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
178324|NCT01910480|Drug|NBI-98854 50 mg capsule once daily|
178325|NCT01910480|Drug|Ketoconazole 400 mg (200 mg twice daily)|
178326|NCT01910493|Behavioral|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
178327|NCT01910506|Drug|RDEA3170 10 mg|
178328|NCT01910519|Biological|Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant|
178329|NCT00111267|Behavioral|vitamin B12 supplementation|
173547|NCT01902251|Drug|Enzalutamide capsule|Oral
173548|NCT00110344|Drug|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
173549|NCT01902264|Drug|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
173550|NCT01902290|Biological|Placebo|Placebo administered SC
173551|NCT01902290|Biological|210 mg brodalumab|210 mg brodalumab administered SC
173552|NCT01902303|Drug|Matching Placebo|Sublingual micro dosing of placebo for 7 days
173553|NCT01902303|Drug|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
173554|NCT01902329|Drug|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
173555|NCT01902329|Drug|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
178011|NCT01905111|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
178012|NCT01905124|Drug|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
178013|NCT01905124|Drug|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
178014|NCT01905137|Drug|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
178015|NCT01905137|Drug|placebo|
178016|NCT01905150|Drug|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin
178017|NCT01907607|Drug|PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.|PD-0332991 dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.
Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day.
178018|NCT01907620|Other|blood sample|
178019|NCT01907633|Drug|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
178020|NCT01907646|Device|bladder training|vescical catheter
178021|NCT01907646|Procedure|No bladder training|
178022|NCT01907659|Other|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
178023|NCT01907672|Procedure|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
178024|NCT00110903|Drug|Etanercept Liquid|
178025|NCT01907685|Drug|AVE8062|Pharmaceutical form:Solution for infusion
Route of administration: Intravenous
178330|NCT01910519|Biological|Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant|
178331|NCT01910532|Drug|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
178332|NCT01910545|Drug|OTS167IV|
178333|NCT01910558|Dietary Supplement|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
177708|NCT01911832|Procedure|wide tube reconstruction after subtotal gastrectomy|
177709|NCT01911832|Procedure|narrow tube reconstruction after subtotal gastrectomy|
177710|NCT01911845|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
177711|NCT01911845|Drug|ABT-333|Tablet
177712|NCT01911845|Drug|Ribavirin (RBV)|Tablet
177713|NCT01911858|Device|Askina Calgitrol Paste|
177714|NCT01911871|Biological|Blood sample|a blood sample was taken on the day of inclusion
177715|NCT01911884|Behavioral|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
177716|NCT01911897|Device|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
177717|NCT01911910|Behavioral|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
177718|NCT00111475|Drug|AMG 531|
177719|NCT01911923|Procedure|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
177720|NCT01911923|Procedure|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
177721|NCT01911936|Drug|LM716|
177722|NCT01904474|Other|Next.Step - e-therapeutic intervention program|
177723|NCT01904474|Other|Standard treatment protocol|
177724|NCT00110565|Device|Pulsed magnetic field pad|
177725|NCT01904487|Radiation|[11C]flumazenil|[11C]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
177726|NCT01904487|Drug|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
177087|NCT01913145|Device|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
177088|NCT01913158|Drug|Hydrocortisone acetate suppositories|Hydrocortisone acetate suppositories
177390|NCT01909141|Drug|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
177391|NCT01909141|Drug|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
177392|NCT01909141|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of > 18 mm or till day 20 of the cycle
177393|NCT01909141|Other|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
177394|NCT01909141|Other|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
177395|NCT01909141|Other|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
177396|NCT01909141|Other|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
177397|NCT01909141|Other|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
177398|NCT01909141|Other|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
177399|NCT01909154|Biological|Mesenchymal stromal cell therapy|
177400|NCT00111072|Drug|dexamethasone 0.01% solution|
177401|NCT01909167|Behavioral|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
177402|NCT01909167|Other|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
177403|NCT01909180|Device|Standard of care scan|
177404|NCT01909180|Device|Investigational Scan|
177405|NCT01911377|Drug|Botulinum Toxin Type A|
177406|NCT01911377|Drug|Normal Saline for Injection|
176817|NCT01917734|Other|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
176818|NCT01920035|Device|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
176819|NCT01920048|Procedure|Percutaneous Coronary Intervention|
176820|NCT01920048|Drug|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
176821|NCT01920048|Device|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
176822|NCT00112242|Biological|Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|1 ml Montanide + 500 mcg Melan-A analog peptide + 500 mcg NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
176823|NCT01920061|Drug|PF-05212384|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
177089|NCT01913158|Drug|Hydrogenated palm kernel oil|Hydrogenated palm kernel oil suppositories
177090|NCT01913171|Other|Exercise|
177091|NCT01913184|Device|AKITA|
177092|NCT01913197|Other|An MRI-based technique to identify prostate cancer|
177093|NCT01913210|Dietary Supplement|Ginseng|
177094|NCT01913223|Device|Nestis® jet injector system with a bi-functional catheter|
177095|NCT01913236|Other|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
177096|NCT01913249|Procedure|LIFT|Ligation of intersphincteric fistula tract
177097|NCT00111618|Drug|AS1404 (DMXAA)|
177098|NCT01913262|Behavioral|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
177099|NCT01913275|Procedure|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
160985|NCT01787448|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
160986|NCT01787461|Dietary Supplement|Imedeen|Two tablets per day for 6 months
160987|NCT00098917|Procedure|surgery|
160988|NCT01787461|Dietary Supplement|Placebo|Two tablets per day for 6 months
160989|NCT01790100|Drug|VX-135|12 weeks of VX-135
160990|NCT01790100|Drug|Ribavirin|12 weeks of ribavirin
160991|NCT01790113|Device|Univers™|Control
160992|NCT01790113|Device|Eclipse™ Total Shoulder Replacement|Investigational
160993|NCT01790126|Drug|ARN-509|
160994|NCT01790126|Drug|LHRH Agonist|
161277|NCT01783041|Drug|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
161278|NCT01783054|Procedure|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
161279|NCT01783054|Genetic|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
161280|NCT01783054|Drug|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
161281|NCT01783067|Other|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
161282|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
161283|NCT01783067|Other|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
161284|NCT01783080|Behavioral|Behavioral Activation for return to work|See Arm Description
161285|NCT01783093|Other|Data Collection|Collection of data from existing medical records
161286|NCT01783106|Drug|Ciprofloxacin|experimental
161287|NCT01783106|Drug|Doxycycline|experimental
177169|NCT01920646|Other|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
177170|NCT01920659|Behavioral|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
177171|NCT00112294|Drug|Paclitaxel (Taxane)|IV, 225 mg/m^2
177172|NCT01920659|Behavioral|REHIT|6 weeks 3 x week (20sec intervals)
177478|NCT01906892|Other|Group drumming (recorded)|Listening to recorded performances of group drumming
177479|NCT01906892|Other|Comparative activity|Taking part in a literary-based activity
177480|NCT01906905|Device|Transcranial Magnetic Stimulation|
177481|NCT01906918|Procedure|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
177482|NCT00110838|Procedure|Supplementation with fish oil versus placebo|
177483|NCT01906931|Device|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
177484|NCT01906931|Device|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
177485|NCT01909193|Behavioral|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
177486|NCT01909193|Behavioral|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
177487|NCT01909219|Drug|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
177488|NCT01909232|Device|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
177489|NCT01909232|Device|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
177490|NCT01909245|Biological|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
177491|NCT00111085|Drug|clazosentan|
176881|NCT00112047|Drug|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
176882|NCT01917799|Drug|Heparin|0.4 mL/day of the Enoxaparin
176883|NCT01917812|Device|Digital Activity Tracker|
176884|NCT01917812|Other|Smart Text Messaging|
176885|NCT01917825|Drug|MDT-15|
176886|NCT01917838|Behavioral|MFG plus MyMFG|Specific aim is to utilize mHealth to improve the "Design" and "Do" process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.
The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the "Design" and "Do" process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the "Do" process.
176887|NCT01917864|Behavioral|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
176888|NCT01917877|Drug|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
176889|NCT01917877|Drug|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
177173|NCT01920672|Behavioral|Timed Planned Activity|
177174|NCT01920672|Behavioral|Home Safety and Education Program|
177175|NCT01920685|Other|Anxiety intervention|
177176|NCT01920698|Device|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
177177|NCT01920698|Other|control|
177178|NCT01920711|Drug|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
177179|NCT01920711|Drug|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
177180|NCT01920737|Drug|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
177181|NCT01920737|Drug|Vincristine|
177182|NCT00112294|Drug|Docetaxel (Taxane)|IV, 75 mg/m^2
177183|NCT01920737|Drug|Prednisone|
176602|NCT01921595|Other|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
176603|NCT01921595|Other|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
176604|NCT01921608|Device|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
176605|NCT00112437|Drug|MK0822|MK0822 3 mg, once weekly for 24 months
176606|NCT01914887|Drug|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
176607|NCT00111761|Drug|5-Fluorouracil|Part 1: IV bolus 500 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m^2 and infusional 2400-3000 mg/m^2 over 46 hours once every other week until disease progression or unable to tolerate.
176608|NCT01914900|Drug|docetaxel, cisplatin, 5 fluorouracil|
176609|NCT01914913|Biological|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
176610|NCT01914926|Drug|Metoprolol|
176611|NCT01914926|Drug|Diltiazem|
176612|NCT01914939|Drug|Oxytocin|
176613|NCT01914939|Behavioral|Social Skills focused CBT|
176614|NCT01914939|Behavioral|Stress management/relaxation training|
176615|NCT01914939|Drug|placebo drug|
176616|NCT01914952|Dietary Supplement|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
176617|NCT01914952|Dietary Supplement|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
176618|NCT00111761|Drug|Leucovorin|Part 1: IV bolus 20 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m^2 every other week until disease progression or unable to tolerate.
176619|NCT01914952|Dietary Supplement|HMB free acid mixed in water|0.8 g HMB free acid in water
176620|NCT01914952|Dietary Supplement|CaHMB in water|1.0 g CaHMB powder mixed in water
176890|NCT01917890|Dietary Supplement|Curcumin|Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)
175989|NCT01916226|Drug|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
175990|NCT01916226|Drug|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
175991|NCT01916226|Drug|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
175992|NCT01916239|Dietary Supplement|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
175993|NCT01916239|Dietary Supplement|Pomegranate extract formulation-1|New pomegranate extract formulation-1
176300|NCT01919008|Drug|FK949E|Oral
176301|NCT01919021|Other|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
176302|NCT01919021|Other|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
176303|NCT01919021|Procedure|Assessment of Gastric motor and sensory function|
176304|NCT01919047|Drug|Betanis|Oral
176305|NCT01919073|Behavioral|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
176306|NCT01919073|Behavioral|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
176307|NCT01919086|Drug|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.3 mg/m2, days 1, 4, 8, and 11
176308|NCT01919086|Drug|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8, and 11 or on a split-dose regimen.
176309|NCT00112203|Drug|Itopride Hydrochloride|
176310|NCT01919086|Drug|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
176311|NCT01919112|Behavioral|Swallowing Exercises|Anodal tDCS will be administered with swallowing exercises
176312|NCT01919125|Drug|IDX719|IDX719 supplied as 50 mg tablets.
175657|NCT00002063|Drug|Zidovudine|
175658|NCT00108615|Drug|Metformin|
175659|NCT01883427|Drug|Placebo|placebo containing saline+glucose
175660|NCT01883427|Drug|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
175661|NCT01883440|Drug|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
175662|NCT01883440|Drug|Saline+glucose|Placebo arm
175663|NCT01883453|Device|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
175664|NCT01883453|Device|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
175665|NCT01883466|Other|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
175994|NCT01916239|Dietary Supplement|Pomegranate extract formulation-2|New pomegranate extract formulation-2
175995|NCT01916252|Drug|bortezomib (Velcade ®)|
175996|NCT00111878|Drug|MEDI-534|
175997|NCT01916252|Drug|lenalidomide (Revlimid®)|
175998|NCT01916252|Drug|busulfan (Busilvex ®)|
175999|NCT01916252|Drug|Dexamethasone acetate|
176000|NCT01916252|Drug|Melphalan|
176001|NCT01916265|Drug|Glucagon|
176002|NCT01916278|Device|Emervel Lips Lidocaine|
176003|NCT01916278|Device|Juvéderma Volbella with Lidocaine|
176004|NCT01916291|Drug|Propess insertion|
176005|NCT01916304|Drug|Levothyroxine sodium new formulation|Levothyroxine tablets
175356|NCT01887821|Drug|Dihydroartemisinin/Piperaquine|
175357|NCT00109174|Procedure|Magnetic Resonance Spectroscopy|To measure relative concentrations of 13C-labeled metabolites with Mass Spectroscopy technique
175358|NCT01887834|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|
175359|NCT01887834|Dietary Supplement|Kyodophilus Matching Placebo Capsules|
175360|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
175361|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
175362|NCT01887860|Other|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
175363|NCT01887873|Device|Hyaluronan Thiomer i.o. implant|
175364|NCT01887886|Drug|erlotinib|150 mg orally daily
175365|NCT01887886|Drug|onartuzumab|15 mg/kg IV every 3 weeks
175366|NCT01887886|Drug|placebo|IV every 3 weeks
175367|NCT01887899|Device|transcranial direct current stimulation|
175368|NCT00109187|Drug|Xolair (omalizumab)|
175369|NCT01890642|Other|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
175370|NCT01890642|Other|Sucrose|Oral Sucrose used for children < 1 year
175371|NCT01890655|Drug|MT-1303-Low|
175372|NCT01890655|Drug|MT-1303-Middle|
175373|NCT01890655|Drug|MT-1303-High|
175374|NCT01890668|Other|Osteopathic Manipulative Treatment|Visit 1 between H60 and discharge :
Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure
To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.
A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.
Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.
The follow-up for each patient is 6 months
174762|NCT01889680|Drug|LV|400 mg/m2 IV day 1 every 14 days until disease progression
174763|NCT01889680|Drug|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
174764|NCT01889680|Drug|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
174765|NCT00109395|Drug|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
174766|NCT01889719|Biological|MVA-CMDR|injections of MVA-CMDR vaccine
175055|NCT01884948|Drug|Omegaven™|
175056|NCT01884961|Other|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
175057|NCT01884974|Other|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
175058|NCT01884987|Drug|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
175059|NCT01885000|Drug|once-daily brimonidine tartrate 0.5% gel|
175060|NCT00108745|Procedure|Quality-of-Life Assessment|Ancillary studies
175061|NCT01885000|Drug|once-daily brimonidine tartrate vehicle gel|
175062|NCT01885013|Drug|Metformin + Myocet + Cyclophosphamide|Metformin + Myocet + Cyclophosphamide:
Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.
* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day.
175063|NCT01885013|Drug|Myocet + Cyclophosphamide|Myocet + Cyclophosphamide:
Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles
175064|NCT01885026|Behavioral|eScreen|
175065|NCT01885026|Other|Assessment only of alcohol and drug use.|
175066|NCT01885052|Behavioral|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
175067|NCT01885052|Behavioral|Low Contact|
175068|NCT01885065|Other|Gel-based artificial saliva|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.
Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks.
174770|NCT01891955|Behavioral|Healthy diet B|Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called "healthy diet without grains and dairy"). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.
174771|NCT01891968|Drug|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 28 day cycle.
174772|NCT01891981|Drug|Moxetumomab Pasudotox|Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.
Phase II Starting Dose: Maximum tolerated dose from Phase I.
174773|NCT01891994|Drug|Eltrombopag|administration of eltrombopag for 6 months
174774|NCT01892007|Behavioral|Cogmed RM - Online adaptive working memory training intervention|
174775|NCT01892007|Behavioral|Cogmed RM - Online (non-adaptive, placebo) working memory training intervention|
174776|NCT01892020|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
174777|NCT00109655|Biological|Oncolytic adenovirus (serotype 5) - CG0070|Intravesical administration of CG0070 (in suspension) directly into the bladder
174778|NCT01892020|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
174779|NCT01892033|Behavioral|Aerobic Exercise|12 weeks of brisk walking
174780|NCT01892046|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
174781|NCT01892059|Procedure|Segmental artery clamping|Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
174782|NCT01892059|Procedure|Main renal artery clamping|Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
175077|NCT01887366|Drug|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
175078|NCT01887366|Drug|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
175079|NCT01887366|Drug|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
174484|NCT00109837|Drug|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
174485|NCT01893905|Drug|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orallly administered once a day for 24 weeks.
174486|NCT01893931|Behavioral|ED Discharge & Medication Call|Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
174487|NCT01893931|Behavioral|Placebo Comparator|
174488|NCT01893944|Other|virtual reality|customized applications using virtual and augmented reality to be developed.
174489|NCT01889004|Drug|Propofol|Escalating concentrations until loss of responsiveness
174490|NCT01889017|Other|patient questionnaire (tablet pc based)|
174491|NCT01889056|Drug|Erythropoietin (Epoetin beta)|
174492|NCT01889056|Drug|Placebo|0.9% sodium chloride solution
174493|NCT01889069|Drug|MabThera/Rituxan|Induction: Subcutaneous doses of 1400 mg once a months for at least 4 cycles; Maintenance: Subcutaneous doses of 1400 mg once every two months for at least 6 cycles
174494|NCT01889069|Drug|Standard chemotherapy|Standard chemotherapy: CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone), CVP (cyclophosphamide, vincristine and prednisone) or bendamustine, as per standard local practice.
174495|NCT01889082|Behavioral|Behavioral Weight Loss Intervention for Young Adults|
174496|NCT01889095|Drug|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
174497|NCT01889095|Drug|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
174498|NCT01889108|Behavioral|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
174499|NCT00109343|Biological|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
174500|NCT01889121|Behavioral|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
174501|NCT01889134|Drug|Sedron (alendronate)|
174502|NCT01889134|Procedure|Parathyroidectomy|
174503|NCT01889147|Biological|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
173881|NCT01897922|Other|An investigational infant formula containing a probiotic source|
174180|NCT01900925|Procedure|Pragmatic low back pain treatment|advise to stay active,
discourage bed rest,
appropriate medication use,
reassurance.
Short term use of manipulation/medication,
supervised exercise,
cognitive behavioral therapy,
multidisciplinary treatment,
termination of use of modalities.
174181|NCT01900938|Procedure|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
174182|NCT01900938|Procedure|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
174183|NCT01900938|Drug|Midazolam|
174184|NCT01900938|Drug|Propofol|
174185|NCT01900951|Drug|Temozolomide|
174186|NCT01900964|Procedure|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
174187|NCT00110214|Drug|prednisone|Given orally
174188|NCT01900964|Procedure|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
174189|NCT01893424|Drug|Sativex buccal spray|buccal spray
174190|NCT01893424|Drug|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
174191|NCT01893437|Drug|RO6799477|Single doses of RO6799477
174192|NCT01893450|Drug|Methimazole|
174193|NCT01893450|Drug|Bromocriptine|
174194|NCT01893450|Drug|Pentoxifylline|
174195|NCT00002073|Drug|Epoetin alfa|
174196|NCT00109811|Other|laboratory biomarker analysis|Correlative studies
174197|NCT01893463|Device|iTClamp50|
173556|NCT01902342|Drug|Oseltamivir 75 mg 1 cap|
173557|NCT01894685|Drug|Placebo|Placebo 3 grams, once daily for six months
173558|NCT01894711|Drug|Trastuzumab|Treatment with trastuzumab in HER2 positive patients
173559|NCT01894724|Device|NeuroSave device|
173560|NCT01894737|Other|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
173561|NCT01894737|Other|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
173562|NCT01894750|Behavioral|group-based skill building self-care program|
173563|NCT01894763|Device|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
173564|NCT01894776|Drug|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
173565|NCT00109837|Drug|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
173566|NCT01894776|Drug|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
173567|NCT01894789|Drug|Ticagrelor|Blinded administration of ticagrelor for 10 days
173568|NCT01894789|Drug|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
173882|NCT01897922|Other|Control: Marketed routine infant formula|
173883|NCT01897948|Other|Milk-based beverage without DHA|
173884|NCT01897948|Other|Milk-based beverage with DHA at mid level|
173885|NCT01897948|Other|Milk-based beverage with DHA at high level|
173886|NCT01897961|Other|Anticorps anti-PLA2R1|
173887|NCT01897974|Other|Survey|Families complete survey to measure medication compliance.
173888|NCT01897987|Biological|Pneumostem®|
173889|NCT01897987|Biological|normal saline|
173890|NCT01898000|Behavioral|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
178334|NCT01910558|Dietary Supplement|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
178335|NCT01910558|Dietary Supplement|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
178336|NCT01910571|Drug|P7435|
178337|NCT01910571|Other|Placebo|
178338|NCT01910584|Procedure|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
178339|NCT01910597|Drug|SBG|
178340|NCT00111267|Behavioral|vitamin B12 + folic acid combined supplementation|
178341|NCT01910610|Biological|FOLFIRI-cetuximab|
178342|NCT01910610|Biological|mFOLFOX6-bevacizumab|
178343|NCT01910610|Biological|OPTIMOX-bevacizumab|
178344|NCT01910610|Biological|irinotecan-based chemo + bevacizumab|
178345|NCT01910610|Biological|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
178346|NCT01910610|Biological|XELOX + bevacizumab|
178347|NCT01910623|Other|Health Related Quality of Life (HRQOL) measures|
178348|NCT01910636|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
178349|NCT01902966|Behavioral|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
178350|NCT01902966|Behavioral|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
178351|NCT01902979|Behavioral|Lifestyle intervention|
178352|NCT01902992|Drug|Depiquick Birch (DPG103)|
178353|NCT01902992|Drug|Placebo|
173569|NCT01894802|Device|Implantation of CRS Arrays in the motor cortex and sensory cortex of the brain|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
173570|NCT01894815|Drug|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
178026|NCT01907685|Drug|Docetaxel|Pharmaceutical form: solution for infusion
Route of administration: Intravenous
178027|NCT01907698|Behavioral|Vaginal intercourse|vaginal intercourse at least twice a week
178028|NCT01907711|Device|Acupuncture.|Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as "De Qi".
178029|NCT01907724|Drug|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
178030|NCT01907724|Drug|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
178031|NCT01907724|Drug|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
178032|NCT01907724|Drug|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
178033|NCT01907737|Other|Active tDCS and active PNS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
178034|NCT01907737|Other|Active tDCS and sham PNS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA). In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
178035|NCT00110916|Drug|Intra-articular metHuIL-1ra (anakinra)|anakinra
178036|NCT01907737|Other|Sham tDCS and active PNS|In sham tDCS, no current will be delivered through the tDCS device. Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
178037|NCT01909999|Procedure|Osteogenic markers Evaluation|The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.
The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA).
178038|NCT01909999|Procedure|Clinical parameters evaluation|The following parameters were assessed:
Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;
Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants.
178039|NCT01909999|Procedure|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
177407|NCT01911390|Dietary Supplement|Bean powder|Arthur Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
177408|NCT01911390|Dietary Supplement|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
177409|NCT01911390|Dietary Supplement|Control arm|No bean or rice bran additive in smoothie or muffin.
177727|NCT01904500|Drug|Pre-operative cefazolin|
177728|NCT01904513|Dietary Supplement|Pasteurized Whole Milk|
177729|NCT01904513|Dietary Supplement|Lactobacillus rhamnosus GR-1|
177730|NCT01904526|Drug|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
177731|NCT01904539|Drug|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
177732|NCT01904552|Device|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
177733|NCT01904565|Radiation|Hyperthermia and Proton Beam|Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade
Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose.
177734|NCT01904578|Other|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
177735|NCT00110578|Procedure|Adoptive transfer of HIV-specific CD8+ T cells|
177736|NCT01904578|Other|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
177737|NCT01904591|Dietary Supplement|Selenium|Selenium 50 micrograms daily per oral
1 year of treatment
177738|NCT01904591|Dietary Supplement|Vitamin E|Vitamin E 400 international units daily per oral
1 year of treatment
177739|NCT01904604|Biological|High-dose DBV712 Viaskin® Patch|250 microgram (mcg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
177740|NCT01904604|Biological|Low-dose DBV712 Viaskin® Patch|100 microgram (mcg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
177100|NCT01913275|Procedure|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
177101|NCT01913288|Other|Biological Maternal Sounds|
177102|NCT01913301|Drug|Alagebrium|
177103|NCT01913314|Drug|[^14C]-LY2835219|Administered as oral solution
177104|NCT01913327|Drug|Aripiprazole|
177105|NCT01913327|Drug|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
177106|NCT01913327|Drug|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
177107|NCT01913340|Drug|Erythropoietin|1000 U/kg/dose IV x 5 doses
177108|NCT00111631|Drug|DPP-IV Inhibitor|Escalating doses po bid
177109|NCT01913340|Drug|Normal saline|placebo: NS IV x 5 doses
177110|NCT01913353|Biological|MVA BN®|0.5 ml MVA BN® with a nominal titre of 1x10E8 TCID50, administered as a subcutaneous injection
177111|NCT01913353|Biological|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
177410|NCT01911390|Dietary Supplement|Bean powder and rice bran|Arthur Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
177411|NCT01911403|Procedure|Manual compression|Closure procedure by Manual compression
177412|NCT01911403|Device|Angio-Seal|Closure procedure by angio-Seal
177413|NCT01911416|Drug|LDE225|
177414|NCT00111371|Drug|Levodopa|
177415|NCT01911429|Drug|Lurasidone 40 mg|Lurasidone 40 mg once daily
177416|NCT01911429|Drug|Lurasidone 80 mg|Lurasidone 80 mg once daily
177417|NCT01911429|Drug|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
177418|NCT01911442|Drug|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
177419|NCT01911442|Drug|Lurasidone|Lurasidone 60 mg once daily
161288|NCT01783106|Drug|Hydroxychloroquine|oral
161289|NCT01783106|Drug|Budesonide|active comparator
161290|NCT01783119|Dietary Supplement|Aloe Barbadensis Miller|
161291|NCT01783119|Dietary Supplement|placebo water|
161292|NCT01783132|Device|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
161293|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
161294|NCT01783158|Procedure|Esophagoscopy and chromoendoscopy|Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.
Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy.
161295|NCT01783171|Drug|Akt Inhibitor MK2206|Given PO
161296|NCT01785355|Other|Dental treatment|The preliminary stage deals with:
assessment of the clinical state of the patient by completing a detailed dental and periodontal chart
education of the patient regarding correct oral hygiene habits;
Phase I Therapy:
plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)
evaluation of response to the treatment
Phase II Therapy - surgical phase:
extraction of hopeless teeth
evaluation of the surgical results.
Maintenance phase:
periodic reevaluation of plaque and calculus and of periodontal conditions.
161592|NCT01865617|Biological|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
161593|NCT01865617|Other|Laboratory Biomarker Analysis|Correlative studies
161594|NCT01865630|Drug|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
161595|NCT01865643|Device|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
161596|NCT01865656|Other|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
161597|NCT01865656|Other|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
161598|NCT01865656|Other|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
161599|NCT01865656|Other|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
161600|NCT00107016|Drug|Letrozole 2.5mg|
161601|NCT01865656|Other|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
177492|NCT01909258|Other|Goniometric measure of pelvic extension reserve.|The pelvic extension reserve (°) is measured via goniometry.
The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes).
177493|NCT01909258|Other|Photographic measure of pelvic extension reserve.|The pelvic extension reserve (°) is measured using photography.
Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements).
177494|NCT01909258|Other|EOS measure of pelvic extension reserve.|The pelvic extension reserve (°) is measured using the imaging system EOS.
Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed.
177812|NCT01912261|Drug|Polysaccharide iron complex|150 mg daily orally times 84 days
177813|NCT01912274|Drug|pracinostat with azacitadine|Elderly newly diagnosed patients will all receive the combination of pracinostat with azacitadine
177814|NCT01912287|Behavioral|Cognitive Behavioral Therapy|
177815|NCT01912287|Behavioral|Stress Education|
177816|NCT01912287|Behavioral|Yoga|
177817|NCT01912300|Behavioral|experimental condition: Passvice Video game; Avtive Video game; Exercise|
177818|NCT01912313|Procedure|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
177819|NCT00111527|Other|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
177820|NCT01912326|Device|Pacemaker Implantation|Implantation of a dual chamber pacemaker
177821|NCT00110578|Drug|Aldesleukin|
177822|NCT01904643|Drug|mitoxantrone hydrochloride|Given IV
177823|NCT01904643|Drug|etoposide|Given IV
177824|NCT01904643|Drug|cytarabine|Given IV
177825|NCT01904656|Behavioral|"Get Behind your health"|Participants are exposed to the "Get Behind Your Health!" media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4.
177826|NCT01904656|Behavioral|Peaches|Participants are exposed to a "Healthy Eating!" media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4.
177184|NCT01920737|Drug|PEG-Asparaginase|
177185|NCT01920737|Drug|Methotrexate|
177186|NCT01920737|Drug|6-MP (6-Mercaptopurine)|
177187|NCT01920737|Drug|Cyclophosphamide|
177188|NCT01913379|Drug|MDV3100|Oral
177189|NCT01913379|Drug|Gemfibrozil|Oral
177190|NCT01913379|Drug|Itraconazole|Oral
177191|NCT01913392|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
177192|NCT01913405|Biological|PEGylated Recombinant factor VIII (rFVIII)|
177193|NCT00111631|Drug|Metformin|As prescribed
177194|NCT01913418|Drug|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
177195|NCT01913418|Drug|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
177196|NCT01913431|Drug|Baracle Tab.®|
177197|NCT01913431|Drug|Baraclude Tab.®|
177198|NCT01913444|Drug|Recombinant Antithrombin|
177495|NCT01909271|Behavioral|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
177496|NCT01909271|Other|Stroke Education Pamphlet Exposure|"Usual Care": Stroke Education pamphlet and brochure distribution.
177497|NCT01909284|Device|Acupuncture|BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.
Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture.
177498|NCT01909284|Procedure|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
177499|NCT01909297|Device|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
177500|NCT01909297|Device|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
176891|NCT01917890|Dietary Supplement|Placebo|Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)
176892|NCT00112060|Drug|PT-523 for Injection|
176893|NCT01917903|Behavioral|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
176894|NCT01920152|Biological|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
176895|NCT01920152|Device|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
176896|NCT01920165|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
176897|NCT01920178|Device|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
176898|NCT00002096|Drug|Didanosine|
176899|NCT00112242|Biological|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide
176900|NCT01920191|Biological|IMA 950|
176901|NCT01920191|Biological|Poly ICLC|
176902|NCT01920191|Other|Immunomonitoring|Blood samples, DTH analysis
176903|NCT01920204|Drug|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
176904|NCT01920230|Behavioral|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams & Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
176905|NCT01920230|Behavioral|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
176313|NCT01921374|Biological|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
176314|NCT01921374|Biological|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
176315|NCT01921387|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
176316|NCT01921387|Drug|carmustine|Given IV
176317|NCT01921387|Drug|etoposide|Given IV
176318|NCT01921387|Drug|cytarabine|Given IV
176319|NCT01921387|Drug|melphalan|Given IV
176320|NCT00112372|Drug|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
176621|NCT01914952|Dietary Supplement|HMB free acid|0.8 g HMB free acid
176622|NCT01914965|Drug|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
176623|NCT01914965|Drug|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
176624|NCT01914978|Other|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
176625|NCT01914978|Other|Food allergy treatment as usual|
176626|NCT01914991|Procedure|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
176627|NCT01917370|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
176628|NCT01917383|Drug|Trabodenoson|Ophthalmic eye drop
176629|NCT00112034|Drug|IV methylprednisolone|
176630|NCT01917383|Drug|Latanoprost|Ophthalmic eye drop
176006|NCT01916317|Drug|0.5% lignocaine 60mM|
176007|NCT00111891|Drug|niacin (+) laropiprant|
176008|NCT01916343|Procedure|Study Laparoscopic Curriculum|
176009|NCT01916356|Other|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
176010|NCT01916369|Biological|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
176011|NCT01916382|Drug|Nitisinone|drug
176012|NCT01916395|Drug|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
176013|NCT01916408|Drug|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
176014|NCT01916408|Drug|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
176015|NCT01916421|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
176016|NCT01916434|Other|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
176017|NCT01918501|Procedure|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
176321|NCT01921387|Procedure|peripheral blood stem cell transplantation|Undergo autologous PBSC transplant
176322|NCT01921387|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSC transplant
176323|NCT01921387|Other|laboratory biomarker analysis|Correlative studies
176324|NCT01921413|Device|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
176325|NCT01921426|Drug|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
176326|NCT01921439|Behavioral|Personalized Feedback|Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
175666|NCT01883479|Behavioral|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
175667|NCT01883479|Behavioral|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
175668|NCT01883492|Device|Femoral Stem|JMDN classification/Class III device
175669|NCT00108615|Drug|Pioglitazone|
175670|NCT01883492|Device|Acetabular Cup|JMDN classification: Class III device
175671|NCT01883492|Device|Acetabular Liner|JMDN classification: Class III device
175672|NCT01883505|Drug|Levodopa and carbidopa|Subcutaneous continuous administration
175673|NCT01883505|Drug|Placebo|Subcutaneous continuous administration
175674|NCT01883518|Biological|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
175675|NCT01883531|Drug|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
175676|NCT01883531|Drug|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
175677|NCT01883544|Drug|ALXN1007|
175678|NCT01883570|Other|training in visual search strategy|
175679|NCT01883570|Other|access to a library of chest x-rays without search strategy|
175680|NCT00108615|Radiation|CT scans|To measure changes in adipose tissue volumes
175681|NCT01886092|Device|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
175682|NCT01886092|Device|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
175683|NCT01886105|Drug|Sm-EDTMP|Subjects receive a "tracer" infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post "tracer" infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. "Tracer" activity will be applied to development of the external beam radiation planning. Second "treatment" infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg. After the "treatment" infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the external beam portion of the treatment plan, as necessary. Autologous stem cell infusion is administered 14 days after "Treatment" infusion of Samarium-153 EDTMP.
175684|NCT01886105|Other|Autologous Stem Cell Infusion|Approximately 14 days after administration of "treatment" dose of Samarium, patients will receive Autologous Stem Cell Infusion.
175069|NCT01885078|Drug|Baricitinib|Administered orally
175070|NCT01885078|Drug|Placebo|Administered orally
175071|NCT00002064|Drug|Clindamycin|
175072|NCT00108758|Drug|activated recombinant human factor VII|
175073|NCT01885091|Other|Kinerase|
175074|NCT01885104|Drug|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
175075|NCT01885104|Drug|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
175076|NCT01885104|Drug|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
175375|NCT01890668|Other|No Osteopathic manipulative Treatment|Visit 1 between H60 and discharge :
Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.
Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.
To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.
A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.
Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.
The follow-up for each patient is 6 months
175376|NCT01890681|Behavioral|Baby NAP SACC|
175377|NCT01890681|Behavioral|Back to Sleep|
175378|NCT00109538|Drug|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
175379|NCT01890694|Drug|Tolvaptan|15 mg once daily
175380|NCT01890694|Drug|Placebo|15 mg once daily
175381|NCT01890694|Behavioral|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
175382|NCT01890694|Behavioral|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
175383|NCT01890694|Biological|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
175080|NCT00109096|Drug|Pemetrexed|
175081|NCT01887379|Drug|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
175082|NCT01887392|Other|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
175083|NCT01887405|Drug|Adrenaline auto-injector|Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.
Valid for both Jext and Epipen:
Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water
175084|NCT01887418|Drug|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
175085|NCT01887418|Drug|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
175086|NCT01887418|Drug|Delatestryl 200 mg IM Treatment C|Standard of care
175087|NCT01887431|Other|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
175088|NCT01887431|Other|Conventional therapy|3-month routine clinic visits
175089|NCT01887444|Dietary Supplement|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
175090|NCT01887444|Other|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
175091|NCT00109109|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
175092|NCT01887457|Drug|VFEND|voriconazole will be administered in iv form
175093|NCT01887470|Drug|Full dose preparation|
175392|NCT01882972|Behavioral|Exercise|
175393|NCT01882972|Behavioral|Meditation|
175394|NCT01882985|Drug|Docetaxel|Given IV
174504|NCT01889147|Biological|Placebo|
174783|NCT01892072|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
174784|NCT01892085|Behavioral|Early initiation|Initiation of breast milk expression <1 hour following delivery.
174785|NCT01892085|Behavioral|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
174786|NCT01884415|Biological|HBV vaccine|Patients receive a second cycle of vaccination
174787|NCT00108732|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
174788|NCT01884415|Biological|HBV vaccine|Patients receive vaccination according to the guidelines.
174789|NCT01884428|Drug|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
174790|NCT01884428|Drug|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
174791|NCT01884428|Drug|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
174792|NCT01884428|Drug|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
174793|NCT01884428|Drug|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
174794|NCT01884441|Drug|Bendamustine|Schedule:
Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles
174795|NCT01884441|Drug|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
174796|NCT01884441|Drug|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
174797|NCT01884454|Behavioral|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
174798|NCT00108732|Biological|Recombinant Vaccinia-TRICOM Vaccine|Given SC
174799|NCT01884467|Drug|Gentamicin|Comparison of Gentamicin versus placebo
174800|NCT01884467|Drug|Placebo|
174801|NCT01884493|Device|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
174198|NCT01893476|Other|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
174199|NCT01893489|Other|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
174200|NCT01893502|Behavioral|Telephone counselling from Quitline|
174201|NCT01893515|Drug|PRC-4016|
174505|NCT01889160|Drug|AZD4721 Solution|1-9 mg/mL liquid solution
174506|NCT01889160|Drug|AZD4721 Placebo|Liquid solution
174507|NCT01889160|Drug|AZD4721 Suspension|9 mg/g liquid suspension
174508|NCT01889173|Drug|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
174509|NCT01889173|Drug|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
174510|NCT00109343|Biological|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
174511|NCT01889173|Drug|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
174512|NCT01889173|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
174513|NCT01889186|Drug|ABT-199|Tablet
174514|NCT01889199|Drug|Flutamide|Flutamide 25 mg orally each 28 day cycle for 6 cycles
174515|NCT01891513|Behavioral|Exercise|All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
174516|NCT01891513|Drug|ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
174517|NCT01891513|Drug|Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
173891|NCT00110032|Procedure|positron emission tomography|Undergo PET
173892|NCT01898000|Behavioral|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
173893|NCT01898013|Drug|Pregnenolone|
173894|NCT01898013|Drug|Placebo|
173895|NCT01898026|Dietary Supplement|Bread|Samples of white bread, with or without the addition of PGX fibre blend
173896|NCT01898026|Dietary Supplement|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
173897|NCT00110149|Radiation|yttrium Y 90 ibritumomab tiuxetan|
173898|NCT01900457|Other|approaches from psychophysics|
173899|NCT01900470|Behavioral|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
173900|NCT01900496|Drug|Brentuximab vedotin & Rituximab|Rituximab and brentuximab vedotin for relapsed classical Hodgkin lymphoma
173901|NCT01900509|Drug|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
174202|NCT01893515|Drug|Placebo|
174203|NCT01893528|Drug|REGN2009|
174204|NCT01893528|Other|placebo|
174205|NCT01893541|Procedure|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
174206|NCT01893541|Drug|PROPRANOLOL|The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
173571|NCT01894815|Device|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
173572|NCT01894815|Other|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
173573|NCT01894828|Dietary Supplement|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
173574|NCT01894841|Behavioral|Coping Long Term with Active Suicide|an intervention to reduce suicide behavior in Veterans recently hospitalized for suicide attempt or ideation with intent.
173575|NCT01894854|Procedure|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
173576|NCT00109837|Drug|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
173577|NCT01894867|Dietary Supplement|magnesium|supply magnesium oxide for 6 weeks
173578|NCT01894867|Dietary Supplement|Placebo|
173579|NCT01894880|Procedure|early SSC|bonding straight after birth
173580|NCT01894880|Procedure|late SSC|bonding after termination of operation
173581|NCT01894906|Drug|Soluble Ferric Pyrophosphate|
173582|NCT01894906|Other|Placebo|
173583|NCT00002075|Drug|Amphotericin B|
173584|NCT00110006|Radiation|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (^18FDG) IV.
173585|NCT01897389|Drug|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
173586|NCT01897389|Drug|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
173587|NCT01897389|Drug|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
173588|NCT01897389|Drug|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
173902|NCT01900509|Drug|Clofarabine|Route of administration: IV days 1-5.
173903|NCT01900509|Drug|Etoposide|Route of administration: IV days 1-5.
178354|NCT01903005|Drug|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
178355|NCT01903018|Drug|P276-00|
178356|NCT00110409|Behavioral|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
178357|NCT01903018|Radiation|Radiation Therapy|
178358|NCT01903018|Drug|Cisplatin|
178359|NCT01903031|Device|Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing)|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
178360|NCT01903031|Drug|Efavirenz|Participants will receive EFV 600 mg daily with two or more NRTIs
178361|NCT01903031|Drug|Atazanavir/Ritonavir|Participants will receive ATV/r 300 mg/ 100 mg daily with tenofovir (TDF) 300 mg and 1 or more additional NRTIs
178362|NCT01903044|Procedure|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
178363|NCT01903057|Drug|azithromycin|
178364|NCT01903057|Drug|ivermectin|
178365|NCT01903057|Drug|albendazole|
178366|NCT01903057|Drug|placebo|
178367|NCT00110409|Behavioral|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
178368|NCT01903070|Drug|Linagliptin|
178369|NCT01903083|Drug|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
178370|NCT01903083|Drug|Gemcitabine|Three doses of gemcitabine (1000 mg / m^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
178371|NCT01903083|Radiation|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
178372|NCT01903083|Procedure|Pancreaticoduodenectomy|Surgical resection.
178373|NCT01903096|Behavioral|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
177741|NCT01904604|Biological|Placebo Viaskin Patch|Placebo (e.g., no antigen) path in an epicutaneous application for 24 hours every 24 hours.
177742|NCT01904617|Other|Dextrose|
177743|NCT01904617|Other|Normal Saline|
177744|NCT01904630|Genetic|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
177745|NCT01904643|Drug|lenalidomide|Given PO
178040|NCT01909999|Procedure|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
178041|NCT01909999|Procedure|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
178042|NCT01909999|Drug|Post-operative care|Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
178043|NCT01910012|Drug|ADI-PEG 20|
178044|NCT01910025|Drug|ADI-PEG 20|
178045|NCT01910038|Drug|corticoids+ tocilizumab 8mg/Kg/month|
178046|NCT00111189|Drug|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
178047|NCT01910064|Drug|GK530G|
178048|NCT01910077|Drug|Tacrobell capsule 1mg|1 capsule, oral, over the period I&II(crossover)
178049|NCT01910077|Drug|Prograf capsule 1mg|1 capsule, oral, over the period I&II(crossover)
178050|NCT01910090|Drug|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
178051|NCT01910090|Drug|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
178052|NCT01910116|Drug|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
178053|NCT01910116|Drug|Placebo|The study medication and placebo were identical in appearance.
178054|NCT01910129|Device|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
177420|NCT01911442|Drug|Placebo|Placebo
177421|NCT01911455|Drug|acamprosate|
177422|NCT01911455|Drug|Placebo|
177423|NCT01911468|Drug|metformin|
177424|NCT01911468|Drug|liraglutide|
177425|NCT00111397|Procedure|Cytokine therapy|
177426|NCT01911468|Drug|metformin and liraglutide|
177427|NCT01911481|Other|hydration|
177428|NCT01911494|Behavioral|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
177429|NCT01911494|Device|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (>160mmHg systolic) or proteinuria (>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
177430|NCT01911494|Drug|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
177431|NCT00110474|Drug|Acetaminophen|
177746|NCT01907139|Behavioral|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
177747|NCT01907152|Other|Protein enriched yoghurt drink and bread|
177748|NCT01907165|Drug|Temozolomide|
177749|NCT01907165|Drug|Disulfiram|
177750|NCT01907165|Dietary Supplement|Copper gluconate|
177751|NCT00110864|Drug|PN2034|
161602|NCT01865669|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
161603|NCT01865695|Drug|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
161604|NCT01865695|Other|Placebo|
161605|NCT01865708|Drug|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
161606|NCT01865721|Drug|Entonox|Entonox will be used according to the allocated method
161607|NCT01868282|Procedure|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
161608|NCT01868295|Behavioral|Sleeping with denture|Sleeping with denture at night
161609|NCT01868334|Behavioral|Pillar 1: Convenient Vaccination Services|Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.
Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap.
161913|NCT01871558|Drug|sulfonylurea (SU)|
161914|NCT00000294|Drug|Carvedilol|
161915|NCT00002050|Drug|Thymopentin|
161916|NCT00107497|Radiation|radiation therapy|
161917|NCT01871558|Drug|Basal Insulin|
161918|NCT01871571|Biological|bevacizumab|Given IV
161919|NCT01871571|Drug|oxaliplatin|Given IV
161920|NCT01871571|Drug|leucovorin calcium|Given IV
161921|NCT01871571|Drug|fluorouracil|Given IV
161922|NCT01871571|Other|laboratory biomarker analysis|Correlative studies
177827|NCT01904682|Drug|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
177828|NCT01904695|Drug|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
177829|NCT01904695|Drug|Thiazide diuretics and ACE inhibitor and β-blocker|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
177830|NCT01904708|Other|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
177831|NCT01904721|Drug|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
177832|NCT00110591|Drug|PRO 140|Monoclonal antibody to CCR5
177833|NCT01904721|Drug|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
177834|NCT01904721|Drug|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
178117|NCT01907802|Other|Laboratory Biomarker Analysis|Correlative studies
178118|NCT01907802|Other|Pharmacological Study|Correlative studies
178119|NCT01907815|Drug|Akt Inhibitor GSK2141795|Given PO
178120|NCT01907815|Other|Laboratory Biomarker Analysis|Correlative studies
178121|NCT00110929|Drug|AMG 073|
178122|NCT01907815|Drug|Trametinib|Given PO
178123|NCT01907828|Device|Renal Artery Ablation Catheter|
178124|NCT01907828|Device|Cardiac Ablation|
178125|NCT01910155|Drug|Ciprofloxacin/Dexamethasone|
178126|NCT01910155|Drug|Ciprodex (R)|
178127|NCT01910155|Drug|Placebo|
178128|NCT01910181|Drug|Vemurafenib|Patients will receive vemurafenib at a dose of 960 mg twice daily orally until progressive disease (PD), unacceptable toxicity, death, loss to follow-up, or withdrawal of consent.
178129|NCT01910194|Drug|Luyxumia versus Lantus|
178130|NCT01910220|Drug|REGN1033 (SAR391786)|
177501|NCT01909297|Device|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
177502|NCT00111098|Drug|Darbepoetin Alfa|QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
177503|NCT01909310|Procedure|head extension|the lungs are ventilated with the patient´s head extended
177504|NCT01911494|Drug|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
177505|NCT01911507|Drug|INC280|Given PO
177506|NCT01911507|Drug|erlotinib hydrochloride|Given PO
177507|NCT01911520|Drug|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
177508|NCT01911520|Drug|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
177509|NCT00111397|Drug|Interferon Gamma, GM-CSF|
177510|NCT01911520|Procedure|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
177511|NCT01911520|Procedure|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
177512|NCT01911533|Procedure|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
177513|NCT01911533|Procedure|No extracorporeal CO2-removal|Patients are their own control group.
177514|NCT01911546|Drug|everolimus + low-dose tacrolimus|
177515|NCT01911559|Device|standing-frame|
177835|NCT01904734|Drug|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
177836|NCT01904747|Drug|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
177837|NCT01904747|Drug|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
177838|NCT01904747|Drug|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
177199|NCT01913457|Radiation|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
177200|NCT01913470|Drug|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
177201|NCT01913483|Drug|Bivalirudin|
177202|NCT01913496|Other|ebalance|using the ebalance application for 14 weeks
177203|NCT01913509|Device|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
177204|NCT00111631|Drug|Placebo|po bid
177205|NCT01913509|Device|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
177206|NCT01913522|Procedure|Pulmonary Vein Isolation|
177207|NCT01913535|Drug|CERC-501|Dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days)
177208|NCT01913535|Drug|CERC-501|Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days)
177209|NCT01913535|Drug|CERC-501|For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.
177210|NCT01913535|Drug|CERC-501|For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
177211|NCT01913535|Drug|Placebo|For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days)
177212|NCT01913561|Device|Master Caution Garment|Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.
The electrodes are dry, textile ECG electrodes.
177213|NCT01916018|Other|Clinical and radiologic exams and blood samples|
177214|NCT01916031|Behavioral|Education|
177215|NCT01916044|Other|Ultrasound|Measure of Uterine Segment by Ultrasound
177216|NCT01916057|Device|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
177217|NCT01916096|Device|Delica Device|
177218|NCT01916109|Drug|Gemcitabine|
176631|NCT01917383|Drug|Timolol|Ophthalmic eye drop
176632|NCT01917396|Drug|Fleet enema|
176633|NCT01917409|Device|conventional laryngoscopy|the device is to assist nasotracheal intubation
176634|NCT01917409|Device|video-stylet|the device is to guide the nasotracheal tube into trachea
176635|NCT01917435|Device|video-stylet|
176636|NCT01917435|Device|fiberoptic bronchoscope|
176637|NCT01917448|Drug|Morphine|spinal morphine 0.15 mg
176638|NCT01917448|Other|control|Patient receive only local infiltration without spinal analgesia
176639|NCT01917474|Dietary Supplement|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
176640|NCT00112047|Drug|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
176906|NCT01920243|Behavioral|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
176907|NCT01920256|Other|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
176908|NCT01920256|Other|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
176909|NCT01920269|Procedure|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
176910|NCT00112242|Biological|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide + low dose IL-2
176911|NCT01912872|Drug|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
176912|NCT01912885|Device|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
176913|NCT01912885|Device|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
176914|NCT01912885|Device|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
176327|NCT01921452|Device|Quantitative POC TSH Kit|A drop (approximately 30 microliter [mcL]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
176328|NCT01921452|Device|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
176329|NCT01921452|Device|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
176330|NCT01921491|Procedure|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
176331|NCT00112385|Drug|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
176332|NCT01921491|Device|Offloading|Provision of offloading cast walker or similar sponsor-approved device. May convert into "instant total contact cast" and/or add felt/foam to supplement offloading.
176333|NCT01921504|Device|Acupuncture|Acupuncture treatment
Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)
Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 ~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea
176334|NCT01914393|Drug|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
176335|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
176336|NCT01914406|Other|continuous moderate training|Continued exercise 45 min.
176337|NCT01914419|Drug|Oxytocin|
176338|NCT01914432|Drug|YH16410|
176641|NCT01917474|Dietary Supplement|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
176642|NCT01917513|Device|G-EYE™ colonoscopy|G-EYE™ colonoscopy
176643|NCT01917513|Device|Standard Colonoscopy|Standard Colonoscopy
176644|NCT01917526|Device|oxygen mask|
176645|NCT01917526|Device|oxygen cannula|
175685|NCT01886105|Radiation|External Beam Radiotherapy|The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.
176018|NCT01918514|Drug|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
176019|NCT01918527|Drug|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
176020|NCT01918527|Drug|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
176021|NCT01918540|Procedure|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
176022|NCT01918540|Procedure|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
176023|NCT01918540|Device|MS-30 femoral stem|This is the stem used in the study.
176024|NCT01918553|Other|clinical parameters|
176025|NCT00112151|Drug|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
176026|NCT01918553|Other|visual acuity exams|
176027|NCT01918553|Other|retinophotography|
176028|NCT01918553|Other|SD-OCT|
176029|NCT01918553|Other|Intra ocular Pressure (IOP)|
176030|NCT01918553|Other|retinal imaging (OPTOMAP)|
176031|NCT01918553|Other|axial length (IOL master)|
176032|NCT01918566|Dietary Supplement|tap water|
176033|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
176034|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
176035|NCT01918566|Dietary Supplement|25g Fructose in 300ml tap water|
176036|NCT00002095|Drug|Ganciclovir|
176037|NCT00112151|Behavioral|Resistance Training|Weight training 45-60 minutes 3 times per week
175384|NCT01890694|Biological|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
175385|NCT01890694|Procedure|Ascites Evaluation|Ascites will be assessed at every visit.
175386|NCT01890694|Procedure|Edema|Edema will be assessed at every visit.
175387|NCT01890707|Procedure|Endotracheal intubation|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
175388|NCT01882933|Drug|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
175389|NCT01882933|Procedure|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
175390|NCT01882946|Biological|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
175391|NCT01882959|Other|Radiofrequncy Denervation|
175686|NCT01886118|Procedure|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
175687|NCT01886118|Other|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
175688|NCT01886118|Other|Conventional media culture|embryos are cultured in conventional media
175689|NCT01886131|Other|Synchronised video-polysomnography|We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.
The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.
The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task.
175690|NCT00108875|Biological|Survivin peptide vaccine|
175691|NCT01886144|Device|Knee OA Brace|
175692|NCT01886157|Procedure|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
175693|NCT01886157|Procedure|Corticosteroid injection|Standard trigger finger corticosteroid injection.
175395|NCT01882985|Dietary Supplement|Lycopene|Given PO
175396|NCT01882998|Behavioral|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
175397|NCT01883011|Drug|Piracetam|
175398|NCT00108576|Other|placebo|Look-a-like placebo
175399|NCT01883011|Other|Placebo|
175400|NCT01883024|Other|A decision support software|
175401|NCT01883024|Other|Insulin Pump|
175402|NCT01883024|Other|Continuous glucose monitoring|
175403|NCT01883037|Other|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
175404|NCT01883050|Device|Self Monitoring Software Application|
175405|NCT01883063|Device|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
175406|NCT01883063|Device|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
175407|NCT01883076|Biological|autologous cell-based delivery|autologous cells (derived from "self")
175408|NCT01883089|Behavioral|Motivational Enhancement Therapy|
175409|NCT00108589|Drug|S-adenosylmethionine|
175410|NCT01883102|Drug|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
175411|NCT01883102|Drug|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
175412|NCT01883128|Device|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
175413|NCT01883128|Procedure|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
175414|NCT01883128|Procedure|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
175415|NCT01885585|Drug|Apixaban|
174802|NCT01884493|Device|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
174803|NCT01884506|Dietary Supplement|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
174804|NCT01884506|Dietary Supplement|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
175094|NCT01887470|Drug|Split dose preparation|
175095|NCT01887483|Dietary Supplement|Vetal Laban active|Dairy product with probiotic
175096|NCT01887483|Dietary Supplement|Placebo|Dairy product without probiotic
175097|NCT01890070|Other|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
175098|NCT01890083|Behavioral|Exercise|
175099|NCT01890083|Behavioral|Health Education|
175100|NCT01890096|Radiation|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
175101|NCT01890096|Radiation|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
175102|NCT01890109|Drug|AMG 334|Single dose level administered via SC in female subjects with hot flashes associated with menopause.
175103|NCT00109460|Behavioral|Tobacco Use Disorder|
175104|NCT01890109|Drug|AMG 334|Single dose level administered via SC in female subjects with hot flashes associated with menopause
175105|NCT01890122|Drug|Alogliptin|Alogliptin tablets.
175106|NCT01890122|Drug|Metformin HCl|Metformin capsules.
175107|NCT01890122|Drug|Alogliptin and Metformin fixed-dose combination (FDC)|Aloglptin and metformin FDC tablets.
175108|NCT01890122|Drug|Alogliptin placebo|Alogliptin placebo-matching tablets.
175109|NCT01890122|Drug|Metformin placebo|Metformin placebo-matching capsules.
175110|NCT01890122|Drug|Alogliptin and metformin FDC placebo|Alogliptin and metformin FDC placebo-matching tablets.
175111|NCT01890135|Drug|Zibotentan (ZD4054)|10 mg
174518|NCT01891513|Drug|Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
174519|NCT01891526|Drug|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
174520|NCT01891565|Behavioral|Feedback|
174521|NCT01891591|Procedure|Roux-en-Y gastric bypass (RYGP)|
174522|NCT01891604|Dietary Supplement|breast milk with Bifidobacterium Longum subp. Infantis R0033|
174523|NCT00109616|Behavioral|Newborn skin cleansing with 0.25% chlorhexidine solution|
174524|NCT01891604|Dietary Supplement|breast milk|
174525|NCT01891617|Other|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
174526|NCT01891643|Drug|Lenalidomide|
174805|NCT01884519|Biological|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
174806|NCT01884532|Device|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
174807|NCT01884545|Behavioral|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
174808|NCT01884545|Genetic|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
174809|NCT00108732|Biological|Sargramostim|Given SC
174810|NCT01886911|Other|Control for Attention Intervention|
174811|NCT01886911|Other|Control for Prosocial Intervention|
174812|NCT01886924|Behavioral|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
174813|NCT01886924|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
174814|NCT01886937|Drug|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
174815|NCT01886937|Drug|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
174207|NCT00109824|Drug|decitabine|Given IV
174208|NCT01893541|Device|a multiband ligation device|
174209|NCT01893554|Biological|RSV ΔNS2 Δ1313 I1314L Vaccine|For participants in Groups 1 and 3: 10^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
For participants in Group 2: 10^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
174210|NCT01893554|Biological|Placebo (1x Leibovitz L-15 medium)|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
174211|NCT01893567|Drug|Clobex Spray|
174212|NCT01896024|Behavioral|Psychiatric Management|
174213|NCT01896024|Behavioral|Motive-oriented therapeutic relationship/Plan Analysis|
174214|NCT01896037|Dietary Supplement|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
174215|NCT01896063|Procedure|Electroacupuncture|
174216|NCT01896076|Other|ultrasound evaluation of caudal space|After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.
First, investigators place the transducer at the sacral cornua to obtain a transverse view.
In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block.
174217|NCT01896102|Genetic|Lenti-D Drug Product|Autologous CD34+ hematopoietic stem cells (HSCs) transduced with the lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D, member 1 (ABCD1) cDNA suspended in CryoStor® CS5 (BioLife® Solutions) cryopreservative solution containing 5% dimethyl sulfoxide (DMSO).
174218|NCT01896102|Drug|Busulfan|
174219|NCT01896102|Drug|Cyclophosphamide|
174220|NCT01896102|Drug|Filgrastim|
174527|NCT01891643|Drug|Dexamethasone|
174528|NCT01891643|Biological|Elotuzumab|
174529|NCT01891656|Behavioral|Motivational Interviewing|MI is a "client centered, directive style of interacting with a person to help explore and resolve ambivalence about change" (Miller & Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment.
173904|NCT01900509|Drug|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
173905|NCT01900509|Drug|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
173906|NCT01900522|Drug|ITI-214 Dose A|ITI-214 Dose A Oral Solution
173907|NCT01900522|Drug|ITI-214 Dose B|ITI-214 Oral Solution Dose B
173908|NCT00110162|Drug|antiandrogen therapy|
173909|NCT01900522|Drug|ITI-214 Dose C|ITI-214 Dose C Oral Solution
173910|NCT01900522|Drug|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
173911|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
173912|NCT01900522|Drug|ITI-214 Dose E|ITI-214 Dose E Oral Solution
173913|NCT01900522|Drug|ITI-214 Dose F|ITI-214 Dose F Oral Solution
173914|NCT01900522|Drug|ITI-214 Dose G|ITI-214 Dose G Oral Solution
173915|NCT01900522|Drug|ITI-214 Dose H|ITI-214 Dose H Oral Solution
173916|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
173917|NCT01900548|Dietary Supplement|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
173918|NCT01900548|Dietary Supplement|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
173919|NCT00110162|Drug|releasing hormone agonist therapy|
173920|NCT01900548|Dietary Supplement|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
173921|NCT01900548|Other|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
173922|NCT01902719|Behavioral|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
173923|NCT01902732|Device|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
178374|NCT01903096|Drug|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
173589|NCT01897402|Biological|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
173590|NCT01897402|Biological|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
173591|NCT01897415|Biological|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
173592|NCT01897428|Drug|Test-Bepotastine salicylate 9.64 mg|
173593|NCT01897428|Drug|Reference-bepotastine besilate 10 mg|
173594|NCT01897441|Drug|Cyclophosphamide|Given IV
173595|NCT00110019|Drug|Carboplatin|Given IV
173596|NCT01897441|Other|Cytology Specimen Collection Procedure|Correlative studies
173597|NCT01897441|Drug|Doxorubicin Hydrochloride|Given IV
173598|NCT01897441|Other|Laboratory Biomarker Analysis|Correlative studies
173599|NCT01897441|Drug|Paclitaxel|Given IV
173600|NCT01897441|Biological|Trastuzumab|Given IV
173601|NCT01897454|Drug|Fluorouracil|Given IV
173602|NCT01897454|Drug|Gemcitabine Hydrochloride|Given IV
173603|NCT01897454|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
173604|NCT01897454|Drug|Irinotecan Hydrochloride|Given IV
173605|NCT01897454|Drug|Leucovorin Calcium|Given IV
173606|NCT00110019|Other|Laboratory Biomarker Analysis|Correlative studies
173607|NCT01897454|Drug|Oxaliplatin|Given IV
173608|NCT01897467|Behavioral|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
178055|NCT01910142|Dietary Supplement|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
178056|NCT01910142|Dietary Supplement|calcium|
178057|NCT00111215|Drug|Tranexamic Acid|
178058|NCT01912339|Device|Rezum System|The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.
A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.
A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.
Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death.
178375|NCT01905618|Behavioral|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
178376|NCT01905618|Behavioral|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
178377|NCT01905618|Behavioral|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
178378|NCT00002084|Drug|Valacyclovir hydrochloride|
178379|NCT00110721|Drug|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
178380|NCT01905644|Procedure|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
178381|NCT01905657|Biological|pembrolizumab|Participants who experience disease progression on docetaxel may be eligible to crossover to receive pembrolizumab.
178382|NCT01905657|Drug|docetaxel|Participants who initially receive docetaxel may be eligible to crossover to receive pembrolizumab.
178383|NCT01905670|Device|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
177752|NCT01907191|Drug|liposomal bupivacaine|(Ultrasound guided injection of liposomal bupivacaine)
177753|NCT01907191|Drug|Bupivacaine|(around the anterior, lateral and medial aspect of hip joint)
177754|NCT01907204|Drug|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
177755|NCT01907204|Drug|Budesonide|Budesonide by metered dose inhaler
177756|NCT01907204|Drug|Budesonide|Budesonide by nebulization
177757|NCT01907217|Device|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
177758|NCT01907217|Drug|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
177759|NCT01907217|Drug|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
177760|NCT01907230|Drug|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
177761|NCT01907243|Procedure|spreader flap|producing of upper lateral cartilage flap as a spreader flap
177762|NCT00110864|Drug|Insulin|
177763|NCT01907256|Procedure|inverted V incision|It is a type of incision
177764|NCT01907256|Procedure|stair step incisions|It is a type of incision
178059|NCT01912339|Procedure|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
178060|NCT01912352|Drug|Methylphenidate|
178061|NCT01912365|Procedure|Above Elbow Cast|
178062|NCT01912365|Procedure|Long Arm Splint|
178063|NCT01912378|Drug|Oxytocin|
178064|NCT01912391|Drug|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
161923|NCT01871584|Device|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
161924|NCT01871597|Device|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
161925|NCT01871610|Drug|[18F]AV-45 PET amyloid binding imaging|
161926|NCT01871623|Procedure|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
161927|NCT00107510|Biological|pegfilgrastim|
161928|NCT01871623|Procedure|One-piece Le Fort I Osteotomy|conventional approach
161929|NCT01871636|Procedure|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
161930|NCT01871636|Procedure|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
161931|NCT01863797|Other|Early induction|
161932|NCT01863797|Other|Expectant mamagement|
161933|NCT01863810|Drug|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
161934|NCT01863810|Drug|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
161935|NCT01863810|Drug|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
161936|NCT01863810|Drug|Placebo of KW21052|Oral,once a day, for 8 weeks
162257|NCT01866774|Other|Fecal calprotectin level|
162258|NCT01866800|Device|Renal Guard|Renal Guard
162259|NCT01866800|Drug|Conventional Treatment|Saline and N-acetylcysteine
162260|NCT01866813|Behavioral|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
162261|NCT01866826|Drug|Rifaximin/ Placebo|subject will receive either three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily) or will receive three capsules of placebo by mouth twice daily.
178131|NCT01910220|Other|placebo|
178132|NCT01910246|Drug|Metformin|
178133|NCT01910259|Drug|Amiloride|Comparison with placebo
178134|NCT01910259|Drug|Riluzole|Comparison with placebo
178135|NCT00000299|Drug|Buprenorphine|
178136|NCT00002087|Drug|Alvircept sudotox|
178137|NCT00111215|Drug|Desmopressin Acetate|
178138|NCT01910259|Drug|Fluoxetine|Comparison with placebo
178139|NCT01910259|Drug|Placebo|Placebo comparator
178140|NCT01910272|Device|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
178141|NCT01910285|Drug|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
178142|NCT01910285|Drug|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
178441|NCT01903226|Other|Moderate intensity training|
178442|NCT00110422|Drug|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
178443|NCT01903239|Procedure|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
178444|NCT01903252|Drug|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
178445|NCT01903252|Drug|Asacol|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
178446|NCT01903265|Drug|TNX-102 SL 2.8mg Tablets|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
178447|NCT01903265|Drug|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
178448|NCT01903278|Drug|PEG-IFN-SA /RBV|
178449|NCT01903278|Drug|Pegasys /RBV|
177839|NCT01904747|Drug|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
177840|NCT01904760|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
177841|NCT01904760|Drug|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
177842|NCT01904773|Drug|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
177843|NCT00002083|Drug|Peptide T|
177844|NCT00110604|Behavioral|folic acid (0.8 mg)|
177845|NCT01904786|Drug|Melatonin|
177846|NCT01907282|Behavioral|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
177847|NCT01907308|Drug|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
177848|NCT01907308|Drug|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
177849|NCT01907321|Behavioral|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
177850|NCT01907321|Behavioral|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
177851|NCT01907321|Drug|Measures perfomed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
177852|NCT00110877|Drug|LPV/rtv|One 400mg LPV tablet twice daily with 100mg RTV
177853|NCT01907321|Behavioral|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
178143|NCT01910298|Procedure|Breast reconstruction, direct to implant with Strattice|
178144|NCT01910298|Procedure|Two stage breast reconstruction|
178145|NCT01910311|Drug|Baricitinib|Administered orally
178146|NCT01910311|Drug|Rifampicin|Administered orally
177219|NCT01916109|Drug|Carboplatin|
177220|NCT01916109|Drug|Panitumumab|
177516|NCT01911585|Behavioral|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
177517|NCT01911598|Drug|5-FU|1000 milligrams per meter square per day (mg/m^2/day) as a continuos IV infusion over Days 1-4 every 3 weeks, up to 6 cycles.
177518|NCT01911598|Drug|Carboplatin|Carboplatin 6 AUC administered by IV infusion at 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 every 3 weeks, up to 6 cycles
177519|NCT01911598|Drug|Cisplatin|100 mg/m^2 IV Day 1 every 3 weeks, up to 6 cycles
177520|NCT00111410|Drug|Anakinra (r-metHuIL-1ra)|
177521|NCT01911598|Drug|MEHD7945A|1650 mg by IV infusion on Day 1 every 3 weeks
177522|NCT01911598|Drug|Paclitaxel|200 mg/m^2 IV Day 1 every 3 weeks, up to 6 cycles.
177523|NCT01911611|Drug|RO6870868|Single ascending doses
177524|NCT01911611|Drug|placebo|Single ascending doses
177525|NCT01911624|Drug|direct thrombin inhibition|
177526|NCT01911624|Drug|enoxaparin|
177527|NCT01911637|Drug|VBY-036|Study drug VBY-036
177528|NCT01911637|Drug|Placebo|Placebo
177529|NCT01904136|Drug|Tacrolimus|0.015 mg /kg by vein daily starting on Day +5 and continued by mouth for at least 4 months post transplant.
177530|NCT01904136|Drug|Mycophenolate mofetil|15 mg/kg by mouth starting on Day +5.
177531|NCT01904136|Drug|G-CSF|5 mcg/kg/day subcutaneously once a day daily starting on Day +7 until neutrophil recovery.
177532|NCT01904136|Radiation|Total Body Irradiation (TBI)|All patients receive TBI 200 cGy administrated on Day -3.
177533|NCT01904149|Drug|Placebo|Placebo single oral dose (first 8 hours)
177534|NCT01904149|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
177535|NCT01904149|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
176915|NCT01912885|Device|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
176916|NCT00111605|Biological|HIV-1 gag DNA|A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
176917|NCT01912885|Device|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
176918|NCT01912898|Device|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
176919|NCT01912924|Device|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
176920|NCT01912937|Device|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
176921|NCT01912950|Device|Prowave LX IPL|
177221|NCT01916109|Procedure|radical cystectomy|
177222|NCT00111852|Drug|Placebo|Dose-Match Placebo, intravenous administration.
177223|NCT01916122|Drug|Fluorestradiol (FES)|
177224|NCT01916122|Procedure|PET/CT Imaging|
177225|NCT01916135|Radiation|[18F]-SKI-249380|
177226|NCT01916135|Procedure|PET/CT scan|
177227|NCT01916135|Other|Blood draws|
177228|NCT01916148|Drug|18F-DOPA|18F-DOPA is a PET scan radiotracer.
177229|NCT01916161|Other|Questionnaire|
177230|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
177231|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
177232|NCT01916187|Drug|Imetelstat|
177233|NCT00111865|Behavioral|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
176646|NCT01917539|Device|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
176647|NCT01917539|Device|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
176648|NCT01917552|Drug|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
176649|NCT01917578|Device|Ultrasound|Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.
Measurement of tumor size refers to WHO standards.
176650|NCT01917578|Procedure|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
176651|NCT00112047|Drug|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
176652|NCT01917578|Procedure|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
176653|NCT01919632|Behavioral|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
176654|NCT01919645|Other|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
176655|NCT01919658|Procedure|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
176656|NCT01919671|Drug|Tongxinluo capsule|for 90 days
176657|NCT01919671|Drug|placebo capsule|for 90 days
176658|NCT00112229|Biological|group 2|Melan-A natural peptide + CpG + Montanide
176659|NCT01919684|Drug|LGD-6972|
176660|NCT01919684|Drug|Placebo (Captisol®)|
176661|NCT01919697|Drug|Plecanatide|
176038|NCT01918566|Dietary Supplement|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
176039|NCT01918566|Dietary Supplement|300ml tap water with 450ppm lactisole|
176040|NCT01918579|Procedure|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
176041|NCT01918592|Device|MRI/acetate-PET imaging|
176339|NCT01914432|Drug|Rosuvastatin|
176340|NCT01914432|Drug|Telmisartan|
176341|NCT01914432|Drug|YH16410 placebo|
176342|NCT00111722|Drug|Comparator: placebo / Duration of Treatment - 1 day|
176343|NCT01914432|Drug|Rosuvastatin placebo|
176344|NCT01914432|Drug|Telmisartan placebo|
176345|NCT01914445|Drug|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
176346|NCT01914458|Procedure|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
176347|NCT01914471|Behavioral|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
176348|NCT01914484|Drug|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
176349|NCT01914484|Drug|Ruxolitinib|In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).
No intra-patient dose-escalation will occur. JAK inhibitor
176350|NCT01914510|Drug|ENMD-2076|
176351|NCT01914523|Device|Macintosh|Laryngeal exposure and tracheal intubation using that device
176352|NCT01914523|Device|King Vision|Laryngeal exposure and tracheal intubation using that device
176353|NCT00111735|Drug|Thyroxine|
176354|NCT01914523|Device|Glidescope|Laryngeal exposure and tracheal intubation using that device
176355|NCT01914523|Device|AirTraq|Laryngeal exposure and tracheal intubation using that device
175694|NCT01886170|Other|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
175695|NCT01886183|Other|Virtual Reality Training|The participants of the study will be trained 10 balance games during 14 sessions
175696|NCT01886183|Other|Physical Therapy|Patients of the control group will be trained with balance exercises.
175697|NCT01886196|Drug|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
175698|NCT01886196|Other|placebo|placebo designed to mimic experimental drug (ibuprofen)
175699|NCT01886196|Behavioral|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
175700|NCT01888432|Drug|Standard tacrolimus|Tacrolimus will be initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should be 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
175701|NCT01888445|Drug|ASP1517|oral
175702|NCT00109265|Drug|Erlotinib HCl (OSI-774)|
175703|NCT01888445|Drug|darbepoetin alfa|iv
175704|NCT01888458|Drug|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
176042|NCT01918605|Device|Diluted spacer|
176043|NCT01918605|Device|Non-diluted spacer|
176044|NCT01918631|Drug|tenofovir disoproxil fumarate|
176045|NCT00112320|Procedure|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
176046|NCT01921010|Drug|Placebo|See Arm Description
176047|NCT01921036|Procedure|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
176048|NCT01921036|Procedure|combined exercise|Moderate endurance and resistance exercise once a week over six months
176049|NCT01921062|Behavioral|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
175705|NCT01888484|Biological|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
175706|NCT01888497|Drug|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
175707|NCT01888497|Drug|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
175708|NCT01888497|Drug|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
175709|NCT01888497|Drug|Placebo|Oral, prior to bedtime on the night before performance testing
175710|NCT01888510|Procedure|computed tomography|Undergo conventional free breathing CT
175711|NCT01888510|Procedure|4-dimensional computed tomography|Undergo 4D CT
175712|NCT01888510|Procedure|computed tomography|Undergo ABC CT
175713|NCT00109278|Biological|V205C, measles, mumps, and rubella virus vaccine live|
175714|NCT01888510|Procedure|cone-beam computed tomography|Undergo ABC CBCT
175715|NCT01888510|Procedure|cone-beam computed tomography|Undergo free breathing CBCT
175716|NCT01888523|Behavioral|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
175717|NCT01888523|Behavioral|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
175718|NCT01888536|Drug|Limaprost|
175719|NCT01888536|Drug|Pregabalin|
175720|NCT01888536|Drug|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
175721|NCT01888536|Drug|Placebo(for Limaprost)|mimic Limaprost tablet
175722|NCT01888549|Drug|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
175723|NCT01888549|Drug|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
175724|NCT00109278|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
175725|NCT01888549|Drug|placebo|
175726|NCT01888562|Drug|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
175112|NCT01890135|Drug|placebo|randomized double blind
175113|NCT01890148|Drug|AZD5069|oral BD administration of 45 mg AZD5069
175114|NCT00109473|Drug|growth hormone|Nutropin AQ 0.075mg/kg/day subcutaneously daily
175115|NCT01890161|Drug|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
175116|NCT01890161|Drug|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
175117|NCT01890200|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
175416|NCT01885598|Drug|Apixaban|
175417|NCT01885611|Other|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
175418|NCT01885611|Dietary Supplement|Virgin Coconut Oil|cold-processed VCO
175419|NCT01885624|Biological|TAB08|monoclonal antibody
175420|NCT01885637|Other|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
175421|NCT01885650|Other|Airway Clearance Techniques|
175422|NCT00108810|Drug|Placebo transdermal patch|12 hours application for 28 days
175423|NCT01885663|Procedure|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
175424|NCT01885676|Device|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
175425|NCT01885676|Other|Saline Solution|Saline Solution mesotherapy micro injection
175426|NCT01885689|Drug|clofarabine|Given IV
175427|NCT01885689|Drug|melphalan|Given IV
175428|NCT01885689|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
175429|NCT01885689|Drug|tacrolimus|Given IV or PO
175430|NCT01885689|Drug|sirolimus|Given PO
175431|NCT01885702|Biological|DC vaccination|DC vaccination
174816|NCT01886963|Procedure|Ventral Hernia Repair with Advancement Flaps with Unblinded Use of Spy Elite (Experimental)|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
174817|NCT00109031|Drug|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
174818|NCT01886963|Procedure|Ventral Hernia Repair with Advancement Flaps with Blinded Use of Spy Elite (Control)|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
174819|NCT01886976|Biological|CART-138 cells|
174820|NCT01886989|Dietary Supplement|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
174821|NCT01887002|Drug|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
174822|NCT01887002|Drug|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
174823|NCT01887015|Device|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
174824|NCT01887028|Device|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
174825|NCT01887041|Procedure|Stent|Endoscopically inserted biliary tract drainage
175118|NCT01890200|Drug|Ribavirin|conventional treatment of Hepatitis C
175119|NCT01890200|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
175120|NCT01890200|Drug|Placebo|Placebo, without acting ingredient.
175121|NCT01890213|Biological|AVX701|
175122|NCT01890226|Behavioral|Mobile Personal Health Record App.|
175123|NCT01892306|Drug|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
175124|NCT01892319|Drug|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
175125|NCT01892319|Drug|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
175126|NCT01892332|Drug|epidural block with lidocaine and fentanyl|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.
Conversely, block success resulted in a reduction in concentration by 0.1%.
174530|NCT01891656|Behavioral|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere & Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman & Massey, 2008). As discussed by Hester & Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
174531|NCT01891669|Drug|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
174532|NCT01891669|Drug|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
174533|NCT01891682|Other|Observational|Observational, Translational non-treatment study
174534|NCT00109616|Behavioral|Cleansing of umbilical cord with soap and water solution|
174535|NCT01891695|Radiation|39.6 Gy radiation|
174536|NCT01883895|Other|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator immediately before and after the exercise.
174537|NCT01883895|Other|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator immediately before and after the exercise.
174538|NCT01883908|Device|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
174539|NCT01883908|Other|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
174540|NCT01883921|Other|Immunoglobulin Therapy|
174541|NCT01883934|Other|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
174542|NCT01883934|Other|Control|
174826|NCT01887041|Procedure|Biliodigestive anastomosis|Biliodigestive anastomosis
174827|NCT01887054|Device|Tower of Hanoi|
174828|NCT00109031|Drug|Placebo|Administered as one daily intravenous bolus.
174829|NCT01887054|Other|Placebo group - non use of Tower of Hanoi|
174830|NCT01887067|Procedure|Renal denervation therapy|
174221|NCT00109928|Drug|gemcitabine|
174222|NCT01896115|Device|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
174223|NCT01896128|Drug|Armodafinil|
174224|NCT01896128|Drug|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
174225|NCT01896154|Dietary Supplement|NPS|Comparison of multiple dietary non-digestible polysaccharides
174226|NCT01896167|Other|Hypoxia|Inhalation of hypoxic air (8-12% oxygen content)
174227|NCT01896167|Other|Placebo|Inhalation of atmospheric air
174228|NCT01896180|Drug|ALZ-1101|ALZ-1101 Ophthalmic Solution
174229|NCT01896180|Drug|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
174230|NCT01896193|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
174231|NCT01896193|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
174232|NCT00109928|Drug|methylprednisolone|
174233|NCT01896206|Device|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
174234|NCT01896219|Device|Navigation station (IMACTIS-CT®)|
174235|NCT01896219|Device|CT|Reference method for gestures (carried out under CT) guidance
174236|NCT01896232|Drug|AMG 416|AMG 416 IV thrice-weekly
174237|NCT01896232|Drug|cinacalcet|Cinacalcet oral once-daily
174238|NCT01896232|Drug|Placebo|Placebo tablet oral once daily
174239|NCT01898468|Procedure|Intracostal Closure Technique|
174240|NCT01898494|Procedure|therapeutic conventional surgery|Undergo transoral surgical resection
174241|NCT00110058|Drug|fludarabine phosphate|
174242|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo low-dose IMRT
174243|NCT01898494|Drug|cisplatin|Given IV
173609|NCT01897467|Behavioral|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
173610|NCT01899924|Behavioral|Event Related Potentials recording|
173611|NCT01899976|Device|X-Suit NIR Covered Biliary Stent|
173612|NCT01899989|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
173924|NCT01902745|Behavioral|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
173925|NCT01902758|Drug|ambrisentan and theophylline|
173926|NCT01902758|Drug|placebo|placebo for comparison group
173927|NCT01902771|Biological|Dendritic Cell Vaccine|Subjects will begin to receive DC vaccination alone, when recovered from pheresis and continue weekly for a total of four vaccinations. The vaccination with loaded DC will be given in the clinic as an intradermal injection in the upper arms. DC will be delivered with each vaccination in 6 separate syringes (3 syringe injections per arm within the area of approximately the size of a silver dollar spaced approximately equally) alternating between anterior and posterior deltoid. For subjects who are missing limbs (e.g., arms), the injection sites will be rotated between the arms and thighs (alternating anterior and lateral thigh) with anterior and posterior deltoid. For subjects who do not have an accessible deltoid, both legs will be used. All injections with DC or lysate will be done after topical treatment with imiquimod to the site of injection the day prior to injection, which will then be applied for two nights after the injection to the sites.
173928|NCT01902771|Biological|Tumor Lysate|After completion of DC vaccination course, lysate of tumor will be administered during weeks 8, 12, 16, and 28. Lysate dose will be 1.5 mg of tumor lysate, divided into 4 equal doses. All lysate will be injected into one (1) arm intradermally in alternating arms/thigh as above within an area of approximately the size of a silver dollar spaced approximately equally. Lysate will be injected from one syringe for each administration. Clinical examination after study treatment ends will be required every three (3) months +/- 14 days
173929|NCT01902771|Other|Imiquimod|Subjects will self-apply imiquimod one night before and each night for two nights after the scheduled administration of DC or lysate. Investigator will instruct the subject to apply a thin layer of imiquimod on the selected area (approximately the area of a silver dollar) of both arms,or thigh. Subjects are advised to rinse the selected area with water (where imiquimod is applied) the morning after application. Subjects will be given a medication diary when supplied with imiquimod in which they will record both the time of application of the imiquimod, and the time of rinse of the imiquimod. The DC and lysate are to be injected in the clinic by the PI or his designee. Subjects will be evaluated 24 hours, and whenever possible, 48 hours after injection for administration site reactions and delayed type hypersensitivity reactions (DTH).
173930|NCT00110370|Drug|Glargine Basal-Bolus Therapy|
173931|NCT01902771|Procedure|Punch Biopsy of the Skin|This procedure is optional
173932|NCT01902771|Procedure|Leukapheresis|Patients enrolled in the study will undergo a leukapheresis procedure performed to collect peripheral blood mononuclear cells. Leukapheresis will be performed using a continuous flow blood cell separator (COBE Spectra, Caridian BCT, Lakewood, CO). This instrument relies on density gradient centrifugation to collect mononuclear cells from the apheresis patients. Leukapheresis is typically performed through a central venous catheter (a catheter inserted into one of the larger veins in the body) or through a peripheral intravenous catheter that may be placed the day of the procedure. An anticoagulant is added to circulate blood to prevent clotting during the procedure. In this study, leukapheresis will be performed to collect 1.5 x 10^09 mononuclear cells. Each procedure may take 3-5 hours.
178384|NCT01905683|Drug|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
178385|NCT01905696|Drug|Oral N-acetylcysteine|
178386|NCT01905709|Biological|Human fecal matter|
178387|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
178388|NCT01905722|Other|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
178389|NCT01905735|Drug|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
178390|NCT00110734|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
178391|NCT01905735|Drug|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
173613|NCT01899989|Drug|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
173614|NCT01900002|Drug|Sorafenib|Starting dose of sorafenib: 400 mg by mouth 2 times a day starting on Day 1 of Cycle 1, 4 weeks before starting TheraSphere treatment
173615|NCT01900002|Radiation|Yttrium-90 Microspheres|After 4 weeks (+/- 1 week) of sorafenib therapy, Y-90 procedure performed. TheraSphere is administered via infusion under imaging guidance through an hepatic arterial catheter appropriately positioned in the arterial anatomy to permit selective infusion of TheraSphere into the target tissue selected for treatment.
173616|NCT01900002|Behavioral|Follow-Up Phone Calls|After completion of End-of-Treatment visit, study staff will contact patient by phone every 3 months. Each follow-up phone call should last about 15-30 minutes.
173617|NCT00110110|Procedure|laser therapy|Local and precise application of laser beams to destroy residual tumor.
173618|NCT01900015|Drug|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
173619|NCT01900015|Drug|Efavirenz|
173620|NCT01900028|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
173621|NCT01900028|Drug|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
173622|NCT01900028|Drug|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
178065|NCT01912391|Drug|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
178066|NCT01912404|Drug|IDN-6556|25 mg BID for 28 days
178067|NCT00002090|Drug|Azithromycin|
178068|NCT00111527|Other|normal RV pacing|PM or ICD implant according to patient indication
178069|NCT01912404|Drug|Placebo|Placebo controlled
178070|NCT01912417|Other|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
178071|NCT01912430|Behavioral|ICC (Integrated Care Coaching) Intervention Group|
178072|NCT01912443|Drug|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
178073|NCT01912456|Biological|Low-volume C1-esterase inhibitor|
178074|NCT01912456|Biological|Higher-volume C1-esterase inhibitor|
178075|NCT01912456|Biological|Low-volume placebo|
178076|NCT01912456|Biological|Higher-volume placebo|
178077|NCT01912469|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
178078|NCT01912469|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
178079|NCT00111540|Drug|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
178080|NCT01905150|Drug|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
178392|NCT01905748|Other|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
178393|NCT01905774|Drug|Deferasirox|
178394|NCT00110968|Drug|Itopride hydrochloride|
162262|NCT00107120|Drug|Placebo|Placebo once daily for up to 8 weeks
162263|NCT01866839|Device|Graft Manipulation (CD34+ Selection)|
162264|NCT01866878|Device|equipment rehabilitation stereognosis|
162265|NCT01866878|Device|TENS|
162266|NCT01866891|Other|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
162267|NCT01866917|Drug|Ropivacaine 0.5% 20cc injectate bilaterally|
162268|NCT01866930|Biological|Pegylated Interferon Lambda-1a|
162269|NCT01866930|Drug|Daclatasvir (DCV)|
162270|NCT01866930|Drug|Ribasphere (RBV)|
162271|NCT01866943|Drug|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
162272|NCT01866943|Drug|Normal Saline Solution|
162273|NCT00107159|Biological|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
162274|NCT01866969|Other|questionnaire administration|Ancillary studies
162275|NCT01866969|Procedure|quality-of-life assessment|Ancillary studies
162276|NCT01866982|Procedure|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
162277|NCT01866982|Procedure|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
162278|NCT01869387|Device|Non-invasive ventilation|
162570|NCT01862315|Drug|Gemcitabine|
162571|NCT01862315|Drug|Oxaliplatin|
162572|NCT01862315|Other|MRI|
162573|NCT01862315|Other|Research blood draws|
162574|NCT01862328|Drug|MLN4924 and Docetaxel|MLN4924 (IV) and Docetaxel (IV) in patients to determine maximum tolerated dose (MTD) on a 21-day cycle:
MLN4924 on Days 1,3,5 of each cycle
Docetaxel on Day 1 of each cycle
On Day 1 of each cycle, patients receive both agents
178450|NCT01903291|Drug|dimethyl fumarate|As described in the treatment arm
178451|NCT01903304|Other|Olive Oil|3 months intervention
178452|NCT01903317|Other|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
178453|NCT00002081|Drug|Zalcitabine|
178454|NCT00110435|Drug|MK0653A, ezetimibe (+) simvastatin|
178455|NCT01905800|Device|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
178456|NCT01905813|Drug|INCB040093|Escalating doses starting at 100 mg every day (QD)
178457|NCT01905813|Drug|INCB040093|INCB040093 monotherapy - dose to be determined at completion of Phase I of the study
178458|NCT01905813|Drug|INCB040093 + INCB039110|INCB040093 dose to be determined at completion of Part 1 of the study + INCB039110 at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
178459|NCT01905878|Drug|DLBS1033|
178460|NCT01905891|Procedure|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
173689|NCT01897597|Drug|BI 144807 intermediate dose|tablet
173690|NCT01897597|Drug|BI 144807 intermediate dose|tablet
173691|NCT01897597|Drug|BI 144807 intermediate dose|tablet
173692|NCT00110019|Other|Pharmacological Study|Correlative studies
173693|NCT01897597|Drug|BI 144807 intermediate dose|tablet
173694|NCT01897597|Drug|BI 144807 intermediate dose|oral solution
173695|NCT01897597|Drug|BI 144807 high dose|tablet
173696|NCT01897610|Drug|Immuncell-LC|intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour
173697|NCT01897623|Other|ultrasound of aorta|
178147|NCT01910324|Behavioral|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
178148|NCT00111228|Device|Guardian RT|
178149|NCT01910324|Behavioral|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
178150|NCT01910337|Device|Use the Polar Cardiac rate meter|
178151|NCT01910350|Behavioral|Kin KeeperSM Cancer Prevention Intervention|
178152|NCT01910350|Other|Standard of care|
178153|NCT01912625|Other|Pharmacological Study|Correlative studies
178154|NCT01912625|Drug|Trametinib|Given PO
178155|NCT01912638|Device|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
178156|NCT01912638|Drug|Mitomycin C (MMC) and Provisc|Mitomycin C is an adjunctive anti-fibrotic agent. Provisc is an cohesive viscoelastic.
178157|NCT01912651|Drug|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
178158|NCT01912664|Other|Mobile phone application|
178159|NCT01912664|Behavioral|Coach support|
178160|NCT00111579|Biological|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
178161|NCT01912664|Behavioral|Network Peer Support|
178162|NCT01912677|Drug|Nifedipine|
178163|NCT01912677|Drug|Labetalol|
178461|NCT01905904|Drug|sevorane|Sevorane 4% Sevorane 7%
177536|NCT00110513|Biological|Recombinant human antithrombin (rhAT)|Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is > 80% and < 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at > 80% and < 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
177854|NCT01907321|Radiation|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
177855|NCT01907334|Drug|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
177856|NCT01907334|Drug|Flovent Diskus 100 µg|Flovent Diskus 100 µg
177857|NCT01907334|Drug|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
177858|NCT01907334|Drug|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
177859|NCT01907360|Drug|HLD200 (B formulation)|
177860|NCT01907360|Drug|HLD200 (C formulation)|
177861|NCT01907373|Drug|olmesartan medoxomil|
177862|NCT01907373|Drug|olmesartan medoxomil+probenecid|
177863|NCT00002085|Drug|Azithromycin|
177864|NCT00110877|Drug|TMC114/rtv|Two 300mg TMC114 tablets twice daily with 100mg RTV
177865|NCT01907386|Other|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
177866|NCT01907399|Other|Blood samples|
177867|NCT01909752|Drug|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
177868|NCT01909752|Drug|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
177869|NCT01909752|Biological|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
177234|NCT01916200|Drug|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
177235|NCT01916213|Procedure|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
177236|NCT01916226|Drug|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
177237|NCT00112112|Biological|FluMist|The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.
177537|NCT01904149|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
177538|NCT01904149|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
177539|NCT01904149|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
177540|NCT01904149|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
177541|NCT01904162|Drug|400 mg finafloxacin (2 x 200 mg tablets)|
177542|NCT01904188|Device|Gene Z|The Gene Z device will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
177543|NCT01904214|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
177544|NCT01904227|Behavioral|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
176922|NCT01912963|Drug|Pertuzumab, Trastuzumab and Eribulin|Each study treatment cycle lasts 21 days. The patient will receive eribulin on the first day (day 1) and on the 8th day (day 8) of the cycle. The patient will also receive trastuzumab and pertuzumab on day 1. All drugs will be given to intravenously in clinic.
In the first portion of the study, we will examine which dose of eribulin is the safest when given in combination with pertuzumab and trastuzumab. For the first 6 participants enrolled onto the study, we will be look to see if the standard dose of eribulin can be administered safely with standard doses pertuzumab and trastuzumab. If this dose of eribulin is not tolerated well, we will test the three-medication combination with a lower dose of eribulin. The highest dose that will be found to be safe will be used in the next participants. The dose you receive will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.
176923|NCT01912976|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
176924|NCT01912976|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
176925|NCT01912989|Behavioral|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
176926|NCT01913002|Drug|LX4211 800 mg|
176927|NCT00111605|Biological|HIV-1 gag DNA plus IL-12 DNA adjuvant|Injection IL-12 DNA adjuvant intramuscularly into the deltoid
176928|NCT01913002|Drug|LX4211 2000 mg|
176929|NCT01913002|Drug|moxifloxacin 400 mg|
176930|NCT01913002|Drug|LX4211 Placebo|
176931|NCT01915485|Radiation|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
176932|NCT01915498|Drug|AG-221|AG-221 administered orally on every day of 28 day cycles until disease progression or unacceptable toxicities. Multiple doses.
176933|NCT01915524|Biological|CV9202|Intradermal injection of CV9202
176934|NCT01915524|Radiation|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
176935|NCT00111813|Drug|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
176936|NCT01915537|Drug|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
176356|NCT01914562|Drug|OCA 10 mg|OCA 10 mg tablet oral
176357|NCT01914562|Drug|OCA 25 mg|OCA 25 mg tablet oral
176358|NCT01914588|Procedure|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
176359|NCT01914588|Other|Standard care|Detailed instruction about medical therapy and lifestyle counseling
Telephonic support by a geriatrician, available from Monday to Friday, two hours/day
Follow-up visits
176360|NCT01914601|Device|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
176361|NCT01916902|Drug|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
176662|NCT01919710|Drug|rHSA/GCSF|for treatment of neutropenia
176663|NCT01919723|Drug|ticagrelor|ticagrelor loading dose
176664|NCT01919723|Drug|Eptifibatide|i.v. infusion
176665|NCT01919736|Behavioral|Gait Retraining|
176666|NCT01919749|Other|treated recommended|Treatment will be recommended after reviewing the profiling analysis
176667|NCT01919788|Drug|Insulin (Insuman Rapid)|
176668|NCT01919788|Drug|Glucose|
176669|NCT00112229|Biological|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
176670|NCT01919788|Other|Saline|
176671|NCT01919801|Drug|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
176672|NCT01919801|Drug|Placebo|
176673|NCT01919814|Dietary Supplement|Appethyl™|• Four hours after breakfast you will be given a small amount of liquid to drink that will contain Appethyl™. You will not know which you are getting and it will be decided randomly, like flipping a coin. You will be presented with a pizza in a quantity more than you could reasonably be expected to eat 5 hours after the start of your lunch meal and be asked to eat to your satisfaction over 30 minutes. You are not expected to eat all of the pizza.
176674|NCT01919814|Other|Placebo|• Four hours after breakfast you will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). You will not know which you are getting and it will be decided randomly, like flipping a coin. You will be presented with a pizza in a quantity more than you could reasonably be expected to eat 5 hours after the start of your lunch meal and be asked to eat to your satisfaction over 30 minutes. You are not expected to eat all of the pizza.
176050|NCT01921075|Other|normal dietary behavior|normal dietary behavior during examination days
176051|NCT01921075|Other|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
176052|NCT01921088|Other|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
176053|NCT01921088|Behavioral|Ambulatory Training|Subjects are provided with an ambulatory training.
176054|NCT01921101|Behavioral|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
176055|NCT01921101|Other|control|participants will receive standard care for nutrition received from hospital admission to discharge
176056|NCT00112333|Procedure|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
176057|NCT01921114|Device|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
176058|NCT01921114|Device|Bard® Dual-Lumen PowerPICC SOLO2®|
176059|NCT01921140|Drug|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
176060|NCT01921140|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
176061|NCT01921140|Other|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
176062|NCT01921140|Other|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
176063|NCT01921153|Other|Healthy meal plates and trays|The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
176362|NCT01916902|Drug|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
176363|NCT00111969|Device|Celacade™ system|
176364|NCT01916902|Procedure|Optical Coherence Tomography|
176365|NCT01916915|Drug|Tramadol infusion via wound catheter|
176366|NCT01916915|Drug|Levobupivacaine|
176367|NCT01916941|Drug|Prazosin|
176368|NCT01916941|Drug|Placebo|
175727|NCT01891110|Procedure|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
176064|NCT01921166|Drug|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
176065|NCT01921166|Drug|Leuprolide flare|Leuprolide flare ovulation induction
176066|NCT01921179|Behavioral|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
176067|NCT00112346|Drug|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
176068|NCT00002092|Drug|Cimetidine|
176069|NCT00111670|Drug|DPP-IV Inhibitor|Escalating doses po bid or qd
176070|NCT01913899|Other|Mirror therapy|- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
176071|NCT01913912|Drug|LDX.|In this study 3 different doses of LDX will be used:
30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine
50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine
70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine
176072|NCT01913912|Drug|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
176073|NCT01913912|Device|computer task (Go/No-Go task)|
176074|NCT01913912|Device|EEG|event-related potentials (ERP) and heart rate measurements
176075|NCT01913912|Device|pupil size measurements (by using eye tracking)|
176076|NCT01913925|Other|Tyrosine-Containing Food Bar|
176077|NCT01913925|Other|Placebo Bar|
176078|NCT01913951|Drug|vosaroxin|Given IV over 10 minutes on Day 1 and 4
176079|NCT01913951|Drug|Azacitidine|Given SC or IV over 15 minutes on days 1-7
176080|NCT00111670|Drug|Placebo|po bid or qd
176081|NCT01913964|Drug|Acetylcarnitine|
175432|NCT01885715|Drug|Injection of neostigmine|At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms.
175433|NCT00108823|Drug|Roflumilast|
175434|NCT01885728|Dietary Supplement|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
175435|NCT01885741|Device|IPBS|
175436|NCT01885780|Device|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
175437|NCT01885793|Device|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
175728|NCT01891110|Procedure|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
175729|NCT01891123|Device|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
175730|NCT01891123|Drug|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
175731|NCT00109590|Drug|Didanosine, enteric-coated|once daily
175732|NCT01891136|Drug|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
175733|NCT01891175|Procedure|Elective caesarean section under spinal anaesthesia.|Patients with scheduled caesarean.
175734|NCT01891175|Procedure|Elective caesarean section under spinal anaesthesia.|
175735|NCT01891201|Drug|Oxytocin|Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
175736|NCT01891214|Other|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
175737|NCT01891227|Drug|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
175738|NCT01891227|Drug|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
175739|NCT01891253|Device|non-invasive determination of cardiac output|
175740|NCT01891266|Procedure|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
175127|NCT01892345|Drug|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every two weeks 6-104
Drug: Placebo Other Names: Placebo
175128|NCT01892358|Behavioral|SKIN Intervention|
175129|NCT01892358|Other|Treatment as Usual|
175130|NCT01892371|Drug|Quizartinib|Phase I Starting Dose: 60 mg my mouth daily of a 28 day cycle. For the first cycle only, quizartinib administered starting on day 5 of the cycle. All subsequent cycles quizartinib will start concomitantly with AZA or cytarabine.
Phase II Starting Dose: Maximum tolerated dose from Phase I.
175131|NCT00109720|Behavioral|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
175132|NCT01892371|Drug|Cytarabine|Phase I Starting Dose: 20 mg subcutaneously twice a day for 10 days of a 28 day cycle as determined by the treating physician.
Phase II Starting Dose: Maximum tolerated dose from Phase I.
175133|NCT01892371|Drug|AZA|Phase I Starting Dose: 75 mg/m2 subcutaneously or intravenously for 7 days of every 28 day cycle (Days 1-7), as determined by the treating physician.
Phase II Starting Dose: Maximum tolerated dose from Phase I.
175134|NCT01892384|Drug|Placebo|matching placebo
175135|NCT01892384|Drug|BI 409306|low dose
175136|NCT01892384|Drug|BI 409306|medium dose
175137|NCT01892384|Drug|BI 409306|high dose
175138|NCT01892397|Device|Optune (NovoTTF-100A)|
175438|NCT01885806|Device|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
175439|NCT01885806|Device|Sham Magnetic Stimulator|This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.
Total of session: 10
175440|NCT01885819|Biological|Autologous stromal vascular fraction cells|
175441|NCT01887899|Device|sham stimulation|
175442|NCT01887912|Biological|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
175443|NCT01887912|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
175444|NCT01887938|Biological|Recombinant human arylsulfatase A|Every other week (EOW) via an intrathecal drug delivery device (IDDD)
175445|NCT01887938|Biological|Recombinant human arylsulfatase A|Every other week (EOW) via an intrathecal drug delivery device (IDDD)
174831|NCT01887080|Other|Exercise|This group had the exercise program, thrice a week for eight weeks.
The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.
The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings.
174832|NCT01887080|Device|Microcurrent|This group had the exercise program after electrolipolysis, thrice a week for eight weeks.
The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).
Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings.
174833|NCT01889732|Device|ROTEM|
174834|NCT01889745|Drug|HX-1171|Anti-oxidatant, Anti-inflamation
174835|NCT01889758|Drug|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
174836|NCT01889758|Drug|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
174837|NCT01889758|Drug|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
174838|NCT01889771|Drug|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
174839|NCT01889784|Device|Phototherapy through light emitting diode (LED)|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode 157 arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm, class 2M 158 LED). The phototherapy will be applied bilaterally on femoral quadriceps muscle during 60 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
174840|NCT01889784|Device|Placebo phototherapy|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode 157 arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm, class 2M 158 LED). The phototherapy will be applied bilaterally on femoral quadriceps muscle during 60 seconds. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
175139|NCT01892410|Other|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
175140|NCT01892423|Other|Cetaphil Moisturizing Lotion Daily Advance|
174244|NCT01898494|Drug|carboplatin|Given IV
174245|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
174246|NCT01898494|Other|laboratory biomarker analysis|Correlative studies
174543|NCT01883947|Procedure|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
174544|NCT01883947|Other|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
174545|NCT01883986|Behavioral|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
174546|NCT00108667|Drug|IV Levodopa|
174547|NCT01883999|Device|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
174548|NCT01884012|Procedure|long term oxygen therapy|
174549|NCT01884025|Behavioral|Get Moving and Get Well|Walking Class
174550|NCT01884025|Behavioral|Health and Humor Class|Class about the role of humor in health
174551|NCT01884038|Drug|treprostinil sodium|A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.
The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative
174552|NCT01884038|Drug|Placebo|
174553|NCT01884064|Device|rTMS|rTMS
174554|NCT01884064|Device|Sham rTMS|Sham rTMS
174555|NCT01884077|Device|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
174556|NCT01886508|Procedure|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
173933|NCT01902784|Behavioral|Storytelling Interview|
173934|NCT01902797|Other|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
173935|NCT01902810|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization
173936|NCT01902810|Drug|Placebo|Placebo by mouth given daily throughout hospitalization
173937|NCT01895387|Dietary Supplement|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
174247|NCT01898494|Other|quality-of-life assessment|Ancillary studies
174248|NCT01898507|Other|Low nicotine cigarettes|15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
174249|NCT01898520|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
174250|NCT01898520|Drug|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
174251|NCT01898546|Procedure|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
174252|NCT00110058|Drug|imatinib mesylate|
174253|NCT01898546|Procedure|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
174254|NCT01898559|Other|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
174255|NCT01898572|Other|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
174256|NCT01898585|Drug|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
174257|NCT01898598|Drug|Placebo|Matching placebo to vismodegib
174258|NCT01898598|Drug|vismodegib|vismodegib 150 mg oral doses once a day for 12 weeks
174259|NCT01898611|Drug|Ghrelin|2:1 ratio placebo to ghrelin
173623|NCT01900041|Drug|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
173624|NCT01900041|Drug|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
173625|NCT01900054|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
173626|NCT01900067|Device|BARRIER® EasyWarm Active Self-Warming Blanket|
173627|NCT01900080|Other|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
173628|NCT00110110|Procedure|neoadjuvant therapy|Administration of therapeutic agents before a main treatment.
173629|NCT01900080|Other|Standard ART Initiation|Standard ART Initiation
173630|NCT01900080|Other|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count >500 cells/mm3 (CD4 count within 7 days of HIV test)
173631|NCT01900080|Other|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count >500 cells/mm3
173632|NCT01900093|Drug|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
173938|NCT01895400|Drug|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
173939|NCT01895400|Drug|Placebo|Take placebo drug 1T bid po medication for 8 weeks
173940|NCT00109850|Radiation|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
173941|NCT01895413|Procedure|Bone marrow aspiration|Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
173942|NCT01895439|Biological|Autologous Mesenchymal Stem Cells|
173943|NCT01895452|Drug|ALKS 9072, Low Dose|Intramuscular injection, given monthly
173944|NCT01895452|Drug|ALKS 9072, High Dose|Intramuscular injection, given monthly
173945|NCT01895465|Device|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
173946|NCT01895478|Behavioral|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
173947|NCT01895491|Biological|VM206DNA|
178395|NCT01908257|Drug|lesinurad 400 mg + ranitidine 150 mg|
178396|NCT01908270|Behavioral|Yoga|
178397|NCT01908270|Other|Usual care|
178398|NCT01908283|Biological|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
178399|NCT01908296|Drug|FK949E|Oral
178400|NCT01908296|Drug|fluvoxamine|Oral
178401|NCT01908309|Drug|Iobitridol 350|
178402|NCT01908309|Drug|Iodixanol 320|
178403|NCT01908322|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
178404|NCT01908335|Drug|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
178405|NCT00110981|Device|NB-UVB|Three times a week (TIW) for 12 weeks
178406|NCT01908335|Drug|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
178407|NCT01908335|Drug|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
178408|NCT01908335|Drug|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
178409|NCT01908348|Dietary Supplement|Erythritol|
178410|NCT01908361|Behavioral|Unilateral Hybrid (InMotion3 plus CIT) Intervention|During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.
During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions.
173633|NCT01900106|Drug|abacavir/lamivudine + raltegravir|
173634|NCT01902550|Drug|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
173635|NCT01902550|Drug|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
173636|NCT01902550|Drug|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
162575|NCT01862328|Drug|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|MLN4924 (IV) Paclitaxel (IV), and Carboplatin (IV) in patients to determine maximum tolerated dose (MTD) on a 21-day cycle:
MLN4924 on Days 1,3,5 of each cycle
Paclitaxel on Day 1 of each cycle
Carboplatin on Day 1 of each cycle
On Day 1 of each cycle, patients receive all 3 agents
162576|NCT01862328|Drug|MLN4924 + Gemcitabine (Arm 3)|MLN4924 (IV) and Gemcitabine (IV) in patients to determine maximum tolerated dose (MTD) on a 28-day cycle:
•MLN4924 and Gemcitabine on Days 1,8,15 of each cycle
162577|NCT01862341|Dietary Supplement|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
162578|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
162579|NCT01862354|Procedure|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
162580|NCT01862354|Procedure|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
162581|NCT01862367|Drug|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
162582|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
162583|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
162584|NCT01862393|Device|Electrically-induced torque using a clinical neuromuscular electrical stimulator (Dualpex 961®, Quark).|
162585|NCT01862406|Other|Label|Participants were presented with either a generic label or a brand-name label
162586|NCT01862419|Other|Alert|
162587|NCT01862432|Other|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
162588|NCT01862458|Biological|tPA alone|
162589|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
162590|NCT01862458|Biological|tPA plus dornase|
162912|NCT01865552|Biological|US sourced Enbrel|SC administration
162913|NCT01867983|Behavioral|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
173698|NCT01897636|Procedure|EUS-guided fine-needle injection of DCs vaccinations|
173699|NCT01897649|Dietary Supplement|NUTRIOSE FB06|15g/day NUTRIOSE FB06
173700|NCT01900106|Drug|abacavir/lamivudine + darunavir/ritonavir|
173701|NCT01900158|Drug|Amphinex and Gemcitabine|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) intravenously over 30 minutes and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, commencing between 7 and 21 days after the laser light application.
173702|NCT01900158|Drug|Gemcitabine and Cisplatin|No PCI treatment (stenting only) followed by systemic gemcitabine (1000 mg/m2) intravenously over 30 minutes and cisplatin intravenously over a period of 1 hour (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, commencing within 21 days after randomization.
173703|NCT01900171|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
173704|NCT01900171|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
173705|NCT00110123|Drug|fotemustine|
173706|NCT01900184|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
173707|NCT01900184|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
173708|NCT01900197|Drug|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
173709|NCT01900210|Behavioral|WaySafe|
173710|NCT01900236|Behavioral|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
174021|NCT01893229|Drug|Valproate|Valproate is used as a mood stabiliser
174022|NCT01893229|Drug|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
174023|NCT01893229|Drug|Quetiapine|Quetiapine is used as a mood stabiliser
174024|NCT01893229|Drug|Olanzapine|Olanzapine is used as a mood stabiliser.
174025|NCT01893229|Drug|Ziprasidone|Ziprasidone is used as a mood stabiliser
174026|NCT01893242|Drug|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
178462|NCT00110747|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
178463|NCT01905917|Other|Tele-rehabilitation|
178464|NCT01905930|Device|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
178465|NCT01905930|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
178466|NCT01905943|Drug|chemotherapy|FC, bendamustine or chlorambucil, 6 cycles
178467|NCT01905943|Drug|obinutuzumab|1000 mg IV on Days 1/2 (split dose), 8 and 15 of Cycle 1, and on Day 1 of Cycles 2-6
178468|NCT01905956|Dietary Supplement|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
178469|NCT01905956|Dietary Supplement|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
178470|NCT01905982|Procedure|reflectory breathing therapy|duration:2x60 minutes
178471|NCT01905982|Procedure|conventional breathing therapy|duration:4x30 minutes
178472|NCT01906008|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
178473|NCT00110747|Drug|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
178474|NCT01906008|Drug|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
178475|NCT01908374|Dietary Supplement|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
178476|NCT01908387|Drug|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
178477|NCT01908400|Biological|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
177870|NCT00111163|Drug|chlorproguanil-dapsone|
177871|NCT01909765|Other|Dorsal slit|Skin and mucosa incision made together
177872|NCT01909765|Other|Double incision|Skin and mucosa incision made separately
177873|NCT01909778|Drug|BI 201335|single oral doses
177874|NCT01909791|Procedure|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
178164|NCT01912677|Drug|Methyldopa|
178165|NCT01912690|Other|aerobic training|
178166|NCT01912690|Other|aerobic and strength training|
178167|NCT01912703|Other|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
178168|NCT01912716|Drug|high dose indomethacin|
178169|NCT01912716|Other|standard dose|
178170|NCT01912729|Other|Mobile phone application|
178171|NCT00111579|Other|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
178172|NCT01912729|Behavioral|Network Peer Support|
178173|NCT01912729|Behavioral|Coach support|
178174|NCT01912742|Behavioral|Very-low calorie diet (VLCD)|
178175|NCT01912742|Behavioral|Low calorie diet (LCD)|
178176|NCT01912755|Drug|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
178177|NCT01912755|Drug|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
178178|NCT01912768|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
178179|NCT01905280|Procedure|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
177545|NCT01904227|Behavioral|Inpatient Adaptation of DBT|The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.
The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.
177546|NCT01904253|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
177547|NCT00110526|Genetic|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
177548|NCT01904253|Drug|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
177549|NCT01906944|Drug|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
177550|NCT01906944|Drug|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
177551|NCT01906957|Other|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
177875|NCT01909791|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
177876|NCT01909791|Procedure|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
177877|NCT01909791|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
177878|NCT01909804|Drug|SOF|SOF 400 mg tablet administered orally once daily
177879|NCT01909804|Drug|GS-5816|GS-5816 tablet administered orally once daily
177880|NCT01909804|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
177881|NCT00111176|Device|Endovascular repair|Endovascular repair.
177882|NCT01909817|Procedure|Routine coronary angiogram|
177238|NCT01918306|Other|laboratory biomarker analysis|correlative studies
177239|NCT01918306|Other|pharmacological study|correlative studies
177240|NCT01918306|Procedure|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
177241|NCT01918306|Drug|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
177242|NCT01918319|Behavioral|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
177243|NCT01918332|Drug|Valsartan 160mg|
177244|NCT01918332|Drug|Rosuvastatin 20mg|
177245|NCT01918332|Drug|Valsartan 160mg placebo|
177246|NCT01918332|Drug|Rosuvastatin 20mg placebo|
177247|NCT01918345|Behavioral|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
177248|NCT00112112|Biological|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
177249|NCT01918345|Behavioral|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
177250|NCT01918358|Drug|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
177251|NCT01918358|Drug|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
177252|NCT01918358|Drug|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
176675|NCT01919827|Biological|Endobronchial infusion of adult mesenchymal stem cells|
176676|NCT01919827|Biological|Autologous mesenchymal stem cells derived from bone marrow|
176677|NCT01921751|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
176678|NCT00112424|Procedure|Diagnostic cardiac MRI|Routine cardiac MRI done under general anesthesia as pre-operative evaluation.
176679|NCT01921751|Other|Laboratory Biomarker Analysis|Correlative studies
176680|NCT01921751|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
176681|NCT01921764|Behavioral|Workplace physical exercise|
176682|NCT01921764|Behavioral|Home physical exercise|
176683|NCT01921777|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
176937|NCT01915537|Drug|Classic DMARDs treatment group|Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.
Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time.
176938|NCT01915550|Drug|Metformin|
176939|NCT01915550|Drug|Humulin Insulin Mixtard|
176940|NCT01915563|Procedure|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
176941|NCT01915576|Drug|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
176942|NCT01915576|Drug|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
176943|NCT01915576|Drug|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
176944|NCT01915589|Drug|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
176945|NCT01915602|Drug|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
176946|NCT00002093|Drug|Bleomycin sulfate|
176947|NCT00111826|Device|Celacade™ system|
176369|NCT01916954|Drug|3-day artemether-lumefantrine|
176370|NCT01916954|Drug|5-day artemether-lumefantrine|
176371|NCT01916967|Drug|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
176372|NCT01916967|Drug|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
176373|NCT01916980|Drug|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
176374|NCT00111982|Biological|Liatermin|Liatermin
176375|NCT01916993|Drug|NBI-98854 50 mg capsule|
176376|NCT01917006|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
176377|NCT01917006|Drug|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
176378|NCT01917019|Drug|Placebo|matching placebo tablets
176379|NCT01917019|Drug|BIIB041 (fampridine)|fampridine prolonged-release tablets
176380|NCT01917032|Dietary Supplement|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
176381|NCT01917032|Dietary Supplement|placebo|
176382|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
176383|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
176384|NCT01917045|Drug|Morphine|morphine 0. 5mg/ml
176385|NCT00111995|Drug|Aranesp®|
176684|NCT01921777|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
176685|NCT01921790|Biological|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
176686|NCT01921790|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
176687|NCT01921790|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
176688|NCT01921790|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
176082|NCT01913964|Drug|Placebo|(sugar pill)
176083|NCT01913977|Device|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
176084|NCT01913977|Device|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
176085|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
176386|NCT01919164|Drug|AS902330 100 microgram (mcg)|AS902330 will be administered at a dose of 100 mcg in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
176387|NCT01919164|Drug|AS902330 100 microgram (mcg)|AS902330 will be administered at a dose of 100 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
176388|NCT01919164|Drug|AS902330 30 microgram (mcg)|AS902330 will be administered at a dose of 30 mcg in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
176389|NCT01919164|Drug|AS902330 30 microgram (mcg)|AS902330 will be administered at a dose of 30 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
176390|NCT01919164|Drug|Placebo|Matching placebo will be administered in 2 cycles (at Months 6 and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
176391|NCT01919164|Drug|Placebo|Matching placebo will be administered in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
176392|NCT01919177|Dietary Supplement|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
176393|NCT00112216|Biological|Melan-A analog peptide|
176394|NCT01919177|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
176395|NCT01919190|Drug|EXPAREL|
176396|NCT01919190|Drug|Placebo|
176397|NCT01919203|Drug|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
176398|NCT01919216|Drug|Citalopram|
176399|NCT01919229|Drug|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
175741|NCT01891266|Procedure|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
175742|NCT00109590|Drug|Lopinavir/ritonavir|twice daily
175743|NCT01891279|Other|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
175744|NCT01891279|Other|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
175745|NCT01891292|Drug|Enalapril|0.25-0.35 mg/kg/day
175746|NCT01891292|Drug|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
175747|NCT01891305|Drug|VT-1161|
175748|NCT01891305|Drug|placebo|
175749|NCT01891318|Radiation|radiosurgery|Undergo radiosurgery
176086|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
176087|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
176088|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
176089|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
176090|NCT01913990|Drug|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
176091|NCT00111683|Drug|MK0457|
176092|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
176093|NCT01914016|Other|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
176094|NCT01914042|Drug|Morphine|
176095|NCT01914042|Drug|Milnacipran|
176096|NCT01916434|Other|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
176097|NCT00002093|Drug|Vincristine sulfate|
175446|NCT01887951|Drug|Penthrox Inhaler|
175447|NCT01887951|Drug|Tramadol Injection|
175448|NCT01887964|Other|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
175449|NCT01887964|Other|Control flour|Wheat flour without resistant starch (type-4)
175450|NCT01887977|Other|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
175451|NCT00002068|Drug|Fluconazole|
175452|NCT00109200|Drug|Xolair (omalizumab)|
175453|NCT01887990|Drug|Ketamine|single dose IV 0.2 mg/kg ketamine
175454|NCT01887990|Drug|placebo|saline infusion
175455|NCT01888003|Drug|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at −14 days and −7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
175456|NCT01888003|Drug|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at −14 days and −7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
175750|NCT01891318|Procedure|therapeutic conventional surgery|Undergo surgical resection
175751|NCT01891318|Procedure|quality-of-life assessment|Ancillary studies
175752|NCT01883583|Device|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
175753|NCT01883596|Drug|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
175754|NCT01883596|Drug|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
175755|NCT01883609|Biological|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
175756|NCT01883609|Biological|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
175757|NCT01883609|Biological|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
175141|NCT01892436|Drug|Secukinumab|Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
175142|NCT00109720|Behavioral|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
175143|NCT01892449|Other|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
175144|NCT01885117|Biological|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
175145|NCT01885130|Other|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
175146|NCT01885143|Radiation|Digital Breast Tomosynthesis|
175147|NCT01885156|Drug|Naftin 1% Cream|Topically applied once a day
175148|NCT01885156|Drug|Placebo Cream|Topically applied once a day
175149|NCT01885169|Biological|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
175150|NCT00108771|Drug|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
175151|NCT01885182|Drug|Oxycodone/Naloxone|
175152|NCT01885182|Drug|Oxycodone|
175153|NCT01885195|Drug|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
175154|NCT01885208|Drug|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
175155|NCT01885208|Drug|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
175156|NCT01885221|Behavioral|Multimedia Support Intervention|
175157|NCT01885234|Other|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
175158|NCT01885234|Other|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
174557|NCT01886508|Procedure|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
174558|NCT01886521|Procedure|Lumbar drain|
174559|NCT01886521|Procedure|Ventricular drain|
174560|NCT01886534|Other|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
174841|NCT01889797|Biological|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
174842|NCT00109395|Drug|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
174843|NCT01889797|Biological|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
174844|NCT01889810|Dietary Supplement|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
174845|NCT01889823|Other|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
174846|NCT01889823|Other|Hyperoxia|Subjects will be breathing 100% oxygen
174847|NCT01889836|Biological|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
174848|NCT01889836|Biological|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
174849|NCT01889849|Drug|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
174850|NCT01889849|Drug|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
174851|NCT01889862|Drug|BMN165 20mg/day|Two different doses of BMN165 compared to each other and compared to placebo
174852|NCT01889862|Drug|BMN165 40mg/day|Two different doses of BMN165 compared to each other and compared to placebo
174853|NCT01892085|Behavioral|Late initiation|Initiation of milk expression >3-6 hours following delivery.
174854|NCT01892098|Dietary Supplement|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
174855|NCT00109668|Drug|beclomethasone dipropionate (QVAR)|
174260|NCT01898611|Other|Resistance training|The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.
174261|NCT01898624|Drug|Betanis|oral
174262|NCT01898637|Other|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
174263|NCT01900977|Other|Universal Testing with immediate ART|• Combination prevention package including:
o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units
174561|NCT01886534|Behavioral|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
174562|NCT01886534|Other|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
174563|NCT01886534|Other|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
174564|NCT01886534|Other|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
174565|NCT00108979|Drug|Escitalopram|
174566|NCT01886547|Other|Prostate health screening|
174567|NCT01886560|Drug|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
174568|NCT01886560|Drug|Placebo|Tablets placebo one PO per day for 12 weeks
174569|NCT01886573|Drug|Azacitidine|Given SC
174570|NCT01886573|Drug|Entinostat|Given PO
173948|NCT01895491|Biological|VM206Ad|
173949|NCT01895504|Device|ColoAssist|Screening colonoscopy with the test instrument
173950|NCT01895504|Device|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
173951|NCT00109863|Biological|hu14.18-IL2 fusion protein|
173952|NCT01895517|Other|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
173953|NCT01895517|Other|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
173954|NCT01895530|Dietary Supplement|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
173955|NCT01895543|Drug|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
173956|NCT01895556|Other|Information|
173957|NCT01895556|Other|Control|
173958|NCT01895569|Drug|Metformin|Metformin will be added to therapy for the first threre months.
173959|NCT01895569|Drug|Pioglitazone|In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin, pioglitazone will be added.
174264|NCT01900977|Other|Universal Testing with ART eligibility according to National Guidelines|Combination prevention package including:
House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units.
174265|NCT01900977|Other|Standard of Care|
174266|NCT01900990|Device|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
174267|NCT01901003|Drug|Lorazepam|
174268|NCT01901003|Other|no premedication|
174269|NCT01901003|Drug|Placebo (microcrystalline celluloses)|
174270|NCT01901016|Behavioral|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
174271|NCT01901016|Behavioral|Schultz's autogenic training|Schultz's autogenic training
173637|NCT01902563|Other|Osteopathic Manipulative Treatment|
173638|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
173639|NCT01902589|Other|Helicobacter Pylori Culture|Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.
The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.
4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere.
173640|NCT01902641|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
173641|NCT01902641|Drug|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
173642|NCT01902641|Drug|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
173643|NCT01902654|Other|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
173644|NCT01902654|Other|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
173645|NCT01902654|Other|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
173646|NCT01902667|Procedure|Magnetic Resonance Imaging|
173647|NCT01902680|Radiation|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
173648|NCT01902693|Other|No intervention for this study|No intervention
173649|NCT00110370|Drug|Lispro Mixture Therapy|
173960|NCT01895569|Drug|Sitagliptin|In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
173961|NCT01895582|Other|Blood samples|4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)
1 blood dry tube (5ml)
162914|NCT01867996|Drug|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
162915|NCT01867996|Drug|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
162916|NCT01868009|Device|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
162917|NCT01868009|Device|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
162918|NCT01868022|Drug|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
162919|NCT01868022|Drug|paclitaxel|paclitaxel will be from commercial stock.
162920|NCT01868022|Drug|carboplatin|carboplatin will be from commercial stock.
162921|NCT00107211|Procedure|neoadjuvant therapy|
162922|NCT01868022|Drug|docetaxel|docetaxel will be from commercial stock.
162923|NCT01868022|Drug|pemetrexed|pemetrexed will be from commercial stock
162924|NCT01868022|Drug|cisplatin|cisplatin will be from commercial stock
162925|NCT01868035|Drug|tositumomab and iodine I-131 tositumomab|Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:
Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.
Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass.
162926|NCT01868048|Drug|Sativex|Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.
Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
162927|NCT01868048|Drug|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
162928|NCT01868061|Drug|lebrikizumab|High dose sc every 4 weeks, Week 1-104 or Week 52-104
162929|NCT01868061|Drug|lebrikizumab|Low dose sc every 4 weeks, Week 1-104 or Week 52-104
162930|NCT01868061|Drug|placebo|lebrikizumab placebo sc every 4 weeks, Week 1-52
174027|NCT01893242|Drug|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
174028|NCT00109798|Drug|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
174029|NCT01893281|Drug|Topical Testosterone Solution|Administered topically to axillae.
174030|NCT01893294|Drug|gemcitabine hydrochloride|Given IT
174031|NCT01893294|Drug|fluorouracil|Given IV
174032|NCT01893294|Radiation|radiation therapy|Undergo radiation therapy
174033|NCT01893294|Other|laboratory biomarker analysis|Correlative studies
174034|NCT00109876|Procedure|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
174035|NCT01895595|Behavioral|Guided Imagery|
174036|NCT01895595|Behavioral|Digital Storytelling|
174037|NCT01895608|Other|Balance rehabilitation + dual-task practice|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
174038|NCT01895608|Other|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
174039|NCT01895608|Behavioral|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
174040|NCT01895608|Behavioral|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
174041|NCT01895621|Procedure|Median nerve decompression at the wrist|Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
174042|NCT01895621|Dietary Supplement|Alpha lipoic acid post median nerve decompression|Daily supplementation of alpha lipoic acid
174343|NCT01898780|Procedure|pancreaticojejunostomy with interrupted suture|
174344|NCT01898793|Drug|Fludarabine|
174345|NCT01898793|Drug|Cyclophosphamide|
174346|NCT01898793|Procedure|Leukapheresis|
178478|NCT00110981|Drug|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
173711|NCT01900249|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
173712|NCT01900249|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
173713|NCT01900249|Drug|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
173714|NCT01900262|Other|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
173715|NCT01900262|Other|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
173716|NCT00110123|Drug|isolated perfusion|
173717|NCT01900262|Other|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
173718|NCT01900275|Other|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
173719|NCT01900288|Behavioral|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
173720|NCT01900288|Behavioral|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
173721|NCT01900301|Drug|Scopolamine|Participants will be randomized to either, .2mg/.01 mL Scopolamine, .3mg/.01 mL Scopolamine or .4mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
173722|NCT01900301|Drug|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
173723|NCT01902069|Dietary Supplement|Phospholean|Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994).
173724|NCT01902069|Dietary Supplement|Placebo|Placebo consists of rice flour
173725|NCT01902082|Drug|Mesenchymal stem cells|
173726|NCT01902082|Drug|Placebo|
173727|NCT01902095|Device|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
178180|NCT01905280|Procedure|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
178181|NCT01905293|Other|Feeding Study|
178182|NCT01905306|Procedure|computer guided implant planning|
178183|NCT01905306|Procedure|free hand implants placement|
178184|NCT00110669|Drug|Prednisone|Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive "dummy" pills of similar look/taste will be supplied to maintain blinding.
178185|NCT01905319|Other|Blood collecting for storage of samples|
173403|NCT01897142|Biological|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
173404|NCT01897142|Drug|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
173405|NCT01897142|Biological|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
173406|NCT00110006|Drug|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
173407|NCT01897142|Drug|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
173408|NCT01897142|Biological|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
173409|NCT01897142|Drug|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
173410|NCT01897142|Biological|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
173411|NCT01897142|Drug|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
173412|NCT01897155|Other|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
173413|NCT01897155|Other|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
173414|NCT01897168|Device|No intervention|
173415|NCT01899625|Behavioral|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
177883|NCT01909830|Drug|Arm A : Gemcitabine + Pemetrexed|Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.
Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days.
177884|NCT01909843|Biological|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
177885|NCT01909856|Drug|Palonosetron|Palonosetron 0.25mg d1,d3
177886|NCT01909856|Drug|Granisetron|Granisetron 3mg d1-3
177887|NCT01909856|Drug|Dexamethasone|Dexamethasone 10mg d1-3
177888|NCT01909856|Drug|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
177889|NCT01909869|Device|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
177890|NCT01912482|Other|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
177891|NCT01912482|Other|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
177892|NCT01912495|Drug|Boceprevir|
177893|NCT01912521|Behavioral|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
177894|NCT01912534|Drug|Valsartan|40, 80 and 160 mg tablets of Valsartan
178186|NCT01905332|Other|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
178187|NCT01905332|Other|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
178188|NCT01905345|Procedure|Training|
178189|NCT01905371|Drug|Dextroamphetamine|
178190|NCT01905371|Other|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
177253|NCT01920737|Drug|Cytarabine|
177254|NCT01920737|Drug|Leucovorin|
177552|NCT01906957|Other|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
177553|NCT01906970|Device|ClampArt|
177554|NCT01906983|Other|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
177555|NCT01906996|Procedure|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
177556|NCT01906996|Procedure|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
177557|NCT00110851|Drug|rosiglitazone|
177558|NCT01907009|Drug|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
177559|NCT01907009|Drug|Lenograstim|Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.
After the third cycle patient will receive 263mcg/day for 10 days.
177560|NCT01907022|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
Arms: Left DLPFC Butterfly Coil
177561|NCT01907035|Behavioral|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
177562|NCT01907035|Other|Usual care|
177563|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
177564|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
177565|NCT01907061|Drug|N-acetylcysteine|drug will be administered via IV,NG
177566|NCT01907061|Drug|Placebo|placebo or NAC will be given
176948|NCT01915602|Drug|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
176949|NCT01915615|Other|None - this is an observational study|None - this is an observational study
176950|NCT01915628|Device|BioMatrix Flex|Percutaneous coronary intervention
176951|NCT01915641|Device|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
176952|NCT01915654|Procedure|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
176953|NCT01915667|Drug|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
176954|NCT01917903|Behavioral|Identification of at risk variables|Participants will complete walking under three conditions: walking alone, walking while talking to an investigator in person, and walking while talking to an investigator on a cell phone. Spatiotemporal measures of gait will be collected.
176955|NCT01917916|Drug|Placebo|Placebo
176956|NCT01917916|Drug|BI 655064|
176957|NCT01917916|Drug|BI 655064|
177255|NCT01920737|Drug|Dexamethasone|
177256|NCT01920750|Biological|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
177257|NCT01920750|Biological|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
177258|NCT00112294|Drug|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
177259|NCT01920750|Other|Mock Antigen|Physiological saline
177260|NCT01920763|Other|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
177261|NCT01920776|Other|ultrasound examination|
177262|NCT01920776|Other|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
177263|NCT01920789|Radiation|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
176689|NCT00112424|Procedure|Cardiac catheterization|Routine cardiac catheterization prior to Glenn operation.
176690|NCT01921790|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
176691|NCT01921803|Radiation|hypofractionation|
176692|NCT01921816|Device|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
176693|NCT01921829|Drug|Protocolized Diuretic Strategy|The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the "stepped pharmacologic care arm" used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide).
176694|NCT01921842|Behavioral|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
176695|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
176696|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
176697|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
176698|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
176699|NCT01921855|Drug|Placebo|Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
176700|NCT01914991|Procedure|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
176701|NCT01915004|Other|Educational Intervention|Bladder Training Video
176958|NCT01917916|Drug|BI 655064|
176959|NCT01917916|Drug|Placebo|Placebo
176960|NCT01917916|Drug|BI 655064|
176961|NCT01917916|Drug|Placebo|
176400|NCT01919229|Drug|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
176401|NCT01919242|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
176402|NCT01919255|Drug|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
176403|NCT01919255|Drug|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
176404|NCT00112216|Biological|FluMa peptide|
176702|NCT00111774|Drug|ABX-EGF|
176703|NCT01915017|Behavioral|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
176704|NCT01915017|Behavioral|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
176705|NCT01915017|Behavioral|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
176706|NCT01915017|Other|Treatment as Usual|Standard medication follow up and limited case management
176707|NCT01915030|Other|High protein diet|controlled feeding trail. Both arms are caloric restricted
176708|NCT01915030|Other|standard protein diet|
176709|NCT01915043|Other|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
176710|NCT01915056|Other|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
176711|NCT01915069|Drug|Cilostazol|
176712|NCT01915082|Drug|Azithromycin|Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):
Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
176713|NCT00111787|Drug|Lapatinib|
176098|NCT00111891|Drug|Comparator: placebo (unspecified)|
176099|NCT01916434|Other|No salmon|The placebo group will continue to consume their habitual diet.
176100|NCT01916447|Drug|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
176101|NCT01916447|Drug|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
176102|NCT01916447|Drug|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
176103|NCT01916460|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
176104|NCT01916460|Device|19 guage fine needle aspiration needle|
176105|NCT01916473|Other|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
176405|NCT01919268|Device|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
176406|NCT01919268|Device|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
176407|NCT01919281|Behavioral|strength training|
176408|NCT01921621|Behavioral|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
176409|NCT01921621|Behavioral|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
176410|NCT00112398|Procedure|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
176411|NCT01921634|Other|Modified Pathologic Analysis|
176412|NCT01921647|Drug|YH4808|
176413|NCT01921647|Drug|Nexium|
175758|NCT01883635|Behavioral|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
175759|NCT01883635|Behavioral|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
175760|NCT01883648|Drug|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
175761|NCT01883648|Other|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
175762|NCT00108615|Procedure|Oral glucose tolerance test|To detect a change in glucose tolerance
175763|NCT01883661|Biological|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
175764|NCT01883674|Other|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
175765|NCT01883687|Procedure|Septoplasty|
175766|NCT01883700|Other|Boiled Pasta|
175767|NCT01883700|Other|Boiled Chickpeas with Oil|
175768|NCT01883700|Other|Instant Mashed Potatoes|
175769|NCT01883700|Other|Instant Mashed Potatoes with Egg Whites|
175770|NCT01883713|Device|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
176106|NCT01916473|Other|Continuous wound infusion|Continuous wound infusion via catheter
176107|NCT01916486|Behavioral|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
176108|NCT01916486|Behavioral|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
176109|NCT00111904|Drug|paclitaxel-loaded polymeric micelle|
176110|NCT01916486|Behavioral|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
176111|NCT01916499|Other|3 tesla magnetic resonance imaging findings; coronary artery status|
175457|NCT01888003|Other|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb < 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
175458|NCT01888016|Other|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
175459|NCT01888016|Other|standard physiotherapies treatment|10 standard treatments in 2 weeks
Deltoid and infraspinatus muscles electrotherapy
Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day
Scar massage
Upper limb, cervical spine and scapula massages
Passive and assisted/active shoulder mobilization exercises
Scapula micro-mobilizations
Gleno-humeral decoaptation
Elbow, wrist and hand active mobilization
Proprioceptive exercise with and without the aid of the mirror
175460|NCT01888029|Device|transcranial direct current stimulation|
175461|NCT01888029|Device|sham stimulation|
175462|NCT01888042|Drug|Everolimus|10 mg (1 tablet of 10 mg)
175463|NCT01890707|Procedure|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
175464|NCT00109538|Other|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
175465|NCT01890707|Drug|Fentanyl (Sublimaze TM)|
175466|NCT01890707|Drug|fluoromethyl hexafluoroisopropyl ether (Sevoflurane TM)|
175467|NCT01890707|Drug|Succinylcholine (Suxamethonium chloride)|
175468|NCT01890707|Drug|Rocuronium (Zemuron TM)|
175469|NCT01890707|Drug|Propofol (Diprivan TM)|
175470|NCT01890707|Drug|Ketamine|
175471|NCT01890720|Device|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
175472|NCT01890720|Other|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
175473|NCT01890733|Device|Best Repair of torn Rotator Cuff|
175474|NCT01890733|Device|InSpace™ system|
174856|NCT01892098|Dietary Supplement|Placebo|Cellulose pill given as placebo
174857|NCT01892111|Other|Structured exercise program.|
174858|NCT01892124|Behavioral|Motivational Interviewing/Cognitive Behavioral-based Therapy|
174859|NCT01892137|Drug|Ingenol mebutate gel 0.05%|Once daily for 2 consecutive days
174860|NCT01892150|Other|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
174861|NCT01892163|Device|Ozurdex|Dexamethasone implant (Ozurdex)
174862|NCT01892176|Dietary Supplement|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
174863|NCT01892189|Drug|Ketamine|Ketamine intravenous administration.
175159|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks + daily metformin
175160|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks + daily metformin
175161|NCT00108771|Drug|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
175162|NCT01885260|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks + daily metformin
175163|NCT01885273|Procedure|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
175164|NCT01885273|Procedure|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
175165|NCT01885286|Procedure|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
175166|NCT01885299|Radiation|SRS/SBRT|Intervention varies by condition being treated.
175167|NCT01887509|Device|Probe-based confocal laser endomicroscopy|Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE
Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.
Biopsies will be harvested in both healthy and tumor tissue as well.
After all procedures are complete, a second assessment of pCLE images by a third party will be performed.
174571|NCT01886573|Other|Laboratory Biomarker Analysis|Correlative studies
174572|NCT01886573|Other|Pharmacological Study|Correlative studies
174573|NCT01886573|Procedure|Therapeutic Conventional Surgery|Undergo surgery
174574|NCT01886586|Behavioral|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
174575|NCT01886586|Behavioral|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
174576|NCT01889199|Other|Placebo|Placebo orally each 28 day cycle for 6 cycles
174577|NCT01889212|Other|11C-erlotinib PET/CT|
174578|NCT01889238|Drug|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
174579|NCT01889251|Drug|Ocriplasmin|
174864|NCT01892189|Drug|TAK-063|TAK-063 tablets
174865|NCT01892189|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
174866|NCT00109681|Drug|Iloprost Inhalation Solution (Ventavis)|
174867|NCT01892215|Procedure|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
174868|NCT01892215|Procedure|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
174869|NCT01892228|Behavioral|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
174870|NCT01892241|Drug|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
174871|NCT01892241|Drug|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
174872|NCT01892254|Drug|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
174873|NCT01892254|Drug|Placebo|Placebo (to metformin)
174874|NCT01892267|Device|PEG-J placement|PEG-J placement
174875|NCT01892280|Behavioral|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
174876|NCT01892280|Behavioral|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
174272|NCT00002079|Drug|Zidovudine|
174273|NCT00110214|Biological|bevacizumab|Given IV
174274|NCT01901042|Dietary Supplement|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
174275|NCT01901042|Dietary Supplement|Maltodextrin|Control patients will receive sachets containing maltodextrin
174276|NCT01901055|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
174277|NCT01901055|Device|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
174278|NCT01901068|Device|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
174279|NCT01901081|Device|IMES|Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.
After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months.
174280|NCT01901094|Procedure|Axillary Lymph Node Dissection (ALND)|
174281|NCT01901094|Radiation|Nodal Radiation Therapy|
174580|NCT01889251|Drug|Sham injection|
174581|NCT01889264|Other|Observational|Observational, Translational non-treatment study
174582|NCT00109356|Drug|AQ4N (Chemotherapy)|
174583|NCT01889277|Drug|MT-3995-Low|
174584|NCT01889277|Drug|MT-3995-High|
174585|NCT01889277|Drug|Placebo|
174586|NCT01889290|Drug|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
173962|NCT01898026|Dietary Supplement|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
173963|NCT01898026|Dietary Supplement|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
173964|NCT01898039|Biological|A2/4-1BBL melanoma vaccine|On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
173965|NCT01898039|Procedure|DNP sensititzation|Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.
On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.
173966|NCT01898039|Drug|Cyclophosphamide|On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
173967|NCT00002076|Drug|Fluconazole|
173968|NCT00110032|Radiation|fluorine F 18 EF5|Given IV
173969|NCT01898052|Drug|single anaesthetic drug|inject periarticular tissue of the knee after implantation
173970|NCT01898052|Drug|multimodal drug injection|inject periarticular tissue of the knee
173971|NCT01898065|Drug|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
173972|NCT01898078|Drug|MLN8237|Patients will be randomly assigned in a crossover fashion to receive a single 50-mg dose of alisertib (administered as 5 x 10 mg enteric-coated tablets) with or without a standard high-fat breakfast on Day 1 of Cycle 1, with the respective alternate food intake condition (fasted to fed, or fed to fasted; n = approximately 9 per sequence) on Day 1 in Cycle 2.
173973|NCT01898091|Drug|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
173974|NCT01898091|Drug|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
173975|NCT01898104|Radiation|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
173976|NCT01898104|Drug|Valproic Acid|
173977|NCT01898104|Drug|Capecitabine|
173978|NCT01898117|Drug|Carbo/cyclo|
173979|NCT00110032|Other|pharmacological study|Correlative studies
173980|NCT01898117|Drug|Carbo/cyclo + bevacizumab|
173981|NCT01898117|Drug|Paclitaxel|
163235|NCT01813708|Behavioral|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
163236|NCT01813708|Behavioral|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
163237|NCT01813734|Drug|Ponatinib|28 day cycle
163238|NCT01813747|Device|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
163239|NCT01816139|Drug|WC3011|
163240|NCT01816139|Drug|Vehicle|
163241|NCT01816152|Other|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
163242|NCT01816152|Other|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
163243|NCT01816165|Drug|Acipimox|Subjects will take acipimox/placebo 250mg (randomized and double-blinded) by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
163244|NCT00101842|Drug|Platinol|
163245|NCT01816165|Drug|Placebo|Subjects will take acipimox/placebo 250mg (randomized and double-blinded) by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
163246|NCT01816178|Behavioral|communication training|Participants were instructed in the use of a voices output communication aid.
163247|NCT01816191|Drug|Diltiazem Hydrochloride Cream and Oral Diltiazem|
163248|NCT01816204|Behavioral|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
163249|NCT01816204|Behavioral|face-to-face individual therapy|weekly individual counseling as usual.
163250|NCT01816204|Behavioral|Group face-to-face counseling|weekly group psychotherapy
163251|NCT01816217|Device|Intubation with The McGrath Mac videolaryngoscope|
163252|NCT01816230|Drug|NiCord®|
174347|NCT01898793|Biological|Cytokine-induced killer cells|
174348|NCT01898793|Biological|Aldesleukin|
174349|NCT01898806|Drug|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
174350|NCT00002077|Drug|Fluconazole|
174351|NCT00110058|Radiation|radiation therapy|
174352|NCT01898806|Drug|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
174353|NCT01901094|Radiation|Axillary Radiation Therapy|
174354|NCT01901107|Drug|Kiklin capsules|oral
174355|NCT00110214|Other|laboratory biomarker analysis|Correlative studies
174356|NCT01901120|Drug|Betanis|oral
174357|NCT01901133|Drug|MDV3100|Oral
174358|NCT01901146|Drug|ABP 980|
174359|NCT01901146|Drug|trastuzumab|
174360|NCT01901146|Drug|epirubicin|
174361|NCT01901146|Drug|cyclophosphamide|
174362|NCT01901146|Drug|paclitaxel|
174363|NCT01901146|Procedure|Lumpectomy or mastectomy with sentinel node or axillary node dissection|
174364|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (tablet)
174365|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (capsule)
174366|NCT00110227|Behavioral|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
174367|NCT01901172|Drug|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
174368|NCT01901172|Drug|RO5503781|Daily for 5 days followed by 23 days rest per cycle
173728|NCT00110305|Drug|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
173729|NCT01902095|Device|Tooth paste (control)|Active Comparator
173730|NCT01902108|Drug|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
174043|NCT01895634|Device|Rev-01|Treatment arm patients have used Rev-01 at least once
174044|NCT01895647|Device|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
174045|NCT00109889|Procedure|magnetic resonance imaging|magnetic resonance imaging (MRI)
174046|NCT01895660|Behavioral|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
174047|NCT01895673|Other|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
174048|NCT01895699|Other|Contrast agent|
174049|NCT01895738|Behavioral|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
174050|NCT01895751|Procedure|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
174051|NCT01895764|Drug|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
174052|NCT01895764|Drug|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
174053|NCT01895777|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
174054|NCT01895777|Drug|standard of care|Low molecular weight heparin or vitamin K antagonist prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
174055|NCT01898169|Other|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
174056|NCT01898182|Other|Kinetin, N6-furfuryladenine, 0.1%|
174057|NCT01898195|Drug|Varenicline|Varenicline will be provided for three months.
173416|NCT01899625|Behavioral|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
173417|NCT01899638|Drug|UMEC/VI 125/25 mcg|Combination in high dose
173418|NCT01899638|Drug|UMEC/VI 62.5/25 mcg|Combination in low dose
173419|NCT01899638|Drug|UMEC 125 mcg|LAMA mono in high dose
173420|NCT01899638|Drug|UMEC 62.5 mcg|LAMA mono in low dose
173421|NCT01899638|Drug|VI 25 mcg|LABA mono
173422|NCT01899664|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
173423|NCT01899677|Other|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
173731|NCT01902108|Drug|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
173732|NCT01902121|Drug|Technosphere® Insulin 10U + 20U|Inhaled Insulin
173733|NCT01902121|Drug|Technosphere® Insulin 30U|Inhaled Insulin
173734|NCT01902134|Drug|Placebo|Placebo single oral dose (first 8 hours)
173735|NCT01902134|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
173736|NCT01902134|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
173737|NCT01902134|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
173738|NCT01902134|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
173739|NCT00110318|Procedure|Manual therapy and therapeutic exercise|
173740|NCT01902134|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
173741|NCT01902134|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
173742|NCT01902147|Other|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
173743|NCT01902160|Drug|Brentuximab Vedotin|Given IV
178191|NCT01905371|Drug|Placebo|
178192|NCT01905384|Device|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
178193|NCT01905384|Device|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
178194|NCT01905397|Device|Conventional wound therapy|Sterile bandages and wound coverings
178195|NCT00110682|Drug|Imiquimod used as an adjunct to cryotherapy|
178196|NCT01905397|Device|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
178197|NCT01905410|Drug|VVZ-149 Injection|VVZ-149 in water for injection
178198|NCT01905410|Drug|placebo|water for injection
178199|NCT01905423|Drug|Albendazole and diethylcarbamazine|Albendazole 400 mg plus diethylcarbamazine 6 mg/kg once yearly vs twice yearly
178200|NCT01905436|Drug|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
178201|NCT01905449|Behavioral|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
178202|NCT01905462|Other|Data Collection|Analyses of data collected within the CPRD GOLD database.
178203|NCT01907841|Other|Ischemic Preconditioning|
178204|NCT01907854|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
178205|NCT01907854|Drug|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
173424|NCT01899677|Drug|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
173425|NCT00110110|Drug|cyclosporine|Given at 33 mg/kg/dose
173426|NCT01899690|Drug|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
173427|NCT01899703|Drug|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
177567|NCT01909310|Procedure|neutral position|the lungs are ventilated with the patient´s head in neutral position
177568|NCT01909310|Procedure|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
177569|NCT01909323|Other|maltitol 85% / FOS15%|
177570|NCT01909323|Other|maltitol alone|
177895|NCT01912534|Drug|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
177896|NCT01912547|Procedure|Blood draw for TEG analysis|Blood drawn for TEG analysis
177897|NCT01912560|Drug|CAT-2003|
177898|NCT01912560|Drug|Placebo|
177899|NCT01912573|Drug|Intranasal (IN) naloxone|
177900|NCT00111553|Biological|Leish-111f + MPL-SE vaccine|
177901|NCT01912573|Drug|Intravenous (IV) naloxone|
177902|NCT01912573|Drug|Intramuscular (IM) naloxone|
177903|NCT01912573|Drug|Intraosseus (IO) naloxone|
177904|NCT01912586|Other|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
177905|NCT01912599|Device|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
177906|NCT01912599|Device|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
177907|NCT01912612|Drug|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
177908|NCT01912625|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
177909|NCT01912625|Drug|Carboplatin|Given IV
177910|NCT01912625|Radiation|Image Guided Radiation Therapy|Undergo IGRT
177911|NCT00111566|Drug|eptifibatide|
177264|NCT01920789|Radiation|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
177265|NCT01920802|Drug|olanzapine|5mg BID up to 4 weeks
177266|NCT01920802|Drug|iloperidone|6 mg BID up to 4 weeks
177267|NCT01920802|Drug|Placebo|BID up to 4 weeks
177268|NCT01920815|Other|No interventions|
177269|NCT00112294|Drug|Cetuximab|Intravenous, 400 mg/m^2, initial dose followed by 250 mg/m^2, weekly starting on Week 2
177270|NCT01920841|Other|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
177271|NCT01920841|Other|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
177272|NCT01920854|Drug|soluble ferric pyrophosphate|
177273|NCT01920854|Drug|Placebo|
177274|NCT01920867|Procedure|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
177275|NCT01920867|Procedure|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
177571|NCT01909323|Other|maltitol 68% / FOS 32%|
177572|NCT01909323|Other|maltitol 50% / FOS 50%|
177573|NCT01909323|Other|FOS alone|
177574|NCT01909323|Other|Placebo|
177575|NCT01909336|Drug|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
177576|NCT00111111|Drug|Etanercept|
177577|NCT01909336|Drug|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
177578|NCT01909336|Drug|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
177579|NCT01909349|Behavioral|self-regulation|Web-based support for behavior change regarding physical activity and fruit & vegetable consumption
176962|NCT01917916|Drug|Placebo|Placebo
176963|NCT00000300|Drug|LAAM|
176964|NCT00002094|Drug|Atevirdine mesylate|
176965|NCT00112073|Drug|bapineuzumab|IV, Q13w
176966|NCT01917929|Device|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
176967|NCT01917942|Device|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
176968|NCT01917942|Other|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
176969|NCT01917968|Device|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
176970|NCT01917968|Procedure|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
176971|NCT01917981|Device|Personal Heart Rhythm Monitor|
176972|NCT01917994|Behavioral|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
176973|NCT01917994|Behavioral|Appointment Reminders|
176974|NCT01918007|Procedure|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of Obstructive SDB.
176975|NCT01918020|Behavioral|Go Wild with Fruits and Veggies!|Fruits and Vegetables
176976|NCT00112073|Other|placebo|IV Q13w
176977|NCT01918020|Behavioral|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
176978|NCT01918033|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
177276|NCT01920867|Procedure|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
177277|NCT01920867|Procedure|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
160492|NCT01791608|Dietary Supplement|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
160493|NCT01791608|Dietary Supplement|Milk without fortification without zinc|Milk without fortification
160494|NCT01791621|Other|Elimination/Challenge Diet|An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.
The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team.
160495|NCT01791634|Procedure|proximal chevron osteotomy|
160801|NCT01787006|Drug|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
160802|NCT01787006|Drug|Cisplatin, 5-FU|5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4
Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle
160803|NCT01787006|Radiation|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
160804|NCT01787019|Other|Oral feeding|
160805|NCT01787032|Drug|BI 113608|tablet
160806|NCT01787032|Drug|BI 113608|tablet
160807|NCT01787032|Drug|BI 113608|tablet
160808|NCT01787032|Drug|Ketoconazole|tablet
160809|NCT01787032|Drug|Voriconazole|tablet
160810|NCT00098917|Drug|autologous tumor cell vaccine|
160811|NCT01787045|Other|Early and Active Physical Therapy|Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.
Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc.
160812|NCT01787045|Other|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
160813|NCT01787058|Other|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
160814|NCT01787071|Other|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
160201|NCT01785862|Drug|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
160202|NCT01785875|Drug|AMG 416|Minimum dose of 2.5 mg to maximum dose of 15 mg, administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
160203|NCT01785901|Other|without interventions|without interventions
160204|NCT01785927|Other|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
160205|NCT01785940|Procedure|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
160206|NCT01785966|Behavioral|Daily checklist and clinician prompting|Interventions are:
Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.
Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items.
160207|NCT01788722|Drug|Visanne (Dienogest, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
160496|NCT00099281|Drug|YMB 1002|
160497|NCT01791634|Procedure|proximal open wedge osteotomy with LPS system|
160498|NCT01791647|Drug|metformin 1500 mg|
160499|NCT01791647|Drug|myoinositol 1500 mg|
160500|NCT01791660|Device|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
160501|NCT01791673|Device|Ultrasound glaucoma treatment|Ultrasound glaucoma treatment with EYEOP1 device
160502|NCT01791686|Drug|CDX-1135|
160503|NCT01791699|Drug|Moxonidine|
159906|NCT01800422|Other|laboratory biomarker analysis|Correlative studies
159907|NCT01800422|Other|questionnaire administration|Ancillary studies
159908|NCT01800435|Drug|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
159909|NCT01800435|Drug|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
159910|NCT01800461|Other|OPC-Stroke|Occupational therapy coaching intervention
159911|NCT01800461|Other|Usual care|Usual community care
159912|NCT01800487|Drug|silymarin|140 mg three times a day for 4 weeks
159913|NCT01800487|Drug|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
159914|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
159915|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using escalating product prices
159916|NCT00100373|Drug|RSV challenge material|
159917|NCT01800500|Other|questionnaire administration|Ancillary studies
159918|NCT01800500|Other|quality-of-life assessment|Ancillary studies
159919|NCT01800500|Other|laboratory biomarker analysis|Correlative studies
159920|NCT01800500|Other|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
159921|NCT01800500|Other|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
159922|NCT01800513|Procedure|Endometrial Biopsy|
160208|NCT01788748|Device|bipolar radiofrequency and infrared|
160209|NCT01788748|Device|fractional bipolar radiofrequency|
160210|NCT01788761|Dietary Supplement|Probiotic Supplemented Group|
160211|NCT01788761|Dietary Supplement|Control Group|
160212|NCT01788774|Drug|Risperidone ISM 50 mg|
160213|NCT01788774|Drug|Risperidone ISM 75 mg|
159634|NCT01797237|Device|InterTAN|
159635|NCT01797263|Other|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
159636|NCT01797263|Other|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
159637|NCT01797276|Drug|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day. They have EEG's done and nerve conduction studies.
159638|NCT00099983|Drug|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
159639|NCT01797289|Other|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
159640|NCT01797302|Dietary Supplement|Vitamin D3|Tablet form
159641|NCT01797315|Drug|Sirolimus|
159642|NCT01797328|Procedure|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
159643|NCT01797328|Procedure|warm arm|To the best of ability avoid feeling cold during 6 weeks
159644|NCT01797341|Drug|Tacrolimus|
159645|NCT01797341|Drug|Tacrolimus|
159646|NCT01797354|Behavioral|Cognitive-behavioral therapy and hypnosis group|
159647|NCT01797354|Behavioral|Support group|
159923|NCT01800513|Procedure|Sham Procedure|
159924|NCT01800526|Drug|N-Acetylcysteine|Oral and Intravenous administration of NAC
159925|NCT01800539|Behavioral|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
159039|NCT01798745|Drug|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
159040|NCT00100126|Drug|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
159343|NCT01802645|Drug|Irinotecan|
159344|NCT01794585|Behavioral|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
159345|NCT01794585|Behavioral|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
159346|NCT01794598|Behavioral|Receiving educational material of depression care|The educational material provides patients about depression management
159347|NCT01794611|Device|laryngoscopy|
159348|NCT01794624|Behavioral|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
159349|NCT00099632|Drug|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
159350|NCT01794624|Behavioral|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
159351|NCT01794650|Dietary Supplement|Meal composition|
159352|NCT01794663|Drug|OPN-305 or Placebo|Intravenous infusion for 1 hour at start of transplant procedure
Phase 0: 1.5 mg/kg, iv single dose
Part A: OPN-305 0.5, 1.5 or 5.0 mg/kg and matching placebo
Part B: Single iv dose chosen by DSMB from Part A and matching placebo
159353|NCT01794676|Genetic|Blood draw|Blood draw
159354|NCT01794689|Drug|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
158723|NCT01777568|Other|30% oxgen|Operating room will be maintained at 30% oxygenation during colorectal surgery.
158724|NCT01777568|Other|80% oxygen|Operating room will be maintained at 80% oxygenation.
158725|NCT01777581|Drug|Milnacipran|
158726|NCT01777581|Drug|Placebo|
158727|NCT01777594|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
158728|NCT01777607|Device|IMPELLA® RP|
158729|NCT01777620|Biological|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
158730|NCT01777620|Drug|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
158731|NCT00098111|Drug|azathioprine|
159041|NCT01798745|Other|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
159042|NCT01798771|Procedure|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
159043|NCT01798771|Procedure|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
159044|NCT01798784|Behavioral|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
159045|NCT01798784|Behavioral|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
159046|NCT01798784|Behavioral|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
159047|NCT01801423|Drug|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at ~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
159048|NCT01801436|Drug|Bortezomib|Bortezomib 1.3 mg per (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
159049|NCT01801449|Drug|Rilonacept|
159050|NCT01801462|Other|Simulation-based training|
158447|NCT01774305|Drug|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
158448|NCT01774305|Drug|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
158449|NCT01774318|Other|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
158450|NCT01774344|Drug|Regorafenib (BAY73-4506)|Regorafenib, 40 mg tablets
158451|NCT01774344|Drug|Placebo|Placebo tablets matching in appearance
158452|NCT01774370|Drug|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
158453|NCT01774396|Drug|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
158732|NCT01777633|Radiation|Palliative re-irradiation for progressive DIPG in children|
158733|NCT01777646|Biological|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
158734|NCT01777659|Device|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
158735|NCT01777672|Behavioral|Dietary and oral hygiene recommendations|
158736|NCT01777672|Dietary Supplement|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
158737|NCT01798082|Other|Pelvic organ prolapse decision aid|
158738|NCT01798095|Biological|Aplisol@ PPD material|Determine equivalency of materials
158739|NCT01798095|Biological|Reference Standard|Reference standard material for comparison to newly produced materials.
158740|NCT01798108|Radiation|Radium-223 dichloride (BAY88-8223)|- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
158741|NCT01798121|Biological|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
158742|NCT01798121|Biological|Reference standard|Response of reference standard material compared to Aplisol@.
163183|NCT01818648|Drug|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
163184|NCT01818648|Drug|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
163185|NCT01818661|Drug|FDG Fluorodeoxyglucose 18|
163186|NCT01818674|Behavioral|Microclinic Social Network Behavioral Health Program|An approximately 7-month participatory program (sessions and educational materials) that will increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement for ~28 participants.
163187|NCT01818674|Behavioral|Modified Microclinic Behavioral Health Program without social network components (education curriculum only)|This program will be provided to Group B and will increase participants knowledge about diabetes self-management. For the education program in group B there are no group-based or team-building activities, group goal setting, and class is pure lecture style with no class participation.
163188|NCT01818674|Other|Risk Factor Measurement|Measurement of metabolic risk factors for obesity and diabetes as described by the primary and secondary outcomes
163189|NCT00001998|Drug|Nystatin|
163190|NCT00102089|Biological|VRC-HIVADV014-00-VP booster|
163191|NCT01818687|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
163192|NCT01818700|Drug|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
158454|NCT00097786|Drug|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
158455|NCT01774396|Drug|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
158456|NCT01774409|Genetic|Blood and tumor samples|Genetic: Establishment of the genetic and immunologic profile
Whole blood sampling :
1 tube for the constitutional DNA extraction;
3 tubes for ancillary studies and research.
Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.
With the established profile, recommendations will be given by a multidisciplinary molecular board.
162877|NCT01863043|Procedure|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
162878|NCT01863043|Procedure|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
162879|NCT01863056|Other|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
162880|NCT00106574|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
162881|NCT01863069|Drug|Interferon beta 1a|
162882|NCT01863069|Drug|(IM) AVONEX®|
162883|NCT01863082|Other|exercise|practice of physical exercise
162884|NCT01863095|Behavioral|Personalized Feedback and Exercise|
162885|NCT01863108|Biological|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
162886|NCT01863134|Drug|Eptifibatide|
162887|NCT01863134|Drug|Placebo|
162888|NCT01863147|Drug|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
162889|NCT01865370|Dietary Supplement|Placebo|Placebo (34.5g/day)
162890|NCT01865383|Behavioral|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
163193|NCT01821027|Drug|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
163194|NCT01821027|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
163195|NCT01821040|Drug|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
163196|NCT01821040|Drug|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
163197|NCT01821066|Drug|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
162551|NCT01869894|Procedure|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
162552|NCT01869907|Drug|Minocycline|100 mg once daily by mouth during 14 days
162553|NCT01869907|Drug|placebo|once daily by mouth during 14 days
162554|NCT01869907|Drug|Amitriptyline|25mg once daily by mouth during 14 days
162555|NCT01869920|Behavioral|Intervention group|Education on breastfeeding
162556|NCT00107367|Radiation|intraoperative radiation therapy|
162557|NCT01869920|Behavioral|Usual care|Usual care
162558|NCT01869933|Drug|OC-10X|
162559|NCT01869946|Drug|Ropivacaine|
162560|NCT01869959|Drug|LY2405319|Administered SQ.
162561|NCT01869959|Drug|Placebo|Administered SQ.
162562|NCT01869985|Drug|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
162563|NCT01870011|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
162564|NCT01870011|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
162565|NCT01870024|Drug|Clonazepam|clonazepam 0,015 mg/kg
162566|NCT01870024|Drug|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
162567|NCT00002048|Drug|Zidovudine|
162568|NCT00107380|Biological|rituximab|
162569|NCT01870024|Drug|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
162891|NCT01865396|Behavioral|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
162943|NCT01870648|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
162944|NCT01870661|Device|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
162945|NCT01870661|Device|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
162946|NCT01870674|Drug|YH12852|
162947|NCT01870674|Drug|Prucalopride|
162948|NCT00107432|Drug|sorafenib tosylate|Given orally
162949|NCT01870674|Drug|Placebo|
162950|NCT01870687|Drug|20mg VAC BNO 1095 FCT|
162951|NCT01870687|Drug|Placebo|
162952|NCT01870700|Drug|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
163254|NCT01816243|Drug|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
163255|NCT00101855|Procedure|An evidence based tailored web site|
163256|NCT01816256|Procedure|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
163257|NCT01816282|Drug|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
163258|NCT01816295|Drug|Testosterone Solution|Administered topically to axillae.
163259|NCT01816295|Drug|Placebo Solution|Administered topically to axillae.
163260|NCT01816321|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
163261|NCT01816321|Drug|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
163262|NCT01816321|Drug|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
163263|NCT01818713|Drug|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
162616|NCT01867528|Procedure|Laparoscopic adhesiolysis|
162617|NCT00107198|Procedure|conventional surgery|Undergo surgery
162618|NCT01867528|Procedure|Open adhesiolysis|
162619|NCT01867554|Genetic|gene analysis|gene analysis
162620|NCT01867567|Procedure|abdominal bandage|
162621|NCT01867580|Device|V.A.C.Ulta with instillation|NPWT with instillation of a wound cleanser
162622|NCT01867580|Device|V.A.C.Ulta without instillation|NPWT only
162623|NCT01867593|Device|C-11 methionine PET|
162624|NCT01867606|Biological|serum-derived bovine immunoglobulin protein isolate|Given PO
162625|NCT01867606|Other|placebo|Given PO
162626|NCT01867606|Other|laboratory biomarker analysis|Correlative studies
162627|NCT01867606|Other|quality-of-life assessment|Ancillary studies
162628|NCT00107198|Drug|cyclophosphamide|Given IV
162629|NCT01867606|Other|questionnaire administration|Ancillary studies
162630|NCT01867619|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
162631|NCT01867619|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
162632|NCT01867619|Drug|Thalidomide|200 mg/m^2 by mouth daily.
162633|NCT01867632|Device|Acellular Dermal Matrix|
162953|NCT01870700|Drug|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
162954|NCT01870726|Drug|INC280|Phase Ib: INC280 will be given at the starting dose of 200mg twice daily. Phase II: INC280 will be given at the dose of 400mg (tablets) twice daily.
162955|NCT01870726|Drug|Buparlisib|Buparlisib will be given at the starting dose of 50mg once daily.
162956|NCT01870739|Drug|LCZ696|
162957|NCT01870739|Drug|olmesartan|
162958|NCT01870739|Other|placebo to LCZ696|placebo
161995|NCT01868945|Dietary Supplement|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
161996|NCT01868984|Drug|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
162315|NCT01871818|Behavioral|Combined program|Combined program with physiotherapy, endurance training and resistance training
162316|NCT01871818|Behavioral|Physiotherapy in private practice|Physiotherapy in private practice
162317|NCT01871831|Device|6 blood glucose monitoring systems for self-testing|
162318|NCT01871844|Drug|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
162319|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
162320|NCT01864395|Procedure|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
162321|NCT01864395|Procedure|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
162322|NCT01864395|Procedure|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
162323|NCT01864408|Other|"Usual practice" counseling|
162324|NCT01864408|Other|Standard "usual practice" clinical counseling with the pelvic organ prolapse web-based tool (iPad).|After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard "usual practice" counseling.
162325|NCT01864434|Device|Stryker PCR TKA|
162326|NCT01864434|Device|Zimmer PCR TKA|
162327|NCT00106860|Drug|a benzodiazepine drug|
162328|NCT01864447|Behavioral|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
162329|NCT01864460|Behavioral|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months.
162330|NCT01864473|Other|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
161687|NCT01865760|Drug|Synthetic Exendin 9-39|At baseline subjects will receive a liquid mixed meal and iv bolus infusion of Exendin(9-39) 43.000 pmol/kg followed by a continuous infusion of 900 pmol/kg/min in the next 5 hours
161688|NCT01865773|Procedure|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
161689|NCT01865812|Drug|obeticholic acid (OCA)|All subjects will be treated with OCA (oral administration, 10 mg, once daily) for 8 weeks and should continue their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8 week study period, subjects will be offered the opportunity to enter an open label long term safety extension for up to years.
161997|NCT01868984|Procedure|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
161998|NCT01868997|Drug|teprotumumab|10mg/kg first infusion then 20mg/kg for remaining 7 infusions administered every 3 weeks over 6 months
161999|NCT01868997|Drug|Placebo|Normal saline solution
162000|NCT00107341|Drug|bortezomib|
162001|NCT01871636|Device|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
162002|NCT01871649|Drug|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
162003|NCT01871649|Drug|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
162004|NCT01871662|Drug|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
162005|NCT01871662|Drug|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
162006|NCT01871662|Drug|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
162007|NCT01871675|Drug|IPI-145|
162008|NCT00107510|Drug|carboplatin|
162009|NCT01871675|Drug|Rituximab|
162010|NCT01871675|Drug|Bendamustine|
162011|NCT01871688|Behavioral|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
161386|NCT01785472|Drug|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
161387|NCT01785485|Other|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
161388|NCT00000281|Behavioral|Amantadine|
161389|NCT00001941|Biological|daclizumab|
161390|NCT00098839|Drug|doxorubicin hydrochloride|Given IV
161391|NCT01785498|Behavioral|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
161392|NCT01785511|Radiation|UVA Radiation|UVA radiation exposure for 20 minutes
161393|NCT01785524|Drug|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
161394|NCT01785524|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
161395|NCT01785550|Other|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
161690|NCT01865825|Radiation|Esophageal Barium Xray|•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
We will have patients complete the Mayo Dysphasia Questionnaire-30 day.
161691|NCT01865838|Device|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
161692|NCT01865851|Device|Classic Face Mask and NuMask|
161693|NCT01868438|Drug|Pyronaridine-artesunate tablets|
161694|NCT00107250|Drug|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
161695|NCT01868451|Drug|Brentuximab vedotin (SGN-35)|
161696|NCT01868451|Drug|Doxorubicin HCL|
161697|NCT01868451|Drug|Vinblastine Sulfate|
161090|NCT01790321|Device|LSF-filtering device|LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 NTU turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
161091|NCT01790334|Other|Ultrasonography|
161092|NCT01782677|Procedure|Bilateral Surgical Resection of Carotid Bodies|
161093|NCT01782729|Drug|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
161094|NCT00098670|Biological|alemtuzumab|Given SC
161095|NCT01782742|Drug|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
161096|NCT01782742|Drug|Placebo|
161097|NCT01782755|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
161098|NCT01782755|Other|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
161099|NCT01782768|Device|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
161100|NCT01782781|Drug|ropivacaine, ketorelac and epinephrine|Active group
161101|NCT01782781|Drug|Placebo|Placebo group
161102|NCT01782794|Other|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
161103|NCT01782807|Procedure|Salpingectomy or Fimbriectomy|
161396|NCT01785563|Procedure|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
161397|NCT01785576|Behavioral|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
160815|NCT01787084|Device|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
160816|NCT01789814|Drug|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
160817|NCT01789814|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
160818|NCT01789827|Other|Laboratory Biomarker Analysis|Correlative studies
160819|NCT01789827|Procedure|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
160820|NCT01789827|Biological|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
160821|NCT01789840|Device|Embosphere Microspheres|
161104|NCT01782833|Drug|Pletaal|
161105|NCT00098670|Biological|rituximab|Given IV
161106|NCT01782846|Drug|Ixprim®|
161107|NCT01782846|Drug|Dafalgan-Codeine®|
161108|NCT01782859|Drug|Prednisone|
161109|NCT01782859|Drug|Hydrocortisone|
161110|NCT01782859|Drug|Placebo (for Prednisone)|
161111|NCT01782872|Procedure|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous (IV): saline
161112|NCT01782872|Procedure|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
161113|NCT01782872|Procedure|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
161114|NCT01782872|Procedure|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
161115|NCT01782885|Procedure|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
161116|NCT00098670|Drug|fludarabine phosphate|Given IV
160504|NCT01791699|Drug|Placebo|
160505|NCT01791712|Procedure|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
160506|NCT01791712|Procedure|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
160507|NCT00099294|Drug|Glufosfamide|
160508|NCT01791725|Drug|ELND005|
160509|NCT01791725|Drug|Placebo|
160510|NCT01791738|Procedure|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
160511|NCT01791751|Drug|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
160512|NCT01783925|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
160513|NCT01783938|Biological|Nivolumab|
160514|NCT01783938|Biological|Ipilimumab|
160515|NCT01783951|Other|S-1 plus DC-CIK|
160516|NCT01783964|Drug|[14C]-Elacytarabine|Single intravenous administration
160517|NCT00098774|Biological|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, & 24 of Cycle 1 nad Days 3 & 10 of Cycle 2
160518|NCT01783977|Biological|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
160519|NCT01783977|Biological|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10^8 PFU/ml; administered as 1 mL IM in participant's deltoid
160822|NCT01789840|Procedure|TURP|
160823|NCT01789853|Behavioral|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
160824|NCT00099112|Procedure|biopsy|
160825|NCT01789853|Behavioral|Conventional Physical Therapy|Regular physical therapy for 8 weeks
160826|NCT01789879|Drug|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
160214|NCT01788774|Drug|Risperidone ISM 100 mg|
160215|NCT01788787|Behavioral|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
160216|NCT01788787|Behavioral|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
160217|NCT00099008|Dietary Supplement|Genistein|oral Genistein twice daily on days 1-84
160218|NCT01788787|Behavioral|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
160219|NCT01788787|Behavioral|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
160220|NCT01788800|Behavioral|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
160221|NCT01788813|Drug|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
160222|NCT01788813|Drug|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
160223|NCT01788826|Procedure|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
160224|NCT01788826|Procedure|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
160225|NCT01791075|Device|Endosaver|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
160520|NCT01783977|Biological|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10^6 PFU/ml for a planned maximum dose of 1.1x10^7 PFU/ml; administered as 1 mL IM in participant's deltoid
160521|NCT01783977|Biological|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
160522|NCT01783977|Biological|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
159926|NCT01800552|Procedure|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
159927|NCT00100386|Procedure|Intensive Control Strategy|
159928|NCT01792947|Behavioral|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
159929|NCT01792986|Behavioral|water-only 24-hour fasting|
159930|NCT01793025|Biological|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
159931|NCT01793038|Drug|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
159932|NCT01793038|Drug|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
159933|NCT00099463|Drug|VRC-SRSDNA015-00-VP|
159934|NCT01793051|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
159935|NCT01793051|Other|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
159936|NCT01793051|Behavioral|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
159937|NCT01793064|Behavioral|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
159938|NCT01793064|Behavioral|Static Intervention (SI)|Static Intervention group (SI) receives a static "usual care" goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website.
159939|NCT01793077|Drug|Depo-Eligard®|Subcutaneous
159940|NCT01793090|Drug|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
159941|NCT01793090|Other|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
159942|NCT01793129|Device|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
159943|NCT01793129|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
160226|NCT01791088|Drug|sirolimus|Given PO
159355|NCT01794689|Drug|Saline Placebo (for Morphine)|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
159356|NCT01794702|Drug|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
159357|NCT01794702|Drug|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
159358|NCT01794702|Drug|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
159648|NCT01797380|Drug|Placebo|Placebo daily for duration of double-blind portion of trial
159649|NCT00099983|Drug|Placebo|Placebo
159650|NCT01797380|Drug|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
159651|NCT01799954|Biological|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
159652|NCT01799954|Biological|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
159653|NCT01799954|Biological|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
159654|NCT01799993|Drug|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
159655|NCT01799993|Drug|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
159656|NCT01800006|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
159657|NCT01800019|Drug|Nicotine Replacement Therapy (NRT)|
159658|NCT01800019|Drug|Varenicline|
159659|NCT01800019|Behavioral|HIV Tailored Quit Smoking Counseling|A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.
People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24.
159660|NCT01800045|Drug|Pitolisant|1 capsule in the morning before breakfast
159661|NCT00001965|Drug|Cyclosporine A|
159662|NCT00100295|Drug|Hypericum perforatum|300 mg capsule taken three times a day
159051|NCT01801475|Drug|Ondansetron|Pregnant & non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
159052|NCT01801514|Device|Computed Tomography scan|Routine Computed Tomography scan
159053|NCT01801527|Behavioral|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
159054|NCT01801540|Dietary Supplement|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
159055|NCT00100477|Drug|Mitozantrone|
159056|NCT01801553|Other|Spinal manipulation|-In the intervention group :
True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:
If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.
-In the control group:
Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body.
159057|NCT01801553|Other|sham spinal manipulation|
159058|NCT01801553|Other|Usual medical care|
159359|NCT01794702|Drug|Clofarabine|Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)
Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion).
159360|NCT00099632|Drug|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
159361|NCT01794715|Procedure|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
159362|NCT01794741|Drug|Dymista Nasal Spray|
159363|NCT01796808|Procedure|Pedal Fat Grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity.
159364|NCT01796808|Drug|Local anesthetic|To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.
Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot.
158743|NCT01798134|Device|TANDEM™|
158744|NCT01798147|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
158745|NCT01798147|Procedure|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
158746|NCT00100061|Drug|Cranberry juice|liquid juice taken daily
158747|NCT01798160|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
158748|NCT01798160|Procedure|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
158749|NCT01798173|Biological|Serum, plasma and DNA samples|
158750|NCT01798173|Procedure|Radiological exploration by CT scan or MRI|
158751|NCT01798186|Drug|Cannabis|Cannabis cigarettes, each containing approximately one gram of cannabis, will be smoked during a 60-minute session.
159059|NCT01801566|Procedure|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
159060|NCT01801605|Procedure|rTMS|Active session with stimulation and placebo session with fictive stimulation
159061|NCT01801631|Other|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
159062|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
159063|NCT01801644|Drug|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
159064|NCT01801670|Procedure|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
159065|NCT01801670|Procedure|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
159066|NCT00100477|Drug|Etoposide|
159067|NCT01794169|Drug|DA|
159068|NCT01794182|Drug|RP-1127 (Glyburide for Injection)|Glyburide (5-chloro-N-(4-[N-(cyclohexylcarbamoyl) sulfamoyl]phenethyl)-2- methoxybenzamide) is an anti-diabetic medication in a class of medications known as sulfonylureas. RP-1127 is a formulation of glyburide designed for intravenous administration.
158457|NCT01774422|Device|Extracorporeal CO2 removal device|
158458|NCT01774435|Drug|EN3342|
158459|NCT01774448|Behavioral|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
158460|NCT01774461|Other|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
158461|NCT01777048|Dietary Supplement|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
158462|NCT01777061|Drug|[11C]Acetate|intravenous injection of an average of 40 mCi of [11C]Acetate
158463|NCT01777074|Other|Data collection|Questionnaire, Vaccination book
158464|NCT01777087|Other|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
158465|NCT00098059|Drug|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
158466|NCT01777100|Drug|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
158467|NCT01777113|Other|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
158752|NCT01798186|Drug|Second-hand cannabis smoke|See description of study arm
158753|NCT01798199|Other|The training by Verve System|
158754|NCT01798212|Procedure|endoscopic full thickness plication|
158755|NCT01798225|Drug|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
158756|NCT01798225|Drug|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
158757|NCT00100061|Dietary Supplement|Cranberry Juice|Taken orally
158758|NCT01798238|Drug|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
163198|NCT01821066|Drug|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
163199|NCT01821066|Drug|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
163200|NCT01821066|Drug|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
163201|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
163202|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
163203|NCT00102310|Drug|YM443|
163204|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
163205|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
163206|NCT01821092|Procedure|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
163207|NCT01821092|Device|osseointegrated implant|
163208|NCT01821105|Procedure|PET Scan|All patients will receive whole body PET scans (chest-abdomen-pelvis).
163209|NCT01821105|Procedure|CT Scan|All patients will receive CT scans of the abdomen and pelvis with contrast.
163210|NCT01821105|Radiation|fludeoxyglucose F 18|Given IV
163211|NCT01821105|Procedure|computer-aided detection/diagnosis|Undergo computer-aided detection/diagnosis during surgery
163212|NCT01821118|Biological|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
163213|NCT01821118|Other|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
163214|NCT00102323|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
158468|NCT01777113|Other|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
162892|NCT01865396|Behavioral|Standard oncologic care|Patients will receive standard oncologic care.
162893|NCT01865409|Behavioral|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
162894|NCT01865422|Other|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
162895|NCT00107003|Procedure|Conventional surgery|
162896|NCT01865435|Genetic|cord blood sample|
162897|NCT01865448|Dietary Supplement|Omega-3 DHA|Patients take daily 2 tablets of placebo
162898|NCT01865474|Drug|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
162899|NCT01865474|Drug|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
162900|NCT01865487|Biological|AERAS-456|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
162901|NCT01865487|Biological|Placebo|0.8 mL sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
162902|NCT01865500|Drug|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
162903|NCT01865500|Drug|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
162904|NCT01865500|Drug|Metil prednisolone|
162905|NCT01865526|Dietary Supplement|Six point diet|The 6-point diet is a list of six items indicating how to modify their dietary habits:
Do not add salt at table and for cooking;
Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;
Replace noodle or bread with special no-protein food;
The second course (meat, fish and eggs) are allowed once a day in the usual quantity;
4-5 servings/day of fruits or vegetables are suggested;
Once or twice a week the main course may be of "normal" noodle with legumes instead of the second course, with fruit and vegetables.
162906|NCT00107003|Procedure|Neoadjuvant therapy|
162907|NCT01865526|Dietary Supplement|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
162908|NCT01865539|Device|Custom Foot Orthotic|Custom foot orthotic with custom design pads
162909|NCT01865539|Device|Sham Orthotic|Leather insert without the custom design pads
162910|NCT01865552|Biological|SB4|SC administration
163264|NCT01818726|Drug|ICL670A and standard immunosupressive therapy (Cyclosporine A)|In the investigational arm all patients recieve a standard immunosuppressant (Cyclosporine A). The starting dose of Exjade will be 20 mg/kg/day with up- and down-titration steps of 5-10 mg/kg/day if necessary, depending on serum ferritin, tolerability and comorbidities. Doses above 30 mg/kg are discouraged as such experience is limited in aplastic anemia. Patients are to take Exjade once daily at least 30 minutes before meals, on the same time each day. A combination of 250 mg and 500 mg tablets may be used to provide a specific dose level. The duration of treatment in this study is 12 months. The investigator muct emphasize complaince and will instruct the patients to take the Exjade exactly as prescribe.
163265|NCT01818726|Drug|Immunosupressive therapy (Cyclosporine A)|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload is undergoing treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
163266|NCT01818739|Procedure|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
163267|NCT01818739|Drug|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
163268|NCT01818739|Drug|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
163269|NCT01818739|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
163270|NCT01818752|Drug|Carfilzomib|Carfilzomib 20 mg/m2 IV over 30 to 60 minutes will be administered on Days 1 and 2 of Cycle 1, followed by escalation to 36 mg/m2 IV over 30 to 60 minutes on Days 8, 9, 22, 23, 29, and 30 of Cycle 1. Carfilzomib 36 mg/m2 IV is administered on days 1, 2, 8, 9, 22, 23, 29 and 30 of Cycles 2 to 9.
163271|NCT00102089|Drug|VRC-HIVADV014-00-VP|
158519|NCT00097786|Drug|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
158520|NCT01774487|Drug|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
158521|NCT01774513|Device|Procore-Needle|
158522|NCT01774526|Other|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
158523|NCT01774539|Other|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
158524|NCT01774552|Device|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
158525|NCT01774565|Device|Fully Automated Closed-Loop Insulin Delivery|
158526|NCT01774565|Device|Conventional insulin therapy|
162959|NCT00002049|Drug|Thymopentin|
162960|NCT00107432|Other|laboratory biomarker analysis|Correlative studies
162961|NCT01870739|Other|placebo to olmesartan|placebo
162962|NCT01863160|Drug|0.1% ZEP-3 cream|Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to "in advanced" demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).
The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.
Right arm, single treatment area - ZEP-3 (0.1%)
Left arm, single treatment area - Placebo cream
162963|NCT01863160|Drug|placebo|Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to "in advanced" demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).
The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.
Right arm, single treatment area - ZEP-3 (1.0%)
Left arm, single treatment area - Placebo cream
162964|NCT00106587|Device|paclitaxel coated balloon catheter (device with drug)|
162965|NCT01863173|Drug|metoprolol|using B blocker in patient group
162966|NCT01863173|Drug|placebo|placebo to control group
162967|NCT01863186|Drug|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
162968|NCT01863186|Drug|Placebo|Lofexidine-matching sugar pills will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo. One lofexidine-matching sugar pill will be taken with each dose for subjects assigned to the 2.4 mg treatment group to maintain the study blind.
162969|NCT01863186|Drug|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
162970|NCT01863199|Drug|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
162971|NCT01863199|Drug|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
163272|NCT01818752|Drug|Bortezomib|Bortezomib 1.3 mg/m2 IV push or subcutaneous will be administered on Days 1, 4, 8, 11, 22, 25, 29, and 32 of Cycles 1 through 4, and on Days 1, 8, 22, and 29 of Cycles 5 through 9.
163273|NCT01818752|Drug|Melphalan|
163274|NCT01818752|Drug|Prednisone|Prednisone 60 mg/m2 will be taken on Days 1-4, all cycles.
163275|NCT01818765|Procedure|Trans-ventricular-septal placement of LV pacing lead|
162331|NCT01864486|Device|Intelligent Retinal Implant System|
162332|NCT01864499|Procedure|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
162333|NCT01864525|Drug|Octanoic acid|
162334|NCT01864538|Drug|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
162634|NCT01867645|Drug|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
162635|NCT01867645|Drug|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
162636|NCT01867658|Device|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
162637|NCT01867671|Biological|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
162638|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
162639|NCT00107198|Drug|prednisone|Given IV or PO
162640|NCT01867671|Biological|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
162641|NCT01870024|Drug|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
162642|NCT01870037|Drug|Placebo (PBS-20% sucrose)|
162643|NCT01870037|Drug|hMaxi-K|Single Treatment/ 2 escalating dose levels (16000 µg and 24000 µg by IM injection)
162644|NCT01870050|Drug|Dapsone gel - verum|
162645|NCT01870076|Behavioral|Healing Touch|
162646|NCT01870076|Behavioral|Healing Touch, Sham|
162647|NCT01870076|Behavioral|Control, Presence|
162648|NCT01870089|Device|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
162649|NCT01870102|Drug|Pelubiprofen IR (Pelubiprofen 30mg) TID|
162650|NCT00107380|Drug|cyclophosphamide|
162012|NCT01871701|Drug|Escitalopram|Escitalopram
162013|NCT01871701|Drug|Quetiapine|Quetiapine
162014|NCT01871701|Drug|Moxifloxacin|Moxifloxacin
162015|NCT01871701|Other|Placebo|Placebo
162016|NCT01871727|Drug|E7777|administered by intravenous (i.v.) infusion over 60 minutes (+/- 10 minutes) on 5 consecutive days during every cycle of 21 days
162017|NCT01871740|Drug|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
162335|NCT01864551|Drug|Lamotrigine|
162336|NCT01864551|Drug|Olanzapine|
162337|NCT01864564|Other|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-18 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
162338|NCT00002041|Drug|Amphotericin B|
162339|NCT00106886|Drug|Folic acid, vitamin B6 and B12 or placebo|
162340|NCT01864577|Other|Negative Pleural Suction at -20 cm H2O|
162341|NCT01864577|Other|Water seal|
162342|NCT01864590|Device|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
162343|NCT01866995|Drug|"Raylis"|"Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)
162344|NCT01866995|Other|standard prostatostasis therapy|
162345|NCT01867021|Biological|Fluvirin(TIVf)|
162346|NCT01867021|Biological|Agriflu (TIV)|
162347|NCT01867034|Other|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
162348|NCT01867034|Other|Bare Metal Stent|
162349|NCT00002044|Drug|Zidovudine|
162350|NCT00107172|Procedure|conventional surgery|No information available
162351|NCT01867047|Drug|Cessation group|Subjects stop ACE-I 48 hours prior to surgery
161698|NCT01868451|Device|Dacarbazine|
161699|NCT01868451|Radiation|Involved-Site Radiation Therapy (ISRT)|
161700|NCT01868451|Procedure|Interim PET|
161701|NCT01868451|Drug|Neupogen|Dosing of Neupogen can be determined at the discretion of the physician. Typically, Neupogen is administered for 3-5 days at the time of nadir (approximately 5-10 days after each treatment).
161702|NCT01868464|Biological|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10^6 cfu, 4x10^6 cfu, 8x10^6 cfu and 16x10^6 cfu, respectively.
161703|NCT01868477|Drug|Erythropoietin alpha|
161704|NCT01868477|Drug|Erythropoietin alpha|
161705|NCT00107250|Drug|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
161706|NCT01868477|Drug|Deferasirox|
161707|NCT01868490|Drug|cytokine induced killer cells|at least 10*9 CIK cells, IV on day 0, 14, 28
161708|NCT01868503|Drug|lapatinib ditosylate|Given PO
161709|NCT01868503|Radiation|radiation therapy|Undergo radiation therapy
161710|NCT01868503|Other|laboratory biomarker analysis|Correlative studies
162018|NCT01871740|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
162019|NCT00107510|Drug|docetaxel|
162020|NCT01871753|Other|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
162021|NCT01871766|Drug|Vincristine|Dosage and route of administration:
< 1 year of age=0.025 mg/kg intravenously (IV)
> 1 year and < 3 years= 0.05 mg/kg IV
≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants.
162022|NCT01871766|Drug|Dactinomycin|Dosage and route of administration:
< 1 year=0.025 mg/kg IV push
≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
162023|NCT01871766|Drug|Cyclophosphamide|Dosage and route of administration:
During VAC chemotherapy:
< 3 years of age = 40 mg/kg IV
≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.
During maintenance for intermediate-risk participants:
oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)
161398|NCT01785589|Procedure|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
161399|NCT01785602|Drug|QAW039|Capsules
161400|NCT01785602|Drug|Placebo|Capsules
161401|NCT00098839|Drug|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
161402|NCT01785615|Drug|Atorvastatin|80mg
161403|NCT01785615|Other|Placebo|80mg
161404|NCT01785628|Dietary Supplement|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
161405|NCT01785628|Dietary Supplement|Placebo Capsule|Placebo is dextrin composition.
161406|NCT01785641|Drug|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
161407|NCT01785641|Drug|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
161408|NCT01788254|Drug|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
161409|NCT01788254|Drug|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
161410|NCT01788267|Other|scan examination HR-pQCT|
161411|NCT01788280|Drug|Fluciclitite , PET imaging, and Bevacizumab|[18F] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
161412|NCT00098982|Drug|leucovorin calcium|
161413|NCT01788293|Other|Intervention group|Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.
This PVI cut-off value was chosen according to previous reports [Cannesson et al., 2008; Zimmermann et al., 2010].
During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation.
161711|NCT01868516|Drug|dexmecamylamine|
161712|NCT01868516|Drug|Placebo|
161117|NCT01782885|Drug|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
161118|NCT01785108|Drug|Vitamin D|
161119|NCT00098813|Other|laboratory biomarker analysis|Correlative studies
161120|NCT01785108|Drug|Ibuprofen|
161121|NCT01785121|Behavioral|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
161122|NCT01785121|Behavioral|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
161123|NCT01785134|Procedure|Omentectomy|
161124|NCT01785134|Procedure|Gastric bypass operation|
161125|NCT01785147|Drug|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
161126|NCT01785147|Drug|Placebo|
161414|NCT01788306|Drug|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
161415|NCT01788319|Procedure|lasertrabeculoplasty|
161416|NCT01788332|Drug|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
161417|NCT01788345|Other|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
161418|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
161419|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
161420|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
161421|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
161422|NCT01788371|Drug|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
160827|NCT01789879|Drug|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
160828|NCT01789879|Drug|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
160829|NCT01789892|Drug|methylprednisolone|Given IV
160830|NCT01789892|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT scan
160831|NCT01789892|Procedure|positron emission tomography|Undergo FDG PET/CT scan
160832|NCT01789892|Procedure|computed tomography|Undergo FDG PET/CT scan
160833|NCT01789905|Drug|Tigecycline (Tygacil)|Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
160834|NCT01789918|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
160835|NCT00099112|Procedure|evaluation of cancer risk factors|
160836|NCT01789931|Device|"Lifebeam"|The "lifebeam" sensor will be attached to the participant's skin during the HTT.
160837|NCT01789944|Behavioral|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
160838|NCT01789957|Drug|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
160839|NCT01789970|Drug|Hydrocodone bitartrate extended-release tablets|
160840|NCT01789970|Drug|Matching placebo|
160841|NCT01791907|Behavioral|Structured education in carbohydrate counting|
160842|NCT01791907|Behavioral|Structured education in healthy food choices and low glycemic index|
160843|NCT01791920|Drug|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
161127|NCT01785160|Drug|Raltegravir|low dose oral administration
161128|NCT01785160|Drug|Raltegravir|low dose oral administration
161129|NCT01785160|Drug|Faldaprevir|medium dose oral administration
161130|NCT00098813|Procedure|positron emission tomography|Correlative studies
160523|NCT01783977|Biological|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
160524|NCT01783990|Drug|Hydroxyurea|Active and Passive groups both are on HU.
160525|NCT01784003|Device|Powered ankle-foot prosthesis|
160526|NCT01784016|Radiation|[11C]-PHNO|[11C]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
160527|NCT01784029|Drug|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
160528|NCT00098774|Drug|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
160529|NCT01784042|Drug|Placebo|placebo
160530|NCT01784042|Drug|Lovaza|
160531|NCT01784042|Other|Dietary energy restriction|
160532|NCT01784068|Drug|Nilotinib followed by treatment-free|Nilotinib will be used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
160533|NCT01784081|Other|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
160534|NCT01784094|Device|StromaGlide|
160535|NCT01784107|Drug|Belotecan and Ifosfamide|
160536|NCT01784120|Drug|Doxorubicin/Genexol-PM|
160537|NCT01784133|Drug|omiganan|
160538|NCT01786460|Other|Blood draw at Days 0, 7, 14, and 21|
160539|NCT01786473|Drug|Testogel 1%|
160540|NCT01786473|Drug|Placebo|
160541|NCT01786486|Device|Amplatzer Cardiac Plug|
160542|NCT01786499|Behavioral|Relaxation Response Training|
160844|NCT01791920|Drug|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
160227|NCT01791088|Other|pharmacological study|Correlative studies
160228|NCT01791088|Other|laboratory biomarker analysis|Correlative studies
160229|NCT00099216|Drug|Rivastigmine|
160230|NCT01791101|Drug|Eltrombopag|
160231|NCT01791114|Other|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
160232|NCT01791114|Other|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
160233|NCT01791114|Other|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
160234|NCT01791114|Other|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
160235|NCT01791114|Other|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
160236|NCT01791114|Other|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
160237|NCT01791114|Other|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
160238|NCT01791127|Device|Patients with a BIOTRONIK pacemaker system and one or two Siello S leads.|
160239|NCT01791153|Drug|prednisone|tapering doses orally daily
160240|NCT00099229|Drug|Licarbazepine|
160241|NCT01791153|Drug|prednisone placebo|incremental doses orally daily
160242|NCT01791153|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneous (SC) every week (qw), 52 weeks
160243|NCT01791153|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw, 104 weeks
160244|NCT01791153|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC every other week (q2w), 52 weeks
159663|NCT01800045|Drug|Placebo|1 capsule in the morning before breakfast
159664|NCT01800071|Drug|MVA-EBNA1/LMP2 vaccine|
159665|NCT01800084|Device|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
159666|NCT01800097|Drug|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
159667|NCT01800097|Drug|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
159668|NCT01800110|Dietary Supplement|pomegranate juice|
159944|NCT00099476|Behavioral|Effects of dark chocolate|
159945|NCT01793142|Drug|Viviant|Viviant (Bazedoxifene) 20mg once daily
159946|NCT01793155|Other|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
159947|NCT01793155|Other|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
159948|NCT01793194|Other|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
159949|NCT01793220|Other|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
159950|NCT01795534|Dietary Supplement|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
159951|NCT01795534|Dietary Supplement|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
159952|NCT01795547|Drug|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
159953|NCT01795547|Drug|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
159954|NCT01795573|Biological|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
159365|NCT01796821|Drug|Vehicle gel|Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.
Total application <1,500 mg gel per day.
159366|NCT01796821|Drug|SR-T100 gel with 1.0 % SM|Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.
Total application <1,500 mg gel per day.
159367|NCT01796821|Drug|SR-T100 gel with 2.3% SM|Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.
Total application <1,500 mg gel per day.
159368|NCT01796834|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
159369|NCT01796860|Other|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
159370|NCT00001961|Procedure|MRI|
159371|NCT00099944|Drug|vildagliptin|
159372|NCT01796886|Other|pupillometry data|
159373|NCT01796899|Other|Brivaracetam 10 mg oral tablet|
159669|NCT01800136|Device|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
159670|NCT01800149|Procedure|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
159671|NCT01800162|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
159672|NCT01800162|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
159673|NCT00100295|Other|Placebo|300 mg given three times a day, containing rice protein powder
159674|NCT01792674|Other|In situ simulation|
159675|NCT01792674|Other|Off site simulation|
159676|NCT01792687|Drug|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
159677|NCT01792687|Drug|Abiraterone acetate|1,000 mg, oral, daily
159069|NCT01794195|Behavioral|Diffusion tensor imaging and fibres tracking|
159070|NCT01794208|Drug|FSH-GEX(TM)|
159071|NCT01794208|Drug|Gonal-f(R)|
159072|NCT01794221|Procedure|application of 2-octyl cyanoacrylate skin adhesive in addition to stitches|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
159073|NCT01794221|Procedure|standard stitches only|standard of care
159074|NCT01794247|Drug|Magnesium sulfate|
159075|NCT01794247|Drug|Fentanyl|
159076|NCT01794247|Drug|Lidocaine|
159077|NCT00099593|Biological|Autologous Dendritic Cell Vaccine|
159078|NCT01794260|Drug|Cream from Zingiber cassumunar Roxb. extract|
159079|NCT01794260|Drug|Placebo cream|
159080|NCT01794273|Drug|ephedrine and phenylephrine|
159374|NCT01796899|Other|Brivaracetam 50 mg oral tablet|
159375|NCT01796899|Other|Brivaracetam 75 mg oral tablet|
159376|NCT01796899|Other|Brivaracetam 100 mg oral tablet|
159377|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
159378|NCT01796912|Other|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
159379|NCT01796912|Other|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
159380|NCT01796925|Device|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
159381|NCT01799356|Drug|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
159382|NCT01799356|Drug|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
159383|NCT00100191|Procedure|uterine artery embolization|
158759|NCT01798238|Drug|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
158760|NCT01798251|Drug|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
158761|NCT01798251|Drug|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
158762|NCT01800838|Drug|silicon phthalocyanine 4|Given topically
158763|NCT01800838|Drug|photodynamic therapy|Undergo DPT
158764|NCT01800838|Other|pharmacological study|Correlative studies
158765|NCT01800838|Other|laboratory biomarker analysis|Correlative studies
158766|NCT01800851|Other|Energy expenditure evaluation in calorimetric chamber|
158767|NCT01800864|Other|obesity|
158768|NCT00100412|Drug|Graded phenylephrine injections|
158769|NCT01800877|Drug|Vasopressors|
158770|NCT01800890|Device|Coloplast A|Coloplast A is a newly developed 2-piece ostomy appliance
158771|NCT01800890|Device|Coloplast B|Coloplast B is a newly developed 2-piece ostomy appliance
158772|NCT01800890|Device|Coloplast C|Coloplast C is a newly developed 2-piece ostomy appliance
158773|NCT01800890|Device|SenSura Click|The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
158774|NCT01800903|Device|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
158775|NCT01800903|Device|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
159081|NCT01794286|Other|Provider bulletins|
159082|NCT01794286|Other|Trigger alerts|
159083|NCT01794299|Biological|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
159084|NCT01794312|Device|T4020|
159085|NCT01794325|Other|Trans-radial|Coronary angiography performed through trans-radial access
158469|NCT01777113|Other|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
158470|NCT01777126|Other|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
158471|NCT01777126|Other|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
158472|NCT01777139|Drug|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
158473|NCT01777152|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
158474|NCT01777152|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
158475|NCT01777152|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
158476|NCT00098072|Procedure|Heart Catheterization|
158477|NCT01777152|Drug|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
158478|NCT01777152|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
158479|NCT01780129|Drug|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
158480|NCT01780181|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
158481|NCT01780181|Drug|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
158482|NCT01780207|Device|PFO Closure|
158483|NCT01780220|Drug|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
158776|NCT01800903|Device|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
162911|NCT01865552|Biological|EU sourced Enbrel|SC administration
163215|NCT01821131|Other|muffin|
163216|NCT01821144|Behavioral|Salt reduction|Salt reduction
163217|NCT01821144|Other|Control|No salt awareness education
163218|NCT01813604|Biological|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
163219|NCT01813604|Biological|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
163220|NCT01813604|Biological|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
163221|NCT01813617|Drug|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
163222|NCT00101543|Device|Electrical Stimulation with Intramuscular Electrodes|
163223|NCT01813630|Drug|DA-3002|
163224|NCT01813630|Drug|Genotropin®|
163225|NCT01813643|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
163226|NCT01813643|Drug|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
163227|NCT01813656|Drug|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
163228|NCT01813656|Drug|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
163229|NCT01813669|Behavioral|Integrative Coping Group|The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:
Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions
163230|NCT01813682|Other|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
163231|NCT01813682|Other|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
158527|NCT01774578|Drug|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
158528|NCT01774578|Biological|HyperAcute®-Lung Immunotherapy|HAL-1, HAL-2 and HAL-3 immunotherapy components.
Up to 16 immunizations of 300 million immunotherapy cells.
158529|NCT01774578|Drug|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
158530|NCT00097786|Drug|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
158531|NCT01774578|Drug|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
158532|NCT01774591|Drug|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
158533|NCT01774591|Drug|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
158534|NCT01774604|Drug|Indomethacin|100 mg Indomethacin PR x 1
158535|NCT01774604|Drug|Placebo|
158536|NCT01774617|Procedure|Comparison of different diagnostic tests|
158835|NCT01798277|Procedure|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
158836|NCT01798277|Drug|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
158837|NCT01798290|Behavioral|narrative medicine: reading workshop|
158838|NCT01798290|Behavioral|critical reading|
158839|NCT01798303|Drug|LY2940094|Administered orally
158840|NCT00001963|Procedure|hemoglobin-transported nitric oxide|
158841|NCT00100061|Dietary Supplement|Placebo cranberry juice|Placebo comparitor
158842|NCT01798303|Drug|Placebo|Administered orally
158843|NCT01798316|Drug|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes
163276|NCT01818765|Other|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
163277|NCT01818765|Other|Acute response assessment|Cardiac output monitoring
163278|NCT01818778|Other|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
163279|NCT01818778|Other|Standard Friendly Visit|Volunteers provided standard "friendly visits" to residents which included a friendly greeting and casual conversation about issues which interest the resident.
163280|NCT01818791|Behavioral|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
163281|NCT01821157|Procedure|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
163282|NCT01821157|Procedure|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
163283|NCT01821170|Drug|Methylphenidate|Patient will take treatment during two months
163284|NCT01821170|Device|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
163285|NCT01821170|Behavioral|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
163286|NCT01821170|Other|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
163287|NCT01821196|Procedure|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
163288|NCT00102323|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
158537|NCT01774630|Drug|Nilotinib|300 mg/twice a day
158538|NCT01777165|Drug|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
158539|NCT01777165|Drug|Placebo|Placebo infusion
162651|NCT01870102|Drug|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
162652|NCT01870115|Dietary Supplement|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
162653|NCT01870115|Dietary Supplement|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
162654|NCT01870128|Drug|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
162655|NCT01870128|Drug|Methotrexate|Methotrexate 15 to 25 mg PO per week
162972|NCT01863199|Drug|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
162973|NCT01863212|Procedure|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
162974|NCT01863212|Behavioral|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
162975|NCT00002039|Drug|Foscarnet sodium|
162976|NCT00106600|Drug|Pixantrone IV infusion|
162977|NCT01863212|Other|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
162978|NCT01863225|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
162979|NCT01863225|Drug|Rosuvastatin|20 mg daily, 28-42 days
162980|NCT01863225|Drug|Atorvastatin|40 mg daily, 28-42 days
162981|NCT01863225|Drug|Rosuvastatin|40 mg daily, 28-42 days
162982|NCT01863225|Drug|Atorvastatin|80 mg daily, 28-42 days
162983|NCT01863238|Other|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
162984|NCT01818154|Other|narrowband UVB phototherapy|
162985|NCT01818167|Drug|10% Benzoyl Peroxide Topical Body Wash|
162986|NCT01818167|Drug|Provodine Topical Cream|
162987|NCT01818180|Dietary Supplement|URELL|
162352|NCT01867047|Drug|Continuation group|Subjects take ACE-I through day of surgery
162353|NCT01867060|Device|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
162354|NCT01867060|Device|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
162355|NCT01867073|Other|Biomarker|
162356|NCT01867086|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
162357|NCT01867086|Drug|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
162656|NCT01870128|Drug|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
162657|NCT01870141|Behavioral|Cognitive-Behavioral Intervention|1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:
self-monitoring
problem solving
goal definition
cognitive restructuring
activation of personal and social resources
162658|NCT01870154|Behavioral|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
162659|NCT01870167|Drug|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
162660|NCT01870167|Dietary Supplement|Placebo|Placebo
162661|NCT00107380|Drug|doxorubicin hydrochloride|
162662|NCT01870180|Device|EyeBag|fabric bag of beads which can be heated in a microwave
162663|NCT01870180|Other|Placebo|
162664|NCT01870193|Dietary Supplement|Glycine, cysteine (as n-acetylcysteine), alanine|Young controls will receive cysteine plus glycine for 2 weeks
The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months
162665|NCT01870206|Biological|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
162666|NCT01862484|Dietary Supplement|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
162024|NCT01871766|Procedure|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
162025|NCT01863940|Device|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
162026|NCT00106717|Procedure|Narrative medicine|
162027|NCT01863953|Drug|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
162028|NCT01863953|Drug|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
162029|NCT01863953|Drug|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
162030|NCT01863953|Drug|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
162031|NCT01863966|Other|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
162032|NCT01863966|Procedure|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
162033|NCT01864005|Drug|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
162034|NCT01864005|Drug|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
162035|NCT01864018|Drug|Cyclophosphamide|Given PO
162036|NCT01864018|Drug|Dexamethasone|Given PO
162037|NCT00106769|Drug|VRC-WNVDNA017-00-VP|
162358|NCT01867086|Drug|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
162359|NCT01867112|Behavioral|Physical Activity|Physical activity either by individualized program or general guidelines
162360|NCT01867125|Drug|lebrikizumab|High dose sc every 4 weeks, Week 1-104 or Week 52-104
162361|NCT00107172|Procedure|therapeutic thoracoscopy|No information available
161713|NCT01868529|Drug|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
161714|NCT01868529|Drug|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
161715|NCT01868542|Drug|insulin detemir|The subjects will have insulin detemir administered once daily. The dose will be titrated twice weekly with changes in dose of +/- 3 units if not on target.
161716|NCT00002046|Drug|Zidovudine|
161717|NCT00107263|Drug|letrozole|
161718|NCT01868542|Drug|insulin detemir|The subjects will have insulin detemir administered once daily. The dose will be titrated twice weekly with changes in dose of 2, 4, 6, 8 units dependent on FPG (fasting plasma glucose) if not on target.
161719|NCT01868555|Drug|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
161720|NCT01871155|Dietary Supplement|Nutri-jelly|an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal
1 serving is considered as food supplement
161721|NCT01871168|Procedure|TAP block|Infusion of 0.5-1% lidocaine
161722|NCT01871168|Procedure|Sham TAP block|Infusion of saline
161723|NCT01871181|Procedure|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
161724|NCT01871181|Procedure|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
161725|NCT01871220|Device|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
161726|NCT01871220|Device|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
161727|NCT01871233|Drug|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
161728|NCT01871272|Procedure|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
161729|NCT00107484|Drug|ferumoxtran-10|
161730|NCT01871285|Drug|Buprenorphine|
161423|NCT00098982|Drug|oxaliplatin|
161424|NCT01788371|Drug|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
161425|NCT01788384|Drug|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
161426|NCT01788384|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
161427|NCT01788384|Drug|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
161428|NCT01790737|Drug|Filgrastim|
161429|NCT01790750|Device|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
161430|NCT01790763|Device|Keramatrix|Dressing for second degree burn
161431|NCT01790763|Device|Mepilex|Dressing for second degree wound
161432|NCT01790776|Radiation|Urografin 30%|Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).
The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled.
161732|NCT01871285|Drug|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
161733|NCT01871285|Drug|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
161734|NCT01871285|Drug|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
161735|NCT01871298|Other|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
161736|NCT01871311|Drug|Nilotinib + Cetuximab|Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
Three dose levels for nilotinib:
Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID
Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity.
161737|NCT01871324|Behavioral|Lifestyle counseling|group therapy
161131|NCT01785173|Procedure|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
161132|NCT01785173|Procedure|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
161133|NCT01785186|Drug|SQ109|SQ109 300 mg
161134|NCT01785186|Drug|Rifampicin|Rifampicin 10 to 35 mg/kg
161135|NCT01785186|Drug|Moxifloxacin|Moxifloxacin 400mg
161136|NCT01785186|Drug|isoniazid|isoniazid 75 mg
161137|NCT01785186|Drug|pyrazinamide|pyrazinamide 400 mg
161138|NCT01785186|Drug|ethambutol|ethambutol 275 mg
161139|NCT01785186|Dietary Supplement|pyridoxine|pyridoxine 25 mg
161140|NCT01785199|Procedure|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
161141|NCT00098826|Drug|ispinesib|Given IV
161142|NCT01785212|Device|Stapler|stapler hepatectomy
161143|NCT01785212|Device|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
161144|NCT01785225|Device|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
161145|NCT01787591|Other|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
161146|NCT01787591|Other|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
161147|NCT01787591|Other|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
161148|NCT01787591|Other|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
161149|NCT01787604|Procedure|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
161433|NCT01790776|Radiation|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
160845|NCT01791933|Drug|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
160846|NCT01791933|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
160847|NCT01791933|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10~20 acupoints 1-2times a week for more than 2 months
160848|NCT00099333|Drug|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
160849|NCT01791933|Procedure|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
160850|NCT01791946|Procedure|Binocular Treatment Training|The binocular treatment training involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
160851|NCT01791946|Procedure|Sham Binocular Treatment Training|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
160852|NCT01791959|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
160853|NCT01791959|Other|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
160854|NCT01791972|Drug|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
160855|NCT01791972|Drug|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
160856|NCT01791985|Drug|AZD4547 / anastrozole or letrozole|Patients will continue or restart the NSAI which they have progressed* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).
AZD4547 will be given on an intermittent schedule of one week on / one week off.
*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment.
160857|NCT01791998|Procedure|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
160858|NCT01791998|Procedure|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
160245|NCT01791153|Drug|tocilizumab placebo|matching SC placebo, 52 weeks
160543|NCT01786512|Drug|Omecamtiv mecarbil|Oral omecamtiv mecarbil dose of 25-mg BID for 7 days
160544|NCT01786512|Drug|Omecamtiv mecarbil|Oral omecamtiv mecardbil dose of 50-mg BID for 7 days.
160545|NCT00098839|Biological|filgrastim|Given SC
160546|NCT01786512|Drug|Placebo|Placebo
160547|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25-mg BID for 20 weeks.
160548|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25 mg BID for 8 weeks followed by 50-mg BID for 12 weeks
160549|NCT01786525|Behavioral|House Calls|60-minute home based educational intervention which will be administered by a health educator
160550|NCT01786525|Behavioral|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
160551|NCT01786538|Drug|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
160552|NCT01786538|Drug|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
160553|NCT01786551|Drug|Eplerenone|50mg daily
160554|NCT01786577|Other|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
160555|NCT01786577|Behavioral|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
160556|NCT00098852|Drug|rosiglitazone maleate|
160557|NCT01786590|Procedure|EBUS-TBNA|Currently EBUS-TBNA is performed in patients with CT and/or PET positive lymph nodes in the mediastinum or hilum. In this study, all patients being considered for SBRT will undergo EBUS-TBNA for the lymph node staging prior to SBRT.
160558|NCT01786603|Drug|Rasagiline|Rasagiline 2mg once a day for 12 months.
160559|NCT01786603|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
160560|NCT01786616|Drug|Formoterol|
159955|NCT01795586|Drug|Eribulin|Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.
Level 1: 0.9 mg/m^2; Level 2: 1.1 mg/m^2; Level 3: 1.4 mg/m^2
159956|NCT01795586|Drug|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
159957|NCT01795599|Drug|Mifegyne ®|
159958|NCT00099788|Drug|Ranolazine|IV to oral transition.
159959|NCT01795599|Drug|Gymiso®|
159960|NCT01795612|Other|physical activity|
159961|NCT01795638|Drug|Sodium chloride|
160246|NCT01791166|Biological|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
160247|NCT01791179|Behavioral|Comprehensive substance abuse services|
160248|NCT01783535|Radiation|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
160249|NCT01783548|Drug|BDP Nasal Aerosol|
160250|NCT01783548|Drug|Placebo|
160251|NCT01783561|Drug|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 30 minutes of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
160252|NCT01783574|Drug|Testosterone|
160253|NCT01783574|Drug|Placebo|
160254|NCT01783587|Drug|Afatinib|Taken orally once per day
160255|NCT01783587|Drug|Docetaxel|15 mg/m2, given intravenously once per week
160256|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
160257|NCT01783587|Radiation|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
159678|NCT01792687|Drug|Prednisone|5 mg, oral, daily
159679|NCT01792700|Drug|esomeprazole|
159680|NCT01792700|Drug|tripotassium dicitrate bismuthate|
159681|NCT01792700|Drug|metronidazole|
159682|NCT01792700|Drug|tetracycline|
159683|NCT01792700|Drug|moxifloxacin|
159684|NCT00099450|Drug|INS50589 Intravenous Infusion|
159685|NCT01792700|Drug|amoxicillin|
159686|NCT01792713|Drug|Sertaconazole 2% cream|
159687|NCT01792713|Drug|Placebo|
159688|NCT01792726|Radiation|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
159689|NCT01792739|Drug|Lactobacillus casei variety rhamnosus granules|Lactobacillus casei variety rhamnosus granules
: 3 gram per day (1g-1g-1g, 3 times per day)
159690|NCT01792739|Drug|Placebo|Placebo granules
: 3 gram per day (1g-1g-1g, 3 times per day)
159962|NCT01795638|Drug|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
159963|NCT01795651|Procedure|identification of take-home message of lecture|
159964|NCT01795664|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
159965|NCT01795664|Drug|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg
At visit 2 or visit 3 (cross-over design)
159966|NCT01795664|Drug|Seretide Evohaler|Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg
At visit 2 or visit 3 (cross-over design)
159967|NCT01795664|Drug|Placebo of Test product|Single dose of 2 puffs
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
159968|NCT01795664|Drug|Placebo of Reference product|Single dose of 2 puffs
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
159969|NCT00099788|Drug|Placebo|IV to oral transition.
159970|NCT01795677|Drug|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
159384|NCT01799369|Behavioral|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
159385|NCT01799382|Other|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
159386|NCT01799382|Device|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
159387|NCT01799434|Other|treadmill run|
159388|NCT01799447|Behavioral|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
159389|NCT01799460|Drug|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day
②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.
③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily.
159390|NCT01799460|Drug|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
159391|NCT01799486|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
159392|NCT01799486|Drug|Enecavir|0.5 mg monotherapy supplied in tablets.
159393|NCT01799486|Drug|Adefovir|10 mg monotherapy supplied in tablets.
159691|NCT01792752|Behavioral|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
159692|NCT01792752|Behavioral|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
159693|NCT01792752|Behavioral|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
159086|NCT01794325|Other|Trans-femoral|Coronary angiography performed through trans-femoral access
159087|NCT01794338|Device|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
159088|NCT00099606|Drug|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
159089|NCT01794338|Device|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
159090|NCT01794351|Dietary Supplement|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
159091|NCT01794351|Other|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
159092|NCT01794364|Drug|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
159093|NCT01794364|Other|placebo|Correspondingly, placebo doses will be administered as suspension.
159094|NCT01796314|Behavioral|Therapeutic Educational Program|The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.
These collective sessions focus on :
Knowledge of the disease
Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia
Crisis situations. Prevention of caregiver's exhaustion
Assistive devices and care pathways.
Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures.
159095|NCT01796327|Drug|dacomitinib oral|Dacomitinib 45 mg oral tablet
159096|NCT01796327|Drug|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
159097|NCT01796340|Behavioral|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
159098|NCT01796340|Behavioral|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
159099|NCT00099866|Drug|Metformin Comparator|
159100|NCT01796353|Other|sexual rehabilitation|exercise plus psycho-education
159394|NCT00100191|Procedure|hysterectomy|
159395|NCT01799499|Device|TC-3 hydrogel|
159396|NCT01799499|Device|TC-3 hydrogel|
159397|NCT01799499|Device|TC-3 hydrogel|
158777|NCT01800916|Device|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
158778|NCT01800916|Device|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
158779|NCT00100412|Behavioral|Psychosocial challenge involving socioevaluative public speaking|
158780|NCT01800916|Device|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
158781|NCT01800916|Device|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
158782|NCT01800929|Device|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
158783|NCT01800942|Drug|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
158784|NCT01800955|Device|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
158785|NCT01800955|Other|sham placebo resistive capacitive diathermy treatment|The sham treatment is administered with the diathermy device set on "on" but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group
158786|NCT01800968|Drug|Liraglutide|Active Drug
158787|NCT01800968|Drug|Placebo|Placebo
158788|NCT01801007|Device|Flow Re-Direction Endoluminal Device|
158789|NCT01793688|Drug|Sulbactam Sodium (SBT)/Ampicillin Sodium (ABPC)|Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).
Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).
158790|NCT01793701|Radiation|intensity modulated radiotherapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy).
This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
158791|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
163232|NCT01813695|Procedure|Preemptive genotyping in medical record|
163233|NCT00101543|Procedure|Body Weight Supported Treadmill Training|
163234|NCT01813695|Procedure|Genotyping not included in electronic medical record|
158484|NCT00098436|Drug|laromustine|
158485|NCT01780233|Drug|Fentanyl 400 µg sublingual spray|
158486|NCT01780233|Drug|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
158487|NCT01780233|Drug|Fentanyl citrate injection 100 µg intravenously|
158488|NCT01780233|Drug|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
158489|NCT01780246|Drug|ISIS-SMNRx|Single intrathecal injection
158490|NCT01780259|Drug|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
158491|NCT01780259|Drug|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
158492|NCT01780259|Drug|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
158493|NCT01780272|Other|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
158494|NCT01780285|Device|Nitinol-framed lightweight PTFE mesh for hiatal repair|The heart-shaped nitinol-framed lightweight PTFE prosthesis "Rebound HRD-Hiatus hernia" (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair.
158495|NCT00098436|Drug|temozolomide|
158496|NCT01771822|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
158844|NCT01798316|Drug|Standard of Care|Morphine 5mg every 10 min for 2 doses
158845|NCT01798329|Dietary Supplement|probiotic VSL#3|VSL#3 is a probiotic that reduces:
urease faecal activity
faecal pH
inflammatory cytokine
158846|NCT01798342|Dietary Supplement|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
158847|NCT01798342|Dietary Supplement|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
158848|NCT01798355|Behavioral|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
158849|NCT01798355|Behavioral|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
158850|NCT01798368|Device|PBASE system 2.0|
158851|NCT01798381|Dietary Supplement|Essential fatty acids|
158852|NCT00100074|Drug|Lobeline|
158853|NCT01798394|Drug|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
158854|NCT01798394|Other|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
158855|NCT01798407|Device|Medtronic Activa Tremor Control System|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions, Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
159167|NCT01801891|Device|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
159168|NCT01801891|Other|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
159169|NCT01794377|Behavioral|30 minutes of high intensity training|This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:
30 sec at 120% of Vo2max,
1 min at 50% of Vo2max,
15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,
1 min at 50% of Vo2max.
The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.
Training three times per week for 5 months under supervision of an exercise physiologist.
Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).
Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study.
158540|NCT01777178|Other|Low bicarbonate dialysis|
158541|NCT01777191|Drug|Ixekizumab Auto-Injector|Administered SC by auto-injector
158542|NCT01777191|Drug|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
158543|NCT01777217|Drug|Solifenacin succinate|IGRT with VESIcare
158544|NCT01777217|Drug|Placebo|IGRT with placebo
158545|NCT01777230|Procedure|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
158546|NCT00098072|Drug|Nitric Oxide|
158547|NCT01777230|Procedure|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
158548|NCT01777230|Procedure|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
158549|NCT01777243|Drug|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg [approximately equivalent to 0.1 mg/ kg]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
158550|NCT01777243|Drug|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
158551|NCT01777256|Drug|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
158552|NCT01777256|Drug|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
158553|NCT01777256|Drug|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
158554|NCT01777256|Drug|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
158555|NCT01777256|Drug|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
158556|NCT01777269|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
158557|NCT00000280|Drug|Nimodipine|
158558|NCT00001926|Drug|O15|
158559|NCT00098072|Drug|Nitric Oxide/INO Pulse Delivery|
158856|NCT01798433|Device|One stent technique alone|One stent technique alone with drug-eluting stent
162988|NCT01818180|Other|Placebo|
162989|NCT01818206|Other|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
162990|NCT01818219|Procedure|Records of EADI derived parameters|
162991|NCT01818232|Drug|[14C]-LX4211|
162992|NCT00102037|Drug|activated recombinant human factor VII|
162993|NCT01818245|Drug|LY2605541|Administered SC.
162994|NCT01818258|Drug|ZDV+3TC+LPV/r|
162995|NCT01818271|Behavioral|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
163289|NCT01821209|Procedure|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
163290|NCT01821222|Device|Wired mothers|The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.
Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider.
163291|NCT01821235|Drug|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
163292|NCT01821235|Drug|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
163293|NCT01821235|Drug|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
163294|NCT01821235|Drug|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
163295|NCT01821248|Drug|Gemcitabine, Cisplatin, S-1|Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery
GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7
163296|NCT01821274|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
162667|NCT01862484|Dietary Supplement|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
162668|NCT01862497|Drug|Carvedilol vs. Prazosin|
162669|NCT01862523|Biological|Capsaicin|Thirty-three* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
162670|NCT01862523|Biological|diluent|diluent
162671|NCT01862536|Drug|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
162672|NCT01862536|Drug|placebo|Daily use in double blind study.
162673|NCT00106548|Drug|Placebo|iv / month
162674|NCT01862549|Behavioral|Dialectical Behavior Therapy for children|
162675|NCT01862549|Behavioral|Treatment as Usual|
162676|NCT01862562|Procedure|Open surgery|Conventional technique
162996|NCT01818271|Behavioral|community-based group rehabilitation|Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:
Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise "assistive" equipment such as mini-exercise stepper or elliptical machines.
Treadmill walking exercise program.
162997|NCT01818284|Drug|Filgrastim|5 µg/kg in the morning daily for 4 days.
162998|NCT01818284|Drug|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
162999|NCT01818284|Procedure|Apheresis Procedure|The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.
The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained.
163000|NCT01818297|Device|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
163001|NCT01818310|Procedure|Group A: Intramuscular|Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.
The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes.
163002|NCT01818310|Procedure|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
163003|NCT00102050|Drug|NM-702 (phosphodiesterase inhibitor)|
162362|NCT01867125|Drug|lebrikizumab|Low dose sc every 4 weeks, Week 1-104 or Week 52-104
162363|NCT01867125|Drug|placebo|lebrikizumab placebo sc every 4 weeks, Week 1-52
162364|NCT01867138|Drug|Cefazolin|
162365|NCT01867138|Drug|Vancomycin|
162366|NCT01867138|Drug|Amikacin|
162367|NCT01869504|Device|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
162368|NCT01869517|Other|intrastromal corneal ring segments (Keraring) implantation|
162369|NCT01869517|Other|Intrastromal corneal continuous ring (Myoring) implantation|
162370|NCT01869543|Other|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
162371|NCT01869543|Other|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
162372|NCT01869556|Drug|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
162373|NCT01869556|Drug|Ergot|Ergot 0.25mg IV
162374|NCT01869556|Drug|Carboprost|Carboprost 0.25mg IM
162375|NCT01869569|Drug|Pregabalin|Pregabalin therapy is initiated at 75mg bid, and titrated to 300mg bid during a 4-week period. Dosage is stable in the following 8 weeks.
162376|NCT00107354|Drug|etoposide|
162377|NCT01869569|Drug|Placebo|Patients in placebo group are given the same size and number of capsules containing placebo.
162378|NCT01869582|Device|Fetoscope, Fetal heart rate|
162379|NCT01869582|Device|Upright Resuscitator, Resuscitation|
162677|NCT01862562|Procedure|Laparoscopic surgery|New minimum invasive technique
162678|NCT01862601|Device|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
162679|NCT01862627|Procedure|Optical coherence tomography|
162680|NCT01862640|Drug|Brexpiprazole, OPC-34712|Once-daily, tablets
161731|NCT01871285|Drug|Placebo film|Matching placebo buccal film
162038|NCT01864018|Drug|Ixazomib Citrate|Given PO
162039|NCT01864018|Other|Laboratory Biomarker Analysis|Correlative studies
162040|NCT01864018|Other|Pharmacological Study|Correlative studies
162041|NCT01864018|Other|Quality-of-Life Assessment|Ancillary studies
162042|NCT01864018|Other|Questionnaire Administration|Ancillary studies
162043|NCT01864057|Drug|thiamine hydrochloride 100 mg|
162044|NCT01864070|Other|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
162045|NCT01864070|Drug|Everolimus|Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.
Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort.
162046|NCT01864070|Other|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
162047|NCT01864083|Procedure|Positron Emission Tomography (PET)|
162048|NCT00106782|Procedure|Transcranial Electrical Polarization (TEP)|
162049|NCT01864083|Drug|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
162050|NCT01864083|Procedure|Positron emission mammography (PEM) When available|
162051|NCT01866462|Other|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
162052|NCT01866475|Device|EZ-IO|To have an EZ-IO placed up to 48 hours
162053|NCT00107081|Drug|i.v. antibiotics|
162054|NCT01866488|Drug|Misoprostol|
162055|NCT01866501|Procedure|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
162056|NCT01866501|Device|EZ-IO|
161738|NCT01871337|Behavioral|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
161739|NCT01871350|Dietary Supplement|Daily intake for 10 weeks (+/- 2 weeks)|
161740|NCT00107484|Procedure|magnetic resonance imaging|
161741|NCT01863602|Drug|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
161742|NCT01863615|Drug|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
161743|NCT01863615|Drug|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
161744|NCT01863628|Other|aerobic exercise|
161745|NCT00106691|Drug|Toremifene 20 mg|20 mg once a day
161746|NCT01863628|Other|psychoeducation|
161747|NCT01863641|Drug|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
161748|NCT01863641|Drug|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
161749|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Reference product
161750|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Test product
161751|NCT01863667|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
162059|NCT01866514|Device|EZ-IO|
162060|NCT01866540|Drug|FLUENZ|live attenuated influenza vaccine
162061|NCT01866553|Drug|Nilotinib|300 mg capsule BID oral use
162062|NCT01866553|Drug|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
162063|NCT01866566|Biological|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
162064|NCT00107081|Procedure|inpatient management|
162065|NCT01866566|Biological|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
161434|NCT01790789|Behavioral|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
161435|NCT01790789|Other|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
161436|NCT01790802|Device|2RT nanosecond laser|active laser therapy
161437|NCT01790828|Drug|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
161438|NCT00099190|Drug|ARQ 501|
161439|NCT01790841|Device|Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego|
161440|NCT01790854|Drug|Prasugrel dose 5 mg/day|
161441|NCT01790854|Drug|Prasugrel dose 10 mg/day|
161442|NCT01790880|Behavioral|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
161443|NCT01790880|Behavioral|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
161444|NCT01790893|Drug|aflibercept|
161445|NCT01790906|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
161446|NCT01790906|Other|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
161447|NCT01783288|Procedure|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
161448|NCT01783288|Other|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
161449|NCT01783301|Drug|FSH|
161450|NCT01783314|Procedure|MRI of liver|MRI of liver with intravenous gadoxetate disodium
161752|NCT01863667|Drug|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
160859|NCT00099333|Drug|Insulin|Insulin will be taken according to the subject's current regimen
161150|NCT01787604|Procedure|Aortic Valve Reimplantation Procedure|David I
161151|NCT01787617|Behavioral|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
161152|NCT01787617|Behavioral|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
161153|NCT01787630|Device|Hyaluronic acid|Injection in connection with ultrasound
161154|NCT00098943|Biological|CNGRC peptide-TNF alpha conjugate|
161155|NCT01787643|Other|Height-Adjustable Desk Intallation in Office|
161156|NCT01787669|Drug|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
161157|NCT01787669|Drug|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
161158|NCT01787682|Dietary Supplement|BOOST High Protein|
161159|NCT01787695|Procedure|UVA1|Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.
The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment.
161160|NCT01787708|Procedure|Red light|
161161|NCT01787721|Procedure|Ankle manipulation|
161162|NCT01787721|Other|Sham manipulation|
161163|NCT01787747|Drug|AVP-786 Dose 1|
161164|NCT01787747|Drug|AVP-786 Dose 2|
161165|NCT00098956|Drug|topotecan hydrochloride|Given IV
161166|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 1|
161167|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 2|
160561|NCT01786629|Drug|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
160562|NCT01786629|Drug|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
160860|NCT01784627|Behavioral|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
160861|NCT01784640|Drug|Hsp90 inhibitor AUY922|Given IV
160862|NCT01784640|Drug|pemetrexed disodium|Given IV
160863|NCT01784640|Other|pharmacological study|Correlative studies
160864|NCT01784640|Other|laboratory biomarker analysis|Correlative studies
160865|NCT01784653|Behavioral|iMET|Self-completed, computerized motivational enhancement therapy
160866|NCT01784653|Behavioral|MET|Clinician-delivered Motivational Enhancement Therapy
160867|NCT01784666|Drug|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
160868|NCT00098787|Drug|irinotecan hydrochloride|Given IV
160869|NCT01784666|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
160870|NCT01784692|Dietary Supplement|Immulina|
160871|NCT01784705|Device|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
160872|NCT01784705|Device|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
160873|NCT01784718|Drug|Buphenyl|
160874|NCT01784731|Behavioral|Willingness to pay|
160875|NCT01784744|Other|Hydroworx Pool at 98 degrees Fahrenheit|
160258|NCT01783600|Device|NanoCross .014 balloon catheter|
160259|NCT01783613|Dietary Supplement|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
160260|NCT01783613|Dietary Supplement|Placebo: 50 mg/kg/day during 12 months|
160261|NCT01783626|Device|Evodial|
160262|NCT01783626|Device|Evodial+ Condition B1|
160263|NCT01783626|Device|Evodial+ Condition B2|
160264|NCT01783626|Device|Evodial+ Condition C|
160265|NCT01783639|Procedure|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
160266|NCT01783652|Behavioral|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
160563|NCT01789333|Drug|Riboflavin 0.1% ophthalmic solution|The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.
During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin).
160564|NCT01789333|Device|UVA Light with irradiance exposure of 18 mW/cm2|The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
The aperture setting will be set at 10 mm, and the eye will be irradiated for 5 minutes at 18 mW/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes).
160565|NCT01789346|Device|532nm potassium titanyl phosphate (KTP) laser|
160566|NCT01789346|Device|595nm pulsed-dye laser (PDL)|
160567|NCT00099086|Drug|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
160568|NCT01789359|Other|Blueberry Juice|Dietary intervention
160569|NCT01789385|Drug|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
160570|NCT01789398|Drug|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
159971|NCT01795703|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
159972|NCT01797848|Drug|Daclatasvir|
159973|NCT01797861|Procedure|Half-dose photodynamic therapy (PDT)|At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent "hot spots" on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
159974|NCT01797861|Procedure|Micropulse laser (ML) treatment|The following ML treatment settings will be used: a power of 1800 mW*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.
* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser "test" spot will always be applied just outside the macular area.
159975|NCT01797874|Drug|Pazopanib|Experimental
159976|NCT01797874|Drug|Placebo|placebo arm
159977|NCT00100048|Drug|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
159978|NCT01797887|Behavioral|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
159979|NCT01797900|Drug|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
160267|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
160268|NCT01783665|Other|aerobic exercise|
160269|NCT01783665|Other|home exercise program|
160270|NCT01783678|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
160271|NCT01783678|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
160272|NCT01783691|Drug|NKTT120|
160273|NCT01785979|Drug|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
159694|NCT01792752|Behavioral|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
159695|NCT00099463|Procedure|Blood Test|
159696|NCT01795222|Drug|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
159697|NCT01795222|Drug|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
159698|NCT01795235|Drug|Saline|Saline s.c.
159699|NCT01795235|Drug|Glucagon|Glucagon s.c.
159700|NCT01795235|Drug|Placebo|Sugar Pill
159701|NCT01795235|Drug|Atenolol|Beta-1 receptor antagonist
159702|NCT01795248|Drug|Liraglutide|1.8 mg liraglutide
159703|NCT01795248|Drug|Placebo|Liraglutide without the GLP-1 analogue
159704|NCT00099710|Dietary Supplement|Curcumin C3 Complex|
159705|NCT01795274|Radiation|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
159706|NCT01795287|Procedure|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
159707|NCT01795287|Procedure|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
159980|NCT01797900|Drug|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
159981|NCT01797900|Radiation|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
159982|NCT01797913|Drug|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1&DAY8
159983|NCT01797926|Drug|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
159984|NCT01797926|Drug|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
159398|NCT01799512|Device|experimental: real-time continuous glucose monitoring|
159399|NCT01799512|Device|Active comparator: blinded continuous glucose monitoring|
159400|NCT01799525|Procedure|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
159401|NCT01799538|Drug|albuterol inhaler|
159402|NCT01799538|Procedure|PFT|
159403|NCT01799538|Drug|albuterol nebulizer|
159404|NCT01799551|Behavioral|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
159405|NCT01801904|Drug|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
159406|NCT01801917|Drug|Placebo|
159407|NCT00100555|Drug|zoledronic acid|
159408|NCT01801917|Drug|BAF312|
159409|NCT01801930|Drug|OCV-103 and OCV-104|0.3 mg of each
159410|NCT01801930|Drug|OCV-103 and OCV-104|1 mg of each
159411|NCT01801930|Drug|OCV-103 and OCV-104|3 mg of each
159412|NCT01801930|Drug|OCV-103 and OCV-104|6 mg of each
159413|NCT01801943|Behavioral|Cognitive Remediation Therapy Group|30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week
159414|NCT01801943|Behavioral|Walking Intervention (WI) Group|60 min Walking Intervention + 30 min low interface reading 3x week
159415|NCT01801943|Behavioral|Combination Group|30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week
159416|NCT01801943|Behavioral|Healthy Living Group|60 Min Healthy Living class + 30 min low interface reading 3x week
159417|NCT01801956|Behavioral|physical activity|free membership of a sport club
159101|NCT01796353|Other|Usual care|usual care
159102|NCT01796366|Drug|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
159103|NCT01796366|Drug|placebo|S.c placebo administered in combination with insulin 338
159104|NCT01796366|Drug|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
159105|NCT01796366|Drug|placebo|Oral placebo administered in combination with s.c. insulin glargine
159106|NCT01796379|Behavioral|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
159107|NCT01796379|Behavioral|Moderate Training|
159108|NCT01796392|Device|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
159109|NCT01796392|Other|Optimal Medical Management|This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
159110|NCT00099879|Drug|BMS-275183|
159111|NCT01796405|Drug|Clofarabine|
159112|NCT01796418|Drug|Beraprost sodium|
159113|NCT01796431|Drug|Eviplera®|
159114|NCT01796444|Procedure|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
159115|NCT01796444|Procedure|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
159116|NCT01796444|Procedure|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
159117|NCT01796444|Procedure|Pathological Evaluation|H&E and IHC
159118|NCT01798810|Procedure|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
159119|NCT01798823|Procedure|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
159467|NCT01797029|Biological|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
159468|NCT01797042|Behavioral|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
159469|NCT01797055|Drug|Human apotransferrin|intravenous infusion
159470|NCT01797068|Behavioral|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
159471|NCT01797068|Other|Standard of Care|
159472|NCT01797081|Biological|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
159473|NCT01797081|Biological|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
159751|NCT01792765|Other|Ultrasound guidance|Patient will have intraoperative ultrasound .
159752|NCT01792778|Device|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
159753|NCT01792778|Device|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
159754|NCT01792791|Procedure|Tissue sample collection at the time of surgery|Spanning surgery
A blood sample (32.5 ml)
joint aspirate (removal of synovial fluid) from both knees
urine sample
ORIF surgery
Joint aspirate (removal of synovial fluid) from both knees
A blood sample (32.5 ml)
Urine Sample
If patients only require one surgery, sample will be collected only once.
159755|NCT01792804|Drug|Trimethoprim-Sulfamethoxazole|study drug 1
159756|NCT01792804|Drug|Clindamycin|study drug 2
159757|NCT01792804|Drug|Linezolid|study drug 3
159758|NCT01792804|Drug|Flucloxacillin|study drug 4
159759|NCT01792804|Drug|Cloxacillin|study drug 5
159760|NCT00001956|Procedure|Oral surgery|
159761|NCT00099463|Procedure|Urine Test|
159762|NCT01792804|Drug|Vancomycin|study drug 6
159763|NCT01792804|Drug|Daptomycin|study drug 7
159170|NCT01794377|Behavioral|40 of an endurance training|The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).
Training three times per week for 5 months under supervision of an exercise physiologist.
Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).
Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study.
159171|NCT01794403|Radiation|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
159172|NCT01794403|Radiation|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
159173|NCT01794403|Procedure|Fiducial Marker Placement|All patients will have 3-4 gold fiducial seeds or tracking markers placed in the prostate under ultrasound guidance (biopsy) prior to treatment planning by MRI and/or CT.
159174|NCT00099619|Drug|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
159175|NCT01794403|Behavioral|Quality of Life Questionnaires|The Expanded Prostate Cancer Index Composite Questionnaire-SF-12 (EPIC-SF-12) at after enrollment, prior to radiation therapy, and post-therapy at 6 weeks, 3 months, 9 months, 15 months, and then yearly to 5.25 years.
Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) at after enrollment, prior to radiation therapy, and post-therapy at at 6 weeks, 3 months, 9 months, 15 months and then yearly to 5.25 years.
International Prostate Symptom Index (IPSS) after enrollment, prior to radiation therapy, last week of therapy, and post-therapy at at 6 weeks, 3 months, and then every 6 months for 5.25 years.
159176|NCT01794403|Procedure|Prostate Biopsy|Prostate biopsy at 2 - 2.5 years post completion of all therapy. Additional as needed.
159177|NCT01794403|Genetic|Biopsy Tissue for Biomarkers|Biomarker analysis of the DNA content (image analysis) and immunohistochemical analyses of Ki-67/MIB-1, p53, bcl-2, bax, MDM2, and PKA in biopsy tissue.
159178|NCT01794403|Genetic|Biofluids for proteomics and genomics studies|Blood and urine samples. Four tubes of approximately 10 cc of blood each will be collected prior to treatment. Approximately 50 mL of urine will be collected.
159179|NCT01794416|Procedure|Thoracoscopic epicardial ablation|
159474|NCT00100230|Drug|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
159475|NCT01799564|Procedure|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
159476|NCT01799577|Procedure|Laparoscopic surgery|Two methods will be compare
159477|NCT01799590|Drug|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
159478|NCT01799603|Drug|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
158857|NCT01798433|Device|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
158858|NCT01801020|Other|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
158859|NCT00100425|Procedure|Viceral Perception Testing|
158860|NCT01801020|Other|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
158861|NCT01801046|Drug|mitoxantrone hydrochloride|Given IV
158862|NCT01801046|Drug|cytarabine|Given IV
158863|NCT01801046|Procedure|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
158864|NCT01801046|Other|laboratory biomarker analysis|Correlative studies
158865|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video and brochure
158866|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video
158867|NCT01801059|Other|questionnaire administration|Ancillary studies
158868|NCT01801072|Drug|Levetiracetam|Details covered in Arm Descriptions.
158869|NCT01801111|Drug|erlotinib [Tarceva]|Post progression: Continued treatment with RO542802 after disease progression will be in combination with Tarceva (100 mg orally daily) in patients with EGFR mutations
158870|NCT00100451|Procedure|exercise|
158871|NCT01801111|Drug|RO5452802|multiple oral doses
158872|NCT01801124|Drug|EXPAREL|single dose 266 mg of undiluted EXPAREL
158873|NCT01801137|Drug|Everolimus (Afinitor®)|
158874|NCT01801150|Device|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
158875|NCT01801163|Drug|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
158876|NCT01801163|Radiation|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
158877|NCT01801176|Other|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
163297|NCT01813760|Device|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
163298|NCT01813773|Drug|Intravitreal Aflibercept Injection (IAI)|
163299|NCT01813786|Device|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
163300|NCT01813786|Device|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
163301|NCT01813786|Device|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
163302|NCT00101569|Drug|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
163303|NCT01813799|Drug|DA-9801|
163304|NCT01813799|Drug|Placebo|
163305|NCT01813812|Drug|DA-6034|
163306|NCT01813812|Drug|Rebamipide 300mg|
163307|NCT01813825|Other|Registry|
158560|NCT01777269|Drug|Placebo|Take one capsule daily
158561|NCT01777282|Drug|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
158562|NCT01777282|Drug|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
158563|NCT01780285|Device|Partially absorbable lightweight mesh for hiatal repair|A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original "sandwich" sub-lay technique).
In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure).
158564|NCT01780311|Drug|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
158565|NCT01780311|Procedure|Catheter Ablation|
158566|NCT01780324|Drug|Lidocaine gel|
158567|NCT01780337|Drug|Oxytocin|Intranasal dose of 20 IU oxytocin
163004|NCT01818310|Procedure|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
163005|NCT01818310|Device|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
163006|NCT01818323|Other|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of T4-positive patient-derived T-cells contained within 1 mL.
163007|NCT01820754|Drug|Ipilimumab|Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes
Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)
Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
163008|NCT01820754|Drug|Paclitaxel, Cisplatin, Carboplatin|Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)
Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)
163009|NCT00102284|Drug|levodopa|
163010|NCT01820767|Drug|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
163011|NCT01820767|Drug|Paricalcitol, atorvastatin|Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.
Atorvastatin: 20 mg/day oral (1 take) during 12 weeks.
163012|NCT01820767|Drug|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
158294|NCT01774032|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
158295|NCT01774045|Drug|PDC-1421|
158296|NCT00097773|Drug|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
158297|NCT01774045|Drug|Placebo|
158298|NCT01774058|Drug|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
158299|NCT01774071|Drug|89Zr- DFO-MSTP2109A|If you are enrolled onto Group 1:
Once you are given the diagnostic agent, the following procedures will be done:
PET scans at the approximate times:
1-4 hours after the injection
24 hours after the injection (the next day, Day 2)
48-120 hours after the injection (on either Day 3, 4, or 5)
144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,
Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.
At each time of your scheduled PET scan.
158300|NCT01776697|Drug|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
162681|NCT01862653|Device|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
162682|NCT01862679|Other|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
162683|NCT01862679|Procedure|Haemodiafiltration|During Haemodiafiltration, the dialysis machine removes more water from the blood than during "normal" hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood.
162684|NCT00106548|Drug|Methotrexate|10-25mg/week
162685|NCT01862692|Behavioral|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
162686|NCT01865123|Behavioral|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
162687|NCT01865123|Behavioral|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
162688|NCT01865123|Behavioral|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
162689|NCT01865136|Other|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
162690|NCT01865149|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
163013|NCT01820780|Other|Natriuretic peptides levels to J7 and J14|
163014|NCT01820780|Other|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
162057|NCT01866514|Procedure|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
162058|NCT01866514|Drug|2% preservative-free lidocaine|
162380|NCT01869582|Device|Doppler, Fetal heart rate|
162381|NCT01869582|Device|Standard Resuscitator, Resuscitation|
162382|NCT01869608|Procedure|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
162383|NCT01869621|Drug|Metformin|6 days treatment with metformin to steady-state
162384|NCT01869634|Drug|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
162385|NCT01869647|Radiation|"high" likelihood of stone group|Ultra low dose CT scan
162386|NCT01869647|Radiation|"moderate" likelihood of stone group|Regular CT or Low Dose CT scan
162387|NCT00107354|Drug|mitoxantrone hydrochloride|
162388|NCT01869647|Radiation|"low" likelihood of stone group|No imaging
162389|NCT01869660|Behavioral|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
162390|NCT01869673|Device|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
162391|NCT01869673|Device|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
162392|NCT01869686|Biological|Denosumab|60 mg
162393|NCT01869699|Drug|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
162394|NCT01869699|Drug|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
162395|NCT00107549|Biological|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
162396|NCT01872286|Device|Pillcam SB2|
162066|NCT01866566|Biological|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
162067|NCT01866566|Biological|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
162068|NCT01866592|Drug|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
162069|NCT01866605|Drug|Midazolam|Intravenous midazolam 0.3 mg/kg
162070|NCT01866605|Drug|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
162071|NCT01866605|Device|Bair Hugger|Forced air warming
162072|NCT01866618|Procedure|Uterine Aspiration and Endometrial Biopsy/Embryo Biopsy|Patients will undergo two uterine aspirations and one endometrial biopsy. Any embryos obtained will undergo embryo biopsy for Comprehensive Chromosome Screening (CCS). All embryos will be cryopreserved for subsequent use in a thaw cycle.
162073|NCT01866618|Drug|Leuprolide Acetate|
162074|NCT01866618|Drug|Human Chorionic Gonadotropin (hCG)|
162075|NCT00107094|Drug|Abraxane|
162076|NCT01869010|Other|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
162077|NCT01869023|Drug|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
162078|NCT01869023|Drug|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
162079|NCT01869036|Drug|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
162402|NCT01872377|Radiation|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
162403|NCT01872390|Other|Combination Intervention Package|
162404|NCT01872390|Other|Standard of Care|
161753|NCT01863667|Drug|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
161754|NCT01863667|Drug|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
161755|NCT01863680|Drug|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent [%] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
161756|NCT00106691|Drug|Placebo|placebo tablet identically appearing to the toremifene 20 mg tablet, administered daily for 360 days.
161757|NCT01863680|Drug|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
161758|NCT01863680|Drug|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
161759|NCT01863680|Drug|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
161760|NCT01863706|Drug|Misoprostol|400µg oral misoprostol
161761|NCT01863706|Drug|Oxytocin|20 IU Oxytocin
161762|NCT01863719|Drug|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
161763|NCT01863719|Drug|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 21 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 21 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 28 doses.
161764|NCT00107042|Biological|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
161765|NCT01865916|Drug|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
161766|NCT01865916|Drug|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
161767|NCT01865929|Device|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
161768|NCT01865929|Procedure|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
161769|NCT01865942|Procedure|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
161168|NCT01787747|Drug|AVP-786 Dose 2/Q Dose 2|
161169|NCT01787747|Drug|AVP-923|
161451|NCT01783327|Behavioral|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
161452|NCT01783327|Behavioral|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
161453|NCT01783340|Drug|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
161454|NCT01783340|Drug|Placebo|Placebo capsules will be administered at each immunization
161455|NCT01783340|Biological|Immunization with falciparum|three inoculations with 5 infected mosquito bites
161456|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
161457|NCT01783353|Dietary Supplement|Zinc gluconate|
161458|NCT01783353|Dietary Supplement|Corn starch pill|
161459|NCT01783366|Device|TUBE EXCHANGER|
161460|NCT01783379|Drug|micafungin|100mg/day infusion in 1 hour
161461|NCT01783392|Procedure|Transcutaneous Electrical Nerve Stimulation|
161462|NCT01783418|Behavioral|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
161463|NCT01783431|Drug|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
161464|NCT01783431|Procedure|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
161465|NCT01783444|Drug|Capecitabine|Capecitabine, for oral use 1250 mg/m2 twice daily for 2 weeks followed by one week rest (3-week cycle). Capecitabine will be locally supplied by the Investigator.
160876|NCT01784744|Other|Hydroworx Pool at 102 degrees Fahrenheit|
160877|NCT01784757|Drug|ODM-201 Tablet A|Tablet A formulation of ODM-201
160878|NCT01784757|Drug|ODM-201 Tablet B|Tablet B formulation of ODM-201
160879|NCT00001940|Drug|Voriconazole|
160880|NCT00098787|Drug|leucovorin calcium|Given IV
161170|NCT01790347|Behavioral|Exercise group|The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.
Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week.
161171|NCT01790360|Behavioral|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
161172|NCT01790360|Behavioral|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
161173|NCT01790373|Behavioral|Suubi+Adherence|Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.
Financial education and workshops on asset-building, future planning, and protection from risks
Mentorship from a young adult/near-peer
Family-based microenterprise development training
Medical Event Monitoring System
Bolstered Standard of Care: Adherence Counseling Practices
-Four to six counseling sessions to review HIV, ART, resistance, and adherence.
Medical Standard of Care:
-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda
Psychosocial Standard of Care:
-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling
161174|NCT01790373|Behavioral|Bolstered Standard of Care|-Medical Event Monitoring System
Bolstered Standard of Care: Adherence Counseling Practices
-Four to six counseling sessions to review HIV, ART, resistance, and adherence.
Medical Standard of Care:
-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda
Psychosocial Standard of Care:
-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling
161175|NCT01790399|Procedure|Excision of sentinel node(s)|Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
161176|NCT01790412|Behavioral|Exercise group|Combined two land aerobic sessions and one aquatic activities session
161177|NCT00099138|Behavioral|Exercise|
160571|NCT01789411|Other|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
160572|NCT01789411|Device|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
160573|NCT01789411|Device|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
160574|NCT01789437|Device|Dexamethasone Intravitreal Implant (Ozuredex)|
160575|NCT01789450|Procedure|Section of Periareolar Dermis in Breast Reduction.|
160576|NCT01789463|Other|Self rehabilitation|
160577|NCT01789463|Other|Self rehabilitation plus physiotherapy|
160578|NCT00099086|Drug|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
160579|NCT01789476|Drug|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
160580|NCT01789476|Drug|Placebo|Matching placebo administered using same dosing algorithm as the active arm
160881|NCT01784757|Drug|ODM-201 capsule formulation|Capsule formulation of ODM-201
160882|NCT01787097|Drug|Symbicort®, Formoterol, Budesonide|Formeterol is Long acting beta 2-agonist (LABA) whereas Budesonide is inhaled corticosteroids (ICS).Patients will randomly receive one-off dose-administration of inhaled treatment (each medication will be taken as two puffs, all via a dry-powder inhaler device = Turbuhaler® to achieve the TOTAL doses).
160883|NCT01787110|Drug|Oxygen|see arm description
160884|NCT01787123|Drug|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
160885|NCT01787136|Drug|Dextromethorphan|added on therapy
160886|NCT01787149|Drug|DMARDs|
160887|NCT00001944|Drug|XR9576|
160888|NCT00098917|Drug|therapeutic autologous dendritic cells|
160889|NCT01787162|Other|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
160890|NCT01787175|Other|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
160274|NCT01785979|Drug|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
160275|NCT01785992|Drug|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
160276|NCT01786005|Device|Transcranial magnetic stimulation|
160277|NCT00098839|Drug|prednisone|Given orally
160278|NCT01786018|Drug|Thiotepa|
160279|NCT01786018|Drug|Busulfan|
160280|NCT01786018|Drug|Fludarabin|
160281|NCT01786018|Procedure|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10^7 CD3 cells/kg recipient weight and cryopreserved.
160282|NCT01786018|Radiation|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
160283|NCT01786018|Drug|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
160284|NCT01786018|Drug|Cyclosporine|CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.
If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.
See guidelines for PO to IV conversion below.
160581|NCT01789489|Device|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
160582|NCT01789502|Device|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
160583|NCT01789502|Device|Plastic stents|Plastic stents were inserted by ERCP
160584|NCT01789528|Drug|CAZ-AVI|IV infusion
160585|NCT01791777|Behavioral|SafeCare Coaching|This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
160586|NCT01791790|Device|Stimulation|
159985|NCT01797926|Drug|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
159986|NCT01797926|Drug|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
159987|NCT01797952|Drug|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
159988|NCT00100048|Drug|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
159989|NCT01797952|Other|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
159990|NCT01797965|Drug|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
159991|NCT01797978|Drug|Intravenous methylene blue administration|Initial history taking and physical examination --> enrollment --> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
159992|NCT01797978|Drug|Placebo|
159993|NCT01800565|Other|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
159994|NCT01800565|Other|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
159995|NCT01800578|Device|monitor for depth of hypnosis|evaluation of depth of hypnosis
159996|NCT01800591|Behavioral|Financial incentive|
159997|NCT01800604|Behavioral|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
160285|NCT01786018|Drug|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
160286|NCT01786018|Drug|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
160287|NCT01786018|Procedure|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
160288|NCT00098839|Drug|pegaspargase|Given IM
160289|NCT01786031|Other|metastasis biopsy|
160290|NCT01786044|Behavioral|MasterMed|An online interactive educational program
159708|NCT01795300|Radiation|Carbon Ion Radiotherapy|Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.
The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV.
159709|NCT01795300|Radiation|Proton Therapy|As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.
The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV.
159710|NCT01795300|Radiation|Hypofractionated Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions.
159711|NCT01795300|Radiation|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
159712|NCT01797393|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
159713|NCT01797393|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
159714|NCT01797393|Other|" Air assisted" water injection.|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
159715|NCT01797406|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
159716|NCT01797406|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
159717|NCT01797419|Drug|GS-5806|Single dose, oral liquid, .5 mL/kg
159718|NCT01797419|Drug|Placebo|Single dose, oral liquid, .5 mL/kg
159120|NCT01798836|Procedure|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
159121|NCT01798836|Procedure|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
159418|NCT00100568|Drug|Efavirenz|600 mg tablet taken orally daily
159419|NCT01801956|Other|Motivational interview|Four motivational interviews by instructors of the local sport club
159420|NCT01801956|Other|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
159421|NCT01801969|Other|Rehabilitation service|Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.
Size of the municipality responsible for providing rehabilitation services after discharge from hospital
159422|NCT01801982|Other|non-interventional|non-interventional
159423|NCT01802008|Procedure|3-minute withdrawal time|For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a "second look" over each segment over 2 minutes by the same endoscopist.
159424|NCT01802008|Procedure|6-minute withdrawal time|For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a "second look" over each segment over 2 minutes by the same endoscopist.
159425|NCT01802021|Drug|Astagalus-based Formula: Qingshu-Yiqi-Tang|Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.
maximal for 6 months
159426|NCT01802047|Procedure|milk expression with electric pump|
159427|NCT01802073|Drug|Oral Vancomycin|
159428|NCT01802086|Drug|Emla-cream|Topical anaesthetic
159429|NCT00100568|Drug|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
159430|NCT01802086|Drug|Miniderm cream|Topical
159431|NCT01802099|Other|Enteral nutrition|
159432|NCT01794741|Drug|Fluticasone propionate nasal spray|
159433|NCT01794754|Other|Care as usual|
159434|NCT01794754|Other|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
159764|NCT01792804|Drug|Cefazolin|study drug 8
159765|NCT01792817|Device|GammaCore|Treatment with active gammacore vagus nerve stimulator
159766|NCT01792817|Device|Sham GammaCore device|Treatment with sham stimulator
159767|NCT01792830|Drug|Metformin|Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.
Patients without a history of diabetes and admission HbA1c < 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.
Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.
159768|NCT01792830|Drug|Glargine insulin|Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.
Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.
Patients with an HbA1c > 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose.
159769|NCT01792830|Drug|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
159770|NCT01792843|Behavioral|data|comparisons of clinical characteristics
comparisons of cognitive profiles
comparisons of grey matter density patterns
comparisons of EEG rhythms features
160054|NCT01795911|Biological|Pegylated Interferon Lambda|
160055|NCT01797991|Drug|Dexamethasone per os|
160056|NCT01797991|Drug|Matching placebo for dexamethasone IV|
160057|NCT01797991|Drug|Dexamethasone IV|
160058|NCT01797991|Drug|Matching placebo for dexamethasone per os|
160059|NCT01798004|Drug|cyclophosphamide|Given IV
160060|NCT01798004|Drug|topotecan hydrochloride|Given IV
160061|NCT00100048|Drug|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
160062|NCT01798004|Drug|cisplatin|Given IV
160063|NCT01798004|Drug|etoposide|Given IV
160064|NCT01798004|Drug|vincristine sulfate|Given IV
160065|NCT01798004|Drug|doxorubicin hydrochloride|Given IV
159479|NCT01799616|Drug|Pamidronate|
159480|NCT01799616|Other|Placebo|
159481|NCT01799629|Drug|Glycerin suppositories|
159482|NCT01799681|Behavioral|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
159483|NCT01799681|Behavioral|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
159484|NCT01799694|Drug|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
159485|NCT00100243|Drug|Plenaxis|
159486|NCT01799707|Behavioral|vision restoration training|
159487|NCT01799707|Behavioral|Discrimination Training|
159488|NCT01799720|Dietary Supplement|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
159489|NCT01799720|Dietary Supplement|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
159490|NCT01799720|Drug|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
159491|NCT01799733|Other|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
159771|NCT01795313|Biological|HLA-A2 restricted synthetic tumor antigen|
159772|NCT01795313|Drug|Imiquimod|
159773|NCT01795313|Other|enzyme-linked immunosorbent assay|
159774|NCT00001959|Drug|Pirfenidone|During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.
158878|NCT01801189|Drug|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
158879|NCT01801189|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
159180|NCT01794416|Procedure|Endocardial catheter ablation|
159181|NCT01794416|Device|Implantable loop recorder|
159182|NCT01794429|Drug|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
159183|NCT01794429|Drug|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
159184|NCT01794455|Drug|Sertraline|50mg - 200mg daily
159185|NCT00099619|Drug|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
159186|NCT01796444|Drug|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
159187|NCT01796444|Radiation|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
159188|NCT01796470|Drug|Entospletinib|Entospletinib tablets administered orally twice daily
159189|NCT00099892|Drug|vildagliptin|
159190|NCT01796470|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
159191|NCT01796483|Device|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
159192|NCT01796483|Device|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
159193|NCT01796496|Other|Manipulative Therapy Techniques|Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.
Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.
Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction.
159194|NCT01796496|Other|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
158568|NCT01780337|Other|Saline|Intranasal dose of saline
158569|NCT01780350|Device|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
158570|NCT01780376|Procedure|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
158571|NCT01780389|Drug|Open-label flexibly dosed milnacipran|
158572|NCT01780402|Behavioral|Hand feeding techniques|Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.
Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.
Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position.
158573|NCT00098462|Drug|gefitinib|
158574|NCT01780415|Other|blastocoele aspiration|
158575|NCT01780428|Drug|CL-108|
158576|NCT01780428|Drug|Placebo|
158577|NCT01780454|Drug|MEDI-507|T-Cell Depleting Agent
158880|NCT01801202|Device|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
158881|NCT00100464|Drug|Paroxetine|
158882|NCT01801228|Drug|Eplerenone|
158883|NCT01801254|Other|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
158884|NCT01793870|Drug|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
158885|NCT01793870|Drug|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
158886|NCT01793883|Drug|40 mg Laninamivir Octanoate|
158887|NCT01793883|Drug|80 mg Laninamivir Octanoate|
158888|NCT00099528|Drug|REN-1654|
158301|NCT01776710|Behavioral|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
158302|NCT01776723|Drug|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
158303|NCT00098020|Drug|Retinoids for Podocyte Disease|
158304|NCT01776736|Device|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
158305|NCT01776749|Device|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
158306|NCT01776762|Dietary Supplement|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
158307|NCT01776775|Device|Abdominal binder|The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from "ETO garments©" with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position.
158578|NCT01780454|Drug|Rituximab|B-Cell Depleting Agent
158579|NCT01780454|Radiation|Total Body Irradiation|Bone Marrow Depletion
158580|NCT01780454|Radiation|Thymic Irradiation|
158581|NCT01780467|Behavioral|Role of dopamine|
158582|NCT01780480|Drug|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
158583|NCT01780480|Drug|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
158584|NCT00098462|Drug|sirolimus|
163015|NCT01820780|Other|Phone calls in 6 months and 12 months|
163016|NCT01820780|Other|Natriuretic peptides levels at 6 months|
163017|NCT01820780|Other|Consultation with the general doctor or the cardiologist to J30 with blood results|
163018|NCT01820793|Drug|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
163019|NCT01820806|Drug|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
163020|NCT00102284|Drug|rivastigmine|
163021|NCT01820832|Drug|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
163022|NCT01820858|Drug|Paclitaxel|175 mg/m(2), intravenously (IV)
163023|NCT01820858|Drug|Paraplatin (Carboplatin Injection)|AUC=5, IV
163024|NCT01820858|Radiation|Pelvic Radiation|45-50 Gy
163025|NCT01820858|Radiation|Vaginal Brachytherapy 1|5 Gy, 3 times
163026|NCT01820858|Radiation|Vaginal brachytherapy 2|5 Gy, 2-4 times
163027|NCT01820871|Other|Self-Management Using Smartphone Application for Type2 DM|
163028|NCT01820871|Other|self-management using booklet for management type 2 DM|
163029|NCT01820884|Procedure|TH|Total hysterectomy
163030|NCT01820884|Procedure|TH/BSO|Total hysterectomy and bilateral salpingo-oophorectomy
163031|NCT00102284|Drug|pergolid|
163032|NCT01813227|Drug|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
158308|NCT01776788|Drug|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
162397|NCT01872312|Device|treatment with valves (The Spiration® IBV Valve System)|treat BPF
162398|NCT01872325|Behavioral|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
162399|NCT01872338|Behavioral|Mindfulness-Based Cognitive Therapy for Suicide|Psychotherapeutic intervention that integrates cognitive behavioral therapy and mindfulness meditation, with a specific focus on reducing suicide risk. It also integrates Safety Planning Intervention.
162400|NCT01872338|Behavioral|Treatment as usual|VA standard care for suicide prevention
162401|NCT01872351|Drug|Nutraceuticals|
162691|NCT01865162|Other|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
162692|NCT01865175|Drug|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
162693|NCT00106964|Biological|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
162694|NCT01865175|Drug|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
162695|NCT01865188|Drug|LCZ696|Experimental monotherapy doses
162696|NCT01865188|Drug|Amlodipine|Active comparator monotherapy doses
162697|NCT01865188|Drug|LCZ696 and amlodipine combination|Experimental combination doses
162698|NCT01865188|Drug|Placebo|Placebo comparator dose
162699|NCT01865201|Drug|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
162700|NCT01865201|Other|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
162701|NCT01865227|Behavioral|Group Counseling|
162702|NCT01865240|Device|Renal Denervation|Renal Denervation Catheter
162703|NCT01865253|Device|Renal Denervation|Renal Denervation
162704|NCT00106964|Biological|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:
A single dose of 1 mL will be administered in the deltoid muscle.
162405|NCT01872403|Drug|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
162406|NCT00107549|Biological|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
162407|NCT01872416|Device|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
162408|NCT01872442|Drug|Dasatinib|Dasatinib 100mg daily starting at inclusion
If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes > 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study
162409|NCT01872442|Drug|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
162410|NCT01872455|Dietary Supplement|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
162411|NCT01872455|Dietary Supplement|Usual diet|Usual diet of the patients
162412|NCT01872468|Behavioral|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
162413|NCT01864590|Device|Double Sylo Bag - Mesh Protocol|double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.
At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure
162414|NCT01864603|Other|ART access with optimized linkage and retention and streamlined care delivery for all persons with HIV|
162415|NCT01864616|Dietary Supplement|Vitamin D3|
162416|NCT01864629|Behavioral|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
162714|NCT01867710|Drug|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
162715|NCT01867710|Drug|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
162080|NCT01869036|Drug|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
162081|NCT01869062|Device|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
162082|NCT01869062|Device|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
162083|NCT01869075|Other|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
162084|NCT01869088|Drug|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery
162085|NCT01869088|Procedure|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
162086|NCT00107341|Drug|carboplatin|
162087|NCT01869114|Drug|Sirolimus|Given PO
162088|NCT01869114|Drug|Azacitidine|Given IV
162089|NCT01869127|Device|Shoes|A unisex canvas slip-on with a sturdy sole.
162090|NCT01869140|Device|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
162091|NCT01869166|Biological|CART-EGFR|
162092|NCT01869179|Behavioral|Choir program|Attend weekly choir sessions for 12 months at the Senior Center. Choir sessions will last about 90 minutes each with a 20 minute break. Take part in 3 informal choir concerts.
162093|NCT01869192|Drug|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
162094|NCT01869192|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
162095|NCT01869192|Drug|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
162096|NCT01869192|Drug|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
162097|NCT00107341|Drug|paclitaxel|
162098|NCT01869192|Radiation|Radiation Therapy|Standard dosing, fields depending on clinical findings
162099|NCT00107536|Drug|lapatinib ditosylate|
162100|NCT01872078|Drug|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
161466|NCT01783444|Drug|Exemestane|Exemestane tablets of 25 mg will be taken orally once per day. Dose modifications in the management of adverse events is allowed.
161467|NCT00098735|Drug|FTY720|
161468|NCT01783444|Drug|Everolimus|Everolimus will be centrally dispensed via IWRS. Everolimus will be taken as oral tablets for oral use 10 mg (2 × 5 mg) daily.
161770|NCT01865942|Procedure|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
161771|NCT01865955|Procedure|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
161772|NCT01865955|Device|The spinal needle|
161773|NCT01865968|Biological|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
161774|NCT01865968|Biological|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
161775|NCT00107055|Drug|REN-1654|
161776|NCT01866007|Drug|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
161777|NCT01866007|Drug|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
161778|NCT01866007|Drug|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
161779|NCT01866007|Drug|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
161780|NCT01866033|Drug|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
161781|NCT01866033|Drug|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
161782|NCT01866033|Drug|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
161783|NCT01866033|Drug|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
161784|NCT01866046|Behavioral|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
161785|NCT01866059|Device|Calcium silicate cement|Calcium silicate cement
161178|NCT01790425|Procedure|to infuse water into colon to open the lumen for water infusion colonoscopy|
161179|NCT01790425|Procedure|Air colonoscopy|
161180|NCT01790438|Drug|LY2605541|Administered SQ
161181|NCT01790438|Drug|Human Insulin NPH|Administered SQ
161182|NCT01790451|Procedure|Irreversible Electroporation|
161183|NCT01790464|Drug|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
161469|NCT01785641|Drug|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
161470|NCT01785641|Drug|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
161471|NCT01785680|Other|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
161472|NCT01785680|Other|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
161473|NCT00098839|Drug|vincristine sulfate|Given IV
161474|NCT01785693|Drug|levobupivacaine, clonidine|
161475|NCT01785719|Behavioral|Commercial diet|Participants will be enrolled in 12 weeks of the Nutrisystem® D weight loss program; a portion-controlled, low calorie and low glycemic index meal delivery system that provides 1250-1500 calories per day. Nutrisystem® D has been proven to help overweight individuals achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, typical weight loss is 1-2 lbs per week, for an average loss of 8% body weight by the end of 3 months. Nutrisystem® D offers a balanced meal plan consistent with the nutritional recommendations of the USDA Dietary Guidelines and American Diabetes Association; individuals can still consume all of their required micro- and macronutrients, but with fewer calories.
161476|NCT01785732|Procedure|Renal Denervation|Sympathetic renal denervation via renal arteries
161477|NCT01785745|Other|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
161478|NCT01785745|Other|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
160891|NCT01787188|Drug|Meloxicam Test Capsules|
160892|NCT01787188|Drug|Meloxicam Test Capsules|
160893|NCT01787188|Drug|Placebo Capsules|
160894|NCT01787201|Behavioral|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 6 weeks.
160895|NCT01787214|Dietary Supplement|Full dose|20% of daily energy needs supplied by walnuts
160896|NCT01787214|Dietary Supplement|Half dose|10% of daily energy needs supplied by walnuts
160897|NCT01787214|Dietary Supplement|Control|Walnut free meals
160898|NCT01787227|Device|xTAG RPP|
160899|NCT00098917|Procedure|adjuvant therapy|
160900|NCT01787240|Drug|Escitalopram 10mg|
160901|NCT01787240|Drug|Placebo|
160902|NCT01787279|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
160903|NCT01787292|Behavioral|Coordination training|finger movement coordination training using sequenced finger movements of varying pressure.
161184|NCT01790464|Drug|placebo|
161185|NCT01790477|Procedure|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
161186|NCT01790490|Drug|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
161187|NCT01782898|Drug|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
161188|NCT01782898|Drug|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
161189|NCT01782911|Dietary Supplement|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
161190|NCT01782911|Dietary Supplement|Placebo pills|The patients will take placebo for 40 days.
161191|NCT01782924|Drug|KHK4827|
161192|NCT01782937|Drug|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
160587|NCT01791790|Device|SHAM|no stimulation
160588|NCT01791803|Behavioral|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
160589|NCT01791803|Drug|Nicotine|free one month supply after hospital discharge
160590|NCT01791816|Drug|Phenylephrine|Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.
If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion.
160591|NCT00099320|Drug|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units [5 μg] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units [10 μg] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
160592|NCT01791816|Drug|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
160593|NCT01791842|Drug|Tocilizumab|8 mg/kg/month
160594|NCT01791842|Drug|Placebo|
160595|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
160596|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
160597|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
160598|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
160599|NCT01791868|Drug|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
160904|NCT01787292|Behavioral|Short Term exercise - supervised|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
160905|NCT01787292|Behavioral|Long Term Exercise|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
160906|NCT01787318|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
160907|NCT01787318|Device|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
160908|NCT01787331|Drug|Itraconazole|Itraconazole is available as pink and blue capsules. Itraconazole should be taken with meals or within 30 minutes after a meal.
160291|NCT01786057|Procedure|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
160292|NCT01786057|Procedure|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
160293|NCT01786070|Drug|Budesonide|
160294|NCT01788839|Behavioral|surveys|A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 1 month.
160295|NCT01788839|Other|Blood draw (optional)|
160296|NCT01788865|Device|cSEMS(Covered self-expandable dual-layered metal stent) implant|
160297|NCT00001951|Drug|TMTDS|
160298|NCT00099008|Dietary Supplement|Placebo|oral Placebo twice daily on days 1-84
160299|NCT01788878|Behavioral|Questionnaires|
160300|NCT01788917|Dietary Supplement|linseed oil|10 ml linseed oil per day over 10 weeks (without control oil)
160301|NCT01788930|Device|CPAP|
160302|NCT01788943|Drug|Nictonie Patch, Verenacline|
160303|NCT01788956|Device|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
160304|NCT01788956|Device|Co-Oximeter|
160305|NCT01788969|Drug|Lexapro|Agent + training vs Placebo + training
160306|NCT01788969|Drug|Placebo|Agent + training vs Placebo + training
160600|NCT01791868|Drug|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
160601|NCT01791881|Drug|Hugeltox|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
159998|NCT01800604|Behavioral|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
159999|NCT01800604|Behavioral|Pain Self-Management Intervention #3|Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of "what are sometimes uncomfortable sensations" so that they are more comfortable.
160000|NCT01800604|Behavioral|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
160001|NCT01800617|Drug|Liothyronine, Sodium|
160002|NCT01800630|Drug|Gemcitabine HCl Oral Formulation|
160003|NCT00100386|Behavioral|Standard Control Strategy|
160004|NCT01800643|Other|Analyze the pharmacokinetics of busulfan for transplantation|Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target "Area Under Curve- AUC" based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target.
160005|NCT01800656|Procedure|Endoloop-assisted "ligate and let go" colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
160006|NCT01800656|Procedure|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
160007|NCT01793233|Other|questionnaire administration|Ancillary studies
160008|NCT01793233|Other|laboratory biomarker analysis|Correlative studies
160009|NCT01793246|Device|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
160010|NCT01793259|Drug|methotrexate prefilled pen|
160011|NCT01793259|Drug|methotrexate prefilled syringe|
159435|NCT01794767|Drug|0,9% NaCl flush|Normal Saline solution
159436|NCT01794767|Drug|Heparin 50U/ml|Heparin solution
159437|NCT01794780|Drug|LABA based treatment: indacaterol|LABA based treatment: indacaterol
159438|NCT01794780|Drug|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
159719|NCT01797432|Drug|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
159720|NCT01797432|Device|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
159721|NCT00099996|Drug|SCH-58235|
159722|NCT01797445|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
159723|NCT01797445|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally once daily
159724|NCT01797445|Drug|E/C/F/TDF Placebo|E/C/F/TDF placebo tablet administered orally once daily
159725|NCT01797445|Drug|E/C/F/TAF Placebo|E/C/F/TAF placebo tablet administered orally once daily
159726|NCT01797458|Procedure|Hall Technique|Technique:
Removal of dental plaque and rest of aliments from the cavity
Selection of the SSC
If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment
Dry the crown and fill with glass-ionomer luting cement
Place the crown over the tooth
Removal of cement excesses from the crown margins
The child should be asked to keep biting on the crown until the cement has set
159727|NCT01797458|Procedure|Opening-up Cavities|Technique:
Use high-speed bur to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area
Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)
Show the cavity to patient/parents and give them tooth-brushing instructions
Tell to parents that good plaque control is the key for this treatment
The recall interval for these patients is every 3 months.
159728|NCT01797458|Procedure|Conventional Restorations|Technique:
Local anesthesia should be used when needed
Complete caries removal should be performed and cavity preparation should be done according to the material you have selected
Use a matrix band and a wedge to tightly hold the band against the tooth
Place the material
Check contacts and occlusion, and polish the restoration (only for resin based materials)
159729|NCT01797471|Radiation|Lattice Extreme Ablative Dose Radiation Therapy|A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
159730|NCT01797471|Radiation|Conventionally Fractionated Radiation|Conventionally fractionated radiation therapy will be delivered to subjects beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy
159731|NCT01797471|Drug|Platinum-based Chemotherapy Doublet|Platinum-based chemotherapy doublet administered beginning day 2 via wither weekly or every 3 week regimen. Platinum-based agent selection is at the discretion of the treating medical oncologist
159732|NCT00099996|Drug|Ezetimibe|
160066|NCT01798004|Radiation|external beam radiation therapy|Undergo EBRT
160067|NCT01798004|Drug|busulfan|Given IV
160068|NCT01798004|Drug|melphalan|Given IV
160069|NCT01798004|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
160070|NCT01798004|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
160071|NCT01798004|Other|pharmacological study|Correlative studies
160072|NCT00100048|Drug|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
160073|NCT01798004|Other|laboratory biomarker analysis|Optional correlative studies
160074|NCT01798004|Biological|filgrastim|Given SC or IV
160075|NCT01798004|Drug|mesna|Given IV
160076|NCT01798017|Drug|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
160077|NCT01798030|Other|Vitamin D|N/A, frozen specimen study
160078|NCT01798043|Other|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
160079|NCT01798043|Other|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
160356|NCT01786122|Other|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
160357|NCT01786122|Behavioral|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
160358|NCT01786135|Drug|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
160359|NCT01786148|Behavioral|mobile phone application|
160360|NCT01786161|Drug|Vancomycin continuous infusion|Vancomycin 24 hour intravenous continuous infusion
160361|NCT01786161|Drug|Vancomycin intermittent dosing interval|Vancomycin intravenous infusion at rate 1000mg/hr
160362|NCT01786174|Drug|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
159775|NCT00099723|Drug|VSL#3|
159776|NCT01795313|Other|flow cytometry|
159777|NCT01795313|Other|immunohistochemistry staining method|
159778|NCT01795313|Other|laboratory biomarker analysis|
159779|NCT01795339|Drug|AZD3293|Oral solution
159780|NCT01795339|Drug|Placebo|Oral solution
159781|NCT01795365|Other|Active surveillance|
159782|NCT01795378|Biological|donor natural killer cell infusion|Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.
The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).
For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.
The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg.
159783|NCT01795404|Behavioral|Inquiry Based Stress Reduction (IBSR)|
159784|NCT01795417|Device|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
159785|NCT01795417|Device|XP200 RF device|4 RF treatments of periorbital region on one side of the face
159786|NCT00099736|Drug|FTY720|
159787|NCT01795430|Drug|etoposide|Given IV
159788|NCT01795430|Drug|ifosfamide|Given IV
159789|NCT01795430|Radiation|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
159790|NCT01795430|Drug|topotecan hydrochloride|Given IV
159791|NCT01795430|Drug|busulfan|Given IV
159792|NCT01795430|Drug|melphalan|Given IV
159793|NCT01795430|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
160080|NCT01798056|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
160081|NCT01798056|Drug|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
159195|NCT01796509|Other|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
159196|NCT01796522|Drug|progesterone 200 mg / day vaginally|
159197|NCT01796522|Drug|nifedipine (60 mg / day orally)|
159198|NCT01796548|Drug|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
159492|NCT01799733|Other|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
159493|NCT01799759|Behavioral|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
159494|NCT01802320|Drug|Akt Inhibitor MK2206|Given PO
159495|NCT01802320|Other|Laboratory Biomarker Analysis|Correlative studies
159496|NCT01802320|Other|Pharmacological Study|Correlative studies
159497|NCT01802333|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
159498|NCT00100581|Drug|Lopinavir/ritonavir|
159499|NCT01802333|Drug|Cytarabine|Given IV
159500|NCT01802333|Drug|Daunorubicin Hydrochloride|Given IV
159501|NCT01802333|Drug|Idarubicin|Given IV
159502|NCT01802333|Other|Laboratory Biomarker Analysis|Correlative studies
159503|NCT01802333|Drug|Vorinostat|Given PO
159504|NCT01802346|Dietary Supplement|dietary intervention|Consume a low-calorie diet
159505|NCT01802346|Procedure|nutritional support|Receive dietary advice
159506|NCT01802346|Other|laboratory biomarker analysis|Correlative studies
159507|NCT01802359|Drug|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
158889|NCT01793883|Drug|Placebo|
158890|NCT01793896|Behavioral|Control period|Analysis at recruitment and after a month without any intervention
158891|NCT01793896|Behavioral|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
158892|NCT01793896|Behavioral|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
158893|NCT01793896|Behavioral|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
158894|NCT01793909|Other|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
158895|NCT01793922|Procedure|PD|pneumodilation
158896|NCT01793922|Procedure|POEM|peroral endoscopic myotomy
158897|NCT01793935|Drug|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
159199|NCT01796561|Dietary Supplement|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
159200|NCT00099905|Drug|vildagliptin|
159201|NCT01796574|Dietary Supplement|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
159202|NCT01796587|Device|LoFric Origo|
159203|NCT01796600|Device|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
159204|NCT01796613|Device|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
159205|NCT01799031|Procedure|management of therapy complications|Receive standard of care
159206|NCT01799031|Other|educational intervention|Receive access to the WISE web-based educational intervention
158585|NCT01771965|Behavioral|CB Intervention|The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
158586|NCT01771978|Drug|Placebo|Received 250 ml of a 5% dextrose solution as placebo
158587|NCT01771978|Drug|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
158588|NCT01771978|Drug|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
158589|NCT01771978|Drug|diltiazem and acetylcystein|Received a combination of drug :diltiazem and acetylcystein
bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution
150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution
158590|NCT01771991|Drug|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
158591|NCT01771991|Drug|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
158592|NCT00097500|Drug|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
158593|NCT01772004|Drug|Avelumab|Avelumab will be administered in study location using a protocol-defined dose escalation scheme until confirmed progression, unacceptable toxicity, or if any criterion for withdrawal from the trial or investigational medicinal product occurs. After determination of the dose and regimen for Expansion Phase, avelumab will be administered to subjects divided into 4 primary cohorts: Non-small cell lung cancer (NSCLC) post platinum doublet, NSCLC first-line, gastric/gastroesophageal junction (GEJ) cancer and metastatic breast cancer (MBC); 8 secondary cohorts: Colorectal cancer (CRC), castrate-resistant prostate cancer (CRPC), melanoma, ovarian cancer, adrenocortical carcinoma (ACC) mesothelioma, urothelial carcinoma, and renal cell carcinoma (RCC); and 4 efficacy expansion cohorts: gastric and GEJ cancer (third line), ovarian cancer (second-line only), urothelial carcinoma, and head and neck squamous cell carcinoma (HNSCC).
158898|NCT01793935|Drug|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
158899|NCT00099541|Drug|zoledronic acid|
158900|NCT01793948|Drug|metformin hydrochloride|Given PO
158901|NCT01793948|Other|placebo|Given PO
158902|NCT01793948|Other|laboratory biomarker analysis|Correlative studies
158903|NCT01793961|Other|electroretinogram|
158309|NCT01776788|Drug|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
158310|NCT01776801|Other|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
158311|NCT01776840|Drug|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
158312|NCT01776840|Drug|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
158313|NCT01776840|Drug|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
158314|NCT00098033|Drug|clofarabine|
158315|NCT01779843|Drug|Cytarabine|
158316|NCT01779843|Drug|Idarubicin|
158317|NCT00001930|Drug|Amantadine|
158318|NCT00098397|Drug|romidepsin|Given IV
158319|NCT01779843|Drug|Alisertib|
158320|NCT01779856|Device|REVEAL Insertable Cardiac Monitor (ICM)|
158321|NCT01779869|Drug|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
158322|NCT01779882|Drug|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
158323|NCT01779882|Drug|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
158324|NCT01779895|Dietary Supplement|Lactobacillus paracasei probiotic strain|
158594|NCT01772017|Device|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
162705|NCT01865266|Drug|Ulinaststin for injection|
162706|NCT01865266|Drug|placebo|
162707|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
162708|NCT01867684|Other|Psychotherapy|
162709|NCT01867697|Drug|Cetuximab|
162710|NCT01867697|Drug|Irinotecan|
162711|NCT01867697|Drug|Oxaliplatin|
162712|NCT01867697|Drug|Folinic Acid|
162713|NCT01867697|Drug|Calcium Carbonate|
163033|NCT01813227|Drug|Rituximab|If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s).
163034|NCT01813227|Drug|Dexamethasone|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter.
163035|NCT01813240|Drug|Minocycline|
163036|NCT01813240|Drug|placebo|
163037|NCT00101452|Drug|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
163038|NCT01813253|Drug|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
163039|NCT01813253|Drug|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
163040|NCT01813279|Other|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
163041|NCT01813305|Drug|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
163042|NCT01813305|Drug|CSTC1 Matched vehicle|
162716|NCT00107198|Drug|vincristine sulfate|Given IV
162717|NCT01867710|Drug|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
162718|NCT01867710|Drug|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
162719|NCT01867710|Drug|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
162720|NCT01867723|Other|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
162721|NCT01867736|Device|Passeo-18 Lux DRB|
162722|NCT01867736|Device|Standard PTA (POBA)|
162723|NCT01867749|Behavioral|Group Interpersonal Psychotherapy (IPT-G)|
162724|NCT01867749|Behavioral|Coping with Depression (CWD)|
162725|NCT01867762|Drug|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
162726|NCT01867762|Drug|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
162727|NCT00002045|Drug|Zidovudine|
162728|NCT00107198|Radiation|radiation therapy|Undergo IFRT
162729|NCT01867775|Drug|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
162730|NCT01867814|Procedure|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
162731|NCT01867827|Other|Neurofeedback and Physical Exercise|
162732|NCT01867827|Other|Physical Exercise|
162733|NCT01867853|Device|PLR|passive leg raising test was done before and at the end of SBT
162734|NCT01870206|Biological|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
162735|NCT01870219|Drug|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
162101|NCT01872091|Other|cryotherapy by immersion|
162417|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|
162418|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
162419|NCT01864655|Drug|saracatinib|oral drug given to experimental group
162420|NCT00106899|Procedure|Magnetic Resonance Imaging (MRI)|MRI scans
162421|NCT01864655|Drug|Placebo|Placebo given to placebo group
162422|NCT01864681|Drug|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
162423|NCT01864681|Drug|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
162424|NCT01864694|Behavioral|TLC-Diet|Participants receive diet intervention through an automated telephone system
162425|NCT01864694|Behavioral|WEB-Diet|Participants receive diet intervention through a web-based system
162426|NCT01864694|Other|Assessment-only control|Assessment-only control
162427|NCT01864707|Other|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
162428|NCT01864707|Other|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
162429|NCT01864707|Other|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
162430|NCT01864720|Behavioral|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
162431|NCT00106899|Procedure|Positron Emission Tomography (PET)|PET scans
162432|NCT01864720|Behavioral|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
162433|NCT01864733|Other|Physical rehabilitation (exercise).|
161786|NCT00107068|Procedure|[A] Aerobic isokinetic cycling exercise|
161787|NCT01866059|Device|Glass Ionomer Cement|Glass Ionomer Cement
161788|NCT01868555|Drug|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
161789|NCT01868555|Drug|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
161790|NCT01868555|Drug|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
162102|NCT01872104|Procedure|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
162103|NCT01872117|Other|Shortwave therapy|
162104|NCT01872117|Other|Microwave therapy|
162105|NCT01872143|Device|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
162106|NCT01872156|Other|Intervention GESTABAC|Intervention based on the "Clinician`s Guide to helping Pregnant Women Quit Smoking" on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth.
162107|NCT01872156|Other|Control Group|The group control will act according to usual management.
162108|NCT01872169|Other|Disordered eating screening questionnaire|
162109|NCT01872182|Drug|ALS-L1023|daily twice for 12 weeks
162110|NCT00107536|Other|laboratory biomarker analysis|Correlative studies
162111|NCT01872182|Drug|placebo|daily twice for 12 weeks
162112|NCT01872195|Other|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
162113|NCT01872208|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration.
161479|NCT01785758|Drug|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
161480|NCT01785771|Drug|ITCA 650 (exenatide in DUROS)|
161481|NCT01785784|Drug|rhGM-CSF Gel|
161482|NCT01785797|Device|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
161483|NCT01785810|Drug|Maraviroc 300 mg|
161484|NCT00098839|Biological|epratuzumab|Given IV
161485|NCT01785823|Other|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
161791|NCT01868568|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin).
161792|NCT01868568|Drug|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
161793|NCT01868568|Drug|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
161794|NCT01868568|Drug|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
161795|NCT01868568|Drug|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
161796|NCT00107263|Drug|zoledronic acid|
161797|NCT01868568|Drug|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
161798|NCT01868568|Drug|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
161799|NCT01868568|Drug|placebo|A single dose administered subcutaneously (s.c., under the skin).
161800|NCT01868581|Drug|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
161801|NCT01868581|Drug|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
161802|NCT01868594|Drug|Subetta|Efficiency and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus
161803|NCT01868594|Drug|Placebo|
161193|NCT01782950|Drug|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
161194|NCT01782963|Drug|Lenalidomide|
161195|NCT01782963|Drug|Bortezomib|
161196|NCT00098683|Drug|amifostine trihydrate|
161197|NCT01782963|Drug|Dexamethasone|
161198|NCT01782976|Drug|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
161199|NCT01782976|Drug|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
161200|NCT01782976|Behavioral|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
161201|NCT01782989|Drug|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
161202|NCT01782989|Drug|Placebo|Placebo capsule daily for 24 months
161203|NCT01783002|Radiation|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
161204|NCT01783002|Radiation|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
161486|NCT01785823|Other|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
161487|NCT01788397|Behavioral|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
161488|NCT01788410|Procedure|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facets for the treatment of radicular pain and pain resulting from facet joint disease.
161489|NCT01788410|Device|MRI Seednet Cryotherapy System|
161490|NCT01788423|Device|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
160909|NCT01789983|Behavioral|Walk With Ease Program|The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.
The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program.
160910|NCT01789983|Other|Collect Blood, GA and Other Survey Tools|Geriatric Assessment (GA) (Version 5)
Functional Assessment of Cancer Therapy-General (FACT)
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36
Outcome Expectations for Exercise (OEE) scale29
Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)
Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35
Visual Analog Scales (VAS)
Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis.
160911|NCT01789996|Behavioral|alternative instruction in exercise testing (6MWT)|
160912|NCT01790009|Dietary Supplement|Flavanol rich drink|
160913|NCT01790009|Drug|Acetaminophen|2x500 mg Acetaminophen
160914|NCT00099125|Drug|irinotecan hydrochloride|
160915|NCT01790022|Drug|Methylprednisolone|
160916|NCT01790035|Drug|LGG|
160917|NCT01790035|Drug|Placebo|
160918|NCT01790048|Dietary Supplement|Whey permeate RUSF|Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.
Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier.
160919|NCT01790048|Dietary Supplement|Soy Protein RUSF|Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.
Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources.
161205|NCT01783002|Radiation|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
161206|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
161207|NCT00098709|Device|Fetal pulse oximeter|
161208|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
161209|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
160602|NCT00099320|Drug|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
160603|NCT01791881|Drug|Botulinum Toxin Type A(Botox®)|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
160604|NCT01791894|Drug|arsenic trioxide|Given IV
160605|NCT01791894|Other|laboratory biomarker analysis|Correlative studies
160606|NCT01784133|Drug|placebo|
160607|NCT00098774|Drug|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
160608|NCT01784146|Other|Oxygen|For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the
nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen.
160609|NCT01784146|Other|Heliox|For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the
nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al.
160610|NCT01784146|Other|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
160611|NCT01784159|Drug|Aspirin|Aspirin administration for 7 days
160612|NCT01784172|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
160613|NCT01784172|Device|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
160614|NCT01784185|Procedure|virtual bronchoscopy guided transbronchial needle aspiration|
160920|NCT01790061|Procedure|Standardized Fecal Microbiota Transplantation|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut (below the second part of duodenum).
160012|NCT00099489|Drug|Interferon Beta-1a|
160307|NCT01788982|Drug|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
160308|NCT01788982|Drug|Placebo|
160309|NCT00099021|Drug|pioglitazone hydrochloride|Given PO
160310|NCT01789008|Other|liver biopsie|
160311|NCT01789021|Device|4 blood glucose monitoring systems|
160312|NCT01789047|Drug|Topiramate|Topiramate as adjunct to amantadine
160313|NCT01789047|Drug|Placebo|Placebo control
160314|NCT01789060|Other|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
160315|NCT01789073|Dietary Supplement|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
160316|NCT01789086|Drug|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
160317|NCT01789086|Drug|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
160318|NCT01789099|Biological|UV1 synthetic peptide vaccine and GM-CSF|
160319|NCT01791192|Drug|FTY720|Fingolimod
160320|NCT01791192|Drug|Oral Corticosteroid|Oral Corticosteroid
160321|NCT01791218|Procedure|CABG, AVR or CABG+AVR and PVI|
160322|NCT00001955|Drug|Celecoxib|
160323|NCT00099242|Drug|rivastigmine transdermal patch|
160324|NCT01791218|Procedure|CABG, AVR or CABG+AVR|
160325|NCT01791231|Drug|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
159733|NCT01800162|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
159734|NCT01800175|Device|Punctum Plug|
159735|NCT01800188|Procedure|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
159736|NCT01800188|Procedure|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
159737|NCT01800188|Procedure|Meal test|A 3 hour standardized liquid meal test without dialysis
160013|NCT01793272|Other|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
160014|NCT01793285|Drug|ETANERCEPT|During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.
This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice.
160015|NCT01793298|Drug|ASM-024|Ascending doses of ASM-024
160016|NCT01793311|Other|decaffeinated coffee|contains caffeine 0.5-2 mg
160017|NCT01793311|Other|regular dose coffee|contains 91.8 mg of caffeine
160018|NCT01793311|Other|high dose coffee|contains 144 mg of caffeine
160019|NCT01793337|Other|Exposure to cold environmental temperature (-20°C)|
160020|NCT01793350|Drug|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
160021|NCT01793363|Procedure|Tracheotomy|
160022|NCT01793389|Procedure|Subepithelial connective tissue graft|
160023|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
160024|NCT01793389|Procedure|Platelet Rich Fibrin|
160025|NCT01793415|Drug|IodoCarb (r)|Powder, 3 grams daily for 28+-2 days
160026|NCT01793415|Other|Placebo|Non-iodinated activated charcoal 3 g daily for 28+-2 days
160027|NCT01793428|Other|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
160363|NCT01786174|Other|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
160364|NCT01786187|Behavioral|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
160365|NCT01786187|Other|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
160366|NCT00098839|Drug|methotrexate|Given IT
160367|NCT01786200|Drug|Aspirin|
160368|NCT01786200|Drug|Ibuprofen|
160369|NCT01786226|Drug|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
160370|NCT01786226|Drug|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
160371|NCT01786239|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
160372|NCT01786239|Drug|Omega-3 capsules|The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
160373|NCT01786239|Drug|Amber 50/50 Soybean/Corn Placebo|The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
160374|NCT01786252|Drug|human chorionic gonadotropin (hCG)|500IU of hCG diluted to a final volume of 50ul in IVF media ("Global"-trademark)
160375|NCT01789112|Other|Blood sample|Taking of blood sample
160376|NCT00099047|Drug|celecoxib|Given PO
160377|NCT01789125|Drug|Nicotine Patch|
160682|NCT01784237|Procedure|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
160683|NCT01784250|Drug|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
160684|NCT01784250|Drug|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
160082|NCT01798069|Behavioral|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
160083|NCT00100048|Drug|Placebo monotherapy|Placebo to MK0518 twice daily
160084|NCT01798069|Behavioral|reading medical publication workshops|
160085|NCT01800669|Other|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
160086|NCT01800669|Other|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
160087|NCT01800682|Drug|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
160088|NCT01800695|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
160089|NCT01800695|Drug|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
160090|NCT01800695|Radiation|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
160091|NCT01800708|Drug|Triamcinolone acetonide|
160092|NCT00100399|Biological|Fluarix|
160093|NCT01800708|Drug|Prednisolone syrup|
160094|NCT01800721|Behavioral|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
160095|NCT01800721|Behavioral|SNAP Control|Behavioral: SNAP control 7 group sessions
160096|NCT01800734|Other|Clamp-Mixed Meal Arm|Standard clinical parameters will be assessed in all patients.
Metabolic tests:
A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).
B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump
This test will determine the time courses of:
1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
160097|NCT01800747|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
160098|NCT01800760|Dietary Supplement|Probiotics|Probiotics once a day for three weeks.
160378|NCT01789125|Behavioral|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
159508|NCT01802372|Behavioral|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
159509|NCT00100581|Drug|Pegylated interferon alfa-2a|
159510|NCT01802372|Behavioral|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
159511|NCT01802385|Drug|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
159512|NCT01802411|Drug|Liposome bupivacaine|
159513|NCT01802411|Drug|Placebo|
159514|NCT01802424|Behavioral|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
159794|NCT01795430|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
159795|NCT01795430|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
159796|NCT01795443|Other|Calibration|Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.
The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a "target" position midway along the pelvic movement range.
159797|NCT01797484|Drug|Ranolazine|Improvement of myocardial microcirculation
159798|NCT01797497|Behavioral|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
159799|NCT01797510|Behavioral|Web Based Health Coaching|
159800|NCT01797523|Drug|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
159801|NCT01797523|Drug|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
159802|NCT01797523|Drug|Everolimus|10 mg by mouth once daily in a 28 day cycle.
159803|NCT01797536|Drug|Elbasvir|
159804|NCT01797562|Drug|T.R.U.E. Test Panel 3.2|Surgical tape containing 12 polyester allergen patches.
159207|NCT01799031|Other|questionnaire administration|Ancillary studies
159208|NCT01799031|Procedure|quality-of-life assessment|Ancillary studies
159209|NCT01799044|Device|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
159210|NCT01799057|Drug|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
159211|NCT01799057|Drug|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
159212|NCT00100165|Drug|3-2,4 dimethoxybenzylidene 75 or 150 mg bid|3-2,4 dimethoxybenzylidene 75 or 150 mg bid
159213|NCT01799083|Drug|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
159214|NCT01799083|Biological|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
159215|NCT01799096|Dietary Supplement|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
159216|NCT01799096|Dietary Supplement|Aspartame|Intensely sweetened soft drink (no energy content)
159217|NCT01799109|Drug|Magnesium Sulfate & albuterol|
159218|NCT01799109|Drug|albuterol|
159219|NCT01799109|Drug|magnesium|
159515|NCT01802437|Drug|Fluoxetine|Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter.
159516|NCT01802437|Behavioral|Interpersonal Psychotherapy|Adolescent randomized to an increase in therapy (4 extra therapy sessions)
159517|NCT01802450|Drug|Dasatinib|
159518|NCT01802476|Drug|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
159519|NCT01802476|Drug|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
159520|NCT00100581|Drug|Ribavirin|
158904|NCT01793961|Other|contrast sensitivity tests|
158905|NCT01793987|Device|Coblation polypectomy|
158906|NCT01794000|Drug|Prasugrel|Administered orally
158907|NCT01794000|Drug|Placebo|Administered orally
158908|NCT01796028|Drug|TAXOTERE®|
158909|NCT01796041|Drug|Indocyanine Green|
158910|NCT01796054|Behavioral|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
158911|NCT01796054|Behavioral|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
158912|NCT01796067|Behavioral|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
158913|NCT01796067|Behavioral|Basic Health Education|This group will receive the comprehensive basic health education intervention.
158914|NCT01796067|Behavioral|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
158915|NCT00001960|Device|Pacemaker therapy|
158916|NCT00099853|Drug|Vildagliptin|Vildagliptin 50 mg tablets
158917|NCT01796067|Behavioral|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
158918|NCT01796080|Other|Mueller manoeuvre|
158919|NCT01796080|Other|Inspiratory threshold|
158920|NCT01796080|Other|Expiratory apnoea|
158921|NCT01796080|Other|Steady state normal breathing|
159220|NCT01799122|Device|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
159221|NCT01799135|Other|DCE-MRI scan|
159222|NCT01799135|Radiation|Stereotactic Body Radiation Therapy|
159223|NCT00001964|Drug|Cyclosporine|
159224|NCT00100165|Drug|Placebo|Placebo
158595|NCT01772030|Other|Use of the Achieve catheter followed by ICE-guided mapping catheter|
158596|NCT01772056|Drug|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
158597|NCT01772056|Drug|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
158598|NCT01772082|Behavioral|Internet mediated walking program|
158599|NCT01772108|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
158600|NCT01772134|Drug|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
158601|NCT01772134|Drug|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
158602|NCT01772134|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
158603|NCT00001911|Drug|Interleukin-12|
158604|NCT00097500|Drug|Metformin|Patients usual dosage
158605|NCT01774656|Device|HeartMate II|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
158606|NCT01774656|Drug|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
158607|NCT01774669|Device|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
158608|NCT00097799|Drug|Tipranavir|500 mg twice daily
158609|NCT01774669|Other|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
158610|NCT01774682|Procedure|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
158611|NCT01774695|Behavioral|Increased physical activity|The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.
The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week.
163043|NCT01813318|Drug|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
163044|NCT01813318|Drug|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
163045|NCT01813357|Drug|Rosuvastatin|encapsulated tablet 20mg daily
163046|NCT01813357|Other|Placebo|Placebo arm included to maintain blinding
163047|NCT01813370|Other|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
163048|NCT00001994|Drug|Atovaquone|
163049|NCT00101452|Drug|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
163050|NCT01813383|Other|There is not any intervention|
163051|NCT01813396|Other|joint mobilization plus massage|
163052|NCT01813396|Other|joint mobilization/shoulder physical activity guide|
158325|NCT01779895|Dietary Supplement|Placebo|maltodextrin
158326|NCT01779908|Dietary Supplement|Vitamin D|
158327|NCT01779908|Other|Placebo|
158328|NCT01779921|Drug|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
158329|NCT00098397|Other|laboratory biomarker analysis|Optional correlative studies
158330|NCT01779921|Drug|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
158331|NCT01779921|Drug|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
158332|NCT01779921|Drug|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
158333|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
158334|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
163053|NCT01813422|Biological|Evolocumab (AMG 145)|Subjects randomized to the Evolocumab (AMG 145) arm will receive Evolocumab (AMG 145) subcutaneously every 4 weeks
163054|NCT01815775|Other|clinical and imaging examinations|Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.
Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation
163055|NCT01815788|Device|Use of a personal sound amplifying device = TeoFirst|
163056|NCT01815801|Other|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
163057|NCT01815801|Other|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
163058|NCT01815814|Other|Rolfing / Myofascial Structural Integration|Rolfing is similar to deep massage. It is also known as "myofascial structural integration."
163059|NCT01815827|Drug|inclacumab|single intravenous doses
163060|NCT01815840|Drug|placebo|orally daily, intermittent with vismodegib
163061|NCT01815840|Drug|vismodegib|150 mg orally once daily, 72 weeks intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib
163062|NCT01815840|Drug|vismodegib|150 mg orally once daily, 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib up to Week 72
163063|NCT00101816|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
163064|NCT01815853|Radiation|Pre-operative chemoradiotherapy|Pre-operative chemoradiotherapy arm:
Radiotherapy (45Grey/25F) + chemotherapy(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)
163065|NCT01815853|Drug|Capecitabine,Oxaliplatin|chemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)
163066|NCT01815866|Procedure|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
163067|NCT01815892|Drug|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
163068|NCT01815892|Drug|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
163069|NCT01815905|Other|Mobile program for occupational and speech therapy|
162434|NCT01867151|Dietary Supplement|Gluten Free Diet|
162435|NCT01867151|Dietary Supplement|Normal Diet|
162736|NCT01870219|Drug|Ketamine|ketamine was given to 1mg/kg ıv bolus
162737|NCT01870232|Procedure|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
162738|NCT01870245|Drug|ACHN-975|Intravenous multiple dose
162739|NCT01870245|Drug|placebo|Intravenous multiple dose
162740|NCT00107380|Drug|prednisone|
162741|NCT01870258|Other|ANN prediction of myocardial infarction|
162742|NCT01870271|Behavioral|Developmentally adapted cognitive processing therapy|
162743|NCT01870284|Drug|Ixekizumab|Administered SC
162744|NCT01870284|Drug|Placebo|Administered SC
162745|NCT01870284|Drug|Adalimumab|Administered SC
162746|NCT01870297|Drug|LY3025876|Administered SQ
162747|NCT01870297|Drug|Placebo|Administered SQ
162748|NCT01870297|Drug|Liraglutide|Administered SQ
162749|NCT01870310|Procedure|Catheterised renal denervation|
162750|NCT01870323|Behavioral|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
162751|NCT00107380|Drug|vincristine sulfate|
162752|NCT01870323|Behavioral|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
162753|NCT01870336|Device|Combined treatment of medial knee osteoarthritis|
162754|NCT01870349|Procedure|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
162755|NCT01870362|Drug|Probiotic (Inersan)|
162114|NCT01872221|Procedure|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
162115|NCT01872234|Device|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
162116|NCT01872260|Drug|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break)
162117|NCT01872260|Drug|Letrozole|Letrozole 2.5 mg/day
162118|NCT01872260|Drug|BYL719|BYL719 Daily
162119|NCT01872273|Other|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
162120|NCT01872286|Device|AKE-1|
162436|NCT01867164|Drug|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
162437|NCT01867164|Drug|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
162438|NCT01867177|Other|HIV testing|HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; "teachable moments" during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable "next steps" with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention.
162439|NCT00107172|Radiation|brachytherapy|No information available
162440|NCT01867177|Other|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
162441|NCT01867177|Behavioral|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS) Community Health Worker (CHW) Program (1-5 sessions with newly dx/dx within 12mo; case management/support services (4 contacts/mo/client for 6mo) linking people to continuous, coordinated care after HIV dx. Another site will do 3, 2hr Motivational Enhancement Intervention (MEI) sessions in 3 wks for HIV+: quality of life workshops, support groups at Butterfly Nest (safe project office for transgender women); 1 booster session (2hrs) after 3-month follow-up; 6mo follow-up assessment. Health Educators recruit clients, make appointments, escort to test sites, intake, review. 4th site will hold monthly risk-reduction workshops, weekly HIV testing for formerly incarcerated.
162442|NCT01867190|Biological|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
162443|NCT01867203|Other|Genotyping|
161804|NCT01868620|Device|Iontophoretic CXL|
161805|NCT01868620|Device|Standard CXL|
161806|NCT01868633|Drug|Dexamethasone|
161807|NCT00107276|Drug|capecitabine|
161808|NCT01868633|Drug|Placebo|
161809|NCT01868646|Drug|Subetta|Efficiency and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus
161810|NCT01868646|Drug|Placebo|
161811|NCT01868659|Behavioral|Diagnostic checklist|Diagnostic checklist used before patient discharged
161812|NCT01868672|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
161813|NCT01868685|Drug|BYM338|BYM338
161814|NCT01868685|Drug|Placebo|Placebo
162121|NCT00002051|Drug|Thymopentin|
162122|NCT01864083|Procedure|MR|
162123|NCT01864096|Drug|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
162124|NCT01864096|Drug|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
162125|NCT01864109|Drug|Cyclophosphamide|
162126|NCT01864109|Device|Doxorubicin|
162127|NCT01864109|Drug|Vincristine|
162128|NCT01864109|Device|Ifosfamide|
162129|NCT01864109|Drug|Etoposide|
162130|NCT00106808|Drug|Muraglitazar|
162131|NCT01864109|Procedure|Surgery|
162132|NCT01864109|Radiation|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
162133|NCT01864109|Drug|Temozolomide|
161491|NCT01788436|Behavioral|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
161492|NCT01788436|Behavioral|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
161493|NCT00098995|Drug|cisplatin|
161494|NCT01788462|Drug|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
161495|NCT01788475|Drug|Dexamethasone|Ozurdex 0.7mg steroid implant
161496|NCT01788488|Other|Use of procalcitonin as biomarker to guide therapy|
161497|NCT01788501|Drug|Tacrolimus|D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
161498|NCT01788501|Drug|Cyclosporine|D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
161499|NCT01788501|Drug|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
161500|NCT01788514|Other|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
161501|NCT01788527|Device|CGM|Real Time Continuous Glucose Monitoring
161502|NCT01788540|Drug|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
161503|NCT01788566|Drug|Necitumumab|Administered IV
161815|NCT01868698|Other|high-voltage electrical stimulation|
161816|NCT01871363|Radiation|chemoradiation|radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),
bevacizumab: at dose 5 mg/kg on days -1, 15, 31.
Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.
161817|NCT01871376|Drug|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
161818|NCT01871402|Drug|000-0551 Lotion|
161210|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
161211|NCT01785238|Other|renal echography|renal echography to analyse the kidney
161212|NCT01785238|Other|Blood sampling|Blood sampling to analyse different parameters of renal function
161213|NCT01785238|Other|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
161214|NCT01785238|Other|Blood pressure measurement|
161215|NCT01785251|Device|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
161216|NCT01785264|Procedure|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
161217|NCT01785264|Procedure|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
161218|NCT00098826|Other|laboratory biomarker analysis|Correlative studies
161219|NCT01785264|Procedure|Mini-invasive surgery|We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.
All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
161220|NCT01785290|Drug|Haloperidol 1 mg/q8h|Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
aged ≥ 80 years
weight ≤ 50 kg
liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.
161504|NCT00098995|Drug|tirapazamine|
161505|NCT01788566|Drug|Gemcitabine|Administered IV
161506|NCT01788566|Drug|Cisplatin|Administered IV
160921|NCT01790061|Drug|Traditional treatments according to associated guidelines|Traditional treatments according to associated guidelines
160922|NCT01790074|Other|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
160923|NCT01790074|Other|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
160924|NCT01790087|Drug|ANX-188 Therapeutic Dose|
160925|NCT00099125|Drug|temozolomide|
160926|NCT01790087|Drug|ANX-188 Supratherapeutic dose|
160927|NCT01790087|Drug|Saline|
160928|NCT01790087|Drug|Moxifloxacin|
160929|NCT01792115|Behavioral|Diet and Exercise|Diet and Exercise
160930|NCT01792167|Behavioral|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
160931|NCT01792180|Behavioral|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
160932|NCT01792206|Drug|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
160933|NCT01792206|Drug|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
160934|NCT01792219|Other|Interprofessional collaboration in health care module|An educational module
160935|NCT01792232|Other|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
160936|NCT01792232|Other|Saline|Saline will be placed in the lung on day 1 of each triad
160937|NCT01792245|Device|Phototherapy|
160938|NCT01792258|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
160939|NCT00099359|Drug|Nevirapine (NVP)|Standard of Care (Zidovudine) plus
NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW > 2000 grams, 8 mg PO per dose if BW < 2000 grams
160326|NCT01791244|Other|Technical support for the RebiSmart™ device|Rebif® will be administered by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) three times a week in accordance to the summary of product characteristics. Subjects will receive only technical support for the RebiSmart™ device.
160327|NCT01791244|Other|Patient support program (MinSupport Plus)|Rebif® will be administered by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) three times a week in accordance to the summary of product characteristics. Subjects will receive support program (MinSupport Plus) which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
160615|NCT01784185|Procedure|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
160616|NCT01784198|Dietary Supplement|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
160617|NCT01784211|Drug|LY2605541|Administered SQ
160618|NCT00098774|Drug|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX < or = 0.05uM Cycles 1-5.
160619|NCT01784211|Drug|Insulin Glargine|Administered SQ
160620|NCT01784224|Procedure|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
160621|NCT01786655|Drug|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
160622|NCT01786655|Drug|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
160623|NCT01786655|Drug|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
160624|NCT01786655|Other|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
160625|NCT00098865|Drug|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
160626|NCT01786668|Drug|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
160627|NCT01786668|Drug|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
160028|NCT01793441|Drug|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
160029|NCT01793441|Drug|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
160030|NCT01793454|Other|Fraction of inspired oxygen 40%|
160031|NCT01793454|Other|Fraction of inspired oxygen 80%|
160032|NCT01793480|Drug|Methadone|
160033|NCT01795703|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
160034|NCT01795716|Drug|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
160328|NCT01791270|Device|Continuous positive airway pressure (CPAP) therapy|Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.
First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).
The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.
We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.
Procedures:
- Respiratory Polygraphy
- Ambulatory Blood Pressure Monitoring
- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.
- ß1en subunit expression in peripheral blood leukocytes.
160329|NCT01791283|Procedure|Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.|
160330|NCT01791296|Drug|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
160331|NCT01791296|Other|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
160332|NCT01791309|Drug|combination panitumumab and vemurafenib|Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
160333|NCT01791348|Other|d2 test of attention|
160685|NCT01784250|Drug|Placebo|Sugar pill manufactured to mimic a drug
160686|NCT01784263|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
160687|NCT01784263|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
160688|NCT01784276|Behavioral|Video|Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.
Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player.
160689|NCT00098774|Drug|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 & 15 Cycles 1, 2, & 3; Day 15 Cycle 4 and Day 1 Cycle 5.
160690|NCT01784302|Dietary Supplement|Multivitamins|
160691|NCT01784302|Dietary Supplement|Sodium bicarbonate|
160692|NCT01784302|Drug|Maalox Plus extra|
160693|NCT01784302|Drug|Raltegravir 400 mg|
160694|NCT01784315|Drug|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
160695|NCT01784315|Drug|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
160696|NCT01784328|Device|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
160697|NCT01784354|Other|Acupressure|
160698|NCT01784354|Other|Acupressure dilatation|
160699|NCT01784354|Behavioral|education|
160700|NCT00098774|Drug|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
160995|NCT01790139|Drug|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
160996|NCT00099125|Procedure|adjuvant therapy|
160997|NCT01790152|Other|Anthropometry|Easily determined in-office physical exam parameters requested include:
Height
Weight
Waist circumference
Blood pressure (BP)
Heart rate
160379|NCT01789125|Behavioral|Education-Supportive Psychotherapy|
160380|NCT01789138|Behavioral|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
160381|NCT01789151|Device|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
160382|NCT01789177|Device|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
160383|NCT01789177|Other|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
160384|NCT01789203|Drug|Ciprofloxacin|Patients will be randomized 2:1 active comparator to placebo comparator.
160385|NCT01789203|Drug|placebo|
160386|NCT01789216|Drug|NSAID|
160387|NCT00099047|Drug|placebo|Given PO
160388|NCT01789216|Drug|Gabapentinoids|
160389|NCT01789216|Drug|placebo|
160390|NCT01789229|Other|Tumor tissue collection|Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.
Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.
Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger.
160391|NCT01789229|Other|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
160392|NCT01789229|Other|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
160393|NCT01789229|Other|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
160394|NCT01789229|Other|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
160395|NCT01789229|Other|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
160396|NCT01789229|Other|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
159805|NCT01797575|Drug|Asprin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
159806|NCT01797575|Dietary Supplement|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
159807|NCT00100009|Drug|TAC-PF|
159808|NCT01797575|Drug|Asprin and NAC|aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
159809|NCT01797575|Drug|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
159810|NCT01797588|Procedure|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
160099|NCT01800773|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
160100|NCT01800773|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
160101|NCT01800786|Device|CPAP|
160102|NCT01800799|Drug|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
160103|NCT00001966|Drug|Mind-body therapy|
160104|NCT00100412|Drug|Graded dobutamine infusions|
160105|NCT01800799|Drug|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
160106|NCT01800812|Biological|Injections of OM-174|
160107|NCT01800825|Drug|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
160108|NCT01800825|Drug|Placebo|This will be an identical placebo comparator made of starch.
160109|NCT01793493|Other|Cognitive stimulation|Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.
Meetings (each lasting about 2 hours) have a common structure:
body awakening (10 minutes)
cognitive stimulation (1 hour and a half) scheduled as follow:
temporospatial orientation
attentional abilities
one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)
160110|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
159521|NCT01794897|Drug|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
159522|NCT01794897|Drug|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
159523|NCT01794910|Other|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
159524|NCT01794923|Drug|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
159525|NCT01794923|Drug|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
159526|NCT01794923|Drug|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
159527|NCT01794923|Drug|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
159528|NCT01794936|Device|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
159529|NCT00099658|Biological|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
159530|NCT01794949|Device|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
159531|NCT01794962|Other|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
159532|NCT01794962|Other|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
159811|NCT01797588|Procedure|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
159812|NCT01797601|Drug|Human Insulin|160 U of insulin
159813|NCT01797601|Drug|Placebo|Insulin dilution medium without insulin
159814|NCT01797653|Other|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
159225|NCT01799135|Other|4D-CT scan|
159226|NCT01799148|Other|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
159227|NCT01799161|Biological|gp96-Ig Vaccine|
159228|NCT01799161|Drug|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
159229|NCT01799161|Other|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
159230|NCT01799161|Procedure|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response [frequency of CD4+, FoxP3 (Treg), et al] in treated patients.
159231|NCT01799174|Procedure|UVA-1 Phototherapy|
159232|NCT01802099|Other|Parenteral nutrition|
159233|NCT01802112|Dietary Supplement|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
159234|NCT01802125|Other|laboratory biomarker analysis|Correlative studies
159235|NCT01802138|Biological|Activated T lymphocyte|intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour.
159236|NCT01802151|Dietary Supplement|B. subtilis R0179|B. subtilis R0179 for a period of 4 weeks. One capsule per day.
159237|NCT01802151|Dietary Supplement|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
159238|NCT01802164|Device|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
159239|NCT01802177|Procedure|UVB excimer light|
159240|NCT00100581|Drug|Efavirenz|
159241|NCT01802190|Genetic|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
159242|NCT01802203|Device|truFreeze Spray Cryotherapy|spray cryotherapy
159243|NCT01802216|Procedure|Scaling and root planing|
159533|NCT01794975|Drug|Ketamine|
159534|NCT01794975|Drug|Atomoxetine|
159535|NCT01794975|Other|Cold pressor test|
158922|NCT01796093|Drug|Digoxin and ivabradine|No more details
158923|NCT01796106|Device|Icon|refer to instructions for use of Icon
158924|NCT01796106|Device|fluoride varnish|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish; Colgate Oral Pharmaceuticals, New York, NY, United States) to all study participants randomized to study arm 2 after the radiograph and visual exam. Topical fluoridation treatment will be provided is varnish (Duraphat) per manufacturer's instructions.
158925|NCT01796119|Procedure|Ridge Splitting|To measure the horizontal bone width before and after implant insertion and 6 months post-op.
To measure BLI measured using PA radiographs taken immediately and 6 months post-op.
To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.
To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length.
158926|NCT01796119|Procedure|Implants placed using drilling technique|To measure the horizontal bone width before and after implant insertion and 6 months post-op.
To measure BLI measured using PA radiographs taken immediately and 6 months post-op.
To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.
To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length.
158927|NCT00099853|Drug|pioglitazone|pioglitazone 45 mg qd
158928|NCT01796132|Drug|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
158929|NCT01796145|Other|TACE or Systemic Therapy|
158930|NCT01798433|Procedure|Provisional approach|Provisional approach with drung-eluting stents
158931|NCT01798433|Device|Elective 2-stent|Elective 2-stent with drug-eluting stents
158932|NCT01798446|Drug|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
158933|NCT01798459|Drug|Methylphenidate|
158934|NCT01798472|Procedure|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
158935|NCT00100087|Device|Ocular Brachytherapy|
158936|NCT01798472|Procedure|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
158335|NCT01779934|Drug|FTY720|Open-label 0.5 mg FTY720 administered orally in patients with primary progressive multiple sclerosis
158336|NCT01779947|Drug|Estradiol Vaginal Tablets 10 mcg|
158337|NCT01779947|Drug|placebo|
158338|NCT00097448|Drug|prednisone|Oral, 19 days
158339|NCT01771445|Drug|IL-1Ra|100mg, s.c, once only
158340|NCT01771445|Drug|Placebo|100mg, s.c., once only
158341|NCT01771458|Drug|Targeted therapy based on molecular profiling : Imatinib|
158342|NCT01771458|Procedure|Tumor biopsy|
158343|NCT01771458|Drug|Standard Chemotherapy|
158344|NCT01771458|Drug|Targeted therapy based on molecular profiling : Everolimus|
158345|NCT01771458|Drug|Targeted therapy based on molecular profiling : Vemurafenib|
158346|NCT01771458|Drug|Targeted therapy based on molecular profiling : Sorafenib|
158347|NCT01771458|Drug|Targeted therapy based on molecular profiling : Erlotinib|
158348|NCT01771458|Drug|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
158612|NCT01774708|Device|Pressure sensitive pad|The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.
This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient.
158613|NCT01774721|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
158614|NCT01774721|Drug|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
158615|NCT01774734|Other|Physical therapy|Physical therapy
Provided by 2 experienced physiotherapist
Applied to every patients 3 times weekly
158616|NCT01774734|Device|Neck Strength Exerciser (NSE)|Neck strength exerciser use 10-20 minutes daily at home
Plus traditional physical therapy three times weekly provided by two experienced physical therapist
158617|NCT01774747|Drug|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
163070|NCT01815905|Other|Traditional rehabilitation therapy|
158349|NCT00097448|Drug|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
158350|NCT01771458|Drug|Targeted therapy based on molecular profiling : Dasatinib|
158351|NCT01771458|Drug|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
158352|NCT01771458|Drug|Targeted therapy based on molecular profiling : Abiraterone|
158353|NCT01771471|Biological|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
158354|NCT01771471|Other|Placebo|0.9% w/v Sodium Chloride for Injection, USP
158355|NCT01771484|Device|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
158356|NCT01771497|Device|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
158357|NCT01771510|Drug|Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger)|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)
Three times a day, oral administration for 24weeks
158358|NCT01771523|Procedure|Thyroidectomy|total thyroidectomy or lobectomy
158359|NCT01771523|Device|use of drain|drain will be used
158360|NCT00097474|Drug|Hydrocortisone|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone (or placebo) and at the target bedtime of (10 pm to midnight local time) they will take 5 mg of melatonin (or placebo) for four days.
158361|NCT01771536|Other|Decision Aid|
158362|NCT01771575|Other|Placebo device|Placebo device
158363|NCT01771575|Device|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance & gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
158364|NCT01774071|Drug|89Zr DFO-MSTP2109A|If you are enrolled onto Group 2:
Once you are given the study drug, the following procedures will be done:
You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (~ 3-7 days after injection).
No research blood work will be drawn in Group 2
158365|NCT01774084|Dietary Supplement|Experimental: PreOp, NutriciaNordica AB|
162756|NCT01870362|Drug|Placebo|
162757|NCT01870388|Drug|Baricitinib|Administered orally
162758|NCT01870401|Device|Lutonix DCB|
162759|NCT01870401|Device|Uncoated PTA Catheter|
163071|NCT01815918|Drug|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
163072|NCT01815918|Drug|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
163073|NCT01815944|Drug|0.75% Ropivacaine|
163074|NCT00101829|Drug|Rituximab|1000 mg intravenous infusion
163075|NCT01815944|Drug|Normal saline|
163076|NCT01818336|Drug|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
163077|NCT01818349|Other|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
163078|NCT01818349|Other|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
163079|NCT01818362|Biological|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
163080|NCT01818362|Biological|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
163081|NCT01818375|Procedure|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
163082|NCT01818375|Other|Standard fluid therapy|
163083|NCT00102063|Drug|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
163084|NCT01818388|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
163085|NCT01818401|Device|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
163086|NCT01818401|Device|Matched patient cutting blocks MyKnee ® LBS|
163087|NCT01818414|Drug|Misoprostol|
163088|NCT01818414|Drug|Folic Acid|
162444|NCT01867216|Drug|Placebo|Administered orally as capsules
162445|NCT01867216|Drug|LY2922470|Administered orally as capsules
162446|NCT01867229|Other|observational|standard of care fore patients with non metastatic breast cancer
162447|NCT01867242|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
162448|NCT01867242|Other|Snus|Winterchill or Robust flavors
162449|NCT01867255|Drug|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
162450|NCT00107172|Radiation|iodine I 125|No information available
162451|NCT01867268|Drug|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
162452|NCT01867268|Other|prone positioning|prone positioning the patient for 10 days following the surgery
162760|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm
162761|NCT01870427|Drug|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
162762|NCT01862692|Behavioral|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
162763|NCT01862705|Other|Thoracic spine manipulation|TSM thrust or non-thrust
162764|NCT01862718|Procedure|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
162765|NCT01862718|Procedure|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
162766|NCT01862796|Behavioral|Weight Loss|Participants receive either a weight-maintaining diet or a 35% calorie reduced diet
162767|NCT01862796|Behavioral|Weight Loss|6-week heart-healthy dietary intervention; 35% calorie reduced diet
162768|NCT01862796|Behavioral|Food Intake|6-week heart-healthy dietary intervention; 35% calorie reduced diet
162769|NCT01862822|Other|upright position|
162134|NCT01864109|Drug|Irinotecan|
162135|NCT01864135|Device|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
162136|NCT01864135|Device|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
162137|NCT01864148|Drug|BIIB033 (anti-LINGO-1 mAb)|Administered as specified in the treatment arm
162138|NCT01864148|Other|Placebo|Participants receive placebo
162139|NCT01864148|Drug|Interferon Beta-1a|All participants receive Interferon Beta-1a intramuscular (IM) injections once weekly
162140|NCT01864161|Drug|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
162141|NCT00106808|Drug|Pioglitazone|
162142|NCT01864161|Drug|Liposomal iron|Sideral forte 30 mg/die
162143|NCT01864174|Drug|Metformin XR|
162144|NCT01864174|Drug|Metformin IR|
162145|NCT01864174|Drug|Placebo matching with Metformin XR|
162146|NCT01864174|Drug|Placebo matching with Metformin IR|
162147|NCT01864187|Drug|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
162453|NCT01867268|Other|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
162454|NCT01867281|Drug|aspirin|
162455|NCT01869712|Other|Cupping therapy|
162456|NCT01869712|Other|Acupuncture|
162457|NCT01869725|Radiation|gallium Ga 68-edotreotide|Given IV
162458|NCT00107354|Procedure|allogeneic bone marrow transplantation|
162459|NCT01869725|Procedure|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
162460|NCT01869725|Radiation|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
162461|NCT01869725|Procedure|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
161819|NCT01871402|Drug|Vehicle Lotion|
161820|NCT01871415|Drug|aleglitazar|150 mcg orally daily
161821|NCT01871415|Drug|metformin|pre-existing background regimen and dose
161822|NCT01871415|Drug|placebo|matching aleglitazar placebo orally daily
161823|NCT01871428|Drug|aleglitazar|150 mcg orally daily
161824|NCT01871428|Drug|placebo|matching aleglitazar placebo orally daily
161825|NCT01871441|Radiation|Total-body irradiation|Undergo TBI
161826|NCT00107484|Procedure|sentinel lymph node biopsy|
161827|NCT01871441|Biological|Donor lymphocytes infusion (DLI)|Undergo DLI
161828|NCT01871441|Drug|Cyclophosphamide|Given IV
161829|NCT01871441|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
161830|NCT01871441|Drug|Tacrolimus|Given IV
161831|NCT01871441|Drug|Mycophenolate mofetil|Given IV
161832|NCT01871454|Radiation|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
161833|NCT01871454|Drug|Pentoxifylline|pentoxifylline
161834|NCT01871467|Drug|Sargramostim|
161835|NCT01871480|Drug|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
161836|NCT01871480|Drug|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
161837|NCT00107497|Procedure|adjuvant therapy|
162148|NCT01864200|Biological|crotilidae polyvalent immune fab (ovine)|crotilidae antivenom
162149|NCT01864200|Biological|Placebo|
162150|NCT01864213|Drug|Ametop cream|
162151|NCT01864226|Drug|RO5545965|Multiple ascending doses
161507|NCT01788579|Behavioral|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
161508|NCT01868113|Drug|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
161509|NCT01868113|Other|Placebo|Placebo to be administered 12hourly
161510|NCT01868126|Drug|DE-117 ophthalmic solution|
161511|NCT01868126|Drug|latanoprost ophthalmic solution|
161512|NCT01868126|Other|Placebo|
161513|NCT01868139|Device|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
161514|NCT01868178|Device|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
161515|NCT00107237|Drug|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
161516|NCT01868191|Drug|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
161517|NCT01868191|Drug|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
161518|NCT01868230|Behavioral|Lifestyle Intervention|
161519|NCT01868243|Drug|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
161520|NCT01868243|Drug|Warfarin|Warfarin adjusted-dose
161521|NCT01868256|Other|early discharge (<72 h)|
161522|NCT01868256|Other|Conventional discharge|
161523|NCT01868269|Drug|Dexamethasone acetate|First step:
immunosuppressive treatment with dexamethasone
161524|NCT01868269|Drug|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
161221|NCT01785290|Drug|Haloperidol 2 mg/q8h|Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
aged ≥ 80 years
weight ≤ 50 kg
liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.
161222|NCT01785290|Drug|Placebo|Sodium Chloride 0.9%
161223|NCT01785303|Behavioral|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
161224|NCT01785303|Procedure|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
161225|NCT01785316|Procedure|IHP|
161226|NCT01785329|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
161227|NCT01785342|Procedure|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
161228|NCT01787760|Device|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
161229|NCT01787760|Device|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
161230|NCT01787760|Device|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
161231|NCT01787773|Device|Veniti Inferior Vena Cava Filter|
161232|NCT01787799|Device|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
161233|NCT01787838|Other|Focused Health Education|A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.
The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it.
161234|NCT00098956|Drug|7-hydroxystaurosporine|Given IV
161235|NCT01787851|Drug|Triheptanoin oil|
161236|NCT01787903|Device|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
161237|NCT01787916|Drug|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
160628|NCT01786668|Drug|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
160629|NCT01786668|Drug|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
160630|NCT01786681|Procedure|Positive pressure|
160631|NCT01786694|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
160632|NCT01786707|Biological|Autologous stem cells and hyperbaric oxygen therapy|Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.
160940|NCT01792271|Other|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
160941|NCT01792284|Drug|LY2605541|Administered SQ
160942|NCT01792284|Drug|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
160943|NCT01792297|Dietary Supplement|Bovine colostrum|
160944|NCT01792297|Dietary Supplement|Whey protein|
160945|NCT01792310|Drug|2-hydroxyoleic acid (2-OHOA/2OHOA)|Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another "general" discontinuation criterion) is met.
Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.
In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of 2-OHOA may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment "holidays" of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances.
160946|NCT01792323|Drug|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
160947|NCT01792349|Behavioral|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
160948|NCT01792362|Other|Weight loss diet|Control the patients diet to make them loosing weight
160949|NCT01784770|Drug|Azithromycin IV|The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.
The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
160334|NCT01783704|Dietary Supplement|Nutrition|All participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the 40-week study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from a registered dietician (RD) within 7 days of randomization with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD within 7 days of randomization and may receive an in-person visit if warranted. Those screening in the normal range and have serum albumin level >3.5 g/dl receive a phone call within 7 days of randomization from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD.
160335|NCT01783704|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
160633|NCT01786733|Behavioral|Behavioral Activation|
160634|NCT01786733|Behavioral|Supportive Therapy|
160635|NCT01786746|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
160636|NCT00098865|Drug|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
160637|NCT01786746|Behavioral|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
160638|NCT01786759|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
160639|NCT01786759|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
160640|NCT01786772|Other|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
160641|NCT01789528|Drug|CXL|IV infusion
160642|NCT01789554|Other|MLS dispatch for bystander CPR|
160643|NCT01789567|Device|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
160644|NCT01789580|Other|Gambling moderator|
160645|NCT00099086|Drug|GnRh analog|A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
160998|NCT01790152|Other|Serum Biomarkers|All participants will have the following analytes collected under standardized conditions and processed centrally.
Cardiac troponins have been associated with acute anthracycline-related cardiotoxicity, and newer high-sensitivity cTnT and cTnI assays may be predictive of late-occurring LV dysfunction. Natriuretic peptides (BNP, NT-ProBNP) are produced in response to myocardial wall stress and are used to monitor CHF progression. Levels, if persistently elevated, correlate well with echocardiographic indices of myocardial dysfunction. In exploratory analyses, we will also examine the effects of selected inflammatory biomarkers.
Fasting lipid profile (total cholesterol, HDL, LDL, triglyceride), glucose, insulin, and hemoglobin AIC)
Provide optional consent to have DNA banked for future research related to analysis of possible genetic polymorphisms associated with differential risk of cardiomyopathy.
160999|NCT01790152|Other|Diagnostic/symptom checklist|The local PI or their designee (e.g. clinician, research nurse, or clinical research associate) will be asked to complete a diagnostic and symptom checklist (see Forms Packet on COG website) related to study outcomes. A copy of the participant's most recent clinic note and current medication list also are requested.
161000|NCT01790152|Procedure|Echocardiogram|Study participants will undergo a one-time standard 2D, M-mode, and Doppler echocardiogram per AHA/ACC task force practice guidelines at participating institutions (or their adult affiliates depending on patient age and institutional practice).
161001|NCT01790152|Other|6 minute walk test (6MWT)|Ambulatory participants will be asked to undergo this simple test of functional exercise capacity.
Contraindications include: 1.) history of angina or myocardial infarction within the past month, 2.) resting heart rate >120 bpm, 3.) systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg. Any other reason for patient inability to perform this test should be documented in the respective Report Form.
161002|NCT01790152|Behavioral|Participant Questionnaires (ages >14 years only)|The time to complete questionnaires is estimated less than 45 minutes. General health status and quality of life will be assessed using the Short-Form-36.
Participants also will be administered the Minnesota Living with Heart Failure questionnaire.
Questionnaires will ascertain family history of cardiovascular and related diseases (e.g. diabetes). Physical activity will be assessed using questions from the Centers for Disease Control & Prevention's (CDC) Behavioral Risk Factor Surveillance System exercise & physical activity modules. Smoking history (current & lifetime) will be assessed using questions from Health and Nutritional Examination surveys.
161003|NCT01790165|Drug|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
161004|NCT01790178|Procedure|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
161005|NCT01790191|Behavioral|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
161006|NCT01782508|Drug|imatinib|a selectively inhibits the KIT protein tyrosine
161007|NCT01782508|Drug|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
161008|NCT00098631|Drug|lapatinib ditosylate|Given orally
161297|NCT00098826|Other|pharmacological study|Correlative studies
160397|NCT01789242|Drug|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
160701|NCT01786772|Other|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
160702|NCT01786798|Device|Transvaginal sonography|Transvaginal sonography will be performed to:
measure the endometrial thickness
detect the endometrial pattern
160703|NCT01786811|Behavioral|Training|Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on "Challenges in discussing advance care planning/values and goals" followed by practice using the SICG.
Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person.
160704|NCT01786824|Drug|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
160705|NCT01786824|Drug|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
160706|NCT01786824|Drug|L-carnitine|Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.
For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed.
160707|NCT00098878|Drug|carboplatin|
160708|NCT01786824|Procedure|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
160709|NCT01786837|Device|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
160710|NCT01786850|Procedure|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
160711|NCT01786863|Procedure|Neuromuscular blockade|
160712|NCT01786876|Drug|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
160713|NCT01786889|Biological|blood and urine|
160111|NCT01793493|Other|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
160112|NCT01793519|Drug|Etanercept|
160113|NCT01793519|Drug|Infliximab|
160114|NCT01793519|Drug|Adalimumab|
160115|NCT01793519|Drug|Placebo|Matching Placebo
160116|NCT01793558|Procedure|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
160117|NCT01793571|Procedure|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
160118|NCT01793584|Procedure|Laparoscopic hysterectomy|LAVH, TLH
160119|NCT01793584|Procedure|Abdominal hysterectomy|TAH
160398|NCT00099047|Other|laboratory biomarker analysis|Correlative studies
160399|NCT00099255|Drug|SGN-30|
160400|NCT01791361|Other|Other|No intervention other than routine medical care
160401|NCT01791374|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
160402|NCT01791374|Drug|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
160403|NCT01791387|Drug|Dovitinib|Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.
If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions.
160404|NCT01791400|Drug|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
160405|NCT01791400|Drug|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
159815|NCT01797653|Procedure|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
159816|NCT01797666|Drug|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
159817|NCT01797679|Other|Strength Training|
159818|NCT00001962|Drug|Daclizumab|Daclizumab, 1mg/kg of body weight, every 2 weeks for a total of 5 infusions.
159819|NCT00100009|Drug|Triamcinolone Acetonide|
159820|NCT01800292|Drug|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
159821|NCT01800305|Drug|Pegylated rhEPO|
159822|NCT01800305|Drug|EPIAO®|
159823|NCT01800318|Device|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
159824|NCT00100308|Drug|saline|Saline placebo
159825|NCT01800318|Behavioral|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
159826|NCT01800318|Device|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
159827|NCT01800318|Behavioral|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
159828|NCT01800331|Behavioral|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
159829|NCT01800344|Device|LMA|
160120|NCT01793610|Drug|Comparator-dose MDMA|Initial comparator-dose MDMA orally at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose MDMA.
160121|NCT00099502|Drug|Copaxone|20 mg administered s.c. once daily.
160122|NCT01793610|Drug|Active Dose 1 MDMA|An initial dose of full-dose MDMA orally given at the start of each of two psychotherapy sessions and possibly followed a dose half the size of the initial dose of MDMA 1.5 to 2.5 hours later.
159536|NCT01794975|Drug|Placebo|
159537|NCT01794988|Behavioral|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
159538|NCT01794988|Behavioral|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
159539|NCT01794988|Behavioral|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
159540|NCT00099671|Drug|Recombinant human interleukin-7|
159541|NCT01794988|Behavioral|NO TIVR|Control - no intervention
159542|NCT01797081|Other|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
159543|NCT01797094|Biological|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
159544|NCT01797094|Biological|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
159545|NCT00099957|Drug|vildagliptin|
159546|NCT01797107|Drug|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
159547|NCT01797120|Drug|Fulvestrant|Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).
If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
159548|NCT01797120|Drug|Everolimus|Everolimus 10 mg (2 tablets) daily x 12 cycles.
If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
159549|NCT01797120|Drug|Placebo (for Everolimus)|Placebo (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
159550|NCT01797133|Procedure|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
159551|NCT01797133|Procedure|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
159830|NCT01800344|Device|Ultra|Ultra
158937|NCT01798472|Procedure|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
159244|NCT01802216|Drug|Minocycline|
159245|NCT01802229|Procedure|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
159246|NCT01802229|Procedure|Fascial suture|The port-site hole is closed with simple suture of the fascia
159247|NCT01802242|Radiation|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|Patients in this group will receive one of 2 treatment arms of their choice:
Arm 1: VMAT delivery with integrated VMAT boost (IB‐VMAT) GTV: 95Gy in 38fractions
Arm 2: HDR‐boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT
159248|NCT01802242|Other|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI‐guided prostate biopsy at 3 years and PSA per standard practice
159249|NCT01802255|Drug|Sevoflurane|Treatment group: Inhalatory sedation with sevoflurane via AnaConDa.
159250|NCT01802255|Drug|Midazolam|Control Group: Intravenous sedation with midazolam.
159251|NCT00100581|Drug|Lamivudine|
159252|NCT01802268|Drug|Conversion from Tacrolimus to Sirolimus|
159253|NCT01802268|Drug|Maintenance on tacrolimus|
159254|NCT01802281|Procedure|Vaginal hysterectomy and uterosacral ligament suspension (USLS)|
159255|NCT01802281|Procedure|Uphold® LITE|
159256|NCT01802294|Behavioral|Parenting Program|Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.
Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.
The program is manualized in isiXhosa.
159257|NCT01802307|Radiation|Brachytherapy|
159258|NCT01794455|Drug|Candesartan|4mg - 32mg daily
159259|NCT01794468|Other|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
158618|NCT01774747|Drug|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
158619|NCT00001919|Drug|Hypericum (LI-160)|
158620|NCT00097799|Drug|Ritonavir|200 mg twice daily
158621|NCT01774760|Drug|18F-EF5|
158622|NCT01774760|Procedure|Pretreatment PET/CT-scan (performed two times)|
158623|NCT01777282|Drug|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
158624|NCT01777282|Drug|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
158625|NCT01777282|Drug|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
158626|NCT01777282|Drug|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
158627|NCT01777295|Biological|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
158628|NCT01777295|Biological|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
158629|NCT01777308|Biological|Nimenrix™|Single dose administered intramuscularly in the deltoid region of the non-dominant arm at Month 72 post primary vaccination (booster visit 1).
158630|NCT00098072|Drug|Sodium Nitrite|
158631|NCT01777321|Biological|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
158938|NCT01798472|Procedure|uncemented hemiarthroplasty|Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by "press-fit"-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
158939|NCT01798485|Drug|Arm A: single agent docetaxel|Single agent docetaxel 75 mg/m2
158940|NCT01798485|Drug|Arm B: Combination of ganetespib and docetaxel|ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2
158941|NCT01798498|Device|Princess® VOLUME|
158942|NCT01798511|Procedure|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
158366|NCT01774084|Dietary Supplement|Placebo Comparator: Water|
158367|NCT01774097|Biological|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
158368|NCT01774097|Biological|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
158632|NCT01777334|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
158633|NCT01777334|Drug|Tiotropium 18 mcg|Inhalation Powder
158634|NCT01777347|Drug|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
158635|NCT01777347|Drug|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
158636|NCT01777360|Device|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
158637|NCT01777386|Procedure|preexpanded perforator flap surgery|
158638|NCT01777412|Drug|Bevacizumab|
158639|NCT01777451|Other|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
158640|NCT01777464|Biological|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
158641|NCT00098085|Biological|HSPPC-96|
158642|NCT01777464|Biological|sham|sham solution
158643|NCT01777477|Drug|Chloroquine|Addition of Chloroquine to Gemcitabine
158644|NCT01777477|Drug|Gemcitabine|
158645|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences Study - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number (see Appendix VI for this pamphlet). The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
158646|NCT01780480|Procedure|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
158647|NCT01780493|Procedure|The Direct Nipple Ureteroneocystostomy Technique|
163089|NCT01818427|Biological|infusion of 2 units of plasma|infusion of 2 units of plasma
163090|NCT01818440|Other|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
163091|NCT01818440|Other|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
158369|NCT01774110|Other|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
158370|NCT01774136|Behavioral|Enhanced HIV and MCH training for CHW|
158371|NCT00097773|Drug|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
158372|NCT01774149|Device|Few Touch Application|Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
158373|NCT01774149|Device|Diastat|Users get the Few Touch Application with Diastat module activated.
158374|NCT01774162|Device|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
158375|NCT01774162|Device|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
158376|NCT01774201|Other|Breathing exercises|
158377|NCT01774214|Procedure|Push-Pull technique|Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the "Push-Pull Technique", the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will "pull" fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is "off" to the bag of NS and "open" to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model.
158378|NCT01774214|Procedure|Disconnect-Reconnect Technique|Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the "Disconnect-Reconnect Technique", the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles.
158379|NCT01774227|Procedure|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
162770|NCT01862835|Drug|Degarelix|
162771|NCT00106561|Drug|Spironolactone|
162772|NCT01862835|Drug|Testosterone|
162773|NCT01862835|Drug|Anastrozole|
162774|NCT01862835|Drug|Estrogen patch|
162775|NCT01862874|Biological|V501|
162776|NCT01862874|Biological|Placebo|
162777|NCT01862887|Drug|PH-797804|Tablet, 24 mg, single dose
162778|NCT01862887|Drug|Moxifloxacin|Tablet, 400 mg, single dose
162779|NCT01862887|Drug|Placebo|Tablet, PH-797804 matched placebo, single dose
162780|NCT01862900|Biological|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
163092|NCT01818453|Behavioral|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
163093|NCT01818479|Biological|stem cell transplant|Open label, single arm dose finding trial with two treatment strata ( high-TBI and low-TBI conditioning regimens) to assess the efficacy of Treg/Tcon addback to CD34 selected partially matched related donor stem cells.
163094|NCT00102063|Drug|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
163095|NCT01818479|Procedure|Stem cell transplant|
163096|NCT01818492|Biological|NI-0501|
163097|NCT01818531|Procedure|Adductor canal block|
163098|NCT01818531|Procedure|Lumbar plexus block|
163099|NCT01818544|Drug|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
163100|NCT01820884|Procedure|BPLND|bilateral pelvic and para-aortic lymph node dissection
163101|NCT01820897|Drug|Fosfomycin-Trometamol|
162462|NCT01869725|Procedure|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
162463|NCT01869738|Device|MGuard Prime|
162464|NCT01869738|Device|(BMS/DES)|
162465|NCT01869751|Drug|Prucalopride|Treatment with prucalopride for slow-transit constipation
162466|NCT01869764|Dietary Supplement|omega-3 fatty acid|Given PO
162467|NCT01869764|Other|placebo|Given PO
162468|NCT01869764|Other|laboratory biomarker analysis|Correlative studies
162469|NCT00107354|Procedure|peripheral blood stem cell transplantation|
162470|NCT01869777|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
162471|NCT01869790|Other|Different fat types|Saturated, monounsaturated fats
162472|NCT01869803|Drug|gemtuzumab ozogamicin|Given IV
162473|NCT01869803|Other|laboratory biomarker analysis|Correlative studies
162474|NCT01869829|Drug|Observational antifungal therapy|Observational study of primary antifungal therapy utilized and outcomes, including:
fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin
Antifungal agents agreed upon (and dosing) at each site.
All agents are given as standard of care.
162475|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
162476|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
162781|NCT01862913|Other|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
162782|NCT00106561|Drug|Irbesartan|
162783|NCT01862913|Other|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
162784|NCT01862926|Drug|Rituximab|
162785|NCT01862926|Drug|Cyclophosphamide|
162152|NCT00106821|Drug|Tiotropium Bromide Inhalation Powder|
162153|NCT01864226|Drug|placebo|Multiple ascending doses
162154|NCT01866644|Drug|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
162155|NCT01866644|Drug|Saline|Bath saline transplanted liver
162156|NCT01866657|Drug|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
162157|NCT01866657|Other|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
162158|NCT01866657|Other|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
162159|NCT01866657|Other|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
162160|NCT01866657|Drug|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
162161|NCT01866657|Biological|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
162162|NCT01866657|Drug|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
162163|NCT01866670|Behavioral|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
162164|NCT00107107|Drug|pramlintide acetate|Syringe vial and Pen-cartridge
162165|NCT01866670|Behavioral|relaxation therapy|Relaxation Therapy: deep breathing
162166|NCT01866683|Behavioral|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
162167|NCT01866683|Behavioral|1 month waiting period|waiting or detraining period
162168|NCT01866696|Device|oral implants|For all cases, the following surgical and prosthetic protocol was followed.:
Clinical examination
Radiological examination
Guided oral implants insertion
Immediate Prosthetic loading
Follow-up
162169|NCT01866709|Drug|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
162170|NCT01866709|Drug|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
162477|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
161838|NCT01871493|Drug|LY2605541|Administered subcutaneous (SQ)
161839|NCT01871493|Drug|Insulin Lispro|Administered SQ
161840|NCT01871506|Behavioral|Standard Care (SC)|Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.
161841|NCT01863719|Drug|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 2.5mg/kg colistin base activity every 8 hours x 3 doses (total exposure 7.5mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 2.5mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 8 hours x 3 doses.
161842|NCT01863719|Drug|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 2.5mg/kg colistin base activity every 12 hours x 2 doses (total exposure: 5mg/kg) intravenously (IV), followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 2.5mg/kg colistin base activity IV every 12 hrs x 2 doses in combination with 75mg colistin base activity via aerosol every 12 hrs x 2 doses.
161843|NCT01863719|Drug|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosolized administration every 8 hours x 3 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 8 hours x 3 doses in combination with 2.5mg/kg colistin base activity IV every 8 hours x 3 doses.
161844|NCT00106704|Drug|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
161845|NCT01863719|Drug|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosolized administration every 12 hours x 2 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 12 hrs x 2 doses in combination with 2.5mg/kg colistin base activity IV every 12 hrs x 2 doses.
161846|NCT01863719|Drug|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 28 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 28 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 21 doses.
161847|NCT01863719|Drug|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
161848|NCT01863732|Biological|Secukinumab|Eligible patients having completed the core study continue in the extension study under the same blinded dosage regimen (1 PFS); because of the double dummy design, placebo containing PFS is administered simultaneously, for a total of two injections. As of week 156, the same dosage regimen is administered open label, thus a single injection takes place.
161849|NCT01863732|Biological|Secukinumab|Eligible patients having completed the core study continue in the extension study under the same blinded dosage regimen (1 PFS); because of the double dummy design, placebo containing PFS is administered simultaneously, for a total of two injections. As of week 156, the same dosage regimen is administered open label, thus a single injection takes place.
161238|NCT01787929|Procedure|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
161525|NCT01868269|Drug|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
161526|NCT00107250|Drug|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
161527|NCT01868282|Procedure|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
161528|NCT01868282|Procedure|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
161529|NCT01870752|Radiation|Chemotherapy|
161530|NCT01870765|Device|non-invasive ventilation|non-invasive ventilation via face mask
161531|NCT01870765|Device|high-flow oxygen|high-flow oxygen via nasal cannula
161532|NCT01870765|Procedure|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
161533|NCT01870778|Drug|RLX030|intravenous infusion
161534|NCT01870778|Drug|Placebo|placebo
161535|NCT01870791|Drug|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
161536|NCT01870804|Drug|Rosuvastatin|
161537|NCT01870804|Drug|Atorvastatin|
161538|NCT00107445|Drug|EF5|Given IV
161539|NCT01870817|Dietary Supplement|Home jejunostomy feeding|
161540|NCT01870830|Other|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
161541|NCT01870843|Drug|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
160950|NCT01784783|Behavioral|HOPE Intervention|If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.
Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session.
160951|NCT01784783|Behavioral|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
160952|NCT01784796|Behavioral|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
160953|NCT01784796|Behavioral|Health Education Program|8 week Health Education Program
161239|NCT01787942|Device|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
161240|NCT01787955|Procedure|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
161241|NCT01787955|Procedure|conventional PPPD|
161242|NCT01787994|Genetic|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF‐T), given via intravenous infusion.|
161243|NCT01788007|Drug|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
161244|NCT01788007|Drug|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
161245|NCT00001946|Procedure|Magnetic resonance angiography|
161246|NCT00098969|Drug|resveratrol|
161247|NCT01788007|Drug|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
161248|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide|
161249|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
161250|NCT01788033|Drug|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
160646|NCT01789593|Other|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
160647|NCT01789606|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
160648|NCT01789619|Drug|Extended release tacrolimus (Advagraf®)|
160649|NCT01789632|Procedure|Group A Platelet Rich Plasma Injection (PRP)|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a needle will then be placed into the tendon followed by 10-12 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites. Whole blood will be drawn from the patient's unaffected arm using a butterfly needle. The blood will be centrifuged and then a dose of the platelet rich plasma will be placed into the common extensor tendon, and the remaining platelet rich plasma will be sent for analysis of platelet, white blood and red blood count concentrations.
160954|NCT01784809|Behavioral|Multimedia WORTH|The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. ***To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:
http://ccnmtl.columbia.edu/projects/worth/presentation
160955|NCT01784809|Behavioral|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
160956|NCT01784809|Behavioral|Wellness Promotion|
160957|NCT01784822|Device|Hybrid Graft|Hybrid Graft for ventral hernia repair
160958|NCT00098787|Drug|Oxaliplatin|Given IV
160959|NCT01784835|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
160960|NCT01784835|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
160961|NCT01784848|Procedure|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
160962|NCT01784861|Drug|X-82|
160963|NCT01784861|Drug|Everolimus|
161298|NCT01785368|Other|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
161299|NCT01785368|Other|Baseline observation|During this period of the study, baseline data will be collected.
161300|NCT01785381|Other|Added value of coordinator|Added value of coordinator
161301|NCT01785394|Drug|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
161302|NCT01785407|Dietary Supplement|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
161303|NCT01785420|Drug|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
161304|NCT01785420|Drug|Placebo|A 90 minute intravenous infusion of saline as placebo
161305|NCT01785433|Drug|Tiotropium HFA BAI 4.5 mcg|
161306|NCT01785433|Drug|Tiotropium HFA BAI 9.0 mcg|
161307|NCT01785433|Drug|SPIRIVA® HandiHaler® 18 mcg/day|
161308|NCT00098839|Drug|L-asparaginase|Given IM
161309|NCT01785433|Drug|Spiriva® Respimat® 5 mcg/day|
161310|NCT01785446|Drug|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
161311|NCT01785446|Drug|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
161312|NCT01785459|Drug|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
161313|NCT01785459|Drug|Standard Care|10 mg Intravenous injection of Prochlorperazine
161314|NCT01785472|Drug|LCZ696|LCZ696 200 mg tablet
160714|NCT01786889|Behavioral|Questionnaire|
160715|NCT01786889|Behavioral|Telephone interview|
160716|NCT01786902|Drug|DA-3002|
161009|NCT01782521|Procedure|No primer|Primer not used when bonding orthodontic brackets
161010|NCT01782547|Behavioral|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
161011|NCT01782547|Other|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
161012|NCT01782560|Drug|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
161013|NCT01782560|Drug|Placebo|
161014|NCT01782573|Drug|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
161015|NCT01782573|Drug|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
161016|NCT01782599|Other|Dual nicotine patch and electronic cigarette|
161017|NCT01782612|Procedure|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
161018|NCT01782612|Procedure|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
161019|NCT00098631|Other|laboratory biomarker analysis|Correlative studies
161020|NCT01782625|Other|NO exercise at depth|Subjects will NOT exercise while at depth
161021|NCT01782625|Other|exercise at depth|Subjects will exercise while at depth
161022|NCT01782638|Behavioral|deep brain stimulation|
161023|NCT01782651|Drug|Lapatinib plus capecitabine|Lapatinib plus capecitabine
160406|NCT01791413|Drug|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
160407|NCT01791426|Device|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
160408|NCT01791426|Device|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
160409|NCT01791439|Other|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
160410|NCT00099268|Drug|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
160411|NCT01791439|Other|placebo|
160412|NCT01791465|Drug|extended-release exenatide|
160413|NCT01791478|Drug|PI3K inhibitor BYL719|Given PO
160414|NCT01791478|Drug|letrozole|Given PO
160415|NCT01791478|Other|laboratory biomarker analysis|Correlative studies
160416|NCT01791478|Other|pharmacological studies|Correlative studies
160417|NCT01791491|Drug|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
160717|NCT01786915|Drug|Bendavia 10mg|
160718|NCT00098891|Drug|entinostat|Given orally
160719|NCT01786915|Drug|Bendavia 50mg|
160720|NCT01786915|Drug|Placebo|
160721|NCT01789684|Other|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
160722|NCT01789697|Other|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
160723|NCT01789710|Drug|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
160724|NCT01789710|Drug|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
160725|NCT01789710|Behavioral|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
160123|NCT01793610|Drug|Active Dose 2 MDMA|
160124|NCT01793623|Other|atrial tissue|retrieval of discarded atrial tissue
160125|NCT01793636|Drug|AZD2014|AZD2014 vs Everolimus
160126|NCT01793636|Drug|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
160127|NCT01793649|Drug|GS-5737|A single dose of GS-5737 in 2.8% saline
160128|NCT01793662|Procedure|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
160129|NCT01793675|Procedure|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
160130|NCT01788579|Behavioral|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
160131|NCT01788605|Drug|ramosetron|
160132|NCT01788618|Other|Cognitive exams|Psychopathological assessment (T0 and T3):
Scale of Spielberger
The self-administered questionnaire CES-D
Cognitive assessment(T0 and T3):
- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)
Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):
Self-assessment FACT-COG (T0,every months until T3)
160133|NCT01788618|Other|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
160134|NCT01788618|Other|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
160135|NCT01788618|Other|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
160418|NCT01791504|Device|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
160419|NCT01791517|Other|RevitaLens OcuTec|Each subject, for each lens type will be exposed to each lens care solution in a random order
160420|NCT01791517|Other|OptiFree PureMoist|Each subject, for each lens type will be exposed to each lens care solution in a random order
160421|NCT00099268|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
159831|NCT01800357|Drug|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
159832|NCT01800357|Drug|placebo|infusion of plabcebo once a day and for 14 days
159833|NCT01800357|Drug|aspirin|infusion of aspirin (100mg) once a day for days
159834|NCT01800370|Drug|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
159835|NCT00100334|Drug|PPI-1019 (APAN)|
159836|NCT01800370|Drug|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
159837|NCT01800370|Other|Exercise|Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.
Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.
159838|NCT01800370|Procedure|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
159839|NCT01800370|Other|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
159840|NCT01800396|Dietary Supplement|Milk protein|
159841|NCT01792856|Other|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
159842|NCT00099463|Procedure|Physical Exam|
159843|NCT01792856|Other|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
159844|NCT01792895|Procedure|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
159260|NCT01794481|Procedure|Resistance Exercise Training (RET)|If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.
There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique.
159261|NCT01794494|Procedure|Bypass surgery|Patients are treated with femoro-popliteal bypass
159262|NCT01794494|Procedure|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
159552|NCT01797146|Procedure|Catheter Reminder and Evaluation Program|This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.
Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.
Type and duration of urinary catheter use.
Indication of urinary catheter _________
Type and duration of central venous catheter use
Indication of urinary catheter _________
Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified.
159553|NCT01797159|Radiation|Hippocampal-sparing Prophylactic Cranial Irradiation|Hippocampal-sparing Prophylactic Cranial Irradiation
159554|NCT01797172|Procedure|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
159555|NCT01797172|Procedure|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
159556|NCT00099970|Drug|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
159557|NCT01799759|Other|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
159558|NCT01799772|Behavioral|Comprehensive Behavioral Intervention|Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.
Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.
Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.
Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c.
158943|NCT01798511|Other|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
158944|NCT01798537|Drug|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
158945|NCT01798550|Drug|Enoxaparin|Twice daily dosing
158946|NCT00100100|Drug|Modafinil|
158947|NCT01798589|Drug|Ethylenediamine dihydrochloride|1 allergen panel containing 2 allergen and 2 control patches
158948|NCT01798602|Drug|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
158949|NCT01798602|Drug|Placebo|Identical placebo for rosuvastatin
158950|NCT01798628|Drug|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
158951|NCT01798628|Drug|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
158952|NCT01801254|Other|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
158953|NCT01801267|Procedure|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
158954|NCT01801267|Procedure|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
158955|NCT01801280|Drug|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application either alone or together with Pantozol®.
158956|NCT01801280|Drug|Pantoprazole|Daily dose: 40mg. Application together with either CellCept® or Myfortic® .
159263|NCT01794507|Drug|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
159264|NCT01794507|Drug|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
159265|NCT01794507|Drug|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
158648|NCT01780506|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
158649|NCT01780506|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally once daily
158650|NCT01780506|Drug|E/C/F/TDF Placebo|E/C/F/TDF placebo tablet administered orally once daily
158651|NCT01780506|Drug|E/C/F/TAF Placebo|E/C/F/TAF placebo tablet administered orally once daily
158652|NCT01780519|Drug|lorazepam|single dose of 1 mg lorazepam
158957|NCT01801280|Drug|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application either alone or with Pantozol® .
158958|NCT01801293|Drug|GS-5806|
158959|NCT01801306|Device|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
158960|NCT00100464|Drug|5HTP|
158961|NCT01801319|Device|Libra Deep Brain Stimulation System|
158962|NCT01801332|Dietary Supplement|intensive nutrition|Patients randomized in " intensive enteral nutrition " arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde.
158963|NCT01801332|Dietary Supplement|usual meals|Patients randomized in " classical oral nutrition " arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily.
158964|NCT01801345|Other|Fatigued|
158965|NCT01801345|Other|Rested|
158966|NCT01801358|Drug|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
158967|NCT01801358|Drug|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
158968|NCT01801371|Drug|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
158969|NCT01801384|Behavioral|Voucher-based incentives|
158970|NCT01801397|Drug|osteoanabolic therapy|
158380|NCT01774227|Procedure|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
158381|NCT01776840|Drug|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
158382|NCT01776853|Dietary Supplement|Glucose|
158383|NCT01776853|Dietary Supplement|Fructose|
158384|NCT01776853|Dietary Supplement|Fructans|
158653|NCT01780532|Procedure|Photoacoustic Imaging (PAI)|Standard of Care
158654|NCT01780545|Drug|OGX-427|Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.
Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity.
158655|NCT01780545|Drug|Docetaxel|For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.
For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles.
158656|NCT00098475|Drug|Dexamethasone|Given PO
158657|NCT01780558|Other|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
158658|NCT01780558|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
158659|NCT01780571|Procedure|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
158660|NCT01780584|Drug|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
158661|NCT01780584|Drug|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
158662|NCT01780584|Drug|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
163102|NCT01820897|Drug|Sulfamethoxazole trimethoprim|
163103|NCT01820910|Drug|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
163104|NCT01820923|Device|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
163105|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
163106|NCT01820923|Device|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
163107|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
163108|NCT01820936|Drug|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
163109|NCT01820936|Drug|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
158385|NCT01776866|Procedure|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
158386|NCT01776892|Drug|Collegenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.
Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
158387|NCT01776892|Procedure|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
158388|NCT01776931|Dietary Supplement|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
158389|NCT01776957|Device|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
158390|NCT01776970|Drug|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
158391|NCT00098046|Drug|famciclovir|
162786|NCT01865279|Drug|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
162787|NCT01865279|Drug|placebo|Ascending single doses - 5 dose levels
162788|NCT01865279|Drug|insulin degludec|A single dose corresponding to that of isophane human insulin
162789|NCT01865279|Drug|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
162790|NCT01865292|Drug|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
162791|NCT01865292|Drug|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
162792|NCT01865305|Drug|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
162793|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
162794|NCT00107003|Drug|lapatinib ditosylate|
162795|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
162796|NCT01865305|Drug|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
162797|NCT01865305|Drug|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
162798|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
162799|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
162800|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
163110|NCT00102284|Drug|modafinil|
163111|NCT01820936|Drug|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
163112|NCT01820936|Drug|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
163113|NCT01820936|Drug|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
163114|NCT01820962|Procedure|heparin|when not in use CVCs are locked with heparin
162478|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
162479|NCT01869855|Procedure|Subdural Drainage|
162480|NCT00107367|Procedure|conventional surgery|
162481|NCT01869855|Procedure|Subperiosteal Drainage|
162482|NCT01869881|Drug|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
162483|NCT01869881|Drug|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
162484|NCT01852721|Behavioral|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
162485|NCT01852721|Behavioral|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
162486|NCT01852734|Procedure|embolizations ,uterine fibroid|26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop ( " cut the tree" appearance)
26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until "near stasis " flow stop
162487|NCT01852734|Procedure|embolizations|comparison between the two microspheres
162488|NCT01852747|Procedure|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
162489|NCT01852773|Procedure|Open repair of thoracic aorta injury|open surgical management of aortic injury
162490|NCT00105365|Other|walking shoes|walking shoes
162491|NCT01852773|Procedure|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
162492|NCT01852786|Other|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
162493|NCT01852786|Other|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
161850|NCT01863745|Drug|nilotinib|Nilotinib can be provided as 200 mg and 150 mg hard gelatin capsules. The starting dose of nilotinib should be the same as the last dose that was given in the parent nilotinib study. After this, the dose of nilotinib is based on the investigator's judgment.
162171|NCT01866722|Behavioral|Usual care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
162172|NCT01866722|Behavioral|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
162173|NCT01866722|Behavioral|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
162174|NCT01866735|Other|Standardized Rehabilitation Therapy|
162175|NCT00107120|Drug|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
162176|NCT01866748|Drug|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
162177|NCT01869205|Device|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
162178|NCT01869231|Dietary Supplement|olive oil|
162179|NCT01869231|Dietary Supplement|olive oil and chewing gum|
162180|NCT01869231|Dietary Supplement|chewing gum|
162181|NCT01869231|Dietary Supplement|water|
162182|NCT01869244|Other|WOODCAST 2 mm|
162183|NCT01869257|Device|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
162184|NCT01869257|Device|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
162185|NCT01869283|Other|Kinesiotherapy|
162186|NCT00002047|Drug|Zidovudine|
162187|NCT00107354|Biological|aldesleukin|
162188|NCT01869283|Other|Ultrasound|
162189|NCT01869283|Other|Diadynamic currents|
161542|NCT01870856|Device|Spectacles|Per participant's habitual prescription
161543|NCT01870856|Device|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
161544|NCT01870856|Device|Etafilcon A contact lenses|Hydrogel single vision contact lenses
161851|NCT01863758|Biological|Human-cl rhFVIII|
161852|NCT01863771|Drug|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
161853|NCT01863771|Other|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
161854|NCT01863784|Drug|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
161855|NCT00106704|Drug|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
161856|NCT01866059|Device|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
161857|NCT01866085|Procedure|AdVance® sling procedure|
161858|NCT01866085|Procedure|ARGUS Sling procedure|
161859|NCT01866098|Drug|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
161860|NCT01866098|Drug|Placebo|
161861|NCT01866111|Drug|YKP3089|
161862|NCT01866111|Drug|Placebo|
161863|NCT01866124|Other|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
161864|NCT01866163|Drug|LEO 90100|
161865|NCT00107068|Procedure|[B] Progressive Resistance Training|
161866|NCT01866163|Drug|Vehicle|
161867|NCT01866176|Device|Stabilizing Knee Brace|Brace with no valgus action
161251|NCT01790490|Drug|ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
161252|NCT00001955|Drug|Etanercept|
161253|NCT00099151|Behavioral|Caloric Restriction (CR)|
161254|NCT01790490|Drug|lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
161255|NCT01790503|Drug|PLX3397|
161256|NCT01790503|Radiation|Radiation Therapy|
161257|NCT01790503|Drug|Temozolomide|
161258|NCT01790516|Drug|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
161259|NCT01790516|Drug|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
161260|NCT01790516|Radiation|Radiation|daily radiation for 7 weeks
161545|NCT01870882|Behavioral|Attentional retraining|
161546|NCT01870882|Behavioral|Control condition|
161547|NCT01870895|Drug|YM060|oral
161548|NCT01870895|Drug|Placebo|oral
161549|NCT00107458|Drug|valproic acid|
161550|NCT01870908|Drug|tacrolimus|
161551|NCT01870908|Drug|biological agents|
161552|NCT01870921|Drug|Ticagrelor|90mg/tablet, 1 tablet bid
161553|NCT01870934|Device|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
161554|NCT01870947|Behavioral|Exercise on stationary recumbent exercise cycle|
161555|NCT01870947|Behavioral|Health Education|Informational brochure ("Better Health and You," Weight Control Information Network, June, 2004)
161556|NCT01870947|Behavioral|Questionnaires|
161557|NCT01870947|Procedure|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
160964|NCT01787344|Drug|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
160965|NCT00098917|Procedure|biological therapy|
160966|NCT01787344|Drug|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
160967|NCT01787357|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
160968|NCT01787357|Drug|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
160969|NCT01787357|Drug|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
161261|NCT01790529|Procedure|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
161262|NCT01790529|Procedure|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
161263|NCT01790542|Other|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
161264|NCT00099151|Behavioral|Exercise|
161265|NCT01790542|Other|Iron fortified cereal with fruit|
161266|NCT01790542|Other|Meat|
161267|NCT01790555|Drug|Namisol|
161268|NCT01790555|Drug|Diazepam/placebo|
161269|NCT01790568|Drug|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
161270|NCT01790568|Drug|Tacrolimus|
161271|NCT01790568|Drug|Methotrexate|
161272|NCT01790581|Behavioral|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
161315|NCT01785472|Drug|Olmesartan|Olmesartan 20 mg capsule
161610|NCT01868334|Behavioral|Pillar 2: Patient notification|Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, "on-hold" messages, clinic websites, and/or social media
161611|NCT01868334|Behavioral|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
161612|NCT01868334|Behavioral|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
161613|NCT01868347|Other|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
161614|NCT01868347|Other|control|PEEP after pneumoperitoneum and trendelenburg
161615|NCT00107250|Drug|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
161616|NCT01868360|Drug|Subconjunctival aflibercept|subconjunctival aflibercept injection
161617|NCT01868360|Other|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
161618|NCT01868373|Biological|Fecal Microbiota Transplantation (FMT)|Active therapy
161619|NCT01868386|Radiation|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
161620|NCT01868412|Device|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
161621|NCT01868412|Device|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
161622|NCT01868425|Drug|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane
161623|NCT01868425|Drug|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane plus placebos of intervention arm meds
161624|NCT01868438|Drug|pyronaridine-artesunate granules|
161024|NCT01782664|Drug|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
161025|NCT01782664|Drug|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
161026|NCT01782664|Drug|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
161027|NCT01782664|Drug|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
161316|NCT01788033|Drug|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
161317|NCT01788046|Drug|AMG 416|Subjects randomized 1:1 to AMG 416. Minimum dose of 2.5mg to maximum dose of 15mg, administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
161318|NCT01788046|Drug|Placebo|Subjects randomized 1:1 to placebo. Minimum dose of 2.5mg to maximum dose of 15mg, administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
161319|NCT01788059|Other|injection the mesenchymal stem cell in non union site|
161320|NCT01788072|Drug|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
161321|NCT01788072|Drug|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
161322|NCT00098982|Drug|bortezomib|
161323|NCT01788085|Device|Bravo pH monitoring procedure|Bravo pH monitoring procedure
161324|NCT01788111|Other|Low back exercises 1|Excentric / concentric extension type exercises
161325|NCT01788111|Other|Low back exercise 2|Traditional low back training
161326|NCT01788137|Drug|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
161327|NCT01788137|Drug|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
161328|NCT01788150|Device|Coronary Stenting|
161329|NCT01788163|Genetic|EGFR mutation test|EGFR mutation being tested in tissue and blood
161330|NCT01788176|Drug|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
160726|NCT01789723|Drug|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
160727|NCT01789723|Drug|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
160728|NCT01789736|Drug|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
160729|NCT01789736|Drug|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
160730|NCT00001954|Drug|Etanercept|
160731|NCT00099099|Behavioral|Caloric Restriction (CR)|
160732|NCT01789736|Drug|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
160733|NCT01789749|Other|Snare Tip Soft Coagulation|
160734|NCT01789749|Other|No Snare Tip Soft Coagulation|
160735|NCT01789762|Biological|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
160736|NCT01789762|Biological|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
160737|NCT01789762|Biological|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
160738|NCT01789775|Drug|Drug: CD07805/47 gel|
160739|NCT01789775|Drug|CD07805/47 gel Placebo|
161028|NCT01784861|Procedure|Blood draws for pharmacokinetic testing|
161029|NCT01784874|Biological|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
161030|NCT01784874|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
161031|NCT01784887|Drug|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
161032|NCT01784900|Drug|Catumaxomab 100µg|
161033|NCT00098800|Drug|fenretinide|
161034|NCT01784900|Drug|Catumaxomab 140µg|
161035|NCT01784913|Biological|UV1 synthetic peptide vaccine and GM-CSF|
160422|NCT00098761|Drug|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
160423|NCT01783821|Drug|Budesonide and formoterol|Patients randomized to one of two intervention arms, will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) every 12 hours, for 5 days or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
160424|NCT01783821|Drug|Placebo|
160425|NCT01783834|Drug|Gefitinib|compare progression free survivla rate and safety to both drugs
160426|NCT01783834|Drug|Pemetrexed|compare PFS rate, safety to both drugs
160427|NCT01783847|Drug|Recombinant human erythropoietin (EPO)|4000 units per vial
160428|NCT01783860|Drug|Azithromycin|
160429|NCT01783860|Drug|Doxycycline|
160430|NCT01783873|Other|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
160431|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
160432|NCT01783886|Procedure|Laser photocoagulation|
160433|NCT00001937|Drug|Fluconazole|
160434|NCT00098774|Biological|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC > or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
160435|NCT01783899|Device|Hemospray|Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.
once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.
Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.
Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.
Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.
Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care
160740|NCT01789788|Drug|Placebo|Matching placebo, multiple doses
160741|NCT01789788|Drug|RO6811135|multiple ascending doses
160742|NCT00099112|Genetic|microarray analysis|
160136|NCT01788631|Drug|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
160137|NCT00098995|Radiation|brachytherapy|
160138|NCT01788631|Drug|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
160139|NCT01788657|Behavioral|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
160140|NCT01788657|Behavioral|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
160141|NCT01788670|Dietary Supplement|Ethanol|
160142|NCT01788670|Other|Water|
160143|NCT01788683|Procedure|Regenexx SD|
160144|NCT01788683|Other|Exercise Therapy|
160145|NCT01788696|Radiation|Group A - Early Imaging|Total of 3 scans
160146|NCT01788696|Radiation|Group B - Delayed Imaging|Total of 2 scans
160147|NCT01788709|Other|preparation cleaning solution|
160148|NCT00098995|Radiation|radiation therapy|
160149|NCT01790919|Behavioral|Cognitive therapy for depression|Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.
160150|NCT01790932|Drug|BKM120|
160151|NCT00099203|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
159559|NCT00100256|Drug|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
159560|NCT01799772|Other|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
159561|NCT01799785|Behavioral|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
159562|NCT01799785|Other|Usual Care|
159563|NCT01799798|Drug|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
159564|NCT01799824|Biological|ANT-1403|
159565|NCT01799824|Biological|placebo|
159845|NCT01792895|Procedure|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
159846|NCT01792895|Procedure|Mobilization with movement|This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.
For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions.
159847|NCT01792908|Device|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
159848|NCT01792921|Behavioral|COG - FUN|
159849|NCT01792934|Drug|XELOX regimen according to standard procedures|
159850|NCT01792934|Drug|FOLFOX regimen according to standard procedures|
159851|NCT01792934|Procedure|Surgery|
159852|NCT01792934|Other|radiofrequency ablation (RFA)|
159853|NCT00099463|Drug|Vaccine|
159854|NCT01792934|Other|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
159855|NCT01792934|Radiation|stereotactic body radiation therapy (SBRT)|
159266|NCT01794520|Drug|ABT-199|ABT-199 dosed at cohort-defined dosing schedules and dose levels for Dose Escalation Cohorts, ABT-199 dosed at defined dose and schedule for Safety Expansion Cohort
159267|NCT01794533|Drug|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
159268|NCT00001958|Drug|Hydroxyurea|
159269|NCT00099632|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
159270|NCT01794533|Drug|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
159271|NCT01794546|Behavioral|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
159272|NCT01794559|Device|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
159273|NCT01794572|Drug|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
159274|NCT01794572|Biological|Autologous Hematopoietic Stem cell|Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day "0" after adequate premedication.
159275|NCT01796613|Device|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
159276|NCT01796626|Device|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
159277|NCT01796665|Drug|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
159278|NCT01796665|Drug|Acanya Gel|
159279|NCT01796665|Drug|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
159566|NCT01799837|Drug|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
159567|NCT01799850|Drug|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
158971|NCT00100477|Drug|Topotecan|
158972|NCT01801410|Device|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
158973|NCT01801410|Drug|Misoprostol|25mcg every 2 hours for maximum of 12 doses
158974|NCT01794013|Behavioral|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
158975|NCT01794013|Behavioral|Routine care|routine care
158976|NCT00099554|Drug|Etanercept|
158977|NCT01794026|Procedure|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
159280|NCT01796678|Drug|Arginine|
159281|NCT00099918|Drug|vildagliptin|
159282|NCT01796678|Drug|Placebo|Saline or Sugar pill was given as placebo
159283|NCT01796717|Drug|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
159284|NCT01796717|Drug|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
159285|NCT01796730|Drug|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
159286|NCT01796730|Drug|Placebo|
159287|NCT01796756|Other|Handover program|
159288|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
159289|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
159290|NCT01796782|Drug|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
159291|NCT01796782|Drug|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
159292|NCT00099931|Drug|vildagliptin|
159293|NCT01796795|Drug|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
158663|NCT01780610|Drug|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
158664|NCT01772134|Drug|Placebo|Inhalation Powder, Placebo
158665|NCT01772147|Drug|Umeclidinium bromide 62.5mcg|Inhalation powder
158666|NCT01772147|Drug|Umeclidinium bromide 125mcg|Inhalation powder
158667|NCT01772147|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
158668|NCT01772160|Other|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
158978|NCT01794039|Drug|Dexamethasone|Given PO
158979|NCT01794039|Drug|Lenalidomide|Given PO
158980|NCT01794039|Drug|Pomalidomide|Given PO
158981|NCT01794052|Other|Evidence based, DSS enabled, health care delivery model|The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.
The components of the interventions that we are developing are:
A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension
Treating patients as per a standard clinical guidelines
Giving health education to patients on lifestyle changes for better self-care
Optimizing the care pathways at the health facilities to enable better delivery of the intervention and
Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm
158982|NCT01794078|Drug|Aminophylline 400 mg|Xanthine derivative
158983|NCT01794078|Drug|Ambrisentan 5 mg|Endothelin receptor antagonist
158984|NCT01794078|Other|Placebo|
158985|NCT01794091|Drug|Eplerenone|Eplerenone 25 mg daily for 6 months
158986|NCT01794091|Drug|Placebo|
158987|NCT00099580|Drug|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
158988|NCT01794104|Drug|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
158392|NCT01776983|Device|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
158393|NCT01776996|Drug|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
158394|NCT01777009|Procedure|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
158395|NCT01777022|Other|A package of interventions|A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the "at risk" fetus in such women, will reduce rates of stillbirth
158396|NCT01777035|Other|early PT OT|Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.
active assisted ROM in supine position.
treatment is advanced to bed mobility activities
sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.
progression to transfer training, and finally pre-gait training and ambulation.
progression of activities dependent on patient tolerance and stability
therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged.
158397|NCT01777048|Dietary Supplement|Omega-3 Fatty Acids Supplementation|
158669|NCT01772186|Device|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
158670|NCT01772199|Drug|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
158671|NCT01772199|Drug|Placebo|White to almost white, round tablets. Once daily orally.
158672|NCT01772212|Drug|Terbinafine 250 mg|Test product
158673|NCT01772212|Drug|Terbinafine 250 mg|Reference product
158674|NCT00097591|Drug|Prasugrel|Administered orally
158675|NCT01772225|Other|Data collection|Medical record abstraction form and patient survey questionnaire.
158676|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
158677|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
158678|NCT01772251|Drug|Oshadi Icp|
163115|NCT01820962|Procedure|concentrated citrate|when not in use the CVC is locked with concentrated citrate
163116|NCT01820975|Dietary Supplement|High protein intake|
163117|NCT01820975|Other|Placebo comparator|No protein intake
163118|NCT01821001|Drug|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
163119|NCT01821014|Other|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
163120|NCT01821014|Other|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
163121|NCT00002000|Drug|Valacyclovir hydrochloride|
163122|NCT00102297|Drug|FG-3019|
163123|NCT01813422|Other|Placebo|Subjects randomized to the placebo arm will receive Placebo subcutaneously every 4 weeks
163124|NCT01813435|Drug|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
163125|NCT01813435|Drug|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
163126|NCT01813435|Drug|Clopidogrel|Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.
Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy
163127|NCT01813448|Drug|Fidaxomicin|oral
163128|NCT01813448|Drug|Placebo|oral
163129|NCT00101452|Drug|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
163130|NCT01813461|Drug|14C-labeled prodrug isavuconazonium sulfate|oral
158398|NCT01779960|Other|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
162801|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
162802|NCT01865318|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin)
162803|NCT01865331|Drug|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
162804|NCT01865331|Drug|placebo|Administered subcutaneously (s.c., under the skin)
162805|NCT00002042|Drug|Epoetin alfa|
162806|NCT00107003|Procedure|Adjuvant therapy|
162807|NCT01865331|Drug|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
162808|NCT01865357|Other|Brain MRI - Clinical and cognitive evaluation|Clinical evaluation (EDSS, MSFC)
Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)
Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI
162809|NCT01865357|Other|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
162810|NCT01865370|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
162811|NCT01867866|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
162812|NCT01867866|Drug|Trifluridine|35 mg/m2, orally, single dose
162813|NCT01867879|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
162814|NCT01867879|Drug|Placebo|Placebo tablets, orally, single dose.
162815|NCT01867892|Drug|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
162816|NCT00107211|Biological|therapeutic autologous dendritic cells|
162817|NCT01867892|Drug|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
162818|NCT01867918|Procedure|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
162819|NCT01867918|Drug|Standard Chemotherapy|
162190|NCT01869296|Procedure|higher flow rates|higher flow rates endoscopy pump water immersion colonoscopy : 10.4 ml/sec
162191|NCT01869296|Procedure|lower flow rates|lower flow rates endoscopy pump water immersion colonoscopy : 1.7 ml/sec
162192|NCT01869309|Drug|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
162494|NCT01852799|Drug|PAD Followed by ASCT|Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)
Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)
Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)
After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
162495|NCT01852812|Drug|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
162496|NCT01852812|Drug|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
162497|NCT01852825|Biological|MK-8237|A single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day
162498|NCT01852825|Other|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day
162499|NCT01852851|Behavioral|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
162500|NCT01864746|Drug|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
162501|NCT01864746|Drug|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
162502|NCT01864759|Biological|ICOVIR-5|
162503|NCT01864772|Drug|Carbo, 5FU, Cetuximab|6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)
Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity
162504|NCT01864785|Procedure|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
162505|NCT01864785|Procedure|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
162506|NCT01864798|Drug|Denosumab|
161868|NCT01866176|Device|Valgus Knee Brace|Valgus brace with traditional three point bending system
161869|NCT01866176|Device|New Knee Brace|Brace with new mechanism to decrease the knee loading.
161870|NCT01866189|Other|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
161871|NCT01866215|Other|exercise|cycling at 100W during 60 min
161872|NCT01866215|Dietary Supplement|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
162193|NCT01869309|Drug|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
162194|NCT01869322|Device|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
162195|NCT01869322|Device|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
162196|NCT01869335|Device|radiography|
162197|NCT01869335|Device|MRI (magnetic resonance imaging)|
162198|NCT00107354|Biological|therapeutic allogeneic lymphocytes|
162199|NCT01869348|Behavioral|Monitor intervention|Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide "idle alerts" that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior.
162200|NCT01869361|Drug|Indomethacin|
162201|NCT01869361|Drug|Placebo|
162202|NCT01869374|Device|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
162203|NCT01869374|Device|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
162204|NCT01871844|Drug|octreotide 50 mcg tid|
162205|NCT01871844|Drug|Placebo|
162206|NCT01871857|Drug|Hypertonic saline and epinephrine|
162207|NCT01871857|Drug|Normal saline and epinephrine|
162208|NCT00107523|Drug|idarubicin|
161558|NCT01870947|Procedure|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
161559|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in left side|
161560|NCT01863238|Drug|Ivacaftor Exposed|
161561|NCT01863251|Drug|Atomoxetine|
161562|NCT01863264|Other|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
161563|NCT00106613|Drug|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
161564|NCT01863277|Drug|Melatonin|
161565|NCT01863277|Drug|placebo|
161566|NCT01863290|Other|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
161567|NCT01863316|Device|I gel|
161568|NCT01863316|Device|LMA Supreme|
161873|NCT01866215|Dietary Supplement|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
161874|NCT01866228|Other|Consultation Recording|
161875|NCT01866241|Drug|Misoprostol|Is a prostaglandin
161876|NCT00002043|Drug|Dapsone|
161877|NCT00107068|Procedure|[A] + [B]|
161878|NCT01866254|Drug|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
161879|NCT01866254|Drug|Morphine|Injection of 200 mcg of intrathecal morphine
161880|NCT01866267|Drug|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
161881|NCT01866280|Behavioral|Normal sleep|Normal sleep= sleep 2300-0700
161273|NCT01790581|Behavioral|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
161274|NCT01790594|Biological|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
161275|NCT01783028|Behavioral|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
161276|NCT01783041|Drug|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
161569|NCT01863329|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
161570|NCT01863342|Procedure|CSI score < 40|
161571|NCT01863342|Procedure|CSI score ≥ 40|
161572|NCT01863355|Drug|B0 group: bolus 0.6mcg/kg without background infusion|
161573|NCT01863355|Drug|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
161574|NCT00106626|Drug|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
161575|NCT01863355|Drug|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
161576|NCT01863368|Other|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
161577|NCT01863368|Other|Systane® ULTRA lubricant eyedrops|
161578|NCT01863368|Other|OPTIVE® lubricating eyedrops|
161579|NCT01863381|Device|Tympanic membrane displacement (TMD)|The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.
For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.
Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device.
161625|NCT00107471|Biological|filgrastim|Given PO
161626|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in right side|
161937|NCT01863810|Drug|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
161938|NCT01863823|Drug|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
161939|NCT01863823|Drug|Mouth washing|Two time washing mouth per day
161940|NCT01863836|Procedure|Fluoroscopy|
161941|NCT00000293|Drug|Nefazodone|
161942|NCT00002040|Drug|Fluconazole|
161943|NCT00106704|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
161944|NCT01863836|Procedure|Radial EBUS-guided biopsy|
161945|NCT01863849|Biological|Fluval AB suspension for injection|Single intramuscular injection of Fluval AB and collect serum samples for immunogenicity
161946|NCT01863862|Radiation|Radiochemotherapy or radiotherapy|50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.
Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.
Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision.
161947|NCT01863888|Drug|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
161948|NCT01863888|Drug|cholestyramine|Pharmaceutical form:powder Route of administration: oral
161949|NCT01863888|Drug|charcoal|Pharmaceutical form:granule Route of administration: oral
161950|NCT01863901|Device|Treatment with Cryo-Touch III device|
161951|NCT01863914|Drug|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
161331|NCT01788176|Drug|Placebo|one single intravenous infusion of 100ml of saline.
161332|NCT01788189|Drug|Lenalidomide|
161333|NCT00098982|Drug|fluorouracil|
161334|NCT01788215|Drug|doxycycline|200mg/day in divided doses of 100mg twice daily
161335|NCT01788215|Other|Sugar Pill|1 pill twice a day
161336|NCT01788228|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
161627|NCT01870973|Procedure|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
161628|NCT01870973|Procedure|no root canal treatment, anesthesia, pain medications, and antibiotic|
161629|NCT01870986|Biological|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
161630|NCT01870986|Biological|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
161631|NCT01870986|Biological|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
161632|NCT01870999|Drug|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
161633|NCT01870999|Drug|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
161634|NCT01871025|Other|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
161635|NCT01871025|Other|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
161636|NCT00107471|Drug|topotecan hydrochloride|Given IV
161637|NCT01871064|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
161638|NCT01871077|Drug|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
161639|NCT01871090|Device|Unpaired remote monitoring transmitter|
161640|NCT01871103|Procedure|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
161036|NCT01784926|Procedure|Scleral suturing versus IOL exhange|
161037|NCT01784952|Dietary Supplement|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
161038|NCT01784965|Drug|liraglutide|
161039|NCT01784978|Drug|Sunitinib|50 mg pd
161040|NCT01784978|Drug|Everolimus|10 mg pd
161041|NCT01784991|Drug|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
161042|NCT01784991|Drug|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
161043|NCT01785004|Dietary Supplement|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
161044|NCT00098813|Drug|romidepsin|Given IV
161045|NCT01785004|Drug|omega-3 fatty acids (fish oil)|
161046|NCT01785030|Drug|50% Nitrous oxide|
161047|NCT01785043|Drug|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
161048|NCT01785043|Drug|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
161049|NCT01785056|Biological|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
161337|NCT01788254|Drug|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
161338|NCT01788254|Drug|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
161339|NCT01788254|Drug|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
160743|NCT01789801|Procedure|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
160744|NCT01789801|Procedure|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
160745|NCT01792375|Procedure|Concurrent membrane sweeping with Dinoprostone|Women assigned to "Sweep" had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix.
160746|NCT00099359|Drug|Epivir (3TC)|Stand of care (Zidovudine) plus
3TC, given for 2 weeks: 6 mg po bid if BW > 2000 grams 4 mg po bid if BW < 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 - 3000 grams 100 mg PO BID if BW < 2000 grams
160747|NCT01792375|Drug|10mg Dinoprostone vaginal insert|For women assigned to "No sweep": The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening
160748|NCT01792388|Dietary Supplement|Vitamin D|Capsule Form
160749|NCT01792388|Dietary Supplement|Soya Bean oil|Capsule form
160750|NCT01792401|Drug|Probiotics|
160751|NCT01792401|Drug|Placebo|
160752|NCT01792414|Device|Sham TES|Neuroconn Eldith device
160753|NCT01792414|Device|Active TES|Neuroconn Eldith device
160754|NCT01792453|Other|Spring water|
160755|NCT01792466|Procedure|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
160756|NCT01792479|Drug|BIND-014|
160757|NCT00099359|Drug|Nelfinavir (NFV)|200 mg BID if birth weight (BW) > 3000 grams for 2 weeks;150 mg BID if BW > 2000-3000 grams for 2 weeks; 100 mg BID BW </= 2000 grams for 2 weeks
160758|NCT01792505|Biological|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
160759|NCT01792518|Drug|Placebo|
160760|NCT01792518|Drug|Linagliptin 5mg|
161050|NCT01785082|Drug|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
160152|NCT01790971|Drug|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
160153|NCT01790971|Drug|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
160436|NCT01783912|Behavioral|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
160437|NCT01783912|Behavioral|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
160438|NCT01783912|Drug|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
160439|NCT01783912|Behavioral|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
160440|NCT01786252|Drug|Placebo Comparator (for hCG)|50ul of IVF medium ("Global"-trademark) to mimic hCG infusion
160441|NCT01786265|Drug|Lupron|7.5 mg by injection monthly, or 30 mg every 4 months at discretion of physician.
160442|NCT00098839|Drug|etoposide|Given IV
160443|NCT01786265|Drug|Zoladex|3.6 mg by injection monthly at discretion of physician.
160444|NCT01786265|Drug|Degarelix|120 mg twice and then 80 mg monthly by injection at discretion of physician.
160445|NCT01786265|Drug|Abiraterone Acetate|4 tablets (250 mg each) by mouth each day.
160446|NCT01786265|Drug|Prednisone|5 mg by mouth daily.
160447|NCT01786278|Radiation|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
160448|NCT01786278|Procedure|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
160449|NCT01786304|Procedure|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
160450|NCT01786317|Device|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
159856|NCT01792934|Drug|Bevacizumab|may be added to both regimens according to standard procedures
159857|NCT01792934|Procedure|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
159858|NCT01792947|Procedure|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
159859|NCT00099749|Drug|FTY 720|
159860|NCT01795443|Other|Practice|Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.
Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required.
160154|NCT01790984|Other|High sugar low starch diet|
160155|NCT01790984|Other|Low sugar high starch diet|
160156|NCT01790997|Drug|DLBS1033|1 tablet of DLBS1033 490 mg thrice daily, after meal
160157|NCT01790997|Drug|Aspirin|1 tablet of aspirin 80 mg once daily, after meal
160158|NCT01790997|Drug|Clopidogrel|1 tablet of clopidogrel 75 mg once daily, after meal
160159|NCT01791010|Other|Inspiratory muscle training|
160160|NCT01791010|Other|Training sham|Conducting fake training with the aim of blind the control group
160161|NCT01791023|Other|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
160162|NCT00099203|Drug|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
160163|NCT01791036|Procedure|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
160164|NCT01791036|Procedure|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
159568|NCT01799850|Drug|placebo|placebo assigned randomly, double blind
159569|NCT01799863|Drug|Ketorolac trometamol 0.45% with carboxymethylcellulose|
159570|NCT00100269|Drug|Menevit anti-oxidant|
159571|NCT01799863|Drug|Preservative free artificial tear|
159572|NCT01799876|Procedure|Autologous Cell|
159573|NCT01799876|Procedure|Standard microfracture arthroscopic surgery|
159574|NCT01799889|Drug|Entospletinib|Entospletinib tablet administered orally
159575|NCT01799889|Drug|Entospletinib SDD|Entospletinib spray-dried dispersion (SDD) tablet administered orally
159576|NCT01799902|Drug|Solifenacin|Oral
159577|NCT01799941|Drug|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
159578|NCT01799954|Biological|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
159579|NCT01799954|Biological|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
159580|NCT01799954|Biological|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
159581|NCT00100282|Drug|PPI-1019 (APAN)|
159582|NCT01802645|Drug|Oxaliplatin|
159583|NCT01802645|Drug|5-FU|
159584|NCT01802645|Drug|Folinic Acid|
159585|NCT01802658|Drug|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
159586|NCT01802658|Drug|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
159587|NCT01802671|Other|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
159294|NCT01796795|Drug|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
159295|NCT01796795|Drug|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
159296|NCT01799174|Procedure|Placebo|
159297|NCT01799187|Procedure|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
159298|NCT01799187|Procedure|apexification|apexification uses calcium hydroxide as root medication
159299|NCT00100178|Drug|Mycophenolate mofeteil (MMF)|
159300|NCT01799213|Drug|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
159301|NCT01799213|Behavioral|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
159588|NCT01802671|Behavioral|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:
Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.
Cognitive restructuring techniques
Behavioural therapy and activity pacing
Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions.
159589|NCT01802671|Behavioral|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
159590|NCT00100594|Drug|Lamivudine/zidovudine|
159591|NCT01802684|Biological|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
159592|NCT01802697|Drug|IdeS|
159593|NCT01802697|Drug|Placebo|
159594|NCT01802710|Behavioral|Psychological support|
159595|NCT01802710|Other|No intervention|
159596|NCT01802723|Drug|Drug: salmeterol xinafoate|
158989|NCT01794117|Drug|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If pustule formation persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4
158990|NCT01794143|Drug|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
158991|NCT01794143|Drug|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
158992|NCT01794143|Drug|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
158993|NCT01794143|Drug|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
158994|NCT01794156|Behavioral|Cognitive behavior therapy|
158995|NCT01794156|Behavioral|Mindfulness-based stress reduction|
158996|NCT01794156|Behavioral|Inference-based therapy|
158997|NCT01794169|Drug|Azacitidine|
158998|NCT00099580|Drug|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
159302|NCT01799226|Other|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
159303|NCT01799226|Other|Triclosan|this intervention will use Colgate Total which contains triclosan
159304|NCT01799239|Device|Test product|The test product consists of an adhesive with a new top film
159305|NCT01799239|Device|SenSura|SenSura is the CE-marked and commercially available comparator product
159306|NCT01799265|Device|Somnetics Transcend Auto|
159307|NCT01799265|Device|Respironics REMstar Auto with C-Flex|
159308|NCT01799278|Drug|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
159309|NCT01799291|Behavioral|Decision Making Tutorial|A web-based presentation focused on key "cognitive de-biasing" strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches).
159310|NCT00100178|Drug|Daclizumab (DZB)|
159311|NCT01799304|Procedure|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
158679|NCT01772264|Drug|PF-05089771|titration from 150mg BID to 450mg BID
158680|NCT01772264|Drug|Placebo|matched placebo
158681|NCT01772290|Drug|fluconazole|Multiple oral doses
158682|NCT01772290|Drug|itraconazole|Multiple oral doses
158683|NCT01772290|Drug|rabeprazole|Multiple oral doses
158684|NCT01772290|Drug|vismodegib|Multiple oral doses
158685|NCT00097591|Drug|Clopidogrel|Administered orally
158686|NCT01772303|Drug|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
158687|NCT01772316|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly or every two weeks, 96 weeks
158688|NCT01772329|Other|Cognitive Therapy|CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
158689|NCT01772342|Other|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
158690|NCT01772342|Other|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
158691|NCT01772355|Device|semi automated core needle biopsy of orbital tumors|
158999|NCT01796158|Behavioral|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
159000|NCT01796158|Behavioral|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
159001|NCT01796171|Drug|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin (177Lu-Dota-HH1), single injection.
159002|NCT01796197|Drug|Trastuzumab|
159003|NCT01796197|Drug|Pertuzumab|
159004|NCT01796197|Drug|Paclitaxel|
159005|NCT01796197|Drug|Doxorubicin|
158399|NCT01779960|Other|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
158400|NCT00098423|Drug|tanespimycin|Given IV
158401|NCT01779973|Behavioral|Remote Observed Dosing|
158402|NCT01779999|Other|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
158403|NCT01780012|Behavioral|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
158404|NCT01780025|Behavioral|Auditory evoked potentials and audiometry|
158405|NCT01780025|Behavioral|Auditory evoked potentials|Different protocols for audiometry and auditory evoked potentials
158406|NCT01780038|Behavioral|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
158407|NCT01780038|Behavioral|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
158408|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.
Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2.
158409|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.
Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2.
158410|NCT01780064|Behavioral|interviews with a psychologist|
158411|NCT00098423|Drug|cytarabine|Given IV
158412|NCT01780064|Behavioral|Questionnaires|
158413|NCT01780077|Drug|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
158414|NCT01780077|Drug|Placebo|Multiple intradermal injections of placebo at incision sites
158415|NCT01780090|Other|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
162820|NCT01867944|Behavioral|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
162821|NCT01867944|Behavioral|Educational Control|Education on conventional treatment options for chronic constipation.
162822|NCT01867957|Biological|Low-dose GC1109|50ug/dose
163131|NCT01813474|Drug|olaparib|tablet oral
163132|NCT01813487|Drug|HBsAg vaccine with Entecavir|
163133|NCT01813500|Other|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
163134|NCT01813513|Drug|IDX719|50 mg tablet for oral administration
163135|NCT01813513|Drug|Simeprevir|150 mg capsule for oral administration
163136|NCT01813526|Other|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
163137|NCT01813539|Drug|ARGX-110|Outpatient intravenous infusion, in step-wise increments, every 3 weeks.
163138|NCT01813552|Drug|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
163139|NCT01813552|Drug|Omeprazole|40 mg delayed-release oral capsules, once daily
163140|NCT00101491|Behavioral|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
163141|NCT01813552|Drug|Ritonavir|100 mg oral tablets, once daily
163142|NCT01813565|Drug|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
163143|NCT01813578|Other|Exercise|Intensive aerobic and muscle endurance exercise
163144|NCT01813591|Drug|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
163145|NCT01813604|Biological|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
163146|NCT01813604|Biological|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
163147|NCT01815944|Drug|Dextrose 5%|
162507|NCT01864811|Behavioral|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
162508|NCT00106899|Procedure|Lumbar Puncture (LP)|collection of cerebrospinal fluid
162509|NCT01864811|Behavioral|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
162823|NCT01867957|Biological|High-dose GC1109|100ug/dose
162824|NCT01867957|Biological|Low-dose Placebo|0.9% Saline 0.5 mL
162825|NCT01867957|Biological|High-dose Placebo|0.9% Saline 1.0 mL
162826|NCT01867970|Device|Tool|The It's LiFe! tool consists of three different elements:
the 3D accelerometer (Figure 7-8);
the application (app) on a Samsung Smartphone (Figure 6);
a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription.
162827|NCT00107211|Procedure|conventional surgery|
162828|NCT01867970|Behavioral|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
162829|NCT01867983|Behavioral|Weight gain prevention and smoking cessation|The two intervention groups will receive weight gain prevention either:
Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls.
162830|NCT00107380|Radiation|tositumomab and iodine I 131 tositumomab|
162831|NCT01870440|Drug|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
162832|NCT01870466|Drug|Cilostazol|cilostazol bid for 7 days
162833|NCT01870466|Drug|Simvastatin|simvastatin qd for 7 days
162834|NCT01870466|Drug|Rosuvastatin|rosuvastatin qd for 7 days
162209|NCT01871870|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
162210|NCT01871883|Procedure|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
162211|NCT01871883|Procedure|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
162212|NCT01871896|Device|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
162510|NCT01864824|Drug|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
162511|NCT01864824|Drug|Placebo|Placebo
162512|NCT01864850|Radiation|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
162513|NCT01864850|Radiation|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
162514|NCT01864863|Drug|HGP1206|
162515|NCT01864863|Drug|Traclear|
162516|NCT01864876|Biological|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
162517|NCT01864876|Biological|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
162518|NCT01864876|Biological|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
162519|NCT00106938|Device|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
162520|NCT01864889|Biological|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
162521|NCT01864902|Biological|CART33 cells|genetically modified lymphocyte therapy
162522|NCT01864902|Biological|anti-CD33 CART|
162523|NCT01864902|Biological|anti-CD33 CAR T cells|
161882|NCT01866280|Behavioral|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
161883|NCT01866280|Behavioral|Late sleep|Late sleep=sleep at 0230-1030 hours
161884|NCT01868698|Other|Kinesiotherapy|
161885|NCT01868698|Other|shortwave diathermy|
161886|NCT00107276|Drug|cyclophosphamide|
161887|NCT01868711|Behavioral|Cognitive Behavior Therapy for Depression|
161888|NCT01868711|Behavioral|Cognitive Behavior Therapy for Depression|The CBT protocol represents incorporation and integration from several sources. These include (a) prior experience with the treatment of depression and (b) previously published cognitive therapy (CT) manuals published by Beck (1995). The present protocol encourages therapist flexibility in approach, yet during the treatment specific tools and methods of coping with depression are given to each patient. The patient will be psycho educated about symptoms of depression. The patient will learn to use the following basic cognitive-behavioral techniques for the treatment of depression:
Constructing an 'Action Schedule', setting goals, doing 'Behavioral Experiments', and constructing a thought record, checking accuracy of thoughts, re framing thoughts when necessary and learn to engage in problem solving for particular situations.
161889|NCT01868737|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
161890|NCT01868737|Dietary Supplement|Placebo|MCT oil
161891|NCT01868750|Dietary Supplement|Calcitriol|1.0ug twice daily for 7 days before surgery
161892|NCT01868750|Dietary Supplement|Control Pill|placebo pill taken twice daily for 7 days before surgery
161893|NCT01868763|Device|telemedical devices (weighing machine and step counter)|
162213|NCT01871922|Drug|Placebo|Saline
162214|NCT01871922|Drug|Atropine|Atropine
162215|NCT01871935|Drug|Remifentanil|Anaesthesia with remifentanil/propofol.
162216|NCT01871935|Drug|Sufentanil|Anaesthesia with sufentanil/propofol
162217|NCT01871948|Other|"We Want to Know" campaign, Patient survey at 2 time points|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
162218|NCT01871961|Drug|Methotrexate (Metoject® prefilled pen)|
162219|NCT00107523|Drug|pravastatin|
162220|NCT01871974|Drug|FK949E|oral
161580|NCT01863381|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
161581|NCT01863394|Other|Screening by mothers|
161582|NCT01863394|Other|Active comparator: Screening by community health workers|
161583|NCT01863407|Drug|DAM|composed of dexamethasone, allantoin and metronidazole
161584|NCT01863407|Drug|Normal Saline|Normal Saline 250ml
161585|NCT01865578|Device|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
161586|NCT01865578|Device|Sham Stimulation|no electrical stimulation
161587|NCT01865591|Device|Ultrasound-based Renal Denervation|
161588|NCT01865604|Device|Anodal tDCS|
161589|NCT00107016|Drug|RAD001, Letrozole 2.5mg|
161590|NCT01865604|Device|Cathodal tDCS|
161591|NCT01865604|Device|sham tDCS|
161894|NCT01868763|Behavioral|care calls once per week for 12 weeks|
161895|NCT01868776|Drug|buffered lidocaine|
161896|NCT01868776|Drug|nonbuffered lidocaine|
161897|NCT00107289|Radiation|iobenguane I 131|Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) IV over 30 minutes to 4 hours on day 0. Patients undergo radiation dosimetry following the first dose of ^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.
After completion of study treatment, patients are followed at 4-6 weeks after ^131I-MIBG administration and then every 3 months for up to 1 year.
161898|NCT01868789|Radiation|Weightbearing CT|
161899|NCT01868802|Drug|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
161900|NCT01868802|Drug|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
161901|NCT01868828|Drug|PAD|Induction Therapy of PAD for 4 cycles.
161902|NCT01868828|Drug|VCD|Induction Therapy of VCD for 4 cycles.
161952|NCT01863927|Other|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
161953|NCT01866280|Behavioral|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
161954|NCT01866293|Drug|Cabozantinib (XL184)|
162279|NCT01869413|Drug|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
162280|NCT01869413|Drug|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
162281|NCT01869426|Dietary Supplement|VSL#3 drops|
162282|NCT01869426|Dietary Supplement|VSL#3 drops placebo|
162283|NCT00107354|Biological|therapeutic autologous lymphocytes|
162284|NCT01869439|Device|"gold standard" LxW manual ruler measurement technique|Currently, the "gold standard" LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length).
162285|NCT01869439|Device|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
162286|NCT01869439|Device|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
162287|NCT01869439|Device|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradiency), mean, and the mode of the thermal wound bed can be measured.
162288|NCT01869452|Behavioral|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
162289|NCT01869465|Other|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
161641|NCT01871116|Behavioral|POWER-remote|Web-based weight loss program.
161642|NCT01871116|Behavioral|Self-directed|Pamphlet entitled "Aim for a Healthy Weight" will be given.
161643|NCT01871129|Drug|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
161644|NCT01871129|Other|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
161645|NCT01871142|Drug|Placebo|100 mL
161646|NCT01871142|Drug|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
161647|NCT00107471|Radiation|radiation therapy|
161955|NCT01866306|Biological|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
161956|NCT01866319|Biological|Pembrolizumab|
161957|NCT00107081|Drug|ciprofloxacin and amoxicillin|
161958|NCT01866319|Biological|Ipilimumab|
161959|NCT01866332|Other|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
161960|NCT01866332|Device|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
161961|NCT01866345|Procedure|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
161962|NCT01866345|Procedure|Conventional orthodontic treatment|Conventional orthodontic Procedure
161963|NCT01866358|Procedure|Intraosseous infusion|Using intraosseous infusion for resustation in this group
161964|NCT01866371|Procedure|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
161340|NCT00099164|Drug|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
161341|NCT01790594|Drug|methylprednisolone|
161342|NCT01790594|Biological|Anti-thymocyte Globulin (Rabbit)|
161343|NCT01790594|Drug|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
161344|NCT01790594|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg PO BID beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
161345|NCT01790607|Drug|ONO-2745 /CNS 7056|
161346|NCT01790620|Other|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
161347|NCT01790620|Other|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
161348|NCT01790633|Other|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
161349|NCT01790633|Other|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
161350|NCT01790646|Other|intubation|intubation using Glidescope videolaryngoscope
161351|NCT00099177|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
161352|NCT01790659|Drug|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
161648|NCT01871142|Drug|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
161649|NCT00106639|Drug|CP-690,550|15 mg twice daily
161051|NCT01785095|Drug|FSH (Follicle Stimulating Hormone)|
161052|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg|
161053|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg X 2|
161054|NCT01787474|Drug|G-CSF|G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.
161055|NCT01787474|Drug|Fludarabine monophosphate|30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.
161056|NCT01787474|Drug|Cytarabine|2 g/m^2 by vein on Days -6, -5, -4, -3, and -2.
161057|NCT01787474|Procedure|Natural Killer (NK) Cell Infusion|NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema.
161058|NCT01787487|Drug|Ruxolitinib (RUX)|Four weeks (28 days) on therapy is considered one standard cycle of therapy. RUX will be given orally and AZA will be administered subcutaneously (SC) in an outpatient setting
AZA will be given on days 1-5 of each 28 day cycle beginning with cycle 4. We propose to initially administer RUX alone at a dose of 5 mg orally twice daily (BID) if the baseline platelet count is 50-100 x 109/L, 15 mg twice daily if the baseline platelet count is 100 - 200 109/L, or at a dose of 20 mg twice daily if the baseline platelet count is > 200 x 109/L. Patients will receive RUX alone for cycles # 1, 2 and 3.
161059|NCT01787487|Drug|Azacitidine (AZA)|Four weeks (28 days) on therapy is considered one standard cycle of therapy. RUX will be given orally and AZA will be administered subcutaneously (SC) in an outpatient setting AZA at 25 mg/sq.m. starting on cycle # 4. If well tolerated, the AZA dose may be further increased to 50 mg/sq.m. after 2 cycles (i.e., concomitantly with cycle # 6).
161060|NCT01787487|Behavioral|Questionnaires|Completion of 2 questionnaires at baseline, Day 1 of Cycles 1 - 7, then every 3 cycles. It should take about 15 minutes total to complete the questionnaires.
161061|NCT01787500|Drug|Vemurafenib|Phase I Dose Escalation: All groups treated. Starting dose of Vemurafenib 480 mg by mouth twice daily of a 14 Day cycle.
Dose Expansion Groups: . Starting dose of Vemurafenib is maximum tolerated dose from Dose Escalation Group.
161062|NCT01787500|Drug|Cetuximab|Phase I Dose Escalation Group and Dose Expansion Groups: 500 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle.
161063|NCT00098917|Procedure|tumor cell derivative vaccine|
161064|NCT01787500|Drug|Irinotecan|Phase I Dose Escalation Group and Dose Expansion Groups: 180 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle.
161065|NCT01787513|Other|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
161066|NCT01787513|Other|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
161067|NCT01787526|Drug|ferric carboxymaltose|1 g intravenously per infusion
161068|NCT01787526|Drug|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
160451|NCT01786330|Device|Procare abdominal binder|
160452|NCT01786330|Other|Standard of Care|
160453|NCT00001944|Drug|Vinorelbine|
160454|NCT00098839|Drug|cyclophosphamide|Given IV
160455|NCT01786343|Drug|Decitabine|20 mg/m2 by vein daily for either 5 or 10 days.
160761|NCT01792531|Behavioral|Parent training group|The More & Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More & Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
160762|NCT01792531|Behavioral|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
160763|NCT01792531|Behavioral|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
160764|NCT01792544|Other|Statement|
160765|NCT01792544|Other|No Statement|
160766|NCT01792557|Drug|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
160767|NCT01784367|Device|ECLA (extracorporeal lung assist)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
160768|NCT01784380|Drug|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
160769|NCT01784393|Radiation|chemoradiation|
160770|NCT01784406|Behavioral|Autonomy supportive counselling|
160771|NCT01784419|Drug|ivacaftor|Prospective randomized double-blinded placebo controlled crossover study of the effects of ivacaftor in selected cystic fibrosis patients
160772|NCT01784432|Device|Low-level laser therapy and training|
160165|NCT01791049|Drug|TD-1607|
160166|NCT01791049|Drug|Placebo|
160167|NCT01791062|Device|HYTOP®|HYTOP® will be implanted once during surgery.
160168|NCT01791075|Device|Tan Endoglide|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
160169|NCT01783457|Other|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
160170|NCT01783457|Other|Individual psychoeducation|Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
Programme of sessions available upon request.
160171|NCT01783470|Drug|beta3-adrenergic receptor agonist|single dose
160172|NCT01783470|Drug|Placebo|
160173|NCT01783483|Device|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
160456|NCT01786356|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
160457|NCT01786356|Other|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B&L MI60 in one eye
160458|NCT01786382|Drug|PPI-668|
160459|NCT01786382|Drug|Midazolam|
160460|NCT01786382|Drug|Omeprazole|
160461|NCT01786382|Drug|Telaprevir|
160462|NCT01786395|Drug|UF-021|
160463|NCT01786395|Drug|Placebo|
160464|NCT01786408|Device|TAP20-C|
160465|NCT00098839|Drug|leucovorin calcium|Given IV
160466|NCT01786408|Device|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
160467|NCT01786434|Drug|Routine medication arm|50 micrograms of fentanyl given before the procedure
160468|NCT01786434|Drug|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
159861|NCT01795443|Other|Measures - no vibration|The movements required are performed without vibration.
The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.
The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to "remember" the target angle by his/herself.
159862|NCT01795443|Other|Measures - low vibration|The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).
The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.
The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to "remember" the target angle by his/herself.
159863|NCT01795443|Other|Measures - high vibration|The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).
The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.
The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to "remember" the target angle by his/herself.
159864|NCT01795469|Device|Zoex compression garment|5-strap compression of abdomen, thighs and legs
159865|NCT01795482|Device|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
159866|NCT01795495|Drug|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
159867|NCT01795495|Drug|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
159868|NCT01795495|Drug|Remifentanil|
159869|NCT01795508|Behavioral|PMTO|Parent Management Training, Oregon
159870|NCT00099775|Drug|Caspofungin|
159871|NCT01795508|Behavioral|TAU|Other kinds of family training
159872|NCT01795521|Radiation|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
159597|NCT01802723|Drug|Drug: Placebo|
159598|NCT01802736|Behavioral|Motivational intervention counselling plus SPP|
159599|NCT01802749|Drug|Bevacizumab|
159600|NCT01802749|Drug|Paclitaxel|
159601|NCT00100607|Drug|AAE581|
159602|NCT01802749|Drug|Carboplatin|
159603|NCT01802749|Drug|pegylated liposomal doxorubicin|
159604|NCT01802749|Drug|Gemcitabine|
159605|NCT01795001|Other|No intervention|
159606|NCT01795027|Drug|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
159607|NCT01795027|Drug|S-1 single|16 courses S-1 single after d D2 resection
159608|NCT01795040|Dietary Supplement|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
159875|NCT01797705|Device|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
159876|NCT01797718|Drug|Testosterone|1mg/kg every 4 weeks for 6 months
159877|NCT01797718|Drug|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
159878|NCT01797731|Device|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
159879|NCT01797731|Device|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
159880|NCT01797744|Other|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
159881|NCT01797757|Dietary Supplement|Fish oil enriched with EPA|
159882|NCT01797757|Dietary Supplement|MAG-EPA oil|
159883|NCT00100035|Procedure|Polarity therapy|
159884|NCT01797757|Drug|Orlistat|
159312|NCT01799304|Procedure|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
159313|NCT01799304|Procedure|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
159314|NCT01799304|Procedure|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
159315|NCT01799317|Drug|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
159316|NCT01799330|Procedure|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
159317|NCT01799343|Other|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
159318|NCT01799356|Drug|Moxifloxacin|daily 400 mg moksifloksasin
159319|NCT01802489|Drug|Amiloride|
159320|NCT01802489|Drug|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
159321|NCT01802502|Drug|Rifampicin intravenous|
159609|NCT01795053|Behavioral|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
159610|NCT01795053|Behavioral|Placebo open play session|
159611|NCT01795066|Device|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
159612|NCT01795079|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
159613|NCT01795092|Other|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
159614|NCT00099684|Drug|Ezetimibe|
159615|NCT01795131|Dietary Supplement|Vitamin B12|
159616|NCT01795131|Dietary Supplement|Placebo|
159617|NCT01795144|Drug|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
159006|NCT01796197|Drug|Cyclophosphamide|
159007|NCT00099853|Drug|Placebo|Vildagliptin matching placebo
159008|NCT01796197|Procedure|Mastectomy|
159009|NCT01796197|Radiation|Radiation Therapy|
159010|NCT01796223|Behavioral|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
159011|NCT01796223|Behavioral|Control|
159012|NCT01796236|Device|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
159013|NCT01796236|Device|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
159014|NCT01796262|Dietary Supplement|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
159015|NCT01796262|Dietary Supplement|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
159016|NCT01796275|Behavioral|Core intervention program|
159017|NCT01796275|Behavioral|Booster session|
159018|NCT00099866|Drug|vildagliptin|
159019|NCT01796275|Behavioral|Control only (Tea gathering)|
159020|NCT01796288|Radiation|simultaneous radiotherapy|
159322|NCT01802502|Drug|Oral rifampicin|
159323|NCT01802515|Drug|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
159324|NCT01802515|Drug|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
159325|NCT01802515|Drug|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
159326|NCT01802541|Dietary Supplement|diacylglycerol oil|
159327|NCT01802541|Dietary Supplement|triacylglycerol oil|
159328|NCT01802554|Behavioral|Pleasant Events Program (PEP)|Behavioral Activation Therapy
158692|NCT01774773|Drug|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.
Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.
The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
158693|NCT01774773|Drug|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.
Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.
The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
158694|NCT01774773|Drug|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.
Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.
The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
158695|NCT01774786|Drug|5-fluorouracil|800 mg/m2/24 hours iv by continuous infusion for 120 hours (Days 1-5) every 3 weeks, 6 cycles (or capecitabine)
158696|NCT01774786|Drug|capecitabine|1000 mg/m2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) every 3 weeks, 6 cycles (or 5-fluorouracil)
158697|NCT01774786|Drug|cisplatin|80 mg/m2 iv every 3 weeks, 6 cycles
158698|NCT01774786|Drug|pertuzumab [Perjeta]|840 mg iv every 3 weeks
158699|NCT01774786|Drug|placebo|pertuzumab placebo iv every 3 weeks
158700|NCT00097812|Drug|zoledronic acid|
158701|NCT01774786|Drug|trastuzumab [Herceptin]|8 mg/kg iv initial dose on Day 1, followed by 6 mg/kg iv every 3 weeks
158702|NCT01774799|Behavioral|Advance care planning intervention|
158703|NCT01774799|Other|Control group|
158704|NCT01774812|Dietary Supplement|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
158705|NCT01774812|Dietary Supplement|Ergocalciferol|50,000IU 1x per week for 6 weeks
158706|NCT01774825|Dietary Supplement|IQP-CL-101|2 softgels twice a day
158707|NCT01774825|Other|Placebo|2 softgels twice a day
163148|NCT01815957|Drug|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
163149|NCT01815970|Behavioral|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
163150|NCT01815983|Other|Videolaryngoscopy review.|Review of video recordings.
163151|NCT01815996|Other|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
163152|NCT01816009|Other|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
158416|NCT01780116|Behavioral|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
158417|NCT01771588|Dietary Supplement|Human milk fortifier|
158418|NCT01771614|Behavioral|Exercise|
158419|NCT01771614|Procedure|Hyperglycemia|
158420|NCT01771627|Drug|varenicline|Given PO
158421|NCT01771627|Drug|nicotine patch|
158422|NCT01771640|Biological|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
158423|NCT01771666|Device|(IC-GREEN™) SPY Elite® Imaging|
158424|NCT00097474|Other|Placebo|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone (or placebo) and at the target bedtime of (10 pm to midnight local time) they will take 5 mg of melatonin (or placebo) for four days.
158425|NCT01771679|Biological|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 6-8mJ Fraxel laser followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kilogram body weight, not to exceed 150 million cells total. Subjects in part 2 will receive a 6-8 mJ Fraxel laser followed by asingle intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1.
158426|NCT01771692|Other|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
158427|NCT01771692|Other|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
158428|NCT01771705|Other|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is <15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 80% the CNI daily dose will be increased by 15%.
162835|NCT01870479|Other|Live music|
162836|NCT01870479|Other|Taped music|
162837|NCT01870492|Drug|Activase|Patients treated with Activase
162838|NCT01870492|Device|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
162839|NCT01870505|Drug|BYL719|
162840|NCT01870505|Drug|Letrozole|
162841|NCT00107393|Biological|trastuzumab|
163153|NCT01816035|Other|Laboratory Biomarker Analysis|Correlative studies
163154|NCT01816035|Other|Pharmacological Study|Correlative studies
163155|NCT01816035|Biological|Trastuzumab Emtansine|Given IV
163156|NCT00101842|Drug|Pemetrexed|
163157|NCT01816048|Drug|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
163158|NCT01816048|Radiation|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
163159|NCT01816048|Procedure|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
163160|NCT01816048|Procedure|Computed Tomography|Undergo 18F NaF PET/CT scan
163161|NCT01816061|Behavioral|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
163162|NCT01816061|Behavioral|Control - COMPASS|Increased hours of patient-provider interactions Group.
163163|NCT01816074|Drug|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
163164|NCT01816074|Behavioral|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
163165|NCT01816087|Other|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
163166|NCT01816100|Other|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
163167|NCT00101842|Drug|Gemcitabine|
162524|NCT01867294|Drug|spironolactone|Given topically
162525|NCT01867294|Other|placebo|Given topically
162526|NCT01867294|Other|questionnaire administration|Ancillary studies
162527|NCT01867294|Drug|sunscreen|Given topically
162528|NCT01867294|Procedure|management of therapy complications|Moisturizer given topically
162529|NCT01867294|Drug|doxycycline|Given PO
162530|NCT00107185|Biological|therapeutic autologous dendritic cells|
162531|NCT01867294|Drug|therapeutic hydrocortisone|Given topically
162532|NCT01867307|Drug|Empagliflozin|
162533|NCT01867307|Drug|BI 10773|open label
162534|NCT01867320|Drug|Raltegravir|
162842|NCT01870505|Drug|Exemestane|
162843|NCT01870518|Device|Bilateral GPi DBS|
162844|NCT01870518|Device|Bilateral STN DBS|
162845|NCT01870544|Dietary Supplement|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
162846|NCT01870544|Dietary Supplement|Placebo|placebo will be administered daily for 44 days
162847|NCT01870570|Other|Reference Glucose|
162848|NCT01870570|Other|Food Product A: Corn Flakes|
162849|NCT01870570|Other|Food Product B: Ginger Bread|
162850|NCT01870570|Other|Food Product C:Sandwiched Breakfast Biscuit|
162851|NCT01870570|Other|Food Product D: Crackers Nature|
162852|NCT00107393|Drug|capecitabine|
162853|NCT01870570|Other|Food Product E: Breakfast Biscuit|
162854|NCT01870570|Other|Food Product F: White Bread|
162855|NCT01870583|Drug|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
162221|NCT01871987|Drug|FK949E|oral
162222|NCT01872000|Procedure|Cataract surgery|
162223|NCT01872013|Drug|ASP7991|oral
162224|NCT01872013|Drug|Placebo|oral
162225|NCT01872026|Drug|ASP7991|oral
162226|NCT01872039|Drug|Perdipine injection|IV
162227|NCT01872065|Drug|ARC-520|
162228|NCT01872065|Drug|Placebo|
162229|NCT01872078|Drug|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
162230|NCT01864239|Other|Medicines Advice Service|The intervention consists of:
Telephone consultations with a pharmacist
Follow-up tailored written information
A medicine reminder chart
162231|NCT01864252|Other|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
162232|NCT01864252|Drug|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
162233|NCT01864252|Drug|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
162234|NCT01864265|Biological|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
162535|NCT01867333|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
162536|NCT01867333|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
162537|NCT01867333|Drug|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
162538|NCT01867411|Drug|Nicotine Patch|
162539|NCT01867411|Drug|E-Cigarettes (V2cigs)|
162540|NCT01867424|Drug|Eovist|0.1 ml/kg Eovist will be administered IV to each patient
162541|NCT00107198|Drug|doxorubicin hydrochloride|Given IV
161903|NCT01868828|Other|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
161904|NCT01868841|Radiation|AdreView|10 millicurie of AdreView (123I-mIBG)
161905|NCT01868841|Other|Single Photon Emission Computed Tomography|
161906|NCT01868867|Behavioral|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
161907|NCT01871506|Behavioral|Intensive Counseling (IC)|The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.
Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.
Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication.
161908|NCT01871519|Device|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
161909|NCT01871532|Drug|Gonal-f®|
161910|NCT01871545|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
161911|NCT01871558|Drug|Vildagliptin|50 mg b.i.d
161912|NCT01871558|Drug|Metformin|metformin is to be kept unchanged
162235|NCT01864278|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
162236|NCT01864291|Device|Nucleus 24 Auditory Brainstem Implant (ABI)|Nucleus 24 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
162237|NCT01864317|Device|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
162238|NCT01864317|Other|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
162239|NCT00106834|Drug|Infliximab|
162240|NCT01864317|Other|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
162241|NCT01864317|Other|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
162242|NCT01864317|Other|Humphrey Perimetry|Visual Field Testing
162290|NCT01869465|Behavioral|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
162291|NCT01869478|Drug|Intravenous Thrombolysis|
162292|NCT01869478|Device|Endovascular Arterial Reperfusion|
162293|NCT01869491|Drug|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
162294|NCT00107354|Drug|cytarabine|
162591|NCT01862471|Device|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
162592|NCT01862471|Device|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
162593|NCT01864915|Drug|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
162594|NCT01864915|Procedure|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
162595|NCT01864941|Procedure|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
162596|NCT01864941|Device|Catheter venography with balloon venoplasty and balloon|
162597|NCT01864954|Behavioral|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
162598|NCT01864980|Procedure|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
162599|NCT00106938|Procedure|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
162600|NCT01864980|Procedure|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
162601|NCT01864993|Dietary Supplement|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
161965|NCT01866384|Procedure|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
161966|NCT01866384|Other|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
161967|NCT01866397|Other|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
161968|NCT00107081|Procedure|Outpatient management|
161969|NCT01866410|Drug|Cabozantinib S-malate|Given PO
161970|NCT01866410|Drug|Erlotinib Hydrochloride|Given PO
161971|NCT01866410|Other|Laboratory Biomarker Analysis|Correlative studies
161972|NCT01866423|Drug|orteronel|Given PO
161973|NCT01866423|Other|laboratory biomarker analysis|Correlative studies
161974|NCT01866436|Other|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
162295|NCT01869491|Drug|Matching placebo tablets|2 tablets four times daily
162296|NCT01871766|Procedure|Radiation|Radiation therapy will be delivered at approximately week 13 after initiation of chemotherapy.
162297|NCT01871766|Drug|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
162298|NCT01871766|Drug|Sorafenib|Dosage and route of administration: 90 mg/m^2/dose twice daily.
162299|NCT01871766|Drug|Myeloid Growth Factor|If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.
High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.
162300|NCT01871766|Procedure|Lymph Node Sampling|Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.
162301|NCT00107510|Procedure|conventional surgery|
162302|NCT01871766|Drug|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m^2 IV (maximum dose 100 mg/day) daily x 5.
161650|NCT01863420|Radiation|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
161651|NCT01863433|Biological|Trivalent Influenza Vaccine|
161652|NCT01863446|Device|Lighting1|Ocular light exposure to a red wavelength light
161653|NCT01863446|Device|Lighting2|Ocular light exposure to a blue/green wavelength light
161654|NCT01863459|Drug|Lisdexamfetamine Dimesylate|
161655|NCT01863459|Drug|placebo|
161656|NCT01863472|Device|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
161657|NCT01863472|Device|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
161658|NCT01863485|Drug|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
161659|NCT01863498|Other|Epidural|Patients will have an epidural for pain control
161660|NCT00106639|Drug|CP-690,550|30 mg twice daily
161661|NCT01863498|Other|PCA|Patients will have PCA for pain control
161662|NCT01863511|Drug|loop diuretic|
161663|NCT01863511|Drug|tolvaptan|
161664|NCT01863511|Procedure|ultrafiltration|
161665|NCT01863537|Behavioral|Multimedia Connect|
161666|NCT01863537|Behavioral|Traditional Connect|
161667|NCT01863550|Drug|bortezomib|Given SC or IV
161668|NCT01863550|Drug|lenalidomide|Given PO
161669|NCT01863550|Drug|dexamethasone|Given PO
161670|NCT01863550|Drug|carfilzomib|Given IV
161671|NCT00106639|Drug|tacrolimus|dose adjusted according to level
161672|NCT01863550|Procedure|quality-of-life assessment|Ancillary studies
161353|NCT01790659|Drug|Paromomycin|Paromomycin alone
161354|NCT01790672|Dietary Supplement|Ethanol|Vodka Absolut
161355|NCT01790672|Other|Water|Lemon-flavored water
161356|NCT01790672|Dietary Supplement|Alcoholized wine|Wine 13º or wine 8º
161357|NCT01790672|Dietary Supplement|De-alcoholized wine|Wine 0º
161358|NCT01790685|Drug|dexamethasone implant|
161359|NCT01790711|Procedure|FMT through mid-gut|
161360|NCT01790724|Behavioral|Walking exercise|
161361|NCT01790737|Drug|Cyclophosphamide|
161362|NCT00099177|Drug|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
161363|NCT01783171|Drug|Dinaciclib|Given IV
161364|NCT01783171|Other|Laboratory Biomarker Analysis|Correlative studies
161365|NCT01783171|Other|Pharmacological Study|Correlative studies
161366|NCT01783197|Drug|Paclitaxel|
161367|NCT01783197|Drug|Carboplatin|
161368|NCT01783197|Drug|Selumetinib|
161369|NCT01783197|Drug|Pemetrexed|
161370|NCT01783197|Drug|Cisplatin|
161371|NCT00001937|Drug|FK463|
161372|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
161373|NCT01783210|Behavioral|Specific Therapeutic Lifestyle Changes program in pregnancy|TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the "talk test" (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks.
160773|NCT01784432|Other|Training|
160774|NCT01784445|Drug|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
160775|NCT01784471|Device|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
160776|NCT01784484|Other|No intervention|
160777|NCT00098787|Biological|bevacizumab|Given IV
160778|NCT01784510|Procedure|distance of dissection of gastrocolic ligament from pylorus|
161069|NCT01787539|Drug|Postoperative Chemotherapy|Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.
Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery.
161070|NCT01787552|Drug|LDE225|
161071|NCT01787552|Drug|INC424|
161072|NCT01787565|Other|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
161073|NCT01787565|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
161074|NCT00098917|Procedure|vaccine therapy|
161075|NCT01787578|Drug|Sobetirome|50 mcg or 100 mcg once-daily oral
161076|NCT01790191|Behavioral|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
161077|NCT00099125|Radiation|radiation therapy|
161078|NCT01790191|Behavioral|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
160469|NCT01789242|Drug|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with <VGPR after 4 cycles.
160470|NCT01789255|Drug|vorinostat|Given PO
160471|NCT01789255|Drug|tacrolimus|Given IV or PO
160472|NCT01789255|Drug|cyclosporine|Given IV or PO
160473|NCT01789255|Drug|methotrexate|Given IV
160474|NCT01789255|Other|laboratory biomarker analysis|Correlative studies
160475|NCT01789255|Other|pharmacological study|Correlative studies
160476|NCT01789268|Device|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
160477|NCT01789281|Drug|Everolimus|Everolimus will be provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. Everolimus can be provided as local commercial material or global supply where appropriate
160478|NCT01789281|Drug|Sandostatin LAR Depot|Patients receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol will be allowed to continue Sandostatin LAR Depot treatment. Sandostatin LAR Depot will continue to be provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections will be administered at the discretion of the treating physician.
160779|NCT01784523|Drug|Hydroxychloroquine|
160780|NCT01784536|Drug|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
160781|NCT01784549|Drug|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
160782|NCT01784562|Drug|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
160783|NCT01784575|Other|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
160784|NCT01784588|Device|Solyx Single Incision Sling System|Solyx Single Incision Sling System
160785|NCT01784588|Device|Obtryx II Sling System|to compare a single incision midurethral sling to a standard outside-in transobturator sling for the treatment of female stress urinary incontinence.
160786|NCT01784614|Drug|LY2624803 - Solution|Administered orally as reconstituted solution
159873|NCT01797679|Other|Aerobic Exercise|
159874|NCT01797692|Other|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
160174|NCT01783483|Device|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
160175|NCT01783496|Device|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
160176|NCT01783522|Drug|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
160177|NCT01783522|Other|quality-of-life assessment|Ancillary studies
160178|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
160179|NCT01783522|Other|placebo|Given PO
160180|NCT01783535|Drug|vincristine|Given via minibag/gravity flow.
160181|NCT01783535|Drug|topotecan|Given IV over 30 minutes.
160182|NCT01783535|Drug|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is >2,000/µL on one occasion after the expected nadir.
160183|NCT01783535|Drug|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is >2,000/µL on one occasion after the expected nadir.
160184|NCT01783535|Drug|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
160185|NCT01783535|Other|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
160186|NCT01783535|Drug|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
160187|NCT01783535|Drug|cyclophosphamide|Given IV.
160188|NCT01783535|Drug|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
160189|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
160190|NCT01783535|Drug|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
160191|NCT01783535|Procedure|enucleation|Eye removal due to advanced disease in Strata C and D participants.
159885|NCT01797770|Drug|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
159886|NCT01797770|Other|No Preparation|No laxatives or bowel preparation
159887|NCT01797783|Device|Nelfilcon A multifocal contact lens with comfort additive|
159888|NCT01797783|Device|Nelfilcon A multifocal contact lens|
159889|NCT01797796|Drug|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
159890|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
159891|NCT01797796|Drug|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
159892|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
159893|NCT01797809|Drug|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
159894|NCT00100048|Drug|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
159895|NCT01797822|Drug|dexamethasone, artificial tears|
159896|NCT01797835|Behavioral|CHAT|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
160194|NCT01785836|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
160195|NCT01785836|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
160196|NCT01785836|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
160197|NCT01785849|Drug|AMG 416|Subjects randomized 1:1 to AMG 416. Minimum dose of 2.5mg to maximum dose of 15mg, administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
160198|NCT01785849|Drug|Placebo|Subjects randomized 1:1 to placebo. Minimum dose of 2.5mg to maximum dose of 15mg, administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
160199|NCT01785862|Drug|Ibuprofen 25 mg|Lozenge, Oromucosal administration
160200|NCT00098839|Drug|cytarabine|Given IT
159618|NCT01795144|Drug|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
159619|NCT01795157|Device|CCADSS|Questionnaire is transferred wireless to the physician's PC
159620|NCT01795157|Device|pen-paper|Questionnaire completed and transferred to the physician using standard methods
159621|NCT01795170|Dietary Supplement|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) [23,24], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
159622|NCT01795170|Drug|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
159623|NCT01795183|Drug|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
159624|NCT01795209|Drug|Ranibizumab|Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg
Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema
Retreatment: visual loss of 5 or more letter compared to previous visit
159625|NCT00099697|Drug|DHEA|
159626|NCT01795209|Device|Sham injection|Three monthly sham injections followed by retreatment (sham injections) as needed
Stop criteria: V/A ≥20/20 and complete disappearance of macular edema
Retreatment: visual loss of 5 or more letter compared to previous visit
159627|NCT01795209|Procedure|Rescue laser|In the Lucentis group: performed if BCVA < 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6
In the standard of care group: performed if BCVA < 20/40 or CFT ≥ 350um from Month 3
159628|NCT01797185|Drug|SPARC1104|Subjects will receive SPARC1104
159897|NCT01797848|Drug|Peginterferon alfa 2a|
159898|NCT01797848|Drug|Ribavirin|
159899|NCT01797848|Drug|Placebo matching Daclatasvir|
159900|NCT01800396|Dietary Supplement|Milk protein rich in phospholipids|
159901|NCT01800409|Device|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
159902|NCT01800422|Drug|telapristone acetate|Given orally
159903|NCT01800422|Other|placebo|Given orally
159904|NCT01800422|Procedure|therapeutic conventional surgery|Undergo surgical resection
159905|NCT00100347|Drug|PPI-2458|
159329|NCT00100581|Drug|Tenofovir disoproxil fumarate|
159330|NCT01802554|Behavioral|Information Support (IS)|Supportive Psychotherapy and informational brochures
159331|NCT01802567|Device|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
159332|NCT01802580|Behavioral|Internet Survey|
159333|NCT01802580|Drug|fluocinonide 0.05% ointment|
159334|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
159335|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)
Thiopurine therapy 2 weeks
159336|NCT01802619|Other|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
159337|NCT01802619|Other|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
159338|NCT01802632|Drug|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
159339|NCT01802645|Drug|Cetuximab|
159340|NCT00001968|Drug|Amprenavir|
159341|NCT00100594|Drug|Efavirenz|
159342|NCT01802645|Drug|Bevacizumab|
159629|NCT01797198|Drug|ASP3652|Oral
159630|NCT01797198|Drug|Gemfibrozil|Oral
159631|NCT01797198|Drug|Repaglinide|Oral
159632|NCT01797211|Dietary Supplement|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
159633|NCT01797237|Device|PFNA|
158708|NCT01774838|Drug|Prasugrel|3 months treatment
158709|NCT01774838|Drug|Clopidogrel|3 months treatment
159021|NCT01796288|Drug|Erlotinib|
159022|NCT01796301|Drug|AMG 785|Sub-cutaneous AMG 785 injections for 12 months
159023|NCT01796301|Drug|Teriparatide (TPTD)|Sub-cutaneous TPTD injections for 12 months
159024|NCT01798628|Drug|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
159025|NCT01798641|Device|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
159026|NCT01798667|Drug|DA-8031|
159027|NCT01798667|Drug|Placebo|Placebo of DA-8031, undistinguishable
159028|NCT01798680|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
159029|NCT00100113|Drug|GBR 12909|
159030|NCT01798680|Other|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
159031|NCT01798693|Dietary Supplement|Placebo (maltodextrin)|
159032|NCT01798693|Dietary Supplement|Multi-nutrient Blend|
159033|NCT01798706|Drug|lixisenatide (AVE0010)|Pharmaceutical form:solution for injection (disposable self injector)
Route of administration: subcutaneous injection
159034|NCT01798706|Drug|placebo|Pharmaceutical form:solution for injection (disposable self injector)
Route of administration: subcutaneous injection
159035|NCT01798706|Drug|antidiabetic therapy|Background therapy, if given to be continued on a stable dose, may include: Basal insulin, metformin, sulfonylurea (except glibenclamide>10mg, gliclazide>160 mg), meglitinides (except repaglinide> 6mg) and/or pioglitazone.
159036|NCT01798719|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
159037|NCT01798719|Behavioral|General Advice|Only general advice about diet
159038|NCT01798732|Procedure|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
158429|NCT01771718|Device|multiphoton microscopy.|multiphoton microscopy.
158430|NCT01771731|Drug|Cannabis|
158431|NCT01771783|Drug|ACEI-ARB-RI|
158432|NCT01771783|Drug|ARB-RI-ACEI|
158433|NCT01771783|Drug|RI-ACEI-ARB|
158434|NCT01771796|Behavioral|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
158435|NCT00097474|Drug|Hydrocortisone and Melatonin|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone (or placebo) and at the target bedtime of (10 pm to midnight local time) they will take 5 mg of melatonin (or placebo) for four days.
158710|NCT01774851|Drug|MM-111|MM-111 (IV)
158711|NCT00097825|Drug|Zoledronic Acid|
158712|NCT01774851|Drug|Paclitaxel|Paclitaxel (IV)
158713|NCT01774851|Drug|Trastuzumab|Trastuzumab (IV)
158714|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences Study - HI FIVES|Caregivers in the HI-FIVES group will receive individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. After the phone calls, caregivers will participate in evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator on the research team and the PI and VA Caregiver Support Staff. Three individual telephone training calls will be tailored to the individual needs of Veteran-caregiver dyad. Four group training sessions will be targeted to address common needs of Veterans and their caregivers. Given that all Veteran care recipients will have at least 2 or 3 ADL limitations. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
158715|NCT01777503|Drug|prasugrel|prasugrel 5 mg o.d.
158716|NCT01777503|Drug|Clopidogrel|75 mg o.d.
158717|NCT01777529|Biological|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
158718|NCT01777542|Drug|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
158719|NCT01777542|Drug|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
158720|NCT00098098|Biological|rBV A/B|
158721|NCT01777555|Drug|CVT-301|
158722|NCT01777555|Drug|Placebo|
163168|NCT01816100|Behavioral|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
163169|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
163170|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
163171|NCT01816113|Biological|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
163172|NCT01816113|Biological|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
163173|NCT01818544|Drug|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
163174|NCT01818557|Behavioral|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
158436|NCT01771809|Drug|PF-00547659|75 mg sterile liquid injected subcutaneously once monthly for 72 weeks in treatment period 1.
158437|NCT01771809|Drug|PF-00547659|225 mg sterile liquid injected subcutaneously once monthly for 72 weeks in treatment period 1.
158438|NCT01771809|Drug|PF-00547659|75 mg sterile liquid injected subcutaneously once monthly for 72 weeks in treatment period 2.
158439|NCT01771822|Drug|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
158440|NCT01771822|Drug|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
158441|NCT01771822|Drug|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
158442|NCT01774240|Other|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
158443|NCT00097786|Drug|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
158444|NCT01774253|Drug|Vismodegib|
158445|NCT01774279|Other|Tissue, blood and clinical data collection|
158446|NCT01774292|Procedure|Endotracheal intubation with injection of liquid in the cuff|
162856|NCT01870583|Drug|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
162857|NCT01870583|Drug|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
162858|NCT01870596|Drug|Cytarabine|Given IV
162859|NCT01870596|Drug|CHK1 Inhibitor SCH 900776|Given IV
162860|NCT01870596|Other|Laboratory Biomarker Analysis|Correlative studies
162861|NCT01870609|Drug|defactinib (VS-6063)|
162862|NCT01862939|Drug|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
162863|NCT01862939|Drug|placebo|placebo to match part 2 DS-7309
162864|NCT01862952|Other|starting of anti-epileptic drug treatment|
162865|NCT01862965|Drug|PredEver|Firstline treatment with prednisone and Everolimus
162866|NCT01862978|Drug|Heparin|
162867|NCT01862978|Drug|Nadroparin|
162868|NCT01862978|Drug|Placebo|
163175|NCT01818570|Drug|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
163176|NCT01818570|Drug|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
163177|NCT01818583|Drug|Potassium chloride|
163178|NCT00102063|Drug|Placebo tablet|Placebo tablet po qd x 42 days
163179|NCT01818596|Drug|E/C/F/TAF|E/C/F/TAF FDC tablet administered orally once daily with food
163180|NCT01818609|Behavioral|Step reduction|taking less than 1500 steps/d
163181|NCT01818622|Device|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
163182|NCT01818622|Device|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
162542|NCT01867437|Drug|Placebo|Sterile solution (vehicle) for subcutaneous infusion
162543|NCT01867437|Drug|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
162544|NCT01867463|Biological|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
162545|NCT01867463|Biological|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
162546|NCT01867463|Biological|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
162547|NCT01867476|Other|Automated Adherence Monitoring System|
162548|NCT01867489|Other|No intervention|
162549|NCT01869894|Procedure|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
162869|NCT00106574|Drug|Placebo|iv every 4 weeks
162870|NCT01862991|Other|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
162871|NCT01862991|Drug|Misoprostol|400 mcg buccal misoprostol 90 pre-op
162872|NCT01862991|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
162873|NCT01862991|Drug|Mifepristone|200 mcg Mifepristone orally
162874|NCT01863004|Drug|Bortezomib|
162875|NCT01863017|Device|tDCS|
162876|NCT01863030|Device|Phasix mesh implant|
162243|NCT01864317|Other|Applanation Tonometry|Measurement of Intraocular Pressure
162244|NCT01864330|Device|Thealoz Duo®|Eye Drops
162245|NCT01864330|Device|Hyabak®|Eye Drops
162246|NCT01864330|Device|Hydrabak®|Eye Drops
162247|NCT01864343|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
162248|NCT01864356|Drug|NT100|
162249|NCT01864356|Drug|Placebo|
162250|NCT00106847|Drug|Infliximab|
162251|NCT01864369|Behavioral|eCounseling + Usual Care|This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of "readiness" for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of "change talk" to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12.
162252|NCT01864382|Other|Core stability|Core stability 5 days a week during 5 weeks
162253|NCT01866748|Drug|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
162254|NCT01866748|Drug|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
162255|NCT01866748|Drug|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
162256|NCT01866761|Procedure|Periodontal treatment|
162550|NCT01869894|Procedure|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
162602|NCT01864993|Dietary Supplement|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
162603|NCT01865019|Device|mechanical ventilation|
162604|NCT01865071|Procedure|loop ileostomi|
162605|NCT01865084|Drug|Tadalafil|Administered orally
162606|NCT01865084|Drug|Placebo|
162607|NCT01865097|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
162608|NCT01865097|Behavioral|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
162609|NCT01865110|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
162931|NCT01868074|Device|Insole|Custom-molded arch-supporting insole
162932|NCT00107237|Drug|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
162933|NCT01868087|Dietary Supplement|Boost Plus®|
162934|NCT01868087|Dietary Supplement|Impact Advanced Recovery®|
162935|NCT01868100|Other|self-completion questionnaire|
162936|NCT01870609|Drug|Placebo|Sugar pill manufactured to mimic defactinib tablet
162937|NCT00107419|Drug|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
162938|NCT01870622|Procedure|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
162939|NCT01870622|Procedure|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
162940|NCT01870635|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
162941|NCT01870635|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
162942|NCT01870648|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
162303|NCT01871766|Drug|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m^2/day IV x 5 Age <1 year: treat with 50% doses calculated on a m^2 basis.
162304|NCT01871766|Drug|Etoposide|Dosage and Route of Administration:
Age >1 year 100 mg/m^2/day IV x 5 Age < 1 year treat with 50% doses calculated on a m^2 basis
162305|NCT01871766|Drug|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m^2/day IV.
162306|NCT01871766|Drug|Doxorubicin|Dosage and route of Administration:
Age ≥1 year, 37.5 mg/m^2 IV over 1 hour x 2 days Age <1 year, 18.75 mg/m^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.
162307|NCT01871766|Drug|Dexrazoxane|Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.
Age ≥1 year, 375 mg/m^2 IV over 15-30 minutes Age <1 year, 187l.5 mg/m^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.
162308|NCT01871779|Other|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
162309|NCT01871779|Other|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
162310|NCT01871792|Drug|Pitavastatin|
162311|NCT01871792|Drug|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
162312|NCT00107523|Drug|cytarabine|
162313|NCT01871805|Drug|RO5424802|multiple escalating doses given orally twice daily
162314|NCT01871805|Drug|RO5424802|Recommended Phase II dose (600 mg) given orally twice daily
162610|NCT00106964|Biological|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
162611|NCT01865110|Drug|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
162612|NCT01865110|Drug|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
162613|NCT01865110|Drug|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
162614|NCT01867502|Drug|MET + Vildagliptin Group|Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.
For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator.
162615|NCT01867502|Drug|MET + Glibenclamide Group|The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.
For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator.
161673|NCT01863550|Other|laboratory biomarker analysis|Optional correlative studies
161975|NCT01866436|Other|Study Day Group|Participants in the control arm of the study attend a conventional teaching "Study Day" involving a series of lectures on Open and Laparoscopic Anterior Resection
161976|NCT01866449|Drug|Cabazitaxel|
161977|NCT01868880|Drug|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
161978|NCT00107315|Biological|bevacizumab|
161979|NCT01868880|Drug|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
161980|NCT01868893|Drug|Obinutuzumab|
161981|NCT01868893|Drug|Chlorambucil|
161982|NCT01868906|Drug|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
161983|NCT01868906|Procedure|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
161984|NCT01868906|Device|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
161985|NCT01868906|Procedure|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
161986|NCT01868906|Radiation|Radiotherapy|Standard radiation therapy
161987|NCT01868906|Drug|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
161988|NCT01868919|Behavioral|Positive Parenting Program|Level 3 or 4 of Triple P
161989|NCT00107315|Drug|capecitabine|
161990|NCT01868932|Other|hypertonic saline|inhaled nebulized 3%NaCl
161991|NCT01868932|Other|saline|inhaled nebulized 0.9% NaCl
161992|NCT01868945|Dietary Supplement|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
161993|NCT01868945|Dietary Supplement|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
161994|NCT01868945|Dietary Supplement|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
161374|NCT01783210|Behavioral|Dietary and behavioral counselling in pregnancy|The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.
30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks.
161674|NCT01863563|Device|QuickClot|1 application of treatment to each tonsil/adenoid removal area
161675|NCT01863576|Dietary Supplement|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
161676|NCT01863576|Dietary Supplement|Placebo Comparador|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
161677|NCT01863589|Drug|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
161678|NCT01865734|Other|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
161679|NCT01865734|Other|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
161680|NCT01865747|Drug|Cabozantinib tablets|
161681|NCT01865747|Drug|Everolimus (Afinitor) tablets|
161682|NCT00107042|Biological|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
161683|NCT01865760|Dietary Supplement|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
161684|NCT01865760|Other|Isoglycemic intravenous glucose infusion (IIGI)|The IIGI will be performed using a sterile 20 % wt/vol glucose infusion. The infusion rate will be adjusted, aiming at a duplication of the plasma glucose profile determined in the corresponding OGGT.
161685|NCT01865760|Dietary Supplement|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
161686|NCT01865760|Drug|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
161079|NCT01790204|Dietary Supplement|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
161080|NCT01790230|Device|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
161081|NCT01790243|Device|Lutonix Drug Coated Balloon|
161082|NCT01790256|Device|Cereve Sleep System at 30 degrees C|
161083|NCT01790256|Device|Cereve Sleep System at 14-16 degrees C|
161084|NCT01790282|Drug|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
161375|NCT01783236|Drug|IV Acetaminophen|
161376|NCT01783236|Drug|Saline Placebo|
161377|NCT01783249|Other|Stationary Exercise cycling|Stationary exercise cycling
161378|NCT01783262|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
161379|NCT01783262|Device|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
161380|NCT01783275|Behavioral|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
161381|NCT01783275|Behavioral|Weight loss|12 weeks of caloric restriction to achieve 7-10% weight loss
161382|NCT01783288|Other|Autonomic Function Testing|heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.
Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed.
161383|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
161384|NCT01783288|Other|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured & collected in the supine (lying) and upright position for each participant.
161385|NCT01785472|Drug|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
160787|NCT01784614|Drug|LY2624803 - Capsule|Administered orally as a capsule
160788|NCT00098787|Drug|fluorouracil|Given IV
160789|NCT01784614|Drug|Placebo - Solution|Administered orally as solution
160790|NCT01784614|Drug|Placebo - Capsule|Administered orally as a capsule
160791|NCT01786928|Other|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
160792|NCT01786941|Other|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
160793|NCT01786941|Other|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
160794|NCT01786954|Device|Icare rebound tonometry|
160795|NCT01786954|Device|Tonopen applanation|
160796|NCT01786954|Device|Goldmann applanation|
160797|NCT01786967|Drug|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
160798|NCT01786993|Device|MultiPoint Pacing|
160799|NCT00098891|Drug|isotretinoin|Given orally
160800|NCT01786993|Device|Traditional Biventricular Pacing|
161085|NCT01790282|Drug|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
161086|NCT01790295|Drug|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
161087|NCT01790308|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
161088|NCT00099138|Behavioral|Caloric Restriction (CR)|
161089|NCT01790308|Drug|Liraglutide|CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
160192|NCT01785823|Other|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
160193|NCT01785836|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
160479|NCT00099060|Drug|lapatinib ditosylate|For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):
Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).
Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.
For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):
• Phase II: 750 mg GW572016 po b.i.d.
For all patients:
• Dose reductions as required based on adverse events.
160480|NCT01789294|Drug|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
160481|NCT01789294|Behavioral|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
160482|NCT01789307|Dietary Supplement|corn syrup solids|oral ingestion 50 grams, 2 doses
160483|NCT01789307|Dietary Supplement|sucrose|oral ingestion 50 grams, 2 doses
160484|NCT01789320|Drug|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
160485|NCT01789333|Device|UVA Light with irradiance exposure of 9 mW/cm2|The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 mW/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes).
160486|NCT01791517|Other|Biotrue Multipurpose Solution|Each subject, for each lens type will be exposed to each lens care solution in a random order
160487|NCT01791517|Other|Clear Care|Each subject, for each lens type will be exposed to each lens care solution in a random order
160488|NCT01791543|Device|Intramural Needle Ablation Catheter|
160489|NCT01791556|Other|HIV-1 viral load testing|
160490|NCT01791595|Drug|AZD3965|AZD3965 will be available as 5, 10, 20 and 30mg capsules and patients will take their dose orally once or twice every day of each 28 day cycle including a single dose at day-7 prior to cycle 1.Patients can have up to 12 cycles of treatment if patient is benefitting.
160491|NCT01791608|Dietary Supplement|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
168715|NCT01848652|Drug|infusion of MYOCET|
168716|NCT01848665|Drug|Indomethacin|
168717|NCT01848665|Drug|Placebo|
168718|NCT01848691|Other|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
168719|NCT00105001|Drug|Fludarabine Phosphate|Given IV
168720|NCT01848704|Behavioral|interpretation of the abstract|
168721|NCT01848717|Device|MINTLIFT®|
168722|NCT01848730|Drug|CNV2197944|
168723|NCT01848730|Drug|Placebo|
168724|NCT01848743|Drug|Tenofovir|
168725|NCT01848743|Drug|lamivudine|
168726|NCT01848756|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
168727|NCT01848769|Drug|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
168728|NCT01848769|Drug|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
168729|NCT01848769|Drug|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
168730|NCT00105001|Radiation|Total-Body Irradiation|Undergo total-body irradiation
168731|NCT01848782|Behavioral|interpretation of the abstract of the systematic review|
168732|NCT01848795|Device|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
168733|NCT01848795|Device|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
168734|NCT01848808|Dietary Supplement|Wobenzym PS|
168735|NCT01848808|Dietary Supplement|Placebo|
168736|NCT01848821|Device|OASIS Ultra|Porcine derived intestinal submucosa
173224|NCT01896804|Dietary Supplement|Calcitriol|Given PO
173225|NCT01896804|Other|Laboratory Biomarker Analysis|Correlative studies
173226|NCT01896804|Other|Pharmacological Study|Correlative studies
173227|NCT01896830|Biological|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
173228|NCT01896830|Biological|0.9% normal saline|0.5 mL, intramuscular
173229|NCT01896843|Drug|STX107|
173230|NCT01896856|Drug|SGI-110|
173231|NCT01896856|Drug|Irinotecan|
173232|NCT01896856|Drug|regorafenib|
173233|NCT00109993|Drug|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
168425|NCT01860170|Drug|Cohort 2-Bortezomib (Velcade ®)|Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.
Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.
Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
168426|NCT01860170|Drug|Cohort 3-Bortezomib (Velcade ®)|Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.
Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.
Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
168427|NCT00105417|Drug|IL-7|
168428|NCT01853020|Drug|THC|Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes.
Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes.
168429|NCT01853020|Drug|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
168430|NCT01853033|Biological|ABT-122|Injection
168431|NCT01853033|Biological|Placebo|Placebo Injection
172924|NCT01875679|Other|Conventional Surgical Training|Surgical training as per participant's residency program
172925|NCT01875705|Drug|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
172926|NCT01875705|Drug|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
172927|NCT01875718|Drug|UC1010|
172928|NCT01875718|Drug|Placebo|
172929|NCT01875731|Behavioral|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
172930|NCT01875731|Behavioral|Guideline|Strategy based on enforced guideline guided antibiotic use
172931|NCT01875744|Drug|Polyethylene glycol 4000|
172932|NCT01875757|Drug|Vitamin D3|
172933|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,2 application)
172934|NCT01875757|Drug|Placebo|
172935|NCT01875783|Device|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
172936|NCT01875796|Behavioral|Cognitive-Behavioral Therapy|
172937|NCT01875796|Behavioral|Motivation Enhancement Therapy|
172938|NCT01875796|Behavioral|Integrated Cannabis and Anxiety Reduction Treatment|
172939|NCT01875796|Behavioral|False Safety Behavior Elimination Therapy|
172940|NCT01875822|Dietary Supplement|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
173234|NCT01896856|Drug|TAS-102|
173235|NCT01896869|Drug|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
173236|NCT01896869|Biological|Vaccine|5x10^8 cells administered in 6 intradermal injections
173237|NCT01896869|Drug|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
173238|NCT01896882|Other|Sodium restriction|
172317|NCT01877382|Drug|DS-3032|DS-3032b will be administered as an oral capsule. It will be supplied in 5 mg, 20 mg, 80 mg, and 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
172318|NCT01877395|Biological|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
172618|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
172619|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD, with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
172620|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
172621|NCT01880749|Drug|RAD001|
172622|NCT01880775|Drug|Prilocaine|experimental
172623|NCT01880775|Drug|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
172624|NCT01872624|Procedure|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
172625|NCT01872637|Behavioral|Progressive Multi-Component Intervention|
172626|NCT00107575|Other|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
172627|NCT01872637|Behavioral|Usual Care|
172628|NCT01872650|Device|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
172629|NCT01872663|Procedure|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
172630|NCT01872663|Procedure|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
172631|NCT01872663|Procedure|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
172632|NCT01872663|Procedure|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
172031|NCT01882166|Drug|fostimon|
172032|NCT01882166|Drug|puregon|
172033|NCT01882179|Drug|Mineralocorticoid receptor antagonist potassium-canrenoate|
172034|NCT00108511|Drug|Gemfibrozil|
172035|NCT01874197|Device|B-TEVAR device|Creation and implantation of the Branched Thorcoabdominal aortic anerysm device
172036|NCT01874236|Drug|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
172037|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
172038|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
172039|NCT01874249|Other|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
172040|NCT00107770|Drug|sodium phenylbutyrate|histone deacteylase inhibitor
172041|NCT01874249|Other|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
172319|NCT01877395|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
172320|NCT01877408|Procedure|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
172321|NCT01877408|Device|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
172322|NCT01877421|Drug|2 mg KSL-W|
172323|NCT01877421|Drug|4 mg KSL-W|
172324|NCT01877421|Drug|6 mg KSL-W|
172325|NCT01877421|Drug|10 mg KSL-W|
172326|NCT00108082|Drug|carvedilol MR|Study drug
172327|NCT01877421|Drug|20 mg KSL-W|
172328|NCT01877421|Drug|30 mg KSL-W|
172329|NCT01877421|Drug|50 mg KSL-W|
172330|NCT01877421|Drug|75 mg KSL-W|
171701|NCT01879111|Other|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
171702|NCT01879150|Device|Cyclaplex bone anchor|Device implantation
171703|NCT01879163|Biological|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
171704|NCT01879163|Biological|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
171705|NCT01879176|Device|CytoSorb|
171706|NCT01881568|Drug|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
171707|NCT01881581|Biological|Saline Solution|Saline Solution is used as control in all arms.
171708|NCT01881581|Biological|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
171709|NCT01881581|Biological|M-GPE|M-GPE is used in Arm D,E,F,G and H
171710|NCT01881594|Procedure|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
171711|NCT01881607|Behavioral|RESPIRNET Program|The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide "Towards a Smoke-Free School" to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the "My risk thermometer" activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program.
171712|NCT01881620|Device|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
171713|NCT01881633|Drug|ISU302|
171714|NCT00108433|Drug|Vancomycin (IV)|
172042|NCT01874249|Other|Transient elastography|Transient elastography values greater than 8 kPa
172043|NCT01874262|Device|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
172044|NCT01874262|Device|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
171389|NCT01922674|Procedure|Standard open tension-free inguinal hernia repair with mesh|
171390|NCT01922687|Drug|amlodipine plus atorvastatin (Caduet)|
171391|NCT01922687|Drug|amlodipine (Norvasc)|
171392|NCT00112489|Drug|paclitaxel|
171393|NCT01922713|Other|white maize and a corn oil capsule|~ 0 ug RAE/d
171394|NCT01922713|Other|orange maize and a corn oil capsule|~600 ug RAE/d
171395|NCT01922713|Other|white maize and a vitamin A capsule|600 ug RAE/d
171396|NCT01922739|Drug|hydrocodone bitartrate extended-release tablets|Tablet strengths of 15 mg, 30 mg, and 45 mg will be available, and patients will take 1 or 2 tablets at each dose, for a total dosage of 15, 30, 45, 60, or 90 mg taken every 12 hours.
171397|NCT01922752|Drug|CEP-37440|CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.
Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined.
171398|NCT01922765|Drug|amoxicillin, clarithromycin, metronidazole, rabeprazole|
171399|NCT01925079|Behavioral|Intensive Education|Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.
Patient education:
Routine education at discharge.
4 education brochures will be delivered to patients.
Calendar with healthy tips will be delivered to patients before discharge.
A follow-up brochure with medical expert letter.
A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).
Telephone follow ups will be performed according to a standard communication document.
At discharge, patients will be given a brochure for future follow up.
171400|NCT01925079|Other|Control|Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.
Patient education:
Routine education at discharge.
A follow-up brochure without medical expert letter.
At discharge, patients will be given a brochure for future follow up.
171401|NCT01925092|Drug|mifepristone|tablets
171402|NCT01925105|Other|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
171403|NCT01925118|Biological|Irradiated donor lymphocyte infusion|
171404|NCT01925131|Drug|cyclophosphamide|Given IV
171405|NCT01925131|Drug|vincristine sulfate|Given IV
171715|NCT01881633|Drug|Placebo|
171716|NCT01881646|Radiation|Positron emission tomography (PET) using [11C]PBR28|
171717|NCT01881659|Other|HPV screening|Women who signed informed consent will be screened with HPV testing.
170739|NCT01931995|Device|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
170740|NCT01931995|Procedure|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
170741|NCT01924013|Dietary Supplement|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
170742|NCT01924013|Dietary Supplement|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
170743|NCT01924039|Behavioral|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
175872|NCT01886391|Behavioral|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
175873|NCT01886404|Drug|Efavirenz|HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.
Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.
Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well.
175874|NCT01886430|Other|Functional electrical stimulation|Functional electrical stimulation for 10 days
175875|NCT01886430|Other|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
175876|NCT01886443|Drug|Antithrombin-III|
175877|NCT01886443|Drug|Infliximab|
175878|NCT01886443|Drug|Apotransferrin|
175879|NCT01886443|Drug|Human recombinant erythropoietin|
175880|NCT00108953|Drug|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
175238|NCT01885364|Drug|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
175239|NCT01885364|Drug|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
175240|NCT01885364|Drug|propofol|intravenous injection after pretreatment
175241|NCT01885377|Other|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
175242|NCT01885377|Other|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
175243|NCT00108797|Drug|activated recombinant human factor VII|
175244|NCT01885390|Device|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
175245|NCT01885403|Device|non-invasive respiratory parameter measurements|
175246|NCT01887587|Drug|Vincristine|
175555|NCT01890837|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
175556|NCT01890837|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
175557|NCT01890850|Other|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
175558|NCT01890863|Drug|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
175559|NCT01890863|Drug|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
175560|NCT01890876|Other|Walking uphill|ascending about 500 m
175561|NCT01890876|Other|Walking downhill|descending about 500 m
175562|NCT01890889|Dietary Supplement|Ad-Chol-Pre|
175563|NCT00109564|Drug|ispronicline (nicotinic acetylcholine receptor agonist)|
175564|NCT01890889|Dietary Supplement|Half-dose Ad-Chol-Pre|
174945|NCT01892475|Behavioral|Incentive-based physical activity program|Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:
Accurately predicting step target attainment the following months (SGD10)
Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)
174946|NCT01892475|Behavioral|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
174947|NCT01892488|Drug|Sultamicillin|Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.
Experimental intervention:
Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD.
174948|NCT01892488|Drug|Placebo|Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.
Control intervention:
Placebo for 5 days as supplement to standard of care for patients with AE-COPD
174949|NCT01892501|Procedure|Guided punction of mediastinal lymphadenopathy by echoendoscopy|EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.
Pathological samples are taken :
3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken.
174950|NCT01892501|Device|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
174951|NCT01892514|Procedure|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
174952|NCT01892527|Drug|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
175247|NCT01887587|Drug|Doxorubicin|
175248|NCT01887587|Drug|Dexamethasone|
175249|NCT01887600|Drug|Roxadustat|tablet
175250|NCT01887600|Drug|Placebo|tablet
175251|NCT01887613|Drug|Regnite|oral
175252|NCT01887626|Drug|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
175253|NCT01887626|Drug|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
170842|NCT01924169|Biological|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
170843|NCT01924182|Device|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
170844|NCT01924182|Other|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
170845|NCT01924195|Drug|Anlotinib|Anlotinib QD po.
170846|NCT01924195|Drug|Placebo capsule|Placebo QD po.
170847|NCT00112593|Drug|fludarabine phosphate|Given IV
170848|NCT01924208|Biological|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
170849|NCT01924208|Biological|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
170850|NCT01924208|Procedure|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
171162|NCT01927341|Drug|MEK162|MEK162 plus panitumumab combination
171163|NCT01927341|Drug|Panitumumab|
171164|NCT01927367|Other|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
171165|NCT01927380|Other|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
171166|NCT01927393|Other|palliative care|Receive PCPI
171167|NCT01927393|Behavioral|educational intervention|Receive education sessions
171168|NCT01927393|Procedure|quality-of-life assessment|Ancillary studies
171169|NCT01927393|Other|questionnaire administration|Ancillary studies
171170|NCT00112749|Biological|infliximab|A single infusion of 1mg/kg will be administered.
171171|NCT01929655|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
170518|NCT01926015|Biological|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
170519|NCT00112684|Drug|alvocidib|Given IV
170520|NCT01928680|Drug|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
170521|NCT01928693|Drug|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
170522|NCT00112853|Drug|etoposide|Given orally
170523|NCT01928693|Drug|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
170524|NCT01928693|Drug|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
170525|NCT01928706|Other|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
170526|NCT01928706|Other|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
170527|NCT01928719|Drug|Reduced Nicotine Content Cigarettes|Cigarettes contain 8 [9 for menthol], 4, 1.7, 0.9 and 0.3 mg of nicotine
170528|NCT01928719|Drug|Same Nicotine Content Cigarettes|about 11.4 mg nicotine per cigarette
170851|NCT01924221|Other|this is an observational study. No intervention|
170852|NCT01924234|Drug|Morphine|
170853|NCT01924234|Drug|Remifentanil|
170854|NCT01924247|Behavioral|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
170198|NCT01923233|Biological|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
170199|NCT00112515|Procedure|psychosocial assessment and care|
170200|NCT01923246|Behavioral|Single WEB intervention|Brief WEB intervention recieved once
170201|NCT01923246|Behavioral|Repeated WEB intervention|WEB intervention recieved twice.
170202|NCT01923246|Behavioral|Single IVR intervention|IVR intervention recieved once
170203|NCT01923246|Behavioral|Repeated IVR intervention|IVR intervention recieved twice
170204|NCT01923259|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
170205|NCT01923272|Device|AlphaCore Device|Active stimulation to the vagal nerve
170206|NCT01923272|Device|AlphaCore|Active AlphaCore treatment
170207|NCT01923285|Device|AXIUM Neurostimulator System|
170208|NCT01925365|Dietary Supplement|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
170209|NCT01925378|Drug|Nelfinavir|All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.
All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration.
170210|NCT01925391|Drug|Tono-pen XL Applanation tonometer + Ocu-film +|
170211|NCT01925404|Behavioral|Free physical activity classes|100 hours of free activity classes will be provided
170212|NCT00112645|Procedure|peripheral blood stem cell transplantation|
170213|NCT01925404|Behavioral|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
170214|NCT01925417|Biological|RBX2660 (microbiota suspension)|
170215|NCT01925430|Device|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
170216|NCT01925430|Device|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
170217|NCT01925443|Other|Low level laser therapy|Will be performed irradiation with low-intensity laser in quadriceps muscle
170218|NCT01925456|Drug|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
169608|NCT01850186|Device|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
169902|NCT01843322|Procedure|endoleak repair procedure (navigation technology )|
169903|NCT00104624|Procedure|quality-of-life assessment|
169904|NCT01843348|Drug|RAD001|
169905|NCT01843348|Drug|Tacrolimus|Tacrolimus: one capsule containing 0.5 mg, 1 mg or 5 mg
169906|NCT01843348|Drug|Cyclosporin A|one capsule containing 10 mg, 25 mg, 50 mg or 100 mg
169907|NCT01843348|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS) or Mycophenolate Mofetil (MMF)|one tablet containing 180 mg or 360 mg (EC-MPS) or or 500 mg (MMF), one capsule containing 250 mg (MMF)
169908|NCT01843348|Drug|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
169909|NCT01843374|Drug|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
169910|NCT01843374|Drug|Placebo|Placebo is to be administered as an IV solution, followed by observation.
169911|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
169912|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
169913|NCT01843400|Drug|BAY73-4506_Regorafenib|Patients treated with Regorafenib under practical manner for colorectal cancer.
169914|NCT00104637|Drug|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
169915|NCT01845623|Other|Placebo Concept 1|Placebo administered via the Concept 1 device.
169916|NCT01845623|Other|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
169917|NCT01845636|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
169918|NCT01845636|Drug|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
169919|NCT01845649|Drug|Estradiol Vaginal Gel|Daily for 14 days followed by 3 times per week for 10 weeks
169920|NCT01845649|Drug|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
169317|NCT01844700|Drug|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
169318|NCT01844700|Drug|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
169319|NCT01844713|Behavioral|Workbook|Subjects will read a workbook about sun protection
169320|NCT01844726|Drug|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
169321|NCT01844726|Drug|Placebo|Single injection of placebo (saline)
169322|NCT01844739|Drug|NVN1000 4% Gel|
169323|NCT00104715|Drug|docetaxel|
169324|NCT01844739|Drug|Vehicle Gel|
169609|NCT01850186|Drug|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
169610|NCT01850199|Other|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
169611|NCT01850199|Other|Usual management|Usual care will be provided, including face-to-face visits
169612|NCT01850225|Device|Auditory brainstem implant|
169613|NCT01850238|Biological|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
169614|NCT01850238|Other|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
169615|NCT00105118|Device|Magstim Super Rapid Magnetic Stimulator|
169616|NCT01850251|Dietary Supplement|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
169617|NCT01850251|Dietary Supplement|Standard nutritional supplement|High protein, high calorie nutritional supplement.
169618|NCT01850264|Device|Application of quadripolar / bipolar LV electrodes|
169619|NCT01850277|Drug|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
169040|NCT01851733|Procedure|MRI-guided Laser Heat Ablation (MLA)|
169041|NCT01851733|Drug|Doxorubicin|
169042|NCT01851733|Other|Blood draw - dendritic cells|Arm A:
before biopsy (up to 3 days before)
2 weeks after biopsy
4 weeks after biopsy
every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)
The second 10 patients enrolled to Arm B:
before MLA (up to 3 days before)
2 weeks after MLA
4 weeks after MLA
every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)
169043|NCT01851759|Drug|cinepazide|2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
169044|NCT01851759|Drug|placebo|2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
169045|NCT00105235|Drug|Mycophenolate mofetil|Oral immunosuppressant
169046|NCT01851772|Device|Treatment with Electronic Brachytherapy|
169325|NCT01847079|Other|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
169326|NCT01847092|Drug|AZD1722|
169327|NCT01847092|Drug|Placebo|Placebo for AZD1722
169328|NCT00104884|Drug|Depsipeptide|Given IV
169329|NCT01847105|Other|RevitaLens|Multi-purpose disinfecting solution
169330|NCT01847105|Other|OptiFree PureMoist|Multi-purpose disinfecting solution
169331|NCT01847118|Drug|Sevacizumab|
169332|NCT01847131|Drug|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
169333|NCT01847131|Drug|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
169334|NCT01847144|Drug|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
169335|NCT01847144|Drug|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
169047|NCT01844167|Procedure|Noxipoint Therapy (NT)|• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the "Rest Period": Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the "Rest Period", which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation.
169048|NCT01844167|Procedure|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
169049|NCT01844180|Drug|ONO-2952|
169050|NCT01844193|Device|Compex Rehab|Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment ("Warm-up", "Work", "Relaxation", and "Recovery") for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated.
169051|NCT01844206|Drug|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
169052|NCT01844206|Drug|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
169053|NCT01844219|Procedure|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
169054|NCT01844232|Drug|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
169055|NCT00104676|Drug|paclitaxel|Given in a dose-dense sequential fashion
169056|NCT01844245|Procedure|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
169057|NCT01844258|Procedure|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
169058|NCT01844258|Procedure|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
169059|NCT01844271|Device|Low Level Laser (LLL)|Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.
We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.
In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups.
168432|NCT01853046|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
168433|NCT01853072|Drug|Nepafenac Ophthalmic Suspension, 0.3%|
168434|NCT01853072|Other|Nepafenac vehicle|Inactive ingredients used as placebo comparator
168435|NCT01853072|Drug|Prednisolone acetate ophthalmic suspension|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
168436|NCT01853085|Drug|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
168437|NCT01853098|Behavioral|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
168438|NCT00105430|Procedure|Deep Brain Stimulation|
168439|NCT01853111|Biological|Interleukin-2|
168737|NCT01848821|Device|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
168738|NCT01848834|Biological|Pembrolizumab|
168739|NCT01848847|Procedure|Hysteroscopy|
168740|NCT01851083|Other|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
168741|NCT01851096|Drug|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
168742|NCT01851109|Behavioral|genetic counseling|The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:
A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;
Discuss how the results - positive or negative - affect cancer risk
Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);
Discuss how the test is conducted and what the results might be (positive, negative, uncertain);
Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc.
168743|NCT01851122|Dietary Supplement|L-theanine capsule|L-theanine 250mg capsule
168744|NCT01851135|Other|Neuropsychological examination and quality of life measures|
173239|NCT01896895|Drug|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
173240|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
173241|NCT01896895|Drug|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
173242|NCT01899287|Behavioral|group education|The experimental intervention consists of:
A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.
C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse.
173243|NCT01899300|Device|Metal Stent (WallFlex™ Esophageal RX)|
173244|NCT01899313|Behavioral|CBT- based SMS text messaging intervention|
173245|NCT01899313|Behavioral|CBT group therapy|
173246|NCT01899326|Drug|Desipramine Hydrochloride|Given PO
173247|NCT01899326|Biological|Filgrastim|Given PO
173248|NCT01899326|Other|Laboratory Biomarker Analysis|Correlative studies
173249|NCT00110084|Drug|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
173250|NCT01899339|Other|Ultra sound energy along with tPA to treat submassive pulmonary embolism|
173251|NCT01899352|Procedure|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
173252|NCT01899378|Dietary Supplement|Lactobacillus reuteri DSM 17938|10^8 CFU
173253|NCT01899378|Dietary Supplement|Bifidobacterium longum infantis|10^9 CFU
173254|NCT01899404|Biological|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
168440|NCT01853124|Drug|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
172633|NCT01872663|Procedure|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
172634|NCT01872663|Procedure|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
172941|NCT01875835|Device|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
172942|NCT01875835|Device|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
172943|NCT01875848|Drug|buprenorphine/naloxone|partial opioid agonist
172944|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,8 application)
172945|NCT01875848|Drug|opioid dose escalation|up to 25% increase in patient's current opioid dose
172946|NCT01875861|Other|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
172947|NCT01875874|Biological|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
172948|NCT01875887|Procedure|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
172949|NCT01875900|Other|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
172950|NCT01878526|Drug|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
172951|NCT01878526|Drug|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
172952|NCT01878526|Drug|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
172953|NCT01878539|Device|coagulometer|
172954|NCT01878539|Behavioral|training programme|
172955|NCT01878565|Drug|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
172956|NCT00002057|Drug|Nystatin|
172331|NCT01877421|Drug|100 mg KSL-W|
172332|NCT01877421|Other|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
172333|NCT01877434|Procedure|Reversed shoulder arthroplasty|
172334|NCT01877447|Device|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
172335|NCT01877460|Other|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
172336|NCT01877473|Procedure|Ablation|
172337|NCT00108082|Drug|atenolol|Comparator
172338|NCT01877486|Procedure|Ablation|Pulmonary vein isolation following dofetilide
172339|NCT01880203|Procedure|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
172340|NCT00108342|Other|Computer learning|
172341|NCT01880216|Drug|Bemiparin sodium|subcutaneous application daily for 7±2 days
172342|NCT01880216|Drug|Enoxaparin sodium|subcutaneous for 7±2 days
172343|NCT01880255|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
172635|NCT01872676|Other|Spine manipulation|
172636|NCT01872676|Other|Manipulation sham|
172637|NCT00107588|Behavioral|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
172638|NCT01872689|Drug|lebrikizumab|SC every 4 weeks
172639|NCT01872689|Drug|pirfenidone|Treated daily with the maximum tolerated dose
172640|NCT01872689|Drug|placebo|SC every 4 weeks
172641|NCT01872702|Drug|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
172642|NCT01872715|Drug|Oracea|
172045|NCT01874275|Device|VECTTOR|The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.
Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence.
172046|NCT01874288|Drug|0.5 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
172047|NCT01874288|Drug|1.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
172048|NCT01874288|Drug|2.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
172049|NCT01874288|Drug|4.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
172050|NCT01874288|Drug|6.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
172051|NCT00107783|Drug|Nitisinone (NTBC)|Treatment
172052|NCT01874288|Drug|8.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
172053|NCT01876758|Behavioral|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
172054|NCT01876758|Behavioral|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
172055|NCT01876771|Other|Lu-DOTA-TATE radiopharmaceutical|
172056|NCT01876784|Drug|vandetanib|300 mg (3 x 100 mg tablets) will be dosed orally, once daily
172344|NCT01880268|Device|BCI-controlled neurorehabilitation device|Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, "arm bike")
172345|NCT01880268|Behavioral|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
171718|NCT01881698|Other|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
171719|NCT01881711|Device|ShuntCheck-Micro-Pumper (SCMP)|ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow "downstream" of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck.
171720|NCT01881711|Device|Imaging|Imaging of ventricle size
171721|NCT01881724|Behavioral|Sleep education|
171722|NCT01881737|Drug|Pregnenolone|With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.
Days 1-14: 100 mg
Week 1 and 2: 200 mg
Week 3 and 4: 350 mg
Week 5 and 6: 400 mg
Week 7 -12: 500 mg
If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs.
171723|NCT01881750|Behavioral|Pivotal Response Training|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
171724|NCT01881750|Behavioral|Parent Education Group|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
171725|NCT00108446|Drug|dextromethorphan|
171726|NCT01881763|Drug|Ketamine|Ketamine 1-2 mgr/ kg IV
171727|NCT01881763|Drug|Methohexital|Methohexital 0.5-1mg/kg IV
171728|NCT01873573|Device|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
171729|NCT01873586|Device|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold
171730|NCT01873599|Behavioral|Positive Affect Journaling|
171731|NCT00107692|Behavioral|Physical activity and diet|
171732|NCT01873612|Procedure|Hypoxic ventilatory response|
171733|NCT01873612|Procedure|Hypercapnic ventilatory response|
171734|NCT01873625|Biological|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
171735|NCT01873625|Biological|placebo|
171736|NCT01873638|Procedure|Cholecystectomy|
175881|NCT01886443|Drug|C1-Inhibitor|
175882|NCT01886443|Drug|Glutathione|
175883|NCT01886443|Drug|Alfa-tocopherol|
175884|NCT01886443|Drug|Melatonin|
175885|NCT01886443|Drug|Epoprostenol|
175886|NCT01886456|Device|Laser trabeculoplasty|
175887|NCT01886469|Drug|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
175888|NCT01886469|Drug|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
175889|NCT01886469|Drug|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
175890|NCT01886482|Other|nutrition intervention|high protein diet
175891|NCT00108953|Drug|Doxorubicin/Placebo|Chemotherapy plus Placebo
176205|NCT01918722|Drug|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
176206|NCT00112164|Drug|Xigris|
176207|NCT01918735|Drug|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
176208|NCT01918735|Drug|GWP42006|Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.
Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects.
176209|NCT01918748|Device|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
176210|NCT01918761|Drug|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 iV (q21d) Dacomitinib 45mg orally (continuous)
176211|NCT01918774|Behavioral|Cognitive behavior therapy for work success|CBT for work success program includes 10 sessions that are delivered in a weekly one-hour group format; sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, and increasing beneficial coping strategies that can be applied across employment settings. The intervention was tailored toward both employed and unemployed persons seeking community work. : Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
175565|NCT01890889|Other|Defatted egg yolk without the active ingredient of the other two interventions|
175566|NCT01890902|Drug|Ketoprofen 10% Cream|
175567|NCT01890902|Drug|Placebo|
175568|NCT01890915|Other|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
175569|NCT01890941|Drug|KCT-0809 ophthalmic solution|
175570|NCT01890941|Drug|Placebo|
175571|NCT01890954|Device|Diabetes Assistant (DiAs)|
175572|NCT01890967|Drug|LY3015014|Administered SC
175573|NCT01890967|Drug|Placebo|Administered SC
175574|NCT00109577|Drug|MCN36 (nutritional supplement)|nutritional supplement
175575|NCT01890980|Biological|WT-1-vaccine Montanide + GM-CSF|Treatment of 6 injections over 12 weeks, administered on weeks 0, 2, 4, 6, 8, and 10. All receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination and may be self administered with appropriate instruction. Participants keep a logbook noting the time and placement of the injection, and will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide which will be administered by a nurse (not self-administered) subcutaneously to the same anatomical site as the GM-CSF as marked by the patient or treating healthcare professional by a permanent marker pen.
175892|NCT01886495|Other|nutrition intervention|
175893|NCT01888822|Drug|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
175894|NCT01888822|Drug|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
175895|NCT01888835|Drug|Mirtazapine|
175896|NCT01888835|Drug|Placebo|
175897|NCT01888848|Dietary Supplement|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
175898|NCT01888848|Dietary Supplement|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
175899|NCT01888861|Dietary Supplement|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
175900|NCT00109304|Biological|VEE 3526|
175901|NCT01888861|Drug|placebo|the patients in this arm were received 900mg placebo through NG tube.
175902|NCT01888874|Drug|GLPG0634|
175254|NCT01887626|Drug|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
175255|NCT00109135|Drug|taranabant|
175256|NCT01887652|Other|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
175257|NCT01887652|Other|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
175258|NCT01887665|Behavioral|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
175259|NCT01887678|Drug|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
175260|NCT01887678|Drug|Placebo|Placebo is an injection of Saline
175261|NCT01887691|Drug|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
175262|NCT01887704|Device|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
175263|NCT01887704|Procedure|conventional angioplasty|Conventional angioplasty was used in both arms.
175264|NCT01887704|Procedure|stenting|Stenting was implanted in both arms.
175265|NCT01887704|Device|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
175266|NCT00109148|Drug|MK0364|
175267|NCT01887704|Drug|Aspirin|Aspirin will be administrated in participants in both arms.
175268|NCT01887704|Drug|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
175576|NCT01883284|Other|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
175577|NCT01883297|Biological|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10^7 TILs (with maximum 3x10^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10^8 TILs (with maximum 1x10^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10^8 TILs (with maximum 3x10^7 autologous dendritic cells)
171172|NCT01929668|Drug|polyethylene glycol|
171173|NCT00112879|Procedure|non-specific immune-modulator therapy|
171174|NCT01929668|Drug|Ascorbic Acid|
171175|NCT01929681|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
171176|NCT01929694|Dietary Supplement|Berocca Boost|
171177|NCT01929694|Dietary Supplement|Placebo|
171178|NCT01929707|Drug|LY3050258|
171179|NCT01929707|Drug|Placebo|
171180|NCT01929720|Behavioral|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
171181|NCT01929746|Biological|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
171182|NCT01929759|Drug|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
171183|NCT01929798|Device|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
171486|NCT01922921|Other|Placebo|Given PO
171487|NCT01922921|Biological|Polysaccharide-K|Given PO
171488|NCT01922921|Biological|Trastuzumab|Given per standard of care
171489|NCT01922934|Behavioral|Commercial weight loss program|vouchers for Weight Watchers
171490|NCT01925183|Drug|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
171491|NCT01925209|Drug|BYM338/bimagrumab|BYM338 will be administered via intravenous infusion to randomized patients beginning on Day 1 through Week 52, and up to Week 104.
171492|NCT01925209|Drug|Placebo|Matching placebo will be administered via intravenous infusion to 60 randomized patients beginning on Day 1 through Week 52, and up to Week 104.
171493|NCT01925235|Procedure|remote ischemic preconditioning|
171494|NCT01925248|Dietary Supplement|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
170855|NCT01924260|Drug|alisertib|Given PO
170856|NCT01924260|Drug|gemcitabine|Given IV
170857|NCT01924273|Drug|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
170858|NCT00112593|Radiation|total-body irradiation|Undergo TBI
170859|NCT01924286|Drug|Prednisone|
170860|NCT01924286|Drug|Placebo|
170861|NCT01924299|Drug|Baricitinib|Administered orally
170862|NCT01924299|Drug|Ketoconazole|Administered orally
170863|NCT01926561|Other|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
170864|NCT01926574|Behavioral|long rehabilitation program|
170865|NCT01926574|Behavioral|short rehabilitation program|
170866|NCT00112710|Drug|carboplatin|
170867|NCT01926574|Behavioral|Acceptance and commitment therapy (ACT)|
170868|NCT01926587|Drug|oral rigosertib|Oral rigosertib will be administered twice a day (BID) in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
170869|NCT01926587|Drug|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
170870|NCT01926613|Behavioral|Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.
171184|NCT00112892|Dietary Supplement|selenium|
171185|NCT01929811|Drug|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
171186|NCT01929811|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
171187|NCT01929811|Drug|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
171188|NCT01929811|Drug|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
170219|NCT01925469|Drug|Benzocaine|
170529|NCT01928732|Behavioral|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
170530|NCT01928732|Behavioral|Prolonged Exposure (PE)|PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: "The world is an utterly dangerous place," and "I am completely incompetent and unable to cope with stress." In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure.
170531|NCT01928758|Drug|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
170532|NCT01928758|Drug|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
170533|NCT00112866|Drug|cilengitide|Given IV
170534|NCT01928771|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
170535|NCT01928771|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
170536|NCT01931124|Behavioral|Moderate Intensity Training|
170537|NCT01931137|Drug|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
170538|NCT01931150|Drug|Topical Dapsone 5% Gel|
170539|NCT01931150|Other|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
170540|NCT01931150|Drug|oral antibiotics|
170541|NCT01931163|Drug|Everolimus|
170542|NCT01931176|Biological|rDEN2Δ30-7169 vaccine|Administered at a dose of 10^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
170543|NCT01931176|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
170544|NCT01931189|Biological|NI-071|100mg/vial
170545|NCT01931189|Biological|Infliximab|100mg/vial
169921|NCT01845662|Other|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
169922|NCT01845675|Drug|temozolomide or dacarbazine-based chemotherapy, endostatin|
169923|NCT01845688|Drug|Losartan Tablets & QingReMoShen Granule|
169924|NCT00104793|Drug|irinotecan hydrochloride|
170220|NCT01925469|Drug|Saline spray|A saline spray will be used in the placebo group
170221|NCT01925482|Drug|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
170222|NCT01925482|Drug|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
170223|NCT00112645|Procedure|umbilical cord blood transplantation|
170224|NCT01925482|Drug|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
170225|NCT01925482|Drug|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
170226|NCT01925482|Drug|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
170227|NCT01925482|Drug|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
170228|NCT01925495|Other|varied middle-ear pressure|
170229|NCT01925495|Drug|varied middle-ear gas composition|
170230|NCT01925495|Other|varied ear-canal pressure|
170231|NCT01925521|Drug|Part1 : OPS-2071|single oral dose under fasted condition
170232|NCT01925521|Drug|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
170233|NCT01925521|Drug|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
170234|NCT00112658|Drug|fluorouracil|
170235|NCT01925521|Drug|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
170236|NCT01928251|Behavioral|Uninformed early monetary incentive|Participants will be informed at 3 months after the baseline recruitment about the monetary incentive of quitting.
Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking).
169620|NCT01832402|Drug|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
169621|NCT01832402|Drug|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
169622|NCT01832402|Other|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
169623|NCT01832402|Behavioral|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
169624|NCT01832402|Behavioral|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
169625|NCT01832415|Drug|Bevacizumab|Observation of bevacizumab administration in first line ovarian cancer treatment
169925|NCT01845688|Drug|Losartan Tablets & Placebo Granule|
169926|NCT01845701|Drug|Artesunate-Amodiaquine|Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.
Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.
The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®).
169927|NCT01845701|Drug|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis[1-(7-chloro-4 quinolyl)-4- piperazinyl]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
169928|NCT01845701|Drug|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
169929|NCT01845714|Procedure|Corneal Cross Linking|
169930|NCT01845714|Procedure|Corneal Cross Linking combined with topoguided PRK|
169931|NCT01845727|Drug|Topical Amphotericin B at 3%|
169336|NCT01847157|Device|tDCS|Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).
During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current.
169337|NCT01847157|Drug|Epidermis anesthesia|15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.
Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
169338|NCT01847157|Drug|sham anesthesia|15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.
10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
169339|NCT00104897|Drug|tanespimycin|
169340|NCT01847157|Other|Repeated passive movement|Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.
Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes.
169341|NCT01847157|Device|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
169342|NCT01847170|Biological|Fecal Microbial Transplantation|
169626|NCT01832428|Other|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
169627|NCT01832441|Other|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
169628|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
169629|NCT00103363|Procedure|study of high risk factors|
169630|NCT01832467|Drug|cetuximab-containing chemotherapy|
169631|NCT01832480|Drug|MTZ 500 mg BID x 7 days|MTZ 500 mg BID x 7days
169632|NCT01832480|Drug|MTZ 2 g|MTZ 2 g
169633|NCT01832493|Device|Medtronic Cardiac Resynchronization Therapy Device|
169634|NCT01832506|Drug|MSC2156119J|MSC2156119J will be administered in the assigned doses in combinations of 15 milligram (mg) and/or 100 mg capsules orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
169060|NCT01844284|Device|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
169061|NCT01844284|Device|Absorb™ BVS|Subjects receiving Absorb™ BVS
169343|NCT01847183|Behavioral|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
169344|NCT01849783|Procedure|autologous stem cell transplant|
169345|NCT01849796|Device|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
169346|NCT00105079|Drug|saquinavir [Invirase]|1000 milligram (mg) Oral (po) twice daily (bid)
169347|NCT01849809|Procedure|Gamma Ventral Capsulotomy|
169348|NCT01849822|Device|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
169349|NCT01849835|Procedure|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
169350|NCT01849835|Procedure|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
169351|NCT01849848|Drug|SyB L-0501|The administration of SyB L-0501 at 90 mg/m^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
169352|NCT01849861|Drug|Methimazole|Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).
After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.
Variables considered in this study:
TSH and FT4
Questionnaire of Quality of life for older adults (WHOQOL-OLD)
Mini-Mental State Examination
Geriatric Depression Scale
Cardiopulmonary exercise testing - cardiopulmonary capacity
169353|NCT01849874|Drug|MEK162, MEK inhibitor; oral|multiple dose, single schedule
168745|NCT01851148|Other|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
168746|NCT00105196|Drug|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
168747|NCT01851148|Other|sham treatment|Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to "treat" the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence
168748|NCT01851148|Drug|triptans|administration of triptans drug treatment according to international guidelines
168749|NCT01851161|Procedure|computed tomography|Undergo conventional CT scan in both supine and prone positioning
168750|NCT01851161|Procedure|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
168751|NCT01851161|Radiation|radiation therapy|Undergo radiation therapy
168752|NCT01851174|Drug|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m^2) IV over 30 minutes after nab-paclitaxel infusion
168753|NCT01851174|Drug|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m^2) IV over 30 minutes before Gemcitabine infusion
168754|NCT01851187|Behavioral|antenatal psychological intervention|emotion management included:
(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms.
169062|NCT01844297|Drug|TDF+3TC+EFV|
169063|NCT01844310|Drug|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
169064|NCT01844310|Drug|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
169065|NCT01846650|Drug|XELODA|Single oral XELODA 2000mg qd
169066|NCT01846663|Drug|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
169067|NCT00104858|Drug|Cyclosporine|Given PO
169068|NCT01846663|Drug|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
169069|NCT01846676|Behavioral|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
169070|NCT01846689|Drug|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
168441|NCT01853124|Drug|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
168442|NCT01853137|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
168443|NCT01853150|Device|rTMS Motor cortex|
168444|NCT01853150|Device|rTMS Supplementary motor area|
168445|NCT01853163|Procedure|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing routine hip or knee replacement who had received Gadolinium-containing contrast agents in the past.
168446|NCT01855516|Drug|Heparin|
168447|NCT00105703|Behavioral|Case management using advanced nurse practitioners|
168448|NCT01855529|Drug|Ropivacaine in one arm and placebo (NaCl) in the other arm|
168449|NCT01855542|Other|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
168450|NCT01855542|Other|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
168451|NCT01855555|Drug|sedation with propofol|When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.
Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported.
168452|NCT01855568|Procedure|Single-dose Methotrexate|Participants in the "single-dose protocol" group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14.
168453|NCT01855568|Procedure|Two-dose methotrexate protocol|Participants in the "two-dose protocol" group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment.
168454|NCT01855581|Drug|pediatric sedation (propofol, ketamine, etc)|Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.
Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively.
172957|NCT00108199|Behavioral|Problem-Solving Training|
172958|NCT01878565|Drug|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
172959|NCT01878578|Drug|Eslicarbazepine acetate|Tablets containing ESL 600 mg
172960|NCT01878578|Drug|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
172961|NCT01878578|Drug|Placebo|Tablets containing matching placebo
173255|NCT01899417|Device|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
173256|NCT01899430|Drug|liraglutide|
173257|NCT01899430|Drug|metformin|
173258|NCT01899443|Other|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
173259|NCT01899456|Device|Catheter-based renal denervation|
173260|NCT00110084|Drug|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
173261|NCT01899469|Procedure|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
173262|NCT01899469|Procedure|Transcutaneous Electrical Neurological Stimulation|Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)
20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
173263|NCT01899482|Other|Manual Lymphatic Drainage|
173264|NCT01899482|Behavioral|Education|Behavioral education.
173265|NCT01901601|Drug|Topical Anesthesia|
173266|NCT01901601|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
172643|NCT01872728|Drug|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
172644|NCT01872741|Procedure|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
172645|NCT01872741|Procedure|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
172646|NCT01875224|Drug|Tacrolimus|Standard administration of tacrolimus
172647|NCT01875237|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
172648|NCT01875237|Drug|Melphalan|140 mg/m2 by vein on Day -2.
172649|NCT01875237|Drug|Alemtuzumab|50 mg by vein on Day -1.
172650|NCT01875237|Procedure|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
172651|NCT01875237|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
172652|NCT01875237|Drug|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
172653|NCT01875237|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
172654|NCT01875237|Procedure|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 106/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
172962|NCT01878604|Other|Gene analysis|Gene analysis
172963|NCT01878617|Radiation|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
172964|NCT01878617|Drug|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
172965|NCT01878617|Drug|Cisplatin|ROA: IV
172966|NCT01878617|Drug|Vincristine|ROA: IV
172967|NCT01878617|Drug|Vismodegib|ROA: Orally (PO)
172968|NCT00108199|Behavioral|Work-Related Social Skills Training|
172969|NCT01878617|Drug|Pemetrexed|ROA: IV
172346|NCT01880281|Other|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
172347|NCT01880294|Drug|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
172348|NCT01880307|Drug|Azathioprine|
172349|NCT01880307|Drug|Infliximab|
172350|NCT01880307|Drug|Prednisolon|
172351|NCT00002059|Drug|Inosine pranobex|
172352|NCT00108355|Drug|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
172353|NCT01880320|Drug|CD0271 0.3% / CD1579 2.5%|
172354|NCT01880320|Drug|CD0271 0.1% / CD1579 2.5%|
172355|NCT01880320|Drug|Topical Gel Vehicle|
172356|NCT01880333|Other|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
172357|NCT01880346|Dietary Supplement|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
172358|NCT01880346|Dietary Supplement|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
172359|NCT01880359|Drug|Cisplatin|
172360|NCT01880359|Radiation|Radiotherapy|
172361|NCT01880359|Drug|Placebo|
172362|NCT01880359|Drug|Nimorazole|
172363|NCT01882465|Device|1Day Acuvue DEFINE (Vivid)|Lenes to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
172057|NCT01876784|Drug|placebo|300 mg (3 x 100 mg tablets) will be dosed orally, once daily
172058|NCT01876797|Drug|ticagrelor/prasugrel|
172059|NCT01876810|Drug|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
172060|NCT00108030|Procedure|Partial Body-weight supported Treadmill Training|
172061|NCT01876810|Drug|Placebo|One lactose pill twice a day for two weeks.
172062|NCT01876823|Drug|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
172063|NCT01876823|Drug|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
172064|NCT01876836|Device|i-gel|i-gel placed after induction
172065|NCT01876836|Device|C-LMA|placed after induction
172066|NCT01876849|Drug|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
172067|NCT01876862|Other|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
172068|NCT01876875|Dietary Supplement|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
172069|NCT01876875|Dietary Supplement|Usual diet|The patients of this group were randomized to continue their usual diet
172070|NCT01876901|Procedure|Delayed coloanal anastomosis (ACAD)|Delayed coloanal anastomosis ACAD Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.
After surgical resection, the colon is exteriorized through the anus and attached to the buttock.
By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation
172071|NCT00002055|Drug|Pentamidine isethionate|
172072|NCT00108030|Procedure|PBWST + Power training|
172073|NCT01876901|Procedure|ACAI Group (coloanal anastomosis Immediate)|After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.
In the absence of fistula, the patient will reoperation for stoma closure of its branch
176212|NCT01918787|Device|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
176213|NCT01918800|Behavioral|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
176214|NCT01918800|Behavioral|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
176215|NCT01918813|Drug|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
176216|NCT01918826|Device|TENS|
176217|NCT00112177|Drug|Itopride Hydrochloride|
176218|NCT01918839|Device|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
176219|NCT01918839|Device|Restylane-L|Restylane-L injected into wrinkle treatment area
176220|NCT01918852|Drug|Capecitabine|
176221|NCT01918852|Drug|Teysuno|
176222|NCT01918852|Drug|Bevacizumab|
176223|NCT01918865|Drug|ISIS-PTP1BRx|
176224|NCT01918865|Drug|Placebo|
176525|NCT01914770|Drug|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
176526|NCT01914770|Drug|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
176527|NCT01914783|Other|ultrafine particles|exposure to ultrafine particles
176528|NCT01914783|Other|ultrafine particles and ozone|exposure to ultrafine particles and ozone
176529|NCT01914783|Other|clean air|Exposure to clean air.
175903|NCT01888874|Drug|Placebo|
175904|NCT01888887|Other|Cetaphil Daily Facial Cleanser|
175905|NCT01888900|Drug|Asunaprevir and Daclatsvir|
175906|NCT01888900|Drug|Asunaprevir, daclatsvir, peginterferon, ribavirin|
175907|NCT01888939|Other|Walking on a Treadmill|
175908|NCT01888939|Other|Sedendary Activities Only|
175909|NCT01888952|Drug|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
175910|NCT01888952|Drug|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
175911|NCT00109317|Drug|Raptiva (efalizumab)|
175912|NCT01888965|Drug|Dovitinib|All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.
175913|NCT01888978|Drug|Gem-OX|
175914|NCT01888978|Drug|Gem-5FU|
175915|NCT01888978|Drug|Gem-Tax|
175916|NCT01888978|Drug|Modified FOLFOX-6|
176225|NCT01918865|Drug|daily OAD (metformin and/or sulfonylurea)|
176226|NCT01918878|Drug|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
176227|NCT01918891|Behavioral|Nurse Practitioner Only|
176228|NCT00112190|Drug|Itopride Hydrochloride|100 mg tid
176229|NCT01918891|Behavioral|Nurse Practitioner + Health Coach|
176230|NCT01921283|Device|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
175578|NCT01883297|Biological|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
175579|NCT01883297|Drug|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
175580|NCT01883310|Device|sham transcranial direct current stimulation+TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
175581|NCT01883310|Device|real transcranial direct current stimulation+TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
175582|NCT01883323|Drug|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
175583|NCT01883323|Drug|Fludarabine|i.v., 25mg/m2 per day for 5 days
175584|NCT00108615|Drug|Pioglitazone|
175585|NCT01883323|Biological|Tumor-Infiltrating Lymphocytes|i.v., 1x10^10 - 1.6x10^11 cells
175586|NCT01883323|Biological|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
175587|NCT01883349|Procedure|Kidney Transplant|Kidney Transplant Surgery
175588|NCT01883362|Drug|Midostaurin (PKC412)|Midostaurin (PKC412) 50mg twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
175589|NCT01883362|Other|Standard of Care|Standard of Care is not defined per protocol. The investigator will prescribe based on the commonly used medications given in the post SCT setting.
175590|NCT01883375|Behavioral|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
175591|NCT01883375|Behavioral|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
175917|NCT01888978|Drug|Ox-Tax|
175918|NCT01888978|Drug|FOLFIRI|
171495|NCT01925248|Dietary Supplement|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
171496|NCT01925261|Drug|TPX-100 50mg|
171497|NCT01925261|Drug|TPX-100 100mg|
171498|NCT01925261|Drug|TPX-100 200mg|
171499|NCT00112645|Drug|methylprednisolone|
171500|NCT01925261|Drug|TPX-100 20mg|
171501|NCT01925261|Drug|Placebo|
171502|NCT01925274|Drug|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
171503|NCT01925274|Drug|irinotecan|90 minutes IV infusion of irinotecan 180mg/m^2 on days 1 and 15 of each cycle
171504|NCT01925274|Drug|Cetuximab|120 minute IV infusion of cetuximab 400mg/m^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
171505|NCT01925274|Drug|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m^2 on days 1 and 15 of each cycle
171506|NCT01925287|Dietary Supplement|curcumin|500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
171507|NCT01925300|Drug|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
171508|NCT01925300|Drug|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
171509|NCT01925300|Drug|Concor 5mg 2T and Crestor 20 mg 1Tab|
171822|NCT01881932|Device|Acupuncture using Seirin® needles|Participants will receive acupuncture weekly until the end of chemotherapy.
Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion.
171823|NCT00002061|Drug|Inosine pranobex|
171824|NCT00108446|Drug|fentanyl|
171825|NCT01873781|Drug|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
171826|NCT01873794|Device|Bright white light|
171827|NCT01873794|Device|Dim red light|
171828|NCT01873807|Drug|IDA|Idarubicin: 15mg/m2/d: -8->-6d
171189|NCT01929824|Other|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
171190|NCT01929837|Device|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
171191|NCT01929837|Device|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
171192|NCT01929837|Device|sham E-field navigated rTMS|
171193|NCT01929837|Device|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
171194|NCT01929850|Procedure|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
171195|NCT00112437|Dietary Supplement|Calcium Carbonate|Patient who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
171196|NCT01922193|Drug|Recombinant Human Follitropin Alfa|for injection
171197|NCT01922206|Behavioral|TRACK Intervention|TRACK Intervention
3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
171198|NCT01922219|Behavioral|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
171199|NCT01922245|Device|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
171200|NCT01922258|Drug|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
171201|NCT01922271|Drug|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
171202|NCT01922271|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
171203|NCT01922271|Drug|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
171510|NCT00112645|Procedure|allogeneic bone marrow transplantation|
171511|NCT01925313|Drug|CJ-30044|20.51mg a day,PO,QD
171512|NCT01925313|Drug|TALION TAB. 10mg|10mg a day,PO,BID
170546|NCT00113022|Drug|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
170547|NCT01931202|Drug|Escitalopram|
170871|NCT01926613|Behavioral|Supported Employment|Supported Employment is an evidence based vocational rehabilitation program
170872|NCT01926626|Drug|Nicotine Patch|Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
170873|NCT01926626|Drug|Moclobemide|Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)
170874|NCT01926639|Biological|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
170875|NCT01926652|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.
Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.
170876|NCT01926665|Drug|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
170877|NCT00002101|Drug|Clarithromycin|
170878|NCT00112710|Drug|cisplatin|
170879|NCT01926665|Drug|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
170880|NCT01926678|Other|Swedish massage therapy|
170881|NCT01926678|Other|Light touch therapy|
170882|NCT01926730|Other|Restriction diet|Selected food items will be limited in the participants diet
170883|NCT01926743|Procedure|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|1.5mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
170884|NCT01926756|Procedure|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
170885|NCT01926756|Procedure|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
170886|NCT01929200|Drug|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
170237|NCT01928264|Behavioral|Physical activity|
170238|NCT01928290|Drug|Irinotecan|
170239|NCT01928290|Drug|Trastuzumab|
170240|NCT01928290|Drug|Oxaliplatin|
170241|NCT00112827|Genetic|cytogenetic analysis|Correlative studies
170242|NCT01928290|Drug|Leucovorin|
170243|NCT01928290|Drug|Fluorouracil|
170548|NCT01931215|Other|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
170549|NCT01931215|Other|TAP-block with ropivacaine and clonidine|
170550|NCT01931228|Procedure|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
170551|NCT01931228|Procedure|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
170552|NCT01931241|Drug|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
170553|NCT01931267|Behavioral|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
170554|NCT01931267|Behavioral|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
170555|NCT01931280|Behavioral|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
170556|NCT01931293|Dietary Supplement|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
170557|NCT00002104|Drug|Thalidomide|
170558|NCT00113022|Drug|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
170559|NCT01931306|Drug|Afatinib|BIBW2992 low to medium dose once daily
169932|NCT01845740|Drug|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
169933|NCT01845740|Drug|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
169934|NCT01848145|Drug|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of >= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE >= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
169935|NCT01848158|Device|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
170244|NCT01928316|Drug|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
170245|NCT01928316|Drug|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
170246|NCT01928329|Drug|Exenatide (Bydureon®)|
170247|NCT01928329|Drug|Placebo|
170248|NCT01928342|Drug|Coenzyme A|Coenzyme A 400mg per day
170249|NCT01928342|Drug|Placebo|Capsule without coenzyme A.
170250|NCT01928368|Drug|AMG 282|Single dose either subcutaneously or intravenously on day 1.
170251|NCT01928368|Drug|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
170252|NCT00002102|Drug|Trimetrexate glucuronate|
170253|NCT00112827|Drug|cyclophosphamide|Given IV
170254|NCT01928381|Drug|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
170255|NCT01928381|Drug|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
170256|NCT01928381|Drug|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
170257|NCT01928394|Biological|Nivolumab|
169635|NCT01832532|Drug|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
169636|NCT01832545|Other|Aquatic Exercise|
169637|NCT01832545|Behavioral|Educational Program|Control Group
169638|NCT01832558|Drug|Eplerenone|
169639|NCT01832558|Drug|Placebo|
169640|NCT00000289|Drug|Ondansetron|
169641|NCT00002007|Drug|Sargramostim|
169642|NCT00103376|Drug|bicalutamide|
169643|NCT01832571|Drug|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
169644|NCT01845168|Other|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
169645|NCT01845168|Device|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
169646|NCT01845168|Device|Computer-alert|
169647|NCT01845181|Drug|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
169936|NCT01848158|Device|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
169937|NCT01848171|Drug|L-thyroxine|
169938|NCT01848184|Device|PARIETEX™ Composite Ventral Patch for ventral hernia repair|
169939|NCT01848197|Drug|paclitaxel|
169940|NCT01848210|Drug|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
169941|NCT01848210|Drug|Placebo|Coumarin / troxerutin placebo-matching tablets
169354|NCT01849874|Drug|Physician's choice chemotherapy|Patients will receive one of the following chemotherapies as determined by the physician:
Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)
Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)
Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
169355|NCT01849887|Biological|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
169356|NCT01849887|Drug|Placebo|Placebo
169648|NCT01845181|Drug|Placebo|1 or 2 or 3 capsules of placebo.
169649|NCT01845194|Drug|Codeine|Treatment period 2:
5 mg Codeine once
169650|NCT00104741|Radiation|radiation therapy|
169651|NCT01845194|Drug|Midazolam|Treatment period 1:
0.2 mg Midazolam 3x
Treatment period 2:
1 mg Midazolam once
169652|NCT01845194|Drug|Pravastatin|Treatment period 2:
5 mg Pravastatin once
169653|NCT01845194|Drug|Torsemide|Treatment period 1:
2.5 mg Torsemide 3x
Treatment period 2:
0.25 mg Torsemide once
169654|NCT01845194|Drug|Talinolol|Treatment period 1:
50 mg Talinolol 3x
Treatment period 2:
2.5 mg Talinolol once
169655|NCT01845194|Drug|Caffeine|Treatment period 1:
50 mg Caffeine 3x
169656|NCT01845194|Drug|Metoprolol|Treatment period 1:
5 mg Metoprolol 3x
169657|NCT01845220|Drug|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
169658|NCT01845220|Drug|Placebo|80% acetone
169659|NCT01845246|Device|Prospective TDM Arm of colistin|
169660|NCT01845259|Drug|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
169661|NCT00002020|Drug|Zidovudine|
169662|NCT00104754|Drug|liposomal SN-38|
169663|NCT01845259|Drug|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
169664|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
169665|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
169071|NCT01846702|Drug|Placebo|Given as a SC injection.
169072|NCT01846702|Drug|LY3084077|Given as a SC injection.
169073|NCT01846715|Biological|Implantation of SRC|
169074|NCT01846728|Drug|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
169075|NCT01846741|Device|M106 VNS Therapy System|
169076|NCT01846767|Other|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton & Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
169077|NCT01846780|Procedure|PTA & stenting|PTA & stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
169078|NCT00104858|Drug|Mycophenolate Mofetil|Given PO
169079|NCT01846793|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
169080|NCT01846806|Drug|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
169081|NCT01846832|Drug|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
169082|NCT01846832|Drug|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
169357|NCT00105079|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg po bid
169358|NCT00105235|Procedure|Liver transplant|Occurs at study entry
169359|NCT01851993|Drug|Ondansetron|
169360|NCT01851993|Drug|Placebo|0.9% saline
169361|NCT01852006|Device|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
169362|NCT01852019|Drug|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
169363|NCT01852019|Drug|Prasugrel|Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.
Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.
168755|NCT01851187|Behavioral|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
168756|NCT01851200|Drug|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
168757|NCT00105196|Drug|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
168758|NCT01843673|Radiation|image-guided adaptive radiation therapy|Undergo IGART
168759|NCT01843686|Device|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
168760|NCT01843686|Other|Placebo Saline Gel and Usual and Customary Standard of Care|
168761|NCT00104650|Genetic|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
168762|NCT01843699|Drug|Topiramate flexible dosage|
168763|NCT01843699|Drug|Placebo matching tablets|
168764|NCT01843699|Behavioral|4-session gambling cognitive restructuring|
168765|NCT01843725|Drug|capecitabine|escalation dose of capecitabine continuously
168766|NCT01843725|Drug|aflibercept|Intravenous 6mg/kg every 3 weeks
168767|NCT01843725|Drug|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
168768|NCT01843738|Radiation|Radiation therapy|
168769|NCT01843738|Drug|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
168770|NCT01843751|Drug|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
168771|NCT01843764|Device|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
168772|NCT00104663|Drug|Quinacrine|
168773|NCT01843777|Behavioral|Standard-of-Care|the standard of care in audiologic practice
168774|NCT01843777|Behavioral|Treatment|motivational interviewing
173267|NCT01901614|Procedure|LALAK|A "dovetail" shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.
The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
173268|NCT01901614|Procedure|IEK|A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.
In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
173269|NCT01901614|Drug|Retrobulbar Block or General Anesthesia|
173270|NCT01901614|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
168455|NCT01855594|Drug|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
168456|NCT01855594|Drug|Placebo|placebo tablet, 6 week course of oral administration
168457|NCT01855607|Other|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
168458|NCT00002032|Drug|Rifabutin|
168459|NCT00105716|Behavioral|Telephone behavioral education|
168460|NCT01855607|Other|placebo cream|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
168461|NCT01855633|Device|Traditional Theta burst stimulation (TBS)|
168462|NCT01855633|Device|Modified TBS rTMS|
168463|NCT01855633|Device|Sham rTMS|
168464|NCT01855646|Other|Structured Sign Out Form|
168465|NCT01855672|Device|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
168466|NCT01855685|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene
168467|NCT01855698|Other|Observation|
172970|NCT01878617|Drug|Gemcitabine|ROA: IV
172971|NCT01878617|Other|Aerobic Training|
172972|NCT01878617|Other|Neurocognitive Remediation|
172973|NCT01878630|Device|Remote Patient Management|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:
weighing scale (Seca 861 with bluetooth, seca gmbh & co. kg.)
blood pressure device (UA767PBT with bluetooth, A&D Ltd.)
ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)
patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)
help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)
at center site:
- electronic patient record (eHealth connect 2.0, T-Systems International)
172974|NCT01878630|Other|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
172975|NCT01881295|Dietary Supplement|High dose potassium gluconate|
172976|NCT01881295|Dietary Supplement|Low dose potato|
172977|NCT01881295|Dietary Supplement|Medium dose potato|
172978|NCT01881295|Dietary Supplement|High dose potato|
172979|NCT00108407|Behavioral|Twelve Step Facilitation Therapy|
172980|NCT01881295|Dietary Supplement|High dose French fries|
172981|NCT01881295|Dietary Supplement|Basal diet control|
172982|NCT01881308|Drug|TNF inhibitors|
172983|NCT01881308|Drug|Synthetic DMARD(s)|
172984|NCT01881308|Drug|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
173271|NCT00110292|Behavioral|Parent-completed Ages & Stages Questionnaires|
173272|NCT01901614|Drug|Topical Anesthesia|
173273|NCT01901614|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
173274|NCT01901640|Drug|DA-8159 (Udenafil)|
173275|NCT01901653|Drug|SC16LD6.5|
172655|NCT01875237|Drug|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade > 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
172656|NCT00002053|Drug|Pentamidine isethionate|
172657|NCT00107939|Drug|Licarbazepine|
172658|NCT01875237|Drug|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
172659|NCT01875237|Behavioral|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
172660|NCT01875250|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
172661|NCT01875250|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
172662|NCT01875250|Drug|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
172663|NCT01875263|Drug|Cloxacilin|2g/4 hours i.v., 5 days
172664|NCT01875263|Drug|Cloxacillin|2g/4h 14 days Standard therapy
172665|NCT01875263|Drug|Levofloxacin|500 mg v.o./24h, 9 days
172666|NCT01875289|Procedure|obturator nerve block|
172667|NCT01875315|Other|Diagnostic Cardiac Imaging|
172668|NCT00107952|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
172669|NCT01877967|Dietary Supplement|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
172670|NCT00108147|Procedure|Circuit Training|
172671|NCT01877967|Dietary Supplement|placebo|
172074|NCT01876927|Other|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
172364|NCT01882465|Device|SEED Eye Coffret 1-Day UV Rich Make|Lenes to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
172365|NCT01882465|Device|Ticon Cosmetic Daily Black|Lenes to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
172366|NCT01882491|Drug|Placebo|Solution for subcutaneous injection
172367|NCT00108537|Drug|bupropion and transdermal patch|
172368|NCT01882491|Drug|gevokizumab|Solution for subcutaneous injection
172369|NCT01882504|Drug|gevokizumab|
172370|NCT01882517|Dietary Supplement|Yogurt that contains plant stanol esters|
172371|NCT01882517|Dietary Supplement|Placebo yogurt|
172372|NCT01882530|Drug|Paracetamol|
172373|NCT01882530|Drug|Nefopam|
172374|NCT01882530|Drug|Ketoprofen|
172375|NCT01882530|Drug|Morphine|
172376|NCT01882543|Drug|AQX-1125|Synthetic SHIP1 activator
172377|NCT01882543|Drug|Placebo|Double blind placebo capsule
172378|NCT00002062|Drug|Spiramycin|
172379|NCT00108537|Drug|transdermal patch and nicotine inhaler|
172380|NCT01882556|Drug|onabotulinumtoxinA|
172381|NCT01882556|Drug|Placebo|
172382|NCT01882595|Other|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
172383|NCT01882595|Other|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
176530|NCT01914796|Drug|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
176531|NCT00111761|Biological|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
176532|NCT01914796|Drug|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
176533|NCT01914809|Other|samples blood|
176534|NCT01914809|Other|biopsy placentaire|
176535|NCT01914822|Drug|methylphenidate hydrochloride|
176536|NCT01914822|Drug|Sugar pill (placebo)|
176537|NCT01914835|Behavioral|Motivational Chess|The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).
The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions).
176538|NCT01914848|Other|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
176539|NCT01914848|Other|Control Group|A routine care discharge planning with the social service
176540|NCT01914874|Behavioral|Mindfulness Meditation|
176824|NCT01920061|Drug|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m^2
176825|NCT01920061|Drug|PF-05212384|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
176826|NCT01920061|Drug|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m^2
176827|NCT01920061|Drug|PF-05212384|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
176828|NCT01920061|Drug|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
176829|NCT01920074|Drug|Nitroglycerin Ointment 0.4%|
176830|NCT01920087|Drug|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
176231|NCT01921283|Drug|no- BIS sensor attachment|
176232|NCT01921296|Drug|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
176233|NCT01921309|Device|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
176234|NCT01921309|Device|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
176235|NCT00112359|Drug|AZLI 75 mg three times a day (TID)|
176236|NCT01921322|Device|Pump|
176237|NCT01921335|Drug|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
176238|NCT01921335|Drug|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
176239|NCT01921335|Drug|Trastuzumab|6 mg/kg IV every 3 weeks
176240|NCT01921348|Device|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
176241|NCT01921348|Device|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
176242|NCT01921361|Drug|Levobupivacaine|Intrathecal 3ml (15 mg)
176243|NCT01921361|Drug|Dexmedetomidine|Intrathecal 3 microgram (diluted 1/10, 0.3 ml)
176541|NCT01917201|Procedure|Non-IVUS group|The randomization on groups was completed in accordance with stents to be implanted: "Xience Prime"/"Xience V", "Promus Element", "Resolute Integrity", "Biomatrix Flex", "Nobori", "Orsiro". In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used.
176542|NCT00002093|Drug|Doxorubicin hydrochloride|
176543|NCT00112021|Drug|pramlintide acetate|
176544|NCT01917214|Other|Sutent: Observational Study|Sutent oral therapy
176545|NCT01917227|Behavioral|Video|
175919|NCT01888978|Drug|Tax-Iri|
175920|NCT01888991|Other|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
175921|NCT01889004|Drug|Dexmedetomidine|Escalating concentrations until loss of responsiveness
175922|NCT00109330|Biological|Combined diphtheria, tetanus, acellular pertussis vaccine|
175923|NCT01918358|Drug|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
175924|NCT01918358|Drug|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
175925|NCT01918358|Drug|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
175926|NCT01918371|Drug|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
175927|NCT01918384|Drug|NPC-14|NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.
An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.
After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14
175928|NCT01918384|Drug|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
175929|NCT00112125|Device|OPTIMIZER System|
175930|NCT01918397|Drug|Levofloxacin|Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4benzoxazine-6-carboxylic acid hemihydrate.
175931|NCT01918397|Drug|Optimized background regimen (OBR)|For this study "OBR" will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses.
175932|NCT01918410|Device|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
175933|NCT01918410|Device|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
175934|NCT01918423|Behavioral|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
176244|NCT01921361|Drug|Dexmedetomidine|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)
171829|NCT01873807|Radiation|TBI|TBI: 4.5 Gy/d, -5d, -4d
171830|NCT01873807|Drug|CTX|CY:60mg/kg/d, -3d, -2d
171831|NCT01873807|Drug|VP-16|VP-16: 15mg/kg, -2d, -1d
171832|NCT01873820|Dietary Supplement|Calcium ascorbate|
171833|NCT01873820|Dietary Supplement|Ascorbic acid|
171834|NCT01873833|Drug|capecitabine|Given PO
171835|NCT00002052|Drug|Ampicillin sodium|
171836|NCT00107731|Drug|quetiapine fumarate|
171837|NCT01873833|Drug|cyclophosphamide|Given PO
171838|NCT01873833|Drug|lapatinib ditosylate|Given PO
171839|NCT01873833|Biological|trastuzumab|Given IV
171840|NCT01873833|Other|laboratory biomarker analysis|Correlative studies
171841|NCT01873859|Drug|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
171842|NCT01873872|Dietary Supplement|Theralac probiotic|
171843|NCT01873872|Dietary Supplement|Culturelle probiotic|
171844|NCT01873872|Other|placebo|
171845|NCT01873885|Drug|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
171846|NCT01873885|Drug|Experimental: Single IV Infusion Vasomera (PB1046)|
171847|NCT00107731|Drug|lithium|
172144|NCT01876992|Drug|Metformin|
172145|NCT01877005|Drug|Ruxolitinib|
172146|NCT01877018|Behavioral|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
172147|NCT01877031|Device|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
172148|NCT01877031|Device|Ultrasound|Standard of Care - Ultrasound guided intervention
171513|NCT01925339|Device|Test (immediate restoration)|Test (immediate restoration)
171514|NCT01925339|Device|Control: delayed restoration|Control: delayed restoration
171515|NCT01925352|Drug|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
171516|NCT01925365|Dietary Supplement|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
171517|NCT01927887|Device|lymphotrophic superparamagnetic nanoparticles (LSN MRI).|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
171518|NCT01927900|Dietary Supplement|HMO|
171519|NCT00112827|Radiation|total marrow irradiation|Undergo irradiation
171520|NCT01927900|Dietary Supplement|Glucose|
171521|NCT01927913|Drug|SPD602|32, 50 or 75 mg/kg/day BID, capsule
171522|NCT01927913|Drug|Deferasirox|Per approved country specific label
171523|NCT01927926|Dietary Supplement|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
171524|NCT01927926|Dietary Supplement|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
171525|NCT01927952|Procedure|Kirschner wire|Surgical fixation utiliziing Kirschner wire
171526|NCT01927952|Procedure|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
171527|NCT01927952|Procedure|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
171528|NCT01927965|Drug|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
171529|NCT01927991|Behavioral|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
171530|NCT00112827|Drug|melphalan|Given IV
171848|NCT01873937|Radiation|Red LED|Phototherapy with red LED on temporomandibular area
170887|NCT01929200|Drug|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
170888|NCT01929213|Drug|Udenafil|Udenafil is administered
170889|NCT01929213|Drug|Bosentan|Bosentan is administered
170890|NCT00112879|Procedure|anti-cytokine therapy|
170891|NCT01929213|Drug|Udenafil/Bosentan|Udenafil and Bosentan are administered
171204|NCT01922271|Drug|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
171205|NCT01922271|Drug|Salbutamol|Used as resuce medication
171206|NCT00112437|Drug|Placebo|Placebo to MK0822 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
171207|NCT01922284|Biological|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
171208|NCT01922284|Biological|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
171209|NCT01922284|Biological|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
171210|NCT01922284|Biological|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
171211|NCT01922297|Other|Day Treatment MDFT-HIV|MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
171212|NCT01922297|Other|Day Treatment SAU|Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall & Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
171213|NCT01922310|Behavioral|Communication intervention|The intervention is a modification of current standard practice procedures for requesting consent for donation.
The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours.
171214|NCT01922336|Biological|SB2|IV infusion
171215|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
170560|NCT01923753|Device|Sham Aerosure|Deactivated but identical Aerosure HFAO device
170561|NCT00002099|Drug|Lentinan|
170562|NCT00112554|Other|placebo|Given IV
170563|NCT01923766|Drug|Cytotoxic T lymphocytes (CTLs).|This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.
Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated.
170564|NCT01923805|Device|Vitagel|Vitagel
170565|NCT01923818|Drug|rivaroxaban|orally active direct factor Xa inhibitor
170892|NCT01929226|Biological|ETI-204|Monoclonal Antibody
170893|NCT01929226|Biological|Placebo|Placebo comparator
170894|NCT01929239|Drug|Anti-PSMA Designer T Cells|
170895|NCT01929252|Drug|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
170896|NCT01929252|Drug|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
170897|NCT01929265|Drug|Bendamustine|INDUCTION PHASE
Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):
Rituximab: 375 mg/sqm iv, day 1*
Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice
Repeat cycles every 28 days for a total of 4 cycles
*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.
CONSOLIDATION PHASE
Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):
Rituximab: 375 mg/sqm iv day 1
Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice
Rituximab two monthly doses
Rituximab: 375 mg/sqm iv week 24 and 28
170898|NCT01929278|Drug|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
170899|NCT01929278|Other|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
170258|NCT01928394|Biological|Ipilimumab|
170259|NCT01928407|Drug|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
170260|NCT01928407|Drug|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
170261|NCT01928420|Drug|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
170262|NCT01928420|Drug|Placebo|Subjects with Alzheimer's Disease placebo comparator
170263|NCT01930617|Procedure|Burr hole surgery with various drainage techniques|Surgical technique
Continuous irrigation and drainage
Passive subdural drain
Active subgaleal drain
170264|NCT01930630|Device|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
170265|NCT01930643|Device|EMS|HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
170266|NCT00112957|Biological|recombinant vaccinia-NY-ESO-1 vaccine|iv
170566|NCT01923818|Drug|Aspirin|non-steroidal anti-inflammatory drugs
170567|NCT01923818|Drug|placebo|
170568|NCT01923831|Drug|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
170569|NCT01923831|Drug|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
170570|NCT01923844|Drug|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached > 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
170571|NCT01923857|Drug|Androxal 25 mg|
170572|NCT01923870|Drug|Androxal 25 mg|
170573|NCT00112567|Drug|fludarabine phosphate|
169942|NCT00104975|Drug|tacrolimus|
169943|NCT01848236|Dietary Supplement|Vitamin D2|Ergocalciferol vitamin D2
169944|NCT01848236|Dietary Supplement|Vitamin D3|Cholecalciferol vitamin D2
169945|NCT01848262|Procedure|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
169946|NCT01848262|Procedure|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
169947|NCT01848275|Device|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
169948|NCT01848275|Device|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
169949|NCT01850784|Dietary Supplement|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
169950|NCT00002027|Drug|Diclazuril|
169951|NCT00105157|Drug|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
169952|NCT01850784|Dietary Supplement|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
169953|NCT01850810|Other|Experimental Study Product|
170267|NCT01930669|Other|Gravitational sympathetic stimulus|Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.
Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.
MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique.
170268|NCT01930682|Drug|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
169666|NCT01845285|Device|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
169667|NCT01845298|Drug|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
169668|NCT01845311|Device|ReZolve2 Scaffold|
169669|NCT01847651|Other|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
169670|NCT01847651|Other|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
169954|NCT01850810|Other|Control Study Product|
169955|NCT01850823|Drug|placebo|
169956|NCT01850823|Drug|Mometasone Nasal Spray|
169957|NCT01850823|Drug|Mometasone nasal spray|
169958|NCT01850836|Procedure|repetitive transcranial magnetic stimulation|
169959|NCT01850849|Drug|LEO 39652 cream|
169960|NCT01850849|Drug|cream vehicle|
169961|NCT01850862|Other|Collective group exercise program in patients with KOA|
169962|NCT00105170|Drug|hCBE-11|
169963|NCT01850862|Other|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
169964|NCT01850875|Behavioral|Eye-Movement-Desensitization-Reprocessing|
169965|NCT01850888|Drug|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
169966|NCT01850888|Drug|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
169967|NCT01850888|Drug|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000).
169364|NCT01852032|Radiation|Computed Tomography and Mammography and Tomosynthesis|Computed Tomography and Mammography and Tomosynthesis
169365|NCT01852045|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
169366|NCT01852058|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
169367|NCT01852071|Genetic|EFS-ADA transduced CD34+ cells from the bone marrow|Eligible subjects will undergo bone marrow harvest under general anesthesia. The marrow will be processed to isolate CD34+ cells and transduced with the EFS-ADA lentiviral vector. If sufficient cells are obtained, the subjects will undergo marrow cytoreduction with busulfan (4 mg/kg). If the transduced CD34+ final cell product meets all release criteria, the cells will be infused intravenously. PEG-ADA enzyme replacement therapy will be discontinued at day +30. After discharge from the hospital, the subject will be seen for interval history and examination by either their home physician, the principal investigator or a clinical investigator and have blood drawn at months 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 21, and 24.
169368|NCT01852097|Behavioral|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|The general approach to the intervention is the following:
Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.
Give feedback to individuals on their questionnaire responses.
Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.
Provide advice on overcoming practical barriers.
Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.
Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation.
169369|NCT00105235|Procedure|Immunosuppression withdrawal|Beginning no earlier than Year 1
169370|NCT01852110|Drug|MK-7622|MK-7622 capsule
169371|NCT01852110|Drug|Placebo|Matching placebo to MK-7622 capsule
169372|NCT01852110|Drug|AChEI|One of the following AChEIs, as prescribed by the participant's primary care physician: donepezil, 10 mg total daily dose administered orally; rivastigmine, 9.5 or 13.3 mg/24 hours administered by transdermal patch or 6-12 mg total daily dose administered orally; galantamine, 16-24 mg total daily dose administered orally
169373|NCT01852123|Device|High-sensitivity troponin I assay|
169671|NCT01847664|Drug|Rifamycin SV-MMX® 400 mg b.i.d.|
169672|NCT01847664|Drug|Rifamycin SV-MMX® 600 mg t.i.d.|
169673|NCT01847664|Drug|Rifamycin SV-MMX® Placebo|
169674|NCT01847677|Drug|Bevacizumab|
169675|NCT01847677|Drug|Paclitaxel|
169676|NCT01847677|Drug|Carboplatin|
169677|NCT01847690|Drug|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
169678|NCT00104936|Radiation|stereotactic radiosurgery|
168775|NCT01843790|Drug|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
169083|NCT01846832|Drug|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is < 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is > or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
169084|NCT01846845|Device|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
169085|NCT01846845|Device|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
169086|NCT01846871|Drug|Tivozanib|
169087|NCT01849289|Drug|insulin degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
169088|NCT01849289|Drug|insulin glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
169089|NCT01849302|Dietary Supplement|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
169090|NCT01849315|Behavioral|AKIDS II|Physically active intervention
169091|NCT00105027|Drug|intravitreal triamcinolone injection|4 mg
169092|NCT01849341|Drug|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
169093|NCT01849341|Drug|Roflumilast 500 mcg per day|
169094|NCT01849367|Device|Eldith Neuroconn tDCS device|
169095|NCT01849380|Drug|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
169096|NCT01849380|Drug|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
169097|NCT01849393|Other|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
168468|NCT01857882|Other|Decision Support Workshop|Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.
Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities
Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system
Social worker (30 mins): values clarification exercise
Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience
168469|NCT00002034|Drug|Zidovudine|
168470|NCT00106041|Behavioral|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
168471|NCT01857895|Drug|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
168472|NCT01857921|Drug|Pravastatin 20mg/day for 12 months after randomization|Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:
Test group:
Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization
Control group:
Pravastatin 20mg daily for 12 months after randomization
168473|NCT01857921|Drug|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:
Test group:
Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization
Control group:
Pravastatin 20mg daily for 12 months after randomization
168474|NCT01857934|Drug|cyclophosphamide|Given intravenously (IV)
168776|NCT01843790|Drug|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
168777|NCT01843803|Other|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
168778|NCT01843803|Other|attention control|Patients will view a brief healthy living video on an iPad
168779|NCT01843829|Drug|Oxaliplatin|
168780|NCT01843829|Drug|Capecitabine|
168781|NCT01843829|Drug|Carboplatin|
168782|NCT01846143|Biological|pBCAR3-phosphopeptide|
168783|NCT01846143|Biological|pIRS2-phosphopeptide|
168784|NCT01846143|Biological|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
173276|NCT01901666|Drug|Growth Hormone|All GH deficient patients with bone age <14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.
Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy
173277|NCT01901679|Drug|Celebrex|200 mg PO BID
173278|NCT01901692|Radiation|TACE+EBRT|Trans-arterial chemoembolization plus external beam radiation therapy
173279|NCT01901692|Drug|Sorafenib|Sorafenib 800 mg/day orally
173280|NCT01901705|Drug|Indigo Naturalis|Topical ointment of Indigo or matching placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
173281|NCT01901705|Drug|Placebo|
173282|NCT00002080|Drug|Rifabutin|
173283|NCT00110292|Behavioral|Clinic-based distribution of children's books|
173284|NCT01901731|Procedure|transjugular coil embolisation of pelvic veins|
173285|NCT01901731|Procedure|endovenous treatment of leg varicose veins|
173286|NCT01901744|Procedure|Cataract Surgery|
173287|NCT01894230|Genetic|Reporting for SLCO1B1*5 allele at randomization|Reporting of genetic test results to patient and provider at randomization
173288|NCT01894230|Genetic|Reporting for SLCO1B1*5 allele at the end|Usual care recommendations provided to patient and provider at randomization. Genotyping results provided at the end of study.
173289|NCT01894230|Genetic|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele
173290|NCT01894243|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
173291|NCT01894256|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
173292|NCT01894269|Drug|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
168475|NCT01857934|Drug|topotecan|Given IV
168476|NCT01857934|Biological|hu14.18K322A|Given IV
168477|NCT01857934|Procedure|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
172672|NCT01878006|Genetic|OPRM1 AA118|
172673|NCT01878006|Drug|Morphine|
172674|NCT01878006|Drug|Placebo|
172985|NCT01881321|Behavioral|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
172986|NCT01881334|Biological|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
172987|NCT01881347|Dietary Supplement|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
172988|NCT01881347|Dietary Supplement|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
172989|NCT01881360|Other|Gluten-free diet|A diet that is free of the gluten component
172990|NCT00108420|Drug|Prazosin|
172991|NCT01881360|Other|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
172992|NCT01881373|Other|CHL program|Multiple component environmentally focused program designed with community engagement.
172993|NCT01881386|Device|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
172994|NCT01881399|Device|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
172995|NCT01881399|Other|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
172996|NCT01881399|Procedure|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
172997|NCT01881412|Drug|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family recieves specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
172998|NCT01873170|Device|IUD insertion|
172999|NCT01873170|Device|subdermal contraceptive implant insertion|
173000|NCT01873183|Other|Goal directed fluid therapy|
172384|NCT01882608|Other|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
172385|NCT01882621|Drug|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
172675|NCT01878006|Genetic|OPRM1 GX118|
172676|NCT01878058|Other|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
172677|NCT01878084|Other|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
172678|NCT01878084|Other|empty extraction socket|Extraction socket will be left empty
172679|NCT01878097|Behavioral|Green Dot Bystander Intevention|Intervention allocated at the school level
172680|NCT01878110|Behavioral|COMB|
172681|NCT00108147|Procedure|Cardiac Rehabilitation|
172682|NCT01878123|Biological|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
172683|NCT01878123|Other|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
172684|NCT01878136|Drug|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
172685|NCT01878162|Other|Exercise|
172686|NCT01878175|Behavioral|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
172687|NCT01878188|Drug|BC-819/PEI|Intravesical instillation
172688|NCT01878188|Drug|BCG Vaccine|intravesical instillations
172689|NCT01878201|Drug|Fimasartan|Fimasartan 30 mg
172690|NCT01878201|Drug|Valsartan|Valsartan 80 mg
176831|NCT01920087|Drug|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
176832|NCT01920113|Drug|Dexmedetomidine - remifentanil group|
176833|NCT00112242|Biological|Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 500 mcg Melan-A analog peptide, 500 mcg + NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
176834|NCT01920113|Drug|Propofol - remifentanil group|
176835|NCT01920126|Drug|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
176836|NCT01920126|Drug|Saline|
176837|NCT01920139|Procedure|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
176838|NCT01920139|Procedure|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
176839|NCT01920139|Other|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
176840|NCT01902823|Behavioral|Services from a Nurse Navigator|Services from a Nurse Navigator
176841|NCT01902836|Biological|Conventional treatment plus DLE|Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:
Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month
177112|NCT01913366|Behavioral|CM-PST|
177113|NCT01913366|Behavioral|SG-PST|
177114|NCT01915823|Drug|Dymista vehicle|
177115|NCT01915836|Other|web-based video game (Quit IT)|
177116|NCT00111839|Drug|Matuzumab + Pemetrexed|matuzumab 1600mg given i.v. every 3 weeks plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity
177117|NCT01915836|Behavioral|Questionnaires|
177118|NCT01915836|Behavioral|Evaluation Interview|
177119|NCT01915849|Drug|LIK066|LIK066 15 mg, 50 mg and 150 mg
176546|NCT01917240|Other|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
176547|NCT01917253|Device|Standard Device for peripheral vein cannulation|
176548|NCT01917253|Device|Long Catheters for peripheral vein cannulation|
176549|NCT01917279|Drug|Docetaxel plus Capecitabine|Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
176550|NCT01917279|Drug|Capecitabine|Capecitabine 500 mg/m2 three times daily on days 1-21 of each 3-week cycle
176551|NCT01917279|Drug|Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3 week cycle
176552|NCT01917292|Procedure|One-Stage Full-Mouth Disinfection|Basic oral hygiene instructions
Dental extractions will be performed (only in cases of teeth that could not be saved)
Standard cycle of supragingival ultrasonic scaling and polishing
Scaling and root planning after the administration of local anesthesia, four quadrants in one session
Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets
176553|NCT01917292|Procedure|Periodontal care|Basic oral hygiene instructions
Standard cycle of supragingival ultrasonic scaling and polishing
176554|NCT00112034|Drug|Methotrexate|
176555|NCT01917305|Device|platform-shifted implant|
176556|NCT01917318|Drug|Iloperidone|Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.
During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)
176557|NCT01917318|Drug|Placebo|During 8 weeks subjects will receive oral placebo
176558|NCT01917331|Drug|Beclometasone/Formoterol/Glycopyrrolate|
176842|NCT01902836|Biological|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
176843|NCT01902849|Other|blood sampling for IL measurement|Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:
T0- before the induction of anesthesia (venous cannula insertion time)
T1- after induction but before starting surgery
In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml
In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%
T2, T3- at 2 and 24 hours after surgery
172456|NCT01882842|Device|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
172457|NCT01882868|Drug|aflibercept AVE0005|Pharmaceutical form:Concentrated solution for infusion Route of administration: Intravenous
172458|NCT00108563|Drug|Citalopram or Placebo|
172459|NCT01882881|Other|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
172460|NCT01882881|Other|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide ~33% of calories from fat. The SFA (~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (~9g).
172461|NCT01882881|Other|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide ~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing ~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
172756|NCT01875445|Drug|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
172757|NCT01875445|Drug|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
172758|NCT01875471|Device|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
172759|NCT01875471|Device|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
172760|NCT01875497|Dietary Supplement|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
172761|NCT01878227|Drug|Fenofibrate 200mg|Fenofibrate 200mg per day
172762|NCT01878240|Procedure|EVAR without coils embolization/ Coils embolization during EVAR|
172763|NCT01878266|Radiation|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
172764|NCT01878266|Radiation|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
172149|NCT01877044|Dietary Supplement|NAXUS|
172150|NCT00108043|Procedure|FES-evoked functional upright gait|
172151|NCT01877044|Dietary Supplement|Placebo|
172152|NCT01877057|Dietary Supplement|Saturn|
172153|NCT01877070|Behavioral|assessments|
172154|NCT01877083|Drug|Lenvatinib|Starting dose of 24 mg orally, once per day
172155|NCT01877096|Behavioral|Motivational Interviewing|A brief motivational interviewing session
172156|NCT01877096|Behavioral|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
172157|NCT01877122|Device|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
172158|NCT01877122|Device|Marlex® Mesh Implant|
172159|NCT01879839|Dietary Supplement|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
172160|NCT01879852|Behavioral|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
172161|NCT01879852|Behavioral|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
172162|NCT01879865|Other|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
172163|NCT01879865|Other|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
172462|NCT01882881|Other|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at ~34-35% and the SFA will match that of the Almond Diet at ~8-9%. The fiber content of this diet will be highest (~35g); cholesterol will remain ≤200 mg/day.
172463|NCT01882894|Device|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
172464|NCT01882894|Other|Faux orthosis|Foam cut out
171849|NCT01873937|Radiation|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
171850|NCT01873937|Radiation|LASER|Phototherapy with LASER INFRARED on temporomandibular area
171851|NCT01873950|Drug|Ranolazine|
171852|NCT01873950|Drug|Dofetilide|
171853|NCT01873950|Drug|Verapamil|
171854|NCT01873950|Drug|Quinidine sulfate|
171855|NCT01873950|Drug|Placebo|
171856|NCT01873989|Drug|Testosterone replacement|
171857|NCT01873989|Other|Waitlist control|
171858|NCT00107731|Drug|divalproex|
171859|NCT01876433|Drug|Placebo|
171860|NCT01876446|Other|Laboratory Biomarker Analysis|Correlative studies
171861|NCT01876446|Drug|Pegylated Irinotecan|Given IV
171862|NCT01876446|Other|Pharmacological Study|Correlative studies
171863|NCT01876459|Other|MRI|
171864|NCT01876459|Procedure|lumbar puncture|
171865|NCT01876459|Behavioral|neuropsychological tests|
171866|NCT01876472|Behavioral|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
171867|NCT01876485|Behavioral|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
171868|NCT00108017|Drug|MK0507A, dorzolamide hydrochloride (+) timolol maleate|
171869|NCT01876485|Behavioral|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
171870|NCT01876498|Procedure|Xiaflex surgery|Xiaflex surgery
171216|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
171217|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
171218|NCT01924780|Device|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
171219|NCT01924780|Device|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
171220|NCT01924780|Device|NEMOS Device sham stimulation 10 minutes|
171221|NCT01924793|Drug|DAS181-F02 Dry Powder in Bulk|Administered via DPI
171222|NCT01924793|Drug|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
171531|NCT01928004|Device|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
171532|NCT01928004|Procedure|Conventional reline|conventional reline of the existing mandibular complete denture
171533|NCT01928030|Biological|recombinant human hyaluronidase|Given SC
171534|NCT01928030|Other|laboratory biomarker analysis|Correlative studies
171535|NCT01928030|Other|pharmacological study|Correlative studies
171536|NCT01928043|Drug|Curcumin|
171537|NCT01928056|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
171538|NCT01928069|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
171539|NCT01928082|Drug|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
171540|NCT01928108|Behavioral|iPhone Application|The iPhone application "waterlogged" will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week.
171541|NCT00112827|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
171542|NCT01930344|Device|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
171543|NCT00112918|Drug|Leucovorin calcium|Administered as a 200 mg/m^2 infusion over 2 hours.
171544|NCT01930357|Biological|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
170900|NCT01929278|Other|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril [approximately 2 cm x 2 cm]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
170901|NCT00112879|Procedure|antiangiogenesis therapy|
170902|NCT01929291|Biological|Boostrix|Single intramuscular injection
170903|NCT01929291|Other|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
170904|NCT01929304|Other|Survey|
170905|NCT01929317|Drug|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
170906|NCT01931657|Drug|Placebo prior to Mirena insertion|
170907|NCT01931670|Drug|Elagolix|Elagolix Dose 1 for 6 month Treatment Period, Elagolix Dose 2 for the 6 month Treatment Period
170908|NCT01931670|Other|placebo|Placebo for 6 Month Treatment Period
171223|NCT00112632|Procedure|neoadjuvant therapy|
171224|NCT01924806|Device|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
171225|NCT01924806|Device|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
171226|NCT01924819|Drug|Epirubicin + cisplatin + 5-fluorouracil|Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).
If it is preferred by the clinician and patient, capecitabine (Xeloda) may be used in place of 5-fluorouracil: Capecitabine 625 mg/m2 oral tablet twice daily, days 1-21.
171227|NCT01924819|Radiation|Preoperative chemoradiotherapy|Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).
Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks.
171228|NCT01924819|Procedure|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers [Siewert Type II and Siewert Type III] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
171229|NCT01924832|Drug|dimethyl fumarate|tablet
171230|NCT01924845|Drug|BMN 701|
170574|NCT01923883|Procedure|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
170575|NCT01923883|Device|Echoendoscope Olympus GF-UCT240|
170576|NCT01923896|Behavioral|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
170577|NCT01923896|Drug|d-cycloserine (DCS)|
170578|NCT01923896|Drug|Placebo|lactose powder
170579|NCT01926028|Biological|NDV-3A|0.5mL injection IM
170580|NCT01926028|Biological|NDV-3|0.5mL injection IM
170581|NCT01926028|Biological|Placebo|aluminum hydroxide and buffered saline
170582|NCT01926041|Other|Smoking cessation clinics|
170583|NCT01926041|Behavioral|Coach-assisted lifestyle change|
170584|NCT01926054|Drug|Acthar gel|
170909|NCT01931683|Drug|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
170910|NCT01931683|Device|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
170911|NCT01931696|Device|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
170912|NCT01931696|Device|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
170913|NCT01931709|Radiation|fludeoxyglucose F 18|Undergo FDG PET
170914|NCT00113087|Drug|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
170269|NCT01930682|Procedure|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
170270|NCT01930682|Procedure|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
170271|NCT01930708|Drug|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
170272|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 60 degrees.
170273|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
170274|NCT01930734|Drug|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
170275|NCT01930734|Drug|Normal Saline|Normal Saline solution 0.9% Placebo Arm
170276|NCT01930747|Drug|rocuronium|measure effect on laparoscopic workspace
170277|NCT00112957|Procedure|adjuvant therapy|additional therapy
170278|NCT01930747|Drug|Sevoflurane|1 MAC sevoflurane inhalation is given
170279|NCT01930747|Drug|remifentanyl|remifentanyl is given in infusion
170280|NCT01930760|Behavioral|Standard Medical Training Educational|Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.
The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour.
170281|NCT01923285|Device|Control Spinal Cord Stimulation Device|
170282|NCT01923298|Drug|Estradiol|
170283|NCT00112515|Procedure|quality-of-life assessment|
170284|NCT01923311|Drug|EVG|Elvitegravir (EVG) tablets or tablets for oral suspension (if unable to swallow) will be administered orally
170585|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU— Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
169968|NCT01850888|Procedure|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum > 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum >2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
169969|NCT01850901|Procedure|Renal sympathetic denervation|
169970|NCT01850927|Procedure|Remote ischaemic preconditioning|
169971|NCT01850927|Procedure|Control|
169972|NCT01850940|Drug|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
169973|NCT01843413|Radiation|stereotactic radiosurgery|Undergo SRS
169974|NCT01843413|Procedure|quality-of-life assessment|Ancillary studies
170285|NCT01923311|Drug|Background regimen|Background regimen may consist of the following RTV-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
170286|NCT01923324|Behavioral|Physician telephone consultation|Pain physician support for family physician treating patient
170287|NCT01923324|Behavioral|Usual family physician care|Usual family physician care without telephone consultation with pain physician
170288|NCT01923337|Drug|irinotecan hydrochloride|Given IV
170289|NCT01923337|Drug|alisertib|Given PO
170290|NCT01923350|Behavioral|Weight Reduction Intervention|The weight trial intervention components were:
Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).
Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.
Print mailings/emailings
3 Get Ready e-messages in the four weeks before the weight intervention began
Pedometers and program guides. (IVR users received printed activity logs with their program guides.)
Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals.
170291|NCT01923350|Behavioral|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
170292|NCT01923350|Behavioral|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
169679|NCT01847703|Procedure|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
169680|NCT01847703|Procedure|Abdominal surgery|Current gold standard
169681|NCT01847742|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|
169682|NCT01847755|Drug|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
169683|NCT01847768|Biological|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
169684|NCT01847768|Procedure|Bronchoalveolar Lavage|
169685|NCT01847768|Drug|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
169686|NCT01847768|Procedure|Nasal Lavage|
169687|NCT01847768|Procedure|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
169688|NCT01847768|Procedure|Bronchial Brushings|
169689|NCT00104949|Biological|trastuzumab|
169690|NCT01847768|Procedure|Lung Mucosal Biopsy|
169691|NCT01847768|Procedure|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer & glycerol negative control.
169692|NCT01847768|Procedure|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
169693|NCT01847768|Procedure|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
169975|NCT01843413|Procedure|cognitive assessment|Ancillary studies
169976|NCT01843426|Drug|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
169977|NCT01843439|Dietary Supplement|Magnesium|
169098|NCT01849406|Drug|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
169099|NCT01849406|Drug|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
169100|NCT01849419|Drug|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
169374|NCT01852136|Device|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
169375|NCT01852136|Device|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
169376|NCT01852136|Device|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
169377|NCT01844752|Drug|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
169378|NCT01844752|Drug|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
169379|NCT01844752|Drug|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
169380|NCT01844765|Drug|nilotinib|Nilotinib will be administered at 230mg/m2 ,twice daily for up to 66 cycles (1 cycle = 28 days). Drug will be supplied in 50mg, 150mg,and 200mg capsules. Dose administration will be rounded to the nearest 50mg dose (to a maximum dose of 400mg).
169381|NCT01844778|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112mg via TOBI® Podhaler, inhaled twice a day for 28 days
169382|NCT01844778|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution administered via nebuliser, 300mg twice a day for 28 days
169383|NCT01844778|Drug|Colistimethate|Colistimethate 1 or 2 million units or other administered via nebulizer one to three times a day for 28 days or continuously dependent on local treatment practise
169384|NCT01844791|Drug|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
169385|NCT01844791|Drug|Platinum|Platinum is given as standard chemotherapy each cycle
169386|NCT00104715|Drug|goserelin acetate|
169387|NCT01844791|Drug|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
169388|NCT01844804|Biological|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
169389|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
168785|NCT01846156|Drug|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics & Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
168786|NCT01846169|Behavioral|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
168787|NCT01846182|Drug|Duloxetine|serotonin norepinephrine reuptake inhibitor
168788|NCT01846182|Drug|Pregabalin|alpha-2-alpha subunit calcium channel ligand
168789|NCT01846182|Drug|Placebo|Placebo
168790|NCT01846195|Device|CM 1500|
168791|NCT00104845|Biological|mouse gp100 plasmid DNA vaccine|
168792|NCT01846208|Drug|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
168793|NCT01846208|Drug|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
168794|NCT01846221|Drug|Clonidine or Fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At onset of stage breakthrough pain one arm of patients will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume and the second group will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
169101|NCT01849419|Drug|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
169102|NCT00105040|Drug|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
169103|NCT01849419|Drug|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
169104|NCT01849445|Procedure|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
169105|NCT01849445|Other|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
169106|NCT01849458|Device|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
169107|NCT01849471|Other|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
168478|NCT01857934|Procedure|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
168479|NCT01857934|Drug|cisplatin|Given IV
168480|NCT01857934|Drug|etoposide|Given IV
168481|NCT00106054|Drug|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
168482|NCT01857934|Drug|doxorubicin|Given IV
168483|NCT01857934|Drug|vincristine|Given IV
168484|NCT01857934|Drug|busulfan|Given IV
168485|NCT01857934|Drug|melphalan|Given IV
168486|NCT01857934|Biological|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
168487|NCT01857934|Biological|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
168488|NCT01860183|Drug|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
168489|NCT01860196|Drug|Meditoxin|
168490|NCT00106340|Drug|vildagliptin|
168491|NCT01860196|Drug|Normal saline|
168492|NCT01860209|Procedure|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
168493|NCT01860222|Procedure|SR|
168494|NCT01860222|Procedure|PLAT|
168495|NCT01860235|Drug|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
168496|NCT01860235|Drug|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
168497|NCT01860235|Drug|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
173001|NCT01873196|Behavioral|Receive extra oil|
173002|NCT01873196|Behavioral|Receives behavior changed messages on CSB package|
173003|NCT01873222|Device|OFDI-guided PCI & IVUS|Assessment by IVUS at post-PCI
Assessment by OFDI at a 8-month follow-up
173004|NCT01873222|Device|IVUS-guided PCI & OFDI|Assessment by OFDI at post-PCI
Assessment by OFDI at a 8-month follow-up
173293|NCT01894282|Procedure|Manual Therapy|Manual Therapy Arm
173294|NCT01894282|Procedure|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
173295|NCT01894295|Dietary Supplement|Placebo|Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
173296|NCT01894295|Dietary Supplement|Vitamin D analogue|1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
173297|NCT00109837|Drug|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC < 3,000
173298|NCT01894308|Drug|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
173299|NCT01894334|Drug|Ulinastatin|
173300|NCT01894334|Drug|Tranexamic acid|
173301|NCT01894334|Drug|Edaravone|
173302|NCT01894347|Other|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
173303|NCT01894360|Drug|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
173304|NCT01894373|Drug|Adoptive Immunotherapy|Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
173305|NCT01894373|Biological|CIK|
173306|NCT01894386|Drug|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
173307|NCT01894386|Drug|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
173308|NCT00109837|Drug|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
172691|NCT01878214|Behavioral|Targeted messaging|6 targeted mailed messages and 6 booster text messages
172692|NCT00108147|Procedure|Flexibility and toning|
172693|NCT01878214|Behavioral|Standard messaging|1 informational letter
172694|NCT01878227|Drug|Coenzyme A|Coenzyme A 400mg per day
172695|NCT01880814|Behavioral|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
173005|NCT01873248|Drug|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
173006|NCT00107640|Behavioral|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
173007|NCT01873274|Dietary Supplement|MK-7 containing capsule|
173008|NCT01873274|Dietary Supplement|basic yogurt enriched with MK-7|
173009|NCT01873274|Dietary Supplement|nutrient-enriched yogurt with MK-7|
173010|NCT01873300|Procedure|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
173011|NCT01873313|Drug|Ropivacaine|
173012|NCT01873326|Drug|Paclitaxel|
173013|NCT01873326|Drug|Ifosfamide|
173014|NCT01873326|Drug|Cisplatin|
173015|NCT01873326|Drug|Mesna|
173016|NCT01873326|Drug|Bleomycin|
173017|NCT00107653|Drug|Copegus|1000-1200mg po daily for 48 weeks
173018|NCT01873326|Drug|Etoposide|
173019|NCT01873339|Drug|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
177120|NCT01915849|Drug|Placebo|
177121|NCT01915875|Other|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
177122|NCT01915888|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
177123|NCT01915901|Drug|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
177124|NCT01915901|Drug|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
177125|NCT01915901|Drug|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
177126|NCT01915914|Drug|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
177127|NCT00111852|Drug|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
177128|NCT01915927|Drug|MSC-AFP|
177129|NCT01915940|Drug|Bimatoprost Ocular Insert|
177130|NCT01915940|Drug|Timolol|0.5% solution
177131|NCT01915940|Drug|Placebo drops|placebo topical eye drops
177132|NCT01915940|Device|Placebo Ocular Insert|ocular insert without any active drug
177133|NCT01915966|Dietary Supplement|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
177432|NCT01904032|Drug|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
177433|NCT01904045|Other|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
177434|NCT01904045|Other|tacrolimus Prograf|intake of Prograf twice daily for 3 months
177435|NCT01904058|Drug|LUM001|
177436|NCT01904058|Drug|Placebo|
177437|NCT01904058|Drug|Ursodeoxycholic Acid|
176844|NCT00110383|Behavioral|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
176845|NCT01902862|Drug|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
176846|NCT01902862|Drug|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
176847|NCT01902875|Drug|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
176848|NCT01902875|Biological|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
176849|NCT01902888|Device|GORE® VIABAHN® Endoprosthesis|
176850|NCT01902901|Genetic|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
176851|NCT01902901|Genetic|Carrier status testing|Carrier status testing
176852|NCT01902914|Procedure|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
176853|NCT01902927|Other|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
176854|NCT01902940|Other|Natural History|Assessment of natural history in IBM and CCFDN
176855|NCT00110396|Biological|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
176856|NCT01902953|Drug|Lymphoseek and VBD Sln dissection|See detailed description of study design
176857|NCT01902966|Drug|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
176858|NCT01902966|Behavioral|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
177134|NCT01915966|Dietary Supplement|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
177135|NCT01915979|Biological|Plasma rich in growth factors (PRGF)|
177136|NCT01915979|Drug|Celestone cronodose (Bethametasone)|
177137|NCT01915992|Other|blood samples|
172765|NCT01878266|Radiation|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
172766|NCT01878279|Other|Underlying medical illness|
172767|NCT01878292|Drug|Placebo|Dose matched placebo tablets, once per day, oral administration.
172768|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
172769|NCT00108160|Drug|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
172770|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
172771|NCT01878305|Device|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
172772|NCT01878318|Drug|methotrexate|stable dose
172773|NCT01878318|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
172774|NCT01878344|Drug|NAC|
172775|NCT01878344|Drug|Saline|
172776|NCT01878357|Drug|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
173076|NCT01899027|Drug|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
173077|NCT01899027|Drug|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
173078|NCT01899040|Device|neuromodulation for episodic migraine headache|
173079|NCT01899053|Drug|MLN0128 + MLN1117 Arm A|MLN0128 and MLN1117 will be administered in combination to subjects for 3 days each week.
173080|NCT01899053|Drug|MLN0128 + MLN1117 Arm B|MLN0128 and MLN1117 will be administered in combination to subjects for 3 days each week.
173081|NCT01899066|Drug|Lucentis, chemotherapy|Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.
chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
173082|NCT01899066|Drug|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
172465|NCT01882907|Drug|vildagliptin|vildagliptin 50mg bid for 16 weeks
172466|NCT01882907|Drug|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
172467|NCT01882920|Drug|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) <2.5 l/min/m2, stroke volume index (SVI) < 35 SVI ml/m2 and stroke volume variation (SVV)> 15%. In the case of CI <2.5 l/min/m2 and SVI <35 ml/m2 with SVV < 15%, an infusion with dopamine was initiated.
172468|NCT01882920|Drug|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
172469|NCT00108576|Drug|Divalproex|anticonvulsant; mood stabilizer
172470|NCT01874860|Drug|Hydrocortisone 1% cream|Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
172471|NCT01874860|Other|Sunscreen|Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
172472|NCT01874860|Other|Moisturizer|Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
172473|NCT01874860|Drug|Clindamycin|Recommended for daily use if rash returns (Topical cream)
172474|NCT01874860|Drug|Medrol-dose pack (Steroid)|Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
172475|NCT00107887|Drug|TST (tuberculin skin test)|Clinics will be trained in the use of TST for assessing exposure to TB
172476|NCT01874873|Drug|Anlotinib|
172477|NCT01874899|Device|RestoreSensor Neurostimulation|
172478|NCT01874938|Biological|LY2875358|Administered IV
172479|NCT01874951|Drug|Naltrexone|1 mg bid of naltrexone will be given to all patients regardless of study arm when they are receiving active drug.
172480|NCT01874951|Drug|Placebo capsule|
172481|NCT01874964|Behavioral|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
172777|NCT01878357|Drug|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
171871|NCT01876511|Drug|MK-3475|MK-3475 10 mg/kg every 14 days
172164|NCT01879878|Dietary Supplement|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
172165|NCT01879878|Dietary Supplement|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
172166|NCT00108342|Drug|Nicotine gum - 2 mg and 4 mg|
172167|NCT01879891|Other|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
172168|NCT01879904|Procedure|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
172169|NCT01879917|Drug|Liraglutide|
172170|NCT01879930|Drug|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
Oral intake during study period (4 weeks) once in the morning and once in the evening
The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100
172171|NCT01879930|Drug|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
Oral intake during study period (4 weeks) once in the morning and once in the evening
The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group
172172|NCT01879943|Device|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
172173|NCT01879943|Procedure|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
172174|NCT01879956|Other|Craft Activities|There is no intervention method used to perform the task.
172175|NCT01879956|Behavioral|OGI Method|metacognitive approach to assess executive functions.
172176|NCT01879969|Procedure|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
172177|NCT01882634|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
171545|NCT01930357|Biological|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
171546|NCT01930370|Drug|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
171547|NCT01930370|Drug|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
171548|NCT01930396|Drug|Tinzaparin|
171549|NCT01930396|Drug|Unfractionated Heparin|
171550|NCT01930396|Drug|Placebo (for Tinzaparin)|0.9% Normal Saline
171551|NCT01930396|Drug|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
171552|NCT01930409|Behavioral|Telephone Support and Coaching|The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:
Health Status
Medication Management
Activity/Exercise Prescription and Goal-Setting
Falls Prevention
Clarification of Appointments
Coordination of Post-Discharge Home Services
What To Do If a Problem Arises
171872|NCT01876524|Device|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
171873|NCT01876537|Device|Hardware wound healing|
171874|NCT01876537|Device|Usual Surgery|
171875|NCT01876550|Drug|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
171876|NCT01876550|Drug|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
171877|NCT01876550|Drug|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
171878|NCT01876563|Dietary Supplement|vitamin D|one tab 4000 IU/day vitamin D
171879|NCT00108017|Drug|Comparator: timolol maleate|
171880|NCT01876563|Dietary Supplement|placebo|one tab per day placebo
171881|NCT01876576|Other|Clear liquids|Clear liquids
171882|NCT01876576|Other|Low residue breakfast and lunch|Low residue
171883|NCT01876589|Device|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
171231|NCT01924858|Drug|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of [18F]-GSK2647544 and a PET scan.
171232|NCT01924858|Drug|[18F]GSK2647544 IV bolus|[18F]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
171233|NCT01924871|Drug|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
171234|NCT00112645|Biological|anti-thymocyte globulin|
171235|NCT01924871|Drug|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
171236|NCT01924897|Behavioral|Exercise training|
171237|NCT01924910|Dietary Supplement|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
171238|NCT01927393|Behavioral|telephone-based intervention|Receive telephone contacts
171239|NCT01927406|Drug|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
171240|NCT01927406|Drug|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
171553|NCT01930409|Behavioral|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
171554|NCT00002103|Drug|Leucovorin calcium|
171555|NCT00112918|Drug|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
171556|NCT01930422|Device|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
171557|NCT01930422|Device|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
171558|NCT01930435|Device|Sterile Humidification Device|
171559|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
170915|NCT01931709|Device|positron emission tomography|Undergo FDG PET
170916|NCT01931709|Device|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
170917|NCT01931709|Other|laboratory biomarker analysis|Correlative studies
170918|NCT01931722|Dietary Supplement|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
170919|NCT01931722|Behavioral|Strength training|Strength training will include a split-training program using all major muscle groups of the body on a three day "on", one day "off" protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions.
170920|NCT01931735|Procedure|Meniscectomy|Arthroscopic meniscectomy
170921|NCT01931735|Procedure|Arthroscopic Lavage|Arthroscopic Lavage
170922|NCT01931748|Drug|MELSMON|
170923|NCT01931748|Drug|UNCNT|
170924|NCT01931761|Drug|[C14] selumetinib (oral)|Single oral administration [C14] 75mg
170925|NCT00113087|Drug|Placebo|Participants will receive placebo
170926|NCT01931787|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
170927|NCT01931800|Biological|Sampling of blood|
170928|NCT01924299|Drug|Fluconazole|Administered orally
171241|NCT01927419|Drug|Nivolumab|
171242|NCT01927419|Drug|Ipilimumab|
171243|NCT01927419|Drug|Placebo|Matching nivolumab
171244|NCT01927445|Other|Practice based quality improvement toolkit|
171245|NCT01927458|Device|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
171246|NCT01927484|Drug|25 mg/week oral methotrexate tablets|
171247|NCT01927484|Drug|25mg/week oral placebo tablets|
170586|NCT01926106|Device|nIPPV|one of the twins was randomly allocated to nIPPV
170587|NCT01926106|Device|nCPAP|another of the twins was allocated to nCPAP
170588|NCT01926119|Device|Transcranial Magnetic Stimulation|
170589|NCT00112684|Other|pharmacological study|Correlative studies
170590|NCT01926132|Drug|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
170591|NCT01926132|Drug|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
170592|NCT01926158|Drug|Denosumb|Prefilled syringe of 1 mL denosumab solution
170593|NCT01926158|Drug|Placebo (for denosumab)|
170594|NCT01926171|Drug|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
170595|NCT01926184|Behavioral|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
170596|NCT01926184|Behavioral|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
170597|NCT01926197|Drug|Oxaliplatin|
170598|NCT01926197|Radiation|SBRT|
170599|NCT01926197|Drug|Irinotecan|
170600|NCT00112684|Other|laboratory biomarker analysis|Correlative studies
170601|NCT01926197|Drug|Leucovorin|
170602|NCT01926197|Drug|5FU|
170603|NCT01926210|Other|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
170604|NCT01926210|Other|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
170605|NCT01926223|Other|Home visiting|
170606|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
170293|NCT01923350|Behavioral|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
170294|NCT00112528|Biological|bevacizumab|
170295|NCT01923363|Drug|Piperacillin/Tazobactam Standard Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose.
170296|NCT01923363|Drug|Piperacillin/Tazobactam High Dose|Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
170297|NCT01923376|Drug|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
170298|NCT01923376|Drug|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
170299|NCT01923389|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
170300|NCT01923389|Drug|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
170607|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
170608|NCT01928797|Drug|Ephedrine and Phenylephrine|
170609|NCT01928810|Behavioral|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
170610|NCT01928823|Behavioral|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
170611|NCT01928823|Drug|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
170612|NCT01928849|Drug|Valproic Acid|"Intervention" patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.
170613|NCT01928849|Other|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
170614|NCT00112866|Procedure|therapeutic conventional surgery|Undergo tumor resection
170615|NCT01928862|Drug|Prepopik™ ½ sachet (9-12 years)|
170616|NCT01928862|Drug|Prepopik™ 1 sachet (9-12 years)|
169978|NCT01843439|Behavioral|Education for asthma action plan|
169979|NCT01843439|Behavioral|hot-lines for acute exacerbation of asthma|
169980|NCT01843439|Behavioral|Inhaler technique training|
169981|NCT01843452|Radiation|RADIOTHERAPY|External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.
Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).
Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV.
169982|NCT01843452|Biological|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
169983|NCT00104637|Drug|Placebo|25 mg po tid
169984|NCT01843452|Drug|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
169985|NCT01843452|Drug|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
169986|NCT01843465|Other|Maneuvers for documenting the disconnection|
169987|NCT01843478|Other|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
169988|NCT01843491|Biological|Ad-PfCA|Vaccine
169989|NCT01843504|Biological|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
169990|NCT01843504|Other|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
169991|NCT01843530|Drug|Berinert|
169992|NCT01843530|Drug|Clemastin|
170301|NCT01925534|Device|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
170302|NCT01925534|Device|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
170303|NCT01925547|Dietary Supplement|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
169390|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
169391|NCT01844817|Drug|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
169392|NCT01844817|Drug|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
169694|NCT01847768|Procedure|Spirometry|
169695|NCT01847781|Biological|Prevenar13|
169696|NCT01850277|Procedure|External electrical cardioversion (EEC)|The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.
If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented.
169697|NCT01850277|Drug|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% >95%
169698|NCT01850277|Procedure|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
169699|NCT01850303|Drug|Pemetrexed|
169700|NCT01850303|Drug|Gemcitabine|
169701|NCT01850303|Drug|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
169702|NCT00105144|Drug|Micafungin|IV
169703|NCT01850316|Radiation|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
169704|NCT01850329|Other|computed-assisted information program|
169108|NCT01851785|Behavioral|Decision Aid (DA) Intervention|Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called "AskMe3." The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?
169109|NCT01851798|Other|Home sleep test administered to all enrolled subjects|
169110|NCT01851824|Drug|acenocoumarol|4 mg single oral doses on Days 1 and 23
169111|NCT01851824|Drug|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
169112|NCT01851837|Other|Exercise time|Continuous training, Interval training
169113|NCT01851850|Drug|Opicapone|25mg or 50mg once per day
169114|NCT01851863|Drug|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
169115|NCT01851863|Drug|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
169116|NCT01851863|Drug|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
169117|NCT00105235|Drug|Tacrolimus|Oral immunosuppressant
169393|NCT01844830|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|
169394|NCT01844830|Drug|Placebo|
169395|NCT01844843|Device|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
169396|NCT01844856|Drug|Eravacycline|
169397|NCT00104715|Procedure|orchiectomy|
169398|NCT01844856|Drug|Ertapenem|
169399|NCT01844856|Drug|Placebo|Administered IV to maintain the blind.
169400|NCT01844869|Drug|omacetaxine mepesuccinate|
169401|NCT01844895|Drug|Abatacept|
168795|NCT01846221|Drug|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At onset of stage breakthrough pain one arm of patients will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine in 10 ml of volume and the second group will receive 100 mcg fentanyl and 12.5 mg bupivacaine in10 ml of volume.
168796|NCT01846221|Drug|Clonidine or fentanyl|
168797|NCT01846247|Other|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
168798|NCT01846247|Other|Standard care|
168799|NCT01846273|Drug|Ranibizumab|Intravitreal injections or 0.5 mg ranibizumab
168800|NCT01846273|Drug|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
168801|NCT01846273|Drug|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
168802|NCT00104858|Drug|Fludarabine Phosphate|Given IV
168803|NCT01846286|Behavioral|Questionnaires|Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
168804|NCT01846286|Other|Quantitative Sensory Testing|Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
168805|NCT01848860|Procedure|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
168806|NCT00105001|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
168807|NCT01848860|Biological|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
168808|NCT01848873|Drug|Amlodipine|amlodipine 5mg daily
168809|NCT01848873|Drug|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
168810|NCT01848873|Drug|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
168811|NCT01848886|Procedure|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
168812|NCT01848886|Procedure|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
173309|NCT01894386|Drug|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
173310|NCT01894386|Drug|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
173311|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 35 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Open-Label Extension: up to 35 Units per eye.
168498|NCT01860235|Drug|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
168499|NCT01860248|Drug|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
168500|NCT01860248|Drug|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
168501|NCT00106340|Drug|glimepiride|
168502|NCT01860261|Behavioral|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
168503|NCT01860274|Device|Mesh|
168504|NCT01860274|Procedure|Control|
168505|NCT01860287|Drug|Buprenorphine|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2, .4 mg) and placebo across 2 sessions.
168506|NCT01860287|Drug|Placebo|
168507|NCT01860300|Drug|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
168508|NCT01860300|Drug|placebo|
168509|NCT01860313|Behavioral|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
168510|NCT01860313|Behavioral|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
168511|NCT01860326|Drug|DEB025|DEB025 single oral dose
168512|NCT00106340|Drug|Metformin|
173020|NCT01873339|Drug|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
173021|NCT01873352|Procedure|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
173022|NCT01875900|Other|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
173023|NCT01875913|Behavioral|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
173312|NCT01896908|Other|Sodium restriction|Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.
The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis.
173313|NCT00110006|Biological|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
173314|NCT01896921|Drug|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
173315|NCT01896934|Drug|Sertraline|50-200mg daily
173316|NCT01896960|Drug|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
173317|NCT01896973|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
173318|NCT01896999|Drug|Brentuximab Vedotin|Given IV
173319|NCT01896999|Biological|Ipilimumab|Given IV
173320|NCT01896999|Other|Laboratory Biomarker Analysis|Correlative studies
177438|NCT01904071|Procedure|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
177439|NCT01904071|Procedure|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
177440|NCT01904071|Drug|IVMS (IV Morphine)|Intravenous Morphine
177441|NCT01904084|Device|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
177442|NCT00002082|Drug|Azithromycin|
177443|NCT00110487|Drug|ERB-041|
177444|NCT01904084|Device|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
177445|NCT01904097|Drug|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
177446|NCT01904097|Other|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
177447|NCT01904097|Other|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
177448|NCT01904110|Drug|Risedronate/Cholecalciferol combination(montly)|once a month
177449|NCT01904110|Drug|Risedronate/Cholecalciferol combination(weekly)|once a week
177450|NCT01904123|Drug|WP1066|Phase I starting dose: 3 mg/kg by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.
Phase II starting dose: Maximum tolerated dose from Phase I.
177451|NCT01904136|Drug|Melphalan|140 mg/m2 by vein on Day -7.
177452|NCT01904136|Drug|Fludarabine|40 mg/m2 by vein daily for four doses on Days -6 to -3.
177453|NCT01904136|Procedure|Expanded NK Cell Infusion|Phase I: Starting dose of NK cells 1x105/kg by vein on Day -2. Day +7 and Day +28 second and third NK infusions.
Phase II: Maximum tolerated dose from Phase I.
177454|NCT00110500|Genetic|hVEGF-A|
177765|NCT01907269|Behavioral|Video-based Intervention|Video clips delivered by DVD and Internet
177766|NCT01907282|Behavioral|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
177767|NCT01909596|Device|8° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 8°
177138|NCT00111852|Drug|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
177139|NCT01916005|Device|18F-FDG PET/CT|
177140|NCT01918163|Dietary Supplement|Pomegranate pills|
177141|NCT01918176|Drug|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
177142|NCT01918176|Drug|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
177143|NCT01918189|Behavioral|behavioral pain self-management intervention (VPMRC)|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
177144|NCT01918202|Drug|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
177145|NCT01918202|Drug|PF-02545920|The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.
This cohort is optional.
177146|NCT01918202|Drug|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
177147|NCT01918215|Device|ICD|
177148|NCT01918215|Device|ILR|
177149|NCT01918228|Behavioral|Lectures in scientific status on the back|Two lectures, a folder and possibility to contact health professional by telephone
177150|NCT00112099|Procedure|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
177151|NCT01918241|Drug|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
177152|NCT01918241|Drug|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
177153|NCT01918241|Drug|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
177154|NCT01918241|Drug|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
177455|NCT01904136|Procedure|Bone Marrow Transplant|Haploidentical bone marrow transplant on Day 0.
177456|NCT01904136|Drug|Mesna|10 mg/kg by vein on Day +3 and +4.
177457|NCT01904136|Drug|Cyclophosphamide|50 mg/kg by vein on Day +3 and +4.
173083|NCT01901367|Behavioral|exercise intervention|Receive exercise intervention
173084|NCT01901367|Other|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
173085|NCT01901367|Behavioral|counseling intervention|Receive phone counseling with a trained health coach
173086|NCT01901367|Other|quality-of-life assessment|Ancillary studies
173087|NCT01901367|Other|laboratory biomarker analysis|Correlative studies
173088|NCT01901367|Other|questionnaire administration|Ancillary studies
173089|NCT01901380|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|
173090|NCT01901393|Drug|IV ibuprofen|
173091|NCT01901393|Drug|Ketorolac|
173092|NCT00110266|Drug|Deferasirox|20 mg/kg/day over one year in patients with MDS
173093|NCT01901419|Drug|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
173094|NCT01901432|Drug|Givinostat|In Part A patients will treated in dose levels at the following daily doses of Givinostat:
50 mg b.i.d.,
100 mg b.i.d.;
150 mg b.i.d.,
200 mg b.i.d.;
150 mg t.i.d.;
200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.
In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
173095|NCT01901445|Behavioral|Educational action with focal group|
173096|NCT01901458|Device|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
173097|NCT01901458|Device|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
173381|NCT01894451|Procedure|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
173382|NCT01894464|Behavioral|Teacher led intervention|
173383|NCT01894477|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
173384|NCT01894477|Drug|Fludarabine Phosphate|Given IV
173385|NCT01894477|Other|Laboratory Biomarker Analysis|Correlative studies
172778|NCT01878370|Other|High risk|Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.
Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches.
172779|NCT01878370|Other|Best Practice|Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.
Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices.
172780|NCT00108160|Drug|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
172781|NCT01880931|Drug|Remifentanil|The effect site concentration of remifentanil
172782|NCT01880944|Other|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
172783|NCT01880957|Drug|Lithium|
172784|NCT01880957|Drug|Lamotrigine|
172785|NCT01880970|Other|starter infant formula with pro and prebiotics|
172786|NCT01880970|Other|Placebo comparator|
172787|NCT00108381|Behavioral|tailored cognitive behavior therapy|tailored psychological treatment
172788|NCT01880996|Other|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
172789|NCT01881009|Device|ePID Algorithm on an Android Platform with Remote Monitoring|Medtronic Overnight Closed-Loop System: Revel insulin pump, Enlite sensor, Minimed transmitter, ePID algorithm on an Android platform with remote monitoring.
172790|NCT01881022|Behavioral|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
172791|NCT01881035|Procedure|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
172792|NCT01881048|Dietary Supplement|Omega-3 fatty acid|Given PO
172793|NCT01881048|Drug|Celecoxib|Given PO
172178|NCT01882647|Drug|000-0551 Lotion|
172179|NCT01882647|Drug|Vehicle Lotion|
172482|NCT01874964|Behavioral|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
172483|NCT01874977|Behavioral|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
172484|NCT01874977|Behavioral|Educational materials|Will receive the educational booklet ("Be Active Your Way: A guide for Adults"; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment.
172485|NCT01874977|Behavioral|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
172486|NCT00107900|Drug|DU-176b|
172487|NCT01874990|Dietary Supplement|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
172488|NCT01874990|Dietary Supplement|low-salt diet|
172489|NCT01875003|Drug|Lebrikizumab|Lebrikizumab High sub-cutaneously (SC) every 4 weeks, Week 1-104 or Week 1-76
172490|NCT01875003|Drug|Lebrikizumab|Lebrikizumab Low SC every 4 weeks, Week 1-104 or Week 1-76
172491|NCT01875003|Drug|Placebo|Lebrikizumab Placebo SC every 4 weeks, Week 1-52 and then lebrikizumab High SC, Week 52-104 or Week 52-76; or Lebrikizumab Placebo SC every 4 weeks, Week 1-52 and then lebrikizumab Low SC, Week 52-104 or Week 52-76\n
172492|NCT01875016|Procedure|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
172493|NCT01875029|Device|sham-tDCS + back school|sham tDCS + back school
172494|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
172495|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
172496|NCT01877681|Procedure|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
172497|NCT01877681|Procedure|Active comparator|Usual care as specified in the PU practice guideline
172498|NCT01877694|Drug|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
171884|NCT01876589|Device|Xience Prime|Drug eluting metallic stent
171885|NCT01876602|Behavioral|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
171886|NCT01879358|Device|Drug-eluting stent|
171887|NCT01879371|Drug|Ibuprofen+caffeine FDC|oral dose
171888|NCT01879371|Drug|Ibuprofen (Nurofen Immedia®)|oral dose
171889|NCT00000295|Drug|Micronized Progesterone|
171890|NCT00002058|Drug|Clofazimine|
171891|NCT00108277|Behavioral|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
171892|NCT01879371|Drug|Ibuprofen (Brufen®)|oral dose
171893|NCT01879384|Device|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
171894|NCT01879397|Device|Research Ultrasound Exam|Collection of backscattered ultrasound data during non-invasive ultrasound exam
ARFI based images of the carotid artery and plaque
Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam.
172180|NCT00108550|Drug|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
172181|NCT01882660|Drug|Decitabine|
172182|NCT01882673|Behavioral|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
172183|NCT01882673|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
172184|NCT01882686|Other|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
172185|NCT01882699|Device|Cereve Sleep System|cerebral hypothermia
172186|NCT01882712|Drug|CD07805/47 Gel 0.5%|
172187|NCT01882712|Drug|CD07805/47 Gel Placebo|
172188|NCT01882725|Device|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
171560|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
171561|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
171562|NCT01930461|Biological|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
171563|NCT01930487|Dietary Supplement|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
171564|NCT01922934|Behavioral|Colorado Weigh|Group behavioral weight loss program
171565|NCT00112502|Drug|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
171566|NCT01922934|Dietary Supplement|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
171567|NCT01922934|Drug|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
171568|NCT01922934|Behavioral|Recreation center passes|1 year pass to a Denver recreation center
171569|NCT01922947|Behavioral|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
171570|NCT01922947|Behavioral|Active Control Condition|20-minute health counseling
171571|NCT01922960|Other|micro-imaging|micro-imaging
171572|NCT01922973|Other|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
171895|NCT01879410|Drug|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
171896|NCT01879410|Drug|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
171897|NCT01879410|Drug|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
171898|NCT01879410|Drug|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
171899|NCT01879423|Drug|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
171248|NCT00112749|Other|Clinical Assessment|Medical, psychiatric, and immune evaluation.
171249|NCT01927497|Procedure|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
171250|NCT01927497|Procedure|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
171251|NCT01927510|Behavioral|Early mobilisation|
171252|NCT01927523|Behavioral|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
171253|NCT01927523|Other|Match|An intensive math tutoring program.
171254|NCT01927536|Device|White LED Flashlight|white light setting
171255|NCT01927536|Device|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
171256|NCT01927549|Procedure|Immediate multivessel PCI|
171257|NCT01927549|Procedure|Culprit Lesion only PCI|
171258|NCT01927562|Device|Fractyl Duodenal Remodeling System|
171259|NCT00002101|Drug|Rifabutin|
171260|NCT00112892|Drug|irinotecan hydrochloride|
171573|NCT01922986|Device|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
171574|NCT01922986|Device|sham rTMS|20 minutes of sham rTMS stimulation
171575|NCT01922986|Behavioral|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
171576|NCT00002098|Drug|Didanosine|
170929|NCT01924312|Behavioral|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
170930|NCT01924325|Drug|Apixaban|orally active direct factor Xa inhibitor
170931|NCT01924325|Drug|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
170932|NCT01924325|Drug|Aspirin|a non-steroidal anti-inflammatory drug
170933|NCT01924325|Drug|placebo|
170934|NCT00112593|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
170935|NCT01924338|Device|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
170936|NCT01924338|Device|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
170937|NCT01924338|Procedure|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
170938|NCT01924351|Radiation|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis|
170939|NCT01924364|Device|Tissue Genesis Cell Isolation System™ (CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) will be used for comparison.
170940|NCT01924377|Procedure|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance >5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
170941|NCT01924377|Procedure|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
170942|NCT01924390|Device|Mineralized freeze-dried bone allograft alone|
170943|NCT01924390|Device|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
170944|NCT01924403|Procedure|Staple Closure|
170945|NCT00112593|Drug|cyclosporine|Given IV or PO
170617|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
170618|NCT01928862|Drug|Prepopik™ 1 sachet (13-16 years)|
170619|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
170620|NCT01928875|Device|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
170621|NCT01928875|Device|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
170622|NCT01928888|Drug|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
170623|NCT01928888|Drug|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
170624|NCT01928888|Drug|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
170625|NCT00112866|Other|pharmacological study|Correlative studies
170626|NCT01928901|Drug|administration of Sinupret|
170627|NCT01928901|Drug|administration of Bronchipret|
170628|NCT01928901|Drug|administration of Sinupret Placebo|
170629|NCT01928901|Drug|administration of Bronchipret Placebo|
170948|NCT01924416|Behavioral|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
170949|NCT01924416|Behavioral|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
170950|NCT01926769|Drug|Metformin|
170951|NCT01926782|Drug|Alirocumab|
170952|NCT01926782|Drug|placebo|
170953|NCT00112710|Drug|gemcitabine hydrochloride|
170954|NCT01926795|Procedure|Short leg cast|
170955|NCT01926795|Procedure|No Immobilization|
170956|NCT01926821|Drug|Sonifilan|Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
170957|NCT01926834|Drug|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
170304|NCT01925547|Dietary Supplement|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
170305|NCT01925560|Other|Agave Inulin|3x3 Latin square with 3 periods
170306|NCT01925560|Other|Placebo|control- 0 (zero) grams/day inulin
170307|NCT01925573|Device|Optune(NOVOTTF-100A)|
170308|NCT01925612|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
170309|NCT01925612|Drug|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
170310|NCT00112658|Drug|gemcitabine hydrochloride|
170311|NCT01925612|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
170312|NCT01925612|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
170313|NCT01925612|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
170314|NCT01925612|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
170315|NCT01925612|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
170316|NCT01925625|Biological|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
170317|NCT01925638|Drug|BAY86-9766|
170318|NCT01925638|Drug|Ketoconazole|
170319|NCT01925651|Radiation|No Bolus|no bolus use
170320|NCT01925651|Radiation|Alternate Bolus|0.5cm bolus use in alternate days
170321|NCT00112658|Drug|irinotecan hydrochloride|
170322|NCT01925651|Radiation|Continuous Bolus|0.5 cm bolus use in continuous days
170323|NCT01925664|Behavioral|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
170630|NCT01928914|Drug|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
169705|NCT01850342|Procedure|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
169706|NCT01850355|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
169707|NCT01850368|Radiation|Stereotactic ablative radiotherapy|The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by >48 hours.
At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy.
169993|NCT01843530|Drug|Cortisone acetate|
169994|NCT01845753|Other|Observation|Observation
169995|NCT00104806|Dietary Supplement|cholecalciferol|100 milligrams orally once a day for 28 days
169996|NCT01845766|Other|exercise rehabilitation|
169997|NCT01845779|Drug|DCF regimen|
169998|NCT01845792|Drug|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
169999|NCT01845792|Drug|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
170000|NCT01845805|Drug|oral azacitidine|
170001|NCT01845805|Other|Observation|
170002|NCT01845805|Drug|First-line chemotherapy after recurrence|After disease recurrence, subjects on both Arm A and Arm B will start on a first-line chemotherapy (such as abraxane or gemcitabine).
170003|NCT01845831|Drug|Sitagliptin + glargine|Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed
170004|NCT01845831|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
170005|NCT01845831|Drug|Metformin and sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
170006|NCT00104806|Drug|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
169402|NCT01847196|Device|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
169403|NCT01847209|Procedure|Video-Assisted Thoracic Surgery (VATS) wedge resection|
169404|NCT01847222|Biological|SANGUINATE™|PEG-bHb-CO
169405|NCT01847222|Drug|Normal Saline Solution|Placebo
169406|NCT01847235|Drug|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
169407|NCT01847261|Dietary Supplement|Soy Dairy Protein Blend|
169408|NCT00104910|Radiation|Internal Radiation Therapy|
169409|NCT01847261|Dietary Supplement|Positive Control (Dairy Whey Protein)|
169410|NCT01847274|Drug|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
169411|NCT01847274|Drug|placebo|
169412|NCT01847300|Behavioral|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
169413|NCT01847313|Drug|Liraglutide|Daily administration of liraglutide for 6 months
169414|NCT01847326|Drug|carboplatin|Given IV
169415|NCT01847326|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
169416|NCT01847326|Drug|fluorouracil|Given IV
169417|NCT01847326|Drug|hydroxyurea|Given PO
169708|NCT01850381|Drug|GM608|For GM608: 320 mg/dose reconstituted with bateriostatic saline, IV ( in the vein) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
For Placebo, matching volume of bacteriostatic saline, IV ( in the vein) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
169709|NCT01850394|Drug|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
169710|NCT01850394|Drug|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
169711|NCT01850407|Behavioral|Education Counseling|
169712|NCT01850420|Drug|IMC-1|
168813|NCT01848886|Procedure|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
168814|NCT01848886|Procedure|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
169118|NCT01851863|Drug|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
169119|NCT01851876|Device|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
169120|NCT01851915|Behavioral|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
169121|NCT01851915|Behavioral|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
169122|NCT01851941|Drug|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
169123|NCT01851954|Drug|Clarithromycin|IV clarithromycin infusion
169124|NCT01851967|Other|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
169125|NCT01851980|Other|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
169126|NCT01851980|Drug|Furosemide|40 mg and 120 mg
169127|NCT01851980|Drug|Placebo|0.9% saline
169128|NCT01844323|Other|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
169129|NCT00104689|Drug|capecitabine|
169130|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
169131|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
169132|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
169133|NCT01844336|Device|PBASE system 1.1 + CT100 (active treatment)|
168513|NCT01853176|Drug|Liposomal Injection Bupivacaine (Exparel)|
168514|NCT01853176|Drug|Standard bupivicaine|
168515|NCT01853189|Other|OMT + Usual Care|patients from this group received 6 sessions of OMT
168516|NCT00105443|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
168517|NCT01853189|Other|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
168815|NCT01848899|Drug|contrast media (ioxaglate or iodixanol)|contrast media used during coronary angiography
168816|NCT01848912|Device|Zephyr Biopatch Device|
168817|NCT00105001|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
168818|NCT01848925|Biological|SANGUINATE™|40 mg/mL intravenous infusion.
168819|NCT01848925|Drug|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
168820|NCT01848938|Behavioral|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
168821|NCT01848951|Drug|Epidural|
168822|NCT01848951|Drug|TAP Block|
168823|NCT01848964|Device|Clinical and instrumented measurements|Clinical examination will include stump pain, wound, scar and unusual shape.
Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)
After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.
Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.
Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate.
168824|NCT01848977|Device|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
168825|NCT01848977|Device|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
168826|NCT01848990|Drug|Commercial Hylenex® recombinant (hyaluronidase human injection)|
168827|NCT01848990|Drug|Precommercial Hylenex recombinant (hyaluronidase human injection)|
173321|NCT01896999|Biological|Nivolumab|Given IV
173322|NCT01897012|Drug|Alisertib|Given PO
173323|NCT01897012|Other|Laboratory Biomarker Analysis|Correlative studies
173324|NCT00110006|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
173325|NCT01897012|Drug|Romidepsin|Given IV
173326|NCT01897025|Device|real-tDCS with MI-BCI|As in Arm Description
173327|NCT01897038|Drug|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
173328|NCT01897038|Drug|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
173329|NCT01897051|Drug|Rifaximin + propranolol|Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)
Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.
(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).
If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.
168518|NCT01853202|Behavioral|Supervised aerobic exercise training|
168519|NCT01853215|Device|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
168520|NCT01853228|Drug|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
168521|NCT01853228|Drug|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
168522|NCT01853228|Drug|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
168523|NCT01853241|Procedure|Single Balloon|All patients in this group will undergo single balloon enteroscopy
168524|NCT01853241|Procedure|Spirus|All patients in this group will undergo Spirus Enteroscopy
168525|NCT01853254|Drug|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
168526|NCT01853254|Drug|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing < 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
177768|NCT01909596|Device|9° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 9°
177769|NCT01909596|Device|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
177770|NCT01909596|Device|Orthotist integrated lateral customized foot orthoses|Foot orthoses with arch support and integrated lateral inclination set according to orthotist experience
177771|NCT01909596|Device|Orthotist lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set according to orthotist experience
177772|NCT01909609|Other|AAP Documents|
177773|NCT01909609|Other|Parent Survival Guide|
177774|NCT01909622|Dietary Supplement|Vitamin D|
177775|NCT00111163|Drug|sulfadoxine-pyrimethamine with artesunate|
177776|NCT01909622|Dietary Supplement|No vitamin D|
177777|NCT01909635|Behavioral|Food Feelings|
177778|NCT01909635|Behavioral|Other Feelings|
177779|NCT01909648|Other|Blood withdrawal|
177780|NCT01909648|Genetic|Blood withdrawal|
177781|NCT01909661|Other|Damira/Celia peptide hydrolyzed casein|
177782|NCT01909661|Other|Picot riz/Celia rice/Sanutri arroz|
177783|NCT01909674|Device|Switch CPAP mask type|
177784|NCT01909687|Device|Blood glucose monitoring systems|
177785|NCT01909700|Device|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
177786|NCT00111163|Drug|amodiaquine with artesunate|
177787|NCT01909700|Device|Single Incision Mesh|Single Incision Mesh is implanted
177788|NCT01909713|Drug|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
177789|NCT01909726|Other|ScreenPlay|Interactive technology
178081|NCT01905150|Dietary Supplement|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
177458|NCT01906762|Drug|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
177459|NCT01906775|Other|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
177460|NCT00110812|Drug|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
177461|NCT01906788|Drug|Artemether Lumefantrine|
177462|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
177463|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
177464|NCT01906801|Drug|Glucosamine sulfate|
177465|NCT01906801|Drug|Diacerein|
177466|NCT01906801|Drug|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
177467|NCT01906814|Drug|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
177468|NCT01906814|Drug|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
177469|NCT01906840|Drug|Turmeric|
177470|NCT01906840|Drug|placebo|
177471|NCT00110825|Behavioral|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
177472|NCT01906853|Biological|BCG|
177473|NCT01906866|Drug|Circadin 2/5/10 mg|Active arm
177474|NCT01906866|Drug|Placebo|
177475|NCT01906879|Drug|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
177476|NCT01906892|Other|Group drumming (participatory)|Active participation in group drumming workshops
177477|NCT01906892|Other|Group drumming (live)|Listening to live performances of group drumming
177790|NCT01909739|Drug|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
173386|NCT01894477|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
173387|NCT01894477|Radiation|Total-Body Irradiation|Undergo TBI
173388|NCT01894477|Drug|Treosulfan|Given IV
173389|NCT01894503|Drug|S8 mometasone furoate sinus implant|
173390|NCT01897051|Drug|Propranolol + Placebo|Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)
Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.
(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).
If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.
173391|NCT01897064|Behavioral|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
173392|NCT01897064|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
173393|NCT01897077|Drug|Peanut Dissolving Film|
173394|NCT01897090|Other|Elimination Diet|
173395|NCT00110006|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
173396|NCT01897090|Other|Dietary Guidelines for Americans|
173397|NCT01897116|Drug|Hydroxychloroquine (HCQ)|
173398|NCT01897116|Drug|Vemurafenib (VEM)|
173399|NCT01897142|Biological|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
173400|NCT01897142|Drug|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
173401|NCT01897142|Biological|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
173402|NCT01897142|Drug|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
168605|NCT01860482|Drug|Newrabell® Tablet 10mg|
168606|NCT01860495|Procedure|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
168607|NCT01860495|Procedure|G2|tradetional occlusive collagen membrane
168608|NCT01860508|Drug|pemetrexed /carboplatin|
173098|NCT01901471|Drug|Single bolus of Placebo of CicloMulsion® (Neurovive).|The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.
The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.
The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.
The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes.
173099|NCT01901471|Drug|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).
Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.
CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.
Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.
CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.
The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes.
173100|NCT01901484|Drug|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
173101|NCT01901497|Device|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
173102|NCT01893957|Procedure|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
173103|NCT01893957|Procedure|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
173104|NCT01893957|Device|Neurodyn High Volt Model (IBRAMED)|
173105|NCT01893970|Behavioral|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
173106|NCT01893970|Behavioral|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
173107|NCT01893983|Behavioral|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
173108|NCT00109837|Drug|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
172499|NCT01877694|Drug|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
172500|NCT01877707|Other|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
172501|NCT00002056|Drug|Pentamidine isethionate|
172502|NCT00108108|Drug|HCD122|
172794|NCT01881074|Drug|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
172795|NCT01881074|Drug|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
172796|NCT01881087|Drug|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
172797|NCT01881100|Other|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
172798|NCT00002060|Drug|Inosine pranobex|
172799|NCT00108381|Behavioral|standard care|standard psychological treatment
172800|NCT01872936|Drug|Miravirsen|
172801|NCT01872936|Drug|Telaprevir|
172802|NCT01872936|Drug|Ribavirin|
172803|NCT01872962|Drug|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
172804|NCT01872962|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
172805|NCT01872975|Radiation|regional nodal XRT|
172189|NCT01882764|Drug|HMPL-004 tablet|HMPL-004 tablet given at a strength of 1800 mg/day, (600 mg t.i.d.)
172190|NCT01882764|Drug|Placebo Tablet|
172191|NCT00108550|Drug|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
172192|NCT01882777|Behavioral|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
172193|NCT01882803|Drug|IPI-145 (duvelisib)|PI3K Inhibitor
172194|NCT01882816|Radiation|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
172195|NCT01882816|Device|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
172196|NCT01882816|Drug|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
172197|NCT01882816|Other|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
172503|NCT01877720|Device|noninvasive respiratory support with NAVA mode and PSV|
172504|NCT01877733|Other|Maximal strength training|
172505|NCT01877746|Drug|Combination of prednisone and azathioprine|Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.
Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
172506|NCT01877746|Drug|Combination of prednisone and azathioprine|Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.
Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
172507|NCT01877746|Other|No intervention|No intervention, only standard medical therapy
172508|NCT01877759|Biological|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow & umbilical cord , IN 6 divided doses , at interval of 1 week .
172509|NCT01877772|Procedure|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
172510|NCT01877785|Drug|MHAA4549A|Single-ascending dose of MHAA4549A
171900|NCT01879423|Drug|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
171901|NCT01879462|Drug|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
171902|NCT00108277|Behavioral|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
171903|NCT01879462|Drug|Placebo|Visually matching GSK2878175
171904|NCT01879475|Device|032-11|Topical haemostat
171905|NCT01879475|Device|Floseal (R)|Topical haemostat
171906|NCT01879488|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
171907|NCT01879488|Device|Vibrating-mesh nebulizer|
171908|NCT01879488|Other|Gamma scintigraphy|
171909|NCT01879488|Other|Preoperative spirometry|
171910|NCT01879501|Behavioral|Low Vision Self-Management Program|The program has been describe above.
171911|NCT01881932|Device|Sham Acupuncture using Park Sham placebo acupuncture device|Participants will receive sham acupuncture until the end of chemotherapy.
Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion.
171912|NCT01881945|Other|Non-invasive physiological signal recording on healthy volunteer|
171913|NCT01881958|Drug|DiaPep277®|
172198|NCT01874392|Device|Artificial Pancreas (AP) device (APS©)|Device includes:
OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.
Dexcom® G4® CGM System (CGM) from Dexcom® Corp
Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)
172199|NCT01874418|Other|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
172200|NCT01874431|Drug|Finerenone (BAY 94-8862)|
172201|NCT01874431|Drug|Placebo|
172202|NCT01874444|Device|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
171577|NCT00112502|Drug|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
171578|NCT01922999|Drug|Melatonin|patients will receive placebo, 1mg melatonin or 3mg melatonin
171579|NCT01923012|Drug|Vitamin K2 (Menaquinone)|
171580|NCT01923025|Drug|RO5545965|Single dose
171581|NCT01923038|Procedure|First arm: patients ventilated with zero end expiratory pressure|
171582|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure|
171583|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
171584|NCT01923064|Drug|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
171585|NCT01923064|Drug|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
171586|NCT01923077|Drug|Simvastatin|usual care with Simvastatin
171587|NCT01923077|Drug|Rosuvastatin|rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
171588|NCT00112515|Drug|modafinil|
171589|NCT01923090|Drug|Finasteride|Finasteride 5mg once daily for 3 weeks
171590|NCT01923090|Drug|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
171591|NCT01923116|Drug|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
171592|NCT01878812|Biological|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
171593|NCT01878825|Biological|Fluviral™|1 dose administered intramuscularly in deltoid region of non-dominant arm.
171594|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
171914|NCT01881971|Drug|Placebo|suger pill manufactured to mimic crestor pills
171915|NCT01881971|Drug|Rouvastatin calcium|
171916|NCT01881984|Drug|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
170946|NCT01924403|Procedure|Vertical Mattress Closure|
170947|NCT01924403|Procedure|Running Subcuticular Closure|
171261|NCT01929850|Behavioral|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
171262|NCT01929863|Drug|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID [45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period]
171263|NCT01929863|Drug|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
171264|NCT01929863|Drug|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
171265|NCT01929876|Drug|Cobimetinib|Treatment 1: single 10 mg dose of cobimetinib on day 1; Treatment 2: single 20 mg dose of cobimetinib on day 4
171266|NCT01929876|Drug|itraconazole|Treatment 2: Itraconazole 200 mg once daily from Day 1 to Day 14
171267|NCT01929889|Drug|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
171268|NCT01929915|Procedure|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
171269|NCT01929915|Drug|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
171270|NCT01929941|Drug|INCB047986|Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
171271|NCT00112905|Drug|sorafenib tosylate|Given PO
171272|NCT01929941|Drug|INCB047986|INCB047986 tablets administered orally at the protocol specified dose and frequency
171273|NCT01929941|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
171274|NCT01929941|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
171275|NCT01929954|Biological|Gintuit|One time placement of Gintuit over socket graft.
171276|NCT01929954|Device|Bio-Gide|One time placement of Bio-Gide over socket graft.
171277|NCT01929980|Drug|Bortezomib|
170958|NCT01926834|Drug|placebo|normal saline, 500ml,i.v.,qd, for 7 days
170959|NCT01926847|Drug|Riociguat (Adempas, BAY63-2521)|
170960|NCT01926847|Drug|Placebo|
170961|NCT01926860|Biological|Prevenar13|
170962|NCT01926860|Biological|Hepatitis A vaccine|
170963|NCT01926886|Drug|trastuzumab [Herceptin]|6 mg/kg intravenously (IV) every 3 weeks, 3 cycles
170964|NCT00112723|Drug|alvocidib|Given IV
170965|NCT01926886|Drug|trastuzumab [Herceptin]|600 mg subcutaneously every 3 weeks, administered via a hand-held syringe by a trained HCP at the hospital, 3 cycles
170966|NCT01926886|Drug|trastuzumab [Herceptin]|600 mg/kg subcutaneously every 3 weeks, administered via a hand-held syringe by a HCP at the patient's home, 6 cycles
170967|NCT01926899|Drug|Bortezomib administration|
170968|NCT01926912|Drug|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
170969|NCT01926951|Device|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
170970|NCT01926977|Drug|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
170971|NCT01926977|Drug|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
170972|NCT01926990|Procedure|perfusion computed tomography|Undergo perfusion CT
171281|NCT01930019|Drug|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
171282|NCT00112905|Other|laboratory biomarker analysis|Optional correlative studies
171283|NCT01922336|Biological|EU Remicade|IV infusion
171284|NCT01922336|Biological|US Remicade|IV infusion
171285|NCT00112463|Drug|romidepsin|
171286|NCT01922349|Drug|BI 113608|Medium dose (Multiple dosing)
171287|NCT01922349|Drug|Placebo|Placebo (Multiple dosing)
170631|NCT01928914|Drug|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
170632|NCT01928914|Drug|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
170633|NCT01931488|Device|SPECT imaging|
170634|NCT01931501|Drug|Torrent's Montelukast Sodium Chewable Tablets 5mg|
170635|NCT01931501|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
170636|NCT01931514|Drug|Torrent's Montelukast Sodium chewable Tablets 5mg|
170637|NCT01931514|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
170638|NCT01931527|Drug|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
170639|NCT01931540|Behavioral|Exercise Training|Three times a week, for four months.
170640|NCT00113074|Drug|Nicotine Replacement Therapy|Nicotine replacement therapy program
170641|NCT01931553|Other|Standardized attending morning rounds|
170642|NCT01931566|Drug|Pioglitazone|Low-Dose Pioglitazone tablets
170643|NCT01931566|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets
170644|NCT01931579|Device|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
170645|NCT01931592|Drug|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
170646|NCT01931592|Drug|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
170647|NCT01931605|Device|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
170648|NCT01931618|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
170007|NCT01845831|Drug|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
170008|NCT01845831|Drug|Metformin and sitagliptin + glargine 80%|Patients with HbA1c > 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
170009|NCT01845844|Drug|Ranibizumab 0.3mg/0.05cc|Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.
Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria.
170010|NCT01845857|Behavioral|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
170011|NCT01845883|Procedure|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
170012|NCT01845896|Behavioral|Training|
170013|NCT01845909|Other|ECG and survey screening|
170014|NCT01845922|Dietary Supplement|Low sodium diet|Low sodium diet
170324|NCT01925677|Device|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
170325|NCT01925690|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
170326|NCT01925690|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
170327|NCT01928433|Drug|Finafloxacin 800 mg i.v. once daily|
170328|NCT00112827|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo transplantation
170329|NCT01928433|Drug|Finafloxacin placebo i.v. once daily|
170330|NCT01928433|Drug|Finafloxacin 800 mg tablets (as four 200 mg tablets) once daily|
170331|NCT01928433|Drug|Finafloxacin placebo tablets (as four tablets) once daily|
170332|NCT01928433|Drug|Ciprofloxacin 400 mg i.v. two times daily|
170333|NCT01928433|Drug|Ciprofloxacin placebo i.v. two times daily|
170334|NCT01928433|Drug|Ciprofloxacin 500 mg oral (as two 250 mg capsules) two times daily|
170335|NCT01928433|Drug|Ciprofloxacin placebo oral (as two capsules each) two times daily|
169713|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
169714|NCT00104572|Dietary Supplement|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
169715|NCT01842958|Device|Roxolid dental implant, 4.1 mm diameter|Placement of the Straumann Bone Level Ø4.1 mm RC SLActive Roxolid Implant available in lengths 8mm, 10mm, 12mm, and 14mm for single tooth replacement in the anterior and pre-molar region.
169716|NCT01842958|Device|Roxolid dental implant, 3.3 mm diameter|Placement of Straumann Bone Level Ø3.3 mm NC SLActive Roxolid Implant available in 8mm, 10mm, 12mm, and 14mm for single tooth replacement in the anterior and pre-molar region.
169717|NCT01842971|Procedure|two stage hepatectomy|
169718|NCT01842984|Behavioral|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
169719|NCT01842997|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
169720|NCT01843010|Drug|Parecoxib|Parecoxib 40mg will be intravenously infused.
169721|NCT01843010|Drug|Placebo|Normal saline 5ml will be intravenously infused.
169722|NCT01843023|Drug|Extended Release Naltrexone|naltrexone for extended release injectable suspension
169723|NCT01843023|Behavioral|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
169724|NCT01843023|Drug|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
169725|NCT00104598|Drug|Bupropion|
170015|NCT01845935|Device|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
170016|NCT01845948|Behavioral|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
170017|NCT00104819|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
169134|NCT01844336|Device|PBASE system 1.1 + CT100 (placebo treatment)|
169135|NCT01844362|Procedure|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
169136|NCT01844375|Dietary Supplement|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
169137|NCT01844375|Other|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
169418|NCT01847326|Procedure|therapeutic conventional surgery|Undergo surgical resection
169419|NCT00104910|Radiation|3-Dimensional Conformal Radiation Therapy|
169420|NCT01847326|Radiation|radiation therapy|Undergo radiation therapy
169421|NCT01847326|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
169422|NCT01847326|Other|laboratory biomarker analysis|Correlative studies
169423|NCT01847339|Drug|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
169424|NCT01847339|Other|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
169425|NCT01847352|Drug|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
169426|NCT01847352|Other|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
169427|NCT01847365|Device|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
169428|NCT01849900|Other|Knowing your body|Women will receive the "Knowing your body" kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits.
169429|NCT01849900|Behavioral|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
168828|NCT01851226|Procedure|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
168829|NCT01851265|Drug|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
168830|NCT01851265|Other|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
168831|NCT01851265|Other|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
168832|NCT01851265|Other|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
168833|NCT01851278|Drug|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
169138|NCT01844388|Drug|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
169139|NCT01844388|Drug|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
169140|NCT00104689|Drug|oxaliplatin|
169141|NCT01844401|Drug|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
169142|NCT01844401|Drug|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
169143|NCT01844414|Behavioral|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
169144|NCT01844414|Behavioral|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
169145|NCT01844414|Behavioral|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
169146|NCT01844427|Drug|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
169147|NCT01844427|Drug|Placebo|
169148|NCT01844440|Procedure|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
168527|NCT00002029|Drug|Fat Emulsion 20%|
168528|NCT00105443|Drug|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
168529|NCT01853267|Procedure|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
168530|NCT01853267|Procedure|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
168531|NCT01853280|Drug|L-methylfolate|15mg/day L-methylfolate.
168532|NCT01853280|Drug|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
168533|NCT01853293|Drug|Kudzu extract|
168534|NCT01853293|Drug|Placebo|
168535|NCT01855711|Drug|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
168536|NCT01855724|Drug|Gemcitabine-Pazopanib|
168537|NCT00105716|Behavioral|Computer behavioral education|
168538|NCT01855737|Drug|Warfarin|Prescribe warfarin to the patients who are needed.
168539|NCT01855750|Drug|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
168834|NCT01851278|Drug|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
168835|NCT01851304|Dietary Supplement|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
168836|NCT01851304|Dietary Supplement|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
168837|NCT01851330|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
168838|NCT00105209|Drug|Aspirin|
168839|NCT01851330|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
168840|NCT01851343|Other|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
178082|NCT01905163|Procedure|Tumor Debulking Surgery by laparoscopy|
178083|NCT01905176|Other|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
178084|NCT00110643|Device|CoolTouch II laser|
178085|NCT01905176|Other|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
178086|NCT01905176|Other|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 & 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 & 2
178087|NCT01905189|Procedure|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
178088|NCT01905202|Drug|Secretrol|
178089|NCT01905215|Biological|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
178090|NCT01905215|Biological|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
178091|NCT01905215|Biological|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
178092|NCT01905215|Biological|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
178093|NCT01905215|Biological|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
178094|NCT01905215|Biological|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
178095|NCT00110656|Other|Observations|This is a non-interventional study- only observational.
178096|NCT01905215|Drug|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
178097|NCT01905228|Drug|CBL0137|All doses are on Days 1, 8 and 15 of every 28 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops
178098|NCT01905254|Device|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
178099|NCT01905254|Other|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
177791|NCT01909739|Drug|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
177792|NCT01909752|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
177793|NCT01909752|Biological|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
177794|NCT01912157|Behavioral|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
177795|NCT01912170|Dietary Supplement|Fish oil|
177796|NCT01912170|Dietary Supplement|Flaxseed oil|
177797|NCT00111501|Behavioral|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
177798|NCT01912183|Behavioral|Communication through PHR outside clinic|
177799|NCT01912183|Behavioral|Monitoring device in PHR|
177800|NCT01912183|Device|Physical activity and sleep monitor|
177801|NCT01912183|Other|PHR|Access to their PHR
177802|NCT01912196|Drug|MSI-195|
177803|NCT01912196|Drug|Placebo|
177804|NCT01912209|Behavioral|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
177805|NCT01912222|Drug|IXAZOMIB|
177806|NCT01912235|Other|2-15N glutamine|Glutamine with N15 isotope tracer
177807|NCT01912235|Other|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
177808|NCT00111514|Biological|Leish-111f + MPL-SE vaccine|
177809|NCT01912235|Other|1-13C glutamine|Glutamine carbon isotope tracer
177810|NCT01912248|Other|strength training|strength training, lower limb.
177811|NCT01912261|Drug|Placebo|one capsule orally daily times 84 days
168609|NCT00106340|Drug|Glimepiride matching placebo|
168610|NCT01853293|Behavioral|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
168611|NCT01853306|Drug|Veliparib|veliparib
168612|NCT01853319|Drug|Regorafenib (BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
168613|NCT01853358|Biological|NK Cell infusion|level 1: 1 x 10e6 NK cells /kg;
level 2: 5 x 10e6 NK cells /kg;
level 3: > 5.10e6 and ≤ 5.10e7 cellules NK/kg
168614|NCT00105469|Drug|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
168615|NCT01853371|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
168616|NCT01853371|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
168617|NCT01853384|Biological|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
168618|NCT01853384|Other|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
168619|NCT01853397|Device|Liposonix System (Model 2)|
168620|NCT01853410|Device|gekoTM|
168621|NCT01853423|Drug|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
168925|NCT01849094|Drug|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
168926|NCT01849107|Biological|Plasma citrulline|
168927|NCT00105001|Drug|Sirolimus|Given PO
173109|NCT01893996|Drug|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
168314|NCT01857661|Device|hearing aids with only amplification|
168315|NCT01857700|Other|Compensation for transport cost|
168316|NCT01857700|Other|Compensation for lost wages|
168317|NCT01857700|Other|Compensation for transport cost and lost wages|
168318|NCT01857700|Other|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
168319|NCT01857713|Device|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
168320|NCT01857726|Drug|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
168321|NCT01857726|Drug|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
168322|NCT00106028|Drug|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
168323|NCT01857752|Drug|Temozolomide|
168324|NCT01857765|Behavioral|Rehabilitation|Range of motion stretching exercises
168325|NCT01857765|Behavioral|Follow-up|Follow-up with surgeon's clinic
168326|NCT01857791|Behavioral|multidisciplinary, behavior modification|
168327|NCT01857804|Drug|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
168328|NCT01857804|Drug|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
168329|NCT01857804|Drug|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
168330|NCT01859858|Drug|Irinotecan|
168331|NCT01859871|Behavioral|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
172806|NCT01872975|Radiation|chestwall XRT|
172807|NCT00107614|Drug|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with < 50% response to induction) OR MEL-DT PACE (Patients with > 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
172808|NCT01872975|Radiation|WBI|
172809|NCT01872988|Drug|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
173110|NCT01893996|Drug|Placebo|
173111|NCT01894009|Procedure|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
173112|NCT01894009|Procedure|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
173113|NCT01894022|Drug|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
173114|NCT01894035|Drug|Ventavis (Iloprost, BAYQ6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
173115|NCT01894048|Drug|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
173116|NCT01894061|Biological|Bevacizumab|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.
173117|NCT01894061|Device|NovoTTF-l00A|NovoTTF-100A will be worn continuously.
173118|NCT01894061|Other|Quality of Life Assessment|Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
173119|NCT00109837|Drug|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
173120|NCT00109967|Biological|rituximab|375 mg/m^2 Given IV
173121|NCT01896531|Drug|mFOLFOX6|Participants will receive mFOLFOX6, consisting of leucovorin, bolus and infusional 5-fluorouracil, and oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling. If leucovorin is unavailable, an equivalent substitute may be used. Oxaliplatin will be discontinued after completion of 8 cycles, whereas leucovorin and 5-fluorouracil will be continued until disease progression or unacceptable toxicity.
173122|NCT01896544|Dietary Supplement|Cholecalciferol|
172511|NCT01877785|Drug|Placebo|Placebo to MHAA4549A
172512|NCT01877798|Procedure|volume resuscitation, vasoactive drug|
172513|NCT00108121|Drug|PEP005|
172514|NCT01877811|Drug|RXDX-105|During Phase 1, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.
During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.
172515|NCT01877824|Other|Fast-track training|
172516|NCT01877837|Drug|Alemtuzumab|Adjusted Ideal Body Weight Formula: AIBW = IBW + [(0.4) x (ABW - IBW)]
b) Medications
i.) Alemtuzumab I. Hb S% must be < or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued >48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below
172517|NCT01880489|Behavioral|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
172518|NCT01880502|Drug|Belviq 10mg|Belviq 10mg single dose administration
172519|NCT01880502|Drug|Belviq 20mg|Belviq 20mg single dose administration
172810|NCT01872988|Drug|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
172811|NCT01873001|Drug|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
172812|NCT01873001|Drug|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
172813|NCT01873014|Drug|chinese herbs-I|two agent per day, twice a day
172814|NCT01873014|Drug|chinese herbs-II|two agent per day, twice a day
172815|NCT01873027|Device|OFDI|OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI
172816|NCT01873027|Device|IVUS|IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI
172817|NCT01873040|Behavioral|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
172203|NCT01874444|Device|2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.
Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS.
172204|NCT01874444|Device|3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.
Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS.
172205|NCT01874444|Device|4|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS.
172206|NCT01874457|Biological|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
172207|NCT01874470|Device|renal denervation|
172208|NCT00107822|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
172209|NCT01874470|Other|standard medication|
172210|NCT01874483|Drug|Placebo|placebo
172211|NCT01874483|Drug|BI 187004|BI 187004, dose 2
172212|NCT01874483|Drug|BI 187004|BI 187004, dose 4
172213|NCT01874483|Drug|BI 187004|BI 187004, dose 5
172214|NCT01874483|Drug|BI 187004|BI 187004, dose 6
172215|NCT01874483|Drug|BI 187004|BI 187004, dose 7
172216|NCT01874483|Drug|BI 187004|BI 187004, dose 1
172217|NCT01874483|Drug|BI 187004|BI 187004, dose 3
172218|NCT01874496|Dietary Supplement|GDS, no meal|GDS, no meal
172520|NCT01880502|Drug|Placebo|Placebo single dose administration
172521|NCT01880515|Drug|Tetracycline|The experimental group will receive tetracycline 250mg every 24hrs for 1 month the same day at initiation of BIBW 2992
172522|NCT01880528|Drug|lisinopril|Given PO
172523|NCT01880528|Drug|placebo|Given PO
172524|NCT01880541|Other|hypnosedation|hypnosedation
172525|NCT01880541|Other|general anesthésia|general anesthesia
171917|NCT01881997|Drug|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
171918|NCT01881997|Drug|Normal Saline|IM normal saline
171919|NCT01882010|Procedure|blood draw|week -8
171920|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week -8
171921|NCT00108446|Drug|lidocaine|
171922|NCT01882010|Procedure|blood draw|week -4
171923|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week -4
171924|NCT01882010|Procedure|blood draw|week 0
171925|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week 0
171926|NCT01882010|Procedure|MEG|week 0
171927|NCT01882010|Drug|sargramostim|lyophilized 250 micrograms/vial
6 micrograms/kg daily subcutaneous injection
56 days
171928|NCT01882010|Drug|placebo|saline solution daily subcutaneous injection 56 days
171929|NCT01882010|Procedure|blood draw|week +2
171930|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +2
171931|NCT01882010|Procedure|blood draw|week +4
171932|NCT00108459|Behavioral|Low Carbohydrate Diet|
171933|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +4
171934|NCT01882010|Procedure|blood draw|week +6
171935|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +6
171936|NCT01882010|Procedure|blood draw|week +8
171937|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +8
171938|NCT01882010|Procedure|MEG|week +12
171939|NCT01882010|Procedure|blood draw|week +12
171940|NCT01882010|Behavioral|physical exam and UPDRS part III assessment|week +12
171278|NCT01929993|Procedure|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
171279|NCT01929993|Procedure|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
171280|NCT01930006|Drug|MGCD265|
171595|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
171596|NCT01878864|Drug|Bupivacaine lozenge|
171597|NCT01878864|Drug|Lidocaine-adrenalin injection|
171598|NCT01878890|Drug|Efavirenz|
171599|NCT00108225|Other|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
171600|NCT01878903|Other|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
171601|NCT01878929|Drug|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
171602|NCT01878942|Drug|Placebo|Capsules containing mannitol looking identical to LSD
per os
171603|NCT01878942|Drug|LSD|200µg per os, single dose
171604|NCT01878955|Genetic|AMH level difference between patient with PCOS and multicystic ovaries.|
171605|NCT01878968|Other|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
171606|NCT01878994|Behavioral|Counselling group|
171607|NCT01878994|Behavioral|Nereu group|
171608|NCT01879007|Drug|Factive® Tab / Factive IV|
171609|NCT01879020|Drug|TA-8995|Drug: TA-8995 1mg
171610|NCT00108238|Drug|Estradiol followed by progesterone|
171611|NCT01879020|Drug|TA-8995|Drug: TA-8995 2.5mg
171612|NCT01879020|Drug|TA-8995|Drug: TA-8995 5mg
171288|NCT01922349|Drug|BI 113608|Low dose (Multiple dosing)
171289|NCT01922349|Drug|Placebo|Placebo (Single dosing)
171290|NCT01922349|Drug|BI 113608|High dose (Single dosing)
171291|NCT01922349|Drug|BI 113608|Medium dose (Single dosing)
171292|NCT01922349|Drug|BI 113608|Low dose (Single dosing)
171293|NCT01922349|Drug|BI 113608|High dose (Multiple dosing)
171294|NCT01922362|Device|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
171295|NCT01922362|Device|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
171296|NCT00112476|Drug|bryostatin 1|Given IV
171297|NCT01922375|Drug|Naftopidil|
171298|NCT01922388|Device|Bilateral deep brain stimulation of the subthalamic nucleus|
171299|NCT01922388|Drug|18F-AV-133|
171300|NCT01922401|Other|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
171301|NCT01922414|Device|Laser|Patients will undergo laser lithotripsy durin PNL
171302|NCT01922414|Device|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
171303|NCT01922427|Drug|RNS60|
171304|NCT01922440|Other|None [Natural history registry]|
171305|NCT01922453|Other|Music and Sound|
171620|NCT01881412|Other|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
170649|NCT01931618|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
170973|NCT01927003|Procedure|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
170974|NCT01927016|Procedure|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
170975|NCT00112736|Drug|erlotinib|Given orally
170976|NCT01927029|Drug|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
170977|NCT01927029|Drug|Placebo|
170978|NCT01929317|Drug|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
170979|NCT01929317|Drug|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
170980|NCT01929330|Drug|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
170981|NCT01929330|Drug|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
170982|NCT01929343|Drug|lidocaine following cue-induced craving|as described in Arm Description
170983|NCT01929343|Drug|lidocaine following neutral stimulus|as described in Arm Description
170984|NCT00112879|Procedure|biological therapy|
170985|NCT01929343|Drug|saline|as described in Arm Description
170986|NCT01929356|Procedure|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
170987|NCT01929382|Drug|interferon gamma 1b|Standard therapy vs dose titration
170988|NCT01929395|Device|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
170989|NCT01929421|Drug|Gemcitabine/S-1|
170990|NCT01929434|Other|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
170336|NCT01928446|Drug|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
170337|NCT01928446|Drug|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
170338|NCT01928459|Drug|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
170339|NCT00112827|Drug|lenalidomide|Given orally
170340|NCT01928459|Drug|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
170341|NCT01928472|Biological|H7N9c low dose with adjuvant|
170342|NCT01928472|Biological|H7N9c medium dose with adjuvant|
170343|NCT01928472|Biological|H7N9c high dose with adjuvant|
170344|NCT01928472|Biological|H7N9c high dose without adjuvant|
170345|NCT01928485|Other|active surveillance|Undergo active surveillance
170346|NCT01928485|Drug|Sunphenon|Given PO
170347|NCT01928485|Other|laboratory biomarker analysis|Correlative studies
170650|NCT01931618|Behavioral|Online multi session follow-up|An online multi session follow-up program (i.e., "Balance"). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group).
170651|NCT00113074|Behavioral|Diet|Diet program
170652|NCT01931631|Behavioral|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
170653|NCT01931657|Drug|Mifepristone prior to Mirena|
170654|NCT01923909|Drug|Intra- articular platelet rich plasma|Intra- articular platelet rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PrP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
170018|NCT01848288|Device|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
170019|NCT01848288|Device|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
170020|NCT01848301|Device|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
170021|NCT01848301|Drug|Acetylcholine|Infusion in the coronary artery to study endothelial function
170022|NCT00104975|Drug|thiotepa|
170023|NCT01848301|Procedure|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
170024|NCT01848314|Procedure|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
170025|NCT01848327|Dietary Supplement|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
170026|NCT01848327|Dietary Supplement|Placebo|Placebo (40 gram packet orally once a day for 90 days)
170027|NCT01848340|Drug|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
170028|NCT01848340|Drug|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
170029|NCT01848340|Drug|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
170030|NCT01848353|Behavioral|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
170031|NCT01848366|Device|Biowave Treatment|Six weekly treatments
170032|NCT01848379|Procedure|ADT+FD|
170033|NCT00000123|Device|Polymethyl Methacrylate-Silicone Contact Lenses|
170034|NCT00000291|Drug|Labetalol|
170035|NCT00002024|Drug|Ganciclovir|
170348|NCT01928485|Other|Questionnaire Administration|Ancillary studies
170349|NCT01928498|Device|Paclitaxel Eluting Balloon Angioplasty|
169430|NCT01849913|Other|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
169431|NCT01849913|Other|Placebo|To provide the "blinding": the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy).
169432|NCT01849926|Drug|Ibuprofen|
169433|NCT01849926|Drug|Mecillinam|
169434|NCT01849939|Drug|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
169435|NCT01849965|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
169726|NCT01843036|Other|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
169727|NCT01843049|Radiation|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
169728|NCT01843049|Drug|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
169729|NCT01843062|Drug|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
169730|NCT01843062|Drug|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
169731|NCT01845337|Drug|Teysuno|
169732|NCT01845337|Drug|Capecitabine|
169733|NCT01845350|Other|M2 macrophage introduction|Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients
Intrathecal introduction of autologous M2 macrophages
169734|NCT01845363|Drug|Cefazolin used in antimicrobial prophylaxis|Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.
Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.
The samples were processed by HPLC.
169735|NCT00104767|Drug|celecoxib|
169149|NCT01844453|Procedure|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
169150|NCT01846910|Behavioral|Tooth Whitening|1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
169151|NCT01846910|Behavioral|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
169436|NCT01849965|Drug|placebo vehicle gel|
169437|NCT01849965|Drug|Standard of Care gel, Aquasite|
169438|NCT00002026|Drug|Acyclovir|
169439|NCT00105079|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
169440|NCT01849978|Behavioral|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
169441|NCT01849978|Behavioral|Changing your habits brochure|Both groups will receive the brochure titled "Changing Your Habits: Steps to Better Health", developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA.
169442|NCT01849978|Behavioral|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
169443|NCT01849978|Behavioral|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
169444|NCT01852318|Drug|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
168841|NCT01851369|Drug|TRC 102|TRC102 has been shown to potentiate the activity of temozolomide by preventing BER and allowing cleavage of TRC102 bound DNA, which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co administered with TMZ and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
168842|NCT01851408|Drug|sorafenib tosylate|Given orally
168843|NCT01851408|Drug|temsirolimus|Given IV
168844|NCT01851460|Device|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer.
168845|NCT01851473|Drug|cocaine|25 mg IV on days 1, 5, and 10
168846|NCT01851473|Drug|quinine|80 mg orally on days 7-10
168847|NCT01851473|Drug|acetazolamide|15 mg orally on days 2-5
168848|NCT01851486|Drug|Clonidine|Clonidine 0.15 mg
168849|NCT00105209|Drug|clopidogrel|
168850|NCT01851486|Drug|Naloxone|naloxone 0.15 mg/kg
168851|NCT01851486|Drug|placebo|
168852|NCT01843829|Drug|Paclitaxel|
168853|NCT00002019|Drug|Amphotericin B, Lipid-based|
168854|NCT00104676|Biological|bleomycin sulfate|At least one course administered
168855|NCT01843829|Radiation|Radiotherapy|
168856|NCT01843829|Procedure|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
169152|NCT00104858|Other|Laboratory Biomarker Analysis|Correlative studies
169153|NCT01846923|Biological|PCV13|
169154|NCT01846936|Procedure|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
169155|NCT01846936|Procedure|BB with conventional technique|The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.
The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation.
178411|NCT01908361|Behavioral|Bilateral Hybrid (BMT plus BAT) Intervention|During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.
During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands.
178412|NCT01908361|Behavioral|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
178413|NCT01910636|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
178414|NCT01910649|Drug|Drisapersen|Subcutaneous and Intravenous
178415|NCT00111280|Drug|TMC125|
178416|NCT01910662|Other|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
178417|NCT01910662|Other|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
178418|NCT01910662|Other|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
178419|NCT01910662|Other|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
178420|NCT01910675|Drug|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
178421|NCT01910675|Drug|FFP|4 units Octaplas. Additional fibrinogen if needed.
178422|NCT01910688|Device|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
178423|NCT01910701|Behavioral|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
178100|NCT01905267|Behavioral|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
178101|NCT01907737|Other|Sham tDCS and sham PNS|No current will be delivered by the tDCS device, or to the radial, ulnar and median nerves.
178102|NCT01907750|Device|biliary drainage tube|
178103|NCT01907763|Drug|SOTB07 200mg|
178104|NCT01907763|Drug|SOTB07 400mg|
178105|NCT01907763|Drug|SOTB 200mg placebo|Placebo of SOTB07 200mg
178106|NCT01907763|Drug|SOTB 400mg placebo|Placebo of SOTB07 400mg
178107|NCT01907776|Drug|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
178108|NCT01907776|Drug|ME1100 placebo inhalation solution|Vehicle placebo
178109|NCT01907789|Other|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
178110|NCT00110916|Drug|placebo|placebo
178111|NCT01907789|Procedure|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
178112|NCT01907789|Procedure|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
178113|NCT01907789|Behavioral|Questionnaire|Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.
Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery.
178114|NCT01907789|Procedure|Transvaginal Ultrasound|Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.
Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline.
168928|NCT01849120|Device|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
168929|NCT01849133|Radiation|external fractionated radiotherapy|conventional external beam radiotherapy
168930|NCT01849133|Radiation|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
168931|NCT01849146|Other|Laboratory Biomarker Analysis|Correlative studies
168932|NCT01851486|Other|saline|
168933|NCT01851499|Dietary Supplement|Ultramicronized PEA (Normast)|600 mg
168934|NCT01851512|Drug|T-R (Test-Reference drug)|
168935|NCT01851512|Drug|R-T (Reference-Test drug)|
168936|NCT01851525|Device|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
168937|NCT01851538|Other|Observational study; no intervention.|
168938|NCT01851551|Drug|Vincristine Sulfate Liposome Injection plus rituximab|
168939|NCT01851564|Device|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
168940|NCT00105222|Drug|Sodium Nitrite|
168941|NCT01851564|Other|Standard Therapy|Standard Medical and Endoscopic Therapy
168942|NCT01851577|Behavioral|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
168943|NCT01851577|Behavioral|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
168944|NCT01851590|Device|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
168945|NCT01851590|Drug|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
168946|NCT01851590|Drug|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
168947|NCT01851603|Device|AVL-3288|Drug
169224|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
168332|NCT01859884|Behavioral|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
168333|NCT01859910|Procedure|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
168622|NCT01853436|Device|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
168623|NCT01853449|Drug|Fentanyl Citrate|
168624|NCT01853449|Other|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
168625|NCT00105469|Drug|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
168626|NCT01853449|Drug|Placebo|0.9% saline
168627|NCT01853462|Device|proprioceptive neuromuscular facilitation exercise program|ten individual sessions (approximately one hour per session) of a proprioceptive neuromuscular facilitation exercise program by a physiotherapist
168628|NCT01853462|Device|balance exercise program|ten individual sessions (approximately one hour per session) of a balance exercise program by a physiotherapist
168629|NCT01855828|Drug|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
168630|NCT01855841|Drug|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
168631|NCT01855841|Drug|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
168632|NCT01855854|Drug|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
168633|NCT01855867|Drug|Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
168634|NCT01855880|Biological|AbGn-168H|
168635|NCT01855880|Biological|placebo|
168636|NCT01855893|Other|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
173123|NCT01896557|Drug|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
173124|NCT01896570|Procedure|Catheter ablation of subsequent atrial tachycardia|
173125|NCT01896583|Drug|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
173126|NCT01896583|Drug|Placebo|
173127|NCT01896596|Biological|Menjugate|Administered with routine vaccinations at 3 months of age
173128|NCT01896596|Biological|Menitorix|Administered with routine vaccinations at 3 months
173129|NCT01896596|Biological|NeisVac-C|Administered with routine vaccinations at 3 months
168334|NCT01859910|Procedure|routine preparation for cataract|
168335|NCT01859923|Drug|100 mg Delamanid|100 mg Delamanid BID for 6 months
168336|NCT01859923|Drug|50 mg Delamanid|50 mg Delamanid BID for 6 months
168337|NCT01859923|Drug|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid for 6 months
168338|NCT01859923|Drug|(Dose to be determined) Pediatric Formulation Delamanid|(Dose to be determined) Pediatric Formulation Delamanid
168339|NCT01859923|Drug|Optimized Background Regimen (OBR)|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
168340|NCT00002035|Drug|Didanosine|
168341|NCT00106314|Drug|Dehydroepiandrosterone [DHEA]|
168342|NCT01859936|Device|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
168343|NCT01859949|Drug|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
168344|NCT01859962|Drug|PPI-668|
168345|NCT01859962|Drug|BI 207127 Dose 1|
168346|NCT01859962|Drug|BI 207127 Dose 2|
168347|NCT01859962|Drug|Faldaprevir|
168348|NCT01859962|Drug|Ribavirin|
172818|NCT00002052|Drug|Ceftriaxone sodium|
172819|NCT00107627|Other|Caprosyn subcuticular sutures.|Caprosyn subcuticular sutures.
172820|NCT01873040|Behavioral|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
172821|NCT01873053|Drug|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
172822|NCT01873053|Drug|Placebo|
172823|NCT01873066|Device|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
172824|NCT01873066|Device|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
172825|NCT01875510|Dietary Supplement|Fish-oil emulsions|Fish -oil emulsions:
Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
172826|NCT01875510|Dietary Supplement|soybean-oil emulsion|soybean-oil emulsion
172827|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,2 application)
172828|NCT01875523|Drug|Serelaxin|
172829|NCT01875536|Device|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
172830|NCT01875536|Behavioral|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
173130|NCT01896609|Biological|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
173131|NCT00002075|Drug|Fluconazole|
173132|NCT00109967|Drug|temsirolimus|25 mg given IV
173133|NCT01896609|Drug|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
173134|NCT01896609|Drug|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
173135|NCT01896609|Drug|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
173136|NCT01896622|Drug|Ritonavir|Impact on dabigatran PK/PD
172526|NCT01880554|Device|Contrast-enhanced intraoperative ultrasound|Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages
172527|NCT00108355|Drug|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
172528|NCT01880567|Drug|Ibrutinib|560 mg by mouth daily for each 28 day cycle.
172529|NCT01880567|Drug|Rituximab|375 mg/m2 by vein given cycle 1 day 1, 8, 15 and 22 +/- 1 day (Cycle 1), followed by rituximab on day one of every cycle starting in cycles 3 - 8. Following cycle 8 rituximab given on day 1 of every other cycle for up to 2 years.
172530|NCT01880593|Drug|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
172531|NCT01880593|Drug|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
172532|NCT01880606|Procedure|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
172533|NCT01880619|Drug|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
172534|NCT01880619|Drug|Solifenacin|Patients in the arm will receive Solifenacin
172535|NCT01880619|Drug|Control|Patients in this are will receive placebo
172536|NCT01880632|Drug|XELOX|Patients will be given the perioperative chemotherapy as below once recruited:
Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）
Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:
Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
172537|NCT01872481|Device|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
172538|NCT01872481|Device|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
172831|NCT01875549|Device|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
172832|NCT01875549|Procedure|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
172833|NCT01875562|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
172834|NCT01875575|Dietary Supplement|Placebo|
172219|NCT00002052|Drug|Amoxicillin trihydrate|
172220|NCT00107835|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
172221|NCT01874496|Dietary Supplement|GDS, meal|GDS, meal
172222|NCT01874496|Dietary Supplement|control, no meal|control, no meal
172223|NCT01877148|Device|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
172224|NCT01877148|Behavioral|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
172225|NCT00108056|Drug|Enzastaurin (LY317615) monohydronchloride|
172226|NCT01877161|Device|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
172227|NCT01877161|Device|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
172228|NCT01877161|Device|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
172229|NCT01877174|Device|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
172230|NCT01877174|Procedure|transcarotid stenting|
172231|NCT01877187|Drug|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
172232|NCT01877200|Other|No treatment given|Patients will fill out a questionnaire by interview.
172233|NCT01877213|Behavioral|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
172234|NCT01877226|Drug|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
172235|NCT01877239|Other|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
171613|NCT01879020|Drug|TA-8995|Drug: TA-8995 10mg
171614|NCT01879020|Drug|TA-8995|Drug: TA-8995 25mg
171615|NCT01879020|Drug|Placebo|Placebo (TA-8995 1mg)
171616|NCT01879020|Drug|Placebo|Placebo (TA-8995 2.5mg)
171617|NCT01879020|Drug|Placebo|Placebo (TA-8995 5mg)
171618|NCT01879020|Drug|Placebo|Placebo (TA-8995 10mg)
171619|NCT01879020|Drug|Placebo|Placebo (TA-8995 25mg)
171941|NCT01874002|Device|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
171942|NCT01874015|Biological|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
171943|NCT01874015|Biological|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
171944|NCT01874028|Drug|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
171945|NCT01874041|Other|Massage|
171946|NCT01874041|Other|Occlusal splint|
171947|NCT01874054|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
171948|NCT01874054|Drug|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
171949|NCT01874067|Device|Arthritis glove|Isotoner three-quarter finger arthritis glove
171950|NCT01874080|Drug|Saxagliptin/Metformin|
171951|NCT00107744|Behavioral|Dietary protein|
171952|NCT01874093|Device|The Ischemic Stroke System|SPG stimulation and standard of care
171953|NCT01874093|Device|Sham control|Sham stimulation and standard of care
171954|NCT01874106|Other|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
171955|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
171621|NCT01881425|Procedure|Glaucoma Surgery|An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.
171622|NCT01881425|Device|InnFocus MicroShunt|An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure.
171623|NCT00108433|Drug|Cefazolin IV|
171624|NCT01881451|Drug|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
171625|NCT01881451|Procedure|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
171626|NCT01881464|Device|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
171627|NCT01881464|Drug|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
171628|NCT01881477|Procedure|kinetics modalities|The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.
The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.
Additionally, it promotes the adoption and sitting positions long and short legged and walk.
171629|NCT01881490|Device|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (PECDID score) and the Pediatric MRE-Based Activity Index (P-MECAI)
171630|NCT01881503|Biological|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
171631|NCT01881516|Device|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
171632|NCT01881516|Device|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
171633|NCT01881555|Procedure|invasive coronary angiography|
171634|NCT00108433|Drug|Linezolid IV|
171963|NCT01874184|Other|counseling intervention|Take part in weekly group counseling sessions
170991|NCT01929434|Procedure|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
170992|NCT01929460|Drug|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
170993|NCT01929460|Other|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
171306|NCT01922466|Procedure|Bee Venom Acupuncture|Bee Venom 1:20,000 under BVA Increment Protocol
- Increment Protocol as
1st week - SC 0.2cc/day, 2 days/week
2nd week - SC 0.4cc/day, 2 days/week
3nd week - SC 0.8cc/day, 2 days/week
171307|NCT00112476|Drug|temsirolimus|Given IV
171308|NCT01922466|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
171309|NCT01922479|Drug|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
171310|NCT01922479|Drug|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
171311|NCT01924910|Dietary Supplement|Placebo|
171312|NCT01924936|Behavioral|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
171313|NCT01924949|Drug|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
171314|NCT01924962|Device|revascularisation|revascularisation of chronic occluded coronary artery
171315|NCT01924975|Procedure|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
171316|NCT01924975|Device|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
171317|NCT01924975|Device|A 22 or 24 G intravenous catheter|
171318|NCT00112645|Drug|busulfan|
171319|NCT01924988|Procedure|Prostatic Embolization|Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudental or obturator branches as well.
The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries.
170655|NCT01923909|Drug|Intra-articular steroid injections|Patients receiving the IA steroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA steroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure maybe performed by senior residents with several years of experience or a consultant Orthopedic surgeon.
170656|NCT01923922|Radiation|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
170657|NCT01923935|Drug|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)
170658|NCT01923935|Drug|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)
170659|NCT00112567|Drug|thiotepa|
170660|NCT01923948|Drug|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
170661|NCT01923948|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
170662|NCT01923961|Drug|5 M NaCl solution|Infusion of 5 M NaCl adjusted at target NaCl concentration in plasma.
170663|NCT01923974|Drug|Melatonin 10 mg|
170664|NCT01923974|Drug|Melatonin 100 mg|
170665|NCT01923974|Drug|Placebo|
170666|NCT01923987|Radiation|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
170994|NCT01929486|Biological|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
170995|NCT00112879|Procedure|chemotherapy|
170996|NCT01929499|Biological|cytokine-induced killer cells|
170997|NCT01929512|Drug|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
170998|NCT01929512|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
170999|NCT01929512|Drug|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
171000|NCT01929538|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
170350|NCT00112840|Drug|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
170351|NCT01928498|Device|Percutaneous Transluminal Angioplasty (PTA)|
170352|NCT01928511|Drug|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
170353|NCT01928511|Drug|Nucleos(t)ide analogue therapy|
170354|NCT01928524|Drug|DOS2W|Docetaxel (30-35 mg/m2), Oxaliplatin (70 mg/m2) and S1 (30-50 mg/2) will be given every 2nd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered
170355|NCT01930760|Behavioral|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
170356|NCT01930773|Device|Genotyping|Patients harboring CYP2C19 *2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
170357|NCT01930773|Device|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
170358|NCT01930786|Drug|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
170359|NCT01930799|Behavioral|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
170360|NCT01930812|Procedure|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
170361|NCT01930812|Procedure|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
170362|NCT00112983|Biological|eculizumab|
170363|NCT01930812|Drug|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
170364|NCT01930825|Other|Analysis|Retrospective analysis of outcome and toxicity
170365|NCT01930838|Procedure|Gastric bypass operation|
170366|NCT01930851|Procedure|Gastric bypass operation|
169736|NCT01845376|Procedure|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
169737|NCT01845376|Procedure|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
169738|NCT01845376|Procedure|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
169739|NCT01845389|Device|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
169740|NCT01845389|Device|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
170036|NCT00104975|Procedure|peripheral blood stem cell transplantation|
170037|NCT01848379|Procedure|FD|
170038|NCT01848444|Other|Breastmilk|to measure levels of contaminants in human breastmilk samples
170039|NCT01848457|Drug|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 & 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 & 2 of treatment Cycles 1 & 2 (Treatment Arms 1, 3) OR Cycles 3 & 4 (Treatment Arms 2, 4)
170040|NCT01848457|Drug|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
170041|NCT01848470|Drug|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
170042|NCT01848470|Drug|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
170043|NCT00105183|Biological|Placebo|placebo infusion, single
170044|NCT01850940|Other|conventional thearpy|conventional therapy with salt limitation ,et al
170045|NCT01850953|Drug|Varenicline|This is an approved smoking cessation medication.
170046|NCT01850953|Drug|Placebo|
170047|NCT01850966|Drug|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
170048|NCT01850979|Drug|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
169445|NCT01852318|Drug|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
169446|NCT01852318|Drug|placebo|
169447|NCT00105300|Drug|Adalimumab|
169448|NCT01852331|Drug|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
169449|NCT01852331|Drug|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
169450|NCT01852344|Drug|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
169451|NCT01852344|Drug|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
169452|NCT01852357|Other|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
169453|NCT01852357|Other|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
169741|NCT01845402|Biological|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
169742|NCT01845415|Behavioral|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
169743|NCT01845415|Behavioral|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
169744|NCT01845428|Drug|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
169745|NCT01845441|Drug|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
169746|NCT00104780|Biological|EP-2101|
169747|NCT01845441|Drug|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
169748|NCT01845441|Drug|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
169156|NCT01846936|Procedure|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
169157|NCT01846962|Drug|Budesonide|The administered dose of topical steroid was 0.5 mg/2 mL. Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
169158|NCT01846962|Drug|Fluticasone|The administered dose of topical steroid was 0.5 mg/2 mL. Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
169159|NCT01846962|Behavioral|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
169160|NCT01846975|Drug|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
169161|NCT01846988|Device|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
169162|NCT01847001|Drug|Propranolol|Propranolol starting dose is 20mg BID; propranolol dose is up-titrated to 40mg BID to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
169163|NCT00002022|Drug|Epoetin alfa|
169164|NCT00104858|Other|Pharmacological Study|Correlative studies
169165|NCT01849484|Radiation|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
169166|NCT01849484|Radiation|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
169167|NCT01849497|Biological|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
169454|NCT01852370|Biological|CD3/CD19 negative allogeneic hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 48 hours of collection and given at time no less that 6 weeks post lung transplant.
173650|NCT01902719|Behavioral|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
173651|NCT01902719|Behavioral|Communication Skills Training|Receipt of "Do My PART" (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training.
173652|NCT01894919|Biological|rMenB + OMV vaccine (1 dose at study month zero)|
173653|NCT01894919|Biological|rMenB + OMV vaccine (2 doses 1 month apart)|
173654|NCT01894932|Behavioral|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams & Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
173655|NCT01894932|Behavioral|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
173656|NCT00109837|Radiation|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
173657|NCT01894958|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
173658|NCT01894958|Drug|Placebo|Strawberry flavored solution
173659|NCT01894971|Device|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
173660|NCT01894984|Drug|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
173661|NCT01894984|Drug|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
173662|NCT01894997|Device|Neuromuscular electrical stimulator|
173663|NCT01894997|Device|AV Impulse System Model 6000|
173664|NCT01895010|Device|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
173665|NCT01895010|Drug|tropisetron|only tropisetron 6mg before TACE
178115|NCT01907789|Behavioral|Phone Call|Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly.
178116|NCT01907802|Drug|Dabrafenib|Given PO
178424|NCT01910714|Behavioral|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
178425|NCT01910714|Behavioral|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
178426|NCT00111306|Drug|epratuzumab|
178427|NCT01910727|Behavioral|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
178428|NCT01903109|Drug|Cevimeline|
178429|NCT01903122|Drug|Cevimeline|
178430|NCT01903135|Procedure|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
178431|NCT00110422|Drug|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
178432|NCT01903135|Procedure|Pneumologist consult to establish the diagnosis of OHS|complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.
Medical history, previous treatments.
178433|NCT01903161|Procedure|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
178434|NCT01903161|Procedure|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
178435|NCT01903174|Device|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
169225|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
169226|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
169227|NCT01844544|Other|inspection of medical records|
169228|NCT01844557|Other|Swallowing Exercises|Participants perform 3 swallowing exercises.
169229|NCT01844557|Behavioral|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
169230|NCT01844557|Behavioral|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
169231|NCT01844583|Drug|alisertib|
169232|NCT01847001|Other|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
169233|NCT01847001|Drug|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
169234|NCT01847001|Drug|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
169235|NCT01847001|Drug|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
169236|NCT01847001|Drug|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
169237|NCT01847001|Drug|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
169238|NCT01847001|Drug|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
169239|NCT01847001|Procedure|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
168637|NCT00105755|Device|personal dermal thermometer (DT)|
168638|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
168639|NCT01855906|Procedure|Gap balanced surgical technique|Gap balanced surgical technique
168640|NCT01855906|Procedure|Measured resection|Measured resection surgical technique
168641|NCT01855919|Drug|Duloxetine|Administered orally
168642|NCT01855919|Drug|Placebo|Administered orally
168948|NCT01851603|Drug|Placebo|Identical diluent to that used for AVL-3288
168949|NCT01851616|Dietary Supplement|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
168950|NCT01851616|Dietary Supplement|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
168951|NCT00002028|Drug|Didanosine|
168952|NCT00105235|Drug|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
168953|NCT01851629|Behavioral|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
168954|NCT01851629|Other|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
168955|NCT01851642|Procedure|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
168956|NCT01851642|Procedure|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
168957|NCT01843998|Drug|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
168958|NCT01844011|Other|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
168959|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
168960|NCT01844037|Device|OneShot Ablation System|Renal denervation
168349|NCT01859962|Drug|BI 207127 Placebo|
168350|NCT01859988|Drug|Dupilumab (REGN668/SAR231893)|
168351|NCT01859988|Drug|Placebo|
168352|NCT00106327|Behavioral|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
168353|NCT00105378|Behavioral|Dutch EASYcare Study Geriatric Intermediate Care Programme|
168354|NCT01852877|Behavioral|Correctional case management|Correctional case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
168355|NCT01852877|Behavioral|Transitional case management|Transitional case management seeks to meet the immediate needs of HIV-positive persons leaving prison, then link them to Ryan White case management and support the Ryan White case manager in assisting these clients.
168643|NCT01855932|Behavioral|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
168644|NCT01855945|Biological|Swine Influenza|Comparison of different dosages of vaccines
168645|NCT01855958|Procedure|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
168646|NCT01855958|Procedure|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
168647|NCT01855971|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
168648|NCT00105755|Device|Device|
168649|NCT01855971|Dietary Supplement|Placebo|No active treatment is given.
168650|NCT01855984|Dietary Supplement|Oral mixed tocotrienols|200mg per day
168651|NCT01855984|Dietary Supplement|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
173137|NCT01896622|Drug|Cobicistat|Impact on dabigatran PK/PD
173138|NCT01896635|Biological|FMT infusions|Active FMT derived from healthy anonymous pre-screened donors
173139|NCT01896635|Other|Placebo infusion|Placebo infusion not containing any donor microbial material
173140|NCT01896661|Drug|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
173141|NCT01896661|Drug|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
173142|NCT01896687|Device|Scrambler|Electrotherapy
173143|NCT00109993|Biological|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
173144|NCT01896700|Drug|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
173145|NCT01896700|Drug|Placebo|Escalating matched dose of placebo
173146|NCT01896713|Other|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
173147|NCT01896726|Drug|Baricitinib|Administered orally
173148|NCT01899092|Drug|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
173149|NCT01899105|Drug|lumacaftor|
173150|NCT00110071|Other|laboratory biomarker analysis|Correlative studies
173151|NCT01899105|Drug|ivacaftor|
173152|NCT01899118|Radiation|Preoperative irradiation|50.4Gy/28F/5.5w
173153|NCT01899118|Drug|Nimotuzumab|400mg/w，0-5w
173154|NCT01899118|Drug|Oxaliplatin|130mg/m2 d1
168356|NCT01852890|Drug|Ascorbate|Intravenous infusion of high-dose ascorbate
168357|NCT01852890|Drug|Gemcitabine|Intravenous chemotherapeutic
168358|NCT01852890|Radiation|Radiation therapy|
168359|NCT01852903|Dietary Supplement|calcium ascorbate|
168360|NCT01852903|Dietary Supplement|ascorbic acid|
172835|NCT01875575|Dietary Supplement|Glucose 25g|
172836|NCT01875575|Dietary Supplement|Glucose 10g|
172837|NCT01875601|Biological|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
172838|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,2 application)
172839|NCT01875601|Biological|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
172840|NCT01875627|Dietary Supplement|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
172841|NCT01875627|Dietary Supplement|Carbohydrate and Konjac Noodles|
172842|NCT01875627|Dietary Supplement|Carbohydrate noodles|
172843|NCT01875640|Behavioral|Decision Support Tool|
172844|NCT01875653|Biological|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
172845|NCT01875653|Biological|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
172846|NCT01875666|Drug|Trastuzumab|8 mg/kg IV, single dose
172847|NCT01875666|Drug|pertuzumab|840 mg IV single dose
172848|NCT01875666|Drug|lapatinib|1000 mg daily for 7 days
172849|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,2 application)
172850|NCT01875679|Other|Comprehensive Surgical Coaching|
172851|NCT01878383|Device|Genexpert assay|
172852|NCT01878396|Drug|Anti-B-RAF|
172853|NCT01878422|Drug|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
172854|NCT01878422|Drug|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
173155|NCT01899118|Drug|Capecitabine|825mg/m2 bid d1-5/w,1-5w
172236|NCT00108069|Drug|Tamoxifen citrate|oral dose 120 mg twice a day, every day
172237|NCT01877252|Procedure|Surgical revascularization|
172539|NCT01872494|Other|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
172540|NCT01872494|Other|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
172541|NCT00107562|Behavioral|Adolescent Safer Sex Social Network Intervention|
172542|NCT01872494|Drug|0.33% ropivacaine 250ml|
172543|NCT01872494|Drug|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
172544|NCT01872507|Other|Biofeedback training|usual treatment +12 biofeedback training
172545|NCT01872533|Other|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at ~ 15% O2 (ca. 2400 m elevation).
172546|NCT01872546|Drug|HUMIRA 40mg|
172547|NCT01872559|Other|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
172548|NCT01872572|Drug|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
172549|NCT01872572|Drug|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
172550|NCT01872572|Drug|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
172551|NCT01872572|Drug|Subcutaneous RB006 2.0 mg|Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration
Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration.
172552|NCT00107575|Behavioral|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
172553|NCT01872572|Drug|Placebo|Placebo
172554|NCT01872585|Behavioral|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
172555|NCT01872598|Drug|Group 1|
171956|NCT01874119|Drug|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
171957|NCT01874132|Behavioral|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
171958|NCT01874145|Drug|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
171959|NCT01874145|Drug|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
171960|NCT01874171|Drug|Cisplatin|
171961|NCT01874171|Drug|Cetuximab|
171962|NCT00107757|Drug|GW685698X|
172238|NCT01877252|Procedure|Endovascular revascularization|
172239|NCT01877252|Other|No vascular intervention|
172240|NCT01877265|Drug|LY2605541|
172241|NCT01877278|Device|Wearable pulsed electromagnetic fields|
172242|NCT01877304|Device|AKITA|
172243|NCT01877317|Device|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
172244|NCT01877330|Procedure|Interscalene block for shoulder arthroscopy|
172245|NCT00108342|Drug|Nicotine lozenges - 2 mg and 4 mg|
172246|NCT01879969|Procedure|computer assisted orthognathic planning and surgery of asymmetric patients|
172247|NCT01880034|Other|Lipid Emulsion Survey|
172248|NCT01880047|Drug|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (> 50,000 and increase by > 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (> 50,000 and > 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
172249|NCT01880047|Drug|Placebo|
171964|NCT01874184|Behavioral|behavioral dietary intervention|Set goals for changing dietary habits
171965|NCT01874184|Behavioral|exercise intervention|Attend group exercise activities
171966|NCT01874184|Other|questionnaire administration|Ancillary studies
171967|NCT01874184|Other|laboratory biomarker analysis|Correlative studies
171968|NCT01876615|Drug|YH4808|experimental drug
171969|NCT01876615|Drug|Diclofenac|Depain tablet 25mg
171970|NCT01876615|Drug|YH4808+Diclofenac|
171971|NCT01876628|Drug|Flucloxacillin and Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
171972|NCT00108017|Drug|Duration of Treatment: Part 1) 6 wk timolol maleate run in|
171973|NCT01876628|Drug|Flucloxacillin and placebo|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
171974|NCT01876641|Drug|Vemurafenib + Cobimetinib, Decitabine|
171975|NCT01876654|Device|TruMatch® patient specific cutting guide|
171976|NCT01876667|Other|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
171977|NCT01876667|Other|Placebo|Usual Care
171978|NCT01876680|Other|Stretching and aerobic exercise|Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.
Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year.
171979|NCT01876680|Other|Strength training|Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year.
171980|NCT01876693|Procedure|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
172256|NCT00108342|Drug|Nicotine inhaler (4 mg yield) - low and high "dosage" by frequency of puffing|can yield 4 mg from 10 mg device - infrequent and frequent puffing
171320|NCT01924988|Drug|Embosphere® Microspheres|Embosphere® Microspheres, Merit Medical, South Jordan, UT
171321|NCT01925001|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
171322|NCT01925001|Drug|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
171323|NCT01925014|Radiation|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert in an average patient.
171324|NCT01925014|Radiation|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert in an average patient.
171635|NCT01881555|Procedure|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
171636|NCT01881568|Drug|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
171637|NCT01873352|Procedure|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
171638|NCT01873365|Other|Data collection|Case report forms (CRFs), logbooks and booklets.
171639|NCT01873378|Drug|Triptorelin 3.75 mg|
171640|NCT01873391|Procedure|Diagnostic hysteroscopy|
171641|NCT01873404|Drug|BG00010|As specified in the treatment arm
171642|NCT01873404|Drug|Placebo|As specified in the treatment arm
171643|NCT00107653|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
171644|NCT01873417|Drug|BG00012 (DMF)|
171645|NCT01873430|Drug|Melatonin|
171646|NCT01873443|Drug|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10~25mg/week Folic acid at least 5mg/week
171647|NCT01873456|Other|multifactorial nutritional intervention|
171648|NCT01873469|Radiation|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
171001|NCT01929538|Device|covered self-expanding biliary metal stent, 12mm in diameter|
171002|NCT01929538|Device|covered self-expanding biliary metal stent, 10mm in diameter|
171003|NCT00113113|Drug|Rubitecan|
171004|NCT01932021|Procedure|adipose tissue grafting|
171005|NCT01932034|Device|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
171006|NCT01932060|Drug|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
171007|NCT01932073|Device|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
171008|NCT01932086|Dietary Supplement|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
171009|NCT01932086|Dietary Supplement|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
171010|NCT01932086|Dietary Supplement|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
171011|NCT01932086|Dietary Supplement|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
171012|NCT01932086|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
171013|NCT01932099|Device|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
171325|NCT01925027|Device|Nano+ DES|All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
171326|NCT01925040|Device|Placement of restoration|Placement of restorations
171327|NCT01925053|Other|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
171328|NCT01925053|Other|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
170667|NCT01923987|Drug|BioChemotherapy|Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1
Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1
Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2
5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).
Bevacizumab 5 mg/kg IV over 90 mins on Day 1
Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.
FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses
Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)
170668|NCT01923987|Procedure|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
170669|NCT01924000|Drug|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
170670|NCT00112567|Procedure|peripheral blood stem cell transplantation|
170671|NCT01924000|Drug|Placebo|
170672|NCT01926236|Other|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
170673|NCT01926236|Drug|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
170674|NCT01926236|Drug|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
170675|NCT01926236|Drug|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
170676|NCT01926262|Behavioral|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
170677|NCT00112697|Drug|cisplatin|
170678|NCT01926275|Device|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
170679|NCT01926275|Device|NPPV|noninvasive positive pressure ventilation
170680|NCT01926275|Device|IMT|inspiratory muscle training
170681|NCT01926288|Drug|Entecavir maleate tablets|
170682|NCT01926288|Drug|blank Baraclude tablets|
170683|NCT01926288|Drug|Blank maleate entecavir tablets|
170684|NCT01926288|Drug|Baraclude tablets|
170685|NCT01926301|Procedure|continuous veno-venous hemodialysis|
170686|NCT01926314|Device|PHENIX Neuromuscular Stimulation Therapy System device|
170049|NCT01850979|Drug|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
170050|NCT01850992|Device|Active CPAP|Effective CPAP will be administered
170051|NCT01850992|Device|Sham CPAP|This is placebo CPAP
170052|NCT01851005|Drug|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
170053|NCT01851005|Drug|Sevoflurane|Control Vol% to maintain BIS 40~45
170054|NCT00105183|Biological|EZ-2053|single IV infusion, 9 mg/kg
170055|NCT01851005|Drug|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40~45 and changes of vital signs within 20%.
170056|NCT01851005|Drug|Normal saline|Use as placebo
170057|NCT01851005|Drug|Rocuronium|0.8 mg/kg for induction
170367|NCT01930864|Drug|Metformin|metformin up to 2500mg/d
170368|NCT01930864|Drug|Irinotecan|Irinotecan 350 mg/m² IV q21d
170369|NCT01930877|Drug|Lidocaine|Lidocaine iv bolus followed by infusion
170370|NCT01930877|Other|Placebo (normal saline)|Normal saline bolus followed by infusion
170371|NCT01930890|Biological|BIIB023|As specified in the treatment arm
170372|NCT01930890|Drug|Background therapy|Includes mycophenolate mofetil (MMF) titrated to a target daily dose of 2 g (1 g twice daily) and oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
170373|NCT00112996|Drug|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
170374|NCT01930903|Device|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
170375|NCT01930916|Device|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
170376|NCT01923415|Procedure|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
170377|NCT01923415|Procedure|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
170378|NCT01923415|Procedure|No intervention, urine collection|Urine will be collected from all participants.
169749|NCT01847794|Device|Cell Search® CTC epithelial kit|Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).
Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.
Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
169750|NCT01847807|Drug|low dose Astragalus|
169751|NCT01847807|Drug|high dose astagalus|
169752|NCT01847820|Device|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
169753|NCT00104962|Drug|lenalidomide|Given orally
169754|NCT01847833|Other|MRI scan|
169755|NCT01847859|Procedure|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
169756|NCT01847872|Drug|IPV IM Needle|
169757|NCT01847872|Drug|IPV ID Needle|
169758|NCT01847872|Drug|IPV IM Device|
169759|NCT01847872|Drug|IPV ID Device|
170058|NCT01851018|Radiation|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
170059|NCT01851018|Radiation|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
170060|NCT01851031|Procedure|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
170061|NCT01851044|Procedure|Platelet Rich Plasma|
170062|NCT01851044|Procedure|Whole Blood Injection|
170063|NCT01851044|Procedure|Saline Injection|
170064|NCT01851057|Behavioral|STAR|Problem-solving and education intervention (8 total sessions)
170065|NCT00105183|Biological|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
170066|NCT01851057|Behavioral|Education Only|Education around epilepsy (8 total sessions)
169455|NCT01852383|Drug|Duloxetine|Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.
Adverse events: All adverse events and serious adverse events were documented.
The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.
Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial.
169456|NCT01852396|Procedure|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
169457|NCT01852409|Drug|bevacizumab|
169458|NCT00105313|Drug|MEDI-507|
169459|NCT01852435|Drug|R-CEOP-70|
169460|NCT01852435|Drug|R-CEOP-90|
169461|NCT01852435|Drug|R-CHOP-50|
169462|NCT01852448|Genetic|Blood or Saliva Sample Collection|A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
169463|NCT01852448|Other|Glucose -potentiated arginine (GPA) stimulation tests|Glucose -potentiated arginine (GPA) stimulation tests and mixed meal tolerance tests (MMTT) will be performed on two separate days in the outpatient setting.
169464|NCT01852461|Drug|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
169465|NCT01852461|Drug|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
169466|NCT01844908|Procedure|Electroacupuncture|
169467|NCT01844934|Other|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
169468|NCT01844947|Drug|Vinflunine|Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance >60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.
For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days.
169469|NCT01844947|Drug|Sorafenib|Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):
Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed.
173666|NCT01895023|Drug|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
173667|NCT00000297|Drug|Labetalol|
173982|NCT01898117|Drug|Paclitaxel + Bevacizumab|
173983|NCT01898130|Biological|bevacizumab|Given IV
173984|NCT01898130|Procedure|quality-of-life assessment|Ancillary studies
173985|NCT01898143|Other|Whole body vibration|
173986|NCT01898156|Drug|BIW-8962|Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.
Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops.
173987|NCT01900561|Behavioral|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
173988|NCT01900561|Behavioral|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
173989|NCT01900574|Drug|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
173990|NCT01900587|Drug|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
173991|NCT01900587|Drug|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
173992|NCT01900600|Other|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
173993|NCT01900600|Other|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
173994|NCT01900613|Behavioral|Ninos Sanos Familia Sana|
173995|NCT00110162|Procedure|orchiectomy|
178436|NCT01903187|Device|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
178437|NCT01903187|Procedure|Sham|Renal artery angiogram
178438|NCT01903200|Drug|FK949E|Oral
178439|NCT01903213|Drug|Kiklin capsules|Oral
178440|NCT01903226|Other|High intensity training|
173668|NCT00002074|Drug|Amphotericin B|
173669|NCT00109837|Drug|allopurinol|300 mg/d PO Days 1-7
173670|NCT01895023|Drug|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
173671|NCT01895023|Drug|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
173672|NCT01895036|Drug|Naltrexone|
173673|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
173674|NCT01897480|Biological|LY2875358|Administered IV
173675|NCT01897480|Drug|Erlotinib|Administered Orally
173676|NCT01897493|Drug|Evacetrapib|Administered orally
173677|NCT01897493|Drug|Digoxin|Administered orally
173678|NCT01897519|Drug|Placebo|Placebo infusion
173679|NCT01897519|Drug|ABT-719|Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
173680|NCT01897532|Drug|Placebo|placebo matching tablets
173681|NCT00110019|Drug|Paclitaxel|Given IV
173682|NCT01897532|Drug|Linagliptin|
173683|NCT01897545|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
169240|NCT01847001|Drug|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
169531|NCT01850108|Radiation|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
169532|NCT01852604|Biological|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
169533|NCT00105352|Procedure|Glucagon Stimulation Test|
169534|NCT01852604|Other|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
169535|NCT01852617|Behavioral|Training in smoking cessation counseling|Midwife facilitators in the intervention clinics will be identified and trained to deliver the "5 A's" to pregnant women and will then disseminate and implement the program. The "5 A's" (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide
169536|NCT01852630|Drug|cefepime + Albumin|cefepime + Albumin will be given for 2 days
169537|NCT01852630|Drug|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
169538|NCT01852643|Procedure|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
169539|NCT01852643|Procedure|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
169540|NCT01852656|Behavioral|Postcard and IVR Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
169541|NCT01852656|Behavioral|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
169542|NCT01852656|Behavioral|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
169543|NCT01852669|Procedure|Inversion|Patients inverted 30 degree head down in Trendelenburg position
168961|NCT01844050|Drug|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
168962|NCT00104676|Drug|ifosfamide|Given in a dose-dense sequential fashion
168963|NCT01844050|Drug|Placebo|
168964|NCT01844063|Genetic|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
168965|NCT01844063|Genetic|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
168966|NCT01844063|Drug|Conventional treatment|Received conventional treatment including:
A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma.
169241|NCT01847001|Drug|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
169242|NCT00104871|Drug|Bortezomib|Administered IV at the dose of 1.3 mg/m^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
169243|NCT01847001|Drug|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
169244|NCT01847014|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
169245|NCT01847027|Drug|NutraStem|
169246|NCT01847027|Drug|Placebo|
169247|NCT01847053|Other|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
169248|NCT01847066|Device|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
169249|NCT01847066|Device|Erbium 2940 plus cosmetics|laser
169250|NCT01849640|Drug|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
169251|NCT01849666|Drug|phenprocoumon|6 mg oral single dose
169252|NCT01849666|Drug|vemurafenib|960 mg bid orally
168652|NCT00106106|Procedure|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
168653|NCT01858090|Drug|Group Fentanyl|
168654|NCT01858090|Drug|Group sufentanil|
168655|NCT01858090|Drug|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to <100 mmHg, fluid loading and ephedrine (5 mg) were administered.
168656|NCT01858090|Drug|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
168657|NCT01858090|Drug|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
168658|NCT01858090|Drug|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
168659|NCT01858090|Drug|Diphenhydramine|for severe pruritus
168660|NCT01858090|Drug|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
168661|NCT01858090|Drug|Diclofenac sodium|as additional analgesic among cases in which VAS>3(Postoperatively)
168662|NCT01858103|Drug|BMN 110|
168967|NCT01844076|Drug|Phase I (Quinacrine)|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
168968|NCT01844076|Drug|Capecitabine|
168969|NCT01844102|Device|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
168970|NCT01844115|Drug|Placebo|
168971|NCT01844115|Drug|Vilazodone|Viibryd
168972|NCT01844128|Dietary Supplement|weight loss|
168973|NCT00104676|Drug|oxaliplatin|Given in a dose-dense sequential fashion
168974|NCT01844141|Drug|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
168361|NCT01852903|Other|placebo|
168362|NCT01852916|Device|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
168363|NCT01852916|Device|NHFOV|Nasal High Frequency Oscillatory Ventilation
168364|NCT00105404|Drug|Triamcinolone Acetonide|
168365|NCT01852929|Other|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
168366|NCT01852942|Drug|Losartan|We will start with 50 mg of losartan by mouth daily. We will increase the dosage to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
168367|NCT01852942|Drug|Placebo|one tablet by mouth daily
168368|NCT01852955|Drug|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
168369|NCT01852955|Drug|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
168370|NCT01852981|Behavioral|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
168371|NCT01852981|Behavioral|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
168372|NCT01852994|Drug|Testosterone replacement|Application quarterly of Testosterone Undecylate
168373|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
168374|NCT01853007|Behavioral|COACH Program|
168375|NCT01855373|Dietary Supplement|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
168663|NCT00106106|Drug|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
168664|NCT01858116|Drug|[68Ga]ABY-025|Intravenous injection followed by PET imaging
173156|NCT01899131|Device|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
173157|NCT01899144|Drug|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
173158|NCT01899144|Drug|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
173159|NCT01899144|Drug|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
173160|NCT01899170|Procedure|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
173161|NCT00110071|Other|flow cytometry|Correlative studies
173162|NCT01899170|Device|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
173163|NCT01899170|Drug|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
173164|NCT01899183|Procedure|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
173165|NCT01899196|Biological|blood sampling,|
173166|NCT01899209|Procedure|STARR|
173167|NCT01899209|Procedure|Laparoscopic Ventral Rectopexy|
173168|NCT01899222|Device|Handheld fundus photography|
173169|NCT01899235|Device|drug eluting balloon|
173170|NCT01899235|Device|drug eluting stent|
173171|NCT01899248|Drug|Sevoflurane|
173172|NCT00110071|Genetic|polymerase chain reaction|Correlative studies
173173|NCT01899248|Drug|Desflurane|
173174|NCT01899261|Radiation|Stereotactic Radiosurgery|Undergo SBRT
173175|NCT01899274|Device|bant iPhone application|
173176|NCT01901510|Drug|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
172556|NCT01872598|Drug|Group 2|
172557|NCT01872598|Drug|Group 3|
172558|NCT01872611|Drug|Nepafenac Ophthalmic Suspension, 0.3%|
172559|NCT01872611|Other|Nepafenac Vehicle|Inactive ingredients used as placebo comparator
172855|NCT01878422|Drug|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
172856|NCT01878422|Drug|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
172857|NCT01878435|Other|SMS reminder|
172858|NCT01878435|Other|Travel subsidy|
172859|NCT01878435|Other|Travel subsidy 2|
172860|NCT01878448|Drug|Anlotinib|
172861|NCT00108173|Drug|Zyban|
172862|NCT01878461|Drug|Vehicle|
172863|NCT01878461|Drug|M518101|
172864|NCT01878474|Drug|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
172865|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
172866|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
172867|NCT01878474|Drug|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
172868|NCT01878474|Drug|Placebo|Single ascending dose in Caucasian men
172869|NCT01878474|Drug|Placebo|Age-effect in Caucasian men
172870|NCT01878474|Drug|Placebo|Gender-effect in Caucasian women
172871|NCT01878474|Drug|Placebo|Single ascending dose in Japanese men
172872|NCT00108186|Drug|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
172250|NCT01880060|Behavioral|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; >20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
172251|NCT01880060|Behavioral|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
172252|NCT01880073|Device|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
172253|NCT01880086|Drug|Clomiphene citrate|
172254|NCT01880086|Drug|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
172255|NCT01880099|Drug|placebo|placebo compared to 8mg of galatamine
172560|NCT01872611|Drug|Prednisolone acetate ophthalmic suspension|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
172561|NCT01875029|Device|real-tDCS + back school|real tDCS + back school
172562|NCT01875042|Device|TENS|Transcutaneous electrical nerve stimulation
172563|NCT01875042|Device|Sham TENS|Sham Transcutaneous electrical nerve stimulation
172564|NCT00107913|Drug|Doxil|
172565|NCT01875055|Device|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
172566|NCT01875055|Device|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
172567|NCT01875068|Behavioral|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
172568|NCT01875068|Behavioral|versus NPs and PAs who are not required to discuss patient referrals (control group).|
172569|NCT01875081|Biological|Livercellgram|Livercellgram
Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃
Injection Method: Directly inject into liver through hepatic artery
172257|NCT01880099|Drug|Galantamine 8mg|8mg of galatamine compared to placebo
172258|NCT01880099|Drug|Galantamine 16mg|16mg of galatamine compared to placebo
172259|NCT01880112|Drug|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
172260|NCT01880125|Drug|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
172261|NCT01880138|Other|watching animated cartoon before general anesthesia|
172262|NCT01880138|Other|not watching animated cartoon beofre general anaesthesia|
172263|NCT01880151|Device|EEG|EEG recorded during a resting condition and during an episodic memory task condition
172264|NCT01880190|Other|Ringer's Lactate|
172265|NCT01880190|Other|HES 130/0.4 and Ringer's Lactate|
172266|NCT01882179|Drug|placebo|
172267|NCT01882192|Behavioral|Family physical activity planning|This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for "when," "where," "how," and "what" physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting.
172268|NCT01882205|Device|Virtual chromoendoscopy|
172269|NCT01882205|Procedure|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
172270|NCT01882218|Drug|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
172271|NCT01882218|Drug|Standard Treatment|Standard liver surgery.
172272|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
172273|NCT01882244|Behavioral|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
171649|NCT01873482|Behavioral|Movement to rhythm|Movement to rhythm
171650|NCT01873495|Drug|Omacetaxine|Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 10 consecutive days every 28 (±3) days for 3 cycles.
Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 5 days, every 28 days for up to 6 cycles
171651|NCT01873508|Drug|RO4917523|Fast release MR capsule, single dose
171652|NCT01873508|Drug|RO4917523|Target release MR capsule, single dose
171653|NCT01873508|Drug|RO4917523|Slow release MR capsule, single dose
171654|NCT00107666|Drug|CTI-01 (ethyl pyruvate)|
171655|NCT01873508|Drug|RO4917523|[13C]-labeled tracer dose i.v.
171656|NCT01873521|Procedure|Non invasive ventilation|
171981|NCT01876706|Device|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
171982|NCT01876719|Drug|AR08|
171983|NCT00108017|Drug|Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds|
171984|NCT01876719|Drug|Placebo|
171985|NCT01876732|Drug|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
171986|NCT01876745|Drug|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
171987|NCT01879514|Drug|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
171988|NCT01879514|Drug|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
171989|NCT00108290|Drug|Chemotherapy|
171329|NCT00112645|Drug|cyclosporine|
171330|NCT01925066|Drug|Vancomycin|
171331|NCT00112749|Other|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
171332|NCT01927575|Device|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
171333|NCT01927575|Device|Standard X-Ray|Standard of Care X-Ray Imaging
171334|NCT01927575|Device|Standard CT Scan or MRI|Standard CT Scan or MRI Imaging - Physician/Site Discretion
171335|NCT01927588|Drug|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
171336|NCT01927588|Drug|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
171337|NCT01927614|Radiation|Cardiac CT|A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).
The CT scan protocol will comprise 3 steps.
Prospectively gated calcium scoring.
Stress-myocardial CT perfusion.
Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus.
171338|NCT01927627|Drug|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
171339|NCT01927640|Drug|Dexmedetomidine|During Visit 2 (Cocaine Study Day), intranasal cocaine will be administered. If randomized to this active drug arm, dexmedetomidine (0.3-0.6 mcg/kg) will then be administered followed by repeat myocardial contrast echocardiography.
171340|NCT01927666|Dietary Supplement|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
171341|NCT01927679|Drug|Vitamin E|
171342|NCT00112749|Other|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
171343|NCT01927679|Drug|Eucerin|Control
171344|NCT01927692|Other|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
171657|NCT01873534|Drug|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
171658|NCT01873547|Procedure|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
171659|NCT01873547|Other|rehabilitation|Patients only receive rehabilitation of limb function.
170687|NCT01926314|Other|usual home care without device|
170688|NCT00112697|Drug|docetaxel|
171014|NCT00113126|Drug|Treatment interruption|
171015|NCT01932112|Drug|Adenosine arm|After pulmonary vein isolation, 12mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
171016|NCT01932138|Other|Enhanced CHW intervention|The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called "home-base carers" (or HBC). The HBC in this study are supervised by another existing cadre, so-called "community-based health care workers" (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention.
171017|NCT01932138|Other|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
171018|NCT01932151|Drug|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water.
171019|NCT01932164|Procedure|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
171020|NCT01924429|Drug|Lisdexamphetamine|Escalating stepped dose titration: 30, 50 or 70mg
171021|NCT01924468|Drug|Oral methylphenidate and Oral haloperidol|
171022|NCT01924481|Dietary Supplement|High Caffeine|
171023|NCT01924481|Dietary Supplement|Low caffeine|
171024|NCT01924481|Dietary Supplement|High theobromine|
171025|NCT01924481|Dietary Supplement|low theobromine|
171026|NCT00002099|Drug|Didanosine|
171027|NCT00112593|Drug|mycophenolate mofetil|Given IV or PO
171028|NCT01924481|Dietary Supplement|No theobromine|
171029|NCT01924507|Device|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
170379|NCT01923428|Drug|AZD1722|
170380|NCT00112528|Drug|gemcitabine hydrochloride|
170381|NCT01923428|Drug|Placebo|
170382|NCT01923454|Procedure|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
170383|NCT01923454|Drug|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
170384|NCT01923454|Procedure|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
170385|NCT01923467|Behavioral|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
170689|NCT01926327|Biological|PRP injection|Injection of PRP in patients with knee osteoarthritis.
170690|NCT01926327|Biological|Placebo|
170691|NCT01926366|Drug|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
170692|NCT01926366|Drug|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
170693|NCT01926379|Other|Combination Intervention Package|At HIV clinics randomly assigned to the combination intervention package (CIP), the intervention will be delivered to all patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate IPT on or after study initiation on July 1, 2013; the interventions will be provided during regular HIV clinic visits as part of routine care. All health care providers will be trained to implement the CIP in HIV clinics. The CIP will contain the five programmatic, structural, and psychosocial components outlined in the CIP study arm description.
170694|NCT01926379|Other|Standard of Care|At HIV clinics randomly assigned to standard of care (SOC), patients will be offered and receive IPT per national guidelines. HIV patients are screened for TB at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Patients with a negative TB screen are assessed for IPT eligibility; and in the absence of contraindications, are counseled by nurses on IPT benefits, potential side effects, and adherence. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued
170695|NCT01926392|Drug|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
170696|NCT01928914|Drug|moxifloxacin|moxifloxacine given on Day 3 only
170067|NCT01851070|Drug|Allogeneic Mesenchymal Precursor Cells|
170068|NCT01851070|Drug|Normal Saline|
170069|NCT01851083|Biological|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
170070|NCT00104650|Genetic|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
170071|NCT01843530|Drug|NaCl|
170072|NCT01843543|Other|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
170073|NCT01843556|Drug|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
170074|NCT01843569|Biological|In Vitro maturation|
170075|NCT01843595|Behavioral|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
170386|NCT01923467|Drug|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
170387|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
170388|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
170389|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
170390|NCT01923493|Other|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
170391|NCT00112528|Drug|oxaliplatin|
170392|NCT01923493|Other|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
170393|NCT01923506|Radiation|stereotactic body radiation therapy|Undergo SBRT
170394|NCT01923506|Procedure|quality-of-life assessment|Ancillary studies
170395|NCT01923506|Other|laboratory biomarker analysis|Correlative studies
169760|NCT01847885|Device|Smartpatch Peripheral Nerve Stimulation (PNS) System|The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a "Lead") that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).
169761|NCT01847898|Procedure|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
169762|NCT01847898|Procedure|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
169763|NCT01847911|Other|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
169764|NCT00104975|Biological|alemtuzumab|
169765|NCT01847911|Other|instructor training|a pre-validated OSCE neonatal resuscitation program
169766|NCT01847924|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
169767|NCT01847924|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
169768|NCT01847950|Dietary Supplement|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
169769|NCT01847950|Dietary Supplement|Maltodextrin|
169770|NCT01847963|Drug|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
169771|NCT01847963|Drug|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
169772|NCT01847976|Drug|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
169773|NCT00105144|Drug|Caspofungin|IV
169774|NCT01850433|Behavioral|Internet based CBT for body dysmorphic disorder|
169775|NCT01850446|Drug|Ergoferon|Safety and Efficiency
169776|NCT01850446|Drug|Oseltamivir|Safety and Efficiency
169777|NCT01850485|Device|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
169778|NCT01850511|Procedure|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
173996|NCT01900626|Drug|epidural catheter|epidural catheter with 0.3% ropivacaine
173997|NCT01900639|Behavioral|change time of intake of aspirin|
173998|NCT01900652|Drug|LY2875358|Administered IV
173999|NCT01900652|Drug|Erlotinib|Administered Orally
174296|NCT01893684|Behavioral|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
174297|NCT01896232|Drug|Placebo|Placebo IV thrice weekly
174298|NCT01896232|Procedure|Hemodialysis|Hemodialysis
174299|NCT01896245|Drug|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
174300|NCT01896245|Drug|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
174301|NCT00109941|Biological|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
174302|NCT01896245|Drug|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
174303|NCT01896271|Drug|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
174304|NCT01896271|Radiation|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
174305|NCT01896284|Drug|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
174306|NCT01896297|Drug|Pradaxa, dabigatran etexilate|75mg BID by oral
174307|NCT01896310|Device|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
174308|NCT01896323|Drug|CC-223|CC-223 20 mg tablets
174309|NCT01896323|Drug|Ketoconazole|Ketoconazole 400 mg tablets
174310|NCT01896336|Drug|Zolpidem Hemitartrate|Patz - 5mg sublingual zolpidem hemitartrate
1 QD
Stilnox - 10mg oral zolpidem hemitartrate
1 QD
174311|NCT01896349|Other|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
173684|NCT01897545|Procedure|PV isolation+renal denervation|The procedure of AF ablation is the same like in the circumferential PV isolation.
After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
173685|NCT01897558|Device|Pacemaker implantation|
173686|NCT01897571|Drug|EPZ-6438|
173687|NCT01897584|Other|inverse IE|in only one group changes of I:E ratio would be applied
173688|NCT01897597|Drug|BI 144807 high dose|oral solution
174000|NCT01900665|Drug|Solanezumab|Administered Intravenously (IV)
174001|NCT01900665|Drug|Placebo|Administered IV
174002|NCT01900678|Device|VytronUS Ablation System|Pulmonary vein isolation.
174003|NCT01900691|Device|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
174004|NCT01900704|Drug|SER120 750 ng|SER120 750 ng
174005|NCT01900704|Drug|SER120 1500 ng|SER120 1500 ng
174006|NCT00110188|Drug|ridaforolimus|
174007|NCT01900704|Drug|Placebo|Placebo
174008|NCT01900717|Drug|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
174009|NCT01900717|Drug|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
174010|NCT01893151|Drug|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
174011|NCT01893164|Procedure|simple decompression|decompression of the ulnar nerve
174012|NCT01893164|Procedure|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
174013|NCT01893164|Procedure|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
174014|NCT01893177|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
169544|NCT00105365|Device|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
169545|NCT01852669|Procedure|Shock Wave Lithotripsy|Shock wave lithotripsy
169546|NCT01852669|Drug|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
169839|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
169840|NCT01845623|Drug|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
169841|NCT00104793|Drug|carboplatin|
169842|NCT01845623|Drug|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
169843|NCT01847989|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
169844|NCT01847989|Drug|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
169845|NCT00104975|Biological|therapeutic allogeneic lymphocytes|
169846|NCT01848002|Drug|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
169847|NCT01848002|Drug|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
169848|NCT01848015|Other|detection of CTCs|
169849|NCT01848041|Drug|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
169850|NCT01848041|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
169851|NCT01848054|Drug|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
169852|NCT01848054|Drug|Buprenorphine|Buprenorphine sublingual tablets
169853|NCT01848067|Drug|Alisertib|Given PO
169854|NCT01848067|Drug|Abiraterone acetate|Given PO
169855|NCT01848067|Drug|Prednisone|Given PO
169856|NCT00104975|Drug|fludarabine phosphate|
169253|NCT01849679|Other|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
169254|NCT01849692|Drug|ESBA1008 solution|Intravitreal injection or infusion
169255|NCT00105066|Drug|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
169256|NCT01849692|Drug|Ranibizumab|Intravitreal injection
169257|NCT01849705|Other|No intervention|
169258|NCT01849731|Other|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
169547|NCT01852682|Drug|PA21|
169548|NCT01852695|Behavioral|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
169549|NCT01845038|Drug|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of ~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
169550|NCT01845038|Drug|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of ~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
169551|NCT01845038|Drug|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
169552|NCT01845064|Drug|DM199|
169553|NCT01845064|Drug|Placebo|
169554|NCT01845077|Drug|2x500 mg Metformin (Glumetza)|2 tablets
169555|NCT01845077|Drug|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
169556|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
169557|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
169558|NCT00104741|Drug|triptorelin|
169559|NCT01845077|Drug|3x500 mg Metformin (Glumetza)|3 tablets
168975|NCT01844141|Drug|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
168976|NCT01846455|Drug|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
168977|NCT01846468|Drug|LHW090|1 mg, 12.5 mg, 100 mg capsules
168978|NCT01846468|Drug|Placebo|Matching placebo capsules
168979|NCT01846481|Drug|RBP-8000|RBP-8000 administered in the vein at either the 100 or 200 mg level on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
168980|NCT01846481|Drug|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
168981|NCT01846481|Drug|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
168982|NCT01846507|Drug|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
168983|NCT00104858|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
168984|NCT01846520|Other|educational intervention|Receive FCPCI home education sessions
168985|NCT01846520|Behavioral|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
168986|NCT01846520|Procedure|quality-of-life assessment|Ancillary studies
169259|NCT01849731|Other|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
169260|NCT01849744|Drug|VS-4718|
169261|NCT01849757|Other|prime crystalloid|used for priming the CPB circuit
169262|NCT01849757|Other|Human Albumin|Used as a constituent for priming the CPB circuit
169263|NCT01849757|Other|Voluven|Used as a constituent for priming the CPB circuit
169264|NCT01849770|Drug|Mexiletine|
169265|NCT01849770|Drug|Placebo|
168665|NCT01858129|Drug|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
168666|NCT01858129|Drug|placebo|
168667|NCT01858142|Behavioral|Parental presence decision tool|
168668|NCT01858142|Behavioral|Standard preparation|
168669|NCT01858155|Drug|Melatonin|
168670|NCT01858168|Drug|Olaparib|Tablets to be taken on an empty stomach twice a day.
168671|NCT01858168|Drug|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
168672|NCT01858181|Biological|ocaratuzumab|
168673|NCT01858194|Device|Renal sympathetic denervation|The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.
After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a "spiral pattern", see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion).
168674|NCT00106119|Drug|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
168675|NCT01858194|Device|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
168676|NCT01858207|Procedure|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
168677|NCT01860521|Procedure|Programmed Intermittent Epidural Bolus|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
168678|NCT01860521|Procedure|Continuous Epidural Infusion|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
168987|NCT01846520|Other|questionnaire administration|Ancillary studies
168988|NCT01846559|Biological|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
168989|NCT01846559|Drug|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
173177|NCT00110279|Biological|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
168376|NCT01855373|Dietary Supplement|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
168377|NCT01855373|Dietary Supplement|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
168378|NCT01855373|Other|Placebo|Placebo: 2 capsules twice daily on an empty stomach
168379|NCT01855386|Other|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 12 month postpartum visits.
168380|NCT01855386|Other|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 12 month postpartum visits.
168381|NCT01855399|Behavioral|Peer Coaching|All participants will be assigned to one of 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants randomized to both groups will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches will call their assigned peers once a week to provide support for their action steps.
168382|NCT01855399|Behavioral|Computer Decision Aid and Self-Management Support Tool|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
168383|NCT01855399|Behavioral|Coach Training|All coaches will receive training in behavioral coaching, with an emphasis on Motivational Interviewing. All coaches will have the opportunity to attend monthly coaching group meeting with other coaches. These meetings will offer additional training and the opportunity for support and sharing of coaching strategies.
168384|NCT01855412|Other|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
168385|NCT00105690|Behavioral|Telemedicine intervention|
168386|NCT01855438|Behavioral|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
168387|NCT01855451|Drug|Cetuximab|
168388|NCT01855451|Radiation|RT (70 Gy in 35 fractions)|
168389|NCT01855451|Drug|Cisplatin|
172873|NCT01878487|Device|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.
All patients will have an Intravascular Ultrasound three times:
At baseline
After thrombus aspiration with a thrombus extraction catheter
After stent deployment
We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such.
172874|NCT01878500|Device|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
172875|NCT01878513|Drug|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
172876|NCT01878526|Drug|Alginic acid|Algycon 1 tab chew tid after meal
173178|NCT01901510|Other|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
173179|NCT01901523|Behavioral|Reporting of discrepancy to journal|
173180|NCT01901536|Behavioral|Family Foundations Coparenting Program|Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.
Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.
Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff.
173181|NCT01901549|Procedure|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
173182|NCT01901549|Drug|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
173183|NCT01901549|Drug|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
173184|NCT01901562|Device|Ductoscopic papillomectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
173185|NCT01901575|Drug|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
173186|NCT01901588|Drug|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
173187|NCT01901588|Other|Placebo|intraoperative dose of intravenous placebo
172570|NCT01875094|Other|Self-Management / MTM using Health IT|
172571|NCT01875107|Drug|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
172572|NCT01875133|Other|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
172573|NCT01875146|Other|4x4 min HIT|Conventional 4x4 min high-intensity interval training
172574|NCT01875146|Other|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
172575|NCT00107926|Drug|Licarbazepine|
172576|NCT01875146|Other|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
172577|NCT01875146|Other|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
172578|NCT01875159|Drug|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
172579|NCT01875172|Drug|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
172580|NCT01875172|Drug|placebo|
172877|NCT01881100|Other|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
172878|NCT01881113|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
172879|NCT01881113|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
172880|NCT01881126|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
172881|NCT01881126|Drug|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
172882|NCT01881126|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
172883|NCT01881126|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
172884|NCT01881139|Behavioral|exercise training|
172885|NCT01881152|Other|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
172886|NCT01881152|Other|Usual care|Information on stroke usually delivered at the community level.
172274|NCT01882244|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
172581|NCT01875172|Behavioral|smoking cessation counseling|
172582|NCT01875185|Drug|Aspirin 81 mg PO daily x 7 days|
172583|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy with Splenectomy|
172584|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
172585|NCT01875224|Drug|Belatacept|
172586|NCT00107926|Drug|Placebo|
172587|NCT01877837|Drug|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
172588|NCT01877837|Drug|Melphalan|I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. *Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.
II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion.
172589|NCT01877850|Procedure|weaning protocol|Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.
When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.
When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator.
172590|NCT01877863|Other|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
172591|NCT01877889|Drug|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 [treatment period 2] or Sequence 2 [treatment period 1]).
172592|NCT01877889|Drug|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 [treatment period 1] or Sequence 2 [treatment period 2]).
172593|NCT01877915|Drug|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 984 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
172594|NCT00108134|Drug|PEP005|
171990|NCT01879527|Drug|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
171991|NCT01879527|Drug|Sugar pill|containing placebo
171992|NCT01879540|Biological|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
171993|NCT01879553|Biological|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
171994|NCT01879566|Other|No intervention will be done. The study is observational|
171995|NCT01879579|Other|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
171996|NCT01879605|Drug|Docusate natrium and sorbitol|
171997|NCT01879605|Drug|Bisacodyl|
171998|NCT01879618|Drug|Fragmin|variable dosing regimen
172275|NCT01882257|Device|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
172276|NCT00108524|Behavioral|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
172277|NCT01882283|Dietary Supplement|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
172278|NCT01882296|Drug|AGSPT_10|AGSPT 10mg for 7days administration
172279|NCT01882296|Drug|AGSPT_20|AGSPT 20mg for 7days administration
172280|NCT01882296|Drug|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
172281|NCT01882296|Drug|Pantoprazole_20|Pantoprazole 20mg for 7days administration
172282|NCT01882296|Drug|Pantoprazole_40|Pantoprazole 40mg for 7days administration
172283|NCT01882322|Drug|Prograf|oral
172284|NCT01882322|Drug|Advagraf|oral
171660|NCT01873573|Device|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
171661|NCT01873573|Drug|Triamcinolone Injection|After endoscopic dilation is performed, a total of 40-80mg(physician preference) of triamcinolone (40mg/ml) will be injected throughout the stricture under direct visualization.
171662|NCT01876082|Drug|PAZOPANIB treatment|Pazopanib
800 mg per day
oral administration
at least 1 hour before or 2 hours after a meal,
until disease progression or for 12 months maximum
171663|NCT01876082|Drug|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
171664|NCT01876095|Procedure|Multidisciplinary medication review|Consists of the following steps:
1. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.
2. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.
3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.
5. Execution of pharmaceutical care plan according to agreed schedule.
171665|NCT01876108|Drug|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
171666|NCT01876121|Drug|Celecoxib|oral
171667|NCT00002054|Drug|Pentamidine isethionate|
171668|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,8 application)
171669|NCT01876160|Other|Transcutaneous electrical nerve stimulation|
171670|NCT01876173|Behavioral|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
171671|NCT01876186|Drug|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
171672|NCT01876186|Drug|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
171673|NCT01876199|Behavioral|intense follow up|
171674|NCT01876212|Biological|DC vaccine|
171675|NCT01876212|Drug|Dasatinib|
171999|NCT01879631|Procedure|radial keratotomy|
172000|NCT00108303|Other|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
171030|NCT01924520|Drug|FK949E|Oral
171031|NCT01924533|Drug|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
171032|NCT01924533|Drug|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
171345|NCT01927692|Other|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
171346|NCT01927705|Biological|FURESTEM-AD Inj.|
171347|NCT01927718|Drug|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
171348|NCT01927718|Drug|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
171349|NCT01927718|Behavioral|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
171350|NCT01927731|Drug|Eltrombopag|300 mg orally for 60 total days. Eltrombopag started on Day -1 (the day prior to stem cell infusion in cord blood patients) and on Day +5 in patients receiving haploidentical transplant.
171351|NCT01927744|Drug|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
171352|NCT01927744|Drug|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
171353|NCT00112775|Drug|dasatinib|
171354|NCT01930045|Drug|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
171355|NCT01930045|Drug|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
171356|NCT01930058|Drug|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
171357|NCT01930084|Other|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
171358|NCT01930084|Other|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
171359|NCT01930084|Behavioral|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
171360|NCT01930084|Other|Non-cash Financial Incentives|Non-cash Financial Incentives
170697|NCT01928914|Drug|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
170698|NCT01928914|Drug|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
170699|NCT00002102|Drug|Leucovorin calcium|
170700|NCT00112866|Other|laboratory biomarker analysis|Correlative studies
170701|NCT01928927|Drug|Telmisartan|
170702|NCT01928940|Drug|dabrafenib|150 mg twice daily
170703|NCT01928940|Drug|trametinib|2 mg once daily
170704|NCT01928966|Other|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
170705|NCT01928979|Other|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
170706|NCT01928992|Device|3D|subjects that underwent 3D mammography
170707|NCT01928992|Device|2D|those subjects that underwent 2D mammography
171033|NCT01924533|Drug|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
171034|NCT01924546|Other|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
171035|NCT01924559|Other|standard clothing|
171036|NCT01924559|Other|Biohazard gear|
171037|NCT01924559|Device|Direct Laryngoscopy|
171038|NCT00112593|Other|laboratory biomarker analysis|Correlative studies
171039|NCT01924559|Device|Glidescope|
171040|NCT01924559|Device|Supraglottic Airway|
171041|NCT01924572|Procedure|cord clamping at 2 minutes|
171042|NCT01924572|Procedure|cord clamping at 5 minutes|
171043|NCT01924572|Procedure|cord milking|
170396|NCT01923519|Procedure|bronchofiberscopy|
170397|NCT01923545|Drug|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
170398|NCT01923545|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
170399|NCT01923558|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
170400|NCT01925703|Drug|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
170401|NCT01925716|Other|Corn oil|corn oil 56 g/day for 21 days
170402|NCT01925716|Other|Olive oil|olive oil 56 g /day for 21 days
170403|NCT01925729|Biological|ragweed|ragweed arm only
170404|NCT01925729|Biological|histamine|histamine arm only
170405|NCT00112658|Drug|leucovorin calcium|
170406|NCT01925729|Drug|pseudoephedrine|pseudoephedrine arm only
170407|NCT01925729|Drug|Oxymetazoline|oxymetazoline arm only
170408|NCT01925742|Other|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
170708|NCT01929005|Other|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
170709|NCT01929018|Behavioral|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
170710|NCT01929018|Behavioral|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
170711|NCT00112879|Drug|arsenic trioxide|
170712|NCT01929018|Behavioral|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
170713|NCT01929031|Drug|Ibuprofen and caffeine|FDC tablet, single dose at stage 1 and multiple doses at stage 2
169779|NCT01850511|Drug|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
169780|NCT01850524|Drug|IXAZOMIB + Lenalidomide + Dexamethasone|Patients will receive single oral dose of IXAZOMIB (4.0mg) on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progression
170076|NCT01843608|Other|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
170077|NCT01843621|Biological|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
170078|NCT01843634|Drug|ODSH|
170079|NCT01843647|Drug|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
170080|NCT01843647|Drug|Chemotherapy|After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine
/cisplatin regimen, until untolerable toxicity or disease progression.
170081|NCT00104650|Drug|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
170082|NCT01843660|Drug|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
170083|NCT01843673|Procedure|computed tomography|Undergo FBCT
170084|NCT01843673|Procedure|cone-beam computed tomography|Undergo dual CBCT
170085|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian kV OBI
170086|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
170087|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian MV OBI
170088|NCT01843673|Procedure|electronic portal imaging|Undergo EPID imaging
170089|NCT01845948|Behavioral|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
174312|NCT00109941|Biological|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
174313|NCT01896349|Drug|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
174314|NCT01896349|Drug|sertraline|
174315|NCT01896349|Drug|paroxetine|
174316|NCT01896349|Drug|Citalopram|
174317|NCT01896349|Drug|escitalopram|
174613|NCT01884077|Device|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
174614|NCT00108667|Drug|Talampanel|
174615|NCT01884090|Behavioral|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
174616|NCT01884116|Drug|NSAID patch|
174617|NCT01884116|Drug|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
174618|NCT01884116|Drug|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
174619|NCT01884116|Drug|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
174620|NCT01884142|Other|Aerobic Exercise Training|
174621|NCT01884155|Procedure|Allogeneic umbilical cord blood therapy|
174622|NCT01884168|Biological|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
174623|NCT01884207|Other|MRI|
174624|NCT01884220|Other|There are no interventions in this study.|
174625|NCT00108706|Drug|Candesartan|
174015|NCT01893190|Drug|Nimodipine|Based upon Investigator Judgement
174016|NCT01893190|Drug|Nimodipine Microparticles|Based upon Investigator Judgement
174017|NCT00109798|Drug|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
174018|NCT01893203|Drug|ALA sensitizer|First the anticipated treatment area will be degreased using ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz-light sensitizer on the field cancerized area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
174019|NCT01893203|Drug|MAL sensitizer|First the anticipated treatment area will be degreased using ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix-light sensitizer on the field cancerized area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
174020|NCT01893229|Drug|Lithium|Lithium is used as a mood stabiliser
174318|NCT01896349|Drug|fluvoxamine|
174319|NCT01896349|Drug|Venlafaxine|
174320|NCT01896349|Drug|Duloxetine|
174321|NCT01896349|Drug|Bupropion|
174322|NCT01896349|Drug|Lithium|
174323|NCT00109954|Drug|cisplatin|
174324|NCT01896349|Drug|Risperidone|
174325|NCT01896349|Drug|tranylcypromine|
174326|NCT01896349|Drug|Imipramine|
174327|NCT01896349|Drug|amitriptyline|
174328|NCT00110058|Drug|mycophenolate mofetil|
174329|NCT01898637|Device|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
174330|NCT01898650|Other|MR scan|
174331|NCT01898663|Biological|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
174332|NCT01898676|Drug|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
169857|NCT01848080|Behavioral|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
169858|NCT01848093|Other|sputum collection|collecting of spontaneous sputum from the patient
169859|NCT01848106|Drug|pegnivacogin/anivamersen|
169860|NCT01848106|Drug|Bivalirudin|
169861|NCT01848119|Drug|Gabapentin|
169862|NCT01848119|Drug|lactose|
170159|NCT01928251|Behavioral|Informed early monetary incentive|Participants will be informed at 1 week after the baseline recruitment about the monetary incentive of quitting.
Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking).
170160|NCT01930487|Dietary Supplement|Placebo|Placebo
Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
170161|NCT01930500|Behavioral|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
170162|NCT00112931|Biological|rituximab|
170163|NCT01930500|Behavioral|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
170164|NCT01930526|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
170165|NCT01930539|Device|Ultraviolet B lamp|Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
170166|NCT01930552|Drug|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
170167|NCT01930552|Drug|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
170168|NCT01930552|Drug|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
170169|NCT01930552|Drug|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
169560|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
169561|NCT01845077|Drug|2 x 500 mg Metformin (Glumetza)|2 tablets
169562|NCT01845077|Drug|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
169563|NCT01845077|Drug|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
169564|NCT01845090|Drug|Lanthanum carbonate|the effect on serum FGF23
169565|NCT01845090|Drug|Calcium Carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
169566|NCT01845116|Drug|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
169567|NCT01845129|Device|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
169568|NCT01845129|Device|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
169863|NCT01848132|Drug|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
169864|NCT01848132|Drug|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
169865|NCT01848132|Drug|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
169866|NCT01848132|Drug|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
169867|NCT00104975|Drug|melphalan|
169868|NCT01848132|Drug|Prednisone|Prednisone: oral, 100 mg, days 1-5
169869|NCT01848132|Drug|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
169870|NCT01850654|Genetic|Genetic testing|Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.
The following study participants will have free genetic testing:
CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors
CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results (MLH1 and PMS2 are absent) and they do not have methylation of the MLH1 promoter
CRC study participants diagnosed with CRC <50 years with normal tumor studies, regardless of family history
CRC study participants diagnosed with CRC ≥ 50 years with normal tumor studies AND a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life.
At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing.
169871|NCT01850654|Behavioral|Genetic Counseling|The participants found to have LS or another type of hereditary cancer will have free genetic counseling.
At-risk relatives of the individuals found to have LS are eligible for free genetic counseling.
169266|NCT00105066|Drug|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
169267|NCT01849783|Drug|dexamethasone|Given PO
169268|NCT01849783|Drug|cisplatin|Given IV
169269|NCT01849783|Drug|doxorubicin|Given IV
169270|NCT01849783|Drug|cyclophosphamide|Given IV or PO
169271|NCT01849783|Drug|etoposide|Given IV
169272|NCT01849783|Drug|bortezomib|Given IV
169273|NCT01849783|Drug|thalidomide|Given PO
169274|NCT01849783|Drug|melphalan|Given IV
169275|NCT01852474|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
169276|NCT01852487|Dietary Supplement|400mg /day during 6 months|
169277|NCT01852500|Other|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
169278|NCT00002029|Drug|Fat Emulsion 2%|
169279|NCT00105326|Drug|paliperidone ER|
169280|NCT01852500|Other|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
169281|NCT01852513|Drug|QNASL|
169282|NCT01852513|Drug|Placebo nasal spray|
169569|NCT00104741|Procedure|neoadjuvant therapy|
169570|NCT01845142|Drug|single administration of 100.000 I.U. vitamin D|
169571|NCT01845142|Drug|Placebo|
169572|NCT01845155|Behavioral|Neuro-Music-Therapy according to the Heidelberg Model|The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.
For more details on the music therapy see Argstatter et al. 2012
168990|NCT01846559|Drug|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
168991|NCT01846585|Behavioral|Arousal Based Therapy for Insomnia|
168992|NCT01846585|Behavioral|Cognitive Behavioral Therapy for Insomnia|
168993|NCT01846611|Drug|Trabectedin|1.1 mg/m2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle
168994|NCT00104858|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
168995|NCT01846611|Drug|DOXIL|30 mg/m2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle
168996|NCT01846611|Drug|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion
168997|NCT01846611|Drug|DOXIL|50 mg/m2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle
168998|NCT01846624|Drug|decitabine|Given IV
168999|NCT01846624|Drug|midostaurin|Given PO
169000|NCT01846624|Other|laboratory biomarker analysis|Correlative studies
169001|NCT01846637|Procedure|laparoscopic sleeve gastrectomy|
169002|NCT01846650|Drug|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
169003|NCT01849146|Other|Pharmacological Study|Correlative studies
169004|NCT01849146|Radiation|Radiation Therapy|Undergo radiation therapy
169005|NCT01849146|Drug|Temozolomide|Given PO
169006|NCT01849146|Drug|WEE1 Inhibitor AZD1775|Given PO
169007|NCT01849159|Biological|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
169008|NCT01849159|Other|Reference therapy: 400 mL of 0.9% NaCl solution|
169009|NCT00002025|Drug|Ganciclovir|
169010|NCT00105027|Other|Standard Care|CRVO: observation; BRVO: standard care
169283|NCT01852526|Device|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
168390|NCT01855464|Procedure|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
168391|NCT01855464|Procedure|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
168392|NCT01855477|Procedure|Histological biopsy procedure|
168679|NCT01860521|Procedure|Procedure of interruption of pregnancy|Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
168680|NCT01860521|Drug|Drug used for analgesia procedures|Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
168681|NCT01860521|Device|Pump for programmed intermittent bolus.|Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
168682|NCT01860521|Device|Pump for continuous epidural infusion.|Pump administering continuous epidural infusion for the maintenance of analgesia was used.
168683|NCT01860521|Drug|Drug used for termination of pregnancy procedure.|Gemeprost pessaries.
168684|NCT01860534|Behavioral|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
168685|NCT01860547|Dietary Supplement|Bilberries|Frozen bilberries, 100 g/d
168686|NCT01860547|Dietary Supplement|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
168687|NCT00106353|Drug|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
168688|NCT01860547|Dietary Supplement|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
168689|NCT01860547|Dietary Supplement|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
168690|NCT01860560|Device|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
173188|NCT00110292|Behavioral|Age-specific parenting newsletters and developmental toys|
173189|NCT01901601|Procedure|LALAK|A "dovetail" shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.
The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
173190|NCT01901601|Procedure|IEK|A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.
In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
173191|NCT01901601|Drug|Retrobulbar Block or General Anesthesia|
168393|NCT01855490|Drug|Exenatide|
168394|NCT01855503|Procedure|Core Biopsy|
168395|NCT01857817|Drug|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
168396|NCT01857817|Drug|Placebo|The placebo capsules will be prepared to match the active drug.
168397|NCT01857830|Behavioral|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
168398|NCT00106028|Drug|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
168399|NCT01857830|Behavioral|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
168400|NCT01857843|Device|Zotalolimus Eluting Stent|Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1.
168401|NCT01857843|Device|Everolimus eluting stent|Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1.
168402|NCT01857843|Drug|Ezetimibe 10mg & Simvastatin 40mg|Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.
Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)
Pravastatin 20mg (mevalotin®, BMS)
172887|NCT00108394|Drug|pamidronate|
172888|NCT01881165|Drug|Cranberry|
172889|NCT01881165|Drug|Placebo|
172890|NCT01881178|Dietary Supplement|NOPALEA|
172891|NCT01881191|Other|MRI|
172892|NCT01881204|Dietary Supplement|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
172893|NCT01881204|Dietary Supplement|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
172894|NCT01881204|Dietary Supplement|Control|Cookies without Hesperidin or Calcilock added.
172895|NCT01881217|Drug|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
172896|NCT01881230|Drug|nab-Paclitaxel 125 mg/m2|
172897|NCT01881230|Drug|Carboplatin AUC 2|
172898|NCT00108407|Behavioral|Integrated Cognitive Behavioral Therapy|
172899|NCT01881230|Drug|gemcitabine 1000 mg|
172900|NCT01881282|Drug|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
173192|NCT01901601|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
173193|NCT01894074|Behavioral|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
173194|NCT01894074|Behavioral|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
173195|NCT01894087|Behavioral|TBI - Cohort 1|
173196|NCT01894087|Behavioral|TBI - Cohort 2|
172595|NCT01877915|Drug|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
172596|NCT01877915|Other|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
172597|NCT01877928|Device|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
172901|NCT01881282|Drug|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
172902|NCT01881295|Dietary Supplement|Placebo control|
172903|NCT01881295|Dietary Supplement|Low dose potassium gluconate|
172904|NCT01881295|Dietary Supplement|Medium dose potassium gluconate|
172905|NCT01873079|Drug|Esomeprazole|
172906|NCT01873079|Other|Standard care|No PPI or other study medication given
172907|NCT01873105|Other|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
172908|NCT01873118|Other|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
172909|NCT01873118|Other|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
172910|NCT00107627|Other|Monocryl subcuticular sutures.|Monocryl subcuticular sutures.
172911|NCT01873118|Other|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
172912|NCT01873131|Drug|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
172285|NCT01882335|Behavioral|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
172286|NCT01874496|Dietary Supplement|control, meal|control, meal
172287|NCT01874509|Behavioral|Check Your Drinking|
172288|NCT01874509|Behavioral|Alcohol Help Centre|
172289|NCT01874522|Drug|TAS-102 tablets|Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.
Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
172290|NCT01874522|Drug|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
172291|NCT01874535|Drug|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
172292|NCT01874561|Drug|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
172293|NCT01874561|Drug|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
172294|NCT00107848|Drug|Modafinil|
172295|NCT01874561|Drug|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
172598|NCT01877928|Device|standard CPAP|Standard of care postoperative treatment for OSA.
172599|NCT01877941|Device|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
172600|NCT01877941|Device|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
172601|NCT01877941|Device|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
172602|NCT01877954|Drug|Extra-fine hydrofluoroalkane beclometasone dipropionate|
172603|NCT01877954|Drug|Fluticasone propionate|
172604|NCT01880645|Procedure|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
172605|NCT00108355|Drug|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
172001|NCT01879644|Behavioral|NF|
172002|NCT01879644|Behavioral|SM|
172003|NCT01879644|Behavioral|PE|
172004|NCT01879644|Behavioral|SU|
172005|NCT01879657|Drug|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
172006|NCT01879670|Device|CircuLite Synergy left ventricular assist device|
172007|NCT01879683|Drug|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
172008|NCT01879696|Device|ECSPRESS catheter with active vacuum|
172009|NCT01879709|Behavioral|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
172010|NCT01882010|Procedure|Motion Analysis|Week -4
172011|NCT01882010|Procedure|Motion Analysis|Week +8
172012|NCT00108485|Drug|Extended release niacin|Extended release niacin 1500-2000mg once daily
172013|NCT01882010|Procedure|Motion Analysis|Week +12
172014|NCT01882036|Procedure|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
172015|NCT01882036|Other|Hypocaloric diet|Hypocaloric liquid diet for 10 days
172016|NCT01882049|Device|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
172017|NCT01882062|Drug|Triheptanoin 1g/kg/day|
172018|NCT01882075|Drug|Open loop|
172019|NCT01882075|Device|Closed-loop|
172020|NCT01882088|Drug|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
172021|NCT01882101|Procedure|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
171361|NCT01930097|Other|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
171362|NCT01930110|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
171363|NCT01930110|Other|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
171364|NCT00112918|Biological|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
171676|NCT01876225|Behavioral|Forced coughing during cervical punch biopsy|
171677|NCT01876238|Other|T-PAT|
171678|NCT01876238|Other|Surveys|Pre-test and posttest surveys and questionnaires
171679|NCT00107978|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
171680|NCT01876251|Drug|PF-03084014|Tablet, 10 mg, twice a day
171681|NCT01876251|Drug|PF-03084014|Tablet, 50 mg, twice a day
171682|NCT01876251|Drug|PF-03084014|Tablet, 100 mg, twice a day
171683|NCT01876251|Drug|Docetaxel|Solution for IV infusion 75 mg/m^2, every 3 weeks
171684|NCT01876251|Drug|Docetaxel|Solution for IV infusion 100 mg/m^2, every 3 weeks
171685|NCT01876264|Procedure|Extended resection|
171686|NCT01876264|Procedure|Conventional resection|
171687|NCT01879033|Device|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
171688|NCT00108238|Drug|Raloxifene|
171044|NCT01924598|Device|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
171045|NCT01924611|Procedure|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
171046|NCT01924611|Procedure|Atraumatic Restorative Technique|Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.
This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.
This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier.
171047|NCT01924624|Drug|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
171048|NCT01927042|Behavioral|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
171049|NCT01927042|Behavioral|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
171050|NCT01927055|Drug|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
171051|NCT01927055|Drug|Placebo|Placebo to match droxidopa capsules and strength designations
171052|NCT01927068|Device|CVI Paclitaxel-Coated PTA Balloon Catheter|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
171053|NCT01927081|Behavioral|discussion group|Participants engage in discussions regarding issues related to coping with advanced cancer and pain
171054|NCT01927081|Behavioral|gentle exercise|Patients learn gentle exercise and breathing techniques
171365|NCT01930123|Other|intravenous fructose challenge|Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a "standard" meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have a standard of care , liver biopsy followed by , and co-localization of liver biopsy with MR.
171366|NCT01930136|Behavioral|Calorie restriction (25%)|
171367|NCT01930136|Behavioral|Ad libitum health diet|
171368|NCT01930149|Behavioral|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
171369|NCT01930162|Drug|HSC835|HSC835 is the expanded umbilical cord blood product used during single umbilical cord blood transplantation.
171370|NCT01930175|Drug|VAY736|VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner.
170714|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet, multiple doses at stage 2
170715|NCT01929031|Drug|placebo|single dose at stage 1
170716|NCT01929031|Drug|caffeine|tablet, single dose at stage 1
170717|NCT01929031|Drug|ibuprofen|tablet, multiple doses at stage 2
170718|NCT01929031|Drug|ibuprofen|tablet, single dose at stage 1
170719|NCT01929031|Drug|placebo|tablet, single dose at stage 1
170720|NCT01929031|Drug|caffeine|tablet, single dose at stage 1
170721|NCT01929031|Drug|ibuprofen|tablet, multiple doses at stage 2¿
170722|NCT01931826|Procedure|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
170723|NCT01931826|Procedure|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
170724|NCT01931839|Drug|Lumacaftor|
170725|NCT01931839|Drug|Ivacaftor|
170726|NCT01931852|Procedure|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
170727|NCT01931852|Other|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations.
171055|NCT01927094|Dietary Supplement|Probiotic|Comparison of probiotics vs. ORS
171056|NCT00112736|Drug|temsirolimus|Given IV
171057|NCT01927094|Dietary Supplement|ORS|ORS ad libitum
171058|NCT01927107|Dietary Supplement|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
171059|NCT01927120|Drug|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
171060|NCT01927120|Drug|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
170090|NCT01845961|Drug|Galantamine Hydrobromide-ER|8mg and 16 mg
170091|NCT01845974|Device|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
170092|NCT01845974|Device|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
170409|NCT01925742|Other|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
170410|NCT01925742|Other|Targeted NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
170411|NCT01925742|Other|Un-targeted NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
170412|NCT01925742|Other|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
170413|NCT01925755|Other|Rivaroxaban ( Xarelto, BAY59-7939)|Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
170414|NCT01925768|Drug|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
170415|NCT01925768|Drug|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
170416|NCT00112658|Drug|oxaliplatin|
170417|NCT01925781|Drug|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
170418|NCT01925781|Other|STAM 1100mAh CE4 eGo Clearomizer|
170419|NCT01925794|Device|COBRA PzF|
170420|NCT01925807|Behavioral|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
170421|NCT01925807|Behavioral|Treatment as usual|This group will receive normal services offered to adolescents that present to the emergency department with mild to moderate suicidal ideation and moderate psychopathological symptoms. This includes an interview with a crisis intervention worker, risk assessment and safety planning, and consultation about community services. In addition, participants will meet with one of our clinicians to confirm a safety plan is in place, and to fill out questionnaires at the beginning and end of the 6-week study.
174626|NCT01884233|Behavioral|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
174627|NCT01884233|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
174628|NCT01884246|Behavioral|patient-centered, culturally appropriate, self-care CVD risk reduction|
174629|NCT01884246|Other|Referral to primary care provider for CVD risk management|
174630|NCT01884259|Drug|Docetaxel|75 mg/m² on day 1 of 21-days cycle
174926|NCT01887210|Behavioral|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
174927|NCT01887210|Behavioral|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
174928|NCT00109395|Drug|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
174929|NCT01889862|Drug|Placebo|Two different doses of BMN165 compared to each other and compared to placebo
174930|NCT01889875|Drug|ALK Grazax 75,000 SQ-T "Phleum pratense"|
174931|NCT01889875|Drug|ALK AluTard 225 "Phleum pratense"|
174932|NCT01889888|Other|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
174933|NCT01889901|Behavioral|Enhanced walking program|The goal is to reach 12,000 steps per day by the end of the 6-month intervention period. If 12,000 steps per day are reached, participants will be encouraged to surpass this goal or to maintain this step count. Participants will be motivated by augmented behavior modification strategies such as: having access to the pedometer web page to view calculated step counts; scanning and discussing neighborhoods for available walking routes; and creating a buddy system for walking. Each will be facilitated by telephone-based physical activity behavior change counselling, occurring weekly, bi-weekly and monthly. Participants will upload their pedometer data wirelessly. At the end of the 6 months, the experimental group will be monitored for an additional 24 weeks with no further incentives.
174934|NCT01889914|Drug|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
174935|NCT01889927|Other|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
174333|NCT01898676|Drug|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
174334|NCT01898689|Drug|perineural infusion|A continuous peripheral nerve block—also termed "perineural local anesthetic infusion"—involves the insertion of a tiny tube (a "catheter") through the skin and adjacent to a peripheral nerve, followed by local anesthetic (numbing medicine) administration via the catheter, providing pain control following surgery. Continuous peripheral nerve blocks may be provided in the hospital setting, but the use of lightweight, portable pumps permits infusion at home as well.
174335|NCT01898702|Behavioral|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
174336|NCT01898715|Drug|ATR-101|
174337|NCT01898728|Drug|topical povidone-iodine after premedication with topical liquid eye drops|
174338|NCT01898728|Drug|topical povidone-iodine after premedication with topical gel|
174339|NCT00110058|Procedure|peripheral blood stem cell transplantation|
174340|NCT01898741|Radiation|24 Gy in 3 fractions|
174341|NCT01898754|Other|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
174342|NCT01898780|Procedure|pancreaticojejunostomy with horizontal mattress suture|
174631|NCT01884259|Drug|Cisplatin|75 mg/m² on day 1 of 21-days cycle
174632|NCT01884259|Drug|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
174633|NCT01884259|Biological|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
174634|NCT00002066|Drug|Thymopentin|
174635|NCT00108992|Drug|Diclofenac, topical|
174636|NCT01886586|Other|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
174637|NCT01886599|Drug|Asunaprevir|
174638|NCT01886612|Device|Duo-STIM neuromuscular electrical stimulator|
174639|NCT01886612|Device|AV Impulse System Model 6000|
174640|NCT01886625|Procedure|unilateral single-port VATS sympathicotomy|
174641|NCT01886638|Drug|Abacavir|
170170|NCT01930565|Other|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
170171|NCT01930565|Other|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
170172|NCT01930578|Other|Treatment with 0.9% normal saline|An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.
An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
170173|NCT00112957|Biological|fowlpox-NY-ESO-1 vaccine|iv
170174|NCT01930578|Other|Treatment with D5+ 0.45 saline|An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.
An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
170487|NCT01923727|Radiation|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
170488|NCT01923740|Device|XIENCE V EECSS|Subjects receiving XIENCE V
170489|NCT01923740|Device|ABSORB BVS System|Subjects receiving ABSORB BVS System
170490|NCT01923753|Device|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
170491|NCT01923753|Device|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
170492|NCT01925833|Procedure|Both insertion and withdrawal|inspection and polypectomy during both insertion and withdrawal of colonoscopy
170493|NCT01925833|Procedure|Only withdrawal|inspection and polypectomy during only withdrawal of colonoscopy
170494|NCT01925859|Drug|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
170495|NCT01925885|Procedure|PVI Ablation|PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
170496|NCT00002101|Drug|Ethambutol hydrochloride|
170497|NCT00112671|Drug|sorafenib tosylate|Given orally 400mg orally twice daily
170498|NCT01925885|Procedure|FIRM Ablation|Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
170499|NCT01925898|Drug|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
169872|NCT01850654|Other|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
169873|NCT01850654|Behavioral|Questionnaire|
169874|NCT01850667|Radiation|Stereotactic body radiotherapy|Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours.
At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)
169875|NCT01850680|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
169876|NCT01850680|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
169877|NCT01850680|Drug|methotrexate|Pharmaceutical form:capsule Route of administration: oral
169878|NCT00105157|Drug|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
169879|NCT01850680|Drug|folic acid|Pharmaceutical form:tablet Route of administration: oral
169880|NCT01850719|Procedure|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
170175|NCT01930578|Other|Treatment with D5|An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.
An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
170176|NCT01930591|Drug|Ticagrelor|180 mg bolus followed by 90 mg BID
170177|NCT01930591|Drug|Clopidogrel|300 mg bolus followed by 75 mg OD
170178|NCT01930604|Drug|Botox (onabotulinumtoxinA)|
170179|NCT01930604|Drug|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
170180|NCT01930604|Drug|NaCl (placebo)|
170181|NCT01923129|Drug|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
170182|NCT01923142|Biological|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
169573|NCT01845155|Behavioral|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
169574|NCT00104923|Drug|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
169575|NCT01847508|Device|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
169576|NCT01847508|Device|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
169577|NCT01847521|Dietary Supplement|Luteolin, Quercetin and Rutin combined in a capsule|
169578|NCT01847534|Other|Supplemental PN|
169579|NCT01847534|Other|Standard Care|
169580|NCT01847573|Drug|HT-100|May be administered in either fed or fasted state
169581|NCT01847586|Procedure|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
169582|NCT01847586|Procedure|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
169583|NCT01847599|Other|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
169584|NCT01847612|Procedure|indocyanine green fluorescent cholangiography|
169585|NCT00104936|Procedure|adjuvant therapy|
169586|NCT01847612|Drug|methylene blue|
169587|NCT01847625|Other|simulator|
169588|NCT01847638|Drug|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
169881|NCT01850719|Other|Physical Therapy|Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.
In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study.
169882|NCT01850732|Other|Ultrasound of aorta|
169284|NCT01852526|Device|Active Comparator: Plif|monosegmental PLIF
169285|NCT01852539|Drug|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
169286|NCT01852539|Drug|propofol|Propofol 2.0 mg/kg was administrated
169287|NCT01852539|Device|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
169288|NCT01852552|Device|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
169289|NCT01852552|Procedure|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
169290|NCT00105352|Procedure|Mixed Meal Tolerance Test|
169291|NCT01852565|Drug|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
169292|NCT01852565|Drug|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
169293|NCT01852578|Drug|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
169294|NCT01852591|Biological|PCV13|
169295|NCT01852604|Drug|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
169296|NCT01852604|Drug|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
169297|NCT01852604|Drug|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
169298|NCT01852604|Drug|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
169299|NCT01852604|Drug|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
169300|NCT00002019|Drug|Amphotericin B|
169301|NCT00104702|Radiation|radiation therapy|
169302|NCT01844583|Drug|esomeprazole|
169303|NCT01844583|Drug|rifampin|
169304|NCT01844596|Behavioral|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
168691|NCT01860560|Device|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
168692|NCT01853475|Drug|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
168693|NCT01853475|Drug|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
168694|NCT01853475|Drug|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
169011|NCT01849172|Other|acupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
169012|NCT01849172|Other|sham acupuncture|Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).
Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually.
169013|NCT01849185|Other|Food supplement|
169014|NCT01849198|Device|accelerometry m. trapezius and m. adductor pollicis|
169015|NCT01849211|Drug|rocuronium|
169016|NCT01849224|Other|Pelvic and lower extremity exercise|
169017|NCT01849237|Genetic|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
169018|NCT01849237|Drug|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
169019|NCT01849250|Drug|Docosahexaenoic Acid|Given PO
169020|NCT01849250|Other|Laboratory Biomarker Analysis|Correlative studies
169021|NCT00105027|Drug|intravitreal triamcinolone injection|1 mg dose
169022|NCT01849250|Other|Placebo|Given PO
169023|NCT01849263|Drug|Ibrutinib|Given PO
169024|NCT01849263|Other|Laboratory Biomarker Analysis|Correlative studies
168403|NCT01857843|Drug|Pravastatin 20mg|Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.
Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)
Pravastatin 20mg (mevalotin®, BMS)
168404|NCT01857856|Drug|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
168405|NCT01857869|Biological|Malaria vaccine 257049_0,1,7M|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
168406|NCT01857869|Biological|Malaria vaccine 257049_0,1,2M|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
168695|NCT01853475|Drug|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
168696|NCT01853488|Radiation|DXA|Osteodensitometry
168697|NCT01853488|Radiation|pQCT|Osteodensitometry
168698|NCT01853501|Procedure|Autologous fat grafting|ADSC ovary injection
168699|NCT00105482|Drug|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
168700|NCT01853540|Drug|Sildenafil|
168701|NCT01853553|Drug|Spironolactone|
168702|NCT01853553|Drug|Sugar pill|
168703|NCT01853566|Drug|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
168704|NCT01853579|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
168705|NCT01853579|Drug|Placebo|Placebo
168706|NCT01853605|Device|Anatomically shaped silicone gel-filled breast implants|Surgical implant
173197|NCT01894100|Device|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
173198|NCT01894113|Procedure|transbronchial lung biopsy|
173199|NCT01894126|Behavioral|Two-way SMS Dialogue|
173200|NCT01894126|Behavioral|One-way SMS Messaging|
173201|NCT01894139|Other|High-Protein/Low-GI Diet|
173202|NCT01894139|Other|Low-protein/High-GI Diet|
173203|NCT00109837|Drug|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
173204|NCT01894152|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
173205|NCT01894165|Drug|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
173206|NCT01894165|Drug|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
173207|NCT01894178|Device|Parker Flex-Tip® tracheal tube|
173208|NCT01894178|Device|Portex® Tracheal Tube|
173209|NCT01894191|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
173210|NCT01894191|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
173211|NCT01894191|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
168407|NCT01857869|Procedure|Sporozoite-infected mosquitoes challenge|Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.
The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21).
168408|NCT01860014|Drug|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
168409|NCT01860014|Drug|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
172913|NCT01873131|Device|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
172914|NCT01873144|Drug|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
172915|NCT01873144|Drug|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
172916|NCT01873144|Device|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
173212|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
173213|NCT01894217|Genetic|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele; reporting of test results to provider and participant
173214|NCT00002074|Drug|Fluconazole|
173215|NCT00109837|Drug|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
173216|NCT01896726|Drug|Microgynon|Administered orally
173217|NCT01896739|Biological|Eutravac|
173218|NCT01896765|Behavioral|Intensive Prevention Program|"Study nurse"-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available).
173219|NCT01896765|Other|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
173220|NCT01896778|Procedure|Hyperthermia Treatment|Undergo B-WARM
173221|NCT01896778|Other|Laboratory Biomarker Analysis|Correlative studies
173222|NCT00109993|Drug|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
173223|NCT01896791|Device|Transcranial Direct Current Stimulation (tDCS).|Active stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
172606|NCT01880645|Procedure|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
172607|NCT01880645|Procedure|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
172608|NCT01880658|Drug|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
172609|NCT01880671|Device|Inactive Migraine Medical Device|
172610|NCT01880671|Device|Migraine Medical Device|
172611|NCT01880697|Biological|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
172612|NCT01880710|Procedure|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
172613|NCT01880710|Procedure|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
172614|NCT01880723|Drug|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
172615|NCT01880723|Drug|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
172616|NCT00108355|Procedure|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
172617|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
172917|NCT01873144|Drug|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
172918|NCT01873157|Drug|Bortezomib|Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.
Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11.
172919|NCT01873157|Drug|Placebo|Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.
Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11.
172920|NCT01873170|Drug|levonorgestrel exposure|
172921|NCT00107627|Other|Skin staples;|Skin staples;
172922|NCT01873170|Drug|DMPA exposure|
172923|NCT01873170|Drug|etonogestrel exposure|
172296|NCT01874574|Drug|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
172297|NCT01874574|Drug|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
172298|NCT01874587|Radiation|adaptative radiotherapy|weekly replanning
172299|NCT01874600|Device|Brain Sentinel Seizure Detection Device and Warning System|
172300|NCT01874613|Device|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
172301|NCT01874613|Device|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
172302|NCT01874626|Drug|Placebo|
172303|NCT01874626|Drug|SST-0225 Topical formulation|
172304|NCT01874639|Device|standard bipolar coagulation|
172305|NCT00107861|Drug|Ad.hIFN-β (BG00001, IDEC-201)|
172306|NCT01874639|Device|Aquamantys® probe for liver hemostasis|
172307|NCT01874652|Device|Light Weight Breast Implants|Light Weight Breast Implants
172308|NCT01874665|Drug|ponatinib|45 mg tablet, taken orally once-daily
172309|NCT01874678|Drug|TS-1/Cisplatin|
172310|NCT01874704|Behavioral|Comparison of biomarkers of stress|
172311|NCT01874717|Other|Conscious sedation for dental care|
172312|NCT01874717|Drug|midazolam|
172313|NCT01877343|Device|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
172314|NCT01877356|Procedure|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
172315|NCT00108069|Drug|Bortezomib|intravenous (IV) injection 1.3 mg/m^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
172316|NCT01877356|Procedure|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
171689|NCT01879033|Other|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
171690|NCT01879046|Procedure|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
171691|NCT01879059|Behavioral|Exercise|short period of inactivity (5 days) followed by a return to physical activity (1 day)
171692|NCT01879085|Drug|Docetaxel|75 mg/m2 IV over 60 minutes on day 8 every 21 days (1 cycle).
171693|NCT01879085|Drug|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, Gem will be given over 67.5 minutes at 10 mg/m2/min.
171694|NCT01879085|Drug|Vorinostat|will be given orally at the specified dose levels (Table 2) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle).
171695|NCT01879085|Drug|Pegfilgrastim|Administered on day 9 subcutaneously at 6 mg.
172022|NCT01882101|Procedure|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
172023|NCT00108498|Drug|mirtazapine|
172024|NCT01882127|Drug|All-Trans Retinoid Acid(ATRA)|patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
172025|NCT01882127|Drug|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
172026|NCT01882140|Other|Electrical Stimulation by Capacitive Field|
172027|NCT01882140|Other|Electrical Stimulation by Capacitive Field Placebo Sham|
172028|NCT01882153|Behavioral|Pivotal Response Training (PRT)|The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, & Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.
172029|NCT01882153|Behavioral|PACE Therapy|The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.
172030|NCT01882153|Behavioral|PACE and PRT Hybrid|The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
171371|NCT01930175|Drug|Placebo to VAY736|Placebo to VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner. All patients that receive placebo will be offered open-label VAY736.
171372|NCT01930175|Drug|VAY736|VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner, following a safety review.
171373|NCT01930188|Drug|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
171374|NCT01922492|Procedure|Autologous islet transplantation|Islet was isolated from the normal part of resected pancreas with modified Ricordi method.
After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization.
171375|NCT01922492|Drug|Oral anti-diabetic drugs|Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.
Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose.
171376|NCT01922505|Drug|PPI triple therapy|
171377|NCT01922518|Procedure|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
171378|NCT01922518|Procedure|Apex pacing|Put RV lead around the apex
171379|NCT01922557|Device|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
171380|NCT01922570|Dietary Supplement|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
171381|NCT00112489|Drug|carboplatin|
171382|NCT01922583|Drug|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
171383|NCT01922596|Drug|Ropivacaine|
171696|NCT01879098|Dietary Supplement|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
171697|NCT01879098|Dietary Supplement|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
171698|NCT01879098|Dietary Supplement|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
171699|NCT00108251|Drug|Eplerenone|aldosterone receptor blocker
171700|NCT01879098|Dietary Supplement|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
171061|NCT01927120|Drug|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
171062|NCT01927159|Biological|ID93 + GLA-SE|
171063|NCT01927159|Other|Placebo|
171064|NCT01927172|Device|AirSonea|
171065|NCT01927198|Drug|Placebo|
171066|NCT01927198|Drug|RDEA3170 5 mg|
171067|NCT00112736|Procedure|therapeutic conventional surgery|Undergo surgical resection
171068|NCT01927198|Drug|RDEA3170 10 mg|
171069|NCT01927198|Drug|RDEA3170 12.5 mg|
171070|NCT01927211|Device|Silver Plated dressing|Silver plated dressing placed over Cesarean wound after skin closure, the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7
171071|NCT01927211|Device|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure, the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7
171072|NCT01927224|Drug|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
171073|NCT01927224|Drug|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
171074|NCT01929551|Other|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
171075|NCT01929551|Other|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
171076|NCT01929551|Other|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
171384|NCT01922596|Drug|Placebo|
171385|NCT01922635|Other|Valadation of the metrological properties of questionnaire of quality of life|
171386|NCT01922648|Procedure|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
171387|NCT01922661|Drug|REGN1908-1909|
171388|NCT01922661|Other|placebo|
170422|NCT01925820|Drug|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
170423|NCT01928524|Drug|DOS3W|Docetaxel (25 mg/m2), Oxaliplatin (100 mg/m2) and S1 (40-60 mg/2) will be given every 3rd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered
170424|NCT01928537|Drug|rigosertib sodium|
170425|NCT01928563|Drug|Dapoxetine|
170426|NCT01928563|Drug|Udenafil|
170427|NCT01928563|Drug|Udenafil+Dapoxetine|
170428|NCT01928576|Drug|Azacitidine|
170728|NCT01931865|Drug|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
170729|NCT01931878|Drug|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
170730|NCT00113100|Drug|Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)|
170731|NCT01931878|Drug|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
170732|NCT01931917|Behavioral|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
170733|NCT01931917|Behavioral|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
170734|NCT01931930|Dietary Supplement|Perilla extract|
170735|NCT01931930|Dietary Supplement|Maltodextrin|
170736|NCT01931943|Drug|selatinib ditosilate tablets|
170737|NCT01931956|Device|MitraClip® System|Percutaneous mitral valve repair using MitraClip implant
170738|NCT01931982|Drug|Victoza|
174936|NCT01889940|Behavioral|Training for professionals (Spinal Cord Injury Unit staff).|Prior to the training, separate focus groups for professionals, patients & families are conducted to determine each party's needs and worries.
Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.
Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period.
174937|NCT01889953|Other|EUS-guided biliary drainage|Based on the patient`s condition, the will receive:
Rendezvous technique
Direct transluminal access transesophageal technique
Direct transluminal access transduodenal technique
or direct transluminal access using transgastric approach
174938|NCT01889966|Drug|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
174939|NCT00109408|Drug|Methotrexate|7.5-20mg po weekly
174940|NCT01889979|Drug|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
174941|NCT01889979|Drug|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
175231|NCT01885325|Other|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
175232|NCT00108784|Behavioral|Reduced-energy-density diet|
175233|NCT01885338|Drug|N-acetylcysteine (NAC)|
175234|NCT01885338|Drug|Inactive placebo capsule|
175235|NCT01885351|Behavioral|MyCRCS+Prefs|Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.
Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers.
175236|NCT01885351|Behavioral|MyCRCS+Prefs+Barriers|Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in "real time".
Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers.
175237|NCT01885364|Drug|Normal saline|intravenous injection with normal saline before injection of propofol
174642|NCT01886664|Drug|sevoflurane|
174643|NCT01886664|Drug|Desflurane|
174644|NCT01886677|Behavioral|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
174645|NCT01886677|Behavioral|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
174646|NCT00109005|Drug|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
174647|NCT01886690|Drug|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
174648|NCT01886690|Drug|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
174649|NCT01886703|Behavioral|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
174650|NCT01886716|Behavioral|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
174942|NCT01889992|Radiation|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short & long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
174943|NCT01889992|Procedure|Coronary angiography with IVUS|Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.
Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart.
174944|NCT01892449|Other|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
170500|NCT01925898|Drug|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
170501|NCT01925911|Drug|IPI-145|25 mg BID Oral Capsule
170502|NCT01925911|Drug|Midazolam|2 mg midazolam syrup
170503|NCT01925924|Other|Resin-modified glass ionomer cement|This material contains fluoride
170504|NCT01925924|Other|Composite resin|This material does not include fluoride
170505|NCT01925937|Drug|Atorvastatin|
170506|NCT01925937|Drug|Coenzyme Q10|
170507|NCT01925937|Drug|placebo for coenzyme Q10|
170508|NCT00112671|Other|laboratory biomarker analysis|Correlative studies
170509|NCT01925950|Drug|orBec|
170510|NCT01925950|Drug|Placebo|
170833|NCT01931449|Procedure|Modified method of digestive tract reconstruction|
170834|NCT01931449|Procedure|Routine digestive tract reconstruction|
170835|NCT01931462|Device|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
170836|NCT00113061|Procedure|Exercise|
170837|NCT01931475|Drug|Duloxetine|Administered orally
170838|NCT01931475|Drug|Placebo|Administered orally
170839|NCT01931488|Other|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
170840|NCT01924169|Drug|Lenalidomide|5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.
If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.
170841|NCT01924169|Biological|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
170183|NCT01923142|Biological|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
170184|NCT01923155|Procedure|Colonoscopy|
170185|NCT01923168|Drug|BYL719|BYL719 + Letrozole
170186|NCT01923168|Drug|BKM120|BKM120 + Letrozole
170187|NCT01923168|Drug|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
170188|NCT00112515|Procedure|cognitive assessment|
170189|NCT01923181|Drug|semaglutide|Once-daily oral administration as tablets.
170190|NCT01923181|Drug|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
170191|NCT01923181|Drug|oral placebo|Once-daily oral administration as tablets.
170192|NCT01923194|Drug|Highly Purified Urofollitropin|for Injection
170193|NCT01923194|Drug|Recombinant Human Follitropin Alfa|for Injection
170194|NCT01923207|Drug|DX-2930|
170195|NCT01923207|Drug|Placebo|placebo, subcutaneous administration
170196|NCT01923220|Drug|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
170511|NCT01925976|Behavioral|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
170512|NCT01925989|Biological|LY2605541|Administered SC
170513|NCT01925989|Biological|Insulin Glargine|Administered SC
170514|NCT01926002|Drug|Low-Dose MK-8351|Single administration of low-dose MK-8351.
170515|NCT01926002|Drug|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
170516|NCT01926002|Drug|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
170517|NCT01926015|Biological|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
169883|NCT01850745|Other|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
169884|NCT01850758|Procedure|Regenexx SD|
169885|NCT01850758|Other|Exercise Therapy|
169886|NCT01850771|Procedure|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
169887|NCT01850771|Procedure|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
169888|NCT01843257|Other|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo)
169889|NCT01843257|Other|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol)
169890|NCT01843270|Device|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
169891|NCT01843270|Device|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
169892|NCT00104624|Drug|docetaxel|
169893|NCT01843283|Behavioral|Daily Enhancement Meaningful Activity (DEMA)|
169894|NCT01843283|Behavioral|Information Support (IS)|
169895|NCT01843296|Drug|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
169896|NCT01843296|Procedure|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
169897|NCT01843296|Drug|Bupivacaine|
169898|NCT01843296|Drug|Fentanyl|
169899|NCT01843309|Drug|Spironolactone 100mg|
169900|NCT01843309|Drug|Spironolactone 200mg|
169901|NCT01843309|Drug|Placebo|
170197|NCT01923220|Other|Aloe Vera Jel|To be applied topically once daily
169589|NCT01847638|Drug|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
169590|NCT01847651|Procedure|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
169591|NCT01847651|Drug|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
169592|NCT01847651|Other|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
169593|NCT01847651|Other|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
169594|NCT01847651|Other|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
169595|NCT01847651|Other|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
169596|NCT00002023|Drug|Zidovudine|
169597|NCT00104936|Radiation|radiation therapy|
169598|NCT01847651|Other|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
169599|NCT01850121|Drug|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
169600|NCT01850134|Other|Experimental Study Product|
169601|NCT01850134|Other|Control Study Product|
169602|NCT01850147|Drug|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
169603|NCT01850160|Drug|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
169604|NCT00105105|Drug|Mifepristone|
169605|NCT01850160|Drug|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
169606|NCT01850160|Drug|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
169607|NCT01850173|Device|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
169025|NCT01849276|Drug|metformin hydrochloride|Given orally
169026|NCT01849276|Drug|cytarabine|Given IV
169027|NCT01849276|Other|laboratory biomarker analysis|Correlative studies
169028|NCT01851642|Procedure|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
169029|NCT01851642|Drug|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
169305|NCT01844596|Behavioral|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
169306|NCT01844609|Behavioral|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
169307|NCT01844609|Behavioral|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
169308|NCT01844622|Other|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
169309|NCT01844635|Drug|Thymoglobulin|
169310|NCT01844648|Drug|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
169311|NCT01844648|Drug|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
169312|NCT00104715|Drug|antiandrogen therapy|
169313|NCT01844661|Biological|CELYVIR|
169314|NCT01844674|Drug|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast >/= 10 hours.
169315|NCT01844674|Drug|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
169316|NCT01844687|Drug|cannabidiol|
168707|NCT01853618|Drug|Tremelimumab|Weekly x6 doses and then 12 weeks apart
168708|NCT01853618|Procedure|TACE|For Cohort A (BCLC Stage C patients): TACE or radiofrequency ablation (RFA) will be performed once only.
For Cohort B (BCLC Stage B patients): TACE may be repeated (as per standard of care) on months 3, 7, and 13, and q6 months thereafter (if indicated).
Cohort B will only be recruited following completion of the dose-escalation portion of Cohort A.
168709|NCT01853618|Procedure|Radiofrequency Ablation (RFA)|For Cohort A (BCLC Stage C patients): TACE or radiofrequency ablation (RFA) will be performed once only.
For Cohort B (BCLC Stage B patients): TACE may be repeated (as per standard of care) on months 3, 7, and 13, and q6 months thereafter (if indicated).
Cohort B will only be recruited following completion of the dose-escalation portion of Cohort A.
168710|NCT00105482|Drug|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
168711|NCT01853618|Radiation|SBRT|Cohorts C (Advanced HCC, BCLC Stage C): SBRT will be performed once only, also on Day 36 (+/- 96hrs).
168712|NCT01853618|Procedure|Cryoablation|Cohorts D (Advanced HCC, BCLC Stage C): cryoablation will be performed once only, also on Day 36 (+/- 96hrs).
169030|NCT01851655|Behavioral|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
169031|NCT01851681|Drug|Amoxicillin|
169032|NCT01851694|Drug|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
169033|NCT01851694|Drug|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
169034|NCT00105235|Drug|Cyclosporine|Oral immunosuppressant
169035|NCT01851707|Drug|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
169036|NCT01851707|Drug|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
169037|NCT01851720|Drug|Low dose fentanyl PCA|
169038|NCT01851720|Drug|Standard IV fentanyl bolus|
169039|NCT01851733|Other|Blood draw - biomarkers|Arm A:
before biopsy (up to 3 days before)
within approximately 3 days after biopsy
2 weeks after biopsy
4 weeks after biopsy
Arm B:
before MLA (up to 3 days before)
within 3 days after MLA
1 week after MLA
2 weeks after MLA
3 weeks after MLA
4 weeks after MLA
5 weeks after MLA
6 weeks after MLA
10 weeks after MLA ONLY IF the 6-week post-MLA scan shows prolonged disruption of the BBB
14 weeks after MLA
every 8 weeks thereafter until progression
Arm C:
before MLA (up to 3 days before)
within 3 days after MLA
weekly before (on the same day as) chemotherapy
weekly within 24 hours after chemotherapy
10 weeks after MLA ONLY IF the 6-week post-MLA scan shows prolonged disruption of the BBB
14 weeks after MLA
every 8 weeks thereafter until progression
168410|NCT01860040|Drug|Cisplatin|
168411|NCT01860040|Drug|Pemetrexed|
168412|NCT01860040|Drug|Gemcitabine|
168413|NCT01860053|Behavioral|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
168414|NCT01860066|Drug|QVA149|QVA149 via inhaler twice a day
168415|NCT01860066|Drug|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
168416|NCT01860079|Procedure|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
168417|NCT01860105|Drug|MDCO-157|intravenous administration
168418|NCT00106327|Behavioral|Diet|11 nutrition education sessions
168419|NCT01860105|Drug|PLAVIX|oral administration
168420|NCT01860131|Behavioral|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
168421|NCT01860144|Drug|Bevacizumab|
168422|NCT01860157|Device|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
168423|NCT01860157|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
168424|NCT01860170|Drug|Cohort 1-Bortezomib (Velcade ®)|Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.
Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.
Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
168713|NCT01848639|Drug|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
168714|NCT01848639|Drug|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
208309|NCT02082730|Device|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
208310|NCT02082743|Behavioral|Outdoor activity in recess time|Outdoor activity in recess time
208311|NCT02085148|Drug|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 28 days each. During each cycle regorafenib is taken for 3 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area.
208312|NCT02085161|Drug|placebo to tiotropium + olodaterol|comparator
208313|NCT02085161|Drug|tiotropium|tiotropium 5 mcg once daily
208314|NCT02085161|Drug|olodaterol|olodaterol 5 mcg once daily fixed dose combination
208315|NCT02085161|Drug|tiotropium|tiotropium 5 mcg once daily fixed dose combination
208316|NCT00127673|Drug|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
208317|NCT02085187|Other|Telemedicine training and counselling|Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.
There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required.
208318|NCT02085200|Other|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
208319|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
208320|NCT02085213|Drug|Glyceryl Trinitrate|
208618|NCT02077556|Drug|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
208619|NCT02077556|Drug|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
208620|NCT02077556|Drug|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
208621|NCT00126841|Procedure|CT and MR fusion|
208034|NCT02089633|Biological|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
208035|NCT02089659|Drug|doravirine|
208036|NCT02089672|Device|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
208037|NCT02089685|Biological|Pembrolizumab|
208038|NCT00128050|Other|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
208039|NCT02089685|Biological|PegIFN-2b|
208040|NCT02089685|Biological|Ipilimumab|
208041|NCT02089698|Device|Mini-flared|Mini-flared Kelman tip
208042|NCT02092194|Procedure|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
208043|NCT02092194|Procedure|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
208044|NCT02092207|Drug|KL7016 900mg|oral administration, 150mg 3tab, bid
208045|NCT02092207|Drug|KL7016 600mg|oral administration, 150mg 3tab, bid
208046|NCT02092207|Drug|Placebo|oral administration, 150mg 3tab, bid
208047|NCT02092220|Device|Bionic Pancreas|
208048|NCT02092220|Device|Patient controlled insulin pump|
208049|NCT02092246|Device|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
208050|NCT00128310|Drug|gemcitabine|
208051|NCT02092246|Device|Unguided injection|Needle placement will take place without ultrasound machine guidance
208052|NCT02092272|Behavioral|instructional exercise video source|instructional exercise video source
208053|NCT02092285|Drug|Golimumab|
208054|NCT02092298|Drug|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
208055|NCT02092298|Drug|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
208321|NCT02085213|Drug|Matched Placebo|
207437|NCT02104284|Procedure|methacholine and mannitol bronchial challenge tests|Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.
Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.
207438|NCT02104297|Drug|deksmedetomidine|deksmedetomidine infused during operation 0.2 mcg/kg/hour
207439|NCT00129584|Procedure|Emphasys Endobronchial Valve and procedure|
207440|NCT02104297|Drug|Remifentanil|Remifentanil infused during operation 0.2 mcg/kg/min
207743|NCT02097342|Drug|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
207744|NCT02097342|Drug|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
207745|NCT02097355|Other|TriVox for clinical care|Use TriVox disease modules to manage patients
207746|NCT02097368|Procedure|tongue strength measurement|tongue strength measurement
207747|NCT02097368|Procedure|respiratory function measurement|respiratory function measurement
207748|NCT02097368|Procedure|swallowing tests|swallowing tests
207749|NCT02097368|Other|Magnetic resonance imaging|Magnetic resonance imaging
207750|NCT02097381|Drug|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.
The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day).
207751|NCT02097394|Drug|Combizym|Combizym( 1 tablet, po, tid)
207752|NCT02097394|Drug|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
207753|NCT00128830|Drug|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
207754|NCT02097394|Drug|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
207755|NCT02097394|Drug|control|have no any drug
207756|NCT02099292|Drug|Rituximab and DexaBEAM|combination treatment
207126|NCT02109354|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
207127|NCT02109354|Biological|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
207128|NCT02109354|Biological|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
207129|NCT02109354|Biological|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
207130|NCT02109354|Biological|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
207131|NCT02111642|Other|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
207132|NCT02111655|Device|Second generation surveillance of AVF|Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.
QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound.
207133|NCT02111655|Procedure|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
207134|NCT00130390|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
207135|NCT02111655|Procedure|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
207136|NCT02111655|Procedure|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
207441|NCT02104297|Drug|Saline|During operation saline infused equal volüme of deksmedetomidine and remifentanil
207442|NCT02104310|Drug|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
207443|NCT02104323|Drug|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
207444|NCT02104336|Drug|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
207445|NCT02104349|Behavioral|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
206818|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
206819|NCT02076698|Drug|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
206820|NCT02076711|Drug|Metoprololsuccinate|
206821|NCT02076711|Drug|Placebo|Placebo
206822|NCT02076724|Device|Biological mesh|
206823|NCT02076724|Device|Synthetic mesh|
206824|NCT02076737|Device|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
206825|NCT02076750|Dietary Supplement|Vitamin D3 (cholecalciferol)|
206826|NCT02076776|Behavioral|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
206827|NCT02076776|Behavioral|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
206828|NCT02079376|Device|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
206829|NCT02079389|Device|Lap+Lus|In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.
All patients are given an CT scan of the abdomen after 3 months.
206830|NCT02079402|Drug|Isotonic crystalloids|
206831|NCT02079415|Other|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
206832|NCT02079428|Other|No interventions|
206833|NCT02079467|Procedure|Unrestricted rehabilitation|Standard care range of motion restrictions will not be used
206834|NCT02079467|Procedure|Standard rehabilitation|Standard care range of motion restrictions will remain in place
206835|NCT02079480|Drug|BMS-986090|
206836|NCT00002211|Drug|Nelfinavir mesylate|
206837|NCT00127062|Other|Exposure|
206838|NCT02079480|Drug|Placebo matching with BMS-986090|
207137|NCT02111655|Procedure|urea method|Quarterly recirculation with urea method.
206214|NCT02091492|Drug|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
206215|NCT02091505|Drug|Ranibizumab|
206216|NCT00128206|Drug|Rifampin|Rifampin 600mg once per day
206520|NCT02084485|Drug|Placebo|matching placebo
206521|NCT02084498|Device|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
206522|NCT02084498|Behavioral|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
206523|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
206524|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
206525|NCT02084511|Drug|BI 1026706|BI 1026706
206526|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
206527|NCT00127608|Biological|Chickenpox infection|
206528|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
206529|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
206530|NCT02084511|Drug|BI 1026706|BI 1026706
206531|NCT00127855|Biological|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
206532|NCT02086604|Drug|Lenalidomide|
206533|NCT02086617|Other|ultrasound of aorta|
206534|NCT02086630|Behavioral|Heart to Heart|
206535|NCT02086643|Procedure|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
206536|NCT02086656|Drug|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
206537|NCT02086669|Procedure|Pneumatic dilatation|
206538|NCT02086669|Procedure|Laparoscopic myotomy|
205910|NCT02098889|Drug|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
205911|NCT02098902|Behavioral|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
205912|NCT02098915|Drug|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
205913|NCT02098915|Other|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
205914|NCT02098928|Behavioral|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
205915|NCT02098928|Device|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
206217|NCT02091518|Behavioral|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
206218|NCT02091518|Device|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
206219|NCT02091531|Drug|MLN0128|
206220|NCT02091544|Other|Lifestyle intervention|
206221|NCT02091557|Drug|GnRH-analogue|
206222|NCT02094131|Other|Cliniflo group (CG)|CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the "happy face" for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions.
206223|NCT02094144|Other|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
206224|NCT02094144|Other|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
206225|NCT02094157|Drug|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
205637|NCT02108678|Behavioral|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
205638|NCT02108678|Behavioral|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
205639|NCT00130104|Procedure|Transthecal Metacarpal Block|
205640|NCT02108691|Dietary Supplement|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
205641|NCT02108691|Dietary Supplement|Placebo|Placebo (2.5g/day)
205642|NCT02108704|Drug|Helicobacter pylori eradication therapy|
205643|NCT02108704|Drug|Placebo|
205644|NCT02108717|Device|Remote CT reading using the iPhone|
205645|NCT02108717|Device|CT reading using LCD monitor|
205646|NCT02108730|Procedure|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
205916|NCT02098954|Drug|Gemcitabine platinum combined with erlotinib|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.
205917|NCT02098967|Drug|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
205918|NCT00129038|Drug|modified-release dipyridamole/aspirin|
205919|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
205920|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose </= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
205921|NCT02101216|Drug|Ziagen|Active comparator
205922|NCT02101229|Drug|Insulin, Asp(B28)-|the insulin dose is calculated by the "Diabeloop" algorithm and then administered to the patient
205346|NCT02115321|Drug|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
205347|NCT02115334|Behavioral|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
205348|NCT02115334|Behavioral|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
205349|NCT02115334|Behavioral|health education|health education of the children with DD.
205350|NCT02115347|Drug|Ertugliflozin 15 mg|
205351|NCT02078752|Drug|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
205352|NCT02078752|Drug|PF-06647263|Part 2- Patients with select tumor types (triple negative breast cancer and ovarian cancer) will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
205353|NCT02078778|Device|CPAP|3 months of CPAP treatment
205354|NCT02078791|Drug|Botox infiltration|botox cervical infiltration in a group
205355|NCT00126984|Biological|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
205356|NCT02078791|Behavioral|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
205357|NCT02078791|Other|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
205647|NCT02108743|Drug|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
205648|NCT02108743|Drug|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
205649|NCT02108756|Drug|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
205650|NCT00130117|Drug|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
205651|NCT02108756|Drug|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
204749|NCT02093468|Drug|Saline|
204750|NCT02093481|Other|Test meal|
204751|NCT02093481|Other|Reference|
205045|NCT02085928|Other|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).
The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.
The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon.
205046|NCT02085941|Procedure|Cryoablation|Type and number (Mean 3, range 1-10) of cryoprobe(s) used depend on size and shape of target lesion
205047|NCT02085941|Device|Biopsy|If target lesion has not been previously biopsied, a core biopsy may be taken prior to the cryoablation.
205048|NCT02085967|Drug|rifampin 600 mg|
205049|NCT02085967|Drug|itraconazole 200 mg|
205050|NCT02085967|Drug|midazolam 2 mg with bupropion 75 mg|
205051|NCT02085967|Drug|E2006|
205052|NCT02085980|Device|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
205053|NCT02086006|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
205054|NCT00127790|Behavioral|CBT for Pain (CBT-P)|
205055|NCT02086019|Drug|Conservative Arm|crossover to angiogram only if predefined criteria met
205056|NCT02086019|Procedure|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
205057|NCT02086032|Drug|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
205058|NCT02086032|Drug|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
205059|NCT02086032|Drug|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
205060|NCT02086045|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|
205061|NCT02086071|Procedure|re biopsy|re biopsy depending on the location of the pathology
182125|NCT02563288|Drug|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
182126|NCT02563288|Drug|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
182127|NCT02563301|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
182128|NCT00186823|Drug|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
182129|NCT02563314|Device|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
182130|NCT02563314|Device|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
182131|NCT02563327|Drug|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
182132|NCT02563327|Drug|Moxifloxacin|A fluoroquinolone
182133|NCT02563327|Drug|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
182134|NCT02563327|Drug|Isoniazid|An anti-tuberculosis agent
182135|NCT02563327|Drug|Pyrazinamide|An anti-tuberculosis agent
182438|NCT02556762|Radiation|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
182439|NCT02556762|Drug|PF|Chemotherapy: Cisplatin and 5fluorouracil
182440|NCT02556775|Biological|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
182441|NCT02556775|Biological|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|
182442|NCT02556788|Drug|CD5789 50µg/g Cream|CD5789 50µg/g cream applied once daily during 12 weeks.
182443|NCT02556788|Drug|Placebo cream|Placebo cream applied once daily during 12 weeks.
182444|NCT02556801|Biological|SUBLIVAC FIX Phleum Prat.|
182445|NCT02556814|Drug|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
182446|NCT02556814|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
181847|NCT02567539|Radiation|IMRT with or without radiosensitive therapy|Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
181848|NCT02567539|Drug|Radiosensitive therapy|Radiosensitive therapy with Temozolomide
181849|NCT02567552|Drug|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
181850|NCT02567552|Drug|Intramuscular progesterone|intramuscular progesterone 50 mg/day
181851|NCT02567565|Other|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
181852|NCT02567578|Drug|YH12852 0.1 mg|
181853|NCT02567578|Drug|YH12852 0.25 mg|
181854|NCT02567578|Drug|YH12852 0.5 mg|
181855|NCT00187122|Drug|L-Asparaginase|See Detailed Description section for description of treatment plan.
181856|NCT02567578|Drug|Placebo|
181857|NCT02567591|Other|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
181858|NCT02569827|Drug|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
181859|NCT02569827|Drug|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
181860|NCT02569827|Drug|Placebo|Placebo Q6H for 5 days
181861|NCT02569827|Drug|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
181862|NCT02569840|Dietary Supplement|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
181863|NCT02569853|Drug|DFN-11|
181864|NCT00187330|Drug|Intravenous N-acetylcysteine|
182136|NCT02563327|Drug|Ethambutol|An anti-tuberculosis agent
182137|NCT02563327|Dietary Supplement|Pyridoxine|An essential vitamin
182138|NCT02563340|Other|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
181254|NCT01936181|Drug|SB2 (proposed biosimilar to infliximab)|
181255|NCT01936194|Dietary Supplement|DHA+EPA|
181256|NCT01936194|Dietary Supplement|High Olive Oil|
181257|NCT01936194|Dietary Supplement|DHA|
181258|NCT01936220|Behavioral|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
181259|NCT01936220|Behavioral|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
181260|NCT01936220|Behavioral|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
181261|NCT00113490|Biological|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
181557|NCT01951911|Drug|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
181558|NCT01951911|Drug|Placebo|
181559|NCT01951924|Drug|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
181560|NCT01951924|Drug|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
181561|NCT01951937|Dietary Supplement|Fish Meals|Herring and Mackerel Meals
181562|NCT01951937|Dietary Supplement|Placebo|No fish meals
181563|NCT01951950|Drug|Nicardipine|
181564|NCT00114972|Procedure|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
181565|NCT01951950|Drug|Esmolol|
181566|NCT01951963|Drug|Ketamine|
181567|NCT01951963|Drug|Morphine|
181568|NCT01951976|Other|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
180562|NCT01946165|Drug|Prednisone|5 mg by mouth once daily for each 28 day cycle.
180563|NCT01946165|Drug|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
180564|NCT01946165|Drug|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
180565|NCT01946178|Device|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
180566|NCT01946191|Behavioral|Health coach electronic communication and support|Health coach reviews responses to weight-related surveys and provides feedback and advice
180567|NCT01946191|Behavioral|Online self-monitoring|Tracking weight, calories, fat grams, and physical activity in electronic personal health record
180568|NCT01946191|Behavioral|Real-time updates to Primary Care physicians|Primary care physicians will receive updates through electronic health record system before each scheduled appointment
180569|NCT01946204|Drug|ARN-509|240 mg tablets administered by mouth on a continuous once daily dosing regimen
180570|NCT01946204|Drug|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
180571|NCT01948674|Behavioral|Computerized tasks|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
180572|NCT00114556|Drug|zoledronic acid|
180573|NCT01948700|Behavioral|Motivational Interviewing|
180574|NCT01948700|Other|Education|
180575|NCT01948713|Other|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
180576|NCT01948713|Other|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
180577|NCT01948726|Radiation|Hypofractionation with simultaneous integrated boost|
180893|NCT01940809|Biological|Ipilimumab|Given IV
180894|NCT01940809|Other|Laboratory Biomarker Analysis|Correlative studies
180895|NCT01940809|Biological|Nivolumab|Given IV
180896|NCT01940809|Drug|Trametinib|Given PO
180897|NCT01940822|Other|Energy Drink|
179656|NCT01945294|Drug|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
179949|NCT01937598|Drug|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
179950|NCT01937611|Drug|Dexmedetomidine|Dexmedetomidine
179951|NCT01937611|Drug|Midazolam|Midazolam
179952|NCT01937624|Device|Diagnostic Ultrasound|
179953|NCT01937624|Radiation|X-ray imaging|
179954|NCT01937637|Behavioral|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
179955|NCT00113659|Dietary Supplement|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
179956|NCT01937650|Drug|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
179957|NCT01937663|Drug|KWA-0711|
179958|NCT01937689|Drug|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
179959|NCT01937702|Other|0.9% NaCl (sodium chloride)|
179960|NCT01937715|Drug|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
179961|NCT01937715|Drug|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
179962|NCT01937715|Biological|Bevacizumab|5 mg/m^2 every 2 weeks or 7.5 mg/m^2 every 3 weeks
179963|NCT01937715|Drug|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
179964|NCT01937728|Drug|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA < 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
179965|NCT01937728|Drug|B: Peg-interferon alpha-2a & Ribavirin|Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.
Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.
179966|NCT00113672|Behavioral|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
179967|NCT01940081|Procedure|Intraoperative biopsy|
179040|NCT01936844|Drug|Placebo|Placebo daily for days 4-14
179041|NCT01936857|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
179042|NCT00002108|Drug|Zidovudine|
179043|NCT00113568|Drug|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
179044|NCT01936857|Drug|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
179340|NCT01950195|Procedure|Stereotactic Radiosurgery (SRS)|
179341|NCT01950195|Biological|Ipilimumab|
179342|NCT00114738|Drug|Bortezomib|Bortezomib is given with EPOCH and rituximab every 3 weeks for 6 cycles.
179343|NCT01950221|Dietary Supplement|POMx|"POMx" is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
179344|NCT01950221|Other|Placebo|
179345|NCT01950234|Drug|ACTH|Acthar gel
179346|NCT01950234|Drug|Placebo|Placebo
179347|NCT01950247|Drug|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
179348|NCT01950247|Drug|iron dextran, ferumoxytol, iron sucrose, sodium ferric gluconate|At a dose and administration regimen as determined by the study site investigator
179349|NCT01950260|Drug|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
179350|NCT01950273|Drug|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
179351|NCT01950273|Drug|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
179352|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
179353|NCT00114738|Drug|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
208622|NCT02077569|Drug|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
208623|NCT02077595|Device|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
208624|NCT02077621|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
208625|NCT02077621|Drug|Placebo|500 mL normal saline
208626|NCT02079948|Procedure|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
208627|NCT02079961|Dietary Supplement|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
208628|NCT02079961|Behavioral|BCC|Behavior Change Campaign (BCC)
A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health.
208629|NCT02079974|Drug|Pravastatin|20 mg pravastatin sodium daily for 3 months
208630|NCT02079987|Behavioral|ED to home care transition|The Area Agency on Aging patient advocate's role is to build self-management capabilities for the patient and caregiver. During each contact, the patient advocate reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The patient advocate assists the patient use the PHR to document and maintain vital information and to communicate with providers.
208631|NCT00002211|Drug|Delavirdine mesylate|
208632|NCT00127140|Drug|vorinostat|
208633|NCT02079987|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
208634|NCT02080000|Other|Optimisation of V-V timing using R wave on surface ECG|
208635|NCT02080000|Other|Standard V-V timing settings|
208636|NCT02080013|Other|radiofrequency|ClosureFAST
203917|NCT02002949|Procedure|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
203918|NCT02002962|Procedure|radiofrequency ablation|
203919|NCT02002962|Drug|Botulinum Toxin Type A injection|
203920|NCT02002975|Drug|Pioglitazone|Pioglitazone tablets
208322|NCT02085226|Other|Creative Engagement Intervention|The CEI has 5 component stages which map the participant's journey with the Artist
Meeting with Artist, discuss interests, stroke and explore initial creative goals.
Introduction to materials and mark making to create interpretations of established images.
From mark making and interpretations to developing personal project ideas.
Turning personal project ideas into creative finished pieces.
Review of completed work, mounting and display of work, future plans.
It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes.
208323|NCT02085226|Other|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
208324|NCT02085239|Drug|Lidocaine Ropivacaine|8-10 ml of Lidocaine given by subcutaneous injection
8-10 ml of Ropivacaine given by subcutaneous injection
208325|NCT02085239|Drug|Lidocaine alone|
208326|NCT02085252|Drug|Leuprorelin|Solution for injection
208327|NCT00127673|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
208328|NCT02085252|Drug|bicalutamide|Bicalutamide tablets
208329|NCT02085265|Drug|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
208330|NCT02087501|Device|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
208331|NCT02087514|Biological|Transfusion of blood randomized to 1 week of storage|A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.
208332|NCT02087514|Biological|Transfusion of blood randomized to 2 weeks of storage|A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.
208333|NCT02087514|Biological|Transfusion of blood randomized to 3 weeks of storage|A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.
208334|NCT02087514|Biological|Transfusion of blood randomized to 4 weeks of storage|A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.
208335|NCT02087514|Biological|Transfusion of blood randomized to 5 weeks of storage|A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.
207757|NCT02099305|Other|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
207758|NCT02099318|Other|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
Inclusion criteria:
Patient age >=18 years old with unruptured or ruptured cerebral aneurysm in the anterior circulation for which craniotomy and microsurgery is recommended
Patients scheduled to undergo surgery for clipping of a cerebral aneurysm
Able to provide written informed consent
Exclusion criteria:
Repeat of aneurysm surgery
Previous history of craniotomy for any reason
Previous history of non-aneurysmal hemorrhagic stroke
Pregnancy
Posterior circulation
Giant (25 mm or larger) aneurysm
Nonsaccular aneurysm
207759|NCT02099318|Other|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
207760|NCT02099331|Drug|Melatonin|
207761|NCT02099331|Drug|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
207762|NCT02099344|Device|Artegraft|Surgical placement of graft for hemodialysis access
208056|NCT02092298|Drug|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
208057|NCT02092311|Procedure|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
208058|NCT02092311|Procedure|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
208059|NCT02092324|Drug|Ruxolitinib Phosphate|Given PO
208060|NCT02092324|Other|Laboratory Biomarker Analysis|Correlative studies
208061|NCT00128323|Drug|Gentian violet 1% solution|
208062|NCT02092324|Other|Quality-of-Life Assessment|Ancillary studies
208063|NCT02092337|Other|computer-assisted speech training|
208064|NCT02092350|Drug|Grazoprevir|
208065|NCT02092350|Drug|Elbasvir|
208066|NCT02092350|Drug|Placebo to Grazoprevir|
207446|NCT02104362|Radiation|exclusive single-fraction irradiation|
207447|NCT02104375|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
207448|NCT02104388|Drug|SJP-0035 Ophthalmic Solution|
207449|NCT02104388|Drug|Vehicle for SJP-0035 Ophthalmic Solution|
207450|NCT00129597|Drug|ketalar|
207451|NCT02104401|Device|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
207452|NCT02106754|Behavioral|Treatment as Usual|
207453|NCT02106767|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
207454|NCT02106767|Drug|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
207455|NCT02106780|Drug|14C-labeled ASP1707|oral
207456|NCT02106793|Drug|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
207457|NCT02106806|Dietary Supplement|Zinc|35 mg of elemental zinc twice daily for 16 weeks
207458|NCT02106806|Other|Placebo|One capsule, twice daily for 16 weeks
207459|NCT02106819|Behavioral|Testing of emotional communication ability|Asssessment of comprehension and expression of emotional facial and prosodic expressions and assesment of emotional reactivity via ratings of emotionally evocative pictures and words.
207460|NCT00129883|Behavioral|Professional audit and feedback|
207763|NCT02099344|Device|Propaten|Surgical placement of graft for hemodialysis access
207764|NCT02099357|Dietary Supplement|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
207765|NCT00129116|Biological|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
207766|NCT02099357|Dietary Supplement|Placebo|
207138|NCT02111681|Device|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
207139|NCT02111694|Behavioral|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
207140|NCT02111707|Drug|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
207141|NCT02111720|Behavioral|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
207142|NCT02111720|Behavioral|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
207143|NCT02111733|Other|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
207144|NCT02111746|Drug|Exparel®|
207145|NCT00130390|Other|Placebo|One placebo tablet twice daily for 28 days
207146|NCT02111746|Drug|Bupivacaine hydrochloride|Standard/regular bupivacaine hydrochloride
207147|NCT02111759|Procedure|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
207148|NCT02113839|Procedure|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
207149|NCT02113839|Procedure|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
207150|NCT02113878|Drug|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
207151|NCT02113878|Drug|Cisplatin|Cisplatin is a chemotherapy drug
207152|NCT02113878|Radiation|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
207153|NCT02113891|Drug|Eculizumab|Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.
(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant).
206539|NCT02086708|Device|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score from liver biopsy.
206540|NCT02086721|Drug|L19-IL2|Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.
Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.
Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.
Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.
Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.
Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.
Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.
206839|NCT02079480|Drug|Keyhole limpet hemocyanin|
206840|NCT02079493|Device|ConforMIS iTotal (CR) knee implant system and any off-the-shelf standard knee implant system from various manufacturers.|
206841|NCT02079506|Drug|Candesartan|
206842|NCT02079506|Drug|Rosuvastatin|
206843|NCT02079519|Drug|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
206844|NCT02079532|Drug|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
206845|NCT02079545|Drug|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
206846|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
206847|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
206848|NCT00127075|Drug|nomegestrol acetate|10 mg/day
206849|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
206850|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
206851|NCT02079558|Drug|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
206852|NCT02079558|Drug|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
206853|NCT02079571|Dietary Supplement|Coconut water|250 ml Coconut water for each subject
206854|NCT02079571|Dietary Supplement|ginger tea|250 ml for each subject
206855|NCT02081924|Other|Saline|Kisspeptin / placebo will be administered via a subcutaneous pump device for up to 3 months.
206226|NCT02094157|Drug|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
206227|NCT00128479|Drug|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
206228|NCT02094183|Other|GLP-1|GLP-1
206229|NCT02094183|Dietary Supplement|low calorie diet|low calorie diet
206230|NCT02094196|Other|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
206231|NCT02094209|Device|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
206232|NCT02094222|Drug|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
206233|NCT02094235|Drug|E6005 0.05%|
206234|NCT02094235|Drug|Placebo|0.5 g placebo ointment
206235|NCT02094235|Drug|E6005 0.2%|
206236|NCT02094248|Drug|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
206541|NCT02086734|Other|Perfusion-CT|Baseline Perfusion CT-Scan (before AAT)
Follow-Up I Perfusion-CT Scan 7 days after start with AAT
Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT
206542|NCT00127855|Biological|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
206543|NCT02086747|Drug|Acetaminophen|100 ml iv, 4 times a day for 72 hours
206544|NCT02086747|Drug|Isotonic|100 ml iv, 4 times a day for 72 hours
206545|NCT02086760|Other|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
206546|NCT02086760|Radiation|Scintigraphy|
206547|NCT02086773|Procedure|RBC Transfusion: restrictive threshold (7 g/dL Hb)|RBC transfusion with transfusion threshold of 7g/dL Hb.
206548|NCT02086773|Procedure|RBC transfusion: standard threshold (8 g/dL Hb)|RBC transfusion with transfusion threshold of 8g/dL Hb
206549|NCT02086786|Drug|Risperidone ISM|
206550|NCT02086799|Drug|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
205923|NCT02101255|Device|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
Application on Day 0 and Day 360
205924|NCT02101255|Device|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
205925|NCT02101268|Drug|Momelotinib|Momelotinib tablet administered orally once daily
205926|NCT02101268|Drug|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
205927|NCT02101281|Biological|Human nerve growth factor 20 µg/mL|1 drop for each eye, twice daily for 28 day
205928|NCT02101281|Biological|Human nerve growth factor 4 µg/mL or 60 µg/mL|either 4 µg/mL, option 1 or 60 µg/mL, option 2; 1 drop each eye, twice daily for 28 day
205929|NCT02101294|Device|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout [actual home row placement order: asdeihotlrn], plus substitutions on the upper row [qwfgjyuk;p] and bottom row [zxcvb'm,.] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
205930|NCT00129259|Other|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
205931|NCT02101294|Device|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
205932|NCT02101320|Device|TRECAM|using the camera during the surgery
206237|NCT02094248|Drug|control|Normal saline，1ml/day, s.c injection
206238|NCT00002219|Drug|Nelfinavir mesylate|
206239|NCT00128492|Drug|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
206240|NCT02094261|Drug|AZD9291|Once daily tablet 80 mg
206241|NCT02094274|Drug|LAS40468|
206242|NCT02094274|Drug|Salmeterol/fluticasone propionate|
206243|NCT02094274|Drug|Placebo|
206244|NCT02094287|Drug|dimetindene|receiving either dimetindene or a placebo (saline) via infusion
206245|NCT02094287|Behavioral|instruction|information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
205652|NCT02108769|Behavioral|Yogic Breathing|Chanting Om
Sharp deep inhalation through nostrils
Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.
Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.
Yogic Breathing:
Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.
Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.
Hold breath in this position for about 16 seconds.
Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.
Go to step a).
205653|NCT02108769|Behavioral|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
205654|NCT02108782|Drug|dovitinib lactate|Given PO
205655|NCT02108782|Other|pharmacological study|Correlative studies
205656|NCT02108782|Other|laboratory biomarker analysis|Correlative studies
205657|NCT02108795|Drug|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
205658|NCT02108795|Drug|Placebo|
205659|NCT02111044|Drug|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
205660|NCT02111044|Drug|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
205661|NCT02111044|Drug|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
205662|NCT02111044|Drug|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
205663|NCT02111070|Biological|IL-YANG FLU Vaccine|0.5mL
205664|NCT02111083|Biological|Insulin Lispro|LY275585 administered SC.
205665|NCT02111096|Drug|LY2409021|Administered orally
205666|NCT02111096|Drug|Sitagliptin|Administered orally
205667|NCT02111096|Drug|Placebo|Administered orally
205668|NCT02111109|Device|Side Stream Dark Field Microscopy|
205933|NCT02101333|Drug|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
205934|NCT02101346|Dietary Supplement|Mixed High Fat Diet|Healthy, Round 1
205935|NCT02101346|Dietary Supplement|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
205062|NCT02086084|Device|NIV|Standard care
205063|NCT02086084|Device|ECCO2R|Application of ECCO2R in addition to NIV
205064|NCT02088333|Behavioral|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
205065|NCT02088346|Other|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
205358|NCT02078804|Procedure|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
205359|NCT02078817|Drug|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
205360|NCT02078830|Device|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
205361|NCT02078830|Device|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
205362|NCT02078843|Drug|Gallium-68-DOTATATE PET/CT (index test)|Somatostatin-based imaging tracer
205363|NCT02078843|Drug|Indium-111-Octreoscan (standard test)|Somatostatin-based imaging tracer
205364|NCT02078856|Drug|A3384|
205365|NCT02078869|Drug|Progesterone in oil|
205366|NCT00126984|Biological|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
205367|NCT02078869|Drug|vaginal progesterone suppositories|
205368|NCT02078882|Biological|abatacept|125 mg subcutaneously each week for 24 weeks
205369|NCT02078895|Drug|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
205370|NCT02078908|Drug|Sodium nitrite, 40 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
205371|NCT02078908|Drug|Sodium nitrite, 120 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
205372|NCT02078908|Drug|Sodium nitrite, 240 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
182447|NCT02556814|Drug|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
182448|NCT00002505|Biological|tumor cell lysate vaccine therapy|
182449|NCT00185835|Drug|ZD-1839|
182450|NCT02559037|Device|Acupuncture-moxibustion|Acupuncture is puncture the needle into specific part of the body according to a certain angle, using specific means to cause the De-qi sensation, and maintain a certain amount of time.
Mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin, keeping the spot warm and making it reddened, but not burnt.The temperature maintained at 43 ± 1℃。
182451|NCT00002507|Drug|mitomycin C|
182452|NCT00186173|Behavioral|After school health education|After school health and nutrition education program
182453|NCT02559037|Device|Placebo acupuncture-moxibustion|Placebo acupuncture is puncture the needle into specific part of the body according to a certain angle, without using specific means to cause the De-qi sensation, and maintain a certain amount of time.
Placebo mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin (farther than the real moxibustion), keeping the temperature maintained at 37 ± 1℃。
182454|NCT02559050|Other|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
182455|NCT02559063|Behavioral|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
182456|NCT02559063|Behavioral|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
182457|NCT02559076|Behavioral|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
182458|NCT02559102|Drug|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
182749|NCT02551978|Other|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
182750|NCT02551991|Drug|nal-IRI|
182751|NCT02551991|Drug|5 fluorouracil|
182752|NCT02551991|Drug|Leucovorin|
182753|NCT02551991|Drug|Oxaliplatin|
182754|NCT02551991|Drug|nab-paclitaxel|
182755|NCT02551991|Drug|Gemcitabine|
182139|NCT00186836|Biological|Engerix-B and Twinrix|
182140|NCT02563340|Other|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
182141|NCT02563353|Other|whole-body vibration|Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,
1 minutes x 6 with 1 minute break between. 3 times a week.
182142|NCT02563353|Drug|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
182143|NCT02563366|Other|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
182144|NCT02563366|Other|Saline|Saline is the placebo of MSCs in this study.
182145|NCT02563392|Procedure|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
182146|NCT02563392|Procedure|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
182147|NCT02563405|Drug|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
182148|NCT02563405|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
182149|NCT02563418|Device|Eye-tracking|
182150|NCT02565394|Other|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
182151|NCT02565407|Behavioral|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
182152|NCT02565407|Behavioral|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
182153|NCT02565420|Procedure|colorectal, orthopedic or similar surgery|During the perioperative period the patient will receive normal saline or lactated Ringer's solution.
182154|NCT02565433|Other|questionnaire administration|Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
182459|NCT02559102|Drug|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
181569|NCT01951976|Other|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
181570|NCT01951989|Drug|Imiglucérase (drug) pharmacokinetics|
181571|NCT01952002|Other|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
181572|NCT01952015|Biological|Secukinumab|Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose)
181573|NCT01952041|Behavioral|Device: Smartphone|
181574|NCT01952041|Behavioral|Treatment as usual|
181575|NCT01933815|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
181576|NCT01933828|Procedure|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
181577|NCT01933828|Procedure|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
181865|NCT02569853|Other|Placebo|
181866|NCT02569866|Drug|Cephalexin|Capsules containing cephalexin/500mg
181867|NCT02569866|Drug|Placebo|Capsules containing placebo/500mg
181868|NCT02569879|Other|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
181869|NCT02569892|Device|Non-damaging thermal laser treatment|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
181870|NCT02569892|Device|Sham macular laser treatment|Sham macular laser treatment with Pascal laser power setting of zero
181871|NCT02569905|Drug|parecoxib sodium|parecoxib sodium 40mg
181872|NCT02569905|Drug|flurbiprofen|flurbiprofen 50mg
181873|NCT02569905|Drug|saline|normal saline
180898|NCT01940822|Other|Placebo Drink|
180899|NCT01940835|Procedure|Upper endoscopy with small bowel biopsies and brushings.|
180900|NCT00113984|Drug|MDX-010|
180901|NCT01940835|Other|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
180902|NCT01940835|Other|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
180903|NCT01940848|Drug|STW5 (Iberogast, BAY98-7411)|
180904|NCT01940848|Drug|Placebo|
180905|NCT01940887|Drug|E10030|
180906|NCT01940887|Drug|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
180907|NCT01940887|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
180908|NCT01940900|Drug|E10030|
180909|NCT01940900|Drug|ranibizumab|
180910|NCT01940900|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
180911|NCT00113984|Drug|Sargramostim|
180912|NCT01940913|Dietary Supplement|Probiotic capsules|
180913|NCT01940913|Dietary Supplement|Placebo capsules|
180914|NCT01940926|Drug|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
180915|NCT01940939|Device|Repetitive Transcranial Magnetic Stimulation|
180916|NCT01940952|Drug|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
180917|NCT01940952|Drug|Placebo + Donepezil 5mg or 10mg|
180918|NCT01940952|Drug|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
180919|NCT01943630|Drug|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
181262|NCT01936233|Drug|Aspirin|Aspirin 0.1 QD po
181263|NCT01936233|Drug|Lamivudine|LAminvudine 0.1 QD po
179968|NCT01940081|Procedure|Intraoperative mapping and/or ablation|
179969|NCT01940094|Drug|Prednisone 5 mg/day|Subjects will remain on daily prednisone dose of 5 mg
179970|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
180256|NCT01932684|Other|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
180257|NCT01932684|Other|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
180258|NCT01932684|Device|5000 Voldyne ® Sherwood Medical, USA|
180259|NCT01932684|Device|Silicone face mask|
180260|NCT01932697|Drug|Docetaxel|Given IV
180261|NCT01932697|Radiation|Hyperfractionation|Undergo hyperfractionated IMRT
180262|NCT01932697|Radiation|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
180263|NCT01932697|Other|Laboratory Biomarker Analysis|Correlative studies
180264|NCT00113230|Drug|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
180265|NCT01932697|Other|Quality-of-Life Assessment|Ancillary studies
180266|NCT01932710|Procedure|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
180267|NCT01932723|Behavioral|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
180268|NCT01932736|Other|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
180269|NCT01932749|Device|Transcranial Magnetic stimulation|
180270|NCT01932762|Drug|Grazoprevir|100 mg every day (QD) orally
180271|NCT01932762|Drug|Elbasvir|50 mg QD orally
179354|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
179355|NCT01950299|Drug|Placebo|Placebo 0.67 ml injections twice daily
179356|NCT01950312|Drug|gevokizumab|
179357|NCT01950325|Biological|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
179358|NCT01952665|Device|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
179359|NCT01952678|Other|Subjects dosed in a separate study|The subjects in this study were dosed with DaTscan drug product in a separate study.
179360|NCT01952691|Device|kinesiotaping|correction method was used to align hallux.
179361|NCT01952704|Behavioral|Aerobic exercise|
179362|NCT00002120|Drug|Trimetrexate glucuronate|
179363|NCT00115037|Behavioral|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
179657|NCT01945333|Behavioral|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
179658|NCT01945346|Drug|PRX167700|Oral capsule
179659|NCT01945346|Drug|Placebo|Oral capsule
179660|NCT01945372|Other|EEG NeuroFeedback|
179661|NCT00114257|Drug|romidepsin|
179662|NCT01945385|Behavioral|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
179663|NCT01945398|Other|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
179664|NCT01945398|Other|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
179665|NCT01945411|Device|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
203921|NCT02002988|Procedure|endomyocardial BT injection|
203922|NCT02003001|Drug|Botulinum Toxin|
203923|NCT00119509|Procedure|Decision aid with choice of management|
203924|NCT02003014|Drug|Pioglitazone|Pioglitazone Tablets
203925|NCT02003027|Drug|BT injection|
203926|NCT02005588|Drug|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
203927|NCT02005588|Drug|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
203928|NCT02005601|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
203929|NCT02005601|Drug|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
203930|NCT02005614|Procedure|Gamma Knife Radiosurgery|Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.
Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours.
203931|NCT02005627|Drug|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
203932|NCT02005627|Drug|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
203933|NCT02005653|Drug|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
203934|NCT02005653|Drug|Albendazole|Experimental
203935|NCT02005653|Drug|Doxycycline|Experimental
203936|NCT00119756|Drug|paliperidone palmitate|
204244|NCT01997853|Drug|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
204245|NCT01997853|Drug|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
208336|NCT02087514|Biological|Transfusion of blood randomized to 6 weeks of storage|A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.
208637|NCT02080026|Biological|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
208638|NCT02080026|Biological|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
208639|NCT02080026|Drug|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
208640|NCT02080026|Drug|atovaquone/proguanil|Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.
One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg
208641|NCT02080039|Device|Electrical Stimulation|
208642|NCT02080052|Device|Robot-assisted prostate biopsy|
208643|NCT00127153|Biological|V110, pneumococcal vaccine polyvalent|
208644|NCT02080065|Procedure|living donor liver transplantation|
208645|NCT02080078|Drug|Theophylline|
208646|NCT02080078|Drug|Erlotinib|
208647|NCT02080104|Drug|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
208648|NCT02080117|Procedure|kidney transplantation, living or deceased donor|
208649|NCT02080130|Dietary Supplement|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
208650|NCT02082756|Drug|Bifidobacterium viable pharmaceutics|
208651|NCT02082756|Drug|Berberine Hydrochloride|
208652|NCT02082769|Drug|Febuxostat|
208653|NCT02082769|Drug|Allopurinol|
208654|NCT02082782|Procedure|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
208655|NCT00127374|Behavioral|Dietary and physical activity modifications|
208656|NCT02082808|Drug|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
208067|NCT02092350|Drug|Placebo to Elbasvir|
208068|NCT02094872|Other|laboratory biomarker analysis|Correlative studies
208069|NCT02094872|Procedure|quality-of-life assessment|Ancillary studies
208070|NCT02094885|Biological|Bioseal Fibrin Sealant|
208071|NCT02094885|Other|Manual Compression|
208072|NCT02094898|Drug|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
208073|NCT02094911|Behavioral|Combined lifestyle intervention|10-month intervention period with:
weekly group-based sports lessons supervised by a physiotherapist
individual dietary advice by a dietician
case management by practice nurse
maintenance programme to guide subjects to maintain lifestyle behaviour change
208074|NCT02094911|Other|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
208075|NCT02094924|Drug|GSK587323|Single dose of FDC tablet formulation to be taken orally.
208076|NCT00002219|Drug|Levocarnitine|
208337|NCT00127920|Drug|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
208338|NCT02087527|Drug|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
208339|NCT02087527|Drug|Normal Saline|IV normal saline every 6 hours for 48 hours
208340|NCT02087540|Drug|Telmisartan 80mg|
208341|NCT02087540|Drug|Rosuvastatin 20mg|
208342|NCT02087540|Drug|Rosuvastatin 10mg|
208343|NCT02087540|Drug|Placebo(for Telmisartan 80mg)|
208344|NCT02087540|Drug|Placebo(for Rosuvastatin 20mg)|
208345|NCT02087540|Drug|Placebo(for Rosuvastatin 10mg)|
208346|NCT02087553|Biological|Transfusion of red blood cells|(non-experimental) PRBC transfusion
208347|NCT02087553|Biological|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
208348|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
208349|NCT02087566|Drug|600 mg linezolid|
207767|NCT02099357|Dietary Supplement|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
207768|NCT02099383|Other|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
207769|NCT02099396|Drug|Docetaxel+lobaplatin|
207770|NCT02099396|Drug|Gemcitabine+lobaplatin|
207771|NCT02099409|Device|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
207772|NCT02099435|Device|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
207773|NCT02099461|Drug|Denosumab|Single sucutaneous dose
207774|NCT02099461|Procedure|Percutaneous core needle breast biopsy|
207775|NCT02099474|Other|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
207776|NCT00129129|Biological|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
207777|NCT02099487|Radiation|Radiation|hypofractionated IMRT
207778|NCT02101970|Dietary Supplement|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
207779|NCT00129324|Procedure|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
207780|NCT02101970|Other|Placebo Capsule|
207781|NCT02101970|Other|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
207782|NCT02101983|Drug|Cytarabine|
207783|NCT02101996|Other|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
208077|NCT00128570|Behavioral|behavioral dietary intervention|
208078|NCT02094924|Drug|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
207461|NCT02106819|Procedure|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
207462|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5mg inhaled twice daily in cycles of 28 days on- and 28 days off-drug
207463|NCT02106832|Drug|Placebo|Placebo inhaled twice a day intermittently administered for 28 days on / 28 days off
207464|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5mg inhaled twice daily in cycles of 14 days on- and 14 days off-drug
207465|NCT02106832|Drug|Placebo|Placebo inhaled twice a day intermittently administered for 14 days on / 14 days off
207466|NCT02106845|Drug|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
207467|NCT02106845|Drug|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
207468|NCT02106845|Drug|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
207469|NCT02106858|Drug|Regorafenib (Stivarga,BAY73-4506)|
207470|NCT02106871|Drug|Sildenafil|50mg of Sildenafil daily for 4 weeks
207471|NCT00129883|Behavioral|Process analysis and redesign|
207472|NCT02106884|Drug|Abraxane (nab-paclitaxel)|
207473|NCT02106884|Drug|Gemcitabine|
207474|NCT02106897|Drug|BIIB059|Participants will be randomized to receive either an IV or SC dose
207475|NCT02106897|Drug|Placebo|Participants will be randomized to receive either an IV or SC dose
207476|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
207477|NCT02109354|Biological|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
207478|NCT00130195|Drug|cyclophosphamide|
207479|NCT02109354|Biological|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
207480|NCT02109380|Behavioral|Bed rest|
206856|NCT02081937|Biological|anti-CD19-CAR vector-transduced T cells|
206857|NCT02081950|Biological|Enoxaparin sodium|comparison of 2 different administration of drug
206858|NCT02081963|Drug|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
206859|NCT02081963|Drug|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
206860|NCT02081976|Behavioral|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
207154|NCT02113904|Drug|Adalimumab|
207155|NCT02113917|Biological|Identification of biological markers|
207156|NCT00130689|Drug|Cetuximab|
207157|NCT02113930|Biological|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
207158|NCT02113930|Genetic|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
207159|NCT02113943|Drug|Citalopram 30mg|
207160|NCT02113956|Behavioral|Guy2Guy (G2G)|G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A "booster" is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active. Participants are matched with another participant (i.e., a "Text Buddy") with whom they can text for support throughout the program. Intervention participants will have access to "G2Genie", an automated service which provides tips and information on topics on demand.
207161|NCT02113956|Behavioral|Healthy Lifestyle Control|
207162|NCT02113969|Device|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
207163|NCT02113982|Drug|SL-401|
206551|NCT02086799|Drug|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
206552|NCT02086825|Drug|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
206553|NCT00127855|Biological|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
206554|NCT02086825|Drug|Lactulose|20g dose titrated
206555|NCT02088905|Behavioral|Parent Child Interaction Therapy|Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
206556|NCT02088918|Drug|Nateglinide|
206557|NCT02088918|Drug|Nateglinide/Metformin|
206558|NCT00127998|Drug|amodiaquine+artesunate|
206559|NCT02088918|Drug|Metformin|
206861|NCT02081976|Other|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
206862|NCT02081989|Procedure|Renal denervation|Renal denervation
206863|NCT02082015|Device|Low frequency rTMS|Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
206864|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
206865|NCT02082028|Device|BGStar|
206866|NCT02082028|Device|glucose meter|
206867|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.36 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with "M27" on scored side and plain on the other side
206868|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.24 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with "M27" on scored side and plain on the other side
206869|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.12 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with "M27" on scored side and plain on the other side
206870|NCT02082054|Drug|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
206246|NCT02094287|Other|conditioning|classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
206247|NCT02096653|Drug|Intra-articular sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine)|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
206248|NCT00128752|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
206249|NCT02096653|Drug|Landmark guided sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine)|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
206250|NCT02096666|Drug|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
206251|NCT02096679|Drug|AZD9291|Volunteer will receive a single oral dose of 20 mg [14C]-AZD9291 as a solution on Day 1
206252|NCT02096692|Device|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
206253|NCT02096692|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
206254|NCT02096705|Drug|Dapagliflozin|
206255|NCT02096705|Drug|Dapagliflozin Placebo|
206256|NCT02096718|Drug|Afatinib healthy|
206257|NCT02096718|Drug|Afatinib severe renally impaired|
206258|NCT02096718|Drug|Afatinib moderate renally impaired|
206259|NCT00128765|Behavioral|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
206260|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Oppanol
206560|NCT02088931|Biological|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease <50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
206561|NCT02088944|Drug|Infliximab|
206562|NCT02088957|Drug|Brivaracetam intravenous solution|Active Substance: Brivaracetam
Pharmaceutical Form: Solution for infusion
Concentration: 10 mg/mL
Route of Administration: Intravenous bolus use
205936|NCT02101346|Dietary Supplement|Monounsaturated fat diet|Healthy, Round 1
205937|NCT02101346|Dietary Supplement|Polyunsaturated fat diet|Healthy, Round 1
205938|NCT02101346|Dietary Supplement|Triolein 13C|Healthy, Round 2
205939|NCT02101346|Dietary Supplement|Low fat|Healthy, Round 1
205940|NCT02101359|Drug|T2380|200 microlitres of T2380 will be administrated intracamerally
205941|NCT00129259|Dietary Supplement|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
205942|NCT02101359|Drug|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
205943|NCT02101359|Drug|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
205944|NCT02103517|Dietary Supplement|Placebo: Corn oil|Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
205945|NCT02103530|Other|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
205946|NCT02103543|Other|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
205947|NCT02103543|Procedure|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
205948|NCT02103543|Drug|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
205949|NCT02103556|Other|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
205950|NCT02103556|Dietary Supplement|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
205951|NCT02103556|Dietary Supplement|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
205952|NCT02103569|Drug|FDC of Daclatasvir, Asunaprevir and BMS-791325|
205953|NCT00002224|Drug|Didanosine|
205954|NCT00129506|Drug|methotrexate + misoprostol|
205373|NCT02078908|Drug|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
205374|NCT02078921|Drug|Sodium Nitrate|
205375|NCT02081222|Procedure|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
205376|NCT02081235|Procedure|surgery for congenital heart disease|surgery for congenital heart disease
205377|NCT02081248|Other|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
205669|NCT00130325|Drug|Isoniazid|Isoniazid 900mg, tablets, twice a week for 6 months
205670|NCT02111122|Drug|Sodium Oxybate|
205671|NCT02111135|Biological|b-OPV|
205672|NCT02111135|Biological|m-OPV2|
205673|NCT02111135|Biological|m-IPV HD|
205674|NCT02111135|Biological|t-IPV|
205675|NCT02111148|Procedure|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
205676|NCT02111148|Procedure|Nitrazine|Nitrazine detection in vaginal wash
205677|NCT02111148|Drug|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
205678|NCT02111161|Drug|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
205679|NCT02111161|Drug|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
205680|NCT00130325|Drug|Isoniazid|INH 900mg twice weekly for 6 months
205681|NCT02111174|Device|Scrambler Therapy|
205682|NCT02111174|Device|Sham Therapy|
205683|NCT02111187|Drug|LDE225|
205684|NCT02111200|Drug|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) until they return on Day 4.
205685|NCT02111200|Drug|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) until they return on Day 4.
182756|NCT02552004|Device|pCLE|Histological examination by pCLE technique preceding the frozen section
182757|NCT02552004|Drug|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
182758|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
182759|NCT02554409|Biological|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
182760|NCT02554422|Device|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
182761|NCT02554435|Device|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
182762|NCT02554435|Behavioral|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
182763|NCT02554435|Device|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
182764|NCT02554448|Other|cellsearch system|Use cellsearch system to test the number of CTCs from patients before and during treatment.
182765|NCT00185601|Behavioral|Internet Diabetes Self-Management Program|
182766|NCT02554461|Other|advise for exercices given by team staff|To respond to questions asked:
it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided
182767|NCT02554474|Behavioral|Education session, Fitbit Flex, and remote counselling by a PT|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a MaC app, and remote counseling by a PT. Intervention will be received immediately.
183055|NCT02548000|Other|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
183056|NCT02548013|Other|outpatient management|patients if stable will be discharged to continue treatment at home
183057|NCT02548013|Other|Inpatient management|patients will continue there treatment in hospital till delivery
183058|NCT02548026|Behavioral|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
183059|NCT00184938|Procedure|ten minute forearm ischemia|
182460|NCT02559102|Procedure|Caudal anaesthesia|single shot caudal anaesthesia
182461|NCT02559102|Procedure|Inguinal hernia surgery|Infant inguinal hernia repair.
182462|NCT02559115|Radiation|68Ga-RM2 (RM2)|
182463|NCT00186186|Drug|Depakote ER|Depakote ER
182464|NCT02559115|Device|PET/CT Scan|
182465|NCT02559141|Drug|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
182466|NCT02559154|Drug|Bortezomib|
182467|NCT02559154|Drug|Dexamethasone|
182468|NCT02559154|Drug|Doxorubicin|
182469|NCT02559154|Drug|Cyclophosphamide|
182470|NCT02559154|Drug|Mitoxsnteone|
182471|NCT02559154|Drug|Thalidomide|
182472|NCT02559167|Drug|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
182473|NCT02559180|Drug|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 12 months of treatment
182474|NCT02561273|Drug|Vincristine Sulfate|Given IV
182475|NCT02561273|Drug|Etoposide|Given IV
182476|NCT02561273|Drug|Prednisone|Given PO
182477|NCT02561273|Drug|Lenalidomide|Given PO
182478|NCT02561273|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
182479|NCT02561273|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
182480|NCT02561273|Other|Laboratory Biomarker Analysis|Correlative studies
182768|NCT02554474|Behavioral|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
181874|NCT02569918|Device|Surface electrical stimulation|Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand "Azzurra" (Prensilia, Italy) and the robotic hand "Multi-sensory Prosthetic Hand" (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
181875|NCT00187343|Device|Breast IMRT|
181876|NCT02569931|Other|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
181877|NCT02569931|Other|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
181878|NCT02569931|Procedure|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
181879|NCT02569944|Procedure|Bladder stimulation|Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.
No other procedure, drug or device was done/used in this patients.
181880|NCT02569944|Procedure|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
181881|NCT02572076|Device|Motus Cleansing System|
181882|NCT00187720|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
181883|NCT02572089|Drug|Naloxone|
181884|NCT02572102|Dietary Supplement|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
181885|NCT02572102|Dietary Supplement|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
182155|NCT02565446|Device|Magnetic Resolution Elastography|Correlation between histology and MRE with respect to liver fibrosis and inflammation.
182156|NCT02565446|Procedure|Bariatric surgery|Recruitment will be of patients who are scheduled to undergo bariatric surgery. During the time of surgery a liver biopsy will be taken clinically to identify liver disease. In addition, liver and fat tissue will be obtained for research purposes.
182157|NCT02565459|Biological|Mesenchymal Stromal Cells|
182158|NCT02565472|Other|White grape juice|
182159|NCT02565472|Other|Apple juice|
182160|NCT00186966|Procedure|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
181264|NCT01936246|Dietary Supplement|Increased protein|
181265|NCT01936272|Device|Surgical placement of Chhabra Shunt|
181266|NCT01936272|Procedure|ETV/CPC|
181267|NCT01936285|Drug|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
181268|NCT01938781|Drug|entecavir|antiviral therapy
181269|NCT01938781|Drug|Peg-IFN|antiviral and antifibrosis therapy
181270|NCT00113763|Other|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
181271|NCT01938807|Behavioral|CareCoach mobile application to assist in diabetes management|
181272|NCT01938820|Drug|entecavir|anti-viral therapy
181273|NCT01938820|Drug|Thymosin-α|antiviral and antifibrosis therapy
181274|NCT01938833|Drug|Romidepsin|
181275|NCT01938833|Drug|Abraxane|
181276|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
181277|NCT01938846|Drug|exemestane|exemestane once daily
181278|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
181279|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
181280|NCT01938846|Drug|paclitaxel|paclitaxel once weekly
181281|NCT00113763|Drug|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
181282|NCT01938859|Drug|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
181283|NCT01938859|Drug|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
181284|NCT01938859|Drug|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
181285|NCT01938872|Procedure|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
180272|NCT01932762|Drug|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
180273|NCT01932775|Device|GlucoTab System|
180274|NCT01935388|Other|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
180275|NCT01935414|Device|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
180276|NCT01935414|Device|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
180277|NCT01935440|Behavioral|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
180578|NCT01948739|Device|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
180579|NCT01948752|Other|Nutrition information on menus|
180580|NCT01948765|Drug|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
180581|NCT01948765|Drug|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
180582|NCT01948778|Device|oXiris™ filter|
180583|NCT00114569|Drug|lorazepam|
180584|NCT01948778|Device|Toraymyxin Filter|
180585|NCT01948778|Device|Standard of Care|
180586|NCT01948791|Drug|Rivastigmine|As a open-label, one-arm, self-control trial, rivastigmine will be administered from 3mg/d at baseline. Then dose escalation will be made in 3mg/d increments, at a minimun of 4 weeks between dose increases (according to investigator's assessment of individual patient tolerability), to a maximum dose of 12mg/d or the individual's best tolerated dose.
180587|NCT01948804|Drug|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
180588|NCT01948804|Drug|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
180589|NCT01948804|Drug|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
180590|NCT01948804|Drug|GnRH antagonist protocol (Cetrotide, Serono)|
180591|NCT01948817|Drug|Deferasirox|Deferasirox 20mg/kg taken BID
180592|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
179666|NCT01945411|Device|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
179667|NCT01945424|Biological|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
179668|NCT01945437|Drug|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
179669|NCT01945450|Drug|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
179670|NCT01945450|Drug|Ampicillin|
179671|NCT01945450|Drug|Gentamycin|
179672|NCT01947842|Device|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
179673|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
179674|NCT01947855|Drug|Empagliflozin|Empagliflozin low dose
179675|NCT00114530|Drug|Cyclophosphamide|
179676|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
179677|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
179971|NCT01940094|Drug|Prednisone 0 mg/day|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
179972|NCT01940107|Other|evaluations|Only evaluations
179973|NCT01940107|Procedure|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
179974|NCT01940120|Device|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
179975|NCT01940133|Drug|PQR309|Dosing will be orally, once a day for the duration of the trial.
179976|NCT01940146|Drug|Placebo|Placebo
179977|NCT01940146|Drug|S0597 low dose|S0597 low dose
179978|NCT01940146|Drug|S0597 mid dose|S0597 mid dose
179979|NCT01940146|Drug|S0597 high dose|S0597 high dose
179980|NCT01940146|Drug|Reference|reference comparator
204246|NCT01997866|Other|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
204247|NCT01997866|Other|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
204248|NCT01997879|Drug|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
204249|NCT01997905|Device|AtriClip LAA Exclusion Device|
204250|NCT00119158|Drug|pimecrolimus|apply daily with fluticasone cream for flares
204251|NCT01997931|Device|Bispectral Index Sedation monitor|
204252|NCT01997944|Biological|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
204253|NCT01997944|Biological|Pegasys|180 mcg dosing every week
204254|NCT02000219|Biological|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily for 6 weeks. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner
204255|NCT02000245|Behavioral|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
204256|NCT02000245|Behavioral|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
204257|NCT02000258|Procedure|Double-bundle ACL reconstruction|
204258|NCT02000258|Device|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
204259|NCT02000271|Procedure|Vaginal packing|
204260|NCT02000271|Procedure|No vaginal packing|
204261|NCT02000297|Procedure|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
204262|NCT00002161|Drug|Adefovir dipivoxil|
204263|NCT00119340|Radiation|radiation therapy|
204569|NCT02035046|Procedure|Measure of the blood pressure|
204570|NCT02035046|Procedure|glycemia test|
208657|NCT02082808|Drug|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
208658|NCT02082834|Other|abdominal MDCT examination|
208659|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
208660|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
203937|NCT02005666|Drug|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
203938|NCT02005666|Drug|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
203939|NCT02005666|Drug|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
203940|NCT02005679|Behavioral|application of the mini-mental state test|
203941|NCT02005692|Device|DynaSense sensor|
203942|NCT02005705|Other|Outpatient Management of Low-risk Patients|Labs will be obtained within 2-3 days of discharge from ED
Clinic visit will be scheduled within 3 days of discharge from ED
EGD will be scheduled within 7 days of discharge from ED
Phone follow-up at day 7 and 30
203943|NCT02005705|Other|Inpatient Management of Low-risk Patients|Labs will be obtained on day of discharge or day 2-3
EGD will be performed in the hospital
Phone follow-up at day 7 and 30
203944|NCT02005718|Drug|Cholecalciferol|
203945|NCT02005731|Device|Low intensity linear focused shockwave device ('Renova')|
203946|NCT02005744|Drug|CKD-501|CKD-501 0.5mg, PO(per oral), once
203947|NCT02008227|Drug|Atezolizumab|1200 mg intravenous infusion on Day 1 of each 21-day cycle
203948|NCT02008227|Drug|docetaxel|75 mg/m2 intravenous infusion on Day 1 of each 21-day cycle
203949|NCT02008240|Procedure|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
203950|NCT02008240|Procedure|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
203951|NCT00119990|Drug|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
208350|NCT02087579|Drug|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
208351|NCT02087579|Drug|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
208352|NCT02087579|Drug|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
208353|NCT02087579|Drug|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
208354|NCT02089698|Device|Reversed tip|Reversed Kelman tip
208355|NCT02089737|Drug|Panitumumab|Panitumumab for intravenous infusion
208356|NCT02089750|Other|Orthotics|
208357|NCT02089750|Other|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
208358|NCT02089750|Other|Wait List|
208359|NCT02089763|Biological|pegylated recombinant human arginase|
208360|NCT02089802|Drug|Pazopanib|
208661|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
208662|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
208663|NCT02082899|Drug|Active Comparator EBI-005 5 mg/mL|
208664|NCT02082899|Drug|Placebo Comparator|
208665|NCT02082912|Drug|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
208666|NCT00127387|Drug|Enbrel|
208667|NCT02082912|Other|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
208668|NCT02082912|Device|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
208669|NCT02082925|Other|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
208079|NCT02094937|Drug|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
208080|NCT02094937|Drug|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
208081|NCT02094937|Drug|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
208082|NCT02094937|Drug|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
208083|NCT02094937|Drug|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
208084|NCT02094937|Drug|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
208085|NCT02094950|Procedure|Acupuncture|
208086|NCT02094963|Drug|Ticagrelor|180mg loading and 90mg bid
208087|NCT02094963|Drug|Clopidogrel|600mg loading and 75mg qd
208088|NCT00128570|Other|educational intervention|
208089|NCT02094976|Device|Jackson surgical table|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
208090|NCT02094976|Device|Wilson frame|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
208091|NCT02094976|Device|Chest roll|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
208092|NCT02094989|Other|posture dependence of VCG-ECG-transformation|
208093|NCT02097407|Drug|Group C : Saline + propofol group|All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.
After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment
208361|NCT00128063|Drug|succinylated human serum albumin|
208362|NCT02089815|Behavioral|Home based exercise|modified Otago exercise program to simple designed home based exercise program
207481|NCT02109393|Other|MIRT and Lokomat|MIRT: a 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The rehabilitation treatment was administered each day in different sessions. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus).
The last was an occupational therapy.
Lokomat: 40 minutes Lokomat assisted training 3 times/week for 4 weeks.
207784|NCT02102009|Dietary Supplement|Complete enteral formula|Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).
Time of intervention: 3 months.
207785|NCT02102009|Other|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
207786|NCT02102022|Drug|ADI-PEG 20|
207787|NCT02102035|Procedure|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
207788|NCT02102048|Drug|Atazanavir|
207789|NCT02102061|Other|multidisciplinary intervention|a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from "Health at Every Size".
207790|NCT00002224|Drug|Nelfinavir mesylate|
207791|NCT00129324|Procedure|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
207792|NCT02102087|Device|Initial Specimen Diversion Device (ISDD)|
207793|NCT02102087|Device|Lab standard practice (LSP)|
207794|NCT02102100|Drug|IV nicotine|Subjects in each arm will receive three infusions in a fixed order one hour apart. The first infusion will be saline, the second infusion will be nicotine (.25 mg / 70kg) and the third infusion will be nicotine (0.5 mg / 70 kg).
207795|NCT02102100|Drug|Tobacco Flavor|A popular 'Burly' tobacco flavor used in e-cigarettes will be used as the placebo comparator.
207796|NCT02102100|Drug|Low dose Menthol|A low dose of menthol will be added to the tobacco flavor.
207797|NCT02102100|Drug|High Dose Menthol|A higher dose of menthol added to tobacco flavor will be an active intervention.
207798|NCT02102113|Drug|Placebo|placebo
207799|NCT02102113|Drug|Very Low Dose THC|Subjects will receive 0.010mg/kg.
207800|NCT02102113|Drug|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
207164|NCT02113995|Other|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
207165|NCT02076776|Behavioral|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
207166|NCT00126737|Other|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
207167|NCT02076802|Behavioral|physical exercises|
207168|NCT02076815|Drug|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
207169|NCT02076815|Drug|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
207482|NCT02109393|Other|MIRT|MIRT: a 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The rehabilitation treatment was administered each day in different sessions. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus).
The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
207483|NCT02109406|Drug|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
207484|NCT02109406|Drug|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
207485|NCT02109406|Drug|Placebo MDI|Placebo MDI administered as two inhalations BID
207486|NCT02109432|Behavioral|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
207487|NCT02109432|Behavioral|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
207488|NCT02109432|Behavioral|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
207489|NCT00130195|Drug|daunorubicin|
207490|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
207491|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
206871|NCT02082054|Drug|Atropine 0.24 mg|Atropine sulfate 0.24 mg white, scored, tablets with "M27" on scored side and plain on the other side
206872|NCT02082067|Procedure|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
206873|NCT02082067|Procedure|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
206874|NCT02082067|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
206875|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
206876|NCT02082067|Procedure|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
206877|NCT02082067|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
206878|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
206879|NCT02084511|Drug|Celecoxib|Celecoxib capsule
206880|NCT02084524|Procedure|Malnutrition screening and perioperative nutritional support|Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines
Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)
Implementation of an adapted nutritional support based on ESPEN Guidelines
207170|NCT02076828|Drug|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
207171|NCT02076828|Drug|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
207172|NCT02076828|Drug|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
207173|NCT02076841|Device|interferon beta-1a|Administered as specified in the treatment arm
207174|NCT02076854|Behavioral|Text-Message Intervention|
206563|NCT02088957|Drug|Brivaracetam oral tablets|Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)
Route of Administration: Oral use
206564|NCT02088957|Drug|Phenytoin intravenous solution|Active Substance: Phenytoin
Pharmaceutical Form: Solution for infusion
Concentration: 50 mg/mL
Route of Administration: Intravenous use
206565|NCT02088957|Drug|Phenytoin oral tablets|Active Substance: Phenytoin
Pharmaceutical Form: Tablet
Concentration: Weight based
Route of Administration: Oral use
206566|NCT02088970|Device|Crosslinking|The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.
Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.
206567|NCT02088970|Drug|antibiotic treatment|If not the contact lens wearer -> Cocci Gram positive cocci
Vancomycin + Fortum
If contact lens wearer -> Gram negative bacillus
Fortum + Amiklin
If corticosteroids, immunosuppression, latent evolution -> Fungus.
= Fortum + vancomycin + Fungizone
206568|NCT02088983|Dietary Supplement|CDP-Choline|Capsule
206569|NCT00127998|Drug|amodiaquine+sulfadoxine-pyrimethamine|
206570|NCT02088983|Dietary Supplement|Cellulose|Capsule
206571|NCT02088996|Device|longwave diathermy on high power and interferential therapy|
206572|NCT02088996|Device|longwave diathermy on low power|
206573|NCT02089009|Other|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
206574|NCT02089009|Other|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
206575|NCT02091570|Other|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
206576|NCT02091583|Dietary Supplement|Butter, sunflower and safflower oil|
206577|NCT02091583|Dietary Supplement|High Oleic Canola Oil and DHA (HOCO-DHA)|
206578|NCT02091583|Dietary Supplement|Barley beta-glucan|
206881|NCT02084537|Procedure|Endoscopic treatment|Treated by single transmural cystgastrostomy, 12mm balloon dilation (10mm if cystduodenostomy), two 7fr double pigtail plastic stents and nasocystic drainage catheter.
206882|NCT02084537|Procedure|Minimally invasive surgical necrosectomy|First line approach is video assisted retroperitoneal debridement (VARD), or transperitoneal tract debridement.
If this is not possible due to the location of the collection, second line approach is a laparoscopic approach. This includes transperitoneal laparoscopy cystgastrostomy, or transgastric cystgastrostomy with internal debridement. If percutaneous tract access and debridement is planned, surgery is to be performed no later than 48 hours after interventional radiology insert percutaneous drain.
206261|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
206262|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
206263|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
206264|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Vistanex
206265|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
206266|NCT02096757|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
206267|NCT02096757|Other|Pro-Omega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
206268|NCT02096783|Other|informational intervention|Given scripted intervention
206269|NCT02096783|Other|counseling intervention|Given standard counseling
206270|NCT00128765|Behavioral|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
206271|NCT02096783|Other|questionnaire administration|Ancillary studies
206272|NCT02096809|Procedure|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
206273|NCT02096809|Device|Cochlear Baha BI300/BA400 Implant System|
206274|NCT02098980|Dietary Supplement|Vitamin D|
206275|NCT02098993|Drug|Unfractionated heparin|
206276|NCT02099006|Drug|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
206277|NCT02099006|Drug|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
206278|NCT02099006|Drug|Ketoprofen|To be applied topically at a 10% concentration
206279|NCT02099006|Drug|Ketamine|To be applied topically at a 10% concentration
206280|NCT02099006|Drug|Loperamide|To be applied topically at a 5% concentration
206281|NCT02099006|Drug|Gabapentin|To be applied topically at a 6% concentration
206282|NCT00129038|Drug|aspirin|
205686|NCT02111200|Drug|Phenylbutyrate and Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) until they return on Day 4.
205687|NCT02111213|Behavioral|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
205688|NCT00130598|Drug|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.
7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).
short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast.
205689|NCT02113046|Procedure|pancreatico-jejunal anastomosis|
205690|NCT02113046|Procedure|traditional anastomosis|
205691|NCT02113072|Drug|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
205955|NCT02103569|Drug|FDC of Norethindrone and Ethinyl Estradiol|
205956|NCT02103569|Drug|BMS-791325|
205957|NCT02103582|Other|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
205958|NCT02103595|Device|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
205959|NCT02103595|Device|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
205960|NCT02103608|Device|Glide|
205961|NCT02103621|Behavioral|Unified Protocol (UP)|
205962|NCT02103621|Behavioral|Taper and Monitoring (TAP-M)|
205963|NCT02103634|Device|NaF PET/MRI|
205964|NCT02103634|Device|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
205965|NCT00129506|Drug|misoprostol|
205966|NCT02103634|Device|FDG PET/CT|
205967|NCT02103647|Drug|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
183060|NCT02548026|Behavioral|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
183061|NCT02549898|Drug|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
183062|NCT02549898|Other|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
183063|NCT02549898|Other|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
183064|NCT02549911|Other|HIPEC,Chemotherapy AND surgery|HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )
after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles
183065|NCT00185120|Drug|Hydroclorothiazide|
183066|NCT02549924|Drug|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
183067|NCT02549924|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
183068|NCT02549937|Drug|sulfatinib|orally once daily (QD) in patients with advanced solid tumor.
183069|NCT02549950|Procedure|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
183070|NCT02549950|Procedure|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
183071|NCT02549963|Device|WATCHMAN Left Atrial Appendage Occlusion Device|
183072|NCT02549963|Drug|Rivaroxaban|
183073|NCT02549976|Procedure|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
183074|NCT02549976|Procedure|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
183372|NCT02543606|Drug|Nexium|powder for injection/ infusion Esomeprazole 40mg
183373|NCT02543619|Other|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
182769|NCT02554487|Device|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (RedMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI ≥ 30/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI < 5)following stroke serve as a control group
182770|NCT02554500|Procedure|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
182771|NCT02554513|Device|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
182772|NCT02554513|Behavioral|SPT|A treatment hierarchy involving integral stimulation
182773|NCT02554539|Procedure|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
182774|NCT02554552|Drug|YY1201 2ml|YY1201 2ml
182775|NCT02554552|Drug|Placebo 2ml|phosphate buffered saline 2ml
182776|NCT00000372|Drug|Glycine|
182777|NCT00002504|Biological|recombinant interferon alfa|
182778|NCT00185614|Procedure|autologous then nonmyeloablative allogeneic transplant|stem cell transplantation
182779|NCT02554552|Drug|YY1201 3ml|YY1201 2ml
182780|NCT02556827|Other|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
182781|NCT02556827|Device|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
182782|NCT02556827|Device|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
182783|NCT02556827|Device|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
182784|NCT02556840|Other|insulin therapy|
182161|NCT02565485|Drug|Lactated Ringer's|IV Fluid (crystalloid) used for preload prior to epidural adminstration
182162|NCT02565498|Radiation|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
182163|NCT02565498|Radiation|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
182164|NCT02565511|Biological|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
182165|NCT02565511|Other|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
182166|NCT02565511|Drug|CNP520|CNP520 capsule for once daily oral (p.o) administration at the dose determined prior to initiation of Cohort II. Not yet active.
182167|NCT02565511|Other|Placebo to CNP520|CNP520 capsule for once daily oral (p.o) administration at the dose determined prior to initiation of Cohort II. Not yet active.
182168|NCT02565524|Other|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
182169|NCT02565537|Procedure|LASIK|WFG vs. WFO LASIK
182170|NCT02567604|Behavioral|Focus Groups|at least three focus groups lasting approximately one hour
182171|NCT02567617|Dietary Supplement|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
182172|NCT02567617|Dietary Supplement|Placebo controlled|Starch capsules
182173|NCT02567630|Behavioral|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
182174|NCT02567643|Radiation|Stereotactic Radiosurgery|
182481|NCT02561286|Behavioral|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
182482|NCT00186537|Behavioral|Weight Loss|
181578|NCT01933828|Device|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
181579|NCT01933841|Device|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
181580|NCT01933841|Procedure|Notify the provider|Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated "Reversal Support" team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio.
181581|NCT01933867|Procedure|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
181582|NCT00113295|Drug|Placebo|
181583|NCT01933867|Procedure|Air insufflation insertion|
181584|NCT01933880|Drug|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
181585|NCT01933880|Other|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
181586|NCT01933906|Drug|P1101|
181587|NCT01933919|Drug|fluvoxamine maleate|
181588|NCT01933919|Drug|placebo|
181589|NCT01933932|Drug|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
181590|NCT01933932|Drug|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
181591|NCT01933932|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
181592|NCT01933932|Drug|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
181593|NCT00113308|Drug|GW406381|
181594|NCT01933945|Procedure|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
181595|NCT01933945|Drug|Sorafenib (Nexavar, BAY43-9006)|
181596|NCT01933958|Drug|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
180593|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
180594|NCT00000304|Drug|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
180595|NCT00002116|Drug|Cidofovir|
180596|NCT00114582|Procedure|family style dinner|
180597|NCT01948843|Drug|ADI-PEG 20|
180598|NCT00114868|Drug|Vitamin A|
180599|NCT01951378|Device|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
180920|NCT01943630|Drug|Vehicle|Administration of Vehicle once a day (overnight)
180921|NCT01943643|Procedure|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
180922|NCT01943656|Device|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
180923|NCT00114179|Radiation|radiation therapy|Undergo radiotherapy
180924|NCT01943669|Device|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
180925|NCT01943682|Drug|CPX-351|Comparison of Different doses of drug
180926|NCT01943695|Behavioral|Aerobic Therapy|
180927|NCT01943695|Behavioral|Educational Information|Subjects will be given material regarding cancer and it's impact.
180928|NCT01943708|Device|SPAP|Novel Auto-algorithm for Auto-CPAP device
180929|NCT01943708|Device|CPAP|Standard CPAP therapy
180930|NCT01943721|Drug|VISION5 Product|
179981|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
179982|NCT01940159|Drug|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
179983|NCT01940159|Drug|Placebo|single oral dose placebo
179984|NCT01940172|Drug|Birinapant|Dose Escalation:
Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );
179985|NCT01940172|Drug|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
179986|NCT01940185|Device|LINX device|
179987|NCT01940224|Drug|Pregabalin|Preoperative administration of pregabalin 300mg
179988|NCT01940224|Drug|Placebo|Preoperative administration of placebo
179989|NCT01940224|Drug|Morphine|Postoperative administration of morphine via PCA pump for 48h
179990|NCT01940237|Behavioral|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
179991|NCT01940250|Drug|Magnesium Sulphate|MgSO4 IV infusion
179992|NCT00113906|Drug|melatonin|
179993|NCT01940250|Drug|Sterile water|H2O IV infusion
179994|NCT01940263|Dietary Supplement|Anthocyanin|
179995|NCT01940263|Dietary Supplement|Placebo|
180278|NCT01935440|Behavioral|Prevention & Testing Control|7 group sessions
180279|NCT01935453|Biological|Recombinant hGM-CSF Herpes Simplex Virus Injection|
180280|NCT01935466|Drug|Pioglitazone|Ever users of Pioglitazone
180281|NCT01935479|Drug|AK159|transdermal administration of teriparatide acetate
180282|NCT01935479|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
180283|NCT01935479|Drug|Placebo|Placebo AK159
180284|NCT00002107|Drug|Aldesleukin|
180285|NCT00113399|Biological|filgrastim|
204571|NCT02035072|Drug|Gemcitabine|Gemcitabine 1000 mg/m2
204572|NCT02035072|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2
204573|NCT02035072|Radiation|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
204574|NCT02035085|Drug|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
204575|NCT02035098|Other|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
204576|NCT00122655|Drug|nucleoside reverse transcriptase inhibitors|
204577|NCT02035111|Drug|Tianshu capsule|
204578|NCT02035111|Drug|Sugar pill|
204579|NCT02035124|Drug|BKM 120|
204580|NCT02035124|Drug|Cabazitaxel|
204581|NCT02035137|Radiation|131I-MIBG|
204582|NCT02035137|Drug|Vincristine|
204583|NCT01995370|Drug|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
204584|NCT01995370|Drug|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
204585|NCT01995370|Drug|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
204586|NCT01995383|Drug|RO6836191|Orally administered, single ascending doses
204587|NCT01995383|Drug|Placebo|Single oral administrations
204588|NCT01995383|Drug|RO6836191|2 single oral doses
204589|NCT00118950|Other|Diet-only.|Diet-only treatment. Duration: One month.
204590|NCT01995383|Drug|Placebo|2 single oral administrations
204591|NCT01995383|Drug|RO6836191|Intravenous administration
203952|NCT02008253|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
203953|NCT02008279|Biological|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
203954|NCT02008279|Biological|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
203955|NCT02008279|Biological|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
203956|NCT02008279|Biological|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
204264|NCT02000297|Procedure|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
204265|NCT02000323|Other|early enteral nutrition|Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.
Patients are targeted to receive calories for 25 kcal/kg/day.
nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day
204266|NCT02000323|Other|modified early enteral nutrition|Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.
Patients are targeted to receive calories for 25 kcal/kg/day.
204267|NCT02000336|Drug|Prednisolone|To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
204268|NCT02000336|Drug|Placebo|
204269|NCT02000349|Other|PGD|PGD using Next generation sequencing
204270|NCT02000362|Biological|Stem cells|
204271|NCT02000375|Drug|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
204272|NCT02000388|Drug|Ketorolac Tromethamine|
204273|NCT02000388|Other|Standard of Care|
204274|NCT00119366|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
204275|NCT02000401|Drug|Ketorolac Tromethamine|
208670|NCT02082938|Device|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
208671|NCT02082951|Behavioral|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
208672|NCT02082951|Behavioral|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
208673|NCT02082964|Other|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
208674|NCT02085265|Drug|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
208675|NCT02085278|Device|Apollo Micro Catheter device|Detachable Tip Micro catheter
208676|NCT02085291|Drug|NE|NE infusion to titrate MAP to usual level
208677|NCT02085291|Drug|Saline|Fluid resuscitation to titrate MAP to usual level
208678|NCT02085304|Procedure|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
208679|NCT02085304|Radiation|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
203957|NCT02008279|Drug|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
203958|NCT02008292|Drug|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
203959|NCT02008305|Device|protocol of optimization ALARA|
203960|NCT02008305|Device|protocol of optimization Philips|
203961|NCT02008318|Drug|LY2157299|Administered orally
203962|NCT00119990|Drug|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
203963|NCT02008318|Drug|Placebo|Administered orally
208363|NCT02089815|Other|fall prevention education and counseling|
208364|NCT02089828|Other|autologous purified CD34+ cells|
208365|NCT02089828|Other|autologous peripheral blood mononuclear cells|
208366|NCT02089841|Drug|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
208367|NCT02089854|Drug|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
208368|NCT02089867|Other|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
208369|NCT02089867|Drug|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
208370|NCT02089867|Dietary Supplement|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
208371|NCT02089880|Device|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
208372|NCT00128076|Procedure|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
208373|NCT02089880|Device|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
208374|NCT02089919|Biological|cancer stem cell vaccine|
208375|NCT02089932|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.
After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.
208376|NCT02089932|Drug|Placebo|
208377|NCT02089958|Procedure|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
208378|NCT02092363|Drug|OMP-54F28, Paclitaxel and Carboplatin|
208379|NCT02092376|Drug|Cholecalciferol|
208380|NCT02092376|Drug|Placebo|
208381|NCT02092402|Other|Fecal transplantation|
207801|NCT02102126|Procedure|Renal denervation|
207802|NCT00129337|Drug|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
207803|NCT02104414|Drug|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
207804|NCT02104414|Drug|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
207805|NCT02104414|Drug|Normal Saline|30mL Normal Saline
208094|NCT02097407|Drug|Group D : Dexmedetomidine + propofol group|All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.
After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment.
208095|NCT02097420|Device|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
208096|NCT02097433|Drug|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
208097|NCT02097446|Device|Guardix-FL|
208098|NCT02097446|Device|Interceed|
208099|NCT02097459|Drug|Anastrozole|
208100|NCT02097459|Drug|Tamoxifen|
208101|NCT00128830|Drug|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
208102|NCT02097459|Drug|Toremifene|
208103|NCT02097472|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
208104|NCT02097472|Biological|pneumococcal polysaccharide conjugate vaccine (adsorbed)|1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
208105|NCT02097472|Biological|Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate|Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection.
207492|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
207493|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
207494|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
207495|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
207496|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
207497|NCT02111759|Procedure|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
207498|NCT02111772|Biological|Rhinovirus|
207499|NCT02111785|Drug|Dexamethasone|
207500|NCT02111785|Procedure|Burr Hole Craniostomy|
207806|NCT02104427|Drug|TG-0054 combined with G-CSF|
207807|NCT02104440|Biological|Sequential infusion of allogeneic mesenchymal stem cells expanded "in vitro"|
207808|NCT02104453|Procedure|airway maneuver|Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.
Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)
207809|NCT02104466|Procedure|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
207810|NCT02104492|Other|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
207811|NCT02104492|Other|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
207175|NCT02076867|Behavioral|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
207176|NCT02076867|Behavioral|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
207177|NCT00126737|Other|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
207178|NCT02076880|Other|Caloric restriction|Caloric restriction of 1000 kcal per day compared to the usual food intake.
usual breakfast of the patient (possibly limited in quantity)
midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened
207179|NCT02076880|Other|No caloric restriction|No change in eating habits to patients in this arm
207180|NCT02076893|Drug|gabapentin|The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
207181|NCT02076893|Drug|Tramadol|Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
207182|NCT02076893|Drug|Ibuprofen|Both study arms will receive as needed (PRN) ibuprofen to take home.
207183|NCT02079610|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
207184|NCT02079610|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
207501|NCT02111798|Drug|Bupropion XL|Cocaine dependent methadone maintenance patients will receive usual care at their methadone clinic. All study participants will be able to earn financial incentives throughout the study for stopping cocaine use. In addition, they will receive double blind medication (active vs placebo) daily at the methadone clinic. Active medication is bupropion XL 300mg/day. Participants will see research staff 3 times per week to deliver urine specimens and may be awarded financial incentives if these test cocaine negative.
207502|NCT02111798|Drug|placebo|Cocaine dependent methadone maintenance patients will receive usual care at their methadone clinic. All study participants will be able to earn financial incentives throughout the study for stopping cocaine use. In addition, they will receive double blind medication (active vs placebo) daily at the methadone clinic. Participants will see research staff 3 times per week to deliver urine specimens and may be awarded financial incentives if these test cocaine negative.
206883|NCT02084550|Dietary Supplement|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
206884|NCT02084550|Other|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
206885|NCT00127621|Procedure|early tracheotomy|
206886|NCT02084563|Drug|Induction Chemotherapy|Induction chemotherapy for patients with AML eligible for intensive chemotherapy:
Cytarabine 200 mg/m2 IV continuous infusion days 1-7
Daunorubicin 90 mg/m2 intravenous piggyback days 1-3
206887|NCT02084563|Drug|Consolidation Chemotherapy|Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:
-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles
206888|NCT02084563|Drug|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:
Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4
Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2
206889|NCT02084563|Drug|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML
Conditioning regimen:
Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4
Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4
206890|NCT02084563|Drug|Low Dose Cytarabine|Chemotherapy for patients with AML who are not fit for intensive chemotherapy:
Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)
Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)
206891|NCT02084563|Drug|Decitabine|Chemotherapy for patients with AML who are not fit for intensive chemotherapy:
Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)
Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)
206892|NCT02084576|Drug|Nepafenac|One drop in the study eye 3 times daily for 30 days
206893|NCT02084576|Drug|Ketorolac|One drop in the study eye 4 times daily for 30 days
206894|NCT02084589|Other|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
206895|NCT02084589|Other|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
206896|NCT00127621|Procedure|prolonged endotracheal intubation|
206897|NCT02086838|Drug|Theragran Hematinic|
206898|NCT02086838|Drug|low molecular weight iron dextran|
207185|NCT02079623|Procedure|Electroporation/ Nano knife treatment|
207186|NCT02079623|Device|NanoKnife|
206283|NCT02099006|Drug|placebo|Compounding base to be used alone as a placebo
206284|NCT02099032|Other|3g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
206579|NCT02091583|Dietary Supplement|HOCO-DHA and Barley beta-glucan|
206580|NCT00128219|Biological|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
206581|NCT02091596|Drug|PluroGel N|Study Drug
206582|NCT02091596|Drug|PluroGel|PluroGel Vehicle Placebo Comparator
206583|NCT02091609|Other|dental interproximal brush|use of this to maintain oral hygiene
206584|NCT02091609|Other|dental floss|use of this to maintain oral hygiene
206585|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
206586|NCT02091635|Drug|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
206587|NCT02091635|Drug|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
206588|NCT02091648|Behavioral|I Can Cope Intervention|Participants randomized to the "I Can Cope" condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques.
206589|NCT02091648|Behavioral|Standard Education Intervention|This group will receive the standard American Lung Association (ALA)"Open Airways for Schools" program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education.
206590|NCT02091661|Procedure|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
206591|NCT00128219|Biological|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
178613|NCT01910987|Drug|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
178614|NCT01911000|Radiation|RT and hyperthermia after TACE|
178615|NCT01911013|Procedure|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
178616|NCT01903486|Drug|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
178617|NCT01903499|Other|Other: Bean patty|
178618|NCT01903499|Other|Other: Beef patty|
178619|NCT01903512|Procedure|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
178620|NCT01903525|Drug|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
178621|NCT00110448|Drug|Aspirin|Aspirin 81 mg or 100 mg per day
178924|NCT01944540|Procedure|Optimized ESD with snaring|
178925|NCT01944540|Procedure|Conventional ESD|
178926|NCT01944553|Device|The ROSA™ robot|The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.
Stabilisation in treatment for spine degenerative disease
178927|NCT01944566|Biological|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
178928|NCT01944579|Other|Blackberries|Participants will receive blackberries as part of a controlled diet.
178929|NCT01944579|Other|Control|Participants will receive a control food (jello) as part of a controlled diet.
178930|NCT01944592|Behavioral|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
183374|NCT02543632|Device|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
183375|NCT02543645|Drug|Combination of Varlilumab and Atezolizumab|Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg.
Phase ll Dose: The planned varlilumab dose will be established from the outcome of the Phase l portion of the study. Patients will receive atezolizumab at a dose of 1200 mg.
183376|NCT02543658|Drug|Neostigmine|Intramuscular injection of neostigmine
183377|NCT02543658|Drug|The traditional treatment|the traditional treatments according to associated guidelines
183378|NCT02543671|Other|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
183379|NCT02545816|Device|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
183380|NCT02545829|Drug|HIP1302|Tenofovir 292mg
183381|NCT02545829|Drug|HGP1406|Tenofovir 300mg
183382|NCT02545842|Drug|INSULIN GLARGINE|Pharmaceutical form: solution
Route of administration: subcutaneous
183383|NCT00002499|Drug|methotrexate|
183384|NCT00184782|Procedure|FDG-PET|
183385|NCT02545855|Device|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
183386|NCT02545855|Device|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
178622|NCT01903538|Device|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
182785|NCT02556853|Device|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
183075|NCT02549976|Procedure|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
183076|NCT00185120|Drug|Benazepril|
183077|NCT02549976|Procedure|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
183078|NCT02549989|Drug|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
183079|NCT02550002|Drug|Aflibercept|Intravitreal injection
183080|NCT02550015|Behavioral|High intensity interval training|Uphill treadmill walking
183081|NCT02550015|Behavioral|General information|Standard care
183082|NCT02550028|Drug|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
183083|NCT02550028|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
183084|NCT02550041|Other|T specific response for diagnostic of aspergillus bronchitis|
183085|NCT02552017|Device|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
183086|NCT02552030|Device|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
183087|NCT02552030|Device|iPhone 4s|
183088|NCT02552043|Other|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
183089|NCT02552056|Other|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
182483|NCT02561286|Behavioral|Health Promotion Intervention|Health Promotion Intervention was designed to provide a control for "Hawthorne effects," reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers—leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals.
182484|NCT02561299|Device|Peripheral Orbital Atherectomy System|Orbital Atherectomy
182485|NCT02561299|Device|014 Drug Coated Balloon|Drug Coated Balloon
182486|NCT02561312|Other|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
182487|NCT02561312|Other|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
182488|NCT02561325|Drug|Sodium Bicarbonate and Sodium chloride|
182489|NCT02561338|Drug|HMS5552|50mgBID/75mgBID/75mgQD/100mgQD
182490|NCT02561338|Other|placebo|placebo BID/QD
182491|NCT02561351|Other|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
182492|NCT02561377|Behavioral|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
182493|NCT00186550|Behavioral|Supportive Expressive Group Psychotherapy|
182494|NCT02561377|Behavioral|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
182495|NCT00186849|Drug|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
182496|NCT02563431|Device|SYSTAM - SP-ED|Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.
Daily passive mobilisation of the upper member by a therapist.
Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)
182786|NCT02556853|Other|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
181597|NCT01936428|Other|interview|
181598|NCT01936441|Behavioral|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
181886|NCT02572102|Other|Placebo|Lime juice, water and cherry flavoring
181887|NCT02572115|Behavioral|Akutknappen - used|
181888|NCT02572115|Behavioral|Akutknappen - not used|
181889|NCT02572128|Other|Fortified rice|Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.
Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.
Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2.
181890|NCT02572141|Drug|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
181891|NCT02572141|Drug|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
181892|NCT02572154|Other|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
181893|NCT00187733|Other|Fasting blood and urine collection|Not applicable no drugs dispensed
181894|NCT02572167|Drug|brentuximab vedotin|1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
181895|NCT02572167|Drug|nivolumab|3 mg/kg by intravenous (IV) infusion for up to 4 cycles
181896|NCT02572180|Behavioral|EMG-based biofeedback training|
181897|NCT02572180|Behavioral|NIRS-based neurofeedback training|
181898|NCT02572193|Procedure|POEM|To determine the feasibility of same-day discharge following a POEM procedure
181899|NCT02572206|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
181900|NCT02572206|Device|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
181901|NCT02572219|Dietary Supplement|Nutraceutical compound|
180931|NCT01943734|Behavioral|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
180932|NCT01943760|Drug|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
180933|NCT01943760|Drug|0.9% saline|
180934|NCT00002112|Drug|Nystatin|
180935|NCT00114179|Biological|bevacizumab|Given IV
180936|NCT01943773|Procedure|Functional Assessment|Both arms of the study will undergo functional assessments at three points during the study progress.
BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.
ASSESSMENT OF INTERVENTION EFFECTIVENESS:
Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.
POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation.
180937|NCT01943773|Procedure|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
180938|NCT01943786|Drug|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
181286|NCT01938898|Other|Invitation letter randomisation|There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:
Male & Study & Confidentiality
Male & Study
Male & Project & Confidentiality
Male & Project
Female & Project & Confidentiality
Female & Project
Female & Study & Confidentiality
Female & Study
Neutral & Study & Confidentiality
Neutral & Study
Neutral & Project & Confidentiality
Neutral & Project
181287|NCT01938911|Drug|Syntocinon-Spray|Intranasal oxytocin (24 IU)
181288|NCT01938911|Drug|Placebo of syntocinon|Intranasal administration
181289|NCT01938911|Behavioral|Social support|Social support from the best friend
181290|NCT01938924|Device|GekoTM|electrical neuromuscular stimulation
181291|NCT01938937|Device|Transcranial bright light device|
181292|NCT00113776|Drug|ABX-EGF|
181293|NCT01938937|Device|Transcranial sham device|
181294|NCT01941121|Behavioral|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
180286|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|st line:
Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.
Bevacizumab until PD or unacceptable toxicity
At PD patients will go to the 2nd treatment line.
nd line:
Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.
At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine.
180287|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|Arm B
st line
Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity
Bevacizumab until PD or unacceptable toxicity
At PD < 3 months after last paclitaxel start 2nd treatment line.
At PD ≥ 3 months after last paclitaxel, start another 4 cycles
Bevacizumab until the next PD or unacceptable toxicity
At the next PD start the 2nd treatment line.
nd line:
Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity
At PD < 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.
At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine
At the next PD start 3rd treatment line.
180288|NCT01935505|Behavioral|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
180289|NCT01935505|Drug|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
180290|NCT01935505|Behavioral|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
180291|NCT01935505|Behavioral|Consulting+Telephone+Drug intervention|Include all the above interventions
180292|NCT01935518|Drug|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
180293|NCT01935531|Drug|3% diclofenac in 2.5% hyaluronic acid gel|
180294|NCT01935544|Device|Botulinum toxin injection|
180295|NCT01937897|Other|Bi-lateral massage|Unilateral massage on the left side of the body.
180600|NCT01951378|Drug|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
180601|NCT01951391|Other|Soap|Commercially available soap will be used to wash the subject's forearms
180602|NCT01951404|Drug|Allopurinol|
180603|NCT01951404|Drug|Placebo (for allopurinol)|
180604|NCT01951417|Drug|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
204592|NCT01995383|Other|LS followed by NS diet condition|LS diet period followed by NS diet period
204887|NCT02108431|Device|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
204888|NCT02108431|Device|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
204889|NCT02108457|Radiation|[18F]Fluorothymidine (FLT) PET/CT Imaging|
204890|NCT00130065|Drug|Sulfadoxine-pyrimethamine/placebo|
204891|NCT02108470|Other|Dental consultation using OHIP|The S-OHIP[M] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
204892|NCT02108483|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
204893|NCT02108483|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
204894|NCT02108496|Device|NUsurface® Meniscus Implant|he NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
204895|NCT02108496|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
204896|NCT02110706|Drug|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
204897|NCT02110706|Drug|Placebo|The placebo group will receive a vehicle control infusion
204898|NCT02110719|Drug|Celebrex|
204899|NCT02110719|Drug|Gabapentin|
204900|NCT02110719|Drug|IV acetaminophen|
204901|NCT00130286|Drug|Rosiglitazone|4 mg tablet twice a day x 12 weeks (double-blind phase)
204902|NCT02110719|Drug|oral acetaminophen|
204903|NCT02110719|Drug|oral ibuprofen|
204904|NCT02110719|Drug|percocet|
204276|NCT02003040|Device|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
204277|NCT02003053|Device|Inspiratory Muscle Trainer|
204278|NCT02003066|Procedure|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
204279|NCT02003066|Procedure|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
204280|NCT02003079|Behavioral|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
204281|NCT02003092|Drug|RX-5902|escalating doses (mg)
204282|NCT02003118|Drug|AKR 202|
204593|NCT01995383|Other|NS followed by LS diet condition|NS diet period followed by LS diet period
204594|NCT01995396|Procedure|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
204595|NCT01995396|Procedure|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
204596|NCT01995409|Behavioral|No smoking material provided in households with newborn infants|
204597|NCT01995422|Other|Physical activity program|One hour sessions of active walking occurring three times a week during three months
204598|NCT01995435|Device|Telemedicine refraction|
204599|NCT01995435|Device|Traditional refraction|
204600|NCT00118963|Drug|Metformin|Tablets of 500 mg; 1000 mg two times daily.
204601|NCT01995448|Biological|Blood test|Residue of blood further to NFS.
204602|NCT01995461|Drug|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
204603|NCT01995474|Other|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
203964|NCT02008331|Dietary Supplement|SYNBIOTIC|INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
203965|NCT02008344|Drug|favipiravir|Administered twice daily over 5 consecutive days for a total of 10 doses.
Day 1: 1800 mg twice daily (loading doses)
Days 2 through 5: 800 mg twice daily
203966|NCT02008344|Drug|placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
Day 1: 1800 mg twice daily (loading doses)
Days 2 through 5: 800 mg twice daily
203967|NCT02008357|Drug|Solanezumab|Administered IV
203968|NCT02008357|Drug|Placebo|Administered IV
203969|NCT02010827|Biological|Oral glucose tolerance test, day A|
203970|NCT02010827|Biological|intravenous iv glucose infusion, day B|
203971|NCT02010840|Behavioral|Psychoeducation program|
203972|NCT02010853|Other|IRMf|evaluation in resting state fMRI during three successive visits:
During the acute phase within 24 hours
In 72 hours
In 3 months
203973|NCT00120328|Drug|SPP301|
203974|NCT02010866|Behavioral|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP
203975|NCT02010892|Procedure|Stent Grafting (ESR)|
203976|NCT02010892|Procedure|Open Surgery (OSR)|
203977|NCT02010905|Drug|Losartan|
203978|NCT02010905|Drug|Placebo|
204283|NCT02003118|Drug|Placebo|
204284|NCT00119535|Behavioral|Implementation of Proactive Diabetes Eye Care Program|
204285|NCT02003131|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
204286|NCT02003144|Biological|eculizumab|
204287|NCT02003157|Procedure|hypnosis during embryo transfer or usual transfer procedure|
208680|NCT02085304|Radiation|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
208681|NCT02085304|Drug|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
208682|NCT00127686|Drug|Dextromethorphan|
208683|NCT02085317|Drug|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
208684|NCT02085317|Drug|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
208685|NCT02085330|Device|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
208686|NCT02085343|Behavioral|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
208687|NCT02085343|Behavioral|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
208688|NCT02085343|Behavioral|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
208689|NCT02087579|Drug|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
208690|NCT02087579|Drug|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
208691|NCT02087579|Drug|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
208106|NCT02097472|Other|Saline|0.9% Sodium Chloride Injection, USP
208107|NCT02097485|Drug|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
208108|NCT02097485|Drug|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
208109|NCT02097498|Other|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
208110|NCT02097498|Other|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
208111|NCT02099500|Procedure|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
208382|NCT00128323|Drug|Gentian violet 0.00165% solution|
208383|NCT02092415|Device|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
208384|NCT02092428|Other|Image Quality|The following procedures may be conducted as part of this study:
Coronary MRI scan with no contrast
Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg
MRI scan with an oral beta blocker (metoprolol)
Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)
Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions.
208385|NCT02092428|Other|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
208386|NCT02092441|Other|Alcohol prep pad group|Subjects inhale scent of alcohol pad
208387|NCT02092441|Other|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
208388|NCT02092454|Drug|Benzocaine|topical otic solution
208389|NCT02092454|Drug|Placebo|topical otic solution
208390|NCT02092467|Drug|tofacitinib|Oral tablet, 5 mg BID
208391|NCT02092467|Drug|tofacitinib|Oral tablet, 10 mg BID
208392|NCT02092467|Biological|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
208393|NCT00128323|Drug|Nystatin solution|
208394|NCT02092467|Biological|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
207812|NCT00000318|Drug|Buprenorphine|Experimental Maintenance treatment with daily medication
Experimental Maintenance treatment with thrice-weekly medication
207813|NCT00002225|Drug|Efavirenz|
207814|NCT00129610|Behavioral|Virtual Reality Therapy|
207815|NCT02104505|Drug|Gamma Tocopherol 700 mg capsules,|2 capsules QD
207816|NCT02104505|Drug|Placebo|Safflower oil capsules
207817|NCT02104557|Other|Non intervention|Non intervention
207818|NCT02104557|Other|Non intervention|Non intervention
207819|NCT02104570|Other|Kinesio taping with tension|
207820|NCT02104570|Other|Kinesio taping without tension|
207821|NCT02104570|Other|Fatigue protocol|
207822|NCT02104583|Drug|Eleclazine|Eleclazine tablets administered orally
207823|NCT02104583|Drug|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
208112|NCT02099500|Other|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
208113|NCT02099513|Device|The Mobile Health Platform|
208114|NCT02099539|Biological|ALT-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
208115|NCT02099578|Dietary Supplement|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
208116|NCT02099578|Dietary Supplement|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
208117|NCT02099578|Dietary Supplement|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
208118|NCT02099591|Drug|Naloxegol|8 new evaluable patients within the same age group, given a dose of Naloxegol, peripherally acting opioid antagonist, equivalent to 12.5 mg adult dose and continue for up to 6 months. Approval of the Safety Pharmacokinetic Review Committee to enrol new patients for the higher dose group will be based on data obtained from at least 8 evaluable patients (patients who contribute enough data for calculating AUC of naloxegol on Day 1 without important protocol deviations or violations thought to significantly affect the PK of the drug) for up to 2 weeks of treatment with naloxegol. For any or all of those patients, if data obtained is from less than 2 weeks of treatment, then the Safety Pharmacokinetic Review Committee evaluation and approval will be based on whatever data is available.
207503|NCT02111811|Other|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
207504|NCT02111824|Device|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
207505|NCT00130403|Drug|risedronate sodium|
207506|NCT02111824|Drug|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
207507|NCT02111837|Other|Standard infant formula|
207508|NCT02111837|Other|Standard infant formula with PL1|
207509|NCT02111837|Other|Standard infant formula with PL2|
207510|NCT02111850|Biological|Anti-MAGE-A3-DP4 TCR|On day 0 (one to four days after the last dose of fludarabine) cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
207511|NCT02111850|Drug|Cyclophosphamide|On days -7 and -6, Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
207512|NCT02111850|Drug|Fludarabine|On days -5 to -1, Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
207513|NCT02111850|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
207514|NCT02111863|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
207515|NCT02111863|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
207516|NCT00130416|Behavioral|E-mail coaching to improve patient communication with doctor|
207517|NCT02111863|Drug|Cylcophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
207518|NCT02111863|Biological|4-1BB Selected TIL|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
207824|NCT02104596|Device|Xylitol|
207825|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
207826|NCT02106923|Drug|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
207827|NCT02106923|Drug|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
207187|NCT00127075|Drug|estradiol|75 mcg, once a week
207188|NCT02079636|Drug|Abemaciclib|Administered orally
207189|NCT02079636|Drug|Pemetrexed|Administered IV
207190|NCT02079636|Drug|Gemcitabine|Administered IV
207191|NCT02079636|Drug|Ramucirumab|Administered IV
207192|NCT02079636|Drug|LY3023414|Administered orally
207193|NCT02079636|Drug|Pembrolizumab|Administered IV
207194|NCT02079649|Drug|AL-53817 Ophthalmic Solution, 0.1%|
207195|NCT02079649|Drug|AL-78843 Ophthalmic Solution, 0.03%|
207196|NCT02079649|Drug|Dexamethasone Ophthalmic Suspension, 0.1%|
207197|NCT02079649|Drug|AL-53817 Vehicle|Inactive ingredients used for masking purposes
207198|NCT00127075|Drug|placebo|matching placebo treatments
207199|NCT02079662|Behavioral|Aerobic Activity|30-60 minutes of moderate-to-vigorous intensity aerobic activity up to 6 days/week.
207200|NCT02079662|Behavioral|Dietician Counseling|Weekly meeting with dietician during radiotherapy to learn how to shop and cook during radiation therapy.
207201|NCT02079662|Behavioral|Yoga|Yoga based biweekly sessions with a mind-body instructor for about an hour.
207202|NCT02079662|Behavioral|Cognitive Behavior Therapy|Participants meet with a psychologist once a week during radiation treatment, during which time they take part in cognitive behavioral therapy to help support behavior changes.
207203|NCT02079662|Behavioral|Smoking Cessation Counseling|Smoking cessation treatment offered if participant smokes.
207204|NCT02079662|Behavioral|Questionnaires|Questionnaire completion at baseline, at end of radiation treatment, and at 3, 6, 12, 18, and 24 months after the end of radiation treatment, and then once a year for up to 3 years. This should take about 60-80 minutes.
207205|NCT02079662|Other|Saliva Samples|Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up.
207206|NCT02079662|Behavioral|Dietary Assessment|Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall.
207207|NCT02079662|Procedure|Blood Samples|At baseline and follow ups, blood drawn to measure hormones and immune system responses.
206592|NCT02091661|Radiation|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
206899|NCT02086851|Behavioral|Lifestyle Intervention|
206900|NCT02086851|Behavioral|Parent Motivational Interviewing|
206901|NCT02086864|Drug|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
206902|NCT02086864|Drug|Placebo lactose/sucrose pill|
206903|NCT02086864|Behavioral|Homeopathic consultation|
206904|NCT02086890|Device|Electro-acupuncture|
206905|NCT02086890|Device|Laser Acupuncture|
206906|NCT00127855|Biological|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
206907|NCT02086890|Device|Transcorneal Electrical Stimulation|
206908|NCT02086890|Device|Sham Electro-acupuncture|
206909|NCT02086890|Device|Sham laser acupuncture|
206910|NCT02086890|Device|Sham transcorneal electrical stimulation|
206911|NCT02086903|Drug|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
206912|NCT02086903|Drug|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
206913|NCT02086929|Drug|Trazodone|
206914|NCT02086929|Drug|Venlafaxine|
206915|NCT02086942|Drug|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
178931|NCT01944592|Behavioral|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
178932|NCT00114231|Drug|capecitabine|
178933|NCT01944618|Drug|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor [DPP 4 inhibitor] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
178934|NCT01944631|Device|Placebo|Nasal spray saline
178935|NCT01944631|Device|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
178936|NCT01944644|Device|Low Field Magnetic Stimulation (LFMS)|
178937|NCT01944644|Device|Sham Low Field Magnetic Stimulation|
178938|NCT01947218|Procedure|bronchial biopsies|
178939|NCT01947218|Other|Determination of CO in exhaled air|
178940|NCT01947231|Other|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
178941|NCT01947231|Other|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
179237|NCT01939509|Drug|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
179238|NCT01939509|Drug|Bisoprolol|
179239|NCT00113841|Drug|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
179240|NCT01939522|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|
179241|NCT01939535|Other|No intervention|Evaluation of an imaging technique ic MRI
179242|NCT01939548|Drug|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
179243|NCT01939548|Drug|Placebo|Placebo BID until the Week 12 visit
179244|NCT01939548|Drug|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
179245|NCT01939561|Drug|Lamotrigine|
178623|NCT01903538|Device|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
178624|NCT01903551|Device|Loco-regional catheter|
178625|NCT01903564|Device|magnetocardiography|recording of magnetic heart activity
178626|NCT01903564|Device|postnatal ECG|postnatal ECG
178627|NCT01903564|Device|fetal echocardiography|fetal echocardiography
178628|NCT01903577|Other|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
178629|NCT01903577|Other|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
178630|NCT01903590|Procedure|TVT surgery TOT surgery|
178631|NCT01903629|Device|MCE|MCE first, followed by standard gastroscopy
178632|NCT00110448|Drug|No aspirin|No aspirin use
178633|NCT01903629|Device|Standard gastroscopy|
178634|NCT01903642|Other|proteomic analysis|
178635|NCT01903655|Other|telomere length|
178636|NCT01903681|Drug|Circadin 2 mg|First arm lower dose
178637|NCT01903681|Drug|Circadin 10 mg|Second arm higher dose
178638|NCT01903694|Drug|Sorafenib + Pravastatin|
178639|NCT01903694|Drug|Sorafenib|
178640|NCT01903707|Other|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
178641|NCT01906216|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
178642|NCT01906216|Procedure|TACE|The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated "on demand" depending on the radiological response.
178643|NCT01906242|Other|water|
183090|NCT02552069|Device|Tritanium® cup|
183091|NCT02552082|Device|Scorpio NRG posterior stabilized (PS)|
183092|NCT02552095|Device|Triathlon PKR|
183093|NCT02552108|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|
183094|NCT02552121|Drug|HuMax-TF-ADC|
183387|NCT02545868|Biological|23-valent PPV|The 23-valent PPV will be administered at 112 days after the first OCR administration or at Day 28 (for participants not receiving OCR).
183388|NCT02545868|Biological|Booster 13-PCV|The booster 13-PCV will be administered on Day 140 for first subgroup of participants with OCR administration.
183389|NCT02545868|Biological|Influenza Vaccine|The influenza vaccine will be administered any time between days 84 and 140 (for second subgroup of participants with OCR administration) or any time between day 1 and 84 (for participants not receiving OCR).
183390|NCT02545868|Biological|KLH Vaccine|The KLH Vaccine will be administered at 84, 112, and 140 days after the first OCR administration or at Day 1, 28, and 56 (for participants not receiving OCR).
183391|NCT02545868|Drug|OCR 300mg|OCR 300 milligram (mg) intravenous infusion administered at Day 1 and Day 15.
183392|NCT02545868|Biological|TT Vaccine|An adsorbed TT-vaccine combined with diphtheria (tetanus-diphtheria [Td] or diphtheria and tetanus toxoid [DT]) or with diphtheria and acellular pertussis (diphtheria-tetanus-acellular pertussis [DTaP] or tetanus-diphtheria-acellular pertussis [Tdap]) will be administered at 84 days after the first OCR administration or at Day 1 (for participants not receiving OCR).
183393|NCT02545881|Other|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
183394|NCT02545894|Behavioral|Cognitive therapy|The tasks are:
visually tracking a picture as it moves across the computer screen
pressing a button every time a picture is seen on the screen
pressing a button every time a specific picture is seen on the screen
Pressing a button every time a specific sound is heard
Matching objects to a picture
Matching gestures to objects
Matching two connected objects
Sorting objects by categories
Matching sounds to objects
"Complete the category" and "odd on out with objects"
Choosing target objects by pointing
Choosing objects to complete the category by pointing
183395|NCT00184795|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
183396|NCT02545907|Drug|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
183397|NCT02545907|Drug|Thalidomide|50mg capsule.
183398|NCT02545907|Drug|Dexamethasone|2mg tablet.
183399|NCT02548052|Drug|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
182787|NCT02556866|Drug|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
182788|NCT02556866|Drug|Prednisone|
182789|NCT02556866|Drug|Placebo|
182790|NCT00185835|Drug|Cisplatin|
182791|NCT02556879|Biological|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
182792|NCT02556879|Biological|Serum bank|Additional samples for serum bank at each visit if possible
182793|NCT02556879|Biological|DNA bank|Additional sample for DNA bank at inclusion visit if possible
182794|NCT02556879|Procedure|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
182795|NCT02556879|Procedure|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
182796|NCT02556892|Drug|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
182797|NCT02556905|Drug|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
182798|NCT02556905|Drug|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
182799|NCT00186212|Behavioral|workbook/journal on coping with breast cancer|
182800|NCT02559193|Other|Observational study, data collection only trial.|Data collection only trial design.
182801|NCT02559206|Drug|Linaclotide|Oral, once daily
182802|NCT02559206|Drug|Matching Placebo|Oral, once daily
182803|NCT02559219|Other|Questionniares|
182804|NCT02559232|Drug|Xarelto, Pradaxa and Eliquis|Direct oral anticoagulants; Treatment pattern following the summary of product characteristics
182805|NCT02559245|Other|Descurainia Sophia|
182806|NCT02559245|Other|Ficus carica|
182807|NCT02559258|Drug|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
181902|NCT02572219|Dietary Supplement|Placebo|
181903|NCT02572232|Device|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
181904|NCT00187746|Drug|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
181905|NCT02574234|Other|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
182175|NCT02567656|Drug|RP6530|Tablet starting at 200 mg
182176|NCT02567669|Radiation|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
182177|NCT02567682|Drug|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
182178|NCT00187122|Drug|Cytarabine|See Detailed Description section for description of treatment plan.
182179|NCT02567695|Drug|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
182180|NCT02567708|Drug|GSK2269557 DPI|GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
182181|NCT02567708|Drug|Placebo DPI|Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
182182|NCT02567721|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
182183|NCT02567734|Procedure|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
182184|NCT02567747|Other|Data collection|Data will be collected retrospectively for cases identified through RIPS*/ DANE** from 2008 until 2014 and through PAI*** from 2009 until 2014. *Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. **Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. ***Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
182185|NCT02567760|Dietary Supplement|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
182186|NCT02567760|Other|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
182187|NCT02567773|Drug|GSK2881078|GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
181295|NCT01941134|Drug|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
181296|NCT01941147|Device|pulsed ELF-MF|(75 Hz, 1,8 mT)
181297|NCT01941160|Dietary Supplement|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
181298|NCT01941160|Dietary Supplement|Placebo|Placebo capsule twice daily
181299|NCT01941173|Biological|ziv-aflibercept|Given IV
181300|NCT01941173|Drug|leucovorin calcium|Given IV
181301|NCT01941173|Drug|irinotecan hydrochloride|Given IV
181302|NCT01941173|Drug|fluorouracil|Given IV
181303|NCT01941186|Other|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
181304|NCT00002110|Drug|Cysteamine|
181305|NCT00114036|Behavioral|Quality improvement strategies|
181306|NCT01941199|Drug|DA-1229|
181307|NCT01941199|Drug|metformin|
181599|NCT01936441|Behavioral|Menopause Education Control (MEC)|See Experimental Arm Description
181600|NCT01936467|Device|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
181601|NCT01936467|Device|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
181602|NCT00113516|Drug|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
181603|NCT01936480|Drug|Moxifloxacin 400mg once time|
181604|NCT01936480|Drug|Placebo|
181605|NCT01936493|Genetic|DNA analysis|At a future time DNA analysis will be performed
180605|NCT01951417|Other|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
180606|NCT01951417|Other|Foam Wash|Foam Wash (twice daily)
180607|NCT01951430|Drug|Antibiotic and antifungal drugs|
180608|NCT01951443|Dietary Supplement|Ginseng|400mg of encapsulated Rg3-KRG
180609|NCT00114894|Other|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
180610|NCT01951443|Dietary Supplement|Wheat Bran|400mg of encapsulated wheat bran
180611|NCT01951456|Behavioral|Resistance training|
180612|NCT01951456|Behavioral|Health and Wellness|
180613|NCT01951469|Drug|Gefitinib and Pemetrexed/cisplatin|Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days
180614|NCT01951469|Drug|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
180615|NCT01951482|Drug|Pemetrexed/cisplatin|receive Pemetrexed/cisplatin every 21 days
180616|NCT01951482|Drug|Bevacizumab and Pemetrexed/cisplatin|receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
180617|NCT01951508|Drug|Methylphenidate|60mg per os, single dose
180618|NCT01951508|Drug|Modafinil|600mg per os, single dose
180619|NCT01951508|Drug|MDMA|125mg per os, single dose
180620|NCT00114894|Other|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
180621|NCT01951508|Drug|Placebo|per os
180622|NCT01951521|Radiation|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
180623|NCT01951534|Behavioral|Breast Reconstruction Decisional Aid (BRDA)|
180624|NCT01951534|Behavioral|Usual Care|
180939|NCT01943799|Biological|GS-4774|GS-4774 2, 10, or 40 YU administered as a subcutaneous injection every 4 weeks for a total of 6 doses
180940|NCT01943799|Drug|OAV Regimen|Oral antiviral (OAV) regimen as administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
204905|NCT02110719|Drug|vicodin|
204906|NCT02110719|Drug|Oxycodone|
204907|NCT02110719|Drug|dilaudid|
205197|NCT02100891|Drug|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
205198|NCT02100904|Procedure|Radiofrequency ablation of fibroids|
205199|NCT02100917|Drug|DMB-3111|
205200|NCT02100917|Drug|trastuzumab|
205201|NCT02100930|Biological|Anti-GD2 3F8 Monoclonal Antibody|
205202|NCT02100930|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
205203|NCT02100930|Drug|oral isotretinoin|
205204|NCT02100956|Drug|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
205205|NCT00129233|Drug|Amlodipine|Amlodipine 5 to 10 mg daily.
205206|NCT02100956|Drug|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
205207|NCT02100969|Drug|HIZENTRA ®|
205208|NCT02100982|Other|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
205209|NCT02100982|Other|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
205210|NCT02100995|Behavioral|Intervention Simultaneously Targeting Obesity and Pain|
205211|NCT02100995|Behavioral|Weight Loss/Weight Self-Management|
205212|NCT02100995|Behavioral|Chronic Pain Self-Management|
205213|NCT02101008|Drug|disulfiram and chelated zinc|
204604|NCT01995474|Other|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
204605|NCT01995487|Device|BioNIR|drug-eluting stent
204606|NCT01995487|Device|Resolute|drug-eluting stent
204607|NCT01995500|Device|BioNIR|drug-eluting stent
204608|NCT01997957|Drug|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
204609|NCT01997970|Behavioral|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
204610|NCT01997970|Behavioral|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
204611|NCT01997983|Device|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
204612|NCT01998009|Other|fecal occult blood tests|
204908|NCT02110719|Drug|Dexamethasone|
204909|NCT02110719|Drug|zofran|
204910|NCT02110732|Dietary Supplement|Lactobacillus rhamnosus GG|
204911|NCT02110745|Drug|Sevofluorane|Comparison of different induction drugs and techniques
204912|NCT00130286|Drug|Recombinant human growth hormone + rosiglitazone|Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
204913|NCT02110745|Drug|Propofol|Comparison of different induction drugs and techniques
204914|NCT02110758|Other|Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track & coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track & coordinate care, and measure and improve performance.
204915|NCT02110771|Behavioral|GAÏA - facial affect recognition targeted|2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).
The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage.
204916|NCT02110771|Behavioral|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
204288|NCT02003183|Radiation|[F-18]FDDNP|[F-18]FDDNP is a molecular imaging probe for PET, with high in vitro binding affinity to NFTs and of the fibrillar tau deposits as shown with fluorescent microscopy with non-radioactive FDDNP.
204289|NCT02003209|Drug|Aromatase Inhibition Therapy|Given at the investigator's discretion
204290|NCT02003209|Drug|Carboplatin|Given IV
204291|NCT02003209|Other|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
204292|NCT02003209|Drug|Docetaxel|Given IV
204293|NCT02003209|Drug|Goserelin Acetate|Given SC
204294|NCT02003209|Other|Laboratory Biomarker Analysis|Correlative studies
204295|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
204296|NCT02003209|Biological|Pertuzumab|Given IV
204297|NCT02003209|Other|Quality-of-Life Assessment|Ancillary studies
204298|NCT02003209|Procedure|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
204299|NCT02003209|Biological|Trastuzumab|Given IV
204300|NCT02003209|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
204301|NCT02003222|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
204302|NCT02003222|Biological|Blinatumomab|Given IV
204303|NCT02003222|Drug|Cyclophosphamide|Given PO or IV
204304|NCT00119769|Drug|Placebo|Placebo, 0.7 mg/day injected subcutaneously
204305|NCT02005757|Drug|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
204306|NCT02005757|Drug|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
204307|NCT02005770|Drug|Sevoflurane|
204308|NCT02005770|Drug|Propofol|
204613|NCT01998035|Drug|Romidepsin|Romidepsin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Romidepsin is classified as a "Histone Deacetylase Inhibitor".
Dose escalation (10, 14 mg/m2)
208692|NCT02087592|Behavioral|Structured exercise training plus mediterranean diet|
203979|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
203980|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
203981|NCT02010918|Drug|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
203982|NCT02010944|Drug|solifenacin succinate|oral
203983|NCT02010944|Drug|mirabegron|oral
203984|NCT00120341|Device|Anodyne Therapy System|
203985|NCT02010944|Drug|mirabegron/solifenacin succinate|oral
203986|NCT02010957|Other|FDG positron emission tomography|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
203987|NCT02010957|Other|Iodometomidate imaging|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
203988|NCT02010970|Drug|Group 1 AZD3293|AZD3293 oral solution
203989|NCT02010970|Drug|Group 2 AZD3293|AZD3293 oral solution
203990|NCT02010970|Drug|Group 3 AZD3293|AZD3293 oral solution
203991|NCT02010970|Drug|Group 1 Itraconazole|itraconazole capsule
203992|NCT02010970|Drug|Group 2 Diltiazem|Diltiazem ER tablet
203993|NCT02010970|Drug|Group 3 Midazolam|midazolam syrup
203994|NCT02010983|Other|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
203995|NCT00120354|Procedure|Blood Testing|
203996|NCT02010996|Procedure|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
203997|NCT02013830|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
203998|NCT02013830|Drug|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
208395|NCT02092480|Behavioral|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
208396|NCT02092493|Device|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
208397|NCT02092506|Drug|10 day triple therapy|10 day triple therapy
208398|NCT02092506|Drug|10 day sequential therapy|10 day sequential therapy
208399|NCT02092506|Drug|10 day concomitant therapy|10 day concomitant therapy
208400|NCT02092519|Device|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
208401|NCT02092519|Device|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
203688|NCT02019108|Other|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
203689|NCT02019108|Other|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
203690|NCT02019134|Behavioral|relaxation exercise|relaxation exercise
203691|NCT02019134|Other|ususal care|
203692|NCT02019160|Drug|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
203693|NCT02019160|Drug|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
203694|NCT02019173|Behavioral|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
203695|NCT02019186|Dietary Supplement|Vitamin C|<30 kg 250 mg 30-60 kg 500 mg >60 kg 750 mg
203696|NCT02019186|Dietary Supplement|Vitamin E|<30 kg 100 IU, 30-60 kg 200 IU, >60 kg 300 IU
208119|NCT02099591|Drug|Naloxegol|8 new evaluable patients within the same age group, given a dose of Naloxegol, peripherally acting opioid antagonist, equivalent to 25 mg adult dose and continue for up to 6 months. Approval of the Safety Pharmacokinetic Review Committee to enrol new patients for the higher dose group will be based on data obtained from at least 8 evaluable patients (patients who contribute enough data for calculating AUC of naloxegol on Day 1 without important protocol deviations or violations thought to significantly affect the PK of the drug) for up to 2 weeks of treatment with naloxegol. For any or all of those patients, if data obtained is from less than 2 weeks of treatment, then the Safety Pharmacokinetic Review Committee evaluation and approval will be based on whatever data is available.
208120|NCT00129129|Biological|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
208121|NCT02099604|Drug|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
208122|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent|
208123|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent|
208124|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent|
208125|NCT02099656|Drug|lebrikizumnab|Given by SC on Day 1, Day 8, Week 4, and Week 8
208126|NCT02099656|Other|placebo|Given by SC on Day 1, Day 8, Week 4, and Week 8
208127|NCT02099669|Other|Red blood cell transfusions|
208128|NCT02099682|Drug|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
208402|NCT02095028|Behavioral|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
208403|NCT02095054|Drug|Regorafenib|Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.
Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.
208404|NCT02095054|Drug|Cetuximab|Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.
208405|NCT02095054|Behavioral|Questionnaire|Symptom questionnaire completed at each study visit.
208406|NCT02095067|Device|Video consultation|
208407|NCT02095080|Dietary Supplement|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
208408|NCT00128570|Other|internet-based intervention|
207828|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
207829|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
207830|NCT00129896|Drug|Myocet|
207831|NCT02106949|Device|SMS contact with patient after discharge in intervention group|
207832|NCT02106962|Drug|Topical Tranexamic Acid|A fixed amount of tranexamic acid and bacitracin will be applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site per visit (8 visits total).
207833|NCT02106962|Drug|Topical Bacitracin|A fixed amount of tranexamic acid and bacitracin will be applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site per visit (8 visits total).
207834|NCT02106975|Drug|Ascorbic Acid|
207835|NCT02106975|Drug|5% Dextrose in water|
207836|NCT02106988|Radiation|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
207837|NCT02106988|Drug|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
207838|NCT02106988|Drug|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
207839|NCT02106988|Drug|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
207840|NCT02106988|Drug|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
207841|NCT00129896|Drug|Taxotere|
207842|NCT02106988|Drug|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
207843|NCT02107001|Procedure|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
207844|NCT02107014|Drug|Low Dose Naltrexone|
207845|NCT02107014|Drug|Placebo|
208129|NCT02099695|Drug|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
208130|NCT02099695|Drug|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
207208|NCT02079675|Drug|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
207519|NCT02114008|Other|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
207520|NCT02114021|Drug|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
207521|NCT00130702|Drug|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
207522|NCT02114021|Drug|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
207523|NCT02114021|Drug|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
207524|NCT02114060|Biological|Matrix-M2 Adjuvant|Matrix-M2 adjuvant (25, 50 or 75 μg), administered in combination with GEN-003 vaccine as a 0.5 mL intramuscular (IM) injection.
Matrix-M2 is made up of immune stimulating complexes derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol. Quillaja saponins are surface-active substances derived from the tree Quillaja saponaria Molina.
207525|NCT02114060|Biological|GEN-003 Vaccine|GEN-003 Vaccine (30 or 60μg of each antigen) in combination with Matrix-M2 Adjuvant, administered as a 0.5mL intramuscular injection
GEN-003 is a HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens:
GB208: a T cell antigen and internal fragment of the immediate early (IE) protein ICP4.
GB217: a B cell antigen (also known as glycoprotein D, or gD)
207526|NCT02114060|Drug|Placebo|
207527|NCT02114073|Drug|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
207528|NCT02114073|Drug|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
207529|NCT02114099|Drug|Atorvastatin|10 mg qd x1 year
207530|NCT02114112|Other|NCPAP cycling|
207531|NCT02114112|Other|NCPAP continuous|
207532|NCT00002231|Biological|APL 400-003|
207533|NCT00130715|Device|Seprafilm Bioresorbable Membrane|
207534|NCT02114125|Behavioral|Physical Activity|group-based physical activity
207535|NCT02114125|Behavioral|Cognitive Training|individual-based, multi-domains cognitive training
206916|NCT02086942|Drug|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
206917|NCT00127855|Biological|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
206918|NCT02086942|Drug|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
207209|NCT00127088|Drug|docetaxel|
207210|NCT02082067|Drug|Ropivacaine 0,75%|
207211|NCT02082067|Drug|Levobupivacaine 0,5%|
207212|NCT02082067|Drug|Levobupivacaine 0,125%|
207213|NCT02082067|Drug|Ketorolac 30mg|
207214|NCT02082067|Drug|Morphine|
207215|NCT02082067|Device|stimulong sono, Pajunk, Germany|
207216|NCT02082080|Other|Education|
207217|NCT02082080|Other|Social support|
207218|NCT00127270|Behavioral|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
207219|NCT02082093|Device|Telemedicine System|
207220|NCT02082106|Other|Alpine skiing|
207221|NCT02082106|Other|cross country skiing|
207222|NCT02082106|Other|Indoor training (cycling)|
207223|NCT02082119|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
207224|NCT02082145|Device|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
207225|NCT02082158|Other|Current Respirator Model|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
207226|NCT02082158|Other|Novel Respirator Design|
207227|NCT02082171|Other|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
179246|NCT01939561|Drug|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
179247|NCT01939574|Other|Chemoradiation Therapy|Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.
Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight.
179248|NCT01939574|Other|Adjuvant Therapy|Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight.
179249|NCT01939587|Drug|PBF-680 5 mg|
179250|NCT00113841|Drug|Bioperine|5 mg (Tablets) orally twice daily
179251|NCT01939587|Drug|PBF-680 20 mg|
179252|NCT01939587|Drug|Placebo|
179253|NCT01939600|Other|Starch-free breakfast|Starch-free breakfast alone
179254|NCT01939600|Other|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
179255|NCT01939600|Other|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
179256|NCT01939600|Other|Amioca|Starch-free breakfast plus 56.4g amioca starch
179257|NCT01939613|Drug|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
179258|NCT01939626|Device|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
179553|NCT00115063|Behavioral|group sessions|group sessions lead by a trained primary care clinic employee
179554|NCT00002106|Drug|Ranitidine hydrochloride|
179555|NCT00113373|Drug|lapatinib ditosylate|Given orally
179556|NCT01934621|Behavioral|Strategy Training|
179557|NCT01934621|Behavioral|Attention Control|
179558|NCT01934634|Drug|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
179559|NCT01934634|Drug|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
178942|NCT01947244|Behavioral|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
178943|NCT01947244|Behavioral|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
178944|NCT00114478|Drug|Epinephrine|
178945|NCT01947257|Other|the measure TRVMAX|by transthoracic echocardiography
178946|NCT01947257|Other|the measure of the pulmonary artery|by transesophageal ultrasound
178947|NCT01947257|Other|the direct measure of the pulmonary pressures|by right catheterization
178948|NCT01947270|Other|" Optimisation de la Prescription MEDicamenteuse " ("Optimization of drug prescribing")|The multidisciplinary intervention program include:
Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.
Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis
178949|NCT01947283|Behavioral|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
178950|NCT01947283|Behavioral|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
178951|NCT01947309|Drug|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
178952|NCT01947322|Drug|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
178953|NCT01947335|Device|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
178954|NCT01947348|Procedure|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
178955|NCT00114478|Drug|albuterol (salbutamol)|
178956|NCT01947374|Procedure|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
178957|NCT01947374|Procedure|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
178958|NCT01947400|Other|Hospitalists|AIDET Training
178959|NCT01947413|Other|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
183400|NCT02548052|Drug|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
183401|NCT02548052|Drug|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
183402|NCT02548052|Drug|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
183403|NCT02548052|Drug|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
178644|NCT01906242|Other|sodium hypochlorite|
178645|NCT01906242|Other|sodium bicarbonate|
178646|NCT01906242|Other|chlorhexidine|
178647|NCT00110773|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
178648|NCT01906268|Other|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)
178649|NCT01906268|Other|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)
178650|NCT01906281|Other|Blood analyse, arthrocentesis, ultrasound examination|
178651|NCT01906294|Drug|antidiabetic treatment (ATC A10B)|
178652|NCT01906307|Drug|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
183095|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
183096|NCT02552134|Other|exercise training|
183097|NCT02552134|Other|recommendation to be active|
183098|NCT02552147|Drug|Transdermal nicotine|
183099|NCT02552147|Other|Transdermal placebo|
183100|NCT02552173|Radiation|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
183101|NCT02552186|Other|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
183102|NCT02552199|Other|gravimetric|
183103|NCT02552212|Biological|Certolizumab Pegol|Active Substance: Certolizumab Pegol
Pharmaceutical Form: Prefilled syringe
Concentration: 200 mg / ml
Route of Administration: Subcutaneous injection
183104|NCT02552212|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Prefilled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous injection
183105|NCT02552225|Drug|Amitriptyline|
183106|NCT00185289|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
183107|NCT02552225|Other|Placebo|
183108|NCT02552238|Drug|sulphur hexafluoride lipid-type A microspheres|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent will be administered as 2 single 2-mL IV injections during rest and stress echocardiography
183109|NCT02554552|Drug|Placebo 3ml|phosphate buffered saline 3ml
183110|NCT02554565|Procedure|Tumor biopsy|Tumor biopsy before treatment
183111|NCT02554565|Procedure|Blood sampling|Blood sample before, during and after treatment
183112|NCT02554578|Other|Multidisciplinary follow-up programme supported by mHealth|The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.
Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.
Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).
mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families.
182188|NCT02567773|Drug|Placebo|Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
182189|NCT00187122|Drug|Methotrexate|See Detailed Description section for description of treatment plan.
182190|NCT02567773|Drug|Itraconazole|Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
182191|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
182192|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
182193|NCT02569957|Drug|Acetylcysteine|Given IV and PO
182497|NCT02563431|Device|Ultrasling ER 15°Donjoy - 4P-ED|Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.
A training of the patient and members of family on pathology, risk, use of material
Daily passive mobilization of the upper member by a therapist.
Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis.
182498|NCT02563444|Device|Ultrasound fusion guiding system|
182499|NCT02563457|Other|periodontal manual treatment|periodontal manual treatment
182500|NCT02563457|Other|no periodontal manual treatment|blood sampling
182501|NCT02563483|Behavioral|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
182502|NCT02563496|Drug|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (150 mg) and fast-dispersing film coated tablet (50 mg)
182503|NCT02563496|Drug|Chloroquine|Subjects will receive chloroquine according to local/national treatment guidelines
182504|NCT02563509|Other|HIV-specific CD8 cells|Only receive HAART
182505|NCT02563522|Genetic|VM202|gene therapy
182506|NCT00186849|Procedure|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
182507|NCT02563522|Other|Placebo|Standard of care plus placebo
182508|NCT02563535|Device|DEB|angioplasty with Litos drug eluting balloon
182509|NCT02563535|Device|PTA|angioplasty with conventional balloon
182510|NCT02563548|Drug|PEGPEM|PEGPH20 + pembrolizumab
181606|NCT01936493|Other|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
181607|NCT01936506|Behavioral|Cognitive Training A|
181608|NCT01936506|Behavioral|Cognitive Training B|
181609|NCT01936519|Drug|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
181610|NCT01936519|Drug|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
181611|NCT01936532|Drug|MLN9708|Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.
Consolidation therapy
Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.
Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.
Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months.
181612|NCT01936532|Drug|Lenalidomide|
181613|NCT00113516|Drug|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
181614|NCT01936532|Drug|Dexamethasone|
181615|NCT01936545|Drug|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
181616|NCT01936545|Drug|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
181617|NCT01936558|Other|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
181906|NCT02574234|Other|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
181907|NCT02574234|Other|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
181908|NCT02574234|Other|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
181909|NCT02574234|Other|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
181910|NCT02574247|Procedure|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 6-week span.
180941|NCT01946386|Drug|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
180942|NCT01946386|Drug|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
180943|NCT01946386|Drug|LEO 90100 Aerosol, foam, vehicle|
180944|NCT01946386|Drug|Daivobet® ointment|
180945|NCT01946386|Drug|Dermovate® cream|
180946|NCT01946386|Drug|Synalar® ointment|
180947|NCT01946399|Drug|Ozurdex implant|Intravitreal injection of Dexamethasone implant
180948|NCT01946412|Drug|Ivacaftor|
180949|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
180950|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
180951|NCT00114387|Drug|DL-alpha-tocopherol|
180952|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
180953|NCT01946438|Biological|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
180954|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
180955|NCT01946438|Biological|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
180956|NCT01946477|Drug|Pomalidomide|
180957|NCT01946477|Drug|Dexamethasone|
180958|NCT01946529|Drug|vincristine|Dosage and route of administration: Infants < 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m^2 IV day 1 (max. dose 2 mg).
180959|NCT01946529|Drug|doxorubicin|Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2.
180960|NCT01946529|Drug|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
205214|NCT02103270|Drug|Peanut Protein 4,000mg|Arm A will be defined as "clinically tolerant" if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of "clinically tolerant" will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity.
205215|NCT02103270|Drug|Oat Flour|Arm C will be defined as "natural loss of responsiveness" if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
205216|NCT02103270|Drug|Peanut Protein 300 mg|Arm B will be defined as "desensitized" to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
205510|NCT02093819|Drug|Placebo to BI 416970|single rising doses
205511|NCT00128466|Drug|streptomycin|
205512|NCT02093819|Drug|BI 416970|single rising doses
205513|NCT02093832|Other|There are no specific Intervention|are no specific Intervention
205514|NCT02093845|Device|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
205515|NCT02093845|Device|SYNERGY stent|Percutaneous coronary intervention involving use of stent
205516|NCT02093871|Device|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
205517|NCT02093884|Other|Text Messaging Intervention|
205518|NCT02093884|Other|Standard Referral|
205519|NCT02093897|Biological|rVIII-SingleChain|
205520|NCT02093910|Drug|Monosialotetrahexosylganglioside|
205521|NCT02093923|Drug|DX-2930|DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody
205522|NCT00128479|Drug|mifepristone|mifepristone 300 mg daily for 7 dats
205523|NCT02093923|Drug|Placebo|Placebo
205524|NCT02093962|Drug|TH-302 combination with pemetrexed|400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration.
205525|NCT02093962|Drug|Matched placebo in combination with pemetrexed|Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration.
204917|NCT02110784|Drug|Eurartesim tablets|dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
204918|NCT02110797|Other|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
204919|NCT02110810|Drug|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
204920|NCT02110810|Drug|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
204921|NCT02110836|Dietary Supplement|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
204922|NCT02112799|Drug|NVR 3-778|
204923|NCT00130559|Procedure|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
204924|NCT02112799|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
204925|NCT02112799|Drug|Pegasys|
204926|NCT02112812|Drug|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
204927|NCT02112812|Drug|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
205217|NCT02103283|Drug|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
205218|NCT00129467|Drug|Placebo|Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.
If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention.
205219|NCT02103296|Procedure|Drawing admission labs from cord blood|
205220|NCT02103296|Procedure|Drawing admission labs from infant blood|
205221|NCT02103309|Device|Nelfilcon A contact lenses|
205222|NCT02103309|Device|Etafilcon A contact lenses|
205223|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
204614|NCT01998035|Drug|Oral 5-Azacitidine|A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.
Dose escalation (100, 200, 300 mg)
204615|NCT00119171|Drug|Ispinesib|
204616|NCT01998048|Procedure|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
204617|NCT01998048|Procedure|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
204618|NCT01998061|Drug|EGFR tyrosine kinase inhibitor|Arm A
204619|NCT01998061|Drug|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
204620|NCT01998074|Dietary Supplement|extensively hydrolyzed rice protein formula|
204621|NCT01998087|Behavioral|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
204622|NCT01998100|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
204623|NCT01998100|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
204624|NCT01998113|Drug|Glyburide vs Insulin trials|Affecting groups 1 and 2
204625|NCT01998113|Drug|Metformin vs Insulin trials|Affecting groups 3 and 4
204626|NCT00002159|Drug|Itraconazole|
204627|NCT02000414|Drug|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
204628|NCT02000427|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval. In the first cycle, the initial dose will be 9 μg/day for the first 7 days of treatment, a dose that then will be escalated (dose step) to 28 μg/day starting at day 8 (week 2) through day 29 (week 4).
For all subsequent cycles (beginning with the second induction cycle and continuing through consolidation for applicable subjects), 28 μg/day will be the dose for all 4 weeks of continuous treatment.
203999|NCT02013843|Behavioral|Community-based treatment of overweight and obesity|Community based treatment of overweight and obese children using the "Holbaek-method".
204000|NCT02013856|Dietary Supplement|Flavanols|70 mg epicatechin and ~ 100 mg procyanidins once daily for 28 days
204001|NCT02013856|Dietary Supplement|Flavanols|140 mg epicatechin and ~ 200 mg procyanidins once daily for 28 days
204309|NCT02005783|Drug|DBD|DBD:one dose of medicine twice per day, orally
204310|NCT02005783|Drug|Epirubicin|Epirubicin:90mg/m2, d1, q3w*4
204311|NCT02005783|Drug|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w*4
204312|NCT02005783|Drug|Docetaxel|Docetaxel:75mg/m2, d1, q3w*4
204313|NCT02005796|Other|Dietary intervention|
204314|NCT02005809|Procedure|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
204315|NCT00119769|Drug|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
204316|NCT02005822|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
204317|NCT02005835|Other|Community based peer support|Community-based Support from Peer Mothers (Expert mothers):
Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment
204318|NCT02005835|Other|Facility-based Peer Support|Facility-based Peer Support to provide the following at the clinic
Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment
204319|NCT02005848|Biological|Alpha-1 Antitrypsin|
204320|NCT02005848|Other|Placebo|Placebo
204321|NCT02005861|Procedure|bone marrow cells transplantation on collagen scaffold|120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.
An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.
After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant.
204322|NCT02005887|Drug|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
204323|NCT02005887|Drug|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
203697|NCT02019225|Other|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
203698|NCT00121173|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|
203699|NCT02019238|Other|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
203700|NCT02019251|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
203701|NCT02019251|Device|MRI|
203702|NCT02021578|Behavioral|Written information|Reading materials about depression
203703|NCT00121303|Drug|cytarabine|
203704|NCT02021591|Behavioral|Early Mobile Diabetes Detective (MoDD)|Study participants will be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
204002|NCT02013856|Dietary Supplement|Flavanols|No epicatechin and ~ 200 mg procyanidins once daily for 28 days
204003|NCT02013856|Other|Flavanols|Placebo control once daily for 28 days
204004|NCT02013869|Device|Flow-I|Desflurane Dialed setting 18 %
204005|NCT00120614|Behavioral|Parental activities to support premature infant information|
204006|NCT02013869|Device|Asys|Desflurane dialed 18%
204007|NCT02013882|Procedure|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
204008|NCT02013895|Device|99mTc-GSA|
204009|NCT02013908|Procedure|Acupuncture plus standard ED management|
204010|NCT02013908|Procedure|Standard ED management alone|
204011|NCT02013921|Other|Physical activity|
204012|NCT02013934|Dietary Supplement|Probiotic|
204013|NCT02013934|Dietary Supplement|Placebo|
208409|NCT02095093|Device|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
208410|NCT02095093|Device|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
208411|NCT02095106|Device|Waterproof Cast|
208412|NCT02095106|Device|Traditional cast|
208413|NCT02095119|Drug|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
208414|NCT02095119|Drug|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is >/= 60. The administration form will be intravenously.
208415|NCT02095119|Drug|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation < 60). The administration form will be intravenously.
208416|NCT02095119|Procedure|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
208417|NCT02095132|Drug|Irinotecan Hydrochloride|Given PO
208418|NCT02095132|Other|Laboratory Biomarker Analysis|Correlative studies
203705|NCT02021591|Behavioral|Late Mobile Diabetes Detective (MoDD)|Study participants will be given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
203706|NCT02021604|Drug|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
208131|NCT02102139|Drug|DXM + Propofol|After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.
The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was "success (SBP during the entire hydrodissection period being ±20% from baseline)," the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was "fail(SBP > ±20% from baseline)," the target concentration was increased by 0.5 ng mL-1.
208132|NCT02102139|Drug|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
208133|NCT02102152|Drug|Tobramycin|
208134|NCT02102165|Procedure|metastatic lesion biopsy|a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
208135|NCT02102178|Other|Tapestry|A gauze screen, wool thread appropriate for tapestry and a large needle were used.
The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges.
208136|NCT02102178|Other|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
208137|NCT02102178|Other|Weaving a scarf on a nail frame|Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.
Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length.
208138|NCT02102178|Other|Domino game|Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became "blocked", i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand.
208139|NCT02102191|Device|e-cigarette|smoking cigarette without tobacco
208140|NCT02102191|Device|cigarette|smoking cigarette with tobacco
208141|NCT00129350|Procedure|Pulmonary rehabilitation programme|
208419|NCT00128570|Other|preventative dietary intervention|
207536|NCT02114138|Procedure|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
207537|NCT02114151|Drug|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
207538|NCT02114151|Drug|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
207846|NCT02107027|Device|nMARQ catheter|In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).
A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted.
207847|NCT02107027|Device|Navistar catheter|In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).
A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted.
207848|NCT02107053|Dietary Supplement|PJ|
207849|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
207850|NCT02109458|Device|Navigation guided bronchoscopy|
207851|NCT02109484|Biological|P2VP8 Subunit Vaccine 10mcg|10 mcg
207852|NCT00130195|Drug|vincristine|
207853|NCT02109484|Biological|P2VP8 Subunit Vaccine 30 mcg|30 mcg
207854|NCT02109484|Biological|P2VP8 Subunit Vaccine 60mcg|60 mcg
207855|NCT02109484|Biological|Placebo|
207856|NCT02109484|Biological|Cohort B2 P2VP8 D1|second highest tolerated dose from Cohort B1
207857|NCT02109484|Biological|Cohort B2 P2VP8 D2|Highest tolerated dose from Cohort B1
207858|NCT02109497|Drug|PBT2|PBT2 250 mg administered
207859|NCT02109510|Drug|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
207860|NCT02109510|Drug|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
207861|NCT02109510|Procedure|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
207228|NCT02082184|Device|Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.
207229|NCT00127283|Drug|eptacog alfa (activated)|
207230|NCT02082184|Device|Standard Blood Glucose Monitoring|Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.
207231|NCT02082197|Drug|ABT-SLV176|ABT-SLV176 administered daily
207539|NCT02114164|Device|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
207540|NCT02114164|Device|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
207541|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks in Arm 1 or 8 weeks in Arm 2.
207542|NCT02076893|Drug|Placebo|Simple syrup suspension
207543|NCT02076906|Device|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
207544|NCT02076919|Drug|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
207545|NCT02076919|Drug|LHA510 Vehicle|Inactive ingredients used for masking purposes
207546|NCT02076932|Behavioral|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
207547|NCT00002208|Drug|Zidovudine|
207548|NCT00126750|Behavioral|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
207549|NCT02076945|Procedure|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
207550|NCT02076958|Behavioral|Community Health Advisor education|
207551|NCT02076984|Procedure|Laparoscopic incisional or ventral hernia repair|
179560|NCT01934634|Drug|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
179561|NCT01934647|Drug|MK-8892|Single oral capsule with up to 14 mg of MK-8892
179562|NCT01934673|Other|No treatment given|Patients will fill out a questionnaire by interview.
179563|NCT01934686|Other|No treatment given|Patients will fill out a questionnaire by interview.
179564|NCT01934699|Device|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
179565|NCT01934699|Device|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
179566|NCT00113373|Other|laboratory biomarker analysis|Correlative studies
179567|NCT01934712|Drug|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
179568|NCT01934712|Drug|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
179569|NCT01934738|Drug|PF-06273340|Tablets, 100 mg TID, 14 days
179570|NCT01934738|Drug|Placebo|Tablets, TID, 14 days
179571|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
179572|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
179573|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
179574|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
179575|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
179576|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
179871|NCT01948089|Behavioral|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
178960|NCT01949857|Biological|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
179259|NCT01939639|Drug|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
179260|NCT01941966|Drug|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
179261|NCT00002110|Drug|Zidovudine|
179262|NCT00114101|Drug|Melphalan|Given IV
179263|NCT01941966|Drug|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
179264|NCT01941966|Radiation|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
179265|NCT01941979|Drug|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
179266|NCT01941992|Drug|SAMITAL®|
179267|NCT01941992|Drug|Placebo sachets|
179268|NCT01942018|Procedure|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
179269|NCT01942031|Behavioral|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
179270|NCT01942044|Device|Promus element, Xience prime, and Nobori|
179271|NCT01942070|Device|Bioresorbable vascular scaffold|
179272|NCT01942070|Device|Durable polymer everolimus-eluting metallic stent|
179273|NCT00114101|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
179274|NCT01942083|Drug|OPB-111077|
179275|NCT01942109|Drug|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
179276|NCT01942109|Drug|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
179277|NCT01942122|Drug|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
178653|NCT01906320|Behavioral|High-Intensity Resistance training|Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).
The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.
Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program.
178654|NCT01906333|Other|Exercise|
178655|NCT01906333|Other|Glucose|
178656|NCT01906333|Other|Fasted|
178657|NCT01906346|Drug|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
178658|NCT00110773|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
178659|NCT01908738|Drug|paracervical block with 1%lidocaine|To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.
Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes
178961|NCT00114699|Drug|CCR5mAb004|
178962|NCT01949857|Biological|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
178963|NCT01949857|Biological|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
178964|NCT01949857|Biological|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose.
178965|NCT01949870|Drug|Cisplatin|day1 and day8 at each cycle
178966|NCT01949870|Drug|Gemcitabine|day1 and day8 at each cycle
178967|NCT01949870|Drug|Selumetinib|25mg/day, 50mg/day and 75mg/day
178968|NCT01949883|Drug|CPI-0610|
178969|NCT01949896|Other|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
178970|NCT01949896|Other|Control group: continue feedings|Feedings will be continued in this group.
178971|NCT01949909|Biological|P27A vaccine candidate|
183113|NCT02554630|Other|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
183114|NCT02554630|Other|Blood Collection|Blood collection will be performed on all groups.
183404|NCT02548052|Drug|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
183405|NCT02548065|Other|Balneotherapy|Bath with mineral water named "Debole of Vetriolo" at 36°C, 15 minutes for 12 consecutive days in bathtubs
183406|NCT02548065|Other|Placebo|Bath with Thermal tap water
183407|NCT02548078|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
183408|NCT00184951|Drug|Rosuvastatin|
183409|NCT02548078|Biological|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
183410|NCT02548091|Other|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|The same amount of blood sample is collected from both arms of study at the same time of the procedure.
In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line.
183411|NCT02548091|Procedure|Non invasive ventilation|
183412|NCT02548091|Procedure|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
183413|NCT02548091|Procedure|Computed tomography (CT)|
183414|NCT02548104|Other|ACB|Before surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): Saline 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: Saline 15 ml
183415|NCT02548104|Other|ACB + AFB|Before the surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): 0.25% Bupivacaine with 1:200,000 epinephrine 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: Saline 15 ml
183416|NCT02548104|Other|ACB + iPACK|Before the surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): Saline 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
183417|NCT02550054|Drug|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
182511|NCT02563561|Drug|Apaziquone|The first dose of either 4 mg/40 mL apaziquone or placebo will be administered by intravesical administration into the bladder at 60±30 minutes post TURBT (randomization date, Day 1) via an indwelling 100% Silicone Foley catheter. The second dose of either 4 mg/40 mL apaziquone or placebo will administered by intravesical administration via an indwelling catheter on Day 15 (±5 days).
182512|NCT02563561|Other|Placebo|Matching placebo containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol is supplied in identical appearing vials.
182513|NCT02563574|Behavioral|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
182514|NCT02563574|Other|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
182515|NCT02563574|Other|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
182516|NCT02563574|Other|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status and other biomarkers.
182517|NCT02565550|Dietary Supplement|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
182808|NCT02559258|Drug|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
182809|NCT02559258|Drug|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
182810|NCT00186212|Behavioral|standard educational materials on breast cancer|
182811|NCT02559258|Drug|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
182812|NCT02559258|Drug|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
182813|NCT02559284|Other|A postoperative care after ethmoid sinus surgery|A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.
Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.
The nasal washing procedure will be as follow:
Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting
Gentle blowing of the nose
Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing).
182814|NCT02559297|Drug|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
182815|NCT02559297|Drug|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
181911|NCT02574260|Biological|Talimogene Laherparepvec|Administered by intratumoral injection.
181912|NCT02574273|Behavioral|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
181913|NCT00188084|Procedure|S-Phase%|
181914|NCT02574273|Other|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
181915|NCT02574286|Drug|Velaglucerase alfa|VPRIV®
181916|NCT02574299|Other|E-learning|Management of auditory processing disorders with serious game (E-learning)
181917|NCT02574299|Device|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
181918|NCT02574312|Device|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
181919|NCT02574312|Device|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
181920|NCT02574325|Drug|Placebo|Control
181921|NCT02574325|Drug|ARI-3037MO|Treatment
181922|NCT02574338|Device|Foley's Catheter|intracervical extraamniotic Foley's catheter
181923|NCT02574338|Drug|prostaglandin E1 analogue|intravaginal misoprostol
181924|NCT00188084|Procedure|CD45 expression|
181925|NCT02574351|Biological|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
182194|NCT02569970|Drug|fluoxetine 20 mg|Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.
At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
182195|NCT02569970|Drug|placebo 20 mg|Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.
At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
182196|NCT00187356|Procedure|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
206093|NCT02079142|Behavioral|High Intensity Strategy: Train-the-trainer|Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT.
Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.
Trainers will then return to Washington University to be trained in how to train their other staff members in IPT.
206094|NCT02079142|Behavioral|Low Intensity Strategy: Expert Consultation|We will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depresion.
206095|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
206096|NCT00127036|Drug|XELOX|XELOX: Oxaliplatin 130 mg/m^2 intravenously (IV); Capecitabine 825 mg/m^2 by mouth (po)
206097|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo R-LESS RP
206098|NCT02079155|Other|laboratory biomarker analysis|Correlative studies
206099|NCT02079155|Other|quality-of-life assessment|Ancillary studies
206100|NCT02079155|Other|questionnaire administration|Ancillary studies
206101|NCT02079168|Drug|RXI-109|
206102|NCT02079168|Drug|Placebo|
206103|NCT02079181|Radiation|fluorine F 18 d-FMAU|Given IV
206104|NCT02081573|Behavioral|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
206105|NCT02081586|Behavioral|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
206106|NCT02081586|Device|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
206107|NCT02081586|Other|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
206108|NCT02081599|Drug|Teneli (Teneligliptin) /Teneli|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
206109|NCT02081599|Drug|Placebo/Teneli (Teneligliptin)|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
205526|NCT02093975|Device|iPad air with 4G/3G SIM card|iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.
Video consultation
205527|NCT02093988|Drug|Topical TXA|
205528|NCT02093988|Drug|Intravenous TXA|
205529|NCT02096315|Drug|POL7080|Intravenous infusion
205530|NCT02096328|Drug|POL7080|Intravenous infusion
205531|NCT00128713|Procedure|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10^11 platelets per m^2 BSA
205532|NCT02096341|Drug|RRx-001|RRx-001 Dose level 1 (16 mg/m2) twice weekly
RRx-001 Dose level 2 (27 mg/m2) twice weekly
205533|NCT02096354|Drug|RRx-001|
205807|NCT02086344|Procedure|PBS|TLH plus PBS
205808|NCT02086344|Procedure|TLH _adnexal preservation|TLH without PBS
205809|NCT02086357|Procedure|SWUE|
205810|NCT02086370|Procedure|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
205811|NCT02086370|Procedure|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
205812|NCT02086396|Dietary Supplement|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
205813|NCT02086396|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
205814|NCT00127816|Procedure|Permanent prostate implant|
205815|NCT02086409|Dietary Supplement|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
205816|NCT02086409|Dietary Supplement|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
205817|NCT02086422|Drug|ivabradine|
205818|NCT02086422|Drug|Placebo|
205819|NCT02086422|Other|Exercise|
205224|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with "400" on one side with score on the other side, and "SL" on each side of the score.
205225|NCT02103335|Drug|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
205226|NCT02103335|Drug|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
205227|NCT02103335|Drug|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
205228|NCT02103374|Drug|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
205229|NCT00129467|Drug|Selective Serotonin Uptake Inhibitor (SSRI)|Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.
A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion
205230|NCT02103374|Drug|Placebo|1 capsule lactose during 48 weeks
205231|NCT02103387|Behavioral|Cognitive Behavioral Training|Cognitive Behavioral Training [CBT] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
205232|NCT02103387|Behavioral|Relaxation Training|Relaxation Training [RT] (muscle relaxation, deep breathing, guided imagery, meditation)
205233|NCT02105922|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
205234|NCT02105922|Procedure|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
205534|NCT02096354|Drug|Regorafenib|
205535|NCT02096354|Drug|Irinotecan|To be dosed after RRx-001 or regorafenib
205536|NCT02096367|Other|Gait analysis|
205537|NCT02096367|Other|Kinematic gait analysis in lower limb|
205538|NCT02096367|Other|Analysis of static posture|
205539|NCT02096367|Other|Gait on treadmill|Treadmill during 2 minutes
205540|NCT02096367|Device|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
204928|NCT02112812|Drug|Eradication therapy for Helicobacter pylori|
204929|NCT02112825|Behavioral|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
204930|NCT02112838|Drug|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
204931|NCT02112838|Drug|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
204932|NCT02112838|Drug|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
204933|NCT02112851|Other|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
204934|NCT00130572|Drug|Pimecrolimus|
204935|NCT02112864|Drug|Dexamethasone|
204936|NCT02112864|Drug|Placebo (normal saline)|2.5 mL normal saline
204937|NCT02112877|Device|Veniti Vici™ Venous Stent System|
204938|NCT02112890|Other|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
204939|NCT02112903|Drug|Encapsulated vortioxetine IR tablet, 20 mg|
204940|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 5.5)|
204941|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 6.0)|
204942|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 7.0)|
204943|NCT02112916|Drug|Bortezomib|Given IV
204944|NCT02112916|Drug|Cyclophosphamide|Given IV
204945|NCT00130585|Behavioral|Controlled diet|
204946|NCT02112916|Drug|Cytarabine|Given IT, IV, or SC
204947|NCT02112916|Drug|Daunorubicin Hydrochloride|Given IV
204948|NCT02112916|Drug|Dexamethasone|Given PO or IV
204949|NCT02112916|Drug|Doxorubicin Hydrochloride|Given IV
204950|NCT02112916|Drug|Etoposide|Given IV
204324|NCT02005887|Drug|Letrozole|Letrozole 2.5 mg orally every day for 6 cycles
204325|NCT02005900|Drug|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
204326|NCT00119782|Behavioral|Diet|A dietary intervention that will promote lower calorie intake
204327|NCT02008370|Drug|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
204629|NCT02000440|Drug|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
204630|NCT02000453|Drug|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
204631|NCT02000466|Other|Data collection|Initial and follow-up data will be collected using questionnaires
204632|NCT02000479|Other|training|
204633|NCT02000492|Behavioral|Football|
204634|NCT02000492|Behavioral|Running|
204635|NCT02000492|Behavioral|Circuit training|
204636|NCT00119366|Drug|fludarabine phosphate|Given IV
204637|NCT02000505|Device|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
204638|NCT02000505|Device|Metronome|5 minutes chest-compression-only CPR, using a metronome
204639|NCT02000505|Device|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
204640|NCT02000518|Radiation|external beam radiotherapy|
204641|NCT02000531|Drug|Erlotinib|150 mg oral dose of erlotinib given once daily
204642|NCT02000531|Drug|Chemotherapy|Cisplatin (75 mg/m^2 intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
204643|NCT02000544|Device|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit that comprises which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
204644|NCT02000570|Procedure|Sitting position (neurosurgery)|
204014|NCT02013947|Other|2 weeks of exercise in low and moderate altitude|Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).
Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).
204015|NCT02013960|Drug|Cytotec|Cytotec medication compared with cytotec and laminaria
204016|NCT00120627|Behavioral|Mantram Repetition Program (MRP) plus Usual Care|The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A "mantram" is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting.
204017|NCT02013973|Other|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
204018|NCT02013986|Drug|etomidate|0.3mg/kg IV only once during induction of general anesthesia
204019|NCT02013986|Drug|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
204020|NCT02013986|Drug|propofol|2mg/kg IV only once during induction of general anesthesia
204021|NCT02016573|Device|Renal Denervation|Renal Denervation Catheter
204022|NCT02016586|Dietary Supplement|Maternal Nutritional Supplement|S348S0
204328|NCT02008383|Biological|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
204329|NCT02008383|Drug|Cabozantinib|There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.
Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily.
204330|NCT02008396|Drug|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapeutic activities during experimental sessions .
204331|NCT00120003|Drug|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
204332|NCT02008396|Drug|MDMA|Participants receive a capsule of 75 or 100 mg during the first of two experimental sessions and a capsule of 100 or 125 mg MDMA on the second of two experimental sessions. They will receive MDMA along with selected therapeutic activities during each experimental session.
203707|NCT02021617|Device|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver—a small battery-powered drill—and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
203708|NCT02021630|Other|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
203709|NCT02021643|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
203710|NCT02021643|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
203711|NCT02021643|Drug|PegIFNα|Pegylated interferon alfa-2a (PegIFNα) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
203712|NCT02021656|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
203713|NCT02021669|Drug|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
203714|NCT00002176|Drug|Stavudine|
203715|NCT00121303|Drug|daunorubicin hydrochloride|
203716|NCT02021669|Drug|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
203717|NCT02021760|Procedure|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
203718|NCT02021773|Biological|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
203719|NCT02024113|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
203720|NCT02024126|Other|Exercise therapy|Exercise therapy
203721|NCT02024139|Other|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
204023|NCT02016599|Other|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, temperature probes, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate levels.
204024|NCT02016612|Device|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
204025|NCT02016625|Drug|Faldaprevir|
208420|NCT02095132|Other|Pharmacological Study|Correlative studies
208421|NCT02095132|Drug|WEE1 Inhibitor AZD1775|Given PO
208422|NCT02097511|Drug|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
208423|NCT00128843|Drug|Exemestane|
208424|NCT02097511|Drug|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
208425|NCT02097511|Drug|Metoprolol|Metoprolol Tartrate 100 mg once a day
208426|NCT02097524|Drug|Sarilumab|
208427|NCT02097524|Drug|Tocilizumab|
208428|NCT02097537|Drug|Methacholine Chloride (SK-1211)|
208429|NCT02097550|Other|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
208430|NCT02097563|Behavioral|High Intensity Training|This is a training method involving a live workshop followed by high intensity technical consultation.
208431|NCT02097563|Behavioral|Low Intensity Training|Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
208432|NCT02097576|Other|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
208433|NCT02097576|Other|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
208434|NCT00128843|Drug|Anastrozole|
208435|NCT02097589|Drug|Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
208436|NCT02097589|Drug|Pneumovax 23|Pneumovax 23 injected once, intramuscularly at Day 7.
208437|NCT02097589|Other|Placebo (lactose pill)|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
208438|NCT02097615|Procedure|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
207862|NCT02109523|Behavioral|Motivational Interviewing (MI|In order to facilitate behavior change by the patients a Motivational Interviewing (MI) is designed to resolve patient ambivalence about change. The interview is conducted individually face to face by an experienced trainer. The MI was used a semi-structured format and lasting for 40 minutes for a single session (the first session). The counselors ask participants to express what they want to discuss about. Moreover, counselors ask some questions which were important in the patient's life (e.g. what they will do after discharge, what they think about their life). These questions help the counselors to make a confident relationship between the counselors and patients. Furthermore, the counselors try to elicit adolescent's concerns on their current situations by asking some questions (What concerns you about your current situation? What are some reasons you might see for making a change? How do you feel about your treatment?)
207863|NCT00130195|Drug|prednisolone|
208142|NCT02102204|Drug|AMG 416|Subjects will be administered IV AMG 416 at the end of their regular dialysis sessions on a thrice weekly (TIW) schedule. Dose titration is at the discretion of the Investigator and will be based upon the values of the site's contracted laboratory provider iPTH and Ca (cCa, total Ca, or ionized Ca), with the frequency of these laboratory draws at the discretion of each individual Investigator, per standard of care for subjects receiving treatment with a calcimimetic agent. At a minimum however, calcium and albumin must be measured monthly. Subjects entering from the open-label parent studies 20120231 or 20120334 will receive a starting dose of AMG 416 identical to the last dose received in the parent study. Subjects entering from the randomized, double-blind parent Study 20120360, will receive a starting dose of 2.5 mg AMG 416. All subjects will continue to receive AMG 416 until approximately 2.5 years after the first subject enrolls.
208143|NCT00129610|Behavioral|Cognitive Behavior Therapy|
208144|NCT02104609|Drug|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
208145|NCT02104622|Device|ReWalk Rehabilitation 2.0|
208146|NCT02104635|Behavioral|Delivery of a Post-Partum Package|
208147|NCT02104648|Other|Placebo RO4602522|Daily oral doses
208148|NCT02104648|Drug|RO4602522|Daily oral doses
208149|NCT02104648|Drug|RO4602522|Single, oral dose
208150|NCT02104648|Drug|moxifloxacin|400 mg oral dose given on Day 1 or 11
208151|NCT02104648|Other|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
208152|NCT02104661|Drug|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
208153|NCT02104661|Drug|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
208154|NCT00129623|Drug|Placebo|po monthly for 1 year
208155|NCT02104674|Drug|lebrikizumab|Given SC on Days 1, 29, and 57
208156|NCT02104674|Drug|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
207552|NCT02076997|Drug|Methotrexate|Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.
207553|NCT02077010|Drug|Milrinone|Milrinone is both the active comparison and experimental arm. The intervention arm will receive milrinone via inhalation of a nebulizer solution. The active comparison arm will receive milrinone via a continuous intravenous infusion.
207554|NCT02077036|Device|Kinetic Oscillation Stimulation Device|
207555|NCT02077036|Device|Kinetic Oscillation Stimulation Device in placebo mode|
207556|NCT02077049|Device|serious games|Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.
The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.
This serious games program is instructed individually by experienced physiotherapists.
207557|NCT02077049|Other|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
207864|NCT02109523|Behavioral|volitional intervention|The second session will be based on action and coping planning strategies, according to the theoretical principles of implementation intention (Sniehotta et al. 2006), a self-regulatory strategy that matches concrete responses to possible future situations. Our intervention consists of two face-to-face meetings (at baseline, during the person's visit to the clinic). With the help of one of the authors, at the baseline interview, participants in the intervention group elaborate up to three action plans about when, where and how they intended to take their medication prescribed for cardioprotection and symptom relief of CAD. Similarly, participants identify up to three barriers to take the medication. Then, one or more strategies to overcome each barrier were identified, to accomplish the coping planning strategy. The number of barriers is limited to three because many of the participants are older adults and would have difficulty in memorizing too many strategies (Scholz et al. 2005).
207865|NCT02109523|Behavioral|Routine discharge counseling|
207866|NCT02109536|Device|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
207867|NCT02109562|Drug|RBP-7000|Subcutaneous injection on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29. RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner.
207868|NCT02109562|Drug|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
207869|NCT02111889|Other|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|[11C] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and [15O]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
207870|NCT02111915|Behavioral|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
179872|NCT01948115|Drug|equimolar mixture of oxygen and nitrous oxide or medical air|We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group "placebo" (medical air), 75 patients in group "treatment" (equimolar mixture of oxygen and nitrous oxide).
Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention.
179873|NCT01950728|Device|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 50 Hz.
179874|NCT01950728|Device|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 50 Hz.
179875|NCT01950741|Drug|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
179876|NCT01950754|Behavioral|standing with both feet|
179877|NCT01950754|Behavioral|descent of the platform|
179878|NCT00114777|Drug|Belatacept MI|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
179879|NCT01950754|Behavioral|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
179880|NCT01950780|Drug|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
179881|NCT01950793|Drug|triamcinolone acetonide|used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
One injection only Steroid
179882|NCT01950793|Drug|Hyaluronic Acid|used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
One injection only
179883|NCT01950806|Other|Pecan-containing diet|
179884|NCT01950806|Other|Nut-free diet|
179885|NCT01950819|Biological|Induction therapy|All subjects will receive induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
179886|NCT01950819|Drug|Corticosteroids|All subjects are to receive maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day must be maintained.
179887|NCT01950819|Drug|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
180183|NCT01942967|Other|Echocardiography|Measurement of:
Left ventricular output (LVO).
Right ventricular output (RVO).
Assessment of the Mesenteric Artery Flow.
179278|NCT01942122|Drug|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
179279|NCT01942122|Drug|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
179280|NCT01942135|Drug|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
179577|NCT00113386|Biological|filgrastim|Consolidation chemotherapy
179578|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
179579|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
179580|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
179581|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
179582|NCT01937221|Other|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
179583|NCT01937234|Drug|Metoclopramide|Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.
Maximum of 3 doses.
179584|NCT01937234|Drug|Placebo|Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.
Maximum of 3 doses.
179585|NCT01937247|Procedure|Putting the patient to sleep in the induction room|
179586|NCT01937247|Procedure|Implementing parallel processing to enhance the turnover process|
179587|NCT01937247|Procedure|Waking up the patient in the recovery room using Bridion|
179588|NCT01937247|Procedure|STANDARD PROCESS|standard process
179589|NCT00113620|Drug|Neurodex|
179590|NCT01937260|Drug|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
179591|NCT01937299|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
179592|NCT01937299|Drug|Vehicle|Inactive ingredients used as a placebo comparator
179593|NCT01937299|Drug|Travoprost 0.004% ophthalmic solution|
179594|NCT01937312|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
178972|NCT00114725|Procedure|Laser-assisted intracytoplasmic sperm injection|
178973|NCT01949922|Procedure|Injection of autologous muscle fibers into the anal sphincter.|
178974|NCT01949922|Procedure|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
178975|NCT01949922|Behavioral|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
178976|NCT01949922|Drug|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
178977|NCT01949935|Drug|Mupirocin|
178978|NCT01949948|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
178979|NCT01949948|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
178980|NCT01949961|Other|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for ~30 minutes, using a Bracco infusion pump.
178981|NCT01949961|Other|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
178982|NCT01949974|Drug|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
179281|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
179282|NCT01942135|Drug|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
179283|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
179284|NCT00114101|Other|Placebo|Given PO
179285|NCT01942148|Drug|Aripiprazole|
179286|NCT01942161|Drug|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
179287|NCT01944774|Drug|Moxifloxacin 400 mg|IV Infusion, once daily for 7~14 days
179288|NCT01944787|Other|Routine|IV Hydration at 125 cc hour
179289|NCT01944787|Other|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
183418|NCT02550054|Drug|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
183419|NCT00002502|Drug|busulfan|
183420|NCT00185120|Drug|Amlodipine|
183421|NCT02550067|Drug|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
178660|NCT01908738|Drug|10%lidocaine spray|
178661|NCT01908751|Procedure|Sliding Hip Screw|
178662|NCT01908751|Procedure|Cancellous Screws|
178663|NCT01908751|Dietary Supplement|Vitamin D|
178664|NCT01908751|Dietary Supplement|Vitamin D Placebo|
178665|NCT01908764|Drug|AL-60371 otic suspension|
178666|NCT01908777|Other|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
178667|NCT01908790|Device|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
178668|NCT01908790|Device|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
178669|NCT00111007|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
178670|NCT01908803|Drug|AL-60371/AL-817 otic suspension|
178671|NCT01908803|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
178672|NCT01908816|Drug|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
178673|NCT01908829|Drug|Mirabegron|Oral tablet
178674|NCT01908829|Drug|Solifenacin succinate low dose|Oral tablet
178675|NCT01908829|Drug|Solifenacin succinate high dose|Oral tablet
178676|NCT01908842|Drug|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
182816|NCT02559310|Drug|lefamulin|antibacterial agent
182817|NCT02559310|Drug|Moxifloxacin|antibacterial agent
182818|NCT02559310|Drug|Linezolid|antibacterial agent
182819|NCT02559323|Other|Survey|
182820|NCT02559336|Other|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
182821|NCT00186225|Procedure|ablative allogeneic hematopoietic cell transplantation|
182822|NCT02561390|Procedure|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
182823|NCT02561390|Other|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
182824|NCT02561403|Behavioral|EVO multitask video game|Participants will play a multitasking game for 4 weeks
182825|NCT02561403|Behavioral|EVO words video game|Participants will play a word puzzle game for 4 weeks
183115|NCT02554643|Other|Diet|Nutrition intervention, once a week during 12 weeks
183116|NCT02554643|Other|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
183117|NCT02554643|Other|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
183118|NCT00185614|Drug|cyclophosphamide|4 gm/m2, IV
183119|NCT02554669|Behavioral|postprandial and postabsorptive physical activity on treadmill|
183120|NCT02554682|Behavioral|Sexual Health|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, STD prevention, and safe sex practices for teenager.
183121|NCT02554682|Behavioral|Alcohol Prevention|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
183122|NCT02554682|Behavioral|Teen Driving|Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
183123|NCT02554695|Drug|placebo|subcutaneous saline injection
183124|NCT02554695|Drug|denosumab|single subcutaneous injection of denosumab 60 mg
182197|NCT02569983|Other|Observational cohort|No intervention - observational study
182198|NCT02569996|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
182199|NCT02570009|Behavioral|TEAMS (Talking about Eating, Activity, Mutual Support)|
182200|NCT02570009|Behavioral|Need Support Training|
182201|NCT02570022|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
182202|NCT02570022|Procedure|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
182203|NCT02570022|Drug|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
182204|NCT02570035|Drug|Mirabegron|oral
182205|NCT02570048|Device|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
182206|NCT02570061|Behavioral|telephone|information given at the primary contact by phone, or at a scheduled later time
182207|NCT00187369|Procedure|Method of Delivery|CS or VB
182208|NCT02570061|Behavioral|consultation face-to-face|information given at a scheduled consultation at the hospital
182209|NCT02570074|Drug|Fosfomycin|Broad spectrum antibiotic
182210|NCT02570087|Procedure|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
182211|NCT02570100|Procedure|Biological collection|Collection of blood samples and tumor specimens :
Biological collection before treatment :
1 tumor specimen (under echographic control)
4 blood collections
Biological collection during treatment :
1 tumor specimen after 3 cycles
4 blood collections after 3 and 6 cycles
182212|NCT02570113|Device|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
182518|NCT00186966|Radiation|Total body irradiation|See Detailed Description section for details of treatment interventions.
182519|NCT02565563|Other|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
182520|NCT02565563|Device|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
206110|NCT02081599|Drug|Insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
206111|NCT00127244|Procedure|Periodontal Treatment|
206420|NCT02113436|Drug|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
206421|NCT02113436|Drug|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
206422|NCT02113449|Drug|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
206423|NCT02113540|Drug|Atorvastatin|
206424|NCT02113553|Drug|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
206425|NCT00130650|Device|Pain Ease|
206426|NCT02113566|Drug|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
206427|NCT02113579|Device|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
206428|NCT02113579|Other|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
206429|NCT02113592|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
206430|NCT02113605|Other|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
206431|NCT02113618|Behavioral|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
206432|NCT02113618|Behavioral|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
206433|NCT02113631|Drug|Telaprevir|
206434|NCT02113631|Drug|Boceprevir|
205820|NCT02088658|Behavioral|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
205821|NCT02088671|Drug|Propofol induction followed by randomized doses of desflurane|Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
206112|NCT02081612|Behavioral|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
206113|NCT02081612|Procedure|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
206114|NCT02081625|Drug|NS-065/NCNP-01|NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:
Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks
206115|NCT02081638|Drug|Aspirin 81 mg daily|81 mg tablet, daily
206116|NCT02081638|Drug|Atorvastatin 40 mg daily|40 mg tablet, daily. In subjects on certain antiretroviral medications, ATV dosing will be adjusted in accordance with DHHS guidelines .
206117|NCT02081651|Dietary Supplement|Parmigiano Reggiano cheese|
206118|NCT02081664|Behavioral|lifestyle intervention|
206119|NCT02081690|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
206120|NCT02081703|Drug|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
206121|NCT02081703|Drug|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
206122|NCT00000124|Procedure|Eye Removal|
206123|NCT00000317|Drug|Risperidone|Risperidone (4mg/day)
206124|NCT00002211|Drug|Didanosine|
206125|NCT00127257|Behavioral|Biofeedback|
205541|NCT02096380|Drug|One cycle TPF induction chemotherapy for NPC|One cycle TPF induction chemotherapy for NPC
Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.
205542|NCT00128713|Procedure|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10^11 platelets per m^2 BSA
205543|NCT02096380|Drug|Three cycles TPF induction chemotherapy for NPC|Three cycles TPF induction chemotherapy for NPC
Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.
205544|NCT02096393|Device|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
205545|NCT02096393|Device|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
205546|NCT02096406|Drug|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
205547|NCT02096406|Drug|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
205548|NCT02096419|Drug|Clopidogrel dose adjustment|Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).
They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.
On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)
205549|NCT02096432|Behavioral|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
205550|NCT02096432|Behavioral|Usual Community Care|Community standard care as usual
205822|NCT02088671|Device|Recording of EEG using NeuroSENSE|The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.
The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.
Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest.
205235|NCT02105948|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
205236|NCT02105948|Drug|Placebo|Sterile 0.9% sodium chloride solution
205237|NCT02105961|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
205238|NCT02105961|Drug|Placebo|Sterile 0.9percent sodium chloride solution
205239|NCT02105974|Drug|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
205240|NCT02105974|Drug|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
205241|NCT02105987|Drug|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
205242|NCT02105987|Drug|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
205243|NCT00002225|Drug|Didanosine|
205244|NCT00129792|Drug|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
205245|NCT02106000|Device|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
205246|NCT02106026|Other|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
205247|NCT02106039|Procedure|intensive monitoring|
205248|NCT02106052|Other|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
205249|NCT02106052|Other|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
204645|NCT02000583|Other|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
204646|NCT02000583|Other|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
204647|NCT00119366|Radiation|total-body irradiation|Undergo TBI
204648|NCT02000596|Drug|Trastuzumab plus Pertuzumab|
204649|NCT02000596|Drug|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
204650|NCT02000596|Drug|Chemotherapy with Eribulin|
204951|NCT02115126|Biological|LMP2A-loaded conventional DC vaccine|Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be > 1.5.
Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be > 1.5.
Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination.
204952|NCT02115126|Biological|DUK-CPG-001|On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.
DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.
Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination.
204953|NCT02115139|Drug|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
204954|NCT02115152|Drug|fluorouracil|
204955|NCT02115152|Drug|capecitabine|
204956|NCT02115152|Drug|cyclophosphamide|
204957|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
204958|NCT02115152|Drug|Epirubicin|
204959|NCT02115165|Drug|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
204960|NCT02115178|Other|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
204961|NCT02115191|Device|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
204333|NCT02008409|Device|EndoLift Liver Retractor|During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is "clipped" onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends.
204334|NCT02008422|Drug|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
204335|NCT02008422|Drug|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
204336|NCT02008422|Drug|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
204337|NCT02008435|Behavioral|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
204338|NCT02008435|Behavioral|Standard GLB|This arm is the standard Group Lifestyle Balance program
204339|NCT02008448|Procedure|Pulmonary vein isolation|
204340|NCT02008448|Procedure|Linear Lesion Ablation|
204341|NCT02008448|Drug|BT injection|
204342|NCT00120003|Drug|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
204343|NCT02008461|Procedure|radiofrequency ablation|
204344|NCT02008461|Drug|botulinum toxin injection|
204345|NCT02008474|Behavioral|Online weight loss + incentives for behavior 3 months|Participants will receive monetary incentives for submitting their behavior change information into a study website
204346|NCT02008474|Behavioral|Online weight loss + incentives for weight loss at month 3|Participants will receive an incentive for meeting their weight loss goal at month 3.
204347|NCT02008474|Behavioral|Online weight loss + Incentives for behavior 12 months|Participants will receive incentives for submitting behavior change information over the course of 12 months.
204651|NCT02003222|Drug|Cytarabine|Given IT, IV, or SC
204652|NCT02003222|Drug|Daunorubicin Hydrochloride|Given IV
204653|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
204654|NCT02003222|Drug|Dexamethasone|Given PO
204655|NCT02003222|Drug|Etoposide|Given IV
204656|NCT02003222|Other|Laboratory Biomarker Analysis|Correlative studies
204026|NCT00120913|Drug|Birth control pills|
204027|NCT02016625|Drug|Faldaprevir|
204028|NCT02016625|Drug|Cyclosporine|
204029|NCT02016625|Drug|Tacrolimus|
204030|NCT02016638|Other|Polysomnography and ambulatory blood pressure recording|
204031|NCT02016651|Behavioral|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
204032|NCT02016664|Drug|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
204033|NCT02016703|Other|Erythritol drink|
204034|NCT02016703|Other|Placebo drink|
204035|NCT02016716|Drug|Romosozumab|Romosozumab formulation A
204036|NCT02016716|Drug|Placebo|Placebo to Romosozumab formulation A
204037|NCT00120926|Drug|Parenteral Nutrition|
204038|NCT02016716|Drug|Romosozumab|Romosozumab formulation B
204039|NCT02016716|Drug|Placebo|Placebo to Romosozumab formulation B
204040|NCT02016729|Drug|AMG 232|Given an an oral tablet in escalating doses.
204041|NCT02016729|Drug|Trametinib|Trametinib is an oral tablet given in a fixed dose.
204042|NCT02016742|Drug|RDC5|
204043|NCT02016755|Genetic|HGF Plasmid|Intramuscular injection in the affected limb.
204044|NCT02016768|Procedure|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
204348|NCT02008474|Behavioral|Online weight loss + Incentives for weight loss 12 months|Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
204349|NCT02008487|Other|Wound powder application|
208439|NCT02097615|Other|deionized water|application every 24 hours six weeks
203722|NCT02024139|Other|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
203723|NCT02024152|Drug|JDP-205 IV high dose|
203724|NCT02024152|Drug|JDP-205 IV low dose|
203725|NCT02024152|Drug|JDP-205 IM|
203726|NCT02024152|Drug|Control: Zyrtec|
203727|NCT02024178|Procedure|Ultrasound Imaging|
203728|NCT02024191|Dietary Supplement|Glutamine|
203729|NCT00002177|Drug|Nelfinavir mesylate|
203730|NCT00121589|Drug|Lutein|
203731|NCT02024204|Drug|Fluticasone propionate 230mcg/salmeterol 21mcg|Subjects will be further classified at V1 as follows based on ACT:
V1 Controlled
V1 Uncontrolled
Patients will treated in the following manner based on assessment at V1
Patients who have uncontrolled LRS (ACT < 20) at time of this visit will be provided with study Advair for a total of 3 months.
Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
203732|NCT02024204|Behavioral|Medication Adherence Counseling|Patients placed on Advair HFA will be instructed in how to use the inhaler and will maintain daily diaries. Inhaler technique will be reviewed in subsequent visits. Notation of the counter denoting actuation of the diskus will be made to assess adherence
203733|NCT02024217|Radiation|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
203734|NCT02024230|Drug|Warfarin or Rivaroxaban|No limitations of previous medication (Warfarin or new oral anticoagulant drugs or no anticoagulant drug) and type of stent (bare metal stent or drug eluting stent) in both arms
203735|NCT02024243|Procedure|Punch Tissue Biopsy|Subjects will have two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) collected on days 0, 14, and 28. Biopsies will not be collected if the wound has closed by day 14 or 28.
203736|NCT02024256|Other|Cold pads soaked in Magnesium sulfate solution|
203737|NCT02024256|Other|Cold pads soaked in water|
203738|NCT02024269|Biological|Adipose Derived Stem Cells|
203739|NCT02024282|Device|Use of C-reactive protein (CRP) point of care test|
208157|NCT02104674|Other|placebo|SC injection given on Days 1, 29, and 57
208158|NCT02104687|Procedure|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
208159|NCT02104687|Procedure|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
208160|NCT02104700|Drug|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
208440|NCT02097628|Procedure|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
208441|NCT02097628|Procedure|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
208442|NCT02097641|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.
208443|NCT02097641|Biological|Plasma-Lyte A|Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.
208444|NCT02097680|Drug|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
208445|NCT00128856|Drug|gemcitabine|
208446|NCT00129129|Biological|Pediarix|Primary phase: 3 IM doses
208447|NCT02099708|Drug|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
208448|NCT02099721|Device|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
208449|NCT02099734|Behavioral|Questionnaires|
208450|NCT02099734|Other|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
208451|NCT02099747|Drug|hATG|
208452|NCT02099747|Drug|CsA|
208453|NCT02099747|Drug|Eltrombopag|
208454|NCT02099760|Device|STD testing (GC/Ct/trich)|
208455|NCT02099786|Other|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
207871|NCT02111915|Other|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
207872|NCT02111928|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
207873|NCT02111941|Other|Laboratory Biomarker Analysis|Correlative studies
207874|NCT02111941|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
207875|NCT02111954|Other|F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
207876|NCT02111967|Other|Questionnaire administration|
207877|NCT00000319|Drug|Buprenorphine|
207878|NCT00002230|Drug|Efavirenz|
207879|NCT00130429|Drug|PYM50028|
207880|NCT02111967|Other|Laboratory biomarker analysis|
208161|NCT02104713|Biological|Allogeneic (MSC's) Application to the Burn Wounds|Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose
Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.
Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.
Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.
Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.
Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.
208162|NCT02104726|Other|Flouroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with flouroscopy will deliver the steroid more accurately and see better outcomes.
208163|NCT02104726|Other|Blind Steroid Injection|Want to compare it to flouroscopy guided, with assumption that it will be less effective in reducing pain
208164|NCT02104739|Drug|Exenatide|Single subcutaneous injection (10 mcg)
208165|NCT00129623|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
208166|NCT02104739|Drug|Saxagliptin|Single dose orally (5 mg)
208167|NCT02104739|Drug|Pioglitazone|Single dose orally (45 mg)
208168|NCT02104739|Other|Placebo|Placebo tablets and Placebo (normal saline) injections
208169|NCT02107053|Drug|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
180184|NCT00114140|Procedure|adjuvant therapy|
180185|NCT01942967|Other|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
180186|NCT01942980|Radiation|Radiation therapy Brain metastasis in breast cancer|Radiation
180187|NCT01942993|Drug|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
180188|NCT01943006|Drug|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
180189|NCT01943006|Drug|Placebo cream without active substance|
180190|NCT01945814|Drug|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
180191|NCT00114296|Dietary Supplement|omega-3 fatty acid|
180192|NCT01945827|Device|DeltaMaxx Microcoil System|
180193|NCT01945840|Procedure|Roux en Y Gastric Bypass Surgery|
180194|NCT01945840|Other|Gut hormone infusion (high dose)|
180195|NCT01945840|Other|Gut hormone infusion (low dose)|
180196|NCT01945840|Other|Placebo infusion|
180197|NCT01945840|Other|Very low calorie diet|
180198|NCT01945853|Device|7 Tesla MRI|
180199|NCT01945866|Drug|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
180200|NCT01945866|Drug|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
180201|NCT01945866|Procedure|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
179595|NCT01937312|Drug|Vehicle|Inactive ingredients used as a placebo comparator
179596|NCT01937312|Drug|Prostaglandin analogue|
179597|NCT01937325|Drug|ivacaftor|active arm
179598|NCT01937325|Drug|placebo|
179599|NCT01937338|Drug|AZD7624|nebuliser solution; 20 mg/mL for inhalation
179600|NCT00113633|Behavioral|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
179601|NCT01937338|Drug|Placebo|nebuliser solution for inhalation
179888|NCT01950819|Drug|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
179889|NCT00114790|Radiation|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
179890|NCT01950832|Other|Investigating clinically normal patients with optic coherence tomography|
179891|NCT01950845|Device|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
179892|NCT01950845|Device|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
179893|NCT01950858|Biological|Weight reduction|
179894|NCT01932320|Drug|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
179895|NCT01932320|Drug|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
179896|NCT01932320|Drug|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
179897|NCT01932320|Drug|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
179898|NCT00113165|Drug|LAMICTAL extended-release|
179290|NCT01944800|Drug|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
179291|NCT01944800|Drug|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/> 75 years or < 60 kg
179292|NCT01944813|Behavioral|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
179293|NCT01944826|Other|Registry of patients with Tako-Tsubo cardiomyopathy|
179294|NCT01944839|Drug|E10030|
179295|NCT01944839|Drug|ranibizumab|
179296|NCT00114231|Radiation|radiation therapy|Undergo radiotherapy
179297|NCT01944839|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
179298|NCT01944852|Drug|Icodextrin|
179299|NCT01944865|Other|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
179300|NCT01944865|Other|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
179301|NCT01944904|Dietary Supplement|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
179302|NCT01944904|Dietary Supplement|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
179303|NCT01944930|Device|Laparoscopic narrow band imaging|
179304|NCT01944930|Device|Standard white-light laparoscopy|
179602|NCT01937351|Device|Pantheris System|
179603|NCT01937364|Drug|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
179604|NCT01937390|Drug|Tiotropium Bromide 2.5 µg|Respimat® inhaler and cartridge Solution for inhalation
179605|NCT01937390|Drug|Indacterol 300 µg|inhalation powder
179606|NCT01937390|Drug|Tiotropium Bromide 18 µg|HandiHaler® device Inhalation powder, hard capsule
179607|NCT01937390|Drug|Indacterol 150 µg|inhalation powder
178677|NCT01908842|Drug|BNX sublingual film|Buprenorphine/naloxone sublingual film
178678|NCT01908842|Drug|Buprenorphine|Buprenorphine sublingual tablets
178679|NCT01908855|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:
20 weekly sessions individual therapy (à 50) minutes
178680|NCT00111007|Drug|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
178681|NCT01908855|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms:
20 weekly sessions individual therapy (à 50) minutes
178682|NCT01908868|Other|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
178983|NCT00114738|Drug|Rituximab (R)|Rituximab is given with EPOCH and bortezomib every 3 weeks for 6 cycles.
178984|NCT01952236|Behavioral|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 2,260 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
178985|NCT01952236|Behavioral|Web Only|A Web-based best practices smoking intervention.
178986|NCT01952249|Drug|Demcizumab|administered intravenously
178987|NCT01952249|Drug|Taxol|administered intravenously
178988|NCT01952262|Other|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
178989|NCT01952275|Procedure|Collection of biological samples|
178990|NCT01952288|Drug|simvastatin|simvastatin 40 mg/day for 12 months
178991|NCT01952288|Drug|placebo|placebo once per day for 12 months
178992|NCT01952301|Device|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
178993|NCT01952301|Device|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
178994|NCT00115037|Drug|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
178995|NCT01952314|Drug|Naftopidil 75mg|naftopidil 75mg 1T qd hs
178996|NCT01952314|Drug|Placebo for Naftopidil|Placebo 1T qd hs
183125|NCT02554708|Device|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
183126|NCT02554721|Drug|Cilostazol|
183127|NCT02554721|Drug|Acetylsalicylic acid|
183128|NCT02554721|Drug|Clopidogrel|
183129|NCT00185614|Drug|Melphalan|200 mg/m2; iv
183130|NCT02554734|Drug|levodopa, carbidopa, ODM-104|
183131|NCT02554734|Drug|levodopa, carbidopa, entacapone|
183132|NCT02556918|Drug|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
183133|NCT02556918|Drug|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
183134|NCT00185848|Radiation|[18F]FHBG|< 7mCi and 2 ug, iv
183422|NCT02550067|Drug|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
183423|NCT02550067|Drug|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
183424|NCT02550080|Drug|Dapsone|For the HLA-B*1301 positive subjects, dapsone will not be administrated.
183425|NCT02550093|Drug|Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.
183426|NCT02550093|Drug|Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.
183427|NCT02550106|Drug|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
183428|NCT02550119|Drug|Aprepitant|Given PO
183429|NCT02550119|Drug|Dexamethasone|Given PO or IV
183430|NCT02550119|Drug|Dolasetron Mesylate|Given PO or IV
183431|NCT00185133|Drug|Olmesartan medoxomil|
183432|NCT02550119|Drug|Placebo|Given PO
182521|NCT02565576|Drug|Placebo|
182522|NCT02565576|Drug|CFZ533|
182523|NCT02565602|Other|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
182524|NCT02565602|Other|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
182525|NCT02565602|Dietary Supplement|Vitamin D|One tablet daily (400IU per tablet)
182526|NCT02565615|Other|No intervention|Because this is a non-interventional study, there is no intervention here.
182527|NCT02565628|Drug|PF-06669571|1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
182528|NCT02565628|Drug|Placebo|Placebo
182529|NCT00186979|Drug|Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.|See Detailed Description section for details of treatment interventions.
182530|NCT02565641|Drug|Capecitabine|Capecitabine will be administered orally at 830 mg/m^2 BID (equivalent to a total daily dose of 1660 mg/m^2) as intermittent treatment (given days 1 to 21 q4w).
182531|NCT02565641|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
182532|NCT02565667|Device|KOL|KOL staple was used for rectal anastomosis
182533|NCT02565667|Device|traditional staple|traditional staple was used for rectal anastomosis
182534|NCT02565680|Drug|placebo|Xyzall 5mg during 5 days + placebo 40mg during 4 days
182535|NCT02565680|Drug|prednisone|Xyzall 5mg during 5 days + prednisone 40mg during 4 days
182536|NCT02565693|Drug|Apixaban|
182537|NCT02565693|Drug|Aspirin|
182538|NCT02565693|Drug|Carbasalate calcium|
182539|NCT02565693|Drug|Clopidogrel|
182826|NCT02561416|Behavioral|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
206435|NCT02076477|Radiation|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors〉3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
206436|NCT02076477|Drug|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
206437|NCT02076477|Drug|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
206731|NCT02109107|Device|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
206732|NCT02109120|Procedure|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
206733|NCT02109133|Procedure|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
206734|NCT02109133|Procedure|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
206735|NCT02109133|Drug|Rocuronium|
206736|NCT02109133|Drug|Sugammadex|
206737|NCT02109133|Drug|Atracurium|
206738|NCT00130156|Drug|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
206739|NCT02109133|Drug|Neostigmine|
206740|NCT02109146|Drug|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization should be used in the experimental group
206741|NCT02109146|Other|No intervention No Transcatheter Arterial Chemoembolization|
206742|NCT02109159|Other|A short online video with emotional content|
206743|NCT02109159|Other|A short online video with less emotional content|
206744|NCT02109172|Drug|TD-4208|
206745|NCT02109172|Drug|Placebo|
206746|NCT02109185|Drug|Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.|
206747|NCT02109185|Drug|Nasonex® Nasal Spray, 50 μg/actuation|
206126|NCT02081703|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
206127|NCT02084316|Behavioral|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
206128|NCT02084316|Behavioral|Standard of Care|The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.
After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.
Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling.
206438|NCT02076477|Drug|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
206439|NCT02076490|Other|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
206440|NCT02076503|Procedure|PET-MR 18f-FACBC|
206441|NCT02076503|Procedure|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
206442|NCT02076516|Device|Drug-eluting stent: CORACTO®|
206443|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
206444|NCT02076529|Drug|Ramosetron 0.3mg|
206445|NCT02076529|Drug|Ramosetron 0.45mg|
206446|NCT02076529|Drug|Ramosetron 0.6mg|
206447|NCT02076542|Behavioral|Education - Diabetes and Sports|Based on the treatment and education programme PRIMAS a problem-specific education module regarding "Diabetes and Sports" was created. The module covers specific and detailed aspects of the topic "sports" such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible.
206448|NCT02076555|Behavioral|Education - Diabetes and Social Issues|Based on the treatment and education programme PRIMAS a problem-specific education module regarding "Diabetes and Social Issues" was created. The module covers specific and detailed aspects of the topic "social issues" such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible.
205823|NCT02088671|Other|Data collection|Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.
The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).
The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).
The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information.
205824|NCT02088671|Other|Drug: Emergence by stepping down the desflurane ET|Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
205825|NCT02088684|Drug|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
205826|NCT02088684|Drug|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
205827|NCT02088684|Drug|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
205828|NCT02088684|Drug|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
205829|NCT00127998|Drug|chloroquine|
205830|NCT02088697|Drug|Placebo|
205831|NCT02088697|Drug|ASC-01|
205832|NCT02091284|Device|transcranial Direct Current Stimulation|Direct currents will be transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode will be placed over F3 according to the 10-20 international system while the anode will be placed over the contralateral F4 region. The currents will flow continuously for 20 minutes with an intensity of 2 milliamperes.
205833|NCT02091297|Drug|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
205834|NCT02091297|Drug|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
206129|NCT02084329|Device|Weighted Compression Vest|
206130|NCT02084342|Drug|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
206131|NCT02084342|Drug|normal saline|100ml, IV for 30min,before incision.
206132|NCT02084342|Drug|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
205551|NCT02098629|Drug|Esmolol|Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.
Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min
205552|NCT02098629|Drug|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
205553|NCT02098642|Other|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
205554|NCT02098642|Other|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
205555|NCT02098655|Other|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
205556|NCT00128999|Procedure|Intensity-Modulated Radiation Therapy|
205557|NCT02098668|Other|Fertility treatment|Fertility treatment
205558|NCT02098694|Other|Physiotherapy follow-up|Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.
Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise.
205559|NCT02098707|Other|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
205560|NCT02098720|Drug|Conbercept|
205561|NCT02098733|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
205562|NCT02098746|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
205563|NCT02098759|Device|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
205564|NCT02098772|Drug|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
205565|NCT02098772|Drug|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
204962|NCT02115191|Procedure|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
204963|NCT02115204|Drug|Epirubicin|
204964|NCT02115204|Drug|Cyclophosphamide|
204965|NCT02115204|Drug|Docetaxel|
204966|NCT02115204|Drug|Methotrexate|
204967|NCT02115204|Drug|5-fluorouracil|
204968|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
205250|NCT02106065|Behavioral|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
205251|NCT02108496|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
205252|NCT02108496|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
205253|NCT02108522|Biological|Multivirus Specific T cells|
205254|NCT02108535|Drug|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
205255|NCT02108535|Drug|Silver Sulphadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
205256|NCT00130078|Drug|1.0% C31G SAVVY vaginal gel|
205257|NCT02108548|Drug|ASP7657|oral
205258|NCT02108548|Drug|Placebo|oral
205259|NCT02108548|Drug|naproxen|oral
205260|NCT02108561|Other|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
205261|NCT02108574|Device|Placebo Filter|
204657|NCT02003222|Drug|Mercaptopurine|Given PO
204658|NCT02003222|Drug|Methotrexate|Given PO, IT or IV
204659|NCT02003222|Drug|Pegaspargase|Given IM or IV
204660|NCT02003222|Drug|Prednisone|Given PO
204661|NCT02003222|Drug|Vincristine Sulfate|Given IV
204662|NCT02003235|Device|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
204663|NCT02003248|Device|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
204664|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
204665|NCT02003261|Behavioral|Unified Protocol with Treatment As Usual|Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.
UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure.
204666|NCT02003261|Other|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
204667|NCT02003274|Other|Clamp-Mixed Meal|Standard clinical parameters will be assessed in all patients.
Metabolic tests:
A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).
B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump
This test will determine the time courses of:
1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
204969|NCT02115217|Device|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
204970|NCT02115217|Device|Sham kinesiotape|KT put with no effects
204971|NCT02115217|Other|Control|absence of tape
204972|NCT00126984|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
204350|NCT02010996|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
204351|NCT02011009|Other|HIV seropositive patients|During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
204352|NCT02011022|Drug|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
204353|NCT02011022|Drug|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
204354|NCT02011048|Procedure|Endoscopic components separation|Endoscopic components separation hernia repair
204355|NCT02011087|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
204356|NCT02011100|Dietary Supplement|Carnosine|
204357|NCT02011113|Drug|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
204358|NCT02011113|Drug|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
204359|NCT00000308|Drug|placebo|placebo
204360|NCT00002168|Drug|Lamivudine|
204361|NCT00120354|Procedure|Percutaneous Liver Biopsy|
204362|NCT02011126|Drug|imetelstat sodium|Given IV
204363|NCT02011126|Other|laboratory biomarker analysis|Optional correlative studies
204364|NCT02011139|Behavioral|Cognitive-behavioral group therapy|
204365|NCT02011165|Procedure|Positioning measuring device|A tennis ball in the night shirt will prevent supine position during sleep.
204366|NCT02011178|Procedure|Optimal medical treatment and surgery|
204367|NCT02011178|Procedure|Optimal medical treatment|
204368|NCT02011191|Dietary Supplement|Biotin Supplementation|10,000 micrograms biotin supplement daily for 8 weeks
204369|NCT02011191|Dietary Supplement|Sugar Pill|Identical sugar pill, identical bottle as the biotin supplementation group
204045|NCT02016781|Procedure|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant. The specific transplant treatment regimen will be at the discretion of the treating physician.
204046|NCT02016781|Procedure|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
204047|NCT02019264|Drug|APD356-Lorcaserin hydrochloride|APD356 10 mg twice daily
204048|NCT02019264|Drug|Placebo|Placebo twice daily
204049|NCT02019277|Drug|Herceptin (trastuzumab)|Subcutaneous administration of 600 mg/5 mL every 3 weeks.
204050|NCT02019277|Drug|Perjeta (pertuzumab)|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
204051|NCT02019277|Drug|Taxane chemotherapy|Administration of docetaxel, paclitaxel, or nab-paclitaxel. Dosing regimen to be determined by the investigator.
204052|NCT02019290|Drug|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
204053|NCT02019290|Drug|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
204054|NCT00121186|Drug|fludarabine phosphate|30 mg/m^2 on days -6 to -2 (2-6 days before transplant).
204055|NCT02019303|Procedure|FNA and Core biopsy|Both procedures will be performed on the same lymph node
204056|NCT02019316|Dietary Supplement|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
204057|NCT02019316|Dietary Supplement|Isoenergetic Control|Participants will ingest 500ml of Gatorade 3 times during an exercise session.
204058|NCT02019329|Other|Placebo|Oral daily administration from Days 1-12
204059|NCT02019329|Drug|RO5545965|Oral daily administration from Days 1-12
204060|NCT02019329|Drug|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
204061|NCT02019342|Other|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
204062|NCT02019342|Other|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
208456|NCT02099786|Other|Standard of care|Hearing testing done upon referral by audiology clinic
208457|NCT00129129|Biological|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
208458|NCT02099786|Other|Program evaluation|Hearing test done by the study research audiologist
208459|NCT02099799|Behavioral|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
208460|NCT02099799|Behavioral|Usual Care|Verbal instructions and written materials about exercise.
208461|NCT02099812|Other|no intervention|
203740|NCT02024282|Other|Brief intervention and parent leaflet|Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely "Are you concerned?", "What exactly concerns you?" and "Why does this concern you?". This intervention is easy to implement in daily practice and no additional training is required.
We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced.
203741|NCT02026817|Drug|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
203742|NCT02026817|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
203743|NCT02026817|Drug|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
203744|NCT02026856|Drug|sodium selenite pentahydrate|
203745|NCT02026856|Other|placebo - continuous saline NaCl 50 ml|
203746|NCT02026869|Drug|Metformin|Metformin is taken either orally or vaginally every 12 hours
203747|NCT00121771|Biological|FP9 CS|
203748|NCT02026882|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
203749|NCT02026895|Genetic|Genetic blood sample|
203750|NCT02026908|Device|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
203751|NCT02026921|Drug|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
208170|NCT02107066|Behavioral|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
208171|NCT02107079|Drug|Melatonin|swallowing 1 piece, collecting saliva afterwards
208172|NCT00129896|Drug|Herceptin|
208173|NCT02107092|Drug|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 2 months.
208174|NCT02107105|Behavioral|Questionnaires|Questionnaires completed regarding participant's quality of life and utilities. Questionnaires completed before surgery for rectal cancer and at multiple time points after the completion of surgery.
208175|NCT02107118|Biological|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
208176|NCT02107118|Other|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
208177|NCT02107131|Drug|Intravitreal ranibizumab 0.3mg|
208178|NCT02107144|Drug|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
208179|NCT02107157|Device|755nm Laser with Cap Array|
208462|NCT02099825|Drug|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
208463|NCT02099838|Drug|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
208464|NCT02099838|Drug|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
208465|NCT02099851|Device|Carotid body ablation (Cibiem)|
208466|NCT02099864|Drug|enzalutamide|Given PO
208467|NCT02099864|Other|laboratory biomarker analysis|Correlative studies
208468|NCT00129129|Biological|Menomune|Primary phase: 1 SC dose
208469|NCT02099877|Drug|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
208470|NCT02099890|Dietary Supplement|Omega-3|
208471|NCT02099890|Dietary Supplement|Vegetation Protein Powder|
180202|NCT00114309|Drug|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
180496|NCT01938196|Drug|KWA-0711|
180497|NCT01938196|Drug|Placebo|
180498|NCT01938209|Other|seated thoracic manipulation|seated general thoracic spine manipulation
180499|NCT01938209|Other|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
180500|NCT01938222|Procedure|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
180501|NCT01938235|Drug|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
180502|NCT01938235|Drug|Placebo|
180503|NCT01938248|Drug|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
180504|NCT01940510|Drug|rifampin|Multiple doses Days 8-16 and Days 17-20
180505|NCT01940523|Drug|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
180506|NCT00113958|Drug|Cinacalcet|
180507|NCT01940523|Drug|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
180508|NCT01940536|Drug|Tranexamic Acid|antifibrinolytic
180509|NCT01940549|Device|Trauma Focused Therapy + tDCS|
180510|NCT01940562|Drug|eltrombopag|Children ≥= 40 kg BW:
From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).
Children 20-40 kg BW:
From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).
Children < 20 kg BW:
From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).
If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.
179899|NCT01932333|Drug|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
179900|NCT01932333|Drug|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
179901|NCT01932333|Drug|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
179902|NCT01932359|Other|rapidly absorbable suture (Vicryl Rapide)|
179903|NCT01932359|Other|non-absorbable suture (Ethilon)|
179904|NCT01932372|Drug|Tofacitinib (Xeljanz)|5 mg Tablet BID
179905|NCT01932372|Drug|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
180203|NCT01945879|Drug|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
180204|NCT01945892|Drug|Ozurdex|- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an "on label" indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of "Uveitis posterior".
180205|NCT01945905|Other|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
180206|NCT01945905|Other|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
180207|NCT01945918|Behavioral|Self-management support education|Same as Arm Description
180208|NCT01945918|Behavioral|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
180209|NCT01945918|Behavioral|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
180210|NCT01948310|Drug|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
180211|NCT01948323|Behavioral|HEDUAfrica IT package+ standard care|The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.
Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group.
179608|NCT01937416|Biological|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
179609|NCT01937429|Device|Colonoscopy with blue Indigo Carmin®|
179610|NCT01939808|Other|Splint Extended|
179611|NCT01939821|Behavioral|Educational and counselling program|Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as "use of providers nominated by their colleges as educationally influential". Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as "use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
179612|NCT01939821|Behavioral|Educational program|Educational program: Educational meeting and printed educational material Educational meeting is defined as "participation of healthcare providers in conference, lectures, workshops or traineeships". The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as "distribution of published or printed recommendations for clinical care, including clinical practice guidelines". In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals.
179613|NCT01939834|Device|AAA control|AAA control is a method to determine insulin dosing to keep glucose in range. AAA control is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the AAA control and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
AAA control will be tested in 40 hours sessions and 5 consecutive overnight sessions.
179614|NCT01939834|Other|CGM + insulin pump at home|The subject will be on their home insulin pump and using a CGM per their usual care.
179615|NCT01939847|Other|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
179616|NCT01939860|Other|Written and verbal patient education on hypertension and its treatment|
179617|NCT01939873|Behavioral|KRISTELLER|
179618|NCT01939886|Drug|Mefloquine - Artesunate|
179619|NCT01939886|Drug|Artemether-lumefantrine combination|
179906|NCT01932385|Drug|Sorafenib|
179907|NCT01932385|Other|Best Supportive Care|
179908|NCT01932424|Device|Pelorus 1500|a bedside blood propofol measurement device
179909|NCT00113178|Device|Catheter-based cardiac cryoablation|
178997|NCT01952314|Drug|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
178998|NCT01952327|Device|The pleurapump system|Implantation of the pleurapump system
178999|NCT01952340|Dietary Supplement|Flaxseed|Milled flaxseed
179000|NCT01952340|Dietary Supplement|Placebo|Wheat germ/wheat bran and mixed dietary oils
179001|NCT01952353|Procedure|Preoprative TACE|
179002|NCT01952353|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
179003|NCT01952405|Behavioral|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
179004|NCT01952418|Device|Monitor size|Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32") video monitor or the standard (24") video monitor.
179005|NCT00115037|Drug|placebo|placebo comparer for 16 weeks in phase 2.
179305|NCT01944943|Drug|Vismodegib|150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
179306|NCT01944969|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
179307|NCT00114244|Drug|sorafenib tosylate|Given PO
179308|NCT01944982|Biological|Expanded haploidentical natural killer cells (NKAEs)|
179309|NCT01944995|Device|glasses broadband|
179310|NCT01944995|Device|nasal CPAP|
179311|NCT01945021|Drug|Crizotinib|
179312|NCT01945034|Drug|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
179313|NCT01945034|Drug|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
179314|NCT01945034|Drug|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
179315|NCT01947556|Drug|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
183433|NCT02550132|Procedure|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
183434|NCT02550132|Device|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
183435|NCT02550145|Drug|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
183436|NCT02550145|Other|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
183437|NCT02550158|Procedure|Educational program EDU-MICI|
183438|NCT02550184|Other|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
183439|NCT02550197|Biological|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
183440|NCT02552251|Biological|Hormonal balance measurements|
183441|NCT02552251|Biological|metabolic balance measurements|
183442|NCT02552251|Biological|bone balance measurements|
178683|NCT01908868|Other|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
178684|NCT01908868|Other|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
178685|NCT01911013|Device|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
178686|NCT01911013|Device|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
178687|NCT00111345|Drug|liposomal daunorubicin|3x80 mg/qm
178688|NCT01911026|Other|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
178689|NCT01911039|Biological|Regulatory T Cells|
178690|NCT01911052|Other|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
182827|NCT02561416|Behavioral|FibroQol|Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.
Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.
Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).
Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV.
182828|NCT02561416|Other|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
182829|NCT02561429|Procedure|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
182830|NCT02561442|Drug|ceftriaxone|
182831|NCT00186550|Behavioral|Education|
182832|NCT02561455|Drug|ASP2215|oral
182833|NCT02561468|Drug|Nefopam|
182834|NCT02561468|Drug|Saline|
182835|NCT02561481|Drug|Sulforaphane|See under active arm description
182836|NCT02561481|Drug|Placebo|See under placebo arm description
182837|NCT02561494|Drug|Nefopam|
182838|NCT02561494|Drug|Saline|
182839|NCT02561507|Behavioral|Survey|
182840|NCT02561520|Biological|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
182841|NCT02561520|Biological|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
182842|NCT00186563|Procedure|Micro-plasmapheresis|
182843|NCT02561533|Other|BRAF detection on fine needle aspiration biopsy (FNAB)|
182844|NCT02561546|Drug|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
182845|NCT02561546|Drug|Trans-catheter embolization|Trans-catheter embolization alone
182846|NCT02561559|Radiation|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
182847|NCT02561572|Other|Acupuncture|Yintang point acupuncture
206748|NCT02109185|Drug|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|
206749|NCT00130169|Drug|E7974|Maximum Tolerated Dose defined as 0.35 mg/m^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
206750|NCT02109185|Drug|Placebo Nasal Spray, 50 μL/actuation|
206751|NCT02109198|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
206752|NCT02109198|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
207065|NCT00129298|Drug|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
207066|NCT02101853|Drug|Etoposide|Given IV
207067|NCT02104063|Procedure|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
207068|NCT02104076|Device|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
207069|NCT02104089|Device|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
207070|NCT02104102|Other|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
207071|NCT02104102|Other|Kinesiotherapy|Hands movements.
207072|NCT00129558|Drug|PT-523 for Injection|
207073|NCT02104115|Other|MRI scanners|
207074|NCT02104115|Other|VAS Symptom scores|
207075|NCT02104128|Drug|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
207076|NCT02104141|Device|ROIA Interbody Cage with VerteBRIDGE plating|
206449|NCT02076568|Behavioral|Education - Diabetes and Partnership|Based on the treatment and education programme PRIMAS a problem-specific education module regarding "Diabetes and Partnership" was created. The module covers specific and detailed aspects of the topic "partnership" such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible.
206450|NCT02076594|Drug|Docetaxel|Powder for solution for infusion
206451|NCT02076594|Drug|Epirubicin|Solution for infusion
206452|NCT02076594|Drug|Oxaliplatin|Powder for solution for infusion
206453|NCT02076594|Drug|Capecitabine|Film coated tablets
206454|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^13 DRP/mL tgAAC94
206455|NCT02076607|Procedure|Arthrodesis|Posterior approach to toracolumbar spine fusion.
206456|NCT02076607|Device|Brace|Toracolumbar imobilization
206457|NCT02079181|Procedure|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
206458|NCT02079181|Procedure|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
206753|NCT02109211|Device|Intubation with Magill forceps|
206754|NCT02109211|Device|Intubation with altered Magill forceps|
206755|NCT02109224|Drug|Ibrutinib|Given PO
206756|NCT02111460|Radiation|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
206757|NCT02111473|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
206758|NCT02111486|Other|breakfast|
206759|NCT02111499|Drug|LAS41004-IMP1|daily topical application
206760|NCT02111499|Drug|LAS41004 IMP2|daily topical application
206761|NCT02111499|Drug|LAS41004 IMP3|daily topical application
206762|NCT02111499|Drug|LAS41004 IMP4|daily topical application
206763|NCT02111499|Drug|LAS41004 IMP6|daily topical application
206764|NCT02111499|Drug|LAS41004 IMP5|once daily, topical
206133|NCT02084355|Drug|oral oxycodone|
206134|NCT02084355|Drug|oral hydromorphone|
206135|NCT00127582|Procedure|Electrophysiological study|
206136|NCT02084355|Drug|fentanyl patch|
206137|NCT02084368|Procedure|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
206138|NCT02084368|Procedure|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8~10mg at L2-3 or L3-4.
206139|NCT02084368|Drug|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
206140|NCT02084368|Drug|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8~10mg.
206141|NCT02084381|Device|MCO-Ci 400|hemodialysis
206142|NCT02084381|Device|Revaclear 400|hemodialysis
206143|NCT02084407|Other|Clinical examination, skin biopsy, blood and urine sampling|
206144|NCT02084420|Drug|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
206145|NCT02084420|Drug|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
206146|NCT00127582|Device|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
206147|NCT02084433|Procedure|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
206148|NCT02086435|Procedure|Extracorporeal morcellation|patients treated with "protected" removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself
206149|NCT02086435|Procedure|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
206150|NCT02086448|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
206459|NCT02079194|Drug|P2Y12 antagonist monotherapy|
206460|NCT00127036|Drug|XELIRI|XELIRI: Irinotecan 240 mg/m^2 IV; Capecitabine 825 mg/m^2 by mouth (po)
205566|NCT02098785|Drug|Caffeine citrate|Oral solution
205567|NCT00129012|Procedure|Tomotherapy|
205835|NCT02091297|Drug|Acetaminophen|Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia
205836|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
205837|NCT02091297|Drug|Morphine|
205838|NCT02091310|Drug|Placebo|
205839|NCT02091310|Drug|GFT505|
205840|NCT02091310|Drug|Moxifloxacin 400 mg|
205841|NCT02091323|Procedure|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 ~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
205842|NCT02091336|Drug|Metformin|patients treatment
205843|NCT02091336|Drug|Glyburide|patients treatment
205844|NCT02091349|Other|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
205845|NCT02091349|Other|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
205846|NCT02091362|Drug|LY2409021|Administered orally
205847|NCT00128193|Other|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
205848|NCT02091362|Drug|Placebo|Administered orally
205849|NCT02091375|Drug|GWP42003-P|GWP42003-P is an oral solution presented as an oily solution containing 25 mg/mL cannabidiol (CBD: FT0086) or 100 mg/mL CBD (FT0095) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
205850|NCT02091375|Drug|Placebo control|Placebo oral solution contains the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
205851|NCT02091388|Drug|LY03004|
205852|NCT02091388|Drug|Risperdal® Consta®|
205262|NCT02108574|Device|Rhinix Nasal Filter|
205263|NCT02108587|Device|optical coherence tomography|Undergo optical coherence tomography
205264|NCT02108600|Drug|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
205265|NCT02108613|Behavioral|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
205266|NCT02108613|Behavioral|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
205267|NCT00130091|Drug|clonidine|2 mcg clonidine added to local anesthetic
205268|NCT02108613|Behavioral|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
205269|NCT02108626|Drug|Nicotine|E-Cigarette with nicotine cartridge
205270|NCT02108626|Drug|Placebo|E-Cigarette with 0mg nicotine cartridge
205568|NCT02098798|Procedure|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
205569|NCT02098798|Procedure|HD Colonoscopy + iSCAN|
205570|NCT02098798|Procedure|HD Colonoscopy + dye spray|
205571|NCT02101021|Drug|Momelotinib|Momelotinib tablets administered orally once or twice daily
205572|NCT02101021|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
205573|NCT00129246|Drug|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
205574|NCT02101021|Drug|Nab-paclitaxel|Nab-paclitaxel administered intravenously over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
205575|NCT02101021|Drug|Gemcitabine|Gemcitabine administered intravenously over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
205576|NCT02101034|Biological|Cetuximab|
205577|NCT02101034|Drug|PD 0332991|
205578|NCT02101047|Drug|Phenylephrine|
205579|NCT02101060|Other|exercise|16-week progressive aerobic and resistance exercise training
204973|NCT02078635|Behavioral|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
204974|NCT02078635|Behavioral|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
204975|NCT02078648|Biological|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated).
204976|NCT02078648|Drug|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
204977|NCT02078661|Drug|PG101|A topical gel containing either 1% or 0.25% PG101 active.
204978|NCT02078674|Biological|Monovalent Avian Influenza VLP (H7N9)|
204979|NCT02078674|Biological|Matrix-M1™ adjuvant|
204980|NCT02078674|Biological|Placebo|
204981|NCT02078687|Dietary Supplement|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
204982|NCT02078687|Dietary Supplement|Enfalac Premature Formula, Mead Johnson Nutritionals|Group 3 received Enfalac containing:
68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml
204983|NCT00002210|Drug|Delavirdine mesylate|
204984|NCT00126984|Biological|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
204985|NCT02078687|Dietary Supplement|Mothers own milk|Group 1 received mothers own milk without fortification
205271|NCT02108639|Drug|DCV 3DAA FDC|
205272|NCT02108639|Drug|BMS-791325|
205273|NCT02108652|Drug|Atezolizumab|1200 mg dose given by intravenous infusion (IV) on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity
205274|NCT02108665|Radiation|Radiographic hysterosalpingography|
205275|NCT02108665|Radiation|Magnetic resonance imaging hysterosalpingography|
204668|NCT02003274|Other|IVGTT-Mixed Meal Arm|Standard clinical parameters will be assessed in all subjects.
Metabolic tests:
A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.
B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.
This test will determine the time courses of:
1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
204669|NCT02003287|Other|VFSS|Videofluoroscopic Swallow Study
204670|NCT02005926|Procedure|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
204671|NCT02005939|Dietary Supplement|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
204672|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
204673|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
204674|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
204675|NCT02006017|Other|Evidence summary alone plus a recommendation|
204676|NCT02006017|Other|Evidence summary alone|
204677|NCT02006030|Drug|ADI-PEG 20|
204678|NCT02006043|Drug|Erlotinib 150mg|
204679|NCT02006056|Drug|Ondissolve|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
204680|NCT00119782|Behavioral|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
204681|NCT02006056|Radiation|Palliative Radiation Therapy|Patient will receive palliative radiation therapy considered emetogenic for bone metastases.
204682|NCT02006069|Device|MPP|All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device
204683|NCT02006082|Device|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
204063|NCT02019355|Drug|5-fluorouracil 5% cream|
204064|NCT02019355|Drug|Calcipotriol 0.005% ointment|
204370|NCT02011204|Device|Electrical impedance myography (EIM)|In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.
EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.
204371|NCT02011217|Other|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
204372|NCT00120354|Procedure|Lamivudine Therapy|
204373|NCT02011217|Other|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
204374|NCT02013999|Other|Virtual reality program for upper extremity rehabilitation|
204375|NCT02013999|Other|standard occupational therapy|
204376|NCT02014025|Procedure|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
204377|NCT02014025|Procedure|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
204378|NCT02014051|Drug|SyB C-1101|SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.
The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.
The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle.
204379|NCT02014064|Drug|Atomoxetine|MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).
Control Group Schedule:
Day 1: 40mg @ 8:00am
Day 2: 40mg @ 8:00am
Day 3: 40mg @ 8:00am, 40mg @ 8:00pm
Day 4: 40mg @ 8:00am, 40mg @ 8:00pm
Day 5: 40mg @ 8:00am, 40mg @ 8:00pm
Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)
204380|NCT00120627|Other|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
204381|NCT02014064|Other|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan & cognitive testing session)
204382|NCT02014077|Procedure|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy for retained haemothorax
203752|NCT02026921|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
203753|NCT02026947|Drug|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
203754|NCT02026947|Drug|Placebo|
203755|NCT02026960|Device|RNA extraction and amplification from biopsy specimens|
203756|NCT02026973|Drug|Fulvestrant|
203757|NCT02026973|Drug|Anastrozole|
203758|NCT00121771|Biological|MVA CS|
203759|NCT02026973|Drug|Placebo|
203760|NCT02026973|Drug|Somatostatin|
204065|NCT00000309|Drug|Risperidone|
204066|NCT00002175|Drug|Dinitrochlorobenzene|
204067|NCT00121186|Drug|melphalan|70 mg/m^2 on days -3 and -2 (2-3 days before transplant).
204068|NCT02019355|Drug|Vaseline|
204069|NCT02019368|Dietary Supplement|Placebo|
204070|NCT02019368|Dietary Supplement|Aged garlic extract|
204071|NCT02019381|Dietary Supplement|Endocrine Society Upper Limit Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
204072|NCT02021773|Biological|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
204073|NCT02021773|Biological|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
204074|NCT02021786|Behavioral|Mobile phone intervention|
204075|NCT02021799|Dietary Supplement|Moringa and Lactobacillus rhamnosus GR-1|
204076|NCT02021812|Device|Branced TAG® Device|
204077|NCT02021825|Drug|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
204078|NCT02021838|Other|Lethality Assessment Program (LAP)|
208472|NCT02099890|Dietary Supplement|InflanNox|
208473|NCT02099890|Dietary Supplement|Anti-oxidant Network|
208474|NCT02099890|Dietary Supplement|Chlorella|
208475|NCT02102217|Procedure|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
208476|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral intervention for insomnia
208477|NCT02102230|Behavioral|quasi-desensitization|behavioral placebo control
208478|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia plus Mobile App|Group-based behavioral intervention for insomnia with adjunct information provided by mobile application
208479|NCT02102243|Drug|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
208480|NCT02102243|Drug|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
208481|NCT02102243|Drug|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
208482|NCT02102243|Procedure|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
203761|NCT02026986|Behavioral|sleep deprivation|sleep deprivation for one night
203762|NCT02027012|Device|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
203763|NCT02027025|Drug|SPARC1103 I|
203764|NCT02027025|Drug|SPARC1103 II|
203765|NCT02027025|Drug|SPARC Placebo|
203766|NCT02027038|Device|Pelvic belt application|
203767|NCT02027064|Drug|Interferon-alpha|
203768|NCT02027077|Behavioral|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
180511|NCT01940575|Device|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
180512|NCT01940575|Device|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
180513|NCT01940588|Behavioral|Neuropsychoanalytic therapy|Psychotherapy, medication management
180827|NCT01933282|Drug|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
180828|NCT00113269|Drug|rabbit anti-thymocyte globulin|IV
180829|NCT01933295|Behavioral|Cognitive Behavioral Therapy for Insomnia|
180830|NCT01933295|Behavioral|Sleep Education|
180831|NCT01933295|Behavioral|Sleep Restriction Therapy|
180832|NCT01933308|Other|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
180833|NCT01933308|Other|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
180834|NCT01935882|Drug|Artemether-lumefantrine combination|
180835|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
180836|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
180837|NCT01935895|Behavioral|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
180838|NCT01935908|Drug|levetiracetam|
180212|NCT01948336|Drug|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
180213|NCT01948336|Drug|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
180214|NCT01948336|Drug|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
180215|NCT01948349|Other|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
180216|NCT01948349|Other|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
180217|NCT01948362|Drug|Sulforadex|Active compound
180218|NCT00114543|Procedure|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
180219|NCT01948362|Drug|Alpha cyclodextrin|Placebo control
180514|NCT01940601|Drug|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
180515|NCT01940601|Drug|Filgrastim|Filgrastim 5 μg/kg
180516|NCT01940614|Other|Water deprivation test|Classical water deprivation test alone
180517|NCT00113971|Drug|epratuzumab|
180518|NCT01940614|Other|Water deprivationtest|classical water deprivation test plus plasma copeptin cut-off levels
180519|NCT01940614|Other|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
180520|NCT01940627|Dietary Supplement|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
180521|NCT01940627|Dietary Supplement|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
180522|NCT01940640|Dietary Supplement|DHA|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
180523|NCT01943240|Drug|10 cc of 0.375% ropivacaine pectoral nerve block|
180524|NCT01943253|Device|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
179910|NCT01932424|Drug|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
179911|NCT01932437|Biological|ETI-204|monoclonal antibody
179912|NCT01932437|Biological|Placebo|Placebo comparator
179913|NCT01932450|Procedure|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
179914|NCT01932450|Drug|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
179915|NCT01932463|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
179916|NCT01932476|Dietary Supplement|Gluten Challenge|Three-day gluten containing dietary challenge.
179917|NCT01932476|Dietary Supplement|Sham Challenge|Three-day sham (gluten free) dietary challenge
179918|NCT01934946|Other|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
179919|NCT01934946|Other|home rehabilitation|6 times home rehabilitation services within 3 months
179920|NCT01934959|Drug|Bifico|
179921|NCT01934972|Other|CR + DCS (D-cycloserine)|CR + DCS
179922|NCT01934972|Other|CR + placebo|CR + placebo
179923|NCT00113386|Drug|docetaxel|
179924|NCT01935011|Other|PD, DBS|PD DBS frequency on swallowing function
179925|NCT01935024|Other|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
179926|NCT01935050|Behavioral|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
179927|NCT01935063|Behavioral|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
179316|NCT01947569|Biological|Biological|
179317|NCT01947582|Device|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
179318|NCT01947595|Behavioral|intensified lifestyle intervention|physical activity 6 hours per week, 50% guided activity
recorded by an accelerometer (Aipermotion 440)
16 sessions per year with a lifestyle advisor
nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)
179319|NCT01947595|Behavioral|normal lifestyle intervention|physical activity 3 hours per week
recorded by an accelerometer (Aipermotion 440)
8 sessions per year with a lifestyle advisor
nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)
179320|NCT01947595|Behavioral|Single lifestyle advice|- Single Health care advice and lifestyle advice (30 minutes) at the beginning
recommend the individual target weight (5% less, if BMI 25> kg/m²)
179321|NCT01947608|Drug|LDK378|
179322|NCT00114517|Drug|Oral 17B-estradiol|Oral 17B-estradiol 1 mg daily
179323|NCT01947634|Other|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
179620|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
179621|NCT01939899|Drug|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
179622|NCT01939912|Drug|Adenosine|Antiarrhythmic agent.
179623|NCT01939925|Other|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
179624|NCT01939925|Other|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
179625|NCT01939938|Device|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
179626|NCT01939951|Dietary Supplement|Activation Energy Serum|7 drops or 21 drops twice daily
179627|NCT01939964|Other|Activation Mist|Activation Mist topical spray
179628|NCT01939977|Drug|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
178691|NCT01911052|Other|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
178692|NCT01911065|Biological|Zostavax™|
178693|NCT01911078|Procedure|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
178694|NCT01911078|Device|EnligHTN™ Renal Denervation System.|
178695|NCT01911091|Behavioral|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
178696|NCT01911104|Behavioral|Exercise|10 weeks of aerobic exercise
178697|NCT01911156|Drug|Continue NA treatment|Prescribed NA during the 72 week study period
178698|NCT00111345|Drug|2-CDA|2x6 mg/qm
178699|NCT01911156|Drug|Discontinue NA Treatment|Discontinue NA Treatment
178700|NCT01911169|Drug|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
178701|NCT01911182|Other|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
178702|NCT01911195|Drug|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
179006|NCT01952431|Device|Total Lung Capacity (TLC) testing|Comparison of TLC results
179007|NCT01952444|Biological|ETI-204|Intravenous (IV)
179008|NCT01952444|Other|IV Ciprofloxacin|
179009|NCT01952444|Other|Oral Ciprofloxacin|
179010|NCT01952457|Device|Zilver PTX|
179011|NCT01952457|Device|prosthetic bypass|
179012|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
183135|NCT02556918|Drug|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
183136|NCT02556918|Drug|Insulin glargine|Patients that required continuous insulin infusion (CII) at a rate >1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.
The total daily insulin dose will be adjusted as follow:
Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between >180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG >241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG <100 mg/dl: stop basal
183137|NCT02556918|Drug|Supplemental insulin (Insulin lispro)|Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin lispro
BG between 221-260 mg/dL; 3-5 units of insulin lispro
BG between 261-300 mg/dL; 4-6 units of insulin lispro
BG between 301-350 mg/dL; 5-7 units of insulin lispro
BG between 351-400 mg/dL; 6-8 units of insulin lispro
BG greater than 400 mg/dL; 7-9 units of insulin lispro
183138|NCT02556918|Drug|Supplemental insulin (Insulin aspart)|Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin aspart
BG between 221-260 mg/dL; 3-5 units of insulin aspart
BG between 261-300 mg/dL; 4-6 units of insulin aspart
BG between 301-350 mg/dL; 5-7 units of insulin aspart
BG between 351-400 mg/dL; 6-8 units of insulin aspart
BG greater than 400 mg/dL; 7-9 units of insulin aspart
183139|NCT02556931|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
183140|NCT02556931|Drug|Cyclophosphamide|Days -6 through -5: 14.5 mg/kg IV daily
183141|NCT02556931|Radiation|Total body irradiation|Day -1: 200 cGy in a single fraction
183142|NCT02556931|Drug|Tacrolimus|Start on Day 5 through either Day 90 or Day 180 depending on GVHD status
183143|NCT02556931|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
183144|NCT02556944|Device|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
183145|NCT00185861|Drug|Arsenic Trioxide|
183146|NCT02556957|Behavioral|HealthScouts|
183147|NCT02556957|Other|Standard of Care|
207077|NCT02104154|Device|Samsung LABGEO PT10 Hepatic Panel|
207078|NCT02104167|Device|ROIC interbody cage with VerteBRIDGE plating|
207079|NCT02104180|Device|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
207080|NCT02104180|Device|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
207081|NCT02104193|Drug|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
207082|NCT02104193|Radiation|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
207083|NCT00129571|Drug|XL820|
207084|NCT02104232|Behavioral|THPP-I|
207380|NCT00128830|Drug|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
207381|NCT00129116|Biological|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
207382|NCT02099188|Radiation|Radiotherapy - Patients not needing ENI|Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.
Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
207383|NCT02099188|Radiation|Radiotherapy - Patients needing curative neck irradiation|LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.
Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
207384|NCT02099201|Drug|ACT-389949 40 mg|
207385|NCT02099201|Drug|ACT-389949 200 mg|Predicted dose
207386|NCT02099201|Drug|ACT-389949 800 mg|Predicted dose
207387|NCT02099201|Drug|ACT-389949 (Group C1 dose to be selected)|
207388|NCT02099201|Drug|ACT-389949 (Group C2 dose to be selected)|
207389|NCT02099201|Drug|Placebo|
206765|NCT00130364|Drug|Placebo|Pimecrolimus vehicle cream (placebo)
206766|NCT02111512|Drug|Administration of Live attenuated influenza vaccine (LAIV)|
206767|NCT02111538|Other|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
206768|NCT02111551|Drug|DMXB-A 150 mg|
206769|NCT02111551|Other|placebo|
206770|NCT02111551|Drug|DMXB-A 75 mg|
206771|NCT02111564|Drug|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening >= 50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
206772|NCT02111564|Drug|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from 30 to 49 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
206773|NCT02111564|Drug|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
206774|NCT02111577|Biological|Dendritic Cells DCVAC|DCVAC is the experimental therapy
206775|NCT02111577|Biological|Placebo|DCVAC placebo is experimental vaccine placebo
206776|NCT00130377|Biological|cell therapy|autologous or allogeneic cells
206777|NCT02111577|Drug|Docetaxel|Docetaxel and prednisone is Standard of Care First Line Chemotherapy
207085|NCT02104232|Behavioral|EUC|
207086|NCT02104245|Drug|Pulmaquin|
207087|NCT02104245|Drug|Placebo|
207088|NCT02104258|Other|Physiotherapy ASPETAR|Standardized physiotherapy protocol
207089|NCT02104258|Other|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
207090|NCT02106663|Procedure|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
207091|NCT00129883|Behavioral|Professional education|
206461|NCT02079194|Drug|aspirin plus P2Y12 antagonist|
206462|NCT02079207|Biological|NBP606|13-valent peumococcal conjugate vaccine(13vPnC)
206463|NCT02079207|Biological|Prodiax-23|23-valent peumococcal polysaccharide vaccine(23vPS)
206464|NCT02079220|Drug|Arm A|Capecitabine
Oxaliplatin
Ziv-aflibercept
206465|NCT02079220|Drug|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
206466|NCT02079233|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
206467|NCT02079246|Drug|Lu AE58054 60 mg (or 30 mg)|once daily, encapsulated tablets, orally
206468|NCT02079259|Procedure|Ultrafiltration|
206469|NCT02079272|Other|Helical tomotherapy for breast cancer|At baseline, before helical tomotherapy is performed, for each included woman will have:
measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)
cardiologic examination including echocardiography for measurement of strain and strain rate
a CT coronary angiogram for measurement of coronary plaque indexes
Helical tomotherapy will be performed for all women included in the cohort.
At the end of tomotherapy, follow-up will include:
measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy
cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy
A CT coronary angiogram 24 months after radiotherapy
206470|NCT02079285|Procedure|EUS-FNA|
206471|NCT00127036|Drug|Bevacizumab|7.5 mg/kg intravenously (IV)
206472|NCT02079298|Drug|Treatment with fluconazole.|
206473|NCT02079298|Drug|2. Treatment with both fluconazole and Ibuprofen.|
206474|NCT02079298|Drug|3. Treatment with ibuprofen.|
206475|NCT02079298|Other|4. No treatment with either fluconazole nor ibuprofen.|
206476|NCT02079311|Device|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
206477|NCT02079311|Device|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
206478|NCT02079324|Biological|GX-051|intratumoral injection
206479|NCT02079337|Drug|Rocuronium|
206480|NCT02079337|Drug|sugammadex|
206481|NCT02079337|Drug|placebo|
205853|NCT02091401|Device|Springfusor infusion pump|
205854|NCT02091401|Other|IV administration|
205855|NCT02094001|Radiation|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
Both groups of patients receiving riociguat therapy will undergo PET imaging.
206151|NCT02086448|Device|sham-CPAP|
206152|NCT02086461|Device|Pneumatic pyloric dilatation|
206153|NCT00127829|Drug|Gefitinib|Oral tablet
206154|NCT02086461|Other|15 mm pyloric balloon dilatation|
206155|NCT02086474|Drug|Hyaluronan|Intra-articular injection
206156|NCT02086474|Drug|Bupivacaine|Extra-capsular injection
206157|NCT02086487|Drug|Nilotinib 300 mg.|Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:
Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript > 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at > 12 months; i.e (BCR-ABL1 0.1 -1%)
206158|NCT02086500|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
206159|NCT02086500|Other|Saline control|Saline Control
206160|NCT02086513|Drug|LDE225|Treatment with LDE225
206161|NCT02086526|Drug|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
206162|NCT02086539|Other|Large Envelope|
206163|NCT02086539|Other|Priority Mail|
206164|NCT00127842|Drug|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
206165|NCT02086539|Other|Amazon|
206166|NCT02086552|Drug|erismodegib|
206167|NCT02086552|Drug|lenalidomide|
206168|NCT02086565|Behavioral|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
205580|NCT02101073|Biological|ALX-0061|single dose, intravenous
205581|NCT02101073|Biological|ALX-0061|single dose, subcutaneous
205582|NCT02101086|Other|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
205583|NCT02101099|Device|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
205584|NCT00129246|Drug|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
205585|NCT02101112|Drug|Apixaban|
205586|NCT02101125|Drug|BMS-986020|
205587|NCT02101125|Drug|Rosuvastatin|
205588|NCT02101138|Drug|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
205589|NCT02101151|Dietary Supplement|Vitamin D3(cholecalciferol)|
205590|NCT02101164|Biological|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
205856|NCT02094014|Behavioral|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
205857|NCT02094014|Behavioral|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
205858|NCT02094014|Behavioral|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
205859|NCT00128479|Drug|mifepristone matched placebo|daily for 7 days
205860|NCT02094027|Behavioral|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
205861|NCT02094027|Other|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
205862|NCT02094040|Behavioral|Receive municipality-based follow-up visit|Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
205276|NCT02110836|Dietary Supplement|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
205277|NCT00130299|Behavioral|low glycemic load diet|
205278|NCT02110849|Radiation|Proton|Proton Therapy for Prostate Cancer
205279|NCT02110862|Other|Transittime. Defecography|
205280|NCT02110888|Device|Subcutaneous peripheral nerve stimulation|
205281|NCT02110888|Other|SCS Only|
205282|NCT02110901|Drug|PRT-201|
205283|NCT02110901|Drug|Placebo|
205284|NCT02110914|Behavioral|Coaching|Coaching is based on the principles of Motivational Interviewing (MI) and performed by a certified coach trained within (MI). At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be "face to face" at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone, Skype/Face Time or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months.
205285|NCT02110927|Device|Transcutaneous microcurrent|Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
205286|NCT02110927|Device|Aerobic exercise|50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
205287|NCT02110940|Other|Neurodynamic mobilization exercise|The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.
Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise.
205288|NCT00130299|Behavioral|low fat diet|
205289|NCT02110940|Other|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
205290|NCT02110953|Device|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
205591|NCT02101164|Drug|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
205592|NCT02101190|Drug|BIA 9-1067|Opicapone, OPC
205593|NCT02101203|Drug|Placebo|
204684|NCT02006095|Other|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
204685|NCT02006095|Behavioral|Neuropsychological testing|
204986|NCT02078700|Other|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
204987|NCT02078713|Behavioral|Contraceptive Decision Support Tool|The decision support tool:
Provides an educational session about different aspects of contraception
Elicits patient preferences about different aspects of contraception
Identifies potential contraindications to certain contraceptive methods
Allows the patient to view details about and compare available contraceptive methods
Suggests methods most appropriate based on the patient's preferences
Collects questions the patient may have for her provider
Generates a printout the patient can bring to her contraceptive counseling visit
204988|NCT02078726|Drug|Glucagon|glucagon (hormone produced by the body)
204989|NCT02078726|Drug|Placebo|
204990|NCT02078739|Behavioral|Yoga Program at home using internet technology|
204991|NCT00127205|Drug|ibandronate sodium|Given orally
204992|NCT02081040|Other|Not applicable (observational study with no active intervention)|
204993|NCT02081053|Device|STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System|Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
204994|NCT02081066|Other|cardiovascular risk factors|
204995|NCT02081079|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
204996|NCT02081105|Other|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
204997|NCT02081118|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
204998|NCT02081118|Drug|Placebo|Placebo for HM11260C
204999|NCT02081131|Procedure|Open surgery|pancreatic head resection by open method
205000|NCT02081131|Procedure|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
205001|NCT02081144|Other|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of ~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
204383|NCT02014077|Procedure|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
204384|NCT02014090|Other|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
204385|NCT02014103|Drug|Tacrolimus|Administration of each formulation will be determined by sequence.
204686|NCT02006108|Drug|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
204687|NCT02006108|Other|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
204688|NCT02006121|Drug|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
204689|NCT02006121|Drug|Placebo|Sodium chloride 9 mg/ml
204690|NCT02006147|Drug|TLC399(ProDex)|
204691|NCT00002163|Drug|Abacavir sulfate|
204692|NCT00119782|Behavioral|Environment|Increase worksite access to both healthy foods and physical activity
204693|NCT02006160|Drug|dalfampridine|10 mg bid
204694|NCT02008500|Other|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
204695|NCT02008500|Other|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
204696|NCT02008500|Other|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
204697|NCT00120016|Behavioral|dietary counseling|telephone counseling
204698|NCT02008513|Biological|AFFITOPE® AD02|
204699|NCT02008513|Biological|Placebo|
204700|NCT02008526|Behavioral|Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support ("pull") are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
204701|NCT02008526|Behavioral|Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
204079|NCT00121303|Drug|gemtuzumab ozogamicin|
204080|NCT02021838|Other|Domestic Violence High Risk Team (DVHRT)|
204081|NCT02021851|Drug|Dexamethasone and aprepitant|
204082|NCT02021851|Drug|Dexamethasone and ondansetron|
204083|NCT02021864|Drug|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
204084|NCT02021864|Drug|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
204085|NCT02021890|Behavioral|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
204086|NCT02021890|Behavioral|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
204386|NCT02014116|Drug|LY3009120 capsule|Administered orally.
204387|NCT02014129|Drug|LY2835219|Administered orally
204388|NCT02014142|Drug|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
204389|NCT02014155|Other|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
204390|NCT02014155|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
204391|NCT00120640|Drug|17 hydroxyprogesterone caproate intramuscular injections|
204392|NCT02014168|Biological|Viroflu® and MVA-NP+M1|2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.
MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu.
204393|NCT02016807|Device|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
203769|NCT00121784|Drug|mycophenolate mofetil [CellCept]; sirolimus [Rapamune]|
203770|NCT02029404|Procedure|Tibial nerve group|After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.
An "information sheet" will be released at the discharge and the medical indication for any "rescue doses" at home.
The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump
203771|NCT02029404|Procedure|Tibial peroneal nerve group|After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.
An "information sheet" will be released at the discharge and the medical indication for any "rescue doses" at home.
The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump
203772|NCT02029417|Drug|cytarabine|Given SC
203773|NCT02029417|Drug|omacetaxine mepesuccinate|Given SC
203774|NCT02029417|Drug|decitabine|Given IV
203775|NCT02029417|Other|laboratory biomarker analysis|Correlative studies
203776|NCT02029430|Drug|aldoxorubicin|
203777|NCT02029443|Drug|ACP-196|
203778|NCT00122044|Drug|trihexyphenidyl|
203779|NCT02029456|Drug|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
203780|NCT02029469|Device|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
203781|NCT02029482|Drug|ACT-128800|
204087|NCT02021903|Other|V1: HGPO + meal and V2: placebo + meal|Ambulatory polysomnography for the night preceding each test
Usual antiparkinsonian treatments at their usual dose and timing
Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test
During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :
continuous digital blood pressure monitoring by Nexfin®
blood pressure monitoring at brachial artery
continuous polysomnographic recording
synchronized continuous digital audiovisual recording
glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP
180839|NCT00113412|Drug|SP01A|
180840|NCT01935921|Biological|Cetuximab|Given IV
180841|NCT01935921|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
180842|NCT01935921|Biological|Ipilimumab|Given IV
180843|NCT01935921|Other|Laboratory Biomarker Analysis|Correlative studies
180844|NCT01935934|Drug|Cabozantinib S-malate|Given PO
181204|NCT01951716|Drug|Graded Glucose Infusion with xenin-25 alone|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes.
181205|NCT01951716|Drug|Graded Glucose Infusion with GIP plus xenin-25|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes.
181206|NCT01951716|Drug|Meal Tolerance Test with Placebo|At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.
Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.
The study is finished at 300 minutes.
181207|NCT01951716|Drug|Meal Tolerance Test with xenin-25|At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.
Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.
The study is finished at 300 minutes.
181208|NCT01951729|Drug|Control|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.
181209|NCT01951729|Drug|Xenin-25 without atropine|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes.
181210|NCT01951729|Drug|GIP without atropine|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.
181211|NCT00114959|Drug|Homoharringtonine|Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.
Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule.
180525|NCT01943253|Device|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
180526|NCT01943266|Dietary Supplement|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
180527|NCT01943279|Other|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
180528|NCT01943279|Other|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
180529|NCT01943292|Drug|Defactinib|
180530|NCT01943305|Biological|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
180531|NCT01943305|Biological|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
180532|NCT01943318|Procedure|Liver biopsy|
180533|NCT00114153|Procedure|conventional surgery|
180534|NCT01943318|Procedure|HVPG measurement|paired measurement
180845|NCT01935934|Other|Laboratory Biomarker Analysis|Correlative studies
180846|NCT01935934|Other|Pharmacological Study|Correlative studies
180847|NCT01935947|Drug|Azacitidine|Given SC
180848|NCT01935947|Drug|Azacitidine|Given PO
180849|NCT01935947|Drug|Docetaxel|Given IV
180850|NCT00113425|Device|V-Beam laser, Candela Corp., 595 nm wavelength|Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
180851|NCT01935947|Drug|Entinostat|Given PO
180852|NCT01935947|Drug|Gemcitabine Hydrochloride|Given IV
180853|NCT01935947|Drug|Irinotecan Hydrochloride|Given IV
180854|NCT01935947|Other|Laboratory Biomarker Analysis|Correlative studies
180855|NCT01935947|Drug|Pemetrexed Disodium|Given IV
180220|NCT01948375|Device|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
180221|NCT01948375|Device|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
180222|NCT01948388|Drug|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
180223|NCT01948401|Drug|LABA|long-acting beta-agonist treatment
180224|NCT01948401|Drug|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
180225|NCT01948401|Drug|prednisolone|additional 0.5 mg/kg orally for 7 days
180226|NCT01948414|Procedure|electroencephalography|
180227|NCT01948414|Biological|Blood sampling|
180228|NCT01951092|Other|Text messaging|
180229|NCT00114816|Drug|docetaxel|
180230|NCT01951105|Drug|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
180231|NCT01951105|Drug|Carbidopa/Levodopa|12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has "responded," the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period.
180232|NCT01951105|Drug|Placebo|Take two placebo capsules three times a day for 12 weeks.
179629|NCT01942356|Procedure|TIVA - Hypertension|Defined as: SBP > 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.
1.) Labetalol 5 mg IV will be administered
179630|NCT01942356|Procedure|TIVA - Bradycardia|Defined as: Heart rate < 45 beats/min
1.) Bolus of 0.2 mg glycopyrrolate
179631|NCT01942356|Procedure|TIVA - Tachycardia|Defined as: Heart Rate > 90 beats/min
If associated with normal NIBP (MAP > 60 mmHg and SAP < 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.
If associated with hypertension (SAB > 140 mmHg): proceed with the management of the hypotention during maintenance protocol.
If associated with hypotension (MAP < 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol.
179632|NCT01942356|Procedure|INH - Hypotension|Defined as: MAP < 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.
give a 200 ml fluid bolus (crystalloid).
If not successful, give ephedrine 5 mg bolus.
If not successful decrease volatile by 0.1 MAC.
Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations
179633|NCT01942356|Procedure|INH - Hypertension|Defined as: SBP > 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.
increase Sevoflurane by 0.1 MAC
If not successful after 3 minutes (SBP >130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.
If still not successful (SBP >130% of baseline), Labetolol 5mg IV will be administered.
179634|NCT01942356|Procedure|INH - Bradycardia|Defined as: Heart Rate < 45 beats/min
1.) Bolus of 0.2 mg glycopyrrolate
179635|NCT01942356|Procedure|INH - Tachycardia|Defined as: Heart rate > 90 beats/min
if associated with normal NIBP (MAP > 70% of baseline and SBP <130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).
If associated with hypertension (SBP >130% of baseline) : proceed with the management of the hypertension during maintenance protocol.
If associated with hypotension (MAP < 70% of baseline) : proceed with the management of the hypotension during maintenance protocol.
179928|NCT01935063|Other|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
179929|NCT01935076|Behavioral|Neonatal exposure to maternal obesity|
179930|NCT01935089|Drug|Pegylated Interferon alpha 2b|1µg/kg/week
179931|NCT01935115|Drug|Propofol|Propofol anesthesia for ECT
179932|NCT01935115|Drug|Ketamine|Ketamine anesthesia for ECT
179933|NCT01935128|Drug|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
179934|NCT00113386|Procedure|adjuvant therapy|
179935|NCT01935141|Procedure|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
179013|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
179014|NCT01934127|Biological|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
179015|NCT01934140|Biological|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
179016|NCT00113347|Drug|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
179017|NCT01934153|Drug|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
179018|NCT01934166|Drug|Nalmefene 18 mg|One single oral dose of 18 mg
179019|NCT01934179|Other|cytology specimen collection procedure|Undergo blood sample collection
179020|NCT01934179|Other|laboratory biomarker analysis|Correlative studies
179021|NCT01934179|Other|questionnaire administration|Ancillary studies
179022|NCT01934192|Drug|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
179023|NCT01934192|Drug|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
179024|NCT01934192|Drug|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
179025|NCT01934192|Drug|Placebo IV|Placebo will be administered IV every 6 hours
179026|NCT01934205|Drug|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
179324|NCT01947647|Behavioral|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
183148|NCT02556970|Procedure|Single port VATS|Performing video-assisted thorascopic surgery through a single port
183149|NCT02559349|Other|Stool Collection|
183443|NCT02552251|Behavioral|quality of life assessment|
183444|NCT02552264|Behavioral|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
183445|NCT02552277|Biological|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
183446|NCT02552277|Drug|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
183447|NCT02552290|Other|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
183448|NCT00002502|Procedure|allogeneic bone marrow transplantation|
183449|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
183450|NCT02552290|Other|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
183451|NCT02552290|Other|No intervention|Wait
183452|NCT02552303|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
183453|NCT02552303|Drug|Armodafinil|Active medication
183454|NCT02552303|Drug|Placebo|Placebo for Nuvigil (armodafinil)
183455|NCT02552316|Device|NB-UVB Phototherapy|
183456|NCT02552329|Other|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
183457|NCT02552342|Drug|methylprednisolone|
183458|NCT02552342|Drug|Normal saline|
183459|NCT02552355|Drug|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
183460|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
183461|NCT02552355|Drug|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
207390|NCT02099214|Device|3Tesla cardiac MRI|
207391|NCT02099214|Device|Electrocardiogram (EKG)|
207392|NCT00129116|Biological|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
207393|NCT02099214|Biological|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
207394|NCT02099214|Biological|Pregnancy test|Beta-hCG
207395|NCT02099214|Device|Echocardiography at rest|Transthoracic echocardiograph
207396|NCT02099214|Biological|Urinary pregnancy test|
207397|NCT02099214|Device|3Tesla abdominal MRI|
207398|NCT02099240|Drug|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
207399|NCT02099240|Procedure|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
207701|NCT02092142|Biological|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
207702|NCT02092168|Drug|BIA 9-1067|
207703|NCT00128297|Drug|Pamidronate|
207704|NCT02092181|Drug|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
207705|NCT02092181|Drug|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
207706|NCT02094781|Dietary Supplement|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
207707|NCT00128544|Drug|telbivudine|
207708|NCT02094781|Dietary Supplement|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
207709|NCT02094781|Dietary Supplement|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
207092|NCT02106663|Procedure|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
207093|NCT02106689|Device|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
207094|NCT02106689|Device|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
207095|NCT02106702|Behavioral|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
207096|NCT02106702|Behavioral|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
207097|NCT02106715|Other|Training|Two exercises for training of core stability and mobility.
207098|NCT02106728|Behavioral|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
207099|NCT02106728|Behavioral|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
207400|NCT02099253|Drug|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
207401|NCT02099253|Drug|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
207402|NCT02099266|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
207403|NCT00129116|Biological|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
207404|NCT02099279|Device|echocardiography examination|patients underwent echocardiography examination
207405|NCT02101853|Other|Laboratory Biomarker Analysis|Correlative studies
207406|NCT02101853|Drug|Leucovorin Calcium|Given IV or PO
207407|NCT02101853|Drug|Mercaptopurine|Given PO
206778|NCT02111577|Drug|Taxotere|
206779|NCT02111590|Drug|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
206780|NCT02111603|Drug|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
206781|NCT02111616|Behavioral|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
206782|NCT02111616|Behavioral|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
206783|NCT02111629|Drug|Fluconazole and Secnidazole|
206784|NCT02113631|Drug|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
206785|NCT00130663|Device|PDA blood pressure screening program and chart reminder|
206786|NCT02113631|Drug|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
206787|NCT02113644|Other|Lifestyle intervention|
206788|NCT02113657|Drug|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
206789|NCT02113670|Other|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
206790|NCT02113696|Dietary Supplement|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
206791|NCT02113696|Dietary Supplement|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
206792|NCT02113709|Device|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
206793|NCT02113709|Device|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
206794|NCT02113722|Procedure|Left cardiac sympathetic denervation via a video|
206795|NCT02113722|Procedure|Standard of Care|
206796|NCT00130676|Drug|Mifepristone|daily for 7 days
206797|NCT02113735|Drug|H.P. Acthar® Gel (repository corticotropin injection)|
206169|NCT02086565|Behavioral|Portal training|training in use of patient portal
206170|NCT02086578|Device|Breast MRI|
206171|NCT02086578|Behavioral|Breast-Q© questionnaire|
206172|NCT02086578|Radiation|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
206173|NCT02086591|Drug|Doxycycline|
206174|NCT02086604|Drug|Brentuximab vedotin|
206482|NCT00127049|Drug|gemcitabine, ifosfamide, cisplatin, G-CSF|
206483|NCT02079350|Drug|%6 HES and %4 Gelofusine|
206484|NCT02079363|Other|No interventions, this is an observational study|
206485|NCT02081703|Drug|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
206486|NCT02081755|Drug|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 24 months
206487|NCT02081755|Drug|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 24 months
206488|NCT02081755|Drug|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 24 months
206489|NCT02081755|Drug|CellCept|CellCept: 500 mg to 1500 mg BID for 24 months
206490|NCT02081768|Radiation|90yttrium colloid|90yttrium colloid will be inserted into a sellar/parasellar cyst
206491|NCT02081781|Procedure|Probing|A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A "Hard" resistance could be felt as the probe touched the end of the nasolacrimal duct. A "Pop" tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner.
206492|NCT02081794|Other|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
206493|NCT02081794|Other|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
206494|NCT00127257|Drug|Diazepam|
205863|NCT02094053|Drug|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
205864|NCT02094053|Drug|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
205865|NCT02094053|Drug|Placebo|placebo (oral) once daily, for 24 weeks
205866|NCT02094066|Drug|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
205867|NCT02094066|Drug|serum physiologic|preoperative 100 cc ıv serum physiologic
205868|NCT02094079|Other|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
205869|NCT02094092|Other|ProTectis drops (five drops per day) for 21 days|
205870|NCT00128479|Drug|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
205871|NCT02094092|Other|Placebo drops (five drops per day) for 21 days|
205872|NCT02094105|Procedure|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
205873|NCT02094118|Biological|Point-of-care washed RBCs.|
205874|NCT02094118|Biological|Standard of Care Blood Transfusion|
205875|NCT02094131|Other|Voldyne group (VG)|VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain "yellow cup" ("yellow flow cup") at a range of flow "Best" in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions.
206175|NCT02088710|Behavioral|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
206176|NCT02088723|Behavioral|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
206177|NCT02088736|Device|Intraosseous|
206178|NCT02088736|Device|Intravenous|
206179|NCT02088749|Behavioral|lifestyle intervention for obesity|
206180|NCT02088762|Procedure|surgical excision|comparison of safety margin 1 versus 2 cm
206181|NCT02088775|Procedure|PET scan|Undergo PET-CT scan
206182|NCT02088775|Procedure|CT Scan|Undergo PET-CT scan
205594|NCT02101203|Drug|0.5 mgTestosterone + 10 mg Buspirone|A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, "on demand") throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days).
205595|NCT00129259|Biological|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
205596|NCT02101216|Drug|Prurisol|Experimental Drug
205597|NCT02103387|Behavioral|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
205598|NCT02103400|Other|Experimental group|Physical therapy sessions will last 50 minutes during 8 consecutive days
205599|NCT02103400|Other|Control group|Physical therapy sessions will last 50 minutes during 8 consecutive days
205600|NCT02103413|Device|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
205601|NCT02103413|Device|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
205602|NCT02103426|Drug|ASP0113|intramuscular injection
205603|NCT02103426|Drug|Placebo|intramuscular injection
205604|NCT00129480|Behavioral|Assistance with Pain treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
205605|NCT02103439|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
205606|NCT02103439|Drug|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
205607|NCT02103452|Procedure|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
205608|NCT02103465|Drug|Rotigotine|transdermal patch
205609|NCT02103465|Drug|Placebo|transdermal patch
205610|NCT02103478|Drug|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
205611|NCT02103478|Drug|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
205002|NCT00127205|Drug|zoledronic acid|Given IV
205003|NCT02081144|Drug|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
205004|NCT02081144|Drug|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
205005|NCT02081144|Behavioral|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
205291|NCT02110953|Procedure|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
205292|NCT02110966|Drug|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
205293|NCT02110966|Drug|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
205294|NCT02110979|Behavioral|Use of a PDA to assist shared decision making|
205295|NCT02110992|Drug|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
205296|NCT02110992|Radiation|Stereotactic Radiation|SBRT will be given over 5 fractions separated by > 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
205297|NCT02111018|Device|CytoSorb Device|
205298|NCT02111018|Procedure|CVVH|
205299|NCT00130312|Drug|Sulodexide|
205300|NCT02112916|Drug|Hydrocortisone Sodium Succinate|Given IT
205301|NCT02112916|Drug|Ifosfamide|Given IV
205302|NCT02112916|Other|Laboratory Biomarker Analysis|Correlative studies
205303|NCT02112916|Drug|Leucovorin Calcium|Given PO or IV
205304|NCT02112916|Drug|Mercaptopurine|Give PO
205305|NCT00130585|Behavioral|folic acid supplement|
205306|NCT02112916|Drug|Methotrexate|Given IT, IV, or PO
205307|NCT02112916|Drug|Pegaspargase|Given IV
205308|NCT02112916|Radiation|Radiation Therapy|Undergo radiation therapy
205309|NCT02112916|Drug|Thioguanine|Given PO
204702|NCT02008539|Drug|MSC_apceth_101|
204703|NCT02008552|Genetic|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
204704|NCT02008565|Drug|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
205006|NCT02081157|Device|GalaFlex Mesh|
205007|NCT02081170|Procedure|Autologous platelet concentrate|pars plana vitrectomy
internal limiting membrane removal
Fluid-air exchange
Intravitreal autologous platelet concentrate injection
Intravitreal gas (14% C3F8) injection
Keep prone position for 7-14 days after surgery
205008|NCT02081183|Drug|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
205009|NCT02081183|Drug|Cyclophosphamide, Maintenance Phase|0.5-1 g/m^2 IV pulse once every 3 months
205010|NCT02081183|Drug|Cyclophosphamide, Induction Phase|0.5 - 1 g/m^2 IV pulse once per month
205011|NCT02081183|Drug|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
205012|NCT02081196|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
205013|NCT00127218|Drug|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
205014|NCT02081209|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
205015|NCT02083796|Procedure|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
205016|NCT02083796|Procedure|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
205017|NCT02083796|Procedure|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
205018|NCT02083796|Procedure|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
204394|NCT00120939|Drug|Motexafin Gadolinium|
204395|NCT02016820|Drug|Omeprazole (suspension)|1 mg/kg/day
204396|NCT02016820|Other|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
204397|NCT02016833|Procedure|Blood Sampling|Sampling of 80mL of whole blood
204398|NCT02016846|Drug|Liraglutide|
204399|NCT02016846|Drug|Placebo|
204400|NCT02016859|Other|Immature Platelet Fraction|
204401|NCT02016872|Drug|18F-FMISO|
204402|NCT02016872|Other|PET/CT|
204403|NCT02016885|Drug|DRM04B, 1.0%|DRM04B, 1.0%
204404|NCT02016885|Drug|DRM04B, 2.0%|DRM04, 2.0%
204405|NCT00120952|Device|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
204705|NCT02008565|Drug|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
204706|NCT02008565|Behavioral|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
204707|NCT02008565|Behavioral|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
204708|NCT00002166|Drug|Nevirapine|
204709|NCT00120029|Behavioral|weight loss counseling|
204710|NCT02008578|Biological|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
204711|NCT02008591|Procedure|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
204712|NCT02011217|Other|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
204088|NCT02021903|Other|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|Ambulatory polysomnography for the night preceding each test
Usual antiparkinsonian treatments at their usual dose and timing
Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test
During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :
continuous digital blood pressure monitoring by Nexfin®
blood pressure monitoring at brachial artery
continuous polysomnographic recording
synchronized continuous digital audiovisual recording
glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP
204089|NCT02021929|Drug|Sorafenib|Sorafenib is a kinase inhibitor indicated for the treatment of:
Unresectable hepatocellular carcinoma
Advanced renal cell carcinoma
Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
204090|NCT00121316|Drug|Pimecrolimus|Pimecrolimus Cream 1 %
204091|NCT02021929|Drug|Placebo|
204092|NCT02021942|Drug|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
204093|NCT00121602|Drug|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
204094|NCT02024282|Device|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
204095|NCT02024295|Drug|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
204096|NCT02024295|Drug|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
204097|NCT02024295|Drug|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
204098|NCT02024308|Drug|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
204099|NCT02024308|Drug|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
204100|NCT02024334|Drug|Leflunomide|
204101|NCT02024360|Behavioral|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
204102|NCT02024373|Drug|Atorvastatin|20 mg (every evening orally) for 8 weeks
204406|NCT02016885|Drug|DRM04B, 3.0%|DRM04B, 3.0%
204407|NCT02016885|Drug|DRM04B, 4.0%|DRM04B, 4.0%
181212|NCT01951729|Drug|Placebo with atropine|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
181213|NCT01951729|Drug|Xenin-25 with atropine|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
181214|NCT01933438|Other|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
181215|NCT01933438|Other|Control|Standard treatment
181216|NCT00113269|Drug|mycophenolate mofetil|oral
181514|NCT01946984|Procedure|ERCP|endoscopy, retrograde cholangio-pancreaticography.
181515|NCT01946984|Drug|Diclofenac hydroxyethylpyrrolidine|
181516|NCT01946984|Drug|Normal Saline|
181517|NCT01946997|Other|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
181518|NCT01947010|Biological|Prevenar 13|
181519|NCT01947010|Biological|Pneumovax|
181520|NCT01947023|Drug|Dabrafenib|Given PO
181521|NCT01947023|Other|Laboratory Biomarker Analysis|Correlative studies
181522|NCT01947023|Drug|Lapatinib Ditosylate|Given PO
181523|NCT00114452|Drug|Provacel|
181524|NCT01947023|Other|Pharmacological Study|Correlative studies
181525|NCT01947049|Other|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
181526|NCT01947062|Drug|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
181527|NCT01949519|Drug|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
180856|NCT01935960|Other|Laboratory Biomarker Analysis|Correlative studies
180857|NCT01935960|Other|Pharmacological Study|Correlative studies
180858|NCT01935960|Other|Placebo|Given PO
180859|NCT01935960|Drug|Retinoid 9cUAB30|Given PO
180860|NCT01935973|Drug|Akt Inhibitor GSK2141795|Given PO
180861|NCT01938456|Drug|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
180862|NCT00113711|Behavioral|reducing diet|
180863|NCT01938456|Drug|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
180864|NCT01938456|Drug|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter^2 or 75 mcg/body
180865|NCT01938469|Other|Liquid Meal|
180866|NCT01938469|Other|Solid Meal|
180867|NCT01938482|Drug|0.3% GSK1940029 gel|Will be supplied as gel for topical application
180868|NCT01938482|Drug|1% GSK1940029 gel|Will be supplied as gel for topical application
180869|NCT01938482|Drug|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
181217|NCT01933451|Other|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
181218|NCT01933464|Drug|Cromolyn Sodium|
181219|NCT01933464|Drug|Normal Saline|
181220|NCT01933477|Other|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
181221|NCT01933490|Other|high carbohydrate test meal|
181222|NCT01933490|Other|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
181223|NCT01933490|Other|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
181224|NCT01933503|Drug|OCA 5 mg|
180233|NCT01951118|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
180535|NCT01943344|Device|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
180536|NCT01943357|Behavioral|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
180537|NCT01943370|Other|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
180538|NCT01943370|Other|Routine Irrigation|Routine initiation of saline irrigation
180539|NCT01943383|Genetic|iPSC|Single blood draw for the production of induced pluripotent stem cells.
180540|NCT01943396|Procedure|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
180541|NCT01943409|Drug|Intralipid|soybean oil-based lipid emulsion
180542|NCT01943409|Drug|ClinOleic|olive oil-based lipid emulsion
180543|NCT01943422|Drug|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
180544|NCT00114153|Radiation|radiation therapy|
180545|NCT01943422|Drug|Vemurafenib|Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal "BRAF" gene.
180546|NCT01943435|Drug|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
180547|NCT01946087|Procedure|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) & 5 min reperfusion (deflation)
180548|NCT01946087|Procedure|Control group|keeping the cuff deflated
180549|NCT01946100|Genetic|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
180550|NCT00114348|Procedure|R-Blocks|
180551|NCT01946126|Other|No Intervention|There is no intervention in this study.
179936|NCT01935141|Device|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
179937|NCT01935141|Drug|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
179938|NCT01935154|Drug|Vx-001|
179939|NCT01935154|Drug|Placebo|
179940|NCT01935167|Drug|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
179941|NCT01935167|Drug|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
179942|NCT01935167|Drug|Placebo|Placebo 2 tablets b.i.d.
179943|NCT00002109|Drug|Thymopentin|
179944|NCT00113659|Dietary Supplement|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
179945|NCT01937585|Behavioral|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
179946|NCT01937598|Drug|Sitagliptin|
179947|NCT01937598|Drug|Placebo|
179948|NCT01937598|Other|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
180234|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
180235|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
180236|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
180237|NCT01951144|Drug|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
180238|NCT01951157|Drug|Docetaxel|Powder for solution for infusion
180239|NCT01951157|Drug|Gemcitabine|Powder for solution for infusion
179325|NCT01947647|Behavioral|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
179326|NCT01947660|Drug|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
179327|NCT01947660|Drug|Systemic analgesia|Systemic analgesia as usual
179328|NCT01947673|Other|Mindfulness Meditation|
179329|NCT01947673|Other|Health Education|
179330|NCT01947686|Device|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
179331|NCT01947699|Drug|Glyburide|
179332|NCT01947699|Device|Continuous glucose monitor|
179333|NCT01950143|Dietary Supplement|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
179334|NCT01950156|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
179335|NCT01950169|Drug|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
179336|NCT01950169|Other|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
179337|NCT01950169|Dietary Supplement|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
179338|NCT01950182|Drug|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
179339|NCT01950182|Drug|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
179636|NCT00114114|Drug|Anastrazole|1 mg by mouth daily
183462|NCT02552355|Dietary Supplement|Carbohydrate beverage|Post-exercise consumption of a isocaloric carbohydrate beverage 3 days/week
183463|NCT02552355|Dietary Supplement|Protein beverage|Post-exercise consumption of a protein beverage 3 days/week
183464|NCT02552368|Device|IpsiHand Device|Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
178703|NCT01911195|Other|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comprable rest period, but will not receive general anesthesia.
178704|NCT01911208|Behavioral|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
178705|NCT01911208|Behavioral|Control|Non-intervention control.
178706|NCT01911221|Biological|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
178707|NCT01911234|Biological|TNF-Kinoid|
178708|NCT01903707|Other|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
178709|NCT01903720|Drug|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
178710|NCT00110461|Drug|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
178711|NCT01903733|Drug|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
178712|NCT01903759|Other|Blood samples|
178713|NCT01903772|Other|Inspiratory Muscle Training|
178714|NCT01903785|Drug|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
178715|NCT01903785|Drug|Placebo|
178716|NCT01903798|Drug|Rilonacept|Interleukin-1 blocker
207710|NCT02094794|Drug|etoposide|Given IV
207711|NCT02094794|Drug|cyclophosphamide|Given IV
207712|NCT02094794|Radiation|total marrow irradiation|Undergo TMLI
207713|NCT02094794|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
207714|NCT02094794|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
207715|NCT02094794|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
207716|NCT02094794|Radiation|fludeoxyglucose F 18|Correlative studies
207717|NCT02094794|Procedure|positron emission tomography|Correlative studies
207718|NCT00128544|Drug|valtorcitabine|
207719|NCT02094794|Procedure|computed tomography|Correlative studies
207720|NCT02094807|Drug|NSAID|Will be used if other drugs are not tolerated.
207721|NCT02094807|Procedure|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
208014|NCT02087475|Procedure|R0 resection|
208015|NCT00127907|Drug|arginine-vasopressin (40 UI/2 mL)|
208016|NCT02087488|Other|auricular acupuncture(AA)|Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.
Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.
Treatment frequency: every 3 days.
Duration: 4 weeks.
208017|NCT02087488|Other|placebo AA|Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).
Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.
Treatment frequency: every 3 days.
Duration: 4 weeks.
208018|NCT02087488|Drug|Eszopiclone|Dosage form: tablet.
Dosage: 1 piece (3mg).
Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.
Production license: NO. H20100074 approved by the state.
Treatment frequency: 15 mins before going to bed everyday.
Duration: 4 weeks.
208019|NCT02089542|Other|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
208020|NCT02089568|Drug|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
208021|NCT02089568|Drug|Normal Saline|Placebo - 0.9% saline
207408|NCT02101853|Drug|Methotrexate|Given IT, IV, and PO
207409|NCT02101853|Drug|Mitoxantrone Hydrochloride|Given IV
207410|NCT02101853|Drug|Pegaspargase|Given IV
207411|NCT02101853|Other|Pharmacological Study|Correlative studies
207412|NCT02101853|Drug|Therapeutic Hydrocortisone|Given IT
207413|NCT02101853|Drug|Thioguanine|Given PO
207414|NCT00129311|Drug|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
207415|NCT02101853|Drug|Vincristine Sulfate|Given IV
207416|NCT02101866|Drug|Vapendavir 300 mg tablet|tablet - single dose
207417|NCT02101866|Drug|Vapendavir 132 mg capsules|2 capsules - single dose
207418|NCT02101892|Drug|Amitriptyline|per os, daily, evening
207419|NCT02101892|Drug|placebo|per os, daily, evening
207420|NCT02101905|Other|Laboratory Biomarker Analysis|Correlative studies
207421|NCT02101905|Drug|Lapatinib Ditosylate|Given PO
207422|NCT02101905|Other|Pharmacological Study|Correlative studies
207423|NCT02101905|Procedure|Therapeutic Conventional Surgery|Undergo surgery
207424|NCT02101918|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
207722|NCT02094807|Drug|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
207723|NCT02094807|Drug|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
207724|NCT02094807|Procedure|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
207725|NCT02094833|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
207726|NCT02094833|Biological|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
206798|NCT02113735|Drug|Placebo|
206799|NCT02113748|Other|Downhill walking training|Walk on a treadmill with a negative inclination.
207100|NCT02106741|Behavioral|Relaxation acupressure|The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).
A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.
Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes.
207101|NCT02106741|Behavioral|Stimulating acupressure|The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).
A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.
Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes.
207102|NCT00002226|Drug|SU5416|
207103|NCT00129883|Behavioral|Implementation of a Critical Care Pathway|
207104|NCT02106754|Behavioral|Brief Intervention|
207105|NCT02106754|Behavioral|Brief Intervention with Coaching|
207106|NCT02109224|Other|Laboratory Biomarker Analysis|Correlative studies
207107|NCT02109224|Other|Pharmacological Study|Correlative studies
207108|NCT02109237|Procedure|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
207109|NCT02109250|Drug|Caprelsa|Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
207110|NCT00130182|Drug|denufosol tetrasodium (INS37217)|
207111|NCT02109263|Procedure|saccharose versus breast-feeding|saccharose versus breast-feeding
207112|NCT02109276|Device|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
207113|NCT02109276|Device|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
207114|NCT02109289|Drug|etanercept|
207115|NCT02109302|Procedure|Blood sample|
206495|NCT02081846|Other|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
206496|NCT02081846|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
206497|NCT02081859|Device|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
206498|NCT02081859|Other|Conventional Criteria|
206499|NCT02081885|Procedure|Tricalcium Phosphate / Chitosan|
206500|NCT02081885|Procedure|Autologous Graft|
206501|NCT02081898|Dietary Supplement|LCD|approximate 100 kcal/d caloric deficit
206800|NCT02113748|Other|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
206801|NCT02113774|Other|antimicrobial treatment according to in-vitro susceptibility|
206802|NCT02113787|Procedure|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
206803|NCT02113800|Drug|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
206804|NCT02113813|Drug|ASP8273|oral
206805|NCT02113813|Drug|midazolam|oral
206806|NCT02113826|Drug|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
206807|NCT00130676|Drug|matching placebo|daily for 7 days
206808|NCT02113839|Procedure|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
206809|NCT02113839|Procedure|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
206183|NCT00127998|Drug|sulfadoxine-pyrimethamine|
206184|NCT02088775|Procedure|hepatic artery embolization|Undergo standard radioembolization
206185|NCT02088788|Device|Board|Also has radio-dense pelvic shielding
206186|NCT02088788|Device|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
206187|NCT02088801|Device|Airtraq, blade without channel for tracheal tube intubation|Intubation
206188|NCT02088801|Device|KingVision , blade without channel for tracheal tube intubation|
206189|NCT02088801|Device|A.P. Advance, blade without channel for tracheal tube intubation|
206190|NCT02088801|Device|Macintosh|
206191|NCT02088814|Behavioral|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
206192|NCT02088827|Other|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
206193|NCT02088827|Other|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
206194|NCT00127998|Drug|amodiaquine|
206195|NCT02088853|Dietary Supplement|high fat diet (hfd)|Sixty % of the energy content is based on fat.
206196|NCT02088853|Dietary Supplement|high carb diet|Sixty % of the energy content is based on carbohydrates.
206197|NCT02088866|Drug|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
206198|NCT02088879|Behavioral|chest compression with kneeling position|
206502|NCT02081911|Procedure|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
206503|NCT02081911|Procedure|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
206504|NCT02081911|Procedure|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
206505|NCT00127257|Behavioral|Pelvic floor retraining|
205876|NCT02096445|Device|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
205877|NCT02096445|Other|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
205878|NCT00002220|Drug|Indinavir sulfate|
205879|NCT00128713|Procedure|Higher Dose Prophylactic Platelet Transfusions|4.4 * 10^11 platelets per m^2 BSA
205880|NCT02096458|Drug|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
205881|NCT02096471|Drug|PD-0325901|
205882|NCT02096484|Behavioral|Group Metacognitive Therapy|
205883|NCT02096484|Behavioral|Mindfulness Meditation Therapy|
205884|NCT02096510|Drug|Solu-Cortef|administration by pump for minimum 2 weeks
205885|NCT02096510|Drug|Cortef|tablet treatment 2 ro 3 times per day for 14 days
205886|NCT02096523|Other|Blood collection for platelet protein samples|
205887|NCT02096536|Drug|Vancomycin|vancomycin administration based on decision of treating physician
205888|NCT02096562|Other|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
205889|NCT02096562|Other|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
205890|NCT00128739|Drug|Budesonide|
205891|NCT02096575|Other|Nitrous oxide administration|All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.
NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.
All patients will get local anesthesia via a standardized PCB.
205892|NCT02096588|Drug|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
205893|NCT02096588|Drug|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
205894|NCT02096601|Drug|Levodopa and carbidopa SC solution|Levodopa and carbidopa SC solution
205310|NCT02112916|Drug|Vincristine Sulfate|Given IV
205311|NCT02112929|Drug|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
205312|NCT02112942|Drug|IDX21459|
205313|NCT02112942|Drug|Matching Placebo|
205314|NCT02112955|Behavioral|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
205315|NCT02112955|Behavioral|Usual care|Usual care such as hospital-based or community-based health education or services.
205316|NCT00130585|Behavioral|13C11-labelled folic acid supplement|
205612|NCT02103491|Dietary Supplement|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
205613|NCT02103491|Dietary Supplement|Placebo administration|
205614|NCT02103504|Device|DePuy Attune posterior stabilized fixed bearing total knee replacement|
205615|NCT00129493|Behavioral|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
205616|NCT02103517|Dietary Supplement|Omega -3 fatty acids|Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
205617|NCT02106065|Other|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
205618|NCT02106078|Behavioral|Moderated Discussion Board|All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our "peer support" control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).
The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group.
205619|NCT02106078|Behavioral|Psychoeducation|Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:
What is bipolar disorder? - Content about symptoms and diagnosis
Stress and triggers of illness
Medication and the biological basis of bipolar disorder
Depression - Symptoms, early detection and helpful strategies
Mania and hypomania - Symptoms, early detection and helpful strategies
205019|NCT02083809|Drug|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
205020|NCT02083822|Procedure|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
205021|NCT02083848|Other|7T MRI|Ultra high field magnetic resonance imaging
205022|NCT00127504|Drug|Azithromycin|
205023|NCT02083861|Device|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
205024|NCT02083874|Drug|CBD|
205025|NCT02083887|Biological|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10^10 vp and MVA ME-TRAP 1 x 10^8 pfu
205317|NCT02112968|Procedure|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
205318|NCT02112968|Procedure|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
205319|NCT02112968|Procedure|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
205320|NCT02112981|Device|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
205321|NCT02112981|Device|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
205322|NCT02112994|Drug|sebelipase alfa|Intravenous infusion of sebelipase alfa: 1mg/kg every other week
205323|NCT02113007|Drug|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
205324|NCT02113020|Drug|TAK-233|Oral administration of TAK-233
205325|NCT02113020|Drug|Placebo|Oral admininstration of Placebo
205326|NCT02113033|Device|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
205327|NCT02115230|Procedure|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
205328|NCT02115243|Drug|Ipilimumab|
204713|NCT02011230|Other|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
204714|NCT02011256|Device|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
204715|NCT02011269|Biological|Trichuris Suis Ova|
204716|NCT02011282|Other|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
204717|NCT02011295|Procedure|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
204718|NCT02011295|Other|Bone Marrow Aspirate injection|
204719|NCT02011308|Device|Green light Laser|Laser vs TURP
204720|NCT02011308|Device|Transurethral Resection of the Prostate (TURP)|Laser vs TURP
204721|NCT00120367|Drug|Enfuvirtide|
204722|NCT02011321|Drug|clevidipine|clevidipine infusion x4 hours
204723|NCT02011334|Drug|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
204724|NCT02011347|Drug|Ketamine|
204725|NCT02011347|Drug|Placebo|
205026|NCT02083900|Device|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
205027|NCT02083900|Drug|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
205028|NCT02083913|Behavioral|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
205029|NCT02083926|Drug|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
205030|NCT02083926|Drug|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
205031|NCT02083952|Other|Swaddle Blanket|Two arms involve varying time spent in blanket
204408|NCT02016885|Other|Vehicle|Vehicle
204409|NCT02016898|Procedure|Placement of the sponge|
204410|NCT02016898|Drug|Mitomycin-C|
204411|NCT02016911|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
204412|NCT02016924|Drug|ATV|Atazanavir (ATV) will be administered once daily (at a dose of 150, 200, or 300 mg depending on weight) according to manufacturer's instructions.
204413|NCT02016924|Drug|DRV|Darunavir (DRV) will be administered once daily (at a dose of 600, 675, and 800 mg depending on weight) according to manufacturer's instructions.
204414|NCT02016924|Drug|Cobicistat|Cobicistat (COBI) 150 mg will be administered as two 75 mg tablets (cohorts 1 and 2), or 20 mg dispersible tablets as an oral suspension (cohorts 3 and 4).
204415|NCT02016924|Drug|BR|Background regimen (BR) must include 2 nucleoside reverse transcriptase inhibitors (NRTI). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
204416|NCT00002172|Biological|HIV-1 Immunogen|
204417|NCT00120965|Device|AutoPulse|Standard device settings
204418|NCT02019381|Dietary Supplement|Institute of Medicine (IOM) Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
204419|NCT02019381|Dietary Supplement|Calcium|
204420|NCT02019394|Drug|Lu AE58054|Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.
Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10.
204421|NCT02019407|Procedure|PVI, CTI block|PVI (pulmonary isolation)
Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation
Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip.
204422|NCT02019407|Procedure|PVI|PVI (pulmonary isolation)
204423|NCT02019420|Drug|TR-701 FA IV|TR-701 FA IV 200 mg once daily
204424|NCT00121186|Drug|methotrexate|5 mg/m^2 on days 1, 3, and 7 post-transplant.
204425|NCT02019420|Drug|Linezolid|Linezolid IV 600 mg twice daily
204426|NCT02019433|Device|Structan®|
204427|NCT02019446|Device|Laser Treatment YAG laser|
181528|NCT01949532|Drug|Carfilzomib|For Cycle 1, subjects will receive carfilzomib 20 mg/m2 IV on Days 1 and 2, followed by escalation to 27 mg/m2 on Days 8, 9, 15, and 16 of a 28-day cycle. For Cycles 2 and higher, subjects will receive carfilzomib 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16, as tolerated.
181529|NCT00114660|Drug|Cocoa butter application|
181530|NCT01949545|Drug|Carfilzomib|Subjects will receive carfilzomib 20 mg/m2 IV over 30 minutes on Days 1 and 2 of Cycle 1, followed by escalation to 27 mg/m2 IV over 30 minutes on Days 8, 9, 15, and 16 of Cycle 1. For patients who have adequately tolerated dosing at 27 mg/m2 in Cycle 1, carfilzomib 56 mg/m2 IV will be administered over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 and beyond.
181531|NCT01949558|Behavioral|Dietary Intervention|
181532|NCT01949571|Drug|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
181533|NCT01949584|Device|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
181534|NCT01949597|Procedure|laparoscopic surgery for deep endometriosis|
181827|NCT02565342|Procedure|Interscalene brachial plexus block|
181828|NCT02565355|Other|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
181829|NCT02565355|Other|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
181830|NCT02565368|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
181831|NCT02565368|Drug|CKD-395 0.5/1000mg|single oral administration
181832|NCT02565381|Drug|Transdermal nicotine patch|≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks
<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks
181833|NCT02565381|Behavioral|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
181834|NCT02565381|Behavioral|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide <8ppm
181835|NCT02565381|Behavioral|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
181836|NCT00186966|Drug|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
181225|NCT01933503|Drug|OCA 10 mg|
181226|NCT01933503|Drug|OCA 25 mg|
181227|NCT00113269|Drug|steroids|IV and/or oral
181228|NCT01933516|Drug|GP2013|GP2013
181229|NCT01933529|Drug|ARA 290|ARA 290 is injected s.c. once daily during the study period
181230|NCT01933542|Drug|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
181231|NCT01933542|Drug|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
181232|NCT01933542|Drug|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
181233|NCT01933542|Drug|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
181234|NCT01933555|Behavioral|Empowerment Program|
181235|NCT01933568|Radiation|SABR|combined CFRT and SABR with concurrent cisplatin
181236|NCT01933568|Drug|Cisplatin|combined CFRT and SABR with concurrent cisplatin
181237|NCT01933594|Drug|Romidepsin|RMD will be administered over 4 hours via an intravenous (IV) catheter placed into a peripheral vein.
181238|NCT00113282|Drug|Interleukin-2 (IL-2)|
181239|NCT01933594|Drug|Placebo for RMD: 0.9% sodium chloride for injection|Placebo for RMD will be administered over 4 hours via an IV catheter placed into a peripheral vein.
181240|NCT01933607|Device|TOPS System|TOPS™ System Post Marketing Study To Evaluate The Safety And Effectiveness Of TOPS™ in the Lumbar Spine
181535|NCT01949610|Drug|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
181536|NCT01949623|Other|AC tap|
181537|NCT01949636|Other|Functional Magnetic Resonance Imaging|
181538|NCT01949649|Behavioral|Peer-Led Group Intervention|
181539|NCT01949649|Behavioral|Internet-Based Intervention|
181540|NCT00002117|Drug|Zidovudine|
181541|NCT00114686|Drug|Quetiapine fumarate|
180552|NCT01946139|Procedure|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
180553|NCT01946139|Other|laboratory biomarker analysis|Correlative studies
180554|NCT01946139|Other|questionnaire administration|Ancillary studies
180555|NCT01946139|Procedure|quality-of-life assessment|Ancillary studies
180556|NCT01946152|Drug|Pomalidomide|Induction Phase Part I Starting Dose: 4 mg by mouth on Days 1-21 of each 28-day cycle for up to 6 cycles during a 6-month induction period.
Induction Phase Part II Starting Dose: Maximum tolerated dose from Part I.
Maintenance Phase: 2 mg by mouth on Days 1-21 of every 28 day cycle.
180870|NCT01938495|Device|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
180871|NCT01938508|Drug|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
180872|NCT01938521|Dietary Supplement|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
180873|NCT00113724|Drug|TPI 287 Injection|
180874|NCT01938521|Dietary Supplement|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
180875|NCT01938534|Drug|Helicobacter pylori eradication|
180876|NCT01938547|Drug|clevidipine|
180877|NCT01938560|Other|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
180878|NCT01938573|Drug|Cisplatin|Given IV
180879|NCT01938573|Drug|Gemcitabine Hydrochloride|Given IV
180880|NCT01938573|Other|Laboratory Biomarker Analysis|Correlative studies
180881|NCT01938573|Drug|Sirolimus|Given PO
180882|NCT01938573|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy when appropriate
180883|NCT01938586|Other|Steri-Strip|
180884|NCT00113737|Drug|fluoxetine|
180240|NCT00114829|Procedure|MR colonography with dynamic contrast uptake|
180241|NCT01951157|Drug|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
180242|NCT01951170|Drug|Tocilizumab (RoActemra/Actemra)|tocilizumab 162 mg subcutaneously once weekly for 24 weeks
180243|NCT01951183|Drug|Placebo|RO681135 placebo subcutaneously daily
180244|NCT01951183|Drug|RO6811135|Subcutaneously daily
180245|NCT01951209|Drug|Rifaximin|550mg orally twice daily for 12 weeks
180246|NCT01951209|Drug|Placebo|Matched placebo
180247|NCT01951222|Drug|V0162|
180248|NCT01951222|Other|Placebo|
180249|NCT01951235|Drug|Imeglimin|
180250|NCT01932593|Procedure|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
180251|NCT01932606|Drug|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
180252|NCT01932606|Drug|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
180253|NCT00113217|Drug|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
180254|NCT01932632|Other|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
180255|NCT01932658|Biological|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
180557|NCT01946152|Drug|Dexamethasone|Induction Phase Part I, II, and Maintenance Phase: 40 mg by mouth once weekly.
180558|NCT01946152|Drug|G-CSF|Induction Phase Part I and Part II: 5 microgram/kilogram by subcutaneous injection for five days during days 22-28 of each cycle of induction therapy(cycles 1 - 6).
G-CSF not be administered during the maintenance phase dosing of pomalidomide and dexamethasone.
180559|NCT01946152|Behavioral|Phone Calls|After end-of-study drug visit, patient called every 3 months for 1 year and every 6 months after that. These calls will take about 2-3 minutes.
180560|NCT01946165|Drug|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
180561|NCT00114348|Procedure|Protocol II-Ida|
179637|NCT01942369|Drug|Triptorelin Acetate 3.75mg intramuscular injection|Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).
Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks.
179638|NCT01942382|Drug|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
179639|NCT01942395|Behavioral|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
179640|NCT01942395|Behavioral|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
179641|NCT01942408|Procedure|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
179642|NCT01942421|Procedure|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
179643|NCT01942447|Biological|FMT|
179644|NCT01942447|Drug|Vancomycin|
179645|NCT01942460|Drug|Ferumoxytol|
179646|NCT01945177|Device|white light endoscopy|white light endoscopy
179647|NCT01945190|Device|Electroacupuncture|
179648|NCT01945216|Drug|Alogliptin|Alogliptin tablets
179649|NCT01945242|Drug|Alogliptin|Alogliptin tablets
179650|NCT00114257|Drug|decitabine|
179651|NCT01945268|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
179652|NCT01945281|Drug|Caspofungin|
179653|NCT01945281|Drug|Amphotericin B Deoxycholate|
179654|NCT01945294|Drug|Boceprevir|800 mg three times daily orally
179655|NCT01945294|Biological|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
178717|NCT01903798|Drug|Mycophenolate mofetil|Immunosuppressive agent
178718|NCT01903798|Drug|Prednisolone|Corticosteroid
178719|NCT01903811|Drug|Carfilzomib|Given IV
178720|NCT01903811|Drug|Dexamethasone|Given IV
178721|NCT00110461|Drug|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
179027|NCT00113347|Drug|Docetaxel|15 mg/m^2 or 20 mg/m^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
179028|NCT01934205|Drug|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
179029|NCT01934218|Device|Gel-One|
179030|NCT01934218|Device|PBS|
179031|NCT01934231|Drug|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
179032|NCT01934244|Device|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
179033|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
179034|NCT01936805|Drug|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
179035|NCT01936831|Drug|Isoniazid|
179036|NCT01936831|Dietary Supplement|Vitamin B6|
179037|NCT01936844|Drug|Anakinra (high dose)|Anakinra 100 mg daily twice daily for days 1, 2, and 3
179038|NCT01936844|Drug|Anakinra (standard dose)|Anakinra 100 mg daily for days 4-14
179039|NCT01936844|Drug|Placebo|Placebo twice daily for days 1, 2, and 3
208022|NCT02089581|Drug|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
208023|NCT02089581|Drug|MRXXX|MRXXX
208024|NCT02089581|Drug|MR1XXX|
208025|NCT02089581|Drug|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
208026|NCT02089594|Drug|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
208027|NCT00128050|Drug|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
208028|NCT02089594|Drug|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
208029|NCT02089607|Device|Zenith Fenestrated-Branched System|The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.
The upper portion of the graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) that allow the graft to be located above the renal arteries without blocking blood flow to them. This is needed when there is not enough healthy aorta below the renal arteries. At least one artery may also be treated with an alignment stent to help keep the arteries open and aligned with the fenestrations or branches.
208030|NCT02089620|Drug|Yasmin|will be used every 21 days for three months by the patient
208304|NCT02082704|Behavioral|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
208305|NCT00127361|Behavioral|doula training|
208306|NCT02082704|Behavioral|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
208307|NCT02082717|Drug|potassium chloride replacement|
208308|NCT02082717|Drug|Experimental - 4% Sodium Bicarbonate|
207727|NCT02094846|Behavioral|Voice messages|Voice messages reinforced with self-efficacy
207728|NCT02094872|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
207729|NCT00128557|Drug|vitamin A supplementation (50,000 IU)|
207730|NCT02094872|Drug|molecularly targeted therapy|molecularly targeted therapy
207731|NCT02094872|Procedure|therapeutic procedure|Receive standard of care therapy
207732|NCT02097303|Drug|Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone|Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
207733|NCT02097316|Device|JewelPump|
207734|NCT02097316|Device|usual insulin pump|
207735|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
207736|NCT02097329|Drug|famotidine|20 mg oral tablet 10 hours before and 2 hours after palbociclib
207737|NCT02097329|Drug|rabeprazole|2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
207738|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
207739|NCT02097329|Drug|antacid|30 mL orally once (2h before palbociclib)
207740|NCT02097329|Drug|antacid|30 mL orally once (2h after palbociclib)
207741|NCT02097342|Drug|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
207742|NCT00128830|Drug|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
208031|NCT02089620|Dietary Supplement|Calver|Calver will be given daily for 3 months
208032|NCT02089620|Drug|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
208033|NCT02089620|Drug|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
207116|NCT02109302|Procedure|Skin biopsy|
207117|NCT02109302|Other|Questionnaire|
207118|NCT02109315|Drug|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
207119|NCT02109315|Drug|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
207425|NCT00129311|Drug|Placebo|
207426|NCT02101918|Other|Laboratory Biomarker Analysis|Correlative studies
207427|NCT02101918|Biological|Ziv-Aflibercept|Given IV
207428|NCT02101931|Drug|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
207429|NCT02101944|Drug|Carfilzomib|Given IV
207430|NCT02101944|Drug|Dexamethasone|Given IV
207431|NCT02101944|Other|Laboratory Biomarker Analysis|Correlative studies
207432|NCT02101944|Biological|Wild-type Reovirus|Given IV
207433|NCT02101957|Drug|RP103|
207434|NCT02101957|Drug|Placebo|
207435|NCT02104271|Procedure|Argon Plasma Coagulation|APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.
All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos.
207436|NCT02104271|Procedure|Historical control|APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.
All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos.
206810|NCT02076620|Drug|Drug: L19TNFα in combination with doxorubicin|Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
L19TNFα will be administered as i.v. 120 minutes infusion via automated device (perfusor) on days 1, 3, and 5 of each 3-week cycle. L19TNFα started 30 minutes after end of doxorubicin infusion.
Study design:
Cohort 1 --> 10.4 μg/kg L19TNFα + Doxorubicin (fixed dose) Cohort 2 --> 13 μg/kg L19TNFα + Doxorubicin (fixed dose) Cohort 3 --> 17 μg/kg L19TNFα + Doxorubicin (fixed dose)
Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 22. Patients will receive additional cycles of combination therapy for a maximum of 4.5 months, or exhaustion of cumulative doxorubicin dose (360 or 550mg/m2) until disease progression, unacceptable toxicity, withdrawal of consent or at the discretion of the treating physician, whichever occurs first.
206811|NCT02076633|Drug|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
206812|NCT02076646|Drug|Arm 1: L19IL2 + Dacarbazine|L19IL2: Intravenous (IV) infusion of on days 1, 8 and 15 of each 21-day cycle over 3 hours via automated device (perfusor).
Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle,administered 30 minutes after the end of the L19IL2 infusion.
L19IL2 starting dosage: 480,000 IU/kg increasing until MTD is reached (in steps of 160,000 IU/kg, i.e., 0.48; 0.64; 0.80 MioIU/kg) Dacarbazine dosage: 1000 mg/m2 (fixed dose)
Treatment will terminate at the earliest of the following: disease progression, unacceptable toxicity, withdrawal of consent. Patients will be followed for one year from the start of the treatment or until withdrawal of consent, whichever occurs first.
206813|NCT02076646|Drug|Arm 2: Dacarbazine|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose)
Treatment will terminate at the earliest of the following: disease progression, unacceptable toxicity, withdrawal of consent. Patients will be followed for one year from the start of the treatment or until withdrawal of consent, whichever occurs first. until disease progression, unacceptable toxicity, withdrawal of consent, whichever occurs first.
206814|NCT02076659|Drug|F8IL10 in combination with methotrexate|Weekly administration of F8IL10 (from 6 to 600 μg/kg) + MTX (10-15 mg, fixed dose) on Day 1 and Folic acid (5 mg, fixed dose) on Day 2.
Patients will receive 4 cycles of 1 week treatment unless there is an unacceptable toxicity or withdrawal of the informed consent.
F8IL10 will be administered intravenously. MTX can be administered orally, subcutaneously or intramuscularly. Folic acid will be administered orally.
Study design :
Coohort 1 to 10 --> 10-15 mg MTX (fixed) + 6/15/30/60/110/160/210/300/450/600 μg/kg F8IL10 (one dosage for each coohort)
ACR and DAS28 responses and safety evaluation will be recorded after 4 cycles of treatment. Patients willing to continue the treatment will receive additional 4 cycles of treatment at the dose they received during the first 4 cycles.
207120|NCT02109328|Drug|Alisertib|SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.
In the randomized phase, Experimental arm will consist of the following drugs:
Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.
Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
207121|NCT00130195|Drug|imatinib|
207122|NCT02109328|Drug|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
207123|NCT02109328|Drug|Placebo|Placebo oral tablets
207124|NCT02109341|Drug|Paclitaxel bound albumine|
207125|NCT02109354|Biological|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of >1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
206506|NCT02081924|Other|Kisspeptin|Kisspeptin / placebo will be administered via a subcutaneous pump device for up to 3 months.
206507|NCT02084433|Procedure|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
206508|NCT02084446|Drug|Everolimus|Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
206509|NCT02084446|Drug|Very Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
206510|NCT02084446|Drug|Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
206511|NCT02084446|Drug|Steroids|Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
206512|NCT02084446|Drug|Thymoglobulin|All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
206513|NCT02084446|Drug|Sodium Mycophenolate|Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
206514|NCT02084459|Behavioral|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
206515|NCT02084472|Other|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
206516|NCT00127595|Drug|gemcitabine, oxaliplatin|
206517|NCT02084472|Other|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
206518|NCT02084472|Other|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
206519|NCT02084485|Drug|PH-797804|30 MG Single dose
206815|NCT02076672|Drug|Artichoke WPC|
206816|NCT02076685|Drug|isoniazid|dose adjustment according to the pharmacogenomic results
206817|NCT02076698|Procedure|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
205895|NCT02096601|Drug|Oral levodopa and carbidopa|Oral levodopa and carbidopa
205896|NCT02096614|Drug|TBI-1201|TBI-1201(5*10^8 or 5*10^9) is administered.
206199|NCT02088879|Behavioral|chest compression with standing position|
206200|NCT02088892|Drug|BCG SSI|Intradermal injection
206201|NCT02088892|Drug|BCG Tice|Intradermal injection
206202|NCT02091401|Drug|Magnesium Sulfate|
206203|NCT02091414|Drug|mycophenolate mofetil (MMF)|1.0 g PO BID
206204|NCT02091414|Drug|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
206205|NCT00128206|Drug|Isoniazid|Isoniazid 900 mg twice weekly
206206|NCT02091414|Drug|corticosteroids|As per the practice of each participating center
206207|NCT02091440|Device|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
206208|NCT02091453|Behavioral|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
206209|NCT02091453|Behavioral|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
206210|NCT02091466|Device|pre-warming|warming patients 30 minutes prior to anesthesia
206211|NCT02091479|Drug|UFH Early group|Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).
Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
206212|NCT02091479|Drug|UFH Late group|Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).
Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
206213|NCT02091492|Drug|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
205620|NCT02106078|Behavioral|Interactive Psychosocial Tools|Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal "relapse prevention plan."
205621|NCT00129792|Behavioral|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
205622|NCT02106091|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
205623|NCT02106104|Drug|Linagliptin 5 mg QD|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
205624|NCT02106104|Drug|Glimepiride 1 mg QD|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
205625|NCT02106130|Drug|Rebamipide|oral administration, 3 times/day
205897|NCT02096614|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
205898|NCT02096614|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
205899|NCT02096640|Procedure|Type of surgical teqnique for tracheostomy|
205900|NCT02098811|Device|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
205901|NCT02098811|Device|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
205902|NCT02098824|Drug|Galantamine|Single administration of capsule containing 16 mg of Galantamine
205903|NCT02098824|Drug|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
205904|NCT02098824|Drug|Placebo|Single administration of capsule containing placebo
205905|NCT02098837|Drug|Dolutegravir|Dolutegravir 50mg once daily
205906|NCT02098876|Device|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
205907|NCT00129025|Procedure|Hypofractionated radiotherapy|
205908|NCT02098876|Device|Xience Xpedition everolimus eluting stent|PCI with Xience stent
205909|NCT02098889|Drug|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
205329|NCT02115256|Drug|Intravenous Terbutaline|0.25mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25mL IV of normal saline.
205330|NCT02115256|Drug|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
205331|NCT02115282|Drug|Entinostat|Given PO
205332|NCT02115282|Drug|Exemestane|Given PO
205333|NCT02115282|Drug|Goserelin Acetate|Given SC
205334|NCT00130845|Drug|Octreotide Acetate in Microspheres|
205335|NCT02115282|Other|Laboratory Biomarker Analysis|Correlative studies
205336|NCT02115282|Other|Placebo|Given PO
205337|NCT02115282|Other|Quality-of-Life Assessment|Ancillary studies
205626|NCT02106130|Drug|Mosapride citrate|oral administration, 3 times/day
205627|NCT02106143|Device|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
205628|NCT02106169|Behavioral|Therapeutic education group|
205629|NCT02106182|Drug|Silodosin|
205630|NCT02106182|Other|Laboratory tests|Subject's overall health state will be evaluated by clinical laboratory tests.
Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)
205631|NCT02106182|Other|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
205632|NCT00129805|Drug|MCI-9042|
205633|NCT02106182|Other|12 weeks|
205634|NCT02106195|Drug|KD025|
205635|NCT02106208|Other|Cheese diet|
205636|NCT02106208|Other|Butter diet|
205032|NCT02083965|Biological|rFVIIIFc|Administered as specified in the treatment arm.
205033|NCT00127517|Drug|peptide-nucleic acid solution AVR118|
205034|NCT02083978|Other|MRI scanning|
205035|NCT02083991|Drug|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
205036|NCT02084004|Drug|Bifidobacterium viable pharmaceutics|
205037|NCT02084004|Drug|Berberine Hydrochloride|
205038|NCT02085863|Drug|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
205039|NCT02085876|Other|2 additional MRI sequences|
205040|NCT02085876|Other|An additional blood sample|
205041|NCT02085889|Other|no intervention: observational study|
205042|NCT02085902|Drug|Ropivacaine|
205043|NCT00127790|Behavioral|CBT for Insomnia (CBT-I)|
205044|NCT02085915|Other|strip Peri Screen|
205338|NCT02115295|Drug|Cladribine|Induction Phase:
Cladribine 5 mg/m2/day by vein on Days 1 - 5.
Consolidation Phase:
Cladribine 5 mg/m2/day by vein on Days 1 - 3.
205339|NCT02115295|Drug|Cytarabine|Induction Phase:
Cytarabine 1 gram/m2/day by vein on Days 1 - 5.
Consolidation Phase:
Cytarabine 0.75 gram/m2/day by vein on Days 1 - 3.
205340|NCT02115295|Drug|Idarubicin|Induction Phase:
Idarubicin 10 mg/m2/day by vein on Days 1 - 3.
Consolidation Phase:
Idarubicin 8 mg/m2/day by vein on Days 1 - 2.
205341|NCT02115295|Behavioral|Phone Calls|After last dose of study drug, participant called every 6 -12 months by a member of the study staff to ask about any side effects they may be having. The phone call should take about 5-10 minutes.
205342|NCT02115308|Drug|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
205343|NCT02115321|Drug|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
205344|NCT02115321|Drug|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
205345|NCT00130845|Drug|Placebo|
204726|NCT02011360|Other|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
204727|NCT02011360|Other|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
204728|NCT02011373|Procedure|fixation technique using a sterile synthetic liquid tissue glue: IFABOND™|
204729|NCT02011386|Drug|Treatment|
204730|NCT02011399|Procedure|Brain Computer Interface for Mu Rhythm|Device: Brain Computer Interface Subjects will wear an EEG (electrode) cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate a computer. Subjects will be asked to participate in 4-20 sessions.
Arms: Brain Computer Interface Keyboard
204731|NCT02011425|Device|mandibular advancement appliance|mandibular advancement appliance
204732|NCT00120367|Drug|Tenofovir-Emtricitabine|
204733|NCT02011438|Behavioral|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
204734|NCT02011451|Drug|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
204735|NCT02011451|Drug|Placebo Comparator:|
204736|NCT02011464|Drug|Exparel|Exparel is infiltrate into posterior compartment for pain control
204737|NCT02093390|Drug|Atorvastatin|
204738|NCT02093403|Drug|decitabine|Given IV
204739|NCT02093403|Drug|selinexor|Given PO
204740|NCT02093403|Other|pharmacological study|Correlative studies
204741|NCT02093403|Other|laboratory biomarker analysis|Correlative studies
204742|NCT02093429|Drug|INCB047986|INCB047986 will be supplied as tablets.
204743|NCT02093442|Procedure|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
204744|NCT00002218|Drug|CI-1012|
204745|NCT00128440|Drug|BEA 2180 BR|
204746|NCT02093455|Dietary Supplement|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
204747|NCT02093455|Dietary Supplement|Placebo|
204748|NCT02093468|Drug|MST-188|
181837|NCT02567461|Drug|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
181838|NCT02567461|Drug|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
181839|NCT02567474|Behavioral|5 A model|self management program based on 5A model
181840|NCT02567487|Drug|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
181841|NCT02567500|Behavioral|Patients with auditory hallucination|Patients with auditory hallucination (20 for each arm):
Evaluation at time 0 and 6 month after of:
The social cognitive marker (NEPSY II) : theory of mind and affect recognition
The emotional marker:
Differential emotion scale IV (DES IV): emotional individual stability
Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
Evaluation of diagnosis with DSM-IV criteria:
MINI-Kids
"Psychosis" section of Kiddie-SADS
181842|NCT02567500|Behavioral|Patients without auditory hallucination|Patients without auditory hallucination (20 for each arm):
Evaluation at time 0 and 6 month after of:
The social cognitive marker (NEPSY II) : theory of mind and affect recognition
The emotional marker:
Differential emotion scale IV (DES IV): emotional individual stability
Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
Evaluation of diagnosis with DSM-IV criteria:
MINI-Kids
"Psychosis" section of Kiddie-SADS
182115|NCT02561195|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
182116|NCT02561195|Biological|Placebo|0.5 mL intramuscular injection
182117|NCT02561208|Other|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
182118|NCT02561221|Behavioral|Lifestyle Counseling|Trained health coaches will deliver the active intervention - a comprehensive, "high-intensity" program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines.
182119|NCT02561234|Drug|Co-ArgI-PEG|modified human arginase I
182120|NCT02561247|Device|Prismaflex HF20 CRRT Filter|
182121|NCT02561247|Device|Prismaflex® System 7.10|
182122|NCT00186537|Drug|Fenofibrate|
182123|NCT02561273|Drug|Cyclophosphamide|Given IV
182124|NCT02561273|Drug|Doxorubicin Hydrochloride|Given IV
181542|NCT01949649|Behavioral|Clinician-Led Group Intervention|
181543|NCT01949649|Behavioral|Education Video|
181544|NCT01949662|Drug|Lorazepam|3 mg by vein one time only.
181545|NCT01949662|Drug|Placebo|Placebo consisting of preservative free 0.9% normal saline given one time by vein.
181546|NCT01949662|Drug|Haloperidol decanoate|8 mg/day by vein.
181547|NCT01949662|Behavioral|Questionnaires|Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
181548|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
181549|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
181550|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
181551|NCT01951885|Drug|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1. Tac will be administered IV over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
181552|NCT01951885|Drug|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient < 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
181553|NCT00114972|Device|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
181554|NCT01951885|Drug|Mycophenolate mofetil|Mycophenolate 1000mg IV twice daily will begin on day +1, and will be converted to oral administration 1000 mg twice a day once patient can tolerate oral route. Patients<40 kg will receive MMF 45 mg/kg/day (15mg/kg IV three times a day).
181555|NCT01951885|Drug|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
181556|NCT01951898|Drug|Montelukast|10mg/day, once a daily after dinner, for 28dyas
181843|NCT02567513|Behavioral|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
181844|NCT00187122|Drug|Daunomycin|See Detailed Description section for description of treatment plan.
181845|NCT02567513|Behavioral|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
181846|NCT02567526|Behavioral|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
180885|NCT01938586|Other|Superficial sutures|
180886|NCT01938599|Drug|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
180887|NCT01938599|Drug|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
180888|NCT01940783|Radiation|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
180889|NCT00113984|Biological|PROSTVAC-F/TRICOM|
180890|NCT01940783|Device|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
180891|NCT01940796|Drug|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
180892|NCT01940809|Drug|Dabrafenib|Given PO
181241|NCT01933633|Behavioral|Exercise|
181242|NCT01933659|Drug|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
181243|NCT01936103|Drug|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
181244|NCT01936116|Device|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
181245|NCT01936116|Device|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
181246|NCT01936129|Drug|Copaxone|
181247|NCT01936129|Drug|Placebo (buffered normal saline w/v)|
181248|NCT01936142|Device|Use of RenalGuard|
181249|NCT01936155|Device|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
181250|NCT00113490|Biological|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
181251|NCT01936168|Device|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
181252|NCT01936168|Procedure|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
181253|NCT01936181|Drug|Remicade (infliximab)|
196754|NCT02048943|Other|pharmacological study|Correlative studies
196755|NCT02048943|Other|laboratory biomarker analysis|Correlative studies
196756|NCT02048956|Other|Hydrotherapy intervention|Participants randomized to the exercise programme received an 8-weeks training in a swimming pool twice per week during 50 minutes each. The 8-week exercise programme is designed to increase strength and muscle mass of all major lower limbs muscle groups. The physiotherapist will select and modify the exercises, monitored, and also answer any questions and supervise the exercises execution.
196757|NCT02048956|Other|Control group|Usual treatment, not hydrotherapy added.
197044|NCT02041962|Behavioral|Chronic Care Model for Mood Disorders|The mood disorders CCM intervention ("Life Goals Collaborative Care") consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session.
197045|NCT02041962|Other|Educational Control|
197046|NCT02041975|Dietary Supplement|Nutriose FB06|Wheat dextrin soluble fibre
197047|NCT00123318|Drug|cisplatin|60mg/m2 IV day 1
197048|NCT02041975|Dietary Supplement|Placebo|
197049|NCT02042001|Drug|Immediate switch to TDF/FTC/RPV|
197050|NCT02042001|Drug|Switch to TDF/FTC/RPV after 12 weeks|Patients will continue current EFV-containing regimen up to week 12 and then will be switched to TDF/FTC/RPV
197051|NCT02042014|Drug|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
197052|NCT02042027|Drug|Gamunex-C|Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
197053|NCT02044211|Behavioral|Collaborative Care for Depression|The care manager will telephone patients randomized to "blended" care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable.
197054|NCT02044224|Drug|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).
Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.
Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required
197055|NCT02044237|Behavioral|Decoupling|
196463|NCT02056600|Drug|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
196464|NCT02056626|Drug|carvedilol|
196465|NCT00124735|Drug|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
196466|NCT02056639|Device|Bioteque cup pessary|
196467|NCT02056652|Device|Bioteque cup pessary|
196468|NCT02056665|Drug|MINOCYCLINE|Pill Minocycline 50 mg capsule
196469|NCT02056665|Drug|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
196470|NCT02056678|Drug|acetaminophen, IV preparation|
196471|NCT02056691|Procedure|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
196472|NCT02056691|Procedure|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
196473|NCT02056704|Device|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
196474|NCT02056717|Drug|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
196758|NCT02048969|Drug|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
196759|NCT02048969|Drug|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
196760|NCT02051582|Procedure|Surgeons using fluoroscopy without laser pointer|Surgeons will attempt to obtain a "perfect" anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.
A "perfect" view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves.
196761|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
196762|NCT02051608|Drug|florbetapir|intravenous injection of florbetapir [Amyvid™] up to 370 MBq (10 mCi) of florbetapir and imaging for up to 15 minutes per PET scan conducted at screening and on 3 subsequent timepoints per protocol
196134|NCT02063867|Drug|Arm 2: Decolonization|Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
196135|NCT02063880|Other|Urgent ART|Children will be started on HAART <48 hours after enrollment.
196136|NCT02063880|Other|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
196137|NCT02063919|Other|the mucosal microbiome in the biopsy specimen was analysed|
196138|NCT00125554|Drug|Metyrapone|
196139|NCT02063932|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
196140|NCT02063945|Drug|Methylphenidate|
196141|NCT02063945|Drug|Risperidone|
196142|NCT02063958|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
196143|NCT02063971|Other|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
196144|NCT02063984|Behavioral|Behavior Therapy|Weekly individual counseling sessions with teen and parent(s) to review and discuss contingency management abstinence-based incentives
196145|NCT02063984|Behavioral|Working Memory Training|25 computer-delivered sessions of neurocognitive training
196146|NCT02063997|Drug|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
196147|NCT02063997|Drug|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
196148|NCT02063997|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
196149|NCT00125567|Drug|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
196150|NCT02063997|Drug|Placebo|Placebo tablets once daily for 12 weeks
196151|NCT02063997|Drug|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
196475|NCT02056717|Drug|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
196476|NCT00124735|Drug|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
195515|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
195803|NCT02066584|Other|Sibling oocyte incubation|
195804|NCT02069288|Drug|Placebo|1 tablet of placebo per os
195805|NCT00126139|Drug|Abciximab|
195806|NCT02069301|Behavioral|Behavioral Activation and Problem Solving Group Therapy|LIFE-DM depression group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
195807|NCT02069301|Drug|Guideline Antidepressant Care|Guideline antidepressant care
195808|NCT02069301|Other|LIvelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
195809|NCT02069314|Dietary Supplement|Whey protein supplementation|subjects are asked to consume a smoothie with whey protein added
195810|NCT02069314|Dietary Supplement|Carbohydrate (polycose) supplementation|Subjects are asked to consume a beverage with polycose added
195811|NCT02069340|Drug|zoledronic acid|Given IV
195812|NCT02069340|Other|pharmacological study|Correlative studies
195813|NCT02069353|Device|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
195814|NCT02069353|Device|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
195815|NCT02069366|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive dronabinol.
195816|NCT00002203|Drug|Zidovudine|
195817|NCT00126152|Behavioral|Exercise, education and medical management|
195818|NCT02069366|Drug|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive placebo.
195819|NCT02069379|Drug|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
195820|NCT02069392|Behavioral|Cognitive remediation training|
195821|NCT02069392|Drug|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
195215|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (low dose).
195216|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (high dose).
195217|NCT02040987|Drug|Placebo|Placebo oral solution - one single dose
195218|NCT02040987|Drug|Moxifloxacin|Moxifloxacin tablet - one single dose
195219|NCT02041000|Other|Adipose Derived Stem Cells|
195220|NCT02041013|Other|Taking Card|Recordable greeting card-style discharge instruction card
195516|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
195517|NCT02074293|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
195518|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
195519|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
195520|NCT02036047|Device|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
195521|NCT02036047|Device|Regular polypectomy snare (Snare Master, SD-210U-10)|
195522|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
195523|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
195524|NCT02036073|Drug|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
195525|NCT02036086|Drug|Vemurafenib|Drug
195526|NCT00002183|Drug|Lamivudine|
195527|NCT00122759|Drug|ketamine|
195528|NCT02036086|Drug|Cobimetinib|Drug
195529|NCT02036099|Other|Driving in Mild Dementia Decision Tool|Study participants will be screening patients for fitness to drive using our DMD-DT, instead of using their usual care strategies.
194918|NCT02048241|Behavioral|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
194919|NCT00123916|Drug|Benznidazole|Daily po Benznidazole or placebo (weight based) during 60 days,
194920|NCT02048241|Other|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
194921|NCT02048241|Drug|Intuniv|Weekly administration of medication in doses as per protocol
194922|NCT02048254|Radiation|brachytherapy|
194923|NCT02048254|Radiation|IMRT|
194924|NCT02048267|Procedure|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
194925|NCT02048280|Procedure|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
194926|NCT02048280|Other|NAVA level|Increase NAVA level every 3 minutes
194927|NCT02048293|Drug|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
195221|NCT02041026|Dietary Supplement|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
195222|NCT02041052|Procedure|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
195223|NCT02041052|Procedure|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
195224|NCT00123240|Behavioral|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
195225|NCT02041065|Device|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
195226|NCT02041065|Device|CUSA induced dissection|Ultrasound based destruction of the liver
195227|NCT02041078|Procedure|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
195228|NCT02043587|Drug|PEG-asp|2,000 IU/m2 IV for ages </= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A & 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
195229|NCT02043587|Drug|CTX|750 mg/m2 IV, days 1 &15 for subjects <40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 & 16 for subjects < 40 years of age if day 14 bone marrow M2 or M3; Courses 1A & 2A
194620|NCT02055924|Drug|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
194621|NCT02055937|Procedure|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
194622|NCT02055950|Procedure|Storage of kidney in refrigerated solution|
194623|NCT02055950|Procedure|Kidney perfused by pulsatile machine|
194624|NCT02055963|Drug|Minocycline|100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
194625|NCT02055963|Drug|Placebo|Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
194626|NCT02055963|Behavioral|Questionnaires|Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
194627|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
194628|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
194629|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
194630|NCT00124657|Drug|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
194631|NCT02055976|Drug|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
194632|NCT02055976|Drug|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
194928|NCT02048293|Drug|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
194929|NCT02048293|Drug|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
194930|NCT00002190|Drug|Lamivudine|
194931|NCT00123916|Drug|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
194008|NCT02068456|Drug|Roflumilast|
194324|NCT02060617|Procedure|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
194325|NCT02060630|Procedure|Open surgical revascularization|
194326|NCT02060630|Device|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
194327|NCT02060656|Drug|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
194328|NCT02060656|Drug|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
194329|NCT02060656|Drug|Rituximab|375mg/m2 IV D1, D15 every 28 days
194330|NCT00125203|Procedure|Injection of salivary glands|
194331|NCT02060656|Drug|Cisplatin|100mg/m2 IV D15 every 28 days
194332|NCT02060656|Drug|Lenalidomide|25mg PO D1-21 every 28 days
194333|NCT02060669|Drug|Xeloda|Xeloda
194334|NCT02060682|Device|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
194335|NCT02063087|Other|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
194336|NCT02063100|Drug|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
194337|NCT02063100|Drug|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
194338|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
194339|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
194340|NCT02063100|Drug|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
194341|NCT02063113|Other|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
194010|NCT00126048|Drug|Placebo|Placebo tablet
194011|NCT02068482|Drug|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
194012|NCT02068495|Drug|Candesartan cilexetil/amlodipine|Candesartan cilexetil/amlodipine tablets
194013|NCT02068508|Drug|Pioglitazone|Pioglitazone Tablets
194014|NCT02068521|Drug|VRS-317|Subcutaneous injection
194015|NCT02068547|Biological|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
194016|NCT02068547|Biological|Bone Marrow Aspirate|
194017|NCT02068560|Drug|dDAVP infusion|
194018|NCT02068573|Device|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
194019|NCT02071121|Drug|Placebo|BIIB061 matching placebo capsules
194020|NCT02071121|Drug|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
194021|NCT00126269|Drug|cisplatin|
194022|NCT02071134|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
194023|NCT02071147|Other|No Clinical Follow up|
194024|NCT02071147|Other|Quality of Life questionnaire|
194025|NCT02071147|Other|Patient satisfaction Questionnaire|Conducted at Research clinic.
194026|NCT02071160|Drug|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
194027|NCT02071173|Device|CRT-D, quadripolar coronary venous lead, defibrillation lead|
194028|NCT02071186|Device|Virtual Reality training|Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.
To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis.
194029|NCT02071186|Other|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
198486|NCT02042573|Other|Genetic samples|
198487|NCT02042586|Other|Analysis of movement before total hip replacement|
198488|NCT02042586|Other|Analysis of movement after total hip replacement|
198489|NCT02042599|Drug|Sedation with sevoflurane during 48-hr in ICU|
193707|NCT02075970|Drug|Epoetin Alpha|Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.
Infant study 2:
Dosing algorithm will be determined by results of Infant Study 1.
193708|NCT02075970|Drug|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
193709|NCT02075983|Biological|GTU®-multiHIV B clade|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
193710|NCT02076009|Drug|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; once only (on Day 1) during treatment cycles 7 onwards.
193711|NCT02076009|Drug|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
193712|NCT02076009|Drug|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants > 75 years old or with a body mass index < 8.5).
193713|NCT02037594|Behavioral|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
193714|NCT02037594|Behavioral|PrEP Information (Active Control)|Standard of Care Information about PrEP
193715|NCT00122915|Device|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
193716|NCT02037594|Behavioral|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
193717|NCT02037620|Device|5-6-5 Specify electrode|
193718|NCT02037620|Device|Restore Advance Pulse Generator|
193719|NCT02037633|Drug|Fentanyl|Fentanyl IV
193720|NCT02037633|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
193721|NCT02037633|Drug|ropivacaine|
189264|NCT01989143|Drug|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
189265|NCT01989143|Drug|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
189266|NCT01989143|Drug|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
189267|NCT01989143|Drug|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
189268|NCT01991509|Biological|LBR-101 SC|LBR-101 Administered Subcutaneously
189269|NCT01991522|Behavioral|Curriculum Group|
189270|NCT01991522|Behavioral|Self-directed learning group|
189271|NCT00118573|Procedure|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
189566|NCT01984073|Dietary Supplement|Oral Fat Challenge|Heavy cream drink with vitamin A (aqueous) 120,000 units, 50 g/m^2 of body surface area (BSA)
189567|NCT01984073|Other|Indocyanine Green|Indocyanine Green 0.5mg/kg at hour -0.5 and 3
189568|NCT00118144|Drug|bortezomib|Given IV
189569|NCT01984073|Dietary Supplement|Nialor|Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6
189570|NCT01984073|Dietary Supplement|Niaspan|Niaspan(R) 2000mg or Placebo at hour 0
189571|NCT01984086|Drug|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
189572|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
189573|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
189574|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
189575|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
188948|NCT01955603|Drug|placebo|Placebo administered corresponding to NNC0215-0384 treatment
188949|NCT01955616|Drug|RM-131|
188950|NCT01955616|Drug|Placebo|
188951|NCT01955629|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: intravenous
188952|NCT01955629|Drug|OXALIPLATIN|Pharmaceutical form:Concentrate for solution for infusion Route of administration: intravenous
188953|NCT01955629|Drug|CAPECITABINE|Pharmaceutical form:Tablets Route of administration: oral
188954|NCT01955642|Drug|Clopidogrel|75 mg milligrams per days of PLAVIX
188955|NCT01955655|Drug|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
188956|NCT01955655|Other|Placebo|
188957|NCT01955668|Drug|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
188958|NCT00115414|Drug|docetaxel|
188959|NCT01955694|Drug|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
188960|NCT01955694|Drug|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
188961|NCT01955694|Drug|Placebo|matching placebo
188962|NCT01955707|Drug|natalizumab|Administered as described in the treatment arm
188963|NCT01955707|Drug|Placebo|Matched placebo
188964|NCT01955720|Drug|BI 655075|
188965|NCT01958307|Behavioral|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
188966|NCT01958320|Other|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
189272|NCT01991535|Device|Spontaneous Ventilation Mode|Respiratory rate and duration of inspiration are controlled by the patient.
Device model: Stellar 150® (ResMed, Australia).
193485|NCT02052921|Procedure|Rectal resection|Surgical rectal resection
193486|NCT02052921|Other|Observation|
188626|NCT01963338|Drug|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
188627|NCT01963364|Dietary Supplement|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
188628|NCT01963364|Dietary Supplement|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
188629|NCT01963377|Device|O2 through nasal cannulae|supplementation of O2 through nasal cannulae during bronchoscopy
188630|NCT01963377|Device|O2-channel|supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
188631|NCT00116194|Behavioral|Physical Activity|
188632|NCT01963390|Drug|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
188633|NCT01963403|Drug|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
188634|NCT01963403|Drug|Placebo|1 pill per day; daily during study participation (up to 84 days)
188635|NCT01963416|Dietary Supplement|macro- and micro-nutrient matched control (240 ml)|
188636|NCT01963416|Dietary Supplement|Orange juice|
188637|NCT01963416|Dietary Supplement|whole orange fruit|
188638|NCT01963416|Dietary Supplement|Processed whole orange|
188639|NCT01963429|Radiation|Proton beam therapy|
188640|NCT01963442|Radiation|Chest X-ray|at Day 0, Day 30 and relapse
188641|NCT01963442|Biological|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
188642|NCT00116207|Drug|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
188643|NCT01963442|Drug|Augmentin|2 tablets 3 times a day for 5 days from Day 3
188644|NCT01965535|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
197923|NCT02062151|Other|Acupuncture|Acupuncture
197924|NCT02062164|Procedure|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
197925|NCT00125385|Biological|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
197926|NCT02062164|Other|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
197927|NCT02062177|Drug|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
197928|NCT02062177|Drug|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged < 70, 0.03 mg/Kg if aged > 70.
197929|NCT02062190|Drug|resveratrol|100mg 2x/day
1 month
198245|NCT02054871|Procedure|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
198246|NCT02054884|Drug|Arm A: F16IL2 in combination with paclitaxel|Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.
Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.
198247|NCT02054884|Drug|Arm B: Paclitaxel|Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m^2 on days 1, 8, 15 of each 28 day cycle.
Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.
198248|NCT02054897|Drug|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
198249|NCT00124579|Drug|thalidomide|100 mg/d PO days 1-21 every 21 days
198250|NCT02054897|Drug|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
198251|NCT02054910|Procedure|Celiac Plexus Block|
198252|NCT02054910|Procedure|Sham|
197632|NCT02070198|Drug|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
197633|NCT02070211|Dietary Supplement|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
197634|NCT00126191|Drug|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
197635|NCT02070211|Other|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
197636|NCT02070211|Dietary Supplement|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
197637|NCT02070224|Other|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month and 24 month (option) to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
197638|NCT02070224|Other|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline and optionally at 24 month
197930|NCT02062203|Drug|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
197931|NCT02062203|Drug|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
197932|NCT02062203|Drug|Placebo|Single oral dose of placebo
197933|NCT02062203|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
197934|NCT02062242|Other|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
197935|NCT02062242|Other|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
197936|NCT00125385|Biological|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
197937|NCT02064725|Drug|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
197349|NCT02075086|Drug|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
197350|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
197351|NCT02036775|Drug|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
197352|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
197353|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
197354|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
197355|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
197356|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
197357|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
197358|NCT00122837|Drug|placebo|
197359|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
197360|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
197361|NCT02036788|Other|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
197362|NCT02036788|Other|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
197363|NCT02036801|Other|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
197364|NCT02036814|Behavioral|Program Health Education|
197639|NCT02070237|Drug|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
197640|NCT02070250|Behavioral|From Cancer to Health (C2H-D)|From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
197056|NCT02044237|Behavioral|Progressive relaxation|
197057|NCT02044250|Drug|Clopidogrel (Copregrel / Plateless / Cloart / Pidogul)|
197058|NCT02044250|Drug|Aspirin|
197059|NCT02044263|Behavioral|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
197060|NCT02044263|Behavioral|face-to-face CBT-i|
197061|NCT02044276|Drug|lipegfilgrastim|6 mg
197365|NCT02036827|Drug|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
197366|NCT02036840|Drug|Antibiotic|
197367|NCT02036853|Drug|Triheptanoin|Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (~1-4g/kg/day, depending on age).
Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established.
197368|NCT02036866|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
197369|NCT00122850|Drug|Duloxetine|
197370|NCT02036866|Other|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
197371|NCT02036866|Other|No Intervention|Patients will be instructed to maintain their usual activity level.
197372|NCT02039180|Drug|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
197373|NCT02039180|Drug|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
197374|NCT02039180|Drug|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
196763|NCT02051608|Drug|gantenerumab|SC q4w up to Week 100
196764|NCT02051608|Drug|placebo|SC q4w
196765|NCT00124202|Behavioral|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
196766|NCT02051621|Drug|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
196767|NCT02051621|Procedure|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
196768|NCT02051621|Procedure|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
196769|NCT02051634|Drug|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
196770|NCT02051634|Drug|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
196771|NCT02051660|Behavioral|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
196772|NCT02051660|Behavioral|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
197062|NCT02044276|Drug|pegfilgrastim|6 mg
197063|NCT00123487|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
197064|NCT02044302|Drug|Bupivacaine|
197065|NCT02044302|Drug|Botulinum Toxins|
197066|NCT02044302|Drug|Analgesics|
197067|NCT02044315|Device|ICD programming|
197068|NCT02044328|Drug|Icotinib|Icotinib is administered 125 mg three times per day.
197069|NCT02044341|Drug|AR01|drops administered an needed for pain
197070|NCT02044341|Drug|Glycerin ear drops|placebo drops administered for ear pain
196477|NCT02056730|Drug|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
196478|NCT02056743|Drug|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
196479|NCT02056743|Drug|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
196480|NCT02056743|Dietary Supplement|Red ginseng|During 4~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
196481|NCT02059044|Other|ISTOP-ADE|Interactive Voice Response System + Pharmacist
196482|NCT02059057|Device|LVRC System|
196483|NCT02059070|Drug|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
196484|NCT00125008|Biological|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
196485|NCT02059070|Drug|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
196486|NCT02059083|Behavioral|Heart rate variability biofeedback|
196487|NCT02059083|Behavioral|CBT|
196488|NCT02059096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
196489|NCT02059109|Procedure|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
196490|NCT02059135|Biological|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
196491|NCT02059135|Other|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
196492|NCT02059148|Drug|LY2835219|Administered orally.
196493|NCT02059161|Drug|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
196773|NCT02051673|Biological|Biological/Vaccine: Enriched Hematopoetic Stem Cell Transplant|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
195822|NCT02069405|Other|Relaxation Music|
195823|NCT02069418|Radiation|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
196152|NCT02064010|Drug|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
196153|NCT02064010|Drug|Placebo|Placebo tablet, administered orally for 4 weeks
196154|NCT02064023|Device|insulin pump|subjects in the experimental arm will administer insulin using a pump
196155|NCT02064023|Other|multiple daily insulin injection|Subjects will continue with usual insulin injections
196156|NCT02064036|Radiation|Stereotactic Radiosurgical Boost3|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
196157|NCT02064036|Drug|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
196158|NCT02064036|Drug|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
196159|NCT02066597|Device|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
196160|NCT02066610|Other|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
196161|NCT02066610|Other|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
196162|NCT02066610|Other|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
196163|NCT02066610|Other|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
196164|NCT02066623|Device|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
196165|NCT02066636|Drug|Nivolumab|
196166|NCT02066649|Drug|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
196167|NCT00125905|Drug|Bupropion|
195530|NCT02036112|Procedure|conventional ELAPE|device
195531|NCT02036112|Procedure|Individual ELAPE|device
195532|NCT02036125|Device|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
195533|NCT02036125|Drug|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
195534|NCT02036138|Procedure|Laparoscopic Sleeve Gastrectomy|
195535|NCT02036138|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
195536|NCT02036138|Drug|Advanced Medical Therapy|
195824|NCT02069418|Radiation|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
195825|NCT02069431|Drug|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
195826|NCT02069431|Other|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
195827|NCT02069444|Procedure|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
195828|NCT00126165|Procedure|radiotherapy|
195829|NCT02071979|Device|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
195830|NCT02071979|Procedure|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
195831|NCT02072005|Other|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
195832|NCT02072018|Drug|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
195833|NCT02072018|Drug|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
195834|NCT02072031|Drug|Anlotinib|Anlotinib p.o. qd
195835|NCT02072031|Drug|Sunitinib maleate|Sunitinib 50 mg p.o. qd
195230|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
195231|NCT02043587|Drug|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A & 2A; Maintenance: Monthly, days 1-5
195232|NCT02043587|Drug|Liposomal AraC|25 mg intrathecal (IT), on days 1 & 15 during Courses 1A & 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
195233|NCT02043587|Drug|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B & 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
195234|NCT02043587|Drug|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B & 2B
195235|NCT02043587|Drug|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C & 2C
195236|NCT02043587|Drug|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C & 2C
195237|NCT02043587|Drug|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
195238|NCT02043587|Drug|Rituximab|375 mg/m2 IV once daily on days 1 & 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C & 2A
195537|NCT02036151|Drug|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
195538|NCT00122772|Radiation|Radiotherapy|External Beam Radiation 46Gy in 23 daily fractions
High Dose Brachytherapy 2 fractions of 9Gy
195539|NCT02036151|Drug|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
195540|NCT02036164|Radiation|Pelvic radiation|Radiation:
Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks
Brachytherapy 30-35 Gy for 4-5 times
195541|NCT02036164|Drug|Cisplatin|Cisplatin 40 mg/m2 i.v.
195542|NCT02036164|Drug|Paclitaxel|Paclitaxel 175 mg m2 i.v.
195543|NCT02036164|Drug|Carboplatin|Carboplatin AUC 5 i.v.
195544|NCT02036177|Device|SCu300A IUB intrauterine device|Spherical copper IUD
195545|NCT02036177|Device|T380A IUD|T-shaped copper IUD
194932|NCT02048306|Behavioral|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
194933|NCT02048306|Behavioral|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
194934|NCT02048319|Drug|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
194935|NCT02048319|Procedure|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
194936|NCT02048319|Drug|Placebo|Saline solution, injected as placebo
194937|NCT02050763|Behavioral|The SHARE Project|SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau & Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska & DiClemente, 1983; Prochaska & Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.
We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior.
194938|NCT02050776|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
194939|NCT00124111|Drug|methotrexate|
194940|NCT02050789|Behavioral|flexible duty hours|If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
194941|NCT02050802|Drug|Moxifloxacin 400 mg|
194942|NCT02050802|Drug|Macitentan 10 mg|
194943|NCT02050802|Drug|Macitentan 30 mg|
194944|NCT02050802|Other|Placebo|
194945|NCT02050815|Drug|MEK162|
194946|NCT02050828|Drug|AKB-9778|
194947|NCT02050828|Drug|ranibizumab|
195239|NCT02043587|Drug|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
195240|NCT02043600|Behavioral|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
194342|NCT02063126|Dietary Supplement|ReConnect (NADH plus CoQ10)|ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)
Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)
194633|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
194634|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
194635|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
194636|NCT02055976|Drug|Placebo|Placebo Q14D SC for 16 week
194637|NCT02055989|Radiation|Dose-escalated radiotherapy level 1|
194638|NCT02055989|Radiation|Sequential dose-escalated radiotherapy level 2|
194639|NCT02056002|Other|Usual Care|- Standard CPAP educational training
194640|NCT02056002|Other|Peer-Buddy System|Two 30-minute in person sessions with Peer Buddy
Standard CPAP educational training
Eight phone conversations with Peer Buddy over 3 months
Subsequent 3 months use of phone system to contact Peer Buddy as needed
One Month Visit:
- Home visit to collect CPAP information
Three Month Visit:
Questionnaires
Psycho Motor Vigilance Test (PVT) "Video Game"
Collect CPAP information
Measure weight
Measure blood pressure
Six Month Visit:
Questionnaires
PVT (Video game)
Collect CPAP information
Measure Weight
Measure Blood Pressure
Evaluate the program and Peer Buddy
194641|NCT00124683|Drug|Bupropion|
194642|NCT02056002|Other|Usual Care|- Educational Brochures
194643|NCT02056002|Other|Usual Care|- Educational DVD videos mailed to participant
194644|NCT02058290|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
194645|NCT02058290|Drug|EXPAREL|Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed.
194646|NCT02058303|Drug|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
194647|NCT02058303|Drug|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
194648|NCT02058316|Device|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
194030|NCT02071186|Other|Standard of care|
194343|NCT02063126|Dietary Supplement|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
194344|NCT00125489|Drug|chloroquine sulfate|
194345|NCT02063139|Drug|Flutiform 50/5 ug (2 puffs bid) pMDI|
194346|NCT02063139|Drug|Fluticasone 50 ug (2puffs bid) pMDI|
194347|NCT02063139|Drug|Beclometasone Autohaler 50 ug (2 puffs bid)|
194348|NCT02063165|Dietary Supplement|High Linoleic Safflower Oil|2 tsp per day (~10g of oil)
194349|NCT02063178|Behavioral|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
194350|NCT02063178|Behavioral|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
194351|NCT02063178|Behavioral|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
194352|NCT02063178|Behavioral|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
194353|NCT02063178|Behavioral|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
194354|NCT02063178|Behavioral|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
194355|NCT00125489|Drug|sulfadoxine/pyrimethamine|
194356|NCT02065713|Drug|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
194357|NCT02065713|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
194358|NCT02065726|Dietary Supplement|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
194359|NCT02065726|Other|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
194360|NCT02065739|Drug|JNJ-42165279|Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
193722|NCT02037646|Other|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
193723|NCT02037646|Other|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
193724|NCT02037646|Procedure|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
193725|NCT02037646|Other|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
194031|NCT02071199|Drug|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
194032|NCT00126269|Drug|gemcitabine|
194033|NCT02071199|Drug|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
194034|NCT02071199|Drug|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
194035|NCT02071212|Drug|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
194036|NCT02071225|Drug|bendamustine|70 mg/m2 given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
194037|NCT02071225|Drug|obinutuzumab|1000 mg given by intravenous (IV) infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
194038|NCT02071238|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
194039|NCT02071238|Behavioral|Group Consultation|Informed consent discussion in group-format
194040|NCT02071251|Procedure|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
194041|NCT02071264|Behavioral|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
194042|NCT02073695|Other|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
194043|NCT02073695|Other|Functional outcome forms filled in|
194044|NCT02073695|Other|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
194045|NCT02073695|Other|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
189576|NCT01984086|Drug|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
189577|NCT01984086|Drug|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
189578|NCT01986413|Device|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
189579|NCT01986426|Drug|LTX-315|Dose escalation:
Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)
189580|NCT01986452|Device|CPAP therapy|
189581|NCT01986452|Other|Support|
189582|NCT00002149|Drug|Pseudoephedrine hydrochloride|
189583|NCT00118274|Biological|melanoma helper peptide vaccine|Given intradermally and subcutaneously
189584|NCT01986465|Drug|Depomedrol|
189585|NCT01986465|Drug|Placebo|
189908|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
189909|NCT01978717|Procedure|epidural anesthesia|
189910|NCT01978717|Procedure|general anesthesia|Patients received general anesthesia for surgery
189911|NCT00117793|Device|Total Surface Bearing Suction Socket|Current clinical practice
189912|NCT01978730|Drug|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
189913|NCT01978730|Drug|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
189914|NCT01978730|Drug|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
189915|NCT01978743|Drug|switch efavirenz (EFV) to raltegravir (RAL)|
189273|NCT01991535|Device|Controlled Ventilation Mode|Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.
Device model: Stellar 150® (ResMed, Australia).
189274|NCT01991535|Device|Simulator Ventilation Mode|Ventilator maintains a continuous positive airway pressure during the entire cycle.
Device model: Stellar 150® (ResMed, Australia).
189275|NCT01991561|Biological|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
189276|NCT01991561|Biological|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
189277|NCT01991561|Biological|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
189278|NCT01991561|Biological|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
189279|NCT01991561|Biological|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
189280|NCT01991561|Biological|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
189281|NCT01991574|Drug|Calcium acetate|
189282|NCT00118612|Biological|Tree MATA MPL|
189283|NCT01991574|Dietary Supplement|Iron Hydroxide Adipate|
189284|NCT01991574|Drug|Placebo|methylcellulose capsules
189285|NCT01991587|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
189286|NCT01991587|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
189287|NCT01991587|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
189288|NCT01991587|Biological|Placebo|A single dose of placebo
189289|NCT01991600|Dietary Supplement|ferrous sulphate|
189290|NCT01991600|Dietary Supplement|ferric iron oxide-organic acid (Fe-OA)|
189291|NCT01991613|Dietary Supplement|liquid protein supplement|The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
189292|NCT01991626|Dietary Supplement|micronutrient powder|
188645|NCT01965535|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
188646|NCT01965548|Procedure|Treatment of splenic injury|There are four possible treatments of splenic injury in this study:
splenectomy
splenic artery embolisation
non-operative management
any combination of the three treatments mentioned
188647|NCT01965561|Device|CRoC|Use of Combat Ready Clamp (CRoC)
188648|NCT01965561|Device|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
188967|NCT00115648|Drug|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
188968|NCT01958320|Other|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
188969|NCT01958333|Procedure|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
188970|NCT01958333|Procedure|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
188971|NCT01958333|Procedure|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
188972|NCT01958346|Other|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
188973|NCT01958346|Other|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
188974|NCT01958346|Device|Fiberoptic Intubation|
188975|NCT01958359|Behavioral|Short IVR|IVR-based alcohol diary with feedback
188976|NCT01958359|Behavioral|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
188977|NCT01958372|Dietary Supplement|soy isoflavones|Given PO
188978|NCT00115648|Drug|NVP|Oral NVP daily to age 14 weeks
188979|NCT01958372|Drug|cisplatin|Given IV
188980|NCT01958372|Drug|etoposide|Given IV
188981|NCT01958372|Drug|pemetrexed disodium|Given IV
188982|NCT01958372|Radiation|radiation therapy|Undergo RT
188983|NCT01958385|Device|placement of g-Cath EZ suture anchors|
188984|NCT01958385|Procedure|Sham procedure|
198253|NCT02054923|Procedure|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
198254|NCT02057289|Drug|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
198255|NCT00124800|Device|Sound therapy|sound therapy and counselling
198256|NCT02057302|Drug|Xuezhikang capsule|
198257|NCT02057315|Drug|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
198258|NCT02057315|Drug|Placebo|One dose of matching placebo over 3 bilateral applications.
198259|NCT02057328|Drug|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
198563|NCT02049749|Behavioral|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
198564|NCT02049762|Drug|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
198565|NCT02049775|Procedure|NBI|
198566|NCT02052336|Drug|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
198567|NCT02052336|Drug|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
198568|NCT00124293|Drug|activated recombinant human factor VII|
198569|NCT02052349|Drug|ABT-333|Dose of ABT-333
198570|NCT02052362|Drug|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
197938|NCT02064738|Behavioral|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
197939|NCT02064751|Device|CRT with MultiPoint Pacing|
197940|NCT02064751|Procedure|Hemodynamic measurements for CRT device programming|
197941|NCT02064764|Drug|Renal nerve denervation|
197942|NCT02064764|Device|Cryoablation|
197943|NCT02064777|Drug|Tacrolimus|
197944|NCT02064803|Procedure|Gastro-entero anastomosis only|Gastro-entero anastomosis only
197945|NCT02064803|Procedure|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
197946|NCT00125658|Other|Upper Extremity Rehabilitation|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of activity practice and 10 weeks of resistance exercise. Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the 20 week therapy program.
197947|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
197948|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
197949|NCT02064829|Drug|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
198260|NCT02057328|Drug|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
198261|NCT02057341|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
198262|NCT02057354|Behavioral|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
198263|NCT02057354|Behavioral|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
198264|NCT02057367|Drug|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
197641|NCT02070276|Procedure|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
197642|NCT02070276|Procedure|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
197643|NCT02070289|Drug|PF-06372865|Tablets, 2.5 mg BID, 14 days
197644|NCT02070289|Drug|Placebo|Tablets, BID, 14 days
197645|NCT02072811|Drug|CLAG|G-CSF 30MU sc, on 0-5 days
Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days
Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days
Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day
197646|NCT02072811|Drug|Consolidation, I HAM cycle|Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days
Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days
197647|NCT02072811|Drug|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
197648|NCT02072811|Drug|Consolidation, III HiDAraC cycle|Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days
2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C
197649|NCT02072824|Drug|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
197650|NCT02072824|Drug|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
197651|NCT02072824|Drug|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
197652|NCT02072850|Device|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
197653|NCT02072850|Other|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (< 12 hours, days 2, 7-10 and at 6 months).
197654|NCT00126477|Procedure|management of therapy complications|
197655|NCT02072863|Drug|Oprozomib|Study subjects will receive oprozomib administered orally.
197656|NCT02072863|Drug|Melphalan|Study subjects will receive melphalan 9 mg/m2.
197950|NCT02064829|Drug|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
197951|NCT02064842|Drug|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
197375|NCT02039193|Behavioral|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, & Brown, 1992; Borkovec & Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
197376|NCT00123058|Behavioral|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
197377|NCT02039206|Device|Deep TMS|1Hz Stimulation
197378|NCT02039219|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
197379|NCT02039219|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
197380|NCT02039232|Device|Pedicle screw system|
197381|NCT02039245|Drug|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
197657|NCT02072863|Drug|Prednisone|Study subjects will receive prednisone 60 mg/m2.
197658|NCT02072889|Other|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
197659|NCT02072915|Procedure|Suction|
197660|NCT02072928|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
197661|NCT02072941|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
197662|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
197663|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|Round, white to off-white sublingual tablets, with "10" on one side within a circle
197664|NCT02072967|Other|Ribomustin|Routine practice
197665|NCT00126477|Procedure|psychosocial assessment and care|
197666|NCT02072967|Other|rituximab|Routine practice
197667|NCT02072980|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses
197071|NCT02044354|Drug|Taxotere|
197072|NCT02044354|Drug|Jevtana|
197073|NCT02044367|Drug|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
197074|NCT00123487|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
197075|NCT02044367|Drug|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
197076|NCT02044367|Drug|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
197077|NCT02044380|Drug|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
197078|NCT02046824|Device|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
197079|NCT02046824|Device|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
197080|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
197081|NCT02046837|Behavioral|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
197082|NCT00002189|Drug|Paclitaxel|
197083|NCT00123682|Procedure|Self-help|Project staff send out self-help materials for smoking cessation
197084|NCT02046837|Behavioral|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
197382|NCT02039258|Drug|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
197383|NCT02039271|Other|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
196774|NCT02051686|Drug|Tranexamic Acid; placebo for the control group will be normal saline of a similar volume|
196775|NCT02051699|Procedure|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
196776|NCT00124215|Biological|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
196777|NCT02051712|Behavioral|exercise training|individualized exercise training
196778|NCT02051712|Behavioral|Adherence measures|Measures to increase adherence to exercise training
196779|NCT02054416|Device|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
196780|NCT02054429|Drug|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
196781|NCT02054442|Drug|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
196782|NCT02054442|Drug|Methotrexate|
196783|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
196784|NCT02054455|Dietary Supplement|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
196785|NCT02054455|Dietary Supplement|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
196786|NCT02054468|Drug|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
196787|NCT02054468|Drug|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
196788|NCT02054468|Drug|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
196789|NCT02054468|Drug|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
196790|NCT02054468|Drug|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
196791|NCT02054468|Drug|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
196792|NCT02054468|Drug|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
196793|NCT02054468|Drug|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
196168|NCT02066649|Procedure|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
196169|NCT02066662|Drug|Rivaroxaban or Marcumar|Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;
Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
196494|NCT02059161|Drug|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
196495|NCT00002196|Drug|CI-1012|
196496|NCT00125008|Biological|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
196497|NCT02059161|Drug|Prandial Insulin|Participants will continue their prandial insulin during the study.
196498|NCT02059174|Drug|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
196499|NCT02059174|Drug|Lantus™|Lantus™ 0.4 units/kg administered subcutaneously
196500|NCT02059174|Drug|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or Lantus™dosing in each dosing period to meet basal insulin requirements
196501|NCT02059187|Drug|MK-1293|MK-1293 administered subcutaneously. Dosing will be initiated based on the participant's prior insulin dosing, and may be modified at the investigator's discretion to meet the individual participant's needs.
196502|NCT02059187|Drug|Lantus™|Lantus™ administered subcutaneously. Dosing will be initiated based on the participant's prior insulin dosing, and may be modified at the investigator's discretion to meet the individual participant's needs.
196503|NCT02061501|Other|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
196504|NCT02061514|Procedure|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
196505|NCT00125294|Drug|Methadone|
196506|NCT02061514|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
196507|NCT02061527|Procedure|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
195836|NCT02072044|Drug|Anlotinib|Anlotinib p.o. qd
195837|NCT00126386|Drug|Zoledronic acid (Zometa)|
195838|NCT02072057|Drug|Ruxolitinib|
195839|NCT02072070|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
195840|NCT02072070|Drug|Placebo|Placebo control(Normal Saline)
195841|NCT02072083|Drug|Dexmedetomidine|via intranasal route 1 mcg/kg
195842|NCT02072083|Drug|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
195843|NCT02072096|Drug|Glimepiride|Administered orally
195844|NCT02072096|Drug|Metformin|Administered orally
196170|NCT02066675|Drug|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
196171|NCT02066688|Drug|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
196172|NCT02066688|Drug|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
196173|NCT02066688|Drug|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
196174|NCT02066727|Drug|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
196175|NCT02066727|Drug|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
196176|NCT02066740|Device|EverFlex™ stent with Entrust™ delivery system|
196177|NCT02066753|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
196178|NCT00125918|Drug|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
196179|NCT02066766|Other|No treatment given|Patients will fill out a questionnaire by interview.
196180|NCT02066792|Drug|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
196181|NCT02069444|Procedure|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
195546|NCT02036203|Device|SCu300A IUB|Spherical copper contraceptive
195547|NCT00122993|Behavioral|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
195548|NCT02038439|Behavioral|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
195549|NCT02038452|Drug|Depo-Medrone|Steroid Injection
195550|NCT02038452|Device|Wrist Splint|Simple wrist splint
195551|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
195552|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
195553|NCT02038478|Biological|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
195554|NCT02038491|Procedure|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
195555|NCT02038543|Drug|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
195845|NCT02072096|Drug|Pioglitazone|Administered orally
195846|NCT02072096|Drug|Acarbose|Administered orally
195847|NCT02072096|Drug|Linagliptin|Administered orally
195848|NCT00126399|Drug|doxycycline|
195849|NCT02072096|Drug|Sitagliptin|Administered orally
195850|NCT02072096|Drug|Liraglutide|Administered orally
195851|NCT02072096|Drug|Insulin Glargine|Administered subcutaneously (SQ)
195852|NCT02072096|Drug|Exenatide once weekly (QW)|Administered SQ
195853|NCT02072096|Drug|Exenatide twice daily (BID)|Administered SQ
195854|NCT02072135|Drug|Exparel|
195241|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
195242|NCT02043600|Behavioral|Self-care|Self-care books are provided for self-directed use
195243|NCT02043613|Other|Contextually enhanced physical surroundings of exercise|Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.
The differences with the physical surroundings of exercise is the primary intervention for this study.
195244|NCT02043613|Other|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
195245|NCT00123630|Drug|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
195246|NCT02046161|Procedure|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
195247|NCT02046174|Biological|RENCA macrobeads|
195248|NCT02046187|Dietary Supplement|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
195249|NCT02046187|Radiation|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
195250|NCT02046187|Drug|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
195251|NCT02046200|Drug|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
195252|NCT02046200|Drug|Placebo|Matched placebo
195253|NCT02046200|Drug|Alcohol|
195254|NCT02046213|Drug|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
195556|NCT02038556|Behavioral|cognitive behaviorial therapy -Insomnia|
194649|NCT02058329|Other|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
194650|NCT00124930|Drug|Olanzapine|
194948|NCT02050841|Biological|octaplas|Octaplas S/D Plasma
194949|NCT02050893|Drug|sedatives(Midazolam and Propofol)|
194950|NCT00124111|Drug|5-fluorouracil|
194951|NCT02050906|Behavioral|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
194952|NCT02050906|Behavioral|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
194953|NCT02050906|Other|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
194954|NCT02050906|Behavioral|telephone based counseling|Undergo behavioral activity and nutritional counseling
194955|NCT02050906|Procedure|quality-of-life assessment|Ancillary studies
194956|NCT02050906|Other|questionnaire administration|Ancillary studies
194957|NCT02050919|Drug|Epirubicin Hydrochloride|Given IV
194958|NCT02050919|Radiation|External Beam Radiation Therapy|Undergo EBRT
194959|NCT02050919|Drug|Ifosfamide|Given IV
194960|NCT02050919|Other|Laboratory Biomarker Analysis|Correlative studies
194961|NCT02053649|Behavioral|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
194962|NCT00124449|Drug|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
194963|NCT02053649|Other|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
194964|NCT02053662|Procedure|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
194965|NCT02053675|Drug|Vasopressin infusion|
194361|NCT02065739|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
194362|NCT02065752|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
194651|NCT02058342|Behavioral|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
194652|NCT02058355|Behavioral|Consequences List Feedback|
194653|NCT02058355|Behavioral|Personalized Normative Feedback|
194654|NCT02058368|Drug|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
194655|NCT02058368|Drug|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
194656|NCT02058368|Drug|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
194657|NCT02058368|Drug|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
194658|NCT02058381|Drug|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
194659|NCT02058381|Drug|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
194660|NCT02058394|Procedure|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
194661|NCT00000314|Drug|M-CPP|
194662|NCT00002195|Drug|Zidovudine|
194663|NCT00124930|Drug|Haldol|
194664|NCT02058407|Drug|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
194665|NCT02060708|Device|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
194666|NCT02060721|Drug|Macitentan|Macitentan 10mg, oral tablet, once daily
194046|NCT02073721|Other|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
194047|NCT00126542|Biological|bevacizumab|Given IV
194048|NCT02073721|Other|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
194049|NCT02073734|Drug|Dexamethasone|Dexamethasone 8mg/IV
194050|NCT02073734|Drug|Placebo|Placebo given IV
194051|NCT02073747|Drug|Normal Saline|One hour inhaled normal saline
194363|NCT02065752|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
194364|NCT02065752|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
194365|NCT02065752|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
194366|NCT00125814|Procedure|Structured treatment interruptions|
194367|NCT02065765|Biological|Ramucirumab|Administered intravenously (IV)
194368|NCT02065778|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
194369|NCT02065791|Drug|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
194370|NCT02065791|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily
194371|NCT02065804|Drug|Bupivacaine, Placebo|injection, once, 5 min
194372|NCT02065817|Other|stable isotope of cholesterol|
194373|NCT02065830|Device|EKSO|The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.
The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training.
194374|NCT02065843|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
194375|NCT02065843|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
194376|NCT02065843|Drug|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
189916|NCT01978756|Other|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
189917|NCT01978782|Drug|raltegravir|
189918|NCT01978782|Drug|citalopram|
189919|NCT01981395|Drug|Placebo|A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
189920|NCT01981408|Drug|[^14C]-LY2801653|Administered orally
189921|NCT01981434|Other|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. We will develop a game that incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
189922|NCT01981447|Drug|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
189923|NCT01981460|Procedure|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
189924|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
189925|NCT01981473|Other|no intervention|
189926|NCT01981473|Other|no intervention|
190236|NCT01973842|Drug|0.1 mg triptorelin|
190237|NCT01973842|Drug|0.2 mg triptorelin|
190238|NCT01973842|Drug|0.4 mg triptorelin|
190239|NCT01973855|Drug|Western Medicine|Physical cooling,Hydrocortisone
190240|NCT01973855|Drug|TCM and Western Medicine|Third Infectious diseases soup recipe
190241|NCT01973868|Drug|Regorafenib (Stivarga, BAY73-4506)|
190242|NCT00117429|Biological|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
190243|NCT01973868|Drug|Cetuximab (ERBITUX)|
189293|NCT00118625|Biological|Tree MATA MPL|
189586|NCT01986491|Drug|JNJ 39393406 30 mg solid X|Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
189587|NCT01986491|Drug|JNJ 39393406 30 mg solid Y|Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
189588|NCT01986491|Drug|JNJ 39393406 120 mg solid X|Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
189589|NCT01986491|Drug|JNJ 39393406 120 mg solid Y|Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
189590|NCT01986491|Drug|JNJ 39393406 30 mg solution|Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
189591|NCT01986517|Behavioral|No feedback|Therapists will receive no feedback.
189592|NCT01986517|Behavioral|Feedback after every fourth session|
189593|NCT01986530|Dietary Supplement|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
189594|NCT00118274|Biological|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
189595|NCT01986530|Other|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
189596|NCT01986543|Drug|drug administration|
189597|NCT01986556|Drug|Lesinurad 400 mg (Site 1)|
189598|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot A)|
189599|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot B)|
189600|NCT01986569|Drug|[18F]fluoroestradiol (FES)|[18F]FES PET/CT will be performed 90 min (± 10 min) after administration of [18F]FES. Patients will undergo core needle biopsy or surgery within 15 days after [18F]FES PET; or patients will undergo core needle biopsy within 30 days before [18F]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
189601|NCT01986582|Drug|Oxymetazoline|Intranasal application
189602|NCT01986582|Other|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
189603|NCT01986582|Other|Placebo (lactose powder)|Intranasal application
189604|NCT01989143|Drug|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
188985|NCT01958385|Behavioral|Diet and Exercise|A structured diet and exercise plan
188986|NCT01958398|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback.
188987|NCT01958398|Behavioral|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
188988|NCT01958437|Device|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
188989|NCT00115648|Drug|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
189294|NCT01953705|Drug|Omega 3 PUFA|fish oil concentrate standardized to long chain n-3 PUFA content
189295|NCT01953705|Drug|Placebo|
189296|NCT00115102|Drug|S-ketamine|
189297|NCT01953731|Drug|Palbociclib|In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
189298|NCT01953731|Drug|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
189299|NCT01953744|Drug|Fluconazole|Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
189300|NCT01953744|Drug|Meglumine Antimoniate|Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
189301|NCT01953757|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
189302|NCT01953757|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
189303|NCT01953770|Drug|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
189304|NCT01953770|Drug|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
189305|NCT01953770|Drug|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
198571|NCT02052375|Drug|ASP2408|subcutaneous injection
198572|NCT02052375|Drug|Placebo|subcutaneous injection
198573|NCT02052388|Drug|Daptomycin|Active Comparator
198574|NCT02052388|Drug|Brilacidin|Experimental Drug
198575|NCT02052401|Other|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
198576|NCT02052414|Drug|Gabapentin ER|Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.
In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits.
198577|NCT02052427|Device|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
198578|NCT02052427|Device|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (<1mL) of autologous blood
198579|NCT00124306|Drug|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
198580|NCT02052440|Drug|Baclofen|Treatment arm: baclofen 10mg tid
198581|NCT02052440|Drug|Placebo|Sugar pill by mouth three times daily
193806|NCT02047669|Behavioral|Reference|
193807|NCT02047682|Behavioral|Biopsychosocial|
193808|NCT02047682|Behavioral|Reference|
193809|NCT02047708|Drug|Zibotentan|Selective endothelin-A antagonist
193810|NCT00123864|Procedure|Intensity-modulated radiation therapy|
193811|NCT02047721|Behavioral|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
193812|NCT02047721|Behavioral|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by ~2000 kcal/week.
193813|NCT02047734|Drug|RPC1063 0.5 mg|oral capsule, daily for 24 months
193814|NCT02047734|Drug|RPC1063 1 mg|oral capsule, daily for 24 months
198265|NCT02057367|Drug|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
198266|NCT00124813|Drug|thalidomide|
198267|NCT02057380|Drug|linsitinib|oral
198268|NCT02057380|Drug|erlotinib|oral
198269|NCT02057380|Drug|paclitaxel|Intravenous (IV) infusion
198270|NCT02057380|Drug|Bortezomib|Subcutaneous or IV
198271|NCT02057380|Drug|Dexamethasone|IV, Oral
198272|NCT02057393|Drug|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
198273|NCT02057393|Drug|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
198274|NCT02059655|Drug|Bimatoprost|
198275|NCT02059655|Drug|Eye drop solution|Artificial tear drops
198276|NCT00002197|Drug|Abacavir sulfate|
198277|NCT00125099|Biological|VRC-HIVDNA009-00-VP|
198278|NCT02059668|Biological|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
198279|NCT02059681|Other|Autologous bone marrow derived-CD133+ cells|Cell therapy
198280|NCT02059694|Drug|Hyaluronidase|
198582|NCT02052479|Other|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
198583|NCT02052492|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
198584|NCT02052505|Procedure|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
198585|NCT02052518|Behavioral|Intervention|Intervention participants will receive behavioral counseling, will develop a Family Wellness Plan and will be linked to community resources.
198586|NCT02052531|Drug|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
197952|NCT02064842|Drug|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
197953|NCT02064842|Drug|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
197954|NCT02064842|Drug|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV [80 mg/mL strength]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
197955|NCT02064868|Drug|Serelaxin|30 µg/kg/day IV infusion
197956|NCT02064868|Drug|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, blockers and aldosterone receptor antagonists, etc.
197957|NCT00125671|Drug|Warfarin|
197958|NCT02064881|Drug|Metformin glycinate|
197959|NCT02064881|Drug|Metformin Hydrochloride|
197960|NCT02064894|Drug|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
197961|NCT02064894|Drug|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
197962|NCT02067260|Device|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
197963|NCT02067273|Device|Transcranial Magnetic Stimulation (TMS)|
197964|NCT02067299|Drug|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
197965|NCT02067299|Other|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
197966|NCT02067312|Other|Thai massage|
197967|NCT02067325|Other|Thai massage|
197968|NCT02067338|Drug|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
197969|NCT02067338|Drug|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
197970|NCT02067351|Behavioral|Mindfulness|Meditation, body scan, yoga.
197971|NCT00125970|Biological|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
197972|NCT02067364|Device|Fit & Function test|
197668|NCT02075099|Other|tensing exercises|Donors will do tensing exercises during blood donation
197669|NCT02075099|Other|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
197670|NCT02075112|Drug|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
197671|NCT02075112|Radiation|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
197672|NCT02075112|Drug|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
197673|NCT02075125|Drug|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
197674|NCT02075125|Drug|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
197675|NCT00126633|Drug|cisplatin|
197676|NCT02075151|Procedure|Bronchial Thermoplasty|Bronchial thermoplasty
197677|NCT02075164|Dietary Supplement|Fructose|High oral Fructose challenge (150g per day for 56 days)
197678|NCT02075164|Dietary Supplement|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
197973|NCT02067377|Dietary Supplement|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
197974|NCT02067377|Dietary Supplement|Placebo (for serum bovine immunoglobulin)|
197975|NCT02067403|Other|Pressure-support Eadi optimization|
197976|NCT02067416|Drug|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
197977|NCT02067416|Drug|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
197978|NCT02067429|Procedure|Limbal Relaxing Incisions|
197979|NCT02067429|Device|Toric Intraocular Lens|
197980|NCT02067442|Drug|oral acetaminophen|1000 milligrams given orally before surgery
197981|NCT02067442|Drug|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
197384|NCT02039284|Device|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
197385|NCT02039284|Device|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
197386|NCT02039284|Device|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
197387|NCT00123058|Device|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
197388|NCT02042053|Device|PET/CT|
197389|NCT02042053|Device|PET/MRI|
197390|NCT02042066|Device|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
197391|NCT02042079|Procedure|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
197392|NCT02042092|Device|Ultrasound|
197393|NCT00002184|Drug|Zidovudine|
197394|NCT00123318|Drug|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
197395|NCT02042092|Device|MRA|
197396|NCT02042118|Device|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
197397|NCT02042118|Device|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
197398|NCT02042131|Behavioral|Treatment As Usual (TAU)|
197399|NCT02042131|Behavioral|Crisis Response Plan (CRP)|
197679|NCT02075177|Drug|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
197680|NCT02075177|Drug|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
197085|NCT02046837|Behavioral|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
197086|NCT02046850|Drug|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
197087|NCT02046850|Drug|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
197088|NCT02046850|Drug|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
197089|NCT02046850|Drug|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
197090|NCT02046863|Device|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
197091|NCT02046876|Other|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
197092|NCT02046889|Behavioral|Bicycle Training Intervention|
197093|NCT02046915|Drug|Imnovid (pomalidomide)|
197094|NCT00123734|Drug|ThromboView|
197095|NCT02046915|Drug|Dexamethasone|
197096|NCT02046915|Drug|Endoxan (Cyclophosphamide)|
197097|NCT02046928|Drug|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
197098|NCT02046941|Behavioral|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
197099|NCT02046967|Procedure|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
197100|NCT02046967|Procedure|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
197101|NCT02048982|Behavioral|Guideline|Physicians will receive information on the Choosing Wisely Guideline
197102|NCT02048982|Behavioral|Cost|Physicians will receive cost information.
197103|NCT02048982|Behavioral|Victim|Physicians will receive information on an identifiable victim.
197104|NCT02048995|Other|Light Therapy|
197105|NCT00123994|Behavioral|Tai Chi classes|
196508|NCT02061527|Procedure|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
196509|NCT02061527|Procedure|Reconstruction with implant|Immediate breast reconstruction with implant
196510|NCT02061527|Procedure|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
196511|NCT02061527|Procedure|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
196512|NCT02061540|Drug|LUM001|
196794|NCT00124566|Drug|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
196795|NCT02054468|Drug|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
196796|NCT02054481|Drug|BI 655066|Medium dose
196797|NCT02054481|Drug|BI 655066|High dose
196798|NCT02054481|Drug|Ustekinumab|
196799|NCT02054481|Drug|BI 655066|Low dose
196800|NCT02054507|Behavioral|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
196801|NCT02054520|Drug|HyperAcute®-Melanoma (HAM) Immunotherapy|
196802|NCT02054520|Drug|Ipilimumab|
196803|NCT02054520|Drug|Pembrolizumab|
196804|NCT02054520|Drug|Nivolumab|
196805|NCT02056743|Dietary Supplement|Fermented-red ginseng|During 4~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
196806|NCT02056756|Drug|Carfilzomib|
196807|NCT02056769|Radiation|CT Perfusion|Quantitative CT Perfusion imaging
196182|NCT02069470|Behavioral|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
196183|NCT02069483|Behavioral|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
196184|NCT02069483|Behavioral|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
196185|NCT02069496|Biological|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
196186|NCT02069522|Other|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
196187|NCT02069522|Other|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
196188|NCT02069535|Biological|AVANZ Cupressus|AVANZ Cupressus
196189|NCT02069561|Dietary Supplement|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
196513|NCT02061553|Behavioral|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the translation of important life values into the planning of rewarding activities that support those values). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
196514|NCT02061553|Behavioral|Motivation|Control condition in which participants receive a single 2-hour session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements .
196515|NCT02061579|Behavioral|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
196516|NCT00125307|Drug|tacrolimus|
196517|NCT02061592|Device|etafilcon A|
196518|NCT02061592|Device|etafilcon A|
196519|NCT02061618|Behavioral|Bollywood Dance Exercise|
196520|NCT02061631|Drug|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
195855|NCT02072148|Procedure|PET/CT|PET scan or CT scan q 4 months for 5 years
195856|NCT02072148|Radiation|Radiotherapy|Postoperative XRT 5000 cGy
195857|NCT00126581|Drug|Erlotinib Hydrochloride|Given PO
195858|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
195859|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
195860|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
195861|NCT02074293|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
195862|NCT02074293|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
195863|NCT02074293|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
195864|NCT02074293|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
196190|NCT02069574|Procedure|non-surgical periodontal therapy|
196191|NCT00126178|Biological|HSPPC-96|
196192|NCT02069587|Dietary Supplement|pomegranate|
196193|NCT02069600|Device|Continuous Positive Airway Pressure|CPAP applies a positive pressure into the airway to avoid its collapse during sleep.
The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing
196194|NCT02069626|Procedure|compression time of the laparoscopic linear stapler|
196195|NCT02069639|Other|no treatment|
196196|NCT02069652|Behavioral|Lifestyle Counseling|Lifestyle Counseling
195557|NCT02038569|Drug|LEO 80185|
195558|NCT00122993|Behavioral|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
195559|NCT02038582|Other|POC CD4 Testing|Point of Care CD4 testing
195560|NCT02038582|Other|CD4 Referral|Referral to CD4 testing
195561|NCT02038582|Behavioral|Lay Counselor Follow-up|Follow-up from a lay counselor
195562|NCT02038582|Behavioral|Clinic Accompaniment|Accompaniment to the clinic by a counselor
195563|NCT02038582|Behavioral|Clinic Referral|Referral to clinic
195564|NCT02038582|Behavioral|SMS Reminder|SMS reminder for male circumcision
195565|NCT02038582|Behavioral|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
195566|NCT02038582|Other|POC VL|POC VL testing for HIV infected persons on ART
195567|NCT02038582|Other|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
195568|NCT02038595|Radiation|PET imaging|
195569|NCT00123006|Behavioral|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
195570|NCT02038608|Device|PET|
195571|NCT02038621|Drug|Paclitaxel|
195572|NCT02041078|Procedure|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
195573|NCT02041091|Drug|Tabalumab Auto-Injector|Administered SC
195574|NCT02041091|Drug|Tabalumab Prefilled Syringe|Administered SC
195575|NCT02041104|Dietary Supplement|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 8 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
195576|NCT02041104|Dietary Supplement|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 8 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
194966|NCT02053688|Device|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
194967|NCT02053688|Device|Toric Soft Contact Lenses|astigmatism correction using toric optics
194968|NCT02053714|Behavioral|Diabetes self-management and education|
194969|NCT02053727|Drug|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
194970|NCT02053727|Drug|Placebo|
195255|NCT02046226|Device|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
195256|NCT00123630|Drug|Placebo|Placebo given IV once every 2-4 weeks based on weight
195257|NCT02046239|Procedure|Suture Group|
195258|NCT02046239|Biological|Staple Group (control)|
195259|NCT02046252|Drug|Oral naltrexone|50 mg/day
195260|NCT02046252|Drug|Naltrexone implant|monthly
195261|NCT02046265|Behavioral|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
195262|NCT02046265|Behavioral|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
195263|NCT02046265|Behavioral|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
195264|NCT02046265|Behavioral|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
195265|NCT02046278|Device|LifeSeal™ Kit|
195266|NCT02046291|Drug|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
195267|NCT00123643|Drug|rosiglitazone|
195268|NCT02048332|Biological|Viral specific CTL Infusion|CTL's will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the following:
Blood adenovirus PCR ≥1,000
Blood CMV PCR ≥ 1,000
Blood EBV PCR ≥ 3,000
Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.
Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis
Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation.
194667|NCT02060734|Procedure|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
194668|NCT02060734|Other|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
194669|NCT02060747|Behavioral|Coordinator-based post fracture program|
194670|NCT02060786|Drug|generic clopidogrel (Plavitor® )|
194671|NCT00125216|Behavioral|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
194971|NCT02053740|Drug|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
194972|NCT02053740|Drug|Routine western medicine|
194973|NCT00124462|Device|Brace and Shoe Insert|Realigning Knee brace and custom orthodic
194974|NCT02053753|Drug|Drug Product CP4|Single dose denosumab 120 mg SC (1.7 mL injection of 70 mg/mL formulation)
194975|NCT02053753|Drug|Drug Product CP2|Single dose denosumab 120 mg SC (1.7 mL injection of 70 mg/mL formulation)
194976|NCT02053766|Drug|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
194977|NCT02053766|Drug|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
194978|NCT02053766|Drug|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
194979|NCT02053779|Drug|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
194980|NCT02053779|Drug|Placebo (1 ml Nacl 0.9% solution)|Placebo (1 ml Nacl 0.9% solution) administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
194981|NCT02053792|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
194982|NCT02053805|Procedure|PSA|PSA. Serum & plasma will be stored for future investigations
194983|NCT02053805|Other|IPSS questionnaire|the validated International Prostate Symptom Score
194984|NCT00124462|Device|Knee brace and shoe insert|Non realigning knee brace and flat orthodic
194985|NCT02053805|Procedure|DRE (Digital Rectal Examination )|
194377|NCT00125827|Drug|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
194378|NCT02065843|Drug|midazolam|15 mg/single dose/1 hour before dental surgery
194379|NCT02068573|Device|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
194380|NCT02068586|Drug|Sunitinib|Given PO
194381|NCT00126061|Drug|Tedisamil sesquifumarate|
194382|NCT02068586|Drug|Valproic Acid|Given PO
194383|NCT02068599|Drug|TV-45070|TV-45070 ointment 4% and 8%
194672|NCT02060786|Drug|original clopidogrel (Plavix® )|
194673|NCT02060812|Procedure|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
194674|NCT02060812|Procedure|Group II, SSNB alone|This is same as the Group I, SSNB & ANB, but ANB was performed with placebo(10mL normal saline).
194675|NCT02060825|Device|Regional saturation monitor|
194676|NCT02060838|Procedure|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
194677|NCT02060851|Drug|Iron sucrose|
194678|NCT02060851|Drug|EPO|
194679|NCT02060864|Dietary Supplement|AN-PEP|Two pills are consumed in the morning with a breakfast
194680|NCT02060864|Dietary Supplement|Placebo|
194681|NCT02060877|Other|observational study: use of patient questionnaires|
194682|NCT00125229|Drug|Mannitol|
194683|NCT02060890|Other|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
190244|NCT01973881|Procedure|T1 Weighted MRI (magnetic resonance imaging)|Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.
Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations.
190245|NCT01973894|Procedure|Blood and urine sampling|Blood and urine sampling will follow this schedule:
24h: blood (3ml)
48h: blood (3ml) and urine
End of infusion: blood (3ml)
6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.
Then all frozen samples will be analyzed to get Midazolam concentrations.
190246|NCT01973907|Other|Fluid Sparing Resuscitation Strategy|Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.
Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.
Intervention end: Patient is free from vasoactive medication support and shock is reversed.
190247|NCT01973920|Drug|Oshadi Icp|
190248|NCT01973933|Drug|Metformin and Pyrimethamine|
190249|NCT01976169|Drug|PD-0332991 and T-DM1|The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.
A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)
190250|NCT01976182|Drug|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
190251|NCT01976182|Drug|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
190252|NCT01976195|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
190556|NCT01968941|Radiation|Conventional Radiotherapy (CRT)|
190557|NCT01968954|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
190558|NCT01968954|Other|Placebo|subcutaneous injection, every 2 weeks for 12 months
190559|NCT01968967|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
190560|NCT01968967|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
189605|NCT01989143|Drug|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
189606|NCT01989156|Other|mTHS|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
189927|NCT01981473|Other|no intervention|
189928|NCT01981486|Drug|Placebo Tablets|BID modified-release tablets
189929|NCT01981486|Drug|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
189930|NCT01981499|Drug|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
189931|NCT01981499|Drug|Placebo|Placebo tablets
189932|NCT01981499|Drug|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
189933|NCT01981499|Drug|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
189934|NCT01981499|Drug|10 mg cetirizine|Single 10 mg dose of cetirizine
189935|NCT00117962|Biological|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
189936|NCT01981499|Drug|Placebo|Placebo tablets
189937|NCT01981525|Drug|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
189938|NCT01981551|Drug|PF-03084014|Treatment with the selective small-molecule & gt;=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
189939|NCT01981564|Behavioral|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
189940|NCT01981564|Behavioral|Asthma Express Control Arm|Asthma Express home nurse visits for asthma education
189941|NCT01981590|Device|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
189942|NCT01981603|Other|navigator|
189943|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
189306|NCT01953770|Drug|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
189307|NCT00115115|Drug|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
189308|NCT01953770|Drug|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
189309|NCT01953770|Drug|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
189310|NCT01953770|Radiation|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients >3 years of age
189311|NCT01953770|Drug|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
189607|NCT01989156|Other|SA|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
189608|NCT01989156|Other|mCC|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
189609|NCT01989169|Drug|Midazolam|
189610|NCT00118378|Drug|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
189611|NCT01989169|Drug|SSP-004184SS|
189612|NCT01989182|Device|Spiration Valve System|
189613|NCT01989182|Other|Medical Management|
189614|NCT01989195|Drug|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT
CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)
CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI
189615|NCT01989208|Other|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
189616|NCT01989221|Drug|Sancuso®|Drug: Placebo
189617|NCT01989234|Drug|YKP10811|
189618|NCT01989234|Drug|Placebo|
189619|NCT01989247|Behavioral|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
189620|NCT01989260|Device|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
193815|NCT02047734|Drug|RPC1063 placebo|oral capsule, daily for 24 months
193816|NCT02047734|Drug|Interferon β-1a|intramuscular injection, 30 µg, weekly for 24 months
193817|NCT02047734|Drug|IFN β-1a placebo|intramuscular injection, weekly for 24 months
193818|NCT02047747|Drug|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
193819|NCT02047773|Other|Duration|If bacterial load checked on day 7 is less than 10^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
193820|NCT02047773|Drug|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
193821|NCT00123877|Drug|GPX-100 (13-deoxydoxorubicin)|
193822|NCT02047773|Drug|Meropenem|
193823|NCT02047799|Dietary Supplement|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
193824|NCT02047799|Dietary Supplement|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
193825|NCT02047825|Other|Upper limbs intervention|An 8 weeks of an intensive intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises. It will take 40 minutes twice a week.
193826|NCT02047825|Other|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
193827|NCT02047838|Other|Anti-mullerian hormone (AMH) level dosage.|
194137|NCT02040571|Device|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
194138|NCT02040571|Device|Open Loop|The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.
In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.
Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants.
194139|NCT02043184|Behavioral|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
198587|NCT02052531|Other|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
198588|NCT02052557|Drug|Bupivacaine|30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
198589|NCT02054923|Behavioral|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
198590|NCT02054936|Drug|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
198591|NCT02054936|Drug|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
198592|NCT02054949|Drug|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
198593|NCT02054975|Drug|Vitamin D2 + vitamin D3|higher dose vitamin D
198594|NCT02054975|Drug|Vitamin D3|lower dose vitamin D
198595|NCT00124605|Drug|pamidronate disodium|Given IV
198596|NCT02054988|Other|caffeine|After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.
Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San Diego, California]) was measured at baseline and after 10-days of coffee intake.
198597|NCT02054988|Other|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
198598|NCT02055014|Drug|Liraglutide|
198599|NCT02055014|Device|Duodenal-jejunal bypass liner - Endobarrier device|
198600|NCT02055027|Other|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
198601|NCT02055040|Procedure|Cardiac Magnetic Resonance Scan|
198602|NCT02055053|Drug|0.5% Bupivicaine|Local anesthetic
193828|NCT02047838|Other|Follicle-stimulating hormone (FSH) level dosage.|
193829|NCT02047838|Other|Antral follicle count (AFC).|
193830|NCT02047851|Other|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
193831|NCT02047864|Dietary Supplement|Creatine monohydrate|
198281|NCT02059694|Other|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
198282|NCT02059707|Device|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
198283|NCT02059720|Procedure|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
198284|NCT02059733|Drug|18F-DTBZ|During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
198285|NCT02059746|Other|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
198286|NCT02059759|Drug|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
198287|NCT02059759|Drug|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
198288|NCT00125112|Behavioral|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
198289|NCT02059759|Drug|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
198290|NCT02059772|Drug|ranibizumab|
198291|NCT02059772|Procedure|micropulse diode laser|
198292|NCT02059785|Drug|Pinocembrin for Injection|
198293|NCT02059811|Other|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
198294|NCT02059811|Other|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
198295|NCT02062242|Other|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
198296|NCT02062242|Other|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
198297|NCT02062255|Drug|Aspirin|
197982|NCT00125970|Biological|VRC-HIVADV014-00-VP|1 x 10^10 PU administered in deltoid
197983|NCT02067455|Other|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
197984|NCT02067468|Device|HPV test|QIAGEN - The Digene HPV test®
197985|NCT02067468|Procedure|COLPOSCOPY|Colposcopy routine health services
197986|NCT02067468|Device|cytology|Cytology routine health services
197987|NCT02067481|Behavioral|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
197988|NCT00002204|Biological|HIV p24/MF59 Vaccine|
197989|NCT00126191|Drug|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
197990|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
197991|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
197992|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
197993|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
197994|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
197995|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
198300|NCT02062281|Biological|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
198301|NCT02062281|Biological|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
198302|NCT02062281|Biological|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
198303|NCT02062333|Drug|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
198304|NCT02062333|Drug|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
198305|NCT00125385|Biological|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
197681|NCT02075190|Other|Computerized intervention|
197682|NCT02075203|Biological|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK & a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 & saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
197683|NCT02075203|Drug|Placebo|Tris buffered saline (10mM Tris,pH 7.4, 150NM sodium chloride)
197684|NCT02075203|Biological|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
197685|NCT02075216|Procedure|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
197686|NCT00126633|Drug|gemcitabine hydrochloride|
197687|NCT02075216|Biological|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
197688|NCT02036879|Drug|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
197689|NCT02036892|Behavioral|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
197690|NCT02036892|Behavioral|Lifestyle counseling|Lifestyle counseling
197691|NCT02036905|Other|Cervical and thoracic mobilization|Described in arm description
197692|NCT02036905|Other|cervical and thoracic manipulation|described in arm description
197693|NCT02036918|Drug|Sipuleucel-T|
197694|NCT02036918|Procedure|Lymph Node Biopsy|
197695|NCT02036931|Device|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
197696|NCT00122850|Drug|venlafaxine|
197400|NCT02042131|Behavioral|Enhanced Crisis Response Plan (E-CRP)|
197401|NCT02042144|Drug|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
197402|NCT02042157|Device|Bidet|A bidet is a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
197403|NCT02042157|Other|Standard of care|Patients in the control arm will receive usual care.
197404|NCT02042170|Drug|human growth hormone self-injection|
197405|NCT00123318|Radiation|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
197406|NCT02042183|Drug|Lubiprostone|12 mcg or 24 mcg administered orally twice daily (BID)
197407|NCT02042183|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
197408|NCT02042196|Drug|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
197409|NCT02042196|Drug|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
197410|NCT02042196|Drug|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
197411|NCT02042196|Drug|Climara|0.075mg/d transdermal patch will be placed on skin.
197412|NCT02042196|Drug|Placebo transdermal patch|Inactive transdermal patch
197413|NCT02042222|Drug|Hydroxyurea|
197414|NCT02042235|Behavioral|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
197415|NCT02044393|Drug|itraconazole|multiple doses of itraconazole given as capsules
197416|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
197417|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
197418|NCT02044406|Drug|BI 1181181|single dose (low to high dose)
197419|NCT02044406|Drug|BI 1181181, R|powder for oral solution
197420|NCT02044406|Drug|BI 1181181, T2|tablet, fasted
196808|NCT02056782|Drug|PGX-ODSH-2013-AML-1|Eligible patients will receive idarubicin at 12 mg/m2 days 1-3 of induction plus a seven-day continuous infusion of cytarabine at 100 mg/m2/day days 1-7 of induction. For consolidation, patients younger than 60 will receive cytarabine at 3 grams/m2 over 3 hours every 12 hours days 1, 3, and 5 of the cycle. Patients over 60 will come off study following induction.
In induction, ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first idarubicin dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for 24 hours daily for seven consecutive days (days 1-7) for a total of 168 hours of continuous ODSH infusion.
In consolidation, ODSH will be administered as a 4 mg/kg bolus 30 minutes after completion of the first 3-hour infusion of cytarabine, followed immediately by a continuous ODSH intravenous infusion of 0.25 mg/kg/hour for 24 hours daily for five consecutive days (days 1-5) for a total of 120 hours of continuous ODSH infusion.
196809|NCT02056795|Device|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
197106|NCT02049008|Other|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
197107|NCT02049008|Other|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
197108|NCT02049021|Device|MECTA SPECTRUM 5000Q ECT|
197109|NCT02049021|Procedure|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
197110|NCT02049034|Other|Lixisenatide|Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.
Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days.
197111|NCT02049034|Other|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
197112|NCT02049047|Drug|Everolimus|Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
197113|NCT02049060|Drug|Tivantinib|•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
196521|NCT02061631|Drug|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
196522|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
196523|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
196524|NCT02061644|Other|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
196525|NCT02064049|Drug|Sofosbuvir and ribavirin|The treatment phase will commence in year 2. The exact drug combination and regimen to be used in the treatment intervention will be determined in year 1 once phase II and III data of sofosbuvir and ledipasvir and other potential interferon-free DAA regimens are published. The likely drug regimen will be either sofosbuvir (400mg daily) and ribavirin (1000-1200mg daily, weight-based) for 12 weeks, or sofosbuvir (400mg daily) and ledipasvir (90mg daily) in a once daily fixed dose combination for 8 or 12 weeks.
196526|NCT00125567|Drug|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
196527|NCT02064062|Biological|Autologous Mesenchymal Stem Cells|
196528|NCT02064075|Drug|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
196529|NCT02064075|Drug|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
196530|NCT02064088|Drug|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
196810|NCT02056795|Device|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
196811|NCT00124748|Drug|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
196812|NCT02056808|Drug|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
196813|NCT02056834|Device|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
196814|NCT02056847|Drug|Pitavastatin calcium 4mg|taking once a day
196815|NCT02056847|Drug|Pitavastatin calcium 2mg|Taking once a day
196816|NCT02056860|Procedure|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
196197|NCT02069665|Other|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
196198|NCT02069665|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
196199|NCT02069665|Drug|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
196200|NCT02069665|Drug|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
196201|NCT02069665|Drug|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
196202|NCT00126191|Drug|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
196203|NCT02072148|Radiation|Concurrent Chemoradiation|CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation
Postoperative XRT 5600 cGy
196204|NCT02072161|Drug|ETC-1002|ETC-1002 capsules, taken once daily oral
196205|NCT00126412|Drug|123I-mIBG (meta-iodobenzylguanidine)|
196206|NCT02072161|Drug|Placebo|Placebo capsules, taken once daily oral
196207|NCT02072161|Drug|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
196208|NCT02072174|Drug|Anaferon for children|Efficiency of tablet dosage form
196209|NCT02072174|Drug|Placebo|Efficiency of tablet dosage form
196210|NCT02072187|Dietary Supplement|Active|
196211|NCT02072187|Dietary Supplement|Placebo|
196531|NCT02064088|Drug|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
196532|NCT02064101|Procedure|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
196533|NCT02064114|Procedure|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
195577|NCT02041117|Drug|Rosuvastatin|Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
195578|NCT02041130|Device|Renal Denervation|
195865|NCT02074293|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
195866|NCT02074293|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
195867|NCT02074293|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
195868|NCT00126581|Other|Laboratory Biomarker Analysis|Correlative studies
195869|NCT02074306|Device|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
195870|NCT02074306|Device|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
195871|NCT02074319|Drug|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
195872|NCT02074332|Behavioral|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight&obese students Family physical activities Parent involvement
195873|NCT02074332|Behavioral|Health education|Knowledge of obesity prevention and control
195874|NCT02074345|Biological|TAK-816 0.5 mL|TAK-816 injection
195875|NCT02036203|Device|TCu380A IUD|T-shaped copper IUD
195876|NCT02036229|Drug|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
195877|NCT00122772|Radiation|Radiotherapy|External Beam Radiotherapy 46Gy in 23 daily fractions
High Dose Brachytherapy 4 fractions of 7Gy
195878|NCT02036242|Drug|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
195879|NCT02036242|Drug|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
195880|NCT02036242|Drug|Ropivacaine|
195269|NCT02048345|Drug|Suspension Fasted State|
195270|NCT02048345|Drug|Suspension Fed State|
195271|NCT02048345|Drug|Solution Fasted State|
195272|NCT02048345|Drug|Solution Fed State|
195273|NCT00123929|Drug|docetaxel|100 mg/m2 every 3 weeks times 4
195274|NCT02048358|Drug|2B3-201|
195275|NCT02048358|Drug|Placebo|
195276|NCT02048358|Drug|Methylprednisolone hemisuccinate|
195579|NCT00123240|Behavioral|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
195580|NCT02041143|Dietary Supplement|Milk protein|Study product will provide 25 g of protein to subjects.
195581|NCT02041143|Dietary Supplement|Placebo|Product with no protein
195582|NCT02041156|Other|aerobic and resistance training|
195583|NCT02041156|Other|aerobic combined with balance training|
195584|NCT02041169|Other|Subsequent walking performance|Subsequent walking performance
195585|NCT02041182|Behavioral|Pre-Visit Questionnaire|
195586|NCT02041195|Drug|RM-493|
195587|NCT02041195|Drug|Placebo|
195588|NCT02041208|Procedure|kidney transplantation|kidney transplantation
195589|NCT02041221|Drug|S0597|The subjects will receive S0597.
195590|NCT00002184|Drug|Stavudine|
195591|NCT00123253|Drug|TH9507|
195592|NCT02041221|Drug|Placebo|
195593|NCT02041234|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
195594|NCT02041234|Drug|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily If unable to take incretin analogues: Januvia up to 100 mg daily
194986|NCT02053805|Procedure|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
194987|NCT02056015|Drug|[68Ga]MLN6907|IV Administration of [68Ga]MLN6907 on Day 1
194988|NCT02056028|Procedure|Hepatic resection|
194989|NCT02056041|Procedure|Hepatectomy|
194990|NCT02056054|Other|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
194991|NCT02056054|Other|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
195277|NCT02048371|Drug|Regorafenib|
195278|NCT02048371|Drug|Placebo|
195279|NCT02048384|Drug|metformin alone (Arm A)|metformin alone
195280|NCT02048384|Drug|metformin (Arm B)|rapamycin + metformin
195281|NCT02048384|Drug|rapamycin (Arm B)|rapamycin + metformin
195282|NCT02048397|Other|Pulmonary Rehabilitation|
195283|NCT02048397|Dietary Supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
195284|NCT00123929|Drug|doxorubicin|75 mg/m2 every 3 weeks times 4
195285|NCT02048410|Dietary Supplement|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
195286|NCT02048410|Other|low satured diet|
195287|NCT02048423|Drug|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
195288|NCT02048475|Other|desflurane|changing concentration
195289|NCT02048488|Drug|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
195290|NCT02048501|Other|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
190864|NCT01964261|Device|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 2 NeuroPort Arrays (Pt) and 1 NeuroPort Array (SIROF). Each Pt array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface. The SIROF Array is similar to the Pt Array, the only difference is a change in the tip of the electrodes from platinum to sputtered iridium oxide film (SIROF).
190865|NCT01964287|Drug|GEMBRAX|
190866|NCT01964287|Drug|FOLFIRINOX|
190867|NCT01964300|Biological|peginterferon alfa-2b|Given SC
190868|NCT01964300|Other|laboratory biomarker analysis|Correlative studies
191190|NCT01959334|Drug|Glucagon IM|1 mg of glucagon solution intramuscularly 3 doses separated by at least 7 days
191191|NCT01959347|Procedure|Miduretheral Sling|
191192|NCT01959347|Other|Miduretheral Sling combined with peri-operative behavioral/pelvic floor therapy|
191193|NCT01959360|Procedure|Direct lateral|Total hip replacement; direct lateral approach
191194|NCT01959360|Procedure|minimal invasive|Total hip replacement; minimal invasive approach
191195|NCT01959360|Procedure|modified minimal invasive|Total hip replacement; modified minimal invasive approach
191196|NCT01959373|Procedure|electroencephalograms (EEG)|
191197|NCT01959373|Procedure|electro-myography (EMG)|
191198|NCT00115739|Drug|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
191199|NCT01959399|Drug|ASP015K|oral tablet
191200|NCT01959399|Drug|Rosuvastatin|oral tablet
191201|NCT01959412|Drug|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
191202|NCT01959412|Drug|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
191203|NCT01959412|Drug|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
191204|NCT01959412|Drug|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
190561|NCT01968980|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
190562|NCT01968980|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
190563|NCT00116857|Drug|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
190564|NCT01968993|Device|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
190565|NCT01969006|Drug|Marcaine ½%|
190566|NCT01969006|Procedure|Needle prick|
190567|NCT01969019|Drug|methylprednisolone, prednisone|
190568|NCT01969032|Drug|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
190569|NCT00117182|Drug|Ipratropium bromide 80mcg|
190570|NCT01971424|Other|healthy diet|
190571|NCT01971437|Procedure|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
190572|NCT01971450|Drug|Iloprost (Ventavis, BAYQ6256)|
190573|NCT01971463|Other|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
190574|NCT01971476|Drug|volasertib|intravenous administration on day 1of a treatment course
190575|NCT01971489|Drug|Buparlisib|Given PO
190576|NCT01971489|Drug|Cisplatin|Given IV
190577|NCT01971489|Drug|Gemcitabine Hydrochloride|Given IV
190578|NCT01971489|Other|Laboratory Biomarker Analysis|Correlative studies
190579|NCT01971489|Other|Pharmacological Study|Correlative studies
190869|NCT01964326|Drug|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
190870|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
189944|NCT00118157|Other|Laboratory Biomarker Analysis|Correlative studies
189945|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
189946|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
189947|NCT01984086|Drug|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
190253|NCT01976195|Drug|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
190254|NCT00117598|Drug|Investigator's choice|Any of the following single agent treatments:
Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.
Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days
Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days
Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days
Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,
Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days
Prednisone 40 (20-60) mg/m2 PO daily or every other day
Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day
190255|NCT01976208|Drug|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg~750mg，then dosing interval is every 2 weeks.
190256|NCT01976208|Drug|placebo|
190257|NCT01976221|Behavioral|Prioritization|team-based multifaceted case-based interactive training program in priority setting and waiting time decision
190258|NCT01976234|Other|Fresh RBC|Patients will receive fresh blood only
190259|NCT01976234|Other|Old RBC|
190260|NCT01976247|Device|High Intensity Focused Ultrasound Device|
190261|NCT01976247|Device|Noninvasive Cryolipolysis Device|
190262|NCT01976260|Device|Fractional Radiofrequency|
190263|NCT01976260|Device|1550-nm Fractional Photothermolysis|
190264|NCT01976273|Device|1064nm Q-switch Laser|
190265|NCT00117611|Drug|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
190266|NCT01976273|Other|Glycolic Acid Peels|
190267|NCT01976286|Other|Salicylic Acid Peels|
189621|NCT00118378|Drug|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
189622|NCT01989273|Device|Ultrasound of inferior vena cava|
189623|NCT01989286|Other|Assessment|The posture, motor development and balance are going to be assessed.
189624|NCT01989299|Device|ILR implantation|
189625|NCT01989312|Procedure|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
189626|NCT01989312|Procedure|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
189627|NCT01989312|Device|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
189628|NCT01989312|Device|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
189629|NCT01989312|Drug|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
189948|NCT01984086|Drug|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
189949|NCT01984099|Drug|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
189950|NCT01984099|Drug|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
189951|NCT01984112|Device|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
189952|NCT01984112|Device|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
189953|NCT01984125|Other|Point-of-Care Prompt|
189954|NCT01984138|Drug|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
189955|NCT00118157|Drug|Lapatinib Ditosylate|Given PO
189956|NCT01984138|Drug|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
189957|NCT01984164|Drug|Candesartan|blinded
194140|NCT02043210|Behavioral|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
194141|NCT02043210|Behavioral|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
194142|NCT02043223|Dietary Supplement|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
194143|NCT02043223|Dietary Supplement|Vitamin A (6 wk postpartum)|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
194144|NCT02043223|Dietary Supplement|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
194145|NCT02043223|Dietary Supplement|Placebo|Placebo supplementation, both at <3-day and 6-wk postpartum.
194146|NCT02043236|Behavioral|Healthy bones pamphlet|written educational material
194147|NCT02043236|Behavioral|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
194148|NCT02043236|Behavioral|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
194149|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
194150|NCT02043249|Other|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
194151|NCT02043262|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
194152|NCT02043262|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
194470|NCT02035657|Biological|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
194471|NCT02035670|Other|Two-step diagnostic strategy|The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.
The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive.
193832|NCT00124072|Drug|Placebo|Placebo vitamin B12/folic acid tablet once daily
193833|NCT02050165|Dietary Supplement|Typical American Snack|Consumption of typical American snacks for 12 weeks
193834|NCT02050178|Drug|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
193835|NCT02050191|Behavioral|www.princetonlivingwell.com|
193836|NCT02050204|Behavioral|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
193837|NCT02050217|Procedure|Neurally Adjusted Ventilatory Assist|
193838|NCT02050230|Biological|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
193839|NCT02050243|Drug|5ALA|20mg/kg of oral suspension of 5ALA
193840|NCT02050256|Other|continuing medical education and electronic decision support|
193841|NCT02050256|Other|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
193842|NCT02050269|Drug|Iohexol|Iohexol, 300 mg/mL
193843|NCT00124085|Behavioral|Disease Management|
193844|NCT02050282|Other|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
193845|NCT02050295|Procedure|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
193846|NCT02050295|Procedure|Sham washout|Infusion of saline to maintain catheter patency.
193847|NCT02050295|Drug|Saline|
194153|NCT02043275|Other|Leg training|Lower body resistance training twice per week for one hour each time.
194154|NCT02043275|Other|Arm training|Upper body resistance training twice per week for one hour each time.
194155|NCT02043288|Drug|NC-6004|Study group (3 week/cycle):
NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1
198298|NCT02062255|Dietary Supplement|Omega 3 FFA|
198299|NCT02062268|Behavioral|health education & law enforcement|
198603|NCT02055066|Drug|ARGX-111|
198604|NCT02055079|Drug|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
198605|NCT02055079|Drug|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
198606|NCT00124605|Drug|arsenic trioxide|Given IV
198607|NCT02055105|Procedure|miRNA in Sepsis|miRNA in Sepsis
198608|NCT02055118|Biological|idursulfase-IT|10mg
198609|NCT02055118|Other|No IT treatment|Standard of Care
198610|NCT02055131|Drug|aspirin|
198611|NCT02055157|Drug|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
198612|NCT02055170|Drug|finasteride 5mg PO OD|
198613|NCT02055196|Biological|carboxylesterase-expressing allogeneic neural stem cells|Given via intracerebral catheter
198614|NCT02055196|Drug|irinotecan hydrochloride|Given IV
198615|NCT02055196|Other|laboratory biomarker analysis|Correlative studies
198616|NCT02057393|Drug|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
198617|NCT02057406|Drug|400/200 EPA/DHA fish oil 2 grams|
198618|NCT02057406|Drug|An almost pure EPA 2 grams|
198619|NCT00124813|Drug|idarubicin|oral idarubicin
198620|NCT02057406|Other|Matched placebo corn oil capsules|
198621|NCT02057432|Device|intra-operative MRI|
198622|NCT02057445|Drug|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
198306|NCT02062346|Drug|BQ123 or BQ123/788|
198307|NCT02062359|Biological|Anti-NY ESO-1 TCR CD62L+ cells|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 TCR CD62L+ cells and high dose aldesleukin.
On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
198308|NCT02062359|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
198309|NCT02062359|Drug|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
198310|NCT02062359|Drug|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
198311|NCT02062372|Device|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
198312|NCT02062372|Procedure|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
198313|NCT02062385|Biological|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
198314|NCT02062385|Biological|Placebo to V260|Placebo control
198315|NCT02062385|Biological|OPV|Oral poliovirus vaccine administered according to the standard of care
198316|NCT00125398|Drug|AQUAVAN (fospropofol disodium; GPI 15715 )|
198317|NCT02062385|Biological|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
198318|NCT02064894|Drug|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
198319|NCT02064907|Drug|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
198627|NCT02057471|Drug|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
198628|NCT02057484|Drug|Advagraf|oral
198629|NCT02057523|Drug|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
198630|NCT00124826|Drug|Insulin|
197996|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
197997|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
197998|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
197999|NCT02070302|Drug|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
198000|NCT00126191|Drug|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
198001|NCT02070302|Drug|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
198002|NCT02070328|Other|Registry|
198003|NCT02070341|Drug|Polyethylene Glycol|
198004|NCT02070341|Drug|Picosalax|
198005|NCT02070367|Other|Somatosensory rehabilitation|
198006|NCT02070367|Other|Usual treatment: physiotherapy|
198007|NCT02070380|Drug|Gadobenate|
198008|NCT02070380|Drug|Gadoterate|
198009|NCT02070393|Radiation|Proton|14-24 Radiation treatments using Protons
198010|NCT02070406|Drug|cyclophosphamide|Given IV
198011|NCT00126191|Drug|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
198012|NCT02070406|Drug|fludarabine phosphate|Given IV
198013|NCT02070406|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
198014|NCT02070406|Biological|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
198015|NCT02070406|Biological|aldesleukin|Given SC
198016|NCT02070406|Radiation|fludeoxyglucose F 18|Correlative studies
198017|NCT02070406|Procedure|positron emission tomography|Correlative studies
198018|NCT02070406|Other|laboratory biomarker analysis|Correlative studies
197421|NCT02044406|Drug|Placebo to BI 1181181|Placebo to BI 1181181
197422|NCT00123500|Behavioral|Diet|Diet
197697|NCT02036931|Drug|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
197698|NCT02036931|Device|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
197699|NCT02036957|Procedure|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
197700|NCT02036957|Procedure|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
197701|NCT02036970|Drug|Bardoxolone methyl|
197702|NCT02036970|Drug|Placebo|
197703|NCT02036983|Procedure|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
197704|NCT02036983|Procedure|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
197705|NCT02036983|Procedure|Opioid IV medications (Control)|Standard anesthetic technique.
197706|NCT02037009|Other|Health care organization (anesthetic surveillance)|
197707|NCT00122850|Drug|placebo|
197708|NCT02037022|Behavioral|Pivotal Response Treatment Package (PRT-P)|
197709|NCT02037035|Drug|Ketamine|
197710|NCT02037048|Drug|oxaliplatin|Given IV
197711|NCT02037048|Drug|leucovorin calcium|Given IV
197712|NCT02037048|Drug|fluorouracil|Given IV
197713|NCT02037048|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
197714|NCT02037048|Radiation|radiation therapy|Undergo radiation therapy
197114|NCT02049073|Drug|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
197115|NCT02049073|Drug|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
197116|NCT00123994|Behavioral|Hydrotherapy classes|
197117|NCT02049086|Behavioral|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
197118|NCT02049086|Behavioral|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
197119|NCT02049112|Device|Salivary equivalent|14-day treatment with salivary equivalent sticks
197120|NCT02049112|Device|Aequasyal|14-day treatment with Aequasyal oral spray
197121|NCT02049112|Device|Biotene|14-day treatment with Biotene oral spray
197122|NCT02051725|Other|Active life-style intervention|
197423|NCT02044406|Drug|BI 1181181, T1|tablet, fed
197424|NCT02044419|Drug|lomitapide|
197425|NCT02044432|Other|ginger compress|Kidney ginger compress
197426|NCT02044445|Procedure|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
197427|NCT02044458|Device|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
197428|NCT02044471|Other|Remote Ischemic Conditioning (using Sphygmomanometer)|Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.
Patient in control group will not perform this.
197429|NCT02044484|Behavioral|Multi-component intervention|The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.
Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.
The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.
At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex.
197430|NCT02044497|Drug|oral oxycodone|
197431|NCT02044510|Drug|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
197432|NCT02044510|Drug|Placebo|Matched placebo capsules to the intervention arm
196817|NCT02056860|Procedure|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
196818|NCT02056860|Procedure|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
196819|NCT02056860|Procedure|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
196820|NCT02056860|Procedure|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
196821|NCT02059200|Behavioral|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
196822|NCT02059213|Drug|PD 0332991|
196823|NCT02059213|Drug|Bicalutamide|
196824|NCT02059213|Drug|Zoladex|
196825|NCT00125021|Drug|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
196826|NCT02059213|Drug|Lupron Depot|
196827|NCT02059226|Behavioral|cognitive behavioural therapy|Internet-based CBT
196828|NCT02059226|Other|Internet-based resource page|Static webpage
197123|NCT02051738|Drug|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
197124|NCT02051738|Drug|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
197125|NCT02051751|Drug|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
197126|NCT02051751|Drug|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
197127|NCT02051764|Drug|18F-AV-1451|
197128|NCT02051764|Drug|Florbetapir F 18|
196534|NCT02064114|Procedure|control group|Followed for a period of 3,6 and 12 months after the procedure.
196535|NCT02064140|Drug|Rocuronium|
196536|NCT02064153|Procedure|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
196537|NCT00125580|Behavioral|Infant sleep instruction|
196538|NCT02064153|Procedure|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
196539|NCT02064166|Drug|Intranasal Insulin|treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;
placebo arm: normal saline, daily, intranasally, for 4 weeks.
196540|NCT02064205|Dietary Supplement|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
196541|NCT02064205|Dietary Supplement|glucose syrup|Glucose syrup is used a control product for the polydextrose
196542|NCT02064218|Drug|Anti-hypertensive drugs|
196543|NCT02064231|Device|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
196544|NCT02064231|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
196545|NCT02064231|Device|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
196546|NCT02064231|Device|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
196547|NCT02066792|Drug|Placebo|Sugar pill
196548|NCT02066792|Behavioral|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
196829|NCT02059239|Drug|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
196830|NCT02059239|Drug|Carmustine|300 mg/m2 on Day -6
196831|NCT02059239|Drug|Etoposide|100 mg/m2 on days -5 to -2
195881|NCT02036255|Drug|Taurolidine Urokinase|
195882|NCT02036255|Drug|Taurolidine Heparin|
195883|NCT02036268|Behavioral|Standard|Standard ostomy education
195884|NCT02036268|Behavioral|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
196212|NCT02072200|Drug|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
196213|NCT02072213|Drug|GL2702 GLARS-NF1|0.4mg once a day
196214|NCT02072213|Drug|Omix Ocas|0.4mg once a day
196215|NCT02072226|Drug|alteplase [Activase]|single intravenous dose of 0.9 mg/kg with a maximal dose of 90mg
196216|NCT00126425|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single dose
196217|NCT02072226|Drug|alteplase placebo|single intravenous dose
196218|NCT02072226|Drug|aspirin|325 mg oral dose
196219|NCT02072226|Drug|aspirin placebo|Single oral dose
196220|NCT02072239|Device|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
196221|NCT02072252|Behavioral|App teaching cognitive behavioral skills|
196222|NCT02072265|Device|Infrared thermal images|
196223|NCT02072278|Drug|Vortioxetine 10 mg|
196224|NCT02072278|Drug|Vortioxetine 20 mg|
196225|NCT02072278|Drug|Escitalopram 15 mg|
196226|NCT02072278|Drug|Placebo|
196227|NCT00126438|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
196228|NCT02072291|Drug|Nifedipine|PO Nifedipine 5mg single dose
196229|NCT02072304|Behavioral|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
195595|NCT02041234|Drug|Xenical|Xenical: Up to 120 mg tds
195596|NCT02041247|Biological|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
195597|NCT02041260|Drug|Cabozantinib|
195598|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
195599|NCT02043626|Other|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
195885|NCT02036268|Behavioral|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
195886|NCT02036281|Drug|Substance P-Saporin|
195887|NCT02036294|Other|Patient and Family-Centered Transitional Care Intervention|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
195888|NCT00122772|Radiation|Radiotherapy/Cisplatin|External Beam Radiation 46Gy in 23 daily fractions
High Dose Brachytherapy 2 fractions of 9Gy
Cisplatin 40 mg/sqm weekly
195889|NCT02036294|Other|Usual Care|Standard Healthcare Services
195890|NCT02036307|Dietary Supplement|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
195891|NCT02036307|Dietary Supplement|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
195892|NCT02036320|Device|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
195893|NCT02036346|Dietary Supplement|Oral Rehydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium gluconate and water.
195894|NCT02036346|Other|Advise on calculated oral fluid requirements|
195895|NCT02036346|Other|No nutritional advice will be given|
195896|NCT02036359|Drug|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
195897|NCT02036359|Drug|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
195898|NCT02036372|Drug|Liraglutide|
195291|NCT02048501|Other|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
195292|NCT02048501|Other|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
195293|NCT00124124|Drug|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
195294|NCT02050919|Drug|Sorafenib Tosylate|Given PO
195295|NCT02050919|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
195296|NCT02050932|Dietary Supplement|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
195600|NCT02043626|Other|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
195601|NCT02043626|Other|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
195602|NCT02043626|Other|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
195603|NCT02043652|Drug|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
195604|NCT02043652|Drug|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
191205|NCT01959412|Drug|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
191206|NCT01962012|Device|AcceleDent Aura|
191207|NCT01962012|Device|Sham Device|
191208|NCT01962025|Procedure|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
191209|NCT01962038|Behavioral|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
191210|NCT01962038|Behavioral|Stretching Exercises|Gym and home based stretching exercises
191211|NCT01962038|Behavioral|Cognitive Training|Group-based cognitive training
191212|NCT01962051|Device|Amplatzer Cardiac Plug|
191213|NCT01962064|Behavioral|Cognitive assessment|
191214|NCT01962064|Other|Brain imaging examination MRI|
191515|NCT01954524|Drug|IV bolus injection of Sildenafil|Dose escalation will be performed (in different participants). The doses will be as follows:
CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
191516|NCT01954550|Behavioral|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
191517|NCT01954550|Behavioral|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
191518|NCT01954563|Biological|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
191519|NCT01954576|Procedure|electric field therapy|Undergo NovoTTF therapy
191520|NCT01954576|Procedure|quality-of-life assessment|Ancillary studies
191521|NCT01954576|Genetic|laboratory biomarker analysis|Correlative study
191522|NCT01954589|Drug|ACT-462206 5 mg|
191523|NCT01954589|Drug|ACT-462206 25 mg|
191524|NCT00115245|Drug|Adefovir Dipivoxil|
191525|NCT01954589|Drug|ACT-462206 100mg|
190871|NCT00116311|Procedure|sputum induction|
190872|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
190873|NCT01964352|Drug|tiotropium|fixed dose combination
190874|NCT01964352|Drug|placebo|
190875|NCT01964352|Drug|olodaterol|fixed dose combination
190876|NCT01964352|Drug|tiotropium|fixed dose combination
190877|NCT01964352|Drug|tiotropium|
190878|NCT01964352|Drug|olodaterol|fixed dose combination
190879|NCT01964365|Drug|Cresto 20mg|tablet, rosuvastatin 20mg
190880|NCT01964365|Drug|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
190881|NCT01964365|Drug|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
190882|NCT00116324|Drug|Montelukast|
190883|NCT01964378|Drug|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
190884|NCT01964378|Drug|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
190885|NCT01964391|Drug|carboplatin|in combination with Herceptin and docetaxel in the adjuvant setting
190886|NCT01964391|Drug|chemotherapy|neo-adjuvant chemotherapy according to local guidelines in combination with Herceptin in the neo-adjuvant setting
190887|NCT01964391|Drug|docetaxel|in combination with Herceptin in the adjuvant setting
190888|NCT01964391|Drug|paclitaxel|in combination with Herceptin in the adjuvant setting
190889|NCT01966523|Behavioral|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
191215|NCT00116025|Drug|Human acylated ghrelin|
190268|NCT01976286|Other|Glycolic Acid Peels|
190269|NCT01976299|Device|AVERT|
190270|NCT01976312|Other|Sham injection|Sham intravitreal injection
190271|NCT01976312|Drug|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
190272|NCT01978795|Other|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
190580|NCT00117182|Drug|Salbutamol 400mcg|
190581|NCT01971489|Other|Questionnaire Administration|Ancillary studies
190582|NCT01971502|Drug|Placebo to BI 1060469|single rising doses
190583|NCT01971502|Drug|BI 1060469|food effect
190584|NCT01971502|Drug|BI 1060469|single rising doses
190585|NCT01971515|Drug|MSC2363318A|MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached.
190586|NCT01971528|Device|Electronic muscle stimulator|Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
190587|NCT01971528|Other|Muscle strength training|Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
190588|NCT01971541|Behavioral|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
190589|NCT01971541|Behavioral|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
190590|NCT01971554|Drug|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
190591|NCT00117195|Device|Automated Neuropsychological Assessment Matrix|This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.
In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome.
190592|NCT01971554|Drug|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
189958|NCT01984164|Drug|Lisinopril|Blinded
189959|NCT01984177|Drug|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. ~15 minutes after Corticorelin/saline injection, [11C]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure ([11C]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
189960|NCT01984203|Other|Low Load Exercises|All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).
The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition).
189961|NCT01984203|Other|Progressive Heavy Strength Exercises|All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).
The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.
Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)
The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition).
189962|NCT01984216|Procedure|Roux-en-Y for the gastrojejunostomy reconstruction|
189963|NCT01986608|Drug|Lacosamide infusion|Strength: 10 mg/mL for infusion
Form: solution for infusion
Dosage: 200 mg, single dose
Duration: 30-minute infusion or 60-minute infusion
189964|NCT00118274|Biological|tetanus toxoid helper peptide|Given intradermally and subcutaneously
190273|NCT01978795|Other|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
190274|NCT01978821|Procedure|Autologous bone marrow mononuclear cell transplantation|
190275|NCT00117793|Device|Vacuum assisted socket system|Novel socket system
190276|NCT01978860|Device|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
190277|NCT01978873|Drug|Arm A: Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.|
190278|NCT01978873|Drug|Arm B: LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.|
190279|NCT01978899|Behavioral|Immediate Weight Loss Program Group|
190280|NCT01978899|Behavioral|Delayed Weight Loss Program Group|
190281|NCT01978912|Drug|KTP-001|KTP-001 is one time dose intradiscally.
194472|NCT02035683|Procedure|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
194473|NCT02035696|Biological|Trivalent influenza vaccine (TIVc)|
194474|NCT02035696|Biological|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
194475|NCT02035709|Drug|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
194476|NCT02035722|Behavioral|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
194477|NCT02037893|Drug|Benzocaine Otic Solution|
194478|NCT02037893|Drug|Placebo Otic solution|
194479|NCT02037906|Radiation|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
194480|NCT02037906|Radiation|Constant Energy SWL|Constant dose at 20 kv
194481|NCT02037906|Radiation|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
194482|NCT02037919|Other|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
194483|NCT02037919|Other|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
194484|NCT02037932|Device|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
194485|NCT00122954|Drug|Fish oil concentrate|fish oil concentrate (triglyceride form) at a daily dose of 6 grams (1.95 grams of EPA and 1.45 grams of DHA).
194486|NCT02037945|Procedure|18F-FCH PET Scan|
194487|NCT02037958|Device|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
194488|NCT02037958|Device|Endotracheal Tube|Patients who receive endotracheal intubation
194780|NCT02071524|Drug|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
194781|NCT02071524|Drug|Cristalloid administration|Only Ringer Lactate administration
194782|NCT02071537|Drug|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
194156|NCT02043288|Drug|Gemcitabine|Study group (3 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)
Control group (4 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15
194157|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
194158|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
194159|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
194160|NCT02045732|Biological|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
194161|NCT02045732|Biological|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
194162|NCT00123578|Drug|Lorazepam|Lorazepam
194163|NCT02045745|Genetic|Implantation of autologous mesenchymal stem cells (CSM) expanded "in vitro" and administered directly into the lung suture line|
194164|NCT02045758|Device|Fingerstick|
194165|NCT02045758|Device|TAP20-C|
194166|NCT02045771|Behavioral|Behavioral Activation|Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce "antidepressant behaviour" (Martell, Dimidjian et al. 2010).
194167|NCT02045771|Behavioral|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
194168|NCT02045784|Dietary Supplement|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
194169|NCT02045784|Other|Breast milk|Unlimited breast feeding
194170|NCT02045797|Drug|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
194171|NCT02045797|Drug|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
198623|NCT02057445|Other|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
198624|NCT02057458|Drug|Acute (1 hour) Sildenafil|Exercise capacity and vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
198625|NCT02057458|Drug|Sub-Chronic (4 weeks) Sildenafil|Exercise capacity and vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
198626|NCT02057458|Drug|Placebo|Sugar pill designed to mimic the sildenafil treatment
193848|NCT02050308|Other|Internet-All Nations Breath of Life (I-ANBL)|Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session
Weekly procedures will follow the same format as for the first session
193849|NCT02050308|Other|Honoring the Gift of Heart Health|These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the "how-to" for leading group education sessions. It offers "hands-on" activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities.
193850|NCT02053090|Behavioral|Group Education and Stretching|
193851|NCT02053090|Procedure|Group Acupuncture|
193852|NCT00002192|Drug|Azithromycin|
193853|NCT00124384|Behavioral|CBT-I|
193854|NCT02053103|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
193855|NCT02053103|Drug|Placebo|Tablet, 0 mg, twice daily, 6 weeks
193856|NCT02053116|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
193857|NCT02053116|Drug|Placebo|Tablet, 0 mg, twice daily, 2 weeks
193858|NCT02053129|Other|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
193859|NCT02053129|Other|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
193860|NCT02053142|Drug|Acyclovir|Single dose of acyclovir 200mg was given for pk study
198631|NCT02057536|Other|Arm A Directed exercise program|
198632|NCT02057536|Other|Observation|
198633|NCT02057549|Drug|Haloperidol|adding haloperidol to conventional therapy
198634|NCT02057575|Drug|PG324 Ophthalmic Solution 0.01%|1 drop daily (evening)
198635|NCT02057575|Drug|PG324 Ophthalmic Solution 0.02%|1 drop daily (evening)
198636|NCT02057575|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily (evening)
198637|NCT02057575|Drug|Latanoprost Ophthalmic Solution|1 drop daily (evening)
198638|NCT02057588|Procedure|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
198639|NCT02057601|Drug|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
198640|NCT02057627|Behavioral|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
198641|NCT02059824|Device|Aesthesiometer|The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.
If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period.
198642|NCT02059837|Procedure|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
198643|NCT02059850|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
198644|NCT02059850|Drug|Cyclophosphamide|Given IV
198645|NCT00125125|Drug|Fluvastatin|
198646|NCT02059850|Other|Laboratory Biomarker Analysis|Correlative studies
193867|NCT02053207|Behavioral|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
193868|NCT02053220|Biological|Colo-Ad1|Oncolytic virus
198019|NCT02072993|Drug|AZD1979|Single dose, oral solution administration
198020|NCT02072993|Drug|Placebo to match|Single dose, oral solution administration
198320|NCT02064907|Drug|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
198321|NCT02064920|Drug|Placebo|Placebo for donepezil hydrochloride capsule
198322|NCT02064920|Drug|Donepezil|5 mg donepezil hydrochloride capsule.
198323|NCT02064920|Drug|Donepezil|10 mg donepezil hydrochloride capsule.
198324|NCT00125684|Drug|morphine|
198325|NCT02064946|Dietary Supplement|vitamin D|50,000IU/week of vitamin D3
198326|NCT02064946|Dietary Supplement|Placebo|
198327|NCT02064959|Other|Hypothermia|rapid induction of hypothermia to 35°C followed by maintenance at 33°C
198328|NCT02064972|Other|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
198329|NCT02064985|Drug|Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
198330|NCT02064998|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
198331|NCT02064998|Behavioral|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
198332|NCT02064998|Behavioral|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
198333|NCT02065011|Drug|UshStat|Long-term follow up of patients who received UshStat in a previous study
198334|NCT02065024|Dietary Supplement|b-cryptoxanthin plus phytosterols|
198335|NCT00125697|Procedure|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
198336|NCT02065037|Device|room temperature air insufflation|control arm
198337|NCT02065037|Device|warmed carbon dioxide insufflation|comparator arm
198338|NCT02065050|Other|team-based care|
197715|NCT02039284|Device|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
197716|NCT02039297|Other|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|
197717|NCT02039323|Drug|Tenofovir|
197718|NCT02039323|Drug|Maraviroc|
198021|NCT02073006|Dietary Supplement|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
198022|NCT02073019|Drug|BL-8040|
198023|NCT02073019|Drug|Placebo|
198024|NCT02073032|Other|No intervention, only observation|
198025|NCT02073045|Other|educational intervention|Receive educational handouts
198026|NCT02073045|Other|lymphedema survey|Ancillary studies
198027|NCT00126477|Procedure|quality-of-life assessment|
198028|NCT02073058|Device|No treatment|
198029|NCT02073071|Other|Preterm infant formula per standard of care|Commercially available preterm infant formula
198030|NCT02073084|Drug|K-877 Low Dose|K-877 Low Dose
198031|NCT02073084|Drug|Moxifloxacin|
198032|NCT02073084|Other|Placebo|
198033|NCT02073084|Drug|K-877 High Dose|K-877 High Dose
198034|NCT02073097|Drug|carfilzomib|Given IV
198035|NCT02073097|Biological|rituximab|Given IV
198036|NCT02073097|Drug|cyclophosphamide|Given IV
198037|NCT02073097|Drug|doxorubicin hydrochloride|Given IV
198038|NCT00126490|Biological|Aldesleukin|Given subcutaneously
198039|NCT02073097|Drug|vincristine sulfate|Given IV
198040|NCT02073097|Drug|prednisone|Given PO
197433|NCT00002186|Drug|Acyclovir|
197434|NCT00123500|Behavioral|Physical Activity|Physical Activity
197435|NCT02044523|Device|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
197436|NCT02044536|Other|No intervention|No intervention (retrospective data review)
197437|NCT02044549|Drug|carbetocin|Oxycontin analogue
197438|NCT02044549|Drug|Syntometrine|Uterotonins
197439|NCT02044562|Dietary Supplement|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
197440|NCT02044562|Dietary Supplement|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
197441|NCT02046980|Procedure|Gufoni|
197442|NCT02046980|Procedure|Vibration|
197443|NCT02046980|Procedure|Sham|
197719|NCT02039336|Drug|Dacomitinib|
197720|NCT02039336|Drug|PD-0325901|
197721|NCT02039336|Drug|Irinotecan|
197722|NCT02039336|Drug|Docetaxel|
197723|NCT02039336|Drug|Capecitabine|
197724|NCT02039349|Drug|PF-05190457|
197725|NCT00123084|Behavioral|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
197726|NCT02039362|Drug|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
197727|NCT02039375|Other|"Hopkins" post tPA for ischemic stroke monitoring protocol|The "Hopkins" post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours.
197728|NCT02039388|Procedure|Lavage of the Cavum uteri and proximal Fallopian tubes|
197729|NCT02039401|Genetic|VM202|
197129|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 1|Containing macro and micronutrients
197130|NCT00124228|Drug|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
197131|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 2|Containing macro and micronutrients
197132|NCT02051777|Dietary Supplement|Dietary Advice|
197133|NCT02051790|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
197134|NCT02051803|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
197135|NCT02051803|Behavioral|Health Education (HE)|
197136|NCT02051816|Device|Video Laryngoscopy|
197137|NCT02051816|Device|Apneic Oxygenation|
197138|NCT02051816|Device|Direct Laryngoscopy|
197139|NCT02051816|Device|No Apneic Oxygenation|
197140|NCT02051829|Other|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
197141|NCT00124241|Drug|telbivudine|
197142|NCT02051842|Drug|Metadoxine|
197143|NCT02051868|Drug|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
197144|NCT02051868|Drug|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
197145|NCT02051868|Drug|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
197444|NCT02046993|Behavioral|Smart phone telemonitoring HBP|Smart phone telemonitoring home Blood pressure (HBP) Patients to do home BP measurement and input into their smart phone which is sent to the central server fortnightly
197445|NCT00123747|Procedure|Positron Emission Tomography (PET) scan Imaging|
197446|NCT02046993|Behavioral|Hypertensive patient on usual care|Patient do home BP monitoring Record the Home BP monitoring in their diary
197447|NCT02047006|Drug|Rivaroxaban 10 mg|Measurement of AUC of rivaroxaban and effect on coagulation assays:
Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.
Effect of dialysis on levels of rivaroxaban:
Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours.
196832|NCT02059239|Drug|Melphalan|140mg/m2 on Day -1
196833|NCT02059239|Drug|Cytarabine|200 mg/m2 on days -5 to -2
196834|NCT02059239|Drug|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
196835|NCT02059239|Biological|Autologous Stem Cell Transplantation|
196836|NCT00125021|Drug|OSI-774|Given once daily
196837|NCT02059239|Biological|Allogeneic Stem Cell Transplantation|
196838|NCT02059239|Drug|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
196839|NCT02059252|Device|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
196840|NCT02059265|Drug|Dasatinib|Given PO
196841|NCT02059265|Other|Laboratory Biomarker Analysis|Correlative studies
196842|NCT02059278|Drug|T-2345|T-2345 Ophthalmic Solution
196843|NCT02059278|Drug|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
196844|NCT02059291|Drug|canakinumab|subcutaneous injection
196845|NCT02059291|Drug|Placebo|subcutaneous injection
196846|NCT02059304|Device|Measurement of cervical length with embryo transfer catheter|
196847|NCT00125034|Biological|Cetuximab|Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).
Until progression or unacceptable toxicity develops
196848|NCT02061657|Drug|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
196849|NCT02061657|Drug|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
196850|NCT00125320|Drug|RSD1235|
196851|NCT02061670|Biological|Ragweed-SPIRE|Intradermal injection
196852|NCT02061670|Biological|Placebo|
196230|NCT02072304|Behavioral|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
196231|NCT02074358|Drug|Apixaban|
196232|NCT02074358|Drug|Cofact (4-Factor PCC)|
196233|NCT02074358|Drug|Beriplex P/N (4-Factor PCC)|
196234|NCT02074358|Drug|Placebo (Saline solution)|
196235|NCT00126581|Drug|Paclitaxel|Given IV
196549|NCT02066805|Drug|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
196550|NCT02066818|Drug|Lidocaine/tetracaine patch|
196551|NCT02066818|Drug|1% lidocaine|
196552|NCT02066831|Behavioral|Telemedical coaching|
196553|NCT02066831|Other|Telemedicine|
196554|NCT02066844|Drug|Celestone|2cc
196555|NCT00002202|Drug|Amprenavir|
196556|NCT00125918|Drug|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
196557|NCT02066844|Drug|Lidocaine|5cc
196558|NCT02066857|Device|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
196559|NCT02066857|Device|Generic "off the shelf" removable splint|Patients will be randomized to receive a generic "off the shelf" removable splint for treatment of a non-displaced distal radius fracture.
196560|NCT02066870|Drug|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
196561|NCT02066870|Drug|Arsenic trioxide|Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.
Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved.
196562|NCT02066896|Device|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
195899|NCT00122772|Radiation|Radiotherapy/Cisplatin|External Beam Radiotherapy 46Gy in 23 daily fractions
High Dose Brachytherapy 4 fractions of 7Gy
Cisplatin 40mg/sqm weekly
195900|NCT02036372|Drug|Insulin bolus|
195901|NCT02038621|Drug|Oxaliplatin and Capecitabine|Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\PR\SD,then randomized into this clinical trial.
195902|NCT02038634|Drug|Betamethasone|
195903|NCT02038634|Device|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
195904|NCT02038647|Drug|Alisertib (MLN8237)|40 mg orally twice a day - 3 days on/4 days off weekly for 3 weeks in a 28-day cycle.
195905|NCT02038647|Drug|Placebo|0 mg orally twice a day - 3 days on/4 days off for 3 weeks in a 28-day cycle.
195906|NCT02038647|Drug|Paclitaxel 60 mg/m2|60 mg/m2 intravenously (IV) once a week for 3 weeks in a 28-day cycle.
196236|NCT02074384|Device|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
196237|NCT02074384|Device|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
196238|NCT02074384|Other|Clinician|Survey of clinicians after study visits
196239|NCT02074397|Procedure|Distant extrafascial injection|
196240|NCT02074397|Procedure|Subfascial injection|
196241|NCT02074410|Drug|OMS643762|
196242|NCT02074410|Drug|Placebo|
196243|NCT02074423|Dietary Supplement|MealShape cinnamon extract|Acute administration of 1 g PO (2 capsules of 500 mg)
196244|NCT02074423|Dietary Supplement|Placebo|Acute administration of 1 g PO (2 capsules of 500 mg)
196245|NCT02074436|Drug|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
196246|NCT00002208|Drug|Indinavir sulfate|
196247|NCT00126594|Drug|Sorafenib Tosylate|Given orally
196248|NCT02074436|Other|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
196249|NCT02074475|Other|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
195605|NCT02043665|Biological|CVA21|
195606|NCT00002186|Drug|Crofelemer|
195607|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
195608|NCT02043678|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles.(nominal change to 55 kBq/kg after implementation of National Institute of Standards and Technology (NIST) update)
195609|NCT02043678|Drug|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
195610|NCT02043678|Drug|Abiraterone|All study subjects will receive treatment with oral abiraterone acetate (1000 mg once daily),with best supportive care
195611|NCT02043678|Drug|Prednisone/Prednisolone|All study subjects will receive treatment with oral prednisone/prednisolone (5 mg twice daily), with best supportive care
195612|NCT02043691|Device|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
195613|NCT02046304|Drug|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
195907|NCT02038647|Drug|Paclitaxel 80 mg/m2|80 mg/m2 intravenously (IV) once a week for 3 weeks in a 28-day cycle.
195908|NCT02038660|Device|Balloon angioplasty|
195909|NCT00123006|Behavioral|Control Diet|4 week feeding intervention
195910|NCT02038673|Drug|ASP5878|oral
195911|NCT02038686|Device|PFN-A|
195912|NCT02038699|Drug|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
195913|NCT02038712|Dietary Supplement|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
195914|NCT02038712|Dietary Supplement|Fasted condition|Subjects will consume 600mL plain water.
195915|NCT02038712|Procedure|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
195916|NCT02038712|Behavioral|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
195917|NCT02038712|Procedure|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
191526|NCT01954589|Drug|ACT-462206 200mg|
191527|NCT01956812|Drug|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
191528|NCT01956812|Drug|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
191529|NCT01956825|Dietary Supplement|"slim water"|
191530|NCT01956838|Dietary Supplement|umami|intraduodenal infusion of umami tastant
191531|NCT01956838|Dietary Supplement|bitter|intraduodenal infusion of bitter tastant
191532|NCT01956838|Dietary Supplement|sweet|intraduodenal infusion of sweet tastant
191533|NCT01956864|Drug|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
191534|NCT01956890|Drug|PET|18F-FLT PET and MRI of the breast
191535|NCT01956903|Genetic|Allogenic Mesenchymal Stem Cell|Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, "Agencia Española de Medicamentos y Productos Sanitarios" with number 06-076)
191536|NCT01956916|Dietary Supplement|Lactobacillus rhamnosus GG|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 cps/die for 12 months
191835|NCT01989962|Other|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
191836|NCT01989988|Procedure|LMGB|
191837|NCT01989988|Procedure|LRYGB|
191838|NCT01989988|Procedure|SADJB|
191839|NCT01990001|Other|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
191840|NCT01990053|Behavioral|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
191841|NCT01990066|Behavioral|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
191216|NCT01962077|Procedure|MedCem MTA pulpotomies in primary teeth.|
191217|NCT01962090|Other|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
191218|NCT01962090|Other|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
191219|NCT01962103|Drug|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
191220|NCT01962116|Drug|Citrate 4%|
191221|NCT01962116|Drug|unfractionated heparin|
191222|NCT01962129|Biological|Sampling of blood|
191223|NCT01962142|Other|Assessment of activity capacities|
191224|NCT01962168|Device|Evolution® Biliary Stent - Uncovered|Commercially available device
191225|NCT01962181|Drug|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
191226|NCT00116038|Device|Femoral implant (Versys Fiber Metal Taper®)|
191227|NCT01962181|Drug|Placebo|
191228|NCT01962194|Device|Deep Brain Stimulation|In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, "Activa PC+S", which has therapy equivalent to "Activa PC", and has a new sensing programmer.
191229|NCT01962207|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
191230|NCT01964391|Drug|trastuzumab [Herceptin]|600 mg subcutaneously every 3 weeks, 18 cycles (adjuvant or neo-adjuvant plus adjuvant therapy)
191231|NCT01964404|Drug|Marijuana|
191232|NCT01964404|Drug|Dronabinol|
191233|NCT01964404|Drug|Placebo|
191234|NCT00116337|Procedure|Spinal Cord Stimulation|Participants will have small electrodes (metal discs) placed — by a routine surgical procedure — over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
191235|NCT01964417|Drug|Colonoscopy after bowel cleansing|
190593|NCT01971567|Device|HIRREM|
190594|NCT01971580|Drug|Ambrisentan|
190595|NCT01971593|Drug|Eplerenone|
190596|NCT01973946|Other|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
190597|NCT01973972|Behavioral|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
190598|NCT01973972|Behavioral|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
190599|NCT01973985|Other|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
190600|NCT00117442|Drug|carboplatin|Chemotherapy
190890|NCT01966523|Other|Control|
190891|NCT01966536|Procedure|CD133+ cells transplantation into ovarian artery of one ovary|
190892|NCT01966549|Drug|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
190893|NCT01966549|Drug|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
190894|NCT01966562|Behavioral|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
190895|NCT01966562|Behavioral|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
190896|NCT00116571|Device|Transurethral light delivery system|
190897|NCT01966575|Drug|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
190282|NCT01978925|Other|Pharmaceutical care|The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.
The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session.
190283|NCT01978938|Drug|Eravacycline|
190284|NCT01978938|Drug|Levofloxacin|
190285|NCT01978951|Behavioral|Integrated Chronic Kidney Disease care|Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
190286|NCT00117806|Behavioral|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
190287|NCT01978951|Behavioral|Conventional CKD care|group counselling about optimal diets for CKD patients
190288|NCT01978964|Biological|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
190289|NCT01979003|Drug|Fluorescein|
190290|NCT01979016|Drug|dupilumab|Dupilumab is an anti-interleukin 4 monoclonal antibody (Anti-IL-4R alpha mAb) that is being studied for the treatment of moderate-to-severe eczema.
[In addition to active dupilumab treatment, patients are also required to apply a topical emollient twice daily from day -7 through day 8 as background treatment.]
190291|NCT01979016|Drug|placebo|Placebo is a look-alike substance with no active medication
[In addition to receiving placebo, patients are also required to apply a topical emollient twice daily from day -7 through day 8 as background treatment]
190601|NCT01973985|Other|Thoracic ultrasonography|Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.
Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.
Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.
Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants.
190602|NCT01973985|Procedure|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
190603|NCT01973985|Procedure|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
190604|NCT01973998|Drug|Roflumilast|PDE4 inhibitor
190605|NCT01973998|Drug|Placebo|
190606|NCT01974011|Procedure|Performing dorsal penile nerve block (DPNB)|
190607|NCT01974024|Drug|methylprednisolone|
194783|NCT02071537|Drug|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
194784|NCT02071537|Drug|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
194785|NCT00126308|Device|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
194786|NCT02071550|Device|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
194787|NCT02071550|Device|FORESIGHT and INVOS monitor|
194788|NCT02071563|Dietary Supplement|CSB14|
194789|NCT02071563|Dietary Supplement|RUSF1|
194790|NCT02071563|Dietary Supplement|SC+|
194791|NCT02071576|Device|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
194792|NCT02074072|Device|30 degree left-lateral tilt wedges|The wedges are made of aluminium
194793|NCT00126555|Radiation|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
194794|NCT02074098|Device|Macintosh laryngoscope|Direct Laryngoscope
194795|NCT02074098|Device|Glidescope|Videolaryngoscope-1
194796|NCT02074098|Device|Airwayscope|Videolaryngoscope-2
194797|NCT02074137|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
194798|NCT02074137|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
194799|NCT02074137|Drug|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
194800|NCT02074150|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.
Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
194801|NCT02074150|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.
Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
194802|NCT02074150|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
195080|NCT02066155|Behavioral|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
194489|NCT02037971|Procedure|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
194490|NCT02037971|Other|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
194491|NCT02037984|Biological|V114|A 0.5-mL intramuscular dose
194492|NCT02037984|Biological|Prevnar 13|A 0.5-mL intramuscular dose
194493|NCT02037997|Drug|docetaxel|docetaxel 75mg/m2 ivgtt D1
194494|NCT02037997|Drug|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
194495|NCT02037997|Drug|Erlotinib|Erlotinib 150mg qd
194496|NCT00002184|Drug|Levocarnitine|
194497|NCT00122980|Procedure|Red Cell Transfusions|Red Blood Cell Transfusions
194498|NCT02038010|Drug|PI3K inhibitor BYL719|Given PO
194499|NCT02038010|Biological|ado-trastuzumab emtansine|Given IV
194500|NCT02038010|Other|pharmacological study|Correlative studies
194501|NCT02038010|Other|laboratory biomarker analysis|Optional correlative studies
194502|NCT02038023|Drug|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
194503|NCT02038036|Drug|Best Available Therapy|Best Available Therapy as selected by the investigator from the below: 1. Hydroxyurea 2. IFN/PEG-IFN 3. Pipobroman 4. Anagrelide 5. IMIDs 6. Observation only
194504|NCT02040584|Drug|Minimisation of TAC|•EVR: Treatment will be started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR will be adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may be modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation is obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR are between 3-8 ng/mL, minimisation of TAC will begin, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which are levels that should be maintained until Week 52 post-transplant. •MMF will be withdrawn at the same time that EVR is introduced. •oral corticosteroids will be administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids is permitted
194505|NCT02040584|Drug|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should be maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs will be maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids will be administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids is permitted (e.g. in patients with a history of HCV). It is recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should follow the same administration protocol for corticosteroids based on history of HCV.
193861|NCT02053142|Drug|Placebo|
193862|NCT02053155|Behavioral|Computer based patient education|
193863|NCT02053168|Device|Phasix Mesh|
193864|NCT00124384|Drug|modafinil|
193865|NCT02053181|Drug|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
193866|NCT02053194|Behavioral|Pharmacist-led educational intervention|1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
194172|NCT02045810|Drug|Levobupivacaine|
194173|NCT00123578|Drug|Pentobarbital|Pentobarbital
194174|NCT02045810|Drug|Saline|
194175|NCT02045836|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
194176|NCT02045836|Biological|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
194177|NCT02045849|Drug|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
194178|NCT02045849|Drug|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
194179|NCT02045849|Drug|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
194180|NCT02045862|Drug|Solifenacin Succinate|oral
194181|NCT02045862|Drug|Mirabegron|oral
194182|NCT00123890|Drug|GW873140|
194183|NCT02047890|Drug|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
194184|NCT02047890|Drug|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
194185|NCT02047903|Drug|Afatinib|50, 40, 30 or 20 mg
193869|NCT02053233|Device|Walkbot group|The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.
The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state.
193870|NCT02053233|Device|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
193871|NCT02053246|Drug|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
193872|NCT02053259|Behavioral|Adaptive Goals|
193873|NCT02055547|Drug|MK-8521|74 mcg sc injection once each day for 5 days (Part 2)
193874|NCT02055547|Drug|MK-8521|100 mcg sc injection once each day for 5 days (Part 2)
193875|NCT02055547|Drug|MK-8521|125 mcg sc injection once each day for 5 days (Part 2)
193876|NCT02055547|Drug|MK-8521|150 mcg sc injection once each day for 5 days (Part 2)
193877|NCT02055547|Drug|MK-8521|72 mcg sc injection once each day for 7 days (Part 2)
193878|NCT02055547|Drug|MK-8521|125 mcg sc injection once each day for 7 days (Part 2)
193879|NCT00124644|Drug|daunorubicin hydrochloride|
193880|NCT02055547|Drug|Placebo|Placebo sc injection once each day for 10 days (Part 2)
193881|NCT02055547|Drug|Placebo|Placebo sc injection once each day for 14 days (Part 2)
193882|NCT02055547|Drug|MK-8521|Single low dose sc injection in a treatment period (Part 3)
193883|NCT02055547|Drug|MK-8521|Single high dose sc injection in a treatment period (Part 3)
193884|NCT02055547|Drug|Placebo|Single Placebo sc injection in a treatment period (Part 3)
193885|NCT02055573|Other|Ready To Learn (RTL)|See arm description
193886|NCT02055573|Other|All Babies Cry (ABC)|See arm description
194192|NCT02047994|Drug|Triple therapy|Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.
Esomeprazole 40 mg bid for 10 days
Clarithromycin 500 mg bid for 10 days
Amoxicillin 1000 mg bid for 10 days
198339|NCT02065063|Drug|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
198340|NCT02065063|Drug|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
198341|NCT02065076|Drug|Sodium polystyrene sulfonate|
198342|NCT02065076|Drug|Lactose with carob gum|
193572|NCT02060279|Other|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
193573|NCT02060279|Other|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
193574|NCT02060305|Drug|Bevacizumab intra-articular injection|Bevacizumab, 20~40mg, intra-articular injection every month for 2~ 4 cycles
193575|NCT02060318|Drug|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
193576|NCT02060357|Device|Optical coherence tomography|
193577|NCT00125164|Drug|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
193578|NCT00125450|Procedure|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
193579|NCT02062788|Dietary Supplement|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
193580|NCT02062801|Drug|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
193581|NCT02062801|Drug|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
193582|NCT02062827|Biological|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
198041|NCT02073097|Other|laboratory biomarker analysis|Correlative studies
198042|NCT02073110|Device|Percutaneous Optical Biopsy (OCT and DRS)|
198043|NCT02073123|Drug|Indoximod|Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth
Dose escalation:
If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled
If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects
If > 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease
If >1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If >1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed
Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity
Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1
198044|NCT02073123|Drug|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
198343|NCT02065089|Other|playing the ipad quiz game|
198344|NCT02065115|Other|Cryotherapy (ice pack)|
198345|NCT02067494|Other|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
198346|NCT02067494|Other|Kinesio taping treatment|Two bands in "I", with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain.
198347|NCT02067507|Behavioral|Tailored education & referral|5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
198348|NCT02067520|Drug|intrathecal hydromorphone (IT hydromorphone)|
198349|NCT02067533|Procedure|soft tissue repair in flexion position|
198350|NCT00002203|Drug|Lamivudine/Zidovudine|
198351|NCT00125970|Biological|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
198352|NCT02067533|Procedure|soft tissue repair in extension position|
198353|NCT02067546|Device|Experimental toilet seat|
198354|NCT02067546|Device|Standard toilet seat|
198355|NCT02067559|Behavioral|ICU Diary|Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
197730|NCT02039427|Drug|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
197731|NCT02039427|Other|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
197732|NCT02039427|Drug|Placebo|Normal saline 2 ml
197733|NCT02039440|Other|Blood draw|One-time blood draw
197734|NCT02039453|Drug|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
197735|NCT02039453|Drug|pethidine dose|pethidine dose 50mg, IV bolus (25mg if < 50kg or >70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
197736|NCT00123084|Behavioral|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
197737|NCT02039466|Procedure|volume controlled ventilation|
197738|NCT02039466|Procedure|pressure controlled ventilation|
197739|NCT02039479|Drug|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
197740|NCT02039479|Drug|Placebo|Placebo as ADD-on to every necessary treatment as usual
197741|NCT02039492|Procedure|Sympathetic Renal Denervation|
197742|NCT02039492|Drug|Treatment with aldactone|
198045|NCT02073123|Drug|Nivolumab|Nivolumab administered intravenously at 3 mg/kg every three weeks
198046|NCT02073123|Drug|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks
198047|NCT02075229|Device|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
198048|NCT02075242|Drug|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
198049|NCT02075242|Drug|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
198050|NCT02075255|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
198051|NCT02075255|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
197448|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
197449|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
197450|NCT02047019|Drug|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
197451|NCT02047019|Drug|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
197452|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
197453|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
197454|NCT02047032|Procedure|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
197455|NCT02047032|Drug|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
197456|NCT00123760|Procedure|Positron Emission Tomography (PET) scan|
197457|NCT02047032|Procedure|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
197458|NCT02047045|Procedure|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
197459|NCT02047045|Drug|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 8 weeks.
197460|NCT02047071|Device|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
197743|NCT02042248|Biological|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
197744|NCT00123331|Drug|Cyclosporine discontinuation|
197745|NCT02042274|Dietary Supplement|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
197746|NCT02042287|Device|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
197146|NCT02051868|Drug|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
197147|NCT02051881|Other|Taking intestinal biopsies|
197148|NCT00124566|Drug|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m^2 per day, once every 3 weeks.
197149|NCT02054559|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
197150|NCT02054559|Radiation|Radiotherapy|
197151|NCT02054572|Drug|[14C]AMG 416|Subjects will each receive 750 nCi of [14C]AMG 416 formulated in a single 10 mg dose of AMG 416 in 2 mL liquid solution for intravenous (IV) administration on day 1
197152|NCT02054585|Other|NaCl 0.9%|Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.
Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid.
197153|NCT02054585|Other|NaCl 0.9 +5% dextrose|Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.
Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid.
197154|NCT02054598|Behavioral|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
197155|NCT02054611|Other|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
197156|NCT02054611|Other|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
197157|NCT02054624|Behavioral|Lifestyle intervention|The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
Phase 1 will be 4 months of weight loss treatment
Phase 2 will be 12 months of follow-up contact by group telephone call.
The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months.
197158|NCT02054624|Behavioral|Health education control|The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
Phase 1 will be 4 months of weight loss treatment
Phase 2 will be 12 months of follow-up contact by email.
The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
During Phase 2 you will receive you will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help you maintain lost weight.
197159|NCT00002194|Drug|Erythromycin|
197160|NCT00124566|Drug|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m^2 twice daily for 15 days every 28 days.
196563|NCT02066896|Device|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
196564|NCT02066909|Drug|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
196565|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
196566|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
196567|NCT00125918|Drug|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
196568|NCT02066909|Drug|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
196569|NCT02069665|Drug|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
196853|NCT02061683|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
196854|NCT02061696|Device|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
196855|NCT02061696|Procedure|Standard Manual Compression|Closure procedure by Manual Compression
196856|NCT02061709|Biological|Ragweed-SPIRE|
196857|NCT02061709|Biological|Placebo|
196858|NCT02061722|Radiation|PET Imaging with [18F]MNI-659|The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.
The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%.
196859|NCT02061748|Drug|Observational|Retrospective Chart Review
196860|NCT02061761|Biological|BMS-986016|
196861|NCT00125333|Drug|NF-kappaB Decoy|
196862|NCT02061774|Drug|Acetaminophen|1 gram of intravenous Acetaminophen
196863|NCT02061774|Other|Placebo comparator|.9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
196250|NCT02074488|Other|Balancing Act exercise curriculum|Balance improvement exercise curriculum titled "Balancing Act"
196251|NCT02074488|Other|Informational Brochure|Informational Brochure on falls prevention
196252|NCT02074501|Other|training capacity in caregivers|The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put "hands on" caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge.
196253|NCT02074514|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
196254|NCT02074514|Drug|RBV|RBV 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
196255|NCT02074540|Other|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
196256|NCT02074553|Drug|Ro542-4802/F03 (Reference)|Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
196257|NCT02074553|Drug|Ro542-4802/F07 (Test)|Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
196570|NCT02069665|Drug|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
196571|NCT02069665|Drug|Ibuprofen Suspension|taken under prescription
196572|NCT02069665|Drug|salbutamol|taken under prescription
196573|NCT02069691|Device|virtual reality-cycling training system|
196574|NCT02069704|Drug|Bevacizumab biosimilar (BEVZ92)|Bevacizumab biosimilar (BEVZ92), Active ingredient Bevacizumab 25 mg/mL (strength = 100mg/mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).
FOLFIRI = Folinic Acid + Fluorouracil + Irinitecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).
*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.
The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
196575|NCT02069704|Drug|Avastin® (bevacizumab, reference product)|Avastin® (bevacizumab, reference product). Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).
*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.
The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
196576|NCT02069717|Other|Not applicable-observational study|
196577|NCT02069730|Drug|Selinexor|
195918|NCT02038738|Drug|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
195919|NCT02038764|Drug|Placebo|Placebo
195920|NCT00123019|Behavioral|Exercise and diet|Advice and measurement only
195921|NCT02038764|Biological|PF-06342674 Dose A|Multiple SC Doses
195922|NCT02038764|Biological|PF-06342674 Dose B|Multiple SC Doses
195923|NCT02038764|Biological|PF-06342674 Dose C|Multiple SC Doses
195924|NCT02038764|Biological|PF-06342674 Dose D|Multiple SC Doses
195925|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
195926|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
195927|NCT02038777|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
195928|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
195929|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
196258|NCT02036372|Drug|GIK infusion|continuous infusion
196259|NCT02036398|Device|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
196260|NCT02036398|Device|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
196261|NCT02036424|Drug|Ozurdex|intravitreal steroid
196262|NCT02036424|Drug|Bevacizumab|antiVEGF
196263|NCT02036437|Drug|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
196264|NCT02036437|Drug|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
191842|NCT01990079|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
191843|NCT01990079|Drug|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
191844|NCT01990079|Other|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
191845|NCT00118430|Drug|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
191846|NCT01990079|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
191847|NCT01992601|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)|For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.
For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.
191848|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
191849|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
191850|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
192140|NCT01985074|Behavioral|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
192141|NCT01985087|Radiation|Hypofractionated radiotherapy|Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
192142|NCT01985087|Drug|Temozolomide|During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
192143|NCT00118209|Drug|vincristine|IV or CIVI
192144|NCT01985100|Other|hyperbaric oxygen chamber|
192145|NCT01985126|Drug|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
192146|NCT01985126|Drug|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
191236|NCT01964430|Drug|nab-Paclitaxel 125 mg/m2|nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles
191537|NCT00115531|Biological|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
191538|NCT01956916|Dietary Supplement|placebo|Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 cps/die for 12 months
191539|NCT01956929|Drug|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
191540|NCT01956929|Drug|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
191541|NCT01956942|Device|Micropulse Laser Trabeculoplasty|
191542|NCT01956942|Device|Selective Laser Trabeculoplasty|
191543|NCT01956955|Drug|enoxaparin ,alteplase, unfractionated heparin|
191544|NCT01956981|Drug|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
191545|NCT01956981|Drug|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
191546|NCT01956994|Dietary Supplement|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
191547|NCT01956994|Dietary Supplement|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
191548|NCT00115544|Drug|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
191549|NCT01957007|Drug|Docetaxel|Docetaxel will be administered IV.
191550|NCT01957007|Drug|vantictumab|Vantictumab will be administered intravenously
191551|NCT01959412|Drug|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
191552|NCT01959425|Other|Off OAT Group (Test)|Discontinuation of OAT Therapy
191553|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
191554|NCT00002123|Drug|Delavirdine mesylate|
190898|NCT01966588|Other|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
190899|NCT01966588|Other|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
190900|NCT01966601|Drug|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
190901|NCT01966601|Drug|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
190902|NCT01966601|Drug|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
190903|NCT01966601|Drug|Placebo|Placebo continuous intravenous infusion
190904|NCT01966614|Drug|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
190905|NCT01966614|Other|Placebo|Single intraprostatic bilateral injection of vehicle only
190906|NCT01969045|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
191237|NCT01964430|Drug|gemcitabine 1000 mg/m2|nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles
191238|NCT01964430|Drug|gemcitabine 1000 mg/m2|Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles
191239|NCT01964456|Other|Joint perception task|
191240|NCT01964456|Behavioral|Body Shape Questionnaire|
191241|NCT01964456|Other|Measure of the heart rate|
191242|NCT01964469|Behavioral|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
191243|NCT01964482|Other|Strength training|Strength training followed by intake of a protein drink
191244|NCT01964495|Drug|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
191245|NCT00116337|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
190608|NCT01974037|Dietary Supplement|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups
190609|NCT01974037|Dietary Supplement|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups
190610|NCT01974050|Behavioral|Text message surveillance|
190611|NCT00117442|Drug|paclitaxel|chemotherapy
190612|NCT01974076|Device|Active tDCS + CBT|
190613|NCT01974076|Device|Sham tDCS + CBT|
190614|NCT01974089|Other|Modified diet|
190615|NCT01974102|Behavioral|Lifestyle counseling|Active and control participants will receive nutritional and physical activity counseling.
190616|NCT01974102|Behavioral|Mindfulness Based Stress Reduction|Active participants will receive 8 weeks of Mindfulness Based Stress Reduction therapy.
190617|NCT01974115|Device|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
190618|NCT01976325|Other|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
190619|NCT01976338|Drug|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
190907|NCT01969045|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
190908|NCT01969058|Drug|Isotretinoin|
190909|NCT01969071|Drug|Levosimendan|The effects of levosimendan on renal function
190910|NCT01969071|Drug|Dobutamine|Standard Inotropic agent
190911|NCT00116870|Drug|lovastatin|
190912|NCT01969084|Drug|Linagliptin|
190913|NCT01969084|Drug|Placebo|
195081|NCT02066181|Other|Laboratory Biomarker Analysis|Optional correlative studies
195082|NCT00125866|Behavioral|Flavonoid rich or flavonoid depleted chocolate drink|
195083|NCT02066181|Other|Placebo|Given PO
195084|NCT02066181|Other|Quality-of-Life Assessment|Optional ancillary studies
195085|NCT02066181|Drug|Sorafenib Tosylate|Given PO
195086|NCT02066194|Procedure|Electroacupuncture|
195087|NCT02066207|Drug|Fenofibrate|
195088|NCT02066207|Drug|Atorvastatin|
195089|NCT02066220|Radiation|Radiotherapy without Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks
LR Arm after Amendment (Protocol version 11- 17 Nov 2014):
Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks
195090|NCT02068885|Behavioral|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
195091|NCT00126100|Other|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
195092|NCT02068898|Drug|XS003|
195093|NCT02068898|Drug|Tasigna|
195094|NCT02068911|Device|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
195095|NCT02068924|Other|Slow freezing versus vitrification|
195096|NCT02068937|Drug|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 miligrams of furosemide)
195097|NCT02068937|Drug|Furosemide|This group received just diuretic adjusted (Furosemide 40 miligrams) by the doctor on the baseline.
195098|NCT02068950|Behavioral|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
195099|NCT02069002|Behavioral|Cognitive-Behavioral Therapy (CBT)|
194506|NCT02040597|Drug|Beclometasone/Formoterol/Glycopyrrolate|
194803|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
194804|NCT00126555|Procedure|Conventional surgery|Undergo surgery
194805|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
194806|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
194807|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
194808|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
194809|NCT02074150|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
194810|NCT02074150|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
194811|NCT02035722|Behavioral|Video|AMD-related information is presented as in the form of a video
194812|NCT02035735|Procedure|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
194813|NCT02035748|Drug|Ocriplasmin 0.125 mg in a 0.1 mL volume|
194814|NCT00122720|Drug|Darbepoetin Alfa|
194815|NCT02035774|Procedure|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
194186|NCT02047929|Other|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), identified by both the Institute of Medicine and the Patient-Centered Outcomes Research Institute as an important new means of improving patient outcomes. In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. Initial results show marked improvement in patient adherence to medications, decreases in utilization of the ED and hospital for asthma care. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
194187|NCT02047942|Behavioral|Center-based cardiac rehabilitation|
194188|NCT02047942|Behavioral|Home-based training with telemonitoring guidance|
194189|NCT02047968|Behavioral|wake therapy|
194190|NCT02047981|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years
194191|NCT02047981|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
194507|NCT02040610|Radiation|Hypofractionated Proton Therapy|
194508|NCT00123175|Device|Intrauterine Device|Mirena and Provera
194509|NCT02040623|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
194510|NCT02040623|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
194511|NCT02040623|Other|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
194512|NCT02040636|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV|0.5 mL, Intramuscular
194513|NCT02040636|Biological|Hepatitis B vaccine|0.5 ml, Intramuscular
194514|NCT02040649|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
194515|NCT02040649|Other|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
194516|NCT02040662|Procedure|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
194193|NCT00123903|Drug|metoprolol xl|
194194|NCT02048007|Drug|Azithromycin|Biannual mass oral azithromycin to children, annual mass oral azithromycin to everyone
194195|NCT02048007|Drug|Placebo|Biannual mass oral placebo to children
194196|NCT02048020|Drug|paclitaxel|Given IV
194197|NCT02048020|Drug|carboplatin|Given IV
194198|NCT02048020|Radiation|intensity-modulated radiation therapy|Undergo IMRT
194199|NCT02048020|Procedure|quality-of-life assessment|Ancillary studies
194200|NCT02048033|Device|Endogastric suturing|The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
194201|NCT02048059|Drug|ANG1005|
194202|NCT02048072|Drug|Gilenya|Autonomic testing during first dose administration of Gilenya.
194203|NCT02048085|Drug|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
194204|NCT00123903|Drug|carvedilol MR|
194205|NCT02048085|Drug|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
194206|NCT02050308|Drug|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
194207|NCT02050321|Drug|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
194208|NCT02050321|Drug|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
194209|NCT02050334|Drug|CC100|CC100 reconstituted in diluent
194210|NCT00124085|Behavioral|Disease Management + Educational Home Visits|
194211|NCT02050334|Drug|Placebo|Diluent. Amount to match CC100 dose.
194212|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 2|Patients will receive one of the following dose levels:
Dose Level 1: 5 ×10^5 cells/kg
Dose Level 2: 1×10^6 cells/kg
Dose Level 3: 5×10^6 cells/kg
193583|NCT02062840|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
193584|NCT02062840|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
193887|NCT02055586|Other|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
193888|NCT02055586|Procedure|positron emission tomography|Undergo FLT-PET/MRI
193889|NCT02055586|Procedure|magnetic resonance imaging|Undergo FLT-PET/MRI
193890|NCT00124644|Drug|etoposide|
193891|NCT02055625|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
193892|NCT02055638|Drug|SRX246|capsules
193893|NCT02055638|Drug|Placebo|
193894|NCT02055651|Behavioral|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
193895|NCT02055664|Drug|Ropivacaine 0.2%|
193896|NCT02055664|Drug|Chlorure de sodium 0.9%|
193897|NCT02055690|Drug|Pazopanib|Tyrosine Kinase Inhibitor
193898|NCT02055690|Drug|Fosbretabulin|Vascular Disrupting Agent
193899|NCT02055703|Drug|E2609|
193900|NCT02055703|Drug|itraconazole|
193901|NCT00124644|Drug|tipifarnib|
193902|NCT02055703|Drug|rifampin|
193903|NCT02055703|Drug|digoxin|
198356|NCT02067559|Behavioral|Psychoeducation|The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
198357|NCT02067572|Other|Saline mouthwash|
198358|NCT02067572|Other|Salvia mouthwash|
198359|NCT02067585|Dietary Supplement|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
198360|NCT02067598|Other|scapular exercise|
198361|NCT02067611|Drug|X0002|Parallel Assignment
198362|NCT00125970|Biological|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
198363|NCT02067611|Drug|Placebo|Parallel Assignment
198364|NCT02067624|Other|Thai massage|
193585|NCT02062840|Device|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
193586|NCT02062840|Other|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
193587|NCT02062853|Other|Video Group|Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
193588|NCT02062853|Other|Verbal Group|The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
193589|NCT00002199|Drug|Abacavir sulfate|
193590|NCT00125450|Procedure|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
193591|NCT02062866|Procedure|Purse-String|The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled" on either side to essentially cinch down the wound, decreasing the size of the wound.
193592|NCT02062866|Procedure|Second Intent|The wound will not be sutured, and allowed to heal on its own.
193593|NCT02062879|Drug|Ketamine|Ketamine administered as patient-controlled analgesia.
193594|NCT02062879|Drug|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
198052|NCT02075255|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
198053|NCT02075268|Drug|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
198054|NCT02075281|Biological|HM11260C|Glucagon-like peptide-1 analogue
198055|NCT02075281|Biological|Placebo|
198056|NCT00002208|Drug|Lamivudine|
198057|NCT00126646|Drug|BL22 immunotoxin|
198058|NCT02075294|Drug|Adefovir dipivoxil or Entecavir|Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.
Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines
198059|NCT02075307|Dietary Supplement|Blueberry Powder|
198060|NCT02075307|Dietary Supplement|Placebo|
198061|NCT02075320|Device|Stationary Digital Chest Tomosynthesis|The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.
Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction.
198062|NCT02075333|Dietary Supplement|Ingestion of sucrose solution|Participants will ingest a 381g blackcurrant drink (cordial and water) providing 50g of sucrose
198063|NCT02075333|Dietary Supplement|Rinsing of sucrose solution|Participants will rinse a 381g blackcurrant drink (cordial and water) providing 50g of sucrose in the oral cavity
198365|NCT02067663|Device|Paragard|The IUD will be placed as part of standard clinical care.
198366|NCT02067663|Drug|Mirena|The IUD will be placed as part of standard clinical care.
198367|NCT02067676|Biological|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
198368|NCT02067676|Drug|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
198369|NCT02067689|Device|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
198370|NCT02070419|Procedure|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
198371|NCT02070419|Radiation|stereotactic radiosurgery|Undergo SBRT
197747|NCT02042287|Drug|Metronidazole|Oral antibiotic
197748|NCT02042300|Device|XIENCE Xpedition/Alpine|
197749|NCT02042313|Other|continuous epidural infusion|
197750|NCT02042313|Other|combined paravertebral infusion and single shot of TAP block|
197751|NCT02042326|Drug|Sirolimus|For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
197752|NCT02042339|Drug|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
197753|NCT02042352|Other|pH glove|
197754|NCT02042365|Procedure|ERAS (Enhanced recovery after surgery)|
197755|NCT00123331|Drug|Rapamycin medication|
197756|NCT02042378|Drug|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
197757|NCT02042391|Drug|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
197758|NCT02042391|Drug|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
197759|NCT02042391|Drug|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
198064|NCT02075372|Other|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
198065|NCT02075385|Procedure|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
197461|NCT02047097|Drug|dimethyl fumarate|Provided under routine clinical care
197462|NCT02049138|Drug|ABT-494|Capsule
197463|NCT02049151|Drug|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
197464|NCT02049151|Drug|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
197465|NCT02049151|Drug|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
197466|NCT02049151|Drug|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent [%] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
197467|NCT00124007|Biological|VRC-HIVADV014-00-VP|
197468|NCT02049164|Drug|AR08|
197469|NCT02049164|Drug|Placebo|
197470|NCT02049190|Drug|onapristone|
197471|NCT02049190|Drug|abiraterone|
197472|NCT02049203|Drug|Ataciguat|
197473|NCT02049203|Drug|Placebo|
197474|NCT02049216|Other|Flexible tape|Flexible, elasticised, adhesive athletic tape
197475|NCT02049216|Other|Fixomull|
197476|NCT02049216|Other|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
197477|NCT02049229|Device|percutaneous coronary intervention|Optimax-stent implantation
197478|NCT00124007|Biological|VRC-HIVDNA016-00-VP|
197479|NCT02049229|Device|percutaneous coronary intervention|Synergy stent implantation
197480|NCT02049242|Procedure|triple tourniquet|Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary.
196864|NCT02061800|Device|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Bergisch Gladbach, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
196865|NCT02061800|Drug|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not be used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
196866|NCT02061800|Drug|Cyclophosphamide|Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
196867|NCT02061800|Drug|Alemtuzumab|Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
196868|NCT02061800|Drug|Tacrolimus|Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
196869|NCT02061800|Drug|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
196870|NCT02061800|Drug|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
196871|NCT02064231|Device|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
197161|NCT02054624|Behavioral|Individual|The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
Phase 1 will be 4 months of weight loss treatment
Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.
The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months.
197162|NCT02054624|Behavioral|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test, accelerometer (an armband device the size of a deck of cards to record physical activity and movement each day).
197163|NCT02054637|Drug|Lanreotide|
197164|NCT02056873|Device|DBS System|The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.
The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS.
197165|NCT00002195|Drug|Amprenavir|
197166|NCT00124761|Procedure|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
196578|NCT02069730|Drug|EGFR or HER2 Inhibitor|
196579|NCT00126191|Drug|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
196580|NCT02069730|Drug|FGFR Inhibitor|
196581|NCT02069730|Drug|C-KIT Inhibitor|
196582|NCT02069730|Drug|Anti-androgen|
196583|NCT02069730|Drug|NOTCH Inhibitor|
196584|NCT02069730|Drug|MEK or PI3K Inhibitor|
196585|NCT02069743|Other|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
196586|NCT02069769|Behavioral|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
196587|NCT02069782|Other|Home visiting|While all of the models try to improve child health and development, some focus more directly on preventing child maltreatment; others focus on improving maternal and child health; and others prioritize promoting positive parenting or increasing school readiness. Some models also explicitly aim to improve parental self-sufficiency and well-being. Most of these models serve families whom they identify as being at risk of poor child outcomes, based on one or more family characteristics. Although the definition of "at risk" differs by model, most models target low-income families. They may also specifically target young, first-time mothers; parents with past negative school experiences; or families with maternal depression or substance abuse problems. Many of the models begin to work with women when they are pregnant or when they have newborns.
196872|NCT00125593|Drug|Simvastatin 20 mg|Once daily
196873|NCT02064244|Other|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
196874|NCT02064257|Behavioral|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
196875|NCT02064270|Device|Single-Use Negative Pressure Wound Therapy (NPWT)|
196876|NCT02064270|Device|Standard postsurgical dressings|
196877|NCT02064283|Procedure|Diffusion MRI|
196878|NCT02064296|Device|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device.
196265|NCT02036450|Device|LOOP recorder (Medtronic LINQ device)|A LOOP recorder will be implanted in a 1:3 randomization
196266|NCT02036463|Drug|Prednisone|
196267|NCT00122785|Drug|dexamethasone|
196268|NCT02036463|Drug|Placebo|
196269|NCT02036476|Drug|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
196270|NCT02036489|Drug|Vincristine|
196271|NCT02036489|Drug|Daunorubicin|
196272|NCT02036489|Drug|Prednisone|
196273|NCT02036489|Drug|L-asparaginase|
196274|NCT02036489|Drug|Ciclophosphamide|
196275|NCT02036489|Drug|Metotrexate|
196276|NCT02036489|Drug|ARA-C|
196277|NCT02036489|Drug|Hidrocortisone|
196278|NCT00122798|Procedure|Stroke treatment|
196279|NCT02036489|Drug|Mercaptopurine|
196280|NCT02036489|Drug|VP-16|
196281|NCT02036489|Drug|Dexametasone|
196588|NCT02069795|Other|Voice recording|
196589|NCT02072317|Drug|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
196590|NCT02072317|Drug|taxol|taxol 135 mg/m2, every three weeks for a cycle
196591|NCT02072330|Drug|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
196592|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
196593|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
196594|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
192147|NCT01985126|Drug|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
192148|NCT01985126|Drug|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
192149|NCT01985126|Drug|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
192150|NCT01985126|Drug|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
192151|NCT01985139|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
192152|NCT01985139|Biological|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
192153|NCT01985152|Drug|Azilsartan Trimethylethanolamine|
192154|NCT00118209|Drug|prednisone|oral
192155|NCT01987557|Behavioral|regular treadmill walking|
192156|NCT01987570|Drug|Allopurinol|
192157|NCT01987570|Drug|Placebo|
192158|NCT01987583|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
192159|NCT01987583|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
192454|NCT01979965|Drug|Ranolazine (Active drug)|Ranolazine therapy for three months
192455|NCT01979965|Drug|Placebo|Placebo therapy for three months
192456|NCT01979978|Other|Healthy Buddies Curriculum|Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors ("Buddies"), teaching a 30-minute lesson to their younger students. The Physical activity (i.e."Go Move!") component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary ("Go Fuel!") component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image ("Go Feel Good!") component, the students are taught to value classmates based on individual traits rather than peer influence.
191555|NCT00115752|Drug|Valdecoxib|
191556|NCT01959438|Drug|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
191851|NCT01992627|Device|HILTERAPIA HIRO 3.0|High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
191852|NCT01992653|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 750 mg/m^2 IV every 3 weeks, for 6 or 8 cycles.
191853|NCT00118755|Drug|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
191854|NCT01992653|Drug|Doxorubicin|Doxorubicin will be administered at 50 mg/m2 IV every 3 weeks, for 6 or 8 cycles.
191855|NCT01992653|Drug|Obinutuzumab|Obinutuzumab will be administered at 1000 mg IV every 3 weeks, for 6 or 8 cycles.
191856|NCT01992653|Drug|Polatuzumab Vedotin|Polatuzumab vedotine will be administered at escalating doses IV every 3 weeks, for 6 or 8 cycles.
191857|NCT01992653|Drug|Prednisone/Prednisolone|Prednisone/prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks, for 6 or 8 cycles.
191858|NCT01992653|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 IV every 3 weeks, for 6 or 8 cycles.
191859|NCT01992666|Genetic|Blood sampling|Immunologic and genetic analysis from a single blood sample.
191860|NCT01992679|Behavioral|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
191861|NCT01992705|Other|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
191862|NCT01992705|Drug|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
191863|NCT01992705|Drug|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
191864|NCT00002155|Drug|Indinavir sulfate|
191865|NCT00118755|Drug|capecitabine|1500 mg/m^2 po bid on Days 1-7 of each 2-week cycle
191246|NCT01964495|Drug|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
191247|NCT01964495|Drug|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
191248|NCT01964508|Other|Fine needle aspiration|
191249|NCT01964521|Device|Mepilex Transfer Ag|
191250|NCT01964534|Drug|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
191251|NCT01964534|Drug|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
191252|NCT01964534|Drug|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
191253|NCT01964547|Drug|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
191254|NCT01966627|Other|ogtt|oral glucose tolerance test
191255|NCT00116584|Drug|heliox|continuous heliox therapy
191256|NCT01966627|Other|genotyping|genotyping to look for risk alleles
191257|NCT01966627|Other|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
191557|NCT01959438|Drug|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
191558|NCT01959451|Drug|Prasugrel|see Arm description
191559|NCT01959451|Drug|Clopidogrel|see arm description
191560|NCT01959464|Drug|Crinone vaginal progesterone gel|Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
191561|NCT01959464|Drug|Placebo vaginal gel|Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
191562|NCT01959477|Drug|busulfan|Given IV
191563|NCT01959477|Drug|etoposide|Given IV
191564|NCT01959477|Drug|cyclophosphamide|Given IV
190914|NCT01969084|Other|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
190915|NCT01969084|Other|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
190916|NCT01969084|Other|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
190917|NCT01969097|Device|tDCS|transcranial direct current stimulation (tDCS)
190918|NCT01969097|Behavioral|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
190919|NCT01969110|Dietary Supplement|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
190920|NCT01969123|Drug|Drug: EVP-6124|
190921|NCT01969123|Drug|Placebo|
190922|NCT00116883|Drug|GW685698X aqueous nasal spray|
190923|NCT01969136|Drug|Drug: EVP-6124|
190924|NCT01969136|Drug|Placebo|
190925|NCT01969149|Drug|Exenatide|
190926|NCT01969149|Drug|Insulin|
190927|NCT01969162|Procedure|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
190928|NCT01969175|Other|Low-glycemic-load and milk-free diet|
190929|NCT01969201|Drug|Urofollitrophin|
196029|NCT02051387|Drug|Quetiapine|
196030|NCT02051387|Drug|Risperidone|
196031|NCT02051387|Drug|Placebo|
196032|NCT02051400|Device|the McGrath® MAC video laryngoscope|
196033|NCT02051400|Device|the GlidesScope® Ranger video laryngoscope|
195399|NCT02061163|Device|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
195400|NCT02061163|Drug|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
195401|NCT02061176|Procedure|Transanal Haemorrhoidal Dearterialization|
195402|NCT02061176|Procedure|Open Haemorrhoidectomy|
195403|NCT02061189|Other|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
195404|NCT02061202|Drug|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
195405|NCT00125255|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
195406|NCT02061202|Drug|Placebo|placebo training inhaler with the same instructions as the experimental group.
195407|NCT02061215|Other|CMV viral load|
195408|NCT02063594|Drug|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
195409|NCT02063594|Drug|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
195410|NCT02063607|Biological|Peginterferon lambda|
195411|NCT02063620|Drug|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
195412|NCT02063646|Dietary Supplement|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
195413|NCT02063646|Dietary Supplement|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
195414|NCT00125515|Drug|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
195415|NCT02063659|Drug|Telotristat etiprate tablets (250 mg)|Telotristat etiprate (250 mg) in tablet form.
195416|NCT02063659|Drug|Placebo|Matching placebo in tablet form
194816|NCT02035787|Drug|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
194817|NCT02035800|Drug|Adalimumab|Patient will received medication as standard of care
194818|NCT02035813|Drug|Everolimus|Everolimus in combination with endocrine therapy
195100|NCT02069002|Behavioral|Applied relaxation group therapy|
195101|NCT02069002|Behavioral|Information session (psychoeducation)|
195102|NCT00126113|Behavioral|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
195103|NCT02069015|Behavioral|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
195104|NCT02069041|Biological|Ramucirumab|Administered IV.
195105|NCT02069041|Drug|FOLFOX4|Administered IV.
195106|NCT02069080|Drug|64-Cu-plerixafor|Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.
The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion.
195107|NCT02069093|Drug|Dexamethasone based mouth|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
195108|NCT02069106|Dietary Supplement|Pro-Omega LDL|
195109|NCT02069106|Other|Placebo|
195110|NCT02069119|Drug|OPC-108459|
195111|NCT02069119|Drug|Placebo|
195112|NCT02071589|Drug|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
195113|NCT02071589|Drug|Nifedipine oral solution|6 mL of Nife Par solution
195114|NCT02071602|Drug|CD-NP|Randomized 1:1:1
195115|NCT02071615|Drug|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
195116|NCT00126321|Drug|cladribine|2-chlorodeoxyadenosine, 2-CdA
194517|NCT02040662|Procedure|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
194518|NCT02040662|Procedure|Patient-Controlled Analgesia with Morphine|Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:
patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)
paracetamol 1000 mg iv every 8 hrs
ketoprofen 100 mg iv every 12 hrs
194519|NCT00123188|Procedure|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
194520|NCT02040714|Procedure|osteotomy|Surgical procedures that improve femoral head containment
194521|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
194522|NCT02043314|Drug|Isoniazida|
194523|NCT02043340|Drug|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
194819|NCT02035813|Drug|Eribulin|
194820|NCT02035826|Behavioral|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
194821|NCT02035839|Device|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
194822|NCT02035839|Device|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
194823|NCT02035839|Device|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
194824|NCT02035852|Other|MRI|3T MRI vs. 7T MRI
194825|NCT00122733|Drug|loxapine|
194826|NCT02035878|Other|Probiotics|probiotic intervention: 400mg of probiotic capsule
194827|NCT02035878|Drug|Placebo|placebo comparator
194524|NCT02043340|Device|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
194525|NCT02043340|Procedure|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
194526|NCT02043366|Drug|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
194527|NCT02043366|Drug|Butorphanol|Butorphanol is intravenously administrated
194528|NCT02043366|Drug|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
194529|NCT02043366|Drug|Remifentanil|Remifentanil is intravenously administrated
194530|NCT02043366|Drug|Sufentanil|Sufentanil is intravenously administrated
194531|NCT02043379|Drug|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
194532|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
194533|NCT02043379|Other|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
194534|NCT02043392|Device|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
194535|NCT02043405|Behavioral|Weight loss and exercise training|
194536|NCT02043444|Radiation|FDG PET-CT|
194537|NCT02043457|Other|phenotyping|
194538|NCT02045875|Drug|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
193904|NCT02057913|Drug|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
193905|NCT02057926|Drug|The effect of tetracycline in degradation and permeability of collagen membranes.|
193906|NCT02057939|Drug|enzalutamide|160 mg orally once daily for six months
193907|NCT02057939|Drug|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
193908|NCT02057939|Radiation|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
193909|NCT02057952|Behavioral|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
194213|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 1|Patients will receive one of the following doses:
Dose Level one: 1x10^5 cells/kg
Dose Level 2: 5x10^5 cells/kg
Dose Level 3: 1x10^6 cells/kg
194214|NCT02050360|Drug|Sildenafil 40 mg|
194215|NCT02050360|Drug|Sildenafil 80 mg|
194216|NCT02050360|Drug|Placebo|
194217|NCT02050373|Radiation|Low-Level laser|
194218|NCT02050386|Other|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
194219|NCT02050386|Other|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
194220|NCT02050399|Other|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
194221|NCT00124098|Drug|Aranesp® (darbepoetin alfa)|
194222|NCT02050412|Other|Cat fur scratch test|
194223|NCT02050425|Device|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
194224|NCT02050425|Device|CPAP|Patients continue therapeutic CPAP therapy
194225|NCT02050438|Procedure|Total Knee Arthroplasty|
194226|NCT02050451|Dietary Supplement|Ensure Plus®|
193595|NCT02062892|Drug|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
193596|NCT00125775|Biological|Engerix-B|Engerix-B at 0, 1, 6 months
193597|NCT02065440|Drug|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
193598|NCT02065440|Drug|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
193599|NCT02065453|Device|disposable device (Ligasure, Covidien), and the reusable devices,(Robi bipolar and Storz laparoscopic shears).|Each patient serve as their own control where one side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien), and the other using the reusable Robi bipolar and Storz laparoscopic shears. We will randomize the side for each energy source used on each side for every case. The number of "sides" performed by the attending surgeon will equal that of the less experienced resident surgeon.
193600|NCT02065466|Drug|nab-paclitaxel|
193601|NCT02065466|Drug|Temozolomide|
193602|NCT02065466|Drug|Bevacizumab|
193603|NCT02065479|Drug|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
193910|NCT02057965|Drug|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight
193911|NCT02057978|Procedure|EXCEL DES implatation|Implant DES for CAD cases
193912|NCT02057978|Procedure|EXCEL-II DES implantation|Implant DES for CAD cases
193913|NCT02057991|Other|educational intervention|Watch an educational video
193914|NCT00124891|Drug|GAP-486|
193915|NCT02057991|Procedure|CAM exercise therapy|Watch a mindfulness exercise video
193916|NCT02057991|Other|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
193917|NCT02057991|Other|questionnaire administration|Ancillary studies
193918|NCT02057991|Other|laboratory biomarker analysis|Correlative studies
193919|NCT02058004|Procedure|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
198372|NCT02070432|Drug|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
198373|NCT00126204|Drug|Doxycycline|
198374|NCT02070458|Drug|ixazomib|Given PO
198375|NCT02070458|Drug|mitoxantrone hydrochloride|Given IV
198376|NCT02070458|Drug|etoposide|Given IV
198377|NCT02070458|Drug|cytarabine|Given IV
198378|NCT02070471|Drug|Placebo|Placebo
198379|NCT02070471|Drug|LC28-0126 Dose A|LC28-0126 Dose A
198380|NCT02070471|Drug|LC28-0126 Dose B|LC28-0126 Dose B
198381|NCT02070471|Drug|LC28-0126 Dose C|LC28-0126 Dose C
198382|NCT02070484|Biological|NuCel|
198383|NCT02070484|Biological|Deminaralized Bone Matrix|
198384|NCT00126217|Biological|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
198385|NCT02070497|Other|case management|case management group will accept the case manager's service; the control group will just accept the routine care
198386|NCT02070510|Drug|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
198387|NCT02070510|Drug|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
198388|NCT02070510|Drug|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
193604|NCT02065479|Drug|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
193605|NCT02065492|Drug|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
193606|NCT02065492|Drug|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
193607|NCT00125788|Drug|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
198066|NCT02075411|Drug|bupivacaine|Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.
Males Single shot peripheral nerve block
198067|NCT02075411|Drug|bupivacaine|Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.
Females Single shot peripheral nerve block
198068|NCT02037048|Drug|carboplatin|Given IV
198069|NCT02037048|Drug|paclitaxel|Given IV
198070|NCT02037061|Drug|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
198071|NCT00122863|Drug|Duloxetine Hydrochloride|
198072|NCT02037061|Other|Normal Saline|
198073|NCT02037074|Drug|Drug: EVP-6308|Arms 1, 2, 3
198074|NCT02037074|Drug|Placebo|Arm 4
198075|NCT02037087|Behavioral|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
198076|NCT02037087|Behavioral|Care seeking|Danger-sign recognition
Reminders for government projects
198077|NCT02037087|Behavioral|Full bank of SMS|Danger-sign recognition
Reminders for government projects
Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
198078|NCT02037126|Drug|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
198079|NCT02037126|Drug|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
198080|NCT02037139|Other|Screening|Standard care screening
198081|NCT02037139|Other|Brochure|Participants are given an illustrated educational brochure
198082|NCT00122863|Drug|placebo|
198083|NCT02037139|Behavioral|Education|Participants undergo a in-person educational intervention
198084|NCT02037152|Behavioral|Body scan exercise|The "body scan" includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions.
198085|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
198389|NCT02070510|Drug|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
197481|NCT02049242|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
197760|NCT02042391|Drug|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
197761|NCT02044588|Biological|HBsAg positive kidney allograft donor|
197762|NCT02044601|Drug|Onartuzumab|Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.
Phase II: Maximum tolerated dose from Phase I.
197763|NCT02044601|Drug|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
197764|NCT02044601|Drug|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
197765|NCT00123500|Behavioral|Environment|Environment
197766|NCT02044601|Drug|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
197767|NCT02044601|Radiation|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
197768|NCT02044614|Other|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
197769|NCT02044627|Drug|[14C-ETC-1002]|
197770|NCT02044640|Procedure|Appendectomy|
197771|NCT02044653|Drug|GX-E2|Each Group hemodialysis patients (n=10) will be administered GX-E2 5ug/kg to 8ug/kg
197772|NCT02044653|Drug|GX-E2|Each Group Peritoneal dialysis (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
197773|NCT02044653|Drug|GX-E2|Each Group Hemodialysis (n=25) and Peritoneal dialysis (n=25) will be administered GX-E2 3ug/kg to 8ug/kg
197774|NCT02044653|Drug|NESP (Aranesp)|Each Group Hemodialysis (n=25) and Peritoneal dialysis (n=25) will be administered NESP 30ug
197775|NCT02044666|Device|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
197776|NCT00123500|Other|Control Group|Control Group
197167|NCT02056873|Device|DBS System (RBS Setting)|The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.
Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.
Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
197168|NCT02056886|Procedure|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
197169|NCT02056899|Drug|Gabapentin|
197170|NCT02056912|Genetic|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
197171|NCT02056912|Biological|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
197172|NCT02056925|Other|Echocardiography|
197173|NCT02056938|Drug|Anti-Thymocyte Globulins treatment|
197174|NCT02056938|Drug|Basiliximab treatment|
197175|NCT02056951|Procedure|Multidisciplinary rehabilitation|Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:
health education
exercise therapy
back school
physical treatments
psychological interventions in groups and individual counselling
rehabilitation/social counselling.
197482|NCT02049255|Drug|Chloroprocaine|The Group "Chloroprocaine" will receive: Chloroprocaine: 50 mg in rachianesthesia
197483|NCT02049255|Drug|Marcaine|The Group "Marcaine" will receive: Marcaine: 12,5 mg in rachianesthesia
197484|NCT02049268|Drug|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
197485|NCT02049268|Drug|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
197486|NCT02051894|Drug|Dobutamine|Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.
If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis.
197487|NCT02051907|Device|KAM1403 Gel|
197488|NCT02051907|Device|aloevera gel|
196879|NCT02064296|Device|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
196880|NCT02064309|Device|Beta-Air device for encapsulation of transplanted human islets|
196881|NCT02064322|Device|SImmetry Implant|The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.
The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.
196882|NCT02064335|Behavioral|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
196883|NCT00125593|Drug|Ezetimibe 10mg|Once daily
196884|NCT02064348|Drug|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
196885|NCT02064348|Drug|placebo|Solution for s.c. injection or tablets for oral administration
196886|NCT02064348|Drug|moxifloxacin|Tablets for oral administration
196887|NCT02064361|Other|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
196888|NCT02064374|Drug|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
197176|NCT02056951|Procedure|Interprofessional rehabilitation|Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:
education about low back pain
behavioural exercise therapy
coping with pain
relaxation
work related informations
197177|NCT00124761|Radiation|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
197178|NCT02056977|Other|Titration|Individualized PEEP according to PEEP titration monitored by EIT
197179|NCT02056977|Other|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
197180|NCT02056990|Other|Advice|
197181|NCT02057003|Drug|DAA against HCV|
197182|NCT02057029|Behavioral|BCI Assay Results|The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
196595|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
196596|NCT00126451|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
196597|NCT02072343|Device|No-DCCM|
196598|NCT02072343|Device|DCCM|
196599|NCT02072343|Other|Water 5ml in tracheal tube|
196600|NCT02072343|Other|Water 10ml in tracheal tube|
196601|NCT02072356|Radiation|yttrium Y 90 glass microspheres|Given Interartrial
196602|NCT02072356|Other|laboratory biomarker analysis|Alpha-fetoprotein assay
196603|NCT02072369|Other|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
196604|NCT02072369|Other|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
196605|NCT02072382|Drug|Metformin|metformin 850mg twice a day for eight weeks
196606|NCT02072382|Drug|Placebo|
196607|NCT00002206|Drug|Adefovir dipivoxil|
196608|NCT00126451|Drug|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
196609|NCT02072395|Procedure|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
196610|NCT02072408|Drug|aflibercept|Three monthly intravitreal aflibercept (2mg) injections
Five bimonthly intravitreal aflibercept (2mg) injections
Rescue treatment: Verteporfin photodynamic therapy
Loss of five ETDRS letters or one Snellen line of vision from baseline
Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection
Presence of active polyp on indocyanine green angiography
196611|NCT02072421|Procedure|PCI|
196889|NCT02064374|Drug|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
196890|NCT02064374|Drug|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
196891|NCT02066909|Drug|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
196892|NCT02066909|Drug|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
192457|NCT01979991|Procedure|CT Imaging and Reconstruction|Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.
Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used.
192458|NCT01980004|Dietary Supplement|Potassium Citrate Supplementation|20 mEq taken twice daily
192459|NCT01980004|Other|Dietary Education|Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
192460|NCT00117884|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
192461|NCT01980017|Behavioral|Ottawa Model for Smoking Cessation|
192462|NCT01980030|Drug|Romiplostim|
192463|NCT01980043|Procedure|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
192464|NCT01980056|Drug|Vosaroxin|Dose level 1: Vosaroxin 50 mg/m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg/m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg/m2 IV on Days 1, 4, 8 and 11 of 28 day cycle Dose level 4: Vosaroxin 72 mg/m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
192465|NCT01980069|Drug|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
192466|NCT01980069|Drug|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
192467|NCT00118040|Procedure|therapeutic conventional surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
192468|NCT01982760|Drug|DDAVP|Patients Receiving DDAVP prior to operation
192469|NCT01982773|Behavioral|Virtual Hope Box Smartphone App|Smartphone app
192470|NCT01982773|Behavioral|Enhanced Treatment as Usual|Printed materials
192768|NCT00117494|Drug|Rosuvastatin|
192769|NCT01974817|Biological|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
192770|NCT01974843|Drug|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
191866|NCT01992705|Drug|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
191867|NCT01954589|Drug|ACT-462206 400mg|
191868|NCT01954589|Drug|ACT-462206 1000 mg|
191869|NCT01954589|Drug|ACT-462206 1500mg|
191870|NCT01954589|Drug|Almorexant 400mg|
192160|NCT01987596|Biological|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
192161|NCT00118313|Procedure|adjuvant therapy|
192162|NCT01987609|Drug|Hylenex|
192163|NCT01987609|Drug|Normal Saline|
192164|NCT01987622|Procedure|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
192165|NCT01987622|Procedure|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
192166|NCT01987635|Device|MEMO 3D ring|The experimental MEMO 3D ring is placed.
192167|NCT01987635|Device|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
192168|NCT01987635|Procedure|3D Echocardiography|
192169|NCT01987648|Procedure|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
192170|NCT01987661|Device|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
192171|NCT01987661|Device|Airtrap|Addional to the individally titrated BiPAP ventilation parameters the function "AirTrap Control" is added.
AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time.
191565|NCT01959477|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
191566|NCT00115752|Drug|COX Inhibitor|
191567|NCT01959477|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
191568|NCT01959490|Biological|trastuzumab|Given IV
191569|NCT01959490|Biological|Pertuzumab|Given IV
191570|NCT01959490|Drug|docetaxel|Given IV
191571|NCT01959490|Drug|carboplatin|Given IV
191572|NCT01959490|Drug|doxorubicin|Given IV
191573|NCT01959490|Drug|cyclophosphamide|Given IV
191574|NCT01959490|Drug|paclitaxel|Given IV
191575|NCT01959490|Other|laboratory biomarker analysis|Correlative studies
191576|NCT01959490|Other|pharmacogenomic studies|Correlative studies
191577|NCT00115765|Drug|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
191871|NCT01954589|Drug|Placebo|
191872|NCT01954602|Procedure|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
191873|NCT01954602|Procedure|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
191874|NCT01954615|Drug|5 mg ACT-281959 prodrug formulation I (Group A)|
191875|NCT00115258|Other|parenteral nutrition titrated to measured REE|
191876|NCT01954615|Drug|20 mg ACT-281959 prodrug formulation I (Group B)|
191877|NCT01954615|Drug|ACT-281959 prodrug formulation I (Groups C to G doses to be defined)|
191878|NCT01954615|Drug|ACT-281959 prodrug formulation II (Group G dose to be defined)|
191879|NCT01954615|Drug|ACT-246475 (Group G dose to be defined)|
191880|NCT01954615|Drug|Placebo (Groups A to F)|
196034|NCT02051400|Device|the Macintosh laryngoscope|
196035|NCT02051413|Drug|Venlafaxine extended release|antidepressant drug
196036|NCT00124176|Drug|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
196037|NCT02051426|Other|D-serine|single P.O. administration of D-serine (2.1g)
196038|NCT02051426|Other|Placebo|single P.O. administration of Placebo
196039|NCT02051439|Procedure|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
196040|NCT02051452|Drug|Methylphenidate|
196041|NCT02051452|Other|Saline|
196042|NCT02051465|Device|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
196043|NCT02051465|Device|Removal without overtube|Endoscopic removal of polyp without overtube
196044|NCT02051478|Other|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
196045|NCT02051478|Other|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
196046|NCT02054130|Drug|MEDI9929 - Medium Dose IP|Subcutaneous repeating dose
196047|NCT02054130|Drug|MEDI9929 - High Dose IP|Subcutaneous repeating dose
196048|NCT02054143|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
196049|NCT02054143|Drug|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
196050|NCT00124527|Drug|Irofulven + capecitabine|
196051|NCT02054156|Drug|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
196052|NCT02054156|Drug|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
196371|NCT02046603|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC weekly, 52 weeks
196372|NCT02046616|Drug|tocilizumab [RoActemra/Actemra]|162 mg administered subcutaneously weekly
195417|NCT02063672|Device|Lutonix DCB|
195418|NCT02063672|Device|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
195708|NCT02056314|Other|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
195709|NCT02056314|Other|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
195710|NCT02056327|Device|A novel monitoring suite of sensors will be inserted into the standard oral device.|
195711|NCT02056340|Drug|Atorvastatin|
195712|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
195713|NCT02056340|Drug|Placebo|
195714|NCT02056353|Device|LOGIC-Insulin algorithm|
195715|NCT02056353|Device|Paper protocol|
195716|NCT02056366|Drug|α-lipoic acid|α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
195717|NCT02056379|Drug|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
195718|NCT02058732|Procedure|ALS Patients receiving stem cells|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
195719|NCT02058732|Procedure|ALS patients not receiving stem cells|Amyotrophic lateral sclerosis patients who will not receive stem cells will have a magnetic resonance imaging(MRI)scan. This scan will be of the cervical spine and brain. The scan will last approximately 60 minutes. This MRI scan will be repeated at both 6 and 12 months. Subjects will also complete a clinical examination that takes about 30 minutes for each MRI scan.
195720|NCT02058745|Behavioral|CAU+ (Enhanced Care as Usual)|CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a "one-stop shopping" resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period.
195117|NCT02071615|Drug|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
195118|NCT02071615|Drug|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
195119|NCT02071615|Drug|placebo|
195120|NCT02071641|Drug|Sunitinib|
195121|NCT02071654|Device|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
195122|NCT02071667|Other|Blood draw|
195419|NCT02063685|Drug|R-CHOP|As induction therapy all patients will receive 6 courses of:
Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.
195420|NCT02063685|Drug|Observation|not maintenance therapy and followed-up with MRD monitoring.
195421|NCT02063685|Drug|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
195422|NCT02063685|Drug|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
195423|NCT02063685|Drug|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
195424|NCT02063698|Drug|auranofin|Given PO
195425|NCT00002200|Drug|Abacavir sulfate|
195426|NCT00125528|Drug|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
195427|NCT02063698|Other|placebo|Given PO
195428|NCT02063698|Other|questionnaire administration|Ancillary studies
195429|NCT02063711|Behavioral|Yoga intervention|
195430|NCT02063724|Biological|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 107 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
195431|NCT02066220|Drug|Reduced-intensity maintenance chemotherapy|Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.
Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.
Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.
194828|NCT02035891|Drug|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
194829|NCT02035891|Drug|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
194830|NCT02035904|Drug|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
194831|NCT02035904|Drug|saline|patient controlled infusion from the 2nd day after surgery
194832|NCT02035904|Drug|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
194833|NCT02035904|Device|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
194834|NCT02035904|Drug|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
194835|NCT02038036|Drug|ruxolitinib|Supplied as tablets. Starting dose of 10 mg bid. Based on efficacy and safety parameters, dose may be increased or decreased. Maximum dose allowed is 25mg bid.
194836|NCT02038049|Drug|VAY736|
194837|NCT02038049|Drug|Placebo|Placebo to VAY736
194838|NCT02038062|Procedure|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
194839|NCT00122980|Procedure|Iron Chelation|Iron Chelation Therapy
194840|NCT02038075|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|
195123|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.
The imaging is done for approximately 24 minutes at each time point.
195124|NCT02071706|Device|PET/MRI system|
195125|NCT02071732|Device|real repetitive Transcranial Magnetic Stimulation|
195126|NCT02071732|Device|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
195127|NCT00002205|Drug|Amprenavir|
195128|NCT00126334|Procedure|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
195129|NCT02071758|Biological|LEISH-F3 + SLA-SE|
195130|NCT02071758|Biological|LEISH-F3 + GLA-SE|
194539|NCT02045888|Device|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
194540|NCT00123591|Drug|activated recombinant human factor VII|
194841|NCT02038075|Behavioral|Treatment As Usual (TAU)|
194842|NCT02038101|Behavioral|Education and Feedback|
194843|NCT02038114|Behavioral|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
194844|NCT02038140|Device|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
194845|NCT02038153|Drug|Lenalidomide|Given PO
194846|NCT02038153|Other|Laboratory Biomarker Analysis|Correlative studies
194847|NCT02038179|Drug|Allopurinol|The subjects will be randomized to receive allopurinol as ULT, at a daily dose of 300 mg once daily by mouth or placebo. Participants will be asked to take 4 weeks of allopurinol or placebo, then will crossover to the other drug (after 4 week washout period) and take either allopurinol or placebo for an additional 4 weeks.
194848|NCT02038179|Drug|Placebo|The subjects will be randomized to receive allopurinol as ULT, at a daily dose of 300 mg once daily by mouth or placebo. Participants will be asked to take 4 weeks of allopurinol or placebo, then will crossover to the other drug (after 4 week washout period) and take either allopurinol or placebo for an additional 4 weeks.
194849|NCT02038192|Behavioral|Living with Hope Program|The Living with Hope Program is based on the research team's grounded theory study "Hope and Connection". The film " Connecting with Hope" reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer.
194850|NCT00122980|Drug|Hydroxyurea|Hydroxyurea
194851|NCT02038192|Behavioral|Stories of the Present|Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
194852|NCT02038218|Drug|4-Demethyl-4-cholestryloxycarbonylpenclomedine|This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.
Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:
Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;
Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.
Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance.
194853|NCT02038231|Behavioral|Parenting Mindfully Program|see Arm Description.
194854|NCT02038231|Other|Parent Education Program|See Arm Description.
194227|NCT02050451|Dietary Supplement|Multivitamin|
194228|NCT02050477|Procedure|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
194229|NCT02050516|Other|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
194230|NCT02050529|Drug|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
194231|NCT02053259|Behavioral|Reinforcement|
194232|NCT02053259|Behavioral|Static Goals|
194233|NCT00124397|Drug|Atorvastatin|
194234|NCT02053272|Drug|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
194235|NCT02053272|Drug|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
194541|NCT02045888|Biological|Placebo|Placebo is visually matched solution
194542|NCT02045901|Drug|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
194543|NCT02045901|Drug|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
194544|NCT02045914|Other|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
194545|NCT02045927|Other|sedation monitoring with RASS score|
194546|NCT02045927|Other|sedation monitoring with BIS-Guided monitoring|
194547|NCT02045940|Drug|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
194548|NCT02045940|Drug|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
194549|NCT02045953|Device|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
194550|NCT02045953|Device|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
193920|NCT02058017|Drug|OPB-51602|
193921|NCT02058030|Device|Insertion of ProSeal laryngeal mask airway|The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.
The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed
193922|NCT02058056|Radiation|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
193923|NCT02058069|Device|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
193924|NCT02058082|Procedure|Intracytoplasmic sperm injection|
193925|NCT00124904|Behavioral|Biofeedback|
193926|NCT02058095|Drug|Tadalafil|Tadalafil 5 mg tablet
193927|NCT02058095|Drug|Placebo|Placebo tablet
193928|NCT02058108|Drug|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
193929|NCT02060370|Drug|Sunitinib|Starting dose: 50 mg by mouth daily given for 2 weeks "on" followed by 1 week "off". 1 cycle is 6 weeks.
193930|NCT02060370|Behavioral|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
193931|NCT02060383|Drug|Pasireotide s.c.|To be administered to Cushing's patients
194236|NCT02053298|Drug|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
194237|NCT02053311|Drug|Orteronel|300mg orteronel
194238|NCT02053311|Drug|Placebo|Placebo
194239|NCT02053324|Radiation|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
194240|NCT02053337|Device|Self adhesive foam dressing|Self adhesive foam dressing
194241|NCT02053350|Drug|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
194242|NCT02053350|Other|Placebo|Glycine, 46g taken by mouth daily for 10 days
194243|NCT02053363|Drug|Tranexamic Acid (Cyklokapron)|
194244|NCT00124423|Procedure|Megavoltage CT scan|
193608|NCT02065505|Other|Mat Pilates|
193609|NCT02065505|Other|Water Pilates|
193610|NCT02065518|Device|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 20-30% of MVC during weeks 3-6 and 30-40% of MVC during weeks 6-9, 40-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
193611|NCT02065518|Behavioral|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved.At week 7, participants will be given a vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
193612|NCT02065518|Behavioral|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
193613|NCT02065531|Other|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
193614|NCT02065531|Other|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
193615|NCT02068144|Other|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
193616|NCT02068157|Other|Laboratory Biomarker Analysis|Correlative studies
193617|NCT02068157|Drug|Photodynamic Therapy|Undergo image-guided I-PDT
193618|NCT02068157|Drug|Porfimer Sodium|Given IV
193619|NCT02068170|Drug|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
193620|NCT02068196|Procedure|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
193932|NCT02060383|Drug|Sitagliptin|Taken for 16 weeks or until the drug is found to be not effective
193933|NCT02060383|Drug|Liraglutide|Patient will switch to liraglutide if sitagliptin is found to be inefficacious.
193934|NCT02060383|Drug|Insulin|Patient will take insulin for 16 weeks.
193935|NCT02060383|Drug|Pasireotide LAR|To be administered to acromegaly patients
198390|NCT02070523|Drug|VDCLD regimen|
198391|NCT02070536|Other|sRAGE|
198392|NCT02070549|Other|Laboratory Biomarker Analysis|Correlative studies
198393|NCT02070549|Other|Pharmacological Study|Correlative studies
198394|NCT02070549|Drug|Trametinib|Given PO
198395|NCT00126230|Drug|docetaxel and samarium|
198396|NCT02070575|Other|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
198397|NCT02070588|Device|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
198398|NCT02073136|Other|Diet with phosphate containing additives|
198399|NCT02073136|Other|Diet without phosphate containing additives|
198400|NCT00002207|Drug|Stavudine|
198401|NCT00126490|Biological|Bevacizumab|Given IV
198402|NCT02073149|Dietary Supplement|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
198403|NCT02073149|Dietary Supplement|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
198404|NCT02073149|Dietary Supplement|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
198405|NCT02073162|Procedure|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
198406|NCT02073175|Drug|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
198407|NCT02073188|Device|iBGStar|
198408|NCT02073188|Device|Traditional Glucometer|
197777|NCT02044679|Other|Water|
197778|NCT02044679|Other|No intervention|
197779|NCT02044705|Behavioral|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
197780|NCT02044731|Behavioral|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
198086|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
198087|NCT02037165|Drug|Pregabalin|Pregabalin hard capsule
198088|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
198089|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
198090|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
198091|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
198092|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
198093|NCT00122876|Procedure|Photodynamic therapy|
198094|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
198095|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
198096|NCT02037165|Drug|Celecoxib|Celecoxib hard capsule
198097|NCT02037178|Other|First ultrasound reading|First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
198098|NCT02039505|Drug|Vedolizumab|Vedolizumab intravenous injection
198099|NCT02039505|Drug|Vedolizumab placebo|Vedolizumab placebo
198100|NCT02039518|Drug|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
198101|NCT02039518|Other|observation group|observation group
198102|NCT00002184|Drug|Saquinavir|
198103|NCT00123084|Behavioral|No intervention (PD)|Subjects with PD in the no intervention group will receive no therapy during the study. Subjects will receive therapy after completion of the study.
198104|NCT02039531|Biological|Plasma rich in growth factors|
197489|NCT02051933|Drug|Botox|At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).
45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U
197490|NCT00124241|Drug|lamivudine|
197491|NCT02051933|Drug|Placebo|At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).
45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U
197492|NCT02051946|Device|Retroject Device only|If the patient agrees to participate in this study, the patient will be asked to lie in a supine position. Then a drop of proparacaine as well as a drop of betadine will be placed in the eye. The sterile, disposable Retroject Device will be pushed down over the eye. It will feel tight around the patient's eye for about a minute. The Retroject device will then be removed without injection of ethacrynic acid
197493|NCT02051946|Device|Retroject device with ethacrynic acid injection|The first 5 patients enrolled will serve as controls and will have the device alone placed on the eye (without an injection of ethacrynic acid). The next 15 patients will have the device placed on the eye with a subsequent injection of ethacrynic acid into the episcleral vein. The Retroject device will then be removed after injection.
197494|NCT02051946|Other|ethacrynic acid or balanced salt solution|randomization of ethacrynic acid or balanced salt solution
197495|NCT02051959|Device|Anodal stimulation of M1 + sham|8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
197496|NCT02051959|Device|Sham + Anodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
197781|NCT02044744|Behavioral|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
197782|NCT02044757|Behavioral|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
197783|NCT02044783|Behavioral|Behavioral Counseling|
197784|NCT02044796|Drug|Cladribine|Given IV
197785|NCT02044796|Drug|Cytarabine|Given IV
197786|NCT02044796|Biological|Filgrastim|Given SC
197787|NCT02047110|Drug|Placebo|Placebo
197788|NCT02047110|Drug|BI 655066|Medium Dose
197183|NCT02059317|Other|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
197184|NCT02059317|Other|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
197185|NCT02059317|Other|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
197186|NCT02059330|Drug|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
197187|NCT02059330|Drug|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
197188|NCT02059330|Drug|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
197189|NCT02059330|Drug|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
197190|NCT02059330|Drug|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
197191|NCT02059369|Procedure|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
197192|NCT02059369|Procedure|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
197497|NCT02051959|Device|Cathodal stimulation of M1 + sham|8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
197498|NCT02051959|Device|Sham + Cathodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
197499|NCT02051972|Device|Implanted with a Nanostim leadless pacemaker system|
197500|NCT02051985|Other|Aerobic exercise training|Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).
Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).
Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).
Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).
In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.
196893|NCT02066909|Drug|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
196894|NCT02066909|Drug|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
196895|NCT02066909|Drug|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
196896|NCT02066922|Device|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
196897|NCT02066922|Device|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
196898|NCT02066922|Device|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
196899|NCT02066935|Other|kidney transplant patient|kidney transplanted patients for at least one year
196900|NCT00125918|Drug|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
196901|NCT02066948|Other|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
196902|NCT02066948|Other|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
196903|NCT02066948|Other|meal pattern|skew or even
196904|NCT02066948|Dietary Supplement|even|even amount of protein distributed between each meal
196905|NCT02066948|Dietary Supplement|skew|a skewed amount of protein is distributed between each meal
196906|NCT02066974|Genetic|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
196907|NCT02066987|Behavioral|Implementation intention|It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!
197193|NCT00125034|Drug|Oxaliplatin|Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).
Until progression or unacceptable toxicity develops
197194|NCT02059382|Behavioral|ChiRunning training|
197195|NCT02059382|Behavioral|unblinded accelerometer|
197196|NCT02059382|Behavioral|participation in online social network|
192771|NCT01974843|Drug|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
192772|NCT01974869|Drug|Anti-tumor necrosis factor alpha agents|Treatment with biologics
192773|NCT01974882|Other|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
192774|NCT01974895|Biological|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
192775|NCT01974895|Biological|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
192776|NCT01974908|Procedure|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
192777|NCT01974921|Device|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
192778|NCT01974934|Drug|Desvenlafaxine Succinate|
192779|NCT00117507|Drug|deferasirox|deferasirox 20 mg/kg/day taken over one year.Deferasirox should be taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets should be dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
192780|NCT01974947|Other|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
192781|NCT01974973|Procedure|Autologous bone marrow mononuclear cell transplantation|
192782|NCT01977482|Drug|Placebo|Matching placebo tablet for GSK1278863
192783|NCT01977482|Drug|rhEPO|rhEPO will be procured from local market
192784|NCT01977495|Behavioral|Financial Incentive: Fixed Lottery|Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
192785|NCT01977508|Device|ePTFE vascular access grafts|
193080|NCT01969994|Other|(−)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (−)-epicatechin and a single-carbon-14 radiolabeled (−)-[2-14C]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (−)-[2-14C]epicatechin.
192172|NCT00118326|Biological|filgrastim|
192173|NCT01987674|Dietary Supplement|Pre-meal protein drink|
192174|NCT01987674|Other|Water drink|
192175|NCT01987687|Behavioral|Exercise|Exercise at 55% of maximum power output for 30 min.
192176|NCT01990079|Other|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
192471|NCT01982786|Radiation|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
192472|NCT01982786|Radiation|Brachytherapy|Brachytherapy boost
192473|NCT01982799|Drug|Oral placebo|placebo
192474|NCT01982799|Drug|Oral ibuprofen|Ibuprofen
192475|NCT01982799|Drug|oral naproxen|naproxen
192476|NCT01982799|Drug|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
192477|NCT01982812|Drug|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
192478|NCT00118040|Other|pharmacological study|Correlative studies
192479|NCT01982812|Drug|Standard AED|Active comparitor, Standard AED
192480|NCT01982825|Behavioral|Online intervention arm|See online intervention arm
192481|NCT01982825|Behavioral|Online control arm|See online control arm
192482|NCT01982838|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
192483|NCT01982838|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
191881|NCT01954628|Drug|AQX-1125|Synthetic SHIP1 activator
191882|NCT01954628|Drug|Placebo|Placebo control
191883|NCT01954641|Other|ACCURE Navigator|The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the "teachback" method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions.
191884|NCT01954641|Other|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
191885|NCT01954654|Device|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
191886|NCT00115271|Drug|Nutritional supplements|
191887|NCT01954654|Other|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
191888|NCT01954680|Behavioral|COGFLEX-skill building levels|COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).
In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.
All children will play COGFLEX twice per week for 8-weeks.
This same approach has shown great success in many psychiatric disorders including schizophrenia.
This is the first such study in children/adolescents with bipolar disorder.
191889|NCT01954680|Behavioral|COGFLEX-control condition|In the R33, the control condition will be the same COGFLEX "game"--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
191890|NCT01954693|Drug|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
192177|NCT01990092|Other|Metanx|Metanx is a prescription medical food.
192178|NCT01990092|Other|Placebo|
192179|NCT01990118|Drug|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
192180|NCT01990118|Drug|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
192181|NCT01990131|Other|Cognitive Anxiety Sensitivity Treatment|
192182|NCT01990131|Other|Physical Health Education Training|
192183|NCT01990144|Drug|Bendamustine+Rituximab|Patients will receive :
Rituximab 375 mg/m2 intravenously on day 1*
Bendamustine 90 mg/m2 intravenously on days 2 and 3** Treatment will be administered on a 28-day cycle basis.
Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.
After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice.
196373|NCT02046629|Drug|Teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
196374|NCT00123682|Procedure|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
196375|NCT02046629|Drug|cholestyramine|Pharmaceutical form:power Route of administration: oral
196376|NCT02046642|Behavioral|Maternal rest in left lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
196377|NCT02046642|Behavioral|Maternal rest in right lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
196378|NCT02046655|Drug|Corifollitropin alfa|
196379|NCT02046655|Drug|rFSH|
196380|NCT02046668|Drug|spironolactone|spironolactone 25mg daily for 12 weeks
196381|NCT02046694|Drug|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
196382|NCT02046707|Other|initial evaluation|
196383|NCT02046707|Other|Period of cardiac rehabilitation|
196384|NCT02046707|Other|final evaluation|
196385|NCT00123682|Procedure|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
196386|NCT02046707|Other|Concentric and eccentric exercise sessions|
196387|NCT00123968|Biological|VRC-HIVDNA016-00-VP|1x10^11 per unit vaccine administered intramuscularly via Bioinjector
196388|NCT02048761|Drug|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
196389|NCT02048774|Behavioral|Designation of Social Positioning|
196390|NCT02048787|Drug|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
196391|NCT02048800|Drug|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged < 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged > 12 months)
196392|NCT02048813|Drug|Cyclophosphamide|Given IV
195721|NCT02058745|Behavioral|Beating the Blues|Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple "homework" after each lesson.
195722|NCT02058745|Behavioral|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
196053|NCT02054156|Drug|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
196054|NCT02054182|Drug|Vitamin D|Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
196055|NCT02054195|Behavioral|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
196056|NCT02054195|Behavioral|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
196057|NCT02054208|Biological|human umbilical cord blood derived mesenchymal stem cells|Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
196058|NCT02054208|Procedure|Ommaya reservoir insertion|
196059|NCT02054208|Other|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
196060|NCT02054221|Procedure|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
196061|NCT00124540|Drug|misoprostol|
196062|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
196063|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
196064|NCT02054247|Device|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
196065|NCT02054247|Device|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
195432|NCT02066220|Radiation|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
195433|NCT02066220|Drug|Maintenance chemotherapy|Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.
Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients).
195434|NCT00125879|Biological|Myozyme|20 mg/kg qow or 40 mg/kg qow
195435|NCT02066233|Device|EG scan (transnasal endoscopy)|
195436|NCT02066246|Device|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
195723|NCT00124982|Drug|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
195724|NCT02058758|Device|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
195725|NCT02058784|Drug|pracinostat|
195726|NCT02058797|Behavioral|Coherence Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
195727|NCT02058797|Behavioral|Cognitive Behavioral Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
195728|NCT02058810|Device|Nasal high flow|
195729|NCT02058810|Device|Conventional nasal oxygen|
195730|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
195731|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
195732|NCT02058823|Drug|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
195733|NCT02058823|Drug|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
195734|NCT00124982|Drug|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
195735|NCT02058836|Drug|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
195131|NCT02071771|Device|Nelfilcon A toric contact lenses|
195132|NCT02071771|Device|Etafilcon A toric contact lenses|
195133|NCT02071797|Device|Induced Therapeutic Hypothermia|Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
195134|NCT02071810|Drug|BIA 9-1067|
195135|NCT02071810|Drug|Placebo|
195136|NCT02071823|Drug|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
195137|NCT02071836|Behavioral|Right Turns web application|
195138|NCT02071836|Behavioral|Treatment as usual|
195139|NCT00126347|Procedure|supplementation with betaine, serine, and folic acid|
195140|NCT02071849|Device|Bicuspid Aortic Valve Repair|Surgical repair of bicuspid aortic valves.
195141|NCT02074150|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
195142|NCT02074150|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
195143|NCT02074150|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
195437|NCT02066246|Device|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
195438|NCT02066285|Drug|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
195439|NCT02066298|Drug|Mometasone 220mcg BID|Mometasone is an ICS
195440|NCT02066298|Drug|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
195441|NCT02066298|Drug|Placebo|
195442|NCT02066311|Drug|Nelfinavir|
195443|NCT02066337|Procedure|scaling and root planing|
194855|NCT02038244|Other|Multimodal integrative medicine inpatient treatment program|
194856|NCT02040714|Procedure|multiple epiphyseal drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
194857|NCT02040727|Behavioral|Resistance Training|Supervised strength training 3 days per week for 24 weeks
195144|NCT02074150|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
195145|NCT00126555|Other|laboratory biomarker analysis|Correlative studies
195146|NCT02074150|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
195147|NCT02074163|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
195148|NCT02074163|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
195149|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195150|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195151|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195152|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 24,|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195153|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195154|NCT02074163|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195155|NCT02074163|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195156|NCT00126568|Drug|sorafenib tosylate|Given orally
194551|NCT00123604|Drug|Carvedilol|25 mg twice daily for five months.
194552|NCT02045966|Drug|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
194553|NCT02045966|Drug|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
194554|NCT02045966|Drug|BMS-791325|
194555|NCT02045979|Drug|BI 695501|BI 695501 single s.c. injection
194556|NCT02045979|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
194557|NCT02045979|Drug|adalimumab-US source|adalimumab-US source single s.c. injection.
194558|NCT02045992|Dietary Supplement|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
194559|NCT02046005|Behavioral|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
194560|NCT02046005|Behavioral|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
194858|NCT02040727|Behavioral|No Resistance Training|No supervised strength training throughout the study
194859|NCT02040753|Behavioral|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
194860|NCT02040766|Drug|Beclomethasone dipropionate|Participants are instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
194861|NCT02040766|Drug|Placebo|Participants are instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
194862|NCT02040766|Drug|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
194863|NCT02040779|Drug|Beclomethasone dipropionate breath-actuated inhaler|Participants are instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
194864|NCT02040779|Drug|Placebo breath-actuated inhaler|Placebo breath-actuated inhaler (BAI) 1 inhalation twice daily for a total daily dose of 0 mcg.
194865|NCT00123201|Drug|Dronabinol MDI|
194245|NCT02053376|Drug|Regorafenib|regorafenib (120 mg) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
194246|NCT02053389|Behavioral|DVD Decision Aid|The decision aid, "Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer" is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation.
194247|NCT02053389|Behavioral|Written decision aid|A written decision aid entitled "Making the Choice: Deciding What to Do About Early Stage Prostate Cancer" that describes treatment options for early stage prostate cancer.
194248|NCT02053402|Drug|Vitamin D|Vitamin D daily for six months
194249|NCT02053415|Dietary Supplement|Krill oil low dose|3 capsules krill oil per day
194250|NCT02053415|Dietary Supplement|Krill oil high dose|9 capsules krill oil per day
194251|NCT02053428|Procedure|percutaneous image-guided gastrostomy|
194252|NCT02053454|Drug|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
194253|NCT02053454|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
194254|NCT02053467|Other|Champlain BASE eConsult Service|Building on a recent successful pilot project, and using a pre-existing secure web-based collaboration space, primary care providers will submit a patient-specific clinical question to a specialist using a standardized electronic form that permits attachments (e.g., laboratory results, digital images). The specialist responds within one week by either: i) directly answering the question (negating the need for referral), ii) asking for additional patient information, or iii) requesting an in-person referral.
194255|NCT00124436|Drug|alitretinoin|
194256|NCT02055703|Drug|donepezil|
194257|NCT02055716|Drug|Sulforadex|
194561|NCT02048098|Drug|Vaginal misoprostol|400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
194562|NCT02048098|Drug|Buccal misoprostol|400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
193936|NCT02060383|Drug|Metformin|If previously normo-glycemic patients experience increases in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they will start anti-diabetic treatment using metformin. If they continue to experience increases in their fasting blood glucose within the first 16 weeks, they will be randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks.
193937|NCT02060396|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
193938|NCT02060409|Genetic|spliceosome|spliceosome mutations
193939|NCT00125177|Behavioral|Knack therapy|
193940|NCT02060422|Behavioral|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
193941|NCT02060422|Behavioral|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
193942|NCT02060435|Other|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
193943|NCT02060448|Behavioral|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
193944|NCT02060448|Behavioral|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
193945|NCT02060461|Device|FS200 Laser|
193946|NCT02060474|Drug|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
193947|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
193948|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
193949|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
193950|NCT00002198|Drug|Abacavir sulfate|
193951|NCT00125190|Drug|rhIGF-1 (mecasermin) for a period of 86 weeks|once a day rhIGF-1 injections
193952|NCT02060500|Procedure|Cardiaplication|
194258|NCT02055716|Drug|alpha-cyclodextrin|
194259|NCT02055729|Biological|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
198409|NCT02073201|Other|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
193621|NCT02068196|Drug|Ipilimumab|
193622|NCT02068209|Drug|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
193623|NCT02068209|Drug|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
193624|NCT00126022|Drug|Tedisamil sesquifumarate|
193625|NCT02068222|Drug|ABT-450/r|Tablet
193626|NCT02068222|Drug|ABT-530|Tablet
193627|NCT02068222|Drug|Ribavirin (RBV)|Tablet
193628|NCT02068235|Drug|Ponesimod 5mg i.v.|
193629|NCT02068235|Drug|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
193630|NCT02068235|Drug|Ponesimod 10 mg tablet|
193631|NCT02068248|Dietary Supplement|Soluble Fibre|
193632|NCT02068261|Behavioral|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
193633|NCT02068261|Behavioral|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
193634|NCT02068287|Drug|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
193635|NCT00126035|Device|Migraid|
193636|NCT02068313|Radiation|Toxicity and outcome measures of IMRT|
193637|NCT02068326|Behavioral|Mentalization Based Treatment|
193638|NCT02068326|Behavioral|Treatment As Usual|Treatment As Usual
193639|NCT02068339|Drug|Oltipraz 1 (90mg)|
193640|NCT02068339|Drug|Placebo|
193641|NCT02068339|Drug|Oltipraz 2 (120mg)|
198105|NCT02039531|Drug|Hyaluronic Acid|
198106|NCT02039544|Drug|Xuebi formula|
198107|NCT02039544|Drug|placebo|
198108|NCT02039557|Genetic|NiCord|
198109|NCT02039570|Other|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
198110|NCT02039583|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
198111|NCT02039596|Other|Diet|
198410|NCT02073201|Other|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
198411|NCT02073201|Other|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
198412|NCT00126490|Other|Laboratory Biomarker Analysis|Correlative studies
198413|NCT02073214|Other|Probiotic|Standard treatment plus probiotic
198414|NCT02073214|Other|Placebo|Standard treatment plus placebo
198415|NCT02073227|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
198416|NCT02073227|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
198417|NCT02073227|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
198418|NCT02073227|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
198419|NCT00126646|Procedure|antibody-drug conjugate therapy|
198420|NCT02075411|Device|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
198421|NCT02075411|Device|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
197789|NCT02047110|Drug|BI 655066|Low Dose
197790|NCT02047110|Drug|BI 655066|High Dose
197791|NCT02047123|Dietary Supplement|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
197792|NCT00123773|Procedure|Positron Emission Tomography|
197793|NCT02047136|Other|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
197794|NCT02047136|Other|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
197795|NCT02047149|Drug|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
197796|NCT02047149|Drug|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
197797|NCT02047149|Drug|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
197798|NCT02047149|Drug|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
197799|NCT02047162|Drug|Bismuth subsalicylate|
197800|NCT02047162|Other|Placebo|Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
198112|NCT02039635|Dietary Supplement|Korean Red Ginseng|Given Orally
198113|NCT02039635|Dietary Supplement|Placebo|Given Orally
198114|NCT00123084|Behavioral|HC control|Subjects without PD in the HC control group will not receive any therapy, either during or after completion of the study.
198115|NCT02039648|Other|Rumex acetosa L. extract|
198116|NCT02039648|Other|Placebo|
198117|NCT02039661|Drug|Lidocaine Spray|These patients received 2 puff lidocaine spray
198118|NCT02039661|Drug|Placebo|
197501|NCT00124254|Procedure|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
197502|NCT02054650|Other|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
197503|NCT02054650|Other|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
197504|NCT02054663|Drug|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
197505|NCT02054676|Radiation|Cone-Beam Computed Tomography preoperative evaluation.|Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. "i-CAT", Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):
Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;
Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).
All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible.
197506|NCT02054676|Procedure|Intraoperative edentulous jaw segment parameters evaluation.|Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.
Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).
The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:
implant drill slippage deeper than planned;
implant threads coverage;
etc.
197507|NCT02054676|Device|Endosseous dental implant placement.|Endosseous dental implant (e.g. "Bone Level SLA" implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.
Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.
Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.
Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).
Bone and soft tissue augmentation are made if necessary after dental implant placement.
197801|NCT02047175|Drug|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
197802|NCT02047175|Drug|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
197803|NCT00123786|Procedure|Positron Emission Tomography|Positron Emission Tomography
197804|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
197805|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
197806|NCT02047201|Radiation|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
197197|NCT02059382|Behavioral|participation in study website|
197198|NCT02059382|Behavioral|Technology support for behavior change|
197199|NCT02059395|Other|Mastery based learning|Participants are allowed to follow the course content at their own speed
197200|NCT02059395|Other|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
197201|NCT02059408|Other|Screen-Educate|
197202|NCT02059408|Other|Screen-Educate and Treat|
197203|NCT02061800|Drug|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
197204|NCT00125346|Drug|Tobramycin Inhalation Powder|
197205|NCT02061800|Drug|Methylprednisolone|Methylprednisolone will be give IV slow infusion over 15-30 minutes.
197206|NCT02061813|Drug|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
197207|NCT02061813|Drug|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
197208|NCT02061813|Drug|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
197209|NCT02061813|Drug|Placebo|
197210|NCT02061839|Other|Sunscream with visible light protection|
197211|NCT02061839|Other|Sunscream|
197212|NCT02061852|Device|Simeox|
197213|NCT02061852|Procedure|Physiotherapy|
197214|NCT02061865|Drug|REGN2176-3|
197215|NCT00125359|Drug|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
197508|NCT02054676|Radiation|Dental implant position evaluation.|Periapical radiograph (e.g. "Kodak RVG 6100 Intraoral Digital Imaging System", Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.
Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).
Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined.
193081|NCT01970007|Device|Zilver Vena Venous Stent|stenting
193082|NCT01970020|Drug|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
193083|NCT01970033|Drug|Placebo|Run in period ：oral tablets of Placebo twice daily for 2 weeks
Phase A : oral tablets of Placebo twice daily for 24 weeks
Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks
193084|NCT01970033|Drug|SP2086 50 mg b.i.d.|Run-in period: placebo twice daily for 2 weeks
Phase A:SP2086 50 mg b.i.d for 24 weeks
Phase B:SP2086 50 mg b.i.d for 28 weeks
193085|NCT01970033|Drug|SP2086 100 mg q.d.|Run-in period:placebo twice daily for 2 weeks
Phase A: SP2086 100 mg q.d. for 24 weeks
Phase B: SP2086 100 mg q.d. for 28 weeks
193086|NCT00116987|Device|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
193087|NCT01970046|Drug|Placebo/Metformin|Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks
Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks
Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks
193088|NCT01970046|Drug|SP2086 50 mg b.i.d/Metformin|Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks
Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks
Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks
193089|NCT01970046|Drug|SP2086 50 mg q.d./Metformin|Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks
Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks
Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks
193090|NCT01970059|Drug|Extended-Release Carvedilol Sulfate|
193091|NCT01970059|Drug|Sustained-release Metoprolol Succinate|
193092|NCT02052687|Drug|Placebo 1|Placebo cream 1
193093|NCT02052687|Drug|Placebo 2|Placebo cream 2
193094|NCT02052713|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
193095|NCT02052713|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
193096|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
193097|NCT02052726|Biological|Placebo|Placebo administered at Month 0, 1, and 3.
193098|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
193099|NCT02052726|Biological|placebo|Placebo administered at Day 1, 8, and 30.
192484|NCT01982851|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
192485|NCT01982851|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
192486|NCT01982864|Drug|Gentamicin|The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.
Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…).
The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD).
192487|NCT01985152|Drug|Placebo|
192488|NCT01985165|Drug|Imrecoxib|
192786|NCT01977521|Device|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
192787|NCT01977521|Device|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
192788|NCT00117676|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet administered orally once daily
192789|NCT01977534|Device|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating [formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating].
192790|NCT01977547|Biological|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
192791|NCT01977560|Behavioral|Optimum Lifestyle Intervention|Participants will follow a high-protein, low-carbohydrate diet and participate in supervised exercise.
192792|NCT01977560|Behavioral|Standard Care|Participants will be given advice on exercise and the American Diabetes Association diet, as if they went to a Diabetes clinic.
192793|NCT01977573|Drug|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
192184|NCT01990157|Drug|TAB08|Weekly intravenous administration in escalating doses.
192185|NCT00118443|Behavioral|Question, Persuade, Refer (QPR) training|
192186|NCT01990183|Device|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home ‐ session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
192187|NCT01990183|Other|Standard Care|Current care advices in the management of preterm infants in the first months of life
192188|NCT01990196|Drug|degarelix|Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.
192189|NCT01990196|Drug|enzalutamide|Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.
192190|NCT01990196|Drug|trametinib|Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician
192191|NCT01990196|Drug|dasatinib|Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician
192192|NCT01990209|Drug|Orteronel|
192193|NCT01990235|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
192489|NCT01985178|Dietary Supplement|Omega-3 Fatty Acid Supplement|
192490|NCT01985191|Drug|SAR405838|Pharmaceutical form:capsule
Route of administration: oral
192491|NCT01985191|Drug|Pimasertib|Pharmaceutical form: capsule
Route of administration: oral
192492|NCT01985204|Dietary Supplement|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
192493|NCT01985204|Dietary Supplement|Placebo tablet|Placebo tablet without iodine
192494|NCT01985230|Device|ReActiv8 Implantable Stimulation System implanted and activated.|
196684|NCT02041689|Behavioral|Guided Activities|This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.
The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.
For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.
The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment.
196685|NCT02041702|Procedure|Cardiac MRI scan|Patients who are randomized into the Cardiac MRI Scan group will undergo a Cardiac MRI scan
196686|NCT00123305|Drug|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
196687|NCT02041702|Device|SJM MRI conditional pacing system implant|Patients in both arms of this study should receive SJM MRI conditional pacing system implant before randomization
196688|NCT02041715|Drug|TKM-100802 for Injection|IV infusion
196689|NCT02041715|Drug|Placebo|IV infusion
196690|NCT02041741|Behavioral|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
196691|NCT02041741|Behavioral|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
196692|NCT02041754|Device|IQP-AK-102|
196693|NCT02041754|Device|Placebo|
196694|NCT02041767|Drug|Ertapenem|One single injection of 1g of ertapenem before surgery
196695|NCT02041780|Procedure|Shearwave electrography|
196696|NCT02041793|Procedure|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
196697|NCT00123305|Drug|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
196698|NCT02041793|Procedure|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
196699|NCT02041819|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
196700|NCT02041832|Other|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
196701|NCT02041832|Device|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
196066|NCT02056379|Drug|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
196067|NCT02056392|Drug|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
196068|NCT02056392|Drug|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
196393|NCT02048813|Drug|Fludarabine Phosphate|Given IV
196394|NCT02048813|Drug|Ibrutinib|Given PO
196395|NCT02048813|Other|Laboratory Biomarker Analysis|Correlative studies
196396|NCT02048813|Other|Quality-of-Life Assessment|Ancillary studies
196397|NCT02048813|Biological|Rituximab|Given IV
196398|NCT00123968|Biological|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
196399|NCT02048826|Device|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
196400|NCT02048826|Device|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
196401|NCT02048826|Device|FINGER III|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting III
196402|NCT02048852|Other|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
196403|NCT02048852|Other|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
196404|NCT02048852|Other|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
196405|NCT02048852|Other|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
196406|NCT02048865|Drug|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
196407|NCT02048865|Drug|Placebo drug|placebo drug 2.5mg BID for 6 months
196408|NCT02048891|Drug|GnRH agonist trigger|
195736|NCT02058836|Procedure|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
195737|NCT02061228|Device|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
195738|NCT02061241|Procedure|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
195739|NCT02061241|Procedure|Pacing in other suitable vein|Pacing in other suitable vein
195740|NCT02061254|Device|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
196069|NCT02056392|Drug|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
196070|NCT02056405|Drug|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
196071|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
196072|NCT02056405|Drug|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
196073|NCT02056418|Dietary Supplement|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
196074|NCT02056418|Drug|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
196075|NCT02056431|Behavioral|IVR Intervention Group|595 participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
196076|NCT02056444|Drug|Tranexamic Acid|
196077|NCT02056457|Behavioral|Responsible Fatherhood or Healthy Marriage Program|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
196078|NCT02056457|Behavioral|Other services in the community|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
195444|NCT02066337|Drug|placebo gel|
195445|NCT00125892|Drug|duloxetine|
195446|NCT02066337|Drug|Ozonated olive oil gel|
195447|NCT02066350|Procedure|Single pancreas transplantation|
195448|NCT02066363|Dietary Supplement|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
195449|NCT02066363|Dietary Supplement|Parenteral nutrition|Supportive parenteral nutrition.
195450|NCT02066376|Drug|NE-58095|NE-58095 tablets
195451|NCT02066376|Drug|NE-58095NF|NE-58095NF tablets
195452|NCT02066389|Drug|ABT-494|
195453|NCT02066389|Drug|Placebo|
195454|NCT02066402|Drug|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
195455|NCT02066402|Drug|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
195456|NCT02069132|Drug|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
195457|NCT00126113|Behavioral|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
195458|NCT02069145|Drug|OMP-54F28 with Sorafenib|
195459|NCT02069158|Drug|PF-05212384|iv administrartion
195460|NCT02069158|Drug|Paclitaxel|iv administration
195461|NCT02069158|Drug|Carboplatin|iv administration
195741|NCT02061254|Device|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
195742|NCT02061254|Device|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
195743|NCT02061254|Procedure|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
195744|NCT02061267|Dietary Supplement|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
195157|NCT02074163|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195158|NCT02074163|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195159|NCT02035904|Drug|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
195160|NCT00122746|Radiation|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
195161|NCT02035917|Device|Locking plate|
195462|NCT02069184|Drug|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
195463|NCT02069184|Other|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
195464|NCT02069197|Other|Ketogenic diet|ketogenic diet will consist of 3:1[fat]:[protein+carbohydrate]weight ratio with 1600 kcal restriction. Diet will last 9 months.
195465|NCT02069197|Drug|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
195466|NCT02069197|Other|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
195467|NCT02069210|Other|Blood transfusion|Intraoperative blood transfusion
195468|NCT00126126|Other|EBAR Program|Evidence Based Amputee Rehabilitation Program
195469|NCT02069223|Procedure|Gastrectomy|
195470|NCT02069223|Procedure|BPD-DS|
195471|NCT02069236|Other|G6PD Test|All subjects are tested by multiple G6PD tests
195472|NCT02069249|Behavioral|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
195473|NCT02069249|Behavioral|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
194866|NCT02040779|Drug|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
194867|NCT02040792|Drug|TD-4208|
194868|NCT02040792|Drug|Placebo|
194869|NCT02040805|Behavioral|Group Cognitive Behavioral Therapy|Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing "clutter buddies", and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF.
194870|NCT02040805|Behavioral|Peer Facilitated Manualized Support Group|Sixteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
194871|NCT02040818|Drug|tigecycline, N-acetylcysteine, heparin combination|
194872|NCT02040818|Device|guide-wire exchange|
194873|NCT02040831|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
194874|NCT02040831|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
194875|NCT02040844|Drug|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
195162|NCT02035917|Device|Non-Locking plate|
195163|NCT02035930|Drug|dexmedetomidine|
195164|NCT02035943|Dietary Supplement|Insulin separated|separate continuos infusion of insulin
195165|NCT02035943|Dietary Supplement|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
195166|NCT02035956|Biological|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
195167|NCT02035969|Behavioral|Enhanced Treatment Support (ETS)|Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.
For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup.
194563|NCT02048111|Biological|IB1001|Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.
The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.
The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator.
194564|NCT02048124|Device|25g standard needle|
194565|NCT02048124|Device|25d ProCor needle|
194566|NCT02048137|Device|Transcranial direct current stimulation|
194567|NCT02048150|Biological|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
194568|NCT02048150|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
194569|NCT02048150|Other|diffuse optical imaging|Undergo IOOI
194570|NCT00123903|Drug|lisinopril|
194571|NCT02048150|Other|pharmacological study|Correlative studies
194572|NCT02048189|Drug|LEVEMIR|
194573|NCT02048189|Drug|APIDRA|
194574|NCT02048215|Drug|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
194575|NCT02048215|Drug|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
194876|NCT00123214|Drug|Controlled Dietary Intervention|
194877|NCT02043496|Behavioral|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
194878|NCT02043496|Behavioral|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
194260|NCT02055729|Biological|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 & 28)
194261|NCT02055729|Biological|Stool sample|Stool samples will be collected on days 0 and 28.
194262|NCT02055729|Biological|Urine sample|Urine samples will be collected on days 0 and 28.
194263|NCT02055742|Device|illumigene CT and NG assays, illumipro-10|
194264|NCT00124644|Procedure|chemotherapy|
194265|NCT02055781|Drug|Pacritinib|
194266|NCT02055781|Drug|Best Available Therapy|
194267|NCT02055794|Procedure|Suturing of the perineal skin|
194268|NCT02055794|Procedure|Closing perineal skin with surgical glue|
194269|NCT02055794|Procedure|No suturing of the perineal skin|
194270|NCT02055807|Other|PEEP and recruitment maneuvers|
194271|NCT02055807|Other|ZEEP (no PEEP nor recruitment maneuver)|
194272|NCT02055820|Drug|CHOP|Standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP)
194273|NCT02055820|Drug|GDC-0199|Daily doses of GDC-0199
194274|NCT02055820|Drug|obinutuzumab|Obinutuzumab 1000 mg on Days 1, 8, 15, Cycle 1. Following cycles on Day 1.
194275|NCT00124644|Procedure|enzyme inhibitor therapy|
194276|NCT02055820|Drug|rituximab [MabThera/Rituxan]|Rituximab 375 mg/m2 on Day 1 of every cycle
194277|NCT02055833|Dietary Supplement|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
194278|NCT02055833|Other|Nutritional counseling|Nutritional counseling
194279|NCT02055846|Procedure|Realisation of blood sample, urinary sample and tumor biopsy|
194280|NCT02055859|Radiation|Radiosurgery|
194281|NCT02055872|Drug|Intravenous albumin|
194282|NCT02055872|Drug|Normal saline|
193642|NCT02068352|Drug|OPA-15406|0.3% or 1% OPA-15406 topical ointment, applied twice daily for 8 weeks
193643|NCT02068352|Drug|Placebo|
193644|NCT02068365|Drug|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
193645|NCT02070939|Drug|PF-06260414|Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
193953|NCT02062892|Drug|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
193954|NCT02062905|Drug|OTX-DP treatment|
193955|NCT02062905|Device|Placebo Plug with no drug|
193956|NCT02062918|Device|Abdominal belt|
193957|NCT02062931|Biological|Stem Cell Preparation and Injection|Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.
Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .
Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue.
193958|NCT00125463|Drug|Candesartan cilexetil|
193959|NCT02062944|Drug|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
193960|NCT02062970|Biological|blood draw|
193961|NCT02062983|Drug|Herceptin|Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.
Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression.
193962|NCT02062996|Drug|Oxymetazoline|
193963|NCT02063022|Drug|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
198422|NCT02075424|Other|salivary sampling by a biomnis swab|Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.
Only one sampling will occur to doctors who are assigned to a single workstation.
Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.
To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.
There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.
They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville.
198423|NCT02075437|Behavioral|Feeling and Body Investigators with Functional Abdominal Pain|Investigator's ten session intervention trains children to be "Feeling and Body Investigators". Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).
If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation.
198424|NCT02075437|Behavioral|Treatment Strategies|identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:
adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;
incorporate caregivers as role models and facilitators based on attachment research.
193646|NCT02070939|Drug|Placebo|Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
193647|NCT02070952|Radiation|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
193648|NCT02070965|Drug|DFD01 Spray|
193649|NCT00002205|Drug|Abacavir sulfate|
193650|NCT00126256|Drug|irinotecan|
193651|NCT02070965|Drug|Comp01 Lotion|
193652|NCT02070978|Drug|Atacicept 75 mg|Subjects who received 75 mg atacicept in the ADDRESS II trial, will continue receiving 75 mg atacicept as subcutaneous injection once weekly for 96 weeks in this trial.
193653|NCT02070978|Drug|Atacicept 150 mg|Subjects who received placebo or 150 mg atacicept in the ADDRESS II trial, will receive 150 mg atacicept as subcutaneous injection once weekly for 96 weeks in this trial.
193654|NCT02070991|Drug|Macitentan|oral tablet, 10 mg once daily
193655|NCT02070991|Drug|Placebo|matching placebo
193656|NCT02071004|Drug|DS-1040b|IV of 6 mg given once over 30 minutes
193657|NCT02071004|Drug|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
193658|NCT02071030|Procedure|Third molar removal|Surgically removing the third molar in the lower jaw
198119|NCT02039674|Drug|Pembrolizumab|intravenously (IV) every 3 weeks (Q3W) on Day 1 of each cycle prior to chemo/immunotherapy
198120|NCT02039674|Drug|Paclitaxel|IV Q3W on Day 1 of each cycle
198121|NCT02039674|Drug|Carboplatin|IV Q3W on Day 1 of each cycle
198122|NCT02039674|Biological|Bevacizumab|IV Q3W on Day 1 of each cycle
198123|NCT02039674|Drug|Pemetrexed|IV Q3W on Day 1 of each cycle
198124|NCT02039674|Biological|Ipilimumab|IV Q3W on Day 1 of each cycle
198125|NCT00123097|Device|Chlorinated polyethylene elastomer|Chlorinated polyethylene
198126|NCT02039674|Drug|Erlotinib|Orally (po) daily (QD)
198127|NCT02039674|Drug|Gefitinib|po QD
198128|NCT02039687|Drug|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
198129|NCT02042404|Device|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
198130|NCT02042417|Device|INRatio2 and CoaguChek|
198131|NCT02042430|Drug|Epacadostat|Given PO
198132|NCT02042430|Other|Laboratory Biomarker Analysis|Correlative studies
198133|NCT02042430|Procedure|Therapeutic Conventional Surgery|Undergo surgery
198134|NCT00123344|Device|AT501 pacemaker|
198135|NCT02042443|Drug|Capecitabine|Given PO
198425|NCT02075450|Device|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
198426|NCT02075450|Other|Just in Time Video|CPR Just in Time training video administered before the simulation case
198427|NCT02075463|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
198428|NCT02075463|Drug|Placebo|Matching placebo tablet for GSK1278863
197807|NCT02047201|Radiation|PET/CT|Assessing tumor response using FDG-PET/CT.
197808|NCT02047201|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
197809|NCT02047201|Drug|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
197810|NCT02047201|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
197811|NCT02049268|Drug|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
197812|NCT02049281|Drug|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
197813|NCT02049294|Biological|Omalizumab (Xolair)|
197814|NCT00124020|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
197815|NCT02049294|Drug|Placebo|
197816|NCT02049307|Drug|Losartan 100mg daily|
197817|NCT02049307|Drug|Matching placebo|
197818|NCT02049320|Drug|Remifentanil|
197819|NCT02049333|Procedure|Phacoemulsification|
197820|NCT02049333|Procedure|Endoscopic Cycloplasty (ECPL)|
197821|NCT02049346|Drug|Epoetin alpha or beta (Epoetin group)|Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.
Doses of erythropoetin were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.
The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study.
198136|NCT02042443|Drug|Fluorouracil|Given IV
198137|NCT02042443|Other|Laboratory Biomarker Analysis|Correlative studies
198138|NCT02042443|Drug|Leucovorin Calcium|Given IV
198139|NCT02042443|Drug|Trametinib|Given PO
198140|NCT02042456|Device|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
198141|NCT02042456|Device|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
198142|NCT02042456|Device|Full Field Digital Mammography|
197509|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
197510|NCT02054676|Drug|Medications.|Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.
Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.
Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days.
197511|NCT02054676|Procedure|Late postoperative soft tissue evaluation.|Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.
The time after surgery is case depending before provisional and final crown placement.
Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.
Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving.
197512|NCT02057042|Behavioral|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
197513|NCT02057042|Behavioral|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
197514|NCT02057055|Other|Soap 300000027003|
197515|NCT02057055|Other|Soap 300000029240|
197516|NCT02057068|Behavioral|SLEEP-E Dyads Sleep Hygiene and Cognitively Based Compassion Training|Adaptive prescriptions for the individualized components of the sleep intervention will be written for each dyad based upon dyad-specific risk factors, sources of sleep disturbance, nature of sleep problems and baseline sleep hygiene practices. In addition to the adaptive prescriptions, each dyad will receive a core intervention component consisting of a sleep hygiene psycho-education curriculum and compassion meditation training delivered by the E-Tablets.
197517|NCT00124774|Procedure|Nucleoplasty|
197518|NCT02057081|Behavioral|Multifamily Group for mTBI for Couples|MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
197519|NCT02057081|Behavioral|Group Health Education|GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
197520|NCT02057094|Dietary Supplement|Protein, High-Protein, and Control|
193417|NCT02045433|Radiation|SABR Boost Therapy|
193418|NCT02045446|Radiation|Stereotactic Body Radiation Therapy|
193419|NCT02045446|Drug|Maintenance chemotherapy|Maintenance chemotherapy
193420|NCT02045459|Behavioral|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
193421|NCT02045459|Drug|Medical Therapy|Subjects will be given medications listed above. They will be contacted periodically throughout the study to maximize effectiveness and to manage side effects if they occur.
193422|NCT02045472|Drug|VIS410|
193423|NCT02045472|Drug|Placebo|
193424|NCT02045498|Device|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
193425|NCT02045511|Behavioral|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
193426|NCT00123552|Drug|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
193427|NCT02045511|Device|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
193428|NCT02045524|Other|Deep muscle injection|
193429|NCT02047500|Drug|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
193430|NCT02047513|Drug|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
193431|NCT02047513|Drug|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
193432|NCT02047539|Drug|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
193433|NCT02047539|Drug|Placebo|
193434|NCT02047552|Drug|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
192794|NCT01977573|Drug|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
192795|NCT01977586|Other|Magnetic Resonance Imaging (MRI)|
192796|NCT01977599|Other|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
192797|NCT01977612|Device|Subcuticular suture|Subcuticular suture will be used instead of staples in closing the skin of patients enrolled in one arm of this study.
192798|NCT01977612|Device|Staple closure|Staples will be used instead of sutures in closing the incision in one arm of the study.
192799|NCT00117689|Biological|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
192800|NCT01977625|Drug|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
192801|NCT01977638|Drug|CXD101|Capsules, administered orally
192802|NCT01977651|Drug|Enzalutamide|Oral
192803|NCT01980082|Drug|Cefazolin|Antibiotic
192804|NCT01980082|Drug|Placebo|Placebo
193100|NCT02052739|Drug|SAGE-547|Intravenous
193101|NCT00124345|Device|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
193102|NCT02052752|Drug|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
193103|NCT02052752|Drug|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
193104|NCT02052752|Drug|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
193105|NCT02052765|Device|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
193106|NCT02052778|Drug|TAS-120|
193107|NCT02052791|Drug|IONIS-SMNRx|Multiple doses by intrathecal injection
192495|NCT01985243|Behavioral|Nutrition and agriculture|The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
192496|NCT01985243|Behavioral|Iron-rich food & business literacy|The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings & business literacy program for young female adolescents to encourage them to stay in school.
192497|NCT00118209|Drug|etoposide|CIVI
192498|NCT01985256|Biological|Toca 511|All subjects will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antibiotic 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after second administration of Toca 511, subjects will take a 7-day course of oral 5-FC. These 7-day courses of 5-FC are repeated every 4 weeks for the duration of the study.
192499|NCT01985269|Other|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
192500|NCT01985282|Behavioral|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
192501|NCT01985295|Drug|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
192502|NCT01985308|Device|MRT-Active|
192503|NCT01985308|Device|MRT-SHAM|
192504|NCT01985321|Drug|ethanol/glycolic acid solution|ethanol/glycolic acid solution
192505|NCT01985321|Drug|Placebo/Ethanol|ethanol solution
192506|NCT01985334|Drug|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
192507|NCT01985334|Drug|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
192805|NCT01980095|Drug|RHB-105|The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:
Rifabutin 150 mg
Amoxicillin 3000 mg
Omeprazole 120 mg
Subjects will take study drug every 8 hours with food for 14 consecutive days.
192806|NCT01980095|Drug|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
192807|NCT00117884|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
196702|NCT02044094|Drug|hydromorphone|Hydromorphone challenges are administered during the screening period (days -17 to -15), during the SUBOXONE film stabilization period (days -3 to -1), and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular injection daily in varying blinded sequences.
Hydromorphone can also be earned during the Reinforcing effects tasks and up to the same randomized dose received in the hydromorphone challenge that morning can be earned (or money can be chosen).
196984|NCT02036671|Device|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
196985|NCT02036684|Behavioral|Prehabilitation (PREHAB)|
196986|NCT02036697|Drug|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
196987|NCT02036697|Drug|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
196988|NCT02036697|Drug|Morphine|morphine 150 mcg.
196989|NCT02036697|Drug|Fentanyl|15 mcg
196990|NCT02036723|Drug|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
196991|NCT02036723|Drug|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
196992|NCT00002183|Drug|Zidovudine|
196993|NCT00122837|Drug|Duloxetine|
196994|NCT02036736|Drug|Intraoperative anesthetic strategy by Propofol|1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL
Sufentanil (0.15 mg / kg intravenously (IV))
Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade
196995|NCT02036736|Drug|Intraoperative anesthetic strategy by Desflurane|2- Arm Desflurane Desflurane induction (2-3 mg / kg)
Sufentanil (0.15 mg / kg IV)
Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade
196996|NCT02036749|Procedure|nerve block|quadratus lumborum block
196997|NCT02036762|Other|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
196998|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
196999|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
197000|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
196409|NCT00123968|Biological|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
196410|NCT02048891|Drug|hCG trigger|
196411|NCT02048904|Drug|Sitagliptin|
196412|NCT02048904|Drug|Placebo|
196413|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
196414|NCT02051491|Device|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
196415|NCT00002192|Drug|Ethambutol hydrochloride|
196703|NCT02044094|Drug|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
196704|NCT02044107|Behavioral|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc & ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc & antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
196705|NCT02044120|Drug|niraparib|
196706|NCT02044120|Drug|Temozolomide|
196707|NCT00123474|Drug|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
196708|NCT02044133|Other|Dosage Vitamine D|
196709|NCT02044146|Drug|Ticagrelor, Prasugrel, Clopidogrel|
196710|NCT02044159|Drug|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
196711|NCT02044159|Other|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
196712|NCT02044172|Procedure|Radical prostatectomy|radical prostatectomy
196713|NCT02044172|Radiation|Conformal radiation therapy|Conformal radiation therapy, external beam
196714|NCT02044172|Other|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
196715|NCT02044185|Drug|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
196079|NCT02056470|Device|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
196080|NCT02056470|Device|Total Knee Replacement|total Knee replacement implant
196081|NCT02056470|Device|Freedom Total Knee System|Total Knee replacement implant
196082|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
196083|NCT02056483|Other|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
196084|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
196085|NCT02058849|Drug|Beetroot|10g Beetroot powder mixed with 4-8 oz.
196086|NCT02058849|Other|Placebo|Placebo
196087|NCT02058875|Drug|Myfortic®|
196416|NCT00124176|Drug|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
196417|NCT02051491|Device|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
196418|NCT02051504|Behavioral|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
196419|NCT02051504|Dietary Supplement|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
196420|NCT02051504|Procedure|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
196421|NCT02051504|Procedure|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
196422|NCT02051504|Procedure|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
196423|NCT02051504|Procedure|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
196424|NCT02051504|Other|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
195745|NCT00125268|Device|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
195746|NCT02061267|Dietary Supplement|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
195747|NCT02061267|Dietary Supplement|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
195748|NCT02061267|Dietary Supplement|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
195749|NCT02061280|Procedure|MICT|Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.
195750|NCT02061280|Procedure|LASST|Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.
195751|NCT02061280|Device|iPad|Participants randomized to MICT will receive an iPad for data entry and FaceTime visits. This form of study participation will be compared with traditional trial participation by the LASST participants
195752|NCT02061293|Drug|Psilocybin|
195753|NCT02061293|Drug|Diphenhydramine|
195754|NCT02061293|Behavioral|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
195755|NCT02063737|Behavioral|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
195756|NCT02063737|Behavioral|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
195757|NCT02063750|Other|strengthening exercises using a Swiss ball|This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.
Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM).
196088|NCT02058875|Drug|Neoral®|
196089|NCT02058875|Drug|Cellcept®|
196090|NCT02058875|Drug|Prednisone|
196091|NCT02058901|Drug|Sunitinib|
195474|NCT02069262|Other|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
195475|NCT02069275|Other|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
195476|NCT02069275|Other|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
195477|NCT02069288|Drug|Fludrocortisone|50 µg of fludrocortisone per os
195478|NCT02071862|Drug|CB-839|CB-839 monotherapy
195479|NCT02071862|Drug|Pac-CB|CB-839 in combination with standard dose paclitaxel
195758|NCT02063750|Other|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
195759|NCT02063789|Drug|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
195760|NCT02063802|Drug|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
195761|NCT00125528|Drug|placebo|placebo bid
195762|NCT02063802|Dietary Supplement|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
195763|NCT02063802|Drug|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
195764|NCT02063802|Behavioral|Healthy habits program|
195765|NCT02063815|Procedure|Fissure sealant application|
195766|NCT02063828|Device|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 8 weeks.
195767|NCT02063828|Device|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 8 weeks.
195768|NCT02063828|Device|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 8 weeks.
195769|NCT02063841|Device|lead-free protective drape containing bismuth and antimony (RADPAD®)|
195770|NCT02063841|Device|sterile identical sham drape|
195771|NCT02063854|Drug|NE-58095|NE-58095 tablets
195168|NCT02035982|Drug|Cholinesterase Inhibitor|For participants randomized into the active treatment arm, they will be provided with the following study medications:
Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg
The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency.
195169|NCT02035982|Drug|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
195170|NCT02035995|Other|Pregnant volunteers with GDM|
195171|NCT00122746|Radiation|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
195172|NCT02036008|Other|Liver MRI with Gdfos|Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.
Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.
This study will be performed within 4 weeks of the MRI study with EcGd.
195173|NCT02036008|Other|Liver MRI with EcGd|Participants will receive a liver MRI with EcGd as per clinical institutional protocol.
Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.
Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging.
195174|NCT02036034|Device|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
195175|NCT02036034|Device|warming blanket|warming blanket placed on torso of patient under the drape.
195480|NCT02071862|Drug|CBE|CB-839 in combination with standard dose everolimus
195481|NCT02071862|Drug|CB-Erl|CB-839 in combination with standard dose erlotnib
195482|NCT02071862|Drug|CBD|CB-839 in combination with standard dose docetaxel
195483|NCT02071875|Device|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
195484|NCT02071888|Drug|CB-839|Glutaminase inhibitor
195485|NCT02071888|Drug|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
195486|NCT02071888|Drug|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
194879|NCT02043509|Behavioral|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
194880|NCT02043522|Drug|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
194881|NCT02043535|Device|Delivery of precise levels of carbon dioxide with the RespirAct™ Gen4 sequential gas delivery system|All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using three target levels of carbon dioxide (CO2) (50 mmHg, 55 mmHg, and 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using adenosine as the stress agent.
Myocardial perfusion stress testing
194882|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
194883|NCT02043535|Device|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (50 mmHg, 55 mmHg, and 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic adenosine stress Rb-82 PET MPI.
194884|NCT02043548|Drug|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
194885|NCT02043548|Drug|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
194886|NCT02043561|Other|induction of urge by rectal distension|
194887|NCT02043574|Behavioral|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
194888|NCT02043574|Behavioral|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
195176|NCT02038257|Procedure|MKTP (melanocyte keratinocyte transplant procedure)|Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
194283|NCT02055898|Drug|Sodium Oxybate|
194576|NCT02048215|Drug|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
194577|NCT02050529|Drug|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
194578|NCT00124111|Drug|pegfilgrastim|
194579|NCT02050542|Procedure|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
194580|NCT02050542|Procedure|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
194581|NCT02050555|Dietary Supplement|Placebo|
194582|NCT02050555|Dietary Supplement|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
194583|NCT02050594|Drug|Ipilimumab|
194584|NCT02050607|Other|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
194585|NCT02050646|Other|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
194586|NCT02050646|Other|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
194587|NCT02050672|Dietary Supplement|Myo-inositol|
194588|NCT02050672|Other|untreated|
194589|NCT00000313|Drug|Fenfluramine|
194590|NCT00002192|Drug|Rifapentine|
194591|NCT00124111|Drug|cyclophosphamide|
194592|NCT02050685|Other|All patients incoming in the sleep study centre for a PSG|All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
193964|NCT02063022|Drug|Intensified chemotherapy|Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks
Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment
Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)
193965|NCT02063035|Drug|Tranexamic Acid|
193966|NCT02063035|Drug|Placebo|
193967|NCT02063048|Behavioral|Text Message Based Weight Loss Support|
193968|NCT02063061|Device|Sham treatment|Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
194284|NCT02055898|Other|placebo (fresh potable water)|
194285|NCT02055911|Drug|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
194286|NCT00124644|Procedure|high-dose chemotherapy|
194287|NCT02058108|Drug|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
194288|NCT02058121|Behavioral|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
194289|NCT02058121|Behavioral|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a dietician and/or physiotherapist.
194290|NCT02058134|Device|cardioPAT cell saver|
194291|NCT02058147|Drug|Insulin glargine/lixisenatide HOE901/AVE0010|Pharmaceutical form:solution for injection (disposable self injector) Route of administration: subcutaneous injection
194292|NCT02058147|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection (disposable self injector) Route of administration: subcutaneous injection
194293|NCT02058147|Drug|Lixisenatide AVE0010|Pharmaceutical form:solution for injection (disposable self injector) Route of administration: subcutaneous injection
194294|NCT00124904|Behavioral|Kegel exercises|
194295|NCT02058147|Drug|Metformin|Pharmaceutical form: tablet Route of administration: Oral
194296|NCT02058160|Drug|Insulin glargine/lixisenatide HOE901/AVE0010|Pharmaceutical form:solution for injection (disposable self injector) Route of administration: subcutaneous injection
193659|NCT02071043|Drug|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3
193660|NCT02071043|Drug|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
193661|NCT00126256|Drug|oxaliplatin|
193662|NCT02071069|Drug|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
193663|NCT02071069|Drug|irinotecan|180 mg/m2 IV every 2 weeks
193664|NCT02071069|Drug|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
193665|NCT02071082|Drug|E/C/F/TAF|Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (E/C/F/TAF) STR administered orally once daily with food
193666|NCT02071095|Drug|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
193969|NCT00125476|Behavioral|Exercise|
193970|NCT02063061|Device|ESWT treatment|ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
193971|NCT02065544|Behavioral|behavioral weight loss and exercise|Weight loss and exercise counseling
193972|NCT02065557|Biological|Adalimumab|Subcutaneous (SC) injection
193973|NCT02065557|Other|Placebo|Placebo
193974|NCT00125788|Drug|maltodextrin|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
193975|NCT02065570|Drug|Adalimumab|
193976|NCT02065596|Drug|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
193977|NCT02065596|Procedure|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
193978|NCT02065609|Drug|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
193979|NCT02065609|Drug|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
198429|NCT02075476|Procedure|Hemiarthroplasty|
198430|NCT00126646|Procedure|immunotoxin therapy|
198431|NCT02075476|Procedure|reverse arthroplasty|
198432|NCT02075489|Other|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for ~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for ~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
198433|NCT02075489|Other|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
198434|NCT02037178|Other|Second ultrasound interpretation|The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
198435|NCT02037191|Drug|Methotrexate|Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):
methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day
198436|NCT02037191|Drug|Placebo|Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):
methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day
198437|NCT02037204|Other|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
198438|NCT02037217|Device|ExAblate Transcranial MRgFUS System|
198439|NCT02037230|Drug|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
198440|NCT00122876|Drug|Talaporfin Sodium|
198441|NCT02037230|Drug|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
198442|NCT02037230|Radiation|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
198443|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment|Compound level meeting
193667|NCT02071095|Drug|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
198143|NCT02042482|Dietary Supplement|Coenzyme Q10U, L-carnitine|
198144|NCT02042495|Drug|Metformin|
198145|NCT00123370|Drug|Modafinil|
198146|NCT02042508|Other|strengthening|
198147|NCT02042508|Other|hybrid training programme|
198148|NCT02042521|Drug|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
198149|NCT02042521|Drug|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
198150|NCT02042534|Drug|Rivaroxaban|Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.
The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety.
198151|NCT02042534|Drug|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
198152|NCT02042547|Other|Tissue samples from the right atrium|
198153|NCT02042547|Other|Blood samples|
198154|NCT00123513|Behavioral|Diet|Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
198155|NCT02044796|Other|Laboratory Biomarker Analysis|Correlative studies
198156|NCT02044796|Drug|Mitoxantrone Hydrochloride|Given IV
198157|NCT02044809|Drug|Cannabidiol|
198444|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
198445|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
198446|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
198447|NCT02037256|Drug|bortezomib|Given IV
198448|NCT02037256|Biological|filgrastim|Given SC
197822|NCT02049346|Drug|Darbepoetin alfa|Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.
The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.
If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used.
197823|NCT02049346|Drug|Methoxy polyethylene glycol-epoetin beta|Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.
Doses of MIRCERA were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.
The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study.
197824|NCT02049359|Other|Texting|Bidirectional texting once weekly for 12 weeks
197825|NCT00124020|Drug|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
197826|NCT02049385|Drug|Diazoxide|A nondiuretic vasodilator thiazide related agent
197827|NCT02049385|Drug|Placebo|
197828|NCT02049411|Drug|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
197829|NCT02049411|Drug|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
197830|NCT02049437|Drug|tocilizumab|Subjects will be randomized 1:1 to one of the following arms:
ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
197831|NCT02051985|Other|Standard physical therapy|Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).
Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).
In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.
197832|NCT02052011|Drug|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
197833|NCT02052011|Drug|Placebo|
197834|NCT02052024|Drug|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
197835|NCT02052024|Drug|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
198158|NCT02044809|Drug|Placebo|
193435|NCT02047552|Drug|Oxandrolone|10 mg PO Q12 hours for seven days
193436|NCT02047552|Other|IV iron placebo|100 mL normal saline.
193437|NCT02047552|Other|Oxandrolone placebo|similar color and size sugar pill
188582|NCT00115648|Drug|AZT|Oral AZT daily
188583|NCT01958242|Other|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
188584|NCT01958255|Behavioral|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
188585|NCT01958268|Procedure|Pretest and validation of a translated questionnaire|
188586|NCT01958281|Drug|SOF 100 mg|Sofosbuvir (SOF) 100 mg tablets administered orally once daily
188587|NCT01958281|Drug|SOF 400 mg|SOF 400 mg tablet administered orally once daily
188588|NCT01958281|Drug|RBV|Ribavirin (RBV) 200 mg tablet administered orally once daily
188589|NCT01958281|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
188590|NCT01958294|Device|MICHI Neuroprotection System|
188591|NCT00115895|Drug|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
188592|NCT01960673|Device|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
188593|NCT01960673|Device|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
188594|NCT01960686|Biological|Low dose RSV F Antigen|
188595|NCT01960686|Biological|High dose RSV F Antigen|
188596|NCT01960686|Biological|Dose 1 of Adjuvant|
188597|NCT01960686|Biological|Dose 2 of Adjuvant|
188598|NCT01960686|Biological|Dose 3 of Adjuvant|
188599|NCT01960686|Biological|Dose 4 of Adjuvant|
188600|NCT01960686|Biological|Placebo|
193108|NCT02052817|Device|Optimal Medical Therapy Debridement + Toad Brace|
193109|NCT02052817|Other|Optimal Medical Therapy - Debridement|
193110|NCT02052830|Behavioral|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
193111|NCT02052843|Behavioral|Steps to Success|
193112|NCT00124358|Drug|Buprenorphine|
193113|NCT02052843|Behavioral|Traditional Healthy Families|
193114|NCT02052869|Procedure|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
193115|NCT02052882|Biological|romiplostim,|
193116|NCT02052882|Other|Control cohort|If patients in the control cohort do not spontaneously achieve adequate platelet correction ≥ 100,000/mcL by the 3 week primary endpoint, they can then be crossed-over to romiplostim treatment.
193117|NCT02055261|Device|Low frequency DBS of the pedunculopontine nucleus|
193118|NCT00124605|Other|laboratory biomarker analysis|Correlative studies
193119|NCT02055274|Drug|LY03003|
193120|NCT02055274|Drug|Neupro|
193121|NCT02055287|Drug|LY03004|
193122|NCT02055300|Drug|LY03005|
193438|NCT00123851|Drug|Capecitabine|
193439|NCT02047565|Drug|60mg edoxaban|
193440|NCT02047565|Drug|180mg edoxaban|
193441|NCT02047565|Drug|50 IU/kg Beriplex P/N|
193442|NCT02047565|Drug|25 IU/kg Beriplex P/N|
193443|NCT02047565|Drug|10 IU/kg Beriplex P/N|
193444|NCT02047578|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
193445|NCT02047604|Drug|SAN-300|
192808|NCT01980108|Other|water|water
192809|NCT01980121|Device|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
192810|NCT01980147|Behavioral|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
192811|NCT01980160|Device|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
192812|NCT01980160|Device|Unactivated Nometex Device|
192813|NCT01980173|Procedure|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
192814|NCT01980173|Device|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
192815|NCT01980186|Device|TUS transcranial 2D ultrasound|
192816|NCT01980199|Drug|Fexinidazole|600 mg tablets given orally, after the main daily meal
at the daily dose of 1800 mg (3 tablets) once a day for 4 days
continued by 1200mg (2 tablets)once a day for 6 days
192817|NCT01980225|Procedure|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
192818|NCT00117884|Drug|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
192819|NCT01980238|Device|cannula ileostomy|
192820|NCT01980238|Device|loop ileostomy|
192821|NCT01980238|Device|LAR|
192822|NCT01980264|Device|Harmonic generation optical biopsy|
193123|NCT02055300|Drug|Placebo|
193124|NCT02055300|Other|Meal|
193125|NCT02055300|Drug|Pristiq|
197001|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
197002|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
197003|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
197004|NCT00122837|Drug|venlafaxine|
197005|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
197302|NCT02072655|Procedure|socio-aesthetic care|care of the face
skin cleansing with cleansing milk to remove impurities
a gentle scrub to exfoliate and cleanse the skin
a relaxing massage
moisturizing mask
application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...
care manicure / pedicure,
massages
makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship.
197303|NCT02072668|Drug|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
197304|NCT02072668|Drug|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
197305|NCT02072694|Other|75 grams of glucose plus water solution|A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
30 minutes before the radiopharmaceutical injection.
12 hours fasting minimum.
197306|NCT02072694|Other|Pure water|Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
30 minutes before the radiopharmaceutical injection.
12 hours fasting minimum.
197307|NCT02072707|Procedure|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
197308|NCT02072707|Procedure|Endocardial VT Ablation|Endocardial Only VT ablation
197309|NCT02072720|Drug|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
197310|NCT00126464|Procedure|neoadjuvant therapy|
197311|NCT02072733|Other|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
197312|NCT02072746|Dietary Supplement|Zinc|
196716|NCT02044198|Biological|FMP2.1/AS01B|50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
196717|NCT02044211|Behavioral|Collaborative Care for Heart Failure|Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.
After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist.
196718|NCT00123474|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
196719|NCT02046720|Drug|Propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)
197006|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
197007|NCT02039037|Device|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
197008|NCT02039037|Device|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
197009|NCT02039050|Drug|Tiotropium|
197010|NCT02039050|Drug|Aclidinium|
197011|NCT02039063|Drug|E6011 2 mg/kg|
197012|NCT00123032|Procedure|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
197013|NCT02039063|Drug|E6011 5 mg/kg|
197014|NCT02039063|Drug|E6011 10 mg/kg|
197015|NCT02039063|Drug|E6011 15 mg/kg|
197016|NCT02039076|Drug|avatrombopag|
197017|NCT02039089|Drug|E2006 2.5 mg|
197018|NCT02039089|Drug|E2006 10 mg|
197019|NCT02039089|Drug|E2006 25 mg|
196425|NCT02051530|Dietary Supplement|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
196426|NCT02051543|Behavioral|Brief Behavioral Treatment of Insomnia -Military Version|
196427|NCT00124189|Drug|GRN163L|Weekly intravenous infusion
196428|NCT02051556|Behavioral|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
196429|NCT02051556|Behavioral|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
196430|NCT02051556|Behavioral|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
196431|NCT02051569|Dietary Supplement|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
196432|NCT02051582|Procedure|Surgeons using fluoroscopy with laser pointer|Surgeons will attempt to obtain a "perfect" anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.
A "perfect" view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves.
196720|NCT02046733|Drug|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
196721|NCT02046733|Drug|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
196722|NCT02046746|Other|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
196723|NCT02046759|Other|Pharmacist- Intervention|Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
196724|NCT02046759|Other|Routine Care|Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
196092|NCT02058914|Dietary Supplement|h fructose (HF) trial|
196093|NCT00124982|Drug|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
196094|NCT02058927|Drug|Measles vaccine|measles revaccination administered at 12 months from start of ART
196095|NCT02058940|Drug|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
196096|NCT02058953|Procedure|Craniotomy scheduled|Resection of affected brain tissue
196097|NCT02058953|Procedure|Collection for non-craniotomy|CSF, Blood, biopsy
196098|NCT02058966|Drug|Entacapone|Entacapone 200 mg oral dose
196099|NCT02058966|Drug|Methamphetamine|Methamphetamine 20 mg oral dose
196100|NCT02058979|Drug|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
196101|NCT02058979|Drug|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
196102|NCT02058992|Drug|Ramelteon|Ramelteon 8 mg tablets
196103|NCT02059005|Behavioral|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
196104|NCT00124995|Drug|terbutaline|
196105|NCT02059005|Behavioral|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
196106|NCT02059018|Drug|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
196107|NCT02059018|Drug|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
196108|NCT02059018|Drug|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
196109|NCT02059031|Drug|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
196110|NCT02059031|Drug|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
195772|NCT00125541|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
195773|NCT02063854|Drug|NE-58095|NE-58095NF tablets
195774|NCT02063854|Drug|NE-58095NF|NE-58095NF tablets
195775|NCT02063854|Drug|NE-58095NF|NE-58095NF tablets
195776|NCT02063854|Drug|NE-58095NF|NE-58095NF tablets
195777|NCT02063854|Drug|NE-58095NF|NE-58095NF tablets
195778|NCT02063854|Drug|NE-58095NF|NE-58095NF tablets
195779|NCT00125905|Behavioral|Advice|
195780|NCT02066402|Drug|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
196111|NCT02059031|Drug|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
196112|NCT02061319|Behavioral|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
196113|NCT00002199|Drug|Indinavir sulfate|
196114|NCT00125268|Device|Sham Device|The sham device is non-active but otherwise identical to the study device.
196115|NCT02061332|Biological|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
196116|NCT02061358|Drug|UV-4B, 3 mg to 1000 mg|Oral solution, single dose
196117|NCT02061358|Drug|Placebo|Oral solution, single dose
196118|NCT02061371|Other|virtual therapy|
196119|NCT02061371|Other|conventional physiotherapy|
196120|NCT02061384|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
196121|NCT02061384|Drug|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
195487|NCT00126360|Drug|Timing of Anastrozole in respect to radiotherapy|
195488|NCT02071901|Drug|eltrombopag olamine|Given PO
195489|NCT02071914|Drug|CT-P27|
195490|NCT02071914|Drug|Placebo|
195491|NCT02071927|Drug|CB-839|Single-agent CB-839
195492|NCT02071927|Drug|CB-Aza|CB-839 in combination with standard dose azacitidine
195493|NCT02071940|Drug|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
195494|NCT02071953|Device|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
195495|NCT02071953|Device|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
195496|NCT02071966|Drug|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
195497|NCT02071966|Drug|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
195498|NCT00126373|Drug|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
195499|NCT02071979|Device|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
195781|NCT02066402|Drug|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
195782|NCT02066415|Drug|AMG 334|Investigational Product
195783|NCT02066415|Drug|Placebo|Placebo Comparator
195784|NCT02066428|Biological|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
195785|NCT02066428|Biological|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
195786|NCT02066441|Dietary Supplement|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
195787|NCT02066441|Other|Placebo|
195177|NCT02038257|Device|Collagen Dressing|Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
195178|NCT02038257|Device|Vaseline Impregnated Gauze|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
195179|NCT02038257|Device|Carbon Dioxide Laser|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
195180|NCT02038257|Device|Dermabrasion|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
195181|NCT00122980|Procedure|Phlebotomy|Phlebotomy
195182|NCT02038296|Procedure|transarterial chemoembolization|
195183|NCT02038322|Device|The Stork - Conception Aid|
195184|NCT02038335|Drug|DMPA|Depot medroxyprogesterone acetate
195185|NCT02038335|Drug|NET-EN|Norethisterone enantate
195186|NCT02038335|Drug|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
195187|NCT02038335|Device|LNG-I|Levonorgestrel subdermal implant
195188|NCT02038335|Device|ENG-I|Etonogestrel subdermal implant
195189|NCT02038335|Device|Cu-IUD|Copper IUD
195190|NCT02038348|Device|PET with 18F-FDOPA|
195191|NCT02038361|Genetic|blood draw|
195192|NCT00122993|Behavioral|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
195193|NCT02038374|Procedure|biopsies|
195194|NCT02038387|Behavioral|normocaloric low cholesterol diet|
195195|NCT02038400|Device|KINETUBE medical Device|
195196|NCT02038400|Device|insertion of tympanic ventilation tubes (tympanostomy)|
195197|NCT02038426|Biological|BLOOD SAMPLES|
195198|NCT02038426|Device|Radiographs of the sacroiliac joints|
195199|NCT02038426|Device|Radiographs of heels|
194593|NCT02050698|Procedure|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
194594|NCT02050698|Procedure|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
194595|NCT02050711|Behavioral|Pulmonary rehabilitation|
194889|NCT02043587|Drug|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
194890|NCT02043587|Drug|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
194891|NCT02046005|Behavioral|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
194892|NCT00123604|Drug|Metoprolol|200 mg twice daily for five months.
194893|NCT02046018|Other|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
194894|NCT02046018|Other|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
194895|NCT02046018|Other|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
194896|NCT02046031|Drug|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
194897|NCT02046044|Drug|Digoxin|
194898|NCT02046044|Drug|Ivabradine|
194899|NCT02046070|Drug|Cyclophosphamide|Cyclophosphamide tablets
194900|NCT02046070|Drug|Ixazomib (MLN9708)|Ixazomib (MLN9708) capsules
194901|NCT02046070|Drug|Dexamethasone|Dexamethasone tablets
194902|NCT02046083|Drug|arachid|
194903|NCT00123617|Procedure|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
194904|NCT02046096|Device|Günther Tulip® Vena Cava Filter and Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
194905|NCT02046109|Procedure|Repair|
194906|NCT02046109|Procedure|Replace|
194297|NCT02058160|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection (disposable self injector) Route of administration: subcutaneous injection
194298|NCT02058160|Drug|Metformin|Pharmaceutical form:tablet Route of administration: oral administration
194299|NCT02058173|Drug|150 mg/daily chloroquine compare to placebo for 12 week|
194300|NCT02058173|Drug|Chloroquine|
194301|NCT02058173|Drug|placebo|
194302|NCT02058186|Drug|oral vitamin D|
194303|NCT02058186|Drug|Placebo|
194304|NCT02058199|Drug|rivaroxaban|Single dose pharmacodynamic study
194596|NCT02050711|Other|Usual care|
194597|NCT02050724|Drug|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
194598|NCT02050724|Device|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
194599|NCT02050724|Device|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
194600|NCT02053493|Drug|Isosorbide Mononitrate|Dispense phase 1 study drug:
Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN
Dispense phase-2 study drug:
Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN
194601|NCT02053493|Drug|Placebo|Dispense phase 1 study drug:
Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo
Dispense phase-2 study drug:
Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo
194602|NCT02053506|Dietary Supplement|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
194603|NCT02053506|Dietary Supplement|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
194604|NCT02053519|Drug|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
194605|NCT02053519|Drug|Mygliol Oil|Matched placebo comparator
194606|NCT02053532|Procedure|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
193980|NCT02065622|Drug|Adalimumab|
193981|NCT02065622|Other|Placebo|
193982|NCT02065635|Procedure|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
193983|NCT02065635|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
193984|NCT02065648|Other|Syngo NATIVE MRA sequence|We are comparing the non-contrast abdominal MR Angiogram Syngo NATIVE sequence performed on a 3T Verio Siemens magnet to a standard of care contrast-enhanced MRA performed as part of routine clinical care in patients with normal renal function to determine if the non-contrast NATIVE sequence is a viable alternative to contrast enhanced MRA in patients with renal insufficiency.
193985|NCT00125801|Drug|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
193986|NCT02065674|Drug|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
193987|NCT02065687|Drug|Carboplatin|Given IV
193988|NCT02065687|Other|Laboratory Biomarker Analysis|Correlative studies
193989|NCT02065687|Drug|Metformin Hydrochloride|Given PO
194305|NCT00124917|Radiation|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 cGy in 180 cGy daily fractions.[1]
194306|NCT02058212|Drug|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
194307|NCT02058251|Drug|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
194308|NCT02058264|Drug|BBI-4000|
194309|NCT02058277|Drug|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
194310|NCT02060526|Drug|Recombinant human heparan N-sulfatase [rhHNS]|
194311|NCT02060539|Device|Biofinity XR|
194312|NCT02060552|Drug|Diacerein|oral administration of IL-1βinhibitory
193668|NCT02071108|Device|Shockwave Lithoplasty System|
193669|NCT02071121|Drug|BIIB061|BIIB061 capsules for oral administration
193670|NCT02073552|Drug|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
193671|NCT02073552|Drug|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
193672|NCT02073565|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
193673|NCT02073565|Device|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
193674|NCT00126516|Drug|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
193675|NCT02073578|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
193676|NCT02073591|Other|Ceradan Cream|
193677|NCT02073591|Other|Ceradan Wash|
193678|NCT02073604|Other|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
193679|NCT02073604|Other|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
193680|NCT02073617|Radiation|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition.
193681|NCT02073630|Other|active cerebellar stimulation|
193682|NCT02073630|Other|sham cerebellar stimulation|
193683|NCT02073656|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
193990|NCT02065687|Drug|Paclitaxel|Given IV
198449|NCT02037256|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
198450|NCT02037282|Drug|Anti-influenza IVIG|
198451|NCT00002184|Drug|Nelfinavir mesylate|
198452|NCT00122889|Drug|Garlic powder with high allicin content|
198453|NCT02037295|Dietary Supplement|Nutritional (over and underfeeding)|
198454|NCT02037295|Dietary Supplement|Oral Vancomycin|
198455|NCT02037308|Dietary Supplement|Bread|
198456|NCT02037334|Device|CERVICAL ASPIRATOR 3.1|No intervention is done except for measuring the stiffness of the cervix in pregnant women
198457|NCT02037347|Drug|Palifermin|
198458|NCT02037360|Behavioral|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
198459|NCT02039687|Other|Placebo|Formulation buffer
198460|NCT02039700|Drug|Lesinurad 400 mg|
198461|NCT02039700|Drug|[14C]lesinurad (100 μg per 10 mL)|
198462|NCT02039713|Device|DeSyne drug eluting stent group|
198463|NCT02039726|Drug|Quizartinib|no details to specify
198464|NCT02039726|Drug|Salvage Chemotherapy|No details to specify.
198465|NCT02039739|Device|Orsiro™ Drug Eluting Stent group|
198466|NCT00123110|Drug|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
198467|NCT02039752|Other|Treatment|
193684|NCT02073656|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
193685|NCT00126516|Drug|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
198159|NCT02044822|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
198160|NCT02044822|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks
198161|NCT02044835|Drug|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
198162|NCT02044848|Drug|Secukinumab|
198163|NCT02044848|Drug|Placebo|Placebo
198164|NCT02044861|Drug|PFK-158|IV dose escalation
198165|NCT00123513|Behavioral|Exercise|Increase routing physical activity, walking routes, stairs intervention, etc.
198166|NCT02044874|Drug|APD356-lorcaserin hydrochloride|
198167|NCT02044874|Drug|Placebo|
198168|NCT02044887|Other|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
198169|NCT02044913|Behavioral|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
198170|NCT02044939|Other|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
198171|NCT02044952|Drug|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
198172|NCT02044965|Other|Antibiotic|2 mg/kg per day via oral ingestion.
198173|NCT02044965|Drug|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
198174|NCT02044978|Device|Zoledronate-coated dental implant|
198175|NCT02044991|Drug|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
198176|NCT00123513|Behavioral|Environment|Cafeteria and vending machine changes and identification of opportunities of physical activity.
198177|NCT02044991|Drug|Placebo Injection|A placebo injection
188601|NCT01960712|Device|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
188602|NCT00115908|Drug|Albuferon|
188603|NCT01960725|Biological|RV5 (Pentavalent Rotavirus Vaccine)|
188604|NCT01960738|Other|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
188924|NCT01953601|Drug|Placebo (Part I)|Matching placebo to verubecestat tablet
188925|NCT01953601|Drug|Verubecestat (Part II)|Verubecestat 40 mg tablet
188926|NCT01953614|Other|Chiropractic adjustment|
188927|NCT01953614|Other|Sham adjustment|
188928|NCT01953627|Procedure|Surgical procedure with the system Kymerax|
188929|NCT01953627|Device|The system Kymerax|
188930|NCT00115102|Drug|fentanyl|
188931|NCT01953640|Other|Laboratory Biomarker Analysis|Correlative studies
188932|NCT01953640|Other|Quality-of-Life Assessment|Ancillary studies
188933|NCT01953653|Behavioral|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
188934|NCT01953666|Other|Rehabilitation program|Rehabilitation program with an occupational therpasit
3 training sessions (one hour) per week for a month (12 sessions)
188935|NCT01953666|Other|Self - Training at home|Only instructions for a self - training at home
188936|NCT01953666|Other|No treatment|No rehabilitation program No instructions
188937|NCT01953679|Drug|Ulipristal Acetate|
188938|NCT01953692|Biological|Pembrolizumab|
188939|NCT01955551|Behavioral|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
193446|NCT02047604|Drug|Placebo|
193447|NCT02047617|Device|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
193448|NCT02047617|Device|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
193449|NCT00123851|Drug|Oxaliplatin|
193450|NCT02047630|Drug|Generic latanoprost|
193451|NCT02047630|Drug|Brand-name latanoprost|
193452|NCT02047643|Device|Algorithm ON|See Arm description.
193453|NCT02047656|Drug|LFF269|LFF269 capsules twice daily (b.i.d)
193454|NCT02047656|Drug|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
193455|NCT02047669|Behavioral|Biopsychosocial|
193456|NCT02049957|Drug|Fulvestrant|Phase 1B: 500 mg monthly; Phase 2: 250 or 500 mg monthly
193457|NCT02049957|Drug|Exemestane|25 mg once daily
193458|NCT02049970|Drug|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
193459|NCT02049970|Drug|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
193460|NCT00124072|Dietary Supplement|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
193461|NCT02049983|Device|Use of Levita Magnetics Grasper|
193462|NCT02050009|Drug|metformin hydrochloride|Given PO
193463|NCT02050009|Drug|carboplatin|Given IV
188605|NCT01960751|Other|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
188606|NCT01960764|Drug|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
188607|NCT01960764|Other|Control|
188608|NCT01960777|Procedure|Onstep|
188609|NCT01960777|Procedure|Laparoscopic repair|
193126|NCT02055326|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
193127|NCT02055326|Behavioral|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
193128|NCT02055326|Behavioral|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
193129|NCT00124605|Other|pharmacological study|Correlative studies
193130|NCT02055339|Device|Fisher & Paykel heated humidified high flow nasal cannula|
193131|NCT02055339|Device|InfantFlow/RAM nasal continuous positive airway pressure|
193132|NCT02055352|Drug|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
193133|NCT02055352|Drug|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
193134|NCT02055352|Drug|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
193135|NCT02055352|Drug|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
193136|NCT02055365|Biological|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
193137|NCT02055378|Drug|Atropine|topical 0.125% atropine eye drops
193138|NCT02055378|Device|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
193139|NCT02055391|Behavioral|Behavioral Weight Loss|Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
193140|NCT00124618|Biological|cetuximab|
193141|NCT02055391|Behavioral|Enhanced Behavioral Weight Loss|Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
193142|NCT02055404|Device|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
193143|NCT02055404|Device|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
193144|NCT00002195|Drug|Lamivudine|
193464|NCT02050009|Drug|paclitaxel|Given IV
197313|NCT02072746|Dietary Supplement|Placebo|
197314|NCT02072759|Dietary Supplement|Carnitine supplement|Carnitine supplement (oral ingestion with meals)
Total dosage of 2g carnitine per day for 36 days.
1 carnitine supplement at breakfast (500mg)
1 carnitine supplement at lunch (500mg)
2 carnitine supplements at diner (2x 500mg=1000mg)
197315|NCT02072759|Dietary Supplement|Placebo|
197316|NCT02072772|Behavioral|Positively Smoke Free group treatment|See Arm Description
197317|NCT02072772|Behavioral|Standard Care|See Arm Description
197318|NCT02072785|Drug|Vincristine Sulfate Liposome|
197319|NCT02072785|Drug|Vincristine Sulfate|
197611|NCT00125645|Drug|irbesartan|
197612|NCT02064712|Other|High CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
197613|NCT02067143|Drug|Maintenance|If MRD negative MRD u/k SR
197614|NCT02067143|Procedure|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
197615|NCT02067156|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
197616|NCT00125957|Drug|Wellbutrin|
197617|NCT02067169|Biological|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
197618|NCT02067182|Drug|Dabigatran|Antral pulmonary vein ablation for patients with AF
left atrial fibrosis/electrical scar assessment by electroanatomical mapping
followed by 6 months OAC (3 months blanking period + 3 months observation period)
in case of AF-recurrence in month 4-6: re- pulmonary vein ablation
followed again by 6 months OAC (3 months blanking period + 3 months observation period)
AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:
Experimental arm (group A): OAC with dabigatran for 12 months
Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later
197619|NCT02067195|Drug|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
197020|NCT02039089|Drug|Placebo|
197021|NCT02039115|Drug|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
197022|NCT02039115|Drug|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
197023|NCT00123045|Behavioral|health education|
197024|NCT02039128|Dietary Supplement|Krill oil or Fish oil|
197025|NCT02039128|Dietary Supplement|Placebo|
197026|NCT02039141|Other|Every Little Step Counts Intervention|Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other "free-play" physical activities i.e. basketball, volleyball etc.
197320|NCT02072798|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
197321|NCT00126477|Procedure|cognitive assessment|
197322|NCT02072811|Drug|DAC|DNR 60 mg/m2 0,5h infusion iv on 1-3 days
2-CdA 5 mg/m2 2h. infusion iv on 1-5 days
Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days
197323|NCT02074904|Drug|Placebo|
197324|NCT00126620|Drug|erlotinib hydrochloride|
197325|NCT02074917|Procedure|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
197326|NCT02074930|Device|Microporation by P.L.E.A.S.E. Professional / Prick needle|
197327|NCT02074943|Biological|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
197328|NCT02074956|Biological|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
197329|NCT02074956|Biological|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
197330|NCT02074969|Device|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
197331|NCT02074969|Device|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
196725|NCT02046772|Drug|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
196726|NCT02046772|Drug|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
196727|NCT02046772|Drug|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
196728|NCT00123682|Procedure|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
196729|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
196730|NCT02046798|Drug|ASP3652|oral
196731|NCT02046811|Behavioral|Patient activation and education (PAE)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
196732|NCT02046811|Behavioral|PAE plus physician activation (PAE + MD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
196733|NCT02046811|Behavioral|PAE physician activation, plus teledermoscopy (PAE +MD +TD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
196734|NCT02046824|Device|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
197027|NCT02039154|Behavioral|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
197028|NCT02039154|Behavioral|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
197029|NCT02039167|Device|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
197030|NCT02041845|Radiation|45 Gy in 30 fractions|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
196433|NCT02054247|Device|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
196434|NCT02054260|Drug|Surgicel|
196435|NCT02054286|Biological|THV01-1|Intramuscular injection of THV01-1 (week 0)
196436|NCT02054286|Biological|THV01-2|Intramuscular injection of THV01-2 (week 8)
196437|NCT02054286|Biological|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
196438|NCT02054299|Drug|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
196439|NCT00124540|Drug|placebo|placebo resembling misoprosotl
196440|NCT02054299|Drug|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
196441|NCT02054299|Drug|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
196442|NCT02054299|Drug|Drug application Proguanil|Proguanil: 200mg, single oral application
196443|NCT02054299|Drug|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
196444|NCT02054299|Drug|Drug application Thiamine|Thiamine: 200mg, single oral application
196445|NCT02054312|Behavioral|Family Based Interpersonal Psychotherapy (FB-IPT)|
196446|NCT02054312|Behavioral|Client Centered Therapy (CCT)|
196447|NCT02054325|Drug|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
196448|NCT02054325|Drug|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
196449|NCT02054338|Drug|vinflunine 320 mg/m² as a 20-minute infusion on day 1 of each cycle repeated every 3 weeks gemcitabine 1000 mg/m² IV on day 1 and 8 repeated every 3 weeks|
196450|NCT00124553|Behavioral|Intensive dietary advice|
196451|NCT02054338|Drug|vinflunine plus gemcitabine|320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
196452|NCT02054338|Drug|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
196122|NCT02061397|Drug|Simvastatin|Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
196123|NCT02061410|Device|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
196124|NCT02061423|Biological|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 107 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
196125|NCT00125281|Drug|S-adenosyl-methionine (SAMe) capsules|
196126|NCT02061449|Drug|Romidepsin|
196127|NCT02061449|Drug|Poly ICLC|
196128|NCT02061449|Radiation|Focal lesional radiation|
196129|NCT02061462|Procedure|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
196456|NCT02054377|Other|Tai chi|Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.
It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.
A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD.
196457|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
196458|NCT02056535|Behavioral|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
196459|NCT02056574|Drug|NA-1|
196460|NCT02056574|Drug|Placebo|
196461|NCT02056587|Drug|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
196462|NCT02056600|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
195788|NCT02066454|Drug|Apixaban|2.5mg x 2 per day during 6 months
195789|NCT02066467|Device|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
195790|NCT00125905|Behavioral|Motivational Interviewing|
195791|NCT02066506|Other|asymptomatic group|2 visits with MRI
195792|NCT02066506|Other|symptomatic group|2 visits with MRI
195793|NCT02066519|Behavioral|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
195794|NCT02066532|Drug|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
195795|NCT02066532|Drug|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab > 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
195796|NCT02066545|Drug|CLS001 Topical Gel|
195797|NCT02066545|Drug|CLS001 Topical Gel Vehicle|
195798|NCT02066558|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
195799|NCT02066558|Other|Placebo|
195800|NCT02066571|Drug|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
195801|NCT00125905|Drug|Nicotine Gum and Patch|
195802|NCT02066571|Drug|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
196130|NCT02061475|Drug|Lidocaine Patches|
196131|NCT02061488|Other|open-loop night|During the open-loop night the patient is using his insulin pump as usual
196132|NCT02061488|Other|closed-loop night|During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
196133|NCT02061501|Other|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
195500|NCT02071979|Device|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
195501|NCT02074163|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
195502|NCT02074163|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
195503|NCT02074163|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
195504|NCT02074189|Drug|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
195505|NCT02074202|Drug|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
195506|NCT02074202|Drug|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
195507|NCT02074215|Other|Aerobic exercises|Aerobic exercises + dual task
195508|NCT02074215|Other|Stretch exercise|Stretch exercise
195509|NCT00126581|Drug|Carboplatin|Given IV
195510|NCT02074228|Drug|Methylphenidate (Concerta)|
195511|NCT02074241|Other|Expression analysis|Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
195512|NCT02074267|Drug|Carbatin|Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.
The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.
195513|NCT02074267|Drug|Neurontin|Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.
The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.
195514|NCT02074280|Drug|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
194907|NCT02046122|Drug|Idarubicin|Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.
Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy.
194908|NCT02046122|Drug|Cytarabine|Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.
Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.
195200|NCT02038426|Device|SCAN|
195201|NCT02038439|Behavioral|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
195202|NCT02038439|Behavioral|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
195203|NCT02040844|Drug|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
195204|NCT02040844|Drug|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
195205|NCT02040857|Drug|Palbociclib|CDK 4/6 inhibitor
195206|NCT02040857|Drug|Endocrine Therapy|Endocrine Therapy
195207|NCT02040870|Drug|LDK378|750 mg once daily
195208|NCT02040883|Drug|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
195209|NCT02040883|Drug|Tandospirone|Tandospirone，30mg per day
195210|NCT02040909|Drug|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
195211|NCT02040935|Drug|trastuzumab [Herceptin]|600 mg subcutaneously every 3 weeks by single-use injection device
195212|NCT02040948|Device|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
195213|NCT00123227|Drug|Rosiglitazone|
195214|NCT02040961|Device|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
194607|NCT02053545|Drug|Conditioning Regimen & GVHD Prophylaxis|Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior CNS disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF
Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disesase), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosmamide, Mesna, Tacrolimus, MMF
Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF
194608|NCT02053558|Drug|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
194609|NCT02053558|Drug|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
194610|NCT00124449|Drug|Abatacept|solution, intravenous injection, monthly, 169 days
weight based:
<60 kg = 500 mg
60 to 100 kg = 750 mg
>100 kg = 1 g
194611|NCT02053571|Procedure|TIPS with 3D Overlay|
194612|NCT02053584|Device|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
194909|NCT02046122|Biological|DLI|HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.
Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2
Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.
194910|NCT02046135|Drug|Sodium Bicarbonate|
194911|NCT02046135|Drug|Sodium Chloride|
194912|NCT02046148|Biological|GBS vaccine|Trivalent GBS vaccine
194913|NCT02046148|Biological|Placebo|Normal saline
194914|NCT00002188|Drug|Alitretinoin|
194915|NCT02048215|Other|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
194916|NCT02048228|Drug|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
194917|NCT02048228|Drug|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
194313|NCT02060552|Drug|Colchicine|Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as "meadow saffron"). It was used originally to treat rheumatic complaints, especially gout as the positive control
194314|NCT02060552|Drug|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
194315|NCT02060578|Other|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
194316|NCT02060591|Drug|Exparel|
194317|NCT02060591|Drug|Marcaine|
194318|NCT02060604|Drug|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
194319|NCT00125203|Drug|Botulinum toxin type B (Myobloc)|
194320|NCT02060604|Drug|Ranibizumab|3 monthly ranibizumab, then as needed
194321|NCT02060617|Behavioral|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
194322|NCT02060617|Procedure|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
194323|NCT02060617|Procedure|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
194613|NCT02053584|Device|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
194614|NCT02053597|Drug|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
194615|NCT02053597|Drug|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
194616|NCT02053610|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
194617|NCT02053610|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
194618|NCT02053610|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
194619|NCT02053636|Drug|lucitanib|
193991|NCT02065687|Other|Placebo|Given PO
193992|NCT02065687|Other|Quality-of-Life Assessment|Ancillary studies
193993|NCT02065687|Other|Questionnaire Administration|Ancillary studies
193994|NCT02065700|Drug|GLPG0634|
193995|NCT02065713|Drug|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
193996|NCT00125814|Drug|Interferon alfa-2b|
193997|NCT02068378|Device|CMPE Optical Sensor Device|Christie Medical Physics & Enginieering visual feedback with optical sensing device.
193998|NCT00126048|Drug|Atorvastatin|40mg tablet
193999|NCT02068391|Behavioral|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
194000|NCT02068391|Behavioral|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at ~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
194001|NCT02068404|Drug|Nifedipine|
194002|NCT02068417|Device|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
194003|NCT02068430|Drug|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
194004|NCT02068430|Other|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
194005|NCT02068443|Drug|SYR-322 + metformin hydrochloride|
194006|NCT02068443|Drug|SYR-322 + metformin hydrochloride|
194007|NCT02068443|Drug|SYR-322 + metformin hydrochloride placebo|
193686|NCT02073669|Procedure|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
193687|NCT02073682|Drug|edoxaban|
193688|NCT02073682|Drug|Dalteparin|
193689|NCT02073695|Procedure|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
193690|NCT02073695|Device|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
193691|NCT02075814|Drug|placebo|40 mg/kg placebo, single dose (day 0), Group 4
193692|NCT02075814|Drug|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
193693|NCT02075827|Behavioral|Competitive video game|1 hour playing video game
193694|NCT02075827|Behavioral|Little Big Planet|1 hour playing video game
193695|NCT00126685|Biological|autologous tumor cell vaccine|
193696|NCT02075840|Drug|Alectinib|Participants will receive Alectinib 600 mg (four 150 mg capsules) BID from visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
193697|NCT02075840|Drug|Crizotinib|Participants will receive Crizotinib 250 mg capsules orally BID from visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
193698|NCT02075879|Behavioral|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
193699|NCT02075879|Other|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
193700|NCT02075892|Dietary Supplement|Mushroom Blend|Scivation
193701|NCT02075892|Dietary Supplement|Placebo|
193702|NCT02075931|Other|Physical activity feedback with group meetings|Physical activity feedback
193703|NCT02075931|Other|Control|No intervention
193704|NCT02075944|Behavioral|High intensity aerobic exercise|
193705|NCT02075944|Behavioral|Low intensity aerobic exercise|
193706|NCT00126685|Biological|therapeutic autologous dendritic cells|
194009|NCT00002203|Drug|Lamivudine|
198178|NCT02045017|Drug|Pomalidomide and Dexamethasone|
198468|NCT02039765|Drug|Brimonidine tartrate|
198469|NCT02039778|Radiation|Stem Cell Radiotherapy (ScRT) and Temozolomide|Stem Cell Radiotherapy (ScRT) and Temozolomide:
The postoperative surgical bed + edema + margin & the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).
Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays).
198470|NCT02039791|Biological|Nimotuzumab|200mg/w,weekly, 6 weeks
198471|NCT02039791|Drug|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
198472|NCT02039791|Drug|Paclitaxel|175 mg/m2, d1
1 cycle/21d, 2 cycles.
198473|NCT02039804|Drug|Corticosteroids|Intra-bursal injection
198474|NCT02039804|Device|Hyaluronic acid|Intra-bursal injection
198475|NCT02039817|Drug|IDN-6556|
198476|NCT02039830|Behavioral|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
198477|NCT00123110|Drug|leuprolide acetate|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
198478|NCT02039830|Behavioral|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
198479|NCT02039843|Other|Service Dog or Emotional Support Dog|Emotional Support Dog. Service Dog - an assistance dog specifically trained to perform tasks that are specific to the person's disability and has public access privileges.
-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran.
198480|NCT02039843|Other|Emotional Support Dog|-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran.
198481|NCT02042560|Other|Blood samples|
198482|NCT02042560|Other|Spleen samples|
198483|NCT00123383|Drug|Modafinil|
198484|NCT02042573|Device|rTMS|
198485|NCT02042573|Drug|SSRI (SEROPLEX ou ZOLOFT)|
188940|NCT01955551|Behavioral|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
188941|NCT01955564|Drug|NW-3509a|single dose
188942|NCT01955577|Drug|Placebo orally everyday|
188943|NCT01955577|Drug|Vitamin D3 cholecalciferol|
188944|NCT01955590|Behavioral|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
188945|NCT01955590|Behavioral|EMDR|8-12 sessions of manualized EMDR
189248|NCT01989000|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
189249|NCT01989000|Drug|Gemcitabine|1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
189250|NCT01989000|Radiation|Radiotherapy|A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
189251|NCT01989000|Procedure|Pancreaticoduodenectomy|
189252|NCT00118365|Drug|sulindac|Given orally
189253|NCT01989013|Other|biweekly treatment intervention|
189254|NCT01989026|Biological|BCG|
189255|NCT01989052|Drug|CTO|
189256|NCT01989052|Drug|Lomustine|
189257|NCT01989065|Behavioral|Lifestyle counseling|see arm description
189258|NCT01989065|Behavioral|Text Messaging|See Arm Description
189259|NCT01989091|Device|B-Lock|Antimicrobial Catheter Lock Solution
189260|NCT01989091|Drug|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
189261|NCT01989130|Device|Roche AMPLICOR CT/NG|
189262|NCT01989130|Device|Cepheid Xpert CT/NG Test|
189263|NCT00118365|Other|laboratory biomarker analysis|Correlative studies
188610|NCT01960803|Radiation|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
188611|NCT01960816|Device|Procedure: thermal coagulation of tissue in the nasal airway|The Aerin Medical Wand is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway in order to shrink the enlarged tissues.
188612|NCT01960829|Drug|Everolimus|
188613|NCT00002124|Drug|Delavirdine mesylate|
188614|NCT00115908|Drug|Ribavirin|
188615|NCT01960842|Drug|ABT-SLV187|Dose levels will be individually optimized.
188616|NCT01960855|Drug|ABT-494|
188617|NCT01960855|Drug|Placebo|
188618|NCT01960868|Other|standard physiotherapy|
188619|NCT01960868|Other|experimental physical therapy|
188620|NCT00116181|Drug|Etanercept|All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.
Subjects randomized to the "continuous therapy" arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the "intermittent therapy" arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
188621|NCT01963312|Procedure|Transarterial Supraselective Embolization of the prostate|
188622|NCT01963312|Procedure|Transurethral Resection of the prostate|
188623|NCT01963325|Drug|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
188624|NCT01963338|Device|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
188625|NCT01963338|Device|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
188946|NCT01955603|Drug|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
188947|NCT00115414|Drug|pegfilgrastim|
193465|NCT02050009|Other|laboratory biomarker analysis|Correlative studies
193466|NCT02050035|Other|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
193467|NCT02050048|Other|Administration of Lactated Ringer's (LR) Solution|Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:
initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour
LR fluid infusion during the procedure at 5 cc/kg/hr
Post-procedure bolus of 20 cc/kg over 90 minutes
193468|NCT02050061|Other|compression stocking|study the impact of compression stocking
193469|NCT02050074|Drug|Colesevelam|
193470|NCT02050074|Drug|Metformin|
193471|NCT00124072|Drug|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
193472|NCT02050074|Other|Placebo|
193473|NCT02050087|Device|Simple sling.|
193474|NCT02050087|Device|Neutral brace|
193475|NCT02050113|Device|Physician modified stent graft|The surgeon will modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. This surgery is done through small incisions in the groin.
193476|NCT02050126|Device|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
193477|NCT02050139|Dietary Supplement|L-cysteine|
193478|NCT02050139|Other|Placebo|
193479|NCT02050152|Behavioral|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
193480|NCT02050152|Drug|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
193481|NCT02050165|Dietary Supplement|KIND Bars|Consumption of KIND Bars for 12 weeks
193482|NCT02052908|Other|Laboratory Biomarker Analysis|Correlative studies
193483|NCT02052908|Drug|Naproxen|Given PO
193484|NCT02052908|Other|Placebo|Given PO
197620|NCT02067195|Drug|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
197621|NCT02067208|Device|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
197622|NCT02067221|Device|RIRS|RIRS arm
Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
197623|NCT02067221|Device|MPCNL|MPCNL arm
A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.
197624|NCT02067234|Other|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
197912|NCT02059616|Drug|Amlodipine 10mg|Daily oral administration for 8 weeks
197913|NCT02059616|Drug|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
197914|NCT02059616|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
197915|NCT02059629|Device|Eluna pacemaker family|New pacemaker generation with new functions, like wandless RF telemetry "SafeSync"
197916|NCT02059629|Device|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
197917|NCT02059642|Drug|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
197918|NCT02059642|Drug|placebo|Placebo 1400 mg administered orally once daily
197919|NCT02062112|Other|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
197920|NCT02062138|Other|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
197921|NCT02062138|Other|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
197922|NCT02062138|Other|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
197332|NCT02074982|Drug|secukinumab 300 mg|
197333|NCT02074982|Drug|ustekinumab 45/90 mg sc and placebo secukinumab|
197334|NCT02074995|Biological|BVS857|Group 1A&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
197335|NCT00126620|Drug|sorafenib tosylate|
197336|NCT02074995|Other|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
197337|NCT02075008|Drug|QGE031|QGE031 SC every 4 weeks
197338|NCT02075021|Drug|Lenalidomide|
197339|NCT02075021|Drug|nab-paclitaxel|
197340|NCT02075034|Drug|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
197341|NCT02075047|Drug|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
197625|NCT02067234|Behavioral|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
197626|NCT02067247|Device|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
197627|NCT00125957|Drug|Placebo|
197628|NCT02067260|Device|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
197629|NCT02070185|Behavioral|7 exposures arm|During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).
During a 4-wk conditioning period, children were exposed either 7 times to each beverage.
After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period).
197630|NCT02070198|Drug|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
197631|NCT02070198|Drug|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
197031|NCT02041845|Radiation|60 Gy in 40 fractions|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
197032|NCT02041858|Other|Altered Alarm Settings|An altered set of alarm parameter settings
197033|NCT02041871|Dietary Supplement|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
197034|NCT02041871|Dietary Supplement|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
197035|NCT02041884|Behavioral|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
197036|NCT00123318|Drug|epirubicin|50mg/m2 IV day 1
197037|NCT02041884|Behavioral|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
197038|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
197039|NCT02041897|Procedure|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
197040|NCT02041910|Biological|Stem Cells|MSCs injection intratesticular
197041|NCT02041910|Biological|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
197042|NCT02041923|Behavioral|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
197043|NCT02041936|Device|NanoKnife IRE System|
197342|NCT02075047|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
197343|NCT02075060|Procedure|IPOI (pre-operative)|
197344|NCT02075060|Procedure|IPOP (post-operative)|
197345|NCT02075073|Biological|SB3|
197346|NCT00126633|Biological|bevacizumab|
197347|NCT02075073|Biological|EU sourced Herceptin®|
197348|NCT02075073|Biological|US sourced Herceptin®|
196453|NCT02054351|Drug|IMAB027|Phase 1
Intrapatient dose escalation: 1 mg/m2, 10 mg/m2, 30 mg/m2, 100 mg/m2
Interpatient dose escalation: 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
196454|NCT02054364|Behavioral|FBT and CRT|
196455|NCT02054364|Behavioral|FBT and art therapy|
196735|NCT02048917|Drug|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
196736|NCT02048917|Drug|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
196737|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
196738|NCT02048917|Drug|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
196739|NCT02048917|Drug|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
196740|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
196741|NCT00123968|Biological|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
196742|NCT02048917|Drug|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
196743|NCT02048917|Drug|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
196744|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
196745|NCT02048917|Drug|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
196746|NCT02048917|Drug|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
196747|NCT02048930|Device|Budesonide Easyhaler|
196748|NCT02048930|Device|Budesonide dry powder inhaler|
196749|NCT02048943|Drug|dovitinib lactate|Given PO
196750|NCT02048943|Drug|gemcitabine hydrochloride|Given IV
196751|NCT02048943|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
196752|NCT00002190|Drug|Zidovudine|
196753|NCT00123981|Procedure|Off-Pump Coronary Artery Bypass Grafting|
180655|NCT01935765|Other|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
180656|NCT01935765|Other|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
180657|NCT01935765|Other|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
180658|NCT01935765|Other|Electrocardiogram (ECG)|Electrocardiogram (ECG)
180659|NCT01935765|Other|Carotid echography|Carotid echography
180660|NCT01935765|Other|Blood pressure|Blood pressure
180661|NCT01935778|Drug|Docetaxel and capecitabine and oxaliplatin|Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
180662|NCT00113399|Drug|paclitaxel|
180663|NCT01935778|Drug|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
180664|NCT01935791|Drug|Glucagon|Hormone
180665|NCT01935791|Drug|Saline|Control
180666|NCT01935804|Drug|Pioglitazone|30 mg/daily for 12 months
180667|NCT01935804|Drug|Metformin|850 mg/daily for 12 months
180668|NCT01935817|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
180669|NCT01935817|Drug|Placebo|
180670|NCT01935830|Radiation|[11c] LAAM|intravenous administration of 15-20 mCi of [11c] LAAM.
181001|NCT01951664|Behavioral|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
181002|NCT00114933|Drug|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
181003|NCT01951664|Behavioral|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
180338|NCT01940497|Drug|trastuzumab [Herceptin]|600 mg SC (vial or single-use injection device) every 3 weeks, 18 cycles
180339|NCT01940510|Drug|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
180340|NCT01943019|Drug|Linagliptin|
180341|NCT01943045|Biological|NGM282|
180342|NCT01943045|Other|Placebo|
180343|NCT01943058|Drug|megestrol acetate|Given PO
180344|NCT01943058|Device|levonorgestrel-releasing intrauterine system|Given IUD
180345|NCT00114140|Radiation|radiation therapy|
180346|NCT01943058|Other|laboratory biomarker analysis|Correlative studies
180347|NCT01943058|Other|questionnaire administration|Ancillary studies
180348|NCT01943071|Behavioral|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
180349|NCT01943084|Drug|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
180350|NCT01943084|Drug|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
180351|NCT01943110|Device|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
180352|NCT01943110|Device|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
180353|NCT01943123|Dietary Supplement|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
180354|NCT01943123|Dietary Supplement|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
180355|NCT01943136|Drug|papaya 1% extract ointment|
180671|NCT01935830|Drug|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
180672|NCT01935830|Drug|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
180049|NCT01948284|Device|Suction Unit|
180050|NCT01948297|Drug|Debio1347 (CH5183284)|Debio1347 (CH5183284) capsules or tablets for oral administration
180051|NCT00114543|Procedure|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
180052|NCT01948310|Drug|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
180053|NCT01948310|Behavioral|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
180054|NCT01950871|Device|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
180055|NCT01950884|Drug|Ezetimibe|Ezetimibe tablets
180056|NCT01950884|Behavioral|Lifestyle|lifestyle
180057|NCT01950923|Drug|sildenafil citrate|Given PO
180058|NCT01950923|Other|placebo|Given PO
180059|NCT01950923|Procedure|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
180060|NCT00114803|Drug|Calcitonin nasal spray (salmon)|
180061|NCT01950936|Other|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
180062|NCT01950949|Other|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
180063|NCT01950962|Other|Sampling of blood|
180064|NCT01950975|Biological|Peripheral blood samples in EDTA tubes|
180065|NCT01950975|Procedure|Skin biopsies|
180066|NCT01950988|Device|Manual toothbrush reference|
180067|NCT01950988|Procedure|Measure of the dental plaque|
180068|NCT01950988|Device|Manual toothbrush Broscyl®|
179457|NCT01942265|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
179752|NCT01934881|Device|voltage adjustment only|Only voltage will be adjusted in all programming sections.
179753|NCT01934881|Device|Combined parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
179754|NCT01934894|Drug|cabazitaxel|
179755|NCT00113386|Drug|cisplatin|
179756|NCT01934894|Drug|lapatinib|
179757|NCT01934907|Other|Washing of packed RBC by normal saline|
179758|NCT01934933|Drug|celebrex|
179759|NCT01934933|Drug|Enbrel|
179760|NCT01934933|Drug|Enbrel plus Celebrex|
179761|NCT01937429|Device|Standard colonoscopy with insufflation of air|
179762|NCT00113646|Drug|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
179763|NCT01937442|Drug|Thalidomide Celgene™|200mg once daily and by mouth
179764|NCT01937455|Biological|rAAV1-PG9DP|4x10^12 vg administered intramuscularly
179765|NCT01937455|Biological|rAAV1-PG9DP|4x10^13 vg administered intramuscularly
179766|NCT01937455|Biological|rAAV1-PG9DP|8x10^13 vg administered intramuscularly
179767|NCT01937455|Biological|rAAV1-PG9DP|1.2x10^14 vg administered intramuscularly
179768|NCT01937468|Other|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
179769|NCT01937468|Drug|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
179157|NCT01950039|Drug|Betaine|Betaine or placebo administered orally in divided doses over 3 months.
179158|NCT01950039|Drug|Placebo|Placebo administered orally in divided doses over 3 months
179159|NCT00114738|Biological|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
179160|NCT01950052|Dietary Supplement|Diet group 800 Kcal diet|800 kcal diet for 4 weeks
179161|NCT01950065|Device|iovera|
179162|NCT01950091|Behavioral|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
179163|NCT01950091|Other|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
179164|NCT01950104|Other|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
179458|NCT01942278|Other|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
179459|NCT01942291|Drug|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
179460|NCT01942304|Procedure|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
179461|NCT01942304|Procedure|Anorganic bovine bone mineral in direct sinus augmentation|
179462|NCT01942317|Other|Balneotherapy|
179463|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 7.5 gms topically each day
179464|NCT01942330|Procedure|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
179465|NCT01942343|Drug|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
179466|NCT01942356|Procedure|TIVA - Hypotension|Defined as: MAP < 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.
Give 200 mL Fluid Bolus
If not successful, give ephedrine 5 mg bolus
Repeat from 1.) if even is not resolved after 3.)
179467|NCT01945034|Drug|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
179468|NCT01945047|Drug|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
178852|NCT01936610|Other|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
178853|NCT01936610|Other|lecture|Describe advantages and disadvantages in one 90-min session
178854|NCT01936623|Behavioral|Computerized Brief Intervention|No additional information needed.
178855|NCT01936636|Drug|Fentanyl|
178856|NCT01936649|Drug|AdreView|AdreView 10 millicuries (mCi) as a single iv. administration
178857|NCT01936662|Device|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
178858|NCT01936662|Device|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
178859|NCT01936675|Other|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
178860|NCT00113542|Drug|Tetrathiomolybdate (TM)|
178861|NCT01936688|Drug|MK-3222 200 mg|MK-3222 200 mg administered SC.
178862|NCT01936688|Drug|MK-3222 100 mg|MK-3222 100 mg administered SC.
178863|NCT01936688|Drug|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
178864|NCT01936688|Drug|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
178865|NCT01936688|Drug|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
178866|NCT01936701|Procedure|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
178867|NCT01936714|Procedure|cataract surgery|
179165|NCT01950104|Other|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
179166|NCT01950117|Procedure|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
179167|NCT01950117|Procedure|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
179168|NCT01950130|Procedure|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
178542|NCT01906008|Behavioral|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
178543|NCT01906008|Behavioral|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
178544|NCT01906021|Procedure|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
178545|NCT01906021|Procedure|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
178546|NCT01906034|Behavioral|Exercise with supervision|
178547|NCT01906034|Behavioral|Home-based without supervision|
178548|NCT01906060|Device|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
178549|NCT01906073|Drug|intranasal fentanyl spray|
178550|NCT01906073|Drug|slow release morphine|
178551|NCT00110760|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
178552|NCT01906086|Other|nutritional intervention|
178553|NCT01906086|Other|life style intervention|
178554|NCT01906099|Other|nutritional intervention|
178555|NCT01906099|Other|life style modification|
178556|NCT01906112|Procedure|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
178557|NCT01906125|Drug|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
178558|NCT01906125|Drug|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
178559|NCT01906125|Drug|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
178560|NCT01906138|Device|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
178868|NCT01936727|Procedure|cataract surgery|
178869|NCT01936740|Procedure|cataract surgery|
183318|NCT02572778|Procedure|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
183319|NCT02572791|Drug|Chlorhexidine|
183320|NCT02572791|Drug|Mupirocin|
183321|NCT00187863|Behavioral|pain perception|pain perception
183322|NCT02393001|Other|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
183323|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
183324|NCT02393014|Procedure|Simple physical exercises|The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.
The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.
The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not.
183325|NCT02393027|Drug|[18F] LBT-999 PET|
183326|NCT00162929|Biological|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
183327|NCT02393040|Other|PRP/Saline|PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.
Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head.
183328|NCT02393053|Procedure|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
183329|NCT02393053|Procedure|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
183330|NCT02393066|Drug|Propofol|Sedation
183331|NCT02393066|Drug|Dexmedetomidine|Sedation
183332|NCT02393079|Device|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
183333|NCT02393079|Device|Sham|A SHAM identical helmet will be used in the control group.
183334|NCT02393092|Behavioral|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
183020|NCT02545712|Other|Exposure to glycerin|The drug source(s) and amount administered daily are noted.
183021|NCT00184756|Drug|somatropin|
183022|NCT02545712|Other|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
183023|NCT02545712|Other|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
183024|NCT02545712|Other|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
183025|NCT02545725|Other|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
183026|NCT02545738|Drug|Liraglutide|active treatment
183027|NCT02545738|Drug|placebo|placebo
183028|NCT02545751|Radiation|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
183029|NCT02545751|Drug|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days each week for a total of 8 weeks. Tumor response is evaluated by assessing clinical and CT/MRI response for all the measurable metastatic sites.
183030|NCT02545764|Other|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
183031|NCT02545777|Drug|diclofenac sodium enteric-coated|
183032|NCT00184769|Drug|somatropin|
183033|NCT02545777|Drug|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
183034|NCT02545777|Drug|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
183035|NCT02545777|Drug|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
183036|NCT02545790|Procedure|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
183336|NCT02393092|Behavioral|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
182436|NCT02556762|Radiation|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
182437|NCT00185796|Procedure|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
182731|NCT02549859|Device|DBS|Patients will have a randomized double-blind prospective crossover study with usual medication "on" state under 3 different DBS stimulation frequency condition (60Hz vs 130Hz vs DBS off). Aspiration frequency on modified barium swallowing test and swallowing difficulty on questionnaire, FOG in stand-walk-sit test and questionnaire, and other axial and motor function will be assessed under each DBS condition. Changes in measurements between 60Hz and 130Hz at each visit and under 60Hz between two visits of 8 months apart on average will be analyzed, with swallowing function and FOG as primary, and the rest as secondary outcomes, correcting for potential carryover effect. Changes between other DBS conditions might also be explored in this 2-year study.
182732|NCT02549872|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
182733|NCT02549885|Other|PNF rhythmic initiation|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation on neck diagonal.
182734|NCT02549885|Other|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
182735|NCT02549885|Other|Static stretching and neck mobilization|Static stretching of neck muscles and active neck mobilization.
182736|NCT02549898|Drug|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
182737|NCT02551900|Other|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
182738|NCT02551913|Behavioral|Control|the adolescents will not receive any specific intervention
182739|NCT02551913|Behavioral|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
182740|NCT02551926|Behavioral|mobile text messages|
182741|NCT02551926|Behavioral|virtual community|
182742|NCT02551926|Behavioral|brochures|
182743|NCT02551926|Other|Usual care|
182744|NCT02551926|Device|mobile phone|
182745|NCT02551939|Procedure|Autologous Fat Grafting|Autologous Fat Grafting
198188|NCT02047266|Procedure|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
198189|NCT02047266|Procedure|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time>250seconds).
198190|NCT02047266|Procedure|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time>450seconds).
198490|NCT02042612|Drug|Sedation with sevoflurane during 48-hr in ICU|
198491|NCT02042625|Procedure|Nasopharyngeal|
198492|NCT02042638|Drug|hCG 1500 IU three times a week|
198493|NCT02042638|Drug|Pregnyl (hCG) ampule 1500 IU/three times a week|
198494|NCT00123396|Behavioral|BioCASES and BioTESTS|
198495|NCT02042651|Device|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
198496|NCT02042651|Device|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
198497|NCT02042664|Drug|BYETTA treatment|
198498|NCT02042664|Drug|Metformine|
198499|NCT02042690|Procedure|Haplo-identical HSCT|Haplo-identical Protocol: GIAC regimen. GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
197856|NCT02054741|Other|Quality-of-Life Assessment|Ancillary studies
197857|NCT02054741|Other|Survey Administration|Ancillary studies
197858|NCT02054754|Drug|Dexanabinol|Oral formulation of dexanabinol
197859|NCT02054754|Drug|Placebo|
197860|NCT02054767|Drug|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
197861|NCT02054780|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. The rationale is that OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems (e.g., depression, anxiety) are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based MH treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
197862|NCT02054780|Behavioral|Psychosocial Counseling|The curriculum "Psychosocial Care and Counseling" was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH.
197863|NCT02054793|Drug|Itraconazole|100 mg 200 mg 300 mg
197864|NCT02054793|Drug|Orteronel|300 mg
197865|NCT02054806|Biological|Pembrolizumab|
197866|NCT00124579|Drug|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
198191|NCT02047266|Device|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
198192|NCT02049437|Drug|Placebo|Subjects will be randomized 1:1 to one of the following arms:
ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
197572|NCT02062034|Drug|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
197573|NCT02062047|Procedure|FMSRP|FMSRP in a maximum of 24 hours.
197574|NCT02062047|Drug|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
197575|NCT02062047|Procedure|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
197576|NCT02062047|Other|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
197577|NCT02062060|Drug|Abametapir Lotion 0.74% w/w|
197578|NCT02062060|Drug|Vehicle Lotion|
197579|NCT02062073|Drug|Abametapir Lotion 0.74% w/w|
197580|NCT02062073|Other|0.1% sodium lauryl sulfate|
197581|NCT00002199|Drug|Lamivudine/Zidovudine|
197582|NCT00125385|Biological|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
197583|NCT02062073|Other|saline 0.9%|
197584|NCT02062073|Other|Vehicle Lotion|
197585|NCT02062086|Dietary Supplement|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
197586|NCT02062099|Drug|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
197587|NCT02064530|Drug|serum physiologic|21 ml serum physiologic is applied interfasially
197588|NCT02064543|Other|GAITRite|mobility test assessing gait parameters
197867|NCT02057146|Procedure|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
197868|NCT02057159|Biological|NeuroVax|
197869|NCT02057159|Biological|IFA Placebo|IFA Placebo
197870|NCT02057172|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
197871|NCT02057172|Drug|liraglutide|Liraglutide is a GLP-1 agonist.
197284|NCT02070016|Device|Transcranial Magnetic Stimulation|
197285|NCT00126191|Drug|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
197286|NCT02070029|Procedure|Acupuncture|Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.
Physical Exam: inspection of tongue and palpation of central and peripheral pulses.
Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire
- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees
197287|NCT02070042|Drug|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
197288|NCT02070042|Drug|Placebo|Placebo capsules (olive oil) twice a day
197289|NCT02070055|Other|No intervention|
197290|NCT02070068|Device|PINPOINT System|
197291|NCT02070081|Procedure|Roux-en-Y gastric bypass surgery or sleeve surgery|
197292|NCT02070107|Other|On Plan|"On Plan" is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance.
197293|NCT02070120|Drug|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
197294|NCT02070120|Procedure|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
197295|NCT02070133|Drug|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
197296|NCT00126191|Drug|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
197297|NCT02070133|Drug|Placebo|Placebo once a day during 12 weeks
197298|NCT02070159|Drug|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
197299|NCT02070159|Drug|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
197300|NCT02070159|Drug|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
197301|NCT02070185|Behavioral|2 exposures arm|During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).
During a 4-wk conditioning period, children were exposed either 2 times to each beverage.
After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period).
181324|NCT01944059|Other|Placebo (l-alanine)|Theramine like placebo comparator
181325|NCT01944072|Other|Aerobic exercise training intensity|
181326|NCT01944085|Drug|Acetaminophen|Syrup
181327|NCT01944085|Drug|Ibuprofen|Syrup
181328|NCT01944085|Other|Vitamin C|Syrup
181329|NCT01944098|Drug|Lidocaine|
181330|NCT01944098|Drug|Placebo|
181618|NCT01936571|Other|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
181619|NCT01936584|Procedure|TAPP repair for inguinal hernias|
181620|NCT01939041|Behavioral|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
181621|NCT01939054|Drug|Nimotuzumab|
181622|NCT01939054|Drug|docetaxel|
181623|NCT01939054|Drug|capecitabine|
181624|NCT01939067|Device|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
181625|NCT01939067|Device|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
181626|NCT01939080|Procedure|Exercise training with supervised sessions|
181627|NCT01939093|Drug|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
181628|NCT01939093|Dietary Supplement|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
180997|NCT01951651|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
180998|NCT01951651|Drug|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
180999|NCT01951664|Other|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
181000|NCT01951664|Behavioral|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
181331|NCT01944111|Device|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
181332|NCT01944124|Behavioral|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
181333|NCT00114192|Drug|thalidomide|
181334|NCT01944124|Behavioral|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
181335|NCT01944137|Other|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
181336|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
181004|NCT01951664|Other|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
181005|NCT01951677|Drug|HBsAg|Standard hepatitis B vaccine antigen
181006|NCT01951677|Biological|PreS HBsAg|preS hepatitis B surface antigen
181007|NCT01951677|Biological|Advax-1(TM)|Adjuvant formulated with vaccine antigen
181008|NCT01951677|Biological|Advax-2(TM)|Adjuvant formulated with vaccine antigen
181009|NCT01951677|Biological|Advax-3(TM)|Adjuvant formulated with vaccine antigen
181010|NCT01951677|Biological|Alum|Adjuvant formulated with vaccine antigen
181011|NCT01951690|Drug|defactinib (VS-6063)|
181012|NCT01951703|Device|senofilcon A|Control, senfilcon A
181013|NCT00114946|Drug|Avastin|
181014|NCT01933308|Other|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
181015|NCT01933321|Biological|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
181016|NCT01933334|Drug|Pirfenidone|antifibrotic drug
181017|NCT01933347|Drug|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
181018|NCT01933360|Drug|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
181019|NCT00113269|Drug|tacrolimus|oral
181347|NCT01946763|Behavioral|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
181348|NCT00114413|Procedure|eNO measurement|measured by Aerocrine® NIOX device
181349|NCT01946763|Behavioral|pre operative education|
180673|NCT00113399|Radiation|radiation therapy|
180674|NCT01935843|Biological|CART-HER-2|
180675|NCT01935856|Drug|KHK7580|Oral administration
180676|NCT01935869|Drug|LEO 90100|
180677|NCT01935869|Drug|Vehicle|
180678|NCT01935869|Drug|Petrolatum ointment|
180679|NCT01938248|Drug|aspirin|aspirin 81 mg once daily
180680|NCT01938261|Drug|paracetamol|
180681|NCT00113698|Other|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
180682|NCT01938261|Drug|0.45 % saline solution|Placebo
180683|NCT01938274|Other|Educational intervention|
180684|NCT01938287|Device|SENSIMED Triggerfish|
180685|NCT01938300|Drug|Magnesium Sulfate|
180686|NCT01938300|Drug|Normal saline|
180687|NCT01938313|Procedure|ERAS perioperative cares|Patient's preoperative counseling & education before surgery
No Bowel preparation
Oral Carbohydrate Solution (OCS) loading until 2hours before surgery
Fluid restriction & Management by pulse contour analysis or transesophageal doppler
Early mobilization
Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))
Epidural patient controlled analgesics (no opioids analgesics)
Postoperative Nausea Active Control
Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)
Perioperative High content Oxygen therapy
No drain insertion
No Levin tube
Patients will be discharged at POD#4 if there's no problem.
180688|NCT01938313|Procedure|Conventional perioperative cares|No Patient's preoperative counseling & education before surgery
Bowel preparation
No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery
Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)
Conventional Mobilization
Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)
IV PCA
Postoperative Nausea Control if needed
No Thromboembolism prophylaxis
No or Low Content Oxygen therapy
Routine drain insertion
Levin tube insertion if needed
180689|NCT01938326|Procedure|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
180690|NCT01938339|Device|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
180691|NCT01938352|Biological|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
180692|NCT00002109|Drug|Stavudine|
180356|NCT00114153|Drug|capecitabine|
180357|NCT01943136|Drug|mupirocin 2% ointment|
180358|NCT01943162|Behavioral|CPT|
180359|NCT01943188|Radiation|stereotactic body radiation therapy|Undergo SBRT
180360|NCT01943188|Drug|cyclophosphamide|Given PO
180361|NCT01943188|Biological|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
180362|NCT01943188|Other|laboratory biomarker analysis|Correlative studies
180363|NCT01943201|Device|new bedsheet|sleeping 5 nights on the new bedsheet
180364|NCT01943201|Device|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
180365|NCT01943227|Other|Enthalpy|
180366|NCT01943240|Drug|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
180367|NCT00114153|Drug|carboplatin|
180368|NCT01945931|Other|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
180369|NCT01945944|Drug|Hypertonic saline (3%)|
180370|NCT01945944|Drug|Placebo (0.9% saline)|
180371|NCT00114309|Drug|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
180372|NCT01945957|Drug|Oxytocin|For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)
For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin.
180373|NCT01945970|Other|Black tea extract|Black tea extract
180374|NCT01945970|Other|Positive control|Positive control
180375|NCT01945970|Other|Placebo|Placebo
180376|NCT01945983|Drug|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
179770|NCT01937481|Behavioral|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
179771|NCT01937494|Drug|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
179772|NCT01937507|Drug|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
180069|NCT01951001|Drug|Prasugrel|For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
180070|NCT01951014|Other|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
180071|NCT00114816|Drug|capecitabine|
180072|NCT01951027|Drug|GX-G3 12.5 μg/kg or Placebo|Single SC injection
180073|NCT01951027|Drug|GX-G3 25 μg/kg or Placebo|Single SC injection
180074|NCT01951027|Drug|GX-G3 50 μg/kg or Placebo|Single SC injection
180075|NCT01951027|Drug|GX-G3 100 μg/kg or Placebo|Single SC injection
180076|NCT01951053|Drug|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
180077|NCT01951053|Drug|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
180078|NCT01951053|Drug|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
180079|NCT01951066|Drug|OZURDEX|Patients will receive a single injection of OZURDEX
180080|NCT01951079|Drug|Intra-amniotic injection of DIGOXIN|
180081|NCT01932489|Procedure|Biopsy of a metastatic lesion.|
180082|NCT01932502|Drug|clobazam (Onfi)|Subject's clonazepam will be converted to the following Onfi doses per day:
Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.
Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.
Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.
Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
The following will be the initial conversion schedule from clonazepam to Onfi:
Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.
Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated
179469|NCT01945047|Drug|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
179470|NCT00114244|Drug|gemcitabine hydrochloride|Given IV
179471|NCT01945060|Device|heart rate Control to Range System (hrCTR) using DiAs Platform|Diabetes Assistant (DiAs) Medical Platform System
A smart-phone medical platform (DiAs);
Continuous Glucose Monitor;
Insulin pump;
Bluetooth connection;
Remote Monitoring Server.
179472|NCT01945060|Other|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
179473|NCT01945073|Behavioral|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
179474|NCT01945073|Other|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
179475|NCT01945086|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
179773|NCT00113646|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
179774|NCT01937520|Device|acupuncture|One half of subjects will receive a standardized acupuncture regiment
179775|NCT01937520|Device|no acupuncture|placebo
179776|NCT01937533|Procedure|Magnetic Resonance Imaging using an endovaginal receiver coil|
179777|NCT01937546|Procedure|Primary delivery of anterior shoulder|
179778|NCT01937546|Procedure|Primary delivery posterior shoulder|
179779|NCT01937559|Biological|Tranexaminic Acid (TXA)|1.5g of TXA in 100ml normal saline solution
179780|NCT01937559|Drug|Normal saline|
179781|NCT01937572|Other|Visionaire system (Knee MRI)|
179782|NCT01937572|Other|No Knee MRI|
179783|NCT01937585|Behavioral|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
179169|NCT01950143|Dietary Supplement|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
179170|NCT00114738|Drug|Bortezomib (B)|Bortezomib is given alone for one cycle.
179171|NCT01950143|Dietary Supplement|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
179172|NCT01952470|Drug|Dornase Alpha|Once daily, 2.5ml inhaled dornase alpha (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
179173|NCT01952470|Drug|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
179174|NCT01952496|Other|Assisted Standing Treatment Program|Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months.
Arm: Force-measuring platform
179175|NCT01952522|Behavioral|Weighted brace|People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
179176|NCT00115037|Behavioral|Medical Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
179177|NCT01952522|Behavioral|Non weighted brace|People will be given a brace with no weight they will have to wear all the day during three months.
179178|NCT01952535|Drug|HMS5552|
179179|NCT01952535|Drug|Placebo|
179180|NCT01952548|Drug|K-312|
179181|NCT01952548|Drug|Placebo|
179182|NCT01952561|Drug|dapivirine ring|
179183|NCT01952574|Drug|AMG 334|Investigational Product
179184|NCT01952574|Drug|Placebo|Placebo Comparator
179476|NCT01945086|Drug|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
179477|NCT01945086|Other|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
179478|NCT01945099|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
178870|NCT01936753|Behavioral|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
178871|NCT00113555|Device|ACT (Adjustable Continence Therapy)|surgically implanted device
178872|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
178873|NCT01939197|Drug|ABT-450/r/ABT-267|Tablet
178874|NCT00113815|Drug|topiramate|5 mg/kg/day
178875|NCT01939197|Drug|ABT-333|Tablet
178876|NCT01939197|Drug|Ribavirin (RBV)|Tablet
178877|NCT01939210|Procedure|4-Dimensional Computed Tomography|Undergo 4D-CT
178878|NCT01939210|Other|Educational Intervention|Participate in breathing training sessions
178879|NCT01939210|Procedure|Meditation Therapy|Participate in breathing training sessions
178880|NCT01939210|Other|Questionnaire Administration|Ancillary studies
178881|NCT01939210|Radiation|Radiation Therapy|Undergo standard radiation therapy
178882|NCT01939210|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
178883|NCT01939223|Drug|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
178884|NCT01939223|Drug|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
178885|NCT00113815|Drug|topiramate|25 mg/kg/day
178886|NCT01939236|Drug|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
178887|NCT01939236|Drug|Placebo (gummeline)|Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.
1 bag of drug 2 times per day for 28 days according to syndrome differentiation.
For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days.
178888|NCT01939249|Device|Abbott Laboratories Xience|
178889|NCT01939249|Device|Biotronik Orsiro|
183335|NCT02393092|Behavioral|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
178561|NCT01906151|Device|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
178562|NCT00110760|Drug|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
178563|NCT01906164|Drug|ALS-008176|
178564|NCT01906164|Drug|Placebo|
178565|NCT01906190|Biological|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
178566|NCT01906203|Device|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
178567|NCT01908530|Device|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
178568|NCT01908543|Drug|Ferrous sulphate 200mg oral tablet|Administration by mouth
178569|NCT01908556|Drug|Letrozole|
178570|NCT01908569|Other|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
178571|NCT01908569|Other|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
178572|NCT01908582|Drug|Evacetrapib|Administered orally
178573|NCT00110994|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
178574|NCT01908582|Drug|Rifampin|Administered orally
178575|NCT01908595|Drug|M518101|
178576|NCT01908621|Drug|G-CSF (filgrastim)|
178577|NCT01908621|Drug|Cytosine arabinoside + G-CSF (filgrastim)|
178578|NCT01908634|Dietary Supplement|Milk-based Strawberry Beverage|
178579|NCT01908634|Dietary Supplement|Water-Based Strawberry Beverage|
183337|NCT00162942|Device|Adacolumn|Ten apheresis sessions:
One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9).
183338|NCT02393118|Device|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
183339|NCT02393131|Radiation|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
183340|NCT02541097|Behavioral|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
183341|NCT02541123|Other|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7
183342|NCT02541136|Behavioral|Aerobic Exercise|Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, < 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.
The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level.
183343|NCT02541149|Procedure|blood sample|
183344|NCT02541162|Behavioral|Oral information and interviews|interviews about sexuality and self experience during the disease
183345|NCT02541188|Genetic|Genetic analysis|
183346|NCT02541201|Dietary Supplement|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
183347|NCT00184132|Procedure|Treatment in PICU|
183348|NCT02541201|Dietary Supplement|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
183349|NCT02541227|Drug|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
183350|NCT02541240|Other|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
183351|NCT02541253|Biological|GC3110A|A single 0.5mL dose intramuscular injection
183352|NCT02541253|Biological|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
183353|NCT02541266|Other|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
182746|NCT02551952|Device|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
182747|NCT00185263|Genetic|AdF5FGF-4 vs. Placebo|Intracoronary infusion
182748|NCT02551965|Other|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
183037|NCT02545790|Biological|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
183038|NCT02545803|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
183039|NCT02547909|Drug|fluorescein 10%|
183040|NCT02547922|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
183041|NCT02547922|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
183042|NCT02547935|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
183043|NCT02547935|Drug|Dapagliflozin 10mg+Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
183044|NCT02547935|Drug|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
183045|NCT02547948|Biological|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
183046|NCT02547961|Biological|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
183047|NCT00002499|Radiation|radiation therapy|
183048|NCT00184938|Procedure|forearm ischemic exercise|
183049|NCT02547974|Biological|Formulation 1 (plain) NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
198500|NCT02042690|Drug|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
198501|NCT02042703|Device|anterior segment OCT|
198502|NCT02042716|Other|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
198503|NCT02042729|Drug|E2022- Current Formula Tape|Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.
Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.
198504|NCT02042729|Drug|E2022- New Formula Tape|Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.
Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.
198505|NCT00123409|Behavioral|Telephone disease management|Telephone based care management
198506|NCT02045030|Drug|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
198507|NCT02045056|Drug|Gemfibrozil|
193726|NCT00122928|Behavioral|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
193727|NCT02037646|Other|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
193728|NCT02037646|Other|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
193729|NCT02037659|Procedure|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
193730|NCT02037672|Drug|metformin|
193731|NCT02037672|Drug|metformin and roflumilast|
193732|NCT02037685|Behavioral|Motivational Interviewing (MINT)|MINT has the following basic structure and goals:
Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.
Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.
Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an "other" enhances the likelihood that the commitment will be acted upon
198193|NCT02049450|Drug|INC424 (ruxolitinib)|INC424 oral tablet (5 miligrams)
198194|NCT02049476|Drug|Dexamethasone pellet|Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.
Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol.
198195|NCT02049489|Biological|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
198196|NCT02049502|Biological|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
198197|NCT00124033|Procedure|Transcystic Stenting (Facilitated ERCP)|
198198|NCT02049502|Procedure|sigmoidoscopy|
198199|NCT02049515|Drug|IPI-145 (duvelisib)|PI3K Inhibitor
198200|NCT02049515|Drug|Ofatumumab|
198201|NCT02049528|Drug|CC-122|CC-122
198202|NCT02049528|Drug|CC-122|CC-122
198203|NCT02049528|Drug|CC-122|CC-122
198204|NCT02049541|Drug|PI3K inhibitor BKM120|Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
198205|NCT02049541|Biological|rituximab|Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
198206|NCT02049541|Other|Pharmacodynamics|Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
198207|NCT02049541|Other|Correlative studies|Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
198508|NCT02045056|Drug|Placebo|
198509|NCT02045069|Drug|2 days Ivermectin|200-400 µg/kg once daily for 2 days and placebo once daily at D3
198510|NCT02045069|Drug|3 days Ivermectin|200 -400 µg/kg once daily for 3 days
198511|NCT02045069|Drug|Placebo|Placebo once daily for 3 days
198512|NCT02045082|Procedure|Corneal sampling|Slit lamp corneal sampling with a Swab
197872|NCT00124787|Drug|Placebo|Placebo PO q 6 hours x 4 doses
197873|NCT02057172|Drug|Placebo|Placebo
197874|NCT02057185|Behavioral|Study questionnaire|Questionnaire based on work situation of enrolled patients.
197875|NCT02057185|Behavioral|SF-36 Questionnaire|Version 1.6
197876|NCT02057198|Drug|Fidaxomicin|
197877|NCT02057198|Drug|Metronidazole|
197878|NCT02057198|Drug|Vancomycin|
197879|NCT02057211|Biological|autologous mesenchymal stem cell transplantation|
197880|NCT02057211|Procedure|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
197881|NCT02057224|Procedure|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
197882|NCT02057237|Drug|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
197883|NCT00124800|Behavioral|Tinnitus retraining therapy|Sound therapy and counseling
197884|NCT02057250|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
197885|NCT02057250|Device|Auto-injector (AID)|
197886|NCT02057250|Device|Pre-filled Syringe (PFS)|
197887|NCT02057263|Drug|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
197888|NCT02057263|Drug|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
197889|NCT02057263|Drug|Placebo|Participants will receive 4 doses of placebo during the course of the study.
198208|NCT00124046|Procedure|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
198209|NCT02049554|Other|Preconception Care Screener|
198210|NCT02049567|Device|Intraocular Lens Implantation|Use of accommodating lens to restore visual function at all distances.
197589|NCT00125619|Behavioral|Rehabilitation: Two Forms of Locomotor Training for Gait|Individuals receive locomotor training on two devices - a treadmill with body weight support while therapists assist the movement of the paretic leg and a robotic device called the Lokomat that moves your legs over a treadmill with body weight support.
197590|NCT02064543|Other|ADPM|mobility test assessing gait parameters
197591|NCT02064556|Drug|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
197592|NCT02064556|Drug|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
197593|NCT02064569|Genetic|GS010|
197594|NCT02064582|Drug|Enzalutamide|160mg by mouth each day
197595|NCT02064582|Drug|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
197596|NCT02064582|Radiation|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
197597|NCT02064595|Procedure|External fixator|Treatment with external fixation
197598|NCT02064595|Procedure|Intramedullary nail|Fracture treated with intramedullary nail
197599|NCT02064608|Drug|AZD2014|mTOR inhibitor
197600|NCT00125632|Procedure|Eccentric Viewing Training for Reading|
197601|NCT02064621|Drug|Candesartan 32mg|Candesartan 32mg 1T, PO, QD for 9days
197602|NCT02064621|Drug|Candesartan 32mg/Amlodipine 10mg|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
197603|NCT02064647|Other|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
197604|NCT02064647|Other|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
197605|NCT02064660|Device|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
197606|NCT02064673|Drug|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
197607|NCT02064673|Drug|placebo|placebo orally twice a day
197608|NCT02064686|Other|Exhaled breath temperature|
181629|NCT01939093|Drug|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
181630|NCT00113815|Drug|topiramate|15 mg/kg/day
181631|NCT01939106|Device|One Piece Drainable Pouch|
181632|NCT01939132|Drug|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
181633|NCT01939145|Drug|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
181926|NCT02574364|Radiation|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
181927|NCT02574364|Other|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
181928|NCT02540395|Drug|Tacrolimus (for Group A)|The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.
Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption.
181929|NCT02540395|Drug|Mycofenolate mofetil (MMF) (for Group A)|Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.
Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).
The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation.
181930|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group A)|At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).
Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day.
181931|NCT02540434|Device|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
181932|NCT02540434|Drug|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
181933|NCT02540434|Drug|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
181337|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
181338|NCT01944163|Other|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
181339|NCT01944176|Drug|simvastatin, placebo|
181340|NCT01946711|Drug|Budesonide|Nasal spray
181341|NCT01946737|Radiation|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
181342|NCT01946737|Radiation|Active Comparator: Invasive coronary angiography (ICA)|
181343|NCT01946750|Biological|Serum|
181344|NCT01946750|Biological|Stools|
181345|NCT01946750|Biological|Saliva|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
181346|NCT01946750|Biological|Whole blood|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
181634|NCT01939145|Device|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
181635|NCT01939158|Biological|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
181636|NCT01939158|Biological|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
181637|NCT01939171|Drug|Thymoglobulin|
181638|NCT01939184|Drug|WC3055|12.5, 25, 50 or 75 mg dose
181639|NCT01939184|Other|Placebo|Placebo
181640|NCT01941537|Drug|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
181350|NCT01946776|Device|implantable heart rate monitor|Implantation of Reveal XT
181351|NCT01946789|Biological|ALT-803|Intravenous infusion for dose level 1-5; subcutaneous injection for dose level 5a-8; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
181352|NCT01946802|Device|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
181353|NCT01946815|Drug|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
181354|NCT01946828|Device|FIM|Field Induced Mydriasis device
181355|NCT01946841|Dietary Supplement|RealDiet®Renal|
181356|NCT01946854|Behavioral|Questionnaire|Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.
Completion of 3 quality of life questionnaires every 3 months for 1 year.
181357|NCT01946867|Device|NBTXR3|
181358|NCT01946880|Drug|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
181359|NCT00114426|Device|non-invasive mechanical ventilation|
181360|NCT01946880|Drug|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular [7, 8]. Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
181361|NCT01946880|Drug|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
181362|NCT01949363|Drug|Cefixime|Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
181363|NCT01949389|Behavioral|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
181653|NCT00114088|Procedure|hysterectomy|
181654|NCT01941615|Drug|BI 207127|oral doses for 10 days (period B)
181020|NCT01933360|Drug|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
181021|NCT01933360|Drug|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
181022|NCT01933360|Drug|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
181023|NCT01933360|Drug|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
181024|NCT01933360|Drug|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
181025|NCT01933360|Drug|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
181026|NCT01933360|Drug|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
181027|NCT01933373|Procedure|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
181028|NCT01933373|Procedure|Dor|Anterior partial fundoplication plus myotomy.
181029|NCT01933386|Device|SoundBite|Non-surgical removable bone conduction device via the teeth.
181030|NCT00113269|Drug|alemtuzumab|Intravenous (IV)
181031|NCT01933399|Other|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
181032|NCT01933399|Other|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
181033|NCT01933399|Other|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
181034|NCT01933412|Biological|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
181035|NCT01933412|Biological|Engerix B Hepatitis B Vaccine|
181036|NCT01933425|Drug|rocuronium|
181037|NCT01933425|Drug|sugammadex|
181038|NCT01933425|Drug|placebo|
181039|NCT00113438|Drug|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
180377|NCT01945983|Drug|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
180693|NCT00113711|Behavioral|smoking cessation|
180694|NCT01938352|Biological|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
180695|NCT01938378|Biological|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
180696|NCT01938391|Device|Stealth 360°® OAS|Cardiovascular Systems Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
180697|NCT01938404|Biological|Octaplas|
180698|NCT01938417|Drug|tobramycin|
180699|NCT01938430|Drug|LDV/SOF|LDV 400 mg/SOF 90 mg FDC tablet administered orally once daily
180700|NCT01938430|Drug|RBV|RBV administered as 200 mg tablets (up to 1000-1200 mg) in a divided daily dose
180701|NCT01938443|Drug|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
180702|NCT01938443|Drug|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
180703|NCT01940640|Dietary Supplement|control|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
180704|NCT01940653|Drug|Progesterone|Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.
Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
180705|NCT01940679|Dietary Supplement|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
180706|NCT01940692|Drug|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
180707|NCT01940692|Drug|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
180708|NCT00113984|Biological|PROSTVAC-V/TRICOM|
180709|NCT01940705|Other|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
180083|NCT00113191|Drug|Veronate|
180084|NCT01932502|Drug|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
180085|NCT01932502|Drug|Conversion schedule - Week 1|The following will be the initial conversion schedule from clonazepam to Onfi:
Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg.
180086|NCT01932502|Drug|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
180087|NCT01932502|Drug|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
180088|NCT01932515|Behavioral|A revised screening instrument for use in Deaf children|
180378|NCT01945996|Behavioral|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
180379|NCT01945996|Behavioral|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
180380|NCT01946009|Drug|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
180381|NCT01946022|Drug|randomization between the two GnRH analogues (agonist and antagonist)|
180382|NCT00114322|Device|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
180383|NCT01946035|Drug|Doxazosin XL|
180384|NCT01946035|Other|Placebo|
180385|NCT01946048|Biological|mesenchymal stem cells|Procedure: Selected patients were randomly divided into a cell therapy group and a control group.
Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million.
180386|NCT01946061|Drug|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
180387|NCT01946074|Drug|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels in 28-day dosing cycles on Day 1 and 15.
180388|NCT01946074|Drug|paclitaxel|Paclitaxel will be administered by intravenous infusion in 28-day dosing cycles on Day 1, 8, and 15. Paclitaxel may also be administered on Day 22 depending on the dose level the subject receives.
180389|NCT01946074|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and 15.
180390|NCT01948414|Behavioral|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
179784|NCT01939977|Drug|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
179785|NCT01939990|Drug|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
179786|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
179787|NCT01939990|Drug|Nebivolol|5 to 10mg per day
179788|NCT01940003|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
179789|NCT01940016|Behavioral|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
179790|NCT01940016|Behavioral|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
179791|NCT01940042|Behavioral|CO2 was removed by means of trandelenburg positions|
180089|NCT01932528|Drug|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as [14C]-LX1606.
180090|NCT01932541|Drug|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
180091|NCT01932554|Drug|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
180092|NCT01932554|Drug|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
180093|NCT01932554|Other|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
180094|NCT00113204|Drug|IPI-504|
180095|NCT01932554|Drug|Ibuprofen|Scheduled ibuprofen,~10 mg/kg every 6-8 hours
180096|NCT01932554|Drug|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
179479|NCT01945099|Drug|hyaluronidase|
179480|NCT01945099|Drug|Lispro-PH20|
179481|NCT00114244|Other|laboratory biomarker analysis|Correlative studies
179482|NCT01945112|Device|Paper-Tape|applied to blister prone areas of the foot
179483|NCT01945125|Other|rhTSH Group|Patients receiving rhTSH for RIT stimulation
179484|NCT01945138|Device|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
179485|NCT01945151|Other|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
179486|NCT01945164|Drug|XL999|The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
179487|NCT01945177|Device|narrow band imaging|narrow band imaging
179488|NCT00114517|Drug|Placebo|Matched placebo oral 17B-estradiol
179489|NCT01947712|Dietary Supplement|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
179490|NCT01947712|Dietary Supplement|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
179491|NCT01947725|Drug|Nicotine patch|Subjects in all arms will receive 12 weeks of nicotine patch. The dosage will be 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches as is approved by the FDA and is standard treatment at the study facility. This dosage may be adjusted based on the needs of the subject as is the standard of care.
179492|NCT01947725|Drug|Nicotine gum or nicotine lozenge|Subjects in all arms will receive either nicotine gum or nicotine lozenge (depending on their preference). Participants who smoke less than 25 cigarettes/day will receive 2-mg gum/lozenge; participants smoking 25 or more cigarettes/day will receive 4-mg gum/lozenge. Participants will be told to try to use one piece of gum every 1-2 hours. However, participants will also be told that they may not be able to take a full, recommended dose of oral Nicotine Replacement Therapy (NRT) given their conjoint use of the patch. Participants will be urged to use at least 5 pieces/day, unless this amount of use produces negative (toxic) effects.
179493|NCT01947725|Behavioral|Standard Smoking Cessation Therapy|Subject in both arms will receive a standard, individual smoking cessation treatment. Treatment will be delivered in eight, 20-minute individual sessions over an 8-week period.
179792|NCT01940055|Behavioral|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
179185|NCT01952587|Biological|A peripheral blood sample|A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
179186|NCT01952613|Device|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
179187|NCT00115037|Behavioral|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
179188|NCT01952626|Drug|Ondansetron|intravenous injection
179189|NCT01952626|Drug|Palonosetron|intravenous injection
179190|NCT01952639|Dietary Supplement|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
179191|NCT01952652|Drug|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
179192|NCT01952652|Drug|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
179193|NCT01952665|Device|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
179194|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
179195|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
179196|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
179197|NCT01934270|Other|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
179198|NCT01934283|Device|urine folly catheter|
179199|NCT00113347|Radiation|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
179200|NCT01934296|Device|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
179201|NCT01934309|Behavioral|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
178580|NCT01908634|Dietary Supplement|Milk-based Fruit-Mixed Beverage|
178581|NCT01908634|Dietary Supplement|Water-Based Fruit-Mixed Beverage|
178582|NCT01908647|Behavioral|RT fMRI|Real-time fMRI with neurofeedback.
178583|NCT01908647|Behavioral|Cognitive Training|Computer based attention training.
178890|NCT01939262|Other|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
178891|NCT01939262|Other|Control|Participants assigned to the control group will be instructed to follow their usual diets.
178892|NCT01939275|Radiation|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
178893|NCT01939275|Device|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
178894|NCT01939275|Other|laboratory biomarker analysis|Correlative studies
178895|NCT01939275|Procedure|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
178896|NCT00113815|Drug|placebo|placebo
178897|NCT01939288|Device|Neuromuscular stimulator followed by IPC|
178898|NCT01939288|Device|IPC followed by neuromuscular stimulator|
178899|NCT01939301|Drug|Nitric Oxide + oxygen|
178900|NCT01941693|Behavioral|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
178901|NCT01941693|Behavioral|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
178902|NCT00114088|Procedure|endometrial ablation|
178903|NCT01941706|Behavioral|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
178584|NCT00110994|Drug|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
178585|NCT01908647|Behavioral|Control RT fMRI|Control condition for real-time fMRI.
178586|NCT01908647|Behavioral|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
178587|NCT01908660|Drug|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
178588|NCT01908673|Behavioral|HRV biofeedback|
178589|NCT01908673|Behavioral|ASTM|
178590|NCT01908686|Behavioral|Pivotal Response Training|Behavioral intervention for autism
178591|NCT01908699|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
178592|NCT01908699|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
178593|NCT01908712|Drug|Lamazym|ERT, i.v. infusions weekly
178594|NCT01908725|Drug|Lamazym|ERT, i.v. infusions weekly
178595|NCT00110994|Drug|Dacarbazine|Dacarbazine, 1000 mg/m^2 intravenous on Study Day 1
178596|NCT01910883|Drug|Finafloxacin i.v. solution 200 mg|
178597|NCT01910883|Drug|Finafloxacin i.v. solution 400 mg|
178598|NCT01910883|Drug|Finafloxacin i.v. solution 600 mg|
178599|NCT01910883|Drug|Finafloxacin i.v. solution 800 mg|
178600|NCT01910883|Drug|Finafloxacin i.v. solution 1000 mg|
178601|NCT01910883|Drug|Placebo i.v. solution|
178602|NCT01910896|Device|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
178603|NCT01910909|Radiation|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
183050|NCT02547974|Biological|Formulation 2 (adjuvanted) NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
183051|NCT02547974|Biological|Formulation 3 (adjuvanted) NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
183052|NCT02547974|Drug|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
183053|NCT02547987|Drug|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV (in the vein) on day 1 of each 21-day cycle. Number of Cycles: 6
183054|NCT02548000|Other|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
183354|NCT02541279|Procedure|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
183355|NCT02541292|Other|No intervention, observational|
183356|NCT02541305|Other|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
183357|NCT02541305|Other|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
183358|NCT00184145|Other|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
183359|NCT02541318|Behavioral|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
183360|NCT02541331|Biological|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
183361|NCT02543554|Procedure|lung protective ventilation|Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
183362|NCT02543567|Biological|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
183363|NCT02543567|Biological|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
183364|NCT02543567|Biological|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
193733|NCT02037685|Other|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
193734|NCT02037698|Device|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
193735|NCT02037711|Drug|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
193736|NCT02040233|Drug|BAY1067197 (10 mg)|10 mg BAY1067197 for 7 d treatment once daily as oral application
193737|NCT02040233|Drug|BAY1067197|The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
193738|NCT02040233|Drug|Placebo (10 mg)|10 mg Placebo for 7 d treatment once daily as oral application
193739|NCT02040233|Drug|Placebo|5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
193740|NCT02040246|Drug|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
193741|NCT02040246|Drug|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
193742|NCT02040272|Procedure|(Extended) pleurectomy decortication|
193743|NCT02040285|Drug|Bisacodyl & PEG-CS|the day before the CTC:
low fiber diet
at 15.00: 2 tablets of bisacodyl (5 mg)
at 17.00: 1 litre of PEG-CS
liquid diet
the day of the exam:
at home: 2 tablets of bisacodyl (5 mg)
at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water
at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im
194052|NCT02073747|Drug|Albuterol|One hour inhaled ten milligrams of albuterol
194053|NCT02073760|Other|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
194054|NCT02073773|Drug|Levodopa|Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.
Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth.
198513|NCT02045095|Drug|MLN7243|Dose escalation stage Schedule A: IV infusion on days 1, 4, 8, 11 for a 21-day treatment cycle Schedule B: IV infusion on days 1, 8, 15 for a 28-day treatment cycle
Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)
198514|NCT00123526|Behavioral|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
198515|NCT02045108|Behavioral|Active Retraining|
198516|NCT02045108|Device|Sham TDCS|
198517|NCT02045108|Device|Active TDCS|
198518|NCT02045108|Behavioral|Sham Retraining|
198519|NCT02045121|Device|Indwelling Pleural Catheter|
198520|NCT02045121|Procedure|Talc Pleurodesis|
198521|NCT02045134|Dietary Supplement|Placebo|Soluble corn flour not rich in anthocyanins
198522|NCT02045134|Dietary Supplement|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
198523|NCT02045147|Behavioral|Grp 1 Low Cognition, Low Activation|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The "teach back" method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation.
198524|NCT02045147|Behavioral|Grp 2 Low Cognition, High Activation|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The "teach back" method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations.
198525|NCT00123526|Behavioral|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
198526|NCT02045147|Behavioral|Grp 3 Normal Cognition, Low Activation|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The "teach back" method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals.
193744|NCT02040285|Drug|Iopamidol|the day before CTC:
low fiber diet
at 15.00: 90 ml of Iopamidol in 250 ml of water
at 17.00: 90 ml of Iopamidol in 250 ml of water
at 20.00: start liquid diet
193745|NCT00123136|Device|foot energizer|
193746|NCT02040298|Drug|Clemastine|4mg tablet twice daily
193747|NCT02040298|Drug|Placebo|Placebo tablet twice daily
198211|NCT02049580|Drug|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
198212|NCT02049580|Drug|Fludarabine|Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:
CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day
198213|NCT02052102|Radiation|Radiation therapy|
198214|NCT02052115|Behavioral|12 month exercise and weight loss intervention|
198215|NCT02052128|Drug|onapristone|
198216|NCT02052141|Biological|CINRYZE|
198217|NCT02052154|Biological|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
198218|NCT00124267|Drug|Intrarectal quinine|
198219|NCT02052167|Drug|methotrexate prefilled pen|
198220|NCT02052180|Drug|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
198221|NCT02052180|Drug|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
198222|NCT02052193|Drug|Dabrafenib|Measurement of toxicity related to UV exposure
198223|NCT02052193|Drug|Vemurafenib|Measurement of toxicity related to UV exposure
198224|NCT02052206|Procedure|Shoulder replacement surgery|
198225|NCT02052219|Drug|Blisibimod|Blisibimod administered subcutaneously
198226|NCT02052219|Drug|Placebo|Placebo administered subcutaneously
198227|NCT02052232|Other|Experimental protein powder sachet|mixed with 8 oz. water
198228|NCT02052232|Other|Control protein powder sachet|mixed with 8 oz. water
198229|NCT00002192|Drug|Clarithromycin|
198230|NCT00124280|Drug|RAD001|
198231|NCT02052258|Drug|Oxytocin|
197609|NCT02064699|Biological|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.
Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV.
197610|NCT02064712|Other|Low CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
197890|NCT02057276|Device|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
197891|NCT02057276|Device|Sham Repetitive Transcranial Magnetic Stimulation|
197892|NCT02057276|Other|Occupational Therapy|
197893|NCT02059512|Procedure|coronary artery bypass grafting with administration of autologous bone marrow stem cells|
197894|NCT02059538|Other|Adipose tissue biopsies (omental and subcutaneous) liver|
197895|NCT02059538|Radiation|CT-scan|
197896|NCT02059538|Other|Stools sampling|
197897|NCT02059538|Other|DNA sampling|
197898|NCT02059538|Other|Blood sampling|
197899|NCT00125073|Behavioral|Postoperative nutritional counseling|
197900|NCT02059538|Other|Urine sampling|
197901|NCT02059538|Radiation|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
197902|NCT02059551|Procedure|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
197903|NCT02059564|Drug|HM11260C|doses of 6 mg, 16 mg
197904|NCT02059564|Drug|Placebo|Normal saline solution
197905|NCT02059564|Drug|Victoza|doses of 1.8 mg
197906|NCT02059577|Dietary Supplement|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
181934|NCT02540447|Other|Purge of graft contents out of the circulation|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
181935|NCT02540460|Drug|LCB01-0371 800mg|LCB01-0371 800mg
181936|NCT00184041|Drug|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
181937|NCT02540460|Drug|LCB01-0371 800mg BID|LCB01-0371 800mg BID
181938|NCT02540460|Drug|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
181939|NCT02540460|Drug|Placebo|Placebo
181940|NCT02540473|Behavioral|Manualized Therapy|Relational psychotherapy mothers
182213|NCT02570126|Biological|GSK Biologicals varicella vaccine live, HSA-free (GSK 208133)|2 doses administered subcutaneously (SC) in the tricep region of the left arm
182214|NCT02572245|Device|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
182215|NCT02572245|Device|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
182216|NCT02572258|Other|Nutritional cookie|
182217|NCT02572271|Procedure|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
182218|NCT02572271|Procedure|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
182219|NCT02572284|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5Gy of SBRT per day for 5 days, the second group will receive 6Gy per day for 5 days and the third group will receive 7Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
182220|NCT02572284|Procedure|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
182221|NCT02572284|Other|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
182222|NCT02572297|Other|video-EEG|Registration of seizures during video-EEG
182223|NCT02572310|Device|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
182224|NCT00187759|Drug|cephalexin|
181641|NCT01941550|Drug|Cabazitaxel chemotherapy|given in 6 cycles
181642|NCT00114075|Procedure|Surgery without gait analysis report|Orthopaedic surgery without access to gait analysis report
181643|NCT01941563|Drug|Condoliase|1.25U, intradiscal injection, one time
181644|NCT01941563|Drug|placebo|
181645|NCT01941576|Drug|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
181646|NCT01941576|Drug|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
181647|NCT01941589|Drug|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
181648|NCT01941589|Drug|corticosteroids only|IV corticosteroids only
181649|NCT01941602|Drug|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
181650|NCT01941602|Procedure|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
181651|NCT01941615|Drug|faldaprevir|oral doses for 10 days (period B)
181652|NCT01941615|Drug|Microgynon®|oral doses for 23 days (period A+B)
181941|NCT02540473|Behavioral|Control Group|one hour of free time to do with as they wish
181942|NCT02540486|Other|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
181943|NCT02540486|Other|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
181944|NCT02540499|Radiation|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
181945|NCT02540512|Procedure|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
181946|NCT02542969|Drug|MGL-3196|
181947|NCT02542982|Device|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
181655|NCT01941628|Drug|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
181656|NCT01941628|Drug|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
181657|NCT01941641|Drug|neoadjuvant FOLFOXIRI|
181658|NCT01941641|Drug|Capecitabine|
181659|NCT01941654|Radiation|preemptive local ablative therapy|
181660|NCT01941667|Behavioral|Daily Messages, Virtual Home Visits|Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level
Daily messages requesting weight, intake, pulse ox and pulse are automated
Virtual home visits occur twice weekly where the investigators see the infant and families.
181661|NCT01941667|Other|Usual Care|Usual care as defined by by the Cardiology Department.
181662|NCT01944267|Procedure|apically positioned flap with Mucograft|Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.
Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures.
181663|NCT01944280|Other|massage|
181664|NCT01944293|Drug|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
181665|NCT01944293|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
181666|NCT01944319|Drug|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
181667|NCT01944319|Drug|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
181668|NCT01944332|Procedure|gamete treatment|
181669|NCT01944371|Drug|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
181670|NCT01944384|Drug|aldactone|aldactone 25 mg for 6 months
181671|NCT01944410|Biological|PRP injection|injection of PRP to traumatic bone cyst defect
181040|NCT01935973|Other|Laboratory Biomarker Analysis|Correlative studies
181041|NCT01935973|Drug|Trametinib|Given PO
181364|NCT01949402|Other|Computed Tomography|The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.
Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study "visit".
181365|NCT01949402|Other|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
181366|NCT01949402|Other|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
181367|NCT01949402|Other|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
181368|NCT01949441|Biological|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
181369|NCT01949441|Biological|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
181370|NCT00114634|Dietary Supplement|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
181371|NCT01949454|Drug|Fluorometholone 0.1% ophthalmic solution|
181372|NCT01949454|Other|Artificial tears (Placebo)|Artificial tears (Placebo)
181373|NCT01949467|Drug|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
181374|NCT01949480|Procedure|Thoracotomy|
181375|NCT01949480|Procedure|Video-Assisted Thoracoscopic Surgery (VATS)|
181376|NCT01949493|Device|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
181377|NCT01949493|Other|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
180710|NCT01940705|Other|Hearing-Aid DVD|Take-home DVD about hearing aids
180711|NCT01940705|Behavioral|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
181042|NCT01935986|Dietary Supplement|probiotic|
181043|NCT01935986|Dietary Supplement|placebo|
181044|NCT01935999|Device|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
181045|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
181046|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
181047|NCT01936025|Drug|Dextrometorphan|
181048|NCT01936025|Drug|Sitagliptin|
181049|NCT01936025|Drug|Placebo|
181050|NCT00113477|Drug|Q10|
181051|NCT01936038|Other|CPAP|CPAP
181052|NCT01936038|Procedure|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
181053|NCT01936064|Dietary Supplement|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
181054|NCT01936064|Drug|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
181055|NCT01936077|Drug|Recombinant LH (Luveris)|150 IU recombinant LH daily.
181056|NCT01936090|Drug|Bortezomib|Given IV
181057|NCT01936090|Radiation|Total-Body Irradiation|Undergo TBI
181058|NCT01936090|Drug|Melphalan|Given IV
181059|NCT01936090|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
181060|NCT01936090|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
181061|NCT00002108|Drug|Lamivudine|
180391|NCT00114543|Procedure|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
180392|NCT01948440|Behavioral|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
180393|NCT01948453|Dietary Supplement|Garlic|Garlic tablet in adjunct to medical treatment
180394|NCT01948466|Behavioral|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
180395|NCT01948479|Device|Optimised instant offloading insole|
180396|NCT01948492|Dietary Supplement|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
180397|NCT01948505|Drug|Intravenous acetaminophen|
180712|NCT01940705|Other|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
180713|NCT01940718|Drug|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosteron increments. The medication will be taken transdermally once daily for 3.5 months. Subjects experiencing a reduction in symptoms will be offered open label treatment for an additional 12 months.
180714|NCT01940731|Drug|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
180715|NCT01940744|Procedure|Prescriptive Mobilization|The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1)". Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5." Patients will be seen for 4 visits.
180716|NCT01940744|Procedure|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
180717|NCT01940757|Biological|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
180097|NCT01932554|Other|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
180098|NCT01932554|Other|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
180099|NCT01932567|Other|Physiotherapy|
180100|NCT01932567|Procedure|Electrical impedance tomography|
180101|NCT01932580|Drug|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
180102|NCT01935180|Device|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
180103|NCT01935193|Drug|lysine acetylsalicylate|
180104|NCT00113386|Procedure|conventional surgery|
180105|NCT01935206|Drug|Naloxone (2 mg/kg)|
180106|NCT01935206|Drug|Placebo|
180107|NCT01935219|Behavioral|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
180108|NCT01935219|Behavioral|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
180109|NCT01935219|Behavioral|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
180398|NCT01948505|Drug|Placebo for IV acetaminophen|
180399|NCT01948518|Drug|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
180400|NCT01948531|Drug|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
180401|NCT01948557|Behavioral|Infant feeding counselling and support|Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.
Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice.
180402|NCT00114543|Procedure|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
179793|NCT01940055|Behavioral|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
179794|NCT01940068|Dietary Supplement|Amino acid based formula|
179795|NCT01940081|Other|Transthoracic echocardiography|
179796|NCT01940081|Other|Exercise test|
179797|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
179798|NCT01940081|Other|24-hour Holter electrocardiogram|
179799|NCT01940081|Other|Contrast-enhanced magnetic resonance imaging|
179800|NCT01940081|Other|123-iodine metaiodobenzylguanidine imaging|
179801|NCT01940081|Other|Blood samples|
179802|NCT01940081|Genetic|Genetic analysis|
179803|NCT01940081|Procedure|Invasive electrophysiological study|
179804|NCT01940081|Procedure|Endomyocardial biopsy|
179805|NCT01942473|Device|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
179806|NCT00114114|Drug|Goserelin acetate|3.6 gms sc every 4 weeks
179807|NCT01942486|Device|Investigational Coating|
179808|NCT01942499|Other|Community-based exercise program|
179809|NCT01942512|Device|Endovascular treatment of intracranial aneurysm|
179810|NCT01942525|Other|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
179811|NCT01942538|Device|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
179812|NCT01942538|Device|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
179813|NCT01942551|Drug|Tadalafil|
179494|NCT01947725|Behavioral|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
179495|NCT01947725|Behavioral|Behavioral Activation Treatment|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
179496|NCT01947738|Drug|VBY-891|Cathepsin S inhibitor
179497|NCT01947738|Drug|Placebo|
179498|NCT01947751|Procedure|CVC exchange|CVC exchange when related infection is suspected
179499|NCT00114530|Procedure|Autologous stem cell transplantation|transplantation of blood stem cells from participant's bone marrow or blood
179500|NCT01947751|Drug|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
179501|NCT01947764|Behavioral|HADITHI Intervention|The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.
In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:
Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.
Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.
Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure.
179502|NCT01947777|Drug|IPI-145|25 mg oral capsule
179503|NCT01947777|Drug|Rifampin|2x 300 mg oral capsule
179504|NCT01947790|Drug|pioglitazone group|
179505|NCT01947790|Drug|Metformin group|
179506|NCT01947803|Drug|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
179507|NCT01950338|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
179508|NCT01950351|Radiation|Proton Beam Therapy|55.5 Gy (RBE) delivered in 15 fractions of 3.7 Gy (RBE) to the prostate. Each fraction will be scheduled once daily allowing at least one day between treated fractions.
179509|NCT01950351|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, during the last weeks of proton therapy, 6 months, 36 months, 48 months, and 60 months after therapy.
178904|NCT01941719|Behavioral|Enhanced foot care education|Personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
179202|NCT01934322|Other|Case Management|Furnish specific assistance and to provide referrals for the patients:
If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.
If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.
If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.
In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent.
179203|NCT01934335|Drug|Vandetanib|
179204|NCT01934335|Other|Placebo|
179205|NCT01934348|Behavioral|Psychological First Aid|
179206|NCT01934348|Behavioral|Usual victim advocacy Services|
179207|NCT01934361|Drug|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
179208|NCT01934361|Drug|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
179209|NCT01934361|Drug|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
179210|NCT00113360|Drug|RAD001|Starting dose of 5 or 10 mg by mouth daily.
179211|NCT01934361|Drug|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
179212|NCT01934374|Behavioral|Task-Oriented Lower Extremity Strengthening Training|On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
179213|NCT01934413|Behavioral|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
179214|NCT01936961|Drug|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
178604|NCT01910935|Behavioral|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
178905|NCT01941719|Behavioral|Standard Foot Care Education|At baseline, a trained staff individually reviewed and dispensed the following brochures: "Prevent diabetes problems: Keep your diabetes under control" (NIH Publication No. 07-4349) and "Prevent diabetes problems: Keep your feet and skin healthy" (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. "Keep your diabetes under control" stresses "sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails." "Keep your skin and feet healthy" emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams.
178906|NCT01941732|Drug|Sildenafil|
178907|NCT01941745|Drug|Half normal saline|2 ml/kg
178908|NCT01941745|Drug|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
178909|NCT01941745|Drug|High dose rhCC10|5 mg/kg in 2 ml/kg
178910|NCT01941758|Biological|trivalent influenza vaccine|
178911|NCT01941758|Other|laboratory biomarker analysis|Correlative studies
178912|NCT01941771|Drug|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
178913|NCT00114101|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
178914|NCT01941771|Drug|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
178915|NCT01941784|Other|educational intervention|Undergo health education program
178916|NCT01941784|Other|counseling intervention|Undergo health education program
178917|NCT01941784|Behavioral|telephone-based intervention|Receive follow-up phone calls
178918|NCT01944449|Dietary Supplement|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
178919|NCT01944462|Behavioral|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
183365|NCT02543567|Biological|MVA‐BN‐Filo 1*10^8 Infectious Unit [Inf. U.]|MVA‐BN‐Filo‐ live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57
183366|NCT02543567|Biological|MVA‐BN‐Filo 5*10^7 Inf. U.|MVA‐BN‐Filo‐ live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
183367|NCT02543567|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
183368|NCT02543580|Other|electroacupuncture|comparison of effects of single acupoint or two combination of acupoints stimulated with electroacupuncture
183369|NCT00184548|Drug|eptacog alfa (activated)|Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.
Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.
183370|NCT02543593|Device|Active tDCS or Sham tDCS|tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
183371|NCT02543606|Drug|Esomelone|powder for injection/ infusion Esomeprazole 40mg
178605|NCT01910948|Drug|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
178606|NCT00002088|Drug|Saccharomyces boulardii|
178607|NCT00111345|Drug|Anthracyclines|3x12 mg/qm
178608|NCT01910961|Procedure|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
178609|NCT01910974|Procedure|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
178610|NCT01910987|Drug|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
178611|NCT01910987|Drug|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
178612|NCT01910987|Drug|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
194055|NCT02073773|Other|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
194056|NCT02073786|Device|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
194057|NCT02073786|Device|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
194058|NCT00126542|Drug|erlotinib hydrochloride|Given orally
194059|NCT02073799|Procedure|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
194060|NCT02073812|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
194061|NCT02073825|Behavioral|Web Brief Intervention (WBI)|4-session WBI
194062|NCT02073838|Drug|Ribavirin|
194063|NCT01993394|Other|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
194064|NCT01993394|Other|gas mixture|breathing air, 44.5%O2 or 100%O2
194065|NCT01993407|Behavioral|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
194066|NCT01993407|Behavioral|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
194067|NCT01993420|Drug|DRM02|
194068|NCT01993420|Other|Vehicle|
194069|NCT00118820|Drug|IV Preoperative antibiotic or placebo|
194384|NCT02068599|Drug|Placebo|Matching placebo
194385|NCT02068612|Behavioral|Moderate Intensity Continuous Training+Interval Training|
194386|NCT02068612|Behavioral|Low Intensity Continuous Training|
194387|NCT02068625|Drug|Rasagiline|Rasagiline 1mg daily orally for 7 days
194388|NCT02068625|Drug|Placebo|Oral treatment with placebo for 7 days
193748|NCT02040311|Drug|Topiramate 96 mg daily|
193749|NCT02040311|Drug|Topiramate 192 mg daily|
193750|NCT02040311|Drug|Placebo|
193751|NCT02040324|Device|Laryngeal mask with gastric access|
193752|NCT02040324|Device|Endotracheal tube|
193753|NCT02040350|Drug|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
193754|NCT02040363|Procedure|Muscular biopsy|
193755|NCT02040363|Other|5-10 weeks sport training|
193756|NCT00002184|Drug|Lamivudine|
193757|NCT00123149|Drug|Epoetin alfa|
193758|NCT02040376|Drug|Metformin|Metformin and placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
193759|NCT02040376|Drug|Placebo|Metformin and placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
193760|NCT02040389|Behavioral|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
193761|NCT02043054|Drug|Liraglutide|Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.
BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or
BMI < 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.
193762|NCT02043054|Drug|Sitagliptin|Sitagliptin (Januvia®, Merck & Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
193763|NCT02043067|Other|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
194070|NCT01993433|Drug|DRM02|
194071|NCT01993433|Other|Vehicle|
194072|NCT01993446|Drug|DRM02|
198527|NCT02047266|Device|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
198528|NCT00123825|Drug|Gemcitabine|
198529|NCT02047279|Procedure|maze procedure|The scheme of lesion pattern: "box" lesion + line to mitral valve + line from "box" to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases.
198530|NCT02047279|Procedure|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
198531|NCT02047279|Procedure|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
198532|NCT02047292|Device|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
198533|NCT02047292|Device|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
198534|NCT02047292|Device|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
198535|NCT02047305|Device|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
198536|NCT02047318|Drug|LUM001|
198537|NCT02047331|Procedure|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
198538|NCT02047331|Procedure|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
198539|NCT00123825|Drug|Cisplatin|
198540|NCT02047344|Drug|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
198541|NCT02047357|Other|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
197907|NCT02059590|Drug|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
197908|NCT02059603|Procedure|Electroacupuncture|
197909|NCT02059603|Procedure|Fast-track program|
197910|NCT00125086|Device|autologous platelet gel|
197911|NCT02059616|Drug|Amlodipine 5mg|Daily oral administration for 8 weeks
198232|NCT02052271|Device|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
198233|NCT02052284|Other|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
198234|NCT02052297|Other|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
198235|NCT02052310|Drug|FG-4592 (roxadustat)|Drug will be dosed orally three times a week.
198236|NCT02052310|Drug|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
198237|NCT02052323|Drug|Artesunate/mefloquine (AS/MQ)|artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours
mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours
primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
198238|NCT02052336|Drug|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
198239|NCT02054819|Other|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
198240|NCT02054819|Other|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
198241|NCT02054832|Dietary Supplement|Glycosade|
198242|NCT02054845|Behavioral|Body awareness therapy|Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.
Specifically the following techniques will be applied:
Body scan
Psychoeducation
Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)
Body Awareness Training
Exposure training (imaginary exposure to induce response fluctuations)
Training in cueing techniques to overcome problems with initiation and freezing
Visual Feedback training
Relaxation techniques
182225|NCT02572323|Drug|Tesamorelin|
182226|NCT02572323|Drug|Placebo|
182227|NCT02572336|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
182228|NCT02572336|Drug|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
182229|NCT02572336|Drug|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
182230|NCT02572349|Drug|IW-1701|
182231|NCT02572349|Drug|Matching Placebo|
182232|NCT02572362|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
182233|NCT02572375|Drug|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
182540|NCT00186992|Procedure|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
182541|NCT02565693|Drug|Dipyridamole|
182542|NCT02565693|Other|No antithrombotic treatment|
182543|NCT02567786|Procedure|Surgery with CPB|
182544|NCT02567786|Other|Fresh Frozen Plasma|
182545|NCT02567786|Other|Plasmalyte|
182546|NCT02567799|Drug|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg BIO 300 dose will be given daily, 7 days/week (day-14 through week 6 day 5) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 10 subjects at a particular dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when three subjects with the cohort (30%) have completed the entire course of chemoradiation therapy with no Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension, provided that no more than three (3) of the accord subjects at the prior dose level have presented with DLTs.
182547|NCT02567799|Drug|Paclitaxel|During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly on day -7 and day 1 of weeks 1-6.
During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart.
182548|NCT02567799|Drug|Carboplatin|During the Concurrent Therapy period, area under the curve (AUC) = 2mg* min/mL will be administered by intravenous drip weekly on day -7 and day 1 of weeks 1-6.
During the Consolidation Therapy period, carboplatin AUC = 6mg*min/mL will be administered by intravenous drip two times, 21 days apart.
181948|NCT02542995|Other|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
181949|NCT02543008|Procedure|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
181950|NCT02543008|Procedure|Physical activity|Information already included in arm/group descriptions.
181951|NCT02543008|Procedure|Placebo|Information already included in arm/group descriptions.
181952|NCT02543021|Device|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
181953|NCT00184444|Behavioral|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
181954|NCT02543021|Procedure|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
181955|NCT02543034|Device|Betafoam Wound Dressing|
181956|NCT02543034|Device|Petrolatum Gauze|
181957|NCT02543034|Device|Allevyn Wound Dressing|
181958|NCT02543047|Device|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
181959|NCT02543060|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
181960|NCT02543060|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
181961|NCT02543073|Biological|MSCs|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 weeks as one cycle treatment.
181962|NCT02543073|Drug|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
182234|NCT02572375|Drug|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
182235|NCT00187772|Behavioral|Child-Parent Psychotherapy (CPP)|
182236|NCT02572388|Biological|R21|
182237|NCT02572388|Biological|Matrix-M1|
182238|NCT02574377|Drug|A: myDC vaccination|
182239|NCT02574377|Drug|B: pDC vaccination|
182240|NCT02574377|Drug|C: combined myDC/pDC vaccination|
181963|NCT02543073|Drug|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
181964|NCT00184457|Behavioral|Strength training intervention|
181965|NCT02543086|Drug|KAE609|Study drug
181966|NCT02543086|Drug|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
181967|NCT02543099|Drug|policosanol|Patients will receive policosanol 20mg Qd
181968|NCT02543099|Drug|placebo|Patients will receive placebo 20mg Qd;
181969|NCT02543112|Drug|Mepolizumab 40mg or 100mg|Mepolizumab will be provided as a lyopholised cake in sterile vials. Lyophilized powder for injection will be reconstituted with Sterile Water for Injection, just prior to use.
181970|NCT02543125|Device|NIPPV|For infants in the NIPPV-group who "fail"NIPPV (see definition below), need immediate intubation, a invasive "Rescue-Treatment" may be provided. The decision to attempt "Rescue-Treatment", the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
181971|NCT02545218|Other|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
181972|NCT02545231|Drug|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
181973|NCT02545231|Drug|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
181974|NCT02545231|Drug|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
181975|NCT02545244|Dietary Supplement|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
181976|NCT02545244|Dietary Supplement|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
181977|NCT02545244|Drug|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
181978|NCT02545257|Other|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
181979|NCT00184717|Drug|somatropin|0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
181980|NCT02545270|Procedure|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
181378|NCT01949506|Radiation|SBRT|Stereotactic Body Radiation Therapy
181379|NCT01951729|Drug|GIP with atropine|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
181672|NCT00114218|Drug|Gemcitabine Hydrochloride|Given IV
181673|NCT01944423|Drug|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
181674|NCT01944423|Drug|Pill Placebo|
181675|NCT01944423|Drug|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
181676|NCT01944423|Behavioral|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
181677|NCT01944436|Drug|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
181678|NCT01944449|Dietary Supplement|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
181679|NCT01944449|Dietary Supplement|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
181680|NCT01947062|Drug|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
181681|NCT01947088|Behavioral|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
181062|NCT00113477|Drug|Selen|
181063|NCT01936090|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
181064|NCT01936090|Other|Laboratory Biomarker Analysis|Correlative studies
181065|NCT01936103|Drug|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
181380|NCT01951729|Drug|GIP plus Xenin-25 without atropine|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.
181381|NCT01951729|Drug|GIP plus Xenin-25 with atropine|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes.
181382|NCT01951742|Biological|ANT-1401|Active
181383|NCT01951742|Biological|Vehicle|Vehicle
181384|NCT01951768|Drug|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
181385|NCT01951768|Drug|Systemic Antibiotic|Antibiotics options per protocol:
Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h
181386|NCT01951781|Other|blood sample|blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)
When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood.
181387|NCT00002119|Drug|WF10|
181388|NCT00114959|Drug|Imatinib Mesylate|Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
181389|NCT01951807|Behavioral|Psychotherapy|
181390|NCT01951820|Drug|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
181391|NCT01951820|Drug|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
181392|NCT01951820|Drug|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
180718|NCT01943435|Procedure|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
180719|NCT01943435|Other|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
180720|NCT01943435|Other|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
180721|NCT01943435|Other|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
180722|NCT01943461|Drug|Avelumab|Avelumab will be administered in study location using a protocol-defined dose escalation scheme until confirmed complete response (CR), confirmed progression, unacceptable toxicity, or withdrawal from the trial or investigational medicinal product (IMP) occurs.
180723|NCT01943474|Device|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
180724|NCT01943474|Device|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
181066|NCT01938612|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
181067|NCT01938612|Drug|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
181068|NCT01938625|Drug|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
181069|NCT01938625|Drug|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
181070|NCT01938625|Drug|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
181071|NCT01938638|Drug|BAY1143572|
181072|NCT01938651|Procedure|high field strength magnetic resonance imaging|Undergo 7T MRI
181073|NCT00113737|Behavioral|cognitive behavioral therapy|
181074|NCT01938651|Procedure|magnetic resonance spectroscopic imaging|Undergo 31P MRS
181075|NCT01938651|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
181076|NCT01938651|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
180403|NCT01948583|Drug|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
180404|NCT01948596|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
180405|NCT01948622|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
180406|NCT01948622|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
180407|NCT01948635|Device|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
180408|NCT01948635|Device|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
180409|NCT01948648|Drug|Colesevelam|
180410|NCT01948648|Other|Placebo|placebo
180411|NCT01948661|Dietary Supplement|Mirtoselect® + Meriva®|
180412|NCT01951235|Drug|Placebo|
180413|NCT00002118|Drug|Zalcitabine|
180414|NCT00114842|Procedure|MR colonography|
180415|NCT01951248|Device|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
180416|NCT01951261|Procedure|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
180417|NCT01951274|Drug|VPD-737|NK1 Receptor Antagonist
180418|NCT01951274|Drug|Placebo|
180725|NCT01943487|Drug|EC905|Oral
180726|NCT00114166|Drug|topotecan hydrochloride|
180727|NCT01943487|Drug|verapamil|Oral
180728|NCT01943513|Biological|BIIB023|Intravenous (IV) infusions
180729|NCT01943513|Biological|Placebo|Matched placebo
180730|NCT01943526|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
180110|NCT01935245|Device|Mini extracorporeal circulation|Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.
The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products.
180111|NCT01935245|Device|Conventional extracorporeal circulation|
180112|NCT01935258|Other|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
180113|NCT01935258|Other|care as usual|usual care of the general practitioner
180114|NCT01935271|Dietary Supplement|Muscle Armor Supplement|
180115|NCT00113386|Procedure|neoadjuvant therapy|
180116|NCT01935271|Dietary Supplement|Placebo|
180117|NCT01935297|Behavioral|Exercise|endurance and resistance exercise 3x/week for 8 weeks
180118|NCT01935310|Drug|Imiquimod|From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.
During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved.
180119|NCT01935323|Other|High Intensity Interval Training|
180120|NCT01935323|Other|Moderate Intensity Training|
180121|NCT01935336|Drug|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
180122|NCT01935362|Dietary Supplement|Citrus supplement|
180123|NCT01935362|Dietary Supplement|Placebo|
180124|NCT01935375|Behavioral|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
180125|NCT01935375|Behavioral|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
180126|NCT00113386|Radiation|radiation therapy|
180127|NCT01937728|Drug|C: Peg-interferon alpha-2a & Ribavirin|Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.
Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
179510|NCT01950364|Drug|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
179814|NCT01942551|Drug|Dutasteride|
179815|NCT01942577|Device|NoSting|Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
179816|NCT01942590|Drug|Clenbuterol|
179817|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day
179818|NCT01942590|Drug|Placebo|
179819|NCT01942616|Other|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
179820|NCT01942616|Other|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
179821|NCT01942616|Other|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
179822|NCT01942629|Other|their will be no intervention in any of the groups, the study is retrospective|
179823|NCT01942655|Other|Blood sample and recto-colic biopsies|
179824|NCT01942668|Drug|Estradiol|
179825|NCT01942668|Drug|Progesterone|
179826|NCT01942668|Drug|Placebo|
179827|NCT01942681|Drug|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
179828|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
179829|NCT01942694|Dietary Supplement|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
179830|NCT01942694|Other|Placebo|Administered as one soft-gel pill daily by mouth
179831|NCT01942707|Procedure|Scarpa Fascia Preservation|
179832|NCT01942720|Device|Capsule endoscopy and Ileocolonoscopy tests|
179833|NCT00114270|Drug|letrozole|
179834|NCT01945450|Drug|Clindamycin|
179215|NCT01936961|Radiation|Hypofractionated Radiotherapy|
179216|NCT01936974|Drug|Gemcitabine|
179217|NCT01936974|Drug|Bevacizumab|
179218|NCT01936974|Drug|Carboplatin|
179219|NCT01936974|Drug|Cisplatin|
179220|NCT01936974|Drug|Oxaliplatin|
179511|NCT01950364|Drug|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
179512|NCT01950390|Biological|Bevacizumab|Given IV
179513|NCT00002117|Drug|Zalcitabine|
179514|NCT00114764|Drug|filgrastim|Filgrastim given daily after induction chemotherapy
179515|NCT01950390|Biological|Ipilimumab|Given IV
179516|NCT01950390|Other|Laboratory Biomarker Analysis|Correlative studies
179517|NCT01950403|Drug|linaclotide acetate|Given PO
179518|NCT01950403|Other|placebo|Given PO
179519|NCT01950403|Other|pharmacological study|Correlative studies
179520|NCT01950403|Other|laboratory biomarker analysis|Correlative studies
179521|NCT01950416|Drug|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
179522|NCT01950416|Drug|Clopidogrel 600mg loading dose and 150mg maintenance dose|
179523|NCT01950442|Device|Balloon dilation|
179524|NCT01950455|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
179525|NCT00114764|Drug|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
179526|NCT01950468|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
179527|NCT01950468|Drug|DaTscan|A single intravenous dose of 3 to 5 mCi
179528|NCT01950481|Drug|LDK378|Oral LDK378 750 mg once
178920|NCT01944488|Drug|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
178921|NCT00114218|Drug|Docetaxel|Given IV
178922|NCT01944501|Procedure|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
178923|NCT01944501|Procedure|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
179221|NCT01937013|Drug|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
179222|NCT00113594|Drug|Olanzapine|
179223|NCT01937013|Drug|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
179224|NCT01937026|Drug|Baricitinib|Administered orally
179225|NCT01937026|Drug|Probenecid|Administered orally
179226|NCT01937039|Procedure|Sample collection|Blood, tissue, urine, and other samples may be collected
179227|NCT01937052|Other|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
179228|NCT01937052|Behavioral|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
179229|NCT01937065|Other|No treatment|
179230|NCT01937078|Drug|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
179231|NCT01937104|Drug|Desflurane|Anesthesia with desflurane in both Group 1 and Group 2
- adjust MAC to maintain BIS between 40-60
179232|NCT01937104|Drug|Remifentanil|Adjuvant continuous administration
- adjust effect site concentration to maintain changes of vital sign below 20%
179233|NCT00113607|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
194684|NCT02060903|Drug|Abametapir Lotion 0.74% w/w|
194685|NCT02060903|Drug|Vehicle Lotion|
194686|NCT02060916|Drug|PAZ320|Single-center pilot study, open label dose escalation design
194687|NCT02060929|Drug|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
194688|NCT02060955|Biological|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
194689|NCT02063178|Behavioral|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
194690|NCT02063178|Behavioral|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
194691|NCT02063178|Behavioral|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
194992|NCT02056054|Other|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
194993|NCT02056054|Other|Adult non-transplant patients with auto-immune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.
The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
194994|NCT02056054|Other|Adult non-transplant subjects with chronic hepatitis C virus|For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
194995|NCT00002194|Drug|Clarithromycin|
194996|NCT00124683|Drug|nicotine transdermal patch|
194997|NCT02056054|Other|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
194998|NCT02056054|Other|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
194389|NCT02068638|Procedure|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
194390|NCT02068638|Procedure|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
194391|NCT02068638|Procedure|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
194392|NCT00126074|Drug|Tedisamil sesquifumarate|
194393|NCT02068638|Procedure|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
194394|NCT02068651|Behavioral|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
194395|NCT02068664|Behavioral|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
194396|NCT02068677|Other|Sympathetic response|Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg.
194397|NCT02068677|Other|no sympathetic response|no Sympathetic response will be defined as change in heart rate by <10 bpm and change in BP <10mmHg.
194398|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
194399|NCT02068690|Drug|Placebo|Placebo
194400|NCT02068690|Drug|Placebo|Placebo
194401|NCT02071277|Other|Pressure targeted modes|Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
194692|NCT02063178|Behavioral|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
194693|NCT02063178|Behavioral|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
194073|NCT01993446|Other|Vehicle|
194074|NCT01993459|Drug|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
194075|NCT01993459|Drug|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
194076|NCT01993472|Drug|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
194077|NCT01993472|Drug|Capecitabine|
194078|NCT01993498|Procedure|blood sampling|blood samples collection
194079|NCT01993524|Dietary Supplement|probiotic|antibiotic plus probiotic
194080|NCT00118833|Drug|Hypericum perforatum (St. John's wort)|
194081|NCT01993524|Other|placebo|antibiotic plus placebo
194082|NCT01993537|Drug|Vitamin D|
194083|NCT01993550|Behavioral|Telephone counseling|
194084|NCT01993550|Behavioral|Education|
194085|NCT01993563|Other|Graded Motor Imagery|GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).
IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15" screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.
EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.
MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror.
194086|NCT01993563|Other|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
194087|NCT01993576|Drug|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
194088|NCT02037711|Drug|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
194089|NCT00122928|Behavioral|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
194090|NCT02037724|Dietary Supplement|supplement containing 60 mg iron sulfate|control agent
193764|NCT02043080|Other|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
193765|NCT02043093|Behavioral|Sources of Strength|Sources of Strength (http://www.sourcesofstrength.com/) has three phases:
Introduction to school and community partners. Staff advisors for the program are identified and trained.
A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.
Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos.
193766|NCT00123422|Behavioral|Exercise|exercise training
193767|NCT02043106|Other|plantar vibration|
193768|NCT02043119|Behavioral|Breastfeeding Clinic|
193769|NCT02043132|Drug|Infusion Tranexamic acid or placebo.|Patients will be randomized in a 1:1 ratio to either an infusion of the standard dose of Tranexamic acid (10mg/kg) or placebo (an equivalent volume of normal saline) within 60 minutes prior to surgery and at wound closure. The day before each patient's surgery the research coordinator will contact the research pharmacy to inform them that a patient is participating in the study. The pharmacy will use the randomization list in sequential order and determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
193770|NCT02043145|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
193771|NCT02043158|Behavioral|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
193772|NCT02043158|Behavioral|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
193773|NCT02043171|Dietary Supplement|Placebo|A Placebo comparator
193774|NCT02043171|Drug|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
193775|NCT02043171|Behavioral|Non-Exercise|This group will not participate in 3 times per week strength training
193776|NCT02043171|Behavioral|Exercise|This group will participate in a supervised 3 times per week strength training program
193777|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
193778|NCT02045524|Other|Sub-Q Injection|
193779|NCT02045550|Drug|Prospan Syrup|2.5 ml twice daily for 4 weeks
193780|NCT02045563|Other|prise de sang|
198243|NCT02054845|Other|Physical therapy|Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
198244|NCT02054858|Procedure|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
198542|NCT02047370|Other|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
198543|NCT02047370|Other|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
198544|NCT02049580|Drug|Cyclophosphamide|Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.
Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)
Cyclophosphamide [50 mg/kg/day IBW] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
198545|NCT02049593|Drug|PARP inhibitor BMN-673|Given PO
198546|NCT02049593|Drug|temozolomide|Given PO
198547|NCT02049593|Drug|irinotecan hydrochloride|Given IV
198548|NCT02049593|Other|pharmacological study|Correlative studies
198549|NCT02049593|Other|laboratory biomarker analysis|Correlative studies
198550|NCT00124046|Procedure|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
198551|NCT02049606|Drug|LAYLA tablet|1 Tablet twice a day
198552|NCT02049606|Drug|CENATONE tablet|2 Tablets once a day
198553|NCT02049619|Device|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
198554|NCT02049632|Procedure|Omission of axillary clearance|
198555|NCT02049671|Drug|Growth Hormone Therapy|
182549|NCT02567799|Radiation|Radiotherapy|Radiation treatment will begin after 4 weeks after subject enrollment. Subjects will receive radiation therapy 5 days per week, once daily fractions, 2.0 Gy per fraction, for 6 weeks.
182550|NCT02567825|Procedure|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used. Participants will be followed overtime for recurrences of AOM and treated with topical antimicrobials.
182551|NCT02567825|Procedure|Nonsurgical management|Participants will be followed overtime for recurrences of AOM and treated with systemic antimicrobials.
182552|NCT00187122|Drug|Mercaptopurine|See Detailed Description section for description of treatment plan.
182553|NCT02567838|Drug|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
182554|NCT02567838|Drug|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
182555|NCT02567851|Drug|Brentuximab Vedotin|Monoclonal antibody drug conjugate
182556|NCT02567864|Other|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
182557|NCT02567864|Other|control|participants maintain their daily activities.
182558|NCT02567877|Procedure|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
182848|NCT00186862|Drug|Interleukin-2|A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.
At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received.
182849|NCT02563587|Other|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
182850|NCT02563587|Other|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
182851|NCT02563587|Drug|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
182852|NCT02563600|Behavioral|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
182241|NCT02574403|Drug|eculizumab|eculizumab discontinuation
182242|NCT02574416|Other|There is no intervention|The study is observational and there is no intervention
182243|NCT02574429|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions & 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
182244|NCT02574442|Device|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
182245|NCT00188084|Procedure|P16 metabolic way|
182246|NCT02574455|Drug|Sacituzumab govitecan|Sacituzumab govitecan (10 mg/kg on Days 1 and 8 of 21-day cycles)
182247|NCT02574455|Drug|Eribulin|Eribulin (1.4 mg/m2 intravenously on Days 1 and 8 of a 21-day cycle)
182248|NCT02574455|Drug|Capecitabine|Capecitabine (1250 mg/m2 orally twice daily for 2 weeks followed by a 1 week rest period given as a 21-day cycle)
182249|NCT02574455|Drug|Gemcitabine|Gemcitabine (1250 mg/m2 intravenously on Days 1 and 8 of a 21-day cycle)
182250|NCT02574455|Drug|Vinorelbine|Vinorelbine (30 mg/m2) weekly IV injection
182251|NCT02574468|Drug|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
182252|NCT02574468|Procedure|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
182253|NCT02574481|Device|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
182254|NCT02574481|Device|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
182255|NCT02574507|Behavioral|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
182559|NCT02567877|Drug|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
182560|NCT02567890|Behavioral|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
182561|NCT02567890|Behavioral|Expressive writing|Participants will be asked to reflect upon issues related to body image.
181981|NCT02545270|Procedure|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
182256|NCT00002514|Biological|sargramostim|
182257|NCT00188097|Behavioral|Diagnosis of variceal bleeding and dits control in cirrhosis|
182258|NCT02574520|Drug|SABER®-Bupivacaine|
182259|NCT02574520|Drug|Placebo (Saline)|
182260|NCT02574533|Biological|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
182261|NCT02574533|Drug|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
182262|NCT02574546|Procedure|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
182263|NCT02540512|Device|ASP Needles|Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear.
182264|NCT00002498|Drug|fluorouracil|
182265|NCT00184054|Drug|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
182266|NCT02540512|Procedure|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
182267|NCT02540512|Drug|hydrocodone / acetaminophen 5mg/325mg|Narcotic/NSAID medication used as the "standard medical treatment"
182268|NCT02540512|Drug|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
182269|NCT02540525|Device|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
182270|NCT02540525|Device|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
182271|NCT02540538|Biological|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
182272|NCT02540538|Biological|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
181682|NCT01947101|Biological|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
181683|NCT01947114|Drug|Propofol|
181684|NCT01947114|Drug|Ketamine|
181685|NCT01947114|Drug|Remifentanil|
181982|NCT02545270|Procedure|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
181983|NCT02545283|Drug|Cytarabine|1 g/m^2 cytarabine administered once daily as an intravenous infusion
181984|NCT02545283|Drug|Idasanutlin|300 mg idasanutlin administered orally twice daily
181985|NCT02545283|Other|Placebo|Placebo administered orally twice daily
181986|NCT02545296|Other|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
181987|NCT02545322|Radiation|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
181988|NCT02545348|Procedure|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
181989|NCT02545361|Drug|KAHR-102|KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.
In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.
Planned doses for stage 1:
Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days).
181990|NCT00184717|Drug|somatropin|0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
181991|NCT02547428|Drug|Placebo|Participants will receive CTN SR matching placebo tablets, orally twice daily, titrated in the same manner as CTN SR to protect the blind.
181992|NCT02547441|Drug|Omiganan|Topical gel
181993|NCT02547441|Drug|Vehicle|Vehicle Gel
181994|NCT02547454|Drug|Methoxy polyethylene glycol-epoetin beta|
181995|NCT02547467|Other|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
181393|NCT01951833|Device|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
181394|NCT01951846|Drug|BIBF 1120|
181395|NCT01951859|Other|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
181396|NCT01951872|Behavioral|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
181397|NCT01933672|Drug|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
181686|NCT01947140|Drug|Pralatrexate|Intravenous drug given on days 1 and 8 of each 21 day cycle in Schedule A and on days 1 and 15 of each 28 day cycle in Schedule B. Dose escalation from 10mg/m2 to 25 mg/m2.
181687|NCT00002114|Drug|Procysteine|
181688|NCT00114465|Drug|VSL#3|VSL#3 1 sachet twice a day
181689|NCT01947140|Drug|Romidepsin|Intravenous drug given on days 1 and 8 of each 21 day cycle in Schedule A and on days 1 and 15 of each 28 day cycle in Schedule B. Dose escalation from 12mg/m2 to 14 mg/m2.
181690|NCT01947153|Drug|Metformin|Free combination
181691|NCT01947153|Drug|Linagliptin|Fixed dose combination
181692|NCT01947153|Drug|Metformin|Combination
181693|NCT01947153|Drug|Linagliptin|Free combination
181694|NCT01947166|Dietary Supplement|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
181695|NCT01947179|Behavioral|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
181696|NCT01947192|Procedure|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
181697|NCT01947192|Procedure|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
181698|NCT01947205|Drug|paracetamol|
181699|NCT00114465|Other|Placebo|Placebo 1 sachel twice a day
181700|NCT01947205|Drug|dexketoprofen trometamol|
181701|NCT01947205|Drug|suction curettage|
181077|NCT01938651|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
181078|NCT01938664|Drug|Candesartan|8 mg, po (by mouth)
181079|NCT01938664|Drug|Placebo|
181080|NCT01938677|Radiation|Initial Gamma knife radiosurgery|
181081|NCT01938690|Device|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
181082|NCT01938716|Drug|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
181083|NCT01938729|Procedure|Liver resection and placement of hepatic artery infusion pump|
181084|NCT00113750|Biological|TreeMATA MPL|
181085|NCT01938729|Drug|FLOXURIDINE|
181086|NCT01938729|Drug|DEXAMETHASONE|
181087|NCT01938729|Drug|GEMCITABINE|
181088|NCT01938742|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen administered as 3.75mcg, 7.5mcg, 15mcg, or 45 mcg HA per dose with or without MF59 adjuvant
181398|NCT01933672|Drug|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
181399|NCT01933672|Drug|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
181400|NCT01933685|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
181401|NCT01933685|Biological|AIDSVAX B/E Placebo|1 mL per injection
181402|NCT01933698|Drug|amoxicillin|Comparison of pharmacokinetics of both formulations
181403|NCT00113295|Drug|Continued Paroxetine CR|
181404|NCT01933711|Drug|rituximab|
181405|NCT01933724|Drug|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
181406|NCT01933724|Drug|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
180731|NCT01943539|Device|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
180732|NCT01943552|Drug|placebo|normal saline
180733|NCT01943552|Drug|ipratropium bromide|ipratropium bromide
180734|NCT01943565|Drug|Hydromorphone 25mcg|
180735|NCT01943565|Drug|Hydromorphone 50mcg|
180736|NCT01943565|Drug|Hydromorphone 100mcg|
180737|NCT00114179|Drug|capecitabine|Given orally
180738|NCT01943565|Drug|Hydromorphone 200mcg|
180739|NCT01943591|Device|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
180740|NCT01943604|Other|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
180741|NCT01943604|Other|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
180742|NCT01943617|Drug|Entecavir|anti-viral therapy
180743|NCT01943617|Drug|Thymosin-α|anti-viral and antitherapy
180744|NCT01946217|Other|questionnaire administration|Ancillary studies
180745|NCT00114361|Drug|Ribavirin|1200 mg a day, 48 weeks
180746|NCT01946243|Drug|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
180747|NCT01946256|Drug|Amoxicillin|
180748|NCT01946256|Drug|Erythromycin|
181089|NCT01938742|Drug|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages (3.75mcg, 7.5mcg, or 15 mcg HA per dose) of sanofi A/H7N9 antigen
181090|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 60 mg dextrose
181091|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 80 mg dextrose
181092|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 100 mg dextrose
181093|NCT01940965|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
180128|NCT01937728|Drug|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
180419|NCT01951287|Other|Acute beverage (water) consumption|Acute beverage consumption includes water.
180420|NCT01951287|Other|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
180421|NCT01951287|Other|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
180422|NCT01951287|Other|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
180423|NCT01951287|Other|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
180424|NCT01951287|Other|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
180425|NCT00114855|Drug|HYPOCOL®|
180426|NCT01951300|Other|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
180427|NCT01951313|Other|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (< 2g) and low carotenoid (< 2000µg) meal as the 2nd meal.
180428|NCT01951326|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
180429|NCT01951326|Drug|Placebo|5 placebo capsules administered orally BID
180430|NCT01951339|Drug|Sitagliptin|100 mg sitagliptin
180431|NCT01951339|Drug|Glimepiride|Active Comparator
2mg glimepiride
180432|NCT01951339|Drug|Placebo|2 mg placebo once daily
180433|NCT01951339|Drug|Placebo|100 mg placebo once daily for three months
180434|NCT01951352|Other|Soap|
180435|NCT01951378|Device|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS > 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
179835|NCT01945476|Drug|midazolam premedication|On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all "prepared medicine," never letting the doctors and subjects know which is midazolam and which is saline.
Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total.
180129|NCT01937728|Drug|E: Peg-interferon alpha-2a & Ribavirin|Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.
Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
180130|NCT01937728|Drug|F: Peg-interferon alpha-2a & Ribavirin|Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.
Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.
180131|NCT01937754|Dietary Supplement|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
180132|NCT01937754|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
180133|NCT01937767|Drug|Remimazolam|
180134|NCT01937767|Drug|Propofol|
180135|NCT01937767|Drug|Sevoflurane|
180136|NCT01937767|Drug|Remifentanil|
180137|NCT00113672|Behavioral|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
180138|NCT01937767|Drug|Fentanyl|
180139|NCT01937767|Drug|Rocuronium|
180140|NCT01937793|Other|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
180141|NCT01937793|Other|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
180142|NCT01937806|Drug|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
180143|NCT01937806|Drug|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
180144|NCT01937819|Device|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
180145|NCT01937832|Drug|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
179529|NCT01950494|Other|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
179530|NCT01950507|Drug|Budesonide|
179531|NCT01950507|Drug|Fluconazole|
179532|NCT01950507|Drug|Voriconazole|
179533|NCT01950533|Procedure|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
179534|NCT01952808|Behavioral|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
179836|NCT01945489|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
179837|NCT01945489|Drug|Normal saline|Normal saline (placebo) injected into the detrusor.
179838|NCT01945515|Device|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere during robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
179839|NCT01945515|Device|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
179840|NCT01945528|Drug|US-guided tenotomy with PRP|Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.
Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure
179841|NCT01945528|Drug|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
179842|NCT01945541|Device|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
179843|NCT01945554|Procedure|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
179844|NCT00114270|Drug|zoledronic acid|
179845|NCT01945554|Procedure|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
179846|NCT01945554|Drug|Mephamesone|
179234|NCT01937104|Device|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
179235|NCT01939496|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
179236|NCT01939496|Drug|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
179535|NCT01952821|Other|Six-Minute Walk Test|
179536|NCT01952821|Other|10-Meter Walk Test|
179537|NCT01952821|Other|30-Second Chair Stand|
179538|NCT01952821|Other|Linear Analog Scale of Function|
179539|NCT01952821|Other|Modified Brief Fatigue Inventory|
179540|NCT01952821|Other|FACIT-Fatigue|
179541|NCT01952834|Dietary Supplement|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
179542|NCT00115050|Drug|TMC114|
179543|NCT01952834|Drug|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
179544|NCT01952847|Other|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
Radiation Therapy to Esophagus Patient Group - Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
179545|NCT01952847|Drug|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
Radiation Therapy to Esophagus Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
179546|NCT01952847|Behavioral|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
Questionnaire completion for Radiation Therapy to Esophagus Patient Group: At baseline, Week 3, 4, 5, and 7 of radiation, and at end of study visit.
194999|NCT02056067|Behavioral|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
195000|NCT02056067|Behavioral|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
195001|NCT02056093|Device|PSV mode|Application of PSV in all patients
195002|NCT02056093|Device|PAV mode|Application of PAV mode in all patients
195003|NCT02056093|Device|NAVA|
195004|NCT02056106|Drug|antidepressant therapy|
195005|NCT02058407|Drug|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
195006|NCT02058407|Drug|Placebo solution|Matching placebo to GSK2793660 solution
195007|NCT02058407|Drug|Placebo capsule|Matching placebo to GSK2793660 capsule
195297|NCT02050945|Behavioral|Resistance training|
195298|NCT02050945|Behavioral|Endurance training|
195299|NCT02050958|Drug|OXP001|
195300|NCT02050958|Drug|Ibuprofen|
195301|NCT02050971|Biological|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
195302|NCT02050971|Biological|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
195303|NCT02051023|Drug|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
195304|NCT00124124|Drug|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
195305|NCT02051023|Drug|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
194694|NCT02063204|Drug|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
194695|NCT02063217|Drug|Sodium Oxybate|Sodium oxybate h.s.
194696|NCT02063217|Behavioral|Sleep deprivation|36hr sleep deprivation
194697|NCT02063230|Drug|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
194698|NCT02063230|Drug|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
194699|NCT00125502|Biological|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
194700|NCT02063243|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
194701|NCT02063256|Dietary Supplement|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
194702|NCT02063256|Other|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
194703|NCT02063269|Drug|Rivastigmine|9-18mg/rivastigmine for 52 weeks
194704|NCT02063295|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
194705|NCT02063295|Drug|ZGN-440 for injectable suspension|
194706|NCT02063308|Dietary Supplement|Oxaloacetate (OAA)|
194707|NCT02063334|Dietary Supplement|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
194708|NCT02063334|Dietary Supplement|Placebo|
194709|NCT02063360|Drug|BMS-663068|
194710|NCT00125502|Drug|MF59 adjuvant|Oil-in-water emulsion
194711|NCT02063360|Drug|Darunavir (DRV)|
194712|NCT02063360|Drug|Ritonavir (RTV)|
194713|NCT02063360|Drug|Etravirine (ETR)|
194714|NCT02063373|Other|Hyaluronic acid|treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
195008|NCT02058420|Drug|Low tocotrienols group|300 mg tocotrienols daily
194402|NCT00126282|Behavioral|behavior therapy|
194403|NCT02071290|Device|Pneumatic tourniquet|Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet
Remote Ischemic Conditioning
194404|NCT02071303|Drug|Tramadol|Tramadol 100mg will be given to 70 women before the procedure.
194405|NCT02071303|Drug|Celecoxib|Celecoxib 200mg will be given to 70 women before the procedure.
194406|NCT02071303|Drug|Placebo|A placebo will be given to 70 women before the procedure.
194407|NCT02071316|Drug|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
194408|NCT02071316|Drug|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
194409|NCT02071329|Drug|Vaccine FP-01.1|
194410|NCT02071329|Drug|Placebo|
194411|NCT02071329|Other|Virus Challenge|
194412|NCT02071342|Procedure|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
194413|NCT00126282|Drug|D-Cycloserine|
194414|NCT02071355|Drug|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
194415|NCT02071355|Drug|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
194416|NCT02071368|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
194417|NCT02071368|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
194418|NCT02071368|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
194419|NCT02071368|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
194420|NCT02071381|Drug|DW330SR 45mg|
194421|NCT02071381|Drug|DW1030 75mg|
194422|NCT02071394|Drug|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours
193781|NCT02045563|Other|magnetic resonance imaging and magnetic resonance spectroscopy|
193782|NCT02045576|Device|sleep position trainer|
194091|NCT02037724|Dietary Supplement|iron rich food supplement (60 mg iron)|contains 60 mg of iron
194092|NCT02037724|Dietary Supplement|iron rich food supplement (10 mg iron)|contains 10 mg iron
194093|NCT02037724|Dietary Supplement|supplement containing 10 mg iron sulfate|control agent
194094|NCT02037737|Drug|Abatacept|
194095|NCT02037750|Behavioral|LINKS|In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be "made up" with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations.
194096|NCT02037776|Drug|Rikkunshito|- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
194097|NCT02037776|Drug|Rikkunshito placebo|- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
194098|NCT02037802|Device|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
194099|NCT02037802|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
194100|NCT00122928|Behavioral|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
194101|NCT02037802|Drug|Propofol|fentanyl propofol atracurium besylate
194102|NCT02037802|Drug|Bupivacaine|
194103|NCT02037802|Drug|Fentanyl|
194104|NCT02037815|Drug|20% mannitol solution, 125 ml, IV infusion in 15 min|
194105|NCT02037815|Drug|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
194106|NCT02037841|Other|Nursing-driven clinical pathway for management of inpatient asthma|
194107|NCT02037854|Other|Nutrient formulation|
194108|NCT02037867|Device|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
198556|NCT02049684|Procedure|Patch|
198557|NCT02049697|Drug|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
198558|NCT02049710|Behavioral|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
198559|NCT02049710|Behavioral|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
198560|NCT02049736|Drug|Telbivudine|
198561|NCT00002191|Drug|Albendazole|
198562|NCT00124059|Drug|Seroquel|400mg/day quetiapine
193783|NCT02045576|Device|Oral Appliance Therapy|
193784|NCT02045589|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
193785|NCT02045589|Drug|Gemcitabine|1000 mg/m2 intravenous administration
193786|NCT00123552|Drug|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to < 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; >35 kg:4 tabs per dose
193787|NCT02045589|Drug|Abraxane®|125 mg/m2 intravenous administration
193788|NCT02045602|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
193789|NCT02045602|Drug|Gemcitabine|1000 mg/m2 intravenous administration
193790|NCT02045602|Drug|Abraxane®|125 mg/m2 intravenous administration
193791|NCT02045615|Procedure|Proposed technique for removal of the Wichita Fusion Nail|
193792|NCT02045628|Behavioral|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
193793|NCT02045641|Procedure|pleuracentesis|Direct needle drainage of pleural effusions with dynamic ultrasound technique
193794|NCT02045667|Drug|Mexiletine|Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.
Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy.
182853|NCT02563600|Behavioral|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
182854|NCT02563613|Behavioral|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
182855|NCT02563613|Behavioral|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
182856|NCT02563613|Other|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
182857|NCT02563678|Drug|Hyperbaric Oxygen|Hyperbaric oxygen therapy
182858|NCT02563678|Other|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
182859|NCT00186875|Drug|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
182860|NCT02563678|Other|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
182861|NCT02563691|Radiation|stereotactic radiotherapy|Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.
The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT.
182862|NCT02563704|Drug|Artesunate|
182863|NCT02563704|Drug|Quinine|
183150|NCT02559362|Behavioral|Survey|
183151|NCT02559375|Other|Survey|
183152|NCT02559388|Drug|Montelukast|
183153|NCT02559388|Drug|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
183154|NCT02559401|Other|MRI|
183155|NCT02559401|Other|Neurocognitive battery|
183156|NCT02559414|Drug|Aspirin|
183157|NCT02559414|Drug|Clopidogrel|
183158|NCT02559427|Other|3-week immediate SPA treatment|a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
182562|NCT02567903|Device|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
182563|NCT00187122|Drug|Etoposide|See Detailed Description section for description of treatment plan.
182564|NCT02570126|Biological|GSK Biologicals varicella vaccine live, (GSK 208133)|2 doses administered subcutaneously (SC) in the tricep region of the left arm
182565|NCT02570139|Device|Cavilon Advanced High Endurance Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
182566|NCT02570139|Device|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
182567|NCT02570152|Procedure|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever [body temperature ≥ 38°C/≥ 100.4°F] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
182568|NCT00187382|Drug|Multiple vs. single courses of antenatalcorticosteroids|
182569|NCT02570165|Drug|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
182570|NCT02570165|Drug|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
182571|NCT02570165|Drug|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
182572|NCT02570178|Other|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
182573|NCT02570191|Drug|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
182864|NCT02563717|Device|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
182865|NCT02563717|Device|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
182273|NCT02540551|Procedure|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
182274|NCT02540590|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
182574|NCT02570204|Behavioral|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
182575|NCT02570217|Device|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
182576|NCT02570217|Device|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
182577|NCT02570230|Other|NSS|NSS infusion
182578|NCT02570230|Drug|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
182579|NCT00187395|Procedure|Randomized to either a 'less tight' group or a 'tight' group|
182580|NCT02570243|Drug|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
182581|NCT02570243|Drug|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
182582|NCT02572401|Behavioral|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
182583|NCT02572401|Behavioral|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
182584|NCT02572414|Behavioral|Men Together Making a Difference Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
181996|NCT00184912|Procedure|ten minutes forearm ischemia|
181997|NCT02547480|Device|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
181998|NCT02547493|Biological|pneumococcal polysaccharide vaccine|Vaccination with Pneumo23 on first day.
181999|NCT02547493|Biological|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23 two months later
182275|NCT02540590|Device|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
182276|NCT00184054|Drug|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
182277|NCT02540603|Device|F&P Jupiter Full Face Mask|Investigative F&P Jupiter full face mask to be used for OSA therapy
182278|NCT02540616|Device|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
182279|NCT02540629|Procedure|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
182280|NCT02540642|Dietary Supplement|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
182281|NCT02540655|Biological|Stemchymal®|Patients will receive dose of 7x10^7 cells/infusion of Stemchymal® through intravenous infusion
182282|NCT02540655|Procedure|Excipients|Patients will receive excipients through intravenous infusion
182283|NCT02543125|Device|NHFOV|For infants in the NHFOV-group who "fail"NHFOV (see definition below), need immediate intubation, a invasive "Rescue-Treatment" may be provided. The decision to attempt "Rescue-Treatment", the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
182284|NCT02543138|Device|Trocar|Closed thoracostomy using the new trocar
182285|NCT02543151|Procedure|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
182286|NCT02543164|Other|REFERENCE: white bread|Determination of glycemic response after consumption of white bread:
Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 75, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC).
182287|NCT00184483|Procedure|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
181702|NCT01947205|Drug|suction curettage|
181703|NCT01947205|Other|without drug|
181704|NCT02553954|Procedure|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
181705|NCT02553967|Device|Functional MRI|Functional MRI
181706|NCT02553980|Behavioral|Follow Your Virtual Trainer (FYVT) program|Participants in intervention group will under the instruction of a web-based computer software termed "Virtual Trainer", which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed.
181707|NCT02553980|Other|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
182000|NCT02547493|Drug|Abatacept|Abatacept started on frst day
182001|NCT02547519|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
182002|NCT02547519|Drug|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
182003|NCT02547532|Other|collection of sputum|
182004|NCT02547558|Procedure|Arterial blood gases|Measured through radial arterial catheter
182005|NCT02547558|Procedure|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
182006|NCT02547558|Procedure|Vital signs|As measured in clinical practice
182007|NCT00184912|Procedure|ischemic forearm exercise|
182008|NCT02547558|Procedure|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
182009|NCT02547558|Procedure|Spirometry|In a daily calibrated spirometer.
182010|NCT02547558|Drug|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
182011|NCT02547571|Drug|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
181407|NCT01933737|Device|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
181408|NCT01933737|Device|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
181409|NCT01933750|Device|PresVIEW Device Implantation|
181410|NCT01933763|Drug|REGN1193|
181411|NCT01933763|Other|Placebo|
181412|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
181413|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
181414|NCT00002105|Drug|Vincristine sulfate|
181415|NCT00113295|Drug|Quetiapine|
181416|NCT01933789|Behavioral|Communication Feedback Form for Patients with Serious Illness|The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are "potentially unmet palliative-care communication needs." All forms include "tips" to help the recipient respond to communication preferences appropriately.
181417|NCT01933802|Biological|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
181708|NCT02553993|Device|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
181709|NCT02553993|Device|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
181710|NCT02553993|Other|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
181711|NCT02554006|Behavioral|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
181712|NCT02554006|Behavioral|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
181713|NCT00185536|Behavioral|Packaging and identification of source|
181094|NCT01940965|Drug|biguanide|Pharmaceutical form:tablet Route of administration: oral
181095|NCT01940965|Drug|TZD|Pharmaceutical form:tablet Route of administration: oral
181096|NCT00113997|Drug|REG1|
181097|NCT01940965|Drug|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
181098|NCT01940965|Drug|glinide|Pharmaceutical form:tablet Route of administration: oral
181099|NCT01940978|Drug|Methylphenidate ER|Watson generic, starting dose 18mg QD
181100|NCT01940978|Drug|Cyproheptadine|cyproheptadine hydrochloride
181101|NCT01940991|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
181102|NCT01940991|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
181103|NCT01941004|Drug|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
181104|NCT01941004|Drug|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
181105|NCT01941030|Device|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
181106|NCT01941030|Device|Balloon Angioplasty|Balloon selection is driven by preference of the operator.
181107|NCT00114010|Drug|AMA1/Alhydrogel|
181108|NCT01941043|Drug|CERC-301|
181109|NCT01941043|Other|Placebo|
181110|NCT01941056|Biological|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
181111|NCT01941056|Other|laboratory biomarker analysis|Correlative studies
181112|NCT01941069|Behavioral|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
181418|NCT01933815|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
181419|NCT01936285|Drug|Placebo|
180436|NCT01932788|Drug|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
180437|NCT00113230|Drug|Capecitabine|900 mg/m^2 by mouth twice a day during days of radiation for all five weeks of therapy.
180749|NCT01946269|Other|Goal-directed Resuscitation Therapy (GDT)|A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.
The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.
When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.
The final step will be red blood transfusion to reach a hematocrit higher than 28%.
If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg.
180750|NCT01946269|Other|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
180751|NCT01946282|Other|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
180752|NCT01946282|Other|FIT plus Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
180753|NCT01946295|Drug|Famotidine|100mg x 2 p.o.
180754|NCT01946295|Drug|Placebo|
180755|NCT01946308|Other|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
180756|NCT00114361|Drug|Peginterferon alpha 2a|180 µg per week, 48 weeks
180757|NCT01946321|Other|Post-amputation functional rehabilitation (normal clinical practice)|
180758|NCT01946334|Device|anorectal manometry and high-resolution three-dimensional|
180759|NCT01946347|Other|mixed meal|Baguette Cheese Gourmet (Crocodile:
180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
180760|NCT01946347|Other|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
180761|NCT01946360|Device|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
180762|NCT01946373|Drug|Cyclophosphamide|
180763|NCT01946373|Drug|Fludarabine|
180146|NCT01937832|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
180147|NCT01937871|Drug|5 mg Tadalafil|Administered orally
180148|NCT00113672|Behavioral|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
180149|NCT01937871|Drug|Placebo|Administered orally
180150|NCT01937871|Drug|0.2 mg Tamsulosin|Administered orally
180438|NCT01932788|Drug|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
180439|NCT01932801|Drug|XR-NTX+HRC|
180440|NCT01932801|Other|Placebo+HRC|
180441|NCT01932801|Behavioral|HRC|
180442|NCT01932827|Behavioral|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
180443|NCT01932840|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
180444|NCT01932866|Other|diabetic risk score|
180445|NCT01932879|Other|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
180446|NCT01932879|Other|Jello|
180447|NCT01932905|Device|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
180448|NCT00113230|Radiation|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
180449|NCT01932918|Drug|Patient controlled analgesia|PCA with morphine in liver transplant:
Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
PCA with morphine and ketorolac:
Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
180450|NCT01932931|Dietary Supplement|Vitamin D supplement (50ug)|
179847|NCT01945554|Drug|0.5% bupivacaine (Bupivacain®)|
179848|NCT01945554|Drug|Kenacort®|
179849|NCT01945567|Device|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
179850|NCT01945567|Device|Empirical unblinded deep brain stimulation programming|
179851|NCT01945580|Procedure|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
179852|NCT01945593|Biological|PEGylated Recombinant Factor VIII|
179853|NCT01945606|Drug|Placebo (treatment 1)|Oral administration of placebo tablets
179854|NCT01945606|Drug|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
180151|NCT01937884|Drug|Parenteral Nutrition|
180152|NCT01940276|Drug|Abiraterone acetate|
180153|NCT01940276|Drug|Prednisone|
180154|NCT01940289|Device|Algometric meter readings for perception of pain|
180155|NCT01940302|Dietary Supplement|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
180156|NCT01940315|Biological|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
180157|NCT01940315|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
180158|NCT01940328|Device|Transchoracic ultrasound Doppler|
180159|NCT00113919|Drug|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin* 10 mg/m, Continuous infusion 1-4 Adriamycin** 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
180160|NCT01940341|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25 mg tablet administered orally once daily
180161|NCT01940341|Drug|Tenofovir DF|Tenofovir DF 300 mg tablet administered orally once daily
180162|NCT01940341|Drug|Placebo to match tenofovir alafenamide|Placebo to match tenofovir alafenamide administered as a tablet orally once daily
179547|NCT01952860|Other|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
179548|NCT01952860|Behavioral|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
179549|NCT01952873|Other|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
179550|NCT01952873|Other|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
179551|NCT01952886|Drug|Granisetron|
179552|NCT01952886|Drug|Ondansetron|
179855|NCT01947985|Drug|Rivaroxoban (Xarelto, Bay59-7939)|The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).
The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).
The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).
Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid]).
179856|NCT01947985|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
179857|NCT01947998|Drug|Rivaroxaban (Xarelto, Bay59-7939)|Patients who have been prescribed Rivaroxaban for the first time, divided in two subgroups: Naïve and Non Naïve. The Non Naïve are also divided in two subgroups: Recent switchers and Distant switchers.
179858|NCT00114530|Drug|Methylprednisolone|
179859|NCT01947998|Drug|Warfarin|Patients who have been prescribed Warfarin for the first time, divided in two subgroups: Naïve and Non Naïve. The Non Naïve are also divided in two subgroups: Recent switchers and Distant switchers.
179860|NCT01948011|Drug|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
179861|NCT01948011|Drug|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
179862|NCT01948024|Drug|SAPHRIS|10 mg BID sublingual tablet
179863|NCT01948024|Drug|Asenapine|10 mg BID sublingual tablet
179864|NCT01948037|Other|hydrotherapy|30-minutes/per day,for 4weeks
195306|NCT02051036|Procedure|Moxibustion|In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).
The moxa pillars will be removed when the patient feel hotness and require to remove them.
The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session.
195307|NCT02051062|Biological|One 5 mL of blood will be collected.|The blood sample should be collected no later than 24 hours post BAT® administration. To ensure sufficient detectable circulating levels of BAT® for pharmacokinetic analysis the target window of time for collection should be between 6 and 24 hours post-BAT® administration.
195308|NCT02051075|Biological|PXN sperm treatment|immotile sperm activation with PXN
195309|NCT02051075|Biological|Sperm activation with PXN and oocyte activation|
195310|NCT02051088|Procedure|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
195311|NCT02051088|Procedure|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
195312|NCT02051088|Device|drug-coated balloons and/or drug-eluting stents|
195313|NCT02051101|Other|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
195314|NCT02053805|Procedure|a multiparametric prostate MRI|
195315|NCT02053805|Procedure|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
195316|NCT02053818|Drug|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
195614|NCT02046304|Radiation|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
195615|NCT02046317|Drug|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
195616|NCT02046330|Device|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
195617|NCT02046343|Behavioral|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
195618|NCT02046343|Behavioral|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
195619|NCT02046343|Other|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
195009|NCT02058420|Drug|High tocotrienols group|600 mg tocotrienols daily
195010|NCT02058433|Other|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
195011|NCT02058433|Other|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
195012|NCT02058446|Drug|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
195013|NCT02058459|Device|Holaira™ Lung Denervation System with energy delivery|
195014|NCT00124943|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
195015|NCT02058459|Device|Holaira™ Lung Denervation System without energy delivery|
195016|NCT02058472|Drug|G3041|
195017|NCT02058472|Drug|SEVIKAR®|
195018|NCT02058485|Drug|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
195019|NCT02058485|Drug|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
195020|NCT02058498|Behavioral|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
195021|NCT02058511|Drug|Anesthesia Premedication, Induction and Maintenance|The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.
The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain.
195022|NCT02058511|Procedure|Pupillometry after administration of anesthetic drugs|All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.
Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period
The administered drugs are:
Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia.
195023|NCT02058524|Biological|fecal microbiota transplantation|
195024|NCT02058537|Drug|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
195025|NCT00124956|Drug|Doxorubicin|
194423|NCT02071394|Other|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment)
194424|NCT00126295|Device|'What you need to know about stroke' education package|
194715|NCT02065856|Biological|AVANZ Salsola|AVANZ Salsola
194716|NCT02065869|Biological|BPX-501 T cells and AP1903|Biological: T cells transduced with CaspaCIDe suicide gene
194717|NCT02065869|Drug|AP1903|AP1903 administered to treat GVHD
194718|NCT02065882|Biological|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
194719|NCT02065895|Device|Gain (reference)|The latest revision of the PID algorithm to verify that the scaling factor used to set KP as a function of TDD is robust to the changes in gain and target resulting from over- or under-calibration of the glucose sensor.
194720|NCT02065895|Device|Gain decreased by a factor 0.8|
194721|NCT02065895|Device|Gain increased by a factor 1.33|
194722|NCT02065934|Other|cardio-pulmonary resuscitation|
194723|NCT02065947|Procedure|paravertebral block|catheter with 3-level-injection
194724|NCT00125840|Drug|clofarabine (IV formulation)|
194725|NCT02065947|Drug|fentanyl, propofol, atracurium|endotracheal intubation
194726|NCT02065947|Drug|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
194727|NCT02065947|Device|catheter with 3-level-injection|
194728|NCT02065947|Drug|sevoflurane and 50% oxygen in air|
194729|NCT02065960|Radiation|Stereotactic body radiotherapy (SBRT)|
194730|NCT02065973|Biological|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
194731|NCT02065986|Drug|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
194732|NCT02066012|Other|dysmetabolic iron overload syndrome|
194733|NCT02066038|Drug|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
194109|NCT02037880|Procedure|Lumbar puncture|
194110|NCT02037880|Device|Magnetic Resonance Imaging (MRI) of the brain|
194111|NCT00122941|Dietary Supplement|multiple micronutrients|
194112|NCT02037893|Drug|Antipyrine and Benzocaine otic solution|
194425|NCT02071407|Drug|Midazolam|For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.
Morphine can be used to supply adequate analgesia.
194426|NCT02071407|Drug|Placebo|
194427|NCT02073838|Drug|Vismodegib|
194428|NCT02073838|Drug|Decitabine|
194429|NCT02073851|Device|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
194430|NCT02073903|Behavioral|Patient Survey|
194431|NCT02073903|Behavioral|Provider Survey|
194432|NCT02073916|Drug|TDM1|•Drug: abraxane Intravenous repeating dose weekly
194433|NCT00000316|Drug|Cocaine|
194434|NCT00002207|Drug|Didanosine|
194435|NCT00126542|Other|laboratory biomarker analysis|Correlative studies
194436|NCT02073916|Drug|Lapatinib|Oral repeating dose daily
194437|NCT02073916|Drug|Abraxane|Intravenous repeating dose weekly
194438|NCT02073929|Drug|Liraglutide|GLP-1-analogue Liraglutide
194439|NCT02073929|Drug|placebo|
194440|NCT02073968|Drug|Carboplatin|Given IV
194441|NCT02073968|Procedure|Computed Tomography|Undergo PET-adjusted IMRT
194442|NCT02073968|Radiation|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
194443|NCT02073968|Drug|Paclitaxel|Given IV
193795|NCT02045667|Drug|Placebo|Placebo tablets do not contain any active medicinal component.
193796|NCT02045693|Drug|Methadone|
193797|NCT00123565|Drug|Hexadecasaccharide (SR123781A)|
193798|NCT02045693|Drug|DCV 3DAA FDC|
193799|NCT02045693|Drug|BMS-791325|
193800|NCT02045693|Drug|Buprenorphine|
193801|NCT02045693|Drug|Naloxone|
193802|NCT02045706|Other|Community Health Worker Trainings|
193803|NCT02045719|Drug|uncaria tomentosa (cat´s claw)|
193804|NCT02045732|Biological|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
193805|NCT02045732|Biological|Placebo|Bi-Weekly Subcutaneous Injections X 6
194113|NCT02037893|Drug|Antipyrine Otic Solution|
194114|NCT02040389|Behavioral|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
194115|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
194116|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
194117|NCT02040415|Drug|DW-1030(eperisone HCl) 75mg|
194118|NCT02040415|Drug|Myonal Tab.(eperisone HCl) 50mg|
194119|NCT02040415|Drug|Placebo drug of DW-1030|
194120|NCT02040415|Drug|Placebo drug of Myonal Tab.|
194121|NCT00123162|Drug|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
194122|NCT02040428|Biological|EVARREST™ Fibrin Sealant Patch|
194123|NCT02040428|Biological|Topical hemostat|
194124|NCT02040441|Drug|Spironolactone|
194125|NCT02040441|Drug|Placebo|
183159|NCT00186238|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
183160|NCT02559427|Other|3-week late SPA treatment|a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
183161|NCT02559440|Drug|mometasone furoate|50μg, 1 puff in each nostril every evening
183162|NCT02559440|Drug|Placebo|1 puff in each nostril every evening
183163|NCT02559440|Drug|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
183164|NCT02559440|Drug|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
183165|NCT02559440|Drug|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
183166|NCT02559440|Drug|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
183167|NCT02559453|Procedure|Debridement|Removing dead tissue from infected wounds.
183168|NCT02559466|Device|Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Class IIa
183169|NCT02559466|Device|Positon Emission Tomography (PET) - Discovery 710®|Class IB
183170|NCT00186251|Procedure|high dose chemo then auto hematopoietic cell transplant|
183171|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 18%-protein diet|
183172|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 35%-protein diet|
183465|NCT02552381|Other|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
183466|NCT02554747|Device|Navigated laser|Aflibercept, Navilas®
183467|NCT02554747|Device|Conventional laser|Aflibercept, Pascal
183468|NCT02554760|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
183469|NCT02554773|Drug|ALN-AT3SC|Multiple doses of ALN-AT3SC by subcutaneous (sc) injection
183470|NCT02554786|Drug|QMF149|
183471|NCT02554786|Drug|QMF149|
182866|NCT02565706|Behavioral|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
182867|NCT02565706|Behavioral|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
182868|NCT02565719|Drug|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
182869|NCT02565719|Drug|Pegasys|immunotherapy
182870|NCT02565719|Drug|Zadaxin|immunotherapy
182871|NCT02565719|Drug|Viread|HBV RT polymerase inhibitor
182872|NCT02565719|Drug|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
182873|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
182874|NCT00187005|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
182875|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
182876|NCT02565732|Biological|Placebo comparator|Placebo, Dose C, Topical
182877|NCT02565745|Device|Hydrocolloid Dressing of Skin|One aplication of Hydrocolloid Dressing of skin, during 3-7 days; One Hydrocolloid by área of risk , in prone 12 areas as weel as in supine.Frequency of change: according to necessity.
Placebo comparator with VASELINE® INTENSIVE CARE cream for usual care moisturizer or lubricant standardized will be applied in the same areas of risk in the intervention group, once by shift, do not use simultaneus with dressings.Compared to a placebo group taken current care with cream.
182878|NCT02565758|Drug|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
182879|NCT02565758|Drug|Nivolumab|It is an intravenous infusion administered every 14 days.
182880|NCT02565758|Drug|Gemcitabine|It is an intravenous infusion administered on day 1, 8 and 15 of a 28-day cycle.
182881|NCT02565758|Drug|nab-paclitaxel|It is an intravenous infusion administered on day 1, 8 and 15 of a 28-day cycle.
182882|NCT02565771|Other|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
183173|NCT02559492|Drug|INCB039110|INCB039110 tablets will be administered orally once daily in the morning.
182585|NCT02572414|Behavioral|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
182586|NCT02572427|Other|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
182587|NCT02572427|Other|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
182588|NCT02572440|Procedure|Sorin XTRA/Sorin Group,|
182589|NCT02572453|Other|Fluorothymidine F-18|Correlative studies
182883|NCT02565784|Device|Restylane|Facial tissue augmentation
182884|NCT02565784|Device|Perlane|Facial tissue augmentation
182885|NCT00187005|Drug|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
182886|NCT02565797|Device|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
182887|NCT02565810|Drug|Adalimumab PFS and Pen|
182888|NCT02565823|Other|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
182889|NCT02567903|Procedure|Knee arthroscopy|Knee arthroscopy
182890|NCT02567916|Drug|Fresofol|
182891|NCT02567916|Drug|Propofol|
182892|NCT02567929|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
182893|NCT02567929|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation.
182894|NCT02567942|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation
182895|NCT02567942|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
182896|NCT02567955|Biological|Gardasil-9 and Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
182897|NCT02567955|Biological|Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
182288|NCT02543164|Other|TEST A: b-glucan enriched bread|Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :
Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 75, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC).
182289|NCT02543164|Other|TEST B: b-glucan enriched bread|Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test B) :
Bread TEST B Will be formulated to contain 50% more beta-glucans as bread TEST A. Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 75, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC).
NOTE: This intervention is optional and might be performed after evaluation of intervention with Test A.
182290|NCT02543177|Procedure|coronary angiography|
182291|NCT02543177|Procedure|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
182292|NCT02543177|Procedure|prior kidney irrigation|
182590|NCT00002510|Procedure|peripheral blood stem cell transplantation|
182591|NCT00187785|Behavioral|Spanish speaker level|
182592|NCT02572453|Drug|Hsp90 Inhibitor AT13387|Given IV
182593|NCT02572453|Other|Laboratory Biomarker Analysis|Correlative studies
182594|NCT02572453|Procedure|Positron Emission Tomography|Correlative studies
182595|NCT02572466|Other|Hemodialysis|ESRD group received long-term hemodialysis
182596|NCT02572492|Drug|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)
Subsequently all patients receive the conditioning regimen:
Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 > 2.0 m CD34+ stem cells/kg body weight on day 0
182597|NCT02572492|Drug|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
182598|NCT02572492|Drug|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
182599|NCT02035423|Dietary Supplement|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
182600|NCT02035423|Dietary Supplement|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
182601|NCT02035423|Dietary Supplement|Non-Fortified Milk|Daily consumption of non-fortified milk
182602|NCT02035436|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
182012|NCT02547571|Drug|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
182013|NCT02549521|Dietary Supplement|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
182014|NCT02549521|Dietary Supplement|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
182015|NCT02549534|Procedure|Axon Reflexes|*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:
Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33*C.
Heat Ramp: Increasing the heat in the heat probe to 42*C at rate of 0.1c/1s.
Skin Heating: Heating the skin of the toe for 30 minutes 42*C.
Heat Ramp: Increasing the heat in the heat probe to 44*C at rate of 0.1c/1s.
Skin Heating: Heating the skin for an additional 5 minutes at 44*C.
The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants only develop CIPN on their left side, the left toe will be substituted.
182016|NCT00185094|Drug|Atenolol|
182293|NCT02543190|Behavioral|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
182294|NCT02543203|Biological|Essential Oil Mixture A|Topical Essential Oils mixture and aromatic method
182295|NCT02543203|Biological|Essential Oils Mixture B|Topical Essential Oils mixture and aromatic method
182296|NCT02543216|Dietary Supplement|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
182297|NCT02543229|Drug|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
182298|NCT00184483|Procedure|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
182299|NCT02543229|Drug|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
182300|NCT02543242|Device|InToneTM (InControl Medical, LLC) - Medical Device|
182301|NCT02543255|Drug|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
182302|NCT02543255|Drug|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
182303|NCT02543255|Drug|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 6 mg per cycle and 3 weeks between cycles.
181714|NCT02554019|Biological|BT063|Repeated IV infusions over 12 weeks
181715|NCT02554019|Biological|Placebo|Repeated IV infusions over 12 weeks
181716|NCT02554032|Procedure|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
181717|NCT02554032|Procedure|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
181718|NCT02554045|Drug|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
181719|NCT02554045|Drug|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
181720|NCT02554058|Device|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
181721|NCT02554071|Other|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
181722|NCT00185744|Radiation|Stereotactic APBI|4 day treatment
181723|NCT02556385|Device|High frequency rTMS|Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
182017|NCT02549534|Procedure|Axon Flares|Axon flares will be generated in the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field, laser perfusion imaging or FLPI).
182018|NCT02549534|Procedure|Self-Reported Signs & Symptoms of CIPN|Self-reported signs & symptoms of CIPN such as tingling, numbness, neuropathic pain, vibration thresholds, and deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
182019|NCT02549547|Behavioral|Group Medical Visits|Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:
Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes
Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes
Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity.
181420|NCT01936298|Device|A-ROM Continuous Passive Rehabilitation|Half an hour of treatment during the morning with the "sequential" program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the "synchronous" program (II-III-IV-V finger are mobilized simultaneously, the thumb individually).
181421|NCT01936298|Device|P-ROM Continuous Passive Rehabilitation|Half an hour of treatment during the morning with the "sequential" program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the "synchronous" program (II-III-IV-V finger are mobilized simultaneously, the thumb individually).
181422|NCT01936311|Behavioral|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
181423|NCT00113503|Drug|IMURAN (azathioprine)|
181424|NCT01936324|Drug|DRM01B|Comparison of active treatment with DRM01B topical gel, 7.5% versus vehicle gel (DRM01B Vehicle gel) applied to the face for acne vulgaris
181425|NCT01936324|Other|DRM01B Vehicle gel|
181426|NCT01936337|Drug|DLX105 Hydrogel|topical administration on psoriatic plaque
181427|NCT01936337|Drug|Placebo|topical administration on psoriatic plaque
181428|NCT01936350|Drug|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
181429|NCT01936350|Drug|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
181430|NCT01936363|Drug|Pimasertib once daily|Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
181431|NCT01936363|Drug|Pimasertib placebo|Placebo matching Pimasertib will be administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
181432|NCT01936363|Drug|SAR245409 placebo|Placebo matching SAR245409 will be administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
181433|NCT01936363|Drug|SAR245409|SAR245409 will be administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
181434|NCT00113516|Drug|carboplatin|AUC of 6 mg*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
181435|NCT01936363|Drug|Pimasertib twice daily|Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
181436|NCT01936389|Drug|AR-12286|
180764|NCT01946373|Biological|T cells|
180765|NCT01946373|Biological|Interleukin-2|
180766|NCT01946373|Biological|Dendritic cell vaccine|
180767|NCT00002113|Drug|Fluconazole|
180768|NCT00114374|Drug|Escitalopram|
181113|NCT01941069|Behavioral|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
181114|NCT01941082|Drug|RO6867461|Single or multiple ascending dose by intravitreal injection
181115|NCT01941095|Drug|DMARD|Permitted non-biologic disease-modifying antirheumatic drugs, at a stable dose that was initiated at least 4 weeks prior to baseline, are: azathioprine, chloroquine, hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine. Treatment is according to standard of care.
181116|NCT01941095|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC weekly
181117|NCT01941108|Behavioral|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
181118|NCT00114023|Drug|Imiquimod 5% cream|
181119|NCT01943812|Drug|Progesterone and estradiol|
181120|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
181121|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
181122|NCT01943825|Biological|CYD Dengue and Japanese Encephalitis Vaccines|0.5 mL, Subcutaneous (CYD) Intramuscular (JE)
181123|NCT01943825|Biological|Japanese Encephalitis and CYD Dengue Vaccines|0.5 mL, Intramuscular (JE), Subcutaneous (CYD)
181124|NCT00114179|Procedure|therapeutic conventional surgery|Undergo surgery
181125|NCT01943838|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
181126|NCT01943851|Drug|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
181127|NCT01943864|Drug|Trametinib (single tablet)|The drug substance is blended with inert
181128|NCT01943864|Drug|Trametinib (Multiple tablet)|The drug substance is blended with inert
180451|NCT01932944|Device|No treatment|
180452|NCT01932957|Procedure|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
180453|NCT01932957|Procedure|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
180454|NCT01932970|Drug|AMG 416|Subjects will be administered IV AMG 416 at the end of their regularly scheduled hemodialysis sessions, for a total of 4 weeks.
180455|NCT01932983|Device|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
180769|NCT01948856|Drug|J022X ST|Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach
First month: 4 consecutive days per week during 3 consecutive weeks
5 next months: 4 consecutive days per month at monthly intervals
180770|NCT01948856|Drug|Placebo|Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach
First month: 4 consecutive days per week during 3 consecutive weeks
5 next months: 4 consecutive days per month at monthly intervals
180771|NCT01948869|Device|Phoenix II (BAY81-2996)|
180772|NCT01948869|Device|Phoenix I (BAY81-2996)|
180773|NCT01948882|Device|ESS505 (BAY1454033)|
180774|NCT01948895|Drug|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
180775|NCT01948908|Drug|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
180776|NCT01948921|Drug|placebo|
180777|NCT01948921|Drug|Meperidine|
180778|NCT00114595|Drug|eicosapentaenoic acid|
180779|NCT01948934|Procedure|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
180780|NCT01948947|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
180163|NCT01940341|Drug|Placebo to match tenofovir DF|Placebo to match tenofovir DF administered as a tablet orally once daily
180164|NCT01940354|Device|AccuCath IV device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
180165|NCT01940354|Device|Conventional IV catheters|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
180166|NCT01940367|Device|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
180456|NCT01935557|Drug|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
180457|NCT00113399|Drug|cisplatin|
180458|NCT01935557|Drug|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
180459|NCT01935570|Drug|Magnesium chloride (ChronoMag Smart Tablet®)|
180460|NCT01935570|Drug|Magnesium carbonate (Mag2® Tablet)|
180461|NCT01935583|Behavioral|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
180462|NCT01935596|Drug|ropivacaïne|spinal anesthesia.
180463|NCT01935596|Drug|lévobupivacaïne|
180464|NCT01935609|Behavioral|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
180465|NCT01935622|Drug|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
180466|NCT01935622|Drug|placebo|Placebo 1 tablet every 12 hours for 14 days
180467|NCT01935635|Biological|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2*105-1*106 cells per time,total 12 times;
179865|NCT01948037|Other|hydrotherapy|30-minutes/per day;4weeks
179866|NCT01948050|Device|non-invasive transcranial direct current stimulation (tDCS)|
179867|NCT01948063|Drug|200mg Ubiquinol|
179868|NCT01948076|Device|resident with GE vscan|resident with GE vscan
179869|NCT00114530|Drug|Growth colony stimulating factor (G-CSF)|
179870|NCT01948089|Behavioral|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
180167|NCT01940367|Device|TENS (Transcutaneous Electrical Nerve Stimulation)|TENS therapy will be administered as follows:
Surface electrodes, 2" x 2" in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.
The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:
Mode: Burst
Cycle: 10 seconds
Frequency: 10 Hz
Pulse Width: 250 µs
Intensity: to subject comfort level
180168|NCT01940393|Drug|Cetirizine|Drug administration
180169|NCT01940393|Drug|Desloratadine|Drug Administration
180170|NCT01942863|Procedure|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
180171|NCT01942863|Other|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
180172|NCT00002111|Drug|Saquinavir|
180173|NCT00114140|Drug|temozolomide|
180174|NCT01942876|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
180175|NCT01942876|Behavioral|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
195620|NCT02046343|Other|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
195621|NCT02046369|Drug|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
195622|NCT02046369|Drug|Placebo|Placebo Comparator once daily
195623|NCT00123643|Drug|glyburide|
195624|NCT02046382|Drug|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
195625|NCT02046382|Drug|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
195626|NCT02046395|Drug|amlodipine, hydralazine, terazosin or hydrochlorothiazide|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
195627|NCT02046408|Other|Computer Tablet|
195628|NCT02046421|Drug|mifepristone|Given PO
195629|NCT02046421|Drug|carboplatin|Given IV
195630|NCT02046421|Drug|gemcitabine hydrochloride|Given IV
195631|NCT02046421|Other|laboratory biomarker analysis|Correlative studies
195632|NCT02046421|Other|pharmacological study|Correlative studies
195633|NCT02046434|Drug|Glycerol Phenylbutyrate|
195930|NCT02041273|Drug|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
195931|NCT02041286|Device|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
195932|NCT00123266|Drug|Microplasmin|2 mg/kg, IA over 75 mins
195933|NCT02041299|Drug|Deferiprone|
195934|NCT02041299|Drug|Deferoxamine|
195935|NCT02041312|Other|No intervention|No intervention will be needed.
195026|NCT02058550|Other|survey administration|Receive reminder email survey
195317|NCT02053818|Drug|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
195318|NCT02053844|Other|lottery for tool users to win a $500 prize|
195319|NCT02053844|Other|enhanced promotion of the tool to employers and members|
195320|NCT02053857|Dietary Supplement|RUTF|
195321|NCT02053857|Dietary Supplement|RUTF-P|
195322|NCT00124475|Drug|alitretinoin|
195323|NCT02053857|Drug|Amoxicillin|
195324|NCT02053870|Other|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
195325|NCT02053870|Drug|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
195326|NCT02053883|Drug|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
195327|NCT02053883|Drug|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
195328|NCT02053909|Drug|Aspirin|
195329|NCT02053909|Drug|Ticagrelor|
195330|NCT02053922|Drug|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
195331|NCT02053922|Drug|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . [Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
195332|NCT02053922|Drug|Misoprostol|Misoprostol (200 mcg Tablet) [Misotac, Sigma Pharmaceutical Industries, SAE, Egypt] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
195333|NCT00002193|Drug|Amprenavir|
195334|NCT00124488|Device|Tomotherapy Treatment Planning|
194734|NCT02066051|Device|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
194735|NCT00000315|Drug|Cocaine|
194736|NCT00002202|Drug|Indinavir sulfate|
194737|NCT00125853|Drug|Nebivolol|Nebivolol 25mg daily
195027|NCT02060955|Drug|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
195028|NCT02060968|Device|Promus PREMIER|
195029|NCT02060981|Behavioral|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
195030|NCT02060981|Behavioral|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
195031|NCT00125229|Drug|Hypertonic Saline|
195032|NCT02060981|Behavioral|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
195033|NCT02060994|Other|No intervention|No intervention
195034|NCT02061007|Drug|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
195035|NCT02061007|Drug|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
195036|NCT02061007|Procedure|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
195037|NCT02061020|Drug|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.
Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.
Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).
Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.
195038|NCT02061046|Device|CPAP therapy|8 weeks of CPAP therapy
194444|NCT02073968|Procedure|Positron Emission Tomography|Undergo PET-adjusted IMRT
194445|NCT02073968|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
194446|NCT00126555|Drug|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
194447|NCT02073994|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
194448|NCT02074007|Drug|AR01|drops administered an needed for pain
194738|NCT02066051|Procedure|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
194739|NCT02066064|Procedure|Standard Colonoscopy|Standard Colonoscopy
194740|NCT02066064|Procedure|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
194741|NCT02066077|Drug|Etomidate|
194742|NCT02066077|Drug|Propofol|
194743|NCT02068690|Drug|BI 425809 tablet|BI 425809 tablet
194744|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
194745|NCT00126087|Drug|dopamine|
194746|NCT02068703|Behavioral|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
194747|NCT02068703|Behavioral|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
194748|NCT02068742|Other|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
194749|NCT02068781|Dietary Supplement|Low-sodium diet|50 mmol NaCl per 24h
194750|NCT02068781|Dietary Supplement|High-sodium diet|250 mmol NaCl per 24h
194751|NCT02068794|Other|Laboratory Biomarker Analysis|Correlative studies
194752|NCT02068794|Procedure|Mesenchymal Stem Cell Transplantation|Given IP
194126|NCT02040441|Drug|Standard care|Standard diabetes care
194127|NCT02040454|Drug|Paclitaxel|
194128|NCT02040454|Procedure|Standard Therapy|
194129|NCT02040480|Drug|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
194130|NCT02040480|Drug|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
194131|NCT02040493|Radiation|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
194132|NCT00123162|Drug|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
194133|NCT02040506|Drug|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
194134|NCT02040519|Behavioral|Filling out voiding diaries.|
194135|NCT02040532|Drug|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
194136|NCT02040558|Drug|MNK-010|
194449|NCT02074007|Drug|Glycerin ear drops|placebo drops administered for ear pain
194450|NCT02074020|Drug|Blisibimod|Administered via subcutaneous injection once per week
194451|NCT02074020|Drug|Placebo|Administered via subcutaneous injection once per week
194452|NCT02074046|Biological|cancer stem cell vaccine|
194453|NCT02074059|Other|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
194454|NCT02074059|Device|nCPAP alone|nCPAP therapy
194455|NCT02074072|Device|15 degree left-lateral tilt wedges|The wedges are made of aluminium
194456|NCT02035592|Other|Half dose blueberry|Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.
Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
194457|NCT02035592|Other|Control|Control: 26g of placebo comparator material to be incorporated into the habitual diet.
Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
183472|NCT02554786|Drug|MF 400|
183473|NCT02554786|Drug|MF 400|
183474|NCT00185614|Drug|cyclosporin|5 mg/kg; iv or po
183475|NCT02554786|Drug|salmeterol /fluticasone|
183476|NCT02554799|Drug|MMV390048 formulation A|MMV390048 formulation A, tablet
183477|NCT02554799|Drug|MMV390048 formulation B|MMV390048 formulation B, tablet
183478|NCT02554812|Biological|Avelumab|Anti-PD-L1 antibody at 10 mg/kg IV every 2 weeks until disease progression.
183479|NCT02554812|Biological|PF-05082566|Anti-4-1BB antibody at 3 dose levels (500 mg, 100 mg, or 20 mg) IV every 4 weeks to optimize the combination with avelumab. Treatment with the combination of avelumab and PF-05082566 will continue until disease progression.
183480|NCT02554825|Behavioral|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels—individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
183481|NCT02554825|Behavioral|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
183482|NCT02554838|Other|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
183483|NCT02554838|Other|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
178722|NCT01903811|Other|Laboratory Biomarker Analysis|Correlative studies
178723|NCT01903824|Drug|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
178724|NCT01903824|Drug|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
178725|NCT01903824|Drug|modafinil|modafinil 200 mg tablet, over-encapsulated
178726|NCT01903824|Drug|Placebo|Placebos formulated to match each active drug
178727|NCT01903837|Drug|Samidorphan (Low Dose)|Tablets taken once daily
183174|NCT02559492|Drug|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
183175|NCT02559492|Drug|INCB039110|INCB039110 tablets will be administered orally once daily in the morning.
183176|NCT02559492|Drug|INCB050465|INCB050465 tablets will be administered orally once daily.
183177|NCT02561585|Drug|LEO 124249|
183178|NCT02561585|Other|Vehicle|
183179|NCT02561611|Behavioral|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
183180|NCT02561624|Behavioral|Behaviour change communication via text message|
183181|NCT02561637|Behavioral|Case management|
183182|NCT00186576|Procedure|nonmyeloablative allogeneic hematopoietic cell transplant|
183183|NCT02561637|Behavioral|Control group|
183184|NCT02561650|Drug|COV155|COV155 tablets
183185|NCT02561663|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
183186|NCT02561663|Other|Placebo|
183187|NCT02561676|Other|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
183188|NCT02561676|Other|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
183189|NCT02561689|Other|Fissure sealing|Procedure:
The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation
Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years
The occlusal surface is sealed by the dentist or dental hygienist.
Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years
183190|NCT02561702|Other|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
183191|NCT02561702|Drug|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
182898|NCT02567968|Drug|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (10 mg/ kg). The time to wake will be measured.
182899|NCT00187122|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
182900|NCT02567968|Drug|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
182901|NCT02567981|Dietary Supplement|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
183192|NCT02561715|Behavioral|Questionnaires|Pre and post deep brain surgery questionnaires
183193|NCT00186589|Drug|90Y Ibritumomab tiuxetan|
183194|NCT02561728|Device|Hangar Helmet|Child will be fitted with the Hangar Helmet
183195|NCT02561728|Device|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
183196|NCT02561741|Drug|COV155|COV155 tablets
183197|NCT02561754|Dietary Supplement|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
183198|NCT02561754|Dietary Supplement|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
183199|NCT02563730|Procedure|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
183200|NCT02563743|Behavioral|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation, relapse prevention during return to work and follow-up. It includes three meetings at the OHS with additional follow-ups.
183201|NCT02563743|Behavioral|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention has the same general structure and intensity as the experimental condition, but the treatment content are different and less standardized.
183202|NCT02563756|Procedure|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
183203|NCT00186875|Drug|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
183204|NCT02563756|Procedure|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
183205|NCT02563769|Drug|Clavulanic acid|
182603|NCT00122681|Biological|Cervarix™|Intramuscular injection, 3 doses
182604|NCT02035436|Other|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
182605|NCT02035449|Device|McGrath MAC|McGrath MAC is a videolaryngoscope
182606|NCT02035475|Device|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
182607|NCT02035488|Drug|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
182608|NCT02035501|Drug|L-Tyrosine|
182609|NCT02035501|Drug|Placebo|
182610|NCT02035514|Biological|Bone marrow autologous mesenchymal stem cells transplantation|
182902|NCT02567981|Dietary Supplement|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado" Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%.
182903|NCT02567981|Dietary Supplement|Ferrous sulphate|Ferrous sulfate drops children <12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).
Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months.
182904|NCT02567981|Dietary Supplement|Vitamin A|Vitamin A Capsules: children <12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
182905|NCT02567994|Drug|Teneligliptin, Sitagliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
182906|NCT02568007|Drug|Cyproheptadine|
182907|NCT02568020|Drug|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
182908|NCT02568033|Drug|Pemetrexed|
182909|NCT02568033|Drug|Carboplatin|
182910|NCT02570256|Behavioral|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
182304|NCT02545374|Other|Telemedicine|
182305|NCT02545374|Other|Control|
182306|NCT02545413|Drug|Probiotic VSL#3|
182307|NCT02545413|Drug|Placebo|
182308|NCT02545426|Other|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
182309|NCT02545439|Drug|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
182310|NCT02545452|Drug|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
182311|NCT02545452|Drug|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
182312|NCT02545452|Drug|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
182313|NCT02545452|Drug|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
182314|NCT00184717|Drug|somatropin|0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
182315|NCT02545452|Other|Tampon|
182611|NCT02035527|Drug|sorafenib tosylate|Given daily PO in the a.m.
182612|NCT02035527|Drug|cisplatin|Given IV over 1 hour following Docetaxel administration
182613|NCT02035527|Drug|docetaxel|Given IV 1 hour prior to cisplatin administration
182614|NCT00122681|Biological|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
182615|NCT02035527|Other|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
182616|NCT02035540|Other|Decellularized human valves|
182617|NCT02035553|Drug|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (taken as two 20 mg tablets), once daily by mouth for 12 weeks
182618|NCT02035553|Drug|Placebo|Placebo, taken as two tablets, once daily by mouth for 12 weeks
182619|NCT02035566|Other|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
182020|NCT02549560|Device|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
182021|NCT02549573|Drug|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
182022|NCT02549573|Behavioral|Physical Therapy|All subjects will participate in a standardized PT intervention
182023|NCT02549586|Other|Autologous Hematopoietic Stem Cell Transplant|Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.
Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT.
182024|NCT02549599|Behavioral|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
182025|NCT02549599|Behavioral|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
182026|NCT02551692|Drug|Placebo Nicotine Patch|In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.
In the VAR group, participants will wear a placebo patch while taking varenicline.
182027|NCT02551692|Drug|Placebo Capsule|In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.
In the NRT group, participants will take a placebo capsule while wearing nicotine patches.
182028|NCT02551705|Other|functional Imaging|Brain responses associated with emotional memory will be investigated
182316|NCT02545465|Drug|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
182317|NCT02545491|Behavioral|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
182318|NCT02545491|Behavioral|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
182319|NCT02545504|Drug|GS-5745|GS-5745 800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
181724|NCT02556385|Device|Low frequency rTMS|Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
181725|NCT02556398|Behavioral|Sugar Sleuth|Educational module and use of smart phone app ("Sugar Sleuth")
181726|NCT02556411|Drug|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
181727|NCT02556411|Drug|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
181728|NCT02556424|Drug|Dexamethasone|Intravitreal implant at D0
181729|NCT02556424|Drug|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
181730|NCT02556437|Drug|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
181731|NCT02556437|Drug|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
181732|NCT02556450|Drug|Spironolacton|Administration of Spironolacton 25 mg per day
181733|NCT00185757|Drug|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
181734|NCT02556463|Biological|MEDI9197|Subjects will receive up to 4 doses of MEDI9197
181735|NCT02556476|Procedure|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
181736|NCT02556476|Procedure|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
181737|NCT02556476|Procedure|renal replacement therapy|the procedures used to treat acute kidney injury
181738|NCT02556476|Procedure|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
181739|NCT02556502|Device|18F-Florbetaben PET|
181740|NCT02556515|Procedure|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
181741|NCT02556515|Procedure|Total joint replacement|Total joint replacement
181742|NCT02556515|Device|Elektra prosthesis|Elektra prosthesis
181129|NCT01943877|Procedure|scaling root planing|scaling root planing
181130|NCT01943877|Drug|Propolis|experimental
181131|NCT01943890|Device|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
181132|NCT01943890|Procedure|Physiotherapy|
181133|NCT01943916|Device|Imagio Scan|The Imagio Breast Imaging System is indicated for use by a qualified and trained healthcare provider for opto-acoustic (OA) evaluation of breasts in women who are referred for a diagnostic breast ultrasound work-up due to a suspicious mass (including both palpable and non-palpable) or an imaging finding (such as architectural distortion, asymmetry, or suspicious calcifications).
181437|NCT01936402|Behavioral|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
181438|NCT01936415|Device|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
181439|NCT01936415|Device|Regenerex|
181440|NCT01938950|Other|Aerobic Exercise|
181441|NCT01938950|Other|Resistance Exercise|
181442|NCT01938950|Other|Aerobic and Resistance Exercise|
181443|NCT01938963|Behavioral|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
181444|NCT01938976|Behavioral|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
181445|NCT01938989|Device|Clear clip-on glasses|Clip-on glasses with no light filtering properties
181446|NCT01938989|Device|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
181447|NCT01939002|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
181448|NCT01939002|Drug|naproxen|Administered as specified in the treatment arm
181449|NCT00113789|Other|PI Discretion|PI Discretion
180781|NCT01948947|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
180782|NCT01948960|Drug|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
180783|NCT01948973|Device|Subsensory|The stimulation is here set to 90% of the sensory threshold
180784|NCT01948973|Device|OFF|The stimulation is here turned OFF
180785|NCT01948973|Drug|Suprasensory|The stimulation is here set suprasensory
180786|NCT01948986|Drug|Ertugliflozin|Single oral administration of tablets.
180787|NCT01948999|Procedure|ECT|
180788|NCT01948999|Procedure|SHAM ECT|
181134|NCT01943942|Drug|Montelukast 10 mg|Reference product
181135|NCT00114179|Drug|gemcitabine hydrochloride|Given IV
181136|NCT01943942|Drug|Montelukast 10 mg|Test product
181137|NCT01943955|Behavioral|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
181138|NCT01943968|Other|Blood test|
181139|NCT01943994|Drug|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
181140|NCT01943994|Drug|Nicotine Replacement Therapy (NRT)|
181141|NCT01944007|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
181142|NCT01944020|Device|Active CPAP|Active CPAP will be a therapeutic dose CPAP each night for 2 months
181143|NCT01944033|Drug|Drug: Ipratropium bromide|
181144|NCT01944046|Drug|Placebo Nasal Spray|
181145|NCT01946529|Procedure|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
181146|NCT01946529|Radiation|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
180468|NCT00113399|Drug|docetaxel|
180469|NCT01935648|Drug|Ropivacaine|
180470|NCT01935674|Drug|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
180471|NCT01935674|Drug|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
180472|NCT01935687|Device|Using of instrumented wheel|Using of instrumented wheel
180473|NCT01935687|Device|Using of ergometer roller|Using of ergometer roller
180474|NCT01935700|Drug|Colchicine|Adjustment the dosage of colchicine during study:
The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day.
180789|NCT00114608|Device|The Focus™ Neuromuscular Stimulation System|Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds "on" and 48 seconds "off" per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles.
180790|NCT01948999|Drug|Anesthesia|
180791|NCT01949012|Other|Capnography|Capnography waveform and capnometry readings
180792|NCT01951547|Procedure|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
180793|NCT01951547|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
180794|NCT01951560|Drug|Valproic Acid|By infusion over 1 hour
180795|NCT01951560|Drug|Isotonic saline solution|By infusion over 1 hour
180796|NCT01951573|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
180176|NCT01942889|Dietary Supplement|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
180177|NCT01942902|Device|Continuous Glucose Monitoring System|
180178|NCT01942915|Biological|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
180179|NCT01942928|Other|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
180180|NCT01942928|Other|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
180181|NCT01942941|Device|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
180182|NCT01942954|Other|Mobile health cognitive stimulation|
180475|NCT01935713|Drug|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
180476|NCT01935713|Drug|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
180477|NCT01935713|Drug|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, >2 packs per day).
180478|NCT01938079|Other|Standard of Care|Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
180479|NCT01938092|Drug|Diazepam|
180480|NCT01938092|Drug|Placebo|
180481|NCT01938105|Other|Nimotuzumab+chemoradiotherapy|Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.
180482|NCT01938118|Behavioral|Obesity Prevention Group|
180483|NCT01938118|Behavioral|Injury Prevention Group|
180484|NCT00113685|Drug|Lactated Ringer's Solution|
180485|NCT01938131|Device|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
195936|NCT02041325|Drug|Lenalidomide|
195937|NCT02041325|Drug|Placebo|
195938|NCT02041338|Drug|Paclitaxel and carboplatin|
195939|NCT02041338|Drug|Paclitaxel|
195940|NCT02041338|Drug|Epirubicin and Paclitaxel|
195941|NCT02041351|Drug|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
195942|NCT02041377|Device|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
195943|NCT00123279|Drug|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
195944|NCT02041390|Other|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
195945|NCT02041390|Other|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
195946|NCT02041429|Drug|Ruxolitinib|
195947|NCT02041429|Drug|Paclitaxel|
195948|NCT02041442|Procedure|Electrical mapping of the urinary bladder|
195949|NCT02041455|Drug|Melatonin and Placebo|
195950|NCT02041455|Drug|Amitriptyline and Placebo|
196282|NCT02036502|Biological|Pembrolizumab|
196283|NCT02036502|Drug|Lenalidomide|
196284|NCT02036502|Drug|Dexamethasone|
196285|NCT02036515|Drug|Ertugliflozin (5 mg)|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
196286|NCT02036515|Drug|Ertugliflozin (15 mg)|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
195335|NCT02053935|Drug|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
195336|NCT02053948|Procedure|Pursestring Wound Closure|
195337|NCT02053948|Procedure|Gunsight Skin Incision and Closure Technique|
195634|NCT00123656|Drug|esomeprazole|esomeprazole dosed qam for 8 weeks
195635|NCT02048501|Other|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
195636|NCT02048514|Device|The Nellix® EndoVascular Aneurysm Sealing System|
195637|NCT00123942|Drug|MEDI-507|
195638|NCT02048527|Other|Global|Single medium for the culture of embryos from Day1 to Day 5
195639|NCT02048527|Other|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
195640|NCT02048540|Biological|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
195641|NCT02048540|Drug|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
195642|NCT02048540|Procedure|Gastrectomy|
195643|NCT02048553|Device|Tablet-guided ventriculostomy|In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups " guided " or " freehand ").
195644|NCT02048553|Procedure|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
195645|NCT02048566|Device|ImaCor PM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
195039|NCT02061059|Other|block 1|shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
195040|NCT02061059|Other|block 2|shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
195041|NCT02061059|Other|standard|patient wears shoes produced with standard method
195338|NCT02056119|Device|Vibrating Mesh Nebulizer Arm|Physician order received for subject, randomization to vibrating mesh nebulizer occurred.
Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the "dry side" of the heater water chamber on the inspiratory ventilator circuit.
Aerosol treatment delivered per physician order.
Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures.
195339|NCT02056119|Device|Jet Nebulizer Arm|Physician order received for subject, randomization to jet nebulizer occurred.
Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).
Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.
Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures.
195340|NCT00124696|Drug|Cocaethylene|
195341|NCT02056132|Other|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
195342|NCT02056145|Procedure|LFCNB|LFCNB - Normal Saline solution 10 cc
195343|NCT02056145|Procedure|FNB|FNB - Normal saline solution 10 cc
195344|NCT02056145|Procedure|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
195345|NCT02056145|Procedure|FNB|FNB - Chirocaine 0.25%, 20 cc
195346|NCT02056171|Drug|quetiapine|
195347|NCT02056171|Other|Placebo|
195348|NCT02056184|Drug|Adalimumab|
195349|NCT02056197|Other|Placebo|Shortwave
195350|NCT02056197|Other|Stable surface exercises|Stable surface exercises
195351|NCT00124709|Drug|Pimecrolimus|Pimecrolimus cream 1 %
195352|NCT02056197|Other|Unstable surface exercises|
195353|NCT02056210|Drug|Mozobil|Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
195354|NCT02056223|Drug|Intravenous paracetamol|15 mg/Kg every 6 hours for three days
194753|NCT02068794|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
194754|NCT02068807|Dietary Supplement|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
194755|NCT02068807|Dietary Supplement|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
194756|NCT00126100|Drug|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
194757|NCT02068820|Device|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
194758|NCT02068820|Device|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
194759|NCT02068833|Procedure|Gastrectomy|
194760|NCT02068833|Procedure|BPD-DS|
195042|NCT00125242|Behavioral|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
195043|NCT02061059|Other|with measurements|patient wears shoes produced with plantar pressure measurements
195044|NCT02063386|Drug|AZD1722|Single oral dose 15 mg of [14C]AZD1722
195045|NCT02063425|Drug|Fluoxetine|1 pill of 20mg / day, during 3 months
195046|NCT02063425|Drug|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
195047|NCT02063438|Procedure|Pericostal suture technique|
195048|NCT02063438|Procedure|Intracostal suture technique|
195049|NCT02063451|Dietary Supplement|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
195050|NCT00125502|Drug|Placebo|Normal saline solution
195051|NCT02063477|Dietary Supplement|Placebo|The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
194458|NCT00122694|Drug|carbon monoxide|
194459|NCT02035605|Drug|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
194460|NCT02035605|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
194461|NCT02035618|Other|Exercises|Strengthening and stretching
194462|NCT02035618|Other|Exercises + Manual Therapy|Mobilization; massage; post-isometric relaxation; strengthening; stretching
194463|NCT02035631|Behavioral|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
194464|NCT02035631|Behavioral|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
194465|NCT02035631|Behavioral|Minimal diet intervention|Some basic diet recommendations
194466|NCT02035631|Behavioral|Minimal physical activity intervention|Some basic recommendations on physical activity
194467|NCT02035644|Drug|Jinlida granules|
194468|NCT02035644|Drug|placebo granules|
194469|NCT00122707|Device|catheters|
194761|NCT02068846|Drug|Ciprofloxacin|20 (SGDHIV) Participants will be randomized to either Ciprofloxacin or a Placebo arm. Ciprofloxacin 500mg will be over encapsulated and taken 2x daily for 28days, Placebo will also be over encapsulated and taken 2x daily for 28days. This study is double blinded. Each study participant will be consented and be required to complete study questionnaires.
194762|NCT02068846|Drug|Placebo|
194763|NCT02068859|Drug|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
194764|NCT02068859|Drug|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
194765|NCT02068872|Procedure|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
194766|NCT02071420|Behavioral|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
178728|NCT01903837|Drug|Samidorphan (Medium Dose)|Tablets taken once daily
178729|NCT01903837|Drug|Samidorphan (High Dose)|Tablets taken once daily
178730|NCT01903837|Drug|Placebo|Tablets taken once daily
178731|NCT01903837|Drug|Olanzapine|Tablets taken once daily
178732|NCT01906346|Drug|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
178733|NCT01906359|Other|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
178734|NCT01906359|Other|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
178735|NCT01906359|Other|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
178736|NCT01906372|Drug|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
178737|NCT01906385|Radiation|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
178738|NCT01906398|Other|ketogenic diet|
178739|NCT01906411|Dietary Supplement|Dopamine depletion vs. Balanced aminoacid drink|
178740|NCT01906424|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
178741|NCT01906437|Device|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
178742|NCT00110786|Biological|Ragweed MATAMPL|
179045|NCT01936870|Drug|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
179046|NCT01936883|Radiation|HDR|High dose rate brachytherapy
179047|NCT01936883|Radiation|LDR|Low dose rate brachytherapy boost
179048|NCT01936896|Drug|Alpha 1-Antitrypsin|
183484|NCT02554838|Behavioral|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
183485|NCT00185614|Drug|Mycophenolate mofetil|15 mg/kg
183486|NCT02556970|Drug|Paracetamol|1g intraoperatively
183487|NCT02556970|Drug|Diclofenac|75mg intraoperatively
183488|NCT02556970|Device|Camera (5mm diameter 30 degree videothoracoscope)|
183489|NCT02556970|Device|Forceps grasper|
183490|NCT02556970|Drug|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
183491|NCT02556983|Radiation|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
183492|NCT02556996|Biological|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
183493|NCT00185861|Procedure|Stereotactic radiosurgery|
183494|NCT02556996|Other|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10^11 heat-killed bacteria per dose)
183495|NCT02557022|Other|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
183496|NCT02557035|Drug|Palonosetron|
183497|NCT02557035|Drug|Dexamethasone|
183498|NCT02557061|Procedure|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
183499|NCT02557061|Biological|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
183500|NCT02557074|Drug|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
183501|NCT02557074|Drug|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
183502|NCT02557087|Drug|Hyoscine|
183503|NCT02557087|Drug|Pethidine|
183206|NCT02563769|Drug|Intravenous cocaine|
183207|NCT02563769|Drug|Placebo|
183208|NCT02563782|Biological|Sub-retinal transplantation of MA09-hRPE cells|
183209|NCT02563782|Drug|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
183210|NCT02563782|Drug|Placebo tacrolimus and mycophenolate mofetil|
183211|NCT02563782|Procedure|Sham Surgery|
183212|NCT02563795|Drug|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
183213|NCT02563795|Drug|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
183507|NCT02557100|Drug|Methotrexate|
183508|NCT02557113|Procedure|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
183509|NCT02557113|Procedure|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
183510|NCT02557126|Drug|URC102|
183511|NCT02557126|Drug|Placebo|
183512|NCT02557139|Drug|KD025 Tablet|
183513|NCT02557139|Drug|KD025 as drug in capsule|
183514|NCT02557152|Device|GentleWave System Treatment|
183515|NCT02559505|Biological|Seasonal IIV|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
183516|NCT02559505|Biological|Seasonal LAIV|Flumist Quadrivalent (MedImmune) 0.2 mL administered intranasally
183517|NCT02559505|Other|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
183518|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
183519|NCT00186264|Drug|venlafaxine XR|
182911|NCT02570256|Behavioral|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
182912|NCT02570256|Behavioral|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
182913|NCT02570269|Procedure|AuraGain|Fiberoptic Intubation
182914|NCT02570269|Procedure|Slotted Guedeltubus|Fiberoptic Intubation
182915|NCT02570282|Drug|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
183214|NCT00002508|Procedure|peripheral blood stem cell transplantation|
183215|NCT00186875|Drug|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
183216|NCT02563808|Other|Survey: Standard|
183217|NCT02563808|Other|Survey: Regret|
183218|NCT02563821|Procedure|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
183219|NCT02563821|Drug|Levobupivacaine|
183220|NCT02563821|Drug|sufentanil|
183221|NCT02563821|Drug|clonidine|
183222|NCT02563821|Device|epidural catheter|
183223|NCT02563834|Drug|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
183224|NCT02563834|Drug|Saline|Saline infusion for control
183225|NCT02563834|Drug|Insulin|Insulin infusion for insulin/glucose clamp procedure
183226|NCT00186875|Drug|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
182620|NCT02035579|Behavioral|Aerobic Training Intervention|
182621|NCT02035579|Behavioral|Stretching Intervention|
182622|NCT02035592|Other|Full dose blueberry|Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.
Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
182623|NCT02540668|Drug|AZD3293|Administered orally
182624|NCT02540668|Drug|Warfarin|Administered orally
182625|NCT02540694|Device|Endosonography|
182626|NCT02540707|Drug|solifenacin|solifenacin 5 mg per day for 12 weeks
182627|NCT00184067|Biological|Montanide ISA 51|
182628|NCT02540707|Drug|mirabegron|mirabegron 25 mg per day for 12 weeks
182629|NCT02540720|Drug|Dexamethasone|
182630|NCT02540720|Drug|Gamma globulin|
182631|NCT02540720|Procedure|Hemoperfusion|
182632|NCT02540746|Behavioral|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
182633|NCT02540746|Behavioral|Motivational Enhancement|Three week Motivational Enhancement group
182916|NCT02570282|Drug|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
182917|NCT02570295|Other|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
182918|NCT00002510|Drug|cyclophosphamide|
182919|NCT00187408|Drug|Low Molecular Weight Heparin (dalteparin)|
182920|NCT02570308|Drug|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific TCR fused to anti-CD3
182921|NCT02570321|Procedure|Bacterial ulcer cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
182922|NCT02570321|Procedure|Bacterial ulcer control|For those bacterial ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for bacterial ulcers. This group will have their eyes irrigated with a balanced salt solution.
182320|NCT02545504|Drug|GS-5745 Placebo|Placebo to match GS-5745 administered intravenously on Days 1 and 15 of each treatment cycle
182321|NCT02545504|Drug|Leucovorin|LV administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
182322|NCT02545504|Drug|5-fluorouracil|5-FU administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
182323|NCT02545504|Drug|Oxaliplatin|OXA administered intravenously per standard of care on Days 1 and 15 of Cycles 1 to 6
182324|NCT02545517|Biological|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM)
182325|NCT00184717|Drug|somatropin|0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
182326|NCT02545530|Drug|transdermal clonidine|2.5mg/patch per week
182327|NCT02545543|Biological|bioCSL QIV|bioCSL QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.
182328|NCT02545543|Biological|Comparator QIV|The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.
182329|NCT02547571|Drug|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
182330|NCT02547571|Drug|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
182331|NCT02547571|Other|Clear liquid diet|
182332|NCT02547571|Other|Low residue diet|
182333|NCT02547571|Other|Early colonoscopy (stratified)|"Early" appointments: 7:30 AM to 10h30 AM
182334|NCT00184925|Procedure|Tracheostomy|trachesotomy with subglottic drainage
182634|NCT02540746|Behavioral|Family Skills Training|12-week group-based family skills training using Family Connections model
182635|NCT02540759|Dietary Supplement|Buglossoides oil|
182636|NCT02540759|Dietary Supplement|High Oleic Sunflower Oil|
181743|NCT02556528|Behavioral|Health Coaching|
181744|NCT00185770|Behavioral|Reducing television and other screen time (SMART curriculum)|
182029|NCT02551718|Other|Chemosensitivity Assay|Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations
182030|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
182031|NCT02551718|Other|Cytology Specimen Collection Procedure|Undergo blood or bone marrow collection
182032|NCT02551718|Genetic|Gene Expression Analysis|Analysis of leukemia cell genes to identify possible drug targets
182033|NCT02551718|Drug|In Vitro Sensitivity-Directed Chemotherapy|Receive personalized chemotherapy with one or more of the following drugs:
Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin
182034|NCT02551718|Genetic|Mutation Analysis|Analysis of leukemia cell genes to identify possible drug targets
182035|NCT02551731|Drug|Cannabidiol Oral Solution|20-40 mg/kg/day BID
182036|NCT02551744|Drug|proton pump inhibitor (PPI) group pantoprazole|pantoprazole 40 mg qd for 6 months.
182037|NCT02551744|Drug|histamine-2 receptor antagonist group famotidine|famotidine 40 mg qd for 6 months.
182038|NCT02551757|Device|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
182039|NCT02551757|Device|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
182040|NCT02551770|Device|Scaling and root planing with Emdogain|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
181450|NCT01939015|Device|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
181451|NCT01939015|Device|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
181452|NCT01939028|Procedure|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
181453|NCT01939028|Procedure|sentinel lymph node biopsy|Undergo SLN biopsy
181454|NCT01939028|Drug|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
181455|NCT01939028|Drug|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
181456|NCT01939028|Procedure|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
181457|NCT01939028|Procedure|lymphadenectomy|Undergo para-aortic lymphadenectomy
181745|NCT02556541|Procedure|IV puncture guided by ultrasound|
181746|NCT02558751|Biological|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
181747|NCT00186134|Behavioral|physical activity|
181748|NCT02558764|Device|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
181749|NCT02558777|Other|Multicomponent nurse-led intervention|Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the "intervention nurses", and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs.
181750|NCT02558790|Drug|MMFS-201-301|
181751|NCT02558803|Behavioral|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
181752|NCT02558816|Drug|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients will receive the combination of Ibrutinib + GA101, as soon as the step A patients are recruited and if no toxicity observed the step B will be initiated, Step B : 24 new patients will receive the combination of Ibrutinib + GA101 + GDC-0199
181147|NCT01946542|Drug|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
181148|NCT01946542|Other|placebo|
181149|NCT01946555|Drug|Morphine|
181150|NCT00114400|Drug|vitamin B12|
181151|NCT01946555|Drug|Fentanyl|
181152|NCT01946555|Drug|Methadone|
181153|NCT01946555|Drug|Buprenorphine|
181154|NCT01946555|Drug|Oxycodone|
181155|NCT01946555|Drug|Hydromorphone|
181156|NCT01946555|Drug|Tapentadol|
181157|NCT01946568|Drug|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients <5 years of age.
181158|NCT01946581|Procedure|Cataract Surgery|
181458|NCT01939041|Device|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
181459|NCT01939041|Device|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
181460|NCT00002109|Drug|Zidovudine|
181461|NCT00113802|Drug|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
181462|NCT01941329|Drug|Intravitreous injection of ranibizumab|
181463|NCT01941342|Procedure|Pancreatoduodenectomy|
181464|NCT01941342|Procedure|ENBD and Pancreatoduodenectomy|
181465|NCT01941342|Procedure|EBD and Pancreatoduodenectomy|
181466|NCT01941342|Procedure|PTCD and Pancreatoduodenectomy|
180797|NCT01951573|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
180798|NCT00114907|Behavioral|Consumption of black tea|
180799|NCT01951586|Drug|Denosumab|Denosumab, previously AMG 162, is a fully human monoclonal IgG2 antibody that binds with high affinity and specificity to the soluble and cell membrane-bound forms of human RANK ligand (RANKL, Kd 3 x 10-12 M), thereby disrupting the interaction with its target RANK.
180800|NCT01951586|Drug|Zometa|For the prevention of skeletal complications in subjects with bone metastasis who are not randomized to receive denosumab, zoledronic acid will be offered in a blinded manner through assignment by the IWRS/IVRS upon the request of the investigator.
180801|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
180802|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
180803|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
180804|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
181159|NCT01946594|Other|Acetaminophen|
181160|NCT01946594|Other|Placebo|
181161|NCT00114400|Drug|vitamin B6|
181162|NCT01946607|Drug|Citalopram|
181163|NCT01946607|Drug|Placebo|
181164|NCT01946620|Drug|Flutiform|
181165|NCT01946620|Drug|Formoterol|
181166|NCT01946633|Device|magnetic-controlled capsule endoscopy(Navicam)|
181167|NCT01946646|Drug|S-1-CCRT|
181168|NCT01946659|Behavioral|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
181169|NCT01946659|Other|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
180486|NCT01938144|Drug|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
180487|NCT01938144|Drug|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
180488|NCT01938144|Drug|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
180489|NCT01938157|Procedure|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
180490|NCT01938170|Biological|FluMist|Subjects receiving Flumist vaccine
180491|NCT01938183|Procedure|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
180492|NCT01938183|Drug|Metronidazole tablet|750 mg metronidazole tablets
180493|NCT01938183|Drug|placebo gel|semi-solid suspension containing carbopol
180494|NCT01938183|Drug|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
180495|NCT00113698|Drug|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
180805|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
180806|NCT01951612|Behavioral|Executive Function Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
180807|NCT01951612|Behavioral|Psychoeducational Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
180808|NCT01951625|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
180809|NCT00114920|Drug|Resiquimod|
180810|NCT01951625|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
180811|NCT01951625|Drug|Placebo|
180812|NCT01951638|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
180813|NCT01951638|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
180814|NCT01951638|Drug|Placebo|
180815|NCT01933204|Other|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
196287|NCT02038777|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
196288|NCT02038777|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
196289|NCT00002184|Drug|Adefovir dipivoxil|
196290|NCT00123019|Behavioral|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
196291|NCT02038790|Drug|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
196292|NCT02038790|Drug|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
196293|NCT02038816|Drug|Deferasirox + Azacitidine|Deferasirox:
20 mg/kg/d for < 14ml/kg/mo pRBCs (~ <4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients
196294|NCT02038816|Drug|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
196295|NCT02038829|Drug|Placebo|Placebo
196296|NCT02038829|Drug|SUN101 3 mcg|SUN-101 3 mcg bid
196297|NCT02038829|Drug|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
196298|NCT02038829|Drug|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
196299|NCT02038829|Drug|SUN-101 50 mcg|SUN-101 50 mcg bid
196300|NCT02038829|Drug|Aclidinium|Aclidinium 400 mcg bid
196301|NCT00123019|Behavioral|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
196302|NCT02038842|Biological|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
196303|NCT02038842|Biological|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
196304|NCT02038842|Biological|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
196612|NCT02072434|Drug|edoxaban|Factor Xa inhibitor anticoagulant, oral, edoxaban tablet, 60 or 30 mg once-daily (QD), 28-49 days dosing
196613|NCT02072434|Drug|Enoxaparin|Vitamin K antagonist, sq, 100mg/kg, 28-49 days
195646|NCT02048566|Device|ImaCor SM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
195951|NCT02041455|Drug|Melatonin and Amitriptylin|
195952|NCT02041481|Drug|MEK inhibitor MEK162|Given PO
195953|NCT02041481|Drug|leucovorin calcium|Given IV
195954|NCT02043691|Device|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
195955|NCT02043691|Device|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Zenith or Cook TX2 device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
195956|NCT02043704|Drug|IV Acetaminophen|Details covered in arm description.
195957|NCT02043717|Dietary Supplement|Vitamin D|According to the new guidelines by:
Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism [Internet]. 2012 May [cited 2012 Oct 31];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505
195958|NCT02043730|Drug|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
195959|NCT00123435|Device|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
195960|NCT02043730|Drug|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
195961|NCT02043743|Biological|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
195962|NCT02043756|Drug|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
195963|NCT02043756|Drug|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
195964|NCT02043782|Device|Coloplast Test|Newly developed 1-piece convex ostomy product
195355|NCT02056223|Drug|Intravenous ibuprofen|10 -5-5 mg/Kg once a day for three days
195356|NCT02056236|Drug|Anti-epileptic drugs|Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.
The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.
Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline "postanoxic coma". Reasons for withdrawal of treatment will be documented.
195647|NCT02048566|Other|Control PM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
195648|NCT00123955|Drug|Spironolactone|25mg tablet daily for 9 months
195649|NCT02051127|Other|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
195650|NCT00124137|Device|Aquadex system|
195651|NCT02051140|Dietary Supplement|Freeze-dried Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
195652|NCT02051140|Dietary Supplement|Strawberry Placebo|12g blue, strawberry-flavored powder, twice daily with water, for 90 days
195653|NCT02051153|Drug|Modafinil|Modafinil (2-[(Diphenylmethyl) sulfinyl]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg & Carter, 2008).
195654|NCT02051153|Drug|Placebo|
195655|NCT02051192|Behavioral|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
195656|NCT02051192|Other|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
195657|NCT02051218|Drug|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
195658|NCT02051218|Drug|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
195052|NCT02063477|Dietary Supplement|Oligopin®|Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:
- TOTAL POLYPHENOL CONTENT > 96
MONOMERS + PHENOLIC ACIDS 30
DIMERS >15
OTHER OLIGOMERS 50
PROCYANIDINS CONTENT (GPC) > 67
The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule
195053|NCT02063490|Behavioral|Adherence support|One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)
+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions
195054|NCT02063503|Other|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
195055|NCT02063516|Device|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
195056|NCT02063516|Device|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
195057|NCT02063529|Drug|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
195357|NCT02056236|Other|No anti-epileptic drugs|The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.
Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline "postanoxic coma". Reasons for withdrawal of treatment will be documented.
195358|NCT02056249|Other|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
195359|NCT02058550|Other|computer-assisted intervention|Receive reminder email survey
195360|NCT02058550|Behavioral|telephone-based intervention|Receive reminder phone call
195361|NCT02058563|Biological|Priorix®|1 dose administered as a subcutaneous (SC) injection.
195362|NCT02058563|Biological|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
195363|NCT02058576|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
195364|NCT02058576|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
195365|NCT02058589|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
194767|NCT02071420|Behavioral|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
194768|NCT02071420|Behavioral|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
194769|NCT02071420|Device|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
194770|NCT02071433|Procedure|Saphenous nerve blockade|
194771|NCT02071433|Procedure|Femoral nerve blockade|
194772|NCT02071459|Drug|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
194773|NCT02071459|Drug|placebo|initial period (4 weeks) followed by 8 weeks
194774|NCT00126308|Device|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
194775|NCT02071472|Other|DP medication reconciliation|
194776|NCT02071498|Device|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
194777|NCT02071498|Other|oral and written information|oral and written information about the most common errors of patients
194778|NCT02071511|Procedure|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
194779|NCT02071511|Procedure|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
195058|NCT02063529|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
195059|NCT02063555|Biological|DAR-901|
195060|NCT02063555|Biological|BCG|
195061|NCT00125515|Drug|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
195062|NCT02063555|Biological|Sterile saline|
195063|NCT02063568|Drug|Oxytocin|
195064|NCT02063581|Drug|ipatasertib (Capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
179049|NCT01936909|Drug|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
179050|NCT01936909|Drug|Anakinra (weeks 3-12)|
179051|NCT01936909|Drug|Placebo|
179052|NCT01936922|Device|GaitAid®|Provides visual and auditory cues for walking.
179053|NCT01936935|Other|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
179054|NCT00113581|Drug|EMD 72000 (matuzumab) + ECX|
179055|NCT01936935|Other|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
179056|NCT01936948|Procedure|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
179057|NCT01939301|Drug|Nitrogen + Oxygen|
179058|NCT01939314|Drug|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
179059|NCT01939314|Drug|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
179060|NCT01939327|Drug|Lenalidomide/Rituximab|
179061|NCT01939353|Drug|EB-1020 SR|100-500 mg flexible titration
179062|NCT01939353|Drug|Matching Placebo|
179063|NCT01939366|Drug|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
179064|NCT00113828|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.
179065|NCT01939366|Drug|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
179066|NCT01939366|Drug|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
179364|NCT01952704|Behavioral|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
179365|NCT01952730|Biological|GVAX|
183504|NCT00185874|Biological|Intratumoral Dendritic Cell Immunotherapy|
183505|NCT02557100|Drug|Abatacept|
183506|NCT02557100|Drug|Adalimumab|
178743|NCT01906450|Drug|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
178744|NCT01906450|Drug|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
178745|NCT01906476|Behavioral|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
178746|NCT01906476|Behavioral|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
178747|NCT01906489|Drug|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
178748|NCT01906489|Drug|Placebo|Oral placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
178749|NCT01906502|Device|Sensimed Triggerfish|
178750|NCT01906515|Device|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
178751|NCT01906528|Drug|Mivacurium|Effect of Mivacurium in males vs females
178752|NCT01906541|Genetic|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
178753|NCT01908881|Behavioral|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
178754|NCT01908881|Behavioral|Usual Care|According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the "Chile Crece Contigo" Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team.
178755|NCT01908894|Drug|BIOD-123|
178756|NCT01908894|Drug|BIOD-125|
178757|NCT01908894|Drug|Humalog|
183520|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
183521|NCT02559518|Device|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
183522|NCT02559518|Device|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
183523|NCT02559518|Device|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
183524|NCT02559518|Device|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
178763|NCT01908920|Other|SHAM|
178764|NCT01908920|Other|CONTROL|
178765|NCT01908933|Device|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
178766|NCT01908946|Behavioral|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
178767|NCT01908959|Behavioral|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
178768|NCT01908972|Drug|Prednisolone|2mg/kg/day for 16weeks
178769|NCT01908972|Drug|Propranolol|2mg/kg/day for 16weeks
178770|NCT01908985|Procedure|high intensity focused ultrasound for cyclodestruction in the eye|
178771|NCT00111020|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
178772|NCT01908998|Other|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
183227|NCT02565836|Drug|fixed-dose activated prothrombin complex concentrate|FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.
Check INR after infusion and may repeat dose if INR still elevated
183228|NCT02565836|Drug|variable-dose inactivated prothrombin complex concentrate|Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.
Check INR after infusion and may repeat dose if INR still elevated.
183229|NCT02565862|Drug|Daclatasvir|
183230|NCT02565862|Drug|Metformin|
183231|NCT02565875|Behavioral|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
183232|NCT02565875|Behavioral|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
183233|NCT02565875|Other|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
183234|NCT00187018|Biological|Bone marrow transplant|
183235|NCT02565888|Drug|Daclatasvir|
183236|NCT02565888|Drug|Atazanavir|
183237|NCT02565888|Drug|Ritonavir|
183525|NCT02559518|Device|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
183526|NCT02559531|Device|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
183527|NCT02559544|Radiation|[18F]Fluoroestradiol (FES) PET/CT Imaging|
183528|NCT02559557|Other|Educational Intervention|Participate in focus groups
183529|NCT02559557|Other|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
183530|NCT00186264|Drug|hydrocortisone|
183531|NCT02559557|Other|Quality-of-Life Assessment|Answer questionnaires
183532|NCT02559557|Other|Questionnaire Administration|Answer questionnaires
183533|NCT02559570|Drug|Linaclotide Dose A|
182923|NCT02570321|Procedure|Fungal ulcer cross-linking|Prior to receiving cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.
For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
182924|NCT02572505|Drug|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
182925|NCT02572531|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
182926|NCT02572531|Dietary Supplement|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
182927|NCT00187798|Drug|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
182928|NCT02572544|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
182929|NCT02572557|Other|Liquid nitrogen spray|TruFreeze Spray CryoTherapy using liquid nitrogen
182930|NCT02572570|Device|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Filtek Bulk Fill Posterior). Procedures will be done using local anesthesia and following ordinary restorative techniques.
182931|NCT02572570|Device|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Filtek Supreme Ultra). Procedures will be done using local anesthesia and following ordinary restorative techniques.
182932|NCT02572583|Drug|Liugan Shuangjie Heji|
182933|NCT02572583|Drug|Shufeng Jiedu Capsule|
183238|NCT02565888|Drug|Cobicistat|
183239|NCT02565901|Drug|Carboplatin|Given IV
183240|NCT02565901|Drug|Docetaxel|Given IV
183241|NCT02565901|Other|Laboratory Biomarker Analysis|Correlative studies
183242|NCT02565901|Drug|Sirolimus|Given PO
183243|NCT02565914|Drug|VX-661/ivacaftor|
183244|NCT02565914|Drug|ivacaftor|
183245|NCT00002509|Drug|cyclophosphamide|
182637|NCT02540772|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
182638|NCT00184080|Drug|Elsamitrusin|
182639|NCT02540785|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
182640|NCT02540785|Procedure|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
182641|NCT02540811|Device|dCELL® ACL Scaffold|
182642|NCT02540824|Drug|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
182643|NCT02540837|Drug|Bupivacaine|Obturator nerve block
182644|NCT02540837|Drug|Saline|Obturator nerve block with saline(placebo)
182645|NCT02540863|Other|myofascial release protocol and Rocabado exercise therapy|
182646|NCT02540863|Other|exercise therapy|
182647|NCT02540876|Drug|Ilorasertib|Given PO
182648|NCT02543268|Biological|Ad26.ZEBOV‐Batch #1|Ad26.ZEBOV ‐ Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
182649|NCT02543268|Biological|Ad26.ZEBOV‐Batch #2|Ad26.ZEBOV ‐ Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
182650|NCT02543268|Biological|Ad26.ZEBOV‐Batch #3|Ad26.ZEBOV ‐ Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
182651|NCT02543268|Biological|MVA‐BN‐Filo|MVA‐BN‐Filo‐ live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57.
182652|NCT02543268|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
182934|NCT02572583|Drug|Oseltamivir Phosphate Capsule|
182041|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
182042|NCT02554084|Device|Optical Coherence Tomography|Digital images of tear film
182043|NCT02554097|Procedure|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
182044|NCT00185549|Behavioral|CF. DOC|
182335|NCT02547571|Other|Later colonoscopy (stratified)|"Later" appointments: 10:30 AM to 4:30 PM.
182336|NCT02547584|Procedure|Catheter ablation|Pulmonary vein antrum isolation (PVAI) will be extended to the entire posterior wall down to the coronary sinus and to the left part of the septum. This intervention will be received by all as standard of care
182337|NCT02547597|Drug|Carvedilol|
182338|NCT02547597|Drug|Atenolol|
182339|NCT02547610|Device|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
182340|NCT02547623|Drug|Dexamethasone|depot intracameral
182341|NCT02547623|Drug|Prednisolone|Prednisolone eye drops 1%
182342|NCT02547636|Other|Observational study|No intervention will be used in this study.
182343|NCT02547649|Biological|V114 Formulation A|Formulation A of V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and 6B (4 mcg) in each 0.5 mL dose
182344|NCT02547649|Biological|V114 Formulation B|Formulation B of V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and 6B (4 mcg) in each 0.5 mL dose
182345|NCT00184925|Device|cannula with subglottic drainage|
182346|NCT02547649|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
182347|NCT02547662|Drug|Dexamethasone|Given PO
182348|NCT02547662|Drug|Ixazomib Citrate|Given PO
182349|NCT02547662|Other|Laboratory Biomarker Analysis|Correlative studies
182350|NCT02547662|Drug|Pomalidomide|Given PO
182351|NCT02547675|Drug|Rociletinib|Rociletinib will be administered to patients orally
181753|NCT02558829|Drug|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
181754|NCT02558829|Drug|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI > 30 kg/m2), intravenous injection, single dose
181755|NCT02558842|Other|Education Strategy|Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.
During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.
During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit.
181756|NCT02558855|Other|Thrust Joint Manipulation of the Lumbar Spine|
181757|NCT02558855|Other|Non-thrust Joint Manipulation of the Lumbar Spine|
181758|NCT00186147|Procedure|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
181759|NCT02558868|Drug|Oxaliplatin, Irinotecan|
181760|NCT02558881|Procedure|Virtual colonoscopy|
181761|NCT02558881|Procedure|Colon capsule|
182045|NCT02554097|Procedure|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
182046|NCT02554097|Procedure|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
182047|NCT02554097|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
182048|NCT02554123|Drug|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
182049|NCT02554123|Drug|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
182050|NCT02554136|Drug|HGP0918|
182051|NCT02554136|Drug|HGP0816|
182052|NCT02554136|Drug|HGP0918 + HGP0816|
182053|NCT02554149|Radiation|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
181467|NCT01941355|Behavioral|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
181468|NCT00114062|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
181469|NCT01941355|Behavioral|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
181470|NCT01941368|Dietary Supplement|Placebo|
181471|NCT01941368|Dietary Supplement|HMB-FA|
181472|NCT01941368|Procedure|High Intensity Interval Training|
181473|NCT01941381|Procedure|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
181474|NCT01941394|Biological|Mesenchymal stem cells|Mesenchymal stem cells infusion
181475|NCT01941407|Drug|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
181476|NCT01941433|Behavioral|Arthritis Health Journal|
181477|NCT01941446|Drug|Eravacyline and Moxifloxacin|
181762|NCT02558894|Drug|MEDI4736 monotherapy|MEDI4736 via IV infusion.
181763|NCT02558894|Drug|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
181764|NCT02558907|Other|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
181765|NCT02560948|Biological|gpASIT+TM|4 x 2 injections over 21 days
181766|NCT02560961|Other|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
181767|NCT02560961|Other|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
181768|NCT02560974|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
181769|NCT02560974|Drug|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m^2 on Day 1 of each 3-week cycle for 8 cycles.
181170|NCT01946672|Procedure|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
181171|NCT01946685|Drug|600 mg/day Mifepristone|
181172|NCT00114413|Drug|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
181173|NCT01946685|Drug|Placebo|
181174|NCT01946711|Drug|Budesonide|Inhalation
181175|NCT01949168|Drug|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
181176|NCT00114621|Procedure|Hematology|
181177|NCT01949168|Drug|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
181178|NCT01949181|Procedure|Lung surgery|
181179|NCT01949194|Drug|Regorafenib|The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A "light meal"consists of less than 30% fat and around 300-550 calories.
181180|NCT01949207|Procedure|EVLA|Endovenous laser ablation of great saphenous vein
181181|NCT01949207|Procedure|phlebectomies|removal of incompetent veins
181478|NCT01941472|Other|fluid administration|
181479|NCT00114075|Procedure|Surgery with gait analysis report|Orthopaedic surgery with access to gait analysis report
181480|NCT01941485|Device|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
181481|NCT01941485|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
181482|NCT01941498|Device|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
181483|NCT01941498|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
181484|NCT01941511|Drug|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
181485|NCT01941524|Drug|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
180816|NCT01933204|Drug|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
180817|NCT00113269|Drug|basiliximab|IV
180818|NCT01933217|Drug|Methylphenidate|
180819|NCT01933217|Drug|Placebo|
180820|NCT01933230|Device|Excel Cryo Cooling System|We will place an Excel Cryo Cooling System collar around your neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool as well. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar that delivers the cold. The cooling pack is similar to, but not the same as, the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration of the study. During the study and for two hours after, we will collect data concerning the brain temperature (if applicable), body temperature, brain oxygen level (if applicable) and pressure both in the head (if applicable) and in the blood (blood pressure).
2 hour neck cooling period
180821|NCT01933243|Drug|Fish oil|Participants will take 4 capsules daily
180822|NCT01933243|Drug|Placebo pill|Participants will take 4 capsules daily
180823|NCT01933256|Drug|HIP2B|
180824|NCT01933256|Drug|Placebo|
180825|NCT01933269|Drug|FACBC|
180826|NCT01933282|Drug|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
181182|NCT01949207|Procedure|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
181183|NCT01949233|Drug|Irbesartan 150-300mg capsules daily for 6 months|
181184|NCT01949233|Drug|Doxycycline 100-200mg capsules daily for 6 months|
181185|NCT01949233|Drug|Doxycycline placebo capsules daily for 6 months|
181186|NCT01949233|Drug|Irbesartan placebo capsules daily for 6 months|
181187|NCT00114621|Procedure|Urinalysis|
181188|NCT01949272|Device|esophageal pressure mesurement|"EXPRESS study" ventilatory setting the optimization of PEEP with esophageal pressure mesurement
181189|NCT01949285|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
181190|NCT01949298|Procedure|dental implant placement|
196614|NCT02072434|Drug|Warfarin|Vitamin K antagonist, oral, 1 or 2.5 mg tablet QD, 28-49 days
196615|NCT02072447|Drug|YH4808 PO and [14C]-YH4808 IV|
196616|NCT02072460|Other|electromyography|
196617|NCT02072460|Other|electroencephalography|
196618|NCT00126594|Biological|Recombinant Interferon Alfa-2b|Given SC
196619|NCT02074553|Drug|Ro542-4802/F08 (Test)|Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
196620|NCT02074553|Drug|Ro542-4802/F14 (Test)|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
196621|NCT02074566|Other|Cryoballoon ablation|PVI using cryoballoon
196622|NCT02074579|Drug|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
196623|NCT02074579|Drug|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
196624|NCT02074592|Behavioral|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
196625|NCT02074592|Behavioral|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
196626|NCT02074605|Biological|Interferon alpha|
196627|NCT02074618|Other|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
196628|NCT02074631|Drug|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
196629|NCT00126594|Other|Laboratory Biomarker Analysis|Correlative studies
196630|NCT02074631|Drug|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
195965|NCT02043782|Device|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
195966|NCT02043782|Device|Competitor soft convex|A commercially available soft convex product
195967|NCT02043795|Device|BVS, Abbott Vascular|The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
195968|NCT02043821|Drug|Capecitabine|14days
195969|NCT02043821|Other|placebo|14 days
196305|NCT02038855|Behavioral|Integrated Intervention for Dual Problems and Early Action|Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
196306|NCT02038868|Drug|ASP4901|oral
196307|NCT02038868|Drug|Tamsulosin|oral
196308|NCT02038868|Drug|Placebo|oral
196309|NCT02038881|Biological|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
196310|NCT00123292|Drug|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
196311|NCT02041481|Drug|fluorouracil|Given IV
196312|NCT02041481|Drug|oxaliplatin|Given IV
196313|NCT02041481|Other|pharmacological study|Correlative studies
196314|NCT02041481|Other|Laboratory Biomarker Analysis|Correlative Studies
196315|NCT02041494|Device|Ventralight|
196316|NCT02041494|Device|Strattice|
196317|NCT02041507|Other|Air insufflation method.|Air insufflation colonoscopy.
196318|NCT02041507|Other|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
196319|NCT02041507|Other|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
195659|NCT02051231|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
195660|NCT02051257|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm or TN/MEM-enriched T Cells given IV
195661|NCT00124137|Drug|IV diuretic|
195662|NCT02051257|Other|laboratory biomarker analysis|Correlative studies
195663|NCT02051270|Other|Descriptive study|More than 65 years old elders
195664|NCT02051283|Other|RFA|RFA
195970|NCT00123461|Drug|Hectorol (doxercalciferol capsules), 0.5mcg|
195971|NCT02043834|Other|Balance Training|Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as "ankle reaching" and "obstacle crossing" using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
195972|NCT02043847|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, or 9Gy.
195973|NCT02043847|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m2 (100mg/m2 day-2 and day-1) conditioning therapy prior to transplant.
195974|NCT02043847|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm3 over period of 3 days.
195975|NCT02046447|Drug|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
195976|NCT02046447|Other|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
195977|NCT02046447|Other|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
195978|NCT02046447|Other|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
195366|NCT02058589|Drug|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
195367|NCT02058602|Other|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
195368|NCT00124969|Drug|Amlodipine|10mg
195369|NCT02058615|Behavioral|Male Spouse Transition Toolkit|
195370|NCT02058628|Drug|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
195371|NCT02058628|Drug|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
195372|NCT02058641|Drug|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
195373|NCT02058654|Drug|Creatine|Creatine powder (5 g)
195374|NCT02058654|Drug|Placebo|Bulking agent powder (5 g)
195375|NCT02058667|Radiation|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
195376|NCT02058680|Biological|PSA/IL-2/GM-CSF|In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.
In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43.
195665|NCT02051296|Drug|Minocycline|RCT blinded placebo trial
195666|NCT02051296|Drug|placebo|
195667|NCT02051309|Drug|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
195668|NCT02051309|Drug|Placebo|
195669|NCT02051322|Device|Jet Nebulizer|
195670|NCT02051322|Device|Trunk Mask Nebulizer|
195671|NCT02051322|Device|Aerobika Nebulizer|
195672|NCT00124150|Drug|Intravenous magnesium sulfate infusion|80mg per day
195673|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
195674|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
195065|NCT02063581|Drug|ipatasertib (Tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
195066|NCT02066077|Device|Bilateral temporal MECT|
195067|NCT02066077|Device|The right temporal MECT|
195068|NCT02066077|Device|Bilateral frontal MECT|
195069|NCT02066090|Device|Real acupuncture|manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks
common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today
195070|NCT02066090|Device|Sham acupuncture|sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks
sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)
placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)
195071|NCT00125853|Drug|Atenolol|Atenolol 25mg daily
195072|NCT02066103|Drug|Paclitaxel|
195073|NCT02066116|Procedure|Kinect-based rehabilitation plus occupational therapy|The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
195074|NCT02066116|Other|sham virtual rehabilitation education plus occupational therapy|For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
195075|NCT02066129|Drug|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
195076|NCT02066129|Drug|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
195077|NCT02066142|Device|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
195078|NCT02066142|Device|Ultrasound|
195079|NCT02066155|Behavioral|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
195377|NCT02058693|Drug|mixed salts amphetamine|adjunctive to ADT
195378|NCT02058706|Drug|enzalutamide|Given PO
195379|NCT00124969|Drug|Placebo|10mg
195380|NCT02058706|Drug|bicalutamide|Given PO
195381|NCT02058706|Procedure|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
179366|NCT01952743|Procedure|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
179367|NCT01952743|Procedure|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
179368|NCT01952756|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
179369|NCT01952756|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
179370|NCT01952769|Biological|MDV9300|The study will be done in the following manner:
Evaluation of MDV9300 and radiation-
Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.
Cohort B -3 patiens: if no toxicity >grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given
Evaluation of MDV9300 and cyclophosphamide
After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:
Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2
179371|NCT01952782|Drug|Kisspeptin 112-121|Subjects will receive up to 10 intravenous doses of kisspeptin 112-121
179372|NCT01952782|Drug|Naloxone|Subjects will receive one intravenous dose of naloxone followed by an intravenous infusion of naloxone.
179373|NCT01952782|Drug|Gonadotropin Releasing Hormone (GnRH)|Subjects will receive up to 10 doses of intravenous Gonadotropin Releasing Hormone (GnRH)
179374|NCT00115037|Other|Treatment as Usual (TAU)|Responders are informed of the benefits of continued treatment with naltrexone and are given a four week supply of medication as well as a prescription for 3 months.
179375|NCT01952795|Behavioral|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
179376|NCT01952808|Behavioral|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
179377|NCT01934413|Other|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
179678|NCT01947855|Drug|Empagliflozin|Empagliflozin high dose tablet once daily
178758|NCT01908907|Dietary Supplement|DHA oil administered at 50 mg/d (0.18ml) Or MCT oil administered at 0.18 ml|
178759|NCT00002086|Drug|Zalcitabine|
178760|NCT00111007|Drug|Placebo|Placebo, 2 tablets bid Study Days 2-19
178761|NCT01908907|Dietary Supplement|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion|
178762|NCT01908920|Other|Osteopathic manipulative treatment|
179067|NCT01939366|Drug|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
179068|NCT01939366|Drug|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
179069|NCT01939379|Drug|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
179070|NCT01939379|Drug|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
179071|NCT01939392|Device|Renal Denervation (OneShot™ Renal Denervation System)|
179072|NCT01939405|Behavioral|built environment use counseling|
179073|NCT01939418|Drug|RAD001|Afinitor 5mg qd. po.
179074|NCT01939418|Drug|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
179075|NCT00113828|Procedure|T-cell depleted peripheral blood stem cell transplant|Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.
179076|NCT01939418|Drug|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
179077|NCT01939444|Drug|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
179078|NCT01939444|Drug|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
179079|NCT01939457|Drug|Misoprostol|
179080|NCT01939483|Drug|irinotecan hydrochloride|Given IV
179081|NCT01939483|Other|laboratory biomarker analysis|Correlative studies
179082|NCT01941784|Other|questionnaire administration|Ancillary studies
178773|NCT01909011|Device|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
178774|NCT01909011|Device|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
178775|NCT01949688|Biological|HLA-A*2402 or A*0201 restricted peptides|Open Label, Non-Randomized, Safety/Efficacy study:
HLA-A*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.
HLA-A*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.
178776|NCT00114686|Drug|lithium|
178777|NCT01949701|Biological|HLA-A*0201restricted URLC10 peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*0201restricted URLC10 peptides with adjuvant.
178778|NCT01949714|Procedure|Removal of adrenal tumor|
178779|NCT01949727|Other|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
178780|NCT01949740|Other|questionnaire administration|Ancillary studies
179090|NCT01941823|Drug|Carnitine|IV Carnitine (20 mg/kg/day) will be given daily to children in the intervention group for the duration of the study
179091|NCT01941836|Drug|ETC-1002|Patients receive ETC-1002
179092|NCT01941836|Drug|Ezetimibe|Patients receive ezetimibe
179093|NCT01941849|Drug|Vandetanib|100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
179094|NCT01941849|Radiation|131I-mIBG|Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
179095|NCT01941862|Behavioral|Psychoeducation and Cognitive Bias Modification|
179096|NCT01941875|Drug|Progesterone Effervescent Vaginal Tablets|Experimental
179097|NCT01941888|Drug|Propofol|
179098|NCT01941888|Drug|Midazolam|
179099|NCT00114101|Drug|Lenalidomide|Given PO
179100|NCT01941888|Device|Target Controlled Infusion|
179101|NCT01941901|Drug|Calcium electroporation|Intratumoral injection, once only treatment.
183534|NCT02559570|Drug|Linaclotide Dose B|
183535|NCT02559570|Drug|Linaclotide Dose C|
183536|NCT02561754|Behavioral|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
183537|NCT02561754|Behavioral|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
183538|NCT02561754|Other|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
183539|NCT02561767|Other|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
183540|NCT02561767|Other|Saline|Saline as placebo of MSCs
183541|NCT00000372|Drug|Clozapine|
183542|NCT00002508|Drug|carboplatin|
183543|NCT00186602|Behavioral|Peer counseling|
183544|NCT02561767|Drug|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
183545|NCT02561767|Drug|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
183546|NCT02561780|Behavioral|Curriculum|A mental health educational resource delivered in the classroom by trained educators
178781|NCT01949740|Procedure|quality-of-life assessment|Ancillary studies
178782|NCT01949753|Behavioral|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
178783|NCT01949753|Behavioral|Exposure therapy|Exposure with response prevention without pharmacological facilitation
178784|NCT01949766|Drug|Glycerol phenylbutyrate|
178785|NCT01949779|Device|TransForm Occlusion Balloon Catheter|
178786|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
178787|NCT00114686|Drug|divalproex|
178788|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
183246|NCT00187031|Drug|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
183247|NCT02565927|Device|Traditional airway stent|process airway stenting
183248|NCT02565927|Drug|Iodine-125 seeds|process intraluminal brachytherapy
183249|NCT02565940|Other|biopsy|
183250|NCT02565953|Device|Paclitaxel-releasing PTA balloon catheter|
183251|NCT02565953|Device|PTA balloon catheter|
183252|NCT02565966|Other|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
183253|NCT00187122|Drug|Prednisone|See Detailed Description section for description of treatment plan.
183254|NCT02568033|Drug|Cisplatin|
183255|NCT02568033|Drug|Docetaxel|
183256|NCT02568033|Drug|Paclitaxel|
183257|NCT02568033|Radiation|stereotactic radiosurgery|
183258|NCT02568046|Drug|Sym004|The Investigational Medicinal Product (IMP) is Sym004. Sym004 is a 1:1 mixture of 2 monoclonal Antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
183259|NCT02568046|Drug|Irinotecan|180 mg/m2 iv, infused over 60-90 minutes
183260|NCT02568046|Drug|Folinic Acid|400 mg/m2 iv, infused over 120 minutes concurrently with Irinotecan
178479|NCT01908413|Drug|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
178480|NCT01908426|Drug|Cabozantinib tablets|
178481|NCT01908426|Drug|Placebo tablets|
178482|NCT01908439|Other|whole-body vibration|High amplitude whole-body vibration
178483|NCT01908452|Drug|Pyridoxine|1200 mg/d during 12 weeks
178484|NCT01908465|Drug|Ebastine|
182935|NCT02572596|Drug|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
182936|NCT02572596|Drug|CTX|CTX 2.5/m2 for 2 days.
182937|NCT02572596|Drug|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
182938|NCT00187811|Procedure|Delta amino leavulinic acid photodynamic therapy|
182939|NCT02572609|Drug|Ambroxol hydrochloride soft pastille|
182940|NCT02572609|Drug|Mucosolvan ® adult syrup|
182941|NCT02572622|Other|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
182942|NCT02572622|Other|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
182943|NCT02572622|Other|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
182944|NCT02572622|Other|exercise|special lumbar stabilization exercises were applied in advanced protocol.
182945|NCT02572635|Biological|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
182946|NCT02572635|Biological|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
182947|NCT02354339|Other|Placebo|Intervention will be administered 30 minutes before meals
182948|NCT02354352|Drug|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
182949|NCT02354352|Drug|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
182950|NCT02354378|Drug|Dexmedetomidine|
182951|NCT02354378|Other|Memory Test|
182952|NCT02354391|Drug|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
182953|NCT02354391|Drug|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
182954|NCT02354391|Procedure|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
182352|NCT02547688|Device|Nasal High Flow|
182353|NCT02547701|Drug|P-3058|
182354|NCT02547714|Drug|secukinumab 150 mg|secukinumab 300 mg during Baseline Visit (Day 1) and at Week 1, 2, 3, 4, 8 and 12
182355|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
182356|NCT00185107|Drug|Colesevelam Hydrochloride|
182357|NCT02549612|Device|Moniri Otovent|Please see arm description.
182358|NCT02549625|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
182653|NCT00184496|Drug|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
182654|NCT02543281|Device|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
182655|NCT02543281|Device|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
182656|NCT02543294|Device|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
182657|NCT02543294|Device|Electrocardiogram|Electrocardiogram performed at baseline.
182658|NCT02543294|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
182659|NCT02543294|Behavioral|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
182660|NCT02543307|Procedure|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
182661|NCT02543320|Device|Electroencephalography (EEG)|Participants undergo a baseline EEG prior to starting radiotherapy, and during each neurotherapy session.
182662|NCT02543320|Behavioral|Questionnaires|Pain and symptom questionnaires completed at baseline, before each LORETA neurofeedback session, 1 week after completion of neurofeedback sessions, and at the end of radiotherapy.
182054|NCT02554162|Other|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
182055|NCT00185562|Drug|Adalimumab|
182056|NCT02554175|Drug|Propofol|Propofol was administered to achieve target propofol Ce
182057|NCT02554188|Biological|Seasonal influenza (flu) vaccine|Seasonal influenza (flu) vaccine
Fluzone Intradermal Vaccine (Sanofi Pasteur), for participants ages 18 - 64 years old
Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older
182058|NCT02554188|Other|Diet|A 5-day low calorie fasting-mimicking diet
182059|NCT02554201|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
182060|NCT02554201|Device|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
182061|NCT02554214|Device|Glafkos drainage device|
182062|NCT02554227|Other|Cytokine Profile|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
182063|NCT02554240|Drug|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
182359|NCT02549638|Genetic|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
182360|NCT02549651|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
182361|NCT02549651|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
182362|NCT02549651|Drug|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
182363|NCT02549677|Drug|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
182364|NCT02549677|Drug|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
182365|NCT02549677|Drug|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
181770|NCT02561000|Drug|PZ-128|
181771|NCT02561000|Drug|Placebo|
181772|NCT02561013|Device|3M™ Coban™ Custom Fit Compression System|3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.
The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together.
181773|NCT02561013|Device|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
181774|NCT02561026|Biological|Frozen plasma|patients randomized to receive frozen plasma transfusions
181775|NCT00002507|Radiation|radiation therapy|
181776|NCT00186511|Behavioral|supportive expressive group therapy using videoconferencing|
181777|NCT02561039|Drug|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
181778|NCT02561052|Procedure|hypoxia/hyperoxia|different levels of hypoxia/hyperoxia through changes in FiO2
181779|NCT02561065|Behavioral|Lifestyle intervention|Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.
The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.
A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday.
182064|NCT02554240|Drug|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
182065|NCT02556554|Device|Dexcom G4 Platinum CGM system|Intervention arm using the Dexcom G4 Platinum® CGM system during pregnancy
182066|NCT02556554|Device|Dexcom G4 Platinum CGM system with Share|Treatment arm using the Dexcom G4 Platinum® CGM system with Share™
182067|NCT02556567|Other|Fitbit® Charge HR wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
182068|NCT02556580|Drug|Albumin 20%|Intervention: intravenious infusion Drug: albumin
182069|NCT02556593|Radiation|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
182070|NCT02556593|Radiation|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
182071|NCT02556593|Drug|erlotinib|erlotinib 150mg daily
181486|NCT01941524|Drug|Beractant instillation|aEEG and NRs monitoring during beractant instillation
181487|NCT01941537|Drug|ILV-094|IV infusion of ILV-094
181488|NCT01944189|Dietary Supplement|Food|Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (> 5 to >15 kg receive 1 tablet and 15 to > 25 kg receive 2 tablets)
Food arms:
Standard arm = Milk
Experimental arm = maize porridge plus oil
Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)
Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)
181489|NCT01944202|Behavioral|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
181490|NCT01944215|Dietary Supplement|Meal|effect of meal
181491|NCT01944215|Other|Exercise|effect of exercise
181492|NCT00114205|Drug|docetaxel|
181493|NCT01944215|Radiation|Sestamibi|reduce radiation dose
181494|NCT01944215|Drug|Caffeine Tablet|effect of caffeine
181495|NCT01944215|Other|External Heating|Heating Pad and warm blanket robe
181496|NCT01944228|Device|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
181497|NCT01944228|Device|Sham Stimulation|Catheter placed in the IJV without stimulation
181498|NCT01944254|Procedure|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
181780|NCT02561078|Drug|Human regular U-500 insulin (CSII)|Administered SC
181781|NCT02561078|Drug|Human regular U-500 insulin (MDI)|Administered SC
181782|NCT02561091|Other|Placebo|
181783|NCT02561091|Drug|AM-111 0.4 mg/ml|
181784|NCT02561091|Drug|AM-111 0.8 mg/ml|
181785|NCT02561104|Procedure|Laser-assisted cataract surgery.|
181786|NCT02561104|Procedure|Traditional manual phacoemulsification|
181787|NCT02563067|Drug|QAW039|QAW039 Dose 2 once daily
181191|NCT01949311|Drug|Dupilumab (REGN668/SAR231893)|
181192|NCT01949324|Biological|Ciliary neurotrophic factor (CNTF)|
181193|NCT01949324|Procedure|Surgery|Surgery to implant device for NT-501 arm and sham surgery for Sham arm
181194|NCT01949337|Drug|enzalutamide|Enzalutamide 160 mg daily, orally
181195|NCT01949337|Drug|abiraterone|abiraterone 1000 mg daily, orally
181196|NCT01949337|Drug|prednisone|prednisone 5 mg twice daily, orally
181197|NCT01949350|Dietary Supplement|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
181198|NCT00114634|Dietary Supplement|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
181199|NCT01949350|Dietary Supplement|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
181200|NCT01949350|Dietary Supplement|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
181201|NCT01951703|Device|senofilcon A|Test, senofilcon A
181202|NCT01951716|Drug|Graded Glucose Infusion with Placebo|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes.
181203|NCT01951716|Drug|Graded Glucose Infusion with GIP Alone|Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes.
181499|NCT01944254|Procedure|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
181500|NCT01944254|Procedure|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
181501|NCT01944267|Procedure|Apically positioned flap|Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
Prepared surgical area will be measured apico-coronally and mesio-distally.
196908|NCT02066987|Behavioral|Action planning|It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).
I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).
196909|NCT02066987|Behavioral|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
196910|NCT02067000|Behavioral|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
196911|NCT00125918|Drug|placebo|placebo tablet taken by mouth once a day for 16 weeks
196912|NCT02067013|Drug|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
196913|NCT02067013|Other|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
196914|NCT02069808|Drug|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
196915|NCT00126191|Drug|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
196916|NCT02069808|Drug|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
196917|NCT02069808|Drug|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
196918|NCT02069808|Drug|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
196919|NCT02069808|Procedure|Transvaginal ultrasound guided needle aspiration of oocytes|
196920|NCT02069821|Drug|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
196921|NCT02069834|Drug|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
196922|NCT02069834|Drug|Arm 2 (control)|Continuation of existing HAART at the time of randomization
196923|NCT02069847|Drug|Budesonide|Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.
The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.
Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide.
196320|NCT02041520|Drug|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
196321|NCT00123292|Drug|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
196322|NCT02041520|Other|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
196323|NCT02041533|Biological|Nivolumab|
196324|NCT02041533|Drug|Gemcitabine|
196325|NCT02041533|Drug|Cisplatin|
196326|NCT02041533|Drug|Carboplatin|
196327|NCT02041533|Drug|Paclitaxel|
196631|NCT02074644|Procedure|Prostatic Arterial Embolization|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is "near stasis" in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way.
196632|NCT02074644|Procedure|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
196633|NCT02074657|Biological|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
196634|NCT02074670|Other|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
196635|NCT02074683|Procedure|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
196636|NCT02074683|Procedure|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
196637|NCT02036515|Drug|Placebo|Matching placebo for ertugliflozin 5 mg, oral, and matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
196638|NCT02036515|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
196639|NCT00122811|Drug|Indapamide SR 1.5mg; Perindopril 2-4mg|
196640|NCT02036515|Drug|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
195979|NCT02046460|Drug|Acetylsalicylic acid|acetylsalicylic acid, 100mg o.p.d.
195980|NCT02046460|Drug|vitamin K-antagonist|vitamin K-antagonist, dosage according to INR 2.0-3.0
195981|NCT02046473|Procedure|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
195982|NCT02046486|Drug|Ticagrelor 180mg whole tablets|
195983|NCT02046486|Drug|Ticagrelor 180mg crushed and dispersed|
195984|NCT02046499|Drug|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
196328|NCT02041533|Drug|Pemetrexed|
196329|NCT02041546|Drug|Lung lavage with surfactant|
196330|NCT02041546|Drug|Bolus surfactant|
196331|NCT02041572|Behavioral|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
196332|NCT00123292|Drug|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
196333|NCT02041598|Other|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
196334|NCT02041611|Procedure|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
196335|NCT02041650|Drug|Ticagrelor|
196336|NCT02041663|Biological|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
196337|NCT02041676|Procedure|Chest physiotherapy|
196338|NCT02043860|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
196339|NCT02043860|Procedure|Autologous Transplant|Subjects will receive standard melphalan 200mg/m2 (100mg/m2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
196340|NCT02043860|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m2 (100mg/m2 day-2 and day-1) conditioning therapy prior to transplant.
195675|NCT02053974|Drug|Spironolactone|Spironolactone
195676|NCT02053974|Other|Placebo|Placebo
195677|NCT02053987|Other|Intensive rehabilitation in the home.|
195678|NCT02054000|Drug|Tirofiban|Intracoronary administering of Tirofiban
195679|NCT02054000|Other|Placebo|Intracoronary serum physiologic
195680|NCT00124501|Behavioral|Biofeedback-assisted relaxation training|10 sessions BART
195681|NCT02054013|Procedure|Prostatic artery embolization|
195682|NCT02054013|Procedure|monopolar transurethral prostatectomy|
195683|NCT02054026|Behavioral|Reducing the Risk|
195684|NCT02054039|Device|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
195685|NCT02054039|Device|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
195686|NCT02054052|Drug|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
195687|NCT02054065|Other|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
195688|NCT02054078|Drug|Bevacizumab|Bevacizumab200mg by intrapleural administration
195689|NCT02054078|Drug|Pulvis talci|Pulvis talci 4g by intrapleural administration
195985|NCT00123656|Drug|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
195986|NCT02046499|Drug|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
195987|NCT02046512|Dietary Supplement|Probiotic|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
195988|NCT02046525|Biological|Autologous fecal microbiota therapy|
195989|NCT02046538|Drug|Leucovorin|400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
195990|NCT02046538|Drug|Oxaliplatin|85 mg/m2 IV over two hours
195991|NCT02046538|Drug|5-FU|400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
195382|NCT02058706|Drug|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
195383|NCT02058706|Drug|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
195384|NCT02058706|Other|laboratory biomarker analysis|Correlative studies
195385|NCT02061072|Device|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
195386|NCT02061085|Drug|Eribulina|
195387|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
195388|NCT02061098|Dietary Supplement|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
195389|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
195390|NCT02061098|Dietary Supplement|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
195391|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
195392|NCT02061098|Dietary Supplement|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
195393|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
195394|NCT00125255|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
195395|NCT02061098|Dietary Supplement|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
195396|NCT02061124|Drug|Sevelamer 1600 mg TID for 7 days|
195397|NCT02061124|Drug|Placebo 1600 mg TID for 7 days|
195398|NCT02061137|Drug|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
195690|NCT02054091|Dietary Supplement|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
179679|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
179680|NCT01947894|Other|Non Interventional Study|Non Interventional Study
179681|NCT01947907|Drug|ACP-001|Once weekly subcutaneous injection
179682|NCT01947907|Drug|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
179683|NCT01947920|Drug|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
179684|NCT01947920|Drug|Placebo|Size-matching capsules containing an appropriate inactive excipient
179685|NCT01947933|Biological|LY3074828 - IV|Administered IV
179686|NCT00002115|Drug|Adefovir|
179687|NCT00114530|Drug|Antithymocyte globulin, equine|
179688|NCT01947933|Biological|LY3074828 - SQ|Administered SQ
179689|NCT01947933|Biological|Placebo - IV|Administered IV
179690|NCT01947946|Biological|Benralizumab|Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.
Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive.
179691|NCT01947946|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
179692|NCT01947959|Drug|Rivaroxaban (Xarelto, Bay59-7939)|The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).
The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).
The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).
Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid]).
179693|NCT01947959|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
179694|NCT01947972|Dietary Supplement|Tailored fortification and nutritional status of preterm neonate|
179083|NCT01941784|Procedure|quality-of-life assessment|Ancillary studies
179084|NCT01941797|Behavioral|interruption of oral hygiene|
179085|NCT01941810|Biological|bovine lactoferrin supplement|Given PO
179086|NCT01941810|Other|questionnaire administration|Ancillary studies
179087|NCT01941810|Procedure|quality-of-life assessment|Ancillary studies
179088|NCT00114101|Other|Laboratory Biomarker Analysis|Correlative studies
179089|NCT01941810|Other|laboratory biomarker analysis|Correlative studies
179378|NCT01934439|Device|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
179379|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
179380|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
179381|NCT01934491|Behavioral|Cognitive Training A|
179382|NCT01934491|Behavioral|Cognitive Training B|
179383|NCT01934504|Procedure|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
179384|NCT00113360|Drug|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
179385|NCT01934530|Procedure|Soft Tissue Grafting|All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.
Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement.
179386|NCT01934543|Other|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
179387|NCT01934543|Other|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
179102|NCT01941901|Drug|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
179103|NCT01941914|Drug|Calcium chloride|
179104|NCT01941927|Drug|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 andMEK2 activation and kinase activity.
179105|NCT01941927|Drug|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Sincephosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA.GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
179106|NCT01941940|Drug|DMARDs|Permitted non-biologic disease-modifying antirheumatic drugs, at a stable dose that was initiated at least 4 weeks prior to baseline, are: azathioprine, chloroquine, hydroxychloroquine, leflunomide, methotexrate, and sulfasalazine. Treatment is according to standard of care.
179107|NCT01941940|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC weekly
179108|NCT01941953|Drug|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
179395|NCT01937104|Procedure|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
179396|NCT01937104|Procedure|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
179397|NCT01937104|Procedure|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
179398|NCT01937117|Procedure|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
179399|NCT01937117|Drug|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
179400|NCT01937117|Drug|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
179401|NCT01937130|Drug|IDN-6556|
179402|NCT01937130|Other|Placebo|
179403|NCT01937143|Behavioral|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant and at 12 months postpartum
179404|NCT00113607|Drug|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
178789|NCT01949805|Drug|Peg-P-IFN-alpha-2b (AOP2014)|
178790|NCT01949805|Drug|Hydroxyurea|
178791|NCT01949818|Drug|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
178792|NCT01949818|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
178793|NCT01949831|Other|Assessment of functional ability in combination with follow-up at home|
178794|NCT01949844|Drug|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
178795|NCT01949844|Drug|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
178796|NCT01949844|Device|Myocardial perfusion MRI|
178797|NCT00114985|Device|Prostate Immobilization Device|Device placed during radiation treatment
178798|NCT01952054|Drug|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
178799|NCT01952067|Procedure|line-to-line reaming and cementing technique|
178800|NCT01952067|Procedure|standard over-reaming with 2 broach sizes|
178801|NCT01952080|Drug|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
179109|NCT01944657|Device|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
179110|NCT01944657|Drug|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
179111|NCT01944670|Device|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
178485|NCT01908465|Drug|Placebo|
178486|NCT01908478|Drug|Veliparib|
178487|NCT01908478|Drug|Gemcitabine|
178488|NCT01908478|Radiation|Intensity modulated radiation therapy|
178489|NCT00110981|Drug|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
178490|NCT01908491|Device|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
178491|NCT01908491|Device|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
178492|NCT01908504|Other|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan — also called computerized tomography or just CT — combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
178493|NCT01908517|Behavioral|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
178494|NCT01910740|Other|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
178495|NCT01910740|Other|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
178802|NCT01952093|Behavioral|Home-based intervention program|
178803|NCT01952093|Behavioral|Clinical-based intervention program|
178804|NCT01952106|Other|play computer game|
178805|NCT01952119|Other|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
182955|NCT00158405|Drug|Lamivudine (3TC)|
183261|NCT02568046|Drug|Fluorouracil|After the Irinotecan and Folinic Acid infusions, 5-Fluorouracil (5-FU) 400 mg/m2 iv bolus, then 2400 mg/m2 5-FU infused over 46 hours
183262|NCT02568059|Drug|Sahastara remedy alcoholic extract|comparison of different dose of drug
183263|NCT02568085|Device|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
183264|NCT00002509|Procedure|autologous bone marrow transplantation|
183265|NCT00187122|Drug|Dexamethasone|See Detailed Description section for description of treatment plan.
183266|NCT02568098|Drug|IVM, IVM+PQ, IVM+DHA-PQP, IVM+DHA-PQP+PQ, ABZ, IVM+DHA-PQP+PQ+ABZ|Regimen 1: IVM; Regimen 2: IVM+PQ; Regimen 3: IVM+DHA-PQP; Regimen 4: IVM+DHA-PQP+PQ; Regimen 8: ABZ; Regimen 9: IVM+DHA-PQP+PQ+ABZ
183267|NCT02568098|Drug|PQ and DHA-PQP+PQ|Regimen 5: PQ; Regimen 7: DHA-PQP+PQ
183268|NCT02568098|Drug|DHA-PQP|Regimen 6: DHA-PQP
183269|NCT02568111|Drug|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
183270|NCT02568111|Drug|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
183271|NCT02568111|Drug|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
183272|NCT02568124|Drug|Tranexamic Acid|
183273|NCT02568124|Drug|Placebo|
183274|NCT02568137|Behavioral|Smart-phone based technology|
183275|NCT02568150|Biological|Single group, open-label|
183276|NCT00187135|Drug|Fentanyl|Fentanyl - 1 mcg/kg in 3 ml normal saline
Fentanyl - 0.5 mcg/kg in 3 ml normal saline
183277|NCT02568163|Other|Non surgical periodontal treatment|
183278|NCT02568176|Drug|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
183279|NCT02568176|Drug|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
183280|NCT02568176|Drug|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
182663|NCT02543320|Procedure|Neurotherapy|Participants undergo neurotherapy once a day, three days a week, for a total of 6 treatments over a two week time period, and during weeks 4 and 5 or 5 and 6 of radiotherapy, depending on when they start to experience pain of at least a 4 on a pain scale of 0-10 for three consecutive days. Neurofeedback training given in a video-game format.
182664|NCT00184509|Behavioral|integrated psychosocial treatment (behavior)|
182665|NCT02543346|Drug|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
182666|NCT02543346|Other|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
182667|NCT02545556|Procedure|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
182668|NCT02545569|Device|hearing aid (MD class IIa) - ITE, BTE, RIC|
182669|NCT02545582|Device|VITARIA System|Implantable vagus nerve stimulator
182670|NCT02545595|Drug|Sugammadex 1 mg/kg|
182956|NCT02354404|Biological|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
182957|NCT02354404|Biological|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
182958|NCT02354404|Biological|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
182959|NCT02354417|Biological|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
182960|NCT02354430|Behavioral|Water-exercise|An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.
One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice
Unsupervised water-exercises (The six AquaMama exercises)
Motivating weekly emails during the 12 week training period.
Brush up sessions is held once every month for guidance in performing the exercises.
182961|NCT02354443|Biological|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
182962|NCT02354482|Other|Care Transition|Patients and their caregivers transitioning care form one site of health care (e.g. hospital) to another (e.g., nursing home or care at home).
182963|NCT02354495|Dietary Supplement|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
182366|NCT02549690|Drug|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
182367|NCT00185107|Drug|Ezetimibe|
182368|NCT02549690|Drug|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
182369|NCT02549716|Drug|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
182370|NCT02549716|Drug|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
182371|NCT02549716|Drug|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
182372|NCT02549716|Drug|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
182373|NCT02549729|Behavioral|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
182374|NCT02549742|Procedure|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
182375|NCT02549742|Device|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
182376|NCT02549742|Drug|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
182671|NCT02545595|Drug|Sugammadex 2 mg/kg|
182672|NCT02545595|Drug|Sugammadex 4 mg/kg|
182673|NCT02545608|Device|Restylane Vital|
182674|NCT00184730|Drug|somatropin|
182675|NCT02545621|Other|RAGE TXNIP Inflammasome axis|
182676|NCT02545634|Dietary Supplement|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
182677|NCT02545634|Other|Placebo|
182678|NCT02545647|Device|BRYGB|65 patients undergo a banded RYGB
182072|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
182073|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
182074|NCT00185783|Drug|Hydrocortisone Administration (Standard of Care Therapy)|
182075|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
182076|NCT02556606|Drug|Midazolam|single 40 min infusion of MID 0.03mg/Kg
182077|NCT02556619|Behavioral|Palliative Care/Symptom Control|The initial consultation will follow a generalized template to pay specific attention to:
Establish palliative care goals
Assist in determination of Medical Power of Attorney
Discuss/plan code status/advance directives
Document palliative care goals
Symptom Assessment and Control
Pain-treatment with opioid and non-opioid medications
Itching-H2 blockers, steroids
Nutrition-appetite stimulated with Megace, review low sodium diet
Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed
Nausea- treated with anti-emetics
Jaundice and Body Image-explaining significance jaundice and counselling regarding symptoms
End-of-Life Care
Spiritual- a chaplain to meet and discuss religious preferences
Assess for distress- coping strategies and ensure interaction with Cancer Resource Center
Hospice- charity Hospice options for select patients.
182078|NCT02556632|Drug|Curcumin-based Gel|Applied topically
182079|NCT02556632|Procedure|Dermatologic Complications Management|Apply HPR Plus topically
182080|NCT02556632|Other|Laboratory Biomarker Analysis|Correlative studies
182081|NCT02556632|Other|Placebo|Apply placebo gel topically
182082|NCT02556632|Other|Questionnaire Administration|Ancillary studies
182083|NCT02556645|Other|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
182377|NCT02551770|Device|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
182378|NCT02551783|Procedure|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
182379|NCT02551783|Procedure|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
182380|NCT02551796|Procedure|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
181788|NCT02563067|Drug|Placebo|Placebo once daily
181789|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
181790|NCT02563093|Biological|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
181791|NCT02563093|Biological|Fluzone High Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
181792|NCT02563093|Biological|Fluzone High Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
181793|NCT02563106|Drug|SYN-004|
181794|NCT02563106|Drug|Placebo|
181795|NCT02563119|Procedure|Gastric Bypass or Sleeve gastrectomy|
181796|NCT00186823|Device|Miltenyi Biotec CliniMACS|A stem cell selection device.
181797|NCT02563132|Procedure|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
181798|NCT02563145|Behavioral|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
181799|NCT02563145|Behavioral|Treatment as usual|Psychoeducation, general counselling
181800|NCT02563158|Procedure|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
181801|NCT02563171|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2-3 clinical visits.
Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
181802|NCT02563171|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
181803|NCT02563184|Biological|Fluzone|
181804|NCT02563197|Device|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
182084|NCT02556645|Other|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
182085|NCT00185796|Procedure|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
182086|NCT02558920|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
181502|NCT01944267|Procedure|Free Gingival Graft|Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.
Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
No vertical incision made. Gingiva coronal to horizontal incision remains intact.
Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures
181503|NCT00114205|Procedure|therapeutic thoracoscopy|
181504|NCT01946893|Behavioral|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
181505|NCT01946893|Behavioral|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
181506|NCT01946906|Drug|Rifaximin|
181507|NCT01946932|Other|Temperature treatment|
181508|NCT01946945|Genetic|Next Generation Sequencing after Blastocyst biopsy|PGD using blastocyst biopsy and testing of the biopsy by NGS
181509|NCT01946958|Behavioral|Training in PC Triple P|PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
181510|NCT01946958|Other|Care As Usual|Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
181511|NCT01946971|Drug|Lansoprazole|
181512|NCT00114439|Drug|Lithium carbonate|
181513|NCT01946971|Drug|Placebo|
181805|NCT02563210|Other|airway resistance measurement|assessment of airway resistance
181806|NCT02563223|Other|Parabolic flight|
181807|NCT00186823|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
181808|NCT02563223|Device|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
196924|NCT02069860|Device|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone, a sealing cap, a twofold valve system and a catheter connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation
197216|NCT02061878|Drug|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
197217|NCT02061878|Drug|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
197218|NCT02061891|Procedure|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
197219|NCT02061891|Procedure|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
197220|NCT02061904|Radiation|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
197221|NCT02061904|Other|Short Form Health Survey 12|questionnaire for general health monitoring
197222|NCT02061904|Other|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
197223|NCT02061904|Other|VAS-pain|questionnaire for pain monitoring
197224|NCT02061904|Other|Harris Hip Score|questionnaire for hip function monitoring
197225|NCT02061917|Other|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
197226|NCT00125372|Drug|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
197227|NCT02061917|Other|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
197228|NCT02061917|Other|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
197229|NCT02064387|Drug|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
197230|NCT02064400|Other|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
197231|NCT02064400|Other|Semi-structured patient interview|Semi-structured patient interview
197232|NCT00125593|Drug|Placebo|Once daily
197233|NCT02064413|Device|ESS310 (BAY1454032)|
196641|NCT02036515|Drug|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
196642|NCT02036515|Biological|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
196643|NCT02036528|Drug|Gentamicin Topical Gel|
196644|NCT02036528|Drug|Ciprofloxacin|
196645|NCT02036528|Drug|Doxycycline|
196646|NCT02036541|Device|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
196647|NCT02036554|Drug|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
196648|NCT02036554|Drug|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
196925|NCT02069873|Behavioral|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
196926|NCT00126191|Drug|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
196927|NCT02069886|Drug|deferasirox|125, 250, 500 mg dispersable tablets
196928|NCT02069899|Drug|NI-0501|In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous study, and upon request of the treating physician, patients will continue receiving NI-0501 in the context of this study.
196929|NCT02069912|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
196930|NCT02069925|Behavioral|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
196931|NCT02069925|Behavioral|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
196932|NCT02072460|Other|approaches from psychophysics|
196933|NCT00126464|Drug|fulvestrant|
196341|NCT02043860|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm3 over period of 3 days.
196342|NCT02043886|Drug|Acarbose|Acarbose 50 mg by mouth given during Meal Test
196343|NCT02043886|Drug|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
196344|NCT00123474|Drug|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
196345|NCT02043899|Drug|[124I]meta-Iodobenzylguanidine|Single intravenous administration of [124I]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq [124I]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
196346|NCT02043912|Drug|Haloperidol|
196347|NCT02043925|Drug|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
196649|NCT02036554|Drug|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
196650|NCT00122824|Drug|duloxetine hydrochloride|
196651|NCT02036580|Biological|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
196652|NCT02036580|Biological|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
196653|NCT02036580|Other|Placebo|
196654|NCT02036593|Behavioral|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
196655|NCT02036606|Behavioral|questionary|
196656|NCT02036632|Device|Eye Patching|
196657|NCT02036645|Biological|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
196658|NCT02036645|Biological|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
196659|NCT02036645|Biological|IV Placebo|Placebo for IV injection
196660|NCT02036645|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
196661|NCT00122824|Drug|placebo|
195992|NCT02046538|Drug|Irinotecan|180 mg/m2 IV over 90 minutes
195993|NCT02046551|Drug|Atomoxetine|
195994|NCT02048566|Other|Control SM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
195995|NCT02048579|Behavioral|Behavior Therapy + Motivational Interviewing|
195996|NCT02048592|Dietary Supplement|Impact-Nutridrink|IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support /(Nutridrink) for another 8 weeks.
195997|NCT02048592|Dietary Supplement|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
195998|NCT02048605|Behavioral|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
195999|NCT02048605|Behavioral|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
196000|NCT02048618|Drug|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
196001|NCT02048618|Drug|Placebo|placebo oral tablets, intake once daily for 20 weeks
196002|NCT02048644|Drug|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
196003|NCT02048644|Drug|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
196004|NCT00123955|Drug|Placebo|Placebo tablet daily for 9 months
196005|NCT02048657|Device|Foley Airway Stylet Tool|
196348|NCT02043938|Drug|propofol|
196349|NCT02043938|Drug|sevoflurane|
196350|NCT02043938|Drug|remifenatnil|
196351|NCT02043951|Device|Lutonix Drug Coated Balloon Catheter|
196352|NCT02043964|Procedure|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
195691|NCT00124514|Drug|Triptorelin pamoate|IM injection given monthly
195692|NCT02054104|Biological|H1299 Lysate Vaccine|1x108 H1299 cells mixed with 1 mL ISCOMATRIX adjuvant diluted to 1 ISCO units administered in 2 IM injections q cycle. (1 cycle = 28 days) for 6 cycles if no toxicity and then up to an additional 6 cycles if immune response is evident after the first 6 cycles.
195693|NCT02054104|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle for 6 cycles if no toxicity and then up to an additional 6 cycles if immune response is evident after the first 6 cycles. Treatment is suspended while evaluating immune response.
195694|NCT02054104|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle for 6 cycles if no toxicity and then up to an additional 6 cycles if immune response is evident after the first 6 cycles. Treatment is suspended while evaluating immune response.
195695|NCT02054117|Other|Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
195696|NCT02054130|Drug|Placebo|Placebo
195697|NCT02054130|Drug|MEDI9929 - Low Dose IP|Subcutaneous repeating dose
195698|NCT02056262|Other|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
195699|NCT02056262|Biological|Saliva sampling|A saliva sample will be harvested.
195700|NCT02056262|Biological|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
195701|NCT00124709|Drug|Corticosteroid|conventional corticosteroid-based treatment
195702|NCT02056275|Other|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
195703|NCT02056275|Other|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
195704|NCT02056288|Drug|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
195705|NCT02056288|Drug|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
195706|NCT02056301|Drug|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
195707|NCT02056301|Drug|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
179695|NCT01950546|Drug|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
179996|NCT01942733|Drug|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
179997|NCT01942746|Dietary Supplement|Blueberry Juice S2|Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
179998|NCT01942746|Dietary Supplement|Blueberry Capsules S2|Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
179999|NCT01942746|Dietary Supplement|Placebo Capsule S2|Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
180000|NCT01942746|Dietary Supplement|Placebo Juice L1|Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
180001|NCT01942746|Dietary Supplement|Blueberry Juice L1|Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
180002|NCT00114127|Drug|Placebo|60mg placebo 1x per day
180003|NCT01942772|Device|Ankle-Foot Orthosis|
180004|NCT01942785|Drug|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
180005|NCT01942798|Device|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
180006|NCT01942798|Device|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
180007|NCT01942811|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
179388|NCT01934556|Drug|Ranibizumab 0.3 mg intravitreal injection|
179389|NCT01934556|Device|Guided Laser Photocoagulation|
179390|NCT01934569|Drug|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
179391|NCT01934582|Drug|UT-15 SR (treprostinil diethanolamine)|
179392|NCT01934582|Drug|treprostinil diethanolamine|Open label study drug.
179393|NCT01934595|Dietary Supplement|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
179394|NCT01934608|Behavioral|Refill synch|
179696|NCT01950559|Other|Oral food challenge|Oral foos challenge to determine allergy to say
179697|NCT00114777|Drug|CsA|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
179698|NCT01950585|Drug|Hydroxyurea|
179699|NCT01950598|Procedure|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
179700|NCT01950598|Procedure|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
179701|NCT01950611|Drug|Bortezomib|Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
179702|NCT01950637|Behavioral|No treatment given|Completion of 90-item online questionnaire.
179703|NCT01950637|Behavioral|survey|Completion of 58-item online questionnarie.
179704|NCT01950650|Behavioral|No treatment given|Survey conducted through computer-assisted telephone interviewing.
179705|NCT01950650|Behavioral|survey|Survey conducted via the Internet.
179706|NCT01950676|Device|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
179707|NCT01950689|Drug|Nimorazole|
179405|NCT01937143|Behavioral|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant and pamphlet with information about pain management during immunizations at 12 months postpartum
179406|NCT01937143|Behavioral|Control|General information about infant immunizations at birth of a newborn infant and at 12 months postpartum
179407|NCT01937156|Drug|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
179408|NCT01937156|Drug|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
179409|NCT01937169|Behavioral|Motor Task|A motor task executed for 30 minutes after drug adminidtration
179410|NCT01937169|Drug|Levodopa tablet|
179411|NCT01937169|Behavioral|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
179412|NCT01937169|Drug|Placebo pill|
179413|NCT01937182|Drug|Citalopram|Citalopram 10-40 mg per day administered orally
179414|NCT01937182|Drug|Placebo|1/2-2 tablets per day with no intrinsic drug activity
179415|NCT00113607|Drug|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
179714|NCT01932164|Procedure|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
179715|NCT01932177|Drug|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
179716|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
179717|NCT01932177|Drug|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
179718|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
179719|NCT00002105|Drug|Doxorubicin hydrochloride (liposomal)|
179720|NCT00113139|Behavioral|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
179112|NCT01944683|Other|Placebo|
179113|NCT01944683|Drug|GGF2|
179114|NCT00002112|Drug|Fluconazole|
179115|NCT00114231|Drug|oxaliplatin|Given IV
179116|NCT01944683|Drug|Midazolam|
179117|NCT01944696|Other|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
179118|NCT01944709|Biological|Dendritic cell application|
179119|NCT01944722|Device|BD HPV assay on Viper LT|The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
179120|NCT01944722|Procedure|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
179121|NCT01944735|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
179122|NCT01944735|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
179123|NCT01944748|Behavioral|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
179124|NCT01944761|Behavioral|Exercise Program|Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes. First, training in a circuit of developmentally appropriate activities (30 minutes) will occur. Second, the training circuit will be followed by participation in an organized sport (i.e. 30 minutes of floor hockey, basketball, or indoor soccer). Following the workout sessions the children will receive a healthy snack and have an opportunity for socialization (30 minutes).
179416|NCT01937195|Device|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
179417|NCT01937208|Radiation|intensity modulated radiation therapy in both arms|
179418|NCT01937208|Drug|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
179419|NCT01939639|Drug|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
179420|NCT00113854|Drug|Mannitol|
178806|NCT01952132|Drug|OMS643762|
178807|NCT01952132|Drug|Placebo|
178808|NCT00115011|Drug|Escitalopram|
178809|NCT01952145|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
178810|NCT01952145|Drug|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
178811|NCT01952184|Device|CBSvit HS device|closed vitrification with closed storage
178812|NCT01952184|Device|Cryotop SC device|open vitrification with closed storage
178813|NCT01952197|Other|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
178814|NCT01952210|Behavioral|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
178815|NCT01952210|Behavioral|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
178816|NCT01952223|Drug|Cabazitaxel|Cabazitaxel administered at 25mg/m2 as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
178817|NCT01952223|Radiation|Pelvic radiotherapy|Prostate+pelvic RT (2 Gy fractions, 5 times per week):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy
178818|NCT01952223|Radiation|prostate radiotherapy|Prostate-only RT (2 Gy fractions, 5 times per week):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy
178819|NCT00115024|Drug|Micronized 17B-estradiol|
178820|NCT01933971|Drug|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
179125|NCT01944774|Drug|Nemonoxacin 500 mg|IV Infusion, once daily for 7~14 days
179126|NCT00114231|Procedure|neoadjuvant therapy|Undergo surgery
179127|NCT01944774|Drug|Nemonoxacin 650 mg|IV Infusion, once daily for 7~14 days
183281|NCT02570321|Procedure|Fungal ulcer control|Prior to receiving sham cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.
For those fungal ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for fungal ulcers. This group will have their eyes irrigated with a balanced salt solution.
178496|NCT01910740|Other|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
178497|NCT01910753|Procedure|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
178498|NCT01910766|Drug|Coenzyme Q10|no more details
178499|NCT01910766|Drug|clomiphene citrate|
178500|NCT01910779|Procedure|100 joule as first biphasic shock energy|
178501|NCT01910779|Procedure|120 joule as first biphasic shock energy|
178502|NCT01910792|Device|UV lamp|UV light exposure 3 times per week for 12 weeks
178503|NCT00111319|Drug|bortezomib|
178504|NCT01910792|Device|UV lamp|Exposure to UV lamp 3 times a week for 12 weeks
178505|NCT01910805|Behavioral|Lifestyle and Risk Assessment class|Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.
The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices.
178506|NCT01910818|Device|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
178507|NCT01910818|Other|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
178508|NCT01910831|Drug|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
178509|NCT01910844|Drug|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
178510|NCT01910844|Drug|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
182964|NCT02354508|Drug|Pasireotide LAR|Pasireotide 40 mg and 60 mg.
182965|NCT02354521|Other|NO INTERVENTIONS|
182966|NCT00158405|Drug|Efavirenz (EFV)|
182967|NCT02354534|Drug|Artesunate Suppositories|
182968|NCT02540876|Other|Laboratory Biomarker Analysis|Correlative studies
182969|NCT00184093|Drug|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
182970|NCT02540889|Behavioral|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
182971|NCT02540902|Device|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
182972|NCT02540915|Other|Standard of Care - Registry|Standard of Care - Registry
182973|NCT02540928|Drug|AMG 319 hydrate|
182974|NCT02540928|Drug|Placebo|
182975|NCT02540941|Other|non|
183282|NCT02570334|Other|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
183283|NCT02570347|Drug|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
183284|NCT02570347|Biological|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
183285|NCT02570360|Behavioral|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
183286|NCT02570360|Behavioral|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
183287|NCT00187421|Procedure|Indocyanine green intraoperative angiogram and transit-time flowmetry|ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.
transit time flowmetry performed on all grafts after all grafts completed.
183288|NCT02570373|Drug|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
182679|NCT02545660|Other|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
182680|NCT02545660|Other|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
182681|NCT02545673|Behavioral|Enhanced linkage to care|
182682|NCT02545673|Behavioral|Standard-of-care plus|
182683|NCT02545686|Behavioral|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
182684|NCT02545686|Behavioral|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
182685|NCT00184743|Drug|somatropin|
182686|NCT02545686|Procedure|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
182687|NCT02545686|Procedure|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
182688|NCT02545699|Device|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
182689|NCT02545699|Device|Standard Colonoscopy|Standard Colonoscopy
182690|NCT02545712|Other|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
182691|NCT02545712|Other|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
182976|NCT02540954|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
182977|NCT02540967|Drug|Gadovist (Gadobutrol, BAY86-4875)|Gadovist dosage following summary of product characteristics
182978|NCT02540993|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
182979|NCT02540993|Drug|Placebo|Matching placebo to be taken orally, once daily.
182980|NCT00184106|Drug|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered opver 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
182381|NCT02551796|Procedure|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
182382|NCT02551796|Procedure|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
182383|NCT02551809|Biological|UB-311|
182384|NCT02551809|Drug|Placebo|
182385|NCT02551822|Device|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
182386|NCT02551848|Drug|Botulinum toxin type A (Xeomin®)|
182387|NCT00185250|Drug|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
182388|NCT02551861|Drug|Daclatasvir|
182389|NCT02551861|Drug|Sofosbuvir|
182390|NCT02551861|Drug|Ribavirin|
182391|NCT02551874|Drug|Saxagliptin|
182392|NCT02551874|Drug|Dapagliflozin|
182393|NCT02551874|Drug|Glargine insulin|
182394|NCT02551887|Behavioral|Automated Reminder|Automated reminder shown to provider
182395|NCT02551887|Behavioral|Automated Reminder Plus Script|Provider sees both reminder and script.
182396|NCT02551900|Other|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
182692|NCT02547727|Biological|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
182693|NCT00184938|Drug|morphine|
182694|NCT02547766|Drug|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
182087|NCT02558933|Dietary Supplement|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
182088|NCT02558946|Behavioral|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 2-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
182089|NCT02558946|Behavioral|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
182090|NCT00186173|Behavioral|After school sports program|After school team sports intervention designed specifically for overweight and obese children
182091|NCT02558959|Drug|Irinotecan|
182092|NCT02558959|Drug|Capecitabine|
182093|NCT02558972|Drug|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
182094|NCT02558972|Drug|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
182095|NCT02558972|Drug|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
182397|NCT02551900|Other|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
182398|NCT00185250|Drug|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
182399|NCT02554240|Drug|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
182400|NCT00185575|Drug|duloxetine|
182401|NCT02554253|Drug|Ketamine|Ketamine used for induction
181809|NCT02563236|Other|Parabolic flight|
181810|NCT02563249|Other|Parabolic flight|
181811|NCT02563249|Other|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
181812|NCT02563262|Other|body angles measurements during weightlessness|
181813|NCT02563275|Other|motion analysis system|
181814|NCT02563275|Other|parabolic flight|
181815|NCT02565251|Device|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
181816|NCT02565251|Device|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
181817|NCT02565264|Other|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
181818|NCT02565277|Biological|Influenza Vaccine|
181819|NCT02565277|Drug|Placebo|
181820|NCT02565290|Dietary Supplement|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
181821|NCT02565290|Dietary Supplement|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
181822|NCT02565303|Procedure|Intervertebral space|
181823|NCT02565303|Drug|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
181824|NCT02565316|Drug|Nepeta menthoides Boiss & Bohse freeze dried extract|
181825|NCT00186966|Drug|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
181826|NCT02565316|Drug|Sertraline|
197234|NCT02064426|Drug|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
197235|NCT02064426|Biological|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
197521|NCT02057107|Radiation|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
197522|NCT02057107|Drug|Cetuximab|Day -7 (One week prior to commencement of stereotactic radiosurgery):
Cetuximab, 400 mg/m2
Days 0 and 8 (The 1st and 2nd week of radiosurgery):
Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)
197523|NCT02057107|Drug|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
197524|NCT02057120|Procedure|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
197525|NCT02057120|Device|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
197526|NCT02057133|Drug|LY2835219|Administered orally.
197527|NCT02057133|Drug|Letrozole|Administered orally.
197528|NCT00124787|Drug|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
197529|NCT02057133|Drug|Anastrozole|Administered orally.
197530|NCT02057133|Drug|Tamoxifen|Administered orally.
197531|NCT02057133|Drug|Exemestane|Administered orally.
197532|NCT02057133|Drug|Everolimus|Administered orally.
197533|NCT02057133|Drug|Trastuzumab|Administered IV infusion.
197534|NCT02059421|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|- Therapy session administered by a clinical psychologist using web-based video conferencing software.
Therapy sessions will include:
Sleep restriction therapy
Stimulus control instructions
Sleep hygiene education
197535|NCT00125047|Biological|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
196934|NCT02072473|Procedure|Coronary sinus / left-sided slow pathway ablation|Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:
coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by
left-sided slow pathway ablation, using trans-septal approach.
196935|NCT02072486|Other|Laboratory Biomarker Analysis|Correlative studies
196936|NCT02072486|Drug|Sorafenib Tosylate|Given PO
196937|NCT02072499|Procedure|KTP Green Light Prostatectomy|
196938|NCT02072499|Device|Green Light|
196939|NCT02072499|Procedure|Open prostatectomy|
196940|NCT02072512|Drug|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
196941|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
196942|NCT02072512|Drug|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
196943|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
196944|NCT00126464|Drug|tamoxifen citrate|
197236|NCT02064439|Drug|BAY 59-7939|10 mg tablet once daily for 12 months
197237|NCT02064439|Drug|BAY 59-7939|20 mg tablet once daily for 12 months
197238|NCT02064439|Drug|ASA|100 mg tablet once daily for 12 months
197239|NCT02064452|Other|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
197240|NCT02064452|Behavioral|Placebo Comparator|Enhanced Usual Community Care-Waitlist
197241|NCT02064465|Drug|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
197242|NCT02064465|Drug|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
197243|NCT00002201|Drug|Ritonavir|
197244|NCT00125606|Procedure|conditioning for allogeneic HSCT|
197245|NCT02064491|Drug|Erlotinib|
196662|NCT02038894|Drug|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
196663|NCT02038894|Drug|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
196664|NCT00123019|Behavioral|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
196665|NCT02038894|Drug|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
196666|NCT02038894|Drug|Propofol|
196667|NCT02038907|Biological|Hepatitis A Vaccine|IM injection
196668|NCT02038907|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and aluminum hydroxide for IM injection
196669|NCT02038920|Drug|Vedolizumab|Vedolizumab intravenous injection
196945|NCT02072525|Biological|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
196946|NCT02072525|Biological|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
196947|NCT02072525|Biological|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
196948|NCT02072525|Biological|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
196949|NCT02072564|Other|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
196950|NCT02072577|Behavioral|Video|The student watched the video prepared individually in the ward where they were interned.
After this step, the student demonstrated again the procedure for oral hygiene.
At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
196951|NCT02072603|Other|HITSystem|Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action "alerts" for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants.
196952|NCT02072603|Other|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
196353|NCT02043977|Drug|propofol injectable emulsion|
196354|NCT02043990|Device|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
196355|NCT00123474|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
196356|NCT02044003|Device|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
196357|NCT02044081|Drug|C16G2|Active gel concentrations are 3.2 mg/mL C16G2, active rinses are 1.6 mg/mL C16G2. Placebo is vehicle without C16G2
196358|NCT02044081|Drug|Placebo|
196359|NCT02044094|Drug|Buprenorphine|A depot of buprenorphine 300 mg delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into the systemic circulation at a consistent rate over an approximately 28-day period.
196360|NCT02044094|Drug|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE Film stabilization period) as soon as they start to experience withdrawal symptoms. SUBOXONE is initially administered several times daily until the stable dose of between 8 mg and 24 mg daily is established.
196361|NCT02046551|Drug|Placebo|
196362|NCT02046564|Drug|ASC-01|
196363|NCT00123669|Drug|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
196364|NCT02046564|Drug|Placebo|
196365|NCT02046577|Dietary Supplement|Vitamin D3|Cholecalciferol administration
196366|NCT02046577|Dietary Supplement|Placebo|Placebo liquid
196367|NCT02046590|Drug|Propofol|
196368|NCT02046590|Other|General anesthesia|
196369|NCT02046603|Drug|DMARDs|non-biologic disease-modifying antirheumatic drugs, up to recommended dose allowed
196370|NCT02046603|Drug|corticosteroids|</= 10 mg/day prednisone or equivalent allowed
196670|NCT02038920|Drug|Vedolizumab placebo|Vedolizumab placebo
196671|NCT02038933|Drug|Nivolumab|
196672|NCT02038946|Drug|Nivolumab|
196006|NCT02048657|Device|introducer-tool|
196007|NCT02048670|Device|Balance Belt|Vestibular habituation therapy for sensitivity to visual motion, visual complex environments, head movements and visual patterns. The exercises will have 3-5 repetitions for each of the head movement or visual stimuli that cause and increase in the symptoms of unsteadiness or self motion. These exercises will be done while wearing the Balance Belt for feedback information as to how much the patient is swaying.
196008|NCT02048683|Drug|Short term sedation with sevoflurane in ICU|
196009|NCT02048696|Other|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
196010|NCT02048709|Drug|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
196011|NCT02048722|Drug|regorafenib|Given PO
196012|NCT02048748|Device|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
196013|NCT02048748|Device|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
196014|NCT02048761|Drug|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
196015|NCT02051335|Drug|Roflumilast|Roflumilast tablets
196016|NCT02051335|Drug|Roflumilast placebo|Roflumilast placebo-matching tablets
196017|NCT02051335|Drug|Donepezil|Donepezil overencapsulated tablets
196018|NCT02051335|Drug|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
196019|NCT02051335|Drug|Scopolamine|Scopolamine subcutaneous injection
196020|NCT02051348|Biological|Pylopass|Pylopass
196021|NCT02051348|Biological|Placebo|Placebo
196022|NCT02051374|Procedure|Decompression alone|
196023|NCT02051374|Procedure|Decompression followed by fusion with instrumentation|
196024|NCT02051387|Drug|Cannabidiol CR|
196025|NCT00124163|Procedure|Imaging procedure of CT colonography|
180008|NCT01942824|Behavioral|Text Messages|
180009|NCT01942837|Drug|Enzalutamide|Administration: 160 mg orally once daily. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.
Dosing: 160 mg orally taken once daily as four 40 mg capsules.
180296|NCT01937910|Behavioral|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
180297|NCT01937936|Behavioral|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
180298|NCT01937936|Behavioral|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
180299|NCT01937949|Device|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the leg (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
180300|NCT01937975|Drug|Grazoprevir|100 mg oral tablet administered once a day for 10 days
180301|NCT01937975|Drug|Elbasvir|50 mg oral tablet administered once a day for 10 days
180302|NCT00113672|Behavioral|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
180303|NCT01937988|Other|Doula Arm|
180304|NCT01938001|Drug|Rituximab|Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
180305|NCT01938001|Drug|Lenalidomide|Lenalidomide 20mg by mouth (PO) QD on Days 1 to 21 every 28 days up to 12 cycles
180306|NCT01938001|Drug|Rituximab|Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
180307|NCT01938001|Drug|Placebo|Placebo (identical matched capsule) PO QD Days 1 to 21 every 28 days
180308|NCT01938027|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
180309|NCT01938040|Biological|caldolor|
180310|NCT01938040|Other|sugar water/placebo|
179708|NCT00114777|Drug|Belatacept LI|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
179709|NCT01950689|Radiation|Radiotherapy|
179710|NCT01950702|Procedure|Laryngoscope assisted lightwand intubation|After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.
Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.
The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis.
179711|NCT01950702|Procedure|Lightwand intubation|After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.
Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.
After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand.
179712|NCT01950715|Device|sacral nerve stimulation|Sacral nerve stimulation
179713|NCT01950728|Device|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 50 Hz.
180010|NCT01942863|Procedure|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
180011|NCT00002113|Drug|Flucytosine|
180012|NCT00114283|Drug|lapatinib ditosylate|Given PO
180013|NCT01945619|Biological|Trivirus-Specific CTLs|Patients will receive up to 2 x 10^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
180014|NCT01945632|Device|conventional gracey curettes|
180015|NCT01945632|Device|Vertically oscillating ultrasonic device|
180016|NCT01945632|Device|piezoelectric ultrasonic scraper|
180017|NCT01945645|Behavioral|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
180018|NCT01945684|Drug|Botulinum toxin type A|Maximum dose 360 U
179721|NCT01932190|Procedure|Early RRT strategy|the "early" strategy : RRT is started immediately when a RIFLE F status is documented
179722|NCT01932190|Procedure|Delayed RRT strategy|The "delayed" strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the "Alert Criteria": see summary
179723|NCT01932203|Drug|aspirin|100mg once a day
179724|NCT01932203|Drug|cilostazol|200mg once a day
179725|NCT01932216|Device|robotic single-site cholecystectomy|
179726|NCT01932216|Device|Laparoscopic multiport cholecystectomy|
179727|NCT01932229|Drug|Afatinib treatment|
179728|NCT01932242|Biological|ETI-204|Monoclonal Antibody
179729|NCT01932242|Biological|Placebo|Placebo comparator
179730|NCT01932255|Procedure|prophylactic spinal tap|
179731|NCT00113139|Other|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
179732|NCT01932255|Procedure|no prophylactic spinal tap|
179733|NCT01932268|Drug|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
179734|NCT01932281|Dietary Supplement|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
179735|NCT01932281|Dietary Supplement|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
180030|NCT01945801|Other|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
180031|NCT01945801|Drug|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
180032|NCT01945814|Drug|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
180033|NCT01948128|Drug|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
179421|NCT01939652|Procedure|Restrictive VS Standard Fluid Regime|
179422|NCT01939652|Drug|Drag: Crystalloids and Colloids|
179423|NCT01939665|Device|NanoKnife "Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
179424|NCT01939691|Drug|Difluprednate 0.05% ophthalmic emulsion|eyedrop
179425|NCT01939691|Drug|Nepafenac 0.1% ophthalmic solution|eyedrop
179426|NCT01939691|Drug|Prednisolone acetate 1% ophthalmic suspension|eye drop
179427|NCT01939704|Other|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
179428|NCT01939704|Other|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
179429|NCT01939717|Other|Dance group|Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.
Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class.
179430|NCT01939730|Drug|Rituximab|375 mg/m^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
179431|NCT00002109|Drug|Zalcitabine|
179432|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
179433|NCT01939730|Drug|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
179434|NCT01939743|Drug|Diclofenac suppository plus lidocaine gel|
179435|NCT01939743|Drug|Lidocaine gel only|
179436|NCT01939756|Device|Intravesical baobab oil|Intravesical baobab oil
179437|NCT01939769|Other|Exercise - Low-intensity exercise|
179736|NCT01932294|Other|No Intervention|Medamacs does not provide intervention or therapy. Medamacs collects data of routine medical care for patients with advanced heart failure who do not receive a mechanical circulatory support device.
179737|NCT01932307|Procedure|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
179128|NCT01947413|Other|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
179129|NCT01947413|Other|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
179130|NCT01947426|Dietary Supplement|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
179131|NCT01947426|Dietary Supplement|Control (milk without DHA)|mothers consuming placebo product and their neonates
179132|NCT01947439|Procedure|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
179133|NCT01947452|Behavioral|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
179134|NCT00114491|Drug|Rosuvastatin|
179135|NCT01947452|Behavioral|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
179136|NCT01947465|Biological|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
179137|NCT01947478|Device|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
179138|NCT01947478|Device|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
179139|NCT01947491|Drug|DFD01 Spray|
179140|NCT01947491|Drug|Comp01 Lotion|
179141|NCT01947491|Drug|Vehicle Lotion|
179142|NCT01947491|Drug|Vehicle Spray|
179143|NCT01947504|Behavioral|eudcation and support intervention|
179438|NCT01939769|Other|Exercise - High-intensity exercise|
178511|NCT01910857|Behavioral|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
178512|NCT01910870|Drug|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
178513|NCT01910870|Drug|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
178514|NCT00111332|Behavioral|Progressive resistance and aerobic training|
178821|NCT01933971|Drug|Filgrastim reference|0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.
Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous
178822|NCT01933984|Drug|salmeterol/fluticasone|Each puff contains 25 mcg salmeterol /250 mcg fluticasone
178823|NCT01933984|Drug|ipatropium/salbutamol|Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg
178824|NCT01933984|Drug|Methylprednisolone|
178825|NCT01933984|Drug|Additional broncho-dilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
178826|NCT01933984|Other|Determining personal target airway resistance|Three consecutive doses of 4, 8 and 16 puffs of fenoterol MDI (100 mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15 minutes apart. The airway resistance measured 15 minutes later is assigned as this patient's personal target airway resistance.
178827|NCT00113321|Drug|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
178828|NCT01933984|Device|Ventilator support|
178829|NCT01933997|Drug|Metadoxine (MG01CI )|
178830|NCT01934010|Drug|AM-101|AM-101 gel for intratympanic injection
178831|NCT01934023|Drug|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
178832|NCT01934023|Drug|Placebo|
178833|NCT01934036|Dietary Supplement|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
178834|NCT01934036|Drug|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
178835|NCT01934049|Procedure|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
178836|NCT01934049|Drug|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
183289|NCT02570386|Procedure|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
183290|NCT02570386|Procedure|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
183291|NCT02570399|Radiation|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
183292|NCT02570412|Drug|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
183293|NCT02570425|Device|Training HCPs with a placebo Budesonide/Formoterol (BF) Spiromax® device|Training with a placebo Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
183294|NCT02570425|Device|Training HCPs with a placebo SYMBICORT® Turbohaler device|Training with a placebo SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
183295|NCT02570451|Other|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
183296|NCT02570451|Other|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
178515|NCT01903317|Other|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B [UVB] or ultraviolet A and psoralen [PUVA]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
178516|NCT01903317|Other|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
178517|NCT01903330|Drug|ERC1671|Given intradermally
178518|NCT01903330|Drug|GM-CSF|Given intradermally
178519|NCT01903330|Drug|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
178520|NCT01903330|Drug|Oral Control (Sucrose pill)|Given PO
178521|NCT01903330|Drug|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
178522|NCT01903330|Drug|Bevacizumab|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
178523|NCT01903343|Device|Shear Wave Elastography|
182981|NCT02541006|Drug|Tiotropium 18 mcg|tiotropium 18 mcg once a day
182982|NCT02541019|Drug|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
182983|NCT02541019|Drug|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
182984|NCT02541032|Procedure|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
182985|NCT02541032|Procedure|Standard dental treatment|Supragingival mechanical scaling and polishing.
182986|NCT02541032|Drug|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
182987|NCT02541045|Drug|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
182988|NCT02541045|Other|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
182989|NCT02541071|Behavioral|Stress Film|
182990|NCT02541071|Drug|Yohimbine|
182991|NCT00184119|Procedure|Psychiatric Intensive Care Unit|
182992|NCT02541071|Drug|Clonidine|
182993|NCT02541071|Drug|placebo|
182994|NCT02541084|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
182995|NCT02543359|Behavioral|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
183297|NCT02572648|Other|Brain Imaging (Neuroimaging)|Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.
Total time in scanner will be approximately 53 minutes.
183298|NCT02572648|Other|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 & 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
183299|NCT00187837|Procedure|Stepwise Excavation, one completed excavation|
182695|NCT02547779|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
182696|NCT02547779|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
182697|NCT02547792|Biological|Influenza B Oral Vaccine Tablets|Enteric coated tablet for oral delivery
182698|NCT02547805|Drug|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
182699|NCT02547805|Drug|Placebo|Placebo 5 capsules PO TID with meals
182700|NCT02547818|Drug|ALZT-OP1a|AB polymerization inhibitor
182701|NCT02547818|Drug|ALZT-OP1b|Anti-inflammatory
182702|NCT02547818|Other|Placebo ALZT-OP1a|Non-active capsules
182703|NCT02547818|Other|Placebo ALZT-OP1b|Non-active tablets
182704|NCT00184938|Drug|naloxone|
182705|NCT02547831|Other|Observational approach|Patients will be placed under wait and see approach without any specific treatment
182706|NCT02547844|Drug|efavirenz + emtricitabina + tenofovir|
182707|NCT02547844|Drug|rilpivirina + emtricitabina + tenofovir|
182708|NCT02547857|Other|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
182709|NCT02547870|Drug|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
182710|NCT02547870|Drug|Rilpivirine Long-Acting Parenteral Formulation (RPV‐LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
182711|NCT02547870|Drug|Aged RPV‐LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
182712|NCT02547883|Drug|Cessation of statin|The intervention evaluated is the cessation of statin
182713|NCT02547896|Drug|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
182714|NCT02547896|Drug|Diclofenac|The patients will receive only diclofenac
182996|NCT02543359|Behavioral|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
182402|NCT02554253|Drug|Propofol|Propofol for induction
182403|NCT02554266|Device|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
182404|NCT02554279|Drug|menotropin|
182405|NCT02554279|Drug|recombinant FSH|
182406|NCT02554292|Device|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
182407|NCT02554305|Device|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
182408|NCT02554305|Device|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
182409|NCT02554318|Drug|Rifampicin|
182410|NCT02554318|Drug|Isoniazid|
182411|NCT00185588|Drug|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
182412|NCT02554318|Drug|Pyrazinamide|
182413|NCT02554318|Drug|Ethambutol|
182414|NCT02554318|Dietary Supplement|Fermented soybean|
182415|NCT02554331|Radiation|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
182416|NCT02554331|Behavioral|neuropsychological evaluation|Assessment of:
overall cognitive function
executive functions
visuospatial functions
Nonverbal memory
verbal memory
Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities
Beck Depression Inventory
182417|NCT02554331|Other|Gait recording with sensors|Gait recording with sensors
182418|NCT02554344|Drug|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
182715|NCT00184938|Drug|Technetium-TC99m-labeled Annexin A5|
182716|NCT02547909|Procedure|probe-based Confocal Laser Endomicroscopy|Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.
At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue.
182717|NCT02547909|Device|Cellvizio|
182096|NCT02558972|Drug|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
182097|NCT02558985|Procedure|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
182098|NCT02558998|Other|Survey|
182099|NCT02559024|Drug|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
182100|NCT00186524|Behavioral|Breast Cancer Support Group|
182101|NCT02561117|Drug|Metronidazole|
182102|NCT02561130|Drug|insulin glargine|
182103|NCT02561130|Drug|Metformin|
182104|NCT02561130|Drug|Forxiga|
182105|NCT02561130|Behavioral|Lifestyle therapy|
182106|NCT02561143|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
182107|NCT02561143|Dietary Supplement|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
182108|NCT02561143|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
182109|NCT02561143|Other|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
182110|NCT02561156|Drug|TAK-653 Placebo|TAK-653 placebo-matching tablets
182111|NCT00186537|Drug|Rosiglitazone|
182112|NCT02561156|Drug|TAK-653|TAK-653 tablets
182113|NCT02561169|Drug|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
197536|NCT02059421|Other|Johrei therapy|Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.
Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.
Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.
Therapy will be administered without physical contact.
During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient.
197537|NCT02059434|Drug|LAS190792 Dose 1|
197538|NCT02059434|Drug|LAS190792 Dose 2|
197539|NCT02059434|Drug|LAS190792 Dose 3|
197540|NCT02059434|Drug|LAS190792 Dose 4|
197541|NCT02059434|Drug|LAS190792 Dose 5|
197542|NCT02059434|Drug|LAS190792 Dose 6|
197836|NCT02052037|Dietary Supplement|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
197837|NCT02052037|Dietary Supplement|Egg exclusion|Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.
During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks.
197838|NCT02052050|Other|core stability|
197839|NCT02052063|Device|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
197840|NCT02052063|Device|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
197841|NCT00124254|Other|Usual care|Non-surgical usual care
197842|NCT02052076|Behavioral|Meal pattern|
197843|NCT02052089|Procedure|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
197844|NCT02052089|Procedure|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (<0.2 mJ/mm2) or high energy (>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
197246|NCT02064491|Drug|Chemotherapy|
197247|NCT02064504|Drug|GSK961081|Dry white to off white powder
197248|NCT02064504|Drug|Fluticasone furoate|Dry white powder
197249|NCT02064517|Device|MTA|Creation of a barrier apicale in the MTA
197250|NCT02064517|Device|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
197251|NCT02064530|Drug|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
197252|NCT02064530|Drug|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
197253|NCT02067026|Dietary Supplement|Aleurone|
197254|NCT02067026|Dietary Supplement|Placebo|
197255|NCT02067039|Device|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home & Sure Check HIV tests
197256|NCT02067052|Procedure|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
197257|NCT02067052|Procedure|Surgery|Vulvectomy & lymphadenectomy
197258|NCT02067065|Drug|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
197543|NCT02059434|Drug|LAS190792 Dose 1 (Part 2)|
197544|NCT02059434|Drug|LAS190792 Dose 2 (Part 2)|
197545|NCT02059434|Drug|Tiotropium 18 μg|
197546|NCT00125047|Biological|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
197547|NCT02059434|Drug|Indacaterol 150 μg|
197548|NCT02059434|Drug|Placebo|
197549|NCT02059447|Other|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
197550|NCT02059447|Behavioral|Mindfulness Based Cognitive Therapy|
197551|NCT02059447|Behavioral|Relaxation Therapy|
196953|NCT02072616|Other|Pancreatic adenocarcinoma diagnosis|
196954|NCT02072629|Other|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
196955|NCT00126464|Procedure|conventional surgery|
196956|NCT02072642|Device|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
196957|NCT02072642|Device|Placebo light therapy|4 weeks with Placebo light therapy
196958|NCT02074709|Drug|Plain bupivacaine|Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .
First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn
196959|NCT02074709|Drug|Liposomal bupivacaine|Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV
First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn
196960|NCT02074735|Drug|Placebo|Inactive ingredient matching the active comparator in appearance
196961|NCT00126607|Biological|trastuzumab|Given IV
196962|NCT02074735|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
197259|NCT02067065|Drug|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
197260|NCT02067065|Procedure|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
197261|NCT00125931|Drug|Talwin Nx|Talwin NX 50mg po twice
197262|NCT02067078|Drug|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
197263|NCT02067078|Drug|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
197264|NCT02067078|Drug|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
197265|NCT02067091|Device|stent implant in a coronary artery|Implantation of device called a stent in a coronary artery
Percutaneous coronary intervention
197266|NCT02067104|Drug|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
197267|NCT02067104|Drug|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
196673|NCT02038959|Other|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
196674|NCT02038972|Genetic|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
196675|NCT00123032|Behavioral|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
196676|NCT02038985|Other|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
196677|NCT02038998|Device|Exer-Rest® TL|Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
196678|NCT02039011|Drug|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
196679|NCT02039011|Drug|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
196680|NCT02039024|Drug|18F- DTBZ|During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.
During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
196681|NCT02041676|Procedure|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
196682|NCT02041689|Behavioral|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
196683|NCT02041689|Behavioral|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
196963|NCT02074761|Device|SImmetry|The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.
The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.
196964|NCT02074774|Device|Aeolus|Automated FiO2 regulator that responds to pulse oximetry measures
196026|NCT02051387|Drug|Cannabidiol|
196027|NCT02051387|Drug|Amisulpride|
196028|NCT02051387|Drug|Olanzapine|
180961|NCT01946529|Drug|ifosfamide|Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5.
180962|NCT00114400|Drug|folic acid|
180963|NCT01946529|Drug|etoposide|Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5.
180964|NCT01946529|Drug|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m^2 PO once daily, days 1-5.
180965|NCT01946529|Drug|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m^2 IV once day 1 and day 8.
180966|NCT01946529|Drug|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
180967|NCT01946529|Drug|sorafenib|Dosage and route of administration: 90 mg/m^2/dose PO BID
180968|NCT01949025|Other|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
180969|NCT01949038|Drug|Oral alprazolam|
180970|NCT01949038|Drug|Sublingual alprazolam|
180971|NCT01949038|Drug|Oral placebo|
180972|NCT01949038|Drug|Sublingual placebo|
180973|NCT01949051|Drug|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
180974|NCT01949051|Drug|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
180975|NCT01949064|Device|Grindcare|
180976|NCT00114621|Drug|Anthrax Vaccine|
180977|NCT01949064|Device|Michigan-type occlusal splint|
180978|NCT01949090|Biological|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
180311|NCT01938053|Other|Call when test results are ready|Patients are called when the test results are ready
180312|NCT01938053|Other|Text message when test results are ready|Patients receive a text message when results are ready
180313|NCT00113685|Drug|Hypertonic Saline-Dextran Solution|
180314|NCT01938053|Other|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
180625|NCT01932996|Drug|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
180626|NCT01932996|Behavioral|Intensive Smoking Intervention|Weekly individual CBT smoking cessation sessions for 3 months followed by monthly booster group sessions for 3 months
180627|NCT01932996|Behavioral|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
180628|NCT00000302|Drug|Buprenorphine|
180629|NCT00002105|Drug|Bleomycin sulfate|
180630|NCT00113243|Drug|adult stem cells|
180631|NCT01933022|Drug|Eligard|Subcutaneous Injection
180632|NCT01933035|Other|Immune Thrombocytopenics|Full blood count with extended platelet parameters
180633|NCT01933035|Other|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
180634|NCT01933035|Other|Control Population|Full blood count with extended platelet parameters
180635|NCT01933048|Drug|FluMist|FluMist Intranasal Vaccine
180636|NCT01933061|Drug|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
180637|NCT01933061|Drug|Abraxane|Abraxane 150 mg/m^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
180638|NCT01933087|Behavioral|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
180639|NCT01933100|Other|Experimental Diet|
180640|NCT01933113|Device|Deep Brain Stimulation of the Lateral Hypothalamic Area|
180019|NCT01945710|Drug|E7389-LF|
180020|NCT01945736|Drug|Methadone|To determine the PK of enteral methadone in children > or = 90 days and <18 years treated for opiate withdrawal per routine medical care.
180021|NCT01945749|Drug|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
180022|NCT01945749|Drug|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
180023|NCT00114283|Other|laboratory biomarker analysis|Correlative studies
180024|NCT01945749|Other|Exercise therapy|The exercise is commenced 2 weeks after injection.
The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.
In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities.
180025|NCT01945762|Drug|Vandetanib 300 mg|Vandetanib commercial tablets
180026|NCT01945775|Drug|talazoparib|Until progression or unacceptable toxicity develops
180027|NCT01945775|Drug|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
180028|NCT01945788|Drug|Teriparatide (rDNA origin)|
180029|NCT01945801|Drug|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
180315|NCT01938066|Device|Procellera|bioelectric wound dressing
180316|NCT01938066|Device|negative pressure therapy|
180317|NCT01938079|Drug|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO (RASS -5).
180318|NCT00113932|Procedure|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, & every 2 weeks until HB >12 gm/dl***; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount <30,000/μl
180319|NCT01940393|Drug|Fexofenadine|Drug administration
180320|NCT01940393|Drug|Ebastine|Drug administration
180321|NCT01940393|Drug|Bilastine|Drug administration
180322|NCT01940406|Procedure|Stimulation procedure|Device
180323|NCT01940419|Drug|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
180034|NCT01948128|Other|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
180035|NCT01948141|Drug|nintedanib|Given PO
180036|NCT01948141|Other|laboratory biomarker analysis|Correlative studies
180037|NCT01948167|Behavioral|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
180038|NCT01948167|Behavioral|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
180039|NCT01948180|Biological|CMD-003|Autologous EBV-specific T-cells
180040|NCT00114530|Radiation|Total body irradiation (TBI)|used to eradicate the immune system thought to be causing the systemic sclerosis
180041|NCT01948193|Biological|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
180042|NCT01948219|Device|ENTegral Artificial Larynx implant|
180043|NCT01948232|Drug|Perindopril|Angiotensin converting enzyme inhibitor
180044|NCT01948245|Device|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
180045|NCT01948245|Device|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
180046|NCT01948271|Drug|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
180334|NCT01940471|Drug|Placebo to match tenofovir alafenamide|Placebo to match tenofovir alafenamide administered as a tablet orally once daily
180335|NCT01940471|Drug|Placebo to match tenofovir DF|Placebo to match tenofovir DF administered as a tablet orally once daily
180336|NCT01940497|Drug|anthracycline|every 3 weeks, 4 cycles prior to initiation of Herceptin treatment
180337|NCT01940497|Drug|taxane|paclitaxel weekly or docetaxel every 3 weeks for 12 weeks, in combination with Herceptin
179738|NCT01934751|Other|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
179739|NCT01934751|Other|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
179740|NCT01934777|Drug|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
179741|NCT01934777|Drug|placebo pearls|placebo
179742|NCT01934790|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
179743|NCT01934803|Dietary Supplement|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
179744|NCT00113386|Biological|pegfilgrastim|Consolidation chemotherapy
179745|NCT01934803|Dietary Supplement|Placebo|
179746|NCT01934816|Other|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
179747|NCT01934829|Drug|urea-based cream|urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .
BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator.
179748|NCT01934842|Device|TAP20-C|
179749|NCT01934842|Device|SAFE-T-FILL|
179750|NCT01934868|Drug|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
179751|NCT01934868|Drug|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
180047|NCT01948284|Procedure|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
180048|NCT01948284|Procedure|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
179439|NCT01939782|Other|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
179440|NCT01939782|Other|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
179441|NCT01939795|Other|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
179442|NCT01939808|Other|Splint Neutral|
179443|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
179444|NCT01942161|Drug|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
179445|NCT01942161|Drug|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
179446|NCT01942174|Biological|Prevenar 13|Vaccination at the beginning of the study (day 0)
179447|NCT01942174|Biological|Pneumo23|Vaccination 2 months later the beginning of the study
179448|NCT01942174|Drug|Methotrexate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
179449|NCT01942174|Drug|Methotrexate|For "period group", methotrexate is Initiated & month after the antipneumococcal vaccination by prevenar 13
179450|NCT01942187|Drug|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
179451|NCT01942187|Drug|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
179452|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10 gms topically each day
179453|NCT01942187|Behavioral|Problem Solving Therapy|Weekly specialized psychotherapy
179454|NCT01942239|Device|real time continuous glucose monitoring|
179455|NCT01942265|Drug|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
179456|NCT01942265|Drug|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
178837|NCT01934062|Procedure|Surgery|All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
178838|NCT00113334|Drug|ABT-510|100 mg subcutaneously twice daily
178839|NCT01934075|Behavioral|Mental health treatment|6 sessions of individual mental health counseling.
178840|NCT01934088|Drug|Propofol|
178841|NCT01934088|Drug|Midazolam|
178842|NCT01934088|Drug|Fentanyl|
178843|NCT01934101|Drug|CHR-5154|CHR-5154
179144|NCT01947517|Device|Parasol Punctal Occluder|
179145|NCT00114504|Drug|simvastatin|simvastatin 5-10 mg/day
179146|NCT01947517|Device|Superflex Punctal Occluder|
179147|NCT01947530|Procedure|Navigational Bronchoscopy|
179148|NCT01947530|Procedure|Standard Bronchoscopy|
179149|NCT01949974|Other|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
179150|NCT01949987|Other|two hours|
179151|NCT01949987|Other|one hour|
179152|NCT01950000|Drug|Fentanyl|
179153|NCT01950000|Other|Placebo|
179154|NCT01950013|Behavioral|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
179155|NCT01950013|Behavioral|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
179156|NCT01950026|Procedure|cryotherapy application|Height, weight and BMI verification
subjects in supine position after 20 minutes of resting
cryotherapy application by cold thermal bag (thermoGel brand) size P
15-20 cm above the ASIS
temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil
178524|NCT01903356|Drug|Trajenta duo|Linagliptin and Metformin
178525|NCT00110435|Drug|Duration of Treatment: 4 wk placebo run in then 6 wk active|
178526|NCT01903369|Device|Shear Wave Elastography|
178527|NCT01903395|Behavioral|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
178528|NCT01903408|Radiation|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
178529|NCT01903421|Drug|Spinal anesthesia group: bupivacaine 10-15mg|
178530|NCT01903421|Drug|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
178531|NCT01903421|Genetic|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
178532|NCT01903421|Other|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
178533|NCT01903421|Behavioral|Montreal Cognitive Assessment (MOCA) and MMSE|
178534|NCT01903434|Drug|Evacetrapib|Administered orally
178535|NCT01903447|Drug|SSRI|
178536|NCT00110435|Drug|Comparator: atorvastatin|
178537|NCT01903447|Behavioral|CBT|
178538|NCT01903460|Drug|LUM001|
178844|NCT01934101|Drug|Placebo|Placebo
178845|NCT01936584|Procedure|TEP repair for inguinal hernia|
178846|NCT01936584|Other|EuraHS-QoL questionnaire|questionnaire administration
178847|NCT01936584|Other|Carolina Comfort Scale|questionnaire administration
178848|NCT01936597|Other|Therapeutic and preventive strategies|Single set (control Arm)
178849|NCT00113529|Drug|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
178850|NCT01936597|Other|Therapeutic and preventive strategies|Controller
178851|NCT01936597|Other|Therapeutic and preventive strategies|Audio
183300|NCT02572661|Radiation|radiation in Squamous Head and Neck Cancer|
183301|NCT02572674|Other|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
183302|NCT02572674|Genetic|Genetic sample|Blood samples
183303|NCT02572687|Drug|Ramucirumab|Administered IV
183304|NCT02572687|Drug|MEDI4736|Administered IV
183305|NCT02572700|Other|Pain and US assessment|All patients will have a baseline visit when treatment is initiated and a follow up visit after 4 months. At each time point, pain mechanisms will be clarified by clinical examination and questionnaires. Besides, ultrasonography of joints and entheses, AMPS test, blood samples, x-ray of hands and feet and interview/additional questionnaires will be applied
183306|NCT02572713|Procedure|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
183307|NCT02572713|Procedure|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
183308|NCT02572713|Drug|DaTSCAN™|
183309|NCT02572726|Device|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
183310|NCT00187850|Procedure|Pulp capping and partial pulpotomy|
183311|NCT02572726|Device|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
183312|NCT02572739|Device|PICCO|measurements based on thermodilution
183313|NCT02572739|Device|NICCOMO|measurements based on impedance
183314|NCT02572752|Drug|Nintedanib|1 soft gelatine capsule, single dose, oral
183315|NCT02572752|Drug|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
183316|NCT02572752|Drug|Nintedanib|
183317|NCT02572765|Other|PET/CT scan|
178539|NCT01903460|Drug|Placebo|
178540|NCT01903473|Drug|Rapamycin|Rapamycin will be given at 6 mg loading dose for one day, followed by approximately 2 mg daily to achieve a target trough level of 5 to 10 ng/mL. Rapamycin could may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.
178541|NCT01903473|Other|T regulatory cells|One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 3-4 weeks after rapamycin treatment. The infusion procedure will take one hour.
182997|NCT02543359|Behavioral|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
182998|NCT02543372|Behavioral|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
182999|NCT02543372|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
183000|NCT02543385|Drug|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
183001|NCT02543398|Procedure|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
183002|NCT02543411|Drug|Lidocaine 1%|Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.
Sedation with fentanyl and propofol
183003|NCT00184522|Drug|Aflurax|
183004|NCT02543411|Drug|Normal saline|Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.
Sedation with fentanyl and propofol
183005|NCT02543424|Behavioral|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
183006|NCT02543437|Device|Trident Acetabular X3 Insert|
183007|NCT02543450|Other|Cardiovascular and task-oriented training|
183008|NCT02543450|Other|Upper limb strength training program|
183009|NCT02543463|Device|Trident X3 Insert with Navigation system|
183010|NCT02543463|Device|Trident X3 Insert with conventional instrumentation|
183011|NCT02543489|Device|Flex IM rod|
183012|NCT02543502|Procedure|periodontal treatment|treatment of periodontal cleaning
183013|NCT02543515|Procedure|office hysteroscopy|diagnostic procedure
183014|NCT00184522|Drug|esomeprazole|
183015|NCT02543541|Behavioral|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
182718|NCT02549755|Drug|11C-Acetate|The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).
There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient
182719|NCT00185107|Drug|Simvastatin|
182720|NCT02549768|Drug|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
182721|NCT02549768|Drug|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
182722|NCT02549781|Other|Go-Nogo test|In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called "Go-Nogo") whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization.
182723|NCT02549794|Procedure|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
182724|NCT02549794|Procedure|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
182725|NCT02549794|Procedure|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
182726|NCT02549807|Device|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
182727|NCT02549820|Device|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|A balloon will be placed in the unborn baby's airway between 27+0/7 -29 + 6/7 gestational age. Balloon removal will occur between 34 +0/7 -34+6/7 gestational age.
182728|NCT02549833|Biological|GBM6-AD and poly-ICLC|subcutaneous vaccination of GBM6-AD in combination with poly-ICLC
182729|NCT02549846|Drug|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
182730|NCT00185120|Drug|Olmesartan medoxomil|
183016|NCT02543541|Behavioral|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
183017|NCT02545712|Other|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
183018|NCT02545712|Other|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
183019|NCT02545712|Other|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
182114|NCT02561169|Other|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
182419|NCT02554357|Drug|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
182420|NCT02554357|Drug|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
182421|NCT02554370|Behavioral|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
182422|NCT00185588|Drug|Gemcitabine|850 mg/m2
182423|NCT02554383|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
182424|NCT02554383|Drug|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
182425|NCT02554396|Drug|PRX-100|ophthalmic solution
182426|NCT02554396|Drug|Placebo|saline ophthalmic solution
182427|NCT02556658|Device|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
182428|NCT02556658|Device|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
182429|NCT02556697|Device|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
182430|NCT02556710|Biological|AMPION™|4 mL Ampion Injection
182431|NCT02556710|Biological|Saline|4 mL Saline Injection
182432|NCT02556723|Drug|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
182433|NCT02556736|Drug|RST-001|RST-001 is a gene therapeutic delivered by intravitreal injection
182434|NCT02556749|Dietary Supplement|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
182435|NCT02556749|Dietary Supplement|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
197845|NCT02052089|Procedure|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
197846|NCT02052089|Procedure|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
197847|NCT02054689|Radiation|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
197848|NCT02054702|Drug|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
197849|NCT02054702|Drug|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
197850|NCT02054715|Other|educational intervention|Undergo print educational intervention
198179|NCT02047214|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
198180|NCT02047214|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
198181|NCT02047227|Drug|Pergoveris®|Pergoveris® (r-hFSH/r-hLH) will be self-administered daily subcutaneously at a starting dose of 300 International Unit (IU) r-hFSH/150 IU r-hLH from stimulation day 1 until recombinant human chorionic gonadotrophin (r-hCG) administration day (when follicle[s] reach a mean diameter of 17-18 millimeter [mm]). Dose adjustment will be done as per Investigator's discretion based upon individual response of the subject to the treatment.
198182|NCT00123799|Procedure|Positron Emission Tomography Imaging|
198183|NCT02047227|Drug|GONAL-f®|GONAL-f® (r-hFSH) will be self-administered daily subcutaneously at a starting dose of 300 IU from stimulation day 1 until r-hCG administration day (when follicle[s] reach a mean diameter of 17-18 mm). Dose adjustment will be done as per Investigator's discretion based upon individual response of the subject to the treatment.
198184|NCT02047227|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 microgram of r-hCG will be administered once subcutaneously.
198185|NCT02047253|Drug|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
198186|NCT02047253|Drug|Dexamethasone|Administered prior to administration of Study drug
198187|NCT02047253|Drug|Acyclovir|Administered orally twice daily
197552|NCT02059460|Drug|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
197553|NCT02059460|Drug|placebo|
197554|NCT02059473|Procedure|Rotator cuff repair|Physiotherapy & Surgery
197555|NCT02059473|Procedure|Physiotherapy|
197556|NCT02059486|Behavioral|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
197557|NCT00125060|Drug|Simvastatin (20mg versus 80mg/day)|
197558|NCT02059499|Drug|imiquimod|Given intra-anally
197559|NCT02059499|Drug|fluorouracil|Given intra-anally
197560|NCT02059499|Other|questionnaire administration|Ancillary studies
197561|NCT02059499|Other|laboratory biomarker analysis|Correlative studies
197562|NCT02061930|Procedure|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
197563|NCT02061969|Drug|linagliptin|5mg linagliptin tablets
197564|NCT02061969|Drug|insulin glargine|
197851|NCT02054715|Other|educational intervention|Undergo multimedia psychoeducational intervention
197852|NCT02054715|Other|questionnaire administration|Ancillary studies
197853|NCT02054728|Other|RHC and IMT|Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).
The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters.
197854|NCT02054741|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
197855|NCT00124579|Drug|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
197268|NCT02067117|Drug|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
197269|NCT02067130|Procedure|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
197270|NCT02067143|Drug|Prephase PDN + CY|
197271|NCT02067143|Drug|Cycle 1 Induction|
197272|NCT00125944|Biological|FluMist|
197273|NCT02067143|Drug|Cycle 2 Induction / Early consolidation|
197274|NCT02067143|Drug|Cycle 3 Early consolidation|
197275|NCT02067143|Drug|Cycle 4 Consolidation|
197276|NCT02067143|Drug|Cycle 5 Consolidation|
197277|NCT02067143|Drug|Cycle 6 Consolidation|
197278|NCT02067143|Drug|Cycle 7 Consolidation|
197279|NCT02067143|Drug|Cycle 8 Reinduction|
197280|NCT02069951|Other|Practice a procedural module on a simulator|
197281|NCT02069977|Drug|Aripiprazole|
197282|NCT02069990|Drug|Cholecalciferol|
197565|NCT02061982|Dietary Supplement|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
197566|NCT02061995|Drug|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
197567|NCT02062008|Device|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
197568|NCT02062021|Other|No intervention|
197569|NCT02062034|Drug|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
197570|NCT00125385|Biological|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
197571|NCT02062034|Drug|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
196965|NCT02074774|Other|Manual control|Standard practice of manually titrating FiO2 as needed.
196966|NCT02074787|Device|Thermography|Standard thermographic images
196967|NCT02074787|Device|Laser Doppler|standard laser doppler analysis
196968|NCT02074787|Device|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
196969|NCT02074800|Drug|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
196970|NCT02074800|Drug|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
196971|NCT02074800|Drug|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
196972|NCT00126607|Other|laboratory biomarker analysis|Correlative studies
196973|NCT02074813|Other|Inspiratory muscle training|Inspiratory muscle training
196974|NCT02074839|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
196975|NCT02074852|Other|Foley urethral catheter|
196976|NCT02074865|Biological|biological samples|
196977|NCT02074878|Drug|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
196978|NCT02074878|Drug|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
196979|NCT02074878|Drug|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
196980|NCT02074891|Drug|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
196981|NCT02074904|Drug|Topiramate|
196982|NCT02036658|Behavioral|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
196983|NCT02036658|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction is completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
197283|NCT02070003|Behavioral|Motivational Interviewing and Physician Guided Opioid Weaning|
180979|NCT01949090|Biological|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
180980|NCT01949103|Drug|TD-1607|
180981|NCT01949103|Drug|Placebo|
180982|NCT01949116|Drug|Methotrexate (MTX)|MTX 5 mg: one 5-mg capsule by mouth once weekly
MTX 10 mg: two 5-mg capsules by mouth once weekly
MTX 15 mg: three 5-mg capsules by mouth once weekly
181308|NCT01941199|Drug|DA-1229 + metformin|
181309|NCT01941212|Behavioral|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
181310|NCT01941225|Drug|Inhaled iloprost 5.0 mcg|Single administration
181311|NCT01941225|Drug|Placebo|Single administration
181312|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|individualized α frequency
left DLPFC 110% motor threshold (MT)
13-15 sessions for 3 weeks
181313|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|- placebo treatment: sham coil
181314|NCT01941264|Other|community based screening and treatment|Already described in intervention arm description.
181315|NCT01941277|Behavioral|Current Recommendations Exercise Group|
181316|NCT00114049|Drug|GW406381|
181317|NCT01941277|Behavioral|Intensive Exercise Group|
181318|NCT01941316|Drug|Carfilzomib|20/ * mg/m2, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
181319|NCT01941316|Drug|Irinotecan|125 mg/m2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
181320|NCT01941329|Procedure|Panretinal Photocoagulation (PRP)|
181321|NCT01944046|Drug|Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and months 1 and 2 until achieving the target dose of 24 IU BID at Month 2. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.
181322|NCT00114192|Drug|docetaxel|
181323|NCT01944059|Drug|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
180641|NCT00113256|Drug|Rubitecan|
180642|NCT01933126|Drug|HCG injection|
180643|NCT01933126|Drug|Placebo|
180644|NCT01933139|Other|Audio-visual presentation|
180645|NCT01933152|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
180646|NCT01933165|Device|LipiView|
180647|NCT01933178|Device|Cirrus AS-OCT|
180983|NCT01949116|Drug|Placebo|Placebo 5 mg: one 5-mg capsule by mouth once weekly
Placebo 10 mg: two 5-mg capsules by mouth once weekly
Placebo 15 mg: three 5-mg capsules by mouth once weekly
180984|NCT01949116|Dietary Supplement|Folic acid|1-mg tablet of folic acid by mouth once a day
180985|NCT01949129|Drug|VP16|60 mg/kg, administration: 1 day
180986|NCT01949129|Radiation|TBI|12 Gy in 6 fractions over 3 days
180987|NCT00114621|Procedure|Blood Chemistry|
180988|NCT01949129|Drug|Thiotepa|2x5 mg/kg, 1 day
180989|NCT01949129|Drug|Treosulfan|14g/m² BS, 3 days
180990|NCT01949129|Drug|Fludarabine|30 mg/m² BS, 5 days
180991|NCT01949129|Drug|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
180992|NCT01949142|Drug|OTO-201|Single, intratympanic injection
180993|NCT01949142|Drug|Sham|Simulated single, intratympanic injection
180994|NCT01949155|Drug|OTO-201|Single, intratympanic injection
180995|NCT01949155|Drug|Sham|Simulated single, intratympanic injection
180996|NCT01949168|Drug|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
180324|NCT01940419|Drug|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
180325|NCT01940432|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
180326|NCT01940432|Behavioral|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
180327|NCT01940445|Device|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
180328|NCT01940445|Device|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
180329|NCT00000303|Drug|Baclofen|
180330|NCT00002109|Drug|Didanosine|
180331|NCT00113945|Drug|Cinacalcet|
180332|NCT01940471|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25 mg tablet administered orally once daily
180333|NCT01940471|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300 mg tablet administered orally once daily
180648|NCT01933191|Behavioral|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
180649|NCT01933191|Behavioral|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
180650|NCT01935752|Other|blood samples|blood samples
180651|NCT00113399|Drug|fluorouracil|
180652|NCT01935752|Other|vascular echotracking|endothelial function study and virtual histology study
180653|NCT01935765|Other|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
180654|NCT01935765|Other|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
188395|NCT01980875|Drug|Obinutuzumab|Obinutuzumab in 1000 mg/40 mL single use vials administered intravenously for a total of 8 doses over 21 weeks
188396|NCT01980888|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
188397|NCT01980888|Drug|Bendamustine|Bendamustine administered intravenously at a starting dose of 90 mg/m^2. Dosing will be based on mg/m^2 of body surface area.
188398|NCT01980888|Drug|Rituximab|Rituximab single-use vials administered intravenously weekly starting at 375 mg/m^2 on Day 1 (Week 0) and 500 mg/m^2 thereafter
188399|NCT01980888|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
188400|NCT01980901|Device|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
188401|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)|One time injection of 2 ug/kg of FGF 1-141, via a catheter
188402|NCT01980927|Procedure|NUCCA atlas correction|A chiropractic procedure involving correcting a misalignment of the atlas or "top" vertebra in the spine.
188403|NCT01980940|Drug|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
188404|NCT01980940|Drug|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
188405|NCT01980940|Drug|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
188738|NCT01973322|Other|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
188739|NCT01973322|Other|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
188740|NCT01973322|Other|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
188741|NCT01973322|Biological|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
188742|NCT01973335|Drug|Combination therapy with acetazolamide and low-dose loop diuretics|Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.
Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.
If diuresis <1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.
In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.
188743|NCT00117572|Drug|fluorouracil|750 mg/m2/day on days 1-5 of induction
193263|NCT02068105|Drug|Placebo|Sublingual tablet
193264|NCT02068118|Device|Telecardiology program|The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.
Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure.
193265|NCT02068131|Drug|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
193266|NCT02068131|Drug|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
193267|NCT00126009|Drug|Amisulpride|
193268|NCT02068144|Dietary Supplement|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
193269|NCT02070744|Drug|ivacaftor placebo|
193270|NCT02070757|Drug|ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta(β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
193271|NCT02070757|Drug|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
193272|NCT02070770|Dietary Supplement|Very low calorie diet|
193273|NCT02070770|Other|Standard weight loss diet|
193274|NCT02070783|Drug|ARA290|
193275|NCT02070783|Drug|Placebo|
193276|NCT02070796|Drug|Rotigotine PR2.2.1|Treatment A:
Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours.
193277|NCT00126256|Drug|5-fluorouracil|
188406|NCT01980940|Drug|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
188407|NCT01980940|Drug|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
188408|NCT01980940|Drug|Placebo|Placebo gel applied topically.
188409|NCT01980940|Drug|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
188410|NCT01980940|Drug|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
192938|NCT01955018|Device|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
192939|NCT01955031|Other|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
192940|NCT01955031|Other|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
192941|NCT01955044|Dietary Supplement|LCPUFA supplement|
192942|NCT01955044|Dietary Supplement|placebo|
192943|NCT01955057|Behavioral|Research interviews|
192944|NCT01955057|Behavioral|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
192945|NCT01955057|Behavioral|Projective methods (Thematic apperception Test, Rorschach)|
192946|NCT01955057|Behavioral|Carbon monoxide test|
192947|NCT00115323|Behavioral|Attention Control|Attention control intervention
192948|NCT01955070|Other|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
192949|NCT01955083|Device|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
192950|NCT01957410|Drug|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
192951|NCT01957423|Dietary Supplement|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
192347|NCT00116649|Drug|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
192348|NCT01967186|Procedure|Intraportal islet transplantation|
192349|NCT01967186|Procedure|Intramuscular islet transplantation|
192350|NCT01967186|Procedure|Intramuscular transpl with stemcells|
192351|NCT01967186|Procedure|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
192352|NCT01967199|Device|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
192353|NCT01967199|Device|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
192354|NCT01967212|Device|Game-based swallow biofeedback|The intervention are divided into two parts：
Traditional swallowing training 30 min by speech therapist.
Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator.
192355|NCT01967212|Behavioral|Swallow training without biofeedback|The intervention are divided into two parts：
Traditional swallowing training 30 min by speech therapist.
Mendelsohn's maneuver and effortful swallow without biofeedback 30 min.
192356|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
192641|NCT01962675|Device|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
192642|NCT01962675|Behavioral|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
192643|NCT00116142|Drug|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
192644|NCT01962688|Device|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
192645|NCT01962688|Device|Sham ultrasound|sham ultrasound to facilitate blinding
192646|NCT01962714|Behavioral|Loving-Kindness Meditation|12-week loving-kindness meditation course
192647|NCT01962714|Behavioral|Cognitive Processing Therapy|12-week CPT course
192648|NCT01962740|Device|Drug-eluting stent implantation|
192649|NCT01962753|Drug|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
192650|NCT01962766|Behavioral|Myofunctionnal therapy|
192046|NCT01974596|Dietary Supplement|Placebo tablets|
192047|NCT01974609|Drug|Narcotic|Hydrocodone 5mg + acetaminophen 325 mg
192048|NCT00117481|Drug|DR-2001b|DR-2001b administered vaginally each month
192049|NCT01974609|Drug|non-narcotic|ibuprofen 600mg + acetaminophen 325 mg
192050|NCT01974622|Drug|Visudyne|Half fluence verteporfin
192051|NCT01974635|Device|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
192052|NCT01974648|Drug|propofol|
192053|NCT01974648|Drug|propofol and remifentanil|
192054|NCT01974661|Biological|COMBIG-DC|Allogenic dendrite-cell based therapeutic vaccine
192055|NCT01974674|Procedure|Allogeneic transplantation of intrahepatic islet|
192056|NCT01974687|Drug|MK-3682|MK-3682 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
192057|NCT01974687|Drug|Placebo|Matching placebo to MK-3682 capsule administered by mouth.
192058|NCT01974687|Drug|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
192059|NCT00117481|Other|Placebo|Placebo administered vaginally each month
192060|NCT01974700|Drug|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
192061|NCT01974726|Other|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
192357|NCT01969669|Drug|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
192358|NCT01969682|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
192359|NCT01969682|Drug|Rifampin|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
191467|NCT01987310|Behavioral|lifestyle counseling|lifestyle modification by dietician counseling and follow up
191468|NCT01987323|Drug|Subconjunctival injection of liposomal latanoprost|
191469|NCT01987349|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
191470|NCT01987349|Biological|Flumist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
191471|NCT01987349|Biological|Fluzone® High-Dose (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3) High-Dose
191472|NCT01987362|Drug|TEN-010|Safety, tolerability and pharmacokinetics of TEN-010 in Patients with Advanced Solid Malignancies.
191473|NCT01987375|Drug|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
191752|NCT01979718|Device|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
191753|NCT01979731|Other|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
191754|NCT00117884|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
191755|NCT01979731|Other|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
191756|NCT01982318|Drug|Dulbecco's Phosphate Buffered Saline|
191757|NCT01982331|Biological|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
191758|NCT01982331|Other|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
191759|NCT00118014|Behavioral|Habit Reversal Training|
191760|NCT01982344|Device|mini-exchange-room|
191761|NCT01982357|Device|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
191762|NCT01982383|Device|Micropulse Laser Treatment|
191763|NCT01982396|Drug|ABC Twice Daily|
191764|NCT01982396|Drug|ABC Once Daily|
191135|NCT01954368|Drug|Sufentanil|As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.
Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.
191136|NCT01954381|Device|transthoracic echocardiographic|
191137|NCT01954381|Device|Doppler ultrasound.|
191138|NCT00115206|Drug|Neulasta® (pegfilgrastim)|
191139|NCT01954381|Biological|blood samples|
191140|NCT01954394|Drug|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
191141|NCT01954407|Behavioral|Smoking-Related Messages|
191142|NCT01954420|Behavioral|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
191143|NCT01954420|Other|Attention Control|Standard care + Cancer education
191144|NCT01954433|Procedure|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
191145|NCT01954433|Procedure|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
191474|NCT01987388|Other|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
191475|NCT00118313|Biological|tetanus toxoid helper peptide|
191476|NCT01987388|Other|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
191477|NCT01989858|Other|post-operative cht + post-operative cht-rtx|CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or
ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:
5FU 225 mg/m² given as a continuous iv infusion or
capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.
191478|NCT01989871|Behavioral|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
190810|NCT01956604|Drug|Clonidine|
190811|NCT01956604|Drug|Placebo|
190812|NCT01956617|Other|lumbar plexus block|
190813|NCT01959087|Procedure|single port surgery|Single port surgery can be converted in multiport surgery if necessary
190814|NCT01959087|Procedure|Multiport surgery|
190815|NCT01959100|Drug|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
190816|NCT01959100|Drug|Placebo|250 mg x 3/week during a meal for a period of 2 years
190817|NCT00115713|Behavioral|Aerobic Exercise Training|
190818|NCT01959113|Biological|Autologous Microbiome Transplant|
190819|NCT01959113|Other|Placebo Arm|
190820|NCT01959126|Behavioral|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
190821|NCT01959139|Drug|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
190822|NCT01959139|Drug|Oxaliplatin|85 mg/m^2, on Day 2, IV over 2 hours
190823|NCT01959139|Drug|Leucovorin|400 mg/m^2, on Day 2, IV over 2 hours
190824|NCT01959139|Drug|Irinotecan|180 mg/m^2, on Day 2, IV over 1.5 hours
190825|NCT01959139|Drug|5-fluorouracil|2,400 mg/m^2, Days 2-4, IV over 46 hours
190826|NCT01959152|Device|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
190827|NCT01959165|Drug|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
191146|NCT01954433|Procedure|Resection interposition suspension arthroplasty (RISA)|One of five surgical techniques can be used in this study, as routinely performed by each surgeon:
RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping
RISA with FCR-Ligament modified according to Weilby
RISA with APL-Ligament (abductor pollicis longus ligament)
RISA with Graftjacket modified according to Weilby
Resection arthroplasty
191147|NCT01954446|Device|3M|Conventional measuring of BP
191148|NCT01954446|Device|ContiPressTM|New way of measuring BP - ContiPressTM
Investigational device
190209|NCT01971268|Device|Dental Implant|place dental implants according to manufacturer guidelines
190210|NCT01971268|Device|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
190211|NCT01971268|Device|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
190212|NCT01971281|Device|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
190517|NCT01964183|Drug|mirabegron|Oral
190518|NCT01964196|Drug|ASP1517|Oral administration
190519|NCT01964196|Drug|Placebo|Oral
190520|NCT01964222|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
190521|NCT01964235|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
190522|NCT00116311|Behavioral|withdrawal of medication|
190523|NCT01964235|Drug|Placebo|Placebo will be administered orally and continuously on a twice a day dosing schedule.
190524|NCT01964248|Drug|Placebo|Placebo cream applied 2 hours before blood sample
190525|NCT01964248|Drug|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
190526|NCT01966380|Device|Leia|
190527|NCT01966393|Other|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
190528|NCT01966406|Device|Nasogastric tube|
190529|NCT01966406|Other|No nasogastric tube|
190530|NCT01966419|Drug|ornithine phenylacetate|dose levels predicated on level of hepatic decompensation
190531|NCT01966419|Drug|placebo intravenous infusion|visually identical to active experimental
189888|NCT01976104|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
189889|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
189890|NCT01976117|Device|enose|
189891|NCT01976130|Procedure|Bronchoscopy|
189892|NCT01976143|Drug|NKTR-102|
189893|NCT01976156|Dietary Supplement|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
189894|NCT01976156|Dietary Supplement|Placebo|Placebo consists of rice flour
189895|NCT01978600|Drug|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
189896|NCT01978613|Drug|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
189897|NCT01978613|Drug|placebo|Tablets for one-daily oral administration.
189898|NCT01978626|Behavioral|App modules|
189899|NCT01978626|Behavioral|Traditional CBT-I|
189900|NCT00117780|Drug|insulin aspart|
189901|NCT01978652|Biological|Peginterferon Beta-1a|As specified in the treatment arm
189902|NCT01978665|Drug|prednisone|
189903|NCT01978678|Drug|Pulmicort|
189904|NCT01978691|Dietary Supplement|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
189905|NCT01978691|Dietary Supplement|Polydextrose|Studied as a prebiotic
189906|NCT01978691|Other|Placebo|Control
189907|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
190213|NCT01971281|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
184966|NCT02562222|Procedure|cathodal tDCS on M1 and anodal on V1|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
184967|NCT02564315|Behavioral|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
184968|NCT02564315|Behavioral|Cessation Phase Skill Training Counseling|Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and "coping reports" that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution.
184969|NCT02564315|Behavioral|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
185242|NCT02555644|Radiation|Intensity Modulated Radiation Therapy|
185243|NCT02555657|Biological|pembrolizumab|
185244|NCT02555657|Drug|capecitabine|
185245|NCT02555657|Drug|eribulin|
185246|NCT02555657|Drug|gemcitaine|
185247|NCT00185692|Drug|Cyclosporine|5 mg/kg BID, PO
185248|NCT02555657|Drug|vinorelbine|
185249|NCT02555670|Other|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
185250|NCT02555683|Drug|QAW039|QAW039 Dose 1 once daily
185251|NCT02555683|Drug|QAW039|QAW039 Dose 2 once daily
185252|NCT02555683|Drug|Placebo|Placebo once daily
184681|NCT02568774|Other|Placebo Acupuncture|Subjects will be treated at non-acupoint and non-meridian site using non-invasive placebo acupuncture needles.
184682|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
184683|NCT02568787|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
184684|NCT02568787|Dietary Supplement|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
184685|NCT02568800|Drug|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
184686|NCT02568800|Drug|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
184687|NCT02568813|Behavioral|Multiscore Depression Inventory for Children scale|
184688|NCT02570750|Behavioral|QUESTIONNAIRE ON SMOKING HABITS|Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).
Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points.
184689|NCT02570763|Device|Active tDCS stimulation|
184690|NCT02570763|Device|Sham tDCS stimulation|
184691|NCT02570789|Drug|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
184692|NCT00187486|Procedure|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
184693|NCT02570802|Procedure|Ultrasonographic examination|
184694|NCT02570815|Drug|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
184695|NCT02570828|Device|Thermal Imaging|FLIR ONE attachment to an iPhone
190930|NCT01969201|Drug|Follitrophin alpha|
189982|NCT01986764|Drug|Estradiol|
189983|NCT01986764|Drug|Placebo|Placebo capsules will be filled with lactose powder.
189984|NCT01986777|Drug|lisdexamfetamine|
189985|NCT01986777|Drug|Placebo|The placebo capsules will be filled with lactose.
189986|NCT00118287|Drug|azacitidine|Given SC or IV
190292|NCT01981616|Drug|Vedolizumab|Vedolizumab for intravenous infusion
190293|NCT01981616|Drug|Placebo|Placebo intravenous infusion
190294|NCT01981616|Biological|Hepatitis B vaccine|
190295|NCT00117962|Drug|carboplatin|AUC = 5 q 21 days for 4 cycles
190296|NCT01981616|Biological|Oral cholera vaccine|
190297|NCT01981629|Device|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
190298|NCT01981642|Other|Recording of LVAD data during routine visits and daily life.|Noninvasive diagnostic intervention.
190299|NCT01981642|Other|Recording of daily activity using wristwatch accelerometers.|Noninvasive diagnostic intervention.
190300|NCT01981655|Drug|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
190301|NCT01981655|Drug|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
190302|NCT01981668|Drug|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
190303|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
190304|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
190305|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
190306|NCT00117962|Drug|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
189663|NCT01953809|Drug|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
189664|NCT00115128|Drug|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
189665|NCT01953822|Other|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
189666|NCT01953835|Drug|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
189667|NCT01953835|Drug|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
189668|NCT01953835|Drug|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
189669|NCT01953835|Drug|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
189670|NCT01953848|Drug|EC905|Oral
189671|NCT01953861|Drug|EC905|Oral
189672|NCT01953874|Device|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
189673|NCT01953874|Drug|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
189674|NCT01953887|Drug|EC905|Oral
189987|NCT01986790|Behavioral|Plain Language|
189988|NCT01989312|Drug|Lidocaine|
189989|NCT01989312|Drug|Epinephrine|
189990|NCT00118391|Behavioral|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
189991|NCT01989312|Drug|Levobupivacaine|
189992|NCT01989325|Drug|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
189993|NCT01989325|Drug|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
189352|NCT00115661|Drug|Rosiglitazone|
189353|NCT01958541|Behavioral|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
189354|NCT01958541|Behavioral|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
189355|NCT01958554|Behavioral|Intervention Group|
189356|NCT01958567|Other|Optical Coherence Tomography|
189357|NCT01958580|Drug|Gemcitabine Hydrochloride|Given IV
189358|NCT01958580|Drug|Docetaxel|Given IV
189359|NCT01958580|Radiation|Internal Radiation Therapy|Undergo brachytherapy
189360|NCT01958580|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
189361|NCT00115934|Procedure|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
189362|NCT01961154|Drug|Asthma medication reduction|The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
189363|NCT01961167|Device|PI 13-05|
189364|NCT01961180|Drug|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
189365|NCT01961193|Device|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
189366|NCT01961193|Device|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
189367|NCT01961206|Other|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
189368|NCT01961219|Procedure|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
189369|NCT01961219|Procedure|Arthroscopic capsular release|Arthroscopic capsular release
189370|NCT01961245|Device|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
188735|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
188736|NCT00117377|Drug|Pimecrolimus|Pimecrolimus cream 1 % bid
188737|NCT01973309|Drug|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
189052|NCT01965821|Device|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
189053|NCT01965834|Drug|Fenofibrate|
189054|NCT01965847|Behavioral|Medication therapy management|
189055|NCT01965860|Other|additional curriculum|
189056|NCT01965873|Dietary Supplement|Enteral nutrition|Same as arm description
189057|NCT01965886|Procedure|Medial approach|Total knee replacement performed through a longitudinal incision medial to the patella
189058|NCT01965886|Procedure|Keblish approach|Total knee replacement performed through a longitudinal incision lateral to the patella
189059|NCT01965899|Device|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
189060|NCT01965912|Drug|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
189061|NCT01965925|Drug|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
189062|NCT01968109|Biological|BMS-936558|
189063|NCT01968122|Device|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
189064|NCT01968135|Drug|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
189065|NCT01968135|Drug|Placebo Sugar Pill|Placebo Sugar Pill
188744|NCT01975467|Device|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
188745|NCT01975480|Drug|Desvenlafaxine|
188746|NCT01975506|Other|developmental delay|developmental delay
188747|NCT01975519|Drug|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
188748|NCT01975545|Drug|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
188749|NCT01975545|Drug|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
188750|NCT01975558|Biological|Sampling (blood, urine, sebum, saliva)|sampling at baseline, during radiation therapy and after
188751|NCT01975571|Device|Cochlear® Nucleus™ Hybrid L24|The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
188752|NCT01975571|Device|Cochlear® Nucleus™ Hybrid S12|The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
189071|NCT01968213|Drug|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
189072|NCT01968213|Drug|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
189073|NCT01968226|Drug|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis >50% who are undergoing planned carotid endarterectomy will be imaged under PET with [F-18] RDG-K5
189074|NCT01968239|Drug|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
189075|NCT01968252|Other|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
189076|NCT01968265|Drug|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
188411|NCT01980953|Drug|GDC-0032|Phase 3 tablet, single doses given under fasted conditions
188412|NCT01983540|Biological|Infanrix hexa + Prevenar + Rotarix vaccine|Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
188413|NCT01983566|Drug|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
188414|NCT01983566|Drug|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
188415|NCT01983566|Drug|BI 207127|BI 207127 as a single dose in fasted state
188416|NCT01983566|Drug|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
188417|NCT01983579|Procedure|Intraocular anti-VEGF injection|
188418|NCT01983579|Device|SENSIMED Triggerfish|
188419|NCT01983592|Other|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
188420|NCT01983592|Other|Unmedicated lactose/sucrose globule|
188421|NCT01983605|Device|LARIAT Suture Delivery Device|LAA exclusion procedure
188422|NCT00118105|Biological|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
188423|NCT01983618|Procedure|Interscalene nerve block and catheter|
188424|NCT01983618|Procedure|Interscalene catheter|
188425|NCT01983631|Other|Whole body vibration training|
188426|NCT01983644|Device|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
188753|NCT01975584|Behavioral|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
188754|NCT00117572|Procedure|chemotherapy|See protocol for details
193278|NCT02070796|Drug|Rotigotine PR2.1.1|Treatment B:
Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours.
193279|NCT02070809|Procedure|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
193280|NCT02070809|Procedure|split-thickness skin graft method|This method is traditional split-thickness skin graft
193281|NCT02070835|Device|ReCell®|ReCell® and skin graft
193282|NCT02070835|Procedure|skin graft|split-thickness skin graft
193283|NCT02070848|Other|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
193284|NCT02070848|Other|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
193285|NCT02070848|Other|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
193286|NCT02070861|Procedure|Changes in cardiac output|
193287|NCT02070874|Behavioral|telehealth enhanced pain management|
193288|NCT00126256|Drug|leucovorin|
193289|NCT02070900|Device|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
193290|NCT02070900|Other|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
193291|NCT02070939|Drug|PF-06260414|Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
193292|NCT02070939|Drug|Placebo|Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
193293|NCT02070939|Drug|PF-06260414|Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
193294|NCT02070939|Drug|Placebo|Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
193295|NCT02073435|Behavioral|donor pain management/ Pre-operative OR Set-up|The evidence-based donor pain management solution entails the following elements:Preoperative Assessment and Management (OSA assessment etc.); At the end of the case in OR (Local anesthetics etc.); Post operative Management (CO2 monitoring etc.)
Standardization and Optimization of the Pre-operative OR Set-up Process The four participating A2ALL Deux TCs will need to engage in additional review of the detailed assessment of the preoperative OR set-up process and will collaboratively design a standardized and optimized preoperative OR set-up solution to reduce the frequency of medical errors medical errors, resource wastage, and team burden and improve LDLT care (anticipated implementation February 2014).
192651|NCT01962766|Behavioral|instructions|
192652|NCT01962779|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
192653|NCT01962792|Drug|Ibrutinib|
192654|NCT00116142|Drug|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
192655|NCT01962792|Drug|Carfilzomib|
192656|NCT01962792|Drug|Dexamethasone|
192657|NCT01962805|Drug|Proellex Formulation A|
192658|NCT01962805|Drug|Proellex Formulation B|
192659|NCT01962818|Other|HFOV combined with sigh breaths|It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).
All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.
Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient "wash-out" period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh
192660|NCT01962831|Drug|Dinoprostone|
192661|NCT01962831|Device|Single balloon foley catheter|
192952|NCT01957423|Dietary Supplement|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
192953|NCT01957436|Drug|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
192954|NCT00115570|Drug|NPH insulin|
192955|NCT01957436|Radiation|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
192956|NCT01957436|Other|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
192957|NCT01957449|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
192958|NCT01957449|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
192959|NCT01957462|Device|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
192360|NCT01969695|Drug|ABT-199|ABT-199 continuous once daily dosing
192361|NCT01969708|Drug|aflibercept|
192362|NCT01969708|Drug|bevacizumab|
192363|NCT01969721|Drug|fluticasone propionate|low dose
192364|NCT01969721|Drug|salmeterol|
192365|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
192366|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
192367|NCT00116948|Device|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
192368|NCT01969721|Drug|tiotropium|tiotropium high dose
192369|NCT01969721|Drug|olodaterol|
192370|NCT01969721|Drug|olodaterol|
192371|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
192372|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
192373|NCT01969721|Drug|tiotropium|tiotropium low dose
192374|NCT01969721|Drug|fluticasone propionate|low dose
192375|NCT01969721|Drug|salmeterol|
192376|NCT01969734|Device|Zephyr endobronchial valve placement|
192377|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
192378|NCT00116961|Drug|Velcade|
192379|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
192380|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
192381|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
192382|NCT01969747|Drug|Empagliflozin medium|Empagliflozin medium
192383|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
191765|NCT01982396|Drug|3TC Once Daily|
191766|NCT01982396|Drug|3TC Twice Daily|
191767|NCT01982409|Biological|Live Attenuated Varicella Vaccine|
191768|NCT01982422|Behavioral|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
191769|NCT01982435|Drug|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
191770|NCT00118027|Drug|sulphadoxine-pyrimethamine intermittent preventive treatment|
191771|NCT01982435|Drug|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
191772|NCT01982448|Drug|Cisplatin|75 mg/m2 IV q 3 weeks x 4 cycles
191773|NCT01982448|Drug|Paclitaxel|80mg/m2 weekly x 12 weeks (4 cycles).
191774|NCT01982461|Drug|Rosuvastatin|10mg,once daily
192062|NCT01974726|Other|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
192063|NCT01977105|Behavioral|Grow Together peer group|Participants in this intervention will:
Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.
Complete an intervention video activity approximately weekly:
1. View educational videos addressing topics related to healthy infant growth
2. Create photos/videos modeling healthy behaviors and post them to the group
3. Provide and receive feedback on posts
4. Be encouraged to share information with key caregivers of their child
Attend group party soon after enrollment, to meet peers and group leader in person.
Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.
Have basic program information provided to pediatrician to enhance conversation during office visits.
192064|NCT01977118|Drug|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
192065|NCT01977118|Other|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
192066|NCT01977131|Other|Cells|
191479|NCT01989884|Drug|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
191480|NCT00118430|Behavioral|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly with a physician-investigator to review cases, the physician-investigator will be available at all times to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
191481|NCT01989897|Drug|saline with 1mg/ml Histamine base|
191482|NCT01989897|Drug|diluent, saline with HSA--phenol|
191483|NCT01989910|Drug|Raltegravir|Raltegravir 400mg oral twice daily
191484|NCT01989910|Drug|Efavirenz|Efavirenz 600mg oral at bedtime
191485|NCT01989923|Other|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
191486|NCT01989923|Device|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
191775|NCT01982461|Drug|Crestor®|10mg,once daily
191776|NCT01982474|Biological|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
191777|NCT01982474|Other|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
191778|NCT01982487|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
191779|NCT01982487|Drug|IDO1 inhibitor INCB024360|Given PO
191780|NCT01982487|Other|laboratory biomarker analysis|Correlative studies
191781|NCT00118040|Drug|genistein|Given orally
191782|NCT01982487|Other|pharmacological study|Correlative studies
191783|NCT01982513|Device|Ultrasound|The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
191149|NCT00115219|Drug|Etanercept|
191150|NCT01954446|Device|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
191151|NCT01954459|Device|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
191152|NCT01954459|Device|Continuous glucose sensor|Glucose sensor inserted without warming patch
191153|NCT01956630|Biological|Genetically modified DCs plus CIK cells|
191154|NCT00115505|Other|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
191155|NCT01956630|Biological|Donor leukocyte infusions (DLI)|
191156|NCT01956643|Other|gum chewing|gum chewing
191157|NCT01956643|Other|Control|Routine care during NPO
191158|NCT01956656|Drug|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
191159|NCT01956669|Drug|Pazopanib GW786034|Pazopanib is supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension is a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
191160|NCT01956682|Dietary Supplement|HA formula + starch + L. reuteri|
191161|NCT01956695|Drug|Lenalidomide|
191162|NCT01956695|Drug|Rituximab|
191163|NCT01956708|Procedure|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
191164|NCT01956721|Procedure|Exercise training,|
191165|NCT00115518|Drug|cetuximab|After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
191166|NCT01956721|Procedure|Muscle biopsy|
191167|NCT01956734|Procedure|DNX2401 and Temozolomide|Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.
Temozolomide oral 14 days after virus injection.
190532|NCT00116571|Drug|Lemuteporfin for injection|
190533|NCT01966432|Behavioral|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
190534|NCT01966432|Behavioral|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
190535|NCT01966445|Biological|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
190536|NCT01966458|Device|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
190537|NCT01966458|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
190828|NCT00115713|Behavioral|Resistance Exercise Training|
190829|NCT01959165|Drug|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
190830|NCT01959165|Drug|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
190831|NCT01959165|Drug|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
190832|NCT01959191|Drug|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
190833|NCT01959204|Drug|Oxycodone|Pain
190834|NCT01959217|Behavioral|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
190835|NCT01959217|Behavioral|Traditional Text Reminders|Traditional text reminders include: "Take your medication."
190836|NCT01959230|Drug|Brimonidine Tartrate|
190837|NCT01959230|Drug|Vehicle|
190838|NCT01959243|Drug|Brimonidine Tartrate|
190839|NCT00115726|Drug|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
190840|NCT00115986|Biological|Influenza A/H5N1 Vaccine|
190841|NCT01961856|Drug|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
190842|NCT01961856|Drug|Ticagrelor|Ticagrelor 180mg loading dose
190214|NCT01971281|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
190215|NCT01971307|Other|SGE-PsyScan|
190216|NCT01971320|Device|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
190217|NCT01971346|Drug|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
190218|NCT00117182|Drug|Budesonide 400mcg administered via turbuhaler|
190219|NCT01971385|Drug|Squaric Acid solution|
190220|NCT01971385|Drug|Placebo solution|
190221|NCT01971398|Behavioral|Positive FASD education brochure|Exposure to a positive FASD education brochure
190222|NCT01971398|Behavioral|Negative FASD education brochure|Exposure to a negative FASD education brochure
190223|NCT01971398|Behavioral|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
190224|NCT01971411|Drug|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
190225|NCT01971411|Procedure|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
190226|NCT01971411|Behavioral|Usual sun exposure documentation|
190227|NCT01971411|Behavioral|Dietary intake of calcium, vitamin D, magnesium|
190228|NCT01971424|Dietary Supplement|Mg oxide|
190229|NCT01973790|Drug|Z-338|100mg TID
190230|NCT01973816|Drug|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
190231|NCT00117416|Procedure|controlling the MAP|
190232|NCT01973816|Procedure|rectal shaving; rectal disc excision; colorectal resection|
190233|NCT01973816|Drug|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
190234|NCT01973816|Drug|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
185253|NCT02557763|Device|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
185254|NCT02557776|Genetic|Germline genetic testing of BRCA1 and BRCA2|
185255|NCT02557789|Drug|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
185256|NCT02557802|Biological|Fluenz Tetra|Intranasal spray, 0.2 ml dose
185257|NCT00186004|Device|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
185258|NCT02557802|Biological|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
185259|NCT02557815|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
185260|NCT02557828|Procedure|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
185261|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
185262|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
185263|NCT02557841|Device|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
185528|NCT02550938|Device|Invisalign|The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
185529|NCT02550951|Procedure|lymphangiography|
185530|NCT02550964|Procedure|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
185531|NCT02550977|Drug|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
185532|NCT02550990|Behavioral|Cognitive training|
190931|NCT01969214|Device|IQP-MM-101|Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day
190932|NCT01969227|Drug|subanesthetic ketamine|
190933|NCT01971606|Drug|Rosuvastatin|Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.
A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
190934|NCT01971632|Drug|Oxycodone & naloxone combination, prolonged release|
190935|NCT01971632|Drug|placebo oxycodone / naloxone|
190936|NCT01971645|Drug|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
190937|NCT01971645|Drug|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
190938|NCT01971658|Drug|Thalidomide®|
190939|NCT00117208|Drug|mannitol|400mg BD for 12 weeks
190940|NCT01971658|Drug|Cyclophosphamide|
190941|NCT01971658|Drug|Velcade®|
190942|NCT01971658|Drug|Dexaméthasone|
190943|NCT01971671|Other|no intervention.|
190944|NCT01971684|Drug|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
190945|NCT01971710|Behavioral|Community leader engagement|
190946|NCT01971710|Behavioral|Community days|
190947|NCT01971710|Behavioral|Community Peer Groups|
190948|NCT01971723|Other|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
190949|NCT01971723|Other|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
190950|NCT00117208|Drug|mannitol + pulmozyme|combination
190307|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
190308|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
190309|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
190310|NCT01981694|Drug|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
190311|NCT01981694|Drug|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
190620|NCT01976338|Other|Sham injection|Sham intravitreal injection
190621|NCT01976364|Drug|Tofacitinib|Tofacitinib 5 mg tablet twice daily
190622|NCT00117624|Drug|darbepoetin alfa|
190623|NCT01976364|Drug|Tofacitinib|Tofactinib 10 mg tablet twice daily
190624|NCT01976390|Drug|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
190625|NCT01976390|Drug|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
190626|NCT01976403|Behavioral|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
190627|NCT01976416|Drug|Hydroxyurea|
190628|NCT01976416|Drug|Placebo|
190629|NCT01976429|Other|flight/diving simulation|measurement of ET function during simulated flight/diving in pressure chamber
190630|NCT01976429|Other|ET function testing at ambient pressure|ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
190631|NCT01976429|Other|nasal video-endoscopy|examination of nose, nasopharynx,and Eustachian tube orifice
190632|NCT01976455|Other|20% fewer calories|
190633|NCT00117637|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
190634|NCT01976455|Other|40% fewer calories|
189994|NCT01989325|Drug|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
189995|NCT01989325|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
189996|NCT01989403|Other|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
189997|NCT01989416|Drug|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
189998|NCT01989416|Drug|Soap|The ICU patients will be bathing with Soap
189999|NCT01989429|Drug|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
190000|NCT01989442|Device|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
190001|NCT00118391|Behavioral|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
190002|NCT01989442|Device|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
190003|NCT01989455|Drug|Deferiprone|Deferiprone for infusion, 10mg/mL for intravenous infusion.
Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)
190004|NCT01989455|Drug|Placebo|Placebo: normal saline solution.
190005|NCT01989468|Biological|Secukinumab|Eligible subjects are randomised to each of three treatment arms in a 1:1:1 ratio
190006|NCT01989468|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
190007|NCT01989494|Device|Pedometer|All groups will receive a pedometer to measure their daily steps
190008|NCT01989507|Drug|Nicotine|
190009|NCT01989507|Behavioral|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
190312|NCT01981707|Device|F-Choline-PET|
190313|NCT01981720|Drug|PRX-102|
190314|NCT01981733|Device|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
190315|NCT01981746|Procedure|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
190316|NCT01984216|Procedure|Billroth II for the gastrojejunostomy reconstruction|
189675|NCT00115141|Drug|Resiquimod|
189676|NCT01953887|Drug|solifenacin|oral
189677|NCT01953887|Drug|tamsulosin|oral
189678|NCT01953900|Genetic|GD2 T cells|On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.
Dose levels 1 and 2 are:
Dose Level 1: 1x10^6 cells/m^2
Dose Level 2: 1x10^7 cells/m^2
The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:
Dose Level 7: 1 x 10^7 cells/m2
Dose Level 8: 1 x 10^8 cells/m^2
The previously planned dose levels 3-6 will not be studied.
189679|NCT01953900|Biological|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
189680|NCT01953913|Drug|Afatinib|Patient will receive afatinib once daily
189681|NCT01953926|Drug|Neratinib|240 mg orally, once daily with food, continuously in 28 day cycles
189682|NCT01955863|Procedure|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
189683|NCT01955863|Procedure|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
189684|NCT01955876|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
189685|NCT01955889|Behavioral|Mobile Health Technology|
189686|NCT01955889|Behavioral|Stretching & Strengthening Exercises|
189687|NCT01955889|Behavioral|Walking with Pedometer|
189688|NCT01955928|Behavioral|Online Cognitive behavioral treatment for insomnia|
189689|NCT01955954|Device|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of normal breathing patterns.
189690|NCT01955967|Drug|Lidocaine|
189691|NCT00115440|Radiation|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
189692|NCT01955980|Drug|Budesonide|Inhalation
189693|NCT01955980|Drug|Budesonide|Nasal Spray
189694|NCT01956006|Drug|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
189695|NCT01956019|Device|MRI scanning|
189066|NCT00116805|Drug|TDF|TDF 300 mg tablet administered orally once daily
189067|NCT01968161|Drug|Asenapine|
189068|NCT01968187|Drug|FE 992097|
189069|NCT01968187|Drug|Placebo|
189070|NCT01968200|Drug|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
189371|NCT01961258|Other|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
189372|NCT00115934|Procedure|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
189373|NCT01961271|Drug|Buprenorphine transdermal patch|Please see Arm Description.
189374|NCT01961284|Device|Zygomatic implant placement|
189375|NCT01961284|Device|conventional implants and augmentation of maxilla|
189376|NCT01961297|Drug|Sodium oxybate|Sodium oxybate
189377|NCT01961310|Biological|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
189378|NCT01961310|Biological|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
189379|NCT01961323|Drug|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
189380|NCT01961336|Drug|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
189381|NCT01961349|Drug|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
189382|NCT01963624|Device|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
189383|NCT01963637|Device|gastric tomodensitometry with gas at 3 months and 12 months|
189384|NCT01963663|Drug|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
189385|NCT01963663|Drug|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
189077|NCT00116805|Drug|ADV|ADV 10 mg tablet administered orally once daily
189078|NCT01968265|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
189079|NCT01968278|Other|Baked milk|
189080|NCT01968291|Behavioral|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
189081|NCT01968304|Other|Iron status follow up|
189082|NCT01968317|Drug|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 4 months.
189083|NCT01968317|Drug|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 4 months.
189084|NCT01968330|Behavioral|Go!®to sleep|
189085|NCT01970800|Drug|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
189086|NCT00117117|Drug|Aranesp|
189087|NCT01970813|Device|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
189088|NCT01970813|Device|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
189089|NCT01970826|Procedure|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
189090|NCT01970826|Procedure|Sterilized Aseptic|Operatory room will be prepared totally aseptic
189091|NCT01970826|Procedure|Sterilized Clean|Operatory room will be prepared clean but not aseptic
189393|NCT01963702|Drug|Oxaliplatin|
189394|NCT01963702|Drug|Capecitabine|
189395|NCT01963715|Drug|IMGN289|
189396|NCT01963728|Drug|Insulin, Isophane|daily dosing based on fasting morning glucose levels
189397|NCT01963728|Drug|insulin glargine|daily dose based on fasting morning glucose levels
188755|NCT01975597|Procedure|Bone marrow aspirates and biopsy|
188756|NCT01975610|Drug|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
188757|NCT01975610|Drug|Placebo|Twice daily for 28 days
188758|NCT01975623|Device|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
188759|NCT01975636|Drug|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
188760|NCT01975649|Drug|Tribulus Terrestris|patients will use 750 mg/day during 120 days
188761|NCT01975649|Other|Placebo|patients will use placebo pills with the same shape of the drug
188762|NCT01978093|Biological|Havrix®|2 doses administered IM in the left upper thigh at Month 10-13 and Month 16-19.
188763|NCT01978119|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
188764|NCT01978119|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
188765|NCT00117728|Drug|nevirapine|
188766|NCT01978132|Procedure|forearm ischemia and reperfusion|both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
188767|NCT01978145|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
188768|NCT01978145|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
188769|NCT01978158|Drug|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
188770|NCT01978184|Drug|gemcitabine|
188771|NCT01978184|Drug|abraxane|
188772|NCT01978184|Drug|hydroxychloroquine|
189092|NCT01970826|Procedure|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
189093|NCT01970826|Procedure|Partial Rehabilitation|two or more implants to support partial rehabilitation
193296|NCT02073448|Drug|GK530G|
193297|NCT02073448|Drug|CD0271|
193298|NCT02073448|Drug|CD1579|
188427|NCT01983644|Device|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
188428|NCT01983657|Drug|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
188429|NCT01983657|Procedure|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
188430|NCT01983670|Other|Temporal electrical stimulation|
188431|NCT01983683|Drug|Cadazolid|Cadazolid 250 mg or matching placebo oral suspension twice daily.
188432|NCT01983683|Drug|Vancomycin|Oral vancomycin 125 mg or matching placebo capsules 4 times daily
188433|NCT00118105|Drug|capecitabine|Pre & Post Operative: 1,700 mg/m^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
188434|NCT01983696|Other|5% oxygen concentration|the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
188435|NCT01985906|Device|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
188436|NCT01985919|Other|Obtaining human tissue for basic research or biospecimen bank|
188437|NCT01985932|Device|MRI|
188438|NCT01985945|Other|Yoga|
188439|NCT01985958|Device|Radiation therapy|
188440|NCT00118248|Drug|tanespimycin|Given IV
188441|NCT01985971|Radiation|PET/CT Imaging|
188442|NCT01985984|Radiation|Radiation alone or in combination with systemic therapy|Treated with radiotherapy alone or in combination with systemic therapy
188443|NCT01986010|Biological|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
188444|NCT01986010|Biological|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
188445|NCT01986010|Biological|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
192960|NCT01957462|Device|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
192961|NCT01957475|Device|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
192962|NCT01957475|Device|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
192963|NCT01957488|Device|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
192964|NCT01957488|Device|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
192965|NCT00115583|Drug|Drug Infusion (BQ-123)|
192966|NCT01957488|Device|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
192967|NCT01957501|Other|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
192968|NCT01957514|Other|Laboratory Biomarker Analysis|Correlative studies
192969|NCT01957527|Device|Peripheral arterial tonometry (EndoPAT)|
192970|NCT01957540|Drug|Ticagrelor|
192971|NCT01957540|Drug|Prasugrel|
192972|NCT01957553|Device|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
192973|NCT01957553|Device|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
192974|NCT01957566|Procedure|APS|
193299|NCT00126503|Other|Pharmacological Study|Correlative studies
193300|NCT02073461|Drug|CD1579 2.5%|
193301|NCT02073461|Drug|CD1579 5%|
193302|NCT02073461|Drug|Vehicle|
193303|NCT02073474|Drug|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
193304|NCT02073487|Drug|Trastuzumab Emtansine|trastuzumab emtansine [Kadcyla] Intravenous repeating dose every 3 weeks
193305|NCT02073487|Drug|Trastuzumab|Trastuzumab (Herceptin) Intravenous repeating dose weekly
192662|NCT01964872|Drug|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
192663|NCT01964872|Drug|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
192664|NCT01964872|Drug|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
192665|NCT01964872|Drug|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
192666|NCT01964885|Dietary Supplement|IQP-AS-105|
192667|NCT00116402|Drug|fluticasone and salmeterol|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID.
192668|NCT01964885|Dietary Supplement|Placebo|
192669|NCT01964898|Behavioral|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
192670|NCT01964898|Behavioral|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
192671|NCT01964898|Drug|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
192672|NCT01964898|Other|Printed Self-help materials for Smoking Cessation|
192673|NCT01964911|Drug|Ropivacaïne|The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN <3/10 : non opioids, EN 3-5/10 : weak opioids, EN>5/10 : strong opioids).
If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.
In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days).
192674|NCT01964924|Drug|Akt Inhibitor GSK2141795|Given PO
192675|NCT01964924|Other|Laboratory Biomarker Analysis|Correlative studies
192676|NCT01964924|Drug|Trametinib|Given PO
192677|NCT01964937|Biological|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
192678|NCT00116415|Drug|efavirenz; didanosine EC; lamivudine|
192679|NCT01964937|Biological|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10^8 PFU.
192067|NCT01977144|Other|Comprehensive Chromosomal Screening|
192068|NCT01977157|Device|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
192069|NCT01977170|Biological|Hib/PRP-T vaccine|Hib liquid vaccine
192070|NCT01977183|Dietary Supplement|MSPrebiotic|Potato Resistant Starch
192071|NCT00117676|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
192072|NCT01977196|Biological|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
192073|NCT01977209|Drug|Gossypol|
192074|NCT01977209|Drug|Placebo|
192075|NCT01977222|Device|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
192076|NCT01977235|Drug|Irinotecan|
192077|NCT01977235|Drug|Cisplatin|
192384|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
192385|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
192386|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
192387|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
192388|NCT01972334|Biological|FMT|as explained in study arm
192389|NCT01972334|Biological|placebo|salt water or saline will be given as placebo
192390|NCT01972347|Drug|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
192391|NCT01972347|Drug|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
192392|NCT00117273|Drug|Portia (LNG/EE)|1 tablet daily x 28 days
191784|NCT01982539|Drug|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
191785|NCT00118209|Biological|rituximab|IV
191786|NCT01984801|Other|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
191787|NCT01984801|Other|Patch only|Only patch will be applied
191788|NCT01984814|Biological|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
191789|NCT01984827|Drug|Moxifloxacin|a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours
a single oral dose of 400mg Moxifloxacin plus C-peptide
a single oral dose of 400mg Moxifloxacin
placebo
Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m.
191790|NCT01984827|Other|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
191791|NCT01984840|Device|Telemedicine|
191792|NCT01984853|Other|OBSERVATIONAL REGISTRY|
191793|NCT01984879|Other|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
191794|NCT01984892|Drug|Poly-ICLC|Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.
Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.
Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.
Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.
Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.
Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.
Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy
Follow Up via phone every 3 months for 30months, after completion of treatments.
192078|NCT01977248|Behavioral|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
192079|NCT01977261|Procedure|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
192080|NCT01977261|Procedure|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
192081|NCT01977274|Other|gynecological cancer|blood and tumor samples
192082|NCT00117676|Drug|ADV|Adefovir dipivoxil (ADV) 10 mg tablet administered orally once daily
192083|NCT01977287|Device|Functional Electrical Stimulation|
191487|NCT01989936|Drug|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
191488|NCT01989936|Drug|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
191489|NCT01992471|Behavioral|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
191490|NCT00118755|Drug|capecitabine|850 mg/m^2 po bid on Days 1-14 of each 3-week cycle
191491|NCT01992471|Other|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
191492|NCT01992471|Behavioral|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
191493|NCT01992471|Behavioral|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
191494|NCT01992497|Dietary Supplement|Probiotic|
191495|NCT01992523|Drug|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
191496|NCT01992523|Drug|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
190843|NCT01961869|Other|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
190844|NCT01961869|Other|Intermed release BRBconfect|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
190845|NCT01961869|Other|Prolong release BRB confect|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
190846|NCT01961882|Drug|OCV-501|
190847|NCT01961882|Drug|Placebo|
190848|NCT01961895|Procedure|Continuous lumbar plexus (LP) block analgesia|
190849|NCT01961895|Drug|Intravenous patient-controlled analgesia|
190850|NCT01961908|Drug|Proellex|
191168|NCT01956747|Procedure|venapunction|
191169|NCT01956747|Procedure|bone marrow punction|
191170|NCT01956760|Other|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
191171|NCT01956773|Other|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
191172|NCT01956786|Drug|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
191173|NCT01956786|Drug|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
191174|NCT01956786|Drug|Amlodipine|5mg amlodipine,once daily
191175|NCT01956812|Drug|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
191176|NCT00115531|Biological|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
191177|NCT01959243|Drug|Vehicle|
191178|NCT01959256|Behavioral|Visual perceptual learning|24 times of training for visual perceptual learning
190235|NCT01973829|Other|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
190538|NCT01966471|Drug|anthracycline-based chemotherapy|3 to 4 cycles of standard of care anthracycline-based chemotherapy
190539|NCT01966471|Drug|pertuzumab|840 mg loading dose followed by 420 mg IV q3w
190540|NCT01966471|Drug|taxane|paclitaxel 80 mg/m2 IV qw or docetacel q3w
190541|NCT01966471|Drug|trastuzumab|8 mg/kg loading dose followed by 6 mg/kg IV q3w
190542|NCT01966471|Drug|trastuzumab emtansine|3.6 mg/kg IV q3w
190543|NCT00116571|Device|Transurethral drug delivery system|
190544|NCT01966484|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
190545|NCT01966484|Drug|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
190546|NCT01966510|Other|Cord Blood Transplantation|
190547|NCT01968850|Drug|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
190548|NCT01968876|Other|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
190549|NCT01968889|Other|Non invasive phrenic nerve stimulation|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
190550|NCT01968902|Biological|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
190551|NCT01968902|Biological|Placebo|Saline injection on the day of injection visit
190552|NCT00116857|Drug|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
185533|NCT02550990|Behavioral|Aerobic exercise training|
185534|NCT02550990|Behavioral|Sequential combination of aerobic exercise and cognitive training|
185535|NCT02550990|Behavioral|Active control|
185536|NCT02551003|Drug|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
185537|NCT02551003|Device|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
185538|NCT00185185|Drug|olmesartan medoxomil|tablets
185539|NCT02551029|Other|Capsaicin|
185540|NCT02551029|Other|Placebo|
185541|NCT02551042|Drug|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
185542|NCT02551042|Drug|0.9% sodium chloride|IV infusion
185543|NCT02551055|Drug|MLN1117|MLN1117 Tablets
185544|NCT02551055|Drug|TAK-659|TAK-659 Tablets
185545|NCT02551055|Drug|Alisertib|Alisertib Tablets
185546|NCT02551055|Drug|Paclitaxel|Paclitaxel intravenous infusion
185547|NCT02551055|Drug|Docetaxel|Docetaxel intravenous infusion
185548|NCT02551068|Other|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
185549|NCT00185185|Drug|atenolol|tablets
185826|NCT02544529|Drug|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
185827|NCT02544529|Drug|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
185828|NCT02544542|Device|Rectum cooling system|
185829|NCT02544542|Device|Hyper-hypothermia blanket|
190951|NCT01971749|Procedure|Coronary stent procedure (CSP)|
190952|NCT01971749|Procedure|Coronary-artery bypass grafting (CABG)|
191258|NCT01966627|Other|stool sample|stool sample taken to investigate metabolites
191259|NCT01966627|Other|liver biopsy|liver biopsy to examine for cellular change and steatosis
191260|NCT01966640|Biological|Basophil Activation Test|blood sample for Basophil Activation Test
191261|NCT01966653|Drug|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
191262|NCT01966653|Drug|fosfomycin|fosfomycin 3g po single dose
191263|NCT01966666|Drug|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
191264|NCT01966666|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
191265|NCT01966666|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
191266|NCT00116597|Genetic|Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|
191267|NCT01966666|Drug|Placebo|500mL 0.9% sodium chloride.
191268|NCT01966679|Drug|AZD7325|
191269|NCT01966679|Drug|Placebo|
191270|NCT01966692|Drug|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
191271|NCT01966692|Drug|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
191272|NCT01966692|Drug|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
191273|NCT01966692|Drug|Fluticasone Propionate Formulation 3*|Fluticasone Propionate dry powder inhaler Formulation 3*
*(The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation.
191274|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Participants are guided by a therapist. Treatment is delivered via the Internet.
190635|NCT01976468|Other|SCC metastasis|occurrence of SCC metastasis
190636|NCT01976481|Device|sunbed exposure|exposure to sunbed ultraviolet radiation
190637|NCT01976494|Device|The domestic PCA equipment 'Accufuser Omnibus®'|Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.
Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.
Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.
After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.
After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab.
190638|NCT01976494|Device|Imported PCA equipment 'Infusor SV®, Baxter, USA'|Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.
Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.
Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.
After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.
After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab.
190953|NCT01971762|Behavioral|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
190954|NCT01971762|Behavioral|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
190955|NCT01971775|Device|Ultrasonically activated Shears|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
190956|NCT01971775|Device|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
190957|NCT01971788|Device|Optical Coherence Tomography of the infarct related artery|
190958|NCT01971801|Dietary Supplement|Vitamin D|Capsule given by mouth once a week
190959|NCT01974128|Procedure|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
190960|NCT01974141|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
190961|NCT01974141|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
190962|NCT01974167|Drug|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
190963|NCT00117442|Drug|pegfilgrastim|Growth factor for mobilization
190317|NCT01984229|Drug|Posaconozole|400 mg Posaconozole adminstered orally twice daily.
190318|NCT01984229|Drug|RO5424802|Single oral dose of RO5424802
190319|NCT00002147|Drug|Doxorubicin hydrochloride (liposomal)|
190320|NCT00118157|Drug|Tamoxifen Citrate|Given PO
190321|NCT01984242|Drug|atezolizumab|1200 mg IV q3w dosed in 6-week cycles until disease progression
190322|NCT01984242|Drug|atezolizumab|Following disease progression: 1200 mg IV q3w dosed in 6-week cycles, until disease progression
190323|NCT01984242|Drug|bevacizumab [Avastin]|15 mg/kg IV q3w (dosed in 6-week cycles), until disease progression
190324|NCT01984242|Drug|bevacizumab [Avastin]|Following disease progression: 15 mg/kg IV q3w (dosed in 6-week cycles), until disease progression
190325|NCT01984242|Drug|sunitinib|50 mg/day orally for 4 weeks, followed by 2 weeks of rest (dosed on 6-week cycles), until disease progression
190326|NCT01984255|Drug|Arm A-Bavituximab with Ipilimumab|Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
190327|NCT01984255|Drug|Arm B-Ipilimumab|Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
190328|NCT01984268|Drug|ACTHAR|
190329|NCT01984268|Drug|NSAID|
190330|NCT01984281|Behavioral|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly increased up to the maximum of 12500 steps per day. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
190331|NCT00118170|Drug|sorafenib tosylate|Given orally
190332|NCT01984294|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
190639|NCT01979029|Procedure|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
189696|NCT01956045|Other|Patient's capacity|
189697|NCT01956058|Radiation|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
190010|NCT01989520|Drug|Phase IIb formulation|Single oral dose 45mg AZD5069
190011|NCT01989520|Drug|Putative phase III formulation|Single oral dose 45mg AZD5069
190012|NCT00118404|Behavioral|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
190013|NCT01989520|Drug|Slow dissolution variant 1|Single oral dose 45mg AZD5069
190014|NCT01989520|Drug|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
190015|NCT01991821|Drug|Placebo|
190016|NCT01991834|Procedure|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
190017|NCT00118677|Procedure|Treatment interruption|
190018|NCT01991834|Drug|Cefazolin|Intravenous administration of 1 g of cefazolin
190019|NCT01991834|Drug|Placebo|Intravenous administration of saline sterile solution
190020|NCT01991847|Behavioral|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
190021|NCT01991860|Drug|APD421|
190022|NCT01991860|Drug|Placebo|
190023|NCT01991873|Drug|Maintenance Chemotherapy|
190024|NCT01991873|Drug|Panitumumab (Within maintenance phase)|
190025|NCT01991873|Drug|mFOLFOX6 (Within re-induction phase)|
190026|NCT01991873|Drug|Panitumumab (Within re-induction phase)|
190027|NCT01991886|Device|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
190028|NCT00118690|Drug|Fluticasone propionate/salmeterol|
190029|NCT01991899|Biological|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
189386|NCT01963676|Device|tDCS|
189387|NCT01963676|Device|Sham stimulation|
189388|NCT01963689|Other|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
189389|NCT01963689|Other|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
189390|NCT00116233|Device|REPEL-CV|
189391|NCT01963689|Other|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
189392|NCT01963702|Drug|Docetaxol|
189698|NCT01956084|Drug|LMP1/2 CTLs (Group A)|Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One:
Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2
Dose Level Two:
Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2
Dose Level Three:
Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2
189699|NCT01956084|Drug|LMP1/2 CTLs (Group B)|Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One:
Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2
Dose Level Two:
Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2
Dose Level Three:
Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2
189700|NCT01956097|Dietary Supplement|HX106 590mg|
189701|NCT01956097|Dietary Supplement|HX106 1180mg|
189702|NCT00115453|Radiation|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
189703|NCT01956097|Dietary Supplement|Placebo|
189704|NCT01956110|Drug|FE 999049|
189705|NCT01956110|Drug|Follitropin Alfa (Gonal-F)|
189706|NCT01956123|Drug|FE 999049|
189707|NCT01956123|Drug|Follitropin alfa (Gonal-F)|
189708|NCT01958580|Radiation|External Beam Radiation Therapy|Undergo EBRT
189709|NCT01958580|Other|Laboratory Biomarker Analysis|Correlative studies
189710|NCT00115687|Drug|placebo|
189711|NCT01958593|Drug|Comparator|Comparator administered in two experimental sessions; may take part in Stage 2 upon learning condition assignment
189398|NCT01963741|Drug|leukotriene D4|Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was <30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
189399|NCT01963741|Drug|histamine|Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was <30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
189400|NCT01963754|Device|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
189401|NCT00116246|Procedure|McRobert's manoeuvre|
189402|NCT01963754|Drug|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
189403|NCT01963754|Drug|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
189404|NCT01963767|Drug|NT-020|Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.
Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract*
Vaccinium angustifolium
Other Ingredients:
Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives.
189405|NCT01963767|Dietary Supplement|Placebo|
189406|NCT00116506|Drug|bevacizumab|
189407|NCT01965925|Drug|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
189408|NCT01965938|Device|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
189409|NCT01965938|Device|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
189410|NCT01965951|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, one hour each session.
189722|NCT01958645|Other|Placebo|Placebo for MEDI8111 saline solution for infusion
189723|NCT01958658|Drug|Cisplatin|Given IV
189724|NCT01958658|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
189094|NCT01970826|Procedure|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
189095|NCT01970839|Device|tourniquet, sensory nerve conduction abnormality|
189096|NCT01970852|Other|Standard tablet computer|No special enhancements or links to personal health information.
189097|NCT00117130|Drug|Aranesp®|
189098|NCT01970852|Other|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
189099|NCT01970865|Drug|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
189100|NCT01970865|Drug|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
189101|NCT01970878|Drug|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
189102|NCT01970878|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
189103|NCT01970878|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
189104|NCT01970878|Drug|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
189105|NCT01970891|Device|neuromuscular stimulation device|effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait relief
189106|NCT01970904|Drug|DEB025 200mg|Dual-therapy with a response-guided treatment duration with DEB025 200 mg BID and RBV
189107|NCT01970904|Drug|DEB025 300mg|Dual-therapy with a response-guided treatment duration with DEB025 300mg BID and RBV
189108|NCT00117143|Drug|AMG 531|
189109|NCT01970904|Drug|DEB025 400mg|Dual-therapy with a response-guided treatment duration with DEB025 400mg BID and RBV
189110|NCT01970917|Device|Olixia pure eye drops|
189111|NCT01973335|Drug|High-dose loop diuretics|Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.
Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.
If diuresis <1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.
In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.
188446|NCT01986010|Biological|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
188447|NCT01986010|Biological|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
188448|NCT01986010|Biological|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
188449|NCT01986010|Other|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
188773|NCT01978197|Drug|Menthol nicotine polacrilex gum 2 mg|
188774|NCT01978197|Drug|Menthol nicotine polacrilex gum 4 mg|
188775|NCT01978197|Drug|Nicotine polacrilex gum 2 mg|
188776|NCT00117741|Behavioral|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
188777|NCT01978197|Drug|Nicotine polacrilex gum 4 mg|
188778|NCT01978197|Drug|Menthol electronic cigarette|
188779|NCT01978197|Drug|Regular electronic cigarette|
188780|NCT01978210|Device|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
188781|NCT01978223|Procedure|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
188782|NCT01978236|Drug|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
188783|NCT01978236|Drug|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
188784|NCT01978249|Procedure|Systemic chemotherapy|
188785|NCT01978249|Procedure|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
188786|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)|One time injection of 20 ug/kg FGF 1-141 via a catheter
193306|NCT02073487|Drug|Lapatinib|Lapatinib repeating dose taken orally every day for 6 weeks
193307|NCT02073487|Drug|Abraxane|Abraxane repeating dose weekly IV for up to 12 weeks
193308|NCT02073487|Drug|Paclitaxel|Paclitaxel IV repeating dose weekly for up to 12 weeks
193309|NCT02073487|Drug|Pertuzumab|Pertuzumab repeating dose weekly IV for up to 12 weeks
193310|NCT00126503|Other|Laboratory Biomarker Analysis|Correlative studies
193311|NCT02073500|Other|Observational study.|Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.
HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.
193312|NCT02073513|Device|Kinesiotape plus thenar pressure (PPTG)|In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.
The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions.
193313|NCT02073513|Device|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
193314|NCT02073526|Drug|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
193315|NCT02073539|Device|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
193316|NCT02073539|Device|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
193317|NCT02075658|Device|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
193318|NCT02075671|Drug|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
193319|NCT02075671|Device|Blu-U Light Therapy|Intervention used in experimental and sham arms
193320|NCT02075671|Other|Placebo vehicle only|Intervention only includes the placebo vehicle solution
188450|NCT01986010|Biological|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
188451|NCT00118261|Biological|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
188452|NCT01986010|Other|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
188453|NCT01986023|Behavioral|SMS- Short Messaging Service|
188454|NCT01986036|Dietary Supplement|Protein|Milk-Protein
192680|NCT01964937|Biological|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10^6 PFU IM, for a planned maximum dose of 1.1×10^7 PFU.
192681|NCT01964937|Biological|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
192975|NCT01959958|Other|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
192976|NCT01959971|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
192977|NCT00115804|Drug|Fluoxetine|fluoxetine po 10-60 mg/day for 12 weeks
192978|NCT01959971|Drug|Placebo|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
192979|NCT01959984|Other|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
192980|NCT01959984|Other|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
192981|NCT01959997|Procedure|Redo PVI|
192982|NCT01959997|Procedure|PVI + RDN|
192983|NCT01960010|Drug|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
192984|NCT01960010|Drug|Vehicle|Vehicle dosed BID
192985|NCT01960023|Drug|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
192986|NCT01960023|Drug|Neratinib|Phase I portion of the study:
Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day
Phase II portion of the study: The recommended dose determined in the Phase I portion of the study.
192987|NCT01960036|Behavioral|Mindful Awareness in Body-oriented Therapy|
192988|NCT00002123|Drug|Didanosine|
192989|NCT00115804|Drug|Fluoxetine|Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
192990|NCT01960036|Behavioral|Womens Health Education|
192991|NCT01960049|Procedure|ropivacaine + iv PCA|
192992|NCT01960049|Procedure|saline and IV PCA|
192393|NCT01972373|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
192394|NCT01972373|Device|NIR fluorescence endoscopy|48 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
192395|NCT01972386|Device|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
192396|NCT01972399|Procedure|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
192397|NCT01972399|Procedure|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
192398|NCT01972412|Behavioral|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
192399|NCT01972425|Other|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
192400|NCT01972438|Drug|Autologous Serum Eye Drops|
192401|NCT01972451|Procedure|Colonoscopy with enhanced dye|
192402|NCT01972464|Drug|Progesterone|
192403|NCT00117286|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
192404|NCT01972464|Drug|Placebo|
192405|NCT01972477|Drug|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
192682|NCT01964937|Biological|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
192683|NCT01964950|Drug|Alogliptin|Alogliptin tablets
192684|NCT01964963|Drug|Alogliptin|Alogliptin tablets
192685|NCT01964976|Drug|Alogliptin|Alogliptin tablets
192686|NCT01967225|Drug|Tedizolid(BAY1192631)|BAY1192631 solution or tablet 200 mg,once daily,Intravenous (IV) or By Mouth (PO)for 7-21 days
192687|NCT01967225|Drug|Linezolid|Linezolid solution or tablet 600 mg,twice daily,every 12 ±3 hours, Intravenous (IV) or By mouth (PO) for 7-21days
192688|NCT00116662|Drug|Resiquimod|
192689|NCT01967238|Biological|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
192084|NCT01979744|Procedure|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
192085|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
192086|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
192087|NCT01979744|Procedure|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
192088|NCT01979757|Other|Puregraft|
192089|NCT01979757|Other|Centrifugation|
192090|NCT01979796|Device|Ecig 24 mg nicotine|
192091|NCT01979796|Device|Ecig 0 mg nicotine|
192092|NCT01979796|Device|Nicotine free inhalator|
192093|NCT00117884|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
192406|NCT01972477|Other|Placebo|Placebo will be given every day for 8 weeks.
192407|NCT01972490|Drug|avastin+chemotherapy of mFOLFOX6 or FOLFIRI|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (180 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
192408|NCT01972490|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
192409|NCT01972503|Drug|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
191497|NCT01992536|Biological|MenABCWY+OMV|Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a "full" dose) plus the fully lyophilized MenACWY vaccine
191795|NCT01984918|Other|SMS|A SMS reminder will be sent to patients 7 - 10 days before his colonoscopy appointment
191796|NCT00118209|Drug|cyclophosphamide|IV
191797|NCT01984918|Other|No SMS|No SMS reminder will be sent
191798|NCT01984931|Drug|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
191799|NCT01984931|Drug|Metoclopramide hydrochloride monohydrate|
191800|NCT01984944|Other|Autistic functional exploration|50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer
25 childs with urinary sample, Circadian rhythms assessed with actometer
191801|NCT01984944|Other|Control functional exploration|50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer
25 childs with urinary sample, Circadian rhythms assessed with actometer
191802|NCT01984957|Procedure|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
191803|NCT01984970|Device|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
191804|NCT01984983|Biological|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
191805|NCT01984983|Other|0.9% saline placebo|
191806|NCT01984996|Device|Freedom ProFlor Inguinal Hernia Implant|
191807|NCT01987388|Other|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
191808|NCT01987388|Other|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
191809|NCT01987414|Behavioral|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
191810|NCT01987414|Device|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
191811|NCT01987414|Other|No treatment|Participants will maintain their daily routines during the no treatment period.
191179|NCT01959269|Drug|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
191180|NCT01959282|Drug|Placebo|Participants will receive placebo once daily
191181|NCT01959282|Drug|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
191182|NCT01959282|Drug|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
191183|NCT01959282|Drug|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
191184|NCT01959282|Drug|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
191185|NCT01959295|Drug|ASP2151|200 mg once daily
191186|NCT01959295|Drug|ASP2151 placebo|once daily
191187|NCT00115726|Drug|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
191188|NCT01959308|Other|N.A.|
191189|NCT01959334|Drug|Glucagon IN|3 mg of glucagon in 30 mg of AMG504-1 dry powder intranasal 3 doses, separated by at least 7 days
191498|NCT01992536|Biological|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
191499|NCT01992536|Biological|Placebo|Saline solution for injection (0.5mL)
191500|NCT01992549|Biological|Human-cl rhFVIII|
191501|NCT00118755|Drug|Oxaliplatin|130 mg/m^2 IV on Day 1 of each 3-week cycle
191502|NCT01992562|Drug|Ziconotide|
191503|NCT01992562|Drug|placebo|
191504|NCT01992588|Drug|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.
The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.
191505|NCT01992588|Drug|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.
The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.
190553|NCT01968915|Drug|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
190554|NCT01968915|Drug|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
190555|NCT01968941|Radiation|Stereotactic Body Radiotherapy (SBRT)|
190851|NCT00115999|Drug|alfimeprase|
190852|NCT01961921|Drug|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
190853|NCT01961934|Drug|Sodium Acetate C11 PET/CT Imaging|
190854|NCT01961947|Biological|ASP7374|subcutaneous
190855|NCT01961947|Biological|approved egg-derived TIV|subcutaneous
190856|NCT01961960|Biological|ASP7374|intramuscular
190857|NCT01961973|Procedure|Cultured Chondrocytes|This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
190858|NCT01961973|Procedure|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
190859|NCT01961986|Procedure|TSR - traditional subscapularis release|Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
190860|NCT01961986|Procedure|TSR - rotator cuff sparing|Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
190861|NCT01961999|Procedure|Early RRT|In the "early" arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours
190862|NCT00116012|Drug|rNAPc2|
190863|NCT01961999|Procedure|Late RRT|In the "late" arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:
persistent and refractory oliguria (<0,5ml/Kg/h >12h), despite therapy refractory extravascular fluid overload azotemia >40mmol/L or 240mg/dL metabolic acidosis (pH<7,2) hyperkaliemia (k+>6mmol/L)
185830|NCT02544555|Procedure|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for CTO (chronic total occlusion) lesion and CTO devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
185831|NCT02544555|Procedure|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
185832|NCT02544568|Other|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
185833|NCT02544581|Other|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
185834|NCT02544594|Device|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
185835|NCT00184626|Drug|insulin glargine|
185836|NCT02544607|Drug|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
185837|NCT02544620|Other|Does fulfil of discharge criteria on the day of the surgery|
185838|NCT02544620|Other|Does not fulfil of discharge criteria on the day of the surgery|
185839|NCT02544633|Drug|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
185840|NCT02544646|Other|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
185841|NCT02544659|Drug|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
185842|NCT02544672|Device|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
186121|NCT02539992|Device|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
186122|NCT00183976|Drug|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
191275|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Participants are not guided by a therapist. Treatment is delivered via the Internet.
191276|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Participants are not guided by a therapist. Treatment is delivered in book form.
191277|NCT00116597|Biological|Intranodal booster immunizations with synthetic melanoma associated epitopes|
191278|NCT00002132|Drug|Fluconazole|
191578|NCT01962220|Behavioral|Study Intervention for Retention (APFU)|Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).
Mama Mshauri tasks will include:
Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.
Providing tailored individualized health education during home visits.
Additional intervention components include:
Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.
Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment.
191579|NCT01962233|Biological|mesenchymal stem cells|Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.
Intravenous infusion of umbilical cord derived mesenchymal stem cells
191580|NCT01962246|Drug|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
191581|NCT01962246|Other|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
191582|NCT01962259|Behavioral|Physical activity|
191583|NCT01962272|Behavioral|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
191584|NCT01962272|Dietary Supplement|Forticare®.|
191585|NCT00116051|Device|Acetabular implant, Monoblock cup|
191586|NCT01962285|Drug|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
191587|NCT01962298|Drug|sugammadex 2mg/kg|
191588|NCT01962298|Drug|neostigmine|
191589|NCT01962298|Drug|sugammadex 4mg/kg|
191590|NCT01962298|Drug|placebo|
190964|NCT01974167|Drug|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
190965|NCT01974193|Drug|Floseal|application of floseal on intervention arm
190966|NCT01974206|Biological|ASP0113|intramuscular injection
190967|NCT01974206|Drug|Placebo|intramuscular injection
190968|NCT01974219|Genetic|Examination of the interaction of HIV directly on the small airway epithelium|
190969|NCT01974245|Drug|Cholecalciferol|100,000 IU/week for 12 weeks
190970|NCT01974245|Drug|Placebo|100 drops/ week for 12 weeks
190971|NCT01974258|Drug|Cobimetinib|Escalating dose
190972|NCT01974258|Drug|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
190973|NCT01974258|Drug|Onartuzumab|Administered by IV infusion every 2 weeks
190974|NCT00117455|Drug|pegfilgrastim|
190975|NCT01974258|Drug|Vemurafenib|Orally administered twice daily
191279|NCT00116896|Drug|OSI-7904L|
191280|NCT01969240|Other|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the ED visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
191281|NCT01969266|Drug|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
191282|NCT01969266|Drug|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
191283|NCT01969292|Other|Colometer|Real time software based image analysis tool.
191284|NCT01969292|Other|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
191285|NCT01969305|Behavioral|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
190640|NCT01979029|Procedure|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
190641|NCT01979055|Behavioral|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
190642|NCT01979055|Behavioral|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
190643|NCT01979081|Other|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
190644|NCT00117806|Behavioral|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
190645|NCT01979107|Behavioral|Proactive action by the general practitioner|Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.
At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results.
190646|NCT01979133|Drug|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
190647|NCT01979146|Other|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
190648|NCT01979159|Behavioral|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
190649|NCT01979185|Drug|Simvastatin|
190650|NCT01979185|Drug|SSP-004184SS|
190651|NCT01979211|Drug|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
190652|NCT01979211|Radiation|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
190976|NCT01974284|Drug|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
190030|NCT01991899|Biological|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
190031|NCT01991912|Procedure|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
190032|NCT01991925|Other|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionaires and focusgroup interviews
190333|NCT01984294|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
190334|NCT01984294|Drug|GS-9669|GS-9669 tablet(s) administered orally once daily
190335|NCT01984320|Procedure|ICSI|Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
190336|NCT01984333|Behavioral|Online cognitive training|Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
190337|NCT01986790|Behavioral|Plain Language + Visuals|
190338|NCT01986790|Behavioral|Plain Language + Narratives|
190339|NCT01986803|Device|Percutaneous Coronary Intervention|Implanting a device ("Xience Xpedition" stent or "Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS)" to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point.
190340|NCT01986829|Procedure|microwave ablation|Undergo microwave ablation
190341|NCT01986829|Procedure|cryosurgery|Undergo cryoablation
190342|NCT01986829|Procedure|radiofrequency ablation|Undergo radiofrequency ablation
190343|NCT01986829|Procedure|Quality-of-life assessment|Ancillary studies
190344|NCT01986829|Other|Questionnaire administration|Ancillary studies
190345|NCT01986842|Dietary Supplement|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
190346|NCT00118287|Biological|etanercept|Given SC
189712|NCT01958593|Drug|Full-dose MDMA|Participants receive full-dose MDMA during two experimental sessions; after learning their condition assignment, participants will receive a third full-dose session.
189713|NCT01958606|Other|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
189714|NCT01958606|Other|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
189715|NCT01958619|Drug|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
189716|NCT01958619|Drug|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
189717|NCT01958619|Drug|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
189718|NCT01958619|Drug|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
189719|NCT01958632|Procedure|Nerve reconstruction|
189720|NCT01958645|Drug|MEDI8111|MEDI8111 lyophilisate for solution for infusion
189721|NCT00115687|Drug|2 mg nicotine polacrilex|
190033|NCT01991938|Drug|VS-5584|
190034|NCT01991951|Drug|warfarin|
190035|NCT01991964|Other|laryngeal ultrasound|
190036|NCT01991977|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
190037|NCT01991977|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
190038|NCT01991977|Procedure|Computed Tomography|Undergo 18F-DOPA-PET/CT
190039|NCT00002154|Drug|Selegiline hydrochloride|
190040|NCT00118703|Drug|GW685698X|
190041|NCT01991977|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
190042|NCT01991977|Procedure|Diffusion Weighted Imaging|Undergo DTI
190043|NCT01991977|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
190044|NCT01953939|Other|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
189725|NCT01958658|Radiation|Internal Radiation Therapy|Undergo pulsed-dose rate or high-dose rate brachytherapy
189726|NCT01958658|Other|Laboratory Biomarker Analysis|Correlative studies
189727|NCT01958658|Other|Pharmacological Study|Correlative studies
189728|NCT01958658|Radiation|Pulsed-Dose Rate Brachytherapy|Undergo pulsed-dose rate or high-dose rate brachytherapy
189729|NCT01958658|Drug|WEE1 Inhibitor AZD1775|Given PO
189730|NCT01958671|Drug|Ertugliflozin (5 mg)|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
189731|NCT01958671|Drug|Ertugliflozin (10 mg)|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
189732|NCT00002122|Drug|Fluconazole|
189733|NCT00115700|Drug|Cyclophosphamide|1000 mg/m2 I.V. on day 1
189734|NCT01958671|Drug|Placebo to Ertuglifozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
189735|NCT01961349|Drug|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
189736|NCT00115947|Drug|Terlipressin|
189737|NCT01961349|Drug|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
189738|NCT01961375|Drug|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
189739|NCT01961388|Drug|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
189740|NCT01961388|Drug|Metformin|Oral, dosage of Metformin as per the directions of treating physician
189741|NCT01961401|Behavioral|exercise|
189742|NCT01961414|Drug|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
189743|NCT01961427|Dietary Supplement|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
189744|NCT01961427|Dietary Supplement|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
189745|NCT01961453|Drug|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
189411|NCT01965951|Other|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, one hour each session.
189412|NCT01965964|Procedure|Questionnaire|
189413|NCT01965977|Drug|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
189414|NCT01965990|Other|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
189415|NCT01966003|Drug|carboplatin|AUC 6 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
189416|NCT01966003|Drug|paclitaxel|200 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
189417|NCT00116519|Drug|PPAR alpha|
189418|NCT01966003|Drug|ABP 215|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of cycles: 6.
189419|NCT01966003|Drug|bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of cycles: 6.
189420|NCT01966016|Procedure|Pacing|In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.
In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared
189421|NCT01966029|Drug|BMN 110|All pateints receive treatment with BMN 110
189422|NCT01966042|Procedure|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
189423|NCT01966042|Procedure|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
189424|NCT01966042|Procedure|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
189425|NCT01968343|Behavioral|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
189426|NCT01968343|Other|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
188787|NCT01980953|Drug|GDC-0032|Tablet formulation, single doses given under fed or fasted conditions
188788|NCT01980953|Drug|GDC-0032|Tablet formulation A, given as single doses
188789|NCT01980953|Drug|GDC-0032|Tablet formulation B, given as single doses
188790|NCT01980953|Drug|GDC-0032|Capsule formulation B, given as single doses
188791|NCT01980953|Drug|GDC-0032|Capsule formulation A, single doses given under fasted conditions
188792|NCT01980966|Drug|MHAA549A|IV dose
188793|NCT01980966|Drug|Placebo|IV dose
189112|NCT01973335|Drug|Upfront therapy with oral spironolactone|Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is >5 mmol/L.
Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not.
189113|NCT01973348|Device|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
189114|NCT01973348|Device|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
189115|NCT00117377|Drug|Placebo|Placebo application bid
189116|NCT01973348|Device|2-hour patching|2-hour patching for moderate amblyopia
189117|NCT01973348|Device|6-hour patching|6-hour patching for severe amblyopia
189118|NCT01973361|Device|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
189119|NCT01973361|Device|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
189120|NCT01973374|Behavioral|Text Message Intervention|
189121|NCT01973387|Drug|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
189122|NCT01973387|Drug|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
189123|NCT01973400|Dietary Supplement|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
189124|NCT01973400|Dietary Supplement|Placebo|Placebo
188455|NCT01986036|Dietary Supplement|Calcium|Soluble calcium powder.
188456|NCT01986036|Dietary Supplement|Porridge-based breakfast.|Oats and water.
188457|NCT01986049|Drug|Bupivacaine|
188458|NCT01986062|Drug|AR11|
188459|NCT01986075|Behavioral|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
188460|NCT01986075|Drug|Mixed amphetamine salts|80 mg/day of Adderall-XR
188461|NCT01986075|Drug|Computer-assisted CBT plus placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
188462|NCT01988506|Drug|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days for 6 months
188463|NCT01988519|Procedure|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
188464|NCT01988519|Procedure|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
188465|NCT01988532|Other|No treatment given|Subject will only fill out a questionnaire
188466|NCT01988545|Other|1,5 nmol/kg,GLP-1 sc injection|
188467|NCT01988545|Other|1,5 nmol/kg GLP-1 9-36amide, sc injection|
188468|NCT01988545|Other|Exendin-4 ;10 ug,sc injection|
188469|NCT01988545|Other|saline|
188470|NCT01988558|Drug|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
188471|NCT01988558|Dietary Supplement|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
188472|NCT00118352|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
188794|NCT01980966|Drug|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
188795|NCT01980979|Drug|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
192993|NCT01960062|Device|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
192994|NCT01960075|Drug|Fosphenytoin|
192995|NCT01960075|Drug|Levetiracetam|
192996|NCT01960075|Drug|Valproic acid|
192997|NCT01960088|Drug|HPV vaccine|
192998|NCT01960101|Other|LactoXeros|
193321|NCT02075684|Procedure|Renal Biopsy|
193322|NCT02075710|Other|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
193323|NCT02075710|Other|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
193324|NCT02075710|Other|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
193325|NCT02075710|Other|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
193326|NCT00126659|Other|laboratory biomarker analysis|Correlative studies
193327|NCT02075723|Dietary Supplement|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
193328|NCT02075723|Behavioral|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
193329|NCT02075736|Procedure|KTP laser|
193330|NCT02075736|Procedure|TUR-P|device
193331|NCT02075749|Drug|Triamcinolone Acetonide|
193332|NCT02075749|Drug|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
193333|NCT02075762|Procedure|Transbronchial biopsy|
193334|NCT02075762|Procedure|Cryoprobe biopsy|
193335|NCT02075762|Procedure|VATS biopsy|
193336|NCT02075788|Other|Commercial white bread|
193337|NCT00126672|Drug|sirolimus|
193338|NCT02075788|Other|Corn based products (porridge etc.)|
192690|NCT01967251|Drug|Udenafil|Udenafil tablets
192691|NCT01967251|Drug|Placebo|Udenafil placebo-matching tablets
192692|NCT01967264|Drug|Udenafil|Udenafil tablets
192693|NCT01967264|Drug|Placebo|Placebo tablets
192694|NCT01967277|Device|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
192695|NCT01967277|Device|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
192696|NCT01967290|Device|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
192697|NCT01967290|Device|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
192698|NCT01967316|Biological|Herpes Zoster Vaccine|0.65-mL dose injection on baseline visit.
192699|NCT00116675|Drug|Resiquimod|
192700|NCT01967329|Drug|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
192701|NCT01967329|Drug|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
192702|NCT01967329|Drug|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
192703|NCT01967342|Behavioral|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
192999|NCT01960101|Device|Aequasyal|
193000|NCT00115817|Drug|Atorvastatin|
193001|NCT01960114|Drug|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
193002|NCT01960114|Drug|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
193003|NCT01960127|Behavioral|Aerobic exercise|
193004|NCT01962844|Dietary Supplement|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
192410|NCT01974726|Other|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
192411|NCT01974726|Other|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
192412|NCT01974726|Other|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
192413|NCT01974726|Other|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
192414|NCT01974726|Other|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
192704|NCT01967342|Behavioral|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
192705|NCT01967342|Other|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
192706|NCT01967355|Other|lipid apheresis|
192707|NCT01967368|Drug|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
191812|NCT01987427|Drug|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
191813|NCT01987427|Drug|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
191814|NCT01987427|Drug|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
192094|NCT01979809|Behavioral|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
192095|NCT01979822|Other|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
192096|NCT01979835|Device|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
192097|NCT01979861|Device|AEGEA Vapor System(TM)|vapor endometrial ablation
192098|NCT01979874|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
192099|NCT01979874|Other|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
192100|NCT01979887|Procedure|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
192101|NCT01982565|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
192102|NCT01982565|Other|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
192103|NCT01982578|Dietary Supplement|Genistein|Subjects will be randomized 1:1 to receive 180 days of double blind treatment of genistein.
192104|NCT01982578|Other|Placebo|180 days of double blind treatment of placebo.
192105|NCT01982591|Other|laboratory biomarker analysis|Correlative studies
192106|NCT01982591|Other|questionnaire administration|Ancillary studies
192107|NCT01982604|Drug|TI-Inhalation Powder A|Inhaled Insulin
192108|NCT00118040|Other|laboratory biomarker analysis|Correlative studies
192109|NCT01982604|Drug|TI-Inhalation Powder B|Inhaled Insulin
191506|NCT01954472|Behavioral|Enhanced portfolio plus structured exercise|Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).
Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute.
191507|NCT01954472|Behavioral|High fiber diet plus routine exercise|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.
Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided.
191508|NCT01954485|Procedure|Dental implant placement with a final prosthetic abutment|
191509|NCT01954498|Dietary Supplement|Walnuts|
191510|NCT01954498|Dietary Supplement|OTC multivitamin|
191511|NCT01954511|Other|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
191512|NCT01954511|Other|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
191513|NCT00115245|Drug|Telbivudine (LdT)|
191514|NCT01954511|Device|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
191815|NCT01987440|Drug|lubricating gel|
191816|NCT00118313|Drug|dimethyl sulfoxide|
191817|NCT01987453|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
191818|NCT01987453|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert.
191819|NCT01987466|Biological|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
191820|NCT01987479|Drug|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
186419|NCT02569437|Drug|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
186420|NCT02569437|Drug|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
186421|NCT02569437|Drug|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
186422|NCT02569437|Drug|sugar pill|placebo pill to match doxycline
186423|NCT02569450|Behavioral|Surgical outcomes monitoring using Shewhart control chart|Assistance by a local surgeon responsible for the implementation of intervention within his/her department
Quarterly team meeting to interpret variations in observed outcomes on the control charts
Restitution of surgical outcomes based on wall posters in operating room
Training sessions provided to local surgeon for appropriate control chart utilization
186424|NCT02571491|Drug|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
186425|NCT02571491|Drug|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
186426|NCT02571504|Behavioral|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
186427|NCT02571517|Drug|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
186428|NCT00187590|Behavioral|Case manager phone call after an ER visit|
186713|NCT00186914|Biological|Marrow stromal cell infusion|This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.
As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.
Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10^6 MSC/kg and the second dose of cells will be 5x10^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion.
186714|NCT02565095|Procedure|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
186715|NCT02565108|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
186716|NCT02565108|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
186717|NCT02565121|Drug|corticosteroids|
186718|NCT02565121|Behavioral|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
186123|NCT02540005|Other|ROTEM analysis|
186124|NCT02540018|Device|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.
Luminor35®-DEB PTA catheter is applied.
186125|NCT02540018|Device|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
186126|NCT02540031|Drug|Additional oral preparation (3L of PEG+Asc, "Coolprep®")|The interventional or experimental arm will receive 1l of additional PEG+Asc, "Coolprep®" on the day of colonoscopy
* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
186127|NCT02540031|Drug|Standard oral preparation (2L of PEG+Asc, "Coolprep®")|The control arm will receive currently used oral preparation (2l of PEG+Asc, "Coolprep®") for colonoscopy
* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
186128|NCT02540044|Behavioral|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
186129|NCT02540044|Behavioral|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
186130|NCT02540057|Procedure|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
186131|NCT02540057|Procedure|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
186132|NCT02540070|Procedure|Periarticular|
186133|NCT00183989|Drug|Fludarabine, Mitoxantrone and Rituximab|
186134|NCT02540070|Procedure|Motor free|
186135|NCT02540070|Procedure|Motor free with dex|
186136|NCT02542384|Drug|CR845 IV 5 mcg/kg|CR845 IV 5 mcg/kg will be administered as an IV bolus one hour prior to anesthetic induction for surgery, again within 30 minutes of the patient being considered stable in the post operative recovery room, then 2 hours following that Baseline dose. Subsequent dosing will be administered at 6, 12 and 18 hours after the Baseline dose.
Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.
Saline infusion (IV 0.45%) for fluid replenishment will be provided.
186429|NCT02571517|Other|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
186430|NCT02571530|Drug|Intra-arterial Cerebral Infusion of Trastuzumab|
191591|NCT01962298|Drug|Single rocuronium dose|
191592|NCT01962298|Drug|Repeated rocuronium dose|
191593|NCT01962298|Drug|Continuous rocuronium infusion|
191594|NCT01962311|Procedure|lumbar puncture|lumbar puncture at enrollment in study
191595|NCT01962324|Radiation|SIB Dose-Escalation Radiotherapy|
191596|NCT00116064|Drug|intranasal lorazepam|
191597|NCT01962337|Drug|FPA008|Infusion
191598|NCT01962337|Drug|Placebo|Infusion
191891|NCT01957033|Behavioral|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
191892|NCT01957033|Behavioral|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
191893|NCT01957033|Behavioral|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
191894|NCT01957033|Other|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
191895|NCT01957033|Other|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
191896|NCT01957033|Other|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
191897|NCT01957033|Other|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
191898|NCT01957033|Other|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
191899|NCT00115557|Other|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
191900|NCT01957033|Other|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
191901|NCT01957046|Drug|Laxative|
191286|NCT01969305|Behavioral|Usual Care Alone|Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:
Facts and Myth about HIV. HIV/STIs modes of transmission;
Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;
Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use.
191287|NCT01969318|Drug|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
191288|NCT01969318|Drug|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
191289|NCT01969318|Drug|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
191290|NCT00116896|Drug|Cisplatin|
191291|NCT01969331|Dietary Supplement|Normia|One capsule twice a day/14 days
191292|NCT01969331|Dietary Supplement|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
191293|NCT01969357|Drug|Placebo|Tablets(n=4),once daily for 84 days
191294|NCT01969357|Drug|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
191599|NCT01962350|Device|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
191600|NCT01962363|Drug|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
191601|NCT01962376|Drug|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
191602|NCT01964547|Drug|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
191603|NCT01964560|Drug|Lacosamide|Pharmaceutical form: oral solution
Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)
Route of administration: oral use
191604|NCT00116350|Drug|Misoprostol|800 mcg sublingual misoprostol
191605|NCT01964560|Drug|Lacosamide|Pharmaceutical form: tablet
Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)
Route of administration: oral use
191606|NCT01964573|Drug|Rotigotine|Day 1-3: 2 mg patch once daily
Day 4-6: 4 mg patch once daily
190977|NCT01974297|Drug|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
190978|NCT01974297|Drug|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
190979|NCT01974310|Procedure|Vitrectomy & Intraocular gas fill|
190980|NCT01974310|Procedure|Postoperative face-down positioning|
190981|NCT01974323|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
190982|NCT01974323|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
190983|NCT01974336|Drug|ursodeoxycholic acid|
190984|NCT01974349|Drug|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
190985|NCT01976507|Drug|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
190986|NCT01976520|Biological|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
190987|NCT01976546|Device|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
190988|NCT01976559|Device|Tympanic Membrane Displacement (TMD)|The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.
For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.
190989|NCT01976559|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
190990|NCT00117637|Drug|Interferon|Interferon
190991|NCT01976572|Drug|colestilan|
190992|NCT01976572|Drug|candesartan|
190347|NCT01986855|Drug|Ertugliflozin|Ertugliflozin, oral, 5 mg or 5 mg and 10 mg tablet once daily for 52 weeks
190348|NCT01986855|Drug|Placebo|Placebo
190349|NCT01986868|Other|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
190350|NCT01986881|Drug|Ertugliflozin|Oral, once daily, up to 6.3 years
190351|NCT01986881|Drug|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to 6.3 years
190352|NCT01986894|Drug|Placebo|Single oral dose of Placebo
190653|NCT01979224|Other|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
190654|NCT01979237|Procedure|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
190655|NCT01981759|Drug|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
190656|NCT00117962|Radiation|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
190657|NCT01981759|Drug|Placebo|Participants will receive 12 weekly administrations of 50mg placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
190658|NCT01981759|Behavioral|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
190659|NCT01981772|Drug|4% lidocaine with 1:100,000 epinephrine|
190660|NCT01981772|Drug|4% buffered lidocaine with 1:100,000 epinephrine|
190661|NCT01981798|Behavioral|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
190662|NCT01981811|Drug|Aripiprazole|
190663|NCT01981811|Device|Ingestible Event Marker (IEM)|
190664|NCT01981837|Drug|ALN-TTRSC (revusiran) for subcutaneous administration|
190665|NCT01981850|Biological|PRM-151|IV infusion
190045|NCT01953952|Procedure|therapeutic conventional surgery|Undergo transoral eHNS
190046|NCT01953952|Radiation|intensity-modulated radiation therapy|Undergo IMRT
190047|NCT01953952|Drug|cisplatin|Given IV
190048|NCT00115154|Drug|Aldara (imiquimod) cream, 5%|
190049|NCT01953952|Procedure|quality-of-life assessment|Ancillary studies
190050|NCT01953952|Other|laboratory biomarker analysis|Correlative studies
190051|NCT01953965|Drug|11C-acetate|For each PET/CT imaging session subject will receive a 15-25 millicurie intravenous injection of 11C-acetate
190052|NCT01953965|Drug|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
190053|NCT01953965|Drug|MultiHance|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups. MultiHance is the contrast that will be given to subjects.
190054|NCT01953978|Drug|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
190055|NCT01953978|Other|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
190056|NCT01953978|Drug|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
190353|NCT01986894|Drug|Pomalidomide|Single oral dose of 4 mg pomalidomide
190354|NCT01986894|Drug|Pomalidomide|Single oral dose of 20 mg pomalidomide
190355|NCT01986894|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
190356|NCT01986907|Drug|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
190357|NCT00118300|Drug|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
190358|NCT01986920|Drug|A-101 25%|Low Dose Concentration of A-101
190359|NCT01986920|Drug|A-101 32.5%|Mid Dose Concentration of A-101
190057|NCT01953978|Drug|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
190058|NCT01953978|Drug|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
190059|NCT00115167|Drug|Placebo|Q4W
190060|NCT01953978|Drug|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
190061|NCT01953991|Device|Dentures|Removable prosthesis to replace missing teeth
190062|NCT01954017|Biological|STP 206|Live Biotherapeutic
190063|NCT01954017|Biological|Sterile Water|
190064|NCT01954030|Drug|CTO and Bevacizumab|
190065|NCT01954030|Drug|CTO alone|
190066|NCT01954043|Drug|Dabrafenib 150 mg twice a day (BID)|Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
190067|NCT01954043|Drug|Rabeprazole 40 mg once daily (OD)|Rabeprazole dosed at 40mg each morning on Days 16 to 19
190068|NCT01954043|Drug|Rifampin 600 mg OD|Rifampin dosed at 600mg each morning on Days 20 to 29
190069|NCT01954056|Drug|Hydrocortisone|• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).
1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose
190070|NCT01956136|Behavioral|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
190071|NCT01956136|Other|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
190072|NCT01956149|Drug|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
190073|NCT01956162|Device|Orthèse Diabète|
190074|NCT01956162|Device|"Conventional" Device|
190075|NCT00115466|Procedure|Non-surgical autologous implant of ASCs|
189427|NCT01968356|Drug|3M CHG/IPA Prep Colorless|Apply topically.
189428|NCT00116805|Drug|TDF placebo|Placebo to match TDF administered orally once daily
189746|NCT01961453|Drug|Placebo capsule|One capsule of placebo administered once daily at 8 am.
189747|NCT00115960|Biological|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
189748|NCT01961466|Other|psychological and social self-administered questionnaires|
189749|NCT01961479|Behavioral|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
189750|NCT01961479|Other|Waiting list|During the waiting period, participants receive no treatment.
189751|NCT01961492|Other|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
189752|NCT01961505|Drug|Compound tripterygium gel|The Compound tripterygium gel were smeared evenly in the selected joint surface for one hour once a day for 8 weeks.（Dosage：wrist joints 3ml, knee joints 10 ml, ankle usage 5 ml）
189753|NCT01961505|Drug|Placebo|The Placebo gel were smeared evenly in the selected joint surface for one hour once a day for 8 weeks.（Dosage：wrist joints 3ml, knee joints 10 ml, ankle usage 5 ml）
189754|NCT01961531|Device|Accuboost APBI|28Gy delivered in 5 daily fractions
189755|NCT01961544|Drug|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
189756|NCT01961583|Drug|18F-Fluciclatide|Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).
Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy
189757|NCT01961596|Other|Cooling Ice Spray|A bursts of the "Cooling Ice Spray" over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
189758|NCT00115960|Biological|IL-15 DNA adjuvant|Cytokine injection
189759|NCT01961596|Other|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
189760|NCT01963780|Device|OCS Lung Preservation|
189761|NCT01963793|Drug|Aprepitant|Aprepitant gel (10 mg/g)
189762|NCT01963793|Drug|Placebo|gel without active component
189125|NCT01973413|Device|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
189126|NCT00117390|Procedure|Measurement of inulin clearance|
189127|NCT01973413|Device|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
189128|NCT01973413|Device|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
189129|NCT01973426|Device|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
189130|NCT01973439|Other|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
189131|NCT01973439|Other|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
189429|NCT01968356|Drug|3M CHG/IPA Prep Tint|CHG 2%/IPA 70%
189430|NCT01968356|Drug|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Apply topically.
189431|NCT01968356|Other|Normal Saline|Apply topically.
189432|NCT01968369|Dietary Supplement|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
189433|NCT01968382|Drug|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
189434|NCT01968382|Drug|Placebo (High protein milk powder)|Subjects will receive a total of 4 bottles (2 in the morning and 2 in the evening) daily
189435|NCT01968395|Drug|Caspofungin 70 mg|Intravenous use
189436|NCT01968408|Dietary Supplement|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
189437|NCT01968408|Dietary Supplement|Placebo|
189438|NCT01968421|Drug|OM-85|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
189439|NCT00002132|Drug|Itraconazole|
188796|NCT01980992|Drug|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
188797|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)|One time injection of 40 ug/kg FGF 1-141, via a catheter
188798|NCT01981005|Drug|RO5424802|Single oral doses followed by IV or oral administration of a 14C-labeled tracer
188799|NCT01981018|Other|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:
Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.
Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.
Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a "video blue print.
188800|NCT01981031|Drug|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
188801|NCT01981031|Drug|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
188802|NCT01981044|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
188803|NCT01981057|Other|Numeta|parenteral receipt prescribed with Numeta
188804|NCT01981057|Other|Individual|parenteral receipt prescribed individually
188805|NCT01981070|Behavioral|Mindfulness Intervention for Parents|See Study Arms
188806|NCT01981070|Behavioral|Support and Information for Parents|See Study Arms
188807|NCT01981083|Dietary Supplement|Egg albumin-based protein supplement|
188808|NCT00002144|Drug|Foscarnet sodium|
188809|NCT01983709|Biological|Allogeneic Human Mesenchymal Stem Cells|This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV 4 days prior to undergoing a planned prostatectomy.
The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy.
188810|NCT01983722|Drug|Stiripentol|
188811|NCT01983735|Drug|TELMINUVO Tab. (80/2.5mg)|Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.
With the others investigation product placebo 1 tab QD 2 weeks.
193339|NCT02075788|Other|Millet based products (porridge etc.)|
193340|NCT02075801|Other|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
193341|NCT02075801|Other|Sealing of amalgam margin defects|A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
C.Control Group: The defective restorations did not receive any treatment.
193342|NCT02075814|Drug|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
193343|NCT02075814|Drug|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
188473|NCT01988571|Drug|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
188474|NCT01988571|Drug|Placebo|One placebo tablet taken each morning orally for 24 months.
188475|NCT01988584|Biological|Autologous Stem Cells|
188476|NCT01988584|Other|Saline Infusion (Placebo)|
188477|NCT01988597|Other|Dry eyes|
188478|NCT01988610|Drug|28 days treatment with Mifepristone.|
188479|NCT01988623|Behavioral|Pivotal Response Treatment (PRT)|
188480|NCT01988636|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
188481|NCT01988636|Drug|Placebo|Placebo
188482|NCT01988649|Drug|Intranasal Oxytocin|Administration of intranasal Oxytocin
188483|NCT00118352|Biological|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
188484|NCT01988649|Drug|Placebo (saline)|Administration of normal saline intranasally.
188485|NCT01988662|Procedure|VEGF level assessment|Blood measurement
188486|NCT01988675|Radiation|Whole Brain Irradiation|
188487|NCT01988675|Radiation|Partial Brain Irradiation|
188488|NCT01988675|Behavioral|Neuropsychological Testing|
193005|NCT01962844|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months
193006|NCT01962857|Behavioral|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
193007|NCT00116142|Drug|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
193008|NCT01962870|Drug|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
193009|NCT01962870|Drug|Placebo|
193010|NCT01962883|Other|Osteopathic treatment|The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.
Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release
Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.
Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.
Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye.
193011|NCT01962896|Drug|Erlotinib|
193012|NCT01962896|Drug|Sirolimus|
193013|NCT01962909|Drug|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
193014|NCT01962922|Drug|LCP-Tacro|once-daily extended release tablet
193015|NCT01962922|Drug|Tacrolimus|twice daily capsules
193016|NCT01962935|Drug|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
193017|NCT01962935|Drug|Placebo|Part A - multiple ascending dose daily
193018|NCT00116155|Biological|CV787 (CG7870)|
193019|NCT01962935|Drug|AZD5069|Part B - one dose decided after part A, twice a day
193020|NCT01962948|Drug|paclitaxel|Given IV
193344|NCT00122889|Drug|Garlic oil|
193345|NCT02037477|Drug|Esomeprazole, TAK-438|Esomeprazole capsules, TAK-438 tablets
193346|NCT02037477|Drug|TAK-438, rabeprazole sodium|TAK-438 tablets, rabeprazole sodiumu tablets
193347|NCT02037477|Drug|Rabeprazole sodium, TAK-438|Rabeprazole tablets, TAK-438 tablets
192708|NCT01967368|Drug|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
192709|NCT01969747|Drug|Empagliflozin low|Empagliflozin low
192710|NCT00116961|Drug|Doxil|
192711|NCT01969747|Drug|Empagliflozin high|Empagliflozin high
192712|NCT01969760|Behavioral|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
192713|NCT01969773|Drug|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
192714|NCT01969773|Drug|Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
192715|NCT01969786|Other|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
192716|NCT01969799|Drug|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
192717|NCT01969799|Drug|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
192718|NCT01969812|Device|Evie Slow-release Insemination Device|
192719|NCT01969812|Other|Traditional Intrauterine Insemination|
192720|NCT01969825|Behavioral|Massage|
192721|NCT00002133|Drug|Itraconazole|
192722|NCT00116961|Drug|Dexamethasone|
192723|NCT01969838|Drug|Momelotinib|Momelotinib tablet administered orally once daily
192724|NCT01969838|Drug|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
193021|NCT01962948|Drug|ganetespib|Given IV
193022|NCT01962948|Other|laboratory biomarker analysis|Correlative studies
192110|NCT01982617|Other|Motivational Interviewing|
192111|NCT01982617|Other|Psychoeducation|
192112|NCT01982630|Drug|MK-8521|
192113|NCT01982630|Drug|Liraglutide|
192114|NCT01982630|Drug|Placebo|
192115|NCT01982643|Drug|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
192415|NCT01974726|Other|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
192416|NCT01974726|Other|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
192417|NCT00117494|Drug|Pravastatin|
192418|NCT01974739|Drug|Hydrochloorthiazide|
192419|NCT01974739|Drug|placebo|
192420|NCT01974752|Drug|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
192421|NCT01977287|Device|Ankle Foot Orthosis|
192422|NCT01977300|Drug|Valproate|serum level of 50 to 125 ug/L
192423|NCT01977300|Drug|Lithium|serum levels of 0.6 to 1.2 mmol/L
192424|NCT01977300|Drug|Risperidone|1 to 6 mg/day
192425|NCT01977300|Drug|Olanzapine|5 to 25 mg/day
192426|NCT01977300|Other|Placebo|manufactured to mimic risperidone and olanzapine
192427|NCT01977326|Behavioral|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
191821|NCT01987492|Drug|Lebrikizumab|Lebrikizumab will be administered as high- or low-dose SC injections every 4 weeks for up to 44 weeks during the DBPC period, up to 32 weeks during the ATE, and until the end of treatment provision (31-Mar-2018) in the LTE.
191822|NCT01987492|Drug|Placebo|Placebo will be administered as SC injections every 4 weeks for up to 44 weeks during the DBPC period. Thereafter, participants may be re-randomized to receive lebrikizumab in the ATE and LTE periods.
191823|NCT01987505|Drug|rituximab [MabThera/Rituxan]|1400 mg injected subcutaneously (SC)
191824|NCT01987518|Other|Procedure surgery behavioral and genetic diagnosis|Observational Study
191825|NCT01987518|Procedure|quality of life after different type of surgery|
191826|NCT01987531|Other|left ventricular epicardial pacing lead|
191827|NCT00118313|Drug|imiquimod|
191828|NCT01987544|Other|Ergometer Training|
191829|NCT01987544|Other|Motivation|
191830|NCT01987557|Behavioral|rate group|walking with a high cadence (steps per minute)
191831|NCT01987557|Behavioral|magnitude treadmill group|
191832|NCT01989936|Drug|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
191833|NCT01989949|Drug|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
191834|NCT00118430|Drug|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
192116|NCT01982656|Other|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
192117|NCT01982669|Other|No Intervention|
192118|NCT01982682|Radiation|Total-Body Irradiation (TBI)|Undergo TBI
192119|NCT00118040|Other|placebo|Given orally
186719|NCT02565134|Drug|PAC-14028 cream 0.1%|Topical application
186720|NCT02565134|Drug|PAC-14028 cream 0.3%|Topical application
186721|NCT02565134|Drug|PAC-14028 cream 1.0%|Topical application
186722|NCT02565134|Drug|PAC-14028 cream vehicle|Topical application
186723|NCT02565147|Procedure|primary PCI|Primary PCI for treatment of patients presenting with STEMI
186724|NCT00186927|Biological|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10^5 to 5 x 10^7 EID(50) units.
186725|NCT02567266|Behavioral|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
186726|NCT02567266|Behavioral|Youth Outcomes Questionnaire|The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging "critical items" that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived "alerts" when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision.
186727|NCT02567266|Behavioral|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
187028|NCT02560831|Behavioral|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
187029|NCT00186498|Drug|memantine|
187030|NCT02560831|Behavioral|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
187031|NCT02560857|Other|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
187032|NCT02560870|Drug|Aleo Vera mouthwash|mouthwash( Aleo Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
187033|NCT02560870|Drug|Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
186431|NCT02571543|Drug|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
186432|NCT02571556|Drug|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
186433|NCT02571569|Drug|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour.Based on safety, PK and PD results the doses for the other cohorts will be determined.
186434|NCT02571595|Behavioral|Digital cognitive behavioural therapy for insomnia (dCBT-I)|dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
186435|NCT02571608|Drug|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
186436|NCT02571608|Drug|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
186437|NCT02571621|Device|Combitube|Intubation with Combitube
186438|NCT02571634|Drug|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
186439|NCT00002510|Drug|mesna|
186440|NCT00187603|Behavioral|tobacco cessation program|
186441|NCT02571647|Other|Non interventional study|Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.
They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus).
186442|NCT02571660|Drug|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
186443|NCT02571660|Drug|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
186444|NCT02573818|Device|SEDASYS System|propofol sedation with the SEDASYS System
186445|NCT02573831|Drug|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
186446|NCT00002511|Radiation|low-LET photon therapy|
186447|NCT00188032|Procedure|electronic therapeutic reminders|
191902|NCT01957059|Drug|Cohort 1|All doses of PRO053 will be administered as IV infusions and SC injections. The proposed doses are as follows:
1 mg/kg (Cohort1)
6 mg/kg (Cohort 1)
191903|NCT01957059|Drug|Cohort 2|All doses of PRO053 will be administered as IV infusions and SC injections. The proposed doses are as follows:
3 mg/kg (Cohort 2)
9 mg/kg (Cohort 2)
191904|NCT01957059|Drug|48-week treatment phase|All doses of PRO053 will be administered as SC injections. The proposed doses for the first 12 weeks are as follows:
6 mg/kg given once weekly
9 mg/kg given once weekly
191905|NCT01957072|Behavioral|Behaviour change intervention|The behaviour change intervention consists of
feedback via a web-based food diary
'coaching' with problem-solving and implementation plans
The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.
The maintenance phase consists of 3 telephone calls and 4 reminder emails.
191906|NCT01957085|Other|Observation only, no intervention|HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory
192194|NCT01992718|Procedure|ARM 1: Evaluation of MRI, US for pelvic and uterine conditions|Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).
A patient survey will be included.
192195|NCT01992718|Procedure|ARM 2 Patient preference between MRI and Ultrasound|Subjects may take part in ARM 2 because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.
Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete.
192196|NCT01992731|Other|Drug: Follitropine Bèta|
192197|NCT01992770|Behavioral|Hierarchical graded exposure|Individual Behavioural goal identification, depending on risk profile
(1a). "Catastrophising and/or fear-avoidance" (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid.
192198|NCT01992770|Behavioral|Graded activity|Individual Behavioural goal identification, depending on risk profile
(1b) "Graded activity";(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention.
192199|NCT01992770|Behavioral|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
192200|NCT01992783|Dietary Supplement|Hi-maize resistant starch|13.5 g/day
192201|NCT01992783|Dietary Supplement|Maltodextrin|13.5 g/day
192202|NCT01992796|Drug|Irbesartan|75 mg/per os/for 15 days
192203|NCT00118755|Drug|Oxaliplatin|85 mg/m^2 IV on Day 1 of each 2-week cycle
191607|NCT01964573|Other|Placebo|Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.
Frequency:
Day 1-3: 2 mg patch once daily
Day 4-6: 4 mg patch once daily
191608|NCT01964586|Drug|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
191609|NCT01964586|Drug|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
191610|NCT01964586|Drug|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
191611|NCT01964599|Dietary Supplement|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
191612|NCT01964599|Dietary Supplement|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
191613|NCT01964599|Dietary Supplement|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
191614|NCT01964599|Dietary Supplement|Control|
191615|NCT00116350|Drug|Oxytocin|40 IU Oxytocin IV
191616|NCT01964625|Other|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
191617|NCT01964638|Procedure|Targeted Biopsy|
191618|NCT01964651|Drug|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
191619|NCT01964651|Drug|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
191907|NCT01957098|Dietary Supplement|Placebo comparator: 0% pentose|14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
191908|NCT01957098|Dietary Supplement|Active comparator: 4% D-xylose|
191909|NCT01957098|Dietary Supplement|Active comparator: 8% D-xylose|
191910|NCT01959490|Drug|Bevacizumab|
191911|NCT01959503|Device|Progel Vascular Sealant|
191912|NCT01959503|Device|Gelfoam Plus|
191913|NCT01959516|Drug|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
190993|NCT01976585|Drug|rhuFlt3L/CDX-301|rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.
RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7.
191295|NCT01969357|Drug|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
191296|NCT01969357|Drug|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
191297|NCT01971801|Other|Placebo|One capsule given by mouth weekly
191298|NCT01971814|Drug|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
191299|NCT00117208|Drug|Dornase alpha|2.5mg daily for 2 weeks
191300|NCT01971827|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
191301|NCT01971840|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
191302|NCT01971853|Drug|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
191303|NCT01971853|Drug|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
191304|NCT01971879|Procedure|Remote ischemic preconditioning|A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.
The treadmill test starts 5 minutes after the end of the last deflation of the cuff.
191305|NCT01971879|Procedure|Control|A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.
The treadmill test starts 5 minutes after the end of the last deflation of the cuff.
191306|NCT01971892|Other|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
191307|NCT01971892|Other|Standard oxygen therapy with facial mask|facial Venturi mask
191308|NCT01971918|Biological|anti drug antibodies dosage|anti drug antibodies dosage
190666|NCT01981863|Drug|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
190667|NCT00117975|Biological|galiximab|given IV
190668|NCT01981863|Drug|Placebo|Placebo administered in same volume as in experimental arm.
190669|NCT01981889|Drug|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
190670|NCT01981902|Device|Non-Invasive Optical Spectroscopic|Non-Invasive Optical Spectroscopic
190671|NCT01981915|Procedure|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
190672|NCT01981915|Procedure|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
190994|NCT01976585|Drug|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
190995|NCT01976598|Other|Sub-Sensory Stimulation|Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
190996|NCT01976611|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
190997|NCT01976624|Drug|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
190998|NCT01976637|Other|no compression|no compression stockings worn during the study
190999|NCT01976637|Device|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
191000|NCT01976650|Drug|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
191001|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
191002|NCT01976676|Dietary Supplement|5-methyltetrahydrofolate|
191003|NCT01976676|Dietary Supplement|folic Acid|
191004|NCT01976702|Behavioral|Enhanced Behavioral Skills Training|
191005|NCT00117819|Drug|[123I]ß CIT and SPECT imaging|To assess [123I]ß CIT and SPECT imaging
190360|NCT01986920|Drug|A-101 40%|High Dose Concentration A-101
190361|NCT01986920|Drug|A-101 Vehicle|Placebo
190362|NCT01989520|Drug|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
190363|NCT01989533|Biological|Ad4-mgag|
190364|NCT01989533|Biological|Ad4-EnvC150|
190365|NCT01989546|Drug|BMN 673|PARP inhibitor; has been shown to cause single-agent synthetic lethality in BRCA1/2- and PTEN-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in DNA repair pathways.
190366|NCT01989559|Biological|gp100:209-217(210M) Peptide Vaccine|Given SC
190367|NCT01989559|Biological|HPV 16 E7:12-20 Peptide Vaccine|Given SC
190368|NCT01989559|Other|Laboratory Biomarker Analysis|Correlative studies
190369|NCT01989572|Biological|sargramostim|Given SC
190370|NCT00118404|Drug|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
190371|NCT01989572|Biological|peptide vaccine|Given SC
190372|NCT01989572|Other|GM-CSF placebo|Given SC
190373|NCT01989572|Other|peptide placebo|Given SC
190374|NCT01989585|Drug|Dabrafenib|Given PO
190375|NCT01989585|Other|Laboratory Biomarker Analysis|Correlative studies
190673|NCT01981928|Drug|ASP7962|Oral
190674|NCT01981928|Drug|Placebo|Oral
190675|NCT01981941|Drug|Gabapentin enacarbil|Oral
190676|NCT01981954|Drug|Solifenacin succinate|Suspension
190677|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
190678|NCT00002145|Drug|Foscarnet sodium|
190679|NCT00117975|Biological|rituximab|Given IV
190680|NCT01984346|Device|Convergent Procedure EPi-Sense-AF Guided Coagulation System|Combined Epicardial Endocardial Ablation
190076|NCT01956175|Device|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
190376|NCT01989585|Biological|Navitoclax|Given PO
190377|NCT01989585|Other|Pharmacological Study|Correlative studies
190378|NCT01989585|Drug|Trametinib|Given PO
190379|NCT01989598|Drug|Akt Inhibitor GSK2141795|Given PO
190380|NCT01989598|Other|Laboratory Biomarker Analysis|Correlative studies
190381|NCT00002152|Drug|WF10|
190382|NCT00118404|Other|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
190383|NCT01989598|Other|Pharmacological Study|Correlative studies
190384|NCT01989598|Drug|Trametinib|Given PO
190385|NCT01989611|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
190386|NCT01989637|Dietary Supplement|Strawberry Meal|
190387|NCT01989637|Dietary Supplement|Control Meal|
190388|NCT01989650|Other|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
190389|NCT01989650|Other|No break|No break will be provided
190390|NCT01989663|Drug|1% vaginally applied tenofovir gel|
190391|NCT01989663|Drug|Tenofovir film- 10mg|
190392|NCT01989663|Drug|Tenofovir Film-40 mg|
190393|NCT01991977|Drug|Temozolomide|Receive temozolomide
190394|NCT01991977|Other|Quality-of-Life Assessment|Ancillary studies
190395|NCT01991990|Drug|placebo|Single i.v. infusion
190396|NCT01991990|Drug|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
190397|NCT01992016|Drug|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
189763|NCT01963806|Behavioral|Smartphone-supplemented iCBT|The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.
Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support.
189764|NCT01963806|Behavioral|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
190077|NCT01956175|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
190078|NCT01956188|Dietary Supplement|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
190079|NCT01956188|Dietary Supplement|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
190080|NCT01956201|Drug|Atorvastatin 20mg|[Atorvastatin Run-in Period] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) [Treatment Period] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) [Extension Period] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
190081|NCT01956201|Drug|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
190082|NCT01956201|Other|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
190083|NCT01956214|Other|FES Exercise|receive FES while exercising
190084|NCT01956214|Other|Mock FES Exercise|participants will receive Mock FES
190085|NCT01956227|Behavioral|Home-based exercise|exercise to look at balance and lower limb strength record in diary
190086|NCT00115479|Drug|intensive insulin therapy to maintain normoglycemia|
190087|NCT01956227|Behavioral|Education|sessions to discuss self-management ideas to modify risk of falling
190088|NCT01956227|Behavioral|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
190089|NCT01956240|Procedure|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
189440|NCT00116805|Drug|ADV placebo|Placebo to match ADV administered orally once daily
189441|NCT01968434|Device|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
189442|NCT01968434|Drug|carbocisteine cough syrup|Mucolytic
189443|NCT01968447|Other|hypocapnia|
189444|NCT01968447|Other|normocapnia|
189445|NCT01968460|Drug|Pramipexole / Rasagiline Mesylate once daily|
189446|NCT01968460|Drug|Placebo|
189447|NCT01968473|Device|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
189448|NCT01968486|Drug|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
189449|NCT01970917|Device|Placebo|0.9% physiological saline solution
189765|NCT01963806|Other|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
189766|NCT00116259|Drug|Aripiprazole|
189767|NCT01963819|Other|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
189768|NCT01963832|Drug|Fluoxetine|
189769|NCT01963832|Drug|Placebo|
189770|NCT01963832|Procedure|eCMIT|
189771|NCT01963832|Procedure|Usual Care|
189772|NCT01963845|Drug|Sitagliptin|
189773|NCT01963858|Procedure|Functional relaxation|Functional relaxation during colonoscopy
189774|NCT01963858|Procedure|No relaxation|No relaxation during colonoscopy
189775|NCT01963871|Other|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
189132|NCT01975662|Drug|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
189133|NCT01975662|Drug|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
189134|NCT01975675|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
189135|NCT00117572|Procedure|radiotherapy|See protocol for details
189136|NCT01975675|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
189137|NCT01975688|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.
Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD.
189138|NCT01975701|Drug|BGJ398|Capsule for oral use.
189139|NCT01975714|Drug|Preservative-free latanoprost|
189140|NCT01975714|Drug|Preservative-free bimatoprost|
189141|NCT01975727|Drug|Injection of Placebo (saline 0.9%)|If the patient becomes nauseous and/or is vomiting postoperatively he/she will be randomised to receive the study treatment. In this arm he/she will receive an injection of saline 0.9% (placebo).
189142|NCT01975727|Drug|Dexamethasone 3 mg intravenously|If the patient becomes nauseous and/or is vomiting postoperatively he/she will be randomised to receive the study treatment. In this arm he/she will receive an injection of 3 mg Dexamethasone.
189143|NCT01975727|Drug|Dexamethasone 6 mg|If the patient becomes nauseous and/or is vomiting postoperatively he/she will be randomised to receive the study treatment. In this arm he/she will receive an injection of 6 mg Dexamethasone.
189144|NCT01975727|Drug|Dexamethasone 12 mg|If the patient becomes nauseous and/or is vomiting postoperatively he/she will be randomised to receive the study treatment. In this arm he/she will receive an injection of 12 mg Dexamethasone.
189145|NCT01975740|Other|Sham manual diaphragm release technique|
189146|NCT00117585|Other|Treatment Phase 1|Patient Education
Physical Therapy Exercises
Increased Salt Intake
Elevation of head of bed with 2-4 inch wedge
Medication Review by MD, Pharma
188489|NCT01988675|Behavioral|Quality of Life Questionnaire|
188490|NCT01988675|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
188491|NCT01988688|Device|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
188492|NCT01991145|Biological|Erythropoietin alfa|
188493|NCT01991145|Other|Rehabilitation|Active rehabilitation
188494|NCT01991145|Procedure|Placebo UCB|
188495|NCT01991145|Biological|Placebo EPO|
188496|NCT01991158|Drug|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
188497|NCT01991158|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
188498|NCT01991158|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
188812|NCT01983735|Drug|TELMINUVO Tab. (80/5mg)|Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.
With the others investigation product placebo 1 tab QD 6 weeks.
188813|NCT01983735|Drug|S-amlodipine 2.5mg|S-amlodipine 2.5mg QD 2 weeks
With the others investigation product placebo 1 tab QD 2 weeks.
188814|NCT01983735|Drug|S-amlodipine 5mg|S-amlodipine 5mg QD 6weeks
With the others investigation product placebo 1 tab QD 6 weeks.
188815|NCT01983748|Biological|Autologous Dendritic Cells loaded with autologous Tumor RNA|
188816|NCT01983761|Drug|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
188817|NCT01983761|Drug|Fludarabine, Melphalan, ATG (Reduced Intensity)|
188818|NCT00118105|Drug|oxaliplatin|130 mg/m^2, IV, Day 1 of cycles 1,2,3,4
188819|NCT01983774|Drug|Esomeprazole|
188820|NCT01983774|Drug|Placebo|Sugar pill
188821|NCT01983800|Drug|Isoflurane|
188822|NCT01983800|Drug|Propofol/midazolam|
193348|NCT02037490|Behavioral|Grow2Gether|Participants in this intervention will:
Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.
Complete an intervention video activity approximately weekly:
View educational videos addressing topics related to healthy infant growth
Create photos/videos modeling healthy behaviors and post them to the group
Provide and receive feedback on posts
Be encouraged to share information with key caregivers of their child
Attend group party soon after enrollment, to meet peers and group leader in person.
193349|NCT02037503|Drug|Ketamine|
193350|NCT02037503|Drug|Saline|
193351|NCT02037516|Device|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
193352|NCT02037516|Drug|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
193353|NCT02037516|Device|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
193354|NCT02037529|Drug|Eribulin|
193355|NCT00122889|Drug|Aged garlic|
193356|NCT02037529|Drug|Paclitaxel|
193357|NCT02037542|Behavioral|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
193358|NCT02037555|Biological|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
193359|NCT02037555|Other|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
193360|NCT02037568|Behavioral|fPER|Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the "new normal."
188499|NCT01991158|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
188500|NCT00118547|Behavioral|In home monitoring with feedback|Behavioral counseling
193023|NCT01962961|Dietary Supplement|PharmaNAC (N-acetylcysteine)|PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.
PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days).
193024|NCT01962961|Dietary Supplement|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
193025|NCT01962974|Biological|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
193026|NCT01964989|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
193027|NCT01964989|Biological|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
193028|NCT01965002|Device|ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound (MRgHIFU)|
193029|NCT00116428|Device|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
193030|NCT01965015|Device|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
193031|NCT01965028|Device|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
193032|NCT01965041|Drug|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
193033|NCT01965054|Dietary Supplement|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
193034|NCT01965067|Drug|sugammadex|sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state
Reversal effect of sugammadex in temperature state
193035|NCT01965080|Drug|Exemestane|One tablet Exemestane 25 mg daily
193036|NCT01965093|Procedure|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
193037|NCT01965093|Procedure|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
193038|NCT01965106|Drug|QPI-1007 Injection|1.5 mg QPI-1007 Injection
192428|NCT01977326|Other|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
192429|NCT01977339|Drug|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
192430|NCT00117676|Drug|TDF placebo|Placebo to match TDF administered orally once daily
192431|NCT01977339|Drug|Bupivacaine|20 cc of 0.25% bupivacaine
192432|NCT01977352|Drug|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
192433|NCT01977352|Drug|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
192725|NCT01969838|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
192726|NCT01969838|Drug|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
192727|NCT01969851|Drug|Lacosamide|Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).
Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively.
192728|NCT01969864|Behavioral|HRSA Video Intervention|
192729|NCT01969864|Behavioral|PI Video Intervention|
192730|NCT01969864|Behavioral|CDC Health Website Intervention|
192731|NCT01969877|Drug|cetuximab|
192732|NCT01969877|Drug|cisplatin|
192733|NCT00116974|Procedure|Scaling and root planing|Scaling and root planing
192734|NCT01969890|Drug|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
192735|NCT01969903|Drug|Precedex injection|
192736|NCT01969916|Drug|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
192737|NCT01972503|Procedure|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
192738|NCT01972516|Drug|Tivozanib|
192739|NCT01972529|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
192120|NCT01982682|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
192121|NCT01982682|Drug|Cyclophosphamide|Given IV
192122|NCT01982682|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
192123|NCT01982682|Drug|Mycophenolate mofetil|Given IV
192124|NCT01982695|Drug|Losartan|
192125|NCT01982695|Drug|Lisinopril|
192126|NCT01982721|Device|Locking mechanism for prosthetic knee|
192127|NCT01982734|Dietary Supplement|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
192128|NCT01982747|Drug|MGN-Placebo|
192129|NCT01982747|Drug|Placebo-MGN|
192130|NCT00002146|Drug|Magnesium sulfate|
192131|NCT00002148|Drug|OPC 14117|
192132|NCT00118209|Drug|doxorubicin|IV or CIVI
192133|NCT01985009|Device|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
192134|NCT01985022|Behavioral|PII with IES|This is an individualized parent-implemented intervention (PII) offered weekly to teach parents how to embed strategies to support social communication skills for 25 hours a week within everyday routines, activities, and places for 9 months. In addition parent will receive twice weekly the IES condition of the study.
192135|NCT01985022|Behavioral|IES|Parents will receive information, education, and support. They once a week for 75 minutes.
192136|NCT01985035|Behavioral|Diet|Reduction of energy intake in order to weight loss
192137|NCT01985061|Drug|BX2|
192138|NCT01985061|Drug|BX3|
192139|NCT01985061|Drug|BX4|
187034|NCT02560909|Biological|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
187035|NCT02560909|Biological|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
187036|NCT02560922|Behavioral|Pain Coping Skills Training (CST)|The pain CST intervention includes 12 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
187037|NCT02560935|Drug|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
187038|NCT02560935|Drug|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
187039|NCT02560948|Biological|Placebo solution|4 x 2 injections over 21 days
187040|NCT00186511|Behavioral|workbook/journal on coping with breast cancer|
187041|NCT02562950|Drug|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
187042|NCT02562950|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
187043|NCT02562950|Drug|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
187044|NCT02562963|Biological|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment.
187045|NCT02562976|Other|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
187354|NCT01980316|Drug|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
187355|NCT01980329|Drug|Maraviroc|
187356|NCT01980342|Drug|Efavirenz|
187357|NCT00002143|Drug|Acitretin|
187358|NCT00117884|Drug|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
187359|NCT01980355|Drug|Tranexamic Acid|
186728|NCT02567279|Drug|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
186729|NCT02567279|Drug|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
186730|NCT02567292|Other|Breast Milk|Participants will receive breast milk (fortified with Prolacta if required per doctor's discretion) for regular feedings while in the neonatal intensive care unit (NICU).
186731|NCT02567305|Other|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
186732|NCT02567318|Device|MRI-scan|Magnetic resonance imaging scan of the brain
186733|NCT02567331|Drug|Capecitabine|Participants will receive 1250 mg/m^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
186734|NCT00187096|Device|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
186735|NCT02567344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
186736|NCT02567344|Device|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
186737|NCT02567357|Behavioral|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
186738|NCT02567357|Behavioral|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
186739|NCT02567370|Drug|AMG 581|Active drug
186740|NCT02567370|Drug|Placebo|Placebo
186741|NCT02567383|Radiation|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
186742|NCT02567383|Device|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
186743|NCT02569463|Drug|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
186744|NCT00187278|Device|RV Pacing|Standard Pacemaker implant
186745|NCT02569476|Drug|BGB-3111 and Obinutuzumab|
192204|NCT01992809|Dietary Supplement|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
192205|NCT01992822|Other|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm.
192206|NCT01992835|Other|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
192207|NCT01992835|Other|placebo|
192208|NCT01992848|Other|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
192209|NCT01992848|Other|4-day food diary|
192210|NCT01992848|Other|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
192211|NCT01992848|Radiation|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
192508|NCT00118209|Drug|filgrastim|IV
192509|NCT01987687|Behavioral|Rest|Rest for 30 min
192510|NCT01987687|Behavioral|Delay|Delay between exercise and OGTT
192511|NCT01987700|Device|FLEX-HD|
192512|NCT01987700|Device|Strattice|
192513|NCT01987713|Behavioral|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
192514|NCT01987726|Other|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
192515|NCT01987726|Other|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
192516|NCT00118326|Procedure|allogeneic bone marrow transplantation|
191914|NCT01959516|Drug|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
191915|NCT01959516|Drug|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
191916|NCT01959516|Drug|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
191917|NCT01959529|Drug|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
191918|NCT01959529|Drug|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
191919|NCT01959542|Device|MRI|
191920|NCT00115765|Drug|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
191921|NCT01959542|Other|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
191922|NCT01959555|Other|No treatment given|Patients will not be treated with any specific product. Data collection only.
191923|NCT01959568|Procedure|Vitrectomy and tamponade|In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.
In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with "conventional" or heavy silicone oil, depending on predominant retinal breaks location.
191924|NCT01959581|Device|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
191925|NCT01959594|Drug|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
191926|NCT01959594|Drug|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
191927|NCT01959594|Drug|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
192212|NCT01992861|Procedure|Computed Tomography|Undergo FDG PET/CT
192213|NCT01992861|Procedure|Diffusion Weighted Imaging|Undergo DW MRI
192214|NCT00118755|Drug|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
192215|NCT01992861|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
192216|NCT01954693|Drug|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
191309|NCT01971970|Biological|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
191310|NCT00117234|Drug|darbepoetin alfa|
191311|NCT01971970|Biological|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
191620|NCT01964651|Drug|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
191621|NCT01964651|Drug|Placebo|Matching placebo orally administered once daily for 10 days.
191622|NCT01964664|Behavioral|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
191623|NCT01964664|Behavioral|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
191624|NCT01964677|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
191625|NCT01964703|Drug|Rubus occidentalis extract|
191626|NCT00116363|Genetic|investigational drug INGN 241|
191627|NCT01966718|Drug|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
191628|NCT01966731|Drug|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
191629|NCT01966770|Device|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
191630|NCT01966770|Device|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
191631|NCT01966770|Device|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
191632|NCT01966770|Device|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
191633|NCT01966770|Device|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
191006|NCT01979250|Procedure|DSAEK surgery|Corneal endothelial transplantation by "Descemet's stripping automated endothelial keratoplasty" (DSAEK).
191007|NCT01979263|Other|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
191008|NCT01979263|Other|Placebo Computer Task|Computer task that does not actively modify attention bias
191009|NCT01979276|Drug|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
191010|NCT01979276|Drug|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
191011|NCT01979276|Drug|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
191012|NCT01979289|Other|computerized cognitive remediation|
191013|NCT01979289|Other|computerized cognitive remediation:Control|
191014|NCT01979302|Other|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
191312|NCT01971983|Other|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
191313|NCT01971983|Other|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
191314|NCT01971983|Other|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
191315|NCT00117455|Drug|filgrastim|
191316|NCT01974362|Device|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
191317|NCT01974362|Device|Monolithic Zirconia|rehabilitation with monolithic zirconia implant-prosthesis
191318|NCT01974362|Device|Zirconia-Feldspathic|restore dental implants with a zirconia suprastructure and feldspathic veneers
191319|NCT01974375|Drug|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing <40 kg)
191320|NCT01974375|Drug|Fluconazole|Fluconazole 100~200mg/day, IV care until oral medication becomes possible
191321|NCT01974388|Procedure|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
191322|NCT01974388|Procedure|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
190681|NCT01984346|Device|Endocardial Catheter Ablation|Endocardial Catheter Ablation only
190682|NCT01984359|Other|Obtaining Human tissue|
190683|NCT01984372|Drug|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
190684|NCT01984398|Drug|Androxal 12.5 mg Formulation A|
190685|NCT00118170|Other|pharmacological study|Correlative studies
190686|NCT01984398|Drug|Androxal 12.5 mg Formulation B|
190687|NCT01984398|Drug|Androxal 25 mg Formulation A|
190688|NCT01984398|Drug|Androxal 25 mg Formulation B|
190689|NCT01984411|Procedure|Radial Technical|Vascular Access for cardiac catheterization
190690|NCT01984411|Procedure|Femoral Technical|Vascular Access for cardiac catheterization
190691|NCT01984411|Drug|Omnipaque|
190692|NCT01984424|Drug|Part A, Atorvastatin|Subjects will receive atorvastatin daily
190693|NCT01984424|Other|Part A, Placebo (administered orally)|Subjects will receive oral placebo daily
190694|NCT01984424|Drug|Part B, Evolocumab|Subjects will receive subcutaneous evolocumab every month
190695|NCT01984424|Other|Part B, Placebo (administered orally)|Subjects will receive oral placebo every day
190696|NCT00118183|Drug|docetaxel|Given IV
190697|NCT01984424|Drug|Part B, Ezetimibe|Subjects will receive oral ezetimibe daily
190698|NCT01984424|Other|Part B, Placebo (administered subcutaneously)|Subjects will receive subcutaneous placebo every month.
191015|NCT01979302|Other|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
191016|NCT00117832|Drug|Azelastine nasal spray|
191017|NCT01979328|Device|geko|
191018|NCT01979328|Device|Plaster cast|
191019|NCT01979341|Procedure|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
190398|NCT01992029|Other|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
190399|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy at M0
190400|NCT00118716|Drug|Fluticasone propionate/salmeterol|
190401|NCT01992029|Procedure|Lumbar puncture|Lumbar puncture at M0 and M12
190699|NCT01984424|Drug|Part C, Evolocumab|Subjects will receive subcutaneous evolocumab every 2 weeks or monthly
190700|NCT01984450|Procedure|ACIC|Autologous Collagen Induced Chondrogenesis (ACIC):
ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
190701|NCT01984450|Procedure|MCIC|Mesenchymal Cell Induced Chondrogenesis (MCIC):
MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
190702|NCT01984450|Device|implant with a collagen + fibrin gel mixture|
190703|NCT01984463|Drug|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
190704|NCT01984463|Drug|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
190705|NCT01984489|Drug|Placebo|
190706|NCT01984489|Drug|SHR117887|
190707|NCT01986933|Drug|nemolizumab (CIM331)|
190708|NCT01986933|Other|Placebo|
190709|NCT01986946|Other|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
190710|NCT01986946|Drug|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
190711|NCT01986959|Procedure|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
190712|NCT01986959|Procedure|Without Periodontal dressing|The dressing was not inserted.
190090|NCT01958671|Drug|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening ) for 2 weeks and 1000 mg (2 tablets 500 mg ) in the morning and 1000 mg (2 tablets 500 mg) in the evening thereafter.
190091|NCT01958671|Drug|Placebo to Metformin|Placebo matching metformin.
190092|NCT01958684|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
190093|NCT01958684|Device|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
190094|NCT01958723|Other|Hospitalists|Introduction of Problem Specific Templates
190095|NCT01958736|Other|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
190402|NCT01992029|Procedure|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
190403|NCT01992029|Other|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
190404|NCT01992029|Procedure|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
190405|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy for patient explored for myopathy
190406|NCT01992029|Procedure|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
190407|NCT01992029|Device|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
190408|NCT01992042|Drug|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
190409|NCT01992042|Drug|Pimonidazole|
190410|NCT01992055|Behavioral|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
190411|NCT00118729|Drug|GW685698X Aqueous Nasal Spray|
190412|NCT01992055|Behavioral|Education & relaxation training|The Education & Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
189776|NCT01963884|Procedure|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
189777|NCT00116272|Drug|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
189778|NCT01963884|Radiation|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
189779|NCT01963884|Other|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
189780|NCT01963910|Drug|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
189781|NCT01963910|Drug|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
189782|NCT01963923|Behavioral|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
189783|NCT01963936|Device|Supreme LMA|
189784|NCT01966042|Biological|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
189785|NCT01966055|Drug|Solithromycin|
189786|NCT01966068|Other|MyAsthma Web Portal|
189787|NCT00116519|Drug|placebo|
190096|NCT01958736|Other|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
190097|NCT01958749|Procedure|Fat graft with Platelet Rich Plasma|
190098|NCT01958762|Other|Invitation for oral cavity cancer screening|
190099|NCT00115700|Radiation|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
190100|NCT01958775|Drug|GLP-2|single subcutaneous dose of 1500mcg
190101|NCT01958775|Drug|Placebo|
190102|NCT01958788|Behavioral|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
189147|NCT01975740|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
189148|NCT01975753|Drug|Morphine|
189450|NCT01970930|Procedure|Blood specimen|4 green top tube 40 cc of blood draw
189451|NCT01970943|Other|Placebo|Placebo will be compared to No Intervention.
189452|NCT01970982|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
189453|NCT01970982|Other|Smoking abstinence (SA)|SA for 5 days in confinement
189454|NCT01970982|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
189455|NCT01970995|Other|mTHS|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
189456|NCT01970995|Other|SA|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
189457|NCT00117156|Drug|Fludarabine|
189458|NCT01970995|Other|mCC|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
189459|NCT01971008|Device|Elastic abdominal binder|
189460|NCT01971008|Device|Placebo binder|
189461|NCT01971021|Device|Randomization between two well established clinical routine vascular access devices|
189462|NCT01971034|Drug|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
189463|NCT01971034|Drug|Metformin|850mg, PO, every 8 hours, daily.
189464|NCT01971047|Drug|Regular Insulin|Group 1 Treatment Arm,Follow dosing for BG >180 per the following formula:
Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin
Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin
Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin
Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose
188823|NCT01983813|Other|PHCVRS Intervention|A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:
Contact via email, phone or text every 2-4 weeks
Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.
Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.
Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk.
188824|NCT01983813|Other|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
188825|NCT01983826|Dietary Supplement|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
188826|NCT01983826|Other|Placebo|Microcrystalline cellulose (daily) for 8 weeks
188827|NCT01983865|Other|Exposure to birch pollen|
188828|NCT01983878|Drug|Ramucirumab|Administered IV
188829|NCT00118105|Procedure|conventional surgery|Resection
188830|NCT01983891|Other|Cooking course|6-week nutrition education and cooking course
188831|NCT01983904|Device|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
188832|NCT01983917|Behavioral|Diabetes Mobile Application|
188833|NCT00118261|Drug|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
189149|NCT01975753|Drug|Fentanyl|
189150|NCT01975766|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
189151|NCT01975779|Drug|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
189152|NCT01978262|Biological|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
189153|NCT00117741|Behavioral|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
189154|NCT01978275|Device|stimulong 100, pajunk, germany|simulating catheter
189155|NCT01978275|Device|plexolong 100, pajunk, germany|nonstimulating catheter
189156|NCT01978301|Drug|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
188501|NCT01991171|Other|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
188502|NCT01991184|Drug|GDC-0853|Multiple escalating doses
188503|NCT01991197|Drug|Sitagliptin|Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.
Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial.
188504|NCT01991197|Drug|Gliclazide|Double-blind phase (week 0-16):
One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.
Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks.
188505|NCT01991197|Drug|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
188506|NCT01991197|Drug|Gliclazide matched placebo capsule|Double-blind phase (week 0-16):
One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks.
188507|NCT01991210|Drug|DNIB0600A|2.4 mg/kg IV every three weeks
188508|NCT01991210|Drug|pegylated liposomal doxorubicin|40 mg/m2 IV every four weeks
188509|NCT01991223|Drug|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
188510|NCT01991223|Drug|NS infusion|Normal saline will be infused during surgery
188511|NCT00002154|Drug|Thioctic acid|
188512|NCT00118560|Behavioral|Physical exercise|treadmill walking
188513|NCT01991236|Behavioral|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
188514|NCT01991236|Behavioral|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
188515|NCT01991249|Other|blood draw|
188516|NCT01991275|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
188517|NCT01991275|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
188518|NCT00115063|Other|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
188519|NCT01953328|Other|Placebo to Evolocumab|Administered by subcutaneous injection
193361|NCT02037581|Behavioral|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
193362|NCT02037581|Behavioral|Standard Care|Standard care as being offered by private psychiatrists
193363|NCT02037594|Behavioral|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
193364|NCT02039999|Other|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
193365|NCT02040012|Drug|AZP-531|
193366|NCT00123110|Drug|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
193367|NCT02040012|Drug|Placebo|
193368|NCT02040038|Behavioral|LIVE|3-D Virtual Environment for DSMT/S
193369|NCT02040038|Behavioral|Website|2-D Website participation for DSMT/S
193370|NCT02040051|Behavioral|Sound isolation / Music therapy|Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.
Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)
193371|NCT02040064|Drug|Gefitinib|Oral tablet
193372|NCT02040064|Drug|Tremelimumab|IV
193373|NCT02040077|Behavioral|Computer + Fluency|
193374|NCT02040077|Behavioral|Computer Only|
193375|NCT02040077|Behavioral|Treatment as Usual|
193376|NCT02040090|Drug|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
193377|NCT00123123|Drug|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
193378|NCT02040090|Biological|KamRAB|
193379|NCT02040090|Biological|FDA approved commercially available HRIG product|
193380|NCT02040103|Device|pneumatic compression|All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
192740|NCT01972529|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
192741|NCT00117299|Drug|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
192742|NCT01972529|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
192743|NCT01972529|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
192744|NCT01972542|Dietary Supplement|Oral fat tolerance test|
192745|NCT01972555|Procedure|Minimally invasive aortic valve replacement|
192746|NCT01972555|Procedure|Conventional aortic valve replacement|
192747|NCT01972568|Drug|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
193039|NCT01965106|Drug|(including placebo)|Sham injection procedure
193040|NCT00116428|Drug|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
193041|NCT01965119|Drug|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
193042|NCT01965145|Drug|Gevokizumab|Sterile solution administered subcutaneously
193043|NCT01965145|Drug|Placebo|Sterile solution administered subcutaneously
193044|NCT01965158|Drug|Naldemedine|Naldemedine tablet from weeks 1-12
193045|NCT01965158|Drug|Placebo|Placebo tablet from weeks 1-12
193046|NCT01965184|Behavioral|Cognitive-Behavioral Therapy for Aggression|
193047|NCT01965184|Behavioral|Supportive Psychotherapy (SPT)|
193048|NCT01965210|Other|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
193049|NCT01967381|Drug|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
193050|NCT00116688|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
192434|NCT01977365|Behavioral|Growth promotion based on child centered approach|- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.
Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.
Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.
- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers.
192435|NCT01977378|Drug|Sustained-Release Desvenlafaxine Hydrochloride|
192436|NCT01977378|Drug|Sustained-Release Venlafaxine Hydrochloride|
192437|NCT01977417|Drug|Salsalate|
192438|NCT01977417|Drug|Placebo|
192439|NCT01977430|Drug|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
192440|NCT01977443|Drug|APD-209 Eye drops|
192441|NCT00117676|Drug|ADV placebo|Placebo to match ADV administered orally once daily
192442|NCT01977443|Drug|APD-209 Placebo Eye drops|
192443|NCT01977456|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
192444|NCT01977469|Behavioral|High and low strength training in COPD Patients|Comparison of different intensity strength training associates with aerobic training in patients with COPD
192445|NCT01977482|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
192446|NCT01979900|Drug|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
192447|NCT01979900|Drug|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
192448|NCT01979913|Drug|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
192449|NCT00117884|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
192450|NCT01979926|Drug|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
192451|NCT01979939|Drug|DCV/ASV/BMS-791325|
187360|NCT01980355|Other|Placebo|
187361|NCT01980368|Other|Tai Chi|
187362|NCT01980368|Other|Educational group|
187363|NCT01980381|Other|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
187364|NCT01980394|Procedure|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
187365|NCT01980407|Drug|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
187366|NCT01980420|Procedure|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
187367|NCT01980433|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
187368|NCT01980433|Other|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
187369|NCT00117884|Drug|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
187370|NCT01980433|Other|WCRS|Writer's cramp rating scale
187371|NCT01980433|Other|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
187372|NCT01980433|Other|visual analog scale of discomfort writing and parameters collected on touchpad|
187373|NCT01980446|Procedure|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
187374|NCT01980459|Dietary Supplement|magnesium lactate|Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
187375|NCT01980472|Biological|bevacizumab, carboplatin and paclitaxel|4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
187657|NCT01975220|Drug|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
187658|NCT01975220|Drug|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
187659|NCT00002140|Drug|Ethambutol hydrochloride|
186746|NCT02569489|Drug|HBI-8000|
186747|NCT02569489|Drug|Trastuzumab|
187046|NCT02562989|Drug|[18F]MK-6240|IV dose of ~185 MBq [18F]MK-6240
187047|NCT02562989|Drug|[18F]MK-6240|IV dose of ~160 MBq [18F]MK-6240
187048|NCT02563002|Drug|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
187049|NCT02563002|Drug|FOLFIRI|Regimen consists of irinotecan 180 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-FU 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
187050|NCT02563002|Biological|pembrolizumab|
187051|NCT00186810|Drug|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
187052|NCT02563002|Biological|bevacizumab|
187053|NCT02563002|Biological|cetuximab|
187054|NCT02563015|Dietary Supplement|cholecalciferol|liquid drops
187055|NCT02563015|Dietary Supplement|Reference 400|liquid drops
187056|NCT02563028|Device|SightSaver Visual Stimulator|Evoked response photic stimulator
187057|NCT02563041|Drug|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
187058|NCT02563041|Drug|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
187059|NCT02563054|Drug|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
187060|NCT02563054|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
187061|NCT02563054|Drug|Cisplatin|Participants will receive cisplastin, 80 mg/m^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
187062|NCT00002508|Procedure|autologous bone marrow transplantation|
192517|NCT01987739|Drug|200 mg almorexant|
192518|NCT01987739|Drug|400 mg almorexant|
192519|NCT01987739|Drug|1000 mg almorexant|
192520|NCT01987739|Drug|20 mg zolpidem|
192521|NCT01987739|Drug|40 mg zolpidem|
192522|NCT01987739|Drug|placebo|
192523|NCT01987752|Drug|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
192524|NCT01987765|Drug|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
192525|NCT01987778|Other|Resistance training|Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
192526|NCT01987804|Drug|Oxytocin 100 i.u.|
192527|NCT00118339|Drug|chemoprotection|
192823|NCT01980277|Drug|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
192824|NCT01982877|Behavioral|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
192825|NCT01982877|Behavioral|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
192826|NCT00118053|Biological|herceptin|
192827|NCT01982890|Other|Control|No intervention as this group is simply followed prospectively.
192828|NCT01982916|Drug|AGR tablet|
192829|NCT01982916|Drug|Placebo (for AGR tablet and/or Active Comparator)|
192830|NCT01982916|Drug|Active Comparator|
192831|NCT01982929|Procedure|TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc), & Oral Meds: Paracetamol 1000 mg PO Q8H, diclofenac 50 mg PO Q8H X 24 hours.|
192832|NCT01982942|Drug|ibudilast|
192217|NCT01954706|Other|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
192218|NCT01954706|Other|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
192219|NCT01954719|Procedure|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
192220|NCT01954719|Procedure|control group|surgeon not dilated cervix after surgery
192221|NCT01954732|Drug|metformin hydrochloride|Given PO
192222|NCT00115284|Behavioral|ABIM asthma practice improvement module|
192223|NCT01954732|Other|pharmacological study|Correlative studies
192224|NCT01954745|Drug|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
192225|NCT01954758|Other|Fresh embryo transfer (A)|
192226|NCT01954758|Other|Elective deferred embryo transfer (B)|
192227|NCT01954758|Other|ERA y EDET (CR)|
192228|NCT01954758|Other|ERA + ERA + Pet (CNR1)|
192229|NCT01954758|Other|ERA +`ERA + EDET (CNR2)|
192230|NCT01954771|Behavioral|SMBG|
192231|NCT01954771|Other|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
192232|NCT01954784|Drug|fludarabine phosphate|
192233|NCT00115297|Drug|Montelukast|Participants who are 2 to 3 years old will receive 5-mg montelukast tablets and participants who are 12 months to 2 years old will receive 4-mg montelukast granules.
192528|NCT01987804|Drug|Oxytocin 400 i.u.|
192529|NCT01987804|Drug|Placebo|
192530|NCT01987817|Biological|peanut protein capsule|characterized peanut allergen provided in break apart capsules for oral immunotherapy
191634|NCT01966770|Device|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
191635|NCT01966783|Drug|Budesonide 2 mg suppository|per day
191636|NCT01966783|Drug|Budesonide 4 mg suppository|per day
191637|NCT00116610|Drug|picoplatin|
191638|NCT01966783|Drug|Mesalazine 1 g suppository|per day
191639|NCT01966783|Drug|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
191928|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
191929|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
191930|NCT01959607|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
191931|NCT00115765|Drug|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
191932|NCT01959607|Other|CC|Single use of subject's own conventional cigarette (CC)
191933|NCT01959607|Other|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette ® 2mg)
191934|NCT01962376|Drug|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
191935|NCT01962389|Device|Winsor Laser Catheter|
191936|NCT01962402|Drug|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
191937|NCT01962402|Behavioral|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
191938|NCT01962415|Drug|Hydroxyurea|Hydroxyurea will be given orally in a single daily dose.
191939|NCT00116064|Drug|intramuscular paraldehyde|
191940|NCT01962415|Drug|Alemtuzumab|Alemtuzumab will be given IV per current institutional guidelines. A test dose will be given prior to conditioning. The treatment dose of alemtuzumab will be given during conditioning based on the patients' assigned stratum. Pre-medications for alemtuzumab include acetaminophen, diphenhydramine, and methylprednisolone on the day of alemtuzumab administration. Diphenhydramine, epinephrine, and methylprednisolone will be available at the bedside during administration of alemtuzumab. If the patient has a fever >38.5 C during or after alemtuzumab infusion, blood cultures will be drawn and antibiotic coverage will be added.
191323|NCT01974401|Device|supragingival irrigators containing chlorhexidine|patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
191324|NCT01974414|Drug|orally administered cedar honey|
191325|NCT01974440|Drug|Bendamustine|90 milligram per meter square (mg/m^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
191326|NCT00002139|Drug|Azithromycin|
191327|NCT00117468|Drug|DR-2011|Administered vaginally from Day 14 to Day 31
191328|NCT01974440|Drug|Rituximab|375 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
191329|NCT01974440|Drug|Cyclophosphamide|750 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
191330|NCT01974440|Drug|Doxorubicin|50 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
191331|NCT01974440|Drug|Vincristine|1.4 mg/m^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
191332|NCT01974440|Drug|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
191640|NCT01966809|Drug|Photofrin photodynamic therapy.|The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:
Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery.
191641|NCT01966822|Drug|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
191642|NCT01966822|Drug|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
191643|NCT01966835|Behavioral|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
191644|NCT01966848|Device|Wich prosthesis is used|
191645|NCT01969357|Drug|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
191020|NCT01979354|Drug|Spinal morphine|0.15 mg spinal morphine
191021|NCT01979367|Device|Anodyne|Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
191022|NCT01979380|Drug|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
191023|NCT01979380|Drug|placebo|PO, once in the morning
191024|NCT01979393|Drug|Cabozantinib|
191025|NCT01979393|Drug|Placebo|
191026|NCT01979406|Biological|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
191027|NCT00117845|Biological|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
191028|NCT01979406|Biological|Ad4-PA-1|Ad4-PA will be given at 10^9, 10^10 and 10^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
191029|NCT01979406|Biological|Ad4-PA-GPI-1|Given at 10^9, 10^10 and 10^11 viral particles
Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15
191030|NCT01979432|Other|Cardiovascular evaluation|
191031|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
191032|NCT01981980|Other|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
191033|NCT01981980|Other|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
191034|NCT01981993|Biological|Urinary proteomic analysis|
191333|NCT01974440|Drug|PCI-32765 (Ibrutinib)|560 mg (4*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
191334|NCT01974440|Drug|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
191335|NCT01974453|Radiation|Radiation dose|Radiation dose adsorbed by operators
190713|NCT00118300|Radiation|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly in weeks 4-8.
190714|NCT01986972|Other|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
191035|NCT01982006|Procedure|Cataract surgery with Phacoemulsification|Each patients randomized in the phaco arm will undergo a conventional cataract surgery.
Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.
Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center.
191036|NCT01982006|Device|Femtosecond laser-assisted cataract surgery|Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.
Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.
Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm
191037|NCT01982019|Behavioral|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
191038|NCT01982032|Procedure|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
191039|NCT01982032|Device|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
191040|NCT01982032|Device|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
191041|NCT00117988|Drug|tanespimycin|
191042|NCT01982045|Device|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
191043|NCT01982045|Other|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
191044|NCT01982058|Other|communication intervention|
191045|NCT01982058|Other|counseling intervention|
191046|NCT01982058|Other|nutrition intervention|
191047|NCT01982058|Other|questionnaire administration|
191048|NCT01982071|Drug|Micafungin|IV
190413|NCT01992081|Device|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
190414|NCT01992081|Other|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
190415|NCT01992094|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
190416|NCT01992094|Biological|TIV1c|Licensed Influenza Vaccine
190417|NCT01992094|Biological|TIV2c|Novartis Investigational Vaccine
190418|NCT00115167|Drug|Darbepoetin alfa|Q4W
190419|NCT01954056|Drug|Placebo|7 days of intravenous or intramuscular placebo (normal saline in equal volume)
1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose
190420|NCT01954069|Device|Semi-quantitative pregnancy test|
190715|NCT01986972|Other|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
190716|NCT01986985|Device|PET/MRI system|Compared to PET CT
190717|NCT01986998|Drug|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
190718|NCT01986998|Drug|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
190719|NCT01987011|Biological|MG1109|
190720|NCT01987011|Biological|Placebo|
190721|NCT01987024|Device|Actim Partus® test|
190722|NCT01987024|Other|usual procedure|
190723|NCT01987037|Behavioral|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
190103|NCT01958801|Other|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
190104|NCT01958801|Other|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
190105|NCT01958814|Drug|Salbutamol|
190106|NCT01958814|Drug|Placebo : physiological serum|
190107|NCT01958827|Biological|Adalimumab|Subjects will be given subcutaneous injections of open-label adalimumab 80 mg eow from Week 0 to Week 50.
190108|NCT01958840|Behavioral|Behavioral Activation for Depression Treatment|
190109|NCT01958840|Behavioral|Supportive Counseling|
190110|NCT00115700|Drug|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
190111|NCT01958853|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
190112|NCT01958866|Drug|Tinospora Crispa-extract Product|
190113|NCT01958866|Drug|Acetaminophen|
190114|NCT01958866|Other|Placebo|
190115|NCT01961609|Biological|Secukinumab 150 mg|Patients will self-administer secukinumab loading dosing with 150 mg secukinumab administered subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then 4-weekly. Following the Primary Endpoint at 16 weeks, patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Patients not achieving the NICE criteria at the Primary Endpoint at 16 weeks on the 150mg dose should be up titrated to 300mg. Following assessment at week 48 patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Patients not achieving the NICE criteria at 48 weeks on the 150mg dose should be up titrated to 300mg.
190421|NCT01954082|Drug|myo-Inositol 5% Injection|Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.
Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose).
190422|NCT01954082|Drug|Placebo|% glucose(dextrose)
190423|NCT01954108|Device|hyaluronic acid sodium salt|
190424|NCT01954108|Device|ESWT|
189465|NCT01971047|Drug|Humalog|Group 2 treatment arm. Follow dosing for Blood glucose > 180, per the following formula:
Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin
Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin
Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin
Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose
189466|NCT01971060|Device|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
189467|NCT01971073|Device|transcranial direct current stimulation|arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.
The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions ).
189468|NCT00117156|Drug|Rituximab|
189469|NCT01971073|Device|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
189788|NCT01966081|Other|Blood sample|
189789|NCT01966081|Other|tissue samples from abdominal subcutaneous adipose|
189790|NCT01966107|Drug|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
189791|NCT01966107|Drug|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
189792|NCT01966120|Procedure|Photodynamic therapy|
189793|NCT01966133|Drug|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
189794|NCT01966146|Device|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
189795|NCT01966159|Device|SYNERGY Investigational Device (Test)|percutaneous coronary intervention
189796|NCT01966159|Device|PROMUS Element Plus Investigational Device (Control)|percutaneous coronary intervention
189797|NCT01966172|Drug|Ibuprofen|oral ibuprofen 400mg 4 times daily
189798|NCT00002129|Drug|Vesnarinone|
189799|NCT00116532|Drug|Escitalopram|
189800|NCT01966172|Drug|Gabapentin|Oral Gabapentin 300mg twice daily
189801|NCT01966172|Drug|Morphine|10 mg morphine orally 4 times daily
189802|NCT01966172|Drug|Paracetamol|oral paracetamol 1000mg four times daily
189157|NCT01978301|Drug|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
189158|NCT01978314|Device|75 mg / 6 mL VFI™|75 mg / 6 mL VFI™
189159|NCT01978327|Drug|GSK2647544|repeat dose
189160|NCT01978327|Drug|drug-drug interaction|drug-drug interaction
189161|NCT01978353|Behavioral|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
189162|NCT01978353|Behavioral|Psychoeducation|Participants receive information about memory functioning and aging
189163|NCT01978366|Drug|HT-100|May be administered in either fed or fasted state
189164|NCT00117754|Drug|Terbinafine hydrochloride|
189165|NCT01978392|Behavioral|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
189166|NCT01978405|Drug|Alpha lipoic acid|
189167|NCT01978418|Drug|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
189168|NCT01978418|Drug|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
189169|NCT01978431|Drug|cocaine hydrochloride|
189470|NCT01971099|Drug|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
189471|NCT01971099|Other|Placebo|patients will take one pill a day (the same shape of the drug)
189472|NCT01973452|Drug|Dexmedetomidine|
189473|NCT01973452|Drug|Placebo|
189474|NCT01973465|Biological|Stool|Implanting fecal matter via colonscope
189475|NCT01973478|Device|DBS|
189476|NCT01973478|Device|SHAM|
188834|NCT01986088|Drug|Placebo|matching placebo
188835|NCT01986088|Drug|Eletriptan 40 mg|40mg oral
188836|NCT01986088|Drug|Eletriptan 80 mg|80mg oral
188837|NCT01986088|Drug|Sumatriptan 50 mg|50mg oral
188838|NCT01986088|Drug|Sumatriptan 100 mg|100mg oral
188839|NCT01986101|Drug|SM-13496 (lurasidone HCl)|SM-13496 20-60mg, SM-13496 80-120mg
188840|NCT01986114|Drug|SM-13496 (lurasidone HCl)|SM-13496 20-120mg
188841|NCT01986127|Drug|Adalimumab|single intralesional administration during endoscopy process
188842|NCT01986127|Drug|placebo|single intralesional administration during endoscopy
188843|NCT01986140|Device|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
188844|NCT00118261|Drug|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
188845|NCT01986140|Other|Control No treatment|No treatment to prevent hair loss
188846|NCT01986166|Drug|MEHD7945A|Multiple doses IV
188847|NCT01986166|Drug|cobimetinib|Multiple escalating doses PO
188848|NCT01986179|Other|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
188849|NCT01986179|Other|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
188850|NCT01986192|Drug|rivaroxaban|
188851|NCT01986192|Drug|Warfarin|
188852|NCT01986205|Drug|Hyperbaric Oxygen|
188853|NCT01986205|Drug|Pressurized Air (1.2)|
188854|NCT01986205|Drug|Pressurized Air (1.0)|
188855|NCT00118261|Drug|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
188856|NCT01986218|Drug|BMS-986115|
193381|NCT02040116|Drug|Rapid Infusion Rituximab|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
188520|NCT01953341|Drug|AMG 333|Oral administration available in varying dose strength.
188521|NCT01953341|Drug|Placebo|Placebo containing no active drug
188522|NCT01953354|Biological|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
188523|NCT01953354|Biological|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
188524|NCT01953367|Drug|Vantobra (tobramycin)|Inhalation
188525|NCT01953367|Drug|TOBI (tobramycin)|Inhalation
188526|NCT01953380|Behavioral|extended information|
188527|NCT01953393|Other|Low-dose TNF-alpha|
188528|NCT01953406|Drug|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
188529|NCT00115076|Drug|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
188530|NCT01953406|Drug|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
188531|NCT01953419|Drug|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
188532|NCT01953432|Drug|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
188533|NCT01953432|Drug|Placebo|Matched placebo daily dosing
188534|NCT01953445|Drug|paclitaxel|
188535|NCT01953445|Drug|BKM120|
188536|NCT01953484|Other|Change in extracorporeal carbon dioxide removal|
188537|NCT01953497|Drug|URC102|
188538|NCT01953497|Drug|Placebo|
193051|NCT01967394|Other|Use of internet based social marketing intervention|Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: "16 and pregnant," "teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention.
193052|NCT01967394|Other|No use of social media|No social media ads will be available in these counties.
193053|NCT01967407|Procedure|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
193054|NCT01967420|Behavioral|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
193055|NCT01967420|Behavioral|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
193056|NCT01967433|Drug|Diphenhydramine|
193057|NCT01967433|Drug|Placebo|
193058|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
193382|NCT02040129|Device|Acrysof Toric IOL|Lens implantation following cataract surgery
193383|NCT02040142|Procedure|HIPEC|
193384|NCT02040155|Device|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
193385|NCT02040194|Drug|AM-101|AM-101 gel for intratympanic injection
193386|NCT02040194|Drug|Placebo|Placebo gel for intratympanic injection
193387|NCT02040207|Drug|AM-101|AM-101 gel for intratympanic injection
193388|NCT00123123|Drug|placebo|
193389|NCT02040220|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
193390|NCT02042976|Behavioral|Pulmonary rehabilitation|
193391|NCT02042989|Drug|MLN9708|Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.
Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase.
192452|NCT01979952|Drug|Matching Placebo|twice daily dosing
192453|NCT01979952|Drug|Nintedanib|gelating capsule
192748|NCT01972568|Drug|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
192749|NCT01972568|Drug|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
192750|NCT01972581|Other|Reaction Time Training|
192751|NCT01972594|Procedure|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
192752|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
192753|NCT01972594|Device|Accelerometer(ActivPAL)|
192754|NCT01972607|Other|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
192755|NCT01972620|Drug|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
192756|NCT01972633|Procedure|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
192757|NCT01972633|Procedure|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
192758|NCT01972659|Drug|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
192759|NCT01972659|Drug|Magnesium Sulphate|Experimental :
50 mg/kg bolus plus 15 mg/kg continuous infusion
192760|NCT01972659|Drug|sugammadex|4 mg/kg iv bolus at the end of the surgery
192761|NCT01974752|Drug|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
192762|NCT01974752|Drug|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
192763|NCT01974765|Drug|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
192764|NCT01974778|Dietary Supplement|Meal|Meal
187660|NCT00117546|Drug|alpha methyldopa|500 mg twice a day
187661|NCT01975220|Drug|25 mg Empafliglozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
187662|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
187663|NCT01975220|Drug|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
187664|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
187665|NCT01975233|Device|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
187666|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
187667|NCT01975246|Drug|hydrochlorothiazide|tablet
187668|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
187669|NCT01975246|Drug|Placebo|placebo matching hydrochlorothiazide tablet
187670|NCT01975259|Drug|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution & have glucose levels recorded up to every 30 mins for 2hours
187671|NCT00117559|Behavioral|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
187672|NCT01975259|Drug|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution & have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
187673|NCT01977794|Drug|Bisoprolol/Amlodipine (Bisoprolol sub-group B)|Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 10mg/5mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 10mg/5mg after Visit 2 and are controlled at visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.
187674|NCT01977794|Drug|Bisoprolol/Amlodipine (Amlodipine sub-group A)|Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 5mg/10mg and are controlled at Visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.
187953|NCT01970449|Biological|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
187063|NCT00186810|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
187064|NCT02563067|Drug|QAW039|QAW039 Dose 1 once daily
187065|NCT02565147|Drug|Bivalirudin|prolonged infusion of bivalirudin with a dose already included in the SmPC to assess it's impact on infarct size compared to standard dose of heparin
187066|NCT02565160|Drug|Steroid injection|
187376|NCT01983033|Behavioral|Drop It training session|8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
187377|NCT00118053|Drug|docetaxel|
187378|NCT01983033|Behavioral|treatment as usual|12 weeks of no intervention other than treatment as usual
187379|NCT01983046|Drug|Three different mixture of acetate, butyrate and propionate and palcebo|
187380|NCT01983072|Dietary Supplement|Infant formula|
187381|NCT01983072|Other|Breastfeeding|Breastfeeding
187382|NCT01983085|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
187383|NCT01983085|Device|Standard of Care|Dressing changed as per normal clinical practice
187384|NCT01983111|Drug|buprenorphine, tramadol/acetaminophen|
187385|NCT01983124|Drug|Fotemustine + Vemurafenib|Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.
Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity.
187386|NCT01983137|Drug|Targinact® (oxycodone/naloxone)|
187387|NCT01983150|Behavioral|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
187388|NCT00118053|Procedure|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
187389|NCT01983150|Behavioral|On the Road to Quitting - Self Help|The control group will receive an evidence-based self-help guide known as "On the Road to Quitting" that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide.
192833|NCT01982942|Drug|Placebo|
192834|NCT01982955|Drug|MSC2156119J|MSC2156119J will be administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment. RP2D will be determined as per safety monitoring committee (SMC) discretion.
192835|NCT01982955|Drug|Gefitinib|Gefitinib will be administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment.
192836|NCT01982955|Drug|Pemetrexed|Pemetrexed will be administered at a dose of 500 milligram per square meter (mg/m^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
192837|NCT00118053|Drug|carboplatin|
192838|NCT01982955|Drug|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
192839|NCT01982968|Procedure|Surgery|Full fundoplication surgery for the treatment of abnormal GER
192840|NCT01982981|Other|water provision|perception behavioral change at the beginning and at the end of the intervention
192841|NCT01982981|Other|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
193145|NCT00124839|Drug|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
193146|NCT02057640|Drug|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
193147|NCT02057640|Drug|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
193148|NCT02057640|Drug|MLN9708|4mg on day 1, 8, 15, 28
193149|NCT02057666|Drug|Tasquinimod|A patient will initially receive 0.25 mg/day dose which will then be titrated through 0.5 mg/day (from Day 15) to a maximum of 1mg/day (from Day 29). If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
193150|NCT02057666|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food (preferably the main evening meal).
193151|NCT02057679|Drug|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
193152|NCT02057679|Drug|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
193153|NCT02057692|Drug|LUM001|
192531|NCT01987830|Device|MRI-PET|[11C] temozolomide for PET scan and a contrast dye for the MRI scan
Drawing blood to assess the radioactivity of [11C] temozolomide
192532|NCT01990274|Procedure|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
192533|NCT01990274|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
192534|NCT00118456|Drug|AEE788|
192535|NCT01990287|Device|SCS and PNfS|Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
192536|NCT01990287|Device|SCS Alone|Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
192537|NCT01990300|Drug|Alogliptin/pioglitazone|Alogliptin/pioglitazone combination tablets
192538|NCT01990313|Device|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
192539|NCT01990326|Drug|XAF5 Gel|
192540|NCT01990326|Drug|Placebo Gel|
192541|NCT01990339|Drug|Lansoprazole|• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.
For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.
• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
192542|NCT01990352|Drug|Pegylated liposomal doxorubicin|
192543|NCT01990378|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
192544|NCT01990391|Dietary Supplement|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
192545|NCT00002153|Drug|A-007|
192546|NCT00118469|Behavioral|Psychoeducation|
192547|NCT01990391|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
192548|NCT01990404|Drug|Premixed nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
191941|NCT01962415|Drug|Fludarabine|Fludarabine will be given IV daily x5 doses
191942|NCT01962415|Drug|Melphalan|Melphalan will be given IV daily x2 doses.
191943|NCT01962415|Drug|Thiotepa|Thiotepa will be given IV x1 dose.
191944|NCT01962428|Drug|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
191945|NCT01962441|Drug|SOF|SOF 400 mg tablet administered orally once daily
191946|NCT01962441|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
191947|NCT01962441|Drug|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
192234|NCT01954784|Radiation|total-body irradiation|Undergo TBI
192235|NCT01954784|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
192236|NCT01954784|Drug|cyclosporine|Given PO
192237|NCT01954784|Drug|mycophenolate mofetil|Given PO
192238|NCT01954784|Drug|bortezomib|Given SC
192239|NCT01954784|Drug|lenalidomide|Given PO
192240|NCT01954784|Other|laboratory biomarker analysis|Correlative studies
192241|NCT01954810|Biological|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
192242|NCT00115557|Other|Practice intervention 2|Performance feedback only.
192243|NCT01957098|Dietary Supplement|Active comparator: 8% L-arabinose|
192244|NCT01957124|Procedure|PRF (Platelet-Rich Fibrin)|
192245|NCT01957137|Device|InterStim® (Device Programming)|
192246|NCT01957150|Drug|Fluticasone Furoate|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI.
192247|NCT01957150|Drug|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
191646|NCT01969370|Behavioral|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
191647|NCT01969383|Other|Heated pool training|
191648|NCT01969396|Device|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
191649|NCT00116909|Drug|OSI 7904L|
191650|NCT01969396|Device|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
191651|NCT01969409|Drug|Rituximab|i.v. rituximab given on two occasions 14 days apart.
191652|NCT01969409|Drug|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
191653|NCT01969422|Procedure|observation|intervention is the contact with online question answering serice ad subseudd
191654|NCT01969435|Drug|Carmustine|
191655|NCT01969435|Drug|Etoposide phosphate|
191656|NCT01969435|Drug|Cytarabine|
191657|NCT01969435|Drug|Melphalan HCl (propylene glycol-free)|
191658|NCT01969448|Procedure|Inframammary Fold Incision or Lateral Radial Incision|
191948|NCT01962454|Drug|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
191949|NCT01962454|Drug|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
191950|NCT00116103|Drug|Tacrolimus Inhalation Aerosol|
191951|NCT01962454|Drug|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
191952|NCT01962467|Drug|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
191953|NCT01962467|Drug|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
191954|NCT01962467|Drug|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
191336|NCT01974466|Other|Goal A|controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
191337|NCT01974466|Other|Goal B|controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:
1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%
191338|NCT00117468|Drug|Progesterone 8% Vaginal Gel|Administered vaginally from Cycle Day 14 to Day 31
191339|NCT01974479|Other|anti-CD19 redirected NK cells|
191340|NCT01974492|Procedure|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
191341|NCT01976728|Drug|Gonadorelin acetate 10µg/pulse|
191342|NCT01976728|Drug|Gonadorelin acetate 15µg/pulse|
191343|NCT01976728|Drug|Gonadorelin acetate 20µg/pulse|
191344|NCT01976728|Drug|Placebo|
191345|NCT01976741|Drug|BAY1163877|Oral administration twice daily. Starting dose is 100 mg per patient in the first cohort and will be escalated in other cohorts depending on any dose-limiting toxicities.
191346|NCT01976754|Drug|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
191347|NCT01976780|Drug|Artesunate|
191348|NCT00117650|Biological|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
191349|NCT01976780|Drug|Artemether Lumefantrine|
191350|NCT01976780|Drug|Mefloquine|
191351|NCT01976806|Drug|Aspirin|
191352|NCT01976806|Drug|Docosahexaenoic acid|
191353|NCT01976806|Drug|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
191354|NCT01976832|Behavioral|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
191659|NCT01969448|Procedure|Lateral Radial Incision|
191660|NCT00116922|Drug|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|[Rosiglitazone 2mg/ Metformin 500mg] twice daily
191049|NCT01982097|Drug|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
191050|NCT01982110|Behavioral|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
191051|NCT01982110|Behavioral|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
191052|NCT00118001|Behavioral|Worry exposure|
191053|NCT00118183|Biological|cetuximab|Given IV
191054|NCT01984502|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
191355|NCT01976832|Behavioral|Social interaction|The control group will receive a protocol for social interaction as the control condition.
The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period.
191356|NCT01976845|Drug|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
191357|NCT01976845|Drug|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
191358|NCT01976845|Drug|Saline|Saline 2 ml IV, in the pre-op area as a premedication
191359|NCT00002140|Drug|Azithromycin|
191360|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
191361|NCT01976858|Drug|PEX168|A injection administered subcutaneously
191362|NCT01976871|Drug|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
191363|NCT01976897|Other|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
191364|NCT01976897|Other|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
191365|NCT01979445|Drug|Cangrelor|Cangrelor administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours
191366|NCT01979445|Drug|Clopidogrel|Clopidogrel 600 mg single dose
191367|NCT01979445|Drug|Prasugrel|Prasugrel 60mg single dose
191368|NCT01979458|Device|PSE|
190724|NCT00118404|Behavioral|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
190725|NCT01989663|Other|HEC Placebo Gel|
190726|NCT01989663|Other|Placebo Vaginal Film|
190727|NCT01989676|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
190728|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
191055|NCT01984515|Behavioral|Referral Management System|Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., "talking about past trauma will be too difficult for me"). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD.
191056|NCT01984528|Biological|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
191057|NCT01984541|Biological|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
191058|NCT01984567|Dietary Supplement|Vitamin E|Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg
191059|NCT01984567|Dietary Supplement|Lipoic acid|Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
191060|NCT01984567|Dietary Supplement|Control|Daily consumption of 3 placebo capsules
191061|NCT01984580|Drug|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
191062|NCT01984593|Other|Yoga|The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.
The two yoga exercises were:
"Left nostril breathing" - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and
"Spinal flex" - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes).
191063|NCT01984606|Drug|Empagliflozin|Empagliflozin once daily
190425|NCT01954121|Drug|Levetiracetam|Immediate release film-coated tablets at strengths of 250 mg and 500 mg.
Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)
Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid
Down-titration Period (Week 30 up to Week 33)
190426|NCT01954121|Drug|Carbamazepine|Immediate release tablets at a strength of 200 mg.
Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)
Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid
Down-titration Period (Week 30 up to Week 33)
190427|NCT01954147|Drug|GLP-1|GLP-1 therapy
190428|NCT01954147|Biological|SC|Stem cell infusion
190429|NCT00115180|Other|No intervention|No intervention
190430|NCT01954147|Other|Standard Medical Treatment|Standard Medical Treatment
190431|NCT01954160|Device|Symplicity Renal Denervation|Renal denervation
190432|NCT01954173|Radiation|3D conformal radiation therapy|Undergo conformal radiation therapy
190433|NCT01954173|Procedure|quality-of-life assessment|Ancillary studies
190434|NCT01954173|Procedure|therapeutic conventional surgery|Undergo surgical resection
190435|NCT01954186|Drug|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
190436|NCT01954186|Procedure|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
190437|NCT01954199|Procedure|Neurodynamic Group|All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.
In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;
In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;
In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner.
190438|NCT01956240|Procedure|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
190729|NCT01989676|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
189803|NCT01966185|Other|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
189804|NCT01966198|Other|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
189805|NCT01966224|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.
Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose.
189806|NCT01966250|Device|electroacupuncture and usual care|Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.
Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
190116|NCT01961609|Biological|Secukinumab 300 mg|Patients will self-administer 300 mg secukinumab administered subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4. And then 300mg secukinumab administered 4-weekly. Following the Primary Endpoint at 16 weeks, patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 32 weeks. Patients not meeting this NICE criterion will return to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 24 weeks. Patients not meeting this NICE criterion will return to routine treatment under the care of their usual Clinical Team.
190117|NCT01961622|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
190118|NCT01961622|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
190119|NCT01961635|Device|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
190120|NCT01961635|Device|Zirconia abutments|place zirconia abutment on the day of implant placement
190121|NCT01961635|Device|Titanium Abutments|place titanium abutment on the day of implant placement
190122|NCT01961635|Device|acrylic abutments|place acrylic abutment on the day of implant placement
190123|NCT01961635|Device|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
190124|NCT00115960|Biological|IL-12 DNA adjuvant|Cytokine injection
189477|NCT00117403|Drug|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
189478|NCT01973491|Drug|ATX-MS-1467|ATX-MS-1467 will be administered as per dosage regimen specified in the protocol for 4 weeks (dose titration period) followed by 16 weeks of treatment, and 16 additional weeks of observation.
189479|NCT01973504|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
189480|NCT01973504|Drug|Control|Crystalloid solution IV infusion drip to keep vein open
189481|NCT01973517|Drug|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
189482|NCT01973517|Drug|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
189483|NCT01973530|Procedure|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
189484|NCT01973530|Procedure|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
189485|NCT01973543|Genetic|AAV2-hAADC|Neurosurgical delivery of AAV2-hAADC to the brain.
189486|NCT01973556|Other|Pharmacist-Physician Collaborative Medication Therapy Management|
189487|NCT01973569|Drug|denosumab|denosumab administered subcutaneously
189488|NCT00002138|Drug|Tecogalan sodium|
189489|NCT00117403|Drug|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
189490|NCT01973569|Drug|placebo|placebo administered subcutaneously to match denosumab
189491|NCT01973595|Dietary Supplement|Almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
189807|NCT01968486|Drug|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
188857|NCT01986231|Drug|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
189170|NCT01978431|Drug|methylphenidate|
189171|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy plus CME|
189172|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy|
189173|NCT01978457|Drug|cocaine hydrochloride|
189174|NCT01978457|Drug|propranolol|
189175|NCT00117767|Drug|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
189176|NCT01978457|Drug|placebo|
189177|NCT01978470|Device|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
189178|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141)|One time injection of 0 ug/kg (placebo group), via a catheter
189179|NCT01981083|Dietary Supplement|Renal-specific oral supplement|
189180|NCT01981096|Behavioral|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
189181|NCT01981096|Behavioral|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
189182|NCT01981122|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
189183|NCT01981122|Drug|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
189184|NCT01981135|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
189185|NCT01981135|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
189186|NCT01981148|Device|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
188539|NCT01953510|Biological|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
188540|NCT00115089|Drug|R926112|
188541|NCT01953510|Biological|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
188542|NCT01953523|Procedure|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
188858|NCT01986257|Behavioral|Emotion Regulation Group Therapy (ERGT).|
188859|NCT01986270|Drug|Placebo|Matching Placebo
188860|NCT01986270|Drug|Eletriptan 40 mg|40mg oral
188861|NCT01988701|Other|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
188862|NCT01988714|Other|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
188863|NCT00118352|Other|laboratory biomarker analysis|Correlative studies
188864|NCT01988714|Other|(CG) plus evidence-based SE|(CG) plus evidence-based SE
188865|NCT01988779|Drug|oral levofloxacin|
188866|NCT01988779|Drug|nebulized levofloxacin|
188867|NCT01988792|Dietary Supplement|Human milk fortifiers|
188868|NCT01988805|Other|Blood Draw|
188869|NCT01988818|Device|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
188870|NCT01988818|Device|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
188871|NCT01988831|Drug|Propranolol hydrochloride|This intervention apply to Propranolol group
188872|NCT01988831|Drug|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
188873|NCT01988844|Other|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
188874|NCT00002151|Drug|Celgosivir hydrochloride|
188875|NCT00118365|Other|placebo|Given orally
193392|NCT02042989|Drug|Vorinostat|Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.
Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase.
193393|NCT02043002|Procedure|18F-FDG-PET scan|
193394|NCT02043015|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
193395|NCT02043015|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
193396|NCT02043015|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
193397|NCT02043015|Drug|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
193398|NCT02043015|Other|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
188543|NCT01953536|Drug|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
188544|NCT01953536|Drug|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m^2.
188545|NCT01955434|Other|Quality-of-Life Assessment|Ancillary studies
188546|NCT00115362|Drug|venlafaxine|
188547|NCT01955434|Drug|Smac Mimetic LCL161|Given PO
188548|NCT01955447|Dietary Supplement|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
188549|NCT01955447|Dietary Supplement|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
188550|NCT01955447|Dietary Supplement|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
192765|NCT01974791|Behavioral|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
192766|NCT01974791|Other|Multidisciplinary Standard Care|Patients who are evaluated at the Pain Treatment Service are given recommendations that include medical, physical therapy, and psychological treatments.
192767|NCT01974804|Procedure|MRI|
193059|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
193060|NCT01967472|Drug|amodiaquine-artesunate (AQAS) co-formulated|
193061|NCT00116701|Drug|Aranesp®|
193062|NCT01967472|Drug|Artemether-lumefantrine combination (AL)|
193063|NCT01967485|Other|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
193064|NCT01967485|Other|Treatment as usual|Children will receive stimulant treatment for ADHD.
193065|NCT01967498|Drug|Montelukast|
193066|NCT01967524|Drug|botulinum toxin A + ropivacaïne|D0 :
Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)
QDSA (Saint-Antoine pain questionnaire)
QCD (Pain questionnaire)
MPI (Multidimensional Pain Inventory)
Beck scale
HAD (Hospital Anxiety and Depression scale)
SF36 (Short Form 36)
injection of botulinum toxin A associated with ropivacaïne
D30, D90, D120 and D150 (phone call): Calcul of the average of EN
D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).
193067|NCT01967524|Drug|Ropivacaïne|D0 :
Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)
QDSA (Saint-Antoine pain questionnaire)
QCD (Pain Questionnaire)
MPI (Multidimensional Pain Inventory)
Beck scale
HAD (Hospital Anxiety and Depression scale)
SF36 (Short Form 36)
injection of ropivacaïne alone
D30, D90, D120 and D150 (phone call): Calcul of the average of EN
D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).
193068|NCT01969929|Procedure|20G Vitrectomy|
193069|NCT01969929|Procedure|23G vitrectomy|
193070|NCT01969942|Biological|allogeneic stem cell transplantation|
193071|NCT01969942|Drug|Clyclophosphamide|
193072|NCT01969942|Drug|Fludarabina|
193073|NCT01969942|Drug|Busulfan|
193074|NCT01969942|Drug|Melphalan|
187954|NCT01970449|Biological|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
187955|NCT01970449|Device|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
187956|NCT01970462|Drug|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
187957|NCT01970462|Drug|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
187958|NCT00002134|Drug|Ganciclovir|
187959|NCT00117052|Drug|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
187960|NCT01970475|Drug|ABP 501|
187961|NCT01970475|Drug|Adalimumab (Humira®)|
187962|NCT01970488|Drug|Adalimumab (Humira®)|
187963|NCT01970488|Drug|ABP 501|
187964|NCT01970501|Drug|bucindolol hydrochloride|
187965|NCT01970501|Drug|metoprolol succinate|
187966|NCT01972958|Other|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
187967|NCT01972971|Other|patient education|one by one patient education
187968|NCT01972984|Drug|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
187969|NCT01972997|Device|SENSIMED Triggerfish|
187970|NCT01973010|Other|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
187971|NCT01973010|Drug|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
187972|NCT01973023|Other|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
187973|NCT00117338|Drug|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
187390|NCT01983163|Other|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
187391|NCT01983163|Other|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
187392|NCT01983189|Procedure|transcranial magnetic stimulation|1 hz transcranial magnetic stimulation
187393|NCT01983215|Device|Prevena vac|
187394|NCT01983228|Behavioral|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
187675|NCT01977794|Drug|Bisoprolol/Amlodipine (Amlodipine sub-group B)|Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43(Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 10mg/5mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 10mg/5mg and are controlled at Visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.
187676|NCT01977807|Device|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
187677|NCT01977820|Drug|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
187678|NCT01977820|Drug|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
187679|NCT01977833|Other|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
187680|NCT00117689|Drug|Mycophenolate Mofetil|for at least 1 month posttransplant
187681|NCT01977833|Other|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
187682|NCT01977859|Drug|Nesiritide|
187683|NCT01977859|Drug|Saline|
187684|NCT01977872|Behavioral|A worksite activity-diet intervention|
193154|NCT02057692|Drug|Placebo|
193155|NCT02057718|Drug|LUM001|
193156|NCT00124852|Behavioral|n-3 Fatty Acid Supplementation|
193157|NCT02057731|Genetic|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
193158|NCT02057757|Drug|Nitazoxanide (NTZ)|Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.
Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.
Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days.
193159|NCT02057757|Drug|Placebo|Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.
Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.
Participants 12 years and older: two placebo tablets orally twice daily for 5 days.
193160|NCT02057770|Drug|busulfan|
193161|NCT02057770|Drug|fludarabine phosphate|
193162|NCT02057770|Radiation|total-body irradiation (TBI)|
193163|NCT02057770|Procedure|Stem cell transplant|
193164|NCT02057770|Drug|cyclophosphamide|
193165|NCT02057770|Drug|tocilizumab|
193166|NCT02057783|Other|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
193487|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral entertoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
193488|NCT00124358|Behavioral|Integrated HIV care and office-based opioid dependence treatment|
193489|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral entertoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
193490|NCT02052947|Radiation|SPECT-DaTscan|Measurement of fixation of DaTscan® in the caudate and lenticular nucleus
LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted).
193491|NCT02052960|Drug|CetuGEX™|
193492|NCT02052960|Drug|Cetuximab|
192842|NCT01982994|Behavioral|Education/Daily Planning|In this study, we will use educational materials delivered at the initial enrollment session and in daily "facts of the day" presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)
192843|NCT01983007|Procedure|High-intensity exercise|Performance of high-intensity exercise
192844|NCT01983007|Procedure|Low-intensity exercise|Performance of low-intensity exercise
192845|NCT01983020|Drug|Lidocaine|
192846|NCT01983020|Drug|Ketamine|
192847|NCT01985334|Drug|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
192848|NCT01985334|Drug|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
192849|NCT01985334|Drug|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
192850|NCT01985334|Drug|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
192851|NCT01985334|Drug|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
192852|NCT01985347|Device|CPAP|Continuous positive airway pressure( CPAP)
192853|NCT01985360|Procedure|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
192854|NCT01985360|Procedure|Coronary Artery Bypass Graft Surgery|Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said "cabbage"). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart.
192855|NCT01985360|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
192856|NCT01985360|Behavioral|Lifestyle|Diet, physical activity, smoking cessation
192857|NCT00118209|Drug|pegfilgrastim|IV
192858|NCT01985360|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
192248|NCT01957163|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
192249|NCT01957163|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
192250|NCT01957163|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
192251|NCT01957163|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
192252|NCT01957176|Drug|ELT|Subjects will be dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets will be white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain ELT olamine equivalent to 20 mg of ELT per gram of powder.
192253|NCT00002122|Drug|Azithromycin|
192254|NCT00115570|Drug|insulin glulisine|
192255|NCT01957189|Drug|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
192549|NCT01990404|Drug|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
192550|NCT01990417|Other|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
192551|NCT01992861|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
192552|NCT01992861|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
192553|NCT01992861|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
192554|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule will be administered at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
192555|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet will be administered at a single dose of 60 mg orally on Day 3 in Part A.
192556|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet will be administered at a single dose of 60 mg orally on Day 1 in Part A.
192557|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule will be administered at a single dose of 60 mg orally on Day 3 in Part A.
191955|NCT01962480|Procedure|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson & Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
191956|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
191957|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
191958|NCT01964729|Device|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
191959|NCT01964729|Device|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
191960|NCT01964742|Genetic|blood samples|
191961|NCT01964755|Drug|Doxorubicin|Doxorubicin 20 mg/m2 intravenously over approximately 3-5 min will be administered on Day 1.
191962|NCT01964755|Drug|Methotrexate|On Day 2 when urine output is >= 150 mL/hr for approximately four consecutive hours, urine pH is >= 7.0 and after at least 1 liter of fluids, give Methotrexate 5 gm/m2 IV in 1000 mL 0.9% sodium chloride over approximately 4 hours x 1 dose only.
191963|NCT01964755|Drug|Leucovorin|Leucovorin 10 mg/m2 IV over 15 minutes-2 hours every 6 hours for 10 doses (see Section 4.1.8) - start approximately 24 hours after the BEGINNING of the methotrexate infusion.
Methotrexate level will be obtained approximately 48 hours after the END of the methotrexate infusion and the leucovorin dose adjusted accordingly.
Once methotrexate level is normal AND the subject has received 5 doses of intravenous zidovudine, the remaining doses of leucovorin and zidovudine may be given orally and the subject discharged from the hospital at the discretion of the investigator. Subject will be provided with a drug diary to record remaining doses taken at home: Leucovorin 25 mg every 6 hours for a total of 10 doses.
192256|NCT01957202|Drug|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
192257|NCT01957202|Drug|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
192258|NCT01957202|Drug|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
192259|NCT01957202|Drug|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
191661|NCT01969448|Procedure|Inframammary Fold Incision|
191662|NCT01969448|Device|Laser-assisted fluorescence angiography|All study arms will utilize this device to evaluate breast perfusion just prior to mastectomy, at the conclusion of the mastectomy procedure, and following conclusion of reconstruction and immediate implant.
191663|NCT01969461|Behavioral|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
191664|NCT01969474|Drug|Cannabis|Cannabis capsules given once daily for a month
191665|NCT01969474|Drug|Placebo|Placebo
191666|NCT01969487|Other|Preoperative warm-up on simulator|
191667|NCT01969500|Behavioral|Mobile Application|
191668|NCT01969500|Behavioral|Treatment as Usual|
191669|NCT01969513|Procedure|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
191670|NCT01972009|Procedure|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
191671|NCT01972022|Device|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
191672|NCT01972022|Device|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
191673|NCT01972035|Drug|Valacyclovir|Experimental Arm
191674|NCT01972035|Drug|Valganciclovir|Standard of care
191675|NCT01972048|Behavioral|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
191676|NCT00002136|Drug|Tecogalan sodium|
191677|NCT00117247|Drug|darbepoetin alfa|
191678|NCT01972048|Other|Print brochure|Mailed print brochure about breast cancer screening and community resources.
191369|NCT01979471|Other|Advanced Care|The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:
Patient assessment
Laboratory assessment of HbA1c and lipids
Individual assessment of CVD risk and education about this risk
Calculation of cardiovascular risk will be facilitated by an online tool
Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options
Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.
Regular communication with the patient's family physician after each contact with the patient
Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months.
191370|NCT01979484|Drug|PPI-668 capsule|
191371|NCT01979484|Drug|PPI-668 tablet|
191372|NCT00000306|Drug|Dextroamphetamine|
191373|NCT00002142|Drug|Probenecid|
191374|NCT00117858|Procedure|Anodal DC polarization of left prefrontal cortex|
191375|NCT01979497|Procedure|Suture with Adhesive Stripping|
191679|NCT01972061|Device|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
191680|NCT01972074|Drug|Memantine|Tablet
191681|NCT01972074|Drug|Placebo|
191682|NCT01972087|Behavioral|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
191683|NCT01972100|Device|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
191684|NCT01972100|Other|isokinetic exercise|
191685|NCT01972100|Device|Placebo low-level laser therapy|
191686|NCT01972113|Dietary Supplement|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
191687|NCT01972113|Dietary Supplement|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
191688|NCT00117260|Drug|Seasonale (levonorgestrel and ethinyl estradiol)|
191689|NCT01972113|Dietary Supplement|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
191064|NCT00118183|Drug|bortezomib|Given IV
191065|NCT01984606|Drug|Placebo|Placebo matching empagliflozin
191066|NCT01984606|Drug|Sitagliptin|Sitagliptin once daily
191067|NCT01984606|Drug|Placebo|Placebo matching sitagliptin
191068|NCT01984619|Device|Cryotherapy for the utilization of wrinkle reduction (iovera)|
191069|NCT01984632|Procedure|Single-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).
191070|NCT01984632|Procedure|Multi-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
191071|NCT01984645|Other|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
191376|NCT01979497|Procedure|Suture without Adhesive Stripping|
191377|NCT01979510|Drug|MK-0663B|MK-0663B once daily for 8 days.
191378|NCT01979510|Drug|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
191379|NCT01979510|Drug|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
191380|NCT01979523|Drug|Akt Inhibitor GSK2141795|Given PO
191381|NCT01979523|Other|Laboratory Biomarker Analysis|Correlative studies
191382|NCT01979523|Other|Pharmacological Study|Correlative studies
191383|NCT01979523|Drug|Trametinib|Given PO
191384|NCT01979536|Drug|Brentuximab Vedotin|Given IV
191385|NCT00117871|Drug|Resiquimod|
191386|NCT01979536|Drug|Crizotinib|Given PO
191387|NCT01979536|Drug|Cyclophosphamide|Given IV
191388|NCT01979536|Drug|Cytarabine|Given IT and IV
191389|NCT01979536|Drug|Dexamethasone|Given PO or IV
190730|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
190731|NCT01989689|Drug|Etanercept|Etanercept 50mg twice weekly
190732|NCT01989689|Drug|Placebo|
190733|NCT01989702|Other|Fermented blueberry drink|
190734|NCT01989702|Other|Placebo drink|
190735|NCT00118417|Drug|Clonazepam|Participants will receive clonazepam.
190736|NCT01989702|Other|Sachets with probiotic bacterial powder|
190737|NCT01989702|Other|Sachets with placebo powder|
190738|NCT01989715|Other|analyzing the position of the body, muscle activity|
190739|NCT01989728|Procedure|psychiatric examination and feedback|
190740|NCT01989741|Other|Sleep restriction|4 hours sleep by night during one week
190741|NCT01989754|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
190742|NCT01989754|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
190743|NCT01989754|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
190744|NCT01989767|Behavioral|control Rehabilitation as usual|Rehabilitation as usual
190745|NCT01992107|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
190746|NCT01992107|Biological|TIV1c|Licensed Influenza Vaccine
190747|NCT01992107|Biological|TIV2c|Novartis Investigational Vaccine
190748|NCT01992120|Other|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
190749|NCT00118742|Drug|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
191072|NCT00118300|Radiation|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
190125|NCT01961635|Procedure|Subcrestal|place implant 2mm below crestal bone
190126|NCT01961635|Device|platform-switch|abutment platform is narrow than implant diameter
190127|NCT01961635|Procedure|one-time one-abutment|place the final abutment on the day of surgery and not remove it
190128|NCT01961635|Procedure|Torque 20 n/cm2|the amount of torque applied to the abutment
190129|NCT01961648|Device|Rebreathing bag|
190130|NCT01961648|Device|Sham rebreathing|
190131|NCT01961648|Device|Mask|
190132|NCT01961661|Dietary Supplement|Lactobacillus rhamnosus GG|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 capsule/die for 1 month
190133|NCT01961661|Dietary Supplement|placebo|Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 cps/die for 12 months
190134|NCT01961674|Dietary Supplement|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
190439|NCT01956253|Drug|Neratinib|240 mg orally once daily
190440|NCT01956266|Behavioral|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
190441|NCT01956266|Behavioral|Standard prosodic treatment|The standard treatment includes tasks in common clinical use for treating the three main aspects of prosodic insufficiency in PD, pitch/stress, loudness, and rate. To address pitch/stress, we will use contrastive stress tasks. To address rate control we will use hand tapping tasks which have been shown to be effective, and to address loudness, patients will be asked to produce sentences of increasing length while maintaining an appropriate loudness level. Participants will receive clinician feedback regarding accuracy of attempts as well as auditory and visual feedback on accuracy of stress/pitch and loudness control via the VisiPitch display.
190442|NCT01956279|Drug|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
190443|NCT01956279|Drug|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
190444|NCT01956305|Drug|DS-7309|DS-7309 powder in bottle
190445|NCT00000304|Drug|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
189808|NCT01968486|Drug|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
189809|NCT00116805|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet administered orally once daily
189810|NCT01968512|Device|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
189811|NCT01968512|Device|Sham|Same character of Transcranial Direct Current Stimulation but without current
189812|NCT01968525|Biological|pre-oxygen|3 min of preoxygenation before anesthesia induction.
189813|NCT01968538|Radiation|Radiation Therapy|
189814|NCT01968551|Drug|E/C/F/TAF|Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (E/C/F/TAF) single-tablet regimen (STR) administered orally once daily
189815|NCT01968551|Drug|DRV|Darunavir (DRV) 800 mg administered orally once daily
189816|NCT01968551|Drug|Pre-existing ARV regimen|Participants will take their preexisting ARV regimen as prescribed.
189817|NCT01968564|Drug|Placebo pill|sugar and other inert substances
189818|NCT01968564|Drug|High-dose curcumin pill|2000mg curcumin pill/day
189819|NCT01968564|Drug|Low-dose curcumin pill|500mg curcumin pill/day
189820|NCT00116818|Drug|GW685698X aqueous nasal spray|
189821|NCT01968577|Drug|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
189822|NCT01968590|Drug|Cholecalciferol|A pharmacist employed by DDrops(trademark) prepares two sets of bottles, one set has 600IU per metered dose and the other set has 4,000IU per metered dose. Participants are randomized to one or the other dose, and they take one measured drop orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
189823|NCT01968616|Drug|Ranibizumab, 0.5mg, Intravitreal|
189824|NCT01968629|Drug|Eovist|
189825|NCT01968642|Behavioral|Educational Intervention|
190135|NCT01963936|Device|Facial mask|
189187|NCT01981161|Procedure|biological samples and clinical data|
189188|NCT01981174|Procedure|30-gauge needle|
189189|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
189190|NCT01981174|Procedure|32-gauge needle|
189492|NCT01973595|Other|No almond consumption|No almonds will be consumed by participants for 3 weeks.
189493|NCT01973608|Drug|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a dose of 0.3 mg/kg as intravenous infusion over approximately 1 hour every 3 weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent.
189494|NCT01973608|Drug|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a dose of 1.0 mg/kg as intravenous infusion over approximately 1 hour every 3 weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent.
189495|NCT01975779|Drug|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
189496|NCT01975779|Drug|Cohort B1: Lu AE58054|Two single oral doses 60 mg with >=7 days washout.
189497|NCT01975805|Other|Chlorhexidine Gluconate|
189498|NCT01975805|Other|Povidone Iodine|
189499|NCT01975818|Drug|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
189500|NCT00117585|Drug|Treatment Phase 2|Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.
Fludrocortisone
Salt tablet
189501|NCT01975818|Biological|Epoetin alfa/beta|
189502|NCT01975831|Drug|MEDI4736|Anti-PD-L1
189503|NCT01975831|Drug|Tremelimumab|Anti-CTLA-4
189504|NCT01975844|Other|Individualized Anemia Mangement Protocol|Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.
Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP .
189505|NCT01975857|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
189506|NCT01975857|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
189507|NCT01975870|Other|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
188876|NCT01988857|Biological|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
188877|NCT01988870|Radiation|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
188878|NCT01988883|Drug|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
188879|NCT01988883|Drug|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
188880|NCT01988883|Drug|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
189191|NCT01981187|Drug|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
189192|NCT01981200|Other|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
189193|NCT01981226|Device|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
189194|NCT01981239|Device|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
189195|NCT01981252|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
189196|NCT01981278|Drug|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
189197|NCT01981278|Drug|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
189198|NCT01983930|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan kriya meditation (12 minute duration) for 12 weeks.
189199|NCT01983930|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
189200|NCT01983943|Dietary Supplement|Hydroxytyrosol, the active ingredient in olive oil.|A 40mg capsule will be taken once daily for 6 months.
189201|NCT01983943|Dietary Supplement|Placebo|A 40mg placebo will be taken once per day for 6 months.
188551|NCT01955447|Dietary Supplement|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
188552|NCT01955460|Drug|Cyclophosphamide|60 mg/kg/day by vein on Day -7 and -6.
188553|NCT01955460|Drug|Mesna|60 mg/kg by vein on Day -7 and -6.
188554|NCT01955460|Drug|Fludarabine monophosphate|25 mg/m2 by vein on Day -5 to Day -1.
188555|NCT01955460|Biological|T-Cells|Starting dose level of DNRII transduced TIL T-cells: 15 x 10^9 by vein on Day 0.
188556|NCT01955460|Drug|Interleukin-2 (IL-2)|720,000 IU/kg by vein every 8-16 hours for up to 15 doses on Days 1 to 5 and 22 to 26.
188557|NCT00115375|Drug|Clopidogrel (SR25990)|
188558|NCT01955460|Behavioral|Questionnaires|Quality of life (QOL) questionnaires completed at baseline, 6 and 12 weeks after T-cell infusion, at 6 month follow up, then yearly.
188559|NCT01955473|Drug|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
188560|NCT01955486|Other|flight simulation|
188561|NCT01955499|Drug|Ibrutinib|Given PO
188562|NCT01955499|Other|Laboratory Biomarker Analysis|Correlative studies
188563|NCT01955499|Drug|Lenalidomide|Given PO
188564|NCT01955499|Other|Pharmacological Study|Correlative studies
188565|NCT01955512|Drug|Clopidogrel|Clopidogrel 75mg daily for 7 days
188881|NCT01988896|Drug|Atezolizumab|Administered via IV infusion.
188882|NCT01988896|Drug|Cobimetinib|Administered via oral tablets.
188883|NCT01988909|Drug|WR 279,396|Paromomycin + Gentamicin Topical Cream
188884|NCT01988922|Drug|ketamine|0.4 mg/kg oral racemic ketamine
188885|NCT01988935|Behavioral|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
188886|NCT00118365|Drug|eflornithine|Given orally
193075|NCT00116987|Device|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
193076|NCT01969955|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
193077|NCT01969968|Other|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
193078|NCT01969981|Procedure|PICC placement with Sherlock 3CG|
193079|NCT01969994|Other|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (−)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
193399|NCT00123422|Behavioral|Heliox|exercise training with a helium oxygen combination
193400|NCT02043015|Behavioral|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
193401|NCT02043015|Behavioral|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
193402|NCT02043028|Device|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
193403|NCT02043028|Device|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
193404|NCT02043041|Other|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
193405|NCT02045303|Device|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
193406|NCT02045303|Device|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
193407|NCT02045342|Other|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
193408|NCT02045342|Other|Placebo|Ingest 500ml of placebo prior to metabolic measures.
188273|NCT01965483|Radiation|once-weekly breast irradiation|
188274|NCT01965496|Drug|PEX168|A injection administered subcutaneously
188275|NCT01965509|Drug|PEX168 or placebo|injection has to administered subcutaneously weekly
188276|NCT01965522|Drug|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
188277|NCT00116493|Drug|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
188278|NCT01965522|Drug|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
188279|NCT01965522|Drug|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
188280|NCT01965522|Drug|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
188281|NCT01965535|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
188282|NCT01965535|Drug|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing < 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
188283|NCT01967823|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
188284|NCT01967823|Biological|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
188285|NCT01967836|Device|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
188286|NCT01967849|Procedure|Oral Glucose tolerance test|
188287|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
188288|NCT01967862|Procedure|computed tomography|Undergo CT
188289|NCT01967862|Procedure|bone scan|Undergo bone scan
188290|NCT01967862|Procedure|3-Tesla magnetic resonance imaging|Undergo axial MRI
188291|NCT01967862|Procedure|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
188292|NCT01967862|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
187685|NCT01977885|Behavioral|High Protein Diet|All participants will be individually counseled by an RD for ~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
187686|NCT01980485|Behavioral|Lung Age feedback and exhaled carbon monoxide|In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a "normal" FEV-1, the intervention will focus on their exhaled carbon-monoxide.
If their lung age is greater than their chronological age, they will be given their "lung age" in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.
Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation.
187687|NCT01980485|Behavioral|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
187688|NCT01980498|Drug|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
187974|NCT01973036|Device|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
187975|NCT01973036|Drug|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
187976|NCT01973049|Drug|Daclatasvir|
187977|NCT01973049|Drug|Asunaprevir|
187978|NCT01973049|Drug|BMS-791325|
187979|NCT01973049|Drug|Ribavirin|
187980|NCT01973049|Drug|Placebo matching Ribavirin|
187981|NCT01973062|Biological|rituximab|Given IV
187982|NCT01973062|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
187983|NCT01973101|Drug|Cisplatin|50 mg/m2 - Day 1
187984|NCT00117338|Drug|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
193493|NCT02052960|Drug|Combination of Cisplatin and 5-Fluorouracil|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
193494|NCT02052973|Other|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
193495|NCT02052986|Other|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
193496|NCT02052999|Drug|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
193497|NCT02052999|Other|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
193498|NCT02052999|Drug|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
193499|NCT00124371|Behavioral|a nurse led home-based education and support programme|
193500|NCT02053012|Device|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
193501|NCT02053025|Dietary Supplement|mycoprotein|
193502|NCT02053025|Dietary Supplement|control protein|
193503|NCT02053038|Device|iFR|Treatment guided by instantaneous wave-free ratio
193504|NCT02053038|Device|FFR|Treatment guided by Fractional Flow Reserve
193505|NCT02053051|Device|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
193506|NCT02053051|Drug|Novorapid|Multiple daily injections(MDI) of insulin
193507|NCT02053064|Genetic|SAF-301|
188649|NCT00116493|Dietary Supplement|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
188650|NCT01965561|Device|JETT|Use of Junctional Emergency Treatment Tool (JETT)
188651|NCT01965561|Device|SJT|Use of SAM Junctional Tourniquet (SJT)
188652|NCT01965574|Procedure|Trendelenburg position|
188653|NCT01965587|Procedure|novasure mirena IUS combined|novasure mirena IUS combined
188654|NCT01965600|Drug|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
192859|NCT01985373|Drug|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
192860|NCT01985386|Dietary Supplement|GDS capsule with meal|GDS capsule with meal
193167|NCT00124865|Biological|rFla-MBP|
193168|NCT02059993|Device|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
193169|NCT00125138|Drug|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
193170|NCT02060006|Drug|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
193171|NCT02060019|Drug|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
193172|NCT02060032|Drug|1.2% Atorvastatin local drug delivery|
193173|NCT02060032|Drug|1.2% simvastatin local drug delivery|
193174|NCT02060032|Drug|Placebo local drug delivery|
193175|NCT02060045|Other|Bundle implementation|
193176|NCT02060058|Drug|Stop trial intervention for boceprevir, PEG-IFN and RBV|Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.
Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.
Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.
193177|NCT02060071|Other|Blood test|Blood test
193178|NCT02060084|Drug|Triple viable Bifidobacterium 0.5 bid po|
193179|NCT02060084|Dietary Supplement|early Micro-feeding|
193180|NCT00125138|Drug|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
193181|NCT02060097|Dietary Supplement|Cocoa flavanol beverage|
193182|NCT02060110|Device|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
193183|NCT02060110|Device|MADIT-CRT ICD ONLY ARM|
192558|NCT01992874|Drug|Pimasertib Capsule (Part B and trial extension phase)|Subjects who complete Part A will receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
192559|NCT01992900|Drug|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
192560|NCT00118768|Drug|valopicitabine|
192561|NCT01992900|Drug|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
192562|NCT01992913|Behavioral|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
192563|NCT01992913|Behavioral|Psychoeducation|Team Solutions psychoeducation model
192564|NCT01992913|Behavioral|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
192565|NCT01992926|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
192566|NCT01992939|Other|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
192861|NCT01985386|Dietary Supplement|Ferrous sulfate with meal|Ferrous sulfate with meal
192862|NCT01985399|Behavioral|Neuropsychological testing|Neuropsychological testing
192863|NCT01985425|Drug|Colchicine|
192864|NCT01985425|Drug|Colchicine Placebo|
192865|NCT01985438|Procedure|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
192866|NCT01985438|Procedure|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
192867|NCT01985451|Drug|Pemetrexe|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
192868|NCT01987830|Device|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of [11C] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
192260|NCT01957215|Drug|Indomethacin|Topical indomethacin
192261|NCT01957215|Drug|Placebo|Placebo patch
192262|NCT01957228|Procedure|bone biopsies|
192263|NCT01957280|Drug|patritumab|
192264|NCT01957293|Drug|Salbutamol|single oral administration, 4 mg
192265|NCT01959620|Behavioral|1-Session Exposure Therapy|One exposure therapy session lasting one hour
192266|NCT01959620|Behavioral|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
192267|NCT01959633|Drug|Vemurafenib|Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
192268|NCT01959633|Drug|Peg-interferon|In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only
In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD.
192269|NCT01959646|Dietary Supplement|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
192270|NCT01959646|Other|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
192271|NCT01959646|Dietary Supplement|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
192272|NCT01959672|Procedure|4-Dimensional Computed Tomography|Correlative studies
192273|NCT00115765|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
192567|NCT01992939|Other|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
192568|NCT01992952|Drug|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
192569|NCT01992952|Drug|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
192570|NCT01992952|Drug|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
192571|NCT00118768|Drug|Pegylated Interferon Alfa|
191964|NCT01964755|Biological|Hydroxyurea|Hydroxyurea 500 mg by mouth twice daily will begin on Day 2 and continue for a total of 10 doses.
Once methotrexate level is normal AND the subject has received 5 doses of intravenous zidovudine, the remaining doses of leucovorin and zidovudine may be given orally and the subject discharged from the hospital at the discretion of the investigator. Subject will be provided with a drug diary to record remaining doses taken at home:
Hydroxyurea 500 mg orally twice daily will be given for a total of 10 doses.
191965|NCT01964755|Drug|Zidovudine|Zidovudine 750 mg/m2 IV over approximately 1 hour twice daily will begin on Day 2 (after methotrexate) and continue for a total of 10 doses.
Once methotrexate level is normal AND the subject has received 5 doses of intravenous zidovudine, the remaining doses of leucovorin and zidovudine may be given orally and the subject discharged from the hospital at the discretion of the investigator. Subject will be provided with a drug diary to record remaining doses taken at home:
Zidovudine 1200 mg orally twice daily for a total of 10 doses.
191966|NCT00002127|Drug|Thalidomide|
191967|NCT00116376|Drug|AEE788|
191968|NCT01964755|Procedure|Urine Alkalization|Urine alkalization will begin on Day 1 with normal saline or 5% dextrose with or without sodium bicarbonate.
191969|NCT01964768|Other|Skin prick-test|
191970|NCT01964781|Drug|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
191971|NCT01964781|Drug|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
191972|NCT01964781|Drug|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
191973|NCT01964781|Drug|tranexamic acid plus saline|
191974|NCT01964781|Drug|saline|
191975|NCT01966861|Other|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score >14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required [CPIS>6], hemglobin>8g/dl triggers transfusion)
191976|NCT01966887|Genetic|MYDICAR-single intracoronary infusion|AAV1/Serca2a
191977|NCT01966887|Genetic|Placebo; single intracoronary infusion|single intracoronary infusion
191978|NCT00002130|Drug|Vesnarinone|
191979|NCT00116623|Drug|Indomethacin|
191980|NCT01966900|Biological|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
191981|NCT01966913|Drug|Bevacizumab|
191690|NCT01972139|Device|Renal Denervation|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
191691|NCT01972139|Other|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
191692|NCT01972152|Drug|G-Pen(TM) 1 mg|
191693|NCT01972152|Drug|Lilly Glucagon(TM) 1 mg|
191694|NCT01974492|Procedure|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
191695|NCT01974505|Device|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
191696|NCT01974518|Drug|Rituximab and Cyclophosphamide IV|
191984|NCT01966965|Drug|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
191985|NCT01966965|Drug|NEDAX|AS SPECIFIED AT THE LEAFLET
191986|NCT01966978|Drug|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
191987|NCT01966978|Drug|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
191988|NCT01966978|Drug|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
191989|NCT01966978|Drug|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180
191990|NCT00116623|Drug|Magnesium sulfate|
191991|NCT01967004|Device|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
191992|NCT01967017|Drug|Lidocaine|
191993|NCT01967043|Drug|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
191994|NCT01967069|Drug|DFD01 Spray|
191995|NCT01967069|Drug|Vehicle Spray|
191390|NCT01979536|Drug|Doxorubicin Hydrochloride|Given IV
191391|NCT01979536|Drug|Etoposide|Given IV
191392|NCT01979536|Drug|Ifosfamide|Given IV
191393|NCT01979536|Other|Laboratory Biomarker Analysis|Correlative studies
191394|NCT01982123|Procedure|Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
191395|NCT01982123|Procedure|Computed Tomography|Undergo 18F FDG PET/CT
191396|NCT01982123|Radiation|Fludeoxyglucose F-18|Undergo 18F FDG PET/CT
191397|NCT01982123|Procedure|Positron Emission Tomography|Undergo 18F FDG PET/CT
191398|NCT01982123|Procedure|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
191399|NCT01982123|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
191400|NCT01982123|Drug|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
191401|NCT01982136|Procedure|end-to-end urethroplasty|
191402|NCT01982136|Procedure|substitution urethroplasty (buccal mucosa)|
191697|NCT01974544|Drug|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
191698|NCT01974544|Procedure|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
191699|NCT01974544|Procedure|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
191700|NCT01974544|Drug|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
191073|NCT01987050|Drug|Intranasal oxytocin|
191074|NCT01987076|Drug|Prednisone|Prednisone:
Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days.
191075|NCT01987076|Drug|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
191076|NCT01987089|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
191077|NCT01987102|Drug|Leucovorin|The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.
All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
191078|NCT01987102|Drug|[6R] 5,10-methylenetetrahydrofolate|The enrolled patients will be treated according to the MAP schedule and will receive the study drug [6R] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.
All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate® dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
191079|NCT01987115|Procedure|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
191080|NCT01987115|Procedure|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
191081|NCT01987128|Procedure|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
191082|NCT01987128|Procedure|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
191083|NCT00118313|Biological|incomplete Freund's adjuvant|
191084|NCT01987128|Drug|Ropivacaine|
191085|NCT01987128|Device|PAJUNK SonoPlex 22G needle.|
191086|NCT01987141|Other|EMR Intervention|Electronic medical record flag/notification in the patient's chart
191087|NCT01987154|Other|Marketed cow milk-based premature infant formula|
190446|NCT00002121|Drug|Diethylhomospermine|
190447|NCT00115492|Drug|Fluticasone Propionate/Salmeterol Combination Product|
190448|NCT01956305|Drug|placebo|placebo to match DS-7309 powder in bottle
190449|NCT01956305|Drug|Metformin|Metformin 500mg tablet for Cohort F
190450|NCT01956318|Behavioral|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
190451|NCT01956344|Behavioral|Cognitive Behavioral Therapy|
190452|NCT01956357|Other|Aquatic exercise|
190453|NCT01956357|Other|Land Exercise|
190454|NCT01956370|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
190455|NCT01956370|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
190750|NCT01992120|Other|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
190751|NCT01992133|Dietary Supplement|Vitamin D3|
190752|NCT01992133|Dietary Supplement|Placebo|
190753|NCT01992146|Drug|Target-controlled naloxone-infusion|
190754|NCT01992146|Drug|Placebo|
190755|NCT01992159|Drug|AMG 785|AMG 785 subcutaneous injections for 12 months
190756|NCT01992159|Drug|Placebo|Placebo subcutaneous injections for 12 months
190757|NCT01992172|Drug|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
190758|NCT01992172|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
190759|NCT01992185|Drug|Photocil for Vitiligo|Photocil for Vitiligo
190136|NCT01963962|Drug|Copper IUD|
190137|NCT01963962|Drug|Levonorgestrel IUD|
190138|NCT01964001|Dietary Supplement|Vitamin B-6|Vitamin B-6 50 mg/d
190139|NCT00116285|Biological|Ragweed MATA MPL|
190140|NCT01964001|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg
190141|NCT01964001|Dietary Supplement|Vitamin B-6+Coenzyme Q10|Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
190142|NCT01964001|Other|Placebo|starch
190143|NCT01964014|Drug|advagrf|All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.
advagrf+sirolimus one time to eat.
190144|NCT01964027|Drug|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
190145|NCT01964040|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.
After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia
190146|NCT01964053|Behavioral|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
190147|NCT01964053|Behavioral|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
190148|NCT01964066|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography balloon dilatation
190149|NCT01964066|Procedure|Thoracic epidural analgesia|Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
190150|NCT00000304|Drug|Placebo|Placebo
190151|NCT00002126|Drug|Filgrastim|
190152|NCT00116298|Drug|stavudine, efavirenz, lamivudine|
190153|NCT01964066|Procedure|Premedication|For premedication used trimeperidine 2%-1ml intravenously.
189508|NCT01975896|Behavioral|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
189509|NCT01975909|Device|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
189826|NCT01968655|Biological|OBI-1|
189827|NCT01968668|Drug|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
189828|NCT01968668|Drug|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
189829|NCT01968668|Drug|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
189830|NCT01971112|Dietary Supplement|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
189831|NCT01971138|Other|this is a survey|
189832|NCT01971151|Behavioral|Exposure therapy|Treatment protocol:
1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments.
189833|NCT01971164|Drug|JTZ-951|Subjects will receive JTZ-951 or Placebo
189834|NCT01971164|Drug|Placebo|
189835|NCT01971177|Device|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.
Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.
All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform.
189836|NCT01971177|Procedure|Manual cataract surgery|"Manual": manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
189837|NCT00000305|Drug|Dextroamphetamine|
189838|NCT00002135|Drug|Ganciclovir|
189839|NCT00117169|Procedure|multi-detector helical computed tomography|
189202|NCT01983943|Behavioral|Nutrition counseling|Nutrition counseling on eating a healthy diet will be offered once at baseline.
189203|NCT01983943|Device|Endopat|An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
189204|NCT01983956|Behavioral|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
189205|NCT00118131|Drug|cisplatin|
189206|NCT01983969|Drug|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
189510|NCT01975922|Behavioral|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
189511|NCT00002140|Drug|Clarithromycin|
189512|NCT00117585|Other|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
189513|NCT01975935|Drug|Amlexanox|
189514|NCT01975935|Drug|Placebo|
189515|NCT01975948|Other|Mental Health Practice Support Program|training and (2) practice support.
Three half day workshop sessions over a 24 week period.
Practice support:
3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes
189516|NCT01978483|Drug|Denosumab|
189517|NCT01978483|Radiation|UVB exposure|
189518|NCT01978483|Drug|Diphenylcyclopropenone|
189519|NCT01978483|Drug|Normal Saline|
189520|NCT01978496|Drug|Placebo|matching placebo
189521|NCT01978496|Drug|Eletriptan 20 mg|20mg oral
189522|NCT01978496|Drug|Eletriptan 40 mg|40mg oral
189523|NCT01978496|Drug|Eletriptan 80 mg|80mg oral
188887|NCT01988935|Behavioral|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
188888|NCT01991288|Procedure|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
188889|NCT01991288|Procedure|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
188890|NCT01991301|Drug|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
188891|NCT01991314|Drug|Ferrous sulphate|200mg tablets.
188892|NCT01991327|Drug|Androxal|
188893|NCT00118560|Behavioral|Physical walking|calf muscle exercise
188894|NCT01991327|Drug|Placebo|
188895|NCT01991353|Procedure|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
188896|NCT01991353|Procedure|Without PRP|Standard of care meniscal repair without augmentation.
188897|NCT01991379|Drug|MEK162|
188898|NCT01991379|Drug|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
188899|NCT01991379|Other|Blood draws|
188900|NCT01991379|Procedure|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies.
188901|NCT01991392|Device|Nasogastric tube|For nasogastric decompression.
189207|NCT01983969|Drug|Vorinostat|1000 mg by vein on Day -11 through Day -2.
189208|NCT01983969|Drug|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
189209|NCT01983969|Drug|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
193409|NCT02045355|Other|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
193410|NCT02045368|Drug|IGF-Methotrexate|765IGF-MTX (iv infusion) at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
193411|NCT02045381|Procedure|MRI Group|One research MRI
193412|NCT02045394|Other|Chest X-ray|
193413|NCT02045394|Other|computed tomography of the chest|
193414|NCT00002187|Drug|Fomivirsen sodium|
193415|NCT00123552|Drug|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
193416|NCT02045394|Procedure|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
188566|NCT01955512|Drug|Placebo|Matched placebo
188567|NCT01955538|Other|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
188568|NCT00002120|Drug|Leucovorin calcium|
188569|NCT00115388|Procedure|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
188570|NCT01955538|Other|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
188571|NCT01955538|Other|Mixed physical activity|20 weeks, 1 hour/week.
188572|NCT01958138|Drug|comparison of group-P (low dose propofol with isoflurane) versus group-D (alone isoflurane)|In both groups, 5 minutes prior to LMA removal, the isoflurane concentration will be adjusted to predetermine value. In group-P, the isoflurane MAC will be 0.5 or less and in group-D, the isoflurane MAC will be 1.2 and the both groups will be ventilated with 50% oxygen and 50% nitrous oxide with a total inflow of 6 L/min and will be maintained until the exhaled end-tidal isoflurane concentration will be same as the inhaled concentration.
The LMA will be removed with cuff inflated in both groups. In group-P, the propofol 1mg/kg at isoflurane 0.5 MAC or less will be given and after 20 seconds the LMA will be removed, In group-D, the LMA will be removed once the set 1.2 MAC of isoflurane achieved and after that the isoflurane and nitrous oxide will be turned off in both group-P & group-D and throat will be suctioned and 100% oxygen will be administered until the patient regain consciousness.
188573|NCT01958151|Other|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
188293|NCT01967862|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
188294|NCT01967862|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
183728|NCT02545933|Drug|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
183729|NCT02545946|Device|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I&D
183730|NCT02545946|Other|traditional I&D with or without packing|abscess will be drained with a traditional I&D with or without packing (as deemed appropriate by ER doctor)
183731|NCT00184795|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
183732|NCT02545959|Drug|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
183733|NCT02545959|Drug|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
183734|NCT02545959|Drug|Rituximab IV|Blood infusion of rituximab (375mg/m2)
183735|NCT02545972|Drug|tacrolimus extended release|daily dosing of tacrolimus
183736|NCT02545985|Device|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
183737|NCT02545998|Other|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
183738|NCT02546011|Other|Fetal Heart Rate Monitor (monitoring of uterine contractions and fetal heart rate)|
183739|NCT02546024|Drug|Standare care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
183740|NCT02546037|Device|FX100 dialyzer|comparison of dialyzers
183741|NCT02546037|Device|SOLACEA 21H|comparison of dialyzers
183742|NCT00184795|Drug|placebo|Placebo tablets for 24 weeks
183743|NCT02546050|Drug|Metformin|
183744|NCT02546063|Other|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
183745|NCT02546076|Device|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
183746|NCT02546076|Device|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
187985|NCT01973101|Drug|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
187986|NCT01973101|Drug|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
187987|NCT01973101|Radiation|Radiotherapy|45 Gy
187988|NCT01973101|Radiation|Brachytherapy|80 Gy
187989|NCT01973114|Drug|Latanoprost|
187990|NCT01973114|Other|Placebo|
187991|NCT01975259|Drug|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
187992|NCT01975259|Drug|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
187993|NCT01975259|Drug|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
188295|NCT01967862|Other|laboratory biomarker analysis|Correlative studies
188296|NCT01967875|Drug|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
188297|NCT01967875|Drug|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
188298|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
188299|NCT01967888|Drug|Reparixin|Solution for iv infusion
188300|NCT01967888|Drug|Placebo|Physiologic solution
188301|NCT01967901|Behavioral|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
188302|NCT01967914|Other|PVI|Measurement of PVI (plethysmography variability index)
188303|NCT01967927|Drug|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
188655|NCT01965600|Drug|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
188656|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
188657|NCT01965600|Drug|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
188658|NCT01965600|Drug|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
188659|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
188660|NCT00116493|Drug|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
188661|NCT01965613|Biological|RA-18C3|IV and Subcutaneous administration
188662|NCT01965626|Drug|Oseltamivir|Oseltamivir 75 mg twice per day, 5 consecutive days
188663|NCT01965626|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
188664|NCT01965639|Other|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
188665|NCT01965652|Drug|Naldemedine|Naldemedine tablet from weeks 1-52
188666|NCT01965652|Drug|Placebo|Placebo tablet from weeks 1-52
188667|NCT01965665|Device|MediHoney HCS dressing|
188668|NCT01965678|Other|Osteopathic Manipulative Treatment|
188669|NCT01965691|Dietary Supplement|Protein intake|Oral consumption of eight hourly experimental meals-
4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil
4 isotopically labeled experimental meals.
188670|NCT01965704|Drug|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
188671|NCT01967940|Drug|ATV|ATV 300 mg tablet administered orally once daily.
188990|NCT01960907|Device|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
188991|NCT01960920|Other|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
188992|NCT01960920|Other|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
188993|NCT01960920|Other|Clean air|No pollution and no filter mask
193184|NCT02060123|Behavioral|Qigong training|a total of 103 hours over a period of 5.5 months, consisting of:
Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),
Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and
Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours).
193185|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
193186|NCT02060149|Drug|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
193508|NCT02055417|Behavioral|Personal Approaches to Treatment Choices for HIV|
193509|NCT02055417|Behavioral|Stress Reduction Skills Program|
193510|NCT02055430|Procedure|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
193511|NCT02055430|Procedure|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
193512|NCT02055430|Procedure|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
193513|NCT02055443|Other|12-lead holter monitor application|-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.
The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.
After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan.
193514|NCT02055456|Drug|Nandrolone Decanoate|
193515|NCT00002194|Drug|Nevirapine|
193516|NCT00124618|Radiation|radiation therapy|
193517|NCT02055482|Drug|BAY85-3934|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
193518|NCT02055482|Biological|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
193519|NCT02055508|Behavioral|Exercise Intervention|
193520|NCT02055508|Other|Care-Management-Phone-Calls|
192869|NCT01987843|Drug|MT-1303-Low|
192870|NCT01987843|Drug|MT-1303-Middle|
192871|NCT01987843|Drug|MT-1303-High|
192872|NCT01987843|Drug|Placebo|
192873|NCT01987856|Procedure|aCGH screen|aCGH screen;laser assisted biopsy of trophectoderm cells for comparative genome hybridization to establish blastocyst ploidy.
192874|NCT00118339|Procedure|complementary or alternative medicine procedure|
192875|NCT01987895|Drug|Cadazolid|Cadazolid 250 mg or matching placebo oral suspension twice daily.
192876|NCT01987895|Drug|Vancomycin|Oral vancomycin 125 mg or matching placebo capsules 4 times daily.
192877|NCT01987908|Drug|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
192878|NCT01987908|Other|Placebo|
192879|NCT01987947|Drug|Placebo|Two administrations by subcutaneous injection
192880|NCT01987947|Drug|Quilizumab|Two administrations by subcutaneous injection
192881|NCT01987960|Drug|Placebo|Once daily, tablets, orally
192882|NCT01987960|Drug|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
193187|NCT02060149|Drug|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
193188|NCT02060149|Drug|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
193189|NCT02060149|Drug|No nebulization|No nebulization will be given to the patients.
193190|NCT02062632|Drug|doxepin hydrochloride|Given orally
193191|NCT02062632|Other|placebo|Given orally
193192|NCT02062632|Procedure|quality-of-life assessment|Ancillary studies
193193|NCT02062632|Other|questionnaire administration|Correlative studies
193194|NCT02062632|Other|laboratory procedure|Correlative studies
193195|NCT00125424|Drug|Midazolam HCl|
192572|NCT01992965|Other|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
192573|NCT01992978|Procedure|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
192574|NCT01954823|Device|e-diary|The e-diary can collect data on:
Medical data: information on diseases, treatments and attending physicians
Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data
Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails
Reports: textual and graphical reports of the data in the diary can be created
192575|NCT01954836|Behavioral|initial fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
192576|NCT00002120|Drug|Dapsone|
192577|NCT00115297|Drug|Placebo|Participants who are 2 to 3 years old will receive placebo montelukast tablets and participants who are 12 months to 2 years old will receive placebo montelukast granules.
192578|NCT01954836|Behavioral|Secondary fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
192579|NCT01954849|Dietary Supplement|Probiotic formulation|
192580|NCT01954862|Other|Air Insufflation method.|Air Insufflation method.
192581|NCT01954862|Other|CO2 insufflation|CO2 insufflation.
192582|NCT01954862|Other|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
192583|NCT01954862|Other|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
192584|NCT01954862|Other|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
192585|NCT01954862|Other|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
192586|NCT01954888|Procedure|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
192883|NCT01987973|Procedure|Partial Rotator Cuff Repair Alone|This is the control group.
192884|NCT01987973|Procedure|Allograft Augmentation of Partial Rotator Cuff Repair|Following initial partial rotator cuff repair, patients in this arm will undergo a second procedure at six week consisting of allograft augmentation of the initial repair.
192885|NCT00002150|Drug|Celgosivir hydrochloride|
191982|NCT01966913|Drug|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
191983|NCT01966926|Behavioral|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
192274|NCT01959672|Drug|Fluorouracil|Given IV
192275|NCT01959672|Drug|Gemcitabine Hydrochloride|Given IV
192276|NCT01959672|Other|Laboratory Biomarker Analysis|Correlative studies
192277|NCT01959672|Drug|Leucovorin Calcium|Given IV
192278|NCT01959672|Drug|Nelfinavir Mesylate|Given PO
192279|NCT01959672|Biological|Oregovomab|Given IV
192280|NCT01959672|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
192281|NCT01959672|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
192282|NCT01959685|Drug|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
192283|NCT01959685|Drug|Placebo|Placebo, single dose
192284|NCT00115778|Drug|Intravenous immunoglobulin|Intravenous immunoglogbulin 400mg/kg IV monthly
192285|NCT01959698|Drug|carfilzomib|Given IV
192286|NCT01959698|Biological|rituximab|Given IV
192287|NCT01959698|Drug|etoposide|Given IV
192288|NCT01959698|Drug|carboplatin|Given IV
192289|NCT01959698|Drug|ifosfamide|Given IV
192290|NCT01959698|Other|pharmacological study|Correlative studies
192291|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
192292|NCT01962493|Other|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
192293|NCT01962493|Drug|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
191996|NCT01967082|Behavioral|Survey|Survey asking about health-related attitudes and behaviors completed at first visit.
191997|NCT01967082|Other|Smart Phone Application|Smoking cessation and prevention smart phone application provided to participants at first visit
191998|NCT01967082|Behavioral|Telephone Survey|Telephone survey performed at 1 and 4 months after participant receives smart phone application.
191999|NCT01969513|Procedure|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
192000|NCT00116935|Drug|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
192001|NCT01969526|Other|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
192002|NCT01969539|Drug|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
192003|NCT01969539|Drug|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
192299|NCT01962545|Drug|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
192300|NCT01962558|Device|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
192301|NCT01962558|Device|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
192302|NCT01962571|Drug|Erythropoietin alfa|
192303|NCT01962571|Drug|Placebo|
192304|NCT01962597|Other|aerobic exercise|
192305|NCT01962597|Other|resistance training|
192306|NCT01962610|Other|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
192307|NCT01962623|Other|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
192308|NCT00116129|Drug|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
192309|NCT01962636|Drug|Fludarabine|25 mg/m^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
191701|NCT01974544|Drug|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration >4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (>4.0 mmol/L).
191702|NCT00117481|Drug|DR-2001a|DR-2001a administered vaginally each month
191703|NCT01974544|Behavioral|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
191704|NCT01974557|Other|Exercise|
191705|NCT01974570|Dietary Supplement|Marealis refined peptide concentrate|2 tablets, once per day before noon
191706|NCT01974570|Dietary Supplement|Placebo|2 tablets, once per day before noon
191707|NCT01974583|Procedure|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
191708|NCT01974583|Procedure|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
191709|NCT01974583|Procedure|covered with paraffin gauze|Group C covered with paraffin gauze
192004|NCT01969565|Drug|Carfilzomib|
192005|NCT01969565|Drug|Dexamethasone|
192006|NCT01969578|Drug|bicalutamide + triptorelin|
192007|NCT01969578|Drug|Cisplatin + Doxorubicin|
192008|NCT01969578|Drug|Carboplatin + Paclitaxel|
192009|NCT01969591|Procedure|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
192010|NCT01969591|Other|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
192011|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
191403|NCT01982136|Procedure|substitution urethroplasty (pedicled skin flap)|
191404|NCT00118001|Behavioral|Applied relaxation|
191405|NCT01982175|Biological|Alemtuzumab|Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.
Escalation to 30mg/day should be accomplished in 3~7 days.
Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.
More than 30mg daily or 90mg weekly dose is prohibited
191406|NCT01982201|Drug|Lesinurad 400 mg|
191407|NCT01982201|Drug|Tums 500 mg and 750 mg|
191408|NCT01982201|Drug|MINTOX 10 mL|
191409|NCT01982214|Device|sedentary|No intervention
191410|NCT01982214|Device|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
191411|NCT01982227|Drug|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
191412|NCT01982240|Drug|Plecanatide|
191413|NCT01982240|Drug|Placebo|
191414|NCT01982253|Drug|Fasiglifam|Fasiglifam tablets
191415|NCT00118014|Drug|Sertraline|
191416|NCT01982253|Drug|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
191417|NCT01982266|Device|GRADION™ Hip Total Cartilage Replacement (TCR)™|
191418|NCT01982292|Drug|Serelaxin|A continuous 48 hour infusion of serelaxin administered every 4 weeks for a total of 3 doses.
191419|NCT01982292|Drug|Placebo|A continuous 48 hour infusion of placebo administered every 4 weeks for a total of 3 doses.
191420|NCT01982305|Procedure|Simulator|Axillary nerve anatomy lecture plus training with the simulator.
191421|NCT01982305|Procedure|Cadaver|Axillary nerve anatomy lecture plus training with the cadaver model.
191422|NCT01982318|Drug|VitroGro® ECM|
190760|NCT00118742|Drug|Tacrolimus|As prescribed, for 12 months
190761|NCT01992185|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
190762|NCT01992198|Drug|cefoperazone + metronidazole|1.Clinical parameters (2 of 3):
1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):
1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h
190763|NCT01992198|Procedure|oral care by chlorhexidine gluconate|oral care by 0.2% chlorhexidine gluconate twice daily
190764|NCT01992198|Procedure|enteral nutrition|
190765|NCT01992198|Drug|Somatostatin|
190766|NCT01992198|Drug|Meropenem|All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.
1.Clinical parameters (2 of 3):
1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):
1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h
190767|NCT01992211|Drug|Rosuvastatin and Metformin SR(Fed)|Co-administration of Rosuvastatin and Metformin SR
190768|NCT01992211|Drug|BCWP_C001(Fasted)|Combination of Rosuvastatin 10mg+Metformin SR 500mg (Fasted)
190769|NCT01992211|Drug|BCWP_C001(Fed)|Combination of Rosuvastatin 10mg+Metformin SR 500mg (Fed)
190770|NCT01992224|Other|early mechanical Ventilation|Fulfillment of three or more criteria below:
respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation
190771|NCT00118742|Drug|Cyclosporine|As prescribed, for 12 months
191088|NCT01987154|Other|Marketed extensively hydrolyzed casein infant formula|
191089|NCT01987167|Drug|ACTHAR|Injectable Gel
191090|NCT01987206|Device|MPC control algorithm|
191091|NCT01989767|Behavioral|education|Education as add on to to rehabilitation as usual
191092|NCT00118417|Drug|Sertraline|Participants will receive sertraline.
191093|NCT01989780|Drug|Paclitaxel|
191094|NCT01989780|Drug|Bevacizumab|
191095|NCT01989780|Drug|Letrozole|
191096|NCT01989780|Drug|Anastrozole|
190456|NCT01958879|Drug|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
190457|NCT01958879|Drug|ringer without corticosteroid|200 mL Ringer solution
190458|NCT01958892|Procedure|TURP, TUERP|
190459|NCT01958905|Drug|Artemether-lumefantrine fixed combination|
190460|NCT01958918|Drug|Ranibizumab|0.5 mg intravitreal injections of ranibizumab monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT disease activity
190461|NCT01958918|Drug|Aflibercept|2 mg intravitreal injections of aflibercept monthly for the first 3 months, followed by 2 mg intravitreal injections once every 2 months (current EU SmPC label)
190462|NCT00115700|Drug|Prednisolone|50 mg/m2 orally daily for days 1 - 5
190463|NCT01958944|Drug|Nitric oxide|
190464|NCT01958957|Drug|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
190465|NCT01958970|Drug|PINTA 745|PINTA 745 will be administered once weekly by IV infusion.
Cohort dose schedules:
3mg/kg weekly for 12 weeks
3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks
6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
190466|NCT01958970|Drug|Placebo|Placebo will be administered once weekly by IV infusion.
Cohort dose schedules:
3mg/kg weekly for 12 weeks
3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks
6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
190467|NCT01958983|Behavioral|Music Therapy Group Session|
190468|NCT01958996|Drug|idarubicin|
190469|NCT01959009|Other|HFOV combined with sigh breaths|We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).
All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.
Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient "wash-out" period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh
190470|NCT01959022|Drug|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
190471|NCT01959035|Drug|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at Baseline
190472|NCT01959048|Drug|fecal microbiota transplantation|
190473|NCT00115700|Drug|Rituximab|375 mg/m2 IV Infusion day 1
189840|NCT01971190|Drug|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
Central subfield thickness is thicker than the previous exam
BCVA letter score is worse than the previous exam (because of the persistent CSC)
189841|NCT01971190|Drug|Sham injection|Sham injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
Central subfield thickness is thicker than the previous exam
BCVA letter score is worse than the previous exam (because of the persistent CSC)
190154|NCT01964079|Drug|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
190155|NCT01966250|Device|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
190156|NCT01966263|Procedure|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
190157|NCT01966263|Procedure|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
190158|NCT00116545|Drug|troglitazone|
190159|NCT01966263|Procedure|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
190160|NCT01966263|Procedure|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
190161|NCT01966276|Drug|Methyl-P plus Nutrient Formula|Week 1 (take the following together twice a day-at breakfast and lunch)
One tablet of Methyl-P (5mg)
Four tablets of CFS Nutrient Formula
Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):
Two tablets of Methyl-P (10mg)
Four tablets of CFS Nutrient Formula
190162|NCT01966276|Drug|Methyl-P plus Nutrient matched placebos|Week 1 (take the following together twice a day-at breakfast and lunch)
One tablet of Methyl-P Placebo
Four tablets of CFS Nutrient Placebo
Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):
Two tablets of Methyl-P Placebo
Four tablets of CFS Nutrient Placebo
189524|NCT00002142|Drug|Cidofovir|
189525|NCT00117767|Drug|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
189526|NCT01978509|Drug|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
189527|NCT01978509|Drug|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
189528|NCT01978509|Drug|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
189529|NCT01978522|Other|Randomisation of questionnaire receipt.|The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.
Self-completion questionnaire handed to participants immediately after completing the CAPI.
189530|NCT01978535|Drug|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
189842|NCT01971190|Procedure|Half-fluence photodynamic therapy|At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
Central subfield thickness is thicker than the previous exam
BCVA letter score is worse than the previous exam (because of the persistent CSC)
189843|NCT01971203|Drug|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
189844|NCT01971203|Behavioral|CBT|16 weeks of treatment
189845|NCT01971216|Behavioral|Relaxation|
189846|NCT01973608|Drug|MSB0010445 (1.5-3.6 mg/kg)|MSB0010445 will be administered at a total dose range of 1.5-3.6 mg/kg as intravenous infusion over approximately 1 hour every 3 weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. If the dose of 1.8 mg/kg is not tolerated, then 1.5 mg/kg will be administered.
189847|NCT01973608|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered at a dose of up to 24 Gray (Gy) on a maximum of 1 lesion or, if the irradiated lesion is located in the thorax, up to 18 Gy.
189848|NCT01973634|Radiation|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
189849|NCT01973634|Radiation|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
189210|NCT01983969|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
189211|NCT01983969|Drug|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
189212|NCT01983969|Other|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
189213|NCT01983969|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
189214|NCT01983969|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
189215|NCT01983969|Drug|Rituximab|375 mg/m2 by vein on Days -9.
189216|NCT00118131|Drug|docetaxel|
189217|NCT01984008|Drug|Picosulfate sodium, magnesium oxide, citric acid|
189218|NCT01984021|Device|Acupuncture|
189219|NCT01984021|Device|Sham acupuncture|
189220|NCT01986270|Drug|Eletriptan 80 mg|80mg oral
189221|NCT01986270|Drug|Sumatriptan 25 mg|25mg oral
189222|NCT01986270|Drug|Sumatriptan 50 mg|50mg oral
189223|NCT01986283|Drug|Capsule|Taken once
189224|NCT01986283|Drug|PF-00345439|40 mg capsule swallowed whole, taken once
189225|NCT00118261|Drug|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
189226|NCT01986283|Drug|PF-00345439|40 mg capsule chewed, taken once
189227|NCT01986283|Drug|oxycodone|40 mg solution, taken once
189228|NCT01986296|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
189229|NCT01986309|Drug|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
189230|NCT01986309|Drug|Normal saline|Sodium Chloride 0.9% infusion
189231|NCT01986322|Biological|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
189531|NCT01978535|Drug|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
188574|NCT01958164|Drug|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
188575|NCT01958164|Drug|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
188576|NCT01958164|Drug|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
188577|NCT01958164|Drug|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
188578|NCT01958177|Biological|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
188579|NCT01958190|Drug|Tacrolimus and Sirolimus|Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.
Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician
188580|NCT01958190|Drug|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
188581|NCT01958216|Other|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
188902|NCT01991392|Device|No nasogastric tube|For nasogastric decompression.
188903|NCT01991405|Device|Computerized Working Memory Training.|Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an "adaptive" level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a "sham" program that is fixed ("non-adaptive" in difficulty level), but otherwise identical.
188904|NCT00118573|Procedure|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
188905|NCT01991444|Other|TAVI|no Intervention planned, Observation only
188906|NCT01991457|Drug|Fludarabine|
188907|NCT01991457|Procedure|Total Body Irradiation|
188908|NCT01991470|Device|Sensor|Subject wears both enlite and enlite 3 sensors
188909|NCT01991483|Drug|LY2928057|Administered intravenously
188910|NCT01991483|Drug|Placebo|Administered intravenously
183747|NCT02546089|Other|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
183748|NCT02546089|Other|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
183749|NCT02546089|Other|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
184037|NCT02541487|Dietary Supplement|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
184038|NCT02541500|Drug|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
184039|NCT02541513|Drug|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
184040|NCT02541526|Drug|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
184041|NCT02541526|Drug|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
184042|NCT02541539|Dietary Supplement|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
184043|NCT02541539|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
184044|NCT00184171|Drug|Budesonide|Budesonide 9 mg
184045|NCT02541552|Drug|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
184046|NCT02541565|Drug|Cyclophosphamide|Given IV
184047|NCT02541565|Drug|Doxorubicin Hydrochloride|Given IV
184048|NCT02541565|Other|Laboratory Biomarker Analysis|Correlative studies
184049|NCT02541565|Biological|Pembrolizumab|Given IV
184050|NCT02541565|Drug|Prednisone|Given PO
184051|NCT02541565|Biological|Rituximab|Given IV
184052|NCT02541565|Drug|Vincristine Sulfate|Given IV
188304|NCT01967940|Drug|TAF|Tenofovir alafenamide (TAF) 25 mg tablet administered orally once daily with food
188305|NCT01967940|Drug|Placebo to match TAF|Placebo tablets to match TAF administered orally once daily with food
188306|NCT01967940|Drug|E/C/F/TAF|Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (E/C/F/TAF) single-tablet regiment (STR) administered orally once daily with food
188307|NCT01967940|Drug|Pre-existing ARV regimen|Participants will continue taking their pre-existing ARV regimen as prescribed in Part 1.
188308|NCT01970514|Device|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
188309|NCT01970527|Biological|Ipilimumab|Given IV
188310|NCT01970527|Other|Laboratory Biomarker Analysis|Correlative studies
188311|NCT01970527|Other|Pharmacological Study|Correlative studies
188312|NCT00117065|Drug|Aranesp®|
188313|NCT01970527|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
188314|NCT01970540|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
188315|NCT01970540|Drug|Doxorubicin|Doxorubicin 50 mg injectable solution
188316|NCT01970553|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
183750|NCT02548104|Other|ACB + AFB+ iPACK|Before the surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): 0.25% Bupivacaine with 1:200,000 epinephrine 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
183751|NCT02548117|Drug|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
183752|NCT00184964|Procedure|CT-scan, PET-scan|
183753|NCT02548130|Other|MELD score|introduction of MELD score
183754|NCT02548143|Biological|Coagulation Factor VIIa (Recombinant)|LR769
183755|NCT02548156|Other|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
183756|NCT02548156|Other|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
188994|NCT01960933|Procedure|Percutaneous coronary intervention|
188995|NCT00115908|Drug|PEG-IFNalfa2a|
188996|NCT01960933|Procedure|FFR|
188997|NCT01960946|Dietary Supplement|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
188998|NCT01960972|Other|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
188999|NCT01960985|Other|Physicaltherapy|
189000|NCT01960998|Behavioral|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
189001|NCT01960998|Behavioral|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
189002|NCT01961037|Other|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
189003|NCT01961050|Behavioral|Dual-Focused Brief Physician Intervention (DFBPI)|The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
189004|NCT01961050|Other|Services as usual|Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
189005|NCT01961063|Drug|busulfan|Given IV
189006|NCT00115921|Behavioral|Provision of antimalarial treatment at home|
189007|NCT01961063|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
189008|NCT01961063|Other|pharmacological study|Correlative studies
189009|NCT01961063|Other|laboratory biomarker analysis|Correlative studies
189010|NCT01961076|Other|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
189011|NCT01961089|Device|Galilei Lens Professional|
189312|NCT01953783|Drug|IXAZOMIB|
189313|NCT01953796|Drug|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
193521|NCT02055521|Procedure|Blood sample, biopsy|
193522|NCT02055534|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
193523|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
193524|NCT02055547|Drug|MK-8521|Single dose 100 mcg sc injection in a treatment period (Part 1)
193525|NCT02055547|Drug|MK-8521|Single dose 150 mcg sc injection in a treatment period (Part 1)
193526|NCT02055547|Drug|MK-8521|Single dose 300 mcg sc injection in a treatment period (Part 1)
193527|NCT00124644|Drug|cytarabine|
188672|NCT00116766|Device|anti-mosquito plant use|
188673|NCT01967953|Procedure|EVLP Group|EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.
Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
188674|NCT01967966|Drug|GDC-0032|Single oral dose
188675|NCT01967966|Drug|GDC-0032|Single IV dose
188676|NCT01967979|Drug|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
188677|NCT01967979|Drug|fluoxetine|Multiple doses
188678|NCT01967979|Drug|itraconazole|Multiple doses
188679|NCT01967992|Behavioral|Behavioral: Low Carbohydrate, Ketogenic Diet|
188680|NCT01967992|Behavioral|American Diabetes Association Diet|
188681|NCT01967992|Behavioral|Mindfulness and Positive Affect Skills|
188682|NCT01968005|Drug|Etoreat®(Etodolac-Lidocaine Topical Patch)|
188683|NCT00116779|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
188684|NCT01968005|Drug|Placebo|
188685|NCT01968018|Drug|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
193196|NCT02062645|Drug|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 160/5 mg, 160/10 mg
193197|NCT02062658|Drug|Ketamine|0.5mg/kg IV
193198|NCT02062658|Behavioral|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
193199|NCT02062671|Procedure|renal denervation|
193200|NCT02062684|Drug|Blisibimod|
193201|NCT02062684|Drug|Placebo|
193202|NCT02062697|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
193203|NCT02062697|Procedure|Liquid-PAP smear|
193204|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
193205|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
193206|NCT00125437|Drug|spironolactone|
193207|NCT02062710|Drug|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
193208|NCT02062710|Drug|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
193209|NCT02062710|Drug|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
193210|NCT02062710|Drug|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
193528|NCT02055547|Drug|MK-8521|Single dose 200 mcg sc injection in a treatment period (Part 1)
193529|NCT02055547|Drug|Mk-8521|Single dose 175 mcg sc injection in a treatment period (Part 1)
193530|NCT02055547|Drug|Placebo|Single dose placebo sc injection in a treatment period (Part 1)
193531|NCT02055547|Drug|MK-8521|50 mcg sc injection once each day for 5 days (Part 2)
193532|NCT02057796|Device|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|The following point-of-care TB tests will be systematically performed:
Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.
TB treatment will depend on the result of the tests:
Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1).
192886|NCT00118339|Procedure|management of therapy complications|
192887|NCT01987986|Biological|Collagenase Clostridium Histolyticum|injectible intervention
192888|NCT01987986|Biological|Placebo|
192889|NCT01987999|Dietary Supplement|Acetogenins|
192890|NCT01988012|Drug|tocilizumab [RoActemra/Actemra]|162 mg administered subcutaneously once a week
192891|NCT01988064|Other|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
192892|NCT01988064|Other|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
192893|NCT01988077|Procedure|Adoptive cell transfer combined with Ipilimumab|
192894|NCT01988090|Drug|800 IU Vitamin D Supplement|Standard Dose
192895|NCT01988090|Drug|50,000 IU Vitamin D supplement|High Dose
192896|NCT01988103|Drug|Apremilast|20 mg tablet twice a day for 68 weeks
192897|NCT01990430|Behavioral|Exercise Intervention|Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.
The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer.
192898|NCT01990443|Drug|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
192899|NCT01990443|Drug|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
192900|NCT01990456|Device|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
192901|NCT01990456|Device|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
193211|NCT02062749|Drug|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
193212|NCT02062762|Behavioral|Online-MBSR|8 week mindfulness based stress reduction online
192294|NCT01962519|Dietary Supplement|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
192295|NCT01962532|Drug|Part 1: JNJ-42756493|JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
192296|NCT00002124|Drug|Zidovudine|
192297|NCT00116116|Drug|efavirenz, stavudine extended release, lamivudine|
192298|NCT01962532|Drug|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
192587|NCT01954888|Procedure|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
192588|NCT00115310|Drug|NGX-4010|
192589|NCT01954901|Procedure|Hyperbaric oxygen therapy|
192590|NCT01954914|Drug|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
192591|NCT01954927|Drug|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
192592|NCT01954927|Drug|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
192593|NCT01954940|Device|Whole Body Vibration Therapy|
192594|NCT01954966|Drug|Progesterone|Participants will consume four pills of Progesterone over a period of three days. Participants will be required to remain abstinent from smoking while taking Progesterone.
192595|NCT01954979|Drug|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
192596|NCT00115570|Drug|insulin lispro|
192597|NCT01957293|Drug|Placebo|single oral administration
192598|NCT01957306|Dietary Supplement|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
192599|NCT01957319|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
192600|NCT01957319|Drug|sugar pill|
192310|NCT01962636|Drug|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
192311|NCT01962636|Radiation|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
192312|NCT01962636|Drug|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
192313|NCT01962636|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
192314|NCT01964807|Other|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
192315|NCT01964807|Other|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
192316|NCT01964807|Other|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
192317|NCT00116389|Drug|talabostat mesylate tablets|
192318|NCT01964807|Other|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
192319|NCT01964807|Other|Moist snuff|Use moist snuff for 30 minutes
192604|NCT01957358|Behavioral|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
192605|NCT01957371|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
192606|NCT01957384|Device|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
192607|NCT00115570|Drug|insulin glargine|
192608|NCT01957384|Device|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
192609|NCT01957384|Device|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|Standard Care was the subject usual ostomy appliance and had to be one of the following:
Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,
Dansac: Nova 1 & Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate
Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate
ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate
B. Braun: Flexima Active & Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate
192012|NCT01969604|Behavioral|Motivational Lifestyle Counselling|The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.
The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.
Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:
• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand.
192013|NCT01969617|Drug|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
192014|NCT01969617|Drug|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
192015|NCT01969630|Device|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
192016|NCT01969630|Device|PES|Systematic Paclitaxel eluting stent angioplasty
192017|NCT01969643|Drug|SGN-LIV1A|by intravenous infusion every 3 weeks
192018|NCT01969656|Drug|2MD|
192019|NCT01969656|Drug|Calcitriol|
192020|NCT01969656|Drug|Placebo|
192021|NCT01969669|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
192022|NCT01972152|Drug|G-Pen(TM) 0.5 mg|
192023|NCT01972165|Procedure|Mini-incision carpal tunnel release|
192024|NCT01972165|Procedure|Endoscopic carpal tunnel release|
192025|NCT01972178|Drug|PRC-4016|
192320|NCT01964807|Other|sham smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
192321|NCT01964807|Other|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
192322|NCT01964807|Other|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
192323|NCT01964807|Other|sham moist snuff|Chew gum for 30 minutes
191423|NCT01984658|Biological|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
191424|NCT01984671|Behavioral|Mobile Pain Coping Skills Training|
191710|NCT01976897|Other|Heel - interface pressure measurements|The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.
The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media.
191711|NCT01976910|Drug|DM-CHOC-PEN|DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.
At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.
The MTD will be where 2 DLTs are noted and the study is discontinued.
191712|NCT01976923|Drug|Intravitreal bevacizumab|A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
191713|NCT01976923|Procedure|Small-gauge pars plana vitrectomy|
191714|NCT01976936|Drug|Low Dose Lovastatin|80 mg daily for 3 days
191715|NCT01976936|Other|Placebo|Placebo for 3 days
191716|NCT00117650|Other|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
191717|NCT01976936|Drug|High Dose Lovastatin|640 mg daily for 3 days
191718|NCT01976949|Behavioral|online social-networking intervention|
191719|NCT01976962|Radiation|Stereotactic body RT with MR-guided boost|
191720|NCT01976988|Drug|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
191721|NCT01977001|Device|MigraineBoxTM|
191722|NCT01977027|Other|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
191097|NCT01989780|Drug|Exemestane|
191098|NCT01989780|Drug|Fulvestrant|
191099|NCT01989780|Drug|Goserelin|
191100|NCT01989780|Device|leuprorelin acetate|
191101|NCT01989793|Drug|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
191102|NCT01989793|Drug|Placebo|
191103|NCT00118417|Behavioral|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
191104|NCT01989806|Device|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
191105|NCT01989806|Device|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
191106|NCT01989819|Other|skin biopsy|
191107|NCT01989845|Drug|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
191108|NCT01989858|Other|peri-operative cht|CHT treatment have to be chosen between the following associations:
Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously
or
Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
191109|NCT01989858|Other|post-operative CHT|CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously
or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line.
191425|NCT01984684|Drug|delafloxacin|1
191426|NCT00118196|Drug|arsenic trioxide|
191427|NCT01984684|Drug|vancomycin|2
191428|NCT01984684|Drug|aztreonam|2
191429|NCT01984697|Biological|V503 (9-valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
191430|NCT01984710|Device|Medtronic Activa PC+S System|
191431|NCT01984723|Drug|Experimental: EVP-6124|
190474|NCT01959061|Drug|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
190475|NCT01959061|Drug|Oxaliplatin|100~150mg, every 4 weeks, transhepatic arterial infusion
190772|NCT01954212|Other|Enhanced complex oral health care|Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:
Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.
Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.
Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available.
190773|NCT01954225|Other|Udumbara Sutra|The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
190774|NCT00002120|Drug|Sulfamethoxazole|
190775|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
190776|NCT01954238|Drug|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.
The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.
GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.
The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.
In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion.
190777|NCT01954238|Drug|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
190778|NCT01954238|Drug|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
190779|NCT01954251|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
190780|NCT01954251|Biological|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
190781|NCT01954264|Procedure|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
190782|NCT01954264|Other|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
190783|NCT01954277|Device|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
190784|NCT01954277|Device|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
190163|NCT01966289|Drug|CY|CY is administered intravenously at 200 mg/m2
190164|NCT01966289|Biological|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
190165|NCT01966289|Drug|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
190166|NCT01966302|Drug|BPS-314d-MR|15-150 mcg po BID,
190167|NCT01966328|Drug|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
190168|NCT01966328|Drug|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
190169|NCT00116558|Device|BiPAP|non-invasive positive pressure ventilation (NIPPV) - Early Intervention with NIPPV NIPPV involves mechanically assisted or generated breaths delivered through a tightly fitting nasal or facial mask
190476|NCT01959061|Drug|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
190477|NCT01959074|Drug|Naftopidil|Naftopidil 75mg 1T qd hs
190478|NCT01959074|Drug|Placebo for Naftopidil|Placebo 1T qd hs
190479|NCT01959074|Drug|Standard treatment|aceclofenac 100mg on demand
190480|NCT00115973|Device|pump|
190481|NCT01961687|Device|Phasix Mesh|
190482|NCT01961700|Other|Physiotherapy|
190483|NCT01961726|Biological|Placebo|Coronary Sinus Delivery
190484|NCT01961726|Biological|30 mg dose of JVS-100|Coronary Sinus Delivery
190485|NCT01961726|Biological|45 mg dose of JVS-100|Coronary Sinus Delivery
190486|NCT01961739|Drug|2% lidocaine|Topical application, twice per day for 15 consecutive days
190487|NCT01961739|Drug|placebo|topical application, twice per day for 15 consecutive days
190488|NCT01961752|Drug|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
190489|NCT01961752|Drug|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
189850|NCT01973634|Radiation|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
189851|NCT00117403|Drug|Placebo capsules|one placebo capsule three times per day with meals
189852|NCT01973634|Radiation|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
189853|NCT01973647|Behavioral|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
189854|NCT01973647|Behavioral|COPD Education|Six weekly sessions of COPD education
189855|NCT01973647|Behavioral|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
189856|NCT01973660|Drug|Lapatinib|
189857|NCT01973660|Drug|Trastuzumab|
189858|NCT01973660|Drug|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
189859|NCT01973660|Drug|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
189860|NCT01973673|Behavioral|Bone health educational materials|
189861|NCT01973686|Behavioral|Physical activity|
190170|NCT01966341|Behavioral|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
190171|NCT01966341|Drug|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
190172|NCT01966354|Procedure|Ultrasound-guided Internal jugular venous approach|The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.
In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane).
190173|NCT01966367|Biological|CD34 Stem Cell Selection Therapy|The CliniMacs (PLUS) Reagent System (Miltenyi CliniMacs CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
190174|NCT01968668|Drug|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
190175|NCT00116831|Drug|Glipizide|oral anti-diabetic medication
190176|NCT01968668|Drug|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
189532|NCT01978548|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
189533|NCT01978548|Drug|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
189534|NCT01978548|Drug|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
189535|NCT01978561|Biological|Post dosing with NT100|
189536|NCT00117780|Drug|insulin detemir|
189537|NCT01978561|Other|Post dosing with Placebo|
189538|NCT01978574|Behavioral|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
189539|NCT01978574|Behavioral|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
189540|NCT01978587|Drug|JTZ-951|
189541|NCT01978600|Drug|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
189542|NCT01981291|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as "intraneural" if nerve cross section expansion and a reduction in echogenicity are observed.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
189543|NCT01981291|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as "intraneural" if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
189544|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
189545|NCT01981291|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
189546|NCT01981291|Procedure|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
189547|NCT01981291|Drug|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
189548|NCT01981317|Behavioral|Stepped Care Cognitive Behavioral Therapy|
189549|NCT01981317|Behavioral|Cognitive Behavioral Therapy|
189550|NCT01981330|Biological|aMSC|aMSC injected into the vocal fold of the patient
188911|NCT01991509|Biological|LBR-101 IV|LBR-101 Administered Intravenously
188912|NCT01953536|Drug|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
188913|NCT01953536|Drug|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
188914|NCT01953536|Drug|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
188915|NCT01953549|Procedure|physical fitness training|
188916|NCT01953549|Procedure|relaxation|
188917|NCT01953575|Device|Mucosal Impedance|Mucosal impedance- a (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) 5 cm above where your stomach and esophagus meet for 5 seconds.
At 10 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds
And at 20 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds.
This will determine if people with eosinophilic esophagitis (EoE) have an increased esophageal mucosa impedance (food getting into the esophageal tissue).
188918|NCT00002120|Drug|Trimethoprim|
188919|NCT00115089|Drug|Beclomethasone dipropionate|
188920|NCT01953588|Drug|fulvestrant|Fulvestrant 500 mg IM
188921|NCT01953588|Drug|anastrozole|Anastrozole 1 mg oral tablet
188922|NCT01953601|Drug|Verubecestat (Part I and Part II)|Verubecestat 12 mg tablet
188923|NCT01953601|Drug|Verubecestat (Part I and Part II)|Verubecestat 40 mg tablet
189232|NCT01986322|Biological|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
189233|NCT01986335|Biological|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
189234|NCT01986348|Drug|Selinexor|One cycle is 28 days (4 weeks).
189235|NCT01986361|Drug|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
189236|NCT00118274|Biological|incomplete Freund's adjuvant|Given intradermally and subcutaneously
189237|NCT01986361|Drug|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
184053|NCT02541591|Other|Neuroprotective goal directed hemodynamic optimization|
184054|NCT02541591|Other|MAP > 65mmHg|MAP > 65mmHg
184055|NCT00184171|Drug|Bismuth|Bismuth mixture
184056|NCT02541604|Drug|MPDL3280A|MPDL3280A will be administered as IV infusion (maximum 1200 mg) on Day 1 of each 3-week cycle.
184057|NCT02541617|Procedure|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
184058|NCT02541617|Procedure|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
184351|NCT02573038|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
184352|NCT02573051|Drug|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
184353|NCT02573051|Drug|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
184354|NCT02573051|Other|placebo|
184355|NCT02573064|Drug|Colistin|
184356|NCT02573064|Drug|Tigecycline|
184357|NCT02573064|Drug|Vancomycin|
184358|NCT02573090|Procedure|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
184359|NCT02573090|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
184360|NCT00187889|Drug|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
184361|NCT02573116|Procedure|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
184362|NCT02573129|Other|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
184363|NCT02573129|Other|Red Meat Rich|Mediterranean diet rich in red meat
183757|NCT02548156|Other|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
183758|NCT02548169|Biological|DC Vaccine + Standard of Care Chemotherapy|4 doses of DC vaccine at 2 weeks interval, combined with either:
Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)
FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation
Gemcitabine + nab-paclitaxel
The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .
The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.
Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL.
183759|NCT02548182|Device|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults [REF]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
183760|NCT02548182|Other|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
183761|NCT02548195|Drug|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
183762|NCT02548195|Drug|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
183763|NCT00184977|Drug|N-acetylcysteine|
183764|NCT02548208|Device|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
184059|NCT02541630|Behavioral|Big Mind|mindfulness based intervention
184060|NCT02543762|Procedure|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
184061|NCT02543775|Procedure|Preoperative and intraoperative SLN Mapping|Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or "hot" nodes and direct visualization will identify blue nodes which will be labelled "Sentinel Nodes" and sent to pathology for intraoperative frozen section.
184062|NCT02543788|Procedure|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
189314|NCT01955720|Drug|BI 655075|
189315|NCT01955720|Drug|Placebo|
189316|NCT01955720|Drug|BI 655075|
189317|NCT01955720|Drug|Placebo|
189318|NCT00115414|Drug|doxorubicin|
189319|NCT01955720|Drug|Placebo|
189320|NCT01955720|Drug|Placebo|
189321|NCT01955720|Drug|BI 655075|
189322|NCT01955733|Drug|BI 695500|
189323|NCT01955759|Drug|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
189324|NCT01955759|Drug|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
189325|NCT01955759|Drug|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
189326|NCT01955772|Drug|Enteral nutrition alanyl-glutamin, Dipeptiven|Enteral nutrition versus parenteral nutrition
189327|NCT01955785|Device|pressure controlled ventilator|
189328|NCT01955785|Device|Pressure Regulated Volume Controlled Ventilator|
189329|NCT00115414|Drug|cyclophosphamide|
189330|NCT01955798|Procedure|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
189331|NCT01955798|Procedure|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
189332|NCT01955798|Device|Trocar|
189333|NCT01955798|Device|Veress needle|
189334|NCT01955811|Drug|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
189335|NCT01955824|Drug|1% lignocaine|
188686|NCT01968031|Drug|Istradefylline 40 mg|Istradefylline 40 mg and placebo
188687|NCT01968031|Drug|Istradefylline 20 mg|Istradefylline 20 mg and placebo
188688|NCT01968031|Drug|Placebo|Placebo
188689|NCT01968044|Drug|Gemigliptin|
188690|NCT01968044|Drug|Placebo to Linagliptin|
188691|NCT01968057|Drug|Baricitinib|Administered orally
188692|NCT01968057|Drug|Ciclosporin|Administered orally
188693|NCT01968070|Drug|LY3127760|Administered orally
188694|NCT00116792|Procedure|Percutaneous Coronary Intervention (PCI)|
188695|NCT01968070|Drug|Celecoxib|Administered orally
188696|NCT01968070|Drug|Placebo|Administered orally
189012|NCT01961102|Procedure|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
189013|NCT01961115|Drug|Epacadostat|Given PO
189014|NCT01961115|Other|Laboratory Biomarker Analysis|Correlative studies
189015|NCT01961115|Biological|MELITAC 12.1 Peptide Vaccine|Given ID/SC
189016|NCT01961128|Behavioral|Exercise Intervention|
189017|NCT01963442|Drug|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
189018|NCT01963442|Drug|Beta-Lactams|administered from Day 0 to Day 3
189019|NCT01963455|Biological|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
189020|NCT01963468|Behavioral|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
189021|NCT01963481|Drug|Exemestane|
189022|NCT01963481|Drug|Cyclophosphamide|
193533|NCT02057796|Drug|ART (Atripla, Truvada, Efavirenz, Combivir)|ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.
ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2
193534|NCT02057796|Drug|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
193535|NCT02057822|Procedure|Cytokins assay in tears|
193536|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
193537|NCT02057835|Drug|BI 691751 high dose|BI 691751 high dose
193538|NCT02057835|Drug|BI 691751 middle dose|BI 691751 middle dose
193539|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
193540|NCT02057835|Drug|BI 691751 low dose 1|BI 691751 low dose 1
193541|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
193542|NCT00124878|Procedure|Male circumcision|Sleeve circumcision
193543|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
193544|NCT02057835|Drug|BI 691751 low dose 2|BI 691751 low dose 2
193545|NCT02057848|Other|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
193546|NCT02057848|Other|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
193547|NCT02057848|Other|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
188697|NCT01968083|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
188698|NCT01968083|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
188699|NCT01968096|Device|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
188700|NCT01968109|Biological|BMS-986016|
188701|NCT01970618|Drug|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
193213|NCT02062762|Behavioral|Expressive Writing Online|Online distributed expressive writing intervention as active control
193214|NCT02062775|Procedure|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
193215|NCT02062775|Procedure|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
193216|NCT02062775|Procedure|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures >2cm
193217|NCT02065310|Other|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed "advanced glycation endproducts" (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.
Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 & 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications.
193218|NCT00002201|Drug|Nelfinavir mesylate|
193219|NCT00125749|Biological|Dendritic cell vaccination|Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells
193220|NCT02065323|Drug|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
193221|NCT02065323|Drug|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
193222|NCT02065336|Drug|ARC-520|
193223|NCT02065336|Drug|Placebo|
193224|NCT02065349|Drug|ASP8477|oral
193225|NCT02065349|Drug|Placebo|oral
193226|NCT02065362|Genetic|DNR.NPC-specific T cells|Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedules:
Dose Level 1:
Day 0 2x10^7 cells/m^2
Day 14 2x10^7 cells/m^2
Dose Level 2:
Day 0 2x10^7 cells/m^2
Day 14 1x10^8 cells/m^2
Dose Level 3:
Day 0 1x10^8 cells/m^2
Day 14 2x10^8 cells/m^2
The doses are calculated according to the total T cell number.
193227|NCT02065375|Drug|RTA 408 0.5% Ophthalmic Suspension|
193228|NCT02065375|Drug|RTA 408 1.0% Ophthalmic Suspension|
193229|NCT02065375|Drug|Placebo|
193230|NCT00125762|Device|FibroScan|
192601|NCT01957332|Procedure|Molecular imaging|On the day of FES-injection&scan or the day after FES-injection, 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
192602|NCT01957332|Procedure|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET.
192603|NCT01957345|Other|Blood punction|T1 and T2: one blood punction of 2X 4,5 ml with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalysation test is detected)
signalisation test is made by flow cytometry
Stage 1: for arm "bleeding disorder" : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.
Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested.
192902|NCT01990469|Drug|Gemigliptin|
192903|NCT00118469|Behavioral|Cognitive behavior therapy|
192904|NCT01990482|Dietary Supplement|caffe|
192905|NCT01990482|Dietary Supplement|Water|
192906|NCT01990495|Other|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
192907|NCT01990495|Other|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
192908|NCT01990508|Behavioral|Targeted beverage education and financial incentives|
192909|NCT01990508|Behavioral|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
192910|NCT01990521|Procedure|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
192911|NCT01990521|Device|MS3TMRI / TRUS Guided Biopsy|Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.
A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished).
192912|NCT01990534|Drug|Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
192913|NCT01990560|Drug|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
192914|NCT00118482|Drug|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
192610|NCT01957397|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
192611|NCT01957397|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
192612|NCT01957397|Device|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
192613|NCT01957410|Drug|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
192614|NCT01959698|Other|laboratory biomarker analysis|Correlative studies
192615|NCT01959711|Procedure|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
192616|NCT01959711|Procedure|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
192617|NCT01959724|Other|Vitrectomy|
192618|NCT00115791|Drug|RSD1235|IV
192619|NCT01959737|Procedure|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
192620|NCT01959750|Behavioral|problem-based sessions|weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
192919|NCT01993017|Other|Standard Care|Participants will receive standard of care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
192920|NCT01993017|Other|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
192921|NCT01993017|Other|No intervention|
192922|NCT01993030|Device|HQ® Matrix Medical Wound Dressing|
192923|NCT00118781|Drug|iseganan hydrochloride|
192924|NCT01993030|Device|Sidaiyi® wound dressing|
192925|NCT01993056|Behavioral|"FIFA 11+"|
192926|NCT01993056|Behavioral|no "FIFA 11+"|
192927|NCT01993069|Behavioral|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
192324|NCT01964820|Behavioral|Positive Affect Skills Training|Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.
The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.
For a full description, see "A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test" (Moskowitz et al., 2012).
192325|NCT01964833|Procedure|Periodontal treatment|Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.
Patient will receive sham PDT.
192326|NCT01964833|Procedure|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
192327|NCT01964846|Dietary Supplement|Resveratrol, curcumin|
192328|NCT00116389|Drug|gemcitabine|
192329|NCT01964846|Dietary Supplement|Placebo|
192330|NCT01964859|Biological|autologous skin fibroblasts|
192331|NCT01964872|Drug|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
192332|NCT01964872|Drug|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
192333|NCT01964872|Drug|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
192334|NCT01967095|Drug|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 & D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 & D2, & will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 & 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 & 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
192621|NCT01959763|Behavioral|Weight loss counseling program|Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
192622|NCT01959776|Procedure|Vitrectomy|
191723|NCT01977053|Other|Clinical and psychosocial phone calls|The standard medical supervision is defined as follows:
Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.
Nominative notebook containing details of chemotherapy administered and medical contacts.
Consultations with psycho-oncologist or psychiatrist (if necessary).
The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported.
191724|NCT01977066|Behavioral|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
191725|NCT01977066|Behavioral|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
191726|NCT01977079|Other|procalcitonin|
191727|NCT00117663|Drug|Cessation of Hormone Replacement Therapy|
192026|NCT01972178|Drug|Placebo|
192027|NCT00117273|Drug|Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]|1 tablet daily
192028|NCT01972178|Drug|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
192029|NCT01972204|Behavioral|Intensive adherence instruction|Instruction with educational brochure
192030|NCT01972204|Behavioral|Control|Instruction as per usual practice
192031|NCT01972217|Drug|Olaparib|Olaparib bid
192032|NCT01972217|Drug|Placebo|Placebo bid
192033|NCT01972217|Drug|Abiraterone|Abiraterone 1000 mg
192034|NCT01972217|Drug|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
192035|NCT01972230|Drug|Sevoflurane|
192036|NCT01972230|Drug|Diprivan + Remifentanil TCI|
192037|NCT01972243|Other|no intervention|
192038|NCT00117273|Drug|Seasonique (LNG/EE and EE)|1 tablet daily
192039|NCT01972269|Drug|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
192040|NCT01972269|Drug|Lidocaine|2% lidocaine
191432|NCT01984736|Drug|Experimental: EVP-6124|
191433|NCT01984749|Drug|Febuxostat|Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.
The starting dose of the investigational product (febuxostat) will be 10 mg/day.
The dose will be increased to 20 mg/day at Week 4.
The aim is to increase the dose to 40 mg/day at Week 8.
191434|NCT01984762|Procedure|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
191435|NCT01984762|Procedure|sleeve gastrectomy|SG = sleeve gastrectomy
191436|NCT01984775|Drug|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% [5 milligram (mg)/gram (g)], 1% [10 mg/g], and 2% [20 mg/g]).
191437|NCT00118196|Drug|azacitidine|
191438|NCT01984775|Drug|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
191439|NCT01984775|Drug|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
191440|NCT01984775|Drug|Negative control|Negative control contains petrolatum.
191441|NCT01984788|Drug|BCX4161|
191442|NCT01984788|Drug|Placebo|
191443|NCT01984801|Drug|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
191444|NCT01984801|Drug|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
191445|NCT01984801|Drug|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
191446|NCT01984801|Other|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
191447|NCT01984801|Other|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
191728|NCT01977092|Behavioral|Motivational interviewing case management|
191729|NCT01977092|Behavioral|Resource referrals|
191730|NCT01979536|Drug|Methotrexate|Given IT and IV
191731|NCT01979588|Other|What's Going Around tool|Provider has access to the What's Going Around tool
191732|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
190785|NCT01954290|Drug|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
190786|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
191110|NCT01989858|Other|peri-operative cht + post-operative cht-rtx|CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or
ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:
5FU 225 mg/m² given as a continuous iv infusion or
capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.
191111|NCT01992224|Other|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
191112|NCT01992250|Device|Visica 2 Treatment System|Cryoablation
191113|NCT01992263|Dietary Supplement|Vitamin D (600 IU)|
191114|NCT01992263|Dietary Supplement|Vitamin D (2000 IU)|
191115|NCT01992263|Dietary Supplement|Vitamin D (4000 IU)|
191116|NCT01992263|Other|Placebo|
191117|NCT01992276|Biological|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
191118|NCT01992276|Biological|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
191119|NCT01992276|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
191120|NCT01992289|Drug|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
191121|NCT00118742|Drug|Sirolimus|2-4 mg orally once daily for 9-11 months
191122|NCT01992315|Device|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
190490|NCT01961752|Drug|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
190491|NCT00002124|Drug|Lamivudine|
190492|NCT00115973|Drug|insulin aspart|
190493|NCT01961765|Drug|cabozantinib|
190494|NCT01961778|Device|Radio-Frequency Ablation|
190495|NCT01961778|Device|Cryotherapy|
190496|NCT01961791|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
190497|NCT01961804|Procedure|Reversion|
190787|NCT01954290|Drug|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
190788|NCT01954290|Drug|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
190789|NCT01954303|Other|Progress of CHD|
190790|NCT01956383|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
190791|NCT01956396|Device|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
190792|NCT00115492|Drug|Salmeterol|
190793|NCT01956409|Drug|18F-FCH|
190794|NCT01956409|Drug|Magnevist|
190795|NCT01956422|Device|Continuous Positive Airway Pressure(CPAP)|
190796|NCT01956422|Device|Venturi Mask FiO2 40%|
190797|NCT01956435|Device|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention
190798|NCT01956448|Device|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
190177|NCT01968668|Drug|Placebo|Placebo tablet once daily in the morning
190178|NCT01968668|Drug|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
190179|NCT01968668|Drug|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
190180|NCT01968681|Procedure|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
190181|NCT01968694|Drug|IV Lidocaine|
190182|NCT01968694|Drug|IV diphenhydramine|
190183|NCT01968707|Drug|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Apply topically.
190184|NCT01968707|Other|Normal Saline|Apply topically.
190185|NCT01968707|Drug|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
190186|NCT00116831|Drug|rosiglitazone maleate|oral antidiabetic medication
190187|NCT01968707|Drug|3M CHG/IPA Prep Tint 26-mL|Apply topically
190188|NCT01968720|Drug|CAT-2003|
190189|NCT01968720|Drug|Placebo|
190190|NCT01968733|Drug|Solithromycin|
190191|NCT01968733|Drug|Moxifloxacin|
190498|NCT01961817|Other|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack & Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
190499|NCT01961817|Other|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack & Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
190500|NCT01961830|Drug|ME1100 inhalation solution|
190501|NCT01961843|Drug|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
190502|NCT01961843|Drug|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
189551|NCT01981330|Biological|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
189862|NCT00117403|Drug|Placebo wafers|two placebo wafers three times per day with meals
189863|NCT01973699|Other|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
189864|NCT01973712|Procedure|Locked Compression Plating|
189865|NCT01973712|Procedure|Retrograde Intramedullary Nailing (RIMN)|
189866|NCT01973725|Drug|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
189867|NCT01973751|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
189868|NCT01973764|Procedure|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
189869|NCT01973764|Procedure|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
189870|NCT01973777|Device|IUB|intrauterine contraceptive device
189871|NCT01975948|Other|Depression Treatment as Usual|Physicians manage patients with depression as usual
189872|NCT01975961|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
189873|NCT01975974|Device|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
189874|NCT01975987|Device|Bonfils fiberscope|
189875|NCT01976000|Procedure|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
189876|NCT01976013|Device|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
189877|NCT01976026|Device|Flow Diversion|
189878|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
189879|NCT01976026|Device|Best Standard Therapy|
189880|NCT01976039|Other|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx
189238|NCT01986374|Drug|HCG is introduced|must have good blastocysts
189239|NCT01986387|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
189240|NCT01986400|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
189241|NCT01986413|Device|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
189242|NCT01986413|Device|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
189243|NCT01988948|Other|Various biological sampling|
189244|NCT01988961|Biological|Golimumab|SC injections
189245|NCT01988974|Behavioral|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
189246|NCT01988987|Other|Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
189247|NCT01989000|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
189552|NCT01981343|Dietary Supplement|A-F Betafood|
189553|NCT01981343|Other|Placebo|
189554|NCT01981356|Behavioral|Acceptance and Commitment Therapy|The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to
experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.
Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life.
189555|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
184364|NCT02573142|Behavioral|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
184365|NCT02573142|Behavioral|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
184366|NCT02573155|Drug|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
184367|NCT02573155|Drug|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
184368|NCT02573155|Drug|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
184369|NCT02573155|Drug|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
184660|NCT02566577|Biological|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
184661|NCT02566577|Biological|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
184662|NCT02566577|Device|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
184663|NCT02566590|Device|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
184664|NCT02568683|Drug|Cyclophosphamide|Cyclophosphamide administered intravenously
184665|NCT02568683|Drug|Doxorubicin|Doxorubicin administered intravenously
184666|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
184667|NCT02568683|Drug|Prednisone|Prednisone administered orally twice daily
184668|NCT02568683|Drug|Etoposide|Etoposide administered intravenously
184669|NCT02568683|Drug|Filgrastim|Filgrastim administered intravenously
184670|NCT02568709|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
184671|NCT02568709|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
184063|NCT02543801|Drug|Liposomal Bupivacaine|Periarticular injection
184064|NCT02543801|Drug|Ropivacaine|Periarticular injection
184065|NCT02543801|Drug|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
184066|NCT02543801|Drug|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
184067|NCT02543801|Drug|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
184068|NCT02543801|Drug|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
184069|NCT00184574|Drug|biphasic insulin aspart|
184070|NCT02543827|Biological|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
184071|NCT02543827|Biological|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
184072|NCT02543840|Other|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
184073|NCT02543840|Other|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 6 or 12 months prior to cross-over to REP-F
184074|NCT02543853|Other|direct trocar entry|direct trocar entry to provide pneumoperitoneum
184075|NCT02543853|Other|veres needle entry|veres needle entry to provide pneumoperitoneum
184076|NCT02543866|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
184077|NCT02543879|Drug|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
184078|NCT02543892|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
184370|NCT02573155|Drug|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
184371|NCT00002510|Radiation|radiation therapy|
184372|NCT00187915|Drug|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
184373|NCT02573155|Drug|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
189630|NCT01991626|Dietary Supplement|micronutrient powder (containing FeSO4), phytase|
189631|NCT01991626|Dietary Supplement|Iron pyrophosphate (FePP)|
189632|NCT01991626|Dietary Supplement|Iron sulphate|
189633|NCT01991639|Other|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
189634|NCT01991652|Drug|SIOP PODC Wilms tumour treatment: Preoperative chemotherapy|
189635|NCT01991652|Procedure|SIOP PODC Wilms tumour treatment: surgery|
189636|NCT01991652|Drug|SIOP PODC Wilms tumour treatment: post operative chemotherapy|
189637|NCT01991665|Other|Digital examination|
189638|NCT01991665|Other|Sonography evaluation|
189639|NCT01991678|Drug|145 mg/m2 NKTR 102|
189640|NCT00118638|Drug|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
189641|NCT01991678|Drug|120 mg/m2 NKTR 102|
189642|NCT01991678|Drug|95 mg/m2 NKTR 102|
189643|NCT01991691|Device|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
189644|NCT01991717|Device|Victus|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
189645|NCT01991717|Device|Conventional Phaco|The capsulotomy as well as the lens fragmentation is performed manually.
189646|NCT01991743|Drug|Group 2.5|Administration of bupivacaine 2.5 mg.
189647|NCT01991743|Drug|Group 5|Administration of 5 mg bupivacaine
189648|NCT01991743|Drug|Group 7.5|Administration of 7.5 mg bupivacaine
189649|NCT01991743|Drug|Group 10|Administration of 10mg bupivacaine.
189650|NCT01991756|Device|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
189651|NCT00118638|Drug|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
189652|NCT01991769|Behavioral|47 min moderate intensity training|
189023|NCT01963494|Behavioral|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
189024|NCT01963494|Behavioral|Individual planning intervention|Target persons form action plans on their own.
189025|NCT01963494|Behavioral|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
189026|NCT00116220|Drug|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
189027|NCT01963507|Behavioral|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
189028|NCT01963546|Other|different types of anesthesia|
189029|NCT01963546|Drug|Dexmedetomidine|After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
189030|NCT01963559|Drug|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
189031|NCT01963572|Other|SG will be screened every time when they visit the clinics.|
189032|NCT01963598|Drug|REGN1033 (SAR391786)|
189336|NCT01955824|Drug|2% lignocaine|
189337|NCT01955837|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
189338|NCT01955837|Drug|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
189339|NCT01955850|Behavioral|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
189340|NCT00115427|Drug|Liatermin (r-metHuGDNF)|
189341|NCT01955863|Procedure|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
189342|NCT01958450|Procedure|Er:YAG laser|acne scar treatment using Er:YAG laser
189343|NCT01958450|Procedure|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
189344|NCT01958463|Procedure|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
188702|NCT01970618|Drug|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
188703|NCT01970618|Drug|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
188704|NCT01970618|Drug|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
188705|NCT01970618|Drug|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
188706|NCT01970631|Behavioral|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the six months following participants' total knee replacement (TKR).
188707|NCT00117091|Drug|Anakinra (Kineret®)|
188708|NCT01970631|Other|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
188709|NCT01970644|Radiation|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
188710|NCT01970657|Biological|HP802-247|(fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts)
188711|NCT01970657|Other|Vehicle Control|(fibrinogen solution & thrombin solution without cells)
188712|NCT01970657|Other|Standard Care|multi layer compression bandage system
188713|NCT01970683|Dietary Supplement|VSL #3 BID|
188714|NCT01970722|Procedure|therapeutic conventional surgery|Undergo surgery
188715|NCT01970722|Drug|cisplatin|Given IP
188716|NCT01970722|Drug|carboplatin|Given IP or IV
188717|NCT01970722|Drug|paclitaxel|Given IP or IV
188718|NCT00117104|Drug|Aranesp®|
188719|NCT01970722|Drug|pegylated liposomal doxorubicin hydrochloride|Given IP or IV
189033|NCT01963598|Drug|placebo|
189034|NCT01963611|Drug|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate will be administered at a dose of 0.5 mg as weekly subcutaneous injection for a minimum of 40 weeks.
189035|NCT01963611|Drug|Copaxone 20 mg|Copaxone will be administered at a dose of 20 mg as subcutaneous injection once daily for a minimum of 40 weeks.
193548|NCT02057874|Device|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
193549|NCT02057874|Drug|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
193550|NCT02057887|Drug|HM10660A|
193551|NCT02057887|Drug|Pegasys|180 mcg Pegasys SC once weekly
193552|NCT02057900|Biological|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
193553|NCT00124891|Drug|Double-blind investigational anti-arrhythmic|
193554|NCT02060162|Other|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
193555|NCT00125138|Drug|Placebo|Syrup formulation
193556|NCT02060175|Device|Cilotax drug-eluting stents implantation|
193557|NCT02060175|Device|DESyne drug-eluting stents implantation|
193558|NCT02060188|Drug|Ipilimumab|
193559|NCT02060188|Drug|Nivolumab|
193560|NCT02060201|Drug|Saxagliptin|
193561|NCT02060201|Drug|Dapagliflozin|
193562|NCT02060201|Drug|Saxagliptin/Dapagliflozin FDC|
193563|NCT02060227|Procedure|Open Latarjet procedure|
193564|NCT02060227|Procedure|Arthroscopic Bankart repair|
193565|NCT02060240|Behavioral|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
193566|NCT00125151|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|
193567|NCT02060253|Drug|ganetespib|Given IV
193568|NCT02060253|Drug|paclitaxel|Given IV
193569|NCT02060253|Biological|trastuzumab|Given IV
192915|NCT01992978|Procedure|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
192916|NCT01992991|Device|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
192917|NCT01993017|Other|Cognitive Behavioral Therapy (CBT)|The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.
CBT will be centrally administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement .
192918|NCT01993017|Drug|Antidepressant Medication|The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.
Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated.
193231|NCT02065388|Behavioral|Standard of care dosing for warfarin|
193232|NCT02065388|Genetic|Genotype-guided dosingTaiwan algorithm for warfarin|
193233|NCT02065388|Genetic|Genotype-guided dosing IWPC algorithm for warfarin|
193234|NCT02065401|Drug|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
193235|NCT02065401|Drug|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
193236|NCT02065401|Drug|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
193237|NCT02065414|Other|Listerine Advance Gum Defense|
193238|NCT02065414|Other|Mouth rinse containing Chlorhexidine|
193239|NCT02065414|Other|Mouth rinse containing 5% Hydroalcohol|
193240|NCT02065427|Behavioral|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
193241|NCT02067884|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
193242|NCT02067884|Procedure|shear wave elastography|Undergo SWE
193243|NCT02067910|Drug|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
193244|NCT02067936|Drug|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
192928|NCT01993082|Behavioral|Aerobic Training Intervention|For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.
A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage.
192929|NCT01993095|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
192930|NCT01993095|Behavioral|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
192931|NCT01993108|Drug|Methylphenidate|All study participants will receive one dose of any three of the following drug compounds 1 hour before fMRI scan and task performance: 40mgs of methylphenidate, 40mgs of naltrexone, or a placebo. There are a total of three scans per participant, therefore all participants will receive one dose of all three drug compounds for any given scan during their participation in the study.
192932|NCT01993108|Drug|Naltrexone|All study participants will receive one dose of any three of the following drug compounds 1 hour before fMRI scan and task performance: 40mgs of methylphenidate, 40mgs of naltrexone, or a placebo. There are a total of three scans per participant, therefore all participants will receive one dose of all three drug compounds for any given scan during their participation in the study
192933|NCT01954992|Drug|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
192934|NCT01954992|Drug|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
192935|NCT01955005|Behavioral|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
192936|NCT00115323|Behavioral|Problem Solving|Problem solving intervention
193255|NCT02068027|Drug|Clonidine Gel 0.1%|
193256|NCT00125996|Drug|Venofer (intravenous iron sucrose)|
193257|NCT02068027|Drug|Placebo|
193258|NCT02068040|Dietary Supplement|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
193259|NCT02068053|Drug|[14C] BMS-986020|
193260|NCT02068079|Drug|Vemurafenib and Trientine|
193261|NCT02068092|Drug|Hydroxytyrosol|
193262|NCT02068105|Drug|ALKS 5461|Sublingual tablet
192623|NCT01959802|Procedure|Vitrectomy|
192624|NCT01959828|Drug|IK-3001|
192625|NCT01959841|Drug|ASP2151|200 mg once daily or 400 mg once daily
192626|NCT01959841|Drug|valaciclovir|1000 mg three times daily
192627|NCT01959854|Device|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
192628|NCT01959854|Device|xanthan gum|0.2% xanthan gum preservative free
192629|NCT00115791|Drug|placebo|IV
192630|NCT01959867|Device|SurgiMend® PRS|
192631|NCT01959880|Device|The Contour Profile Gel (CPG) breast implants|The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.
The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study.
192632|NCT01959919|Device|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
192633|NCT01959932|Other|THS 2.2|THS 2.2 ad libitum for 5 days in confinement
192634|NCT01959932|Other|SA|SA for 5 days in confinement
192635|NCT01959932|Other|CC|Subject's own preferred brand of CC ad libitum for 5 days in confinement
192636|NCT01959945|Biological|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
192637|NCT01959945|Biological|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
192638|NCT01962636|Biological|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
192639|NCT01962662|Other|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
192640|NCT01962662|Other|U/E exercise|strengthening and stretching
192937|NCT01955005|Other|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
192041|NCT01972308|Behavioral|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients
192042|NCT01972321|Other|Technology supported supervision|CHWs will be provided with mobile phones and solar chargers to carry out the following:
Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.
Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians
Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance.
192043|NCT01972321|Behavioral|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
192335|NCT01967108|Other|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
192336|NCT00116636|Drug|Kaletra|
192337|NCT01967121|Device|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
192338|NCT01967121|Other|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
192339|NCT01967134|Biological|Aeras-456|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
192340|NCT01967147|Drug|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
192341|NCT01967147|Drug|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
192342|NCT01967173|Drug|Flovent Diskus® 100 mcg|Flovent is an ICS
192343|NCT01967173|Drug|Flovent Diskus® 250 mcg|Flovent is an ICS
192344|NCT01967173|Drug|Flovent Diskus® 500 mcg|Flovent is an ICS
192345|NCT01967173|Drug|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
192346|NCT01967173|Drug|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
191733|NCT01979601|Drug|LGT209|150 mg lyophilized powder in glass vial
191734|NCT01979601|Drug|Placebo|Placebo comparator
191735|NCT01979614|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
191736|NCT01979614|Other|Placebo|5% v/v glucose solution
191737|NCT01979627|Procedure|transulnar approach interventional procedure|
191738|NCT01979627|Procedure|transradial approach interventional procedure|
191739|NCT01979640|Procedure|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
191740|NCT01979640|Procedure|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
191741|NCT01979640|Procedure|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
191742|NCT01979653|Drug|dexmedetomidine alone or dexmedetomidine + midazolam|
191743|NCT00117884|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
191744|NCT01979666|Drug|nitrate patch|patients in the study group will get a nitrate patch
191745|NCT01979666|Drug|placebo patch|control group patients will get a placebo patch
191746|NCT01979666|Device|MRI scan|MRI scan after 6 weeks of treatment
191747|NCT01979679|Drug|Lurasidone 80 mg|
191748|NCT01979679|Drug|Lurasidone 120 mg|
191749|NCT01979679|Drug|Lurasidone 160 mg|
191750|NCT01979692|Procedure|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
191751|NCT01979692|Device|CT guided trans thoracic needle biopsy|
192044|NCT01972321|Other|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
192045|NCT01974596|Dietary Supplement|Probiotic tablets of Lactobacillus reuteri|
191123|NCT01992328|Drug|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
191124|NCT01992341|Drug|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
191125|NCT01992341|Drug|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
191126|NCT01992354|Device|PET MR Device|GE PET/MRI system
191448|NCT01987206|Device|PID control algorithm|
191449|NCT01987219|Drug|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
191450|NCT01987219|Drug|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
191451|NCT00000307|Drug|Naltrexone|
191452|NCT00002149|Drug|Amoxicillin trihydrate|
191453|NCT00118313|Biological|multi-epitope melanoma peptide vaccine|
191454|NCT01987219|Other|placebo|Saline solution 3 cc NA
191455|NCT01987232|Drug|Carfilzomib|
191456|NCT01987232|Drug|Carboplatin|
191457|NCT01987232|Drug|Etoposide|
191458|NCT01987258|Behavioral|Interval Walking|
191459|NCT01987258|Behavioral|Continuous walking|
191460|NCT01987271|Device|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
191461|NCT01987284|Drug|SER100|
191462|NCT01987284|Drug|Placebo|
191463|NCT01987297|Drug|ATRA+arsenic|experimental
191464|NCT00118313|Biological|sargramostim|
191465|NCT01987297|Drug|ATRA+chemo|control
191466|NCT01987310|Drug|atorvastatin|atorvastatin 20 mg per day for 6 months
190799|NCT01956474|Other|Theralight crosslinking and Riboflavin|Corneal Collagen cross linking with UV light and riboflavin
190800|NCT01956487|Drug|Propafenone|Comparison of drug from 2 manufacturing sites
190801|NCT01956500|Dietary Supplement|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
190802|NCT01956500|Dietary Supplement|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
190803|NCT00115505|Other|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
190804|NCT01956513|Other|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
190805|NCT01956526|Device|CORolla™ TAA device|
190806|NCT01956552|Other|biopsy or cytopuncture|
191127|NCT01992367|Drug|ASLAN003 ACTIVE|This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
191128|NCT01992380|Drug|18F-AV-1451|
191129|NCT01992393|Behavioral|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
191130|NCT01992471|Behavioral|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
191131|NCT01954316|Drug|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
191132|NCT01954355|Drug|LDE225|400, 600 and 800 mg OD
191133|NCT01954355|Drug|Paclitaxel|80 mg/m2 (days 1, 8, 15)
191134|NCT01954368|Drug|Placebo|As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).
Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.
190503|NCT01964079|Drug|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
190504|NCT01964092|Behavioral|Individual Placement and Support|
190505|NCT01964092|Behavioral|Ordinary employment schemes|
190506|NCT01964105|Device|3D Imaging|
190507|NCT01964118|Other|Intermittent Fasting group|Intermittent fasting for 12 months
190508|NCT01964118|Other|control group|usual diet for 6 months and intermittent fasting for other 6 months
190509|NCT01964131|Drug|D961H sachet 20 mg|Each subject will be randomised evenly to one of "Treatment: A-->B (Sequence 1)" or "Treatment: B-->A (Sequence 2)".
Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg
190510|NCT01964131|Drug|D961H HPMC capsule 20 mg|Each subject will be randomised evenly to one of "Treatment: A-->B (Sequence 1)" or "Treatment: B-->A (Sequence 2)". Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg
190511|NCT00116311|Behavioral|allergen inhalation|
190512|NCT01964144|Drug|Dovitinib|Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
190513|NCT01964157|Drug|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
190514|NCT01964170|Drug|ASP3550|subcutaneous
190515|NCT01964170|Drug|Goserelin|subcutaneous
190516|NCT01964183|Drug|tolterodine|Oral
190807|NCT01956565|Other|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
190808|NCT01956578|Other|Breathing Exercise Cohort|All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
190809|NCT01956591|Drug|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
189881|NCT01976065|Drug|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
189882|NCT01976065|Other|Standard Treatment|Standard Treatment no use of study drug
189883|NCT01976078|Drug|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
190192|NCT01968759|Drug|Sevelamer|
190193|NCT01968759|Drug|Ramipril and Irbesartan|
190194|NCT01968772|Other|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
190195|NCT01968785|Radiation|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
190196|NCT01968785|Radiation|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
190197|NCT00116844|Drug|Valaciclovir|Valtrex 1g QD
190198|NCT01968798|Drug|Aspirin|100mg enteric-coated aspirin, taken daily
190199|NCT01968798|Drug|Placebo|100mg enteric-coated placebo, taken daily
190200|NCT01968811|Device|Avance Foam dressing kit|
190201|NCT01968824|Procedure|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
190202|NCT01968837|Other|Cervical cancer screening|
190203|NCT01971229|Other|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
190204|NCT01971229|Other|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
190205|NCT01971242|Drug|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
190206|NCT01971242|Other|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
190207|NCT00117182|Drug|Dry powder mannitol|
190208|NCT01971255|Biological|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
189556|NCT01981356|Other|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
189557|NCT01981369|Drug|Dexmedetomidine|Intravenous sedation with dexmedetomidine
189558|NCT01981369|Drug|Propofol|Intravenous sedation with propofol
189559|NCT01981369|Procedure|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
189560|NCT01981395|Drug|Fenobam|Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
189561|NCT01984034|Behavioral|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
189562|NCT01984034|Other|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
189563|NCT01984047|Drug|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
189564|NCT01984047|Drug|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
189565|NCT01984060|Other|HOME-EX|Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.
Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise
189884|NCT01976091|Drug|scAAVrh74.tMCK.hSGCA|
189885|NCT01976104|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
189886|NCT01976104|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
189887|NCT01976104|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
184672|NCT02568722|Other|Standard RRT initiation|In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:
serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization.
184673|NCT02568722|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
184674|NCT02568735|Procedure|Hip arthroplasty|After total hip replecement surgery patient were given either etoricoxib or dexketoprofen
184675|NCT02568748|Biological|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
184676|NCT02568748|Procedure|TACE|Trans-arterial chemoembolization
184677|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
184678|NCT02568761|Procedure|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
184963|NCT02562222|Procedure|anodal tDCS on V1|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
184964|NCT02562222|Procedure|cathodal tDCS on V1|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
184965|NCT02562222|Procedure|anodal tDCS on M1 and cathodal on V1|The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
184374|NCT00183911|Drug|floxuridine, 5-Fluorouracil, leucovorin|
184375|NCT02539186|Biological|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
184376|NCT02539186|Device|splint|
184377|NCT02539199|Drug|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
184378|NCT02539199|Drug|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
184379|NCT02539212|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
184380|NCT02539212|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
184381|NCT02539225|Drug|Ramucirumab|Administered IV
184382|NCT02539225|Drug|Placebo|Administered IV
184383|NCT02539225|Drug|S-1|Administered PO
184384|NCT02539225|Drug|Oxaliplatin|Administered IV
184385|NCT00183911|Procedure|External Beam Radiotherapy|
184386|NCT02539225|Drug|Paclitaxel|Administered IV
184387|NCT02539238|Other|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
184388|NCT02539251|Behavioral|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
184389|NCT02539264|Other|Smoking|Influence of smoking on parameters derived from overnight PSG
184390|NCT02539264|Other|Obesity|Influence of obesity on parameters derived from overnight PSG
184391|NCT02539264|Other|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
184392|NCT02539277|Drug|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
184679|NCT02568761|Other|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
184680|NCT02568774|Other|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
189653|NCT01991769|Behavioral|exercise healthy volunteers|
189654|NCT01991769|Behavioral|control; no exercise training|
189965|NCT01986608|Drug|Lacosamide oral|Strength: 200 mg
Form: film-coated tablet
Dosage: 200 mg, single dose
Duration: single oral intake
189966|NCT01986634|Device|Laser Treatment|Patient will have split face laser resurfacing. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
189967|NCT01986647|Behavioral|On the Move group exercise|
189968|NCT01986647|Behavioral|Standard group exercise|
189969|NCT01986660|Drug|Ibuprofen Cream (SST-0225)|
189970|NCT01986673|Drug|5% Sildenafil Cream (SST-6006)|5 % Sildenafil Cream
189971|NCT01986673|Drug|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
189972|NCT01986699|Procedure|Laparoscopic Assisted Polypectomy|
189973|NCT01986725|Behavioral|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
189974|NCT01986725|Behavioral|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
189975|NCT00118274|Drug|cyclophosphamide|Given IV
189976|NCT01986738|Radiation|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
189977|NCT01986738|Device|Active Breathing Control Device (ABC)|
189978|NCT01986738|Device|Computed Tomography Scan (CT)|
189979|NCT01986751|Drug|Clonidine|
189980|NCT01986751|Drug|ropivacaine|
189981|NCT01986764|Drug|LDX|
189345|NCT01958476|Drug|Neonatal Morphine Solution|Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A "double dummy" design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose.
189346|NCT01958476|Drug|Methadone|Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a "double dummy" design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose.
189347|NCT01958476|Drug|Phenobarbital|A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally >8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.
Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores <8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period.
189348|NCT01958489|Drug|Evacetrapib|Administered orally
189349|NCT01958489|Drug|Pravastatin|Administered orally
189655|NCT01991782|Other|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
189656|NCT01991795|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
189657|NCT01991795|Drug|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
189658|NCT01991808|Radiation|Radiotherapy|
189659|NCT01991821|Drug|APD421|
189660|NCT01953809|Drug|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
189661|NCT01953809|Drug|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
189662|NCT01953809|Drug|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
189036|NCT01963611|Drug|Plovamer acetate 3 mg|Plovamer acetate will be administered at a dose of 3 mg as weekly subcutaneous injection for a minimum of 40 weeks.
189037|NCT00116220|Radiation|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
189038|NCT01963611|Drug|Plovamer acetate 10 mg|Plovamer acetate will be administered at a dose of 10 mg as weekly subcutaneous injection for a minimum of 40 weeks.
189039|NCT01963611|Drug|Plovamer acetate 20 mg|Plovamer acetate will be administered at a dose of 20 mg as weekly subcutaneous injection for a minimum of 40 weeks.
189040|NCT00116506|Drug|erlotinib|
189041|NCT01965704|Drug|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
189042|NCT01965730|Drug|epsilon-aminocaproic acid (EACA)|
189043|NCT01965743|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
189044|NCT01965756|Drug|Metformin|
189045|NCT01965769|Other|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
189046|NCT01965782|Drug|[^14C]-LY3023703|Administered orally
189047|NCT01965795|Dietary Supplement|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain‐Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
189048|NCT01965795|Dietary Supplement|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
189049|NCT01965808|Drug|LY2157299|Administered orally
189050|NCT01965821|Device|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
189051|NCT00116506|Drug|FOLFOX|
189350|NCT01958502|Genetic|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
189351|NCT01958515|Other|research blood draw and tissue biopsy|
193570|NCT02060253|Biological|pertuzumab|Given IV
193571|NCT02060266|Drug|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
188720|NCT01970722|Drug|gemcitabine hydrochloride|Given IP or IV
188721|NCT01970722|Procedure|quality-of-life assessment|Ancillary studies
188722|NCT01970722|Other|laboratory biomarker analysis|Correlative studies
188723|NCT01970735|Biological|Blood test|
188724|NCT01970748|Drug|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
188725|NCT01970748|Procedure|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
188726|NCT01970774|Other|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
188727|NCT01970787|Device|Radiofrequency Ablation (RFA) using the HALO Ablation System|
188728|NCT01973231|Drug|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
188729|NCT01973244|Drug|NNC0195-0092|A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.
Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation.
188730|NCT01973244|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
188731|NCT01973257|Procedure|imaging diagnostics|
188732|NCT01973270|Behavioral|Neuroadaptive cognitive training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
188733|NCT01973283|Drug|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
188734|NCT01973296|Behavioral|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
193245|NCT00125983|Drug|Ortho Evra|
193246|NCT02067936|Drug|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
193247|NCT02067936|Drug|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
193248|NCT02067936|Drug|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
193249|NCT02067949|Drug|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
193250|NCT02067962|Biological|Blood sample|Blood sample
193251|NCT02067975|Drug|Tryptophan|
193252|NCT02067975|Drug|Placebo|
193253|NCT02067988|Device|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
193254|NCT02068001|Procedure|Roux-en-Y Gastric Bypass|
188385|NCT01978093|Biological|Prevnar 13®|4 doses administered IM in the left lower thigh at Day 0, Month 2, Month 4 and Month 10-13.
188386|NCT01978093|Biological|PedvaxHIB®|3 doses administered IM in the right upper thigh at Day 0, Month 2 and Month 10-13.
188387|NCT01980823|Drug|Atorvastatin|Atorvastatin is in a group of drugs called HMG CoA reductase inhibitors, or "statins." Atorvastatin reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).
Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors.
188388|NCT01980823|Procedure|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
188389|NCT01980836|Biological|Seasonal influenza vaccine|
188390|NCT00117923|Drug|Resiquimod|
188391|NCT01980849|Drug|Nadroparin, long term|
188392|NCT01980849|Drug|Nadroparin: short-term|
188393|NCT01980875|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
188394|NCT01980875|Drug|Chlorambucil|Chlorambucil 2 mg tablet administered orally every other week for a total of 12 doses
203509|NCT00119145|Drug|artesunate-amodiaquine|
203510|NCT01997606|Other|placebo|
203511|NCT01997632|Biological|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
203512|NCT01997632|Biological|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
203513|NCT01997645|Procedure|LIFT|
203514|NCT01997645|Procedure|RAF|
203515|NCT00119314|Procedure|positron emission tomography|
203516|NCT01999920|Drug|Vilazodone|10mg to 40mg per day for 12 weeks
203517|NCT01999920|Drug|Placebo|One to two pills per day for 12 weeks
203518|NCT01999933|Radiation|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
203519|NCT01999933|Drug|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
203520|NCT01999933|Drug|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
203521|NCT01999933|Drug|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
203522|NCT01999946|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
203523|NCT01999959|Procedure|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
203524|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
203525|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
203526|NCT00119340|Drug|cyclosporine|
198786|NCT00126659|Procedure|therapeutic conventional surgery|Undergo cytoreductive nephrectomy
198787|NCT02075554|Device|CALIBER|Expandable interbody spacer
198788|NCT02075567|Procedure|Experimental|
202900|NCT02013323|Drug|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
202901|NCT02013336|Drug|MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide|
202902|NCT00120549|Procedure|Assisted embryo hatching|
202903|NCT02013349|Device|Subjects receiving the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System|
202904|NCT02013362|Drug|Pralatrexate injection|
202905|NCT02013362|Dietary Supplement|Vitamin B12|
202906|NCT02013362|Dietary Supplement|Folic Acid|
203215|NCT02005367|Behavioral|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
203216|NCT02005380|Other|Text-based task|Participants are required to take text-based exercise.
203217|NCT02005380|Other|Graphic-based Task|Participants are required to take the graphic-based exercise.
203218|NCT02005393|Device|FICE Image Acquisition System|Images Captured with FICE Device
203219|NCT02005393|Device|NBI Image Acquisition System|Images Captured with NBI Image Acquisition System
203220|NCT02005406|Device|Experimental group and control groupl|JET
203221|NCT02005419|Drug|Gemcitabine|Patients receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
203222|NCT02005419|Drug|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
203223|NCT00119730|Drug|Mitoxantrone|Given on day 1 of each 28-day cycle
203224|NCT02005419|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
203225|NCT02005432|Drug|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
203226|NCT02005432|Drug|panfotocoagulation (PASCAL)|
202598|NCT02018692|Dietary Supplement|Placebo:Starch|
202599|NCT02018718|Device|Magnetic Resonance Imaging (MRI)|
202600|NCT02018731|Drug|Metformin and Metformin & L-Citrulline|
202601|NCT02018731|Drug|L-Citrulline and Metformin & L-Citrulline|
202602|NCT02018757|Drug|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
202603|NCT02018757|Drug|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
202604|NCT02018770|Radiation|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
202605|NCT00121134|Drug|Methotrexate|Twice daily for the first two days of every week for 6 months
202606|NCT02018770|Radiation|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
202607|NCT02018783|Procedure|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
202907|NCT02013375|Procedure|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
202908|NCT02013375|Drug|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
202909|NCT02013375|Radiation|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
202910|NCT02013375|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
202911|NCT02013375|Drug|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
202912|NCT02013388|Drug|N91115|Given PO daily for 14 days
202913|NCT00120562|Procedure|Gastric Bypass Surgery|
202914|NCT02013388|Drug|Placebo|Given PO daily for 14 days
202300|NCT02026115|Behavioral|PAINReportIt|PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
202301|NCT02026115|Behavioral|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
202302|NCT02026115|Behavioral|PAINUCope|We tested the prototype of the PAINUCope component of the intervention in three completed studies. PAINUCope is a multimedia, computer generated tool that provides tailored patient information to overcome their misconceptions about pain and to help them engage in self-care activities that contribute to reducing their pain. PAINUCope focuses on two crucial aspects of pain management: 1) reporting cancer pain; and 2) safe and effective use of pain medicines. All the educational materials were written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person living with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt govern the specific health information that is shared with the patient via PAINUCope.
202303|NCT02026141|Drug|Dexmedetomidine|
202304|NCT02026141|Drug|Normal Saline Placebo|
202305|NCT02026167|Behavioral|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
202306|NCT02026180|Device|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
202307|NCT02026193|Procedure|oocyte vitrification|
202308|NCT02026193|Procedure|embryo freezing|
202309|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.15 mg/m^2 administered on Days 1, 8, 15 of 28-day cycle.
202608|NCT02018783|Procedure|Sensodyne|Digital application for 60 seconds.
202609|NCT02021123|Drug|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
202610|NCT00121264|Procedure|magnetic resonance imaging|Correlative studies
202611|NCT02021136|Device|Rebel reliever|The patient must have the rebel reliever
202612|NCT02021136|Other|No brace|The patient must not have the rebel reliever and no brace
201736|NCT01996514|Behavioral|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
202014|NCT02031211|Drug|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
202015|NCT02031211|Drug|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
202016|NCT02031224|Behavioral|Conventional low protein diet|
202017|NCT02031224|Dietary Supplement|Very low protein diet supplemented with Ketosteril|
202018|NCT02031237|Radiation|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
202019|NCT02031237|Radiation|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
202020|NCT02031237|Radiation|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
202021|NCT02031237|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
202022|NCT02031250|Drug|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
202023|NCT00122369|Behavioral|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
202024|NCT02031250|Drug|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
202025|NCT02031250|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
202026|NCT02031250|Radiation|Boost Radiation to Hypoperfused Volumes|
202027|NCT02033824|Procedure|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
202028|NCT02033850|Behavioral|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
202029|NCT00122590|Drug|nelfinavir|
202030|NCT02033876|Drug|Ursodiol|
202031|NCT02033889|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
202032|NCT02033889|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
226543|NCT02188576|Drug|high dose TXA|Subjects will be randomized to either high dose TXA or low dose TXA to be given as an infusion in a blinded fashion during the surgery.
226544|NCT02188576|Drug|Low dose TXA|Subjects will be randomized to either high dose TXA or low dose TXA to be given as an infusion in a blinded fashion during the surgery.
226545|NCT02188589|Device|Nasal implant|Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)
226546|NCT02188615|Procedure|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
226547|NCT02188615|Drug|Cisplatin|only Radical Chemoradiotherapy
226548|NCT00138229|Drug|cyclophosphamide|
226549|NCT02188615|Device|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
226550|NCT02188628|Device|H-Man|H-man is a portable end-effector planar upper limb robot.
226551|NCT02188628|Other|Additional Conventional Therapy|Repetitive goals based arm therapy
226833|NCT02181075|Drug|lyso-thermosensitive liposomal (LTSL) doxorubicin|ThermoDox® infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
226834|NCT02181088|Biological|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10^9 vp
226835|NCT02181088|Biological|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10^10 vp
226836|NCT02181088|Biological|MVA RH5 low dose|MVA RH5 at 1 x 10^8 pfu
226837|NCT02181088|Biological|MVA RH5 full dose|MVA RH5 at 2 x 10^8 pfu
226838|NCT02181101|Drug|FEC-DocGemzar adjuvant chemotherapy|
226839|NCT02181101|Drug|FEC-Doc adjuvant chemotherapy|
226840|NCT00137449|Drug|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
226841|NCT02181101|Drug|Zoledronic acid i.v. 2 years|
226842|NCT02181101|Drug|Zoledronic acid i.v. 5 years|
226843|NCT02181114|Behavioral|Expert System Coaching|
226844|NCT02181127|Device|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
226243|NCT02193581|Device|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
226244|NCT02195960|Dietary Supplement|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
226245|NCT00002301|Drug|Foscarnet sodium|
226246|NCT00139243|Drug|5-Fluorouracil|
226247|NCT02195973|Drug|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
226248|NCT02195986|Drug|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
226249|NCT02195986|Drug|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
226250|NCT02195986|Drug|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
226251|NCT02195999|Other|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
226252|NCT02195999|Other|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
226253|NCT02195999|Other|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
226552|NCT02188641|Other|Diet|
226553|NCT02188641|Other|Exercise|
226554|NCT02188641|Other|Diet and Exercise|
226555|NCT02188641|Other|Healthy Lifestyle (Control) Group|
226556|NCT02188654|Drug|Metformin|500mg/day retarded formulation of metformin
226557|NCT02188654|Drug|Placebo|500 mg/day of placebo tablets
226558|NCT02188667|Other|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
226559|NCT00138229|Drug|fludarabine phosphate|
225918|NCT02162576|Device|Propeller Health intervention|The Propeller Health system works through the provision of information to patients and their providers. With the Propeller Health sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller Health where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
225919|NCT02162615|Device|Restorelle Direct Fix A|
225920|NCT02162615|Device|Restorelle Direct Fix P|
225921|NCT02162615|Procedure|Native Tissue Repair Anterior|
225922|NCT02162615|Procedure|Native Tissue Repair Posterior|
225923|NCT02162628|Device|Exair Prolapse Repair System|
225924|NCT02165111|Drug|Onabotulinumtoxin A|
225925|NCT02165111|Drug|sterile saline solution|
225926|NCT02165124|Device|Artificial Embolization Device|Embosphere Microspheres
225927|NCT00135629|Procedure|Venepuncture: 100ml blood sample taken on 12 separate visits|
225928|NCT02165150|Other|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
225929|NCT02165163|Other|Balance Training|Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as "ankle reaching" and "obstacle crossing" using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
225930|NCT02165176|Drug|Oral cannabis|
225931|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
225932|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
225933|NCT02165189|Drug|Ribavirin|Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram ([kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
225934|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
225935|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
226254|NCT02195999|Other|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
225293|NCT02183038|Drug|Naproxen sodium|
225294|NCT02183038|Drug|Meloxicam placebo low|
225295|NCT02183038|Drug|Meloxicam placebo high|
225296|NCT02183038|Drug|Naproxen sodium placebo|
225297|NCT02183051|Drug|Meloxicam 7.5 mg|
225298|NCT00137735|Drug|Gabapentin|300mg tds
225604|NCT02172352|Drug|Ba 679 BR middle dose|
225605|NCT02172352|Drug|Ba 679 BR high dose|
225606|NCT02172352|Drug|Placebo inhalation powder|
225607|NCT02172378|Drug|Tiotropium inhalation capsules|
225608|NCT02172378|Drug|Placebo inhalation capsules|
225609|NCT02172391|Drug|Tiotropium inhalation powder capsules|
225610|NCT02172391|Drug|Placebo inhalation powder capsules|
225611|NCT02172404|Device|Placebo capsule administered via the HandiHaler®|
225612|NCT02172404|Device|Ipratropium metered dose inhaler (MDI)|
225613|NCT00136448|Drug|interleukin-2|
225614|NCT02172417|Drug|Cimetidine + Tiotropium|
225615|NCT02172417|Drug|Ranitidine + Tiotropium|
225616|NCT02172417|Drug|Tiotropium|
225617|NCT02172430|Drug|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
225618|NCT02175238|Drug|BI 691751 fasted|single dose BI 691751 in fasted state
225619|NCT02175238|Drug|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
225620|NCT02175251|Procedure|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
225621|NCT02175251|Procedure|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
224983|NCT02189980|Other|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
224984|NCT02189980|Other|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
224985|NCT02189980|Other|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
224986|NCT02190019|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
224987|NCT02190032|Device|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
224988|NCT02190032|Device|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
225299|NCT02183051|Drug|Meloxicam 3.75 mg|
225300|NCT02183051|Drug|Meloxicam 1.875 mg|
225301|NCT02183051|Drug|Ibuprofen 200 mg|
225302|NCT02183051|Drug|Placebo|
225303|NCT02183051|Drug|Meloxicam 15 mg|
225304|NCT02183051|Drug|Ibuprofen 400 mg|
225305|NCT02183064|Drug|Meloxicam|
225306|NCT02183064|Drug|NSAID|
225307|NCT02183077|Drug|Meloxicam gel|
225308|NCT02183077|Drug|Meloxicam tablet|
225309|NCT00137735|Other|placebo|tds
225310|NCT02183090|Drug|Meloxicam ampoule|
225311|NCT02183090|Drug|Meloxicam tablet|
225312|NCT02183103|Drug|meloxicam rapid release tablet, 12mg, UH AC62MU|
225313|NCT02183116|Drug|Meloxicam|
201859|NCT02009943|Drug|Iron sucrose|
201860|NCT02012777|Drug|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
201861|NCT02012790|Other|Diet|The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
201862|NCT02012803|Procedure|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
201863|NCT02012803|Other|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
201864|NCT02012816|Other|Peer‐referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
202153|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
202154|NCT02004951|Device|Misago RX|
202155|NCT02004951|Device|Zilver PTX|
202156|NCT02004977|Behavioral|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
202157|NCT02004990|Procedure|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
202158|NCT02005003|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
202159|NCT02005003|Procedure|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
202160|NCT02005003|Biological|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
202161|NCT02005003|Procedure|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
201555|NCT02018289|Procedure|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
201556|NCT02018289|Procedure|No triclosan|Suture of the abdominal wall with suture without triclosan coat
201557|NCT00121095|Drug|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
201558|NCT02018302|Drug|Triheptanoin|
201559|NCT02018315|Drug|Triheptanoin|Triheptanoin is a 7-carbon medium chain triglyceride
201560|NCT02018328|Dietary Supplement|Curcumin|
201561|NCT02018341|Other|homeopathic remedy in 30C potency|
201562|NCT02018341|Other|Placebo|
201563|NCT02018354|Procedure|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith & Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 900 flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
201564|NCT02018354|Procedure|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
201565|NCT02020694|Drug|Placebo (for vitamin D)|
201566|NCT02020707|Biological|Bevacizumab|Given IV
201567|NCT00121251|Drug|Gemcitabine Hydrochloride|Given IV
201568|NCT02020707|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
201569|NCT02020707|Other|Pharmacological Study|Correlative studies
201570|NCT02020720|Procedure|Biopsy|Undergo image-guided biopsy
201571|NCT02020720|Procedure|Computed Tomography|Undergo 18F-DOPA-PET/CT
201572|NCT02020720|Procedure|Diffusion Weighted Imaging|Undergo DTI
201573|NCT02020720|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
200920|NCT02030652|Procedure|CPAP|Nasal continuous positive airway pressure
200921|NCT02030665|Behavioral|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
200922|NCT02030665|Behavioral|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
200923|NCT02030665|Behavioral|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
200924|NCT02030678|Drug|irinotecan|irinotecan , 100mg/m2,day1,day 8;21days a cycle;at least 3cycles.
200925|NCT00122291|Procedure|Pelvic radiation|
200926|NCT02030691|Device|Nasal continuous airway positive pressure (nCPAP)|
201258|NCT00121680|Drug|E7080|Oral.
201259|NCT02025621|Drug|Placebo|matching placebo
201260|NCT02025634|Drug|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
201261|NCT02025634|Drug|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
201262|NCT02025660|Drug|Mw, 0.3ml x three days sc|
201263|NCT02025660|Drug|Placebo|
201264|NCT02025686|Drug|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
201265|NCT02025686|Other|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
201266|NCT02025712|Drug|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
201267|NCT02025712|Drug|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
201268|NCT02025725|Drug|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
201269|NCT00121693|Behavioral|Music therapy (listening to specific music)|Listening to Music
201270|NCT02025725|Drug|Placebo Nasal Spray|nasal spray formulation with vehicle only
201271|NCT02028234|Drug|Omeprazole|os, 20 mg, once per day, for 30 days
201272|NCT02028247|Behavioral|Personalized Cognitive-behavioral therapy|
200307|NCT02001181|Drug|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
200308|NCT02001194|Behavioral|Individual Incentives|
200309|NCT02001194|Behavioral|Team Incentives|
200310|NCT02001194|Behavioral|Individual plus Team Incentives|
200311|NCT02001207|Other|Salivary cortisol test|
200312|NCT02001220|Procedure|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.
The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre.
200596|NCT01993784|Drug|nimotuzumab|
200597|NCT01993797|Other|Lung US|
200598|NCT01993810|Radiation|photon beam radiation therapy|Undergo photon beam radiation therapy
200599|NCT00118859|Behavioral|Conventional treatment for low back pain|
200600|NCT01993810|Radiation|proton beam radiation therapy|Undergo proton beam radiation therapy
200601|NCT01993810|Drug|paclitaxel|Given IV
200602|NCT01993810|Drug|carboplatin|Given IV
200603|NCT01996176|Behavioral|Intervention group|The intervention consists of four components, which as described below:
Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.
Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.
Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.
Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project.
200604|NCT01996176|Behavioral|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
200605|NCT01996189|Device|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
200606|NCT01996189|Device|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
200607|NCT01996202|Drug|Ipilumimab|
200608|NCT01996202|Radiation|Radiation|
199701|NCT02014584|Drug|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
199702|NCT02014597|Device|HOCD|comparison of HOCD results between subjects with and without glaucoma
199703|NCT02014623|Other|Grass pollen sublingual immunotherapy tablet|
199704|NCT02014623|Drug|Control|
199705|NCT02014636|Drug|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
199706|NCT00120705|Drug|darbepoetin alfa|
199707|NCT02014636|Drug|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
199708|NCT02014649|Drug|20 mg laninamivir octanoate|
199709|NCT02014649|Drug|Placebo|
199710|NCT02014649|Drug|40 mg laninamivir octanoate|
199711|NCT02014662|Other|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
199712|NCT02014675|Device|SD01 ICD lead|
200002|NCT00119821|Behavioral|Smoking Cessation|Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.
NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant.
200003|NCT02006628|Drug|GWP42003|Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.
200004|NCT02008916|Drug|Secukinumab|Eligible patients are randomised to each of the three treatment arms in a 1:1:1 ratio.
200005|NCT02008916|Drug|Secukinumab|Eligible patients are randomised to each of the three treatment arms in a 1:1:1 ratio.
200006|NCT02008916|Drug|Placebo secukinumab|Eligible patients are randomised to each of the three treatment arms in a 1:1:1 ratio.
200007|NCT00120068|Procedure|Academic detailing to MDs; concurrent review and feedback|
200008|NCT02008929|Biological|MG4101|Ex vivo expanded allogeneic NK cell
200009|NCT02008942|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
199062|NCT02024737|Other|MRI lung imaging (not an intervention per se but the focus of the study)|The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).
This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD.
199063|NCT02027324|Drug|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
199064|NCT02027337|Drug|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
199065|NCT02027337|Drug|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
199066|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
199067|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
199068|NCT00121810|Drug|Corticosteroids|As prescribed
199069|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
199070|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
199071|NCT02027350|Device|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
199072|NCT02027363|Drug|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
199073|NCT02027363|Other|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
199377|NCT02019706|Drug|Ga-DOTATATE|
199378|NCT02019706|Drug|Octreoscan|
199379|NCT02019706|Other|CT, MRI|
199380|NCT02019719|Drug|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
199381|NCT02019719|Drug|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
198789|NCT02075580|Behavioral|psychological support (interactive/cognitive strategies)|cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)
metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)
psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)
questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)
198790|NCT02075593|Drug|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
198791|NCT02075606|Drug|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
198792|NCT02075619|Drug|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
198793|NCT02075619|Drug|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
198794|NCT02075619|Drug|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
198795|NCT02075632|Drug|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
198796|NCT02075645|Other|Team training course|A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the "pre-course" team performance and simulation #4 will be the "post-course" performance.
198797|NCT00126659|Drug|sorafenib tosylate|Given orally
198798|NCT02075658|Device|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
198799|NCT02037360|Behavioral|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
198800|NCT02037373|Biological|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
198801|NCT02037373|Biological|Plasma|Plasma as prescribed by the treating physician.
198802|NCT02037386|Device|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
198803|NCT00122889|Drug|Garlic powder with low allicin content|
199074|NCT02027376|Drug|LDE225|
199075|NCT02027376|Drug|Docetaxel|
203227|NCT02005432|Drug|panfotocoagulation (PRP) single shoot (ETDRS)|
203228|NCT02005445|Device|CPAP|Continuous positive airway pressure
203229|NCT02005445|Behavioral|HLSE|Healthy living and sleep education
203230|NCT02005458|Drug|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
203231|NCT02005458|Drug|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
203232|NCT02007928|Other|Rispéridone, aripiprazole, olanzapine|Study:
We propose a prospective, interventional multicenter study.
Method:
Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.
The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug.
203233|NCT02007941|Drug|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
203527|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
203528|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
203529|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
203530|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
203531|NCT01999985|Drug|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
203532|NCT01999985|Drug|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
203533|NCT01999985|Drug|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
203534|NCT01999985|Drug|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
203535|NCT01999998|Radiation|Radiotherapy|
203536|NCT02000011|Other|comprehensive geriatric assessment (CGA)|
203537|NCT00119340|Drug|fludarabine phosphate|
203538|NCT02000011|Other|Geriatric intervention plan (GIP)|
202915|NCT02013388|Drug|N91115|Given PO only on Day 1
202916|NCT02013388|Drug|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
202917|NCT02013414|Procedure|PET/Ultrasound Fusion Targeted Biopsy of the Prostate|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
202918|NCT02013427|Drug|Naproxen|Take one 500mg naproxen capsule twice a day.
202919|NCT02013427|Drug|Placebo|Take one placebo capsule twice a day.
202920|NCT02013427|Drug|Omeprazole|Take one 40mg omeprazole capsule twice a day.
202921|NCT02013453|Drug|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
202922|NCT02016157|Drug|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
202923|NCT00002171|Drug|Nelfinavir mesylate|
202924|NCT00120861|Drug|pegylated interferon|
202925|NCT02016170|Drug|Ticagrelor 180mg|After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:
A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.
B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days
203234|NCT02007954|Device|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
203235|NCT02007993|Other|PDT|A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.
Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5
203236|NCT02007993|Other|Tongue Scraper|The pacient will scrap the tongue 10 times.
203237|NCT02008006|Drug|BeEAM|High Dose Chemotherapy (HDT) containing :
Bendamustine 200 mg/m2 for 2 days (D-8 and D-7)
Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)
Melphalan 140 mg/m2 on D-2
HDT will be followed by an Autologous Stem Cell Transplantation on D0
203238|NCT00119951|Behavioral|Participation on the ACOR Listserv|
202613|NCT02021149|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
202614|NCT02021149|Behavioral|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
202615|NCT02021149|Other|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
202616|NCT02021149|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
202617|NCT02021175|Behavioral|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
202618|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
202619|NCT02021201|Drug|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
202620|NCT02021201|Drug|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
202621|NCT00121277|Drug|capecitabine|
202622|NCT02021214|Drug|Methylphenidate|
202623|NCT02021214|Drug|Placebo|
202624|NCT02021227|Procedure|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for > 1 hour
202625|NCT02021240|Drug|Ketamine|
202626|NCT02021240|Drug|Dexamethasone|
202627|NCT02021240|Drug|Normal Saline|
202628|NCT02021253|Dietary Supplement|Probiotic|Lactibiane TOLERANCE vs Placebo
202926|NCT02016170|Drug|Prasugrel 10mg|After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:
A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.
B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days
202033|NCT02033889|Drug|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
202310|NCT02026206|Device|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
202311|NCT02026206|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
202312|NCT02026219|Drug|Clopidogrel|Clopidogrel 600mg loading
202313|NCT02026219|Drug|Ticagrelor|Ticagrelor 180mg loading
202314|NCT02026232|Drug|Hydroxychloroquine|200mg twice daily
202315|NCT02026232|Other|Hydroxychloroquine Placebo|200mg placebo twice daily
202316|NCT02028754|Drug|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
202317|NCT02028754|Drug|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
202318|NCT02028767|Drug|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
202319|NCT02028767|Drug|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
202320|NCT00121966|Drug|Insulin NPH|
202321|NCT02028767|Drug|Metformin 500 mg|Metformin 500 mg tablet
202322|NCT02028767|Drug|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
202323|NCT02028780|Drug|Placebo to dose|placebo
202324|NCT02028780|Drug|Idarucizumab|short infusion
202325|NCT02028780|Drug|Placebo to Idarucizumab|Placebo to Idarucizumab
202326|NCT02028780|Drug|dabigatran|2 capsules dabigatran
202327|NCT02028780|Drug|Idarucizumab|short infusion
226845|NCT02181140|Device|EUS guided FNA and fine needle punction|punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
226846|NCT02181153|Other|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
226847|NCT02181166|Other|Kinesiotherapy|
226848|NCT02181166|Other|Isquemic compression|
226849|NCT02181166|Other|High voltage electrical stimulation|
226850|NCT02183571|Drug|BMS Glucophage® high dose|Part I: Treatment B
226851|NCT02183571|Drug|Merck Glucophage® low dose|Part II: Treatment C
226852|NCT02183571|Drug|BMS Glucophage® low dose|Part II: Treatment D
226853|NCT02183584|Drug|Rifampicin|
226854|NCT02183584|Drug|Linagliptin|
226855|NCT02183610|Drug|[14C] BI 1356 as oral (p.o.) solution|
226856|NCT02183610|Drug|[14C] BI 1356 solution for i.v. infusion|
226857|NCT02183623|Drug|Simvastatin|
227160|NCT02175953|Behavioral|Psychotherapy|The program is designed for 10 participants and consists of two modules of caregiver education followed by ten psychotherapeutic group modules. The major overarching topics will be (i) caregiver´s emotional and physical limits, (ii) conscious and unconscious feelings and emotions towards the people with dementia and (iii) activation of caregivers´ social resources. Duration of each module is planned to be 90 minutes including a relaxation exercise at the end of each module.
227161|NCT02175966|Drug|DCV/ASV/BMS-791325|
227162|NCT02175966|Drug|Ribavirin|
227163|NCT02175966|Drug|Sofosbuvir|
227164|NCT02175966|Drug|Peginterferon α-2a|
227165|NCT02175979|Dietary Supplement|enriched enteral nutrition|enriched enteral tube feeding perioperative
227166|NCT02175979|Dietary Supplement|standard|standard of care
227167|NCT02176005|Device|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
227168|NCT02176005|Drug|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
226560|NCT02188667|Other|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
226561|NCT02190838|Drug|Metformin|per os 850 mg BID
226562|NCT02190838|Drug|Melatonin|per os 3 mg daily
226563|NCT02190838|Drug|Dacarbazine|IV 1 hour 1000 mg/m^2 once in 28 days
226564|NCT02190851|Device|TENS|Two electrodes are attached around the internal malleolus and connected to the TENS unit.
The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months.
226565|NCT02190851|Device|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
226566|NCT02190890|Procedure|Dry needling|
226567|NCT02190890|Procedure|Placebo|
226568|NCT02190903|Other|General endotracheal anesthesia|General Anesthesia
Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol.
226858|NCT02183623|Drug|10 mg BI 1356 BS|
226859|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
226860|NCT00137813|Drug|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
226861|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
226862|NCT02183636|Drug|Linagliptin tablet|5 mg
226863|NCT02183636|Drug|pioglitazone tablet (Actos®)|45 mg
226864|NCT02183649|Drug|pentoxyverine citrate|
226865|NCT02183649|Drug|Placebo|
226866|NCT02183662|Drug|BI 224436|
226867|NCT02183662|Drug|Placebo to BI 224436|
226868|NCT02183675|Drug|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
226255|NCT02196012|Behavioral|Intervention group|
226256|NCT02196012|Behavioral|attention control condition|
226257|NCT00139243|Drug|Leucovorin|
226258|NCT02196025|Device|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
226259|NCT02196038|Behavioral|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
226260|NCT02196038|Behavioral|Attention Control|Usual care with bi-weekly contact from study staff
226261|NCT02196051|Other|Exercise Training|Six weeks of exercise
226262|NCT02196077|Drug|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 1|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 1; PT009 administered as 2 inhalations, twice daily (BID)
226263|NCT02196077|Drug|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 2|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 2; PT009 administered as 2 inhalations, twice daily (BID)
226264|NCT02196077|Drug|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 3|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 3; PT009 administered as 2 inhalations, twice daily (BID)
226265|NCT02196077|Drug|Budesonide metered dose inhaler (BD MDI)|Budesonide metered dose inhaler (BD MDI); PT008 administered as 2 inhalations, twice daily (BID)
226266|NCT02196077|Drug|Formoterol fumarate metered dose inhaler (FF MDI)|Formoterol fumarate metered dose inhaler (FF MDI); PT005 administered as 2 inhalations, twice daily (BID)
226267|NCT02157350|Procedure|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
226268|NCT02157363|Procedure|Repositioning|
226269|NCT02157363|Procedure|Single positioning|
226270|NCT02157376|Drug|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
226271|NCT00000125|Drug|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
226272|NCT00000326|Drug|Heroin Dependence|
226273|NCT00002262|Drug|Tumor Necrosis Factor|
226274|NCT00134719|Biological|Varivax®|One subcutaneous dose at 12 to 15 months of age
225622|NCT02175251|Procedure|Sham Comparator|10 session in 5 days with sham-controlled
225623|NCT02175264|Genetic|Blood sample|
225624|NCT02175277|Drug|Darbepoetin Alfa|Darbepoetin Alfa will be given at 500 μg three-times per week/two-times per week. The first dose and dosing frequency on day 1 / week 1 should carry forward from the last dose and frequency from the parent study (darbepoetin alfa MDS 20090160 study) administered at week 70 / 71. The day 1 / week 1 visit should align within +10 days of the End of Active Treatment Period (EOATP) visit at week 72 / 73 from the darbepoetin alfa MDS 20090160 study. The investigator may choose to increase the dose of darbepoetin alfa with the maximum dose permitted of 500 μg two-times per week. Dose increases should follow a step-wise approach, (eg, 300 μg to 500 μg; 200 μg to 300 μg) with at least 8 weeks at a given dose before the dose may be increased.
225625|NCT02175303|Biological|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals.
225626|NCT02175316|Device|Enhanced External Counterpulsation|Enhanced External Counterpulsation
225627|NCT00136786|Drug|Memantine|
225936|NCT02165202|Drug|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
225937|NCT02165202|Drug|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
225938|NCT00000327|Drug|Heroin Dependence|
225939|NCT00002270|Drug|Interferon alfa-2b|
225940|NCT00135642|Biological|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
225941|NCT02165215|Drug|Etrolizumab|105 mg will be administered by subcutaneous injection every 4 weeks (q4w).
225942|NCT02165215|Drug|Placebo|Given by subcutaneous injection every 4 weeks (q4w).
225943|NCT02165228|Behavioral|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
225944|NCT02165228|Behavioral|Nutrition Enhancement|Nutrition education class and behavioral intervention
225945|NCT02165254|Behavioral|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
225946|NCT02165254|Behavioral|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
225314|NCT02185456|Drug|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
225315|NCT02185456|Drug|Standard of care|oral metronidazole 500 mg twice a day for 7 days
225316|NCT02185469|Procedure|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
225317|NCT02185469|Procedure|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
225318|NCT02185469|Drug|sulfur hexafluoride (SF6)|
225319|NCT02185469|Device|5/8-in 25-gauge needle|
225320|NCT02185469|Device|laser|intraoperative laser retinopexy
225321|NCT02185482|Behavioral|Physician Supported Care|
225322|NCT02185482|Other|Usual care|
225628|NCT02175329|Device|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
225629|NCT02175329|Device|Manually layered veneering|
225630|NCT02175342|Drug|Tiotropium 0.625 mcg/puff|
225631|NCT02175342|Drug|Tiotropium 1.25 mcg/puff|
225632|NCT02175342|Drug|Tiotropium 2.5 mcg/puff|
225633|NCT02175342|Drug|Tiotropium 5 mcg/puff|
225634|NCT02175342|Drug|Placebo solution|
225635|NCT02175342|Drug|Tiotropium-18 lactose powder|
225636|NCT02175342|Drug|Placebo lactose powder|
225637|NCT02175342|Drug|Tiotropium 10 mcg/puff|
225638|NCT00136799|Drug|Fluvastatin|
225639|NCT02175342|Device|Respimat|
202162|NCT02005003|Behavioral|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
202163|NCT02007512|Drug|exemestane|50 mg capsule administered as a single capsule by mouth once daily after food.
202164|NCT02007525|Behavioral|Yoga intervention|Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
202165|NCT02007551|Behavioral|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
202166|NCT02007564|Behavioral|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
202167|NCT02007577|Drug|salsalate|
202168|NCT02007577|Drug|Placebo|
202169|NCT00119925|Behavioral|patient education|patient leaflets about national guideline contents
202170|NCT02007590|Device|Aerosure 25 Hz|Active Aerosure device
202459|NCT01999595|Device|Large pads|5cm x10cm each
202460|NCT01999595|Device|small pads|2.5cm x2.5cm each
202461|NCT01999634|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
202462|NCT02002156|Biological|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
202463|NCT02002156|Biological|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
202464|NCT02002156|Biological|NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
202465|NCT02002169|Other|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
202466|NCT00119470|Procedure|EUS-FNA|
201865|NCT02012829|Behavioral|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
201866|NCT02012842|Other|Non surgical periodontal treatment|Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
201867|NCT00002168|Drug|Zidovudine|
201868|NCT00120510|Drug|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
201869|NCT02012855|Behavioral|Exercise|
201870|NCT02012855|Other|Diet (meal type)|
201871|NCT02012868|Procedure|bariatric surgery|
201872|NCT02012881|Behavioral|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
201873|NCT02012881|Behavioral|Usual practice|Normal curriculum
201874|NCT02012920|Drug|VT-464: given orally once daily in 28 day cycles|
201875|NCT02012933|Drug|3,4-diaminopyridine|10mg tablets for up to 100mg per day
201876|NCT02012946|Drug|Levosimendan|patient receiving levosimendan
201877|NCT02012946|Drug|Dobutamine|patient receiving dobutamine
201878|NCT02012959|Drug|Tolvaptan|SAMSCA®
201879|NCT00120510|Drug|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
201880|NCT02015689|Behavioral|CDC VIS|CDC Vaccine Information Statement (VIS)
201881|NCT02015702|Other|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
201882|NCT02015702|Other|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
201273|NCT02028247|Behavioral|Standard Practice Cognitive-behavioral therapy|
201274|NCT02028260|Drug|Modafinil|
201275|NCT02028286|Drug|CLS001|
201276|NCT02028299|Procedure|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
201277|NCT02028312|Drug|Loteprednol etabonate|
201278|NCT02028312|Drug|Artificial Tears|
201279|NCT02028312|Drug|Restasis|
201280|NCT00121901|Drug|glyceryl nitrate|
201574|NCT02020720|Other|Laboratory Biomarker Analysis|Correlative studies
201575|NCT02020720|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
201576|NCT02020720|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
201577|NCT02020720|Procedure|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
201578|NCT00121251|Drug|Sorafenib Tosylate|Given PO
201579|NCT02020733|Device|Balloon catheter|
201580|NCT02020733|Device|metal cannula|
201581|NCT02020746|Drug|EscharEx|
201582|NCT02020746|Drug|Gel Vehicle|
201583|NCT02020759|Device|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral embolism Near-Infrared Spectroscopy is used to detect cerebral hypoperfusion
201584|NCT02020772|Other|coordinating primary health care|
201585|NCT02020772|Other|usual primary health care|
201586|NCT02020785|Behavioral|Dietary Education on Phosphorus Additives|All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives
201587|NCT02020785|Other|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks
201588|NCT02020785|Other|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks
200609|NCT01996228|Device|Stem Cell Educator|
200610|NCT01996241|Behavioral|Educational enhancement intervention|Receive educational enhancement intervention
200611|NCT00119015|Drug|Placebo|
200612|NCT01996254|Device|Smartpatch Peripheral Nerve Stimulation (PNS) System|The Smartpatch System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The Smartpatch System includes a small wire (called a "Lead") that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).
200613|NCT01996267|Drug|PTC+Pertuzumab|Cycle repeated every 21 days
200614|NCT01996267|Drug|FEC-T+Pertuzumab|Cycle is repeated every 21 days
200615|NCT01996280|Behavioral|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
200927|NCT02030691|Device|Nasal high frequency percussive ventilation (nHFPV)|
200928|NCT02030717|Drug|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
200929|NCT02030717|Drug|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
200930|NCT02030730|Behavioral|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
200931|NCT02030743|Other|Visual training|6 training sessions with computerised visual attention paradigm
200932|NCT02030756|Device|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
200933|NCT02030756|Device|sham vibrating capsule|patients will receive sham vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
200934|NCT00122551|Procedure|Intermittent antiretroviral therapy|
200935|NCT02033330|Dietary Supplement|phenolics form orange peel|
200936|NCT02033343|Radiation|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
200937|NCT02033356|Procedure|Adductor canal block with lidocaine 1%|US-guided adductor canal block
200938|NCT02033356|Drug|Lidocaine|
200010|NCT02008942|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
200011|NCT02008955|Dietary Supplement|Lysine intake provided as a milkshake|
200012|NCT02008968|Drug|allopurinol 300 mg./day|
200013|NCT02008968|Other|No intervention|
200014|NCT02008968|Drug|Normouricemic|
200015|NCT02008981|Drug|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
200016|NCT02008981|Drug|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
200017|NCT02008981|Drug|Siwu Tang|TCM formulation "Siwu Tang" consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
200018|NCT00120081|Biological|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
200019|NCT02008981|Drug|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
200020|NCT02008994|Other|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
200313|NCT02001220|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
200314|NCT00119392|Drug|cyclosporine|Given orally
200315|NCT02001233|Biological|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
200316|NCT00119600|Drug|AMG 114|
200317|NCT02003911|Drug|Azithromycin|Azithromycin suspension (200mg/5mL)
200318|NCT02003911|Drug|Placebo|
200319|NCT02003924|Drug|Enzalutamide|160 mg by mouth once daily
199382|NCT02019732|Other|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
199383|NCT02019745|Biological|LAIV|Standard dose of LAIV administered by a licensed health care providers.
199384|NCT02019758|Drug|Oral Viscous Budesonide|Oral Viscous Budesonide - 1mg/4mL, 4mL of slurry twice daily
199385|NCT02019758|Drug|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
199386|NCT02022163|Biological|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
199387|NCT02022163|Biological|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
199388|NCT02022163|Biological|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
199389|NCT02022163|Biological|Placebo|Placebo, 2 doses given 21 days apart
199390|NCT02022176|Other|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
199391|NCT02022176|Other|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
199392|NCT02022176|Other|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
199393|NCT02022189|Procedure|Renal Biopsy|
199394|NCT02022215|Drug|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
199395|NCT02022215|Drug|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
199396|NCT00121355|Device|autocover needle|
199397|NCT02022215|Drug|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
199398|NCT02022228|Drug|triptorelin|0.2 mg triptorelin, ih
199399|NCT02022228|Drug|hCG|1000 IU hCG, im
199400|NCT02022228|Drug|hCG|500IU hCG, im
199713|NCT02014701|Procedure|Echocardiogram|Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.
Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software.
199076|NCT02027402|Procedure|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
199077|NCT02027415|Dietary Supplement|Beet juice|2 cups of beet juice will be given before the car ride
199078|NCT02027415|Dietary Supplement|Orange juice|2 cups of orange juice will be given before the car ride
199079|NCT00121810|Drug|Calcineurin inhibitors|As prescribed
199080|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
199081|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
199082|NCT02027428|Drug|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
199083|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
199084|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
199085|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
199086|NCT02029742|Behavioral|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
199087|NCT02029742|Behavioral|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
199088|NCT02029755|Procedure|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
199089|NCT02029755|Procedure|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
199090|NCT02029755|Procedure|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
199091|NCT02029781|Procedure|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
199092|NCT00002179|Drug|Indinavir sulfate|
203539|NCT02002741|Drug|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
203540|NCT02002741|Drug|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
203541|NCT00119496|Drug|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
203542|NCT02002754|Drug|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
203543|NCT02002767|Drug|GS-5816|GS-5816 100 mg (2 x 50 mg tablets) administered orally
203544|NCT02002780|Behavioral|Day Camp|The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the "camp" activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project.
203545|NCT02002793|Other|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
198804|NCT02037399|Drug|intravenous dexamethasone|Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.
At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
198805|NCT02037399|Drug|intravenous normal saline|Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.
At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
198806|NCT02037412|Drug|Ticagrelor|Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
198807|NCT02037412|Drug|Clopidogrel|Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
198808|NCT02037425|Drug|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
198809|NCT02037438|Other|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention will utilize standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
203239|NCT02008019|Drug|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
203240|NCT02008019|Drug|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
203241|NCT02008032|Device|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
203242|NCT02008045|Procedure|Imaging|
203243|NCT02008045|Device|MRI|
203244|NCT02008058|Behavioral|Telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
203245|NCT02008071|Behavioral|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
203246|NCT02008071|Behavioral|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
203247|NCT02010463|Other|Exercise|
203248|NCT00120302|Drug|Pimecrolimus|Pimecrolimus cream 1 %
203546|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
203547|NCT02002806|Other|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
203548|NCT02002806|Other|Placebo Injection|
203549|NCT02002819|Drug|levetiracetam|
203550|NCT02002832|Drug|Lurasidone tablets|40 or 80mg, dose escalation
203551|NCT02002832|Drug|Risperidone tablets|2-6 mg, dose escalation
203552|NCT00000124|Procedure|Brachytherapy|
202927|NCT02016170|Drug|Ticagrelor 90mg|After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:
A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.
B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days
202928|NCT02016183|Drug|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
202929|NCT02016196|Drug|Rifaximin|6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS
202930|NCT02016196|Drug|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
202931|NCT02016209|Drug|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
202932|NCT02016222|Procedure|tears sampling|
202933|NCT02016235|Drug|Phosphorus Supplement|250 mg po qid
202934|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
202935|NCT00120861|Drug|ribavirin|
202936|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
202937|NCT02016261|Drug|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
202938|NCT02016274|Other|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
202939|NCT02016287|Other|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
202940|NCT02016300|Device|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
202941|NCT02016300|Device|Non-Bracing|Microfracture performed with no post-operative unloader bracing
202942|NCT02018783|Procedure|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
202943|NCT02018783|Procedure|Cocorico|Digital application for 60 seconds
202328|NCT02028806|Drug|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
202329|NCT02028819|Drug|Dolutegravir|Dolutegravir taken 50mg orally twice daily
202330|NCT02028819|Drug|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
202331|NCT00121966|Drug|Metformin|
202629|NCT02021253|Dietary Supplement|Placebo|
202630|NCT02021266|Biological|Enriched Hematopoetic Stem Cell Transplant|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
202631|NCT02021279|Device|MatriStem Pelvic Floor Matrix|
202632|NCT00121277|Drug|vorinostat|
202633|NCT02021279|Procedure|native tissue repair|
202634|NCT02023632|Behavioral|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
202635|NCT02023632|Behavioral|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
202636|NCT02023645|Dietary Supplement|active supplement|tablet
202637|NCT02023645|Other|placebo|tablet
202638|NCT02023658|Other|pMTCT systems analysis and improvement|Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
202639|NCT00121524|Device|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
202640|NCT02023684|Drug|control saline|Surgical bed irrigation with saline 40ml
202641|NCT02023684|Drug|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
202642|NCT02023684|Drug|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
227169|NCT02176005|Other|Negative Control|Moxifloxacin is used alone
227170|NCT00136890|Procedure|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
227171|NCT02176018|Drug|Dextromethorphan and quinidine|
227172|NCT02176018|Drug|Placebo|
227173|NCT02176031|Drug|Natalizumab|
227174|NCT02176031|Drug|Methylprednisolone|
227175|NCT02176044|Drug|Sodium Nitroprusside infusion|
227176|NCT02176044|Other|Placebo|
227177|NCT02176057|Drug|Azithromycin|
227178|NCT02176083|Behavioral|Text message management prompts|
227179|NCT02176096|Dietary Supplement|Glycosade|
227180|NCT02176122|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
227181|NCT00136903|Drug|Prochymal - 2 million cells|2 million cells/kg actual body weight, intravenously on study Days 1 and 4
227182|NCT02176122|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
227183|NCT02176135|Drug|Auranofin|3 mg tablets
227184|NCT02176148|Drug|fluocinonide 0.05% cream|
227495|NCT02170532|Other|levalbuterol MDI|
227496|NCT02170532|Device|breath actuated nebulizer|
227497|NCT02170532|Device|aerochamber max|
227498|NCT02170532|Drug|ipratroprium|
227499|NCT02170545|Other|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
227500|NCT02170558|Device|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
227501|NCT02170571|Drug|Dabigatran etexilate|
227502|NCT02170584|Drug|BIBR 953 ZW IV|
226869|NCT02183675|Drug|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
226870|NCT02183675|Drug|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
226871|NCT00137826|Drug|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
226872|NCT02183688|Drug|Low dose ASA|
226873|NCT02183688|Drug|High dose ASA|
226874|NCT02183688|Drug|Low dose paracetamol|
226875|NCT02183688|Drug|High dose paracetamol|
226876|NCT02183688|Drug|Caffeine|
226877|NCT02183688|Drug|Placebo|
226878|NCT02183701|Drug|Telmisartan|
226879|NCT02183701|Drug|Losartan + Hydrochlorothiazide|
226880|NCT02183701|Drug|Placebo|
226881|NCT02183714|Drug|Songha Night ®|
226882|NCT02186002|Drug|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
226883|NCT02186002|Drug|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
226884|NCT02186002|Drug|Placebo|
227185|NCT02178319|Procedure|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
227186|NCT02178332|Other|Yhteispeli, whole school programme|
227187|NCT02178332|Other|Two theoretical lectures|
227188|NCT02178345|Procedure|diffusion weighted (DW) MRI|
227189|NCT02178345|Procedure|dynamic contrast agent (DCE) MRI|
227190|NCT02178358|Drug|LY2157299|Administered orally
227191|NCT02178358|Drug|Sorafenib|Administered orally
227192|NCT02178358|Drug|Placebo|Administered orally
226569|NCT02190903|Other|Regional (spinal) Anesthesia|Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed. Propofol dose will be titrated to achieve light to moderate sedation, defined as a Richmond Agitation/Sedation Scale (RASS) score of -1 to -318. In the event of block failure induction and maintenance of general endotracheal anesthesia will occur via the procedures outlined above. For all patients, post-operative pain management will be via hydromorphone PCA or PRN hydromorphone bolus, followed by oral oxycodone and acetaminophen.
226570|NCT00138632|Drug|PTK787|Visudyne® + PTK787, 500 mg/day
226571|NCT02190968|Behavioral|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
226572|NCT02190968|Behavioral|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
226573|NCT02190981|Device|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
226574|NCT02190994|Drug|Hydrocortisone|used intravenously
226575|NCT02190994|Drug|Prednisone|used as tablet form
226576|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
226577|NCT02191007|Drug|Calcipotriol Betamethasone ointment|
226578|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Urea Cream|
226579|NCT02191020|Drug|Total glucosides of paeony & Acitretin Capsules|
226580|NCT02191020|Drug|Acitretin Capsules|
226581|NCT02193594|Radiation|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
226582|NCT00138970|Drug|Sandimmun Neoral®, CellCept® and prednisolone|
226583|NCT02193594|Procedure|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
225947|NCT02165267|Biological|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
225948|NCT00135902|Drug|17 alpha-Hydroxyprogesterone Caproate and Omega-3 fish oils|
225949|NCT02167698|Drug|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
225950|NCT02167698|Other|Restrictive fluid therapy|Fluid & hemodynamics would be titrated as per pre-designed decision-making protocols
225951|NCT02167698|Drug|sedo-analgesia titration|
225952|NCT02167698|Other|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
225953|NCT02167698|Other|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care & bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
225954|NCT02167698|Other|Biomarker Assay|Biomarker Assay for patients in both arms
225955|NCT02167711|Drug|SIRT Yttrium-90|
225956|NCT02167724|Other|Bucco-dental examination|
226275|NCT02157376|Drug|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
226276|NCT02157389|Other|Administration of a pharmacological placebo|
226277|NCT02157402|Behavioral|Social marketing activities and pop-up events to promote healthy lifestyles|
226278|NCT02157415|Device|Uro-Tainer Polihexanide 0.02%|Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
226279|NCT02157428|Drug|Flumazenil|
226280|NCT02157428|Drug|saline|
226281|NCT02157441|Procedure|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
226282|NCT02157454|Other|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
226283|NCT02157467|Drug|BMS-955176|
226284|NCT02157467|Drug|Ortho Cyclen|
225640|NCT02175342|Device|Handihaler|
225641|NCT02175355|Drug|Low dose of Micardis®|
225642|NCT02175355|Drug|Medium dose of Micardis®|
225643|NCT02175355|Drug|High dose of Micardis®|
225644|NCT02175355|Drug|Hydrochlorothiazide|
225645|NCT02175355|Drug|Placebo|
225646|NCT02175368|Device|Adhese One F Upgrade|
225647|NCT02177682|Drug|Bortezomib|Vial containing 3 mg of bortezomib to be administered IV or subcutaneous
225648|NCT02177682|Drug|Dexamethasone|Tablet containing 4 mg of dexamethasone to be administered orally.
225649|NCT02177695|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
225650|NCT02177695|Drug|Cisplatin|Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).
Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
225651|NCT02177695|Drug|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
225652|NCT02177695|Drug|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
225957|NCT02167724|Other|Blood sample|
225958|NCT02167724|Other|Clinical and social questionnaire|
225959|NCT00002272|Drug|Foscarnet sodium|
225960|NCT00135928|Drug|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
225961|NCT02167737|Behavioral|Bedside Decision Aid|The "intervention"--or Bedside Decision Aid group--will have an initial Falls Efficacy Scale (FES) and Vulnerable Elders Survey (VES) screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using a worksheet called the "Bedside Decision form." A study team member will explain to the participant what they can do to decrease their risk of falling and discuss what mobility goals are the most important to them.
Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history.
202467|NCT02002169|Other|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
202468|NCT02002182|Biological|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
202469|NCT02002195|Drug|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
202470|NCT02002195|Drug|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
202471|NCT02002208|Drug|OC000459|
202472|NCT02002221|Drug|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
202473|NCT02002221|Drug|Placebo|Matching placebo of vildagliptin 50 mg twice daily
202474|NCT02002221|Drug|Insulin|Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.
The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion.
202475|NCT02002221|Drug|Metformin|Patients continued their prescribed metformin dose, if applicable.
202476|NCT02002234|Procedure|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
202763|NCT01996995|Device|Sham procedure|Sham procedure
202764|NCT01997008|Behavioral|Intervention|Positive Affect Skills Training
202765|NCT01997021|Other|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
202766|NCT01997021|Other|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
202767|NCT01997021|Other|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
202768|NCT01997034|Behavioral|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
202769|NCT00119106|Device|Tenofovir|
201883|NCT02015715|Drug|RO6864018|Single ascending oral doses.
202171|NCT02007590|Device|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
202172|NCT02007603|Drug|Administration of Amoxicillin / clavulanic acid|Patients receive amoxicillin / clavulanic acid due to clinical necessity
202173|NCT02007603|Drug|Ampicillin / sulbactam|Patients receive ampicillin / sulbactam due to clinical necessity
202174|NCT02007603|Procedure|Blooddraws for pharmacokinetic profiling|Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
202175|NCT02007616|Other|Non-action video game training|Based on cognitive training Lumosity
202176|NCT02007629|Drug|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
202177|NCT02007642|Procedure|Blood sampling / Body fluid sampling|During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.
Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite...
202178|NCT02007655|Drug|Eliquis|
202179|NCT02007668|Other|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
202180|NCT00119925|Behavioral|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
202181|NCT02007681|Behavioral|Reduction of sedentary time by breaking it with low intensity physical activity|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
202182|NCT02007694|Behavioral|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
202183|NCT02009956|Device|Subjects receiving DESyne Novolimus Eluting CSS - Arm A|
202184|NCT02009956|Device|Subjects receiving DESyne BD Novolimus Eluting CSS - Arm B|
202185|NCT02009982|Procedure|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
202186|NCT02009982|Device|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
201589|NCT00121264|Drug|sorafenib tosylate|Given orally
201590|NCT02020798|Other|Dietary Intervention|
201591|NCT02020811|Device|Sentinel|
201592|NCT02020824|Behavioral|Exposure to anxiogenous environments|The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms "Exposure to anxiogenous environments (with or without control)".
201593|NCT02023216|Device|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
201594|NCT02023229|Dietary Supplement|Branched-chain aminoacids|
201884|NCT02015728|Device|Tumor biology testing|Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the "best available" combination of low-dose oral cytotoxic agents, including temozolomide and etoposide.
201885|NCT00120809|Drug|Sulfadoxine-pyrimethamine|
201886|NCT02015728|Drug|Temozolomide|Temozolomide combined with Etoposide is considered the "best available" combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
201887|NCT02015728|Drug|Etoposide|Etoposide combined with Temozolomide is considered the "best available" combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
201888|NCT02015728|Drug|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
201889|NCT02015728|Drug|Everolimus|Everolimus is an mTOR pathway inhibitor.
201890|NCT02015728|Drug|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
201891|NCT02015728|Drug|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
201892|NCT02015741|Device|EEG monitoring with Bispectral Index and NeuroSENSE|
201893|NCT02015741|Behavioral|Clinical observation|Patients will be observed during awake periods and during natural sleep.
200939|NCT02033369|Drug|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day
200940|NCT02033408|Drug|AB (antibiotics)|PO Vancomycin 250mgX4/d for 3 weeks
PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks
PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks
Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.
200941|NCT02033408|Drug|CS (corticosteroids) Only|methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)
PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks
200942|NCT02033434|Drug|Intranasal Ketamine|Atomized Intranasal Ketamine, 50mg
200943|NCT02033447|Other|Magnetic Nanoparticle Injection|
200944|NCT02033460|Other|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
200945|NCT00122564|Biological|HIV-1 gp 160|
201281|NCT02028325|Drug|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
201282|NCT02028338|Device|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
201283|NCT02028338|Drug|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
201284|NCT02028364|Drug|Everolimus|10mg orally daily
201285|NCT02028364|Drug|Exemestane|25mg orally daily
201286|NCT02028377|Procedure|PET/MRI|PET/MRI
201287|NCT02028390|Device|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
201288|NCT02028390|Device|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
201289|NCT02028390|Device|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
201290|NCT02028390|Device|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
200320|NCT02003924|Drug|Placebo|Sugar pill to mimic enzalutamide
200321|NCT02003937|Behavioral|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
200322|NCT02003950|Other|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
200323|NCT02003963|Behavioral|Klub Kinect|The Microsoft Kinect gaming console and Dance Central and Just Dance game series are commercially available, off-the-shelf, products. Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.
The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention.
200324|NCT02003976|Procedure|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
200325|NCT02003976|Other|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
200326|NCT02003989|Other|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
200327|NCT00119613|Drug|placebo|placebo
200328|NCT02004002|Behavioral|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
200616|NCT01996280|Behavioral|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
200617|NCT01996293|Drug|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
200618|NCT01996306|Biological|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
200619|NCT01996306|Drug|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
200620|NCT01996306|Drug|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
199714|NCT02014714|Drug|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
199715|NCT02014714|Drug|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
199716|NCT02014727|Biological|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
199717|NCT00120718|Drug|fasudil|
199718|NCT02014727|Biological|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
199719|NCT02014727|Biological|Group B2 : Placebo|
199720|NCT02017405|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
199721|NCT02017405|Other|Matching Placebo|
199722|NCT02017418|Dietary Supplement|zeaxanthin|softgel
199723|NCT02017418|Dietary Supplement|combinatory supplement|softgel
199724|NCT00121004|Behavioral|Advance Directive Selection|
199725|NCT02017431|Other|Allergen|Subject specific allergen is inhaled on day 1 of the triad
199726|NCT02017431|Other|Saline|Saline is inhaled on day 1 of the triad
199727|NCT02017431|Other|Particle depleted diesel exhaust|High-efficiency particulate filtration of diesel exhaust
199728|NCT02017444|Drug|AZD4017|
199729|NCT02017444|Other|Placebo|Matched placebo (matched to AZD4017 arm)
199730|NCT02017457|Biological|Donor lymphocyte infusion|On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .
Patients with a sibling donor will receive:
5x10exp7 CD3+/kg on day 1 of cycle 2
5x10exp7 CD3+/kg on day 1 of cycle 4
10x10exp7 CD3+/kg on day 1 of cycle 6
Patients with an unrelated donor will receive:
1x10exp7 CD3+/kg on day 1 of cycle 2
5x10exp7 CD3+/kg on day 1 of cycle 4
10x10exp7 CD3+/kg on day 1 of cycle 6
200021|NCT02009007|Drug|dopamine|continuous infusion during operation
200022|NCT02009007|Drug|phenylephrine|continuous infusion of phenylephrine during operation
199401|NCT02022241|Drug|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
199402|NCT02022254|Drug|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
199403|NCT02022254|Drug|placebo|Semaglutide placebo will be administered s.c.
199404|NCT02022254|Drug|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
199405|NCT02022254|Drug|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
199406|NCT02022280|Drug|Lansoprazole|
199407|NCT00121381|Drug|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
199408|NCT02022293|Drug|Atorvastatin|Patients in this group will take 20mg per night.
199409|NCT02022293|Other|Placebo|
199410|NCT02022306|Drug|TD-6450|
199411|NCT02022306|Drug|Placebo|
199412|NCT02022319|Device|Ultrasonographic Shear Wave Elastography|
199413|NCT02022345|Procedure|Percutaneous Coronary Intervention|
199414|NCT02024750|Behavioral|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
199415|NCT02024763|Behavioral|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
199416|NCT02024776|Behavioral|Prehabilitation|Tailored exercise training program
199417|NCT02024789|Drug|Placebo|Orally twice daily, 26 weeks
199418|NCT00121641|Drug|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
199419|NCT02024789|Drug|RG1662|120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
198810|NCT02037438|Other|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention will follow a new methodology for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal is designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
198811|NCT02037451|Procedure|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
198812|NCT02037464|Dietary Supplement|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
198813|NCT02037477|Drug|TAK-438, esomeprazole|TAK-438 tablets, esomeprazole capsules
198814|NCT02039856|Other|Evidence Based Quality Improvement (EBQI) Intervention Practices|Intervention at eight of 12 study sites consisting of VISN/facility-level stakeholder panel meetings designed to set evidence-based priorities for quality improvement (QI) in the context of local data and needs; local practice quality improvement team design meetings; QI training and education; iterative formative data feedback; across intervention-practice QI collaboration calls; and practice facilitation. Local leadership, QI champions and frontline staff will develop and implement innovation projects aimed at improving aspects of WH PACT implementation based on site-level and VISN priorities in the context of national PACT and WH guidelines.
199093|NCT00122122|Behavioral|Enhanced Pharmacy Care|
199094|NCT02029794|Procedure|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
199095|NCT02029794|Procedure|visual inspection with acetic acid (VIA)|
199096|NCT02029794|Drug|3-5% acetic acid|
199097|NCT02029820|Device|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
199098|NCT02029833|Other|Regular Canola Oil|
199099|NCT02029833|Other|High Oleic Canola Oil|
199100|NCT02029833|Other|Western Type Diet - Common Dietary Oils|
199101|NCT02029846|Drug|Standard Treatment (insulin, metformin, sulfonylureas, TZDs)|traditional drugs only
199102|NCT02029846|Drug|Incretin-Based Treatment (GLP-1, DPP-4, amylin analogues)|incretin-based drugs
199103|NCT02029859|Procedure|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
199104|NCT00122135|Other|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
203553|NCT00000308|Drug|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
203554|NCT00002162|Drug|Stavudine|
203555|NCT00119509|Procedure|HPV DNA testing|
203556|NCT02002845|Device|robotic surgery using the da Vinci Surgical System|
203557|NCT02002858|Drug|Nicotine Patch|
203558|NCT02002858|Behavioral|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
203559|NCT02002858|Behavioral|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
203560|NCT02002871|Device|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
203561|NCT02002884|Drug|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
203562|NCT02005458|Drug|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
203563|NCT02005458|Drug|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
203564|NCT00119730|Drug|Rituximab|Given on day 1 of each 28-day cycle
203565|NCT02005471|Drug|Bendamustine|70 mg/m2 IV dose given on Days 1 and 2 of a 28-day cycle for 6 cycles.
203566|NCT02005471|Drug|GDC-0199|4-5 week ramp-up until target daily dose of 400 mg is reached. The daily 400 mg dose will be taken orally for six 28-day cycles. Treatment will continue until disease progression or 2 years after treatment start, whichever comes first.
198815|NCT02039856|Other|Routine PACT Implementation (Naturalistic Control Practices)|PACT implementation is a nationally mandated initiative in VA primary care and women's health clinic settings, with audit-and-feedback of PACT-related performance measures, incentives for achievement of PACT attributes and continual guidance on PACT and WH policy and procedures from VA primary care and women's health leaders.
198816|NCT02039869|Device|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
198817|NCT02039869|Drug|Proton pump inhibitor|Acid suppressing medication (over the counter)
198818|NCT02039869|Drug|Sucralfate|Coating agent for damaged intestinal lining.
198819|NCT02039895|Radiation|HITS|Helical irradiation of the total skin by helical tomotherapy
203249|NCT02010489|Other|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
203250|NCT02010502|Dietary Supplement|Beetroot juice|
203251|NCT02010502|Dietary Supplement|Beetroot powder|
203252|NCT02010502|Dietary Supplement|Placebo|
203253|NCT02010554|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
203254|NCT02010554|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
203255|NCT02010567|Drug|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
203256|NCT02010567|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
203257|NCT02010567|Radiation|Radiotherapy|This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.
Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if <T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.
Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV1 and PTV2 shall be no less than 95% of the protocol specified dose for that volume.
203258|NCT02010567|Procedure|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
203259|NCT00120302|Drug|Placebo|Matching vehicle cream
203260|NCT02010593|Drug|Dapivirine Vaginal Ring|
203261|NCT02010606|Biological|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.
202643|NCT02023697|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
202644|NCT02023710|Drug|Paclitaxel|175 mg/m^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
202645|NCT02023710|Drug|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
202646|NCT02023710|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
202647|NCT02023723|Dietary Supplement|Monster Energy Drink|16oz Monster Energy drinks - 2 consumed within 60 minutes
202648|NCT02023723|Dietary Supplement|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
202944|NCT02018796|Drug|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
202945|NCT02018809|Behavioral|Medication Adherence Partner|
202946|NCT02018809|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
202947|NCT02018822|Device|urethane dimethacrylate|
202948|NCT02018822|Device|TPH3|
202949|NCT00121134|Drug|Capecitabine|Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)
Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
202950|NCT02018835|Device|MRI|
202951|NCT02018835|Device|cardiac echography transthoracic|
202952|NCT02018848|Behavioral|Attention Training Program|
202953|NCT02018861|Drug|INCB050465|
202954|NCT02018861|Drug|INCB039110|
202955|NCT02018861|Drug|Rituximab|
202956|NCT02018861|Drug|Bendamustine|
202957|NCT02018861|Drug|Ifosfamide|
202958|NCT02018861|Drug|Carboplatin|
202959|NCT02018861|Drug|Etoposide|
202960|NCT00121147|Drug|Travatan|
227503|NCT02170584|Drug|BIBR 1048 MS tablet|
227504|NCT00002275|Drug|Fat Emulsion 20%|
227505|NCT00136318|Drug|Escitalopram|
227506|NCT02170584|Drug|BIBR 1048 MS oral solution|
227507|NCT02170584|Drug|BIBR 953 ZW IV Placebo|
227508|NCT02170597|Drug|BIBR 1048 MS HPMC capsule|
227509|NCT02170597|Drug|BIBR 1048 MS gelatine capsule|
227510|NCT02170610|Drug|BIBR 1048 MS|
227511|NCT02170610|Drug|Pantoprazole|
227512|NCT02170623|Drug|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
227513|NCT02170623|Drug|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
227514|NCT02170623|Drug|Pantoprazole|40 mg pantoprazole
227515|NCT02170623|Drug|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
227516|NCT00136318|Drug|Placebo|
227517|NCT02170636|Drug|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
227518|NCT02170636|Drug|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
227519|NCT02170636|Drug|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
227520|NCT02170636|Drug|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
227521|NCT02170636|Drug|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
227522|NCT02170636|Drug|Pantoprazole|40 mg Pantoprazole
227833|NCT02163356|Drug|Ketoconazole|
227834|NCT00135473|Drug|Actrapid® (Insulin)|
227835|NCT02163356|Drug|Vincristine|
227836|NCT02163369|Drug|Peppermint and Lavender Essential Oils|
227837|NCT02163382|Device|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
227193|NCT02178371|Procedure|mCIMT|
227194|NCT00002282|Drug|Clotrimazole|
227195|NCT00137163|Device|Dermafill Dressing|
227196|NCT02178384|Procedure|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
227197|NCT02178384|Device|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
227198|NCT02178384|Procedure|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
227199|NCT02178397|Drug|ERLOTINIB WITH CHEMOTHERAPY|
227200|NCT02178397|Drug|CHEMOTHERAPY ONLY|
227201|NCT02178410|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
227202|NCT02178410|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
227203|NCT02178410|Dietary Supplement|Fish oil placebo|Fish oil placebo
227204|NCT02178410|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
227205|NCT02178423|Procedure|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
227206|NCT00137176|Drug|Rebif|Rebif 44mcg TIW
227207|NCT02178436|Drug|gemcitabine hydrochloride|Given IV
227208|NCT02178436|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
227209|NCT02178436|Drug|selinexor|Given PO
227523|NCT02170649|Drug|BIA 2-093|
227524|NCT02170662|Drug|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
227525|NCT02170662|Drug|Placebo|
227526|NCT02170675|Drug|Dabigatran etexilate|
227527|NCT00136318|Drug|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
226584|NCT02193594|Drug|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA＜1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA＞1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
226585|NCT02193607|Procedure|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
226885|NCT02186015|Drug|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
226886|NCT02186028|Drug|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
226887|NCT00002290|Drug|Zidovudine|
226888|NCT00137995|Drug|Cytarabine|100 mg/m² from D-6 to D-3
226889|NCT02186041|Device|Sacral Nerve Modulation|
226890|NCT02186054|Device|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
226891|NCT02186067|Other|Referral System|Primary Level:
Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)
Secondary Level:
Community health center at Aga Khan University will serve as the secondary care center.
Family physician will manage patients with CVD, CKD or more than 3 drugs.
Tertiary care:
Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.
Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months
226892|NCT02186080|Drug|Gemigliptin|
226893|NCT02186106|Drug|Cholecalciferol|
226894|NCT02186119|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
226895|NCT02186119|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
226896|NCT02186119|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
226897|NCT02186132|Drug|Atropine 0.6 mg|Atropine 0.6 mg intravenous
226898|NCT02186132|Drug|Atropine 1.2 mg|Atropine 1.2 mg intravenous
226899|NCT00137995|Drug|Melphalan|140 mg/m² on D-2
226900|NCT02186145|Drug|Association of metronidazole; nystatin and dexamethasone|
226901|NCT02186145|Drug|Flagyl|Vaginal cream of metronidazole and nystatin
226285|NCT00134719|Biological|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
226286|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
226287|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
226288|NCT02157493|Behavioral|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
226289|NCT02157493|Behavioral|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
226290|NCT02157506|Drug|CXL-1427|
226291|NCT02160119|Other|EEG|ERP
226292|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
226293|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
226586|NCT02193607|Procedure|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
226587|NCT02193620|Drug|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
226588|NCT02193620|Drug|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
226589|NCT02193620|Drug|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
226590|NCT02193633|Drug|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
226591|NCT02193633|Drug|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
226592|NCT02193659|Dietary Supplement|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
226593|NCT00138983|Drug|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
225962|NCT02167737|Behavioral|Control Arm|The "control group," will also have an initial Falls Efficacy Scale (FES) and Vulnerable Elders Survey (VES) screening completed in the ED and two mobility tests. These tests are the "TUG" (Timed Up and Go) test and the "Chair 30-Second Stand" test. Study staff will advise participants on how to take action to prevent falls and they will be given the brochure, "What YOU Can Do to Prevent Falls," that contains standardized information recommended in the STEADI Tool Kit for Health Care Providers by the CDC.
Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history.
225963|NCT02167750|Other|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
225964|NCT02167763|Device|VeraCept Intrauterine Copper Contraceptive|
225965|NCT02167763|Device|TCu380 IUD|
225966|NCT02167776|Behavioral|Church-based teaching and practice about male circumcision|
225967|NCT02167789|Device|Paradym CRT 8770|
225968|NCT02167815|Device|Mepilex XT|Experimental arm
225969|NCT02167815|Other|standard care|
225970|NCT02167828|Behavioral|Social Support|
225971|NCT02169973|Drug|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
225972|NCT02169973|Drug|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
225973|NCT02169986|Behavioral|electronic reminders|
225974|NCT02169999|Other|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
225975|NCT02170012|Drug|PF-06743649|20 mg tablet once daily dosing for 14 days
226294|NCT02160145|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
226295|NCT02160145|Drug|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
226296|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
226297|NCT02160158|Drug|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
202770|NCT01997060|Behavioral|Intensive Lifestyle Intervention|
202771|NCT01997086|Procedure|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
202772|NCT01997086|Procedure|Microendoscopic discectomy (MED)|Microendoscopic discectomy
202773|NCT01997099|Device|CADD®-Solis VIP Pump|
202774|NCT01997099|Device|CADD™ Solis Medication Safety Software Administrator|
202775|NCT01997112|Drug|Paracetamol|
202776|NCT01997125|Device|Neural Bridging System|Implanted device
202777|NCT01997138|Drug|Anakinra 100 mg in 2 ml saline IA|
202778|NCT01997151|Behavioral|Healthy Pregnancy: Step by Step|
202779|NCT01997164|Drug|REGN910-3|
202780|NCT00002158|Drug|Nitazoxanide|
202781|NCT00119119|Drug|pentoxyphilline|
202782|NCT01997164|Drug|REGN910|
202783|NCT01997164|Drug|Intravitreal Aflibercept Injection (IAI)|
202784|NCT01997190|Biological|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
202785|NCT01997203|Drug|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
202786|NCT01997216|Device|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
203092|NCT02034331|Other|Heat application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
203093|NCT02034344|Procedure|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
203094|NCT02034344|Procedure|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
202187|NCT02009995|Behavioral|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
202188|NCT00120250|Drug|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
202477|NCT00119470|Procedure|Conventional Surgical Technique|
202478|NCT02002234|Procedure|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
202479|NCT02002247|Drug|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive a continuous infusion of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
202480|NCT02005003|Behavioral|Memory task|Participants perform short memory tasks on each visit
202481|NCT00119691|Drug|Nesiritide|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
202482|NCT02005003|Behavioral|Food consumption task|Participants are given a selection of food items to consume on each visit
202483|NCT02005016|Behavioral|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
202484|NCT02005029|Drug|Erythromycin|
202485|NCT02005029|Drug|placebo|
202486|NCT02005042|Behavioral|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
202487|NCT02005055|Procedure|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
202488|NCT02005068|Drug|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
201894|NCT02015754|Drug|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
201895|NCT02015754|Device|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
201896|NCT00120822|Drug|Folic acid|
201897|NCT02015754|Procedure|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
201898|NCT02015780|Drug|Fasiglifam|Fasiglifam tablets
201899|NCT02015780|Drug|Placebo|Fasiglifam placebo-matching tablets
201900|NCT02015780|Drug|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
201901|NCT02018367|Drug|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
202189|NCT02009995|Behavioral|AT plus Primarily Supervised Group Resistance Band Training|Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.
Participants in the primarily supervised intervention group will be asked to attend supervised group sessions twice per week for the 24 week program. Participants in this group will be responsible to complete one additional RBT session at home on their own time every week.
202190|NCT02009995|Behavioral|AT plus Primarily Home-Based Resistance Band Training|Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.
Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time.
202191|NCT02010008|Behavioral|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
202192|NCT02010021|Drug|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
202193|NCT02010034|Drug|Omegaven|Omegaven will be used in place of soy oil Intralipid
202194|NCT02010047|Device|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
201291|NCT00002178|Drug|Saquinavir|
201292|NCT00121914|Procedure|percutaneous ethanol instillation (PEI)|
201293|NCT02028390|Device|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
201294|NCT02028403|Drug|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
201295|NCT02028403|Drug|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
201296|NCT02028416|Drug|ATG-fresenius|we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.
the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days
201297|NCT02030769|Drug|Pronase|use pronase to improve visibility during endoscopical iodiine staining
201298|NCT02030769|Drug|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
201299|NCT00122304|Drug|eculizumab|
201595|NCT02023229|Other|High-fiber high protein diet|
201596|NCT02023242|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
201597|NCT00121472|Device|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
201598|NCT02023242|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
201599|NCT02023255|Drug|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
201600|NCT02023255|Other|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
201601|NCT02023268|Device|T2762|1 drop in each eye 3 to 6 times daily during 84 days
201602|NCT02023268|Device|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
201603|NCT02023281|Behavioral|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
201604|NCT02023294|Procedure|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
200621|NCT01996306|Drug|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
200622|NCT00119015|Drug|Montelukast|
200623|NCT01998724|Behavioral|Tai Chi|24 week tai chi intervention designed for individuals with COPD
200624|NCT01998724|Behavioral|Group Walking|24 week group walking intervention
200625|NCT01998763|Dietary Supplement|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
200626|NCT01998763|Dietary Supplement|Vitamin D3|Vitamin D3 2000 IU per day
200627|NCT00119249|Drug|sorafenib tosylate|Given orally
200628|NCT01998776|Drug|Misoprostol|Misoprostol 200ug four times daily
200629|NCT01998789|Drug|Everolimus|
200630|NCT01998789|Drug|Standard Tacrolimus|Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.
Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels.
200631|NCT01998802|Drug|Active Comparator EBI-005|
200632|NCT01998802|Drug|Placebo Comparator|
200633|NCT01998815|Procedure|Laparoscopic Roux-en-Y gastric bypass surgery|
200634|NCT01998828|Drug|Momelotinib|Momelotinib tablet administered orally once daily
200635|NCT01998841|Drug|Crenezumab|Crenezumab will be administered subcutaneously every 2 weeks.
200636|NCT01998841|Drug|Placebo|Placebo will be administered subcutaneously every 2 weeks.
200637|NCT01998854|Device|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
200946|NCT02033460|Other|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
200947|NCT02033460|Other|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
200948|NCT02033473|Drug|Apelin|An apelin clamp in which an apelin infusion will be administered
200023|NCT02009033|Drug|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
200024|NCT02009033|Drug|Hydroxyethylstarch|
200025|NCT02009046|Behavioral|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
200026|NCT02011971|Drug|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
200027|NCT00120406|Procedure|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
200028|NCT02011997|Procedure|patients undergo cVATS segmentectomy|
200029|NCT02011997|Procedure|Patients undergo cVATS lobectomy|
200030|NCT02012010|Procedure|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
200031|NCT02012010|Procedure|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
200032|NCT02012023|Device|Low anterior resection|
200033|NCT02012023|Device|tube ileostomy|
200034|NCT02012023|Device|loop ileostomy|
200035|NCT02012023|Device|accept reversal operation|
200036|NCT02012023|Device|remove the tube ileostomy|
200037|NCT02012036|Drug|Hexvix|As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.
The detection with Hexvix should be in accordance with local Summary of Product Characteristics [SmPC].
Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required.
200038|NCT00002168|Drug|Stavudine|
200039|NCT00120419|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
200040|NCT02012049|Drug|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
200041|NCT02012049|Drug|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
199420|NCT02024789|Drug|RG1662|240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
199421|NCT02024815|Radiation|External Beam radiotherapy|External Beam radiotherapy
199731|NCT02017457|Drug|Azacytidine|Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.
Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.
All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.
In case of stable disease or partial response, Azacytidine will be continued until progression.
In case of disease progression after cycle 6, Azacytidine will be stopped.
199732|NCT02017470|Other|Gender-tailored women's heart health outpatient programme|
199733|NCT02017509|Procedure|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
199734|NCT02017509|Procedure|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
199735|NCT00121017|Drug|Kaletra (lopinavir/ritonavir)|
199736|NCT02017509|Procedure|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
199737|NCT02017509|Genetic|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
199738|NCT02019758|Drug|Placebo slurry|Slurry of sucralose - 4mL twice daily
199739|NCT00121199|Biological|bevacizumab|Given IV
199740|NCT02019758|Drug|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
199741|NCT02019784|Drug|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
199742|NCT02019797|Drug|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
199743|NCT02019810|Drug|Norepinephrine|
199744|NCT02019810|Drug|Dobutamine and norepinephrine|
199105|NCT02029872|Drug|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
199106|NCT02029872|Drug|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
199107|NCT02029872|Drug|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
199108|NCT02029885|Device|Investigational Therapy (Surround Sound)|
199109|NCT02029885|Device|Sham Control|
199110|NCT02029898|Drug|Remifentanil|
199111|NCT02032446|Biological|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|pentostatin, dose 1 mg/m2
§ MSC doses:
3 patients → 3 infusions of 1x106 cells /kg
3 patients → 3 infusions of 2x106 cells /kg
3 patients → 3 infusions of 3x106 cells /kg
199112|NCT02032472|Other|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
199113|NCT02032485|Drug|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
199114|NCT00122460|Drug|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
199422|NCT02024828|Other|Early/Slow|
199423|NCT02024828|Other|Early/Fast|
199424|NCT02024828|Other|Late/Slow|
199425|NCT02024828|Other|Late/Fast|
199426|NCT02024841|Drug|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
199427|NCT02024854|Behavioral|skin-to-skin|
199428|NCT02024854|Behavioral|standard care|
199429|NCT00121641|Drug|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
199430|NCT02024867|Drug|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
199431|NCT02024880|Device|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
199432|NCT02024880|Device|Conventional catheter group|A standard embryo catheter
199433|NCT02024893|Other|Observational study|Observation and type of data collected are listged in detail under 'description"
198820|NCT02039908|Drug|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
198821|NCT00123110|Drug|placebo pill|matching pill twice a day for 12 weeks
198822|NCT02039934|Other|High intensity interval training|The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.
Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down.
198823|NCT02039947|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
198824|NCT02039947|Drug|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
198825|NCT02039960|Drug|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
198826|NCT02039973|Behavioral|Task-sharing approach to group therapy|Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.
Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions.
198827|NCT02039973|Behavioral|Enhanced standard of care|
198828|NCT02039999|Other|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
198829|NCT02039999|Other|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
198830|NCT02042729|Drug|E2022 Matching Placebo- Current Formula Tape|
198831|NCT02042729|Drug|E2022 Matching Placebo- New Formula Tape|
199115|NCT02032498|Drug|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
199116|NCT02032524|Drug|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
199117|NCT02032537|Drug|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
203262|NCT02010606|Biological|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
203567|NCT02005471|Drug|Rituximab [MabThera/Rituxan]|Intravenous (IV) infusions given on Day 1 of a 28-day cycle for 6 cycles. First dose (Cycle 1): 375 mg/m2 Subsequent doses (Cycles 2-6): 500 mg/m2
203568|NCT02005484|Drug|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
203569|NCT02005497|Other|HealthLinks|
203570|NCT02005510|Behavioral|In-home HPV screening|
203571|NCT02005510|Other|Usual care|Patient- and provider-level services to promote adherence to Pap screening
203572|NCT02005523|Drug|RNS60|
203573|NCT02005523|Drug|Saline|
203574|NCT02005536|Biological|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
203575|NCT00119730|Drug|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
203576|NCT02005549|Drug|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
203577|NCT02005549|Drug|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
203578|NCT02005549|Drug|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
203579|NCT02005562|Drug|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (*) height (h)/ liter(L).
203580|NCT02005562|Drug|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
203581|NCT02005562|Drug|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
203582|NCT02005562|Drug|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
203583|NCT02005562|Drug|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
202961|NCT02018874|Drug|LY2780301|LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :
Dose level -1: 300 mg Q.D.
Dose level -0.5: 400 mg Q.D.
Dose level 1: 400 mg Q.D.
Dose level 1.5: 500 mg Q.D.
Dose level 2 : 500 mg Q.D.
202962|NCT02018874|Drug|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
202963|NCT02018887|Drug|LY2969822|Capsules administered orally
202964|NCT02018887|Drug|Placebo|Capsules administered orally
202965|NCT02018900|Dietary Supplement|Ecologic 825/scFOS|
202966|NCT02018900|Dietary Supplement|Placebo|
202967|NCT02018926|Drug|Mocetinostat|Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
202968|NCT02018926|Drug|Azacitidine|Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
203263|NCT02010619|Behavioral|Cognitive behavior therapy|
203264|NCT02013453|Drug|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
203265|NCT02013453|Drug|5FU|Administered by infusion.
203266|NCT00120575|Procedure|hemofiltration|
203267|NCT02013453|Drug|Paclitaxel|Administered by infusion.
203268|NCT02013453|Drug|Pemetrexed|Administered by infusion.
203269|NCT02013466|Dietary Supplement|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
203270|NCT02013466|Dietary Supplement|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
203271|NCT02013466|Dietary Supplement|Bolus ONS C|High casein-protein, high-caloric control product.
203272|NCT02013466|Dietary Supplement|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
203273|NCT02013479|Dietary Supplement|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
203274|NCT02013479|Dietary Supplement|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
203275|NCT02013492|Drug|propranolol hydrochloride|Given PO
227838|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
227839|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
227840|NCT02165943|Device|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
227841|NCT02165956|Dietary Supplement|New Infant Cereal|New Infant Cereal
227842|NCT02165956|Dietary Supplement|Standard Infant Cereal|Standard Infant Cereal
227843|NCT02165969|Procedure|endoscopic endonasal surgery with UPSIT|
227844|NCT00135707|Dietary Supplement|Vitamins|Vit C (500 mg) and Vit E (200 IU) per capsule, two capsules daily between 9 - 16 weeks gestation.
Placebo - two capsules daily between 9 - 16 weeks gestation.
227845|NCT02165995|Procedure|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
227846|NCT02165995|Procedure|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
227847|NCT02166008|Drug|Repamipide|
227848|NCT02166008|Drug|Placebo|
227849|NCT02166021|Biological|Mesenchymal stem cells|
227850|NCT02166034|Behavioral|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
227851|NCT02166047|Drug|GS-9620|GS-9620 tablets administered orally every 7 days
227852|NCT02166047|Drug|Placebo to match GS-9620|Placebo to match GS-9620 tablets administered orally every 7 days
227853|NCT02166060|Drug|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
227854|NCT02166112|Procedure|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
228168|NCT02158377|Device|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
227528|NCT02173093|Other|laboratory evaluations of immune responses|Correlative studies
227529|NCT02173106|Drug|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
227530|NCT02173119|Other|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
227531|NCT02173132|Drug|Acetyl-L-carnitine|
227532|NCT02173132|Other|Placebo|
227533|NCT02173145|Drug|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
227534|NCT02173145|Drug|placebo|Placebo will be given 3 times a wek over a period of 3 months.
227535|NCT02173158|Drug|lomitapide|
227536|NCT02173171|Other|Information collection|Q3M Information collection
227537|NCT00002277|Drug|Amphotericin B|
227538|NCT00136539|Drug|Cytoxan|Given every three weeks for 12 weeks after surgery.
227539|NCT02173184|Biological|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
227540|NCT02173184|Biological|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
227541|NCT02173223|Drug|Rho-Kinase Inhibitor|
227542|NCT02173236|Other|platform-switched implants|
227543|NCT02173236|Other|platform-matched implant|
227544|NCT02173249|Drug|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
227545|NCT02173262|Drug|G-CSF|
227546|NCT02173262|Drug|Ciprofloxacin|
227547|NCT02173288|Drug|Standard medical therapy|
227855|NCT00002270|Drug|Zidovudine|
227856|NCT00135720|Drug|Enbrel (Etanercept)|
226902|NCT02186158|Drug|Vitamin C|
226903|NCT02186158|Drug|Placebo|
226904|NCT02186171|Drug|AMG 785|Subcutaneous injections of AMG 785 montly for 12 months.
226905|NCT02186171|Drug|Placebo|Subcutaneous injections of placebo monthly for 12 months.
226906|NCT02186184|Device|Orthokeratology|
226907|NCT02186184|Device|Spectacle|
227210|NCT02178436|Other|pharmacological study|Correlative studies
227211|NCT02178436|Other|laboratory biomarker analysis|Correlative studies
227212|NCT02178449|Drug|Dexamethasone acetate|
227213|NCT02178449|Drug|Placebo|
227214|NCT02178449|Drug|Ropivacaine|
227215|NCT02181179|Behavioral|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
227216|NCT00137462|Drug|torcetrapib/atorvastatin|
227217|NCT02181192|Device|PET/CT|particularly PET/CT, bone scintigraphy
227218|NCT02181192|Radiation|Instant Radiotherapy according to guidelines|
227219|NCT02181192|Radiation|Radiotherapy after achievement of PSA marginal value|
227220|NCT02181205|Drug|bupivacaine|
227221|NCT02181205|Drug|placebo|
227222|NCT02181218|Drug|Romidepsin|
227223|NCT02181218|Drug|Gemcitabine|
227224|NCT02181218|Drug|Oxaliplatin|
227225|NCT02181218|Drug|Dexamethasone|
227226|NCT02181218|Drug|Pegfilgrastim|
227227|NCT00137462|Drug|atorvastatin|
226594|NCT02193672|Drug|[18F] Fluciclatide|[18F] Fluciclatide given by vein before PET/CT scan.
226595|NCT02193672|Procedure|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
226596|NCT02193672|Behavioral|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
226597|NCT02193698|Drug|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
226598|NCT02193711|Other|Topical Arthritis Cream|
226599|NCT02193724|Other|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
226600|NCT02193724|Other|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
226601|NCT02193737|Procedure|Early oral fluid recovery.|
226602|NCT02193737|Procedure|Delayed oral fluid recovery.|
226603|NCT02196090|Behavioral|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
226604|NCT00139256|Drug|Betamethasone|Betamethasone injection
226605|NCT02196090|Device|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
226606|NCT02196103|Device|Double balloon cervical catheter|
226908|NCT02186197|Other|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
226909|NCT02188680|Other|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
226910|NCT02188706|Drug|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
226911|NCT02188706|Drug|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
226912|NCT02188706|Drug|Arsenic Trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
226913|NCT02188719|Biological|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is <50/mm^3 or when the maximal dose of 4.5/mg/kg has been given.
203388|NCT02026778|Drug|ondansetron-betahistine|The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.
The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.
203389|NCT02026791|Device|I-gel|The patient was monitored at 1-5 minute intervals.
While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.
After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).
Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted.
203390|NCT02026791|Device|Supreme-LMA|The patient was monitored at 1-5 minute intervals.
While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.
After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).
Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted.
203391|NCT02029235|Drug|Acetaminophen/Hydrocodone|Patients will be treated with acetaminophen 325 mg / Hydrocodone 5 mg
203392|NCT02029235|Drug|Acetaminophen/Ibuprofen|Acetaminophen 500 mg / Ibuprofen 400 mg
203393|NCT02029248|Other|Quality of life questionnaire|
198669|NCT02062424|Other|DIPI|
198670|NCT02062463|Drug|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 mcg)
198671|NCT02062463|Drug|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 mcg)
198672|NCT02062476|Dietary Supplement|Lactobacillus GG|
198673|NCT02062489|Drug|Tamoxifen|20 mg(2#)/day, PO, daily
198674|NCT02062489|Drug|Placebo|2#/day, PO, daily
198675|NCT00125411|Drug|satraplatin and docetaxel|Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.
Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush.
198676|NCT02062502|Biological|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
198677|NCT02062502|Biological|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
198678|NCT02062502|Biological|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
203095|NCT00122616|Biological|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
203096|NCT02034344|Procedure|Urine collection|Urine will be collected from all participants.
203097|NCT02034357|Other|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
203098|NCT02034357|Other|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
203099|NCT02034370|Device|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
203100|NCT02034370|Device|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
203101|NCT02034383|Other|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
203102|NCT02034383|Other|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
203103|NCT02034383|Other|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
203104|NCT02034383|Other|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
203105|NCT02034383|Other|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
203106|NCT00122616|Drug|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
203107|NCT02034396|Procedure|Blood Draw|One blood draw at enrollment
203108|NCT02034409|Device|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
203109|NCT02034409|Device|Sham Comparator|20 minutes daily for 48 weeks
203110|NCT02034422|Dietary Supplement|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
203111|NCT02034422|Other|Exercise rehabilitation|8 weeks of exercise rehabilitation
203394|NCT02029274|Drug|BAF312 0.5 mg|BAF312 0.5 mg once daily
203395|NCT02029274|Drug|BAF312 2 mg|BAF312 2 mg once daily
203396|NCT02029274|Drug|BAF312 10 mg|BAF312 10 mg once daily
203397|NCT02029274|Drug|Placebo to BAF312|Placebo to BAF312 once daily
202489|NCT02005081|Device|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
202490|NCT02005081|Device|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
202491|NCT02005107|Drug|Venlafaxine IR and Venlafaxine XR|
202492|NCT00119704|Drug|Botulinum toxin A injection or normal saline|
202493|NCT02005120|Drug|Bevacizumab|Intrapleural administration of bevacizumab
202787|NCT01999647|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as "intraneural" if nerve cross section expansion and a reduction in echogenicity are observed.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
202788|NCT01999647|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as "intraneural" if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
202789|NCT01999647|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
202790|NCT01999647|Procedure|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
202791|NCT01999647|Drug|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
202792|NCT01999660|Device|SpaceOAR™ implantation|
202793|NCT00119301|Drug|trimetrexate glucuronate|
202794|NCT01999673|Biological|bavituximab|
202795|NCT01999673|Drug|Docetaxel|
202796|NCT01999673|Other|Placebo (for bavituximab)|
202797|NCT01999686|Drug|DLBS3233|
202798|NCT01999686|Drug|Metformin XR|
202799|NCT01999686|Drug|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
202800|NCT01999686|Drug|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
202195|NCT02010060|Behavioral|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week [KKW]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
202196|NCT02012972|Behavioral|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
202197|NCT02012985|Biological|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
202198|NCT02012985|Drug|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
202199|NCT02012998|Biological|HBVAXPRO 5µg|0.5mL intramuscular injection
202200|NCT02013011|Procedure|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
202201|NCT02013024|Other|cryopreservation technique|
202494|NCT02005120|Drug|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
202495|NCT02005159|Other|Microbiological studies|
202496|NCT02005172|Device|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
202497|NCT02005198|Other|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
202498|NCT02005211|Drug|AZD3293|Oral solution
202499|NCT02005211|Drug|Placebo|Oral solution
202500|NCT02005224|Other|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
202501|NCT02007707|Behavioral|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
201605|NCT02023294|Procedure|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
201606|NCT02023307|Device|V-Loc Suture|
201607|NCT02023320|Dietary Supplement|Low dose of blueberry dry powder|
201608|NCT00121485|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
201609|NCT02023320|Dietary Supplement|High dose of blueberry dry powder|
201610|NCT02023333|Device|Regorafenib|All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
201611|NCT02023346|Behavioral|surveys and cognitive tests|
201612|NCT02023359|Drug|Everolimus and exemestane|
201613|NCT02023372|Biological|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
201614|NCT02025738|Device|MAGNET APPLICATION|
201615|NCT02025738|Device|REPROGRAMING|
201902|NCT02018380|Other|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
201903|NCT02018406|Drug|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
201904|NCT00121108|Biological|MEDI-524|15 mg/kg motavizumab administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season
201905|NCT02018406|Drug|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
201906|NCT02018419|Biological|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
201907|NCT02018419|Procedure|Cryoablation|Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
200949|NCT02033473|Drug|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
200950|NCT02033486|Device|TOBI + DBT|
200951|NCT02033499|Behavioral|SMBG|Blood glucose levels are tested once daily.
200952|NCT02033512|Drug|Transdermal Hormone Replacement Therapy|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.
All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications.
200953|NCT02033512|Drug|Transdermal Nanoformulation|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
200954|NCT01993810|Drug|etoposide|Given IV
200955|NCT01993810|Drug|cisplatin|Given IV
200956|NCT01993810|Procedure|quality-of-life assessment|Ancillary studies
200957|NCT01993810|Other|questionnaire administration|Ancillary studies
200958|NCT01993823|Drug|G238|Five drops into the ear canal twice daily for 14 days
200959|NCT01993823|Drug|Clotrimazole|Five drops into the ear canal twice daily for 14 days
200960|NCT01993836|Drug|Total intravenous anesthesia with propofol|
200961|NCT00118872|Drug|LGG yogurt|Lactobacillus GG containing yogurt
200962|NCT01993836|Drug|General anesthesia with isoflurane|
200963|NCT01993849|Drug|N-Acetylcysteine (NAC)|
200964|NCT01993849|Other|Placebo|
200965|NCT01993862|Other|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
201300|NCT02030782|Other|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
201301|NCT02030782|Other|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
200329|NCT02004002|Behavioral|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
200330|NCT02004015|Drug|injection of placebo|0.5 mg/kg milligram(s)/kilogram
200331|NCT02004015|Drug|injection of NMBA|
200332|NCT02004028|Drug|VS-6063|
200333|NCT02004041|Drug|VLY-686|capsules containing 50 mg VLY-686
200334|NCT02004041|Drug|Placebo|Sugar capsule to mimic VLY-686 50 mg capsule
200335|NCT02004054|Other|measure of pupil diameter|The measure will use infra-red cameras
200336|NCT02004067|Drug|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
200337|NCT02004067|Drug|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
200338|NCT00119613|Drug|darbepoetin alfa|darbepoetin alfa
200339|NCT02006641|Drug|Placebo|Once daily, matching placebo capsules, orally
200340|NCT02006641|Drug|Lu AE58054|Once daily, encapsulated tablets, orally
200341|NCT02006654|Drug|Placebo|Once daily, matching placebo capsules, orally
200342|NCT02006654|Drug|Lu AE58054|Once daily, encapsulated tablets, orally
200343|NCT02006667|Drug|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
200344|NCT02006667|Drug|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
200345|NCT02006667|Drug|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
200346|NCT02006693|Device|XEN Gel Stent|The XEN Gel Stent will be placed as a standalone procedure.
200347|NCT02006693|Device|XEN Gel Stent with cataract surgery|Patient has been diagnosed with a cataract and has elected to have cataract surgery. The XEN Gel Stent will be placed along with cataract surgery.
200348|NCT00119834|Device|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a FDA approved Mechanical Circulatory Support Device.
200349|NCT02006706|Drug|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
200350|NCT02006706|Drug|methotrexate|10 - 25 mg/week
199745|NCT02019823|Behavioral|Informational SMS-text|
199746|NCT02019823|Behavioral|Interactive SMS-text|
199747|NCT02019823|Behavioral|Enhanced usual care|
199748|NCT02019836|Other|Determining maternal and neonatal vitamin D levels|
200042|NCT02012062|Drug|TPF neoadjuvant chemotherapy|
200043|NCT02012062|Drug|Concurrent chemotherapy with cisplatin during radiotherapy|
200044|NCT02012062|Drug|Concurrent nimotuzumab during radiotherapy|
200045|NCT02012062|Radiation|Radical radiotherapy|
200046|NCT02012075|Drug|Extended-Release Carvedilol Sulfate|
200047|NCT02012075|Drug|Sustained-release Metoprolol Succinate|
200048|NCT02012088|Drug|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
200049|NCT02012088|Drug|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
200050|NCT00120432|Drug|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
200051|NCT02012101|Device|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
200052|NCT02012101|Device|oxygen therapy|
200053|NCT02014740|Drug|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
200054|NCT02014740|Drug|Metformin|
200055|NCT02014753|Device|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
200056|NCT02014753|Device|bare metal stent (BMS)|
200057|NCT02014766|Procedure|Interscalene block|Ultrasound-guided interscalene block is performed.
199434|NCT02024906|Dietary Supplement|soy protein isolate (SPI)|
199435|NCT02024906|Dietary Supplement|milk protein isolate (MPI)|
199436|NCT02024919|Drug|intracoronary administration of diltiazem|
199437|NCT02024919|Drug|intracoronary injection of 5 mL saline|
199438|NCT02024932|Drug|BVS857|BVS857 i.v. and escalating s.c. doses
199439|NCT02024932|Drug|Placebo|Placebo i.v. and s.c. doses
199440|NCT00002177|Drug|Stavudine|
199441|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
199442|NCT02027441|Other|Standard Counseling and Testing|Individuals who opt for standard counseling and testing will complete the following procedures:
• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines
199443|NCT02027454|Drug|GSK1265744|White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
199444|NCT02027454|Drug|GSK1265744 matching placebo|GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
199445|NCT00121810|Drug|Sirolimus|As prescribed
199749|NCT02019849|Device|Plasmafit® Total Hip Arthroplasty|
199750|NCT00121199|Drug|cyclophosphamide|Given IV
199751|NCT02019862|Device|TRJ® Total Hip Arthroplasty|
199752|NCT02019875|Drug|Rifampin|P450 inducer
199753|NCT02019875|Drug|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
199754|NCT02019875|Other|Grapefruit Juice|CYP3A4 inhibitor in intestine
199755|NCT02019875|Other|Placebo|
199756|NCT02019901|Other|Nurse-led clinic|
199118|NCT02032537|Drug|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
199119|NCT02032550|Other|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
199120|NCT02032563|Drug|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
199121|NCT02032576|Device|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
199122|NCT02032589|Behavioral|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
199123|NCT02032602|Other|Deep Dry Needling|
199124|NCT02032615|Dietary Supplement|Education plus Gudness Nutritional Bar|
199125|NCT00122473|Drug|Imatinib (Glivec)|
199126|NCT02032615|Other|Education|
199127|NCT02032628|Behavioral|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
199128|NCT02032641|Device|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
199129|NCT02032654|Drug|Flucloxacillin|
199130|NCT02032654|Drug|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
199131|NCT02032667|Behavioral|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
199132|NCT02035137|Drug|Irinotecan|
199133|NCT02035137|Drug|Vorinostat|
199446|NCT02027454|Drug|Moxifloxacin|Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
199447|NCT02027467|Dietary Supplement|StemAlive®|
199448|NCT02027467|Dietary Supplement|Placebo (For StemAlive®)|
203584|NCT02005575|Drug|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
203585|NCT02005575|Drug|Placebo|
203586|NCT00119743|Biological|undecavalent pneumococcal-protein D conjugate vaccine|
203587|NCT02008084|Drug|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
198832|NCT02042742|Dietary Supplement|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
198833|NCT02042742|Dietary Supplement|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
198834|NCT02042755|Device|trifocal intraocular lens|Standard cataract surgery
198835|NCT02042781|Drug|PG545|PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
198836|NCT02042807|Drug|Placebo|
198837|NCT02042807|Drug|MCS®|
198838|NCT02042820|Other|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
198839|NCT02042846|Device|SportWelding Fiji Anchor|
198840|NCT00123409|Behavioral|Usual Care|Usual care
198841|NCT02042859|Device|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
198842|NCT02042872|Drug|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
198843|NCT02042885|Drug|OPB-111001|
198844|NCT02042898|Other|Restrictive Transfusion Strategy|
198845|NCT02042898|Other|Liberal transfusion strategy|
198846|NCT02042911|Drug|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
203276|NCT02013492|Other|Correlative Studies|Correlative studies will be conducted using the following materials:
Plasma derived from peripheral blood.
Peripheral blood mononuclear cells (PBMC) derived from patient blood
Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.
Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease.
203277|NCT00120588|Drug|magnesium|
203278|NCT02013505|Other|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
203279|NCT02013518|Behavioral|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
203280|NCT02013531|Drug|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
203281|NCT02013544|Drug|Placebo|
203282|NCT02013544|Drug|Prasterone (DHEA)|
203283|NCT02013557|Behavioral|Text-message reminder|
203588|NCT02008084|Drug|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
203589|NCT00119964|Behavioral|internet based weight management tools|
203590|NCT02008097|Device|GE LOGIQ E9 Ultrasound System|Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new "B-Flow" method of ultrasound.
203591|NCT02008110|Drug|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
203592|NCT02008110|Drug|CA125 guided strategy|Consider statins in all patients in the active arm
203593|NCT02008110|Drug|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
203594|NCT02008110|Other|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
203595|NCT02008110|Drug|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
228169|NCT02158390|Behavioral|Jasper-EMT with words and AAC|Jasper-EMT with words and AAC
A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months.
228170|NCT02158403|Other|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
228171|NCT02158429|Other|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
228172|NCT02160886|Behavioral|parent-goal|The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.
The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.
The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .
The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions.
228173|NCT00135226|Drug|Placebo omega-3-Ethyl Esters|
228174|NCT02160899|Drug|ISIS-APO(a)Rx|
228175|NCT02160899|Drug|Placebo|
228176|NCT02160925|Other|Preoperative 99mTc-Sestamibi SPECT/CT|
228177|NCT02160938|Other|3-year follow-up|When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.
At the age of 3, the following exams will be performed and are described below:
The Vineland-II Adaptive Behavior Scale (VABS)
Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)
Children will also be photographed (for review by the study dysmorphologist)
228178|NCT02160951|Drug|LGH447|LGH447, QD
228179|NCT02160977|Procedure|total knee arthroplasty|
228180|NCT02160990|Drug|Exenatide|Qualifying participants will be assigned either Exenatide or placebo for 30 days.
228181|NCT02160990|Drug|placebo|
228182|NCT02161003|Procedure|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
228183|NCT02161003|Procedure|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
228483|NCT02423915|Drug|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
227857|NCT02166138|Procedure|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
227858|NCT02166151|Drug|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
227859|NCT02166164|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
227860|NCT02168348|Other|biological examination at consultations at 3 and 6 months|
227861|NCT02168361|Drug|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
227862|NCT02168361|Drug|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
227863|NCT02168361|Drug|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
227864|NCT02168361|Drug|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
227865|NCT02168374|Other|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
227866|NCT00135993|Drug|Rotigotine|
227867|NCT02168387|Device|continuous high frequency oscillator (CHFO)|
227868|NCT02168387|Drug|Acetylcysteine|
227869|NCT02168387|Drug|dornase alfa|
227870|NCT02168400|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS will be performed with Neuroelectrics Starstim Enobio 20, an approved research device without an investigational device exemption due to meeting criteria for non-significant risk. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
227871|NCT02168426|Procedure|Guardix|Applying 6g of guardix during abdominal surgery
227872|NCT02168426|Procedure|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
227228|NCT02181231|Drug|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
227229|NCT02181231|Drug|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
227230|NCT02181231|Drug|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
227231|NCT02181244|Other|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
227548|NCT02173288|Drug|Tolvaptan|
227549|NCT00136552|Drug|rituximab|
227550|NCT02173288|Drug|Midodrine|
227551|NCT02173301|Drug|XP23829 400 mg QD|XP23829 400 mg QD
227552|NCT02173301|Drug|XP 23829 800 mg QD|XP23829 800 mg QD
227553|NCT02173301|Drug|XP23829 400 mg BID|XP23829 400 mg BID
227554|NCT02173301|Drug|Placebo|Placebo
227555|NCT02173314|Other|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
227556|NCT02173314|Other|Family Search and Engagement (FSE)|Intense search practices to identify possible permanency resources
227557|NCT02173327|Device|Continuously helm CPAP|6 hours
227558|NCT02173327|Device|Intermittent Mask CPAP|10min every 2 hour for 18 hours
227559|NCT02176161|Drug|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
227560|NCT02176187|Drug|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
227561|NCT02176187|Drug|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
227562|NCT02176200|Drug|Berodual® Respimat®, low inspiratory flow rate|
227563|NCT02176200|Drug|Berodual® Respimat®, medium inspiratory flow rate|
227564|NCT02176200|Drug|Berodual® Respimat®, high inspiratory flow rate|
226914|NCT02188719|Biological|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
226915|NCT02188719|Drug|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
226916|NCT02188719|Drug|Tacrolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Tacrolimus will be initiated within 72 hours of liver transplantation, targeting 12 hour trough levels of 6-8 μg/L. At 5-6 weeks after transplantation, after EVR is initiated, the tacrolimus target 12 hour trough levels will be decreased to 3-5 μg/L
226917|NCT02188719|Drug|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
226918|NCT00138242|Drug|carboplatin|
226919|NCT02188719|Drug|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
226920|NCT02188719|Drug|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
226921|NCT02188719|Drug|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
226922|NCT02188719|Drug|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
227232|NCT02181244|Other|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
227233|NCT02181257|Drug|Methoxsalen|Procedure ECP Treatments will be performed using Therakos UVAR XTS system or the Therakos CELLEX system
227234|NCT02181270|Other|high intensity exercise|
227235|NCT02181283|Behavioral|W+W|Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored "change plan".
Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps.
227236|NCT00137826|Drug|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
198679|NCT02062515|Drug|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
198680|NCT02062528|Dietary Supplement|omega-3 fatty acids|highly dosed in EPA
198681|NCT02062528|Dietary Supplement|placebo|
198682|NCT02062541|Other|Funct. assessment+fast rehabilitation|
198683|NCT02062541|Other|Funct. assessment+usual rehabilitation|
198684|NCT02062541|Other|usual assessment+fast rehabilitation|
198685|NCT02062580|Biological|BCG|
198686|NCT00125424|Drug|AQUAVAN® (fospropofol disodium) Injection|
198687|NCT02062593|Procedure|Coronary angioplasty|Percutaneous coronary intervention with drug-eluting stents and modern techniques
198688|NCT02062606|Device|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
198689|NCT02062619|Behavioral|Computer-based behavioural word reading therapy|Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.
Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)
198690|NCT02062619|Other|Real tDCS|Real tDCS 20 minutes per session, three times per week
198691|NCT02062619|Other|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
198971|NCT02014220|Other|dietary treatment|
198972|NCT02014233|Dietary Supplement|Omega-3|
198973|NCT02014233|Dietary Supplement|Olive oil|
198974|NCT02014259|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
198975|NCT02014272|Drug|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
198976|NCT00120653|Drug|Metoclopramide|
198977|NCT02014272|Drug|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
198978|NCT02014285|Procedure|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
203398|NCT02029287|Other|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
203399|NCT02029300|Other|Fiberoptic Intubation through the nasal route|
203400|NCT00122018|Drug|fenoldopam|
203401|NCT02029300|Other|Fiberoptic intubation through the oral route|
203402|NCT02029313|Drug|Montelukast|
203403|NCT02029313|Drug|Montelukast sodium|
203404|NCT02029339|Device|Continuous topical triple-tube irrigation and suction|The triple-tube device was continuous operated: instilled the topical solution through the "washing tube", delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of "sleeve tubes" through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China).
203405|NCT02029339|Device|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
203406|NCT02029352|Drug|Sinecatechins 10%|
203407|NCT02029352|Drug|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
203408|NCT02029365|Other|Autoquestionnary|autoquestionnary completed during the consultation for infertility
203409|NCT02029365|Other|semi-structured interview|phone interview
203410|NCT02029378|Drug|Eculizumab|
203411|NCT00122031|Device|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
203412|NCT02029391|Other|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
203413|NCT02029391|Other|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
203414|NCT02031744|Drug|Placebo|15 mg/kg intravenous administration every 3 weeks
203415|NCT02031744|Drug|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
202801|NCT01999699|Biological|HEPLISAV|
202802|NCT01999712|Procedure|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
202803|NCT01999725|Drug|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
202804|NCT00119314|Drug|capecitabine|
202805|NCT01999725|Drug|Placebo|Matching placebo capsules or matching suspension
202806|NCT01999738|Drug|EC1456 and etarfolatide (EC20)|
202807|NCT01999751|Device|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
203112|NCT01994876|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
203113|NCT01994889|Drug|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
203114|NCT00118924|Biological|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
203115|NCT01994889|Drug|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
203116|NCT01994889|Drug|Placebo|Placebo in soft gel capsules administered once a day for 30 months
203117|NCT01994902|Device|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
203118|NCT01994902|Device|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
203119|NCT01994915|Other|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
203120|NCT01994928|Device|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
203121|NCT01994928|Device|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
203122|NCT01994928|Procedure|Intubation|Intubation
203123|NCT01994941|Drug|Clopidogrel|A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.
Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.
A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients.
202502|NCT02007707|Behavioral|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
202503|NCT02007720|Drug|Serelaxin|Intravenous infusion
202504|NCT02007720|Drug|Placebo|Intravenous infusion
202505|NCT02007720|Other|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
202506|NCT02007733|Other|Serial Weights|We will collect serial weights on all children enrolled in this study.
202507|NCT02007733|Other|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
202508|NCT02007733|Other|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
202509|NCT00119925|Behavioral|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
202510|NCT02007746|Other|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
202511|NCT02007746|Other|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
202808|NCT01999764|Drug|QLT091001|QLT091001 administered orally at multiple time points.
202809|NCT01999764|Other|Placebo|Placebo is administered orally at multiple time points.
202810|NCT01999777|Drug|USL261|
202811|NCT01999777|Drug|Placebo|
202812|NCT01999790|Procedure|blepharotomy|upper eyelid surgery by blepharotomy
202813|NCT02002247|Drug|Placebo (for sodium-selenite)|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive a continuous infusion of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
202814|NCT02002260|Device|Levonorgestrel intrauterine system|
202815|NCT02002260|Drug|Combined oral contraceptives|
201908|NCT02018432|Drug|Roflumilast escalation dosage|This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.
Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks
201909|NCT02018432|Drug|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
201910|NCT02018445|Device|Accell Evo3 Demineralized Bone Matrix|
201911|NCT02018458|Biological|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
201912|NCT02018458|Biological|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
201913|NCT02018471|Behavioral|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
201914|NCT02018484|Procedure|Unicompartmental Knee Replacement|
201915|NCT00121108|Other|Placebo|15 mg/kg placebo administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season.
202202|NCT02013037|Drug|Eculizumab|At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.
202203|NCT02013050|Drug|SGX942|
202204|NCT02013050|Drug|Placebo|
202205|NCT02013089|Drug|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
202206|NCT00120523|Drug|Pimecrolimus|Pimecrolimus cream 1 %
201302|NCT02030795|Other|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
201303|NCT02030795|Other|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
201304|NCT02030808|Drug|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
201305|NCT02030808|Drug|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
201306|NCT02030821|Drug|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
201307|NCT02030821|Drug|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
201308|NCT02030834|Biological|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
201309|NCT02030847|Biological|CART-19 cells|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 108 transduced CAR T cells
201310|NCT00122317|Drug|eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
201311|NCT02030860|Drug|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
201312|NCT02030860|Drug|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
201313|NCT02030860|Drug|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
201314|NCT02030873|Other|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
201315|NCT02030886|Device|Sensimed Triggersfish®|All subjects will be monitored by Sensimed Triggerfish for 24 hours.
201316|NCT02030899|Procedure|Cage fusion|Randomized selection of surgery type
201317|NCT02030899|Procedure|Plate fusion|Randomized selection of surgery type
201318|NCT02030912|Drug|3 doses of amoxicillin daily for 7 days|
201319|NCT02030912|Drug|2 doses of minocycline daily for five days|
201616|NCT02025738|Device|NO ACTION|
200351|NCT02006706|Drug|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
200352|NCT02006719|Biological|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
200638|NCT00119249|Other|laboratory biomarker analysis|Correlative studies
200639|NCT01998880|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
200640|NCT01998880|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
200641|NCT01998880|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
200642|NCT01998893|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
200643|NCT01998906|Drug|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
200644|NCT01998906|Drug|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
200645|NCT01998906|Drug|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
200646|NCT01998906|Drug|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
200647|NCT01998919|Drug|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
200648|NCT01998919|Drug|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
200649|NCT02001246|Behavioral|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
200650|NCT02001246|Behavioral|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
200651|NCT02001259|Drug|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
200652|NCT02001259|Drug|epidural lidocaine|add into catheter at 48 hr after surgery
200653|NCT02001272|Drug|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
200058|NCT02014766|Procedure|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
200059|NCT02014779|Behavioral|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
200060|NCT02014779|Behavioral|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
200061|NCT00120731|Drug|Potassium Citrate|
200062|NCT02014805|Radiation|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
200063|NCT02014818|Device|CoCr-EES|
200353|NCT02006719|Other|Placebo|Placebo injection
200354|NCT02006732|Drug|olodaterol|fixed dose combination
200355|NCT02006732|Drug|tiotropium|fixed dose combination
200356|NCT02006732|Drug|placebo|
200357|NCT02006745|Drug|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
200358|NCT02006745|Drug|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA >25 but <1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA >1000 iU/mL at week 4).
200359|NCT00119847|Drug|Beta Adrenergic Blockers|
200360|NCT02006758|Device|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
200361|NCT02006771|Other|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
200362|NCT02006771|Other|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
200363|NCT02006771|Other|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
200364|NCT02009046|Behavioral|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
199757|NCT02019927|Device|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
199758|NCT02019940|Drug|Riluzole|
199759|NCT02019940|Drug|Placebo|
199760|NCT02019953|Other|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
199761|NCT00121199|Drug|doxorubicin hydrochloride|Given IV
199762|NCT02019953|Other|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
199763|NCT02022358|Drug|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
199764|NCT02022358|Drug|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
199765|NCT02022358|Drug|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
199766|NCT02022371|Procedure|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
199767|NCT00121381|Drug|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
199768|NCT02022384|Other|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
199769|NCT02022410|Other|CAS after primary and revision TKA|CAS and RAPT
200064|NCT02014831|Drug|Cetuximab|Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :
CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.
In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
200065|NCT02014831|Drug|TIP|The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :
PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.
IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.
CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.
In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
200066|NCT02014844|Drug|aldoxorubicin|
199449|NCT02027493|Drug|Reiferon R|subcutaneous injection of 100 μg/m2
199450|NCT02027493|Drug|Ribavirin|15 mg/kg daily on two divided doses
199451|NCT02027519|Other|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|Partners of the index participants and other household members will be offered HIV self-testing by the mobile "testing team". Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:
Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results
Self-administer HIV rapid test and read test results
Provide study staff with self-testing result
Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance
199452|NCT02027532|Drug|Cefazolin|
199453|NCT02027532|Drug|Vancomycin|
199454|NCT02027545|Behavioral|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
199455|NCT02027545|Behavioral|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
199456|NCT00000310|Drug|Risperidone|
199457|NCT00002178|Drug|Nelfinavir mesylate|
199458|NCT00121823|Biological|FP9 ME-TRAP|
199459|NCT02027545|Behavioral|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
199460|NCT02027545|Behavioral|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
199461|NCT02027558|Behavioral|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided by allied health personnel in individual sessions.
199462|NCT02029898|Drug|sodium chloride 0,9%|
199463|NCT02029911|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
199464|NCT02029924|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
199465|NCT02029924|Drug|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
199770|NCT02022423|Behavioral|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
198847|NCT02042924|Radiation|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
198848|NCT02042924|Device|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
198849|NCT02042937|Other|Exercise|Exercise to improve gluteus maximus recruitment
198850|NCT02042950|Drug|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
198851|NCT00000312|Drug|M-CPP|
199134|NCT02035150|Dietary Supplement|Oatmeal|A breakfast consisting of oatmeal
199135|NCT02035150|Dietary Supplement|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
199136|NCT00122655|Drug|protease inhibitors|
199137|NCT02035150|Dietary Supplement|No Breakfast|A breakfast consisting of plain water
199138|NCT02035163|Procedure|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
199139|NCT02035202|Behavioral|CBT2go|CBT administered using mobile intervention.
199140|NCT02035202|Device|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
199141|NCT02035215|Drug|Atorvastatin 20mg|
199142|NCT02035215|Drug|Omega-3-acids ethylesters 90 4g|
199143|NCT02035215|Other|Placebo(Omega-3-acids ethylesters 90)|
199144|NCT02035228|Device|Abdominal Stimulation - low / early|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at low stimulation current for the first half of exhalation
199145|NCT02035228|Device|Abdominal stimulation - low/late|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at low stimulation current for the second half of exhalation
199146|NCT02035228|Device|Abdominal Stimulation - low/full|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at low stimulation current throughout exhalation
199147|NCT00122668|Drug|non-nucleoside reverse transcriptase inhibitors|
203596|NCT02008110|Drug|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
203597|NCT02008123|Drug|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
203598|NCT02008136|Drug|Botulinum Toxins|intramuscular injections
203599|NCT02008149|Other|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
203600|NCT00119977|Procedure|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
203601|NCT02008162|Drug|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
203602|NCT02008175|Radiation|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
203603|NCT02008188|Device|Closed Loop Control with the Advisory/Automated Adaptive (AAA) Control system|During the experimental week, subjects will wear a standard CGM and insulin pump during the day and will follow their usual diabetes care. During the nighttime hours, the subjects will return to the study site and will resume closed-loop control overnight from 23:00-07:00. This study design will also allow for testing of system transitions from CGM-augmented pump therapy to closed loop control and back to CGM-augmented pump therapy.
203604|NCT02008201|Dietary Supplement|vitamin D|
198852|NCT00002185|Drug|Nelfinavir mesylate|
198853|NCT00123422|Behavioral|Breathing retraining|exercise training with computerized training program
198854|NCT02042976|Behavioral|Mindfulness-based cognitive therapy|
198855|NCT02045147|Behavioral|Grp 4 Normal Cognition, High Activation|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
198856|NCT02045173|Other|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
198857|NCT02045173|Device|Polysomnography|1 night polysomnography
228484|NCT02423915|Drug|Cyclophosphamide|50 mg/kg by vein on Day -8.
228485|NCT02423915|Radiation|Total Body Radiation|2 Gy delivered on Day -4.
228486|NCT02423915|Procedure|Fucosylated Regulatory T Cells|Participants assigned to a dose level of Tregs based on when they joined the study. Up to 2 dose levels of Tregs tested. The cells are infused on Day -1.
Phase I dose level of Tregs: 1 x 106 Tregs/kg body weight.
Phase II dose level of Tregs: 1 x 107 Tregs/kg body weight.
228487|NCT00167232|Drug|Naltrexone|
228488|NCT02423915|Procedure|Cord Blood Transplant|Cord blood transplant infused on Day 0.
228489|NCT00167505|Behavioral|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
228490|NCT02425917|Device|IPC-Calf|
228491|NCT02425930|Procedure|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
228492|NCT02425930|Drug|S-1+Oxaliplatin|A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:
S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）
Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
228493|NCT02425943|Device|injectable poly-L-lactic acid Sculptra Aesthetic|
228494|NCT02425956|Device|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
228495|NCT02425969|Procedure|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
228496|NCT02425969|Drug|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
228497|NCT02425982|Procedure|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
228498|NCT02425982|Procedure|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
228184|NCT00135239|Procedure|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
228185|NCT02161016|Device|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
228186|NCT02161029|Device|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
228187|NCT02161029|Device|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
228188|NCT02161055|Drug|Insulin|Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.
• Amount of insulin (u) = [fasting blood glucose (mmol/L) × 18-100] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2
228189|NCT02161081|Procedure|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
228190|NCT02161094|Behavioral|Give incentives to physicians based on their patient's HbA1c improvement|
228191|NCT02163382|Device|Neurovent Monitor XIII|RIP jacket installation
228192|NCT02163382|Device|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
228193|NCT02163382|Device|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
228194|NCT02163382|Device|Neurovent Monitor XIII|Second period with conventional NIV settings
228195|NCT02163395|Device|FullCeram implant|FullCeram implantation
228196|NCT02163408|Other|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
228197|NCT02163421|Drug|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
228198|NCT00135486|Biological|MenC-TT|
228199|NCT02163421|Drug|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
228200|NCT02163434|Drug|Gabapentin|
228201|NCT02163434|Drug|Metoclopramide|
228202|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
227565|NCT02176200|Drug|Berodual® HFA-MDI, low inspiratory flow rate|
227566|NCT00136903|Drug|Prochymal - 8 million cells|8 million cells/kg actual body weight intravenously on study Days 1 and 4
227567|NCT02176200|Drug|Berodual® HFA-MDI, medium inspiratory flow rate|
227568|NCT02176200|Drug|Berodual® HFA-MDI, high inspiratory flow rate|
227569|NCT02176213|Drug|Pomalidomide|4 mg PO x 21 days
227570|NCT02176213|Drug|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
227571|NCT02176213|Drug|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
227572|NCT02176226|Behavioral|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application.
227873|NCT02168439|Drug|Dexmedetomidine|
227874|NCT02168439|Drug|Midazolam|
227875|NCT02168452|Procedure|sentinel lymph node biopsy(SLNB)|incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.
double check after removal of the sentinel lymph node
sending frozen biopsy
227876|NCT02168465|Behavioral|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
227877|NCT00002273|Drug|Ganciclovir|
227878|NCT00136006|Behavioral|Study to determine the burden of disease|Unspecified
227879|NCT02168478|Drug|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
227880|NCT02170675|Drug|Ketoconazole|
227881|NCT02170688|Drug|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
227882|NCT02170688|Other|Weight calculation|
227883|NCT02170701|Drug|BIBR 1048|Ascending doses (in mg) given twice daily
227237|NCT02183714|Drug|Placebo|
227238|NCT02183727|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
227239|NCT02183727|Procedure|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
227240|NCT02183740|Behavioral|Multifaceted educational program|
227241|NCT02183753|Other|wood smoke|
227242|NCT02183753|Other|clean air|
227243|NCT02183766|Dietary Supplement|Galactooligosaccharide prebiotic|6 mL once a day
227244|NCT02183766|Drug|Maltodextrin|6 mL once a day
227245|NCT02183779|Procedure|post-occlusive hyperemia|
227246|NCT02183779|Procedure|cooling box|
227247|NCT00137839|Drug|Erlotinib|Given orally once a day until disease progression or serious side effects occur.
227248|NCT02183779|Drug|L-NMMA and Fluconazole dermic injection|
227249|NCT02183792|Drug|Tolvaptan|
227573|NCT02176252|Drug|AZD1722|
227574|NCT02176252|Drug|Placebo|
227575|NCT02176265|Device|Qvanteq bioactive coronary stent|PCI
227576|NCT02176278|Other|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
227577|NCT00136916|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
227578|NCT02176278|Other|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c<7%, BP<130/80 mmHg, LDL-C<1.8 mmol/l, triglyceride<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
198979|NCT02014298|Radiation|non-ablative fractional laser|3 treatments with 4-6 weeks interval
198980|NCT02014298|Other|control|observation, comparison to laser-treated area
198981|NCT02014311|Procedure|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
198982|NCT02014311|Procedure|CTA guided treatment strategy|CTA guided treatment strategy
198983|NCT02014324|Procedure|Endosonography|Complete endosonographic mediastinal staging is performed in 2 steps:
Systematic EBUS (airways)
Systematic EUS-B (esophagus)
198984|NCT02014337|Drug|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
198985|NCT02014350|Device|DePuy Delta Xtend Reverse TSA|
198986|NCT02014363|Drug|ETS6103 (low dose)|
198987|NCT00120679|Drug|darbepoetin alfa|
198988|NCT02014363|Drug|ETS6103 (high dose)|
198989|NCT02014363|Drug|Amitriptyline|
198990|NCT02014376|Drug|3% SD-101 dermal cream|applied topically once a day for 90 days
198991|NCT02014376|Drug|6% SD-101 dermal cream|applied topically once a day for 90 days
198992|NCT02014376|Drug|Vehicle (0% SD-101)|applied topically once a day for 90 days
198993|NCT02014402|Biological|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
199279|NCT02008656|Drug|Leucovorin|
199280|NCT00120042|Drug|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
199281|NCT02008656|Drug|Capecitabine (Xeloda®)|
199282|NCT02008656|Radiation|intensity modulated radiotherapy (IMRT)|
199283|NCT02008656|Behavioral|Quality of Life Questionnaires|
199284|NCT02008656|Procedure|DRE-Endoscopy|
199285|NCT02008669|Procedure|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
198692|NCT02065128|Other|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
198693|NCT00125723|Other|PI Discretion|PI Discretion
198694|NCT02065141|Drug|Indomethacin to induce small changes in absorption|Indomethacin 125 mg
198695|NCT02065154|Drug|Cyclophosphamide|
198696|NCT02065167|Biological|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
198697|NCT02065180|Dietary Supplement|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
198698|NCT02065180|Dietary Supplement|placebo|
198699|NCT02065193|Behavioral|ADOS/ADI-R/Clinical assessment|
198700|NCT02065219|Drug|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
198701|NCT02065219|Drug|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
198702|NCT02065232|Drug|Tilmanocept|
198703|NCT02065232|Drug|Sulfur Colloid|
198704|NCT00125736|Drug|Teprenone|
198705|NCT02065245|Biological|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|
198706|NCT02065245|Biological|Placebo|
198707|NCT02065258|Other|Breathing exercise|It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.
All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana
198708|NCT02065258|Other|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
203124|NCT01994941|Drug|Ticagrelor|A platelet aggregation inhibitor.
Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.
A loading dose of 180mg will be used.
203125|NCT00000308|Drug|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
203126|NCT00002156|Drug|Fomivirsen sodium|
203127|NCT00118924|Biological|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
203128|NCT01994954|Other|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
203129|NCT01994967|Drug|Levobupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
203130|NCT01994967|Drug|Bupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
203131|NCT01994980|Drug|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
203416|NCT02031757|Other|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
203417|NCT02031757|Other|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
203418|NCT02031770|Drug|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
203419|NCT02031770|Other|Control|subjects will receive no treatment
203420|NCT02031783|Dietary Supplement|Mixture of glucose and fructose|
203421|NCT00122421|Behavioral|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
203422|NCT02031783|Dietary Supplement|glucose|
203423|NCT02031796|Other|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
203424|NCT02031822|Procedure|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
203425|NCT02031835|Procedure|BWSTT (3 days a week for maximum of 20 minutes session)|
203426|NCT02031848|Other|Diet Intervention|
202816|NCT02002273|Procedure|Switching level of suction|
202817|NCT02002286|Drug|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
202818|NCT02002286|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
202819|NCT02002312|Drug|Lu-177-DOTA-girentuximab|Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.
Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments.
202820|NCT02002325|Drug|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
202821|NCT00119483|Drug|Nebido (Testosterone Undecanoate)|
202822|NCT02002325|Other|Standard care|Standard treatment for acute stroke without intravenous alteplase.
202823|NCT02002364|Procedure|tracheal intubation|
202824|NCT02002377|Drug|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
202825|NCT02002390|Drug|Fingolimod|A sphingosine-1-phosphate receptor regulator
202826|NCT02002403|Drug|Danazol|
202827|NCT02002429|Procedure|Intra-articular steroid|
202828|NCT02002429|Procedure|Medial branch block|
203132|NCT01994993|Drug|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
203133|NCT01994993|Drug|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
203134|NCT01994993|Drug|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
203135|NCT01997216|Device|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
203136|NCT01997229|Biological|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks 5-26
202207|NCT02013089|Drug|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
202208|NCT02013089|Drug|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
202209|NCT02013089|Drug|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
202210|NCT02013089|Drug|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
202211|NCT02013102|Drug|Decitabine Injection|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
202212|NCT02013115|Drug|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
202213|NCT02013128|Drug|Ublituximab|Ublituximab (IV infusion)
202214|NCT02013128|Drug|Ibrutinib|Ibrutinib oral daily dose
202215|NCT02013141|Drug|Telavancin|
202216|NCT02013154|Drug|DKN-01|Administered by IV infusion
202217|NCT00120523|Drug|Topical corticosteroids|TCS
202218|NCT02013154|Drug|Paclitaxel|Administered by IV infusion
202219|NCT02015793|Biological|Adalimumab|Subjects will be given subcutaneous injections of adalimumab.
202220|NCT02015806|Behavioral|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
202512|NCT02007746|Procedure|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
202513|NCT02007759|Device|VitalStim|This group will receive active VitalStim treatment.
202514|NCT02007759|Device|Sham VitalStim|This group will receive a sham VitalStim intervention.
202515|NCT02007772|Device|nHF|nasal high-flow is used over a period of 6 weeks (outpatient)
202516|NCT02007772|Device|BiPAP|BiPAP is used over a period of 6 weeks (outpatient)
201617|NCT02025751|Drug|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
201618|NCT02025751|Drug|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
201619|NCT02025777|Device|Capsule Endoscopy|
201620|NCT02025790|Procedure|Per Oral Endoscopic Myotomy (POEM)|Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.
Long endoscopic myotomy is performed 10 cm proximal to GEJ extending
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips
201621|NCT02025790|Procedure|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
201622|NCT02025803|Drug|TAS-114/capecitabine|Part 1 (dose-escalation phase):
Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated
Part 2 (expansion phase):
TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle).
201623|NCT00002177|Drug|Didanosine|
201624|NCT00121706|Behavioral|Condition A (see detailed summary)|
201625|NCT02025855|Drug|Methadone|
201626|NCT02025855|Drug|Placebo|
201627|NCT02025868|Behavioral|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
201628|NCT02025868|Drug|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.
Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)
201629|NCT02025881|Drug|Carboplatin + etoposide|Carboplatin 160 mg/m2 Day 1 to day 5 As an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).
Etoposide 100 mg/m2 D ay 1 to day 5 As an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle.
201630|NCT02025881|Drug|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1 As an intravenously infusion over 1 hour dilution in 200 ml/m² of 5% glucose saline or sodium chloride 9 mg/ml (0.9%)
201631|NCT02025881|Drug|Cyclophosphamide + Busilvex|Cyclophosphamide Level 1 20 mg/kg/day Level 2 30 mg/kg/day Level 3 40 mg/kg/day Level 4 50 mg/kg/day
Busilvex < 9 kgs 0.8 mg/kg/dose - 3.2 mg/kg/day 9 à < 16 kgs 0.96 mg/kg/dose - 3.84 mg/kg/day 16 à 23 kgs 0.88 mg/kg/dose - 3.52 mg/kg/day > 23 à 34 kgs 0.76 mg/kg/dose - 3.04 mg/kg/day > 34 kgs 0.64 mg/kg/dose
201632|NCT02025907|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
200654|NCT02001272|Drug|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
200655|NCT02001272|Drug|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
200656|NCT02001285|Drug|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
200657|NCT02001298|Drug|remifentanil|
200966|NCT01993862|Device|Merlin.net|
200967|NCT01993875|Drug|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
200968|NCT01993875|Drug|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
200969|NCT01993888|Biological|EVARREST™ Fibrin Sealant Patch|
200970|NCT01993888|Other|Standard of Care (SoC)|
200971|NCT01993901|Other|CSRT led telephone follow up|Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
200972|NCT00118872|Other|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
200973|NCT01993927|Drug|Voglibose|Voglibose Tablets / Voglibose OD Tablets
200974|NCT01993940|Drug|Naldemedine|Naldemedine tablet from weeks 1-12
200975|NCT01993940|Drug|Placebo|Placebo tablet from weeks 1- 12
200976|NCT01993953|Other|BodyPump|Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
200977|NCT01993953|Other|Personal training|Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
200978|NCT01993953|Other|Resistance training with instructor|Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT`s from group B will also serve as training instructors.
200365|NCT02009046|Behavioral|3 School Wide Components|Participants receive all three school wide components. The peer education and advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. This clinical services linkages includes "clinic without walls" health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
200366|NCT02009046|Behavioral|1 School Wide Component|Participants receive one of the three school wide components, the clinical services linkages. This component includes "clinic without walls" health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
200367|NCT00120081|Biological|Saline placebo|Inactive saline placebo control
200368|NCT02009059|Device|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
200369|NCT02009072|Procedure|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
200658|NCT00119392|Drug|fludarabine phosphate|Given IV
200659|NCT02001298|Drug|nitroprusside|
200660|NCT02001311|Drug|Chlorhexidine gluconate|
200661|NCT02001324|Other|Web-based data collection|
200662|NCT02001324|Other|Paper-based data collection|
200663|NCT02001337|Other|medical chart review|baseline, quarterly follow-up for 24 months
200664|NCT02001337|Other|survey administration|baseline
200665|NCT02001337|Other|Specimen collection|baseline
200666|NCT02001350|Other|Ultrasonography|
200667|NCT02001363|Drug|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
200668|NCT02001363|Drug|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
200669|NCT00119392|Drug|mycophenolate mofetil|Given orally
200670|NCT02001376|Other|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
200067|NCT02014857|Procedure|Gingival Crevicular Fluid Sampling|
200068|NCT02014870|Other|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
200069|NCT02014870|Other|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
200070|NCT02014870|Other|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
200071|NCT02014883|Drug|GLUT1 DS|
200072|NCT00120731|Drug|Acetazolamide|
200073|NCT02014896|Other|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
200074|NCT02014909|Biological|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
200075|NCT02014922|Drug|TheraTears® Lubricant Eye Drop|
200076|NCT02017522|Device|11C-PBR PET|Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.
Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes.
200077|NCT02017535|Drug|Fluoxetine|Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter.
200078|NCT02017535|Behavioral|Interpersonal Psychotherapy|Adolescent randomized to an increase in therapy (4 extra therapy sessions)
200079|NCT02017548|Behavioral|Life-extension default advance directive|
200080|NCT02017548|Behavioral|Comfort default advance directive|
200081|NCT02017561|Behavioral|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
200370|NCT02009072|Procedure|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
200371|NCT02009098|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
199771|NCT02022423|Behavioral|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals, a personalized website with an online community, and tailored tips.
199772|NCT02022436|Drug|contrast ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
199773|NCT02022449|Behavioral|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
199774|NCT02022462|Behavioral|Health Navigation|Experimental: Immediate peer health navigator intervention vs. waitlist control.
The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention.
199775|NCT02022475|Drug|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
199776|NCT02022475|Other|placebo|2 placebo capsules will be applied as a single dose
199777|NCT02022488|Drug|midazolam|Group M
199778|NCT00121394|Procedure|Chlorhexidine vaginal and infant wash|
199779|NCT02022488|Drug|alfentanil|Group MA
199780|NCT02022488|Drug|ketamine|Group MK
199781|NCT02022501|Drug|DE-120|
199782|NCT02022514|Other|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
199783|NCT02022514|Drug|Conventional medical treatment|
199784|NCT02022527|Drug|Acetyl Salicylic Acid|
199785|NCT02022527|Drug|Warfarin|
199786|NCT02022527|Drug|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
199787|NCT02022540|Drug|PAN-90806 Ophthalmic Solution|
199788|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
199789|NCT02024932|Drug|BVS857|BVS857 i.v. doses
199790|NCT02024932|Drug|Placebo|Placebo i.v. doses
199148|NCT02035228|Device|Abdominal stimulation - med/early|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at medium stimulation current for the first half of exhalation
199149|NCT02035228|Device|Abdominal stimulation - med/late|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at medium stimulation current for the second half of exhalation
199150|NCT02035228|Device|Abdominal Stimulation - med/full|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at medium stimulation current throughout exhalation
199151|NCT02035228|Device|Abdominal Stimulation - high/early|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at high stimulation current for the first half of exhalation
199152|NCT02035228|Device|Abdominal Stimulation - high/late|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at hig stimulation current for the second half of exhalation
199153|NCT02035228|Device|Abdominal Stimulation - high/full|Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at high stimulation current throughout exhalation
199466|NCT00122148|Behavioral|Feedback on provision of care|
199467|NCT02029937|Drug|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
199468|NCT02029950|Drug|Cytarabine|Given IV
199469|NCT02029950|Drug|Daunorubicin Hydrochloride|Given IV
199470|NCT02029950|Drug|Etoposide|Given IV
199471|NCT02029950|Other|Laboratory Biomarker Analysis|Correlative studies
199472|NCT02029950|Drug|Pomalidomide|Given PO
199473|NCT02029963|Device|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
199474|NCT02029963|Behavioral|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
199475|NCT02029976|Behavioral|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
199476|NCT02029976|Behavioral|Mailed monthly newsletters|Newsletters
199477|NCT00122161|Behavioral|ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers|
198858|NCT02045186|Other|Assessment of Oral HPV Infection|Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:
Polymerase chain reaction (PCR) for HPV DNA.
Fluorescent in-situ hybridization (FISH).
Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry.
198859|NCT02045199|Device|Tested product : V0111 cream|Application twice a day during 28 days
198860|NCT02045199|Device|Placebo|Application twice a day during 28 days
198861|NCT02045212|Drug|RPh201|SC injection twice a week during 13/26 weeks
198862|NCT02045212|Drug|Placebo|SC injection twice a week during 13/26 weeks
198863|NCT02045225|Behavioral|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
198864|NCT00123539|Drug|Estrogen Replacement Therapy|
198865|NCT02045238|Drug|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
198866|NCT02045238|Radiation|Chest X-Ray|
198867|NCT02045238|Other|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
198868|NCT02045251|Drug|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
198869|NCT02045264|Drug|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
198870|NCT02045277|Drug|IDP-118 Lotion|
199154|NCT02035241|Dietary Supplement|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
199155|NCT01995500|Device|Resolute|drug-eluting stent
199156|NCT01995513|Drug|Enzalutamide|160 mg by mouth once daily
199157|NCT01995513|Drug|Abiraterone|1000 mg by mouth once daily
199158|NCT00002156|Drug|Ganciclovir|
228499|NCT02425995|Procedure|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
228784|NCT02419755|Drug|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
228785|NCT02419755|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
228786|NCT00166439|Drug|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|rituximab 375 mg/m2 IV Weekly x 4 1 cycle only
dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles
oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles
cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles
pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles
228787|NCT02419755|Drug|Mercaptopurine|Given orally (PO).
228788|NCT02419755|Drug|Doxorubicin|Given intravenously (IV).
228789|NCT02419768|Other|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
228790|NCT02419781|Procedure|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
228791|NCT02419781|Procedure|No endovascular therapy|
228792|NCT02419794|Procedure|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
228793|NCT02421653|Dietary Supplement|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
228794|NCT02421653|Dietary Supplement|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
228795|NCT02421653|Dietary Supplement|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
228796|NCT02421653|Dietary Supplement|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
228797|NCT02421653|Dietary Supplement|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
228798|NCT02421653|Dietary Supplement|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
228799|NCT02421666|Behavioral|PNMI|eligible patients will receive patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care. Bilingually trained patient navigators will be recruited from our existing patient navigator training network and receive intensive training on HBV prevention, diagnosis and treatment management. The PN-led plus mobile phone text messaging intervention will offer three education sessions and serve as a liaison with respective clinics. The phone-based, text messaging will be designed by and for HBV patients who will craft appropriate reminders for follow up appointments or treatment, educational and motivational messages
228203|NCT02163447|Drug|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
228204|NCT02163447|Drug|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
228500|NCT00167518|Drug|Triamcinolone acetate|
228501|NCT02426008|Other|Growth Factors and Cytokine adding to embryo culture media|
228502|NCT02426021|Drug|MLN1202|Subcutaneous administration of MLN1202
228503|NCT02426021|Drug|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
228504|NCT02426034|Drug|Apatinib|Apatinib Mesylate Tablets 850 mg qd p.o. The observation period is 28 days
228505|NCT02426047|Dietary Supplement|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
228506|NCT02426060|Drug|Imrecoxib|
228507|NCT02426060|Drug|Warfarin|
228508|NCT02426086|Drug|Imetelstat 9.4 milligram/kilogram (mg/kg)|Participants will receive imetelstat intravenously as 9.4 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end.
228509|NCT02428062|Drug|Norepinephrine|Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
228510|NCT02428062|Drug|Dopamine|Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
228511|NCT02428075|Behavioral|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
228512|NCT02428088|Drug|Dasotraline|Dasotraline 2 mg once daily
228513|NCT02428088|Drug|Dasotraline|Dasotraline 4 mg once daily
228514|NCT02428088|Drug|Placebo Comparator|Placebo once daily
228515|NCT02428101|Genetic|polymorphism analysis|
228516|NCT02428127|Dietary Supplement|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
228517|NCT02428127|Dietary Supplement|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
228518|NCT00167778|Device|Transverse plane rotation adaptor pylon|Potential future practice
227884|NCT02170714|Other|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
227885|NCT02170727|Drug|DCV/ASV/BMS-791325|
227886|NCT02170740|Drug|BIBR 1048 MS - low dose|
227887|NCT02170740|Drug|BIBR 1048 MS - high dose|
227888|NCT02170740|Drug|BIBR 1048 MS + Pantoprazole|
227889|NCT02170753|Procedure|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
227890|NCT00136318|Drug|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
227891|NCT02170753|Procedure|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
227892|NCT02170766|Drug|BIBR 1048 low1|
228205|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
228206|NCT02163447|Drug|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
228207|NCT02163460|Procedure|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde [Health Ministry registry]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
228208|NCT02163460|Procedure|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
228209|NCT00135486|Biological|Hib-MenC-TT|
228210|NCT02163473|Procedure|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
228211|NCT02163473|Procedure|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
228212|NCT02163486|Device|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
227579|NCT02176278|Other|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
227580|NCT02176291|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
227581|NCT02176291|Drug|Placebo|matched placebo
227582|NCT02176304|Drug|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
227583|NCT02176304|Drug|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
227584|NCT02176317|Biological|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
227585|NCT02178488|Drug|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
227586|NCT02178488|Other|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
227587|NCT00137189|Procedure|Resource-oriented music therapy|
227588|NCT02178501|Dietary Supplement|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
227589|NCT02178514|Other|Formula fed with BabyNes Nutrition System|
227590|NCT02178527|Other|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
227591|NCT02178527|Other|Usual Care|Usual general podiatry care provded by UK National Health Service
227592|NCT02178540|Drug|Placebo|one dose (4 capsules) of placebo
227593|NCT02178540|Device|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
227893|NCT02170766|Drug|BIBR 1048 low2|
227894|NCT02170766|Drug|BIBR 1048 medium|
227895|NCT02170766|Drug|BIBR 1048 high|
227896|NCT02170766|Drug|Pantoprazole|
227897|NCT02170779|Behavioral|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
199286|NCT02008669|Other|Gustatory sensitivity test using Taste strips|16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.
Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)
199287|NCT02008669|Other|Questionnaires|Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):
Fatigue (EMIF-SEP)
Dysphagia (DYMUS)
Food intake (semi-structured questionnaire)
Depression (BDI-II)
Daily energy expenditure (NAP)
Visual analog scale to study quality of sleep
199288|NCT02008682|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
199289|NCT02008682|Drug|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
199290|NCT02008695|Behavioral|adult microfinance|Female piglet provided to household member. Participants agrees to repay their "loan" by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households
199291|NCT00120042|Drug|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
199292|NCT02008695|Behavioral|Youth microfinance only|One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
199293|NCT02008695|Behavioral|youth and adult micro finance|One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
199294|NCT02008708|Behavioral|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
199295|NCT02011646|Behavioral|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
199606|NCT02003547|Drug|AMA0076|
199607|NCT02003547|Drug|Placebo|
199608|NCT02003560|Radiation|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
199609|NCT02003573|Drug|decitabine iv|decitabine iv fixed dose
199610|NCT02003573|Drug|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
198709|NCT02065271|Dietary Supplement|herbal supplement|
198710|NCT02065271|Other|placebo supplement|
198994|NCT02016963|Biological|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
198995|NCT02016976|Drug|EMLA Analgesic Cream|
198996|NCT02016976|Drug|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
198997|NCT02016989|Device|RGTA OTR4120 (CACICOL20)|
198998|NCT02016989|Device|physiological salt solution|
198999|NCT02017002|Procedure|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
199000|NCT02017002|Procedure|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
199001|NCT02017015|Drug|Abraxane|Abraxane in combination with gemcitabine used in the initial treatment of metastatic pancreatic cancer for that patient
199002|NCT02017015|Drug|Gemcitabine|Abraxane in combination with gemcitabine used in the initial treatment of metastatic pancreatic cancer for that patient
199003|NCT02017041|Device|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
199004|NCT00120965|Other|Manual CPR|Manual CPR
199005|NCT02017041|Device|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
199006|NCT02017054|Other|Cath|No intervention - registry
199007|NCT02017067|Procedure|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
199008|NCT02017093|Device|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
199009|NCT02017093|Device|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
203427|NCT02031848|Other|Assessments and Diet Intake|
203428|NCT02031861|Drug|nifedipine CR tablets (Xin Ran)|
203429|NCT02031861|Drug|nifedipine CR tablets (Adalat)|
203430|NCT02031887|Dietary Supplement|formula with synbiotics|
203431|NCT02031887|Dietary Supplement|formula without synbiotics|
203432|NCT00122421|Other|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
203433|NCT02031900|Device|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
203434|NCT02031926|Device|Positive expiratory pressure|
203435|NCT02031939|Drug|Induction and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy(capecitabine combine with oxaliplatin) alone with standard chemoradiotherapy before surgery.
203436|NCT02031939|Radiation|standard chemoradiotherapy|All rectal patients in this group will receive standard chemoradiotherapy and surgical resection.
203437|NCT02031952|Procedure|hepatectomy combined with lymphadenectomy|
198711|NCT02065284|Other|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
198712|NCT02065297|Other|1 blood sample|
198713|NCT02065297|Other|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
198714|NCT02067702|Procedure|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
198715|NCT02067715|Drug|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
198716|NCT02067728|Behavioral|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
198717|NCT00125983|Drug|Lopinavir/ritonavir|
203137|NCT01997229|Drug|Placebo|Placebo
203138|NCT01997255|Drug|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
203139|NCT01997268|Drug|Placebo|Corn Oil
203140|NCT00119119|Drug|tocopherol|
203141|NCT01997268|Drug|SC401B 2 capsules|
203142|NCT01997268|Drug|SC401B 4 capsules|
203143|NCT01997268|Drug|SC401B 6 capsules|
203144|NCT01997281|Dietary Supplement|dietary fiber-enriched cereal|provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)
one serving of steamed egg is added for dinner and breakfast
203145|NCT01997281|Other|conventional cereal|provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)
one serving (40g) of steamed egg is added for dinner and breakfast
203146|NCT01997294|Drug|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
203147|NCT01997320|Other|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
203148|NCT01997320|Other|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
203149|NCT01997333|Drug|CDX-011|
203150|NCT01997333|Drug|Capecitabine|
203151|NCT00119132|Drug|artesunate-amodiaquine|
203438|NCT02031952|Procedure|hepatectomy alone|
203439|NCT02031965|Biological|oncolytic HSV-1716|Given IT
203440|NCT02034435|Other|glucose and insulin testing|
203441|NCT02034448|Procedure|Continuous Renal Replacement Therapy|
203442|NCT02034461|Device|Utah Slanted Electrode Array|This study is using the microelectrode array device for scientific purposes only. This device will not be promoted or test marketed, and is not available for commercial distribution. There will be no costs to the participants for this device. This study is not aimed at collecting data for pre-market approval.
202517|NCT02007785|Behavioral|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
202518|NCT02007798|Drug|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
202519|NCT02007798|Drug|normal saline|100 ml per bag
202520|NCT00002165|Drug|Nelfinavir mesylate|
202521|NCT02010060|Behavioral|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
202522|NCT02010086|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
202523|NCT02010086|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
202524|NCT00120263|Procedure|Plasma Exchange|
202525|NCT02010099|Drug|PP110 Gel|
202526|NCT02010099|Drug|PP110 Medicated wipes|
202527|NCT02010099|Drug|Preparation-H Cream|
202528|NCT02010112|Other|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
202529|NCT02010138|Procedure|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
202829|NCT02002429|Procedure|Sham intra-articular block|
202830|NCT02002442|Other|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
202831|NCT02002455|Device|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
201633|NCT02025907|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
201916|NCT02020824|Other|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
201917|NCT02020824|Other|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
201918|NCT02020824|Other|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
201919|NCT02020824|Other|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
201920|NCT02020837|Procedure|Lymphaticovenous Micro-Anastomosis|
201921|NCT02020863|Device|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
201922|NCT02020876|Other|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
201923|NCT00002176|Drug|Nelfinavir mesylate|
201924|NCT00121264|Drug|tanespimycin|Given IV
201925|NCT02020889|Biological|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
201926|NCT02020889|Drug|Placebo|Placebo will be available as 0.9% sodium chloride
201927|NCT02020902|Other|Cetrizine hydrochloride|As provided on the patient information leaflet
201928|NCT02020915|Procedure|lateral sphincterotomy|
201929|NCT02020915|Procedure|ultrasound guided lateral sphincterotomy|
201930|NCT02020928|Device|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
201931|NCT02020941|Drug|carfilzomib|Given IV
201932|NCT02020941|Drug|dexamethasone|Given IV or PO
201933|NCT02020941|Other|laboratory biomarker analysis|Correlative studies
200979|NCT01996306|Drug|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
200980|NCT01996306|Biological|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
200981|NCT01996306|Drug|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
200982|NCT01996306|Drug|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
200983|NCT01996319|Drug|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
200984|NCT01996319|Drug|Placebo|Placebo once a day via Breezhaler® device
200985|NCT01996332|Drug|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
201320|NCT02033512|Drug|Transdermal formulation|66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
201321|NCT02033525|Drug|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
201322|NCT00122564|Biological|DC-Chol|
201323|NCT02033525|Other|Rehabilitation|Standard rehabilitation program
201324|NCT02033538|Drug|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
201325|NCT02033551|Drug|Veliparib|
201326|NCT02033551|Drug|Carboplatin|
201327|NCT02033551|Drug|Paclitaxel|
201328|NCT02033551|Drug|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
201329|NCT02033564|Device|Macintosh/Miller Laryngoscope|
201330|NCT02033564|Device|Glidescope Laryngoscope|
201331|NCT02033577|Procedure|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
201332|NCT02033577|Procedure|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
201333|NCT00122577|Drug|Tenofovir|
200671|NCT02001376|Other|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
200672|NCT02001376|Other|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
200673|NCT02001389|Drug|EVP-6308|Arms 1, 2, 3, 4
200674|NCT02004080|Other|Intensive Care treatment|intensive care treatment
200675|NCT02004093|Drug|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
200676|NCT02004093|Drug|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
200677|NCT02004093|Drug|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
200678|NCT02004093|Drug|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
200679|NCT02004106|Drug|RO6895882|Single ascending dose IV
200680|NCT02004106|Drug|RO6895882|Multiple ascending doses IV q2W or q3W
200681|NCT02004106|Drug|RO6895882|MTD IV, q2W or q3W
200986|NCT01996345|Procedure|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
200987|NCT01996358|Drug|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
200988|NCT01996358|Drug|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
200989|NCT00002157|Drug|Thalidomide|
200990|NCT00119015|Drug|Fluticasone propionate|
200991|NCT01996358|Drug|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
200992|NCT01996371|Device|Pedicle Screw|
200372|NCT02009111|Behavioral|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 — 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 — 12 hrs).
200373|NCT02009124|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
200374|NCT02009137|Device|EVERA|EVERA apply for 12 weeks
200375|NCT02009137|Device|ESTES|ESTES apply for 12 weeks
200376|NCT02009163|Drug|Lisdexamfetamine dimesylate|
200377|NCT02009163|Other|Placebo|
200378|NCT00120107|Drug|Black Tea|
200379|NCT02009176|Procedure|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
200380|NCT02009176|Procedure|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
200381|NCT02012114|Other|Cysteamine bitartrate|No intervention
200382|NCT02012140|Drug|ticagrelor|
200383|NCT02012153|Biological|Mesenchymal Stromal Cells|
200384|NCT02012166|Drug|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
200385|NCT02012166|Drug|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
200386|NCT02012166|Drug|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
200387|NCT02012166|Drug|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
200388|NCT02012166|Drug|Placebo|Placebo administered orally in 240 mL of water
200389|NCT00120445|Procedure|air|0.3 ml of filtered air
200682|NCT02004119|Drug|KHK4577|
200683|NCT02004119|Drug|Placebo|
199791|NCT02024945|Drug|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
200082|NCT02017561|Drug|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
200083|NCT02017574|Behavioral|Reaching Task|Learn a reaching task that requires coordination of the arm segments
200084|NCT00121017|Drug|Sustiva (efavirenz)|
200085|NCT02017600|Drug|ND-420|ND-420 50 mg/m2 on day1
200086|NCT02017600|Procedure|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
200087|NCT02017600|Drug|Cisplatin|cisplatin 70 mg/m2 on day1
200088|NCT02017600|Drug|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
200089|NCT02017613|Drug|RP6530|Escalating doses starting at 25 mg BID
200090|NCT02017626|Biological|mCyp c 1|2 patient groups with different doses of allergen.
200091|NCT02017639|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
200092|NCT02017639|Drug|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
200093|NCT02017678|Biological|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
200094|NCT02017691|Device|Near Infrared Spectroscopy|If crSO2 is <10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable >10th centile, or if crSO2 is > 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
200095|NCT00121017|Drug|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
200096|NCT02019953|Other|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
200097|NCT02019979|Drug|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
200098|NCT02019979|Behavioral|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
200099|NCT02020005|Other|Non-flavored 2mg nicotine gum|
199478|NCT02029989|Device|Glucose and lipids|Point-of-care (POCT) screening for diabetes and dyslipidemia.
Glucose and Lipids
199479|NCT02029989|Device|Glycosylated Hemoglobin A1c|Point-of-care (POCT) screening for diabetes
Glycosylated Hemoglobin A1c
199480|NCT02029989|Device|Blood Pressure and Heart Rate|Point-of-care (POCT) screening for hypertension
Blood Pressure and Heart Rate
199481|NCT02029989|Device|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
199482|NCT02029989|Device|Waist and Hip circumference|Measurement for Central Obesity
Waist and Hip circumference
199483|NCT02029989|Behavioral|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
199484|NCT02030002|Device|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
199485|NCT02030002|Device|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
199486|NCT02030015|Drug|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
199487|NCT02030015|Other|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
199488|NCT00122161|Behavioral|Profiling performance|
199792|NCT02024971|Drug|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
199793|NCT02024984|Drug|Clomiphene Citrate|Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.
Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle.
199794|NCT02024997|Other|Magnetic Resonance Imaging (MRI)|
199795|NCT02025010|Drug|abiraterone acetate|Daily four 250 mg tablets (1,000 mg) of AA taken orally for 28 day cycles. No food should be consumed for at least two hours before the dose and for at least one hour after the dose. The tablets should be swallowed whole with water. Tablets should not be crushed or chewed.
199796|NCT02025010|Drug|prednisone|Take with food 5 mg Oral Twice daily
199797|NCT02025010|Procedure|pre-treatment and progression tumor biopsies|Participants will undergo pre-treatment and progression tumor biopsies. After the progression biopsy is performed, protocol therapy will be discontinued. Participants who stop protocol therapy before receiving four cycles of AA will not be asked to undergo the second biopsy.
199159|NCT00118963|Drug|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
199160|NCT01995513|Drug|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
199161|NCT01995513|Drug|Prednisone|5 mg by mouth twice daily
199162|NCT01995526|Drug|Insulin Peglispro|Administered subcutaneously
199163|NCT01995539|Device|Second iPro2 test|
199164|NCT01995552|Device|External Loop Recorder|
199165|NCT01995565|Other|PLR|
199166|NCT01995578|Drug|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
199167|NCT01995604|Other|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
199168|NCT01995604|Other|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
199169|NCT01995617|Biological|Placebo|normal saline, 0.5 mL per dose
199170|NCT00118963|Drug|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
199171|NCT01995617|Biological|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
199172|NCT01995617|Biological|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
199173|NCT01995617|Biological|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
199174|NCT01995617|Biological|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
199489|NCT02032680|Behavioral|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
199490|NCT02032680|Behavioral|In-persons multi-family psycho-educational treatment|This intervention will provide the VA's evidence-based, in-person delivered, multi-family psychoeducational treatment, termed Multi-Family group (MFG). This intervention is delivered to Veterans and their families or other supporters using an in-person format.
228800|NCT02421679|Drug|TNX-102 SL|TNX-102 Sublingual tablets
228801|NCT02421692|Other|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER)|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
228802|NCT00166777|Procedure|exercise training|
229100|NCT02415660|Procedure|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
229101|NCT02415660|Behavioral|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
229102|NCT02415660|Behavioral|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
229103|NCT02415660|Procedure|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 2-3 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
229104|NCT00165763|Drug|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
229105|NCT02415660|Device|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
229106|NCT02417662|Other|Non-investigational platinum-based doublet chemotherapy|There is no intervention in the control group, patients will receive standard chemotherapy alone.
229107|NCT02417675|Other|Community-based Adherence Clubs|Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.
Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care.
229108|NCT02417675|Other|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
228519|NCT02428127|Other|Water|lukewarm water
228520|NCT02428140|Device|Medtronic Reveal LINQ|
228521|NCT02428140|Device|Sorin Spiderflash-t|
228522|NCT02428153|Other|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
228803|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
228804|NCT02421718|Radiation|Radiotherapy|
228805|NCT02421731|Device|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
228806|NCT02421731|Other|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
228807|NCT02421744|Behavioral|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
228808|NCT02423915|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
228809|NCT02423915|Drug|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
228810|NCT02423915|Procedure|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
228811|NCT02423915|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
228812|NCT02423928|Biological|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
228213|NCT02163486|Device|I-GEL|Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.
I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc
228214|NCT02163499|Drug|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for up to 12 months.
228215|NCT02166164|Other|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
228216|NCT02166164|Other|Heat-pain-detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.
4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
228217|NCT02166177|Drug|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
228218|NCT02166190|Procedure|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
228219|NCT02166190|Procedure|Stenting only|Stenting only
228220|NCT02166229|Drug|Divalproex sodium|
228221|NCT02166242|Drug|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
228222|NCT00135733|Drug|Amevive (Alefacept)|
228223|NCT02166255|Biological|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
228523|NCT02428179|Procedure|StOP? - Control group|Control group - Surgical procedure without Study Intervention
228524|NCT02428179|Procedure|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
228525|NCT02428192|Other|Laboratory Biomarker Analysis|Correlative studies
228526|NCT02428192|Biological|Nivolumab|Given IV
228527|NCT02428205|Drug|Propranolol|
228528|NCT02428205|Drug|Placebo|
228529|NCT00167778|Device|Rigid pylon|Current clinical practice
228530|NCT02428218|Drug|dimethyl fumarate|enteric-coated microtablets
228531|NCT02428218|Drug|Placebo|enteric-coated microtablets
227898|NCT02170779|Other|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
227899|NCT02170792|Drug|BIBR 1048 MS|Low, medium or high dose
227900|NCT02170792|Drug|Ranitidine|150mg
227901|NCT00136331|Biological|Pandemic influenza vaccine|
227902|NCT02170805|Drug|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
227903|NCT02170805|Drug|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
227904|NCT02170805|Drug|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
227905|NCT02170805|Drug|Pantoprazole|Pantoprazole 40 mg
227906|NCT02170818|Other|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
227907|NCT02173353|Device|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
227908|NCT00136565|Drug|Velcade + ACVBP regimen|
227909|NCT02173366|Behavioral|Change Club Intervention|
227910|NCT02173379|Device|Absorb BVS|Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
227911|NCT02173379|Device|XIENCE|Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition
Stent lengths: 8, 12, 15, 18, 23, and 28 mm
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
227912|NCT02173392|Drug|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
227913|NCT02173405|Drug|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
228224|NCT02166255|Other|laboratory biomarker analysis|Correlative studies
228225|NCT02166268|Drug|AVANZ Phleum pratense 15,000 SQ+|
228226|NCT02166268|Drug|Placebo|
199611|NCT02003586|Dietary Supplement|plant-based ingredient|
199612|NCT00002162|Drug|Zidovudine|
199613|NCT00119561|Behavioral|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
199614|NCT02003586|Dietary Supplement|No plant-based ingredient|
199615|NCT02003599|Device|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
199616|NCT02003599|Device|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
199617|NCT02003612|Other|Not applicable - observational study|No intervention exists as this is a retrospective observational study
199618|NCT02003625|Drug|GCSF|
199619|NCT02003625|Drug|meloxicam|
199620|NCT02003625|Drug|Placebo|
199621|NCT02003638|Drug|Niacin|Niacin titrated to 6000 mg daily
199622|NCT02003638|Drug|Placebo|Placebo provided in the same pill quantity as niacin arm
199623|NCT02006303|Procedure|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
199624|NCT02006303|Procedure|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
199916|NCT01998477|Biological|TIVb|Licensed influenza vaccine
199917|NCT01998490|Other|Animal-assisted activity|
199918|NCT01998490|Other|Robot-assisted activity|
199919|NCT01998503|Drug|Bortezomib|
199010|NCT02017106|Procedure|Endovenous Laser ablation and concomitant phlebectomies|
199011|NCT02017106|Procedure|Endovenous Laser ablation and sequential phlebectomies|
199012|NCT02017119|Drug|Comparison between Lactulose and Lactulose-Paraffin|
199013|NCT02017132|Dietary Supplement|Pomegranate extract|
199296|NCT02011646|Behavioral|Controlled Intervention|"The Weight of the World" is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
199297|NCT02011659|Drug|Ramosetron|
199298|NCT02011672|Other|nutrient-enriched milk|
199299|NCT02011672|Other|regular milk|
199300|NCT02011685|Behavioral|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
199301|NCT02011685|Behavioral|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
199302|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
199303|NCT00120393|Drug|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
199304|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
199305|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
199306|NCT02011724|Device|Apligraf|
199307|NCT02011737|Drug|naftopidil 75mg|
198718|NCT02067728|Behavioral|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
198719|NCT02067741|Drug|CR1447|Three prespecified dose levels will be tested (100 mg, 200 mg, 400 mg), corresponding to one 4 g stick pack application a day, two 4 g stick packs applications a day, and two 4 g stick packs applications twice daily, respectively
198720|NCT02067767|Drug|Abacavir/Lamivudine/Dolutegravir|At Day 1 (D1):
group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;
group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1.
198721|NCT02067780|Drug|Levofloxacin 500mg|One tablet per day for 7days.
198722|NCT02067793|Drug|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
198723|NCT02067793|Drug|Placebo|Single intravenous injection into the arm on Day 0
198724|NCT02067793|Drug|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
198725|NCT02067793|Drug|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
198726|NCT02067806|Drug|Spinal administration of chloroprocaine|
198727|NCT02067819|Device|Active Orthotic Device|
198728|NCT00125983|Drug|Ortho Novum 1/35|
198729|NCT02067819|Device|Sham Oral Orthotic|
199014|NCT02017145|Drug|Chloraprep|
199015|NCT00120978|Drug|Advair|
199016|NCT02017158|Other|Virtual Sprouts|The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
199017|NCT02017171|Drug|Allopurinol|
199018|NCT02019524|Biological|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
203443|NCT02034474|Drug|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
203444|NCT02034474|Drug|Placebo|intravenously via iv drip over 60 min
203445|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
203446|NCT02034487|Other|retrospective data collection|
203447|NCT02034500|Biological|1790GAHB vaccine|
203448|NCT02034500|Biological|GAHB-Placebo|
203449|NCT02034513|Drug|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
203450|NCT02034513|Drug|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
203451|NCT02034513|Drug|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
203452|NCT02034526|Device|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
203453|NCT02034526|Device|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
203454|NCT02034539|Device|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
203455|NCT02034552|Drug|Radium-223 dichloride (Xofigo,BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg every 4 weeks x 6 doses intravenous injection (slow bolus)
203456|NCT00002183|Drug|Abacavir sulfate|
203457|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
203458|NCT02034552|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily
203459|NCT02034552|Drug|Prednisone|Prednisone 5 mg capsule taken orally twice daily
198730|NCT02067845|Behavioral|Adapted Many Men, Many Voices (3MV) group level intervention|The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.
Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.
Delivery methods include discussion, role-plays and risk-reduction planning.
202832|NCT00119496|Drug|rosiglitazone|oral tablet, 4mg bd for 4 weeks
202833|NCT02002468|Other|Test result sent by letter|
202834|NCT02002468|Other|Test result conveyed by general practitioners|
202835|NCT02002481|Other|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
202836|NCT02005237|Behavioral|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
202837|NCT02005263|Procedure|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
202838|NCT00119717|Device|NeuroFlo™ catheter|45 minute treatment
202839|NCT02005276|Behavioral|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
202840|NCT02005276|Behavioral|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
202841|NCT02005276|Behavioral|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
202842|NCT02005289|Biological|MOR00208|Given by IV infusion
202843|NCT02005289|Drug|lenalidomide|Given PO
202844|NCT02005289|Other|Correlative Studies|Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
202845|NCT02005302|Drug|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
202846|NCT02005302|Drug|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
202847|NCT02005302|Dietary Supplement|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
202848|NCT02005302|Dietary Supplement|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
203152|NCT01997372|Drug|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) ＞1×109/L.
201934|NCT02020954|Procedure|ECG, echocardiography, cardiac MRI, sera biomarkers|
201935|NCT00121264|Other|laboratory biomarker analysis|Correlative studies
202221|NCT02015806|Behavioral|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
202222|NCT02015806|Behavioral|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
202223|NCT02015819|Biological|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
202224|NCT02015819|Drug|flucytosine|Given orally
202225|NCT00120835|Drug|valopicitabine|
202226|NCT02015819|Drug|leucovorin calcium|Given orally
202227|NCT02015819|Other|pharmacological study|Correlative studies
202228|NCT02015819|Other|laboratory biomarker analysis|Correlative studies
202229|NCT02015832|Device|Coronary stent|
202230|NCT02015832|Radiation|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
202231|NCT02015832|Device|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
202232|NCT02015832|Device|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
202233|NCT02015832|Device|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
202234|NCT02015845|Device|Accuvein|
202235|NCT02015845|Device|Routine technique|Placement of peripheral intravenous catheters using the routine technique
202236|NCT00120835|Drug|pegylated interferon|
202237|NCT02015858|Procedure|Chest drain withdrawal|
202238|NCT02015858|Device|Pain Monitor|
201334|NCT02033590|Device|Biodegradable (purified) surgical silk scaffold|
201335|NCT02033603|Drug|Ropivacaine|30mls of 0.5% ropivacaine
201336|NCT02033616|Biological|ovapuldencel-T|Comparison of a cancer treatment containing autologous irradiated tumor cells mixed with autologous antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing autologous immune cells suspended in an immune system stimulant.
201337|NCT02033616|Biological|MC: Autologous PBMCs in GM-CSF|Comparison of a cancer treatment containing autologous irradiated tumor cells mixed with autologous antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing autologous immune cells suspended in an immune system stimulant.
201338|NCT02033629|Drug|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
201339|NCT02033629|Drug|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
201340|NCT02033629|Drug|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
201634|NCT02025907|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily.
201635|NCT00121706|Behavioral|Condition B (see detailed summary)|
201636|NCT02028429|Drug|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
201637|NCT02028442|Biological|Enadenotucirev|Oncolytic virus
201638|NCT02028455|Biological|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
201639|NCT02028468|Procedure|hemiarthroplasty|
201640|NCT02028481|Procedure|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
201641|NCT02028494|Drug|Capecitabine|Two dosages comparison
201642|NCT00121927|Behavioral|Atkins diet (15 grams/day carbohydrates)|
201643|NCT02028507|Drug|Palbociclib|
201644|NCT02028507|Drug|Capecitabine|
201645|NCT02028507|Drug|Exemestane|
201646|NCT02028520|Device|SPY imaging|
201647|NCT02028533|Drug|Oxytocin|
201648|NCT02028533|Drug|Placebo|
200993|NCT01996384|Procedure|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
200994|NCT01996384|Procedure|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
200995|NCT01996384|Drug|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
200996|NCT01996397|Procedure|Cardiac resynchronization therapy device implantation|
200997|NCT01996410|Device|Acupuncture|
200998|NCT00002159|Drug|Amphotericin B|
200999|NCT00119262|Drug|doxorubicin hydrochloride|Given IV
201000|NCT01998919|Drug|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
201001|NCT01998919|Drug|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
201002|NCT01998919|Drug|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
201341|NCT02033642|Behavioral|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to train parents or family members of adolescent/young adult participants with intellectual disability to monitor diet and physical activity behavior, set goals, provide support and reinforcement, and assess and make changes to the home environment.
201342|NCT02033642|Behavioral|Maintenance|The Maintenance condition in this study is a 12-session intervention for parent/family member of adolescents with intellectual disability, designed to teach families to continue lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports and prevent relapse.
201343|NCT02033655|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
201344|NCT01993979|Drug|Chemotherapy|
201345|NCT01993979|Other|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
201346|NCT01994005|Behavioral|Facebook|Facebook page with contraception information used for counseling
200684|NCT00119626|Drug|NXY-059|
200685|NCT02004132|Drug|Axiron|Solution administered topically using pump and applicator
200686|NCT02004145|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
200687|NCT02004145|Behavioral|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
200688|NCT02004158|Behavioral|Positive psychology intervention|
200689|NCT02004171|Other|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
200690|NCT02004171|Drug|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
200691|NCT02004184|Drug|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
200692|NCT02004184|Drug|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
200693|NCT02004197|Drug|Quadruple Allopathic therapy|
200694|NCT02004197|Drug|Pylorex plus|
200695|NCT00119639|Drug|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
200696|NCT02004210|Procedure|transarterial radioembolization (TARE)|transarterial radioembolization
200697|NCT02004210|Procedure|transarterial chemoembolization (TACE)|transarterial chemoembolization
200698|NCT02004223|Radiation|Dose escalation using stereotactic boost|This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.
The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.
Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes.
200699|NCT02004236|Device|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
200700|NCT02004236|Device|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
200701|NCT02006771|Other|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
200702|NCT02006797|Other|reconciliation|medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
200100|NCT02020005|Other|Non-flavored 4mg nicotine gum|
200101|NCT02020005|Other|Mint-flavored 2mg nicotine gum|
200102|NCT02020005|Other|Mint-flavored 4mg nicotine gum|
200390|NCT02012166|Biological|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
200391|NCT02012166|Biological|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
200392|NCT02012166|Biological|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
200393|NCT02012179|Other|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
200394|NCT02012192|Drug|Ganetespib|
200395|NCT02012192|Drug|Paclitaxel|
200396|NCT02012205|Procedure|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
200397|NCT02012218|Drug|ADT|
200398|NCT02012218|Drug|Brexpiprazole|
200399|NCT02012231|Drug|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
200400|NCT00120445|Procedure|expansile gas|0.3 ml of perfluoropropane gas
200401|NCT02012244|Drug|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
200402|NCT02012244|Drug|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
200403|NCT02012257|Procedure|AMSA nerve block injectio|Sites of injection
200404|NCT02012270|Procedure|PRINCIPLES technique|Principles technique for closure of midline laparotomy incisions
closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)
the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other
the SL/WL ratio should be at least 4/1
SL/WL = (150cm x number of sutures used) - (the suture remnants)
the mean stitch length should be less than 4 cm (suture length / number of stitches placed)
199798|NCT02025010|Genetic|assessment of serum corticosteroid intermediates and ACTH|•Participants will undergo assessment of serum corticosteroid intermediates and ACTH at baseline and subsequent treatment visits for correlation with symptoms of mineralocorticoid excess.
199799|NCT00121641|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
199800|NCT02025023|Drug|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
199801|NCT02025023|Drug|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
199802|NCT02025023|Procedure|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
199803|NCT02025023|Drug|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
199804|NCT02025036|Drug|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
199805|NCT02025036|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
199806|NCT02025036|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
199807|NCT02025049|Drug|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
199808|NCT02025049|Drug|Placebo|mannitol-based DP-b99 look-alike
200103|NCT02020005|Other|Non-flavored nicotine inhaler|
200104|NCT02020005|Other|Mint-flavored nicotine ihaler|
200105|NCT00121199|Drug|vincristine sulfate|Given IV
200106|NCT02020018|Device|wound VAC (Prevena)|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
200107|NCT02020018|Other|standard wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after strenotomy
200108|NCT02020031|Drug|Vancomycin|1g IV
200109|NCT02020031|Drug|Vancomycin|500 mg intraosseous
200110|NCT02020044|Other|Endothelial Keratoplasty|
200111|NCT02020057|Procedure|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
199491|NCT02032680|Other|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
199492|NCT02032693|Dietary Supplement|Everycell™|
199493|NCT00122486|Drug|Tenofovir Disoproxil Fumarate|
199494|NCT02032693|Other|Placebo|
199495|NCT02032706|Device|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
199496|NCT02032719|Behavioral|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
199497|NCT02032719|Behavioral|Lifestyle counseling|Lifestyle counseling
199498|NCT02032732|Other|leukocyte esterase test|leukocyte esterase test on fluid removed by intra-articular aspiration
199499|NCT02032758|Drug|Propranolol|Single oral dose of propranolol
199500|NCT02032771|Device|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
199501|NCT02032784|Drug|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
199502|NCT02032797|Drug|Progesterone|
199503|NCT02032810|Drug|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
199504|NCT00122499|Drug|tadalafil|
199505|NCT02032810|Drug|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
199506|NCT02032823|Drug|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
199507|NCT02032823|Drug|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
199508|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
199809|NCT02027558|Behavioral|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided by allied health personnel in individual sessions.
229109|NCT02417675|Other|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
229110|NCT02417688|Device|Cu[64]-25%-CANF-Comb PET-MR|Injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
224260|NCT02192580|Drug|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
224261|NCT02192593|Behavioral|Computer CBT|
224262|NCT02192606|Device|Storz 3D Laparoscopy System|
224263|NCT02192606|Device|2D Laparoscopy|
224264|NCT00138814|Procedure|Radiotherapy (boost versus no boost)|
224265|NCT02192619|Other|observational|
224266|NCT02192632|Drug|Epiduo once daily with detailed instruction for how to apply it|
224267|NCT02192632|Drug|Epiduo- once daily, simple instruction for application|
224268|NCT02192632|Drug|BPO once daily|
224269|NCT02192645|Drug|Sanfujiu|
224270|NCT02192645|Drug|placebo|
224271|NCT02192671|Procedure|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
224272|NCT02192671|Procedure|Radiofrequency Ablation|
224273|NCT02192684|Drug|Pioglitazone|45 mg daily Insulin sensitizing
224274|NCT02192684|Drug|placebo|Compare with pioglitazone
224275|NCT00138827|Drug|Biotene (mouth care)|
224276|NCT02192697|Drug|ASP8273|Oral administration
224277|NCT02192710|Procedure|electronic tab|classic use of an electronic tab with age specific games
224278|NCT02192710|Drug|Midazolam oral intake|
228813|NCT02423928|Drug|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
228814|NCT02423928|Drug|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
228815|NCT02423941|Procedure|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
228816|NCT02423941|Procedure|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
229111|NCT02417701|Other|Laboratory Biomarker Analysis|Correlative studies
229112|NCT02417701|Other|Pharmacological Study|Correlative studies
229113|NCT02417701|Drug|Sapanisertib|Given PO
229114|NCT02417753|Drug|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
229115|NCT02417779|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
229116|NCT00166166|Drug|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
229117|NCT02417779|Device|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
229118|NCT02417805|Procedure|Intervention: Remote Ischemic Preconditioning|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
229119|NCT02417818|Device|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
229120|NCT02417818|Device|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
229121|NCT02417831|Drug|tamsulosin capsules|
229122|NCT02417831|Drug|tamsulosin HCl|
229123|NCT02417844|Drug|tamsulosin (Astellas)|
229124|NCT02417844|Drug|Tamsulosin HCL|
229125|NCT02419807|Drug|Indocyanine Green Solution|Given subdermally
229126|NCT02419807|Radiation|Technetium Tc-99m Sulfur Colloid|Given via injection
228532|NCT02428231|Drug|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
228533|NCT02428244|Behavioral|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
228534|NCT02428244|Behavioral|Motivational Interviewing + Follow-up|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months.
228535|NCT02395081|Dietary Supplement|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
228536|NCT02395094|Behavioral|Child Life|Child Life preparation in surgical daycare can include:
role-play using dolls and medical equipment (either toy doctor kits or true medical materials)
the use of books/storyboards that show pictures of operating room and daycare routines
teaching & rehearsing coping and relaxation skills such as deep breathing and guided imagery
age-appropriate explanation of what to expect throughout the day in SDCU
228537|NCT02395120|Behavioral|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
228538|NCT02395120|Behavioral|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
228539|NCT02395120|Behavioral|Reduced intervention letter|Reduced (removing text corresponding to "timeline") CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control).
228540|NCT02395120|Behavioral|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
228541|NCT02395120|Behavioral|Reduced DIG|Text and illustrations related to the "timeline" construct of the CSM have been removed in the reduced dental information guide.
228817|NCT00167245|Drug|Topiramate|300mg/day for 13 weeks
228818|NCT02423954|Drug|Temsirolimus|
228819|NCT02423954|Drug|Irinotecan|
228820|NCT02423954|Drug|Irinotecan + capecitabine|
228821|NCT02423954|Drug|nivolumab|
228822|NCT02423967|Biological|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
228823|NCT02423967|Biological|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
228227|NCT02166294|Other|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
228228|NCT02166294|Procedure|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
228229|NCT02166320|Device|Partially covered SEMS|
228230|NCT02166320|Device|Fully covered SEMS|
228231|NCT02166333|Dietary Supplement|200 IU/d cholecalciferol|
228232|NCT02166333|Dietary Supplement|1000 IU/d cholecalciferol|
228233|NCT00135733|Drug|Placebo|
228234|NCT02166333|Dietary Supplement|2000 IU/d cholecalciferol|
228235|NCT02166333|Dietary Supplement|4000 IU/d cholecalciferol|
228236|NCT02166346|Drug|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
228237|NCT02166346|Drug|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
228238|NCT02166359|Drug|Extraneal (Icodextrin)|
228239|NCT02166359|Drug|Glucose solution|
228240|NCT02166372|Other|Observation of natural course of Diabetes Mellitus Type 2|
228241|NCT02166385|Drug|pregabalin|Given PO
228242|NCT02168478|Other|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
228243|NCT02168478|Other|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
228244|NCT02168491|Drug|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
228542|NCT02395133|Drug|Dupilumab|
199920|NCT01998503|Drug|dexamethasone|Given orally
199921|NCT01998503|Biological|filgrastim|Given subcutaneous
199922|NCT01998503|Procedure|autologous hematopoietic stem cell transplantation (ASCT)|Given on day 0
199923|NCT01998503|Drug|Melphalan|
199924|NCT01998529|Drug|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
199925|NCT01998529|Drug|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
199926|NCT00119210|Other|placebo|
199927|NCT01998542|Biological|AlloVax|Personalized anti-cancer vaccine Intradermal injection AlloSimt followed immediately by the intradermal injection of CRCL
199928|NCT01998542|Biological|CRCL|autologous tumor-derived chaperone protein mixture
199929|NCT01998542|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
199930|NCT01998542|Other|PlasmaLyteA with 1% human serum albumin|PlasmaLyteA with 1% human serum albumin, packaged, labeled and shipped to appear the same as the active experimental products and under the same storage conditions.
199931|NCT01998555|Other|CBT|
199932|NCT02000947|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
199933|NCT02000947|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
199934|NCT00119366|Other|laboratory biomarker analysis|Correlative studies
199935|NCT02000947|Drug|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
199936|NCT02000947|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
199937|NCT02000947|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
199938|NCT02000960|Drug|Triheptanoin|Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
199939|NCT02000973|Drug|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
199940|NCT02000973|Drug|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
199308|NCT02011750|Drug|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
199309|NCT02011750|Drug|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
199310|NCT02014402|Biological|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
199625|NCT02006316|Procedure|Microsurgical subinguinal varicocelectomy|
199626|NCT02006329|Device|acupuncture|
199627|NCT02006342|Drug|Insulin Glargine|
199628|NCT02006342|Drug|Regular Insulin|
199629|NCT02006355|Drug|Ropivacaine|
199630|NCT00119795|Behavioral|Health Education Control|Lectures on information relevant to successful aging
199631|NCT02006368|Other|Blood Collection and autologous re-infusion|Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.
After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated.
199632|NCT02006394|Dietary Supplement|Fish Oil|fish oil capsules
199633|NCT02006394|Dietary Supplement|Polyphenol Capsules|delphinidin polyphenol capsules
199634|NCT02006394|Dietary Supplement|Corn Oil Capsules|Corn Oil Capsules
199635|NCT02006394|Dietary Supplement|Corn starch capsules|Maltodextrin capsules
199636|NCT02006394|Other|Reduced glycemic index bread products|Made by Zone Labs
199637|NCT02006394|Other|Market variety bread products|placebo bread products
199019|NCT02019524|Biological|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
199020|NCT02019537|Procedure|Steroid injection into the subacromial space|Group: Steroid
Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)
The number of injections : only once during the study period
Injection site : subacromial space
Material : 25-gauze spinal needle
Subacromial injections were performed using ultrasonographic guidance.
199021|NCT02019537|Procedure|Allogeneic PRP injection into the subacromial space|Group: Allogeneic PRP
Total volume of injection drugs: 4ml
The number of injections : only once during the study period
Injection site : subacromial space
Material : 25-gauze spinal needle
Subacromial injections were performed using ultrasonographic guidance.
199022|NCT02019550|Device|Rebif® Rebidose®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week (12 injections) by using Rebif® Rebidose® self-injector device in Period 1 (4 weeks). Total treatment duration will be of 8 weeks.
199023|NCT00121186|Procedure|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
199024|NCT02019550|Device|Rebiject II®|Subjects who will receive Rebif® by using Rebif® Rebidose® in Period 1 will be receiving Rebif® at a dose of 44 mcg subcutaneously three times a week (12 injections) by using Rebiject II® self-injector device in Period 2 (4 weeks). Total treatment duration will be of 8 weeks.
199025|NCT02019550|Device|Rebiject II®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week (12 injections) by using Rebiject II® self-injector device in Period 1 (4 weeks). Total treatment duration will be of 8 weeks.
199026|NCT02019550|Device|Rebif® Rebidose®|Subjects who will receive Rebif® by using Rebiject II® in Period 1 will be receiving Rebif® at a dose of 44 mcg subcutaneously three times a week (12 injections) by using Rebif® Rebidose® self-injector device in Period 2 (4 weeks). Total treatment duration will be of 8 weeks.
199027|NCT02019563|Procedure|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
199311|NCT02014415|Procedure|Liver Biopsy|Liver biopsy will be performed in Year 1 and Year 5 of the study.
199312|NCT02014428|Dietary Supplement|Hyaluronic acid|
199313|NCT02014428|Drug|Placebo|
199314|NCT00120679|Drug|recombinant human erythropoietin (rHuEPO)|
199315|NCT02014441|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
198731|NCT02067845|Behavioral|A group-based HIV/STI prevention intervention for women who have sex with women|
198732|NCT02067858|Radiation|Stereotactic Radiosurgery|
198733|NCT02067871|Other|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
198734|NCT02067871|Other|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
198735|NCT02070627|Drug|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
198736|NCT02070627|Device|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
198737|NCT02070640|Drug|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
198738|NCT02070640|Device|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
198739|NCT02070653|Drug|Ticagrelor|
198740|NCT02070653|Drug|Placebo|
198741|NCT02070666|Behavioral|Protective mechanical ventilation|Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).
Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure < 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.
Fraction of inspired oxygen inspired oxygen fraction (FiO2) > 0.21 to maintain oxygen saturation 90-92%.
PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).
Plateau pressure ≤ 25 cmH2O
198742|NCT02070666|Behavioral|Control group|Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).
Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.
· FiO2 > 0.21 to maintain oxygen saturation 90-92%.
PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).
Plateau pressure ≤ 25 cm H2O.
198743|NCT00126243|Drug|rituximab|
199028|NCT02019563|Procedure|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
203153|NCT01997385|Procedure|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
203154|NCT01997385|Procedure|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
203155|NCT01997411|Drug|Intranasal Glucagon|
203156|NCT01997411|Drug|Glucagon|
203157|NCT01997424|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
203158|NCT01997424|Device|FibroScan, Echosens, Paris, France|
203159|NCT01999790|Procedure|posterior approach|upper eyelid surgery by posterior approach
203160|NCT01999803|Drug|sNN0029|
203161|NCT00119314|Drug|docetaxel|
203162|NCT01999803|Drug|Placebo|
203163|NCT01999816|Behavioral|Lifestyle Redesign|Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
203164|NCT01999829|Drug|citrate of caffeine|
203165|NCT01999829|Drug|placebo|
203166|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
203167|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
203168|NCT01999842|Biological|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
203169|NCT01999855|Other|Phoniatric tests|
203170|NCT01999868|Biological|Ustekinumab|Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.
Dose:
Participants who weigh <= 100 kg at study entry will receive 45 mg of ustekinumab.
Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab.
203171|NCT01999868|Biological|Abatacept|Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.
Dose:
125 mg sub-cutaneous injection
202239|NCT02015871|Drug|Degarelix|
202240|NCT02015897|Procedure|Physical TherapyA|Group A:
Skin care
Manual lymphatic drainage
Bandaging using Coban™2Lite
Guidance on physical activity
202241|NCT02015897|Procedure|Physical TherapyB|Group B:
Skin care
Bandaging using Coban™2Lite
Guidance on physical activity
202530|NCT02010138|Procedure|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
202531|NCT02010151|Other|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
202532|NCT02010164|Dietary Supplement|Co-enzyme Q10|600mg for 3 months
202533|NCT02010203|Biological|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
202534|NCT02010203|Biological|Placebo|Injection containing sterile solution but no cells
202535|NCT00002168|Drug|Indinavir sulfate|
202536|NCT00120276|Device|Less invasive mitral valve repair|
202537|NCT02010203|Biological|BCG|Vaccine derived from a live bacterium
202538|NCT02010216|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
202539|NCT02010242|Drug|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
202540|NCT02010242|Drug|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
202541|NCT02010255|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
202542|NCT02010255|Drug|RBV|RBV administered as 200 mg tablets (up to 1000-1200 mg) in a divided daily dose
202543|NCT02010268|Other|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
202544|NCT02013167|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. In the first induction cycle, the initial dose of blinatumomab will be 9 μg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles (beginning with the second induction cycle and continuing through consolidation and maintenance, for applicable subjects) 28 μg/day will be the dose for all 4 weeks of continuous treatment.
201649|NCT02028546|Procedure|bathing and moisturizer application|regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.
regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))
201650|NCT02028559|Device|Propulse 1|Move kidney stones with Propulse 1 device.
201651|NCT02028585|Dietary Supplement|Low-fat milk group|
201652|NCT02028598|Drug|Treatment 1|An oral single dose administration
201653|NCT00121940|Behavioral|Guided Care|Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; "best practices" for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources.
201654|NCT02028598|Drug|Treatment 2|An oral single dose administration
201655|NCT02028598|Drug|Treatment 3|Co-administration of oral single doses
201936|NCT02020967|Other|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
201937|NCT02020980|Drug|Botulinum Toxin Type A (BoNT-A) Injection|This is an observational study designed to reflect the clinical practice in real life as closely as possible.
Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines.
201938|NCT02023385|Device|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
201939|NCT02023385|Device|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
201940|NCT02023398|Device|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
201941|NCT02023398|Device|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
201942|NCT02023411|Drug|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneously every day at 8-9 pm
201943|NCT00002177|Drug|Hydroxyurea|
201944|NCT00121498|Drug|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
201945|NCT02023424|Drug|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
201347|NCT01994005|Behavioral|Pamphlet|Contraceptive knowledge pamphlets
201348|NCT00118885|Behavioral|Tai Chi Chih|
201349|NCT01994031|Drug|Paclitaxel liposome injection|
201350|NCT01994031|Drug|Paclitaxel injection|
201351|NCT01994044|Procedure|Cervical fusion|
201352|NCT01994070|Drug|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
201353|NCT01994070|Drug|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
201354|NCT01994083|Drug|Placebo|Administered orally
201355|NCT01994083|Drug|IX-01|Administered orally
201356|NCT01994096|Drug|Caspofungin|
201357|NCT01994109|Drug|MYOBLOC|MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the "B" serotype of botulinum toxin. It is the only commercially available "B" serotype, and also the only available botulinum toxin that does not require reconstitution for use.
201358|NCT01994109|Other|PLACEBO|
201656|NCT02028624|Behavioral|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
201657|NCT02028637|Other|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
201658|NCT02028650|Biological|the first donor's stem cell|HLA-matched stem cell infusion
201659|NCT02028650|Biological|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
201660|NCT02028663|Drug|CJ-12420|Once daily, Oral administration
201661|NCT02028663|Drug|Esomeprazole|Once daily, Oral administration
201003|NCT01998945|Behavioral|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
201004|NCT01998945|Behavioral|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
201005|NCT01998958|Drug|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
201006|NCT01998958|Drug|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
201007|NCT01998958|Drug|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
201008|NCT01998958|Drug|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
201009|NCT01998958|Drug|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
201010|NCT00119262|Drug|cyclophosphamide|Given IV
201011|NCT01998971|Drug|Daratumumab|Administered by intravenous infusion in combination with the applicable backbone treatment.
201012|NCT01998971|Drug|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
201013|NCT01998971|Drug|Pomalidomide|Administered orally in accordance with product labeling and local standards.
201014|NCT01998971|Drug|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
201015|NCT01998971|Drug|Melphalan|Administered orally in accordance with product labeling and local standards.
201016|NCT01998971|Drug|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
201017|NCT01998971|Drug|Thalidomide|Administered orally in accordance with product labeling and local standards.
201018|NCT01998971|Drug|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
201019|NCT01998971|Drug|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
200405|NCT02014922|Drug|TheraTears® preservative-free single-use containers|
200406|NCT02014922|Dietary Supplement|TheraTears® Nutrition|
200407|NCT02014922|Other|TheraTears® TheraLid® Eyelid Cleanser|
200408|NCT02014935|Other|Low intensity laser|The study wants to evaluate the use of low intensity laser on the spastic muscle.
Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate.
200703|NCT02006810|Behavioral|Induction of endothelial function variations|
200704|NCT02006836|Dietary Supplement|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
200705|NCT02006836|Dietary Supplement|Glucose|We dissolved 50 g of glucose in 200 ml water.
200706|NCT02006836|Other|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
200707|NCT00119847|Drug|Platelet Inhibitors|
200708|NCT02006836|Drug|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
200709|NCT02006836|Drug|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
200710|NCT02006849|Drug|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
200711|NCT02006875|Device|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
200712|NCT02006888|Drug|IBI-10090|
200713|NCT02006888|Drug|Placebo|Placebo
200714|NCT02006901|Procedure|microdecompression|a minimal invasive surgical technique
200715|NCT02006901|Procedure|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
200716|NCT02006914|Dietary Supplement|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
200717|NCT02006927|Device|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
200112|NCT02020070|Drug|Degarelix|
200113|NCT02020070|Drug|Ipilimumab|
200114|NCT02020070|Procedure|Radical Prostatectomy|
200115|NCT02020096|Procedure|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.5 and 1.0 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.2mA, otherwise intraneural needle position should be suspected.
200116|NCT00002176|Drug|Hydroxyurea|
200117|NCT00121199|Drug|prednisone|Given PO
200118|NCT02020096|Procedure|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.5 and 1.0 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.2mA, otherwise intraneural needle position should be suspected.
200119|NCT02022540|Drug|Lucentis|
200120|NCT00002176|Drug|Didanosine|
200121|NCT00121407|Drug|Visudyne for injection|
200122|NCT02022553|Procedure|usual rectal cancer surgery|
200123|NCT02022553|Procedure|RACHEL|
200409|NCT02014948|Other|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
200410|NCT02014961|Procedure|Dermal biopsy|Skin biopsy
200411|NCT02014961|Behavioral|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
200412|NCT00120731|Behavioral|Diet low in oxalate and purines|
200413|NCT02014961|Genetic|Whole-exome sequencing|Whole-exome sequencing (WES)
200414|NCT02014987|Behavioral|Training programmes|Runners with a high body mass index follow two types of training programmes:
a running programme of 3 kilometres per week
a running programme 6 kilometres per week
The amount of running will be increased with 10 % per week.
200415|NCT02015000|Procedure|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
199810|NCT02027571|Behavioral|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
199811|NCT02027584|Other|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
199812|NCT02027597|Other|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
199813|NCT02027597|Other|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
199814|NCT02027597|Other|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
199815|NCT02027623|Behavioral|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
199816|NCT00121823|Biological|MVA ME-TRAP|
199817|NCT02027623|Behavioral|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
199818|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-F)|The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
199819|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-T)|The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
199820|NCT02027662|Drug|Osvaren Granules|
199821|NCT02027662|Drug|Osvaren film-coated tablets|
199822|NCT02027675|Other|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
224279|NCT02192723|Drug|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day), twice per day, 8 weeks
224280|NCT02192723|Drug|Risperidone|2~6mg/day, twice per day, 8 weeks
224281|NCT02192723|Drug|Olanzapine|Olanzapine, 400~750mg/day, twice per day, 8 weeks
224282|NCT02192723|Drug|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
224283|NCT02192723|Device|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
224284|NCT02192723|Drug|Ziprasidone|Ziprasidone 80~160mg/day, twice per day, 8 weeks
224605|NCT02187627|Drug|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6924963 injected will be less than or equal to (</=)10 micrograms (ug), injection volume </=20 milliliter (ml). Target injected activity for [11C]RO6924963 will be 370-740 megabecquerel (MBq) [10-20 millicurie (mCi)].
224606|NCT02187627|Drug|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6931643 injected will be </=10 ug, injection volume </=20 ml. Target injected activity for [11C]RO6931643 will be 370-740 MBq (10-20 mCi).
224607|NCT02187627|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [18F]RO6958948 injected will be </=10 ug, injection volume </=20 ml. Target injected activity for [18F]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of [18F] RO6958948 ill be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
224608|NCT02187640|Behavioral|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
224609|NCT02187640|Behavioral|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
224610|NCT02187679|Drug|Abobotulinum toxin A|
224611|NCT02187692|Behavioral|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
224612|NCT02187705|Drug|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
224613|NCT02187718|Procedure|Sentinel Node Procedure under Local Anaesthesia|
224614|NCT00138177|Drug|vorinostat|Given orally
224615|NCT02187718|Procedure|Sentinel Node Procedure under General Anaesthesia|
229127|NCT02419807|Procedure|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
229128|NCT02419807|Procedure|Axillary Lymph Node Biopsy|Undergo biopsy
229129|NCT00166452|Drug|Lenalidamide|
229130|NCT02419820|Drug|APD791|Temanogrel
229131|NCT02419820|Drug|Clopidogrel|Clopidogrel
229132|NCT02419820|Drug|Aspirin|Aspirin
229133|NCT02419820|Drug|Placebo for APD791|Placebo for APD791
224285|NCT02195141|Radiation|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
224286|NCT02195141|Radiation|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
224287|NCT02195154|Drug|18F-DTBZ|During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.
The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
224288|NCT02195167|Drug|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg." The language should precede the text that is currently there
224289|NCT02195180|Drug|ERY001|
224290|NCT02195180|Drug|Gemcitabine|
224291|NCT02195180|Drug|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
224292|NCT02195193|Other|Integrated care model for ACS and depression|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
228824|NCT02423980|Drug|Glucagon|
228825|NCT02423993|Behavioral|Education by structured programme|Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time ("CGM-RT"); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients.
228826|NCT02423993|Device|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
228827|NCT02423993|Device|CGM-RT|Continuous glucose monitoring ("CGM") will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month.
228828|NCT00167245|Drug|placebo|placebo pills
228829|NCT02426086|Drug|Imetelstat 4.7 mg/kg|Participants will receive imetelstat intravenously as 4.7 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end.
228830|NCT02426099|Drug|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
228831|NCT00167531|Behavioral|treadmill walking with partial weight support|
228832|NCT02426099|Other|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
228833|NCT02426112|Drug|Azithromycin|
228834|NCT02426112|Drug|Placebo|
228835|NCT02426125|Drug|Ramucirumab|Administered IV
228836|NCT02426125|Drug|Docetaxel|Administered IV
228837|NCT02426125|Drug|Placebo|Administered IV
229134|NCT02419833|Procedure|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
229135|NCT02419833|Procedure|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
229136|NCT02419833|Device|Coronary artery stenting|Implantation of coronary stents
229137|NCT02419846|Other|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
228543|NCT02395133|Drug|Placebo|
228544|NCT00163202|Drug|Atorvastatin|
228545|NCT02395146|Procedure|Monitoring|intraoperative EBSLN monitoring
228546|NCT02395159|Device|Prevena™ IMS|Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.
The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells.
228547|NCT02395159|Other|sterile plaster dressings|standard wound management method of sterile plaster dressings
228548|NCT02395172|Drug|Avelumab|Subjects will receive 10 milligram per kilogram (mg/kg) of avelumab as a 1-hour intravenous (IV) infusion once every 2 weeks.
228549|NCT02395172|Drug|Docetaxel|Subjects will receive 75 mg per square meter (m^2) (per label) of docetaxel by IV infusion once every 3 weeks.
228550|NCT02395185|Other|Bottle Administration|Patients are given a bottle during the casting process. Contents of bottle depend on the arm to which they are randomized.
228551|NCT02395211|Behavioral|Usual Physiotherapy|Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.
The intervention will last 30 minute a day x 4 weeks
228552|NCT02395211|Device|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
228553|NCT02395224|Other|cancer treatment and follow-up according to current regional and national guidelines|
228554|NCT02395237|Drug|: Amaryl® M IR 2/1000|
228555|NCT00163215|Drug|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
228556|NCT02397525|Drug|LIPO-202|
228557|NCT02397538|Drug|Fimasartan|
228558|NCT02397538|Drug|Amlodipine|
228559|NCT02397538|Drug|Rosuvastatin|
228560|NCT00163553|Drug|Placebo|
228561|NCT02397551|Procedure|IVF/ICSI|
228562|NCT02397551|Drug|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
200236|NCT01993602|Procedure|Breathing exercises|The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.
The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.
The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.
Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise.
200237|NCT01993615|Procedure|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
200238|NCT01993615|Procedure|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
200239|NCT01993628|Other|Rey figure test|
200240|NCT01993628|Other|MRI|
200241|NCT01993641|Drug|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
200242|NCT01993641|Drug|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
200243|NCT01993641|Drug|Decitabine|All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.
The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks.
200244|NCT00118846|Other|Matching placebo|Milk protein administered twice daily
200245|NCT01993654|Procedure|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
200246|NCT01993667|Drug|Acetazolamide|Administration of low dose acetazolamide
200247|NCT01993680|Drug|Pyridostigmine bromide|Drug doses during the trial:
Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days
200248|NCT01993680|Drug|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
200249|NCT01996085|Drug|lisinopril|Angiotensin converting enzyme inhibitor recommended in case of:
"hyperconstrictive" profile (SVRI > 2500-2800 dyn•s•cm-5•m2)
"hyperdynamic" profile (CI > 4.2 l/min/m2 and/or HR > 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)
"hypervolemic" profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)
"balanced" profile
199638|NCT02006407|Radiation|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
199639|NCT02006407|Device|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
199640|NCT02006407|Behavioral|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
199641|NCT00119821|Behavioral|Weight Reducing Diet|Behavioral intervention
199642|NCT02006420|Device|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
199643|NCT02008708|Other|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
199644|NCT02008721|Drug|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
199645|NCT02008721|Drug|Placebo|Placebo
199941|NCT02000973|Drug|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
199942|NCT02000973|Drug|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
199943|NCT02000986|Behavioral|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
199944|NCT02000999|Other|brushing of bile duct strictures for cytology|
199945|NCT00119379|Drug|NucleomaxX|NucleomaxX 36 grams TID every other day
199946|NCT02001012|Drug|Artemether-lumefantrine combination|
199947|NCT02001012|Drug|Chloroquine|
199948|NCT02001025|Device|Absorb scaffold|
199949|NCT02001025|Device|Xience stent|
199950|NCT02001038|Other|Survey|
199951|NCT02001051|Procedure|Adrenalectomy|Surgical removal of one or both adrenal glands
199952|NCT02001051|Other|Observation|Observation for 6 months prior to surgery
199316|NCT02014454|Drug|Propranolol eye drops|All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.
The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group.
199317|NCT02014467|Drug|Denosumab|injection
199318|NCT02014467|Drug|Placebo|injection
199319|NCT02014480|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
199320|NCT02014480|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
199321|NCT02014480|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
199322|NCT02014493|Procedure|High Flow Nasal Cannulae (HFNC)|HFNC 6 l/pr.min
199323|NCT02014493|Procedure|Continuous Positive Airway Pressure (CPAP)|CPAP 6 l/pr.min
199324|NCT02014506|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -2
199325|NCT00120692|Drug|Darbepoetin Alfa|
199326|NCT02014506|Drug|Cyclophosphamide|50 mg/kg IV on day -3 and -2
199327|NCT02014506|Biological|anti-thymocyte globulin|
199328|NCT02014506|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
199329|NCT02014506|Radiation|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 & -4 (severe aplastic anemia)
199330|NCT02014506|Procedure|TCRαβ-depleted hematopoietic cell transplantation|
199331|NCT02014506|Device|CliniMACS|Immunogenetic depletion of TCRαβ cells
199332|NCT02014519|Procedure|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
199333|NCT02014519|Other|Data collection|Active questioning
199646|NCT02008734|Drug|PD0332991|
199647|NCT02008747|Drug|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
199648|NCT02008760|Dietary Supplement|Omega Krill with D3|
199029|NCT02019576|Radiation|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if < 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
199030|NCT02019589|Drug|Progesterone|
199031|NCT02022111|Behavioral|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
199032|NCT00121329|Drug|Intrauterine lidocaine infusion 4%|
199033|NCT02022111|Behavioral|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
199034|NCT02022111|Other|Psychiatrist and Diabetologist Reviews|A senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline (patients do not attend) case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients (who can access prescription changes at local pharmacies) and their usual care providers.
199035|NCT02022111|Other|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
199036|NCT02022111|Other|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
199037|NCT02022124|Drug|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
203460|NCT02034552|Drug|Enzalutamide|Enzalutamide 160 mg (4 x 40 mg tablets) taken orally once daily
203461|NCT02034565|Drug|Apixaban|
203462|NCT02034578|Drug|Apixaban|
203463|NCT02034591|Drug|Apixaban|
203464|NCT02034604|Drug|Naftofidil|
203465|NCT02034604|Drug|Tamsulosin|
203466|NCT02034617|Behavioral|LiMoNid|
203467|NCT01994993|Drug|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
203468|NCT01994993|Drug|metronidazole, clindamycin, or peracillin-tazobactam|IV infusion of metronidazole, clindamycin, or peracillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
203469|NCT01995006|Drug|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
203470|NCT00118937|Drug|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
203471|NCT01995006|Drug|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
203472|NCT01995019|Drug|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
203473|NCT01995019|Drug|Physiologic saline|1 ml intra-articular placebo
203474|NCT01995032|Drug|750 mg metformin and 7.5 g L-citrulline daily p.o.|
203475|NCT01995032|Drug|Placebo|
203476|NCT01995045|Drug|Triamcinolone|Retrobulbar anesthesia
203477|NCT01995045|Drug|Bupivicaine Hydrochloride|Retrobulbar anesthesia
203478|NCT01995058|Drug|cabozantinib|Tablets taken orally
203479|NCT01995058|Drug|abiraterone|Tablets taken orally daily
203480|NCT01995058|Drug|prednisone|Tablets taken orally twice daily
203481|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
203482|NCT01995071|Drug|ABT-493|tablet
202545|NCT02013167|Drug|Standard of Care Chemotherapy|FLAG ± anthracycline based regimen (such as Idarubicin 10 mg/m2 days 1, 3; fludarabine 30 mg/m2 days 1-5; cytarabine 2g/m2 days 1-5)
HiDAC based regimen that utilize doses of cytarabine arabinoside at least 1 g/m2 or greater per day ± anthracycline and/or in combination with other drugs such as native E.coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents
High-dose methotrexate based regimen (such as 500 mg/m2 - 3 g/m2 HDMTX (infusion time up to 24 hours) in combination with other drugs such as native E.coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents
Clofarabine or clofarabine based regimens
202546|NCT02013193|Device|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
202547|NCT02013193|Device|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
202849|NCT00119717|Other|Control|ASA Guidelines
202850|NCT02005315|Drug|Vantictumab|Administered intravenous (IV) infusion.
202851|NCT02005315|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
202852|NCT02005315|Drug|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
202853|NCT02005328|Device|Tested product : DC161-DP0291|Application of product in the mouth twice daily
202854|NCT02005328|Device|Tested product : DC161-DP0292|Application of product in the mouth twice daily
202855|NCT02005328|Device|Tested product : DC161-DP0293|Application of product in the mouth twice daily
202856|NCT02005328|Device|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
202857|NCT02005341|Device|nanOSS|
202858|NCT02005341|Device|Autograft|
202859|NCT00119925|Other|information tools|tools and checklists to improve information provision
202860|NCT02007811|Biological|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
202861|NCT02007824|Device|ULSD-12D|wound cleansing and debridement using ULSD-12D
202862|NCT02007824|Device|SONOCA-180|wound cleansing and debridement using SONOCA-180
202863|NCT02007837|Drug|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
202864|NCT02007837|Other|Daily text reminder text messages|
201946|NCT02023437|Device|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
201947|NCT02023437|Device|Manual cataract surgery|"Manual": manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
201948|NCT02023450|Drug|saquinavir and ritonavir|micro and low dose
201949|NCT02023450|Drug|saquinavir and ritonavir|standard dose
201950|NCT02023463|Drug|Enzalutamide|Given PO
201951|NCT02023463|Drug|Goserelin acetate|Given SC
201952|NCT02023463|Drug|Leuprolide acetate|Given IM or SC
201953|NCT02023463|Radiation|Radiation therapy|Undergo image-guided radiation therapy
201954|NCT02023476|Radiation|MRI|MRI- imaging on the upper arm
201955|NCT00121511|Drug|Efudex (5-fluorouracil)|
202242|NCT02018510|Biological|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
202243|NCT02018510|Biological|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
202244|NCT02018510|Biological|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
202245|NCT02018510|Biological|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
202246|NCT02018510|Biological|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
202247|NCT02018510|Biological|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
202248|NCT02018523|Drug|Lenalidomide|lenalidomide 10mg/day orally until disease progression
202249|NCT02018536|Drug|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
202250|NCT02018536|Drug|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
202251|NCT02018536|Drug|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
202252|NCT00121121|Biological|Lipopeptides LIPO-4|
201662|NCT02030912|Other|2 doses of placebo daily for five days|
201663|NCT00122317|Drug|eculizumab|eculizumab 600 mg x 4 every week then eculizumab 900 mg every two weeks
201664|NCT02030925|Drug|IW-3718|
201665|NCT02030925|Drug|Matching Placebo|
201666|NCT02030938|Device|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
201667|NCT02030964|Drug|DFMO|
201668|NCT02030964|Drug|Celecoxib|
201669|NCT02030964|Drug|Cyclophosphamide|
201670|NCT02030964|Drug|Topotecan|
201671|NCT02030977|Dietary Supplement|Resveratrol|
201672|NCT02030977|Other|placebo|
201673|NCT02030990|Drug|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
201674|NCT00122330|Drug|eculizumab|
201675|NCT02030990|Drug|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
201676|NCT02031003|Dietary Supplement|Infant formula|Infant formula
201677|NCT02031016|Drug|Fentanyl|fentanyl bolus injections on an "as needed" base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
201678|NCT02031016|Drug|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
201679|NCT02031016|Drug|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
201956|NCT02023489|Device|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
201020|NCT01998971|Drug|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
201021|NCT02001415|Other|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
201359|NCT00002155|Drug|Zidovudine|
201360|NCT00118898|Drug|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
201361|NCT01994135|Other|Reference food|Reference food will be used to which test food samples will be compared to.
201362|NCT01994135|Other|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
201363|NCT01994135|Other|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
201364|NCT01994148|Procedure|Laparoscopy|In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
201365|NCT01994161|Procedure|intracranial stenting|all the participants in this group will be performed with intracranial stenting
201366|NCT01996410|Other|No Acupuncture- Standard of Care|
201367|NCT01996423|Dietary Supplement|Vitamin D3|
201368|NCT01996423|Dietary Supplement|Placebo|
201369|NCT00119028|Procedure|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
201370|NCT01996436|Drug|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
201371|NCT01996436|Drug|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
201372|NCT01996436|Drug|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
201373|NCT01996449|Drug|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
201374|NCT01996449|Drug|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
200718|NCT00002164|Drug|Nelfinavir mesylate|
200719|NCT00119847|Drug|ACE Inhibitors|
200720|NCT02006940|Device|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
200721|NCT02006953|Procedure|Bolus feeding schedule following gastrostomy tube placement|
200722|NCT02006953|Procedure|Continuous chimney feeds following gastrostomy tube placement|
200723|NCT02006966|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
201022|NCT02001415|Other|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
201023|NCT02001415|Other|Orthokeratology|Orthokeratology lenses.
201024|NCT02001428|Drug|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
201025|NCT02001467|Other|Simulation-based training|
201026|NCT02001480|Device|12 lead Holter|12 lead Holter measurements will be performed for 7 days
201027|NCT00119392|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
201028|NCT02001480|Device|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
201029|NCT02001506|Drug|FEC3-D3|Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks
Docetaxel 75 mg/m2, every 3 weeks
201030|NCT02001519|Drug|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
201031|NCT02001558|Drug|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
201032|NCT02001558|Other|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
201033|NCT02001571|Drug|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
201034|NCT02001584|Drug|Baclofen|
200416|NCT02015039|Drug|BoNT Injections|
200417|NCT02015039|Procedure|Occupational Therapy|
200418|NCT02015065|Drug|Vandetanib|Administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
200419|NCT02015091|Biological|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
200420|NCT02015104|Biological|TICE Bacillus Calmette-Guerin (BCG)|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
200421|NCT02015104|Biological|PANVAC|A recombinant virus vector vaccine containing genes for human CEA, MUC-1 and three co-stimulatory molecules (designated TRICOM): B7.1, ICAM-1 (intercellular adhesion molecule-1), and LFA-3 (leukocyte function-associated antigen-3).
200422|NCT02015117|Other|Laboratory Biomarker Analysis|Correlative studies
200423|NCT00120744|Drug|Ondansetron Oral Disintegrating Tablet|
200424|NCT02015117|Other|Pharmacological Study|Correlative studies
200425|NCT02015117|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
200426|NCT02015117|Drug|Trametinib|Given PO
200427|NCT02015117|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
200428|NCT02015130|Other|Individual treatment|See detailed description
200429|NCT02015156|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
200724|NCT02006966|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
200725|NCT02009189|Drug|2% Taurolidine Lock|Catheter lock with 2% Taurolidine
200726|NCT02009189|Drug|1.35% Taurolidine|Catheter lock with 1.35% Taurolidine + citrate
200727|NCT02009202|Drug|polyethylene glycol|
200728|NCT02009202|Drug|picosulphate|
200729|NCT02009215|Drug|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
200124|NCT02022566|Behavioral|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
200125|NCT02022579|Procedure|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
200126|NCT02022592|Drug|Lormetazepam|
200127|NCT02022592|Drug|Midazolam|
200128|NCT02022605|Device|Hands-on EMS training|A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
200129|NCT02022605|Other|Standard training|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
200130|NCT02022631|Other|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
200131|NCT02022631|Other|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
200132|NCT00121420|Drug|Motexafin gadolinium|
200133|NCT02022644|Drug|nanoliposomal irinotecan|
200134|NCT02022657|Drug|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
200135|NCT02022670|Drug|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
200136|NCT02022670|Drug|Sodium Nitrite|80 mg/d or 160 mg/d
200137|NCT02022683|Device|ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve|Standard Medical Care
200138|NCT02022696|Genetic|Lentiviral Gene Transfer|
224616|NCT02187744|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
224617|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
224618|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
224619|NCT02187744|Biological|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
224912|NCT02182830|Drug|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
224913|NCT02182830|Drug|Empagliflizon high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
224914|NCT02182843|Biological|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
224915|NCT02182856|Drug|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
224916|NCT02182856|Drug|Ipratropium 500 µg|
224917|NCT02182856|Drug|Salbutamol sulphate 3 mg|
224918|NCT02182856|Drug|Salbutamol sulphate 6 mg|
224919|NCT02182869|Drug|Combivent® HFA inhalation aerosol|
224920|NCT02182869|Drug|Combivent® CFC inhalation aerosol|
224921|NCT02182882|Drug|GINSANA|
224922|NCT00137722|Behavioral|Education of providers and their staff|
224923|NCT02182882|Drug|Placebo|
224924|NCT02182895|Drug|Saxagliptin|2.5-5 mg daily
224925|NCT02182908|Other|PET-Scan|PET-Scan
224926|NCT02182934|Drug|Ginsana|
224927|NCT02182934|Drug|Placebo|
224293|NCT00002300|Drug|Megestrol acetate|
224294|NCT00139217|Drug|iNO|
224295|NCT02195219|Procedure|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
224296|NCT02195219|Other|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
224297|NCT02195232|Drug|Isoquercetin|
224298|NCT02195245|Device|memsorb|
224299|NCT02195271|Device|Transcranial Direct Current Stimulation (tDCS)|
224300|NCT02195271|Drug|Melatonin|
224301|NCT02195284|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
224620|NCT02189850|Drug|BLI800 - Dose 1|BLI800 oral solution
224621|NCT02189850|Drug|BLI800 - Dose 2|BLI800 oral solution
224622|NCT00138476|Biological|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses [reverse transcription polymerase chain reaction (RT-PCR) Units] 4800, 48, 4.8, 0.48.
224623|NCT02189863|Device|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
224624|NCT02189863|Device|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
224625|NCT02189863|Device|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
224626|NCT02189863|Device|Comfilcon A MF|Multifocal contact lenses worn in both eyes
224627|NCT02189863|Device|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
224628|NCT02189876|Behavioral|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
229138|NCT02419846|Procedure|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
229139|NCT02419846|Other|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
229140|NCT00166465|Drug|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
229141|NCT02419846|Other|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
229142|NCT02419846|Other|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
229143|NCT02419846|Other|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
229144|NCT02419859|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
229145|NCT02419859|Drug|Insulin, Asp(B28)-|a fast-acting analog of human insulin
229146|NCT02419872|Drug|Marketed antagonists|Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
229147|NCT02421744|Behavioral|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
229148|NCT02421757|Device|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
229149|NCT02421757|Device|Placebo|The placebo TCMS device
229150|NCT02421770|Other|Chamaemelum nobile 2%|Experimental Chamaemelum Nobile 2% gel Active "During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are
229151|NCT02421770|Other|placebo|
224302|NCT02195284|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
224303|NCT02195284|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
224304|NCT02195284|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
224305|NCT00139217|Procedure|Non-invasive nitric oxide|
228563|NCT02397564|Device|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
228838|NCT02426138|Other|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
228839|NCT02426138|Other|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure
228840|NCT02426151|Drug|BEPO-A|BEPO-A (Bioreactor manufacturing process)
228841|NCT02426151|Drug|REPO-A|REPO-A (Roller bottle manufacturing process)
228842|NCT00167531|Behavioral|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
228843|NCT02426164|Drug|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
228844|NCT02426164|Drug|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
228845|NCT02426177|Drug|Labetalol|anti-hypertensive agents
228846|NCT02426177|Drug|Nifedipine|calcium channel blocker ,for lowering blood pressure
228847|NCT02426190|Device|Anti-gravity treadmill|
228848|NCT02426190|Device|PENS - neuro-muscular stimulation|
228849|NCT02426190|Device|Recumbent bike or Nu-step|
228850|NCT02426203|Procedure|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
228851|NCT02426229|Drug|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
228852|NCT02426242|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
228853|NCT00167544|Drug|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
228854|NCT02426255|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
228855|NCT02426281|Drug|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
200250|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
200546|NCT02030431|Device|Cancellous screws|
200547|NCT02030444|Procedure|PET-MRI and EBUS-TBNA|
200548|NCT00122226|Drug|Lopinavir/ritonavir + nevirapine|
200549|NCT02030457|Drug|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
200550|NCT02030457|Drug|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
200551|NCT02030470|Other|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
200552|NCT02030483|Drug|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
200553|NCT02030483|Drug|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
200554|NCT02030483|Drug|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
200555|NCT02030496|Procedure|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
200556|NCT02030496|Other|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
200557|NCT02030509|Other|Quick diagnosis program|
200558|NCT02030522|Behavioral|Accelerated Resolution Therapy (ART)|The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the "director of the movie" of the memory they are working on.
200559|NCT00002179|Drug|Lamivudine|
200560|NCT00122278|Drug|dexamethasone 10mg IV|corticosteroid
199953|NCT02001064|Behavioral|Application + Standard of care|Care4Today mobile application will send automated medication alert messages to HIV+ persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV+ persons who experience adherence difficulties over standard of care.
199954|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
199955|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Pain (CBT-P)|
199956|NCT00002162|Drug|Saquinavir|
199957|NCT00119379|Drug|Tenofovir disoproxil fumarate|Swicth thymidine NRTI to tenofovir
199958|NCT02001103|Drug|Memantine|Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.
The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3.
199959|NCT02003651|Dietary Supplement|Quick Defense|Echinacea product from Gaia Herbs.
199960|NCT00119574|Procedure|Collaborative Chronic Illness Model|
199961|NCT02003664|Drug|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
199962|NCT02003664|Drug|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
200251|NCT01996085|Drug|Nebivolol|Beta-blocker recommended in case of:
1."hyperdynamic" profile (CI > 4.2 l/min/m2 and/or HR > 80/min)
200252|NCT01996085|Drug|Indapamide/hydrochlorothiazide|"hypervolemic" profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm)
"hyperconstrictive" profile (SVRI > 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)
200253|NCT01996085|Drug|Amlodipine|1/ SVRI > 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
200254|NCT01996085|Drug|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
200255|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
200256|NCT01996085|Drug|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
200257|NCT00119002|Drug|dexamethasone|1mg/kg dexamethasone
200258|NCT01996085|Drug|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
200259|NCT01996085|Drug|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
200260|NCT01996098|Drug|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
199649|NCT02008773|Drug|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
199650|NCT00120055|Drug|Atorvastatin (Lipitor)|
199651|NCT02008773|Drug|placebo|placebo capsules 6/day oral for 16 weeks
199652|NCT02008786|Drug|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
199653|NCT02008786|Drug|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
199654|NCT02008786|Drug|placebo|Placebo
199655|NCT02008799|Procedure|Bone marrow stem cell injection|Injection should be in testis and testicular artery
199656|NCT02008812|Device|Ad sensor|Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.
The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens.
199657|NCT02008825|Device|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
199658|NCT02008825|Device|Usual non suction Bougie|Usual non suction Bougie
199659|NCT02008838|Dietary Supplement|Synbiotic|
199660|NCT02008838|Dietary Supplement|Placebo|
199661|NCT00120068|Behavioral|Nursing inservices|
199662|NCT02008851|Biological|Neo-kidney augment|Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
199663|NCT02008864|Drug|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
199664|NCT02008864|Drug|Placebo|Placebo tablet/ 2 times per day
199665|NCT02008877|Drug|ganetespib|200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
199666|NCT02008877|Drug|Sirolimus|2mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
199667|NCT02008890|Biological|Secucinumab|Secucinumab will be used as 150 mg pre-filled syringes in a double-blinded fashion. Until Week 16 patients will perform a self-administration under the supervision of the investigator. After Week 16 patients will have regular office visits and apply the treatment under supervision of the investigator and in between office visits apply treatment at home. The investigator must emphazie compliance and instruct patients to take the treatment exactly as described.
199963|NCT02003677|Drug|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
199334|NCT02014532|Drug|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
199335|NCT02014532|Drug|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
199336|NCT02017171|Drug|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
199337|NCT02017184|Biological|Noninvasive core temperature thermistor|
199338|NCT02017197|Drug|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
199339|NCT02017197|Drug|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
199340|NCT02017197|Drug|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
199341|NCT02017210|Other|PART 2: 12 week calorie restriction weight loss program|
199342|NCT02017223|Device|Knowme Device Wear|
199343|NCT02017236|Drug|Volitinib|600mg Volitinib ,single dose,oral
199344|NCT00120978|Drug|Flovent|
199345|NCT02017249|Drug|arginine in powder form|
199346|NCT02017262|Behavioral|Self-management group|8 weekly sessions of group self-management
199347|NCT02017262|Behavioral|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
199348|NCT02017275|Device|BuMA|This group will contain 1175 subjects.
199349|NCT02017275|Device|EXCEL|This group will contain 1175 subjects.
199350|NCT02017314|Drug|Morphine|
199351|NCT02017327|Drug|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
199352|NCT02017327|Drug|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
199353|NCT02017327|Drug|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
203483|NCT01995071|Drug|ABT-530|tablet
203484|NCT01995071|Drug|ABT-450/r/ABT-267|tablet
203485|NCT01995071|Drug|ABT-333|tablet
198744|NCT02070666|Other|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
198745|NCT02070679|Drug|Vitamin E|
198746|NCT02070692|Drug|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
198747|NCT02070692|Drug|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
198748|NCT02070705|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
198749|NCT02070718|Drug|Standard Dose Kappa Agonist|
198750|NCT02070718|Drug|Half Dose Kappa Agonist|
198751|NCT02070718|Other|Placebo|
198752|NCT02070731|Device|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
198753|NCT02070744|Drug|VX-661|
198754|NCT00126243|Drug|CHOP|
198755|NCT02070744|Drug|ivacaftor|
198756|NCT02070744|Drug|VX-661 placebo|
198757|NCT02073240|Behavioral|Enhanced TB IC Package|Facilities randomized to the intervention group will receive:
Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility
Audits and Feedback of performance
A TB IC collaborative membership
A standardized unit-level daily checklist of critical IC activities
198758|NCT02073253|Other|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
198759|NCT02073266|Procedure|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
198760|NCT02073279|Drug|SA237|
202865|NCT02007850|Drug|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
202866|NCT02007863|Procedure|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
202867|NCT02007863|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
202868|NCT02007863|Drug|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
202869|NCT02007863|Drug|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
202870|NCT00119938|Behavioral|Access to online patient portal|
203172|NCT00119314|Drug|gemcitabine hydrochloride|
203173|NCT01999868|Procedure|Placebo for Ustekinumab|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
203174|NCT01999868|Drug|Placebo for Abatacept|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
203175|NCT01999881|Behavioral|exercise intervention|Receive aerobic and exercise intervention
203176|NCT01999881|Procedure|standard follow-up care|Receive usual care
203177|NCT01999881|Procedure|quality-of-life assessment|Ancillary studies
203178|NCT01999881|Other|laboratory biomarker analysis|Correlative studies
203179|NCT01999894|Drug|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
203180|NCT01999907|Dietary Supplement|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
203181|NCT01999907|Dietary Supplement|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
203182|NCT01999907|Other|Placebo|placebo given in a 2ml dose by mouth at baseline.
203183|NCT02002494|Other|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
202253|NCT02018536|Drug|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
202254|NCT02018536|Drug|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
202255|NCT02018536|Drug|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
202256|NCT02018536|Drug|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
202257|NCT02018549|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
202258|NCT02018562|Device|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
202259|NCT02018575|Dietary Supplement|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
202260|NCT02018575|Dietary Supplement|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
202261|NCT02018588|Dietary Supplement|tryptophan|graded levels of tryptophan will be given to each subject
202262|NCT02018601|Procedure|BRILMA|
202263|NCT00002174|Drug|Thalidomide|
202548|NCT02013206|Drug|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
202549|NCT02013219|Drug|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and PO RP2D BID in Stage 2.
202550|NCT02013219|Drug|Atezolizumab|Participants will receive 1200 mg IV atezolizumab infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and IV RP2D infusion q3w in Stage 2.
202551|NCT02013219|Drug|Erlotinib|Participants will receive 150 mg PO erlotinib QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and PO RP2D QD in Stage 2.
202552|NCT02013232|Drug|Aripiprazole|
202553|NCT00120536|Drug|vildagliptin|
202554|NCT02013245|Biological|Biological MTBVAC and biological BCG (commercial)|
202555|NCT02013258|Drug|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
201957|NCT02023489|Other|Meal Tolerance Test|A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.
At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T).
201958|NCT02025920|Other|Salmon Group|
201959|NCT02025920|Other|Cod Group|
201960|NCT02025920|Other|Meat Group|
201961|NCT02025933|Other|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
201962|NCT02025933|Other|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
201963|NCT02025933|Other|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
201964|NCT02025959|Behavioral|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders|
201965|NCT02025972|Procedure|Allogeneic umbilical cord blood therapy|
201966|NCT02025985|Drug|Selinexor|35 mg/m2 twice weekly, 50 mg/m2 twice weekly, 50 mg/m2 once weekly, or 60 mg/m2 twice weekly. Cycles are 4 weeks.
201967|NCT02025998|Drug|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
201968|NCT00121706|Behavioral|Condition C (see detailed summary)|
201969|NCT02025998|Other|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
201970|NCT02026011|Drug|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
201971|NCT02026011|Drug|Placebo|Sugar pill, matched to the active study medication in capsule size and color
201972|NCT02026037|Behavioral|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
201973|NCT02026050|Procedure|intraarticular dexamethasone|2ml 8 mg dexamethasone administration for intraarticular
202264|NCT00121134|Drug|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
201375|NCT01996449|Procedure|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
201680|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of [14C]FTD administered as an oral solution on Day 1 (mass balance part)
201681|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of [14C]TPI administered as an oral solution on Day 1 (mass balance part)
201682|NCT02031055|Drug|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
201683|NCT02031068|Behavioral|Active Rehabilitation Program|The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:
Sub-maximal aerobic training for up to 15 minutes
Light coordination and sport-specific exercises for up to 10 minutes
Visualization and imagery techniques
Home program
A physiotherapist will supervise the rehabilitation.
201684|NCT02031068|Behavioral|Treatment-as-usual (TAU)|The TAU program will be implemented after the initial assessment. It will consist of 2 components:
An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school
201685|NCT00122577|Drug|Atazanavir|
201686|NCT02033655|Behavioral|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
201687|NCT02033668|Drug|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
201688|NCT02033668|Drug|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
201689|NCT02033668|Drug|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
201690|NCT02033681|Procedure|"One-per-mil" Tumescent Solution Injection|"One-per-mil" tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger.
201691|NCT02033681|Procedure|Saline Solution|Saline solution is injected into the tissue as a placebo control.
201035|NCT02001584|Drug|Memantine|
201036|NCT02001584|Drug|Placebo|
201037|NCT02001610|Dietary Supplement|Acidophilus pearls|Acidophilus pearls are encapsulated using patented process
Subjects take one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days
201038|NCT00119392|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
201039|NCT02001610|Dietary Supplement|Hard shell gelatin capsules|Hard-shelled gelatin capsule with same microbial formulation as pearl supplement
Subjects consume one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days
201040|NCT02001623|Drug|HuMax-TF-ADC|
201041|NCT02001636|Drug|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
201042|NCT02001636|Drug|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
201376|NCT01996449|Procedure|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
201377|NCT01996449|Procedure|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
201378|NCT01996449|Procedure|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
201379|NCT01996449|Procedure|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
201380|NCT00119041|Behavioral|The Diabetes Treatment Satisfaction Questionnaire|A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
201381|NCT01996449|Procedure|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
201382|NCT01996462|Drug|Escitalopram Oxalate Tablets|
201383|NCT00119262|Biological|bevacizumab|Given IV
201384|NCT01998971|Drug|Lenalidomide|Administered orally in accordance with product labeling and local standards.
200730|NCT02009228|Procedure|Ovarian cystectomy|
200731|NCT02009241|Other|Pulmonary Rehabilitation|
200732|NCT02009254|Other|Dietary treatment|
200733|NCT00120120|Drug|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
200734|NCT02009267|Device|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
200735|NCT02009267|Procedure|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation—including the sensation of pain—by blocking the transmission of signals through nerve fibers in or near the spinal cord.
200736|NCT02009267|Procedure|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
200737|NCT02009280|Drug|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
200738|NCT02009280|Drug|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
200739|NCT02009293|Other|Cough monitor|questionnaires about cough and quality of life
200740|NCT02009306|Drug|PecFent and Epistatus|
200741|NCT02009306|Drug|Standard subcutaneous medication|
200742|NCT02009332|Drug|ABI-009|
200743|NCT02009358|Other|mental health promotion|
200744|NCT00002167|Drug|Tin ethyl etiopurpurin|
200745|NCT00120133|Drug|Atorvastatin|
201043|NCT02001649|Genetic|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
201044|NCT02001649|Genetic|SNP genotyping|
201045|NCT02004236|Device|tRNS with sham|the subjects receive 35 session with sham
201046|NCT02004262|Biological|GVAX Pancreas Vaccine|
201047|NCT02004262|Biological|CRS-207|
201048|NCT02004262|Drug|gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib|
200139|NCT02022709|Drug|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
200430|NCT02017691|Device|Pulse-oximetry|If SpO2 remains <10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is >90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
200431|NCT02017704|Radiation|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
200432|NCT02017704|Drug|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
200433|NCT02017704|Radiation|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
200434|NCT02017704|Drug|FOLFOX6|Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion
Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions
5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion.
200435|NCT02017704|Procedure|Surgery|After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:
Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.
Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis.
200436|NCT02017717|Biological|Nivolumab|
200437|NCT02017717|Biological|Bevacizumab|
200438|NCT02017717|Biological|Ipilimumab|
200439|NCT02017730|Drug|BMS-986020|
200440|NCT00121030|Drug|darbepoetin alfa|
200441|NCT02017730|Drug|[11C]BMT-136088|
200442|NCT02017782|Device|Dust|Dust (250-300µg/m3),
200443|NCT02017782|Device|Ozone|(0,1ppm ozone),
200444|NCT02017782|Device|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
200445|NCT02017782|Device|Placebo (Filtered air)|Placebo treatment (Filtered air <20 ug/m3)
200446|NCT02017795|Other|electronic asthma action plan (eAAP)|An electronic asthma action plan (eAAP) will be provided to intervention group
200447|NCT02017795|Other|written asthma action plan (WAAP)|A written asthma action plan will be given to control group arm
224928|NCT02182947|Device|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
224929|NCT02182960|Drug|Ibuprofen syrup|
224930|NCT02182960|Drug|Brufen syrup|
224931|NCT02182973|Dietary Supplement|donor human milk|Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.
GI-subscores from the Finnegan NAS Scoring system will be computed.
224932|NCT02182986|Procedure|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, small intestine, or liver with small intestine transplants).
224933|NCT00137722|Behavioral|Case management|
224934|NCT02182986|Drug|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
225240|NCT02177578|Drug|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
225241|NCT02177578|Radiation|Subventricular Zone radiation|Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
Initial treatment plan:
Will be prescribed to 46 Gy in 2 Gy fractions
Cone down treatment plan:
Will be prescribed to 14 Gy in 2 Gy fractions
225242|NCT02177578|Radiation|Neural Progenitor Cell Sparing radiation|Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
Initial treatment plan:
Will be prescribed to 46 Gy in 2 Gy fractions
Cone down treatment plan:
Will be prescribed to 14 Gy in 2 Gy fractions
225243|NCT02177604|Other|Wingate HIT|3 sessions of Wingate based High-Intensity Interval Training (4 x 30 second "all out" sprints on a cycle ergometer interspersed by 3.5 minutes recovery)
225244|NCT02177604|Other|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
225245|NCT00002281|Drug|Zidovudine|
225246|NCT00137098|Drug|Caffeine|
225247|NCT02177604|Other|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
225248|NCT02177617|Drug|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
225249|NCT02177617|Behavioral|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
224629|NCT02189876|Behavioral|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will including discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
224630|NCT02189889|Drug|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
224631|NCT02189889|Drug|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
224632|NCT02189902|Dietary Supplement|4000 IU/d D3 over 12 weeks|
224633|NCT00138515|Drug|vildagliptin|
224634|NCT02189902|Dietary Supplement|7000 IU/d D3 over 12 weeks|
224635|NCT02189915|Drug|Creatine monohydrate|
224636|NCT02189928|Device|Lower limb tourniquet|Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.
The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations').
224637|NCT02189928|Other|Usual care|
224935|NCT02182999|Device|InfiltraLong-Katheter 19G x 420mm, Pajunk|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
224936|NCT02185300|Drug|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
224937|NCT02185313|Other|visual stimulus to follow|
224938|NCT02185326|Drug|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
224939|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
224940|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
224941|NCT02185352|Drug|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
224306|NCT00134680|Drug|Trastuzumab|Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
224307|NCT02156336|Drug|Ranolazine|Oral administration, BID; for a maximum of 51 days.
224308|NCT02156336|Drug|Placebo|Oral administration, BID; for a maximum of 51 days.
224309|NCT02156349|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
224310|NCT02156349|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of bloog glucose meter devices
224311|NCT02156362|Other|follow up visit|At least 1 follow up visit per year will be done and an additional visit if needed.
224312|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
224313|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
224314|NCT02156388|Biological|GW003|freeze-dried powder；single SC injection
224315|NCT02156414|Procedure|Radical Prostatectomy|Radical Prostatectomy
224316|NCT02156414|Procedure|Extended Lymphadenectomy|Extended Lymphadenectomy
224317|NCT00002261|Biological|gp160 Vaccine (MicroGeneSys)|
224318|NCT00134693|Drug|Prednisolone|
224319|NCT02156427|Device|VITICELL|
224320|NCT02156427|Device|PLACEBO|
224321|NCT02156440|Dietary Supplement|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
224322|NCT02156440|Dietary Supplement|Placebo|
224323|NCT02156453|Procedure|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
224324|NCT02156466|Drug|MSB0010841 (Anti-IL-17A/F Nanobody)|MSB0010841 (Anti-IL-17A/F Nanobody) will be administered at a dose ranging from 30 milligram (mg) to 240 mg as subcutaneous injection every other week for a total duration of 6 weeks.
224638|NCT02189941|Drug|Deferiprone sustained-release|
224639|NCT02189941|Drug|Deferiprone immediate-release|
228856|NCT02428257|Procedure|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
228857|NCT02428257|Drug|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
228858|NCT02428257|Drug|isobaric bupivacaine|0.5% isobaric bupivacaine
228859|NCT02428257|Drug|ephedrine|
229152|NCT00166790|Drug|chemotherapy agents|
229153|NCT02421822|Other|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
229154|NCT02421835|Dietary Supplement|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
229155|NCT02421835|Dietary Supplement|Placebo|700 mg Maltodextrin per day
229156|NCT02421861|Behavioral|Anxiety Management in the ICU|The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and "optional" modules based on each participant's anxiety experience and preference.
229157|NCT02421861|Other|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C&L service; (2) referral to psychiatry C&L service; or (3) pharmacologic management.
229158|NCT02421874|Behavioral|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
229159|NCT02421874|Behavioral|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
229160|NCT02421887|Drug|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
229161|NCT02421887|Other|Placebo|Placebo
229162|NCT02421900|Other|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
229163|NCT00166790|Procedure|suction curettage|
229164|NCT02421913|Drug|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
200561|NCT02030535|Drug|olodaterol|free combination with tiotropium
200562|NCT02030535|Drug|tiotropium|free combination with olodaterol
200563|NCT02030535|Drug|Placebo|
200868|NCT02025387|Behavioral|Physical activity feedback|
200869|NCT02025387|Behavioral|Usual care except physical activity measurement|
200870|NCT02025400|Other|eRehab|Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as "e-rehabilitation" or "eRehab." This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders.
200871|NCT02025400|Other|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
200872|NCT02025413|Device|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
200873|NCT02025426|Drug|Phenylephrine|
200874|NCT02025426|Drug|Ephedrine|
200875|NCT02025439|Device|rTMS|
200876|NCT02025439|Drug|Amantadine|
200877|NCT00121667|Drug|Placebo + Metformin|Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
200878|NCT02025452|Other|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
200879|NCT02025452|Dietary Supplement|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
200880|NCT02025452|Other|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
200881|NCT02025465|Drug|Metoprolol|The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.
Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team.
200882|NCT02025465|Drug|Diltiazem|The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.
Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team.
200261|NCT01996098|Drug|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
200262|NCT01996111|Procedure|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
200263|NCT01996111|Procedure|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
200264|NCT01996111|Procedure|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
200265|NCT01996111|Procedure|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
200266|NCT01996124|Drug|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
200267|NCT01996124|Drug|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
200268|NCT00119002|Drug|Placebo|1mg/kg placebo
200269|NCT01996137|Device|VASST|Stroke patients with hemiparesis undergo gait training via VASST
200270|NCT01996150|Drug|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
200271|NCT01998568|Other|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
200564|NCT02033174|Other|Oral fat diet|
200565|NCT02033187|Other|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
200566|NCT02033187|Other|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
200567|NCT02033200|Drug|Stendra 200 mg|
200568|NCT02033200|Drug|Placebo|
200569|NCT02033213|Other|Restrictive group|A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
199964|NCT02003677|Drug|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
199965|NCT02003690|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy
199966|NCT02003690|Behavioral|Standard of Care Psychotherapy|Standard of Care Psychotherapy
199967|NCT02003690|Drug|Pharmacotherapy|Standard of Care Pharmacotherapy
199968|NCT02003703|Biological|Recombinant Hepatitis B Virus Vaccine|
199969|NCT02003729|Device|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
199970|NCT02003742|Drug|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
199971|NCT00119587|Drug|darbepoetin alfa|
199972|NCT02003742|Drug|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
199973|NCT02003755|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
199974|NCT02003768|Drug|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
199975|NCT02003768|Drug|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
199976|NCT02003794|Drug|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
199977|NCT02003820|Behavioral|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
199978|NCT02003833|Device|Poly-L-lactic acid|Sculptra injections
199979|NCT02003833|Device|Placebo comparator|saline injections
199980|NCT02003872|Device|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
199981|NCT02003885|Drug|increment of desflurane|After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.
After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.
Reduction of BP is managed by the increment of phenylephrine infusion
199354|NCT02017340|Drug|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
199355|NCT00120991|Procedure|Coronary artery bypass grafting|
199668|NCT02008890|Drug|Placebo|matching placebo
199669|NCT02011763|Biological|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
199670|NCT02011789|Dietary Supplement|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
199671|NCT02011789|Dietary Supplement|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
199672|NCT02011802|Device|Algosteril TM|
199673|NCT00120393|Drug|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
199674|NCT02011802|Device|Sorbact TM|
199675|NCT02011828|Drug|ergocalciferol 50,000 U/ week|Participants will randomly be assigned to receive either ergocalciferol or placebo for the first 12 weeks, followed by a 4 week wash-out and cross-over for 12 weeks.
199676|NCT02011841|Drug|Rifaximin|rifaximin 1200 mg/day orally for 6 months
199677|NCT02011841|Drug|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
199678|NCT02011854|Device|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
199679|NCT02011854|Device|Acupuncture|
199680|NCT02011867|Device|Cork Electrode|
199681|NCT02011880|Dietary Supplement|Chinese Herbs|Dietary Supplement:Experiment group:
Fructus Cnidii,Psoralea Corylifolin L.，monkshood
-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity
Breast Cancer Postoperative Prescription
-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity
Dietary Supplement:Contrast Group:
Breast Cancer Postoperative Prescription
-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity
199682|NCT02011893|Device|Tonic Stimulation|Prodigy Neurostimulation System with associated components
199683|NCT02011893|Device|Burst Stimulation|Prodigy Neurostimulation System with associated components
199684|NCT00120406|Device|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
198761|NCT00126503|Biological|Bevacizumab|Given IV
198762|NCT02073279|Drug|Placebo|
198763|NCT02073292|Procedure|c-RFA|
198764|NCT02073292|Procedure|tRFA|
198765|NCT02073305|Other|No Sleep Apnea|No intervention
198766|NCT02073305|Other|Sleep Apnea - untreated|No intervention
199038|NCT02022137|Dietary Supplement|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
199039|NCT02022137|Dietary Supplement|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
199040|NCT02022137|Dietary Supplement|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
199041|NCT02022150|Behavioral|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
199042|NCT02022163|Biological|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
199043|NCT00121355|Device|safety glide|
199044|NCT02024633|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
199045|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
199046|NCT02024646|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
199047|NCT02024646|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
199048|NCT02024646|Drug|Placebo|Placebo administered via subcutaneous injection.
199049|NCT02024659|Drug|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
199050|NCT02024659|Other|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
199051|NCT02024672|Other|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
203184|NCT02002507|Other|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
203185|NCT02002533|Behavioral|Brief Behavioral Therapy|Undergo BBT intervention
203186|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo BBT intervention
203187|NCT02002533|Other|Educational Intervention|Undergo HEAL
203188|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo HEAL
203189|NCT02002572|Other|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
203190|NCT00119496|Drug|theophylline|Oral theophylline, 200mg bd
203191|NCT02002585|Procedure|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
203192|NCT02002598|Drug|Bendamustine|Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.
Dose escalation is as follows:
-1 / 60 mg/m2
/ 70 mg/m2
/ 70 mg/m2
/ 90 mg/m2
/ 90mg/m2
/ 90 mg/m2
203486|NCT01995071|Drug|Ribavirin (RBV)|tablet
203487|NCT01995084|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
203488|NCT01995097|Behavioral|Scheduled Gradual Reduction Text Messages|
203489|NCT01995097|Behavioral|Support Text Messages|
203490|NCT01995110|Other|high-fat meal A|
203491|NCT01995110|Other|high-fat meal B|
203492|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
203493|NCT01995110|Other|high-fat meal C|
203494|NCT01995123|Behavioral|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
203495|NCT01997437|Device|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
203496|NCT01997463|Drug|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
202556|NCT02013258|Other|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
202557|NCT02013271|Device|Lutonix Paclitaxel Drug Coated Balloon|
202558|NCT02013297|Radiation|SBRT treatment|For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.
For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.
For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.
For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.
For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy.
202559|NCT02013310|Drug|HT-0712|
202560|NCT02013310|Drug|Placebo|
202561|NCT02015910|Drug|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
202562|NCT02015910|Drug|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
202563|NCT02015923|Procedure|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
202564|NCT02015923|Drug|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
202565|NCT02015936|Behavioral|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
202566|NCT00120848|Biological|HPV 16/18 VLP AS04|
202871|NCT02007876|Behavioral|Mobility and Activity Training|Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.
Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2.
202872|NCT02007889|Drug|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
202873|NCT02007902|Other|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|Patient inclusion at birth
Total plasma protein values measurement on cord blood sample at birth
Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler
Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth
Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 [regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy] will be monitored over 24 hours after birth.
202265|NCT02018601|Procedure|paravertebral block|
202266|NCT02018601|Drug|dexketoprofen|
202267|NCT02018601|Drug|paracetamol|
202268|NCT02021006|Drug|nitrofurantoin|antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
202269|NCT02021006|Other|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
202270|NCT02021006|Drug|Amoxicillin-Potassium Clavulanate Combination|antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
202271|NCT02021006|Drug|Trimethoprim/sulfamethoxazole|antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
202272|NCT02021006|Drug|Cefixime|antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
202273|NCT02021019|Procedure|Renal Denervation|Renal Denervation
202274|NCT02021032|Device|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
202275|NCT02021045|Device|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
202276|NCT00121264|Other|pharmacological study|Correlative studies
202277|NCT02021058|Other|Experimental Formula|Experimental formula
202278|NCT02021058|Other|Standard control formula|Standard Infant formula
202279|NCT02021071|Radiation|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
201692|NCT02033707|Drug|Hallucinogens and psychoactive substances|One of the following or placebo will be given:
Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis
Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem
Antihistamines: diphenhydramine, chlorpheniramine
Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion
Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine
Other: alcohol, scopolamine, nicotine
Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are "blind" to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.
201693|NCT02033720|Other|No treatment|No therapeutic hypothermia was induced.
201694|NCT02033720|Other|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
201974|NCT02026050|Procedure|interscalene dexamethasone|2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
201975|NCT02026050|Procedure|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
201976|NCT02026063|Drug|Telotristat etiprate tablets (250 mg)|
201977|NCT02026076|Other|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
201978|NCT02026089|Biological|Varicella vaccine|
201979|NCT00121719|Drug|Lenvatinib|Lenvatinib tablets taken orally, once daily.
201980|NCT02026102|Behavioral|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
201981|NCT02028676|Other|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
201982|NCT02028676|Other|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
201983|NCT00121953|Drug|Rosiglitazone|
201385|NCT01998971|Drug|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
201386|NCT01998984|Drug|ingenol mebutate|
201387|NCT01998997|Behavioral|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
201388|NCT01999010|Device|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
201389|NCT01999023|Dietary Supplement|Low protein formula group|Low protein formula formula (28.5 g) twice a day
201390|NCT01999062|Other|IMRT + CT + MR scan|
201391|NCT01999075|Device|Lung Volume Recruitment (LVR)|LVR will be used twice per day
201392|NCT01999075|Other|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
201695|NCT02033733|Drug|Cisatracurium infusion|This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.
Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group).
201696|NCT00002182|Drug|Megestrol acetate|
201697|NCT00122577|Drug|Ritonavir|
201698|NCT02033733|Drug|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
201699|NCT02033746|Device|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
201700|NCT02033759|Device|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
201701|NCT02033759|Other|Anxiety Questionnaire|21 item questionnaire
201702|NCT02033759|Other|Traditional Circumferential Measurements|
201703|NCT02033772|Procedure|Thoracoscopic surgery|
201049|NCT02004262|Drug|cyclophosphamide|
201050|NCT00119652|Drug|quetiapine fumarate (Seroquel)|
201051|NCT02004275|Drug|pomalidomide|given PO
201052|NCT02004275|Drug|ixazomib|given PO
201053|NCT02004275|Drug|dexamethasone|given PO
201054|NCT02004288|Dietary Supplement|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken once a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
201055|NCT02004301|Drug|Radiolabelled T4 Tablet|
201056|NCT02004301|Drug|Radiolabelled T6 Tablet|
201057|NCT02004314|Drug|Chloroquine|
201058|NCT02004327|Drug|DW1029M300mg|DW1029M300mg PO Once
201059|NCT02004327|Drug|DW1029M600mg|DW1029M300mg 2 tablets Once
201060|NCT02004327|Drug|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
201061|NCT00119652|Drug|paroxetine|
201062|NCT02004340|Device|ear vagus nerve stimulator|
201063|NCT02004353|Device|Cochlear® Hearing Implants|Nucleus Cochlear implants, Cochlear Baha implants, Cochlear Acoustic Implants
201064|NCT02004366|Drug|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
201065|NCT02004366|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
201066|NCT02004366|Drug|Linagliptin|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
201067|NCT02004366|Drug|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
201393|NCT01999088|Other|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
201394|NCT00119262|Drug|paclitaxel|Given IV
200448|NCT02017821|Behavioral|high intensity aerobic training|
200449|NCT02017834|Procedure|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
200746|NCT02009371|Device|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
200747|NCT02009371|Device|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
200748|NCT02009384|Drug|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
200749|NCT02009397|Drug|Ipilimumab|
200750|NCT02009397|Drug|GM-CSF|
200751|NCT02012270|Procedure|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
200752|NCT02012283|Other|Food consumption|Cooked vegetables with spices or without spices
200753|NCT02012296|Drug|enzalutamide|Given PO
200754|NCT02012296|Drug|mifepristone|Given PO
200755|NCT02012296|Other|laboratory biomarker analysis|Correlative studies
200756|NCT02012296|Other|pharmacological study|Correlative studies
200757|NCT00120458|Dietary Supplement|Black cohosh|32 to 128 mg (black cohosh)
1 to 4 capsules daily (placebo)
200758|NCT02012309|Biological|PCV-13|
200759|NCT02012309|Biological|PPSV-23|
200760|NCT02012322|Dietary Supplement|Coenzyme Q10|100mg/day for three months
200761|NCT02012322|Dietary Supplement|Coenzyme Q10|300mg/day for three months
200762|NCT02012322|Dietary Supplement|Placebo|Three month period
200763|NCT02012335|Drug|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
200764|NCT02012348|Other|Antibacterial soap with triclocarban|
225250|NCT02177617|Procedure|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
225251|NCT02177630|Other|Endomyocardial Biopsy|
225252|NCT02177643|Drug|Diacerein|Diacerein oral capsules
225253|NCT02177643|Drug|Placebo|Placebo oral capsules
225254|NCT02177656|Behavioral|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
225255|NCT02177669|Other|quick Contrast Sensitivity Function test|
225558|NCT02167698|Device|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
225559|NCT02167698|Other|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
225560|NCT02169856|Drug|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
225561|NCT02169856|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
225562|NCT02169869|Device|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
225563|NCT02169869|Device|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
225564|NCT02169882|Drug|Placebo|Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.
Patients receiving 1350 mg rifampicin will not receive any placebo tablet.
With this arrangement, every subject will receive 3 tablets of study drugs.
225565|NCT02169882|Drug|Rifampicin|Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.
Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.
224942|NCT02185365|Other|Gadolinium|Gadolinium is a contrast agent used to visualize cartilage during an MRI.
224943|NCT00002289|Drug|Thymopentin|
224944|NCT00137995|Drug|Rituximab|375 mg/m² D-2/D1
224945|NCT02185378|Procedure|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
224946|NCT02185378|Procedure|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
224947|NCT02185391|Procedure|Audience Response System|patients use during oral presentations an audience response system
224948|NCT02185391|Behavioral|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
224949|NCT02185404|Device|wearing the GEMS|The GEMS mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This GEMS does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. While the movements of the GEMS are similar to the split belt treadmill, and the GEMS generates a similar aftereffect, the efficacy of this shoe in modifying the gait of an individual with stroke is not yet verified. This research aims to test the GEMS on individuals with stroke to determine if the related effects that show up on healthy subjects can benefit individuals with stroke.
224950|NCT02185417|Drug|Hydrochlorothiazide|Thiazide-type diuretic. Daily dose of 50 or 25 mg for duration of the study.
224951|NCT02185417|Drug|Chlorthalidone|Thiazide-type diuretic. Daily dose of 25 or 12.5 mg for duration of the study.
225256|NCT02177682|Drug|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
225257|NCT00137111|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
225258|NCT02180243|Other|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
225259|NCT02180256|Procedure|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
225260|NCT02180269|Drug|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
225261|NCT02180269|Drug|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
225262|NCT02180269|Drug|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
225263|NCT02180269|Drug|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
224640|NCT02192736|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
224641|NCT00138840|Drug|STA-5326 mesylate|
224642|NCT02192749|Biological|Umbilical cord mesenchymal stem cells|
224643|NCT02192762|Behavioral|Withdrawal regulation training|Withdrawal coping skills
224644|NCT02192762|Behavioral|Relaxation training|Relaxation skills instruction
224645|NCT02192775|Drug|MV-NIS|one dose in conjunction with a 4 day course intravenously
224646|NCT02192788|Radiation|Stereotactic Body Radiation Therapy for Oligometastases|
224647|NCT02192814|Drug|Lacosamide (200 mg/20 mL)|Active Substance: Lacosamide
Pharmaceutical form: Solution for intravenous (iv) infusion
Concentration: adapted on concentration of oral dose in EP0009
Route of Administration: Drip infusion
224648|NCT02192827|Drug|Dexamethasone Sodium Phosphate Injection|
224649|NCT02192840|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
224650|NCT02192853|Drug|sitagliptin|In randomized order:
Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion
224651|NCT02192853|Drug|Placebo|Day 4: placebo tablet
224652|NCT00138853|Device|Tibial component|Tibial component inserted at the time of surgery
224653|NCT02192879|Device|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
224654|NCT02192879|Device|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
224655|NCT02192879|Drug|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
224656|NCT02192892|Dietary Supplement|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
229165|NCT02423993|Procedure|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
229166|NCT02423993|Procedure|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
229167|NCT02423993|Procedure|QoL assessment|For Quality of Life ("QoL") assessment will be used the following validated questionnaires (in Russian):
The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.
The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003).
224325|NCT02156466|Drug|Placebo matched to MSB0010841 (Anti-IL-17A/F Nanobody)|Placebo matched to MSB0010841 (Anti-IL-17A/F Nanobody) will be administered as subcutaneous injection every other week for a total duration of 6 weeks.
224326|NCT02156492|Drug|Evacetrapib|Administered orally.
224327|NCT02156492|Drug|Simvastatin|Administered orally.
224328|NCT02156492|Drug|Atorvastatin|Administered orally.
224329|NCT00134693|Drug|SB-681323|
224330|NCT02156505|Procedure|placement of double bare stent|
224331|NCT02156505|Device|DoubleBare stent|
224332|NCT02156518|Procedure|Vocal Function Exercises|Vocal Function Exercises
224333|NCT02156518|Procedure|Vocal Hygiene|Vocal Hygiene
224334|NCT02159196|Drug|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
224335|NCT02159222|Procedure|Additional physical therapy|
224336|NCT00135044|Procedure|intravenous taurine in nutritional supplement|
224337|NCT02159248|Drug|Tolfenamic acid + gemcitabine + radiation|Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
224338|NCT02159261|Drug|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
200883|NCT02025478|Biological|Breastmilk|A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.
If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician.
200884|NCT02025491|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
201216|NCT02020642|Procedure|Renal transplantation|Renal transplantation from cadaveric or live donor
201217|NCT02020655|Other|Shear- force model|Shear- force model
201218|NCT02020668|Other|Physiotherapy|
201219|NCT02020668|Other|Wait list control|
201220|NCT02020681|Device|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
201221|NCT02020681|Other|Placebo|Formulation of Curodont Repair without the peptide P11-4
201222|NCT02020681|Device|Fluoride|Single application on day D90
201223|NCT02020694|Drug|Vitamin D|
201224|NCT02023086|Procedure|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
201225|NCT02023086|Procedure|Visual field testing|Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.
In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later.
201226|NCT02023086|Procedure|Oxygen flow at the optic nerve head measurement|Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.
During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer.
201227|NCT00121446|Procedure|percutaneous coronary intervention|
201228|NCT02023086|Drug|Tropicamide|Used to dilate patient's pupil during testing
200570|NCT02033213|Other|Liberal group|A group of patients who received > 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
200571|NCT00122538|Drug|Didanosine (ddI)|
200572|NCT02033226|Device|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
200573|NCT02033226|Device|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
200574|NCT02033239|Drug|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
200575|NCT02033239|Drug|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
200576|NCT02033252|Device|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
200577|NCT02033265|Procedure|Brachial plexus block|Ultrasound guided axillary brachial plexus block
200578|NCT02033278|Drug|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells more conventional medical treatment
200885|NCT02025504|Device|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
200886|NCT02028052|Procedure|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
200887|NCT02028052|Device|22 gauge Vizishot needles|
200888|NCT02028065|Drug|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
200889|NCT02028065|Drug|Placebo|Placebo administered as a single IV bolus over 10 seconds
200890|NCT02028078|Drug|Insulin human|Induces hypoglycaemia
200891|NCT02028104|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
200892|NCT02028117|Biological|Enadenotucirev|Oncolytic Virus
200272|NCT01998594|Procedure|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
200273|NCT01998607|Other|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
200274|NCT01998620|Drug|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
200275|NCT01998620|Drug|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
200276|NCT00119236|Drug|tanespimycin|
200277|NCT01998620|Drug|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
200278|NCT01998633|Biological|Hematopoietic Stem Cell Transplant|NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)
200279|NCT01998646|Drug|ASP4058|Oral tablet
200280|NCT01998646|Drug|Placebo|Oral tablet
200281|NCT01998659|Drug|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
200282|NCT01998659|Drug|Placebo|Oral drinking solution
200283|NCT01998672|Drug|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
200284|NCT01998672|Drug|Placebo|Drinking solution
200285|NCT01998685|Drug|Propofol|
200286|NCT01998685|Drug|remifentanyl|
200287|NCT00119236|Drug|irinotecan hydrochloride|
200288|NCT01998685|Drug|Midazolam|
200289|NCT01998685|Drug|Fentanyl|
199685|NCT02011906|Dietary Supplement|omega 3|
199686|NCT02011906|Dietary Supplement|vitamin E|
199687|NCT02011906|Dietary Supplement|placebo of omega 3|
199688|NCT02011906|Dietary Supplement|placebo of vitamin E|
199689|NCT02011919|Device|Echopulse|HIFU Under ultrasound guidance
199982|NCT02006433|Device|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
199983|NCT02006472|Drug|Pridopidine|22.5 mg and 45 mg capsules
199984|NCT02006472|Other|Placebo|Capsules matching drug
199985|NCT02006485|Drug|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
199986|NCT02006485|Drug|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
199987|NCT02006498|Drug|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
199988|NCT02006498|Drug|Placebo|Placebo capsule with same appearances as study drug
199989|NCT02006511|Device|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
199990|NCT02006511|Other|Standard of Care wound therapy|Gauze type dressing.
199991|NCT00119821|Behavioral|Exercise|Moderate exercise implemented plus behavioral intervention.
199992|NCT02006524|Device|`MyDiagnostick|
199993|NCT02006537|Drug|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
199994|NCT02006576|Drug|600 mg ibuprofen three times daily for 48 weeks|
199995|NCT02006576|Other|Placebo three times daily|
199996|NCT02006589|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
199997|NCT02006589|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
199052|NCT02024685|Behavioral|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
199053|NCT02024685|Behavioral|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
199054|NCT02024698|Device|omafilcon A|Study participants are randomized to wear omafilcon A or etafilcon A pair of study lenses then crossover to the alternate pair.
199356|NCT02017340|Drug|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
199357|NCT02017353|Dietary Supplement|Curcuphyt|
199358|NCT02017366|Other|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
199359|NCT02017379|Drug|Erythromycin|
199360|NCT02017379|Drug|Metoclopromide|
199361|NCT02017392|Drug|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
199362|NCT02019602|Procedure|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
199363|NCT02019602|Procedure|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
199364|NCT02019602|Procedure|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
199365|NCT00121186|Procedure|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
199366|NCT02019602|Biological|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection
Concentration: 200 mg/ml
Route of Administration: Subcutaneous Use
199367|NCT02019615|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
203497|NCT01997476|Procedure|Combined EUS, e-PFT and sEUS Testing|advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.
Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately.
203498|NCT00119132|Drug|sulphadoxine-pyrimethamine|
203499|NCT01997489|Drug|Enzyme replacement|Observational study of current treatment and with no comparative groups
203500|NCT01997515|Drug|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
203501|NCT01997515|Drug|placebo|Group P (placebo) will receive the same amount of saline.
203502|NCT01997528|Device|Change of blood flow or sweep gas flow ( ILA Activve)|
203503|NCT01997554|Other|Blood sample|An extra blood sample of 10 ml is collected
203504|NCT01997567|Drug|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
203505|NCT01997567|Drug|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
198767|NCT02073305|Device|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
198768|NCT02073318|Other|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
198769|NCT02073318|Other|Upper extremities exercise|4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session
weeks
198770|NCT02073344|Procedure|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
198771|NCT02073344|Other|no intervention|no renal replacement therapy
198772|NCT00126503|Drug|Sorafenib Tosylate|Given PO
198773|NCT02073357|Procedure|Light general anaesthesia (BIS = 50)|
198774|NCT02073357|Procedure|deep general anaesthesia (BIS = 35)|
198775|NCT02073383|Procedure|Axillary brachial plexus block|
202874|NCT02007915|Drug|Pamidronate Disodium|Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
202875|NCT02010281|Device|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
202876|NCT02010294|Genetic|DNA samples, GAS strains|DNA samples,GAS strains
202877|NCT02010307|Other|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
202878|NCT00120289|Drug|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
202879|NCT02010320|Other|Computer dosing|Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates
202880|NCT02010320|Other|Standard dose determination|Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
202881|NCT02010333|Drug|Ha44 Gel 0.74% w/w|
202882|NCT02010346|Procedure|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
202883|NCT02010359|Drug|Lovaza|
202884|NCT02010359|Drug|Placebo|
202885|NCT02010372|Other|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
203193|NCT02002598|Drug|Carfilzomib|Patients will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days.
Dose Escalation is as follows:
-1 / 27 mg/m2
/ 27 mg/m2
/ 36 mg/m2
/ 36 mg/m2
/ 45 mg/m2
/ 56 mg/m2
203194|NCT02002598|Drug|Dexamethasone|Dexamethasone will be given by mouth or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
203195|NCT02002611|Drug|Lobeglitazone|
203196|NCT02002611|Drug|Warfarin|
203197|NCT02002624|Device|PSI|
203198|NCT02002624|Device|Conventional instrumentation|
203199|NCT02002637|Device|Latella Knee Implant System|
203200|NCT02002650|Drug|Pre-operational rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP for all patients.
202280|NCT02021071|Radiation|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
202567|NCT02015936|Other|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
202568|NCT02015949|Drug|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
202569|NCT02015949|Drug|Placebo|Twice daily placebo tablet for two weeks
202570|NCT02015962|Drug|Intravenous potassium chloride|
202571|NCT02015962|Drug|Oral potassium chloride|
202572|NCT02015988|Drug|Fenofibrate|
202573|NCT02015988|Drug|Simvastatin|
202574|NCT02016001|Other|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
202575|NCT02016001|Other|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
202576|NCT02016014|Device|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
202577|NCT00120861|Drug|valopicitabine|
202578|NCT02016014|Behavioral|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
202579|NCT02016027|Drug|Carica folia|
202580|NCT02016040|Procedure|High Intensity Focused Ultrasound|
202581|NCT02016066|Drug|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
202582|NCT02016066|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
202583|NCT02016079|Dietary Supplement|omega-3|200 ml fruit drink containing omega-3
202584|NCT02016105|Drug|GP2017 Adalimumab|
202585|NCT02016105|Drug|Humira ® Adalimumab|
201984|NCT02028676|Drug|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
201985|NCT02028676|Drug|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
201986|NCT02028676|Drug|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
201987|NCT02028676|Drug|Once-daily ABC+3TC|
201988|NCT02028676|Drug|Twice-daily ABC+3TC|
201989|NCT02028676|Drug|Continued cotrimoxazole prophylaxis|
202281|NCT02021084|Dietary Supplement|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
202282|NCT02021084|Dietary Supplement|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
202283|NCT02021097|Drug|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
202284|NCT02021097|Drug|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
202285|NCT02021110|Drug|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
202286|NCT02023489|Other|Hyperglycemic-hyperinsulinemic clamp|All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.
At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at ~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with [1-13C]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS.
202287|NCT02023502|Other|collection of urine and blood sample|
202288|NCT02023515|Behavioral|Emotional brain training|Stress management based program
202289|NCT02023515|Behavioral|Behavioral weight loss|Standard behavioral weight loss
202290|NCT02023541|Radiation|Proton beam therapy|
201704|NCT02033798|Drug|Tamsulosin|Once Daily 0.2mg per oral for 6 months
201705|NCT02033824|Other|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
201706|NCT01994187|Procedure|Carotid endarterectomy|
201707|NCT01994187|Procedure|carotid angioplasty|
201708|NCT01994200|Other|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
201709|NCT01994200|Other|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
201710|NCT01994213|Drug|Famitinib|Famitinib 25 mg p.o. qd
201711|NCT00118898|Drug|Atazanavir|300 mg tablet taken orally daily
201712|NCT01994226|Drug|Low-dose colchicine|
201713|NCT01994226|Drug|Naproxen|
201714|NCT01994239|Drug|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
201990|NCT02028676|Other|Stopped cotrimoxazole prophylaxis|
201991|NCT02028689|Drug|Lesinurad 400 mg|
201992|NCT02028689|Drug|Metformin 850 mg|
201993|NCT02028689|Drug|Furosemide 40 mg|
201994|NCT00121966|Drug|Insulin Aspart|
201995|NCT02028702|Dietary Supplement|Placebo|water with color
201996|NCT02028702|Dietary Supplement|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
201997|NCT02028715|Drug|Placebo (normal saline)|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
201998|NCT02028715|Drug|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
201395|NCT01999088|Other|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
201396|NCT01999101|Drug|Px-104|28 days treatment
201397|NCT01999114|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied transdermally for 7-day wear
201398|NCT01999114|Drug|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
201399|NCT01999114|Drug|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
201400|NCT01999114|Drug|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
201401|NCT01999153|Drug|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
201402|NCT01999153|Drug|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
201403|NCT01999166|Radiation|radiography (X-ray)|
201404|NCT01999166|Genetic|DNA sampling|
201405|NCT00119262|Biological|filgrastim|Given SC
201406|NCT02001662|Procedure|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
201407|NCT02001662|Procedure|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
201408|NCT02001675|Device|magnetic resonance imaging (MRI)|
201409|NCT02001675|Device|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
201410|NCT00119392|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
201411|NCT02001688|Biological|Kamada-API for Inhalation, 80mg|
201412|NCT02001688|Drug|Placebo|
201413|NCT02001688|Biological|Kamada-API for Inhalation, 160mg|
201414|NCT02001701|Procedure|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
201715|NCT01994239|Radiation|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
200765|NCT02012348|Other|Antibacterial soap + benzalkonium chloride|
200766|NCT02012348|Other|Control soap|
200767|NCT02012361|Procedure|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.
200768|NCT00120471|Drug|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
201068|NCT02004366|Drug|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
201069|NCT02004392|Drug|EVP-6124|
201070|NCT02004405|Other|strengthening exercise|The experimental group (STRE) will receive strengthening training in "Station for lifting weight exercises" (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks.
201071|NCT02004405|Other|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
201072|NCT02006979|Other|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
201073|NCT02006992|Other|RTF Infant Formula|a RTF extensively hydrolyzed infant formula
201074|NCT02006992|Other|Powder Infant Formula|a powdered extensively hydrolyzed infant formula.
201075|NCT02007005|Drug|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
201076|NCT02007018|Device|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
201077|NCT00119847|Procedure|PTCA and/or Stents|
201078|NCT02007018|Other|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending > 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
225566|NCT02169882|Drug|Other TB drugs|Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
225567|NCT02169882|Drug|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
225568|NCT02169895|Drug|BIA 9-1067|
225569|NCT02169895|Drug|Placebo|
225570|NCT00002275|Drug|Fat Emulsion 2%|
225571|NCT00136201|Drug|tigecycline|
225572|NCT02169895|Drug|Prolopa®|levodopa/benserazide 100/25 mg
225573|NCT02169908|Device|Thermotest|
225574|NCT02169908|Device|von Frey hairs|
225575|NCT02169921|Device|TurboHawk™ LS-C, TurboHawk™ LX-C ,TurboHawk™ SS-C, TurboHawk™ SS-CL and TurboHawk™ SX-C|
225576|NCT02169934|Drug|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
225577|NCT02169947|Behavioral|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
225902|NCT02160067|Drug|First generation BuTrans patch|
225903|NCT02160080|Drug|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
225904|NCT02160106|Drug|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
225905|NCT00135148|Procedure|Filling out a questionnaire on libido and possible partner relationship|
225906|NCT02160119|Other|MRI-based techniques|fMRI, DTI
225907|NCT02162524|Behavioral|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
225908|NCT02162537|Drug|Cisplatin|Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
225909|NCT02162537|Drug|Pemetrexed|500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
225264|NCT02180282|Device|M22-IPL|The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.
The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm.
225265|NCT02180295|Biological|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
225266|NCT02180295|Biological|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
225267|NCT00137358|Drug|Amifostine|
225268|NCT02180295|Biological|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
225269|NCT02180308|Device|PET/MRI|Simultaneous PET/MRI (3T system)
225270|NCT02180321|Drug|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
225271|NCT02180321|Drug|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
225272|NCT02180334|Drug|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
225273|NCT02180334|Drug|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
225274|NCT02180334|Drug|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
225275|NCT02180347|Device|Contact lenses|
225578|NCT02169947|Behavioral|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
225579|NCT02169960|Behavioral|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
225580|NCT02169960|Behavioral|Breaking Free|Online based intervention for Drug and Alcohol Use
225581|NCT02169960|Behavioral|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
225582|NCT00136227|Behavioral|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
225583|NCT02169960|Behavioral|Resiliency Training|Op Volle Kracht (OVK)
225584|NCT02172235|Drug|BI 10773 - low dose|
224657|NCT02192892|Dietary Supplement|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
224952|NCT02185430|Drug|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
224953|NCT02185430|Drug|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
224954|NCT02185443|Radiation|SBRT|60Gy in 3 fractions (20Gy/fraction) over 14 days
60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above
224955|NCT00137995|Drug|Etoposide|100 mg/m² D1-D2-D3
224956|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
224957|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
224958|NCT02187757|Dietary Supplement|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
224959|NCT02187757|Dietary Supplement|Placebo|
224960|NCT02187770|Device|IMED-4|Non invasive recording electrode used to assess lung fluid
224961|NCT00138177|Drug|fluorouracil|Given IV
224962|NCT02187783|Drug|LEE011|LEE011 600 mg (hard gelatin capsules) will be administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle is defined as 28 days.
224963|NCT02187809|Drug|Clobazam|
224964|NCT02187822|Drug|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
224965|NCT02187822|Procedure|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
224966|NCT02187848|Drug|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
224967|NCT02187861|Drug|Bendamustine|Bendamustine chemotherapy per standard administration procedures, Cycles 1-6
224968|NCT02187861|Drug|GDC-0199; ABT-199; RO5537382|Daily oral dose of GDC-0199, administered prior to infusions where applicable, for up to 1 year
224339|NCT02159287|Drug|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
224340|NCT02159287|Drug|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
224341|NCT02159300|Behavioral|experience brain activity recording|Intervention: experience brain activity recording
224342|NCT02159313|Drug|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
224343|NCT02159326|Drug|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
224344|NCT02159326|Drug|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
224345|NCT02159352|Drug|Daclatasvir|
224346|NCT02159352|Drug|Darunavir|
224658|NCT02192892|Dietary Supplement|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
224659|NCT02192892|Dietary Supplement|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
224660|NCT02192892|Dietary Supplement|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
224661|NCT02192892|Dietary Supplement|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
224662|NCT02195297|Other|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
224663|NCT02195310|Device|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
224664|NCT02195310|Device|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
224665|NCT02195323|Biological|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
224666|NCT02195336|Device|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
224667|NCT02195336|Drug|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
224668|NCT02195336|Drug|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
224669|NCT02195349|Biological|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
201229|NCT02023086|Device|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
201230|NCT02023099|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
201231|NCT02023099|Drug|Placebo|Tablet
201232|NCT02023112|Drug|ABT-450/r/ABT-267 plus Ribavirin|
201233|NCT02023125|Other|Hight fat and calorie meal|High fat and calorie meal served prior to RO5424802 administration
201234|NCT02023125|Drug|RO5424802|Single oral dose
201533|NCT02015650|Drug|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
201534|NCT02015650|Drug|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
201535|NCT02015663|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
201536|NCT02015676|Drug|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
201537|NCT00120796|Biological|Recombinant hepatitis B surface antigen|
201538|NCT02015676|Drug|paclitaxel|60 mg/m^2 IV weekly; dose increased to 70 mg/m^2, and subsequently 80 mg/m^2, after 2 treatment cycles with no evidence of DLT until disease progression
201539|NCT02015676|Drug|Myocet|40 mg/m^2 IV weekly; dose increased to 50 mg/m^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
201540|NCT02015689|Behavioral|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
201541|NCT02015689|Behavioral|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
201542|NCT02015689|Behavioral|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
201543|NCT02018224|Procedure|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
201544|NCT02018224|Procedure|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
200893|NCT02028130|Procedure|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
200894|NCT00121888|Behavioral|Prolonged Exposure Therapy|
200895|NCT02028143|Device|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
200896|NCT02028143|Device|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
200897|NCT02028143|Procedure|Pulmonary vein isolation|
200898|NCT02028143|Procedure|ICE catheter placed through one of two existing 8F sheaths|
200899|NCT02028156|Other|Partially Hydrolyzed Infant Formula|Commercially available infant formula
200900|NCT02028182|Biological|Lyral®|T.R.U.E. Test allergen panel (0.40 mg/cm^2, 0.20 mg/cm^2, 0.10 mg/cm^2 and negative control)
200901|NCT02028195|Other|Health check|The program includes four components:
Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).
The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).
Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.
Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview.
200902|NCT02028208|Biological|Mercury, Aluminum, Palladium|T.R.U.E. Test metal allergen panels containing ascending doses of mercury, aluminum or palladium
201235|NCT02023125|Other|Standard meal|Standard meal served prior to RO5424802 administration
201236|NCT02023125|Drug|esomeprazole|40 mg esomeprazole administered daily for 6 days prior to RO5424802 administration
201237|NCT02023138|Other|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
201238|NCT00121459|Device|Ortho All-Flex diaphragm and Replens lubricant gel|
201239|NCT02023138|Other|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
201240|NCT02023151|Drug|Omalizumab|
200290|NCT01998685|Drug|Sevoflurane|
200291|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
200579|NCT02033278|Drug|Placebo infusion|Placebo infusion more conventional medical treatment
200580|NCT02033291|Procedure|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
200581|NCT02033317|Drug|patiromer|15 grams/day (5 grams 3 times daily) administered orally
200582|NCT01993693|Device|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
200583|NCT01993693|Device|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
200584|NCT01993706|Drug|VRC-HIVMAB060-00-AB|
200585|NCT01993719|Drug|Aldesleukin|Arms 1 and 2 Administered at a dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1hr)beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
200586|NCT01993719|Drug|Fludarabine|Arm 1 (standard chemotherapy regimen) Fludarabine 25 mg/m(2)/day IVPB daily over 30 minutes for 5 days.
Arm 2 (low dose chemotherapy regimen) Fludarabine 30 mg/m(2)/day IVPB daily over 30 minutes for 3 days.
200587|NCT01993719|Drug|Cyclophosphamide|Arm 1 (standard chemotherapy regimen) Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mlD5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
Arm 2 (low dose chemotherapy regimen) Cyclophosphamide 300 mg/m(2)/day X 3 days IV
200588|NCT00118859|Behavioral|Integrative care for low back pain|
200589|NCT01993719|Biological|Young Tumor Infiltrating Lymphocytes (Young TIL)|Arms 1 and 2 Cells (young TIL) will be infused intravenously (i.v.) on the Patient Care Unti via non-filtered tubing, gently agitating the bag during infusion to prevent clumping.
200590|NCT01993719|Drug|Keytruda|Arms 1 and 2 and ONLY FOR RETREATMENT
Patients who do not respond or who experience a partial or complete response and subsequently progress and have received prior therapy with either pembrolizumab or nivolumab may receive a second treatment
Patients in the RETREATMENT ARM will receive 4 doses of Pembrolizumab at the NIH Clinical Center as follows:
Day 0 (two to four days after the last dose of fludarabine) - Pembrolizumab 2mg/kg IV approximately 4 hours prior to cell infusion given over approximately 30 minutes
Day 21 (+/- 2 days) following cell infusion - Pembrolizumab 2mg/kg IV given over approximately 30 minutes
Day 42 (+/- 2 days) following cell infusion - Pembrolizumab 2mg/kg IV given over approximately 30 minutes
Day 63 (+/- 2 days) following cell infusion - Pembrolizumab 2mg/kg IV given over approximately 30 minutes
200591|NCT01993732|Procedure|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
199998|NCT02006602|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
199999|NCT02006602|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
200000|NCT02006615|Device|rTMS|5Hz rTMS over M1 and inferior frontal lobe
200001|NCT02006628|Drug|Placebo|Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.
200292|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
200293|NCT01998711|Behavioral|Memory group|Five 1-1.5 hour weekly session of memory training
200294|NCT02001103|Drug|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
200295|NCT02001116|Other|Quality Improvement intervention|Training for local trainers and medical staff on the National Adaptation of the WHO guidelines "Pocket Book of Hospital Care for Children".
Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care
200296|NCT02001129|Behavioral|Patient Appointment Messages 2000 (PAM2000)|
200297|NCT02001129|Behavioral|Personalized Telephone Call|
200298|NCT02001129|Behavioral|Usual Care|
200299|NCT02001142|Other|Exercise|single session of exercise
200300|NCT02001155|Procedure|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
200301|NCT02001168|Drug|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
200302|NCT02001168|Drug|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
200303|NCT00119392|Biological|rituximab|Given IV
200304|NCT02001168|Drug|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
200305|NCT02001168|Drug|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
200306|NCT02001181|Drug|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
199368|NCT02019628|Dietary Supplement|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
199369|NCT02019641|Other|Aerobic Exercise Training|
199370|NCT02019641|Other|Education|
199371|NCT02019667|Drug|SGS-742|
199372|NCT02019667|Drug|Placebo|
199373|NCT02019693|Drug|INC280|Supplied by Novartis as film-coated tablet for oral use.
199374|NCT02019706|Drug|F-DOPA PET Scan|
199375|NCT02019706|Drug|Mifepristone|
199376|NCT00121199|Biological|rituximab|Given IV
199690|NCT02011945|Drug|Dasatinib|
199691|NCT02011945|Drug|Nivolumab|
199692|NCT02011958|Drug|Liposomal Amphotericin B|40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)
30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)
199693|NCT02011958|Drug|Miltefosine|Orally taken every day during 28 days
1 x 50 mg capsule per day if the patient weights less or equal to 25 kg
2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)
199694|NCT00002169|Drug|Nelfinavir mesylate|
199695|NCT00120692|Drug|Recombinant Human Erythropoietin|
199696|NCT02014545|Drug|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
199697|NCT02014558|Drug|ASP2215|tablet
199698|NCT02014571|Drug|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
199699|NCT02014571|Drug|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
199700|NCT02014584|Drug|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
198776|NCT02073396|Other|Global Thrombosis Test|Patients will undergo the Global Thrombosis Test, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study. The Global Thrombosis Test assesses thrombotic and thrombolytic status, by measuring the time of thrombus (occlusion time, OT), and time needed for lysis of the thrombus (lysis time, LT).
198777|NCT02073422|Device|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
198778|NCT02073422|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
198779|NCT02075502|Behavioral|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
198780|NCT02075502|Procedure|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
198781|NCT02075502|Procedure|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
198782|NCT02075515|Biological|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
198783|NCT02075528|Drug|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
198784|NCT02075541|Biological|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
198785|NCT02075541|Drug|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
199055|NCT02024698|Device|etafilcon A|Study participants are randomized to wear omafilcon A or etafilcon A pair of study lenses then crossover to the alternate pair.
199056|NCT00121641|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
199057|NCT02024711|Device|EYEFILL® C.-US Viscoelastic|A comparison between EYEFILL ® C.-US and Healon® Viscoelastic (CONTROL) for the identical use during cataract extraction.
199058|NCT02024711|Device|Healon® Viscoelastic (CONTROL)|
199059|NCT02024724|Drug|Bupivacaine|4 mL of 0.25% bupivacaine
199060|NCT02024724|Drug|Triamcinolone|40 mg of Triamcinolone
199061|NCT02024724|Drug|Dexamethasone|4 mg of Dexamethasone
203201|NCT00119496|Drug|beclomethasone|inhaled beclomethasone, 200mcg bd
203202|NCT02002650|Drug|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP just for high-risk patients.
203203|NCT02002663|Drug|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
203204|NCT02002663|Drug|Methylprednisolone 1mg/kg|
203205|NCT02002663|Drug|saline 0.9%|
203206|NCT02002689|Drug|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
203207|NCT02002702|Drug|Serelaxin|Intravenous infusion
203208|NCT02002702|Drug|Placebo|Placebo
203209|NCT02002715|Drug|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
203210|NCT02005354|Device|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (>50Hz and below the pain threshold for the patient).
203211|NCT00002162|Drug|Didanosine|
203212|NCT00119730|Drug|Fludarabine|Given on days 1-3 of each 28-day cycle
203213|NCT02005354|Drug|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
203214|NCT02005367|Behavioral|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.
Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures.
203506|NCT01997580|Drug|escitalopram|SSRI antidepressant
203507|NCT01997593|Drug|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
203508|NCT01997606|Other|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
202586|NCT02016118|Device|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
202587|NCT02018614|Other|algoplus|
202588|NCT02018627|Drug|Xeris glucagon|
202589|NCT02018627|Drug|Lilly glucagon|
202886|NCT02010372|Other|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
202887|NCT02010385|Drug|Octreotide|
202888|NCT02010385|Drug|Saline|
202889|NCT00120289|Drug|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
202890|NCT02010398|Other|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
202891|NCT02010398|Other|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
202892|NCT02010398|Other|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
202893|NCT02010411|Drug|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
202894|NCT02010424|Other|control group|standard IVF protocol
202895|NCT02010424|Device|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
202896|NCT02010437|Drug|Sodium Tetradecyl Sulphate (STS)|
202897|NCT02010450|Other|Wearable Blanket (Sleep Sack)|
202898|NCT02010450|Other|Incentive Item|
202899|NCT02013323|Drug|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
202291|NCT02023554|Drug|Theophylline with azithromycin|Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.
Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7.
202292|NCT02023554|Drug|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
202293|NCT02023567|Drug|SSIRs|fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
202294|NCT00121524|Drug|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
202295|NCT02023567|Procedure|Modified Electraconvulsive therapy (MECT)|8 times
202296|NCT02023580|Behavioral|Video treatments|The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDUAI); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.
Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 & 10) Support of HIV disclosure and perceived responsibility.
202590|NCT02018653|Drug|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
202591|NCT02018653|Other|Placebo|1 by mouth every 6 hours for up to 6 days.
202592|NCT02018653|Behavioral|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
202593|NCT02018666|Device|NAVA endotracheal tube|
202594|NCT00121134|Drug|Cyclophosphamide|Once a day for 6 months
202595|NCT02018679|Procedure|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
202596|NCT02018679|Procedure|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
202597|NCT02018692|Dietary Supplement|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
201999|NCT02028741|Other|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
202000|NCT02028754|Drug|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
202001|NCT00122343|Drug|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
202002|NCT02031081|Drug|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
202003|NCT02031081|Drug|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
202004|NCT02031094|Other|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
202005|NCT02031107|Device|cTBS|
202006|NCT02031107|Device|cathodal tDCS|
202007|NCT02031107|Device|sham stimulation|
202008|NCT02031133|Drug|Miravirsen|
202009|NCT02031146|Procedure|Lumbar puncture|
202010|NCT02031185|Behavioral|FitBit only|Participants will use the FitBit device
202011|NCT02031185|Behavioral|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
202012|NCT00122356|Drug|Alendronate sodium|70mg tablets, once weekly
202013|NCT02031198|Drug|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
202297|NCT02023593|Drug|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
202298|NCT02023606|Drug|SPN-810M|
202299|NCT02023632|Behavioral|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
201716|NCT01994252|Device|Optimal Medical therapy plus ICD|
201717|NCT01994252|Device|Optimal Medical therapy plus CRT/ICD|
201718|NCT01994265|Drug|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
201719|NCT01994265|Drug|Dabigatran|
201720|NCT01994278|Device|Peri Clean|
201721|NCT01994291|Drug|Ranibizumab|Intravitreal Injection supplied as:
10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.
6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.
Adminstered once a month for 12 weeks
201722|NCT00118898|Drug|Efavirenz|600 mg tablet taken orally daily
201723|NCT01994291|Drug|Placebo|Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.
Dose is 4 tablets each day for 12 weeks
201724|NCT01994291|Drug|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
201725|NCT01994291|Drug|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
201726|NCT01994304|Behavioral|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce perinatal mortality (still births and early neonatal mortality).
201727|NCT01994317|Other|Algorithm|IV sedation dosing calculated by algorithm
201728|NCT01994317|Other|Standard care|IV sedation dosing calculated by standard care.
201729|NCT01994330|Drug|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
201730|NCT01996475|Drug|Escitalopram Oxalate Tablets|
201731|NCT01996488|Drug|Olanzapine Orally Disintegrating Tablets 5mg|
201732|NCT01996501|Drug|Olanzapine Orally Disintegrating 5mg Tablets|
201733|NCT01996514|Dietary Supplement|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
201734|NCT01996514|Dietary Supplement|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
201735|NCT01996514|Behavioral|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
201079|NCT02007044|Drug|Ibrutinib|Ibrutinib Subgroup 1 started on Day 1 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle.
Ibrutinib Subgroup 2 started on Day 2 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle.
Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions.
201080|NCT02007044|Drug|Rituximab|Rituximab 375 mg/m2 given intravenously on Day 1, Day 8, Day 15, and Day 22 , and then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
201081|NCT02007057|Procedure|Suprascapular nerve block|
201082|NCT02007057|Procedure|Interscalene nerve block|
201083|NCT02007070|Biological|Pembrolizumab|
201084|NCT02007083|Procedure|Bilateral laminotomy (BL)|
226530|NCT00137995|Drug|Etoposide|200 mg/m² from D-6 to D-3
226531|NCT02185989|Other|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
226532|NCT02186002|Drug|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
226533|NCT02186002|Drug|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
226534|NCT02186002|Drug|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
226535|NCT02186002|Drug|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
226536|NCT02188537|Drug|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
226537|NCT00138229|Biological|therapeutic autologous lymphocytes|
226538|NCT02188537|Drug|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
226539|NCT02188537|Drug|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
226540|NCT02188550|Drug|everolimus and letrozole|This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
The duration of the study will be until disease progression
Everolimus and Letrozole will be administered as noted below;
6.1.1 Dosing regimen
Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally
226541|NCT02188563|Other|Comprehensive smoking cessation intervention|
226542|NCT02188563|Behavioral|Enhanced usual care|
225910|NCT02162537|Drug|Bevacizumab|7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
225911|NCT02162537|Radiation|Cerebral Radiotherapy|Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
225912|NCT02162550|Drug|Bydureon|once weekly injection
225913|NCT02162550|Drug|placebo|once weekly injection
225914|NCT02162563|Drug|FOLFOX/ FOLFIRI with bevacizumab|FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
225915|NCT02162563|Drug|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
225916|NCT00135395|Drug|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
226233|NCT02193490|Drug|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
226234|NCT00138970|Drug|Zenapax®, CellCept® and prednisolone|
226235|NCT02193503|Other|Treatment|Treatment is the implantation of loaded macrocapsules + injection of irradiated autologous tumor cells
226236|NCT02193555|Device|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
226237|NCT02193568|Procedure|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
226238|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
226239|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Undergo craniotomy
226240|NCT02193568|Other|Arm II (intubated general anesthesia)|Ancillary studies
226241|NCT02193568|Procedure|Arm I (light sedation)|Undergo craniotomy
226242|NCT02193568|Other|Arm I (light sedation)|Ancillary studies
225585|NCT02172235|Drug|BI 10773 - medium dose|
225586|NCT02172235|Drug|BI 10773 - high dose|
225587|NCT02172248|Drug|BI 10773|
225588|NCT02172248|Drug|Metformin|
225589|NCT02172261|Drug|BI 10773|
225590|NCT02172261|Drug|Glimepiride|
225591|NCT00136448|Drug|cytosine arabinoside (ara-C)|
225592|NCT02172274|Drug|[14C]-BI 10773 - oral solution|
225593|NCT02172287|Drug|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
225594|NCT02172287|Drug|Salmeterol|Inhalation aerosol twice daily
225595|NCT02172287|Drug|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
225596|NCT02172287|Drug|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
225597|NCT02172300|Drug|Tiotropium inhalation capsules|
225598|NCT02172300|Drug|Placebo inhalation capsules|
225599|NCT02172313|Drug|semaglutide|For oral administration.
225600|NCT02172326|Drug|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
225601|NCT02172339|Drug|Tiotropium, solution ampoules|
225602|NCT00136448|Drug|daunomycin|
225603|NCT02172352|Drug|Ba 679 BR low dose|
225917|NCT02162563|Drug|FOLFOX/ FOLFIRI with panitumumab|FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
224969|NCT02187861|Drug|Rituximab [MabThera/Rituxan]|Rituximab infusion 375 mg/m2 administered per package insert. For Arm A, 4 weekly doses followed by 5 additional doses spread across one year. For Arm B and Arm C, cycles 1-6.
224970|NCT02187874|Procedure|delayed umbilical cord occlusion|
224971|NCT02187874|Procedure|early umbilical cord occlusion|
225276|NCT02180360|Other|Capoeira training group|Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.
In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the "ginga") and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.
An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol.
225277|NCT02180386|Behavioral|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
225278|NCT00137371|Drug|PVC (daily for 21 days, 7 days off)|
225279|NCT02182999|Drug|NaCl 0,9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
225280|NCT02182999|Drug|Ropivacaine|The catheter is connected to the perfusor line filled with ropivacain 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
225281|NCT02183012|Drug|Ibuprofen extrudate|
225282|NCT02183012|Drug|Ibuprofen lysinate|
225283|NCT02183012|Drug|Ibuprofen|
225284|NCT02183025|Drug|Meloxicam 7.5 mg|
225285|NCT02183025|Drug|Meloxicam 15 mg|
225286|NCT02183025|Drug|Mefenamic acid 500 mg|
225287|NCT00137722|Behavioral|Payment for desired behaviors|
225288|NCT02183025|Drug|Placebo matching 7.5 mg meloxicam|
225289|NCT02183025|Drug|Placebo matching 15 mg meloxicam|
225290|NCT02183025|Drug|Placebo matching 500 mg mefenamic acid|
225291|NCT02183038|Drug|Meloxicam low|
225292|NCT02183038|Drug|Meloxicam high|
224670|NCT02195349|Biological|Placebo|Commercial saline solution administered by IV over approximately 2 hours
224671|NCT02195375|Drug|Flutiform 500/20 µg BID|
224672|NCT00139230|Drug|Taxotere|
224673|NCT02195375|Drug|Flutiform 250/10 µg BID|
224674|NCT02195375|Drug|Seretide Accuhaler 50/500 µg BID|
224675|NCT02195388|Other|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
224676|NCT02195401|Other|Cleanroom|Cleanroom with air the quality of the pre-industrial age
224972|NCT00138203|Drug|vorinostat|Given PO
224973|NCT02187874|Drug|Oxytocin|
224974|NCT02187887|Behavioral|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
224975|NCT02187900|Drug|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
224976|NCT02187900|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
224977|NCT02187913|Dietary Supplement|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
224978|NCT02189954|Procedure|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
224979|NCT02189954|Procedure|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
224980|NCT02189967|Radiation|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
224981|NCT02189967|Radiation|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
224982|NCT00138528|Drug|Fluvastatin|
201545|NCT02018237|Behavioral|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen and meals will be picked up every 3-4 days.
201546|NCT00121069|Drug|Escitalopram|
201547|NCT02018237|Behavioral|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet ( low in high fructose corn syrup)for 4 weeks. The food will be prepared by the bio-nutrition kitchen and meals will be picked up every 3-4 days.
201548|NCT02018250|Drug|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
201549|NCT02018250|Drug|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
201550|NCT02018263|Drug|Cocaine hydrochloride|
201551|NCT02018263|Behavioral|Exercise|
201552|NCT02018263|Drug|Nicotine|
201848|NCT02009813|Procedure|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
201849|NCT02009826|Radiation|[18F]-PBR111 Positron Emission Tomography (PET)|[18F]-PBR111 radioligand to assess binding to TSPO
201850|NCT02009826|Behavioral|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
201851|NCT02009826|Biological|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
201852|NCT02009839|Behavioral|Meeky Mouse program|
201853|NCT02009839|Other|Computer Games|
201854|NCT00120237|Drug|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
201855|NCT02009865|Drug|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
201856|NCT02009865|Drug|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
201857|NCT02009878|Drug|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
201858|NCT02009943|Drug|Ferric carboxymaltose|
201241|NCT02023151|Drug|Placebo injection|
201242|NCT02023164|Drug|JDP-205 Injection|
201243|NCT02023164|Drug|Diphenhydramine|
201244|NCT02023203|Procedure|Totally Extraperitoneal laparoscopic inguinal hernia repair|Laparoscopic hernioplasty
201245|NCT02025517|Other|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
201246|NCT02025530|Other|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
201247|NCT00121667|Drug|Pioglitazone|Tablets, Oral, 15 - 45 mg (as needed for rescue)
201248|NCT02025543|Other|MRI|R2 MRI scan
201249|NCT02025556|Biological|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
201250|NCT02025556|Biological|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
201251|NCT02025556|Biological|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
201252|NCT02025569|Other|Strain Counterstrain|
201253|NCT02025569|Other|Sham strain counterstrain|
201254|NCT02025582|Device|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
201255|NCT02025608|Drug|Pramipexole|
201256|NCT02025608|Drug|Placebo|
201257|NCT02025621|Drug|Levosimendan|
201553|NCT02018276|Drug|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
201554|NCT02018276|Drug|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
200592|NCT01993758|Procedure|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
200593|NCT01993758|Procedure|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
200594|NCT01993771|Procedure|Surgery with general anaesthesia.|
200595|NCT01993771|Procedure|Raw EEG|
200903|NCT02028221|Drug|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
200904|NCT02028221|Drug|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
200905|NCT00121888|Drug|Paroxetine-CR|
200906|NCT02028234|Drug|Pantoprazole,|os, 20 mg, once per day, for 30 days
200907|NCT02030535|Drug|tiotropium|fixed dose combination with olodaterol
200908|NCT02030535|Drug|olodaterol|fixed dose combination with tiotropium
200909|NCT02030561|Drug|Trastuzumab + NK cells|
200910|NCT02030574|Drug|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
200911|NCT02030587|Procedure|Radiofrequency Ablation|
200912|NCT02030587|Procedure|Laparoscopic Adrenalectomy|
200913|NCT02030600|Drug|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
200914|NCT00122291|Drug|Capecitabine|
200915|NCT02030600|Drug|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
200916|NCT02030613|Genetic|Blood test|
200917|NCT02030626|Device|active or placebo rTMS or active or placebo tDCS|
200918|NCT02030639|Drug|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
200919|NCT02030652|Procedure|Intermittent nasal positive pressure positive ventilation.|
212462|NCT02140840|Drug|Trametinib|2 mg of Trametinib daily by mouth in 28 day cycles
212463|NCT02140866|Other|Hand Exercise|
212464|NCT02140866|Other|Compensatory Intervention Program (CIP)|
212465|NCT02140879|Dietary Supplement|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
212466|NCT02140879|Dietary Supplement|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
212467|NCT02140892|Procedure|respiratory physical therapy manual technique- Autogenic Drainage|
212468|NCT00133419|Drug|Vitamin A + Zinc|
212469|NCT02140892|Device|respiratory physical therapy technique- IPV|
212470|NCT02140918|Drug|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
212471|NCT02140918|Drug|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
212472|NCT02140918|Drug|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
212473|NCT02140918|Drug|Placebo|
212474|NCT02140931|Procedure|Injections|Intra-muscular injections
212761|NCT02133482|Drug|BI 639667|oral solution BI 639667, single rising doses
212762|NCT02133495|Procedure|Non Cadaveric Human Acellular Dermal Tissue|
212763|NCT02133521|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
212764|NCT02133521|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
212765|NCT02133534|Drug|Atorvastatin|
212766|NCT02133560|Behavioral|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
212767|NCT00002240|Drug|Stavudine|
212162|NCT02148250|Drug|U-500 insulin|Subjects are randomized to receive 100 or 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
212163|NCT02148263|Device|senofilcon A|
212164|NCT02148289|Dietary Supplement|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
212165|NCT00134004|Drug|mycophenolate mofetil|
212166|NCT02148289|Dietary Supplement|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
212167|NCT02148302|Device|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
212168|NCT02148315|Behavioral|garden|
212169|NCT02148328|Biological|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
212170|NCT02148328|Biological|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
212171|NCT02148328|Biological|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
212172|NCT02148328|Biological|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
212173|NCT02148341|Other|Community of Practice Facilitation|
212174|NCT02148341|Other|Usual Care|
212175|NCT02148354|Behavioral|Smiling is Fun|Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) "How am I?" offers a set of graphs and feedbacks to chart the user's progress.
212176|NCT00134004|Drug|tacrolimus|
212475|NCT02140957|Behavioral|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
216639|NCT02312804|Drug|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
216640|NCT02312804|Drug|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
216641|NCT02312804|Drug|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
216642|NCT02312817|Other|Mailed Outreach Invitation|Individuals randomized to Group 2 will receive:
Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.
"Live" phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.
Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic.
216643|NCT02312817|Other|Mailed Outreach Invitation and Patient Navigation|Individuals randomized to Group 3 will receive:
Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.
"Live" phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion "and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.
Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic.
216644|NCT02312843|Behavioral|Exercise/Aerobic|
216645|NCT02312843|Behavioral|Exercise/Stretching|
216646|NCT02312856|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
216647|NCT00152893|Drug|Placebo|
216648|NCT02315196|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
216649|NCT02315196|Drug|epirubicin hydrochloride|Given IV
216650|NCT02315196|Drug|carboplatin|Given IV
216651|NCT02315196|Procedure|therapeutic conventional surgery|Undergo definitive surgery
216652|NCT02315196|Drug|paclitaxel|Given IV
216653|NCT02315196|Other|laboratory biomarker analysis|Correlative studies
216654|NCT02315196|Other|quality-of-life assessment|Ancillary studies
216655|NCT02315209|Device|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
216656|NCT02315222|Dietary Supplement|Regenium|
216657|NCT02315222|Dietary Supplement|Placebo|
215996|NCT02126891|Procedure|Tests|Individual parameters of echocardiography and heart rate variability
215997|NCT02126904|Drug|IVA group|
215998|NCT02126917|Drug|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
216326|NCT02122146|Drug|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
216327|NCT02122146|Drug|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
216328|NCT02122159|Biological|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
216329|NCT02122172|Drug|afatinib dimaleate|Given PO
216330|NCT00131482|Drug|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
216331|NCT02122172|Other|laboratory biomarker analysis|Correlative studies
216332|NCT02122185|Drug|paclitaxel|Given IV
216333|NCT02124148|Drug|Fluorouracil|Administered IV
216334|NCT02124148|Drug|LY3023414|Administered PO
216335|NCT02124148|Drug|Leucovorin|Administered IV
216336|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
216337|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
216338|NCT00131742|Drug|lamivudine|
216339|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
216340|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
216341|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
215699|NCT02134743|Procedure|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
215700|NCT02134756|Drug|NutraStem Active|
215701|NCT00132808|Drug|Placebo|Physiologic 0.9% normal saline
215702|NCT02134769|Device|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
215703|NCT02134782|Behavioral|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
215704|NCT02136927|Drug|SPARC1210|
215999|NCT02126917|Drug|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
216000|NCT02129439|Drug|Placebo|Intervention of placebo-treated subjects does not vary to SB012-treated subjects.
The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.
The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.
216001|NCT02129478|Drug|Olanzapine|Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.
Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg).
216002|NCT02129504|Device|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
216003|NCT00132288|Behavioral|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
216004|NCT02129517|Other|IMPACT intervention|Tailored, web-based educational short video clips
216005|NCT02129517|Other|Online education materials|Online NCI-based educational materials
216006|NCT02129517|Other|survey administration|Ancillary studies
216007|NCT02129530|Behavioral|Community Social Mobilization program|
216008|NCT02129543|Procedure|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis at the following intervals: Within 30 days pre-transplant; Post-transplant Day 30 (+/- 7 business days); Day 60 (+/- 14 business days); Day 100 (+/- 21 business days); 6 months (+/- 21 business days); 1 year (+/- 21 business days) and annually (+/- 21 business days) thereafter
215379|NCT02142322|Drug|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
215380|NCT02142335|Drug|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 & 3 (days 1 & 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
215381|NCT02142361|Device|enfilcon A|Subject's habitual hydrogel toric lenses will be evaluated at the first visit and then re-fitted with a pair of silicon hydrogel toric lenses. After 1 week of daily wear, subjects will return for a second and final evaluation.
215382|NCT02142387|Other|BLS CPR program with dispatcher assisted CPR simulation|
215383|NCT02142400|Drug|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
215384|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
215385|NCT02142400|Drug|placebo|matching placebo capsules to DS-1093 capsules
215386|NCT02142439|Behavioral|Strength training|Three times per week with strength training
215387|NCT02142452|Behavioral|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
215388|NCT02142452|Other|Usual Prenatal Care|
215705|NCT02136927|Drug|Reference1210|
215706|NCT02136940|Drug|AMA0076|
215707|NCT02136940|Drug|Placebo|
215708|NCT02136953|Behavioral|Exercise|12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
215709|NCT02136953|Behavioral|Cognitive Behavioural Therapy (CBT)|CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
215068|NCT02149550|Other|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
215069|NCT02149550|Other|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
215070|NCT02149550|Other|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
215071|NCT02149563|Device|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
215072|NCT02149576|Procedure|Low Dose Computed Tomography Imaging|
215073|NCT02149576|Procedure|Chest Radiograph Imaging|
215074|NCT02149589|Procedure|Mechanical ventilation|
215075|NCT02149602|Radiation|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
215076|NCT00134030|Procedure|quality-of-life assessment|Ancillary studies
215077|NCT02149615|Other|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
215078|NCT02149628|Drug|propofol|
215079|NCT02149628|Drug|Desflurane|
215080|NCT02149641|Radiation|Intensity modulated radiotherapy with chemotherapy|
215081|NCT02149654|Device|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
215082|NCT02149667|Device|total hip arthroplasty implant|
215083|NCT02149693|Other|high-fidelity simulation and teamwork training|
215084|NCT02149693|Other|traditional resuscitation training|
215085|NCT02149706|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
215086|NCT02149706|Biological|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
214468|NCT02121496|Behavioral|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad — the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
214469|NCT00131404|Drug|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
214470|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
214471|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
214472|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
214473|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
214474|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
214475|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
214781|NCT02154737|Drug|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
214782|NCT02154750|Device|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
214783|NCT02116777|Drug|Temozolomide|Given PO
214784|NCT02116790|Drug|Naproxen|Subjects will take one 250mg Naproxen capsule
214785|NCT02116790|Drug|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
214786|NCT02116790|Drug|Sinemet|Subjects will take one 25mg/100mg Sinemet.
214787|NCT02116790|Drug|Placebo|Subjects will take two placebos.
214788|NCT02116803|Drug|dovitinib|
214789|NCT02116803|Drug|fulvestrant|
214790|NCT02116816|Dietary Supplement|Polyphenol|Polyphenol
214791|NCT00131027|Drug|Vincristine|
214792|NCT02116829|Other|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
214793|NCT02116829|Other|Olive oil|
214156|NCT02128802|Other|Weight Loss Program|
214157|NCT02128815|Other|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
214158|NCT02128828|Drug|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
214159|NCT00132184|Drug|Vitamin D|
214160|NCT02128841|Drug|Rivaroxaban|Direct Factor Xa Inhibitor
214161|NCT02128854|Behavioral|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
214162|NCT02128867|Other|Assisted Autogenic Drainage (AAD)|
214163|NCT02128867|Other|bouncing and AAD|
214164|NCT02128867|Other|bouncing|
214165|NCT02128880|Behavioral|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
214166|NCT02128880|Behavioral|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
214167|NCT02128893|Drug|Isavuconazole|oral
214168|NCT02128893|Drug|Esomeprazole|oral
214476|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
214477|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
214478|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
214479|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
214480|NCT00131417|Drug|ready-to-use therapeutic food|
214481|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
214482|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
218607|NCT02298478|Behavioral|NO-FEAR Airlines|"NO-FEAR Airlines" is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.
"NO-FEAR Airlines" divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes.
218608|NCT02298491|Drug|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
218609|NCT02298504|Drug|Mineral Trioxide Aggregate|
218610|NCT02298504|Drug|Biodentin|
218611|NCT02298504|Drug|Vitrebond|
213827|NCT02136199|Other|Active Implementation of ShareEBM Toolkit|
213828|NCT02136199|Other|Passive Dissemination of Share EBM|
213829|NCT02136212|Behavioral|Approach-positive AAT|
213830|NCT02136212|Behavioral|Control AAT|
213831|NCT02136225|Behavioral|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
213832|NCT00133016|Procedure|Amniotomy|
213833|NCT02136238|Device|Hosmer 5XA voluntary opening hook|Voluntary opening prosthetic terminal device ("hand")
213834|NCT02136238|Device|TRS Grip 3 voluntary closing hook|Voluntary closing prosthetic terminal device ("hand")
213835|NCT02136264|Other|PCFA interventional dietary counselling|
213836|NCT02136264|Other|conventional DASH diet counselling|
213837|NCT02136277|Drug|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
213838|NCT02136290|Behavioral|Prepackaged meals|Portion-controlled prepackaged meals
213839|NCT02136290|Behavioral|Usual Care|Usual care dietary counseling
213840|NCT02136303|Dietary Supplement|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
213841|NCT02136303|Other|S2: Kale extract versus kale purée|
213842|NCT02136303|Other|S3: Kale extract: AMD-patients|
209430|NCT02087930|Dietary Supplement|EHCF|
209744|NCT02080455|Drug|lomitapide|20 mg dose
209745|NCT02080455|Drug|Atorvastatin|80 mg
209746|NCT02080468|Drug|lomitapide|20 mg
209747|NCT02080468|Drug|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
209748|NCT02080481|Device|InfinitiPlus (TM) needle system|
209749|NCT02080494|Drug|Tranexamic Acid|
209750|NCT02080507|Device|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
209751|NCT02080507|Device|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
209752|NCT00127179|Drug|MK0906, finasteride / Duration of Treatment: 48 weeks|
209753|NCT02080520|Dietary Supplement|Nattokinase|
209754|NCT02080520|Dietary Supplement|Placebo|
209755|NCT02080533|Other|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
209756|NCT02080546|Procedure|Cut-Coag|Incision using electrothermal cautery, with an attempt made to use the "cut" (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the "coag" (pulsed high-voltage, low-current) mode.
209757|NCT02080546|Procedure|V-mode|Incision using electrothermal cautery in the "V mode". The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures.
209758|NCT02080546|Device|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
209759|NCT02080559|Biological|4CMenB|0.5ml IM
209760|NCT02080585|Behavioral|Physical Activity advice.|Subjects receive advice regarding physical activities.
209761|NCT00127413|Behavioral|Treat as Usual|Treatment as usual
209762|NCT02083315|Drug|Morphine 10 mg|Morphine 10 mg IV x 1 dose
209763|NCT02083315|Drug|Placebo|Dextrose 5% in water IV x 1 dose
209126|NCT02095366|Drug|Morphine|Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.
Pain is controlled by:
at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg
at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg
at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg
209127|NCT02095366|Drug|Sufentanil|Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.
Pain is controlled by:
at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV
at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
209128|NCT02095366|Drug|Placebo|Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.
Pain is controlled by:
at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV
at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
209129|NCT02095366|Drug|Placebo|Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.
Pain is controlled by:
at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg
at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg
at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg
209130|NCT02095379|Other|oligosecretary|not abvailable
209431|NCT00127946|Procedure|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
209432|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
209433|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
209434|NCT02087943|Drug|Placebo|Orally twice a day (BID)
209435|NCT02087943|Drug|Placebo|Orally twice a day (BID)
209436|NCT02087956|Behavioral|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
209437|NCT02087956|Behavioral|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
209438|NCT02087969|Procedure|Dry Needling|
209439|NCT02087969|Procedure|Stretching|
209440|NCT02087995|Device|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
209441|NCT02088008|Drug|cinidipine, valsartan|
208826|NCT02100007|Drug|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
208827|NCT02100020|Other|Direct Referral to physical activity|Participants randomized to the Direct Referral Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
208828|NCT02100033|Device|acupuncture|
208829|NCT02100046|Drug|Zarontin® (ethosuximide) and Stodal®|
208830|NCT02102308|Other|Education classes|
208831|NCT02102321|Drug|albendazole|
208832|NCT00129376|Drug|docetaxel|
208833|NCT02102321|Drug|placebo|
208834|NCT02102347|Other|exercise|
208835|NCT02102347|Other|Phototherapy|
208836|NCT02102360|Device|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
209131|NCT00128596|Drug|arsenic trioxide|
209132|NCT02095392|Dietary Supplement|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate [1g phosphorus/d]
209133|NCT02095392|Dietary Supplement|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [0,5 g calcium]
209134|NCT02095392|Dietary Supplement|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [1 g calcium]
209135|NCT02095392|Dietary Supplement|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
209136|NCT02095405|Drug|Caffeine|SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.
AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring.
209137|NCT02095405|Other|Placebo|SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.
AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring.
209138|NCT02095418|Drug|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
209139|NCT02095418|Drug|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
213623|NCT00134186|Drug|motexafin gadolinium|
213624|NCT02151591|Drug|Varenicline|12-weeks of treatment. Dose will be titrated as follows:
Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day
213625|NCT02151604|Other|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
213626|NCT02154048|Drug|Ropivacaine|
213627|NCT02154048|Drug|Dexamethasone|
213628|NCT02154048|Other|Placebo|
213629|NCT02154061|Drug|Arm 1 and Arm 2: Inactivated Flu Vaccine|This is an FDA approved and tested Flu Vaccine.
213630|NCT02154061|Drug|Metronidazole|This is a standard antibiotic
213631|NCT02154061|Drug|Neomycin|This is a standard antibiotic.
213632|NCT02154061|Drug|Vancomycin|This is a standard antibiotic.
213633|NCT00134433|Drug|oral L-arginine supplementation (at a dose of 6 g/day)|
213634|NCT02154074|Drug|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
213635|NCT02154074|Drug|Isoflurane|inhale Isoflurane 1.5MAC
208837|NCT02102360|Device|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
208838|NCT02102373|Device|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
208839|NCT02102399|Behavioral|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
208840|NCT02102399|Behavioral|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
208841|NCT02102412|Biological|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
208842|NCT02102425|Procedure|Patients with or without bandage over exit site|
208843|NCT00129389|Drug|FAC|FAC x 6: 5-fluorouracil 500 mg/m2 i.v. + doxorubicin 50 mg/m2 i.v. + cyclophosphamide 500 mg/m2 i.v. every 3 weeks, for 6 cycles.
213319|NCT02118675|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
213320|NCT02118675|Other|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
213321|NCT02118675|Other|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
213322|NCT02118675|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
213323|NCT02120950|Other|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
213324|NCT00131352|Other|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
213325|NCT02120963|Behavioral|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
213326|NCT02120976|Drug|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
213327|NCT02120976|Drug|JTT-252|Subjects will receive JTT-252
213328|NCT02120989|Behavioral|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
213329|NCT02121002|Drug|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
213330|NCT02121002|Drug|Voltaren Topical Gel, 1%|Opaque, white gel
213331|NCT02121002|Drug|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
213636|NCT02154074|Drug|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
213637|NCT02154074|Drug|normal saline|the same volume of saline + Isoflurane during operation
212757|NCT02133443|Device|Neurally Adjusted Ventilatory Assist|Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the " optimal " level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%).
212758|NCT02133469|Biological|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
212759|NCT02133469|Biological|Hib Vaccine|Single Dose
212760|NCT02133482|Drug|Placebo|placebo solution
213034|NCT02125461|Drug|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
213035|NCT02125461|Other|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
213036|NCT02125474|Radiation|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
213037|NCT02125487|Behavioral|Teaching using Hybrid Simulation of breast examination|Students in the "intervention/experimental" group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)
213038|NCT00131885|Dietary Supplement|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
213039|NCT02125487|Behavioral|Teaching using traditional method|Students in the "control" group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE.
213040|NCT02125500|Drug|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
213041|NCT02125513|Drug|carboplatin and paclitaxel followed by surgery|
213042|NCT02125526|Device|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
213043|NCT02128243|Drug|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
213044|NCT02128243|Drug|Chemotherapy by Investigator's choice|Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.
Two-Drug combinations:
FLO / mod. FOLFOX-6 Cisplatin, S-1
Three-drug combinations:
EOX/EOF FLOT
213045|NCT02128256|Device|Cerament G|
213046|NCT02128269|Biological|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
212768|NCT02135731|Other|Medication review software with pictures|The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
212769|NCT02135744|Behavioral|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
212770|NCT02135770|Drug|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
212771|NCT00132951|Drug|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
212772|NCT02135783|Procedure|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
212773|NCT02135783|Procedure|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
212774|NCT02135796|Other|Echocardiography|
212775|NCT02135809|Device|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
212776|NCT02135822|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
212777|NCT02135822|Drug|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
212778|NCT02135835|Drug|Shenfu Zhusheye|
212779|NCT02135835|Drug|5% glucose injection|
213053|NCT02128308|Drug|Levofloxacin and Streptomycin added|
213054|NCT02128308|Drug|Moxifloxacin and Kanamycin added|
213055|NCT02128321|Drug|Isavuconazole|oral
213056|NCT02128321|Drug|Repaglinide|oral
213057|NCT02128321|Drug|Caffeine|oral
213058|NCT02128334|Drug|Eligard 45 mg Exposure|Subcutaneous injections
212476|NCT02140970|Drug|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
212477|NCT02140970|Drug|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
212478|NCT02140983|Drug|Liraglutide|90 days of liraglutide up to 1.8mg/day.
212479|NCT00002245|Drug|Lamivudine|
212480|NCT00133432|Drug|Zinc|
212481|NCT02143427|Behavioral|Social Skills Training|Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.
Arms: Social Skills Training
212482|NCT02143427|Behavioral|Treatment Program with techniques to activate resources|Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.
Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training
212483|NCT02143440|Behavioral|The initial assessment of daily insulin dose.|
212484|NCT02143453|Other|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
212485|NCT02143453|Other|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
212486|NCT02143466|Drug|AZD9291 in combination with MEDI4736|AZD9291 and MEDI4736 will be administered. Part A: If initial dosing is tolerated then subsequent cohorts will test increasing doses of AZD9291 and/or MEDI4736, until a recommended dose for further clinical evaluation is defined. Part B: The recommended dose from Part A will be further evaluated in an expansion cohort.
212487|NCT02143466|Drug|AZD9291 in combination with AZD6094|AZD9291 and AZD6094 will be administered in combination. Part A: If tolerated, subsequent cohorts will test increasing doses of AZD9291 and/or AZD6094, until a recommended dose for further clinical evaluation is defined. Part B: The recommended dose from Part A will be further evaluated in an expansion cohort.
212488|NCT02143466|Drug|AZD9291 in combinatin with selumetinib|AZD9291 and selumetinib will be administered in combination. Part A: If tolerated, subsequent cohorts will test increasing doses of AZD9291 and/or selumetinib, until a recommended dose for further clinical evaluation is defined. Part B: The recommended dose from Part A may be further evaluated in an expansion cohort.
212780|NCT02135848|Drug|GSK1278863|GSK1278863
212781|NCT02135848|Drug|Placebo|Placebo
212782|NCT00132964|Device|Below knee walking cast|Not required
216658|NCT00152906|Procedure|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
216659|NCT02315222|Procedure|Full Mouth Disinfection|
216939|NCT02307669|Behavioral|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
216940|NCT02307682|Drug|RTH258 solution for IVT injection|
216941|NCT02307682|Drug|Aflibercept solution for IVT injection|Administered as a 2 mg/50 µL dose
216942|NCT02307695|Drug|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
216943|NCT02307695|Drug|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
216944|NCT00152217|Procedure|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
216945|NCT02307708|Device|8° incline shoe|Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).
The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.
During the walk we will have:
In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).
In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction).
216946|NCT02307708|Other|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
216947|NCT02307721|Drug|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
216948|NCT02307721|Drug|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
216949|NCT02307721|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
216950|NCT02310256|Other|Five plus exercise training|calf raise exercise
216951|NCT02310269|Drug|SOM230|
216952|NCT02310282|Device|Telemedicine|In-hospital telemedicine
216953|NCT02310295|Device|Laser|focal macular laser therapy
216954|NCT02310295|Drug|Bevacizumab|Intravitreal injection of Bevacizumab
216342|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
216343|NCT02124174|Drug|Vidaza and Valproic Acid|Days 1-5: 5-Azacytidine 40 mg/m^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily
*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days.
216344|NCT02124187|Device|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
216345|NCT02124187|Device|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
216346|NCT02124187|Device|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
216660|NCT02315235|Biological|Normal saline|Normal saline is injected in one leg of patient.
216661|NCT02315235|Biological|stem-cell|Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.
The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient.
216662|NCT02315248|Radiation|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
216663|NCT02315261|Procedure|Epidural Anesthesia|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
216664|NCT02315274|Other|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
216665|NCT02315287|Drug|Thiazolidinedione|comparison of different thiazolidinedione
216666|NCT02315300|Device|medilog® DARWIN FD12|
216667|NCT02315300|Device|Continuous Glucose Monitoring|
216668|NCT02315326|Drug|Ibrutinib|Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the "3+3" design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1.
216669|NCT00152919|Drug|Meloxicam|
216670|NCT02315352|Drug|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
216671|NCT02278627|Other|manual lymphatic drainage|
216009|NCT02129556|Drug|MK-3475|The phase Ib trial will determine the recommended phase to dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
216010|NCT02129569|Other|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
216011|NCT02129569|Behavioral|behavioral intervention|Receive individualized walking prescription and wear pedometer
216012|NCT02129569|Other|counseling intervention|Receive supplemental counseling support over the phone
216013|NCT02129569|Other|educational intervention|Receive NCI educational booklets and a link to the ACS website
216014|NCT00132288|Behavioral|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
216015|NCT02129569|Other|telephone-based intervention|Receive calls that are primarily social in nature
216016|NCT02129569|Other|questionnaire administration|Ancillary studies
216347|NCT02124200|Device|EGO/CE4, 9mg nicotine|
216348|NCT02124213|Drug|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
216349|NCT00131755|Drug|diazoxide|
216350|NCT02124213|Drug|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
216351|NCT02124213|Drug|PF-06412562|The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
This Cohort is optional.
216352|NCT02124226|Drug|Methotrexate|
216353|NCT02124226|Drug|Placebo|
216354|NCT02124239|Drug|Ingenol mebutate|
216355|NCT02124252|Behavioral|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
216356|NCT02124252|Behavioral|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
216357|NCT02126917|Drug|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
216358|NCT00131989|Other|laboratory biomarker analysis|Correlative studies
215710|NCT02136966|Other|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
215711|NCT02136992|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
215712|NCT02136992|Drug|placebo|placebo will be taken two tablets 3 times a day during the whole study process
215713|NCT00133094|Drug|Simvastin|
215714|NCT02137018|Device|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
215715|NCT02137018|Device|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
215716|NCT02137031|Device|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
215717|NCT02137044|Behavioral|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care will be delivered through an interdisciplinary team, organized around a CC manager (CCM) who guides the patient through various aspects of care during the 16-week treatment phase. The team will also include the patient's MS physician and the CC Supervisors, a group of study domain experts. The CCM will offer all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient has both pain and depression, he or she will receive care management and collaborative medical management for both.
215718|NCT02137070|Procedure|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
216017|NCT02129569|Other|quality-of-life assessment|Ancillary studies
216018|NCT02129582|Radiation|total marrow irradiation|Undergo TMI
216019|NCT02129582|Drug|fludarabine phosphate|Given IV
216020|NCT02129582|Drug|busulfan|Given IV or PO
216021|NCT02132039|Other|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
215389|NCT02144675|Drug|choline magnesium trisalicylate|Given PO
215390|NCT02144675|Drug|idarubicin|Given IV
215391|NCT02144675|Drug|cytarabine|Given IV
215392|NCT02144675|Other|laboratory biomarker analysis|Correlative studies
215393|NCT02144688|Drug|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
215394|NCT02144701|Dietary Supplement|Lactobacillus rhamnosus GG|Given PO
215395|NCT02144701|Other|laboratory biomarker analysis|Correlative studies
215396|NCT02144714|Biological|SB5|
215397|NCT02144714|Biological|EU sourced Humira®|
215398|NCT02144714|Biological|US sourced Humira®|
215399|NCT00133718|Drug|Combined lifestyle interventional program and optimisation of pharmacological treatment|6 months non-pharmacological treatment, 18 months with polypharmacy for glucosecontrol (metformin, repaglinide/glimepiride, pioglitazone or insulin)
standard care
215400|NCT02144727|Procedure|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
215401|NCT02144727|Procedure|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
215402|NCT02144740|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
215403|NCT02144740|Dietary Supplement|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
215404|NCT02144753|Dietary Supplement|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
215405|NCT02144753|Drug|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
215406|NCT02144766|Drug|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
215407|NCT02144766|Drug|saline|caudal block with 1 ml/kg of saline
214794|NCT02116842|Drug|0.1% bupivacaine|Epidural block in early labour.
214795|NCT02116842|Drug|0.075% bupivacaine|Epidural block in early labour.
214796|NCT02116842|Drug|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
214797|NCT02116855|Other|according to the efficacy of AJBRs|
214798|NCT02116868|Device|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
214799|NCT02116868|Drug|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
214800|NCT02116868|Drug|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
214801|NCT02116881|Procedure|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
214802|NCT00002233|Drug|Amprenavir|
214803|NCT00131027|Drug|Prednisolone|
215087|NCT00134030|Other|questionnaire administration|Ancillary studies
215088|NCT02152033|Behavioral|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
215089|NCT02152046|Procedure|ROP exam with spring loaded retractor|
215090|NCT02152046|Procedure|ROP exam with screw retractor|
215091|NCT02152059|Drug|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
215092|NCT02152072|Other|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
215093|NCT02152085|Device|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
215094|NCT02152085|Device|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
214483|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
214484|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
214485|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
214486|NCT00131664|Drug|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
214487|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
214488|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
214489|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
214490|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
214491|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
214492|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
214493|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
214494|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
214495|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
214496|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
214804|NCT02116894|Biological|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
214805|NCT02116894|Drug|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
214806|NCT02116907|Drug|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
213843|NCT00133029|Drug|Timing of prophylactic antibiotic administration|
213844|NCT02136316|Drug|ASP7962|Oral
213845|NCT02136316|Drug|Placebo|Oral
213846|NCT02136329|Drug|Sildenafil|The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate.
The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.
Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc
213847|NCT02136342|Drug|chlorogenic acid|
213848|NCT02136355|Radiation|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
214169|NCT02128906|Drug|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
214170|NCT00132197|Behavioral|Cognitive Behavioral Therapy|1. Specialised treatment includes cognitive groups therapy in 9 modules of 3,5 hours within 3½ months, in all 31,5 hours, consultancy over the phone to the patients' GPs and tuition in groups headed by an experienced social worker. Detailed treatment manuals are worked out separately for each module. Experienced psychotherapists (clinical psychologists and psychiatrists), who also function as consultants, will do the treatment. The Ph.D.-student functions as co-therapist.
214171|NCT02131116|Behavioral|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
214172|NCT00002239|Drug|Efavirenz|
214173|NCT00132535|Drug|sulfadoxine-pyrimethamine intermittent preventive treatment|
214174|NCT02131116|Behavioral|Treatment as Usual|Treatment as Usual
214175|NCT02131129|Device|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
Ten sessions over a two week duration
214176|NCT02131129|Device|Sham Comparator|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
Ten sessions over a two week duration
214177|NCT02131142|Device|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
214178|NCT02131155|Drug|Placebo|Once daily
214179|NCT02131155|Drug|Afatinib|Once daily
209764|NCT02083328|Dietary Supplement|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
209765|NCT02083328|Dietary Supplement|Placebo (Mannitol)|Mannitol filled in gelatine capsules
209766|NCT02083341|Device|Lelo® Siri vibrator|external vibration device
210050|NCT02114905|Behavioral|Comprehensive Behavioral Treatment for Tic Disorders|Comprehensive Behavioral Intervention for Tics (CBIT) is an efficacious intervention for tic disorders across the lifespan. CBIT is a highly structured therapy that typically takes place in a therapist's office on a weekly basis. The standard treatment is 8 sessions over 10 weeks. The first step in CBIT is to teach the patient to become more aware of his or her tics and the urge to tic. Next, the patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This "competing response" helps to reduce, and in some cases, even eliminate the tic. The final step of CBIT, the functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily.
210051|NCT02114918|Behavioral|Attention Modification Program|Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter "E" or "F") appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe.
210052|NCT00130819|Behavioral|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
210053|NCT02114918|Behavioral|Attention Control Condition|Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter "E" or "F") appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word.
210054|NCT02114931|Drug|ABP 501|ABP 501 (Open Label)
210055|NCT02114944|Device|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
210056|NCT02114944|Device|CPAP|Patient treated, as per attending physician's decision, with CPAP
210057|NCT02114944|Device|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
210058|NCT02078102|Drug|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
210059|NCT02078128|Dietary Supplement|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
210060|NCT00126919|Device|SonoPrep|
209442|NCT00127959|Drug|tenofovir|
209443|NCT02088021|Device|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
209444|NCT02088034|Behavioral|Prometra led intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
209445|NCT02088034|Drug|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
209446|NCT02088034|Other|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
209447|NCT02090335|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
209448|NCT02090335|Behavioral|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
209449|NCT02090348|Drug|dimethyl fumarate|Administered as specified in the treatment arm
209767|NCT02083341|Device|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
209768|NCT02083354|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
209769|NCT02083354|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
209770|NCT02083380|Drug|A) OZ439 800mg: PQP 1440mg|
209771|NCT02083380|Drug|B) OZ439 800mg: PQP 960mg|
209772|NCT00002213|Drug|Abacavir sulfate|
209773|NCT00127439|Procedure|Manually Assisted Locomotor Training|Individuals will receive 45 sessions of robotic or manually assisted locomotor training. The goal for each training session is to walk for no more than 30 minutes.
209774|NCT02083380|Drug|C) OZ439 800mg: PQP 640mg|
209775|NCT02083406|Drug|800mg OZ439 prototype formulation 1|
209776|NCT02083406|Drug|800mg OZ439 prototype formulation 2|
209777|NCT02083406|Drug|800mg OZ439 prototype formulation 3|
209778|NCT02083406|Drug|960mg PQP|
209140|NCT02095444|Drug|Menstrual blood stem cells|10*7 cells/kg, intravenous injection for 4 times during two weeks
209141|NCT02095457|Behavioral|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
209142|NCT00128622|Biological|denileukin diftitox|
209143|NCT02095470|Device|video laryngoscope|newly developed innovatory device
209144|NCT02095470|Device|traditional laryngoscope|traditional way for intubation
209145|NCT02095483|Behavioral|Mindfulness Group Therapy Study|
209146|NCT02097849|Biological|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
209147|NCT02097849|Drug|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
209148|NCT02097862|Procedure|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
209149|NCT02097875|Drug|BLZ-100|
209150|NCT02097901|Procedure|Microfracture|Rotator Cuff Repair AND Microfracture
209151|NCT02097901|Procedure|NO microfracture|Rotator Cuff Repair without microfracture
209450|NCT02090361|Procedure|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
209451|NCT02090374|Other|TLR Agonist|Preceding incremental ascending dose study to be used to assess top safe dose.
209452|NCT02090374|Other|Tuberculin nasal challenge|Preceding incremental ascending dose study to be used to assess safe top dose.
209453|NCT00128115|Drug|MK0677|
209454|NCT02090374|Other|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
209455|NCT02090387|Other|ONS without AN777|2 servings a day
209456|NCT02090387|Other|ONS containing AN777|2 servings a day
209457|NCT02090400|Drug|Bazedoxifene|20 mg Oral daily for 12 months
209458|NCT02090400|Drug|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
209459|NCT02090413|Drug|dimethyl fumarate|Administered as specified in the treatment arm
208844|NCT02102438|Drug|Trastuzumab|Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.
After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles.
208845|NCT02102438|Drug|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
208846|NCT02102438|Drug|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
208847|NCT02102451|Drug|Sofosbuvir and ribavirin|Exact drug combination and regimen/s to be determined, based on phase II and III data released before the treatment phase commences.
208848|NCT02102464|Device|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
208849|NCT02102477|Procedure|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
208850|NCT02102477|Other|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
208851|NCT02102490|Drug|Abemaciclib|Administered orally
208852|NCT02102503|Behavioral|Standard Treatment|
208853|NCT02102503|Behavioral|MI and Medication review|
208854|NCT00129389|Drug|paclitaxel|FAC x 4 -> Taxol x 8:
5-fluorouracil 500 mg/m2 i.v. + doxorubicin 50 mg/m2 i.v. + cyclophosphamide 500 mg/m2 i.v. every 3 weeks, for 4 cycles followed by weekly Taxol 100 mg/ m2 for 8 cycles (days 1, 8, 15, 22, 29, 36, 43 y 50).
208855|NCT02104908|Procedure|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
208856|NCT02104934|Procedure|Adductor Canal Block|
209152|NCT00002220|Drug|Levocarnitine|
209153|NCT00128869|Procedure|spine mobilizations|
209154|NCT02097914|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
209155|NCT02097927|Behavioral|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
213638|NCT02154087|Biological|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
213639|NCT02154100|Dietary Supplement|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
213640|NCT02154100|Dietary Supplement|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
213641|NCT02154113|Device|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
213642|NCT02154113|Device|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
213643|NCT02154126|Device|Continuous Glucose Monitoring Device (Senseonics)|
213644|NCT00134446|Device|transcranial magnetic stimulation|
213645|NCT02154139|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
213646|NCT02154152|Drug|Homoeopathic Medicine causticum 200c|
213647|NCT02154165|Other|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
213648|NCT02154178|Other|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
213649|NCT02154191|Procedure|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
213650|NCT02154217|Drug|Bimatoprost|
213651|NCT02154217|Drug|Latanoprost/Timolol|
213652|NCT02154230|Dietary Supplement|"Acqua Santa di Chianciano"® (sulphate-bicarbonate-calcium water)|During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of "Acqua Santa di Chianciano"® at room temperature.
213653|NCT02116270|Biological|Blood sample|3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
213654|NCT02116283|Behavioral|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
213655|NCT02116283|Other|Smartphone|Participants will use an Android-based smartphone as their own for one month
213656|NCT02116296|Behavioral|ToyBox-intervention|
213657|NCT02116309|Drug|Rectal Indomethacin|
213658|NCT02116309|Drug|Epinephrine|
213047|NCT02128282|Drug|CX-4945|Capsules administered twice daily on Days 0, 1 and 2, and Days 7, 8 and 9 of each 21 day cycle.
213048|NCT02128282|Drug|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21 day cycle.
213049|NCT02128282|Drug|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21 day cycle.
213050|NCT02128295|Device|Electric breast pump - A|
213051|NCT00132132|Behavioral|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
213052|NCT02128295|Device|Electric breast pump - B|
213332|NCT02121015|Behavioral|Share|
213333|NCT02121015|Behavioral|Self-Directed|
213334|NCT02121041|Drug|Amlodipine|Amlodipine 5 mg or 10 mg
213335|NCT00131365|Device|ExAblate 2000|
213336|NCT02121041|Drug|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
213337|NCT02121041|Drug|Losartan|Losartan 50 mg or 100 mg
213338|NCT02121067|Drug|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
213339|NCT02121080|Drug|REGN2222(SAR438584)|
213340|NCT02121080|Drug|placebo|
213341|NCT02121093|Procedure|vibration|
213342|NCT02121106|Behavioral|Cognitive Remediation|
213343|NCT02121106|Behavioral|Sham Cognitive Remediation|
213344|NCT02121119|Drug|Lidocaine|Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
213345|NCT02121119|Drug|Bupivacaine|Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
213346|NCT00131378|Drug|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
213347|NCT02121145|Biological|Vivotif|3 oral doses
213348|NCT02121145|Biological|Typherix|one intramuscular dose
213059|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
213060|NCT02128360|Drug|Letrozole, Gonadotropins|
213061|NCT02128360|Drug|Gonadotropins|
213062|NCT00132145|Behavioral|Vascular Management Program|
213063|NCT02128373|Procedure|Usual care|Health care provided by physician, physician's nurse, and social worker
213064|NCT02128373|Other|computer-assisted intervention|Caregiver will virtually attend visit using the CLOSER intervention
213065|NCT02128373|Other|Distress Thermometer|Average score of a one item scale (range 0-10) where higher scores indicate more distress
213066|NCT02128373|Other|Profile of Mood States (POMS-B)|average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
213067|NCT02128373|Other|Quality of Life: Functional Assessment in Cancer Therapy - (FACT)|Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
213068|NCT02130804|Drug|Placebo (4 g/day)|Given orally twice daily
213069|NCT02130817|Drug|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
213070|NCT02130817|Drug|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
213355|NCT02123394|Other|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
213356|NCT02123407|Drug|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
213357|NCT02123407|Procedure|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
212783|NCT02135861|Procedure|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
212784|NCT02135861|Other|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
212785|NCT02135874|Drug|Clofarabine|Induction:
Clofarabine 15 mg/m2 by vein Days 1-4.
Consolidation:
Clofarabine 15 mg/m2 by vein on Days 1-3.
212786|NCT02135874|Drug|Idarubicin|Induction:
Idarubicin 10 mg/m2 by vein on Days 1-3.
Consolidation:
Idarubicin 6 mg/m2 by vein on Days 1-2
212787|NCT02135874|Drug|Cytarabine|Induction:
Cytarabine 1,000 mg/m2 by vein on Days 1-4.
Consolidation:
Cytarabine 1,000 mg/m2 by vein on Days 1-3.
212788|NCT02135874|Drug|Vincristine|Induction and Consolidation:
Vincristine 2 mg by vein Days 1, 8, and 15.
212789|NCT02135874|Drug|Rituximab|For patients with CD20 positive disease:
Induction and Consolidation:
Rituximab 375 mg/m2 by vein on Days 1 and 8.
212790|NCT02135874|Drug|Dexamethasone|Induction and Consolidation:
Dexamethasone 40 mg by vein daily for 4 days on days 1 - 4 and days 15 - 18.
212791|NCT02138253|Drug|Placebo|Placebo control
212792|NCT02138266|Device|Topcon Specular Microscope SP-1P|
212793|NCT02138266|Device|Konan Specular Microscope CELLCHEK XL|
212794|NCT00133250|Drug|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
212795|NCT02138292|Drug|Trametinib (2mg)/Digoxin (.25mg)|Trametinib (2mg) will be administered orally on a daily basis.
Digoxin (0.25mg) will be administered orally on a daily basis.
On a 8 week cycle, duration of treatment can last from 8 to 104 weeks.
212796|NCT02138305|Device|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
212797|NCT02138305|Procedure|'SPY' NIRF During Off-Pump CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
212798|NCT02138318|Other|High definition (HD) endoscopy|
212799|NCT02138318|Other|chromoendoscopy|
212800|NCT02138331|Biological|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
216955|NCT02310295|Drug|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
216956|NCT02310308|Dietary Supplement|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
216957|NCT02310321|Drug|ASP2215|Once-daily repeated oral administration in every period
217234|NCT02302820|Other|Advance Care Planning Intervention|ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for "living well" and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids.
217235|NCT02302833|Drug|Cabozantinib|60 mg by mouth once daily.
217236|NCT02302833|Behavioral|Questionnaire|Questionnaire completion regarding symptoms completed at baseline, 4 days before starting Cabozantinib, and weekly while taking the drug.
217237|NCT02302846|Drug|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
217238|NCT02302859|Drug|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
217239|NCT00151697|Drug|Novorapid and Amaryl|
217240|NCT02302859|Behavioral|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
217241|NCT02302859|Other|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
217242|NCT02302859|Behavioral|Phone Counseling Sessions|Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.
Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.
Participants also have access to additional counseling content on the smart phone, which can be used at any time.
217243|NCT02302859|Other|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
217244|NCT02302859|Device|Smart phone|Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.
Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.
217245|NCT02302872|Device|MVRx System (Percutaneous Septal Sinus Shortening)|
217246|NCT02302885|Other|Blood collection|Blood Collection
216672|NCT02278640|Device|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
216673|NCT00148902|Drug|lapatinib and docetaxel|
216674|NCT02278653|Other|Questionnaires for the evaluation of Quality of Life|European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score
Short Form (36) health survey
EORTC CR38
Vaizey score
Low Anterior Resection Syndrome (LARS) score
International Index of Erectile Function for men
International Prostate Symptom Score for men
Female Sexual Function Index for women
216675|NCT02278653|Other|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
216958|NCT02310321|Drug|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m2 idarubicin on 3 consecutive days.
216959|NCT00152438|Other|Placebo|3 identical placebo pills daily, no active ingredient.
216960|NCT02310321|Drug|Cytarabine|Induction period: Once-daily intravenous injection of 100 mg/m2 cytarabine on 7 consecutive days. Consolidation period: Twice-daily intravenous injection of 1.5 g/m2 cytarabine at 12-hour intervals on Days 1, 3, and 5.
216961|NCT02310334|Other|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
216962|NCT02310334|Other|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
216963|NCT02310347|Drug|dronabinol|
216964|NCT02310347|Drug|Placebo|
216965|NCT02310360|Radiation|Fallypride|
216966|NCT02310373|Other|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
216967|NCT02310386|Device|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
216968|NCT02310399|Device|Nucleus 24 Auditory Brainstem Implant (ABI)|Surgical implantation of the Nucleus 24 Auditory Brainstem Implant (ABI) device
216969|NCT02310412|Biological|INTERCEPT treated platelets|
216970|NCT00152451|Drug|Seletracetam (ucb 44212)|
216971|NCT02310425|Drug|S. boulardii|50 mg/kg twice daily
216359|NCT02126930|Other|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
216360|NCT02126930|Other|Routine care|Patients randomized to this arm will receive care in the habitual manner.
216361|NCT02126943|Drug|Opsumit (macitentan)|10 mg tablets
216362|NCT02126956|Drug|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
216363|NCT02126969|Radiation|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
216364|NCT02126969|Drug|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
216365|NCT02126995|Drug|MG01CI extended-release tablet|
216366|NCT02127008|Procedure|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
216367|NCT02127008|Procedure|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
216368|NCT02127021|Drug|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
216676|NCT02278666|Procedure|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
216677|NCT02278666|Device|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
216678|NCT02278666|Device|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
216679|NCT02278679|Procedure|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
216680|NCT02278692|Dietary Supplement|Vitamin K|Oral vitamin K
216681|NCT02278692|Other|Placebo|Oral placebo tablet
216682|NCT02278705|Other|BMI screened/interpreted|Provider identified and interpreted BMI percentile.
216683|NCT02278705|Other|Provider addressed weight and weight-related disease risk|Provider addressed high weight status, including completing assessment of weight-related disease risk (indicated labs completed)
216684|NCT00148915|Drug|ibandronate|
216022|NCT02132065|Drug|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
216023|NCT02132091|Other|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
216024|NCT00132626|Procedure|[123I]ß-CIT and SPECT imaging|
216025|NCT02132091|Dietary Supplement|400 IU Vitamin E|once each day in morning; oral pill form
216026|NCT02132091|Dietary Supplement|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
216027|NCT02132104|Procedure|Uterine application of amnion membrane|Uterine application of amnion membrane following hysteroscopic adhesiolysis.
216028|NCT02132104|Device|Foley balloon|Uterine application of Foley balloon
216029|NCT02132104|Drug|Femoston|Hormones treatment after surgery.
216030|NCT02132117|Drug|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
216031|NCT02132117|Drug|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
216032|NCT02132130|Drug|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
216033|NCT02132143|Radiation|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
216034|NCT02132143|Radiation|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
216035|NCT00132639|Drug|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
216036|NCT02132169|Drug|Drug: AC-170 0.24%|
216037|NCT02132169|Drug|AC-170 0%|
216369|NCT00132002|Drug|vorinostat|Given PO
216370|NCT02127021|Drug|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
216371|NCT02127034|Drug|Mirabegron|oral
216372|NCT02127034|Drug|Solifenacin|oral
215408|NCT02144779|Behavioral|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
215409|NCT02144779|Behavioral|Usual Care|usual hospital care, not assigned to palliative care team
215719|NCT02137070|Other|Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
215720|NCT02137083|Drug|Docetaxel|75mg/m2 D2 every 21 days
215721|NCT02139566|Behavioral|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
215722|NCT02139566|Behavioral|FAQ format consent|This consent modality will present the basic information from the informed consent in an interactive, "frequently asked questions" format. Upon clicking each question, the participant will be shown a short text response to that question.
215723|NCT02139566|Behavioral|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
215724|NCT02139566|Behavioral|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
215725|NCT02139579|Drug|Bevacizumab|7.5 mg/kg every 3 weeks
215726|NCT02139592|Drug|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
215727|NCT02139605|Procedure|D2 versus D3 Lymphadenectomy|
215728|NCT02139618|Drug|Methyl Aminolevulinate (MAL)|
215729|NCT00133367|Drug|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
215730|NCT02139618|Drug|Placebo|
215731|NCT02139631|Other|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
215732|NCT02139644|Drug|fluticasone propionate MDPI|50 mcg or 100 mcg, inhaled corticosteroid
215733|NCT02139644|Drug|Fluticasone propionate/salmeterol MDPI|50/12.5 mcg or 100/12.5 mcg, Inhaled corticosteroid and long-acting beta-agonist
215734|NCT02139644|Drug|Placebo MDPI|0 mcg MDPI
215735|NCT02139657|Biological|RIG-C|
215736|NCT02139683|Device|HIFU treatment|HIFU treatment in patients with fibroadenoma
215095|NCT02152098|Procedure|Acute Early onset of rehabilitation|Early onset of rehabilitation
215096|NCT02152098|Procedure|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
215097|NCT02152098|Procedure|Chronic Exercise|Exercise
215098|NCT00134238|Drug|atorvastatin|
215099|NCT02152098|Procedure|Chronic Control|Control
215100|NCT02152111|Dietary Supplement|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
215101|NCT02152111|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months.
215102|NCT02152137|Drug|efatutazone|Given PO
215103|NCT02152137|Drug|paclitaxel|Given IV
215104|NCT02152150|Other|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
215105|NCT02152150|Other|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
215106|NCT02152163|Drug|IV Ibuprofen|
215107|NCT02152163|Drug|placebo|
215410|NCT00133718|Drug|the "Polypill"|
215411|NCT02144792|Drug|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
215412|NCT02144805|Procedure|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
215413|NCT02147015|Drug|Long-Acting Muscarinic Antagonists(LAMA)|
215414|NCT02147015|Drug|Short-acting beta2-agonist (SABA)|
215415|NCT00133978|Other|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
215416|NCT02147015|Other|Physical treatments|
215417|NCT02147015|Drug|long-acting beta2-agonist (LABA)|
215418|NCT02147028|Radiation|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
214807|NCT02116933|Procedure|Adipose Derived Stem Cells|Adipose derived stem cells harvested from autologous lipoaspirate
214808|NCT02116933|Procedure|SVF Enriched Autologous Fat Grafting|Cell assisted lipotransfer
214809|NCT00002234|Drug|Adefovir dipivoxil|
214810|NCT00131144|Drug|Placebo|
214811|NCT02119156|Drug|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
214812|NCT02119169|Device|Pigtail catheter|pigtail catheter for pleural drainage
214813|NCT02119182|Behavioral|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
214814|NCT02119182|Behavioral|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
214815|NCT02119182|Procedure|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
214816|NCT02119182|Procedure|Blood Draw for Plasma, DNA, Serum, RNA|Blood draw at baseline, 2 weeks, and 6 months.
214817|NCT02119195|Procedure|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
214818|NCT02119208|Behavioral|Intensity and timing of exercise|
214819|NCT02119221|Drug|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of [14C]
214820|NCT02119234|Drug|Beclometasone/formoterol/glycopyrrolate|
214821|NCT00131157|Procedure|expert support for interpretation of spirometry|
214822|NCT02119234|Drug|Placebo|
214823|NCT02119247|Device|CHF 6001 dry powder for inhalation via NEXThaler®|
214824|NCT02119247|Device|CHF 6001 DPI capsules for inhalation via Aerolizer|
214825|NCT02119260|Drug|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
215108|NCT02152176|Device|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
215109|NCT00134251|Drug|SLV308|
215110|NCT02152189|Other|Screening for Fabry disease|
214180|NCT02131194|Dietary Supplement|Lenstatin|Dietary Supplement Lenstatin
214181|NCT02131194|Drug|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
214182|NCT02131207|Device|magnetic resonance imaging|Undergo pelvic MRI
214183|NCT02131207|Procedure|prostate biopsy|Undergo prostate biopsy
214184|NCT00132535|Drug|chloroquine|
214185|NCT02131220|Drug|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
214186|NCT02131220|Drug|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
214187|NCT02131220|Drug|normal saline|intracoronary bolus infusion using selective catheter during PCI
214188|NCT02131233|Drug|Reformulated Raltegravir|Reformulated raltegravir for once-daily administration
214189|NCT02131233|Drug|Raltegravir|Raltegravir for twice-daily administration
214497|NCT00131677|Drug|tenofovir disoproxil fumarate|study product taken daily
214498|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
214499|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
214500|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
214501|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
214502|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
214503|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
214504|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
214505|NCT02126033|Procedure|take blood samples|
214506|NCT02126046|Genetic|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
214507|NCT02126059|Behavioral|Reminiscence|The 10 session topics include "Happy to seeing you", "Childhood stories", "Food flavor", "Our old songs", "Festival", "My family", "My Carrier", "Unforgettable events", "My home", and "My award".
small group intervention (8-12 per group), expected total number of group is 5.
210061|NCT02078128|Drug|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
210062|NCT02078141|Drug|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
210063|NCT02078167|Other|nutraceutical combination (red yeast rice, policosanols and berberine)|
210064|NCT02078180|Drug|generic bupropion|
210065|NCT02078193|Drug|Belatacept|Patients will be converted from their MMF to Belatacept
210373|NCT02110602|Other|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
210374|NCT02110602|Other|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
210375|NCT02110615|Other|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
210376|NCT02110628|Procedure|Roux-en-Y anastomosis|Roux-en-Y anastomosis
210377|NCT02110628|Procedure|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
210378|NCT02110641|Behavioral|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
210379|NCT02110654|Drug|Montelukast|
210380|NCT00130273|Behavioral|Standard care|Participants will receive standard of care for 12 months.
210381|NCT02110654|Drug|mometasone furoate nasal spray|
210382|NCT02110667|Device|Transperineal Ultrasound|
210383|NCT02110680|Device|Sports TENS 2|transcutaneous electric stimulation
210384|NCT02110693|Other|Tablet administration|Participant will self-administer substance use screening instrument on a tablet computer.
209779|NCT02083419|Device|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
209780|NCT02083432|Behavioral|5 session of CBT performed by specially trained dentists|A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.
The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
209781|NCT02083445|Other|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
209782|NCT02083445|Other|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
209783|NCT02083445|Device|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
209784|NCT00127452|Dietary Supplement|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
209785|NCT02083445|Other|Intermittent hypobaric hypoxia|
209786|NCT02085577|Drug|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
209787|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
210066|NCT02078206|Other|Neurocognitive stimulation|
210067|NCT02078219|Drug|RDEA3170|Oral Treatment
210068|NCT02078219|Drug|Allopurinol|Oral Treatment
210069|NCT02078219|Drug|Placebo|Oral Treatment
210070|NCT02078232|Device|puncture of head of pancreas|puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.
randomization: puncture with either 22G needle or 19G flex needle
210071|NCT00126932|Device|SonoPrep|
210072|NCT02078232|Device|puncture of head of pancreas|puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.
randomization: puncture with either 22G needle or 19G flex needle
210073|NCT02078245|Other|MRI|MRI
210074|NCT02078258|Behavioral|dot-probe task|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
209460|NCT02090413|Drug|acetylsalicylic acid|Administered as specified in the treatment arm
209461|NCT02090413|Drug|ASA-Placebo|Matched placebo
209462|NCT02090426|Other|Link2Care|
209463|NCT02090439|Drug|Silodosin|
209464|NCT00128128|Drug|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
209465|NCT02090452|Device|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
209466|NCT02090465|Drug|Ingenol Mebutate|No intervention: observation of routine use of Picato®
209467|NCT02090478|Other|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
209468|NCT02090478|Other|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
209469|NCT02090504|Drug|Sodium Oxybate (SMO)|
209470|NCT02090504|Drug|Oxazepam|
209471|NCT02090517|Device|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
209472|NCT02090517|Device|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
209788|NCT02085577|Drug|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
209789|NCT02085590|Biological|BCG vaccine|
209790|NCT02085590|Biological|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
209791|NCT02085603|Drug|Saracatinib|
209792|NCT02085603|Drug|Placebo|
209793|NCT00127738|Procedure|Angiographic renal revascularization|
209794|NCT02085616|Behavioral|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
209795|NCT02085616|Behavioral|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
209156|NCT02097940|Other|proprioceptive exercises|Exercises with movements, jumping and imbalance.
209157|NCT02097953|Drug|Daptomycin|
209158|NCT02097953|Drug|Rifampin|
209159|NCT02097966|Drug|Daclatasvir|
209160|NCT02097966|Drug|Sofosbuvir|
209161|NCT02097966|Drug|Ribavirin|
209162|NCT02097979|Behavioral|Glaucoma Educational Intervention|
209163|NCT02097992|Drug|roflumilast|4-week treatment of roflumilast
209164|NCT00128869|Procedure|spine manipulations|
209165|NCT02097992|Drug|placebo|4-week treatment of placebo
209166|NCT02097992|Drug|roflumilast 500µg single dose|single dose of roflumilast 500µg 60 minutes before albuterol inhalation
209167|NCT02097992|Drug|placebo single dose|single dose of placebo 60 minutes before albuterol inhalation
209168|NCT02098005|Other|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
209169|NCT02098005|Other|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
209170|NCT02100059|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
209171|NCT02100072|Device|Nd:YAG 1440 nm laser|
209473|NCT02092857|Dietary Supplement|Arachidonic acid (34 mg/100 kcal)|
209474|NCT00128388|Other|PFPP|Psychoanalytic Psychotherapy for panic disorder
209475|NCT02092857|Dietary Supplement|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
209476|NCT02092870|Drug|Adipose derived stem cells|ASCs harvested from autologous lipoaspirate
208857|NCT02104947|Drug|idarucizumab|idarucizumab
208858|NCT00129662|Behavioral|Pictorial action plan|
208859|NCT02104960|Other|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
208860|NCT02104960|Other|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
208861|NCT02104960|Other|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
208862|NCT02104973|Behavioral|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
208863|NCT02104986|Drug|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
208864|NCT02104986|Drug|Vepeside-ifosfamide-Cisplatin|
208865|NCT02104999|Device|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
208866|NCT02105012|Drug|Budesonide Inhalation Aerosol (BD MDI; PT008) Dose 1|Budesonide Inhalation Aerosol (BD MDI; PT008) administered as 2 inhalations BID
208867|NCT02105012|Drug|Budesonide Inhalation Aerosol (BD; PT008) Dose 2|Budesonide Inhalation Aerosol (BD MDI; PT008) administered as 2 inhalations BID
208868|NCT02105012|Drug|Budesonide Inhalation Aerosol (BD MDI; PT008) Dose 3|Budesonide Inhalation Aerosol (BD MDI; PT008) administered as 2 inhalations BID
208869|NCT00129675|Drug|[123I]ß CIT|Single Photon Emission Computed Tomography
SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
208870|NCT02105012|Drug|Budesonide Inhalation Aerosol (BD MDI: PT008) Dose 4|Budesonide Inhalation Aerosol (BD MDI: PT008) administered as 2 inhalations BID
208871|NCT02105012|Drug|Placebo MDI|Placebo MDI administered as 2 inhalations BID
208872|NCT02105038|Other|Spinner knob|
208873|NCT02105038|Other|No Knob|
208874|NCT02105064|Device|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
213349|NCT02121158|Device|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
213350|NCT02123368|Biological|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
213351|NCT02123368|Biological|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
213352|NCT02123381|Radiation|preoperative radiotherapy|Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.
Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f.
213353|NCT02123381|Drug|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
213354|NCT02123394|Other|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
213659|NCT02116322|Procedure|EUS-FNA with Corkscrew technique|
213660|NCT02116322|Device|Expect 19 G Flex needle|
213661|NCT02116335|Drug|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
213662|NCT00130949|Drug|ALGRX 4975|
213663|NCT02116335|Drug|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
213664|NCT02116348|Drug|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
213665|NCT02116361|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
213666|NCT02116361|Drug|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
213667|NCT02116374|Other|Physiopathology study|
213668|NCT02116387|Other|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
213669|NCT02116387|Device|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
213670|NCT02116400|Other|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
213671|NCT02116400|Other|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
213358|NCT00131638|Drug|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
213359|NCT02123420|Device|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).
Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, St-Stevens-Woluwe, Belgium).
213360|NCT02123433|Biological|pneumococcal conjugate 13 valent vaccine|Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).
Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.
Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm.
213361|NCT02123446|Drug|Cephalexin|Administered orally.
213362|NCT02123459|Drug|Cephalexin|Administered orally
213363|NCT02123472|Drug|Cephalexin|Administered Orally
213364|NCT02123485|Device|Right prefrontal Low frequency (1 hz) rTMS,|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
213365|NCT02123485|Device|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
213366|NCT02123498|Drug|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
213367|NCT02123498|Drug|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
213368|NCT02125539|Behavioral|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
213369|NCT02125539|Behavioral|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
213680|NCT02118675|Other|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
213681|NCT02118675|Other|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
213071|NCT02130817|Procedure|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
213072|NCT02130817|Drug|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
213073|NCT00132483|Behavioral|Instruction in physical training program|Instruction in physical training program.
213074|NCT02130817|Drug|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
213075|NCT02130817|Drug|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
213076|NCT02130830|Drug|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
213077|NCT02130830|Drug|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
213078|NCT02130843|Device|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
213079|NCT02130856|Device|Neonatal kit|Contents of the neonatal kit:
Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.
4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.
Sunflower oil emollient (50 mL)
ThermoSpot
Mylar infant sleeve
Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.
Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker.
213080|NCT02130869|Device|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
213081|NCT02130869|Biological|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
213082|NCT02130869|Biological|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
213083|NCT02130869|Drug|Busulfan|Given IV - Group A only.
213084|NCT00132496|Drug|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
213085|NCT02130869|Drug|Melphalan|Given IV - All groups.
217247|NCT02302898|Behavioral|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
217248|NCT02305238|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
217249|NCT02305251|Other|Survey|Standard Gamble Survey
217250|NCT00151983|Drug|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
217251|NCT02305264|Drug|18F-DPA-714 and 18F-FDG|Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.
18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter.
217541|NCT02298166|Other|Allogeneic stem cell transplantation|Allogeneic HSCT from a matched related or unrelated donor is the preferred form of consolidation for patients achieving CR. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.
Allogeneic HSCT is intended at the earliest time point possible for patients in second CR or CRi . This can be directly after first salvage induction MC therapy, but also after two salvage induction therapies. Stem cell graft administration should not be later than 49 days after start of last chemotherapy.
217542|NCT02298179|Biological|RSV F subunit vaccine-Low dosage; no adjuvant|Low dosage; no adjuvant
217543|NCT02298179|Biological|RSV F subunit vaccine-Medium dosage; no adjuvant|Medium dosage; no adjuvant
217544|NCT02298179|Biological|RSV F subunit vaccine-High dosage; no adjuvant|High dosage; no adjuvant
217545|NCT00151242|Drug|Cytarabine|100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
217546|NCT02298179|Biological|RSV F subunit vaccine-Low dosage; with aluminum hydroxide|Low dosage; with aluminum hydroxide
217547|NCT02298179|Biological|RSV F subunit vaccine-Medium dosage; with aluminum hydroxide|Medium dosage; with aluminum hydroxide
217548|NCT02298179|Biological|RSV F subunit vaccine-High dosage; with aluminum hydroxide|High dosage; with aluminum hydroxide
217549|NCT02298179|Biological|RSV F subunit vaccine-Low dosage; with MF59|Low dosage; with MF59
217550|NCT02298179|Biological|RSV F subunit vaccine-Medium dosage; with MF59|Medium dosage; with MF59
217551|NCT02298179|Biological|RSV F subunit vaccine-High dosage; with MF59|High dosage; with MF59
217552|NCT02298179|Biological|Placebo-Sterile Saline|Sterile Saline
217553|NCT02298179|Biological|Placebo-Sterile Saline|Sterile Saline
217554|NCT02298179|Biological|Placebo-Sterile Saline|Sterile Saline
216972|NCT02310425|Drug|Placebo|he control group (group C) did not receive S. boulardii (nor other probiotics)
216973|NCT02310438|Other|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
216974|NCT02310451|Biological|blood test|blood test to J0-M3-M6-M12
216975|NCT02310464|Drug|OBI-833/OBI-821|
216976|NCT00152724|Drug|emla|
216977|NCT02312869|Other|No intervention|not applicable, observational study
216978|NCT02312882|Drug|Tofacitinib administration|5 mg of tofacitinib will be taken by mouth twice a day for three months.
217252|NCT02305277|Drug|BIA 9-1067 (clinical micronized, CM)|
217253|NCT02305277|Drug|BIA 9-1067 (to-be-marketed, TBM)|
217254|NCT02305290|Procedure|Endoscopic Mucosal Resection|
217255|NCT02305303|Procedure|Diary|A diary written prospectively during the ICU stay by the staff and relatives
217256|NCT02305316|Drug|BIA 9-1067 non-micronized|
217257|NCT02305316|Drug|BIA 9-1067 micronized|
217258|NCT02305329|Drug|BIA 9-1067|
217259|NCT02305355|Drug|Omega-3-acids ethylesters 90 4g|
217260|NCT02305355|Drug|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
217261|NCT00151996|Drug|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
217262|NCT02305368|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
217263|NCT02305381|Drug|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
217264|NCT02305381|Drug|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
217265|NCT02305394|Drug|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
216685|NCT02278705|Other|Provider reassessed high weight status|Provider and patient completed one or more interim visits to reassess progress or patient completed referral to nutrition, weight-management program, or relevant specialist
216686|NCT02278705|Other|No weight-status assessment|There is no indication that the provider assessed the child as overweight, including evidence of addressing weight, weight-related disease risk, scheduling an interim visit to readdress weight management
216687|NCT02278718|Drug|NexoBrid|
216688|NCT02278718|Procedure|Standard of Care|
216689|NCT02278731|Other|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
216690|NCT02280980|Other|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
216691|NCT02280993|Drug|DHAP|DHAP
216692|NCT00149214|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
216693|NCT02280993|Drug|Brentuximab Vedotin|Brentuximab Vedotin
216694|NCT02280993|Other|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
216695|NCT02281006|Drug|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
216979|NCT02312895|Other|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
216980|NCT02312895|Other|Dry needling|Dry needling involves inserting a dry, acupuncture needle through the skin and into a taut-band of muscle known as a myofascial trigger point (MTrP). The two-inch needles will be placed in all MTrPs identified by the treating physical therapist. Following initial penetration into the skin over the MTrP, the therapist carefully advances the needle into the muscle tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the MTrP identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the muscle for up to 5 minutes, removed, and appropriately disposed of.
216981|NCT02312895|Other|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 3x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
216373|NCT02127034|Drug|Digoxin|oral
216374|NCT02127047|Drug|Sitagliptin|
216375|NCT02127047|Drug|Exercise|
216376|NCT02127060|Drug|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
216377|NCT02127060|Drug|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
216378|NCT02127073|Drug|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
216379|NCT02127086|Other|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
216380|NCT00132002|Other|laboratory biomarker analysis|Correlative studies
216381|NCT02129582|Procedure|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
216382|NCT02129582|Biological|anti-thymocyte globulin|Given IV
216383|NCT02129582|Drug|tacrolimus|Given IV or PO
216384|NCT02129582|Drug|methotrexate|Given IV
216385|NCT00002239|Drug|Abacavir sulfate|
216386|NCT00132301|Drug|Docetaxel|Chemotherapy agent
216387|NCT02129582|Other|laboratory biomarker analysis|Correlative studies
216388|NCT02129595|Dietary Supplement|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
216389|NCT02129595|Dietary Supplement|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
216390|NCT02129608|Device|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
216696|NCT02281019|Procedure|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
215737|NCT02139709|Dietary Supplement|Ganglioside|
215738|NCT02139709|Dietary Supplement|Placebo|
215739|NCT02139722|Behavioral|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
216038|NCT02132182|Biological|Blood draw|The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
216039|NCT02132195|Drug|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
216040|NCT02132221|Behavioral|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
216041|NCT02132234|Drug|Etanercept|biological treatment according to rheumatologic indication
216042|NCT02132234|Drug|Adalimumab|biological treatment according to rheumatologic indication
216043|NCT02132234|Drug|Certolizumab|biological treatment according to rheumatologic indication
216044|NCT02134782|Other|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
216045|NCT02134795|Device|TNM (trade name), a form of Caloric Vestibular Stimulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation is thermal.
216046|NCT02134808|Drug|Creatine|Creatine is a nutritional supplement.
216047|NCT02134808|Drug|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
216048|NCT02134821|Procedure|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
216049|NCT02134834|Drug|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
216050|NCT02134834|Drug|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
216051|NCT02134847|Other|SCS intervention schedule|
215419|NCT02147028|Radiation|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
215420|NCT02147041|Drug|EGCG(Epigallocatechin Gallate)|500mg, three times a day, duration:12 weeks
215421|NCT02147041|Drug|Placebo|
215422|NCT02147054|Drug|Rocuronium|
215423|NCT02147054|Drug|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
215424|NCT02147067|Drug|Ranolazine|Ranolazine 1,000 mg twice daily
215425|NCT02147067|Drug|Placebo|Placebo
215426|NCT00002253|Drug|Octreotide|
215427|NCT00133978|Other|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
215428|NCT02147080|Behavioral|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
215429|NCT02147080|Behavioral|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
215430|NCT02147093|Device|Near Vision Spectacles (no contact lenses)|Glasses
215431|NCT02147093|Device|CLARITI 1Day|Multifocal
215432|NCT02147093|Device|Clariti 1Day|Single focal contact lens
215433|NCT02147106|Other|Videoconsultation|
215740|NCT00133367|Drug|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
215741|NCT02139735|Other|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
215742|NCT02139735|Other|Ultrasound associated with stretching|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.
Active stretching of the masseter muscles with mouth opening and closed lips
215743|NCT02139735|Other|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
215744|NCT02139748|Procedure|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
215111|NCT02152202|Other|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
215112|NCT02152202|Other|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
215113|NCT02154750|Device|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
215114|NCT02154763|Drug|Ropivacaine|
215115|NCT00002261|Biological|Smallpox Vaccine|
215116|NCT00134511|Drug|Torcetrapib/atorvastatin|
215117|NCT02154776|Drug|LEE011|3 weeks on and 1 week off
215118|NCT02154776|Drug|Buparlisib|daily
215119|NCT02154776|Drug|Letrozole|2.5 mg daily;
215120|NCT02154789|Drug|polidocanol|
215121|NCT02154789|Procedure|infra-red coagulation|
215122|NCT02154789|Procedure|cryotherapy|
215123|NCT02154802|Behavioral|video: community member|
215124|NCT02154802|Behavioral|video: physician|
215125|NCT02154802|Behavioral|video: choice of video|
215126|NCT02154815|Other|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, and 24 months
215127|NCT00134524|Procedure|MME procedure|
215128|NCT02154828|Behavioral|Integrative practices|
215129|NCT02154841|Behavioral|Questionnaire, taste test, visual food test|
215130|NCT02154854|Drug|Tacrolimus targeted half-dose|
215131|NCT02154854|Drug|Tacrolimus targeted plain dose|
215132|NCT02154867|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
215434|NCT02147119|Procedure|Coronary angiography|
214508|NCT02126059|Behavioral|Cognitive stimulation|The 10 session topics include "psycial activities", "sound", "face", "food", "word association", "number and games", "being creative", "categorizing objects", "orientation", and "team qiuz".
small group intervention (8-12 per group), total number of group is 5.
214509|NCT00131937|Drug|sorafenib tosylate|Given orally
214510|NCT02126059|Behavioral|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
214511|NCT02126072|Dietary Supplement|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
214512|NCT02126072|Dietary Supplement|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
214513|NCT02126085|Procedure|Endovascular recanalisation|Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a "bridging concept"
214514|NCT02126111|Biological|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
214515|NCT02126111|Biological|DEPIGOID Placebo|Placebo for subcutaneous administration
214516|NCT02126124|Device|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
214826|NCT02119260|Drug|GSK2798745 suspension|Aqueous suspension of GSK2798745 (>=0.5 mg)
214827|NCT02119260|Drug|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (>=0.5 mg)
214828|NCT02119260|Drug|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
214829|NCT02119260|Drug|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
214830|NCT02119260|Drug|Placebo capsule|Matching white opaque placebo blend filled capsule
214831|NCT02119273|Drug|Prednisone|See arm description
214832|NCT00131170|Procedure|paravertebral block|
214833|NCT02119273|Drug|Placebo|See arm description
214834|NCT02119286|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
214835|NCT02119286|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
210385|NCT02110693|Other|Interviewer administration|Interviewer will administer the substance use screening instrument
210386|NCT02112604|Drug|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
210387|NCT02112617|Radiation|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
210388|NCT02112630|Drug|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
210389|NCT00130546|Device|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
210390|NCT02112630|Drug|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
210708|NCT02152761|Other|placebo|Matching placebo will be administered as intravenous infusion starting on Day 1 until week 20.
210709|NCT02152774|Drug|Rho-Kinase Inhibitor|
210710|NCT02152787|Drug|Injection of propofol 1.0mg/kg|
210711|NCT02152787|Drug|propofol 0.5mg/kg|
210712|NCT02152787|Drug|normal saline|
210713|NCT02152800|Drug|valacyclovir hydrocholoride|
210714|NCT02152813|Behavioral|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
210715|NCT00134290|Behavioral|"standard diet advice"|
210716|NCT02152826|Device|Potassium oxalate|Professional application
210717|NCT02152839|Behavioral|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
210718|NCT02152852|Behavioral|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
210719|NCT02152865|Drug|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
210075|NCT02078271|Other|FBDG group|The group received food based dietary guidelines for complementary feeding
210076|NCT02078271|Other|Stimulation|The group received psychosocial stimulation
210077|NCT02078271|Other|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
210078|NCT02078271|Other|Control group|
210079|NCT02078284|Biological|CPP|One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
210080|NCT02078284|Biological|LSP|
210081|NCT02078310|Drug|ITI-007|
210082|NCT00126945|Biological|Meningococcal Vaccine|
210083|NCT02078310|Drug|Placebo|
210084|NCT02078323|Drug|Linaclotide|
210085|NCT02078323|Drug|Placebo|
210086|NCT02078336|Drug|Midazolam Mylan|
210087|NCT02080598|Behavioral|2 cigarettes in 15 minutes|
210391|NCT02112630|Drug|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
210392|NCT02112630|Drug|Boceprevir|800 mg PO three times daily starting at week 4
210393|NCT02112643|Dietary Supplement|Sodium selenite|A 100 microgram pill will be orally administered twice a day for 6 months.
210394|NCT02112643|Dietary Supplement|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
210395|NCT02112656|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
210396|NCT02112656|Drug|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
210397|NCT02112669|Device|VasQ|
210398|NCT02112682|Procedure|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
210399|NCT02112695|Other|[11C]diprenorphine|3 micrograms [11C]diprenorphine - intravenous use - 1 time
209796|NCT02085629|Biological|Donor M reg (Mreg_UKR)|Experimental: M reg treatment
Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description).
209797|NCT02085642|Other|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
209798|NCT02085642|Other|Sham needle|Retractable needle with no skin puncture
209799|NCT02085655|Drug|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
209800|NCT02085655|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
209801|NCT02085655|Drug|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
209802|NCT02085655|Drug|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
209803|NCT02085655|Drug|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
209804|NCT00127751|Behavioral|Enhance health lifestyle changes and medication compliance|
209805|NCT02085655|Drug|Thalidomide|100-200mg, PO, after chemotherapy
209806|NCT02085668|Device|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
209807|NCT02085681|Other|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
210088|NCT02080624|Drug|Drug: Topical Rapamycin|After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.
A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.
A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.
Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.
A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment.
210089|NCT00127179|Drug|Comparator: placebo / Duration of Treatment: 48 weeks|
210090|NCT02080637|Drug|Ambrisentan|Once daily oral dosing
210091|NCT02080637|Other|Placebo|
209477|NCT02092883|Drug|ACTH|PK PET scan before and after ACTH treatment
209478|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
209479|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
209480|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
209481|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
209482|NCT02092909|Drug|IMO-8400|
209483|NCT02092922|Drug|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
209484|NCT02092922|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
209485|NCT00128388|Other|ART|Applied Relaxation Training
209486|NCT02092935|Drug|SMT19969|
209487|NCT02092935|Drug|Vancomycin|
209488|NCT02092948|Radiation|[124I] PSCA-Minibody PET/CT imaging of the whole body|
209489|NCT02092961|Drug|Fostamatinib|Fostamatinib 100mg twice daily.
209490|NCT02092961|Drug|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
209491|NCT02092961|Drug|Placebo of Fostamatinib|Placebo bid for 6 weeks.
209492|NCT02092961|Drug|Placebo of Adalimumab|Placebo injection once every two weeks.
209493|NCT02092974|Procedure|tDCS|
209494|NCT02092974|Drug|Citalopram|
209495|NCT02092987|Other|Social work support|All study participants will be provided access to social support services at Riverstone Senior Life services
209496|NCT00128401|Drug|D-Cycloserine|
209808|NCT02085681|Other|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
208875|NCT02105064|Device|SHAM rTMS|Sham rTMS, without brain stimulation
208876|NCT02105077|Drug|Anesthesia with inhalative application of xenon gas|
209172|NCT02100085|Biological|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
209173|NCT00129168|Drug|Zosuquidar|
209174|NCT02100124|Behavioral|Reproductive Life Planning (RLP)|
209175|NCT02100124|Behavioral|Contraceptive Action Planning|
209176|NCT02100124|Behavioral|Contraception information|
209177|NCT02100137|Other|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
209178|NCT02100150|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
209179|NCT02100150|Drug|Placebo|Strawberry flavored solution
209180|NCT02100163|Behavioral|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
209181|NCT02100163|Behavioral|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
209182|NCT02100163|Other|Standard treatment|
209183|NCT02100176|Other|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
209184|NCT00129168|Drug|Daunorubicin|
209185|NCT02100176|Drug|Rotigotine|Rotigotine 2-8 mg/24 h
209186|NCT02100189|Other|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
209187|NCT02100189|Procedure|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
209188|NCT02100189|Other|Laboratory Biomarker Analysis|Correlative studies
209189|NCT02100202|Other|Placebo|
209190|NCT02100202|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
213672|NCT02116400|Biological|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
213673|NCT00130962|Drug|ALGRX 4975|
213674|NCT02116413|Procedure|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
213675|NCT02116413|Procedure|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
213676|NCT02116426|Biological|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
213677|NCT02116426|Biological|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
213678|NCT02116426|Biological|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
213679|NCT02116452|Dietary Supplement|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
208877|NCT02105090|Drug|Anesthetics, Local|
208878|NCT02105090|Drug|Sodium Chloride 0.9%|
208879|NCT02107417|Device|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
208880|NCT02107430|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
208881|NCT02107430|Radiation|Standard radiotherapy|radiotherapy
208882|NCT02107443|Other|Informational Intervention|Complete GA summary
208883|NCT02107443|Other|Questionnaire Administration|Ancillary studies
208884|NCT02107443|Other|Quality-of-Life Assessment|Ancillary studies
208885|NCT02107456|Device|Dry Needling|Dry needling was performed for one week, three times a week.
208886|NCT00002227|Drug|Efavirenz|
208887|NCT00129935|Drug|capecitabine|
213682|NCT00131092|Behavioral|The TLC system|
213683|NCT02118675|Other|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
213684|NCT02118688|Drug|Risperidone|
213685|NCT02118688|Drug|Trazodone|
213686|NCT02118688|Drug|Placebo|
213687|NCT02118701|Other|Shared Decision-Making educational training|
213688|NCT02118714|Drug|Atrasentan|Atrasentan
213689|NCT02118727|Drug|Memantine|All randomized patients will be instructed to take one tablet once a day for the first week from a blinded bottle that contains 5 mg tablets or matching placebo. At week two, patients will be instructed to take one tablet twice a day from the 5 mg bottle or matching placebo. At week three, patients will be instructed to take one tablet in the morning from the 5 mg bottle and one tablet from the 10 mg bottle or the matching placebo bottle in the evening. At week four patients will be instructed to take one pill twice a day from the 10 mg bottle or matching placebo. At week five patients will be instructed to take 2 pills from the 10 mg bottle or matching placebo in the morning and one pill in the evening. At week six patients will start 2 pills twice a day from the 10 mg bottles or matching placebos
213690|NCT02118727|Drug|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first week from a blinded bottle that contains 5 mg tablets or matching placebo. At week two, patients will be instructed to take one tablet twice a day from the 5 mg bottle or matching placebo. At week three, patients will be instructed to take one tablet in the morning from the 5 mg bottle and one tablet from the 10 mg bottle or the matching placebo bottle in the evening. At week four patients will be instructed to take one pill twice a day from the 10 mg bottle or matching placebo. At week five patients will be instructed to take 2 pills from the 10 mg bottle or matching placebo in the morning and one pill in the evening. At week six patients will start 2 pills twice a day from the 10 mg bottles or matching placebos
213691|NCT02118753|Drug|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
213692|NCT02118766|Drug|AN2728 Topical Ointment, 2%|
213693|NCT00131105|Behavioral|The Stanford Active Choices program|
213694|NCT02118766|Drug|Matching vehicle control|
208897|NCT02107521|Other|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
208898|NCT00129948|Drug|Troxatyl™ (troxacitabine)|
208899|NCT02107521|Other|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
213086|NCT02130869|Biological|GM-CSF|Given SQ - All groups.
213087|NCT00132717|Drug|Comparator: simvastatin|
213370|NCT02125552|Procedure|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
213371|NCT02125552|Procedure|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
213372|NCT02125565|Other|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
213373|NCT02125578|Drug|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
213374|NCT00002237|Drug|Peldesine|
213375|NCT00131885|Dietary Supplement|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
213376|NCT02125578|Drug|Placebo|Each participant will receive placebo every other week or every 4 weeks.
213377|NCT02125591|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
213378|NCT02125591|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
213379|NCT02125604|Drug|dimethyl fumarate|BG00012 capsules administered according to the prevailing product label.
213380|NCT02125617|Drug|Abiraterone|1000 mg/day
213381|NCT02125617|Drug|Prednisolone|10 mg/day
213382|NCT02125630|Procedure|Surgery|Surgery to primary tumor
213383|NCT02125630|Drug|Systemic therapy|Systemic therapy based on tumor phenotype
213384|NCT02125643|Drug|Caffeine|
213385|NCT02125643|Other|Flour|Flour will be administered as the placebo.
213386|NCT00131885|Drug|Levonorgestrel|Levonorgestrel in a single oral dose
213387|NCT02125656|Other|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
217555|NCT02298192|Drug|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
217556|NCT00002379|Drug|Levocarnitine|
217557|NCT00151242|Drug|Idarubicin|12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
217558|NCT02298205|Other|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
217559|NCT02298205|Other|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
217849|NCT02293564|Drug|gevokizumab|Solution for subcutaneous injection
217850|NCT00150709|Drug|Levetiracetam (Keppra)|
217851|NCT02293577|Device|continuous glucose monitor|In this study all subjects will wear a continuous glucose monitor for 5 days.
217852|NCT02293590|Drug|Certolizumab Pegol|
217853|NCT02293603|Biological|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002
217854|NCT02293616|Dietary Supplement|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
217855|NCT02293616|Dietary Supplement|Placebo|
217856|NCT02293629|Drug|BMS-986147|
217857|NCT02293629|Drug|Placebo matching BMS-986147|
217858|NCT02293655|Drug|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
217859|NCT02293668|Drug|FSH 225IU and hMG 225IU|
217860|NCT02293668|Drug|FSH 150IU and hMG 150IU|
217861|NCT00150722|Drug|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
217862|NCT02293668|Drug|Letrozole 5mg and hMG 150IU|
217863|NCT02293681|Drug|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
217864|NCT02293681|Drug|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
217266|NCT02305394|Drug|propofol and normal saline|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.
217267|NCT02305407|Procedure|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
217268|NCT02305407|Other|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
217269|NCT02305420|Device|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/BlastGen)
217270|NCT02305420|Device|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
217271|NCT02305433|Other|Home-based physiotherapy|Each physiotherapy session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
217272|NCT00151996|Drug|Amphetamine + SPD503|
217273|NCT02307721|Device|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
217560|NCT02298218|Drug|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
217561|NCT02300428|Dietary Supplement|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
217562|NCT02300441|Other|ECG, blood pressure and oximetry|
217563|NCT02300454|Device|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
217564|NCT02300454|Device|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
217565|NCT00002379|Drug|Stavudine|
217566|NCT00151437|Procedure|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
217567|NCT02300467|Drug|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
217568|NCT02300480|Procedure|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
216982|NCT02312908|Drug|Clonazepam|For experimental treatment of RBD
216983|NCT02312908|Drug|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
216984|NCT02312921|Other|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
216985|NCT02312934|Drug|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
216986|NCT02312934|Other|Placebo Transdermal Patch|
216987|NCT00152724|Drug|capsaicin|
216988|NCT02312947|Device|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
216989|NCT02312947|Device|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
216990|NCT02312960|Other|Data Collection|No study treatment will be provided in this long term follow up study
216991|NCT02312973|Drug|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
216992|NCT02312973|Drug|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
216993|NCT02312986|Biological|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
217274|NCT02307734|Behavioral|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
217275|NCT02307734|Behavioral|Healthy Living|In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about "Healthy Living" focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout.
217276|NCT02307747|Other|blood samples|Blood samples will be collected every 4 hours during 24 h
216697|NCT02281019|Device|SpyGlass DVS and SpyGlass DS|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
216698|NCT02281032|Other|interRAI PC|PREPARATORY PHASE
Step 0: Introductory information
Step 1: Training on the interRAI PC and the BelRAI webapplication
Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization
IMPLEMENTATION PHASE
Step 3: Identification of residents with palliative care needs, based on the surprise question
Step 4: Informed consent signature requirements
Step 5: Login to the BelRAI webapplication
Step 6: Definitions of roles and functions
Step 7: Completion of the interRAI PC
Step 8: Interpretation of results
Step 9: Use of results
216699|NCT02281045|Device|EVODIAL membrane and Selectbag citrate|
216700|NCT02281045|Device|Regional citrate anticoagulation|
216701|NCT02281058|Drug|Abatacept|self-injected subcutaneous biologic medication
216702|NCT02281071|Procedure|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
216703|NCT00149214|Drug|doxorubicin|60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
216704|NCT02281084|Drug|CC-486 (ORAL AZACITIDINE)|200 mg CC-486 (Oral Azacitidine) will be given for the first 21 days of each 28-day treatment cycle
216705|NCT02281084|Drug|Durvalumab|
216706|NCT02281097|Other|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
216707|NCT02281097|Other|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
216708|NCT02281110|Device|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
216709|NCT02281123|Other|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
216710|NCT02283489|Drug|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
216711|NCT00149513|Behavioral|Usual care|Participants will receive usual care.
216712|NCT02283502|Device|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
216052|NCT00132821|Drug|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
216053|NCT02134860|Other|Bed rest|8 days of full bed rest
216054|NCT02134860|Other|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
216055|NCT02134860|Other|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
216056|NCT02134860|Other|Cognitive testing|Daily testing of memory and concentration using standardized tests
216057|NCT02134860|Other|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
216391|NCT02129608|Drug|Lorcaserin|10 mg pills twice daily for 12 weeks.
216392|NCT02129621|Procedure|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
216393|NCT02129621|Drug|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
216394|NCT02129634|Device|CB-PTA|
216395|NCT02129634|Device|DEB-PTA|
216396|NCT02129647|Drug|Axitinib|
216397|NCT00132301|Drug|Prednisone|steroid in combination with chemotherapy agent
216398|NCT02129660|Drug|Dose 1 of DRM04B|
216399|NCT02129660|Drug|Dose 2 of DRM04B|Not provided
216400|NCT02129660|Drug|Dose 1 of DRM04|Not provided
216401|NCT02129660|Drug|Dose 2 of DRM04|
216402|NCT02129660|Other|Vehicle|
216403|NCT02129673|Drug|VS101 Insert Dose A|Sustained release of latanoprost into the eye
216404|NCT02129673|Drug|VS101 Insert Dose B|Sustained release of latanoprost into the eye
216405|NCT02129673|Drug|VS101 Insert Dose C|Sustained release of latanoprost into the eye
216406|NCT02129673|Drug|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
216407|NCT02129686|Procedure|Immediate Acupuncture Group|
215745|NCT02142478|Behavioral|Adapted Exercise for Health (EFH) scheme|12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:
Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.
Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.
Opportunities to attend daily.
Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme.
215746|NCT02142478|Behavioral|Standard Exercise for Health (EFH) scheme|12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.
The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members).
215747|NCT02142504|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
215748|NCT02142504|Drug|Placebo (Saline)|Norovirus bivalent placebo vaccine
215749|NCT02142504|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted without MPL and aluminum hydroxide for IM injection
215750|NCT02142517|Procedure|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
215751|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
215752|NCT02142517|Procedure|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
215753|NCT02142530|Drug|Carfilzomib|
216058|NCT02134860|Other|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
216059|NCT02134860|Other|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
216060|NCT02134873|Other|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
215435|NCT02147132|Drug|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
215436|NCT02147132|Drug|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
215437|NCT02147132|Drug|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
215438|NCT00133978|Other|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
215439|NCT02147132|Drug|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
215440|NCT02149719|Other|Desensitisation using boiled peanut|
215441|NCT02149719|Other|Desensitisation using boiled peanut (deferred start)|
215442|NCT02149732|Biological|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
215443|NCT02149745|Procedure|Calling the patient's name|calling the patient's name during anesthesia reversal
215444|NCT02149745|Procedure|Not calling the patient's name|giving verbal stimulus other than the patient's name during anesthesia reversal
215445|NCT02149758|Drug|Etoricoxib|
215446|NCT02149771|Procedure|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
215447|NCT02149771|Device|endovascular stents implantation|Bare stents implant within portal vein.
215448|NCT02149771|Procedure|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
215449|NCT02149784|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy`
215450|NCT00134043|Drug|vorinostat|Given orally
215451|NCT02149797|Procedure|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
211027|NCT00133770|Drug|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
211028|NCT02145390|Behavioral|Quality of Life Questionnaires|
211029|NCT02147808|Drug|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
211030|NCT00133991|Drug|leucovorin calcium|
211031|NCT02147808|Drug|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup [2mg/mL]).
211032|NCT02147821|Procedure|No Pleural Chest Tube|
211375|NCT02142998|Other|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
211376|NCT02143011|Other|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
211377|NCT02143011|Other|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
211378|NCT02143024|Behavioral|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
211379|NCT02143024|Behavioral|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
211380|NCT02143037|Behavioral|prize contingency management for attending treatment|
211381|NCT00133562|Drug|Glycine|
211382|NCT02143037|Behavioral|usual care|
211383|NCT02143037|Device|The Secure Continuous Remote Alcohol Monitor (SCRAMx®)|
211384|NCT02143050|Drug|Dabrafenib|
211385|NCT02143050|Drug|Trametinib|
211386|NCT02143050|Drug|Metformin|
211387|NCT02143063|Behavioral|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
210720|NCT02152865|Drug|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
210721|NCT02152878|Device|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
210722|NCT02152878|Device|Active stimulation|For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as "bifrontal" setup and has been previously used in major depression trials
210723|NCT02152891|Behavioral|CHAP-EMS|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
210724|NCT02152917|Drug|Tranexamic acid|
210725|NCT02152917|Drug|Floseal®|
210726|NCT00134290|Behavioral|"personal diet advice"|
210727|NCT02155517|Drug|Evaluation of propofol effect|The study will make in two stages:
STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
211033|NCT02147834|Drug|Ranolazine|Ranolazine 500mg tablet
500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks
211034|NCT02147834|Drug|Sugar pill|sugar pill manufactured to mimic ranolazine 500mg tablet
500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks
211035|NCT02147847|Behavioral|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
211036|NCT02147847|Behavioral|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
211037|NCT02147860|Device|Diabetes Assistant (DiAs) with USS Virginia|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
211038|NCT02147860|Other|Sensor Augmented Pump Therapy|Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
211039|NCT02147873|Drug|birinapant|
211040|NCT02147873|Drug|Azacitidine|
211041|NCT00133991|Drug|methotrexate|
211042|NCT02147873|Drug|Placebo|
210400|NCT00130546|Device|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
210401|NCT02112708|Other|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
210402|NCT02112708|Other|Control Group usual care|In the control group the depression is treated as usual with the conventional treatment.
210403|NCT02112721|Dietary Supplement|Vitamin D|
210404|NCT02112721|Dietary Supplement|Placebo|
210405|NCT02112734|Drug|Vitamin D|400 IU/daily for 10 months
210406|NCT02112734|Drug|placebo|identical placebo daily
210407|NCT02112747|Other|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
210408|NCT02112760|Other|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
210409|NCT02112786|Device|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
210410|NCT02114944|Device|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
210411|NCT02114957|Dietary Supplement|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
210412|NCT02114970|Other|Randomized- paper consent|
210728|NCT02155517|Drug|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
210729|NCT02155530|Drug|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
210730|NCT02155530|Drug|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
210731|NCT02155543|Drug|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
210732|NCT02155543|Drug|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
210092|NCT02080650|Device|Mesenchymal-marker based ferrofluid (c-MET)|
210093|NCT02080650|Device|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
210094|NCT02080663|Procedure|Proximal row carpectomy|
210095|NCT02080689|Other|Decipher|
210096|NCT02080702|Device|Monosyn|Monosyn will be used to perform the gastrointestinal anastomoses
210097|NCT02080715|Drug|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
210098|NCT02080715|Drug|Placebo|
210099|NCT02080728|Drug|Ropivacaine 500mg/100ml Naropeine|
210100|NCT00127192|Drug|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
210101|NCT02080728|Drug|0.9% sodium chloride BAXTER|
210102|NCT02080741|Other|Blood sample of 12 ml|
210103|NCT02080754|Other|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
210104|NCT02080754|Other|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
210105|NCT02080767|Drug|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
210106|NCT02080780|Drug|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
210107|NCT02080780|Drug|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 & Day 8 to the perianal area (~2.5 cm [1 inch]; ~8.5 mg)
210108|NCT02080793|Other|Questionnaire|
210413|NCT02114970|Other|Randomized- Tablet-delivered consent|
210414|NCT02114970|Other|Focus Group- paper and tablet consent|
210415|NCT00130819|Behavioral|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
210416|NCT02114983|Other|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
210417|NCT02115035|Drug|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
209809|NCT02085694|Drug|Lactobacillus brevis CD2|
209810|NCT02088047|Device|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
209811|NCT02088060|Drug|Cannabidiol|Cannabidiol tablets
209812|NCT02088060|Drug|Olanzapine|Olanzapine capsules
209813|NCT02088060|Drug|Placebo Cannabidiol|Placebo cannabidiol tablets
209814|NCT02088060|Drug|Placebo Olanzapine|Placebo olanzapine capsule
209815|NCT02088073|Drug|Zirconium silicate (acute phase)|Oral 10g three times a day with meals for 48 hours.
209816|NCT00127959|Drug|emtricitabine|
209817|NCT02088073|Drug|Zirconium silicate (maintenance phase)|Oral doses (either 5g, 10g, or 15g) once daily with breakfast for 28 days.
209818|NCT02088073|Other|Silicilate microcrystaline cellulose (maintenance phase)|Oral dose once daily with breakfast for 28 days.
209819|NCT02088086|Behavioral|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
209820|NCT02088086|Behavioral|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
209821|NCT02088086|Behavioral|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
209822|NCT02088099|Other|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
209823|NCT02088099|Other|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
209824|NCT02088112|Drug|Gefitinib|Gefitinib QD
209825|NCT02088112|Drug|MEDI4736|MEDI4736 IV Q2W
209191|NCT02100202|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
209192|NCT02100202|Dietary Supplement|MaQxan (Tagetes erecta flower extract)|
209193|NCT02100215|Other|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
209497|NCT02092987|Other|Educational material|All participants receive educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
209498|NCT02095496|Device|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
209499|NCT02095496|Device|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
209500|NCT02095509|Drug|Enoxaparin|Drug class: Low-molecular weight heparin
209501|NCT02095522|Drug|Colchicine|Colchicine 1mg per day for one month
209502|NCT02095522|Drug|Placebo|Placebo
209503|NCT02095535|Drug|Chlorhexidine gluconate|antiseptic
209504|NCT02095548|Drug|SM04690, 0.03mg/2mL|
209505|NCT00128622|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
209506|NCT02095548|Drug|SM04690, 0.07mg/2mL|
209507|NCT02095548|Drug|SM04690, 0.23mg/2mL|
209508|NCT02095548|Drug|Placebo|
209509|NCT02095561|Other|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
209510|NCT02095574|Drug|[14C]ABT-199 (GDC-0199)|[14C]ABT-199 will be administered as a single oral administration
209511|NCT02095587|Drug|IPI-145|25 mg single oral capsule
209512|NCT02095600|Radiation|Radiosurgical thalamotomy|
209513|NCT02095613|Other|traditional food|
209514|NCT02095613|Other|food that is nutrient dense|
208888|NCT02107469|Drug|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
208889|NCT02107469|Drug|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
208890|NCT02107469|Drug|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
208891|NCT02107469|Drug|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
208892|NCT02107469|Other|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
208893|NCT02107469|Other|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
208894|NCT02107482|Device|Levia NB-UVB light|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
208895|NCT02107482|Device|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
208896|NCT02107495|Device|Samsung LABGEO IVD-A20 CHF Test|
209194|NCT02100215|Other|Expert Modeling|70 minutes of expert modeling videos
209195|NCT02102516|Drug|SPRIX (intranasal ketorolac tromethamine)|
209196|NCT02102529|Procedure|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
209197|NCT02102555|Drug|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
209198|NCT02102555|Drug|placebo|placebo (IV normal saline)
209199|NCT02102581|Procedure|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
209200|NCT02102594|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
209201|NCT02102607|Other|age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
208900|NCT02107534|Behavioral|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
208901|NCT02107547|Procedure|Biceps tenodesis|
208902|NCT02109965|Drug|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
208903|NCT02109991|Device|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
208904|NCT02110004|Procedure|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
208905|NCT00130221|Drug|2% chlorhexidine gluconate impregnated cloth|
208906|NCT02110004|Device|Picasso NAV Catheter|
208907|NCT02110017|Other|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
208908|NCT02110030|Device|Transcutaneous nerve stimulation|The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and "V" deltoid " (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain.
208909|NCT02110030|Device|Interferential Currents|The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and "V" deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain).
208910|NCT02110043|Device|tDCS|transcranial direct current stimulation (tDCS)
208911|NCT02110043|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
208912|NCT02110056|Device|tDCS|transcranial direct current stimulation (tDCS)
208913|NCT02110056|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
208914|NCT02110069|Drug|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 weeks (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
208915|NCT02110069|Drug|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
213388|NCT02125669|Procedure|Laser treatment|Pulsed dye laser 595nm
213389|NCT02125669|Device|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
213390|NCT02125682|Drug|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
213695|NCT02121158|Other|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
213696|NCT02121171|Device|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
213697|NCT02121171|Procedure|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
213698|NCT02121184|Drug|Lactated Ringers bolus of 1000 mL|LR bolus of 1000 mL initiated at patient positioning for epidural placement
213699|NCT02121184|Drug|Lactated Ringers infusion @ 125 ml/hr|Regular maintenance infusion; no additional fluids
213700|NCT02121184|Drug|Routine oxytocin|per regular oxytocin protocols
213701|NCT02121184|Drug|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
213702|NCT00131378|Drug|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
213703|NCT02121197|Drug|Ozurdex|
213704|NCT02121210|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
213705|NCT02121223|Device|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (>=16atm) for at least 15 seconds.
213706|NCT02121223|Device|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
213707|NCT02121249|Device|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
213708|NCT02121249|Procedure|free hand technique|No specific device is necessary in the "free hand technique"
213709|NCT02121262|Drug|700 μg dexamethasone|700 μg dexamethasone intravitreal injection in the study eye on day 1, month 5, and month 10.
217865|NCT02293681|Drug|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
217866|NCT02293694|Drug|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
217867|NCT02293707|Biological|GX301|GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.
Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).
Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.
217868|NCT02293720|Device|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
218168|NCT02288923|Procedure|Local Infiltration Analgesia|Local infiltration analgesia to be administered by surgeon towards the end of operation:
40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
218169|NCT02288923|Procedure|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
218170|NCT02288923|Procedure|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
218171|NCT02288923|Drug|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
218172|NCT02288923|Drug|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
218173|NCT02288923|Drug|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight >70kg 2 hourly.
217569|NCT02300480|Procedure|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
217570|NCT02300493|Behavioral|Experimental|Asked to weigh themselves
217571|NCT02300506|Other|No intervention|
217572|NCT02300519|Other|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
217573|NCT02300532|Other|No intervention|
217574|NCT02300545|Drug|Pazopanib|
217575|NCT02300558|Drug|Eleclazine|Eleclazine tablet administered orally
217576|NCT02300558|Drug|Eleclazine placebo|Eleclazine placebo tablet administered orally
217577|NCT00151437|Procedure|MRI|
217578|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
217579|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
217580|NCT02300584|Device|iPad|a tablet computer with an internet connection
217869|NCT02293746|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
217870|NCT02293759|Procedure|HoLEP|Holmium laser enucleation of the prsotate
217871|NCT02293759|Procedure|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
217872|NCT02296099|Drug|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
217873|NCT02296112|Drug|trametinib|Given PO
217874|NCT02296112|Other|laboratory biomarker analysis|Correlative studies
217875|NCT02296112|Other|pharmacological study|Correlative studies
217876|NCT02296125|Drug|AZD9291 80 mg/40 mg + placebo|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.
Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
217277|NCT02307760|Other|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
217278|NCT00152230|Drug|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
217279|NCT02307760|Other|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
217280|NCT02307773|Drug|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
217281|NCT02307812|Drug|Ramucirumab|Administered intravenously (IV)
217282|NCT02307812|Drug|Paclitaxel|Administered IV
217283|NCT02307825|Drug|Azithromycin|The drug will be taken three times a week for four months.
217284|NCT02307825|Drug|Placebo|The placebo will be taken three times a week for four months.
217285|NCT02307838|Other|Assessment arm|Protocol required assessments not provided in standard of care
217286|NCT02307851|Biological|Quadrivalent VLP Vaccine|
217287|NCT02307851|Biological|Comparator TIV|
217288|NCT02307864|Drug|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
217289|NCT00152230|Procedure|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
217290|NCT02307864|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
217291|NCT02307864|Drug|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
217292|NCT02307864|Drug|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
217581|NCT02300597|Other|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
217582|NCT02300610|Drug|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
217583|NCT02300610|Drug|Cisplatin|Cisplatin at 70 mg/m^2 IV on day 1, repeated every 21 days for total of 6 cycles.
216994|NCT02312999|Drug|Plasmalyte|
216995|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
216996|NCT02315352|Drug|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
216997|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
216998|NCT02315352|Drug|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
216999|NCT02315378|Behavioral|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
217000|NCT02315378|Behavioral|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
217001|NCT02315391|Dietary Supplement|isolated whey protein|isolated whey protein
217002|NCT02315391|Dietary Supplement|micellar whey protein|micellar whey protein
217003|NCT02315391|Dietary Supplement|glycine|glycine
217004|NCT00152932|Drug|Dorzolamide 2% drops|
217005|NCT02315391|Dietary Supplement|citrulline|citrulline
217006|NCT02315404|Procedure|CAP|CAP fitted to the end of the endoscope
217007|NCT02315417|Drug|gevokizumab|
217008|NCT02315417|Drug|Placebo|
217009|NCT02315417|Drug|gevokizumab open-label|
217010|NCT02315430|Drug|Cabozantinib S-malate|Given PO
217011|NCT02315430|Other|Laboratory Biomarker Analysis|Optional correlative studies
217012|NCT02315443|Drug|NA-1|
217013|NCT02315443|Drug|Placebo|
217014|NCT02315456|Procedure|capsulorhexis|
216408|NCT00132314|Drug|IM risperidone|long-acting injectable risperidone
216409|NCT02129686|Procedure|Delayed Acupuncture Group|
216410|NCT02132234|Drug|Infliximab|biological treatment according to rheumatologic indication
216411|NCT02132247|Drug|Diclofenac hydroxyethylpyrrolidine|
216412|NCT00132639|Drug|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
216413|NCT02132260|Drug|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
216414|NCT02132260|Drug|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
216415|NCT02132260|Drug|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
216713|NCT02283515|Drug|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
216714|NCT02283528|Device|Stryker Hybrid|Place Hybrid arch bars
216715|NCT02283528|Device|Erich|Control group is Erich arch bars
216716|NCT02283541|Behavioral|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
216717|NCT02283554|Procedure|open flap debridement (OFD)|
216718|NCT02283554|Other|Platelet rich fibrin (PRF)|
216719|NCT02283554|Drug|Metformin|
216720|NCT02283580|Other|Single limb|Low load, high-repetitive resistance training.
single limb at a time (e.g., one arm or one leg)
elastic bands
8 weeks
3 times/week,
each session 60 minutes
seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension
maximal number of repetitions (RM) * 3 sets in each exercise.
216721|NCT02283580|Other|Two limb|Low load, high-repetitive resistance training.
two limbs at a time (e.g., both arms or both legs)
elastic bands
8 weeks
3 times/week,
each session 60 minutes
seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension
maximal number of repetitions (RM) * 3 sets in each exercise.
216722|NCT00002374|Drug|Nelfinavir mesylate|
216723|NCT00149526|Behavioral|Shared Decision-Making|
216061|NCT02134886|Drug|Erlotinib Hydrochloride|Given PO
216062|NCT02134886|Other|Laboratory Biomarker Analysis|Correlative studies
216063|NCT00132821|Drug|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
216064|NCT02134886|Other|Pharmacological Study|Correlative studies
216065|NCT02134886|Other|Quality-of-Life Assessment|Ancillary studies
216066|NCT02134899|Drug|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
216067|NCT02137083|Drug|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
216068|NCT02137096|Drug|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
216069|NCT02137096|Drug|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
216070|NCT00133094|Procedure|Computer-based decision support technology|
216071|NCT02137096|Drug|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
216072|NCT02137096|Procedure|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
216073|NCT02137109|Drug|natalizumab|Administered as specified in the treatment arm.
216074|NCT02137122|Device|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
216075|NCT02137122|Device|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
216076|NCT02137135|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
216077|NCT02137135|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
216078|NCT02137135|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
216416|NCT02132273|Other|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
216417|NCT02132286|Drug|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
215452|NCT02149797|Procedure|SILC-Pick'n roll-Beginning (group I)|SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a "half-knot". The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided
215754|NCT02142530|Drug|Belinostat|
215755|NCT02142543|Drug|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
215756|NCT02142543|Drug|Placebo Comparator|
215757|NCT02142556|Drug|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
215758|NCT02142569|Drug|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
215759|NCT02142569|Drug|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
215760|NCT02142569|Drug|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
215761|NCT02144805|Procedure|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
215762|NCT02144818|Drug|Ovitrel|Triggering of ovulation with Ovitrel
215763|NCT02144818|Drug|Decapeptyl|Triggering with GnRH agonist
215764|NCT02144831|Drug|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
215765|NCT02144844|Behavioral|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
215766|NCT02144857|Drug|etanercept|50 mg
215767|NCT02144857|Drug|ustekinumab|45 mg
215768|NCT02144857|Drug|cyclosporine|Cyclosporine 2.5-3 mg/kgr
215769|NCT00002250|Drug|CD4-IgG|
215770|NCT00133731|Drug|Otamixaban (XRP0673)|
211388|NCT02143063|Behavioral|prize contingency management on a variable interval schedule for cocaine abstinence|
211389|NCT02143063|Behavioral|standard care|
211390|NCT02143076|Behavioral|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
211391|NCT02143076|Behavioral|Medical Adherence Measure Questionnaire|At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.
In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment.
211392|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 intramuscularly (IM).
211677|NCT00132899|Drug|Placebo|Placebo and infliximab combination therapy.
211678|NCT02137759|Radiation|Standard Radiation Therapy|Radiation therapy to 60 Gy
211679|NCT02137759|Drug|Standard Temozolomide|Temozolomide 75mg/m²/day given orally
211680|NCT02137759|Drug|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
211681|NCT02137772|Drug|MK-8228|
211682|NCT02137772|Drug|Placebo|
211683|NCT02137785|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
211684|NCT02137785|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
211685|NCT00133198|Drug|Pramipexole|
211686|NCT02137785|Device|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
211687|NCT02137798|Device|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude < o.5 mV) will also be ablated.
211688|NCT02137811|Other|MICK Assay|An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
211689|NCT02137824|Procedure|sinus floor elevation|
211690|NCT02137837|Drug|Fulvestrant|
211043|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
211044|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|
211045|NCT02147899|Drug|SYM-1219|
211046|NCT02147899|Drug|Placebo|
211047|NCT02147912|Other|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
211048|NCT02147925|Drug|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
211049|NCT02147925|Drug|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
211050|NCT02147925|Drug|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
211051|NCT02147938|Drug|Prograf®|oral
211052|NCT00002254|Drug|Alovudine|
211053|NCT00133991|Drug|prednisone|
211054|NCT02147938|Drug|Advagraf®|oral
211393|NCT02143076|Behavioral|Acceptability Questionnaire|At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.
In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment.
211394|NCT02145390|Genetic|Urine Collection for Molecular Analysis|10-20mL clean-catch urine at the following timepoints: i. Pre-treatment (Evaluation 1) ii. Post-neoadjuvant chemotherapy (Evaluation 2) iii. Post-consolidation chemoradiotherapy or cystectomy iv. At one year follow-up v. At the time of relapse
211395|NCT02145390|Genetic|Blood Collection for Molecular Analysis|Whole blood and plasma at the following timepoints.
a. Serum: 5-10mL of whole blood in 1 red-top tube and centrifuge i. Pre-treatment (Evaluation 1) ii. Post-neoadjuvant chemotherapy (Evaluation 2) iii. Post-consolidation chemoradiotherapy or cystectomy iv. At one year follow-up v. At the time of relapse
b. Plasma: 5-10mL of anticoagulated whole blood in EDTA tube (purple/lavender top) and centrifuge i. Pre-treatment (Evaluation 1) ii. Post-neoadjuvant chemotherapy (Evaluation 2) iii. Post-consolidation chemoradiotherapy or cystectomy iv. At one year follow up v. At the time of relapse
211396|NCT02145403|Drug|Carfilzomib|Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.
Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels.
211397|NCT02145403|Drug|Fludarabine|Fludarabine will be administered at 40 mg/m2/day IV x 4 on day -5 to day -2 when combined with busulfan (FluBu), or at 30 mg/m2 IV x 4 on day -5 to day -2 when combined with melphalan (FluMel).
210733|NCT02155543|Drug|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
210734|NCT02155543|Drug|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
210735|NCT02155569|Procedure|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
210736|NCT02155569|Procedure|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
210737|NCT00002261|Biological|HIVAC-1e|
210738|NCT00134615|Behavioral|RQP patient health education module|
210739|NCT02155582|Drug|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
210740|NCT02155595|Other|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
210741|NCT02155595|Other|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
210742|NCT02155608|Device|Active TNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks.
210743|NCT02155608|Device|Sham TNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks.
210744|NCT02155621|Genetic|Genome sequencing|Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
210745|NCT02155634|Drug|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
210746|NCT02155647|Drug|Avelumab|Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
211055|NCT02147951|Drug|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
211056|NCT02150356|Other|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
211057|NCT02150356|Other|Control|Diet based on refined cereal products for a period of 8 weeks.
211058|NCT02150395|Other|music therapy|
211059|NCT02150408|Other|PET-CT|
210418|NCT02115048|Drug|Letrozole|
210419|NCT02115048|Drug|Afatinib|
210420|NCT02115061|Device|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
210421|NCT02115061|Device|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
210422|NCT02115074|Drug|Fluvastatine|Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.
Per os from D1 to D14 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
210423|NCT02115074|Drug|Celebrex|Dose levels : 100 mg twice a day (< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (> 50 kg)
Per os from D1 to D28 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
210424|NCT02115087|Procedure|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
210425|NCT02115087|Drug|Morphine|
210426|NCT00130832|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
210427|NCT02115100|Procedure|procedure|Renal ablation+pulmonair vein isolation/ Renal ablation / Pulmonair vein isolation
210428|NCT02115113|Drug|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
At 5 months after transplant, doses will be adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL.
Tacrolimus withdrawal should be completed by 6 months after transplant.
210429|NCT02115113|Drug|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL.
210430|NCT02115113|Drug|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
210431|NCT02078336|Drug|Lorazepam Mylan|
210432|NCT02078336|Drug|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
210747|NCT02155660|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
210748|NCT02117492|Procedure|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
210749|NCT02117505|Drug|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
210109|NCT02080806|Device|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
210110|NCT02083458|Procedure|Catheterization of the axillary vein.|
210111|NCT02083471|Dietary Supplement|Specific Oral Tolerance Induction with Egg or Cow's milk|
210112|NCT02083484|Biological|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
210113|NCT02083497|Other|rigid bandage|
210114|NCT02083497|Other|elastic bands|
210115|NCT02083497|Other|without the use of banding|
210116|NCT02083510|Drug|Colchicine|
210117|NCT02083523|Behavioral|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
210118|NCT02083523|Behavioral|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
210119|NCT00127465|Procedure|Issue of information booklet|
210120|NCT02083536|Radiation|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
210121|NCT02083536|Drug|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
210122|NCT02083549|Other|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
210123|NCT02083575|Drug|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
210124|NCT02083575|Drug|deferiprone , deferesarox|iron chelator
210125|NCT02083588|Device|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
209515|NCT02095626|Drug|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
209516|NCT00128622|Biological|therapeutic autologous dendritic cells|
209517|NCT02095626|Drug|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
209518|NCT02095665|Drug|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
209519|NCT02095665|Drug|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
209520|NCT02095665|Drug|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
209826|NCT02088125|Other|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
209827|NCT00127959|Drug|zidovudine|
209828|NCT02088125|Other|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
209829|NCT02088138|Device|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
209830|NCT02090517|Device|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
209831|NCT02090517|Procedure|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
209832|NCT00128141|Behavioral|Tactile stimulus|four times a day
209833|NCT02090530|Other|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
209834|NCT02090543|Drug|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
209835|NCT02090543|Drug|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
209836|NCT02090556|Drug|Abatacept|
209202|NCT02102620|Drug|Intra-articular injection with corticosteroid|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
209203|NCT02102620|Drug|Intra-articular injection with lidocaine|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
209204|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
209205|NCT00129402|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
209206|NCT02102633|Drug|Bosutinib|Bosutinib 500 mg orally
209207|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
209208|NCT02102646|Drug|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
209209|NCT02102646|Procedure|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
209210|NCT02102659|Genetic|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy" will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium
209211|NCT02102659|Genetic|Formula Nutrition Support Therapy|"Formula nutrition support therapy" will be used in patens assigned in this group based on Harris Bendiest Formula.
209212|NCT02102672|Drug|Trimetazidine|
209521|NCT02095678|Procedure|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
209522|NCT02095678|Procedure|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to <8 seconds and validate quantifiable techniques which improve liver image quality
209523|NCT02095691|Device|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
209524|NCT02095704|Drug|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
209525|NCT02098018|Behavioral|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
209526|NCT02098018|Behavioral|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
209213|NCT02102685|Procedure|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
209214|NCT02102685|Procedure|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
209215|NCT02102698|Drug|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
209216|NCT02105103|Device|Accu-Chek® Insight Insulin Pump|A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
209217|NCT00129688|Drug|cloxacillin and amikacin (once or twice daily dosage)|
209218|NCT02105116|Drug|fludarabine phosphate|Given IV
209219|NCT02105116|Drug|cytarabine|Given IV
209220|NCT02105116|Biological|donor lymphocytes|Undergo infusion of donor lymphocytes
209221|NCT02105116|Other|laboratory biomarker analysis|Correlative studies
209222|NCT02105116|Drug|G-CSF|Given IV
209223|NCT02105129|Drug|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
209224|NCT02105129|Drug|Placebo|Oral administration
209225|NCT02105142|Behavioral|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
209226|NCT02105142|Behavioral|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
209227|NCT02105142|Behavioral|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
209228|NCT00129701|Procedure|Telephone consultation|
213710|NCT02121262|Procedure|Laser Photocoagulation|Laser photocoagulation on day 1, and on months 3, 6, and 9, if retreatment indicated.
213711|NCT02121275|Device|Ultrasound of the lungs|Ultrasound examination of the lungs
213712|NCT02121275|Device|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
213713|NCT00131391|Drug|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
208916|NCT00130234|Drug|Xolair® (Omalizumab)|
208917|NCT02110082|Biological|Urelumab|
208918|NCT02110082|Biological|Cetuximab|
208919|NCT02110095|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
208920|NCT02110108|Device|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
208921|NCT02110121|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
208922|NCT02110121|Device|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
208923|NCT02110134|Device|Revlite Laser System|Revlite Laser System for the Treatment of Melasma
208924|NCT02110147|Drug|uridine triacetate|
208925|NCT02110160|Device|FDG PET/CT|
208926|NCT02112097|Drug|Gadolinium|For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
208927|NCT02112097|Drug|Gadolinium|For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
208928|NCT02112097|Drug|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
208929|NCT02112110|Drug|BMS-791325|
208930|NCT02112110|Drug|[13C]-BMS-791325|
208931|NCT02112123|Drug|Icariin|
218174|NCT02288923|Drug|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
218175|NCT02288923|Drug|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
218176|NCT02288936|Drug|Enzalutamide|Enzalutamide 160 mg/day
218177|NCT02288949|Other|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
218178|NCT00150124|Drug|Methimazole|
218179|NCT02288962|Drug|cabergoline|
218180|NCT02291198|Device|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
218181|NCT02291211|Drug|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
218471|NCT02284399|Other|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
218472|NCT02284412|Drug|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
218473|NCT02284412|Drug|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
218474|NCT02284412|Drug|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
218475|NCT02284425|Drug|REGN1193|
218476|NCT00149630|Drug|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
218477|NCT02284425|Drug|Placebo|
218478|NCT02284438|Device|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
218479|NCT02284451|Other|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
218480|NCT02284464|Drug|Prednisone withdrawal|Withdrawal of steroids
218481|NCT02284464|Drug|Prednisone continuation|Continuation of steroids
217877|NCT02296125|Drug|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
217878|NCT02296125|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
217879|NCT02296125|Drug|Erlotinib 150/100 mg|The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.
Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
217880|NCT00151034|Drug|Paclitaxel|
217881|NCT02296125|Drug|Gefitinib 250 mg|The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.
Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
217882|NCT02296125|Drug|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
217883|NCT02296138|Drug|olodaterol|fixed dose combination
217884|NCT02296138|Drug|tiotropium|fixed dose combination
218182|NCT00150462|Drug|Dexamethasone|Administered orally prior to carfilzomib
218183|NCT02291224|Behavioral|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
218184|NCT02291224|Behavioral|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
218185|NCT02291224|Behavioral|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
217584|NCT02300610|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
217585|NCT02300623|Drug|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
217586|NCT02302898|Other|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
217587|NCT02302898|Other|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
217588|NCT00151697|Drug|Lantus|
217589|NCT02302911|Behavioral|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
217590|NCT02302911|Behavioral|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
217591|NCT02302911|Other|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
217592|NCT02302937|Procedure|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
217593|NCT02302937|Procedure|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
217594|NCT02302950|Drug|raltegravir|HIV therapy component
217595|NCT02302963|Device|Diabetes Assistant (DiAs) (Unified Safety System (USS) Virginia)|Subject will participate in (2) 24-hour study insulin pump and DiAs training session. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
217596|NCT02302963|Device|Sensor-Augmented Pump Therapy (placebo)|
217597|NCT02302976|Drug|cocaine hydrochloride|
217598|NCT02302976|Drug|exenatide|
217599|NCT00151710|Drug|Pioglitazone|
217600|NCT02302976|Drug|placebo|
217601|NCT02302989|Drug|Ranibizumab 0.5mg|
217885|NCT02296138|Drug|tiotropium|
217886|NCT02296151|Other|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
217887|NCT02296151|Other|iliotibial band stretches|Iliotibial band stretches
217015|NCT00002388|Drug|Abacavir sulfate|
217016|NCT00152932|Device|HRF and CLBF|
217017|NCT02315469|Other|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
217293|NCT02307916|Drug|FGF-1|The FGF-1 method of use comprises a pledget of gelfoam, USP, with human fibroblast growth factor-1 (FGF-1) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery. FGF-1 will be administered in one of three doses up to 3 times every 21 days until there is complete closure of the perforation.
217294|NCT02310477|Drug|regorafenib|regorafenib for all groups
217295|NCT02310490|Device|DermaVeil right with left side Sculptra left side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
217296|NCT02310490|Device|DermaVeil left with left side Sculptra right side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
217297|NCT02310503|Procedure|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
217298|NCT02310516|Device|preoperative adequate explanations about awake surgery|
217299|NCT00152464|Drug|LEVOCETIRIZINE|
217300|NCT02310516|Other|no preoperative explanation|
217301|NCT02310529|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.
Intervention will be delivered by trained clinical psychologists.
217302|NCT02310542|Device|MARS albumin dialysis system|
217303|NCT02310542|Device|SPAD albumin dialysis system|
217304|NCT02310555|Procedure|Gastric bypass|
217305|NCT02310555|Procedure|Modified gastric bypass.|
217306|NCT02310555|Procedure|Slevee Gastrectomy|
217307|NCT02310568|Drug|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
216724|NCT02283593|Behavioral|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
216725|NCT02283606|Device|Accuvix SnonAce UGEO|vaginal ultrasonography
216726|NCT02283619|Other|None - no intervention, observational study|No intervention, observational study
216727|NCT02283632|Procedure|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
216728|NCT02283645|Drug|3 % minoxidil lotion|
216729|NCT02283645|Drug|Placebo|
216730|NCT02283658|Drug|Everolimus|Given PO
216731|NCT02283658|Drug|Letrozole|Given PO
216732|NCT02283658|Other|Laboratory Biomarker Analysis|Correlative studies
217018|NCT02315469|Other|Questionnaire Administration|Ancillary studies
217019|NCT02315482|Procedure|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
217020|NCT02315495|Drug|Saxagliptin|
217021|NCT02315495|Drug|Acarbose|
217022|NCT02315508|Drug|AUT00063|800 mg orally, once a day, for 4 weeks
217023|NCT02278744|Radiation|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 18 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
217024|NCT02278744|Device|MRI and/or CT|
217025|NCT02278757|Other|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
216418|NCT02132299|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
216419|NCT02132299|Biological|Normal Saline (Placebo)|
216420|NCT02132312|Drug|OMS302|
216421|NCT02132312|Drug|Phenylephrine HCl|
216422|NCT02132325|Behavioral|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
216423|NCT00132652|Drug|Lamivudine|
216424|NCT02132338|Behavioral|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
216425|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
216426|NCT02132390|Drug|Goserelin|
216427|NCT02132390|Drug|Toremifene|
216428|NCT02132403|Drug|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
216429|NCT02132403|Drug|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
216430|NCT02132403|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
216431|NCT02132416|Drug|NSAID|Will be used if tolerated.
216432|NCT02132416|Drug|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
216433|NCT02132416|Drug|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
216434|NCT02293083|Drug|trigger point injection|
216435|NCT02293096|Drug|metoprolol succinate|
216733|NCT02283671|Biological|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
215771|NCT02144870|Behavioral|Habit Reversal Training|awareness training, competing response training
215772|NCT02144870|Behavioral|Resources activation|
215773|NCT02144883|Behavioral|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
216079|NCT02137148|Device|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
216080|NCT02137161|Drug|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
216081|NCT00002241|Drug|Stavudine|
216082|NCT00133107|Drug|efalizumab|
216083|NCT02137161|Drug|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
216084|NCT02137174|Other|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
216085|NCT02137187|Procedure|AV junction ablation|AV junction ablation
216086|NCT02137187|Device|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
216087|NCT02137187|Drug|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
216088|NCT02137187|Device|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
216089|NCT02137200|Procedure|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
216090|NCT02137200|Procedure|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
216091|NCT02137213|Drug|Naloxone|Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1
216092|NCT02139748|Procedure|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
211691|NCT02137837|Drug|Anastrozole|
211692|NCT02137837|Drug|Everolimus|
211693|NCT02137837|Drug|Placebo - Anastrozole|
211694|NCT02137837|Drug|Placebo - Everolimus|
211695|NCT02137850|Drug|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
211696|NCT00002243|Drug|Calanolide A|
211697|NCT00133211|Procedure|Radiofrequency ablation|Pulmonary vein isolation
211698|NCT02137863|Drug|Dexmedetomidine|Intravenously 1μg/kg/10min administered just before the procedure.
1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.
211699|NCT02137863|Drug|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
212014|NCT02130466|Biological|Pembrolizumab|
212015|NCT02130466|Drug|Dabrafenib|
212016|NCT02130466|Drug|Trametinib|
212017|NCT02130479|Behavioral|Contingency Management-Family Engagement|
212018|NCT00002239|Drug|Amprenavir|
212019|NCT00132418|Drug|Placebo|Placebo
212020|NCT02133014|Drug|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
212021|NCT02133027|Procedure|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
212022|NCT02133027|Device|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
212023|NCT02133053|Other|Medical Device, drug-like|Ectoin Allergy Nasal Spray
212024|NCT00132717|Drug|MK0653A (ezetimibe [+] simvastatin)|
212025|NCT02133053|Drug|Beclomethasone|Beclomethasone nasal spray
211398|NCT02145403|Drug|Busulfan|Busulfan will be administered at 3.2 mg/kg/day IV x 2 on day -5 to day -4 (FluBu2), or at 3.2 mg/kg/day IV x 4 on day -5 to day -2 (FluBu4).
211399|NCT02145403|Drug|Melphalan|Melphalan will be administered at 140 mg/m2 IV x 1 on day -1 (FluMel 140) or at 180 mg/m2 IV x 1 on day -1 (FluMel 180).
211400|NCT02145403|Drug|Methotrexate|Methotrexate will be administered at 5 mg/m2 IV per day on day +1, +3, +6 and +11 as standard graft-versus-host disease prophylaxis.
211401|NCT02145403|Drug|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
211402|NCT02145429|Behavioral|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.
Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services.
211403|NCT00133783|Behavioral|intermedin|
211404|NCT02145442|Dietary Supplement|Obex|Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
211405|NCT02145455|Device|Unity Total Knee Replacement System|
211406|NCT02145455|Device|Unity Total Knee Replacement System|
211407|NCT02145468|Drug|Losmapimod 7.5 mg twice daily|Losmapimod P38 MAPK inhibitor administered in addition to standard therapy.Other Name: GW856553
211700|NCT02137863|Drug|0.9 % NaCl|100 ml/10min infusion just before the angiography
1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure
211701|NCT02137876|Procedure|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
211702|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
211703|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
211704|NCT02140385|Device|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
211060|NCT00134082|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
211061|NCT02150434|Device|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
211062|NCT02150434|Drug|Compressed air|compressed air delivered at a fixed flow of 2 L/min
211063|NCT02150434|Drug|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
211064|NCT02150447|Drug|Proton pump inhibitor|Lansoprazole 30 mg, daily
211065|NCT02150460|Procedure|One-site peribulbar injection|injection into the inferior medial orbital compartment
211066|NCT02150460|Procedure|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
211067|NCT02150473|Drug|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
211068|NCT02150473|Drug|Placebo|Placebo the same amount as adalimumab
211069|NCT02150499|Drug|levalbuterol tartrate HFA inhalation aerosol|
211070|NCT02150499|Drug|placebo|
211071|NCT00134082|Biological|filgrastim|
211072|NCT02150512|Device|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV >10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still >10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
211073|NCT02150512|Device|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
211074|NCT02150525|Dietary Supplement|omega-3 fatty acid|Given PO (by mouth) daily
211075|NCT02150525|Other|placebo|Given PO(by mouth)daily
211408|NCT02145468|Drug|Placebo twice daily|Placebo administered in addition to standard therapy
211409|NCT02145481|Behavioral|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
211410|NCT02145481|Behavioral|CAD Education|Education for patients with coronary artery disease
210750|NCT02117505|Drug|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5*30 mg tablet=150 mg) in one of the treatment periods.
210751|NCT02117518|Other|blood drawing|
210752|NCT00131040|Drug|Aprotinin|
210753|NCT02117544|Device|Lotrafilcon B multifocal contact lenses (new)|
210754|NCT02117544|Device|Lotrafilcon B multifocal contact lenses|
210755|NCT02117557|Procedure|Single incision laparoscopic surgery|
210756|NCT02117557|Procedure|Conventional laparoscopic surgery|
210757|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
210758|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
210759|NCT02117570|Biological|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
210760|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
210761|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
210762|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
210763|NCT00002233|Drug|Lamivudine|
210764|NCT00131053|Drug|Methotrexate|
210765|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
210766|NCT02117596|Drug|Sirolimus|Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.
Sirolimus (Rapamune®):
At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours).
210767|NCT02117609|Dietary Supplement|New DELICAL formula|3 months with the option of continuing until 6 months.
210768|NCT02117609|Dietary Supplement|Standard DELICAL formula|3 months with the option of continuing until 6 months.
211076|NCT02150525|Behavioral|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
210126|NCT02083601|Behavioral|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
210433|NCT02078349|Drug|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA >2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
210434|NCT02078375|Dietary Supplement|Protein|whey protein plus casein protein
210435|NCT02078375|Dietary Supplement|Carbohydrate (Placebo)|The twice daily placebo will consist of a carbohydrate and a small amount of protein
210436|NCT02078375|Other|Resistance Exercise Program|ALL participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
210437|NCT00126958|Procedure|urinary analysis|
210438|NCT02078388|Drug|Doxorubicin|
210439|NCT02078427|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|
210440|NCT02078440|Drug|Bromocriptine mesylate|Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
210441|NCT02078453|Procedure|Dental treatment|Dental treatment of all dental needs present in the children related or not to the dental caries.
210442|NCT02078466|Other|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
210443|NCT02078479|Procedure|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
210444|NCT02078479|Procedure|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
210445|NCT02078492|Drug|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
210446|NCT02078492|Drug|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
210447|NCT02078492|Drug|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
210448|NCT00126971|Drug|chlorproguanil-dapsone|
210449|NCT02078505|Behavioral|diet|Carbohydrate poor diet
210450|NCT02078518|Other|Questionnaires|
210451|NCT02078544|Other|Integrated Molecular Analysis|
210452|NCT02078557|Drug|MK-8892|
209837|NCT02090569|Device|Functional micro-Doppler Sonography (fmDS)|Craniotomy according to MRI images
Dura opening
Sulcal Localization using neuronavigation
Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.
Exeresis of the dysplasic tissue
Control using fmDS before wound closure
209838|NCT02090582|Other|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
209839|NCT02090582|Other|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
209840|NCT02090595|Behavioral|Mindfulness Based Cognitive Therapy fpr Anxious Children (MBCT-C)|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
210127|NCT02083601|Behavioral|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
210128|NCT02083614|Procedure|to clamp or release the catheter for 2 days before removal|
210129|NCT02083627|Drug|rosuvastatin|Oral
210130|NCT00127478|Drug|Atrasentan|
210131|NCT02083627|Drug|fidaxomicin|Oral
210132|NCT02085707|Procedure|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
210133|NCT02085707|Procedure|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
210134|NCT02085720|Device|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
210135|NCT02085746|Other|Defining Sexual Activity Questionnaire|
210136|NCT02085772|Other|Blood samples at 37-38 Weeks of amenorrhea|
210137|NCT00127764|Drug|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
210138|NCT02085772|Other|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
209527|NCT02098031|Other|Improving nutrition knowledge among mothers|
209528|NCT02098057|Dietary Supplement|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
209529|NCT02098057|Drug|Placebo|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
209530|NCT00128882|Drug|Anti-D|Subcutaneous injection
209531|NCT02098096|Other|Negative Work|Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:
Familiarization
Acclimatization
Progression
Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.
All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer.
209532|NCT02098096|Other|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
209533|NCT02098109|Drug|XM02 Filgrastim|
209534|NCT02098109|Drug|Filgrastim|
209535|NCT02098109|Procedure|Apheresis|
209536|NCT02098109|Drug|Plerixafor|
209537|NCT02098135|Device|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
209538|NCT02098148|Drug|Xenon|
209539|NCT02098148|Drug|Placebo|
209841|NCT02090595|Behavioral|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
209842|NCT02090608|Drug|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
209843|NCT00128154|Drug|Chromium picolinate|
209844|NCT02090621|Procedure|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
209229|NCT02105155|Drug|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
209230|NCT02105155|Drug|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
209540|NCT02098161|Drug|LCL-161|Starting dose of LCL-161 1500 mg by mouth on Days 1, 8, 15, and 22 of each 28 day cycle.
209541|NCT00128895|Drug|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
209542|NCT02098161|Behavioral|Questionnaires|Questionnaire completion at baseline, day 1 of cycle 2 and beyond, and at end of treatment visit. The questionnaires should take about 5-10 minutes to complete.
209543|NCT02098161|Other|Phone Calls|Study staff to call participant 1 time each month, and at 30 days after end of treatment visit.
209544|NCT02098174|Drug|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) will be administered by IV injection (2.5 mL to 3.5 mL for subject weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. Iohexol (Omnipaque 300, 5 mL) (comparator agent) will then be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
209545|NCT02098174|Other|Iohexol comparator|The MP-3180 (1 µmol/kg or 0.372 mg/kg) will be administered by IV injection (2.5 mL to 3.5 mL for subject weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. The iohexol (Omnipaque 300, 5 mL) will then be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
209546|NCT00129168|Drug|Cytarabine|
209547|NCT02100215|Other|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
209548|NCT02100228|Drug|Apixaban|Oral, 2.5 or 5 mg BID
209549|NCT02100228|Drug|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
209550|NCT02100241|Procedure|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
209551|NCT02100254|Behavioral|behavioral intervention|View personal narrative informational video
209552|NCT02100254|Behavioral|behavioral intervention|View fact-based informational video
209553|NCT02100267|Drug|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
209554|NCT02100280|Drug|moderate block|neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block
209555|NCT02100280|Drug|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
208932|NCT00130468|Drug|Hyalgan (sodium hyaluronate)|
208933|NCT02112123|Dietary Supplement|Matching placebo|
208934|NCT02112136|Other|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
208935|NCT02112149|Behavioral|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
208936|NCT02112162|Radiation|fludeoxyglucose F 18|Undergo FDG PET/MRI
208937|NCT02112162|Device|positron emission tomography|Undergo FDG PET/MRI
209231|NCT02105168|Procedure|Blood sample|Optional
209232|NCT02105168|Procedure|Tumorous biopsy|Optional
209233|NCT02105168|Procedure|Healthy material sample|Optional
209234|NCT02105181|Device|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
209235|NCT02105194|Drug|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
209236|NCT02105207|Other|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
209237|NCT02105207|Other|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
209238|NCT02105220|Other|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
209239|NCT02107547|Procedure|Labral repair|
209240|NCT02107573|Procedure|Traditional rotator cuff repair|
209241|NCT02107573|Procedure|Rotator cuff repair with suprascapular nerve decompression|
209242|NCT02107586|Procedure|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
209243|NCT02107586|Procedure|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
218482|NCT02284477|Other|non- PVC containing packing materials|Beverage which was stored in glass bottle for 24 hours in 4 ℃.
218483|NCT02284477|Other|PVC containing packing materials|Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
218484|NCT02284490|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
218485|NCT02284503|Drug|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
218486|NCT02284516|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
218487|NCT00149630|Behavioral|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
218488|NCT02284516|Drug|Placebo|Placebo to match active treatment, BID for 84 days
218489|NCT02284529|Drug|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
218490|NCT02286778|Dietary Supplement|Acetogenins|Acetogenins BID for 12 months
218491|NCT00002375|Drug|Nelfinavir mesylate|
218492|NCT00149838|Procedure|Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
218782|NCT02279511|Drug|PLACEBO|Infusion of 500 mL of saline solution. (IV)
218783|NCT02279524|Drug|Aramchol|Subjects will be administered Aramchol as follows:
One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).
Subjects are allowed to omit study drugs up to 3 consecutive days during the study.
218784|NCT02279537|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
218785|NCT00149032|Procedure|DLI sensitized against antigens expressed by the host.|
218786|NCT02279563|Drug|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.
During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days
218787|NCT02279563|Drug|Dymista™ Nasal Spray|
218788|NCT02279563|Drug|Placebo|
218789|NCT02279576|Drug|Pazopanib|Pazopanib 800mg/day continuously administered.
218186|NCT02291237|Drug|Eleclazine|Eleclazine tablets administered orally once daily
218187|NCT02291237|Drug|Placebo|Placebo to match eleclazine administered orally once daily
218188|NCT02291250|Dietary Supplement|Blackcurrants with polycal OGTT|Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups
218189|NCT02291250|Dietary Supplement|Greencurrants with polycal OGTT|Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups
218190|NCT02291250|Dietary Supplement|Blackcurrants with glucose OGTT|Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups
218191|NCT02291250|Dietary Supplement|Sugar matched water with polycal OGTT|Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups
218192|NCT02291263|Biological|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
218193|NCT00150735|Drug|LEVETIRACETAM|
218493|NCT02286778|Dietary Supplement|Placebo|
218494|NCT02286791|Behavioral|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
218495|NCT02286791|Behavioral|Health Education Program|For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.
Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support
218496|NCT02286804|Device|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
218497|NCT02286817|Drug|NFC-1|Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
217888|NCT02296164|Drug|Valchlor|Valchlor gel 0.016%
217889|NCT02296177|Behavioral|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
217890|NCT02296190|Drug|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
217891|NCT02298231|Other|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
217892|NCT02298231|Other|Mystic Isle Balance Intervention|Balance therapy using virtual reality
217893|NCT02298231|Other|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
217894|NCT02298244|Procedure|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
217895|NCT02298244|Procedure|PV isolation + GP ablation + Pulmonary GP ablation|The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.
8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min.
217896|NCT02298257|Drug|brentuximab vedotin|given IV
217897|NCT02298257|Drug|Doxorubicin Hydrochloride|Given IV
217898|NCT00151242|Drug|Etoposide|100mg/m² i.v. day 1-3 (induction therapy)
217899|NCT02298257|Drug|Vinblastine|Given IV
217900|NCT02298257|Drug|Dacarbazine|Given IV
217901|NCT02298270|Behavioral|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
218194|NCT02293772|Other|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
217308|NCT02310581|Drug|Buprenorphine sublingual spray|Each dose is delivered in a single 100-μL spray.
217309|NCT02310581|Drug|Matching Placebo|Each dose is delivered in a matching single 100-μL spray.
217310|NCT00152477|Drug|Carboplatin|10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.
Each cycle to be repeated every three weeks for a maximum of six cycles.
217311|NCT02310594|Other|cytology specimen collection procedure|Undergo blood sample collection
217602|NCT02303002|Biological|Botulinum Toxin Type A|Intramuscular injection (IM)
217603|NCT02303002|Biological|Active Comparator botulinum toxin|IM injection
217604|NCT02303002|Biological|Placebo Comparator|IM injection
217605|NCT02303028|Drug|Topotecan and Pazopanib|Dose escalation of low-dose metronomic Topotecan with a fixed dose of Pazopanib
217606|NCT02303041|Drug|buparlisib|Given PO
217607|NCT02303041|Drug|erismodegib|Given PO
217608|NCT02303041|Other|laboratory biomarker analysis|Correlative studies
217609|NCT02303041|Other|questionnaire administration|Ancillary studies
217610|NCT00151723|Procedure|treatment with 131I|
217611|NCT02303054|Procedure|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
217612|NCT02303054|Device|Encage Bipolar Radiofrequency Probe|
217613|NCT02305446|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
217614|NCT02305459|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
217615|NCT02305459|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
217026|NCT02278757|Other|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
217027|NCT02278783|Drug|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
217028|NCT00148928|Biological|P501-AS15 vaccine|
217029|NCT02278796|Drug|BeEAM|chemotherapy regimen consisting of bendamustine intravenously on days −7 and −6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
217030|NCT02278796|Drug|BEAM|chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
217031|NCT02278809|Behavioral|Movie Models|The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)
After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…
217032|NCT02278822|Other|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
217312|NCT02310594|Other|laboratory biomarker analysis|Correlative studies
217313|NCT02310607|Other|Not an interventional study|Not an interventional study
217314|NCT02310620|Behavioral|Cognitive training|regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
217315|NCT02310633|Behavioral|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
217316|NCT02312999|Drug|Volulyte|
217317|NCT02313012|Drug|CC-90003|CC-90003 PO once daily
217318|NCT02313025|Other|speech sound intervention|An intervention that stimulates speech sound perception and production in four-year-olds.
Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks
217319|NCT00152724|Drug|aspirin|
217320|NCT02313025|Other|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
217321|NCT02313051|Drug|Everolimus|mTOR inhibitor
216734|NCT02286089|Biological|OpRegen|50,000 - 500,000 cells will be delivered into the subretinal space following vitrectomy procedure
216735|NCT02286102|Device|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
216736|NCT02286102|Device|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
216737|NCT02286115|Behavioral|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
216738|NCT02286154|Drug|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
216739|NCT00149786|Behavioral|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
216740|NCT02286167|Other|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
216741|NCT02286193|Behavioral|Patient clinical encounters with Community liaison role|Community liaison will work with patients to create goals, develop action plans and link to community resources to support goals
216742|NCT02286206|Drug|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
216743|NCT02286219|Drug|FS102|Experimental
216744|NCT02286232|Behavioral|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
216745|NCT02286232|Behavioral|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
216746|NCT02286245|Other|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
216747|NCT02286245|Other|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
216748|NCT02286258|Drug|Calcium EDTA|Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.
Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR
216093|NCT02139761|Drug|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
216094|NCT02139761|Drug|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
216095|NCT02139774|Behavioral|Walk with Ease|A six week walking program by the Arthritis Foundation
216096|NCT02139787|Other|Radio Story|
216436|NCT02293096|Genetic|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
216437|NCT02293096|Procedure|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
216438|NCT02293109|Drug|carfilzomib|Given IV
216439|NCT02293109|Drug|cyclophosphamide|Given IV
216440|NCT02293109|Drug|vincristine sulfate|Given IV
216441|NCT00150644|Drug|Placebo|Placebo Tablet, oral Daily for 12 weeks
216442|NCT02293109|Drug|doxorubicin hydrochloride|Given IV
216443|NCT02293109|Drug|dexamethasone|Given PO
216444|NCT02293109|Drug|methotrexate|Given IV
216445|NCT02293109|Drug|cytarabine|Given IV
216446|NCT02293109|Drug|leucovorin calcium|Given IV or PO
216447|NCT02293109|Drug|methylprednisolone|Given IV
216448|NCT02293109|Biological|rituximab|
216449|NCT02293109|Other|laboratory biomarker analysis|Correlative studies
212026|NCT02133066|Procedure|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
212027|NCT02133066|Device|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
212028|NCT02133066|Procedure|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
212029|NCT02133079|Biological|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
212030|NCT02133092|Other|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
212031|NCT02133105|Drug|Levosimendan|
212032|NCT02133105|Drug|Dobutamine|
212033|NCT02133118|Drug|individual SUs, insulin, pioglitazone|
212034|NCT02133131|Drug|Grazoprevir/Elbasvir FDC|FDC tablet (100mg grazoprevir/50mg elbasvir), once daily by mouth
212035|NCT00132717|Drug|Comparator: atorvastatin|
212036|NCT02133131|Drug|Sofosbuvir|Sofosbuvir 400mg tablet, once daily by mouth
212326|NCT02125136|Drug|FOLFIFINOX|All patient receive:
2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)
Then:
Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.
To be repeated on D1 of each cycle.
212327|NCT02125149|Other|Exercise Intervention|
212328|NCT02125162|Drug|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
212329|NCT02125175|Radiation|Hypofractionated IMRT boost Radiotherapy|
212330|NCT02125188|Drug|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
212331|NCT00131846|Drug|Thiazide diuretics|Any dosage, frequency, and duration
212332|NCT02125201|Drug|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
212333|NCT02127892|Biological|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
211705|NCT02140385|Device|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
211706|NCT02140385|Device|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
211707|NCT02140398|Procedure|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
211708|NCT02140411|Drug|Lucentis Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
211709|NCT02140437|Drug|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
211710|NCT02140437|Drug|Anastrozole|standard endocrine therapy
211711|NCT00133406|Drug|Vitamin A|100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
211712|NCT02140450|Drug|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
211713|NCT02140450|Drug|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
211714|NCT02140450|Drug|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
211715|NCT02140450|Drug|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
211716|NCT02140450|Drug|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
211717|NCT02140476|Device|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
211718|NCT02140476|Procedure|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
212037|NCT02133144|Behavioral|overeating fat|
212038|NCT02133144|Behavioral|overeating carbohydrate|
212039|NCT02133157|Drug|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
212040|NCT02133170|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
211411|NCT02145494|Radiation|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
211412|NCT02145507|Drug|SOLX|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
211413|NCT02147964|Drug|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months [all subjects]
211414|NCT02147964|Drug|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months [all subjects]
211415|NCT02147964|Drug|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
211416|NCT02147964|Drug|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
211417|NCT02147964|Drug|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
211418|NCT02147964|Drug|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
211419|NCT02147964|Drug|placebo ketoconazole|placebo ketoconazole daily for 4 months
211420|NCT02147977|Dietary Supplement|dietary supplement: n-3 PUFA|
211421|NCT00133991|Drug|therapeutic hydrocortisone|
211422|NCT02147977|Dietary Supplement|olive oil|
211423|NCT02147990|Drug|Rociletinib|Rociletinib will be administered to patients orally
211424|NCT02148003|Procedure|Radiofrequency ablation|Radiofrequency ablation will be performed at either 80 degrees Celsius or 90 degrees Celsius
211425|NCT02148016|Procedure|LSCs and amniotic membrane (Modified Technique)|Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.
The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.
211426|NCT02148016|Procedure|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
211427|NCT02148016|Procedure|PRK, LSCs, and amniotic membrane (Modified Technique)|Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.
The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.
211719|NCT02140489|Drug|amosartan|
211720|NCT02140489|Drug|rosuvastatin|
211077|NCT02150538|Device|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
211078|NCT02150538|Device|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
211079|NCT02150551|Biological|Allogeneic bone marrow-derived mesenchymal stromal cells|A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 8 consecutive weeks. Toxicity will be monitored, using the department specific Standard Operating Procedure (SOP).
211080|NCT02152930|Drug|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
211081|NCT02152943|Drug|Everolimus|Escalation Group Starting Dose of Everolimus: 5 mg by mouth daily.
Expansion Group Starting Dose of Everolimus: Maximum tolerated dose from Escalation Group.
211082|NCT02152943|Drug|Trastuzumab|Escalation Group Starting Dose of Trastuzumab: 4 mg/Kg loading dose by vein every 3 weeks, then 2 mg/Kg maintenance dose by vein every 3 weeks.
Expansion Group Starting Dose of Trastuzumab: Maximum tolerated dose from Escalation Group.
211083|NCT02152943|Drug|Letrozole|Escalation Group and Expansion Group Letrozole Dose: 2.5 mg by mouth daily.
211084|NCT02152956|Drug|MGD006|MGD006 is a CD123 x CD3 bi-specific antibody-based molecular construct referred to as a dual affinity re-targeting (DART) molecule. MGD006 will be administered as a single agent.
211085|NCT02152969|Drug|Telmisartan|
211086|NCT02152969|Drug|Amlodipine|
211087|NCT02152969|Drug|Chlorthalidone|
211088|NCT02152982|Other|Laboratory Biomarker Analysis|Correlative studies
211089|NCT02152982|Other|Placebo|Given PO
211090|NCT00134303|Drug|Metformin|Metformin is used.
211091|NCT02152982|Other|Quality-of-Life Assessment|Ancillary studies
211092|NCT02152982|Other|Questionnaire Administration|Ancillary studies
211093|NCT02152982|Drug|Temozolomide|Given PO
211094|NCT02152982|Drug|Veliparib|Given PO
211095|NCT02152995|Procedure|Computed Tomography|Undergo iodine I-124 PET/CT
211096|NCT02152995|Radiation|Iodine I 124|Undergo iodine I-124 PET/CT
211097|NCT02152995|Radiation|Iodine I-131|Given PO
210453|NCT02078583|Drug|Fentanyl|
210454|NCT02078583|Drug|Remifentanil|
210455|NCT02078583|Drug|Normal saline|
210456|NCT02078596|Drug|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
210769|NCT02117622|Drug|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study.
210770|NCT02117635|Biological|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
210771|NCT02117648|Drug|LY2835219|Administered orally
210772|NCT02117648|Drug|Clarithromycin|Administered orally
210773|NCT02117661|Dietary Supplement|L-carnitine capsules|Oral
210774|NCT02117661|Dietary Supplement|Cellulose capsules|oral
210775|NCT02119988|Procedure|Embolization|Embolization of SPSS was conducted via the same jugular vein before TIPS implantation. The major procedures included (a)angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b)embolization of SPSS with coils of varying diameters, which resulted in the SPSS disappearing at postembolization angiography.
210776|NCT00131248|Drug|Metaclopramide|
210777|NCT02120001|Device|ETT cleaning maneuver|EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.
We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period.
210778|NCT02120014|Procedure|blood volume measurement|Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.
A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream.
210779|NCT02120014|Procedure|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
210780|NCT02120027|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
210781|NCT02120027|Drug|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
210139|NCT02085785|Behavioral|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials [e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
210140|NCT02085785|Behavioral|Self-directed control group|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group [e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
210141|NCT02085798|Other|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
210142|NCT02085811|Other|radiography standard|
210143|NCT02085824|Drug|Enoxaparin|
210144|NCT02085824|Drug|rivaroxaban|
210145|NCT02085824|Drug|dabigatran|
210146|NCT02085837|Other|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
210147|NCT02085837|Other|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
210457|NCT02078609|Drug|LGH447|
210458|NCT02078622|Other|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
210459|NCT02080819|Drug|levodopa/carbidopa 400/100 BID|Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.
Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance.
210460|NCT00002211|Drug|Stavudine|
210461|NCT00127192|Drug|Comparator: placebo (unspecified)|placebo QD 12-weeks
210462|NCT02080832|Drug|Citalopram|20 mg or 40 mg daily for 8 weeks
210463|NCT02080832|Drug|Placebo|Placebo daily for 8 weeks
210464|NCT02080845|Dietary Supplement|no caffeine|
210465|NCT02080845|Dietary Supplement|high caffeine|
210466|NCT02080845|Dietary Supplement|no theobromine|
210467|NCT02080845|Dietary Supplement|low theobromine|
209845|NCT02090634|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
209846|NCT02093013|Other|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
209847|NCT02093026|Drug|methylprednisolone|100 mg given IV at minimum 30 min before MabThera infusion on Days 1 and 15 of each treatment period
209848|NCT02093026|Drug|rituximab [MabThera]|1 g given by intravenous (IV) infusion on Days 1 and 15 of each treatment period
209849|NCT02093039|Device|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
209850|NCT02093052|Behavioral|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
209851|NCT02093052|Behavioral|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
209852|NCT02093078|Behavioral|CARD|Intervention: CARD
This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay.
209853|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
209854|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
209855|NCT00128401|Drug|Placebo|
210148|NCT00127777|Drug|Amantadine sulphate (in addition to standard treatment)|
210149|NCT02085837|Other|Universal Dietary education|To improve diet and health
210150|NCT02085837|Other|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
210151|NCT02085837|Other|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
209556|NCT02100280|Device|deep block|Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of PTC1-2
209557|NCT00129181|Drug|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
209558|NCT02100280|Device|moderate block|Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of TOF1-2
209856|NCT02093117|Procedure|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
209857|NCT02093117|Procedure|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
209858|NCT02093130|Dietary Supplement|Pomegranate Juice|
209859|NCT02093130|Dietary Supplement|Placebo|
209860|NCT02093143|Drug|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
209861|NCT02093156|Other|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
209862|NCT02093169|Drug|Part A: Lu AF35700|One 30 mg single dose for one day; orally
209863|NCT02093169|Drug|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
209864|NCT02093195|Drug|Bosentan|
209865|NCT02095704|Drug|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
209866|NCT02095717|Drug|Curcumin|
209867|NCT00002219|Drug|Adefovir dipivoxil|
209868|NCT00128635|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
209869|NCT02095717|Drug|Placebo|
209870|NCT02095717|Drug|Taxotere|
209871|NCT02095730|Drug|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
209244|NCT02107599|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
209245|NCT02107612|Device|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
209246|NCT00129961|Drug|sirolimus|
209247|NCT02107612|Other|Denture|
209248|NCT02107625|Behavioral|Diet A i.e. Low FODMAP diet|
209249|NCT02107625|Behavioral|Diet B, i.e. Traditional IBS diet|
209250|NCT02107638|Procedure|OMM treatment arm|OMM is a gentle hand-on manual therapy. The research team created a protocol coined "PARK-OMM" protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion.
209251|NCT02107638|Other|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
209252|NCT02107664|Radiation|Palliative RT for bone cancer pain|
209253|NCT02107690|Procedure|Low temperature lidocaine injection|4 °C
209559|NCT02100293|Drug|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
209560|NCT02100293|Drug|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
209561|NCT02100306|Behavioral|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
209562|NCT02100306|Behavioral|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
209563|NCT02100319|Drug|Azilsartan|Azilsartan tablets
209564|NCT02100371|Drug|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
209565|NCT02100384|Procedure|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
209566|NCT02100397|Biological|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
209567|NCT02100410|Device|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
209568|NCT00129402|Drug|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
218790|NCT02279576|Drug|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
218791|NCT02279589|Biological|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
218792|NCT02279589|Biological|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
218793|NCT02279589|Biological|Prevenar13® 0,5|The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).
One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197).
218794|NCT02279602|Drug|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
218795|NCT02279615|Drug|Mirabegron|50mg of mirabegron per day will be given.
218796|NCT00149058|Drug|Erythropoietin|
218797|NCT02279615|Drug|Tamsulosin|0.4mg of flomax per day.
218798|NCT02279628|Drug|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
218799|NCT02279628|Drug|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
218800|NCT02279641|Drug|RDEA3170 10 mg|
214044|NCT02116582|Drug|Enzalutamide|Oral
214045|NCT02116595|Other|high or low acid diet|high or low acid diets
214046|NCT02116608|Drug|Betadine|Apply locally as needed.
214047|NCT02116608|Drug|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
214048|NCT02116608|Drug|Hydrocortisone Butyrate Cream, 0.1%|Hydrocortisone butyrate cream, 0.1% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
214049|NCT02116621|Behavioral|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
214050|NCT02116621|Device|smartphone|
218498|NCT02286830|Drug|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
218499|NCT02286843|Radiation|89Zr-trastuzumab|
218500|NCT02286843|Device|PET/CT scan|
218501|NCT02286856|Behavioral|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
218502|NCT02286869|Procedure|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
218503|NCT00149838|Drug|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
218504|NCT02286882|Drug|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
218505|NCT02286895|Biological|pentavalent rotavirus vaccine (PRV)|At enrollment, infants will be randomized 1:1 to receive one dose of 2.0ml orally
218506|NCT02286895|Biological|measles vaccine (MV)|At enrollment, all infants will receive one dose of 0.5ml subcutaneously
218507|NCT02286895|Biological|yellow fever vaccine (YFV)|At enrollment, all infants will receive one dose of 0.5ml intramuscularly
218508|NCT02286895|Biological|meningitis conjugate vaccine (PsA-TT-5μg)|At enrollment, all infants will receive one dose of 0.5ml intramuscularly
218509|NCT02286921|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
218510|NCT02288975|Device|CytoSorb 300ml device (3804606CE01)|
218801|NCT02282007|Behavioral|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
218802|NCT02282020|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
218803|NCT02282020|Drug|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
218195|NCT02293772|Other|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
218196|NCT02293772|Other|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
218197|NCT02293785|Drug|Oxycodone-Naloxone|
218198|NCT02293798|Device|silk surgical scaffold|surgical implant
218199|NCT02293811|Other|Analysis|An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.
We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.
Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating).
218200|NCT02293824|Drug|Caffeine|Given per standard of care.
218201|NCT02293837|Drug|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight >/=30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
218202|NCT02293837|Drug|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight >/=30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
218203|NCT02293850|Biological|OBP-301|In phase I part, a range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
After assessing the clinical safety profiles by escalating doses of OBP-301 in patients with hepatocellular carcinoma, the phase II study to determine the response rate will be performed.
218204|NCT00150748|Drug|Levetiracetam 166 mg|Active Substance: Levetiracetam
Pharmaceutical Form: Tablet
Concentration: 166 mg
Route of Administration: Oral use
218205|NCT02293863|Drug|MHAA4549A|Single dose MHAA4549A, IV administration
218206|NCT02293863|Drug|Oseltamivir [Tamiflu]|75 mg or 150 mg oseltamivir administered BID for up to a 10-day course. Dosage and administration should follow local prescribing information for oseltamivir.
218207|NCT02293863|Drug|Placebo|Matching placebo dose, IV administration
218208|NCT02293876|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
218209|NCT02293876|Device|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
218210|NCT02293876|Device|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
218211|NCT02293889|Dietary Supplement|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (>50nmol/L) by 3 months.
217616|NCT02305472|Device|NeoVas BCS|Subjects receiving NeoVas BCS
217617|NCT02305485|Device|NeoVas BCS|Subjects receiving NeoVas BCS
217618|NCT02305485|Device|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
217619|NCT02305498|Other|Vigorous yoga practice|
217620|NCT02305498|Other|Restorative (gentle) yoga practice|
217621|NCT02305511|Device|Peripheral venous catheterization|Cannulation using standard method
217622|NCT02305511|Device|Jamshidi|intraosseous access using the Jamshidi device
217902|NCT02298283|Drug|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
217903|NCT02298283|Drug|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
217904|NCT02298283|Drug|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
217905|NCT02298283|Drug|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
217906|NCT02298283|Drug|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
217907|NCT02298283|Drug|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
217908|NCT02298283|Drug|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
217909|NCT00151242|Drug|All-trans retinoic acid|45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)
217910|NCT02298283|Drug|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
217911|NCT02300623|Drug|Antiretroviral therapy alone|Standard antiretroviral therapy
217912|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
217913|NCT00151450|Drug|Pregabalin|
217914|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
217915|NCT02300636|Other|Training|Standard ACL rehabilitation
217322|NCT02313051|Drug|Goserelin|
217323|NCT02313051|Drug|Letrozole|
217324|NCT02313064|Drug|CXA-10|Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
217325|NCT02313064|Drug|CXA-10 placebo|
217326|NCT02313077|Biological|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose [TCID50]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
217327|NCT02313077|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
217328|NCT02313077|Other|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
217329|NCT02313090|Other|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
217330|NCT00000348|Drug|Dihydrexidine|
217331|NCT00002386|Drug|Didanosine|
217332|NCT00152724|Drug|clopidogrel|
217333|NCT02313103|Drug|lofexidine HCl|400 micrograms
217623|NCT00152009|Drug|SPD503 (Guanfacine hydrochloride) (2 mg)|
217624|NCT02305511|Device|BIG|intraosseous access using the BIG device
217625|NCT02305511|Device|Cook|intraosseous access using the Cook device
217626|NCT02305511|Device|EZIO|intraosseous access using the EZIO device
217627|NCT02305524|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
217628|NCT02305524|Device|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
217629|NCT02305537|Behavioral|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
217630|NCT02305550|Device|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
216749|NCT02286258|Drug|Gd-DOTA|Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.
Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR
217033|NCT02278822|Other|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
217034|NCT02278835|Other|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
217035|NCT02278835|Device|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
217036|NCT02278835|Device|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
217037|NCT02278835|Device|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
217038|NCT02278848|Other|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
217039|NCT00148941|Biological|Diphtheria, tetanus, pertussis, poliovirus type 1, 2 & 3|
217040|NCT02281136|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
217041|NCT02281136|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
217042|NCT02281162|Other|Blood Draw|Blood Draw
217043|NCT02281175|Behavioral|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
217044|NCT00149214|Drug|docetaxel|100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)
217045|NCT02281175|Behavioral|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
217046|NCT02281201|Biological|BE1116 (Prothrombin Complex Concentrate)|
217047|NCT02281214|Other|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
217048|NCT02281227|Procedure|skin compression|skin compression with an indicator for determination of needle entry point
217049|NCT02281240|Drug|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
216450|NCT02293122|Other|Observational|Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F&A Specular Microscope.
216451|NCT02293135|Device|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
216452|NCT00150657|Drug|bevacizumab|
216453|NCT02293135|Device|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
216454|NCT02293148|Drug|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
216455|NCT02293148|Drug|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
216456|NCT02293148|Drug|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
216750|NCT00149786|Behavioral|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
216751|NCT02286284|Device|Apheresis for extracorporal removal of sFlt-1|
216752|NCT02286297|Device|McGRATH® MAC|video-laryngoscopy-1
216753|NCT02286297|Device|AirTraq|video-laryngoscopy-2
216754|NCT02288338|Drug|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
216755|NCT02288338|Drug|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
216756|NCT02288338|Drug|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
216757|NCT00150046|Drug|Everolimus|
216758|NCT02288338|Drug|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
216759|NCT02288351|Other|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
212334|NCT02127892|Biological|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
212335|NCT02127892|Biological|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
212336|NCT02127905|Biological|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
212337|NCT02127918|Drug|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
212338|NCT02127931|Device|Groundskeeper|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
212339|NCT02127957|Other|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
212340|NCT02127970|Drug|Single Dose Dalbavancin|Single dose of dalbavancin 1500 mg on day 1
212341|NCT02127970|Drug|Two Dose Dalbavancin|Two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8)
212342|NCT00132093|Drug|Eplerenone|
212343|NCT02127983|Behavioral|Early intervention|Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.
Front line public health personnel and community leaders were sensitised to support the intervention
212344|NCT02127983|Behavioral|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
212644|NCT02120781|Biological|Azficel-T (autologous fibroblasts)|Autologous fibroblasts will be cultured from two 3-mm hard palate punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.
Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril.
212645|NCT02120781|Drug|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
212646|NCT02120794|Device|Threshold Suspend (TS) in Pediatrics at home|Use of Threshold Suspend (TS) feature at home with a sensor-augmented insulin pump (Mini Med 530G) in Pediatrics 7-15 years with Type 1 diabetes over a period of 1 year
212647|NCT02120807|Drug|Certolizumab|
212648|NCT02120807|Drug|cisplatin|
212649|NCT00131339|Drug|D-cycloserine|
212650|NCT02120807|Drug|pemetrexed|
212041|NCT02133170|Behavioral|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
212042|NCT02135419|Drug|imiquimod|Applied topically
212043|NCT02135419|Drug|fluorouracil|Applied topically
212044|NCT02135419|Procedure|infrared photocoagulation therapy|Undergo infrared coagulation
212045|NCT02135419|Procedure|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
212046|NCT02135419|Procedure|laser therapy|Undergo laser therapy
212047|NCT02135419|Other|clinical observation|Undergo active monitoring
212048|NCT02135419|Other|laboratory biomarker analysis|Correlative studies
212049|NCT02135419|Procedure|quality-of-life assessment|Ancillary studies
212050|NCT02135432|Drug|Ivacaftor|
212051|NCT02135432|Drug|Placebo|
212052|NCT00132912|Drug|SCH 530348|
212053|NCT02135445|Drug|TAK-385|TAK-385 tablet
212054|NCT02135445|Drug|Degarelix|Degarelix injection
212055|NCT02135458|Other|Telemonitoring|
212056|NCT02135458|Other|Conventional care|
212057|NCT02135471|Drug|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
212058|NCT02135471|Drug|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
212345|NCT02127996|Drug|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
212346|NCT02128009|Other|osteoporosis|
212347|NCT02128022|Drug|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
211721|NCT02140489|Drug|amosartan and rosuvastatin|
211722|NCT00133406|Drug|glycine|0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
211723|NCT02140515|Drug|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
211724|NCT02140515|Drug|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
211725|NCT02140528|Biological|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
211726|NCT02140528|Biological|Placebo|
211727|NCT02140554|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
211728|NCT02143089|Device|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
211729|NCT02143115|Procedure|Optical colonoscopy|
211730|NCT02143115|Radiation|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
211731|NCT02143141|Drug|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
211732|NCT02143141|Drug|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
211733|NCT02143167|Drug|SR-fampridine|One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.
The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks.
211734|NCT02143167|Drug|Placebo|
211735|NCT02143193|Behavioral|Skin-to-Skin Contact|
211736|NCT02143219|Drug|Oxaliplatine|Oxaliplatine : 85mg/m², 2-hours IV infusion (D1), then,
211737|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 subcutaneously (SC).
211738|NCT02143219|Drug|Folinic acid|Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
211739|NCT02143219|Drug|Irinotecan|Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts
Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.
Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance.
211428|NCT02148016|Procedure|PRK only (Traditional Technique)|PRK alone will be performed.
211429|NCT02148016|Drug|Levofloxacin|
211430|NCT02148016|Drug|Betamethasone|
211431|NCT02148016|Drug|Limbal stem cells (LSCs)|
211432|NCT00133991|Drug|vincristine sulfate|
211433|NCT02148029|Other|Exercise|Upper and Lower extremity exercise
211434|NCT02148029|Other|Control|Standard care: anticoagulation, compression & ad-lib ambulation
211435|NCT02148055|Other|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
211436|NCT02148068|Procedure|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
211437|NCT02150564|Device|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
211438|NCT02150564|Procedure|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
211439|NCT00134082|Biological|rituximab|
211440|NCT02150577|Behavioral|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
211441|NCT02150590|Drug|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
211442|NCT02150590|Drug|sham oxygen (room air)|
211443|NCT02150616|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
211444|NCT02150616|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
211445|NCT02150616|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
211446|NCT02150616|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
210782|NCT02120040|Other|evaluation of anxiety with psychosocial scales|
210783|NCT02120053|Device|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
210784|NCT02120053|Device|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
210785|NCT02120066|Procedure|Vitrectomy for submacular hemorrhage|
210786|NCT02120066|Drug|subretinal injection of tissue-plasminogen activator|
211098|NCT02152995|Other|Laboratory Biomarker Analysis|Correlative studies
211099|NCT02152995|Other|Pharmacological Study|Correlative studies
211100|NCT02152995|Procedure|Positron Emission Tomography|Undergo iodine I-124 PET/CT
211101|NCT00134316|Behavioral|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
211102|NCT02152995|Drug|Trametinib|Given PO
211103|NCT02153021|Radiation|Phototherapy|phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.
Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J
211104|NCT02153047|Behavioral|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
211105|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
211106|NCT02155660|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
211107|NCT00134628|Procedure|Hyperbaric Oxygen Therapy|HBO at 2.0 ATA
211108|NCT02155660|Drug|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
211109|NCT02155660|Drug|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
211110|NCT02155673|Drug|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
211111|NCT02155686|Device|Biosensors|Device: Biometric sensors; Home automation; telecare
211112|NCT02155686|Device|Home automation|
210468|NCT02080845|Dietary Supplement|high theobromine|
210469|NCT02080858|Drug|Ticagrelor + Apixaban + ASA|
210470|NCT02080858|Drug|Ticagrelor + Apixaban|
210471|NCT02080910|Behavioral|Psychoeducation|
210472|NCT00127205|Drug|clodronate disodium|Given orally
210473|NCT02080923|Behavioral|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
210474|NCT02080949|Radiation|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
210475|NCT02080962|Radiation|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
210476|NCT02080962|Radiation|40 Gy in 10 fractions|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
210787|NCT00131248|Drug|Ranitidine|
210788|NCT02120079|Drug|Lotemax|
210789|NCT02120079|Drug|Artificial Tears|
210790|NCT02120092|Drug|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
210791|NCT02120092|Drug|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
210792|NCT02120092|Drug|ASA|7x 100mg acetylsalicylic acid (clopidogrel arm)
1x 300 mg acetylsalicylic acid (ticagrelor arm)
210793|NCT02120092|Drug|Placebo|7x 300mg acetylsalicylic acid placebo
210794|NCT02120118|Radiation|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
210795|NCT02120118|Other|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
210796|NCT02120118|Drug|Cisplatin|30mg/m2
210797|NCT02122185|Drug|carboplatin|Given IV
210152|NCT02085837|Other|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
210153|NCT02085863|Drug|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
210154|NCT02088138|Device|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
210155|NCT02088151|Device|Selective retinal pigment epithelium laser therapy using SRT Vario Laser|Patients receive selective retinal pigment epithelium laser treatment using SRT Vario Laser by the Medizinisches Laserzentrum Lübeck GmbH, Germany
210156|NCT02088177|Drug|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
210157|NCT02088190|Procedure|Sleeve gastrectomy|Type of bariatric surgery
210158|NCT02088203|Dietary Supplement|Russian Tarragon Nutrasorb|Russian Tarragon Nutrasorb 0.3 g
210159|NCT02088203|Dietary Supplement|Russian Tarragon Nutrasorb|Russian Tarragon Nutrasorb 1 g
210160|NCT02088203|Dietary Supplement|Placebo|Placebo
210161|NCT02088203|Dietary Supplement|Russian Tarragon Nutrasorb|Russian Tarragon Nutrasorb 3 g
210162|NCT00127959|Drug|efavirenz|
210163|NCT02088203|Dietary Supplement|Russian Tarragon Nutrasorb|Russian Tarragon Nutrasorb 10 g
210164|NCT02088203|Dietary Supplement|Russian Tarragon Nutrasorb|Russian Tarragon Nutrasorb 20 g
210165|NCT02088203|Dietary Supplement|Russian Tarragon Nutrasorb|Russian Tarragon Nutrasorb 30 g
210166|NCT02088216|Drug|N-acetylcysteine|600mg po twice a day for 12 months
210167|NCT02088216|Drug|Placebo|Oral tablet po twice a day for 12 months
210168|NCT02088242|Drug|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
210477|NCT02080975|Other|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
210478|NCT02081001|Drug|Novo Nordisk GlucaGen®|single subcutaneous infusion of each of 0.3 μg/kg, 1.2 μg/kg, and 2.0 μg/kg
209872|NCT02095730|Drug|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
209873|NCT02095730|Device|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
209874|NCT02095730|Device|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
209875|NCT02095743|Device|implanted port for chemo administration (X-port isp)|
209876|NCT02095743|Device|Use of a PICC line for chemo administration (PowerPICC SOLO²)|The description of the device could found on the published marketing authorisation
209877|NCT02095756|Other|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
210169|NCT02088242|Drug|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
210170|NCT02088255|Procedure|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
210171|NCT02088255|Procedure|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
210172|NCT02088268|Other|wound healing|wound healing
210173|NCT00127972|Drug|stavudine|
210174|NCT02088281|Drug|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
210175|NCT02088294|Behavioral|Lifestyle Education (LS)|See arm description
210176|NCT02088294|Behavioral|LS + Stress Reduction Guided Imagery|See Arm Description
210177|NCT02088294|Behavioral|LS + Activity/Eating Guided Imagery|See arm description
210178|NCT02088307|Dietary Supplement|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
210179|NCT02088333|Behavioral|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
210180|NCT02090634|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
210181|NCT02090647|Behavioral|aesthetic outcome|
209569|NCT02102711|Dietary Supplement|Vitamin A oral drops|
209570|NCT02102724|Dietary Supplement|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
209571|NCT02102737|Drug|6-DIG|injection of 6-DIG
209572|NCT02102737|Procedure|clamp|hyperinsulinemic euglycemic clamp
209573|NCT02102750|Drug|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
209574|NCT02102776|Procedure|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
209575|NCT02102776|Procedure|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
209576|NCT02102776|Procedure|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
209577|NCT02102776|Procedure|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
209578|NCT02102789|Drug|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
209878|NCT02095756|Other|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
209879|NCT00128661|Biological|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
209880|NCT02095782|Drug|Intercalated combination of chemotherapy and erlotinib|Primary therapy stage:
Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.
Maintenance therapy stage:
Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death.
209881|NCT02095795|Device|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
209882|NCT02095795|Other|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
209883|NCT02095808|Procedure|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
214051|NCT02116634|Biological|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
214052|NCT02118779|Behavioral|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
214053|NCT02118792|Drug|AN2728 Topical Ointment, 2%|
214054|NCT02118792|Drug|Matching vehicle control|
214055|NCT02118818|Genetic|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
214056|NCT02118831|Drug|Aflibercept|Subjects will receive intravitreal aflibercept as part of their routine medical care.
214057|NCT02118831|Drug|Bevacizumab|Subjects will receive intravitreal bevacizumab as part of their routine medical care.
214058|NCT02118831|Drug|Ranibizumab|Subjects will receive intravitreal ranibizumab injections as part of their routine medical care.
214059|NCT02118844|Drug|rocuronium|
214060|NCT02118857|Other|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
214061|NCT00131118|Drug|Zoledronic Acid|
214062|NCT02118870|Drug|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
214063|NCT02118870|Drug|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
214367|NCT02151851|Biological|Certolizumab Pegol|Active substance: Certolizumab Pegol
Pharmaceutical Form: Prefilled syringes
Concentration: 200 mg/ml
Route of administration: Subcutaneous injection
214368|NCT02151851|Drug|Methotrexate|Active substance: Methotrexate
Pharmaceutical form: Tablet
Concentration: Maximum dose 10 mg per week
Route of administration: Oral
214369|NCT02151851|Other|Placebo|Active substance: Placebo
Pharmaceutical form: Prefilled syringes
Concentration: 0.9 % saline
Route of Administration: Subcutaneous injection
214370|NCT02151864|Drug|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
214371|NCT00134212|Drug|Epinephrine|
218804|NCT02282033|Device|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
218805|NCT02282059|Drug|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
218806|NCT00149292|Drug|placebo|
218807|NCT02282072|Device|Deep brain stimulation：PINS Stimulation System|
218808|NCT02282085|Drug|Aripiprazole Once-Monthly|
218809|NCT02282085|Drug|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
218810|NCT02282098|Drug|Colchicine|Colchicine 0.6mg twice daily
218811|NCT02282098|Drug|Placebo|Placebo Colchicine
218812|NCT02282111|Device|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|A core-needle will be used to take a biopsy from the subepithelial lesion
218813|NCT02282111|Device|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Needle knife sphincterotome will be used to take a biopsy of the subepithelial lesion
218814|NCT02282124|Behavioral|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
218815|NCT02282124|Behavioral|Usual Care, containing one session|Session takes place within the first three months after transplantation
218816|NCT02282137|Drug|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
218817|NCT00002373|Drug|Maribavir|
218818|NCT00149305|Other|Genetic analyses|
218819|NCT02282150|Drug|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
214064|NCT02118883|Other|Essentia Water|
214065|NCT02118883|Other|Bottled water|
214066|NCT02118896|Drug|FK506E|oral
214067|NCT02118909|Drug|Pracinostat|
214068|NCT02118909|Drug|Itraconazole|
218511|NCT02288988|Procedure|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
218512|NCT02289001|Behavioral|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
218513|NCT02289014|Other|online stress Management program|Active treatment group
218514|NCT02289027|Biological|cAd3-EBOZ vaccine|
218515|NCT02289027|Biological|Placebo (for cAd3-EBOZ vaccine)|Diluent
218516|NCT02289040|Procedure|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
218517|NCT02289079|Drug|Bupivacaine|
218518|NCT02289079|Drug|liposomal bupivacaine|
218519|NCT00150137|Drug|Methimazole|
218520|NCT02289092|Behavioral|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
218521|NCT02289105|Behavioral|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
218522|NCT02289118|Drug|[18F]-T807 imaging tracer|Tau Imaging tracer
218523|NCT02289131|Procedure|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
218524|NCT02289144|Drug|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
218525|NCT02289157|Device|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
218526|NCT02289170|Device|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
217916|NCT02300649|Drug|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
217917|NCT02300649|Drug|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
217918|NCT02300662|Device|Cycle Ergometer|Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
217919|NCT02300662|Other|Conventional physiotherapy|Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
217920|NCT02300675|Behavioral|therapeutic education program|
217921|NCT02300688|Drug|Treatment A|administration of 1 time administration of the test drug (Treatment A)
217922|NCT02300688|Drug|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
217923|NCT02300701|Drug|Xolair|According to manufacturer's instructions
218212|NCT02293889|Behavioral|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
218213|NCT02293889|Other|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
218214|NCT00151034|Drug|Carboplatin|
218215|NCT02296190|Drug|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
218216|NCT02296203|Drug|cetuximab|
218217|NCT02296203|Drug|irinotecan|
218218|NCT02296216|Device|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
218219|NCT02296229|Radiation|stereotactic body radiation therapy|Undergo SBRT
218220|NCT02296229|Other|quality-of-life assessment|Ancillary studies
218221|NCT02296229|Other|laboratory biomarker analysis|Correlative studies
218222|NCT02296229|Drug|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
218223|NCT02296242|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
217631|NCT02305563|Drug|BMS-936564|
217632|NCT02305563|Drug|Cytarabine|
217633|NCT02305589|Drug|Sugammadex|Muscle relax reversing agent
217634|NCT00152009|Drug|SPD503 (3 mg)|
217635|NCT02305602|Biological|VentriGel|VentriGel will be injected via MyoStar catheter and NOGA mapping
217636|NCT02305654|Procedure|ILND - Inguinal Lymph Node Dissection|
217637|NCT02305654|Drug|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
217638|NCT02307942|Procedure|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
217639|NCT02307955|Device|firefly|
217640|NCT02307955|Other|Standard of care|
217641|NCT02307968|Other|insulin injection site|insulin injected site between inner thigh and out thigh
217642|NCT02307981|Other|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
217643|NCT02307994|Drug|75IU uFSH|
217644|NCT00152243|Drug|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
217645|NCT02308007|Drug|Terconazole|
217646|NCT02308007|Drug|Metronidazole|
217924|NCT00151450|Drug|Venlafaxine XR|
217925|NCT02300701|Drug|Placebo|Placebo
217926|NCT02300714|Procedure|oblique view approach|
217927|NCT02300727|Drug|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
217928|NCT02300727|Drug|Mouthwash-standard pharmacy preparation|Standard mouth wash preparation administered by ingested mouth rinse three times per day.
The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.
217050|NCT02281253|Dietary Supplement|dietary fibre plus L-carnitine bread|The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.
Patients were recommended to consume the bread twice per day with main meals.
217051|NCT02281253|Dietary Supplement|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
217052|NCT02281266|Procedure|curative resection|
217334|NCT02313116|Device|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
217335|NCT02313142|Behavioral|Leg exercises|
217336|NCT02313155|Drug|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
217337|NCT02313155|Drug|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
217338|NCT02313168|Other|observation, inspection|
217339|NCT02313181|Other|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
217340|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
217341|NCT02313194|Device|Epidural Stimulation|Determine if epidural stimulation can improve motor function
217342|NCT00134641|Drug|gemcitabine|
217343|NCT02155803|Drug|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
217344|NCT02155816|Dietary Supplement|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
217345|NCT02155816|Dietary Supplement|Omega 3|Omega 3 daily for 8 weeks.
217346|NCT02155816|Dietary Supplement|Placebo|Medium chain triglycerides
217347|NCT02155829|Drug|Riluzole|
217348|NCT02155829|Drug|Placebo (for Riluzole)|
217349|NCT02155842|Behavioral|High intensity endurance exercise|
217350|NCT02155842|Behavioral|Moderate continuous endurance exercise|
216760|NCT02288351|Other|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
216761|NCT02288351|Other|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
216762|NCT02288351|Other|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
216763|NCT02288351|Other|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
216764|NCT02288351|Device|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
216765|NCT02288364|Drug|1% Lidocaine|
216766|NCT02288364|Drug|1% Lidocaine plus sodium bicarbonate|
216767|NCT02288377|Drug|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
216768|NCT00150059|Drug|Pimecrolimus Cream 1%|
216769|NCT02288390|Procedure|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
217053|NCT02281266|Drug|thymalfasin|1.6mg twice a week, 12 months
217054|NCT02281266|Drug|nucleoside analog (suggest to use entecavir)|
217055|NCT00149227|Drug|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
217056|NCT02281279|Biological|rituximab|Given IV
217057|NCT02281279|Drug|lenalidomide|Given PO
217058|NCT02281279|Drug|romidepsin|Given IV
217059|NCT02281279|Other|laboratory biomarker analysis|Correlative studies
217060|NCT02281292|Biological|LKA651 ophthalmic solution|
217061|NCT02281292|Biological|Ranibizumab ophthalmic solution|
217062|NCT02281292|Biological|Sham injection|Mock injection administered as an empty hub without needle
217063|NCT02281305|Drug|Colchicine|
212651|NCT02120820|Behavioral|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
212652|NCT02120820|Behavioral|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
212653|NCT02120820|Other|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
212654|NCT02123082|Device|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
212655|NCT02123108|Drug|Basiliximab|Peri-operative 40 mg IV dose and 20mg IV postoperative dose will be given in the treatment arm
212656|NCT00131573|Device|bion|battery powered bion microstimulator
212657|NCT02123121|Drug|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
212658|NCT02123121|Drug|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
212659|NCT02123121|Other|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
212660|NCT02123121|Other|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
212661|NCT02123134|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
212662|NCT02123134|Drug|Placebo|Phosphate buffered saline placebo for injection
212953|NCT02115997|Drug|prednisone|Tapered dose (start at 1 mg/kg) given daily until patients are off the drug.
212954|NCT02115997|Drug|rituximab [Ristova]|375 mg/m2 of body surface area given by intravenous infusion once weekly during Weeks 1 to 4.
212955|NCT00130923|Drug|oral risperidone|0.50-6.00 mg oral risperidone daily
212956|NCT02116010|Drug|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
212957|NCT02116010|Drug|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
212958|NCT02116010|Drug|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
212959|NCT02116023|Other|Orange flavored beverage|
212348|NCT02128022|Drug|Glibenclamide|Oral Glibenclamide 5mg
212349|NCT02128035|Procedure|With Lead Shield|A pelvic lead shield will be draped on patient from umbilicus to knees.
Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures.
212350|NCT02128048|Device|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
212351|NCT02128061|Drug|Lenalidomide|
212352|NCT02128061|Drug|Rituximab|
212353|NCT00132106|Drug|phentolamine|
212354|NCT02128074|Drug|KRX-0502|1g tablets of KRX-0502
212355|NCT02128087|Behavioral|Two-way SMS intervention|Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond "well" or press 2 or write 'Unwell" in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds "unwell" then the study coordinator will follow up with a call within 24 hours.
212356|NCT02130479|Behavioral|Treatment as Usual|
212357|NCT02130492|Radiation|FDG|The intervention arm consists of treatment with increasing doses of [18F]-Fluorodeoxyglucose.
212358|NCT02130505|Dietary Supplement|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
212359|NCT02130518|Drug|Auriclosene Irrigation Solution, 0.2%|
212360|NCT02130518|Drug|Auriclosene Vehicle Solution|
212361|NCT02130531|Drug|Emixustat HCl Tablet|Tablet for oral administration
212362|NCT02130531|Other|Placebo Tablet|Tablet for oral administration
212363|NCT02130557|Drug|Bosutinib|
212364|NCT02130557|Drug|Imatinib|
212365|NCT02130570|Other|Multi-Model Intensive Discharge Intervention|Inpatient medication safety interventions
Inpatient "discharge advocate"
Structured visiting nurse (VNA) appointments
Post-discharge phone call by primary care personnel within 2 business days of discharge
Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge
Improved communication between inpatient and primary care teams
High-risk patients will receive additional interventions as needed:
Home pharmacist visit
Enrollment in the Partners integrated Care Management Program (iCMP)
Enrollment in telemedicine programs for patients with CHF
Palliative care consultation regarding goals of care
Novel health information technology to facilitate communication and transfer of clinical information
212059|NCT02135484|Drug|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
212060|NCT02135510|Drug|metoclopramide|
212061|NCT02135510|Drug|dexamethason|
212062|NCT02135510|Drug|palonosetron|
212063|NCT00132925|Drug|Triamcinolone|
212064|NCT02135523|Radiation|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
212065|NCT02135536|Biological|NGM282|NGM282
212066|NCT02135549|Dietary Supplement|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
212067|NCT02135562|Dietary Supplement|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
212068|NCT02135562|Other|Informational Material|Receive carbohydrate reintroduction handout
212069|NCT02135562|Other|Dietary Education|Receive education on nutrition label reading for carbohydrates
212070|NCT02137889|Drug|VAY736|VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
212071|NCT02137902|Behavioral|Counselor intervention for tobacco/physical activity|Counselor-facing computer-assisted psychosocial intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program. for participants randomized to this intervention condition. With the focus on physical activity, Group 1 participants will receive a pedometer, a booklet for tracking their daily steps, and information and goal setting for increasing steps by 10% weekly to reach 10,000 steps/day. The focus of the physical activity intervention will be on building in more lifestyle moderate-to-vigorous physical activity.
212072|NCT02137902|Drug|Nicotine replacement therapy|The study will provide 12-weeks of NRT patch, lozenge, and gum of varying strengths, depending on patient level of nicotine dependence.
212073|NCT02137902|Behavioral|Intervention for managing hypertension/hypercholesterolemia|Counselor-facing computer-assisted psychosocial intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. The AN health plan covers antihypertensive and statins as a benefit to patients and would be prescribed as part of standard of care (i.e., not prescribed for the purposes of this research). Participants will receive a regionally-tailored AN cookbook of heart healthy recipes; have their blood pressure taken with the telecart by the health aid at each counseling session; and receive lipid profile feedback at 6-months.
212074|NCT02137915|Biological|Human Central Nervous System Stem Cells|
211447|NCT02150655|Biological|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
211448|NCT02150655|Biological|Placebo|
211740|NCT02143219|Drug|5-FU|5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:
If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one
If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course.
211741|NCT02143232|Device|remote patient monitor (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
211742|NCT02143245|Other|percutaneous synovial biopsy|
211743|NCT02143258|Procedure|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
211744|NCT02143271|Drug|KHK7580|Oral administration
211745|NCT02143284|Device|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
211746|NCT02143310|Device|EVP|
211747|NCT02143323|Drug|Augmentin tablet|
211748|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
211749|NCT02143336|Procedure|subcuticular suture|
211750|NCT02143336|Procedure|Skin staples|
211751|NCT02145520|Drug|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
211752|NCT00133796|Drug|Herceptin|IV
211753|NCT02145520|Other|placebo|use of placebo with standard therapy
211754|NCT02145546|Drug|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
211755|NCT02145546|Drug|Propafenone|150mg per 8 hours, 3 times per day
211756|NCT02145546|Drug|Sotalol|80mg twice per day.
211757|NCT02145559|Drug|Metformin XR|
211758|NCT02145559|Drug|Delayed Metformin|
211113|NCT02155699|Behavioral|Exercise 1|65% of VO2max and 2 sessions per week
211114|NCT02155699|Behavioral|Exercise 2|85% intensity and 3 sessions per peek
211115|NCT02155712|Device|Triathlon Tritanium Knee|Cementless
211116|NCT02155712|Device|Triathlon Knee|Cemented
211117|NCT02155725|Drug|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
211118|NCT00134628|Procedure|Sham treatment|Normal air under pressure (1.1 ATA)
211119|NCT02155725|Drug|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
211449|NCT02150668|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|
211450|NCT00134082|Drug|cyclophosphamide|
211451|NCT02150668|Behavioral|Homework Support Intervention (HSI)|
211452|NCT02150681|Behavioral|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
211453|NCT02150694|Procedure|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
211454|NCT02150694|Procedure|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
211455|NCT02150694|Other|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
211456|NCT02150694|Other|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
211457|NCT02150707|Drug|Insulin|Insulin therapy to treat hyperglycaemia
211458|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
211459|NCT02153073|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
211460|NCT02153086|Drug|Ramelteon|Ramelteon tablets 8 mg
210798|NCT02122185|Drug|docetaxel|Given IV
210799|NCT02122185|Drug|metformin hydrochloride|Given PO
210800|NCT02122185|Drug|placebo|Given PO
210801|NCT02122185|Other|laboratory biomarker analysis|Correlative studies
210802|NCT02122198|Drug|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
210803|NCT02122198|Drug|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
210804|NCT02122198|Drug|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
210805|NCT00131495|Drug|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
210806|NCT02122198|Drug|Placebo|placebo
210807|NCT02122211|Drug|Betaine supplement|
210808|NCT02122224|Other|High fiber breakfast|Breakfast will contain 10-11g fiber.
210809|NCT02122224|Other|High Protein Breakfast|Breakfast will contain 19-20g of protein.
210810|NCT02122224|Other|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
211120|NCT02155738|Drug|IV Acetaminophen|
211121|NCT02155738|Drug|IV normal saline|
211122|NCT02155751|Behavioral|Nutrition Lifestyle Intervention Program (NLIP)|The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
211123|NCT02155751|Behavioral|Exercise Lifestyle Intervention Program (ELIP)|The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
211124|NCT02155764|Device|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
210479|NCT02081001|Drug|G-Pump™ (glucagon infusion)|single subcutaneous infusion of each of 0.3 μg/kg, 1.2 μg/kg, and 2.0 μg/kg
210480|NCT02081014|Drug|G-Pen Mini™ (glucagon injection)|
210481|NCT02081027|Drug|Riluzole|
210482|NCT02081027|Drug|placebo|
210483|NCT02083640|Drug|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
210484|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
210485|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
210486|NCT02083653|Drug|Sym004|Sym004 will be administered as an intravenous infusion at a dose of 12 milligram per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
210487|NCT02083653|Drug|Sym004|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
210488|NCT02083653|Other|Best supportive care (BSC)|BSC will be provided at the Investigator's discretion and may include antibiotics, analgesics, antiemetics, blood transfusions and nutritional support.
210489|NCT02083653|Drug|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
210490|NCT02083653|Drug|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
210491|NCT02083666|Drug|SOBI002|Test Product
210492|NCT00127491|Procedure|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
210493|NCT02083666|Drug|Placebo|Reference product
210494|NCT02083679|Drug|Sym004 plus Platinum-Doublet Chemotherapy|Sym004 will be administered as an intravenous infusion at a dose range of 6 to 18 milligram per kilogram (mg/kg) as defined in the protocol until unacceptable toxicity, progressive disease, or withdrawal of consent in combination with 1 of the 3 platinum-doublet chemotherapy regimens as intravenous infusion: cisplatin/gemcitabine (cisplatin on Day 1 plus gemcitabine on Days 1 and 8, every 3 weeks), cisplatin/pemetrexed (cisplatin plus pemetrexed on Day 1, every 3 weeks), or carboplatin/paclitaxel (carboplatin plus paclitaxel on Day 1, every 3 weeks). Platinum-doublet chemotherapy will continue for a maximum of 6 treatment cycles.
210811|NCT02122237|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
210182|NCT02090660|Other|ICG Localization with Spy thoracoscope localization|
210183|NCT02090673|Drug|Exenatide|
210184|NCT02090686|Device|Pulsatile Cupping|8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.
Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)
210185|NCT02090686|Device|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
210186|NCT02090712|Procedure|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
210187|NCT02090725|Drug|3-4 Diaminopyridine|
210188|NCT00128167|Drug|Liquid CAIV-T|
210189|NCT02090738|Drug|Acetazolamide group|
210190|NCT02090738|Drug|Standard regimen group|
210495|NCT02083692|Drug|Metformin|
210496|NCT02083705|Procedure|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
210497|NCT02083705|Procedure|Control|CPR using 3:1 ratio
210498|NCT02083718|Biological|PBSC|
210499|NCT02083718|Biological|MSCs|
210500|NCT02083731|Biological|MSCs|
210501|NCT02083744|Behavioral|PsychoEducational Support|
210502|NCT02083744|Behavioral|Usual Care|Standard Heart Failure Care
210503|NCT00127504|Drug|Rifampin|
210504|NCT02083770|Behavioral|Cancer Clinical Trials Education Program|
210505|NCT02083783|Drug|TRI102|formulation containing active moiety
210506|NCT02083783|Other|Placebo|formulation without active moiety
210507|NCT00132652|Drug|Telbivudine|
210508|NCT02132416|Drug|Paracetamol|1g QID will be given to all patients unless allergies.
209884|NCT02095834|Drug|Carfilzomib|Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of a 28‐day cycle for Cycles 1-12 and on Days 1, 2, 15, and 16 for a 28‐day cycle for maintenance Cycles 13 and higher.
Expansion Cohort Starting Dose: Maximum tolerated dose from Phase I.
209885|NCT02095834|Drug|Bendamustine|Phase I Starting Dose: 50 mg/m2 by vein on Days 1 and 2 of cycles 1 - 3 and on Day 1 of each subsequent cycle.
Expansion Cohort Starting Dose: Maximum tolerated dose from Phase I.
209886|NCT02095834|Drug|Dexamethasone|20 mg by mouth or vein administered weekly on Days 1 , 2, 8, 9, 15, 16, 22 and 23 of cycles 1 - 3, on days 1, 2, 15 and 16 for cycles 4 - 12, then on days 1 and 2 of each subsequent cycle.
209887|NCT02098187|Drug|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) will be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. Iohexol (Omnipaque 300, 5 mL) (comparator agent) will then be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
209888|NCT02098187|Drug|At target dose MP-3180|MP-3180 1µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) will be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. Iohexol (Omnipaque 300, 5 mL) (comparator agent) will then be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
209889|NCT02098187|Drug|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) will be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. Iohexol (Omnipaque 300, 5 mL) (comparator agent) will then be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
209890|NCT02098187|Drug|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) will be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. Iohexol (Omnipaque 300, 5 mL) (comparator agent) will then be administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
210191|NCT02090764|Drug|Ozenoxacin|
210192|NCT02090764|Drug|Placebo|
210193|NCT02090777|Behavioral|Health Coach|
210194|NCT02090790|Drug|iv dexamethasone|2 ml 8 mg iv dexamethasone
210195|NCT02090790|Drug|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
210196|NCT02090790|Drug|serum physiologic|2 ml iv serum physiologic
210197|NCT02090816|Procedure|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
210198|NCT02090829|Drug|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
210199|NCT00128180|Drug|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
214372|NCT02151877|Drug|Inhaled NO|delivering inhaled NO into the cardiopulmonary bypass circuit during neonatal cardiac surgery
214373|NCT02151877|Drug|placebo|inhaled NO not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
214374|NCT02151890|Biological|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
214375|NCT02151903|Drug|DI-Leu16-IL2|
214376|NCT02154399|Other|Laboratory Biomarker Analysis|Correlative studies
214377|NCT00134472|Procedure|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
214378|NCT02154399|Procedure|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
214379|NCT02154399|Other|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
214380|NCT02154412|Other|Respiratory Muscle Training|
214381|NCT02154425|Procedure|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
214382|NCT02154425|Biological|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
214383|NCT02154438|Drug|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
214384|NCT02154451|Device|Infrared Imaging Device- ALIAS|Infrared Camera
214385|NCT02154464|Drug|Paracetamol|
214706|NCT00133965|Behavioral|Dignity Psychotherapy|At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
214069|NCT02118909|Drug|Ciprofloxacin|
214070|NCT02118922|Procedure|Brillouin imaging|
214071|NCT02118935|Other|Previously marketed cow's mlik-based infant formula|
214072|NCT00131131|Behavioral|exercise|
214073|NCT02118935|Other|Marketed cow's milk-based infant formula with prebiotics|
214074|NCT02118948|Behavioral|Abuse-focused intervention|
214075|NCT02118948|Behavioral|Sexual behavior-focused intervention|
214076|NCT02118961|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
214077|NCT02118961|Biological|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
214078|NCT02118974|Procedure|Hysterectomy|Hysterectomy
214079|NCT02121301|Drug|Placebo SkQ1 (Vehicle)|
214080|NCT02121314|Drug|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
214081|NCT02121327|Other|disease management|disease management program include self management education
214082|NCT02121327|Other|usual care|usual care group receive regular outpatient treatment
214083|NCT02121340|Behavioral|Behavioral Activation|
214084|NCT02121353|Drug|Lucentis|Single‐use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha‐trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra‐vitreal
214085|NCT02121353|Drug|PF582|Single‐use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha‐trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra‐vitreal
214086|NCT00131391|Drug|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
214087|NCT02121366|Procedure|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
214386|NCT02154464|Drug|Placebo|
214387|NCT02154477|Drug|intranasal insulin|
218527|NCT02289170|Device|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
218820|NCT02282150|Drug|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
218821|NCT02282163|Drug|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
218822|NCT02282176|Drug|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
218823|NCT02282176|Drug|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
218824|NCT02284542|Procedure|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
218825|NCT02284542|Procedure|Non-Awake|The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.
(Falowski et al., 2011).
218826|NCT02284555|Drug|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
218827|NCT02284568|Drug|Laquinimod|Laquinimod 0.6 mg, 1.5 mg
218828|NCT02284568|Drug|Placebo|Placebo
218829|NCT02284594|Behavioral|text message|series of text messages regarding influenza vaccination
218830|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
218831|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
218832|NCT00149630|Other|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
218833|NCT02284607|Drug|Placebo|Matching placebo to MHAA4549A administration
218834|NCT02284620|Procedure|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
218835|NCT02284620|Procedure|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
218836|NCT02284646|Other|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
218224|NCT02296255|Biological|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
218225|NCT00151034|Drug|Gemcitabine|
218226|NCT02296268|Behavioral|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
218227|NCT02296281|Drug|Pirfenidone|
218228|NCT02296294|Drug|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
218229|NCT02296294|Device|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
218230|NCT02296307|Other|Blood test: CA-125 biomarker|CA-125 biomarker blood test at visit 1, day 1.
CA-125 biomarker blood test at visit 3, week 6.
218231|NCT02296307|Other|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 2, week 2
218232|NCT02296307|Other|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
218528|NCT02289183|Procedure|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
218529|NCT02289183|Procedure|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
218530|NCT00150475|Procedure|Powered Air purifying respirator|
218531|NCT02291263|Biological|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
218532|NCT02291263|Biological|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
218533|NCT02291289|Drug|Cetuximab|500 mg/m2 via IV infusion on Day 1 of every 2-week cycle
218534|NCT02291289|Drug|FOLFOX induction regimen|Administered per investigator discretion in accordance with local standards (e.g. FOLFOX-4, FOLFOX-6, modified FOLFOX-6, or FOLFOX-7)
218535|NCT02291289|Drug|Fluoropyrimidine (5-FU or capecitabine)|Per Investigator discretion; or 3,000 mg 5-FU administered via 46-hour IV infusion on Day 1 of every 2-week cycle; or 1000 mg/m2 twice-daily capecitabine (b.i.d.) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
218536|NCT02291289|Drug|MPDL3280A|800 mg MPDL3280A via 60-minute IV infusion on Day 1 of every 2-week cycle
218537|NCT02291289|Drug|Vemurafenib|960 mg vermurafenib b.i.d. by mouth
217929|NCT02300727|Drug|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
217930|NCT02300740|Dietary Supplement|Nicotinamide riboside|NIAGEN, ChromaDex
217931|NCT02300753|Drug|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
217932|NCT02300779|Dietary Supplement|Low-residue diet|Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.
Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.
Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted.
217933|NCT02303080|Other|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
217934|NCT02303080|Other|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
217935|NCT02303080|Other|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
217936|NCT02303080|Other|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
217937|NCT02303093|Biological|Octagam IVIG 5% or 10%|
217938|NCT02303106|Drug|Lamotrigine|
217939|NCT02303119|Drug|Rituximab IV|intra-venous, 375 mg/m²
217940|NCT02303119|Drug|Rituximab SC|sub-cutaneous, 1400 mg
217941|NCT00151736|Drug|Chlorambucil|Chlorambucil 2mg tablets
217942|NCT02303132|Other|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
217943|NCT02303171|Drug|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
217944|NCT02303171|Drug|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
217945|NCT02303184|Drug|suprachoroidal CLS-TA + IVT aflibercept|suprachoroidal injection of CLS-TA following a 2 mg intravitreal injection of aflibercept
218233|NCT02296320|Drug|MEDI4893|MEDI4893 (low or high dose)
218234|NCT02296320|Other|Placebo|Placebo
218235|NCT02296333|Drug|ondansetron|8 mg intravenous in the skin closure
217351|NCT02155855|Other|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
217352|NCT02155855|Other|Control|Routine care
217353|NCT00134641|Drug|vinorelbine|
217647|NCT02308007|Drug|Terconazole/metronidazole|
217648|NCT02308020|Drug|Abemaciclib|Administered orally
217649|NCT02308033|Drug|Metronidazole|
217650|NCT02308033|Drug|Gel vehicle|
217651|NCT02308046|Drug|Terconazole|
217652|NCT02308046|Drug|Placebo|
217653|NCT02308059|Other|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
217654|NCT02308059|Other|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
217655|NCT00152243|Procedure|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
217656|NCT02308072|Drug|Olaparib|50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
217657|NCT02308072|Drug|Cisplatin|35 mg/m^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m^2)
217658|NCT02308072|Radiation|IMRT|2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
217659|NCT02308085|Other|Endocrine therapy interruption|3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.
Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference.
217660|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
217661|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
217662|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
217064|NCT02281318|Biological|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
217065|NCT00149539|Drug|Buprenorphine/naloxone|
217066|NCT02283684|Procedure|Greenlight laser PVP|Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
217067|NCT02283684|Procedure|Bipolar PKVP|Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
217068|NCT02283697|Behavioral|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the DASH diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
217069|NCT02283697|Other|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
217070|NCT02283710|Drug|Pentoxifylline|Pentoxifylline 600 mg BD
217071|NCT02283710|Behavioral|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
217072|NCT02283723|Other|TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
217073|NCT02283723|Other|Usual care|While waiting for the TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
217354|NCT02155868|Other|Correction rSO2 desaturation.|Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it.
In case of rSO2 decrease less than 60% correct:
head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood < 35 mmHg; mean arterial pressure < 60 mmHg; central venous pressure > 10 mmHg; cardiac index < 2.0 l/min/m2; mixed venous oxygen saturation < 60%; hemoglobin < 65 g/L during cardiopulmonary bypass or hemoglobin < 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption.
217355|NCT02155868|Other|Standard treatment|Standard treatment
217356|NCT02155881|Drug|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
217357|NCT02155881|Drug|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
212960|NCT02116036|Drug|Rivaroxaban|
212961|NCT02116049|Behavioral|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
212962|NCT02116049|Behavioral|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
212963|NCT02116062|Device|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
212964|NCT02116062|Device|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
212965|NCT02116062|Device|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
212966|NCT00130936|Drug|Epirubicin|
212967|NCT02116075|Procedure|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
212968|NCT02116075|Procedure|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
212969|NCT02116088|Behavioral|Teacher Coaching|
213242|NCT02151279|Other|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
213243|NCT02151279|Other|Control|
213244|NCT02151305|Drug|Propofol, remifentanil|
213245|NCT02151305|Drug|Sevoflurane|
213246|NCT02151331|Behavioral|External Facilitation|Non-responding sites randomized to receive external facilitation
213247|NCT02151331|Behavioral|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
213248|NCT02151344|Biological|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
212663|NCT02123160|Behavioral|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
212664|NCT02123160|Behavioral|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
212665|NCT02123186|Other|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
212666|NCT02123199|Drug|Indacaterol (Onbrez®) /QAB149|
212667|NCT00131599|Drug|5FU/LV|5FU/LV
212668|NCT02123212|Other|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
212669|NCT02123212|Other|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
212670|NCT02123212|Other|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
212671|NCT02123238|Other|bed positioning|
212672|NCT02125214|Device|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
212673|NCT02125227|Drug|Rosuvastatin, Metformin, YH14755|single dose
212674|NCT02125227|Drug|YH14755|single dose
212675|NCT02125240|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
212676|NCT02125240|Drug|Placebo|1 tablet three times daily by mouth
212677|NCT02125253|Drug|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
212075|NCT02137928|Drug|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
212366|NCT00132431|Drug|Sensipar|
212367|NCT02130583|Behavioral|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
212368|NCT02130583|Behavioral|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
212369|NCT02130596|Behavioral|Acceptance-Based Behavioral Intervention|
212370|NCT02130596|Other|Nutritional Counselling|
212371|NCT02130609|Device|Skintel|
212372|NCT02130622|Drug|Promethazine|
212373|NCT02130622|Drug|Sugar pill|
212374|NCT02130635|Drug|GSK2269577 1000 mcg|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
212375|NCT02130635|Drug|Placebo|Lactose administered using a dry powder inhaler device
212376|NCT02130648|Other|A sampling of blood|A sampling of blood de 14 ml
212377|NCT00132444|Drug|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
212378|NCT02130661|Drug|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
212379|NCT02130661|Drug|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
212380|NCT02130661|Drug|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
212381|NCT02133170|Behavioral|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
212382|NCT02133183|Other|Laboratory Biomarker Analysis|Correlative studies
212383|NCT02133183|Other|Pharmacological Study|Correlative studies
212384|NCT02133183|Drug|Sapanisertib|Given PO
212385|NCT00132717|Drug|Comparator: fluvastatin|
211759|NCT02145559|Drug|Sirolimus|
211760|NCT02145585|Device|Test of pharmacologic anesthesia robot (labVIEW® software)|
211761|NCT02145598|Drug|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
211762|NCT02145598|Drug|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
212076|NCT00133224|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
212077|NCT02137928|Drug|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
212078|NCT02137941|Behavioral|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
212079|NCT02137941|Behavioral|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
212080|NCT02137954|Drug|Lidocaine|
212081|NCT02137954|Drug|Placebo|
212082|NCT02137967|Procedure|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medicament for primary molars
212083|NCT02137967|Procedure|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament for primary molars
212084|NCT02137967|Drug|2.5% NaOCl|
212085|NCT02137967|Drug|20% Formocresol|
212086|NCT02137993|Drug|A-prexa|A-prexa 5-20 mg for 6 weeks
212087|NCT00133224|Drug|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
212088|NCT02137993|Drug|Zyprexa|Zyprexa 5-20 mg for 6 weeks
212089|NCT02138006|Drug|Intensive insulin treatment|
212090|NCT02140580|Device|Minimally invasive surfactant therapy|Active Comparator
212091|NCT02140580|Other|Continuation on CPAP|Sham Comparator
212092|NCT02140593|Drug|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
211461|NCT02153099|Drug|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
211462|NCT02153099|Drug|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
211463|NCT02153112|Biological|GI.1/GII.4 (15/15) - MPL (50)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 50 µg monophosphoryl lipid A (MLP) for IM injection
211464|NCT00134329|Procedure|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
211465|NCT02153112|Biological|GI.1/GII.4 (15/50) - MPL (50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 50 µg monophosphoryl lipid A (MLP) for IM injection
211466|NCT02153112|Biological|GI.1/GII.4 (50/50) - MPL (50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 50 µg monophosphoryl lipid A (MLP) for IM injection
211467|NCT02153112|Biological|GI.1/GII.4 (15/15) - MPL (15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 15 µg monophosphoryl lipid A (MLP) for IM injection
211763|NCT00002251|Drug|Ganciclovir|
211764|NCT00133809|Drug|Transplantation of Human Islets|Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
211765|NCT02145611|Drug|Glibenclamide|Glibenclamide
211766|NCT02145611|Drug|Vildagliptin|Vildagliptin
211767|NCT02145624|Drug|Repevax|vaccine
211768|NCT02145624|Drug|Boostrix-IPV|vaccine
211769|NCT02145637|Drug|Afatinib plus Ruxolitinib combination therapy|
211770|NCT02145650|Other|No Intervention|There is no intervention administered in this study.
211771|NCT02145676|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
211772|NCT02145676|Drug|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
211773|NCT02145689|Biological|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
211774|NCT02145702|Other|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
211775|NCT00133822|Drug|Sertraline and Risperidone|
211125|NCT02155764|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
211126|NCT02155764|Device|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
211127|NCT02155777|Drug|OrthoNovum 1/35|
211128|NCT02155790|Device|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
211129|NCT00131053|Drug|Prednisolone|
211130|NCT02117674|Procedure|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
211131|NCT02117674|Procedure|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
211132|NCT02117674|Procedure|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
211133|NCT02117687|Drug|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
211134|NCT02117687|Drug|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
211135|NCT02117700|Dietary Supplement|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
211136|NCT02117700|Dietary Supplement|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
211137|NCT02117700|Other|Placebo twice/day|Placebo capsules twice/day for 16 weeks
211138|NCT02117713|Drug|LUM001|
211468|NCT02153112|Biological|GI.1/GII.4 (15/50) - MPL (15)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 15 µg monophosphoryl lipid A (MLP) for IM injection
211469|NCT02153112|Biological|GI.1/GII.4 (50/50) - MPL (15)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 15 µg monophosphoryl lipid A (MLP) for IM injection
211470|NCT02153112|Biological|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
211471|NCT02153112|Biological|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
211472|NCT02153112|Biological|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
210812|NCT02122250|Behavioral|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
210813|NCT02122250|Behavioral|Static web-based materials|Static web-based materials
210814|NCT02122276|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
210815|NCT02122289|Device|Application of Smartphone|Weekly questionnaire on smartphone
210816|NCT00131495|Drug|Placebo patch|placebo patch changed twice a week for one year
210817|NCT02122289|Other|No application Smartphone|No weekly questionnaire on smartphone
210818|NCT02122302|Device|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
210819|NCT02122315|Other|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
210820|NCT02122315|Other|Physical therapy|Best-evidence physical therapy intervention
210821|NCT02122328|Procedure|Sequential laser photocoagulation of communicating vessels.|
210822|NCT02122328|Procedure|Selective laser photocoagulation of communicating vessels|
210823|NCT02124265|Drug|CeraLyte 90|This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).
Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.
Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.
5. Patients will be monitored according to standard of care.
a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used.
210824|NCT02124278|Drug|PUL-042 Inhalation Solution|
210825|NCT02124291|Device|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
210826|NCT00131768|Device|Synvisc (hylan G-F 20)|
210827|NCT02124304|Device|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
210509|NCT02132416|Procedure|Surgical management|Fracture stabilization
210510|NCT02132429|Drug|AMG 333|Oral administration available in varying dose strength.
210511|NCT02132429|Drug|Placebo|Placebo containing no active drug
210512|NCT02132442|Dietary Supplement|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
210513|NCT02132455|Procedure|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
210514|NCT02132468|Drug|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
210515|NCT02132481|Other|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
210516|NCT02132481|Other|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
210829|NCT02124317|Drug|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
210830|NCT02124330|Dietary Supplement|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
210831|NCT02124330|Dietary Supplement|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
210832|NCT02124330|Dietary Supplement|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
210833|NCT02124343|Other|Interval Exercise|
210834|NCT02124356|Other|Evaluation of functional performance|
210835|NCT02124369|Drug|Abraxane|125mg/m2, IV, on days 1,8 & 15 of each 28 day cycle, up to 6 cycles.
210836|NCT02124369|Drug|Gemcitabine|1000mg/m2, IV, on days 1,8 & 15 of a 28 day cycle, up to 6 cycles.
210837|NCT00131781|Behavioral|Cognitive Therapy|
210838|NCT02124408|Behavioral|Personalized Behavioral Intervention|
210839|NCT02124421|Procedure|Cytoreductive Surgery (CRS)|Cytoreductive surgery
210200|NCT02090829|Other|Placebo|Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.
Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.
One dose equals 6 spray puffs (3 puffs in each nostril).
210201|NCT02090842|Dietary Supplement|Ca-caseinate|
210202|NCT02090842|Dietary Supplement|Maltodextrin|
210203|NCT02090842|Dietary Supplement|Whey protein isolate|
210204|NCT02090868|Other|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
210205|NCT02093195|Drug|Symbicort turbuhaler|
210206|NCT00128414|Drug|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
210207|NCT02093221|Biological|180 mg/kg Alpha1-PI|
210208|NCT02093221|Biological|90 mg/kg Alpha1-PI|
210209|NCT02093221|Biological|Placebo|
210210|NCT02093234|Behavioral|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
210211|NCT02093234|Behavioral|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
210212|NCT02093234|Behavioral|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
210517|NCT02132481|Other|EMA+EMI|The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current "risk of use in the next 7 days" .
210518|NCT00132665|Procedure|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
210519|NCT02132481|Other|Neither - RSAU|The "neither" smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens.
210520|NCT02132494|Behavioral|Physical activity|
210521|NCT02132520|Device|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
214707|NCT02146716|Other|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
214708|NCT02146729|Procedure|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
214709|NCT02146729|Procedure|Open Treatment|Midline posterior incision with instrumentation.
214710|NCT02146742|Drug|ASP1707|oral
214711|NCT02146742|Drug|Placebo|oral
214712|NCT02146781|Biological|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.
Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe.
214713|NCT02146781|Other|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
214714|NCT02146794|Device|Renal denervation|Renal denervation
214715|NCT02146807|Device|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
214716|NCT02146820|Device|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
214717|NCT00134030|Biological|peginterferon alfa-2b|Given subcutaneously
214718|NCT02149381|Behavioral|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
214719|NCT02149381|Behavioral|Befriending|Social support intervention, sessions once per week
214720|NCT02149381|Other|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
214721|NCT02149394|Other|Ice popsicle|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.
The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
215011|NCT02142166|Procedure|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
215012|NCT02142166|Procedure|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
214388|NCT00134485|Drug|torcetrapib/atorvastatin|
214389|NCT02154477|Drug|placebo (intranasal saline)|
214390|NCT02154490|Drug|Docetaxel|Given IV
214391|NCT02154490|Biological|Durvalumab|Given IV
214392|NCT02154490|Drug|Erlotinib Hydrochloride|Given PO
214393|NCT02154490|Drug|FGFR Inhibitor AZD4547|Given PO
214394|NCT02154490|Biological|Ipilimumab|Given IV
214395|NCT02154490|Other|Laboratory Biomarker Analysis|Correlative studies
214396|NCT02154490|Biological|Nivolumab|Given IV
214397|NCT02154490|Drug|Palbociclib|Given PO
214398|NCT02154490|Biological|Rilotumumab|Given IV
214399|NCT00134485|Drug|atorvastatin|
214400|NCT02154490|Drug|Taselisib|Given PO
214401|NCT02154503|Device|topical 5% Minoxidil (Microneedling)|
214402|NCT02154516|Device|ODH Hip System|
214403|NCT02154529|Drug|Tesevatinib in combination with Trastuzumab|
214404|NCT02154542|Device|Neurovent Monitor XIII|
214405|NCT02116647|Behavioral|Psychoanalytic therapy|
214406|NCT00131001|Procedure|contrast-enhanced magnetic resonance angiography|
214407|NCT02116660|Drug|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
214408|NCT02116660|Drug|Nevirapine|Nevirapine (NVP) 200 mg tablets
214409|NCT02116660|Drug|Lamivudine|Lamivudine (3TC) 150 mg tablets
214410|NCT02116660|Drug|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
214411|NCT02116660|Drug|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
214412|NCT02116660|Drug|Lopinavir|Lopinavir (LPV) 200 mg tablets
218837|NCT02284659|Device|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
218838|NCT02284659|Device|FES- Sham|
218839|NCT02284672|Drug|Dexmedetomidine|
218840|NCT02284672|Drug|Normal saline|
214088|NCT02121379|Behavioral|pulmonary rehabilitation|
214089|NCT02121392|Device|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 6ml/h.
214090|NCT02121392|Device|Adductor Canal Nerve Block Sham Catheter|
214091|NCT02121392|Drug|lidocaine|
214092|NCT02121405|Procedure|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
214093|NCT02121405|Radiation|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
214094|NCT02121405|Drug|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
214095|NCT02121405|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
214096|NCT02121418|Drug|Cytarabine|Given IV
214097|NCT00002235|Drug|Indinavir sulfate|
214098|NCT02123602|Other|lower extremity training only|
214099|NCT02123615|Drug|Gadolinium For abdomen|Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
214100|NCT00002236|Drug|Indinavir sulfate|
218538|NCT02291289|Drug|bevacizumab|5 mg/kg bevacizumab via 15-30 minute intraveneous (IV) infusion on Day 1 of every 2-week cycle per local prescribing information
218539|NCT02291302|Other|integrated pest management|integrated pest management and environmental strategy
218540|NCT02291302|Other|air purifier|air purifiers
218541|NCT00150488|Device|Uracyst|2% weekly for 6 weeks, monthly for 4 months
218542|NCT02291302|Other|No intervention (control)|no integrated pest management and sham air purifier
218543|NCT02291328|Other|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
218544|NCT02291328|Other|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
218545|NCT02291341|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
218546|NCT02291341|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
218547|NCT02291354|Drug|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
218548|NCT02291354|Other|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
218549|NCT02291354|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
218841|NCT02284685|Behavioral|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
218842|NCT02284698|Other|Health Education|Heath education will be given through awareness creation & pamphlet distribution
218843|NCT00149643|Drug|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
218844|NCT02284711|Device|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
218845|NCT02284711|Device|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
218846|NCT02284724|Procedure|Dry Needling|
218847|NCT02284724|Procedure|Sham Needling|
218236|NCT00151047|Drug|Capecitabine|
218237|NCT02296333|Drug|isotonic|8 mg intravenous in the skin closure
218238|NCT02296346|Drug|SoluMedrol|Infusion of drug subcutaneously, once a month.
218239|NCT02296346|Device|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
218240|NCT02298283|Drug|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
218241|NCT02298283|Radiation|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
218242|NCT02298309|Other|Test-and-Treat TB|
218243|NCT02298322|Device|CoolSculpting System|
218244|NCT02298335|Drug|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
218245|NCT02298348|Drug|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
218246|NCT02298348|Drug|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
218247|NCT02298348|Drug|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
218248|NCT02298361|Other|Health insurance outreach IT tools|IT tools that support Community Health Centers in children's health insurance outreach efforts ("insurance outreach IT tools"), adapted from tools proven to support chronic disease management.
218249|NCT00151242|Drug|Pegfilgrastim|6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
218250|NCT02298374|Other|Homecare reablement|
218251|NCT02298374|Other|usual care|
218252|NCT02298387|Drug|OMP-305B83|intravenous (in the vein) infusions
218253|NCT02298400|Device|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
218254|NCT02298400|Device|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
218255|NCT02298400|Device|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
217663|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
217664|NCT02310633|Behavioral|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
217665|NCT02310633|Behavioral|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
217666|NCT02310646|Drug|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
217667|NCT02310646|Drug|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
217946|NCT02303184|Drug|suprachoroidal sham + IVT aflibercept|suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
217947|NCT02303197|Drug|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
217948|NCT02303210|Device|Naida UP/SP|Standard Power Hearing instruments including different frequency lowering techniques
217949|NCT02303223|Drug|Propofol|
217950|NCT02303249|Other|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
217951|NCT02303262|Drug|Mocetinostat|
217952|NCT00151736|Drug|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
217953|NCT02303262|Drug|Gemcitabine|
217954|NCT02303275|Behavioral|Lifestyle Change|Intervention: Lifestyles Change Program (LCP)
The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:
Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes.
217955|NCT02303275|Behavioral|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
217956|NCT02305654|Drug|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
217957|NCT02305654|Drug|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
217358|NCT02155894|Behavioral|Disease control, Telemedicine, doctor|Control of disease activity by a telemedicine consultation carried out by a doctor.
The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.
Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.
During telephone consultation, updated clinical test results will be available through the electronic medical system.
217359|NCT02155894|Behavioral|Disease control, Telemedicine, nurse|Control of disease activity by a telemedicine consultation carried out by a nurse.
The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.
Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.
During telephone consultation, updated clinical test results will be available through the electronic medical system.
217360|NCT02155920|Drug|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
217361|NCT02278861|Drug|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
217362|NCT02278861|Drug|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
217363|NCT02278861|Drug|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
217364|NCT02278887|Procedure|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
217365|NCT02278887|Drug|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
217366|NCT02278887|Drug|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
217367|NCT02278887|Drug|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
217368|NCT02278887|Drug|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
217369|NCT02278900|Other|Communication aids|Question Prompt list Audiofile
217370|NCT02278913|Drug|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
217668|NCT02310659|Other|No intervention|No intervention
217669|NCT00002386|Drug|Stavudine|
217670|NCT00152477|Drug|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
217671|NCT02310672|Drug|Macitentan|All patients take open-label macitentan 10mg o.d.
213249|NCT02151344|Biological|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
213250|NCT02151357|Drug|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
213251|NCT02151383|Drug|Serelaxin|Serelaxin will be administered intravenously for up to 48 hours.
213252|NCT00134160|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
213253|NCT02151396|Behavioral|Working memory training|
213254|NCT02151396|Device|Functional magnetic resonance imaging (fMRI)|
213255|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
213256|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
213257|NCT02151409|Drug|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
213258|NCT02151422|Behavioral|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
213259|NCT02151448|Biological|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
213260|NCT02151448|Drug|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
213559|NCT02143960|Device|VelaShape III|Subjects will receive one treatment to their entire waist / love‐handle/ flanks area in a split‐waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
213560|NCT02143960|Device|CoolSculpt|Noninvasive Cryolipolysis
213561|NCT02146261|Drug|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
213562|NCT02146261|Drug|Placebo|Subcutaneous administration of placebo
212678|NCT02125253|Drug|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
212970|NCT02118480|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
212971|NCT02118480|Other|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
212972|NCT02118493|Device|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
212973|NCT02118506|Other|Physical practice|The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.
Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility.
212974|NCT02118506|Other|Mental and physical practice|The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.
Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.
Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.
Finally, they were submitted to a physical gait training. They executed 400 steps.
They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility.
212975|NCT02118519|Biological|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
212976|NCT00131079|Behavioral|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
212977|NCT02118532|Device|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
212978|NCT02118558|Device|Negative Pressure Wound Therapy (NPWT)|
212979|NCT02118558|Drug|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
212980|NCT02118584|Drug|etrolizumab|105 mg administered subcutaneously every 4 weeks for up to 7 years or until either commercial availability or the Sponsor's decision to terminate the study.
212981|NCT02118610|Drug|L-tetrahydropalmatine (30mg)|Active comparator
212386|NCT02133183|Procedure|Therapeutic Conventional Surgery|Undergo surgery
212387|NCT02133196|Drug|Aldesleukin|Aldesleukin at 720,000 (cohort 1) or 72,000 (cohort 2) IU/kg IV based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in cohort 1 and 12 doses in cohort 2.
212679|NCT02125253|Drug|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
212680|NCT02125266|Drug|V404|Sustained Release
212681|NCT00131846|Drug|No diuretics|Any antihypertensive regimen other than diuretics
212682|NCT02125279|Drug|Calcitriol|
212683|NCT02125292|Drug|Mesalamine|
212684|NCT02125305|Drug|Metformin|
212685|NCT02125318|Drug|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
212686|NCT02125331|Procedure|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
212687|NCT02125344|Drug|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
212688|NCT02125344|Drug|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
212689|NCT02125344|Drug|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
212690|NCT02125344|Drug|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
212691|NCT02125344|Drug|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
212692|NCT00131859|Procedure|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
212693|NCT02125344|Drug|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
212694|NCT02125344|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
212695|NCT02125344|Drug|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is <70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is <50 kg, both dosages will be reduced to 500 mg each.
212093|NCT02140593|Drug|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
212094|NCT02140606|Drug|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
212095|NCT00133406|Drug|zinc|40 mg twice weekly for 12 months
212096|NCT02140619|Behavioral|multiple health education interventions|
212097|NCT02140632|Procedure|Local methylprednisolone acetate and lidnocaine injection|
212098|NCT02140632|Device|wrist splinting|
212388|NCT02133196|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
212389|NCT02133196|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
212390|NCT02133196|Biological|Young TIL|On day 0, TIL will be administered intravenously over 20 to 30 minutes one to four days after last dose of fludarabine.
212391|NCT02133209|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. Intervention involves a standardized mindfulness-based stress reduction (MBSR) group intervention following the guidelines originally conceived and developed by the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
212392|NCT02133209|Behavioral|Stress Management for Headaches (SMH)|Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
212393|NCT02133222|Procedure|blood sample|
212394|NCT02133235|Procedure|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
212395|NCT02133235|Procedure|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
212396|NCT00132717|Drug|Comparator: lovastatin|
212397|NCT02133274|Behavioral|Brief Psychosocial Intervention|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
212398|NCT02133274|Other|Early Palliative Care|Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
212399|NCT02133287|Device|AVI® Arsenic trioxide drug eluting stent delivery system|
211776|NCT02145702|Procedure|Standard Care Dialysis|12 weeks of standard of care.
211777|NCT02145715|Drug|Velcade|
211778|NCT02145715|Drug|Thalidomide|
211779|NCT02145715|Drug|Dexamethasone|
211780|NCT02148094|Drug|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
211781|NCT02148107|Drug|BI 691751|BI 691751 Dose 1
211782|NCT02148107|Drug|BI 691751|BI 691751 Dose 2
211783|NCT02148107|Drug|BI 691751|BI 691751 Dose 3
211784|NCT02148107|Drug|BI 691751|BI 691751 Dose 4
211785|NCT02148107|Drug|BI 691751|BI 691751 Dose 5
212099|NCT02140658|Behavioral|multiple health education interventions|
212100|NCT02140658|Behavioral|conventional health education|
212101|NCT02140684|Device|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
212102|NCT02140697|Dietary Supplement|Hippophae rhamnoides L. Leaf Extract (3g/day)|
212103|NCT02140697|Dietary Supplement|Placebo (3g/day)|
212104|NCT02140710|Procedure|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
212105|NCT02140723|Radiation|preoperative short course radiation|
212106|NCT00133419|Drug|Vitamin + Zinc + micronutrient mixture|
212107|NCT02140736|Drug|Epoetin biosimilar|
212108|NCT02140749|Dietary Supplement|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
212109|NCT02140749|Dietary Supplement|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
211473|NCT02153112|Biological|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
211474|NCT02153112|Biological|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 167 μg aluminum hydroxide for IM injection
211475|NCT00134342|Other|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
211476|NCT02153112|Drug|Placebo|Placebo saline solution
211477|NCT02153125|Drug|Eplerenone|
211478|NCT02153138|Device|Endo-pat 2000|The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:
The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.
The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution
211479|NCT02153138|Device|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
211480|NCT02115360|Drug|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
211481|NCT02115360|Drug|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
211482|NCT02115373|Drug|MSC2156119J|MSC2156119J tablet will be administered in a total dose of 300 to 500 milligram (mg) orally once daily for repeated 21-day cycles until disease progression, intolerable toxicity, death, or withdrawal from treatment.
211786|NCT00134004|Drug|cyclophosphamide|
211787|NCT02148107|Drug|BI 691751|BI 691751 Dose 6
211788|NCT02148107|Drug|Placebo|Placebo
211789|NCT02148120|Drug|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
211790|NCT02148120|Drug|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
211791|NCT02148120|Drug|Placebo|
210828|NCT02124317|Drug|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
211139|NCT02117726|Drug|Dexmedetomidine,midazolam|
211140|NCT00131053|Drug|Dexamethasone|
211141|NCT02117726|Drug|Propofol,midazolam|
211142|NCT02117739|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
211143|NCT02117739|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
211144|NCT02117752|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
211145|NCT02117752|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
211146|NCT02117752|Drug|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
211147|NCT02117752|Drug|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
211148|NCT02117765|Drug|Ustekinumab|
211149|NCT02117778|Procedure|Continuous Nerve Block|
211150|NCT02117791|Drug|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
211151|NCT00131053|Drug|Vincristine|
211152|NCT02117804|Other|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
211153|NCT02117817|Drug|BKM120|
211154|NCT02117817|Drug|Nabpaclitaxel|Given IV
211155|NCT02117830|Drug|Androxal 25 mg capsules|
211156|NCT02120118|Drug|Taxotere|20mg/m2
211157|NCT00131248|Drug|placebo|
211158|NCT02120144|Other|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
210840|NCT02124421|Drug|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
210841|NCT02124421|Other|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
210842|NCT02124421|Procedure|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
210843|NCT02124421|Drug|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
210844|NCT02124421|Drug|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
210845|NCT02124421|Drug|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
210846|NCT02127112|Procedure|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
210847|NCT02127112|Procedure|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
210848|NCT02127125|Drug|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
210849|NCT02127125|Drug|Synbiotic|Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
210850|NCT02127125|Drug|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
210851|NCT02127138|Device|XIENCE V® , Abbott Vascular|
211163|NCT02120157|Other|Bone Marrow Infusion|Bone Marrow Transplant
211164|NCT02120157|Drug|Tacrolimus|Immunosuppressive Drug Administered
211165|NCT02120157|Drug|Mycophenolate mofetil|Immunosuppressive Drug Administered
211166|NCT02120170|Procedure|Colon polypectomy|
211167|NCT02120183|Behavioral|Psycho-educational support group therapy|Weekly sessions lasting 60 minutes. Topics addressed each week:
Week 1: Coping with the diagnosis of loved one and dealing with uncertainty
Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)
Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)
Week 4: The emotions of caregiving (handling emotional reactivity)
211168|NCT00131261|Drug|PXD101|
211169|NCT02120196|Drug|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
211170|NCT02120196|Drug|Norfloxacin|FDA approved:400mg once daily
210522|NCT02132520|Behavioral|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
210523|NCT02132533|Drug|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
210524|NCT02132533|Drug|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
210525|NCT02132533|Other|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
210526|NCT02132546|Drug|Chlorhexidine|
210527|NCT02132559|Drug|DHEA|
210528|NCT02132572|Device|NATRELLE® 410 Breast Implants|Surgical implant
210529|NCT02134899|Drug|Calcineurin inhibitors maintenance|Usual treatment
210530|NCT02134912|Drug|crizotinib|Given PO
210531|NCT02134912|Drug|pemetrexed disodium|Given IV
210532|NCT02134912|Other|laboratory biomarker analysis|Correlative studies
210533|NCT02134912|Other|pharmacological study|Correlative studies
210534|NCT02134925|Other|Laboratory Biomarker Analysis|Correlative studies
210535|NCT02134925|Biological|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
210536|NCT00132821|Drug|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
210537|NCT02134925|Other|Placebo|Given SC
210538|NCT02134925|Other|Quality-of-Life Assessment|Ancillary studies
210852|NCT02127151|Drug|BMN 673|Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
210853|NCT02127164|Device|"Veraflo" device, Dakin's solution|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
210854|NCT02127177|Device|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
215013|NCT02142179|Behavioral|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
215014|NCT02142192|Drug|natalizumab|Administered as specified in the treatment arm
215015|NCT02142205|Biological|BG00002|IV Infusion
215016|NCT00133523|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
215017|NCT02142218|Drug|Nivolumab|
215018|NCT02142231|Device|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
215019|NCT02142231|Device|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
215020|NCT02142244|Procedure|Near infra red sentinel node biopsy|Explicated in the protocol arm
215021|NCT00133692|Drug|Atenolol/HCTZ/Trandolapril|
215022|NCT02144532|Device|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
215023|NCT02144545|Procedure|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
215024|NCT02144545|Procedure|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
215025|NCT02144545|Procedure|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
215026|NCT02144545|Procedure|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
215027|NCT02144558|Other|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
215325|NCT02136888|Drug|Ponesimod Placebo|
215326|NCT02136888|Drug|Moxifloxacin Placebo|
214413|NCT02116660|Drug|Ritonavir|Ritonavir (r) 100 mg tablets
214722|NCT02149394|Other|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
214723|NCT02149407|Drug|Glycerin|Glycerin group "GG" will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery.
214724|NCT02149407|Procedure|Rectal stimulation|Rectal stimulation "SG" by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall.
214725|NCT02149407|Other|Control|Control group "CG" will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes.
214726|NCT02149420|Drug|VAY736|
214727|NCT02149420|Drug|Placebo|
214728|NCT00000325|Behavioral|Gonadorelin|
214729|NCT00002255|Drug|Epoetin alfa|
214730|NCT00134030|Drug|ifosfamide|Given IV
214731|NCT02149433|Drug|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
214732|NCT02149433|Drug|Placebo|
214733|NCT02149446|Device|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
214734|NCT02149459|Radiation|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
214735|NCT02149459|Drug|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
214736|NCT02149459|Behavioral|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
214737|NCT02149524|Drug|Herceptin (trastuzuamb)|Intravenous administration
214738|NCT02149524|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
214739|NCT02149537|Drug|hydroxyurea|
214101|NCT00131664|Drug|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
214102|NCT02123615|Drug|Gadolinium For abdomen|Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.
Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs.
214103|NCT02123615|Drug|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
214414|NCT02116660|Drug|Atazanavir|Atazanavir (ATV) 300 mg tablets
214415|NCT02116660|Drug|Darunavir|Darunavir (DAR) 400 mg tablets
214416|NCT02116673|Other|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
214417|NCT00131027|Drug|Cyclophosphamide|
214418|NCT02116673|Other|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
214419|NCT02116686|Device|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
214420|NCT02116699|Other|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, followed by brief swabbing, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
214421|NCT02116699|Other|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, followed by brief swabbing, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
214422|NCT02116712|Drug|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
214423|NCT02116725|Other|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
214424|NCT02116725|Other|Plain shower gel|Standard shower gel (Sanex).
214425|NCT02116725|Other|Distilled water|Sterile distilled Water.
214426|NCT02116738|Procedure|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
214427|NCT02116777|Other|Laboratory Biomarker Analysis|Correlative studies
218848|NCT02286921|Drug|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
218849|NCT02286921|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
218850|NCT02286934|Drug|Carvedilol|Day 1 to 3 : Carvedilol 12.5 mg qd
Day 4 to 8 : Carvedilol 25 mg qd
Day 9 to 11 : Carvedilol 12.5 mg qd
218851|NCT02286934|Other|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
218852|NCT00149838|Procedure|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
218853|NCT02286947|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
218854|NCT02286960|Drug|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
218855|NCT02286960|Dietary Supplement|Lactose Pills|4 day course 2 x 20mg per da
218856|NCT02286973|Drug|Tranexamic Acid|
218857|NCT02286986|Drug|Cannabidiol|
218858|NCT02286999|Drug|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
218859|NCT02286999|Drug|Placebo|
214104|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.
214105|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.
214106|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
214107|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
214108|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
218550|NCT02291367|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
218551|NCT02291367|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
218552|NCT00150514|Drug|Oralgen|
218553|NCT02291380|Drug|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
218554|NCT02293902|Drug|sarilumab SAR153191 (REGN88)|
218555|NCT00002378|Drug|Saquinavir|
218556|NCT00150748|Drug|Levetiracetam 250 mg|Active Substance: Levetiracetam
Pharmaceutical Form: Tablet
Concentration: 250 mg
Route of Administration: Oral use
218557|NCT02293902|Other|placebo|
218558|NCT02293902|Drug|methotrexate|
218559|NCT02293902|Drug|folic acid|
218560|NCT02293915|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
218561|NCT02293915|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
218562|NCT02293928|Procedure|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
218563|NCT02293941|Drug|JKB-122|Participants were randomized to receive JKB-122 5mg/15mg/35mg/placebo for 12 weeks
218564|NCT02293941|Drug|Placebo|Participants were randomized to receive JKB-122 5mg/15mg/35mg/placebo for 12 weeks
218565|NCT02293954|Procedure|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
218566|NCT02293954|Procedure|positron emission tomography|Undergo PET
218567|NCT00150748|Drug|Levetiracetam 500 mg|Active Substance: Levetiracetam
Pharmaceutical Form: Tablet
Concentration: 500 mg
Route of Administration: Oral use
218568|NCT02293954|Other|laboratory biomarker analysis|Correlative studies
218569|NCT02293954|Other|pharmacological study|Correlative studies
218570|NCT02293954|Drug|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
217958|NCT02305654|Radiation|Intensity modulated radiation treatment (IMRT)|
217959|NCT02305654|Procedure|Prophylactic PLND - pelvic lymph node dissection|
217960|NCT02305667|Device|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
217961|NCT02305667|Device|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
217962|NCT02305667|Device|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
217963|NCT00152009|Drug|SPD503 (4 mg)|
218256|NCT02298413|Device|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
218257|NCT02298426|Behavioral|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
218258|NCT02298426|Behavioral|General Management|We provide general information about health. Information is provided through telephones and materials.
218259|NCT02298426|Other|Placebo|We use placebo to replace the health product.
218260|NCT00151255|Drug|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
218261|NCT02298426|Dietary Supplement|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
218262|NCT02298452|Device|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
218263|NCT02300779|Dietary Supplement|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.
Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.
Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made.
218264|NCT02300792|Dietary Supplement|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
218265|NCT00151463|Drug|sildenafil citrate|
217672|NCT02310685|Other|Comprehensive e-health wellness program|Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not "of interest".
217673|NCT02310698|Device|contrast enhanced digital mammography (CEDM)|
217674|NCT02310698|Device|whole breast screening ultrasound (WBUS)|
217675|NCT02310711|Other|Standard of Care|Standard of care for early stage breast cancer is breast conserving therapy at this center.
Other concomitant standard of care treatment • Radiation therapy to the whole breast
o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions
217676|NCT02310724|Other|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
217677|NCT02310737|Procedure|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
217678|NCT02310737|Procedure|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
217679|NCT02310750|Drug|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
217680|NCT02310750|Other|Placebo|Matching placebo given during the single ascending and multiple dose periods
217681|NCT00152477|Drug|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
217682|NCT02310750|Drug|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
217683|NCT02310763|Biological|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
217684|NCT02310763|Drug|Placebo|
217685|NCT02313207|Dietary Supplement|FODMAP|patients will undergo a specific FODMAP diet for a period of 2 weeks.
217686|NCT00152724|Drug|celecoxib|
217687|NCT02313220|Drug|Dapagliflozin|Oral use
217688|NCT02313220|Drug|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
213563|NCT02146287|Other|Cycled Light|Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.
Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630).
213564|NCT02146300|Biological|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
213565|NCT02146313|Drug|DMCU4064A|Escalating doses given by intravenous infusion
213566|NCT02146313|Drug|DMUC4064A|Recommended Phase II dose given by intravenous infusion
213567|NCT02146326|Behavioral|Training Staff in Motivational Interviewing or BREATHE|
213568|NCT02146339|Other|Cheese n°1- cheese n°2 - cheese n°3|Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
213569|NCT00002252|Drug|Octreotide|
213570|NCT00133900|Procedure|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
213571|NCT02146339|Other|Cheese n°1- cheese n°3 - cheese n°2|Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
213572|NCT02146339|Other|cheese n°2 - cheese n°1- cheese n°3|Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
213573|NCT02146339|Other|Cheese n°2- cheese n°3 - cheese n°1|Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
208769|NCT02095223|Behavioral|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
208770|NCT02095236|Behavioral|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
208771|NCT02095249|Drug|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
212982|NCT02118610|Drug|Sugar pill|Placebo
213261|NCT02151448|Drug|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
213262|NCT02151448|Biological|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
213263|NCT00134173|Drug|torcetrapib/atorvastatin|
213264|NCT02153814|Procedure|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
213265|NCT02153814|Procedure|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
213266|NCT02153827|Other|Eccentric Shoulder External Rotator Training|
213267|NCT02153827|Other|General Shoulder exercise|general exercise consisting of active shoulder movements
213268|NCT02153840|Drug|PSORI-CM01（YXBCM01） granule|
213269|NCT02153840|Drug|placebo|
213270|NCT02153866|Biological|rotavirus vaccine|3ml/dose, oral
213271|NCT02153866|Biological|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
213272|NCT02153866|Biological|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
213273|NCT02153879|Drug|Fenofibrate|fenofibrate 145/day for 12 weeks
213274|NCT00134420|Procedure|Neuropsychological Testing|
213275|NCT02153879|Drug|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
213276|NCT02153892|Device|GDS Accucinch System|Percutaneous Coronary Intervention
213277|NCT02153905|Drug|Aldesleukin|Administered at a dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
213278|NCT02153905|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
213279|NCT02153905|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
212696|NCT02128087|Behavioral|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
212697|NCT02128100|Drug|Folfirinox|Oxaliplatin 85 mg/m² for over 2 hours,
Leucovorin 400n mg/m² for over 2 hours,
Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion
Fluorouracil 400 mg/m² as a fast infusion over 15 minutes
Fluorouracil 2400 mg/m² as a slow infusion over 46 hours
212698|NCT02128100|Radiation|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
212983|NCT02118623|Behavioral|Moderated discussion board|All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our "peer support" control condition, although we do expect some modest benefit from this intervention alone.
The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group.
212984|NCT02120820|Behavioral|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
212985|NCT02120833|Device|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
212986|NCT02120833|Drug|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
212987|NCT02120846|Other|Flywheel leg-press resistance exercise|
212988|NCT02120859|Device|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
212989|NCT02120859|Device|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
212990|NCT00131352|Device|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
212991|NCT02120872|Drug|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
212992|NCT02120872|Biological|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
212993|NCT02120872|Procedure|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
212400|NCT02133287|Device|Firebird2® sirolimus eluting stent system|
212401|NCT02133300|Other|electrical stimulation|
212402|NCT02133326|Drug|Caldolor|Subject will be given Caldolor by IV prior to surgery.
212403|NCT02133326|Drug|Ofirmev|Subject will be given Ofirmev prior to surgery.
212404|NCT02133339|Drug|TRN-157|
212405|NCT02135562|Dietary Supplement|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
212406|NCT02135562|Other|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
212699|NCT02128113|Drug|Placebo|Opthalmic suspension manufactured to mimic RTA 408 suspension
212700|NCT02128113|Drug|0.5% Omaveloxolone Ophthalmic Suspension|0.5% ophthalmic suspension of RTA 408
212701|NCT02128113|Drug|1% Omaveloxolone Ophthalmic Suspension|1% ophthalmic suspension of RTA 408
212702|NCT02128126|Drug|ISA101|Four dose levels ISA101
212703|NCT02128152|Device|Ekso exoskeleton|
212704|NCT00132119|Drug|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
212705|NCT02128165|Device|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
212706|NCT02128165|Device|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
212707|NCT02128178|Drug|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
212708|NCT02128178|Drug|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
212709|NCT02128191|Drug|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
212710|NCT02128191|Drug|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
212711|NCT02128204|Device|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
212712|NCT02128204|Device|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
212110|NCT02140749|Dietary Supplement|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
212111|NCT02140749|Dietary Supplement|Placebo|Chewing tablets without short-chain Fructooligosaccharides
212112|NCT02140762|Biological|MenABCWY|Effectiveness
212113|NCT02140762|Biological|MenACWY|Effectiveness
212114|NCT02140775|Behavioral|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
212115|NCT02140788|Drug|Metformin|
212116|NCT02143349|Dietary Supplement|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
212117|NCT02143349|Other|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
212118|NCT02143362|Drug|Anesthesia induction,propofol, remifentanil ,cisatracurium|Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.
Intermittent injection cisatracurium (0.15mg/kg).
A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60.
212407|NCT02135575|Behavioral|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
212408|NCT02135588|Drug|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
212409|NCT00132938|Drug|telithromycin|
212410|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
212411|NCT02135614|Drug|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
212412|NCT02135614|Drug|Presatovir placebo|Presatovir placebo tablets administered orally
212413|NCT02135627|Drug|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
212414|NCT02135627|Other|Current standard therapy|
212415|NCT02135640|Drug|denosumab 60mg|solution
211792|NCT02148133|Drug|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
211793|NCT02148133|Drug|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
211794|NCT02148146|Drug|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
211795|NCT02148159|Device|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
211796|NCT02148159|Device|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
211797|NCT00134004|Drug|fludarabine phosphate|
211798|NCT02148172|Procedure|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
211799|NCT02148172|Procedure|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
211800|NCT02148185|Drug|MT-1303|
211801|NCT02148198|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
211802|NCT02148198|Dietary Supplement|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
211803|NCT02148211|Other|Data collection|Initial and follow-up data will be collected using questionnaires.
211804|NCT02148237|Behavioral|Contingency Management|Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
211805|NCT02150707|Drug|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
211806|NCT02150707|Drug|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
211807|NCT02150720|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
212119|NCT02143362|Drug|Anesthesia maintenance , propofol,remifentanil,cisatracurium|Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.
Target Controlled Infusion remifentanil , targeted plasma concentrations are 3~6ng/ml ,maintain heart rate to 60~100 beats per minute and mean blood pressure to 70~105 mmHg.
Intermittent injection cisatracurium (0.05mg/kg).
211159|NCT02120144|Other|Reading|A 10 minutes reading phase of François Mauriac's "Therese Desqueyroux" on a computer
211160|NCT02120157|Drug|Post-transplantation Cyclophosphamide|Chemotherapy administration
211161|NCT02120157|Radiation|TBI cGy|Radiation Therapy
211162|NCT02120157|Drug|Busulfan|Chemotherapy Administered
211483|NCT02115386|Drug|Nilotinib|300 mg
211484|NCT02115425|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
211485|NCT00002233|Drug|Indinavir sulfate|
211486|NCT00130858|Drug|Topotecan|
211487|NCT02115425|Other|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
211488|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
211489|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
211490|NCT02115425|Other|add name here|
211491|NCT02115464|Drug|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with standard radiotherapy of 60-63 Gy for 6 weeks.
211492|NCT02115464|Radiation|Chemo-radiotherapy|Cisplatin-based chemotherapy with standard radiotherapy of 60-63 Gy for 6 weeks.
211493|NCT02115477|Procedure|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
211494|NCT02115490|Drug|Bisphosphonates|
211495|NCT02115516|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
211496|NCT02115516|Biological|0.9% Sodium Chloride (Placebo)|
211497|NCT00130858|Drug|Carboplatin|
211171|NCT02120222|Drug|selinexor|Given PO
211172|NCT02120222|Other|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
211173|NCT02120248|Other|Telephone-based breastfeeding peer counseling|
211174|NCT02120261|Drug|Lidocaine|
211175|NCT02120261|Drug|Triamcinolone Acetonide|
211176|NCT02120261|Drug|Saline|
211177|NCT02120274|Drug|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
211178|NCT02120274|Drug|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
211179|NCT00131261|Drug|Dexamethasone|
211180|NCT02120287|Drug|Bevacizumab|Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
211181|NCT02120287|Procedure|Magnetic Resonance Spectroscopy (MRS)|Subjects will have MRS prior to BZ-SRS.
211182|NCT02120287|Procedure|Border Zone Stereotactic Radiosurgery (BZ-SRS)|The 'border zone' of the tumor will be targeted by SRS in a single session.
211183|NCT02120300|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally
211184|NCT02122341|Device|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
211504|NCT02117856|Procedure|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
211505|NCT00131053|Drug|Pirarubicin|
211506|NCT02117856|Procedure|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
211507|NCT02117856|Device|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
211508|NCT02117856|Device|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
210855|NCT02127190|Drug|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
210856|NCT00132015|Drug|tanespimycin|
210857|NCT02127190|Drug|Placebo|
210858|NCT02127216|Behavioral|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
210859|NCT02127229|Procedure|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
210860|NCT02127242|Procedure|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
210861|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
210862|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
210863|NCT02127268|Drug|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
210864|NCT02127281|Device|Prevena|Device will be applied at end of procedure over closed incision.
210865|NCT02127294|Device|transcatheter patent foreman ovale closure|
210866|NCT02129699|Drug|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
210867|NCT02129699|Other|None, standard chemotherapy only|Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):
Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1
210868|NCT02129712|Behavioral|Cognitive training|
211185|NCT02122354|Behavioral|"Hide and Seek" videogame|
211186|NCT02122367|Other|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
211187|NCT02122380|Drug|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
215327|NCT02136888|Drug|Ponesimod 10 mg|
215328|NCT02136888|Drug|Ponesimod 20 mg|
215329|NCT00133068|Behavioral|Control|No intervention
215330|NCT02136888|Drug|Ponesimod 40 mg|
215331|NCT02136888|Drug|Ponesimod 60 mg|
215332|NCT02136888|Drug|Ponesimod 80 mg|
215333|NCT02136888|Drug|Ponesimod 100 mg|
215334|NCT02136888|Drug|Moxifloxacin 400 mg|
215335|NCT02136901|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
215336|NCT02136901|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
215337|NCT02136901|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
215338|NCT02136901|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
215339|NCT02136914|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
215340|NCT00133081|Drug|All registered antiepileptic drugs|
215341|NCT02136914|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
215342|NCT00133354|Drug|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
215343|NCT02139371|Other|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
215344|NCT02139397|Drug|DFMO|
215345|NCT02139397|Drug|Bortezomib|
215346|NCT02139410|Procedure|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
214740|NCT02151916|Other|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
215028|NCT02144571|Behavioral|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
215029|NCT02144584|Drug|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
215030|NCT02144584|Drug|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
215031|NCT02144597|Dietary Supplement|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
215032|NCT00133705|Drug|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
215033|NCT02144597|Dietary Supplement|Control diet|The control diet will be a conventional food diet aiming to provide 800 to 1000 kcal/day. It will be prescribed by the dietitian at the Imperial Weight Centre.
215034|NCT02144610|Genetic|HGF Plasmid (AMG0001)|IM
215035|NCT02144610|Genetic|Matching Placebo|IM
215036|NCT02144623|Drug|Valproate|
215037|NCT02144636|Dietary Supplement|herbalife protein shake|
215038|NCT02144649|Dietary Supplement|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
215039|NCT02144649|Dietary Supplement|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
215040|NCT02144649|Other|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
215041|NCT02144649|Other|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
215042|NCT02144662|Drug|Ranibizumab|0.5mg ranibizumab intravitreal injection
215043|NCT00133705|Drug|Inert Capsule|sugar pill
214428|NCT00131027|Drug|Daunorubicin|
214429|NCT02116777|Other|Pharmacological Study|Correlative studies
214430|NCT02116777|Drug|Talazoparib|Given PO
214431|NCT02118987|Drug|Omalizumab|
214432|NCT02119000|Drug|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
214741|NCT02151916|Other|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
214742|NCT02151929|Device|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
214743|NCT02151929|Device|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
214744|NCT02151955|Behavioral|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
214745|NCT02151955|Behavioral|Group|10 to 15 Group parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
214746|NCT00134225|Device|Muscle Pattern Recognition (MPR)|
214747|NCT02151968|Procedure|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
214748|NCT02151968|Procedure|Ultrasound-Guidance|Device: Ultrasound Machine
Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance.
214749|NCT02151981|Drug|Chemotherapy|Randomization to either AZD9291 or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (AZD9291:platinum-based doublet-chemotherapy) ratio
214750|NCT02151981|Drug|Cross-over to AZD9291|Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with AZD9291 80mg, once daily. These subjects may continue treatment with AZD9291 even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.
Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to AZD9291.
214751|NCT02151994|Drug|BIA 5-1058|oral administration
214752|NCT02151994|Drug|Placebo|oral administration
214753|NCT02152007|Drug|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
214109|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
214110|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
214111|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
214112|NCT00131664|Drug|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
214113|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
214114|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
214115|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
214116|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
214117|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
214118|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
214119|NCT02125812|Other|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
214120|NCT02125812|Other|scaling and root planing|scaling and root planing
214121|NCT02125838|Device|Laryngeal Mask Airway-Supreme|Group LM-S (laryngeal mask group)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson & Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
214433|NCT02119000|Drug|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|Bisacodyl 15 mg x 3
At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:
PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes
214434|NCT02119013|Drug|Octeotride|
214435|NCT00131144|Drug|Octreotide Acetate in Microspheres 20 mg|
214436|NCT02119013|Drug|Placebo|
214437|NCT02119026|Drug|Capecitabine|800mg/m2 bid d1-14
± 1000 mg/m2 bid,days 1-14 q3w: maintenance
218571|NCT02293967|Drug|MT-1303|
218572|NCT02293980|Drug|PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment for this patient population.
213788|NCT02131064|Drug|carboplatin|Given IV at a dose eliciting an area under the concentration-time curve (AUC) of 6
213789|NCT02131064|Drug|docetaxel|75 mg/m2 given IV every 3 weeks
213790|NCT00132522|Drug|EMD 273066|dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.
Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2.
213791|NCT02131064|Drug|pertuzumab [Perjeta]|420 mg given IV every 3 weeks (840 mg loading dose)
213792|NCT02131064|Drug|trastuzumab [Herceptin]|6 mg/kg given IV every 3 weeks (8 mg/kg loading dose)
213793|NCT02131064|Drug|trastuzumab emtansine [Kadcyla]|3.6 mg/kg given as an intravenous (IV) infusion every 3 weeks
213794|NCT02131077|Biological|ALLO-ASC-TI|
213795|NCT02131077|Drug|Placebo|
213796|NCT02131090|Device|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
213797|NCT02131090|Device|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
213798|NCT02131090|Device|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
213799|NCT02131103|Other|Percutaneous coronary intervention|All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.
Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct.
213800|NCT02133833|Device|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
213801|NCT02133846|Drug|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
218266|NCT02300792|Dietary Supplement|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
218267|NCT02300818|Device|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
218268|NCT02300818|Drug|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
218269|NCT02300831|Other|Data Collection|Non interventional prospective data collection
218270|NCT02300844|Drug|NNC0174-0833|Subjects will receive a single s.c. (subcutaneously /under the skin) dose of NNC0174-0833.
Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated.
218271|NCT02300844|Drug|placebo|Subjects will receive a single s.c. (subcutaneously /under the skin) dose.
218272|NCT02300857|Behavioral|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
218573|NCT02293993|Drug|SGI-110|
218574|NCT02294006|Drug|Everolimus plus Octreotide LAR plus Metformin|
218575|NCT02294019|Drug|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
218576|NCT02294032|Drug|Immunosuppressive Agents|standard of care for patients post-transplant
218577|NCT02294058|Drug|RPC1063|
218578|NCT00150761|Drug|Levocetirizine (drug)|
218579|NCT02294058|Drug|Beta interferon|
218580|NCT02294071|Drug|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
218581|NCT02294071|Drug|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
218582|NCT02294084|Drug|Sitagliptin|Each subject will be randomized to receive either Sitagliptin or placebo for 12 weeks. The compounds will be packed so that the subject nor the investigator will know which compound is administered (double blind)
218583|NCT02294084|Drug|placebo|
218584|NCT02296359|Biological|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
218585|NCT02296372|Device|Continuous glucose monitoring|Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.
In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems.
217964|NCT02305667|Device|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
217965|NCT02305693|Drug|Letrozole|
217966|NCT02305693|Procedure|Laparoscopic ovarian drilling|
217967|NCT02305706|Procedure|starting position in colonoscopy|
217968|NCT02305732|Biological|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
217969|NCT02305745|Other|Observational|
217970|NCT02305758|Drug|Veliparib|Veliparib will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.
217971|NCT02305758|Drug|Placebo|Placebo will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.
217972|NCT02305771|Device|Electroencephalography|
217973|NCT02305771|Device|MRI|
217974|NCT00152009|Drug|Placebo|
217975|NCT02305797|Drug|EDG004|EDG004
217976|NCT02305797|Drug|Placebo|Placebo
217977|NCT02305810|Drug|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
217978|NCT02305823|Drug|Aripiprazole|
217979|NCT02305823|Drug|Quetiapine|
217980|NCT02305823|Drug|Ziprasidone|
217981|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
217982|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
217983|NCT00002385|Drug|Fozivudine tidoxil|
217984|NCT00152256|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
208772|NCT02095262|Other|reactive auditory training|
208773|NCT02095262|Other|Interactive auditory training|
208774|NCT00128583|Biological|polyvalent melanoma vaccine|
208775|NCT02095288|Procedure|None, a blood draw|This is a single blood donation, no drugs or devices administered
208776|NCT02095301|Other|Herbal Beverage|
208777|NCT02095314|Biological|Pentavalen|Batch 5010613
208778|NCT02095340|Other|Positive Interpretation Bias Training|
208779|NCT02095340|Other|Neutral Interpretation Bias Training|
208780|NCT02097680|Drug|Placebo|One placebo capsule every two days during four months
208781|NCT02097706|Drug|NMDA receptor antagonist (active drug)|
208782|NCT02097706|Other|Lactose packed capsule (inert/inactive arm)|
208783|NCT02097719|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
208784|NCT02097719|Drug|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
208785|NCT02097719|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
208786|NCT02097719|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
208787|NCT02097732|Drug|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
208788|NCT02097732|Procedure|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
208789|NCT02097745|Drug|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
208790|NCT00128856|Drug|doxorubicin|
208791|NCT02097745|Drug|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
209094|NCT02090218|Device|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
209095|NCT02090231|Device|rTMS, Magstim Rapid2|5 Hz rTMS
213280|NCT02153905|Biological|Anti-MAGE-A3 HLAA* 01-restricted TCR|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
213281|NCT02153918|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
213574|NCT02146339|Other|Cheese n°3 - cheese n°1- cheese n°2|Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
213575|NCT02146339|Other|Cheese n°3- cheese n°2 - cheese n°1|Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
213576|NCT02146352|Device|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
213577|NCT02146365|Procedure|nasopharyngeal swab|
213578|NCT02146378|Drug|Vyndaqel|20mg/day
213579|NCT02146391|Drug|Androxal 25 mg Capsules|
213580|NCT02148835|Other|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
213581|NCT02148835|Other|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
213582|NCT02148848|Drug|Risedronate|Take risedronate 35 mg orally every week
213583|NCT00134017|Procedure|allogeneic bone marrow transplantation|
213584|NCT02148861|Drug|insulin 287|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
213585|NCT02148861|Drug|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
213586|NCT02148861|Drug|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
213587|NCT02148861|Drug|placebo|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
213588|NCT02148874|Biological|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
213589|NCT02148913|Drug|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
212994|NCT02120885|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
212995|NCT02120898|Drug|Imiquimod|Subjects will apply the assigned test article to the designated treatment area (full face or balding scalp) identified by the investigator at Visit 1. The assigned test article will be applied once daily for two, 2-week treatment cycles separated by a 2-week no treatment interval.
212996|NCT02120911|Drug|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
213282|NCT02153918|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
213283|NCT02153944|Drug|Propanolol|
213284|NCT02153944|Drug|Methylphenidate|
213285|NCT00002260|Drug|Alovudine|
213286|NCT00134433|Genetic|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
213287|NCT02153957|Behavioral|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
213288|NCT02153983|Drug|Colchicine 0.6 mg given|Colchicine 0.6 mg given twice daily
213289|NCT02153983|Drug|Placebo capsules given|Placebo capsules given twice daily
213290|NCT02116101|Dietary Supplement|Bright Momchilovtsi Yogurt|Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
213291|NCT02116101|Dietary Supplement|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
213292|NCT02116114|Other|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
213293|NCT02116127|Device|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
212713|NCT02128217|Drug|Ribavirin|Participants will receive weight-based RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV will be based on subject's weight at entry. Changes in weight after entry do not require a change in dose. Doses will only be changed for toxicity management.
212714|NCT02128217|Drug|Sofosbuvir|Participants will receive one 400 mg tablet of sofosbuvir orally every morning with food.
212715|NCT00002239|Drug|Enfuvirtide|
212716|NCT00132119|Other|Placebo|Placebo tablet
212717|NCT02128217|Drug|Ledipasvir/Sofosbuvir|Participants will receive one daily fixed-dose combination tablet orally every morning of 90 mg of LDV and 400 mg of SOF.
212718|NCT02128230|Drug|MEL-CFZ-TD-PACE|Melphalan and Carfilzomib will be given into a central venous catheter. Dexamethasone is a pill that is taken by mouth daily for 4 days. Thalidomide is a capsule taken by mouth for 4 days. Cisplatin, Adriamycin, Cyclophosphamide and Etoposide are all given into the vein (IV) by a continuous infusion through a central catheter for 4 days. After completion of the four days of continuous chemotherapy, a drug G-CSF will be given. This is a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy.
212997|NCT02120924|Drug|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
212998|NCT02120937|Behavioral|Mindfulness Based Cognitive Therapy-Children|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations). Group sessions consist of guided meditation practices, teacher-led discussion of experiences, and psychoeducation. By fostering the ability to pay closer attention to thoughts, emotions and body sensations, participants learn to make better choices to deal with oncoming stress, anxiety, depression, pain and other challenges, allowing them to more effectively use the principles of cognitive-behavioral therapy.
212999|NCT02120950|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
213000|NCT02123251|Behavioral|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
213001|NCT02123251|Behavioral|Control|
213002|NCT02123264|Drug|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
213003|NCT02123277|Device|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
213004|NCT02123290|Drug|DSM265 400mg|
213005|NCT02123290|Drug|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
212416|NCT02135640|Drug|denosumab 120 mg|solution
212417|NCT02135640|Drug|placebo|solution
212418|NCT02135653|Radiation|Radiotherapy|
212419|NCT02135653|Other|Eischens Yoga|
212420|NCT00002241|Drug|Ritonavir|
212421|NCT00132951|Drug|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
212422|NCT02135666|Procedure|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
212423|NCT02135679|Radiation|Radiotherapy|
212424|NCT02135692|Biological|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
212425|NCT02135692|Drug|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
212426|NCT02135705|Drug|Lomitapide|As prescribed by Physician.
212427|NCT02135718|Device|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
212719|NCT02130674|Drug|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
212720|NCT02130687|Drug|Placebo|Subjects will receive two capsules of placebo to preserve the blinding of the study.
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.
212721|NCT02130687|Drug|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
212722|NCT02130687|Drug|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
212723|NCT02130687|Other|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
212724|NCT02130700|Drug|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
212725|NCT02130713|Drug|Third generation fluoroquinolone|Prulifloxacin 600 mg
212120|NCT02143362|Procedure|Awaken test|Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.
In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .
Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.
Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .
Patients will receive initial anesthesia after finish awaken test.
212121|NCT02143375|Device|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
212122|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
212123|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
212124|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
212125|NCT02143401|Other|Laboratory Biomarker Analysis|Correlative studies
212126|NCT02143401|Biological|Navitoclax|Given PO
212127|NCT02143401|Other|Pharmacological Study|Correlative studies
212128|NCT02143401|Drug|Sorafenib Tosylate|Given PO
212129|NCT02143414|Biological|Blinatumomab|Given IV
212130|NCT02143414|Drug|Dasatinib|Given PO
212131|NCT02143414|Other|Laboratory Biomarker Analysis|Correlative studies
212132|NCT02143414|Drug|Mercaptopurine|Given PO
212133|NCT02143414|Drug|Methotrexate|Given PO
212134|NCT02143414|Drug|Prednisone|Given PO
212135|NCT00002248|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
212136|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^6 or 10^7 TCID50 intradermally (ID).
212137|NCT02143414|Drug|Vincristine Sulfate|Given IV
211498|NCT02115529|Drug|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
211499|NCT02117830|Drug|Androxal 250 Capsules|
211500|NCT02117830|Drug|Placebo Capsules|
211501|NCT02117830|Drug|Moxifloxacin 400 mg|
211502|NCT02117843|Device|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
211503|NCT02117856|Procedure|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
211808|NCT00134095|Drug|irinotecan hydrochloride|
211809|NCT02150720|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
211810|NCT02150720|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
211811|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
211812|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
211813|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
211814|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
211815|NCT02150746|Procedure|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
211816|NCT02150746|Procedure|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
211817|NCT02150759|Drug|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
211818|NCT02150759|Drug|Fentanyl|add dexmedetomidine during position change
211819|NCT00134095|Drug|tegafur-gimeracil-oteracil potassium|
211820|NCT02150759|Drug|Ketamine|add dexmedetomidine during position change
211821|NCT02150772|Procedure|Shear Wave Elastography (SWE)|
211822|NCT02150785|Drug|Streptokinase|
211509|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
211510|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
211511|NCT02117869|Other|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
211512|NCT02117869|Other|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
211513|NCT02117869|Other|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
211514|NCT02117895|Procedure|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
211515|NCT02117895|Procedure|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
211516|NCT00131053|Drug|Cyclophosphamide|
211517|NCT02117908|Device|RESMED AUTOSET S9|Continuous positive pressure during surgery
211518|NCT02117921|Behavioral|One-on-one interview and educational sessions. Reading material for educational series as below|A one-on-one interview with the patient and the principal investigator and group educational sessions. Participants will also be provided with the following books during the intervention period:
"Healing Back Pain" by Dr. John Sarno "Unlearn Your Pain" by Dr. Howard Schubiner "The Mindful Way through Anxiety: Break Free from Chronic Worry and Reclaim Your Life" by Susan Orsillo, PhD & Lizabeth Roemer
211519|NCT02117934|Biological|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
211520|NCT02117934|Biological|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
211521|NCT02120300|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
211831|NCT02150824|Drug|BI 187004|BI 187004 medium dose once daily
211832|NCT02153138|Device|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
211833|NCT02153151|Other|Cytology specimen|Correlative studies
211834|NCT02153151|Other|Laboratory biomarker analysis|Correlative studies
211835|NCT02153177|Procedure|Rotator cuff repair|Arthroscopic procedure
211188|NCT00131508|Drug|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
211189|NCT02122380|Drug|Placebo|1 placebo pill by mouth per day for 30 days
211190|NCT02122393|Drug|Sertraline|
211191|NCT02122393|Behavioral|Cognitive Behavioural Therapy|
211192|NCT02122419|Other|lateral|spinal anesthesia performed during lateral position
211193|NCT02122419|Other|sitting|spinal anesthesia performed during sitting position
211194|NCT02122432|Other|Teledermatology|General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.
Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)
Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?
211195|NCT02122445|Device|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
211196|NCT02122458|Device|mild-gain hearing aids|open-fit hearing aids with mild amplification in the high frequencies.
211197|NCT02122471|Drug|Plecanatide|
211198|NCT02122471|Drug|Placebo|
211199|NCT00131508|Drug|Placebo|Placebo
211200|NCT02122484|Drug|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
211201|NCT02122497|Procedure|abdominal aortic surgery|
211202|NCT02122510|Drug|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
211203|NCT02122510|Drug|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
211204|NCT02122523|Procedure|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
211205|NCT02122536|Drug|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
216307|NCT02119975|Behavioral|Placebo training|
215347|NCT02139423|Other|CMV PCR|
215665|NCT02131909|Procedure|mirror therapy|During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image
215666|NCT02131909|Procedure|bimanual rehabilitation exercises|During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
215667|NCT02131922|Procedure|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
215668|NCT02131922|Procedure|Dental Hygienization Treatment|
215669|NCT02131922|Drug|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
215670|NCT02131948|Drug|Intranasal insulin|Intranasal spray
215671|NCT02131948|Drug|Intranasal placebo|Intranasal spray
215672|NCT02131961|Drug|Collagenase ointment|250 collagenase units/g
215673|NCT02131961|Device|Modified Contact Cast System|1 Unit
215674|NCT00002240|Drug|Atazanavir|
215675|NCT00132613|Drug|Pericardial instillation of bleomycin after drainage|
215676|NCT02132000|Drug|toremifene or tamoxifen|
215677|NCT02132013|Behavioral|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
215678|NCT02132026|Drug|Denosumab|
215679|NCT02132026|Drug|Alendronic Acid|
215680|NCT02132026|Drug|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
215681|NCT02132026|Drug|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
215682|NCT02132039|Other|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
215683|NCT02134613|Other|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
215684|NCT02134626|Drug|Simvastatin|40mg / pill, one pill orally once a day for three months
215685|NCT02134626|Drug|Placebo pill|
215044|NCT00133965|Behavioral|Supportive Psychotherapy|you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
215045|NCT02146833|Drug|Selinexor|Comparison of different dosages and dosing schedules of drug.
215348|NCT02139436|Other|FES-row-training|
215349|NCT02139436|Other|Arms-only-row training|
215350|NCT02139449|Procedure|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
215351|NCT02139462|Other|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
215352|NCT02139462|Other|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
215353|NCT00133354|Drug|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of ~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
215354|NCT02139475|Procedure|Colonoscopy|
215355|NCT02139488|Other|Fiducial markers|
215356|NCT02139488|Other|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
215357|NCT02139501|Drug|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
215358|NCT02139514|Behavioral|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
215359|NCT02139527|Device|Total Disc Replacement|
215360|NCT02139540|Drug|Nitrous Oxide|Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or "placebo" (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.
215361|NCT02139540|Drug|Placebo|50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup
215362|NCT02139553|Procedure|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
215363|NCT02139553|Other|Stroke patients|Evaluation of the stability of the patients during one month before the rhythmic therapy
214754|NCT02152007|Drug|placebo cream (vehicle control)|placebo cream (vehicle control)
214755|NCT02152020|Behavioral|Survey|
214756|NCT02152033|Behavioral|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
214757|NCT00134238|Drug|torcetrapib/atorvastatin|
214758|NCT02154555|Procedure|debridement|post-operative debridement at 1 week follow-up visit
215046|NCT02146846|Drug|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
215047|NCT02146885|Other|Weight Control|Weight Control
215048|NCT02146898|Other|Position|
215049|NCT02146911|Drug|Bupropion|
215050|NCT02146911|Drug|Varenicline|
215051|NCT02146911|Behavioral|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
215052|NCT02146924|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
215053|NCT02146924|Other|laboratory biomarker analysis|Correlative studies
215054|NCT02146924|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
215055|NCT00133965|Behavioral|Standard Palliative Care|If you are in the "Standard Palliative Care" group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes.
215056|NCT02146937|Drug|Bicalutamide plus Finasteride- Combination therapy|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
215057|NCT02146976|Drug|propofol|introvenious infusion of propofol
214438|NCT02119026|Drug|Capecitabine|1000mg/m2 bid d1-14,
214439|NCT02119026|Drug|Bevacizumab|7,5 mg/kg given on d1 q3w
214440|NCT02119026|Drug|Oxaliplatin|130mg/m2 iv. d 1 q3w
214441|NCT02119026|Drug|Irinotecan|200mg/m2 iv. d 1 q3w .
214442|NCT02119039|Device|RGTA OTR 4120 (CACICOL20)|
214443|NCT02119039|Device|Genteal HA eye drops|
214444|NCT02119052|Drug|octeotride|
214445|NCT02119052|Drug|placebo|
214446|NCT00131144|Drug|Octreotide Acetate in Microspheres|
214447|NCT02119065|Procedure|positron emission tomography|Undergo PET/CT scan
214448|NCT02119065|Procedure|computed tomography|Undergo PET/CT scan
214449|NCT02119078|Other|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
214450|NCT02119091|Drug|Moxifloxacin|
214451|NCT02119104|Drug|Prevenar (13v)|Prevenar (13v)
214452|NCT02119117|Dietary Supplement|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
214453|NCT02119117|Dietary Supplement|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
214454|NCT02119130|Device|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
214455|NCT02119143|Dietary Supplement|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
214759|NCT02154568|Drug|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
214760|NCT02154581|Device|SLActive implant|
214761|NCT02154594|Drug|Acacia catechu|
214762|NCT02154594|Drug|Chlorhexidine gluconate|
213802|NCT02133846|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
213803|NCT02133846|Drug|Placebo|500mL 0.9% sodium chloride
213804|NCT00132730|Drug|Placebo to MK-0873|
214122|NCT02125838|Device|Endotracheal Tube|ETT
214123|NCT02125851|Other|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
214124|NCT02125851|Other|Honey|esophageal mucosal contact time of honey vs sucralose slurry
214125|NCT02125864|Drug|Aflibercept|
214126|NCT02125877|Drug|Deferasirox dispersible tablet|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
214127|NCT02125877|Drug|Defearisox film-coated tablet|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
214128|NCT02125890|Drug|Tranexamic Acid administration|
214129|NCT00131911|Drug|sorafenib tosylate|400 mg given orally
214130|NCT02125903|Drug|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
214131|NCT02125916|Other|oxygen therapy|
214132|NCT02125929|Procedure|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
214133|NCT02125929|Procedure|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
214134|NCT02125929|Procedure|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
214135|NCT02125942|Behavioral|Central Meditation and Imagery Therapy|mindfulness, guided imagery, meditation
214136|NCT02125955|Dietary Supplement|Prebiotic fiber|Dissolved in water.
214137|NCT02125955|Dietary Supplement|Placebo|Dissolved in water
214138|NCT02125968|Other|interactive video game|short- and medium-term therapeutic effects
214139|NCT02125968|Other|therapeutic exercise|short- and medium-term therapeutic effects
214140|NCT00131924|Biological|esterified estrogens|
218586|NCT02296385|Dietary Supplement|Triple Strength Fish Oil|Triple Strength Fish Oil
218587|NCT02296398|Drug|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
218588|NCT02296411|Drug|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
218589|NCT02296411|Drug|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
218590|NCT02296424|Drug|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
218591|NCT00151047|Drug|Docetaxel|
218592|NCT02296437|Other|Transcranial direct current stimulation combined with cognitive training|
218593|NCT02296450|Behavioral|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale), ONYCHO (Nail-specific QoL questionnaire), Scalpdex
213805|NCT02133846|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
213806|NCT02133872|Drug|Minocycline 100mg Group|Subjects will be randomized to receive Minocycline 100mg
213807|NCT02133872|Drug|Minocycline 200mg Group|Subjects will be randomized to receive Minocycline 200mg.
213808|NCT02133885|Drug|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
213809|NCT02133885|Other|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
213810|NCT02133898|Other|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
213811|NCT02133911|Drug|Ranolazine|
213812|NCT02133924|Drug|natalizumab|Natalizumab 300mg (or 4.3 mg/kg for subjects <18y or <50kg) on days 0 and 14.
213813|NCT02133924|Drug|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
217985|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
217986|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
217987|NCT02308111|Drug|Obeticholic Acid (OCA)|5 mg to 10 mg tablets of OCA once daily for the duration of the study based on tolerability at 3 months
218273|NCT02300857|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
218274|NCT02300857|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
218275|NCT02300870|Drug|Optison|Echocardiogram with IV contrast
218276|NCT00151476|Drug|Celecoxib|800 mg total daily dosing
218277|NCT02300896|Other|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
218278|NCT02300909|Procedure|Lumbar Decompression Surgery|Lumbar Decompression Surgery
218279|NCT02300909|Procedure|Microdiscectomy Surgery|Microdiscectomy Surgery
218280|NCT02300909|Other|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
218281|NCT02300922|Drug|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
218282|NCT02300922|Drug|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
218283|NCT02300922|Drug|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
218284|NCT02300935|Drug|trametinib|
218285|NCT02300935|Drug|nab-paclitaxel|
218286|NCT02303288|Device|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
218287|NCT02303301|Dietary Supplement|Probiotics|Cultures from the oropharynx
218288|NCT02303301|Dietary Supplement|Placebo|Cultures from the oropharynx
209096|NCT02090244|Drug|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
209097|NCT02090257|Behavioral|TRANSIT|Educational Modules, staff follow up.
209098|NCT02090283|Drug|SD-101 dermal cream (6%)|applied topically once a day to the entire body for 1080 days
209099|NCT00128102|Drug|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
209100|NCT02090296|Drug|Hydroxyurea|
209101|NCT02090309|Drug|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
209102|NCT02090309|Drug|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
209103|NCT02090322|Procedure|Injection of bevacizumab intravitreal (Avastin)|The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.
When there is a Retinopathy of prematurity type 1, is the indication for the infection
209104|NCT02092688|Device|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
209105|NCT00128362|Procedure|Axillary sampling|
209106|NCT02092701|Drug|Cholecalciferol|
209107|NCT02092714|Other|laboratory biomarker analysis|Correlative studies
209108|NCT02092727|Behavioral|Behavioral Interventions for Dialysis Facilities|Educational seminars and monthly educational webinars
Peer-to-peer mentoring program
Bulletin boards about transplantation
Facility-specific feedback reports detailing transplant referral data for their center compared to state average
Formulate a facility-specific improvement plan to increase transplant referrals.
Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.
Monthly monitoring and reporting of patient referrals to ESRD Network
Conduct a patient and family education session about transplantation
Host a movie day to show Living ACTS (About Choices in Transplantation & Sharing) video
209109|NCT02092753|Other|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
209110|NCT02092753|Other|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
209111|NCT02092753|Other|Experimental 2: "Low glycämic and insulinemic" diet (LOGI)|Nutritional intervention: patients were instructed to follow the "LOGI" diet regimen
213590|NCT02148913|Drug|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
213591|NCT02148913|Drug|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
213592|NCT02148913|Drug|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
208792|NCT02097758|Device|Transcatheter device closure|Closure of atrial septal defect with device
choosing device size with 3D image and the formula
we do not use sizing balloon for choosing of the device size
208793|NCT02097771|Device|LMA SupremeTM|
208794|NCT02097771|Device|AuraOnceTM|
208795|NCT02097784|Procedure|Echocardiography|
208796|NCT02097797|Other|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
208797|NCT02097797|Other|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
208798|NCT02097810|Drug|Entrectinib|
208799|NCT02097823|Drug|Olanzapine|
208800|NCT02097823|Drug|Aprepitant|
208801|NCT00128856|Drug|paclitaxel|
208802|NCT02097836|Device|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
208803|NCT02097849|Drug|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera
208804|NCT02097849|Biological|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
208805|NCT02097849|Biological|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
208806|NCT02099903|Device|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
208807|NCT02099916|Drug|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
213294|NCT02116127|Device|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
213295|NCT02116140|Other|[C11]Acetate and HED PET|
213296|NCT02116179|Behavioral|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
213297|NCT00002233|Drug|Abacavir sulfate|
213298|NCT00130936|Drug|Carboplatin|
213299|NCT02116192|Behavioral|Experimental: Low-fructose, reduced carbohydrate diet|Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)
● Aim for less than 25g fructose daily.
213593|NCT02148952|Behavioral|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
213594|NCT00134017|Procedure|bone marrow ablation with stem cell support|
213595|NCT02148965|Behavioral|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
213596|NCT02148978|Drug|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
213597|NCT02149017|Radiation|SNUBH-NM-333(18F)|5-10 mCi
213598|NCT02149030|Other|Cytological screening in A1 and A3|Cytological screening.
213599|NCT02149043|Device|Thermography|Infrared imaging of the abdomen surface
213600|NCT02149043|Procedure|Colonoscopy|Endoscopic examination of the colon
213601|NCT02149056|Behavioral|observation|
213602|NCT02151461|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
213603|NCT02151461|Drug|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
213604|NCT02151461|Drug|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
213605|NCT02151461|Drug|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
213006|NCT00131612|Drug|FEC 100|5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
213007|NCT02123290|Drug|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
213008|NCT02123316|Biological|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
213009|NCT02123316|Biological|Placebo|Placebo for subcutaneous injection
213010|NCT02123329|Behavioral|Pharmacist delivered smoking cessation program|The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.
To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.
• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems
213011|NCT02123329|Other|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
213300|NCT02116192|Behavioral|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
213301|NCT02116205|Biological|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
213302|NCT02116205|Biological|Placebo|0.9% sodium chloride
213303|NCT02116218|Procedure|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
213304|NCT02116218|Procedure|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
213305|NCT02116231|Drug|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
213306|NCT02116231|Radiation|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
213307|NCT02116244|Drug|Civamide Nasal Spray|
213308|NCT02116257|Drug|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
213309|NCT00130936|Drug|Capecitabine|
213310|NCT02116257|Drug|PCA regimen|
212726|NCT00132457|Procedure|Self-collected vaginal swab for chlamydia testing|
212727|NCT02130713|Dietary Supplement|Nutritional supplement + third generation fluoroquinolone|Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
212728|NCT02130726|Procedure|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
212729|NCT02130726|Procedure|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
212730|NCT02130739|Procedure|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
212731|NCT02130739|Procedure|mastectomy|mastectomy with/without breast reconstruction
212732|NCT02130739|Drug|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
212733|NCT02130739|Drug|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
212734|NCT02130739|Drug|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
212735|NCT02130752|Device|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
212736|NCT02130752|Device|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
212737|NCT00132470|Drug|AX200 (G-CSF)|
212738|NCT02130765|Device|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
213012|NCT02123342|Behavioral|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
213013|NCT02123355|Drug|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
213014|NCT02123355|Procedure|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35~40 mmHg，pulse oxygen saturation is more than 95%.
213015|NCT02123355|Drug|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
213016|NCT02123355|Drug|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
212428|NCT02135718|Device|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
212429|NCT02138006|Drug|Standard insulin treatment|
212430|NCT02138019|Procedure|Fibrin Glue assisted external eye surgery|
212431|NCT02138019|Device|Fibrin glue|
212432|NCT02138032|Behavioral|Gains Framed Message|
212433|NCT02138032|Behavioral|Loss Framed Message|
212434|NCT02138045|Drug|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
212435|NCT02138045|Drug|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
212436|NCT02138058|Drug|Topiramate|
212437|NCT00133237|Device|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
212438|NCT02138058|Behavioral|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
212439|NCT02138084|Drug|BMS-663068|
212440|NCT02138084|Drug|Rifabutin|
212441|NCT02138084|Drug|Ritonavir|
212442|NCT02138110|Device|Neuro-Spinal Scaffold|
212443|NCT02138123|Procedure|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
212444|NCT02138123|Procedure|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
212445|NCT02138136|Drug|Lubiprostone|12 or 24 mcg capsules twice daily (BID) for 9 months
212446|NCT02138162|Drug|enzalutamide|oral
212447|NCT02138214|Procedure|thyroidectomy|Undergo total thyroidectomy
212448|NCT00133237|Device|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
211823|NCT02150798|Other|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
211824|NCT02150798|Other|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
211825|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily
211826|NCT02150824|Drug|Placebo|BI 187004 medium dose matching placebo once daily
211827|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
211828|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily add on to background metformin
211829|NCT02150824|Drug|Placebo|BI 187004 low dose matching placebo once daily
211830|NCT00134095|Procedure|adjuvant therapy|
212138|NCT02145715|Drug|Panobinostat|
212139|NCT02145728|Behavioral|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
212140|NCT02145728|Behavioral|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
212141|NCT02145741|Drug|BI 836845, low dose, every week (qw)|Patient to receive low dose of BI 836845 IV
212142|NCT02145741|Drug|BI 836845, middle dose, qw|Patient to receive middle dose of BI 836845 IV
212143|NCT02145741|Drug|BI 836845, high dose, qw|Patient to receive high dose of BI 836845 IV
212144|NCT00133835|Procedure|Extracorporeal shock wave lithotripsy|
212145|NCT02145754|Other|MKP media|one half of skin specimen was put in MKP media
212146|NCT02145754|Other|BSK-H media|one half of skin specimen was put in BSK-H media
212147|NCT02145767|Drug|Progesterone|
212148|NCT02145767|Drug|Placebo|
211836|NCT02153177|Drug|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
211837|NCT02153177|Drug|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
211838|NCT00002259|Drug|Mitoxantrone hydrochloride|
211839|NCT00134355|Drug|PTK787|
211840|NCT02153190|Device|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
211841|NCT02153190|Device|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
211842|NCT02153203|Behavioral|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
211843|NCT02153203|Other|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
211844|NCT02153229|Radiation|Photodynamic Therapy|
211845|NCT02153229|Procedure|Radical Pleurectomy|
211846|NCT02153229|Radiation|Chemotherapy|
211847|NCT02153229|Drug|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
211848|NCT02153268|Procedure|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).
BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose.
211849|NCT02153281|Other|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
211850|NCT00134368|Drug|Etanercept|
211851|NCT02153294|Procedure|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
211852|NCT02153294|Procedure|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
212159|NCT02145871|Other|fluid management guided by the EV1000|
212160|NCT02145884|Drug|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
212161|NCT02145884|Drug|Placebo vehicle/solution|Apply 1-2 drops twice a day to lesion
216308|NCT02119988|Procedure|TIPS|TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months to one year and lifelong aspirin were routinely prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction. Intravenous arginine and branched-chain amino acids and antibiotics were administered for five days as prophylactics for encephalopathy and operation-related infection, respectively. TIPS revision was planned if any evidence of shunt dysfunction was seen; thereafter, long-term anticoagulation was prescribed.
216309|NCT02122055|Drug|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
216310|NCT02122055|Drug|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
216311|NCT02122068|Behavioral|Central Meditation and Imagery Therapy|4 week long meditation and mindfulness intervention
216312|NCT02122068|Behavioral|Relaxation cd|
216313|NCT02122081|Radiation|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
216314|NCT02122081|Drug|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
216315|NCT02122081|Biological|anti-thymocyte globulin|
216316|NCT02122081|Drug|tacrolimus|Given IV or PO
216317|NCT02122081|Drug|methotrexate|Given IV
216318|NCT02122081|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
216319|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
216320|NCT02122081|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
216321|NCT02122081|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
216322|NCT02122081|Other|laboratory biomarker analysis|Correlative studies
216323|NCT02122094|Behavioral|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
216324|NCT02122120|Dietary Supplement|HEN|Patients with tube feeding with FSMP for at least twelve months
216325|NCT02122133|Device|PC 400|
215686|NCT02134639|Procedure|68Ga-DOTATOC PET-CT Imaging|
215977|NCT02126787|Behavioral|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, & Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, & Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
215978|NCT02126813|Procedure|increased interventional threshold for urinary bladder catheterization (800 ml)|
215979|NCT00131989|Drug|sorafenib tosylate|Given orally
215980|NCT02126813|Procedure|Current used interventional threshold for urinary bladder catheterization (500 ml)|
215981|NCT02126813|Device|Intermittent bladder catheter|
215982|NCT02126826|Drug|BI 1026706|Multiple Rising Doses (oral solution, tablet)
215983|NCT02126826|Drug|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
215984|NCT02126839|Drug|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
215985|NCT02126839|Drug|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
215986|NCT02126839|Drug|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
215987|NCT02126852|Device|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
215988|NCT02126852|Device|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
215989|NCT02126852|Device|Electromyography (EMG)|Neuromuscular monitoring
215990|NCT00131989|Other|pharmacological study|Correlative studies
215991|NCT02126865|Drug|Placebo to BI 1060469|tablet
215992|NCT02126865|Drug|BI 1060469 Healthy|tablet
215993|NCT02126865|Drug|Placebo to BI 1060469 asthmatics|tablet
215994|NCT02126865|Drug|BI 1060469 asthmatics|tablet
215995|NCT02126878|Drug|Kenalog|
215364|NCT00133367|Drug|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
215365|NCT02139553|Other|Stroke patients|Evaluation of the after effects of the rhythmic therapy, three months follow-up
215366|NCT02139566|Behavioral|Video consent (high-tech)|Consent provided by an animated video with captions
215367|NCT02142244|Drug|Indocyanine green|Explicated in the protocol arm
215368|NCT02142244|Device|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
215687|NCT02134652|Other|diagnostic bedside ultrasound|Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:
FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic
Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.
215688|NCT02134678|Behavioral|self-system therapy|
215689|NCT02134678|Behavioral|cognitive therapy|
215690|NCT00132808|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous
215691|NCT02134691|Behavioral|Prolonged Exposure|
215692|NCT02134691|Behavioral|Applied Relaxation|
215693|NCT02134704|Other|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
215694|NCT02134717|Drug|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
215695|NCT02134717|Procedure|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
215696|NCT02134717|Procedure|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
215697|NCT02134717|Procedure|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
215698|NCT02134730|Behavioral|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
215058|NCT02146976|Drug|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
215059|NCT02146989|Other|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
215060|NCT02147002|Dietary Supplement|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
215061|NCT02147015|Drug|Glucocorticoids|
215062|NCT02147015|Drug|Antibiotics|
215063|NCT02147015|Drug|Inhaled corticosteroid (ICS)|
215064|NCT02149550|Other|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
215065|NCT00134030|Drug|etoposide|Given IV
215369|NCT02142257|Procedure|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
215370|NCT02142257|Device|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
215371|NCT02142283|Device|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
215372|NCT02142283|Other|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
215373|NCT00133523|Other|Placebo|Physiological saline administered as an intramuscular injection.
215374|NCT02142296|Drug|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
215375|NCT02142309|Drug|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
215376|NCT02142309|Drug|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) <45 mL/min
215377|NCT02142309|Drug|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
215378|NCT02142309|Drug|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
214763|NCT00134498|Drug|torcetrapib/atorvastatin|
214764|NCT02154594|Other|Distilled water|
214765|NCT02154607|Device|CO2-Laser Treatment|
214766|NCT02154620|Procedure|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
214767|NCT02154620|Device|Synthes TCP volar plate|
214768|NCT02154633|Behavioral|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
214769|NCT02154633|Behavioral|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
214770|NCT02154646|Drug|LY2157299|Administered orally
214771|NCT02154646|Drug|Gemcitabine|Administered IV
214772|NCT02154659|Device|24hr pH monitoring|
214773|NCT02154685|Behavioral|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
214774|NCT00134498|Drug|atorvastatin|
214775|NCT02154685|Behavioral|Non-Retrieval Extinction|Neutral cue exposure.
214776|NCT02154698|Other|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
214777|NCT02154698|Other|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
214778|NCT02154724|Device|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
214779|NCT02154724|Device|DBS|The aDBS s applied for two hous in DBS modality.
214780|NCT02154737|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
215066|NCT02149550|Other|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
215067|NCT02149550|Other|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
214141|NCT02125981|Drug|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
214142|NCT02125981|Drug|Placebo|taking placebo drug
214143|NCT02125994|Procedure|Interscalene nerve block|
214144|NCT02126007|Behavioral|Sleep and Rhythm Intervention|
214145|NCT02126007|Behavioral|Dietary Modifications|
214146|NCT02126020|Drug|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
214456|NCT02119143|Dietary Supplement|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
214457|NCT00000320|Drug|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
214458|NCT00131404|Drug|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
214459|NCT02121418|Drug|Decitabine|Given IV
214460|NCT02121431|Behavioral|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
214461|NCT02121444|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|
214462|NCT02121444|Device|BETACONNECT auto-injector.|
214463|NCT02121457|Dietary Supplement|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
214464|NCT02121457|Dietary Supplement|selenium|
214465|NCT02121483|Drug|empagliflozin medium dose|
214466|NCT02121483|Drug|empagliflozin high dose|
214467|NCT02121483|Drug|empagliflozin low dose|
213814|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
213815|NCT00132730|Drug|Usual Care|
213816|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a lyophilized formulation
213817|NCT02133950|Procedure|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
213818|NCT02133950|Procedure|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
213819|NCT02133976|Behavioral|cognitive therapy|
213820|NCT02133976|Behavioral|mindfulness training|
213821|NCT02133976|Behavioral|behavioral therapy|
213822|NCT02133976|Other|treatment as usual|
213823|NCT02133989|Drug|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
213824|NCT02133989|Drug|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
213825|NCT02136173|Device|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
213826|NCT02136186|Device|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
214147|NCT02128737|Behavioral|Sleep|
214148|NCT00132171|Drug|Sequential therapy|
214149|NCT02128750|Other|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
214150|NCT02128763|Drug|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
214151|NCT02128763|Drug|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
214152|NCT02128776|Other|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
214153|NCT02128776|Other|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
214154|NCT02128789|Other|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
214155|NCT02128802|Procedure|Gastric Bypass|
218289|NCT02303314|Drug|Trigonella Foenum-graecum Seed Extract|
218290|NCT02303314|Drug|Drug: Placebo|
218291|NCT02303327|Radiation|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
218292|NCT02303327|Radiation|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
218293|NCT00151749|Drug|Colesevelam hydrochloride|
218594|NCT02296463|Biological|RSV F Vaccine with adjuvant (0.5mL injection)|
218595|NCT02296463|Biological|RSV F Vaccine (0.5mL injection)|
218596|NCT02296463|Biological|Hepatitis A Vaccine (0.5mL injection)|
218597|NCT02296463|Biological|Placebo (0.5mL injection)|
218598|NCT02296476|Drug|OTX015|OTX015 is to be administered per os daily in a fasted state just before breakfast (around 8 a.m. [±2h]), without a rest period. A treatment cycle will be 4-weeks (Day 1= Day 29). Dosing not performed at the same time (±2h) as on other days will be omitted. Patients are to be instructed that if they vomit or omit their dose in that time frame, it is not to be replaced.
218599|NCT02296489|Device|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
218600|NCT02296502|Other|DSM|Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
218601|NCT02296515|Procedure|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
218602|NCT00151060|Drug|Estramustine|
218603|NCT02296528|Device|Swallowing Expansion Device|SED looks like the letter "T" and has a plate and a post. The plate is like the top part of the "T" or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the "T" with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates.
218604|NCT02298465|Procedure|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
218605|NCT02298465|Procedure|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
218606|NCT02298465|Device|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
209411|NCT02085525|Other|Nurse Practitioner Clinic|The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.
Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs.
209412|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
209413|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
209414|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
209415|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
209416|NCT02085551|Device|Mechanical Thrombectomy by the Indigo System|
209417|NCT02085564|Procedure|Peritoneal washing cytology|The methode is describes in the detailed study description
209418|NCT02085577|Drug|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
209419|NCT02085577|Drug|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
209420|NCT02085577|Drug|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
209421|NCT00127725|Device|Pulsed electromagnetic field stimulation|
209422|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
209423|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
209424|NCT02085577|Drug|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
209425|NCT02087904|Biological|ABT-981|
209426|NCT02087904|Other|Placebo|
209427|NCT02087917|Drug|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
209428|NCT02087917|Drug|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
209429|NCT02087930|Dietary Supplement|EHCF + LGG|EXtensively hydolyzed casein formula plus Lactobacillus GG
208808|NCT02099916|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
208809|NCT02099929|Other|Coffee with Sugar|300mL of Coffee with 30g of Sugar
208810|NCT00002222|Drug|Valganciclovir|
208811|NCT00129142|Drug|Toremifene Citrate|
208812|NCT02099929|Other|Coffee without Sugar|300mL of Coffee without Sugar
208813|NCT02099929|Other|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
209112|NCT02092766|Drug|artesunate|
209113|NCT02092766|Drug|quinine|
209114|NCT02092792|Drug|DLYE5953A|Escalating doses of DLYE5953A
209115|NCT02092792|Drug|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
209116|NCT00128375|Behavioral|Financial incentives|
209117|NCT02092805|Procedure|Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)|
209118|NCT02092805|Procedure|Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).|
209119|NCT02092818|Drug|Riociguat(BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study report
209120|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 1
209121|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 2
209122|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 3
209123|NCT02092831|Drug|GDC-0941|Single dose Phase 2 tablet formulation
209124|NCT02092844|Behavioral|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
209125|NCT02092857|Dietary Supplement|Arachidonic acid (25 mg/100 kcal )|
213606|NCT02151474|Drug|INCB047986|
213607|NCT02151474|Drug|Placebo|
213608|NCT02151487|Drug|Ropivacaine|Ropivacaine alone
213609|NCT02151487|Drug|Ropivacaine, dexamethasone|Ropivacaine combination with dexamethasone
213610|NCT02151487|Drug|Ropivacaine, dexamethasone, clonidine|Ropivacaine combination with dexamethasone and clonidine
213611|NCT02151487|Drug|Ropivacaine, clonidine|Ropivacaine together with clonidine
213612|NCT00134173|Drug|atorvastatin|
213613|NCT02151500|Behavioral|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
208814|NCT02099929|Other|Water with Sugar|300mL of Water with 30g of Sugar
208815|NCT02099929|Other|Water without Sugar|300mL of Water without Sugar
208816|NCT02099942|Device|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|The V8 device can be used for BAV as follows:
as stand-alone intervention
as a bridge to transcatheter aortic valve replacement (TAVR)
as a bridge to surgical aortic valve replacement (SAVR)
as an intraprocedural predilatation prior to TAVR
208817|NCT02099955|Drug|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
208818|NCT02099968|Behavioral|Comprehensive Lifestyle Modification|Vegeterian diet
Fasting (1st week)
Meditation
Yoga
Aerobic exercise
208819|NCT02099968|Behavioral|DASH|DASH diet (dietary approaches to stop hypertension)
Aerobic exercise
Progressive muscle relaxation
208820|NCT02099994|Biological|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
208821|NCT02099994|Biological|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
208822|NCT00129155|Drug|treosulfan|
208823|NCT02099994|Biological|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
208824|NCT02099994|Biological|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
208825|NCT02100007|Drug|ME-344|Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.
Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator.
213311|NCT02118623|Behavioral|Psychoeducation|Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:
What is bipolar disorder? - Content about symptoms and diagnosis
Stress and triggers of illness
Medication and the biological basis of bipolar disorder
Depression - Symptoms, early detection and helpful strategies
Mania and hypomania - Symptoms, early detection and helpful strategies.
213312|NCT02118623|Behavioral|Interactive Psychosocial Tools|Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal "relapse prevention plan".
213313|NCT02118649|Behavioral|Game|
213314|NCT00131092|Behavioral|The Stanford Active Choices program|
213315|NCT02118662|Other|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
213316|NCT02118662|Other|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
213614|NCT02151513|Device|Intrathecal Pump Placement|
213615|NCT02151526|Genetic|LentiGlobin BB305 Drug Product|autologous CD34+ hematopoietic stem cells (HSCs) transduced with the LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene
Subjects with beta-thalassemia major will undergo HSC procurement by bone marrow harvest or apheresis after mobilization with filgrastim, a granulocyte-colony stimulating factor (G-CSF), alone or in combination with plerixafor, as decided by the clinical transplant team.
Stem cell mobilization by is contraindicated in sickle cell disease (SCD), as it could induce a sickle cell crisis; thus, procurement of HSCs for subjects with severe SCD will be conducted by bone marrow harvest.
213616|NCT02151539|Other|medical chart review|Ancillary studies
213617|NCT02151539|Other|quality-of-life assessment|Ancillary studies
213618|NCT02151552|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
213619|NCT02151552|Drug|[18F](+/-)NOS|7 mCi of [18F](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
213620|NCT02151565|Device|HTEMS|
213621|NCT02151565|Device|TENS|
213622|NCT02151578|Other|home/community case management|
213017|NCT00131625|Behavioral|Health education according to WHO recommendations|
213018|NCT02123355|Drug|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
213019|NCT02123368|Drug|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
213020|NCT02125357|Drug|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
213021|NCT02125357|Drug|Enzalutamide|160mg PO OD as per standard of care.
213022|NCT02125370|Other|Qualitative and survey|
213023|NCT02125383|Procedure|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
213024|NCT02125383|Procedure|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
213025|NCT02125396|Other|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
213026|NCT02125396|Other|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
213027|NCT00131872|Device|Expedial Vascular Access Graft|
213028|NCT02125409|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
213029|NCT02125409|Procedure|Screening colonoscopy|
213030|NCT02125422|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
213031|NCT02125435|Drug|ASP2408|intravenous
213032|NCT02125435|Drug|Placebo|intravenous
213033|NCT02125448|Device|MRI and PET-CT|
213317|NCT02118662|Other|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
213318|NCT02118662|Other|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
212449|NCT02138214|Procedure|thyroidectomy|Undergo total thyroidectomy with ipsilateral prophylactic CND
212450|NCT02138214|Procedure|central lymph node dissection|Undergo total thyroidectomy with ipsilateral prophylactic CND
212451|NCT02138214|Procedure|quality-of-life assessment|Ancillary studies
212739|NCT02130778|Drug|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
212740|NCT02130778|Other|500 ml 0.9% saline|infusion of saline
212741|NCT02130791|Behavioral|Sleep|
212742|NCT02130804|Drug|Salsalate (4 g/day)|Given orally twice daily
212743|NCT02133339|Drug|Placebo|
212744|NCT02133352|Drug|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
212745|NCT00132717|Drug|Comparator: pravastatin|
212746|NCT02133365|Behavioral|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
212747|NCT02133378|Device|Hemopatch|Baxter Hemopatch
212748|NCT02133378|Behavioral|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
212749|NCT02133391|Other|Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques
212750|NCT02133404|Drug|ASP7991|oral
212751|NCT02133404|Drug|Cinacalcet|oral
212752|NCT02133404|Drug|Placebo|oral
212753|NCT02133417|Device|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
212754|NCT02133430|Device|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
212755|NCT02133443|Device|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
212756|NCT00132717|Drug|Comparator: rosuvastatin|
212149|NCT02145780|Dietary Supplement|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
212150|NCT02145780|Dietary Supplement|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
212151|NCT02145793|Behavioral|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
212152|NCT02145819|Drug|hCG|
212153|NCT02145832|Drug|Fluconazole|
212154|NCT02145832|Drug|Micafungin|
212155|NCT00133835|Procedure|Endoscopic drainage of the main pancreatic duct|
212156|NCT02145845|Device|Injectable SIS|Injectable SIS
212157|NCT02145858|Device|Blood drainage post cardiac surgery using PleuraFlow System|
212158|NCT02145871|Other|standard fluid management|
212452|NCT02138227|Behavioral|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
212453|NCT02138227|Behavioral|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
212454|NCT02138240|Behavioral|Social network intervention|
212455|NCT02138253|Drug|IDN-6556|
212456|NCT02140788|Drug|Fish Oil|
212457|NCT00133419|Drug|Vitamin A|
212458|NCT02140801|Drug|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
212459|NCT02140801|Drug|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
212460|NCT02140814|Dietary Supplement|Niacinamide|
212461|NCT02140827|Other|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
215911|NCT00131235|Drug|Sulfadoxine-pyrimethamine treatment twice during pregnancy|Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
2 placebo tablets for azithromycin taken at the same time points.
215912|NCT02119806|Drug|Benzodiazepine|
215913|NCT02119806|Drug|Fentanyl|
215914|NCT02119806|Drug|Propofol|
215915|NCT02119819|Drug|LY2944876|Administered SC
216224|NCT02152605|Drug|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
216225|NCT02152618|Other|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
216226|NCT02152631|Drug|Abemaciclib|Administered orally
216227|NCT02152631|Drug|Erlotinib|Administered orally
216228|NCT02152657|Other|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
216229|NCT00134277|Procedure|Laser therapy|Laser therapy
216230|NCT02152670|Drug|Methylphenidate|
216231|NCT02152670|Drug|Alpha Methyl Para Tyrosine (AMPT)|
216232|NCT02152670|Other|[11C]PHNO|
216233|NCT02152670|Other|[11C]raclopride|
216234|NCT02152683|Device|Renova|Low- Intensity Shockwave
216235|NCT02152696|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
216236|NCT02152696|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
216237|NCT02152696|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
216238|NCT02152709|Biological|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
215607|NCT02126579|Other|PolyICLC|1 mL administered half intradermally and half subcutaneously
215608|NCT02126579|Other|Resiquimod|500 mg applied to vaccine site after vaccine administration
215609|NCT02126579|Other|IFA|2 mL administered half intradermally and half subcutaneously
215610|NCT02126644|Drug|70% glycolic acid|
215611|NCT02126657|Drug|70% glycolic acid|
215612|NCT02126670|Drug|ACT01|
215613|NCT00131963|Drug|doxorubicin|Given IV
215614|NCT02126670|Drug|Comp01|
215615|NCT02126670|Drug|Comp02|
215616|NCT02126670|Drug|Comp03|
215617|NCT02126670|Drug|Comp04|
215618|NCT02126683|Drug|Hydroxychloroquine|
215619|NCT02126709|Drug|Repigel|Repigel will be used as the intervention in the treatment group
215620|NCT02126722|Procedure|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
215916|NCT02119819|Drug|Exenatide extended-release|Administered SC
215917|NCT02119819|Drug|Placebo|Administered SC
215918|NCT02119832|Device|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
215919|NCT02119845|Device|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
215920|NCT02119858|Drug|indocyanine green solution|Given transperineally
215921|NCT02119858|Other|diffuse optical imaging|Undergo near infrared fluorescence imaging
215922|NCT00131235|Drug|Sulfadoxine-pyrimethamine at 4-week intervals|Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.
2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
215923|NCT02119858|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
215298|NCT02131818|Drug|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
215299|NCT02131844|Other|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
215300|NCT02134444|Behavioral|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
215301|NCT02134444|Behavioral|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
215302|NCT02134457|Biological|ranibizumab|
215303|NCT00132795|Behavioral|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
215304|NCT02134470|Drug|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
215305|NCT02134483|Biological|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
215306|NCT02134496|Procedure|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
215621|NCT02126722|Device|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
215622|NCT02126722|Other|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
215623|NCT02126722|Other|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
215624|NCT00131963|Drug|paclitaxel|Given IV
215625|NCT02126748|Other|inhalation 4ml hypertonic saline 3% 3x/day|
215626|NCT02126748|Device|Intrapulmonary Percussive Ventilation|
215000|NCT02139358|Drug|Gemcitabine|The phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000mg/m2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850mg/m2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
215001|NCT02139358|Drug|Trastuzumab|Trastuzumab will be given using an 8mg/kg loading dose on cycle one, day one (C1D1), followed by 6mg/kg IV on subsequent cycles every (q) 21 days.
215002|NCT02139358|Drug|Pertuzumab|Pertuzumab will be given using an 840mg IV loading dose on C1D1, followed by 420mg IV on subsequent cycles q21 days.
215003|NCT00002245|Drug|Abacavir sulfate|
215004|NCT02142140|Behavioral|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
215005|NCT00133510|Biological|Trivalent Subviron Influenza vaccine (Fluzone)|
215006|NCT02142140|Behavioral|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
215007|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
215008|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
215009|NCT02142153|Drug|F901318|Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.
Pharmacokinetic profile
215010|NCT02142153|Drug|Placebo|Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
215307|NCT02134509|Behavioral|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
215308|NCT02134509|Behavioral|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
215309|NCT02134522|Device|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
199180|NCT01995643|Dietary Supplement|Placebo Capsule|Placebo Capsule
199181|NCT00119171|Drug|Capecitabine|
199182|NCT01998113|Drug|Metformin vs Glyburide trials|Affecting groups 5 and 6
199183|NCT01998126|Drug|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
199184|NCT01998126|Drug|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
199185|NCT01998126|Drug|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
199186|NCT01998126|Drug|Nivolumab|
199187|NCT01998152|Procedure|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
199188|NCT01998165|Drug|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
199189|NCT01998191|Other|Explicit case note review checklist (nurse)|A checklist to be used to screen notes for features of avoidable death used by nurses.
to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.
199190|NCT01998191|Other|Explicit case note review checklist (physician)|A checklist to be used to screen notes for features of avoidable death, used by a nurse.
to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.
199191|NCT01998191|Other|Explicit case note review checklist (MDT)|A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.
to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.
199192|NCT00119184|Procedure|External cephalic version with and without spinal anesthesia|7.5 mg bupivacaine intrathecally
199193|NCT01998217|Drug|Remifentanil|Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
199509|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
199510|NCT02032849|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
199511|NCT02032849|Device|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
203646|NCT02013765|Drug|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
198888|NCT02047474|Drug|leucovorin calcium|Given IV
198889|NCT02047474|Drug|irinotecan hydrochloride|Given IV
198890|NCT02047474|Drug|fluorouracil|Given IV
198891|NCT02047474|Procedure|therapeutic conventional surgery|Undergo surgical resection
198892|NCT02047474|Other|laboratory biomarker analysis|Correlative studies
198893|NCT02047500|Drug|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
198894|NCT00002190|Drug|Saquinavir|
198895|NCT00123851|Drug|Tarceva (OSI-774)|
198896|NCT02047500|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
198897|NCT02049788|Behavioral|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
198898|NCT02049788|Behavioral|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
198899|NCT02049801|Drug|MEK inhibitor MEK162|Given PO
198900|NCT02049801|Drug|idarubicin|Given IV
198901|NCT02049801|Drug|cytarabine|Given IV
198902|NCT02049801|Other|pharmacological study|Correlative studies
198903|NCT02049801|Other|laboratory biomarker analysis|Correlative studies
198904|NCT00124059|Drug|Placebo|400mg/day placebo
198905|NCT02049814|Drug|Metformin|Metformin tablets
198906|NCT02049814|Drug|Voglibose|Voglibose tablets
203326|NCT02021461|Drug|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
203327|NCT02021461|Drug|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
203328|NCT02021474|Drug|Histamine Dihydrochloride|
203329|NCT02021474|Drug|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|
203330|NCT02021500|Drug|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
203331|NCT02021513|Dietary Supplement|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
203332|NCT00121290|Other|pharmacological study|Correlative studies
203333|NCT02021513|Dietary Supplement|Olive Oil|Placebo group
203334|NCT02021526|Drug|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
203647|NCT02013778|Drug|HCQ|
203648|NCT02013791|Drug|Placebo|Vehicle of cyclosporine administered as per protocol on Day 1
203649|NCT02013791|Other|Sham|Sham administered to non-study eye as per protocol on Day 1
203650|NCT02013791|Drug|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
203651|NCT02013804|Drug|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
203652|NCT02013817|Drug|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
203653|NCT00120614|Behavioral|Premature infant behavior and development information|
203654|NCT02013817|Drug|fludarabine|Every 4 weeks, 6 cycles
203655|NCT02013817|Drug|cyclophosphamide|Every 4 weeks, 3 cycles
203656|NCT02016417|Drug|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
203657|NCT02016430|Behavioral|MeLT Dietary intervention|Mediterranean diet containing food with low TMAO content.
203043|NCT02029053|Device|Vaginal Lubrication Ring for Vaginal Dryness|Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.
Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.
The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.
The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.
Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study.
203044|NCT02029066|Drug|SR-T100 gel|2g of SR-T100 will topical apply on 100 cm^2 once for 24 hours.
203045|NCT02029079|Dietary Supplement|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
203046|NCT02029105|Biological|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
203047|NCT02029118|Drug|Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
203048|NCT02029118|Device|acupoint|select acupoint according to traditional Chinese medicine
203335|NCT02021539|Procedure|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
203336|NCT02021539|Biological|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
203337|NCT02021539|Drug|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
203338|NCT02021539|Procedure|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
203339|NCT02021552|Other|no intervention|
203340|NCT02021565|Behavioral|In-home Training and Provision of Assistive Technology (prn)|Assistive Technology Specialists (ATSs), experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform four activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, ATSs also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, ATSs provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
202731|NCT02034227|Drug|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
202732|NCT02034253|Drug|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
202733|NCT02034266|Dietary Supplement|Omega-3 supplementation|5 mL twice daily, administered under the tongue
202734|NCT02034279|Drug|Albumin|Intravenous infusion of 20% albumin
202735|NCT00122603|Drug|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
202736|NCT02034292|Drug|Clopidogrel|
202737|NCT02034292|Drug|Aspirin|
202738|NCT02034292|Drug|APD791|
202739|NCT02034292|Drug|Placebo|
202740|NCT02034331|Drug|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. For preparation and instrumentation, the arms will be uncovered below the elbow and rested on an insulated tray table; the participant's lower extremities will be uncovered below the. For leg evaluations, the laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a laser LDF lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. For each set-up, a temperature electrode will be secured next to the LDF lead. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
202741|NCT01994720|Drug|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily or corresponding placebo given orally.
202742|NCT01994733|Drug|Calcium carbonate ( Intensive phosphate control)|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
202743|NCT01994733|Drug|Calcium carbonate (Liberalized phosphate control)|Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). "Rescue" P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L.
203049|NCT02029118|Drug|Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.|foundation treatment
203050|NCT00002178|Drug|Delavirdine mesylate|
203051|NCT00122005|Biological|GM-CSF gene transduced allogeneic vaccine GVAX|
202150|NCT02004899|Drug|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
202151|NCT02004912|Other|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
202152|NCT02004938|Device|Sonosite Titan Ultrasound Machine|
202436|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
202437|NCT01999452|Behavioral|Paleolithic diet|
202438|NCT01999452|Behavioral|Diabetes diet|
202439|NCT01999465|Device|Standard NMES device|Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.
Rate(35 Hz)
Width (300 us)
Ch1 Ramp+ (2 seconds)
On Time 1 (10 seconds)
Ch1 Ramp - (2 seconds)
202440|NCT01999465|Device|Sham NMES device|Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.
Rate(35 Hz)
Width (48 us)
Ch1 Ramp+ (0 seconds)
On Time 1 (0 seconds)
Ch1 Ramp - (0 seconds)
202441|NCT01999491|Drug|NC-4016|Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
202442|NCT01999504|Other|PAL-2|meal
202443|NCT01999504|Other|TFH-1|Meal
202444|NCT01999504|Other|Reference|Meal
202445|NCT00119301|Drug|leucovorin calcium|
202446|NCT01999517|Drug|Intravenous Nitroglycerin|
202447|NCT01999517|Drug|IV Fluids|
202448|NCT01999530|Drug|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
202449|NCT01999543|Dietary Supplement|plant-based dietary supplement|
202450|NCT01999543|Other|Placebo|
202451|NCT01999569|Drug|Letrozole|Letrozole administered daily through the time of ovulation.
202452|NCT01999582|Biological|Sotatercept|Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
218306|NCT02303405|Drug|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
218307|NCT02303405|Drug|Pioglitazone|Anti-hyperglycemic agent
218308|NCT02303418|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
218309|NCT02303418|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
218310|NCT02305836|Procedure|acupuncture|For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after "de qi" without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and K14 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand.
218311|NCT02305836|Drug|donepezil|cholinesterase inhibitors (ChE-Is)
218312|NCT02305849|Drug|ASP015K|oral
218313|NCT02305849|Drug|Placebo|oral
218314|NCT00002382|Drug|Saquinavir|
218612|NCT00151255|Drug|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
218613|NCT02298517|Procedure|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
218614|NCT02298517|Procedure|inspiratory load equipment|Threshold and Power breathe
218615|NCT02298530|Other|Combination of caffeine and theanine|Beverage containing caffeine and theanine
218616|NCT02298530|Other|Caffeine|Beverage containing caffeine
218617|NCT02298543|Other|coronary spasm|
218618|NCT02298569|Behavioral|multi-pronged program to improve early postpartum discharge|Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.
Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration).
218619|NCT02298582|Drug|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
218018|NCT00152477|Drug|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
218019|NCT02310815|Device|ReSure Sealant|
218020|NCT02310828|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
218021|NCT02310828|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
218022|NCT02310841|Device|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
218023|NCT02310854|Procedure|ACL Repair|augmented suture of acute ACL rupture (<3 weeks after injury)
218024|NCT02310854|Procedure|ACL reconstruction|reconstruction hamstring autograft
218025|NCT02310867|Drug|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
218026|NCT02310867|Procedure|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
218027|NCT02310893|Behavioral|Combined Contingency Management and Peer Navigation|
218028|NCT02310893|Behavioral|Contingency Management|
218029|NCT00152490|Drug|Certolizumab Pegol (CDP870)|
218030|NCT02310893|Behavioral|Peer Navigation|
218031|NCT02310906|Drug|Placebo|
218032|NCT02310906|Drug|SRP-4053|
218033|NCT02310919|Drug|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
218034|NCT02310919|Drug|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
218315|NCT00152022|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
218316|NCT02305862|Drug|Rosuvastatin 5mg|drug intervention
218317|NCT02305862|Drug|Rosuvastatin 20mg|drug intervention
218318|NCT02305875|Other|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
217721|NCT02279043|Behavioral|Birth Control Connect (control)|Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. "If you're using a birth control method right now, how did you choose it?"). Participants will also be able to pose questions to other members of the group and respond to other members' questions. No participants in Birth Control Connect control groups will be current IUC users.
217722|NCT02279056|Behavioral|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
217723|NCT02279056|Behavioral|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
217724|NCT02279069|Device|4-roll canne|
217725|NCT02279082|Drug|DFN-02|Active Experimental Drug
217726|NCT02279095|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
217727|NCT02279108|Drug|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
217728|NCT02279108|Drug|isotope|One injection, 20 MBq techntium99, intradermal use
217729|NCT02279121|Device|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
217730|NCT00148967|Device|Implantable Cardioverter Defibrillator|
217731|NCT02279121|Drug|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
217732|NCT02279134|Radiation|Adjuvant Chemoradiation|Patients receive Paclitaxel 150mg/m2 (D1 and D29) and Cisplatin 75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
217733|NCT02279134|Radiation|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
217734|NCT02279134|Drug|Paclitaxel|150mg/m2 (D1 and D29)
217735|NCT02279134|Drug|Cisplatin|75mg/m2 (D1 and D29)
217145|NCT02290847|Behavioral|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, & Chard, 2008; Resick & Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
217146|NCT02290860|Procedure|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
217436|NCT00149799|Drug|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
217437|NCT02286440|Other|AssureRx GeneSight genotyping results|
217438|NCT02286440|Other|Treatment as usual|
217439|NCT02286453|Drug|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
217440|NCT02286453|Drug|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
217441|NCT02286466|Behavioral|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
217442|NCT02286466|Behavioral|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
217443|NCT02286466|Behavioral|CBT Mobile Application|The CBT mobile application for anxiety is delivered on a mobile tablet device which participants self-administer over the course of 8-12 weeks.
217444|NCT02286479|Procedure|Insicion and Drainage|
217445|NCT02286479|Procedure|Loop drainage|
217446|NCT02286492|Drug|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
217447|NCT00149812|Behavioral|Family Functioning Intervention|
217448|NCT02286505|Device|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
216862|NCT02298036|Behavioral|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
216863|NCT02298049|Other|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
216864|NCT02298049|Device|MRI|
216865|NCT02298062|Drug|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
216866|NCT02298062|Drug|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
216867|NCT02298075|Drug|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
216868|NCT02298075|Drug|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
216869|NCT02300168|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
217147|NCT02290873|Drug|Remimazolam|For induction and maintenance of sedation
217148|NCT00150423|Drug|Pregabalin|
217149|NCT02290873|Drug|Midazolam|For induction of maintenance and sedation
217150|NCT00150670|Drug|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
217151|NCT02293278|Behavioral|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
216567|NCT02304952|Device|Arthrocare Topaz MicroDebrider|
216568|NCT02304965|Behavioral|Daily physical activity|A combination of walking (> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
216569|NCT02304978|Biological|Group CRC|blood samples
216570|NCT02304978|Biological|Group control|Blood samples
216571|NCT02304991|Drug|Liquid Peanut Extract|5000mcg/ml peanut protein
216572|NCT02304991|Drug|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
216573|NCT02305017|Drug|BIA 9-1067|BIA 9-1067 50 mg
216574|NCT02305017|Drug|Paracetamol|Paracetamol 1g
216575|NCT02305030|Drug|BIA 9-1067|
216576|NCT00000127|Procedure|Optic Nerve Sheath Decompression Surgery|
216577|NCT00000347|Drug|Risperidone|
216578|NCT00002381|Drug|Stavudine|
216579|NCT00151970|Drug|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
216580|NCT02305030|Drug|Warfarin|
216581|NCT02305043|Other|non-interventional|non-interventional
216582|NCT02305056|Drug|C13 N15 Valine|C13 N15 Valine administration
216583|NCT02305069|Drug|Pioglitazone|Described elsewhere
216584|NCT02305069|Drug|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
216585|NCT02305069|Drug|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
216586|NCT02305069|Drug|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
216587|NCT02305069|Drug|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
216239|NCT02152709|Biological|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
216240|NCT00134290|Drug|metformin|
216241|NCT02155335|Drug|Golimumab Prefilled Syringe|Golimumab 50 mg via subcutaneous injection.
216242|NCT02155335|Drug|Golimumab Smartject™ Device|Golimumab 50 mg via subcutaneous injection.
216243|NCT00134576|Behavioral|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
216244|NCT02155348|Procedure|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
216589|NCT02307487|Drug|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml TheraCoat's TC-3 gel
216590|NCT02307487|Drug|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml TheraCoat's TC-3 gel
216591|NCT02307487|Drug|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml TheraCoat's TC-3 gel
216592|NCT02307500|Drug|Regorafenib|oral therapy
216593|NCT02307513|Drug|Apremilast (CC-10004)|
216594|NCT02307513|Drug|Placebo|
216595|NCT02307526|Drug|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
216596|NCT02307539|Procedure|Psychosocial Assessment and Care|Undergo PCPI
216597|NCT02307539|Other|Palliative Therapy|Undergo PCPI
216598|NCT00152204|Drug|IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
216599|NCT02307539|Other|Quality-of-Life Assessment|Undergo QOL assessment
216600|NCT02307539|Other|Questionnaire Administration|Undergo questionnaire administration
215924|NCT02119858|Procedure|therapeutic lymphadenectomy|Undergo lymphadenectomy
215925|NCT02121951|Procedure|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
215926|NCT02121951|Drug|MAC|Incremental doses are given to the targed sedation and analgesia
215927|NCT02121964|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
215928|NCT02121964|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
215929|NCT02121977|Device|Elevate Anterior and Apical|
215930|NCT02121977|Procedure|Native Tissue Repair for pelvic organ prolapse|
215931|NCT02121990|Drug|Paclitaxel,|
215932|NCT02121990|Drug|Bevacizumab|
215933|NCT02121990|Drug|Cisplatin|
215934|NCT02121990|Drug|Olaparib|
215935|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
216245|NCT02155348|Procedure|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
216246|NCT02155348|Device|Lentis LS-313|
216247|NCT02155361|Drug|Topical Citrullus colocynthis fruit oil (1%)|
216248|NCT02155361|Drug|Topical vehicle oil|
216249|NCT02155374|Drug|Sliding scale insulin|
216250|NCT02155374|Drug|Intermediate acting insulin|
216251|NCT02155374|Behavioral|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
216252|NCT02155374|Drug|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
215627|NCT02126748|Procedure|Assisted Autogenic Drainage|
215628|NCT02126761|Biological|Adjuvanted, trivalent subunit influenza vaccine|Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
215629|NCT02126761|Biological|Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
215630|NCT02126761|Biological|Antigen level modified adjuvanted, trivalent subunit influenza vaccine|Group 3 is experimental with double the usual antigen dosage
215631|NCT02126761|Biological|Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
215632|NCT02129270|Drug|Lidocaine HCl 2% .|comparison of different dosages of drug
215633|NCT02129270|Drug|Lidocaine HCl 1%|comparison of different dosages of drug
215634|NCT02129283|Behavioral|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
215635|NCT02129296|Device|Air filled balloon|Balloon filled with air according to the manufacturing company orders
215636|NCT02129296|Device|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
215637|NCT02129309|Procedure|Forearm plethysmography|Dose response study
215638|NCT00132262|Behavioral|Standard Care including referral for treatment|Standard hospital care provided the patient with information and referral for treatment as necessary.
215639|NCT02129309|Procedure|Haemodynamic studies|Dose response study
215640|NCT02129322|Drug|Sorafenib|
215641|NCT02129322|Drug|S-1|
215642|NCT02129322|Drug|Oxaliplatin|
215936|NCT02122003|Drug|Sorafenib|Sorafenib 400 mg bid
215937|NCT02122016|Device|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
215938|NCT02122016|Other|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
215939|NCT02122029|Behavioral|Lifestyle counselling|Behavioral techniques for weight management
215310|NCT02134561|Behavioral|psychological interview|
215311|NCT02134561|Radiation|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
215312|NCT02134561|Other|cognitive tests|
215313|NCT02134561|Other|neurological tests|
215314|NCT00132795|Behavioral|control group|standard care (no added treatment)
215315|NCT02134574|Biological|hematologic malignancy|hematologic malignancy with a sampling of blood
215316|NCT02134587|Other|Multifaceted educational intervention|Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.
Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material
Distribution of educational material
Practical class to explain the correct fill of adverse drug events form
Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance.
215317|NCT02134600|Dietary Supplement|Omega-3 enriched fruit juice|Different doses of omega-3 will be administered to five different groups:
400, 800, 1200, 2400 and 3000 mg/m2.
215318|NCT00133068|Behavioral|Computer intervention & reduction of financial barrier|computer intervention & copay
215319|NCT02136823|Drug|Isradipine|
215320|NCT02136823|Drug|Memantine|
215321|NCT02136823|Procedure|Therapeutic muscle stretching|
215322|NCT02136875|Drug|Double dose of Salmeterol + Fluticasone Propionate|
215323|NCT02136875|Behavioral|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
215324|NCT02136875|Drug|Self-administered prescription|An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.
Standing prescriptions for exacerbation:
1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.
2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days
215643|NCT02129335|Other|stress|stress level and survival
215644|NCT02129348|Drug|Lithium|
215645|NCT02129348|Drug|Placebo|
215646|NCT02129361|Behavioral|Adapted Screening and Brief Intervention (Adapted SBI)|
199512|NCT02035241|Dietary Supplement|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
199513|NCT02035241|Dietary Supplement|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
199514|NCT02035241|Dietary Supplement|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
199515|NCT00000311|Drug|Buprenorphine|Experimental Therapeutic Contracting (TC)
Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
199516|NCT00002183|Drug|Amprenavir|
199517|NCT00122668|Drug|nucleoside reverse transcriptase inhibitors|
199518|NCT02035241|Dietary Supplement|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
199519|NCT02035241|Dietary Supplement|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
199520|NCT02035254|Other|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
199521|NCT02035267|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
199522|NCT02035267|Drug|Placebo|Phosphate buffered saline placebo for injection.
199523|NCT02035293|Other|PEP|
199524|NCT02035306|Other|non invasive co-oximetry haemaglobin measurement|
199525|NCT02035332|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
199526|NCT02035345|Drug|Carboplatin|
199527|NCT02035358|Biological|HyperAcute®-Renal (HAR) Immunotherapy|HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.
Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization.
199528|NCT00122668|Drug|protease inhibitor|
199823|NCT02027675|Other|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
198907|NCT02049814|Drug|Acarbose|Acarbose tablets
198908|NCT02049827|Other|participation in the study|
198909|NCT02049840|Device|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
199194|NCT01998217|Drug|Flurbiprofen and remifentanil|Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
199195|NCT01998230|Dietary Supplement|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
199196|NCT01998243|Device|preoperative intragastric balloon ( IGB-BIB®)|An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM)is placed endoscopically under conscious sedation was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors, and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
199197|NCT01998256|Device|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
199198|NCT01998295|Drug|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
199199|NCT01998308|Drug|Crespine gel|50 Knees will have single injection of Crespine gel
199200|NCT02000609|Drug|CHF 1535 NEXThaler 800/48|
199201|NCT02000609|Drug|CHF 1535 NEXThaler 200/12|
199202|NCT02000609|Drug|CHF 1535 NEXThaler PLACEBO|
199203|NCT02000609|Drug|CHF 1535 pMDI 200/12|
199204|NCT02000609|Drug|CHF1535 pMDI 800/48|
199205|NCT02000622|Drug|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
199206|NCT02000622|Drug|Physician's choice chemotherapy|Investigators will declare one of the following regimens:
Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days
Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days
Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days
199207|NCT00119366|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
199208|NCT02000635|Other|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
199209|NCT02000661|Device|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
203658|NCT02016430|Behavioral|TLC Dietary intervention|Standard American Heart Association (AHA) recommendations for dietary counseling
203659|NCT02016430|Behavioral|MeLT dietary intervention with TMAO|Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
203660|NCT02016443|Drug|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
203661|NCT02016443|Drug|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
203662|NCT02016456|Device|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
203663|NCT02016456|Device|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
203664|NCT00120887|Drug|Atorvastatin|
203665|NCT02016469|Other|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
203666|NCT02016469|Other|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
198910|NCT02049853|Device|NTproBNP measurement with point of care device "Cobash232" in the POCT group|
198911|NCT02049866|Drug|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 24 months
198912|NCT02049879|Drug|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
198913|NCT02049892|Other|Metal Ion Levels|
198914|NCT02049905|Drug|Aldoxorubicin|
198915|NCT00124072|Drug|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
198916|NCT02049905|Drug|Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)|
198917|NCT02049931|Device|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
198918|NCT02049931|Device|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
198919|NCT02049931|Device|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
203341|NCT02021578|Behavioral|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
203342|NCT02023970|Device|Patients receiving animal-derived bioprosthetic heart valves.|
203343|NCT02023970|Other|Echocardiography (1)|
203344|NCT02023970|Other|Echocardiography (2)|
203345|NCT02023970|Other|Echocardiography (3)|
203346|NCT02023970|Biological|Blood sample (1)|
203347|NCT00121537|Procedure|Wound Care - Wet to Dry Dressing Changes|
203348|NCT02023970|Biological|Blood sample (2)|
203349|NCT02023970|Biological|Blood sample (3)|
203350|NCT02023983|Other|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
203351|NCT02023983|Other|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
203667|NCT02016469|Dietary Supplement|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
203668|NCT02016482|Biological|Adalimumab (ADA)|Adalimumab (ADA)
203669|NCT02016482|Other|Placebo|Placebo
203670|NCT02016495|Dietary Supplement|Magnesium plus alpha-lipoic acid|
203671|NCT02016495|Drug|Placebo|
203672|NCT02016508|Drug|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
203673|NCT02016521|Other|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
203674|NCT02016521|Other|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
203675|NCT00120900|Drug|GW406381|
203676|NCT02016534|Drug|AMG 337|AMG 337 300mg orally daily.
203677|NCT02016547|Procedure|abciximab IV and thrombectomy|
203052|NCT02029131|Behavioral|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
203053|NCT02029157|Drug|ARQ197|
203054|NCT02029157|Drug|Placebo|
203055|NCT02029170|Procedure|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
203056|NCT02029170|Procedure|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
203057|NCT02029183|Device|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
203058|NCT02029183|Device|bi-level positive airway pressure|
203059|NCT02029196|Other|E-vapour product|
203060|NCT02029196|Other|Conventional cigarette|
203061|NCT02029209|Drug|Anlotinib|Anlotinib QD
203062|NCT00122018|Drug|N-acetylcysteine|
203063|NCT02029209|Drug|Placebo Capsule|Placebo capsule QD
203064|NCT00122395|Behavioral|Screening via pen and paper|
203065|NCT02031601|Drug|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
203066|NCT02031601|Drug|Erlotinib|150mg po once a day daily until disease progression
203067|NCT02031601|Drug|Gefitinib|250mg po once a day daily until disease progression
203068|NCT02031601|Drug|Icotinib|125mg po three times a day daily until disease progression
203069|NCT02031614|Procedure|Phlebotomy|Withdrawal of 500 mL of whole blood.
203070|NCT02031627|Device|pneumatic compression 1 hour per day|Pneumatic compression treatment once per day (1 hour)
203071|NCT02031627|Device|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day (am and pm = 2 hours)
203072|NCT02031627|Device|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM & PM (4 hours)
203352|NCT02023996|Radiation|89Zr-DFO-trastuzumab|
202453|NCT01999582|Biological|Sotatercept|Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
202454|NCT01999595|Device|Sham TENS|TENS with no current while applied with the participant told "TENS is at a turn-on level whether or not you feel it"
202455|NCT01999595|Device|High frequency (80 Hz) TENS|High frequency TENS is defined as the transcutaneous electrical nerve stimulation delivered at 80Hz
202456|NCT00002160|Drug|Ziconotide|
202457|NCT00119301|Drug|methotrexate|
202458|NCT01999595|Device|Low frequency TENS|Low frequency TENS is defined as the transcutaneous electrical nerve stimulation delivered at 3Hz
202744|NCT01994746|Drug|Intranasal Glucagon|
202745|NCT01994746|Drug|Glucagon|
202746|NCT01994759|Other|Training|Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
202747|NCT01994759|Drug|Glucocorticosteroid injection|Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.
Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections).
202748|NCT01994759|Behavioral|Reduction in impact|advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
202749|NCT01994772|Procedure|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
202750|NCT00118911|Other|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
202751|NCT01994772|Procedure|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
202752|NCT01994785|Device|Capnostream 20 (Covidien, Mansfield, MA) Capnography monitoring device|
202753|NCT01994824|Drug|rabbit antithymocyte globulin|Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
202754|NCT01994837|Drug|ABT-199|Tablet
218620|NCT02298595|Drug|cisplatin|75 mg/m2 IV day 1 of each cycle
218621|NCT02298595|Drug|Cetuximab|XXXX day 1, 8, and 15 of each cycle
218622|NCT02298595|Drug|BYL719|200, 250, 300, or 350 mg/day by mouth every day
218623|NCT00151255|Drug|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
218624|NCT02298608|Device|Nano Knife|Percutaneous, CT guided, ablation of renal mass
218625|NCT02298621|Other|pomegranate juice|Randomized clinical trial or RCT
218626|NCT02300948|Drug|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
218627|NCT00151476|Other|Routine Medical Care|
213849|NCT02136368|Behavioral|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
213850|NCT02138799|Drug|enzalutamide|oral
213851|NCT02138799|Drug|rifampin|oral
213852|NCT02138812|Drug|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily, on 14 day cycle - D1, D2, D8, D9 and 28 day cycle - D8, D9 D15 and D16 of a 28 day cycle.
FOR PK COHORT ONLY:Given orally at morning dose only on C1D1
213853|NCT02138812|Drug|Paclitaxel|Paclitaxel will be given once per week (intravenous) IV at 75 mg/m2 on D1, D8, and D15 of a 28 day cycle
Paclitaxel will be given once per week (intravenous) IV at 90 mg/m2 on D1, D8, and D15 of a 28 day cycle
213854|NCT02138812|Drug|Paclitaxel|After MTD(75) + BAY1161909 is established:
BAY1161909 will then be refined for the combination with 90 mg/m2 IV paclitaxel MTD(90) following the same dosing schedules as noted in Arm 1 for both drugs.
213855|NCT02138825|Drug|Adempas, Riociguat (BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for the first 10 weeks of arm 1 and Week 26 - 36 of arm 2. The starting dose will be 0.5mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5mg increments up to a maximum dose of 2.5mg TID based on patient's systolic blood pressure and well-being
213856|NCT02138825|Device|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
213857|NCT00133302|Drug|Standard CHOP|
218319|NCT02305888|Drug|LEO 43204|Treatment of actinic keratosis
218320|NCT02305901|Drug|repaglinide|single dose on day 1 of visits 2 and 3
218321|NCT02305901|Drug|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
218322|NCT02305901|Drug|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
218323|NCT02305927|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
218324|NCT02305927|Other|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
218325|NCT02305940|Drug|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
218326|NCT00152035|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
218327|NCT02305940|Drug|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
218328|NCT02305966|Procedure|surgery|All patients will receive a Delta XTEND reverse shoulder implant
218329|NCT02305966|Device|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
218330|NCT02305979|Drug|Loratadine|
218331|NCT02305992|Procedure|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
218332|NCT02305992|Procedure|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
218333|NCT02308267|Other|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
218628|NCT02300948|Drug|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
218629|NCT02300961|Behavioral|Cognitive rehabilitation program|
218035|NCT02313324|Device|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
218036|NCT02313337|Other|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
218037|NCT02313337|Other|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
218038|NCT02313337|Other|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
218039|NCT02313337|Other|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
218040|NCT02313337|Drug|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
218041|NCT00152724|Drug|acetylcholine|
218042|NCT02313337|Procedure|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
218043|NCT02313337|Drug|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
218044|NCT02313350|Device|Chemonucleolysis with Discogel|
218045|NCT02313350|Procedure|open discectomy|
218046|NCT02313363|Device|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
218047|NCT02313376|Biological|GAP3KO|GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
218048|NCT02313389|Drug|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
218049|NCT02313402|Device|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
217449|NCT02286505|Other|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
217450|NCT02286518|Drug|TAK-114 10 mg capsule|
217451|NCT02286518|Drug|TAK-114 matched placebo|
217452|NCT02286531|Drug|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
217736|NCT02279147|Drug|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
217737|NCT02279160|Drug|APD811|
217738|NCT02279160|Drug|Placebo|
217739|NCT02279173|Drug|Romiplostim|Romiplostim subcutaneous weekly injection
217740|NCT02281487|Device|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
217741|NCT02281500|Biological|Human Plasma-Derived Fibrinogen Concentrate|A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20mg/ml of active substance fibrinogen when reconstituted.
217742|NCT02281513|Other|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
217743|NCT02281513|Other|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
217744|NCT02281513|Other|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
217745|NCT02281526|Drug|BIA 2-093|
217746|NCT02281539|Device|Neuromotus|
217747|NCT00149266|Procedure|Surgery: abdominal and transhiatal approach|
217748|NCT02281552|Drug|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
217749|NCT02281552|Drug|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
217152|NCT02293291|Dietary Supplement|Lithium Water|To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.
To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI
217153|NCT02293304|Other|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
217154|NCT02293304|Other|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
217155|NCT02293317|Biological|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
217156|NCT02293317|Drug|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
217157|NCT02293317|Other|Saline|Placebo
217158|NCT02293330|Drug|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
217159|NCT02293330|Drug|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
217160|NCT02293343|Other|blood profile|
217161|NCT00150670|Drug|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
217453|NCT02286544|Biological|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
217454|NCT02288637|Other|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
217455|NCT02288637|Other|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
217456|NCT00150098|Behavioral|Enhanced HIV risk reduction and HIV vaccine education|
216588|NCT02307474|Drug|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
216870|NCT00151424|Drug|Olanzapine|10-20 mg QD
216871|NCT02300181|Dietary Supplement|Placebo|
216872|NCT02300181|Dietary Supplement|Bacillus subtilis var natto DC-15|
216873|NCT02300194|Drug|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
216874|NCT02300194|Drug|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
216875|NCT02300207|Device|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
216876|NCT02300220|Drug|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
216877|NCT02300220|Drug|Placebo|One capsule, twice daily for 1 week
216878|NCT02300233|Drug|volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks
216879|NCT02300233|Drug|Placebo|Placebo administered subcutaneously once-weekly for 26 weeks
216880|NCT02300246|Procedure|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
216881|NCT00151437|Drug|Pegvisomant treatment|
216882|NCT02300259|Drug|LY2623091|Administered orally
216883|NCT02300259|Drug|Itraconazole|Administered orally
216884|NCT02300259|Drug|Simvastatin|Administered orally
216885|NCT02300259|Drug|Tadalafil|Administered orally
216886|NCT02300259|Drug|Diltiazem|Administered orally
216887|NCT02300272|Device|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
216601|NCT02307552|Device|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
216602|NCT02307565|Drug|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
216603|NCT02307565|Drug|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
216604|NCT02307578|Drug|Perampanel|Perampanel will be available in 2-mg and 4-mg tablets. Subjects will start this EAP with the dose that they were receiving at the end of their participation in Study 332. Doses of perampanel can be adjusted based on clinical judgment.
216889|NCT02300285|Device|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
216890|NCT02302612|Behavioral|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
216891|NCT02302612|Other|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
216892|NCT02302625|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
216893|NCT02302638|Other|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
216894|NCT02302651|Device|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
216253|NCT02155374|Drug|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
216254|NCT00134589|Behavioral|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
216255|NCT02155439|Drug|5-fluorouracil|antimitotic drug
216256|NCT02155439|Drug|Triamcinolone|
216257|NCT02155452|Procedure|ALA Test group|Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.
The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation
216258|NCT02155465|Drug|Ruxolitinib|Ruxolitinib 10mg PO BID
Ruxolitinib 15mg PO BID
Ruxolitinib 20mg PO BID
216259|NCT02155465|Drug|Erlotinib|Erlotinib 150mg PO QD
216260|NCT02155478|Device|ISERT 250 (HOYA, Japan): a standard IOL|
216261|NCT02155478|Device|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
216262|NCT02155504|Drug|ASP3700|oral
216263|NCT02155504|Drug|itraconazole|oral
216264|NCT02155504|Drug|Placebo|oral
216265|NCT00134602|Behavioral|Needs assessment followed by tailored intervention|
216266|NCT02117362|Biological|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
216267|NCT02117375|Device|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
216605|NCT02307591|Drug|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
215940|NCT02122029|Procedure|Bariatric Surgery|Vertical Banding Gastroplasty
215941|NCT02122042|Biological|HBOT|
215942|NCT02122055|Drug|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
215943|NCT02122055|Procedure|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
215944|NCT02122055|Procedure|Screen of weaning|1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
215945|NCT02122055|Drug|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
215946|NCT00002235|Drug|Nelfinavir mesylate|
215947|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
215948|NCT00131716|Drug|sulfadoxine-pyrimethamine|
215949|NCT02123914|Other|No exercise|Sedentary control.
Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,
Nasal peak flow measurement,
Nasal blood flow measurement,
Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
215950|NCT02123927|Drug|TAK-438|TAK-438 tablets
215951|NCT02123927|Drug|Placebo|TAK-438 placebo-matching tablets
215952|NCT02123940|Device|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
215953|NCT02123953|Drug|TAK-438|TAK-438 tablets
215954|NCT02123953|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
215955|NCT02123966|Drug|Sirolimus|
215956|NCT02123979|Drug|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
215957|NCT02123992|Device|Elevate Apical and Posterior|
216268|NCT02117375|Other|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
216269|NCT02117375|Other|brain MRI follow-up|
215647|NCT02129361|Behavioral|Screening & Education Attention Control|
215648|NCT02129374|Procedure|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
215649|NCT00132275|Drug|Amoxicillin potassium clavulanate|
215650|NCT02129400|Drug|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
215651|NCT02129400|Drug|Aer medicinalis Linde 100%|
215652|NCT02129413|Device|Delta system|
215653|NCT02129426|Drug|Ketamine|
215654|NCT02129426|Drug|Midazolam|
215655|NCT02129426|Drug|Dexmedetomidine|
215656|NCT02129439|Drug|SB012|The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.
SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)
The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.
No modifications are permitted to the dosing regimen except for premature study discontinuation.
215657|NCT02131844|Other|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
215658|NCT02131857|Behavioral|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
215659|NCT02131870|Dietary Supplement|L plantarum DSM 9843 or placebo|
215660|NCT02131883|Behavioral|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
215661|NCT02131883|Other|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
215662|NCT02131896|Other|Interventional arm-Mediterranean diet|
215663|NCT00132613|Procedure|Observation alone after pericardial drainage|
215664|NCT02131896|Other|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
215958|NCT02123992|Procedure|Native Tissue Repair for pelvic organ prolapse|
199824|NCT02030028|Drug|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
199825|NCT02030041|Drug|vitaminD|Vitamin D will be given to achieve normal serum levels
199826|NCT02030041|Drug|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
199827|NCT02030041|Drug|Placebo|Placebo will be provided in an arm with simvastatin
199828|NCT02030054|Drug|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
199829|NCT02030054|Drug|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
199830|NCT02030067|Drug|RX-3117|escalating doses
199831|NCT02030080|Behavioral|Financial incentives|
199832|NCT02030080|Behavioral|Teams|
199833|NCT02030080|Behavioral|Framing of feedback|
199834|NCT00122174|Behavioral|Stress Busting Program for family caregivers|
199835|NCT02030080|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
199836|NCT02030093|Behavioral|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
199837|NCT02030119|Behavioral|Financial Incentives|
199838|NCT02030119|Behavioral|Daily feedback|
199839|NCT02030132|Behavioral|Feedback compared to 75th percentile|
199840|NCT02030132|Behavioral|Forgiveness|
199841|NCT02030132|Behavioral|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
199842|NCT02030132|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
199210|NCT02000674|Drug|Succinylcholine : 1mg/kg|
199211|NCT02000674|Drug|Rocuronium : 1.2 mg/kg|
199212|NCT02000700|Drug|Canagliflozin 100 mg|One 100-mg tablet of canagliflozin orally administered daily for 14 days.
199213|NCT02000700|Drug|Canagliflozin 50 mg|One 50-mg tablet of canagliflozin orally administered daily for 14 days.
199214|NCT02000700|Drug|Canagliflozin 300 mg|One 300-mg tablet of canagliflozin orally administered daily for 14 days.
199529|NCT02035371|Drug|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
199530|NCT02035371|Drug|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
199531|NCT02035384|Drug|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
199532|NCT02035397|Drug|Botulinum Toxin Type A|
199533|NCT02035397|Drug|Saline solution|
199534|NCT02035410|Procedure|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
199535|NCT00118963|Drug|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
199536|NCT01995656|Drug|Placebo - Capsule|Administered orally
199537|NCT01995656|Drug|LY3108743 - Capsule|Administered orally
199538|NCT01995656|Drug|Placebo - Solution|Administered orally
199539|NCT01995656|Drug|LY3108743 - Solution|Administered orally
199540|NCT01995669|Drug|Lenalidomide|Phase I Starting Dose: 10 mg by mouth on Days 2-22 of Cycles 1-6. Each cycle is 28 days. Participants with diagnosis of small lymphocytic lymphoma (SLL) begin cycle #1 at a maximum dose of 10 mg total daily on days 2 to 22 of a 28 day cycle. Dose escalated by 5 mg each cycle up to MTD if no toxicity is encountered.
Phase II: Lenalidomide administered orally at maximum tolerated dose (MTD) from Phase I on days 2 to 22 of a 28 day cycle in participants with follicular lymphoma and marginal zone lymphoma.
199541|NCT01995669|Drug|Obinutuzumab (GA101)|Phase I: 1000 mg by vein on Day 1, 8, 15, and 22 of cycle one and on day 1 of each subsequent cycle up to 6 cycles during lenalidomide dosing.
Phase II and Maintenance: 1000 mg by vein - Extended dosing of obinutuzumab begins after 6 cycles of combination therapy if participant demonstrates at least stable disease on response assessment. In extended dosing schedule, obinutuzumab administered every 2 months, and in absence of progression, dosed for maximum of 30 months (combination + maintenance).
198920|NCT02049944|Drug|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
198921|NCT02049957|Drug|MLN0128|Phase 1B: 2, 3, 4, or 5 mg once daily; Phase 2: dose determined after Phase 1B
198922|NCT02052557|Drug|Bupivacaine liposome suspension|30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
198923|NCT00124306|Other|Placebo|Placebo will be dosed exactly as active arm.
198924|NCT02052583|Procedure|therapeutic hypothermia at 32 ° C|
198925|NCT02052583|Procedure|therapeutic hypothermia at 34 ° C|
198926|NCT02052596|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
198927|NCT02052596|Biological|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
198928|NCT02052609|Drug|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
198929|NCT02052609|Drug|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
198930|NCT02052622|Procedure|Examinations and surveys|Clinical evaluation, measurement of fat deposit beneath the chin by skinfold caliper, patient-reported outcome questionnaires, photographs, recording of adverse events
199215|NCT02000700|Drug|Placebo|One matching placebo tablet orally administered at baseline phase.
199216|NCT02000713|Procedure|Amyotrophic Lateral Sclerosis|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
199217|NCT02000726|Drug|Placebo|
199218|NCT00119366|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
199219|NCT02000726|Drug|Citalopram|
199220|NCT02000726|Drug|Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session|Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
199221|NCT02000739|Genetic|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
203678|NCT02016547|Drug|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
203679|NCT02016560|Drug|florbetapir F 18|
203680|NCT02016560|Drug|18F-AV-1451|
203681|NCT02019056|Drug|metadoxine|
203682|NCT02019069|Drug|liposomal cytarabine-daunorubicin CPX-351|Given IV
203683|NCT02019069|Other|laboratory biomarker analysis|Correlative studies
203684|NCT02019082|Device|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
203685|NCT02019082|Device|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
203686|NCT02019095|Other|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
203687|NCT00121160|Behavioral|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
198931|NCT02052635|Drug|ticagrelor|Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
198932|NCT02052635|Drug|clopidogrel|Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
198933|NCT02052648|Drug|Indoximod|
198934|NCT00124332|Drug|Rimonabant (SR141716)|
198935|NCT02052648|Drug|Temozolomide|
198936|NCT02052648|Drug|Bevacizumab|
198937|NCT02052648|Radiation|Stereotactic Radiation|
198938|NCT02052661|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
203353|NCT02023996|Device|PET imaging|
203354|NCT02024009|Drug|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
203355|NCT02024009|Radiation|60Gy in 30#|
203356|NCT02024009|Radiation|50.4Gy in 28#|
203357|NCT02024009|Drug|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
203358|NCT00121550|Drug|clarithromycin|
203359|NCT02024009|Drug|Capecitabine|Given in combination with gemcitabine, known as GemCap.
203360|NCT02024009|Drug|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
203361|NCT02024022|Drug|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
203362|NCT02024022|Drug|Individualized approach|
203363|NCT02024035|Radiation|Radiotherapy|
203364|NCT02024048|Other|OCT|Optical coherence tomography in enhanced depth imaging mode
203365|NCT02024061|Behavioral|Peer support|
203366|NCT02024061|Behavioral|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
203367|NCT02024074|Other|Sestamibi (Tc-MBI) scan of the breast|Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
203368|NCT02024087|Drug|Dalantercept plus sorafenib|Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
203369|NCT00121563|Drug|Thalidomide, Ibuprofen or Diazepam|
203370|NCT02026609|Other|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
203371|NCT02026622|Behavioral|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
203372|NCT02026622|Device|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
203373|NCT02026622|Device|transcranial doppler and TPI|transcranial doppler TPI
202755|NCT01994850|Drug|brentuximab vedotin|
202756|NCT01994863|Device|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
202757|NCT01994863|Device|Standard Care|Standard care consists of three already marketed 1-piece ostomy products
Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima
202758|NCT01994876|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
202759|NCT01996956|Other|volume expansion|fluid loading of 10 ml/kg colloid or blood product
202760|NCT01996969|Drug|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
202761|NCT01996982|Device|CCS Device|Core Cooling System Device
202762|NCT01996995|Device|Nd:YAG laser pulse therapy|
203073|NCT02031640|Drug|Beclomethasone dipropionate|
203074|NCT02031640|Drug|Placebo|
203075|NCT00122395|Behavioral|Screening via audiotape|
203076|NCT02031640|Drug|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
203077|NCT02031666|Drug|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
203078|NCT02031666|Drug|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
203079|NCT02031679|Drug|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
203080|NCT02031679|Drug|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
203081|NCT02031692|Drug|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
203082|NCT02031705|Procedure|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
203083|NCT02031705|Procedure|control group|Control group was performed no additional cavotricuspid isthmus ablation.
203084|NCT02031718|Behavioral|Virtual Counseling|
213858|NCT02138838|Drug|Cinacalcet HCl|Subjects will receive oral administration of cinacalcet daily in addition to standard of care therapy. Cinacalcet will be provided in 5 mg capsules that must be sprinkled onto soft food or suspended into a liquid suspension for administration and 30 mg tablets for swallowing. The protocol specified doses for use in this study are: 2.5, 5, 10, 15, 30, 60, 90, 120, and 180 mg (the lowest dose available in Spain, Germany, Greece, and Portugal is 5 mg). The maximum dose of cinacalcet that will be administered at any time during the study will be 2.5 mg/kg/day based on the subject's dry weight during randomization or 180 mg daily, whichever is lower. The treatment period consists of Weeks 1 - 20. Following completion of the treatment period, all subjects will enter a 4 week safety follow-up period through Week 24.
213859|NCT02138838|Dietary Supplement|Standard of Care|At the investigator's discretion, subjects will receive standard of care, which can include vitamin D sterols, calcium supplements or phosphate binders. The treatment period consists of Weeks 1 - 20. Following completion of the treatment period, all subjects will enter a 4 week safety follow-up period through Week 24.
213860|NCT02138851|Dietary Supplement|Ficus Carica (300g/day)|
213861|NCT02138851|Dietary Supplement|Placebo (300g/day)|
213862|NCT02138864|Drug|18F-FP-(+)-DTBZ|
213863|NCT02138877|Procedure|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
213864|NCT02138877|Procedure|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
213865|NCT02138890|Device|APS|Intra-articular Injection
214190|NCT02131233|Drug|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
214191|NCT02131233|Drug|Placebo to Reformulated Raltegravir|
214192|NCT02131233|Drug|Placebo to Raltegravir|
214193|NCT02131246|Drug|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
214194|NCT02131246|Drug|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
214195|NCT00132548|Drug|Pyrimethamine/sulfadoxine|
214196|NCT02131259|Drug|Afatinib dimaleate|20mg - 50mg
214197|NCT02134002|Drug|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
214198|NCT00132743|Device|Stent|Stent
218630|NCT02300987|Drug|LEE011|
218631|NCT02300987|Drug|LEE011 Placebo|
218632|NCT02301000|Biological|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
218633|NCT02301000|Drug|Metronidazole|Peroral Metronidazole 500 mg t.i.d. for ten days
218634|NCT02301013|Procedure|Urinary incontience surgery|Surgery for stress or mixed urinary incontience
218635|NCT02301013|Drug|300 cc saline|
218636|NCT02301026|Drug|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
218637|NCT02301039|Drug|Pembrolizumab|
218638|NCT00151489|Drug|pregabalin|
218639|NCT02301052|Drug|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
218640|NCT02301052|Drug|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
218641|NCT02301052|Drug|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
218642|NCT02301078|Procedure|Percutaneous Needle Aponeurotomy|single procedure (day 0)
218643|NCT02301078|Drug|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
218644|NCT02301091|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
218645|NCT02301091|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
218646|NCT02301091|Drug|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
218647|NCT02301104|Drug|TAS-102|
218648|NCT02303431|Drug|Edoxaban low dose|Edoxaban low dose
213866|NCT02138890|Device|Placebo|Intra-articular injection
213867|NCT02138903|Other|trans thoracic echocardiography|
218050|NCT02313415|Procedure|collagen scaffold loaded|Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.
If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and collagen scaffold loaded with umbilical cord blood-derived mesenchymal stem cells will be putted in the uterine cavity. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
218334|NCT02308267|Other|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
218335|NCT02308267|Procedure|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
218336|NCT02308280|Drug|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
218337|NCT02308293|Behavioral|High intensity exercise|3x30 seconds 'all out' sprints
218338|NCT02308293|Behavioral|Lay down comfortably|rest
218339|NCT00152269|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
218340|NCT02308319|Drug|Tenofovir disoproxil fumarate|300mg q.d. per oral
218341|NCT02308332|Drug|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
218342|NCT02308345|Other|Pre-chemotherapy visit summary Video|
218343|NCT02308371|Device|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
218344|NCT02308384|Behavioral|Intervention|CME, Start-package and status mail
218345|NCT02308397|Other|Normal gluten containing bread|Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
218346|NCT02308397|Other|Bread with reduced gliadins content|Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
217750|NCT02281565|Behavioral|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
217751|NCT02281578|Behavioral|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
217752|NCT02281578|Behavioral|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
217753|NCT02281591|Drug|BIA 2-093|Tablets containing 900 mg
217754|NCT02281591|Drug|S-licarbazepine|capsules containing 225 mg
218051|NCT02313415|Drug|umbilical cord blood-derived mesenchymal stem cells|
218052|NCT00152724|Drug|sodium nitroprusside|
218053|NCT02313428|Device|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
218054|NCT02276807|Behavioral|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
218055|NCT02276807|Other|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
218056|NCT02276820|Biological|Viralym-A|Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
218057|NCT02276833|Other|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
218058|NCT02276846|Device|Paclitaxel-Eluting Balloon|
218059|NCT02276859|Drug|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
218060|NCT02276859|Drug|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
218061|NCT02276859|Drug|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
218062|NCT02276872|Drug|oral treprostinil|
218063|NCT02276885|Radiation|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
217457|NCT02288637|Other|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
217458|NCT02288650|Other|early refeeding|
217459|NCT02288650|Other|refeeding only in the recovery room (usual practice).|
217460|NCT02288663|Other|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
217461|NCT02288663|Biological|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
217462|NCT02288663|Biological|albumin or blood in urine|dipstick analysis for albumin or blood in urine
217463|NCT02288663|Device|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
217464|NCT02288663|Device|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
217465|NCT02288663|Biological|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
217466|NCT02288689|Device|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
217467|NCT00150111|Drug|Methimazole|
217468|NCT02288702|Device|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
217469|NCT02288715|Other|no interventions|
217755|NCT02281591|Drug|R-licarbazepine|capsules containing 225 mg
217756|NCT02281617|Behavioral|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
217757|NCT02281630|Drug|KWA-0711|
217758|NCT00149266|Procedure|Surgery: left thoraco-abdominal approach|
217759|NCT02281630|Drug|Placebo|
217760|NCT02281643|Drug|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
216888|NCT02300272|Device|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
217162|NCT02293356|Drug|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
217163|NCT02293369|Procedure|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
217164|NCT02293369|Procedure|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
217165|NCT02293395|Drug|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
217166|NCT02293395|Drug|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
217167|NCT02293395|Drug|Clopidogrel|Clopidogrel 75 mg once daily orally.
217168|NCT02295865|Drug|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
217169|NCT02295865|Drug|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
217170|NCT02295865|Drug|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
217171|NCT02295865|Drug|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
217172|NCT00150995|Drug|Tetrathiomolybdate|
217173|NCT02295878|Dietary Supplement|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
217174|NCT02295878|Dietary Supplement|Placebo|
217175|NCT02295891|Device|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
217176|NCT02295917|Device|Transvaginal sonography|Transvaginal sonography
217177|NCT02295930|Other|folfoxiri+cetuximab+surgery+cetuximab|Induction FOLFOXIRI plus cetuximab will consist of:
CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
l-LV 200 mg/sqm IV over 2-h, day 1 followed by
5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
Surgical revaluation will be performed after the induction phase (8 cycles).
Patients deemed unsuitable for surgery will received maintenance treatment as follows:
•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal.
216895|NCT02302664|Procedure|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
216896|NCT02302664|Procedure|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
216897|NCT02302690|Biological|Blood sample for immunology|
216898|NCT00151684|Drug|Diazoxide|
216899|NCT02302703|Other|low FODMAP diet vs Gluten free diet|
216900|NCT02302716|Drug|LY2963016|Administered SC
216901|NCT02302716|Drug|LANTUS®|Administered SC
216902|NCT02302716|Drug|Oral Antihyperglycemic Medication|Administered orally
217180|NCT02295956|Behavioral|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
217181|NCT02295956|Other|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
217182|NCT02295956|Other|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
217183|NCT00151008|Drug|Bexarotene/NBUVB vs placebo NBUVB|
217184|NCT02295956|Behavioral|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
217185|NCT02295956|Other|Booklet|Exercise instructional booklet given to all participants describing all exercises.
217186|NCT02295969|Drug|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
217187|NCT02295982|Procedure|Hand assisted laparoscopic nephrectomy|patients with renal cancer will undergo hans assisted laparoscopic nephrectomy
217188|NCT02298088|Drug|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
216606|NCT02310061|Procedure|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
216607|NCT02310074|Drug|Pulsatile Gonadotropin Releasing Hormone|
216608|NCT02310074|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
216609|NCT02310074|Drug|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
216610|NCT02310087|Dietary Supplement|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
216611|NCT02310087|Other|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
216612|NCT02310100|Device|TactiCath Quartz treatment|
216613|NCT02310113|Other|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
216614|NCT02310126|Device|Multifocal Contact Lens|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
216615|NCT02310126|Device|1-Day Acuvue® MOIST ®|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
216616|NCT00152425|Drug|Certolizumab Pegol (CDP870)|
216617|NCT02310139|Procedure|Colonoscopy|
216618|NCT02310152|Behavioral|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
216619|NCT02310152|Behavioral|CBT|Cognitive Behavioral Therapy
216620|NCT02310165|Procedure|Z-tract Insertion Technique|
216621|NCT02310165|Procedure|Coaxial Insertion Technique|
216622|NCT02310178|Procedure|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
216903|NCT02302729|Dietary Supplement|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
216270|NCT02117388|Behavioral|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
216271|NCT02117388|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
216272|NCT00131027|Drug|Doxorubicin|
216273|NCT02117388|Behavioral|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
216274|NCT02117401|Drug|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
216275|NCT02117401|Drug|midazolam|Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children
Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
216276|NCT02117401|Drug|ketamine|mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children
Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
216277|NCT02117401|Drug|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
216278|NCT02117401|Drug|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
216279|NCT02117414|Device|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
216280|NCT02117414|Other|Waiting Period Visit|Waiting period time will equate to 1 hour
216281|NCT02117427|Biological|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
216282|NCT02117453|Drug|Rosuvastatin|Rosuvastatin 20 mg/day
216283|NCT00131027|Drug|Methotrexate|0.5 g/sqm (intermediate dose)
216284|NCT02117453|Drug|Placebo|Placebo
216285|NCT02117466|Drug|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
216286|NCT02117466|Drug|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
216287|NCT02117479|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily [BID] 15 mg BID
216288|NCT02117479|Drug|Placebo|500 mg tablets to be administered by mouth twice daily [BID]
215959|NCT00131729|Behavioral|Educational programme|
215960|NCT02124005|Drug|Bupivacaine|
215961|NCT02124018|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
215962|NCT02124018|Device|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
215963|NCT02124044|Drug|Asunaprevir and Dalatasvir|ASV (100 mg twice a day) and DCV (60 mg once a day) will be administered orally for 24 weeks
215964|NCT02124044|Drug|Daclatasvir and Asunaprevir, with or without BMS-791325|DCV (30 mg), ASV (200 mg) and BMS-791325 (75 mg) combined in a fixed-dose combination pill (FDC) will be administered orally twice a day for 12 weeks
215965|NCT02124070|Drug|rh Growth Hormone|
215966|NCT02124083|Drug|Vorinostat|Histone deactylase inhibitor
215967|NCT02124122|Biological|Lactobacillus reuteri|
215968|NCT02124122|Biological|Placebo|
215969|NCT02124135|Behavioral|Diet/Nutrition Education|As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.
Participants in the "clinic" arm will receive the education intervention in the clinic.
Participants in the "restaurant" arm will receive the education intervention while dining in a restaurant.
215970|NCT00131742|Drug|telbivudine|
215971|NCT02124148|Drug|LY2606368|Administered IV
215972|NCT02124148|Drug|Cisplatin|Administered IV
215973|NCT02124148|Drug|Cetuximab|Administered IV
215974|NCT02124148|Drug|G-CSF|Administered SC
215975|NCT02124148|Drug|Pemetrexed|Administered IV
215976|NCT02126787|Behavioral|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes & Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
216289|NCT02117479|Drug|Capecitabine|500 mg tablets to be administered by mouth twice daily [BID]
216290|NCT02119871|Procedure|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
199843|NCT02030145|Procedure|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
200140|NCT02025062|Other|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
200141|NCT00121654|Device|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
200142|NCT02025075|Drug|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
200143|NCT02025088|Procedure|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
200144|NCT02025088|Procedure|Microneedling|Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of "coming and going" in each direction.
200145|NCT02025114|Drug|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
200146|NCT02025127|Other|Enteral nutrition|Enteral nutrition introduced via a feeding tube
200147|NCT02025140|Device|Computer controlled anesthesia|The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
200148|NCT02025140|Device|conventional anesthesia syringe|Active control
200149|NCT02025153|Other|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
200150|NCT02025166|Drug|Paracetamol|Pain treatment with "aniline analgesics" (paracetamol) at the time of the procedure
200151|NCT02025166|Drug|lornoxicam|Pain treatment with "NSAID" (lornoxicam) at the time of the procedure
200152|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
200153|NCT02025179|Drug|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
200154|NCT02025179|Device|Vibration|Vibration 10 min/day for 12 months
199542|NCT01995695|Biological|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
199543|NCT01995695|Biological|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
199544|NCT01995708|Biological|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x106 LCs per vaccine x 3.
199545|NCT01995708|Other|Standard of care|No vaccines
199546|NCT00118963|Drug|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
199844|NCT02030145|Procedure|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
199845|NCT00122187|Device|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
199846|NCT02030171|Other|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
199847|NCT02030184|Drug|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
199848|NCT02032862|Drug|Sage extract, 3400 mg , DER 1:17|
199849|NCT02032875|Drug|Daclatasvir|
199850|NCT02032875|Drug|Sofosbuvir|
199851|NCT00002181|Drug|Cidofovir|
199852|NCT00122512|Drug|Tenofovir Disoproxil Fumarate|
199853|NCT02032875|Drug|Ribavirin|
199854|NCT02032888|Drug|Daclatasvir|
199855|NCT02032888|Drug|Sofosbuvir|
199856|NCT02032901|Drug|Daclatasvir|
199857|NCT02032901|Drug|Sofosbuvir|
199222|NCT02000752|Device|Acupuncture|
199223|NCT02000752|Device|Sham acupuncture|Sham point acupuncture
199224|NCT02003287|Other|FEES|Fiberoptic Endoscopic Swallow Study
199225|NCT02003313|Biological|Group T|0.5ml, Intramuscular
199226|NCT02003313|Biological|Group C|0.5ml, Intramuscular
199227|NCT02003326|Other|Inflammatory markers|
199228|NCT02003339|Other|Additional RMIs|
199229|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
199230|NCT02003352|Procedure|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
199231|NCT02003352|Behavioral|Psychological Counselling|Psychological counselling Involves the interaction of the subject with a licensed psychologist/psychiatrist. A variety of techniques are utilized to empower the subject to be able to minimize conflict and maximize performance. This is a nonpharmaceutical intervention.
199232|NCT02003365|Drug|FX006 10 mg|
199233|NCT02003365|Drug|FX006 40 mg|
199234|NCT02003365|Drug|TCA IR 40 mg|
199235|NCT02003378|Device|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
199547|NCT01995721|Biological|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
199548|NCT01995734|Drug|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
199549|NCT01995786|Device|Goal Directed Fluid Therapy FloTrac/Vigileo|
199550|NCT01995799|Device|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
199551|NCT01995812|Behavioral|Hula and heart health education|
199552|NCT01995825|Drug|lamotrigine|lamotrigine tablet 100mg twice a day for two weeks
199553|NCT01995838|Drug|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
198939|NCT02052674|Device|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
198940|NCT02052674|Device|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
198941|NCT02052687|Drug|LFX453 H1|LFX453 high dose cream 1
198942|NCT02052687|Drug|LFX453 L1|LFX453 low dose cream 1
198943|NCT02052687|Drug|LFX453 H2|LFX453 high dose cream 2
198944|NCT02052687|Drug|LFX453 L2|LFX453 low dose cream 2
198945|NCT00124332|Drug|Placebo|
198946|NCT02052687|Drug|Imiquimod|Imiquimod cream
198947|NCT02011477|Other|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
198948|NCT02011477|Other|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
198949|NCT02011490|Drug|sugammadex|sugammadex 4 mg/kg IV bolus
199236|NCT02003378|Device|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
199237|NCT02003391|Drug|Beta-blocker monotherapy|Per subject's current prescribed therapy
199238|NCT02003391|Drug|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
199239|NCT02003404|Device|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
199240|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
199241|NCT02003404|Device|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
203374|NCT00121745|Genetic|Rexin-G Dose 4|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose
IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml
203375|NCT02026622|Behavioral|explicitative interview|
198647|NCT02059863|Behavioral|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
198648|NCT02059876|Drug|carboplatin and paclitaxel and or without trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer
198649|NCT02059889|Device|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
198650|NCT02059889|Device|4-dimensional computed tomography|Undergo 4D CT
198651|NCT02059889|Radiation|fludeoxyglucose F 18|Undergo FDG-PET
198652|NCT02059889|Device|FDG-PET|Undergo FDG-PET
198653|NCT02059902|Drug|Lidocaine|Lidocaine infusion runs for a total of 24 hours
198654|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
198655|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
198656|NCT00125138|Drug|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
198657|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
198658|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
198659|NCT02059928|Device|Intraosseous Device|
198660|NCT02059954|Procedure|Hysterectomy|
198661|NCT02059967|Drug|Paclitaxel|Given IV
198662|NCT02059967|Radiation|image-guided adaptive radiation therapy|Undergo IGART
198663|NCT02059967|Drug|carboplatin|Given IV
198664|NCT02059980|Behavioral|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
198665|NCT02059980|Behavioral|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
203085|NCT02031731|Drug|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
203086|NCT00122408|Dietary Supplement|Ergyphilus|5 pills a day of Ergyphilus or placebo
203087|NCT02031731|Drug|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
203088|NCT02031731|Drug|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
203089|NCT02031744|Drug|erlotinib [Tarceva]|150 mg oral administration once daily
203090|NCT02034331|Drug|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
203091|NCT02034331|Drug|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
203376|NCT02026674|Device|FloRite|Disposable home use urine flow meter.
203377|NCT02026687|Procedure|Epidural|
203378|NCT02026687|Procedure|Intrathecal|
203379|NCT02026700|Device|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
203380|NCT02026713|Other|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
203381|NCT02026739|Procedure|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
203382|NCT02026739|Procedure|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
203383|NCT02026765|Device|traditional lens|A random eyes with traditional lens
203384|NCT02026765|Device|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
203385|NCT00002178|Drug|Ritonavir|
203386|NCT00121758|Biological|LIPO-5|
203387|NCT02026778|Drug|ondansetron|The ondansetron group is given placebo (pyridoxin) instead of betahistine.
The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.
214199|NCT02134002|Drug|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
214200|NCT02134015|Drug|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
214201|NCT02134015|Drug|erlotinib:|Oral erlotinib 150 mg/day.
214202|NCT02134015|Drug|Placebo|Placebo infusion every 3 weeks
214203|NCT02134028|Drug|dupilumab SAR231893 (REGN668)|
214204|NCT02134041|Other|traumatic brain injury|mild TBI, GCS >/=13 after traumatic brain injury
214205|NCT02134067|Drug|TAS-119|
214206|NCT02134067|Drug|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
214207|NCT02134080|Drug|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
214208|NCT02134080|Drug|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
214209|NCT00132743|Behavioral|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
214210|NCT02134093|Drug|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03~0.05 mg/kg), sufentanil(0. 5~0.8 μg/kg), etomidate ( 0.2~0.6mg/kg) and rocuronium(0.6mg/kg)
214517|NCT02126124|Device|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
214518|NCT02126137|Drug|Ezetimibe|
214519|NCT02126163|Behavioral|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
214520|NCT00131950|Other|physiologic testing|
214521|NCT02126202|Procedure|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
214522|NCT02126215|Procedure|MRI CO2 stress testing|Pre and post operatively
213868|NCT00133302|Drug|Bi-CHOP (dose intensified CHOP)|
213869|NCT02138916|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
213870|NCT02138916|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
213871|NCT02141581|Biological|2011-2012 Flumist®|This vaccine is given intranasally
213872|NCT02141620|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
213873|NCT00133484|Biological|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
213874|NCT02141620|Drug|n-Acetylcysteine|
213875|NCT02141620|Drug|Placebo|
213876|NCT02141633|Drug|placebo|4 weeks treatment
213877|NCT02141633|Drug|Fluticasone propionate|4 weeks treatment
213878|NCT02141646|Behavioral|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
213879|NCT02141646|Behavioral|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
213880|NCT02141659|Drug|TAK-385|Drug (including placebo)
213881|NCT02141672|Drug|Voclosporin High Dose|
213882|NCT02141672|Drug|Voclosporin Low Dose|
213883|NCT02141672|Drug|Placebo|
213884|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Bacillus anthrax|
213885|NCT02141698|Drug|TAK-438|TAK-438 tablets
213886|NCT02141698|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
213887|NCT02141698|Drug|Esomeprazole|Esomeprazole tablets
213888|NCT02141711|Drug|TAK-438|TAK-438 tablets
213889|NCT02141711|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
213890|NCT02141724|Other|Positioning consultation|Assessment of pain,bedsores and postural troubles
218347|NCT02308397|Other|Bread with reduced ATIs content|Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
218348|NCT02308397|Other|Bread with reduced overall protein content|Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
218349|NCT02308410|Procedure|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
218350|NCT00152269|Drug|Asoprisnil|25mg Tablet, oral Daily for 12 months
218649|NCT02303431|Drug|Edoxaban high dose|Edoxaban high dose
218650|NCT02303444|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study
218651|NCT02303444|Drug|Other Multikinase inhibitors|Patients can get MKIs at any time during study
218652|NCT02303457|Procedure|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
218653|NCT00151775|Drug|olmesartan medoxomil|Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.
Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily
218654|NCT02303457|Procedure|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
218655|NCT02303470|Behavioral|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
218656|NCT02303470|Behavioral|Moderate Exercise|
218657|NCT02303483|Dietary Supplement|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
218658|NCT02303483|Dietary Supplement|Placebo|
218659|NCT02303496|Biological|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
218660|NCT02303496|Biological|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
218661|NCT02303509|Drug|UCB5857 Part 1|Active substance: UCB5857
Pharmaceutical form: Capsule
Concentration: 1 mg, 5 mg, 10 mg or 15 mg
Route of administration: Oral
218662|NCT02303509|Drug|UCB5857 Part 2|Active substance: UCB5857
Pharmaceutical form: Capsule
Concentration: 5 mg, 8 mg, 15 mg
Route of administration: Oral
218663|NCT02303509|Other|Placebo|Active substance: Placebo
Pharmaceutical form: Capsule
Concentration: Avicel PH 102, 50 mg
Route of administration: Oral
218664|NCT00002381|Drug|Nelfinavir mesylate|
218064|NCT00148720|Drug|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
218065|NCT02276885|Radiation|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
218066|NCT02276898|Drug|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
218067|NCT02276898|Drug|Isotonic Saline 0.9% (Placebo)|
218068|NCT02276911|Drug|Ibuprofen|
218069|NCT02276911|Other|normal saline|
218070|NCT02276924|Device|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
218071|NCT02276937|Drug|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
218351|NCT02308423|Radiation|XR of shoulder|Radiologic examination: Axial view, Axillary view and Anterior posterior view- to evaluate the level of osteoarthritis by Kellgren Lawrence score and Samilson score.
218352|NCT02310932|Behavioral|Healthy Living Intervention|Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based "Healthy Living groups," in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support.
218353|NCT02310945|Other|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
218354|NCT02310958|Procedure|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
218355|NCT02310971|Biological|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
218356|NCT02310997|Other|Umbilical Cord Blood Transplant|
218357|NCT00152503|Drug|Seletracetam (ucb 44212)|
218358|NCT02310997|Drug|Cyclophosphamide|
218359|NCT02310997|Radiation|Total body irradiation|
218360|NCT02310997|Drug|Busulfan|
218361|NCT02310997|Drug|Melphalan|
217761|NCT02281656|Procedure|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
217762|NCT02281656|Procedure|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
217763|NCT02284009|Biological|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
217764|NCT02284022|Device|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
217765|NCT02284035|Drug|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
217766|NCT02284035|Drug|EFV/TDF/FTC|standard combination therapy
217767|NCT00149604|Drug|conjugated estrogens|
217768|NCT02284035|Drug|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
217769|NCT02284035|Drug|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
217770|NCT02284035|Drug|EFV plus ABC/3TC or RPV/TDF/FTC|
217771|NCT02284035|Drug|ATV/r plus ABC/3TC|
217772|NCT02284035|Drug|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
217773|NCT02284035|Drug|RAL plus ABC/3TC|
217774|NCT02284035|Drug|Other ART regimens|
217775|NCT02284048|Drug|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
217776|NCT02284061|Other|physical activities adapted to children|
217777|NCT02284074|Other|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
217778|NCT00149604|Drug|Raloxifene|
218072|NCT02276950|Procedure|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
218073|NCT02276950|Procedure|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
218074|NCT02276963|Drug|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
217178|NCT02295930|Other|folfoxiri+cetuximab+surgery+bevacizumab|Induction FOLFOXIRI plus cetuximab will consist of:
CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
l-LV 200 mg/sqm IV over 2-h, day 1 followed by
5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
Surgical revaluation will be performed after the induction phase (8 cycles).
Patients deemed unsuitable for surgery will received maintenance treatment as follows:
•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal.
217179|NCT02295943|Other|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
217470|NCT02288728|Procedure|Gastric tube anastomosis|In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.
(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)
217471|NCT02288728|Procedure|Double-track anastomosis|Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).
(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)
217472|NCT02288741|Drug|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
217473|NCT02290873|Drug|Placebo|For induction and maintenance of sedation
217474|NCT02290886|Other|Intravenous administration of placebo|
217475|NCT02290886|Drug|Intravenous administration of 1 million of MSC|
217476|NCT02290886|Drug|Intravenous administration of 2 million of MSC|
217477|NCT02290886|Drug|Intravenous administration of 4 million of MSC|
217478|NCT02290912|Behavioral|Health education program|The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes "cafeteria style" (i.e. based on their individual preferences).
217479|NCT02290925|Drug|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (Salacia reticulata). This herb has been used by traditional physicians to control blood sugar.
217480|NCT02290925|Dietary Supplement|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
217481|NCT02290938|Behavioral|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
217189|NCT00151216|Genetic|AAV2CUhCLN2|gene transfer; one-time administration via neuro surgery procedure
217190|NCT02298088|Drug|Clopidogrel|300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.
For patients with > 75 years the recommended load dose is 75 mg instead 300 mg.
217191|NCT02298101|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
217192|NCT02298101|Device|Aeroneb Solo Adapter|Nebulizer
217193|NCT02298101|Device|Opti-Mist Plus Nebulizer|Standard jet nebulizer
217194|NCT02298101|Other|Planar scintigraphy|Imaging technique to investigate whole lung deposition
217195|NCT02298101|Other|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
217196|NCT02298101|Other|Spirometry|FEV1, FVC assessment
217197|NCT02298114|Device|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
217198|NCT02298114|Other|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
217199|NCT02298127|Other|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
217200|NCT00151229|Other|target blood pressure|
217487|NCT02290990|Behavioral|"Imaginative Distention" technique|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
217488|NCT02291016|Drug|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
217489|NCT02291016|Other|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
217490|NCT02291029|Drug|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
217491|NCT02291029|Drug|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
217492|NCT02291029|Drug|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
216904|NCT02302729|Behavioral|Responsive feeding|Strategy
Mother ensures that feeding area is set up with infant and mother able to see one another.
Mother mirrors the infant's facial expressions to attract the infant's attention.
Mother interprets infant's behavior with a positive voice, "Oh, you like the spinach." Mother extends infant's behavior by saying, "Oh the cereal is all gone" and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil
216905|NCT02302729|Dietary Supplement|Placebo|Riboflavin Vitamin B2
216906|NCT02302755|Drug|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
216907|NCT02302768|Dietary Supplement|Selenomethionine|
216908|NCT02305069|Other|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
216909|NCT02305069|Other|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
216910|NCT00151970|Drug|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
216911|NCT02305082|Other|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
216912|NCT02305095|Drug|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
216913|NCT02305108|Other|fascial manipulation|Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.
Specific points of fascial tissue will be treated with a deep friction to improve elasticity.
The number of point treated will be refered to a specific evaluation for each patient.
Fascial manipulation provide 3 session treatment (one treatment for week).
216914|NCT02305108|Other|standard treatment|Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.
After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training.
216915|NCT02305121|Device|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
216916|NCT02305134|Drug|Tipepidine Hibenzate|
216917|NCT02305134|Drug|Placebo|
216918|NCT02305147|Other|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
216919|NCT02305160|Drug|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
216623|NCT02310191|Procedure|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
216624|NCT02310204|Behavioral|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
216625|NCT02310204|Other|standard psoriasis care alone|
216626|NCT02310230|Device|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
216627|NCT00152438|Drug|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
216628|NCT02310243|Drug|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
216629|NCT02312739|Procedure|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
216630|NCT02312739|Drug|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
216631|NCT02312739|Drug|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
216632|NCT02312739|Drug|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
216633|NCT02312739|Other|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
216634|NCT02312739|Other|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
216635|NCT02312752|Device|Intra-epidermal stimulation electrode|A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small "sticker" electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds.
216636|NCT00152724|Drug|scopolamin|
216637|NCT02312765|Behavioral|AirCare App|Tablet software to encourage adherence and support
216291|NCT02119871|Procedure|Right Pleura Open|Right pleura open Left ventricular apical drainage
216292|NCT02119884|Drug|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
216293|NCT02119884|Drug|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
216294|NCT02119897|Device|Low Level Light Therapy|
216295|NCT02119910|Behavioral|Technology Supported Manual|
216296|NCT02119923|Behavioral|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
216297|NCT02119923|Behavioral|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
216298|NCT00002234|Drug|Lamivudine|
216299|NCT00131235|Drug|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.
2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
216300|NCT02119936|Device|Heart Rate Variability Biofeedback, emWave too|
216301|NCT02119936|Behavioral|use of emWave Technology (Heartmath)|
216302|NCT02119949|Behavioral|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
216303|NCT02119949|Behavioral|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
216304|NCT02119962|Behavioral|Working memory training|
216305|NCT02119962|Behavioral|Placebo training|
216306|NCT02119975|Behavioral|Working memory training|
200155|NCT02025192|Drug|ONT-380|Phase 1b dose escalation: 21-day cycles of ONT-380 and capecitabine, ONT-380 and trastuzumab, and ONT-380, capecitabine and trastuzumab until disease progression or unacceptable toxicity. ONT-380 and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
200450|NCT02017860|Drug|Everolimus|Everolimus will be provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration
200451|NCT00002173|Biological|HIV-1 Immunogen|
200452|NCT00121030|Drug|recombinant human erythropoietin (rHuEPO)|
200453|NCT02017873|Drug|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
200454|NCT02020096|Procedure|Nerve stimulator guided sciatic nerve block|We performed the sciatic nerve block using the classic Labat's approach. The stimulating needle was inserted with a 90° angle to the skin and advanced until stimulation of the tibial nerve (plantar flexion of the foot) was obtained. The intensity of the stimulating current, initially set to deliver 2 mA, was gradually decreased to 0.5 mA while the appropriate motor response was maintained. Then,20 mL of 0.5% ropivacaine was injected slowly after careful intermittent aspirations. If dorsiflexion was elicited as a result of stimulation of the common peroneal nerve, the needle was withdrawn and redirected 2-3mm more deeply and medially. Contraction should stop below a current of 0.2mA, otherwise intraneural needle position should be suspected.
200455|NCT02020109|Radiation|splenic irradiation|
200456|NCT02020122|Drug|Duloxetine|duloxetine 60mg
200457|NCT02020122|Drug|Pregabalin|pregabalin 150mg
200458|NCT02020122|Drug|Placebo|non active placebo
200459|NCT02020135|Drug|PSMA ADC|PSMA ADC administered IV
200460|NCT02020161|Drug|Atra|
200461|NCT02020161|Drug|Idarubicin|
200462|NCT02020161|Drug|methotrexate|
200463|NCT00121199|Other|laboratory biomarker analysis|Correlative studies
200464|NCT02020187|Other|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
200465|NCT02020200|Drug|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.
200466|NCT02020200|Drug|Placebo|
200467|NCT02020213|Drug|Posaconazole|400 mg po bid for 8 weeks
199858|NCT02032927|Drug|Codeine/paracetamol|Randomization to one of the two treatments will be done through appropriate randomization list.
During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.
The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking.
199859|NCT02032927|Drug|Oxycodone/naloxone|Randomization to one of the two treatments will be done through appropriate randomization list.
During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.
The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking.
199860|NCT02032953|Dietary Supplement|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
199861|NCT02032953|Drug|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg*min. Ten minuts after starting the insulin, and when the the blood glucose is<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
200156|NCT02025192|Drug|Capecitabine|Phase 1b dose escalation: 21-day cycles of ONT-380 and capecitabine, ONT-380 and trastuzumab, and ONT-380, capecitabine and trastuzumab until disease progression or unacceptable toxicity. ONT-380 and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
200157|NCT02025192|Drug|Trastuzumab|Phase 1b dose escalation: 21-day cycles of ONT-380 and capecitabine, ONT-380 and trastuzumab, and ONT-380, capecitabine and trastuzumab until disease progression or unacceptable toxicity. ONT-380 and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
200158|NCT02027688|Other|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
200159|NCT02027688|Other|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
200160|NCT02027701|Biological|IgPro20|
200161|NCT00121836|Drug|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
200162|NCT02027727|Other|No Intervention|no intervention- tihs is an observational study
200163|NCT02027740|Dietary Supplement|almond|
200164|NCT02027753|Drug|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
200165|NCT02027753|Drug|Metformin|Pharmaceutical form: tablet Route of administration: oral
199554|NCT01995838|Drug|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
199555|NCT01998308|Drug|Intragel|50 Knees will have single injection of 2 ampules of Intragel
199556|NCT01998308|Drug|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
199557|NCT01998308|Drug|Monovisc|50 Knees will have single injection of Monovisc
199558|NCT00119197|Biological|killed whole cell oral cholera vaccine|Bivalent oral killed cholera vaccine: each dose of this vaccine contains:
Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells
Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells
Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells
Inactivated V.Cholerae O139 - 50.109 cells
each 1.5 mL dose given orally, two doses given 14 days apart
199559|NCT01998321|Other|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation & PSI designing and PSI production
199560|NCT01998321|Other|conventional technique for TKA|
199561|NCT01998334|Other|CVVH 6h|CVVH 6h for first three days
199562|NCT01998334|Other|CVVH 10h|CVVH 10h for first three days
199563|NCT01998334|Other|CVVHDF 6h|CVVHDF 6h for first three days
199564|NCT01998347|Drug|Paclitaxel liposome|
199565|NCT01998347|Drug|Cisplatin|
199566|NCT01998347|Drug|5-fluorouracil|
199567|NCT01998360|Procedure|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
199568|NCT01998360|Procedure|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
199862|NCT02032966|Procedure|Nonsurgical|Randomized to "nonsurgical": patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically).
199863|NCT00122525|Procedure|Male Circumcision|
199864|NCT02032966|Procedure|Surgical|Randomized to "surgical": patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays.
199865|NCT02032979|Behavioral|Psychiatric test|
199242|NCT02003443|Behavioral|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
199243|NCT02003456|Procedure|Cardiac PET w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
199244|NCT02003456|Device|PET Scan|
199245|NCT02003469|Device|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
199246|NCT02003482|Radiation|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
199247|NCT02003482|Device|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
199248|NCT02006160|Drug|placebo|10 mg bid
199249|NCT02006173|Drug|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
199250|NCT02006173|Drug|Normal Saline|
199251|NCT02006186|Behavioral|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
199252|NCT02006199|Behavioral|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
199253|NCT02006212|Procedure|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
199254|NCT02006225|Drug|Plerixafor|
199255|NCT02006238|Device|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
199569|NCT00119197|Biological|Heat Killed E. coli|Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.
Each 1.5 mL dose given orally, two doses given 14 days apart
199570|NCT01998373|Behavioral|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
198666|NCT02062398|Device|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
198667|NCT02062411|Behavioral|CBT only|Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
198668|NCT02062411|Behavioral|CBT with booster sessions|Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
198950|NCT02011503|Procedure|Multi-layer compression therapy|Application of multi-layer compression therapy.
198951|NCT02011503|Other|Application of dHACM|Application of dHACM to ulcer.
198952|NCT02011516|Drug|Baclofen|
198953|NCT00120380|Drug|Aerosolized iloprost|
198954|NCT02011516|Behavioral|Psychosocial|
198955|NCT02011516|Drug|Placebo|
198956|NCT02011529|Other|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
198957|NCT02011542|Drug|VSL#3|This is a probiotic mixture
198958|NCT02011542|Drug|Placebo|This is a pill with inactive ingredients.
198959|NCT02011568|Other|Therapeutic Hypothermia|
198960|NCT02011594|Drug|Nimotuzumab|400mg Q2W intravenously
198961|NCT02011594|Drug|Placebo|Normal saline
198962|NCT02011620|Other|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
198963|NCT02011633|Drug|HCP1201 500/10mg|500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
198964|NCT00120380|Drug|Placebo|
198965|NCT02011633|Drug|Metformin SR 500mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
214836|NCT02119286|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
214837|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
214838|NCT02121522|Drug|BI 144807|twice daily
214839|NCT02121535|Drug|T80/A5 mg FDC tablet|
214840|NCT02121535|Drug|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
214841|NCT02121535|Drug|H12.5 mg tablet|
214842|NCT02121535|Drug|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
214843|NCT02121535|Drug|H12.5 mf tablet|A HCTZ 12.5 mg tablet
214844|NCT02121535|Drug|T80/A5/H12.5 mg FDC tablet|
214845|NCT02121548|Behavioral|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
214846|NCT00131430|Drug|taranabant|
214847|NCT02121548|Behavioral|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
215133|NCT02154867|Other|Placebo fecal transplant|Fecal transplantation with own feces
215134|NCT02154880|Procedure|PFT|Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
215135|NCT02154880|Procedure|lab work|The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
215136|NCT02154880|Procedure|6MWT|The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
215137|NCT02154880|Other|questionnaires|TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
215138|NCT00134537|Device|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
214523|NCT02126241|Other|NICaS guided CRT optimization|Baseline CO measurement by NICaS
AV delay optimization:
AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS
The AV delay yielding the maximal CO, will be considered the optimal AV delay
The device will be programmed using the optimal AV delay
VV delay optimization:
After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS
The VV delay yielding the maximal CO, will be considered the optimal VV delay
The device will be programmed using the optimal VV delay
214524|NCT02126254|Device|Hemodynamic group|NICAS guided treatment
214525|NCT02128906|Radiation|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
214526|NCT02128906|Drug|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
214527|NCT02128906|Drug|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
214528|NCT02128919|Device|tDCS|Transcranial Direct Current Stimulation
214529|NCT02128932|Drug|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
214530|NCT02128932|Drug|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly and 4 doses (4 weeks) of 0.5 mg semaglutide subjects will receive 1.0 mg semaglutide weekly for 22 weeks.
214531|NCT02128932|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
214532|NCT02128945|Other|[18F] - Fludarabine PET/CT|[18F] - Fludarabine PET/CT before treatment
214533|NCT02128958|Drug|CF102|orally q12h
214534|NCT02128958|Drug|Placebo|orally q12 hours
214535|NCT00002239|Drug|Ritonavir|
214848|NCT02121561|Behavioral|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
214849|NCT02121574|Device|Zero flux and ingestible thermometers|
214211|NCT02134093|Drug|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
214212|NCT02134093|Drug|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
214213|NCT02134093|Drug|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3~6 mg/kg/h）, remifentanil （0.05~0.3 μg/kg/min）is required to maintain Entropy within 40~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05~0.1mg/kg） as needed to maintain muscle relaxation.
214214|NCT02134106|Drug|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
214215|NCT02134106|Drug|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
214216|NCT02134119|Dietary Supplement|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 4,000mg/day by mouth
214217|NCT02134119|Dietary Supplement|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day by mouth
214218|NCT02134119|Drug|Placebo|Sugar pill manufactured to mimic echinacea-based dietary supplement
214219|NCT02136368|Behavioral|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
214220|NCT02136368|Behavioral|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
214221|NCT02136381|Behavioral|LEAP intervention|LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.
Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.
Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.
Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles
214222|NCT02136381|Behavioral|Control|Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).
The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.
Participants in the control group will be assessment after two months.
214223|NCT00002241|Drug|Lamivudine|
218665|NCT00151775|Drug|placebo|Cohorts A, B, C: placebo, once daily
218666|NCT02303522|Other|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
218667|NCT02303535|Procedure|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
218668|NCT02303535|Procedure|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
218669|NCT02303548|Drug|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
218670|NCT02303548|Drug|Normal saline|Placebo
213891|NCT02141737|Drug|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
213892|NCT02141737|Drug|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
213893|NCT02141737|Drug|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
213894|NCT02141737|Drug|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
213895|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Escherichia coli|
213896|NCT02141737|Drug|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
213897|NCT02141737|Drug|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
213898|NCT02143973|Drug|nalbuphine HCl ER 60mg BID|nalbuphine HCl ER 60mg BID for up to 24 weeks
213899|NCT02143973|Drug|nalbuphine HCl ER 90mg BID|nalbuphine HCl ER 90mg BID for up to 24 weeks
213900|NCT00133640|Behavioral|Physiotherapy|
213901|NCT02143973|Drug|nalbuphine HCl ER 120mg BID|nalbuphine HCl ER 120mg BID for up to 24 weeks
213902|NCT02144012|Drug|trastuzumab + docetaxel|For the first cycle, trastuzumab 8 mg/kg IV plus docetaxel at either 75 mg/m2 or 100 mg/m2 IV. For the subsequent cycles, trastuzumab 6 mg/kg IV plus docetaxel 75 mg/m2 or 100 mg/m2 IV Q3W
213903|NCT02144012|Drug|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg intravenous (IV) over 30-90 minutes every 3 weeks (Q3W)
213904|NCT02144025|Drug|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
218362|NCT02310997|Drug|Fludarabine|
218363|NCT02311010|Drug|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
218364|NCT02311023|Other|Intermittent fasting|
218365|NCT02311036|Other|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
218366|NCT02311049|Radiation|Hypofractionation|
218367|NCT02311062|Other|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
218368|NCT00152516|Drug|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
218369|NCT02311062|Other|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
218370|NCT02311062|Other|Control|Only soccer training
218371|NCT02311075|Biological|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
218671|NCT02303561|Behavioral|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
218672|NCT02303561|Behavioral|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
218673|NCT02303574|Drug|AZD7986, oral solution, 1 to 50 mg/mL|Starting dose in single ascending dose part: 5 mg
218674|NCT02305992|Procedure|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
218675|NCT02306018|Device|EV1000™/volumeView™|
218676|NCT02306031|Drug|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
218677|NCT02306031|Drug|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
218678|NCT00152048|Drug|Eflornithine hydrochloride|
218679|NCT02306057|Procedure|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
218075|NCT00002371|Drug|Lamivudine|
218076|NCT00148733|Drug|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
218077|NCT02279186|Drug|Tranexamic Acid|Intravenous Injection
218078|NCT00002372|Drug|Indinavir sulfate|
218079|NCT00148980|Device|DBM for creation of bone marrow microenvironment|
218080|NCT02279225|Radiation|Group Phototherapy|
218081|NCT02279225|Radiation|Phototherapy + Physical activity|
218082|NCT02279225|Other|Physical activity|
218083|NCT02279225|Other|Placebo|
218084|NCT02279238|Procedure|cardiac rehabilitation|It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest [Washout time] in between the two test.
6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.
3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.
The data of [HR, SPO2, PSG RPE scale, Distance walked, BP] the participants are collected before, during and after the completion of each lap [according to American Thoracic Society [ATS] protocol].
218085|NCT02279251|Behavioral|VÅG|Low-intensity CBT intervention
218086|NCT02279251|Behavioral|CHILLED|Evidence based CBT intervention
218087|NCT02279264|Device|RightSpot Infant pH Indicator|pH indicator
218088|NCT02279277|Behavioral|Supervised physical therapy program prior to total knee replacement surgery|
218089|NCT02279290|Behavioral|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
218090|NCT00148993|Biological|Tumor Cell Vaccine|
218091|NCT02279290|Behavioral|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
218372|NCT02311088|Drug|Caffeine|
218373|NCT02311088|Drug|Placebo|
217482|NCT00150436|Drug|Pregabalin|
217483|NCT02290938|Other|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
217484|NCT02290951|Drug|REGN1979 multiple dose levels|
217485|NCT02290964|Procedure|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
217486|NCT02290977|Radiation|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
217779|NCT02284087|Device|PAS|
217780|NCT02284100|Behavioral|animal assisted therapy|For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.
The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions.
217781|NCT02284113|Device|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
217782|NCT02284113|Device|iovera° Sham|iovera° device used for sham treatment
217783|NCT02284126|Drug|Vancomycin|Topically applied powder and paste to surgical site at time of closure
217784|NCT02284139|Drug|Arm 1|EGF Ointment (Arm1 drug) evenly apply to skin lesion every 12 hr/ day
217785|NCT02284139|Drug|Arm 2|EGF Ointment 20 (Arm 2 drug) evenly apply to skin lesion every 12 hr/ day
217786|NCT02284152|Behavioral|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
217787|NCT02284165|Other|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
217788|NCT02286544|Drug|Oxygen (Oxymask®)|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.
Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
217789|NCT02286544|Drug|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
217493|NCT00002377|Drug|Valganciclovir|
217494|NCT00150449|Drug|Pregabalin|
217495|NCT02293395|Drug|Ticagrelor|Ticagrelor 90 mg twice daily orally.
217496|NCT02293421|Other|Obstructive sleep apnea|
217497|NCT02293447|Drug|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
217498|NCT02293447|Drug|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
217499|NCT00150683|Device|vibration and passive standing versus passive standing alone|
217500|NCT02293460|Drug|I10E|Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.
Duration of treatment period: 21 weeks +/- 7 days.
217501|NCT02293473|Device|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
217502|NCT02293473|Device|BIS-Bispectral Index Monitor|Depth of anaesthesia
217503|NCT02293473|Device|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
217504|NCT02293473|Other|Standard of care|Using standard of care
217505|NCT02293486|Dietary Supplement|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
217797|NCT02286596|Device|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
217798|NCT02286596|Device|dextran sulfate adsorption|Lipid apheresis for 3 hours
217799|NCT02286609|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
217800|NCT02286622|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
217201|NCT02298140|Other|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
217202|NCT02298153|Drug|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
217203|NCT02298153|Drug|epacadostat|epacadostat: Oral daily dosing
217204|NCT02298166|Drug|chemotherapy (Mitoxantrone, Cytarabine)|Induction therapy:
Mitoxantrone 10 mg/m² IV, push d 1-3
Cytarabine 1000 mg/m² IV (500 mg/m² for patients > 60 years of age), over 3 hours, d 1-6
Consolidation therapy:
Younger adult patients (18 to 60 yrs):
1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).
Older patients (> 60 yrs) and or previous allogeneic HSCT:
1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²).
217205|NCT02298166|Drug|Placebo|Induction therapy:
Placebo to be given as p.o. TID starting d 7+, given continuously thereafter, except for days of chemotherapy
Consolidation therapy:
Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.
Maintenance therapy with placebo is intended in all patients in CR after allogeneic HSCT or high-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HSCT or HiDAC.
Maintenance with placebo will be given at the same dose tolerated during induction therapy
217206|NCT02300298|Drug|Nintedanib|Nintedanib
217207|NCT02300298|Drug|Docetaxel|Docetaxel
217208|NCT00151437|Procedure|Medical History, demographics|
217209|NCT02300311|Drug|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
217210|NCT02300311|Drug|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
217211|NCT02300324|Dietary Supplement|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
217212|NCT02300324|Dietary Supplement|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
217213|NCT02300324|Dietary Supplement|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
217214|NCT02300337|Device|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
217215|NCT02300350|Drug|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
217216|NCT02300350|Drug|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
216638|NCT02312778|Other|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
216920|NCT02305160|Drug|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
216921|NCT00151970|Drug|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
216922|NCT02305173|Drug|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
216923|NCT02305173|Drug|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
216924|NCT02305186|Drug|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
216925|NCT02305186|Radiation|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
216926|NCT02305199|Drug|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
216927|NCT02305199|Drug|Normal saline|Fluid containing Sodium chloride 9 g/L
216928|NCT02305212|Behavioral|Cogmed|
216929|NCT02305225|Behavioral|Sleep Deprivation|
216930|NCT02307591|Drug|Best Supportive Care + Amiodarone|This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .
During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).
Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.
Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.
Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).
Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:
Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)
Children < 29 kg: 5 mg/kg 3 times a day
216931|NCT02307604|Genetic|Tumour markers testing|
216932|NCT02307630|Biological|124I-Humanized 3F8|
216933|NCT00152217|Drug|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
216934|NCT02307643|Drug|MT-1303 Low dose|
216935|NCT02307643|Drug|MT-1303 High dose|
216936|NCT02307656|Drug|Atazanavir|
201085|NCT02007083|Procedure|Unilateral laminotomy with crossover (UL)|
201086|NCT02007083|Procedure|Spinous Process Osteotomy (SPO)|
201087|NCT02007096|Drug|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight <100kg: 50ml total; weight >100kg: 60ml total
201088|NCT00119873|Biological|VRC-HIVADV014-00-VP|
201089|NCT02007096|Drug|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight <100kg: 50ml; weight >100kg: 60ml
201090|NCT02007122|Other|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
201091|NCT02007122|Other|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
201092|NCT02007148|Drug|capecitabine|twice a day
201093|NCT02007148|Drug|Docetaxel|cycles repeated every 3 weeks
201094|NCT02009410|Drug|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
201095|NCT02009410|Drug|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
201096|NCT02009423|Drug|Masitinib|
201097|NCT02009423|Drug|Placebo|
201098|NCT02009436|Drug|Azacitidine|Given via nebulizer
201099|NCT00120146|Drug|Metformin|
201100|NCT02009436|Other|Laboratory Biomarker Analysis|Correlative studies
201101|NCT02009436|Other|Pharmacological Study|Correlative studies
201102|NCT02009449|Drug|AM0010|Daily subcutaneous injections of AM0010 up to 12 months
201103|NCT02009449|Drug|Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Day 1 of every 21 day cycle
201104|NCT02009449|Drug|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Intravenous administration on Day 1 and 2 of every 14 day cycle
201105|NCT02009449|Drug|gemcitabine/nab-paclitaxel|Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
201106|NCT02009449|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
200468|NCT02020226|Drug|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
200469|NCT02020239|Other|Exercise|
200470|NCT02020252|Other|Touchscreen Computer Program|A program which allows patients to see information on a computer screen regarding cancer care, and specifically clinical trials
200471|NCT02020265|Device|EEG neurofeedback|
200472|NCT02020278|Drug|Tolvaptan|
200769|NCT02012361|Procedure|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.
200770|NCT02012361|Procedure|Muscle Biopsy|During the course of the operation a small muscle biopsy will be collected.
200771|NCT02012374|Behavioral|Intensive Language Action Therapy|
200772|NCT02012387|Biological|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
200773|NCT02012387|Biological|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
200774|NCT02012387|Biological|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
200775|NCT02012400|Other|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks.
200776|NCT02015156|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
200777|NCT02015169|Drug|Lapatinib|lapatinib 1250mg qd daily up to 8 cycles (3 weeks * 8 cycles = 24 weeks)
200778|NCT02015182|Other|Blood sample for bupivicaine pharmacokinetics|Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).
Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA).
200779|NCT02015195|Other|Acetic Acid (5%)|
200780|NCT00120757|Drug|Alendronate|
200166|NCT02027753|Drug|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
200167|NCT02027753|Drug|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
200168|NCT02027766|Other|Calf muscle stretching|
200169|NCT02027779|Biological|GreenGene™ F|Prophylaxis safety and efficacy substudy:
intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days
200170|NCT02027779|Biological|GreenGene™ F|On-demand safety and efficacy substudy:
minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg
200171|NCT02027792|Other|Cabbage leave wraps|
200172|NCT00121836|Drug|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
200173|NCT02027792|Drug|Diclofenac Gel|
200174|NCT02027805|Biological|T-Guard|
200175|NCT02027818|Drug|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
200176|NCT02027831|Drug|Indocyanine Green|
200177|NCT02027844|Behavioral|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
200473|NCT02020291|Drug|Foxy-5|
200474|NCT00121212|Procedure|carbon-11 acetate PET scan|
200475|NCT02020304|Drug|combined spinal epidural|Combined Spinal Epidural
200476|NCT02020317|Behavioral|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
200477|NCT02020330|Drug|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
200478|NCT02020330|Drug|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
200479|NCT02022709|Drug|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
200480|NCT02022709|Drug|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
199866|NCT02033018|Drug|Aflibercept Injection|Aflibercept intravitreal injection
199867|NCT02033031|Drug|Lucentis intravitreal injection|Lucentis intravitreal injection
199868|NCT02033031|Drug|Avastin intravitreal injection|Avastin intravitreal injection
199869|NCT01952912|Procedure|PkEP|
199870|NCT01952912|Procedure|OP|
199871|NCT01952925|Procedure|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
199872|NCT01952938|Procedure|LINK SL versus EnduRo|
199873|NCT01952951|Drug|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
199874|NCT01952951|Radiation|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
199875|NCT01952964|Other|JUC spray dressing|Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.
Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals.
199876|NCT01952977|Dietary Supplement|Test breakfast|
199877|NCT01952990|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
199878|NCT01953003|Drug|vinflunine|intraveinous administration day 1 once every 3 weeks, 280 mg/m²
199879|NCT00115063|Drug|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
199880|NCT01953003|Drug|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
200178|NCT02027844|Behavioral|parental presence|parental presence during inhalational induction of sevoflurane
200179|NCT02027857|Device|EIT monitoring|
200180|NCT02027857|Device|non-invasive ICP monitoring|
199571|NCT01998386|Other|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
199572|NCT01998386|Other|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
199573|NCT02000765|Drug|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing [14C] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
199574|NCT02000765|Drug|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing [14C] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
199575|NCT02000778|Drug|EC17|
199576|NCT02000791|Other|Comparison of fibreoptic view|
199577|NCT02000804|Drug|darapladib 160mg|drug
199578|NCT00119366|Drug|cyclosporine|Given IV or PO
199579|NCT02000817|Biological|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
199580|NCT02000817|Biological|Placebo|Placebo is available 0.9% w/v sodium chloride
199581|NCT02000830|Drug|stannsoporofin|
199582|NCT02000843|Procedure|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
199583|NCT02000856|Dietary Supplement|Beetroot juice|
199881|NCT01953029|Procedure|cardiac imajing|Cardiac MRI
199882|NCT01953042|Behavioral|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
198966|NCT02011633|Drug|Rosuvastatin 10mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
198967|NCT02014168|Biological|Viroflu® and saline placebo|2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.
0.9% saline placebo.
198968|NCT02014181|Dietary Supplement|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
198969|NCT02014194|Behavioral|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
198970|NCT02014207|Other|dietary treatment|
199256|NCT02006238|Device|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
199257|NCT00119795|Behavioral|Exercise|Increase Physical Activity to 150 min/wk
199258|NCT02006264|Drug|TDF Intravaginal Ring|
199259|NCT02006264|Drug|Placebo Intravaginal Ring|
199260|NCT02006277|Drug|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
199261|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
199262|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
199263|NCT02006277|Drug|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
199264|NCT02006277|Drug|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
199265|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
199266|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
199267|NCT02006277|Drug|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
199268|NCT00119795|Behavioral|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
199269|NCT02006277|Drug|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
215139|NCT02154893|Device|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
215140|NCT02154893|Device|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
215141|NCT02116946|Biological|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
215142|NCT02116959|Drug|Melphalan|
215143|NCT02116959|Drug|Carboplatin|
215144|NCT02116959|Drug|Etoposide|
215145|NCT02116959|Drug|Vincristine|
215146|NCT00131027|Drug|L-asparaginase|
215147|NCT02116972|Drug|FX006|Single intra-articular injection
215148|NCT02116972|Drug|Normal saline|Single intra-articular injection
215149|NCT02116985|Device|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
215150|NCT02116985|Device|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
215151|NCT02116998|Biological|GEN-004 with Aluminum Hydroxide Adjuvant|GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.
GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:
GB104: ABC transporter, substrate-binding protein
GB144: Maltose/maltodextrin binding protein, ABC transporter
GB152: Hypothetical protein
GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).
Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL.
215453|NCT02149797|Procedure|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
215454|NCT02149810|Behavioral|Automatic Self Transcending Meditation|as above
215455|NCT02149823|Drug|Syntocinon 24 Intranasal Units (IU)|On Visit 1, all patients (schizotypal and borderline) will be randomized into 3 equally sized sub-groups, each of which will receive the 3 acute treatments (oxytocin 24IU or 40IU or placebo) in a different sequence: group 1 will receive placebo on visit 1, oxytocin 40IU on visit 2 and oxytocin 24IU on visit 3; group 2 will receive oxytocin 24IU on visit 1, placebo on visit 2, and oxytocin 40IU on visit 3; group 3 will receive oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, and placebo on visit 3, in double blind fashion. HCs will not receive drug/placebo
215456|NCT02149823|Drug|Syntocinon 40 Intranasal Units (IU)|
215457|NCT02149823|Drug|Intranasal Placebo|
214850|NCT02121587|Behavioral|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
214851|NCT02121600|Other|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.
214852|NCT02121600|Radiation|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
214853|NCT02121600|Radiation|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
214854|NCT02121613|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
214855|NCT02121613|Drug|Tamsulosine LP|Oral administration - 0.4 mg daily.
214856|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
214857|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
214858|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
214859|NCT00131677|Drug|placebo|study product taken daily
214860|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
214861|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
214862|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
214863|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
214864|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
215152|NCT02116998|Biological|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
214224|NCT00133042|Drug|omalizumab|
214225|NCT02136394|Other|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
214536|NCT00132197|Procedure|Recommendation of care (letter to general practitioner [GP])|After the diagnostic assessment the patient does not receive any treatment offers at the research clinic, but the patient and the GP will be informed about the diagnosis, and the GP will receive advice on further treatment possibilities.
214537|NCT02128971|Dietary Supplement|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214538|NCT02128971|Dietary Supplement|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214539|NCT02128971|Dietary Supplement|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214540|NCT02128971|Dietary Supplement|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214541|NCT02128971|Dietary Supplement|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
214542|NCT02128971|Dietary Supplement|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
214543|NCT02128984|Dietary Supplement|Symbiotic Formula with DHA and antioxidants|6 months intervention.
214544|NCT02128984|Dietary Supplement|Standard Formula|6 months intervention.
214545|NCT02128997|Device|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
214546|NCT02129023|Device|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
214547|NCT00132210|Drug|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
214548|NCT02129049|Other|educational intervention|Participate in the Enhancing Connections Telephone Program
214549|NCT02131272|Drug|insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial metformin treatment should continue unchanged during the treatment period.
214550|NCT02131272|Drug|insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial metformin treatment should continue unchanged during the treatment period.
214551|NCT02131285|Other|Sensory training|
213905|NCT02144038|Drug|LGH447|pan-PIM inhibitor
213906|NCT02144038|Drug|BYL719|PI3K-alpha inhibitor
213907|NCT02144051|Drug|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
213908|NCT02144064|Drug|Heparin|Group A (n = 70) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
213909|NCT02144077|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
213910|NCT02144077|Drug|methyl-aminolevulinate|topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
214226|NCT02136420|Drug|Promethazine|Subject receives promethazine
214227|NCT02136420|Behavioral|Hyper gravity training|Subject receives hypergravity training before testing
214228|NCT02136420|Drug|Placebo|Placebo
214229|NCT02136420|Behavioral|No hypergravity training|Subjects do not receive normal Earth gravity
214230|NCT02136433|Device|Tablet - self exercise|
214231|NCT02136433|Other|GRASP self exercise|
214232|NCT02136446|Device|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
214233|NCT02136446|Device|Pajunk® Nerve Block Catheter|Nerve Block Catheter
214234|NCT02136459|Other|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
214235|NCT00133055|Behavioral|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
214236|NCT02136459|Other|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
214237|NCT02136485|Behavioral|Mindfulness-based stress reduction (MBSR)|8 sessions of MBSR
214238|NCT02136485|Other|waiting list control|
214239|NCT02136498|Drug|Varenicline|Standard 12 week course of varenicline
218680|NCT02306057|Procedure|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
218681|NCT02306057|Procedure|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
218682|NCT02306057|Procedure|TCPC|Surgical procedure Total CavoPulmonary Connection
218683|NCT02306070|Drug|Metformin|
218684|NCT02306070|Other|No treatment|
218685|NCT02306083|Drug|Placebo three times a day|
218686|NCT02306083|Drug|glucosamine sulfate 1500 mg three times a day|
218687|NCT02306109|Procedure|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
218688|NCT02306109|Procedure|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
218689|NCT00152061|Drug|3TC and FTC|
218690|NCT02306122|Behavioral|Pharmacist calls patient unless physician cancels call|
218691|NCT02306122|Behavioral|Patient nonadherence information sent to physician|
213911|NCT00133653|Behavioral|Observational|
213912|NCT02144090|Device|Fractional flow reserve measurement|Fractional flow reserve measurement
213913|NCT02144103|Other|Subtenon administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected into subtenon space of patient's eye.
213914|NCT02144103|Procedure|Liposuction|
213915|NCT02144103|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
213916|NCT02144116|Other|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
213917|NCT02144116|Other|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
218374|NCT02311101|Drug|Mitomycin C|Given intravesically
218375|NCT02311114|Other|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
218376|NCT02311114|Other|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
218377|NCT02313441|Other|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
218378|NCT02313454|Device|Oculeve Intranasal Lacrimal Neurostimulator|Neurostimulation applied intranasally and extranasally.
218379|NCT02313467|Drug|Topical application of 1.5% Butenyl ALA|
218380|NCT02313467|Drug|Topical application of sham control|
218381|NCT02313480|Other|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
218382|NCT02313493|Behavioral|Baby Triple P|
218383|NCT02313506|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counselling by a PT. Intervention will be received immediately.
218384|NCT02313506|Behavioral|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
218385|NCT02313519|Dietary Supplement|Probiotics|Probiotics are prepared in capsule form
218386|NCT00152724|Drug|brethyllium|
218387|NCT02313519|Dietary Supplement|Placebo|Glucose powder
218388|NCT02313545|Drug|IZN-6NVS Cream|IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.
Cream concentration: 5%
218389|NCT02313558|Drug|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
218390|NCT02313558|Drug|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
218391|NCT02313584|Drug|dabigatran|
218392|NCT02313584|Drug|placebo|
218393|NCT02313597|Procedure|VAAFT|Video assisted Anal fistula Treatment is minimal invasive method of treatment of complex and high anal fistulas.
217790|NCT02286557|Drug|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
217791|NCT02286557|Drug|Placebo|
217792|NCT00149825|Drug|Escitalopram|5 to 20 mg for 12 weeks
217793|NCT02286570|Device|Glidescope|videolaryngoscope used for endotracheal intubation
217794|NCT02286570|Device|Airtraq|videolaryngoscope used for endotracheal intubation
217795|NCT02286570|Device|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
217796|NCT02286583|Device|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
218092|NCT02279303|Behavioral|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
218093|NCT02279303|Behavioral|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
218094|NCT02279316|Drug|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
218095|NCT02279316|Other|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
218096|NCT02279316|Other|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
218097|NCT02281669|Drug|Pentostam|Intralesional injection of Pentostam
218098|NCT02281682|Drug|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
218099|NCT02281682|Drug|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
218100|NCT02281682|Drug|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
218101|NCT02281682|Procedure|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
217801|NCT02286635|Drug|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
217802|NCT02286635|Drug|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis, uncomplicated skin infections, upper and lower respiratory tract infections caused by susceptible strains of microorganisms
217803|NCT02288741|Drug|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
217804|NCT02288741|Drug|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
217805|NCT02288741|Procedure|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 * 10E6/kg
217806|NCT02288741|Drug|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
217807|NCT02288741|Procedure|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2*10E6 CD34-cell/kg per transplantation)
217808|NCT00150111|Drug|Rituximab|
217809|NCT02288754|Drug|Chemotherapy|Chemotherapy as prescribed for cancer
217810|NCT02288767|Device|Conventional arterial blood pressure monitoring|
217811|NCT02288767|Device|Stroke volume variation monitoring with arterial blood pressure monitoring|
218110|NCT02281773|Drug|Placebo|
218111|NCT02281773|Drug|BI 498306 25 mg QD|
218112|NCT02281773|Drug|BI 409306 10 mg QD|
218113|NCT02281786|Drug|Placebo|Matching placebo to RO6926496
218114|NCT00149279|Procedure|Surgery: D2+paraaortic dissection|
218115|NCT02281786|Drug|RO6926496|single, ascending dose, intravenous administration
217217|NCT02300350|Drug|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
217506|NCT02293499|Behavioral|PLASMA|A structured asthma self-management manual ("Let's Talk about Asthma [LTAA],"developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site.
217507|NCT02293512|Behavioral|Coping Effectiveness Training for tinnitus|A CET psycho-educational intervention to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
217508|NCT02293512|Behavioral|Cognitive-behavioral therapy (CBT)|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
217509|NCT02293512|Behavioral|Acceptance and Commitment Therapy for tinnitus|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
217510|NCT00150696|Drug|Risedronate|
217511|NCT02293525|Device|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
217512|NCT02293525|Drug|Ropivacaine|
217513|NCT02293525|Drug|Saline|
217514|NCT02293525|Drug|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
217515|NCT02293525|Drug|Oxycodone|10mg every 4-6 hours
217516|NCT02293538|Drug|FID# 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye.
217517|NCT02293538|Drug|Saline eye drops (15 ml)|
217518|NCT02293538|Device|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power.
217519|NCT02295995|Behavioral|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Eighty Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
217520|NCT02296008|Device|3D high resolution anorectal manometry|Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.
3D picture of pressures of anorectal will be recorded.
216937|NCT02307656|Drug|Cobicistat|
216938|NCT02307656|Drug|Active Pharmaceutical Ingredient|
217218|NCT02300363|Drug|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
217219|NCT00151437|Procedure|Sign and symptoms: questionnaire|
217220|NCT02300363|Drug|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
217221|NCT02300363|Drug|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
217222|NCT02300376|Drug|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
217223|NCT02300389|Radiation|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
217224|NCT02300389|Radiation|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
217225|NCT02300415|Biological|blood sample|Dosage of presepsine
217226|NCT02302768|Other|Placebo|
217227|NCT00002380|Drug|Saquinavir|
217228|NCT00151697|Drug|Novomix 30|
217229|NCT02302781|Other|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
217230|NCT02302794|Procedure|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
217231|NCT02302794|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
217232|NCT02302807|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab, 1200 mg by intravenous infusion on Day 1 of each 21-day cycle
201107|NCT02009449|Drug|Pazopanib|Pazopanib will be administered orally daily continuously
201108|NCT02009449|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
201415|NCT02001714|Behavioral|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
201416|NCT02001727|Other|13C-Urea breath test for Helicobacter Pylori|
201417|NCT02001727|Other|Questionaire|
201418|NCT02001740|Drug|Triamcinalone (steroid) and lidocaine|receive once
201419|NCT02001740|Other|Lidocaine|receive once
201420|NCT02001753|Device|CMR|
201421|NCT00119392|Radiation|total-body irradiation|Undergo TBI
201422|NCT02001766|Behavioral|Exercise training|
201423|NCT02001779|Procedure|Stenting|Comparison of a self-expandable metallic biliary stent loaded with 125 iodine seeds or a self-expandable metallic stent insertion in patients with inoperable cholangioma.
201424|NCT02001779|Device|self-expandable metallic biliary stent loaded with 125 iodine seeds|
201425|NCT02001779|Device|conventional biliary self-expandable stent|
201426|NCT02001779|Procedure|brachytherapy|
201427|NCT02001792|Procedure|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
201428|NCT02001792|Device|pulse oximeter|
201429|NCT02001818|Drug|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
201430|NCT02001831|Dietary Supplement|Supplement|
201431|NCT02001831|Dietary Supplement|Placebo|
201432|NCT00119418|Drug|TU 025 Keishi Bukuryo Gan|
201433|NCT00002162|Drug|Zalcitabine|
201434|NCT00119652|Behavioral|mood stabilizing activity|
200781|NCT02015195|Other|Sodium Bicarbonate Slurry (50%)|
200782|NCT02015195|Other|Papain Slurry (70%)|
200783|NCT02015195|Other|Ammonia (10%)|
200784|NCT02015195|Drug|Lidocaine (4%)|
200785|NCT02015195|Other|Isopropyl Alcohol (70%)|
200786|NCT02015195|Other|Hot Tap Water (40 degrees Celsius)|
200787|NCT02015195|Other|No treatment|
200788|NCT02015208|Drug|Ruxolitinib|20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
201109|NCT02009449|Drug|Paclitaxel|Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)
• Paclitaxel 80 mg/ m2 IV
201110|NCT00120172|Drug|oxaliplatin, capecitabine, bevacizumab|
201111|NCT02009449|Drug|nivolumab|Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
201112|NCT02009449|Drug|Gemcitabine/carboplatin|gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
201113|NCT02009462|Drug|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
201114|NCT02009475|Other|Interval exercise training|
201115|NCT02009475|Other|Continues aerobic training|
201116|NCT02009488|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
201117|NCT02009488|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
201118|NCT02009488|Drug|Placebo|One placebo capsule (inactive medication) once daily.
201119|NCT02009501|Device|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
201120|NCT02009501|Device|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
201121|NCT02012413|Device|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
200481|NCT02022709|Drug|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
200482|NCT00121433|Drug|leptin|
200483|NCT02022709|Drug|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
200484|NCT02022709|Behavioral|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
200485|NCT02022722|Drug|Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride|The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
200486|NCT02022722|Procedure|Pelvic Rehabilitation|Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
200487|NCT02022735|Device|R ON|
200488|NCT02022735|Device|BL ON|
200489|NCT02022735|Device|BL OFF|
200490|NCT02022735|Device|L ON|
200491|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
200789|NCT02015221|Device|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
200790|NCT02015221|Device|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
200791|NCT00120770|Drug|Cellulose Sulfate Vaginal Gel (Microbicide)|
200792|NCT02015234|Drug|TNX-102 SL|TNX-102 2.8 mg SL taken daily at bedtime.
200793|NCT02015247|Procedure|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
200794|NCT02015260|Drug|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
200795|NCT02015260|Drug|Placebo|Placebo
200796|NCT02015273|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
200797|NCT02015286|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
200181|NCT02027870|Device|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
200182|NCT02027883|Device|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
200183|NCT00121849|Biological|Leish-111f + MPL-SE vaccine|
200184|NCT02027883|Device|Educated T shock setting|Experimental Parameter Set 2 Programming Values
200185|NCT02027896|Other|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
200186|NCT02030197|Behavioral|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
200187|NCT02030197|Other|Control Group|no treatment
200188|NCT02030223|Procedure|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
200189|NCT02030236|Device|Cooling|Temperature reached Duration of exposure to cold.
200190|NCT02030249|Behavioral|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
200191|NCT02030249|Behavioral|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
200192|NCT02030249|Behavioral|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
200193|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
200194|NCT00122213|Behavioral|Behavior change on physical activity and diet|
200195|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
200196|NCT02030275|Drug|RXI-109|surgery.
200197|NCT02030275|Drug|Placebo|surgery.
200492|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
199883|NCT01953055|Radiation|Stereotactic ablative radiotherapy|
199884|NCT01953081|Drug|TD-8954|
199885|NCT01953081|Drug|Metoclopramide|
199886|NCT01953094|Procedure|Screening Anal Pap Smear - No High Resolution Anoscopy|
199887|NCT01953094|Procedure|Screening Anal Pap Smear - With High Resolution Anoscopy|
199888|NCT01953107|Other|Oral Ferrous Fumarate|
199889|NCT01953107|Other|Placebo|
199890|NCT00115063|Behavioral|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
199891|NCT01953120|Drug|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
199892|NCT01995864|Behavioral|CTI-TS|The following briefly describes the three phases of CTI-TS:
Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.
Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.
Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual.
199893|NCT01995877|Procedure|Subjects scheduled for IVC filter placement|Subjects will have an intra vascular ultrasound (IVUS) performed while you are lying down on the exam table; this will be performed before the IVC(inferior vena cava) filter is placed and again after the filter has been placed. During the ultrasound measurements of the diameter of different areas of the IVC(inferior vena cava) will be taken. The table will then be moved so that you are in a standing position; the same measurements will be taken while you are standing.
The ultrasound will be performed by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS(intra vascular ultrasound)catheter will be inserted through the sheath and used to measure the size of the IVC(inferior vena cava) at various places.
The IVUS(intra vascular ultrasound) procedure will add approximately 30 to 45 minutes to the filter placement procedure.
199894|NCT00118976|Drug|Lisinopril|
199895|NCT01995890|Drug|nepafenac|
199896|NCT01995903|Device|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
199897|NCT01995916|Behavioral|Mindfulness Intervention|The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
199898|NCT01995916|Behavioral|Social Support Group|The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
199899|NCT01995929|Procedure|transnasal functional endoscopy|
199270|NCT02006290|Drug|PF-06412562|single oral split dose 30+20 mg QD
199271|NCT02006290|Drug|Placebo|tablet, matching placebo, QD
199272|NCT02008617|Drug|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
199273|NCT02008617|Drug|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
199274|NCT02008630|Other|Animal-assisted activity|
199275|NCT02008630|Other|Animal-assisted therapy|
199276|NCT02008643|Other|filling questionnary to quality of life|filling questionnary to quality of life
199277|NCT02008656|Drug|Oxaliplatin (OXAL)|
199278|NCT02008656|Drug|5-Fluorouracil (5-FU)|
199584|NCT02000882|Drug|BKM120|
199585|NCT02000882|Drug|capecitabine|
199586|NCT02000908|Device|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
199587|NCT02000908|Other|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
199588|NCT02000908|Other|Physiotherapy|Chiropractic massage and lymphedema treatment
199589|NCT00119366|Drug|mycophenolate mofetil|Given PO
199590|NCT02000921|Other|VLNC cigarettes|Modified risk tobacco product
199591|NCT02000921|Other|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
199592|NCT02000921|Other|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
199593|NCT02000921|Other|CN cigarettes|Experimental cigarettes with conventional nicotine content.
199594|NCT02000934|Drug|TAK-659|Dose escalation stage (Part A) Modified 3+3 dose escalation in patients with advanced solid tumor/lymphoma, with no effective treatment available projected.
Dose expansion stage (Part B) CLL, DLBCL, iNHL, MCL, and PTLD Expansions Cohort in patients with relapsed or refractory diseases.
199595|NCT02000947|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
199596|NCT02000947|Drug|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
215458|NCT02149836|Drug|ezogabine|Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).
Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).
Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).
Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).
Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.
Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:
250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue
215459|NCT02152215|Procedure|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
215460|NCT02152215|Procedure|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
215461|NCT02152228|Drug|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
215462|NCT02152254|Drug|Targeted Therapy Based on Molecular Profiling|Patients randomized to receive targeted therapy will participate in clinical trials, and will be treated at the expansion phase of Phase I clinical trials or in Phase II clinical trials. If a clinical trial is not available and a commercially available targeted therapy exists (FDA-approved for another indication), patients may receive the FDA-approved drug.
215463|NCT02152254|Drug|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
215464|NCT02152267|Device|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
215465|NCT02152280|Drug|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
215466|NCT00134264|Drug|torcetrapib/atorvastatin|
215774|NCT02144883|Behavioral|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
215775|NCT02144896|Other|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
215776|NCT02144909|Behavioral|Partners in Care with Semi-Structured Support Group|
215777|NCT02144922|Drug|Pitavastatin|
215153|NCT02117011|Other|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
215154|NCT02117024|Drug|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
215155|NCT02117024|Drug|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
215156|NCT02117024|Drug|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:
Vinorelbine
Erlotinib
Gemcitabine
Paclitaxel
Docetaxel
Pemetrexed
215157|NCT00131027|Drug|Cytarabine|
215158|NCT02117037|Other|blood sample|
215159|NCT02117050|Drug|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 mcg in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
215160|NCT02117063|Behavioral|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
215161|NCT02119286|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
215162|NCT02119325|Dietary Supplement|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
215163|NCT02119325|Dietary Supplement|0% fibre|Placebo is an energy matched powdered beverage
215164|NCT02119338|Drug|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
215165|NCT02119351|Device|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
215166|NCT02119351|Device|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
215167|NCT00131183|Drug|Nebido|
215168|NCT02119364|Other|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
214552|NCT02131298|Drug|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
214553|NCT02131298|Drug|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
214554|NCT02131311|Device|disposable, single-use pessary|
214555|NCT02131324|Drug|DFD06 Cream|
214865|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
214866|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
214867|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
214868|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
214869|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
214870|NCT00131690|Drug|Nescafé Gold Blend (exposed)|
214871|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
214872|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
214873|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
214874|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214875|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214876|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214877|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
214878|NCT02126267|Procedure|Scaling and root planing|Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
214240|NCT02136498|Behavioral|Self-help education|Standard self-help education for smoking cessation, delivered via the Internet and accessible via smart phone or other internet-capable device.
214241|NCT02138916|Drug|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
214242|NCT02138929|Drug|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
214243|NCT02138929|Drug|LDE 225|Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.
Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase.
214244|NCT02138942|Device|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
214245|NCT02138955|Drug|Liposomeal curcumin|
214246|NCT02138968|Other|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
214556|NCT02131324|Drug|Comp01|
214557|NCT02131337|Other|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
214558|NCT00132548|Drug|Amodiaquine|
214559|NCT02131350|Procedure|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
214560|NCT02131350|Drug|Ranibizumab|
214561|NCT02131363|Device|Ingrowing Toenail Treatment Kit|detailed in arm description
214562|NCT02131376|Procedure|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
214563|NCT02131376|Procedure|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
214564|NCT02131389|Device|Iconacy Hip System|
214565|NCT02131402|Device|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
214566|NCT02131402|Device|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
214567|NCT02131402|Device|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
213918|NCT02144129|Other|active Whole Body Electromyostimulation|
213919|NCT02144129|Other|Passive WB-EMS|
213920|NCT02144129|Device|WB-EMS application|
213921|NCT02144142|Biological|Moisturizer with each subject's own antimicrobial bacteria|
213922|NCT02146404|Other|hypoglycemia|Blood glucose levels will be kept at ~3.0 mmol/l
213923|NCT00133913|Procedure|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
213924|NCT02146404|Other|euglycemia|Blood glucose levels will be kept at ~5.0 mmol/l
213925|NCT02146417|Procedure|Low pressure pneumoperitoneum|
213926|NCT02146417|Procedure|Normal pressure pneumoperitoneum (12 mmHg)|
213927|NCT02146417|Procedure|Deep neuromuscular block|
213928|NCT02146430|Drug|DS-5565 15mg tablet|
213929|NCT02146430|Drug|150mg pregabalin capsule|
213930|NCT02146430|Drug|placebo tablet|matching DS-5565 tablet
213931|NCT02146430|Drug|placebo capsule|matching pregabalin capsule
213932|NCT02146430|Drug|75mg pregabalin capsule|
213933|NCT02146443|Other|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
214247|NCT02138981|Procedure|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
214248|NCT02138981|Procedure|Immediate Resection|patients received immediate surgical resection.
214249|NCT00133315|Drug|Infliximab|
214250|NCT02138994|Device|Next Science Wound Gel|
214251|NCT02138994|Drug|Triple Antibiotic Ointment Neosporin|Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:
Subject may continue the application of Neosporin until wound closure or
Subject may cross over to the treatment group for 3 months
214252|NCT02139007|Drug|Alendronate|
218692|NCT02306122|Behavioral|Pharmacist calls patient if physician requests call|
218693|NCT02306122|Behavioral|Patient HMO/PPO status revealed to physician|
218694|NCT02306135|Other|n/a- this is an observational study|
218695|NCT02306148|Other|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
218696|NCT02306161|Drug|Cyclophosphamide|Given IV
218697|NCT02306161|Drug|Doxorubicin Hydrochloride|Given IV
218698|NCT02306161|Drug|Etoposide|Given IV
218699|NCT02306161|Radiation|External Beam Radiation Therapy|Undergo EBRT
218700|NCT02308436|Device|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries & acidic challenges
218701|NCT02308449|Drug|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
218702|NCT02308449|Drug|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
218703|NCT02308462|Behavioral|CHIMPS intervention|CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).
The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid & Plass, 2011).
218704|NCT02308475|Device|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
218705|NCT02308488|Radiation|Radiation|Whole breast/chest wall, level 1- III (includes Cohort A) and SCV nodes IMRT at 2.7 Gy x 15 fractions. The treatment will consist of 15 fractions, with one fraction daily for five days a week, for 3 consecutive weeks.
218706|NCT02308501|Drug|Lastacaft ®|
218707|NCT02308501|Drug|Tears Naturale ®|
218708|NCT02308514|Device|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
218709|NCT00152269|Drug|Placebo|Placebo, Tablet, oral Daily for 12 months
218710|NCT02308514|Other|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
218102|NCT02281695|Other|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
218103|NCT00149279|Procedure|Surgery: D2 dissection|
218104|NCT02281708|Drug|vinorelbine plus cisplatin|Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days
vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks
218105|NCT02281721|Device|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
218106|NCT02281760|Drug|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
218107|NCT02281760|Drug|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
218108|NCT02281773|Drug|BI 409306 100 mg QD|
218109|NCT02281773|Drug|BI 498306 50 mg QD|
218394|NCT02313610|Drug|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
218395|NCT02313610|Drug|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
218396|NCT02313623|Procedure|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
218397|NCT00152724|Device|general and local heating|
218398|NCT02313662|Device|NBI and PDD|
218399|NCT02313675|Drug|Acetaminophen|
218400|NCT02313675|Drug|Ketorolac Tromethamine|
218401|NCT02313675|Drug|Saline|
218402|NCT02276989|Drug|acetazolamide|On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.
On Day 1, pregabalin PK measures will be collected.
On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.
On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On the mornings of Days 7-8 subjects will receive their PGB dose only.
218116|NCT02281799|Drug|Azathioprine|Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.
For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa.
218117|NCT02281812|Device|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
218118|NCT02281838|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
218119|NCT02281864|Behavioral|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
218120|NCT02284178|Other|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
218121|NCT00149604|Behavioral|exercise plus mild caloric restriction for weight loss|
218122|NCT02284178|Other|Usual Care|Oral suction with suction swab every 4 hours
218123|NCT02284191|Radiation|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
218124|NCT02284204|Drug|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
218125|NCT02284204|Drug|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
218126|NCT02284217|Device|EVD|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
218127|NCT02284217|Device|HS-1000|
218128|NCT02284230|Drug|Liraglutide|
218129|NCT02284230|Drug|Placebo|
218130|NCT02284243|Drug|Intranasal Dexmedetomidine|
218414|NCT02277041|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
218415|NCT02277041|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
217521|NCT02296021|Drug|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
217522|NCT02296021|Drug|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
217812|NCT02288793|Other|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
217813|NCT02288806|Drug|Melatonin|Melatonin 20mg once daily by mouth
217814|NCT02288806|Drug|Vitamin D|Vitamin D 2000 IU once daily by mouth
217815|NCT02288806|Drug|Placebo|Placebo pill taken once daily by mouth
217816|NCT02288819|Device|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
217817|NCT02288819|Drug|Loop diuretic downtitration|The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose >40 mg furosemide OR >1 mg bumetanide OR >20 mg torsemide, the loop diuretic dose is halved.
217818|NCT02288832|Other|-self-collected vaginal samples|
217819|NCT00002376|Drug|Stavudine|
217820|NCT00150111|Biological|Immunization with various vaccines|
217821|NCT02288832|Drug|zithromax|
217822|NCT02288832|Other|usual practices|
217823|NCT02288845|Drug|ITI-007|
217824|NCT02288858|Dietary Supplement|Viviscal Oral Supplement Tablets|Tablet (512 mg)
217825|NCT02288871|Radiation|Cardiac CT-scan|ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).
In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves.
217826|NCT02288884|Device|Acticoat PostOp|
217827|NCT02288884|Device|OpSite PostOp|
217828|NCT02288897|Drug|PV-10 (10% rose bengal disodium)|
217829|NCT02291029|Drug|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
217233|NCT02302807|Drug|Chemotherapy|vinflunine, paclitaxel, or docetaxel per the investigator's choice and administered according to local label
217523|NCT02296021|Drug|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
217524|NCT02296021|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
217525|NCT00151021|Behavioral|Tailored web-based walking program|
217526|NCT02296021|Drug|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
217527|NCT02296047|Drug|Placebo|physiological saline
217528|NCT02296047|Drug|ipratropium bromide|80 µg inhalation once
217529|NCT02296047|Drug|salbutamol|400 µg inhalation once
217530|NCT02296060|Procedure|6 minutes walking test|
217531|NCT02296073|Drug|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
217532|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
217533|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
217534|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
217535|NCT02296073|Drug|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
217536|NCT00002378|Drug|Stavudine|
217537|NCT00151034|Drug|Trastuzumab|
217538|NCT02296073|Other|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
217539|NCT02296099|Drug|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
201435|NCT02004418|Radiation|11C-Choline|
201436|NCT02004457|Behavioral|ABBT|
201437|NCT02004457|Other|TAU|
201438|NCT02004470|Procedure|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
201737|NCT01996527|Device|3-Tesla magnetic resonance imaging|3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
201738|NCT00119041|Behavioral|Diabetes Empowerment Scale|A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
201739|NCT01996527|Device|CEST-MRI|Undergo CEST-MRI
201740|NCT01996527|Device|DW-MRI|Undergo DWI-MRI
201741|NCT01996527|Device|DCE-MRI|Undergo DCE-MRI
201742|NCT01996527|Device|DSC-MRI|Undergo DSC-MRI
201743|NCT01996527|Drug|IV administration of gadolinium-containing contrast agent|Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
201744|NCT01996540|Other|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
201745|NCT01996579|Dietary Supplement|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
201746|NCT01996579|Other|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
201747|NCT01996605|Drug|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
201748|NCT01996605|Drug|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
201749|NCT00119041|Behavioral|CBOC's undergo half-day joint-clinics via teleconference|A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
201750|NCT01996605|Drug|Placebo|placebo will be administered spinally
201122|NCT02012413|Device|Placebo - Sham PST|Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.
9 sessions of application of Sham PST - during 60 minutes
201123|NCT02012426|Behavioral|Weight management program|
201124|NCT00120471|Drug|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
201125|NCT02012439|Behavioral|Mindfulness Based Cognitive Therapy|
201126|NCT02012439|Behavioral|Cognitive Therapy|
201127|NCT02012452|Behavioral|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
201128|NCT02012452|Behavioral|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
201439|NCT02004483|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
201440|NCT02004496|Device|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
201441|NCT02004509|Drug|anticoagulant by physician criteria|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
201442|NCT02004522|Drug|IPI-145 (duvelisib)|
201443|NCT02004522|Drug|Ofatumumab|
201444|NCT02004535|Procedure|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
201445|NCT00119665|Drug|MF101|
201446|NCT02004548|Drug|Metatinib Tromethamine|
201447|NCT02004574|Drug|Calcipotriol/betamethasone dipropionate gel|All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be "Responder" by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks.
201448|NCT02004587|Drug|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
200798|NCT02015299|Drug|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
200799|NCT02015299|Drug|placebo|one tablet matching placebo/day for 26 weeks
200800|NCT02015312|Drug|Epigallocatechin-3-gallate (EGCG)|Pharmaceutical formulation: capsules
Dose:
400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
200801|NCT02015312|Drug|Placebo|Pharmaceutical formulation: capsules
Dose:
400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
200802|NCT02017886|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
200803|NCT02017886|Dietary Supplement|Placebo|Placebo tablet twice daily for three weeks
200804|NCT02017899|Biological|1790GAHB vaccine|
200805|NCT02017899|Biological|GAHB-Placebo|
200806|NCT02017912|Biological|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
200807|NCT02017912|Biological|Placebo|Excipient administration by combined intramuscular and intrathecal administration
200808|NCT02017925|Behavioral|exercise intervention|Undergo pulmonary rehabilitation
200809|NCT02017925|Procedure|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
200810|NCT02017925|Procedure|quality-of-life assessment|Ancillary studies
200811|NCT00121043|Device|SimpleJectTM|
201129|NCT02012465|Biological|Insulin protocol|Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.
The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.
Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours
The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro).
201130|NCT02012478|Behavioral|MI- informed SMS program|
201131|NCT02012491|Drug|Misoprostol|
201132|NCT02012491|Drug|Mifepristone|
201133|NCT02012517|Drug|Prolonged antibiotic treatment|
200493|NCT00121446|Drug|tenecteplase|
200494|NCT02022748|Drug|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
200495|NCT02022761|Drug|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
200496|NCT02022774|Drug|Fimasartan|Fimasartan 60 ~ 120 mg/po take one tablet once a day
200497|NCT02022787|Other|patients with renal cell carcinoma|Chemokines that may be elevated in patients with RCC
200498|NCT02022800|Other|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
200499|NCT02022813|Dietary Supplement|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
200500|NCT02022826|Device|SmartPill Monitoring System|
200501|NCT02022852|Drug|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
200502|NCT02025205|Device|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
200503|NCT02025218|Drug|Gefitinib standard dose|
200504|NCT02025231|Radiation|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
200505|NCT02025244|Procedure|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
200506|NCT02025244|Procedure|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
200507|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
200812|NCT02017925|Other|questionnaire administration|Ancillary studies
200813|NCT02017938|Procedure|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
200198|NCT02030288|Behavioral|Relational Agent Intervention|Relational Agents are on-screen characters that speak to the patient and establish a "relationship" with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change.
200199|NCT02030301|Biological|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
200200|NCT02030301|Biological|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
200201|NCT02030301|Biological|PBS|Phosphate-buffered saline
200202|NCT02030314|Drug|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
200203|NCT02030340|Procedure|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
200204|NCT02030353|Behavioral|Self-regulation plus activity monitoring|Individual in-person session, digital smart scale, online intervention, and an activity monitor.
200205|NCT00122226|Drug|Lopinavir/ritonavir + zidovudine + lamivudine|
200206|NCT02030353|Behavioral|Self-regulation|Individual in-person session, digital smart scale, and online intervention.
200207|NCT02030379|Behavioral|QPL-CT|Use the QPL-CT to prioritize questions
200208|NCT02030392|Behavioral|Intervention group|Cognitive-behavioral intervention
200209|NCT02030392|Behavioral|Active control group|Education and information
200210|NCT02033044|Other|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
200211|NCT02033044|Other|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
200212|NCT02033057|Procedure|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
200213|NCT02033083|Device|Laminaria|
200214|NCT02033083|Device|Dilapan-S|
199597|NCT02000947|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
199598|NCT02003495|Biological|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
199599|NCT02003495|Biological|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
199600|NCT02003495|Biological|MPV-A Vaccine Group|0.5ml, intramuscular
199601|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
199602|NCT02003495|Biological|MCV-AC Vaccine Group|0.5ml, intramuscular
199603|NCT02003495|Biological|Hib Vaccine Group|0.5ml, intramuscular
199604|NCT02003521|Device|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
199605|NCT02003534|Drug|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
199900|NCT01995955|Procedure|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
199901|NCT01995968|Other|Antenatal identification of fetal growth restriction|FGR is considered as "identified" if:
FGR was mentioned in medical charts
OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)
OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts
OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)
OR utero-placental Doppler ultrasound indicated for suspicion of growth failure
199902|NCT01995981|Drug|Pazopanib|
199903|NCT01996046|Other|FDG PET/CT scan|[18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
199904|NCT01996059|Procedure|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
199905|NCT00118989|Drug|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
199906|NCT01996059|Procedure|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
199907|NCT01996072|Drug|EC17|
215778|NCT02144922|Drug|Antihypertensive treatment|
215779|NCT02144948|Drug|e.-coli-nissle|1 ml qd for 24 weeks
215780|NCT02144987|Biological|Bone Marrow CD133+ Stem Cell Transplantation|Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.
BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.
The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.
CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization
Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients
Hysteroscopy will be performed 2-3 months after stem cell transplantation
Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation
215781|NCT00133731|Drug|Unfractionated Heparin|
215782|NCT02147158|Drug|Ulipristal acetate (UPA) 5 mg|
215783|NCT02147158|Drug|Ulipristal acetate (UPA) 10 mg|
215784|NCT02147158|Drug|Placebo|
215785|NCT02147171|Dietary Supplement|VisionAce|
215786|NCT02147171|Dietary Supplement|Placebo|
215787|NCT02147197|Drug|Ulipristal acetate 5 mg|
215788|NCT02147197|Drug|Ulipristal acetate 10 mg|
215789|NCT02147197|Drug|Placebo|
215790|NCT02147210|Other|biological analysis|
215791|NCT00133978|Other|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
215792|NCT02147223|Dietary Supplement|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
215793|NCT02147223|Dietary Supplement|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
215794|NCT02147236|Behavioral|Social Skills Training|
216097|NCT02139787|Other|Control -listened to a brochure|
216098|NCT00133367|Drug|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
216099|NCT02139800|Procedure|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
216100|NCT02139800|Procedure|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
215169|NCT02119377|Other|questionnaire|
215467|NCT02152280|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
215468|NCT02152306|Drug|Fimasartan and Amlodipine|
215469|NCT02152306|Drug|Fimasartan|
215470|NCT02152319|Device|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
215471|NCT02152319|Procedure|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
215472|NCT02152332|Drug|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
215473|NCT02152332|Drug|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
215474|NCT02152332|Drug|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
215475|NCT02152332|Drug|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
215476|NCT02152332|Drug|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
215477|NCT00134264|Drug|atorvastatin|
215478|NCT02152345|Drug|Belatacept|Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84
215479|NCT02152345|Drug|Tacrolimus|Drug will be administered twice a day, starting on the day after transplantation, and dose adjusted to maintain a trough level of 8-10ng for the first 6 months and then 6-8ng for the next 6 months and then 4-6 ng for the rest of the follow up
215480|NCT02154893|Device|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
215481|NCT02154906|Device|DFDBA|
215482|NCT02154906|Device|autologous platelet rich fibrin|
215483|NCT02154919|Procedure|Percutaneous coronary intervention|
215484|NCT02154932|Drug|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
215485|NCT02154932|Drug|single dose misoprostol|1 dose, 1 hours, prior surgery
215486|NCT02154984|Behavioral|behavioral dietary intervention|Follow tRD
214879|NCT02126267|Procedure|Full mouth disinfection|Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
214880|NCT02126267|Drug|Chlorhexidine gel and gluconate|application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
214881|NCT02126267|Drug|Chlorhexidine gluconate solution|Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
214882|NCT02126267|Drug|Azithromycin|Azithromycin (500 mg) once daily for 3 consecutive days.
215170|NCT02119390|Behavioral|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
215171|NCT02119390|Other|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
215172|NCT02119390|Other|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
215173|NCT02119403|Other|There are no other inteventions.|This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
215174|NCT02119416|Drug|Placebo Administration first|All participants received each dose on two days and the order of administration was counterbalanced.
Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
215175|NCT02119416|Drug|Low Caffeine Administration first (1mg/kg body weight)|On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.
Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
215176|NCT02119416|Drug|High Caffeine Administration first (2mg/kg body weight)|On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.
Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
215177|NCT02119429|Dietary Supplement|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
215178|NCT00131209|Dietary Supplement|fortified spread (RUTF)|
215179|NCT02119429|Dietary Supplement|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
215180|NCT02119442|Device|Transcather Valve Implantation|Transcather Valve Implantation
215181|NCT02119455|Device|Vibration Device|Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
215182|NCT02119468|Drug|ixazomib citrate|Given orally
214568|NCT02131441|Procedure|laparoscopic hepatectomy|
214569|NCT00132548|Drug|Artesunate|
214570|NCT02131441|Procedure|open liver resection|
214571|NCT02131454|Other|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
214572|NCT02131467|Drug|Perampanel|
214573|NCT02131480|Drug|Doxorubicin|60 mg/m²
214574|NCT02131480|Drug|Trabectedin|1,1 mg/m²
214575|NCT02131493|Drug|S-1, Gemcitabine|
214576|NCT02134132|Biological|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
214577|NCT00132743|Drug|Cilostazol|Cilostazol, 100 mg twice a day
214578|NCT02134132|Other|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
214579|NCT02134158|Device|anodal tDCS and sham tDCS stimulations|Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.
All the investigations will associate with clinical, functional and 3D motion analysis assessments.
214883|NCT02126280|Other|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
214884|NCT00131950|Other|study of socioeconomic and demographic variables|
214885|NCT02126293|Drug|Zinc Supplement|
214886|NCT02126293|Procedure|Repeat blood and urine tests|
214887|NCT02126306|Drug|Beta Glucosylceramide|Beta Glucosylceramide
214888|NCT02126306|Drug|Placebo|normal saline
214889|NCT02126319|Behavioral|Cognitive Affective preparation|Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate ("pre-live") and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
214253|NCT02139020|Other|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
214254|NCT02139033|Drug|Retaine™|
214255|NCT02139046|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
214256|NCT02139046|Drug|Febuxostat XR|Febuxostat XR over-encapsulated capsules
214257|NCT02139046|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
214258|NCT02139046|Drug|Colchicine|Colchicine tablets
214259|NCT02139046|Drug|Naproxen|Naproxen tablets
214260|NCT00133315|Drug|Etanercept|
214261|NCT02139046|Drug|Lansoprazole|Lansoprazole capsules
214262|NCT02139059|Procedure|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
214263|NCT02139059|Procedure|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
214264|NCT02139072|Device|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
214265|NCT02139072|Procedure|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
214266|NCT02141763|Drug|UCB4940 40 mg|Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous
214267|NCT02141763|Drug|UCB4940 80 mg|Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous
214580|NCT02134171|Other|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
214581|NCT02134184|Biological|Fluzone® 2012-2013 Formula|This vaccine is given intramuscularly
214582|NCT02134197|Drug|BAY1129980|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
214583|NCT02134210|Drug|Etanercept|Head-to-head comparison
214584|NCT02134210|Drug|CHS-0214|
218711|NCT02308527|Drug|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
218712|NCT02308527|Drug|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
213934|NCT00133926|Procedure|Treatment of periodontal disease|
213935|NCT02146443|Other|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
213936|NCT02146443|Device|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
213937|NCT02146456|Drug|Tranexamic Acid|
213938|NCT02146469|Biological|2 doses with an 3 months interval|varicella vaccination
213939|NCT02146469|Biological|A second dose with an 1 year interval|varicella vaccine
213940|NCT02146469|Biological|A second dose with an 3 year interval|varicella vaccine
213941|NCT02146469|Biological|A second dose with an 5 year interval|varicella vaccine
213942|NCT02146469|Biological|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
213943|NCT02146469|Biological|1 dose MMR|MMR
213944|NCT02146482|Other|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
213945|NCT00133939|Procedure|Mechanical ventilation|
213946|NCT02146495|Device|EEG-NF|
213947|NCT02146508|Procedure|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
213948|NCT02146508|Device|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
213949|NCT02149056|Other|Impaired Glucose Tolerance|Impaired Glucose Tolerance
213950|NCT02149082|Device|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
218403|NCT02276989|Drug|Quinine|On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.
On Day 11, PK testing of QUIN and PGB will be repeated.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week.
218404|NCT02276989|Drug|Riboflavin|All subjects will receive riboflavin on the following days of the study:
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
218405|NCT02277002|Device|Cabin Air Filtration|
218406|NCT02277002|Other|Placebo|No Cabin Air Filtration
218407|NCT02277015|Device|Miller Laryngoscope|Direct Laryngoscopy
218408|NCT02277015|Device|The Berci-Kaplan DCI|Videolaryngoscope-1
218409|NCT02277015|Device|The AirTraq|Videolaryngoscope-2
218410|NCT02277015|Device|GlideScope GVL|Videolaryngoscope-3
218411|NCT02277015|Device|The Pentax AWS|Videolaryngoscope-4
218412|NCT00148746|Drug|Pimecrolimus|
218413|NCT02277028|Behavioral|priming and task specific training|This task specific training protocol has been used in several clinical trials.
218713|NCT02308527|Drug|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
218714|NCT02308527|Drug|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
218715|NCT02308527|Drug|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
218716|NCT02308540|Biological|SIILPCV10|10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate [alum]) and preservative (thiomersal).
218717|NCT02308540|Biological|Pneumovax 23|23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
218718|NCT02308540|Biological|Prevenar 13|13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
218719|NCT02308553|Drug|Nintedanib|Nintedanib (150 mg or 200 mg BID)
218720|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
218721|NCT02308553|Drug|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
218416|NCT02277054|Device|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
218417|NCT02277067|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
218418|NCT02277067|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
218419|NCT02277093|Drug|Pacritinib|
218420|NCT02277106|Drug|SAGE-547|
218421|NCT02277106|Drug|Placebo|
218422|NCT02277119|Device|Maestro|OCT machines used for diagnostic purposes
218423|NCT02279329|Other|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
218424|NCT02279342|Drug|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
218425|NCT02279368|Behavioral|Family Counselling and safeguarding|
218426|NCT02279381|Drug|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
218427|NCT00149006|Procedure|Cell therapy|
218428|NCT02279381|Other|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
218429|NCT02279381|Other|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
218430|NCT02279394|Drug|Elotuzumab|Both Arms:
10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
218431|NCT02279394|Drug|Lenalidomide|Both Arms:
25 mg Oral; Days 1-21 days Cycles 1-24
217830|NCT02291042|Drug|B+O Suppository|
217831|NCT02291055|Drug|ADXS11-001|
217832|NCT02291055|Drug|Medi4736|
218131|NCT02284243|Drug|Intranasal Placebo|
218132|NCT00149617|Drug|Buspirone|
218133|NCT02284256|Drug|Fibrocaps|
218134|NCT02284256|Drug|TachoSil|
218135|NCT02284269|Drug|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
218136|NCT02284282|Drug|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
218137|NCT02284282|Drug|subcutaneum injection lidocaine|placebo injection
218138|NCT02284295|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
218139|NCT02284295|Other|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
218140|NCT02284308|Other|Blood withdrawal|An extra withdrawal of blood, during a routine blood withdrawal
218141|NCT02284334|Other|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
218142|NCT02284360|Drug|APOSEC™ for cutaneous use|On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.
Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.
From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.
On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure.
218143|NCT00002374|Drug|Saquinavir|
218144|NCT00149825|Behavioral|CBTI|Cognitive Behavioral Treatment for Insomnia
218145|NCT02286648|Drug|Formocresol|pulpotomy with formocresol
218146|NCT02286648|Drug|Mineral Trioxide Aggregate|pulpotomy with MTA
218147|NCT02286661|Procedure|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
217540|NCT02298166|Drug|Crenolanib|Induction therapy:
Crenolanib to be given as p.o. TID starting d 7+, given continuously thereafter, except for days of chemotherapy
Consolidation therapy:
Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.
Maintenance therapy with Crenolanib is intended in all patients in CR after allogeneic HSCT or high-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HSCT or HiDAC.
Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy
217833|NCT02291068|Behavioral|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
217834|NCT02291081|Other|Comprehensive non invasive cardiovascular examination|Comprehensive non invasive cardiovascular examination
Anamnesis with the participants
File recherche,Physical examination
Documentation of the cardiovascular and antiretroviral medical therapy
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
Exercise Montreal Cognitive Assessment test
Exercise the Grooved Pegboard test
Blood collection
Questionnaire to quality of life and health economics
217835|NCT02291094|Drug|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
217836|NCT02291094|Drug|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
217837|NCT02291107|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
217838|NCT02291107|Other|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
217839|NCT00150462|Drug|Carfilzomib|Administered as an IV bolus dose
217840|NCT02291120|Procedure|Pulpotomy|
217841|NCT02291133|Procedure|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
217842|NCT02291133|Device|Cliniporator Vitae®|Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
The maximum duration of procedure is 90 minutes, after liver mobilization.
217843|NCT02291133|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
217844|NCT02291146|Behavioral|LA Sprouts intervention|see arm 1 description
201751|NCT01996618|Drug|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
201752|NCT01999179|Drug|Heparin, Low-Molecular-Weight|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team following a catheter related blood clot
201753|NCT01999192|Drug|Tregalizumab|
201754|NCT01999192|Drug|Placebo|
202034|NCT02033889|Other|Glimepiride|Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of blinded glimepiride is at the discretion of the investigator.
202035|NCT02033889|Drug|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
202036|NCT02033889|Biological|Basal Insulin|Basal insulin will be used for participants requiring rescue therapy in Phase B. Dosing and titration of basal insulin is at the discretion of the Investigator.
202037|NCT02033889|Drug|Metformin|Metformin >=1500 mg/day, orally, once a day
202038|NCT02033902|Drug|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
202039|NCT02033915|Other|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
202040|NCT00122590|Drug|lopinavir/r|
202041|NCT02033941|Drug|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
202042|NCT02033941|Drug|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
202043|NCT02033967|Procedure|vasodilator induced hypovolemia|
202044|NCT02033980|Device|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
202045|NCT02033993|Drug|Nab-Paclitaxel|
202046|NCT02033993|Drug|Paclitaxel|
201449|NCT02004600|Procedure|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
201450|NCT02004613|Drug|Dexmedetomidine|Dexmedetomidine
201451|NCT02004613|Drug|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
201452|NCT02004626|Drug|Collagenase|Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.
Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.
Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).
Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.
Photographic records.
201453|NCT02007161|Drug|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
201454|NCT02007174|Drug|Bevacizumab|
201455|NCT02007187|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
201755|NCT01999205|Behavioral|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
201756|NCT01999218|Drug|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
201757|NCT01999218|Drug|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
201758|NCT01999218|Drug|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
201759|NCT01999218|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
201760|NCT01999218|Drug|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
201761|NCT01999218|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
201762|NCT00119262|Biological|pegfilgrastim|Given SC
201763|NCT01999218|Drug|Sitagliptin|Open label, oral, once daily, rescue medication as required.
201764|NCT01999231|Biological|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
201765|NCT01999244|Behavioral|Self-monitoring skills|
201134|NCT02012517|Drug|Short antibiotic course (standard of care)|
201135|NCT00120471|Drug|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
201136|NCT02012530|Procedure|HA|HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
201137|NCT02012530|Procedure|PRP|PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
201138|NCT02012543|Dietary Supplement|Agar jelly|
201139|NCT02012556|Drug|Tesamorelin|
201140|NCT02012569|Drug|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
201141|NCT02012569|Drug|Placebo|
201142|NCT02012582|Drug|VAS203|i.v. infusion
201143|NCT02012582|Drug|Saline|i.v. infusion
201144|NCT00120783|Drug|Indinavir|
201145|NCT02015325|Behavioral|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health & Hygiene education program.
201146|NCT02015351|Drug|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
201456|NCT02007187|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
201457|NCT02007187|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
201458|NCT00119886|Drug|Botulinum toxin|
201459|NCT02007200|Other|Laboratory Biomarker Analysis|Correlative studies
200814|NCT02017964|Drug|Vincristine Sulfate|Given IV
200815|NCT02017964|Drug|Cyclophosphamide|Given IV
200816|NCT02017964|Drug|Methotrexate|Given IV
200817|NCT02017964|Drug|Etoposide|Given IV
200818|NCT02017964|Drug|Carboplatin|Given IV
200819|NCT02017964|Other|Laboratory Biomarker Analysis|Correlative studies
200820|NCT02017964|Other|Cognitive Assessment|Optional ancillary studies
200821|NCT02018029|Other|cardiac resynchronisation therapy|
200822|NCT00121043|Drug|Kineret® (Anakinra)|
200823|NCT02018042|Drug|Abatacept|After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.
The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug.
200824|NCT02018055|Drug|Ticagrelor|
200825|NCT02018055|Drug|Clopidogrel|
200826|NCT02018068|Other|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
200827|NCT02020343|Behavioral|taste tests|Subjects undergo "sham feeding" in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling.
200828|NCT02020356|Behavioral|Music therapy|"U" sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase.
200829|NCT02020356|Behavioral|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
200830|NCT02020369|Biological|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
200831|NCT02020382|Device|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
200215|NCT00122538|Drug|Efavirenz (EFV)|
200216|NCT02033096|Drug|stannsoporfin|
200508|NCT02025257|Other|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
200509|NCT02025270|Biological|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
200510|NCT02025283|Procedure|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA]
200511|NCT02025296|Device|U-healthcare|use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
200512|NCT02025309|Device|Neuromuscular monitorisation|
200513|NCT02025322|Behavioral|Peer Mentoring|Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.
Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors.
200514|NCT02025348|Drug|IntelliCap|Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
200515|NCT02025361|Drug|intrarectal lidocaine gel anesthesia|
200516|NCT02025361|Drug|periprostatic nerve blockade|
200517|NCT02025374|Drug|Hyperbaric levobupivacaine|
200518|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
200519|NCT02025374|Drug|Hyperbaric bupivacaine % 0.5|
200520|NCT02027909|Device|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
200521|NCT02027922|Other|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
200522|NCT02027935|Drug|Cyclophosphamide|300 mg/m2 by vein 2 days prior to T cell infusion.
200523|NCT02027935|Procedure|CD8+ T Cells|T cells administered at a dose of 10^10 cells/m2 by vein on Day 0.
199908|NCT01998386|Other|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
199909|NCT01998386|Other|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
199910|NCT01998399|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
199911|NCT01998399|Drug|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
199912|NCT01998438|Drug|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
199913|NCT01998451|Drug|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
199914|NCT01998477|Biological|TIVa|Novartis investigational influenza vaccine
199915|NCT00119210|Drug|Bupropion SR|
200217|NCT02033109|Drug|PC-1005|Intravaginal use
200218|NCT02033109|Drug|HEC gel|
200219|NCT02033122|Other|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
200220|NCT02033122|Other|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
200221|NCT02033135|Procedure|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
200222|NCT02033135|Other|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
200223|NCT02033135|Device|Zilver PTX|
200224|NCT02033148|Drug|icotinib hydrochloride|Given PO
216101|NCT02139813|Procedure|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass will consist of:
a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His
a narrow gastric tube will be calibrated to be approximately 1.5 cm wide
an Omega loop of 200 cm
a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
216102|NCT02139813|Procedure|Procedure of reference in bariatric surgery|The laparoscopic Roux-en-Y Gastric Bypass will consist of:
a small gastric pouch (about 30cc)
an antecolic alimentary limb
a gastro-jejunal anastomosis using a linear stapler
a 150cm long alimentary limb
a 50cm biliary limb
a latero-lateral jejuno-jejunal anastomosis
closure of the mesenteric defects
216103|NCT02139826|Drug|IX-01|
216104|NCT02139839|Other|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
216105|NCT02139839|Drug|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
216106|NCT02139852|Dietary Supplement|Capsaicin|
216107|NCT02139865|Behavioral|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
216108|NCT02139865|Behavioral|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
216109|NCT00133367|Drug|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
216110|NCT02139878|Other|Wild blueberry juice|
216111|NCT02139878|Other|Placebo wild blueberry juice|
216112|NCT02139891|Device|Cardiac Resynchronization Therapy with MultiPoint Pacing|
216113|NCT02142569|Device|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
216114|NCT00133523|Other|Placebo|Normal allantoic fluid administered annually as an internasal spray.
216115|NCT02142582|Dietary Supplement|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
216116|NCT02142582|Dietary Supplement|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
216457|NCT02293148|Drug|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
216458|NCT02293148|Drug|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
216459|NCT02295540|Radiation|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
215487|NCT02154984|Behavioral|telephone-based intervention|Receive coaching calls
215488|NCT00134537|Device|Conservative Care|Medication, exercise and spinal injections
215489|NCT02154984|Other|laboratory biomarker analysis|Correlative studies
215795|NCT02147249|Drug|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
215796|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 14 days|
215797|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 28 days|
215798|NCT02147288|Device|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
215799|NCT02147301|Device|LC Bead|Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):
Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first.
215800|NCT02147353|Drug|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
215801|NCT02147353|Drug|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
215802|NCT00133991|Biological|filgrastim|
215803|NCT02147366|Behavioral|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
215804|NCT02147366|Behavioral|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
215805|NCT02147379|Drug|Lurasidone|
215806|NCT02147392|Drug|[11C]ER-176|
215807|NCT02147431|Drug|semaglutide|2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.
Each treatment period will be followed by a hypoglycaemic clamp
215808|NCT02149849|Procedure|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
215809|NCT02149862|Other|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
215183|NCT02121613|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
215184|NCT00131443|Drug|Topiramate|
215185|NCT02121613|Drug|Placebo matching Tamsulosine LP|Oral administration - daily.
215186|NCT02121639|Drug|Placebo|
215187|NCT02121639|Drug|AZD5363|
215188|NCT02121652|Behavioral|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
215490|NCT02155010|Drug|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
215491|NCT02155010|Drug|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
215492|NCT02155023|Drug|Insulin dosing|
215493|NCT02155023|Device|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
215494|NCT02155036|Other|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) ~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
215495|NCT02155049|Drug|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
215496|NCT02155062|Other|Whole grain rye|
215497|NCT02155062|Other|Whole grain wheat|
215498|NCT02155062|Other|Refined cereal|
215499|NCT00134550|Drug|Atorvastatin (10 mg or 80 mg)|
215500|NCT02155088|Drug|BYL719|Dose escalation beginning at 250 mg/day
215501|NCT02155088|Drug|Gemcitabine|Dose escalation beginning at 800 mg/m^2
215502|NCT02155088|Drug|(nab)-paclitaxel|125 mg/m^2 dose
215503|NCT02155101|Drug|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and trimethylene carbonate on the other side.
214890|NCT02126319|Behavioral|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
214891|NCT02126332|Other|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
214892|NCT02126332|Other|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
214893|NCT02126345|Device|MASTER SL femoral stem and DELTA TT acetabular cup|
214894|NCT02126358|Drug|Gemigliptin and/or Rosuvastatin|
214895|NCT00131950|Procedure|breast imaging study|
214896|NCT02126371|Drug|LEO32731|
214897|NCT02126384|Drug|pneumovax vaccination|vaccination
214898|NCT02129049|Behavioral|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
214899|NCT02129049|Other|questionnaire administration|Ancillary studies
214900|NCT02129062|Drug|Ibrutinib|Given PO
215189|NCT02121652|Behavioral|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
215190|NCT02121665|Drug|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
215191|NCT02121665|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
215192|NCT02121678|Other|Resistance training|Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:
Week 0-4: 70-80 % of 1-RM
Week 5-8: 75-86 % of 1-RM
Week 9-12: 80-92% of 1-RM
Participants trains unilateral, the opposite site serves as reference.
MMN patients train elbow (flexion/extension) and wrist (flexion/extension)
CIDP patients train knee (flexion/extension) and elbow (flexion/extension)
215193|NCT02121678|Other|Aerobic training|Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.
Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data.
214585|NCT02134223|Behavioral|Dialectical behavior therapy|in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.
DBT participants will be assigned to the next available individual therapist and relevant skills training group.
Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module.
214586|NCT02134249|Drug|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
214587|NCT02134249|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
214588|NCT00132756|Drug|Doxil and Estramustine|
214589|NCT02134262|Drug|Cyclophosphamide or Bendamustine|Cyclophosphamide [1.5 g/m^2 x 1 day Intravenous (IV)] or Bendamustine [120 mg/m^2 x 2 days Intravenous (IV)] is administered as Pre-treatment medication of CD19-CAR-T.
214590|NCT02134262|Genetic|Dose Level -1|CD19-CAR-T [1 x 10^5 cells/kg x 1 day and 2 x 10^5 cells/kg x 1 day Intravenous (IV)] are administered.
214591|NCT02134262|Genetic|Dose Level 1|CD19-CAR-T [1/3 x 10^6 cells/kg x 1 day and 2/3 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
214592|NCT02134262|Genetic|Dose Level 2|CD19-CAR-T [1 x 10^6 cells/kg x 1 day and 2 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
214593|NCT02134262|Genetic|Dose Level 3|CD19-CAR-T [1/3 x 10^7 cells/kg x 1 day and 2/3 x 10^7 cells/kg x 1 day Intravenous (IV)] are administered.
214594|NCT02134275|Behavioral|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
214595|NCT02134275|Behavioral|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
214596|NCT02134288|Drug|Belatacept|
214597|NCT02134288|Drug|Everolimus|
214598|NCT02134301|Drug|Oritavancin|
214599|NCT02136498|Behavioral|MyMAP (My Mobile Advice Program)|Standard self-help intervention for smoking cessation accessed via smart phone or other internet-capable device + personalized feedback and advice for managing nicotine withdrawal symptoms and medication side-effects + motivational encouragement (ie, the MyMAP program).
214901|NCT02129062|Other|Laboratory Biomarker Analysis|Correlative studies
214902|NCT02129075|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
214903|NCT02129075|Other|Laboratory Biomarker Analysis|Correlative studies
213951|NCT02149095|Drug|TransCon PEG treprostinil|
213952|NCT00134030|Drug|doxorubicin hydrochloride|Given IV
213953|NCT02149108|Drug|Nindetanib (BIBF 1120)|
213954|NCT02149108|Drug|Placebo|
213955|NCT02149108|Drug|BSC|
213956|NCT02149108|Drug|BSC|
214268|NCT02141763|Drug|UCB4940 160 mg|Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous
214269|NCT02141763|Drug|UCB4940 240 mg|Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous
214270|NCT02141763|Drug|UCB4940 320 mg|Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous
214271|NCT02141763|Drug|UCB4940 560 mg|Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous
214272|NCT02141763|Other|Placebo|Pharmaceutical Form: solution
Concentration: 0.9 % sodium chloride
Route of Administration: intravenous
214273|NCT02141776|Device|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
214274|NCT00000324|Drug|Tryptophan|
214275|NCT00002246|Drug|Stavudine|
214276|NCT00133497|Biological|MF-59|Microfluoridized adjuvant 59 (MF59).
214277|NCT02141776|Other|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
214278|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
214279|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
214280|NCT02141802|Behavioral|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
218722|NCT02308553|Drug|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
218723|NCT02311114|Other|Survey|Surveys with participants will be conducted using validated survey tools.
218724|NCT02311127|Device|SecurAcath|Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC
218725|NCT00152529|Behavioral|Screening (Behavior)|
218726|NCT02311127|Device|StatLock|Device secures PICC however, device has to be changed weekly
218727|NCT02311140|Other|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
218728|NCT02311153|Device|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
218729|NCT02311153|Device|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
218730|NCT02311179|Device|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
218731|NCT02311179|Device|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
218732|NCT02311192|Device|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
213957|NCT02149121|Biological|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
213958|NCT02149121|Drug|Rituxan|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
213959|NCT02149121|Drug|MabThera|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
213960|NCT02149134|Dietary Supplement|TeHF2013-01|
213961|NCT02149160|Drug|FRM-0334|
213962|NCT02149160|Drug|Placebo|
213963|NCT00134030|Drug|cisplatin|Given IV
213964|NCT02149173|Radiation|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET
213965|NCT02149173|Radiation|Fludeoxyglucose F-18|Undergo FDG PET
213966|NCT02149173|Other|Laboratory Biomarker Analysis|Correlative studies
218733|NCT02311205|Procedure|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
218734|NCT02311205|Drug|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
218735|NCT02311218|Dietary Supplement|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
218736|NCT00152542|Drug|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
218737|NCT02311218|Dietary Supplement|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
218738|NCT02311231|Drug|bivalirudin|Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
218739|NCT02311231|Drug|Heparin|Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
218740|NCT02311309|Other|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration >8 g/dL.
218741|NCT02311309|Other|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration < 8 g/dL.
218742|NCT02311361|Drug|MEDI4736|Cohorts A: Every two weeks Cohort C: To be determined
218743|NCT02311361|Drug|Tremelimumab|Cohorts B: Every 4 weeks for 6 doses followed by every 12 weeks for 3 doses. Total of 9 doses over 12 months Cohort C: To be determined
218744|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
218745|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
218746|NCT02313701|Other|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
218747|NCT02313714|Device|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
218148|NCT02286661|Procedure|Casting (short arm)|
218149|NCT02286674|Other|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
218150|NCT02286687|Drug|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
218151|NCT02286687|Behavioral|Phone Call|Study staff calls participant after completion of the treatment.
218432|NCT02279394|Drug|Dexamethasone|Arm A ONLY 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
218433|NCT02279407|Drug|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
218434|NCT02279407|Drug|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
218435|NCT02279407|Drug|Dapagliflozin|10 mg administered as 10 mg tablet
218436|NCT02279407|Drug|Placebo|Placebo matching to dapagliflozin 10 mg
218437|NCT02279420|Device|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
218438|NCT00149019|Drug|Cell therapy with bispecific antibodies|
218439|NCT02279433|Drug|DS6051b|DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative RP2D determined.
218440|NCT02279446|Other|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
218441|NCT02279472|Procedure|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
218442|NCT02279485|Drug|Perampanel|
218443|NCT02281864|Other|Control Group: Quitline|Referral to the Quitline
218444|NCT02281877|Procedure|Neuromuscular electrical stimulation (NMES)|4x/day for 15 minutes/session
218445|NCT02281877|Behavioral|Standard Rehabilitation Protocol|Standard physical therapy after TKA
217845|NCT02291159|Device|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
217846|NCT02291159|Device|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
217847|NCT02291172|Behavioral|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
217848|NCT02293551|Drug|Lispro|Administered SC
218152|NCT02286700|Drug|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
218153|NCT02286700|Other|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
218154|NCT02286713|Behavioral|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
218155|NCT00149825|Behavioral|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
218156|NCT02286713|Behavioral|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
218157|NCT02286713|Behavioral|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
218158|NCT02286726|Drug|CPX-351|CPX-351 - Lower Dose Group Induction: CPX-351 50 units/m2 by vein on Days 1, 3, and 5 for up to 2 courses.
Consolidation: Participants achieving complete remission may receive consolidation treatment with CPX-351. A course of consolidation treatment consists of 2 doses of CPX-351 (Days 1 and 3). Up to 4 cycles of consolidation may be administered.
CPX-351 - Higher Dose Group Induction: CPX-351 75 units/m2 by vein on Days 1, 3, and 5 for up to 2 courses.
Consolidation: Participants achieving complete remission are eligible to receive consolidation treatment with CPX-351. A course of consolidation treatment consists of 2 doses of CPX-351 (Days 1 and 3). Up to 4 cycles of consolidation may be administered.
CPX-351 - Maximum Tolerated Dose Level Group If safety demonstrated for both of the sub-MTD dose levels, and escalation deemed feasible above 75 units/m2, then CPX-351 100 units/m2 administered.
218159|NCT02286726|Behavioral|Phone Call|After completion of treatment, participant receives phone call from study staff every month for as long as the study doctor thinks it is needed. Each call should last about 5-10 minutes.
218160|NCT02286739|Device|TKA with "Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA 510K clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
218161|NCT02286739|Procedure|TKA without "Verasense"|TKA will be performed manually without the use of Verasense
202047|NCT02034006|Drug|Ranibizumab|All patients will receive a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per CHMP approval. Further injections might be required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, will be evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment is allowed provided at least 14 days of intercurrence.
202048|NCT02034019|Drug|Dexamethasone|
202049|NCT02034019|Drug|Punctum Plug|
202050|NCT01994343|Other|Assessment|An assessment of the women is performed.
202051|NCT01994356|Behavioral|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
202052|NCT01994356|Behavioral|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
202332|NCT02028832|Procedure|Pediatric Integrative Medicine consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
202333|NCT02028832|Procedure|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
202334|NCT02028845|Device|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
202335|NCT02028845|Device|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
202336|NCT02028871|Drug|Intranasal Insulin|
202337|NCT02028871|Drug|Placebo|
202338|NCT02028884|Drug|SA237|
202339|NCT02028884|Drug|Placebo|
202340|NCT02028897|Other|Conventional embryo culture|
202341|NCT02028897|Other|Enclosed embryo culture|
202342|NCT00121966|Drug|Rosiglitazone|
202343|NCT02031263|Procedure|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
202344|NCT02031276|Drug|BI 655066 period 2|multiple high dose BI 655066
202345|NCT02031276|Drug|BI 655066 (high dose)|multiple high dose BI 655066
202346|NCT02031276|Drug|BI 655066 (low dose)|multiple low dose BI 655066
201766|NCT01999244|Behavioral|Technology|
201767|NCT01999244|Behavioral|Interventionist Contact|
201768|NCT01999257|Other|Online pre-test genetic education tool|See Arm Descriptions above.
201769|NCT01999270|Drug|Irinotecan|Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)
Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
201770|NCT01999270|Drug|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
201771|NCT01999270|Device|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
201772|NCT01999283|Other|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
201773|NCT00119262|Radiation|radiation therapy|Undergo radiation therapy
202053|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
202054|NCT01994369|Drug|EC17|
202055|NCT01994382|Drug|cerdulatinib (PRT062070)|cerdulatinib oral pill
202056|NCT01994395|Device|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
202057|NCT01994395|Other|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
202058|NCT01994408|Other|default intensification|The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
202059|NCT01994421|Other|Kinesiotape|
202060|NCT01994434|Procedure|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
202061|NCT01994447|Other|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
201460|NCT02007200|Drug|Soy Isoflavones|Given PO
201461|NCT02007200|Other|Survey Administration|Ancillary studies
201462|NCT02007239|Drug|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
201463|NCT02007252|Drug|ACZ885|Monthly doses of ACZ885 subcutaneous (s.c.)
201464|NCT02007252|Drug|Placebo|Monthly doses of placebo to match ACZ885 s.c
201465|NCT02007278|Drug|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
201466|NCT02007278|Drug|glimepiride|
201467|NCT02007278|Drug|Metformin|
201468|NCT02007304|Behavioral|Eccentric exercise training|12 weeks of lower leg eccentric training
201469|NCT00119899|Procedure|FDG-PET scan|
201470|NCT02007317|Drug|Oshadi D & Oshadi R|Anti tumor agents
201471|NCT02007330|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
201472|NCT02007330|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
201473|NCT02007356|Biological|IFN-γ positive selected T-cells|
201474|NCT02007369|Behavioral|Peer to peer support and delivery of information through WhatsApp groups|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp. In order to sustain the abstinence among the participants in the social groups, the intervention content is about (1) Encourage to maintain abstinence; (2) Importance of remaining abstinence; (3) Prevent smoking triggers; (4) Withdrawal symptoms & lapse; (5) Stress and mood management; (6) weight control. In addition to the information delivered by the moderators, the moderators will encourage other participants to support each other and discuss certain topics related to smoking and quitting. Also, moderators of the social groups will send messages of brief advice, give feedback to participants' enquiries and facilitate conversations in the platform. We propose the moderator to spend about 1 to 2 hours a day in total for the social group conversation in a flexible time schedule, and the duration of the intervention will be 6 weeks.
201774|NCT02001844|Device|Trial Foot Orthoses (FOs)|Trial Group:
The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.
Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked.
201147|NCT02015364|Procedure|Controlled early mobilization|1. The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 - 8.
201148|NCT02015390|Procedure|Iliac crest autogenous bone grafting|
201149|NCT02015390|Procedure|Reamer-Irrigator-Aspirator autogenous bone grafting|
201150|NCT02015403|Drug|Standard Care + NAC (N -ACETYLCYSTEINE)|
201151|NCT02015403|Drug|Standard Care (in control arm)|
201152|NCT02015416|Biological|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
201153|NCT02015429|Dietary Supplement|Pasta meal with added fractions or control with no fractions|
201154|NCT02015442|Dietary Supplement|Sucrose|
201155|NCT00002170|Drug|Nelfinavir mesylate|
201156|NCT00120783|Drug|Lamivudine|
201157|NCT02015455|Other|Epidemiologic benchmarks included in lumbar imaging reports|Epidemiologic benchmarks inserted into lumbar imaging reports
201158|NCT02015468|Other|Early mobilization|Early weightbearing and physiotherapy
201159|NCT02015468|Other|Late mobilization|Late mobilization, none-weightbearing and home exercises
201160|NCT02015481|Drug|Cabaletta|
201161|NCT02015494|Biological|VAX2012Q|Recombinant influenza HA vaccine delivered IM
201162|NCT02015507|Drug|ivacaftor|
201163|NCT02015507|Drug|VX-661|
201164|NCT02015507|Drug|ciprofloxacin|
201165|NCT02015520|Drug|Clazakizumab|
201166|NCT02015520|Drug|Placebo (Matching with Clazakizumab)|
201167|NCT00120783|Drug|Ritonavir|
201168|NCT02015533|Drug|CR8020|CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
201169|NCT02015533|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion.
201170|NCT02015546|Drug|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
200524|NCT02027935|Drug|Interleukin-2|250,000 U/m2 administered subcutaneously every 12 hours begins within 6 hours of T cell infusion and continues for a total of 14 days On Day 0 to Day +14.
200525|NCT02027935|Drug|Ipilimumab|3 mg/kg by vein 24 hours after T cell infusion. Subsequent infusions administered on Days +22, +43 and +64.
200832|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
200833|NCT00121225|Drug|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
200834|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
200835|NCT02020408|Drug|[11C]raclopride|1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
200836|NCT02020408|Drug|[11C]DASB|BPND of [11C]DASB.
200837|NCT02020408|Drug|amphetamine|The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
200838|NCT02020421|Device|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
200839|NCT02020421|Device|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
200840|NCT02020421|Device|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
200841|NCT02020421|Device|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
200842|NCT02020434|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
200843|NCT02020460|Device|Subdural trial lead|
200844|NCT00121238|Drug|cilengitide|Given IV
200845|NCT02020460|Device|Epidural trial lead|
200846|NCT02020486|Drug|Perampanel|2 mg up to 4 mg
200225|NCT02033148|Other|laboratory biomarker analysis|Correlative studies
200226|NCT00122538|Drug|Lamivudine (3TC)|
200227|NCT02033148|Other|pharmacological study|Correlative studies
200228|NCT02033161|Behavioral|Internet-delivered CBT|The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.
Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.
The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment.
200229|NCT02033174|Other|Alcoholic beverages|
200230|NCT01993589|Drug|comparison of pain relievers during curattage|
200231|NCT01993589|Drug|comparison of pain relievers|
200232|NCT01993589|Drug|comparison of pain relievers during curattage|
200233|NCT00118846|Dietary Supplement|25 g soy protein supplement|25 g soy protein admisitered in equally divided dosage twice daily
200234|NCT01993589|Drug|comparison of pain relievers during curattage|
200235|NCT01993589|Drug|comparison of pain relievers during curattage|
200526|NCT02027948|Other|nutritional and functional assessments|Patients will undergo nutritional & functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, & baseline weight loss. Patients will receive chemotherapy & radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) & radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, & post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, & Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as "normal nutrition," "at risk for malnutrition," or "malnourished" & receive the appropriate intervention.
200527|NCT02027961|Biological|MEDI4736|MEDI4736
200528|NCT00121862|Biological|Leish-111f + MPL-SE vaccine|
200529|NCT02027961|Drug|Dabrafenib|Dabrafenib
200530|NCT02027961|Drug|Trametinib|Trametinib
200531|NCT02027974|Device|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
200532|NCT02027974|Device|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
216460|NCT02295540|Procedure|therapeutic conventional surgery|Undergo surgery
216461|NCT00150943|Device|Renal artery stent|
216462|NCT02295540|Other|laboratory biomarker analysis|Correlative studies
216463|NCT02295553|Drug|Ketamine|
216464|NCT02295553|Drug|Propofol|
216465|NCT02295566|Drug|Nitric Oxide|Not required
216466|NCT02295566|Drug|Control|Not required
216467|NCT02295579|Other|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
216468|NCT02295592|Procedure|TSTstarr+|TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler, " +" means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation .
216469|NCT02295592|Procedure|PPH|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
216470|NCT02295605|Other|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
216471|NCT02295605|Other|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
216472|NCT00150956|Procedure|Daily home hemodialysis|
216473|NCT02295618|Device|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
216474|NCT02295618|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
216475|NCT02295631|Device|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
216476|NCT02295631|Device|ETView VivaSight SL|ETI with ETView VivaSight SL
216477|NCT02295644|Device|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
216478|NCT02295657|Device|standard double-lumen tube|intubation using standard double-lumen tube
216479|NCT02295657|Device|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
216480|NCT02295670|Device|Vividtrac|video-laryngoscopy
216770|NCT02288403|Behavioral|Aerobic interval training|
215810|NCT00134056|Drug|atrasentan hydrochloride|Given orally
215811|NCT02149875|Drug|"Dl-3-n-butylphthalide", "Cerebrolysin" and "Placebo" separately|
215812|NCT02149888|Drug|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
215813|NCT02149901|Drug|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
215814|NCT02149901|Drug|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
216117|NCT02142595|Drug|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
216118|NCT02142595|Drug|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
216119|NCT02142608|Drug|BR55|
216120|NCT02142621|Other|transpyloric feeding|
216121|NCT02142621|Other|gastric feeding|
216122|NCT02142634|Drug|Budesonide granules 9 mg|per day
216123|NCT02142634|Drug|Placebo granules|per day
216124|NCT02142647|Behavioral|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
216125|NCT00133536|Biological|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
216126|NCT02142647|Behavioral|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
216127|NCT02142660|Procedure|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
216128|NCT02142673|Device|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
216129|NCT02142673|Device|Filling pressure 50|The hysteroscope filling pressure will be reduced to 50mm Hg
216130|NCT02142673|Device|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
216131|NCT02142686|Device|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
215504|NCT02155101|Drug|ART with 2 NRTIs plus LPV/r (or ATV/r)|Following the Cameroon AIDS Treatment Guidelines for adults, patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
215505|NCT02155127|Behavioral|walking|
215506|NCT02117076|Drug|Gabapentin immediate release|up to 1200 mg per day
215507|NCT02117076|Drug|Gabapentin enacarbil extended release|up to 1200 mg per day
215508|NCT02117089|Device|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
215509|NCT02117102|Other|Bladder and lumbar stimulation technic|
215510|NCT02117115|Radiation|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
215815|NCT02149901|Other|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
215816|NCT02149901|Other|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
215817|NCT02149914|Device|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
215818|NCT02149914|Device|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
215819|NCT02149914|Device|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
215820|NCT02149914|Other|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
215821|NCT00134056|Drug|docetaxel|Docetaxel given IV and prednisone given orally
215822|NCT02149914|Drug|PPI|
215823|NCT02149927|Drug|Sevoflurane|
215824|NCT02149940|Other|heart-failure related pharmaceutical intervention|
215825|NCT02149953|Dietary Supplement|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
215826|NCT02149966|Drug|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
215827|NCT02149966|Drug|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
215194|NCT02121691|Behavioral|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
215195|NCT00131456|Drug|Venlafaxine|375mg/day
215196|NCT02121704|Device|Magnetic Endoscope Imaging (Scope Guide)|
215197|NCT02121717|Drug|Chiglitazar|Take orally
215198|NCT02121717|Drug|Placebo|Take orally
215199|NCT02121743|Device|strattice|use of a strattice
215200|NCT02121743|Procedure|No strattice|no use of a strattice
215201|NCT02121756|Drug|Dipyridamole|Dipyridamole 100 mg 4 times daily for 24 weeks
215202|NCT02121756|Drug|Placebo, then Dipyridamole|Dipyridamole placebo 1 capsule 4 times daily for 12 weeks, then Dipyridamole 100 mg 4 times daily for 12 weeks.
215203|NCT02121769|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
215204|NCT02121782|Biological|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
215205|NCT02121782|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
215206|NCT00131456|Drug|Placebo|Placebo
215207|NCT02121795|Drug|FTC/TDF|FTC/TDF FDC tablets administered orally once daily
215208|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
215511|NCT02117115|Drug|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
215512|NCT02117128|Drug|Tranexamic acid|
215513|NCT00131027|Drug|Etoposide|
215514|NCT02117141|Drug|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
215515|NCT02117141|Drug|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
215516|NCT02117154|Device|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
214904|NCT02129075|Biological|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Given SC
214905|NCT02129075|Other|Pharmacological Study|Correlative studies
214906|NCT02129075|Biological|Recombinant Flt3 Ligand|Given SC
214907|NCT00132223|Drug|Contrast agent|
214908|NCT02129088|Drug|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
214909|NCT02129088|Drug|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
214910|NCT02129101|Drug|Azacitidine|Given SC or IV
214911|NCT02129101|Drug|Decitabine|Given IV
214912|NCT02129101|Other|Laboratory Biomarker Analysis|Correlative studies
214913|NCT02129101|Other|Quality-of-Life Assessment|Ancillary studies
214914|NCT02129101|Drug|Sonidegib|Given PO
214915|NCT02129114|Device|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
214916|NCT02129114|Device|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
214917|NCT02129127|Device|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
214918|NCT00132236|Drug|nicotine sublingual tablets|
214919|NCT02129140|Device|Hernia graft/mesh|observational group
214920|NCT02129153|Behavioral|LIFT (Parent Information)|Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication
Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish.
214921|NCT02129166|Drug|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
214281|NCT02141802|Behavioral|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
214282|NCT02141815|Dietary Supplement|Arabinoxylan-oligosaccharides|
214283|NCT02141828|Drug|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
214284|NCT02141854|Drug|Fluticasone propionate (Fp) MDPI|100 mcg or 200 mcg, inhaled corticosteroid
214285|NCT02141854|Drug|Fluticasone propionate/Salmeterol (FS) MDPI|100/12.5 mcg or 200/12.5 mcg inhaled corticosteroid and long-acting beta-agonist
214286|NCT02141854|Drug|Placebo MDPI|0 mcg
214287|NCT00133497|Drug|Placebo|0.5 mL of saline placebo.
214600|NCT02136511|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
214601|NCT02136511|Drug|Rituximab|Rituximab administered intravenously starting at 375 mg/m^2 at Week 0 and continuing with a dose of 500 mg/m^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
214602|NCT02136524|Drug|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
214603|NCT02136524|Drug|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
214604|NCT00133055|Behavioral|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
214605|NCT02136537|Device|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
214606|NCT02136537|Other|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
214607|NCT02136550|Behavioral|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
214608|NCT02136589|Drug|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
214609|NCT02136628|Procedure|Method RTL|The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.
Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement.
213967|NCT02149173|Procedure|Positron Emission Tomography|Undergo F-18 FES PET
213968|NCT02149173|Procedure|Positron Emission Tomography|Undergo FDG PET
213969|NCT02149186|Device|iCTuS-L|
213970|NCT02149199|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
213971|NCT02149199|Drug|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
213972|NCT02149199|Drug|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
213973|NCT02149212|Drug|Phlebotonic|Aminaftone -- 75 mg BID
213974|NCT00134030|Drug|methotrexate|Given IV
213975|NCT02149212|Device|Stent|Iliac Vein Stenting
213976|NCT02149212|Procedure|Limb elastic compression support|CEAP 3-5 > 20-30 mmHg compression stockings CEAP 6 > elastic bandages
213977|NCT02149212|Procedure|Unna boot dressing|CEAP 6 > Unna boot dressing
213978|NCT02151617|Drug|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
213979|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
214288|NCT00002249|Drug|Levofloxacin|
214289|NCT00133666|Behavioral|Asthma Communication Education|
214290|NCT02144155|Drug|Oxytocin: 24IU - 168 IU|
214291|NCT02144168|Dietary Supplement|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
214292|NCT02144168|Dietary Supplement|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
214293|NCT02144181|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214294|NCT02144194|Drug|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
218748|NCT02313714|Device|Sham|very low electric muscular stimulation
218749|NCT02313727|Drug|Pamidronate|intravenous infusion of pamidronate 60 mg
213980|NCT02151617|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
213981|NCT02151617|Drug|Placebo|Placebo tablet once daily dosing for 14 days
213982|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
213983|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
213984|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
213985|NCT02151617|Drug|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
213986|NCT00134199|Drug|CP-945,598|
213987|NCT02151617|Drug|PF-06743649|Tablet, to be decided dose, once daily, 14 days
213988|NCT02151617|Drug|Placebo|Tablet, once daily, 14 days
213989|NCT02151630|Drug|Pyruvic acid|
213990|NCT02151630|Drug|Salicylic Acid|
213991|NCT02151643|Drug|PT20|Modified ferric oxide adipate
213992|NCT02151643|Drug|Placebo|Placebo matched to each drug arm
213993|NCT02151656|Drug|F17464|
213994|NCT02151656|Drug|Placebo|
213995|NCT02151669|Behavioral|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
213996|NCT02151682|Drug|Tapentadol prolonged release|Participants aged from 6 years to less than 18 years with body weight less than 22.5 kg (but more than 17.5 kg) will start on 25 mg of tapentadol orally (by mouth) twice daily during the first 24 hours and then if necessary gradually stepwise increase the dose.
213997|NCT00002257|Drug|Ganciclovir|
213998|NCT00134199|Drug|sibutramine|
218446|NCT02281890|Other|Proven sepsis|Exposure is proven sepsis
218447|NCT02281903|Device|The TrueCPR feedback device|feedback devices
218448|NCT00149292|Drug|LY2140023|
218449|NCT02281903|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
218450|NCT02281916|Drug|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
218451|NCT02281929|Drug|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
218750|NCT00152737|Procedure|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
218751|NCT02313727|Other|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
218752|NCT02313740|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
218753|NCT02313753|Behavioral|CLASP|
218754|NCT02313753|Behavioral|SAFE|
218755|NCT02313766|Other|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
218756|NCT02313766|Other|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
218757|NCT02313779|Behavioral|Lovingkindness Meditation (LKM)|Compassionate behavior training (REVISE)
218758|NCT02313779|Behavioral|Mindfulness Meditation|
218759|NCT02313792|Drug|Palifermin|
218760|NCT02313805|Other|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
218761|NCT00152737|Procedure|Ankle and arm pressure values|one test before and one test after surgery
218762|NCT02313818|Behavioral|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
218763|NCT02313831|Other|Interval training|Patients of this group will be submitted to an interval training program
218162|NCT02286752|Drug|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
218163|NCT02286752|Drug|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
218164|NCT02286765|Device|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
218165|NCT02288897|Drug|Dacarbazine, temozolomide or talimogene laherparepvec|
218166|NCT02288923|Procedure|Femoral nerve block|Supine position
If using peripheral nerve stimulator for localisation of the femoral nerve:
50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine
If using ultrasound for localisation of the femoral nerve:
High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic
218167|NCT00150124|Drug|MTZ+LT4|
218452|NCT02281929|Drug|Placebo|Placebo in three daily doses during 30 days
218453|NCT02281929|Drug|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
218454|NCT02281942|Behavioral|Yoga|
218455|NCT02281942|Behavioral|Education|
218456|NCT02281955|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
218457|NCT02281955|Drug|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
218458|NCT02281955|Procedure|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
218459|NCT00149292|Drug|olanzapine|
218460|NCT02281968|Drug|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
218461|NCT02281968|Drug|Placebo|
202347|NCT02031276|Drug|BI 655066 one dose|multiple SC dose BI 655066
202348|NCT02031276|Drug|placebo dose|multiple dose placebo
202349|NCT02031289|Drug|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).
Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.
Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po.
202350|NCT00002179|Drug|Zidovudine|
202351|NCT00122369|Behavioral|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
202352|NCT02031302|Device|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
202353|NCT02031328|Radiation|Stereotactic Ablative Radiation|
202649|NCT02023736|Other|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
202650|NCT00121524|Drug|Atropine|Atropine 3 mg iv in initial systole
202651|NCT02023736|Other|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
202652|NCT02023749|Dietary Supplement|Nut group|
202653|NCT02023775|Device|Melody valve implantation|
202654|NCT02026245|Device|Using the electronic data gloves to perform a set routine of movements|
202655|NCT02026258|Procedure|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
202656|NCT02026258|Device|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-1mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
202657|NCT02026271|Biological|INXN-2001|approximately 2.0 x 10^11 viral particles (vp) per injection
one intratumoral injection of INXN-2001
202062|NCT01994460|Drug|Linezolid|
202063|NCT01994460|Drug|Ethambutol|
202064|NCT00118898|Drug|Ritonavir|100 mg tablet taken orally daily
202065|NCT01994473|Drug|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
202066|NCT01994473|Drug|Placebo|single oral dose placebo
202067|NCT01994473|Drug|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
202068|NCT01994486|Drug|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
202069|NCT01994499|Device|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
202070|NCT01994499|Drug|Medical drainage|Medical pleural drainage
202071|NCT01994512|Procedure|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
202072|NCT01996644|Drug|Sertaline|
202354|NCT02031354|Dietary Supplement|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
202355|NCT02031367|Drug|Triamcinolone Acetonide|Corticosteroid arm
202356|NCT02031367|Other|Platelet Rich Plasma|Platelet Rich Plasma
202357|NCT02031380|Device|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
202358|NCT02031406|Other|Post-discharge counseling on medication adherence & literacy|
202359|NCT02031419|Drug|CC-122|2mg or 3 mg administered orally once daily
202360|NCT02031419|Drug|CC-223|20mg or 30mg administered orally once daily.
202361|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
202362|NCT00122382|Drug|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
202363|NCT02031419|Drug|CC-122|2mg or 3mg administered orally once daily.
201775|NCT02001844|Device|placebo foot orthoses (FOs)|The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).
The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial.
201776|NCT02001857|Drug|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
201777|NCT02001870|Procedure|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
201778|NCT02001870|Procedure|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
201779|NCT02001883|Drug|Association low-dose statin and nutraceuticals|
201780|NCT02001896|Drug|gemcitabine; cisplatin or carboplatin; erlotinib|
201781|NCT02001896|Drug|erlotinib|
201782|NCT02001909|Drug|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
201783|NCT02001909|Drug|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
201784|NCT00002162|Drug|Lamivudine|
201785|NCT00119431|Drug|C1 inhibitor concentrate|
201786|NCT02001922|Other|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
201787|NCT02001935|Drug|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
201788|NCT02001948|Drug|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
201789|NCT02001948|Drug|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
201790|NCT02001948|Device|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
202073|NCT01996657|Drug|Warfarin|
201475|NCT02007369|Behavioral|Peer to peer support and delivery of information through Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook. They will be strongly suggested to follow the regulations and set up instructions for the participation to protect their privacy.
201476|NCT00120185|Drug|Interleukin-2|
201477|NCT02009514|Other|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
201478|NCT02009527|Drug|N-hydroxy-nor-arginine|
201479|NCT02009527|Drug|NaCl|
201480|NCT02009540|Drug|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
201481|NCT02009540|Drug|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
201482|NCT02009553|Other|Information sheet|
201483|NCT02009553|Other|No information sheet|
201484|NCT02009566|Radiation|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
201485|NCT02009579|Drug|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
201486|NCT02009579|Drug|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
201487|NCT00120198|Drug|CDOP plus rituximab|
201488|NCT02009592|Drug|Rifaximin|Both arms receive Rifaximin
201489|NCT02009605|Drug|Icotinib|125mg, oral administration, three times per day.
201490|NCT02009618|Drug|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
201491|NCT02009618|Drug|placebo|
201492|NCT02009631|Drug|Veliparib (ABT-888)|
201493|NCT02009631|Drug|Placebo|
201494|NCT02009644|Device|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
200847|NCT02022852|Drug|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
200848|NCT02022878|Procedure|PCI of CTO|
200849|NCT00121446|Drug|enoxaparin|
201171|NCT02018068|Other|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
201172|NCT02018081|Drug|Levofloxacin|8 blood sampling by patients between the 48th and 60th
201173|NCT02018094|Drug|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
201174|NCT02018094|Drug|Iodine|Intra-operative skin preparation prior to incision to skin.
201175|NCT02018094|Drug|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
201176|NCT02018094|Drug|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
201177|NCT00121056|Drug|Enbrel®|
201178|NCT02018094|Drug|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
201179|NCT02018094|Drug|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
201180|NCT02018107|Radiation|N-13 ammonia|
201181|NCT02018107|Device|PET/CT scanner|
201182|NCT02018120|Procedure|connective tissue graft|
201183|NCT02018120|Procedure|platelet rich fibrin|
201184|NCT02018133|Drug|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
201185|NCT02018133|Drug|Placebo|
201186|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
200533|NCT02027987|Drug|valproate acid|valproate acid is a common drug which is applied for epilepsy prevention and treatment.
200534|NCT02028000|Procedure|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
200535|NCT02028000|Procedure|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
200536|NCT02028000|Procedure|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
200537|NCT02028026|Drug|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
200538|NCT02028026|Drug|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
200539|NCT00121875|Drug|somatropin (rDNA)|Form/Strength: 10 mg aqueous suspension; 5 mg/ml
Dosage/Frequency: 0.35 mg/kg/week, daily divided doses
Duration: 6 months with 3-month washout period
200540|NCT02028039|Drug|IPI-145|75 mg orally twice daily for 4 weeks.
200541|NCT02028039|Behavioral|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
200542|NCT02030405|Drug|ixazomib|Given PO
200543|NCT02030405|Other|laboratory biomarker analysis|Correlative studies
200544|NCT02030418|Device|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
200545|NCT02030431|Device|Dynaloc|
200850|NCT02022891|Behavioral|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
200851|NCT02022904|Device|Near infrared (NIR) emissive nanotechnology|
200852|NCT02022917|Drug|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
200853|NCT02022930|Device|Hydros|
200854|NCT02022930|Device|Hydros-TA|
200855|NCT02022930|Drug|Triamcinolone Acetonide|
200856|NCT02022956|Drug|Lorcaserin|
216771|NCT02288403|Behavioral|Continuous training|
216772|NCT02288416|Other|educational intervention|Undergo video-based intervention
216773|NCT02288416|Other|questionnaire administration|Ancillary studies
216774|NCT02288416|Other|quality-of-life assessment|Ancillary studies
216775|NCT02288416|Other|Best Practice|
216776|NCT02288429|Drug|colistimethate sodium|
216777|NCT02288442|Other|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week) + training cessation ('detraining') for 4 weeks
216778|NCT02290587|Other|Brain MRI - Clinical and cognitive evaluation|Neuropsychological evaluation :
Questionnaire for depression and anxiety
Evaluation of executive functions
Evaluation of attention, information processing speed, verbal memory and working memory
Theory of mind evaluation
Clinical Evaluation
MRI Evaluation :
morphological MRI
functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention
216779|NCT02290587|Device|MRI|
216780|NCT02290600|Device|Continuous Glucose Monitor|CGM sensor calibration individualization
216781|NCT02290613|Drug|Ambrisentan|Titration:
As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.
Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.
Maximum dose allowed: not to exceed 10 mg/die.
Administration:
Ambrisentan and placebo will be administered orally with or without food intake.
216782|NCT00150384|Drug|Amlodipine/Atorvastatin|
216783|NCT02290613|Drug|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
216784|NCT02290626|Drug|Elmental diet|elemental diet is administered using PEG.
216785|NCT02290626|Drug|Semi-solid diet|Semi-solid diet is administered using PEG.
216786|NCT02290639|Behavioral|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
216787|NCT02290639|Behavioral|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
216132|NCT02142686|Device|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
216133|NCT02142686|Device|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
216134|NCT02142699|Drug|Heme arginate|
216135|NCT02142712|Drug|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
216136|NCT00002247|Drug|Ganciclovir|
216137|NCT00133536|Drug|Placebo|Normal saline administered intramuscularly.
216481|NCT02295670|Device|MIL|direct-laryngoscopy
216482|NCT02295683|Device|Renal Denervation|
216483|NCT00150969|Dietary Supplement|vitamin K1 (phylloquinone)|
216484|NCT02295696|Behavioral|EMMA|Consultations using dialogue tools
216485|NCT02295709|Procedure|SNR steroid (dexamethasone) injection|deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.
Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
216486|NCT02295709|Procedure|CTF steroid (dexamethasone) injection|deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.
Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
216487|NCT02297724|Other|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
216488|NCT02297737|Behavioral|Tai Chi|
216489|NCT02297737|Other|Health Education|
216490|NCT02297750|Procedure|double-wire technique in patients undergoing ERCP with biliary cannulation|
216491|NCT00151177|Device|non-invasive continuous positive airway pressure ventilation|
216492|NCT02297750|Procedure|single-wire technique in patients undergoing ERCP with biliary cannulation|
216493|NCT02297763|Drug|quetiapine|patient body weight <50kg : quetiapine 12.5mg patient body weight >=50kg : quetiapine 25mg
quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water).
216494|NCT02297763|Drug|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
215828|NCT02149979|Device|Temperature Controlled Laser Soldering|This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
215829|NCT02149992|Dietary Supplement|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
215830|NCT02149992|Device|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
215831|NCT02152358|Drug|Aciclovir|Intravenous 15 mg/kg/d during 14 days
215832|NCT02152358|Drug|Ganciclovir|intravenous 10 mg/kg/d for 14 days
215833|NCT02152358|Drug|Placebo|
215834|NCT02152371|Drug|Dulaglutide|Administered SQ
215835|NCT02152371|Drug|Placebo|Administered SQ
215836|NCT02152371|Drug|Insulin Glargine|Administered SQ
216138|NCT02145000|Biological|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
216139|NCT02145000|Biological|Placebo|
216140|NCT02145013|Procedure|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
216141|NCT02145026|Drug|epoetin beta [Recormon]|Injectable solution of Recormon 30,000 or 60,000 international units (IU) per week given subcutaneously over the 12-week treatment phase.
216142|NCT02145039|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
216143|NCT02145039|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
216144|NCT02145039|Radiation|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
216145|NCT02145039|Biological|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
216146|NCT02145052|Other|Continuous suture|A continuous suture is considered standard of care.
216147|NCT02145052|Other|Interrupted suture|Interrupted sutures are considered standard of care.
216148|NCT00133731|Procedure|Percutaneous Coronary Intervention|
215517|NCT02117167|Drug|AZD2014|Target: m-TOR
215518|NCT02117167|Drug|AZD4547|Target: FGFR
215519|NCT02117167|Drug|AZD5363|Target: AKT
215520|NCT02117167|Drug|AZD8931|Target: HER2, EGFR
215521|NCT02117167|Drug|Selumetinib|Target: MEK
215522|NCT02117167|Drug|Vandetanib|Target : VEGF, EGFR
215523|NCT02117167|Drug|Erlotinib|Standard maintenance for squamous NSCLC
215524|NCT00131027|Drug|Dexamethasone|
215525|NCT02117167|Drug|Pemetrexed|Standard maintenance for non squamous NSCLC
215526|NCT02117167|Drug|MEDI4736|Target: PD-L1
215527|NCT02117180|Other|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
215528|NCT02117193|Other|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
215529|NCT02117193|Other|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
215530|NCT02117206|Drug|L-arginine (L-arginine Veyron)|
215531|NCT02117206|Drug|Nacl|
215532|NCT02117219|Biological|MEDI4736|MEDI4736 will be administered by IV infusion
215533|NCT02117219|Drug|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
215534|NCT02119468|Drug|dexamethasone|Given orally
215535|NCT02119468|Drug|pomalidomide|Given orally
215837|NCT02152371|Drug|Metformin|Administered orally
215838|NCT02152384|Drug|Insulin Peglispro|Administered SC
215839|NCT00134277|Procedure|Infragenual dilatation|Infragenual dilatation
215840|NCT02152384|Drug|Insulin Lispro|Administered SC
215209|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
215210|NCT02123628|Drug|duration of the antibiotic therapy|
215211|NCT00131690|Drug|Nescafé Decaffeinated (controls)|
215212|NCT02123641|Other|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
215213|NCT02123641|Other|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.The subjects are encouraged to do supplemental endurance training.
215214|NCT02123641|Other|Control|No training
215215|NCT02123654|Drug|Daclatasvir|
215216|NCT02123654|Drug|Asunaprevir|
215217|NCT02123654|Drug|DCV 3DAA|
215218|NCT02123654|Other|Placebo for DCV 3DAA|
215219|NCT02123654|Other|Placebo for Daclatasvir|
215220|NCT02123654|Other|Placebo for Asunaprevir|
215221|NCT02123693|Other|Osteopathic manipulative treatment|
215222|NCT00131703|Drug|Amodiaquine|
215223|NCT02123693|Other|Sham Therapy|
215224|NCT02123693|Other|No Intervention|
215225|NCT02123719|Other|Surgery|
215226|NCT02123732|Dietary Supplement|DbXell|
215227|NCT02123732|Dietary Supplement|Placebo|
215228|NCT02123745|Device|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
215229|NCT02123758|Drug|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
215230|NCT02123758|Drug|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
214610|NCT02136641|Drug|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
214611|NCT02136641|Drug|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
214612|NCT02136641|Drug|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
214613|NCT02136654|Behavioral|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
214614|NCT02136680|Other|CASA Education|Basic palliative competencies for outpatient use.
214615|NCT00133068|Behavioral|Computer|Computer intervention only
214616|NCT02136693|Drug|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
214617|NCT02136693|Drug|Placebo|3.5 g /day of inert compound for 180 days after STARR
214922|NCT02131506|Drug|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die
214923|NCT02131519|Procedure|internal jugular vein catheter placement|
214924|NCT02131532|Behavioral|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
214925|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
214926|NCT00132561|Drug|Sulfadoxine/pyrimethamine and artesunate|
214927|NCT02131545|Drug|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
214928|NCT02131545|Drug|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
214929|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
214930|NCT02131558|Procedure|ICG Dye|ICG Dye injections
214931|NCT02131584|Drug|Ruxolitinib|Starting dose: 10 mg by mouth twice a day.
214932|NCT02131584|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, then 2 weeks after study dose, and again at 3 months.
214295|NCT02144194|Drug|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
214296|NCT02144207|Device|Glidescope|
214297|NCT02144220|Other|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
214298|NCT02144233|Procedure|Occlusal adjustment|The first step consists of the elimination of premature tooth contacts during retruded jaw closure.
The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)
214299|NCT02144233|Procedure|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
214300|NCT00133666|Behavioral|Standard Asthma Education|
214301|NCT02144246|Other|Non-hormonal period|
214302|NCT02144246|Drug|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
214303|NCT02144259|Drug|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
214304|NCT02144259|Drug|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogesterel.
214305|NCT02144272|Drug|LY3114062 SC|LY3114062 administered SC.
214306|NCT02144272|Drug|Placebo|Placebo administered SC.
214307|NCT02144272|Drug|LY3114062 IV|LY3114062 administered IV.
214308|NCT02144285|Drug|LY3113593|Administered IV
214309|NCT02144285|Drug|LY3113593|Administered SC
214310|NCT02144285|Drug|Placebo|Administered IV
214618|NCT02136706|Procedure|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
214619|NCT02136719|Procedure|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
214620|NCT02139085|Device|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
213999|NCT02151682|Drug|Morphine prolonged release|Participants aged from 6 years to less than 18 years with body weight less than 22.5 kg (but more than 17.5 kg) will start on 10 mg of morphine orally twice daily during the first 24 hours and then and then if necessary gradually stepwise increase the dose.
214000|NCT02151695|Procedure|panretinal photocoagulation|
214001|NCT02151695|Drug|Aflibercept intravitreal injections|
214002|NCT02151708|Drug|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
214311|NCT00133679|Drug|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
214312|NCT02144285|Drug|Placebo|Administered SC
214313|NCT02144311|Procedure|PET/CT Scan|
214314|NCT02144311|Procedure|MRI|
214315|NCT02144324|Device|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
214316|NCT02146521|Other|non interventional study|
214317|NCT02146534|Drug|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
214318|NCT02146534|Drug|Placebo|placebo will be taken PO BID
214319|NCT02146547|Drug|Aripiprazole|Administration in once-a-day schedule without regard to meals.
214320|NCT02146547|Drug|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
214321|NCT02146547|Drug|Paliperidone|Administration once a day orally standardised in relation to food intake.
214322|NCT02146547|Drug|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
214323|NCT00133952|Drug|Ruboxistaurin|Administered orally
214324|NCT02146573|Behavioral|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
218764|NCT02313844|Biological|Viralym-B|Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
218765|NCT00148746|Drug|Tacrolimus|
218766|NCT02277119|Device|iVue|OCT machines used for diagnostic purposes
218767|NCT02277132|Drug|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
218768|NCT02277132|Drug|Placebo|Placebo tablets three times daily orally from randomization until delivery
218769|NCT02277145|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
218770|NCT02277158|Drug|Chemoradiotherapy|S-1 CCRT
214003|NCT02151708|Drug|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
214004|NCT02154230|Dietary Supplement|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
214005|NCT02154243|Drug|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
214006|NCT00134459|Drug|Bifeprunox|
214007|NCT02154243|Other|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
214008|NCT02154256|Behavioral|Increasing incentives|Offer incentives that increase over time.
214009|NCT02154256|Behavioral|Decreasing incentives|offer incentives that decrease over time
214010|NCT02154256|Behavioral|stable incentives|offer incentives that are stable over time, but higher than usual care
214011|NCT02154269|Drug|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
214012|NCT02154269|Drug|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
214013|NCT02154282|Behavioral|ipod games|Patients will be given ipod games for 2 weeks and tested in related and unrelated cognitive measures
214014|NCT02154295|Device|Infraredx Test Catheter|
214015|NCT02154308|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
218462|NCT02281981|Dietary Supplement|Curcumin|333mg CurcuWin OAHTCUR002-2014
218463|NCT02281981|Dietary Supplement|Placebo|OAHTCUR005-2014
218464|NCT02281994|Device|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
218465|NCT00149630|Drug|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
218466|NCT02284373|Other|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
218467|NCT02284373|Other|Routine wound care for venous ulcers and lymphedema|wound care /dressings
218468|NCT02284373|Device|Flexitouch pneumonic compression|pneumonic compression only
218469|NCT02284386|Drug|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
218470|NCT02284386|Drug|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
218771|NCT02277171|Device|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
218772|NCT02277184|Drug|Ficlatuzumab|Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.
Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.
Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)
218773|NCT02277184|Drug|Cisplatin|Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.
Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.
Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes.
218774|NCT02277184|Radiation|Intensity Modulated Radiotherapy (IMRT)|Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.
Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).
The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue.
202658|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.37 mg/m^2 administered on Days 1 and 8 of 21-day cycle.
202659|NCT02026271|Drug|veledimex|4 dose cohorts (20mg/day, 40mg/day, 80mg/day, and 120mg/day)
14 oral daily doses of INXN-1001
1 Expansion cohort at a single dose level at or below MTD
202660|NCT02026284|Other|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
202661|NCT02026297|Drug|Tranexamic Acid|1 gram IV over 10 minutes
202662|NCT02026310|Drug|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
202663|NCT02026310|Drug|glargine and metformin|
202664|NCT02026323|Other|acupuncture|acupuncture
202665|NCT02026336|Other|electronic nose|Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L "Tedlar bag". Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile.
202969|NCT02018939|Other|Pharmacokinetic profiling|Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
202970|NCT02021292|Drug|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
202971|NCT02021292|Drug|Placebo|Matching placebo oral tablet, to be taken once daily.
202972|NCT02021318|Drug|FG-4592|oral tablet
202973|NCT02021318|Drug|darbepoetin alfa|subcutaneous or intravenous injection
202974|NCT02021331|Device|immediate implant placement without provisionalization|
202975|NCT02021331|Device|immediate implant placement with immediate provisionalization|
202976|NCT02021344|Behavioral|Mental Health First Aid|Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
202977|NCT02021357|Behavioral|hyperboloid associated with the exercise of proprioceptive|
202978|NCT02021357|Other|hyperboloid|
202364|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
202365|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
202366|NCT02031419|Drug|CC-223|20mg or 30mg per day administered orally daily.
202367|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
202368|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
202369|NCT02034032|Procedure|Regenexx SD|
202370|NCT00122590|Drug|indinavir|
202371|NCT02034032|Behavioral|Exercise Therapy|
202372|NCT02034045|Other|Community Paramedicine|
202373|NCT02034045|Other|Usual Care|
202374|NCT02034058|Device|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
202375|NCT02034071|Drug|DCCR|
202376|NCT02034071|Drug|Placebo|
202377|NCT02034084|Procedure|left radial approach|Coronary diagnostic procedures performed through left radial approach
202666|NCT02026349|Drug|favipiravir|Administered twice daily over 5 consecutive days for a total of 10 doses.
Day 1: 1800 mg twice daily (loading doses)
Days 2 through 5: 800 mg twice daily
202667|NCT02026349|Drug|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
202668|NCT02026362|Biological|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
202669|NCT00121745|Genetic|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
202670|NCT02026362|Other|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
202671|NCT02026401|Biological|NGM282|
202672|NCT02026401|Biological|Placebo|
202074|NCT01996683|Drug|desferal, ferriprox, blood transfusion|Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving "normal" body iron stores in poly-transfued arm1.
Arm 2 will only recieve blood transfusion with no chelation
202075|NCT01996696|Drug|Metformin|Metformin 500 mg PO TID x 30-36 months
202076|NCT01996696|Drug|Placebo|Identical placebo TID x 30-36 months
202077|NCT01996709|Device|Hydrogen peroxide-based contact lens solution|
202078|NCT01996709|Device|Habitual contact lens solution|Biguanide-preserved
202079|NCT01996709|Device|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
202080|NCT00119054|Behavioral|In Home Health Messaging Device|
202081|NCT01996735|Drug|Ticagrelor 180 mg single dose|
202082|NCT01996735|Drug|Placebo|
202083|NCT01996748|Drug|DF277|Two administrations daily for 7 days
202084|NCT01996748|Drug|Placebo|Two administrations daily for 7 days
202085|NCT01996761|Drug|porcine brain peptide (Cerebrolysin)|
202086|NCT01996761|Drug|Placebo|
202087|NCT01996787|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
202088|NCT01996787|Device|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
202089|NCT01996800|Procedure|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
202090|NCT01996800|Procedure|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
202091|NCT00119067|Biological|BioThrax or Anthrax Vaccine Adsorbed|
202092|NCT01996813|Device|Compression Hose|Intervention in this case is placement of compression hose on patients
201495|NCT02009670|Dietary Supplement|13C inulin|Oral 13C inulin
201496|NCT02009670|Other|Placebo|Oral maltodextrin
201791|NCT02001948|Drug|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
201792|NCT02001974|Drug|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
201793|NCT02001987|Drug|tocilizumab [RoActemra/Actemra]|162 mg administered once weekly by subcutaneous injection.
201794|NCT02004626|Drug|Kollagenase|Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.
Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.
Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).
Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.
Photographic records.
201795|NCT02004639|Radiation|Masticators sparing techniques|
201796|NCT02004639|Other|electro-acupunture treatment|electro-acupunture treatment and sham-EA
201797|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
201798|NCT02004652|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
201799|NCT02004652|Drug|Placebo|Vitamin, 50mg, tablet.
201800|NCT02004678|Drug|DS-1150b|
201801|NCT02004678|Other|Placebo|
201802|NCT02004691|Drug|placebo (saline)|Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
Route of administration: intravenous infusion
201803|NCT02004691|Drug|GZ402665|Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
Route of administration: intravenous infusion
201804|NCT02004704|Drug|GZ402665|Pharmaceutical form:Powder for concentrate for solution for infusion
Route of administration: intravenous infusion
201805|NCT02004717|Drug|DS-8895a|
201806|NCT02004730|Device|ABSORB implantation|ABSORB implantation for long (> 24mm) single vessel disease
201807|NCT02004743|Behavioral|Psychological guidelines and PET|Psychological guidelines and PET
201187|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
201188|NCT00121056|Drug|Kineret®|
201189|NCT02018159|Drug|menotropin|
201190|NCT02018172|Drug|somatropin|
201191|NCT02018185|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
201192|NCT02018185|Device|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
201497|NCT02009696|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
201498|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiation Therapy 6 fractions per week
201499|NCT02009696|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
201500|NCT02009709|Drug|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
201501|NCT02009709|Device|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
201502|NCT02012595|Other|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand [11C]donepezil
201503|NCT02012608|Drug|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
201504|NCT00120484|Drug|Vitamin B12|
201505|NCT02012608|Drug|Placebo|For subjects undergoing breast conserving therapy
201506|NCT02012647|Procedure|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
201507|NCT02012647|Procedure|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
201508|NCT02012660|Other|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
200857|NCT02022982|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
200858|NCT02022982|Drug|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
200859|NCT02023008|Procedure|yoga therapy|Undergo integral yoga intervention with videoconferencing
200860|NCT00121446|Drug|clopidogrel|
200861|NCT02023008|Other|internet-based intervention|Undergo integral yoga intervention with videoconferencing
200862|NCT02023008|Other|questionnaire administration|Ancillary studies
200863|NCT02023021|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
200864|NCT02023021|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
200865|NCT02023034|Other|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
200866|NCT02023047|Drug|Nifedipine 12 mg coated suppositories|
200867|NCT02023086|Procedure|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
201193|NCT02018211|Other|control|passive recovery following exercise test
201194|NCT02018211|Device|graduated compression socks|graduated compression socks worn after test exercise
201195|NCT02018211|Device|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
201196|NCT02020486|Drug|Perampanel|2 mg up to 6 mg
201197|NCT02020499|Drug|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
217074|NCT02283736|Other|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
217075|NCT02283736|Other|Talc powder|Tablet containing talc powder
217076|NCT00149552|Dietary Supplement|zinc|supplementation with zinc gluconate
217077|NCT02283736|Procedure|Periodontal treatment|Scaling and root planning
217078|NCT02283749|Biological|Xofigo|This is a radio-isotope
217079|NCT02283762|Drug|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5mg very 2 weeks until highest possible dose of 2.5 mg TID
217080|NCT02283762|Drug|Placebo|Sham-titration
217081|NCT02283775|Drug|SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
217082|NCT02283775|Drug|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
217083|NCT02283775|Drug|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
217084|NCT02283788|Drug|BIA 2-093|
217085|NCT02283788|Drug|Moxifloxacin|
217086|NCT02283788|Drug|Placebo|
217087|NCT00149565|Drug|IFN-α2b|
217088|NCT02283801|Drug|Eslicarbazepine acetate|
217089|NCT02283801|Drug|Lamotrigine|
217090|NCT02283814|Drug|BIA 2-093|
217091|NCT02286297|Device|GlideScope|video-laryngoscopy-3
217092|NCT02286297|Device|Miller|Direct laryngoscopy
217093|NCT02286310|Other|Kinetic Chain Exercises|Exercises include kinetic chain segments.
217094|NCT02286310|Other|Traditional Exercises|Stretching, strengthening exercises.
217095|NCT02286323|Device|Bonfils|Bonfils Intubation Fiberoscope
217096|NCT02286323|Device|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
217097|NCT02286336|Other|brachial plexus block|brachial plexus block with ropivacaine 40ml
216495|NCT02297789|Device|Investigative Full Face Mask with Headgear|
216496|NCT02297802|Drug|PD-0325901|
216497|NCT02297815|Drug|Broad-spectrum antibiotics AOM:|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, or ceftriaxone
216498|NCT02297815|Drug|Broad spectrum antibiotics acute sinusitis|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil or ceftriaxone
216499|NCT02297815|Drug|Broad spectrum antibiotics GAS pharyngitis|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cephalexin, ceftriaxone, or sodium cefadroxil
216500|NCT02297815|Drug|Narrow spectrum antibiotics AOM|Amoxicillin
216501|NCT02297815|Drug|Narrow spectrum antibiotics GAS pharyngitis|Amoxicillin or penicillin
216502|NCT00151177|Device|CPAP-treatment|night time CPAP-mask ventilation
216788|NCT02290652|Other|Prospective - Factors affecting sexual function pre-THR|A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.
Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.
Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI.
216789|NCT02290652|Other|Retrospective- Factors affecting sexual function post-THR|A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.
Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).
Maximum retrospective collection of data 12 months.
216790|NCT02290665|Drug|Thermosensitive gel rectal formulation|
216791|NCT02290665|Drug|Saline enema|
216792|NCT02290678|Behavioral|Adventure-based Programming|
216793|NCT00150397|Drug|Tofimilast|
216794|NCT02290691|Biological|Influenza Vaccine|Influenza Vaccine
216795|NCT02290717|Device|Fractional CO2 laser|
216796|NCT02290717|Other|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
216797|NCT02293161|Drug|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
216798|NCT02293161|Drug|Placebo|It is Sodium Chloride Intravenous Infusion
216149|NCT02145065|Drug|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
216150|NCT02145065|Device|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
216151|NCT02145078|Drug|docetaxel|Given IV
216152|NCT02145078|Drug|pemetrexed disodium|Given IV
216153|NCT02145078|Drug|gemcitabine hydrochloride|Given IV
216154|NCT02145078|Other|laboratory biomarker analysis|Correlative studies
216155|NCT02145091|Drug|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
216156|NCT02145091|Drug|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
216157|NCT02145091|Drug|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
216158|NCT02145091|Drug|Placebo|An oral placebo (lactose pill).
216159|NCT00133744|Dietary Supplement|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
216160|NCT02145104|Drug|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
216503|NCT02297815|Drug|Narrow spectrum antibiotics acute sinusitis|Amoxicillin
216504|NCT02297828|Device|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
216505|NCT02297828|Device|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
216506|NCT02297841|Device|Experimental: Novel lubricant Miama w/ frag|
216507|NCT02297841|Device|Experimental: Novel Miami w/o frag|
216508|NCT02297841|Device|KY Liquid lubricant|
216509|NCT02297841|Device|Astroglide Gel lubricant|
216510|NCT02297854|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
216511|NCT02297867|Drug|ADSCs|autologous ADSCs
216512|NCT02297880|Other|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
215841|NCT02152384|Drug|Insulin Glargine|Administered SC
215842|NCT02152397|Behavioral|Therapist-led brief intervention (TBI)|
215843|NCT02152410|Device|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
215844|NCT02152410|Drug|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS> 30).
215845|NCT02152423|Drug|LOVENOX|
215846|NCT02152423|Drug|ENOXAMED|
215847|NCT02152436|Other|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
215848|NCT02152449|Dietary Supplement|Oral nutritional supplementation|
215849|NCT02152462|Other|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
215850|NCT00002258|Drug|Interleukin-3|
215851|NCT00134277|Procedure|Infragenual dilatation with stenting|Infragenual dilatation with stenting
215852|NCT02152475|Drug|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
215853|NCT02152475|Device|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
215854|NCT02152501|Other|Exercise Energy Expenditure 300 kcal/day|
215855|NCT02152501|Other|Exercise Energy Expenditure 600 kcal/day|
215856|NCT02152514|Drug|Intrathecal Morphine/Sufentanil|
215857|NCT02152514|Device|PCA|
215858|NCT02152540|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
215859|NCT02152540|Device|Sham rTMS|Placebo Device that simulates active rTMS treatment
216161|NCT02145117|Behavioral|MBSR|Behavioral
216162|NCT02145130|Other|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
215231|NCT02123758|Drug|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
215232|NCT02123810|Other|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
215233|NCT00131703|Drug|Sulphadoxine-pyrimethamine|
215536|NCT02119468|Other|laboratory biomarker analysis|Correlative studies
215537|NCT02119481|Behavioral|Mindfulness-based stress reduction|
215538|NCT02119481|Behavioral|Expressive writing condition|
215539|NCT02119507|Device|Curodont Repair|Single application on Day 0
215540|NCT00131209|Dietary Supplement|maize and soy flour|
215541|NCT02119507|Other|No treatment - control|
215542|NCT02119520|Drug|Platelet rich fibrin +Atorvastatin|
215543|NCT02119520|Drug|Platelet rich fibrin|
215544|NCT02119520|Procedure|open flap debridement|
215545|NCT02119546|Other|Aerobic exercise|Aerobic exercise and dual-task training
215546|NCT02119546|Other|Stretch exercise|Stretch exercise & sitting balance
215547|NCT02119559|Other|Blood analysis by EPISPOT and CellSearch®|
215548|NCT02119572|Behavioral|peer support|
215549|NCT02119572|Other|usual education lectures|
215550|NCT02119611|Other|Deep Brain Stimulation Management|Therapy
215551|NCT00131222|Procedure|Food supplement: fortified spread|
215552|NCT02119650|Drug|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase
(Ruxolitinib 15mg BID or Ruxolitinib 10mg BID)
215553|NCT02119650|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
215554|NCT02119650|Drug|Pemetrexed|500 mg/m^2 administered as an intravenous infusion over 10 minutes
215555|NCT02119650|Drug|Cisplatin|75 mg/m^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
214933|NCT02131597|Drug|SGI-110|60 mg/m2 subcutaneously daily for 5 days every 4 weeks.
214934|NCT02131636|Drug|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
214935|NCT02131636|Drug|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
214936|NCT02131649|Device|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
214937|NCT00132574|Behavioral|Minimization of milk and dairy products in the diet|
214938|NCT02131662|Drug|BAY1002670|0.5 mg of BAY1002670 once daily for 12 weeks
214939|NCT02131662|Drug|BAY1002670|1 mg of BAY1002670 once daily for 12 weeks
214940|NCT02131662|Drug|BAY1002670|2 mg of BAY1002670 once daily for 12 weeks
214941|NCT02131662|Drug|BAY1002670|4 mg of BAY1002670 once daily for 12 weeks
214942|NCT02131662|Drug|Placebo|Once daily for 12 weeks
215234|NCT02123823|Drug|Everolimus|10mg dose
215235|NCT02123823|Drug|Everolimus|at recommended dose as per Phase I data
215236|NCT02126397|Procedure|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
215237|NCT02126397|Procedure|polyps resection with bipolar electrode|
215238|NCT02126423|Other|Conjunctival and nasopharyngeal swabs|For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
215239|NCT02126436|Other|Acupuncture|Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:
using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks.
215240|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
215241|NCT02126449|Other|Fasting mimicking diet|
214621|NCT02139085|Device|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
214622|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
214623|NCT02139098|Drug|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
214624|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
214625|NCT00133315|Drug|Adalimumab|
214626|NCT02139098|Drug|Placebo|Placebo
214627|NCT02139111|Drug|Placebo|Oral placebo capsule
214628|NCT02139111|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
214629|NCT02139111|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
214630|NCT02139111|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
214631|NCT02139111|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
214632|NCT02139124|Drug|Placebo|Oral placebo capsule
214633|NCT02139124|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
214634|NCT02139124|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
214635|NCT02139124|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
214636|NCT00133328|Drug|valsartan|
214637|NCT02139124|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
214638|NCT02139137|Other|Computerized Cognitive Training - active|
214639|NCT02139137|Other|Computerized cognitive training - sham|
214640|NCT02139150|Radiation|[18F] FLT|
214641|NCT02139150|Device|PET/CT scans|
214943|NCT02131675|Dietary Supplement|Boost shake|Blood draw after mixed-meal consumption
214944|NCT02131688|Drug|Mitoxantrone Hydrochloride Liposome|
214325|NCT02146573|Behavioral|Continuity Care Intensivist (CCI) Provider Program|After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:
CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.
Help patients/families navigate decisions in concert with preferences and beliefs
Help patients/families and other care providers look at "bigger picture"; trajectory of illness, goals, and hopes for the patient.
Serve as point person for active intensivists on service and other specialists
Help resolve conflict when multiple providers have different opinions on course of action
214326|NCT02146599|Other|Administration of patient self-assessment|
214327|NCT02146612|Other|Amino Acid Supplement Group|Group receiving nutritional supplement
214328|NCT02146625|Drug|CJ-40002|
214329|NCT02146638|Drug|Morphine|
214330|NCT02146638|Drug|Fentanyl|
214642|NCT02139163|Other|Cohort Study|
214643|NCT02139176|Behavioral|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
214644|NCT02139176|Behavioral|patient referral|A patient agrees to recruit their partner using the invitation.
214645|NCT02139189|Device|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
214646|NCT02139202|Behavioral|Social Influence|
214647|NCT00133341|Drug|Goldnatriomthiosulphate, MDBGN, parthenolide|
214648|NCT02139202|Behavioral|Electronic Pill Bottles|
214649|NCT02139202|Behavioral|Financial Incentives|
214650|NCT02141893|Behavioral|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
214651|NCT02141893|Behavioral|CALMA|Family Education Intervention on management of pediatric asthma
214652|NCT02141906|Device|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
214653|NCT02141919|Radiation|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
214654|NCT02141932|Procedure|Bed-side pocket size ultrasound imaging|
214016|NCT02154321|Device|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
214017|NCT00134459|Drug|Placebo|
214018|NCT02154334|Drug|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
214019|NCT02154334|Drug|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
214020|NCT02154334|Drug|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
214021|NCT02154347|Drug|KAD-1229|
214331|NCT02146651|Drug|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
214332|NCT02146651|Drug|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
214333|NCT02146651|Drug|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
214334|NCT00133952|Drug|Placebo|Administered orally
214335|NCT02146651|Drug|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
214336|NCT02146664|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
214337|NCT02149225|Drug|APVAC1 vaccine plus Poly-ICLC and GM-CSF|APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.
Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.
The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs.
218775|NCT02277197|Drug|Ficlatuzumab|Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.
Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.
Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)
218776|NCT00148746|Drug|Prednisolone|
218777|NCT02277197|Drug|Cetuximab|Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.
Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended.
218778|NCT02277210|Other|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
218779|NCT02279498|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
218780|NCT02279498|Drug|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
218781|NCT02279511|Drug|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
214022|NCT02154347|Drug|Placebo|
214023|NCT02154347|Drug|Insulin|
214024|NCT02154360|Drug|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
214025|NCT02154386|Device|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
214026|NCT02154399|Drug|EF5|Given IV
214027|NCT02116465|Drug|Levodopa Carbidopa immediate release tablets|oral administration
214028|NCT02116478|Procedure|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
214029|NCT02116491|Device|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
214030|NCT02116504|Procedure|Sampling of blood|Sampling of blood for dosage of antibodies
202979|NCT00121290|Drug|SJG-136|Given IV
202980|NCT02021370|Drug|BAY85-3934|25mg Tablet
202981|NCT02021370|Drug|Placebo|Matching placebo tablet
202982|NCT02021383|Behavioral|Bi-weekly in person meetings with a Registered Dietician|Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.
Participants in the Contest only and Control group were not eligible to receive these meetings.
202983|NCT02021383|Behavioral|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
202984|NCT02021396|Procedure|Embolisation|this arm of the study was interventional (embolization) the scans of the inclusion (D0, to validate the inclusion criteria) in one month (J30-validating the primary endpoint) and 6 months (D180).
202985|NCT02021409|Drug|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
202986|NCT02021409|Biological|Darbepoetin alfa|
202987|NCT02021422|Drug|anakinra|Dosage Route Administration 100 mg SC Every Other Day
202988|NCT02021422|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
203284|NCT02013570|Drug|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
203285|NCT02013583|Other|No intervention|This is an observational registry. No interventions are required or provided.
203286|NCT02013596|Other|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
203287|NCT02013596|Other|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
203288|NCT00120601|Drug|Naltrexone|
203289|NCT02016313|Other|physiotherapy|
203290|NCT02016326|Device|HD Colon|High Definition White Light
203291|NCT02016326|Device|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
202673|NCT02028910|Drug|Ondansetron|The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.
The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.
The dosage should be adjusted according to the weight of the child
202674|NCT02028923|Drug|Morphine gel|Topical
202675|NCT02028923|Other|Neutral gel|Topical
202676|NCT02028936|Other|Grape juice R@isol|
202677|NCT02028936|Other|Commercially-available grape juice|
202678|NCT02028949|Drug|Zavedos®|
202679|NCT02028949|Other|Blood samples|
202680|NCT02028962|Behavioral|Lifestyle counseling|
202681|NCT02028975|Other|Measure the threshold of detection for linoleic acid|
202682|NCT02028975|Other|Oral stimulation tests|
202683|NCT00121979|Drug|Racivir, a non-nucleoside reverse transcriptase inhibitor|
202684|NCT02028975|Other|Venous blood samples|
202685|NCT02028975|Other|Samples for genetic studies (ancillary study)|
202686|NCT02028988|Drug|Enzalutamide|
202687|NCT02028988|Radiation|External Beam Radiation|Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.
EBRT shall receive prescription doses to the PTV 75.6- 79.2 Gy delivered in 1.8 Gy fractions.
202989|NCT02021422|Drug|Irinotecan|Irinotecan 180 mg/m2 90 minutes
202990|NCT00121290|Other|laboratory biomarker analysis|Correlative studies
202991|NCT02021422|Drug|fluorouracil|fluorouracil 2400 mg/m2 48 hours
202992|NCT02021435|Dietary Supplement|salt substitute|Free salt substitute provided
202993|NCT02023788|Biological|PNEUMOSTEM|A single intratracheal administration
Low Dose Group (3 patients): 1.0 x 10^7 cells/kg High Dose Group (6 patients): 2.0 x 10^7 cells/kg
* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study.
202093|NCT01996826|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
202378|NCT02034084|Procedure|Right radial approach|coronary diagnostic procedures performed through right radial approach
202379|NCT02034097|Drug|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
202380|NCT02034097|Drug|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
202381|NCT00122590|Drug|ritonavir|
202382|NCT02034110|Drug|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis.
202383|NCT02034110|Drug|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
202384|NCT02034123|Drug|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
202385|NCT02034136|Dietary Supplement|Ginsenoside|3.0 g/ d for 28 days
202386|NCT02034136|Dietary Supplement|Dietary fiber fill|3g/day, 28days
202387|NCT02034149|Behavioral|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
202388|NCT02034149|Behavioral|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
202389|NCT02034149|Behavioral|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
202390|NCT02034162|Drug|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
202391|NCT01994512|Procedure|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
202392|NCT01994525|Biological|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
202393|NCT01994525|Biological|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
201808|NCT00119678|Drug|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
201809|NCT02004743|Other|treatment as usual|Participants will experience treatment as usual.
These patients will receive questionnaires at recruitment, 1 month,3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD
202094|NCT01996826|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
202095|NCT01996839|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
202096|NCT01999283|Other|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
202097|NCT01999296|Device|Use of Thunderbeat (TM) in laparoscopic surgery|
202098|NCT01999309|Drug|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
202099|NCT01999309|Drug|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
202100|NCT01999322|Drug|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
202101|NCT01999322|Drug|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
202102|NCT01999335|Drug|Oprozomib|Study subjects will receive oprozomib tablets once daily on Days 1-5 and 15-19 (QD × 5 bimonthly schedule) of each 28-day treatment cycle.
202103|NCT01999335|Drug|Pomalidomide|Study subjects will receive pomalidomide once-daily on Days 1-21 of every 28-day cycle.
202104|NCT01999335|Drug|Dexamethasone|Study subjects will receive dexamethasone once daily on days 1-2, 8-9, 15-16, and 22-23 of every 28-day cycle.
202105|NCT01999348|Drug|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
202106|NCT00119262|Drug|tamoxifen citrate|Given orally
202107|NCT01999361|Drug|Myfortic|treatment with myfortic
202108|NCT01999387|Dietary Supplement|Allergenic food|
202109|NCT01999400|Drug|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
202110|NCT01999400|Drug|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
201509|NCT02012673|Device|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
201510|NCT02012686|Device|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
201511|NCT02012712|Behavioral|Personal Health Record (PHR)|Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.
Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE‐3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login.
201512|NCT02012725|Drug|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
201810|NCT02004756|Other|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
201811|NCT02004769|Drug|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
201812|NCT02004769|Drug|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
201813|NCT02004769|Drug|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
201814|NCT02004782|Drug|Prednisolone|
201815|NCT02004795|Radiation|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
201816|NCT02007408|Drug|Paracervical block|
201817|NCT02007408|Drug|Lidocaine spray|
201818|NCT02007408|Drug|Paracervical block + lidocaine spray|
201198|NCT02020512|Drug|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
201199|NCT02020525|Procedure|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
201200|NCT02020525|Procedure|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
201201|NCT02020538|Other|Low-chloride perioperative intravenous fluid strategy|The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
201202|NCT02020551|Drug|Lidocaine Spray|
201203|NCT02020551|Drug|Placebo|
201204|NCT00121238|Other|laboratory biomarker analysis|Correlative studies
201205|NCT02020564|Behavioral|Speed of Processing Training|
201206|NCT02020577|Drug|Cetuximab( erbitux®)|once per week
201207|NCT02020577|Drug|Afatinib|once per day
201208|NCT02020590|Drug|ALLOB® Implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
201209|NCT02020603|Device|epinephrine injection plus soft coagulation using hemostatic forceps|
201210|NCT02020603|Device|epinephrine injection plus argon plasma coagulation|
201211|NCT02020616|Drug|LY3053102|Administered SC
201212|NCT02020616|Drug|Exenatide extended release|Administered SC
201213|NCT02020616|Drug|Placebo|Administered SC
201214|NCT02020629|Drug|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
201215|NCT00121251|Drug|Capecitabine|Given PO
201513|NCT02012738|Behavioral|FORNET|8 individual sessions:
1 lifeline
6 exposure sessions
1 outlook
201514|NCT02012738|Behavioral|CBT|7 individual sessions, according to the "Integrated cognitive behavior change program" manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice.
217098|NCT00149799|Drug|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
217371|NCT00148954|Device|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
217372|NCT02278913|Drug|Human Insulin|NPH twice a day + Regular insulin before meals
217373|NCT02278926|Other|Ultrasound|Ultrasound measurements
217374|NCT02278926|Other|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
217375|NCT02278939|Behavioral|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
217376|NCT02278965|Drug|Metformin|Metformin 850mg, oral, twice a day for 12 months
217377|NCT02278965|Drug|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
217378|NCT02278978|Drug|BIBF1120|BIBF1120 200 mg two times per day orally
217379|NCT02278991|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
217380|NCT02279017|Behavioral|mHealth Texting for Weight Loss|
217381|NCT02279030|Other|MIBG nuclear scan|To have scan to help define pathways for PVC ablations.
217382|NCT00148954|Device|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
217383|NCT02281318|Drug|Placebo|Sterile 0.9% sodium chloride solution
217384|NCT00002372|Drug|Saquinavir|
217385|NCT00149227|Drug|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
217386|NCT02281318|Drug|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
217387|NCT02281331|Dietary Supplement|Supplement|supplement/placebo plus exercise training
217388|NCT02281344|Drug|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
216799|NCT02293174|Device|Topcon TRC-NW400|Retinal Fundus Camera
216800|NCT02293174|Device|TRC-NW8|Retinal Fundus Camera
216801|NCT00002378|Drug|Nelfinavir mesylate|
216802|NCT00150657|Drug|carboplatin|
216803|NCT02293174|Device|TRC-NW400|Retinal Fundus Camera
216804|NCT02293174|Device|Canon-CR2|Retinal Fundus Camera
216805|NCT02293174|Device|Zeiss Visucam PRO|Retinal Fundus Camera
216806|NCT02293187|Dietary Supplement|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level <70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
216807|NCT02293187|Other|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
216808|NCT02293200|Device|Standard BLS|basic life support without any feedback device
217099|NCT02286349|Device|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
217100|NCT02286349|Device|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
217101|NCT02286375|Behavioral|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
217102|NCT02286388|Procedure|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|Instruments and procedures:
Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.
Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.
Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.
The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin).
217103|NCT02286388|Procedure|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|Instruments and procedures:
Idem partial excavation arm.
In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin.
216513|NCT00151190|Behavioral|Education for diabetes self-management|
216514|NCT02299999|Drug|Mitomycine C|Alkylating agents
216515|NCT02299999|Drug|Eribuline|Microtubule modulator
216516|NCT02299999|Drug|MEDI4736|Target: PD-L1
216517|NCT02300012|Procedure|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
216518|NCT00151424|Drug|asenapine|Asenapine 5-10mgBID
216519|NCT02300025|Drug|cobimetinib|single oral 10-mg dose of cobimetinib
216520|NCT02300038|Drug|Lidocaine (Xylocaine)|perineuromally administration of 1 ml lidocaine
216521|NCT02300038|Dietary Supplement|NaCl|perineuromally administration of NaCL
216522|NCT02300051|Behavioral|STPGP and RPGT|
216523|NCT02300051|Drug|TAU|
216524|NCT02300064|Dietary Supplement|Vitamin E|400 international units
216525|NCT02300064|Dietary Supplement|Vitamin C|1000 milligrams
216526|NCT02300064|Dietary Supplement|Alpha Liopic Acid|600 milligrams
216527|NCT02300064|Dietary Supplement|Placebo|
216809|NCT02293200|Device|TrueCPR|CPR with feedback device
216810|NCT02293213|Behavioral|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
216811|NCT02293213|Behavioral|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
216812|NCT02293213|Behavioral|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
216813|NCT00150657|Drug|gemcitabine|
216814|NCT02293213|Behavioral|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
216815|NCT02293213|Behavioral|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
216816|NCT02293213|Behavioral|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
216163|NCT02145130|Other|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
216164|NCT02145143|Drug|Vemurafenib|
216165|NCT02145143|Device|serial 124I PET/CT|
216166|NCT02147431|Drug|placebo|2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.
Each treatment period will be followed by a hypoglycaemic clamp.
216167|NCT02147470|Drug|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
216168|NCT02147483|Behavioral|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
216169|NCT02147483|Behavioral|Treatment as usual|Treatment usually provided by clinician
216170|NCT02147496|Other|Dietary Intervention|
216171|NCT00133991|Biological|pegfilgrastim|
216172|NCT02147509|Drug|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
216173|NCT02147509|Drug|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
216174|NCT02147509|Other|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
216175|NCT02147509|Drug|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
216176|NCT02147522|Behavioral|Self-care management|The behavioral intervention is provided by promotoras
216177|NCT02147535|Drug|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
216178|NCT02147548|Drug|etifoxine|
216179|NCT02147548|Drug|lorazepam|
216180|NCT02147548|Drug|Placebo|
216181|NCT02147561|Biological|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
216182|NCT00133991|Biological|rituximab|
216528|NCT02300077|Drug|methadone|Escalating dose of methadone up to .3mg/kg.
216529|NCT00151424|Drug|Placebo|Matched against asenapine and olanzapine
215556|NCT02119663|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily [BID]
215557|NCT02119663|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
215558|NCT02119663|Drug|Capecitabine|500 mg tablets to be administered by mouth twice daily [BID]
215559|NCT02119676|Drug|Ruxolitinib|5 mg tablets to be administered by mouth
Ruxolitinib 15mg BID (NOTE: Starting dose of randomized portion of study may be 10mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study, based on results from safety run-in.)
215860|NCT02155140|Dietary Supplement|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
215861|NCT02155153|Other|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
215862|NCT02155166|Drug|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
215863|NCT02155166|Drug|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
215864|NCT00134563|Drug|Teriflunomide|Film-coated tablet
Oral administration
215865|NCT02155192|Drug|No Intervention|
215866|NCT02155205|Drug|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
215867|NCT02155205|Drug|Placebo|Matching placebo
215868|NCT02155205|Drug|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
215869|NCT02155218|Other|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
215870|NCT02155218|Other|Patient Tailored Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted "best" way to inject the main bolus - likely slower and "multi-phasic", meaning different flow rates as the bolus injection evolves.
215871|NCT02155218|Other|gadolinium contrast|
215872|NCT02155257|Drug|Modafinil|
215873|NCT02155257|Drug|Gabapentin|
215874|NCT02155257|Drug|Placebo|
215875|NCT00134563|Drug|Placebo (for teriflunomide)|Film-coated tablet
Oral administration
215242|NCT02126462|Biological|Na-APR-1 (M74)/Alhydrogel®|
215243|NCT02126462|Biological|Na-GST-1/Alhydrogel®|
215244|NCT00000321|Drug|Desipramine|
215245|NCT00002238|Drug|Interferon beta-1b|
215246|NCT00131950|Procedure|study of high risk factors|
215247|NCT02126462|Biological|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
215248|NCT02126488|Behavioral|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
215249|NCT02126488|Behavioral|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
215250|NCT02126488|Behavioral|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
215251|NCT02126501|Other|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
215252|NCT02126514|Drug|AZD3293|7 subjects will receive AZD3293
215253|NCT02126527|Drug|auranofin|Given PO
215560|NCT02119676|Drug|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
215561|NCT02119676|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
215562|NCT00131222|Procedure|Food supplement: maize and soy flour|
215563|NCT02121795|Drug|F/TAF|F/TAF FDC tablet administered orally once daily
215564|NCT02121795|Drug|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, ritonavir-boosted darunavir, efavirenz (as individual agent only), rilpivirine (as individual agent only), nevirapine, raltegravir, dolutegravir, and maraviroc.
215565|NCT02121795|Drug|Placebo to match FTC/TDF|Placebo to match FTC/TDF FDC tablets administered orally once daily
215566|NCT02121795|Drug|Placebo to match F/TAF|Placebo to match F/TAF FDC tablets administered orally once daily
214945|NCT02131701|Behavioral|Physical activity|
214946|NCT00000322|Behavioral|Tyrosine|
214947|NCT00002240|Drug|Didanosine|
214948|NCT00132769|Drug|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
214949|NCT02134314|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses
214950|NCT02134314|Drug|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses
214951|NCT02134327|Drug|Combination of Dexmedetomidine with Midazolam|
214952|NCT02134340|Drug|[I-124]-CPD-1028 Injection|A single intravenous dose of [I-124]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
214953|NCT02134340|Biological|CPD-1061|[Optional] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of [I-124]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
214954|NCT02134353|Drug|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
214955|NCT02134353|Drug|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
214956|NCT02134366|Drug|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
214957|NCT02134366|Drug|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
214958|NCT02134366|Drug|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
214959|NCT00132769|Drug|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
214960|NCT02134379|Device|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
214961|NCT02134392|Biological|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
214962|NCT02134405|Drug|Rebamipide|Rebamipide 100mg tid
214963|NCT02134405|Drug|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
214655|NCT02141932|Device|GE Ultrasound Vscan|
214656|NCT02141958|Drug|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
214657|NCT02141958|Drug|Placebo|A matching placebo will be used to keep the study double-blind.
214658|NCT02141997|Biological|adalimumab|Double-blind Every Other Week (EOW)
214659|NCT02141997|Biological|ABT-122|Double-Blind Every Week (EW)/ EOW
214660|NCT00133497|Biological|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
214661|NCT02142010|Drug|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
214964|NCT02134405|Drug|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
214965|NCT02134418|Behavioral|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
214966|NCT02134431|Device|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
214967|NCT02136732|Other|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
214968|NCT02136732|Other|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
214969|NCT02136745|Behavioral|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
214970|NCT02136758|Behavioral|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
214971|NCT02136771|Dietary Supplement|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
214338|NCT02149225|Drug|APVAC2 vaccine plus Poly-ICLC and GM-CSF|APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.
Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.
GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs.
214339|NCT02149238|Dietary Supplement|flavanol|
214340|NCT02149238|Dietary Supplement|methylxanthine|
214341|NCT02149238|Dietary Supplement|flavanol + methylxanthine|
214342|NCT02149251|Genetic|Pre-genetic diagnosis|
214343|NCT02149264|Drug|Testosterone Gel (FE 999303)|Testosterone Gel delivered using an applicator
214344|NCT00134030|Procedure|therapeutic conventional surgery|Undergo amputation or limb salvage surgery
214345|NCT02149277|Drug|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
214662|NCT02142036|Drug|EMA-approved single-agent ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
214663|NCT02142049|Drug|Ibrutinib, DA-EPOCH-R|
214664|NCT02142049|Drug|Ibrutinib, Lenalidomide, DA-EPOCH-R|
214665|NCT02142075|Drug|Daptomycin|
214666|NCT02142088|Device|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
214667|NCT02142114|Device|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
214668|NCT02142127|Drug|14C-labelled GFT505 120 mg|
214669|NCT02142140|Behavioral|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
214031|NCT00130975|Drug|Candesartan|
214032|NCT02116517|Dietary Supplement|green tea extract|500 mg three times per day
214033|NCT02116517|Dietary Supplement|Placebo|cellulose 500mg three times a day for 6 weeks
214034|NCT02116530|Drug|Olanzapine|oral
214035|NCT02116530|Drug|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
214036|NCT02116530|Drug|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
214037|NCT02116530|Other|Placebo|oral
214038|NCT02116543|Drug|TD-6450|
214039|NCT02116543|Drug|Placebo|
214040|NCT02116556|Drug|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
214041|NCT02116556|Drug|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
214042|NCT00130988|Behavioral|DEPENAS cognitive and behavioural techniques|
214043|NCT02116569|Drug|Daratumumab|Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
214346|NCT02149290|Device|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; activity data collection; ability to perform a health survey; ability to guide patients through a walk test
214347|NCT02149303|Drug|Dabigatran 75 mg|PO BID
214348|NCT02149303|Drug|Dabigatran 150 mg|PO BID
214349|NCT02149316|Procedure|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
214350|NCT02149316|Procedure|control|a deflated cuff placed on the right upper arm
214351|NCT02149329|Drug|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
214352|NCT02149342|Drug|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014) 2% Hexylaminolaevulinate (Hexvix Photocure) mixed with Unguentum M (Allmiral) cream (2015)
203292|NCT02016326|Device|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
203293|NCT00120874|Behavioral|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
203294|NCT02016339|Behavioral|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
203295|NCT02016339|Behavioral|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
203296|NCT02016352|Biological|patient CSF extraction with hydrocephalus|CSF extraction
203297|NCT02016352|Biological|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
203298|NCT02016365|Drug|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
203299|NCT02016365|Drug|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
203300|NCT02016378|Behavioral|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
203605|NCT02008214|Drug|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
203606|NCT02008214|Drug|Placebo|Placebo matching pentoxifylline dosage
203607|NCT02010619|Behavioral|Supportive therapy|
203608|NCT02010632|Drug|Generic clopidogrel product Apolets®|Clopidogrel 75 mg once daily for 7 days
Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7
203609|NCT02010632|Drug|Original clopidogrel product Plavix®|Clopidogrel 75 mg once daily for 7 days
Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7
203610|NCT02010645|Drug|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
203611|NCT02010645|Drug|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
203612|NCT02010658|Other|Cognitive Aid|
202994|NCT02023801|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
202995|NCT02023827|Behavioral|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
202996|NCT02023840|Drug|metronidazole gel|
202997|NCT02023840|Procedure|ultrasonics|
202998|NCT02023840|Procedure|erythritol|
202999|NCT02023840|Drug|placebo|
203000|NCT00121524|Drug|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
203001|NCT02023853|Procedure|ultrasonic|
203002|NCT02023853|Procedure|erythritol|
203003|NCT02023853|Drug|metronidazole gel|
203004|NCT02023866|Drug|Cysteamine Bitartrate Delayed-release Capsules (RP103)|
203005|NCT02023879|Drug|Alirocumab|Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous
203006|NCT02023879|Drug|Placebo (for alirocumab)|Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous
203007|NCT02023879|Drug|Non-statin Lipid Modifying Therapy (LMT)|Ezetimibe or fenofibrate at stable dose as background therapy
203008|NCT02023892|Drug|atorvastatin|
203009|NCT02023892|Drug|placebo|
203010|NCT02023905|Drug|Everolimus|
203011|NCT00121537|Device|Wound Care -Wound Vacuum Assisted Closure (VAC)|
203012|NCT02023905|Drug|Temozolomide|
203301|NCT02016378|Behavioral|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
203302|NCT02016391|Drug|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
202394|NCT00118898|Drug|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
202395|NCT01994525|Other|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
202396|NCT01994538|Other|Longer therapy duration|14 days of antimicrobial treatment
202688|NCT02029001|Drug|Nilotinib (400 mg BID)|Patients whose tumor harbors mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
202689|NCT02029001|Drug|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy).
202690|NCT02029001|Drug|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDFGRB, FLT3, BRAF (other than V600 mutations), CRAF, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
202691|NCT02029001|Drug|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
202692|NCT02029001|Drug|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT* or amplification /translocation of the genes and/or of the ligands.
202693|NCT02029014|Device|LAA closure system|
202694|NCT00121992|Drug|Docetaxel/Doxorubicin/cyclophosphamide (75/50/500) mg/m2 q3w|
202695|NCT02029027|Device|GYNEFFIK(R)|Vaginal electro-stimulation medical device
202696|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
202697|NCT02031432|Drug|Cebranopadol|Cebranopadol 200 µg to 1000 µg per day taken once a day in the morning.
202698|NCT02031445|Drug|MRX-6|
202699|NCT02031458|Drug|Atezolizumab|1200 mg IV every 3 weeks
202700|NCT02031471|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly
202701|NCT00122382|Drug|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
202702|NCT02031497|Dietary Supplement|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
202703|NCT02031497|Dietary Supplement|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
202111|NCT01999400|Drug|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
202112|NCT01999400|Drug|Asacol 400 mg tablet x 1 with 240 mL water; single dose|
202113|NCT01999413|Drug|OMEGAVEN|AML Study treatment induction phase
202114|NCT01999413|Drug|Daunorubicin|AML Study treatment induction phase
202115|NCT01999413|Drug|Cytarabine|AML Study treatment induction phase
202397|NCT01994538|Other|Shorter therapy duration|7 days of antimicrobial treatment
202398|NCT01994590|Drug|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
202399|NCT01994590|Drug|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
202400|NCT01994590|Drug|Prednisone|5 mg by mouth twice daily.
202401|NCT01994603|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
202402|NCT01994603|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
202403|NCT01994616|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
202404|NCT01994629|Biological|MenACWY-CRM|MenACWY-CRM
202405|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
202406|NCT01994629|Biological|MenACWY-TT|MenACWY-TT
202407|NCT01994642|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
202408|NCT01994642|Drug|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
202409|NCT01994642|Drug|Placebo Sterile Otic Suspension|
202410|NCT01994655|Other|Doing exercise|We want to investigate the effects of exercise on climacteric symptoms
202411|NCT01994655|Other|Doing exercise|Doing exercise at least 6 months including walking, running, yoga etc.
202412|NCT01994668|Drug|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
202413|NCT01994668|Drug|Placebo|A single intravenous administration of 0.9% saline over 1 minute
201819|NCT02007421|Procedure|Participants asked questions about recent experiences of anal intercourse in the last six months.|Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.
At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews.
201820|NCT00119912|Procedure|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
201821|NCT02007421|Procedure|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
201822|NCT02007434|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
201823|NCT02007434|Drug|Placebo|Phosphate buffered saline placebo for injection
201824|NCT02007434|Other|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
201825|NCT02007434|Drug|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
201826|NCT02007434|Drug|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
202116|NCT01999426|Other|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
202117|NCT00119262|Drug|aromatase inhibition therapy|Receive aromatase inhibition therapy
202118|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.
Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
202119|NCT02002000|Drug|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
201515|NCT00120497|Drug|somatropin (rDNA)|Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml
Dosage regimen: 0.48 mg/kg/week
Route/rate of administration: subcutaneous injection, daily dose
201516|NCT02012738|Other|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
201517|NCT02012738|Other|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
201518|NCT02012751|Device|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
201519|NCT02015559|Drug|mucoadhesive oral wound rinse|Given PO
201520|NCT02015559|Other|laboratory biomarker analysis|Correlative studies
201521|NCT02015572|Behavioral|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
201522|NCT02015572|Other|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
201523|NCT02015585|Procedure|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
201524|NCT02015585|Procedure|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
201525|NCT02015585|Procedure|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
201526|NCT00120796|Drug|Lamivudine|
201527|NCT02015598|Drug|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
201528|NCT02015598|Device|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
201529|NCT02015611|Dietary Supplement|Vitamin D|2,000 IU/ day of Vitamin D3
201530|NCT02015611|Dietary Supplement|Placebo|Placebo
201531|NCT02015637|Drug|delafloxacin|1
201532|NCT02015637|Drug|ceftriaxone|2
201827|NCT02007434|Drug|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
217389|NCT02281344|Drug|MMV390048 x mg|Supplied as a powder to be prepared as a suspension for oral use
217390|NCT02281344|Drug|MMV390048 y mg|Supplied as a powder to be prepared as a suspension for oral use
217391|NCT02281357|Biological|Tralokinumab|Tralokinumab dose
217689|NCT02313220|Drug|Placebo|Oral and Subcutaneous use.
217690|NCT02313233|Dietary Supplement|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
217691|NCT02313233|Dietary Supplement|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
217692|NCT02313246|Behavioral|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
217693|NCT02313259|Other|Speed discrimination test|The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.
The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm.
217694|NCT02313259|Behavioral|Driving simulation|25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.
Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).
A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes).
217695|NCT02313272|Radiation|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
217696|NCT02313272|Drug|Pembrolizumab|Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.
Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase.
217697|NCT00152724|Drug|indomethacin|
217698|NCT02313272|Drug|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a > 10% change in weight.
217699|NCT02313298|Radiation|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
217104|NCT02286388|Device|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.
The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds.
217105|NCT02286388|Device|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
217106|NCT02286414|Drug|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants
217107|NCT02286414|Drug|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
217108|NCT02286427|Device|Amniotic Membrane|
217109|NCT02288455|Device|GTU Artificial Urinary Sphincter|A totally implantable Artificial Urinary Sphincter (AUS) for the treatment of male Stress Urinary Incontinence (SUI)
217110|NCT00150072|Drug|imatinib|
217111|NCT02288468|Device|Vercise™ Deep Brain Stimulation System|The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.
The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit.
217392|NCT02281357|Other|Placebo|Placebo dose
217393|NCT02281370|Drug|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
217394|NCT02281370|Drug|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
217395|NCT02281383|Biological|Bacillus Calmette-Guérin (BCG)|
217396|NCT00149240|Drug|Botulinum toxin type A (Dysport)|
217397|NCT02281396|Biological|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
217398|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
217399|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
217400|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
216817|NCT02293226|Device|CoopDech|Video-laryngoscopy 1
216818|NCT02293226|Device|CoPilot|video-laryngoscopy 2
216819|NCT02293226|Device|Intubrite|Video-laryngoscopy 3
216820|NCT02293226|Device|Vividtrack|video-laryngoscopy 4
216821|NCT02293239|Other|Whole Body Electromyostimulation (WB-EMS), dietetic treatment|
216822|NCT02293252|Device|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
216823|NCT02293265|Drug|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
216824|NCT02295709|Drug|Dexamethasone|One of the most efficient steroids
216825|NCT02295709|Device|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
216826|NCT02295709|Radiation|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
216827|NCT02295722|Drug|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
216828|NCT02295722|Drug|Melphalan|200 mg/m2
216829|NCT02295722|Other|ASCT|Day 0 - Stem cell infusion
216830|NCT02295735|Device|Mepilex® Border Sacrum and Mepilex® Border Heel|
216831|NCT00150969|Dietary Supplement|placebo|1 pill daily
217112|NCT02288481|Drug|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
217113|NCT02288481|Other|Placebo|Placebo Suspension
217114|NCT02288494|Other|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia < 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
217115|NCT02288507|Drug|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with DLT, Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
217116|NCT02288507|Radiation|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
216530|NCT02300077|Drug|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
216531|NCT02300103|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered once daily
216532|NCT02300103|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
216533|NCT02300129|Drug|CD07805/47 0.5% gel (Brimonidine tartrate)|Experimental product
216534|NCT02300129|Drug|CD07805/47 gel placebo|Placebo
216535|NCT02300142|Biological|Matrix-M2 Adjuvant|Matrix-M2 adjuvant (25, 50 or 75 μg), administered in combination with GEN-003 vaccine as a 0.5 mL intramuscular (IM) injection.
Matrix-M2 is made up of immune stimulating complexes derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol. Quillaja saponins are surface-active substances derived from the tree Quillaja saponaria Molina.
216536|NCT02300142|Biological|GEN-003 Vaccine|GEN-003 Vaccine (30 or 60μg of each antigen) in combination with Matrix-M2 Adjuvant, administered as a 0.5mL intramuscular injection.
GEN-003 is a HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens:
GB208: a T cell antigen and internal fragment of the immediate early (IE) protein ICP4.
GB217: a B cell antigen (also known as glycoprotein D, or gD).
216537|NCT02300155|Drug|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
216538|NCT02300155|Drug|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
216539|NCT02302417|Other|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
216540|NCT02302430|Drug|Oxytocin|20 International Units Intranasal Oxytocin
216541|NCT02302430|Other|Placebo comparator|Saline nasal spray
216542|NCT02302443|Biological|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
216543|NCT02302443|Biological|Active comparator|Single dose subcutaneous administration of active comparator
216544|NCT02302456|Drug|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
216545|NCT02302456|Drug|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
215876|NCT02155270|Procedure|Corneal precut 600µm|
215877|NCT02155270|Procedure|Corneal stabincision|
215878|NCT02155283|Device|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
215879|NCT02155296|Behavioral|Restorative Practices Intervention|RPI has the 3 core components of an optimal comprehensive positive youth development intervention:
(1) sustained relationships with adults—RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in "circles"; (2) skills building—RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building—As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension.
216183|NCT02147574|Procedure|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
216184|NCT02147587|Drug|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
216185|NCT02147587|Drug|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
216186|NCT02147613|Other|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
216187|NCT02147613|Other|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
216188|NCT02147626|Behavioral|Web-based educational and motivational modules|
216189|NCT02147626|Behavioral|Information and Screening Group|
216190|NCT02147639|Dietary Supplement|Sodium Nitrate|
216191|NCT02147639|Dietary Supplement|Sodium Nitrate - double dose|
216192|NCT02149992|Device|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
216193|NCT00134056|Drug|prednisone|Docetaxel given IV and prednisone given orally
216194|NCT02150005|Procedure|Periodontal treatment|
216195|NCT02150018|Other|non invasive ventilation|
215567|NCT02121808|Procedure|NIPPV|Ventilation: non-invasive positive pressure ventilation (NIPPV)
Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)
215568|NCT02121808|Procedure|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
215569|NCT02121821|Behavioral|SMS reminder messages|The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
215570|NCT02121834|Drug|LY3050258|
215571|NCT02121834|Drug|Placebo|
215572|NCT00131469|Drug|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
215573|NCT02121847|Drug|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
215574|NCT02121847|Drug|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
215575|NCT02121860|Drug|IDN-6556|
215576|NCT02121873|Device|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
215577|NCT02121873|Device|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
215578|NCT02121873|Device|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
215880|NCT02155309|Drug|Scopolamine|
215881|NCT02155309|Drug|Placebo|
215882|NCT02155322|Biological|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
215883|NCT02155322|Biological|Pegylated Interferon Alfa-2b|3 μg/kg, weekly dosing, subcutaneous administration, Maintenance Phase - Up to 12 months after the 1st dose of PEG-IFN at 6 μg/kg
215254|NCT02126527|Drug|sirolimus|Given PO
215255|NCT02126527|Other|laboratory biomarker analysis|Correlative studies
215256|NCT02126527|Other|pharmacological study|Correlative studies
215257|NCT00131963|Drug|cyclophosphamide|Given IV
215258|NCT02126540|Device|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
215259|NCT02129166|Drug|Dasatinib+Imatinib|In this group, subjects will take imatinib prior to dasatinib administration.
Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose
215260|NCT02129179|Drug|Glucagon-Like Peptide 1|
215261|NCT02129192|Drug|Amlodipine 5mg capsule|Amlodipine 5mg capsule
215262|NCT02129192|Drug|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
215263|NCT02129192|Drug|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
215264|NCT02129205|Drug|PF-06650808|Dose Escalation Phase [Part 1] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
215265|NCT02129205|Drug|PF-06650808|Dose Expansion Phase [Part 2] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
215266|NCT00132236|Behavioral|low and high behavior support|
215267|NCT02129218|Other|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
215268|NCT02129218|Other|laboratory biomarker analysis|Correlative studies
215269|NCT02129218|Behavioral|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
215270|NCT02129218|Behavioral|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
215271|NCT02129218|Behavioral|Low glycemic load|
215272|NCT02129218|Behavioral|Medium Glycemic Load|
214972|NCT02136771|Dietary Supplement|Placebo|
214973|NCT00133068|Behavioral|Reduction in financial barrier|Copay only
214974|NCT02136784|Drug|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214975|NCT02136784|Drug|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214976|NCT02136784|Drug|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214977|NCT02136784|Drug|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
215275|NCT02129231|Drug|Rosuvastatin|We ensured the patient took the drug at night before meals
215276|NCT02129244|Other|NCM-Plus|The NCM will follow the domains of the chronic care model by:
Assuring effective, efficient clinical care and self-management support
Promoting clinical care consistent with scientific evidence and patient preferences
Organizing data to facilitate efficient, effective care
Empowering and preparing patients to manage their health and health-care needs
Mobilizing community resources to meet the needs of patients
215277|NCT00132262|Behavioral|Brief intervention based on motivational interviewing|The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
215278|NCT02129257|Drug|AFLIBERCEPT|
215279|NCT02129257|Drug|Irinotecan|
215280|NCT02129257|Drug|5-Fluorouracil|
215281|NCT02129257|Drug|Folinic Acid|
215282|NCT02131714|Behavioral|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
215283|NCT02131714|Behavioral|lifestyle counseling|
215284|NCT00132587|Device|cement Palacos R40 and LV40|
214670|NCT02144337|Behavioral|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
214671|NCT02144350|Procedure|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
214672|NCT02144350|Procedure|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
214673|NCT02144376|Dietary Supplement|Ispaghula|
214674|NCT02144376|Dietary Supplement|Maltodextrin|
214675|NCT02144389|Drug|Praziquantel (PZQ)|40 mg/kg, a single dose, administered orally
1 g of corn/soybean oil (50%/50%), administered orally
214676|NCT00133679|Drug|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
214677|NCT02144389|Dietary Supplement|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
214678|NCT02144389|Dietary Supplement|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
214679|NCT02144402|Other|infant formula with DHASCO|
214680|NCT02144402|Other|infant formula with DHASCO-B|
214681|NCT02144415|Drug|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
214682|NCT02144415|Drug|EB-1020 800 mg|8 x EB-1020 100-mg capsules
214978|NCT02136784|Drug|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214979|NCT02136784|Drug|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214980|NCT02136784|Drug|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214981|NCT02136797|Genetic|CMVpp65 Specific T-cells|
214982|NCT02136823|Drug|sugar pill|
214983|NCT02136823|Drug|Riluzole|
214984|NCT02139228|Biological|Hib-CRM197|No vaccine administered in V37_07E2 study
214353|NCT02149342|Drug|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
214354|NCT02149355|Other|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
214355|NCT02151721|Drug|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
214356|NCT02151734|Drug|KALOMIN™ Tab.|
214357|NCT02151734|Drug|Umckamin syrup|
214358|NCT02151760|Drug|18F-DCFPyL|
214359|NCT02151773|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
214360|NCT00134212|Drug|Dopexamine and norepinephrine|
214361|NCT02151786|Drug|Lansoprazole|Lansoprazole intravenous 30 mg
214362|NCT02151799|Procedure|Abdominoplasty and liposuction|
214363|NCT02151812|Device|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
214364|NCT02151812|Device|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
214365|NCT02151825|Dietary Supplement|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
214366|NCT02151825|Other|Placebo|3 capsules of Maltodextrin per day
214683|NCT02144415|Drug|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
214684|NCT02144415|Drug|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
214685|NCT02144415|Drug|Placebo|8 x matching placebo capsules
214686|NCT02144441|Drug|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
214687|NCT00133692|Drug|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
214688|NCT02144454|Dietary Supplement|Saturated fat|
214689|NCT02144454|Dietary Supplement|Monounsaturated fat|
203613|NCT00120315|Drug|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
203614|NCT02010671|Other|Survey|Survey
203615|NCT02010684|Behavioral|Empowerment and CBT Classes|Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers "Understanding Depression and Diabetes", Module 2 "How Thoughts Affect Your Mood and Diabetes Care", Module 3 "How Activities Affect Your Mood and Diabetes Care". The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources.
203616|NCT02010697|Behavioral|Messages targeting nonsmokers|
203617|NCT02010697|Behavioral|Messages targeting smokers|
203618|NCT02010710|Device|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
203619|NCT02010723|Procedure|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
203620|NCT02010723|Drug|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
203621|NCT02010736|Other|Single treadmill gait training with additional loading|
203622|NCT02010762|Drug|Vitamin D|25.000 IU oral drops
203623|NCT02010762|Drug|Placebo|placebo oral drops
203624|NCT00120315|Procedure|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
203625|NCT02010775|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
198871|NCT02045277|Drug|IDP-118 Monad HP 0.01% Lotion|Active Comparator
198872|NCT02045277|Drug|IDP-118 Monad Taz 0.045% Lotion|Active Comparator
198873|NCT02045277|Drug|IDP-118 Vehicle Lotion|Vehicle
198874|NCT02045290|Drug|Metformin|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
198875|NCT00123539|Procedure|Surgery|
198876|NCT02045290|Drug|Placebo|
203303|NCT02016404|Other|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
203304|NCT00120874|Drug|Memantine|Patients receive 10 milligrams of memantine twice daily.
203305|NCT02016404|Other|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
203306|NCT02016417|Drug|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
203307|NCT02018952|Other|Ultrasonography assessment|All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).
Day 0 :
Information of patient and no opposition getting
Clinical exam
Laboratory tests
Radiography of the targeted joint
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
Day 4 :
Clinical exam
Laboratory tests
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
Day15 :
Clinical exam
Laboratory tests
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
M3 :
Clinical exam
Laboratory tests
Radiography of the targeted joint
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
Functional outcome
203308|NCT00121147|Drug|Azopt|
203309|NCT02018965|Drug|Niacin|• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.
Participants will continue to take their ART treatment as prescribed throughout the study.
203310|NCT02018965|Drug|Niacin|• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.
Participants will continue to take their ART treatment as prescribed throughout the study.
203311|NCT02018978|Behavioral|Comprehensive Triaged HIV Prevention (CTHP)|HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.
Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.
Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.
Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential.
203312|NCT02018991|Procedure|Everolimus-Eluting Stent (EES)|Patients treated with EES
203313|NCT02018991|Procedure|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
203626|NCT02010775|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
202704|NCT02031510|Drug|placebo|transversus abdominis plane block with saline 0.9%
202705|NCT02031510|Drug|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
202706|NCT02031510|Drug|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
202707|NCT02031523|Drug|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
202708|NCT02031523|Drug|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
203013|NCT02023918|Drug|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
203014|NCT02023931|Drug|Broccoli Sprout Extract (BSE)|The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.
The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.
The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane.
203015|NCT02023944|Other|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
203016|NCT02023957|Behavioral|Interactive computer-assisted screening (iCAS)|
203017|NCT02026414|Dietary Supplement|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
203018|NCT02026414|Other|Exercise|
203019|NCT02026453|Other|Pharmacist obtains admission medication history|
203020|NCT02026453|Other|Pharmacy technician obtains admission medication history|
203021|NCT02026479|Drug|Dexamethasone Phosphate|5mg; postauricular injection
203022|NCT02026479|Drug|Dexamethasone Phosphate|10mg; postauricular injection
203023|NCT02026479|Drug|Ginaton|40mg/pill, 3times/day,oral
203024|NCT00121745|Genetic|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
202414|NCT01994707|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
202415|NCT01994707|Procedure|Placebo|Deflated cuff on arm for 30 minutes.
202416|NCT00118911|Behavioral|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
202417|NCT01994720|Drug|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily or corresponding placebo given orally.
202418|NCT01996839|Drug|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
202419|NCT01996839|Drug|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
202709|NCT02031536|Drug|everolimus|Given PO
202710|NCT02031536|Other|placebo|Given PO
202711|NCT02031536|Other|laboratory biomarker analysis|Correlative studies
202712|NCT00122382|Drug|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
202713|NCT02031549|Other|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
202714|NCT02031562|Other|chiropractic|chiropractic
202715|NCT02031562|Other|physical therapy|physical therapy
202716|NCT02031575|Behavioral|Interactive Treatment|Mobile phone text messaging service about reproductive health
202717|NCT02031575|Behavioral|Basic Treatment|Mobile phone text messaging service about reproductive health
202718|NCT02031601|Drug|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
202719|NCT02031601|Drug|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
202720|NCT02031601|Drug|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
202721|NCT02031601|Drug|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
202722|NCT02031601|Drug|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
202120|NCT02002000|Drug|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
202121|NCT00119444|Procedure|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
202122|NCT02002026|Procedure|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
202123|NCT02002039|Drug|Erythropoietin|500 units /kg /day every other day for 5 doses
202124|NCT02002052|Drug|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
202125|NCT02002052|Radiation|Standard Radiotherapy, 60 Gy in 30 fractions.|
202126|NCT02002052|Radiation|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
202127|NCT02002065|Biological|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
202128|NCT02002065|Biological|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
202129|NCT02002078|Drug|methylprednisolon|
202130|NCT02002091|Other|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
202131|NCT02002117|Other|DNA mass|DNA mass spectrometry
202132|NCT00119457|Drug|TTP889|
202133|NCT02002130|Drug|Maltodextrin|Maltodextrin as a placebo formulation for GABA
202134|NCT02002130|Drug|Placebo GAD-alum|Placebo for GAD-alum injection
202420|NCT01996839|Drug|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
202421|NCT01996852|Behavioral|Cognitive-behavioral Meetings|The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.
Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.
Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min.
202422|NCT01996852|Drug|sildenafil citrate|100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.
To increase external validity, participants will be given the choice of using Sildenafil in the study.
201828|NCT02007434|Other|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
201829|NCT02007447|Drug|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
201830|NCT02007460|Behavioral|Exercise|multidirectional unilateral hopping exercise
201831|NCT00119912|Procedure|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
201832|NCT02007486|Other|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
201833|NCT02007512|Drug|Enzalutamide|160 mg/day administered as four 40-mg soft gelatin capsules by mouth once daily with or without food.
201834|NCT02007512|Drug|exemestane|25 mg capsule administered as a single capsule by mouth once daily after food.
201835|NCT02007512|Drug|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
201836|NCT02009709|Device|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
201837|NCT02009722|Drug|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
201838|NCT02009722|Drug|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
201839|NCT02009735|Device|virosensor|virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.
The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens.
201840|NCT02009748|Dietary Supplement|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
201841|NCT02009748|Dietary Supplement|Placebo|oral administration of placebo (vehicle) once daily
201842|NCT02009761|Drug|BI 655064|subcutaneous injection
201843|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiotherapy 5 fractions per week
201844|NCT02009774|Procedure|NBI Function|
201845|NCT02009787|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
201846|NCT02009787|Drug|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
217700|NCT02313311|Other|time-lapse imaging|Embryos are observed using time-lapse imaging (Primo Vision®). It is an incubator with a compact, sealed, and digitally inverted camera unit which can automatically acquire images.The system can record the actual developmental stage of the embryos, all the recorded images can be saved to be analyzed later using a special software program.
217701|NCT02313324|Device|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
217702|NCT02276690|Biological|hepcidin|In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.
Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels
217988|NCT02308111|Drug|Placebo|One tablet daily for the remainder of the study
217989|NCT02308124|Drug|Midodrine|
217990|NCT02308124|Drug|Pyridostigmine Bromide|
217991|NCT02308124|Drug|Midodrine + pyridostigmine bromide|
217992|NCT02308137|Drug|Domperidone|Simon-2-stage design for domperidone futility
217993|NCT02308150|Device|transcatheter aortic valve replacement|
217994|NCT02308163|Drug|ASP015K|oral
217995|NCT00152256|Drug|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
217996|NCT02308163|Drug|Placebo|oral
217997|NCT02308163|Biological|Etanercept|subcutaneous injection
217998|NCT02308176|Behavioral|APP + health advice|health advice and reinforcement to it
217999|NCT02308176|Behavioral|health advice|health advice
218000|NCT02308189|Behavioral|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
218001|NCT02308189|Behavioral|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
218002|NCT02308202|Drug|doxazosin|
218003|NCT02308202|Drug|Perindopril|
218004|NCT02308202|Drug|Placebo|
217401|NCT02281409|Biological|Mogamulizumab (KW-0761)|
217402|NCT02281422|Drug|BIA 2-093|
217403|NCT02281435|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
217404|NCT02281448|Drug|BIA 2-093|
217405|NCT02281448|Drug|Contraceptives, Oral, Combined|
217406|NCT02281461|Device|Male circumcision using a non-surgical device|Male Circumcision
217407|NCT00149253|Drug|a single-dose of Etoricoxib before induction of anesthesia|
217408|NCT02281474|Drug|Nilotinib|
217409|NCT02281487|Procedure|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
217410|NCT02281487|Procedure|Hysterectomy|standard hysterectomy
217411|NCT02283814|Drug|Topamax|
217412|NCT02283827|Drug|BIA 2-093|
217413|NCT02283827|Drug|Phenytoin|
217414|NCT02283840|Drug|BIA 2-093|
217415|NCT02283853|Drug|dimethyl fumarate|administered orally
217703|NCT02276690|Biological|ferritin and transferrin saturation|In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.
Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels.
217704|NCT02276703|Device|Skin Conductance Monitor|monitors skin conductance values
217705|NCT02276716|Dietary Supplement|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
217706|NCT02276729|Other|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
217117|NCT02288533|Device|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
217118|NCT02288559|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab
217119|NCT02288559|Drug|lampalizumab|10-mg dose of lampalizumab administered intravitreally
217120|NCT02288572|Dietary Supplement|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
217121|NCT00150085|Drug|cyclosporine micro-emulsion|
217122|NCT02288572|Dietary Supplement|Placebo|Taking dietary supplement on a daily basis for 3 months.
217123|NCT02288585|Dietary Supplement|Plant sterols|Plant sterols
217124|NCT02288585|Dietary Supplement|Placebo product|Placebo product
217125|NCT02288598|Device|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
217126|NCT02288598|Behavioral|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
217127|NCT02288611|Dietary Supplement|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
217128|NCT02288611|Dietary Supplement|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
217129|NCT02288624|Dietary Supplement|Processed orange juice|3 different formulation of edible orange drinks
217130|NCT02290717|Drug|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
217416|NCT02283853|Drug|Interferon β-1a|administered by intramuscular injection
217417|NCT02283866|Drug|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
217418|NCT00149578|Drug|Gemcitabine Oxaliplatin 5FU and Leucovorin|
217419|NCT02283866|Drug|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
217420|NCT02283879|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
216832|NCT02295748|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
216833|NCT02295761|Behavioral|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
216834|NCT02295761|Behavioral|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
216835|NCT02295774|Procedure|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
216836|NCT02295774|Drug|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
216837|NCT02295787|Drug|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
216838|NCT02295787|Drug|Placebo|
216839|NCT02295800|Other|Standard of care|
216840|NCT02295800|Other|Semi-structured interviews|
216841|NCT02295813|Biological|FBF001|
216842|NCT00150982|Drug|Mechanism of action of alefacept|
216843|NCT02295813|Drug|Placebo|
216844|NCT02295826|Drug|Dabigatran|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
216845|NCT02295826|Drug|Acetylsalicylic acid|participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
216846|NCT02295839|Behavioral|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
216847|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
216848|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID DIET|2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
216849|NCT02297880|Other|Still water|Still water (no flavour)
216850|NCT02297893|Behavioral|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
216196|NCT02150031|Drug|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
216197|NCT02150031|Drug|1% Chlorhexidine|subgingival irrigation
216198|NCT02150031|Drug|1% Chlorhexidine|supragingival irrigation
216199|NCT02150031|Procedure|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
216200|NCT02150031|Drug|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
216201|NCT02150031|Procedure|Tooth extraction|dental extraction
216202|NCT02150044|Device|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
216203|NCT02150057|Device|Fusion OA Knee Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
216546|NCT02302469|Drug|Revlimid|Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
216547|NCT00151671|Drug|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
216548|NCT02302482|Other|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
216549|NCT02302495|Drug|Carfilzomib|DOSING REGIMEN.
The regimen will have 2 parts:
Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².
In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.
Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study.
216550|NCT02302508|Drug|Clopidogrel, Prasugrel, Ticagrelor|
216551|NCT02302521|Device|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
216552|NCT02302534|Device|MRI|MRI
216553|NCT02302547|Drug|triple therapy|Dosage treatment and usual prescription
216554|NCT02302547|Drug|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
216555|NCT02302573|Drug|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
216556|NCT02302586|Drug|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
215884|NCT02117232|Device|Visualization balloon|The "Visualization" Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the "Visualization" Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The "Visualization" Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The "Visualization" Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon.
215885|NCT00131027|Drug|Methotrexate|3 g/sqm (high dose)
215886|NCT02117232|Device|Traditional CO2 insufflation colonoscopy|Traditional colonoscopy performed with CO2 insufflation without "Visualization" balloon
215887|NCT02117258|Drug|Z-360|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
215888|NCT02117258|Drug|Placebo|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
215889|NCT02117271|Device|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
215890|NCT02117271|Other|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
215891|NCT02117297|Drug|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
215892|NCT02117310|Drug|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
215893|NCT02117336|Drug|P1446A-05|The study have dose escalation phase, followed by a dose extension phase.
Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death.
215894|NCT02117349|Drug|Fibrocaps plus gelatin sponge|During the surgical procedure on Day 1 (Visit 2), subjects will be initially treated with Fibrocaps plus gelatin sponge at the target bleeding site and the time to stop bleeding will be assessed. Subjects may be retreated with Fibrocaps and gelatin sponge treatment as necessary during the 5-minute assessment period.
216204|NCT00134056|Other|placebo|Given orally
216205|NCT02150070|Drug|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
216206|NCT02150070|Drug|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
215273|NCT02129231|Drug|calcined magnesia|We ensured the patient took the drug at night before meals
215274|NCT02129231|Drug|Ezetimibe/simvastatin|We ensured the patient took the drug at night before meals
215579|NCT02121886|Procedure|venous reconstruction with the parietal peritoneum|
215580|NCT02121912|Device|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
215581|NCT02121912|Device|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
215582|NCT02121951|Procedure|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
215583|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
215584|NCT02123823|Drug|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
215585|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
215586|NCT02123823|Drug|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
215587|NCT02123823|Drug|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
215588|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
215589|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
215590|NCT02123836|Biological|NK cells|7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.
Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.
NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.
The NK cells will then be infused into the vein, through a peripheral catheter.
215591|NCT02123849|Drug|Aspirin|Given PO
215592|NCT00131703|Drug|Chloroquine|
215593|NCT02123849|Other|Laboratory Biomarker Analysis|Correlative studies
215594|NCT02123849|Other|Placebo|Given PO
215595|NCT02123875|Other|Physiotherapy|
215596|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
215285|NCT02131727|Behavioral|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
215286|NCT02131727|Behavioral|Ask Me 3|Participants in the control group received a 4 minute training video about the "Ask Me 3" program to promote effective communication with health care providers, along with an "Ask Me 3" brochure and a key-chain with the "Ask Me 3" principles for effective communication with health care providers.
215287|NCT02131740|Other|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest & eye rubbing for a further 1 minute.
215288|NCT02131740|Other|No eye rubbing|This eye will not be rubbed
215289|NCT02131753|Drug|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
215290|NCT02131766|Device|Diabetes Assistant (DiAs)|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
215291|NCT02131779|Behavioral|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
215599|NCT02123901|Other|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
215600|NCT02123901|Other|No exercise|Sedentary life style.
215601|NCT02123914|Other|Aerobic exercise with Vit. C|walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.
Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,
Nasal peak flow measurement,
Nasal blood flow measurement,
Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
215602|NCT02123914|Other|Aerobic exercise|walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.
Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,
Nasal peak flow measurement,
Nasal blood flow measurement,
Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
215603|NCT00002236|Drug|Delavirdine mesylate|
215604|NCT02126553|Drug|Lenalidomide|Starting dose: 10 mg by mouth on days 1- 28 of a 28 day cycle.
215605|NCT02126566|Device|Administration of light therapy - measurement of results before and after therapy|
215606|NCT02126579|Biological|Peptide Vaccine (LPV7) + Tetanus peptide|1.5 mL administered half intradermally and half subcutaneously.
214985|NCT02139228|Biological|Hib-TT|No vaccine administered in V37_07E2 study
214986|NCT02139241|Drug|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
214987|NCT02139241|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
214988|NCT02139267|Biological|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
214989|NCT02139280|Drug|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
214990|NCT02139293|Device|PrimeStim|
214991|NCT02139306|Drug|Ataluren (PTC124®)|
214992|NCT00133354|Drug|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
214993|NCT02139306|Drug|Placebo|
214994|NCT02139319|Drug|Botulinum toxin|
214995|NCT02139319|Drug|Placebo|
214996|NCT02139332|Behavioral|PFR Group|The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 "consultation strategies," labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.
215292|NCT02131779|Behavioral|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
215293|NCT02131792|Procedure|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
215294|NCT02131805|Radiation|Electronic Skin Surface Brachytherapy|
215295|NCT00132600|Drug|bacitracin (allergen)|
215296|NCT02131805|Behavioral|Quality of life assessment|
215297|NCT02131818|Drug|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
214690|NCT02144454|Dietary Supplement|n-6 polyunsaturated fat|
214691|NCT02144480|Behavioral|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
214692|NCT02144480|Behavioral|traditional training|usual care: conventional rehabilitation
214693|NCT02144493|Other|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
214694|NCT02144493|Other|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
214695|NCT02144506|Other|T&E|
214696|NCT02144506|Other|OTAGO|
214697|NCT02144519|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
214698|NCT02146664|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
214699|NCT02146677|Other|Osteopathic manipulative treatment|
214700|NCT02146677|Other|Sham therapy|
214701|NCT02146677|Other|Usual care|
214702|NCT02146690|Other|osteopathic manipulative treatment|
214703|NCT02146690|Other|sham therapy|
214704|NCT02146690|Other|usual care|
214705|NCT02146703|Drug|Gemcitabine, and S-1|Treatment will be delivered as a 3-week cycle.
Gemcitabine 1000 mg/m2 iv on day 1, 8
S-1 60 mg/day po on day 1-14
214997|NCT02139332|Behavioral|Resource & Referral Group|The Resource & Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
214998|NCT02139345|Device|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
214999|NCT02139345|Device|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
198877|NCT02047383|Other|Respiratory infection|An assessment of the patients included in the study will be conducted
198878|NCT02047422|Drug|Furosemide|furosemide (doubling previous furosemide dose)
198879|NCT02047422|Drug|metolazone|metolazone (add 2.5mg qod)
198880|NCT02047422|Drug|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
198881|NCT02047422|Drug|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
198882|NCT02047435|Behavioral|Information, event and workshops at a cartoon museum|An event at the Storm P. Museum consisting of:
A guided tour at the museum
A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.
The museum serves a refreshment and offer participants a season pass to the museum.
And
Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as "narrative interview", to share similar stories from their life.
198883|NCT00123838|Device|Calypso® 4D Localization System|Localization of prostate irradiation.
198884|NCT02047435|Behavioral|Information and event at a cartoon museum|1. An event at the Storm P. Museum consisting of:
A guided tour at the museum
A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.
The museum serves a refreshment and offer participants a season pass to the museum.
198885|NCT02047448|Procedure|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
198886|NCT02047461|Drug|ALXN1101|IV infusion
198887|NCT02047474|Drug|oxaliplatin|Given IV
199175|NCT01995617|Biological|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
199176|NCT01995617|Biological|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
199177|NCT01995630|Device|AMO Tecnis ZA9003|
199178|NCT01995630|Device|AMO Sensar AR40e|
199179|NCT01995643|Dietary Supplement|Active Capsule|GSE Capsule
203627|NCT02010788|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
203628|NCT02010801|Procedure|irreversible electroporation|
203629|NCT02010801|Device|nanoknife AngioDynamics US Ltd|
203630|NCT02010827|Biological|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
203631|NCT02013609|Drug|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
203632|NCT02013622|Drug|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
203633|NCT02013648|Drug|Dasatinib|
203634|NCT02013648|Drug|Cytarabine|
203635|NCT02013648|Drug|Daunorubicin|
203636|NCT02013661|Procedure|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
203637|NCT02013674|Biological|Allogeneic hMSCs|
203638|NCT02013687|Biological|Pfs25 VLP- FhCMB|
203639|NCT02013700|Biological|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
203640|NCT02013700|Biological|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
203641|NCT00002168|Drug|Didanosine|
203642|NCT00120601|Drug|Acamprosate|
203643|NCT02013726|Device|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
203644|NCT02013726|Device|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
203645|NCT02013752|Device|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
203025|NCT02026492|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
203026|NCT02026492|Other|Methacholine challenge|nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
203027|NCT02026492|Other|Exercise challenge in room temperature|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
203028|NCT02026505|Drug|Bortezomib|
203029|NCT02026518|Dietary Supplement|Soy isoflavones|
203030|NCT02026518|Dietary Supplement|cholecalciferol|
203031|NCT02026518|Dietary Supplement|Placebo of soy isoflavones|
203314|NCT02018991|Procedure|Biolimus-Eluting-Stent (BES)|Patients treated with BES
203315|NCT02019004|Drug|Onabotulinum Toxin A|
203316|NCT02019004|Drug|Incobotulinum Toxin A|
203317|NCT02019017|Drug|Botulinum Toxin Type A 25 IU|
203318|NCT02019017|Drug|Botulinum Toxin Type A 50 IU|
203319|NCT00121147|Drug|Alphagan P|
203320|NCT02019043|Other|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
203321|NCT02019056|Drug|Placebo /bid P.O|
203322|NCT02019056|Drug|MG-1|
203323|NCT02019056|Drug|MG-2 : MG1000mg, Placebo /bid P.O|
203324|NCT02021448|Other|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
203325|NCT02021461|Drug|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
202723|NCT02034162|Drug|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
202724|NCT00122603|Drug|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
202725|NCT02034188|Biological|Umbilical cord mesenchymal stem cells|
202726|NCT02034201|Drug|Lisdexamfetamine|
202727|NCT02034201|Drug|Placebo|
202728|NCT02034214|Behavioral|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
203032|NCT02026518|Dietary Supplement|placebo of cholecalciferol|
203033|NCT02026531|Other|3-Helium gas|3-Helium gas for MRI contrast
203034|NCT02026544|Device|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
203035|NCT00121745|Genetic|Rexin-G Dose 3|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose
III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml
203036|NCT02026570|Behavioral|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
203037|NCT02026570|Behavioral|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
203038|NCT02026583|Drug|Simvastatin|
203039|NCT02026596|Procedure|Magnetic resonance imaging|
203040|NCT02026596|Procedure|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
203041|NCT02026609|Other|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
203042|NCT02029040|Drug|3% Hypertonic Saline versus 0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
202423|NCT01996852|Device|Vacuum Constriction Device|The medical treatment entails a 10-minute daily use of VCD (pump).
The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call.
202424|NCT00119080|Biological|meningococcal conjugate vaccine (Menactra)|
202425|NCT01996865|Drug|Lenalidomide|
202426|NCT01996865|Drug|Rituximab|
202427|NCT01996891|Other|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
202428|NCT01996904|Procedure|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
202429|NCT01996904|Procedure|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
202430|NCT01996917|Device|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
202431|NCT01996930|Drug|Haelan tape (steroid impregnated tape)|Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
202432|NCT01996930|Drug|Silver Nitrate|Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
202433|NCT01996943|Drug|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
202434|NCT01996943|Drug|Placebo|The placebo with be 0.45% saline solution ("half normal saline").
202435|NCT00119093|Procedure|Laboratory and clinical monitoring regimens|
202729|NCT02034214|Other|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
202730|NCT02034214|Behavioral|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
201847|NCT02009800|Biological|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
202135|NCT02002130|Drug|Glutamic Acid Decarboxylase in alum formulation|GAD-alum SQ injection
202136|NCT02002130|Drug|Gamma-Aminobutyric Acid|GABA powder taken by mouth
202137|NCT02002143|Behavioral|Group Appointments|Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).
Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs.
202138|NCT02002143|Behavioral|Individual Appointments (IAs)|Participants randomly assigned to the "IAs" group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life.
202139|NCT02004821|Dietary Supplement|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
202140|NCT02004834|Procedure|ultrasound guided paravertebral blocks in breast surgery|
202141|NCT02004847|Device|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
202142|NCT00119678|Drug|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
202143|NCT02004860|Drug|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
202144|NCT02004860|Drug|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
202145|NCT02004873|Device|Micra Pacemaker Implant|
202146|NCT02004886|Drug|MK-0893|10 mg and 100 mg tablets
202147|NCT02004886|Drug|Metformin|500 mg metformin tablets
202148|NCT02004886|Drug|Placebo|Placebo tablets matching MK-0893
202149|NCT02004886|Drug|Placebo|Placebo tablets matching metformin
218005|NCT02308228|Behavioral|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
218006|NCT00152256|Drug|Placebo|Placebo Tablet, oral Daily for 6 months
218007|NCT02308228|Drug|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
218008|NCT02308241|Drug|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
218009|NCT02308254|Drug|Lixisenatide|Abdominal administration
218010|NCT02308254|Drug|Placebo|Abdominal administration
218011|NCT02310776|Device|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
218012|NCT02310776|Device|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
218294|NCT02303327|Drug|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
218295|NCT02303340|Radiation|Dual Energy X-ray Absorptiometry|
218296|NCT02303366|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
218297|NCT02303366|Drug|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
218298|NCT02303379|Other|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
218299|NCT02303379|Other|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
218300|NCT02303379|Other|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
218301|NCT02303392|Drug|Selinexor|Given PO
218302|NCT02303392|Drug|Ibrutinib|Given PO
218303|NCT02303392|Other|Pharmacological Study|Correlative studies
218304|NCT00151762|Drug|Colesevelam hydrochloride|
218305|NCT02303392|Other|Laboratory Biomarker Analysis|Correlative studies
217707|NCT02276742|Behavioral|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
217708|NCT00148694|Drug|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
217709|NCT02276742|Other|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
217710|NCT02276755|Dietary Supplement|cholecalciferol (vitamin D)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
217711|NCT02276755|Other|Placebo|Placebo group will receive placebo (Tishcon, USA) bi-weekly.
217712|NCT02276768|Drug|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
217713|NCT02276768|Drug|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
217714|NCT02276768|Drug|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
217715|NCT02276768|Drug|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
217716|NCT02276768|Other|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
217717|NCT02276794|Other|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
217718|NCT02276794|Other|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
217719|NCT00148707|Drug|CT-2103 (Xyotax)|
218013|NCT02310789|Drug|Ivacaftor|150mg Q12 p.o. Protocol describes Ivacaftor treatment to be given in two-week intervals. The patient will serve as their own controls. Diagnostic procedures to be performed on and off Ivacaftor.
218014|NCT02310802|Drug|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
218015|NCT02310802|Drug|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
218016|NCT02310802|Drug|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
218017|NCT02310802|Drug|Placebo|Placebo dispersible tablets for single oral administration
217421|NCT02283892|Other|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
217422|NCT02283892|Other|Conventional evaluation|Physician evaluation without the use of checklists
217423|NCT02283905|Drug|amphotericin-B|continuously infused
217424|NCT02283905|Drug|voriconazole|intravenously or orally administered
217425|NCT02283931|Device|TTE / NICOM|
217426|NCT02283944|Device|TMS|Pulsed non-invasive brain stimulation using electromagnets
217427|NCT02283957|Drug|CNTX-4975|
217428|NCT02283957|Other|Placebo|
217429|NCT00149591|Procedure|coronary balloon-angioplasty with stenting|
217430|NCT02283983|Other|mittens and booties|
217431|NCT02283983|Other|cooling helmet|
217432|NCT02283996|Other|Physical Therapy|The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.
Brigham and Women's Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:
http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf
217433|NCT02283996|Drug|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
217434|NCT02284009|Biological|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
217435|NCT02284009|Biological|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
217720|NCT02279043|Behavioral|Birth Control Connect (intervention)|Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for eleven days. Each day, participants will be prompted to respond to questions in the group (e.g. "If you're using a birth control method right now, how did you choose it?"). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users.
216851|NCT02297893|Behavioral|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
216852|NCT02297906|Drug|Ketorolac|Non-steroidal anti-inflammatory drug
217131|NCT02290730|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
217132|NCT02290743|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
217133|NCT02290756|Behavioral|Parenting Program|The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
217134|NCT02290756|Behavioral|Low cost evidence based toolkit|The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:
Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials
Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information
217135|NCT02290769|Device|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
217136|NCT02290769|Device|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
217137|NCT00150410|Drug|Inhaled insulin|
217138|NCT02290782|Radiation|Intraoperative radiotherapy (IORT)|The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.
To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm.
217139|NCT02290795|Other|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
217140|NCT02290808|Behavioral|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
217141|NCT02290821|Drug|diclofenac sodium gel 1%|
217142|NCT02290834|Other|Cognitive, functional and subjective assessments|Cognitive and functional assessments
217143|NCT02290834|Device|MRI|Magnetic Resonance Imaging (MRI) Scan
217144|NCT02290834|Radiation|PET Scan|Positron Emission Tomography (PET) Scan
216557|NCT02302586|Drug|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
216558|NCT00151671|Drug|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
216559|NCT02302599|Biological|Umbilical cord mesenchymal stem cells|Infusion treatment
216560|NCT02302599|Biological|Controlled suspension liquid|Infusion treatment
216561|NCT02304939|Procedure|changeover|
216562|NCT02304939|Device|use of automatic infusion pump|
216563|NCT02304939|Behavioral|datas collection|
216564|NCT02304952|Procedure|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
216565|NCT00151957|Drug|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
216853|NCT02297919|Behavioral|Effectiveness of Internet Based Obesity Control Programme|
216854|NCT02297932|Behavioral|Strength training|Participants will engage in a home-based strength training program.
216855|NCT02297932|Behavioral|Stretching|Participants will engage in a home-based stretching training program
216856|NCT02297945|Drug|metyrapone|Single arm study
216857|NCT02297997|Drug|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
216858|NCT02297997|Drug|Placebo|Control group takes the placebo for the same period.
216859|NCT00151203|Drug|Clarithromycin, Lenalidomide, Dexamethasone|Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.
Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.
Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles.
216860|NCT02298010|Drug|Capecitabine, oxaliplatin|
216861|NCT02298023|Biological|allogenic adipose stem cell treatment|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
216207|NCT02150083|Procedure|OR retrograde fill|
216208|NCT02150096|Other|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
216209|NCT02150096|Other|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
216210|NCT02150096|Other|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
216211|NCT02150109|Device|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
216212|NCT02150109|Device|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
216213|NCT02150122|Dietary Supplement|Vitamin D3|
216214|NCT02150135|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
216215|NCT00134069|Drug|sorafenib tosylate|Given orally
216216|NCT02152553|Drug|Hydrocortisone|
216217|NCT02152553|Drug|Placebo|
216218|NCT00134277|Procedure|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
216219|NCT02152566|Device|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
216220|NCT02152579|Drug|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
216221|NCT02152592|Drug|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
216222|NCT02152592|Drug|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
216223|NCT02152605|Drug|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
216566|NCT02304952|Other|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
215597|NCT02123888|Radiation|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
215598|NCT02123901|Other|Walking Meditation|Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced "Budd" and "Dha" with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
215895|NCT02117349|Drug|Gelatin Sponge|During the surgical procedure on Day 1 (Visit 2), subjects will be initially treated with a gelatin sponge alone at the target bleeding site and the time to stop bleeding will be assessed. Subjects may be retreated with gelatin sponge during the 5-minute time to stop bleeding assessment period.
215896|NCT00131027|Drug|Mercaptopurine|
215897|NCT02117362|Biological|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
215898|NCT02117362|Biological|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
215899|NCT02117362|Biological|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
215900|NCT02117362|Biological|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
215901|NCT02119715|Drug|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
215902|NCT02119715|Drug|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
215903|NCT02119715|Drug|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
215904|NCT02119728|Drug|HPPH|Undergo photodynamic therapy with HPPH
215905|NCT02119728|Device|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
215906|NCT02119728|Procedure|therapeutic conventional surgery|Undergo standard of care surgery
215907|NCT02119754|Drug|Plurogel PN|
215908|NCT02119780|Device|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
215909|NCT02119780|Device|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
215910|NCT02119793|Device|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
207366|NCT02097225|Other|Pharmacological Study|Correlative studies
207367|NCT00000317|Behavioral|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills.
207368|NCT00002220|Drug|Efavirenz|
207369|NCT00128817|Procedure|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
207370|NCT02097225|Drug|Trametinib|Given PO
207371|NCT02097238|Drug|Eribulin Mesylate|Given IV
207372|NCT02097238|Other|Pharmacological Study|Correlative studies
207373|NCT02097251|Drug|UX003|Open Label
207374|NCT02097264|Drug|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
207375|NCT02097264|Drug|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
207376|NCT02097264|Drug|placebo|Solution for injection administered subcutaneously (s.c. - under the skin).
1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
207377|NCT02097277|Biological|BMS-986036|
207378|NCT02097277|Biological|Placebo (Matching with BMS-986036)|
207379|NCT02097290|Device|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
207677|NCT02091960|Drug|trastuzumab|Intravenous infusion (IV) or subcutaneous if it is standard of care within a country
207678|NCT02091973|Drug|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
207679|NCT02091973|Drug|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
207680|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
207681|NCT00128258|Biological|Biological bone marrow cell therapy|Biological implant into the heart
207682|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
213089|NCT02133560|Behavioral|Education|During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.
Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation.
213090|NCT02133573|Drug|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
213091|NCT02133573|Drug|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
213092|NCT02133586|Other|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
213093|NCT02133586|Other|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
213094|NCT02133599|Drug|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
213095|NCT02133612|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
213096|NCT02133625|Drug|carboplatin|
213097|NCT02133625|Drug|pioglitazone|
213098|NCT00132730|Drug|MK-0873 2.5 mg|
213099|NCT02133638|Drug|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
213100|NCT02133638|Drug|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
213101|NCT02133664|Drug|Alpha lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
213102|NCT02133664|Drug|Placebo|placebo lipoic acid and placebo oil
213103|NCT02133677|Drug|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
213391|NCT02128373|Other|Tension-Anxiety Subscale|six item scale which asks to qualitatively describe which areas in you life are causing stress
212520|NCT02148393|Device|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
212521|NCT02148406|Behavioral|Yoga Skills Training (YST)|Undergo YST
212522|NCT00134004|Procedure|allogeneic bone marrow transplantation|
212523|NCT02148406|Other|questionnaire administration|Ancillary studies
212820|NCT02141048|Behavioral|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
212821|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation A|
212822|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation B|
212823|NCT02141074|Drug|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
212824|NCT00133445|Biological|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
212825|NCT02141087|Drug|Pirfenidone|
212826|NCT02141100|Drug|6-thioguanine|All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.
In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy.
212827|NCT02141113|Drug|Guanfacine Hydrocholride|mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
212828|NCT02141113|Drug|Guanfacine Hydrocholride|mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
212829|NCT02141126|Other|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
212830|NCT02141126|Other|Usual care|Standard inpatient 'usual care' physiotherapy
212831|NCT02141139|Drug|NSAIDS (ketorolac and ibuprofen)|
212832|NCT02141165|Device|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
212225|NCT02115711|Behavioral|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
212226|NCT02115724|Dietary Supplement|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
212227|NCT02115724|Other|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
212228|NCT02115724|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
212229|NCT02115724|Drug|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
212524|NCT02148406|Other|fatigue and depressive symptom assessment and management|Ancillary studies
212525|NCT02148406|Other|psychological stress assessment|Ancillary studies
212526|NCT02148406|Other|laboratory biomarker analysis|Correlative studies
212527|NCT02148406|Other|Attention Control|
212528|NCT02148419|Other|no intervention|
212529|NCT02148432|Drug|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
212530|NCT02148432|Drug|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
212531|NCT02148445|Other|Smoking cessation|Standard smoking cessation program using nicotine replacement therapy for smokers with COPD ready to make a quit attempt at the beginning of the study.
212532|NCT02148445|Other|Guided maintenance therapy with NRT|12 months of treatment with nicotine replacement therapy for smokers with COPD regardless of immediate interest in quitting.
212533|NCT00134004|Radiation|radiation therapy|
212534|NCT02148458|Other|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
212535|NCT02148458|Other|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
212536|NCT02148484|Behavioral|Prolonged Exposure for Adolescents|
211921|NCT02120586|Other|Inspiratory Muscle Training (IMT).|Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).
The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10.
211922|NCT02122770|Drug|MLN4924|MLN4924 Intravenous Solution
211923|NCT00131534|Behavioral|Individual therapy|Stage-based individual therapy for trauma survivors
211924|NCT02122770|Drug|Fluconazole|Fluconazole Tablets
211925|NCT02122770|Drug|Itraconazole|Itraconazole Oral Solution
211926|NCT02122770|Drug|Docetaxel|Docetaxel Intravenous Solution
211927|NCT02122770|Drug|Carboplatin|Carboplatin Intravenous Solution
211928|NCT02122770|Drug|Paclitaxel|Paclitaxel Intravenous Solution
211929|NCT02122783|Device|ADR™-based brace resistance (Adjustable Dynamic Response™)|
211930|NCT02122783|Device|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
211931|NCT02122796|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
211932|NCT02122809|Drug|Chiauranib|Take orally
212230|NCT02115737|Behavioral|Dialectical Behavior Therapy Skills Group|
212231|NCT02115737|Behavioral|Psychoeducation group treatment|
212232|NCT00130897|Drug|Sutent|Sutent, 25, 37.5. or 50 mg daily
212233|NCT02115750|Drug|Etanercept|Head-to-head comparison
212234|NCT02115750|Drug|CHS-0214|
212235|NCT02115763|Drug|Caffeine|
212236|NCT02115763|Drug|Placebo|
212237|NCT02115776|Drug|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
212238|NCT02115776|Drug|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
211604|NCT02127658|Other|Intervention number 2, Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (a cup of 6% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each gallon of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
211605|NCT02127671|Other|IDEAL intervention|
211606|NCT02127671|Other|Control|
211607|NCT02127684|Drug|ranibizumab|ranibizumab 0.3mg intravitreally monthly
211608|NCT02127684|Drug|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
211609|NCT02127697|Drug|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
211610|NCT02127697|Drug|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
211611|NCT02127697|Drug|salbutamol/ albuterol|Taken as rescue medication
211612|NCT02127710|Drug|AZD6094|AZD6094 is a potent and selective small molecule cMet kinase inhibitor.
211613|NCT00132054|Drug|irinotecan hydrochloride|
211614|NCT02130141|Dietary Supplement|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
211615|NCT00132379|Drug|docetaxel|75mg/m^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
211616|NCT02130141|Other|Dietary counselling|Usual snacks are limited.
211617|NCT02130154|Other|18-FDG PET CT scan and 123I-MIBG SPECT scan|
211618|NCT02130167|Drug|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
211619|NCT02130193|Drug|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
211620|NCT02130193|Drug|Placebo|Subjects will receive danirixin matching placebo
211621|NCT02130206|Other|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
211622|NCT02130206|Other|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
211623|NCT02130206|Other|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
210970|NCT02140086|Behavioral|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
210971|NCT02140099|Other|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
210972|NCT02140099|Other|Control Condition (Classroom Activities)|
210973|NCT02140112|Biological|Trichuris suis ova|
211305|NCT02135172|Behavioral|Walking|
211306|NCT00132873|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
211307|NCT02135185|Other|custom work endurance|Experimental: Rehabilitation effort
211308|NCT02135185|Behavioral|dietary management adapted to the nutritional status|dietary management adapted to the nutritional status
211309|NCT02135198|Drug|2 mg AZD7325|A single 2 mg oral dose of AZD7325
211310|NCT02135198|Drug|10 mg AZD7325|A single 10 mg oral dose of AZD7325
211311|NCT02135198|Drug|Placebo|A single oral dose
211312|NCT02135211|Behavioral|Lifestyle counseling|
211313|NCT02135224|Drug|Fentanyl|
211314|NCT02135224|Drug|Normal saline|
211315|NCT02135237|Behavioral|Prize Contingency Management for Alcohol Abstinence|
211316|NCT02135237|Behavioral|Standard Care|
211317|NCT00132886|Drug|tolvaptan|
211318|NCT02135250|Drug|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
211319|NCT02135250|Other|placebo|the placebo is not drug.
211320|NCT02135263|Drug|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
211321|NCT02135263|Drug|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
211322|NCT02137525|Drug|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
210661|NCT02147678|Drug|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2~0.4 μg/kg/min.
210662|NCT02147678|Drug|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
210663|NCT02147691|Drug|Azelaic acid 15%|Applied to the face each AM and PM
210664|NCT02147691|Drug|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
210665|NCT02147704|Dietary Supplement|High- and low-sodium diet|One of high- or low sodium intake for 7 days during each period
Low sodium intake : 50 mmol/day by diet
High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets
210666|NCT00133991|Drug|cytarabine|
210974|NCT02140112|Other|Placebo|
210975|NCT02140125|Drug|ASP2408|subcutaneous administration
210976|NCT00002245|Drug|Amprenavir|
210977|NCT00133380|Drug|atorvastatin|
210978|NCT02140125|Drug|Placebo|subcutaneous administration
210979|NCT02140138|Biological|CV9104|
210980|NCT02140138|Device|needle free injection device (Tropis™)|
210981|NCT02140151|Drug|Ranibizumab 0.5mg|
210982|NCT02140164|Drug|Minocycline|Capsules for oral administration
210983|NCT02140203|Other|Yoga Training|one-year experimental training (three times per week and one hour per session)
210984|NCT02140229|Device|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
210985|NCT02140229|Other|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
210986|NCT02140229|Other|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
210987|NCT02140242|Drug|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5 versus 90 mg/m2
210988|NCT00133380|Drug|placebo|
210989|NCT02142816|Other|PVI`|Fluid therapy guided by PVI
210337|NCT02105714|Device|CCA RDT|
210338|NCT02105714|Procedure|Koga agar plate culture|
210339|NCT02105714|Procedure|Kinyoun staining|
210340|NCT02105714|Device|Multiplex PCR|
210341|NCT00129766|Biological|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
210342|NCT02105714|Procedure|Metagenomics analysis|
210343|NCT02105727|Behavioral|Community-based salt reduction|
210344|NCT02108158|Drug|Azzalure|
210345|NCT02108171|Drug|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
210346|NCT02108171|Drug|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
210347|NCT02108184|Drug|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
210348|NCT02108184|Drug|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
210349|NCT02108184|Drug|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
210350|NCT00130039|Drug|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
210351|NCT02108184|Drug|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
210352|NCT02108197|Device|Continuous positive airway pressure (S9, ResMed)|
210667|NCT02147717|Device|Laser stimulation|Infants will be divided in 2 groups:
Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS
Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.
This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)
210668|NCT02147717|Device|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
210669|NCT02147730|Procedure|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
210034|NCT02112591|Procedure|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
210035|NCT02112591|Procedure|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
210036|NCT02112604|Device|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
210037|NCT02112604|Device|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
210038|NCT02112604|Other|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
210039|NCT02112604|Other|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
210040|NCT02112604|Other|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
210041|NCT00130806|Drug|Comparator: placebo|
210042|NCT02114827|Behavioral|FAQ Sheet|
210043|NCT02114840|Procedure|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
210044|NCT02114840|Procedure|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
210045|NCT02114840|Procedure|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
210046|NCT02114879|Behavioral|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
210047|NCT02114879|Behavioral|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
210048|NCT02114892|Drug|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
210049|NCT02114892|Drug|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
210353|NCT02108210|Drug|Anakinra|
204439|NCT02019498|Other|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
204440|NCT02019524|Biological|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
204441|NCT02021955|Behavioral|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
204442|NCT02021968|Biological|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
204443|NCT02021968|Biological|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
204444|NCT02021968|Biological|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
204445|NCT02022007|Drug|Metformin XR|Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study
204752|NCT02093481|Other|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
204753|NCT02093481|Other|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
204754|NCT02093494|Device|Initial Specimen Diversion Device (ISDD)|
204755|NCT02093494|Procedure|Lab standard practice (LSP)|
204756|NCT00128440|Drug|tiotropium|
204757|NCT02093494|Device|Peripheral Intravenous Catheters (PIVC)|
204758|NCT02093507|Other|parents manipulation|parents perform manipulation the child foot to correct the deformity
204759|NCT02093520|Procedure|Minimally Invasive Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
204760|NCT02093520|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
204761|NCT02093533|Drug|Eculizumab|
204131|NCT02027181|Device|Device FreeO2 v2.0|Automatic adjustment of oxygen through the "Free O2" device.
"FreeO2" device in mode medical data collecting(SpO2,EtCO2...).
204132|NCT02027181|Device|Device FreeO2 v2.0|Manual adjustment of oxygen without the assistance of the "FreeO2" device.
Only "FreeO2" device in mode medical data collecting(SpO2,EtCO2...).
204133|NCT02027194|Drug|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
204134|NCT02027194|Drug|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
204135|NCT02027194|Drug|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
204136|NCT02029521|Dietary Supplement|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
204137|NCT02029521|Dietary Supplement|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
204138|NCT02029534|Drug|Atorvastatin 20 mg|
204139|NCT02029534|Drug|Atorvastatin 80 mg|
204140|NCT02029547|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
204141|NCT02029573|Drug|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
204142|NCT02029573|Drug|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
204143|NCT02029573|Radiation|Radiotherapy|60 Gy in 30 fractions
204446|NCT02022007|Drug|Saxagliptin|Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study
204447|NCT02022007|Drug|Saxagliptin-Metformin XR|Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study
204448|NCT02022033|Drug|FOLFOXA|Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
204449|NCT00121316|Drug|Placebo|Vehicle cream (placebo cream)
204450|NCT02022046|Other|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
204451|NCT02022059|Drug|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
203824|NCT02034708|Drug|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
203825|NCT02034708|Drug|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
203826|NCT02034721|Dietary Supplement|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
203827|NCT00122629|Drug|ribavirin|
203828|NCT02034734|Drug|ASP3652|oral
203829|NCT02034747|Drug|Advagraf|oral
203830|NCT02034747|Drug|Corticosteroid|oral
203831|NCT02034760|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
203832|NCT02034760|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
203833|NCT02034760|Dietary Supplement|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
203834|NCT02034760|Dietary Supplement|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
203835|NCT02034760|Dietary Supplement|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
203836|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 14 days
203837|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
203838|NCT00122629|Drug|amantadine|
203839|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 28 days
203840|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
203841|NCT02034773|Drug|Placebo|Placebo will be administered once daily for up to 28 days
203842|NCT01995123|Behavioral|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
203843|NCT01995123|Behavioral|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
203844|NCT01995136|Drug|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
208252|NCT02114346|Drug|Placebo|
208253|NCT02114346|Drug|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
208254|NCT02077322|Device|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
208545|NCT02109757|Other|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
208546|NCT02109757|Other|Education only|
208547|NCT02109783|Dietary Supplement|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
208548|NCT00130195|Drug|dexamethasone|
208549|NCT02109783|Dietary Supplement|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
208550|NCT02109783|Dietary Supplement|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
208551|NCT02109796|Device|transcranial Direct current stimulation|
208552|NCT02109809|Radiation|total nodal irradiation|Undergo TLI
208553|NCT02109809|Other|laboratory biomarker analysis|Correlative studies
208554|NCT02109809|Other|questionnaire administration|Ancillary studies
208555|NCT02109861|Drug|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
208556|NCT02109861|Drug|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
208557|NCT02109861|Drug|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
208558|NCT02109874|Biological|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
208559|NCT00130208|Drug|Sulodexide|
208560|NCT02109874|Biological|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
208561|NCT02109900|Other|Serum Progesterone Levels|
207972|NCT02082522|Drug|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
207973|NCT02082522|Procedure|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
207974|NCT02082522|Drug|Chemotherapy regimen Gemcitabine/Cisplatin|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
207975|NCT02082548|Other|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
207976|NCT02082561|Behavioral|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
208255|NCT02077335|Radiation|HDR brachytherapy monotherapy|Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:
Prostate :
V100 > 95%
V150 30-35%
V200 < 15%
D90 > 90% (12,15Gy)
Bladder
• V75 < 1cc
Rectum
• V75 < 1cc
Urethra
V125 = 0cc D10 < 120%
Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure.
208256|NCT02077348|Drug|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
208257|NCT00126789|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
208258|NCT02077348|Drug|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
208259|NCT02077361|Genetic|rAAV2.REP1 vector|No additional details needed.
208260|NCT02077374|Drug|IDN-6556|25 mg BID for 28 days
208261|NCT02077374|Other|Placebo|
207668|NCT02089451|Drug|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
207669|NCT02089464|Device|NBS-guided rTMS|
207670|NCT02089464|Device|Sham rTMS|
207671|NCT02089477|Other|Support group|The participants in the intervention group receives the intervention and support consisting of:
Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.
SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking.
207672|NCT02089490|Device|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
207673|NCT02089503|Other|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
207674|NCT00128050|Drug|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
207675|NCT02089529|Drug|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
207676|NCT02089529|Drug|Placebo|Placebo with no information, positive information and neutral information
207977|NCT02082600|Other|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
207978|NCT02084979|Behavioral|telepsychiatry consultation to primary care|
207979|NCT02084992|Other|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
207980|NCT02084992|Other|Telephonic disease management|
207981|NCT02085005|Drug|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
207982|NCT02085005|Drug|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
207983|NCT00127647|Drug|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
207984|NCT02085005|Drug|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
207985|NCT02085018|Drug|Omeprazole|Drug
207986|NCT02085018|Drug|Matched placebo|Matched placebo
207683|NCT02091986|Other|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
207684|NCT02091999|Drug|ASG-22CE|intravenous (IV) infusion
207685|NCT02092012|Drug|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
207686|NCT02092012|Drug|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
207687|NCT02092025|Drug|Azilsartan|Azilsartan tablets
207688|NCT02092038|Drug|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
207689|NCT02092038|Radiation|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
207690|NCT02092038|Procedure|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
207691|NCT02092038|Procedure|craniotomy and tumor resection|maximal safe resection
207692|NCT00128271|Drug|Bavituximab|
207693|NCT02092051|Device|Continuous glucose monitoring with DexCom G4 platina|
207694|NCT02092077|Drug|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
207695|NCT02092077|Drug|somatropin|Dose may be adjusted as required
207696|NCT02092090|Behavioral|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
207697|NCT02092103|Procedure|Cord Milking|See description in cord milking arm.
207698|NCT02092116|Drug|Romidepsin (Istodax®)|
207699|NCT02092116|Biological|Vacc-4x|
207700|NCT02092116|Biological|rhuGM-CSF (Leukine®)|
207997|NCT02085109|Dietary Supplement|Theobromine|
207998|NCT02085122|Other|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
207999|NCT02085135|Drug|ALKS 5461|Sublingual tablet taken once daily
213392|NCT02128412|Device|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
213393|NCT02128412|Device|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
213394|NCT02128425|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
*reduced in UGT1A1 7/7 patients
213395|NCT02128425|Drug|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
213396|NCT00132145|Behavioral|Clinical Care Coordinators|
213397|NCT02128451|Drug|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
213398|NCT02128451|Drug|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
213399|NCT02128464|Procedure|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
213400|NCT02128464|Procedure|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
213401|NCT02128490|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
213402|NCT02128490|Drug|Febuxostat XR|Febuxostat over-encapsulated capsules
213403|NCT02128490|Drug|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
213404|NCT02128490|Drug|Colchicine|Colchicine tablets
213405|NCT02128490|Drug|Naproxen|Naproxen tablets
213406|NCT02128490|Drug|Lansoprazole|Lansoprazole capsules
213407|NCT00132145|Behavioral|Web-based Vascular Tracker for Patient and Physician|
213408|NCT02128503|Other|HBV DNA level monitoring|HBV DNV level being monitoring regularly
213409|NCT02128516|Other|oral powder in sachet|
213410|NCT02128542|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
212833|NCT02141178|Drug|Bupivacaine|
212834|NCT02141178|Drug|Exparel|
212835|NCT00133445|Biological|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
212836|NCT02143518|Biological|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
213104|NCT02133690|Biological|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
213105|NCT02133690|Other|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
213106|NCT02135887|Drug|MB-6|6# TID with meal
213107|NCT02135887|Drug|Placebo|6# TID with meal
213108|NCT00132964|Device|Removable ankle brace|not required
213109|NCT02135900|Drug|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
213110|NCT02135913|Dietary Supplement|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
213111|NCT02135926|Device|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
213112|NCT02135926|Other|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
213113|NCT02135939|Behavioral|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
213114|NCT02135952|Procedure|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
213115|NCT02135952|Other|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
213116|NCT02135952|Drug|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
212537|NCT02148484|Behavioral|Client Centered Therapy|
212538|NCT02148497|Procedure|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
212539|NCT02148510|Device|Monobloc|Construction fitted to upper and lower jaw
212540|NCT02148510|Device|Bibloc|Biblock construction
212541|NCT02148523|Behavioral|Comparison to peers|
212542|NCT02148523|Behavioral|Adherence feedback|
212543|NCT02150941|Device|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
212544|NCT02150954|Drug|pitocin|
212545|NCT02150967|Drug|BGJ398|Capsule for oral use
212546|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
212837|NCT02143518|Biological|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
212838|NCT02143531|Drug|4 mg of Ondansetron IV|
212839|NCT02143531|Drug|1mg of Haloperidol IV|
212840|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
212841|NCT02143544|Device|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
212842|NCT02143557|Other|Fat-Modified Breast Milk|
212843|NCT02143557|Other|MCT formula|
212844|NCT02143570|Drug|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
212845|NCT02143570|Procedure|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
212239|NCT02115776|Drug|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
212240|NCT02115789|Behavioral|Visual Analog Scale|Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being "normal skin" and 10 being "the worst scar imaginable".
212241|NCT02115802|Device|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
212242|NCT02115815|Biological|MEDI7510|RSV sF antigen plus adjuvant
212243|NCT00130910|Drug|Albendazole|Albendazole 400mg x 3 first dose observed
212244|NCT02115815|Biological|RSV sF|antigen
212245|NCT02115815|Biological|Placebo|sterile saline
212246|NCT02115828|Drug|Vismodegib|
212247|NCT02115841|Device|"Enraf-Nonius" Muscle stimulator|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
212248|NCT02118103|Procedure|Spinal Manipulation|Lumbar spinal manipulation
212249|NCT02118116|Other|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
212250|NCT02118129|Behavioral|an educational video|
212251|NCT02118142|Dietary Supplement|Betaine|6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
212547|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
212548|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
212549|NCT00002256|Drug|Zalcitabine|
212550|NCT00134095|Procedure|neoadjuvant therapy|
212551|NCT02151006|Drug|DHEA|
211933|NCT02122822|Biological|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
211934|NCT00002235|Drug|Efavirenz|
211935|NCT00131534|Behavioral|Group therapy|Stage-based group therapy for trauma survivors
211936|NCT02122835|Behavioral|aerobic exercise training|12 weeks of supervised aerobic exercise training
211937|NCT02122848|Device|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
211938|NCT02122861|Biological|ID-LV305|
211939|NCT02122874|Device|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
211940|NCT02122874|Other|1200 Kcal diet|
211941|NCT02122887|Behavioral|Peace-Building Intervention Process|The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the "Other" - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,"gift giving", summary of process by group leaders.
211942|NCT02122913|Drug|LOXO-101|Oral LOXO-101
211943|NCT02122926|Other|Intensive discharge intervention|The intervention is a multi-modal program consisting of the following:
Inpatient protocol for adjusting the discharge diabetes regimen;
Nurse practitioner "discharge advocate" to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;
Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);
Visiting nurse intervention after discharge;
Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;
Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and
Follow-up with PCP or endocrinologist within 1 week of discharge.
211944|NCT02122939|Drug|Escitalopram|
211945|NCT02124824|Drug|BQ-123|Endothelin subtype A antagonist
211946|NCT02124837|Behavioral|Park walk during lunch break|
211947|NCT02124837|Behavioral|Relaxation during lunch break|
211948|NCT00131820|Biological|Typhoid Vi vaccine|
211949|NCT02124850|Drug|Motolimod|
211950|NCT02124850|Drug|Cetuximab|
211951|NCT02124850|Drug|Nivolumab|
211323|NCT02137538|Drug|Letrozole|
211324|NCT02137538|Drug|Anastrozole|
211325|NCT02137551|Other|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
211326|NCT00133172|Drug|Prednisone|IV
211327|NCT02137564|Drug|gamma secretase inhibitor PF-03084014|Given PO
211328|NCT02137564|Other|pharmacological study|Correlative studies
211329|NCT02137564|Other|laboratory biomarker analysis|Correlative studies
211330|NCT02137577|Procedure|DEB catheter|DEB catheter (trade name: Lotus/Tulip)
211624|NCT02130206|Other|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
211625|NCT02130219|Device|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
211626|NCT00132392|Drug|ALGRX 4975|
211627|NCT02130219|Device|Brain MRI/CT|1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.
Brain CT performed to evaluate hemorrhage and stroke volume.
211628|NCT02130219|Procedure|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
211629|NCT02130232|Behavioral|Lifestyle Intervention|
211630|NCT02130232|Other|Usual Care|
211631|NCT02130245|Procedure|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
211632|NCT02130245|Procedure|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
211633|NCT02130258|Device|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
210990|NCT02142829|Drug|EXPAREL|
210991|NCT02142829|Drug|On-Q Pain Ball|bupivacaine HCl 0.25%
210992|NCT02142842|Biological|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
210993|NCT02142855|Behavioral|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
210994|NCT00133549|Biological|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
210995|NCT02142855|Behavioral|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
210996|NCT02142868|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
211331|NCT02137577|Procedure|common PTA balloon catheter|common PTA balloon catheter
211332|NCT02137590|Dietary Supplement|Spanish Black Radish product|
211333|NCT02137603|Other|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
211334|NCT02137616|Drug|risperidone|Risperdal tablets
211335|NCT02137616|Drug|olanzapine|olanzapine tablets
211336|NCT02137616|Drug|Quetiapine|quetiapine tablets
211337|NCT00133185|Drug|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
211338|NCT02137616|Drug|Aripiprazole|Aripiprazole tablets
211339|NCT02137629|Drug|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
211340|NCT02137642|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
211341|NCT02137642|Drug|Placebo|Double blind placebo will be delivered once by injection during study procedure.
211342|NCT02137668|Drug|Oral Vancomycin|
211343|NCT02137681|Drug|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
210670|NCT02147730|Procedure|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
210671|NCT02147743|Behavioral|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
210672|NCT02147743|Behavioral|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
210673|NCT02147756|Device|CO2RE|Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).
Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation.
210674|NCT02147756|Device|Repair|
210675|NCT02147769|Device|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
210676|NCT02150148|Behavioral|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
210677|NCT02150161|Drug|Lidocaine/ ketamine|
210678|NCT02150161|Drug|Fentanyl|
210679|NCT02150174|Behavioral|Retrieval practice effect using word pairs and cued recall tests with feedback|In the first phase (encoding), people study a list of 48 word pairs non semantically associated.
Then (initial test), they recall half of word pairs or restudy the other half.
In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs.
210680|NCT02150187|Dietary Supplement|HCap Formula|Pill should be taken every other day during the treatment phase.
210681|NCT02150187|Dietary Supplement|Placebo|Similar pills without active ingredients
210682|NCT02150200|Other|shorter hospitalization stay|
210683|NCT02150200|Other|questionnaires|
210684|NCT02150213|Procedure|MRI|MRI of the abdomen
210997|NCT02142868|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
210998|NCT02142881|Other|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of <130 mmHg.
210354|NCT02108210|Drug|Placebo|
210355|NCT02108223|Drug|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
210356|NCT02108223|Drug|r-LH supplementation|recombinant luteinizing hormone
210357|NCT02108223|Drug|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
210358|NCT02108236|Device|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
210359|NCT02108249|Device|Annex™ Adjacent Level System|
210360|NCT02108262|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
210361|NCT00002227|Drug|Lamivudine|
210362|NCT00130039|Drug|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
210363|NCT02108262|Biological|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
210364|NCT02108288|Drug|OPC-1085EL ophthalmic solution|
210365|NCT02108288|Drug|Carteolol long-acting ophthalmic solution|
210366|NCT02108288|Drug|Latanoprost ophthalmic solution|
210367|NCT02108301|Drug|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
210368|NCT02110537|Drug|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
210369|NCT00130273|Behavioral|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
210370|NCT02110550|Other|IPS.emmax endocrown|
210371|NCT02110563|Drug|DCR-MYC|Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.
Starting dose: 0.1mg/kg/dose
Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.
Number of cycles: until progression or unacceptable toxicity develops.
204762|NCT02093546|Procedure|Blood Draw and Biopsy|Participant undergoes tumor biopsy to check for biomarkers during screening and at Day 28. Blood drawn to test for biomarkers and CTCs between Day 3 and Day 5 and at Day 56.
204763|NCT02093559|Behavioral|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
204764|NCT02093572|Other|3 standard meals/day|
204765|NCT02093572|Other|2 meals/day (omit breakfast)|
204766|NCT02093585|Drug|abacavir (600 mg QD)|
204767|NCT02096016|Procedure|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
204768|NCT02096029|Other|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
204769|NCT02096029|Behavioral|Ask, Advise, Refer (physician brief advice)|
204770|NCT02096042|Drug|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.
Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.
Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle.
204771|NCT02096042|Drug|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
205066|NCT02088359|Other|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
205067|NCT02088359|Other|Continue near darkness|We covered the incubator with blanket all days.
205068|NCT00127972|Drug|lamivudine|
205069|NCT02088372|Device|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
205070|NCT02088385|Device|Hemospray|
205071|NCT02088385|Device|Combined Conventional Technique|
205072|NCT02088398|Drug|ACY-1215|
205073|NCT02088411|Drug|Diclofenac|
205074|NCT02088411|Dietary Supplement|Wobenzym|
205075|NCT02088411|Other|Placebo|
204452|NCT02022059|Drug|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
204453|NCT02022072|Device|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
204454|NCT02022085|Device|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
204455|NCT02022098|Drug|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
204456|NCT02022098|Radiation|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
204457|NCT02022098|Drug|Debio 1143|Debio 1143 solution
204458|NCT02022098|Drug|Placebo|Matching placebo solution
204459|NCT02024464|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
204460|NCT02024464|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
204461|NCT02024477|Drug|Saxagliptin|5 mg tablet once daily for 12 weeks
204462|NCT02024477|Drug|placebo|1 tablet daily for 12 weeks
204463|NCT02024516|Other|50 gr concentrated pomegranate juice|
204464|NCT02024529|Biological|Ampion|kDa ultrafiltrate of 5% human serum albumin
204465|NCT02024542|Other|Surgery|
204772|NCT02096055|Drug|SGI-110|Group A Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days.
Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days.
Group B Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 10 days.
Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 10 days for 2 additional cycles, then daily for 5 days in later cycles.
Group C Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase.
Group D Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase.
204773|NCT02096055|Drug|Idarubicin|Group C Induction Phase: Idarubicin 6 mg/m2 by vein daily for 2 days. Maintenance Phase: Idarubicin 6 mg/m2 by vein on Day 1.
204774|NCT00128700|Drug|temozolomide|
204775|NCT02096055|Drug|Cladribine|Group D Induction Phase: Cladribine 3 mg/m2 by vein daily for 5 days.
Maintenance Phase: Cladribine 2 mg/m2 by vein daily for 5 days.
204144|NCT02029586|Drug|MB12066 200mg|oral administration, 100mg bid
204145|NCT02029586|Drug|Placebo|oral administration, 100mg bid
204146|NCT00122070|Drug|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
204147|NCT02029599|Drug|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
204148|NCT02029599|Drug|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
204149|NCT02029599|Drug|Methotrexate|7.5-15mg per week，All patients should be used
204150|NCT02029599|Drug|Acetaminophen tablets|Oral,0.5g, 1~2 times a day, when vas=10
204151|NCT02029612|Drug|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
204152|NCT02029612|Behavioral|Phone Counseling|Each participant counseled on quitting smoking at baseline.
204153|NCT02029612|Behavioral|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
204154|NCT02029612|Behavioral|Breath Test|Breath test performed at 3 month and 6 month visit.
204155|NCT02029612|Behavioral|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
204156|NCT02029612|Behavioral|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
204157|NCT00122083|Device|Health education information|
204158|NCT02029625|Drug|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
204159|NCT02029625|Drug|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
204160|NCT02029638|Biological|Antithymocyte globulin (ATG)|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
204161|NCT02029638|Drug|Fludarabine|Fludarabine at dose 30 mg/m2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
204162|NCT02032147|Drug|NGF group|This group will be treated with NGF 18u per day im for 60 days
204163|NCT00122447|Drug|Aspirin|325 mg PO QD
204164|NCT02032160|Biological|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
208562|NCT02109913|Drug|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
208563|NCT02109926|Other|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
208564|NCT02109939|Genetic|GeneSight Psychotropic|The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.
The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.
tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented.
203845|NCT01995149|Behavioral|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
203846|NCT01995162|Device|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
203847|NCT01995175|Procedure|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
203848|NCT01995175|Procedure|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
203849|NCT01995175|Other|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI symptoms.
203850|NCT00118950|Drug|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
203851|NCT01995188|Drug|DNIB0600A|Escalating doses of intravenously administered DNIB0600A
203852|NCT01995188|Drug|DNIB0600A|Intravenous administration of a fixed dose of DNIB0600A
203853|NCT01995188|Drug|bevacizumab [Avastin]|IV infusion at 15 mg/kg
203854|NCT01995188|Drug|carboplatin|An IV infusion at a dose of AUC 6 mg/mL * min
203855|NCT01995201|Drug|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
203856|NCT01995201|Drug|methotrexate|stable dose
208262|NCT02077387|Behavioral|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
208263|NCT02077387|Behavioral|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
208264|NCT02077400|Drug|Cephazolin|Cephazolin
208265|NCT02077413|Procedure|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
208266|NCT02077413|Procedure|Stretch-Contract Pre-rehabilitation Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the "stretch-contract" protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes.
208267|NCT02077413|Procedure|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
208268|NCT00126802|Procedure|Tomotherapy|Standard 45 Gy in 25 fractions in 5 weeks
208565|NCT02109965|Drug|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
208566|NCT02109965|Drug|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
208567|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 36|sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of "clear" or "minimal" by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from "5 = severe" to "0 = none" indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of "clear" or "minimal" consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque.
208568|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 12|sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of "clear" or "minimal" by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from "5 = severe" to "0 = none" indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of "clear" or "minimal" consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque.
208569|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 24|sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of "clear" or "minimal" by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from "5 = severe" to "0 = none" indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of "clear" or "minimal" consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque.
207987|NCT02085031|Procedure|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
207988|NCT02085031|Procedure|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
207989|NCT02085044|Dietary Supplement|Ready-to-Used Supplement Food administration|
207990|NCT02085057|Procedure|Functional Magnetic Resonance Imaging|
207991|NCT02085070|Drug|MK-3475|IV MK-3475
207992|NCT02085083|Behavioral|Regular telephone and email access to an Inflammatory Bowel Disease Nurse|The IBD pediatric-adult transition nurse will send an email each month containing:
Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.
Direct Nurse Contact: The email will also provide the option to correspond directly to the nurse.
Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.
MyHealth Passport
Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email.
207993|NCT02085083|Behavioral|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
207994|NCT00127660|Behavioral|Fast Food Menu Choices|
207995|NCT02085096|Behavioral|Problem-Solving Therapy|
207996|NCT02085109|Dietary Supplement|Fat milkshake|
208269|NCT02077413|Procedure|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
208270|NCT02079909|Drug|T-817MA|224 mg or 448 mg T-817 MA once daily
208271|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208272|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208273|NCT00127114|Drug|amantadine|
208274|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208275|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208000|NCT02087397|Other|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
208001|NCT02087397|Other|Stem Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
208002|NCT02087423|Drug|MEDI4736|MEDI4736 by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
208003|NCT02087436|Device|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
208004|NCT00127907|Drug|epinephrine (1 mg/1 mL)|
208005|NCT02087436|Device|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
208006|NCT02087449|Device|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
208007|NCT02087462|Other|Electroacupuncture (EA)|Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.
Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.
Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.
Duration: 6 weeks.
208008|NCT02087462|Other|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
208009|NCT02087462|Drug|Voltaren|Medication: 50 mg, twice per day
Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.
Duration: 6 weeks.
208010|NCT02087462|Drug|Vitamin B1|Medication: 10mg, twice per day.
Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.
Duration: 6 weeks.
208011|NCT02087475|Drug|Irinotecan|
208012|NCT02087475|Drug|5-fluorouracil|
208013|NCT02087475|Radiation|Local radiotherapy|
208287|NCT02079948|Drug|Methotrexate + Folic Acid|Participants in the methotrexate + folic acid condition will have a
Blood draw at each monthly visit
Cognitive performance testing to assess memory performance
Physical function testing to assess walking speed and measure muscle endurance
Pain assessment testing to assess the presence and location of daily pain
Self-reported function and quality of life to measure disability and mobility limitations, and
Depression assessment testing to assess participants' level of depression.
213411|NCT02128542|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
213714|NCT02121288|Drug|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
213715|NCT02121288|Drug|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
213716|NCT02121301|Drug|SkQ1|
213717|NCT02123498|Drug|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
213718|NCT00131638|Drug|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
213719|NCT02123498|Procedure|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
213720|NCT02123498|Procedure|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
213721|NCT02123511|Drug|acetylcysteine|Oral rinse
213722|NCT02123511|Other|placebo|Oral rinse
213723|NCT02123511|Other|quality-of-life assessment|Ancillary studies
213724|NCT02123511|Other|questionnaire administration|Ancillary studies
213725|NCT02123524|Drug|Rivaroxaban|
213726|NCT02123524|Drug|Placebo|
213727|NCT02123537|Device|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
213728|NCT02123563|Other|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
213729|NCT00131651|Drug|ATN-161|
213117|NCT02135965|Drug|2mg of Albuterol|2mg of Albuterol on metabolic rate
213118|NCT02135965|Drug|4mg of Albuterol|4mg of Albuterol on metabolic rate
213119|NCT00132977|Device|Cardiac Resynchronization Therapy|
213120|NCT02135965|Drug|100mg of Caffeine|100mg of caffeine on metabolic rate
213121|NCT02135965|Drug|200mg of Caffeine|200mg of Caffeine on metabolic rate
213122|NCT02135965|Drug|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
213123|NCT02135965|Drug|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
213412|NCT02128555|Procedure|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
213413|NCT02128555|Procedure|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
213414|NCT02130869|Drug|Bendamustine|Given IV - Group B only.
213415|NCT02130869|Drug|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
213416|NCT02130869|Drug|Cytarabine|Given IV - Group B only.
213417|NCT02130869|Drug|Carboplatin|Given IV - Group C only.
213418|NCT02130869|Device|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
213419|NCT02130869|Biological|G-CSF|Given SQ - All Groups.
213420|NCT02130869|Drug|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
213421|NCT02130882|Drug|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
213422|NCT00132509|Drug|DFIL|Alteplase : 0.8mg/kg over 90 minutes
213423|NCT02130882|Other|Placebo|A sterile solution containing 20 mM histidine/histidine-HCl, 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
212846|NCT02143596|Other|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
212847|NCT02143609|Drug|oxygen|Nocturnal nasal oxygen during stay at 2048 m
212848|NCT02143609|Drug|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
212849|NCT02143622|Biological|LJM716|antibody
212850|NCT02143622|Biological|cetuximab|antibody
212851|NCT00133588|Biological|Trivalent split Inf|
212852|NCT02143635|Drug|HDM201|
212853|NCT02143648|Drug|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
212854|NCT02143648|Drug|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
212855|NCT02143648|Drug|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
213124|NCT02135965|Drug|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
213125|NCT02135965|Drug|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
213126|NCT02135978|Other|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
213127|NCT02135991|Behavioral|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
213128|NCT02135991|Behavioral|Project CHOICE|Sites will receive standard training for Project CHOICE.
213129|NCT02138435|Other|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
213130|NCT02138435|Other|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
213131|NCT00133263|Behavioral|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
213132|NCT02138448|Behavioral|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
213133|NCT02138474|Other|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
212552|NCT02151019|Radiation|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
212553|NCT02151032|Behavioral|Booklet|Participants read a booklet about colorectal cancer screening tests.
212554|NCT02151032|Behavioral|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
212555|NCT02151032|Behavioral|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
212556|NCT02151032|Behavioral|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
212557|NCT02151032|Behavioral|Questionnaires|Questionnaire completion before and after viewing the program.
212558|NCT02151045|Procedure|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
212559|NCT02151045|Procedure|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
212560|NCT02151058|Drug|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
212561|NCT00134108|Behavioral|Cognitive Behaviour Therapy|
212562|NCT02151058|Drug|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
212563|NCT02151058|Other|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
212564|NCT02151071|Device|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
212565|NCT02151071|Device|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
212566|NCT02151084|Drug|Selumetinib|
212856|NCT02143674|Other|Muscle stretching and Strength Training|Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.
Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol.
212857|NCT02145988|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
211952|NCT02124863|Device|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
212252|NCT02118142|Dietary Supplement|Dextrose|6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
212253|NCT02118155|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
212254|NCT02118168|Other|No intervention|No intervention is forseen in this Observational Study
212255|NCT00131053|Drug|Hydrocortisone|
212256|NCT02118181|Dietary Supplement|HMB|
212257|NCT02118207|Other|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
212258|NCT02118220|Other|Concussion Questionnaire|
212259|NCT02118246|Device|Dry Needling|Dry needling was performed for one week, three times a week.
212260|NCT02118246|Device|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
212261|NCT02118259|Other|Before-after study|The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.
The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.
The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.
During the second observational phase, the same data as in the first observational phase will be collected a second time.
212262|NCT02118272|Device|Physica KR|
212263|NCT02118285|Drug|Fludarabine|Fludarabine 25 mg/m^2 IV on days -6 through -2 from NK cell infusion
212264|NCT02118285|Drug|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
212265|NCT02118285|Biological|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
212266|NCT00131053|Drug|Mercaptopurine|
212267|NCT02118285|Biological|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
212268|NCT02118285|Drug|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
212269|NCT02118311|Biological|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
212270|NCT02118311|Drug|Fludarabine|Fludarabine 30mg/m^2 IV over 1 hour on days -6 through -2 from transplant
211634|NCT02130271|Drug|Radioactive dye|The radioactive dye [11C]PBR28 will be administered through an intravenous line (IV).
211635|NCT02132910|Other|RESTORE Intervention|
211636|NCT02132923|Biological|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
211637|NCT02132936|Drug|LEO 90100 aerosol foam|
211638|NCT02132936|Drug|Aerosol foam vehicle|
211639|NCT02132936|Drug|Calcipotriol BDP gel|
211640|NCT02132936|Drug|Gel vehicle|
211641|NCT02132949|Drug|5-fluorouracil|500 mg/m2 IV given every 3 weeks for 12 weeks (Cycles 1-4)
211953|NCT02124889|Behavioral|Weekly Internet surveys|Subjects in this arm will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
211954|NCT02124902|Drug|Docetaxel|
211955|NCT02124902|Drug|Carboplatin|
211956|NCT02124928|Procedure|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
211957|NCT02124941|Drug|N-acetyl cysteine|
211958|NCT02124941|Drug|riluzole|
211959|NCT00131820|Biological|Hepatitis A (control)|
211960|NCT02124941|Drug|pentoxifylline|
211961|NCT02124941|Drug|13C MRS|
211962|NCT02124941|Behavioral|Continued abstinence|
211963|NCT02124954|Drug|TA-8995|
211964|NCT02124954|Drug|Midazolam|
211965|NCT02124954|Drug|Digoxin|
211344|NCT02137694|Other|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
211345|NCT02137707|Drug|Gilenya|All patients will receive Gilenya
211346|NCT02137720|Behavioral|Telephonic Diabetes Self-Management Support|
211347|NCT02137720|Other|Educational Print Materials|
211348|NCT00133185|Drug|losartan 50 mg/hydrochlorothiazide 12.5 mg|
211349|NCT02137733|Drug|Bisoprolol|
211350|NCT02137733|Drug|Carvedilol|
211351|NCT02137746|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
211352|NCT02140242|Procedure|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
211353|NCT02140255|Drug|Intensive ART regimen|Nucleoside reverse transcriptase inhibitor (1) chosen by clinician
Nucleoside reverse transcriptase inhibitor (2) chosen by clinician
Nevirapine
Lopinavir boosted with ritonavir
211354|NCT02140268|Drug|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
211642|NCT00132704|Radiation|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
211643|NCT02132949|Drug|cyclophosphamide|600 mg/m2 IV given every 2 weeks for 8 weeks (Cycles 1-4)
211644|NCT02132949|Drug|cyclophosphamide|600 mg/m2 IV given every 3 weeks for 12 weeks (Cycles 1-4)
211645|NCT02132949|Drug|docetaxel|100 mg/m2 (75 mg/m2 first dose) IV given every 3 weeks for 12 weeks (Cyles 5-8)
211646|NCT02132949|Drug|doxorubicin|60 mg/m2 IV given every 2 weeks for 8 weeks (Cycles 1-4)
211647|NCT02132949|Drug|epirubicin|100 mg/m2 IV given every 3 weeks for 12 weeks (Cycles 1-4)
211648|NCT02132949|Drug|paclitaxel|80 mg/m2 IV given weekly for 12 weeks (Cycles 5-8)
211649|NCT02132949|Drug|pertuzumab [Perjeta]|420 mg (840 mg first dose) IV given every 3 weeks for 17 cycles
211650|NCT02132949|Drug|trastuzumab [Herceptin]|6 mg/kg (8 mg/kg first dose) IV given every 3 weeks for 17 cycles
211651|NCT02132962|Dietary Supplement|Amino acid infusion|
210999|NCT02142881|Other|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
211000|NCT02142894|Device|CST001|
211001|NCT02142920|Drug|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
211002|NCT02142933|Other|vagino-perineal swab|
211003|NCT02142959|Drug|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
211004|NCT02142959|Drug|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
211005|NCT00133562|Drug|Alanyl-glutamine|
211006|NCT02142959|Drug|Lotion vehicle/Placebo|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
211007|NCT02142959|Radiation|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
211008|NCT02142985|Drug|Plasmagel|vascular filling with 500 ml of colloid solution (plasmagel) over 30 minutes
211009|NCT02142998|Other|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
211010|NCT02145299|Device|CROSSER CTO Device|
211011|NCT02145312|Drug|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
211012|NCT02145325|Drug|Expanded Tregs|
211013|NCT02145338|Drug|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
211014|NCT02145338|Other|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
211015|NCT02145351|Device|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Advisa DR model A2DR01 is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
211355|NCT02140268|Drug|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
210372|NCT02110589|Device|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
210685|NCT02150213|Procedure|Dexamethasone Supression Test|Dexamethasone Supression test
210686|NCT00002255|Drug|Zidovudine|
210687|NCT00134069|Drug|cetuximab|Given IV
210688|NCT02150213|Procedure|Sonogram|Sonogram of the uterus (females only)
210689|NCT02150213|Procedure|Biopsy|Uterine endometrial biopsy (females only)
210690|NCT02150213|Drug|BGG492|No study-drug gets administered in this study
210691|NCT02150226|Device|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
210692|NCT02150239|Procedure|operation|
210693|NCT02150252|Drug|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
210694|NCT02150265|Behavioral|SMART manual cognitive behavioral therapy|
210695|NCT02150278|Behavioral|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
210696|NCT02150291|Dietary Supplement|Folic acid|
210697|NCT02150291|Drug|Neurobion|
210698|NCT00134069|Drug|irinotecan hydrochloride|Given IV
210699|NCT02150291|Drug|placebo|
210700|NCT02150317|Procedure|TACE+Sorafenib|TACE followed by Sorafenib
210701|NCT02150317|Procedure|TACE|TACE alone
210702|NCT02150330|Drug|Dehydroepiandrosterone (DHEAS)|
210703|NCT02150343|Drug|HDM-SPIRE|1 dose every 4 weeks
210704|NCT02150343|Drug|Placebo|1 dose every 4 weeks
205076|NCT02088424|Other|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
205077|NCT02088437|Other|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
205078|NCT02088437|Other|Usual Care|once daily physiotherapy whilst acute hospital inpatient
205079|NCT00127972|Drug|nevirapine|
205080|NCT02088450|Drug|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
205081|NCT02088463|Procedure|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
205082|NCT02088463|Procedure|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
205083|NCT02088463|Device|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
205084|NCT02088489|Device|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
205085|NCT02088489|Device|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
205086|NCT02088502|Drug|N-acetylcysteine|
205378|NCT02081248|Other|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
205379|NCT02081261|Procedure|Coronary artery bypass surgery|coronary artery bypass surgery
205380|NCT02081274|Procedure|Surgery for congenital heart disease|
205381|NCT02081287|Drug|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
205382|NCT02081287|Drug|Lamotrigine|Dose up to 200 mg per day over 10 weeks
205383|NCT02081300|Drug|Oral testosterone undecanoate, LPCN 1021|
205384|NCT00127218|Drug|niacin|long-acting niacin daily for 18 months
204776|NCT02096068|Drug|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
204777|NCT02096068|Drug|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
204778|NCT02096081|Drug|IncobotulinumtoxinA|20U/injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
204779|NCT02096081|Drug|Toxin II|20U/injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
204780|NCT02096094|Procedure|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
204781|NCT02096094|Procedure|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
204782|NCT02096094|Procedure|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
204783|NCT02096107|Drug|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
204784|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
204785|NCT00128700|Drug|vatalanib|
204786|NCT00128934|Drug|levonorgestrel/ethinyl estradiol|
204787|NCT02098395|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will remain on this dose throughout the trial (26 weeks). Administered subcutaneously (s.c., under the skin) once daily.
204788|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
205087|NCT02088502|Drug|Theophylline|
205088|NCT02090894|Device|UV Light (Laser Genesis)|
205089|NCT02090907|Drug|Levothyroxine|
205090|NCT02090907|Drug|Placebo|
204165|NCT02032160|Biological|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
204466|NCT02024555|Drug|Levofloxacin|
204467|NCT02024555|Drug|Ethambutol|
204468|NCT02024555|Drug|Azithromycin|
204469|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term [ST], 42 months long term [LT])
204470|NCT02024555|Drug|Rifampin|
204471|NCT02024555|Drug|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
204472|NCT02024568|Drug|Pregabalin|See arm description
204473|NCT02024568|Drug|Placebo|See arm description
204474|NCT02024581|Drug|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
204475|NCT02024581|Drug|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
204476|NCT02024594|Drug|Nitrous Oxide-Oxygen conscious sedation|
204477|NCT02024594|Behavioral|cognitive-behavioral therapy|
204478|NCT02024607|Drug|BBI608|
204479|NCT02024607|Drug|Fluorouracil|
204480|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
204481|NCT02024607|Drug|Oxaliplatin|
204482|NCT02024607|Drug|Leucovorin|
204483|NCT02024607|Drug|Irinotecan|
204484|NCT02024607|Drug|Bevacizumab|
204485|NCT02024607|Drug|Capecitabine|
204486|NCT02024607|Drug|Regorafenib|
204487|NCT02024620|Behavioral|Behavioral activation plus mobile app|
204488|NCT02024620|Behavioral|Standard behavioral activation|
203857|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
203858|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
203859|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
203860|NCT01995214|Drug|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
203861|NCT00118950|Drug|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
203862|NCT01995214|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
203863|NCT01995227|Biological|AlloVax|Personalized anti-cancer vaccine
203864|NCT01995227|Biological|CRCL|Personalized anti-cancer vaccine
204166|NCT02032173|Drug|Main group|Patient will start in the main group with 6 monthly ranimizumab IVTs until month 5. Additional mandatory IVTs will be done at months 8 and 11. At months 14, 17, 20 and 23, IVTs will be done if BCVA loss is comprised between 9 and 5 letters (included). If patient did not loose more than 4 letters, no injection has to be performed at the visit. Criteria to stay in the main group are : 1°) at Month 3, 4 letters (included) improvement compared to baseline (Day 0) OR an improvement in CSF ≥ 0.1 log OCT compared to baseline (Day 0); 2°) at Month 6, a stable VA is obtained based on the months 4, 5 and 6 BCVA score; 3°) at Months 8, 11, 14, 17, 20 and 23, no BCVA decrease by more than 10 letters (excluded) compared with the highest BCVA score since the beginning of the study.
204167|NCT02032186|Drug|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
204168|NCT02032212|Other|EVP unflavoured|
204169|NCT02032212|Other|EVP flavoured|
204170|NCT02032212|Other|Nicotine inhalator 15mg|
204171|NCT02032212|Other|Conventional cigarette|
204172|NCT02032225|Other|Skin biopsy|
204173|NCT02032238|Device|Navigated laser|Standard Anti-VEGF Injections will be combined with Navigated laser in a pre-defined manner
204174|NCT00122447|Drug|Alpha lipoic acid|600 mg PO BID
204175|NCT02032238|Drug|Anti-VEGF Injections|Monotherapy
204176|NCT02032251|Drug|oral administration of ginger|Oral administration of ginger in patients with infertility.
204177|NCT02032251|Drug|Placebo|
208570|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 36|sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of "clear" or "minimal" by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from "5 = severe" to "0 = none" indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of "clear" or "minimal" consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque.
208571|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
208572|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
208573|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
208574|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
208575|NCT00130455|Drug|escitalopram|
208576|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
208577|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
203865|NCT01997658|Drug|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
203866|NCT01997658|Drug|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
203867|NCT01997671|Other|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
203868|NCT01997684|Procedure|Colonic Stenting with Elective Surgery|After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.
If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.
Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.
Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
208276|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208277|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208278|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208279|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
208280|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
208281|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
208282|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
208283|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
208284|NCT00127127|Drug|vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|vorinostat; level 1: 100 mg BID 14-day, level 2: 200 mg BID 14-day, level 3: 400 mg QD 14 day, level 5: 500 mg QD 14-day
208285|NCT02079935|Behavioral|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
208286|NCT02079935|Behavioral|Physical Activity and Diet Therapy|Guided physical activity and diet therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
208578|NCT02112097|Drug|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
208579|NCT02112097|Drug|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
208580|NCT02114359|Drug|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
208581|NCT02114359|Drug|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
208582|NCT02114359|Drug|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
208288|NCT02079948|Drug|Placebo + Folic Acid|Participants in the placebo + folic acid condition will have a
Blood draw at each monthly visit
Cognitive performance testing to assess memory performance
Physical function testing to assess walking speed and measure muscle endurance
Pain assessment testing to assess the presence and location of daily pain
Self-reported function and quality of life to measure disability and mobility limitations, and
Depression assessment testing to assess participants' level of depression
208289|NCT02079948|Procedure|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
208290|NCT02082600|Other|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
208291|NCT02082613|Procedure|Lord´s procedure|
208292|NCT02082613|Procedure|Sclerotherapy|
208293|NCT02082626|Drug|Eribulin mesylate|
208294|NCT00127348|Device|CPAP (Continuous Positive Airway Pressure)|
208295|NCT02082639|Biological|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
208296|NCT02082639|Biological|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
208297|NCT02082652|Drug|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
208298|NCT02082665|Drug|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
208299|NCT02082665|Drug|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
208300|NCT02082665|Drug|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
208301|NCT02082678|Drug|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
208302|NCT02082678|Drug|Placebo|Inactive ingredient matching the active medication in appearance
208303|NCT02082691|Drug|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
208597|NCT00130767|Drug|finasteride|
213730|NCT02123563|Other|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
213731|NCT02123576|Drug|Pentoxyfylline|
208938|NCT02112162|Device|magnetic resonance imaging|Undergo FDG PET/MRI
208939|NCT02112162|Other|laboratory biomarker analysis|Correlative studies
208940|NCT02112175|Drug|Lenalidomide|
208941|NCT02112175|Drug|Placebo|
208942|NCT02112188|Behavioral|In-depth Patient Interviews|
208943|NCT00130481|Drug|Atorvastatin 20 mg daily for 3 months|
208944|NCT02112188|Behavioral|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
208945|NCT02112201|Behavioral|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
208946|NCT02112214|Drug|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
208947|NCT02112227|Other|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
208948|NCT02112240|Other|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
208949|NCT02114463|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
208950|NCT02114463|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
208951|NCT02114463|Drug|ropivacaine|0.2% ropivacaine
208952|NCT02114463|Drug|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
213424|NCT02130895|Other|STOPP Criteria Decision Support Content|55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing "Clinical Decision Alerts" box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion "Consider: avoiding b-blockers in elderly diabetics with >=1 hypoglycaemic episodes / month" will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation.
213425|NCT02130908|Other|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
213426|NCT02130908|Other|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
213427|NCT02130908|Other|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
213428|NCT02130921|Behavioral|Intervention to Address Drug Use and HIV in Vietnam|Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.
Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.
Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change.
213732|NCT02123576|Drug|Placebo|
213733|NCT02123576|Drug|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
213734|NCT02123589|Drug|Deep sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
213735|NCT02123589|Drug|Deep and daily interruption of sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
213736|NCT02123589|Drug|Light sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
213737|NCT02123602|Other|core stabilization|
213738|NCT02125682|Drug|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
213739|NCT02125695|Procedure|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
213740|NCT02125695|Procedure|Blood Sampling|Sampling for biomarker and basic research in CLE, SSc and AD
213741|NCT02125695|Procedure|Skin Biopsy|As described in the treatment arm
213134|NCT02138474|Other|Placebo|Unmedicated sucrose pillules
213135|NCT02138487|Other|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
213136|NCT02138487|Other|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
213137|NCT02138500|Drug|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
213138|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
213139|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
213140|NCT02138513|Behavioral|Mindfulness Based Cognitive Therapy|This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
213141|NCT02138526|Drug|pazopanib|pazopanib 800mg OD without food
213142|NCT00133263|Behavioral|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
213143|NCT02138526|Other|continental breakfast|pazopanib 600mg OD with food
213429|NCT02130934|Procedure|Cardiac 3D MRI|
213430|NCT02130947|Behavioral|Exercise|
213431|NCT02130973|Drug|18 months teriparatide followed by 18 months denosumab|
213432|NCT02130973|Drug|three separate 6 month cycles of daily teriparatide, each followed by one of denosumab|
213433|NCT00132509|Drug|NINDS|Alteplase : 0.9mg/kg over 60 minutes
213434|NCT02130986|Other|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
213435|NCT02133703|Behavioral|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
213436|NCT02133703|Behavioral|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
212858|NCT02145988|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
212859|NCT02146001|Other|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
212860|NCT02146001|Other|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
212861|NCT02146014|Other|Placebo|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
In the placebo group the current will be off.
212862|NCT02146014|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
212863|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks.
212864|NCT00133874|Drug|SB-275833 ointment, 1%|
212865|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
212866|NCT02146053|Dietary Supplement|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
212867|NCT02146053|Dietary Supplement|Placebo|placebo capsules: methyl cellulose
212868|NCT02146066|Biological|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
212869|NCT02146079|Drug|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
213144|NCT02138539|Other|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
213145|NCT02138539|Drug|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
213146|NCT02138552|Drug|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
212271|NCT02118311|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
212567|NCT02153541|Other|Mineral oil|50% of participants will receive the mineral oil. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
212568|NCT02153554|Behavioral|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
212569|NCT02153567|Drug|Escitalopram|
212570|NCT02153567|Other|Placebo|
212571|NCT02153580|Drug|cyclophosphamide|Given IV
212572|NCT02153580|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
212573|NCT02153580|Other|laboratory biomarker analysis|Correlative studies
212574|NCT02153580|Drug|Bendamustine Hydrochloride|Given IV
212575|NCT02153580|Drug|Etoposide|Given IV
212576|NCT00134407|Procedure|Nutrition via jejunal needle-catheter|
212577|NCT02153580|Drug|Fludarabine Phosphate|Given IV
212578|NCT02153593|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
212579|NCT02153593|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
212580|NCT02153593|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
212581|NCT02153606|Drug|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
212582|NCT02153606|Other|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
212583|NCT02153619|Behavioral|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
212584|NCT02153619|Behavioral|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSKCC Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
211966|NCT02124967|Other|Exercise|A one hour exercise class including both aerobic activity and resistance training
211967|NCT02124980|Behavioral|Recovery Line|
211968|NCT02124993|Other|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
211969|NCT02125006|Behavioral|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
211970|NCT00131833|Biological|Typhoid Vi vaccine|
211971|NCT02127723|Device|Hyaluronic acid injection (Macroalne VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
211972|NCT02127736|Drug|Amitriptyline|
211973|NCT02127736|Drug|Placebo|
212272|NCT02120586|Other|Peripheral muscle training|The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.
The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10.
212273|NCT02120599|Dietary Supplement|ready-to-use supplementary food|
212274|NCT02120599|Dietary Supplement|corn-soy blend|
212275|NCT02120599|Dietary Supplement|iron|
212276|NCT02120599|Dietary Supplement|folic acid|
212277|NCT02120599|Dietary Supplement|UNIMMAP|
212278|NCT02120612|Other|Naloxone Education Intervention|The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, "Opioid Overdose Prevention" program for non-medical responders.
212279|NCT02120625|Device|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
211652|NCT02132962|Other|Bloodsamples, Biopsies.|
211653|NCT00132704|Radiation|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
211654|NCT02132975|Device|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
211655|NCT02132975|Procedure|Biopsies using UroStation® (image fusion)|
211656|NCT02132988|Biological|OPT-822/OPT-821|
211657|NCT02133001|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
211658|NCT02133001|Drug|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
211659|NCT02133014|Procedure|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
211660|NCT02135276|Drug|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
211974|NCT02127749|Drug|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
211975|NCT02127749|Drug|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
211976|NCT02127762|Behavioral|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
211977|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 1)|
211978|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 2)|
211979|NCT02127788|Drug|Micafungin|intravenous
211980|NCT02127801|Drug|REGN1908-1909|
211981|NCT00132067|Drug|vorinostat|Given orally
211982|NCT02127801|Drug|placebo|
211356|NCT02140268|Drug|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
211357|NCT02140281|Drug|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
211358|NCT02140281|Drug|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
211359|NCT02140294|Dietary Supplement|Polymeric nutritional supplements|
211360|NCT02140294|Dietary Supplement|Standard Nutrional Treatment|
211361|NCT02140307|Behavioral|Relaxation Response-based Mental Health Promotion (RR-MHP)|The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled "The focus you feel like", where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship).
211362|NCT00133393|Drug|Pentoxifylline|
211363|NCT02140320|Drug|RV1729 single dose|Safety and tolerability of single dose
211364|NCT02140320|Drug|RV1729 matching placebo single dose|Safety and tolerability of single dose
211365|NCT02140320|Drug|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
211366|NCT02140320|Drug|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
211367|NCT02140320|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
211368|NCT02140320|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
211369|NCT02140333|Drug|Erlotinib|100mg vs. 150mg
211370|NCT02140346|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
211371|NCT02140346|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
211372|NCT02140359|Behavioral|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
211373|NCT00133406|Drug|Glutamine|0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
210705|NCT02152735|Procedure|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
210706|NCT02152748|Genetic|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
210707|NCT02152761|Drug|bimagrumab|Bimagrumab will be administered as intravenous infusion starting on Day 1 until week 20.
211016|NCT00133757|Drug|Bupropion SR|
211017|NCT02145351|Device|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
211018|NCT02145364|Device|Ultherapy® treatment|Microfocused ultrasound treatment
211019|NCT02145377|Biological|PXVX0200 10E8|Oral dose of PXVX0200 10E8
211020|NCT02145377|Biological|PXVX0200 10E9|Oral dose of PXVX0200 10E9
211021|NCT02145377|Biological|Placebo|Oral dose of sodium bicarbonate buffer
211022|NCT02145377|Biological|Shanchol|Licensed comparator
211023|NCT02145390|Procedure|Transurethral Resection of the Bladder Tumor & Cystoscopy|The following will be performed by the participating urologist:
cystoscopic evaluation
bimanual examination under anesthesia,
as thorough as possible a transurethral resection (TUR) of the bladder tumor,
and a biopsy of the prostatic urethra including both mucosa and stroma using a resection loop.
211024|NCT02145390|Drug|Cisplatin|All patients will receive the neoadjuvant course of chemotherapy. This regimen will begin within 8 weeks following the TURBT and cystoscopic evaluation by the urologic surgeon. Ideally, treatment should start within 8 weeks and on a Monday.
Neoadjuvant chemotherapy: Cisplatin (70 mg/m2) will be administered as a sixty-minute infusion (+/- 10 minutes) on day 1 (outpatient regimen) or day 2 (inpatient regimen) of each 21-day cycle, for four cycles. Cisplatin therapy will begin within 8 weeks following the TURBT & Cystocopy
Concurrent Chemotherapy w/Radiation: Cisplatin (35 mg/m2) will be administered as a 60 minute infusion (+/- 10 minutes) starting on day 1 of radiation, and on days 8,15,22,29.
211025|NCT02145390|Drug|Gemcitabine|All patients will receive the neoadjuvant course of chemotherapy. This regimen will begin within 8 weeks following the TURBT and cystoscopic evaluation by the urologic surgeon. Ideally, treatment should start within 8 weeks and on a Monday.
Neoadjuvant chemotherapy: Gemcitabine (1000 mg/m2) will be administered intravenously over 30-60 minutes (preferably 30 minutes) on Days 1 and 8 of each 21-day cycle, for four cycles.
211026|NCT02145390|Radiation|Intensity Modulated Radiation Therapy|All patients will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. Radiation therapy will be started within 6 weeks following the neoadjuvant chemotherapy. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes. The pelvic lymph nodes will receive 45 Gy in 25 fractions at 1.8 Gy per fraction. The whole bladder and prostate will receive 50 Gy in 25 fractions at 2.0 Gy per fraction. The tumor boost area will be defined as the area of bladder involved by tumor based on TURBT, CT imaging, and lipiodol injection at time of cystoscopy, and will receive 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day. Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume.
205385|NCT02081300|Drug|Topical testosterone gel 1.62 %|
205386|NCT02081313|Other|Biopsy|
205387|NCT02081313|Other|Blood sample|
205388|NCT02081326|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
205389|NCT02081326|Biological|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
205390|NCT02081339|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|
205391|NCT02081352|Other|DermaPure™|A minimally manipulated human tissue regulated as "human cells, tissues, and cellular and tissue-based products" (HCT/Ps)
205392|NCT02081352|Other|Standard care|
205393|NCT02081365|Behavioral|Computerized Dental Anxiety Treatment|The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
205394|NCT02081378|Drug|ABL001|ABL001 capsules will be administered orally in a dose escalation schedule.
205395|NCT00127218|Drug|Placebo|matching placebo pill daily for 18 months
205396|NCT02081378|Drug|ABL001 + Nilotinib|ABL001 and Nilotinib capsules will be administered orally in CML patients
205397|NCT02081378|Drug|ABL001|ABL001 capsules will be administered orally in Ph +ve ALL patients
205398|NCT02081391|Drug|Tapentadol 4 mg/mL|Participants aged from 2 years to less than 18 years with body weight less than 20 kg will receive tapentadol 4 mg/mL solution orally (by mouth) every 4 hours for up to 72 hours. The dose during the first 24 hours will be 1.25 mg/kg. After 24 hours, the dose can be reduced to 1.0 mg/kg, based on investigator's judgment. Dose of tapentadol 4 mg/mL solution for participants aged birth to less than 2 years with body weight less than 20 kg will be decided based on the forthcoming pharmacokinetic (PK) [what the body does to a medication] data.
205692|NCT02113072|Drug|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
205693|NCT02113072|Drug|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
205694|NCT02113085|Behavioral|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
205695|NCT02113098|Other|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
205091|NCT02090920|Drug|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
205092|NCT02090933|Drug|Celecoxib|Given PO
205093|NCT00128180|Drug|Placebo|Placebo
205094|NCT02090933|Other|Laboratory Biomarker Analysis|Correlative studies
205095|NCT02090933|Procedure|UV Light Therapy|Undergo UV-irradiation
205096|NCT02090959|Drug|Ataluren|
205097|NCT02090985|Procedure|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
205098|NCT02090998|Procedure|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
205099|NCT02090998|Drug|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
205100|NCT02091024|Dietary Supplement|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
205101|NCT02091024|Dietary Supplement|Placebo|Placebo 200mg, twice a day
205102|NCT02091050|Other|2D HDR planning|HDR planning using simple radiograph (2D)
205103|NCT02091050|Other|3D HDR planning|HDR planning using computed homograph (3D)
205104|NCT00002217|Drug|Lamivudine/Zidovudine|
205105|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
205106|NCT02091063|Drug|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
205107|NCT02091076|Device|Silk fibroin with bioactive coating layer dressing|
205108|NCT02091076|Device|Bactigras wound dressing|
205109|NCT02091089|Device|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
205110|NCT02091102|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
205399|NCT02084017|Device|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
204489|NCT02024633|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
204789|NCT02098395|Drug|placebo|Subjects randomised to 0.2 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 24 weeks. Administered subcutaneously (s.c., under the skin) once daily.
204790|NCT02098395|Drug|placebo|Subjects randomised to 0.1 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the trial (26 weeks). Administered subcutaneously (s.c., under the skin) once daily.
204791|NCT02098408|Behavioral|Cognitive remediation|Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.
The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients.
204792|NCT02098408|Behavioral|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
204793|NCT02098421|Drug|Oxytocin|Use of oxytocin while the Foley bulb is in place
204794|NCT02098434|Behavioral|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
204795|NCT02098447|Device|PrimeStim|
204796|NCT02098460|Drug|Atorvastatin, Probucol, Cilostazol|
204797|NCT00128947|Drug|Mycophenolic Acid|
204798|NCT02098473|Drug|RPC4046|
204799|NCT02098473|Drug|Placebo|
204800|NCT02098486|Drug|Moxifloxacin|
204801|NCT02098486|Drug|ceftriaxone|
204802|NCT02098499|Drug|Haloperidol|5mg IV
204803|NCT02098499|Drug|Metoclopramide 10mg|10mg IV
204804|NCT02098499|Drug|Diphenhydramine|25mg IV
204805|NCT02098512|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:
42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1
105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
204178|NCT02032264|Other|Comprehensive Chromosome Screening|On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
204179|NCT02032264|Other|Morphologically Best|Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
204180|NCT02032277|Drug|Veliparib|Veliparib
204181|NCT02032277|Drug|Carboplatin|Carboplatin
204182|NCT02032277|Drug|Paclitaxel|Paclitaxel
204183|NCT02032277|Drug|Doxorubicin|Doxorubicin
204184|NCT02032277|Drug|Cyclophosphamide|Cyclophosphamide
204185|NCT00122447|Drug|Olmesartan|40 mg PO QD
204186|NCT02032277|Drug|Placebo|Placebo for Veliparib
204187|NCT02032277|Drug|Placebo|Placebo for Carboplatin
204490|NCT02027207|Biological|Shanchol|We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.
Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume.
204491|NCT00121797|Drug|antibiotics according to culture|
204492|NCT02027207|Biological|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
204493|NCT02027220|Drug|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
204494|NCT02027220|Drug|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
204495|NCT02027220|Drug|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
204496|NCT02027220|Drug|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
204497|NCT02027233|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
203869|NCT01997684|Procedure|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
203870|NCT00119145|Drug|coartem|
203871|NCT01997697|Other|behavior change program|behavior change program among patients with obesity
203872|NCT01997710|Device|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
203873|NCT01997710|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
203874|NCT01997723|Device|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
203875|NCT01997723|Other|Polysomnography|One attended diagnostic sleep study.
203876|NCT01997723|Device|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
203877|NCT01997723|Device|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
203878|NCT01997736|Device|Ablation|
203879|NCT01997749|Dietary Supplement|Ketocal 4:1 (Nutricia)|
203880|NCT01997749|Dietary Supplement|Control diet: Regular diet offered at the hospitals|
203881|NCT00119145|Drug|artesunate-lapdap|
203882|NCT01997749|Dietary Supplement|Ketogenic meals|
204188|NCT02032290|Procedure|Assessment of Coronary Flow Reserve|
204189|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
204190|NCT02034773|Drug|CC-220|CC-220 1mg (once every 7 days for 28 days)
204191|NCT02034773|Drug|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
204192|NCT02034786|Procedure|Adipose tissue collection|Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.
The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia.
204193|NCT02034786|Biological|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
208583|NCT02114359|Drug|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
208584|NCT02114359|Drug|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 1000mg/m2 po bid)
208585|NCT02114359|Drug|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 30mg/m2 po bid)
208586|NCT00130754|Drug|Thymoglobuline|IV 7.5 mg/kg
208587|NCT02114359|Drug|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
208588|NCT02114372|Genetic|No intervention|This is an observational study that does not include the use of any specific treatments. Participants enrolled will undergo neuropsychological evaluations over a 4 year period to characterize patterns of cognitive and functional change.
208589|NCT02114385|Biological|V503|
208590|NCT02114385|Biological|GARDASIL|
208591|NCT02114398|Other|usual treatment|usual treatment
208592|NCT02114398|Other|usual treatment + sophrology|usual treatment + sophrology
208593|NCT02114411|Procedure|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
208594|NCT02114411|Procedure|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
208595|NCT02114424|Device|Positional vibrator belt|Belt with vibarator to avoid sleep supine
208596|NCT02114437|Device|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
203883|NCT01997762|Dietary Supplement|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
203884|NCT01997762|Dietary Supplement|Placebo|
203885|NCT02000024|Behavioral|Weight Watchers|The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial "orientation session" designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk.
203886|NCT02000024|Behavioral|National Diabetes Education Program|
208598|NCT02114437|Device|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
208599|NCT02114450|Behavioral|Robot-assisted training with the H2 lower limb powered exoskeleton|The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
208600|NCT02114450|Behavioral|Supervised motor practice|Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
208601|NCT02077426|Other|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
208602|NCT02077439|Device|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
208603|NCT02077439|Device|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
208604|NCT02077439|Other|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
208605|NCT02077452|Drug|HMS5552|
208606|NCT02077452|Drug|Placebo|
208607|NCT02077465|Drug|GS-5745|400 mg GS-5745 administered intravenously
208608|NCT02077465|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
208609|NCT02077478|Device|Remifentanil and propofol administration using TCI|
208610|NCT00126828|Procedure|External beam radiotherapy|
208611|NCT02077478|Device|Remifentanil and propofol administration using MCI|
208612|NCT02077491|Other|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
208613|NCT02077504|Other|MEG and MRI|CONDUCTOME
208614|NCT02077517|Procedure|Roux en Y Gastric Bypass|
208615|NCT02077543|Device|Molecular and cellular tumor print Medical Device (ProTool)|Proteomic, genomic and cellular culture
208616|NCT02077556|Drug|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
208953|NCT02114476|Device|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
208954|NCT02114489|Drug|ibandronate|Unique perfusion of ibandronate 3 mg IV
208955|NCT02114489|Drug|Placebo|
209254|NCT02107690|Procedure|Room temperature lidocaine injection|20 °C
209255|NCT02107690|Procedure|Body temperature lidocaine injection|37 °C
209256|NCT02107703|Drug|Abemaciclib|Administered Orally
209257|NCT00129961|Drug|cyclosporine or tacrolimus|
209258|NCT02107703|Drug|Fulvestrant|Administered IM
209259|NCT02107703|Drug|Placebo|Administered Orally
209260|NCT02107716|Procedure|Lidocaine injection with bicarbonate|bicarbonate added to change pH
209261|NCT02107716|Procedure|lidocaine injection|Lidocaine injection with pH unchanged
209262|NCT02107729|Procedure|Large needle gauge lidocaine injection|21 G
209263|NCT02107729|Procedure|Normal needle gauge lidocaine injection|23 G
209264|NCT02107729|Procedure|Small needle gauge lidocaine injection|27 G
209265|NCT02107742|Procedure|Normal speed lidocaine injection|30 seconds
209266|NCT02107742|Procedure|Slow lidocaine injection|speed 45 seconds
209267|NCT02107742|Procedure|Fast lidocaine injection|speed 15 seconds
209268|NCT00129974|Drug|pemetrexed and gemcitabine|
209269|NCT02110160|Biological|Fluorodeoxyglucose F 18 Injection (FDG)|
209270|NCT00130247|Drug|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
209271|NCT02110186|Device|Dynamic Stabilization|
209272|NCT02110186|Procedure|Discectomy|
209273|NCT02110186|Device|Instrumentation and fusion|
213742|NCT02125708|Device|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensored thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
213743|NCT02125721|Drug|CBTD 0-3 gm|Oral CBTD 0-3 gm dose/day for 7 days, dose escalation
213744|NCT00131898|Procedure|Surgical Resection|
213745|NCT02125734|Drug|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
213746|NCT02125734|Drug|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
213747|NCT02125747|Other|No Respiratory Therapy|Patients received conventional treatment.
213748|NCT02125747|Other|Respiratory Therapy|Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.
The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.
Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period.
213749|NCT02125760|Other|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
208956|NCT00130780|Drug|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
208957|NCT02114502|Drug|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
208958|NCT02114502|Drug|SAHA|1,000 mg by mouth on Days -8 to -3.
208959|NCT02114502|Drug|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
208960|NCT02114502|Drug|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
208961|NCT02114502|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
208962|NCT02114502|Procedure|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
213437|NCT02133703|Behavioral|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
213438|NCT00132730|Drug|MK-0873 1.25 mg|
213439|NCT02133703|Behavioral|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
213440|NCT02133703|Behavioral|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
213441|NCT02133716|Other|expressed breast milk|The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.
A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment.
213442|NCT02133716|Behavioral|sucrose 24% oral|The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.
A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment.
213443|NCT02133729|Other|Blood sampling and OGTT|
213444|NCT02133742|Drug|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
213445|NCT02133742|Drug|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
213750|NCT02125760|Other|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
213751|NCT02125773|Behavioral|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
213752|NCT02125786|Radiation|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
213753|NCT02125786|Procedure|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
213147|NCT02138552|Drug|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
213148|NCT02138565|Procedure|Gastric by-pass surgery|
213149|NCT02138578|Radiation|SBRT|
213150|NCT02138578|Radiation|RFA|
213151|NCT02138591|Procedure|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
213152|NCT02138591|Procedure|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
213153|NCT02141191|Drug|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
213154|NCT02141204|Biological|Liquid Human Rotavirus Vaccine 444563|Oral administration
213155|NCT02141204|Biological|Lyophilized Human Rotavirus Vaccine 444563|Oral administration
213156|NCT02141217|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
213157|NCT02141217|Drug|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
213158|NCT02141230|Drug|Alli® 60 mg|Participants purchasing Alli®
213159|NCT02141243|Procedure|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
213160|NCT02141243|Procedure|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
213161|NCT02141243|Procedure|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
213162|NCT02141256|Dietary Supplement|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
213163|NCT00133445|Drug|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
213446|NCT02133755|Drug|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
212585|NCT02153619|Behavioral|questionnaires assessments|
212586|NCT02153632|Drug|Amantadine HCl ER (ALLAY-LID II)|
212587|NCT00134420|Drug|Nutropin AQ|
212588|NCT02153632|Drug|Placebo|
212870|NCT02146079|Drug|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
212871|NCT02146092|Procedure|Incentive spirometry|
212872|NCT02146092|Other|Physiotherapy|Standard of care exercise training and supervision
212873|NCT02146105|Other|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
212874|NCT02146118|Drug|Erlotinib|Erlotinib 150 mg/day q 4 weeks
212875|NCT00133887|Drug|rapamycin|3 to 5 mg/day
212876|NCT02148523|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
212877|NCT00134017|Drug|busulfan|
212878|NCT02148536|Procedure|Transjugular intrahepatic portosystemic shunt|
212879|NCT02148549|Drug|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
212880|NCT02148575|Behavioral|Self-Management Group|
212881|NCT02148575|Behavioral|Symptom Management Group|
212882|NCT02148588|Drug|Ultrasound-guided peripheral nerve block with 2% lidocaine|Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)
Assessment of spontaneous and evoked pain responses
Completion of NPSI questionnaire
Mapping of the affected limb
212883|NCT02148601|Other|Fecal Microbiota Transplantation|
212884|NCT02148601|Drug|Standard Antibiotic Therapy|
212885|NCT02148601|Drug|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
212280|NCT00002234|Drug|Didanosine|
212281|NCT00131326|Device|Synvisc (hylan G-F 20)|
212282|NCT02120638|Drug|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, ＞70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, ＞70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, ＞50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
212283|NCT02120638|Drug|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, ＞70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, ＞50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
212284|NCT02120651|Procedure|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
212285|NCT02120651|Procedure|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
212286|NCT02120664|Drug|Florbetapir (18F)|
212287|NCT02120664|Drug|11C-PiB|
212589|NCT02153645|Drug|Amantadine ER Tablets|
212590|NCT02153645|Drug|Placebo Tablets for Amantadine ER Tablets|
212591|NCT02153658|Procedure|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
212592|NCT02153658|Procedure|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
212593|NCT02115854|Other|labial biopsy|
212594|NCT02115867|Dietary Supplement|Probiotic|Symprove probiotic
212595|NCT02115880|Behavioral|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
212596|NCT02115893|Dietary Supplement|Sodium Nitrate|
212597|NCT02115893|Dietary Supplement|Sodium Chloride|
212598|NCT02115906|Other|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
212599|NCT00130910|Drug|Placebo|Albendazole Placebo 400mg x 3 first dose observed
211983|NCT02127814|Dietary Supplement|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
211984|NCT02127827|Device|Automated Ambulatory Glycemic Controller (AAGC)|
211985|NCT02127840|Drug|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
211986|NCT02127853|Drug|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
211987|NCT02127853|Drug|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
211988|NCT02127866|Drug|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
211989|NCT02127866|Drug|Foster 100/6 µg|Active comparator
Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
211990|NCT02127879|Device|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
211991|NCT02127879|Device|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
211992|NCT00132080|Drug|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
212288|NCT02120677|Drug|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
212289|NCT02122952|Biological|scAAV9.CB.SMN|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
212290|NCT00131547|Behavioral|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
212291|NCT02122965|Other|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
212292|NCT02122978|Behavioral|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
211374|NCT02140372|Drug|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
211661|NCT02135302|Drug|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
211662|NCT02135315|Drug|Isosorbide Dinitrate|continuous infusion of Isosorbide dinitrate (40 mg per 40 ml) depending on the systolic blood pressure value.
SBP: under 120 mmHg : no drug SBP: 120 to 130: 1 mg per hour SBP: 130 to 140: 2 mg per hour SBP: 140 to 150: 3 mg per hour SBP: 150 to 160: 4 mg per hour SBP: above 160 mmHg : 6 mg per hour
211663|NCT02135315|Drug|Labetalol|continuous infusion of Labetalol (TRANDATE) is used if the arterial pressure objectives are not reached with the Isosorbide Dinitrate alone.
Dilution Labetalol: 200 mg in 40 ml: 4mg per ml SBP: under 110 mmHg: no drug SBP: 110 to 130: 4 mg per hour SBP: 130 to 150: 8 mg per hour SBP: above 150 mmHg: 16 mg per hour
211664|NCT02135328|Behavioral|Radio Story|For the purposes of this study a "Radio Story" is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management.
211665|NCT02135328|Behavioral|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
211666|NCT00132899|Drug|Methotrexate|Methotrexate and infliximab combination
211667|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
211668|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
211669|NCT02135354|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
211670|NCT02135354|Drug|Placebo|From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
211671|NCT02135367|Biological|PRP|injections of Platelet rich Plasma
211672|NCT02135380|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
211673|NCT02135380|Biological|Autologous Adipose Derived MSCs (ADMSCs)|Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
211674|NCT02135380|Other|Control|Standard Therapy
205968|NCT02103647|Drug|sustained release tablet|sustained release tablet
205969|NCT02106208|Other|CHO diet|
205970|NCT02106208|Other|MUFA diet|
205971|NCT02106208|Other|PUFA diet|
205972|NCT02106221|Other|Intervention|Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
205973|NCT02106221|Other|Control|Will receive payments based on achievement in meeting goals.
205974|NCT02106234|Other|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
205975|NCT00129805|Drug|Aspirin|
205976|NCT02106247|Drug|BI 1181181 high dose|two tablet
205977|NCT02106247|Drug|BI 1181181 low dose|one tablet
206285|NCT02099032|Other|5g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
206286|NCT02099032|Other|Unfortified cheese product consumption|Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
206287|NCT02099045|Device|Point of Care Ultrasonography|
206288|NCT02099058|Drug|ABBV-399|It is administered by infusion in 21-day dosing cycles.
206289|NCT02099058|Drug|Erlotinib|It is administered orally everyday.
206290|NCT02099058|Drug|Cetuximab|It is an intravenous infusion administered every 7 days.
206291|NCT02099058|Drug|Bevacizumab|It is an intravenous infusion administered every 21 days.
206292|NCT02099058|Drug|Nivolumab|It is an intravenous infusion administered every 14 days.
206293|NCT00129051|Procedure|Tomotherapy|
206294|NCT02099058|Drug|ABBV-399|It is administered by infusion in 28-day dosing cycles.
206295|NCT02099071|Drug|ACT-389949 1 mg|
206296|NCT02099071|Drug|ACT-389949 5 mg|
205696|NCT02113098|Other|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
205697|NCT02113111|Behavioral|Fasting|Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
205698|NCT02113137|Drug|group 1: drug: chlorine dioxide|First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.
group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.
At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing.
205699|NCT00002230|Drug|Didanosine|
205700|NCT00130611|Other|BNP measurement|
205701|NCT02113137|Device|group 2: device: small tooth brush for tongue cleaning|First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.
group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.
At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing.
205702|NCT02113150|Drug|remifentanil|renal function
205703|NCT02113150|Drug|Ketamine|renal function
205704|NCT02113163|Drug|Metformin Eicosapentaenoate|
205705|NCT02113163|Drug|Metformin HCl and Vascepa|
205706|NCT02113176|Drug|Minocycline|
205707|NCT02113189|Other|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
205708|NCT02076165|Behavioral|Behavioral treatment for insomnia-Group I|Participants will attend 5 individual sessions with a trained instructor.
205709|NCT02076165|Behavioral|Behavioral treatment for insomnia-Group II|Participants will attend in 5 individual sessions with a trained instructor.
205978|NCT02106247|Drug|Placebo|tablet
205979|NCT02106260|Drug|CLS003|
205980|NCT02106273|Device|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
205981|NCT02106273|Device|LMA-ProsealTM|
205982|NCT02106286|Drug|Bisoprolol|
205400|NCT02084017|Device|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
205401|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 15 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
205402|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 25 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
205403|NCT02084056|Drug|Linagliptin|Linagliptin
205404|NCT02084056|Drug|Metformin|Metformin
205405|NCT00127530|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
205406|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
205407|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
205408|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
205409|NCT02084056|Drug|Linagliptin|Linagliptin
205410|NCT02084056|Drug|Metformin|Metformin
205411|NCT02084056|Drug|Metformin|Metformin
205412|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
205413|NCT02084056|Drug|Linagliptin|Linagliptin
205414|NCT02084056|Drug|Metformin|Metformin
205415|NCT02084056|Drug|Linagliptin|Linagliptin
205416|NCT00127530|Drug|Placebo|sugar pill, twice a day (b.i.d.)
205417|NCT02084069|Drug|Atorvastatin|
205418|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
205419|NCT02084082|Drug|Linagliptin|1x Linagliptin tablet
205420|NCT02084082|Drug|Linagliptin|1x Linagliptin tablet
205421|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
204806|NCT02098512|Procedure|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
204807|NCT02098512|Drug|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
204808|NCT00128947|Drug|Mycophenolate 7-O-Phenolic Glucuronide|
205111|NCT02091115|Dietary Supplement|dairy drink with probiotic culture|The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
205112|NCT02091115|Dietary Supplement|Dairy drink|
205113|NCT02091141|Drug|Erlotinib [Tarceva]|A daily dose of 150 mg given orally in cycles of 28 days (4 weeks) duration
205114|NCT02091141|Drug|Pertuzumab [Perjeta]|An 840 mg IV loading dose, followed by 420 mg, given by IV every 3 weeks
205115|NCT00128453|Drug|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients>70Kg) or 0.5mg once daily
205116|NCT02093585|Drug|tenofovir (245 mg QD)|
205117|NCT02093598|Drug|Temsirolimus|
205118|NCT02093611|Dietary Supplement|Placebo|
205119|NCT02093611|Dietary Supplement|ATP|400 mg of ATP
205120|NCT02093637|Other|Placebo acupuncture|Placebo Comparator
205121|NCT02093637|Other|Battlefield Acupuncture|Experimental
205122|NCT02093650|Drug|black cohosh extract|Black cohosh extract 80 mg
205123|NCT02093650|Drug|Placebo|Soy bean oil
205124|NCT02093663|Drug|MMX Mesalamine/Mesalazine|
205125|NCT02093676|Behavioral|experimental protocol treatment "The New Authority"|
205126|NCT00128453|Drug|Placebo|placebo
205127|NCT02093689|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
204498|NCT02027246|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
204499|NCT02027259|Behavioral|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
204500|NCT02027272|Drug|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
204501|NCT02027285|Dietary Supplement|fortified milk|"Fortified"Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus "placebo" Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) of the same manufacturer.
The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml.
204502|NCT00121810|Drug|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
204503|NCT02027298|Drug|Abatacept|by SC injection of 125 mg weekly for 6 months
204504|NCT02027311|Drug|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
204505|NCT02027311|Drug|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
204809|NCT00129220|Drug|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
204810|NCT02100618|Procedure|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
204811|NCT02100631|Biological|PXVX0200|
204812|NCT02100631|Biological|Placebo|
204813|NCT02100644|Drug|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
204814|NCT02100657|Drug|Plitidepsin|
204815|NCT02100657|Drug|Bortezomib|
204816|NCT02100657|Drug|Dexamethasone|
204817|NCT02100670|Drug|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
204194|NCT02034786|Procedure|Transdermal injection|Transdermal injection of hyaluronic acid only.
204195|NCT02034799|Biological|Bioseal Fibrin Sealant|
204196|NCT00122642|Procedure|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
204197|NCT02034799|Other|Standard of Care (SoC)|
204198|NCT02034812|Other|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
204199|NCT02034825|Other|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
204200|NCT02034838|Drug|atazanavir 300mg boosted with ritonavir 50 mg|atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.
atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)
204201|NCT02034864|Other|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
204202|NCT02034864|Other|Placebo of osteopathic manipulative treatment|A standardized placebo of manipulative treatment consisting in "light touch" and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment.
204203|NCT02034877|Biological|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
204204|NCT02034877|Procedure|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
204506|NCT02027311|Drug|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders > 80 years old were administered 25mg iv bolus.
204507|NCT02027324|Drug|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
204508|NCT02029638|Drug|Low dose Pre-transplant cyclophosphamide|Pre-transplant cyclophosphamide will be administered as an intravenous infusion over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplantation cyclophosphamide is 14.5 mg/kg/day.
204509|NCT02029638|Radiation|Total Body Irradiation|Total body irradiation, consisting of 200 centigray cGy AP/PA with 4MV or 6MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
204510|NCT02029638|Drug|Acetaminophen|650 mg orally prior to antithymocyte globulin infusion
203887|NCT02000037|Device|IR Reflexotherapy|18 IR reflexotherapy sessions :
Once a week for 12 weeks at the beginning of the study
Once a week for 3 weeks, 9 months after the beginning of the study
Once a week for 3 weeks, 15 months after the beginning of the study
203888|NCT02000037|Behavioral|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
203889|NCT02000050|Drug|FOLFOX4|FOLFOX4
203890|NCT02000050|Radiation|Tomotherapy|Tomotherapy
203891|NCT02000050|Procedure|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
203892|NCT02000076|Behavioral|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
203893|NCT02000089|Drug|Human synthetic secretin|I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
203894|NCT00119340|Drug|mycophenolate mofetil|
203895|NCT02000102|Drug|Intravitreal Injection of Aflibercept|
203896|NCT02000115|Device|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
203897|NCT02000115|Device|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
203898|NCT02000128|Device|bioimpedance monitoring|
203899|NCT02000128|Other|clinical monitoring|clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
203900|NCT02000141|Procedure|Endoscopic Mucosal Resection|
203901|NCT02000154|Drug|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
204205|NCT02034890|Drug|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
204206|NCT02034903|Other|Feedings warmed with commercial warmer|
204207|NCT00122642|Drug|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
208617|NCT02077556|Drug|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell < 4000/mcL)
203902|NCT02000180|Behavioral|Progressive Group|
203903|NCT02000193|Drug|fulvestrant|Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.
The treatment will continue until disease progression or intolerable AE.
203904|NCT02000206|Drug|Propofol|
203905|NCT00119340|Procedure|peripheral blood stem cell transplantation|
203906|NCT02000206|Drug|Ketamine|
203907|NCT02000206|Drug|Alfentanil|
203908|NCT02002884|Drug|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% odium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
203909|NCT02002884|Drug|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
203910|NCT02002897|Device|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
203911|NCT02002897|Device|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
203912|NCT00119509|Procedure|Conventional management (repeat Pap smear at 6 months)|
203913|NCT02002923|Procedure|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
203914|NCT02002923|Drug|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
203915|NCT02002936|Drug|SyB C-1101|SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.
The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).
From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
209274|NCT02110212|Procedure|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
209275|NCT02110212|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
209276|NCT02110225|Drug|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
209277|NCT02110225|Drug|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
209278|NCT02110225|Drug|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
209579|NCT00129415|Procedure|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
209580|NCT02102789|Drug|HAI|Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
209581|NCT02102802|Drug|Low or Medium dose MDMA|Participants receiving 30 or 75 mg MDMA
209582|NCT02102802|Drug|Full dose MDMA|Participants receiving 125 mg MDMA
209583|NCT02102815|Drug|Dexamethasone|Dexamethasone 8-12 mg mixed with NSS up to 50 mL IV slowly push over 5 minutes
209584|NCT02102815|Drug|Normal saline|NSS 50 mL IV slowly push over 5 minutes
209585|NCT02102828|Device|extended compression & aspirin|Home use of extended compression therapy
209586|NCT02102828|Drug|Aspirin only|Subjects will receive standard therapy of aspirin; no extended compression
209587|NCT02102841|Procedure|Skin biopsy|
209588|NCT02102841|Procedure|Skin suction blister|
209589|NCT02102841|Biological|Mantoux test|
209590|NCT00002224|Drug|Stavudine|
209591|NCT00129415|Procedure|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
209592|NCT02102854|Drug|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent & treat acute rejection in organ transplantation
209593|NCT00002225|Drug|Stavudine|
209594|NCT00129714|Other|cervical collar|
208963|NCT02114502|Drug|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
208964|NCT02114502|Drug|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
208965|NCT02114502|Drug|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
208966|NCT02114502|Drug|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
208967|NCT02077634|Drug|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
208968|NCT02077634|Drug|abiraterone acetate + prednisone|ormon therapy will be stopped
208969|NCT02077660|Dietary Supplement|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
208970|NCT02077660|Other|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
208971|NCT02077686|Behavioral|Education - Diabetes and Travel|Based on the treatment and education programme PRIMAS a problem-specific education module regarding "Diabetes and Travel" was created. The module covers specific and detailed aspects of the topic "travel" such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible.
208972|NCT02077699|Dietary Supplement|Lactobacillus casei DG|Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
208973|NCT00126854|Procedure|Magnetic Resonance Spectroscopy Imaging|
208974|NCT02077712|Drug|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
209279|NCT02110238|Device|Supartz, 2.5 ml unit dose|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2. Subjects will be observed an additional 24 weeks. Participation will be approximately 28 weeks (including the screening period) for the duration of the study.
209280|NCT02110238|Device|Euflexxa, 2 ml unit dose|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2. Subjects will be observed an additional 24 weeks. Participation will be approximately 28 weeks (including the screening period) for the duration of the study.
209281|NCT00130247|Drug|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
209282|NCT02110251|Behavioral|Supervised Exercise Therapy|
209283|NCT02110264|Drug|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
209284|NCT02110264|Behavioral|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
213754|NCT02125799|Device|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
213755|NCT00131898|Procedure|Intensity Modulated Radiation Therapy (IMRT)|
213756|NCT02128568|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
213757|NCT02128581|Drug|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
213758|NCT02128581|Other|Saline|
213759|NCT02128594|Behavioral|Serosorting Intervention|Single session, behavioral intervention
213760|NCT00132145|Behavioral|Automated Telephone Reminder System|
213761|NCT02128607|Device|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
213762|NCT02128607|Device|Sham|
213763|NCT02128620|Behavioral|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
213764|NCT02128633|Drug|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
213765|NCT02128633|Drug|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
213766|NCT02128633|Drug|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
208975|NCT02077725|Other|interdisciplinary polypharmacy clinic visit|
208976|NCT02077738|Device|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
208977|NCT02077751|Drug|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
208978|NCT02077764|Procedure|OCT and coronary angiography|
208979|NCT02077764|Procedure|Right heart cat.|
208980|NCT02077764|Radiation|PET|
213447|NCT02133781|Biological|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
213448|NCT02133781|Biological|Flumist® 2009-2010 Formula|This vaccine is given intranasally
213449|NCT00132730|Drug|MK-0873 0.75 mg|
213450|NCT02133794|Device|Tomosynthesis|
213451|NCT02133807|Procedure|Specific Lp(a) apheresis|Specific Lp(a) apheresis procedures were carried out weekly with "Lp(a) Lipopak" columns (POCARD Ltd., Moscow, Russia) according to the standard protocol
213452|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fasted|
213453|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fed|
213454|NCT02133820|Drug|12 hourly capsule strong painkiller with antagonist fasted)|
213455|NCT02133820|Drug|4 mg 12 hourly capsule strong painkiller with antagonist fed|
213456|NCT02136030|Drug|Liposomal amphotericin B|4mg/kg/day, IV infusion
213457|NCT00132990|Device|Deep brain stimulation|
213458|NCT02136030|Drug|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
213459|NCT02136043|Device|PBASE system 1.1 (active treatment)|
213460|NCT02136056|Behavioral|Chronic disease self-management program (CDSMP)|A self-management course
213461|NCT02136069|Drug|etrolizumab|105 mg administered by subcutaneous injection every four weeks until Week 52
213462|NCT02136069|Drug|infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
213463|NCT02136069|Other|placebo (IV)|Administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
213464|NCT02136069|Other|placebo (injection)|administered by subcutaneous injection every four weeks until Week 52
213465|NCT02136082|Behavioral|Asha Support + Training|
213466|NCT02136082|Behavioral|Asha Support + Food|
213467|NCT02136082|Behavioral|Asha Support + Training + Food|
213468|NCT00133003|Drug|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute [maximum, 10 microg/min] infusion for 12 hours, plus heparin, 70 U/kg of body weight
212886|NCT02148614|Drug|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
212887|NCT02148614|Drug|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
212888|NCT00002255|Drug|Filgrastim|
212889|NCT00134017|Drug|cyclophosphamide|
212890|NCT02148627|Drug|LY3041658 (SC)|Administered SC
212891|NCT02148627|Drug|LY3041658 (IV)|Administered as slow IV infusion
213164|NCT02141282|Drug|ABT-199|ABT-199 monotherapy
213165|NCT02141295|Drug|5-fluorouracil (5-FU)|A 400 mg/m2 starting bolus followed by 2400 mg/m2 given by IV Q2W.
213166|NCT02141295|Drug|RO5520985|2000 mg given by intravenous (IV) infusion once every two weeks (Q2W)
213167|NCT02141295|Drug|bevacizumab [Avastin]|5 mg/kg given by IV Q2W
213168|NCT02141295|Drug|folinic acid|400 mg/m2 given by IV Q2W
213169|NCT02141295|Drug|oxaliplatin|85 mg/m2 given IV Q2W
213170|NCT02141321|Drug|Misoprostol|
213171|NCT02141321|Drug|Placebo|
213172|NCT02141347|Drug|Tremelimumab|Tremelimumab administered intravenously
213173|NCT02141347|Drug|MEDI4736|MEDI4736 administered intravenously.
213174|NCT00133458|Drug|Albendazole|
213175|NCT02141360|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
213176|NCT02141373|Device|Glubran 2|
213177|NCT02141386|Other|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
213178|NCT02141399|Drug|ALKS 5461|Sublingual tablet, taken daily
213179|NCT02143674|Other|Educated about physical exercises|
213180|NCT02143687|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
212600|NCT02115906|Other|oral glucose tolerance testing|In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.
Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling.
212601|NCT02115906|Other|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
212602|NCT02115919|Drug|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
212603|NCT02115919|Drug|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
212604|NCT02115932|Other|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
212892|NCT02148627|Drug|Placebo|Administered as slow IV infusion
212893|NCT02148640|Drug|Innovator infliximab|
212894|NCT02148640|Drug|Biosimilar infliximab|
212895|NCT02148653|Other|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
212896|NCT02148653|Other|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
212897|NCT02148679|Other|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
212898|NCT02148692|Procedure|Higher PEEP|
212899|NCT02148692|Procedure|Lower PEEP|
212900|NCT00134017|Drug|mycophenolate mofetil|
212901|NCT02148705|Drug|NexoBrid|
212293|NCT02122978|Behavioral|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
212294|NCT02122978|Behavioral|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
212295|NCT02123004|Drug|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
212296|NCT02123004|Drug|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
212297|NCT02123017|Drug|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
212298|NCT02123017|Drug|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
212299|NCT02123017|Drug|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
212300|NCT02123043|Behavioral|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
212301|NCT00131560|Genetic|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
212302|NCT02123043|Behavioral|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
212303|NCT02123056|Drug|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
212304|NCT02123069|Device|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
212305|NCT02123069|Drug|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
212605|NCT02115945|Other|DN4 test|The DN4 test was used to evaluate neuropathic pain.
212606|NCT02115945|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
212607|NCT02115945|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
212608|NCT02115945|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
212609|NCT02115945|Procedure|femoral block|
211675|NCT02135393|Dietary Supplement|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
211676|NCT02135406|Biological|CART-19 T cells|
211993|NCT02127892|Biological|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
211994|NCT02130271|Radiation|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
211995|NCT02130271|Other|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
211996|NCT00132405|Drug|ALGRX 3268|
211997|NCT02130284|Device|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
211998|NCT02130297|Device|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
211999|NCT02130310|Biological|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
212000|NCT02130310|Other|Placebo injection|Normal saline injected at each centimeter of ulcer bed
212001|NCT02130323|Drug|Imiquimod|12.5mg (5%) once a week vaginally for 16 weeks
212002|NCT02130323|Procedure|Loop Electrosurgical Excision Procedure|Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
212003|NCT02130336|Behavioral|Aerobic interval training|
212004|NCT02130336|Behavioral|Continuous moderate-intensity exercise|
212005|NCT02130375|Procedure|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
212006|NCT02130388|Dietary Supplement|Zinc|
212007|NCT00132418|Drug|Enbrel|Enbrel
206297|NCT02099071|Drug|ACT-389949 20 mg|
206298|NCT02099071|Drug|ACT-389949 50 mg|
206299|NCT02099071|Drug|ACT-389949 100 mg|
206300|NCT02099071|Drug|ACT-389949 200 mg|
206301|NCT02099071|Drug|ACT-389949 500 mg|
206302|NCT02099071|Drug|ACT-389949 1000 mg|
206303|NCT02099071|Drug|Placebo|
206304|NCT00129064|Behavioral|Electronic referral system|
206305|NCT02101372|Behavioral|treatment as usual|case management
206306|NCT02101372|Behavioral|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
206307|NCT02101385|Drug|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
206308|NCT02101385|Other|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
206593|NCT02094300|Device|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
206594|NCT02094313|Drug|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
206595|NCT02094339|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
206596|NCT00128505|Drug|Mifepristone|
206597|NCT02094339|Procedure|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
206598|NCT02094339|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
205983|NCT02106299|Device|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
205984|NCT02106299|Device|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
205985|NCT02106312|Radiation|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
205986|NCT00129818|Drug|Famciclovir|
205987|NCT02106325|Drug|Ketamine|IV of Ketamine (.25mg/kg)
205988|NCT02106325|Drug|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
205989|NCT02106338|Other|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
205990|NCT02106338|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
205991|NCT02106351|Drug|AbobotulinumtoxinA Dysport®|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
205992|NCT02106364|Drug|Insulin Peglispro|Administered SQ
205993|NCT02106364|Drug|Insulin Glargine|Administered SQ
205994|NCT02108808|Drug|Ticagrelor|
205995|NCT02108808|Drug|Prasugrel or Clopidogrel|
205996|NCT00130117|Drug|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
205997|NCT02108821|Biological|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
206309|NCT02101398|Device|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
206310|NCT02101398|Device|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
206311|NCT02101398|Device|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
205422|NCT02084082|Drug|Linagliptin|Linagliptin
205710|NCT02076178|Drug|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
205711|NCT02076178|Drug|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
205712|NCT02076178|Drug|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
205713|NCT02076178|Drug|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
205714|NCT02076191|Drug|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
205715|NCT02076191|Drug|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
205716|NCT02076204|Behavioral|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
205717|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^11 DRP/mL
205718|NCT02076217|Drug|Copper T-380 IUD|
205719|NCT02076217|Drug|LNG IUD|
205720|NCT02076217|Device|Contraceptive implant Nexplanon|
205721|NCT02076217|Drug|Depo-Provera|
205722|NCT02076230|Drug|[14C] TH-302 (Label 1)|[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
205723|NCT02076230|Drug|[14C] TH-302 (Label 2)|[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
205724|NCT02076230|Drug|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
205725|NCT02076243|Drug|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
205128|NCT02093689|Drug|Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
205129|NCT02093702|Behavioral|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
205130|NCT02093702|Behavioral|Unstructured Physical Activity and Exercise Education|
205131|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
205132|NCT02093728|Drug|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
205423|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
205424|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
205425|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
205426|NCT02084082|Drug|Linagliptin|Linagliptin
205427|NCT00002213|Drug|Amprenavir|
205428|NCT02086097|Drug|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
205429|NCT00127803|Biological|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
205430|NCT02086097|Drug|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
205431|NCT02086097|Drug|PLACEBO|INACTIVE SUGAR PILLS
205432|NCT02086110|Dietary Supplement|Synbiotic|
205433|NCT02086110|Dietary Supplement|Prebiotic|
205434|NCT02086123|Procedure|Epidural Analgesia|Bupivacaine + Fentanyl
205435|NCT02086123|Procedure|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
205436|NCT02086149|Behavioral|Aerobic Exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
205437|NCT02086149|Behavioral|Health Education|12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
205438|NCT02086162|Behavioral|Web-based motivational decision support system|
204818|NCT02100670|Drug|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
204819|NCT02100670|Drug|3% menthol|To be applied four times daily for 10 days.
204820|NCT00129220|Drug|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
204821|NCT02100670|Drug|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
204822|NCT02100696|Drug|etrozulimab|105 mg administered by subcutaneous injection every 4 weeks
204823|NCT02100696|Drug|placebo|administered by subcutaneous injection every 4 weeks
204824|NCT02100709|Device|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
204825|NCT02100722|Procedure|FFR guided PCI|
204826|NCT02100722|Procedure|CABG|
204827|NCT02100735|Other|Sedation protocol|
204828|NCT02100748|Drug|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
204829|NCT02100748|Drug|Morphine|Morphine 4 mg will be administered every 4 hours
204830|NCT02100748|Drug|Placebo|Placebo will be administered every 4 hours
204831|NCT00129220|Drug|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
205133|NCT02093728|Drug|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
205134|NCT02093728|Drug|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
205135|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
205136|NCT02093728|Drug|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
205137|NCT00128466|Drug|gentamicin|
205138|NCT02093728|Drug|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
205139|NCT02093728|Drug|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
204511|NCT02029638|Drug|Diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
204512|NCT02029638|Drug|Methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
204513|NCT02029638|Biological|Bone Marrow|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0
204514|NCT00122096|Drug|valdecoxib|
204515|NCT02029638|Drug|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
204516|NCT02029638|Drug|Mycophenolate mofetil (MMF)|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
204517|NCT02029638|Drug|Prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
204518|NCT02029638|Drug|Filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day -5 until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
204519|NCT02029638|Drug|High dose post-transplant cyclophosphamide|High dose post- transplant cyclophosphamide [50mg/kg (Ideal Body Weight)] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume.
204520|NCT02029651|Device|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
204521|NCT02029651|Procedure|Conventional occupational therapy|conventional occupational therapy
204522|NCT02029664|Device|Visual distortion increment based on the gait pattern|
204523|NCT02029690|Drug|ADI-PEG 20|
204524|NCT02029703|Device|Synvisc-One Injection|
204832|NCT02100761|Drug|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance <50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
204833|NCT02100787|Other|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
204834|NCT02100800|Other|MR and CT measurements of emphysema quantification|
204208|NCT02034916|Drug|talazoparib|
204209|NCT01995227|Biological|AlloStim|ID injections IV infusion
204210|NCT01995240|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
204211|NCT01995253|Device|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
204212|NCT01995253|Device|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
204213|NCT01995266|Drug|Asunaprevir|
204214|NCT01995266|Drug|Daclatasvir|
204215|NCT01995279|Device|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
204216|NCT00118950|Drug|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
204217|NCT01995279|Other|Sham Ultrasound|Ultrasound turned off.
204218|NCT01995292|Device|bronchoscope|
204219|NCT01995292|Device|Enk Fiberoptic Atomizer|
204220|NCT01995305|Genetic|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
204221|NCT01995305|Genetic|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
204222|NCT01995318|Other|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
204223|NCT01995331|Drug|cyclophosphamide,cyclosporine A|Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.
Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was >1×109/L.
204525|NCT00122109|Behavioral|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
203916|NCT02002949|Procedure|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
204224|NCT01995344|Drug|Cyclophosphamide|
204225|NCT01995344|Drug|Fludarabine|
204226|NCT01995344|Genetic|Tumour Infiltrating Lymphocytes|
204227|NCT00118950|Drug|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
204228|NCT01995344|Drug|Interleukin-2|
204229|NCT01995357|Device|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
204230|NCT01995357|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
204231|NCT01995357|Device|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
204232|NCT01997775|Drug|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 > 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
204233|NCT01997788|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
204234|NCT01997788|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
204235|NCT01997788|Drug|Demerol on demand|Demerol 25 mg intravenously when pain scores more than 5.
204236|NCT01997801|Drug|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
204237|NCT01997801|Drug|NS infusion|Normal saline will be infused intraoperatively.
204238|NCT01997814|Drug|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
204239|NCT00119158|Drug|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
204240|NCT01997814|Drug|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
209595|NCT02105233|Biological|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
209596|NCT02105246|Behavioral|Home-based cardiac rehabilitation|The intervention is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
209597|NCT02105246|Behavioral|Center-based cardiac rehabilitation|The intervention is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
209598|NCT02105259|Behavioral|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
209599|NCT02105259|Other|Waiting list|Waiting list, where participants wait for delayed treatment
209600|NCT02105272|Drug|OPC-1085EL ophthalmic solution|
209601|NCT02105272|Drug|Latanoprost ophthalmic solution|
209891|NCT02098187|Device|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and Iohexol, four of the ORFM sensor probes will be affixed to each of the subjects. Four separate sensor probes will be attached via standard adhesive pads to four locations on each subject: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and Iohexol infusion should occur at least 15 minutes after the start of the data acquisition software.
209892|NCT02098187|Other|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) will be administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
209893|NCT00128908|Drug|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
209894|NCT02098200|Device|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
209895|NCT02098213|Other|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
209896|NCT02098213|Other|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
209897|NCT02098239|Drug|G17DT|
209898|NCT02098252|Procedure|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
209899|NCT02098252|Radiation|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
209900|NCT02098252|Procedure|Embolization|Curative embolization, when the lesion is considered curable by embolization.
209901|NCT02098265|Device|Transcranial Magnetic Stimulation|Electrical stimulation of the brain, through direct cortical stimulation
209285|NCT02110264|Behavioral|ETAU|Participants assigned to the ETAU group will receive drug education.
209286|NCT02110277|Device|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
209287|NCT02110303|Drug|Ticagrelor|oral, 90mg tablets, twice daily, 12 month duration
209288|NCT02110303|Drug|Placebo|Oral tablet (identical to ticagrelor), twice daily, 12 month duration
209289|NCT02110316|Other|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
209290|NCT02110329|Genetic|evaluation of the recurrence rate according to molecular analysis|
209291|NCT02110342|Drug|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of [14C] PF-04449913
209292|NCT00130247|Drug|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
209293|NCT02112240|Drug|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
209294|NCT02112240|Other|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
209295|NCT02112240|Procedure|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
209296|NCT02112240|Radiation|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
209297|NCT02112253|Device|Deep brain stimulator ventral electrode up to 2 mA|
209298|NCT00130494|Drug|Zoledronic acid|
209299|NCT02112253|Device|Deep brain stimulator ventral electrode up to 3 mA|
209602|NCT02105285|Drug|OPC-1085EL ophthalmic solution|
209603|NCT02105285|Drug|Carteolol long-acting ophthalmic solution|
209604|NCT02105311|Device|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
209605|NCT00129714|Other|physiotherapy|
209606|NCT02105311|Drug|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
208981|NCT02077764|Procedure|Echocardiography|
208982|NCT02077764|Procedure|exercise test|
208983|NCT02077764|Other|blood samples|
208984|NCT00126880|Drug|AVX754|apricitabine, 600mg BID or 800mg BID
208985|NCT02077777|Drug|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
208986|NCT02077790|Device|CASIA Cornea/Anterior Segment OCT SS-1000|The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of "Swept Source" OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second.
208987|NCT02077803|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
208988|NCT02077803|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
208989|NCT02077803|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
208990|NCT02077803|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
208991|NCT02077829|Behavioral|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
208992|NCT02080130|Dietary Supplement|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
208993|NCT02080130|Other|Placebo|Placebo
208994|NCT02080143|Device|Thermal Adhesion Patch|
208995|NCT02080143|Device|Thermal Adhesion Patch|
208996|NCT00127166|Drug|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
209300|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 2 mA|
209301|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 3 mA|
209302|NCT02112253|Device|Deep brain stimulator empirical programming|
209303|NCT02112266|Other|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
213469|NCT02136082|Behavioral|Asha Support Only|
213767|NCT02128646|Drug|EXPAREL|
213768|NCT02128646|Drug|Ketorolac|
213769|NCT02128646|Procedure|laparoscopic abdominal hernia repair|
213770|NCT02128646|Procedure|an open surgery for abdominal hernia repair|
213771|NCT00132158|Drug|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
213772|NCT02128659|Behavioral|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
213773|NCT02128672|Procedure|Spinal Cord Stimulator Lead Placement|
213774|NCT02128685|Drug|Dydrogesterone|
213775|NCT02128685|Drug|Placebo|
213776|NCT02128698|Dietary Supplement|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
213777|NCT02128698|Dietary Supplement|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
213778|NCT02128698|Behavioral|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
213779|NCT02128698|Behavioral|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
213780|NCT02128724|Drug|BKM120|BKM120 is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). BKM120 is supplied as 10mg and 50mg hard gelatin capsules.
213781|NCT02130986|Other|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (<1 hour goal) provide clinicians the procalcitonin result.
213782|NCT02130986|Other|Provide procalcitonin guideline to treating clinician|Procalcitonin antibiotic guideline --
Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation
< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)
0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)
> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)
> 0.5 -- Very likely -- Antibiotics strongly recommended(2)
Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.
For outpatients, antibiotic duration based on level (> 0.25-0.5 ug/L:3 days; > 0.5-1.0 ug/L:5 days; >1.0 ug/L:7 days). Physician follow-up is recommended.
213783|NCT02130986|Other|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
213784|NCT02130999|Drug|tasimelteon 20 mg capsule|
213181|NCT02143687|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
213182|NCT02143687|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
213183|NCT02143687|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
213184|NCT00133601|Behavioral|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
213185|NCT02143700|Other|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
213186|NCT02143713|Drug|Elagolix|Two different doses with matching placebo (to maintain blind) daily in two different arms over a 6-Month Treatment Period
213187|NCT02143726|Drug|sorafenib|Given PO
213470|NCT02136095|Procedure|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
213471|NCT02136108|Other|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
213472|NCT02136108|Other|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
213473|NCT02136121|Device|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
213474|NCT02136134|Drug|Daratumumab|Daratumumab will be administered as an IV infusion at a dose of 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter.
213475|NCT02136134|Drug|VELCADE (Bortezomib)|VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
213476|NCT02136134|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
213477|NCT02136147|Drug|methylphenidate medication|
213478|NCT02136147|Drug|atomoxetine medication|
213479|NCT00133003|Drug|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
213480|NCT02136147|Drug|lisdexamphetamine medication|
213481|NCT02136160|Behavioral|attitude change, behavioral change|
213482|NCT02136160|Behavioral|prevention program|
212902|NCT02151084|Drug|Cisplatin|
212903|NCT02151084|Drug|Gemcitabine|
212904|NCT02151110|Biological|MEDI4920|CD40L antagonist
212905|NCT02151110|Other|Placebo|0.9% saline for injection
212906|NCT02151136|Drug|TootSweet (24% sucrose)|
212907|NCT00134134|Drug|efalizumab|
212908|NCT02151136|Drug|Sterile water|
212909|NCT02151136|Other|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
212910|NCT02151149|Drug|nab-paclitaxel|
212911|NCT02151149|Drug|Carboplatin|
212912|NCT02151162|Behavioral|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
212913|NCT02151162|Dietary Supplement|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
213188|NCT02143726|Drug|everolimus|Given PO
213189|NCT02143752|Behavioral|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
213190|NCT02143752|Behavioral|Quit Line|see arm
213191|NCT02143765|Drug|Mitiglinide|three times a day, orally, for 12 weeks
213192|NCT02143765|Drug|Acarbose|three times a day, orally, for 12 weeks
213193|NCT02143778|Device|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
213194|NCT02143791|Procedure|Burst stimulation|
213195|NCT00133614|Procedure|Prone Positioning|
213196|NCT02143791|Device|Prodigy system|
213197|NCT02143804|Biological|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
212610|NCT00130923|Drug|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
212611|NCT02115945|Procedure|epidural block|
212612|NCT02115958|Biological|cancer stem cell vaccine|
212613|NCT02118311|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
212614|NCT02118324|Behavioral|Exergaming Program|Participants will exercise through exergaming play.
212615|NCT02118337|Biological|MEDI0680 (AMP-514): MEDI0680 and AMP-514 are interchangable nomenclature|anti-PD-1
212616|NCT02118337|Biological|MEDI4736|anti-PD-L1
212617|NCT02118350|Behavioral|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
212618|NCT00002234|Drug|Efavirenz|
212619|NCT00131066|Other|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
212620|NCT02118376|Drug|Exenatide|5ug bid,Subcutaneous injection
212621|NCT02118389|Dietary Supplement|Glucerna|Glucerna 52g meal replacement
212622|NCT02118402|Dietary Supplement|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
212623|NCT02118415|Other|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
212624|NCT02118428|Device|Mirasol-treated Whole Blood|Fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
212625|NCT02118428|Other|Untreated Whole Blood|Fresh Whole Blood for transfusion
212626|NCT02118441|Device|Ultrasound-guided Radial Artery Catheter Insertion|
212627|NCT02118441|Device|Direct Palpation-guided Radial Artery Catheter insertion|
212628|NCT02118454|Behavioral|Daily IVR Calls Intervention|
212914|NCT02151162|Behavioral|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
212915|NCT02151162|Dietary Supplement|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
212008|NCT02130401|Device|TNM (thermoneuromodulation device)|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
212009|NCT02130414|Drug|Sandimmun® IV|2 mg/kg IV
212010|NCT02130414|Drug|CyCol® capsules|37.5 mg CyCol® capsules
212011|NCT02130427|Radiation|Radiation Therapy|
212012|NCT02130440|Drug|Resveratrol nasal spray|
212013|NCT02130453|Drug|Regadenoson|0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
212306|NCT02123069|Drug|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
212307|NCT02123069|Drug|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
212308|NCT02123069|Drug|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
212309|NCT02123082|Device|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
212310|NCT02125032|Device|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
212311|NCT02125032|Device|Placebo Transcranial low voltage electromagnetic fields|
212312|NCT02125045|Dietary Supplement|L-GSH|Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
212313|NCT02125045|Dietary Supplement|Placebo|Placebo will be prepared using the same excipients of the dietary supplement without active substance.
212314|NCT02125058|Procedure|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
212315|NCT02125058|Procedure|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
212316|NCT02125071|Other|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
212317|NCT02125084|Drug|Everolimus|
212318|NCT02125084|Drug|Enzalutamide|
206599|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
206600|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
206601|NCT02094339|Drug|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
206602|NCT02094352|Drug|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
206603|NCT02094352|Drug|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
206604|NCT02094352|Drug|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
206605|NCT02094352|Drug|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
206606|NCT02094365|Drug|ALS-008176|
206607|NCT00128518|Drug|Indapamide (T2)|1.5 mg/day during 4 weeks
206608|NCT02094365|Drug|vehicle|
206609|NCT02094378|Drug|Esketamine|84 mg esketamine administered intranasally
206610|NCT02094378|Drug|Placebo|Placebo administered intranasally
206919|NCT02086955|Behavioral|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
206920|NCT02089009|Other|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
206921|NCT02089022|Other|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
206922|NCT02089035|Dietary Supplement|MUFA-rich dairy products (UHT milk, cheese and butter)|
206923|NCT02089035|Dietary Supplement|Conventional dairy products (UHT milk, cheese, butter)|
206924|NCT02089048|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
206925|NCT00127998|Drug|sulfadoxine-pyrimethamine+artesunate|
206926|NCT02089061|Drug|BMS-919373|
206312|NCT02101398|Device|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
206313|NCT00002223|Drug|Ritonavir|
206314|NCT00129272|Drug|Bupropion|150mg tablets taken orally twice daily.
206315|NCT02101398|Device|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
206316|NCT02101411|Drug|clopidogrel, ticagrelor, cilostazole|
206317|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
206318|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
206319|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
206320|NCT02101450|Procedure|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
206321|NCT02101463|Device|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
206322|NCT02101476|Drug|Percocet|10mg/650mg
206323|NCT02101476|Drug|Xartemis|15mg/650mg
206324|NCT02101489|Other|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
206325|NCT00129272|Drug|Placebo|Participants will receive placebo in this treatment group.
206326|NCT02101502|Other|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
206327|NCT02101515|Other|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
206328|NCT02101541|Procedure|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
206329|NCT02103660|Drug|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
206330|NCT02103660|Drug|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
205726|NCT02076256|Behavioral|The helping relationships intervention program|
205727|NCT02076269|Other|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
205998|NCT02108834|Procedure|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
205999|NCT02108834|Procedure|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
206000|NCT02108847|Drug|.2% Ropivacaine|
206001|NCT02108847|Drug|Saline|
206002|NCT02108847|Procedure|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
206003|NCT02108860|Drug|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
206004|NCT02108860|Drug|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
206005|NCT02108886|Drug|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
206006|NCT02108886|Drug|Placebo|empty capsule filled with sugar
206007|NCT00130143|Drug|Ethyol (Amifostine)|
206008|NCT02108886|Other|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
206009|NCT02108899|Behavioral|Retrieval practice effect using descriptive stories and free-call tests without feedback|In the first phase (encoding), people study 2 short prose passages covering general scientific topics.
In the second phase (initial test), they recall one text or restudy the other one.
In the third phase (final test) which takes place 2 days later, they recall both texts.
206010|NCT02108912|Other|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
206011|NCT02108912|Other|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
206012|NCT02108925|Drug|Oxygen|supplementary oxygen during exercise
205439|NCT02086162|Behavioral|NCI Education|
205440|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
205441|NCT02086175|Drug|Imprime PGG|
205442|NCT02086175|Drug|Rituximab|
205443|NCT02086188|Drug|Mirabegron|see detailed information in associated Arm Description
205444|NCT02086188|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
205445|NCT02086201|Behavioral|Problem Solving Therapy|
205446|NCT02086201|Behavioral|Engage|
205447|NCT02086214|Device|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
205728|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
205729|NCT02078921|Drug|Placebo|
205730|NCT02078934|Procedure|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
205731|NCT00126997|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
205732|NCT02078947|Behavioral|High Intensity Exercise|
205733|NCT02078947|Behavioral|Moderate Continuous Exercise|
205734|NCT02078947|Behavioral|Usual Care|
205735|NCT02078960|Drug|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
205736|NCT02078973|Drug|15 mg tolvaptan|15 mg pr day for 1 day
205737|NCT02078973|Drug|30 mg tolvaptan|30 mg pr day for 1 day
205738|NCT02078973|Drug|45 mg tolvaptan|45 mg pr day for 1 day
205739|NCT02078973|Drug|Placebo|1 tablet Unikalk pr day for 1 day
205740|NCT02078986|Other|Whole Body Electromyostimulation|Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks
205140|NCT02096133|Drug|Cholecalciferol|Vitamin D3 solution
205141|NCT02096133|Other|Placebo comparator|Placebo comparator
205142|NCT02096146|Procedure|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
205143|NCT02096146|Procedure|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
205144|NCT02096159|Drug|trimethoprim-sulfamethoxazole|
205145|NCT02096159|Other|placebo|
205146|NCT02096185|Radiation|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
205147|NCT02096185|Radiation|2 dimensional digital imaging|
205148|NCT02096211|Device|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
205149|NCT02096224|Drug|Sevoflurane|Sevoflurane will be used.
205150|NCT00128700|Procedure|adjuvant therapy|
205151|NCT02096224|Drug|Desflurane|Desflurane will be used
205152|NCT02096237|Device|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
205153|NCT02096250|Other|NaFeEDTA|
205154|NCT02096250|Other|Ferrous fumarate|
205155|NCT02096250|Other|NaFeEDTA + ferrous fumarate|
205156|NCT02096263|Biological|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
205448|NCT02086214|Device|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
205449|NCT02086227|Drug|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
205450|NCT02086227|Drug|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
205451|NCT00002215|Drug|Emivirine|
205452|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
204835|NCT02103114|Drug|Anti-thrombin III|If the Activated clotting time (ACT) is below the goal of 480 seconds the patient will first be given an additional dose of 200u/kg of heparin. If the patient's ACT remains below 480 seconds, they will be given 20ml/kg of Fresh Frozen Plasma (FFP). The above dose of heparin and FFP will be repeated until an ACT of greater than 480 seconds is achieved.
If Preoperative ATIII functional assay level is less than 70% - patients would be enrolled and randomized to either Placebo (normal saline) or ATIII. Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
expressed as a % normal level based on functional ATIII assay
204836|NCT00129454|Behavioral|Cognitive Behavioral Therapy|
204837|NCT02103114|Other|Placebo|Normal saline placebo
204838|NCT02103127|Device|755nm Alexandrite laser with lens array|
204839|NCT02103140|Other|Exergaming|The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months.
204840|NCT02103153|Device|Picosure Laser System|
204841|NCT02103166|Drug|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
204842|NCT02103166|Drug|Physiological serum|100 ml of physiological serum (0.9% NaCl).
204843|NCT02103179|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
204844|NCT02103192|Other|Anti-Oxidant Drink|
204845|NCT02103205|Dietary Supplement|Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin|
204846|NCT02103205|Dietary Supplement|Formula with low iron concentration (2mg/L) without lactoferrin|
204847|NCT00129467|Drug|Methylphenidate|Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.
If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.
Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is > 10 at day 18, the dose may be increased to 15 mg bid.
204848|NCT02103205|Dietary Supplement|Formula with normal iron concentration (8 mg/L) without lactoferrin|
205157|NCT02096263|Biological|Pediarix|3 doses administered intramuscularly in the right thigh
205158|NCT02096263|Biological|ActHIB|4 doses administered intramuscularly in the upper left thigh
205159|NCT02096263|Biological|Pentacel|4 doses administered intramuscularly in the right thigh
204526|NCT02029703|Other|Sham Injection|
204527|NCT02029716|Drug|RTA 408 Lotion 0.5%, 1%, 3%|
204528|NCT02029716|Drug|Lotion vehicle/placebo|
204529|NCT02029729|Drug|omaveloxolone|
204530|NCT02032290|Procedure|Percutaneous coronary intervention|
204531|NCT02032290|Drug|ticagrelor loading|
204532|NCT02032290|Drug|Clopidogrel loading|
204533|NCT02032303|Procedure|Assessment of coronary flow reserve|
204534|NCT02032303|Procedure|Percutaneous Coronary Intervention|
204535|NCT02032303|Drug|Ticagrelor loading|
204536|NCT02032303|Drug|Prasugrel loading|
204537|NCT00122447|Drug|Placebo|Identical placebo for each active comparator:
placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD
204538|NCT02032316|Device|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
204539|NCT02032329|Device|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
204540|NCT02032342|Device|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
204541|NCT02032342|Device|Arndt® blocker|Arndt® blocker for selective lobar deflation
204542|NCT02032342|Device|Cohen blocker|Cohen blocker for selective lobar deflation
204543|NCT02032342|Device|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
204544|NCT02032355|Procedure|spinal anesthesia|
204545|NCT02032368|Procedure|transarterial chemoembolization (TACE)|
204546|NCT02032381|Other|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
204547|NCT02032394|Drug|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
204241|NCT01997827|Device|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
204242|NCT01997827|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
204243|NCT01997840|Drug|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
204548|NCT00122460|Drug|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
204549|NCT02032394|Drug|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
204550|NCT02032394|Drug|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
204551|NCT02032407|Drug|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
204552|NCT02032420|Behavioral|STAR|
204553|NCT02032420|Behavioral|ART|
204554|NCT02032433|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
204555|NCT02032433|Drug|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
204556|NCT02034929|Device|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
204557|NCT02034929|Device|Standard colonoscopy|Standard colonoscopy
204558|NCT02034942|Other|Non-sedation|
204559|NCT02034942|Other|Sedation, control|
204560|NCT02034955|Radiation|Post-operative Adaptive Radiation Therapy|
204561|NCT02034968|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
204562|NCT02034981|Drug|Crizotinib|Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.
-250 mg twice daily for adults ≥ 18 years of age
280 mg/m2 twice daily for children and adolescents aged from 1 to 17 (except ALCL).
165 mg/m² twice daily for ALCL patients aged from 1 to 17.
209902|NCT02098265|Behavioral|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
209903|NCT02098265|Other|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
209904|NCT00128908|Drug|Rapidly Cycled HAART|
209905|NCT00129181|Drug|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
209906|NCT02100410|Device|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
209907|NCT02100410|Device|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
209908|NCT02100410|Device|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
209909|NCT02100410|Device|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
210213|NCT02093260|Biological|Vaccine|Flubio (Influenza HA) Vaccine
The vaccine will be given intramuscularly.
210214|NCT02093273|Biological|tOPV pilot batch|the tOPV vaccine is given orally
210215|NCT02093273|Biological|tOPV commercial batch|tOPV vaccine is given orally
210216|NCT02093299|Drug|Clopidogrel|a blood sample is drawn on all patients to determine responder status
210217|NCT00128414|Drug|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
210218|NCT02093312|Dietary Supplement|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
210219|NCT02093325|Drug|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
210220|NCT02093325|Drug|Placebo|
210221|NCT02093338|Dietary Supplement|Lactobacillus fermentum CECT5716|
210222|NCT02093338|Other|Placebo Comparator: maltodextrin|Placebo
210223|NCT02093351|Drug|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
210224|NCT02093351|Drug|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
209607|NCT02105324|Device|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
209608|NCT02105324|Other|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
209609|NCT02105350|Drug|MEK 162|
209610|NCT02105350|Drug|Gemcitabine|
209611|NCT02105350|Drug|Oxaliplatin|
209612|NCT02105363|Other|measure of skin movement on surface of the back|
209613|NCT02105363|Other|Measurement of skin movement on surface of back|
209614|NCT02105376|Device|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
209615|NCT02105389|Behavioral|Individualized Yoga Intervention|
209616|NCT00129727|Drug|Paclitaxel|Given intravenously
209617|NCT02105402|Behavioral|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
209618|NCT02105415|Drug|Ketamine / Propofol Admixture|
209619|NCT02105415|Drug|Etomidate|
209620|NCT02107755|Biological|ipilimumab|Given IV
209621|NCT02107755|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
209622|NCT02107755|Other|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
209910|NCT02100410|Device|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
209911|NCT02100423|Dietary Supplement|curcumin|Given PO
209912|NCT02100423|Dietary Supplement|cholecalciferol|Given PO
209913|NCT02100423|Other|laboratory biomarker analysis|Correlative studies
209914|NCT02100423|Other|pharmacological study|Correlative studies
209304|NCT02112266|Other|no mail support|follow-up without mail support
209305|NCT02112279|Biological|Donor microbiota applied via colonoscopy.|B. Preparation of donor sample 1. Instillation via Colonoscopy
1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.
Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe.
209306|NCT02112292|Drug|tetrahydrocannabinol|
209307|NCT02112292|Drug|cannabidiol|
209308|NCT02112292|Drug|Placebo|
209309|NCT00130507|Drug|Control Group|Vinorelbine 25 mg/m2 iv days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, p.o., b.i.d. days 1-14 each cycle (21 days).
209310|NCT02112305|Drug|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
209311|NCT02112305|Drug|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
209312|NCT02112331|Other|Raw human milk|
209313|NCT02112331|Other|Pasteurized human milk|
209314|NCT02112331|Other|Pasteurized-homogenized human milk|
209315|NCT02112331|Other|Gastric samples|
209316|NCT02112344|Radiation|IMRT|
209317|NCT02112370|Drug|Ropivacaine with epinephrine injection|According to the Ministry of Health and Welfare, ropivacaine is classified as no. 121- local analgesic and epinephrine as no. 245- adrenal hormone drug.
209318|NCT02112383|Behavioral|Cognitive behavior group therapy|For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
209623|NCT02107768|Other|Aerobic exercise|Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .
Two fitness goals was to be achieved during the training session
1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.
2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate.
209624|NCT02107781|Device|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
213785|NCT02130999|Drug|tasimelteon 2 mg I.V.|
213786|NCT02131012|Drug|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
213787|NCT02131038|Other|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
208997|NCT02080156|Device|CPAP|
208998|NCT02080169|Drug|midazolam|If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.
If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.
208999|NCT02080169|Drug|Dexmedetomidine|If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.
If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.
209000|NCT02080169|Drug|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS <3.
209001|NCT02080182|Drug|Acetylcysteine|
209002|NCT02080182|Drug|placebo acetylcysteine|
209003|NCT02080195|Drug|Cyclophosphamide|Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
209004|NCT02080195|Drug|Sodium-2-mercapto ethane sulphonate|Antineoplastic detoxifying agent
209005|NCT02080195|Drug|Fludarabine monophosphate|Purine antimetabolite
209006|NCT02080195|Drug|Tacrolimus|Calcineurin inhibitor
209007|NCT00127166|Drug|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
209008|NCT02080195|Drug|Mofetil|Immunosuppressant
209009|NCT02080195|Drug|Rabbit antithymocyte globulin|Selective immunosuppressant
209010|NCT02080208|Device|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
209011|NCT02080221|Drug|FOLFOXA|
209012|NCT02080234|Drug|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
209013|NCT02080234|Radiation|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
213483|NCT00133276|Drug|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
213484|NCT02138591|Procedure|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
213485|NCT02138617|Drug|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
213486|NCT02138617|Drug|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
213487|NCT02138617|Drug|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
213488|NCT02138617|Drug|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
213489|NCT02138630|Dietary Supplement|Capsaicin|
213490|NCT02138630|Dietary Supplement|Placebo|Sugar capsule
213491|NCT02138643|Procedure|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
208693|NCT02087618|Other|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
208694|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
208695|NCT02087618|Other|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
208696|NCT02087631|Drug|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
208697|NCT02087644|Biological|CYT003|Injections
208698|NCT02087644|Biological|Placebo|Injections
208699|NCT02087657|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
208700|NCT02087670|Other|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
208701|NCT02087670|Other|exercise protocol no supervised|Exercise program at the community
213198|NCT02143817|Dietary Supplement|L-citrulline supplementation|
213199|NCT02143817|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
213200|NCT02143830|Drug|Busulfan|A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).
A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.
A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.
213201|NCT02146118|Dietary Supplement|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
213202|NCT02146131|Device|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
213203|NCT02146131|Device|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
213204|NCT02146144|Procedure|ILM Peeling|common surgical procedure:
For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens
For all patients:
Central and peripheral 25 Gauge vitrectomy
dissection of the epimacular membrane
injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity
Intraoperative picture to see the possible spontaneous ILM peeling
If no spontaneous ILM peeling, the patient will be randomized at the operating block
Specific surgical procedure:
• • Randomization into two groups:
Arm 1: "no peeling", where the ILM peeling will not be made
Arm 2: "active peeling", where the ILM peeling will be made
213492|NCT02138643|Procedure|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
213493|NCT02138656|Other|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
213494|NCT00002244|Drug|WF10|
213495|NCT00133276|Other|Placebo|
213496|NCT02138656|Other|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
213497|NCT02138669|Device|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
213498|NCT02138682|Drug|l-123 Ioflupane|5 millicuries of Ioflupane
213499|NCT02138708|Other|Pharmacological test of pulmonary endothelial|
212916|NCT02151175|Device|LIFUP|
212917|NCT02151188|Dietary Supplement|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
212918|NCT00134147|Drug|Inhaled Insulin|
212919|NCT02151188|Device|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
212920|NCT02151201|Behavioral|Influenza vaccination video education|Influenza vaccination video education
212921|NCT02151201|Behavioral|Hand washing video education|Hand washing video education
212922|NCT02151214|Other|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
212923|NCT02151240|Drug|Foscarnet Sodium|
212924|NCT02151240|Drug|Acyclovir|
212925|NCT02151253|Drug|Armodafinil 50 - 250 mg pills|
212926|NCT02151266|Behavioral|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
212927|NCT02151266|Behavioral|Exercise Only|
212928|NCT02151266|Behavioral|Stretching and Flexibility|
212929|NCT00134160|Drug|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
212930|NCT02153671|Biological|Orniflu inactivated influenza vaccine|
212931|NCT02153697|Device|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
212932|NCT02153697|Drug|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
212933|NCT02153710|Behavioral|Speech therapy for aphasia: comparing two treatments|The investigators will compare two treatments for aphasia. Each participant will receive only one form of treatment.
212934|NCT02153710|Behavioral|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
212935|NCT00134420|Procedure|Arginine and Clonidine Stimulation Testing|
212936|NCT02153723|Drug|Glatiramer Acetate|
212319|NCT02125097|Device|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
212320|NCT00131833|Biological|Meningococcal A (control)|
212321|NCT02125110|Device|MRI|
212322|NCT02125110|Other|neuropsychological assessment|
212323|NCT02125123|Other|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
212324|NCT02125123|Other|Counseling|Dietary counseling
212325|NCT02125136|Drug|Gem/nab-Pac|All patient receive:
2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)
Then:
Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle
212629|NCT02118454|Behavioral|Weekly IVR Survey Only|
212630|NCT00131079|Behavioral|Experimental Programme for Physical Activity Promotion|General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.
Educational materials summarizing benefits, risks and motivation.
Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log.
212631|NCT02118467|Drug|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
212632|NCT02118467|Drug|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
212633|NCT02118467|Drug|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
212634|NCT02118467|Drug|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
212635|NCT02120690|Device|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
212636|NCT02120703|Drug|Pregabalin|Pregablin 75 mg per oral two times a day
212637|NCT02120703|Drug|Gabapentin|Gabapentin 200 mg twice daily per oral
212638|NCT00131339|Behavioral|Cognitive behavioral therapy|
206927|NCT02089061|Drug|Rosuvastatin|
206928|NCT02089061|Drug|Atorvastatin|
206929|NCT02089074|Behavioral|Drug use counselling|
206930|NCT02089087|Biological|CFZ533|Single dose at varying dosage levels depending on treatment assignment
206931|NCT02089087|Drug|Placebo|
206932|NCT02089100|Radiation|stereotactic body radiation therapy|
206933|NCT02089100|Radiation|Systemic treatment|
206934|NCT02089113|Drug|Dexamethasone|
206935|NCT02089113|Device|Punctum Plug|
206936|NCT00127998|Drug|artemether-lumefantrine|
206937|NCT02089126|Drug|Gemigliptin/Glimepiride combination|
206938|NCT02089139|Device|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
206939|NCT02089139|Other|conventional treatment|Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:
medications (analgesics, NSAIDs, muscle relaxants),
physical therapy,
manual techniques,
transcutaneous electrical nerve stimulation (TENS),
blocks
206940|NCT02089152|Other|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
207232|NCT02082210|Drug|LY2875358|Administered Intravenously (IV)
207233|NCT02082210|Drug|Ramucirumab|Administered Intravenously (IV)
207234|NCT02082223|Behavioral|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
207235|NCT02082236|Drug|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
207236|NCT02082236|Drug|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
207237|NCT02084602|Drug|Artesunate|Orally administration of artesunate 4mg/Kg by three days
207238|NCT02084602|Drug|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
206611|NCT02094391|Drug|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
206612|NCT02094417|Drug|AMG531|Subcutaneous, weekly injection
206613|NCT02096822|Behavioral|Facilitated tucking + non-nutritive sucking|
206614|NCT02096822|Other|non-nutritive sucking|
206615|NCT02096835|Device|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
206616|NCT02096835|Device|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
206617|NCT02096835|Drug|Tropisetron|will be given at the start of skin closure
206618|NCT02096835|Drug|Dexamethasone|will be given after induction
206619|NCT02096861|Biological|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
206620|NCT00128765|Behavioral|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
206621|NCT02096861|Biological|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
206622|NCT02096874|Drug|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
206623|NCT02096887|Behavioral|Patient Education|Patient Education using the following two instruments:
Framingham Risk Score calculator:
Know your numbers patient booklet
206624|NCT02096900|Drug|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
206625|NCT02096900|Drug|Midazolam|
206626|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).
In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period.
206013|NCT02108951|Drug|Nilotinib|Nilotinib 300 mg BD will be prescribed by the Investigator for use under the Pharmaceutical Benefits Scheme (PBS) as per standard practice. Patients will be instructed on compliance and asked to complete compliance questionnaires at each visit.
206014|NCT02111213|Behavioral|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
206331|NCT02103673|Drug|DAOIB|Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
206332|NCT02103673|Drug|Placebo|Intervention drug: placebo by mouth. Duration: 6 weeks
206333|NCT02103686|Drug|Lyrica|
206334|NCT02103686|Drug|Experimental drug|sustained release formulation of pregabalin
206335|NCT02103686|Dietary Supplement|High fat meal|
206336|NCT00129519|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
206337|NCT02103686|Dietary Supplement|fasted|
206338|NCT02103699|Drug|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
206339|NCT02103712|Other|Qualitative|
206340|NCT02103725|Drug|pimecrolimus 10 mg/g cream|
206341|NCT02103725|Drug|Vehicle cream|
206342|NCT02103738|Other|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
206343|NCT02103764|Drug|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
206344|NCT02103764|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
206345|NCT02103777|Drug|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
206346|NCT02103790|Device|Home NIV installation|
206347|NCT00129532|Drug|1.0% C31G SAVVY vaginal gel|
205741|NCT02078986|Other|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
205742|NCT00127010|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
205743|NCT02079012|Behavioral|10-week walking program|
205744|NCT02079025|Device|High-resolution ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
205745|NCT02079025|Device|Standard ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using standard of care ultrasound system
205746|NCT02079038|Device|Totalis|
205747|NCT02079038|Device|Sham|
205748|NCT02079051|Behavioral|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
206015|NCT02111213|Behavioral|Food Literacy and Nutrition|In a small group format, participants will participate in educational sessions to learn the components of a 'heart healthy' diet, and learn how food choices are influenced by individual, social and environmental factors.
206016|NCT02111226|Other|SMS text messaging|short message service
206017|NCT00002230|Drug|Hydroxyurea|
206018|NCT00130325|Drug|Placebo of Isoniazid tablets 300mg|Isoniazid BP 0mg twice weekly for 6 months
206019|NCT02111239|Device|CTA|pelvic/abdominal CTA scan
206020|NCT02111239|Device|MRA|pelvic/abdominal MRA scan
206021|NCT02111252|Drug|TAK-850|TAK-850 injection
206022|NCT02111265|Drug|Remifentanil|Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.
Remifentanil is stopped before skin closure
206023|NCT02111265|Drug|Cisatracurium|Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.
Cisatracurium is stopped before skin closure.
206024|NCT02111265|Drug|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
205453|NCT02086240|Drug|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
205454|NCT02086253|Drug|BQ-788 and/or BQ-123|
205455|NCT02086266|Other|PILATES|
205456|NCT02086266|Other|PFMT and AES|
205457|NCT02088502|Drug|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
205458|NCT02088515|Drug|Nedaplatin|
205459|NCT00002216|Drug|Abacavir sulfate|
205460|NCT00127972|Drug|efavirenz|
205461|NCT02088515|Drug|Cisplatin|
205462|NCT02088515|Drug|Docetaxel|
205463|NCT02088528|Device|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
205464|NCT02088528|Procedure|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
205465|NCT02088541|Drug|Selinexor|
205466|NCT02088541|Drug|Hydroxyurea|
205467|NCT02088541|Drug|Ara-C|
205468|NCT02088541|Drug|azacitidine|
205469|NCT02088541|Drug|Decitabine|
205470|NCT02088554|Device|Model 400 aortic valve bioprosthesis|
205471|NCT00127972|Drug|trizivir|
205472|NCT02088567|Procedure|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
205160|NCT02096263|Biological|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
205161|NCT00128700|Radiation|radiation therapy|
205162|NCT02096263|Biological|Infanrix|1 dose administered intramuscularly in the right thigh
205163|NCT02096263|Biological|Hiberix|1 dose administered intramuscularly in the left thigh
205164|NCT02096263|Biological|Prevnar13|3 doses administered intramuscularly in the lower left thigh
205165|NCT02096263|Biological|Rotarix|2 doses administered orally
205166|NCT02096276|Other|Data collection|Initial and follow-up data will be collected using questionnaires
205167|NCT02096289|Drug|Thioridazine|
205168|NCT02096302|Dietary Supplement|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
205169|NCT02096302|Dietary Supplement|Standard formula|Standard formula without probiotics
205170|NCT02098538|Drug|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
205171|NCT02098551|Other|SPT and APT|All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.
Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone.
205172|NCT02098564|Other|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
205173|NCT02098564|Other|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
205174|NCT02098577|Other|Crossover|Crossover cycle
205175|NCT02098577|Other|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
205473|NCT02088567|Other|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
204849|NCT02103218|Behavioral|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
204850|NCT02103218|Behavioral|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
204851|NCT02103244|Drug|Carboplatin|carboplatin will be dosed according to newly developed dosing algorithm.
204852|NCT02103257|Drug|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
204853|NCT02103257|Drug|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
204854|NCT02105740|Behavioral|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
204855|NCT02105740|Behavioral|Control x Experimental Group|The control and experimental groups respond in 7 different distinct moments, with the Visual Analog Scale (VAS) for the evaluation of pain, and the Hospital Anxiety and Depression Scale (HADS) to evaluate the depression and the anxiety. The first evaluation will be made before the research. The second within an interval of 7 days, so being that in the experimental group the same will happen after the hypnosis session and in the control group after the follow-up visit. The third evaluation will be two weeks later, in order to provide a follow-up to assess the efficacy of the technique. The experimental group and the control group will be compared in relation to the intensity of the pain, depression and anxiety
204856|NCT02105753|Device|1210nm Diode Laser treatments|
204857|NCT02105766|Drug|Alemtuzumab|Immunosuppressant
204858|NCT02105766|Drug|Sirolimus|Immunosuppressant
204859|NCT02105766|Drug|Cyclophosphamide|Immunosuppressant
204860|NCT02105766|Drug|Pentostatin|Immunosuppressant
204861|NCT02105766|Drug|Radiotherapy|Immunosuppressant and myelosuppressant
204862|NCT00129766|Biological|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
204863|NCT02105779|Other|Targeted Cognitive Training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
204563|NCT02034994|Behavioral|Eating behavior and physical activity change|A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
204564|NCT02035007|Device|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
204565|NCT00122655|Drug|non-nucleoside reverse transcriptase inhibitors|
204566|NCT02035020|Drug|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
204567|NCT02035046|Procedure|Samplings of blood|
204568|NCT02035046|Procedure|Sampling of urine|
204865|NCT02105792|Drug|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
204866|NCT02105805|Behavioral|Dietetic group sessions|Group sessions to improve dietary adherence
204867|NCT02105831|Other|Contrast ultrasound skeletal muscle perfusion imaging|1. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
204868|NCT02105857|Other|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
204869|NCT02105870|Drug|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
204870|NCT02105883|Other|Use of identification badge during scenarios|
204871|NCT02105909|Other|GWAS|
204872|NCT02105922|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
204873|NCT00129779|Behavioral|Intermediate care package|
204874|NCT02108314|Behavioral|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
204875|NCT02108327|Procedure|surgical blade|Using surgical blade all the time of surgery
204876|NCT02108327|Procedure|electrocautery|Using electrocautery all the time except at skin incision
210225|NCT02093351|Drug|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
210226|NCT02093351|Drug|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
210227|NCT02093351|Procedure|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
210228|NCT00128427|Drug|Colchicine (for 1 month)|
210229|NCT02093377|Device|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
210230|NCT02093390|Drug|TAK-385|
210231|NCT02093390|Drug|Fluconazole|
210232|NCT02095847|Procedure|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
210233|NCT02095847|Drug|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
210234|NCT02095860|Drug|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
210539|NCT02134938|Dietary Supplement|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
210540|NCT02134951|Drug|Ketamine|intravenous infusion of saline solution with ketamine
210541|NCT02134951|Drug|Normal saline|Normal saline will be used for placebo in this group
210542|NCT02134964|Drug|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
210543|NCT02134964|Drug|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
210544|NCT02134977|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg Injection Kit
210545|NCT02134990|Drug|Oshadi D and Oshadi R|Anti cancer agents
210546|NCT02134990|Drug|Docetaxel|Chemotheraphy
210547|NCT00132821|Drug|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
209915|NCT02100436|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
209916|NCT00129181|Procedure|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
209917|NCT02100449|Other|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
209918|NCT02100449|Other|Lung ultrasound and Doppler (Day 0 and Day 3 to 5)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
209919|NCT02100462|Drug|Chlorthalidone 12.5 mg|
209920|NCT02100462|Drug|Hydrochlorothiazide 25 mg|
209921|NCT02100462|Drug|Aspirin 81 mg|
209922|NCT02100475|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.
Dose individually adjusted.
209923|NCT02100475|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.
Dose individually adjusted.
209924|NCT02100475|Drug|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
209925|NCT02102880|Genetic|the polymerase chain reaction (PCR)|
209926|NCT02102906|Procedure|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
209927|NCT02102919|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
209928|NCT02102919|Device|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
210235|NCT00128661|Biological|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
210236|NCT02095873|Dietary Supplement|Glyoxalase 1 inducer|Dietary bioactive
210237|NCT02095873|Dietary Supplement|Placebo|Mannitol, 210 mg
209625|NCT02107794|Other|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
209626|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
209627|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
209628|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
209629|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
209630|NCT00129987|Behavioral|Self management education|
209631|NCT02107820|Behavioral|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
209632|NCT02107820|Device|Percutaneous Tibial Nerve stimulation|A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2") cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾") posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each.
209633|NCT02107833|Drug|OPRX-106|
209634|NCT02107846|Drug|PRX-112|
209635|NCT02107859|Drug|Ataluren (PTC124®)|Oral powder for suspension taken 3 times per day (10-, 10-, and 20-mg/kg morning, midday and evening, respectively) for 48 weeks
209636|NCT02107872|Drug|REGN1500|
209637|NCT02107872|Drug|placebo|
209638|NCT02107885|Drug|DS-1971|6 subjects in each group will receive DS-1971.
209639|NCT02107885|Drug|placebo|2 subjects in each group will receive placebo.
209640|NCT02107898|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
209929|NCT02102919|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
209930|NCT02102919|Device|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
209931|NCT02102932|Drug|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
209014|NCT02080247|Drug|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
209015|NCT02082964|Other|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
209016|NCT02082977|Drug|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
209319|NCT00130780|Drug|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
209320|NCT02114502|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
209321|NCT02114515|Behavioral|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
209322|NCT02114515|Behavioral|Patient Navigator|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
209323|NCT02114515|Behavioral|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
209324|NCT02114528|Drug|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
209325|NCT02114528|Procedure|Catheter ablation|Ventricular tachycardia catheter ablation.
209326|NCT02114567|Other|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
209327|NCT02114580|Other|physical training|Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on "one on one" basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the "talk" test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).
Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises.
209328|NCT02114593|Behavioral|Parent support program|Parent support program
209329|NCT02114619|Drug|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
208702|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
208703|NCT02087683|Other|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
208704|NCT02087696|Drug|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
208705|NCT00127933|Drug|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
208706|NCT02087709|Other|Low-calorie diet|
208707|NCT02087722|Drug|KI1001|
208708|NCT02087722|Drug|Placebo|
208709|NCT02087735|Dietary Supplement|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
208710|NCT02087748|Drug|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
208711|NCT02089984|Behavioral|Internet Based CBT Training|
209017|NCT02082990|Behavioral|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
209018|NCT00127400|Behavioral|anger management therapy|
209019|NCT02082990|Behavioral|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
209020|NCT02083003|Dietary Supplement|Polyamine low-diet|
209021|NCT02083003|Dietary Supplement|Liberal alimentation|
209022|NCT02083016|Device|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
209023|NCT02083016|Device|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
209024|NCT02083029|Procedure|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
209025|NCT02083055|Drug|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
213500|NCT02138721|Procedure|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
213501|NCT02138734|Biological|BCG+ALT-803|BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks in phase I and phase II. Phase II includes maintenance treatment consisting of BCG+ALT-803 for 3 consecutive weeks at 3, 6 and 12 months.
213502|NCT02138734|Biological|BCG|BCG-only will be administered via intravesical instillation weekly for 6 consecutive weeks. Phase II includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6 and 12 months.
213503|NCT02138747|Drug|Myrbetriq|Oral
213504|NCT02138747|Drug|Detrol LA|Oral
213505|NCT02138760|Procedure|MRI UroNav fusion biopsy|
213506|NCT00133289|Device|Pacemaker with Automatic Capture|
213507|NCT02138773|Drug|Tamsulosin formulation-A|oral
213508|NCT02138773|Drug|Tamsulosin formulation-B|oral
213509|NCT02138786|Drug|selinexor|60 mg, may be increased to 80 mg after Cycle 1
213510|NCT02141412|Drug|dexmedetomidine 0.25 µg/kg IV|
213511|NCT02141412|Drug|dexmedetomidine 0.5 µg/kg IV|
213512|NCT02141412|Drug|dexmedetomidine 1 µg/kg IV|
213513|NCT02141425|Drug|ASP015K|oral
213514|NCT02141425|Drug|Placebo|oral
208712|NCT02089997|Drug|Sodium risedronate|Sodium risedronate tablets
208713|NCT02090010|Procedure|Seldinger technique|The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.
After that catheter is passed over the guidewire into the vessel.
208714|NCT02090010|Procedure|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
208715|NCT02090036|Drug|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
208716|NCT00128076|Procedure|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
213205|NCT02146157|Dietary Supplement|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
213206|NCT02146157|Dietary Supplement|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
213207|NCT02146183|Dietary Supplement|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
213208|NCT02146183|Dietary Supplement|Placebo Corn Starch|500 mg/day
213209|NCT02146196|Device|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
213210|NCT02146196|Device|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
213211|NCT00133887|Drug|ciclosporine|Blood residual level < or = to 125 ng/ml
213212|NCT02146209|Drug|Metronidazole benzoate|Single oral dose of 400 mg
213213|NCT02146209|Drug|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
213214|NCT02146209|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
213215|NCT02146222|Drug|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
213216|NCT02146222|Drug|docetaxel|Given IV
213217|NCT02146222|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
213218|NCT02146222|Procedure|positron emission tomography/computed tomography|Undergo FLT PET/CT
213219|NCT02146222|Other|pharmacological study|Correlative studies
213220|NCT02146222|Other|laboratory biomarker analysis|Correlative studies
213221|NCT02146235|Behavioral|Psycho-Music Therapy|
213222|NCT00133887|Drug|tacrolimus|Blood residual level < or = to 8 ng/ml
213223|NCT02146248|Drug|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
213224|NCT02146248|Drug|DepoProvera|injectable hormonal contraceptive
213225|NCT02148705|Procedure|Standard of Care (SOC)|
212639|NCT02120716|Behavioral|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet PC after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
212640|NCT02120729|Other|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 1 day of analysis of patient consent, and 2 days of admission. Buccal cell DNA is analyzed for 19 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
212641|NCT02120742|Behavioral|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
212642|NCT02120755|Biological|AmnioClear™ Human Allograft Amniotic Membrane|
212643|NCT02120768|Procedure|barrier resection/1cm resection|For Arm "Barrier resection", if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm "1cm resection", if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas.
212937|NCT02153736|Behavioral|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
212938|NCT02153749|Behavioral|Cognitive Behavioral Therapy for Addiction|Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction "LATER" during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life.
212939|NCT02153749|Behavioral|Mindfulness Based Therapy for addiction|Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy ("notice craving and accept the feeling without judgment or reaction"). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., "I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?'") Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction "ACCEPT" during the task. All other components will be identical.
212940|NCT02153762|Drug|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
212941|NCT02153762|Drug|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
212942|NCT02153775|Behavioral|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
212943|NCT02153788|Drug|Temazepam|Temazepam 15 mg orally at bedtime
212944|NCT02153788|Drug|Placebo|
207239|NCT02084615|Drug|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
207240|NCT02084628|Drug|Gadoxetate disodium (Eovist/Primovist, BAY 86-4873)|One-time intravenous bolus injection of the study drug 0.1 mL/kg body weight (0.025 mmol/kg BW), administered at a flow rate of 1-2 mL/second
207241|NCT02084628|Drug|Sodium chloride solution|Followed by a flush of at least 5 mL saline (sodium chloride 0.9% solution), administered at a flow rate of 1-2 mL/second
207242|NCT02084641|Other|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
207243|NCT02084654|Drug|Exenatide 5 and 10 mcg 2 times a day|
207244|NCT02084654|Drug|placebo|
207245|NCT02084667|Drug|Pravastatin|20 mg pravastatin sodium daily for 3 months, plus Coenzyme Q10 supplementation
207246|NCT02084680|Behavioral|community health workers|community health workers offering individual prenatal education to pregnant women
207247|NCT00127634|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
207248|NCT02084693|Device|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
207249|NCT02084706|Procedure|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
207250|NCT02084706|Drug|2% Lidocaine|
207251|NCT02084706|Drug|Triamcinolone (20 g)|
207252|NCT02084706|Procedure|J-tip lidocaine administration|
207253|NCT02084706|Procedure|Triamcinolone (20 g) Injection over the A1 pulley.|
207254|NCT02084719|Device|Oraquick HCV Rapid Antibody Test|
207558|NCT02077075|Behavioral|Web-based weight loss program|A 4-week web-based wellness program.
207559|NCT00126763|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
207560|NCT02077075|Behavioral|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
206627|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).
In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment.
206628|NCT02096926|Drug|Placebo|
206941|NCT02089165|Dietary Supplement|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
206942|NCT02089165|Dietary Supplement|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
206943|NCT02089165|Dietary Supplement|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
206944|NCT02089178|Procedure|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
206945|NCT02089178|Procedure|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
206946|NCT02091674|Device|Hyaluronic acid|Injected gel
206947|NCT02091700|Other|Fluorescein angiography|
206948|NCT02091713|Other|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
206949|NCT02091726|Procedure|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
206950|NCT02091739|Drug|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
206951|NCT02091739|Drug|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
206952|NCT02091739|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
206953|NCT02091752|Drug|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to <200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
206954|NCT02091765|Behavioral|Internet-based cognitive behavioral therapy.|
206348|NCT02103816|Device|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
206349|NCT02103829|Behavioral|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
206350|NCT02103829|Behavioral|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
206351|NCT02103829|Behavioral|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
206352|NCT02103842|Drug|Omega-3 fatty acids|
206629|NCT02096926|Drug|Ibuprofen|400 mg PO
206630|NCT02096939|Procedure|Adrenal extirpation|
206631|NCT00128778|Drug|Pegylated liposomal doxorubicin (Caelyx)|
206632|NCT02096939|Drug|Antihypertensive medication|
206633|NCT02096952|Drug|Methylphenidate extended-release liquid formulation|
206634|NCT02096965|Drug|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
206635|NCT02096965|Drug|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
206636|NCT02096978|Procedure|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
206637|NCT02096991|Other|Can 1|drink the beverage in a can and a glass bottle
206638|NCT02099084|Drug|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
206639|NCT02099084|Drug|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
206640|NCT02099097|Other|web-based video game (Quit IT)|
206641|NCT02099097|Behavioral|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 and 3 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
206642|NCT02099097|Other|Salvia sample|We will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
206643|NCT02099110|Drug|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
206025|NCT02111265|Device|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
206026|NCT02111278|Other|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
206027|NCT02111278|Other|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
206028|NCT02111278|Other|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
206029|NCT00130338|Drug|Rivastigmine|
206030|NCT02111291|Biological|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
206353|NCT02103855|Drug|Belatacept|
206354|NCT02103868|Behavioral|Tobacco Cessation Counseling|Doing group and personal counseling for tobacco cessation
206355|NCT02106377|Drug|loteprednol etabonate (Lotemax)|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
206356|NCT02106377|Drug|Soothe Tired Eyes Lubricant Eye Drop|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear whichis used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
206357|NCT02106390|Biological|rMenB+OMV and MenACWY|rMenB+OMV given concomitantly with MenACWY at 3,5,7 and 13 months of age
206358|NCT00129831|Drug|QAB149|
206359|NCT02106390|Biological|rMenB+OMV|rMenB+OMV given at 3,5,7 and 13 months of age
205749|NCT02079051|Behavioral|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
205750|NCT02081391|Drug|Tapentadol 20 mg/mL|Participants aged from 2 years to less than 18 years with body weight greater than or equal to 20 kg will receive tapentadol 20 mg/mL solution orally every 4 hours for up to 72 hours. The dose during the first 24 hours will be 1.25 mg/kg. After 24 hours, the dose can be reduced to 1.0 mg/kg, based on investigator's judgment. Dose of tapentadol 20 mg/mL solution for participants aged birth to less than 2 years with body weight greater than or equal to 20 kg will be decided based on the forthcoming PK data.
205751|NCT02081391|Other|Placebo|Matching placebo solution will be administered orally every 4 hours for 72 hours.
205752|NCT02081404|Drug|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
205753|NCT02081404|Drug|Placebo|placebo
205754|NCT02081417|Behavioral|Seeking Safety|SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
205755|NCT02081430|Procedure|CT Manipulation|
205756|NCT02081430|Procedure|Upper trapezius stretch|
205757|NCT00127231|Behavioral|Brief alcohol intervention based on Project Treat|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
205758|NCT02081443|Drug|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
205759|NCT02081443|Drug|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
205760|NCT02081456|Other|Soft Tissue Mobilization|
205761|NCT02081456|Device|Therapeutic Ultrasound|
205762|NCT02081469|Other|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
205763|NCT02081482|Radiation|18F-FDG PET|
205764|NCT02081495|Drug|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
205474|NCT02088580|Procedure|Triple Chronotherapy|
205475|NCT02088593|Device|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
205476|NCT02088593|Behavioral|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
205477|NCT02088606|Device|TactiCath Quartz treatment|Catheter ablation for the treatment of paroxysmal atrial fibrillation
205478|NCT02088619|Behavioral|Quality of Life Therapy (QOLT)|
205479|NCT02088619|Behavioral|Heart Healthy Education (HHE)|
205480|NCT02088632|Biological|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
205481|NCT02088632|Other|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
205482|NCT00127985|Drug|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
205483|NCT02088645|Drug|177Lu-PP-F11N|
205484|NCT02091141|Drug|Trastuzumab [Herceptin]|An 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg, given by IV infusion every 3 weeks
205485|NCT00128193|Other|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
205486|NCT02091141|Drug|Vemurafenib [Zelboraf]|960 mg given twice-daily (BID) orally in cycles of 28 days (4 weeks) duration
205487|NCT02091141|Drug|Vismodegib [Erivedge]|A daily dose of 150 mg given orally in cycles of 28 days (4 weeks) duration
205488|NCT02091154|Behavioral|USDA Regulations|Implement new USDA regulations assigned school cafeterias.
Fruit or vegetable on every tray
Meet requirements for vegetable varieties
50% of all grains must be whole grain
Milk must be 1% or skim; flavored milk must be skim
205489|NCT02091154|Behavioral|Marketing Kit|This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:
56''x72'' vinyl sign with the words "[school mascot] Cafe"
8.5''x11'' signs describing the foods offered on a specific day
2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.
Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift.
205490|NCT02091154|Behavioral|Smarter Lunchrooms Makeover (SLM)|Implement three basic Smarter Lunchrooms techniques. It consists of the following components:
Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.
Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.
Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take.
204864|NCT02105779|Other|Social Cognitive Training|We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
205176|NCT02098590|Biological|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
205177|NCT02098590|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
205178|NCT02098590|Biological|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
205179|NCT02098590|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
205180|NCT00002220|Drug|Adefovir dipivoxil|
205181|NCT00128986|Procedure|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
205182|NCT02098590|Drug|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
205183|NCT02098603|Behavioral|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
205184|NCT02098616|Drug|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
205185|NCT02098616|Drug|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
205186|NCT02098629|Drug|Milrinone|Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.
Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min
205187|NCT02100813|Drug|LEO 43204|
205188|NCT02100813|Drug|Placebo|
205189|NCT02100826|Drug|Cephalexin|Administered orally.
205190|NCT02100839|Drug|AEM-28|Solution for injection
205191|NCT02100839|Drug|Normal Saline|0.9% saline for injection
204877|NCT02108340|Procedure|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
204878|NCT02108353|Drug|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
204879|NCT00130065|Drug|Sulfadoxine-pyrimethamine/folic acid|
204880|NCT02108353|Drug|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
204881|NCT02108366|Drug|Celecoxib|Celecoxib 200mg daily
204882|NCT02108366|Drug|Oseltamivir|Oseltamivir 75mg bid
204883|NCT02108366|Drug|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
204884|NCT02108379|Device|Rhinix Nasal Filters|
204885|NCT02108418|Drug|TG-2349 as the original formulation|single oral dose under fed condition
204886|NCT02108418|Drug|TG-2349 as a new capsule formulation|single oral dose under fed condition
211206|NCT02124421|Drug|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
211207|NCT02124447|Drug|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
211208|NCT00131781|Behavioral|Supportive Therapy|
211209|NCT02124447|Drug|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
211210|NCT02124447|Drug|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
211211|NCT02124447|Drug|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
211212|NCT02124460|Behavioral|Connect 4 Health: Using Health Coaches for Behavioral Counselling and Community Connections|Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .
The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.
Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study.
211213|NCT02124473|Other|Homeopathy|
211214|NCT02124473|Other|Placebo|
210548|NCT02135003|Other|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
210549|NCT02135016|Drug|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
210550|NCT02135016|Drug|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
210551|NCT02135016|Drug|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
210552|NCT02135029|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
210553|NCT02135029|Drug|Atorvastatin|Atorvastatin PO QD
210554|NCT02135029|Other|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
210555|NCT02135029|Other|Placebo for atorvastatin|PO QD
210556|NCT02137213|Drug|Placebo|Normal saline will be added to oral methadone preparations as placebo.
210557|NCT00133133|Drug|ALGRX 4975|
210558|NCT02137226|Drug|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
210559|NCT02137226|Drug|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
210560|NCT02137239|Drug|Thymoglobulin|
210869|NCT02129725|Procedure|muscle biopsy|A muscle biopsy will be obtained before and after the hyperinsulinemic clamp in the parent study. The purpose of the biopsy will be to assess Akt signaling.
210870|NCT02129738|Device|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
210871|NCT02129751|Drug|bupropion hydrobromide|study drug
210872|NCT02129751|Drug|Placebo|
210873|NCT02129764|Drug|Prednisone|
210874|NCT02129764|Drug|Allopurinol|
210875|NCT00132314|Drug|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
210876|NCT02129777|Drug|Namilumab|Namilumab subcutaneous injection
210238|NCT02095886|Drug|BMS-955176|
210239|NCT02095899|Drug|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
210240|NCT02095938|Drug|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
210241|NCT02095951|Drug|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
210242|NCT02095977|Procedure|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
210243|NCT02095977|Procedure|synchronized high-voltage shock|If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.
For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist.
210244|NCT02095977|Procedure|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
210245|NCT02095990|Drug|Hydroquinone|
210246|NCT00128687|Behavioral|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
210247|NCT02095990|Drug|Placebo|
210248|NCT02096003|Drug|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
210249|NCT02096003|Drug|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
210250|NCT02098265|Other|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
210561|NCT02137239|Drug|Belatacept|
210562|NCT02137239|Drug|mycophenolate mofetil(MMF)|
209932|NCT02102932|Drug|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
209933|NCT02102932|Drug|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
209934|NCT00129428|Procedure|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
209935|NCT02102932|Drug|850 mg metformin|850mg metformin tablet
209936|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
209937|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
209938|NCT02102932|Drug|850 mg metformin|850 mg metformin
209939|NCT02102932|Drug|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
209940|NCT02102932|Drug|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
209941|NCT02102932|Drug|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
209942|NCT02102932|Drug|500 mg metformin|500 mg metformin
209943|NCT02102932|Drug|500 mg metformin|500 mg metformin
209944|NCT02102945|Procedure|Computed tomography perfusion|
209945|NCT00129441|Drug|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
209946|NCT02102958|Behavioral|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
209947|NCT02102958|Behavioral|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
209948|NCT02102971|Procedure|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
210251|NCT02098278|Drug|CAT-2003|
210252|NCT02098278|Drug|Placebo|
210253|NCT02098291|Drug|G17DT|
209330|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
209331|NCT02114619|Drug|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
209332|NCT02114619|Drug|High dose|We will administer 200 micro currie of iodine per thyroid gram
209333|NCT02114632|Dietary Supplement|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
209334|NCT02114645|Drug|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
209641|NCT02110355|Drug|AMG 232|Given as an oral tablet in escalating doses
209642|NCT02110355|Drug|Trametinib|Trametinib is an anti-cancer agent
209643|NCT02110355|Drug|Dabrafenib|Dabrafenib is an anti-cancer agent
209644|NCT02110368|Drug|Testosterone Topical Gel, 1.62% Metered Pump|
209645|NCT02110368|Drug|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
209646|NCT02110381|Device|Device guided breathing RESPeRATE|Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.
Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit.
209647|NCT02110381|Device|Isometric hand grip Zona Plus|Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.
Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit.
209648|NCT02110394|Other|bendamustine|Routine practice
209649|NCT02110394|Other|rituximab|Routine practice
209650|NCT02110407|Device|tDCS|transcranial direct current stimulation (tDCS)
209651|NCT00130247|Drug|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
209652|NCT02110407|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
209653|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered as a single dose
209026|NCT02083055|Drug|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
209027|NCT02083068|Biological|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 4
209028|NCT02083068|Biological|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015
209029|NCT00127413|Behavioral|Cognitive Behavioral Therapy - Pain|Pain treatment
209030|NCT02083068|Biological|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
209031|NCT02083081|Behavioral|Community level intervention|Community intervention plus individual counseling
209032|NCT02083107|Drug|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
209033|NCT02083107|Other|Placebo|
209034|NCT02083120|Device|NHF therapy|AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
209035|NCT02083120|Other|Long term Oxygen Therapy (LOT)|Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
209036|NCT02083172|Device|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
209037|NCT02083185|Drug|TAK-385, 80 mg|
209335|NCT02114645|Drug|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
209336|NCT02114645|Drug|4 mg oral estradiol valerate|estrofem is given twice a day
209337|NCT02114658|Drug|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
209338|NCT02077842|Device|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
209339|NCT02077842|Device|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
209340|NCT02077868|Other|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
209341|NCT00002209|Drug|CPI-1189|
209342|NCT00126880|Drug|3TC|3TC, 150mg BID
208717|NCT02090036|Drug|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
208718|NCT02090049|Dietary Supplement|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
208719|NCT02090049|Dietary Supplement|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
208720|NCT02090075|Drug|apixaban|5 po or 2.5 po bid.
208721|NCT02090075|Drug|warfarin|
208722|NCT02090088|Drug|Not applicable- observational study|
208723|NCT02090101|Drug|ANAKINRA|
208724|NCT02090114|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
208725|NCT02090114|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
208726|NCT02090114|Drug|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
208727|NCT00002216|Drug|Nelfinavir mesylate|
208728|NCT00128089|Behavioral|Dietary treatment|
209038|NCT02083185|Drug|TAK-385, 120 mg|
209039|NCT02085356|Behavioral|Protect your family|"Protect Your Family" intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.
Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)
209040|NCT02085382|Procedure|Kangaroo Mother Care|The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.
When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered.
213226|NCT02148705|Drug|Gel Vehicle|
213227|NCT02148718|Biological|ADALIMUMAB|ADALIMUMAB
213515|NCT02141438|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|An alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
213516|NCT00133471|Biological|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
213517|NCT02141451|Drug|Rituximab|Rituximab 375 mg/m2 IV after day +28 re-staging and again 1 and 7 weeks later
213518|NCT02141451|Drug|INCB7839|INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
213519|NCT02141477|Drug|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
213520|NCT02141477|Drug|Decitabine|Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.
Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I.
213521|NCT02141490|Drug|Ferumoxytol|All patients will receive a dose of 7.5mg/kg Fe Ferumoxytol
213522|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
213523|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
213524|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
213525|NCT02141529|Procedure|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
213526|NCT02141529|Procedure|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
213527|NCT00133471|Drug|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
213528|NCT02141542|Drug|Tremelimumab|
213529|NCT02141542|Drug|MEDI3617|
213530|NCT02141555|Drug|Vaginal Misoprostol|Misoprostol inserted into vagina
213531|NCT02141555|Drug|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
212945|NCT02153801|Procedure|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.
For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter.
212946|NCT00134420|Procedure|Growth Factors Laboratory Testing|
212947|NCT02115971|Other|Jumping exercise|Total 120min exercise
212948|NCT02115971|Other|Strength exercise|Total 120 min exercise
212949|NCT02115984|Drug|Panagen|
212950|NCT02115984|Drug|Placebo|
212951|NCT02115984|Procedure|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
212952|NCT02115997|Drug|methylprednisolone|1 to 3 pulses of 1000 mg
213228|NCT02148731|Other|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
213229|NCT02148744|Biological|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
213230|NCT02148744|Biological|Placebo|
213231|NCT02148757|Procedure|Doppler Ultrasound|
213232|NCT02148770|Behavioral|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 4 training-sessions spread over 2 weeks. Two training-session days have to be at least 3 days apart. In the up-regulation condition subjects will learn to up regulate their functional connectivity between vmPFC and dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
213233|NCT02148770|Behavioral|Sleep Deprivation|Half of the participants will have regular night sleep, whereas the other half will undergo complete sleep deprivation after every neurofeedback training session. First all participants will fill in several memory questionnaires and perform computer reaction time tests. Afterwards participants can enjoy a normal night of sleep, or be kept awake the whole night under the supervision and in the company of the experimenter. During the night a sleep EEG is registered. The next morning all participants will again fill in the memory questionnaires and perform a computer reaction time tests.
213234|NCT00134017|Drug|tacrolimus|
207561|NCT02077088|Other|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
207562|NCT02077101|Other|Questionnaire|
207563|NCT02079675|Drug|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
207564|NCT02079675|Drug|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
207565|NCT02079688|Drug|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).
Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.
Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
207566|NCT02079688|Drug|Multiple W/O/W formulation, active ingredient-free vehicle|Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).
Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.
Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
207567|NCT02079701|Biological|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
207568|NCT02079701|Biological|Placebo|
207569|NCT02079727|Drug|chondroitin sulfate|
207570|NCT02079727|Drug|celecoxib|
207571|NCT02079727|Drug|placebo|
207572|NCT02079740|Other|Laboratory Biomarker Analysis|Correlative studies
207573|NCT00127088|Procedure|laparoscopic radical prostatectomy|
207881|NCT02111980|Device|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
206955|NCT00128232|Drug|Octreotide LAR|
206956|NCT02091778|Device|Fast gelling dressing|
206957|NCT02091791|Procedure|Traction sessions|
207255|NCT02084719|Device|Standard algorithm|
207256|NCT02084732|Drug|Sorafenib|drug
207257|NCT02084745|Device|Boston keratoprosthesis type 2|The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
207258|NCT00002213|Drug|Efavirenz|
207259|NCT00127634|Drug|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
207260|NCT02084745|Device|Glaucoma drainage device|The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
207261|NCT02084758|Dietary Supplement|Nitrate supplementation|7 days of supplementation with sodium nitrate solution
207262|NCT02084758|Dietary Supplement|Placebo supplementation|7 days of supplementation with sodium chloride solution
207263|NCT02086968|Drug|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
207264|NCT02086968|Drug|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
207265|NCT02086994|Drug|misoprostol|given after the delivery of the anterior shoulder of the baby.
207266|NCT02086994|Drug|carbetocin|given after delivery of anterior shoulder
207267|NCT02087007|Drug|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
207268|NCT02087020|Procedure|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (> 9 litre) with 0.9 % sodium chloride and then closed.
207269|NCT02087033|Dietary Supplement|ritmonutra|2 tablets a day by mouth for 4 weeks
207270|NCT02087033|Dietary Supplement|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
207271|NCT00002215|Drug|Nelfinavir mesylate|
206644|NCT02099110|Drug|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
206645|NCT02099110|Drug|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
206646|NCT02099110|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
206647|NCT02099110|Drug|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
206648|NCT00129077|Procedure|plastic wrap over eye & lubrication applied q6 hrs|
206649|NCT02099110|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
206650|NCT02099110|Drug|Metformin >= 1500 mg/day|Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
206958|NCT02091804|Behavioral|Immediate Group|The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 "consultation strategies," labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.
206959|NCT02091804|Behavioral|Wait-List group|The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 "consultation strategies," labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.
206960|NCT02091817|Drug|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
206961|NCT02091817|Drug|Placebo|Placebo will be given to control group and experimental group as well.
206962|NCT02091830|Drug|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
206963|NCT02091830|Other|Physiotherapy|
206964|NCT02094430|Drug|biological: human fibrinogen concentrate|
206965|NCT02094443|Drug|DEB025 and RBV|Dual-therapy with a response-guided treatment duration with DEB025 400 mg BID and RBV
206966|NCT02094443|Drug|DEB025 and RBV|Dual-therapy with a response-guided treatment duration with DEB025 300 mg BID and RBV
206360|NCT02106390|Biological|MenACWY|MenACWY given at 3,5,7 and 13 months of age
206361|NCT02106403|Other|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
206362|NCT02106403|Other|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
206363|NCT02106403|Other|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
206364|NCT02106416|Device|PET/MRI|Simultaneous PET/MRI (3T system)
206365|NCT02106442|Drug|Sodium risedronate|Sodium risedronate tablets
206366|NCT02106455|Drug|Sodium risedronate|Sodium risedronate tablets
206367|NCT02106468|Drug|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
206368|NCT02106468|Drug|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
206369|NCT00129844|Drug|Motexafin Gadolinium|
206370|NCT02106481|Drug|Femoral Nerve Catheters|Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.
Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)
206651|NCT02099110|Biological|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
206652|NCT02099110|Drug|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
206653|NCT02099123|Drug|Atorvastatin|Atorvastatin 20 mg tablet
206654|NCT02099123|Drug|Placebo (for Atorvastatin)|Sugar pill manufactured to mimic Atorvastatin 20 mg tablet
206655|NCT02099136|Procedure|UV Light Therapy|Undergo UV-irradiation
206656|NCT02099136|Other|Placebo|Given PO
206657|NCT02099136|Drug|Celecoxib|Given PO
206658|NCT02099136|Procedure|Biopsy|Undergo skin biopsy
205765|NCT02081495|Drug|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
206031|NCT02111291|Biological|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
206032|NCT02111304|Drug|iOWH032|
206033|NCT02113189|Other|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
206034|NCT02113189|Other|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
206035|NCT02113202|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
206036|NCT00130611|Other|Clinical examination|
206037|NCT02113202|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
206038|NCT02113215|Procedure|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
206039|NCT02113241|Drug|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
206040|NCT02113241|Drug|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
206041|NCT02113254|Other|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
206042|NCT02113267|Drug|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
206043|NCT02113267|Drug|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
206044|NCT02113280|Procedure|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
206045|NCT02113280|Procedure|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
206046|NCT02113293|Drug|CyclASol®|Cyclosporine A Solution
206047|NCT00130624|Procedure|Multidisciplinary intervention: primary or secondary care|
206048|NCT02113293|Drug|Placebo (vehicle)|Vehicle Solution
205766|NCT02081508|Behavioral|Interference onset|Temporal duration of interference onset.
205767|NCT02081521|Behavioral|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
205768|NCT00127231|Behavioral|Standard care|Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.
205769|NCT02081534|Drug|AZD1722|AZD1722, oral tablet
205770|NCT02081534|Drug|Placebo|Placebo bid, double dummy technique
205771|NCT02081560|Drug|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
205772|NCT00127543|Behavioral|Medication Education for Children|
205773|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
205774|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
205775|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
205776|NCT02084108|Other|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
205777|NCT02084121|Biological|Enriched Hematopoetic Stem Cell Transplant|
205778|NCT02084134|Drug|hydrocortisone|100mg at the time of surgery
205779|NCT02084134|Drug|dexamethasone|0.5mg every 6 hours for a total of four doses
205780|NCT02084147|Procedure|positron emission tomography|Undergo PET
205781|NCT02084147|Procedure|computed tomography|Undergo CT
205782|NCT02084147|Procedure|magnetic resonance imaging|Undergo MRI
205783|NCT00127556|Procedure|Label applied to blood bag|
205784|NCT02084173|Behavioral|MET + CRA|
205785|NCT02084186|Other|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
205192|NCT02100852|Drug|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
205193|NCT02100865|Device|Solar powered oxygen|
205194|NCT00129233|Drug|Valsartan|valsartan 80 to 160 mg daily
205195|NCT02100865|Device|Oxygen from cylinders|
205196|NCT02100891|Procedure|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
205491|NCT02091167|Device|transcranial Direct Current Stimulation|Direct currents will be transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode will be placed over F3 according to the 10-20 international system while the anode will be placed over the contralateral F4 region. The currents will flow continuously for 20 minutes with an intensity of 2 milliamperes.
205492|NCT02091180|Drug|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
205493|NCT02091180|Drug|Control|Saline infusion
205494|NCT02091193|Dietary Supplement|Krill Oil (Supplement A)|
205495|NCT02091193|Dietary Supplement|Placebo (Supplement B)|
205496|NCT00128193|Other|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
205497|NCT02091206|Drug|GWP42003-P|GWP42003-P is an oral solution presented as an oily solution containing 25 mg/mL cannabidiol (CBD: FT0086) or 100 mg/mL CBD (FT0095) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Subjects will be randomly assigned to receive either 5, 10 or 20 mg/kg/day.
205498|NCT02091206|Drug|Placebo control|Placebo oral solution contains the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
205499|NCT02091219|Drug|Vitamin D|2400 IU/day by mouth for 16 weeks
205500|NCT02091219|Drug|25(OH)D3|20 micrograms/day by mouth for 16 weeks
205501|NCT02091232|Biological|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
205502|NCT02091245|Drug|KPT-330|
205503|NCT02093741|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
211215|NCT02124486|Procedure|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
211216|NCT02124486|Behavioral|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
211217|NCT02124512|Drug|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
211218|NCT02124512|Other|Placebo|80 mg placebo once daily
211219|NCT00131794|Biological|BCG|
211220|NCT02124525|Drug|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
211221|NCT02124564|Drug|Lacosamide|Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.
4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .
The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day.
211222|NCT02124590|Other|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
211223|NCT02124590|Other|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
211522|NCT02120300|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
211523|NCT02120313|Other|inpatient rehabilitation|
211524|NCT02120313|Other|outpatient rehabilitation|
211525|NCT02120326|Device|Transcranial direct current stimulation of the motor cortex|The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.
Stimulation parameters:
2 mA intensity
Continuous stimulation for 20 min with rise times and fall times of 10 seconds each
211526|NCT02120326|Device|simulation of Transcranial direct current stimulation of the motor cortex|The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.
Stimulation parameters:
The intensity of the stimulation current is 2 mA
The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation.
211527|NCT00131274|Drug|Imatinib Mesylate (Gleevec)|
211528|NCT02120339|Drug|Carvedilol|
211529|NCT02120352|Drug|GSK744|White to almost white oval shaped film coated 30 mg tablets for oral administration.
210877|NCT02129777|Drug|Placebo|Placebo subcutaneous injection
210878|NCT02129790|Behavioral|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
210879|NCT02129803|Device|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
210880|NCT02129803|Device|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
210881|NCT02129816|Drug|Bryophyllum|
210882|NCT02129829|Drug|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
210883|NCT02129868|Device|Closed-loop (Android Closed-Loop platform)|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes.
210884|NCT02129881|Biological|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
210885|NCT02129894|Device|abdominal Binder|placement of abdominal binder
210886|NCT00132340|Device|Electrodes|
210887|NCT02129920|Other|This is an observational study|
210888|NCT00132665|Drug|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
210889|NCT02132585|Procedure|Speckle tracking echocardiography|
211224|NCT02124642|Dietary Supplement|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
211225|NCT02127372|Drug|Docetaxel, Cisplatin and STI571|Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.
Phase 1 dose levels are:
Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg
Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg
Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg
Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg
Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg
Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg
Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II.
211226|NCT00002238|Drug|Zidovudine|
211227|NCT00132028|Drug|vorinostat|Given orally
210563|NCT02137239|Drug|Corticosteroids|
210564|NCT02137239|Drug|Everolimus(EVL)|
210565|NCT02137239|Drug|Tacrolimus(TAC)|
210566|NCT02137252|Drug|Naltrexone|
210567|NCT02137252|Drug|Sugar Pill|
210568|NCT00133146|Biological|Grass MATAMPL|
210569|NCT02137265|Drug|Clomiphene|Clomiphene citrate 50 mg orally daily
210570|NCT02137265|Drug|Placebo|One pill every other day
210571|NCT02137278|Drug|Vasoactive drug therapies|Continue current vasoactive therapy
210572|NCT02137278|Other|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
210573|NCT02137304|Device|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
210574|NCT02137317|Device|LAPPE (locally adapted personal protective equipment)|Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.
Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.
Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes.
210575|NCT02137330|Device|Swallowable Obalon® Gastric Balloon|
210576|NCT02137343|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
210577|NCT02137343|Drug|Placebo|Placebo
210578|NCT02137343|Drug|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
210579|NCT00133159|Biological|Grass MATAMPL|
210580|NCT02137343|Drug|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
210581|NCT02137356|Radiation|standard dose pelvic radiation therapy|radiation therapy to pelvis delivered using standard conformal or IMRT techniques.
50.4-55 Gy
210890|NCT02132598|Drug|cabozantinib|
210254|NCT02098304|Device|Calcivis Caries Activity Imaging System|Unrestored sound molars imaged with the Calcivis Caries Activity Imaging System
210255|NCT02098304|Device|Calcivis Caries Activity Imaging System|Unrestored erupting or erupted third molars, with ICDAS score of 1, 2 or 3, imaged with the Calcivis Caries Activity Imaging System
210256|NCT02098317|Drug|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
210257|NCT02098317|Drug|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
210258|NCT02098330|Drug|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
210259|NCT02098330|Drug|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
210260|NCT00128921|Drug|VELCADE™|Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:
Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.
Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.
210261|NCT02098343|Drug|APR-246|Intravenous infusion.
210262|NCT02098343|Drug|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
210263|NCT02098356|Other|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
210264|NCT02098369|Behavioral|Written education material (basic)|Education material on COPD distributed to all participants.
210265|NCT02098369|Behavioral|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
210266|NCT02098369|Behavioral|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
210267|NCT02098369|Behavioral|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
210268|NCT02098382|Device|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
210269|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
209654|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered as a single dose
209655|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered as a single dose
209656|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered as a single dose
209657|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered as a single dose
209658|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered daily for 14 days
209659|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered daily for 14 days
209660|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered daily for 14 days
209661|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered daily for 14 days
209662|NCT00130260|Biological|Staph aureus types 5 and 8 conjugate vaccine|each IM dose contains 200 mc total conjugate
209949|NCT02105428|Behavioral|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
209950|NCT02105441|Device|Cochlear implant|Implantable hearing device
209951|NCT02105454|Drug|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
209952|NCT02105454|Drug|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
209953|NCT02105454|Drug|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
209954|NCT02105467|Drug|Grazoprevir 100mg/Elbasvir 50 mg fixed-dose combination|
209955|NCT02105467|Drug|Placebo to grazoprevir + elbasvir fixed-dose combination|
209956|NCT00129727|Drug|Carboplatin|Given intravenously
209957|NCT02105480|Device|Computer aided auscultation (CAA)|
209958|NCT02105493|Drug|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
209959|NCT02105493|Drug|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
209960|NCT02105506|Drug|Tachosil patch|
209343|NCT02077868|Drug|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
209344|NCT02077881|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
209345|NCT02077881|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
209346|NCT02077881|Drug|Indoximod|Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth
Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity.
209347|NCT02077907|Dietary Supplement|Super Cereal Plus (SC+)|
209348|NCT02077907|Dietary Supplement|Super Cereal (SC), fortified oil, sugar|
209349|NCT02077907|Dietary Supplement|Plumpy Sup|
209350|NCT02077907|Dietary Supplement|Corn Soy Blend 14 (CSB14) and fortified oil|
209351|NCT02077920|Drug|Chlorhexidine|SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China
Drug administration and preparation:
Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions
Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving
209352|NCT02077920|Drug|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
209353|NCT00126893|Drug|CC-401|
209354|NCT02077920|Device|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
209355|NCT02077920|Device|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
209663|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered daily for 14 days
209664|NCT02110420|Drug|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
209665|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered as a single oral dose
209666|NCT02110420|Drug|CC-90001|CC-90001 720mg will be administered as a single oral dose
209041|NCT02085382|Procedure|Conventional Mother Care|This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.
Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted.
209042|NCT02085395|Drug|SR-T100 ® Gel|
209043|NCT00127686|Drug|Buckwheat Honey|
209044|NCT02085408|Drug|clofarabine|Given IV
209045|NCT02085408|Drug|daunorubicin hydrochloride|Given IV
209046|NCT02085408|Other|clinical observation|Undergo clinical observation
209047|NCT02085408|Drug|cytarabine|Given IV
209048|NCT02085408|Drug|decitabine|Given IV
209049|NCT02085408|Other|laboratory biomarker analysis|Correlative studies
209050|NCT02085408|Procedure|quality-of-life assessment|Ancillary studies
209051|NCT02085408|Other|questionnaire administration|Ancillary studies
209052|NCT02085421|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
209053|NCT02085434|Behavioral|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
209054|NCT00127699|Procedure|Alcohol swab of umbilical cord|
209356|NCT02077933|Drug|alpelisib|alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.
In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.
In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.
In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.
In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily.
213532|NCT02141568|Other|Medical and psychological treatment|Medical and psychological treatment by the staff of the "functional neurology" clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist).
213533|NCT02141568|Other|Routine medical care|Treatment by an internal medicine physician on staff at Soroka UMC. Treatment will include an initial visit to the physician and further treatment as per his decision.
213534|NCT02141581|Biological|2011-2012 Fluzone® (IM)|This vaccine is given intramuscularly (IM)
213535|NCT02141581|Biological|2011-2012 Fluzone® (ID)|This vaccine is given intradermally (ID)
208729|NCT02090114|Drug|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
208730|NCT02090127|Drug|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
208731|NCT02092532|Drug|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
208732|NCT02092532|Procedure|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
208733|NCT00128336|Behavioral|Lifestyle: diet and exercise intervention|
208734|NCT02092545|Other|Ketogenic diet|
208735|NCT02092558|Drug|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
208736|NCT02092558|Drug|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
208737|NCT02092571|Drug|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
208738|NCT02092584|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
208739|NCT02092584|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
208740|NCT02092597|Drug|Exenatide|
208741|NCT02092597|Drug|Linagliptin|
208742|NCT02092597|Drug|Gliclazide|
208743|NCT02092610|Device|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
213235|NCT02148770|Behavioral|Normal Sleep|Half of the participants will have regular night sleep, whereas the other half will undergo complete sleep deprivation after every neurofeedback training session. First all participants will fill in several memory questionnaires and perform computer reaction time tests. Afterwards participants can enjoy a normal night of sleep, or be kept awake the whole night under the supervision and in the company of the experimenter. During the night a sleep EEG is registered. The next morning all participants will again fill in the memory questionnaires and perform a computer reaction time tests.
213236|NCT02148770|Device|fMRI-based Brain Computer Interface (BCI)|
213237|NCT02148783|Drug|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with [11C]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
213238|NCT02148783|Drug|Placebo|
213239|NCT02148796|Drug|Broncho-Vaxom|Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma SA, Switzerland; Storage: Store in the original package
213240|NCT02148796|Drug|Placebo|
213241|NCT02148809|Radiation|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
213536|NCT02143830|Drug|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
213537|NCT02143830|Drug|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
213538|NCT02143830|Drug|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
213539|NCT02143830|Drug|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
213540|NCT02143830|Biological|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
213541|NCT00133627|Drug|Ketotifen|
213542|NCT02143843|Drug|ForSight VISION5 Product|ForSight VISION5 Product used continuously for 7 months, then replaced with a new ForSight VISION5 Product and used continuously for another 6 months.
213543|NCT02143856|Drug|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
213544|NCT02143869|Device|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
207882|NCT02111993|Device|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
207883|NCT02111993|Device|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
207884|NCT02112006|Procedure|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
207885|NCT02112006|Procedure|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
207886|NCT02112019|Procedure|Sialoendoscopy|
207887|NCT02112019|Drug|saline|
207888|NCT02112019|Drug|hydrocortisone|
207889|NCT02112032|Drug|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
207890|NCT00130442|Drug|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
207891|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1 or 8 weeks in Arm 2.
207892|NCT02114190|Behavioral|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
207893|NCT00130728|Drug|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
207894|NCT02114190|Behavioral|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
207895|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
207896|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
207897|NCT02114203|Drug|placebo for PDE9i|oral dose, every 12 hours for 28 days
207898|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
207272|NCT00127855|Biological|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
207273|NCT02087046|Device|Deep Brain Stimulation with the Libra System|Deep Brain Stimulation programmed to eliminate tremor
207274|NCT02087059|Drug|Ruxolitinib|
207275|NCT02087072|Other|Collaborative visit with provider and pharmacist|
207276|NCT02087085|Drug|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye on Day 1, and every 3 months through Month 21.
207574|NCT02079740|Biological|Navitoclax|Given PO
207575|NCT02079740|Other|Pharmacological Study|Correlative studies
207576|NCT02079740|Drug|Trametinib|Given PO
207577|NCT02079753|Device|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
207578|NCT02079753|Device|Combination system of a portable and a stationary device.|Combination system of a portable and a stationary device (reservoir of liquid oxygen "Liberator 30, Caire" and a liquid Stroller oxygen pack "Caire" for patients using previously liquid oxygen, or a VisionAire5 "Airsep" stationary concentrator and an Inogen One G2 portable "Inogen" concentrator for patients using previously concentrators)
207579|NCT02079766|Drug|florbetapir F 18|
207580|NCT02079766|Drug|18F-AV-1451|
207581|NCT02079779|Other|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
207582|NCT02082236|Drug|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
207583|NCT02082236|Drug|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
207584|NCT02082249|Drug|ABT-SLV187|Dose levels will be individually optimized
207585|NCT00127296|Device|FlexPen®|
207586|NCT02082262|Drug|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
207587|NCT02082275|Other|OB Nest|Reduction in the number of clinic office visits
Assignment to a specific nursing care team
Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.
Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.
Augmentation of in-person visits between care providers and patients with video conversations.
Maternal outcomes will be monitored through surveys and questionnaires.
206967|NCT02094456|Procedure|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
206968|NCT02094456|Procedure|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
206969|NCT00128518|Drug|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
206970|NCT02094469|Drug|Cilostazol|Oral, Bid, 24 weeks
206971|NCT02094482|Device|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
206972|NCT02094521|Drug|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
206973|NCT02094534|Biological|ORMD-0801 capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
206974|NCT02094547|Dietary Supplement|New infant formula|New infant formula
207277|NCT02087085|Other|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
207278|NCT02087098|Drug|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
207279|NCT02087111|Drug|Telaprevir|375 mg film coated tablets
207280|NCT02087111|Drug|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
207281|NCT02087111|Drug|Ribavirin|200 mg tablets
207282|NCT02087124|Other|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
207283|NCT00127855|Biological|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
207284|NCT02087137|Behavioral|Memory and Aging Program|
207285|NCT02087163|Device|Movement Enhancement Technique|Conventional Orthodontic treatment
207286|NCT02087163|Device|Clear Aligner|Orthodontic treatment with Clear Aligner
207287|NCT02087176|Drug|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
207288|NCT02087176|Drug|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
206659|NCT00129090|Drug|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
206660|NCT02099136|Other|Imaging Biomarker Analysis|Correlative studies
206661|NCT02099162|Device|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
206662|NCT02101554|Drug|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
206663|NCT02101554|Drug|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
206664|NCT02101567|Drug|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head|In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
206665|NCT02101567|Drug|Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv|In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
206666|NCT02101580|Drug|ADI-PEG 20|
206667|NCT02101593|Drug|ADI-PEG 20|
206668|NCT02101606|Drug|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
206669|NCT00129272|Behavioral|CBT Treatment|Participants will undergo nine weeks of behavioral modification therapy only.
206670|NCT02101632|Dietary Supplement|Bee Venom Ointment|2 weeks
206671|NCT02101632|Other|Vaseline Ointment|2 weeks
206672|NCT02101645|Procedure|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
206975|NCT02094547|Dietary Supplement|Standard infant formula|Standard infant formula
206976|NCT02094560|Drug|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
206977|NCT02094573|Drug|AP26113|90 mg tablet, taken orally once daily,continuously in a 28-day cycle
206978|NCT02094573|Drug|AP26113|90 mg tablet, taken orally once daily for a 7 days, then a 180 mg tablet taken orally once daily, continuously in a 28-day cycle
206979|NCT02094586|Biological|PXVX0200|comparing 3 lots of PXVX0200
206049|NCT02113306|Device|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
206050|NCT02113306|Device|sham stimulation|electrodes will be put upside down
206051|NCT02113319|Drug|dasatinib|dasatinib 50 mg and 20 mg During one year
206371|NCT02106481|Drug|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
206372|NCT02106494|Drug|Dexamethasone 12 mg IV|
206373|NCT02106494|Drug|fosaprepitant 150 mg IV|
206374|NCT02106507|Drug|ARN-509|ARN-509, 240 mg/day, oral
206375|NCT02106507|Drug|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
206376|NCT02108964|Drug|EGF816|EGF816 will be dosed once daily. On the first day of each treatment Cycle, the patient receives an adequate drug supply for self-administration at home. The investigator must emphasize compliance with the study treatment and will instruct the patient to take EGF816 exactly as prescribed.
206377|NCT02108977|Other|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
206378|NCT02108977|Other|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
206379|NCT02108990|Drug|Acetaminophen|
206380|NCT00130156|Drug|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
206381|NCT02109003|Device|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
206382|NCT02109003|Device|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
206383|NCT02109016|Drug|Lucitanib|Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.
Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability.
206384|NCT02109029|Drug|LY2605541|Administered IV
206385|NCT02109029|Drug|Human Insulin|Administered IV
206386|NCT02109029|Drug|Sinistrin|Administered IV
205786|NCT02084186|Other|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
206052|NCT02113332|Drug|Liraglutide|
206053|NCT02113332|Drug|Placebo|
206054|NCT02113345|Behavioral|Metamemory Cognitive Intervention|Metamemory Cognitive Intervention
206055|NCT02113358|Drug|Intravenous colloid bolus with Voluven|
206056|NCT02113371|Behavioral|Intervention|
206057|NCT02113384|Other|Observational study.|Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
206058|NCT02076282|Other|1 MRI scan|For healthy volunteers: 1 MRI scan without contrast
For patients: 1 MRI scan with contrast
206059|NCT02076308|Other|Electroacupuncture and physical therapy|real electroacupuncture
206060|NCT02076308|Other|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
206061|NCT02076321|Drug|Acetaminophen|
206062|NCT02076321|Drug|Ibuprofen|
206063|NCT02076334|Device|Far Infrared Fabric|
206064|NCT02076334|Device|Spandex|
206065|NCT02076347|Behavioral|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
206066|NCT02076347|Behavioral|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
206067|NCT02076360|Behavioral|Preoperative Video|Patients will watch preoperative instructional video
206068|NCT00126724|Genetic|tgAAC94 placebo|placebo
206069|NCT02076373|Drug|recombinant human Erythropoietin|Intervenous administration
206070|NCT02076386|Drug|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
206071|NCT02076399|Drug|Fostamatinib Disodium 100mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.
205504|NCT02093754|Procedure|MRI and biopsy|
205505|NCT02093767|Dietary Supplement|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
205506|NCT02093780|Behavioral|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
205507|NCT02093780|Behavioral|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
205508|NCT02093793|Device|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
205509|NCT02093806|Other|measurment|
205787|NCT02084199|Drug|GLPG0634|100 mg oral tablet, intake once daily for 10 days
205788|NCT02084212|Other|Microperimetry|
205789|NCT02084225|Procedure|ultrasound guided regional nerve block|participants were the physicians performing the procedure
205790|NCT02084238|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
205791|NCT02084251|Drug|PB-119|
205792|NCT02084277|Device|Self-ligating brackets (SLB)|
205793|NCT02084277|Device|Conventional brackets (CB)|
205794|NCT00127569|Drug|Rituximab|
205795|NCT02084290|Behavioral|Shared Decision Making Program|This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
205796|NCT02084303|Other|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
205797|NCT02086279|Drug|GnRH analogue|Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.
Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured.
205798|NCT02086292|Procedure|2 ml 1% Lidocaine|
211530|NCT02120352|Drug|GSK744 LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
211531|NCT02120352|Drug|TMC278 LA|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
211532|NCT02120352|Drug|ABC/3TC|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
211533|NCT02120352|Drug|RPV|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. It will be co-administered with GSK744+ABC/3TC, from Week (-4) through Day 1, during the Induction Period. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
211534|NCT02120365|Drug|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
211535|NCT02120365|Drug|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
211536|NCT02120391|Other|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
211537|NCT02120404|Drug|Esmolol administration|Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.
Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 10 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.
The titrated dose will be maintained for a total duration of 24 hours.
211538|NCT00131287|Drug|Extract of Agaricus blazei Murill|
211853|NCT02153307|Device|Implantable loop recorders system Reveal ICM LINQ®,|
211854|NCT02153320|Procedure|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
211855|NCT02153333|Procedure|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
211856|NCT02115529|Drug|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
211857|NCT02115542|Drug|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (<30% fat) breakfast.
211858|NCT02115555|Behavioral|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
211228|NCT02127372|Drug|Docetaxel|
211229|NCT02127372|Drug|Cisplatin|
211230|NCT02127398|Biological|fecal microbiota|fecal microbiota in capsule form
211231|NCT02127411|Behavioral|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
211232|NCT02127424|Procedure|Nurse-driven HIV targeted screening|
211233|NCT02127424|Procedure|Current practice|
211234|NCT02127437|Drug|Lanreotide|120 mg, subcutaneously, once every 4 weeks
211235|NCT02127437|Drug|saline|0,5 ml, subcutaneously, once every 4 weeks
211236|NCT02127463|Drug|MC-1101|Topically, two times a day, morning and bedtime
211237|NCT02127463|Drug|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
211238|NCT00132028|Other|laboratory biomarker analysis|Correlative studies
211239|NCT02127476|Drug|KHK6640|Single ascending dose and multiple ascending doses administration
211240|NCT02127476|Drug|Matching Placebo|Single ascending dose and multiple ascending doses administration
211241|NCT02127489|Drug|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
211242|NCT02127515|Procedure|Non Invasive Prenatal Testing|
211243|NCT02127515|Procedure|Invasive Prenatal Testing|
211244|NCT02127541|Other|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
211539|NCT02120417|Drug|Ruxolitinib|5 mg tablets to be administered by mouth
Ruxolitinib 15 mg BID (starting dose)
211540|NCT02120417|Drug|Capecitabine|Capecitabine 2000 mg/m^2 daily given as 1000 mg/m^2 BID (starting dose) Day 1-14 of each 21 day cycle
211541|NCT02122536|Drug|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
210891|NCT02132611|Device|Diamondback 360® Micro Crown OAS|The Diamondback 360® micro crown OAS consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material and restores luminal patency. During rotation, centrifugal forces press the crown laterally against the coronary plaque, reducing a thin layer of that plaque on the vessel wall.
210892|NCT02132624|Biological|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
210893|NCT02132637|Drug|Insulin Peglispro|Administered SQ
210894|NCT02132637|Drug|Insulin Glargine|Administered SQ
210895|NCT02132650|Behavioral|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
210896|NCT02132650|Behavioral|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
210897|NCT02132663|Other|Control: Marketed routine infant formula|
210898|NCT02132663|Other|An investigational infant formula containing an alternate source of DHA|
210899|NCT00132678|Drug|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
210900|NCT02132689|Drug|Actilyse (Thrombolytic therapy)|
210901|NCT02132689|Drug|Heparine (Standard anticoagulation therapy)|
210902|NCT02132702|Device|Ekso|
210903|NCT02132715|Behavioral|Resistance Exercise|
210904|NCT02132715|Behavioral|KAATSU exercise|
210905|NCT02132728|Other|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
210906|NCT02132754|Biological|MK-4166|
210907|NCT02132754|Biological|Pembrolizumab|
210908|NCT02132767|Drug|Amiodarone|Amiodarone Initial Dose
Oral: 400 mg po TID for 3 days is recommended
For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
Oral: at least 200 mg/day to be continued until 60 days after randomization
If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started
210582|NCT02139904|Drug|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
210583|NCT02139904|Other|Active Symptom Control|
210584|NCT02139917|Behavioral|Transitional community based palliative care|transitional palliative care include:-
telephone follow up for early identification of signs and symptoms
relief of signs and symptoms encountered
home visit with spiritual support
210585|NCT02139930|Behavioral|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
210586|NCT02139930|Behavioral|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
210587|NCT02139930|Behavioral|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
210588|NCT02139943|Drug|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
210589|NCT00133367|Drug|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
210590|NCT02139943|Drug|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
210591|NCT02139943|Drug|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
210592|NCT02139956|Device|ultrasonography|open
210593|NCT02139969|Device|GreenLight XPS Laser System|
210594|NCT02139982|Procedure|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
210595|NCT02139982|Drug|ropivacaine|Different concentration of ropivacaine
210596|NCT02139995|Behavioral|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
210597|NCT02140008|Device|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
210598|NCT02140008|Device|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
210599|NCT02140021|Procedure|Anal Pap Test|During scheduled colposcopy or surgery, an anal pap test performed.
210600|NCT00133367|Drug|Melphalan|Given intravenously on day 2 before transplant.
209961|NCT02105519|Biological|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
209962|NCT02105532|Other|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
209963|NCT02105532|Other|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
209964|NCT02105545|Other|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
209965|NCT02105558|Procedure|Epidural|An epidural involves injecting pain-blocking medication into a space between the
vertebrae and the spinal fluid; it usually takes about 15 minutes to work.
209966|NCT02105558|Procedure|CSE|Combined Spinal Epidural: A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes. With either an epidural or CSE, the catheter that delivers the drug is left in the epidural space until the baby is born so the medication can be administered continuously.
209967|NCT00129727|Drug|bevacizumab|Given intravenously
210270|NCT02098395|Drug|liraglutide|Subjects randomised to 1.2 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for for 24 weeks. Administered subcutaneously (s.c., under the skin) once daily.
210271|NCT02100488|Device|Closed-loop insulin infusion system|Each subject will undergo two "Open-loop" and two "Closed-loop" meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
210272|NCT02100488|Other|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
210273|NCT00129194|Drug|KP-1461|
210274|NCT02100514|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
210275|NCT02100514|Other|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
210276|NCT02100527|Drug|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
210277|NCT02100527|Drug|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
209667|NCT02112383|Behavioral|Internet-based cognitive behavior therapy|For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
209668|NCT00130507|Drug|Experimental|Trastuzumab, 4 mg/kg (charge dose in first week); Later 2 mg/kg iv. in following weeks plus Vinorelbine 25 mg/m2 iv days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, p.o., b.i.d. days 1-14 each cycle (21 days).
209669|NCT02112396|Behavioral|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
209670|NCT02112409|Procedure|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
209671|NCT02112409|Procedure|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
209672|NCT02112422|Drug|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
209673|NCT02112422|Drug|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
209674|NCT02112435|Device|Somnyx ®|Active mandibular advancement splint
209675|NCT02112435|Device|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
209676|NCT02112448|Drug|continuous infusion|This arm will receive continuous morphine/midazolam and 'as needed' doses. This group will receive adjunctive medications, acetaminophen and ketorolac.
209677|NCT02112448|Drug|as needed dosing|This group will receive morphine and midazolam as needed to control their pain. Acetaminophen and ketorolac will also be given for pain control in the same manner as the continuous infusion group.
209678|NCT02112448|Drug|Acetaminophen|Acetaminophen will be given as a loading dose of 30 mg/kg rectally post surgery to all subjects and then 15 mg/kg every 4 hours for a total of 24 hours.
209679|NCT00130520|Drug|bevacizumab|10mg/kg every two weeks IV-bevacizumab
209680|NCT02112448|Drug|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
209968|NCT02105571|Behavioral|Intervention|
209969|NCT02105584|Device|Implantation of LAA closure device|
209357|NCT02077933|Drug|everolimus|everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.
In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation.
209358|NCT02080247|Drug|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
209359|NCT02080260|Drug|regorafenib|Single agent drug therapy with regorafenib
209360|NCT02080273|Drug|Colgate Cavitity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), control toothpaste
209361|NCT00127166|Drug|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
209362|NCT02080273|Drug|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. active comparator toothpaste
209363|NCT02080273|Drug|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), active comparator toothpaste
209364|NCT02080286|Behavioral|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
209365|NCT02080286|Device|Anodal tDCS|Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.
The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy.
209366|NCT02080286|Device|Sham tDCS|Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.
The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy.
209367|NCT02080299|Procedure|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
209368|NCT02080299|Procedure|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
209369|NCT02080312|Drug|Magnevist (gadopentetate dimeglumine)|
209370|NCT02080325|Other|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
208744|NCT00002217|Drug|Amprenavir|
208745|NCT00128362|Procedure|Radio-guided sentinel node biopsy|
208746|NCT02092610|Device|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
208747|NCT02092623|Device|Transvaginal posterior mesh|A trocar-free fixation system with low-weight mesh
208748|NCT02092636|Other|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
209055|NCT02085447|Behavioral|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
209056|NCT02085460|Drug|Placebo|
209057|NCT02085460|Drug|2% Rebamipide liquid|
209058|NCT02087748|Drug|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
209059|NCT02087774|Behavioral|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
209060|NCT02087787|Behavioral|BMT Legal Clinic|2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
209061|NCT02087800|Behavioral|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
209062|NCT02087800|Behavioral|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
209063|NCT00002216|Drug|Lamivudine/Zidovudine|
209064|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
209065|NCT02087813|Drug|Alpha1-antitrypsin|
209066|NCT02087813|Drug|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
209067|NCT02087826|Other|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
213545|NCT02143882|Drug|Fluenz|Live attenuated influenza vaccine
213546|NCT02143895|Drug|etifoxine|
213547|NCT02143895|Drug|Lorazepam|
213548|NCT02143895|Drug|Placebo|
213549|NCT02143908|Dietary Supplement|lysine supplementation|
213550|NCT02143908|Dietary Supplement|Placebo|
213551|NCT02143921|Behavioral|Training intervention|Intervention group service providers received intervention training
213552|NCT00133640|Drug|cholecalciferol|
213553|NCT02143934|Drug|Primaquine|
213554|NCT02143934|Drug|Placebo|Sugar pills, appearance identical to Primaquine tablets
213555|NCT02143934|Drug|Chloroquine|
213556|NCT02143934|Drug|Artemether Lumefantrine|
213557|NCT02143947|Device|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
213558|NCT02143947|Device|Full Contact Orthosis|The Full Contact orthosis is constructed from a 5/32" blue polypropylene with posting material comprised of white polypropylene.
208749|NCT02092636|Other|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
208750|NCT02092636|Other|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
208751|NCT02092649|Dietary Supplement|Omega-3 Complete|
208752|NCT02092649|Dietary Supplement|Placebo Pill|
208753|NCT02092662|Other|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
208754|NCT02092662|Other|Healthy controls|no treatment
208755|NCT02095145|Other|Laboratory Biomarker Analysis|Correlative studies
208180|NCT02107170|Drug|Sevoflurane|sevoflurane-based general anesthesia
208181|NCT02107170|Drug|Propofol|total intravenous anesthesia
208182|NCT02107170|Drug|Remifentanil|
208183|NCT00129909|Drug|fixed dose combination therapy|
208184|NCT02107183|Device|Optiflow (Fisher & Paykel Healthcare)|This device delivers high-flow oxygen through nasal cannula
208185|NCT02107183|Device|Venturi mask|This device delivers low-flow oxygen at predetermined concentrations
208186|NCT02107196|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
208187|NCT02107196|Drug|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
208188|NCT02107209|Procedure|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
208189|NCT02107222|Device|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
208190|NCT02107235|Drug|oral rigosertib|
208191|NCT02107235|Drug|cisplatin|
208192|NCT02107235|Radiation|Radiotherapy|
208193|NCT02107248|Behavioral|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
208194|NCT00129922|Drug|paclitaxel|
208195|NCT02107248|Behavioral|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
208196|NCT02109562|Drug|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets will help to confirm that study participants do not have any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
208197|NCT02109588|Behavioral|A supervised physical exercise program|Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate
208198|NCT02109601|Other|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
207588|NCT02082288|Other|Edessy ICSI Outcome Embryo Score|EIOS:
Age (ys) >35 (0) 30-35 (1) <30 (2) No of retrived oocyte <5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos <2 (0) 2-4 (1) >4 (2) No of good quality embryos <3 (0) 3-5 (1) >5 (2) No of embryos transferred -------- (0) ≤2 (1) >2 (2)
207589|NCT02082327|Drug|IV migalastat HCl|
207590|NCT02082327|Drug|IV placebo|
207591|NCT02082327|Drug|oral migalastat HCl|
207592|NCT02082340|Behavioral|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
207593|NCT02082340|Other|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
207899|NCT02114229|Drug|alisertib|Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
207900|NCT02114229|Drug|methotrexate|Methotrexate will be given at a dose of 5 g/m^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m^2/dose.
207901|NCT02114229|Drug|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
207902|NCT02114229|Drug|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
207903|NCT02114229|Drug|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
207904|NCT00130728|Drug|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
207905|NCT02114229|Drug|etoposide|Etoposide will be given 100 mg/m^2 IV infusion.
In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day.
207906|NCT02114229|Drug|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL*hr.
207907|NCT02114229|Drug|vincristine|Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
207908|NCT02114229|Procedure|Surgical resection|For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a "second-look" operation is encouraged if and may be performed prior to consolidation therapy.
207909|NCT02077101|Other|Interview|
207289|NCT02089178|Drug|propofol-remifentanil|
207290|NCT00000317|Drug|Placebo|Placebo
207291|NCT00002216|Drug|Amprenavir|
207292|NCT00127998|Drug|mefloquine|
207293|NCT02089178|Drug|sevoflurane-remifentanil|
207294|NCT02089191|Device|Nelfilcon A contact lenses|
207295|NCT02089191|Device|Stenfilcon A contact lenses|
207296|NCT02089204|Radiation|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
207297|NCT02089204|Radiation|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
207298|NCT02089204|Radiation|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
207594|NCT02082340|Other|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
207595|NCT02082340|Behavioral|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
207596|NCT00127296|Device|vial and syringe|
207597|NCT02082340|Behavioral|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
207598|NCT02082366|Device|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
207599|NCT02082379|Behavioral|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
207600|NCT02082392|Drug|Escitalopram|
207601|NCT02082405|Drug|bortezomib|Given SC or IV
206980|NCT00128518|Drug|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
206981|NCT02094586|Biological|Placebo|
206982|NCT02094599|Drug|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
206983|NCT02094599|Drug|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
206984|NCT02094599|Drug|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
206985|NCT02094612|Device|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
206986|NCT02094612|Behavioral|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
206987|NCT02096991|Other|Can 2|Consume two canned beverage
206988|NCT02096991|Other|Glass|consume two glass bottled beverage
206989|NCT02097004|Biological|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
206990|NCT02097004|Biological|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
206991|NCT00128791|Drug|Nitroprusside|
206992|NCT02097004|Drug|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
206993|NCT02097017|Drug|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
206994|NCT02097017|Other|placebo comparator|
206995|NCT02097030|Device|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
206996|NCT02097030|Device|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
206997|NCT02097030|Device|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
207299|NCT02089217|Procedure|Carotid endarterectomy|
207300|NCT02089217|Device|Carotid stenting|
207301|NCT02089230|Drug|MEK 162|Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.
Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.
206387|NCT02109042|Drug|Blosozumab|Administered subcutaneous (SC)
206388|NCT02109055|Other|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
206389|NCT02109055|Other|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
206673|NCT02101645|Procedure|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
206674|NCT02101658|Other|clinic-based weight measurements|
206675|NCT02101684|Drug|Orteronel 300mg BID|
206676|NCT02101697|Behavioral|HIV Stigma Reduction Intervention|The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.
Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.
Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.
Our previous research has found that these modules address factors identified as contributing to health professionals' stigma.
206677|NCT02101710|Drug|Elantan SR 60 mg|Trade Name: Elantan
Active Substance: Isosorbide 5-mononitrate
Pharmaceutical form: Tablet
Concentration: 60 mg
Route of Administration: Oral administration
206678|NCT02101710|Drug|Imdur SR 60 mg|Trade Name: Elantan
Active Substance: Isosorbide 5-mononitrate
Pharmaceutical form: Tablet
Concentration: 60 mg
Route of Administration: Oral administration
206679|NCT02101723|Dietary Supplement|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
206680|NCT00129285|Drug|Modafinil Low Dose|modafinil 200 mg/day
206681|NCT02101723|Dietary Supplement|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
206682|NCT02101723|Dietary Supplement|Placebo|Placebo powder without micronutrients
206683|NCT02101736|Drug|Cabozantinib|Open label Phase II clinical trials. All subjects will start cabozantinib at 40 mg. Subjects who tolerate 40 mg for 2 cycles will escalate to 60 mg.
206684|NCT02103881|Drug|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
206685|NCT02103881|Drug|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
206686|NCT02103894|Drug|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an [18F]MNI-777 PET imaging visit. For individuals with AD or CTE, [18F]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by [18F]florbetapir imaging) and tau protein uptake (measured by [18F]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, [123I]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
206072|NCT02076399|Drug|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
206073|NCT02076399|Drug|Fostamatinib Disodium 150mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening) over the course of 24 weeks.
206074|NCT02076412|Drug|Fostamatinib Disodium 100mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.
206390|NCT02109068|Behavioral|Weight Loss Counseling- Phone|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change.
206391|NCT00002227|Drug|Stavudine|
206392|NCT00130156|Drug|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
206393|NCT02109068|Behavioral|Weight Loss Counseling- In-Person|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change.
206394|NCT02111317|Drug|ASP015K|oral
206395|NCT02111317|Drug|verapamil|oral
206396|NCT02111330|Drug|PBF-509|
206397|NCT02111330|Drug|Placebo|
206398|NCT02111343|Other|Computer-based auditory training (CBAT)|There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.
Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day.
206399|NCT02111356|Device|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
206400|NCT02111369|Drug|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
205799|NCT02086292|Procedure|1 ml 2% Lidocaine|
205800|NCT02086305|Behavioral|Transitional Care Model|Symptom assessment and management, care goal setting, post-discharge support
205801|NCT02086305|Behavioral|Usual care|Usual care is the routine practice in the hospital
205802|NCT02086318|Other|OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle
205803|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
205804|NCT02086331|Procedure|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
205805|NCT02086331|Behavioral|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
205806|NCT02086331|Procedure|Contrast enhanced ultrasound|
206075|NCT02076412|Drug|Placebo|Placebo tablet PO bid (morning and evening)
206076|NCT02076412|Drug|Fostamatinib Disodium 150mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening) over the course of 24 weeks.
206077|NCT02076425|Behavioral|PCIT-ED|
206078|NCT02076438|Dietary Supplement|Probiotics|Randomized to receive probiotics or placebo
206079|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^12 DRP/mL tgAAC94
206080|NCT02076451|Drug|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
206081|NCT02076464|Behavioral|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
206082|NCT02079064|Drug|Desflurane|Inhalational anesthetic
206083|NCT02079064|Drug|Propofol|Intravenous anesthetic that can be given by continuous infusion
206084|NCT02079077|Drug|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
206085|NCT00127023|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
211859|NCT02115555|Behavioral|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
211860|NCT02115555|Behavioral|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
211861|NCT02115581|Drug|Coenzyme Q10|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
211862|NCT02115581|Drug|Placebo|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
211863|NCT02115594|Drug|Fulvestrant|
211864|NCT02115594|Drug|Entinostat|
211865|NCT00130871|Drug|levosimendan|
211866|NCT02115594|Drug|Placebo|
211867|NCT02115607|Drug|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
211868|NCT02115620|Other|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
211869|NCT02115646|Device|fractionated carbon dioxide laser|patients will have serial laser treatments
211870|NCT02115659|Drug|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
211871|NCT02115659|Drug|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
212177|NCT02148367|Drug|Erythropoietin|This is a double blind randomized study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.
Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock.
212178|NCT02148380|Drug|pemetrexed plus carboplatin|
212179|NCT02148380|Drug|gefitinib|
211542|NCT02122549|Device|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
211543|NCT02122562|Drug|Ketamine|Treatment
211544|NCT02122562|Other|Alcohol Infusion|Biomarker
211545|NCT00131521|Drug|mucomyst|
211546|NCT02122601|Drug|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
211547|NCT02122614|Behavioral|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
211548|NCT02122614|Behavioral|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
211549|NCT02122627|Drug|Vitamin D|Colecalciferol 16.800 IU per week
211550|NCT02122627|Drug|Placebo|
211551|NCT02122653|Other|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
211552|NCT02122653|Device|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
211553|NCT02122666|Procedure|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
211554|NCT02122679|Drug|Tranexamic Acid|
211555|NCT02122679|Drug|placebo|
211556|NCT00131521|Drug|sodium chloride (saline)|
211557|NCT02122692|Drug|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
211558|NCT02122692|Drug|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
211559|NCT02122692|Drug|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
211560|NCT02122705|Device|VPIA remifentanil|Vital signs controlled patient assisted intravenous analgesia using remifentanil
211561|NCT02122718|Drug|Allopurinol|
211872|NCT02115672|Drug|BL-8040|BL-8040 will be added to imatinib to improve CML response.
210909|NCT02132767|Procedure|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
211245|NCT02127567|Other|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
211246|NCT02127567|Other|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
211247|NCT02127580|Procedure|BAV|
211248|NCT02127580|Procedure|no BAV|
211249|NCT02129933|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.
* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)
211250|NCT02129933|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
211251|NCT02129946|Other|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
211252|NCT02129972|Device|Colon videocapsule endoscopy (PillCam colon 2)|This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.
Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.
In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a "comfort score" questionnaire.
In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy.
211253|NCT02129985|Drug|Exenatide|Exenatide (10 ug/bid for 3 months)
211254|NCT02129985|Drug|Metformin|Metformin 850 mg/bid for 3 months
211255|NCT02129998|Other|IVF/ICSI treatment|
211256|NCT02130011|Other|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
211257|NCT02130024|Drug|Ranibizumab|Patients will receive 0.5mg ranibizumab via intravitreal injection
211258|NCT00132379|Drug|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
210601|NCT02140021|Procedure|Anoscopy|During scheduled colposcopy or surgery, an anoscopy performed.
210602|NCT02140034|Procedure|Extensive Peritoneal Lavage|
210910|NCT00132678|Drug|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
210911|NCT02132767|Drug|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
210912|NCT02135042|Drug|Cisplatin|Given IV
210913|NCT02135042|Other|Clinical Observation|Undergo clinical observation
210914|NCT00002241|Drug|Indinavir sulfate|
210915|NCT00132834|Device|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
210916|NCT02135042|Drug|Fluorouracil|Given IV
210917|NCT02135042|Drug|Gemcitabine Hydrochloride|Given IV
210918|NCT02135042|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
210919|NCT02135042|Other|Laboratory Biomarker Analysis|Correlative studies
210920|NCT02135042|Drug|Paclitaxel|Given IV
210921|NCT02135042|Other|Quality-of-Life Assessment|Ancillary studies
210922|NCT02135055|Other|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
210923|NCT02135055|Drug|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
210924|NCT02135055|Drug|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
210925|NCT02135055|Procedure|Sedation interruption|Sedation interruption is performed at 8 am every morning.
210926|NCT00132847|Biological|German Cockroach Allergen extract|
210278|NCT02100540|Drug|I placebo capsule|I placebo capsule
210279|NCT02100540|Drug|II RDC 0.3mg capsule|II RDC 0.3mg capsule
210280|NCT02100540|Drug|III RDC 0.6mg capsule|III RDC 0.6mg capsule
210281|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
210282|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
210283|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
210284|NCT00129207|Drug|bortezomib|
210285|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
210286|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
210287|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
210288|NCT02100566|Behavioral|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
210289|NCT02100566|Behavioral|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
210290|NCT02100579|Drug|Bupivacaine|10 ml of 0.25% bupivacaine
210603|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
210604|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
210605|NCT02140047|Biological|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
210606|NCT02140060|Drug|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
210607|NCT02142712|Drug|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
210608|NCT02142712|Drug|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
210609|NCT02142712|Drug|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
210610|NCT02142725|Drug|LT-02|four times per day
209970|NCT02105597|Other|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
209971|NCT02105610|Drug|desflurane, isoflurane, sevoflurane|
209972|NCT00130000|Drug|Eculizumab|
209973|NCT02107898|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
209974|NCT02107898|Drug|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
209975|NCT02107924|Procedure|APPI of TKR-Stimulan|
209976|NCT02107937|Biological|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
209977|NCT02107937|Biological|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
209978|NCT02107937|Drug|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
209979|NCT02107950|Biological|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
209980|NCT02107950|Drug|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
209981|NCT02107963|Biological|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
209982|NCT02107963|Drug|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
209983|NCT00130013|Drug|Oral Amoxicillin|
209984|NCT02107963|Drug|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
209985|NCT02108002|Drug|Vorinostat|
209986|NCT02108015|Procedure|Brain Imaging (PET)|
209987|NCT02108015|Procedure|Aterial Line|
209988|NCT02108015|Procedure|Blood Sampling|
209989|NCT02108093|Procedure|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
209990|NCT02108106|Drug|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
209681|NCT02112461|Behavioral|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
209682|NCT02112474|Device|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
209683|NCT02112474|Device|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
209684|NCT02112474|Device|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
209685|NCT02114671|Drug|Faldaprevir high dose|capsules, oral
209686|NCT02114671|Drug|Placebo|capsule, oral
209687|NCT02114671|Drug|Ciprofloxacin|tablets, oral
209688|NCT00002232|Biological|APL 400-003|
209689|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
209690|NCT02114671|Drug|Faldaprevir low dose|capsules, oral
209691|NCT02114684|Drug|moxifloxacin|[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)]
209692|NCT02114697|Drug|Rosuvastatin|Rosuvastatin 20 mg - drug administered orally, once a day, for the duration of the trial, which is 3 years (to be discontinued on account of unacceptable adverse effects)
209693|NCT02114697|Behavioral|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
209694|NCT02114710|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
209695|NCT02114723|Device|Medical Taping Concept|The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.
The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears
209696|NCT02114736|Procedure|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
209697|NCT02114736|Drug|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
209698|NCT02114749|Device|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
209068|NCT02087826|Drug|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
209069|NCT02087839|Drug|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
209070|NCT02087839|Radiation|Radiation Therapy|Phase I: 45 Gy at 3 Gy per fractions once a day.
Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.
209071|NCT02087852|Other|salvia for germline DNA|
209072|NCT02087852|Behavioral|the Kidney Cancer Questionnaire|
209073|NCT02087852|Behavioral|Family History Questionnaire (when applicable)|
209074|NCT02087865|Drug|donepezil HCL|
209075|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
209371|NCT02080325|Other|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
209372|NCT00127166|Drug|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
209373|NCT02080338|Device|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
209374|NCT02080351|Behavioral|Simple cognitive task|
209375|NCT02080364|Drug|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
209376|NCT02080364|Drug|Placebo|Placebo administered orally, once daily for 18 months
209377|NCT02080377|Drug|Glibenclamide|
209378|NCT02080377|Drug|Insulin|
209379|NCT02083185|Drug|Leuprorelin|
209380|NCT00127413|Behavioral|Cognitive Behavioral Therapy-Integrated|Integrated treatment
209381|NCT02083211|Drug|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
209382|NCT02083211|Device|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
208756|NCT02095145|Other|Pharmacological Study|Correlative studies
208757|NCT02095145|Other|Placebo|Given PO
208758|NCT02095145|Drug|Pomegranate-Extract Pill|Given PO
208759|NCT02095158|Drug|AGN-199201|AGN-199201 applied to the face once daily for 52 weeks.
208760|NCT02095171|Drug|PRX002|
208761|NCT02095171|Other|Placebo|
208762|NCT02095184|Drug|Anastrozole|1 mg daily
208763|NCT00128570|Procedure|evaluation of cancer risk factors|
208764|NCT02095184|Drug|Letrozole|2.5 mg daily
208765|NCT02095197|Procedure|Interlaminar cervical epidural steroid injection|C7-T1 Cervical interlaminar epidural steroid injection
208766|NCT02095197|Procedure|Targeted cervical epidural steroid injections|Targeted cervical epidural steroid injections with an epidural catheter introduced at the C7-T1 level
208767|NCT02095210|Other|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
208768|NCT02095223|Device|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
209076|NCT02087865|Drug|Placebo|
209077|NCT02087891|Behavioral|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
209078|NCT02087891|Behavioral|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
209079|NCT02087891|Behavioral|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
208199|NCT02109601|Other|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
208200|NCT02109614|Drug|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
208483|NCT02102243|Procedure|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
208484|NCT00129363|Drug|Carvedilol|
208485|NCT02102243|Procedure|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
208486|NCT02102243|Procedure|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
208487|NCT02102256|Device|Auditory Brainstem Implant|
208488|NCT02102269|Device|actimove sling|
208489|NCT02102269|Device|shoulderlift|
208490|NCT02102295|Drug|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
208491|NCT02102295|Drug|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
208492|NCT02102308|Other|Exercise|Multicomponent exercise
208493|NCT02104752|Drug|Curcumin|360 mg/day (divided into twice daily oral doses)
208494|NCT02104765|Drug|LY2951742|Administered subcutaneously.
208495|NCT02104765|Drug|Placebo|Administered subcutaneously.
208496|NCT02104778|Drug|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
208497|NCT02104778|Drug|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
207910|NCT02077114|Biological|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
207911|NCT02077140|Drug|MDT-10013|
207912|NCT02077140|Drug|Standard of care for pain|
207913|NCT02077153|Behavioral|Reminiscence therapy|
207914|NCT02077153|Behavioral|Active participation in group setting|
207915|NCT02077166|Drug|Ibrutinib|
207916|NCT00126776|Behavioral|case management|case/self management for COPD vs usual care
207917|NCT02077166|Drug|Lenalidomide|
207918|NCT02077166|Drug|Rituximab|
208201|NCT00130195|Drug|methotrexate|
208202|NCT02109614|Drug|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
208203|NCT02109627|Drug|Ficlatuzumab|5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
208204|NCT02109627|Drug|Cytarabine|2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
208205|NCT02109640|Drug|Targinact|Post-operative analgesia
208206|NCT02109640|Drug|Oxycodone|Postoperative analgesia
208207|NCT02109640|Procedure|Laparoscopic segmental colectomy|
208208|NCT02109653|Drug|LGX818|Oral LGX818 300mg daily
208209|NCT02109666|Drug|Abatacept|
208210|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
208211|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
208212|NCT00002228|Drug|Enfuvirtide|
208213|NCT00130195|Drug|cytarabine|
208214|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
208215|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
207602|NCT02082405|Drug|cyclophosphamide|Given PO
207603|NCT02082405|Drug|dexamethasone|Given PO
207604|NCT02084771|Drug|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
207605|NCT02084771|Biological|Oral Salt and Water|Oral salt capsules and water, based on patient weight
207606|NCT02084784|Drug|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
207607|NCT02084784|Drug|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
207608|NCT02084797|Drug|V2R (Vasopressin 2 receptor)|All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
207609|NCT02084810|Drug|activated recombinant human factor VII|All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.
Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
207610|NCT02084810|Drug|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
207611|NCT00127634|Drug|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
207612|NCT02084823|Biological|cancer stem cell vaccine|
207919|NCT02077179|Behavioral|HIP Program|The entirety of the HIP Program is delivered through an interactive mobile website.
The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.
The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays.
207920|NCT02077192|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
207921|NCT02077205|Behavioral|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
207922|NCT02077218|Procedure|computed tomography|Undergo cardiac CT
207923|NCT02077218|Other|cytology specimen collection procedure|Undergo collection of blood samples
207924|NCT02077218|Other|laboratory biomarker analysis|Correlative studies
207302|NCT02089243|Procedure|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
207303|NCT00128011|Biological|killed oral cholera vaccine|
207304|NCT02089243|Procedure|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
207305|NCT02089256|Drug|Liraglutide|Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.
GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).
207306|NCT02089282|Device|Ultrasound|
207307|NCT02089295|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
207308|NCT02089295|Drug|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
207309|NCT02089295|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
207310|NCT02089308|Drug|Test treatment : V0116 transdermal patch|
207311|NCT02089308|Drug|Reference treatment : Nicotine transdermal patch|
207312|NCT02089334|Drug|RX-0201|RX-0201 will be administered in a dose up to 250mg/m^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.
In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles.
207313|NCT02091830|Drug|Cortisone Injection|
207314|NCT02091830|Other|Others|
207315|NCT00002217|Drug|Abacavir sulfate|
207316|NCT00128245|Drug|Pimecrolimus|
207317|NCT02091843|Procedure|DBS of the Basolateral Nucleus of the Amygdala|
207318|NCT02091843|Device|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
207319|NCT02091856|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
207613|NCT02084836|Other|Functional Magnetic Resonance Imaging|
206687|NCT00129545|Device|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
206688|NCT02103907|Other|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
206998|NCT02097043|Drug|DA-7218|
206999|NCT02097043|Drug|Placebo|
207000|NCT02097056|Drug|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
207001|NCT02097069|Dietary Supplement|Folic acid|Folic acid 400 mcg/day
207002|NCT00128804|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
207003|NCT02097069|Dietary Supplement|Myo-inositol|myo-inositol 2000 mg twice a day
207004|NCT02097069|Dietary Supplement|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
207005|NCT02097069|Dietary Supplement|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
207006|NCT02097082|Device|STANZA Drug-eluting resorbable Scaffold|
207007|NCT02097108|Drug|Raltegravir|
207008|NCT02097121|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
207009|NCT02097134|Drug|Melphalan|Given IA
207010|NCT02097147|Drug|Vilazodone 20 mg|Oral administration, once per day.
207011|NCT02097147|Drug|Vilazodone 40 mg|Oral administration, once per day.
207012|NCT02097147|Drug|Paroxetine 20 mg|Oral administration, once per day.
207013|NCT00128817|Radiation|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
207014|NCT02097147|Drug|Placebo|Oral administration, once per day.
207015|NCT02097160|Other|Vitamin D fortified yogurt and cheese products|
207016|NCT02099175|Drug|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
206401|NCT00130351|Device|formoterol|
206402|NCT02111369|Procedure|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
206689|NCT02103946|Procedure|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
206690|NCT02103946|Procedure|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
206691|NCT02103959|Drug|CMX-2043|Slow bolus IV administration of CMX-2043
206692|NCT02103959|Drug|Placebo comparator|Slow bolus IV administration of PBS
206693|NCT02103972|Dietary Supplement|GM080|
206694|NCT02103972|Dietary Supplement|Maltodextrin|
206695|NCT02103985|Drug|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
206696|NCT02103998|Drug|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
206697|NCT02103998|Drug|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
206698|NCT00129545|Drug|Warfarin|Subjects receive warfarin
206699|NCT02104011|Drug|Propranolol|
206700|NCT02104024|Other|Contrast Enhanced Ultrasound Scanning|
206701|NCT02104037|Procedure|Lumbar puncture|
206702|NCT02104050|Drug|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
206703|NCT02104050|Drug|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
206704|NCT02106520|Drug|Bevacizumab|
206086|NCT02079077|Drug|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
206087|NCT02079090|Drug|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
206088|NCT02079090|Drug|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
206089|NCT02079103|Device|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
206090|NCT02079103|Behavioral|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
206091|NCT02079116|Other|60 grams of fat plus water solution|A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
60 minutes before the radiopharmaceutical injection.
12 hours fasting minimum.
206092|NCT02079116|Other|Pure water|Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
30 minutes before the radiopharmaceutical injection.
12 hours fasting minimum.
206403|NCT02111382|Other|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.
When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.
The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths.
206404|NCT02111382|Other|CV4 (4th ventricle technique) manual therapy sham technique|The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.
The CV4 sham will be performed by a registered physiotherapist.
206405|NCT02111395|Behavioral|Personalized Cognitive-behavioral therapy|
206406|NCT02111395|Behavioral|Standard Practice Cognitive-behavioral therapy|
206407|NCT02111421|Drug|Dexmedetomidine|Initial dose of DEX was 1μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points,as soon as the umbilical cord was clapped.The wight used to calculate the dose of DEX would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
206408|NCT02111434|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
206409|NCT02111447|Drug|Propofol|Propofol infusion with nasal oxygen
212180|NCT02148393|Procedure|Vitrification with subsequent-cycle embryo thawing/transfer|The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).
In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.
212181|NCT02150824|Drug|BI 187004|BI 187004 low dose once daily
212182|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily
212183|NCT02150837|Other|5 & 2 & 2 Plan|Medifast has developed the 5 & 2 & 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 & 2 & 2 Plan consists of 5 Medifast meal replacements, 2 Lean & Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, >72g protein, >100g of carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
212184|NCT02150837|Other|4 & 2 & 1 Plan|Medifast has developed the 4 & 2 & 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 & 2 & 1 Plan consists of 4 Medifast meal replacements, 2 Lean & Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, >72g protein, >100g carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
212185|NCT02150863|Device|Ultrapulse Carbon Dioxide Laser|
212186|NCT02150863|Device|Cellutome epidermal harvesting system|
212187|NCT02150889|Behavioral|Running Program|16 week supervised running program
212188|NCT02150889|Behavioral|Yoga Program|once weekly supervised yoga
212189|NCT02150902|Procedure|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF >10g, FTI > 500 g-sec and minimum ablation duration >10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
212190|NCT00134095|Procedure|conventional surgery|
212489|NCT02143466|Drug|AZD9291 in combination with selumetinib|AZD9291 will be administered with intermittent doses of selumetinib. Part A: If tolerated, subsequent cohorts will test increasing doses of AZD9291 and/or selumetinib, until a recommended dose for further clinical evaluation is defined. Part B: The recommended dose from Part A may be further evaluated in an expansion cohort.
212490|NCT00133575|Biological|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
211873|NCT02115685|Other|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
211874|NCT02115698|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
211875|NCT02115698|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
211876|NCT00130884|Drug|levosimendan|
211877|NCT02115698|Dietary Supplement|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
211878|NCT02115698|Dietary Supplement|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
211879|NCT02117947|Behavioral|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
211880|NCT02117947|Behavioral|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
211881|NCT02117960|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
211882|NCT02117960|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
211883|NCT02117973|Procedure|iAssist Technique using Persona system vs. the conventional technique using Persona system|
211884|NCT02117986|Drug|colistin|One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
211885|NCT00131053|Drug|L-asparaginase|
211886|NCT02117999|Device|Transepithelial corneal cross-linking using iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
211887|NCT02117999|Device|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
211888|NCT02118012|Drug|Chlorcyclizine HCL plus Ribavirin|RBV+ chlorcyclizine HCl (75 mg twice daily)
211889|NCT02118012|Drug|Chlorcyclizine HCL Only|chlorcyclizine HCl (75 mg twice daily)
211890|NCT02118025|Procedure|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
211259|NCT02130024|Drug|Aflibercept|Patients will receive 2.0mg aflibercept via intravitreal injection.
211260|NCT02130037|Behavioral|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
211562|NCT02122718|Drug|Placebo|
211563|NCT02122731|Drug|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
211564|NCT02122744|Device|Super Rapid Magstim Stimulator|The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.
The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil.
211565|NCT02122757|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
211566|NCT02124642|Dietary Supplement|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
211567|NCT02124655|Drug|Essential oils|
211568|NCT02124655|Drug|0.2% chlorhexidine|
211569|NCT02124655|Drug|Sterile water|
211570|NCT02124668|Drug|Enzalutamide|oral
211571|NCT00131807|Procedure|Blood Pressure Measurement|
211572|NCT02124681|Drug|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
211573|NCT02124681|Other|Placebo|Placebo PO for 13±1 weeks
211574|NCT02124694|Behavioral|HTUG|HTUG is a group psychotherapy...
211575|NCT02124707|Drug|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
211576|NCT02124707|Drug|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
211577|NCT02124707|Drug|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
211578|NCT02124720|Behavioral|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
210927|NCT02135068|Device|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed closed loop system is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
210928|NCT02135068|Other|Snacking|Up to 45 g of oral glucose via Gatorade
210929|NCT02135094|Device|Sam Ultrasonic Diathermy Device (Active Device)|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
211261|NCT02130037|Other|psychotherapy|standard psychotherapy for eating disorders
211262|NCT02130063|Drug|iron isomaltoside 1000 (Monofer®)|
211263|NCT02130063|Drug|iron sucrose (Venofer®)|
211264|NCT02130089|Behavioral|Intensive Tailored Education|
211265|NCT02130102|Device|The ModuLAAr Ambient Assisted Living System|The system consists of the following modules which will be provided to the volunteers according to their needs:
tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies
211266|NCT02130115|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
211267|NCT02130128|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
211268|NCT02132793|Behavioral|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
211269|NCT02132793|Behavioral|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
211270|NCT02132806|Procedure|Piezosurgery with biomaterial mp3 + bracket|
211271|NCT02132806|Procedure|Piezosurgery with biomaterial mp3|
211272|NCT02132806|Procedure|Piezosurgery|
211273|NCT02132819|Other|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
210611|NCT02142725|Drug|LT-02|two times per day
210612|NCT02142725|Drug|Placebo|four times per day
210613|NCT02142738|Drug|Pembrolizumab|Pembrolizumab IV solution
210614|NCT02142738|Drug|Paclitaxel|Paclitaxel IV solution
210615|NCT02142738|Drug|Carboplatin|Carboplatin IV solution
210616|NCT02142738|Drug|Pemetrexed|Pemetrexed IV solution
210617|NCT00133549|Drug|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
210618|NCT02142738|Drug|Cisplatin|Cisplatin IV solution
210619|NCT02142738|Drug|Gemcitabine|Gemcitabine IV solution
210620|NCT02142751|Drug|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
210621|NCT02142751|Drug|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
210622|NCT02142751|Drug|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
210623|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
210624|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
210930|NCT02135094|Device|Sam Ultrasonic Diathermy Device (Placebo Device)|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
210931|NCT02135107|Drug|E3810|E3810 10mg will be administered orally twice daily during the treatment period (unblinded), and 10mg will be administered once daily during the maintenance period (double-blind).
210932|NCT02135107|Drug|E3810|E3810 10mg will be administered orally twice daily during the treatment period, and 10mg will be administered twice daily during the maintenance period.
210933|NCT02135107|Drug|E3810|E3810 20mg will be administered orally twice daily during the treatment period, and 10mg will be administered once daily during the maintenance period.
210934|NCT02135107|Drug|E3810|E3810 20mg will be administered orally twice daily during the treatment period, and 10mg will be administered twice daily during the maintenance period.
210935|NCT02137356|Drug|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
210291|NCT02100579|Drug|Preservative free normal saline|10 ml of preservative free normal saline
210292|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
210293|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
210294|NCT02100605|Device|Phytosun, decongestant, nasal spray|one time application of the nasal spray
210295|NCT00002223|Drug|Indinavir sulfate|
210296|NCT02102984|Device|covered biliary stents|endoscopic placement of covered biliary stents
210297|NCT02102984|Device|uncovered biliary stents|endoscopic placement of uncovered biliary stents
210298|NCT02103023|Drug|Imiquimod ointment|5% 250mg imiquimod ointment
210299|NCT02103023|Drug|Aqueous cream|aqueous cream
210300|NCT02103023|Biological|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
210301|NCT02103023|Biological|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
210302|NCT02103036|Procedure|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
210303|NCT00129441|Drug|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
210304|NCT02103036|Procedure|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
210305|NCT02103036|Device|TENS|Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.
Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes.
210306|NCT02103036|Device|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
210307|NCT02103049|Drug|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
209699|NCT02114762|Procedure|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
209991|NCT02108106|Drug|Placebo|
209992|NCT02108119|Dietary Supplement|Probiotics|
209993|NCT02108119|Dietary Supplement|Control placebo|
209994|NCT00130026|Drug|Caffeine|500 mg IV
209995|NCT02108132|Biological|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
209996|NCT02108132|Biological|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
209997|NCT02108145|Procedure|bilateral metal stent insertion|
209998|NCT02108145|Procedure|unilateral metal stent insertion|
209999|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered daily for 14 days
210000|NCT02110433|Device|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
210001|NCT02110433|Device|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
210002|NCT02110433|Device|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP < 100 pg/ml or remaining stable (< 30% increase).
210003|NCT02110446|Drug|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.
SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
210004|NCT02110446|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
210005|NCT00002229|Drug|Saquinavir|
209383|NCT02083237|Behavioral|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
209384|NCT02083250|Drug|Fludarabine|10 mg/m2 by vein on Days -6 to -3.
209385|NCT02083250|Drug|Clofarabine|40 mg/m2 by vein on Days -6 to -3.
209386|NCT02083250|Drug|Busulfan|Busulfan test dose, 32 mg/m2, administered within 10 days prior to admission as an outpatient or as an inpatient on Day -8. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-6. Busulfan adjusted dose determined to achieve a systemic exposure represented by an average daily AUC of 5500 µMol-min ± 5% for the entire 4-day treatment period, Days -6 to -3. If pharmacokinetic analysis cannot be completed for any reason, Busulfan given in a dose of 130 mg/m2 daily.
209387|NCT02083250|Drug|SAHA|Starting dose of SAHA: 200 mg by mouth daily on Days -6 to -3, within one hour prior to fludarabine administration for total 4 doses.
209388|NCT02083250|Procedure|Stem Cell Infusion (SCT)|Stem cell infusion on Day 0.
209389|NCT02083250|Drug|Thymoglobulin|Participants who receive a graft from an unrelated donor receive 0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1.
209700|NCT00130806|Drug|MK0478 (muraglitazar)|
209701|NCT02114775|Drug|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
209702|NCT02114775|Drug|Sildenafil|50 mg by mouth daily
209703|NCT02114775|Drug|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
209704|NCT02114788|Other|Internet-based|
209705|NCT02114801|Device|manual brushing|Tooth brushing
209706|NCT02114801|Device|electric toothbrush linked|Tooth brushing
209707|NCT02114801|Device|off electric toothbrush|Tooth brushing
209708|NCT02114814|Behavioral|Experimental: Diabetes Self Management|
209709|NCT02114814|Behavioral|General Health Education|
209710|NCT02114827|Behavioral|Video|23-minute video
209711|NCT02077933|Drug|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
209080|NCT02090140|Procedure|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
209081|NCT02090140|Procedure|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
209082|NCT02090153|Drug|S-1|40~60mg bid，d1~7 q2W
209083|NCT02090153|Drug|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
209084|NCT02090166|Other|Blood test|a blood test will be taken from each patient
209085|NCT02090192|Procedure|WBV training|
209086|NCT02090192|Procedure|PRT training|
209087|NCT02090205|Procedure|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
209088|NCT00128102|Drug|vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
209089|NCT02090205|Procedure|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
209090|NCT02090205|Procedure|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
209091|NCT02090205|Device|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
209092|NCT02090205|Device|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
209093|NCT02090218|Device|I-Gel|I-Gel supraglottic airway device
209390|NCT02083263|Device|Bilevel|3 months
209391|NCT00127413|Behavioral|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
209392|NCT02083263|Device|PEP mask|3 months
209393|NCT02083276|Drug|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
209394|NCT02083289|Drug|ONO-9054|
209395|NCT02083289|Drug|Latanoprost|
208498|NCT02104791|Drug|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
208499|NCT02104804|Drug|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
208500|NCT00129636|Procedure|Additional specific letter written to patient|
208501|NCT02104804|Drug|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
203782|NCT02029482|Drug|Placebo|
203783|NCT02029495|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
203784|NCT02029495|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
203785|NCT02029495|Drug|Placebo|Placebo administered via subcutaneous injection
203786|NCT02029508|Procedure|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
203787|NCT02029508|Procedure|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
203788|NCT02029508|Procedure|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
203789|NCT00122057|Drug|antibiotic treatment|
203790|NCT02031965|Drug|dexamethasone|Given IV
203791|NCT02031965|Procedure|therapeutic conventional surgery|Undergo surgical resection
203792|NCT02031965|Other|laboratory biomarker analysis|Correlative studies
203793|NCT00122434|Drug|BEA 2180 BR|
203794|NCT02031991|Biological|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
203795|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
208216|NCT02109692|Other|blood sample|dosage of miRNA
208217|NCT02109718|Drug|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
208218|NCT02109718|Drug|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
208219|NCT02112032|Drug|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
208220|NCT02112045|Drug|Granix|
208221|NCT02112045|Drug|High dose melphalan (HDR)|
208222|NCT02112045|Procedure|Autologous Stem Cell Transplant (ASCT)|
208502|NCT02104817|Drug|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
208503|NCT02104817|Drug|corn oil control|corn oil control arm
208504|NCT02104830|Biological|empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
208505|NCT02104830|Biological|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
208506|NCT02104830|Biological|Placebo №1|
208507|NCT02104830|Biological|Placebo №2|
208508|NCT02104830|Biological|empegfilrastim 7,5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
208509|NCT02104843|Drug|Daclatasvir, Asunaprevir and BMS-791325 FDC|
208510|NCT02104843|Drug|BMS-791325|
208511|NCT00129649|Behavioral|Telephone reminder call|
208512|NCT02104843|Drug|Rosuvastatin|
208513|NCT02104856|Device|Alair System (Bronchial Thermoplasty)|
208514|NCT02104869|Biological|Trivalent influenza vaccine (inactivated and fragmented).|
207925|NCT02077218|Other|questionnaire administration|Ancillary studies
207926|NCT02077231|Drug|Vitamin A|use one drop in the eye
207927|NCT00126776|Behavioral|usual care|usual care for COPD
207928|NCT02077231|Drug|carbomer eye gel|use one drop in the eye
207929|NCT02077244|Behavioral|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
207930|NCT02077257|Drug|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
207931|NCT02077270|Procedure|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
207932|NCT02077309|Drug|Linagliptin|
207933|NCT02077309|Drug|Placebo|
207934|NCT02077322|Device|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
207935|NCT02079779|Other|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
207936|NCT02079792|Procedure|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
207937|NCT00127101|Drug|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
207938|NCT02079792|Procedure|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
208223|NCT02112058|Behavioral|A Family-Strengthening Program for Low-Income Families|The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.
Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.
The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program.
208224|NCT02112071|Behavioral|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
207614|NCT02084862|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
207615|NCT02084862|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
207616|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
207617|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
207618|NCT02084901|Device|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
207619|NCT02084901|Device|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
207620|NCT02084914|Procedure|Endometrial scratching|Group A: pipelle Group B: sound
207621|NCT02084927|Biological|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
207622|NCT00127647|Drug|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
207623|NCT02084940|Drug|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
207624|NCT02084953|Drug|BMS-791325|
207625|NCT02084953|Drug|Moxifloxacin|
207626|NCT02084953|Drug|Placebo matching BMS-791325|
207627|NCT02084966|Procedure|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
207628|NCT02087176|Drug|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
207629|NCT02087176|Drug|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
207630|NCT02087189|Device|First ICD/CRT-D implantation or upgrade from pacemaker|
207631|NCT02087202|Drug|Magnesium Sulfate|magnesium sulfate is added to the patients
207632|NCT02087202|Drug|ketamine|ketamine is added to the patients.
207017|NCT02099175|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
207018|NCT02099175|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
207019|NCT02099175|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
207020|NCT02099175|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
207021|NCT02099175|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
207022|NCT02099175|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
207320|NCT02091869|Other|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
207321|NCT02091869|Device|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
207322|NCT02091882|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one IEM tablet approximately every 2 hours, for a total of 4 ingestions. The subject will ingest one 10 mg aripiprazole-embedded IEM tablet without food (Hour 0), one placebo-embedded IEM tablet without food (approximately Hour 2), one placebo-embedded IEM tablet with a high fat meal (approximately Hour 4), and one placebo-embedded IEM tablet without food (approximately Hour 6). Aripiprazole-embedded IEM tablets are being tested along with the placebo-embedded IEM tables to assess any differences in accuracy of IEM detection and latency. The time of ingestion will be recorded by clinic staff, and the time of IEM detection by the MIND1 System phone will be evaluated to determine the period of latency.
207323|NCT02091895|Procedure|probe-based confocal laser endomicroscopy|After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.
Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.
Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this.
207324|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
207325|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
207326|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
207327|NCT00128258|Procedure|Injection of bone marrow cells in the heart|Biological implant into the heart
207328|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
207329|NCT02091921|Drug|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
207330|NCT02091934|Procedure|Wavefront-guided PRK|Wavefront-guided PRK
206705|NCT02106520|Drug|placebo|
206706|NCT02106533|Other|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
206707|NCT02106546|Drug|veliparib|Oral Capsule
207023|NCT02099175|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|Particle boost with ENI:
HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost with ENI:
HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed
207024|NCT00002221|Drug|Peripheral blood stem cells|
207025|NCT00129116|Biological|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
207026|NCT02099175|Radiation|Radiotherapy - Patients not needing ENI|Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.
Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed
207027|NCT02099175|Radiation|Radiotherapy - Patients needing curative neck irradiation|LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.
Particle boost:
HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
207028|NCT02099188|Drug|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
207029|NCT02099188|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
207030|NCT02099188|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
207031|NCT02099188|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
207032|NCT02099188|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
207033|NCT02099188|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
207034|NCT02099188|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
206410|NCT02111447|Drug|Propofol|Propofol infusion with an LMA
206411|NCT02111447|Drug|Sevoflurane|Sevoflurane with an LMA
206412|NCT00130364|Drug|Pimecrolimus|Pimecrolimus 1 % cream
206413|NCT02111447|Drug|Isoflurane|Isoflurane with an LMA
206414|NCT00130637|Drug|Daclizumab|
206415|NCT02113397|Drug|TOBI™ Podhaler™ 112 mg inhaled twice daily|
206416|NCT02113397|Drug|Colistimethate 75 mg inhaled two times daily|
206417|NCT02113410|Behavioral|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
206418|NCT02113410|Behavioral|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attend twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
206419|NCT02113423|Radiation|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID*2F
206708|NCT00129857|Drug|Dexanabinol|
206709|NCT02106546|Drug|carboplatin|Intravenous infusion
206710|NCT02106546|Drug|paclitaxel|Intravenous infusion
206711|NCT02106546|Drug|placebo|Oral Capsule
206712|NCT02106559|Drug|porfimer sodium|Given IV
206713|NCT02106559|Procedure|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
206714|NCT02106559|Drug|photodynamic therapy|Undergo PDT
206715|NCT02106572|Drug|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
206716|NCT02106572|Drug|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
206717|NCT02106585|Drug|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
206718|NCT02106598|Drug|fluorescent cRGDY-PEG-Cy5.5-C dots|
206719|NCT00129870|Drug|oxaliplatin|
212491|NCT02143466|Drug|MEDI4736 Flat-Dose|AZD9291 and MEDI4736 Flat-Dose will be administered. Part A: If initial dosing is tolerated then subsequent cohorts will test increasing doses of AZD9291 and/or MEDI4736, until a recommended dose for further clinical evaluation is defined. Part B: The recommended dose from Part A will be further evaluated in an expansion cohort.
212492|NCT02143466|Drug|MEDI4736 in combination with MEDI4736 Flat-Dose plus Tremelimumab|AZD9291 and MEDI4736 Flat-Dose plus Tremelimumab will be administered. Part A: If initial dosing is tolerated then subsequent cohorts will test increasing doses of AZD9291 and/or MEDI4736 Flat-Dose plus Tremelimumab, until a recommended dose for further clinical evaluation is defined. Part B: The recommended dose from Part A will be further evaluated in an expansion cohort.
212493|NCT02143466|Drug|Selumetinib Continuous (non-Asia only)|AZD9291 and selumetinib will be administered in combination. Part A: If tolerated, subsequent cohorts will test increasing doses of AZD9291 and/or selumetinib, until a recommended dose for further clinical evaluation is defined. Part B: The recommended dose from Part A may be further evaluated in an expansion cohort.
212494|NCT02143479|Drug|Prograf|oral
212495|NCT02143479|Drug|Advagraf|oral
212496|NCT02143505|Drug|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
212497|NCT02145897|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
212498|NCT02145897|Biological|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
212499|NCT02145897|Other|Control|
212500|NCT02145910|Drug|Vemurafenib|Given PO
212501|NCT00133848|Drug|SB-275833 ointment, 1%|
212502|NCT02145910|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
212503|NCT02145910|Radiation|Radiosurgery (SRS)|Undergo SRS
212504|NCT02145923|Procedure|Peripheral blood stem cell mobilisation and collection|
212505|NCT02145923|Drug|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
212506|NCT02145923|Drug|Bone marrow derived allogeneic MMSCs infusion|
212507|NCT02145923|Procedure|Autologous peripheral blood stem cells infusion|
212801|NCT02138357|Drug|buprenorphine transdermal delivery system (BTDS)|
212802|NCT02138357|Drug|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
211891|NCT02118025|Procedure|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
212191|NCT02150902|Procedure|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
212192|NCT02150915|Other|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
212193|NCT02150928|Drug|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)
All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)
Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit
212194|NCT02150941|Device|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
212195|NCT02153346|Other|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
212196|NCT02153346|Other|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
212197|NCT02153359|Device|High Efficiency Particulate Air Cleaner|
212198|NCT02153359|Device|Sham air cleaner|
212199|NCT02153372|Other|BMC2012|
212200|NCT00134381|Drug|Green Tea|green tea product and placebo will be applied in cream formulation immediately after and at 1/2 hour, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 24 hours, 25 hours, and 27 hours after exposure to a 0.5-1.5 MED dose of UV light
212201|NCT02153385|Other|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
212202|NCT02153398|Drug|D961H sachet 10 mg|
212203|NCT02153398|Drug|D961H capsule 10mg|
212204|NCT02153398|Drug|D961H capsule 20 mg|
212205|NCT02153424|Drug|Apixaban|
212206|NCT02153437|Drug|BMS-919373|
211579|NCT02124733|Procedure|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
211580|NCT02124746|Drug|Momelotinib|Momelotinib tablets administered orally once daily
211581|NCT02124759|Drug|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
211892|NCT02118051|Drug|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle> 14mm.
211893|NCT02118051|Drug|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles> 17 mm are observed
211894|NCT02118051|Drug|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
211895|NCT02118064|Biological|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
211896|NCT00131053|Drug|Cytarabine|
211897|NCT02118077|Biological|G17DT|
211898|NCT02118090|Drug|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
211899|NCT02118090|Drug|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
211900|NCT02120417|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
211901|NCT02120430|Other|Video|The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes "the birth of a new relationship" between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children.
211902|NCT02120443|Device|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
211903|NCT02120456|Drug|LEO 43204|
211904|NCT02120456|Drug|Placebo|
211905|NCT02120469|Drug|everolimus|Given PO
211274|NCT02132819|Other|feeding during transfusion|The feeding process will be continued during the transfusion
211275|NCT02132832|Drug|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors.
211276|NCT02132832|Drug|Placebo|
211277|NCT00002240|Drug|Nelfinavir mesylate|
211278|NCT00132691|Drug|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
211279|NCT02132845|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
211280|NCT02132845|Drug|targeted therapy|Receive target-directed therapy
211582|NCT00002236|Drug|Zidovudine|
211583|NCT00131807|Procedure|Questionnaire|
211584|NCT02124759|Drug|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
211585|NCT02124759|Drug|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
211586|NCT02124772|Drug|Trametinib|Trametinib is available in tablet (0.125mg, 0.5mg, 2mg dose) as well as in powder form for Oral Solution (0.05mg/mL dose). It is recommended that subjects drink 4 to 6 mL of water/kg body weight following dosing.
211587|NCT02124772|Drug|Dabrafenib|Dabrafenib will be administered in combination with trametinib in Part C once the RP2D of dabrafenib and trametinib monotherapy is established in children.
211588|NCT02124785|Procedure|Blood sampling|At Years 21 to 25 after their second vaccine dose.
211589|NCT02124798|Device|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
211590|NCT02124811|Drug|Minocycline|
211591|NCT00132041|Procedure|radiofrequency ablation|
211592|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
211593|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
210936|NCT02137356|Drug|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
210937|NCT02137369|Drug|Escitalopram|Escitalopram, 20mg-40mg daily for 12 weeks
210938|NCT02137369|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
210939|NCT02137369|Other|Combination treatment (Escitalopram + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
210940|NCT02137382|Drug|Creon®|active comparator
210941|NCT02137382|Drug|Creon N|experimental drug
210942|NCT02137395|Drug|Dexamethasone|dexamethasone administration, intravenously
210943|NCT00133172|Drug|Tacrolimus|IV
210944|NCT02137395|Drug|Placebo|saline administration intravenously
210945|NCT02137408|Dietary Supplement|Docosahexaenoic acid 200 mg|Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
210946|NCT02137408|Drug|Docosahexaenoic acid 1000 mg|Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
210947|NCT02137421|Dietary Supplement|Resveratrol (3, 4´, 5 trihydroxystilbene)|Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
210948|NCT02137434|Other|Dietary calcium|Dietary calcium from skimmed milk
210949|NCT02137434|Dietary Supplement|Supplementary calcium|Supplementary calcium from calcium carbonate
210950|NCT02137447|Device|Negative Pressure treatment|
211281|NCT02132845|Procedure|therapeutic procedure|Receive standard of care therapy
211282|NCT02132845|Other|laboratory biomarker analysis|Correlative studies
211283|NCT02132858|Other|cytology specimen collection procedure|Correlative studies
211284|NCT02132858|Other|laboratory biomarker analysis|Correlative studies
211285|NCT02132871|Device|Impedance cardiography Physioflow ®|
211286|NCT02132884|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
210308|NCT02103062|Drug|ABI-007|
210625|NCT02142777|Drug|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
210626|NCT02142777|Drug|Placebo|The placebo has no active ingredients but is made to look like the study drug.
210627|NCT02142790|Drug|paclitaxel liposome injection|
210628|NCT00133549|Biological|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
210629|NCT02142803|Biological|Bevacizumab|Given IV
210630|NCT02142803|Other|Laboratory Biomarker Analysis|Correlative studies
210631|NCT02142803|Other|Pharmacological Study|Correlative studies
210632|NCT02142803|Drug|Sapanisertib|Given PO
210633|NCT02142816|Device|Doppler|Fluid therapy guided by doppler
210634|NCT02145143|Drug|thyrotropin alpha|
210635|NCT02145156|Behavioral|Tailored educational materials|The tailored intervention will use an automated "tailoring engine" to retrieve participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. To do this, the survey engine retrieves from a "message library" the specific educational messages that are linked to each individual participant's survey. These educational messages will be individually tailored to reflect the top concerns indicated by the participant about the HPV vaccine for themselves or their adolescent child. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
210636|NCT02145156|Behavioral|Untailored educational materials|The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV "Vaccine Information Sheet" that has been created by the Centers for Disease Control and Prevention and is required to be given to patients prior to HPV vaccine administration
210637|NCT02145156|Behavioral|Survey-only|For those in the "Standard of Care" arm, a random ½ of the sample will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
210638|NCT00133744|Dietary Supplement|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
210639|NCT02145169|Drug|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
210640|NCT02145182|Drug|Eculizumab|Eculizumab will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).
210641|NCT02145182|Drug|Placebo|Placebo will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).
210006|NCT00130260|Biological|placebo|placebo to match StaphVAX
210007|NCT02110459|Drug|POL7080|Intravenous infusion
210008|NCT02110472|Device|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
210309|NCT02103075|Device|Neuromuscular electrical stimulation|All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
210310|NCT02103088|Behavioral|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
210311|NCT02103101|Other|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
210312|NCT02103101|Genetic|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
210313|NCT02105610|Drug|total intravenous anesthetics|
210314|NCT02105623|Behavioral|Standard Therapy|Risk factor control Diet Exercise for 24months
210315|NCT02105623|Drug|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
210316|NCT02105636|Drug|Nivolumab|
210317|NCT02105636|Drug|Cetuximab|
210318|NCT02105636|Drug|Methotrexate|
210319|NCT00129740|Drug|Nilotinib|400 mg orally twice daily
210320|NCT02105636|Drug|Docetaxel|
210321|NCT02105649|Other|Strengthening exercise + Electrical stimulation of calf muscle|
210322|NCT02105649|Other|selected physical therapy program|
210323|NCT02105662|Drug|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
210324|NCT02105675|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
210325|NCT02105675|Drug|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
209712|NCT02077946|Drug|liraglutide|No treatment given.
209713|NCT02077946|Drug|sitagliptin|No treatment given.
209714|NCT02077959|Drug|lenalidomide|Given PO
209715|NCT02077959|Biological|pidilizumab|Given IV
209716|NCT02077959|Other|pharmacological study|Correlative studies
209717|NCT00126906|Drug|Monthly sulfadoxine/pyrimethamine|
209718|NCT02077959|Other|laboratory biomarker analysis|Correlative studies
209719|NCT02077972|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
209720|NCT02077985|Behavioral|Sensory Adapted Dental Environment|See study arm description.
209721|NCT02077998|Radiation|carbon C 14 oxaliplatin|Given IV
209722|NCT02077998|Drug|oxaliplatin|Given IV
209723|NCT02077998|Other|laboratory biomarker analysis|Correlative studies
210009|NCT02110485|Other|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
210010|NCT02110511|Other|blended lentils|blended lentils burritto breakfast
210011|NCT02110511|Other|whole lentils|whole lentils breakfast burritto
210012|NCT02110511|Other|no lentils|No lentils control breakfast burritto
210013|NCT02110524|Device|Percutaneous Transluminal Angioplasty|
210014|NCT02110537|Procedure|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
209396|NCT02083302|Behavioral|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
209397|NCT02083302|Behavioral|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.
Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention.
209398|NCT02083302|Behavioral|SCREAM Theater Dose 4|Booster Session
209399|NCT02083315|Drug|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
209400|NCT02083315|Drug|TRV130 3 mg|TRV130 3 mg IV x 1 dose
209401|NCT02083315|Drug|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
209402|NCT02085460|Drug|4% Rebamipide liquid|
209403|NCT02085473|Biological|Subcutaneous Injection|Subcutaneous Injection
209404|NCT02085486|Device|Ultrasound-assisted puncture|Portable ultrasound device
209405|NCT02085486|Other|Standard|Standard inspection, palpation.
209406|NCT02085499|Device|non-synchronized NIMV|During the study each infant will undergo a 2-hour period of NIMV at a frequency of 30 cycles per minute.
NIMV will be provided by a time cycled, pressure limited neonatal ventilator (Puritan Bennett 840, Covidien, Boulder, CO).
209407|NCT02085499|Device|Synchronized NIMV|During the study each infant will undergo a 2-hour period of S-NIMV at a frequency of 30 cycles per minute.
S-NIMV will be provided by a time cycled, pressure limited neonatal ventilator, with leak compensation capacity and nasal flow triggered ventilation (Puritan Bennett 840, Covidien, Boulder, CO). Synchronization will be achieved by the leak compensation software and the internal sensor of the ventilator.
209408|NCT02085512|Procedure|Neurocognitive retraining|
209409|NCT00002214|Drug|Capravirine|
209410|NCT00127712|Drug|Amiodarone|
209724|NCT02078011|Device|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
209725|NCT02078024|Drug|IVM plus ALB|
209726|NCT02078024|Drug|IVM|
209727|NCT02078037|Device|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
203796|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
203797|NCT02032004|Biological|Allogeneic Mesenchymal Precursor Cells (MPC)|CEP-41750 consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo,and cryopreserved
203798|NCT02032004|Other|Sham Comparator|Scripted sham intracardiac mapping and cell delivery
203799|NCT02032017|Procedure|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
203800|NCT02032017|Procedure|Percutaneous assisted approach|
203801|NCT02032017|Procedure|Anterolateral approach|
204103|NCT02024373|Drug|placebo|20 mg (every evening orally) for 8 weeks
204104|NCT00121615|Drug|etanercept|
204105|NCT02024386|Drug|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
204106|NCT02024399|Other|Exercise|Strength training, aerobic exercise and core strengthening, running
204107|NCT02024412|Drug|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
204108|NCT02024412|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
204109|NCT02024425|Dietary Supplement|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
204110|NCT02024425|Dietary Supplement|Control supplement|
204111|NCT02024438|Drug|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
204112|NCT02024438|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
204113|NCT02024451|Device|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
204114|NCT02024451|Device|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
204115|NCT00121628|Drug|AMG 706|
208515|NCT02104882|Radiation|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
208516|NCT02104895|Radiation|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
208517|NCT02104895|Radiation|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
208518|NCT02104908|Procedure|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
208519|NCT02107261|Drug|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
208520|NCT02107274|Drug|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
208521|NCT02107274|Drug|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
208522|NCT02107287|Radiation|IMRT Technique|
203802|NCT02032017|Other|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
203803|NCT02032043|Drug|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
203804|NCT00002180|Drug|Tenofovir|
203805|NCT00122434|Drug|tiotropium|
203806|NCT02032056|Dietary Supplement|Probiotic (10^9 CFU/day)|
203807|NCT02032056|Dietary Supplement|Probiotic (10^8 CFU/day)|
203808|NCT02032069|Other|no intervention|
203809|NCT02032082|Other|Carbone monoxide|
203810|NCT02032095|Drug|GB-0998|
203811|NCT02032108|Behavioral|lifestyle counselling|A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.
Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress.
203812|NCT02032121|Procedure|Blood specimen|
208225|NCT02112084|Behavioral|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
208226|NCT02112097|Drug|Gadolinium|For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine)
.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
208227|NCT02112097|Drug|Gadolinium|For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine)
.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
208228|NCT02112097|Drug|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
208229|NCT00130442|Drug|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
208230|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 12|sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of "clear" or "minimal" by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from "5 = severe" to "0 = none" indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of "clear" or "minimal" consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque.
208231|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 24|sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of "clear" or "minimal" by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from "5 = severe" to "0 = none" indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of "clear" or "minimal" consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque.
208232|NCT02114229|Radiation|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
208233|NCT02114242|Other|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
208234|NCT02114242|Other|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
208523|NCT02107300|Drug|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
208524|NCT02107300|Drug|Placebo (for NeutraSal)|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
207633|NCT00127868|Drug|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
207939|NCT02079805|Drug|Azilsartan|Azilsartan tablets
207940|NCT02079805|Drug|Telmisartan|Telmisartan tablets
207941|NCT02079818|Device|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
207942|NCT02079831|Behavioral|Energy Restriction|Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.
Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity.
207943|NCT02079831|Behavioral|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
207944|NCT02079831|Behavioral|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
207945|NCT02079844|Drug|Roflumilast|Roflumilast tablets
207946|NCT02079844|Drug|Placebo|Roflumilast placebo-matching tablets
207947|NCT02079844|Drug|Second generation antipsychotic|
207948|NCT00127101|Drug|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
207949|NCT02079857|Other|Standard protocol|Subjects will receive a standard treatment
207950|NCT02079857|Other|Individualized protocol|Subjects will receive an individualized treatment
207951|NCT02079857|Other|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
207952|NCT02079870|Drug|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
207953|NCT02079870|Drug|placebo|Solution for subcutaneous (s.c. - under the skin) injection
207954|NCT02079896|Drug|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
207331|NCT02091934|Procedure|Wavefront-optimized PRK|Wavefront-optimized PRK
207332|NCT02091947|Device|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
207333|NCT02091960|Drug|enzalutamide|oral
207334|NCT02094625|Drug|N-Acetylcysteine|NAC will be administered intravenously over ~30 minutes starting 4 hours following completion of cisplatin for the first 3 cycles of chemotherapy. Patients will have the option to continue with NAC for any remaining cycles.
Three dose levels have been pre-determined:
Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg
Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will "de-escalate" from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.
207335|NCT02094651|Drug|divalproex sodium|
207336|NCT02094651|Other|Placebo|
207634|NCT02087215|Drug|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
207635|NCT02087215|Drug|Placebo|
207636|NCT02087228|Device|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
207637|NCT02087228|Device|radiofrequency energy ablation device|
207638|NCT02087241|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
207639|NCT02087241|Drug|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
207640|NCT02087241|Drug|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
207641|NCT02087241|Drug|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
207642|NCT02087267|Procedure|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
207643|NCT02087293|Behavioral|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
207644|NCT00127881|Drug|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
207645|NCT02087306|Drug|CMX001|CMX001 administered twice weekly, dose depending on weight.
207035|NCT02099188|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.
Particle boost with ENI:
HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
207036|NCT02101749|Biological|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
207037|NCT02101775|Drug|Gemcitabine Hydrochloride|Given IV
207038|NCT02101775|Other|Laboratory Biomarker Analysis|Correlative studies
207039|NCT02101775|Other|Pharmacological Study|Correlative studies
207337|NCT02094664|Device|Heated and humidified oxygen|
207338|NCT00128518|Drug|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
207339|NCT02094677|Device|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
207340|NCT02094677|Device|etafilcon A|Participants were randomized to wear etafilcon A control lens.
207341|NCT02094677|Device|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
207342|NCT02094690|Device|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
207343|NCT02094690|Device|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
207344|NCT02094703|Drug|Levofloxacin|
207345|NCT02094703|Drug|Solifenacin succinate|
207346|NCT02094703|Drug|Placebo (for Solifenacin succinate)|
207347|NCT02094716|Drug|PF-045|Topical application, single whole-body treatment
207348|NCT02094716|Drug|PF-055|Topical application, single whole-body treatment
207349|NCT00128531|Drug|leuprolide acetate|
207350|NCT02094716|Drug|Vehicle|Topical application, single whole-body treatment
207351|NCT02094729|Drug|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
206720|NCT02106611|Other|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
206721|NCT02106611|Procedure|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
206722|NCT02106611|Procedure|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
206723|NCT02106624|Other|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
206724|NCT02106637|Drug|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
206725|NCT02106637|Drug|placebo|placebo
206726|NCT02106650|Drug|Folotyn and Leucovorin|
206727|NCT02106650|Drug|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
206728|NCT02106650|Drug|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
206729|NCT02109081|Drug|Dexamethasone|
206730|NCT02109081|Drug|Placebo|
207040|NCT02101775|Other|Placebo|Given PO
207041|NCT02101775|Drug|WEE1 Inhibitor AZD1775|Given PO
207042|NCT02101788|Other|Laboratory Biomarker Analysis|Correlative studies
207043|NCT00129285|Drug|Modafinil High Dose|modafinil 400 mg/day
207044|NCT02101788|Drug|Letrozole|Given PO
207045|NCT02101788|Drug|Paclitaxel|Given IV
207046|NCT02101788|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
207047|NCT02101788|Other|Pharmacological Study|Correlative studies
207048|NCT02101788|Other|Quality-of-Life Assessment|Ancillary studies
207049|NCT02101788|Drug|Tamoxifen Citrate|Given PO
212803|NCT02138383|Drug|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
212804|NCT02138383|Drug|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
212805|NCT00133250|Other|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
212806|NCT02138383|Drug|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
212807|NCT02138396|Drug|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
212808|NCT02138396|Drug|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
212809|NCT02138396|Drug|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
212810|NCT02138409|Drug|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
212811|NCT02138409|Drug|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
212812|NCT02138422|Biological|Xilonix|
212813|NCT02138422|Biological|Placebo|
212814|NCT02140996|Drug|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
212815|NCT02141009|Biological|Prevnar 13|
212816|NCT02141022|Other|plasticity-based computerized cognitive remediation program|
212817|NCT02141022|Drug|Gileyna|
212818|NCT02141035|Drug|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
212819|NCT02141035|Drug|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
213088|NCT02133560|Behavioral|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
212207|NCT02153437|Drug|Sotalol|
212208|NCT02153437|Drug|Placebo for BMS-919373|
212209|NCT02153450|Drug|metformin hydrochloride|Given PO
212508|NCT02145936|Other|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
212509|NCT02145949|Drug|Essential Amino Acids (EAA)|Twice daily ingestion of 20 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
212510|NCT02145949|Drug|Placebo (Alanine)|Twice daily ingestion of 20 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
212511|NCT02145962|Device|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
212512|NCT00133861|Drug|Botulinum toxin|
212513|NCT02145962|Device|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
212514|NCT02145975|Drug|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
212515|NCT02145975|Drug|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
212516|NCT02148393|Procedure|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
212517|NCT02148393|Drug|Pregnyl®|1500 IU
212518|NCT02148393|Drug|Utrogestan®|200 mg tid
212519|NCT02148393|Drug|Progynova®|2 mg bid
211906|NCT02120469|Drug|eribulin mesylate|Given IV
211907|NCT02120469|Other|pharmacological study|Correlative studies
211908|NCT00131300|Device|Synvisc (hylan G-F 20)|
211909|NCT02120469|Other|laboratory biomarker analysis|Optional correlative studies
211910|NCT02120482|Device|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
211911|NCT02120495|Procedure|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
212210|NCT02153450|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
212211|NCT00134394|Drug|Etanercept plus tacrolimus|
212212|NCT02153463|Behavioral|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
212213|NCT02153476|Drug|2.0mg of ALG-1001|
212214|NCT02153476|Drug|Balanced Salt Solution|
212215|NCT02153489|Drug|Aclidinium bromide|
212216|NCT02153489|Drug|Placebo|
212217|NCT02153502|Drug|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
212218|NCT02153502|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
212219|NCT02153515|Other|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
212220|NCT02153528|Drug|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
212221|NCT02153528|Drug|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
212222|NCT00134407|Procedure|Normal diet|
212223|NCT02153541|Drug|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
212224|NCT02115698|Dietary Supplement|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
211594|NCT02127606|Device|Vibration with tilt-table standing|
211595|NCT02127619|Device|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
211596|NCT02127632|Device|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
211597|NCT02127632|Device|Laryngeal Mask Airway-Supreme|Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson & Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
Other Names:
LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7
211598|NCT02127645|Procedure|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
211599|NCT02127645|Procedure|LRT-TEM|TEM following 46 Gy RT
211600|NCT02127645|Procedure|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
211601|NCT02127645|Procedure|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
211912|NCT02120508|Device|rTMS|To test the efficacy of this specific setting.
211913|NCT02120547|Drug|Cenicriviroc in mild liver impaired|Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
211914|NCT02120547|Drug|Cenicriviroc in moderate liver impaired|Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
211915|NCT02120560|Procedure|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
211916|NCT02120573|Other|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
211917|NCT02120573|Other|Workshop using Educational Film|workshops using film review about CPR
211918|NCT02120573|Other|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
211919|NCT00131313|Drug|Nipent, Cytoxan, Rituxan|
211920|NCT02120573|Other|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
211287|NCT02132884|Procedure|therapeutic procedure|Receive standard of care treatment
211288|NCT02132884|Drug|targeted therapy|Receive specific targeted therapy
211289|NCT00132691|Drug|oral corticosteroid with immunosuppressive agents as needed|Prednisone
211290|NCT02132884|Other|laboratory biomarker analysis|Correlative studies
211291|NCT02132897|Drug|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
211292|NCT02132897|Drug|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
211293|NCT02135120|Drug|Combined spinal epidural anesthesia technique with intrathecal morphine|
211294|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
211295|NCT00132860|Drug|azithromycin|
211296|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
211297|NCT02135133|Drug|Idelalisib|150 mg BID Oral Daily
211298|NCT02135133|Drug|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
211299|NCT02135146|Drug|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
211300|NCT02135146|Drug|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
211301|NCT02135159|Drug|TDM1|administration of the TDM1 by IV perfusion
211302|NCT02135159|Radiation|Brain Sequential RT|local RT
211303|NCT02135172|Behavioral|Sitting|
211304|NCT02135172|Behavioral|Standing|
211602|NCT00132054|Drug|amrubicin hydrochloride|
211603|NCT02127658|Other|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
210642|NCT02145195|Dietary Supplement|Vitamin D3 (cholecalciferol)|
210643|NCT02145208|Device|TIND System|An implant
210644|NCT02145221|Other|Music Therapy|
210951|NCT02137473|Other|Human milk-based fortifier|
210952|NCT02137473|Other|Bovine protein-based fortifier|
210953|NCT02137499|Device|geko device|
210954|NCT00133172|Drug|mycophenolate mofetil|IV
210955|NCT02137512|Device|Closed-Loop Control System|The devices that will be used in the Closed-Loop Control System include the following components:
DiAs - a smart-phone medical platform;
Dexcom Dexcom G4 Platinum connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and
Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class
210956|NCT02137525|Drug|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
210957|NCT02137525|Drug|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
210958|NCT02137525|Drug|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
210959|NCT02137525|Drug|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
210960|NCT02137525|Drug|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
210961|NCT02140060|Drug|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
210962|NCT02140060|Drug|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
210963|NCT02140060|Drug|Brinzolamide 1% ophthalmic suspension AZOPT®|
210964|NCT02140060|Drug|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
210965|NCT00133380|Drug|PPAR alpha|
210966|NCT02140060|Drug|Travoprost solution vehicle|Inactive ingredients used for masking purposes
210967|NCT02140060|Drug|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
210968|NCT02140073|Drug|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
210969|NCT02140073|Drug|omeprazole|40mg in the morning
210326|NCT02105688|Drug|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablets|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablets, taken once daily by mouth for 12 weeks.
210327|NCT02105688|Drug|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablets|Grazoprevir 100 mg/Elbasvir 50 mg FDC placebo tablets, taken once daily by mouth for 12 weeks.
210328|NCT02105701|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
210329|NCT02105701|Drug|Ribavirin|200 mg capsule
210645|NCT02145234|Drug|BMS-986089|
210646|NCT02145234|Drug|Placebo matching with BMS-986089|
210647|NCT02145247|Drug|hCG|3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.
4. Blood samples will be obtained at T = -0.5, 0, and +24 hours.
210648|NCT02145260|Drug|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
210649|NCT00133744|Dietary Supplement|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
210650|NCT02145260|Drug|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
210651|NCT02145273|Behavioral|Interpersonal Psychotherapy for Depression -Group|
210652|NCT02145286|Radiation|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
210653|NCT02145299|Device|TruePath CTO Device|The TruePath CTO Device is composed of a 0.018" guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions.
210654|NCT02147639|Dietary Supplement|Placebo|
210655|NCT00133991|Drug|cyclophosphamide|
210656|NCT02147639|Procedure|Increased exercise intensity|
210657|NCT02147652|Other|Personalized music|
210658|NCT02147665|Other|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
210659|NCT02147678|Drug|Etomidate|
210660|NCT02147678|Drug|Propofol|
210015|NCT02110537|Procedure|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
210016|NCT02112487|Drug|Macitentan|10 mg once daily
210017|NCT02112500|Biological|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
210018|NCT02112526|Drug|ACP-196|
210019|NCT02112539|Other|platelet aggregation measurement|
210020|NCT02112552|Drug|Paclitaxel|Given IV
210021|NCT00002230|Drug|Stavudine|
210022|NCT00130520|Drug|erlotinib|150mg daily by mouth-erlotinib
210023|NCT02112552|Drug|Carboplatin|Given IP
210024|NCT02112552|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
210025|NCT02112552|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
210026|NCT02112552|Other|Quality-of-Life Assessment|Ancillary studies
210027|NCT02112552|Other|Laboratory Biomarker Analysis|Correlative studies
210028|NCT02112565|Drug|RNR inhibitor COH29|Given PO
210029|NCT02112565|Other|laboratory biomarker analysis|Correlative studies
210030|NCT02112565|Other|pharmacological study|Correlative studies
210330|NCT00129753|Drug|Alemtuzumab (Campath-1H)|Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
210331|NCT02105714|Procedure|Stool culturing for pathogenic bacteria|
210332|NCT02105714|Procedure|Kato-Katz technique|
210333|NCT02105714|Procedure|Baermann technique|
210334|NCT02105714|Device|Mini-FLOTAC|
210335|NCT02105714|Device|Crypto/Giardia Duo Strip|
210336|NCT02105714|Procedure|Formalin-ether concentration technique|
209728|NCT00126906|Drug|2-dose sulfadoxine/pyrimethamine|
209729|NCT02078037|Other|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
209730|NCT02078050|Other|Phrenic nerves magnetic stimulations|
209731|NCT02078063|Drug|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
209732|NCT02078063|Drug|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
209733|NCT02078076|Device|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
209734|NCT02078089|Drug|Morphine|Morphine will be given to patients as part of their standard care
209735|NCT02078089|Drug|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
209736|NCT02078102|Drug|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
209737|NCT02080390|Procedure|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
209738|NCT02080403|Drug|2.5 mg Chlorhexidine gluconate chip|Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
209739|NCT02080416|Drug|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
209740|NCT02080429|Procedure|Passive Descent|
209741|NCT00127166|Drug|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
209742|NCT02080429|Procedure|Pushing|
209743|NCT02080442|Other|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
210031|NCT02112578|Drug|Meclizine|25 mg, 3 times per day up to 30 days
210032|NCT02112578|Drug|Dimenhydrinate|50 mg, 3 times per day up to 30 days
210033|NCT00130533|Drug|Capecitabine|1000 mgrs/m2 twice a day, tablets, 8 cycles
204116|NCT02027077|Behavioral|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
204117|NCT02027090|Drug|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
204118|NCT02027090|Drug|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
204119|NCT02027103|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
204120|NCT02027103|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
204121|NCT02027116|Biological|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
204122|NCT02027129|Other|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
204123|NCT02027142|Other|Pittsburgh Sleep Quality Index.|Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating "poor" from "good" sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score > 5 was indicated poor sleep quality.
204428|NCT02019446|Drug|Standard Treatment (control group) terbinafine hydrochloride tablets|
204429|NCT02019459|Other|Very low nicotine content cigarettes|
204430|NCT02019459|Other|standard nicotine content cigarettes|
204431|NCT02019472|Biological|adalimumab 40 mg|SC injections
204432|NCT02019472|Biological|sirukumab 100 mg|SC injections
204433|NCT02019472|Biological|sirukumab 50 mg|SC injections
204434|NCT02019472|Drug|Placebo|SC injections
204435|NCT00121186|Drug|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
204436|NCT02019485|Drug|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
204437|NCT02019485|Drug|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
204438|NCT02019498|Behavioral|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
203813|NCT02032121|Procedure|Echocardiography|
203814|NCT02032134|Biological|Transfusion of Pooled Platelets Cryopreserved In DMSO|Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic "P. Giaccone"- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing
203815|NCT02034630|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
203816|NCT00122629|Drug|peg-interferon alfa-2b|
203817|NCT02034643|Procedure|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
203818|NCT02034669|Device|Laminectomy|surgical laminectomy with glial scar resection
203819|NCT02034669|Device|Intradural space|ADSCs injection into Intradural space at damage site
203820|NCT02034669|Device|Intrathecal|ADSCs Intrathecal into lumbar puncture
203821|NCT02034669|Device|Intravenous|ADSCs intravenous
203822|NCT02034682|Drug|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
203823|NCT02034682|Drug|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
204124|NCT02027142|Other|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
204125|NCT02027142|Other|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
204126|NCT00121797|Procedure|urine culture|
204127|NCT02027142|Other|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
204128|NCT02027155|Drug|AR09 solution|moderate levels of sedation
204129|NCT02027155|Drug|placebo|Sterile Saline, USP
204130|NCT02027168|Other|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
208525|NCT02107313|Drug|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
208526|NCT02107313|Drug|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
208527|NCT02107326|Device|Webdia Software|
208528|NCT00129935|Drug|epirubicin|
208529|NCT02107339|Drug|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
208530|NCT02107339|Drug|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
208531|NCT02107365|Drug|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
208532|NCT02107365|Drug|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
208533|NCT02107365|Drug|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
208534|NCT02107365|Drug|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
208535|NCT02107378|Biological|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
208536|NCT02107378|Drug|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
208537|NCT02107391|Biological|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
208538|NCT02107391|Drug|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
208539|NCT00129935|Drug|docetaxel|
208540|NCT02107391|Drug|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
208541|NCT02107404|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
208542|NCT02107417|Device|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
208543|NCT02109731|Other|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
208544|NCT02109744|Drug|Decitabine|
207955|NCT02079896|Drug|Placebo|
207956|NCT02082405|Other|laboratory biomarker analysis|Optional correlative studies
207957|NCT02082405|Other|quality-of-life assessment|Ancillary studies
208235|NCT02114255|Other|Placebo|Administration of 0.9% NaCl.
208236|NCT02114255|Biological|BCG|Vaccination with the live attenuated BCG vaccine.
208237|NCT02114268|Drug|MEDI8897|Dose 1 - intramuscular (IM) delivery; Dose 2 - intravenous (IV) and intramuscular (IM) delivery; Dose 3 - intravenous (IV) delivery; Dose 4 - intravenous (IV) delivery
208238|NCT00130728|Drug|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
208239|NCT02114268|Drug|Placebo|Solution containing no active ingredients
208240|NCT02114281|Other|Care|
208241|NCT02114281|Other|Not care|
208242|NCT02114294|Other|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
208243|NCT02114294|Other|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
208244|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
208245|NCT02114307|Device|REVITIVE IX|neuromuscular electrical stimulation device
208246|NCT02114320|Device|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
208247|NCT02114333|Biological|Zostavax|0.65ml, subcutaneous
208248|NCT02114333|Biological|HZ/su vaccine|0.5ml, intramuscular
208249|NCT00130741|Drug|CHT - herbal therapy|
208250|NCT02114333|Biological|Placebo|0.65ml, subcutaneous
208251|NCT02114346|Drug|Atorvastatin|
207646|NCT02087319|Other|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
207647|NCT02087332|Drug|Prolonged release Torasemide (Britomar)|
207648|NCT02087332|Drug|Torasemide (Diuver)|
207649|NCT02087384|Biological|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
207650|NCT02087384|Drug|Placebo|injection of 0.9% saline
207651|NCT02089334|Drug|Everolimus|Everolimus 10mg oral will be taken daily in 3 week cycles for up to 8 cycles (24 weeks).
207652|NCT00128024|Drug|lipid-lowering treatment|
207653|NCT02089347|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
207654|NCT02089347|Biological|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
207958|NCT02082418|Dietary Supplement|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
207959|NCT00127309|Drug|Glutathione|
207960|NCT02082418|Dietary Supplement|Whey|commercially available whey protein
207961|NCT02082444|Other|Skipping lunch|
207962|NCT02082457|Drug|YKP10811 5mg|
207963|NCT02082457|Drug|YKP10811 20mg|
207964|NCT02082457|Drug|YKP10811 placebo|
207965|NCT02082470|Other|follow-up care|Undergo survivorship care planning
207966|NCT02082470|Other|active surveillance|Undergo cancer surveillance
207967|NCT02082470|Other|questionnaire administration|Ancillary studies
207968|NCT02082483|Other|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
207969|NCT02082496|Drug|Liraglutide|S.c. liraglutide 3.0mg once daily
207970|NCT00002212|Drug|Bexarotene|
207971|NCT00127335|Drug|cellulose placebo vs. atorvastatin|drug
207352|NCT02094729|Drug|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
207353|NCT02094729|Drug|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
207354|NCT02094729|Drug|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
207355|NCT02094742|Procedure|biopsy|
207356|NCT02094755|Other|Blood draw only|Blood draw only
207357|NCT02094768|Dietary Supplement|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
207358|NCT02094768|Dietary Supplement|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
207359|NCT02097160|Other|Control Group 1|
207360|NCT02097173|Drug|Methotrexate|
207655|NCT02089373|Procedure|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
207656|NCT02089373|Procedure|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
207657|NCT02089386|Drug|Tamoxifen|
207658|NCT02089386|Procedure|Endoscopy|
207659|NCT02089399|Drug|Sevikar(amlodipne/olmesartan)|Treatment AB
207660|NCT02089399|Drug|crestor(Rosuvastatin)|Treatment AB/Treatment C
207661|NCT02089412|Drug|E2006|
207662|NCT02089425|Drug|K-103-IP|
207663|NCT00128037|Drug|mitomycin C, vindesine, cisplatin and radiotherapy|
207664|NCT02089425|Drug|Placebo|Placebo comparator
207665|NCT02089438|Drug|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
207666|NCT02089438|Drug|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
207667|NCT02089438|Drug|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
207050|NCT02101788|Drug|Topotecan Hydrochloride|Given IV
207051|NCT02101788|Drug|Trametinib|Given PO
207052|NCT02101801|Other|vegetables from fresh or recycled water|
207053|NCT02101801|Other|receives vegetables from fresh water or recycled waste water farms|
207054|NCT00129285|Drug|Placebo|placebo 400 mg/day
207055|NCT02101814|Procedure|Roux-en-Y gastric bypass (bariatric surgery)|
207056|NCT02101840|Drug|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
207057|NCT02101840|Drug|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
207058|NCT02101840|Drug|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
207059|NCT02101853|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
207060|NCT02101853|Drug|Asparaginase|Given IM or IV
207061|NCT02101853|Biological|Blinatumomab|Given IV
207062|NCT02101853|Drug|Cyclophosphamide|Given IV
207063|NCT02101853|Drug|Cytarabine|Given IT and IV or SC
207064|NCT02101853|Drug|Dexamethasone|Given PO or IV
207361|NCT02097186|Procedure|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
207362|NCT02097199|Other|Increased sports workload|At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The "Recommendations for Adults From the American College of Sports Medicine and the American Heart Association" clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study.
207363|NCT02097225|Drug|Dabrafenib|Given PO
207364|NCT02097225|Drug|Hsp90 Inhibitor AT13387|Given IV
207365|NCT02097225|Other|Laboratory Biomarker Analysis|Correlative studies
223373|NCT02182245|Drug|Paclitaxel|
223374|NCT02182245|Drug|Carboplatin|
223375|NCT02182258|Drug|BIBF 1120 soft gelatine capsule|
223376|NCT00002284|Drug|Zidovudine|
223377|NCT00137605|Biological|Pneumovax|
223378|NCT02182258|Drug|BIBF 1120 intravenous solution|
223379|NCT02182258|Drug|Placebo ampoule|
223380|NCT02182271|Drug|BI 201335 ZW - single rising dose|
223381|NCT02182271|Drug|Placebo|
223382|NCT02182284|Drug|low dose BI 201335 NA soft gelatine capsule (SGC)|
223383|NCT02182284|Drug|high dose BI 201335 NA soft gelatine capsule (SGC)|
223384|NCT02182284|Drug|low dose BI 201335 NA powder in bottle (PIB)|
223385|NCT02182284|Drug|high dose BI 201335 NA powder in bottle (PIB)|
223386|NCT02182297|Drug|BI 201335 NA in single rising doses|
223387|NCT02182297|Drug|Placebo|
223388|NCT00137605|Biological|Prevnar|
223389|NCT02182310|Drug|BI 201335 low dose|
223390|NCT02182310|Drug|BI 201335 placebo|
223391|NCT02182310|Drug|Moxifloxacin|
223729|NCT02174523|Drug|40mg lurasidone placebo|
223730|NCT02174536|Biological|Decidual stromal cells|Decidual stromal cells (approximately 1x10^6 cells/kg) will be infused intravenously.
223731|NCT02174536|Biological|Placebo|
223732|NCT02174549|Drug|Tirapazamine|Intravenous administration
223733|NCT02174549|Procedure|Transarterial embolization (TAE)|A standard of care for hepatocellular carcinoma.
222780|NCT02194478|Behavioral|Meditation|30 minute, 8 week meditation
222781|NCT02194491|Other|[11C]AS2471907|intravenous radiotracer
223085|NCT02187094|Drug|TC-6499|
223086|NCT00138125|Drug|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
223087|NCT02187094|Drug|Placebo|
223088|NCT02187107|Drug|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
223089|NCT02187107|Drug|rtv|100 mg tablet of Norvir®
223090|NCT02187120|Drug|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
223091|NCT02189356|Behavioral|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
223092|NCT02189356|Behavioral|standard care|standard pregnancy follow up
223093|NCT02189369|Other|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
223094|NCT02189369|Other|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
223095|NCT02189382|Device|Potassium Oxalate|
223096|NCT02189382|Other|Water|
223097|NCT02189395|Drug|NPH and regular insulin|
223098|NCT00138398|Biological|Commercial TriValent Split Influenza Virus|
223099|NCT02189395|Drug|glargine and humalog|
223100|NCT02189408|Biological|Platelet rich plasma|
223101|NCT02189421|Device|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
222451|NCT02161120|Other|Low FODMAP rye bread|
222452|NCT02161133|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
222453|NCT02161133|Behavioral|Health Education|Health Education provides didactic information about Gulf War Illness
222454|NCT02161146|Drug|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
222455|NCT02161146|Drug|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
222456|NCT02161146|Drug|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
222457|NCT02161159|Biological|botulinum toxin Type A|botulinum toxin Type A administered in accordance with physician standard practice.
222458|NCT02161185|Drug|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
222459|NCT02161198|Dietary Supplement|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
222460|NCT02161198|Dietary Supplement|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
222461|NCT00135252|Procedure|nasal cannula oxygen delivery|
222462|NCT02161211|Behavioral|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
222782|NCT02194491|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
222783|NCT00139139|Biological|Hepatitis A vaccine|
222784|NCT02194491|Drug|ASP3662|oral
222785|NCT02194504|Other|Dietary advice, Western|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
222786|NCT02194504|Other|Dietary advice, Targeted|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
222787|NCT02194517|Device|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
222788|NCT02194556|Drug|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
222123|NCT02288338|Drug|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
222124|NCT02288338|Drug|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222125|NCT02288338|Drug|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222126|NCT02288338|Drug|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222127|NCT02288338|Drug|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
222128|NCT02290457|Behavioral|core strength training|Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the "big 3" exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only.
222129|NCT02290470|Drug|Olanzapine|Drug: Olanzapine 10 mg oral
Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.
Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).
222130|NCT02290470|Drug|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
222131|NCT02290496|Behavioral|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
222132|NCT02290496|Behavioral|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
222133|NCT02290509|Biological|Flublok Quadrivalent|Intramuscular injection of study vaccine
222463|NCT02161211|Behavioral|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
222464|NCT02161211|Behavioral|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
222465|NCT02161224|Drug|FG-4592|Oral
221838|NCT02295488|Procedure|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
221839|NCT02295488|Biological|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
221840|NCT02295501|Biological|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
221841|NCT02295514|Biological|PTP1B dosage|PTP1B sampled and dosed during sepsis
221842|NCT02295527|Other|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
221843|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
221844|NCT02295540|Radiation|hypofractionated radiation therapy|Undergo hypofractionated IMRT
221845|NCT02297607|Dietary Supplement|Tube Feeding|
221846|NCT02297620|Drug|Suglat®|oral
221847|NCT02297646|Behavioral|Endurance Training|
221848|NCT02297659|Procedure|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
221849|NCT02297659|Device|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
221850|NCT02297672|Radiation|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
221851|NCT02297672|Device|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
221852|NCT02297672|Device|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
221853|NCT02297685|Device|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
221186|NCT00152139|Drug|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
221187|NCT02307058|Behavioral|Expanded Prostate Cancer Index Composite-SF12 Questionnaire|EPIC SF-12 Quality of Life questionnaire - Recommended after enrollment and prior to fiducial marker placement, as well as during the last week of treatment, and post-RT at 3 mo, 9 mo and then yearly to 5.25 years.
221188|NCT02307071|Device|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
221189|NCT02307084|Procedure|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
221190|NCT02307084|Device|Ultrasound|
221191|NCT02307097|Procedure|Cognitive-Behavioural Bibliotherapy|
221192|NCT02307097|Procedure|Cognitive-Behavioural Therapy|
221526|NCT02302157|Biological|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
221527|NCT02302170|Biological|H. pylori vaccine|
221528|NCT02302170|Biological|placebo|
221529|NCT00151632|Drug|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
221530|NCT02302183|Device|FreeO2 v2.0 automatic adjustment|
221531|NCT02302183|Device|FreeO2 v2.0 data collecting|
221532|NCT02302196|Procedure|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
221533|NCT02302196|Other|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
221534|NCT02302209|Drug|Oxytocin|
221535|NCT02302209|Other|Placebo Comparator|
221536|NCT02302222|Device|Customizable Dressing with ActiV.A.C. Therapy Unit|
221537|NCT02302222|Device|Standard of Care Dressing|
220892|NCT02312245|Drug|Gemcitabine Hydrochloride|Given IV
220893|NCT00152646|Drug|placebo, aspirine, clopidogrel|
220894|NCT02312245|Drug|Paclitaxel|Given IV
220895|NCT02312245|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
220896|NCT02312245|Drug|Topotecan Hydrochloride|Given IV
220897|NCT02312258|Drug|Ixazomib|Ixazomib capsules
220898|NCT02312258|Drug|Placebo|Ixazomib placebo-matching capsules
220899|NCT02312271|Other|enteral formula|standard tube feeding formulas
220900|NCT02312297|Drug|Minocycline hydrochloride|extended release tablets 135 mg
220901|NCT02312310|Dietary Supplement|cocoa flavanols|12 weeks administration of cocoa flavanol
220902|NCT02312323|Device|Definitive 65 HPT contact lenses|
220903|NCT02312323|Device|Definitive 65 contact lenses|
220904|NCT00002386|Drug|Zalcitabine|
220905|NCT00152659|Procedure|Tissue sample (procedure/screening)|Tissue sampling
220906|NCT02312336|Other|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
221193|NCT02307097|Other|WAIT|
221194|NCT02307110|Other|cross-sectional observation|cross-sectional opthalmic examination
221195|NCT02307123|Procedure|Intubation|HEMS physician prehospital intubation
221196|NCT02307149|Biological|CAVATAK|CAVATAK is a purified preparation of CVA21
221197|NCT00152152|Procedure|Radiostereometric Analysis beads inserted during surgery|
221198|NCT02307149|Drug|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
221199|NCT02307162|Drug|RPL554|Phosphodiesterase 3 and 4 Inhibitor
221200|NCT02307162|Drug|Placebo|Dummy solution
220600|NCT02280187|Procedure|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
220601|NCT02280200|Device|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
220602|NCT02280213|Device|MIL|Direct laryngoscopy 1
220603|NCT02280213|Device|MAC|Direct laryngoscopy 2
220604|NCT02280213|Device|WIS|Direct laryngoscopy 3
220605|NCT02280213|Device|PHIL|Direct laryngoscopy 4
220606|NCT00149110|Drug|duloxetine|60 mg daily
220607|NCT02280226|Device|magnetic resonance imaging (MRI)|
220608|NCT02280239|Drug|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
220609|NCT02280239|Drug|Placebo|
220610|NCT02280252|Drug|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
220611|NCT02280252|Radiation|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
220612|NCT02280265|Drug|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
220613|NCT02280278|Procedure|Radical surgery|
220614|NCT02280278|Drug|Adjuvant chemotherapy|
220615|NCT02280278|Biological|Cytokine-induced killer cell immunotherapy|
220616|NCT02280291|Procedure|GA/sedation with a Single Shot, peripheral nerve block|A single shot peripheral nerve block will be used as the primary mode of pain control intraoperatively with adjunct pain medications prescribed for the patient to take as needed
220617|NCT00149110|Drug|duloxetine|60 mg daily
220618|NCT02280291|Procedure|GA/sedation with continuous, peripheral nerve block|A continuous peripheral nerve block delivered by the OnQ infusion system will be given in the post-operative period and removed within 48 hours of surgery. Adjunct pain medications will be prescribed for the patient to take as needed
220619|NCT02280291|Drug|lidocaine|
219986|NCT02292082|Drug|Bupivacaine|
219987|NCT02292082|Drug|Morphine|
219988|NCT00150553|Drug|Extended-release carbamazepine|
219989|NCT02292082|Drug|Methylprednisolone|
219990|NCT02292082|Drug|Cefazolin|
219991|NCT02292082|Drug|Normal saline|
219992|NCT02292082|Drug|Midazolam|
220304|NCT02287636|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
220305|NCT02287636|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
220306|NCT02287636|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
220307|NCT02287636|Procedure|positron emission tomography|Undergo PET/MRI
220308|NCT02287636|Procedure|magnetic resonance imaging|Undergo PET/MRI
220309|NCT02287649|Other|blood sample|
220310|NCT02287662|Other|Vancouver 3M Clinical Pathway|
220311|NCT02287675|Drug|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
220312|NCT02287675|Drug|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
220313|NCT00149916|Drug|Mycophenolate sodium (enteric coated)|
220314|NCT02287688|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
220315|NCT02287701|Device|PET/MRI|Simultaneous PET/MRI (3T system)
220316|NCT02287714|Procedure|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
219694|NCT02299193|Behavioral|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
219695|NCT02299193|Behavioral|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
219696|NCT02299206|Drug|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
219697|NCT00151307|Device|INVOS cerebral oximeter|
219698|NCT02299206|Drug|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
219699|NCT02299219|Behavioral|Taking Charge: Managing Cancer Online|n addition to standard medical care, adolescents in the experimental group will receive the "Taking Charge: Managing Cancer Online" Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French.
219700|NCT02299219|Behavioral|Standard Medical Care and Cancer Resource Center|The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer ("Cancer Resource Centre") and online assessments.
219701|NCT02299232|Drug|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
219993|NCT02292082|Drug|Propofol|
219994|NCT02292082|Drug|Dexamethasone|
219995|NCT02292082|Device|8 MHz. Chiba needle, 22 G / 4 inches|
219996|NCT02292095|Procedure|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
219997|NCT02292095|Procedure|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
219998|NCT02294474|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
219999|NCT02294474|Drug|insulin lispro|Pharmaceutical form:solution Route of administration: subcutaneous
220000|NCT02294474|Drug|insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
221969|NCT00152399|Drug|Somatostatin UCB (drug)|
221970|NCT02309983|Other|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
221971|NCT02309983|Other|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
221972|NCT02309996|Behavioral|Supervisor Training Program|
221973|NCT02310009|Drug|Anakinra (AN)|
221974|NCT02310009|Behavioral|Exercise (EX)|
221975|NCT02310009|Behavioral|Control (CON)|
221976|NCT02310022|Drug|Drug Omega 3|4 g (4 capsules) once a day, administered with food
221977|NCT02310022|Drug|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
221978|NCT02310048|Drug|MT-1303-FormA|
221979|NCT02310048|Drug|MT-1303-FormB|
221980|NCT00152412|Drug|Levocetirizine oral solution|
221981|NCT02312596|Other|Usual and Customary Practice|Usual and customary care for non-healing wounds
221982|NCT02312609|Drug|Minocycline hydrochloride|extended release tablets 135 mg
221983|NCT02312622|Drug|pegylated irinotecan NKTR 102|Given IV
221984|NCT02312622|Other|laboratory biomarker analysis|Correlative studies
221985|NCT00152711|Device|nCPAP|
221986|NCT02312635|Drug|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
221987|NCT02312635|Behavioral|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
221353|NCT02283203|Drug|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
221354|NCT00149734|Drug|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
221355|NCT02285621|Other|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
221356|NCT02285634|Drug|Oxymetazoline 0.05%|sterile gauze soaked in 5mL of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
221668|NCT02278341|Drug|darbepoetin alfa|Subcutaneous or Intravenous Injection
221669|NCT02278354|Drug|18F-AV-1451|
221670|NCT02278367|Drug|18F-AV-1451|370 megabecquerel (MBq) (10 millicurie [mCi])
221671|NCT02278380|Other|Low GI Standard Breakfast|Low GI Standard Breakfast
221672|NCT02278380|Other|Medium GI Standard Breakfast|Medium GI Standard Breakfast
221673|NCT02278380|Other|Enfamama A+|Nutritional pregnant milk supplement
221674|NCT00002371|Drug|Zidovudine|
221675|NCT00148876|Drug|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
221676|NCT02278380|Other|Glucerna Triple Care|Nutritional product for diabetics
221677|NCT02278380|Other|Dumex Precima|Pregnant and lactation women milk powder
221678|NCT02278380|Other|Diasip|Nutritional drinks for diabetics
221679|NCT02278380|Other|Test product|Test product not patented yet
221680|NCT02278393|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
221681|NCT02278393|Other|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
221682|NCT02278406|Other|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
221030|NCT02288000|Drug|Memantine|Memantine will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
221031|NCT02288000|Drug|Placebo|the placebo will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
221032|NCT02288013|Procedure|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
221033|NCT02288039|Other|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
221034|NCT02288052|Behavioral|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
221035|NCT02288052|Behavioral|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
221036|NCT02288065|Drug|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
221037|NCT00149994|Drug|Cyclosporine A|
221038|NCT02288078|Other|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
221039|NCT02288078|Other|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
221040|NCT02288078|Other|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
221041|NCT02290067|Device|Blood glucose monitoring system (Omnitest 3)|
221042|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5)|
221043|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5D)|
221044|NCT02290080|Drug|Oxygen|see arm description
221045|NCT02290093|Drug|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
221357|NCT02285634|Drug|Phenylephrine 0.25%|sterile gauze soaked in 5mL of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
221358|NCT02285634|Drug|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5mL of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
221359|NCT02285634|Drug|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5mL of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
220421|NCT02299440|Drug|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
220422|NCT02299440|Drug|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
220423|NCT02299440|Other|Follow-up after perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, and 4 hours after the end of the second perfusion, and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
220424|NCT02299453|Behavioral|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
220425|NCT02299479|Device|Dexcom G4 Platinum|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
220426|NCT02299479|Device|Activity Monitor|Patients will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
220427|NCT02299492|Other|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
220428|NCT02299505|Drug|ceritinib|
220429|NCT02299518|Drug|mitoxantrone hydrochloride|Given IV
220430|NCT00151346|Drug|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
220431|NCT02299518|Drug|etoposide|Given IV and PO
220432|NCT02299518|Drug|cytarabine|Given IV
220433|NCT02299518|Drug|selinexor|Given PO
220434|NCT02299518|Other|laboratory biomarker analysis|Correlative studies
220435|NCT02299518|Other|pharmacological study|Correlative studies
220436|NCT02299531|Other|Varying meal energy density and portion size|
220437|NCT02301663|Other|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
220438|NCT02301663|Other|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
220439|NCT02301663|Other|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
219505|NCT02279823|Drug|CB-03-01 solution|Investigational drug solution
219506|NCT02279823|Drug|Minoxidil Solution 5%|FDA approved marketed product
219793|NCT02311790|Dietary Supplement|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
219794|NCT02311790|Dietary Supplement|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
219795|NCT02311803|Procedure|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
219796|NCT02311803|Procedure|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
219797|NCT02311829|Other|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
219798|NCT02311855|Biological|Influenza vaccine|Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:
Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)
At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine.
219799|NCT02311868|Dietary Supplement|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
219800|NCT00152607|Procedure|donor right hepatic lobectomy|
219801|NCT02311868|Dietary Supplement|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
219802|NCT02311881|Drug|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
219803|NCT02311881|Drug|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
218888|NCT02289300|Drug|DCB-BO1202|The assignment will be as follows:
(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)
DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.
Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)
218889|NCT02291380|Drug|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
218890|NCT02291393|Device|80 lead ECG|
218891|NCT02291406|Procedure|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
218892|NCT02291406|Procedure|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
218893|NCT02291419|Drug|ticagrelor|ticagrelor 90 mg bid
218894|NCT02291419|Drug|aspirin|aspirin 81 mg daily
218895|NCT02291432|Biological|autologous muscle-derived cells (AMDC)|Cell treatment
219183|NCT02284750|Procedure|Simple stenting technique|Stenting of the side branch in the simple stenting group was required if TIMI flow was <3, or presence of type B dissection or greater after kissing balloon inflation.
219184|NCT00149643|Other|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
219185|NCT02284750|Procedure|Percutaneous Coronary Intervention|
219186|NCT02284763|Other|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
219187|NCT02284776|Behavioral|Therapeutic education|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
219188|NCT02284789|Other|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
219189|NCT02284802|Procedure|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
219190|NCT02284815|Dietary Supplement|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
219191|NCT02284828|Drug|BIA 2-093|
223734|NCT02174562|Behavioral|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
223735|NCT02174562|Behavioral|Enhanced Usual Care|Usual care enhanced with education and attention
223736|NCT02174575|Drug|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
223737|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the "2-sites, TRC", updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.
223738|NCT00002281|Drug|Epoetin alfa|
223739|NCT00137007|Drug|Ampicillin/sulbactam|
223740|NCT02177045|Drug|Sonovue, Bracco|Intravenous injection
223741|NCT02177058|Other|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
223742|NCT02177058|Other|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
223743|NCT02177071|Drug|INFLIXIMAB|
223744|NCT02177071|Drug|AZATHIOPRINE|
223745|NCT02177071|Drug|MERCAPTOPURINE|
223746|NCT02177071|Drug|Methotrexate|
223747|NCT02177084|Device|PTNS|
223748|NCT02177097|Biological|Blood samples|4 x 10 ml blood samples.
223749|NCT02177123|Device|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
223750|NCT00137020|Drug|ziprasidone|
223751|NCT02177136|Drug|OCA|
223752|NCT02177136|Drug|Placebo|
218896|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
223102|NCT02189434|Other|Serum procalcitonin lab draws|Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.
These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients.
223103|NCT02189447|Procedure|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
223104|NCT02189473|Radiation|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
223392|NCT02182310|Drug|BI 201335 high dose|
223393|NCT02182323|Drug|BI 201335 NA|
223394|NCT02182323|Drug|Placebo solution|
223395|NCT02182336|Drug|BI 201335 NA|480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10
240 mg BI 201335 NA bid from day 11 to 23
223396|NCT02182336|Drug|Caffeine|days 1, 10 and 19
223397|NCT02182336|Drug|Warfarin sodium|days 1, 10 and 19
223398|NCT02182336|Drug|Vitamin K|days 1, 10 and 19
223399|NCT00137618|Behavioral|Educational Intervention to Increase Informed Decision Making for Prostate Cancer Screening|
223400|NCT02182336|Drug|Omeprazole|days 1, 10 and 19
223401|NCT02182336|Drug|Dextromethorphan hydrobromide|days 1, 10 and 19
223402|NCT02184637|Drug|Artemether + Lumefantrine|Light yellow, round tablet with "NC" debossed on one side and "CG" on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally
223403|NCT02184650|Other|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
223404|NCT02184663|Other|without APA program|Control Arm : chemotherapy alone
223405|NCT02184663|Other|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
223406|NCT00137943|Behavioral|Control Parent Intervention|
223407|NCT02184676|Biological|Analysis of early immune modifications|blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)
cord blood sampling
stool sampling in mothers and newborns at birth (day 7)
blood and stool sampling in children at the age of 8, 18, 30 and 42 months
222789|NCT02194556|Drug|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
222790|NCT02194569|Drug|Citrate|
222791|NCT02194595|Drug|Basal insulin and exenatide|
222792|NCT02197156|Drug|40 mg HC-ER|Single dose
222793|NCT02197156|Drug|10 mg HC / 325 mg APAP|Single dose
222794|NCT00139399|Procedure|Coronary artery bypass surgery|Radial artery versus long saphenous vein grafted to the left circumflex coronary artery territory during CABG surgery
222795|NCT02197156|Drug|Matching Placebo|Single dose
222796|NCT02197169|Drug|Single intratumoral injection of DNX-2401|In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)
No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula.
222797|NCT02197169|Drug|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
222798|NCT02197182|Drug|LUXSOL copper containing cream|Active comparator arm
222799|NCT02197182|Drug|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
222800|NCT02197195|Dietary Supplement|Chocolate Milk|
222801|NCT02197195|Dietary Supplement|Fruit Drink|
223105|NCT02189499|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
223106|NCT02189512|Other|blood sampling|cases - blood sampling controles - blood sampling
223107|NCT02189538|Dietary Supplement|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
223108|NCT02189538|Dietary Supplement|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
223109|NCT00138411|Drug|Ciprofloxacin 500 mg|
223110|NCT02189551|Behavioral|Gait training with Lokomat Pro|
223111|NCT02189551|Behavioral|Gait training with Lokomat Pro FreeD|
222466|NCT02161237|Drug|Advagraf®|oral
222467|NCT02161250|Dietary Supplement|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
222468|NCT02161250|Dietary Supplement|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
222469|NCT02161263|Other|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
222470|NCT02161276|Drug|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
222471|NCT02163525|Procedure|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
222472|NCT02163525|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
222473|NCT02163525|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
222474|NCT02163538|Device|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
222475|NCT02163538|Device|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
222476|NCT00002269|Drug|Ampligen|
222477|NCT00135499|Drug|CHOP plus rituximab|
222478|NCT02163564|Behavioral|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
222479|NCT02163577|Drug|KRN23|
222480|NCT02163590|Other|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
222481|NCT02163590|Other|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
222802|NCT02197195|Behavioral|Exercise|
222134|NCT02290509|Biological|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
222135|NCT02290522|Procedure|Tumor biopsy|Biopsy of lesion for molecular characterization
222136|NCT02290535|Procedure|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
222137|NCT00150371|Drug|atorvastatin|
222138|NCT02290535|Procedure|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
222139|NCT02290548|Device|high flow nasal cannula|High flow nasal cannula used in postextubation patients
222140|NCT02290561|Procedure|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
222141|NCT02290561|Device|MRI|
222142|NCT02290561|Device|high intensity focused ultrasound (HIFU)|
222143|NCT02290574|Radiation|Hyperthermia with concurrent chemo-radiation therapy|
222144|NCT02292914|Procedure|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
222145|NCT02292914|Procedure|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
222146|NCT02292927|Behavioral|Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
222147|NCT02292953|Other|Serum Prolactin levels|blood samples will be drawn from patients undergoing ICSI to analyse serum prolactin levels
222148|NCT02292966|Drug|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
222149|NCT02292979|Drug|Doxorubicin|25mg/m2
222150|NCT02292979|Drug|Bleomycin|10mg/m2
222151|NCT02292979|Drug|Vinblastine|6mg/m2
221538|NCT02302235|Other|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction.
221539|NCT02302235|Other|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
221540|NCT00151632|Drug|Tacrolimus|In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.
In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.
221541|NCT02302248|Behavioral|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
221542|NCT02302248|Behavioral|Expressive writing intervention|3 week access to a web-based expressive writing platform.
221543|NCT02302274|Drug|flecainide iv|infusion over 10 min
221544|NCT02304679|Other|Follow-up questionnaires 3 months after Wave 1|(Month 4)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.
221854|NCT02297685|Device|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
221855|NCT00151164|Procedure|donor bone marrow cell injection into thymus gland|
221856|NCT02297685|Device|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
221857|NCT02297698|Biological|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy.
221858|NCT02297698|Drug|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
221201|NCT02307188|Device|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
221202|NCT02307201|Drug|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
221203|NCT02307214|Other|BaroReflex Sensitivity, endothelial function measurement|no other
221204|NCT02307227|Drug|Trastuzumab|
221205|NCT02307227|Drug|Paclitaxel|
221206|NCT02307227|Drug|Epirubicin|
221207|NCT02307227|Drug|Docetaxel|
221208|NCT00152165|Procedure|Radiostereometric Analysis beads inserted during surgery|
221209|NCT02307240|Drug|CUDC-907|CUDC-907 oral with meals.
221210|NCT02307253|Device|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
221211|NCT02307266|Behavioral|supplementary education|
221212|NCT00152334|Drug|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
221213|NCT02309528|Other|Educational computerized digital stories|computerized digital stories made by American Indians
221214|NCT02309541|Device|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
221215|NCT02309554|Other|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
221545|NCT02304679|Device|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
221546|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 2|(Month 6)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
221547|NCT02304679|Other|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
220620|NCT02280291|Drug|Propofol|
220621|NCT02280291|Drug|Fentanyl|
220907|NCT02314559|Procedure|Target controlled infusion|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
220908|NCT02314572|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
220909|NCT02314585|Other|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
220910|NCT02314585|Other|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
220911|NCT02314598|Other|No treatment|
220912|NCT02314611|Device|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
220913|NCT02314624|Behavioral|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
220914|NCT02314624|Behavioral|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
220915|NCT02314637|Drug|Teneligliptin|Teneligliptin for 52 weeks
220916|NCT02314637|Drug|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
220917|NCT00152841|Drug|Iron supplement 300-600 mg/day|
220918|NCT02314650|Other|acupoint stimulation|stimulation was given at acupoints
220919|NCT02314650|Other|non-acupoint stimulation|stimulation was given at non-acupoints
220920|NCT02314650|Other|electrodes attached|electrode were attached to skin
220921|NCT02314663|Device|"COMBINED STRATEGY"|Participants in the intervention group will be supplied with: a) "printed matter" containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) "mobile-telephone text messages" containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) "self-report cards" to check compliance with recommendations (across the entire follow-up).
220922|NCT02314676|Biological|PEG-somatropin|
220317|NCT02287714|Procedure|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
220318|NCT02287727|Other|Laboratory Biomarker Analysis|Correlative studies
220319|NCT02287727|Drug|Regorafenib|Given PO
220320|NCT02287740|Behavioral|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
220321|NCT02287740|Behavioral|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
220322|NCT02287740|Behavioral|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
220622|NCT02280291|Drug|epinephrine,|
220623|NCT02280291|Drug|bupivacaine|
220624|NCT02280291|Device|OnQ infusion system|
220625|NCT02282774|Drug|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
220626|NCT02282774|Drug|Sham subtenon block|
220627|NCT02282787|Drug|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
220628|NCT02282800|Genetic|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
220629|NCT02282813|Drug|CTAP101 Capsules|At week 12, eligible subjects will continue to take 2 capsules(30 mcg each capsule) CTAP101 daily
220630|NCT02282813|Drug|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
220631|NCT00149396|Drug|NV1020|NV1020 dose levels: 3x10E6, 1x10E7, and 3x10E7 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
220632|NCT02282813|Drug|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
220001|NCT02294513|Device|Standard audiologic rehabilitation (incl. HI)|The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
220002|NCT02294513|Device|Activity tracker|The intervention in the active comparator group consists of the use of a wireless activity tracker, the Fitbit™ Zip.
220003|NCT02294526|Other|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
220004|NCT02294539|Drug|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
220005|NCT02294539|Drug|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
220006|NCT00150839|Drug|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
220007|NCT02294539|Drug|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
220008|NCT02294539|Drug|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
220009|NCT02294552|Drug|Cyclophosphamide|
220010|NCT02294552|Drug|Busulfan|
220011|NCT02294552|Drug|Fludarabine monophosphate|
220012|NCT02294552|Drug|Tacrolimus|
220013|NCT02294552|Drug|Mycophenolate mofetil|
220014|NCT02294552|Procedure|Allogeneic hematopoietic stem cell transplantation|
220015|NCT02294565|Drug|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
220323|NCT02287753|Other|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
220324|NCT00149929|Drug|Mycophenolate sodium (enteric coated)|
220325|NCT02289742|Device|Nelfilcon A sphere contact lenses|
220326|NCT02289755|Drug|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
220327|NCT02289768|Drug|5-fluorouracil/salicylic acid|
221988|NCT02312648|Other|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
221989|NCT02312648|Other|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
222290|NCT02184364|Drug|High dose of Klimadynon®|
222291|NCT02184364|Drug|Oestrofeminal®|
222292|NCT02184364|Drug|Placebo|
222293|NCT02184390|Other|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
222294|NCT02184416|Other|observational|The study is non interventional. All drugs will be prescribed
222295|NCT00137891|Drug|Modified Release rhTSH|
222296|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
222297|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
222298|NCT02184429|Drug|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
222299|NCT02184429|Drug|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
222300|NCT02186665|Drug|placebo comparator|
222301|NCT02186678|Other|PET-CT|
222302|NCT02186691|Other|MRI|
222303|NCT02186704|Device|Implantable cardioverter-defibrillator DX system (Biotronik)|
222304|NCT00138060|Drug|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
222305|NCT02186717|Dietary Supplement|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
222306|NCT02186730|Behavioral|Stressbusters|cCBT
221683|NCT02278419|Drug|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
221684|NCT02280642|Biological|2nd dose on time and 3rd dose late|
221685|NCT02280642|Biological|Both doses late|
221686|NCT02280655|Biological|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
221687|NCT02280655|Biological|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
221688|NCT00149188|Drug|Lanreotide (Autogel formulation)|
221689|NCT02280668|Other|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
221990|NCT02312661|Drug|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
221991|NCT02312661|Drug|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
221992|NCT02312661|Drug|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
221993|NCT02312674|Dietary Supplement|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
221994|NCT02312687|Drug|KRN23|KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
221995|NCT02312700|Behavioral|Interactive empowerment tool|
221996|NCT00152724|Device|pressure strain system, iontophoresis|
221997|NCT02312713|Behavioral|Internet Based Exercise Training|Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be "semi-standardized," meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content.
221998|NCT02312713|Behavioral|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
221360|NCT02285647|Drug|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
221361|NCT02285647|Drug|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
221362|NCT02285660|Procedure|4D PET-CT Scan|
221363|NCT02285660|Other|No intervention|
221364|NCT02285673|Biological|Umbilical Cord Mesenchymal Stem Cell|
221365|NCT00149747|Behavioral|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
221366|NCT02285699|Drug|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
221367|NCT02285712|Device|Vascular ultrasound system|
221368|NCT02285725|Procedure|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
221369|NCT02285725|Biological|Injections of BMAC + PRP + HA|All patients will receive up to 12 post-operative intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA (Supartz)
221370|NCT02285738|Drug|Aspirin|81mg/day for 4 weeks
221371|NCT02285738|Drug|Simvastatin|Daily dose of Simvastatin for 4 weeks
221372|NCT02285738|Other|Observation|participants will be observed for thrombotic evens for 4 weeks
221373|NCT02285751|Drug|acetylsalicylic acid|
221374|NCT02285751|Drug|clopidogrel|
221375|NCT02285751|Drug|prasugrel|
221376|NCT02288078|Other|Clinical findings|Blood and lymphatic system disorders: febrile neutropenia
Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting
General disorders and administration site conditions: fatigue and malaise
Immune system disorders: allergic reaction
Metabolism and nutrition disorders: anorexia
Nervous system disorders: dysgeusia and peripheral sensory neuropathy
Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)
Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome
Vascular disorders: hypertension
Symptomatic pancreatitis
221690|NCT02280668|Other|the eccentric muscle damage exercise|
221691|NCT02280681|Other|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
220749|NCT02294786|Drug|Lapatinib|Lapatinib is supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contains 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
220750|NCT02294786|Drug|Capecitabine|Capecitabine (Xeloda™) is supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contains 150mg Capecitabine and each peach colored tablet contains 500mg Capecitabine.Generic versions of capecitabine may be used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
220751|NCT02294786|Drug|Octreotide|Octreotide (Sandostatin LAR™) is supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections are given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol is added to the microspheres to improve suspendability
220752|NCT02294799|Procedure|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization. 3 times a week during 4 weeks.
220753|NCT02294812|Behavioral|Cognitive training|Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.
Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.
After eight weeks, participants will no longer partake in training.
220754|NCT02294825|Procedure|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
220755|NCT02294838|Device|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
220756|NCT02294838|Other|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
220757|NCT02294838|Other|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
220758|NCT00150891|Procedure|Kidney transplantation|
220759|NCT02294851|Drug|BMS-986168|
220760|NCT02294851|Drug|BMS-986168 Placebo|
220761|NCT02294864|Device|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
220762|NCT02294864|Procedure|Physical Therapy|
220763|NCT02294877|Drug|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
219804|NCT02314182|Procedure|Primary tumor resection + chemotherapy|Step 1: Primary Tumor (PT) resection
Within 3 weeks after randomization
Immunonutrition given 7 days prior to PT resection
Mechanical bowel preparation performed before surgery according to the local practices
Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)
Step 2: postoperative CT-scan
Must be performed within 4 weeks after surgery
CT-scan/MRI with the same criteria as pre-treatment evaluation
Step 3: Chemotherapy +/- target therapy
Within 4 weeks after the surgery
Chemotherapy administered according to the usual scheme for the chosen protocol
All validated and/or registered perioperative rectal cancer treatments authorized
The duration of one treatment cycle depending on the type of treatment administered
Radiotherapy is allowed after randomization if indicated
219805|NCT02314182|Drug|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.
If complications occur, emergency surgery can be performed according to the local practices of each investigator center.
Radiotherapy is allowed after randomization if indicated (MDOC).
220111|NCT02306681|Other|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
220112|NCT02306694|Drug|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
220113|NCT02306707|Procedure|Endoscopic Mucosal Resection|
220114|NCT02306733|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
220115|NCT00002383|Drug|Saquinavir|
220116|NCT00152113|Device|CliniMACS|
220117|NCT02306733|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
220118|NCT02306746|Dietary Supplement|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
220119|NCT02306746|Dietary Supplement|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
220120|NCT02306759|Drug|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
220121|NCT02306759|Drug|Placebo|Normal saline 50ml, administered over 15 minutes
220122|NCT02306772|Drug|TP05 Coating A|One radio-labelled tablet given to subjects
220123|NCT02306772|Drug|TP05 Coating B|One radio-labelled tablet given to subjects
220124|NCT02306785|Drug|TP05 Coating D|One radio-labelled tablet given to subjects
220125|NCT02306785|Drug|TP05 Coating E|One radio-labelled tablet given to subjects
220126|NCT02306785|Drug|TP05 Coating H|One radio-labelled tablet given to subjects
219192|NCT02284841|Device|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
219193|NCT02284854|Drug|BIA 2-093|
219194|NCT02284854|Drug|Carbamazepine|
219195|NCT02287116|Device|Easy Flow system and INCA® nasal cannulae set|
219196|NCT02287129|Drug|Oxaliplatin|130 mg/m2
219197|NCT02287129|Drug|Epirubicin|50 mg/m2
219198|NCT02287129|Drug|Capecitabine|625 mg/m2
219199|NCT02287129|Drug|5-FU|200 mg/m2
219200|NCT02287129|Drug|Carboplatin|2 mg/ml min
219201|NCT00149851|Drug|Tegaserod|
219202|NCT02287129|Drug|Paclitaxel|50 mg/m2
219203|NCT02287129|Radiation|radiation|total dosage 41,4 Gy
219204|NCT02287129|Procedure|Biopsy|translational analysis
219507|NCT02279823|Drug|Placebo solution|Vehicle solution
219508|NCT02279836|Device|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
219509|NCT02279849|Other|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
219510|NCT02279849|Other|Pricing|The pricing incentives were used to help promote sales of healthier food items.
219511|NCT02279849|Other|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
219512|NCT02279862|Drug|Ipilimumab|
219513|NCT02279875|Drug|Linezolid|
219514|NCT00149071|Device|rTMS|daily for three weeks
219515|NCT02279875|Drug|HRZE (soniazid rifampicin,pyrazinamide,ethambuto)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
219516|NCT02279888|Device|CardioMEMS HF System|Pulmonary artery pressure sensor
218897|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
218898|NCT00150514|Procedure|Nasal biopsy|
218899|NCT02291458|Drug|L-arginine|9 gram L-arginine / day for 6 weeks
218900|NCT02291458|Drug|Placebo|9 gram placebo / day for 6 weeks
218901|NCT02291471|Drug|T0001，10mg|
218902|NCT02291471|Drug|T0001，20mg|
218903|NCT02291471|Drug|T0001，35mg|
218904|NCT02291471|Drug|T0001，50mg|
218905|NCT02291471|Drug|T0001，65mg|
218906|NCT02291471|Drug|T0001，75mg|
218907|NCT02291484|Device|Cardiac CT scan|CT-guided management
218908|NCT02291510|Drug|Met DR|metformin delayed-release tablets
218909|NCT00150514|Procedure|Nasal washing|
218910|NCT02291510|Drug|Met XR|metformin extended-release tablets
218911|NCT02291510|Drug|Met IR|metformin immediate-release tablets
218912|NCT02291523|Biological|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
218913|NCT02291536|Drug|tetrahydrocannabinol|
218914|NCT02291536|Drug|cannabidiol|
218915|NCT02291536|Other|placebo|
218916|NCT02291549|Drug|S8 Sinus Implant|S8 Sinus Implant placed in both ethmoid sinuses.
218917|NCT02291549|Drug|Control Arm|topical nasal steroid spray 200mcg once daily
218918|NCT02294097|Procedure|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
218919|NCT02294110|Other|spinal anesthesia|non diabetes mellitus
223408|NCT02184676|Other|Collection of clinical and socio-demographic data|Questionnaire filled in by clinicians at enrollment and at birth
Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42
223409|NCT02184689|Drug|fexinidazole|
223410|NCT02184715|Other|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
223411|NCT02184728|Device|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
223412|NCT02184741|Drug|GB-0998|Subjects recieved GB-0998 at a dose of 400mg/kg/day for five days until the 6th gestational week.
223413|NCT02184741|Drug|Placebo|Subjects recieved saline of the same volume as GB-0998 for five days until the 6th gestational week.
223753|NCT02177149|Device|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
223754|NCT02177149|Device|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
223755|NCT02177162|Other|Education to physiotherapists|
223756|NCT02177175|Drug|Carvedilol|
223757|NCT02177175|Other|placebo|
223758|NCT02177188|Device|LBNP Lower Bodi Negative Pressure Chamber|
223759|NCT02177201|Other|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
223760|NCT02177201|Other|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
223761|NCT00137033|Drug|Celecoxib|
223762|NCT02179619|Device|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
223763|NCT00137293|Drug|GAP-486 (ZP-123)|
223112|NCT02189564|Behavioral|Feedback about good performance|
223113|NCT02189564|Behavioral|Feedback about good performance + money|
223114|NCT02189564|Behavioral|Feedback about average performance|
223115|NCT02189577|Drug|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
223116|NCT02192138|Device|Pleural manometer|
223117|NCT02192164|Behavioral|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
223118|NCT00138749|Drug|SS-RBX|
223119|NCT02192190|Drug|LY2951742|Administered SC
223120|NCT02192190|Other|Placebo - Oral|Administered orally
223121|NCT02192190|Other|Placebo - SC|Administered SC
223122|NCT02192190|Drug|Celecoxib|Administered orally
223123|NCT02192203|Drug|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
223124|NCT02192203|Drug|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
223125|NCT02192203|Drug|Menthol Only Gel|3% menthol
223126|NCT02192203|Drug|Placebo Only Gel|0.09% menthol
223127|NCT02192216|Behavioral|Exercise|
223128|NCT02192229|Drug|50.000 IU vitamin D3 (Biodal 50,000 IU)|
223129|NCT00138762|Drug|torcetrapib/atorvastatin|
223414|NCT02184754|Procedure|Magnetic endoscope imaging (MEI)|
223415|NCT02184767|Drug|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
223416|NCT02184793|Device|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
223417|NCT00137956|Device|Emphasys Endobronchial Valve (EBV) Device and Procedure|
223418|NCT02184806|Procedure|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
222803|NCT02197208|Procedure|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
222804|NCT02197208|Procedure|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is >/= 17 mm and the endometrium measures >/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
222805|NCT00139425|Behavioral|Disease Management Assessment|
222806|NCT02197208|Device|ultrasound|
222807|NCT02197221|Drug|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
222808|NCT02197221|Drug|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
222809|NCT02197234|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
222810|NCT02197234|Drug|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
222811|NCT02197234|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
222812|NCT02197234|Procedure|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
222813|NCT02197234|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
222814|NCT02158572|Drug|AG200-15|Transdermal contraceptive delivery system
222815|NCT02158585|Drug|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, 100 mg twice a day and 150mg twice a day during titration; 150mg twice a day or 100mg twice a day for the 12-week study period; 150mg once a day or 100mg once a day for Week 1 of the taper; and 75mg once a day, or 50mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
222816|NCT02158585|Drug|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
222817|NCT02158598|Drug|Vitamin D chewable tablet supplementation|
222818|NCT02158598|Drug|Vitamin D pill supplementation|
222152|NCT00150644|Drug|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
222153|NCT02292979|Drug|Dacarbazine|375mg/m2
222154|NCT02292979|Drug|Brentuximab Vedotin|1.2 mg/kg
222482|NCT02163590|Other|Placebo|Intervention that mimics the experimental procedures
222483|NCT02163603|Procedure|Pelvic osteotomy|
222484|NCT02163616|Drug|Misoprostol|800 mcg of sublingual misoprostol
222485|NCT02163629|Behavioral|Stress management|
222486|NCT02163642|Device|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
222487|NCT02163655|Drug|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
222488|NCT00135499|Drug|ACVBP plus rituximab|
222489|NCT02163655|Drug|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
222490|NCT02163668|Other|Yoga Group|8 months of Yoga training
222491|NCT02163681|Drug|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
222492|NCT02163694|Drug|Veliparib|Veliparib on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
222493|NCT02163694|Drug|Carboplatin|Day 1 of 21-day cycle
222494|NCT02163694|Drug|Paclitaxel|Day 1 of 21-day cycle
222495|NCT02163694|Other|Placebo|Placebo on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
222496|NCT02166385|Drug|placebo|Given PO
222497|NCT02166385|Other|questionnaire administration|Ancillary studies
222498|NCT00135746|Drug|nicotine transdermal system|
222499|NCT02166398|Drug|UI15AML055MT|tab, PO
222500|NCT02166398|Drug|Amosartan 5/50|tab, PO
221859|NCT02297698|Drug|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy.
221860|NCT02297711|Procedure|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
221861|NCT02297711|Procedure|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
221862|NCT02299921|Other|Characterize alcohol and drug use|Characterize alcohol and drug use in all patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. We will collect blood, exhaled breath condensate, urine and hair samples over the first 10 day s of hospitalization. A select subset of subjects will have bronchoalveolar lavage BAL obtained.
221863|NCT02299934|Other|MRI|MRI sequences for visualisation of the blood supply of liver without contrast agent
221864|NCT02299947|Drug|Haemocomplettan P|
221865|NCT02299947|Drug|Placebo|
221866|NCT02299960|Device|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
221867|NCT02299960|Device|NICOM|Non-invasive measurement of cardiac output
222155|NCT02292992|Device|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
222156|NCT02293005|Drug|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
222157|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Once Daily|
222158|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Twice Daily|
222159|NCT02293018|Drug|1.5% (w/w) MTC896 Gel Once Daily|
222160|NCT02293031|Device|Gene-activated matrix "Nucleostim"|Gene-activated matrix "Nucleostim" is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug "Neovasculgen"®.
222161|NCT02293044|Device|Crest® Sensi-Stop™ Strips|
222162|NCT02293057|Behavioral|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 90 minutes long and include required and optional activities.
222163|NCT00150644|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
221548|NCT02304679|Other|Final follow-up questionnaires 12 months after Wave 2|(Month 17)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
221549|NCT02304692|Device|Bone anchored hearing aid|
221550|NCT02304705|Drug|Sildenafil|20 mg TID PO for 90 days
221551|NCT02304705|Drug|Placebo|One capsule TID PO for 90 days
221552|NCT02304718|Behavioral|Stationary bike|
221553|NCT00151918|Drug|Lanthanum carbonate|
221554|NCT02304731|Other|Physical Exercise|Incremental running
221555|NCT02304744|Other|Observational study, no intervention.|Observational study, no intervention.
221556|NCT02304757|Drug|99Tc-MDP|99Tc-MDP, H20000218
221557|NCT02304757|Drug|fosamax|H20080172
221558|NCT02304757|Drug|Caltrate|Calcium 600 mg and vitamine D3 125iu.
221559|NCT02304770|Drug|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
221560|NCT02304783|Drug|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam per day and were contacted at the seven day by telephone call to investigate the efficacity and the side effects of the treatment.
221561|NCT02304796|Behavioral|Unified Cognitive-Behavioral Therapy|20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.
The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention.
221562|NCT02304796|Behavioral|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
221563|NCT02307266|Behavioral|additional visits|
221868|NCT02299973|Procedure|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
220923|NCT02314689|Drug|Intravenous (IV) citrulline|
220924|NCT02314702|Device|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
220925|NCT02314728|Drug|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
221216|NCT02309554|Other|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
221217|NCT02309554|Other|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
221218|NCT02309567|Other|Blood Collection|
221219|NCT02309580|Drug|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
221220|NCT02309593|Device|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
221221|NCT02309606|Other|PET scan with two different 5-HT receptor ligands|
221222|NCT02309619|Procedure|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
221223|NCT00152347|Drug|Botox|See Detailed Description
221224|NCT02309632|Other|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
221225|NCT02309632|Other|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
221226|NCT02309645|Biological|EVICEL® Fibrin Sealant|
221227|NCT02309645|Other|Sutures Only|
221228|NCT02309658|Drug|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
221229|NCT02309658|Drug|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
220633|NCT02282813|Drug|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
220634|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
220635|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: intravenous
220636|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
220637|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
220638|NCT02282826|Drug|acyclovir|Pharmaceutical form:tablet Route of administration: oral
220639|NCT02282839|Dietary Supplement|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
220640|NCT02282839|Dietary Supplement|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
220641|NCT02282852|Device|Wireless Capsule Endoscopy|
220926|NCT02314728|Drug|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
220927|NCT02277938|Drug|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
220928|NCT02277951|Device|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
220929|NCT02277951|Device|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
220930|NCT02277951|Device|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
220931|NCT02277951|Device|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
220932|NCT02277977|Other|Contrast enhanced ultrasound|Contrat enhanced ultrasound during septic shock
220933|NCT02277990|Device|TYRX Absorbable Antibacterial Envelope|
220934|NCT00148837|Drug|Ribavirin (drug)|
220935|NCT02278003|Other|memory test|
220936|NCT02278003|Drug|Propofol|
220937|NCT02278042|Other|Beverage Consumption|
220328|NCT00150241|Drug|CP-526,555 (varenicline)|
220329|NCT02289768|Drug|Vehicle|
220330|NCT02289781|Device|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
220331|NCT02289794|Biological|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
220332|NCT02289794|Biological|Placebo|Single dose, intramuscular injection (0.5 mL)
220333|NCT02289807|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
220334|NCT02289807|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
220335|NCT02289820|Biological|MEDI7510|RSV sF antigen plus adjuvant
220336|NCT02289820|Biological|IIV|Marketed Inactivated Influenza Vaccine
220337|NCT02289820|Biological|Placebo|Sterile saline
220338|NCT02289833|Drug|trastuzumab emtansine|3.6 mg/kg trastuzumab emtansine will be given intravenously on Day 1 of each 21-day cycle
220339|NCT00150254|Drug|CP-526,555 (varenicline)|
220340|NCT02289846|Drug|IW-9179|
220341|NCT02289846|Drug|Matching Placebo|
220342|NCT02289859|Procedure|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
220343|NCT02289859|Procedure|Wound Closure without Undermining|One side of the wound will remain un-undermined.
220344|NCT02289872|Device|Macintosh Laryngoscope|Direct-Laryngoscopy
220642|NCT00000342|Drug|Risperidone|
220643|NCT00002374|Drug|Ritonavir|
220644|NCT00149409|Dietary Supplement|Omacor|
220645|NCT02282852|Device|Magnetically steerable capsule endoscopy|
220646|NCT02282878|Dietary Supplement|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
222307|NCT02186730|Behavioral|Websites|Self help websites
222308|NCT02186743|Other|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
222309|NCT02186756|Other|EMG-Biofeedback and Usual care|Please refer to arm description
222310|NCT02186769|Drug|Risperdal® Consta®|
222311|NCT02186769|Drug|LY03004|
222312|NCT02186782|Drug|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
222629|NCT00002282|Drug|Fluconazole|
222630|NCT00137254|Drug|Stable Isotopes|IV administration of stable isotopes
222631|NCT02179229|Dietary Supplement|CONTROL|Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
222632|NCT02179229|Dietary Supplement|SYNBIOTIC|Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
222633|NCT02179242|Other|Cardiac rehab|
222634|NCT02179255|Drug|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
222635|NCT02179255|Drug|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
222636|NCT02179268|Drug|sertraline|50mg, 50-150mg/d,qd for one year
222637|NCT02179268|Drug|citalopram|20mg, 20-40mg/d,qd,for one year
222638|NCT02179268|Drug|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
222639|NCT02179268|Drug|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
222640|NCT02179268|Behavioral|control|50min, every week for three months, every month, for nine months
222641|NCT00137254|Drug|Indocyanine Green|IV administration of ICG
222642|NCT02181803|Drug|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
221999|NCT02312726|Procedure|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
222000|NCT02315027|Biological|autologous mesenchymal stem cells|There will be three treatment groups of up to 8 patients each. Groups 1 will receive a single dose of cells. Groups 2 and 3 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:
Group 1: single intrathecal dose of 1 x 107 cells.
Group 2: one intrathecal dose of 5 x 107 cells followed one month (+/- 4 days) later by a second intrathecal dose of 5 x 107 cells.
Group 3: one intrathecal dose of 1 x 108 cells followed one month (+/- 4 days) later by a second intrathecal dose of 1 x 108 cells.
222001|NCT02315040|Device|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
222002|NCT02315040|Other|Standard Intrauterine Insemination|standard intrauterine insemination procedure
222003|NCT02315053|Other|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
222004|NCT02315066|Drug|PF-04518600|Part 1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
222005|NCT02315066|Drug|PF-04518600|Part 2 - patients with select tumor types (hepatocellular carcinoma and melanoma ) will be treated at dose levels based on the MTD selected in Part 1.
222313|NCT02186782|Drug|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
222314|NCT02186808|Device|Procera® Bridge Zirconia|
222315|NCT00138073|Device|Web-based waveform interpretation guide|Use of an educational website.
222316|NCT02186821|Drug|Ceritinib (LDK378)|Ceritinib will be dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
222317|NCT02186834|Drug|Selinexor|After the initial screening visit and registration in the study, patients will receive Selinexor orally at a dose of 80 mg for 2 weeks. After 2 weeks of dosing with selinexor and dexamethasone, patients will receive weekly selinexor at a starting dose of 40 mg/m² in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone at 40 mg orally weekly.
222318|NCT02186834|Drug|Pegylated Liposomal Doxorubicin|During the induction phase, patients will receive pegylated liposomal doxorubicin (Lipodox) at a starting dose of 20 mg/m² on Day 1 of the cycle.
222319|NCT02186834|Drug|Dexamethasone|Patients will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Patients older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
222320|NCT02186847|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiation therapy
221692|NCT02280694|Drug|Capecitabine|
221693|NCT02280694|Drug|Cyclophosphamide|
221694|NCT02280694|Drug|Methotrexate|
221695|NCT02280694|Drug|Celecoxib|
221696|NCT02280707|Other|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
221697|NCT02280720|Procedure|Stenting using Optimax™|
221698|NCT02280720|Procedure|Stenting using PROMUS Element™ Plus|
221699|NCT00149201|Drug|5-FU continuous infusion|
221700|NCT02280733|Other|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
221701|NCT02280746|Other|Gluten challenge|Intervention will be continued for at least 6 months
221702|NCT02280759|Drug|Gelatin Tannate|
221703|NCT02280759|Drug|Placebo|Placebo consists of an identical formulation, except active substance
221704|NCT02280772|Dietary Supplement|Glucomannan|
221705|NCT02280772|Dietary Supplement|Maltodextrin|
221706|NCT02280785|Drug|Brentuximab vedotin|
221707|NCT02280798|Procedure|Endometrial Biopsy|4 endometrial biopsy
221708|NCT02280811|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
221709|NCT02280811|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
221710|NCT02283216|Device|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
221711|NCT02283216|Device|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
221712|NCT02283216|Device|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
221713|NCT02283229|Behavioral|Newborns with preventive caring advices|Advices to prevent head molding
220764|NCT02294890|Procedure|Total knee arthroplasty|
220765|NCT02294903|Procedure|Coiled Bipolar Radiofrequency Ablation|Radiofrequency ablation by use of bipolar electrodes
221046|NCT02290093|Drug|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
221047|NCT02290093|Drug|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
221048|NCT02290106|Drug|pitavastatin|
221049|NCT00150306|Drug|Zoloft (Sertraline)|
221050|NCT02290106|Other|PLACEBO|
221051|NCT02290119|Device|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofermoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
221052|NCT02290119|Procedure|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
221053|NCT02290132|Drug|Rabbit Anti－human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
221054|NCT02290145|Drug|TPF group|The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.
docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day
221055|NCT02290145|Procedure|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
221056|NCT02290145|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
221057|NCT02290158|Other|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
221058|NCT02290171|Behavioral|Activity groups|Children attend to activity groups weekly during the intervention periode.
221059|NCT02290171|Behavioral|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
221060|NCT00150319|Drug|Vfend®; I.V.|
221061|NCT02290171|Behavioral|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
220127|NCT00152113|Drug|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
220128|NCT02306798|Drug|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
220129|NCT02306811|Drug|Vatelizumab SAR339658|Pharmaceutical form:solution for infusion Route of administration: intravenous
220130|NCT02306837|Drug|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
220131|NCT02306850|Drug|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
220440|NCT02301676|Behavioral|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
220441|NCT02301676|Drug|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
220442|NCT02301676|Drug|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
220443|NCT00151567|Drug|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
220444|NCT02301676|Device|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
220445|NCT02301702|Biological|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
220446|NCT02301702|Biological|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
220447|NCT02301715|Drug|Oxytocin|
220448|NCT02301728|Other|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
219517|NCT02279901|Behavioral|Telemedicine Education|Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:
OSA program
CPAP program
Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor.
219518|NCT02279901|Behavioral|IVR|Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.
Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform.
219519|NCT02279914|Drug|Misoprostol 400 mcg 3 hours prior to procedure|
219520|NCT02279914|Drug|Misoprostol 600 mcg 90 minutes prior to procedure|
219521|NCT02279927|Device|Ureteroscopy|Ureteroscopy with laser stone fragmentation
219522|NCT02279953|Drug|Vortioxetine 10-20 mg|
219523|NCT02279953|Drug|Placebo|
219524|NCT02279953|Drug|SSRI|escitalopram, citalopram or sertraline
219525|NCT02282371|Drug|Cetuximab|
219526|NCT02282371|Drug|BYL719|
219806|NCT02314195|Drug|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
219807|NCT02314195|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
219808|NCT02314195|Other|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
219809|NCT02314208|Drug|Xenbilox|
219810|NCT02314208|Dietary Supplement|Resveratrol|
219811|NCT02314208|Drug|Tahor|
219812|NCT00152789|Procedure|Oxygen measurement - Eppendorf machine|
219813|NCT02314221|Device|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
219205|NCT02287142|Procedure|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
219206|NCT02287155|Behavioral|occupation based health promotion|The description of the intervention is provided in the "detailed description" of the study.
219207|NCT02287168|Procedure|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
219208|NCT02287168|Procedure|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
219209|NCT02287168|Procedure|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
219210|NCT02287181|Drug|Remifentanil|short acting opiate
219211|NCT02287181|Drug|Propofol|hypnotic drug
219212|NCT00149864|Drug|Mycophenolate sodium (enteric coated)|
219213|NCT02287181|Other|Bispectral index|electroencephalograph
219214|NCT02287194|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
219215|NCT02287207|Device|transcranial direct current stimulation (tDCS)|
219216|NCT02287220|Device|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
219217|NCT02287233|Drug|ABT-199|ABT-199 will be taken orally once daily on Days 2 through 28 of Cycle 1 and Days 1 through 28 of each subsequent cycle. This is a dose escalation study, therefore the dose of ABT-199 will change.
219218|NCT02287233|Drug|Cytarabine|Cytarabine will be taken orally on Days 1 to 10 of each 28-day cycle.
219219|NCT02287246|Drug|Extended-Release liposomal bupivacaine (Exparel)|20mL
219220|NCT02287246|Drug|Normal saline|20mL
219221|NCT02287259|Drug|olanzapine|
219222|NCT02287259|Drug|lithium|
219223|NCT00149877|Drug|Tegaserod|
219224|NCT02289300|Drug|Placebo|The assignment will be as follows:
Placebo: 4 matched placebo, t.i.d., orally.
Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)
219225|NCT00150176|Drug|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
223764|NCT02179619|Device|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
223765|NCT02179632|Behavioral|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
223766|NCT02179645|Drug|GRC 27864|
223767|NCT02179645|Drug|Celecoxib|
223768|NCT02179645|Drug|Placebo|
223769|NCT02179658|Drug|OPT-80|oral
223770|NCT02179658|Drug|vancomycin|oral
223771|NCT02179671|Drug|Gefitinib|Gefitinib once daily followed by MEDI4736
223772|NCT02179671|Drug|AZD9291|AZD9291 once daily followed by MEDI4736
223773|NCT02179671|Drug|Selumetinib+Docetaxel|Selumetinib twice daily + docetaxel, followed by MEDI4736
223774|NCT00137293|Drug|0.9% Sodium Chloride, USP|
218920|NCT02294123|Other|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
218921|NCT02294136|Behavioral|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
218922|NCT02294136|Behavioral|Educational Control|Attention Control
218923|NCT00150774|Drug|Levetiracetam|
218924|NCT02294149|Drug|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
218925|NCT02294149|Drug|placebo|
218926|NCT02294162|Drug|Ketamine i.v|
218927|NCT02294175|Device|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
218928|NCT02294175|Procedure|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
223419|NCT02184806|Procedure|heterotopic graft|put under the skin
the ovarian fragments can be put under the skin of the abdomen
223420|NCT02184819|Drug|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
223421|NCT02184819|Drug|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
223422|NCT02184832|Drug|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
223423|NCT02184832|Other|Low tryptophan diet|
223424|NCT02184832|Other|High tryptophan diet|
223425|NCT02184845|Device|Implant NobelActive 3.0|
223426|NCT02187120|Drug|Placebo|
223427|NCT02187133|Drug|Carfilzomib|IV; mg/m2; Days 1, 2, 8, 9, 15, 16
223428|NCT02187133|Drug|Bendamustine|IV; mg/m2; Days 1, 2
223429|NCT02187133|Drug|Rituximab|IV; mg/m2; Day 9 Cycle 1, Day 1 subsequent cycles
223430|NCT02187159|Drug|DS-5565 15mg tablet|
223431|NCT02187159|Drug|150mg pregabalin capsule|
223432|NCT00138125|Biological|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
223433|NCT02187159|Drug|placebo tablet|matching DS-5565 tablet
223434|NCT02187159|Drug|placebo capsule|matching pregabalin capsule
223435|NCT02187159|Drug|75mg pregabalin capsule|
223436|NCT02187172|Drug|Ustekinumab|
223437|NCT02187172|Drug|Placebo|
223438|NCT02187185|Device|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
223439|NCT02187185|Device|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
223775|NCT02179671|Drug|Tremelimumab|Tremelimumab every 4 weeks followed by MEDI4736
223776|NCT02179684|Procedure|Baby-sitter surgery N. fascialis|
222819|NCT02158611|Other|Lifestyle counseling|
223130|NCT02192229|Drug|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
223131|NCT02192242|Other|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
223132|NCT02192255|Behavioral|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
223133|NCT02192268|Other|PEP|
223134|NCT02192268|Other|HFOO|
223135|NCT02192268|Other|Assisted Coughing|
223136|NCT02192281|Other|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
223137|NCT02192294|Drug|Oral Bosutinib|a single dose of 500 mg oral bosutinib
223138|NCT02192294|Drug|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
223139|NCT02192307|Device|Potassium oxalate|
223140|NCT00138762|Drug|atorvastatin|
223141|NCT02192320|Drug|Atorvastatin|20 mg (every evening orally) for 5 weeks
223142|NCT02192320|Drug|Atorvastatin and Dexamethasone|Atorvastatin: 20 mg (every evening orally) for 5 weeks;
Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)
223143|NCT02192333|Procedure|Management of Therapy Complications|Receive survivorship care
223144|NCT02194595|Drug|Basal insulin only|
223145|NCT02194595|Drug|Basal insulin and bolus insulin|
223146|NCT00139152|Drug|Placebo|Saline, Sub-Cuteanous (SQ)
223147|NCT02194608|Device|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
222501|NCT02166411|Procedure|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
222502|NCT02166411|Procedure|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
222820|NCT02158624|Drug|Intravitreal Lucentis 0.5mg|
222821|NCT02158650|Behavioral|Video-Based Informed Consent|
222822|NCT02158663|Device|Repetitive Transcranial Magnetic Stimulation|TMS Device
222823|NCT02158676|Dietary Supplement|Prebiotic|Fructooligosaccharides
222824|NCT00134953|Drug|Rivastigmine|
222825|NCT02158676|Dietary Supplement|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
222826|NCT02158676|Other|Placebo|Maltodextrin
222827|NCT02158689|Drug|Letrozole|
222828|NCT02158689|Drug|human menopausal gonadotropin (hMG)|
222829|NCT02158702|Drug|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
222830|NCT02158715|Device|Site of smartphone on chest compressor' arm|
222831|NCT02158741|Behavioral|Home Visits and Lifestyle Education Support|
222832|NCT02158754|Other|CORUS CAD gene expression test|Corus CAD is a gene expression test blood test. The test result informs the clinician of the likelihood (%) of the presence of a 50% (by quantitative coronary angiography) or greater stenosis.
222833|NCT02158767|Biological|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
222834|NCT02158780|Procedure|Scrotal Orchidopexy|Single incision
222835|NCT00134966|Drug|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
222164|NCT02293057|Behavioral|Standard of Care|The Standard of Care (SOC) comparison condition includes: court monitoring and one or several of the following options: community service (e.g., cleaning schools, volunteering, charity work), mental health and/or substance use evaluation and/or treatment, drug screens, tracking and outreach (i.e., community-based case management or wrap around services) and/or detention
222165|NCT02293070|Other|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
222166|NCT02293070|Procedure|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
222167|NCT02173691|Drug|Placebo inhalation powder capsules|
222168|NCT02173704|Biological|Meningoccal B recombinant vaccine together with routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)|Meningococcal B recombinant vaccine + DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)
222169|NCT02173704|Biological|Routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)|DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)
222170|NCT02173717|Drug|Dabigatran etexilate|150 mg Dabigatran etexilate
222171|NCT02173717|Drug|Rifampicin|600 mg Rifampicin
222172|NCT02173730|Drug|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
222173|NCT02173730|Drug|Pantoprazole|Pantoprazole tablet 40 mg
222174|NCT02173743|Other|PRP|platelet enriched autologous blood plasma
222175|NCT02173743|Other|Control|Regular barbotage/care as usual
222503|NCT02166424|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
222504|NCT02166424|Dietary Supplement|Olive oil|
222505|NCT02166450|Drug|Nystatin|100 000 IU every 6 h as a suspension
222506|NCT02166463|Biological|Bleomycin Sulfate|Given IV or SC
222507|NCT02166463|Drug|Brentuximab Vedotin|Given IV
222508|NCT02166463|Drug|Cyclophosphamide|Given IV
222509|NCT00135759|Drug|Naltrexone|low dose naltrexone in addition to daily methadone taper
222510|NCT02166463|Drug|Doxorubicin Hydrochloride|Given IV
222511|NCT02166463|Drug|Etoposide|Given IV
221869|NCT02299973|Procedure|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
221870|NCT02299986|Other|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
221871|NCT00151411|Drug|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
221872|NCT02299999|Drug|AZD2014|Target: m-TOR
221873|NCT02299999|Drug|AZD4547|Target: EGFR
221874|NCT02299999|Drug|AZD5363|Target: AKT
221875|NCT02299999|Drug|AZD8931|Target: HER2, EGFR
221876|NCT02299999|Drug|Selumetinib|Target: MEK
221877|NCT02299999|Drug|Vandetanib|Target: VEGF, EGFR
221878|NCT02299999|Drug|Bicalutamide|target: Androgen receptor
221879|NCT02299999|Drug|Olaparib|Target: PARP
221880|NCT02299999|Drug|Anthracyclines|DNA intercalation
221881|NCT02299999|Drug|Taxanes|Target: mitotic tubulin and microtubules
221882|NCT00151411|Drug|Placebo|Placebo
221883|NCT02299999|Drug|cyclophosphamide|Alkylating agents
221884|NCT02299999|Drug|DNA intercalators|DNA intercalators
221885|NCT02299999|Drug|Methotrexate|DNA intercalators
221886|NCT02299999|Drug|vinca alkaloids|Target: mitotic tubulin and microtubules
221887|NCT02299999|Drug|Platinum based chemotherapies|Platinum based chemotherapies
221888|NCT02299999|Drug|Bevacizumab|Target: VEGF
221889|NCT02302287|Dietary Supplement|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
222176|NCT00136604|Biological|Diphtheria-tetanus-pertussis-hep B/Hib-meningococcal A&C|
221230|NCT02309658|Radiation|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
221231|NCT02309671|Drug|FE 999049|
221232|NCT02312336|Other|Cohort B - Cooled coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).
The research intervention is the infusion of Hartmans solution cooled to 15 degrees.
221233|NCT02312362|Procedure|Combined sclerotomy ab interno and phaco|
221234|NCT02312362|Procedure|Phacoemulsification with IOL implantation|
221564|NCT02307266|Behavioral|no supplementary education|
221565|NCT02307279|Device|Gelesis100|
221566|NCT02307279|Device|placebo|
221567|NCT02307292|Device|POLARIS Peripheral Vascular Self Expanding Stent System|
221568|NCT02307305|Drug|Duloxetine|Phase I (preemptive): 2 hour before surgery (30mg for 1 day)
Phase II (titration): POD#1~6 (30mg for another 6 days)
Phase III (maintenance): POD#7~13(60mg for 7 days)
Phase IV (tapering-1): POD#14~20 (30mg for 7 days)
Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)
221569|NCT02307305|Drug|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
221570|NCT00152178|Drug|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
221571|NCT02307318|Device|SoftSeal - STF Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
221572|NCT02307331|Device|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
221573|NCT02307331|Device|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
221574|NCT02307331|Device|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
221575|NCT02307331|Device|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
221576|NCT02307331|Device|Sirius stem|
221577|NCT02307344|Dietary Supplement|Nigella Sativa|
220938|NCT02278055|Drug|Radium-223|
220939|NCT02278068|Device|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
220940|NCT02278081|Drug|lansoprazole|the lansoprazole will be taken orally.
220941|NCT02278081|Drug|placebo|the lansoprazole placebo will be taken orally.
220942|NCT02278094|Device|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
220943|NCT02278094|Device|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
220944|NCT02278094|Procedure|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
220945|NCT00148837|Drug|Prazosin (drug)|
221235|NCT02312375|Drug|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
221236|NCT02312375|Drug|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
221237|NCT02312388|Other|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
221238|NCT02312388|Other|Thin-wall needle technique|using 18 - 21 G introducer needle
221239|NCT02312401|Device|multi-parametric MRI(MP-MRI)|
221240|NCT02312401|Device|dynamic contrast-enhanced MRI (DCE)|
221241|NCT00152672|Device|nCPAP vs oral appliance|
221242|NCT02312401|Procedure|biospy|
221243|NCT02312414|Drug|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
221244|NCT02312427|Drug|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
220647|NCT02282891|Drug|Propofol|Induction of general anesthesia using propofol 2mg/kg
220648|NCT02285309|Procedure|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
220649|NCT02285335|Dietary Supplement|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
220650|NCT02285348|Procedure|Lumbar puncture|Lumbar puncture is done according to general practice
220651|NCT02285361|Drug|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
220652|NCT02285361|Drug|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
220653|NCT02285361|Drug|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
220654|NCT02285374|Drug|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
220655|NCT00149708|Drug|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
220656|NCT02285387|Procedure|Rhythm control|Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation
Cardioversion after 1 month
Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)
If AF recur, RFCA
220657|NCT02285387|Procedure|Rate control|No AAD, just anticoagulation
HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)
Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study.
220658|NCT02285400|Procedure|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
220659|NCT02285413|Biological|DC vaccination|DC vaccination without cisplatinum
220660|NCT02285413|Biological|DC vaccination with cisplatinum|DC vaccination with cisplatinum
220661|NCT02285426|Device|Pentax EB-1990i HD-bronchoscope guided biopsy|3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.
When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality [visual scale adapted from Herth 2009 and Zaric 2013] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control.
220946|NCT02278094|Device|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
220947|NCT02278107|Device|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
220948|NCT02278107|Device|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
222643|NCT02181803|Drug|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
222644|NCT02181816|Drug|Azilsartan/amlodipine|Azilsartan/amlodipine combination tablets LD & HD
222645|NCT02181829|Radiation|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
222646|NCT02181842|Drug|Pioglitazone|Pioglitazone tablets
222647|NCT02181855|Procedure|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
222648|NCT02181868|Other|Biodegradable and titanium fixation used in mandibular fractures.|
222649|NCT00137540|Drug|anti-arrhythmic drug therapy|
222954|NCT00136669|Procedure|Acupuncture|
222955|NCT02174172|Drug|MPDL3280A|MPDL3280A administered intraveneously (IV) every three weeks (q3w)
222956|NCT02174185|Behavioral|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
222957|NCT02174198|Other|BioOss Collagen at the time of implant placement|Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
222958|NCT02174211|Drug|Ranibizumab|
222959|NCT02174224|Behavioral|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
222960|NCT02174224|Behavioral|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
222961|NCT02174224|Behavioral|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
222962|NCT02176759|Other|Administration of rice fortified with regular FePP|
222963|NCT02176759|Other|Administration of rice fortified with regular FePP with citrate added during extrusion|
222321|NCT02186847|Drug|Carboplatin|Given IV
222322|NCT02186847|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiation therapy
222323|NCT02186847|Other|Laboratory Biomarker Analysis|Correlative studies
222324|NCT02186847|Drug|Metformin Hydrochloride|Given PO
222325|NCT02186847|Drug|Paclitaxel|Given IV
222326|NCT02189096|Other|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
222327|NCT02189109|Drug|NVX-108|0.2% emulsion administered i.v.
222328|NCT02189122|Drug|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
222329|NCT02189122|Drug|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
222330|NCT00138294|Biological|Live attenuated influenza vaccine and inactivated influenza vaccine|live attenuated influenza vaccine; 0.2 ml intranasal dose, 0.1 ml to each nostril inactivated influenza vaccine; 0.5 ml dose by intramuscular injection
222331|NCT02189122|Drug|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
222332|NCT02189122|Drug|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
222650|NCT02181881|Behavioral|DuoPACT|Intervention sessions are administered weekly by a counselor.
222651|NCT02181881|Behavioral|Life Steps|Intervention sessions are administered weekly by a counselor.
222652|NCT02181907|Drug|UH-AC 62 XX tablet|
222653|NCT02181907|Drug|UH-AC 62 XX capsule|
222654|NCT02181920|Drug|Metamizole|
222655|NCT02181920|Drug|Diclofenac|
222656|NCT02181920|Drug|Diclofenac placebo|
222657|NCT02181920|Drug|Metamizole placebo|
222658|NCT02181933|Drug|Nevirapine|
222659|NCT02181933|Drug|Zidovudine (ZDV)|
222006|NCT02315079|Other|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
222007|NCT02315079|Other|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
222008|NCT02315092|Device|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
222009|NCT00152893|Drug|chromium nicotinate|
222010|NCT02315105|Procedure|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
222011|NCT02315118|Drug|T-cell therapy + Rituximab + IL-2|T cells collection
T cells expansion and modification in the laboratory
T cells infusion back to the patients
222012|NCT02315131|Drug|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
222013|NCT02315131|Drug|Placebo|Placebo Comparator
222014|NCT02315144|Drug|TV48108|TV48108 15, 60, 120 μg
222015|NCT02315144|Drug|Placebo|Placebo Comparator
222016|NCT02315157|Drug|Bendamustine|Given IV
222017|NCT02315170|Device|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
222018|NCT02315170|Device|standard lid speculum|standard wire lid speculum
222019|NCT02315183|Other|This is an observational Study|THis study has no intervention
222020|NCT02278419|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
222021|NCT02278445|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
222022|NCT00148876|Drug|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
222023|NCT02278445|Device|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
221062|NCT02292459|Drug|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
221063|NCT02292472|Drug|Botulinum Toxin Type A|Inject intramuscularly once in visit 2
221064|NCT02292485|Behavioral|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
221377|NCT02288078|Other|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
221378|NCT02288078|Other|Coagulation and fibrinolysis system|international normalized ratio (INR)
221379|NCT02288078|Other|Urinalysis|Proteinuria (qualitative)
221380|NCT02288078|Other|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
221381|NCT02288078|Other|Adverse event|CTCAE ver.4.0
221382|NCT02288078|Other|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
221383|NCT00149994|Drug|Tacrolimus|
221384|NCT02288078|Other|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
221385|NCT02288078|Other|Brain MRI|If any symptom of brain metastasis is suspected
221386|NCT02288078|Drug|Dexamethasone|Capsule filled with dexamethasone and lactose
221387|NCT02288078|Drug|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
221388|NCT02288078|Drug|Placebo|Capsule filled with lactose
221389|NCT02288078|Drug|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
221390|NCT02288091|Drug|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
221391|NCT02288104|Device|Dual Source CT - SOMATOM Definition from Siemens|Standard interventional radiology procedure
221392|NCT02288104|Drug|Novartis sodium fluorescein|Sodium fluorescein contrast agent administration for endomicroscopy imaging
220449|NCT02301741|Behavioral|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
220450|NCT02301754|Biological|INVAC-1|intradermal injection combined with electroporation
220451|NCT02301780|Drug|Aspirin|
220452|NCT02301780|Drug|Placebo|
220453|NCT02301793|Behavioral|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
220454|NCT00151580|Drug|Ribavirin|18 months of oral ribavirin maintenance treatment
220455|NCT02301793|Behavioral|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
220456|NCT02301806|Other|dieting|
220457|NCT02301806|Drug|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
220458|NCT02301806|Drug|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
220766|NCT02294916|Device|AWS|Video-laryngoscopy 1
220767|NCT02294916|Device|Intubrite|Video-laryngoscopy 2
220768|NCT02294916|Device|AirTraq|Optical-laryngoscopy
220769|NCT02297191|Drug|Ropivicaine|
220770|NCT02297204|Procedure|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
220771|NCT00151125|Drug|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
220772|NCT02297204|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
220773|NCT02297217|Drug|Carboplatin and Taxol (paclitaxel)|patients will receive receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on days 1, 8. Patients are seen weekly during concurrent chemoradiation then every 4 weeks until 6 months after enrollment.
219814|NCT02314234|Drug|sugammadex (Bridion)|single dose of sugammadex at skin incision
219815|NCT02314247|Drug|Selinexor|20 mg oral tablets: Oral 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle. Number of Cycles: up to 12 but there is no maximal duration for treatment.
219816|NCT02314260|Other|bishop score calculation|Assessment of bishop score by vaginal examination
219817|NCT02314260|Other|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
219818|NCT02314260|Other|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
219819|NCT02314260|Procedure|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
219820|NCT02314273|Drug|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
219821|NCT02314286|Drug|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
219822|NCT02314286|Drug|Placebo|
219823|NCT00152802|Biological|The polysaccharide vaccine Pneumovax (Merck-Frosst)|
219824|NCT02277496|Behavioral|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting via social media (text messaging) and school-based food and physical activity led by students.
220132|NCT02306863|Device|vibrating chair|vibration provided via physioacoustic method
220133|NCT02308995|Procedure|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
220134|NCT00152308|Device|2% rapamycin-eluting YUKONdes PEARL-stent|
220135|NCT02308995|Device|V-Loc (Covidien, Mansfield, MA)|
220136|NCT02308995|Device|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
220137|NCT02309008|Drug|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
219226|NCT02289300|Drug|DCB-BO1202+Placebo|The assignment will be as follows:
(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)
DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.
Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)
219527|NCT02282371|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
219528|NCT02282384|Drug|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
219529|NCT02282397|Device|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
219530|NCT00149331|Behavioral|Structured education program|
219531|NCT02282397|Other|Continuous Subcutaneous insulin infusion|Insulin pump with an insulin reservoir, angled infusion set, automated inserter, pumping mechanism and power supply contained in a pod worn on the skin which transmits wirelessly between a Personal Diabetes Manager with built-in Blood Glucose Meter
219532|NCT02282410|Drug|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
219533|NCT02282423|Behavioral|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
219534|NCT02282423|Procedure|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
219535|NCT02282423|Procedure|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
219536|NCT02282423|Procedure|VO2max.|VO2max.
219537|NCT02282423|Behavioral|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
219538|NCT02282423|Procedure|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
219539|NCT02282436|Other|No specific intervention for this study|No specific intervention for this study
218929|NCT02294188|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
218930|NCT02294188|Device|Active ingredient|Transfluthrin (Active ingredient)
218931|NCT02294188|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
218932|NCT02294201|Device|Spatial Repellent product with active ingredient|Spatial Repellent product
218933|NCT02294201|Device|Active ingredient|Transfluthrin (Active ingredient)
218934|NCT00150787|Drug|LEVETIRACETAM|
218935|NCT02294201|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
218936|NCT02294214|Device|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
218937|NCT02294214|Device|Active ingredient|Transfluthrin (Active ingredient)
218938|NCT02294214|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
218939|NCT02294227|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
218940|NCT02294227|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
219227|NCT02289313|Behavioral|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
219228|NCT02289339|Device|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
219229|NCT02289352|Drug|Brimonidine|
219230|NCT02289352|Drug|placebo|
219231|NCT02289365|Drug|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
219232|NCT02289365|Drug|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
219233|NCT02289365|Drug|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
223777|NCT02179684|Other|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
223778|NCT02179697|Other|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
223779|NCT02179697|Procedure|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
223780|NCT02179710|Behavioral|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
223781|NCT02179723|Device|Leukosan Adhesive|Leukosan adhesive applied to one wound
223782|NCT02179723|Device|Transcutaneous suture|Transcutaneous suture applied to one wound
223783|NCT02179736|Device|Restylane|
223784|NCT02179749|Drug|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
223785|NCT00137306|Procedure|Facilitate evidence-based treatment for depression|
223786|NCT02179749|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
223787|NCT02179749|Drug|Mifepristone 600 mg daily|Mifepristone, 300 mg tablets, Two tablets daily/am plus two placebo tablets daily/am for 1-week duration.
223788|NCT02179749|Drug|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
223789|NCT02182336|Drug|Midazolam HCl solution|Days 3 and 21
223790|NCT02182336|Drug|Midazolam HCl oral syrup|days 1, 10 and 19
223791|NCT02182336|Drug|Digoxin|Days 2 and 20
223792|NCT02182349|Drug|BI 201335 NA soft gelatin capsule|
223793|NCT02182349|Drug|[14C]-BI 201335 NA radiolabelled drug|
223794|NCT02182362|Drug|BI 201335 NA|
223795|NCT02182362|Drug|Placebo|
223796|NCT02182375|Drug|BI 201335 NA|
223797|NCT00137631|Behavioral|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
223148|NCT02194621|Drug|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
223149|NCT02194621|Drug|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
223150|NCT02194621|Drug|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
223440|NCT02187198|Drug|Buprenorphine|
223441|NCT02187211|Drug|Minocycline|
223442|NCT02187211|Drug|Placebo (for Minocycline)|
223443|NCT00138138|Drug|Ritalin|
223444|NCT02187224|Drug|Progesterone|
223445|NCT02187224|Drug|Placebo (for Progesterone)|
223446|NCT02187237|Device|YOLO TOUCH Low Level Laser|
223447|NCT02187250|Drug|metformin|
223448|NCT02187250|Drug|liraglutide|
223449|NCT02187250|Drug|roflumilast|
223450|NCT02187276|Drug|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
223451|NCT02187289|Device|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
223452|NCT02187289|Device|Compression Sleeve, daytime wear|
223453|NCT02187289|Device|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
223454|NCT00138151|Biological|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
223455|NCT02187302|Drug|CRLX101 + bevacizumab|
223456|NCT02187302|Drug|sorafenib / everolimus / pazopanib / axitinib / bevacizumab / sunitinib / other approved drug|
223457|NCT02189577|Drug|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
222836|NCT02158780|Procedure|Inguinal Orchidopexy|Double Incision (Standard)
222837|NCT02158793|Procedure|Craniomaxillofacial allotransplantation|Transplantation of donor face
222838|NCT02158806|Drug|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
222839|NCT02161276|Drug|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
222840|NCT00135252|Procedure|supplemental oxygen delivery by hood|
222841|NCT02161302|Device|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
223151|NCT02194634|Drug|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
223152|NCT02194634|Other|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
223153|NCT02194634|Procedure|Laser|Laser treatment at first month, then repeated as needed.
223154|NCT02194634|Other|Sham laser|Sham laser at first month, then repeated as needed.
223155|NCT02194673|Other|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
223156|NCT02194673|Other|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
223157|NCT00139152|Drug|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
223158|NCT02194673|Other|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
223159|NCT02194686|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
223160|NCT02194686|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
223161|NCT02194699|Biological|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
223162|NCT02194699|Other|Placebo|Placebo subcutaneous injection
223163|NCT02194712|Other|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
223164|NCT02194738|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue
222512|NCT02166463|Other|Laboratory Biomarker Analysis|Correlative studies
222513|NCT02166463|Drug|Prednisone|Given PO
222514|NCT02166463|Other|Quality-of-Life Assessment|Ancillary studies
222515|NCT02166463|Other|Questionnaire Administration|Ancillary studies
222516|NCT02166463|Drug|Vincristine Sulfate|Given IV
222517|NCT02166476|Drug|Carbavance|Carbavance for IV injection, administered as a 2 g/2 g dose
222518|NCT02166476|Drug|Piperacillin/tazobactam|Piperacillin/tazobactam for IV injection, administered as a 4.5 g (4 g piperacillin/0.5 g tazobactam) dose diluted in NS to a volume of 100 mL and infused over 30 minutes q8h
222519|NCT02166476|Drug|Levofloxacin oral|Levofloxacin oral tablets administered as a 500 mg dose q24h after a minimum of 15 doses of IV therapy, if clinically indicated.
222520|NCT00135759|Drug|Placebo comparator|1 capsule/day for 6 days
222521|NCT02166489|Biological|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
222522|NCT02168621|Procedure|Section-wise scaling and root planing|
222523|NCT02168634|Drug|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
222524|NCT02168634|Drug|Placebo|1cc normal saline, local injection
222525|NCT02168647|Behavioral|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
222842|NCT02161302|Device|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
222843|NCT02161328|Other|EIT belt|
222844|NCT02161354|Drug|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
222845|NCT02161354|Drug|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
222177|NCT02173756|Drug|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
222178|NCT02173756|Drug|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
222179|NCT02173769|Drug|A|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
222180|NCT02173782|Drug|Berodual® Respimat ® high dose|
222181|NCT02173782|Drug|Berodual® Respimat ® low dose|
222182|NCT02173782|Drug|Berodual® MDI|
222183|NCT02173782|Drug|Placebo|
222184|NCT02173795|Drug|Berodual® Respimat®|
222185|NCT02173795|Drug|Berodual® MA HFA|
222186|NCT02173808|Biological|levonorgestrel butanoate|
222187|NCT00136617|Drug|chlordiazepoxide|
222188|NCT02173821|Procedure|Blood sampling|Blood sample will be collected at a single visit
222189|NCT02173834|Other|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
222190|NCT02173847|Procedure|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
222191|NCT02173847|Device|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
222192|NCT02173847|Device|Diode laser|Low power, near infrared diode laser for welding the surgical wound
222193|NCT02173860|Procedure|FFR-guided surgical revascularization|
222194|NCT02173860|Procedure|Angio-guided surgical revascularization|
222195|NCT02176408|Behavioral|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
221578|NCT02307344|Dietary Supplement|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
221579|NCT02307357|Behavioral|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
221580|NCT02307370|Device|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
221581|NCT00152178|Drug|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
221582|NCT02307383|Drug|Lactitol|
221583|NCT02307383|Drug|Lactobacillus|
221584|NCT02307396|Drug|Olanzapine|
221890|NCT02302287|Other|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
221891|NCT02302287|Other|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
221892|NCT02302300|Device|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
221893|NCT02302313|Device|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
221894|NCT02302326|Drug|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
221895|NCT02302326|Dietary Supplement|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
221896|NCT00151645|Drug|activated lymphocytes|
221897|NCT02302339|Drug|glembatumumab vedotin|
221898|NCT02302352|Other|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
221899|NCT02302352|Other|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
221900|NCT02302365|Device|Spectra Optia® Apheresis System|White Blood Cell Depletion
221901|NCT02302378|Procedure|Lumbar paramedian approach at L3-L4 interspace|Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)
221245|NCT02312427|Drug|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
221246|NCT02312440|Drug|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
221247|NCT02312440|Drug|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
221248|NCT02312440|Drug|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
60 Milliliters（ml） by irrigation for 3 minutes before wound closure.
221249|NCT02312453|Procedure|Posterior approach|We adopted the technique as described by Hebbard et al.
221250|NCT02312479|Device|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
221585|NCT02307396|Drug|Amisulpride|
221586|NCT02307396|Drug|Risperidone|
221587|NCT02307396|Drug|Haloperidol|
221588|NCT02307396|Drug|Quetiapine|
221589|NCT02309671|Drug|follitropin beta|
221590|NCT02309710|Device|ShangRing|ShangRing administered to males seeking medical male circumcision
221591|NCT00152360|Drug|Orlistat|See Detailed Description.
221592|NCT02309723|Device|Beta amyloid imaging|
221593|NCT02309736|Device|ReSure Sealant|
221594|NCT02309749|Other|CAP|
221595|NCT02309762|Drug|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
221596|NCT02309762|Drug|Placebo|Solution containing no active ingredients
223600|NCT02161705|Drug|Saline|Up to 0.8 mL/kg of normal saline administered
223601|NCT02161718|Drug|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
223602|NCT00135304|Drug|Vitamin D|Vitamin D administered IV
223603|NCT02161718|Drug|Placebo|Oral tablet, taken once daily
223604|NCT02161731|Drug|Evacetrapib|Oral administration
223605|NCT02161731|Drug|Warfarin|Oral administration
223606|NCT02161744|Procedure|Lipoaspiration and intravenous injection of SVF cells in saline solution|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
223607|NCT02161757|Biological|Tralokinumab|Subcutaneous injection
223608|NCT02161757|Other|Placebo|Subcutaneous injection
223609|NCT02161770|Drug|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
223610|NCT02161770|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
223611|NCT02161770|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
223612|NCT02161783|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
223613|NCT00135317|Drug|darbepoetin alfa|
223614|NCT02164019|Procedure|long-stem cemented hemiarthroplasty (LSCH)|
223615|NCT02164019|Procedure|intramedullary nailing (IMN)|
223616|NCT02164019|Behavioral|questionnaires|
223617|NCT02164032|Drug|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
223618|NCT00135551|Drug|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
222964|NCT02176759|Other|Administration of rice fortified with regular FePP and citrate added at consumption|
222965|NCT00136981|Drug|torcetrapib/atorvastatin|
222966|NCT02176759|Other|Administration of rice fortified with ferrous sulphate|
222967|NCT02176772|Other|Stable iron isotopes, non-drug intervention|
222968|NCT02176785|Device|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
222969|NCT02176824|Behavioral|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
222970|NCT02176824|Behavioral|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
222971|NCT02176824|Other|Treatment as usual|
222972|NCT02176837|Drug|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
222973|NCT02176850|Drug|Micardis®|
223272|NCT00136071|Device|Transobturator tape-ARIS|
223273|NCT02169011|Procedure|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
223274|NCT02169011|Procedure|TAP Flap Reconstruction|Delayed, unilateral breast reconstrucion with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
223275|NCT02169024|Behavioral|Expect With Me prenatal care|
223276|NCT02169037|Procedure|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
223277|NCT02169037|Procedure|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
223278|NCT02169063|Radiation|carbon-11 acetate|Given IV
223279|NCT02169063|Radiation|fluorine F 18 sodium fluoride|Given IV
223280|NCT02169063|Procedure|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
223281|NCT02169063|Other|laboratory biomarker analysis|Correlative studies
222660|NCT00137553|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
222661|NCT02181933|Drug|Lamivudine (3TC)|
222662|NCT02181946|Drug|Fluconazole|
222663|NCT02181946|Drug|Nevirapine|
222664|NCT02181959|Drug|Pharmaton® with DMAE|
222665|NCT02181959|Drug|Pharmaton® without DMAE|
222666|NCT02181959|Drug|Placebo|
222667|NCT02181972|Drug|Gingko biloba|
222668|NCT02181972|Drug|Placebo|
222669|NCT02181985|Drug|Full dose TNK-tPA|
222670|NCT02181985|Drug|Half dose TNK-tPA|
222671|NCT00137566|Drug|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
222672|NCT02184429|Drug|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
222673|NCT02184429|Drug|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
222674|NCT02184429|Drug|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
222675|NCT02184442|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Inoperable and high risk operable patients requiring the transcatheter aortic heart valve replacement
222974|NCT02176863|Biological|Flebogamma 5% DIF|Human plasma-derived immunoglobulin
222975|NCT02176863|Other|Placebo|Normal saline solution
222976|NCT00136981|Drug|atorvastatin|
222977|NCT02176876|Drug|GS-5745|GS-5745 400 mg administered intravenously
222978|NCT02176876|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
222979|NCT02176889|Dietary Supplement|Lactospore|Bacillus coagulans MTCC 5856
222980|NCT02176889|Other|Placebo|
222024|NCT02278458|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
222333|NCT02189122|Drug|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
222334|NCT02189122|Drug|Placebo|Subjects will take matching placebo for five days.
222335|NCT02189135|Device|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
222336|NCT02189161|Device|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
222337|NCT02189174|Drug|CLR457|
222338|NCT02189187|Behavioral|Mindfulness|
222339|NCT02189187|Behavioral|Psychoeducation|
222340|NCT02189200|Dietary Supplement|oat bran - 40g per day|oat bran - 40g per day
222341|NCT00138359|Drug|Niclosamide|
222342|NCT02189213|Drug|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
222343|NCT02189213|Drug|Fluoxetine|Fluoxetine will be administered to treat anxiety disorders in children and adolescents.
222344|NCT02189213|Drug|Escitalopram|Lexapro will be administered to treat anxiety disorders in children and adolescents.
222345|NCT02191748|Drug|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
222346|NCT02191761|Drug|SM04755|Escalating Doses
222347|NCT02191774|Other|Medical abortion at home|Medical abortion at home
222348|NCT02191787|Drug|Seresis®|
222349|NCT02191787|Drug|Placebo|
222350|NCT00138710|Drug|Letrozole (Femara)|
221393|NCT02288104|Device|Cellvizio with AQ-Flex confocal mini probe (Mauna Kea Technologies)|Needle-based confocal laser endomicroscopy imaging of the lesion
221394|NCT00149994|Drug|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
221395|NCT02288130|Drug|GnRHa|
221396|NCT02288130|Drug|Ulipristal|
221397|NCT02288143|Drug|COOL-COS|Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:
Oral clomiphene citrate: 100 mg/day until the day of the triggering.
Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.
hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.
The triggering will be performed using urinary hCG (5,000 IU subcutaneous).
1-2 days after the identification of one follicle ≥ 17 mm
0-1 days after the identification of one follicle ≥ 19 mm.
221714|NCT00149487|Behavioral|Tailored Problem Solving Intervention|
221715|NCT02283229|Other|Newborns with normal caring advices|Normal handling
221716|NCT02283242|Drug|Galantamine|Oral use for 12 weeks
221717|NCT02283242|Drug|Placebo (for galantamine)|Oral use for 12 weeks
221718|NCT02283255|Other|Physical Activity|Physical Activity, Exercise training: aerobic and respiratory exercise with POWERbreathe device
221719|NCT02283268|Biological|Recombinant von Willebrand Factor (rVWF)|rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
221720|NCT02283281|Drug|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
221721|NCT02283281|Drug|Acetaminophen|50 ml intravenous vial
221722|NCT02283281|Drug|Midazolam|2 ml prefilled syringe
221723|NCT02283281|Drug|Dummy oromucosal spray|Oromucosal spray containing only alcohol vehicle without the active compound (i.e.: without nabiximols)
221724|NCT02283294|Drug|Apixaban|
221725|NCT00149487|Behavioral|Family Education Intervention|
221726|NCT02283294|Drug|Warfarin|
221727|NCT02283307|Other|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
221728|NCT02283307|Other|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
220774|NCT02297217|Radiation|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on days 1, 8. Treatment will be delivered using 3D radiotherapy planning to encompass the primary tumor and surrounding clinical target volume. Preparation and administration of chemotherapy will be according to local site standard operating procedures. Patients are seen weekly during concurrent chemoradiation then every 4 weeks until 6 months after enrollment.
220775|NCT02297230|Radiation|radiation therapy|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
220776|NCT02297230|Drug|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
220777|NCT02297230|Drug|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
220778|NCT02297230|Drug|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
220779|NCT02297243|Device|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
220780|NCT02297256|Biological|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
221065|NCT02292498|Device|FLIR ONE|
221066|NCT02292511|Behavioral|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
221067|NCT02292524|Other|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
221068|NCT02292537|Drug|IONIS-SMN Rx|Administered by intrathecal injection
221069|NCT00002378|Drug|Ritonavir|
221070|NCT00150618|Drug|SPD503 (1 mg)|
221071|NCT02292537|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
221072|NCT02292550|Drug|LEE011|CDK 4/6 inhibitor
220138|NCT02309008|Other|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
220139|NCT02309021|Other|Sport|
220140|NCT02309021|Other|Non-sport activities|
220141|NCT02309034|Behavioral|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
220142|NCT02309034|Behavioral|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
220143|NCT02309034|Other|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
220144|NCT02309060|Behavioral|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
220145|NCT00152308|Device|1% rapamycin-eluting YUKONdes PEARL-stent|
220146|NCT02309086|Biological|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
220147|NCT02309099|Device|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
220148|NCT02309112|Other|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
220149|NCT02309125|Procedure|immediate progressive loading using gingival formers|Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.
The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm).
220150|NCT02309125|Procedure|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
220151|NCT02309138|Other|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
220459|NCT02304185|Biological|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
220460|NCT02304185|Drug|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
220461|NCT02304198|Drug|Udenafil|Udenafil 50mg tablet
220462|NCT02304211|Drug|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
219540|NCT02282449|Device|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
219541|NCT00149344|Radiation|Vertical scar versus inferior pedicle reduction mammoplasty|Vertical Scar Reduction Mammoplasty Inferior Pedicle Reduction Mammoplasty
219542|NCT02282449|Device|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
219825|NCT02277496|Behavioral|HC Students -wait listed control schools|The HealthCorps curriculum, which the HC students in the wait-listed control school will receive, addresses the learning objectives related to health, physical activity and nutrition from state and federal curriculum standards.
219826|NCT02277509|Behavioral|Chinese DPP|The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.
219827|NCT02277509|Behavioral|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
219828|NCT02277522|Biological|RNA anti-CD19 CAR T cells|
219829|NCT02277535|Other|Feedback/Reminder email.|
219830|NCT00148772|Drug|Erlotinib (Tarceva)|
219831|NCT02277548|Drug|Lyrica 300 mg|Lyrica 300 mg per day
219832|NCT02277561|Procedure|diffusion tensor imaging|Undergo VB-DTI
219833|NCT02277561|Radiation|whole-brain radiation therapy|Undergo WBRT
219834|NCT02277561|Radiation|stereotactic radiosurgery|Undergo SRS
219835|NCT02277561|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
219836|NCT02277561|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
219837|NCT02277574|Biological|AMP-110|2, 5, or 10 mg/kg
219838|NCT02277574|Other|Placebo|Placebo
219839|NCT02277587|Drug|Plenadren|Oral Tablets: 20-25-30 mg
219840|NCT02277587|Drug|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
219841|NCT00148785|Drug|Indinavir/Ritonavir/Fosamprenavir|
219842|NCT02277600|Drug|BMS-663068|
219234|NCT02289378|Drug|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
219235|NCT02289391|Drug|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
219236|NCT00150176|Drug|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
219237|NCT02289391|Drug|Anesthesia maintenance|Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3~8mg/(kg•h).
Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30~40 mmHg and bispectral index (BIS) to 45~60.
219238|NCT02289391|Drug|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
219239|NCT02289404|Drug|NVP-1203(Fed)|fed
219240|NCT02289404|Drug|NVP-1203(Fasting)|fasting
219241|NCT02289417|Drug|Apremilast|
219242|NCT02289417|Drug|Placebo|
219243|NCT02289430|Drug|Crestor+Ezetrol|rosuvastatin+ezetimibe
219244|NCT02289430|Drug|Ezetrol|ezetimibe
219245|NCT02289430|Drug|Crestor|rosuvastatin
219246|NCT02289443|Other|complete denture|Comparison of different procedures
219247|NCT00150189|Behavioral|Sucrose|
219248|NCT02289456|Drug|nab-Paclitaxel|
219249|NCT02289456|Drug|Carboplatin|
219543|NCT02282462|Other|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
219544|NCT00149656|Dietary Supplement|Multivitamins|dietary supplement of multivitamins
219545|NCT02284867|Other|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
219546|NCT02284880|Drug|BIA 2-093|MF - Marketed formulation
219547|NCT02284880|Drug|BIA 2-093|TBM - to-be-marketed
218941|NCT02294227|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
218942|NCT02296541|Biological|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218943|NCT02296541|Biological|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218944|NCT02296541|Biological|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218945|NCT02296541|Biological|MVA-CMDR|1×10^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218946|NCT02296541|Biological|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218947|NCT02296541|Biological|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218948|NCT02296541|Biological|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218949|NCT02296541|Biological|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218950|NCT02296554|Procedure|SLAP Repair|SLAP repair for SLAP tear
218951|NCT00151060|Drug|Etoposide|
218952|NCT02296554|Procedure|Biceps Tenodesis|Biceps tenodesis for SLAP tear
218953|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
218954|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
218955|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
218956|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
218957|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
218958|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
223458|NCT02189590|Device|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
223459|NCT02189590|Device|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
223460|NCT02189603|Biological|Recombinant (E. Coli) Hepatitis E Vaccine|
223461|NCT00138411|Drug|ETI-204 (Anthim)|
223462|NCT02189616|Behavioral|SMS reminder|send weekly mobile phone short message reminders to the intervention group
223798|NCT02182375|Drug|Raltegravir|
223799|NCT02182388|Drug|Placebo|
223800|NCT02182388|Drug|BI 207127 NA powder for solution|
223801|NCT02182388|Drug|BI 207127 NA tablet|
223802|NCT02182401|Drug|BI 207127 NA|Days 3-8 and days 25-30
223803|NCT02182401|Drug|BI 201335 NA|Days 15-30
223804|NCT02182401|Drug|Midazolam|Days 1, 7, 23 and 29
223805|NCT02182401|Drug|Tolbutamide|Days 1, 7, 23 and 29
223806|NCT02182414|Drug|BI 207127 NA (TF-I)|200 mg tablet
223807|NCT02182414|Drug|BI 207127 NA (TF-II)|400 mg tablet
223808|NCT00137644|Behavioral|Preventing AIDS Through Live Movement and Sound (PALMS)|
223809|NCT02182414|Drug|BI 207127 NA delayed release|400 mg tablet
223810|NCT02182414|Drug|BI 207127 NA extended release (10% HPMC)|400 mg tablet
223811|NCT02182414|Drug|BI 207127 NA extended release (15% PEO)|400 mg tablet
223812|NCT02182414|Drug|BI 207127 NA extended release (20% HPMC)|400 mg tablet
223813|NCT02182440|Biological|recAP|One hour infusions once daily for three days
223814|NCT02182440|Other|Placebo|1 hour IV infusion once daily for 3 days
223165|NCT02194738|Other|Laboratory Biomarker Analysis|Undergo laboratory analysis via direct sequencing and FISH
223166|NCT02194751|Biological|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
223167|NCT02194764|Drug|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
223168|NCT02076022|Device|Enhanced Fat Grafting|The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™
The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.
To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject.
223463|NCT02189616|Other|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
223464|NCT02189616|Other|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
223465|NCT02189629|Drug|CD5789|
223466|NCT02189655|Procedure|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
223467|NCT02189668|Drug|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
223468|NCT02189681|Procedure|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
223469|NCT02189681|Procedure|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
223470|NCT02189681|Device|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
223471|NCT02189694|Device|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
222846|NCT02161354|Drug|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
222847|NCT02161367|Drug|Simethicone|Pharmacological category: antiflatulent
160mg Simethicone orally, 4 times a day for the first five postoperative days
222848|NCT02161367|Drug|Oral Suspending Vehicle|ORA-Plus is an aqueous-based vehicle.
Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days
222849|NCT02161380|Drug|injection of scAAV2-P1ND4v2 5.00x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
222850|NCT02161380|Drug|injection of scAAV2-P1ND4v2 2.46X10e10 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
222851|NCT00002266|Drug|AS-101|
222852|NCT00135265|Behavioral|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
222853|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.0X10e11vg (High)|injection of Total Volume of each intravitreal injection is 200 µL
222854|NCT02161393|Behavioral|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
222855|NCT02161393|Behavioral|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
222856|NCT02161406|Drug|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
222857|NCT02161406|Drug|Placebo|125 mg of Placebo
222858|NCT02163707|Drug|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
223169|NCT02076022|Procedure|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
223170|NCT02076074|Radiation|accelerated partial breast irradiation|Undergo HG-PBI
222196|NCT02176408|Behavioral|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
222526|NCT02168647|Other|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
222527|NCT02168660|Drug|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
222528|NCT02168686|Genetic|AAVrh.10halpha1AT|gene transfer vector administration
222529|NCT02168699|Other|Ultrasound examination of the axilla|
222530|NCT02168712|Other|Moderate continuous exercise training|
222531|NCT02168712|Other|Interval exercise training|
222532|NCT00136032|Drug|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
222533|NCT02168725|Drug|briciclib|
222534|NCT02168738|Drug|13-C labeled AceDoPC-DHA|Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months
222535|NCT02168738|Drug|13-C labeled TG-DHA|Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months
222536|NCT02168738|Drug|13-C labeled PC-DHA|Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months
222537|NCT02168751|Drug|propofol|
222538|NCT02168751|Drug|Sevoflurane|
222539|NCT02168764|Device|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
222540|NCT02168777|Drug|Refametinib (BAY86-9766)|Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.
In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.
221902|NCT02302378|Procedure|Taylor's approach (paramedian approach at L5-S1 interspace)|Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
221903|NCT02302391|Other|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
221904|NCT02302404|Drug|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
221905|NCT02302404|Drug|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
221906|NCT02302404|Drug|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
221907|NCT00151658|Device|Coronary Drug Eluting Stents for PCI|
221908|NCT02302404|Drug|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
222197|NCT02176421|Device|VOLBELLA® with lidocaine|Up to 1.5 mL product administered to correct hollows during initial treatment and optional top-up treatment 14 days later.
222198|NCT02176434|Procedure|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
222199|NCT02176434|Biological|hematopoietic stem cell|
222200|NCT02176460|Drug|Colchicine|0.5mg twice daily for 16 weeks
222201|NCT02176460|Drug|Placebo|1 tablet twice daily
222202|NCT02176473|Behavioral|Computerized Cognitive Behavioral Therapy|The c-CBT software focuses on the same principles of traditional CBT, namely, "identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors."9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/.
222203|NCT00136929|Procedure|Percutaneous coronary intervention (PCI)|
222204|NCT02176486|Drug|Ixazomib|Ixazomib capsules
222205|NCT02176486|Drug|Placebo|Ixazomib placebo-matching capsules
222206|NCT02176499|Drug|Telmisartan, low dose|
222207|NCT02176499|Drug|Telmisartan, high dose|
222208|NCT02176499|Drug|Placebo|
221597|NCT02309775|Other|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
221598|NCT02309801|Dietary Supplement|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
221599|NCT02309801|Dietary Supplement|Alcohol|Alcohol single oral dose
221600|NCT02309814|Device|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
221601|NCT02309827|Drug|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
221602|NCT00002386|Drug|Lamivudine|
221603|NCT00152373|Drug|Levetiracetam|
221604|NCT02309840|Behavioral|choice architecture|Place vegetables at the beginning of the lunch line.
Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.
Promote fruits and vegetables with prominently displayed signage and images.
Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level.
221605|NCT02309840|Other|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
221606|NCT02309853|Other|Visual and tactile scanning training|20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.
Visual or tactile scanning in the personal space
Visual or tactile scanning and trunk rotation in the peripersonal space
Visual scanning and trunk rotation in the extrapersonal space
221909|NCT02302417|Procedure|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
221910|NCT02304809|Drug|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
221911|NCT00151931|Drug|Lanthanum carbonate|
221912|NCT02304822|Drug|Multiple-dose of Ciprofloxacin prophylaxis|Patients in Group 1 undergo RIRS using Multiple-dose of Ciprofloxacin prophylaxis with intravenous ciprofloxacin one time preoperatively and postoperatively, respectively.The patients administered a preoperative single dose 30min before the operation; the postoperative was discontinued following the one given in the 12th hour.
223619|NCT02164032|Drug|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
223932|NCT02156219|Other|Separation of women and men in the metro of Mexico City|The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.
The implementation of the measure of separation of men and women on the subway consists of three operational tasks:
Control: Surveillance that men do not use cars corresponding to women.
Dosage: Regulation of entry women.
Assignment: Of the women, to the part of the platform where the first wagons stop.
223933|NCT02156232|Procedure|TIPS|TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months to one year and lifelong aspirin were routinely prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction. Intravenous arginine and branched-chain amino acids and antibiotics were administered for five days as prophylactics for encephalopathy and operation-related infection, respectively. TIPS revision was planned if any evidence of shunt dysfunction was seen; thereafter, long-term anticoagulation was prescribed.
223934|NCT02156232|Procedure|embolization|Embolization of SPSS was conducted via the same jugular vein before TIPS implantation. The major procedures included (a)angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b)embolization of SPSS with coils of varying diameters, which resulted in the SPSS disappearing at postembolization angiography.
223935|NCT00134680|Drug|Letrozole|Letrozole tablets 2.5 mg by mouth daily
223936|NCT02156245|Other|classical cycle ergometer|
223937|NCT02156245|Other|eccentric cycle ergometer|
223938|NCT02156258|Device|FFDM Mammography|Standard mammography image collection
223939|NCT02156258|Device|DBT Mammography|Collection of breast images using DBT mammography
223940|NCT02156271|Drug|ramelteon|
223941|NCT02156271|Drug|placebo|
223942|NCT02156284|Behavioral|Empathic behaviour by nurses|Control group: patients without specific empathic behaviour
Intervention group: patients who received the empathic behaviour was performed by a trained nurse.
223943|NCT02156323|Drug|CMS|Multiple doses of CMS over 2.5 days
223944|NCT02156323|Drug|RO7033877|Multiple doses of RO7033877 over 2.5 days
223945|NCT02156323|Drug|RO7033877 + CMS|Multiple doses of RO7033877 and CMS over 2.5 days
223946|NCT02159066|Drug|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
223282|NCT02169076|Device|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
223283|NCT00136071|Device|TVT-O|
223284|NCT02169089|Drug|Eplerenone|Patients will be given Eplerenone 25 mg on week 0 (visit 2). Patients will be escalated to 50 mg bid Eplerenone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
223285|NCT02171208|Drug|dimethyl fumarate - Test form|single dose 240 mg
223286|NCT02171221|Drug|Oral DFP-11207|
223287|NCT02171234|Drug|Placebo|
223288|NCT02171234|Drug|BIA 2-093|
223289|NCT02171247|Drug|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
223290|NCT02171247|Drug|Visipaque 320|Visipaque 320 is standard protocol.
223291|NCT00136396|Drug|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
223292|NCT02171260|Drug|Eribulin Mesilate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
223293|NCT02171273|Behavioral|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
223620|NCT02164032|Other|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
223621|NCT02164045|Drug|BMS-663068|
223622|NCT02164058|Device|TandemHeart System|
223623|NCT02164058|Procedure|Percutaneous coronary intervention|
223624|NCT02164071|Other|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
223625|NCT02164084|Drug|SB204|SB204 Gel with hydrogel
223626|NCT02164084|Drug|Vehicle Gel|Vehicle Gel with hydrogel
223627|NCT02164097|Drug|ODSH|
223628|NCT02164110|Biological|Euvichol|Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose
222981|NCT02176902|Behavioral|behavioral dietary intervention|Receive dietary counseling
222982|NCT02176902|Behavioral|behavioral dietary intervention|Receive guidelines for low-fat diet
222983|NCT02176902|Dietary Supplement|omega-3 fatty acid|Given PO
222984|NCT02176902|Other|laboratory biomarker analysis|Correlative studies
222985|NCT02176915|Behavioral|Group program|
222986|NCT02176915|Behavioral|Print Materials|
222987|NCT00136994|Drug|Ziprasidone|
222988|NCT02176928|Device|AutoPAP|PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
AutoPAP treatment 7 nights a week for four months (16 weeks).
222989|NCT02179281|Device|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
222990|NCT02179294|Drug|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
222991|NCT02179294|Drug|Remifentanil|Dedicated intravenous cannula for remifentanil administration PCA protocol
PCA bolus remifentanil 40 μg
Lockout interval 2 minutes
In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes.
222992|NCT02179307|Behavioral|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
222993|NCT02179320|Procedure|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
222994|NCT02179320|Device|acupuncture needle 0,25 x 40mm|
223294|NCT02171273|Behavioral|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
223295|NCT02171273|Behavioral|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
223296|NCT02171299|Procedure|Wound infiltration with local anaesthetic|
223297|NCT02171299|Drug|Ropivacaine|
222351|NCT02191813|Drug|Seresis®|
222352|NCT02191813|Drug|Placebo|
222353|NCT02191826|Drug|SOM0226|Oral
222354|NCT02191839|Drug|Alpha 1-Antitrypsin|
222355|NCT02191852|Drug|Seresis®|
222676|NCT02184455|Biological|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
222677|NCT02184468|Other|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
222678|NCT00137917|Biological|Meningococcal serogroup B vaccine|
222679|NCT02184481|Behavioral|Working memory training|
222680|NCT02184481|Behavioral|Placebo training|
222681|NCT02184494|Device|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.
Whole Body Vibration
222682|NCT02184507|Dietary Supplement|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
222683|NCT02184507|Dietary Supplement|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
222684|NCT02184507|Dietary Supplement|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
222685|NCT02184507|Drug|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
222686|NCT02184520|Device|TRANSITION|
222687|NCT02184520|Device|REVERE|
222688|NCT02184533|Drug|sodium selenite|Given PO
222689|NCT00137930|Biological|Live attenuated rotavirus vaccine|
222690|NCT02184533|Radiation|radiation therapy|Undergo radiation therapy
222691|NCT02184533|Other|laboratory biomarker analysis|Correlative studies
222692|NCT02184533|Other|pharmacological study|Correlative studies
221729|NCT02283320|Drug|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
221730|NCT02283333|Behavioral|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
221731|NCT02283333|Behavioral|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
221732|NCT02283346|Radiation|HDR brachytherapy + hypofractionated EBRT|Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).
+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints).
221733|NCT02283359|Drug|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
221734|NCT00149747|Behavioral|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
221735|NCT02285751|Drug|ticagrelor|
222025|NCT02278458|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
222026|NCT02278471|Drug|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
222027|NCT02278484|Device|XprESS device and PathAssist confirmation tools|XprESS Multi-Sinus Dilation Tool intended to remodel sinus outflow tracts. PathAssist confirmation tools intended to access, locate and illuminate sinus spaces.
222028|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
222029|NCT02278510|Drug|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
222030|NCT02278510|Drug|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
222031|NCT02278510|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
222032|NCT02278523|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
222033|NCT00148889|Device|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
221073|NCT02292550|Drug|Ceritinib|ALK inhibitor
221074|NCT02292563|Procedure|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
221075|NCT02292563|Procedure|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
221076|NCT02292576|Other|Cocoa Pure|Cocoa Pure.
221077|NCT02292576|Other|Placebo|Placebo.
221078|NCT02292589|Device|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
221079|NCT02292589|Device|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
221080|NCT02292589|Device|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
221081|NCT00150618|Drug|SPD503 (2 mg)|
221082|NCT02292602|Behavioral|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
221083|NCT02292615|Other|Medical Imaging|
221084|NCT02292628|Drug|Infusion of mesenchymal stem cells from adipose tissue|
221085|NCT02292628|Other|Infusion of placebo|
221086|NCT00150891|Drug|cyclosporine A|
221398|NCT02290184|Behavioral|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
221399|NCT02290197|Procedure|Surgery|Surgical reconstruction of all injured ligaments.
221400|NCT02290197|Device|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
221401|NCT02290197|Device|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
220463|NCT02304224|Other|eye masks|eye masks from 21:00 to 6:00 each night during admission
220464|NCT00002381|Drug|Nevirapine|
220465|NCT00151853|Drug|PPSB-SD|
220466|NCT02304237|Drug|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
220467|NCT02304237|Drug|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
220468|NCT02304250|Drug|Dexamethasone|dexamethasone 1ml (5mg)
220469|NCT02304250|Drug|saline|saline 1ml
220470|NCT02304263|Drug|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
220471|NCT02304276|Radiation|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
220472|NCT02304276|Radiation|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
220473|NCT02304289|Drug|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
220474|NCT02304302|Drug|Memantine|Encapsulated Namenda 10 mg bid (after four week dose escalation protocol)
220475|NCT02304302|Drug|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic dose escalation protocol)
220476|NCT00151866|Procedure|platelet transfusion|
220477|NCT02304315|Biological|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
220478|NCT02304315|Biological|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
220479|NCT02304328|Other|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
220480|NCT02304354|Drug|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
220781|NCT02297256|Biological|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
220782|NCT00151125|Drug|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
219843|NCT02277600|Drug|Darunavir|
219844|NCT02277600|Drug|Cobicistat|
219845|NCT02277613|Biological|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
219846|NCT02277613|Other|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
219847|NCT02277626|Device|Electro Flo 5000|Airway clearance device
219848|NCT02277626|Device|Incourage Vest System|Airway Clearance Device
220152|NCT02309138|Other|Gestational diabetes screening with fasting 2 hour 7g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
220153|NCT02309151|Procedure|Acute coronary angiography|Acute coronary angiography for patients with out of hospital cardiac arrest with no signs of ST elevation in ECG
220154|NCT02309151|Other|Routine care ICU|Routine care at ICU for out of hospital cardiac arrest patients with with no signs of ST elevation in ECG.
220155|NCT02309151|Other|Routine care STEMI|Routine care with acute coronary angiography for STEMI patients.
220156|NCT02311881|Drug|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
220157|NCT02311894|Drug|Nutropin AQ v1.1|Nutropin AQ v1.1 administered via subcutaneous injections at a dose of 0.043 mg/kg/day and adjusted for a change in body weight of +/- 2 kg from baseline at the Month 6 study visit, if appropriate
220158|NCT02311907|Drug|Carboplatin|Given IV
220159|NCT02311907|Drug|Glutathione|Given IV
220160|NCT02311907|Other|Laboratory Biomarker Analysis|Correlative studies
220161|NCT02311907|Drug|Paclitaxel|Given IV
220162|NCT02311907|Other|Placebo|Given IV
220163|NCT00152620|Drug|Dexamethasone|
220164|NCT02311907|Other|Quality-of-Life Assessment|Ancillary studies
220165|NCT02311920|Biological|Ipilimumab|Given IV
220166|NCT02311920|Other|Laboratory Biomarker Analysis|Correlative studies
220167|NCT02311920|Biological|Nivolumab|Given IV
219548|NCT02284893|Drug|Saxagliptin|
219549|NCT02284893|Drug|Dapagliflozin|
219550|NCT02284893|Drug|Sitagliptin|
219551|NCT02284893|Drug|Placebo matching with Saxagliptin|
219552|NCT02284893|Drug|Placebo matching with Dapagliflozin|
219553|NCT02284893|Drug|Placebo matching with Sitagliptin|
219554|NCT02284906|Drug|Pioglitazone|Pioglitazone tablets
219555|NCT00149656|Dietary Supplement|Selenium|dietary supplement of selenium only
219556|NCT02284906|Drug|Placebo|Pioglitazone placebo-matching tablets
219557|NCT02284919|Drug|[18F]ISO-1|[18F]ISO-1 PET/CT scan
219558|NCT02284932|Other|No specific intervention for this study|No specific intervention for this study
219559|NCT02284945|Procedure|Open fixation|
219560|NCT02284945|Procedure|Keyhole surgery|
219561|NCT02284958|Behavioral|Standard|Back care advice
219562|NCT02284958|Behavioral|Walking|Back care advice, individualized 12 week pedometer-driven walking program
219563|NCT02284971|Biological|CDX1127|
219564|NCT02284971|Radiation|SBRT|
219565|NCT02284984|Drug|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
219566|NCT00149656|Other|Placebo|placebo pill
219849|NCT02277639|Device|CD3+/CD19+ delpletion using CliniMACs device follwing reduced intensity conditioning|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
219850|NCT02277652|Device|The Miller Laryngoscope|Direct laryngoscopy
219851|NCT00002372|Drug|Amprenavir|
219852|NCT00149084|Drug|Lansoprazole, clarithromycin, amoxicillin|
219853|NCT02279966|Drug|Vortioxetine 10 mg|
218959|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
218960|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
219250|NCT02291562|Drug|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
219251|NCT02291562|Drug|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
219252|NCT00150514|Procedure|Peak nasal inspiratory flow|
219253|NCT02291562|Drug|placebo|placebo (capsule, once) oral intake
219254|NCT02291575|Other|Training|(please see Arm Description)
219255|NCT02291575|Other|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
219256|NCT02291588|Drug|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
219257|NCT02291588|Drug|Placebo|contains no active drug
219258|NCT02291601|Drug|Chlorhexidine Gluconate|comparison with other CHG products
219259|NCT02291601|Other|Vehicle|Cloth with Excipients no CHG
219260|NCT02291601|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
219261|NCT02291614|Drug|AMG 211|200-6,400 µg/day cIV infusion in cycles from 7 to 28 days
219262|NCT02291627|Device|MAC|direct laryngoscopy
219263|NCT00150527|Drug|Citalopram|40 mg, pill, single dose
219264|NCT02291627|Device|Coopdech|Video laryngoscopy
219265|NCT02291627|Device|AirTraq|optical laryngoscopy
219266|NCT02291640|Device|MIL|direct laryngoscopy
219267|NCT02291640|Device|CoPilot|video laryngoscopy
219268|NCT02291653|Device|McGrath|video-laryngoscopy
219269|NCT02291653|Device|MIL|direct-laryngoscopy
219270|NCT02291666|Drug|CRCHUM-MT cocktail|
223815|NCT02182453|Drug|BI 10773 - single rising dose|
223816|NCT02182453|Drug|Placebo|
223817|NCT02182466|Device|Colon capsule endoscopy|
223818|NCT02182479|Drug|Berodual® via Respimat®, high dose|
223819|NCT00137657|Drug|Cotrimoxazole (trimethoprim sulfamethoxazole)|
223820|NCT02182479|Drug|Berodual® via Respimat®, low dose|
223821|NCT02182479|Drug|Berodual® via MDI, high dose|
223822|NCT02182479|Drug|Placebo Respimat®|
223823|NCT02184858|Drug|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
223824|NCT02184871|Other|exposure to different risk factors and molecular assessment|
218961|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
218962|NCT00151060|Drug|Paclitaxel|
218963|NCT02296567|Other|Control Group|Control group Subjects will no previous anti-VEGF treatment
218964|NCT02296580|Device|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
218965|NCT02298621|Other|placebo|Randomized clinical trial or RCT
218966|NCT02298660|Drug|BOTOX|BOTOX® Total dose OR units/kg (per patient): 200U Number of cycles:1 cycle
200 units of BOTOX will be injected per procedure. BOTOX will be diluted in 15mL saline to 20U/mL. BOTOX injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia.
218967|NCT02298725|Other|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
218968|NCT02298725|Other|NHANES Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES "What we eat in America" report.
218969|NCT02298751|Behavioral|Cue Exposure Treatment|
218970|NCT02298764|Other|Standard back pain treatment|Standard back pain treatment
223472|NCT00138424|Drug|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
223473|NCT02189694|Device|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
223474|NCT02189694|Device|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
223475|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
223476|NCT02192333|Other|Quality-of-Life Assessment|Ancillary studies
223477|NCT02192333|Other|Questionnaire Administration|Ancillary studies
223478|NCT02192333|Behavioral|Telephone-Based Intervention|Receive phone-based booster intervention
223479|NCT02192346|Drug|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for 28 days.
223480|NCT02192346|Drug|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for 28 days.
223825|NCT00137969|Drug|Rituximab|Rituximab will be supplied as a sterile liquid for IV administration.
223826|NCT02184884|Device|MACE after OPCAB|
223827|NCT02184884|Device|without MACE after OPCAB|
223828|NCT02184897|Drug|lenograstim 10 microgram/kg/day|
223829|NCT02184910|Drug|pepsinogen and gastrin|
223830|NCT02184923|Other|presentation of visual vertical|
223831|NCT02184936|Other|standard of care|
223832|NCT02184949|Procedure|Percutaneous Coronary Intervention|
223833|NCT02184949|Procedure|Primary Percutaneous Coronary Intervention|
223834|NCT02184975|Procedure|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
223171|NCT02076087|Procedure|Liposuction/lipectomy|Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
223172|NCT00126698|Drug|trimethoprim-sulfamethoxazole|
223173|NCT02076100|Drug|MK-8408|MK-8408 capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
223174|NCT02076113|Procedure|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
223175|NCT02076113|Procedure|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
223176|NCT02076113|Procedure|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
223177|NCT02076139|Dietary Supplement|Nyaditum resae® 10e4|
223178|NCT02076139|Dietary Supplement|Nyaditum resae® 10e5|
223179|NCT02076139|Other|Distilled water|
223180|NCT02076152|Device|FMISO PET|
223181|NCT02076152|Device|MRI|MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2*-weighted perfusion scans, and MR Spectroscopy. The "Autoalign" package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs.
223182|NCT02076152|Drug|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
223183|NCT00002208|Drug|Stavudine|
223184|NCT00126698|Drug|ciprofloxacin|
223185|NCT02076152|Drug|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
223186|NCT02158806|Drug|Placebo|Matching placebo capsule containing inert bulking agent
223481|NCT02192346|Drug|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for 28 days.
222541|NCT02168777|Drug|Regorafenib (Stivarga, BAY73-4506)|Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.
In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.
222542|NCT02170974|Drug|BIBR 1048 MS polymorph II|
222543|NCT02170974|Drug|BIBR 1048 MS polymorph I|
222544|NCT02170987|Drug|Dabigatran etexilate low|
222545|NCT02170987|Drug|Dabigatran etexilate high|
222859|NCT02163720|Drug|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
222860|NCT02163733|Drug|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
222861|NCT00135512|Drug|bupropion hydrochloride|Study drug
222862|NCT02163733|Procedure|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
222863|NCT02163733|Other|Dietary Fasted|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
222864|NCT02163733|Other|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
222865|NCT02163733|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
222866|NCT02163746|Procedure|CO2 (carbon dioxide) laser|
222867|NCT02163746|Procedure|Surgical Deroofing|
222868|NCT02163759|Drug|adalimumab|160 mg administered SC at Week 0; 80 mg administered SC at Week 2; 40 mg SC at Weeks 4, 6 and 8
222869|NCT02163759|Other|adalimumab placebo|Administered SC at Weeks 0, 2, 4, 6 and 8
222870|NCT02163759|Drug|etrolizumab|105 mg administered SC Q4W
222871|NCT02163759|Other|etrolizumab placebo|Administered SC Q4W
222872|NCT00135525|Drug|Paroxetine|Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.
Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan.
222873|NCT02163772|Procedure|Intracordal hyaluronate injection|
222209|NCT02176512|Drug|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
222210|NCT02176512|Drug|BIBR 277 SE|Treatment B - Monocomponent
222211|NCT02176512|Drug|HCTZ|Treatment B -Monocomponent
222212|NCT02176525|Drug|BI 207127 NA|
222213|NCT02176525|Drug|Placebo|
222214|NCT00136942|Drug|Atorvastatin|
222215|NCT02176538|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days
222216|NCT02176538|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
222217|NCT02176551|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
222218|NCT02178878|Genetic|Progress, Pain|Progress, Pain
222219|NCT02178891|Device|extra short implant|
222546|NCT02170987|Drug|Moxifloxacin|
222547|NCT02170987|Drug|Placebo|
222548|NCT02171000|Drug|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
222549|NCT00136370|Drug|Chlorhexidine|
222550|NCT02171013|Drug|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
222551|NCT02171013|Drug|Dabigatran polymorph I|
222552|NCT02171026|Drug|Dabigatran etexilate|
222553|NCT02171026|Drug|Amiodarone|
222554|NCT02171039|Drug|Dabigatran|
222555|NCT02171039|Drug|Atorvastatin|
222556|NCT02171052|Drug|Dabigatran etexilate|
222557|NCT02171052|Drug|Digoxin|
222558|NCT02171065|Device|sham|
222559|NCT02171065|Device|ABSORB BVS|
221913|NCT02304822|Drug|Single-dose of Ciprofloxacin prophylaxis|Patients in Group 2 undergo RIRS using single-dose of Ciprofloxacin prophylaxis with intravenous ciprofloxacin one time preoperatively only.The patients administered a preoperative single dose 30min before the operation; the postoperative was discontinued without any antibiotic administration.
221914|NCT02304822|Drug|Zero-dose of Ciprofloxacin prophylaxis|Patients in Group 3 undergo RIRS using zero-dose of Ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
221915|NCT02304848|Other|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
221916|NCT02304861|Procedure|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
221917|NCT02304861|Procedure|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
221918|NCT02304874|Other|Phlebotomy|
221919|NCT02304887|Drug|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
221920|NCT02304900|Other|white implant|st intervention (in the month following the inclusion): Randomization of the color of the implant
nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye
221921|NCT02304900|Other|yellow implant|st intervention (in the month following the inclusion): Randomization of the color of the implant
nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye
221922|NCT00151944|Drug|SPD476 (mesalazine)|
221923|NCT02304913|Other|Hypoglossal acupuncture|
222220|NCT02178904|Procedure|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
222221|NCT02178917|Other|Neurofeedback therapy|
222222|NCT02178917|Other|No neurofeedback therapy|
222223|NCT02178930|Other|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
222224|NCT02178956|Drug|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
223947|NCT02159079|Other|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
219095|NCT02311582|Device|MRI-guided laser ablation|
219096|NCT02313857|Biological|Viralym-C|Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
219097|NCT02313870|Drug|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
219098|NCT02313870|Drug|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
219099|NCT02313883|Drug|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
219100|NCT02313896|Behavioral|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
219101|NCT02313909|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
219102|NCT02313909|Drug|Aspirin (Acetylsalicylic acid, BAY1019036)|100 mg, once daily, orally, tablet
219103|NCT00152750|Drug|APO-clonidine|
219104|NCT02313909|Other|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
219105|NCT02313909|Other|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
219106|NCT02313922|Drug|etanercept combined with methotrexate or etanercept combined with placebo|
219107|NCT02313935|Other|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
219108|NCT02313935|Other|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
223629|NCT00135551|Drug|β-blockers|benidipine+β-blockers, titlation scheme
223630|NCT02164110|Biological|Shanchol|Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose
223631|NCT02164123|Other|Spinal mobilization|Experimental group
223632|NCT02164123|Other|Spinal Mobilization II|Active comparator group
223633|NCT02164123|Other|Placebo|Placebo group
223634|NCT02164136|Procedure|L-PANP-TME|
223635|NCT02164136|Procedure|O-PANP-TME|
223636|NCT02164149|Other|Patients with primary colon cancer|CT scan two days after surgery
223637|NCT02164162|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
223638|NCT02166801|Behavioral|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand & Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
223948|NCT02159092|Behavioral|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
223949|NCT02159105|Device|FAST scan and non-invasive hemoglobin measurement|A "FAST scan", or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.
Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours).
223950|NCT02159118|Device|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
223951|NCT02159118|Device|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
223298|NCT02171312|Device|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
223299|NCT02171312|Behavioral|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
223300|NCT02171325|Drug|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
223301|NCT02171338|Other|PCT-level|PCT-level is available to the treating doctor.
223302|NCT00136409|Drug|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
223303|NCT02171338|Behavioral|Antibiotic treatment based on PCT-level|PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.
The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above.
223304|NCT02171351|Device|effect of neuromuscular electrostimulation (NMES)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of neuromuscular electrostimulation (NMES).
223305|NCT02171351|Device|effect of neuro electrostimulation (NES)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of neuro electrostimulation (NES)
223306|NCT02171351|Other|effect of voluntary contractions (VC)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of voluntary contractions (VC)
223307|NCT02171364|Procedure|Virtual ablation in based 3D CT of patient who diagnosed AF|
223308|NCT02174237|Drug|LNP1892|Tablets of two strengths (5 and 25 mg)
223309|NCT02174237|Drug|Placebo|Matching placebo
223310|NCT02174250|Drug|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
223311|NCT00136682|Drug|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
222693|NCT02184533|Other|questionnaire administration|Ancillary studies
222694|NCT02184559|Drug|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
222695|NCT02184559|Device|The infiltration continues catheter|
222696|NCT02184572|Biological|GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762)|1 dose administered subcutaneously (SC) in the tricep region of left arm.
222697|NCT00000330|Drug|Opioid-Related Disorders|
222698|NCT00002290|Drug|Acyclovir|
222699|NCT00138086|Drug|Zevalin plus BEAM|
222995|NCT02179333|Other|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
222996|NCT02179359|Drug|Anti-thymocyte globulin (ATG)|2.5 mg/kg once daily IV over 6 hours Days -8 to -2
222997|NCT02179359|Drug|Fludarabine monophosphate|40 mg/m2 IV once daily over 1 hour Days -5 to -2
222998|NCT02179359|Drug|Busulfan|IV once daily over 3 hours Days -5 to -2
222999|NCT00137267|Behavioral|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
223000|NCT02179359|Drug|Alemtuzumab|0.2mg/kg IV over 2 hours Days -10 to -6
223001|NCT02179359|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours Day -7
223002|NCT02179359|Drug|Fludarabine monophosphate|35 mg/kg IV over 2 hours Days -6 to -02
223003|NCT02179359|Drug|Mesna|per standard institutional guidelines
223004|NCT02179359|Radiation|total body irradiation|300 centigray as a single dose
223005|NCT02179372|Dietary Supplement|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
223006|NCT02179372|Dietary Supplement|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
222034|NCT02278562|Drug|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
222035|NCT02278562|Drug|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
222036|NCT02278562|Other|placebo|placebo capsules and injection
222037|NCT02278575|Drug|Atenativ|intravenous transfusion
222038|NCT02278588|Drug|Rasagiline|
222039|NCT02278601|Device|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
222040|NCT02278614|Drug|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
222041|NCT02278614|Drug|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
222042|NCT00149201|Drug|MTX + 5-FU sequential therapy|
222043|NCT02280811|Biological|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
222356|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
222357|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
222358|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
222359|NCT02191878|Drug|TKM-080301|TKM-080301 intravenous infusion
222360|NCT02191891|Drug|BI 836845|Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
222361|NCT00138723|Drug|SPM 907|
222362|NCT02191891|Drug|afatinib|Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
222363|NCT02191904|Other|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
222364|NCT02191917|Procedure|Respiratory muscle strength measurements by different techniques.|
222365|NCT02191930|Drug|B-CAP|
222366|NCT02191930|Drug|Brentuximab Vedotin|
221402|NCT02290210|Drug|URC102 0.25mg|
221403|NCT02290210|Drug|URC102 0.5mg|
221404|NCT02290210|Drug|URC102 1.0mg|
221405|NCT02290210|Drug|URC102 2.0mg|
221406|NCT02290210|Drug|placebo|
221407|NCT00000344|Drug|Buprenorphine/naloxone|
221408|NCT00002376|Drug|Didanosine|
221409|NCT00150332|Drug|linezolid|
221410|NCT02290223|Behavioral|Behavioral Based Treatment Model|The experimental procedure is a behavioral based treatment model, structured in the form of four group sessions, one meeting per week.
221411|NCT02290236|Device|Pulseoximetry|Peripheral saturation will be recorded continuously
221412|NCT02290249|Device|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
221413|NCT02290249|Device|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
221414|NCT02290262|Other|Comprehensive phase one rehabilitation|Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.
The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse.
221415|NCT02290275|Dietary Supplement|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
221416|NCT02290275|Other|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
221417|NCT02290275|Dietary Supplement|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
221736|NCT02285764|Other|Nutritional Supplement|Modified carbohydrate
221737|NCT02285764|Other|Standard of Care|As determined by the study site
221738|NCT02285777|Biological|1 dose of MenABCWY|
221739|NCT02285777|Biological|1 dose of placebo|
221740|NCT02285790|Device|Reflectance confocal microscopy|
220783|NCT02297269|Device|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
220784|NCT02297269|Device|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
220785|NCT02299544|Device|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
220786|NCT02299557|Drug|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
220787|NCT02299557|Drug|Placebo gel|Placebo gel applied intra-anally once daily
220788|NCT02299570|Biological|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
220789|NCT00151359|Device|SoleSensor|
220790|NCT02299570|Other|Placebo|A suspension of saline and cryoprotectant
220791|NCT02299583|Other|Preventive intervention trauma-informed early intervention|Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
220792|NCT02299596|Other|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
220793|NCT02299609|Other|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
220794|NCT02299622|Genetic|Genetic test|Next-generation sequencing (AmpliSeq) & fusion analysis
220795|NCT02299635|Drug|PF-03084014|Tablet, 10 mg, twice a day.
220796|NCT02299635|Drug|PF-03084014|Tablet, 50 mg, twice a day
220797|NCT02299635|Drug|PF-03084014|Tablet, 100 mg, twice a day
220798|NCT02299648|Other|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
220799|NCT02299661|Drug|DS-1093a|DS-1093a, single oral doses up to 50 mg
220800|NCT00151372|Behavioral|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
220168|NCT02311920|Drug|Temozolomide|Given PO
220169|NCT02311933|Other|Laboratory Biomarker Analysis|Correlative studies
220170|NCT02311933|Other|Pharmacological Study|Correlative studies
220171|NCT02311933|Drug|Tamoxifen Citrate|Given PO
220172|NCT02311933|Drug|Z-Endoxifen Hydrochloride|Given PO
220173|NCT02311946|Drug|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
220174|NCT00152620|Drug|Methylprednisolone|
220481|NCT02304367|Drug|KRN23|KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
220482|NCT02304393|Drug|MPDL3280A|MPDL3280A administered at fixed dose 1200 mg, by i.v. infusion on Day 1 of every cycle by an every 3 weeks schedule (except for Part IA, where MPDL3280A schedule follows 21 days after RO7009789 administration in all the sequential cohorts).
220483|NCT02304393|Drug|RO7009789|Single-, or multiple-dose RO7009789 administered either i.v. or s.c.
220484|NCT02304419|Drug|Galunisertib|Administered orally.
220485|NCT02306863|Device|sham treatment|simulated whole-body vibration
220486|NCT02306876|Drug|PF-06412562 3mg BID|PF-06412562
220487|NCT02306876|Drug|PF-06412562 15mg BID|PF-06412562
220488|NCT02306876|Other|Placebo|Placebo
220489|NCT02306889|Drug|Fenofibrate|130mg Capsules
220490|NCT00152126|Procedure|Stem Cell Transplantation|Autologous stem cell transplantation
220491|NCT02306889|Drug|ANTARA® (fenofibrate)|130mg Capsules
220492|NCT02306902|Drug|fenofibrate|130mg, Capsules
220493|NCT02306902|Drug|ANTARA® (fenofibrate)|130mg, Capsules
220494|NCT02306915|Drug|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
220495|NCT02306928|Other|Blood draw|
219854|NCT02279966|Drug|Paroxetine 20 mg|
219855|NCT02279966|Drug|Placebo|
219856|NCT02279979|Device|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
219857|NCT02279992|Drug|Vardenafil|
219858|NCT02279992|Drug|Carboplatin|
219859|NCT02280005|Device|WAK Treatment|Hemodialysis with WAK device.
219860|NCT02280018|Drug|JNJ-49122944, 5 milligram (mg)|Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
219861|NCT02280018|Drug|Placebo|Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
219862|NCT02280031|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
219863|NCT00149110|Procedure|Sleep deprivation|3 days with a normal night between
219864|NCT02280031|Drug|Placebo|Capsule containing placebo pill with lactose
219865|NCT02280044|Biological|Challenge with C. jejuni|Challenge with C jejuni
219866|NCT02280057|Drug|Metformin|1500 mg per day in six months
219867|NCT02280057|Drug|Placebo|
219868|NCT02280070|Other|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
219869|NCT02280070|Other|Medical history and physical examination|medical history and physical examination
219870|NCT02280070|Other|BW and height|Body weight (kg) and height (cm)
220175|NCT02311946|Drug|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
220176|NCT02311959|Procedure|Nipple sparing mastectomy|Standardized surgical procedure by :
Nipple sparing mastectomy with nipple core histopathology.
Immediate breast reconstruction (flap and/or implant).
+/- lymph node evaluation (sentinel node procedure or axillary dissection).
220177|NCT02311972|Device|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
219271|NCT02291679|Drug|Linaclotide|Oral, once daily
219272|NCT02291679|Drug|Matching Placebo|Oral, once daily
219273|NCT02291692|Procedure|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
219274|NCT00002377|Drug|Ganciclovir|
219275|NCT00150527|Drug|Escitalopram|20 mg, pill, single dose
219567|NCT02284997|Device|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
219568|NCT02285010|Drug|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
219569|NCT02287272|Drug|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
219570|NCT02287272|Drug|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
219571|NCT02287285|Drug|Exendin9|Dosed at 600 pmol/kg/min for 210 minutes.
219572|NCT02287298|Procedure|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
219573|NCT02287311|Biological|MABEL CTLs|Dose escalation:
Dose Level One: 2 x 10^7 cells/m2 + 2 x 10^7 cells/m2
Dose Level Two: 2 x 10^7 cells/m2 + 5 x 10^7 cells/m2
Dose Level Three: 5 x 10^7 cells/m2 + 1 x 10^8 cells/m2
219574|NCT02287324|Procedure|Manipulation|
219575|NCT02287324|Procedure|Manual Contact|
219576|NCT02287337|Procedure|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
219577|NCT02287337|Procedure|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
219578|NCT02287350|Drug|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
219579|NCT00149890|Drug|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight <35 kg) or 20 mg (body weight ≥35 kg) strength.
219580|NCT02287363|Other|No intervention involved|No interventions will be involved since it is an observational study
218971|NCT02298764|Other|Standard back pain treatment + 10 psychotherapeutic sessions|Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method "somatic experiencing".
218972|NCT02298777|Procedure|- Skin biopsy - Urine sample - Blood sample|
218973|NCT00151255|Drug|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
218974|NCT02298790|Behavioral|Meal schedule|
218975|NCT02298803|Device|Holter and Glucose monitoring|(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.
(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities.
218976|NCT02298829|Drug|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
218977|NCT02298842|Device|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
219276|NCT02291705|Procedure|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
219277|NCT02291705|Drug|Tramadol|tramadol 1 mg/kg iv
219278|NCT02291718|Drug|Isovue|iodine contrast
219279|NCT02291731|Drug|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
219280|NCT02294240|Dietary Supplement|Energy dense biscuits|Energy dense biscuits will be provided
219281|NCT02294240|Other|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
219282|NCT02294253|Drug|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
219283|NCT00150800|Drug|Brivaracetam|Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 10 mg and 25 mg
Route of Administration: Oral
219284|NCT02294266|Drug|Mephedrone and alcohol|Single oral dose mephedrone
Single oral dose alcohol
219285|NCT02294266|Drug|Mephedrone|Single oral dose mephedrone
223835|NCT02184975|Procedure|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
223836|NCT00137969|Drug|Placebo|Placebo will be supplied as a sterile liquid for IV administration.
223837|NCT02184988|Biological|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
223838|NCT02185001|Procedure|Direct Medial Patellofemoral Ligament (MPFL) Repair|The MPFL will be repaired directly at the site of the traumatic injury.
223839|NCT02185001|Procedure|Physical therapy|Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
223840|NCT02185014|Drug|Adalimumab|Subjects will receive the standard every other week dosing regimen until Week 40. Subjects have the ability to dose-escalate to weekly dosing and de-escalate back to every other week.
223841|NCT02185027|Other|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
223842|NCT02185040|Drug|CC-220|0.3 mg oral capsules once every other day with or without food
223843|NCT02185040|Drug|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
223844|NCT02185040|Drug|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
223845|NCT02185040|Drug|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
218978|NCT02298842|Device|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
218979|NCT02298855|Behavioral|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
218980|NCT02301117|Drug|TAS-102|
218981|NCT00151489|Drug|placebo|
223482|NCT02192346|Drug|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for 28 days.
223483|NCT00138762|Drug|placebo|
223484|NCT02192346|Drug|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for 28 days.
223485|NCT02192346|Drug|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for 28 days.
223486|NCT02192346|Drug|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for 28 days.
223487|NCT02192346|Drug|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for 28 days.
223488|NCT02192346|Drug|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for 28 days.
223489|NCT02192359|Biological|carboxylesterase-expressing allogeneic neural stem cells|Given intracranially
223490|NCT02192359|Drug|irinotecan hydrochloride|Given IV
223491|NCT02192359|Other|laboratory biomarker analysis|Correlative studies
223492|NCT02192359|Other|pharmacological study|Correlative studies
223493|NCT02192398|Drug|Guanfacine|Subjects will be randomized into 1 of the following 3 treatment groups:
guanfacine (2mg)
guanfacine (1mg)
placebo
To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo).
223494|NCT00002297|Drug|Inosine pranobex|
223495|NCT00138775|Drug|D-serine|
223496|NCT02192398|Drug|Placebo|Subjects will be randomized into 1 of the following 3 treatment groups:
guanfacine (2mg)
guanfacine (1mg)
placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo).
223497|NCT02192411|Drug|Lidocaine|1/4 dose lidocaine
223498|NCT02192424|Drug|Metformin alone|
223499|NCT02192424|Drug|Metformin + Intermittent Insulin Therapy|
223500|NCT02192437|Other|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
223501|NCT02192450|Drug|Insulin aspart/glargine|
223502|NCT02192450|Drug|Insulin aspart/degludec|
223503|NCT02192463|Drug|NVP ER 300 mg (KCR 20%) Medium Release|
222874|NCT02163785|Procedure|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
222875|NCT02163798|Behavioral|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
222876|NCT02163798|Behavioral|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
223187|NCT02158819|Device|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
223188|NCT02158832|Device|Acupuncture + Electrical Stimulation|2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current >sensation threshold & maintained at a level that is comfortable/painless & does not elicit skeletal muscle contractions (~5mA, <10mA).
Needle locations are in the vicinity of nerves that supply the affected upper limb:
EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', ~15⁰ perpendicular to the skin, ~15⁰ lateral to the midline. Depth: ~1.5 cm (secure anchorage).
EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' ~15⁰ perpendicular to the skin, ~15⁰ medial. Depth: ~1.5 cm (secure anchorage).
223189|NCT02158845|Drug|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
223190|NCT02158845|Drug|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
223191|NCT02158858|Drug|CPI-0610|
223192|NCT02158871|Behavioral|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
223193|NCT00134979|Drug|Formoterol|
223194|NCT02158871|Behavioral|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
223195|NCT02158884|Device|IDEO brace|All participants will receive the IDEO brace.
222560|NCT00136370|Procedure|Birth canal wipe|
222561|NCT02171104|Procedure|blood stem cell transplant|Patients with various Inherited Metabolic Disorders and males with Rett syndrome:
PBSC: ≥ 10 x 106 CD34+ cells (max. 20 x 106)/kg recipient body weight
Related and Unrelated Bone Marrow: ≥ 2.5 x 108 nucleated cells (target ≥ 5 x 108)/kg recipient body weight
UCB: unit(s) selected in accordance with the protocol and with the University of Minnesota Umbilical Cord Blood Graft Selection Algorithm
Patients with Osteopetrosis:
PBSC: ≥ 15 x 106 CD34+ cells (max. 20 x 106)/kg recipient body weight
Related and Unrelated Bone Marrow: ≥ 2.5 x 108 nucleated cells (target ≥ 6 x 108)/kg recipient body weight
UCB: unit(s) selected in accordance with the protocol and with the University of Minnesota Umbilical Cord Blood Graft Selection Algorithm
222562|NCT02171104|Drug|Rabbit Anti-Thymocyte Globulin (ATG)|2.5 mg/kg IV once daily for 4 consecutive days (total = 10 mg/kg IV)
Graft Source:
UCB: Days -8, -7, -6, -5
HLA-matched sibling donor: no ATG will be used
Other graft: Days -5, -4, -3, -2
222563|NCT02171104|Drug|Fludarabine|All Patients: 40 mg/m2 IV once daily, days -5, -4, -3 and -2 (total preparative regimen exposure = 160 mg/m2)
222564|NCT02171104|Drug|Busulfan|Patients with IMD and males with Rett syndrome: Once daily IV, days -5, -4, -3 and -2 (total preparative regimen drug exposure, AUCcum targeted to 21,000 - 22,000 µM•min∙L-1)
Osteopetrosis Recipients of Bone Marrow or Peripheral Blood Stem Cell Grafts (Including Haplo): Once daily IV, days -3 and -2 (total preparative regimen drug exposure, AUCcum, targeted to 10,000 - 11,000 µM•min∙L-1)
Osteopetrosis Recipients of Umbilical Cord Blood: Once daily IV, days -5, -4, -3 and -2 (total preparative regimen drug exposure, AUCcum, targeted to 21,000 - 22,000 µM•min∙L-1)
222565|NCT02171104|Drug|Cyclophosphamide|Osteopetrosis patients receiving haploidentical graft: 50 mg/kg IV once daily, days +3 and +4 (total exposure = 100 mg/kg IV) utilizing hyperhydration and MESNA
222566|NCT02171104|Drug|Cyclosporine A (CSA)|Osteopetrosis patients receiving haploidentical graft: Begin Day +5
All other patients, all graft sources: Begin Day -2
222877|NCT02166541|Procedure|BCSK|The "BCSK" is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier.
222878|NCT02166541|Procedure|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
222879|NCT02166541|Procedure|INRS|The "INRS" is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called "Reflexotherapy".
222880|NCT02166554|Other|Saline|On the day of initial surgery
222881|NCT02166554|Device|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
222882|NCT02166567|Procedure|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
222883|NCT02166567|Procedure|Swim-up|Semen processing will be carried out with the conventional swim-up method.
222884|NCT02166593|Drug|Pravastatin40mg/Fenofibrate160mg|
222225|NCT02178956|Drug|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
222226|NCT00137228|Procedure|figure-of-eight hand measurements|
222227|NCT02178956|Other|Placebo|Orally two times daily
222228|NCT02178995|Drug|Methylphenidate|Participants with epilepsy will first receive blinded, single-dose capsules which contain either:
Placebo 20mg of methylphenidate or 40mg of methylphenidate.
At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.
222229|NCT02179008|Drug|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
222230|NCT02179008|Drug|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
222231|NCT02179008|Drug|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
222232|NCT02179008|Drug|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
222233|NCT02179008|Drug|DE-117 High Dose ophthalmic solution|High Dose DE-117
222234|NCT02179008|Drug|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
222235|NCT02179034|Drug|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
222236|NCT02179034|Other|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
222237|NCT00137228|Procedure|water volumetry hand measurements|
222238|NCT02179034|Other|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
222239|NCT02179047|Procedure|coronary angiography|percutaneous coronary intervention. coronary angiography.
222240|NCT02179086|Radiation|3-dimensional conformal radiation therapy|Undergo standard-dose 3D-CRT
222241|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
222567|NCT02171104|Drug|Methylprednisolone|All UCB Recipients, All Diagnoses: Day 0 through Day +42
222568|NCT02173873|Drug|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
222569|NCT02173886|Drug|Bupropion SR and XL|
219109|NCT02313935|Other|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
219110|NCT02313935|Other|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
219111|NCT02313961|Other|Remote ischaemic conditioning|Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
219112|NCT02313974|Procedure|Renal Biopsy|
219113|NCT02314000|Device|Precision Spinal Cord Stimulator System|
219410|NCT02306421|Procedure|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
219411|NCT02306421|Procedure|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
219412|NCT02308722|Radiation|5-fraction stereotactic body radiation therapy|The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.
Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.
Level -1:
Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)
Level 1:
Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)
Level 2:
Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)
Level 3:
Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)
219413|NCT02308735|Other|N/A - No intervention|
219414|NCT02308748|Drug|Dofetilide|8 am: Placebo
12 pm (noon): 250 µg
5:30 pm: 250 µg
219415|NCT02308748|Drug|Mexiletine|8 am: weight x 4 mg/kg
12 pm (noon): Same as at 8 am
5:30 pm: Same as at 8 am
219416|NCT02308748|Drug|Lidocaine|9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes
2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes
7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes
219417|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
219418|NCT02308748|Drug|Moxifloxacin|9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)
2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)
7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)
223952|NCT02159131|Drug|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
223953|NCT02159131|Drug|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
223954|NCT00135031|Drug|Bifidobacterium infantis 35624|
223955|NCT02159131|Drug|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
223956|NCT02159144|Other|cold stress|
223957|NCT02159157|Behavioral|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
223958|NCT02159170|Biological|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
223959|NCT02159183|Device|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
223960|NCT02159183|Device|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
223961|NCT02159196|Drug|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
223962|NCT02159196|Drug|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
223963|NCT02161783|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
219114|NCT00002387|Drug|Indinavir sulfate|
219115|NCT00152763|Behavioral|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
219116|NCT02314013|Drug|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
219117|NCT02277223|Dietary Supplement|Curcumin|Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.
Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with "induction treatment failure" will be re-randomized to receive oral corticosteroids induction with or without curcumin.
223639|NCT02166801|Behavioral|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
223640|NCT02166814|Drug|Fimasartan and Rosuvastatin|
223641|NCT02166814|Drug|Fimasartan|
223642|NCT02166814|Drug|Rosuvastatin|
223643|NCT02166827|Device|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
223644|NCT02166827|Device|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
223645|NCT02166840|Procedure|Plastic stent (7-10Fr)|
223646|NCT02166840|Procedure|Self Expanding Metal Stent|
223647|NCT02166853|Drug|sevoflurane|Sedation with inhaled sevoflurane
223648|NCT00135785|Drug|Placebo|
223649|NCT02166853|Drug|midazolam|Sedation with intravenous midazolam
223650|NCT02166866|Other|Quality of Life Questionairre and Education|
223651|NCT02166879|Behavioral|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
223652|NCT02166892|Other|Specially designed plates|
223653|NCT02166905|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
223654|NCT02166905|Drug|Epacadostat|Given PO
223655|NCT02166905|Other|Laboratory Biomarker Analysis|Correlative studies
223656|NCT02166905|Other|Pharmacological Study|Correlative studies
223657|NCT02166905|Drug|Poly ICLC|Given SC
223658|NCT02166931|Dietary Supplement|Chicken Essence|BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
223659|NCT00002271|Drug|Alovudine|
223007|NCT02179385|Behavioral|Health Coaching|
223008|NCT02179398|Biological|Allocation to the Lab-score group|
223009|NCT02179398|Biological|Allocation to the control group|
223010|NCT02181985|Drug|Heparin|
223011|NCT02181985|Drug|Enoxaparin|
223012|NCT02181985|Drug|Abciximab|
223013|NCT02181998|Drug|Full dose tenecteplase|
223014|NCT02181998|Drug|Unfractioned heparin|
223015|NCT02181998|Drug|Enoxaparin|
223016|NCT02182011|Drug|Tenecteplase|
223312|NCT02174250|Drug|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
223313|NCT02174263|Biological|tocilizumab|Given IV
223314|NCT02174263|Other|laboratory biomarker analysis|Correlative studies
223315|NCT02174263|Other|quality-of-life assessment|Ancillary studies
223316|NCT02174276|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablets administered orally once daily.
223317|NCT02174276|Biological|GS-4774|GS-4774 administered as a subcutaneous injection every four weeks for a total of 6 doses
223318|NCT02174289|Device|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
223319|NCT02174315|Behavioral|Contingency Management|
223320|NCT02174328|Drug|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
223321|NCT02174328|Drug|Placebo|Placebo once a day until 36 week
223322|NCT00136682|Drug|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
223323|NCT02174367|Device|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
222367|NCT02191943|Device|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
222368|NCT02191943|Device|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
222369|NCT02191956|Behavioral|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
222370|NCT02191969|Behavioral|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
222371|NCT02191982|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
222372|NCT02194309|Drug|Telmisartan high|
222373|NCT02194309|Drug|amlodipine|
222374|NCT02194322|Drug|BIBN 4096 BS - in single rising doses|
222375|NCT02194322|Drug|Placebo|
222376|NCT02194335|Drug|BIBN 4096 BS - in single rising doses|
222377|NCT02194335|Drug|Placebo|
222700|NCT02186847|Radiation|Volume Modulated Arc Therapy|Undergo radiation therapy
222701|NCT02186860|Biological|Third generation CAR-T cells|Given IV
222702|NCT02186873|Drug|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12 in treatment group 1 and intravenous infusions of placebo at Week 16 to maintain the blind in treatment group 2.
222703|NCT02186873|Drug|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52 in treatment group 1.
222704|NCT02186886|Drug|Golimumab|Physiological Intermolecular Modification Spectroscopy
222705|NCT02186899|Other|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
222706|NCT02186899|Other|General Anesthesia femoral bolus|
222707|NCT02186899|Other|General anesthesia femoral continuous|
221741|NCT02285790|Procedure|Punch biopsy|
221742|NCT02285790|Procedure|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
221743|NCT02285803|Device|transcranial direct current stimulation (tDCS)|
221744|NCT02285816|Biological|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
221745|NCT00149760|Behavioral|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
221746|NCT02285816|Biological|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
221747|NCT02285829|Drug|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
221748|NCT02285842|Device|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
221749|NCT02285855|Drug|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
221750|NCT02285855|Other|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
221751|NCT02285855|Radiation|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
221752|NCT02285881|Behavioral|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
221753|NCT02285894|Other|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
222044|NCT02280811|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
222045|NCT02280824|Procedure|CA-TAVR|Transcaval acesss for transcatheter
222046|NCT02280837|Other|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
221087|NCT02294916|Device|MIL|Direct-laryngoscopy
221088|NCT02294929|Procedure|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
221089|NCT02294942|Drug|RANCAD|Extended-Release RANCAD
221090|NCT02294955|Device|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
221091|NCT02294955|Drug|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
221092|NCT02294955|Drug|Sotalol|Dosage orally 80-160 mg twice daily
221093|NCT02294955|Drug|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
221094|NCT02294955|Drug|Propafenone|Dosage orally 300 mg twice daily
221095|NCT02294955|Drug|Disopyramide|Dosage orally 250-375 mg twice Daily
221096|NCT02294955|Drug|Dronedarone|Dosage orally 400 mg twice daily
221097|NCT00150891|Drug|tacrolimus|
221098|NCT02294968|Other|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
221099|NCT02294981|Device|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
221100|NCT02294994|Drug|tirofiban|
221101|NCT02295007|Behavioral|text message|
221102|NCT02295020|Drug|Standard treatment with NSAIDs|
221103|NCT02295020|Device|Bioskin Ten-7 knee brace|
221104|NCT02295033|Radiation|Boost irradiation|
221105|NCT02295046|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
221106|NCT02295059|Dietary Supplement|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
221107|NCT02295072|Behavioral|A 5-months physical exercise-based program|The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus "exercise homework" in the weekends, and will focus on high-intensity aerobic exercise mainly.
220496|NCT02306941|Behavioral|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
220497|NCT02306954|Biological|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
220498|NCT02306954|Radiation|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
220499|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected.
220500|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected
220501|NCT00152126|Drug|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
220801|NCT02299674|Other|Level overground ambulation|
220802|NCT02299687|Drug|Omeprazole|
220803|NCT02299700|Other|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
220804|NCT02299713|Device|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
220805|NCT02299726|Drug|Spironolactone|
220806|NCT02299726|Other|Placebo|Matching placebo
220807|NCT02301819|Device|Veno-arterial extracorporeal membrane oxygenation (ECMO)|
220808|NCT02301819|Other|Early conservative therapy according to standard practice|
220809|NCT02301845|Drug|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
220810|NCT02301858|Genetic|Genome analysis of tissue samples.|Genome analysis of tissue samples.
220811|NCT02301871|Device|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
220178|NCT02311972|Device|Standard of care feeding tube|
220179|NCT02311985|Other|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR >1.5 or PTT >50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen <150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
220180|NCT02314299|Drug|MTP-131|
220181|NCT02314312|Drug|Everolimus + low dose cyclosporin A + prednisolone|
220182|NCT02314312|Drug|Standard immunosupressive regimen|
220183|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
220184|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
220185|NCT02314338|Other|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
220186|NCT02314351|Drug|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
220187|NCT02314351|Drug|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
220188|NCT02314351|Drug|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
220189|NCT02314364|Radiation|SBRT with protons or photons|
220190|NCT00152802|Biological|The conjugate vaccine used will be Prevnar (Wyeth vaccines)|
220191|NCT02314377|Drug|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
220192|NCT02314390|Behavioral|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
220193|NCT02314390|Behavioral|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
220194|NCT02314403|Drug|Belatacept|A selective T-cell (lymphocyte) costimulation blocker
220502|NCT02306980|Other|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
219581|NCT02287376|Drug|Diclofenac Potassium for Oral Solution|NSAID
219582|NCT02287389|Device|balloon dilation|
219583|NCT02287389|Procedure|cryotherapy|
219584|NCT02287389|Procedure|spiculiform electrosurgery|
219585|NCT02287389|Drug|mitomycin C|
219586|NCT02287402|Drug|AO-128|AO-128 tablet
219587|NCT02287415|Drug|BIA 2-093|
219588|NCT02287415|Drug|Warfarin|
219871|NCT02280070|Other|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
219872|NCT02280070|Other|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft & Gault method using serum creatinine (mg/dL), age and body weight (kg).
219873|NCT02280070|Other|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
219874|NCT00149110|Procedure|Light therapy|Daily light therapy for 29 weeks
219875|NCT02280070|Radiation|Contrasting CT|Computed tomography
219876|NCT02280070|Other|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
219877|NCT02280070|Other|HBs antigen and HCV antibody|check for exclusion criteria
219878|NCT02282462|Other|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
219879|NCT02282462|Other|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
219880|NCT02282462|Other|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
219881|NCT02282462|Other|Passive Drainage (Dig)|Thopaz+ digital chest drainage device set at -8cmH2O at the patient ("physiologic")
219882|NCT02282462|Other|Passive Drainage (Trad)|Pleur-Evac, Atrium-Maquet or similar set by gravity ("water-seal')
219883|NCT02282488|Other|Low protein formula|
219286|NCT02294266|Drug|Alcohol|Single oral dose alcohol
219287|NCT02294266|Drug|Placebo|Single oral dose placebo
219288|NCT02294279|Drug|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
219289|NCT02294292|Drug|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
219290|NCT02294292|Drug|Ivabradine|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction
219291|NCT02294292|Procedure|Endoscopic Variceal Ligation|
219292|NCT02294305|Drug|Vortioxetine|
219293|NCT02294305|Drug|Placebo|
219294|NCT00150813|Drug|LEVETIRACETAM|
219295|NCT02294318|Behavioral|HealthCall+Motivational Interviewing (MI)|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
219296|NCT02294318|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
219589|NCT02287428|Radiation|Radiation Therapy|Standard radiotherapy (approximately 60 Gy over 6 weeks)
219590|NCT00149890|Drug|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
219591|NCT02287428|Biological|Personalized NeoAntigen Vaccine|NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
219592|NCT02287441|Other|Tomato|Tomato Products (tomato)
219593|NCT02287441|Other|Raw|Vegetables Prepared Raw (raw).
219594|NCT02289469|Other|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
219595|NCT02289482|Drug|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
219596|NCT02289482|Drug|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
218982|NCT02301130|Biological|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
218983|NCT02301130|Biological|MEDI4736|MEDI4736 will be administered intravenously (IV).
218984|NCT02301130|Biological|tremelimumab|Tremelimumab will be administered intravenously (IV).
218985|NCT02301143|Drug|nab-Paclitaxel|
218986|NCT02301143|Drug|Gemcitabine|
218987|NCT02301143|Drug|Chemoradiation|
218988|NCT02301143|Drug|Capecitabine|
218989|NCT02301143|Procedure|Surgery|Surgical intervention
218990|NCT02301156|Drug|Ublituximab|Ublituximab IV infusion
218991|NCT02301156|Drug|ibrutinib|Ibrutinib oral daily dose
218992|NCT00151502|Drug|Atorvastatin|
218993|NCT02301169|Behavioral|Heat pain stimuli A|
218994|NCT02301169|Behavioral|Video A|
218995|NCT02301169|Drug|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
218996|NCT02301169|Behavioral|Heat pain stimuli B|
218997|NCT02301169|Behavioral|Video B|
218998|NCT02301169|Drug|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
218999|NCT02301182|Device|ADM X3-MoP Cup|
219297|NCT02294344|Other|DFPP&CTX|First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.
Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented.
223504|NCT02192463|Drug|NVP ER 300 mg (KCR 25%) Medium Release|
223846|NCT02185040|Drug|Placebo|Matching oral placebo daily
223847|NCT00137969|Drug|Prednisone|
223848|NCT02187315|Device|Chrono-chemotherapy pump:Melodie|
223849|NCT02187315|Device|Routine intravenous drip|
223850|NCT02187315|Drug|induction chemotherapy|
223851|NCT02187315|Drug|cisplatin chrono-chemotherapy|
223852|NCT02187315|Radiation|intensity-modulated radiation therapy|
223853|NCT02187315|Drug|cisplatin routine-chemotherapy|
223854|NCT02187328|Other|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
223855|NCT02187328|Other|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
223856|NCT00138151|Drug|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
223857|NCT02187341|Dietary Supplement|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
223858|NCT02187341|Dietary Supplement|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
223859|NCT02187354|Drug|Blinatumomab|A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. In the first induction cycle, if the patient shows an M3 bone marrow at screening, the initial dose of blinatumomab will be 5 μg/m2/day for the first 7 days which then will be escalated to 15 μg/m2/day starting on day 8 through day 29. For all subsequent 15 μg/m2/day will be the dose for all 4 weeks of continuous treatment. In case of an M2 bone marrow at screening, the initial dose will start at 15 μg/m2/day for the first 7 days of treatment and no dose step will be performed at day 8. For all subsequent cycles the dose will stay 15 μg/m2/day. A dose of 9 μg/day for the initial dose (if applicable) and 28 μg/day for the escalated dose after dose step should not be exceeded. The dose for the next cycle has to be recalculated in case a weight change of ≥ 10% occurs within a cycle.
223860|NCT02187367|Biological|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
223861|NCT02187406|Procedure|Modified ankle athletic taping|
223196|NCT02158897|Other|Prolon diet|3 cycles of a 5-day Prolon diet very month
223197|NCT02158910|Drug|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
223198|NCT02158923|Procedure|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
223199|NCT02158923|Procedure|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
223200|NCT02158923|Procedure|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
223505|NCT00139165|Drug|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
223506|NCT02194764|Drug|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
223507|NCT02194777|Drug|BIBN 4096 BS - in single rising doses|
223508|NCT02194777|Drug|Placebo|
223509|NCT02194790|Behavioral|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
223510|NCT02194829|Drug|Gemcitabine Hydrochloride|Given IV
223511|NCT02194829|Other|Laboratory Biomarker Analysis|Correlative studies
223512|NCT02194829|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223513|NCT02194829|Other|Pharmacological Study|Correlative studies
223514|NCT02194829|Other|Placebo|Given PO
223515|NCT02194829|Drug|WEE1 Inhibitor AZD1775|Given PO
223516|NCT00139165|Procedure|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
223517|NCT02194842|Drug|Ra223|
223518|NCT02194842|Drug|Enzalutamide|
222885|NCT02166593|Drug|Atorvastatin Sodium 10mg|
222886|NCT00135759|Drug|naltrexone|0.125 mg capsule/day for 6 days
222887|NCT02166606|Device|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
222888|NCT02166619|Device|tDCS + physical therapy|Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.
Other: Physical Therapy
222889|NCT02166632|Procedure|Intracapsular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively "bathing" the joint in the medication.
222890|NCT02166632|Procedure|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
222891|NCT02166645|Other|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
222892|NCT02166645|Other|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
222893|NCT02166658|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
223201|NCT02158936|Drug|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
223202|NCT02161419|Drug|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
223203|NCT02161419|Drug|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
223204|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fed state
223205|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fasted state
223206|NCT02161432|Drug|BI 187004|single dose BI 187004 given as oral solution
222570|NCT02173899|Biological|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
222571|NCT00136643|Drug|Invisible Condom®|
222572|NCT02173899|Biological|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
222573|NCT02173899|Biological|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
222574|NCT02173912|Drug|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.
Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
222575|NCT02173912|Drug|CJ-30059 (Test)|Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.
Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
222576|NCT02173938|Other|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
222577|NCT02173951|Drug|Deferiprone|in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.
Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.
Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6 will start deferiprone 75 mg/kg/d
222578|NCT02173964|Drug|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
222579|NCT02173964|Drug|water|same amount of water for pinverin administration
222580|NCT02173977|Other|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
222581|NCT02173977|Other|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
222582|NCT00002278|Drug|Diclazuril|
222583|NCT00136656|Drug|antibiotic|cephalosporine by oral route : cefixime
222584|NCT02173990|Drug|Aflibercept-FOLFIRI|Aflibercept : 4 mg/kg, IV over 1 h on Day 1
FOLFIRI :
Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :
5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :
5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.
*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²
222894|NCT02166671|Biological|HBV booster vaccination 1dose|
222895|NCT02168790|Device|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
219419|NCT02308748|Drug|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
219420|NCT02308748|Drug|Placebo|Placebo (#2 Gelcap or IV saline)
219421|NCT02308761|Drug|TEN-010|
219422|NCT02308787|Device|Spectra Optia Apheresis System|Platelet Depletion
219423|NCT02308800|Device|ITI Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
219424|NCT02308800|Device|ITI Quantum™ Therapy|Negative pressure wound therapy without irrigation.
219425|NCT02308813|Other|Braking and functionality|
219426|NCT02308826|Behavioral|Turtle Program|
219719|NCT02301468|Other|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
219720|NCT02301468|Other|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
219721|NCT02301481|Radiation|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
219722|NCT02301481|Drug|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
219723|NCT02303860|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
219724|NCT00151814|Drug|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
219725|NCT02303860|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
219726|NCT02303860|Drug|ORM-12741 IR|Immediately release formulation of ORM-12741
219727|NCT02303873|Drug|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp & Dohme．LTD.).
219728|NCT02303886|Drug|Methylene blue|In NaCL0.9% 100 ml
219729|NCT02303886|Drug|Methylene blue|in NaCl 0.9% 100 ml
219118|NCT02277223|Drug|Placebo|Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.
Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with "induction treatment failure" will be re-randomized to receive oral corticosteroids induction with or without curcumin.
219119|NCT02277236|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
219120|NCT02277236|Radiation|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
219121|NCT02277249|Drug|Digoxin (transvaginal administration)|Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a "Procedure/Surgery" type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
219122|NCT02277249|Drug|Digoxin (transabdominal administration)|Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a "Procedure/Surgery" type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
219123|NCT02277262|Device|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
219124|NCT02277262|Procedure|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
219125|NCT00148746|Drug|Ciclosporin A|
219427|NCT02308826|Behavioral|Cool Little Kids|
219428|NCT00152282|Drug|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
219429|NCT02308839|Device|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
219430|NCT02308852|Device|tDCS|
219431|NCT02308865|Other|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
219432|NCT02308878|Behavioral|Mobile health cognitive stimulation|
223660|NCT02169102|Other|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
223661|NCT02169102|Radiation|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
223964|NCT02161783|Radiation|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
223965|NCT02161783|Biological|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
223966|NCT02161796|Drug|FG-4592|Oral
223967|NCT02161796|Drug|Placebo|Oral
223968|NCT02161809|Behavioral|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of snacks and physical activity opportunities in settings where children are found such as afterschool programs and summer day camps. Through community partnerships with local grocery stores, healthy snacks are offered to participating programs at a discounted price. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity.
223969|NCT02161822|Drug|simvastatin|simvastatin 80mg qd for 5weeks
223970|NCT02161835|Other|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
223971|NCT02161848|Other|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
223972|NCT02161861|Other|cFFE increase the fusiogenic capacities of a gamete|
223973|NCT00135330|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
223974|NCT02161874|Device|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
223975|NCT02161874|Device|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
223976|NCT02161900|Other|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
223977|NCT02161913|Behavioral|Multi-Family Group Treatment|
223978|NCT02161913|Behavioral|SCI Education Control Group|
223979|NCT02161926|Other|dietary restrictions|Dietary restrictions during 8 weeks
223980|NCT02161939|Drug|Daclatasvir (BMS-790052)|
223324|NCT02174380|Other|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
223325|NCT02174393|Drug|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
223326|NCT02174393|Procedure|Microneedling|Microneedling: is a device for all skin types that creates micro "injuries" in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.
For this protocol, the needle depth will be increased over the 3 sessions:
Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.
Each Session: Microneedling procedure on Day 1, followed by skin care regimen
223327|NCT02174393|Drug|Post-Microneedling Skin Care|On Day 1 (after Microneedling procedure):
Gentle Antioxidant Soothing Cleanser daily
Soothing Recovery Ointment and Sheer Physical Sunscreen
On Day 2-7:
AM: Physical sheer sunscreen and recovery ointment
PM: Retinol/Vitamin C in the evening and soothing recovery ointment
On Day 7:
AM: BD Hydrating Day/Night Cream
PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)
223328|NCT02176928|Device|Sham PAP|Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.
Sham PAP treatment 7 nights a week for four months (16 weeks)./
223329|NCT02176954|Device|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
223662|NCT02169102|Radiation|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
223663|NCT02169102|Radiation|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
223664|NCT02169115|Drug|Omalizumab|150mg, s.c., every 4 weeks
223665|NCT02169115|Drug|Omalizumab|300mg, s.c., every 4 weeks
223666|NCT02169115|Drug|Placebo|Placebo, s.c., every 4 weeks
223667|NCT02169141|Other|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
223668|NCT02169154|Drug|1% Diclofenac Sodium|1% diclofenac sodium
223669|NCT00136084|Drug|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
223670|NCT02169154|Drug|3% Menthol|3% Menthol
223671|NCT02169154|Drug|0.09% Menthol|0.09% Menthol
222708|NCT02186912|Device|Nobel Active, Nobel Procera IBO|
222709|NCT02186938|Device|FloTrac|
222710|NCT00138099|Drug|Fragmin (dalteparin sodium)|
222711|NCT02186951|Drug|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
222712|NCT02186951|Drug|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
222713|NCT02186964|Procedure|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
222714|NCT02186964|Procedure|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
222715|NCT02186964|Procedure|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
222716|NCT02186977|Device|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur - MSD)
222717|NCT02186977|Drug|HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|
222718|NCT02186990|Drug|propofol|2,5 mg/kg
222719|NCT02186990|Drug|etomidate|0,3 mg/kg
222720|NCT02186990|Drug|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
222721|NCT00138112|Drug|Empirical Vancomycin|
223017|NCT02182011|Drug|Alteplase|
223018|NCT02182011|Drug|Streptokinase|
223019|NCT02182024|Drug|Dabigatran etexilate high dose|
223020|NCT00137566|Other|Placebo|
223021|NCT02182024|Drug|Dabigatran etexilate low dose|
223022|NCT02182037|Drug|Single rising doses of BIBT 1011 BS|
223023|NCT02182037|Drug|BIBT 1011 BS placebo|
223024|NCT02182050|Drug|BIBF 1120 ES low dose|
223025|NCT02182050|Drug|BIBF 1120 ES high dose|
223026|NCT02182050|Drug|Placebo to BIBF 1120 ES|
222047|NCT02280850|Drug|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
222048|NCT02280850|Drug|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
222049|NCT02280850|Drug|nitroglycerine|Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.
The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.
222050|NCT02280863|Device|Hybrid Closed Loop|Research staff will be remotely monitoring subjects at all times. If their sensor reads <70 mg/dl or >300 mg/dl, a health care member will intervene if no response from pt. or monitor within 5 and 10 minutes respectively. Treatment will be given as per the treatment interventions in the MM JDRF Hotel Studies Protocol (Table 2-1- Hypoglycemia and Hyperglycemia Monitoring and Treatment Procedures). At night a bedtime glucose, 3 AM glucose and a morning glucose will be obtained. During the day meter readings will be obtained before all meals and exercise.
222051|NCT02280876|Drug|1 - Andrographis paniculata p/st extract|Andrographis paniculata p/st extract, standard coated tablets, containing 170 mgs., 40% total Andrographolide, plus excipients, one tablet, BID, for 12 months.
222052|NCT02280876|Drug|2 - Placebo Comparator|Placebo Comparator : Standard customized coated tablets, containing 650 mgs of excipients , one tablet, twice a day, during 12 months.
222053|NCT00149214|Drug|pemetrexed|500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
222054|NCT02280902|Biological|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
222055|NCT02280915|Other|Savoury food product|
222056|NCT02280928|Other|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
222057|NCT02280928|Other|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
222058|NCT02280928|Other|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
222059|NCT02280941|Other|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
222060|NCT02280954|Drug|Indocyanine Green (ICG)|
222378|NCT02194348|Drug|BIBN 4096 BS - in single rising doses|
222379|NCT02194348|Drug|Placebo|
221108|NCT00150891|Drug|azathioprine|
221109|NCT02295098|Other|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
221418|NCT02290288|Procedure|vaginal surgery|
221419|NCT02290288|Procedure|laparoscopic surgery|
221420|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, early treatment
221421|NCT02290301|Drug|gemigliptin|
221422|NCT02292641|Procedure|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
221423|NCT02292654|Drug|GZ402665|Pharmaceutical form:powder for concentrate for solution for infusion Route of administration: intravenous infusion
221424|NCT02292667|Procedure|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
221425|NCT02292667|Drug|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
221426|NCT02292667|Drug|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
221427|NCT02292693|Device|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
221428|NCT00150618|Drug|SPD503 (3 mg)|
221429|NCT02292693|Device|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
221430|NCT02292693|Device|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
221431|NCT02292706|Drug|Sofosbuvir|Exposure of interest for participants who received a sofosbuvir-based regimen in a previous Gilead study for chronic hepatitis C virus infection.
221432|NCT02292719|Drug|Ombitasvir/ABT-450/r|Tablet
221433|NCT02292719|Drug|Sofosbuvir|Tablet
220812|NCT02301871|Procedure|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
220813|NCT00151580|Drug|Placebo|18 months oral placebo treatment
220814|NCT02301871|Procedure|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
220815|NCT02301884|Biological|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
220816|NCT02301897|Drug|Telapristone Acetate|Evaluate the safety and efficacy of 6 and 12 mg Proellex in the treatment of Premenopausal Women with confirmed symptomatic uterine fibroids
220817|NCT02301897|Drug|Placebo|
220818|NCT02301910|Drug|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
221110|NCT02295098|Other|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
221111|NCT02295111|Device|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
221112|NCT02297282|Behavioral|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
221113|NCT02297295|Other|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
221114|NCT02297334|Device|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
221115|NCT02297360|Dietary Supplement|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
221116|NCT02297360|Other|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
221117|NCT02297386|Drug|[18F] DIHYDRO-TESTOSTERONE|
220503|NCT02306993|Other|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
220504|NCT02306993|Other|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
220505|NCT02306993|Other|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
220506|NCT02307006|Drug|Ceftaroline|Surgical prophylaxis
220507|NCT02307006|Drug|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
220508|NCT00152308|Device|YUKONdes PEARL-stent coated with placebo (ethanol)|
220509|NCT02309164|Procedure|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
220510|NCT02309164|Behavioral|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
220511|NCT02309177|Drug|nab-Paclitaxel|
220512|NCT02309177|Drug|Nivolumab|
220513|NCT02309177|Drug|Gemcitabine|
220514|NCT02309177|Drug|Carboplatin|
220515|NCT02309203|Device|FRED|Flow Re-Direction Endoluminal Device
220516|NCT02309216|Other|Whol-Body MRI scan|
220517|NCT02309242|Behavioral|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
220518|NCT02309255|Other|no intervention|
220519|NCT00152321|Behavioral|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
220520|NCT02309281|Drug|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
220521|NCT02309307|Device|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
219884|NCT02282488|Other|High protein formula|
219885|NCT02282501|Other|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
219886|NCT00149357|Other|Thrombophilia Testing|TP testing in Group 1 and 3 only
219887|NCT02282514|Biological|Autologous Hematopoietic Stem Cell Transplantation|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
219888|NCT02282527|Biological|Liquid Alpha1-PI|Liquid Alpha1-PI, 60 mg/kg, 8-weekly intravenous infusion
219889|NCT02282527|Biological|Prolastin-C|Prolastin-C, 60 mg/kg, 8-weekly intravenous infusion
219890|NCT02282540|Procedure|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
220195|NCT02314403|Drug|ATG|A T-Cell Depleting Agent
220196|NCT02314403|Drug|Rituximab|B-Cell Depleting Agent
220197|NCT02314403|Radiation|Total Body Irradiation|
220198|NCT02314403|Radiation|Thymic Irradiation|
220199|NCT02314403|Procedure|Combined Bone Marrow/Kidney Transplantation|
220200|NCT02314416|Biological|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix`. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
220201|NCT00152815|Drug|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
220202|NCT02314429|Device|Vaginal ring releasing lactic acid (racemic mixture)|
220203|NCT02314442|Drug|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
220204|NCT02314442|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
220205|NCT02277652|Device|The Bonfils intubation fibrescope|Optical laryngoscopy
220206|NCT00148798|Drug|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
220207|NCT02277652|Device|The GlideScope Ranger|Videolaryngoscopy
219597|NCT02289482|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
219598|NCT02289482|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
219599|NCT02289495|Drug|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
219600|NCT02289495|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
219601|NCT02289495|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
219602|NCT00150202|Drug|pegaptanib sodium|
219603|NCT02289508|Device|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
219604|NCT02289508|Device|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
219891|NCT02282553|Device|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
219892|NCT02282553|Device|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
219893|NCT02282566|Other|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
219894|NCT02282579|Drug|Pazopanib|Non interventional study
219895|NCT02282592|Other|Observation about the presence of metabolic syndrome|
219896|NCT02282605|Drug|XF-73 nasal gel|
219897|NCT00149370|Procedure|Breast reduction surgery|
219898|NCT02282605|Drug|Placebo nasal gel|
219298|NCT02294344|Drug|CTX|First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.
After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).
The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count ＜3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count ＜3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study.
219299|NCT02294357|Drug|Carfilzomib|
219300|NCT02294357|Drug|Dexamethasone|If the patient was receiving steroids at the equivalent of > 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
219301|NCT02296593|Device|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
219302|NCT02296619|Procedure|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
219303|NCT02296619|Procedure|Control|A sham band-aid will be applied to the abdomen of subjects
219304|NCT02296632|Behavioral|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
219305|NCT02296645|Drug|ChloraPrep|ChloraPrep 10.5 mL Applicator (Scrub Teal Tint)
219306|NCT02296658|Radiation|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
219307|NCT02296658|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
219308|NCT02296671|Drug|Pemetrexed|
219309|NCT00151073|Drug|Zoledronic acid|
219310|NCT02296671|Drug|Oxaliplatin|
219311|NCT02296671|Drug|Leucovorin|
219312|NCT02296671|Drug|Fluorouracil|
219313|NCT02296671|Genetic|Germline genotyping analyses for TSER|
219314|NCT02296684|Biological|MK-3475|
223862|NCT02187406|Procedure|Traditional ankle athletic taping|
219000|NCT02301182|Device|CoC Cup|
219001|NCT02301195|Other|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
219002|NCT02301195|Other|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
219003|NCT00002379|Drug|Zidovudine|
219004|NCT00151515|Drug|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
219005|NCT02301208|Drug|Nedaplatin|Nedaplatin combine with IMRT
219006|NCT02301208|Drug|Cisplatin|Cisplatin combine with IMRT
219007|NCT02301221|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
219008|NCT02301221|Drug|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
219009|NCT02301234|Drug|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
219010|NCT02301234|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
219011|NCT02303574|Drug|Placebo, oral solution|Matching placebo
219012|NCT02303587|Drug|methylprednisolone|
219013|NCT00151775|Drug|olmesartan medoxomil|Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.
Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg
219014|NCT02303600|Drug|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
219015|NCT02303600|Other|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
219016|NCT02303613|Other|Mapping|Mapping of current triage situation regarding 30 days mortality
219017|NCT02303626|Drug|BCX4161|
219018|NCT02303626|Drug|Placebo|
223519|NCT02194855|Drug|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
223520|NCT02194855|Drug|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
223521|NCT02194868|Biological|Recipients|Adult recipient:
collected 20 ml pre-transplant
collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,
collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360
Children recipients
collected residual blood pre-transplant
collected residual blood on day 20 post-transplant at engraftment for cell phenotype,
collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT
223522|NCT02194868|Biological|Donors|Adult donors :
collected 20 ml of blood, (if possible before GCSF administration)
collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.
Children donors samples
collected residual blood
2ml of bone marrow (bottom of tube)
223523|NCT02194881|Drug|CF patients with a G551D mutation and treated with Ivacaftor|
223524|NCT02194894|Drug|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
223525|NCT02194907|Device|Functional Magnetic Resonance Imaging|Participants in each group will be randomly assigned to be trained using functional magnetic resonance imaging.
223863|NCT02187419|Other|Hypnosis|Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.
However, it is generally agreed that hypnosis is a "state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood". Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings.
223864|NCT02187445|Drug|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
223865|NCT02187471|Drug|DS-5565 15mg tablet|
223866|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
223867|NCT02189707|Other|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
223868|NCT02189720|Drug|Amifampridine Phosphate|Dosage form: 250 mg tablets, each containing the equivalent of 10 mg amifampridine base per tablet.
Amifampridine Phosphate is taken with food and each patient is given an individualized dose based on Investigator assessment of optimal neuromuscular benefit. Doses range from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day, with a maximum single dose of 20 mg.
223869|NCT02189733|Biological|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
223207|NCT00135278|Procedure|CSF will be drained using an epidural catheter inserted via lumbar puncture for 72 hours.|See Detailed Description
223208|NCT02161458|Drug|Escitalopram or Placebo|30 cognitively normal adults aged 65-85 will receive escitalopram (10mg daily for days 1-5 then 20mg daily for days 6-14, then 10mg daily for days 15-17) and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and at two week follow-up.
Additionally, 30 cognitively normal adults aged 65-85 will receive placebo (10mg daily for days 1-5 then 20mg daily for days 6-14, then 10mg daily for days 15-17) and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and at two week follow-up.
223209|NCT02161484|Procedure|Continuous Lumbar Plexus Block|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
223210|NCT02161484|Procedure|Parasacral Nerve Block|A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
223211|NCT02161484|Drug|Ropivacine 0.2%|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
223212|NCT02161484|Drug|Bupivacaine 0.0625%|In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
223213|NCT02161510|Drug|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
223214|NCT02161536|Device|Motus GI CleanC Device|
223215|NCT02161549|Device|Motus Gl Clean-Up Device|
223216|NCT02161562|Drug|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
223217|NCT02161562|Drug|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
223526|NCT02194907|Device|ETG-4000, Hitachi Medical corp|Participants in each group will be randomly assigned to be trained using functional near-infrared spectroscopy.
223527|NCT00139178|Drug|Different HAART regimens|
223528|NCT02194920|Procedure|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
223529|NCT02155933|Other|Blood sampling|Blood sampling for later hormone measurements
223530|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
223531|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
222896|NCT00136045|Drug|Rotigotine|
222897|NCT02168803|Drug|Evacetrapib|Administered orally
222898|NCT02168816|Drug|piperacillin/tazobactam, cefepime, metronidazole, aztreonam,vancomycin, daptomycin, linezolid ,meropenem|Individuals are not assigned to specific medications. Rather, individuals are only assigned to a route of therapy. Individuals assigned to intravenous therapy will receive an intravenous therapy as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
222899|NCT02168816|Drug|sulfamethoxazole/trimethoprim , clindamycin ,linezolid, moxifloxacin ,ciprofloxacin ,metronidazole|Individuals are not assigned to specific medications. Rather, individuals are only assigned to a route of therapy. Individuals assigned to oral therapy will receive an oral therapy as determined by their primary healthcare provider. Individuals assigned to oral therapy will usually receive at least one of the following medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
222900|NCT02168829|Drug|Rivaroxaban|
222901|NCT02168829|Drug|Acetylsalicylic acid|
222902|NCT02168842|Drug|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
222903|NCT02168842|Drug|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
222904|NCT02168855|Drug|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
222905|NCT02168855|Behavioral|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
222906|NCT02168881|Drug|Misoprostol|
222907|NCT00136058|Procedure|bone densitometry (DEXA)|
222908|NCT02168881|Drug|Dinoprostone|
222909|NCT02168894|Procedure|Acupuncture|Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.
Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.
Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment.
222910|NCT02168894|Procedure|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
222911|NCT02168894|Behavioral|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
223218|NCT00135291|Procedure|Leukoreduced blood transfusion|
219730|NCT02303899|Drug|Gemcitabine|infusion drug
219731|NCT02303899|Drug|Imatinib mesylate|oral drug
219732|NCT02303912|Drug|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
219733|NCT02303925|Device|NESTER COILS|
219734|NCT02303938|Behavioral|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
219735|NCT00151827|Drug|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
219736|NCT02303951|Drug|Vemurafenib + cobimetinib|
219737|NCT02303964|Biological|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
220038|NCT02297074|Other|Precooked-Frozen White Bread|The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
220039|NCT02297074|Other|Candeal-flour White Bread|The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
220040|NCT02297074|Other|Alfacar White Bread|The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
220041|NCT02299271|Drug|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
220042|NCT02299271|Drug|Saline|Saline as a one-time, 60 milliliter injection.
220043|NCT02299284|Other|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
219433|NCT02308891|Drug|lactated Ringer's solution (vigorous hydration arm)|Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP
Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.
At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour
219434|NCT02311595|Procedure|reduced port laparoscopic distal gastrectomy|
219435|NCT02311608|Drug|Terlipressin|administered as a first-line medicine or as salvage
219436|NCT02311608|Drug|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
219437|NCT00002386|Drug|Zidovudine|
219438|NCT00152568|Behavioral|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
219439|NCT02311608|Drug|High Dose Somatostatin/Octreotide|administered as salvage
219440|NCT02311621|Biological|Patient Derived CD171 specific CAR T cells expressing EGFRt|T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt
219441|NCT02311621|Biological|Patient Derived CD171 specific CAR T cells expressing EGFRt|T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
219442|NCT02311634|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
219443|NCT02311634|Device|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
219444|NCT02311660|Device|Vagus Nerve Stimulation Device|Cyberonics VNS System
219445|NCT02311673|Drug|RM-493|
219446|NCT02311673|Drug|Placebo|
219738|NCT02303964|Drug|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
219739|NCT02303977|Drug|Abraxane|
219740|NCT02303977|Drug|Gemcitabine|
219741|NCT02303990|Drug|Pembrolizumab|
219742|NCT02303990|Radiation|Radiotherapy|
223981|NCT02161939|Drug|Sofosbuvir|
223982|NCT02161952|Drug|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
223983|NCT02161952|Drug|Matched equivalent placebo|
223984|NCT00135330|Drug|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
223985|NCT02161965|Drug|Rivaroxaban|20mg or 15mg
219126|NCT02277275|Dietary Supplement|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
219127|NCT02277275|Dietary Supplement|Placebo (For BCAA)|Placebo will be provided to the other two arms for six months
219128|NCT02277288|Other|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
219129|NCT02277301|Behavioral|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
219130|NCT02279641|Drug|allopurinol 300 mg|
219131|NCT02279654|Drug|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
219132|NCT02279667|Drug|BIA 2-093|oral suspension 50 mg/mL
219133|NCT02279667|Drug|BIA 2-093|200 mg tablet
219134|NCT02279667|Drug|BIA 2-093|800 mg tablet
219135|NCT02279680|Device|Electroencephalography|
219136|NCT00149071|Device|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
219137|NCT02279680|Behavioral|Neuropsychological assesments|
219138|NCT02279693|Other|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
219139|NCT02279693|Other|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
219140|NCT02279693|Radiation|IGRT Associated With IMRT|
219141|NCT02279706|Other|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
223672|NCT02169154|Drug|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
223673|NCT02169154|Drug|0.9% Saline|0.9% Saline
223674|NCT02169167|Device|Resin salve treatment|Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
223675|NCT02169167|Device|Octenidine treatment|Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
223676|NCT02169180|Drug|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
223677|NCT02169193|Radiation|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
223678|NCT02169206|Radiation|Bilateral shoulder anteroposterior radiography|Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.
In the same position, the patient only elevates the arm up to 90 degrees of abduction.
223986|NCT02161965|Drug|Fluindione|
223987|NCT02161965|Drug|Warfarin|
223988|NCT02161991|Drug|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
223989|NCT02164162|Other|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
223990|NCT02164175|Device|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
223991|NCT00135551|Drug|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
223992|NCT02164188|Behavioral|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
223027|NCT02182063|Drug|BIBF 1120 low dose|
223028|NCT02182063|Drug|BIBF 1120 high dose|
223029|NCT02182076|Drug|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
223030|NCT02182102|Drug|BIBF 1120|
223031|NCT00137579|Procedure|Influenza vaccine intramuscular administration route|
223032|NCT02182102|Drug|Pemetrexed|
223033|NCT02182115|Drug|antiseptic bundle|Chlorhexidine gluconate liquid soap for bathing daily.
Chlorhexidine gluconate mouthrinse to use twice daily.
Nasal mupirocin to apply twice daily.
223034|NCT02182115|Drug|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
223035|NCT02182128|Drug|BIBF 1120|
223036|NCT02182141|Drug|BIBF 1120 ES|
223037|NCT02182154|Drug|BIBF 1120 ES|
223038|NCT02182167|Drug|IV N-acetylcysteine (NAC)|
223039|NCT02182167|Drug|Water|
223040|NCT02182193|Drug|BIBF 1120 capsules charge 1|
223041|NCT02182193|Drug|BIBF 1120 capsules charge 2|
223042|NCT00137592|Behavioral|small media, group education (multicomponent)|
223043|NCT02182193|Drug|BIBF 1120 drinking solution|
223044|NCT02182206|Drug|BIBF 1120|
223330|NCT02176954|Device|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
223331|NCT02176954|Device|Comparator|Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.
Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.
223332|NCT02176967|Other|Clinical Observation|Undergo clinical observation
223333|NCT02176967|Drug|Carboplatin|Given IV
223334|NCT02176967|Drug|Etoposide|Given IV
222380|NCT00139100|Drug|antimicrobial agent in soap|
222381|NCT02194361|Drug|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
222382|NCT02194361|Drug|Placebo|
222383|NCT02194374|Procedure|ROR1R-CAR-T Cell Infusion|Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.
Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort.
222384|NCT02194374|Drug|Fludarabine|FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.
FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3.
222385|NCT02194374|Drug|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
222386|NCT02194374|Drug|Rituximab|FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.
BR Regimen: 375-500 mg/m2 by vein on Day -4.
222387|NCT02194374|Drug|Bendamustine|BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.
FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3.
222388|NCT02194387|Behavioral|Telephone Coaching|Participant has 30-40 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.
222389|NCT02194387|Behavioral|Text Messaging|Participant receives 8-12 messages/week, 1-3 messages/day during the 16 week intervention period.
222390|NCT02194387|Behavioral|Social Networking|Participant invited to use an online forum to discuss their fitness goals with other participants in study who are receiving social networking.
222391|NCT00000331|Drug|Test Drug|
222392|NCT00002299|Drug|Ganciclovir|
222393|NCT00139113|Biological|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
222394|NCT02194387|Behavioral|Daily Self-Monitoring|Participant enters additional information about their diet and activity every day through the FitBit website.
222395|NCT02194387|Behavioral|Weekly Self-Monitoring|Participant enters additional information about their diet and activity once a week through the FitBit website.
222396|NCT02194387|Behavioral|Questionnaires|Questionnaire completion at baseline, 8 weeks and 16 weeks.
222397|NCT02194387|Behavioral|Email Coaching|Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 2-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.
222398|NCT02197026|Drug|Hylan G-F 20|
221434|NCT02292719|Drug|Ribavirin (RBV)|Tablet
221435|NCT02292732|Drug|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter [mm]) to be taken orally and once daily
221436|NCT02292732|Drug|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
221754|NCT02285907|Other|Beef vs. Soy Protein|The study will compare macronutrient and fiber matched BEEF vs. SOY lunch meals and serving size matched BEEF vs. SOY lunch meals.
221755|NCT02288156|Drug|Capsaicin|via nasal spray
221756|NCT02288156|Drug|placebo|via nasal spray
221757|NCT02288169|Behavioral|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
221758|NCT02288169|Behavioral|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
221759|NCT02288182|Device|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
221760|NCT02288182|Device|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
221761|NCT02288195|Drug|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
221762|NCT00149994|Drug|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
221763|NCT02288195|Drug|capecitabine|825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B.
221764|NCT02288195|Radiation|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
221765|NCT02288208|Drug|Antiviral Therapy (tenofovir or entecavir)|
221766|NCT02288208|Drug|Birinapant|
221767|NCT02288208|Drug|Placebo (for birinapant)|
221768|NCT02288221|Other|Patient's answer with non pharmacological therapeutic|Installation at patient's home of :
aromatherapy
music therapy
cognitive training in multimedia application offering cognitive games
221118|NCT02297386|Device|PET scan|
221119|NCT02297386|Device|MRI|
221120|NCT00151125|Drug|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
221121|NCT02297386|Other|Blood draw|
221122|NCT02297399|Drug|PEG-ascorbate 2L|Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.
Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken.
221123|NCT02297399|Drug|PEG 4L|Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.
Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken.
221124|NCT02297412|Drug|Minocycline|
221125|NCT02297412|Drug|Placebo|
221437|NCT02292732|Drug|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
221438|NCT02292732|Drug|Placebo|Each green tablet will contain only inert ingredients: D&C yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
221439|NCT00150618|Drug|SPD503 (4 mg)|
221440|NCT02292745|Radiation|stereotactic radiotherapy|
221441|NCT02292758|Drug|Bevacizumab|
221442|NCT02292758|Drug|Irinotecan|
221443|NCT02292758|Drug|Cetuximab|
221444|NCT02295111|Behavioral|TCM health consult|Traditional Chinese Medicine Health Consult without needling
221445|NCT02295111|Other|Usual Care|Standard NHS care
221446|NCT02295124|Drug|Oxycodone|Patients will receive oxycodone 10mg (5mg if > 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
220522|NCT02309320|Biological|ALX-0171|
220819|NCT02301910|Drug|Tenecteplase|50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)
55 to <60 30 mg 6 ml
60 to <70 35 mg 7 ml
70 to <80 40 mg 8 ml
220820|NCT02301936|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally
220821|NCT02301949|Drug|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
220822|NCT02301949|Other|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
220823|NCT02301962|Drug|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
220824|NCT00002380|Drug|Nelfinavir mesylate|
220825|NCT00151593|Other|Celsior®|Graft preservation solution
220826|NCT02301975|Drug|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
220827|NCT02301975|Drug|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
220828|NCT02304432|Drug|D-cycloserine|
220829|NCT02304432|Drug|placebo|
220830|NCT00151879|Drug|SPM 927|
220831|NCT02304445|Procedure|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
220832|NCT02304445|Radiation|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
220833|NCT02304458|Biological|Ipilimumab|Given IV
220834|NCT02304458|Other|Laboratory Biomarker Analysis|Correlative studies
220835|NCT02304458|Biological|Nivolumab|Given IV
220836|NCT02304458|Other|Pharmacological Study|Correlative studies
220208|NCT02277652|Device|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
220209|NCT02277665|Behavioral|CUD Treatment|
220210|NCT02277665|Behavioral|Tobacco Treatment|
220211|NCT02277678|Drug|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
220212|NCT02277678|Drug|Opioid administration morphine|
220213|NCT02277691|Drug|TAK-536TCH tablet, TAK-536CCB tablet, and HCTZ 12.5 mg tablet|
220214|NCT02277704|Drug|TNX-102 SL|
220215|NCT02277704|Drug|Placebo|
220216|NCT02277717|Drug|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
220217|NCT00002371|Drug|Stavudine|
220218|NCT00148798|Drug|cisplatin + vinorelbine|cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
220523|NCT02309320|Other|Placebo|
220524|NCT02309346|Drug|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
220525|NCT02309359|Biological|ALX-0061|
220526|NCT02309359|Other|Placebo|
220527|NCT02309372|Behavioral|Beating the Blues|Computerized depression treatment intervention
220528|NCT02309385|Drug|8% Dexamethasone Sodium Phosphate - Visulex|
220529|NCT02309385|Drug|15% Dexamethasone Sodium Phosphate - Visulex|
220530|NCT00152321|Behavioral|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
220531|NCT02309385|Drug|Prednisolone Acetate (1%) Eye Drops|
220532|NCT02309411|Drug|Rivaroxaban(Xarelto,BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
220533|NCT02309424|Dietary Supplement|Vinegar|0,50mmol vinegar (6% acetic acid)
219899|NCT02282605|Other|Chlorhexidine gluconate 2% topical cloths|
219900|NCT02282618|Device|Cardiac Sympathetic Blockade|
219901|NCT02282631|Behavioral|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
219902|NCT02285010|Drug|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
219903|NCT02285023|Other|CU-Q2oL|The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.
At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.
At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire.
219904|NCT02285036|Biological|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
219905|NCT02285036|Biological|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
220219|NCT02277730|Device|vasopressor delivery automated system w/|vasopressor delivery using phenylephrine and ephedrine
220220|NCT02277730|Drug|phenylephrine|
220221|NCT02277730|Drug|ephedrine|
220222|NCT02277730|Device|manual vasopressor delivery|
220223|NCT02277743|Drug|dupilumab|
220224|NCT02277743|Drug|placebo|
220225|NCT02277756|Device|thermode|thermal stimulation with test thermode
220226|NCT02277769|Drug|dupilumab|
220227|NCT02277769|Drug|placebo|
220228|NCT02277782|Drug|Hydromorphone|
220229|NCT00148824|Biological|7-valent pneumococcal conjugate vaccine (vaccine)|
220230|NCT02277782|Drug|Hyperbaric bupivacaine|
219605|NCT02289521|Device|Transcranial Direct Current Stimulation|We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.
Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).
Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation).
219606|NCT02289547|Drug|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
219607|NCT02289560|Device|Transcranial ExAblate|Transcranial ExAblate
219608|NCT02289573|Device|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
219609|NCT02289586|Procedure|invasive ventilation|
219610|NCT02289586|Procedure|interventional bronchoscopy|
219611|NCT02289586|Device|noninvasive ventilation|
219612|NCT02289586|Drug|sedation(dezocine and midazolam)|
219613|NCT02291744|Procedure|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
219614|NCT02291744|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
219615|NCT02291757|Dietary Supplement|NEM Eggshell Membrane|
219616|NCT02291770|Biological|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
219617|NCT02291783|Drug|HTL0009936|
219618|NCT02291783|Drug|HTL0009936 placebo|
219619|NCT00150527|Drug|Dexamethasone|1 mg, pill, single dose
219620|NCT02291796|Drug|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
219621|NCT02291809|Biological|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
219622|NCT02291822|Drug|Gadobenate Dimeglumine|gadolinium contrast agent
219019|NCT02303639|Procedure|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
219020|NCT02303639|Drug|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
219315|NCT02296684|Procedure|Surgery|
219316|NCT02296684|Radiation|Intensity modulated radiation therapy|
219317|NCT02296684|Radiation|Image-guided radiation therapy|
219318|NCT02296684|Drug|Cisplatin|
219319|NCT02296697|Device|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
219320|NCT00002378|Drug|Zidovudine|
219321|NCT00151073|Drug|Estramustine|
219322|NCT02296697|Device|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
219323|NCT02296697|Other|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
219324|NCT02296710|Procedure|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
219325|NCT02296723|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
219326|NCT02296736|Radiation|Computerised tomography (CT) scan|Retrospective review of CT scans
219327|NCT02298868|Drug|Baclofen|
219328|NCT02298920|Drug|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
219329|NCT02298933|Drug|Eculizumab|300 mg single-use vials
219330|NCT02298946|Drug|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
219331|NCT00151255|Drug|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
219332|NCT02298946|Radiation|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
223870|NCT02189746|Other|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
223871|NCT02189746|Other|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
223872|NCT02189746|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
223873|NCT00138424|Drug|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
219021|NCT02303652|Procedure|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
219022|NCT02303652|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
219023|NCT02303665|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
219024|NCT00151788|Drug|Pactimibe sulfate|
219025|NCT02303665|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
219026|NCT02303678|Drug|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
219027|NCT02303691|Behavioral|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
219028|NCT02303691|Behavioral|Neutral Training|A control version of computerized attention training.
223532|NCT00134654|Drug|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
223533|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
223534|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
223535|NCT02155959|Device|toric intraocular lens|toric intraocular lens
223536|NCT02155972|Dietary Supplement|Bifidobacterium infantis|Probiotic supplement
223537|NCT02155972|Other|Placebo|Placebo capsules
223538|NCT02155985|Drug|Aspirin|
223539|NCT02155985|Drug|Aspirin placebo|
223540|NCT02156024|Drug|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
223541|NCT02156037|Behavioral|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
223542|NCT02156037|Behavioral|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
223543|NCT00134667|Drug|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
223544|NCT02156050|Device|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
223545|NCT02156063|Drug|NT100|
223546|NCT02156063|Drug|Placebo|
223547|NCT02156076|Drug|BMS-919373|
223548|NCT02156076|Drug|Placebo (Matching with BMS-919373)|
223874|NCT02189746|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
223219|NCT02161575|Drug|Ranibizumab|
223220|NCT02161588|Drug|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
223221|NCT02161588|Drug|placebo|Once-daily oral administration as tablets.
223222|NCT02163811|Behavioral|VETPALS|VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.
VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care.
223223|NCT02163811|Behavioral|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
223224|NCT02163824|Drug|KPI-121|KPI-121 drug product will be supplied in two strengths: 0.25% and 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
223225|NCT02163837|Drug|rifaximine|
223226|NCT02163850|Device|Direct Flow Medical Transcatheter aortic valve replacement|
223227|NCT02163850|Device|Medtronic CoreValve Transcatheter aortic valve replacement|
223228|NCT00135525|Drug|Placebo|Placebo
223229|NCT02163863|Device|Femoropopliteal stenting|
223230|NCT02163876|Drug|HuCNS-SC cells|surgery arm
223231|NCT02163902|Drug|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
223232|NCT02163902|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
223233|NCT02163915|Drug|TAK-137|TAK-137 tablets
223234|NCT02163915|Drug|TAK-137 Placebo|TAK-137 placebo-matching tablets
223235|NCT02163928|Other|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
223236|NCT02163941|Behavioral|Compassion Training|
220044|NCT00151320|Drug|Bortezomib, CHOP, Rituximab|Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles
Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:
Level Dose/Schedule
2 0.7 mg/m2 on day 1 of each cycle
1 0.7 mg/m2 on days 1 and 8 0 0.7 mg/m2 on days 1 and 4
1 1.0 mg/m2 on days 1 and 4
2 1.3 mg/m2 on days 1 and 4
220045|NCT02299297|Drug|Tofacitinib|
220046|NCT02299310|Drug|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
220047|NCT02299310|Drug|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
220048|NCT02299323|Device|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
220049|NCT02299336|Drug|Aflibercept|pro re nata (PRN)
220050|NCT02299336|Procedure|Focal Laser|Focal laser administered based on pre-specified criteria
220051|NCT02299349|Drug|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
220052|NCT02299349|Drug|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
220365|NCT02292212|Device|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
220366|NCT02292225|Drug|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
220367|NCT02292225|Drug|Obinutuzumab|1000mg/40mL single-use vials
220368|NCT02292238|Drug|Benfotiamine|To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).
To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate.
220369|NCT02292251|Behavioral|Device-assisted therapy|
220370|NCT02292251|Behavioral|Therapy-based occupational therapy|
220371|NCT02292264|Procedure|Ventral hernia repair|
220372|NCT02292277|Drug|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
220373|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
219743|NCT02304003|Other|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
219744|NCT02304003|Other|Standard Care|Standard follow up in primary care.
219745|NCT02304016|Behavioral|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
219746|NCT00151827|Drug|Losartan|Medications are taken once daily before breakfast with water.
219747|NCT02304029|Device|MRI|
219748|NCT02304042|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
219749|NCT02306421|Procedure|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
219750|NCT02306434|Behavioral|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
219751|NCT02306434|Other|Standard care-counselling|Standard care (Counselling by midwives)
219752|NCT02306447|Device|rPMS and rTMS|rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.
rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.
For stimulation we use MagPro X100 (Medtronic, Denmark).
219753|NCT00152100|Device|Miltenyi CliniMACS|
219754|NCT02306473|Drug|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
219755|NCT02306486|Other|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
220053|NCT02299375|Drug|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
219142|NCT02279719|Drug|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
219143|NCT02279719|Drug|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
219144|NCT02279719|Drug|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
219145|NCT02279732|Biological|Paclitaxel|
219146|NCT02279732|Biological|Carboplatin|
219147|NCT00149071|Device|TMS|Transcraniel Magnetic Stimulation active and sham
219447|NCT02311686|Dietary Supplement|10 g ethanol|Alcohol single oral dose
219448|NCT02311686|Dietary Supplement|20 g ethanol|Alcohol single oral dose
219449|NCT00152581|Drug|Pegylated interferon-alfa2a (Pegasys); ribavirin|
219450|NCT02311686|Dietary Supplement|40 g ethanol|Alcohol single oral dose
219451|NCT02311686|Dietary Supplement|60 g ethanol|Alcohol single oral dose
219452|NCT02311686|Dietary Supplement|80 g ethanol|Alcohol single oral dose
219453|NCT02311699|Behavioral|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two‐hour session per group of participants.
219454|NCT02311712|Device|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
219455|NCT02311725|Behavioral|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
219456|NCT02314052|Drug|DCR-MYC|Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.
Starting dose: 0.125mg/kg/dose
Number of cycles: until progression or unacceptable toxicity develops.
PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.
PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety
223993|NCT02164214|Drug|etanercept Treatment|
223994|NCT02164227|Other|Respiratory pattern|
223995|NCT02164240|Drug|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
223996|NCT02164240|Drug|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
223997|NCT02164253|Drug|Deferiprone|30 mg/kg per day, oral use
223998|NCT02164266|Drug|Placebo|Matching placebo daily oral administration
223999|NCT02164266|Drug|RO6799477|Daily oral administration of RO6799477
224000|NCT02164279|Other|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( < or > than 100mg/L)
224001|NCT02164292|Procedure|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
224002|NCT00135564|Biological|MenC-TT|
224003|NCT02164305|Other|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
219148|NCT02279732|Biological|Ipilimumab|
219149|NCT02279732|Other|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
219150|NCT02279745|Drug|APD811|
219151|NCT02279758|Drug|Metformin|
219152|NCT02279771|Procedure|transanal anastomotic reinforcement|a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.
Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12.
219153|NCT02279771|Procedure|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
219154|NCT02279771|Device|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
223335|NCT02176967|Drug|Cyclophosphamide|Given IV
223336|NCT02176967|Drug|Doxorubicin Hydrochloride|Given IV
223337|NCT00137007|Drug|Azithromycin|
223338|NCT02176967|Other|Laboratory Biomarker Analysis|Correlative studies
223339|NCT02176967|Other|Pharmacological Study|Optional correlative studies
223340|NCT02176980|Behavioral|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
223341|NCT02176980|Behavioral|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
223342|NCT02177006|Behavioral|Sun Protection Program|The intervention includes two phases:
Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.
Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys
223343|NCT02177019|Other|Personalized health plan|
223344|NCT02177032|Biological|Rabies vaccine|12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the "4-sites, 1-week" regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8).
223345|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the "4-sites, 1-week" regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.
223346|NCT02177032|Biological|Rabies vaccine|8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the "2-sites, TRC", updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29).
223679|NCT02171364|Procedure|conventional ablation based on physician's personal experience|
223680|NCT02171377|Device|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
223681|NCT02171377|Other|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
223682|NCT02171377|Device|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
223683|NCT02171377|Other|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
222722|NCT02187003|Drug|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
222723|NCT02187003|Other|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
222724|NCT02189226|Device|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
222725|NCT02189239|Drug|Zeller Entspannung film coated tablet|
222726|NCT02189239|Drug|Placebo|
222727|NCT02189239|Other|No Treatment|
222728|NCT02189252|Drug|Epanova|
222729|NCT02189252|Drug|Lovaza|
222730|NCT02189265|Other|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
222731|NCT00138385|Biological|FluMist|
222732|NCT02189278|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
222733|NCT02189291|Procedure|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
222734|NCT02189291|Procedure|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
222735|NCT02189304|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
222736|NCT02189304|Drug|PT009|PT009 administered as 2 inhalations
222737|NCT02189304|Drug|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
221769|NCT02288221|Other|Patient's answer without non pharmacological therapeutic|No installation at patient's home
221770|NCT02288247|Drug|Enzalutamide|Oral
221771|NCT02288247|Drug|Docetaxel|intravenous infusion
221772|NCT02288247|Drug|Prednisolone|Oral
221773|NCT00002376|Drug|Lamivudine|
221774|NCT00149994|Drug|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
221775|NCT02288247|Drug|Placebo|Oral
222061|NCT02280967|Behavioral|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
222062|NCT02283359|Drug|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
222063|NCT02283372|Drug|nab-Paclitaxel|
222064|NCT00149500|Behavioral|Coaching|
222065|NCT02283372|Drug|Gemcitabine|
222066|NCT02283372|Radiation|Intensity modulated radiation|
222067|NCT02283385|Behavioral|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
222068|NCT02283398|Other|without RIPC|the cuff will be placed around the left arm without being inflated
222069|NCT02283398|Procedure|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
222070|NCT02283411|Device|No Treatment|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
222071|NCT02283424|Drug|Icotinib|compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
222072|NCT02283424|Drug|chemotherapy (Carboplatin and Docetaxel)|as control group,compared with Icotinib
222073|NCT02283437|Behavioral|Problem-solving Based Bibliotherapy Program|The PSBBP will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
221447|NCT02295124|Drug|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if > 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
221448|NCT02295137|Procedure|Using pre-procedural CTA to guide advanced EVAR procedure|
221449|NCT02295150|Drug|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
221450|NCT02295163|Procedure|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
221451|NCT00150891|Drug|mycophenolate mofetil|
221452|NCT02295163|Procedure|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
221453|NCT02295176|Dietary Supplement|Armolipid Plus|
221454|NCT02295176|Dietary Supplement|Placebo|
221455|NCT02295189|Drug|Ketorolac Tromethamine|anti-inflammatory injection
221456|NCT02295189|Drug|Triamcinolone Acetonide|corticosteroid injection
221457|NCT02295202|Device|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
221458|NCT02295202|Device|Nasal strips|
221776|NCT02288273|Drug|Bydureon|Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
221777|NCT02288273|Drug|Placebo|Placebo
221778|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
221779|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
221780|NCT02290314|Procedure|minimally invasive MID-line Lumbar Fusion (MIDLF)|
221781|NCT02290314|Procedure|Posterior lumbar interbody fusion (PLIF)|
221782|NCT02290327|Drug|Pantoprazole|Proton pump inhibitor
221783|NCT02290327|Drug|Placebo|50 ml of 0.9% normal saline
221784|NCT02290340|Drug|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life.
220837|NCT02304484|Biological|Evolocumab|All subjects will receive open-label evolocumab for approximately 2 years (or until the investigator's recommendation of discontinuation, Amgen's recommendation of discontinuation, the subject's decision to discontinue for any reason, or until an administrative decision is made to end the study).
220838|NCT02304497|Other|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
221126|NCT02297425|Drug|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
221127|NCT02297438|Drug|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
221128|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
221129|NCT02297438|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
221130|NCT02299739|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
221131|NCT02299739|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
221132|NCT02299739|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
221133|NCT02299739|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
221134|NCT00151372|Behavioral|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
221135|NCT02299739|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
221136|NCT02299752|Procedure|single-gloving system|single-gloving system was used during Catheterization
220534|NCT02309424|Other|Placebo|50 ml water
220535|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
220536|NCT02311985|Other|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex <80 sec. and A10ex >40 mm, then no blood transfusion is performed; when CTex >80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex <40 mm or A10fib >10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex <40 mm or A10fib <10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
220537|NCT02311985|Other|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR >5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
220538|NCT02311998|Drug|Bosutinib|Phase I Dose Escalation - Starting dose of Bosutinib at 300 mg by mouth once daily in a 28 day cycle.
Phase II Dose Expansion - Starting dose of Bosutinib is maximum tolerated dose from Phase I Dose Escalation.
220539|NCT02311998|Drug|Inotuzumab Ozogamicin|Phase I Dose Escalation and Phase II Dose Expansion - Inotuzumab Ozogamicin given by vein on a weekly schedule 0.8 mg/m2 by vein Day 1, 0.5 mg/m2 Day 8, and 0.5 mg/m2 Day 15 in a 28 day cycle.
220540|NCT02311998|Behavioral|Phone Call|After end of treatment visit, participants called 1 time about every 12 weeks for up to 1 year, and asked about any anti-cancer therapy they may have started. This call will last about 5 minutes.
220541|NCT00152633|Drug|Losartan|
220542|NCT02312011|Drug|IONIS-DMPKRx|Drug
220839|NCT02304523|Drug|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
220840|NCT02304523|Drug|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
220841|NCT00151892|Drug|SPD476|2.4 g/day Once Daily (QD)
220842|NCT02304523|Drug|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
220843|NCT02304536|Drug|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
220844|NCT02304536|Procedure|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
220231|NCT02277782|Drug|Fentanyl|
220232|NCT02277795|Device|AccuCirc|Circumcision with the use of the AccuCirc device.
220233|NCT02277808|Drug|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
220234|NCT02277808|Device|Respirgard II|
220235|NCT02277808|Device|Isoneb®|
220236|NCT02280070|Other|Endoscopy|Endoscopy for lower digestive tract
220237|NCT02280070|Other|HBs antibody and HBc antibody|Check according to hepatitis B guideline
220238|NCT02280070|Drug|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
220239|NCT02280070|Drug|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
220240|NCT02280070|Drug|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
220241|NCT02280070|Drug|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
220242|NCT02280070|Drug|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
220243|NCT00149110|Procedure|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
220543|NCT02312011|Drug|Placebo|Placebo
220544|NCT02312024|Device|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
220545|NCT02312037|Biological|Antibody Drug Conjugate Chemotherapeutic|Three Treatment Regimens:
Mylotarg <=9 mg/m2 as a single agent on Day 1 & 14 of a 28-day cycle for a total of two cycles
Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen
Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL
220546|NCT02312050|Drug|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
220547|NCT02312050|Drug|Placebo|
220548|NCT02312063|Drug|Sitagliptin|
220549|NCT02312063|Drug|Glimepiride|
219906|NCT02285049|Other|Urticaria Control Test|The patients get the 1st UAS28 form and four-week appointment to follow up.
Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)
Then patients fill the 1st UCT and DLQI questionnaire by themselves.
The patients get the 2nd UAS28 form and four-week appointment to follow up.
At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves.
219907|NCT02285062|Drug|lenalidomide|
219908|NCT02285062|Drug|Placebo|
219909|NCT02285062|Drug|Rituximab|
219910|NCT00149669|Behavioral|Contingency management|
219911|NCT02285062|Drug|Cyclophosphamide|
219912|NCT02285062|Drug|Doxorubicin|
219913|NCT02285062|Drug|prednisone|
219914|NCT02285062|Drug|vincristine|
219915|NCT02285075|Drug|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T > MIC of 8 and 16 mg/L).
219916|NCT02285088|Drug|GBT440|GBT440 will be administered as oral capsules
219917|NCT02285088|Drug|Placebo|Matching placebo will be administered as oral capsules
219918|NCT02285101|Biological|PEG-BCT-100|
219919|NCT02285114|Drug|F/TAF|F/TAF tablets administered orally once daily
219920|NCT02285114|Drug|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets administered orally once daily
219921|NCT00002374|Drug|Stavudine|
219922|NCT02287454|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
219333|NCT02298946|Drug|Cyclophosphamide|200mg/m2 IV on day 0
219334|NCT02298959|Other|Laboratory Biomarker Analysis|Correlative studies
219335|NCT02298959|Biological|Pembrolizumab|Given IV
219336|NCT02298959|Biological|Ziv-Aflibercept|Given IV
219337|NCT02298972|Behavioral|Nurse support and selfmanagement intervention|
219623|NCT02291848|Biological|TAA-specific CTLs|Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:
Dose Level One:
Day 0: 5 x 10^6 cells/m2 and Day 14: 5 x 10^6 cells/m2
Dose Level Two:
Day 0: 1 x 10^7 cells/m2 and Day 14: 1 x 10^7 cells/m2
Dose Level Three:
Day 0 2 x 10^7 cells/m2 and Day 14 2 x 10^7 cells/m2
Dose Level Four:
Day 0 4 x 10^7 cells/m2 and Day 14 4 x 10^7 cells/m2
If patients with active disease have stable disease or a partial response by the International Working Group (IWG) criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion.
219624|NCT02291861|Drug|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks.
219625|NCT02291861|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks
219626|NCT02291874|Drug|Ipragliflozin|oral
219627|NCT02291887|Drug|Ranibizumab|Intravitreal injection of Ranibizumab
219628|NCT02291887|Drug|Aflibercept|Intravitreal injection of Aflibercept
219629|NCT02291900|Procedure|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
219630|NCT00150527|Behavioral|Cold Pressor Test|single test
219631|NCT02291913|Drug|Everolimus|
219632|NCT02291913|Drug|Exemestane|Anti-estrogen therapy
219633|NCT02291913|Drug|Tamoxifen|Anti-estrogen therapy
219634|NCT02291913|Drug|Fulvestrant|Anti-estrogen therapy
219635|NCT02291913|Drug|Anastrozole|Anti-estrogen therapy
219636|NCT02291913|Drug|Letrozole|Anti-estrogen therapy
219637|NCT02291913|Drug|Toremifine|Anti-estrogen therapy
219638|NCT02294357|Drug|Prednisone|f the patient was receiving prednisone, at the equivalent of > 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
219029|NCT02303704|Procedure|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
219030|NCT02303704|Procedure|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
219031|NCT00152074|Behavioral|Reduce salt intake|
219032|NCT02306161|Biological|Ganitumab|Given IV
219033|NCT02306161|Drug|Ifosfamide|Given IV
219034|NCT02306161|Other|Laboratory Biomarker Analysis|Correlative studies
219035|NCT02306161|Other|Pharmacological Study|Correlative studies
219036|NCT02306161|Radiation|Stereotactic Radiosurgery|Undergo SBRT
219037|NCT02306161|Procedure|Therapeutic Surgical Procedure|Undergo surgery
219038|NCT02306161|Drug|Vincristine Sulfate|Given IV
219039|NCT02306174|Behavioral|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|
219338|NCT02298985|Drug|Curcumin|3 g/day (3 capsules/day) for 6 months
219339|NCT02298985|Drug|placebo|3 g/day (3 capsules/day) for 6 months
219340|NCT02298998|Other|EAU surveillance|Patients randomized into the intervention group will follow the EAU surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
219341|NCT02299011|Device|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
219342|NCT00151281|Drug|Rituximab, Thalidomide, Prednisone, Etoposide, Procarbazine, Cyclophosphamide|Induction phase (month 1-3)
PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC < 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.
Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.
Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.
Maintenance phase (month 4-12)
Daily low dose thalidomide (50-100 mg/d)
PEPC QOD or fractionated weekly basis.
Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.
Post-Month 12 Maintenance phase (post-month 12 until disease progression)
Daily low dose thalidomide (50-100mg/d)
PEPC QOD or fractionated weekly basis
Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months
219343|NCT02299011|Drug|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
223875|NCT02189759|Other|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
223876|NCT02192463|Drug|NVP ER 300 mg (KCR 30%) Slow Release|
223877|NCT00138788|Procedure|Radiotherapy, dose fractionation|
223878|NCT02192463|Drug|NVP ER 400 mg (KCR 25%) Medium Release|
223879|NCT02192463|Drug|NVP ER 300 mg (KCR 40%) Slow Release|
223880|NCT02192463|Drug|NVP ER 300 mg (ECR 20%) Fast Release|
223881|NCT02192463|Drug|NVP ER 400 mg (KCR 20%) Medium Release|
223882|NCT02192463|Drug|NVP ER 400 mg (KCR 30%) Slow Release|
223883|NCT02192463|Drug|NVP ER 400 mg (KCR 40%) Slow Release|
223884|NCT02192463|Drug|NVP ER 400 mg (ECR 20%) Fast Release|
223885|NCT02192463|Drug|Nevirapine immediate release (IR) 200 mg|
223886|NCT02192476|Other|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
223887|NCT02192476|Other|California tri-pull taping (CTPT)|Two types of tape was used, a self-adhesive 1.5ʺ cotton undercover tape and a 1ʺ rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape.
223888|NCT00138801|Drug|Ceftriaxone|
223889|NCT02192489|Drug|CC-220 0.3 mg Daily|
223890|NCT02192489|Drug|CC-220 0.6mg Daily|
223891|NCT02192489|Drug|Placebo|
219040|NCT02306187|Drug|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
223237|NCT02163954|Drug|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
223549|NCT02156089|Other|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
223550|NCT02156128|Behavioral|Cogmed working memory training|
223551|NCT02156128|Behavioral|Control group|
223552|NCT02156141|Other|Supervised high intensity training|8 weeks of supervised training
223553|NCT02156141|Other|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
223554|NCT00134667|Drug|Macugen (pegaptanib sodium)|
223555|NCT02156141|Other|Control period|8 weeks with no training.
223556|NCT02158936|Drug|Azacitidine|Subcutaneous Injection (IV if local standard)
223557|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets will be supplied
223558|NCT00134992|Drug|Prednisolone acetate|
223559|NCT02158949|Behavioral|mROAD|
223560|NCT02158962|Behavioral|Behavioral - Education|Behavioral - Education
3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections
223561|NCT02158975|Drug|MLN9708|
223562|NCT02158988|Procedure|HIPEC|HIPEC:
Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.
223563|NCT02159001|Device|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
223564|NCT02159014|Behavioral|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
223565|NCT02159014|Behavioral|Online, video prompted, individual aerobic dance|Supported online activity intervention
223566|NCT02159014|Behavioral|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
223567|NCT02159014|Behavioral|Self-paced online aerobic dance activity|Self paced physical activity
223568|NCT02159014|Behavioral|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
220374|NCT02294630|Drug|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
220375|NCT02294643|Drug|Sarpogrelate|
220376|NCT02294643|Drug|Aspirin|
220377|NCT00150852|Drug|Vancomycin|
220378|NCT02294643|Drug|Clopidogrel|
220379|NCT02294643|Drug|Placebo (for Sarpogrelate)|
220380|NCT02294656|Drug|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
220381|NCT02294656|Drug|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
220382|NCT02294669|Device|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
220383|NCT02294682|Drug|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
220384|NCT02294708|Behavioral|postoperative postures|two postoperative postures: supine and temporal-lateral
220686|NCT02287857|Drug|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
220687|NCT02287870|Drug|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
220688|NCT02287870|Drug|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
220689|NCT02287883|Other|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
220690|NCT02287896|Drug|ROLEDUMAB|See Arm description
220691|NCT02287909|Drug|Clopidogrel|Swiching from ticagrelor to clopidogrel
220692|NCT02287909|Drug|Ticagrelor|Continue treatment with ticagrelor
220054|NCT02299375|Drug|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
220055|NCT00151333|Drug|SRA-333|
220056|NCT02299388|Drug|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
220057|NCT02299401|Drug|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
220058|NCT02299401|Device|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
220059|NCT02299414|Other|Anti-hypertensive therapy|1st line anti-hypertensive (labetalol) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER)
220060|NCT02299414|Other|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains <160/105; for blood pressure ≥160/105, treatment with labetalol will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
220061|NCT02299427|Behavioral|dog safety|use of dog safety website at home for about 2 weeks
220062|NCT02299427|Behavioral|transportation safety|use of transportation safety website at home for about 2 weeks
220063|NCT02301481|Procedure|Surgery|Surgery, preferred D2 lymphadenectomy
220064|NCT02301481|Drug|SOX|SOX (S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
220065|NCT02301494|Drug|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
220066|NCT02301494|Drug|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
220067|NCT02301507|Behavioral|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
220068|NCT00151554|Behavioral|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
219457|NCT02314065|Behavioral|CBT, exposure and response prevention (Face-to-face)|This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week.
219458|NCT02314065|Behavioral|CBT, exposure and response prevention (Internet-based)|This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system.
219459|NCT02314091|Procedure|onlay mesh hernioplasty|
219460|NCT02314104|Drug|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
219461|NCT02314117|Drug|Ramucirumab|Administered IV
219462|NCT02314117|Drug|Capecitabine|Administered orally
219463|NCT02314117|Drug|Cisplatin|Administered IV
219464|NCT02314117|Drug|Placebo|Administered IV
219756|NCT02306499|Procedure|ICSI|Intracytoplasmic Sperm Injection
219757|NCT02306512|Procedure|H&E|Sample will be stained with H&E according to standard procedures
219758|NCT02306512|Procedure|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
219759|NCT02306512|Procedure|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
219760|NCT02306512|Procedure|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
219761|NCT02306525|Procedure|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
219762|NCT02306551|Other|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
219763|NCT02306564|Drug|Cabergoline|given to patients at high risk for OHSS
219764|NCT00152113|Procedure|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
219765|NCT02306577|Drug|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
219766|NCT02306590|Dietary Supplement|Calogen|
219155|NCT02279784|Device|Freeway PTA|angioplasty with Freeway drug-eluting balloon
219156|NCT02282189|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
219157|NCT02282202|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
There is only one intervention for this study. Subjects are "on" treatment for three weeks and "off" for the alternate three weeks.
219158|NCT02282215|Biological|CLT-008|Single intravenous infusion
219159|NCT02282215|Biological|G-CSF|Daily subcutaneous injections
219160|NCT02282228|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
219161|NCT00149305|Other|Genetic analyses|
219162|NCT02282241|Drug|Melatonin|
219163|NCT02282241|Other|Placebo|
219164|NCT02282254|Other|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
219165|NCT02282267|Drug|Gefitinib|
219465|NCT00152763|Other|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
219466|NCT02314117|Drug|Fluorouracil|Administered IV
219467|NCT02314130|Dietary Supplement|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
219468|NCT02314143|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
223684|NCT00136422|Biological|autologous tumor cells|
223685|NCT02171390|Drug|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
223686|NCT02171390|Drug|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
223687|NCT02171416|Drug|Rilonacept|
223688|NCT02171416|Drug|Placebo|
223689|NCT02171429|Drug|adalimumab|160 mg administered SC at Week 0; 80 mg administered SC at Week 2; 40 mg SC at Weeks 4, 6 and 8
223690|NCT02171429|Other|adalimumab placebo|Administered SC at Weeks 0, 2, 4, 6 and 8
223691|NCT02171429|Drug|etrolizumab|105 mg administered SC Q4W
223692|NCT02171429|Other|etrolizumab placebo|Administered SC Q4W
223693|NCT02171442|Drug|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
223694|NCT02171442|Drug|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
223695|NCT00136435|Drug|prednisone|Induction Phase: Given orally on days 1-28
223696|NCT02171455|Drug|Dabigatran etexilate low dose|
223697|NCT02171455|Drug|Dabigatran etexilate medium dose|
223698|NCT02171455|Drug|Dabigatran etexilate high dose|
223699|NCT02171455|Drug|Placebo|
223700|NCT02171468|Drug|Dabigatran high dose|
223701|NCT02171468|Drug|Dabigatran low dose|
223702|NCT02171481|Drug|Dabigatran etexilate polymorph II|
223703|NCT02171481|Drug|Dabigatran etexilate polymorph I|
223704|NCT02171494|Drug|IVAX Warfarin|
218860|NCT02287012|Other|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
218861|NCT02287025|Drug|Regorafenib (Stivarga, BAY 73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
222738|NCT02189317|Drug|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
222739|NCT02189330|Drug|Tafamidis|20 mg of current commercial formulation.
223045|NCT02184572|Biological|Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine|1 dose administered SC in the tricep region of left arm.
223046|NCT02184572|Biological|Varivax® (Merck & Co., Inc.)|1 dose administered SC in the tricep region of right arm at Visit 1 (Day 0), with either Inv_MMR vaccine or one of the two Com_MMR vaccine lots.
223047|NCT02184572|Biological|Havrix®|1 dose administered intramuscularly (IM) in the anterolateral region of the right thigh at Visit 1 (Day 0), with either Inv_MMR vaccine or one of the two Com_MMR vaccine lots.
223048|NCT00002288|Drug|Zidovudine|
223049|NCT00137943|Behavioral|Full Parent communication intervention|
223050|NCT02184572|Biological|Prevnar 13® (Pfizer Inc.)|1 dose administered IM in the anterolateral region of the left thigh at Visit 1 (Day 0), with either Inv_MMR vaccine or one of the two Com_MMR vaccine lots in US children only.
223051|NCT02184585|Drug|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
223052|NCT02184585|Drug|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
223053|NCT02184585|Drug|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
223054|NCT02184598|Behavioral|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
223055|NCT02184598|Behavioral|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
223056|NCT02184611|Drug|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
223057|NCT02184611|Drug|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
223058|NCT02184624|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
223059|NCT02184624|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
222074|NCT02283437|Behavioral|Psychoeducation Group Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) psychoeducation programs for schizophrenia.
222075|NCT00149513|Behavioral|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
222076|NCT02283450|Drug|Qiliqiangxin Capsule|
222077|NCT02283463|Device|Intrauterine device (IUD) insertion|
222078|NCT02283463|Procedure|Endometrial biopsy|
222079|NCT02283476|Drug|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
222080|NCT02283476|Drug|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
222081|NCT02283476|Drug|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
222399|NCT02197026|Drug|Standard treatment|Standard drug treatment at the discretion of the investigator
222400|NCT02197026|Procedure|Physiotherapy|
222401|NCT02197026|Procedure|Hydrotherapy|
222402|NCT00139373|Drug|donepezil|
222403|NCT02197039|Drug|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
222404|NCT02197039|Procedure|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
222405|NCT02197065|Drug|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
222406|NCT02197065|Drug|Placebo|
222407|NCT02197091|Other|questionnaire administration|Ancillary studies
222408|NCT02197091|Other|medical chart review|Ancillary studies
221785|NCT02290340|Drug|Placebo|Solution containing no active ingredients.
221786|NCT02290353|Device|FEATHERS|FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer [2]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.
During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants.
221787|NCT02290366|Radiation|Focal prostate brachytherapy with Cesium-131|
221788|NCT02290379|Drug|TNX-201 35 mg|Drug: TNX-201 35 mg
221789|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, deferred treatment
221790|NCT02290379|Drug|TNX-201 70 mg|Drug: TNX-201 70 mg
221791|NCT02290379|Drug|TNX-201 140 mg|Drug: TNX-201 140 mg
221792|NCT02290379|Drug|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
221793|NCT02290379|Drug|Placebo|Drug: Placebo
221794|NCT02290405|Behavioral|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
221795|NCT02290418|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
222082|NCT02283476|Drug|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
222083|NCT02283489|Drug|recombinant human endostatin adenovirus|Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).
Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study.
222084|NCT02283489|Drug|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
222085|NCT02285920|Drug|Spironolactone|The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
222086|NCT00002375|Drug|Indinavir sulfate|
221137|NCT02299752|Procedure|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
221138|NCT02299765|Drug|Gefitinib|patients in arm A will be given gefitinib as target therapy
221139|NCT02299765|Drug|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
221140|NCT02299765|Drug|carboplatin|patients in arm A will be given carboplatin chemotherapy
221459|NCT02295215|Other|Exercise|Exercise Training for 4 months
221460|NCT02295228|Other|No intervention|There are no interventions. This is an observational trial.
221461|NCT02295241|Other|No intervention|This is an observational trial, no interventions are being used.
221462|NCT00150904|Procedure|venous blood puncture|
221463|NCT02295254|Other|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
221464|NCT02295267|Other|walnut allergy provocation|double blind placebo controlled food challenge
221465|NCT02295280|Drug|Metoclopramide|IV
221466|NCT02295280|Drug|Diphenhydramine|iv
221467|NCT02295280|Drug|Codeine|PO
221468|NCT02295293|Drug|Rhus Coriaria L. (Sumac)|500 mg of Rhus Coriaria L. (Sumac) powder in capsule: 1 capsule twice daily for 6 weeks
221469|NCT02295293|Drug|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
221470|NCT02295306|Device|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
221471|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
221472|NCT00151138|Drug|Atenolol (drug), Lisinopril (drug)|
221473|NCT02297451|Procedure|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
221474|NCT02297464|Other|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
221475|NCT02297464|Other|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
220845|NCT02304562|Biological|UCB Mesenchymal Stem Cells treatment|reduce skin injury
220846|NCT02304575|Other|Questionnaires|Questionnaires:
For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.
For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory.
220847|NCT02304575|Other|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
220848|NCT02307019|Other|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
220849|NCT02307019|Other|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
220850|NCT02307045|Drug|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
220851|NCT02307045|Drug|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
220852|NCT00152139|Procedure|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
221141|NCT02299778|Dietary Supplement|13C6-p-aminobenzoic acid|
221142|NCT02299791|Other|ALL|This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.
EHR tools to expedite identification
a. EHR automated point-of-care alerts (Best Practice Alerts)
EHR tools to expedite prescribing
EHR order sets
EHR text shortcuts for notation
patient education materials (handout, poster)
EHR-based outreach support tools a. EHR registries
221143|NCT02299791|Other|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
221144|NCT02299804|Drug|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
221145|NCT00151385|Procedure|single blood draw|
221146|NCT02299804|Drug|Placebo|No active ingredient
221147|NCT02301975|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
221148|NCT02301975|Drug|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
221149|NCT02301975|Drug|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
220550|NCT02312076|Drug|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
220551|NCT02312089|Drug|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
220552|NCT00152633|Drug|Metoprolol|
220553|NCT02312102|Drug|Lenalidomide|Chemotherapy
220554|NCT02312102|Drug|Velcade|Chemotherapy
220555|NCT02312115|Drug|Furosemide|Diuretic
220556|NCT02312115|Drug|Placebo|Saline
220557|NCT02312128|Other|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
220558|NCT02312128|Radiation|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
220559|NCT02314455|Other|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
220560|NCT02314468|Procedure|Negative pressure wound therapy|NPWT changed twice a week.
220561|NCT02314468|Procedure|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
220562|NCT02314481|Drug|MPDL3280A|Intravenous (IV) infusion
220563|NCT02314481|Drug|Vemurafenib|Film coated tablet
220853|NCT02307058|Radiation|LEAD RT|LEAD RT: Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over ~8 weeks. The multiparametric-MRI (MP-MRI) defined gross tumor volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SVs, usually 7-10 mm and/or <= 50%, whichever is less), the CTV1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full IMRT dose of 76 Gy, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
220854|NCT02307058|Radiation|HEIGHT RT|HEIGHT RT: Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 38 fractions over ~7.5 weeks. The MRI defined GTV will receive a higher dose per day than the clinical tumor volume (CTV) by dose painting. The GTV will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles CTV1 will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full IMRT dose of 76 Gy, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
219923|NCT02287467|Biological|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
219924|NCT02287467|Biological|Placebo for IVIG|Administered IV as 500 mL of normal saline
220244|NCT02280083|Drug|Botulinum Toxin Type A for Injection|HengLi002(Botulinum Toxin Type A for Injection,also known as "HengLi®")
220245|NCT02280083|Drug|placebo|placebo
220246|NCT02280096|Drug|4-aminopyridine|Each patient will take two capsules every 6 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study. After 22 weeks of treatment and 2 weeks of wash-out period, this group of patients will start placebo branch.
220247|NCT02280096|Drug|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
220248|NCT02280109|Drug|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
220249|NCT02280109|Drug|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
220250|NCT02280122|Other|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
220251|NCT02280135|Biological|Intravitreal injection of Autologous bone marrow Stem Cell|We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.
After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.
After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.
220252|NCT02280135|Other|Subconjunctival injection of saline|In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.
After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.
220253|NCT02280148|Procedure|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
220254|NCT00149110|Behavioral|Exercise|Moderate intensity daily exercise for 30 minutes at least
220255|NCT02280148|Device|Driving Simulator|
220256|NCT02282644|Biological|Bone marrow sampling|
219639|NCT02294357|Drug|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of > 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
219640|NCT02294396|Drug|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
219641|NCT02294396|Drug|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (may be increased to 2 tablets)
219642|NCT00150826|Drug|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
219643|NCT02294396|Drug|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (may be increased to 1 tablet twice daily after breakfast and after dinner)
219925|NCT02287480|Biological|VSV-ZEBOV|See arm/group descriptions.
219926|NCT02287493|Other|Pharmacokinetic Analysis|
219927|NCT02287506|Other|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
219928|NCT02287519|Behavioral|Group Session|
219929|NCT00149890|Drug|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
219930|NCT02287519|Behavioral|Telephone Coaching Session|
219931|NCT02287519|Behavioral|Webinar|
219932|NCT02287532|Device|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
219933|NCT02287545|Procedure|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
219934|NCT02287558|Drug|Pomalidomide|
219935|NCT02287571|Device|Derotation splint|This group is the actual intervention group.
219936|NCT02287571|Device|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
219937|NCT02287584|Drug|DSP-5423P|
219344|NCT02299024|Behavioral|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
219345|NCT02299050|Drug|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
219346|NCT02299063|Drug|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
219347|NCT02299063|Drug|0.9% NaCl|
219348|NCT02299076|Behavioral|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
219349|NCT02299076|Other|Minimal incentives|Minimal incentives to promote engagement, and outcomes in a smoking cessation intervention.
219350|NCT02299089|Drug|octreotide FluidCrystal® injection depot|
219351|NCT02301234|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
219352|NCT02301234|Drug|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
219353|NCT02301234|Drug|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
219354|NCT02301247|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
219355|NCT00151528|Drug|Pregabalin|
219644|NCT02294396|Drug|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (may be increased to 2 tablets twice daily after breakfast and after dinner)
219645|NCT02294396|Drug|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (must not be increased)
219646|NCT02294409|Behavioral|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
219041|NCT02306213|Drug|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
219042|NCT00152087|Device|Brachytherapy|
219043|NCT02306213|Other|standard volume therapy|
219044|NCT02306239|Drug|Terlipressin|
219045|NCT02306239|Drug|Norepinephrine|
219046|NCT02306252|Other|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
219047|NCT02306265|Device|Full-Field Digital Mammogram|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
219048|NCT02306265|Device|Digital Breast Tomosynthesis|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
219049|NCT02306278|Drug|gabapentin|gabapentin capsules 0.3g
219050|NCT02306278|Drug|vitamin capsules|
219051|NCT02306291|Drug|GMI-1271|Dose escalation
219052|NCT02306291|Drug|GMI-1271|Dose expansion
219053|NCT00152100|Procedure|Stem cell transplant|
219054|NCT02306291|Drug|GMI-1271|Safety run-in then dose expansion
219055|NCT02306304|Other|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
219056|NCT02306317|Other|Standard procedure|FiO2 manually controlled by nursing
219057|NCT02306317|Other|Experimental procedure|FiO2 manually controlled by parents, after training.
219058|NCT02306330|Device|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
219059|NCT02306330|Other|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
219060|NCT02308566|Procedure|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
219061|NCT02308566|Procedure|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
223569|NCT00002263|Drug|Sargramostim|
223570|NCT00135005|Drug|AMN107, STI571|
223571|NCT02159027|Drug|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
223572|NCT02159027|Drug|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
223892|NCT02192502|Drug|human albumin 5%|
223893|NCT02192502|Drug|HES 130/0.4 (Voluven)|
223894|NCT02192515|Drug|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
223895|NCT02192515|Drug|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
223896|NCT02192515|Drug|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
223897|NCT02192515|Drug|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
223898|NCT02192515|Drug|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
223899|NCT00138801|Drug|Doxycycline|
223900|NCT02192515|Drug|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
223901|NCT02192515|Drug|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
223902|NCT02192515|Drug|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
223903|NCT02194933|Drug|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
223904|NCT02194946|Drug|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
223905|NCT02194946|Drug|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
223906|NCT02194959|Behavioral|Peer PN|Navigation by Peer Patient Navigators
220693|NCT00149968|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
220694|NCT02287922|Biological|ALX-0061|
220695|NCT02287922|Biological|Placebo|
220696|NCT02287922|Biological|Tocilizumab|
220697|NCT02287935|Procedure|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
220698|NCT02289911|Other|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
220699|NCT02289924|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
220700|NCT02289937|Drug|Ropivacaine|
220701|NCT02289937|Drug|Placebo|
220702|NCT02289937|Device|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
220703|NCT02289950|Drug|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
220704|NCT02289950|Drug|Placebo|Placebo will be administered intravenously (IV) weekly
220705|NCT02289963|Drug|alirocumab SAR236553/REGN727|Pharmaceutical form:solution for injection Route of administration: subcutaneous
220706|NCT02289963|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
220707|NCT00150280|Drug|celecoxib and ibuprofen SR|
220991|NCT02282956|Drug|morphine and droperidol|i.v PCA
220992|NCT02282969|Behavioral|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
220993|NCT02282969|Behavioral|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
220994|NCT02282982|Drug|Palivizumab|Palivizumab is a humanized IgG1 monoclonal antibody specific for the F-glycoprotein on the RSV surface.
220995|NCT02283008|Behavioral|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
220385|NCT02294721|Device|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
220386|NCT02294721|Device|The CPREazy|feedback device-1
220387|NCT02294721|Device|TrueCPR|feedback device -2
220388|NCT00150865|Drug|ropivacaine|
220389|NCT02294721|Device|The CPR PRO APP|feedback device -3
220390|NCT02294721|Device|The CardioPump|feedback device- 4
220391|NCT02294734|Drug|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
220392|NCT02294734|Drug|Placebo|Dry powder for inhalation via DISKUS 'device'
220393|NCT02294747|Device|Sliding Hip Screw with Trochanteric Stabilization Plate|
220394|NCT02294747|Device|Sliding Hip Screw without Trochanteric Stabilization Plate|
220395|NCT02294760|Device|Subsensory|The stimulation is set to 90% of the sensory threshold.
220396|NCT02294760|Device|OFF|The stimulation is turned OFF.
220397|NCT02294773|Procedure|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
220398|NCT02294773|Drug|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
220399|NCT00150878|Other|Conditioning therapy|Preparation before allogeneic transplantation
220400|NCT02297074|Other|Wholemeal Bread|The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
220401|NCT02297074|Other|Glucose|50 g of glucose were administered as a reference
220402|NCT02297087|Genetic|Standard of care based on target(s) identified via GWS.|
220403|NCT02297100|Drug|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
220404|NCT02297100|Procedure|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
219767|NCT02306590|Dietary Supplement|Placebo|
219768|NCT02306603|Procedure|Endoscopic Mucosal Resection|
219769|NCT02308891|Drug|lactated Ringer's solution (standard hydration arm)|- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
219770|NCT02308891|Device|endoscopic retrograde cholangiopancreatography (ERCP)|endoscopic retrograde cholangiopancreatography
219771|NCT02308904|Other|Blood Draw/Semen Exam|Females:
1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.
Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.
Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older).
219772|NCT02308904|Other|Retrospective data/Chart Review/Relevant Clinical Results|1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2* MRI. 4. Ferritin levels.
NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.
1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.
1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).
Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement.
220069|NCT02301533|Behavioral|Shikamana Intervention|See arm description
220070|NCT02301533|Behavioral|Standard Care|See arm description
220071|NCT02301546|Behavioral|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
220072|NCT02301559|Behavioral|Pilates exercises|Pilates exercises with emphasis on pelvic region
220073|NCT02301585|Procedure|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
220074|NCT02301585|Procedure|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
220075|NCT02301598|Procedure|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
220076|NCT02301611|Drug|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
220077|NCT02301611|Drug|Placebo|
220078|NCT02301624|Biological|Eculizumab|Open-Label eculizumab 1200mg IV every 2 weeks
219469|NCT02314143|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
219470|NCT02314156|Drug|Telapristone Acetate|Given transdermally
219471|NCT02314156|Other|Placebo|Given PO
219472|NCT02314156|Drug|Telapristone Acetate|Given PO
219473|NCT02314156|Other|Placebo|Given transdermally
219474|NCT02314156|Other|Laboratory Biomarker Analysis|Correlative studies
219475|NCT02314156|Other|Questionnaire Administration|Ancillary studies
219476|NCT00152776|Drug|ovaria comp 10 globuli 3 times per day|
219477|NCT02314169|Other|Laboratory Biomarker Analysis|Correlative studies
219478|NCT02314169|Biological|Nivolumab|Given IV
219479|NCT02277314|Procedure|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
219480|NCT02277327|Behavioral|Plans of Action and Care Transitions|Subjects randomized to the "intervention" will participate in action planning and care transitions (if hospitalized during the study period)
219481|NCT02277327|Behavioral|Routine Care|Subjects randomized to the "control" group will continue to receive routine care within the medical home program
219482|NCT02277340|Procedure|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
219483|NCT02277353|Other|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
219773|NCT02308904|Other|Pituitary MRI|MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.
MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted.
219774|NCT00002386|Drug|Indinavir sulfate|
219775|NCT00152295|Drug|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
219776|NCT02308930|Dietary Supplement|Vitamins + DHA supplement (Vitamins A,D, E and algal oil)|
218862|NCT02287064|Drug|Intravenous Immune Globulin (IVIG)|IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.
There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from "induction dose" IVIG (2 g/kg) continued each month, than with the "booster dose" maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion
218863|NCT00149838|Procedure|Lower Dose rTMS|Participants who are unresponsive to Phase I treatment with rTMS will continue a lower dose of rTMS for an additional 3 to 7 weeks in Phase II.
218864|NCT02287077|Procedure|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
218865|NCT02287090|Other|Observational Cohort|
218866|NCT02287103|Other|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
218867|NCT02287103|Other|Eating Breakfast|YesB: will eat all three meals
218868|NCT00150150|Procedure|Interstitial laser photocoagulation|
218869|NCT02289196|Drug|Vx-006: 0,5mg|
218870|NCT02289196|Drug|Vx-006: 1mg|
218871|NCT02289196|Drug|Vx-006: 5mg|
218872|NCT02289209|Radiation|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
218873|NCT02289209|Drug|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
218874|NCT02289222|Drug|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
218875|NCT02289222|Drug|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
218876|NCT02289222|Drug|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
218877|NCT02289235|Drug|Ginger|Ginger powder capsule 500 mg daily for 3 months
218878|NCT02289235|Drug|Placebo|Placebo powder 1 capsule daily for 3 months
219166|NCT02282280|Drug|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
219167|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
223060|NCT00137943|Behavioral|Brief Parent Communication Intervention|
223061|NCT02184624|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
223062|NCT02184624|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
223063|NCT02184624|Device|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
223347|NCT00137267|Behavioral|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
223348|NCT02179411|Other|tilt test|
223349|NCT02179424|Behavioral|Motivational intervention|Use motivational interview strategies to provide smoking cessation intervention
223350|NCT02179476|Device|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation at a single lumbar facet level
223351|NCT02179489|Procedure|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
223352|NCT02179502|Drug|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
223353|NCT02179502|Drug|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
223354|NCT02179502|Drug|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
223355|NCT02179502|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
223356|NCT02179515|Biological|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
223357|NCT02179528|Drug|Etoposide|
223358|NCT00137280|Behavioral|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
223359|NCT02179541|Other|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
222409|NCT02197104|Drug|citocoline|
222410|NCT02197117|Device|Remote ischemic conditioning|
222411|NCT02197117|Device|Control|
222412|NCT02197130|Drug|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
222413|NCT00139386|Drug|Candesartan|Candesartan Cilexetil (4-12 mg per day)
222414|NCT02197130|Drug|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
222415|NCT02197130|Other|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
222416|NCT02197143|Drug|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
222417|NCT02197143|Drug|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
222740|NCT02189330|Drug|Tafamidis|12.2 mgA free acid tablet.
222741|NCT02189330|Drug|Tafamidis|20 mg new soft gelatin capsule.
222742|NCT00138385|Biological|Fluzone|
222743|NCT02189330|Drug|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
222744|NCT02189330|Drug|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
222745|NCT02189343|Drug|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
222746|NCT00138736|Drug|Mannan Binding Lectin (MBL)|
222747|NCT02191995|Behavioral|yoga|
222748|NCT02192008|Biological|Salmonella Typhi|
222749|NCT02192008|Biological|Salmonella Paratyphi|
222750|NCT02192021|Drug|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
222751|NCT02192034|Behavioral|Navigation|
222087|NCT00149760|Behavioral|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
222088|NCT02285933|Other|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
222089|NCT02285933|Other|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
222090|NCT02285946|Procedure|major spine surgery|
222091|NCT02285959|Drug|Bevacizumab|
222092|NCT02285972|Drug|saline|before the anesthesia induction, 2mL saline iv injection
222093|NCT02285972|Drug|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
222094|NCT02285972|Drug|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
222095|NCT02285985|Drug|Saxagliptin|Tablets: 5 mg
222096|NCT02285985|Drug|Placebo|Tablets: 5mg
222097|NCT02285998|Biological|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
222098|NCT00149773|Behavioral|Cognitive Therapy|
222099|NCT02285998|Biological|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
222418|NCT02197143|Drug|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
222419|NCT02197156|Drug|10 mg HC-ER|Single dose
222420|NCT02197156|Drug|20 mg HC-ER|Single dose
222421|NCT02197156|Drug|30 mg HC-ER|Single dose
221476|NCT02297477|Drug|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
221477|NCT02297477|Drug|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
221478|NCT02297490|Drug|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
221479|NCT02297490|Biological|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
221480|NCT02297503|Drug|Azzalure|Glabellar lines
221796|NCT02290418|Procedure|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
221797|NCT02290431|Drug|LBH589 (panobinostat)|
221798|NCT02290431|Drug|bortezomib|
221799|NCT02290431|Drug|dexamethasone|
221800|NCT00150358|Drug|Sildenafil Citrate|
221801|NCT02290444|Drug|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
221802|NCT02292771|Drug|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
221803|NCT02292771|Drug|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
221804|NCT02292771|Drug|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
221805|NCT02292771|Drug|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
221806|NCT02292784|Drug|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
221807|NCT02292784|Drug|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
221808|NCT00150618|Drug|Placebo|
221150|NCT02301988|Drug|Ipatasertib|400 mg daily oral administration on Days 1-21, every 28 days for 3 cycles
221151|NCT02301988|Drug|Paclitaxel|80 mg/m2 intravenous infusion on Days 1, 8, 15, and 22 of each 4-week cycle, for a total of 3 cycles of treatment
221152|NCT02301988|Drug|Placebo|Matching placebo to ipatasertib, oral administration daily on Days 1-21, every 28 days for 3 cycles
221153|NCT02302001|Device|Silicone Implant|
221154|NCT02302014|Other|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
221155|NCT00151606|Procedure|Reinforced isolation + Muciprocine|
221156|NCT02302027|Device|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 * 67 * 36 cm
221157|NCT02302040|Behavioral|Team Speak|Team Speak is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
221158|NCT02302040|Behavioral|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
221481|NCT02297503|Device|Restylane/Emervel filler|Facial tissue augmentation
221482|NCT02297503|Device|Restylane Skinbooster|Facial skin rejuvenation
221483|NCT00000345|Drug|Lofexidine|
221484|NCT00002379|Drug|Indinavir sulfate|
221485|NCT00151151|Behavioral|Computer-Assisted Motivational Intervention|
221486|NCT02297516|Drug|Azzalure or Dysport|Glabellar lines
221487|NCT02297516|Device|Restylane or Emervel filler|Facial tissue augmentation
221488|NCT02297516|Device|Restylane Skinbooster|Facial skin rejuvenation
221489|NCT02297529|Drug|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
221490|NCT02297542|Biological|Flu Vaccine|
220855|NCT02307058|Procedure|Prostate Biopsy|Research biopsies may be obtained during the placement of fiducial markers. For all research biopsies, the patient will be informed of the presence of tumor cells and the Gleason score if one is described.
At 2-2.5 years (2 yr endpoint biopsy) after completion of treatment (RT or ADT - whichever is longer) all patients, with or without documented failure will undergo transrectal needle biopsy of the prostate, unless clinically contraindicated or the patient refuses.
220856|NCT02307058|Genetic|Blood and Urine Collection for Research|Blood (up to 4 tubes total) and approximately 50 mL of urine will be collected pre-RT and in post-RT follow-up for research.
220857|NCT02307058|Procedure|Fiducial Marker Placement|Patients who meet eligibility criteria and have been enrolled on study will undergo the placement of fiducial markers (typically gold markers) in the prostate, unless an FDA approved fiducial-less tracking device is employed.
220858|NCT02307058|Procedure|Post-Fiducial CT and MRI Simulation|CT-simulation will then be obtained under the same conditions with typical pelvic immobilization. Images will be taken at 1.5-2.5 mm intervals from approximately the top of the sacrum to below the ischial tuberosities (to include the entire bladder and rectum).
The limited planning MRI will be fused to the CT-simulation scan using the fiducial markers as an aid.
220859|NCT02307058|Genetic|Prostate biopsy samples used for research|Tissue from paraffin blocks from prostate biopsy samples obtained will be used for biomarker/gene expression correlative studies with treatment outcome (primary and secondary endpoints).
220860|NCT02307058|Drug|Androgen Deprivation Therapy|ADT is used in routine management of prostate cancer. This study does not specify the use of drugs used for ADT outside that of standard of care for prostate cancer. ADT is counted from the date of first LHRH agonist injection, not the antiandrogen.
220861|NCT02307058|Behavioral|International Prostate Symptom Score|International Prostate Symptom Score will be administered pretreatment, at the end of treatment and at each follow-up visit.
220862|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
220863|NCT02309450|Drug|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
220864|NCT02309463|Drug|Endothelin receptor antagonist therapy|
220865|NCT02309476|Device|PASCAL Laser, Green Laser 0.75|Barely Visible Pascal laser grid using 532nm "green" wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
221159|NCT02302053|Dietary Supplement|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
221160|NCT02302053|Dietary Supplement|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
220257|NCT02282657|Device|ECCO2R will be initiated during the 2-hour run-in time|A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).
Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.
Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.
Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation.
220258|NCT02282657|Other|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
220564|NCT02314481|Drug|Alectinib|capsule
220565|NCT02314481|Drug|Trastuzumab emtansine|Powder for concentrate for solution for infusion
220566|NCT00152815|Behavioral|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
220567|NCT02314494|Behavioral|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
220568|NCT02314507|Other|Gua sha|A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
220569|NCT02314507|Other|Hot pack|A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
220570|NCT02314520|Device|peripherally inserted central catheter|Any complication associated with central access
220571|NCT02314520|Device|centrally inserted central catheter|Central access not associated with any complication
220572|NCT02314533|Drug|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
220573|NCT02314546|Drug|Midazolam|Study participants will be randomly assigned to one of three treatment groups:
Group 1 - Placebo - Control patients will receive intranasal saline.
Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.
Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
220574|NCT02314546|Drug|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
220575|NCT02314546|Drug|saline placebo|Placebo - Control patients will receive intranasal saline.
219938|NCT02287610|Drug|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
219939|NCT02287623|Drug|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
219940|NCT00002376|Drug|Indinavir sulfate|
219941|NCT00149903|Drug|Mycophenolate sodium (enteric coated)|
219942|NCT02287623|Drug|bupivacaine|patients will receive a tap with bupivacaine
219943|NCT00002376|Drug|Zidovudine|
219944|NCT00150215|Drug|PF-00184562|
219945|NCT02289586|Drug|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
220259|NCT02282657|Device|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
220260|NCT02282657|Other|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
220261|NCT02282657|Other|Respiratory Rate|RR will be kept what it was at baseline
220262|NCT00149383|Drug|Rosiglitazone|
220263|NCT02282657|Other|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
220264|NCT02282657|Other|Ventilation will be adapted|If PaCO2> 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
220265|NCT02282657|Other|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
220266|NCT02282670|Drug|DA-5204|
220267|NCT02282670|Drug|Stillen tab.|
220268|NCT02282683|Drug|prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
220269|NCT02282696|Other|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
220270|NCT02282709|Drug|Daclatasvir|60 mg once daily
220271|NCT02282709|Drug|asunaprevir|100 mg BID
219647|NCT02294409|Behavioral|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
219648|NCT02294422|Device|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
219649|NCT02294422|Device|LOR|
219650|NCT02294422|Device|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
219651|NCT02294435|Device|TAAA Debranching Stent Graft|Endovascular stent
219652|NCT02294448|Drug|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
219653|NCT00150826|Drug|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
219654|NCT02294461|Drug|enzalutamide|oral
219655|NCT02294461|Drug|Placebo|oral
219656|NCT02296749|Drug|Sirolimus|Sirolimus tablets 2 mg
219657|NCT02296762|Drug|Sirolimus|Sirolimus tablets 2 mg
219658|NCT02296775|Biological|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
219659|NCT02296775|Biological|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
219660|NCT02296775|Biological|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
219946|NCT02289599|Drug|E2307|
219947|NCT02289599|Drug|E2307 Matching Placebo|
219948|NCT02289612|Other|Yellow Mustard Gum Fibre|
219949|NCT02289612|Other|Soluble Flaxseed Gum Fibre|
219950|NCT02289612|Other|Fenugreek Gum Fibre|
219951|NCT02289625|Other|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
219356|NCT02301247|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
219357|NCT02301260|Behavioral|Speed of Processing Training (SPT)|
219358|NCT02301260|Behavioral|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
219359|NCT02301273|Other|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
219360|NCT02301273|Other|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
219361|NCT02301286|Drug|Acetylsalicylic acid|
219362|NCT02301286|Drug|Placebo Acetylsalicylic acid|
219363|NCT02301299|Behavioral|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
219364|NCT02301312|Device|POSS-PCU vascular graft|
219365|NCT02301325|Behavioral|Smoking research cigarettes with or without NRT|
219366|NCT00151541|Drug|Dapsone Topical Gel + adapalene gel 0.1%|
219367|NCT02301338|Other|Usual care|
219368|NCT02301338|Other|Videoconferencing|
219369|NCT02301338|Device|IPad|
219370|NCT02301351|Other|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
219371|NCT02301351|Other|Text Warning Label|All packs provided will include standard text warning labels
219372|NCT02301364|Drug|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
219373|NCT02301377|Device|Spiro PD personal spirometer|
219374|NCT02301390|Drug|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
223907|NCT02194959|Behavioral|Pro PN|Navigation by Standard Hospital Navigators
223908|NCT02194972|Drug|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
223909|NCT02194985|Drug|migalastat HCl 150 mg|Capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on the days between migalastat HCl.
223910|NCT02194998|Drug|ABT-450/r/ABT-267|ABT-450/r/ABT-267 will be given by mouth once a day (total daily dose 150/100/25 mg, consisting of two 75/50/12.5 mg fixed-dose combination tablets) with food.
223911|NCT02194998|Drug|ABT-333|ABT-333 (250mg) will be given by mouth twice a day with food.
219062|NCT02308592|Behavioral|Electronic Patient Decision Aid|The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
219063|NCT02308592|Behavioral|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
219064|NCT02308605|Device|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
219065|NCT02308618|Other|Traditional Immobilization|After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed
The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises
219066|NCT02308618|Other|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
219067|NCT02308631|Procedure|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
219068|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
219069|NCT02308644|Drug|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
219070|NCT02308683|Dietary Supplement|Moringa oleifera|12 weeks supplementation
220996|NCT02283021|Other|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
220997|NCT00149448|Behavioral|TB Contact Priority Model|
220998|NCT02283034|Device|The CPRmeter|Feedback device - 1
220999|NCT02283034|Device|The PocketCPR|Feedback device - 2
221000|NCT02283034|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
221001|NCT02283034|Device|The CPREazy|Feedback device - 3
221002|NCT02283034|Device|The CPR PRO APP|Feedback device - 4
221003|NCT02283034|Device|The CardioPump|Feedback devices - 5
221004|NCT02285517|Procedure|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
221005|NCT02285517|Procedure|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
221006|NCT02285530|Drug|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle.
221007|NCT02285530|Procedure|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
221008|NCT02285530|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
221009|NCT00149734|Drug|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
221317|NCT02280564|Behavioral|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
221318|NCT02280590|Drug|Rosuvastatin(Cresnon®)|10mg
221319|NCT02280590|Drug|Rosuvastatin(Crestor®)|10mg
221320|NCT02280603|Drug|DA-4001C|1ml by topical application twice a day
220405|NCT02297100|Procedure|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
220708|NCT02289976|Procedure|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
220709|NCT02289989|Drug|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
220710|NCT02289989|Drug|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
220711|NCT02290002|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
220712|NCT02290002|Other|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
220713|NCT02290015|Other|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
220714|NCT02290028|Device|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
220715|NCT02290041|Drug|Infusion of MSC|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
220716|NCT02290041|Drug|Infusion of placebo|Infusion of placebo
220717|NCT02290054|Procedure|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
220718|NCT00150293|Drug|Pregabalin|
220719|NCT02290054|Procedure|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
220720|NCT02290054|Procedure|Intra-venous anesthesia|
220721|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
220722|NCT00150592|Drug|SPD503 (Guanfacine HCl)|
220723|NCT02292290|Drug|Sulfonylurea or Pioglitazone|Addition to Metformin
220724|NCT02292290|Drug|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
220079|NCT00151567|Drug|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
220080|NCT02301637|Device|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
220081|NCT02301650|Drug|Lamivudine|mothers use Lamivudine in late pregnancy
220082|NCT02301650|Drug|Telbivudine|mothers use Telbivudine in late pregnancy
220083|NCT02301650|Drug|Tenofovir|mothers use Tenofovir in late pregnancy
220084|NCT02304042|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
220085|NCT02304055|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
220086|NCT02304055|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
220087|NCT02304068|Other|Home monitoring|
220088|NCT02304068|Other|Hospital assessment|
220089|NCT02304081|Drug|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
220090|NCT02304081|Drug|Placebo for Saxagliptin|
220406|NCT02297113|Device|Macintosh blade|conventional endotracheal intubation
220407|NCT00151112|Procedure|Positioning and plexus anesthesia|positioning during plexus anesthesia
220408|NCT02297113|Device|C-MAC videolaryngoscope|
220409|NCT02297126|Device|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
220410|NCT02297139|Drug|Dasatinib|
220411|NCT02297152|Device|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
219777|NCT02308930|Dietary Supplement|Vitamins supplement (Vitamins A,D, E and corn oil)|
219778|NCT02308956|Behavioral|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
219779|NCT02308956|Behavioral|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
219780|NCT02308969|Drug|LSD|100ug per os, single dose
219781|NCT02308969|Drug|Placebo|Capsules containing mannitol looking identical to LSD
219782|NCT02308982|Drug|Immunoglobulins, Intravenous (Privigen)|
219783|NCT02308982|Drug|Placebo|
219784|NCT02308995|Procedure|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
219785|NCT02311725|Behavioral|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
219786|NCT02311738|Other|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
219787|NCT02311751|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
219788|NCT02311764|Drug|Carboplatin|Carboplatin will be administered weekly
219789|NCT00152594|Drug|voriconazole|
219790|NCT02311777|Drug|Pregabalin|Pregabalin will be given orally during preoperative period
219791|NCT02311777|Drug|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
219792|NCT02311777|Drug|Placebo|
220091|NCT02304094|Drug|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine
220092|NCT00151827|Drug|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
220093|NCT02304094|Other|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
219168|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
219169|NCT02282293|Drug|Placebo|
219170|NCT02282306|Behavioral|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
219171|NCT02282319|Drug|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
219172|NCT00149318|Other|Biochemical analyses.|Biochemical analyses.
219173|NCT02282319|Other|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
219174|NCT02282319|Drug|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
219175|NCT02282332|Drug|Ticagrelor|
219176|NCT02282345|Drug|BMN 673|1 mg by mouth daily for 2, 28 day cycles.
219177|NCT02282358|Drug|Mocetinostat|
219178|NCT02284737|Procedure|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
219179|NCT02284737|Drug|Sildenafil|Patients in the drug treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
219180|NCT02284737|Drug|Bosentan|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
219181|NCT02284737|Drug|Prostacyclin|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
219182|NCT02284750|Procedure|Two-stenting technique|
223360|NCT02179567|Drug|Docetaxel|Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
223361|NCT02179567|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
223362|NCT02179580|Drug|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
223363|NCT02179580|Drug|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
223364|NCT02179593|Other|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
223705|NCT02171494|Drug|BMS Coumadin|
223706|NCT00136435|Drug|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
223707|NCT02171507|Drug|Dabigatran etexilate|
223708|NCT02171507|Drug|Diclofenac|
223709|NCT02171520|Drug|Dabigatran etexilate generation I|
223710|NCT02174393|Drug|Post-Universal Peel Skin Care|Gentle Antioxidant Soothing Cleanser daily
Physical Sunscreen daily
Soothing recovery ointment fortified with silver only when peeling occurs
After completely peeling, vitamin c product in the morning and the retinol in the evening
223711|NCT02174406|Procedure|breast ultrasound|
223712|NCT02174406|Procedure|DBT (Full field digital mammography + tomosynthesis)|
223713|NCT02174419|Drug|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
223714|NCT02174419|Drug|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
223715|NCT00136695|Drug|anastrozole|1 mg QD
223716|NCT02174419|Drug|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
223717|NCT02174432|Drug|nalbuphine HCl ER 90 mg BID|nalbuphine HCl ER 90 mg BID for up to 50 weeks
223718|NCT02174432|Drug|nalbuphine HCl ER 120 mg BID|nalbuphine HCl ER 120 mg BID for up to 50 weeks
223719|NCT02174432|Drug|nalbuphine HCl ER 180 mg BID|nalbuphine HCl ER 180 mg BID for up to 50 weeks
223720|NCT02174445|Drug|Imatinib|Imatinib, 400 to 800 mg p.o., daily
222752|NCT02192047|Other|Palm Olein|8 weeks
222753|NCT02192047|Other|IE Palm olein|8 weeks
222754|NCT02192047|Other|IE soybean oil-based|8 weeks
222755|NCT02192060|Other|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
222756|NCT02192060|Other|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
222757|NCT00138736|Drug|Mannan Binding Lectin|MBL dose at a twice weekly dose interval (3 or 4 days):
0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval
222758|NCT02192073|Procedure|Suprapectoral Biceps tenodesis|
222759|NCT02192073|Procedure|Subpectoral biceps tenodesis|
222760|NCT02192086|Other|goal directed fluid therapy|The "treatment" group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).
a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe.
223064|NCT02184624|Device|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
223065|NCT02184637|Drug|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
223066|NCT02184637|Drug|Dihydroartemisinin + Piperaquine tetraphosphate|White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two "σ" letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally
223067|NCT02187016|Device|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
223068|NCT02187016|Device|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
223069|NCT02187016|Device|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
223070|NCT02187016|Device|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
223071|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
223072|NCT02187029|Other|Placebo|Daily dosing (tablet) for 14 days
222422|NCT02158442|Procedure|Percutaneous Isolated Limb Perfusion (PILP) delivery intervention|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
222423|NCT00134901|Drug|Memantine|Memantine
222424|NCT02158442|Drug|Timentin|
222425|NCT02158455|Procedure|NT SVG grafts|
222426|NCT02158468|Device|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
222427|NCT02158468|Device|Postconditioning|After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
222428|NCT02158481|Dietary Supplement|A capsule containing both polyphenols and carotenoids|
222429|NCT02158481|Dietary Supplement|Placebo intervention|Placebo intervention
222430|NCT02158494|Device|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
222431|NCT02158507|Drug|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
222432|NCT02158520|Biological|Bevacizumab|Given IV
222433|NCT02158520|Biological|Ipilimumab|Given IV
222434|NCT00134901|Drug|placebo|placebo
222435|NCT02158520|Other|Laboratory Biomarker Analysis|Correlative studies
222436|NCT02158520|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
222437|NCT02158520|Other|Pharmacological Study|Correlative studies
222438|NCT02158533|Drug|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
222439|NCT02158533|Drug|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
221809|NCT02292784|Drug|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
221810|NCT02292797|Other|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
221811|NCT02292810|Device|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
221812|NCT02292810|Device|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
222100|NCT02286011|Biological|MNC (Mononuclear cells)|The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.
For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device.
222101|NCT02286011|Other|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
222102|NCT02286050|Other|CF Nursing Program|
222103|NCT02286063|Drug|Ambulatory Oxygen|The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).
Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm.
222104|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
222105|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
222106|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
222107|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
222108|NCT02288299|Device|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
222109|NCT00150007|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
221491|NCT02297555|Device|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
221492|NCT02297568|Drug|Calciferol|Comparison 25OHD levels between calciferol and placebo
221493|NCT02297568|Drug|placebo|
221494|NCT02297594|Drug|AK0529|AK0529 capsule for oral administration
221495|NCT02297594|Drug|Placebo|Sugar placebo capsule for oral administration
221496|NCT00151151|Behavioral|Didactic Educational Counseling|
221497|NCT02299817|Drug|Denosumab|Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.
Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.
Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast.
221498|NCT02299817|Drug|Placebo|Placebo
221499|NCT02299830|Procedure|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
221500|NCT02299830|Procedure|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
221501|NCT02299830|Procedure|stent placement|use stent placement to open the airway compressed by out neoplasm
221502|NCT02299830|Procedure|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
221813|NCT02292823|Device|MGuard™ Prime Embolic Protection Stent System|
221814|NCT02292836|Other|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
221815|NCT02292849|Behavioral|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
221816|NCT02292849|Other|Standard Mental Health Referral|Standard mental health referral to a community agency
221817|NCT02292862|Procedure|Lymph node and blood sampling|By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.
Blood (1ml) is taken from mother and infant.
221818|NCT02292888|Other|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
221819|NCT00150631|Drug|Candesartan|placebo controlled double blind
221161|NCT02302066|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
221162|NCT02302066|Drug|TDV Placebo|Takeda's tetravalent dengue placebo-matching vaccine
221163|NCT02302079|Drug|ASP8232|oral capsule
221164|NCT02302079|Drug|ranibizumab|intravitreal (IVT) injection
221165|NCT02302079|Drug|Placebo|oral capsule
221166|NCT00151619|Drug|Amlodipine|
221167|NCT02302079|Other|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
221168|NCT02304588|Biological|Mesenchymal stem cells|10-20 x 10^6 cells/20mL
221169|NCT02304614|Other|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
221170|NCT02304614|Other|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
221171|NCT02304614|Other|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
221172|NCT00151892|Drug|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
221173|NCT02304614|Other|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
221174|NCT02304627|Drug|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
221175|NCT02304653|Other|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
221176|NCT02304666|Procedure|Colonoscopy for biopsies samples|
221177|NCT02304679|Other|Pre-inclusion questionnaires|(Month -2)
During this visit, the investigator will:
Validate the patient's inclusion and exclusion criteria;
Obtain informed consent from the patient;
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
Prescribe 1 month of PDE5i treatment.
The next visit will be scheduled
221503|NCT02299843|Procedure|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
221504|NCT02299843|Procedure|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
220576|NCT02314559|Procedure|Manual titration|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
220577|NCT00152828|Drug|Celecoxib|
220578|NCT02277821|Device|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
220579|NCT02277847|Drug|Idarubicin(8mg/m2) and cytosine arabinoside|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
220866|NCT02309476|Device|PASCAL Laser, Green Laser 1|Barely Visible Pascal laser grid using 532nm "green" wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
220867|NCT00152321|Other|Usual Care|
220868|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 0.75|Pascal EM at 70% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
220869|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 1|Pascal EM at 70% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid
220870|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 0.75|Pascal EM at 40% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
220871|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 1|Pascal EM at 40% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
220872|NCT02309489|Behavioral|Partner involvement|Partner is involved in maternity care
220873|NCT02309502|Device|Green Pascal|Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session
Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%
Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants
220874|NCT02309502|Device|Yellow Pascal|: Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern "landmark" burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants
220272|NCT02282722|Other|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
220273|NCT00149383|Drug|Placebo|
220274|NCT02282722|Other|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
220275|NCT02282748|Other|No intervention|
220276|NCT02282761|Drug|ITI-007|
220277|NCT02282761|Drug|Placebo|
220278|NCT00149682|Behavioral|6-month educational program|
220279|NCT02285114|Drug|3rd ARV agent|A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: ritonavir boosted atazanavir (ATV/r), ritonavir boosted lopinavir (LPV/r), ritonavir boosted darunavir (DRV/r), efavirenz (EFV), nevirapine (NVP), raltegravir (RAL), or dolutegravir (DTG).
220280|NCT02285127|Procedure|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
220580|NCT02277847|Drug|Idarubicin(10mg/m2), cytosine arabinoside|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
220581|NCT02277860|Behavioral|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
220582|NCT00148824|Biological|23-valent pneumococcal conjugate vaccine (vaccine)|
220583|NCT02277873|Behavioral|pregnancy|Observational study in order to establish relationship between moon and births
220584|NCT02277886|Drug|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
220585|NCT02277886|Drug|esomeprazole|40mg/tablet, one tablet once before breakfast
220586|NCT02277899|Other|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
220587|NCT02277899|Other|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
220588|NCT02277899|Other|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
220589|NCT02277899|Other|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
219952|NCT02289638|Device|Intubrite|Video-Laryngoscopy
219953|NCT02289638|Device|MIL|Direct-Laryngoscopy
219954|NCT02289651|Device|Venner|Video-laryngoscopy
219955|NCT00150215|Drug|Olanzapine|
219956|NCT02289651|Device|Miller|Direct-Laryngoscopy
219957|NCT02289664|Device|MAC|Direct-Laryngoscopy
219958|NCT02289664|Device|Coopdech|Video-Laryngoscopy -1
219959|NCT02289664|Device|CoPilot|Video-Laryngoscopy -2
219960|NCT02289664|Device|Intubrite|Video-Laryngoscopy -3
219961|NCT02289677|Device|ATMOS Scope|Video-laryngoscopy 1
219962|NCT02289677|Device|COOPDECH|Video-laryngoscopy-1
219963|NCT02289677|Device|AirTraq|Optical-laryngoscopy
219964|NCT02289690|Drug|Veliparib|Varying doses administered on Days -2 to 5 in a 21-day cycle
219965|NCT02289690|Drug|Carboplatin|Administered on Day 1 via intravenous infusion in a 21-day cycle
219966|NCT00150228|Drug|CP-526,555 (varenicline)|
219967|NCT02289690|Drug|Etoposide|Administered on Days 1 to 3 via intravenous infusion in a 21-day cycle
219968|NCT02289703|Drug|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
219969|NCT02289716|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
219970|NCT02289716|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
219971|NCT02289716|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
220281|NCT02285140|Drug|Cefazolin|administration as outlined
220282|NCT02285140|Drug|Vancomycin|administration as outlined
220283|NCT02285153|Drug|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
219375|NCT02301390|Device|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
219376|NCT02303717|Device|Percutaneous coronary intervention|Percutaneous coronary stent implantation
219661|NCT00151073|Drug|Docetaxel|
219662|NCT02296788|Behavioral|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
219663|NCT02296801|Drug|Letrozole|
219664|NCT02296801|Drug|palbociclib|
219665|NCT02296814|Drug|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
219666|NCT02296814|Drug|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
219667|NCT02296840|Drug|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
219668|NCT02296840|Drug|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
219669|NCT02296853|Drug|TAF|Tenofovir alafenamide (TAF) 25 mg tablet administered orally
219670|NCT02296879|Genetic|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
219671|NCT02296892|Drug|Remimazolam|For induction and maintenance of sedation
219672|NCT00151086|Drug|Estramustine|
219673|NCT02296892|Drug|Placebo|For induction and maintenance of sedation
219674|NCT02296892|Drug|Midazolam|For induction and maintenance of sedation
219675|NCT02296905|Drug|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
219676|NCT02296905|Drug|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
219677|NCT02296918|Drug|ACP-196 in combination with obinutuzumab|
219678|NCT02296931|Other|Saline|Standard IV Saline Fluids
219679|NCT02296931|Drug|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
219071|NCT02308696|Behavioral|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
219072|NCT02308696|Behavioral|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
219073|NCT02308709|Radiation|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
219074|NCT02311361|Radiation|Sterostatic body radiation Cohort A1: 1 dose therapy (SBRT)|Cohort A1: 1 dose Cohort A2: 5 doses Cohort B1: 1 dose Cohort B2: 5 doses Cohort C1: 1 dose Cohort C2: 5 doses
219075|NCT02311374|Other|Brain connectivity and physiology|fMRI to measure ADC during wake and sleep states
219377|NCT02303717|Drug|Dual antiplatelet therapy|Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
219378|NCT02303730|Drug|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose<2.9 mmol/l or < 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
219379|NCT02303730|Drug|insulin glargine|The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c <8% use 0.1 -0.2 U/kg per day;HbA1c >8% use 0.2 -0.3 U/kg per day).
Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):
fasting blood glucose(FBG) > 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.
If hypoglycemia, reduce insulin glargine by:
blood glucose <70mg/dl（3.9mmol/l）: 10%-20%; blood glucose <40mg/dl（2.2mmol/l）: 20%-40%.
219380|NCT00151801|Drug|estroprogestins|
219381|NCT02303743|Device|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
219382|NCT02303743|Device|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
219383|NCT02303756|Device|Pillcam® COLON Capsule|colonoscopy
219384|NCT02303769|Drug|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
219385|NCT02303769|Drug|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
219386|NCT02303782|Drug|OTX015|
219387|NCT02303782|Drug|Vidaza (azacitidine)|
221321|NCT02280603|Drug|5% minoxidil|1ml by topical application twice a day
221322|NCT02280616|Drug|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
221323|NCT02280616|Drug|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
221324|NCT02280616|Drug|high dose budesonide suspension|placebo tablet twice daily AND 5ml [0.4mg budesonide/ml] suspension twice daily
221325|NCT00149175|Other|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
221326|NCT02280616|Drug|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
221327|NCT02280629|Drug|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
221328|NCT02280629|Drug|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
221329|NCT02280629|Drug|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
221330|NCT02280642|Biological|Both 2nd and 3rd doses on time|
221331|NCT02280642|Biological|2nd dose late and 3rd dose on time|
221332|NCT02283034|Device|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
221333|NCT02283047|Behavioral|DIET|Lifestyle intervention through hypocaloric diet
221334|NCT02283047|Behavioral|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
221335|NCT02283047|Behavioral|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
221336|NCT00149461|Behavioral|Written Asthma Action Plan|
221337|NCT02283047|Behavioral|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
221338|NCT02283060|Drug|Stribild|To be administered orally, once daily with food.
221339|NCT02283060|Drug|Atripla|To be administered orally, once daily at bedtime on an empty stomach
221647|NCT02314975|Device|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
221648|NCT02314975|Other|Fixed appliance only|Fixed appliance treatment only
220725|NCT02292303|Dietary Supplement|zinc-enriched yeast|
220726|NCT02292303|Dietary Supplement|Zinc references|
220727|NCT02292316|Behavioral|gait and cognitive assessments|several tests are given in each domain
221010|NCT02285543|Drug|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.
Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, 66Gy
221011|NCT02285543|Procedure|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
221012|NCT02285543|Radiation|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
221013|NCT02285556|Behavioral|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
221014|NCT02285556|Behavioral|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
221015|NCT02285556|Radiation|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
221016|NCT02285556|Radiation|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
221017|NCT02285582|Other|Registry study|No intervention.
221018|NCT02285595|Device|Sonendo GentleWave™ System|
221019|NCT02285608|Other|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
221020|NCT02287935|Procedure|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
220412|NCT02297165|Behavioral|olfactory stimulation program|8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one the begining of the trial, the second 5 weeks later and the third at 6 month).
For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor.
220413|NCT02297178|Procedure|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
220414|NCT02297178|Procedure|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
220415|NCT02297191|Procedure|Thoracolumbar Interfascial Plane Block|All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.
Ultrasound images will be saved using the nomenclature TLIP Anatomy
Photos will only include surface anatomy of the low-to-mid back.
Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped.
220416|NCT02299440|Other|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
220417|NCT02299440|Drug|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
220418|NCT02299440|Drug|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
220419|NCT00151346|Drug|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
220728|NCT02292316|Biological|blood sample|routine analyses in rheumatology such blood count and 25OH-D
220729|NCT02292316|Other|osteodensitometry|Looking for osteoporosis
220730|NCT02292329|Dietary Supplement|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
220731|NCT02292329|Dietary Supplement|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
220732|NCT02292342|Dietary Supplement|(-)-epicatechin|epicatechin to be delivered to study participants in water.
220733|NCT00150592|Drug|Placebo|
220734|NCT02292355|Other|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
220094|NCT02304107|Drug|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
220095|NCT02304107|Drug|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
220096|NCT02304120|Other|Proprioceptive postural training|
220097|NCT02304120|Other|Treadmill training|
220098|NCT02304120|Other|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
220099|NCT02304133|Other|Education|
220100|NCT02304159|Drug|daclatasvir|
220101|NCT02304159|Drug|Sofosbuvir|
220102|NCT02304159|Drug|Ribavirin|
220103|NCT00151840|Drug|IVIG-L|
220104|NCT02304172|Device|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
220105|NCT02304172|Device|Harmonic (Group B)|hemostatic device utilized intraoperatively
220106|NCT02304185|Biological|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
220107|NCT02304185|Biological|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
220108|NCT02304185|Biological|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
220109|NCT02306629|Biological|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
220110|NCT02306629|Biological|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
220420|NCT02299440|Other|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion.
219484|NCT02277366|Procedure|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
219485|NCT00148746|Drug|Dermatop|
219486|NCT02277392|Biological|Vaccine--‐primed, CD3/CD28--‐costimulated autologous peripheral blood T--‐cells|
219487|NCT02277392|Biological|SB--‐485232 (Human recombinant Interleukin--‐18)|
219488|NCT02277405|Device|Shikani Optical Stylet|Optical intubation
219489|NCT02277405|Device|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
219490|NCT02277418|Device|VAVL|Videolaryngoscope
219491|NCT02277418|Device|MIL|Direct laryngoscopy
219492|NCT02277431|Dietary Supplement|Probiotic dietary supplement (Trenev Trio®)|Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:
Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])
Bifidobacterium bifidum Malyoth super strain (40 billion CFU)
Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)
219493|NCT02277431|Dietary Supplement|placebo|
219494|NCT02277444|Drug|Golimumab|Golimumab 80 mg/m^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244.
219495|NCT02277444|Drug|Methotrexate|Methotrexate 10-30 mg/m^2 per week through Week 28.
219496|NCT00148759|Drug|LPV/r|LPV/r 800/200 mg once daily
219497|NCT02277457|Radiation|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
219498|NCT02277457|Drug|Erlotinib|150 mg once daily
219499|NCT02277457|Drug|Crizotinib|250 mg twice daily
219500|NCT02277483|Drug|LAIS®|10 X 1,000 / twice a week
219501|NCT02279784|Device|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
219502|NCT02279797|Behavioral|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
219503|NCT00149071|Device|rTMS|active Transcranial Magnetic Stimulation
219504|NCT02279810|Behavioral|survey|Survey
223721|NCT02174445|Drug|Nilotinib|300mg p.o., twice-daily
223722|NCT02174458|Procedure|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
223723|NCT02174510|Drug|20mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
223724|NCT02174510|Drug|40mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
223725|NCT02174510|Drug|80mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
223726|NCT00136708|Procedure|Neonatal Resuscitation|
223727|NCT02174510|Drug|placebo|
223728|NCT02174523|Drug|40mg lurasidone|
218879|NCT00150176|Drug|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
218880|NCT02289248|Drug|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
218881|NCT02289248|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
218882|NCT02289261|Drug|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
218883|NCT02289261|Drug|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
218884|NCT02289274|Drug|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
218885|NCT02289274|Drug|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
218886|NCT02289287|Behavioral|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
218887|NCT02289287|Behavioral|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
223073|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
223074|NCT02187029|Other|Placebo|Daily dosing (tablets) for 14 days
223075|NCT00138112|Drug|Prophylactic Vancomycin|
223076|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
223077|NCT02187042|Other|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
223078|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
223079|NCT02187055|Drug|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
223080|NCT02187055|Drug|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
223081|NCT02187055|Biological|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
223082|NCT02187068|Drug|Dexmedetomidine|Dexmedetomidine administered intravenously
223083|NCT02187081|Procedure|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
223084|NCT02187081|Procedure|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
223365|NCT02179593|Other|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
223366|NCT02179606|Device|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
223367|NCT02179606|Device|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
223368|NCT02182219|Drug|BIBF 1120|
223369|NCT02182232|Drug|BIBF 1120|
223370|NCT02182232|Drug|Paclitaxel|
223371|NCT02182232|Drug|Carboplatin|
223372|NCT02182245|Drug|BIBF 1120|
222761|NCT02192086|Other|Control Group|Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).
a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values).
222762|NCT02192099|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm. Can be adjusted to 5 mg/kg weekly or biweekly.
222763|NCT02192125|Device|REWIRE-System|The REWIRE rehabilitation platform consists of three hierarchical components:
"patient station" (PS), which is installed in the home environment of the patient:
Includes:
Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking
"Hospital Station" (HS), which allows an exchange of information with more "patient station" and is served by the therapists in the hospital;
Includes:
Laptop MySQL- database
"station networking" (NS), which allows a combination of a several of HS. database
222764|NCT02192138|Procedure|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
222765|NCT02192138|Device|Pleural catheter|
222766|NCT02194400|Biological|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
222767|NCT02194413|Procedure|therapeutic touch|receiving healing touch
222768|NCT02194413|Other|quality-of-life assessment|Ancillary studies
222769|NCT02194413|Other|questionnaire administration|Ancillary studies
222770|NCT02194426|Drug|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
222771|NCT02194452|Radiation|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
222772|NCT00139126|Behavioral|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
222773|NCT02194452|Procedure|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
222774|NCT02194452|Procedure|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
222775|NCT02194452|Other|laboratory biomarker analysis|Correlative studies
222776|NCT02194465|Drug|LY2623091|Administered orally
222777|NCT02194465|Drug|Tadalafil|Administered orally
222778|NCT02194465|Drug|Spironolactone|Administered orally
222779|NCT02194465|Drug|Placebo|Administered orally
222110|NCT02288312|Drug|BIA 2-093|
222111|NCT02288325|Drug|Levomilnacipran ER|Once daily, oral administration
222112|NCT02288325|Drug|Placebo|Once daily, oral administration
222113|NCT02288338|Drug|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
222114|NCT02288338|Drug|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222115|NCT02288338|Drug|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222116|NCT02288338|Drug|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222117|NCT02288338|Drug|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222118|NCT02288338|Drug|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
222440|NCT02158533|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
222441|NCT02158546|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
222442|NCT02158546|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
222443|NCT02158559|Drug|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
222444|NCT02158559|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
222445|NCT00134914|Drug|Buprenorphine|single doses given by sublingual and parenteral routes
222446|NCT02161094|Behavioral|Give incentives to patients based on their own HbA1c improvement|
222447|NCT02161107|Biological|Grass-SPIRE|Intradermal injection
222448|NCT02161107|Biological|Placebo|Intradermal injection
222449|NCT02161120|Other|Traditional Finnish rye bread|
222450|NCT00135239|Procedure|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
221820|NCT02292901|Device|Macintosh laryngoscope|
221821|NCT02292901|Device|McGrath Mac videolaryngoscope|
221822|NCT02295319|Other|Individual discharge|See previous description in "Arms"
221823|NCT02295332|Drug|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
221824|NCT00002378|Drug|Lamivudine|
221825|NCT00150917|Behavioral|Supportive-Expressive Group Therapy|
221826|NCT02295332|Drug|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
221827|NCT02295345|Other|Cognitive Behavioural Therapy for Insomnia|
221828|NCT02295384|Other|Retrospective Audit|Retrospective Audit
221829|NCT02295397|Other|food|food provocation, skin testing, blood sampling
221830|NCT02295410|Behavioral|CPT|
221831|NCT02295436|Drug|minodronic acid|comparison of different doses, ages and medication conditions
221832|NCT02295449|Device|biopsy sample performed after the SonoVue® injection|
221833|NCT02295462|Other|Person-centered Care|Medication Review + Person-centered Care
221834|NCT02295462|Other|Optimised Treatment|Medication Review only
221835|NCT02295475|Drug|Apixaban|Study subjects will be randomized to receive Apixaban.
221836|NCT00150930|Device|narrowband UVB phototherapy at home|
221837|NCT02295475|Drug|Warfarin|Study subjects will be randomized to receive Warfarin.
222119|NCT02288338|Drug|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
222120|NCT00150020|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
222121|NCT02288338|Drug|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
222122|NCT02288338|Drug|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
221505|NCT02299856|Other|Cardiac magnetic resonance scan|
221506|NCT00002379|Drug|Lamivudine|
221507|NCT00151398|Drug|lecozotan SR|evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.
Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil.
221508|NCT02299869|Device|Verde|Study pair 1 or 2
221509|NCT02299869|Device|Green|Study pair 1 or 2
221510|NCT02299869|Device|Cinza|Study pair 1 or 2
221511|NCT02299869|Device|Grey|Study pair 1 or 2
221512|NCT02299869|Device|Esmeralda|Study pair 3 or 4
221513|NCT02299869|Device|Jade|Study pair 3 or 4
221514|NCT02299869|Device|Azul|Study pair 3 or 4
221515|NCT02299869|Device|Blue|Study pair 3 or 4
221516|NCT02299882|Drug|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
221517|NCT02299908|Drug|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
221518|NCT00151398|Drug|Donepezil|10 mg donepezil QD dosed up to 40 weeks
221519|NCT02299908|Drug|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
221520|NCT02302092|Drug|Flomoxef|Solution for intravenous administration
221521|NCT02302092|Drug|Cefepime|Solution for intravenous administration
221522|NCT02302105|Radiation|IGRT|Image Guided RT to the prostate
221523|NCT02302118|Procedure|Esophagogastrectomy|Esophagogastrectomy
221524|NCT02302131|Other|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
221525|NCT02302144|Behavioral|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
220875|NCT02309515|Other|Laboratory Biomarker Analysis|Correlative studies
220876|NCT02309515|Drug|Lenalidomide|Given PO
220877|NCT02309515|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
220878|NCT02312128|Other|Grip Strength|Grip strength measurement
220879|NCT02312128|Other|VAS Score|Measurement pain according to the visual analogue scale (VAS)
220880|NCT02312128|Other|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
220881|NCT02312154|Device|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
221178|NCT02304679|Drug|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
221179|NCT02304679|Other|PDE5i follow-up questionnaires|(Month -1)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).
The next visit will be scheduled
221180|NCT02304679|Other|Inclusion questionnaires|(Day 0)
During this visit the investigator will:
Verify inclusion and exclusion criteria, and proceed with final inclusion
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Randomize the patient at the end of the visit
The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit.
221181|NCT02304679|Device|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
221182|NCT02304679|Device|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
221183|NCT00151905|Drug|3 % hypertonic saline|
221184|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 1|(Month 2)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
221185|NCT02307058|Behavioral|Memorial Anxiety Scale for Prostate Cancer patients|MAX-PC Quality of Life questionnaire - Recommended after enrollment and prior to fiducial marker placement, as well as during the last week of treatment, and post-RT at 3 mo, 9 mo and then yearly to 5.25 years.
220590|NCT02277899|Other|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
220591|NCT02277912|Device|navigated repetitive Transcranial Magnetic Stimulation|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
220592|NCT02277912|Device|navigated repetitive Transcranial Magnetic Stimulation|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
220593|NCT00148837|Drug|Peg-interferon alpha 2b (drug)|
220594|NCT02277912|Device|SHAM repetitive Transcranial Magnetic Stimulation|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
220595|NCT02277925|Device|polytetrafluoroethylene, Gore-Tex permanent suture|polytetrafluoroethylene, Gore-Tex permanent suture
220596|NCT02277925|Device|2-0 polydioxanone, PDS delayed absorbable monofilament suture|2-0 polydioxanone, PDS delayed absorbable monofilament suture
220597|NCT02280148|Drug|Propofol|2mg / kg
220598|NCT02280161|Other|cytology specimen collection procedure|Correlative studies
220882|NCT00152633|Drug|Losartan|Treatment with Losartan
220883|NCT02312167|Device|confocal laser endomicroscopy|probe-based and needle-based confocal laser endomicroscopy
220884|NCT02312180|Biological|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
220885|NCT02312206|Drug|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
220886|NCT02312206|Other|Placebo|Placebo
220887|NCT02312219|Drug|Folic Acid|1 mg folic acid once daily
220888|NCT02312219|Drug|Placebo|placebo once weekly
220889|NCT02312219|Drug|Low Dose Methotrexate|An anti-inflammatory drug
220890|NCT02312232|Drug|levodopa, carbidopa, ODM-104|
220891|NCT02312245|Biological|Bevacizumab|Given IV
220284|NCT02285153|Drug|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
220285|NCT02285166|Drug|Omega-3-acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
220286|NCT02285166|Drug|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
220287|NCT02285179|Drug|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
220288|NCT02285179|Drug|Tamoxifen|daily dose of 20 mg
220289|NCT00149682|Behavioral|6-month standard care program|
220290|NCT02285192|Radiation|18F-Fluorodeoxyglucose (18F-FDG)|
220291|NCT02285192|Device|PET/CT imaging|
220292|NCT02285205|Drug|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
220293|NCT02285218|Other|serum blood sampling|
220294|NCT02285231|Dietary Supplement|Arginyl-fructose|
220295|NCT02285231|Dietary Supplement|Placebo|
220296|NCT02285244|Drug|sotrastaurin acetate|Given PO
220297|NCT02285244|Other|pharmacological study|Correlative studies
220298|NCT02285244|Other|laboratory biomarker analysis|Correlative studies
220299|NCT02285270|Device|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
220300|NCT00149695|Behavioral|Weekly home delivery of milk products|
220301|NCT02285283|Drug|Itraconazole|
220302|NCT02285283|Drug|Placebo|
220303|NCT02285296|Other|personalized support program|interview of the primary caregivers to identify their needs and expectations, the implementation of a "personalized support program", including telephone follow-up
220599|NCT02280174|Drug|linagliptin|linagliptin 5 mg/d for12 weeks
219680|NCT02296944|Other|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
219681|NCT02296957|Procedure|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
219682|NCT02296970|Procedure|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
219972|NCT02289742|Device|Nelfilcon A multifocal contact lenses|
219973|NCT02289742|Device|Nelfilcon A toric contact lenses|
219974|NCT02291926|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
219975|NCT02291939|Procedure|Parotidectomy|Surgical Intervention with the FMwand Surgical System
219976|NCT02291952|Behavioral|Meal schedule|
219977|NCT00150540|Drug|Lanthanum carbonate|
219978|NCT02291978|Device|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
219979|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
219980|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
219981|NCT02292017|Device|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
219982|NCT02292030|Drug|HTEA|usually high thoracic epidural anesthesia
219983|NCT02292043|Drug|HTEA|HTEA
219984|NCT02292056|Behavioral|1-on-1 counseling|Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method
Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.
Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.
10 minute video entitled "The Contraceptive Choice Project: Which Birth Control Method is Right for You?" by Washington University in St. Louis.
Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.
Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling
219985|NCT02292069|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
219388|NCT02303795|Drug|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
219389|NCT02303795|Drug|Warfarin|Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day.
219390|NCT02303808|Device|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
219391|NCT00151801|Drug|interferon-beta 1a|
219392|NCT02303821|Drug|Carfilzomib|
219393|NCT02303821|Drug|Dexamethasone|
219394|NCT02303821|Drug|Mitoxantrone|
219395|NCT02303821|Drug|PEG-asparaginase|
219396|NCT02303821|Drug|Vincristine|
219397|NCT02303821|Drug|Intrathecal (IT) Methotrexate|
219683|NCT02299102|Device|Jamshidi Manual Standard Device|Jamshidi Manual Standard Device
219684|NCT02299102|Device|OnControl Powered Ported Device|OnControl Powered Ported Device
219685|NCT00002379|Drug|Adefovir dipivoxil|
219686|NCT00151294|Drug|escitalopram oxalate antidepressant|
219687|NCT02299115|Drug|Prednisolone|Corticosteroid
219688|NCT02299115|Drug|Vigabatrin|Antiepileptic
219689|NCT02299128|Other|Physical Therapy Treatment|
219690|NCT02299141|Drug|Nintedanib|
219691|NCT02299154|Behavioral|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
219692|NCT02299167|Drug|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
219693|NCT02299180|Behavioral|ACP|
221649|NCT02314988|Drug|Tranexamic Acid|3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.
TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL.
221650|NCT02314988|Drug|Placebo|Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.
The placebo solution will be 100 mL of sterile normal saline.
221651|NCT02315001|Drug|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
221652|NCT02315001|Other|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
221653|NCT02315014|Other|whey protein|whey protein.
221654|NCT00152867|Drug|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
221655|NCT02315014|Other|placebo|placebo.
221656|NCT02278289|Device|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
221657|NCT02278289|Procedure|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
221658|NCT02278302|Drug|Aggrenox®|
221659|NCT02278302|Drug|Placebo|
221660|NCT02278302|Other|Ethanol|
221661|NCT02278315|Drug|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
221662|NCT02278315|Drug|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
221663|NCT00148863|Drug|Interferon gamma (drug)|
221664|NCT02278328|Drug|STX209|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate.
221665|NCT02278328|Drug|placebo|
221666|NCT02278341|Drug|roxadustat|Oral Tablet
221667|NCT02278341|Drug|epoetin alfa|Subcutaneous (SC) or Intravenous (IV) Injection
221021|NCT02287948|Device|Nintendo Wii Fit Balance Board|Clinical and instrumental evaluations carry out on the same day.
1) Instrumental evaluations
All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:
Open eyes, monopodalic balance for 20 seconds
Closed eyes, monopodalic balance for 20 seconds
Open eyes, balance on both feet for 60 seconds
Closed eyes, balance on both feet for 60 seconds
During trials subjects can leave arms in the most comfortable position they prefere
Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials.
221022|NCT02287961|Procedure|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
221023|NCT02287961|Procedure|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
221340|NCT02283086|Behavioral|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
221341|NCT02283099|Biological|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10^6 pfu, 2x10^7 pfu or 3x10^5)
221342|NCT02283112|Other|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
221343|NCT02283151|Dietary Supplement|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
221344|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
221345|NCT02283164|Behavioral|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
221346|NCT02283177|Drug|crenolanib|
221347|NCT00149474|Behavioral|Peak Flow Monitoring|
221348|NCT02283177|Drug|cytarabine|
221349|NCT02283177|Drug|daunorubicin|
221350|NCT02283177|Drug|idarubicin|
221351|NCT02283190|Drug|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
221352|NCT02283203|Drug|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
220735|NCT02292368|Behavioral|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
220736|NCT02292368|Procedure|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
220737|NCT02292368|Procedure|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
220738|NCT02292381|Other|Isometric exercise|
220739|NCT02292394|Behavioral|Multicomponent Cognitive Behavioral Telephone Intervention|
220740|NCT02292394|Behavioral|Telephone Intervention Pleasant Activities|
220741|NCT02292407|Device|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
220742|NCT02292433|Drug|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
220743|NCT02292433|Drug|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
220744|NCT00150605|Drug|Extended-release carbamazepine|
220745|NCT02292433|Drug|Placebo|tablets, breakfast plus lunch, 7 days
220746|NCT02292446|Drug|Ruxolitinib|
220747|NCT02292459|Drug|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
220748|NCT02294773|Drug|Letrozole|Patient is to take letrozole during cycle days 3-7.
221024|NCT02287961|Procedure|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
221025|NCT02287961|Procedure|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
221026|NCT00149981|Drug|everolimus (RAD)|Everolimus
221027|NCT02287974|Drug|Stem cell infusion|Unique stem cell infusion of the randomized group
221028|NCT02287987|Procedure|Clamp Robotic partial nephrectomy|Renal artery clamping during partial nephrectomy
221029|NCT02287987|Procedure|Clampless Robotic partial nephrectomy|Robotic partial nephrectomy without renal artery clamping
232362|NCT02427451|Biological|Obinutuzumab|Given IV
232363|NCT02427451|Drug|Ibrutinib|Given PO
232364|NCT00167674|Drug|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight > 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
232365|NCT02427451|Other|Pharmacological Study|Correlative studies
232366|NCT02427451|Other|Laboratory Biomarker Analysis|Correlative studies
232367|NCT02427451|Other|Quality-of-Life Assessment|Ancillary studies
232368|NCT02427464|Genetic|VM202|gene therapy
232369|NCT02427464|Genetic|placebo|
232370|NCT02427477|Device|Test Contact Lens (senofilcon A)|Subjects will wear the contact lenses in both eyes for seven days
232371|NCT02427477|Device|Control Contact Lens (delefilcon A)|Subjects will wear the contact lenses in both eyes for seven days
232372|NCT02427490|Behavioral|Problem-Solving Intervention for Family Caregivers|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
232373|NCT02427490|Other|Unenhanced Monitoring of Behavioral Health Outcomes|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
232374|NCT02427503|Procedure|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
232375|NCT00167674|Drug|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
232376|NCT02427529|Drug|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
232377|NCT02427529|Drug|Placebo|
232378|NCT02427529|Other|Low calorie diet|
231769|NCT02403687|Drug|Menthol, NF 5.00 %|compound topical cream
231770|NCT02403700|Device|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
232055|NCT02396797|Behavioral|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
232056|NCT02396810|Other|intra-operative MRI|Intra-operative magnetic resonance imaging under general anesthesia
232057|NCT00163436|Drug|Ciclesonide|
232058|NCT02396810|Procedure|Transsphenoidal resection of pituitary macroadenoma|Routine transsphenoidal resection of pituitary macro adenomas
232059|NCT02399059|Procedure|Normal saline lavage|Peritoneal irrigation with normal saline
232060|NCT02399085|Drug|MOR00208|12 mg/kg
232061|NCT02399085|Drug|Lenalidomide|25 mg
232062|NCT02399098|Behavioral|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
232063|NCT02399111|Device|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
232064|NCT02399124|Device|ICESENSE3™|single arm, open label, IceSense3TM treatment
232065|NCT02399137|Drug|MM-141|
232066|NCT02399137|Drug|Placebo|
232067|NCT02399137|Drug|Gemcitabine|
232068|NCT00163813|Procedure|Early jejunal feeding (using frictional NJ tube)|
231437|NCT00164970|Dietary Supplement|folate|
231438|NCT02407626|Drug|Sevoflurane|Volatile anesthesia is a clinical standard procedure
231439|NCT02407639|Other|CO2|gas
231440|NCT02407639|Other|air|air
231441|NCT02407652|Behavioral|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
231771|NCT02403713|Drug|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
231772|NCT02403713|Drug|Formoterol|Formoterol
231773|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
231774|NCT02403713|Drug|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
231775|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
231776|NCT00164476|Behavioral|Preventive Services Prevention Kit|
231777|NCT02403726|Procedure|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
231778|NCT02403726|Procedure|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
231779|NCT02403739|Other|No Intervention|No Intervention
231780|NCT02403752|Behavioral|Paired PLIE Program|Integrative exercise as described above
231781|NCT02403778|Drug|All-Trans Retinoic Acid|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). ATRA is a standard treatment for patients with acute promyelocytic leukemia (APL).
231782|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
231783|NCT02405611|Behavioral|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
231139|NCT02414165|Drug|Temozolomide|
231140|NCT00165555|Drug|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
231141|NCT02414165|Biological|Bevacizumab|
231142|NCT02414178|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
231143|NCT02414191|Behavioral|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
231144|NCT02414191|Behavioral|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
231145|NCT02414204|Drug|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
231146|NCT02414204|Other|Placebo|Placebo will be over encapsulated to identical to drug comparison
231147|NCT02414217|Behavioral|In-Person Diabetes Numeracy Education|Each participant randomized to the in-person education group will attend four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class can include a stable group of 8 and 16 participants, we will run classes in "cohorts" of 8-16 people. A participant will always attend classes with his/her cohort.
231148|NCT02414217|Behavioral|Online Diabetes Numeracy Education|Each participant randomized to the online education group will attend a single session, at which he/she will complete a computerized education module that addresses understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
231442|NCT02407652|Behavioral|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
231443|NCT02407665|Behavioral|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
231444|NCT02407678|Genetic|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
231445|NCT02407691|Other|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
231446|NCT02407691|Other|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
231447|NCT02407704|Drug|Venlafaxine XR|
230833|NCT02420418|Dietary Supplement|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
230834|NCT02420418|Other|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
230835|NCT02420431|Behavioral|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
230836|NCT02420431|Behavioral|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
230837|NCT02420444|Biological|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
230838|NCT02420444|Biological|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
230839|NCT02420444|Biological|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
230840|NCT02420457|Procedure|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
230841|NCT02420483|Other|Cardiopulmonary resuscitation chest compressions|
230842|NCT00166530|Drug|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
230843|NCT02420496|Drug|Enteral fish oil|
230844|NCT02420496|Drug|Ursodeoxycholic Acid|
230845|NCT02420496|Drug|Placebo|
230846|NCT02420509|Drug|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
230847|NCT02420522|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
231149|NCT02414230|Drug|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
231150|NCT02414243|Other|New Amino Acid formula|Ordesa's Amino-Acid based Infant Formula
231151|NCT00165568|Drug|Bevacizumab|
230269|NCT02393469|Other|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
230270|NCT02393482|Drug|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
230271|NCT02393482|Drug|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
230555|NCT02424630|Device|Ultrasound-guided ISB|ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
230556|NCT02424630|Device|Arthroscopy-guided SSNB|At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
230557|NCT02424630|Drug|Placebo|
230558|NCT02424630|Drug|Ropivacaine|All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
230559|NCT02424643|Behavioral|Monetary Incentive|$20 Amazon.com gift card
230560|NCT02424643|Behavioral|Altruistic Incentive|A preliminary statement of the importance of participation, and periodic "inspirational" messages throughout the length of the survey emphasizing the value to men's health by completing the survey
230561|NCT02424643|Behavioral|Dashboard Incentive|A sample "dashboard" will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data.
230562|NCT02424656|Procedure|MRI|EEG-functional MRI, structural MRI, diffusion MRI
230563|NCT00167323|Behavioral|Adherence therapy|
230564|NCT02424656|Procedure|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
230565|NCT02424656|Procedure|FDG-PET|
230566|NCT02424656|Other|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
230567|NCT02424669|Other|ALS Functional rating Scale-revised (ALS FRS-R)|
229982|NCT02400645|Drug|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
229983|NCT02400645|Drug|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
229984|NCT02400645|Drug|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
229985|NCT02400658|Device|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
229986|NCT02400671|Behavioral|SMS messaging|
230272|NCT02395939|Procedure|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
230273|NCT02395939|Procedure|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
230274|NCT02395952|Drug|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
230275|NCT02395952|Device|Acuvue Oasys Bandage Contact Lens|
230276|NCT00163293|Drug|Placebo|two puffs once daily, in the evening
230277|NCT02395952|Device|Ambiodisk|
230278|NCT02395952|Device|Prokera|
230279|NCT02395978|Drug|PDC-1421 Capsule|
230280|NCT02395978|Drug|placebo|
230281|NCT02395991|Drug|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
230282|NCT02395991|Other|Magnetic resonance imaging (MRI)|Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.
230283|NCT02396004|Device|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
230284|NCT02396017|Device|Capsule endoscopy|Endoscopic device
230285|NCT02396017|Drug|Polyethylene Glycol|Bowel purgative
230286|NCT02396030|Drug|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
229691|NCT00164892|Drug|Oral Vioxx (Rofecoxib)|
229692|NCT02406989|Drug|Placebo|Matching placebo to MS-553
229693|NCT02407015|Other|Nintendo 3DS gameplay|
229694|NCT02407028|Drug|Oxygen|HBO Oxygen; 2.0 ATA, no NBH everyday X five days or until patient following commands or brain dead
229695|NCT02407028|Drug|Oxygen|HBO Oxygen; 2.5 ATA, no NBH everyday X five days or until patient following commands or brain dead
229696|NCT02407028|Drug|Oxygen|HBO Oxygen; 1.5 ATA, with NBH everyday X five days or until patient following commands or brain dead
229697|NCT02407028|Drug|Oxygen|HBO Oxygen; 2.0 ATA, with NBH everyday X five days or until patient following commands or brain dead
229698|NCT02407028|Drug|Oxygen|HBO Oxygen; 2.5 ATA, with NBH everyday X five days or until patient following commands or brain dead
229699|NCT02407028|Drug|Oxygen|HBO Oxygen; 1.5 ATA, no NBH twice per day X five days or until patient following commands or brain dead
229700|NCT02407028|Drug|Oxygen|HBO Oxygen; 2.0 ATA, no NBH twice per day X five days or until patient following commands or brain dead
229701|NCT02407028|Drug|Oxygen|HBO Oxygen; 2.5 ATA, no NBH twice per day X five days or until patient following commands or brain dead
229702|NCT00164905|Device|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
229987|NCT02400684|Biological|blood samples|Evolution of AMH before and after deep endometriosis surgery
229988|NCT02400697|Other|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
229989|NCT02400710|Behavioral|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
229990|NCT02400710|Behavioral|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
229991|NCT00164099|Drug|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
229992|NCT02400723|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
229993|NCT02400723|Behavioral|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
229994|NCT02400723|Other|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
239029|NCT02463383|Drug|Alcohol + placebo|2.3 g alcohol + a placebo tablet
239030|NCT02463396|Behavioral|MBCT for ADHD|
239031|NCT02463409|Drug|Theophylline|
239032|NCT02463435|Behavioral|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
239033|NCT02463435|Other|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
239034|NCT02463435|Dietary Supplement|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
239035|NCT02463448|Biological|Autologous muscle derived cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the ample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
239036|NCT02463461|Device|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
234316|NCT02459197|Behavioral|Positive Video|
234317|NCT02459197|Behavioral|Neutral Video|
234318|NCT02459197|Drug|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
234319|NCT02459197|Drug|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
234320|NCT02459210|Behavioral|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
234321|NCT02459210|Behavioral|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
234322|NCT02459223|Dietary Supplement|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
234323|NCT00172003|Drug|Zoledronic acid|
234324|NCT02459223|Dietary Supplement|Khichadi|Khichadi.
234325|NCT02459236|Drug|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
234326|NCT02459236|Drug|Placebo|
238736|NCT02432521|Other|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
238737|NCT00168428|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
238738|NCT02432534|Drug|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
238739|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
238740|NCT02432547|Drug|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
239037|NCT00173654|Procedure|blood drawing|
239038|NCT02465593|Drug|5-fluorouracil|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy, starting at 24 hours later. Patients will have concurrent continuous IV infusion (CVI) of 5-FU(5-fluorouracil) or oral capecitabine. Once the concurrent chemoradiotherapy is completed, and patients have recovered from radiation effects , surgical resection of the tumor will be performed once the tumor become resectable.
239039|NCT02465593|Drug|capecitabine|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy, starting at 24 hours later. Patients will have concurrent continuous IV infusion (CVI) of 5-FU(5-fluorouracil) or oral capecitabine. Once the concurrent chemoradiotherapy is completed, and patients have recovered from radiation effects , surgical resection of the tumor will be performed once the tumor become resectable.
239040|NCT02465593|Procedure|surgical resection|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy, starting at 24 hours later. Patients will have concurrent continuous IV infusion (CVI) of 5-FU(5-fluorouracil) or oral capecitabine. Once the concurrent chemoradiotherapy is completed, and patients have recovered from radiation effects , surgical resection of the tumor will be performed once the tumor become resectable.
239041|NCT02465593|Radiation|Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy, starting at 24 hours later. Patients will have concurrent continuous IV infusion (CVI) of 5-FU(5-fluorouracil) or oral capecitabine. Once the concurrent chemoradiotherapy is completed, and patients have recovered from radiation effects , surgical resection of the tumor will be performed once the tumor become resectable.
239042|NCT02465606|Drug|Lebrikizumab|
239043|NCT02465606|Drug|Topical corticosteroid (TCS) cream|
239044|NCT02465632|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
229458|NCT02417948|Other|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
229459|NCT00166166|Drug|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
229460|NCT02417948|Other|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
229461|NCT02417961|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
229462|NCT02417974|Biological|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
229463|NCT02417987|Other|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
229464|NCT02417987|Drug|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
229465|NCT02417987|Biological|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
229466|NCT02418000|Drug|E6201|Single Group Assignment
229467|NCT02418013|Other|Fresh cord blood(experimental group A)|Cord blood is administered through intravenous at CHA clinical trail institute.
Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment.
229468|NCT02418013|Other|Frozen cord blood(experimental group B)|Cord blood is administered through intravenous at CHA clinical trail institute.
Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered
229469|NCT02418013|Other|Frozen plasma(experimental group C)|Cord blood is administered through intravenous at CHA clinical trail institute.
Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered
229470|NCT02419911|Procedure|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
229471|NCT02419911|Device|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
229472|NCT02419911|Device|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
229758|NCT02413554|Drug|Rivastigmine patch|acetylcholine esterase inhibitor
229759|NCT02413567|Device|DMR Procedure (Fractyl)|Endoscopic procedure
229760|NCT02413580|Biological|IGIV-C|an IV dose of 2 g/kg of IGIV-C will be administered as 2 doses of 1 g/kg on two consecutive days
229761|NCT02413593|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
229762|NCT00165490|Device|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
233794|NCT02397395|Drug|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
233795|NCT02397408|Drug|Choline PET/MR|
229168|NCT02423993|Procedure|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
229169|NCT02424006|Device|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
229170|NCT02424006|Device|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
229171|NCT02424019|Drug|ILUVIEN®|
229172|NCT02424032|Behavioral|"Exercise" and "connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
229173|NCT02424032|Behavioral|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
229174|NCT02424045|Drug|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
229175|NCT00167258|Behavioral|Voucher Reinforcement|
229176|NCT02424058|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
229177|NCT02424058|Behavioral|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
229178|NCT02424071|Drug|Melatonin|
229179|NCT02424071|Drug|placebo|
229180|NCT02424084|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
229181|NCT02426281|Drug|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
233514|NCT02404337|Drug|Betaine|
233515|NCT02404350|Biological|Secukinumab|Anti IL-17a monoclonal antibody
233516|NCT00164567|Behavioral|Onsite IPV specialist|
233517|NCT02404363|Drug|Clopidogrel|Clopidogrel tablets 75 mg for six months:
In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --> clopidogrel 150 mg/d x 7days then 75mg/d
233796|NCT02397421|Drug|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
233797|NCT00163540|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
233798|NCT02397421|Drug|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
233799|NCT02397434|Radiation|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
233800|NCT02397447|Drug|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
233801|NCT02397447|Drug|Placebo|Placebo: 2000 mg per day for three months
233802|NCT02397460|Drug|AF-219|
233803|NCT02397460|Drug|Placebo (for AF-219)|
233804|NCT02397473|Drug|LY2951742|Administered SC
233805|NCT02397473|Drug|Placebo|Administered SC
233806|NCT02397486|Drug|Pentoxifylline|
233807|NCT02397486|Drug|Vitamin E|
233808|NCT00163553|Drug|Pethidine|
233809|NCT02397486|Drug|Cisplatin|
233810|NCT02397486|Radiation|Radiation therapy|
233811|NCT02397499|Drug|LIPO-202|
233812|NCT02397499|Drug|Placebo|
233813|NCT02397512|Drug|application of lactulose|Subjects will ingest 50g of lactulose once
233814|NCT02397512|Other|application of sucrose|Subjects will ingest 50g of sucrose once
233227|NCT00165087|Drug|asparaginase (E. Coli)|
233228|NCT02410577|Device|MRI|
233229|NCT02410590|Drug|Rocuronium|
233230|NCT02410590|Drug|Sugammadex|
233518|NCT02404363|Drug|Placebo|Placebo tablets 75 mg for six months:
In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --> placebo 150 mg/d x 7days then 75mg/d
233519|NCT02404376|Drug|Exenatide|Intravenous administration of Exenatide
233520|NCT02404376|Other|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
233521|NCT02404376|Drug|Placebo|Intrevenous administration of Placebo
233522|NCT02404389|Drug|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
233523|NCT02404389|Drug|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
233524|NCT02404402|Other|LED|Low Level Light Therapy
233525|NCT02404402|Other|sham LED|Inactive (sham) LED treatment
233526|NCT02404428|Dietary Supplement|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
233527|NCT00164567|Behavioral|Empowerment focused intervention|
233528|NCT02404428|Dietary Supplement|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
233529|NCT02404441|Biological|PDR001|anti-PD1 antibody
233530|NCT02404454|Procedure|Hysteroscopic metroplasty|
233531|NCT02404454|Device|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
233532|NCT02404454|Procedure|Office second look hysteroscopy|Second-look hysteroscopy after three months
233533|NCT02404467|Device|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
233534|NCT02404480|Drug|PTC596|
232936|NCT02414945|Biological|Interleukin-2|
232937|NCT02414958|Drug|Empagliflozin|
232938|NCT00165659|Drug|DONEPEZIL HYDROCHLORIDE|
232939|NCT02414958|Drug|Empagliflozin|
232940|NCT02414958|Drug|Placebo|
232941|NCT02414971|Other|There is no intervention|this is an observational study without intervention
232942|NCT02414984|Biological|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
232943|NCT02414997|Procedure|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
232944|NCT02414997|Procedure|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
232945|NCT02415010|Device|Enterprise 2 Vascular Reconstruction Device|
233231|NCT02410590|Drug|Cisatracurium|
233232|NCT02410590|Drug|Neostigmine/Atropine|
233233|NCT02410590|Drug|Succinylcholine|
233234|NCT02410616|Behavioral|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
233235|NCT02410616|Behavioral|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
233236|NCT00165191|Drug|Doxorubicin|
233237|NCT02410629|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
233238|NCT02410629|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
233239|NCT02410642|Procedure|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
232658|NCT02421120|Drug|Ceftolozane/Tazobactam|1 hour intravenous infusion
232659|NCT02421133|Other|Transitional care program.|During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.
The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.
During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit.
232660|NCT02421133|Other|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician…) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
232661|NCT02421146|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
232662|NCT02421146|Device|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
232663|NCT02421159|Behavioral|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
232664|NCT00166673|Device|FreeStyle Navigator Continuous Glucose Monitoring System|
232946|NCT02415023|Drug|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
232947|NCT00166049|Behavioral|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
232948|NCT02417064|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
232949|NCT02417064|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
232950|NCT02417064|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
232665|NCT02421159|Behavioral|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
232666|NCT02421172|Biological|CJM112|Fully human IgG1 monoclonal antibody
232667|NCT02423252|Behavioral|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
232668|NCT02423252|Other|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
232669|NCT02423265|Drug|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
232670|NCT02423265|Drug|Placebo|Matching placebo: up-titration after 1 week
232671|NCT02423278|Procedure|Radical Gastrectomy Plus D2 Lymphadenectomy|This surgical procedure is performed by the same high-experienced surgical team as the control arm.
All lymph nodes around stomach (station 1&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams.
232672|NCT02423278|Procedure|Radical Gastrectomy Plus D4 Lymphadenectomy|This surgical procedure is also performed by the same high-experienced surgical team as the control arm.
Lymph nodes around stomach (station 1&2 LNs) and para-aortic lymph nodes must be removed during the operation.
232673|NCT00167167|Procedure|Donor Lymphocyte Infusion|Certain immune cells in your donor's blood called "lymphocytes" have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's "lymphocytes" in the hope of activating the recipient's immune system to attack cancer.
232674|NCT02423278|Drug|S-1+Oxaliplatin|A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:
S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）
Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
232675|NCT02423291|Drug|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
232676|NCT02423304|Genetic|blood samples collected from all patients|blood samples collected from brachial pluxes
232677|NCT02423317|Device|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
232678|NCT02423317|Device|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
232069|NCT02399137|Drug|Nab-Paclitaxel|
232070|NCT02399150|Other|No intervention as observational study|
232071|NCT02399163|Drug|Fluoride free toothpaste|Brushing with fluoride free toothpaste
232072|NCT02399163|Drug|Fluoride toothpaste|Brushing with fluoride containing toothpaste
232073|NCT02399163|Drug|Fluoride mouthwash|Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in "Placebo dentifrice/Fluoride rinse" arm and in "Fluoride dentifrice/Fluoride rinse" arm
232074|NCT02399176|Behavioral|Yoga|Subjects assume 10 physical postures for 30 seconds each
232379|NCT02427542|Other|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
232380|NCT02427542|Other|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
232381|NCT02427555|Other|Barley kernel bread|3 days intervention with barley kernel bread
232382|NCT02427555|Other|white wheat bread|3 days intervention with white wheat bread
232383|NCT02427568|Drug|MDMA|Subjects undergo two day-long experimental sessions of psychotherapy
232384|NCT02427568|Drug|Placebo|Subjects undergo two day-long experimental sessions of psychotherapy
232385|NCT02427581|Biological|Personalized synthetic long peptide vaccine (Poly ICLC)|
232386|NCT02394366|Other|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
232387|NCT00163111|Drug|Conventional amphotericin B|
232388|NCT02394366|Other|OHS base only|Olive and beeswax salve base
232389|NCT02394379|Device|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
232390|NCT02394418|Drug|Sevoflurane|Treatment of delirium by inhaled sevoflurane
232391|NCT02394418|Drug|Propofol|Treatment of delirium by propofol i.v. infusion
232392|NCT02394418|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
232393|NCT02394431|Other|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
231784|NCT02405624|Procedure|continuous positive airway pressure|CPAP training for muscle strength
231785|NCT02405637|Drug|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
231786|NCT00164723|Procedure|Capsule endoscopy|Capsule endoscopy and colonoscopy
231787|NCT02405637|Drug|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
231788|NCT02405663|Procedure|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
232075|NCT02399189|Drug|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
232076|NCT02399202|Drug|osilodrostat|
232077|NCT02399215|Other|Laboratory Biomarker Analysis|Correlative studies
232078|NCT02399215|Drug|Nintedanib|Given PO
232079|NCT00163813|Procedure|Standard feeding (using nasogastric [NG] tube)|
232080|NCT02399215|Other|Pharmacological Study|Correlative studies
232081|NCT02399215|Other|Quality-of-Life Assessment|Ancillary studies
232082|NCT02399228|Drug|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
232083|NCT02399241|Device|Bluetooth enabled nebuliser device (I-neb)|
232084|NCT02401516|Device|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
232085|NCT02401529|Drug|IV dexamethasone|0.15 mg/kg
232086|NCT02401529|Drug|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
232087|NCT00164177|Drug|HalfLytely|
232088|NCT02401529|Drug|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
231448|NCT00164996|Procedure|Local pharyngeal anaesthesia|
231449|NCT02407704|Other|Aerobic Exercise|
231450|NCT02407704|Drug|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
231451|NCT02407743|Behavioral|Surgical patients' clinical progression|Study the dynamic nature of pain
231452|NCT02407743|Genetic|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
231453|NCT02407756|Drug|Dupilumab|
231454|NCT02409953|Other|Lying in a bath during 2 hours|
231455|NCT02409953|Other|Lying in a bed during 2 hours|
231456|NCT02409966|Procedure|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.
Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study.
231457|NCT02409966|Procedure|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.
Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study.
231458|NCT02409979|Other|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
231459|NCT02409979|Other|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
231460|NCT02409979|Other|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
231789|NCT02405663|Procedure|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
231790|NCT02405676|Drug|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
231791|NCT02405676|Drug|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
231792|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 60mg/m2, D3~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1;
231152|NCT02414243|Other|Commercially available Amino Acid Formula|Commercially available Amino Acid Formula
231153|NCT02414256|Other|regional anesthesia in breast surgery|
231154|NCT02414269|Genetic|iCasp9M28z T cell infusions|On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T-Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of PI.
231155|NCT02414269|Drug|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2)
231156|NCT02414282|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
231157|NCT02414295|Drug|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
231158|NCT02416414|Device|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
231159|NCT02416414|Device|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
231160|NCT02416427|Drug|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
231161|NCT02416440|Other|blood sample|blood sample
231162|NCT02416453|Biological|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
231163|NCT02416453|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
231164|NCT02416453|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
231165|NCT02416466|Biological|anti-CEA CAR-T cells|Gene modified patient T cells.
231166|NCT00165893|Procedure|Physical Therapy|
231167|NCT02416466|Device|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
231461|NCT02409992|Behavioral|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
230568|NCT02426788|Behavioral|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS, and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to prevent ongoing symptoms and disruption to healthy living. The approach is de factor transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
230569|NCT00167596|Device|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
230570|NCT02426801|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
230848|NCT02420522|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
230849|NCT02420535|Behavioral|Immediately Receive Tool|
230850|NCT02420535|Behavioral|One Month Delay|
230851|NCT02420548|Behavioral|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
230852|NCT02420548|Behavioral|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
230853|NCT00166543|Drug|TAS-108|
230854|NCT02420561|Behavioral|Motivational Interviewing|One in-person motivational interviewing session intervention that lasts for 45-minutes
Additional two 15-minute telephone "booster" sessions post in-person 45 minute sessions
230855|NCT02422511|Genetic|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
230856|NCT02422511|Other|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
230857|NCT02422524|Drug|PA-824|PA-824 is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg PA-824 on day 1.
230858|NCT02422537|Dietary Supplement|Unmodified wheat bran|
230859|NCT02422537|Dietary Supplement|Wheat bran with reduced particle size|
230860|NCT02422537|Dietary Supplement|Destarched pericarp-enriched wheat bran|
230287|NCT00163306|Drug|Pantoprazole|
230288|NCT02396030|Drug|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
230289|NCT02396043|Drug|induction|Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.
Pegaspargase :3750U/m2 im on days 8,22
230290|NCT02396043|Drug|induction|Cyclophosphamide: 1000 mg/m2 iv on days 29, 57,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41, 45-48, 52-55,Mercaptopurine: 60 mg/m2 po on days 29-56
230291|NCT02396043|Drug|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
230292|NCT02396043|Drug|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
230571|NCT02426801|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
230572|NCT02426814|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
230573|NCT02426814|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
230574|NCT02426827|Device|Spinal Cord Stimulation|
230575|NCT02426840|Dietary Supplement|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
230576|NCT02426840|Dietary Supplement|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
230577|NCT02426853|Behavioral|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
230578|NCT02426853|Other|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
230579|NCT02426853|Behavioral|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
230580|NCT00167596|Device|conventional|resuscitation will be based according to Surviving Sepsis Campaign
230581|NCT02426866|Drug|Efavirenz|
229995|NCT02402920|Radiation|Radiation Therapy|Limited Stage SCLC MK-3475 + Radiation Group: Radiation therapy delivered to chest at 45 Gy twice a day for 15 days.
Extensive Stage SCLS MK-3475 + Radiation Group: Radiation therapy delivered to chest at 45 Gy once a day for 15 days.
229996|NCT00164359|Drug|chlorproguanil-dapsone plus artesunate|
229997|NCT02402933|Drug|Glucagon|3 mg glucagon powder
229998|NCT02402946|Behavioral|Biofeedback|
229999|NCT02402946|Drug|Placebo|
230000|NCT02402959|Other|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
230001|NCT02402972|Drug|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
230002|NCT02402972|Drug|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
230003|NCT02402985|Other|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
230004|NCT02402985|Other|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
230005|NCT02402998|Drug|Eltrombopag|Eltrombopag 50 mg/daily.
230293|NCT02396043|Drug|reinduction|Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.
Pegaspargase :3750U/m2 im on days 8
230294|NCT02396043|Drug|reinduction|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
230295|NCT02396043|Drug|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
230296|NCT02398318|Device|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
230297|NCT02398318|Device|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
230298|NCT02398331|Other|Standardised information and education on sexuality in women with spinal cord injury|Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:
Educational footage
Clinical neurological examination with educational aim
Structured consultation providing information on the physiology of sexual response in women with spinal cord injury
230299|NCT02398344|Device|tDCS active|Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
234327|NCT02459249|Other|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
234328|NCT02459249|Other|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
234329|NCT02459262|Biological|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
234330|NCT02459275|Other|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day. A promotility agent will be started empirically concomitant with EN initiation. GRV will be checked every 4 hours and will be reinfused to the patient each time it is checked. GRV threshold is 500 ml. Once the patient shows tolerance of semi-elemental formula, the tube feeds will then be converted to standard polymeric formula. Daily, the patient will be reassessed for the need to continue promotility agents.
234331|NCT02459288|Drug|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
234332|NCT02459288|Drug|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
234333|NCT02461355|Behavioral|Aphasia therapy|Aphasia therapy using a computerized scripting program
234334|NCT02461355|Device|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
234635|NCT02454647|Drug|Induction chemotherapy|
234636|NCT02454647|Radiation|Radiotherapy with concurrent chemotherapy|
234637|NCT02454647|Procedure|Salvage surgery|
234638|NCT02454660|Behavioral|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
234639|NCT02454699|Other|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
234640|NCT02454699|Drug|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
234641|NCT00171314|Drug|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
234642|NCT02454712|Drug|PF614|PF614 is an oxycodone prodrug
234643|NCT02454712|Drug|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
239045|NCT02465632|Drug|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
239046|NCT02465632|Drug|Placebo|
239047|NCT02465645|Drug|Carvedilol|
239048|NCT00174330|Drug|amlodipine|
239049|NCT02465645|Drug|Carvedilol + Simvastatin|
239050|NCT02465658|Other|Medical records were reviewed.|retrospective study
239051|NCT02465684|Procedure|unicondylar knee arthroplasty|
239052|NCT02465697|Behavioral|Reappraisal Training|
239053|NCT02465710|Procedure|Pelvic organ prolapse surgery without mesh|retrospective study
239054|NCT02465710|Procedure|Pelvic organ prolapse surgery with mesh|
239055|NCT02465723|Device|MRI with IVIM DW-MRI|
239056|NCT02465723|Other|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
239057|NCT02465736|Drug|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
234335|NCT02461355|Device|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
234336|NCT02461368|Drug|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
234337|NCT00172380|Drug|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
234338|NCT02461368|Drug|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
234339|NCT02461368|Drug|Glenohumeral lidocaine injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
234340|NCT02461368|Drug|Glenohumeral lidocaine injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
229763|NCT02413593|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
229764|NCT02413606|Other|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
229765|NCT02413619|Procedure|Vitrectomy|Vitrectomy
229766|NCT02413619|Procedure|Cataract surgery|Cataract surgery
229767|NCT02413619|Procedure|Combined surgery|Combined vitrectomy and cataract surgery at the same time
229768|NCT02413632|Other|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
229769|NCT02413632|Other|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
229770|NCT02413645|Biological|TriMix_100|100 μg of TriMix in
229771|NCT02413645|Biological|TriMix_300|300 μg of TriMix in
229772|NCT02413645|Biological|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
229773|NCT00165490|Procedure|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
229774|NCT02413645|Biological|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
229775|NCT02413645|Biological|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
229776|NCT02413658|Drug|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
229777|NCT02413658|Drug|Sugar solution|
229778|NCT02413671|Dietary Supplement|Lupine Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupine protein.
229779|NCT02413671|Dietary Supplement|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
230055|NCT02409342|Drug|Atezolizumab (MPDL3280A)|1200 mg IV infusion every 21 days until loss of clinical benefit, unacceptable toxicity, or death
230056|NCT02409342|Drug|Carboplatin|Area under the concentration-time curve (AUC) 6 intravenous (IV) infusion every 21 days for 4 or 6 cycles until disease progression, unacceptable toxicity, or death
230057|NCT02409342|Drug|Cisplatin|75 mg/m^2 IV infusion every 21 days for 4 or 6 cycles until disease progression, unacceptable toxicity, or death
229182|NCT02426294|Drug|Pioglitazone|
229183|NCT02426294|Drug|Glimepiride|
229184|NCT02426307|Procedure|TAVR|TAVR: Transcatheter Aortic Valve Replacement
229185|NCT02426307|Procedure|SAVR|SAVR: surgical Aortic Valve Replacement
229186|NCT02426320|Other|Sedation Interruption Protocol|
229473|NCT02419924|Device|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
229474|NCT00166478|Drug|Exisulind Therapy|
229475|NCT02419937|Drug|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
229476|NCT02419937|Drug|Placebo|Saline injection
229477|NCT02419950|Device|Fixation of mesh in TEP|An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
229478|NCT02419963|Procedure|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
229479|NCT02419963|Other|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
229480|NCT02419963|Other|Stool Sample|Stool sample to evaluate microbiome fingerprint.
229481|NCT02419976|Other|a breath analysis using the Aeonose|using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.
Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure.
229482|NCT02419976|Device|Aeonose|
229483|NCT02420002|Drug|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
229484|NCT02420002|Other|Use of Hyponosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hyponosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
229485|NCT00166491|Drug|Insulin|
229486|NCT02420002|Procedure|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
233815|NCT02399826|Device|Offloading|Provision of an offloading cam walker or cast boot, may also convert to "total contact cast" and add felt or foam to supplement
233816|NCT02399826|Procedure|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
233817|NCT02399839|Drug|lomitapide|As prescribed by Physician.
233818|NCT02399852|Drug|Lomitapide|
229187|NCT02426320|Other|Standard Sedation Protocol|
229188|NCT02426333|Other|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
229189|NCT00167544|Drug|Placebo|Saline
229190|NCT02426346|Behavioral|Behavioral weight control|Prescription of diet & physical activity and behavioral strategies for weight control
229191|NCT02426346|Behavioral|Group-based physical activity|Teens exercise for 60 minutes with their group
229192|NCT02426346|Behavioral|Group-based incentives|Adolescents earn reinforcements within group
229193|NCT02426346|Behavioral|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
229194|NCT02426359|Drug|Q301 Cream|
229195|NCT02426359|Drug|Placebo|
229196|NCT02426372|Biological|QBECO SSI|QBECO Site Specific Immunomodulators
229197|NCT02426385|Device|FineVision Toric|Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
229198|NCT02426411|Drug|EMA401 200 mg|
229199|NCT02426411|Drug|EMA401 600 mg|
229200|NCT00167557|Drug|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
229201|NCT02426411|Drug|Placebo|
229202|NCT02426424|Device|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
229203|NCT02426424|Device|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
233535|NCT02404493|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
233536|NCT02404493|Drug|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
233537|NCT02404506|Drug|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
233538|NCT02406352|Device|Multispectral Digital Colposcope with probe|Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.
The standard of care for research participants will not change.
233539|NCT02406365|Device|Diagnostic imaging aid for one-visit management of cervical lesions|
233819|NCT02399865|Other|Youth Social Behaviour and Network Therapy|The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.
Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements.
233820|NCT02399878|Drug|Inspiratory oxygen|
233821|NCT02399891|Other|Quality Assurance Implementation|
233822|NCT02399891|Other|Standard of Care|
233823|NCT02399904|Other|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
233824|NCT02399917|Drug|5-azacytidine|Phase I Starting Dose: 75 mg/m2 a day by vein or subcutaneously on Days 1 - 7 of a 28 day cycle.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I.
233825|NCT00163943|Behavioral|Dietary weight loss +/- aerobic exercise|
233826|NCT02399917|Drug|Lirilumab|Phase I Starting Dose: 1.0 mg/kg by vein on Day 8 of a 28 day cycle.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I.
233827|NCT02399917|Behavioral|Phone Call|If participant cannot come to the clinic, they will be called about 30 days after they go off study. This call will last about 5 minutes.
If participant goes off study for reasons other than the disease getting worse, they will be called every 3-6 months for up to 5 years. Each call should last about 5 minutes.
233240|NCT02410655|Drug|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
233241|NCT02410655|Drug|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
233242|NCT02410668|Dietary Supplement|flaxseed|
233243|NCT02410668|Dietary Supplement|Placebo|
233244|NCT02410668|Behavioral|Exercise recommendation|
233245|NCT02410681|Device|Electromyographic recording of temporalis muscle activity during sleep|Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.
3 recordings after the baseline visit
3 recordings 6 weeks after the baseline visit
3 recordings one year after the baseline visit
233246|NCT02410681|Radiation|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
233247|NCT00165191|Drug|Cisplatin|
233248|NCT02410681|Other|Collection of biofilm sample|Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:
At the baseline visit
Three months after the baseline visit
One year after the baseline visit
233249|NCT02410694|Drug|Ixazomib|
233540|NCT00164788|Drug|Oral esomeprazole|40mg every 12 hours for 24 hours
233541|NCT02406404|Behavioral|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
233542|NCT02406417|Device|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
233543|NCT02406417|Device|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
233544|NCT02406430|Procedure|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
232951|NCT02417064|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
232952|NCT02417064|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
232953|NCT02417077|Other|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
232954|NCT02417090|Drug|Insulin|Pregnant women who used insulin to treat gestational diabetes
232955|NCT02417090|Drug|Metformin|Pregnant women who used metformin to treat gestational diabetes
232956|NCT02417103|Drug|GLP-1 (Liraglutide)|GLP-1 Analogon
232957|NCT02417103|Drug|Placebo|Placebo
232958|NCT00166049|Behavioral|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
232959|NCT02417116|Other|Tear supplement|Application as required to improve comfort
232960|NCT02417116|Other|Tear supplement 2|Application as required to improve comfort
232961|NCT02417116|Dietary Supplement|Omega 3 nutrition supplement|Taken each day
232962|NCT02417116|Device|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
232963|NCT02417116|Other|Saline|Application as required to improve comfort
232964|NCT02417129|Drug|Rituximab|BI 695500 375 mg/M2
233250|NCT02410694|Drug|Thalidomide|
233251|NCT02410694|Drug|Dexamethasone|
233252|NCT02412748|Behavioral|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
233253|NCT02412761|Drug|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
233254|NCT02412761|Drug|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
233255|NCT02412761|Drug|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
232679|NCT02423330|Device|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
232965|NCT02417129|Drug|BI 695500|BI 695500 375 mg/M2
232966|NCT02417142|Drug|Exenatide|Exenatide (plus existing treatment) 2mg/week for 24 weeks.
232967|NCT02417142|Drug|Placebo|Placebo (plus existing treatment) for 24 weeks.
232968|NCT02419391|Other|Placebo|Tris Buffered Saline, sterile
232969|NCT02419417|Drug|BMS-986158|
232970|NCT02419417|Drug|Paclitaxel|
232971|NCT02419430|Behavioral|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
232972|NCT02419430|Behavioral|Phone application only|Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:
Joys of Life
Count your blessings
Think differenc, feel better
Exercising --> Happier
+ Exercising --> Sleep
Pre-Sleep routine
Eat that frog
Mindful Meditation
232973|NCT02419430|Behavioral|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
232974|NCT00166348|Behavioral|Cognitive Group Therapy|
232975|NCT02419443|Drug|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
232976|NCT02419443|Drug|Placebo|
232977|NCT02419456|Drug|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
232978|NCT02419456|Drug|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
232979|NCT02419469|Drug|Cytarabine|Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.
Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.
Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11.
232394|NCT02394431|Other|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
232395|NCT02394431|Other|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
232396|NCT02394444|Other|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
232397|NCT02394457|Drug|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
232398|NCT00163111|Drug|Diflucan IV, oral|
232399|NCT02394457|Procedure|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
232400|NCT02394470|Other|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
232680|NCT02423343|Drug|Galunisertib|Administered orally
232681|NCT02423343|Drug|Nivolumab|Administered IV
232682|NCT02423356|Procedure|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
232683|NCT02423369|Procedure|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
232684|NCT00167180|Procedure|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10^8 CD3+T-cells/kg
232685|NCT02425384|Behavioral|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
232686|NCT02425384|Other|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
232687|NCT02425397|Genetic|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
232688|NCT02425397|Genetic|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
232689|NCT02425410|Other|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
232089|NCT02401529|Drug|IV saline|IV saline
232090|NCT02401542|Drug|B-701|
232091|NCT02401542|Drug|Docetaxel|
232092|NCT02401542|Drug|placebo|
232093|NCT02401555|Device|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
232094|NCT02401568|Device|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
232095|NCT02401568|Procedure|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
232401|NCT02394470|Other|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
232402|NCT02394470|Other|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
232403|NCT02394483|Drug|F901318 safety|Safety assessments
232404|NCT02394483|Drug|F901318 tolerability|Tolerability assessments
232405|NCT02394483|Drug|F901318 pharmacokinetics|Pharmacokinetic assessments
232406|NCT02394483|Other|Placebo safety|Safety assessments
232407|NCT02394483|Other|Placebo tolerability|Placebo tolerability
232408|NCT02394483|Other|Placebo pharmacokinetics|Plaacebo pharmacokinetics
232409|NCT00163124|Procedure|spinal manipulation & patient education/nutrition|
232410|NCT02394496|Drug|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
232411|NCT02394496|Drug|Lapatinib|1500mg (TBD) O.S. qd
232412|NCT02394496|Drug|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
232413|NCT02396823|Behavioral|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
231793|NCT02405676|Drug|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
231794|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 100mg/m2, D3~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
231795|NCT02405676|Drug|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
231796|NCT02405689|Drug|Remifentanil|
231797|NCT00164736|Drug|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
231798|NCT02405689|Drug|Dexmedetomidine|
231799|NCT02405689|Drug|Sevoflurane|
231800|NCT02405702|Other|restrospective study|
231801|NCT02405715|Drug|Oxytocin|
231802|NCT02407769|Dietary Supplement|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
231803|NCT02407782|Drug|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
231804|NCT02407782|Drug|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
231805|NCT02407795|Radiation|conventional radiotherapy|1x8Gy
231806|NCT02407795|Radiation|stereotactic radiotherapy|1x20Gy
231807|NCT00164996|Device|Ultrathin endoscope|
231808|NCT02407808|Drug|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
232096|NCT02401581|Other|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
232097|NCT02401594|Drug|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
231462|NCT02409992|Behavioral|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
231463|NCT02410005|Dietary Supplement|Calcitriol|
231464|NCT00165178|Drug|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
231465|NCT02410005|Drug|Losartan|
231466|NCT02410018|Device|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
231467|NCT02410031|Drug|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
231468|NCT02410057|Dietary Supplement|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula
231469|NCT02410057|Dietary Supplement|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
231470|NCT02410057|Dietary Supplement|Standard infant formula|Standard infant formula
231471|NCT02410070|Procedure|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
231472|NCT02410083|Drug|Clopirin 1|
231473|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 1|
231474|NCT02410083|Drug|Clopirin 2|
231475|NCT00165178|Drug|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
231476|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 2|
231477|NCT02410096|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
231478|NCT02412150|Drug|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
231479|NCT02412150|Procedure|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
231480|NCT02412150|Other|Vital signs|Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.
And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed.
230861|NCT02422550|Device|MRI|Patients enrolled on this protocol may undergo multiple MRI examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
230862|NCT00166881|Drug|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
230863|NCT02422563|Procedure|hysterectomy|radical hysterectomy
230864|NCT02422563|Radiation|Radiation|
230865|NCT02422563|Drug|Cisplatin|
230866|NCT02422563|Drug|Paclitaxel|
230867|NCT02422563|Drug|Carboplatin|
230868|NCT02422563|Drug|Ifosfamide|
231168|NCT02416479|Behavioral|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
231169|NCT02416479|Behavioral|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
231170|NCT02416492|Biological|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
231171|NCT02416492|Procedure|Sham Control|Sham Surgery (Partial burr hole only)
231172|NCT02416505|Behavioral|Verbal+Anatomic Model|
231173|NCT02416505|Behavioral|Verbal+Video|
231174|NCT02416531|Drug|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
231175|NCT02416531|Radiation|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
231176|NCT02416531|Radiation|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
231177|NCT00165919|Other|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
231178|NCT02416544|Other|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
230582|NCT02426879|Procedure|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
230583|NCT02426892|Biological|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
230584|NCT02426892|Drug|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
230585|NCT02426905|Drug|trientine dihydrochloride|A retrospective review of patients' medical records
230586|NCT02426918|Drug|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
230587|NCT02393482|Drug|Add back therapy 1 (tibolone)|tibolone 5 mg/die
230588|NCT02393482|Drug|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
230589|NCT02393495|Device|intrauterine device TCu 380A|
230869|NCT02422576|Other|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
230870|NCT02422576|Other|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
230871|NCT02422576|Other|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
230872|NCT02422576|Other|Thicken Up clear: TUC|
230873|NCT00166907|Behavioral|Balance and Exercise|
230874|NCT02422589|Drug|ceritinib|
230875|NCT02422589|Drug|warfarin|
230876|NCT02422589|Drug|midazolam|
230877|NCT02422602|Drug|Xarelto|Taking conventional charge
230878|NCT02422602|Other|Experimental: Personalized information intervention|
230879|NCT02422615|Drug|Ribociclib|Riblociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle)
230880|NCT02422615|Drug|fulvestrant|fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
230881|NCT02422615|Drug|Ribociclib placebo|Riblociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle)
230300|NCT02398344|Device|tDCS Sham|Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
230301|NCT00163683|Behavioral|Dietary Therapy|
230302|NCT02398357|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
230303|NCT02398370|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
230304|NCT02398383|Other|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
230305|NCT02398383|Other|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
230306|NCT02398383|Other|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
230590|NCT02393508|Other|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
230591|NCT02393508|Other|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
230592|NCT00002433|Drug|Interferon gamma-1b|
230593|NCT00163007|Procedure|Nutritional support|
230594|NCT02393521|Device|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
230595|NCT02393534|Other|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
230596|NCT02393547|Drug|Varenicline|All subjects receive Varenicline
234644|NCT02454725|Behavioral|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
234645|NCT02454725|Behavioral|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
234646|NCT02454738|Radiation|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
234647|NCT02454751|Drug|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
234648|NCT02454764|Drug|Tenofovir + Interferon alpha 2b|
234649|NCT02454764|Drug|Tenofovir disoproxil Fumarate|
234650|NCT02454777|Behavioral|Exercise Intervention|Undergo HIT
234651|NCT02454777|Behavioral|Exercise Intervention|Undergo MCT
234652|NCT00171327|Drug|valsartan, fluvastatin|
234653|NCT02454777|Other|Laboratory Biomarker Analysis|Correlative studies
234654|NCT02454777|Other|Quality-of-Life Assessment|Ancillary studies
234655|NCT02457091|Behavioral|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
234933|NCT00002463|Drug|Mechlorethamine Hydrochloride|
234934|NCT00170690|Drug|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
234935|NCT02450240|Behavioral|behavioral tasks|
234936|NCT02450240|Other|physiological measurements|
234937|NCT02450240|Other|structural and functional magnetic resonance imaging and EEG|
234938|NCT02450240|Other|biomarker and microbiome assessments|
234939|NCT02450240|Other|blood to derive induced pluripotent stem cells|
234940|NCT02450240|Other|genetic and epigenetic assessments|
234941|NCT02450253|Drug|Tadalafil|single dose, 20 mg capsule p.o.
234341|NCT02461368|Drug|Glenohumeral normal saline injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
234342|NCT02461368|Drug|Glenohumeral normal saline injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
234343|NCT02461368|Drug|Glenohumeral Omnipaque injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
234344|NCT02461368|Drug|Glenohumeral Omnipaque injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
234345|NCT02461381|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
234346|NCT02461394|Device|Blood glucose monitoring systems for self-testing|
234347|NCT02461407|Drug|Anlotinib|Anlotinib p.o. qd
234348|NCT00002471|Drug|asparaginase|
234349|NCT00172419|Drug|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
234350|NCT02461407|Drug|Placebo|Placebo p.o. qd
234351|NCT02461433|Device|Prevena|Prevena Incision Management system
234352|NCT02461433|Device|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
234353|NCT02461472|Other|not intervention|This is a cross-sectional study, no intervention was performed.
234656|NCT02457091|Behavioral|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
234657|NCT02457104|Procedure|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
234658|NCT02457104|Behavioral|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
234659|NCT02457117|Radiation|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
234660|NCT02457130|Drug|Ticagrelor|
234661|NCT02457130|Drug|Clopidogrel|
230058|NCT00165139|Drug|Cisplatin|Described under detailed description
230059|NCT02409342|Drug|Pemetrexed|500 mg/m^2 IV infusion every 21 days for 4 or 6 cycles followed by maintenance therapy according to local standard of care
230060|NCT02409355|Drug|Atezolizumab (MPDL3280A)|1200 mg IV infusion every 21 days until loss of clinical benefit, unacceptable toxicity, patient or physician decision to discontinue, or death
230061|NCT02409355|Drug|Carboplatin|Area under the concentration-time curve (AUC) 5 IV infusion on Day 1 every 21 days for 4 or 6 cycles until unacceptable toxicity, patient or physician decision to discontinue, or death
230062|NCT02409355|Drug|Cisplatin|75 mg/m^2 IV infusion on Day 1 every 21 days for 4 or 6 cycles until unacceptable toxicity, patient or physician decision to discontinue, or death
230063|NCT02409355|Drug|Gemcitabine|1000 mg/m^2 (when coadministered with carboplatin) or 1250 mg/m2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 every 21 days for 4 or 6 cycles until unacceptable toxicity, patient or physician decision to discontinue, or death
230064|NCT02409368|Drug|Nivolumab|
230065|NCT02409381|Drug|Motore|250 mg
230066|NCT02409381|Drug|Alivium|600 mg
230067|NCT02409394|Drug|Hetrombopag Olamine|
230068|NCT02409407|Drug|Misoprostol , Prostaglandins E1 analogue|
230069|NCT00165139|Drug|Carboplatin|Described under detailed description
230070|NCT02409420|Behavioral|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
230071|NCT02409433|Drug|lacosamide|Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.
The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
230072|NCT02409433|Drug|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
230073|NCT02409446|Dietary Supplement|Anthocyanin|Open pilot study. 30 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
230074|NCT02409459|Drug|Injectafer|
230075|NCT02409459|Drug|Normal Saline|
230363|NCT02405130|Other|no intracoronary epinephrine|patients will receive standard therapy only
229487|NCT02420015|Drug|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
229488|NCT02420015|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
229489|NCT02420015|Behavioral|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
229780|NCT02413671|Other|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
229781|NCT02415907|Drug|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 ([ethyl-1-14C]-idalopirdine) in one capsule for oral administration, single dose
229782|NCT02415907|Drug|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 ([benzyl-7-14C]-idalopirdine) in one capsule for oral administration, single dose
229783|NCT02415920|Drug|Oxytocin|Participants will be randomly assigned to intranasally administer either oxytocin or a placebo.
229784|NCT02415920|Drug|Placebo|
229785|NCT02415933|Behavioral|Trickle Up|Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:
Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;
Provision of seed grants to assist in business start-ups through microfinance loans;
One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;
Trainings on financial planning and household livelihoods.
229786|NCT02415933|Behavioral|Trickle Up Plus|In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).
Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage).
229787|NCT02415946|Procedure|Sinus floor augmentation (lateral)|
229788|NCT02415946|Procedure|Sinus floor augmentation (transcrestal)|
229789|NCT00165802|Drug|E7974|Maximum Tolerated Dose defined as 0.45 mg/m^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
229790|NCT02415959|Drug|Creon IR|
229791|NCT02415959|Drug|Creon® (DR/GR)|
229792|NCT02415972|Other|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
229204|NCT02426437|Other|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
229205|NCT02426437|Other|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
229206|NCT02426450|Procedure|RFA|RFA:
RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
229207|NCT02426450|Drug|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
229208|NCT02315508|Drug|Placebo|orally, once a day, for 4 weeks
229490|NCT02421926|Drug|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
229491|NCT02421939|Drug|ASP2215|tablet, oral
229492|NCT02421939|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
229493|NCT02421939|Drug|Azacitidine|SC or IV injection
229494|NCT02421939|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
229495|NCT02421939|Drug|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
229496|NCT02421965|Behavioral|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
229497|NCT02421965|Behavioral|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
229498|NCT02421991|Behavioral|Telephone Delivered Intervention|
229499|NCT00166803|Drug|Rosiglitazone|Rosiglitazone , 4 mg daily
229500|NCT02422004|Other|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
229501|NCT02422004|Other|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
233828|NCT02399930|Other|Respiratory & Heart Rate Data Collection|This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.
Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.
If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns.
233829|NCT02399943|Drug|Trametinib|
233830|NCT02399943|Drug|Panitumumab|
233831|NCT02399956|Other|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
233832|NCT02399969|Other|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
233833|NCT02445508|Drug|Cholecystokinin|
229209|NCT02315521|Procedure|Fetal Intervention for LUTO|Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.
Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves.
229210|NCT02315534|Drug|BBI608|In arm A, BBI608 will be administered at the RP2D twice daily for 7 days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time not to exceed 28 days following surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.
In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide.
229211|NCT02315534|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m^2.
229212|NCT00152945|Drug|Intravenous Intralipid|intravenous infusion
229213|NCT02315547|Drug|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
229214|NCT02315560|Device|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
229215|NCT02315573|Procedure|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
233545|NCT02406443|Drug|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
233546|NCT02406443|Other|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
233547|NCT02406456|Other|Neurofeedback|
233548|NCT02406469|Dietary Supplement|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
233549|NCT02406482|Behavioral|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
233550|NCT02406482|Behavioral|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
233551|NCT00164801|Drug|Baclofen, Diltiazem|
233552|NCT02406495|Device|ocufilcon D|Habitual wearers of (FILCON IV 1) sphere lenses refitted with asphere ocufilcon D lenses.
233553|NCT02406495|Device|filcon IV 1|Habitual wearers of (FILCON IV 1) sphere lenses refitted with asphere ocufilcon D lenses.
233554|NCT02406508|Device|Melphalan/HDS|
233834|NCT02445508|Drug|Sevelamer placebo|
233835|NCT00002462|Drug|vinblastine sulfate|
233836|NCT00169832|Drug|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
233837|NCT02445508|Drug|Isotonic saline|
233838|NCT02445534|Biological|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
233839|NCT02445547|Drug|Telbivudine and Tenofovir|Telbivudine and Tenofovir administered at least 64 weeks
233840|NCT02445560|Dietary Supplement|Probiotic capsule and Fiber Sachet|A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.
During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
233256|NCT02412774|Behavioral|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
233257|NCT02412774|Behavioral|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
233258|NCT02412787|Drug|Idursulfase-IT|Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 mg. Idursulfase will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
233259|NCT02412813|Device|LEGION OXINIUM|Investigational Group
233260|NCT00165451|Drug|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
233261|NCT02412813|Device|LEGION Cobalt Chrome|Control Group
233262|NCT02412826|Device|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
233263|NCT02412852|Drug|Sodium nitrite|Sustained release formulation of sodium nitrite
233264|NCT02412852|Drug|Placebo|Placebo tablets
233265|NCT02412865|Behavioral|Quit4Baby|
233266|NCT02412865|Behavioral|Text4Baby|
233267|NCT02412878|Drug|Carfilzomib|
233268|NCT02412878|Drug|Dexamethasone|
233269|NCT02412891|Device|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
233270|NCT02412891|Device|Sham UroShield device|
233271|NCT00165451|Drug|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
233555|NCT02408354|Drug|Triheptanoin|Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.
Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
233556|NCT02408354|Drug|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
233557|NCT02408367|Behavioral|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
233558|NCT02408367|Behavioral|Relaxation|30
232980|NCT02419469|Drug|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
232981|NCT02419469|Drug|Vincristine|Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.
Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.
Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.
Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.
Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.
Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days.
233272|NCT02412904|Drug|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
233273|NCT02412904|Drug|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
233274|NCT02412917|Drug|FV-100|antiviral nucleoside analog
233275|NCT02412917|Drug|valacyclovir|antiviral nucleoside analog
233276|NCT02415036|Device|Delcath Hepatic Delivery System|
233277|NCT02415036|Drug|Melphalan|
233278|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
233279|NCT02415049|Other|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
233280|NCT02415049|Other|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
233281|NCT02415062|Drug|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
233282|NCT02415075|Behavioral|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
233283|NCT02415088|Procedure|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
233284|NCT02415088|Procedure|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
233285|NCT02415101|Procedure|Resective surgery|
233286|NCT02415114|Dietary Supplement|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
232690|NCT02425410|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
232691|NCT02425423|Dietary Supplement|New thickened formula|
232692|NCT02425436|Drug|Ginkgo Biloba Extract|
232693|NCT02425436|Other|Placebo|
232694|NCT00167414|Radiation|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
232695|NCT02425449|Drug|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
232696|NCT02425462|Drug|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
232982|NCT02419469|Drug|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
232983|NCT02419469|Drug|PEG asparaginase|Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.
Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.
Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.
Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.
Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3.
232984|NCT02419469|Drug|Ofatumumab|Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.
Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.
Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.
Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3.
232985|NCT02421185|Drug|Part 1: JNJ-42756493|Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 6 mg orally once daily from Day 1 to 21 of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
232986|NCT02421185|Drug|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered by mouth once daily (28-day cycles).
232987|NCT02421198|Behavioral|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
232988|NCT02421211|Drug|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
232989|NCT02421211|Drug|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
232990|NCT02421211|Drug|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
232991|NCT02421224|Behavioral|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
232414|NCT02396836|Other|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
232415|NCT02396836|Other|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
232416|NCT02396849|Device|CPAP|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
232417|NCT02396849|Device|CPAP Sham|Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
232418|NCT02396862|Drug|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
232419|NCT02396875|Procedure|Blood sampling and exercise protocol pre and post CRT implant|
232420|NCT02396875|Procedure|Peripheral blood sampling|
232421|NCT02396875|Procedure|Central blood sampling pre and post CRT implant|
232422|NCT00163449|Drug|Ciclesonide|Efficacy and Safety of Ciclesonide
232697|NCT02425475|Device|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
232698|NCT02425488|Behavioral|Nursing therapeutics education|Educational intervention will focus on
Appropriate lifestyles
Early recognition of signs/prodromal symptoms of HF
Early recognition of signs of inflammation of the ICD-pocket
Good management of the device
1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI
232699|NCT02425501|Drug|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
232700|NCT02425514|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
232701|NCT02425514|Device|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
232702|NCT00167687|Drug|prazosin|Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:
Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg
232703|NCT02427581|Drug|Poly ICLC|
232098|NCT00164190|Procedure|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
232099|NCT02401594|Drug|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
232100|NCT02401607|Other|Karasek questionnaire|
232101|NCT02401633|Procedure|CO-CPR|CPR provided by bystander with chest-compressions only
232102|NCT02401633|Procedure|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
232103|NCT02401646|Dietary Supplement|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
232104|NCT02401646|Dietary Supplement|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
232105|NCT02401659|Device|CareLinK|
232106|NCT02403778|Drug|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
232107|NCT02403791|Device|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
232108|NCT02403791|Device|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
232109|NCT02403804|Dietary Supplement|phosphatidylcholine|phosphatidylcholine 3600 mg qam and 2700 mg qpm
232110|NCT02403804|Dietary Supplement|betaine|Betaine anhydrous 588 mg qam and 412 mg qpm
232111|NCT00164476|Behavioral|peer mentors (control group)|
232112|NCT02403804|Dietary Supplement|betaine|Betaine anhydrous 1000 mg BID
232113|NCT02403817|Behavioral|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
232114|NCT02403817|Behavioral|Eye Motor Training|Gameplay will be controlled by the player's eye movements (via an eye tracking device)
232115|NCT02403817|Behavioral|Hand Motor Training|Gameplay will be controlled by the player's hand movements (via a joystick).
232116|NCT02403830|Drug|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
232423|NCT02396875|Procedure|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
232424|NCT02396888|Drug|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
231481|NCT00165386|Procedure|Bone Marrow Biopsy|
231809|NCT02407808|Drug|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
231810|NCT02407821|Drug|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
231811|NCT02407821|Drug|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
231812|NCT02407834|Other|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
231813|NCT02407834|Other|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
231814|NCT02407834|Other|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
231815|NCT02407834|Other|S4|Immersion in Saline solution for 20 minutes, during 7 days.
231816|NCT02407847|Other|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
231817|NCT02407860|Other|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
231818|NCT00165009|Device|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
231819|NCT02407860|Other|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
231820|NCT02407873|Other|Non|
231821|NCT02407899|Drug|Saxagliptin|saxagliptin tablet 5 mg p.o. qd, 104 week
231822|NCT02407899|Drug|Vitamin D3|vitamin D drops 2000 IU, qd, 104 week
231823|NCT02407899|Drug|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
231824|NCT02407912|Drug|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
231825|NCT02407925|Behavioral|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
231826|NCT02407938|Other|Rice meal|
231827|NCT02410096|Other|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
231179|NCT02416557|Procedure|PEEP|application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
231180|NCT02416570|Drug|Clarithromycin|
231181|NCT02416570|Drug|Placebo|
231182|NCT02418598|Genetic|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10^11 vg/subject.
231183|NCT00166244|Drug|Mycophenolate Mofetil|1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.
Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma.
231184|NCT02418611|Device|Zenith® Dissection Endovascular System|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
231185|NCT02418624|Drug|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
231186|NCT02418637|Other|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
231482|NCT02412150|Behavioral|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. [Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)]
231483|NCT02412150|Behavioral|Ramsay Sedation Scale|When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.
Awake Patient anxious and agitated or restless or both!
Patient cooperative, oriented and tranquil!
Patient responds to commands only!
Asleep A brisk response to a light glabellar tap or loud auditory stimulus!
A sluggish response to a light glabellar tap or loud auditory stimulus!
No response to a light glabellar tap or loud auditory stimulus
231484|NCT02412150|Other|Extubation time and Recovery time|The time from discontinuing anesthetic gas to endotracheal extubation is measured.
And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured.
231485|NCT02412150|Behavioral|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
231486|NCT02412150|Other|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
231487|NCT02412150|Other|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
231488|NCT02412150|Other|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
231489|NCT02412150|Drug|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
230882|NCT02424669|Other|slow vital capacity|
230883|NCT02424669|Other|Blood sample|
230884|NCT02424669|Other|Cerebrospinal Fluid (CSF) sample|
230885|NCT02424682|Other|No intervention|No intervention administered in this study
230886|NCT02424695|Drug|Gabapentin Enacarbil (GEn)|HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with "GS LFG", supplied as:
600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc.
230887|NCT02424695|Drug|Placebo|
230888|NCT00167362|Behavioral|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
230889|NCT02424708|Drug|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
231187|NCT02418650|Drug|ODM-201 300 mg tablet|
231188|NCT02418650|Drug|intravenous14C-ODM-201|
231189|NCT02418650|Drug|300 mg 14C-ODM-201 oral solution|
231190|NCT02418663|Drug|Fluid challenge (250 ml Lactated Ringer's solution)|When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.
Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above
231191|NCT02418676|Drug|Gel with HPβCD-I complex|Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.
The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.
231192|NCT02418676|Drug|Gel with insulin|Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.
The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.
230597|NCT02393547|Drug|Lorcaserin|All subjects receive Lorcaserin
230598|NCT02393560|Procedure|DECT scan|
230599|NCT02393573|Drug|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
230600|NCT02393573|Drug|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
230601|NCT02393586|Drug|Faropenem|Single oral dose
230602|NCT02393586|Drug|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
230603|NCT02393586|Drug|Rifampicin|Single oral dose
230604|NCT00163020|Drug|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
230605|NCT02393599|Drug|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
230606|NCT02393599|Drug|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
230607|NCT02393599|Drug|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
230608|NCT02393612|Drug|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
230609|NCT02393612|Drug|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
230890|NCT02424708|Drug|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
230891|NCT02424708|Drug|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
230892|NCT02424734|Drug|Ceftaroline Fosamil|Ceftaroline Fosamil
230893|NCT02424747|Other|Acute Kidney Injury|We will identify and observe "exposure" to Acute Kidney Injury during Intensive Care admission.
230894|NCT02424760|Device|Shoulder hemi-arthroplasty|
230895|NCT02424773|Device|High Flow Nasal Canula (HFNC)|
230896|NCT02424773|Device|Venturi mask|
234942|NCT02450253|Drug|Placebo|single dose, matching capsule p.o.
234943|NCT02450253|Behavioral|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
234944|NCT02450253|Behavioral|Neuropsychological tests|Neuropsychological tests will be performed prior to pre IMP dose MRI scan & then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.
Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart
234945|NCT00170690|Drug|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
234946|NCT02450253|Other|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
234947|NCT02450266|Device|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
234948|NCT02450266|Device|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
234949|NCT02450279|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
234950|NCT02450279|Device|Vibrating-mesh nebulizer|
234951|NCT02450279|Device|Jet Nebulizer|
234952|NCT02450279|Other|Planar scintigraphy|
234953|NCT02450279|Other|Preoperative spirometry|
234954|NCT02450292|Procedure|Bioabsorbable screw fixation|
234955|NCT02450318|Other|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
234956|NCT00170703|Device|Cortical Electrical Stimulation|
235220|NCT02446041|Other|Non-Interventional Study|Non-Interventional Study
235221|NCT02446054|Dietary Supplement|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
235222|NCT00169923|Drug|rosiglitazone|
235223|NCT02446067|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
234662|NCT02457143|Behavioral|Letter|
234663|NCT00002466|Drug|ifosfamide|
234664|NCT00171704|Drug|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
234665|NCT02457143|Behavioral|Phone call|
234666|NCT02457156|Procedure|Blumgart Anastomosis|Trans pancreatic suture "U" stich incorporating pancreatic parenchyma and jejunal serosa, left loose.
Pancreatic duct to jejunal mucosa sutures, inserted and tied.
Trans pancreatic suture "U" stich brought back through the jejuanl serosa anteriorly, tied.
234667|NCT02457156|Procedure|Cattell-Warren Anastomosis|Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.
Pancreatic duct to jejunal mucosa sutures, inserted and tied.
Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.
234668|NCT02457156|Drug|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
234669|NCT02457169|Behavioral|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
234670|NCT02457169|Behavioral|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
234671|NCT02457182|Other|Mindfulness-based Stress Reduction (MBSR)|
234672|NCT02457182|Other|Usual medical therapy|
234673|NCT02457195|Drug|granisetron|Application granisetron transdermal patch preoperatively
234674|NCT02457208|Drug|Isoniazid (H)|
234675|NCT00171704|Drug|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
234957|NCT02450331|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Anti-programmed death-ligand 1 (PD-L1) antibody
234958|NCT02452554|Other|Laboratory Biomarker Analysis|Correlative studies
234959|NCT02452554|Biological|Lorvotuzumab Mertansine|Given IV
234960|NCT02452554|Other|Pharmacological Study|Correlative studies
230364|NCT02405143|Device|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
230365|NCT02405143|Device|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
230366|NCT02405156|Drug|Letrozole|
230367|NCT00164684|Behavioral|Father Friendly Initiative|
230368|NCT02405156|Drug|Placebo|
230369|NCT02405156|Drug|Misoprostol|
230370|NCT02405169|Device|4 vs 6 implant treatment in the maxilla|
230371|NCT02405182|Other|Magnetic Resonance Imaging|
230372|NCT02405195|Procedure|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
230373|NCT02405208|Device|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
230374|NCT02405221|Biological|TA-CIN/GPI-0100|TA-CIN/GPI-0100 every 4 weeks for a total of 3 doses. Three dose levels of TA-CIN/GPI-0100 are planned.
230375|NCT02405234|Device|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
230376|NCT02407236|Drug|Placebo SC|Placebo will be administered Subcutaneously.
230377|NCT02407236|Drug|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
230378|NCT02407236|Drug|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
230379|NCT00164931|Procedure|Scheduled second endoscopy|
230380|NCT02407262|Dietary Supplement|Black seed oil|
230381|NCT02407262|Other|Placebo|vegetable oil
230382|NCT02407275|Other|Biological sample|
229793|NCT02415985|Drug|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
229794|NCT02415985|Drug|Rifabutin|
229795|NCT02415998|Procedure|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
229796|NCT02416011|Behavioral|GENERIC|The initial Stopy Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
229797|NCT02416011|Behavioral|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
230076|NCT02411578|Other|Diachieve Glucose Tabs|1st BG check, 1st treatment
BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates
BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates
15 min later, 2nd BG check, 2nd treatment
BG is 60-69 mg/dl, no treatment
BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates
BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
30 minutes later, 3rd BG check, 3rd treatment
(1) BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)
230077|NCT02411591|Drug|Necitumumab|Administered IV.
230078|NCT02411591|Drug|Abemaciclib|Administered orally.
230079|NCT02411604|Drug|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
230080|NCT02411617|Device|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
230081|NCT02411630|Drug|Emtricitabine/tenofovir disoproxil|ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.
The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed.
230082|NCT02411643|Drug|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
230083|NCT02411656|Drug|MK-3475|200 mg administered on Day 1 of each 21 day cycle as a 30 minute infusion by vein.
230084|NCT02411656|Behavioral|Follow Up/Phone Call|About 1 and 3 months after last dose of study drug, participant to have follow up or phone call. If participant is called, each call should last about 2 minutes.
230085|NCT00165308|Drug|Tamoxifen|Given orally, daily for one year.
229502|NCT02422017|Drug|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest
229503|NCT02422017|Other|Local care treatment|Local care treatment with dressing compression in accordance with standards applied every other day
229504|NCT02422030|Drug|Lipitor Tab. 40mg|
229505|NCT02422030|Drug|Trilipix 135mg|
229506|NCT02422043|Other|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
229507|NCT02422056|Drug|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
229508|NCT02422056|Drug|Saline|Infusion of saline in the same rate used for the intervention group
229798|NCT02416024|Device|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
229799|NCT02416037|Device|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
229800|NCT00002447|Drug|Saquinavir|
229801|NCT00166166|Drug|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
229802|NCT02418013|Other|Placebo group|A placebo agent is administered through intravenous at CHA clinical trail institute.
It should be certain that when administered, participants are not aware of which treatments are preformed.
229803|NCT02418026|Other|hypnosis|Conversational hypnotic induction and therapeutic suggestions
229804|NCT02418039|Dietary Supplement|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
229805|NCT02418039|Dietary Supplement|Normal protein|A normal protein diet will be administrated in patients with MHE.
229806|NCT02418052|Procedure|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
229216|NCT02315612|Biological|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
229217|NCT02315625|Drug|Sunitinib|37.5 mg once daily will continue until progression
229218|NCT02315625|Drug|Everolimus|10 mg daily
x 10 mg tablets or
x 5 mg tablets or
4 x 2.5 mg tablets
229219|NCT02315625|Procedure|Surgery|Cytoreductive surgery only on patients for whom it is indicated. Performed within 3 months of first dose of study drug.
229220|NCT02315651|Dietary Supplement|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
229221|NCT02315651|Dietary Supplement|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
229222|NCT02315664|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
229223|NCT00152945|Drug|Intravenous leucine, glycerol|intravenous infusion
229509|NCT02422082|Dietary Supplement|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
229510|NCT00166816|Drug|sirolimus, cyclosporine, tacrolimus|
229511|NCT02422082|Dietary Supplement|Placebo|Dietary supplementation with placebo twice daily for 12 months
229512|NCT02424097|Drug|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|MI Paste & MI Varnish- in-office:
varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)
- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray
229513|NCT02424097|Drug|1,100pm F-toothpaste and 0.5%NaF rinse|Standard of care at-home:
Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)
229514|NCT02424110|Procedure|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
229515|NCT02424110|Procedure|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
229516|NCT02424110|Device|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
229517|NCT00167258|Behavioral|Extra Counseling Services|
229518|NCT02424110|Device|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
233841|NCT02445560|Dietary Supplement|Probiotic capsule and Placebo sachet|A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.
During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
233842|NCT02445560|Dietary Supplement|Placebo capsule and Fiber Sachet|A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.
During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
233843|NCT02445560|Dietary Supplement|Placebo capsule and Placebo sachet|A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.
During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
233844|NCT02445573|Other|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
233845|NCT02445573|Other|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
233846|NCT02445586|Drug|Docetaxel|Docetaxel should be administered after pertuzumab and trastuzumab.
229224|NCT02315664|Behavioral|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
229225|NCT02315677|Device|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
229226|NCT02395419|Device|Orotracheal intubation with Totaltrack|
229227|NCT02395419|Device|Orotracheal intubation with Airtraq|
229228|NCT00163254|Drug|abciximab|
229229|NCT02395432|Device|orotracheal intubation|
229230|NCT02395445|Device|orotracheal intubation|
229231|NCT02395458|Drug|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
233559|NCT02408393|Drug|Saline|
233560|NCT02408393|Drug|Ropivacaine|
233561|NCT02408406|Other|Internet-Based Intervention|Use PatientCareAnywhere system
233562|NCT02408406|Other|Educational Intervention|Use PatientCareAnywhere system
233563|NCT02408406|Other|Communication Intervention|Use PatientCareAnywhere system
233564|NCT02408406|Other|Questionnaire Administration|Answer questionnaires
233565|NCT00165087|Drug|asparaginase (Erwina)|
233566|NCT02408406|Other|Quality-of-Life Assessment|Ancillary studies
233567|NCT02408419|Drug|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
233568|NCT02408419|Drug|Saline|Saline is injected as a placebo
233569|NCT02408432|Biological|Human Mesenchymal Stem Cells (hMSCs)|hMSCs by vein delivered as 2 x 10^6 cells/Kg per week (one cycle) over 4 weeks.
233570|NCT02408432|Other|Standard of Care|Participants receive standard of care drugs for heart failure.
233571|NCT02408445|Drug|testosterone cypionate 200mg/ml|Half of the subjects will be randomized to receive testosterone cypionate 200 mg/ml will be given intramuscularly every 4 weeks for a total of 3 doses.
233572|NCT02408458|Device|MIROMESH®|
233573|NCT02408471|Device|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
233574|NCT02408484|Biological|Octafibrin|Plasma-derived Fibrinogen concentrate
233575|NCT02408523|Drug|Lacosamide Tablet|Active Substance: Lacosamide
Pharmaceutical Form: Film-coated Tablet
Concentration: 50 mg
Route of Administration: Oral use
233576|NCT00165087|Drug|dexrazoxane|
233847|NCT00169845|Dietary Supplement|Alpha-Tocopherol and Beta-Carotene supplements|Alpha-Tocopherol (400 IU/d during RT and 3 years) and Beta-Carotene: 30 mg/d (stopped during the trial)
233848|NCT02447601|Drug|PEX168|200µg,injected subcutaneously,once a week.
233849|NCT02447601|Drug|Simvastatin|40mg,oral,two times
233850|NCT02447614|Procedure|Adenotonsillectomy|Adenotonsillectomy
233287|NCT02415127|Drug|Interferon γ-1b|Approximately 45 subjects will receive subcutaneous (SC) doses of ACTIMMUNE three times a week (TIW) for a total of 26 weeks. The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By week 13, all subjects are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related AEs.
233288|NCT02415127|Drug|Placebo|Approximately 45 subjects will receive subcutaneous (SC) doses of placebo three times a week (TIW) for a total of 26 weeks. The volume of placebo is planned to correspond with volume of study drug that would be given to the patient if the patient was randomized to the study drug arm.
233577|NCT02408523|Drug|Lasosamide Oral Solution|Active Substance: Lacosamide
Pharmaceutical Form: Oral Solution
Concentration: 10 mg/ml
Route of Administration: Oral use
233578|NCT02408523|Other|Placebo Tablet|Active Substance: Placebo
Pharmaceutical Form: Film-coated Tablet
Concentration: 50 mg
Route of Administration: Oral use
233579|NCT02408523|Other|Placebo Oral Solution|Active Substance: Placebo
Pharmaceutical Form: Oral Solution
Concentration: 10 mg/ml
Route of Administration: Oral use
233580|NCT02408549|Drug|Lacosamide Tablet|Active substance: Lacosamide
Pharmaceutical form: Tablet
Concentration: 50 mg and 100 mg
Route of Administration: oral administration
233581|NCT02410707|Drug|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
233582|NCT02410707|Drug|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
233583|NCT02410707|Drug|Oxygen|
233584|NCT02410720|Other|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
233585|NCT02410720|Other|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
233586|NCT02410720|Other|Explanation of paper and application instructions|The research fellow will explain instructions to patients
233587|NCT00165191|Drug|5-fluorouracil|
233588|NCT02410720|Other|Picoprep solution|
233589|NCT02410733|Biological|Lipo-MERIT|vaccination
233590|NCT02410746|Other|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
232992|NCT02421224|Behavioral|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
232993|NCT00166686|Drug|Clonidine|
232994|NCT02421224|Behavioral|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
232995|NCT02421224|Behavioral|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
232996|NCT02421224|Behavioral|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
232997|NCT02421224|Behavioral|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
233289|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
233290|NCT02415140|Other|Rate of depression|
233291|NCT02415153|Other|Laboratory Biomarker Analysis|Optional correlative studies
233292|NCT02415153|Other|Pharmacological Study|Correlative studies
233293|NCT02415153|Drug|Pomalidomide|Given PO
233294|NCT02415166|Biological|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
233295|NCT02415166|Other|NaCl-saline placebo|placebo
233296|NCT02415179|Drug|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
233297|NCT02415179|Drug|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
233298|NCT02415192|Drug|Levacalm|
233299|NCT02415192|Drug|Valsartan/amlodipine|
233300|NCT02417155|Behavioral|Hyper/hypoventilation|Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes ("retention phase"). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins.
232704|NCT02427594|Drug|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
232705|NCT02427594|Other|Controlled diet|Diet without sodium bicarbonate supplementation
232706|NCT02427607|Drug|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
232707|NCT02427620|Drug|Ibrutinib|Part 1: 560 mg by mouth on Days 1 - 28 of a 28-day cycle.
232708|NCT02427620|Drug|Rituximab|Part 1: 375 mg/m2 by vein every week during the first cycle, then Day 1 of Cycles 3 - 12 of a 28 day cycle.
Part 2 First Combination: 375 mg/m2 by vein on Day 1 of a 28 day cycle.
Part 2 Second Combination: 375 mg/m2 by vein on Day 1 of a 21 day cycle.
232709|NCT02427620|Drug|Cyclophosphamide|Part 2 First Combination: 300 mg/m2/per dose by vein every 12 hours for 6 doses starting at any time after Rituximab infusion ends on Days 2 - 4 of a 28 day cycle.
232710|NCT02427620|Drug|Dexamethasone|Part 2 First Combination: 40 mg by mouth or vein on Days 1 - 4 of a 28 day cycle.
232711|NCT02427620|Drug|Mesna|Part 2 First Combination: 600 mg/m/dose by vein daily on Days 2, 3, and 4 of a 28 day cycle.
232712|NCT02427620|Drug|Vincristine|Part 2 First Combination: 1.4 mg/m2 (maximum 2 mg) by vein on after last dose of Cyclophosphamide on Day 5 of a 28 day cycle.
232998|NCT02421237|Behavioral|Narrative Enhancement and Cognitive Therapy|
232999|NCT02421237|Behavioral|Supportive Group Therapy|
233000|NCT02421250|Device|Radical-7 Noninvasive Hgb Monitor|
233001|NCT02421263|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
233002|NCT02421276|Other|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
233003|NCT02421289|Drug|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
233004|NCT00166699|Procedure|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
233005|NCT02421289|Drug|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
233006|NCT02423369|Other|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
233007|NCT02423369|Other|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
232425|NCT02396888|Drug|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
232426|NCT02396901|Other|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
232427|NCT02396927|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
232428|NCT02396927|Device|2D HD laparoscopy|Placebo
232429|NCT02396940|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
232430|NCT02396940|Device|2D HD laparoscopy|Placebo
232431|NCT02396953|Drug|Lanreotide PRF|
232432|NCT02396979|Drug|Methadone|
232433|NCT00163449|Drug|Placebo|Placebo
232434|NCT02396979|Behavioral|Holistic Health Recovery Program|
232435|NCT02396992|Other|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
232436|NCT02397005|Drug|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
232437|NCT02397005|Drug|Placebo matching ZL-2102|
232438|NCT02399267|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
232439|NCT02399267|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
232440|NCT02399267|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =< 8 cm H2O with PEEP =< 5 cm H2O.
232441|NCT02399267|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
232442|NCT02399280|Behavioral|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
232443|NCT02399280|Behavioral|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
231828|NCT02410096|Dietary Supplement|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
231829|NCT02410096|Dietary Supplement|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
232117|NCT02403830|Other|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
232118|NCT02403830|Drug|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
232119|NCT02403830|Drug|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
232120|NCT02403843|Device|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
232121|NCT02403856|Drug|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
232122|NCT00164489|Behavioral|Weight control and physical activity promotion|
232123|NCT02403856|Drug|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
232124|NCT02403856|Procedure|Ultrasound-guided Needling and Lavage|
232125|NCT02403882|Behavioral|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
232126|NCT02403882|Behavioral|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
232127|NCT02403882|Behavioral|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
232128|NCT02403882|Behavioral|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
232129|NCT02405728|Device|Central Venous Catheters|Randomization between two well established clinical routine vascular access devices
232130|NCT02405728|Device|PICCs|Randomization between two well established clinical routine vascular access devices
232131|NCT02405741|Device|Hyperbaric chamber treatment|
232132|NCT02405767|Other|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
231490|NCT02412150|Drug|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
231491|NCT02412163|Device|Ellipse IM HTO Nail|
231492|NCT00165399|Drug|Docetaxel|Given intravenously on day 2 of four three-week cycles
231493|NCT02412176|Procedure|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
231494|NCT02412176|Procedure|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
231495|NCT02412189|Procedure|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
231496|NCT02412189|Drug|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
231497|NCT02412202|Other|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
231498|NCT02414308|Drug|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
231499|NCT02414334|Radiation|Stereotactic Ablative Radiotherapy (SABR)|
231500|NCT02414347|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
231830|NCT02410109|Behavioral|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
231831|NCT02410135|Drug|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
231832|NCT02410148|Device|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
231833|NCT02410161|Dietary Supplement|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
231834|NCT02410174|Radiation|Stereotactic Body Radiotherapy (SBRT)|
231193|NCT02418676|Drug|Control gel|Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.
The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.
231194|NCT00166257|Device|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
231195|NCT02418689|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
231196|NCT02418702|Drug|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
231197|NCT02418702|Other|placebo|20 patients will randomly be assigned a placebo
231198|NCT02420561|Behavioral|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
231199|NCT02420574|Drug|albendazole BENDEX|randomized clinical trial with 2 parallel arms
231200|NCT02420574|Drug|albendazole OVIS|
231201|NCT02420587|Drug|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
231501|NCT02414360|Other|Shortened Format|Shortened format of a systematic review
231502|NCT00165581|Device|High Dose Intracavitary Brachytherapy|
231503|NCT02414360|Other|Full Length|Full length systematic review
231504|NCT02414373|Drug|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
231505|NCT02414373|Drug|Bupivacaine|local anesthetics, which will epidurally administered
231506|NCT02414373|Device|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
231507|NCT02414373|Device|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
231508|NCT02414386|Other|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
231509|NCT02414399|Drug|Azithromycin|oral administration of Azithromycin
231510|NCT02414399|Drug|Placebo|5 days of taste/appearance/bottle-matched inactive substance
231511|NCT02414412|Dietary Supplement|Ulmus macrocarpa water extract|
230897|NCT02424773|Drug|Oxygen|
230898|NCT02424786|Other|STOPP/START criteria|Evaluation of medication lists
230899|NCT00167362|Behavioral|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
230900|NCT02424799|Drug|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
230901|NCT02424799|Drug|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
230902|NCT02424799|Drug|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
230903|NCT02426918|Drug|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
230904|NCT02426918|Drug|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
230905|NCT02426918|Drug|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
230906|NCT02426918|Drug|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
230907|NCT00167609|Drug|dehydroepiandrosterone 100 and 400 mg|
230908|NCT02426918|Drug|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
230909|NCT02426931|Device|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
231202|NCT02420587|Behavioral|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
231203|NCT02420613|Drug|Vorinostat|Newly Diagnosed DIPG Group:
Dose Escalation Phase Starting Dose of Vorinostat: 230 mg /m2 by mouth daily. During radiation, participants receive Vorinostat daily from Mon-Friday along with radiation. After radiation therapy, participant rests for 4 weeks in which no radiation therapy or study drug received .
Maintenance Phase Starting Dose for Vorinostat: 230 mg/m2/dose by mouth once daily in a 28 day cycle.
Progressive DIPG Group:
Dose Escalation Phase Starting Dose of Vorinostat: at 230 mg/m2 by mouth from Day 1 to Day 8.
Maintenance Phase Starting Dose for Vorinostat: 230 mg/m2/dose by mouth once daily of a 28 day cycle.
231204|NCT02420613|Radiation|Radiation Therapy|Radiation therapy (RT) administered in single daily fractions of 1.8 Gy for 30 treatments over 6-7 weeks. Total dose of radiation 54 Gy.
235224|NCT02446080|Dietary Supplement|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
235225|NCT02446080|Dietary Supplement|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
235226|NCT02446093|Biological|GMCI|Intratumoral cytotoxic immunotherapy using an adenoviral vector expressing HSV-tk followed by anti-herpetic prodrug valacyclovir
235227|NCT02446093|Drug|mFOLFIRINOX|fluorouracil, irinotecan and oxaliplatin
235228|NCT02446093|Drug|Gemcitabine|Gemcitabine chemotherapy given with radiation
235229|NCT02446093|Radiation|Radiation|
235230|NCT02446093|Procedure|Surgery|Pancreaticoduodenectomy (Whipple)
235231|NCT02446106|Dietary Supplement|Soup with MSG|0.5% MSG + 0.48% salt
235232|NCT02446106|Dietary Supplement|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
235233|NCT00169936|Device|Magnetocardiograph|
235234|NCT02446119|Device|EndoFLIP|Measurement of pyloric resistance and compliance
235235|NCT02446132|Drug|AVP-786|
235236|NCT02446145|Drug|Eltrombopag|Patients will receive EPAG in addition to their background standard treatment with Decitabine
- concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes
235237|NCT02446145|Drug|Placebo|Patients will receive Placebo in addition to their background standard treatment with Decitabine
- concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes
235238|NCT02446158|Drug|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
235239|NCT02446171|Drug|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
235533|NCT02438696|Drug|BI 1060469, TF1, Reference|
235534|NCT02438696|Drug|BI 1060469, iFF, Test|
235535|NCT02438696|Drug|BI 1060469, iFF, Test|
235536|NCT00169104|Drug|saline|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
230951|NCT02396238|Other|Placebo|Placebo
230952|NCT00163345|Drug|Ciclesonide|
230953|NCT02396251|Device|HA experimental|
230954|NCT02396251|Device|HA comparator|
230955|NCT02396264|Other|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
230956|NCT02396264|Other|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
230957|NCT02396277|Procedure|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
230958|NCT02396290|Procedure|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
230959|NCT02396290|Procedure|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
230960|NCT02396303|Drug|Carbetocin|
230961|NCT02396316|Drug|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
230962|NCT02396316|Drug|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
230963|NCT00163358|Drug|Ciclesonide|
230964|NCT02396329|Drug|Chlorhexidine|
230965|NCT02396329|Drug|Povidone-Iodine|
230966|NCT02396342|Genetic|AAV5-hFIX|
230967|NCT02396355|Device|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
230968|NCT02396355|Device|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
231263|NCT02424942|Drug|GZ389988|Pharmaceutical form:suspension for injection
Route of administration: intraarticular
231264|NCT00167375|Behavioral|General cognitive/behavioral interventions for insomnia|
231265|NCT02424968|Biological|Anti-Thymocyte Globulin|Given per standard institutional practice
230383|NCT02407288|Device|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
230667|NCT02400970|Other|malignant cells|
230668|NCT02400983|Device|Pacemaker, ICD|
230669|NCT02401009|Other|HCT or other cellular therapies|Hematopoietic stem cell transplantation or other cellular infusion therapy
230670|NCT02401022|Drug|AZD8529|comparison of different dosages of drug
230671|NCT02401035|Drug|iv pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg iv pantoprazole determined by weight
230672|NCT02401048|Drug|Ibrutinib|
230673|NCT02401048|Drug|MEDI4736|
230674|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
230675|NCT00164112|Drug|Levofloxacin plus Cooperstown 5+1|
230676|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
230677|NCT02403219|Other|Saline solution injection|Injection of saline solution
230678|NCT02403232|Procedure|ASCs injection|In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.
The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.
The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.
Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue.
230679|NCT02403232|Device|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
230680|NCT02403232|Device|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
230681|NCT00164411|Biological|Tetanus-diphtheria toxoids (Td)|
230682|NCT02403245|Other|Psychosocial stimulation|Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the "four season" of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music.
230086|NCT02411669|Other|Operational patient centered care tools|The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.
They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done.
230087|NCT02411682|Other|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
230088|NCT02411682|Other|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
230089|NCT02411695|Drug|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
230090|NCT02411708|Drug|SANGUINATE|Single two-hour infusion of SANGUINATE
230091|NCT02411708|Drug|Placebo|Single two-hour infusion of placebo
230384|NCT02407288|Device|Sham tDCS|
230385|NCT02407301|Other|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
230386|NCT02407301|Other|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
230387|NCT02407301|Other|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
230388|NCT02407301|Other|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
230389|NCT02407301|Other|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
230390|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
230391|NCT02407314|Procedure|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
230392|NCT02407314|Device|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
230393|NCT02407314|Other|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
229807|NCT02418065|Other|training on ergonomic bicycle|
229808|NCT02418065|Drug|Testosterone|
229809|NCT02418065|Drug|Oral nutritional supplementation|
229810|NCT02418065|Drug|n3 polyunsaturated fatty acid|
229811|NCT02418078|Procedure|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
229812|NCT00002448|Drug|Saquinavir|
229813|NCT00166166|Drug|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
229814|NCT02418091|Behavioral|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
230092|NCT02413684|Behavioral|Patient engagement toolkit|Pack Health LLC and Duke will develop a patient engagement toolkit known as "Packs" to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care
230093|NCT02413697|Device|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
230094|NCT02413697|Device|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
230095|NCT00165503|Drug|Cisplatin|Heated cisplatin will be given as a one-hour lavage of the chest and abdominal cavity following surgery.
Cisplatin will also be administered intravenously as part of chemotherapy 6-10 weeks after surgery. It will be given on day 1 of each 21-day treatment cycle for 3 cycles.
230096|NCT02413710|Other|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
230097|NCT02413710|Behavioral|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
230098|NCT02413723|Device|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
230099|NCT02413723|Device|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
230100|NCT02413736|Drug|Imatinib|Imatinib 400 mg/day
230101|NCT02413762|Other|No intervention|No intervention
229519|NCT02424136|Other|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
229520|NCT02424136|Other|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
229521|NCT02424136|Other|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures
229522|NCT02424136|Other|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures
229523|NCT02424136|Other|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
229524|NCT02424136|Other|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
229525|NCT02424136|Other|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
229526|NCT02424149|Drug|Phenazopyridine|
229527|NCT02424162|Device|+2.75 diopters multifocal intraocular lens|
229528|NCT00167258|Behavioral|Voucher Reinforcement + Extra Counseling Services|
229529|NCT02424162|Device|+3.25 diopters multifocal intraocular lens|
229815|NCT02418104|Drug|CHS-1701|
229816|NCT02418104|Drug|Pegfilgrastim (Neulasta)|
229817|NCT02418117|Other|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
229818|NCT02418130|Drug|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
229819|NCT02418130|Drug|Placebo|
229820|NCT02418143|Device|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
229821|NCT02418156|Device|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair.
229822|NCT02418182|Drug|Acetaminophen|Acetaminophen total dose of 1000mg given to experimental group to study pain control as compared to placebo.
229823|NCT02420015|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
229232|NCT02395458|Drug|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
229233|NCT02395497|Procedure|Penile Transplant|
229234|NCT02395497|Biological|Monoclonal Antibody (Humanized Anti-CD52)|
229235|NCT02395497|Drug|Tacrolimus|
229236|NCT02395510|Drug|Vortioxetine|Vortioxetine 5-20mg
229237|NCT02395523|Radiation|Proton Beam Therapy|Definition of target volume:
Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan
Clinical target volume (CTV) = GTV + internal target volume
Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.
Radiation dose and planning
Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week
Dose prescription : 95% isodose volume of prescribed dose encompassed PTV
229238|NCT02395536|Other|Insertion of Reveal LINQ device in office or traditional hospital setting|The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.
229239|NCT00163254|Device|stent and drug eluting stent|
229240|NCT02395549|Drug|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
229241|NCT02395549|Drug|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
229242|NCT02395549|Drug|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
229243|NCT02395549|Drug|Vehicle Control Gel|
229244|NCT02395588|Other|Guideline based care|Patient education using guideline based teaching guides
229245|NCT02395601|Drug|CPI-1205|Small molecule inhibitor of the enzyme EZH2
229246|NCT02395614|Drug|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket
229530|NCT02424175|Biological|Fecal Microbiota Transplantation|
229531|NCT02424188|Other|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
229532|NCT02424201|Drug|Misoprostol|experimental
229533|NCT02424201|Drug|vitamin c|control
229534|NCT02424214|Other|Artificial Oocyte activation|
229535|NCT02424214|Drug|Ca Ionophore|
233851|NCT02447614|Other|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
233852|NCT00170261|Device|Use of an Implantable Loop Recorder|
233853|NCT02447614|Other|no treatment|just regular follow-up
233854|NCT02447640|Drug|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
233855|NCT02447640|Radiation|[18F]FPEB|radiotracer used for PET scanning
233856|NCT02447653|Device|G7 HA Acetabular Component|G7 HA Acetabular Component
233857|NCT02447653|Device|G7 PPS Acetabular Component|G7 PPS Acetabular Component
233858|NCT02447666|Drug|Azacitidine|
233859|NCT02447679|Drug|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
233860|NCT02447679|Drug|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
233861|NCT02447692|Other|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
233862|NCT02447692|Other|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
233863|NCT00170274|Device|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
233864|NCT02447705|Drug|telbivudine|telbivudine replace Lamivudine
233865|NCT02447718|Biological|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-8 months post-completion of chemotherapy.
233866|NCT02447718|Biological|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
233867|NCT02447718|Biological|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-8 months post-completion of chemotherapy.
229247|NCT02395614|Drug|triple antibiotic irrigation|-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket
229248|NCT02395627|Drug|Tamoxifen|
229249|NCT02395627|Drug|Vorinostat|
233591|NCT02410746|Other|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
233592|NCT02410746|Other|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
233593|NCT02410759|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
233594|NCT02410759|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
233595|NCT02410772|Drug|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
233596|NCT02410772|Drug|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
233868|NCT02447731|Device|Induction of sound waves in lungs by "sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
233869|NCT02447744|Behavioral|Mindfulness based stress reduction|The intervention will be an 8-week structured program about mindfulness based stress reduction that teaches skills of mindfulness meditation and mindful yoga.
233870|NCT02447757|Drug|remifentanil|Remifentanil analgesia during delivery
233871|NCT02447770|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
233872|NCT02449746|Biological|Intravenous immunoglobulin|Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.
IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed.
233873|NCT02449759|Behavioral|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
233874|NCT02449772|Other|No intervention|No intervention
233875|NCT02449785|Device|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
233876|NCT00170612|Biological|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
233877|NCT02449785|Device|CT measurements of lung morphological changes in cystic fibrosis|
233878|NCT02449798|Device|AccuCath 2.25" BC Intravascular Catheter|Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
233301|NCT00166062|Procedure|Screening patients for IPV|
233302|NCT02417155|Behavioral|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
233303|NCT02417181|Other|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
233304|NCT02417207|Drug|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
233305|NCT02417207|Drug|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
233306|NCT02417220|Behavioral|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
233597|NCT02410772|Drug|control|standard six-month treatment
233598|NCT00165204|Drug|Tibolone|
233599|NCT02410785|Device|Polyglucosamine|ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
233600|NCT02410785|Other|Placebo|Placebo tablet
233601|NCT02410798|Device|TransLoc electrode|Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
233602|NCT02410811|Other|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
233603|NCT02410824|Device|stenfilcon A|Each subject will be randomized to wear either the test or control as a matched pair first and then crossover to the alternate pair.
233604|NCT02410824|Device|etafilcon A|Each subject will be randomized to wear either the test or control as a matched pair first and then crossover to the alternate pair.
233605|NCT02412930|Procedure|Ultrasound-guided Paravertebral Block|paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.
After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
233008|NCT02423382|Procedure|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
233009|NCT02423395|Drug|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
233010|NCT02423395|Drug|Placebo|calcium in muscle cramps in cirrhotic patients
233011|NCT02423408|Drug|TNX-201|TNX-201 capsule
233012|NCT02423408|Drug|Placebo|Placebo capsule
233013|NCT02423421|Other|Faecal microbiota transplantation|Human Stool.
233014|NCT02423434|Other|Exposure: Corneal nerve fibre morphology by the CCM Procedure|CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.
In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed.
233015|NCT02423447|Device|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
233016|NCT00167180|Drug|Induction Chemotherapy + DLI|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV Donor Lymphocyte Infusion (DLI)
233017|NCT02423447|Device|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
233307|NCT02417220|Other|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
233308|NCT02417233|Behavioral|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
233309|NCT02417233|Behavioral|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
233310|NCT02417246|Drug|Toprol XL|Both groups will receive this to compare if there is a difference in the clinical response.
233311|NCT02417246|Device|SmartPill Capsule|Both groups will have a continuous measure of pH by a SmartPill Capsule as it moves through the gastrointestinal tract.
233312|NCT00166075|Procedure|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
233313|NCT02417246|Procedure|Exercise Treadmill|Both groups will have a treadmill exercise test performed.
232713|NCT00167700|Behavioral|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
232714|NCT02427620|Drug|Doxorubicin|Part 2 First Combination: 50 mg/ m2/day by vein after last dose of Cyclophosphamide and before or after Vincristine on Day 5 of a 28 day cycle.
232715|NCT02427620|Drug|G-CSF|Part 2 First Combination: 480 mcg subcutaneously daily starting 24 - 36 hours after last dose of Cyclophosphamide until granulocytes more than 4 x 10 3/dl.
Part 2 Second Combination: 480 mcg daily starting 24 - 36 hours after last dose of Cytarabine until granulocytes more than 4 x 10 3/dl.
232716|NCT02427620|Drug|Methotrexate|Part 2 Second Combination: 200 mg/m2 by vein, then 800 mg/m2 by vein on Day 2 of a 21 day cycle.
232717|NCT02427620|Drug|Cytarabine|Part 2 Second Combination: 3 g/m2 by vein every 12 hours for 4 doses on Day 3 and Day 4 of a 21 day cycle.
232718|NCT02427620|Drug|Citrovorum|Part 2 Second Combination: 50 mg by mouth 2 hours after Methotrexate infusion is completed followed by 15 mg by mouth every 6 hours for 8 doses in a 21 day cycle.
232719|NCT02427633|Other|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
232720|NCT02427633|Other|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
232721|NCT02427646|Drug|IncobotulinumtoxinA|A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
232722|NCT02394496|Drug|Placebo Lapatinib|1500mg (TBD) O.S. qd
232723|NCT02394509|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
232724|NCT02394522|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
232725|NCT02394522|Device|Active Ingredient|Transfluthrin (Active ingredient)
232726|NCT02394522|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
232727|NCT02394535|Drug|Abraxane|Dose Escalation Starting dose of Abraxane: 50 mg/m2 by vein weekly Day 1, 8, 15, 22 and 29.
Dose Expansion Starting Dose of Abraxane: MTD dose from Dose Escalation.
232728|NCT02394535|Drug|Capecitabine|Dose Escalation and Dose Expansion Dose of Capecitabine: 825 mg/m2 by mouth twice a day only on days of radiation.
232133|NCT02405780|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
232134|NCT02405780|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
232135|NCT00164736|Drug|Infant nevirapine|Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.
To 28 weeks while breastfeeding.
232444|NCT00163839|Behavioral|Dietary Therapy|
232445|NCT02399293|Behavioral|N-back|The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.
Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day.
232446|NCT02399293|Behavioral|Visual Search|The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.
Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day.
232447|NCT02399306|Drug|nutrison|Enteral nutrition intervention：nutrison，15-25kcal/kg/d，according to the eating situation of patients，tube feeding or oral
232448|NCT02399306|Radiation|radiotherapy|Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.
Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f.
232449|NCT02399306|Drug|Docetaxel, cisplatin|Concurrent chemotherapy：docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
232450|NCT02399319|Device|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
232451|NCT02399319|Device|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
232452|NCT02399332|Other|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
232453|NCT02399345|Drug|ombitasvir/paritaprevir/ritonavir|tablet
232454|NCT02399345|Drug|dasabuvir|tablet
232455|NCT00163852|Drug|Normal saline IV, salt tablets|
232456|NCT02399345|Drug|sofosbuvir (SOF)|tablet
232457|NCT02399345|Drug|Ribavirin (RBV)|tablet
232458|NCT02399371|Biological|Pembrolizumab|Given IV
231835|NCT00165178|Drug|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
231836|NCT02410187|Radiation|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
231837|NCT02410187|Drug|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.
Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT.
231838|NCT02410187|Radiation|palliative RT|fraction size of RT = < 3 Gy
231839|NCT02410200|Drug|dimethyl fumarate|administered orally
231840|NCT02410213|Drug|Ferric Carboxymaltose (FCM)|
231841|NCT02410226|Procedure|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
231842|NCT02410226|Radiation|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
231843|NCT02410226|Radiation|Sham ultrasound procedure|Applying the ultrasound probe on the patient`s back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
231844|NCT02410239|Biological|Mesenchymal Stem Cells|
232136|NCT02405793|Drug|Meloxicam Test Capsules|
232137|NCT02405793|Drug|Meloxicam Test Capsules|
232138|NCT02405793|Drug|Meloxicam Tablets|
232139|NCT02405806|Dietary Supplement|low carbohydrate food|low carbohydrate food
232140|NCT02405806|Dietary Supplement|standard food|standard food
232141|NCT02405819|Other|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
232142|NCT02405819|Other|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
232143|NCT02405832|Dietary Supplement|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
232144|NCT02405832|Dietary Supplement|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
231512|NCT02414425|Procedure|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
231513|NCT00165594|Drug|E7070|
231514|NCT02414425|Procedure|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
231515|NCT02414425|Drug|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
231516|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
231517|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
231518|NCT02414451|Drug|Propranolol|
231519|NCT02414451|Drug|Placebo|
231520|NCT02414464|Other|35% hydrogen peroxide|Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.
Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.
In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth.
231521|NCT02416583|Drug|Oxytocin|
231522|NCT02416583|Drug|Dinoprostone|
231845|NCT02412215|Procedure|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
231846|NCT02412215|Device|NanoFlex toric Intraocular Lens|
231847|NCT02412228|Drug|Ixazomib|Cycle 1:
Ixazomib: 4mg/day 1, 8, 15
Cycles 2-6:
Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,
Maintenance:
Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years
231848|NCT02412228|Drug|Cyclophosphamide|Cycle 1:
Cyclophosphamide: 50 mg/day continuous daily
Cycles 2-6:
Cyclophosphamide: 50 mg/day continuous daily
231849|NCT02412228|Drug|Dexamethasone|Cycle 1:
Dexamethasone: 20 mg/day 1, 8, 15
Cycles 2-6:
Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18
231850|NCT00165399|Drug|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
231851|NCT02412241|Other|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
231205|NCT02420613|Drug|Temsirolimus|Newly Diagnosed DIPG Group:
Maintenance Phase Starting Dose for Temsirolimus: 25 mg/m2 by vein on Day 1 and Day 8 of a 28 day cycle.
Progressive DIPG Group:
Dose Escalation Phase Starting Dose of Temsirolimus: 25mg/m2 by vein on Day 1 and Day 8.
Maintenance Phase Starting Dose for Temsirolimus: 25 mg/m2 by vein on Day 1 and Day 8 of a 28 day cycle.
231206|NCT02420639|Device|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
231207|NCT00166556|Drug|Campath-1H and Tacrolimus|
231208|NCT02420652|Drug|Aspirin|Given PO
231209|NCT02420652|Other|Laboratory Biomarker Analysis|Correlative studies
231210|NCT02420652|Drug|Metformin Hydrochloride|Given PO
231211|NCT02420652|Other|Placebo|Given metformin hydrochloride placebo PO
231212|NCT02420652|Other|Placebo|Given aspirin placebo PO
231213|NCT02420665|Drug|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
231214|NCT02420665|Device|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
231215|NCT02420665|Behavioral|Phone Call|Study staff follow up with participant by phone one month after procedure.
231216|NCT02420665|Procedure|Colposcopy|Colposcopy performed after visual inspection of cervix.
231217|NCT02420665|Drug|Acetic Acid|3 - 5% added to cervix before visual inspection.
231218|NCT00166582|Device|electronic medication monitoring system|
231219|NCT02420691|Drug|LEE011|600 mg by mouth daily on Days 1 - 21 of a 28 day cycle.
231220|NCT02420704|Procedure|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
231221|NCT02420717|Drug|Ruxolitinib|Starting dose of Ruxolitinib: 15 mg by mouth twice daily.
231523|NCT02416583|Procedure|Membrane sweeping|
231524|NCT02416596|Procedure|Hysteroscopy|Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.
All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.
Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.
235537|NCT02440984|Procedure|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
235538|NCT02440997|Other|aromatherapy|
235539|NCT02440997|Other|foot bath|
235540|NCT02441010|Device|meridian therapy instrument|The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
235541|NCT02441010|Other|health information push technology|The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
235542|NCT00169286|Procedure|professionally-led cognitive behavioral psychotherapy group|
235543|NCT02441010|Device|monitoring device|The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
235544|NCT02441023|Behavioral|Nutritional therapy and education|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials.
235545|NCT02441023|Behavioral|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
235546|NCT02441036|Device|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
235547|NCT02441049|Behavioral|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
235548|NCT02441062|Drug|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
235549|NCT02441075|Other|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
235848|NCT02436213|Other|Cardiopulmonary exercise test|On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are "cooling down" (within the hour on Day 1), they will fill in a short questionnaire describing how they feel.
231266|NCT02424968|Drug|Cyclosporine|Given PO
231267|NCT02424968|Other|Laboratory Biomarker Analysis|Correlative studies
231268|NCT02424968|Drug|Mycophenolate Mofetil|Given PO
231269|NCT02424968|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic HSCT
231270|NCT02424968|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
231271|NCT02427022|Other|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
231272|NCT02427035|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
231273|NCT02427035|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
231274|NCT02427048|Behavioral|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
231275|NCT02427061|Behavioral|Intervention Program (Manhood 2.0)|
231276|NCT02427061|Behavioral|Control Program (Job Skills Training)|
231277|NCT02427074|Procedure|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
231278|NCT02427074|Procedure|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
231279|NCT02427087|Behavioral|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
231280|NCT00167622|Procedure|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
231281|NCT02427087|Behavioral|Healthy Diet|Diet group (21) Recommendation for healthy diet.
231282|NCT02427100|Behavioral|Diet/Physical Activity|Diet/Physical Activity Intervention
231605|NCT00002452|Drug|L-756423|
230683|NCT02403258|Other|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
230684|NCT02403258|Behavioral|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
230685|NCT02403271|Drug|Ibrutinib|BTK Inhibitor
230969|NCT02396355|Device|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
230970|NCT02396368|Drug|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
230971|NCT02398591|Drug|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
230972|NCT02398604|Drug|Allo-hMSCs|
230973|NCT02398604|Drug|Placebo|
230974|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
230975|NCT02398630|Radiation|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
230976|NCT02398630|Other|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
230977|NCT02398630|Other|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
230978|NCT02398630|Other|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
230979|NCT02398643|Other|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
230980|NCT00163735|Drug|Administration of wine fined with potential food allergens|
230981|NCT02398643|Other|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
230982|NCT02398656|Drug|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
230394|NCT02407314|Other|Six minute walk distance assessment|Assessment of the walking distance in 6 minutes.
230395|NCT02407314|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
230396|NCT02409472|Other|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
230397|NCT02409485|Behavioral|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
230398|NCT02409498|Drug|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
230399|NCT02409498|Drug|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
230400|NCT00165139|Drug|Melphalan|Described under detailed description
230686|NCT02403271|Drug|Durvalumab (MEDI4736)|Anti PDL-1
230687|NCT02403284|Drug|Liraglutide|Subcutaneous injection by patient
230688|NCT02403284|Drug|Sugar Pill|Subcutaneous injection daily
230689|NCT02403297|Device|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
230690|NCT02403310|Drug|Selinexor|Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.
Dose Level 2: 80 mg twice weekly.
Dose Level 1 (starting dose): 60 mg twice weekly.
Dose Level -1: 40 mg twice weekly.
Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.
Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months.
230691|NCT02403310|Drug|Daunorubicin|Induction: Daunorubicin 60 mg/m^2/day (days 1-3).
Consolidation: Daunorubicin 45 mg/m^2/day (days 1-2).
230692|NCT00000359|Behavioral|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
230693|NCT00002440|Drug|Ritonavir|
230694|NCT00164411|Biological|7-valent pneumococcal conjugate vaccine|
230695|NCT02403310|Drug|Cytarabine|Induction: Cytarabine 100 mg/m^2/day (days 1-7).
Consolidation: Cytarabine 100 mg/m^2/day (continuous infusion on days 1-5).
230102|NCT02413788|Other|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
230103|NCT02413788|Other|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
230104|NCT02413788|Device|treadmill|
230105|NCT02413814|Behavioral|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
230106|NCT00165503|Drug|Sodium Thiosulfate|Given intravenously over 6 hours following heated cisplatin lavage.
230107|NCT02413814|Behavioral|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
230108|NCT02413827|Drug|Combination of varlilumab and ipilimumab|Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.
Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg.
230109|NCT02413827|Drug|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.
Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC.
230110|NCT02413840|Behavioral|Baduanjin qigong|
230401|NCT02409511|Other|non intervention|
230402|NCT02409524|Biological|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
230403|NCT02409524|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
230404|NCT02409524|Biological|CRCL|Autologous tumor-derived chaperone protein mixture
230405|NCT02409537|Dietary Supplement|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
230406|NCT02409537|Dietary Supplement|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
230407|NCT02409537|Other|placebo|the individuals were given placebo for 1 month
230408|NCT02409550|Other|CARATKids Questionnaire|
230409|NCT02409563|Drug|Budesonide nasal spray (100 mcg bid)|
230410|NCT02409563|Drug|Budesonide nasal spray (50 mcg bid|
230411|NCT00165139|Drug|Ifosfamide|Described under detailed description
229824|NCT02420015|Behavioral|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
229825|NCT02420015|Behavioral|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
229826|NCT02420028|Device|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
229827|NCT02420028|Device|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
229828|NCT02420041|Procedure|Active comparator: Fluoroscopic Guided SIJ injection|Needle entry point is in the lower one-third of the SIJ
Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry
Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4" needle is inserted in a coaxial fashion into the SIJ
1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake
Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine
Patient observed in recovery bay for 20 minutes and then discharged home
229829|NCT00002451|Drug|Indinavir sulfate|
229830|NCT00166504|Drug|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
230111|NCT02413853|Drug|CBP/beta-catenin Antagonist PRI-724|Given IV
230112|NCT02413853|Biological|Bevacizumab|Given IV
230113|NCT02413853|Drug|Leucovorin Calcium|Given IV
230114|NCT02413853|Drug|Oxaliplatin|Given IV
230115|NCT02413853|Drug|Fluorouracil|Given IV
230116|NCT00165815|Drug|ARICEPT|
230117|NCT02416037|Device|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
230118|NCT02416050|Procedure|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
230119|NCT02416063|Drug|Caudal Dexmedetomidine|Drug:Caudal bupivacaine 0.25% 1ml/kg
Drug: Caudal dexmedetomidine 1µg/kg
Intravenous: 10 ml normal saline
sevoflurane Induction and maintenance of anesthesia
230120|NCT02416063|Drug|Intravenous dexmedetomidine|Drug:Caudal bupivacaine 0.25% 1ml/kg.
Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml
sevoflurane Induction and maintenance of anesthesia
229536|NCT02424214|Drug|Strontium Chloride|
229537|NCT02426450|Drug|5-Fluorouracil/Leucovorin|4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.
Repeated every 2 weeks
229538|NCT02426463|Drug|propofol|
229539|NCT02426463|Drug|oxycodone|
229540|NCT00167557|Drug|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
229541|NCT02426476|Behavioral|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
229542|NCT02426476|Behavioral|sham HRVB training|passive relaxation
229543|NCT02426489|Device|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
229544|NCT02426502|Drug|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
229545|NCT02426502|Drug|conversion of non-immunosuppressant drugs to once daily|Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.
Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative.
229546|NCT02426502|Drug|Conversion to once daily MPA|Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.
Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.
Patients taking azathioprine will be maintained on the same dose.
Patients will be maintained on the same prednisone dose.
229547|NCT02426515|Device|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
229831|NCT02420041|Procedure|Ultrasound Guided Sacroiliac Joint Injection|Sterile preparation (with chlorhexidine) and drape
Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer
3 mL of 1% lidocaine is injected subcutaneously at site of needle entry
Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4" needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not "spill out" onto sacrum).
After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.
Patient observed in recovery bay for 20 minutes and then discharged home
229832|NCT02420041|Device|Havel's Inc. EchoStim (facet tip) 21 Gauge 4" needle|
229833|NCT02420041|Device|SonoSite S-nerve|
229250|NCT00163267|Drug|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
229251|NCT02395627|Drug|pembrolizumab|
229252|NCT02395640|Drug|Epirubicin|50mg/m2 ivgtt d1
229253|NCT02395640|Drug|Oxaliplatin|
229254|NCT02397850|Behavioral|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
229255|NCT02397850|Behavioral|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
229256|NCT02397863|Drug|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
229257|NCT02397876|Other|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
229258|NCT02397889|Drug|Ketamine|
229259|NCT02397889|Drug|Midazolam|
229260|NCT02397902|Dietary Supplement|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
229261|NCT02397902|Dietary Supplement|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
229262|NCT00163605|Device|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
229263|NCT02397915|Drug|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
229264|NCT02397915|Drug|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
229265|NCT02397928|Device|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
229266|NCT02397928|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
233879|NCT02449811|Drug|Perindopril|
233880|NCT02449811|Drug|Olmesartan|
233881|NCT02449811|Drug|Amlodipine|
233882|NCT02449811|Drug|Hydrochlorothiazide|
233883|NCT02449824|Other|magnetic resonance imaging|early MRI
233884|NCT02449837|Other|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up clinic visit, but no more than every 3 months, up until 24 months after completion of radiation.
233885|NCT02449850|Other|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
233886|NCT02449850|Other|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
233887|NCT00170625|Drug|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
229267|NCT02397928|Drug|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
229268|NCT02397941|Other|Ultrasound|ultrasound measures
229269|NCT02397954|Drug|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
229270|NCT02397967|Other|Neuropsychological assessments|Neuropsychological assessments:
Intelligence Quotient (WISC-IV)
Reading tests (reading accuracy, reading speed, reading comprehension and strategy):
Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)
229271|NCT02397980|Behavioral|Behavioral intervention|What the dementia is
How to deal with behavioral problems in patients with dementia
How to manage caregiver's stress
How to care dementic patients as well as caregivers themselves
229272|NCT02397993|Procedure|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
229273|NCT00163618|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
229274|NCT02397993|Procedure|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
229275|NCT02397993|Procedure|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
229276|NCT02400281|Drug|idarubicin|Idarubicin 12 mg/m2 IV over 1 hr daily on Days 1-3 of Induction; Idarubicin 8 mg/m2 IV over 1 hr daily on Days 1-2 of Consolidation.
233606|NCT02412930|Drug|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
233607|NCT02412930|Drug|Bupivacaine|
233608|NCT02412930|Device|Ultrasound|
233609|NCT02412943|Other|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
233610|NCT02412956|Behavioral|SmokefreeMOM Text|
233611|NCT00165451|Drug|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
233612|NCT02412969|Procedure|Lumbar Epidural|control group will receive lumbar puncture epidural
233613|NCT02412969|Procedure|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
233614|NCT02412982|Drug|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
233615|NCT02412982|Drug|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
233888|NCT02449863|Other|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
233889|NCT02449876|Other|Neuroscience Education|The following topics will be discussed in the education
Basic structure of the nervous system
Basic physiology of the nervous system
The function and importance of pain
Strategies to lessen the impact of pain
The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.
Session 2:
The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear.
233890|NCT02449889|Drug|highly purified human chorionic gonadotropin|
233891|NCT02449889|Drug|recombinant human chorionic gonadotropin|
233892|NCT02449902|Drug|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
233893|NCT02449902|Drug|placebo|1 placebo capsule inserted vaginally for 14 days.
233894|NCT02452203|Behavioral|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
233895|NCT02452216|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
233314|NCT02417246|Procedure|24 hour holter monitor|Both groups will have a 24 hour holter monitor performed.
233315|NCT02417246|Other|24-hour pharmacokinetic parameters|Both groups will have this test performed.
233316|NCT02417246|Drug|Wockhardt metoprolol|Both groups will receive this to compare if there is a difference in the clinical response.
233317|NCT02417246|Drug|Activas metoprolol|Both groups will receive this to compare if there is a difference in the clinical response.
233318|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
233319|NCT00166361|Device|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
233320|NCT02419469|Drug|Rituximab|Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.
Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.
Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.
Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3.
233321|NCT02419469|Drug|Methotrexate|Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.
Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.
Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.
Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.
Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.
Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.
Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses.
233322|NCT02419469|Drug|Cyclophosphamide|Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.
Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1.
233616|NCT02412995|Other|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233617|NCT02412995|Other|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
232729|NCT00163137|Drug|lasofoxifene|lasofoxifene 0.25mg
232730|NCT02394535|Radiation|Radiation Therapy|Radiation Therapy delivered at a dose of 50.4 Gy in 1.8 Gy fractions, 1 time each day on Monday through Friday for 5½ weeks.
233018|NCT02423460|Other|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
233019|NCT02423473|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
233020|NCT02423473|Procedure|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
233021|NCT02423486|Device|Electromagnetic stimulation therapy (BIOCON-2000)|
233022|NCT02423486|Device|Electromagnetic stimulation therapy with biofeedback|
233023|NCT02423525|Drug|Afatinib|
233024|NCT02423538|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
233025|NCT02423538|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
233026|NCT02423551|Other|MRE|MRE consumption
233027|NCT00167206|Procedure|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
233028|NCT02425527|Behavioral|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
233029|NCT02425527|Behavioral|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
233030|NCT02425540|Device|Pelvic MRI|
233031|NCT00167453|Procedure|Exercise, Education|
233032|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
232459|NCT02399371|Other|Laboratory Biomarker Analysis|Correlative studies
232460|NCT02401672|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
232461|NCT02401685|Other|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
232462|NCT02401685|Procedure|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
232731|NCT02394535|Behavioral|Questionnaires|Symptom and Quality of Life (QOL) Questionnaire completed at baseline, and 4 - 6 weeks after radiation therapy.
232732|NCT02394548|Radiation|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
232733|NCT02394561|Biological|Secukinumab|Secukinumab 300 mg will be administered to Cw6 positive and negative patients with plaque type psoriasis
232734|NCT02394574|Other|Clean Cookstove|Ethanol
232735|NCT02394574|Other|Traditional Cookstove|Firewood / Kerosene
232736|NCT02394587|Behavioral|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
232737|NCT02394600|Drug|Grastek®|one tablet daily for four months
232738|NCT02394600|Drug|Placebo|one tablet daily for four months
232739|NCT02394613|Drug|ANX776|Single intravenous injection
232740|NCT00163137|Drug|raloxifene|raloxifene 60 mg/day
232741|NCT02394626|Procedure|Surgery followed by adjuvant second-line therapy|Surgery:
Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.
Adjuvant second-line therapy:
Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol.
232742|NCT02394626|Procedure|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
232743|NCT02394639|Other|video-EEG monitoring|
232145|NCT02405845|Radiation|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
232146|NCT00164736|Dietary Supplement|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
232147|NCT02405858|Drug|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
232148|NCT02405858|Drug|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
232149|NCT02405884|Other|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
232150|NCT02405897|Device|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
232151|NCT02407951|Behavioral|CBIT group|Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.
During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.
Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.
Meetings executed by two trained clinicians.
232463|NCT00164203|Behavioral|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
232464|NCT02401698|Other|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
232465|NCT02401711|Behavioral|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
232466|NCT02401711|Behavioral|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
232467|NCT02401711|Behavioral|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
232468|NCT02401724|Other|Transcranial direct current stimulation|
231852|NCT02412241|Procedure|Technical measure|Undergo standard CT scan
231853|NCT02412241|Procedure|Technical measure|Undergo standard ultrasound
231854|NCT02412254|Other|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
231855|NCT02412254|Other|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
231856|NCT02412267|Drug|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
231857|NCT02412280|Other|retrospecive observational|
231858|NCT02412293|Behavioral|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
231859|NCT02412293|Other|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
231860|NCT02412293|Behavioral|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
231861|NCT00165399|Drug|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
231862|NCT02412306|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A cycle = 6 weeks (4 weeks of blinatumomab treatment, 2-week treatment-free) . Each cohort in the study will receive a combination of 2 dose levels. In the first induction cycle, the initial dose of blinatumomab will be the lower assigned dose level (Days 1-7), then escalated (dose step) to the higher assigned dose (Days 8-29). For all subsequent cycles (beginning with the second induction cycle and continuing through consolidation and maintenance, for applicable subjects) the higher assigned dose level will be the dose for all 4 weeks of continuous treatment.
232152|NCT02407951|Behavioral|Psycho-Educational group|Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.
During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.
Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.
All group meetings will be executed and managed by two trained clinicians.
232153|NCT00165035|Device|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
232154|NCT02407977|Other|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
232155|NCT02407990|Biological|BGB-A317|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the dose expansion part, patients will be assigned to different groups based on their tumor type.
231525|NCT02416596|Device|Hysteroscope|The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).
Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg
231526|NCT02416609|Radiation|LDR|LDR will be delivered on days 1 and 2, 8 and 9 of each of four GemOx cycles
231527|NCT00165958|Procedure|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
231528|NCT02416609|Drug|Gem|Gemcitabine (1.000 mg/sqm in a 30-minute infusion) will be administered on day 1-8 of each 21-day cycle, concurrent with LDR (for four cycles). Further two cycles of additional GemOx without LDR can be administered after SBRT
231529|NCT02416609|Drug|Ox|Oxaliplatin (130 mg/sqm in a 2-hour infusion) will be administered on day 1 of each 21-day cycle, concurrent with LDR (for four cycles). Further two cycles of additional GemOx without LDR can be administered after SBRT
231530|NCT02416609|Radiation|SBRT|SBRT will be administered after the fourth GemOx cycle, if no progression; three fractions will be administered
231531|NCT02416622|Biological|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
231532|NCT02416622|Drug|CAI|carbonic anhydrase inhibitor
231533|NCT02416635|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
231534|NCT02416635|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
231535|NCT02416648|Behavioral|Clinician Client Centered (CCC) Counseling|Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action.
231536|NCT02416674|Procedure|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
231537|NCT02416674|Drug|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
231538|NCT00002448|Drug|Ritonavir|
231539|NCT00165958|Procedure|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
231540|NCT02416687|Device|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
236470|NCT02462330|Drug|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
235849|NCT02436213|Procedure|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
235850|NCT02436226|Drug|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
235851|NCT02436226|Drug|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
235852|NCT00168844|Drug|Tiotropium Inhalation Solution|
235853|NCT02436239|Drug|Vilazodone|Vilazodone tablets, once daily, oral administration
235854|NCT02436252|Drug|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
235855|NCT02436265|Drug|Dexamethasone|IV dexamethasone
235856|NCT02436265|Drug|Ropivacaine|Ropivacaine only
235857|NCT02436278|Other|4MGS|Usual walking speed measured over 4 metres
235858|NCT02436291|Device|CURE-EX device|Treatment with CURE-EX device twice daily for 24-30 weeks.
235859|NCT02436304|Drug|EXE844 Sterile Otic Suspension, 0.3%|
235860|NCT02436304|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
235861|NCT02436317|Device|Point Of Care Ultrasound|Examination with an ultrasound machine
235862|NCT02436330|Behavioral|Exergaming|6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent "exergaming", which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc.
235863|NCT00002461|Drug|cisplatin|
235864|NCT00168844|Other|Placebo|
235865|NCT02436330|Behavioral|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
235866|NCT02436343|Other|echocardiogram|At each echocardiographic evaluation, the investigator will obtain the following parameters:
Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume
231606|NCT00167102|Drug|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
231607|NCT02422836|Other|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
231608|NCT02422849|Other|hospital specialist|
231609|NCT02422849|Other|General Practitioner|
231610|NCT02422862|Other|UC-TSM|Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30" series of translatoric mobilizations of the upper cervical spine with 10" rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization.
231611|NCT02422888|Drug|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
231612|NCT02424968|Biological|Therapeutic Allogeneic Lymphocytes|Receive CD8+ memory T-cells via IV
231613|NCT02424968|Radiation|Total Nodal Irradiation|Undergo TLI
231614|NCT02424981|Device|Threshold inspiratory muscle training|Inspiratory muscle training
231615|NCT02424994|Other|No intervention|
231616|NCT00167388|Procedure|feed during blood transfusion|
231617|NCT02425007|Device|Incentive spirometry|
231618|NCT02425020|Dietary Supplement|Meat Protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
231619|NCT02425020|Dietary Supplement|Whey protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
231620|NCT02425020|Dietary Supplement|Carbohydrate|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
230983|NCT02398656|Drug|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
230984|NCT02398669|Drug|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
230985|NCT02398682|Other|Rapid diagnosis of AKI cause|The Outreach team will advise on an evidence-based package of care:
1) Rapidly establish a credible diagnosis of the cause of AKI including:
Improved assessment of volume status
Standardised use of urine dipstick .
Appropriate sepsis investigations.
Urgent ultrasound with suspected obstruction.
230986|NCT02398682|Other|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
231283|NCT02427113|Other|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
231284|NCT02427113|Other|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
231285|NCT02427126|Drug|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
231286|NCT02427126|Drug|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
231287|NCT02427139|Device|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
231288|NCT02427165|Drug|RPL554|A dual PDE3 and PDE4 inhibitor
231289|NCT02427165|Drug|Salbutamol|a beta-2 receptor agonist
231290|NCT02427165|Drug|Placebo|RPL554 placebo containing no active ingredients
231291|NCT00167635|Behavioral|cognitive-behavioral|Cognitive-behavioral over 9 weeks
231292|NCT02427178|Biological|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
231293|NCT02393807|Drug|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
231294|NCT02393807|Drug|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
231295|NCT02393820|Drug|pazopanib|treatment will be given until progression or unacceptable toxicity .
231296|NCT02393833|Drug|Cyclophosphamide|
230696|NCT02403323|Drug|etrolizumab|105 mg etrolizumab subcutaneous administration every 4 weeks
230697|NCT02405234|Device|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
230698|NCT02405247|Other|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
230699|NCT00164697|Behavioral|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
230700|NCT02405260|Drug|TTP399 400 mg|once daily
230701|NCT02405260|Drug|TTP399 800 mg|once daily
230702|NCT02405260|Drug|Sitagliptin 100 mg|once daily
230703|NCT02405260|Drug|Placebo|once daily
230704|NCT02405273|Procedure|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
230987|NCT02398682|Other|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
230988|NCT02398682|Other|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
230989|NCT02398682|Other|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
230990|NCT02398682|Other|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
230991|NCT00163748|Drug|gemcitabine, vinorelbine|
230992|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation.
230993|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation.
230412|NCT02409576|Biological|Expanded , Activated NK cells|Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.
Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days
Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy
Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses
NK cells - Expanded activated haploidentical NK cells will be infused on day 0.
230413|NCT02409589|Device|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
230414|NCT02409589|Procedure|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
230415|NCT02409602|Other|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
230416|NCT02411721|Behavioral|Animal Assisted Intervention|Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.
The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.
Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination.
230417|NCT02411734|Behavioral|Rehabilitation|Rehabilitation after hospitalization
230705|NCT02405273|Procedure|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
230706|NCT02405286|Other|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
230707|NCT02405299|Other|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
230708|NCT02405312|Behavioral|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
230709|NCT02405325|Behavioral|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, participation in daily activities such as Take 10 breaks, attendance at Peer lead group walks and normal senior center PA classes at least three times a week, and recognition of efforts through weekly prizes and bi-weekly goal tracking with peer Health Coaches.
230710|NCT00164710|Drug|sulfadoxine-pyrimethamine|
230711|NCT02405338|Biological|WT1/PRAME vaccination|
230121|NCT02416063|Drug|Placebo|Drug:Caudal bupivacaine 0.25% 1ml/kg
Intravenous: Normal saline 10 ml
sevoflurane Induction and maintenance of anesthesia
230122|NCT02416076|Device|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
230123|NCT02416076|Device|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
230124|NCT02416089|Device|Tampostat|
230125|NCT02416089|Device|Condom catheter tamponade|
230126|NCT02416102|Drug|Losartan 50 mg|COPD and subjects with chronic bronchitis not on ARB treatment will receive 50 mg for 4 weeks
230127|NCT00165828|Drug|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
230128|NCT02416102|Drug|losartan 100 mg|COPD and subjects with chronic bronchitis not on ARB treatment will receive 100 mg for 4 weeks
230129|NCT02416115|Drug|Ramosetron|Ramosetron was given iv.
230130|NCT02416115|Drug|Naloxone|Naloxone added to PCA was given iv.
230131|NCT02416115|Drug|saline|Saline was given iv.
230132|NCT02416115|Drug|Morphine|Morphine in the PCA was given iv.
230133|NCT02416128|Drug|Euphrasia|1 drop in the treated eye QID X 10 days
230134|NCT02416128|Drug|Prednisolone acetate|1 drop in the treated eye QID X 10 days
230418|NCT02411747|Behavioral|Testing|
230419|NCT02411747|Behavioral|Directed self-regulated simulation training|
230420|NCT00165334|Drug|Cetuximab|
230421|NCT02411760|Procedure|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
230422|NCT02411773|Drug|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum HCO3 > 30).
230423|NCT02411773|Drug|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session
229834|NCT02420041|Device|iohexol|
229835|NCT02420041|Drug|triamcinolone/lidocaine|
229836|NCT02420054|Behavioral|Intermittent fasting|Eating every other day for at total of 20 days.
229837|NCT02420054|Other|Time control|Time control period with no change in eating habits.
229838|NCT02420080|Drug|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
229839|NCT02420093|Device|"Pelvis Support Assembly"|Use of a portable and adjustable "Pelvis Support Assembly" in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2.
229840|NCT02422095|Procedure|EUS of pancreatic cyst lesion|All pancreatic cyst lesions evaluated by EUS will be documented in this registry. Information collected will include patient demographics, pancreatic cyst characteristics, tests undertaken on cyst contents and follow-up data.
229841|NCT02422108|Drug|Denosumab|
229842|NCT02422121|Drug|RNS60|
229843|NCT02422121|Drug|Placebo|
229844|NCT02422134|Other|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
229845|NCT02422147|Procedure|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
229846|NCT02422160|Other|No interventions are planned|No interventions are planned
229847|NCT02422173|Device|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
229848|NCT02422173|Device|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
230135|NCT02416141|Drug|fast release oro dispersible tramadol 50 mg|idem arm 1
230136|NCT02416154|Procedure|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
230137|NCT02416167|Drug|FYU-981|
229548|NCT02426528|Other|Cultural and Social exposure|The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the "Casa del Popolo". The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase).
229549|NCT02426541|Drug|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
229550|NCT02426541|Drug|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
229551|NCT00002455|Procedure|adjuvant therapy|
229552|NCT00167557|Procedure|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
229553|NCT02426554|Dietary Supplement|A combination of DHA, vitamin D3 and uridine (DDU-supplement)|
229554|NCT02426554|Dietary Supplement|Placebo supplement|
229555|NCT02426567|Other|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
229556|NCT02426567|Other|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
229557|NCT02393131|Radiation|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
229558|NCT02393144|Device|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
229559|NCT02393144|Device|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
229560|NCT02393144|Other|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
229561|NCT02393144|Drug|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
229562|NCT02393144|Drug|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
229563|NCT02393144|Drug|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
229564|NCT02393144|Drug|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
229565|NCT00162942|Device|Sham|Sham, ten apheresis sessions within 9 weeks
229566|NCT02393157|Drug|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
229277|NCT02400281|Drug|cytarabine|Cytarabine 1.5 g/m2 IV continuously over 3 hr daily on Days 1- 4 (≤ 60 yrs) or Days 1-3 (> 60 yrs) of Induction; Cytarabine 0.75 g/m2 IV continuously over 90 min daily on Days 1-3 of Consolidation.
229278|NCT02400281|Drug|azacytidine|Azacytidine 75 mg/m2/day on Days 1-7 IV or SC
229279|NCT00164021|Procedure|Physiotherapy, exercise, percutaneous gastrostomy feeds|
229280|NCT02400294|Other|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
229281|NCT02400307|Drug|GS-9883|GS-9883 75 mg tablet administered orally
229282|NCT02400320|Drug|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
229283|NCT02400320|Drug|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
229284|NCT02400320|Other|Saline|Saline
229285|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
229286|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
229287|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
229568|NCT02393157|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
229569|NCT02393157|Drug|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
229570|NCT02393157|Drug|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
229571|NCT02393170|Other|self-training using video-games|Individuals will receive a video-game console and will be taught how to play the games.
They will be requested to play 60 minutes a day for 5 weeks.
229572|NCT02393170|Other|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
229573|NCT02393183|Drug|ASTED|A tablet of ASTED will be taken twice a day
229574|NCT02393183|Dietary Supplement|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
229575|NCT02393183|Other|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
229576|NCT00162955|Drug|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
233896|NCT02452216|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification
233897|NCT02452216|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
233898|NCT02452229|Other|Review of the Literature for Human Herpes Virus infections|Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.
PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used.
233899|NCT02452242|Drug|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
233900|NCT02452242|Other|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
233901|NCT02452255|Drug|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
233902|NCT02452255|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
233903|NCT02452255|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
233904|NCT00170950|Drug|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
233905|NCT02452268|Drug|hetIL-15|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
233906|NCT02452281|Drug|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
233907|NCT02452281|Drug|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
229288|NCT02400333|Drug|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
229289|NCT02400346|Drug|Adjunct brexpiprazole|Weeks 1-4: titration from 0.5 up to 2 mg once daily. Weeks 4-26: Maintenance with 1-3 mg once daily.
Tablets for oral use once daily during 26 weeks. Tablet strenghts: 0.5 mg, 1 mg, 2 mg and 3 mg.
229290|NCT00002437|Drug|Probenecid|
229291|NCT00164021|Drug|Anti-reflux pharmacotherapy|
229292|NCT02400359|Drug|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
229293|NCT02400359|Drug|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
229294|NCT02400372|Device|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
233618|NCT02412995|Other|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233619|NCT02412995|Other|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233620|NCT00165685|Drug|Sibutramine Hydrochloride Monohydrate|
233621|NCT02415218|Biological|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
233622|NCT02415231|Behavioral|humor|
233623|NCT02415244|Procedure|TEE|Spinal cord segments will be imaged using the TEE
233624|NCT02415257|Drug|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
233625|NCT02415270|Drug|Reduced Nicotine Content Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
233626|NCT02415270|Drug|Reduced ROS/RNC|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
233627|NCT02415270|Other|Control|Control Group
233628|NCT02415283|Device|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
233629|NCT02415296|Other|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
233908|NCT02452294|Drug|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
233909|NCT02452307|Biological|Peptide vaccine|subcutaneous
233910|NCT02452307|Drug|Montanide ISA-51|subcutaneous
233911|NCT02452307|Drug|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
233033|NCT02425553|Other|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
233034|NCT02425553|Other|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
233035|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
233323|NCT02419469|Drug|Mercaptopurine|Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.
Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly.
233324|NCT02419469|Drug|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
233325|NCT02419469|Drug|Dexamethasone acetate|Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.
Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days.
233326|NCT02419469|Drug|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
233327|NCT02419482|Behavioral|4x4 minutes high intensity interval training|"Uphill" treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
233328|NCT02419482|Behavioral|10x1 minute high intensity interval training|"Uphill" treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
233329|NCT02419495|Drug|Selinexor|Dose Escalation Phase Starting Dose of Selinexor: 60 mg given orally twice a week.
Dose Expansion Phase Starting Dose of Selinexor: MTD from dose escalation phase given orally twice a week.
In dose expansion phase, there is one tumor-specific cohort of 25 ovarian carcinoma participants to receive Selinexor 50 mg orally twice a week.
233330|NCT00166361|Device|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
233331|NCT02419495|Drug|Carboplatin|Dose Escalation and Dose Expansion Phase - Selinexor + Carboplatin Group and Selinexor + Carboplatin + Pemetrexed Group: Carboplatin given at fixed dose of 6 AUC intravenously on day 1 of every 21 day cycle.
Dose Escalation Phase and Dose Expansion Phase - Selinexor + Carboplatin + Paclitaxel Group: Carboplatin given intravenously at fixed dose of 5 AUC on day 1 of each 21 day cycle.
In dose expansion phase, there is one tumor-specific cohort of 25 ovarian carcinoma participants to receive 5 AUC Carboplatin given intravenously on day 1 of each 21 day cycle.
233332|NCT02421289|Other|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
233333|NCT02421302|Dietary Supplement|RUTF|This is ready-to-use-therapeutic-food
233334|NCT02421315|Behavioral|Exposure & Response Prevention (EX/RP) and when indicated medication treatment|
232744|NCT02397018|Biological|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
232745|NCT02397031|Behavioral|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
232746|NCT02397031|Behavioral|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
232747|NCT02397044|Procedure|Implant surgery|Compare surgical protocols
232748|NCT02397057|Drug|Injectafer|
232749|NCT02397057|Other|Placebo|
232750|NCT00163462|Drug|Ciclesonide|
233036|NCT02425566|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
233037|NCT02425579|Drug|Inhaled Carbon Monoxide at 100ppm|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
233038|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 100ppm|Inhaled Medical Air for up to 90 minutes daily for 5 days
233039|NCT02425579|Drug|Inhaled Carbon Monoxide at 200ppm|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
233040|NCT02425579|Drug|Algorothim Specified dose of inhaled carbon monoxide to achieve COHb of 6-8%|Algorothim Specified dose of inhaled carbon monoxide not to exceed 500 ppm to achieve a COHb of 6-8% for up to 90 minutes daily for 5 days
233041|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 200ppm|Inhaled Medical Air for up to 90 minutes daily for 5 days
233042|NCT00167466|Device|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
233043|NCT02425579|Drug|Algorothim Specified dose of inhaled carbon monoxide to achieve COHb of 6-8% with muscle biopsies|Algorithm Specified dose of inhaled carbon monoxide not to exceed 500 ppm to achieve COHb of 6-8% for up to 90 minutes daily for 5 days with per cutaneous muscle biopsies on day 1 and day 7 (Duke Only)
233044|NCT02425579|Drug|Placebo for algorithm specified dose of inhaled carbon monoxide to achieve COHb of 6-8%|Inhaled Medical Air for up to 90 minutes daily for 5 days
233045|NCT02425605|Radiation|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
233046|NCT02425605|Drug|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
232469|NCT02401724|Other|Action Training|
232470|NCT02401737|Drug|NVR 3-778|
232471|NCT02401737|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
232472|NCT02401737|Drug|Pegasys|
232473|NCT02401750|Drug|Oxycodone Naltrexone (a)|
232474|NCT00164203|Behavioral|School-based CBT|12 sessions, weekly
232475|NCT02401750|Drug|Oxycodone Naltrexone (b)|
232476|NCT02401750|Drug|Placebo|Matches both experimental drugs
232477|NCT02401776|Dietary Supplement|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
232478|NCT02401776|Dietary Supplement|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
232479|NCT02401776|Dietary Supplement|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
232480|NCT02401776|Dietary Supplement|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
232481|NCT02403895|Drug|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
232482|NCT02403895|Drug|paclitaxel|Taxane
232751|NCT02397070|Procedure|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
232752|NCT02397070|Device|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
232156|NCT02408003|Drug|Levosimendan|Data is collected before intervention as two controls, then after a first (half) dose, and finally after a second (full) dose.
232157|NCT02408003|Drug|Milrinone|Data is collected before intervention as two controls, then after a first (half) dose, and finally after a second (full) dose.
232158|NCT02408016|Biological|Aldesleukin|Given SC
232159|NCT02408016|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
232160|NCT02408016|Drug|Cyclophosphamide|Given IV
232161|NCT02408016|Other|Laboratory Biomarker Analysis|Correlative studies
232162|NCT02408016|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
232163|NCT02408029|Other|Observational study - no intervention|
232164|NCT00165035|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
232165|NCT02408042|Drug|Pembrolizumab|
232166|NCT02408042|Drug|Etoposide|
232167|NCT02408042|Drug|Ifosfamide|
232168|NCT02408042|Drug|Mesna|
232169|NCT02408042|Drug|Carboplatin|
232170|NCT02408042|Drug|Brentuximab vedotin|
232171|NCT02408042|Drug|Rituximab|
232172|NCT02408055|Drug|TA-8995|
232173|NCT02408068|Drug|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
232483|NCT02403908|Device|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery <2 mm proximal from both ostia of right and left pulmonary arteries.
232484|NCT02403934|Device|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
232485|NCT00002440|Drug|Abacavir sulfate|
232486|NCT00164502|Behavioral|Community-based eight session group self-management program|
232487|NCT02403947|Drug|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
236471|NCT02464657|Drug|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
236472|NCT02464657|Drug|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
236473|NCT02464657|Drug|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
236474|NCT02464670|Biological|INO-4201|INO-4201 delivered IM followed by Electroporation
236475|NCT02464670|Biological|INO-4202|INO-4202 delivered IM followed by Electroporation
236476|NCT02464670|Biological|INO-4201|INO-4201 delivered ID followed by Electroporation
236477|NCT02464670|Biological|INO-4212|INO-4212 delivered IM followed by Electroporation
236478|NCT02464670|Biological|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
236479|NCT02464683|Dietary Supplement|VitaminD|200 International Units (oral dose) daily of 60 days
236480|NCT00174187|Drug|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
236481|NCT02464696|Other|Non-Invasive Positive Pressure Ventilation (NIPPV)|2 hours on NIPPV, alternating with < 2 hours off NIPPV, with continuous NIPPV at night or while sleeping with a minimum recommended time of 8 total hours of NIPPV/day.
236482|NCT02464696|Other|High Flow Nasal Cannula Oxygen Therapy|Participants maintained on high flow nasal cannula oxygen therapy.
236483|NCT02464709|Drug|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
236484|NCT02464709|Drug|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
236485|NCT02464722|Drug|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
236486|NCT02464722|Drug|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
236487|NCT02464722|Drug|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
236488|NCT02464722|Drug|Propofol|Anesthesia was induced with propofol 2 mg kg-1
236489|NCT02464722|Drug|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
236490|NCT02464735|Device|Polysomnography|
236140|NCT02429063|Device|Dim Red Light|The light will be administered via a Litebook Elite (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
236141|NCT02431533|Dietary Supplement|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
236142|NCT02431546|Behavioral|Mobile Health Application|Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.
A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant.
236143|NCT02431559|Drug|Motolimod|
236144|NCT00168298|Other|Sham Injection|Sham injection on Day 0.
236145|NCT02431559|Drug|Durvalumab|
236146|NCT02431559|Drug|Pegylated Liposomal Doxorubicin|
236147|NCT02431572|Other|PBR PET|
236148|NCT02431572|Biological|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
236149|NCT02431572|Radiation|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
236150|NCT02431585|Dietary Supplement|gluten|
236151|NCT02431585|Dietary Supplement|placebo|
236152|NCT02431598|Drug|gadoxetate disodium|
236153|NCT02431598|Drug|gadoterate dimeglumine|
236154|NCT02431598|Drug|Saline|
236155|NCT00000362|Behavioral|Chin-down position|
236156|NCT00002460|Drug|tamoxifen citrate|
236157|NCT00168311|Device|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
236158|NCT02431611|Behavioral|Biomarker feedback (phone based smoking cessation counseling)|Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
231621|NCT02425033|Procedure|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
231923|NCT02418988|Drug|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
231924|NCT02419001|Drug|SYN-004|
231925|NCT02419014|Device|Active CES Device Alpha-Stim®|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
231926|NCT02419014|Device|Sham Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
231927|NCT02419027|Dietary Supplement|GI Flora|
231928|NCT00166283|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
231929|NCT02419027|Dietary Supplement|Placebo|
231930|NCT02419040|Procedure|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
231931|NCT02420782|Drug|Itraconazole|oral
231932|NCT02420782|Drug|Pilocarpine|oral
231933|NCT02420782|Drug|Placebo|oral
231934|NCT02420795|Drug|ONC201|Phase I starting dose of ONC201: 125 mg taken by mouth taken Day 1 of every 21-day cycle.
Phase II starting dose: Maximum tolerated dose from Phase I.
231935|NCT02420795|Behavioral|Phone Call|After end-of-dosing visit, study staff will call participant every 3 months for 1 year.
231936|NCT02420821|Drug|Atezolizumab|Atezolizumab will be given as a fixed dose of 1200 millgrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
231937|NCT00166608|Procedure|Blood sampling|
231297|NCT02393833|Drug|Doxorubicin hydrochloride|
231298|NCT02393833|Drug|Epirubicin hydrochloride|
231299|NCT02393833|Drug|Fluorouracil|
231300|NCT02393833|Drug|Methotrexate|
231301|NCT02393833|Procedure|Adjuvant therapy|
231302|NCT02393833|Drug|Docetaxel|
231303|NCT00163046|Drug|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
231304|NCT02393833|Drug|Paclitaxel|
231305|NCT02393846|Drug|Ketoprofen gel|Topical ketoprofen as used in gel form.
231622|NCT02425046|Behavioral|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
231623|NCT02425046|Behavioral|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
231624|NCT02425059|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
231625|NCT02425059|Device|NanoKnife|
231626|NCT02425072|Device|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
231627|NCT00002454|Biological|autologous tumor cell vaccine|
231628|NCT00167388|Procedure|nothing by mouth (NPO) during blood transfusion|
231629|NCT02425085|Procedure|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
231630|NCT02425085|Procedure|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
231631|NCT02425098|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
231632|NCT02425098|Biological|Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)|High-dose TDV subcutaneous injection
231633|NCT02425111|Drug|Vedolizumab|Vedolizumab intravenous injection
231634|NCT02427191|Other|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
230994|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation.
230995|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation.
230996|NCT02401074|Biological|Segmental Bronchoprovocation with Allergen (SBP-Ag)|
230997|NCT02401087|Procedure|Anaesthesiological procedure|
230998|NCT02401113|Dietary Supplement|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
230999|NCT02401126|Dietary Supplement|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
231000|NCT02401126|Dietary Supplement|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
231001|NCT00002438|Drug|Itraconazole|
231002|NCT00164125|Drug|polyethyleneglycol3350|
231003|NCT02401139|Drug|Ketamine|
231004|NCT02401139|Drug|Placebo|
231005|NCT02401152|Other|Sports drink 1|Sports drink with a specific source of CHO.
231006|NCT02401152|Other|Sports drink 2|Sports drink with a specific source of CHO
231007|NCT02401152|Other|Placebo|iso-caloric sports drink with maltodextrin as CHO source
231306|NCT02393846|Drug|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
231307|NCT02393859|Drug|Blinatumomab|If the patient is enrolled in the initial phase of the study, he/she will receive one cycle of blinatumomab. If the patient is enrolled in the adaptive phase of the study, the patient will receive three cycles of blinatumomab.
231308|NCT02393859|Drug|Conventional Consolidation Chemotherapy|If the patient is enrolled in the initial phase of the study, he/she will receive one block of standard consolidation chemotherapy. If the patient is enrolled in the adaptive phase of the study, the patient will receive three blocks of consolidation chemotherapy.
231309|NCT02393872|Behavioral|Feel4Diabetes-intervention|Community-based intervention.
231310|NCT02393885|Device|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
231311|NCT02393898|Other|No intervention|No intervention administered in this study
230712|NCT02405351|Behavioral|Adaptive Working Memory Training|The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.
Adaptive refers to the increase in the number of items that the patient is required to remember.
230713|NCT02405364|Drug|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
230714|NCT02407314|Drug|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels. Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
230715|NCT02407340|Drug|oxytocin|40IU 3xday delivered as 5 sprays (0.1 mL) per nostril
230716|NCT02407340|Drug|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
230717|NCT02407353|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
230718|NCT02407353|Drug|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
230719|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
230720|NCT02407366|Drug|Icotinib|Icotinib (125 mg ,Three times daily)
230721|NCT02407366|Drug|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
231008|NCT02401165|Other|Blood test|blood test
231009|NCT02401191|Drug|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
231010|NCT02401204|Other|Longitudinal surveillance study|Regular specimens will be routinely collected as standard of practice.
A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.
If participant is intubated/ventilated, a throat swab will be collected.
231011|NCT02401217|Other|Phase 1- Arm 1 Infant Formula|Powder infant formula
231012|NCT02401217|Other|Phase 2- Arm 2 Infant Formula|Powder infant formula
231013|NCT00164138|Procedure|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
231014|NCT02401217|Other|Phase 2- Arm 3 Infant Formula|Powder infant formula
231015|NCT02401230|Drug|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
230424|NCT02411773|Other|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
230425|NCT02411773|Other|Stretching|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
230426|NCT02411786|Biological|pTVG-AR|Given ID
230427|NCT02411786|Biological|gm-csf|Given ID
230428|NCT02411812|Device|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
230429|NCT02411812|Device|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
230430|NCT02411825|Drug|SAR425899|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
230431|NCT00165334|Drug|Vinorelbine (Navelbine)|
230432|NCT02411825|Drug|placebo|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
230433|NCT02411825|Drug|metformin|Pharmaceutical form: tablet
Route of administration: oral
230434|NCT02413853|Other|Laboratory Biomarker Analysis|Correlative studies
230435|NCT00002446|Drug|Fluconazole|
230436|NCT00165503|Drug|ALIMTA|Given intravenously on day 1 of each 21-day treatment cycle for a total of 3 cycles beginning 6-10 weeks after surgery.
230722|NCT02407366|Drug|Carboplatin|Carboplatin (AUC，5) every 21 days
230723|NCT02407366|Radiation|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
230724|NCT02407379|Device|Photoablative - photodynamic 4x4 dental Laser System p/n 88832224|Photoablative gingival epithelium was performed with at 810 nm diode laser‖ (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes¶The periodontal tissues and the dental root, were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications). Sham-treatment was similar but with switched off laser
230725|NCT02407379|Procedure|Scaling - Root Planing|
230138|NCT00165841|Drug|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
230139|NCT02416167|Drug|Placebo|
230140|NCT02416180|Device|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
230141|NCT02416180|Device|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
230142|NCT02418182|Drug|placebo|will serve as a placebo control for the acetaminophen group
230143|NCT00166166|Drug|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
230144|NCT02418195|Drug|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
230145|NCT02418221|Dietary Supplement|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
230146|NCT02418221|Procedure|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure & pulse
230147|NCT02418234|Other|mutation detection|
230148|NCT02418234|Other|ARMS and ddPCR|
230149|NCT02418234|Genetic|ctDNA analysis|
230150|NCT02418247|Drug|I-131|
230151|NCT02418247|Drug|I-125|
230152|NCT02418260|Procedure|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
230153|NCT02418260|Procedure|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
230154|NCT00166166|Drug|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
230155|NCT02418260|Procedure|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
230156|NCT02418273|Drug|denosumab|These subjects will receive two doses of denosumab.
230157|NCT02418286|Other|Observation|There are no interventions associated with this registry as it is purely observational.
229567|NCT02393157|Drug|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
229849|NCT00002451|Drug|Stavudine|
229850|NCT00166829|Drug|sirolimus, tacrolimus, mycophenolate mofetil|
229851|NCT02422173|Device|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
229852|NCT02422173|Device|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
229853|NCT02422186|Drug|Esketamine|All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
229854|NCT02422186|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
229855|NCT02422186|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
229856|NCT02422186|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
229857|NCT02422186|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
229858|NCT02422186|Drug|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
229859|NCT02422199|Drug|pyrotinib|
229860|NCT02424240|Other|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 & IGFBP-3 combination
229861|NCT02424253|Drug|ZPL-3893787|ZPL-3893787
229862|NCT00167271|Behavioral|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
229863|NCT02424253|Drug|Placebo|Matched Placebo
229864|NCT02424266|Device|None invasive imaging of the tear film (AdOM)|White light tomography imaging
229577|NCT02393196|Drug|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
229578|NCT02393196|Drug|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
229579|NCT02393209|Drug|Docetaxel|Docetaxel IV.
229580|NCT02393209|Drug|MLN1117|MLN1117 orally.
229581|NCT02393222|Other|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
229582|NCT02395640|Drug|Capecitabine|1000mg/m2 po d1-14
229583|NCT02395653|Drug|Fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
229584|NCT02395666|Drug|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
229585|NCT02395679|Biological|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
229586|NCT02395692|Other|Laboratory Biomarker Analysis|Correlative studies
229587|NCT02395692|Drug|Methoxyamine|Given PO
229588|NCT02395692|Drug|Temozolomide|Given PO
229868|NCT02424305|Drug|LEO 43204 gel 0.1%|
229869|NCT02424305|Drug|LEO 43204 gel 0.037%|
229870|NCT02424318|Drug|Topiramate|topiramate 25mg twice 1 week -> topiramate 50mg twice 7 weeks
229871|NCT02424331|Other|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
229872|NCT02424331|Other|Quiet Breathing|
229873|NCT00000361|Drug|Methotrexate|
229874|NCT00002453|Drug|Tenofovir disoproxil fumarate|
229875|NCT00167284|Behavioral|physician and patient education; physician practice redesign|
229876|NCT02424344|Drug|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
229877|NCT02424344|Drug|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
229295|NCT02400385|Drug|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
229296|NCT02400385|Drug|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
229297|NCT02400398|Other|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Pepatmen(medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
229298|NCT02400411|Other|Wheat bread|
229299|NCT02400411|Other|margarine|
229300|NCT02400411|Other|ham|
229301|NCT02400411|Other|soup|
229302|NCT00164034|Device|Real time computer prompted trauma algorithms|
229303|NCT02400411|Other|rye bread|
229304|NCT02402582|Other|Family-centered empowerment model|First stage was including the perceived intensity and the perceived sensitivity. Self-efficacy in stage two was that the individual gets belief in that they can do a special task. Self- efficacy alludes to the individual's expectation of themselves and the ability to do action. Self-esteem in third stage was to clarify and identify the level of approval, acceptance and merit that the individual feels they have. Formative assessment was to encourage the patients more toward internalizing their locus of control and summative evaluation was to evaluate the effectiveness of this model on modifying, balancing and improving the health related quality of life (HRQOL) dimensions of MI patients after 3 months for eight points in the stage four.
229305|NCT02402595|Drug|AVP-923|
229306|NCT02402595|Drug|AVP-786|
229307|NCT02402595|Drug|Itraconazole|
229308|NCT02402608|Dietary Supplement|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
229309|NCT02402608|Dietary Supplement|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
229589|NCT00163280|Drug|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
229590|NCT02395705|Drug|cisplatin and paclitaxel|Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
229591|NCT02395718|Other|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
229592|NCT02395718|Other|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
233912|NCT02452307|Drug|Imiquimod|epicutaneous
233913|NCT02452307|Drug|mRNA|subcutaneous
233914|NCT02452307|Drug|Protamin|subcutaneous
233915|NCT00002463|Drug|Procarbazine Hydrochloride|
233916|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
233917|NCT02452307|Procedure|local hyperthermia|
233918|NCT02452320|Drug|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
233919|NCT02454348|Drug|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
233920|NCT02454348|Drug|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
233921|NCT02454361|Drug|KBP-7072|KBP-7072
233922|NCT02454361|Drug|Placebo|Placebo
233923|NCT02454374|Procedure|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
233924|NCT02454374|Procedure|Routine Physiotherapy Care|Routine Physiotherapy Care
233925|NCT00171262|Drug|Fluvastatin|
233926|NCT02454387|Drug|ONO-4474 Part A1|Healthy volunteers
233927|NCT02454387|Drug|Placebo Part A1|Healthy volunteers
233928|NCT02454387|Drug|ONO-4474 Part A2|Healthy volunteers
233929|NCT02454387|Drug|Placebo Part A2|Healthy volunteers
229310|NCT02402621|Drug|fentanyl|fentanyl with antiemetic drug
229311|NCT02402634|Other|Mechanical ventilatory lung care|
233335|NCT02421328|Device|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
233336|NCT02421328|Device|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
233337|NCT02421341|Drug|Fentanyl|During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
233630|NCT02415296|Other|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
233631|NCT00002447|Drug|Efavirenz|
233632|NCT00165698|Drug|menatetranone|15 mg three times a day orally for 12 months
233633|NCT02415296|Other|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
233634|NCT02415309|Dietary Supplement|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
233635|NCT02415309|Dietary Supplement|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
233636|NCT02415309|Other|Placebo|40 patients will randomly receive a placebo/sugar pill
233637|NCT02415322|Other|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
233638|NCT02415335|Drug|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
233639|NCT02415335|Drug|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
233640|NCT02415348|Device|Fibroscan|
233641|NCT02415361|Other|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
233642|NCT02415374|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
233643|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
233644|NCT02417285|Drug|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
233047|NCT02427659|Behavioral|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
233048|NCT02427659|Behavioral|Audio (sound of nature)|The subjects will listen to an audio recording called "Sounds of Nature" during their wound care.
233049|NCT00167700|Behavioral|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
233050|NCT02427659|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
233051|NCT02427672|Device|Transcranial direct current stimulation|
233052|NCT02427672|Device|Sham transcranial direct current stimulation|
233053|NCT02427685|Device|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
233054|NCT02427698|Procedure|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
233338|NCT02421341|Procedure|Catheters|A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
233339|NCT02421341|Other|Exercise|You will be asked to exercise, ride a stationary bike, at maximal exertion.
233340|NCT02421341|Radiation|DEXA|During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
233341|NCT00002451|Drug|Lamivudine|
233342|NCT00166712|Drug|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
233343|NCT02421341|Other|Pulmonary Function Tests|During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
233344|NCT02421341|Other|Blood Draw|You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
233345|NCT02421341|Other|Chemosensitivity Test|Using a bag you breath in and out your own air.
233346|NCT02421341|Drug|Placebo|
233347|NCT02421354|Drug|Nivolumab|3 mg/kg given by vein approximately every 2 weeks for 8 doses followed by a maintenance regimen of one dose every 12 weeks.
232753|NCT02397083|Device|Levonorgestrel Intrauterine Device (LIUD)|Participants undergo treatment with the LIUD. Placement of LIUD done at the time of the dilation and curettage (D&C) or during a routine clinic visit.
232754|NCT02397083|Drug|Everolimus|At 3 months after LIUD procedure, participants receive Everolimus administered at 10 mg taken by mouth daily for three months.
232755|NCT02397083|Behavioral|Questionnaire|Quality of life (QOL) questionnaire completed at baseline visit.
232756|NCT02397096|Drug|MK-1439A|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
232757|NCT02397096|Drug|Baseline regimen of ritonavir-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir administered according to the product circulars
232758|NCT02397096|Drug|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circulars
232759|NCT02397122|Biological|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
232760|NCT02397122|Procedure|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
232761|NCT00163475|Drug|Roflumilast|
232762|NCT02399371|Other|Pharmacogenomic Study|Correlative studies
232763|NCT02399397|Procedure|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
232764|NCT02399397|Procedure|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
232765|NCT02399397|Procedure|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
233055|NCT02427698|Procedure|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
233056|NCT02427711|Device|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
233057|NCT02427724|Drug|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
233058|NCT02427724|Drug|lidocaine 7%/tetracaine 7% topical anesthetic|
233059|NCT02427724|Drug|placebo vehicle|
233060|NCT00167700|Dietary Supplement|Placebo capsules|Placebo capsules
232488|NCT02403947|Drug|Suspension media|injection suspension media
232489|NCT02403960|Dietary Supplement|probiotic|the patients used probiotic tablets in addition to scaling and root planning
232490|NCT02403960|Dietary Supplement|placebo|the patients used placebo tablets in addition to scaling and root planning
232491|NCT02403973|Other|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
232492|NCT02403986|Device|Restylane Vital Skinboosters Lidocaine|
232493|NCT02403999|Other|Test shampoo|Oilatum Soothe &amp; Protect Shampoo
232494|NCT02403999|Other|Test bath foam|Oilatum Soothe & Protect Bath Foam
232495|NCT02403999|Other|Test head to toe wash|Oilatum Soothe & Protect Head to Toe Wash
232496|NCT02404012|Dietary Supplement|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
232497|NCT00164515|Behavioral|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
232498|NCT02404025|Biological|Eltrombopag|Eltrombopag is provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
232499|NCT02404025|Biological|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection will be administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
232500|NCT02404025|Biological|CsA|CsA as capsules, oral solution, or fine granule, will be administered at a dose of 3 mg per kg twice a day.
232501|NCT02404038|Drug|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
232502|NCT02404038|Device|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
232766|NCT02399397|Drug|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
232767|NCT02399397|Procedure|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
232768|NCT00163878|Procedure|Sensory Stimulation|
236794|NCT02458131|Behavioral|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
236795|NCT02458144|Procedure|Total hip arthroplasty|The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.
The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed.
236796|NCT02458157|Drug|Furosemide (Furix)|Loading dose: 40 mg I.V.
Infusion rate 40 mg/h
Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours.
236797|NCT02460055|Drug|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
236798|NCT02460055|Drug|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
236799|NCT02460055|Drug|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
236800|NCT02460055|Drug|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
236801|NCT02460068|Drug|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
236802|NCT00002470|Biological|recombinant interferon alfa|
236803|NCT00172107|Drug|placebo|placebo powder for subcutaneous injection
236804|NCT02460068|Drug|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
236805|NCT02460068|Drug|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
236806|NCT02460081|Drug|PDA-002|
236807|NCT02460081|Drug|Placebo|
236808|NCT02460094|Drug|BMS-986168|
236809|NCT02460094|Drug|Placebo|(0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
236810|NCT02460107|Biological|Botulinum toxin type A|
236811|NCT02460107|Other|Normal saline|Placebo
236159|NCT02431611|Behavioral|Control condition (phone based smoking cessation counseling)|phone-based behavioral smoking cessation counseling
236160|NCT02431624|Drug|BTDS|
236491|NCT00174200|Drug|Risperidone 2 mg|
236492|NCT02464748|Other|TiM telehealth arm|
236493|NCT02464761|Drug|Visudyne|
236494|NCT02464774|Procedure|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
236495|NCT02464774|Procedure|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
236496|NCT02464774|Drug|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
236497|NCT02429076|Drug|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
236498|NCT00167908|Drug|Ethyol (drug)|
236499|NCT02429076|Drug|Placebo|
236500|NCT02429076|Drug|Propofol|
236501|NCT02429076|Drug|Sevoflurane|
236502|NCT02429089|Drug|LEE011|The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.
In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients.
236503|NCT02429102|Drug|MT-8554|
236504|NCT02429102|Drug|Placebo|
236505|NCT02429115|Other|Mentoring|Six months of peer-mentoring.
236506|NCT02429128|Other|14 weeks exercise training|
236507|NCT02429141|Procedure|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
236508|NCT02429141|Procedure|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
236509|NCT00167921|Drug|Premarin® Vaginal Cream|
236510|NCT02429154|Other|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
231938|NCT02420821|Drug|Bevacizumab|Bevacizumab will be given as 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
231939|NCT02420821|Drug|Sunitinib|Sunitinib will be given as 50 mg orally (PO) once daily on Days 1 through 28 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
231940|NCT02420834|Other|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
231941|NCT02420834|Other|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
232238|NCT02414685|Drug|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
232239|NCT02414698|Procedure|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
232240|NCT02414698|Drug|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
232241|NCT02414711|Other|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (<1.75)
232242|NCT02414711|Other|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
232243|NCT00165633|Drug|Placebo|Placebo capsule, orally, three times a day, after meals.
232244|NCT02414724|Drug|Gemcitabine Hydrochloride|Given IV
232245|NCT02414724|Other|Laboratory Biomarker Analysis|Correlative studies
232246|NCT02414724|Other|Pharmacological Study|Correlative studies
232247|NCT02414724|Drug|Ribociclib|Given PO
232248|NCT02416817|Other|Point of Care guided|Based on massive transfusion triggers and thrombelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the Thrombelastometry. The dosis of each drug will be based on the analysis of the thrombelastometry curves (established algorithm).
232249|NCT02416843|Other|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
232250|NCT02416869|Procedure|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
232251|NCT02416869|Procedure|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
232252|NCT02416869|Drug|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
231635|NCT02427191|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
231636|NCT02427217|Biological|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
231637|NCT02427230|Behavioral|Pelvic floor muscle training|The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.
At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.
231638|NCT02427230|Behavioral|Pelvic floor muscle training|The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.
At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.
Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks.
231639|NCT02427230|Drug|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
231640|NCT02427243|Drug|Crenezumab|
231942|NCT02420834|Other|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
231943|NCT02420834|Other|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
231944|NCT02420847|Drug|Ixazomib|Phase I Starting Dose of Ixazomib: 4.0 mg by mouth on Day 1 of every 14-day cycle.
Phase II Starting Dose of Ixazomib: MTD from Phase I.
231945|NCT02420847|Drug|Gemcitabine|Phase I Starting Dose of Gemcitabine: 559 mg/m2 by vein on Day 1 of each 14 day cycle.
Phase II Starting Dose of Gemcitabine: MTD from Phase I.
231946|NCT02420847|Drug|Doxorubicin|Phase I Starting Dose of Doxorubicin: 33 mg/m2 by vein on Day 1 of each 14 day cycle.
Phase II Starting Dose of Doxorubicin: MTD from Phase I.
231947|NCT02420860|Drug|Elotuzumab|10 mg/kg by vein on Days 1, 8, 15, and 21 for the first 2 cycles, then on Days 1 and 15 only during Cycles 3-6, and then on Day 1 each cycle after that. Cycles beyond 6, once per cycle at 20 mg/kg on Day 1 of each cycle.
231948|NCT00166621|Drug|Buspirone|
231949|NCT02420860|Drug|Dexamethasone acetate|28 mg by mouth between 3-24 hours prior to the start of Elotuzumab infusion. Dexamethasone 8 mg by vein on day of Elotuzumab infusion prior to the start of infusion.
231950|NCT02420860|Drug|Diphenhydramine|25-50 mg by mouth or vein prior to Elotuzumab.
231951|NCT02420860|Drug|Ranitidine|50 mg by vein prior to Elotuzumab.
231312|NCT02393911|Dietary Supplement|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
231313|NCT02393924|Other|No intervention|No intervention administered in this study
231314|NCT00163059|Drug|NMDA Antagonist, CP-101,606 (traxoprodil)|
231315|NCT02393937|Drug|Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
231316|NCT02393950|Drug|ODM-106|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
231317|NCT02393950|Drug|Placebo|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
231318|NCT02393963|Drug|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
231319|NCT02396368|Radiation|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
231320|NCT02396381|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
231321|NCT02396381|Other|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
231322|NCT00163371|Drug|Ciclesonide|
231641|NCT02427243|Drug|Crenezumab|
231642|NCT02427256|Device|Device: Topcon Specular Microscope SP-1P|Device: Topcon Specular Microscope SP-1P
231643|NCT00002456|Drug|cyclosporine|
231644|NCT00167648|Drug|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
231645|NCT02427269|Other|Esophageal biopsies|Up to 10 research-specific esophageal biopsies obtained from the esophagus during the routine care EGD.
Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),
Two biopsies from normal squamous epithelium, and
One biopsy from each area of esophageal nodularity seen during the procedure
231646|NCT02427269|Other|Blood|The following blood will be collected for this research study: 1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection
231647|NCT02427282|Device|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
231016|NCT02401230|Device|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
231017|NCT02403336|Other|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
231018|NCT02403336|Behavioral|Behavioral group intervention|Intervention on patients (educational workshop).
231019|NCT02403336|Other|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
231020|NCT02403349|Drug|Fimasartan|
231021|NCT02403349|Drug|Valsartan|
231022|NCT02403349|Drug|Atenolol|
231023|NCT02403362|Drug|EPO-018B|
231024|NCT02403375|Device|ACCU-CHEK Insight Diabetes Therapy System|Continuous subcutaneous insulin infusion pump
231025|NCT00164411|Biological|23-valent polysaccharide vaccine|
231026|NCT02403375|Drug|Insulin injections|Multiple daily insulin injections
231027|NCT02403388|Other|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
231028|NCT02403401|Drug|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
231029|NCT02403414|Device|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
231323|NCT02396394|Behavioral|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
231324|NCT02396407|Behavioral|Combined water, sanitation, and hygiene|Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.
Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.
Handwashing: Handwashing stations including soapy water bottles and detergent soap.
Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children < 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces.
231325|NCT02396420|Device|Embosphere Microspheres|
230726|NCT02407392|Drug|Acetic Acid|During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
230727|NCT02407392|Procedure|Non targeted quadrantic biopsies|During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
230728|NCT02407405|Other|Laboratory Biomarker Analysis|Correlative studies
230729|NCT02407405|Other|Pharmacological Study|Correlative studies
230730|NCT00164957|Device|continuous pump feeding|
230731|NCT02407405|Other|Quality-of-Life Assessment|Ancillary studies
230732|NCT02407405|Drug|Selumetinib|Given PO
230733|NCT02407418|Other|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
230734|NCT02407418|Other|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
230735|NCT02409615|Other|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
230736|NCT02409615|Other|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
230737|NCT02409628|Device|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
230738|NCT02409641|Drug|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
230739|NCT02409654|Other|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
230740|NCT02409654|Other|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
231030|NCT02403427|Device|VoiceDiab expert system|Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.
Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab.
231031|NCT02403440|Drug|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
231032|NCT02403466|Behavioral|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
230437|NCT02413866|Behavioral|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
230438|NCT02413866|Behavioral|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
230439|NCT02413879|Device|CleanCision|Wound protection during colorectal surgery.
230440|NCT02413905|Biological|Stool samples|Stool samples
230441|NCT02413918|Drug|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
230442|NCT02413931|Other|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
230443|NCT02413944|Procedure|ACTH stimulation test|ACTH stimulation test
230444|NCT02413957|Other|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
230445|NCT02413957|Other|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
230446|NCT02413970|Device|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
230447|NCT00165516|Drug|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
230448|NCT02413983|Procedure|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
230449|NCT02413983|Procedure|hepatectomy midline incision|
230450|NCT02413983|Procedure|hepatectomy transverse incision|
230451|NCT02413996|Device|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
230452|NCT02413996|Behavioral|Functional activities|Stairs, walking
230453|NCT02413996|Other|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
230454|NCT02413996|Other|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
229865|NCT02424279|Procedure|Splanchnicectomy|
229866|NCT02424292|Other|Physical activity|Physical activity in a personalised program.
229867|NCT02424305|Drug|LEO 43204 gel 0.018%|
230158|NCT02418299|Device|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
230159|NCT02418312|Drug|histamine-2 receptor antagonist (famotidine)|famotidine (40 mg qd) plus thienopyridine
230160|NCT02418312|Drug|Placebo|placebo plus thienopyridine
230161|NCT02418325|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
230162|NCT02418325|Other|Liberation therapy|
230163|NCT02418338|Other|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
230164|NCT02418351|Biological|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
230165|NCT00166192|Procedure|Jessner's solution chemical peel|
230166|NCT02418351|Other|Liberation therapy|
230167|NCT02420106|Procedure|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
230168|NCT00166504|Drug|atorvastatin|atorvastatin 10 mg
230169|NCT02420106|Drug|botulinum toxin intramuscular injection|
230170|NCT02420119|Other|non intervational|
230171|NCT02420132|Other|No intervention|No intervention administered in this study
230172|NCT02420145|Behavioral|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
230173|NCT02420158|Device|Trans-cutaneous vagal nerve electrical stimulation|
230174|NCT02420171|Other|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
229878|NCT02424357|Drug|5%povidone iodine ophthalmic solution|At the conclusion of the surgery, all patients will receive a strip of ophthalmic ointment containing antibiotics and corticosteroids into the conjunctival fornix. The subjects will then be randomized (use computer program to generate random digit) into two groups:
Group 1: Patients will receive one drop of 5% povidone iodine instilled into the conjunctival fornix.
Group 2: Patients will not receive 5% povidone iodine into conjunctival fornix.
229879|NCT02424370|Procedure|TAVR|Percutaneous aortic valve replacement
229880|NCT02424383|Device|Percutaneous Transluminal Angioplasty (Lutonix® DCB)|Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.
The Lutonix® DCB through the blood vessel to the narrowed area to be treated.
229881|NCT02424396|Drug|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
229882|NCT02426580|Behavioral|wechat|The wechat model of dietary education every 1 month by cellphone
229883|NCT02426593|Device|IMED-4|Non-invasive novel lung hydration status sensor.
229884|NCT02426606|Other|Various lentil varieties (varying in slow digested starch content)|Randomized, cross-over block design.
Comparison of glycemic and insulinemic responses following meals composed of:
white rice or white rice combined with 1 of 3 different lentil varieties or
white potato or white potato combined with 1 of 3 different lentil varieties
Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.
Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit).
229885|NCT02426619|Device|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
230180|NCT02420197|Behavioral|Multidisciplinary rehabilitation program|
230181|NCT02420210|Drug|Bendamustine Hydrochloride|Given IV
230182|NCT02420210|Biological|Obinutuzumab|Given IV
230183|NCT02420210|Drug|Dexamethasone|Given PO
230184|NCT02420210|Other|Quality-of-Life Assessment|Ancillary studies
230185|NCT02420210|Other|Laboratory Biomarker Analysis|Correlative studies
230186|NCT02420223|Drug|Propranolol|
230187|NCT02420236|Behavioral|High-intensity resistance training|
230188|NCT02420236|Behavioral|General physical activity|
229593|NCT02395731|Behavioral|MIND at Home-Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
229594|NCT02395744|Other|Paclitaxel administration using the OPC|
229595|NCT02395757|Device|MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|
229596|NCT02395770|Other|Rehabilitation program|Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.
Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.
Stretching & Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.
Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports
229597|NCT02395783|Drug|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
229598|NCT02395783|Drug|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
229599|NCT02395783|Other|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
229600|NCT02398006|Other|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
229601|NCT02398006|Other|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
229886|NCT02426619|Device|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
229887|NCT02426632|Drug|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
229888|NCT00167570|Device|Prosthetic socket fabricated using selective laser sintering|
229889|NCT02426632|Drug|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
229890|NCT02426632|Drug|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
229312|NCT02402647|Behavioral|CREST|Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.
Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET.
229313|NCT02402647|Behavioral|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
229314|NCT00164333|Behavioral|TAP: Treatment Advocacy Program|
229315|NCT02402660|Drug|ALK-001|Daily, oral administration for 24 months
229316|NCT02402660|Drug|Placebo|Daily, oral administration for 24 months
229317|NCT02402673|Other|Temporary activity modification and graded exercises|
229318|NCT02402712|Drug|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
229319|NCT02402712|Drug|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
229320|NCT02402712|Drug|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
229321|NCT02402725|Drug|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
229322|NCT02402738|Behavioral|Interpersonal and Social Rhythm Therapy|
229323|NCT02402738|Behavioral|Enhanced Treatment as Usual|
229324|NCT02402751|Procedure|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
229325|NCT02404701|Dietary Supplement|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
233645|NCT02417285|Drug|CC-122|1mg, 2mg, 3mg or 4mg administered orally once daily on a 5/7-day schedule in each 28-day cycle
233646|NCT02417298|Drug|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
233647|NCT00000361|Drug|Corticosteroids|
233648|NCT00002448|Drug|Efavirenz|
233649|NCT00166088|Dietary Supplement|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
233650|NCT02417298|Drug|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
233930|NCT02454387|Drug|ONO-4474 Part B|Healthy volunteers
233931|NCT02454387|Drug|Placebo Part B|Healthy volunteers
233932|NCT02454387|Drug|ONO-4474 Part C|Healthy volunteers
233933|NCT02454387|Drug|Placebo Part C|Healthy volunteers
233934|NCT02454387|Drug|ONO-4474 Part D|Healthy volunteers
233935|NCT02454387|Drug|Placebo Part D|Healthy volunteers
233936|NCT00171275|Drug|Fluvastatin|
233937|NCT02454400|Other|Pre-surgery physiotherapy|Physiotherapy guided intervention twice a week for nine weeks. The program includes:
Active physiotherapy according to a treatment based classification:
Specific exercises and mobilization
Motor control exercises
Traction
Tailor-made general supervised exercise program
Behavioral approach to reduce fear avoidance and increase activity level.
Standardized information about:
the surgery
post-surgery rehabilitation
to stay active
233938|NCT02454400|Other|Waiting-list|Standardized information about:
the surgery
post-surgery rehabilitation
to stay active
233939|NCT02454413|Other|denture brushing with water and soap|denture brushing with water and soap
233940|NCT02454413|Other|ultrasonic denture cleaning|ultrasonic denture cleaning
233941|NCT02454413|Other|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
233942|NCT02454426|Drug|Vortioxetine|open label treatment
233943|NCT02454439|Other|CRT implantation|
233348|NCT02421354|Behavioral|Questionnaire|Questionnaire completed about participant's quality of life completed at baseline, Day 1, 7, 14 of Cycle 1, Days 1 and 14 of Cycles 2 - 5, and Day 1 of every third cycle after that. It should take about 10 minutes to complete each time.
233349|NCT02421354|Behavioral|Phone Call|Study staff to call participant to ask about side effects about 30, 60, and 100 days after last dose of the study drug. This call should last about 10 minutes.
233350|NCT02421367|Biological|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
233351|NCT02421380|Drug|Hyperpolarized Pyruvate|
233352|NCT02423564|Dietary Supplement|Digesta Lac|
233353|NCT02423564|Other|Placebo|
233354|NCT02423577|Drug|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
233355|NCT02423577|Drug|Placebo|Placebo dry powder administered by nasal inhalation
233356|NCT02423590|Drug|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
233357|NCT02423590|Drug|Gemcitabine|Gemcitabine is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Gemcitabine is classified as an antimetabolite
233358|NCT02423590|Drug|Carboplatin|Carboplatin is an anticancer drug ("antineoplastic" or "cytotoxic") chemotherapy drug. Carboplatin is classified as an "alkylating agent."
233651|NCT02417311|Other|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
233652|NCT02417337|Procedure|Root Canal Treatment|A standardized endodontic procedures performed.
233653|NCT02417337|Drug|Paracetamol|
233654|NCT02417337|Drug|Ibuprofen|
233655|NCT02417337|Drug|Mefenamic acid|
233656|NCT02417337|Drug|Diclofenac|
233657|NCT02417350|Other|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
233658|NCT02417350|Other|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
233061|NCT02427724|Device|Q-switched 532nm Laser|
233062|NCT02427737|Behavioral|Comfort Talk® Training|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post training support, and access to a post-training support web module resulting in at least 20 hrs training.
233063|NCT02427750|Biological|Aggripal®|TIV
233064|NCT02427763|Device|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
233065|NCT02427763|Other|collect saliva|the patient spit during 30 seconds in a small bottle
233066|NCT02427763|Other|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
233067|NCT02427763|Other|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
233068|NCT02427776|Biological|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
233069|NCT02427789|Other|Physical Exercise|physical exercise
233070|NCT02427802|Drug|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
233071|NCT00167700|Dietary Supplement|Probiotics|
233072|NCT02394652|Drug|Metformin|
233073|NCT02394652|Drug|Cisplatin|
233074|NCT02394652|Drug|FAZA|
233075|NCT02394665|Radiation|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV60.
233076|NCT02394665|Drug|Temozolomide|Concurrent with six weeks of radiation therapy. After 28 day break then daily on days 1 - 5 of each cycle, for up to 12 cycles. One cycle = 28 days
233359|NCT02423603|Drug|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
233360|NCT02423603|Drug|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
233361|NCT02423603|Drug|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
233362|NCT00167206|Procedure|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
232769|NCT02399410|Drug|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
232770|NCT02399410|Procedure|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
232771|NCT02399410|Drug|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
232772|NCT02399423|Behavioral|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
232773|NCT02399423|Behavioral|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
232774|NCT02399436|Behavioral|School-Based Healthy Snacking Campaign|The school-based healthy snacking campaign includes the following activities:
Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;
The installation of new filtered water fountains outfitted with water-filling stations;
The distribution of re-usable water bottles to students at participating schools; and
A social marketing campaign to support adoption of the healthy snacks and water consumption by students.
232775|NCT02399436|Behavioral|Community Cooking Classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
232776|NCT02399449|Drug|sodium ferric gluconate (brand)|brand product
232777|NCT02399449|Drug|sodium ferric gluconate (generic)|generic product
232778|NCT02399462|Drug|Acthar|
232779|NCT00163878|Device|Sesnory Modality Assessment and Rehabilitation Technique|
232780|NCT02399475|Drug|Levothyroxine|The initial total daily dose for Levothyroxine will be 30 mcg divided into three daily doses for a minimum of 7 weeks and maximum of 25 weeks duration. The total daily dose will be titrated to a target TSH level of 0.5 -1.5mU/L
232781|NCT02399475|Drug|Liothyronine|The initial total daily dose for Liothyronine will be 10 mcg divided into three daily doses for a minimum of 7 weeks and maximum of 25 weeks duration. The total daily dose will be titrated to a target TSH level of 0.5 -1.5mU/L
232782|NCT02399475|Drug|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
232783|NCT02401789|Device|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
232784|NCT02401802|Dietary Supplement|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
233077|NCT02394665|Device|Three Dimensional Volumetric MRS Imaging|3D MRSI at week 3 of radiation therapy, and at the end of radiation therapy, and prior to cycle 1, 4, 7 and 10 of adjuvant (post-radiation) therapy
236812|NCT02460120|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
236813|NCT02460133|Drug|Paritaprevir|
237130|NCT02453503|Drug|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
237131|NCT02453516|Procedure|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
237132|NCT02453516|Procedure|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
237133|NCT02453516|Drug|ropivacaine|Drug indicated for regional anesthesia
237134|NCT02453516|Drug|epinephrine|Drug indicated to prolong the action of regional anesthesia
237135|NCT02453516|Other|sterile saline|Neutral injection (no drug involved)
237136|NCT02453529|Drug|WCK 4873|Oral tablets
237137|NCT02453555|Drug|Linagliptin|
237138|NCT02453555|Drug|Empagliflozin placebo + linagliptin placebo|Matching placebo empagliflozin + linagliptin
237139|NCT02453555|Drug|Empagliflozin + linagliptin low dose|tablet
237140|NCT00171132|Drug|valsartan|
237141|NCT02453555|Drug|Linagliptin lacebo|Matching placebo linagliptin
237142|NCT02453555|Drug|Empagliflozin + linagliptin high dose|tablet
237143|NCT02453568|Drug|Tranexamic Acid|1g TXA in 50mL Lactated Ringers solution administered via IV rapid infusion bolus over a 3 minute period after the delivery of the anterior shoulder.
237144|NCT02455778|Dietary Supplement|Placebo|
237145|NCT02455791|Procedure|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
237146|NCT02455804|Device|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
237147|NCT02455830|Biological|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
236511|NCT02429154|Other|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
236814|NCT00172107|Drug|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
236815|NCT02460133|Drug|Ritonavir|
236816|NCT02460133|Drug|Dasabuvir|
236817|NCT02460133|Drug|Ombitasvir|
236818|NCT02460133|Drug|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
236819|NCT02460146|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
236820|NCT02460146|Other|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
236821|NCT02460159|Drug|EZ 10 mg/Atorva 20 mg FDC|
236822|NCT02460159|Drug|EZ 10 mg/Atorva 10 mg FDC|
236823|NCT02460172|Device|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
236824|NCT02460172|Device|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision.
236825|NCT02462330|Drug|Placebo comparator|injections of human albumin
236826|NCT02462343|Other|walk tests|
236827|NCT02462356|Procedure|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
236828|NCT00173017|Device|wearing N95 masks|
236829|NCT02462356|Procedure|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
236830|NCT02462369|Drug|Saxagliptin|
236831|NCT02462369|Drug|glimepiride|
236832|NCT02462382|Procedure|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
236833|NCT02462382|Drug|Ropivacaine|
236834|NCT02462382|Drug|Saline|
232253|NCT02416869|Drug|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
232254|NCT02416869|Procedure|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
232255|NCT02416869|Procedure|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
232256|NCT00166036|Drug|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
232257|NCT02416882|Other|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
232258|NCT02416882|Other|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
232551|NCT02410460|Drug|scopolamine|
232552|NCT02410460|Drug|midazolam|
232553|NCT02410460|Device|ondansetron|
232554|NCT02410460|Drug|metoclopramide|
232555|NCT02410460|Drug|glycopyrrolate|
232556|NCT02410460|Drug|lidocaine|
232557|NCT02410460|Drug|famotidine|
232558|NCT00000359|Behavioral|ShamManeuver|Passive movement of the head
232559|NCT00002443|Drug|Indinavir sulfate|
232560|NCT00165178|Drug|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
232561|NCT02410460|Drug|desflurane|
232562|NCT02410460|Drug|sevoflurane|
232563|NCT02410473|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
232564|NCT02412475|Drug|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
232565|NCT02412475|Drug|Liposomal Daunorubicin|60 mg per meter squared per day - start after administration of fludarabine IV over 1 hour on days 6,8,10
232566|NCT02412475|Drug|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
231952|NCT02420860|Drug|Lenalidomide|10 mg/day; after three cycles, provided the ANC is >/= 1000/mL, platelet count >/= 100,000/mL and all non-hematologic toxicity is </= grade 1, dose may be increased to 15 mg/day at discretion of physician.
231953|NCT02420860|Behavioral|Symptom Questionnaire|Symptom questionnaire completion on Day 1.
231954|NCT02420873|Drug|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
231955|NCT02422888|Drug|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
231956|NCT02422901|Drug|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
231957|NCT02422914|Behavioral|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
231958|NCT02422914|Behavioral|Smoking cessation program TFC-free and activity tracker|Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.
The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
232259|NCT02416882|Other|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
232260|NCT02416895|Other|In vivo immunity model|A measure of in vivo immune function.
232261|NCT02416908|Drug|Selinexor|
232262|NCT02416908|Drug|Cladribine|
232263|NCT02416908|Drug|G-CSF|
232264|NCT02416908|Drug|Cytarabine|
232265|NCT02416908|Procedure|Bone marrow biopsy|
232266|NCT02416921|Behavioral|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
232267|NCT00166036|Drug|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
231648|NCT02427282|Device|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
231649|NCT02427295|Drug|Sandostatin (Octreotide Acetate)|For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:
Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.
Frequency: every 4 weeks.
Route of administration: IM injection.
231650|NCT02427308|Drug|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
231651|NCT02427321|Device|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
231652|NCT02427334|Drug|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
231653|NCT02427334|Drug|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
231654|NCT02393963|Other|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
231655|NCT02393976|Dietary Supplement|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
231656|NCT02393976|Dietary Supplement|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
231657|NCT02393989|Procedure|posterior restoration|restorations for caries effected teeth
231658|NCT02394002|Drug|Propofol|
231659|NCT02394015|Drug|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
231660|NCT00163072|Drug|transdermal Megace|oral vs transdermal levels
231959|NCT02422914|Behavioral|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
231960|NCT00167115|Drug|Alcohol|
231961|NCT02422927|Dietary Supplement|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
231962|NCT02422927|Other|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
231963|NCT02422927|Other|Placebo|placebo
231964|NCT02422940|Drug|dalfampridine-ER 7.5 mg|
231326|NCT02396433|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle.
231327|NCT02396433|Drug|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
231328|NCT02396433|Drug|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
231329|NCT02396446|Other|Abdominal acoustic measurement|
231330|NCT02396459|Drug|Triac|Triac, following a dose-escalation scheme
231331|NCT02396472|Behavioral|Order by time and topic|
231332|NCT02396472|Behavioral|Order by information relevance|
231333|NCT00163384|Drug|Ciclesonide|
231334|NCT02396472|Behavioral|Order by social relationship|
231335|NCT02396472|Behavioral|Order by help giving|
231336|NCT02396472|Behavioral|Order by self-disclosure|
231337|NCT02396485|Other|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
231338|NCT02396498|Drug|HIPEC|Using cisplatin in HIPEC plus oral S-1
231339|NCT02396511|Biological|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
231340|NCT02398695|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
231341|NCT02398708|Other|Questionnaires|Both groups will have questionnaires collected and compared.
231661|NCT02394028|Drug|Etrolizumab 210 mg|Induction phase only: 210 mg dose subcutaneous injection administration at Weeks 0,2,4,8 and 12
231662|NCT02394028|Drug|Etrolizumab 105 mg|Induction Phase : 105 mg dose subcutaneous administration at Weeks 0,4,8 and 12; Maintenance Phase : Single 105 mg dose subcutaneous administration Q4W
231663|NCT02394028|Drug|Placebo|Matching placebo to either etrolizumab 105 mg or etrolizumab 210 mg according to the treatment schedule
231664|NCT02394041|Device|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
231665|NCT02394041|Device|Sham acupuncture|Sham acupuncture with sham needles
231033|NCT02403479|Drug|Topical silver colloid|Patients will be provided with a standardized silver colloid spray and asked to place two sprays into each nostril daily for a total of three consecutive months. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
231034|NCT02403479|Other|Topical Saline|
231035|NCT02403492|Device|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
231036|NCT00164424|Drug|Acyclovir|
231037|NCT02403492|Device|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
231038|NCT02403492|Device|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
231039|NCT02403505|Drug|ABIRATERONE|Janssen Biotech, Inc.
Purchased on USA market and approved by FDA
231040|NCT02403505|Drug|PREDNISONE|Pharmacia and Upjohn and Company
Purchased on USA market and approved by FDA
231041|NCT02403505|Drug|ENZALUTAMIDE|Astellas Pharma US, Inc.
Purchased on USA market and approved by FDA
231042|NCT02403505|Drug|DEGARELIX|Ferring Pharmaceuticals Inc.
Purchased on USA market and approved by FDA
231043|NCT02405377|Procedure|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
231044|NCT02405377|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
231045|NCT02405377|Drug|0.9% sodium chloride ﬂuid administration|
231046|NCT02405377|Device|5-French catheter|
231047|NCT02405390|Procedure|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
231048|NCT02405390|Procedure|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
231342|NCT02398708|Other|Blood Sample|Both groups will have a blood sample collected and compared.
231343|NCT02398708|Other|Stool Sample|Both groups will have a stool sample collected and compared.
231344|NCT02398708|Other|Clinical data|Both groups will have clinical data collected and compared.
230455|NCT02414009|Drug|Capecitabine|
230456|NCT02414009|Drug|Temozolomide|
230457|NCT02414009|Drug|Irinotecan|
230741|NCT00165139|Drug|G-CSF (granulocyte-colony stimulating factor)|Described under detailed description
230742|NCT02409667|Biological|Secukinumab|Secukinumab 300 mg
230743|NCT02409680|Drug|Low dose aspirin|Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 12 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
230744|NCT02409680|Drug|Placebo|Placebo
230745|NCT02409693|Procedure|Myringotomy with tube insertion|
230746|NCT02409719|Other|Schedule|Illustrative daily planner to point the day that the exercise was performed
230747|NCT02409732|Drug|aminolevulinic acid hydrochloride|
230748|NCT02409732|Procedure|Photodynamic therapy with blue light|
230749|NCT02409745|Procedure|endometrial scratch|local injury to the endometrium by Pipelle
230750|NCT02409758|Behavioral|Voice therapy|Voice therapy applied during 6 weeks.
230751|NCT02409771|Device|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
230752|NCT00002442|Drug|Stavudine|
230753|NCT00165139|Drug|Mesna|Described under detailed description
230754|NCT02409784|Dietary Supplement|Ketogenic diet|4 days 4:1 (lipids:protein/carbohydrates) ketogenic diet
230755|NCT02409797|Other|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2‐week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
230756|NCT02411838|Other|Calorie restriction|Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.
Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI <28 will follow a regimen of fasting for two days per week while patients with BMI>28 will follow a regimen of fasting for three days per week.
230175|NCT02420184|Device|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
230176|NCT02420184|Other|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
230177|NCT02420197|Behavioral|High-intensity resistance training|
230178|NCT02420197|Behavioral|General physical activity|
230179|NCT00166517|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
230458|NCT02416180|Device|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
230459|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
230460|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
230461|NCT02416206|Drug|BeEAM|BeEAM
230462|NCT02416219|Procedure|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
230463|NCT02416219|Device|Ultrasound|
230464|NCT02416232|Drug|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
230465|NCT00165854|Drug|E7070|
230466|NCT02416232|Drug|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
230467|NCT02416245|Dietary Supplement|Beverage powder fortified with micronutrients and Bacopa monnieri extract|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
230468|NCT02416245|Other|Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
230469|NCT02416258|Drug|LP0113 aerosol spray|
230470|NCT02416258|Drug|Aerosol spray vehicle|
230471|NCT02416258|Drug|LEO 90100 aerosol foam|
230189|NCT02420236|Behavioral|Multidisciplinary rehabilitation program|
230190|NCT00166517|Biological|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
230191|NCT02420249|Behavioral|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong [in Chinese]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
230192|NCT02420262|Drug|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
230193|NCT02420262|Drug|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
230194|NCT02420262|Drug|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
230195|NCT02422199|Drug|Lapatinib|
230196|NCT00166842|Drug|sirolimus, cyclosporine, tacrolimus|
230197|NCT02422199|Drug|capecitabine|
230198|NCT02422212|Other|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
230199|NCT02422225|Device|Eldith DC-STIMULATOR|Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients
tDCS intervention]
Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany
Stimulation site <Experimental group>
Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit
Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex
Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit <Control group> Sham stimulation
230481|NCT02416271|Drug|Placebo-SC|Administered SC
230482|NCT02416284|Other|NFBDG|Intervention consists of:
Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where "Vegetable of the day" was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)
230483|NCT02418364|Other|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
230484|NCT02418364|Other|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
229891|NCT02426632|Drug|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
229892|NCT02426632|Drug|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
229893|NCT02426632|Drug|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
229894|NCT02426632|Drug|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
229895|NCT02426632|Drug|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
229896|NCT02426632|Drug|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
229897|NCT02426632|Drug|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
229898|NCT02426632|Drug|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
229899|NCT00167583|Drug|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
229900|NCT02426632|Drug|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
229901|NCT02426658|Other|Laboratory Biomarker Analysis|Correlative studies
229902|NCT02426658|Drug|Pemetrexed Disodium|Given IV
229903|NCT02426658|Other|Quality-of-Life Assessment|QOL studies
229904|NCT02393235|Other|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
229905|NCT02393248|Drug|INCB054828|
229906|NCT02393261|Other|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
229907|NCT02393261|Other|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
230200|NCT02422225|Device|Sham Eldith DC-STIMULATOR|
230201|NCT02422251|Device|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
230202|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
229602|NCT02398019|Device|OXIRIS®|OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [OXIRIS® (Baxter Gambro)].
PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.
OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time.
229603|NCT02398032|Device|CPAP nasal|During the night
229604|NCT02398032|Device|sham CPAP nasal|During the night
229605|NCT02398045|Other|Computerised CBT for OCD|Computerised CBT for OCD
229606|NCT02398058|Drug|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
229607|NCT02398058|Drug|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
229608|NCT00002436|Drug|Zidovudine|
229609|NCT00163644|Procedure|aereobic plus resisted exercise|
229610|NCT02398071|Device|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
229611|NCT02398084|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
229612|NCT02398097|Biological|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
229613|NCT02398097|Biological|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
229614|NCT02398097|Biological|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
229615|NCT02398110|Procedure|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
229616|NCT02398110|Procedure|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
229617|NCT02398123|Other|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
229618|NCT02398123|Other|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
233944|NCT02456844|Drug|Methotrexate, Leucovorin and BMS-986142|Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)
Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)
BMS-986142 on Days 6 through 10.
233945|NCT02456857|Drug|Temsirolimus|25 mg by vein on Days 1, 8, and 15 of each 21 day cycle.
233946|NCT02456857|Drug|Liposomal Doxorubicin|30 mg/m2 by vein on Day 1 of each 21 day cycle.
233947|NCT02456857|Drug|Bevacizumab|10 mg/kg by vein on Day 1 of each 21 day cycle.
233948|NCT02456870|Other|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
233949|NCT02456883|Drug|gilteritinib|oral
233950|NCT02456883|Drug|14C-labeled gilteritinib|oral
233951|NCT02456896|Drug|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
233952|NCT00171652|Drug|Diclofenac sodium gel 1%|
229326|NCT02404701|Dietary Supplement|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
229327|NCT00164619|Behavioral|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). [see Brief Summary above]
229328|NCT02404701|Dietary Supplement|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
229329|NCT02404701|Dietary Supplement|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
233659|NCT02417376|Device|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
233660|NCT00166088|Dietary Supplement|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
233661|NCT02417376|Device|Gracey curettes|set of 7 instruments number #1-14
233662|NCT02417389|Drug|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
233663|NCT02417389|Drug|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
233664|NCT02417402|Other|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
233665|NCT02419495|Drug|Paclitaxel|For Selinexor + Paclitaxel Group: Paclitaxel given intravenously at a fixed dose of 80 mg/m2 on Day 1 and Day 8 of every 21-day cycle (weekly for 2 weeks on and 1 week off).
For Selinexor + Carboplatin + Paclitaxel Group: Starting dose of Paclitaxel 175 mg/m2 given intravenously on day 1 of each 21 day cycle.
233666|NCT02419495|Drug|Eribulin|Eribulin given intravenously at fixed dose of 1.0 mg/m2 on days 1 and 8 of every 21-day cycle.
233667|NCT02419495|Drug|Doxorubicin|Doxorubicin given intravenously at fixed dose of 60 mg/m2 on day 1 of each 21 day cycle.
233668|NCT02419495|Drug|Cyclophosphamide|Cyclophosphamide given intravenously at fixed dose of 600 mg/m2 on day 1 of each 21 day cycle.
233953|NCT02456909|Device|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
233954|NCT02456909|Device|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
233955|NCT02456909|Drug|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
233956|NCT02456922|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
233957|NCT02456935|Drug|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
233363|NCT02423616|Other|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
233364|NCT02423629|Device|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
233365|NCT02423642|Procedure|Continuous renal replacement therapy with regional citrate anticoagulation|CRRT with anticoagulant : regional citrate anticoagulation
Filter : AQUAMAX™ (Edwards Lifesciences)
233366|NCT02423642|Procedure|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
233367|NCT02423655|Other|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
233368|NCT02423655|Other|Algorithm for routine dialysis intervention|Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.
Or patients have indications below: 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
233369|NCT02423668|Procedure|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
233370|NCT02423668|Procedure|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
233371|NCT02423668|Procedure|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
233372|NCT02425618|Procedure|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
233373|NCT02425618|Procedure|pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
233374|NCT02425618|Device|I-gel|
233669|NCT02419495|Drug|Pemetrexed|Pemetrexed given intravenously at fixed dose of 500 mg/m2 on day 1 of each 21 day cycle.
233670|NCT02419495|Drug|Topotecan|Starting Dose of Topotecan: 0.5 mg/m2 given intravenously on days 1 - 5 of each 21 day cycle.
233671|NCT02419508|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
233078|NCT02394665|Behavioral|FACT-BR Questionnaire|FACT-BR Quality of Life (QOL) Questionnaire to be completed by study patients as protocol specific timepoints
233079|NCT00163137|Drug|Placebo|0 mg/day
233080|NCT02394665|Radiation|Stereotactic Radiosurgery Boost|Administered one week prior to fractionated radiation therapy
233081|NCT02394665|Radiation|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to PTV60 and 75 Gy in 30 fractions to PTV75
233082|NCT02394665|Device|MRI|MRI w/ or w/Gadolinium at week 3 of radiation therapy, and at the end of radiation therapy, and prior to cycle 1, 4, 7 and 10 of adjuvant (post-radiation) therapy
233083|NCT02394678|Device|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
233084|NCT02394691|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
233085|NCT02394704|Other|Sensory attention training|Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible whenever the stimulus is different from the preceding stimulus. At low intensities attention will need to be voluntarily recruited. At high initial intensities, attention is expected to be automatically captured by each stimulus (not effortful). Patients will rate their subjective attention to the stimulus every minute. At block breaks every 5 minutes, participants will rate mood and body-focus (interoceptive awareness proxy). Stimuli will consist of non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2" electrodes placed on the left forearm). Sessions will be approximately 45 minutes 3 session over the course of two weeks.
233086|NCT02394717|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
233087|NCT02394730|Drug|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
233088|NCT02394730|Drug|Placebo|Sugar pill taken orally once daily for 12 weeks
233089|NCT02394743|Radiation|18FDG-PET|
233090|NCT00163150|Drug|Atorvastatin|
233091|NCT02394756|Device|Marketed Soft Contact lens|Replacement schedule every 2 weeks
233092|NCT02394756|Device|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
233093|NCT02394756|Device|Biofinity®|Replacement schedule every 4 weeks
233094|NCT02394769|Drug|Aspirin|
233095|NCT02394769|Drug|Placebo for Aspirin|
237148|NCT02455843|Other|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
237149|NCT02455856|Drug|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6.
237150|NCT00171483|Drug|Tegaserod|
237151|NCT02455856|Drug|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
237449|NCT00170443|Biological|rHAO Trivalent Influenza Vaccine|
237450|NCT02449018|Drug|QBW251|QBW251 capsule(s) taken orally twice per day
237451|NCT02449018|Drug|Placebo|Matching placebo capsule(s) taken orally twice per day
237452|NCT02449031|Drug|TOBI Podhaler|
237453|NCT02449031|Drug|TOBI|tobramycin inhalation solution, USP
237454|NCT02449031|Drug|Bethkis|tobramycin inhalation solution
237455|NCT02449031|Drug|Cayston|aztreonam for inhalation solution
237456|NCT02449044|Drug|Tolvaptan|Once Daily
237457|NCT02449057|Other|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
237458|NCT02449070|Drug|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
237459|NCT02449083|Procedure|MRI|MRI
237460|NCT00170456|Biological|rPA vaccine containing alhydrogel|
237461|NCT02449083|Procedure|coronary angiography|coronary angiography
237462|NCT02449096|Device|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
237463|NCT02449096|Other|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
237464|NCT02449109|Procedure|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
237465|NCT02449122|Procedure|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
237466|NCT02449135|Procedure|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
236835|NCT02462395|Device|tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
ECH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 2 weeks.
CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks.
Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software.
237152|NCT02455869|Drug|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
237153|NCT02455869|Drug|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
237154|NCT02455869|Drug|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
237155|NCT02455895|Device|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
237156|NCT02455908|Drug|Proleukin®|
237157|NCT02455921|Drug|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
237158|NCT02455921|Drug|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
237159|NCT02455934|Dietary Supplement|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and <12 days apart.
237160|NCT02455947|Other|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
237161|NCT00171496|Drug|Cyclosporine microemulsion|
237162|NCT02455960|Dietary Supplement|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
237163|NCT02455960|Dietary Supplement|Placebo|
237164|NCT02458157|Other|Continuous renal replacement therapy (CRRT)|Initiated in case of contraindications or inadequate effect of furosemide.
Fluid removal is started at 2 ml/kg/h
The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved
237165|NCT02458157|Other|Resuscitation|The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:
Mottling beyond the edge of kneecaps
Hypotension (MAP < 50) resistant to inotropes and vasopressors
Plasma lactate ≥ 4 mmol/l
Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:
Fluid removal is paused
A crystalloid fluid bolus of 250-500 ml is given
Circulatory status is reevaluated within 30 minutes
Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour
Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect.
232567|NCT00002445|Drug|IM862|
232568|NCT00165412|Procedure|Mammogram|Repeated once a year for three years
232569|NCT02412475|Drug|Cytarabine|Patient Age (years) IT Cytarabine Dose > 1 30 mg
2 and < 3 50 mg
3 and ≤ 18 70 mg > 18 100 mg
given IT on day 0 or -1
232570|NCT02412475|Drug|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
232571|NCT02412488|Other|Insertion of the Reveal LINQ device in the out of cathlab setting|Insertion of the Reveal LINQ device in the "out-of-cathlab" setting (out of the operating room, cardiac catheterization or electrophysiology laboratory).
232572|NCT02412501|Device|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
232573|NCT02412514|Biological|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
232574|NCT02412514|Biological|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
232575|NCT02412514|Biological|IPV|IPV administered at 6 weeks of age
232847|NCT02406144|Drug|Lenalidomide|
232848|NCT02406144|Drug|Dexamethasone|
232849|NCT02406157|Device|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
232850|NCT02406157|Device|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
232851|NCT00164775|Drug|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
232852|NCT02406170|Drug|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
232853|NCT02406170|Drug|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
232854|NCT02406183|Radiation|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
232855|NCT02406183|Drug|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
232856|NCT02408146|Procedure|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
232268|NCT02416921|Behavioral|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
232269|NCT02416934|Drug|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
232270|NCT02416934|Drug|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
232271|NCT02416947|Dietary Supplement|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
232272|NCT02419040|Procedure|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
232273|NCT02419040|Procedure|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
232274|NCT02419053|Other|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
232275|NCT02419092|Device|Continuous Positive Airway Pressure (CPAP)|
232276|NCT02419105|Drug|Testosterone|transdermal gel, 75 mg daily
232277|NCT02419105|Drug|Colecalciferol|drink solution, 24000 IU once per month
232576|NCT02412527|Other|Patch III heart rate sensor|
232577|NCT02412540|Behavioral|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
232578|NCT02412553|Other|Specific carbohydrate diet|
232579|NCT00165425|Procedure|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram and the results will be interpreted by a cardiologist
232580|NCT02412553|Other|Elemental diet|
232581|NCT02412566|Drug|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
232582|NCT02412579|Other|None - Standard of Care|
231965|NCT02422940|Drug|dalfampridine-ER 10 mg|
231966|NCT02422953|Dietary Supplement|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of WSB will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
231967|NCT02422953|Dietary Supplement|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
231968|NCT02422953|Dietary Supplement|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of MNP in alternate days
231969|NCT02422953|Behavioral|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
231970|NCT02422966|Drug|Paracetamol|
231971|NCT00167128|Device|hearing aid, Phonak EduLink-FM System|
231972|NCT02422966|Drug|Ibuprofen|
231973|NCT02422979|Drug|RM-1929|Dose-escalation, fixed low fluency light application study to determine the drug dose that can be safely given to saturate the epidermal growth factor receptor (EGFR) at the tumor
231974|NCT02422979|Device|Photoimmunotherapy|Light dose-escalation, fixed drug dosing infusion study to determine the optimal light application, in combination with the Part I drug dose, needed to achieve clinical response with an acceptable safety profile.
231975|NCT02425124|Behavioral|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
231976|NCT02425137|Drug|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
231977|NCT02425150|Procedure|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
232278|NCT02419105|Drug|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
232279|NCT02419105|Drug|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
232280|NCT00166296|Drug|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
232281|NCT02419118|Drug|Daratumumab|Treatment of myeloma patients with Daratumumab
232282|NCT02419118|Drug|Lenalidomide|Treatment of myeloma patients
232283|NCT02419118|Drug|Dexamethasone|Treatment of myeloma patients
231666|NCT02394054|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
231667|NCT02394054|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
231668|NCT02394067|Other|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
231669|NCT02394080|Device|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
231670|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAY1019036)|One Fast Release packet containing 500 mg acetylsalicylic acid dry powder
231671|NCT00163085|Drug|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
231672|NCT02394093|Drug|Acetylsalicylic acid|One tablet containing 500 mg acetylsalicylic acid
231673|NCT02394093|Drug|Acetylsalicylic acid|One effervescent tablet containing 500 mg acetylsalicylic acid
231674|NCT02394106|Drug|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
231675|NCT02394106|Other|Placebo|Normal saline, 1000 ml, administered once
231676|NCT02394119|Drug|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
231677|NCT02394119|Drug|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
231678|NCT02394132|Drug|Imiquimod|
231679|NCT02396511|Biological|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
231680|NCT02396524|Behavioral|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
231978|NCT02425150|Procedure|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
231979|NCT02425163|Device|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
231980|NCT00167401|Drug|docetaxel|
231345|NCT02398721|Other|Fine Needle Aspiration Cytology|
231346|NCT02398734|Device|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
231347|NCT02398747|Drug|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
231348|NCT02398760|Other|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
231349|NCT02398773|Procedure|Computed Tomography|Undergo PET/CT
231350|NCT00002436|Drug|Zalcitabine|
231351|NCT00163761|Drug|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
231352|NCT02398773|Radiation|F-18 16 Alpha-Fluoroestradiol|Given IV
231353|NCT02398773|Other|Laboratory Biomarker Analysis|Correlative studies
231354|NCT02398773|Procedure|Positron Emission Tomography|Undergo PET/CT
231355|NCT02398786|Other|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
231356|NCT02398799|Behavioral|Psychoeducational support|The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.
Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort.
231357|NCT02398812|Other|Medication assessment and treatment plan based on it|Intervention
Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.
Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician.
231358|NCT02398825|Drug|Ponatinib|Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to > 1%. Dose adjustments for toxicity are detailed in the protocol.
231681|NCT02396537|Drug|Lidocaine|Administered intranasally prior to Midazolam administration.
230757|NCT02411851|Drug|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
230758|NCT02411851|Other|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
230759|NCT02411864|Other|different low b-values distribution|
230760|NCT02411877|Procedure|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
231049|NCT02405390|Device|Storz C-Mac® laryngoscope|
231050|NCT00002440|Drug|Nelfinavir mesylate|
231051|NCT00164710|Drug|amodiaquine plus sulfadoxine-pyrimethamine|
231052|NCT02405403|Drug|[18F]DPA-714 PET|[18F]DPA-714 Positron Emission Tomography
231053|NCT02405416|Procedure|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
231054|NCT02405416|Procedure|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
231055|NCT02405416|Procedure|Portal triad clamping|Portal triad are clamped in hepatectomy.
231056|NCT02405442|Drug|GS-5745|GS-5745 administered via subcutaneous (SC) injection
231057|NCT02405442|Drug|Placebo|Placebo to match GS-5745 administered via subcutaneous (SC) injection
231058|NCT02405455|Procedure|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
231059|NCT02405455|Device|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
231060|NCT02405481|Behavioral|SEPA III|
231061|NCT02405494|Dietary Supplement|Beverage 1|
231062|NCT00164710|Drug|amodiaquine plus artesunate|
231063|NCT02405494|Dietary Supplement|Beverage 2|
231064|NCT02405494|Dietary Supplement|Beverage 3|
231065|NCT02405494|Dietary Supplement|Beverage 4|
231066|NCT02405494|Dietary Supplement|Beverage 5|
230472|NCT02416258|Drug|Betamethasone dipropionate aerosol spray|
230473|NCT02416258|Drug|Calcipotriol aerosol spray|
230474|NCT02416258|Drug|Daivobet® gel|
230475|NCT02416271|Drug|Teriparatide|Administered SC
230476|NCT00165867|Drug|E7070|
230477|NCT02416271|Drug|Alendronate|Administered orally
230478|NCT02416271|Dietary Supplement|Calcium|Administered orally
230479|NCT02416271|Dietary Supplement|Vitamin D|Administered orally
230480|NCT02416271|Drug|Placebo-Oral|Administered orally
230761|NCT02411877|Procedure|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
230762|NCT02411877|Device|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
230763|NCT02411877|Device|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
230764|NCT00002444|Drug|Nitazoxanide|
230765|NCT00165347|Drug|PTK787/ZK222584|
230766|NCT02411890|Procedure|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
230767|NCT02411890|Procedure|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
230768|NCT02411890|Procedure|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
230769|NCT02411890|Procedure|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
230770|NCT02411903|Drug|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
230771|NCT02411903|Drug|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
230772|NCT02411916|Biological|misoprostol|rectal insertion
230485|NCT02418390|Procedure|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
230486|NCT02418403|Behavioral|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
230487|NCT02418403|Behavioral|Educational website|Research-verson of the "Prepare for your care" website (www.prepareforyourcare.org)
230488|NCT02418416|Other|Oocyte double chemical activation|Oocyte double chemical activation
230489|NCT02418429|Other|waxy maize starch|pancake test meal with waxy maize starch only
230490|NCT02418429|Other|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
230491|NCT02418429|Other|Resistant Starch|pancake test meal with resistant starch only
230492|NCT00166192|Procedure|Trichloroacetic acid chemical peel|
230493|NCT02418429|Other|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
230494|NCT02418455|Drug|UX003|
230495|NCT02418468|Drug|Indacaterol|Patients are randomized to receive indacaterol plus prn salbutamol
230496|NCT02418468|Drug|Placebo|Patients are randomized to receive placebo for indacaterol plus prn salbutamol
230497|NCT02418481|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
230498|NCT02418481|Biological|γδ T Cell|γδ T cells will be used against breast tumor.
230499|NCT02418481|Biological|Combination|γδ T/DC-CIK cells will be used against breast tumor.
230500|NCT02418494|Other|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
230782|NCT02414061|Dietary Supplement|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
230783|NCT02414061|Other|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
230784|NCT02414074|Behavioral|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
230785|NCT02414074|Behavioral|Parent Education|Everyday Parenting is a parent training curriculum.
230203|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
230204|NCT02422264|Biological|Infanrix hexa|• All subjects will receive Infanrix hexa at 2, 4 and 6 months or 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
230205|NCT02422264|Drug|Prevnar13|• All subjects will receive Infanrix hexa co-administered with Prevenar13* at 2, 4 and 6 months or 2, 3 and 4 months, depending on the immunisation schedule of the country. * In some countries/regions, Prevenar 13 is given as a 2-dose schedule at 2 and 4 months of age as a part of the routine immunisation programme. Prevnar13 is administered intramuscularly to the left thigh.
230206|NCT02422277|Device|LI-ESWT group|The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.
-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week.
230207|NCT00166855|Procedure|dynamic MRI and bone marrow sampling|
230208|NCT02422277|Drug|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
230209|NCT02422290|Drug|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
230210|NCT02422303|Drug|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
230211|NCT02422316|Other|Non-contrast Cardiac CT scan|
230212|NCT02422329|Behavioral|Questionnaires|Participants complete questionnaires at baseline and after intervention.
230213|NCT02422329|Behavioral|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
230214|NCT02424409|Behavioral|2: Intervention|The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.
A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter
A written action plan with formalized recommendations for the patient
A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.
The ED doctor at discharge will explain all these documents orally
Recommendations for an early contact with the general practitioner;
Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner.
230215|NCT02424409|Behavioral|1: Control|patients without discharge protocol
230216|NCT02424435|Drug|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
230501|NCT02418494|Other|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
229619|NCT02398123|Drug|Bupivacaine|
229620|NCT00163644|Procedure|aerobic plus active exercise|
229908|NCT02393274|Device|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
229909|NCT00162968|Drug|escitalopram|
229910|NCT02393287|Other|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
229911|NCT02393300|Drug|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
229912|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
229913|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
229914|NCT02393313|Procedure|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
229915|NCT02393313|Device|Rayner T-flex Toric IOLs|
229916|NCT02393326|Procedure|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
229917|NCT02393326|Procedure|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
229918|NCT02393326|Drug|biodentine|
229919|NCT02393326|Drug|formocresol|1: 5 Buckley's solution
229920|NCT00162981|Drug|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
229921|NCT02393339|Drug|paracetamol|Pre-operative administration of Paracetamol syrup
229922|NCT02393339|Drug|placebo|Pre-operative administration of placebo syrup
229330|NCT02404701|Dietary Supplement|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
229331|NCT02404701|Dietary Supplement|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
229332|NCT02404714|Device|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
229333|NCT00164866|Drug|Omeprazole|
229334|NCT02406846|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
229621|NCT02398136|Drug|Ketamine|
229622|NCT02400424|Radiation|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
229623|NCT02400437|Drug|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
229624|NCT02400437|Drug|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
229625|NCT02400437|Drug|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
229626|NCT02400450|Dietary Supplement|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
229627|NCT02400450|Dietary Supplement|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
229628|NCT02400463|Drug|Ruxolitinib|
229629|NCT02400476|Drug|Neratinib|
229630|NCT02400476|Drug|Loperamide|
229631|NCT00164047|Drug|Nitrous Oxide|
233958|NCT02456935|Drug|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
233959|NCT02456948|Drug|Minocycline|6 weeks 200mg/day Minocycline add-on
233960|NCT02456948|Drug|Placebo|6 weeks Placebo add-on
233961|NCT02456961|Procedure|iontophoresis of riboflavin|
233962|NCT02456961|Procedure|epithelium-off|
233963|NCT00171665|Drug|Diclofenac topical sodium gel 1%|
233964|NCT02456961|Procedure|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
233965|NCT02456961|Device|galvanizator, Potok-1|Device for providing iontophoresis procedure
233966|NCT02456961|Drug|Dextralink|Riboflavin 0,1% + Dextran T-500
233967|NCT02456961|Drug|Riboflavin 0,1%|
233968|NCT02456961|Device|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
233969|NCT02456974|Procedure|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
233970|NCT02459041|Other|Elastography, contrast enhancement|Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.
Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors.
233971|NCT02459054|Device|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
233972|NCT02459067|Biological|ImmuniCell®|Autologous γδ T Lymphocytes
229335|NCT02406859|Behavioral|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds.
Following the training, each subject will complete similar training at home for 6weeks.
229336|NCT02406859|Behavioral|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
229337|NCT02406872|Drug|Remimazolam Tosilate|IV pumping for anesthesia
233672|NCT02419508|Drug|Brinz/brim vehicle|Inactive ingredients used as a placebo for masking purposes
233673|NCT02419508|Drug|Prostaglandin analogue|
233674|NCT00002450|Drug|Tenofovir disoproxil fumarate|
233675|NCT00166374|Procedure|balloon kyphoplasty|
233676|NCT02419521|Device|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
233677|NCT02419534|Drug|Polyethylene glycol|Laxative to treat constipation
233678|NCT02419534|Drug|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
233679|NCT02419547|Drug|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
233680|NCT02419547|Drug|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
233681|NCT02419547|Drug|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
233682|NCT02419547|Drug|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
233683|NCT02419560|Drug|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
233684|NCT02419573|Device|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
233685|NCT02419573|Device|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
233686|NCT00166387|Procedure|Blood draw|A single blood draw.
233687|NCT02419586|Other|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
233688|NCT02419599|Other|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
233973|NCT02459080|Drug|TD-4208|
233974|NCT02459093|Device|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
233975|NCT02459093|Device|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
233096|NCT02397122|Procedure|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
233375|NCT02425631|Device|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
233376|NCT02425644|Drug|ponesimod|20 mg
233377|NCT02425644|Drug|teriflunomide|14 mg
233378|NCT00167466|Device|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
233379|NCT02425657|Behavioral|Training of junior doctors|Training program
233380|NCT02425670|Other|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
233381|NCT02425683|Drug|Regorafenib|120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
233382|NCT02425709|Drug|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
233383|NCT02425709|Drug|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
233384|NCT02425709|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
233385|NCT02425722|Drug|ASP0456|oral
233386|NCT02425722|Drug|Placebo|oral
233387|NCT02425735|Biological|DC-CIK cells|DC-CIK cells will be used against tumor cells.
233388|NCT02425735|Biological|γδ T cells|γδ T cells will be used against breast tumor.
233389|NCT00167479|Drug|risperidone (Risperdal)|
233390|NCT02425735|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
233391|NCT02425748|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
233392|NCT02425748|Biological|γδ T Cell|γδ T cells will be used against non small lung tumor.
233393|NCT02425748|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
233394|NCT02425761|Procedure|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
237467|NCT02449148|Other|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
237468|NCT02451189|Dietary Supplement|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
237469|NCT02451202|Procedure|Deep Neuromuscular Blockade|During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).
At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2.
237470|NCT02451202|Procedure|Moderate Neuromuscular Blockade|- During maintenance phase, if recovery at the presence of <10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
237471|NCT02451202|Drug|Sugammadex|
237767|NCT02444507|Drug|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
237768|NCT02444507|Drug|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
237769|NCT02444520|Behavioral|Integrated GP Care|The overall aims of the intervention are to help the patient:
develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;
understand factors that may be maintaining the problem;
learn how to modify the behavioral and cognitive responses which may be maintaining the problem;
adopt a healthy sleep routine which can promote healthy living.
The approach will be manual based, which is important for subsequent roll-out. Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed.
237770|NCT02444533|Drug|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
237771|NCT00169702|Behavioral|weight management program|2 weekly, 12 sessions, psychoeducational weight management
237772|NCT02444546|Other|Laboratory Biomarker Analysis|Correlative studies
237773|NCT02444546|Biological|Sargramostim|Given SC
237774|NCT02444546|Biological|Wild-type Reovirus|Given IV
237775|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
237776|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Placebo|
237777|NCT02444572|Drug|Enoxaparin 4000 UI|
237778|NCT02444585|Drug|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
237779|NCT02444598|Device|Vaccum Assisted Closure device|Negative-pressure wound therapy
237166|NCT00171847|Drug|Trastuzumab plus Letrozole|
237167|NCT02458157|Other|Usual Care|All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:
Hyperkalaemia (p-K+ > 6 mmol/l)
Severe metabolic acidosis attributable to AKI (pH < 7.25 and standard base excess < -10 mmol/l) resistant to IV bicarbonate infusion
Severe respiratory failure with PaO2/FiO2 < 13 kPa and bilateral infiltrates/oedema on the chest x-ray.
Progressive azotaemia and a blood urea nitrogen (BUN) > 25 mmol/l.
237472|NCT02451202|Drug|Rocuronium|
237473|NCT00170846|Drug|Everolimus (RAD001)|
237474|NCT02451215|Device|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
237475|NCT02451241|Other|acupuncture|electroacupuncture
237476|NCT02451254|Procedure|circumferential ablation|circumferential ablation of the pulmonary veins
237477|NCT02451254|Device|SVT ablation|SVT ablation
237478|NCT02451267|Other|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
237479|NCT02451267|Other|physical therapy treatment|neck exercise strengthening program with neck massage
237480|NCT02451280|Procedure|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
237481|NCT02451280|Procedure|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
237482|NCT02451280|Device|BMT robot|
237483|NCT02451280|Other|Training|
237484|NCT00170846|Drug|Calcineurin Inhibitors (CNI)|
237485|NCT02451280|Procedure|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with unilateral and bilateral protocols for 90 minutes. The tasks will be tailored according to the level
237486|NCT02451293|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|
237487|NCT02451293|Drug|Placebo|
232857|NCT02408146|Drug|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
232858|NCT00165061|Procedure|Esophagectomy|
232859|NCT02408146|Procedure|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
232860|NCT02408146|Drug|fentanyl citrate+ ondansetron hydrochloride + normal saline|
232861|NCT02408146|Drug|celecoxib|
232862|NCT02408159|Drug|Varicella Zoster Vaccine|
232863|NCT02408159|Drug|Placebo|
232864|NCT02408172|Drug|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
232865|NCT02408172|Drug|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
233157|NCT02402088|Behavioral|Stress Imagery|The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as "most stressful". "Most stressful" is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where "1=not at all stressful" and "10=the most stress they felt recently in their life". Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work.
233158|NCT02402088|Behavioral|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
233159|NCT02402088|Behavioral|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
233160|NCT02402101|Device|Procedure: active tDCS|Intensity 2 mA during 20 minutes
233161|NCT02402101|Device|Procedure: sham tDCS|sham condition as delivered by the stimulator
233162|NCT00164242|Drug|Galantamine|
233163|NCT02404207|Other|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
233164|NCT02404207|Other|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
232583|NCT02412605|Procedure|Trophectoderm embryo biopsy|Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.
Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred.
232584|NCT02412618|Drug|Mifepristone|Progesterone antagonist
232585|NCT02412618|Drug|Misoprostol|Prostaglandin E1
232586|NCT02412618|Dietary Supplement|Placebo|Tasteless, odorless, sugar based pill
232587|NCT02412631|Drug|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
232588|NCT02412631|Drug|Varenicline|Chantix is an FDA approved medication for smoking cessation
232589|NCT02414737|Drug|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
232590|NCT02414750|Drug|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
232591|NCT02414750|Device|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
232592|NCT02414750|Procedure|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
232593|NCT02414750|Procedure|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
232594|NCT02414763|Behavioral|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
232595|NCT00165646|Drug|E3810|E3810 5mg: once daily orally for 4 weeks
232596|NCT02414776|Drug|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
232866|NCT02408185|Drug|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
232867|NCT02408185|Drug|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
232868|NCT02408198|Behavioral|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
232869|NCT00002442|Drug|Nelfinavir mesylate|
232284|NCT02419131|Behavioral|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
232285|NCT02419131|Behavioral|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
232286|NCT02419131|Behavioral|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
232287|NCT02419144|Behavioral|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
232288|NCT02419157|Drug|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
232289|NCT02419157|Drug|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
232290|NCT02419157|Device|Clearfil SE Bond|
232291|NCT00166296|Drug|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
232292|NCT02419157|Device|Xeno V|
232293|NCT02419170|Procedure|Standard of care surgery|
232294|NCT02419170|Procedure|Apheresis|
232295|NCT02420886|Other|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
232296|NCT02420899|Drug|rosuvastatin|10mg/d or 20mg/d,po
232297|NCT02420912|Drug|Nivolumab|3 mg/kg by vein on Days 1 and 15 of Cycles 1-24 for the first cycle to assess for monotherapy toxicities of Nivolumab.
232298|NCT02420912|Drug|Ibrutinib|Group 1: Ibrutinib 420 mg given by mouth daily at the start of Course 2 on Days 1 and 15 of Cycles 1-24. Cycle of therapy is 28 days.
Group 2: Ibrutinib given by mouth daily, at same dose currently receiving, on Days 1 and 15 of Cycles 1-24. Cycle of therapy is 28 days.
232299|NCT00166634|Procedure|Ambulatory Blood Pressure Monitoring (ABPM)|
232597|NCT02414789|Procedure|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
232598|NCT02414802|Device|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
232599|NCT02414802|Procedure|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
231981|NCT02425163|Procedure|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
231982|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 50U|Drug intervention:
The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Drug is only injected once at baseline
231983|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
231984|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
231985|NCT02425202|Drug|Ketamine|Post-operative continuous infusion until 0600 the next day
231986|NCT02425202|Other|Saline infusion|Post-operative continuous infusion until 0600 the next day
231987|NCT02425228|Device|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
231988|NCT02425241|Biological|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
231989|NCT02425241|Biological|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10^10 vp at week 12.
231990|NCT02425241|Biological|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10^8 pfu at week 20
231991|NCT00167401|Drug|cisplatin|
231992|NCT02425241|Drug|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
231993|NCT02425241|Other|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
231994|NCT02425254|Drug|Intravenous paracetamol|1000mg intravenous solution for infusion
231995|NCT02425254|Drug|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
231996|NCT02427334|Drug|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
231997|NCT00167648|Drug|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
232300|NCT02420925|Procedure|Celiac Plexus Block|Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
231682|NCT02396537|Drug|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
231683|NCT00163397|Drug|Ciclesonide|
231684|NCT02396537|Drug|0.9% Saline|Administered intranasally prior to Midazolam administration.
231685|NCT02396550|Behavioral|Positive Expectations|Give positive expectation of the treatment efficacy to patients
231686|NCT02396550|Procedure|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
231687|NCT02396563|Procedure|epidural analgesia|
231688|NCT02396563|Drug|Ropivacaine|
231689|NCT02396576|Behavioral|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
231690|NCT02396589|Behavioral|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
231691|NCT02396589|Behavioral|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
231692|NCT02396602|Behavioral|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
231693|NCT02396615|Dietary Supplement|SATIN pineapple|Active juice with added fibre and ginseng
231694|NCT00002435|Drug|Zidovudine|
231695|NCT00163410|Drug|Ciclesonide|
231696|NCT02396615|Dietary Supplement|SATIN pineapple control|Control products without active ingredients
231697|NCT02396628|Drug|Treatment with Ruxolitinib|Treatment with Ruxolitinib at a starting dose of 5 mg BID orally
231698|NCT02396641|Other|Best Supportive Care Checklist|
231699|NCT02396654|Other|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
231700|NCT02396667|Other|5D ultrasound|
231067|NCT02405494|Dietary Supplement|Beverage 6|
231068|NCT02405494|Dietary Supplement|Beverage 7|
231069|NCT02407444|Other|Physiotherapy treatment & leg cycling|All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.
In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale.
231359|NCT02398838|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
231360|NCT02401243|Drug|INSULIN GLARGINE (U300)|Pharmaceutical form: pre-filled disposable pen
Route of administration: subcutaneous
231361|NCT02401256|Drug|Efavirenz|The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
231362|NCT02401256|Drug|Bupropion|The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
231363|NCT02401256|Drug|Rosuvastatin|The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
231364|NCT02401256|Drug|Montelukast|The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
231365|NCT02401269|Drug|Aspirin|
231366|NCT02401269|Drug|Placebo|
231367|NCT00164151|Drug|HalfLytely|
231368|NCT02401282|Behavioral|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
230773|NCT02411929|Drug|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
230774|NCT02411929|Drug|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
230775|NCT02411929|Drug|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
230776|NCT00165360|Drug|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
230777|NCT02411942|Drug|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
230778|NCT00165516|Drug|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
230779|NCT02414009|Drug|Fluorouracil|
230780|NCT02414009|Drug|Leucovorin|
230781|NCT02414048|Drug|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
231070|NCT02407444|Other|Physiotherapy treatment & music listening|All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.
In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.
Overall treatment session will last 50 minutes.
231071|NCT02407457|Device|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
231072|NCT02407457|Device|FDA Approved EVAR AAA Graft Systems|
231073|NCT02407470|Drug|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
231074|NCT02407470|Procedure|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
231075|NCT00002442|Drug|Indinavir sulfate|
231076|NCT00164957|Other|intermittent bolus feeding|
231077|NCT02407470|Procedure|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
231078|NCT02407483|Device|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
231079|NCT02407483|Device|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
230786|NCT02414087|Device|ICB Medical insoles|Study group:
Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.
Control group:
Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months
230787|NCT02414100|Other|Laboratory Biomarker Analysis|Correlative studies
230788|NCT02414100|Other|Cytology Specimen Collection Procedure|Correlative studies
230789|NCT00165555|Drug|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
230790|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|Comparison of three periods of 3 hours
st period: Spontaneous breathing for 10 minutes
nd period: CPAP for 10 minutes
rd period: Spontaneous breathing for 10 minutes to check the return to baseline.
After each period, the following parameters will be recorded during 5 minutes:
oesogastric pressures
air flow
gas exchange
right and left cardiac function
Patients > 6 years old will assess their dyspnea on a visual analogue scale
230791|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|Comparison of three periods of 3 hours
st period: Spontaneous breathing for 10 minutes
nd period: CPAP for 10 minutes
rd period: Spontaneous breathing for 10 minutes to check the return to baseline.
After each period, the following parameters will be recorded during 5 minutes:
oesogastric pressures
air flow
gas exchange
right and left cardiac function
Patients > 6 years old will assess their dyspnea on a visual analogue scale
230792|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|Comparison of three periods of 3 hours
st period: Spontaneous breathing for 10 minutes
nd period: CPAP for 10 minutes
rd period: Spontaneous breathing for 10 minutes to check the return to baseline.
After each period, the following parameters will be recorded during 5 minutes:
oesogastric pressures
air flow
gas exchange
right and left cardiac function
Patients > 6 years old will assess their dyspnea on a visual analogue scale
230793|NCT02414126|Device|CPAP|
230794|NCT02414139|Drug|INC280 (capmatinib)|
230795|NCT02414152|Drug|anakinra|100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
230796|NCT02414165|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
230797|NCT02414165|Drug|Toca FC|Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with "TOCA FC" embossed on one side and "500" embossed on the other side
230798|NCT02414165|Drug|Lomustine|
231090|NCT02407548|Dietary Supplement|coenzyme Q10 softgel|2 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
230502|NCT02418507|Dietary Supplement|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
230503|NCT00166205|Device|Swedish Adjustable Gastric Band|Long term implantable device.
230504|NCT02418507|Other|Placebo|The placebo is administered to randomized healthy participants
230505|NCT02418520|Biological|Oral hygiene with Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
230506|NCT02418533|Drug|menotropin|Menopur is used for controlled ovarian stimulation (COH)
230507|NCT02418533|Drug|Urofollitropin/Menotropin|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
230508|NCT02420275|Other|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
230509|NCT02420275|Device|"Luminette",Lucimed Belgium|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
230510|NCT02420288|Behavioral|Exercise Group|Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
230511|NCT02420301|Other|Tuina exercises|
230512|NCT02420301|Other|Placebo Tuina exercises|
230513|NCT02420314|Drug|Paclitaxel|Administered intravenously (IV)
Prescribed at 200 mg/m2 (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 4 cycles are administered depending on disease response
230514|NCT00166530|Drug|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
230515|NCT02420314|Drug|Carboplatin|Administered intravenously (IV)
Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 4 cycles are administered depending on disease response
230516|NCT02420314|Drug|Ascorbic Acid|Administered intravenously (IV)
75g per infusion
Two infusions per week
1 cycle is 3 weeks
given up to 4 cycles
may be given while chemotherapy if delayed due to low counts
230517|NCT02420327|Drug|Nicotine|nicotine patch (7 mg/24 hrs)
230518|NCT02420327|Drug|Galantamine|galantamine capsule (4 mg)
230519|NCT02420340|Behavioral|HOPES Program ("Helping Older People Experience Success")|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
229923|NCT02393352|Other|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
229924|NCT02393352|Other|Electrical Stimulation Therapy|
229925|NCT02393365|Other|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
229926|NCT00163293|Drug|Ciclesonide|100µg, two puffs once daily, in the evening
230217|NCT02424448|Procedure|Biopsies, blood and urine samples|Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.
Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken.
230218|NCT00167297|Drug|Atomoxetine|
230219|NCT02424461|Drug|Ceftriaxone|1 injection 1 g per day for 2 days
230220|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
230221|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
230222|NCT02424461|Drug|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
230223|NCT02424474|Device|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
230224|NCT02424474|Biological|Regular serum screening|
230225|NCT02424487|Procedure|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
230226|NCT02424513|Radiation|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
230227|NCT02424526|Other|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
230228|NCT02424526|Device|Treadmill|
230229|NCT00167310|Drug|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
230230|NCT02424539|Drug|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
229632|NCT02400502|Behavioral|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
229633|NCT02400515|Other|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
229634|NCT02400528|Behavioral|quality of life questionnaires|
229635|NCT02400541|Behavioral|Cognitive remediation therapy|Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.
Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients.
229636|NCT02400541|Other|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
229637|NCT02400554|Behavioral|Yappalli|Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, & women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership & personal change goals on the main outcome.
Month 2: Overnight Culture Camp to strengthen group cohesion & synthesize goals.
Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal & leadership goals & experience on the Trail.
Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD & obesity prevention. Includes: digital storytelling training to create a story related to ATOD & obesity prevention & an individual MI booster session to revise their personal & community leadership goals.
Month 12: Share digital stories & community event experiences & undergo a ceremony to transition to health leaders within their communities.
229638|NCT02400567|Drug|Fluorouracile|
229639|NCT02400567|Drug|Epirubicin|
229927|NCT02395796|Procedure|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
229928|NCT02395809|Procedure|lateral internal sphincterotomy|
229929|NCT02395809|Procedure|TENS|
229930|NCT02395822|Biological|IL-15|Preparative Regimen:
Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if < 4 months from prior transplant, omit day -4 dose)
IL-15 Activated Donor NK Cells:
The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.
IL-15 to Facilitate NK Cell Survival and Expansion:
IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total
229931|NCT02395848|Drug|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
229338|NCT02406872|Drug|Propofol|IV bolus for anesthesia
229339|NCT02406885|Drug|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
229340|NCT02406898|Device|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
229341|NCT02406911|Drug|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
229342|NCT02406924|Procedure|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
229343|NCT02406924|Radiation|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
229344|NCT00164879|Procedure|Endoscopic stenting followed by elective laparoscopic resection|
229345|NCT02406924|Other|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
229346|NCT02406924|Other|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
229347|NCT02406937|Dietary Supplement|Oral intake|Oral intake
229348|NCT02406950|Drug|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
229349|NCT02406963|Other|Digital Photograph|A digital photograph sent by the family of the surgical site
229350|NCT02406963|Other|Telephone Call|Standard telephone call with the nurse practitioner
229351|NCT02406976|Other|G1 -Exercise|20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
Furthermore the similar treatment to G3.
229352|NCT02406976|Behavioral|G2- Exercise and Lifestyle|Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.
Furthermore the similar treatment to G3.
229640|NCT02400567|Drug|Cyclophosphamide|
229641|NCT02400567|Drug|Letrozole|
229642|NCT00164073|Procedure|Liver biopsy|
233976|NCT00171977|Drug|Imatinib Mesylate|
233977|NCT02459119|Drug|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
233978|NCT02459132|Behavioral|High-intensity aerobic interval exercise|See arm/group description
233979|NCT02459145|Behavioral|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
233980|NCT02459158|Drug|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
233981|NCT02459158|Drug|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
233982|NCT02459158|Drug|Placebo|Placebo inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
233983|NCT02459171|Other|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
233984|NCT02459171|Other|Blood sample|Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.
For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs.
233985|NCT02459171|Other|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
233986|NCT02459171|Other|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
233987|NCT00171990|Drug|Famciclovir|
233988|NCT02461173|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
233989|NCT02461173|Device|shepherd catheter|
233990|NCT02461186|Drug|Arterolane maleate-piperaquine phosphate (Synriam)|
233395|NCT02425774|Procedure|Vagus stimulation|
233396|NCT02425774|Procedure|Sham stimulation|
233397|NCT02425774|Drug|Prucalopride|
233398|NCT02425774|Drug|Placebo|
233689|NCT02421393|Other|supervised exercise training|Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of "weight bearing" exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity.
233690|NCT00166712|Drug|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
233691|NCT02421406|Behavioral|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
233692|NCT02421406|Behavioral|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
233693|NCT02421419|Drug|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
233694|NCT02421419|Drug|Xylocaine|a local anesthetic agent
233695|NCT02421419|Drug|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
233696|NCT02421432|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
233697|NCT02421458|Radiation|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
233698|NCT02421458|Radiation|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
233699|NCT02421471|Drug|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
233700|NCT02421484|Biological|Allogeneic bone marrow derived mesenchymal stromal cells|The allogeneic bone marrow derived mesenchymal stromal cells will be administered intravenously.
237780|NCT02444598|Procedure|Conventional wound dressings|Conventional wound dressings
237781|NCT02444611|Drug|BCG Vaccine|intradermal vaccination
237782|NCT00169715|Procedure|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
237783|NCT02444611|Drug|Hepatitis B Vaccine|intramuscular vaccination
237784|NCT02444637|Drug|Rivastigmine|
237785|NCT02446860|Drug|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
237786|NCT00170144|Drug|Branchamin 4%|
238082|NCT02439749|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
238083|NCT02439762|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
238084|NCT02439762|Behavioral|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
238085|NCT02439775|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
238086|NCT02439775|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
238087|NCT02439788|Drug|cyclophosphamide|500 mg/m2/day x 2 days; for patients <12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
238088|NCT00169208|Drug|rituximab|
238089|NCT02439788|Drug|Fludarabine|30 mg/m2/day x 3 days; for patients <12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
238090|NCT02439788|Genetic|GINAKIT Cells|Dose Level 1 = 3 x 10^6
Dose Level 2 = 1 x 10^7
Dose Level 3 = 3 x 10^7
Dose Level 4 = 1 x 10^8
After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future.
238091|NCT02439801|Procedure|PEEP 0|0 cmH2O positive end expiratory pressure
237488|NCT02451306|Drug|Quetiapine|See information in arm description.
237489|NCT02451306|Drug|Placebo|See information in arm description.
237490|NCT02451319|Procedure|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
237491|NCT02453568|Drug|Oxytocin|3 IU Oxytocin administered IV rapid infusion bolus over a 3 min period after delivery of the anterior shoulder.
237492|NCT02453568|Drug|Placebo|50mL Lactated Ringers solution administered via IV rapid infusion bolus over a 3 minute period after the delivery of the anterior shoulder.
237787|NCT02446873|Other|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
237788|NCT02446886|Drug|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).
ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors.
237789|NCT02446899|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
237790|NCT02446899|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
237791|NCT02446912|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
237792|NCT02446912|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
237793|NCT02446925|Device|Surefire® Infusion System|Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
237794|NCT02446925|Device|Standard End-hole catheter|Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
237795|NCT02446938|Procedure|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
237796|NCT02446964|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
237797|NCT00170157|Drug|Combination Androgen Ablative Therapy|Lupron 7.5 mg monthly times 3 months (leuprolide acetate)
Casodex 50 mg daily times 3 months (Bicalutamide)
237798|NCT02446964|Drug|Cyclophosphamide|Given IV
237799|NCT02446964|Drug|Fludarabine Phosphate|Given IV
233165|NCT02404220|Drug|Entospletinib|Entospletinib tablet(s) administered orally
233166|NCT00164541|Behavioral|Curriculum|
233167|NCT02404220|Drug|VCR|Vincristine (VCR) administered intravenously
233168|NCT02404220|Drug|Dexamethasone|Dexamethasone tablet(s) administered orally
233169|NCT02404220|Drug|CNS Prophylaxis|CNS prophylaxis per institutional standard
233170|NCT02404233|Drug|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
233171|NCT02404233|Drug|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
233172|NCT02404246|Behavioral|Peer support program|
233173|NCT02404259|Drug|TDF (Tenofovir)|
233174|NCT02404259|Drug|Efavirenz|
233175|NCT02404259|Drug|lopinavir/ritonavir, atazanavir/ritonavir|
233462|NCT02397369|Behavioral|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
233463|NCT02397369|Behavioral|Tobacco users:Behavioural therapy Only|Focus Group discussion:
This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.
Individual tobacco cessation counseling sessions:
Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant.
233464|NCT02397369|Other|Tobacco users:Pharmacologic|Pharmaco Therapy will consist of:
Nicotine Chewing Gums:
Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc
Nicotine Transdermal patches:
Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc
233465|NCT00002436|Drug|Lamivudine|
233466|NCT02399631|Other|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
232870|NCT00165061|Procedure|Chemoradiation|
232871|NCT02408211|Drug|nitrofurantoin monohydrate/macrocrystalline|Nitrofurantoin monohydrate/macrocrystalline is currently indicated for the treatment of acute uncomplicated urinary tract infections.
antibiotic
232872|NCT02408211|Drug|ampicillin|IV 2 g
232873|NCT02408211|Drug|gentamicin or vancomycin /ceftriaxone|gentamicin IV (5 mg/kg) (or vancomycin(1 g) /ceftriaxone (2 g)
232874|NCT02408237|Device|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
232875|NCT02410473|Other|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
232876|NCT02410499|Drug|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
232877|NCT02410499|Drug|MLN1202|MLN1202 solution for SC injection
232878|NCT02410512|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab administered intravenously
232879|NCT02410512|Drug|MOXR0916|MOXR0916 administered intravenously
232880|NCT02410525|Drug|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug [11C]PF-06427878 on Day 1 of all 3 Periods
232881|NCT02410525|Drug|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
232882|NCT00165178|Drug|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
232883|NCT02410525|Drug|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
232884|NCT02410538|Other|list of "FAQ"|
232885|NCT02410551|Drug|Pacritinib|200 mg by mouth twice a day for 60 days.
233176|NCT02404272|Other|Educational oral feeding nurse program|A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.
The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.
Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained
232600|NCT02414802|Drug|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
232601|NCT02414802|Drug|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
232602|NCT02414815|Device|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
232603|NCT02414828|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area.
232604|NCT02414828|Biological|AERAS-402 3 x 10^8 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
232605|NCT02414828|Biological|AERAS-402 3 x 10^9 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
232606|NCT00165646|Drug|E3810|E3810 10mg: once daily orally for 4 weeks
232607|NCT02414828|Biological|AERAS-402 3 x 10^10 vp|AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
232608|NCT02414841|Drug|vonapanitase|
232609|NCT02414841|Drug|Placebo|
232610|NCT02414854|Drug|dupilumab SAR231893 (REGN668)|Pharmaceutical form:solution Route of administration: subcutaneous
232611|NCT02414854|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
232612|NCT02416947|Dietary Supplement|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
232613|NCT02416947|Dietary Supplement|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
232614|NCT02416960|Other|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
232615|NCT02416960|Other|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
232616|NCT02416973|Device|Provant|
232886|NCT02410551|Drug|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
232301|NCT02420938|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
232302|NCT02420938|Drug|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
232303|NCT02420951|Drug|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
232304|NCT02420951|Other|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
232305|NCT02420964|Other|video instruction|Patient Directed Video Instruction
232306|NCT02420964|Other|Nurse instruction|Nurse directed instruction
232307|NCT02420977|Drug|Pelvic DCFPyL PET-MRI fusion or PET/MRI|Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT
Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months
232308|NCT02420990|Behavioral|Medication Integration Protocol (MIP)|
232309|NCT02420990|Behavioral|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
232310|NCT00166647|Procedure|Blood Sampling|
232311|NCT02421003|Procedure|heart surgery|
232312|NCT02421016|Device|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
232313|NCT02421016|Device|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
232314|NCT02421029|Drug|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
232315|NCT02421042|Drug|Lenvatinib|5- or 10-mg single oral dose of E7080, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
232316|NCT02421055|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
232317|NCT02421055|Procedure|Laparoscopic Sleeve Gastrectomy|
232318|NCT02421081|Procedure|vessel microsurgery|That is a surgery ro repair artery laceration.
232319|NCT02421081|Procedure|tendon repair|That is a surgery ro repair tendon cut.
232320|NCT02423005|Device|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
232321|NCT02423005|Device|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
231701|NCT02396693|Device|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) < 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) < 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
231998|NCT02427347|Other|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
231999|NCT02427347|Other|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
232000|NCT02427373|Dietary Supplement|fish oil ethyl ester|
232001|NCT02427373|Dietary Supplement|fish oil triglyceride|
232002|NCT02427373|Dietary Supplement|krill oil|
232003|NCT02427386|Drug|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
232004|NCT02427386|Drug|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
232005|NCT02427399|Other|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
232006|NCT02427399|Other|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
232007|NCT02427399|Other|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
232008|NCT00167661|Drug|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
232009|NCT02427399|Other|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
232010|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
232011|NCT02427412|Drug|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
231369|NCT02401282|Behavioral|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
231370|NCT02401295|Drug|ATRA|
231371|NCT02401295|Drug|Celecoxib|
231372|NCT02401295|Drug|Itraconazole|
231373|NCT02401308|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
231374|NCT02401321|Behavioral|Telephone-Based Intervention|Complete Taking Care of Her program
231375|NCT02401321|Other|Caregiver-Assisted Training|Complete Taking Care of Her program
231702|NCT02398838|Drug|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
231703|NCT02398851|Behavioral|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
231704|NCT00163761|Drug|gemcitabine, vinorelbine, filgastrim|Drug
231705|NCT02398851|Behavioral|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
231706|NCT02398864|Procedure|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
231707|NCT02398877|Other|stress|
231708|NCT02398890|Other|routine care|routine care
231709|NCT02398903|Other|Blood samples for measurement of drug Css|
231710|NCT02398903|Other|DXA and impedancemetry|Body composition by DXA and impedancemetry
231711|NCT02398916|Behavioral|Music listening|
231712|NCT02398929|Drug|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
231713|NCT02398929|Drug|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
231714|NCT02398955|Device|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
231715|NCT00163774|Device|Brain oxygenation and microdialysis catheters|
231716|NCT02398968|Dietary Supplement|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
231080|NCT02407496|Other|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
231081|NCT02407509|Drug|RO5126766|
231082|NCT02407522|Dietary Supplement|Black rice|They asked to keep their normal life style during intervention
231083|NCT02407522|Other|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
231084|NCT02407535|Device|Intraoperative ultrasound|Diagnostic intraoperative ulatrasound in the uterus after hysterectomy for assesing depth of tumor invasion
231085|NCT02407548|Dietary Supplement|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
231086|NCT02407548|Dietary Supplement|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
231087|NCT00164970|Dietary Supplement|Vitamin B12|
231088|NCT02407548|Dietary Supplement|vitamin E softgel|4 vitamin E softgels per day. Keep normal lift style unchanged.
231089|NCT02407548|Dietary Supplement|coenzyme Q10 vitamin E softgel|2 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
231376|NCT02401321|Other|Questionnaire Administration|Ancillary studies
231377|NCT02401321|Other|Quality-of-Life Assessment|Ancillary studies
231378|NCT00164151|Drug|Visicol|
231379|NCT02401334|Device|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
231380|NCT02403518|Device|Freedom Spinal Cord Stimulator System|
231381|NCT02403531|Drug|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
231382|NCT02403531|Drug|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
231383|NCT02403531|Radiation|Radiotherapy|definitive radiotherapy
231384|NCT00164437|Behavioral|educational CD-ROM|
231385|NCT02403544|Radiation|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
231091|NCT02409810|Drug|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
231092|NCT02409823|Drug|Atypical Antipsychotics|any atypical antipsychotic
231093|NCT02409836|Drug|Marketed Dentifrice|Marketed Dentifrice
231094|NCT02409836|Drug|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
231095|NCT02409836|Drug|Marketed Flavored Dentifrice|Bubble Gum Flavored
231096|NCT02409849|Drug|Octreotide lar|
231097|NCT02409862|Drug|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
231098|NCT02409862|Drug|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
231099|NCT00165152|Procedure|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
231100|NCT02409888|Behavioral|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
231101|NCT02409888|Behavioral|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
231102|NCT02409888|Other|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
231103|NCT02409888|Other|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
231104|NCT02409901|Behavioral|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
231105|NCT02409914|Other|PET and MRI exams|FDG PET scan and T1-weight MRI were obtained within an average time frame of 3 weeks.
231106|NCT02409927|Dietary Supplement|MCT oil|100% pure MCT oil mixed with skim milk in a standardized breakfast
231107|NCT02409927|Dietary Supplement|MCT homogenate|10% MCT homogenate mixed with skim milk in a standardized breakfast
230799|NCT02416297|Procedure|Micro-osteoperforation|Flapless cortical perforations will be made after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, minimum cortical perforations will be done with manual instrument, between 4-6 mm apical to the contour of free gum between the canine and second pre-molar. Two perforations near each tooth adjacent to the extraction area.
230800|NCT02416310|Device|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
230801|NCT02416323|Other|AIM HI Training|
230802|NCT02416336|Device|Sentinella Intraoperative imaging protocol|There is a "holding" time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.
In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed.
230803|NCT00165880|Drug|E7070|
230804|NCT02416349|Other|Respiratory Muscles Stretching|Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.
Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching
230805|NCT02416349|Other|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
230806|NCT02416362|Other|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
230807|NCT02416362|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
230808|NCT02416388|Drug|Idarubicin|Induction chemotherapy :
Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)
+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)
Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
230809|NCT02416388|Drug|Daunorubicin|Induction chemotherapy :
Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)
+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)
Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
230810|NCT02416388|Drug|Cytarabine|Consolidation chemotherapy course (s) :
High dose cytarabine: 3g/m² /12h on D1, D3 and D5
Intermediate dose cytarabine : 1.5g/m² /12h on D1, D3 and D5
For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)
Up to 3 consolidation courses, depending on the patient AML risk group
230811|NCT02416388|Drug|Cyclosporine|GvHD prophylaxis post allogeneic SCT :
-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100
230812|NCT02416388|Drug|Methotrexate|GvHD prophylaxis post allogeneic SCT :
-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11
230231|NCT02424539|Other|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
230232|NCT02424552|Drug|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
230233|NCT02424552|Drug|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
230234|NCT02426671|Device|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
230235|NCT02426684|Drug|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
230520|NCT02420353|Drug|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
230521|NCT02420353|Drug|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
230522|NCT02420379|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
230523|NCT02420392|Drug|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
230524|NCT02420405|Other|NGS technique|For the same species,we will apply NGS technique to detect gene mutations,including EGFR mutation,ALK fusion,etc.
230525|NCT00166530|Drug|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
230526|NCT02420405|Other|classical methods|For the same species,we will apply SARMS to detect the EGFR mutation,IHC/FISH to detect the ALK fusion,etc.
230527|NCT02422329|Behavioral|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
230528|NCT02422342|Device|Pulse Oximeter CMS50FW (Contec Medical)|The patients will be wearing the pulse oximeter during the test period (20-30 minutes).
The data from the oximeter will be sent by Bluetooth to the mobile application
230529|NCT02422355|Device|FNS|Surgical intervention using the FNS
229932|NCT02395861|Other|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
229933|NCT02395874|Procedure|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
229934|NCT02395900|Dietary Supplement|Flaxseed|
229935|NCT02395900|Other|control|
229936|NCT02395913|Drug|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
229937|NCT00000359|Behavioral|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
229938|NCT00002435|Drug|Thymic Humoral Factor|
229939|NCT00163293|Drug|Ciclesonide|200µg, two puffs once daily, in the evening
229940|NCT02395913|Drug|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
229941|NCT02395913|Drug|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
229942|NCT02395913|Drug|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
229943|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
230236|NCT02426697|Drug|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
230237|NCT02426697|Drug|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
230238|NCT02426710|Device|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
230239|NCT02426723|Drug|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
230240|NCT00167583|Drug|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
229643|NCT02400567|Drug|Palbociclib|
229644|NCT02400580|Drug|IV acetaminophen|
229645|NCT00164346|Behavioral|neurocognitive habilitation|
229646|NCT02402751|Device|MRI|
229647|NCT02402764|Drug|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m^2).
229648|NCT02402803|Other|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
229649|NCT02402816|Device|MultiPoint Pacing ON|MultiPoint Pacing ON
229650|NCT02402816|Device|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
229651|NCT02402829|Procedure|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
229652|NCT02402842|Drug|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
229653|NCT02402855|Other|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
229654|NCT02402855|Other|Interview with a sociologist|For a sub-group of 40 womens
229655|NCT02402855|Other|No intervention|
229656|NCT00164359|Drug|Amodiaquine plus artesunate|
229657|NCT02402868|Drug|Ketamine and saline|Ketamine intravenous and intranasal
229658|NCT02402881|Behavioral|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
229659|NCT02402894|Other|no intervention|
229660|NCT02402907|Device|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
229944|NCT02395926|Drug|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
229353|NCT02406976|Other|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
229354|NCT02409069|Device|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
229355|NCT02409069|Device|Sham stimulation (Nemos®, Cerbomed GmbH)|
229356|NCT02409095|Biological|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
229357|NCT02409095|Device|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
229358|NCT00165139|Drug|Vincristine|Described under detailed description
229359|NCT02409095|Other|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
229360|NCT02409108|Device|Exatherm-TBH system|One treatment of Total Body Hyperthermia
229361|NCT02409121|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
229362|NCT02409147|Procedure|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
229363|NCT02409160|Procedure|Standard Roux-en-Y gastric bypass|
229364|NCT02409173|Device|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
229365|NCT02409173|Procedure|Bariatric Surgery|Standard Roux-en-Y gastric bypass
229366|NCT02409186|Drug|Nimotuzumab|400mg/w，d1, week 1-7
229367|NCT02409186|Radiation|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
229368|NCT02409186|Drug|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
229369|NCT00165139|Drug|Cyclophosphamide|Described under detailed description
229370|NCT02409186|Drug|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
229371|NCT02409186|Other|placebo|400mg/w，d1, week 1-7
233701|NCT00166712|Drug|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
233702|NCT02421510|Drug|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
233703|NCT02421510|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
233991|NCT00172354|Drug|Hydrocortisone|
233992|NCT02461186|Drug|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
233993|NCT02461199|Biological|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
233994|NCT02461212|Procedure|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
233995|NCT02461238|Other|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
233996|NCT02461238|Other|Nutrition education|Nutrition education workshops taught by a dietician
233997|NCT02461251|Device|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
233998|NCT02461264|Drug|Single red blood packed cells Transfusion|
233999|NCT02461264|Drug|Two packed red blood cells Transfusion|
234000|NCT02461277|Other|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
234001|NCT02461290|Radiation|Chemotherapy|
234002|NCT00172367|Drug|Lycopene|
234003|NCT02461290|Drug|Rituximab|
238092|NCT02439801|Procedure|PEEP 5|5 cmH2O positive end expiratory pressure
238093|NCT02439801|Procedure|PEEP 8|8 cmH2O positive end expiratory pressure
238094|NCT02439814|Drug|Pregnenolone|Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
238095|NCT02439814|Other|Placebo|Inactive comparator
238096|NCT02439827|Behavioral|"Fortaleça sua Saúde" program|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
238097|NCT02441933|Drug|Taxane|Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.
Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles
Paclitaxel (80 mg/m2) IV weekly for 12 doses
238098|NCT02441946|Drug|Abemaciclib|Administered orally
238405|NCT02434861|Drug|Rolapitant|
238406|NCT02434861|Drug|Digoxin|P-gp substrate
238407|NCT02434861|Drug|Sulfasalazine|BCRP substrate
238408|NCT02434861|Drug|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
238409|NCT02434874|Device|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
238410|NCT02434887|Device|KL029 Intimate Lubricant Gel|
238411|NCT02434913|Device|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
238412|NCT02434939|Drug|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
238413|NCT02434939|Drug|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
238414|NCT02434952|Drug|Dihydroartemisinin piperaquine (DHA PP)|
238415|NCT00168740|Drug|rituximab|
238416|NCT02434952|Drug|Primaquine|
237800|NCT02446964|Other|Laboratory Biomarker Analysis|Correlative studies
237801|NCT02446964|Drug|Mycophenolate Mofetil|Given PO
237802|NCT02446964|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
237803|NCT02446964|Drug|Tacrolimus|Given IV and PO
237804|NCT02446964|Radiation|Total Marrow Irradiation|Undergo TMLI
237805|NCT02446977|Drug|Vitamin B2 Streuli®|4ml IV
237806|NCT02446977|Other|Solution for injection|4ml IV
238099|NCT02441946|Drug|Loperamide|Administered orally
238100|NCT00169377|Procedure|deep brain stimulation|Stimulator on followed by off
238101|NCT02441946|Drug|Anastrozole|Administered orally
238102|NCT02441959|Procedure|Lumbar discectomy Open|Open Discectomy
238103|NCT02441959|Procedure|Lumbar discectomy Endoscopic|Endoscopic Discectomy
238104|NCT02441972|Drug|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
238105|NCT02441985|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
238106|NCT02441985|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
238107|NCT02441985|Other|Fahn-Tolosa-Marin Tremor Rating Scale (TRS)|All participants will receive a clinical assessment of tremor severity by using the TRS test.
238108|NCT02441985|Other|Timed "Up & Go" Test (TUG) test|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
238109|NCT02441985|Other|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
238110|NCT02441985|Other|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
238111|NCT00169377|Procedure|Off|Stimulator off followed by on
238112|NCT02441985|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
233467|NCT02399644|Behavioral|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
233468|NCT02399644|Other|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
233469|NCT02399657|Drug|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
233470|NCT02399683|Biological|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
233471|NCT02399696|Behavioral|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
233472|NCT02399696|Behavioral|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
233473|NCT02399709|Drug|simvastatin|
233474|NCT02399709|Drug|Placebo|
233475|NCT02399722|Device|WICVAC|combined wound therapy
233476|NCT00163904|Behavioral|High carbohydrate/low fat diet|
233758|NCT02428062|Procedure|Hemodynamic target|The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:
vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)
intravenous fluids
patient's positioning
reduction of depth of anesthesia
233759|NCT02428062|Drug|Phenylephrine|Phenylephrine 0.1-0.2 mg intravenous bolus
233760|NCT02428062|Drug|Intravenous fluids|A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
233761|NCT02428062|Procedure|Patient's positioning|The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
233762|NCT02428062|Procedure|Reduction of depth of anesthesia|The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
233763|NCT02428062|Drug|Ephedrine|Ephedrine 5-25 mg intravenous bolus
233764|NCT00167765|Drug|Abciximab|
233765|NCT02428062|Drug|Epinephrine|Epinephrine 5-10 mcg intravenous bolus
233177|NCT00164554|Behavioral|Parent-child Interaction Therapy (PCIT)|
233178|NCT02404285|Drug|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
233179|NCT02404285|Drug|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
233180|NCT02404298|Drug|IVIg|
233181|NCT02404311|Biological|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
233182|NCT02404311|Biological|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
233183|NCT02404311|Biological|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
233184|NCT02406209|Drug|NS2|NS2 ophthalmic drops (0.5%)
233185|NCT02406209|Drug|Prednisolone acetate ophthalmic suspension (1%)|
233186|NCT02406222|Drug|Pomalidomide|
233187|NCT02406222|Drug|Dexamethasone|
233188|NCT02406222|Drug|Cyclophosphamide|
233189|NCT02406248|Drug|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
233190|NCT00164775|Drug|Imipramine placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
233191|NCT02406261|Drug|AZD3293|Oral doses of 50 mg AZD3293 will be administered as 1 × 50-mg tablet
233192|NCT02406261|Drug|Simvastatin|Oral doses of 20 mg simvastatin will be administered as 1 × 20-mg tablet
233193|NCT02406261|Drug|Midazolam|Oral doses of 500 mcg midazolam will be administered as 0.25 mL of 2-mg/mL syrup
233477|NCT02399722|Device|VAC mono therapy|mono therapy
233478|NCT02399735|Biological|Low Dose NK cells|Received conventional treatment and NK cells once per 2-week for the first month, at a dose of 5×10E9 NK cells.
232887|NCT02410551|Behavioral|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
232888|NCT02410551|Behavioral|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
232889|NCT02410551|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
232890|NCT02410551|Drug|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
232891|NCT02410564|Behavioral|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
232892|NCT02410564|Behavioral|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
232893|NCT00165178|Drug|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
232894|NCT02410577|Drug|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours and 4-7 days post injection. The 48 hour scan is strongly suggested, but optional.
232895|NCT02410577|Device|PET/CT Scan|
232896|NCT02412631|Drug|Placebo|Placebo for lorcaserin
232897|NCT00165438|Procedure|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
232898|NCT02412644|Drug|apremilast|
232899|NCT02412657|Drug|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
232900|NCT02412657|Drug|Normal Saline|
232901|NCT02412670|Drug|Methotrexate|Given IV
232902|NCT02412670|Drug|Vinblastine|Given IV
232617|NCT02416986|Behavioral|6 hour smoking abstinence|
232618|NCT00166049|Behavioral|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
232619|NCT02416986|Behavioral|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
232620|NCT02416986|Behavioral|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
232621|NCT02416999|Drug|Ultra-low dose Bevacizumab|
232622|NCT02416999|Drug|Temozolomide|
232623|NCT02417012|Behavioral|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
232624|NCT02417012|Behavioral|Standard care|Standard individual diabetes support
232625|NCT02417025|Behavioral|PE|Prolonged Exposure
232626|NCT02417038|Device|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
232627|NCT02417051|Behavioral|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
232628|NCT02417064|Drug|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
232629|NCT02419170|Drug|Cyclophosphamide|
232630|NCT02419170|Biological|Personalized mature dendritic cell vaccine|
232012|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
232013|NCT02427425|Device|TENS|
232014|NCT02427438|Other|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
232015|NCT02427438|Other|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
232322|NCT02423018|Drug|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
232323|NCT02423018|Drug|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
232324|NCT02423057|Drug|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
232325|NCT02423083|Drug|Guanabenz|
232326|NCT02423096|Drug|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
232327|NCT00167141|Drug|injection of hormonal male contraceptive|testosterone injections 4 times
232328|NCT02423122|Drug|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
232329|NCT02423135|Biological|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
232330|NCT02423148|Drug|Indocyanine green (ICG)|
232331|NCT02423148|Device|FluoSCOPE|
232332|NCT02423174|Procedure|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
232333|NCT02423174|Device|FMwand Surgical System|
232334|NCT02423187|Other|No Intervention|
232335|NCT02423200|Drug|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
231717|NCT02398981|Other|Clinical decision support tool|
231718|NCT02398994|Drug|Intravenous Methylprednisolone|
231719|NCT02398994|Drug|Intravenous Immunoglobulin|
231720|NCT02399007|Device|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
231721|NCT02399007|Device|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
231722|NCT02399020|Behavioral|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
231723|NCT02399033|Drug|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
232016|NCT02427451|Drug|Bcl-2 Inhibitor GDC-0199|Given PO
232017|NCT02394132|Radiation|Radiotherapy|
232018|NCT02394145|Drug|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
232019|NCT02394145|Drug|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
232020|NCT00163098|Drug|UK-369,003|
232021|NCT02394158|Drug|Metformin|
232022|NCT02394158|Drug|placebo|
232023|NCT02394171|Behavioral|Group Cohesion|See description in arm/group above
232024|NCT02394184|Procedure|transcatheter aortic valve replacement|
232025|NCT02394197|Drug|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
232026|NCT02394197|Drug|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
232027|NCT02394223|Procedure|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
231386|NCT02403544|Drug|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
231387|NCT02403544|Drug|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
231388|NCT02403557|Behavioral|Waitlist|Weekly check up.
231389|NCT02403557|Behavioral|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
231390|NCT02403570|Other|Brain MRI|
231391|NCT02403583|Behavioral|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
231392|NCT02403596|Drug|Exacyl®|
231393|NCT02403596|Other|Placebo of Exacyl®|
231394|NCT02403609|Other|BPT, Computerized Assessment|
231395|NCT00164450|Drug|Rifapentine + isoniazid once weekly for 3 months|
231396|NCT02403622|Drug|Fecal Microbiota Preparations|Processed human fecal material for treating recurrent clostridium difficile infections.
231397|NCT02403635|Drug|Midazolam|
231398|NCT02403635|Drug|ASP2151|
231724|NCT02399046|Device|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
231725|NCT02399046|Device|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
231726|NCT00163787|Behavioral|outcome measures and self report|
231727|NCT02399059|Procedure|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
231728|NCT02401347|Drug|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
231729|NCT02401360|Drug|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
231730|NCT02401360|Drug|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
231399|NCT02403648|Drug|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
231400|NCT02403648|Drug|Lilly Glucagon|
231401|NCT02403648|Drug|Novo Glucagon|
231402|NCT02403661|Procedure|Post surgical electrical stimulation|Post surgical electrical stimulation immediately after surgical nerve repair
231403|NCT02403674|Drug|MK-1439A|One MK-1439A tablet taken by mouth
231404|NCT02403674|Drug|ATRIPLA™|One ATRIPLA™ tablet taken by mouth
231405|NCT02403687|Drug|baclofen 2%|compound topical cream
231406|NCT00164463|Drug|Moxifloxacin|400 mg po qd 5/7 days per week
231407|NCT02403687|Drug|Bupivacaine hydrochloride 1%|compound topical cream
231408|NCT02405494|Dietary Supplement|Beverage 8|
231409|NCT02405494|Dietary Supplement|Beverage 9|
231410|NCT02405507|Dietary Supplement|wheat bread with wheat germ|
231411|NCT02405507|Dietary Supplement|wheat bread without wheat germ|
231412|NCT00164710|Drug|chlorproguanil-dapsone plus artesunate|
231413|NCT02405520|Biological|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
231414|NCT02405520|Biological|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
231415|NCT02405520|Biological|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
231416|NCT02405520|Biological|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
231417|NCT02405533|Dietary Supplement|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
231418|NCT02405533|Other|Placebo|Placebo supplementation x 12 months
231419|NCT02405546|Other|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
231420|NCT02405546|Other|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
230813|NCT02416388|Drug|Mycophenolic acid (MPA)|GvHD prophylaxis post allogeneic SCT :
720 mg BID from D0 to D+28 for HLA-identical siblings
720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
231108|NCT02409927|Dietary Supplement|Placebo|skim milk with a standardized breakfast
231109|NCT02409940|Biological|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
231110|NCT00165152|Procedure|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
231111|NCT02411942|Drug|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
231112|NCT02411942|Drug|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
231113|NCT02411955|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
231114|NCT02411955|Drug|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
231115|NCT02411955|Drug|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
231116|NCT02411968|Other|111In-Girentuximab DOTA SPECT|
231117|NCT02411981|Other|Autogenic drainage|
231118|NCT02411994|Drug|Pyronaridine-artesunate|
231119|NCT02411994|Drug|Artemether-lumefantrine combination|
231120|NCT00165373|Drug|rhEndostatin|Given by continuous infustion for 28 days (one of two dosing groups) for a total of 2 cycles. Treatment can be extended if tolerated well.
231121|NCT02412007|Other|Individualized comprehensive home centred activity based programme|Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to
Standing up from squatting position to catch an object of interest.
Squatting from standing position to pick an object of interest.
Walking to reach an object of interest.
Climbing up steps to get an object of interest.
Climbing down steps to keep the above object of interest.
Cycling
Kicking a football
Dancing
231122|NCT02412020|Drug|PA101|
231123|NCT02412020|Drug|Placebo|
231124|NCT02412033|Drug|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
231125|NCT02412033|Drug|Placebo|This group will receive placebo
230530|NCT02422368|Drug|Methylprednisolone + ASTED|ASTED tablet: Twice daily for 6 months
Methylprednisolone:
Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
230531|NCT00166868|Drug|Lactobacillus casei rhamnosus (Lcr35)|
230532|NCT02422368|Drug|Methylprednisolone +Placebo|Placebo: twice daily
Methylprednisolone:
Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
230533|NCT02422381|Drug|MK-3475|Investigational drug.
230534|NCT02422381|Drug|Gemcitabine|Standard care drug.
230535|NCT02422394|Drug|Eltrombopag|
230536|NCT02422420|Behavioral|Financial Incentives|Use of financial incentives to promote health behaviors.
230814|NCT00165893|Device|Accu-Spina Device/IDD therapy|
230815|NCT02416401|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
230816|NCT02416401|Other|Commercially available computerized training|
230817|NCT02418546|Behavioral|In-Person Nutritional Counseling by a Registered Dietitian|
230818|NCT02418546|Behavioral|Nutritional counseling using an e-Health Application|
230819|NCT02418559|Drug|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
230820|NCT02418559|Drug|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2*300 mg) tablet orally once on Day 1 under fasted conditions.
230821|NCT02418559|Drug|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4*300 mg) tablet orally once on Day 1 under fasted conditions.
230822|NCT02418559|Drug|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
230823|NCT00166218|Device|near-infrared spectroscopy|
230241|NCT02426723|Drug|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
230242|NCT02426736|Drug|Dexamethasone|
230243|NCT02426736|Drug|Bupivacaine|
230244|NCT02426736|Procedure|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
230245|NCT02426749|Device|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
230246|NCT02426749|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
230247|NCT02426762|Procedure|Laparoscopic surgery|Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:
4-5 trocar-produced incisions (5/10mm, minor incision)
1 sample-retrieval incision (4-5cm, small incision)
230248|NCT02426762|Device|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
230249|NCT02426775|Drug|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
230250|NCT02393365|Procedure|HCV serology|In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.
In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation.
230251|NCT02393378|Drug|Namilumab 150 mg|Namilumab 150 mg/mL solution for injection.
230537|NCT02422433|Device|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
230538|NCT02422446|Drug|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
230539|NCT02422459|Behavioral|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
230540|NCT02422472|Device|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
229945|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
229946|NCT02398136|Drug|Midazolam|
229947|NCT02398162|Procedure|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
229948|NCT02398162|Procedure|Single Blood Collection|On the enrollment day
229949|NCT02398175|Other|reanimation/intubation|
229950|NCT02398188|Drug|LIPO-202|
229951|NCT02398188|Drug|Placebo|
229952|NCT02398201|Drug|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
229953|NCT02398214|Behavioral|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to < 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
229954|NCT02398227|Behavioral|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
229955|NCT00163644|Other|No formal exercise plus phone calls|
229956|NCT02398227|Behavioral|PCT|Present Centered Therapy for PTSD
229957|NCT02398240|Drug|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
229958|NCT02398240|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
229959|NCT02398240|Drug|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
229960|NCT02398240|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
229961|NCT02398253|Behavioral|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
229962|NCT02398253|Behavioral|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
229963|NCT02398266|Procedure|Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)|Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest.
229372|NCT02409199|Drug|Docetaxel|
229373|NCT02409199|Drug|apatinib|
229661|NCT02402907|Device|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
229662|NCT02402920|Drug|Etoposide|100 mg/m^2 given by vein on Days 1, 2, and 3 of each 3 week cycle.
229663|NCT02402920|Drug|Cisplatin|80 mg/m^2 by vein on Day 1 of each 3 week cycle.
229664|NCT02402920|Drug|Carboplatin|AUC 5 by vein on Day 1 of each 3 week cycle.
229665|NCT02402920|Drug|MK-3475|Limited Stage SCLC MK-3475 + Radiation Group - Part A: MK-3475 given by vein at starting dose of 100 mg on Day 1 of every 3 week cycle. The first group of participants will receive the lowest dose level of MK-3475. Each new group will receive a higher dose of MK-3475 than the group before it.
Extensive Stage SCLS MK-3475 + Radiation Group and Extensive Stage SCLS MK-3475 Group - Part B: MK-3475 given by vein at starting dose of 100 mg on Day 1 of every 3 week cycle. The first group of participants will receive the lowest dose level of MK-3475. Each new group will receive a higher dose of MK-3475 than the group before it.
229666|NCT02404727|Procedure|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
229667|NCT02404727|Device|Avantage® Cup|
229668|NCT02404740|Device|Pulse oximetry|Pulse oximetry
229669|NCT02404753|Drug|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
229670|NCT02404753|Procedure|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
229671|NCT00164619|Biological|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
229672|NCT02404753|Procedure|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
229673|NCT02404753|Drug|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
229674|NCT02404766|Other|C0-C1 dorsal glide manual mobilization|
229675|NCT02404766|Other|C7-T1 ventral cranial glide manual mobilization|
229676|NCT02404779|Drug|cisatracurium besilate|
229677|NCT02404792|Other|High-intensity cardiovascular and resistance exercise|
229678|NCT02404792|Other|Moderate-intensity cardiovascular and resistance exercise|
234004|NCT02461303|Other|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and the option of providing a semen sample for semen analysis will be discussed. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
234005|NCT02461316|Other|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
234006|NCT02461329|Drug|Gelofusine® B. Braun|Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
234007|NCT02461329|Drug|Ringerfundin ® B. Braun|Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
234008|NCT02461342|Other|not intervention|This is a cross-sectional study, no intervention was performed.
229374|NCT02409212|Behavioral|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
229375|NCT02409212|Behavioral|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
229376|NCT02409225|Device|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
229377|NCT02409225|Device|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
229378|NCT02411227|Behavioral|VR Driving|Baseline: Tactical scenario, composite score Post-Assessment: Tactical scenario composite score
229379|NCT02411240|Device|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
229380|NCT02411253|Drug|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
229381|NCT02411253|Drug|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
229382|NCT02411266|Other|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
229383|NCT02411279|Other|Equiped group with telemedicine systems|
238417|NCT02434965|Drug|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 7.
238418|NCT02434965|Drug|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
238419|NCT02434978|Device|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
238420|NCT02434978|Drug|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
238421|NCT02434978|Other|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
238709|NCT02429999|Drug|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
238710|NCT02430012|Behavioral|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
238711|NCT00002459|Radiation|radiation therapy|
238712|NCT00168038|Biological|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
238713|NCT02430051|Behavioral|Sensory Adapted Dental Environment|The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
238714|NCT02430064|Other|Low PAMP diet|
238715|NCT02430077|Drug|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
238716|NCT02430077|Drug|Placebo|Identical to Obeticholic Acid - placebo drug
238717|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
238718|NCT02430090|Drug|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
238719|NCT02430090|Drug|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
238720|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
238113|NCT02441998|Other|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
238114|NCT02442024|Behavioral|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
238115|NCT02442024|Behavioral|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
238116|NCT02442037|Biological|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10^6/kg) ,once every week，a total of three times.
238117|NCT02442037|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
238118|NCT02442050|Other|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
238119|NCT02442050|Other|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
238422|NCT02437214|Other|Use of music for anxiety in children|The "Baby Go to Sleep" CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the "Baby Go to Sleep" CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the "Baby Go to Sleep" CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song.
238423|NCT02437227|Drug|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
238424|NCT02437240|Behavioral|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
238425|NCT02437240|Behavioral|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
238426|NCT02437253|Drug|Adalimumab|Subjects will be treated with adalimumab (20 mg [weight 15-<30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
238427|NCT00168961|Dietary Supplement|High Protein Energy, Fresenius-Kabi (nutritional intervention)|
238428|NCT02437253|Other|Placebo|Saline placebo
238429|NCT02437266|Other|Scapular mobilization|
238430|NCT02437279|Procedure|Surgery of the tumor|
233766|NCT02394964|Other|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
233767|NCT02394977|Device|Cardio First Angle|Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel TM (InotechGruppe, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible "click" sound to alert the rescuer to cease compression. The "click" sound is also audible upon spring decompression alerting the rescuer to resume compression. When used properly rescuers may deliver approximately 100-120 compressions per minute. The device functions purely mechanically and does not require electrical power supply.
233768|NCT02394990|Behavioral|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
233769|NCT02394990|Behavioral|ABI|
233770|NCT02395003|Other|Palmitate Oil Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
233771|NCT02395016|Drug|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
233772|NCT00002434|Drug|Leucovorin calcium|
233773|NCT00163189|Drug|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
233774|NCT02395016|Drug|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
233775|NCT02395016|Other|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
234063|NCT02430623|Device|NanoKnife|
234064|NCT02430636|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
234065|NCT02430636|Device|NanoKnife|
234066|NCT02430649|Procedure|Irreversible electroporation (IRE)|
234067|NCT02430649|Device|NanoKnife|
234068|NCT00168116|Procedure|radiation treatment and surgery|
234069|NCT02430662|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
234070|NCT02430662|Device|NanoKnife|
234071|NCT02430675|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
233479|NCT02399735|Biological|Normal Dose NK cells|Received conventional treatment and NK cells once per 2-week for the first month, at a dose of 1×10E10 NK cells.
233480|NCT02399735|Biological|High Dose NK cells|Received conventional treatment and NK cells once per 2-week for the first month, at a dose of 2×10E10 NK cells.
233481|NCT02399774|Device|Leboride|Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
Control group: participants will not receive any device for breastfeeding pain control
Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
233482|NCT02399787|Other|blastocyst biopsy|Performed on day 5
233483|NCT02399800|Procedure|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
233484|NCT02399800|Procedure|No Celiac Block|EUS but no celiac block performed
233485|NCT02399800|Drug|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
233486|NCT02399813|Drug|ADXS11-001|
233487|NCT00163917|Device|Virtual reality relaxation|
233488|NCT02402114|Drug|Hydrocortisone|120 mg Hydrocortisone given orally one time.
233489|NCT02402127|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses, worn and unworn
233490|NCT02402127|Device|Somofilcon A contact lenses|Silicone hydrogel contact lenses, worn and unworn
233491|NCT02402127|Device|Stenfilcon A contact lenses|Silicone hydrogel contact lenses, worn and unworn
233492|NCT02402140|Other|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
233493|NCT02402153|Device|Hyposafe device|Subcutanous EEG recorder for EEG measurements
233494|NCT02402166|Drug|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
233495|NCT02402179|Other|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
232903|NCT02412670|Drug|Doxorubicin Hydrochloride|Given IV
233194|NCT02406261|Drug|Midazolam|Intravenous doses of 250 mcg midazolam will be administered as 0.25 mL of 1-mg/mL injection solution
233195|NCT02406261|Drug|Donepezil|Oral doses of 5 mg donepezil will be administered as 1 × 5-mg tablet
233196|NCT02406261|Drug|AZD3293|Oral doses of 50 mg AZD3293 will be administered as 1 × 50-mg tablet
233197|NCT02406274|Other|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated & or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) & record their findings. They will then interpret the CESM & record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding & will either be called negative & followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
233198|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
233199|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
233200|NCT02406300|Procedure|Subarachnoid Anesthesia|
233201|NCT00164788|Drug|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
233202|NCT02406300|Procedure|PNB/GA|
233203|NCT02406300|Drug|ropivacaine|
233204|NCT02406300|Drug|sevoflurane or desflurane|
233205|NCT02406300|Drug|bupivacaine or levobupivacaine|
233206|NCT02406313|Other|CTS|Standardized Thermal Cure
233207|NCT02406313|Other|ETP|Patient Therapeutic Education
233208|NCT02406339|Device|NMES|Neuromuscular Electrical Stimulation
233209|NCT02406339|Device|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
233210|NCT02408237|Device|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
232631|NCT02419183|Other|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
232904|NCT02412670|Drug|Cisplatin|Given IV
232905|NCT02412670|Drug|Gemcitabine Hydrochloride|Given IV
232906|NCT02412670|Drug|Carboplatin|Given IV
232907|NCT02412670|Procedure|Therapeutic Conventional Surgery|Undergo nephroureterectomy and lymph node dissection
232908|NCT00165438|Procedure|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
232909|NCT02412670|Other|Laboratory Biomarker Analysis|Correlative studies
232910|NCT02412683|Other|oxaliplatin|
232911|NCT02412696|Device|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
232912|NCT02412696|Other|Nasal Dilator Strips|Nasal dilator strips
232913|NCT02412709|Device|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
232914|NCT02412722|Drug|Milled MLN0128 API|Capsules containing milled MLN0128 active pharmaceutical ingredient (API)
232915|NCT02412722|Drug|Unmilled MLN0128 API|Capsules containing unmilled MLN0128 active pharmaceutical ingredient (API)
232916|NCT02412722|Drug|Paclitaxel|Paclitaxel
232917|NCT02412735|Drug|rexlemestrocel-L|rexlemestrocel-L alone": 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with saline - Intervention will be injected into the painful intervertebral disc
232918|NCT02412735|Drug|rexlemestrocel-L + HA|rexlemestrocel-L + HA": 2.0mL 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with 1% HA - Intervention will be injected into the painful intervertebral disc
232919|NCT00165451|Drug|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
232920|NCT02412735|Drug|Placebo|saline control: 2.0 mL saline solution
232921|NCT02412748|Behavioral|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
232922|NCT02414880|Drug|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
232336|NCT02423226|Procedure|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
232337|NCT02423226|Drug|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
232338|NCT00167154|Drug|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
232339|NCT02423239|Drug|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
232340|NCT02423239|Drug|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
232341|NCT02423239|Drug|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
232632|NCT02419183|Other|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
232633|NCT02419196|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
232634|NCT02419209|Other|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
232635|NCT02419222|Behavioral|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
232636|NCT00166309|Drug|FEIBA and NovoSeven|
232637|NCT02419235|Other|20% ethanol|Unmedicated 20% ethanol.
232638|NCT02419235|Other|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
232639|NCT02419261|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
232640|NCT02419261|Procedure|Arthroscopic surgical repair of the anterior cruciate ligament|
232641|NCT02419287|Drug|crizotinib|
232642|NCT02419300|Device|ultrasoungraphy|pelvic ultrasonography and Doppler
232028|NCT02394236|Other|Aerobic exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
232029|NCT02394249|Behavioral|Physical activity regime|Information already included in arm descriptions
232030|NCT02394262|Radiation|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
232031|NCT00002434|Drug|Trimetrexate glucuronate|
232032|NCT00163111|Drug|VFENDÂ® I.V., Oral|
232033|NCT02394262|Other|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
232034|NCT02394275|Biological|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
232035|NCT02394288|Procedure|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
232036|NCT02394314|Drug|MEDI0382|MEDI0382 administered subcutaneously
232037|NCT02394314|Drug|Placebo|Placebo administered subcutaneously
232342|NCT02423239|Drug|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
232343|NCT02425267|Other|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
232344|NCT02425280|Behavioral|Narrative Exposure Therapy|
232345|NCT02425280|Behavioral|Treatment as Usual|
232346|NCT02425293|Behavioral|asthma patient education|
232347|NCT02425306|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
232348|NCT02425306|Drug|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
232349|NCT00167401|Procedure|radiation treatment|
232350|NCT02425306|Drug|polyICLC|polyICLC, local adjuvant
231731|NCT02401373|Biological|Ad5-EBOV|intramuscular injection
231732|NCT02401386|Behavioral|The Lu Eight Brocades|LEB Intervention:The 12-week LEB program will meet in groups of about 30 persons. Each 1-hour session twice a week will include each of 8 forms of LEB movements, a review of principles, and breathing techniques in LEB. Participants will be asked to practice LEB at home for 30 minutes each day, using an instructional Digital Video Disc. The program will be taught by experienced LEB masters.
231733|NCT02401399|Dietary Supplement|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
231734|NCT02401399|Dietary Supplement|High protein formula|The patients receive high protein formula during 15 days before surgery
231735|NCT02401399|Dietary Supplement|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
231736|NCT02401412|Device|Test Ostomy Barrier|
231737|NCT00164164|Drug|HalfLytely|
231738|NCT02401412|Device|Control Ostomy Barrier|
231739|NCT02401425|Drug|Letrozole|
231740|NCT02401425|Drug|Misoprostol|
231741|NCT02401425|Other|Placebo|
231742|NCT02401438|Other|5D ultrasound|
231743|NCT02401438|Other|2D ultrasound|
231744|NCT02401451|Device|RhythmPadGP|ECG acquisition using a novel device
231745|NCT02401464|Drug|TAK-536|TAK-536 dry syrup formulation + TAK-536 10 mg tablet
231746|NCT02401464|Drug|TAK-536|TAK-536 10 mg tablet + TAK-536 dry syrup formulation
231747|NCT02401464|Drug|TAK-536|TAK-536 granule formulation + TAK-536 10 mg tablet
232038|NCT02394327|Device|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
232039|NCT02394327|Device|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
232040|NCT02394340|Drug|Omeprazole 40mg|Each subject will receive a single dose of omeprazole 40mg on Day 1, 24 hours prior to starting treatment with Luliconazole Cream 1%, and on Day 8 after treatment
232041|NCT02394353|Device|Transient hepatic elastography|
231421|NCT02405559|Drug|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
231422|NCT02405572|Other|infant formula|infant formulas
231748|NCT00164164|Drug|NuLytely|
231749|NCT02401464|Drug|TAK-536|TAK-536 10 mg tablet + TAK-536 granule formulation
231750|NCT02401477|Drug|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
231751|NCT02401490|Drug|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
231752|NCT02401490|Drug|Placebo|
231753|NCT02401503|Drug|Bendamustine|Debulking: Cycles 1-2, d1 & 2: 70mg/m² i.v.
231754|NCT02401503|Drug|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
231755|NCT02401503|Drug|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
231756|NCT02403687|Drug|Cyclobenzaprine hydrochloride 2%|compound topical cream
231757|NCT02403687|Drug|Diclofenac Sodium 3%|compound topical cream
231758|NCT02403687|Drug|Flurbiprofen 10%|compound topical cream
231759|NCT02403687|Drug|Gabapentin 6%|compound topical cream
231760|NCT02403687|Drug|Ketamine 10%|compound topical cream
231761|NCT02403687|Drug|Lidocaine 2%|compound topical cream
231762|NCT02403687|Drug|Prilocaine 2.5%|compound topical cream
231763|NCT02403687|Drug|Meloxicam 0.09%|compound topical cream
231764|NCT02403687|Drug|Sumatriptan 5%|compound topical cream
231765|NCT00164463|Drug|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
231766|NCT02403687|Drug|Tizanidine 0.1%|compound topical cream
231767|NCT02403687|Drug|Topiramate 2.5%|compound topical cream
231768|NCT02403687|Drug|Capsaicin, USP 0.0375%|compound topical cream
231126|NCT02412046|Procedure|Muscle biopsy|
231127|NCT02412059|Drug|Prednisolone acetate|
231128|NCT02412085|Drug|Golimumab|Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)
Maintenance regimen:
body weight < 80kg: 50 mg every 4 weeks
body weight ≥ 80 kg: 100 mg every 4 weeks
231423|NCT00164710|Drug|lumefantrine-artemether|
231424|NCT02405585|Drug|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
231425|NCT02405585|Biological|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
231426|NCT02405585|Radiation|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
231427|NCT02405585|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection.
231428|NCT02405598|Drug|Salbutamol|Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)
VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)
231429|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
231430|NCT02407548|Dietary Supplement|vitamin E softgel|2 vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
231431|NCT02407574|Device|External Pacing Box|Atrial pacing using an external pacing box
231432|NCT02407587|Device|cochlear implants|PET scans for the mature patients with unilateral cochlear implants and preserved hearing
4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation
231433|NCT02407600|Drug|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
231434|NCT02407600|Drug|Placebo|
231435|NCT02407613|Device|Philips Sonalleve MR-HIFU Breast Tumor Therapy System|Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
231436|NCT02407626|Drug|Propofol|Total intravenous anesthesia is a clinical standard procedure
230824|NCT02418572|Drug|Testosterone gel|Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.
TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)
230825|NCT02418572|Drug|Placebo gel|Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.
Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG
230826|NCT02418585|Drug|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
230827|NCT02418585|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
230828|NCT02418585|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
230829|NCT02418585|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
231129|NCT02412098|Drug|Eleclazine|Eleclazine tablets administered orally
231130|NCT02412111|Drug|ivacaftor|
231131|NCT00165386|Procedure|Magnetic Resonance Imaging|
231132|NCT02412111|Drug|VX-661|
231133|NCT02412111|Drug|Placebo|
231134|NCT02412124|Procedure|Supportive Care|Complete W2W mentoring program
231135|NCT02412124|Other|Quality-of-Life Assessment|Complete the FACT-G
231136|NCT02412124|Other|Questionnaire Administration|Complete the W2W Patient Survey
231137|NCT02412137|Other|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
231138|NCT02412150|Drug|Desflurane|Anesthesia is maintained with desflurane
230541|NCT02422485|Drug|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
230542|NCT00166868|Drug|Neomycin|
230543|NCT02422498|Radiation|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
230544|NCT02422498|Drug|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 or 40 mg/m^2 ivpb once a week for 1-2 weeks prior to radiation.
230545|NCT02422498|Procedure|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
230546|NCT02424565|Drug|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
230547|NCT02424565|Other|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
230548|NCT02424578|Drug|Diclofenac Capsules low dose|
230549|NCT02424578|Drug|Diclofenac Capsules high dose|
230550|NCT02424591|Drug|Ketamine|Infusion at a rate of 10 mcg/kg/min
230551|NCT02424591|Drug|Placebo|Placebo IV
230552|NCT00167310|Drug|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
230553|NCT02424617|Drug|erlotinib|erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
230554|NCT02424617|Drug|BGB324|Study investigational product.
230830|NCT02418585|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
230831|NCT02418585|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
230832|NCT02418598|Genetic|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10^11 vg/subject.
229964|NCT02398266|Procedure|Contrast ultrasound of leg muscle with Sonazoid (Stress microvascular ultrasound perfusion imaging)|Skeletal muscle perfusion assessment of the calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid during plantar flexion exercise (15 W).
229965|NCT02398266|Drug|Contrast enhanced ultrasound (Sonazoid)|
230252|NCT02393378|Drug|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously
230253|NCT02393378|Drug|Methotrexate|methotrexate at existing stable dose
230254|NCT02393378|Drug|Folic Acid|
230255|NCT00162981|Drug|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
230256|NCT02393391|Device|Neuroelectrics STARSTIM|
230257|NCT02393404|Other|PT-FMT|Physiotherapeutic functional movement-power training
230258|NCT02393404|Other|FMT alone|Physiotherapeutic power training
230259|NCT02393417|Biological|CANDIN|Candida albicans Skin Test Antigen for Cellular Hypersensitivity
230260|NCT02393417|Other|Placebo|0.9% Sodium Chloride Injection USP (non-preserved)
230261|NCT02393430|Drug|Rebamipide|Rebamipide is a
230262|NCT02393430|Behavioral|optimization of life style|
230263|NCT02393443|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
230264|NCT02393443|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
230265|NCT02393456|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
230266|NCT00162994|Procedure|adenoidectomy and tymapanostomy|
230267|NCT02393456|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
230268|NCT02393469|Other|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
229679|NCT02404805|Drug|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
229680|NCT02404805|Drug|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
229681|NCT02404818|Procedure|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
229682|NCT00164632|Behavioral|counselling, exercise, referrals (behavior)|
229966|NCT00163657|Drug|Daclizumab|
229967|NCT02398279|Dietary Supplement|L-Arginine|Experimental supplement
229968|NCT02398279|Other|Placebo|Placebo capsules in the same color and shape with the experimental supplement
229969|NCT02398292|Other|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
229970|NCT02398305|Device|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
229971|NCT02398305|Device|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
229972|NCT02400580|Drug|placebo|
229973|NCT02400593|Behavioral|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
229974|NCT02400606|Other|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
229975|NCT02400606|Other|Solving VP cases|See above
229976|NCT02400619|Device|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
229977|NCT02400619|Drug|Botulinum Toxin Type A|Botulinum toxin type A Botox
229978|NCT02400632|Device|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
229979|NCT02400645|Procedure|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
229980|NCT00164086|Drug|atorvastatin|
229981|NCT02400645|Procedure|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
229384|NCT02411292|Drug|Enoxparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment using a clinical protocol developed with our inpatient pharmacists.
229385|NCT02411318|Other|Exercise|Subjects will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
229386|NCT02411318|Drug|ProLab 200mg caffeine capsule|Subjects will swallow one ProLab caffeine 200mg tablet.
229387|NCT00165269|Procedure|Mantle irradiation|Limited to above the diaphragm
229388|NCT02411318|Other|Ethanol ingestion|Subjects will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
229389|NCT02411331|Drug|Ethanol 40% + Enoxaparine 400UI/ml|
229390|NCT02411331|Drug|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
229391|NCT02411344|Drug|Pertuzumab|Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles
Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle
Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery).
229392|NCT02411357|Behavioral|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
229683|NCT02404818|Procedure|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
229684|NCT02404831|Other|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
229685|NCT02404831|Other|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
229686|NCT02404844|Drug|BKM120|daily oral
229687|NCT02404844|Drug|Tamoxifen|daily oral
229688|NCT02404857|Device|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
229689|NCT02404870|Drug|Placebo|
229690|NCT02406989|Drug|MS-553|Study Drug
238721|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
238722|NCT02430116|Procedure|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
238723|NCT00168051|Drug|ReFacto|
238724|NCT02430129|Procedure|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
238725|NCT02430129|Procedure|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
238726|NCT02430129|Device|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
238727|NCT02430129|Device|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
238728|NCT02430142|Other|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
239016|NCT02463331|Drug|azathioprine|
239017|NCT02463344|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
239018|NCT02463357|Dietary Supplement|Quercetin|
239019|NCT02463357|Drug|Nifedipine extended release|
239020|NCT02463357|Drug|Methazolamide|
239021|NCT02463357|Drug|Metformin|
239022|NCT02463357|Drug|Placebo|
239023|NCT02463370|Other|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
239024|NCT02463370|Other|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
239025|NCT02463370|Other|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
239026|NCT00173641|Procedure|blood drawing|
239027|NCT02463370|Other|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
239028|NCT02463383|Drug|Alcohol + ibuprofen|2.3 g alcohol + 400mg ibuprofen
238431|NCT02437279|Drug|Infusion with ipilimumab 3 mg/kg q3wks|
238432|NCT02437279|Drug|Infusion with nivolumab 1 mg/kg q3wks|
238433|NCT02437292|Other|Ischemic compression with stretching|
238434|NCT02437305|Behavioral|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
238435|NCT02437305|Behavioral|ABCDEs of Melanoma|Conventional melanoma educational intervention.
238436|NCT02437318|Drug|Fulvestrant|
238437|NCT02437318|Drug|Alpelisib|
238438|NCT00168987|Drug|oral nutritional supplement rich in eicosapentanoic acid|
238439|NCT02437318|Drug|Alpelisib placebo|
238440|NCT02437344|Drug|CI-581|92 minute infusion of CI-581
238441|NCT02437344|Drug|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
238442|NCT02437357|Other|Metacognitive Training|8 group sessions á 60 min
238729|NCT02432469|Behavioral|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
238730|NCT02432482|Behavioral|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
238731|NCT02432482|Behavioral|Standard care|Brief advice to quit (<5 minutes) Self-help brochure Offer of nicotine patches
238732|NCT02432495|Other|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
238733|NCT02432495|Other|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
238734|NCT02432508|Device|Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (50mW, 655nm)
238735|NCT02432508|Device|Sham Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
234072|NCT02430675|Device|NanoKnife|
234073|NCT02430688|Procedure|Irreversible electroporation (IRE)|
234074|NCT02430688|Device|NanoKnife|
234075|NCT02432833|Drug|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
234076|NCT02432846|Biological|Intuvax|Therapeutic vaccine: allogeneic, pro-inflammatory dendritic cells.
234077|NCT02432846|Drug|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
234078|NCT02432859|Procedure|Electrical Stimulation|Direct current with sensory intensity for one hour
234079|NCT02432859|Procedure|Placebo|Direct current with zero intensity for one hour
234080|NCT02432872|Drug|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
234081|NCT02432872|Drug|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
234082|NCT00168467|Drug|Ramipril|
234083|NCT02432885|Drug|Enalapril|up to 20mg bid
234084|NCT02432898|Device|3D OCT-1|Spectral Domain OCT Device
234085|NCT02432898|Device|3D OCT-2000|Spectral Domain OCT Device
234086|NCT02432898|Device|DRI OCT-1|Swept Source OCT Device
234087|NCT02432898|Device|NW-300|Fundus Camera
229452|NCT02417909|Other|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
229453|NCT02417922|Other|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
229454|NCT02417922|Other|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
229455|NCT02417935|Drug|Duloxetine|Administered orally
229456|NCT02417935|Drug|Pregabalin|Administered orally
229457|NCT02417935|Drug|Placebo|Administered orally
233776|NCT02395029|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
233777|NCT02395042|Drug|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
233778|NCT02395042|Drug|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
233779|NCT02395055|Drug|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
233780|NCT02395055|Drug|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
233781|NCT02395068|Drug|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
233782|NCT02395068|Drug|irinotecan|Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
233783|NCT02395081|Dietary Supplement|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
233784|NCT00163202|Procedure|Blood samples|
233785|NCT02395081|Dietary Supplement|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
233786|NCT00163527|Drug|Roflumilast|
233787|NCT02397382|Drug|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8.
233788|NCT02397382|Drug|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
233789|NCT02397382|Drug|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
233790|NCT02397382|Drug|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
233791|NCT02397382|Drug|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
233792|NCT02397382|Drug|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
233793|NCT02397395|Drug|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
233211|NCT02408237|Device|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
233496|NCT02402192|Drug|Corifollitropin alfa|
233497|NCT02402205|Behavioral|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
233498|NCT00164255|Drug|sulfadoxine/pyrimethamine|
233499|NCT02402218|Other|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
233500|NCT02402218|Other|Usual care plus incentives|Participants are given incentives after completing treatment goals.
233501|NCT02402218|Other|Usual Care|Participants receive standard of care in the clinic from their health care team.
233502|NCT02402231|Drug|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
233503|NCT02402244|Other|cytology specimen collection procedure|Undergo cytology specimen collection
233504|NCT02402257|Behavioral|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
233505|NCT02402270|Drug|NuLYTELY® (PEG 3350)|
233506|NCT02402270|Drug|ECP-019|
233507|NCT02402270|Drug|MoviPrep® (PEG 3350)|
233508|NCT02402283|Drug|Metronidazole benzoate oral granules|Single oral dose of 400 mg
233509|NCT00164255|Drug|sulfadoxine/pyrimethamine plus artesunate|
233510|NCT02402283|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
233511|NCT02402296|Drug|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
233512|NCT02404311|Biological|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
233513|NCT02404324|Other|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
232923|NCT02414880|Drug|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
233212|NCT02408237|Device|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
233213|NCT02408250|Procedure|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
233214|NCT02408263|Procedure|Total Hip Replacement|Total Hip Replacement is a surgical procedure whereby the diseased cartilage and bone of the hip joint is surgically replaced with artificial materials.
233215|NCT02408263|Procedure|Total Knee Replacement|Total Knee Replacement is a procedure which involves replacement of all three compartments of the knee (the medial compartment (inside aspect of the knee), the lateral compartment (outside of the knee) and the patellofemoral compartment (in front of the knee)).
233216|NCT00165074|Drug|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
233217|NCT02408276|Other|dGEMERIC MRI technique|Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.
All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.
233218|NCT02408289|Dietary Supplement|Lo-Flav|low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
233219|NCT02408289|Dietary Supplement|Hi-Flav|High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
233220|NCT02408289|Dietary Supplement|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
233221|NCT02408289|Dietary Supplement|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
233222|NCT02408302|Drug|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
233223|NCT02408315|Drug|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
233224|NCT02408328|Drug|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
233225|NCT02408328|Device|Home monitor|Use of home monitor until 44 weeks postmenstrual age
233226|NCT02408328|Other|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
232643|NCT02419313|Drug|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
232644|NCT02419313|Drug|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
232645|NCT02419326|Behavioral|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
232646|NCT02419339|Procedure|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
232647|NCT00166322|Procedure|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
232648|NCT02419352|Drug|Sugammadex|
232649|NCT02419352|Drug|Neostigmine/atropine|
232650|NCT02419378|Drug|Alemtuzumab|
232924|NCT02414880|Drug|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
232925|NCT02414893|Procedure|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
232926|NCT02414906|Other|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
232927|NCT00165646|Drug|Placebo|Placebo: once daily orally for 4 weeks
232928|NCT02414919|Device|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
232929|NCT02414919|Device|ParaGard|Copper T380A
232930|NCT02414919|Device|Implanon/Nexplanon|Etonorgestrel contraceptive implant
232931|NCT02414932|Drug|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
232932|NCT02414932|Drug|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
232933|NCT02414945|Drug|Cyclophosphamide|
232934|NCT02414945|Drug|Fludarabine|
232935|NCT02414945|Biological|Autologous tumor infiltrating lymphocytes (TILs)|
232351|NCT02425306|Drug|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
232352|NCT02425332|Device|Lokomat gait trainer|
232353|NCT02425345|Behavioral|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.An interactive voice response (IVR) coach will be available. The intervention is conducted primarily by mail and optionally by phone and the IVR.
232354|NCT02425358|Other|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
232355|NCT02425358|Other|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
232356|NCT02425358|Other|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
232357|NCT02425358|Other|PCI only|The saline was intracoronary infusion with the use of microtubular.
232358|NCT02425371|Other|Screening and treatment of comorbidities|Screening and treatment of comorbidities
232359|NCT02425371|Other|Placebo Comparator|No screening of comorbidities
232651|NCT02419391|Biological|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
232652|NCT02421081|Procedure|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
232653|NCT00166660|Behavioral|NIDCAP (Newborn Individualized Developmental Care)|The NIDCAP model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account the infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists formally observed each infant's behavior weekly throughout the hospitalization, starting with the phase of the infant's initial stabilization, and then every seven days throughout hospital discharge and to 2wCA.
232654|NCT02421094|Drug|GR-MD-02|GM-MD-02 active
232655|NCT02421094|Drug|Placebo|Placebo
232656|NCT02421107|Other|Glysure CGM|
232657|NCT02421107|Other|iStat intermittent testing|
232042|NCT02396693|Device|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
232043|NCT02396693|Device|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
232044|NCT02396706|Drug|Ivy Leaves Cough Liquid|
232045|NCT02396706|Drug|Placebo|
232046|NCT00163423|Drug|Ciclesonide|
232047|NCT02396719|Device|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
232048|NCT02396732|Drug|Aspirin|
232049|NCT02396732|Drug|Enoxaparin|
232050|NCT02396745|Device|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|TECR will be performed to resect the entire length and area of the BE lesion in the in-patient setting.
ECM PLACEMENT:
Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA).
232051|NCT02396758|Device|EkosSonic Endovascular System plus thrombolytic|
232052|NCT02396771|Procedure|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
232053|NCT02396771|Procedure|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
232054|NCT02396797|Behavioral|The new atWork intervention|atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or "inappropriate" behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting.
232360|NCT00167414|Procedure|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
232361|NCT02425384|Behavioral|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
235999|NCT02450773|Drug|Furosemide|40 mg furosemide on postpartum day 1-6
236000|NCT02450773|Drug|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
236290|NCT02446431|Drug|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
236291|NCT00169988|Drug|sertraline-primary|
236292|NCT02446431|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
236293|NCT02446431|Drug|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
236294|NCT02446431|Drug|Temsirolimus|Temsirolimus [an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
236295|NCT02446444|Drug|Enzalutamide|
236296|NCT02446444|Drug|Conventional NSAA|
236297|NCT02446444|Drug|LHRHA|
236298|NCT02446444|Radiation|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
236299|NCT02446457|Drug|Rituximab|375 mg/m2 by vein weekly for 4 weeks on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycle 2.
236300|NCT02446457|Drug|Pembrolizumab|200 mg by vein every 3 weeks for a maximum of 16 infusions on Day 2 of Cycles 1 and 2, and on Day 1 of Cycles 3 - 16.
236301|NCT02446470|Procedure|Sinus Tarsi approach|
236302|NCT00170001|Drug|Nexium|40 mg bid dosing
235711|NCT02457650|Drug|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
235712|NCT02457650|Drug|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
236001|NCT02450773|Drug|Placebo #1|Placebo (for furosemide)
236002|NCT02450773|Drug|Placebo #2|Placebo (for KCl)
236003|NCT02453100|Behavioral|Education|Education on simple ways to manage incontinence
236004|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
236005|NCT02453139|Behavioral|Exercise|6 month supervised and home based aerobic exercise intervention
236006|NCT00171054|Drug|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
236007|NCT02453152|Other|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
236008|NCT02453152|Other|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
236009|NCT02453152|Other|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
236010|NCT02453152|Other|Peak cough flow|Subjects' strongest coughs will be measured.
236011|NCT02453152|Other|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
236012|NCT02453152|Other|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
236013|NCT02453152|Other|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
236014|NCT02453165|Procedure|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
236015|NCT02453165|Procedure|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
236016|NCT02453178|Behavioral|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
236017|NCT00171067|Drug|valsartan|
235397|NCT02464254|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
235398|NCT02464280|Other|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
235399|NCT02464280|Other|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
235400|NCT02464280|Other|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
235401|NCT02464293|Other|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
235402|NCT02464306|Drug|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
235403|NCT00173901|Drug|ceftazidime|
235404|NCT02464319|Drug|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
235713|NCT02457650|Biological|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
235714|NCT02457663|Procedure|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
235715|NCT00171782|Drug|VALSARTAN+HYDROCHLOROTHIAZIDE|
235716|NCT02457676|Behavioral|Alert Program for Self-Regulation|Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own "engine speed" in different situations.
235717|NCT02457689|Biological|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
235718|NCT02457689|Other|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
235719|NCT02459678|Behavioral|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
235720|NCT02459678|Other|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
235118|NCT02431234|Other|serum RANKL|
235119|NCT02433249|Behavioral|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
235120|NCT02433249|Behavioral|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
235121|NCT02433262|Other|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
235122|NCT02433262|Other|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
235123|NCT00168519|Drug|nitroprusside, pentalong, imdur, AICAR, isoptin|Sodium Nitroprusside - one 30 minute intravenous infusion
Pentalong - two tablets orally (total 160mg)
Imdur - two tablets orally (total 120mg)
235124|NCT02433288|Other|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
235125|NCT02433288|Other|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
235126|NCT02433314|Drug|SAGE-547|
235405|NCT02464319|Drug|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
235406|NCT02464332|Drug|BLZ-100|All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.
Three different imaging windows will be investigated during the study:
Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)
All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups.
235407|NCT02464345|Behavioral|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
235408|NCT02464345|Behavioral|CBT-E|CBT-E therapy
234841|NCT02438358|Drug|LUM015|
234842|NCT02440685|Drug|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
234843|NCT02440685|Drug|ASN002 MTD|MTD of ASN002 from Part A
234844|NCT02440698|Behavioral|Genetic test for personalized nutrition|
234845|NCT02440711|Device|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
234846|NCT02440711|Device|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
234847|NCT02440724|Device|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
234848|NCT02440724|Device|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
234849|NCT00169273|Behavioral|Structured behavioral weight loss group|Structured group weight loss program
234850|NCT02440737|Other|Educational Intervention|Receive publication, "When Someone You Love is Being Treated for Cancer" (intervention arm only), a preliminary individualized SCP (intervention arm only), a final individualized SCP (both arms), and the "REACH for Survivorship" handbook (both arms)
234851|NCT02440737|Other|Educational Intervention|Receive an individualized final SCP and the "REACH for Survivorship" handbook
234852|NCT02440737|Other|Follow-Up Care|Complete SCP at end of treatment
234853|NCT02440737|Procedure|Psychosocial Assessment and Care|Undergo the NEST project
234854|NCT02440737|Other|Questionnaire Administration|Ancillary studies
234855|NCT02440750|Procedure|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
234856|NCT02440750|Drug|Dienogest|21 days administration of dienogest 2 mg/die
234857|NCT02440750|Drug|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
234858|NCT02440789|Drug|Sirolimus|
234255|NCT02452333|Other|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
234256|NCT02452346|Drug|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
234257|NCT02452359|Device|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
234258|NCT02452359|Other|IPL gel|water based gel used to protect the skin during light based treatments. Is also commonly used during ultrasound treatments.
234259|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
234557|NCT02445820|Drug|Crystalloid|2500 mL of balanced crystalloid.
234558|NCT02445833|Behavioral|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
234559|NCT02445846|Device|dual HIV/syphilis rapid diagnostics tests|
234560|NCT02445859|Drug|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
234561|NCT02445859|Drug|Cefuroxime bolus-continuous infusion|Cefuroxime 1.5 grams pre-operatively, repeated 4 hourly during surgery.
234562|NCT02445872|Drug|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
234563|NCT02447926|Procedure|Leukapheresis|Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.
On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.
During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.
Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours.
234564|NCT02447939|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
238962|NCT02456649|Device|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to < 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as < 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
238963|NCT02456662|Drug|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
238964|NCT02456662|Drug|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
238965|NCT02456675|Drug|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
238966|NCT02458716|Other|Quality-of-Life Assessment|Ancillary studies
238967|NCT02458716|Drug|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
238968|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
238969|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
238970|NCT02458729|Drug|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
238971|NCT02458729|Drug|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
238972|NCT02458729|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
238973|NCT02458742|Drug|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
238974|NCT02458742|Drug|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
234260|NCT02452372|Drug|ALN-AS1|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
234261|NCT02452372|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
234262|NCT02452385|Drug|CM082 tablet|CM082 tablets taken orally
234263|NCT02452398|Device|Venus Versa|The Venus Versa system is a multi-application device intended to be used in aesthetic and cosmetic procedures.
The device consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated. The applicator that will be used for this study (HR 690) has a wavelength of 690 nm and has a spot size (treatment area) of 30 mm by 10 mm.
238674|NCT02463214|Other|Engineered Room|Touchless devices:
Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors
Copper products:
Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.
Titanium dioxide paint:
Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote
238675|NCT02463227|Biological|VRC01|40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.
Administered over about 30 to 60 minutes using a volumetric pump.
238676|NCT02463266|Behavioral|SUSTAIN Clinical Monitoring|SUSTAIN Clinical Program participants who agree to follow-up Monitoring which consists of up to 4 brief (5-10 minutes), structured assessments following the baseline assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor adherence, side effects, and response to treatment.
238677|NCT02463266|Behavioral|SUSTAIN Clinical Care Management|SUSTAIN Clinical Program participants who agree to Care Management which incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies for disorders such as depression and anxiety. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
238678|NCT02463292|Other|no intervention|no intervention
238679|NCT02463305|Drug|Creatine monohydrate|
238680|NCT02463318|Drug|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
238681|NCT02463318|Other|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
238682|NCT02465476|Procedure|telemedicine|treatment pathway organized by telemedicine
238683|NCT00174317|Drug|Celecoxib|
238684|NCT02465489|Drug|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
238685|NCT02465489|Drug|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
238686|NCT02465502|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
238687|NCT02465515|Biological|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
238975|NCT00171925|Dietary Supplement|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
238976|NCT02458755|Drug|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
238977|NCT02458768|Drug|IVF-M HP Inj.|
238978|NCT02458768|Drug|Menopur® Inj.|
238081|NCT02439749|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
238392|NCT02432443|Behavioral|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, & Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice & McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
238393|NCT02432443|Other|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
238394|NCT02432456|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
238395|NCT02432456|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
238396|NCT02432456|Procedure|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
238397|NCT02432456|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
238398|NCT02432456|Drug|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
238399|NCT02432456|Drug|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
238400|NCT00168415|Biological|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
238401|NCT02432456|Drug|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
238402|NCT02432456|Drug|Opioid|All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and "ketamine/placebo" solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
222275|NCT02184299|Drug|Prednisone|
222276|NCT02184312|Drug|Nevirapine XR low dose|
222277|NCT02184312|Drug|Nevirapine XR medium dose|
222278|NCT02184312|Drug|Nevirapine XR high dose|
222279|NCT02184312|Drug|Nevirapine (VIRAMUNE®)|
222280|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets|
222281|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
222282|NCT02184325|Drug|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
222283|NCT02184338|Drug|BIBR 1017 BS powder|
222284|NCT00137878|Drug|TNFerade™|
222285|NCT02184338|Drug|Placebo|PEG 400
222286|NCT02184351|Drug|Roxanes's clotrimazole troches|
222287|NCT02184351|Drug|Mycelex® troches|
222288|NCT02184364|Drug|Low dose of Klimadynon®|
222289|NCT02184364|Drug|Medium dose of Klimadynon®|
222605|NCT02176668|Drug|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
222606|NCT00136968|Drug|Voriconazole|
222607|NCT02176668|Drug|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
222608|NCT02176681|Drug|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 12 weeks
222609|NCT02176681|Drug|Insulin|insulin alone
222610|NCT02176694|Behavioral|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
222611|NCT02176720|Drug|FDOPA PET|[18F]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
222612|NCT02176733|Drug|cyclosporine|
238450|NCT02439866|Drug|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
238451|NCT02439866|Drug|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
238452|NCT02439879|Drug|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased >3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
238453|NCT02439892|Behavioral|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
238454|NCT02439892|Behavioral|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
238455|NCT02439905|Drug|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
238456|NCT02439905|Drug|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
238457|NCT02439931|Behavioral|Remote psychosocial intervention|
238458|NCT02439944|Drug|Nicotine patch|
238459|NCT02439944|Drug|Nicotine mouthspray|
238460|NCT00169208|Drug|mitoxantrone|
238461|NCT02439957|Drug|Brincidofovir|
238741|NCT02432547|Procedure|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
238742|NCT02432560|Drug|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
238146|NCT02444780|Procedure|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
238147|NCT02446990|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
238148|NCT02447003|Biological|Pembrolizumab|
238149|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/rilpivirine|
238150|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/efavirenz|
238151|NCT02447029|Drug|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
238152|NCT02447029|Drug|standard lidocaine paracervical block|1% lidocaine paracervical injection
238153|NCT02447042|Procedure|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
238154|NCT02447042|Device|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
238155|NCT02447055|Biological|Tocilizumab|
238156|NCT02447055|Drug|Melphalan|
238157|NCT00170183|Drug|Nesiritide|
238158|NCT02447055|Drug|Fludarabine|
238159|NCT02447055|Drug|Cyclophosphamide|
238160|NCT02447055|Drug|Tacrolimus|
238161|NCT02447055|Drug|Mycophenolate mofetil|
238162|NCT02447055|Drug|Filgrastim|
238163|NCT02447068|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
238164|NCT02447068|Device|Luma Light|NBUVB light
238165|NCT02447068|Device|Occlusive Dressing|Off-the-shelf occlusive dressing
238462|NCT02439957|Drug|Valganciclovir|
238463|NCT02439970|Drug|Brincidofovir|
238464|NCT02439970|Drug|Valganciclovir|
237848|NCT02451436|Behavioral|Study Skills Control Group|
237849|NCT02451462|Drug|Zoledronic acid|
237850|NCT02451475|Drug|Amitriptyline|Amitriptyline 25 mg/day
237851|NCT02451475|Drug|Venlafaxine|Venlafaxine 75 mg/day
237852|NCT02451475|Drug|Paroxetine|Paroxetine 25 mg/day
237853|NCT02451488|Drug|GM-CSF|14 days in a dose of 125 µg/m^2
237854|NCT02451488|Other|Standard of Care|
237855|NCT02451501|Device|AKITA|
237856|NCT02453685|Drug|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
237857|NCT02453685|Drug|insulin aspart|Injected s.c./subcutaneously once daily.
237858|NCT02453698|Drug|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, & Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
237859|NCT02453698|Other|Placebo|Lactose Placebo
237860|NCT02453711|Drug|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
237861|NCT00171145|Drug|Darifenacin|Darifenacin 15 mg tablets once daily
237862|NCT02453711|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
237863|NCT02453711|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
237864|NCT02453724|Device|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
237865|NCT02453737|Radiation|Brachytherapy APBI|
237866|NCT02453737|Radiation|3D-CRT (photon) APBI|
237867|NCT02453737|Radiation|Proton APBI|
238166|NCT02447081|Device|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
237245|NCT02465034|Device|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
237555|NCT02458339|Drug|Methotrexate|4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
237556|NCT02458352|Device|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
237557|NCT00171873|Drug|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
237558|NCT02458352|Device|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
237559|NCT02458365|Behavioral|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
237560|NCT02460367|Drug|Docetaxel|Docetaxel given as an IV infusion over one hour at a dose of 75mg/m2 given every three weeks (on Day 1 of each cycle ) until disease progression or significant toxicity.
237561|NCT02460367|Biological|Tergenpumatucel-L|HAL-1, HAL-2 and HAL-3 immunotherapy components. 300M cells administered as an intradermal injection given every 3 weeks for up to a total of 18 doses.
237562|NCT02460367|Drug|Indoximod 600mg|600mg by mouth three times a day everyday until disease progression or significant toxicity.
237563|NCT02460367|Drug|Indoximod 1200mg|1200mg by mouth three times a day everyday until disease progression or significant toxicity.
237564|NCT02460380|Drug|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
237565|NCT02460380|Other|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
237566|NCT02460393|Drug|Humanized TNFα monoclonal antibody|Subcutaneous injection of different doses for healthy people
Subcutaneous injection of different doses in healthy people
237567|NCT00172159|Procedure|Hepatic resection|
237568|NCT02460393|Other|placebo|Subcutaneous injection of different doses for healthy people
236929|NCT02434224|Procedure|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
236930|NCT02434250|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
236931|NCT02434263|Device|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
236932|NCT02434276|Biological|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
236933|NCT00168662|Biological|Measles and inactivated polio vaccine|
236934|NCT02434276|Biological|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
236935|NCT02434289|Dietary Supplement|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
236936|NCT02434289|Other|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
236937|NCT02434315|Device|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
237246|NCT02465034|Device|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1ms rectangular pulses at an intensity to evoke a 1mV response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
237247|NCT02465034|Device|Corticocortical Paired Associative Stimulation|Corticocortical Paired associative stimulation (ccPAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25Hz for 12 minutes. The interstimulus interval will range from 5-15ms depending on site of stimulation.Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This corticocortical paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
237248|NCT02429414|Device|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
237249|NCT02429414|Procedure|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
237250|NCT02429414|Device|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
237251|NCT02429427|Drug|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
237252|NCT02429427|Other|Placebo|Two capsules once daily with food
236617|NCT02439164|Drug|propofol|
236618|NCT02441387|Drug|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
236619|NCT02441387|Other|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
236620|NCT02441387|Other|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
236621|NCT02441400|Device|EndoStim LES Stimulation System|
236622|NCT02441413|Radiation|High Resolution Computed Tomography scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.
An Upper Airway (UA) scan will be taken on visit 1.
236623|NCT02441439|Dietary Supplement|Iron sucrose 200 mg|
236624|NCT02441439|Dietary Supplement|Iron sucrose 500 mg|
236625|NCT02441452|Other|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
236626|NCT02441465|Drug|Vemurafenib|Oral vemurafenib twice daily (BID)
236627|NCT02441465|Drug|^14 C-labeled vemurafenib|Intravenous (IV) infusion of ^14 C-labeled vemurafenib solution
236628|NCT00169312|Dietary Supplement|dietary intervention|
236629|NCT02441478|Radiation|functional magnetic resonance imaging exam|
236630|NCT02441491|Drug|Cyclophosphamide|Cyclophosphamide will be given by vein once a day for four straight days.
Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster.
236631|NCT02441504|Other|Low intensity Exercise|aerobic exercise training using walking and running
236632|NCT02441517|Drug|Enzalutamide|oral
236938|NCT02434315|Device|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
236939|NCT02436707|Drug|Ibrutinib|
236303|NCT02446470|Procedure|Extensile Lateral approach|
236304|NCT02446483|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
236305|NCT02446483|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
236306|NCT02446496|Drug|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
236633|NCT02441530|Dietary Supplement|Vitamin D|
236634|NCT02441530|Dietary Supplement|Vitamin E|
236635|NCT02441530|Drug|Ibuprofen|
236636|NCT02441556|Device|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
236637|NCT02441556|Other|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
236638|NCT02441569|Behavioral|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
236639|NCT02443974|Device|Brace (Fisiotensor®)|
236640|NCT02443974|Device|Sleeve (Fisiotensor®)|
236641|NCT02443987|Other|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
236642|NCT02444000|Drug|PCV alone|PCV cycles are 6 weeks long
PCV chemotherapy is given as:
Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
236643|NCT02444000|Drug|RT+PCV|Radiotherapy followed by 6 cycles of PCV
236644|NCT02444013|Drug|Folic acid|
236645|NCT02444013|Drug|Placebo|
236646|NCT02444026|Behavioral|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
236647|NCT00169637|Drug|rhGH|
236648|NCT02444039|Device|SL-D301|Slit Lamp
236649|NCT02444039|Device|DC-4|Digital Camera Attachment
236018|NCT02453191|Drug|talimogene laherparepvec|talimogene laherparepvec
236019|NCT02453191|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
236020|NCT02453204|Behavioral|Sitting|
236021|NCT02453204|Behavioral|Standing|
236307|NCT02446496|Drug|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
236308|NCT02448576|Radiation|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
236309|NCT00170404|Drug|Folic Acid|
236310|NCT02448589|Drug|TAS-119|
236311|NCT02448602|Other|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
236312|NCT02448602|Other|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
236313|NCT02448602|Other|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
236314|NCT02448628|Drug|CS-3150|
236315|NCT02448641|Biological|SB623 Implant (2.5M)|2.5 million SB623 cells
236316|NCT02448641|Biological|SB623 Implant (5.0M)|5 million SB623 cells
236317|NCT02448641|Procedure|Sham surgery|
236318|NCT02448654|Drug|Tolcapone|Tolcapone will be compared to sugar pill
236319|NCT02448654|Drug|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
236320|NCT00170404|Drug|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
236321|NCT02448667|Dietary Supplement|FAXE Kondi|Sucrose and glucose containing softdrink
235721|NCT02459691|Behavioral|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
235722|NCT02459691|Other|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
235723|NCT02459704|Procedure|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
235724|NCT02459704|Device|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
235725|NCT02459717|Other|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
235726|NCT02459717|Other|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
235727|NCT02459730|Procedure|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
236022|NCT02453204|Behavioral|Walking|
236023|NCT02453217|Behavioral|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve CPN collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
236024|NCT02453217|Other|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
236025|NCT02455284|Device|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
236026|NCT00171392|Drug|Enteric-coated mycophenolate sodium|
236027|NCT02455297|Drug|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
236028|NCT02455310|Behavioral|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
235409|NCT02428647|Dietary Supplement|preventive placebo supplement|dispersible daily placebo tablet
235410|NCT02428647|Dietary Supplement|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
235411|NCT02428647|Dietary Supplement|placebo powder|placebo powder
235412|NCT02428660|Genetic|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
235413|NCT02428660|Other|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
235414|NCT02428660|Other|MTM|Medication Therapy Management
235415|NCT02428673|Other|Assisted Standing Treatment Program|
235416|NCT02428686|Drug|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
235417|NCT02428699|Other|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
235418|NCT02428699|Other|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
235419|NCT00167843|Drug|sulfadoxine-pyrimethamine|
235420|NCT02428712|Drug|PLX8394|PLX8394 tablets, 75mg
235421|NCT02428725|Other|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
235422|NCT02428751|Drug|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
235423|NCT02428751|Drug|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
235424|NCT02428751|Drug|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
235728|NCT02459730|Procedure|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
235729|NCT00172081|Drug|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
235730|NCT02459756|Other|Beverage: Spray dried blackcurrant powder dissolved in water|
235731|NCT02459756|Other|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
235127|NCT02433327|Other|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
235128|NCT02433327|Other|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
235129|NCT02433340|Drug|ABT-122|Injection
235130|NCT02433353|Drug|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
235131|NCT02433353|Behavioral|EMDR|psychotherapy
235132|NCT02433353|Drug|Placebo|Look-alike venlafaxine XR tablets containing no active drug
235133|NCT02433379|Device|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
235134|NCT02435862|Drug|2.0mg Luminate®|
235135|NCT02435862|Drug|3.0mg Luminate®|
235136|NCT02435862|Other|Balanced Salt Solution for intravitreal injection in 0.10cc|
235137|NCT02435875|Other|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
235138|NCT02435901|Drug|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
235139|NCT02435901|Drug|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
235140|NCT02435901|Drug|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
235141|NCT02435901|Drug|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
235142|NCT02435901|Drug|Mycophenolate mofetil|Immunosuppresant to prevent graft vs host disease is given on Day -1.
235143|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
234565|NCT02447939|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
234566|NCT02447952|Device|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
234567|NCT02447952|Device|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
234568|NCT02447952|Procedure|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
234569|NCT00170287|Device|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
234570|NCT02447965|Drug|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
234859|NCT02440802|Genetic|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
234860|NCT00169273|Behavioral|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
234861|NCT02440815|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
234862|NCT02440828|Drug|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
234863|NCT02440828|Drug|placebo|NaCl 0.9% inhalation 4 ml twice daily
234864|NCT02440841|Drug|fedovapagon|
234865|NCT02440841|Drug|Itraconazole|
234866|NCT02443142|Drug|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
234867|NCT02443155|Drug|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 week. Subjects will continue their pre-trial insulin treatment
234868|NCT02443155|Drug|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
234264|NCT02452398|Other|IPL gel|water based gel used to protect the skin during light based treatments. Also used during ultrasound treatments.
234265|NCT02452411|Behavioral|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
234266|NCT02452424|Drug|PLX3397|PLX3397 capsules, 200 mg
234267|NCT02452424|Biological|Pembrolizumab|Pembrolizumab, 200 mg, IV
234268|NCT02452437|Drug|Oxycodone|Controlled release oxycodone 40 mg twice daily
234269|NCT02454452|Procedure|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
234270|NCT02454452|Procedure|Saphenous vein stripping|Saphenous vein stripping
234271|NCT02454452|Procedure|CHIVA|conservative hemodynamic treatment venous insufficiency
234272|NCT00171288|Drug|fluvastatin, ezetimibe|
234273|NCT02454465|Other|Acceptance and Commitment Therapy group|Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
234274|NCT02454478|Drug|Lenvatinib|
234275|NCT02454478|Drug|Everolimus|
234276|NCT02454491|Drug|Heparin|intraradial administration of heparin 5000 ui
234277|NCT02454491|Drug|Verapamil|intraradial administration of verapamil 5 mg
234278|NCT02454504|Drug|sugammadex|
234279|NCT02454504|Drug|Neostigmine|
234571|NCT02447965|Drug|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
234572|NCT02447978|Biological|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
234573|NCT02447978|Biological|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
238979|NCT02458781|Drug|Metronidazole|Metronidazole 500mg given twice daily for 14 days
238980|NCT02458781|Drug|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
238981|NCT02458781|Drug|Placebo|Placebo given twice daily for 14 days
238982|NCT02458794|Procedure|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
238983|NCT02458794|Device|LMA SupremeTM|
238984|NCT02458794|Device|Ambu-Aura GainTM|
238985|NCT02458820|Procedure|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
238986|NCT00171938|Drug|imatinib mesylate|
238987|NCT02458833|Behavioral|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
238988|NCT02458846|Device|Pediatric Vision Scanner|
238989|NCT02458846|Device|Preschool Randot Stereo test|
238990|NCT02458846|Other|Gold Standard Eye Exam|
238991|NCT02458846|Device|Spot photorefractor|
238992|NCT02458846|Device|PlusoptiXphotorefractor|
238993|NCT02460978|Drug|Dapagliflozin|
238994|NCT02460978|Drug|Insulin|
238995|NCT02460978|Other|Placebo|
238996|NCT00172263|Procedure|blood sampling|
238997|NCT02460991|Device|DEB-TACE|
238998|NCT02460991|Drug|Sorafenib|
238999|NCT02461004|Drug|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
234280|NCT02454517|Behavioral|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
238403|NCT02434848|Drug|Fendrix|Fendrix suspension for injection GlaxoSmithKline UK
Route of Administration, dose regimen:
Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.
Prescription and administration:
The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.
Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).
The shelf life is 3 years.
238404|NCT00168727|Drug|ibritumomab tiuxetan (Zevalin®)|
238688|NCT02465515|Biological|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
238689|NCT02465515|Biological|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
238690|NCT02465528|Drug|Ceritinib (LDK378)|Ceritinib will be dosed on a flat scale of 750 mg (e.g. 5 x 150 mg capsules) once daily for continous dosing cycle. Complete dosing cycle is 28 days.
238691|NCT02465541|Procedure|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
238692|NCT02465541|Other|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
238693|NCT02465541|Other|educational intervention|Undergo enhanced usual care
238694|NCT00174317|Drug|Diclofenac|
238695|NCT02465541|Other|quality-of-life assessment|Ancillary studies
238696|NCT02465541|Other|questionnaire administration|Ancillary studies
238697|NCT02465554|Procedure|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
238698|NCT02465567|Drug|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
238699|NCT02465567|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
238700|NCT02465567|Drug|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
238701|NCT02465567|Drug|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
238702|NCT02465580|Drug|hrIL-2 active|active group: placebo group =1:1
238703|NCT02465580|Drug|hrIL-2 placebo|active group: placebo group =1:1
222613|NCT02176746|Biological|cancer stem cell vaccine|
222614|NCT02179086|Radiation|proton beam radiation therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
222615|NCT02179086|Drug|temozolomide|Given PO
222616|NCT02179086|Other|laboratory biomarker analysis|Correlative studies
222617|NCT02179099|Device|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
222618|NCT00137254|Drug|Insulin|IV insulin
222619|NCT02179112|Procedure|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
222620|NCT02179125|Device|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
222621|NCT02179138|Drug|TFV 1% gel|
222622|NCT02179151|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
222623|NCT02179151|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
222624|NCT02179177|Drug|Apixaban|Drug is taken by mouth twice a day for 6 months
222625|NCT02179177|Drug|Placebo|
222626|NCT02179190|Device|BARREL VRD|BARREL VRD placement adjunctive to coiling treatment.
222627|NCT02179216|Other|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
222628|NCT02179216|Other|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
222929|NCT02171143|Drug|ASP2409|intravenous (IV)
222930|NCT02171143|Drug|Placebo|intravenous (IV)
222931|NCT02171156|Drug|nintedanib|soft gelatin capsule
222932|NCT00136383|Drug|paroxetine versus duloxetine|
222933|NCT02171182|Drug|Qutenza|capsaicin patch
222934|NCT02171195|Drug|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
238743|NCT02434991|Device|Barostat|During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.
A urine pregnancy test for females of childbearing years.
Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.
At this point healthy controls have completed the study.
Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.
Patients will be contacted to complete a phone survey 3 & 6 months and 2 & 4 years after treatment.
238744|NCT02435004|Device|Spinal Modulation Axium™|The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).
If during the trial treatment the pain will decrease significantly (> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket.
238745|NCT02435043|Other|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
238746|NCT02435043|Other|standard management after stroke|standard management after stroke is individualised.
238747|NCT00168753|Drug|Alefacept|IM
238748|NCT02435056|Other|IEPR Approach|Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:
Minimum Data Set for supporting the diagnosis
Electronic Diary with associated alerting system for monitoring the patient during the follow-up period
Second opinion system for improving the management
238749|NCT02435069|Drug|NS and USP Glycerin - Dose Response|This trial uses a repeated measures, single subjects alternating treatments A-B-C-Bʹ-Cʹ-B1ʹ withdrawal design in which all subjects are tested under all conditions and each subject acts as his or her own control. The subjects will be randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A will serve as the control and will be obtained pre-operatively. This arm will evaluate dose-response relationship and will be used to identify the minimum dosing volume and frequency while promoting fecal continence of ACE administration for NS and USP glycerin. When the optimal dose has been identified, the child will continue on that dose for 2 weeks to insure treatment stability and effectiveness.
238750|NCT02435069|Drug|NS and USP Glycerin - Effectiveness|To prevent statistical bias from subject loss due to treatment failure, each child will be randomized to a second treatment sequence once they have achieved continence on optimal dosing with minimal side effects. The second phase Bʹ-Cʹ-B1ʹ of the study will compare the two regimens at optimal dose and administration frequency. This phase will establish the effectiveness of NS and USP Glycerin on degree of continence, procedural time, side effects, parent/patient satisfaction, colonic microbiota, and gut mucosal health
239058|NCT02465736|Drug|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
239059|NCT00174343|Drug|exemestane (Aromasin®)|
239060|NCT02465736|Radiation|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
239061|NCT02465736|Procedure|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
238465|NCT02439983|Dietary Supplement|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
238466|NCT02439983|Dietary Supplement|Placebo|2 capsules taken by mouth with morning and evening meals.
238467|NCT02442063|Drug|paclitaxel|90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
238468|NCT00169403|Procedure|Deep brain stimulation|
238469|NCT02442089|Behavioral|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
238470|NCT02442102|Behavioral|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
238471|NCT02442115|Other|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
238472|NCT02442128|Drug|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
238473|NCT02442128|Drug|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
238474|NCT02442154|Procedure|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
238475|NCT02442180|Drug|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
238476|NCT02442180|Drug|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
238477|NCT02442180|Drug|placebo|equivalent to G-CSF doses
238478|NCT02442193|Other|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
238479|NCT00169416|Drug|valaciclovir HCl granules|
238480|NCT02442206|Drug|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
238481|NCT02442206|Drug|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
238167|NCT02447094|Drug|Alteplase|Intravenous (i.v.) tPA per the standard of care
238168|NCT00170196|Drug|prednisone|
238169|NCT02447107|Other|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
238170|NCT02447107|Other|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
238171|NCT02447120|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
238172|NCT02447133|Device|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
238173|NCT02449278|Radiation|Consolidation involved-site radiotherapy (ISRT)|6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).
Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR).
238174|NCT02449278|Radiation|Consolidation involved-field radiotherapy (IFRT)|6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).
Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR).
238175|NCT02449278|Drug|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
238176|NCT00170508|Biological|Fluzone®|
238177|NCT02449278|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
238178|NCT02449278|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy
238179|NCT02449278|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy
238180|NCT02449291|Drug|APD421|
238181|NCT02449291|Drug|Placebo|
238182|NCT02449304|Device|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
238183|NCT02449317|Other|Bioimpedance guided|bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water
extracellular water/total body water < 0.36 : 4 ml/kg/hr
extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr
extracellular water/total body water > 0.4 : 1 ml/kg/hr
237569|NCT02460406|Other|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching & walking so on).
237570|NCT02460406|Other|progressive functional strength training|Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to "National Strength and Conditioning Association (NSCA)" protocols. Intensity of exercise is gradually increased 10% bi-weekly.
237571|NCT02460419|Drug|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
237868|NCT02453750|Drug|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls <10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls >10%, the previous step will be repeated.
237869|NCT02453750|Drug|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
237870|NCT02453763|Device|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
237871|NCT02453763|Procedure|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
237872|NCT00171145|Drug|Placebo|Placebo tablets once daily
237873|NCT02453776|Drug|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
237874|NCT02453789|Drug|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
237875|NCT02453789|Drug|Placebo|
237876|NCT02456155|Procedure|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
237877|NCT02456155|Procedure|placing nasal jejunal tube endoscopically|
237878|NCT02456181|Behavioral|JumpMath|
237253|NCT02429440|Biological|peptide vaccine|subcutaneous
237254|NCT02429440|Drug|Granulocyte Macrophage Colony Stimulating Factor|intradermal
237255|NCT02429440|Drug|Montanide ISA-51|subcutaneous
237256|NCT02429453|Drug|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
237257|NCT02429453|Biological|Fresh Frozen Plasma|A pooled collection of plasma from donors
237258|NCT00167947|Drug|Cyclosporine|Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
237259|NCT02429466|Drug|SGI-110|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
237260|NCT02429479|Behavioral|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
237261|NCT02429479|Behavioral|Standard advance care planning|This is a online simple living will form.
237262|NCT02429492|Device|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
237263|NCT02429505|Drug|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
237572|NCT02460419|Other|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
237573|NCT02460432|Device|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
237574|NCT02460432|Device|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
237575|NCT02460445|Procedure|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
237576|NCT02460445|Drug|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
237577|NCT02460445|Drug|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
237578|NCT00172172|Drug|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
237579|NCT02460471|Radiation|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
237580|NCT02460484|Biological|Autologous Cord Blood Infusion|Intravenous infusion
236940|NCT02436707|Drug|Rituximab|
236941|NCT02436707|Drug|Gemcitabine|
236942|NCT02436707|Drug|Dexamethasone|
236943|NCT02436707|Drug|Cisplatin|
236944|NCT02436707|Drug|Mesna|
236945|NCT02436707|Drug|Cyclophosphamide|
236946|NCT02436707|Drug|Etoposide|
236947|NCT00168883|Drug|Paclitaxel|
236948|NCT02436707|Drug|G-CSF|
236949|NCT02436733|Procedure|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
236950|NCT02436733|Drug|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
236951|NCT02436759|Drug|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
236952|NCT02436759|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
236953|NCT02436785|Other|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
236954|NCT02436785|Other|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
236955|NCT02436798|Drug|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
236956|NCT02436811|Behavioral|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
236957|NCT02436811|Behavioral|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
236958|NCT00168883|Drug|Vinorelbine|
237264|NCT02429518|Drug|Miltefosine|
236650|NCT02444039|Device|SL-3G|Slit Lamp
236651|NCT02444052|Device|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
236652|NCT02444052|Device|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
236653|NCT02444065|Behavioral|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
236959|NCT02436811|Behavioral|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
236960|NCT02436824|Drug|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
236961|NCT02436824|Other|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
236962|NCT02436837|Other|sessions with virtual reality|sessions with virtual reality to improve the balance
236963|NCT02436850|Procedure|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
236964|NCT02439164|Drug|Dexmedetomidine|
236965|NCT02439177|Device|Blood glucose monitoring system (Omnitest 3)|
236966|NCT02439177|Device|Blood glucose monitoring system (Omnitest 5)|
236967|NCT02439190|Drug|BMS-986120|
236968|NCT02439190|Drug|Aspirin|
236969|NCT02439190|Drug|Clopidogrel|
236970|NCT00169156|Drug|Rituximab + CHOP regimen|
236971|NCT02439203|Drug|JM-010|
236972|NCT02439203|Drug|Placebo|
236973|NCT02439216|Drug|CAT-1004|
236974|NCT02439216|Drug|Placebo|
236975|NCT02439242|Drug|fluid challenge of saline|250 ml of saline
236322|NCT02448667|Dietary Supplement|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
236323|NCT02448680|Biological|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
236324|NCT02448693|Device|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
236325|NCT02448693|Device|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
236326|NCT02448706|Device|Hearing Aid Fitting A|
236654|NCT02444065|Behavioral|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter & Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
236655|NCT02444078|Other|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
236656|NCT02444078|Other|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
236657|NCT02444091|Drug|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
236658|NCT00169650|Other|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
236659|NCT02444117|Other|functional rehabilitation of social communication|
236660|NCT02446509|Behavioral|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
236661|NCT02446509|Behavioral|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
236029|NCT02455323|Other|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
236030|NCT02455323|Other|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
236031|NCT02455323|Other|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
236032|NCT02455323|Other|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
236033|NCT02455336|Drug|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
236034|NCT02455336|Other|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
236035|NCT02455349|Behavioral|Engaging in Community Roles &Experiences|This includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeduation, cognitive therapy, and social skills training.
236327|NCT02448706|Device|Hearing Aid Fitting B|
236328|NCT02448719|Drug|TAK-792 30 mg|TAK-792 30 mg will be administered in the morning after a fast.
236329|NCT02448719|Drug|TAK-792 30 mg placebo|TAK-792 30 mg placebo will be administered in the morning after a fast.
236330|NCT02448719|Drug|TAK-792 100 mg|TAK-792 100 mg will be administered in the morning after a fast.
236331|NCT00170404|Drug|Selenium|
236332|NCT02450786|Drug|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
236333|NCT02450799|Device|AcrySof IOL|Acrylic IOL for long-term implantation in the cataract patient
236334|NCT02450799|Device|Silicone/PMMA IOL|Silicone or PMMA IOL for long-term implantation in the cataract patient
235732|NCT02459769|Behavioral|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
235733|NCT02459782|Procedure|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
235734|NCT02459795|Drug|Ingenol Mebutate (Perrigo)|
235735|NCT02459795|Drug|Ingenol Mebutate (Reference)|
235736|NCT02459795|Drug|Placebo gel|
235737|NCT02461901|Other|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
235738|NCT02461901|Other|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
235739|NCT02461901|Other|Fecal sampling|Collection of fecal samples for C. difficile spores
235740|NCT02461914|Drug|PEX168|200µg,injected subcutaneously,once a week.
235741|NCT02461914|Drug|Warfarin|5mg,oral,two times.
235742|NCT02461927|Drug|Ketamine|
235743|NCT02461927|Drug|Placebo|
235744|NCT02461940|Behavioral|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
235745|NCT00172536|Other|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
235746|NCT02461953|Device|hemoperfusion apparatus|
235747|NCT02461953|Device|low flux dialyzer|
235748|NCT02461953|Device|high flux dialyzer|
235749|NCT02461966|Other|Aflatoxin|Evaluation of Aflatoxin level
236036|NCT02455349|Behavioral|Health & Wellness|Education on ways to better manage health-related concerns
236037|NCT00171405|Drug|aliskiren|
235144|NCT02435901|Drug|Tacrolimus|Immunosuppresant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
235145|NCT02435901|Biological|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
235425|NCT02428751|Drug|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
235426|NCT02428751|Drug|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
235427|NCT02428751|Drug|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
235428|NCT02428764|Drug|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
235429|NCT02428764|Drug|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
235430|NCT00167856|Drug|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
235431|NCT02428764|Drug|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
235432|NCT02428764|Procedure|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
235433|NCT02428777|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
235434|NCT02428777|Drug|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
235435|NCT02431247|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
235436|NCT02431247|Drug|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
235437|NCT02431247|Drug|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
235438|NCT02431247|Drug|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
235439|NCT02431247|Drug|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
235440|NCT02431247|Drug|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
235441|NCT00168272|Device|Transcranial Magnetic Stimulation|
235442|NCT02431260|Drug|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in three treatment groups, with subsequent cohort escalations in the three treatment groups based on protocol-specific criteria
234869|NCT02443155|Drug|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
234870|NCT02443168|Drug|AG-221|Part 1: oral solution containing 100 mg [14C]-AG-221
234871|NCT02443168|Radiation|14C AG-221|5 mL of 100 micrograms [14C] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
234872|NCT02443181|Device|Activa PC+S|Implementation of closed loop DBS for essential tremor
234873|NCT02443194|Drug|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
234874|NCT02443194|Drug|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
234875|NCT02443220|Device|TEAS(transcutaneous electric acupoint stimulation)|transcutaneous electric acupoint will commence at 30 min on "Danzhong" and "Hegu" before anesthesia
234876|NCT00169559|Drug|fenofibrate|Marketed Drug
234877|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|transcutaneous electric acupoint will commence at 30 min on "Danzhong" and "Juque" before anesthesia
234878|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|transcutaneous electric acupoint will commence at 30 min on 2 cm parallel to the right of "Danzhong" and "Juque" before anesthesia
234879|NCT02443246|Drug|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
235146|NCT02435914|Drug|AGN-223575 ophthalmic solution|AGN-223575 ophthalmic solution once or twice daily
235147|NCT02435914|Drug|AGN-223575 vehicle ophthalmic solution|Vehicle to AGN22375 ophthalmic solution once or twice daily.
235148|NCT02435927|Drug|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
235149|NCT02435927|Drug|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
235150|NCT02435953|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
235151|NCT02435953|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
235152|NCT02435966|Device|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
235153|NCT02435966|Device|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
234574|NCT02447978|Biological|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
234575|NCT02447991|Drug|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
234576|NCT02447991|Drug|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
234577|NCT02448004|Drug|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
234578|NCT02448017|Device|The Herbst appliance|Orthodontic functional appliance
234579|NCT02448017|Device|Twin block appliance|Orthodontic functional appliance
234580|NCT02450058|Drug|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
234581|NCT02450058|Drug|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
234582|NCT02450058|Drug|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
234583|NCT02450084|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
234584|NCT02450084|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
234585|NCT00170677|Drug|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
234586|NCT02450084|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
234587|NCT02450084|Drug|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
234588|NCT02450097|Other|Caloric restriction|
234589|NCT02450110|Device|Spinal cord stimulation|
234590|NCT02450123|Drug|sunitinib|
234591|NCT02450136|Drug|pazopanib|
234592|NCT02450149|Drug|sorafenib|
234880|NCT02443246|Drug|Placebo|
234881|NCT02443272|Procedure|Vessel Loop Drainage|Detailed above.
234882|NCT02443272|Procedure|Incision and Drainage|Detailed above.
234281|NCT02454517|Behavioral|Exercise Intervention|Undergo DPP lifestyle intervention
234282|NCT02454517|Other|Informational Intervention|Receive oral and written guidelines and meet with dietician
234283|NCT00171301|Drug|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
234284|NCT02454517|Other|Laboratory Biomarker Analysis|Correlative studies
234285|NCT02454517|Procedure|Quality-of-Life Assessment|Ancillary studies
234286|NCT02454517|Other|Questionnaire Administration|Ancillary studies
234287|NCT02454530|Biological|Nivestim®|
234288|NCT02454543|Procedure|Radical prostatectomy|Study participants randomized in the intervention arm receive continuous hormone therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
234289|NCT02454543|Drug|Androgen deprivation therapy|For the antiandrogenic therapy a non-steroidal antiandrogen (eg, flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.
The selection of standard hormone therapy is up to the judgment of the treating urologist.
234290|NCT02454556|Drug|FOLITIME®|
234291|NCT02454556|Drug|Gonal-F®|
234292|NCT02454582|Device|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
234293|NCT02454595|Behavioral|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
234294|NCT00171314|Drug|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
234295|NCT02456974|Procedure|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
234296|NCT02456974|Procedure|blood sampling in patients receiving vancomycin as part of routine clinical care.|
234297|NCT02456987|Device|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
234298|NCT02457013|Device|HFNC|Hygh flow nasal canula HFNC
234299|NCT00171678|Drug|Diclofenac Topical Sodium Gel 1%|
234300|NCT02457013|Device|nCPAP|nasal nCPAP
238704|NCT02465593|Drug|PEP503|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy, starting at 24 hours later. Patients will have concurrent continuous IV infusion (CVI) of 5-FU or oral capecitabine. Once the concurrent chemoradiotherapy is completed, and patients have recovered from radiation effects , surgical resection of the tumor will be performed once the tumor become resectable.
238705|NCT00174330|Drug|atorvastatin|
238706|NCT02429973|Drug|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
238707|NCT02429986|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
238708|NCT02429999|Drug|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
239000|NCT02461004|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
239001|NCT02461017|Other|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
239002|NCT02461017|Other|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
239003|NCT02461030|Drug|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
239004|NCT02461030|Drug|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
239005|NCT02461030|Procedure|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
239006|NCT02461043|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
239007|NCT00172302|Drug|vitamin C, intravenous injection|
239008|NCT02461043|Radiation|radiation|radiation
239009|NCT02461056|Drug|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
222935|NCT02171195|Drug|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
222936|NCT02171208|Drug|dimethyl fumarate - Reference form|single dose 240 mg
222937|NCT02174029|Procedure|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
222938|NCT02174029|Procedure|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
222939|NCT02174042|Drug|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
222940|NCT02174055|Behavioral|Patient Interviews|
222941|NCT02174055|Behavioral|newly developed questionnaire|
222942|NCT02174068|Drug|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
222943|NCT00136656|Drug|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
222944|NCT02174094|Drug|Clobazam|
222945|NCT02174094|Drug|Placebo|
222946|NCT02174107|Radiation|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1*8 Gy; 5*4 Gy and 10*3 Gy
222947|NCT02174107|Procedure|Percutaneous vertebroplasty|
222948|NCT02174120|Drug|propofol|
222949|NCT02174120|Drug|etomidate|
222950|NCT02174146|Procedure|non-surgical periodontal therapy|supra and subgingival debridement
222951|NCT02174159|Drug|MK-8507|MK-8507 administered as a single oral dose
222952|NCT02174172|Drug|Interferon alfa-2b|Interferon alfa-2b administered subcutaneously every other day for up to 3 doses per week
222953|NCT02174172|Drug|Ipilimumab|Ipilimumab IV, single dose, or multiple-dose regimen every Q3W for up to 4 cycles
223252|NCT02166723|Device|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
239062|NCT02430155|Device|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
239063|NCT02430155|Device|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
239064|NCT02430168|Procedure|Percutaneous nephrolithotomy|
239065|NCT02430168|Procedure|Retrograde intrarenal surgery|
239066|NCT02430181|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
239067|NCT00168051|Drug|Advante|
239068|NCT02430181|Drug|peginterferon|immunomodulator
239069|NCT02430181|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
239070|NCT02430194|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
239071|NCT02430194|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
239072|NCT02430207|Procedure|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
239073|NCT02430207|Procedure|temporary pacing subclavian vein|
239074|NCT02430233|Drug|micronized progesterone 400 mg (Utrogestan)|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
239075|NCT02430233|Other|Placebo|The control group will receive the inert solvent material as a placebo
239076|NCT02430246|Dietary Supplement|Urex Plus|Probiotic
239077|NCT02430246|Other|Placebo|capsule without active ingredient
239078|NCT00168064|Drug|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
239079|NCT02430259|Drug|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
239080|NCT02430272|Drug|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
234354|NCT02461485|Other|Fermented milk product containing Probiotics|2 pots/day during 28 days
234355|NCT02463747|Drug|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
238751|NCT02435095|Drug|Maintenance treatment|Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.
All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
238752|NCT02435095|Drug|Intermittent treatment|Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.
All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
238753|NCT02435108|Drug|crizotinib|crizotinib 250mg bid daily
238754|NCT02437383|Drug|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
238755|NCT02437383|Drug|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
238756|NCT00169000|Drug|Capecitabine|Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1
Dose level -2 600 mg/m2 po BID
Dose level -1 700 mg/m2 po BID
Dose level 1 825 mg/m2 po BID
Dose level 2 1000 mg/m2 po BID
238757|NCT02437409|Device|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
238758|NCT02437422|Biological|SANGUINATE|Single two-hour infusion of SANGUINATE
238759|NCT02437435|Other|Reproductive Technique Gimilio|Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.
Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.
Hand therapist will keep in touch at all times on the suprapubic region of the patient.
238760|NCT02437448|Other|No intervention|
238761|NCT02437461|Drug|Triamcinolone hexacetonide|intraarticular knee injection
238762|NCT02437474|Behavioral|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
238763|NCT02437474|Behavioral|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
238764|NCT02437474|Behavioral|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
238765|NCT02437487|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
238184|NCT02449317|Other|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
238482|NCT02442245|Dietary Supplement|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
238483|NCT02442245|Other|Placebo: Microcrystalline Cellulose|
238484|NCT02442245|Other|Control: No supplementation|
238485|NCT02442258|Drug|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
238486|NCT02442258|Drug|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
238487|NCT02442271|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet
238488|NCT02442271|Drug|Dasabuvir|Tablet
238489|NCT02442271|Drug|Ribavirin|Tablet
238490|NCT00002462|Drug|doxorubicin hydrochloride|
238491|NCT00169442|Biological|Diphtheria, tetanus, pertussis, hepatitis B & Hib|
238492|NCT02444793|Drug|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
238493|NCT02444793|Drug|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
238494|NCT02444806|Other|Full sleep and respiratory monitoring|Standard montage PSG will be used to monitor sleep stages and sleep disordered breathing throughout titration night.
238495|NCT02444806|Other|Limited respiratory monitoring|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
238496|NCT02444819|Drug|HM61713 (BI 1482694)|HM61713 will be administered to evaluate efficacy and safety of subjects.
238497|NCT00169741|Other|Renogram|Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
238498|NCT02444858|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10^5/kg) ，once a day,a total of three times.
238499|NCT02444858|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
238500|NCT02444884|Drug|MLN8237|
237879|NCT02456194|Device|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
237880|NCT02456207|Drug|SCT400|
237881|NCT02456207|Drug|Rituximab|
237882|NCT02456220|Device|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
237883|NCT00171522|Drug|Tegaserod and Polyethylene Glycol 3350|
237884|NCT02456233|Procedure|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
237885|NCT02456233|Procedure|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will then be performed.
238185|NCT02449330|Drug|Teneligliptin|
238186|NCT02449343|Drug|Anlotinib|Anlotinib p.o. qd
238187|NCT00170534|Behavioral|Behavior|
238188|NCT02449343|Drug|Placebo|Placebo p.o. qd
238189|NCT02449356|Device|prone ventilation endotracheal tube|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
238190|NCT02449369|Drug|Preop acetaminophen IV|
238191|NCT02449369|Drug|Preop orphenadrine IV|
238192|NCT02449369|Drug|Postop oral oxycodone & acetaminophen|
238193|NCT02449369|Drug|Postop hydromorphone IV|
238194|NCT02449369|Drug|Postop oral orphenadrine|
238195|NCT02449369|Drug|Postop oral oxycodone|
238196|NCT02449369|Drug|Postop acetaminophen IV|
238197|NCT02449369|Drug|Postop orphenadrine IV|
238198|NCT02451514|Biological|MenABCWY|MenABCWY
238199|NCT00170859|Drug|Everolimus|
238200|NCT02451527|Drug|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
237581|NCT02460497|Drug|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
237582|NCT02460510|Drug|Mannitol|
237583|NCT02460510|Drug|3% hypertonic saline|
237584|NCT02462655|Other|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
237585|NCT02462668|Procedure|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
237586|NCT00173407|Procedure|immunohistochemical, methylation, gene transfection|
237587|NCT02462668|Procedure|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
237588|NCT02462668|Procedure|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
237589|NCT02462681|Drug|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
237590|NCT02462694|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
237591|NCT02462694|Behavioral|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
237886|NCT02456246|Procedure|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
237887|NCT02456259|Procedure|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
237888|NCT02456272|Device|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
237889|NCT02456272|Procedure|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
237890|NCT02456285|Procedure|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
237265|NCT02429531|Biological|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
237266|NCT02429531|Biological|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
237267|NCT02429544|Behavioral|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
237268|NCT02429544|Behavioral|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
237269|NCT00167947|Drug|Steroids|Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
237270|NCT02429544|Device|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
237271|NCT00168337|Drug|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
237272|NCT02431962|Procedure|Computed Tomography|Low dose chest CT screening annually x 3
237273|NCT02431962|Behavioral|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
237274|NCT02431962|Behavioral|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
237275|NCT02431975|Drug|Nevirapine (NVP)|Early ART
237276|NCT02431975|Drug|Zidovudine (ZDV)|Early ART
237277|NCT02431975|Drug|Lamivudine (3TC)|Early ART
237278|NCT02431988|Procedure|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
237279|NCT02431988|Drug|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
237280|NCT02431988|Drug|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
237281|NCT02431988|Biological|CAR19 T-Cells|The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.
Three dose cohorts are planned:
Dose Level 1: 2x105 CAR19 T-cells/kg
Dose Level 2: 1x106 CAR19 T-cells/kg
Dose Level 3: 5x106 CAR19 T-cells/kg
237282|NCT00168337|Other|Sham|Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
236976|NCT02439255|Other|Laboratory Biomarker Analysis|Correlative studies
236977|NCT02439255|Dietary Supplement|Phytochemical|Given BRB nectar PO
236978|NCT02439255|Other|Placebo|Given PO
236979|NCT02439255|Other|Screening Questionnaire Administration|Ancillary studies
236980|NCT02439281|Drug|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
236981|NCT00000362|Behavioral|Thickened liquid administration|
236982|NCT00002461|Procedure|in vitro-treated bone marrow transplantation|
236983|NCT00169169|Drug|ACVBP|
237285|NCT02432014|Behavioral|PMTO Individual home-based|
237286|NCT02432014|Behavioral|PMTO Individual clinic-based|
237287|NCT02432014|Behavioral|Services as Usual|
237288|NCT02432027|Drug|C-82 Topical Gel, Placebo|placebo
237289|NCT02432027|Drug|C-82 Topical Gel, 1%|active
237290|NCT02432027|Drug|Daivonex cream|comparator
237291|NCT02432027|Drug|Diprosis gel|comparator
237292|NCT02432040|Drug|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
237293|NCT00168350|Drug|memantine|
237294|NCT02432040|Drug|Placebo|Placebo tablets, made to look like the interventional drug
237295|NCT02432053|Drug|Advagraf|
237296|NCT02432066|Drug|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
237297|NCT02432066|Drug|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
237298|NCT02432105|Drug|EXE844 Sterile Otic Suspension, 0.3%|
237299|NCT02434315|Device|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
236662|NCT02446522|Procedure|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
236663|NCT02446522|Procedure|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
236664|NCT02446535|Other|achievement of the DW by means of the BIA DW (RE.S.T.)|
236665|NCT00170001|Drug|Sugar Pill|40 mg BID
236666|NCT02446548|Drug|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
236984|NCT02439281|Drug|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
236985|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|
236986|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|
236987|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|
236988|NCT02439294|Device|CPAP|
236989|NCT02439307|Drug|Rifaximin|1200 mg of rifaximin for 2 weeks.
236990|NCT02439307|Drug|Placebo|Placebo for 2 weeks
236991|NCT02439320|Drug|Lasmiditan 100 mg|
236992|NCT02439320|Drug|Lasmiditan 200 mg|
236993|NCT02439320|Drug|Placebo (matches lasmiditan doses)|
236994|NCT00169169|Drug|ACE|
236995|NCT02439333|Device|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
236996|NCT00169312|Other|educational intervention|
236335|NCT02450812|Drug|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
236336|NCT02450825|Procedure|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
236337|NCT00170768|Drug|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
236338|NCT02450825|Procedure|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
236339|NCT02450825|Device|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
236340|NCT02450838|Biological|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
236341|NCT02450838|Biological|Alhydrogel™|Aluminum hydroxide gel adjuvant
236342|NCT02450838|Biological|Placebo|
236343|NCT02450864|Other|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
236344|NCT02450877|Drug|Azacitidine|
236345|NCT02450877|Other|Control Arm|
236667|NCT02446548|Drug|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
236668|NCT02446548|Other|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
236669|NCT02446561|Drug|MRXXX|
236670|NCT02446561|Drug|MR1XXX|
236671|NCT02446561|Drug|MR2XXX|
236672|NCT02446561|Drug|MR3XXX|
236038|NCT02455362|Drug|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
236039|NCT02455362|Drug|Placebo|
236040|NCT02455388|Dietary Supplement|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
236041|NCT02455388|Dietary Supplement|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
236042|NCT02457702|Other|Orally administered labeled glycerol|Oral administration of labeled glycerol
236043|NCT02457728|Device|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
236044|NCT02457780|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
236045|NCT02457780|Behavioral|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
236046|NCT02457793|Drug|Cobimetinib|
236047|NCT02457793|Drug|GD0-994|
236048|NCT02457806|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
236049|NCT00171795|Drug|Rivastigmine|
236050|NCT02457806|Drug|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
236051|NCT02457819|Drug|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
236346|NCT02450890|Drug|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
235443|NCT02431273|Drug|TDF IVR|
235444|NCT02431273|Drug|TDF-FTC IVR|
235445|NCT02431273|Drug|TDF-FTC-MVC IVR|
235446|NCT02431286|Drug|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
235447|NCT02431286|Drug|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
235750|NCT02461979|Other|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
235751|NCT02461992|Drug|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
235752|NCT02462018|Device|WalkAide|Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.
For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.
During the assessments each child will go through:
A. Medical interview and neurological and physical therapist examination. B. Motor function tests: "6 min walk test", Gross motor function measure (GMFM) ,"Timed up and down stairs test" (TUDS), walking on a ramp ,with and without the FES device.
C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.
E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES.
235753|NCT02462031|Drug|KD101|200mg, 400mg, 800mg, 1400mg
235754|NCT02462031|Drug|placebo|200mg, 400mg, 800mg
235755|NCT02462044|Drug|240 mg Iodine|
235756|NCT00172601|Procedure|mobilization|
235757|NCT02462044|Drug|300 mg Iodine|
235758|NCT02462044|Drug|370 mg Iodine|
235759|NCT02462057|Other|Email message regarding the HealthyFood benefit|
235760|NCT02462070|Drug|IDP-118|
235761|NCT02462083|Drug|IDP-118 Lotion|
235762|NCT02464358|Behavioral|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
235763|NCT02464358|Behavioral|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
235154|NCT00168818|Drug|enoxaparin|40 mg once daily
235155|NCT02435966|Other|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
235156|NCT02435979|Other|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
235157|NCT02438358|Device|LUM 2.6 Imaging Device|
235158|NCT02438371|Drug|Nifedipine|Nifedipine will be given for the treatment of preterm labor
235159|NCT02438371|Drug|Indomethacin|Nifedipine and indomethacin will be give for the treatment of pretermlabor
235160|NCT02438384|Behavioral|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
235161|NCT02438384|Behavioral|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
235162|NCT00169104|Drug|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
235163|NCT02438397|Drug|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
235164|NCT02438397|Drug|metformin|500 mg tid by Merck
235165|NCT02438397|Drug|Acarbose|100mg tid by Bayer
235448|NCT02431286|Drug|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
235449|NCT02431312|Biological|Group A: INO-1800 alone delivered by EP|
235450|NCT02431312|Biological|Group B: INO-1800 + INO-9112 delivered by EP|
235451|NCT02431312|Drug|Entecavir/Tenofovir|Continue treatment with ETV or TDF
235452|NCT00168285|Behavioral|Pulmonary Rehabilitation|
235453|NCT02431325|Drug|Teduglutide|
235454|NCT02431325|Drug|Placebo|
235455|NCT02431338|Procedure|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
234883|NCT02443285|Drug|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
234884|NCT02443285|Drug|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
234885|NCT02443298|Drug|Placebo|Matching Placebo
234886|NCT02443298|Drug|BI 655066|Monoclonal IgG Antibody
234887|NCT00169572|Drug|Aprepitant|
234888|NCT02443311|Drug|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
234889|NCT02443311|Drug|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
234890|NCT02443324|Drug|Ramucirumab|Administered IV
234891|NCT00169897|Behavioral|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
234892|NCT02445872|Drug|Palonosetron|
234893|NCT02445872|Drug|Dexamethasone|
234894|NCT02445885|Procedure|PCI|Guideline directed Percutaneous Coronary Intervention
234895|NCT02445898|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
234896|NCT02445898|Drug|Isotonic Sodium Chloride|Placebo
234897|NCT02445911|Drug|KQ-791|Capsules administered orally
234898|NCT02445911|Drug|Placebo|Capsules administered orally
234899|NCT02445937|Other|ICU Family Communication|The Comparator group for this Comparison Effectiveness Trial will receive an ICU Family Communication intervention delivered by key nurse/social workers within the ICU. The nurse/social worker interventionist will have received 4hours of training designed to aid in clinician-family communication. The nurse/social worker will touch base with families daily, attend to emotion, and facilitate a clinician-family meeting on or before day 4 of the ICU admission with at least the MD and family and nurse/social worker who acts as their advocate.
235166|NCT02438423|Biological|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
235167|NCT02438423|Other|Placebo|
234301|NCT02457026|Drug|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
234593|NCT02450162|Procedure|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
234594|NCT02450175|Drug|Everolimus|10 mg of Everolimus daily (by mouth)
234595|NCT02450175|Drug|Letrozole|2.5mg taken daily (by mouth)
234596|NCT00170677|Drug|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
234597|NCT02450188|Drug|Vardenafil|In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.
Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
234598|NCT02450188|Behavioral|CBST|The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.
On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.
CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
234599|NCT02450201|Drug|Pyruvate|
234600|NCT02450214|Drug|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
234601|NCT02450214|Drug|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
234602|NCT02450214|Drug|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
234603|NCT02452450|Drug|Ibuprofen Acid|
234604|NCT00170963|Drug|valsartan/amlodipine|
234605|NCT02452450|Drug|Ibuprofen Lysine|
234606|NCT02452450|Drug|Ibuprofen Sodium|
234607|NCT02452450|Drug|Ibuprofen Liquid Capsules|
234608|NCT02452450|Drug|Paracetamol|
234609|NCT02452463|Other|Laboratory Biomarker Analysis|Correlative studies
234610|NCT02452463|Drug|Nintedanib|Given PO
239010|NCT02461056|Drug|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
239011|NCT02461069|Drug|Dimethyl fumarate|Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
239012|NCT02461082|Device|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainsville, FL).
239013|NCT02463331|Drug|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
239014|NCT02463331|Drug|prednisone|
239015|NCT00173628|Procedure|blood drawing|
234302|NCT02457026|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
234303|NCT02457026|Drug|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
234304|NCT02457039|Procedure|Dense cranial electroacupuncture stimulation|DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.
Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz).
234305|NCT02457039|Procedure|Body acupuncture|Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered.
234306|NCT02457039|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
234307|NCT02457039|Drug|Cytoxan-containing chemotherapy regimens|Each subject shall receive either one of the below chemotherapy regimens, as decided by clinical oncologist:
AC (x4) [Adriamycin + Cytoxan], TC (x4) [Taxotere + Cytoxan], AC-P (4+4) [Adriamycin + Cytoxan + Paclitaxel], TAC (x6) [Taxotere + Adriamycin + Cytoxan], or AC-PH (4+4) [Adriamycin + Cytoxan + Paclitaxel + Herceptin].
234308|NCT02457052|Device|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
223253|NCT02166736|Device|iFR|Treatment guided by Instantaneous wave-free ratio (iFR®)
223254|NCT02166736|Device|FFR|Intervention guided by Fractional Flow Reserve
223255|NCT02166749|Procedure|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
223256|NCT02166762|Procedure|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
223257|NCT02166788|Procedure|Inguinal Lymphadenectomy|
223258|NCT02166788|Procedure|Ilio-inguinal Lymphadenectomy|
223259|NCT00135785|Drug|Bupropion|
223260|NCT02168920|Drug|3 mg/day|Once daily for 10 weeks
223261|NCT00136058|Drug|alendronate or risedronate|
223262|NCT02168920|Drug|6 mg/day|Once daily for 10 weeks
223263|NCT02168920|Drug|Placebo (0 mg/day)|Once daily for 10 weeks
223264|NCT02168933|Device|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
223265|NCT02168933|Device|Sham laser|Sham laser treatment to the control side.
223266|NCT02168946|Drug|Carbavance|Carbavance for IV injection, administered as a 2 g/2 g dose
223267|NCT02168946|Drug|Best Available Therapy|
223268|NCT02168959|Drug|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
223269|NCT02168972|Device|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
223270|NCT02168985|Behavioral|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
223271|NCT02168998|Behavioral|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
223599|NCT02161705|Drug|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
234356|NCT02463760|Other|Medical imaging|
234357|NCT02463773|Device|Ultrasound|Diaphragmatic excursion ultrasound assessment
234358|NCT02463786|Other|No intervention|No intervention
234359|NCT02463799|Drug|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
234360|NCT02463799|Biological|Sipuleucel-T|3 infusions of sipuleucel-T alone
234361|NCT02463812|Drug|Intralipid|
234362|NCT00173719|Device|Standard cane|
234363|NCT02463812|Drug|Saline|
234364|NCT02463825|Drug|Pimozide 2 mg per day|
234365|NCT02463825|Drug|Pimozide 4 mg per day|
234366|NCT02463825|Drug|Placebo (Lactose tablet)|
234367|NCT02463838|Other|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
234368|NCT02463851|Device|PVAC GOLD multielectrode catheter|Cardiac ablation for Atrial Fibrillation
234369|NCT02463851|Device|Contact Force single-tip ablation catheter|
234370|NCT02463864|Other|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
234371|NCT02463864|Other|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
234372|NCT02463877|Procedure|Minimally-Invasive Procedure|Laparoscopy
234373|NCT00173745|Drug|botulinum toxin A injection|
234374|NCT02463890|Other|Training|
234375|NCT02463890|Other|Control|
234376|NCT02463903|Behavioral|Coping Effectiveness Training (CET)|The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
234377|NCT02463916|Other|Exercise|8 week structured exercise programme
238766|NCT02437487|Drug|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
239081|NCT02430285|Procedure|Endoscopic Ultrasound|Endoscopic Ultrasound
239082|NCT02430285|Device|Olympus 180 series echoendoscope|
239083|NCT02430298|Drug|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
239084|NCT02430298|Drug|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
239085|NCT02430311|Drug|Olaparib|Tablet-150mg, Oral
239086|NCT02430311|Drug|Paclitaxel|Injection
239087|NCT02430311|Drug|Olaparib|Tablet-100mg, Oral
239088|NCT02430324|Other|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
239089|NCT02432560|Drug|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
239090|NCT02432573|Behavioral|Delayed rounds|
239091|NCT02432586|Behavioral|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
239092|NCT02432599|Radiation|F18-choline PET examination|F18-choline PET examination will be performed before surgery
239093|NCT02432612|Drug|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
239094|NCT00168428|Other|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
239095|NCT02432651|Drug|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
239096|NCT02432651|Drug|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
239097|NCT02432651|Drug|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
239098|NCT02432651|Drug|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
238501|NCT02444897|Drug|Epidural PCA Ropivacaine|Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.
Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S
238502|NCT02444897|Drug|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
238767|NCT00169000|Drug|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
238768|NCT02437500|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
238769|NCT02437513|Device|NewBreez|Intralaryngeal prosthesis to protect the airways
238770|NCT02437526|Other|Analytic treatment interruption|
238771|NCT02437539|Drug|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
238772|NCT02437539|Device|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
238773|NCT02437552|Device|ergometer cycle exercise|
238774|NCT02437552|Other|routine physiotherapy|routine physiotherapy
238775|NCT02437565|Other|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
238776|NCT02437565|Other|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
238777|NCT02439996|Drug|IVIG (1g/kg,once)|The KD children will be randomly assigned to three groups and receive three doses of IVIG (1g/kg once, 1g/kg twice, 2g/kg once). Patient age, gender, white blood cell count, hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be analyzed among the three groups. All the patients will be detected the 6 genes polymorphisms including ITPKC、CASP3、HLA、BLK、FCGR2A and CD40. The final outcome is the rates of IVIG unresponsiveness and the incidence of coronary artery lesions .
238778|NCT02439996|Drug|IVIG (1g/kg,twice)|The KD children will be randomly assigned to three groups and receive three doses of IVIG (1g/kg once, 1g/kg twice, 2g/kg once). Patient age, gender, white blood cell count, hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be analyzed among the three groups. All the patients will be detected the 6 genes polymorphisms including ITPKC、CASP3、HLA、BLK、FCGR2A and CD40. The final outcome is the rates of IVIG unresponsiveness and the incidence of coronary artery lesions .
238779|NCT02439996|Drug|IVIG (2g/kg.once)|The KD children will be randomly assigned to three groups and receive three doses of IVIG (1g/kg once, 1g/kg twice, 2g/kg once). Patient age, gender, white blood cell count, hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be analyzed among the three groups. All the patients will be detected the 6 genes polymorphisms including ITPKC、CASP3、HLA、BLK、FCGR2A and CD40. The final outcome is the rates of IVIG unresponsiveness and the incidence of coronary artery lesions .
238780|NCT02440009|Drug|Itraconazole|Oral itraconazole 200 mg BD for 6 months
238201|NCT02451527|Drug|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
238202|NCT02451540|Radiation|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
238203|NCT02451540|Drug|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
238204|NCT02451540|Drug|Roflumilast|Roflumilast, once a day in the morning during 3 months
238205|NCT02451553|Drug|Afatinib Dimaleate|Given PO
238206|NCT02451553|Drug|Capecitabine|Given PO
238207|NCT02451553|Other|Laboratory Biomarker Analysis|Correlative studies
238208|NCT02451566|Device|Ovation Prime Abdominal Stent Graft System|
238209|NCT02451579|Drug|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
238210|NCT00002463|Drug|Prednisone|
238211|NCT00170872|Drug|Lumiracoxib|
238503|NCT02444910|Drug|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
238504|NCT02444923|Device|Scleral rigid gas permeable contact lenses (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
238505|NCT02444923|Device|Corneal lenses (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
238506|NCT02444936|Drug|ZOSTAVAX|Shingles vaccine
238507|NCT02444949|Drug|endostar|
238508|NCT00169754|Other|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
238509|NCT02444949|Radiation|intensity modulated radiation|
238510|NCT02444949|Drug|cisplatin|
238511|NCT02444962|Device|HAVD-implant|
238512|NCT02444975|Dietary Supplement|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
238513|NCT02444975|Other|Coaching program|Coaching program to support increased water intake
237891|NCT02456285|Procedure|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
237892|NCT02456285|Procedure|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
237893|NCT02456285|Procedure|No surgery|Patients who have no surgery.
237894|NCT00171535|Drug|valsartan/amlodipine|
237895|NCT02456298|Behavioral|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
237896|NCT02456298|Behavioral|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
237897|NCT02456311|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
237898|NCT02456324|Device|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
237899|NCT02458365|Behavioral|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
237900|NCT02458391|Other|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
237901|NCT02458404|Drug|Estradiol Valerate|Participants will undergo three, separate "endometrial preparatory cycles". These cycles will consist of estrogen supplementation to mimic normal, above normal, and highly elevated estradiol levels.
237902|NCT02458404|Drug|Progesterone|Patients will receive 2 doses of 10mg of intramuscular progesterone on consecutive days
237903|NCT02458404|Drug|Leuprolide acetate|Patients will begin leuprolide acetate in the luteal phase of the cycle immediately preceding the study cycle in order to down regulate the pituitary during the treatment cycle.
238212|NCT02451579|Other|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
238213|NCT02451605|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
238214|NCT02451605|Procedure|Total knee replacement surgery.|Total knee replacement surgery.
238215|NCT02451631|Other|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
237283|NCT02432001|Procedure|Image-Guided Biopsies|
237284|NCT02432014|Behavioral|PMTO-PTC Group clinic-based|
237592|NCT02462707|Drug|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
237593|NCT02462720|Drug|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
237594|NCT02462720|Device|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
237595|NCT02462733|Behavioral|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
237596|NCT02462733|Behavioral|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
237597|NCT00173472|Drug|Chemotherapy|
237598|NCT02462746|Dietary Supplement|L-Cysteine|The trade name is New Root Herbal Inc.
237599|NCT02462759|Drug|ISIS-SMN RA|Administered by intrathecal injection.
237600|NCT02462759|Procedure|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
237601|NCT02462772|Drug|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
237602|NCT02462772|Drug|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
237603|NCT00174239|Drug|controlled-release levodopa / carbidopa|
237604|NCT02465034|Device|Sham Paired Associative Stimulation|The sham paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25Hz for 12 minutes. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
237605|NCT02465047|Other|Self-help booklet|See Arm/Group Description
237300|NCT02434328|Drug|RTH258 solution for IVT injection|Administered as a 6 mg/50 µL dose
237301|NCT02434328|Drug|Aflibercept solution for IVT injection|Administered as a 2 mg/50 µL dose
237302|NCT02434354|Drug|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
237303|NCT02434367|Behavioral|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
237304|NCT00168688|Dietary Supplement|multi micronutrient supplement|
237305|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
237306|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
237610|NCT02465060|Drug|Dasatinib|Given PO
237611|NCT02465060|Drug|Defactinib|Given PO
237612|NCT02465060|Other|Laboratory Biomarker Analysis|Undergo molecular analysis
237613|NCT02465060|Drug|Osimertinib|Given PO
237614|NCT00174252|Drug|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
237615|NCT02465060|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
237616|NCT02465060|Drug|Sunitinib Malate|Given PO
237617|NCT02465060|Drug|Taselisib|Given PO
237618|NCT02465060|Drug|Trametinib|Given PO
237619|NCT02465060|Biological|Trastuzumab Emtansine|Given IV
237620|NCT02465060|Drug|Vismodegib|Given PO
237621|NCT02465073|Device|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
237622|NCT02465073|Device|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
237623|NCT02465073|Device|Standard of Care Group|Subjects will receive Standard of Care only.
236997|NCT02441569|Behavioral|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
236998|NCT02441582|Other|Telemetry|
236999|NCT02441582|Other|Non-telemetry|
237000|NCT02441595|Behavioral|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
237001|NCT02441595|Behavioral|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
237002|NCT02441608|Device|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
237003|NCT02441621|Other|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
237004|NCT02441621|Other|premedication|patients receive premedication with midazolam 7.5 mg p.o.
237307|NCT02434406|Behavioral|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
237308|NCT02434419|Device|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
237309|NCT02434419|Other|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
237310|NCT02434432|Behavioral|music therapy selected by mothers|mothers' choice of music
237311|NCT02434432|Behavioral|Music therapy recorded lullaby|recorded lullaby
237312|NCT02434471|Device|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
Respiratory-triggered T1w DISCO LAVA precontrast
Respiratory-triggered T1w DISCO LAVA in the portal venous phase
Respiratory-triggered T1w DISCO LAVA in the equilibrium phase
237313|NCT02434497|Drug|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
237314|NCT02434523|Drug|Amitriptyline|
236673|NCT02446574|Drug|Paclitaxel|starting dose 20mg/m2 qw
236674|NCT02446574|Drug|Cisplatin|dose 25mg/m2 qw
236675|NCT02446574|Radiation|Radiation|60Gy/2Gy/30f
236676|NCT00170014|Device|Magnetocardiograph|
236677|NCT02446587|Device|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
236678|NCT02446600|Drug|Carboplatin|Given IV
236679|NCT02446600|Drug|Cediranib Maleate|Given PO
236680|NCT02446600|Drug|Gemcitabine Hydrochloride|Given IV
236681|NCT02448719|Drug|TAK-792 100 mg placebo|TAK-792 100 mg placebo will be administered in the morning after a fast.
236682|NCT02448719|Drug|TAK-792 250 mg|TAK-792 250 mg will be administered in the morning after a fast.
236683|NCT02448719|Drug|TAK-792 250 mg placebo|TAK-792 250 mg placebo will be administered in the morning after a fast.
236684|NCT02448719|Drug|TAK-792 500 mg|TAK-792 500 mg will be administered in the morning after a fast or after breakfast.
236685|NCT02448719|Drug|TAK-792 500 mg placebo|TAK-792 500 mg placebo will be administered in the morning after a fast or after breakfast.
236686|NCT02448719|Drug|TAK-792 750 mg|TAK-792 750 mg will be administered in the morning after a fast or after breakfast.
236687|NCT02448719|Drug|TAK-792 750 mg placebo|TAK-792 750 mg placebo will be administered in the morning after a fast or after breakfast.
236688|NCT02448719|Drug|TAK-792 1250 mg|TAK-792 1250 mg will be administered in the morning after a fast.
236689|NCT02448719|Drug|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo will be administered in the morning after a fast.
237005|NCT02441621|Other|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
237006|NCT02441621|Other|central venous catheter|a central venous catheter in the right or left internal jugular vein.
237007|NCT00002462|Biological|bleomycin sulfate|
236347|NCT02450890|Drug|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
236348|NCT00002463|Drug|Methotrexate|
236349|NCT00170768|Drug|Placebo|Placebo once daily tablet (sham titration)
236350|NCT02450903|Drug|LDK378|Oral LDK378 750mg once daily
236351|NCT02450942|Drug|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
236352|NCT02453230|Behavioral|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
236353|NCT02453243|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
236354|NCT02453243|Behavioral|A Lean Implementation Strategy|The Safety Planning Intervention will be implemented using Lean performance improvement strategies.
Sites will be trained on the Safety Planning Intervention and Lean.
236355|NCT00171067|Drug|lisinopril|
236356|NCT02453256|Drug|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
236357|NCT02453256|Drug|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment, followed by the same regimen for 48 weeks of open-label treatment.
236358|NCT02453269|Behavioral|Transdisciplinary program|
236359|NCT02453282|Biological|MEDI4736|
236360|NCT02453282|Biological|MEDI4736+Tremelimumab|
236361|NCT02453282|Drug|Paclitaxel + Carboplatin|Chemotherapy Agents
236362|NCT02453282|Drug|Gemcitabine + Cisplatin|Chemotherapy Agents
236363|NCT02453282|Drug|Gemcitabine + Carboplatin|Chemotherapy Agents
236364|NCT02453282|Drug|Pemetrexed + Cisplatin|Chemotherapy Agents
236365|NCT02453282|Drug|Pemetrexed + Carboplatin|Chemotherapy Agents
236366|NCT00171080|Drug|valsartan|
236367|NCT02453282|Biological|Tremelimumab|
235764|NCT02464371|Other|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
235765|NCT02464384|Procedure|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
235766|NCT02464397|Device|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
235767|NCT00173953|Procedure|immune response|
235768|NCT02464410|Behavioral|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
235769|NCT02464410|Behavioral|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
236052|NCT02457832|Behavioral|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
236053|NCT02457832|Behavioral|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
236054|NCT02457845|Biological|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
236055|NCT02457858|Drug|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
236056|NCT02457871|Behavioral|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
236057|NCT02457884|Other|Temporal Group|Visual Processing Training
236058|NCT02457884|Other|Spatial Group|Spatial visual span training
236059|NCT02457884|Other|Combined Group|Visual processing speed and spatial visual span training
236060|NCT00171808|Drug|Letrozole|
235456|NCT02431351|Drug|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
235457|NCT02431364|Drug|Verdinexor|
235458|NCT02431364|Other|Placebo|
235459|NCT02431377|Other|S-26 Gold|A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
235460|NCT02431390|Device|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
235461|NCT02431390|Behavioral|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
235462|NCT00168532|Drug|Sulfamethoxazole-Trimethoprim|
235463|NCT02433392|Procedure|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
235464|NCT02433405|Biological|Fetuin-A|Acute phase protein
235465|NCT02433405|Biological|Serum Amyloid A|Acute phase protein
235466|NCT02433418|Procedure|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
235467|NCT02433418|Drug|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
235468|NCT02433431|Behavioral|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
235469|NCT02433431|Behavioral|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
235770|NCT02464410|Other|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
235771|NCT02464423|Behavioral|Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)|
235772|NCT02464436|Drug|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
235773|NCT02464449|Behavioral|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
235168|NCT02438436|Dietary Supplement|simo decoction|
235169|NCT02438436|Other|gum chewing|
235170|NCT02438449|Procedure|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
235171|NCT02438462|Other|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
235172|NCT02438475|Device|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
235173|NCT00169104|Drug|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
235174|NCT02438475|Other|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
235175|NCT02438501|Radiation|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
235176|NCT02438501|Radiation|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
235177|NCT02438514|Other|Biological Sample Collection|Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.
Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.
Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits
235178|NCT02438527|Behavioral|Chart for CPR guidance|
235179|NCT02438540|Drug|metformin|
235180|NCT02438540|Other|acupuncture|Electro body acupuncture and auricular acupuncture
235181|NCT02440841|Drug|rifampicin|
235182|NCT02440867|Device|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
235183|NCT02440867|Device|Sham TBS|Sham stimulation
235184|NCT02440880|Drug|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
235185|NCT02440880|Drug|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
235186|NCT00002461|Radiation|radiation therapy|
234611|NCT02452463|Other|Placebo|Given PO
234612|NCT02452463|Procedure|Quality-of-Life Assessment|Ancillary studies
234613|NCT02452476|Drug|CHF5633|Rescue treatment (if needed)
234614|NCT02452476|Drug|Poractant alfa|Rescue treatment (if needed)
234900|NCT02445937|Behavioral|PARTNER II|The PARTNER intervention is a multifaceted intervention delivered by a trained "PARTNER Champion" who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists.
234901|NCT02445950|Behavioral|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
234902|NCT00169910|Drug|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
234903|NCT02445950|Behavioral|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
234904|NCT02445963|Biological|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
234905|NCT02445976|Drug|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
234906|NCT02445989|Drug|NuvaRing|Provide NuvaRing to women seeking contraception
234907|NCT02446002|Drug|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
234908|NCT02446015|Drug|SYSTANE® ULTRA Lubricant Eye Drops|
234909|NCT02446028|Drug|BIOD-531|
234910|NCT02446028|Drug|Humalog® Mix 75/25|
234911|NCT00170300|Device|Implantable Cardiac Resynchronisation (pacing) device|
234309|NCT02457065|Behavioral|Sun protection behaviors|We give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin-protective behaviors
234310|NCT00171691|Drug|Diclofenac Topical Sodium Gel 1%|
234311|NCT02457078|Dietary Supplement|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
234312|NCT02457078|Dietary Supplement|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
234313|NCT02459184|Other|Income Security Health Promotion|The ISHP will work to improve the income security of participants within this study. To that end, her activities include:
Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.
Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population
Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.
Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs.
234314|NCT02459197|Behavioral|Heat Pain Stimuli A|
234315|NCT02459197|Behavioral|Heat Pain Stimuli B|
234615|NCT00170976|Drug|valsartan + amlodipine|
234616|NCT02452489|Device|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
234617|NCT02452489|Device|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
234618|NCT02452489|Device|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
234619|NCT02452502|Device|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
234620|NCT02452515|Drug|BAY1142524|5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
234621|NCT02452515|Drug|BAY1142524|10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
234622|NCT02452515|Drug|BAY1142524|25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
234623|NCT02452515|Drug|BAY1142524|50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
234624|NCT02452515|Drug|Placebo|The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
234961|NCT02452567|Other|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose ~8-10% of their body weight through diet-intervention.
234962|NCT02452580|Other|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
234963|NCT02452593|Other|"Tibial stimulation" and "pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
234964|NCT00171002|Drug|valsartan/amlodipine|
234965|NCT02452606|Drug|Stalevo®|Sleep disorders in Parkinson's disease
Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.
If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective.
234966|NCT02452619|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
234967|NCT02452632|Drug|ASP1941|oral
234968|NCT02452632|Drug|Placebo|oral
234969|NCT02452645|Behavioral|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
234970|NCT02452645|Behavioral|Comparison Group|Written materials and books.
234971|NCT02452658|Other|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
234972|NCT02452684|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
234973|NCT02452697|Biological|NK Cell enriched-DLI only|The first NK cell-enriched DLI will be administered around 6 weeks post transplant. The second NK cell-enriched DLI will be administered around 8 weeks post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.
If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started.
235240|NCT02446171|Drug|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
235241|NCT02446171|Drug|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
235242|NCT02446171|Drug|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
235243|NCT02448160|Drug|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
234676|NCT02457208|Drug|Rifampicin (R)|
234677|NCT02457208|Drug|Pyrazinamide (Z)|
234678|NCT02457208|Drug|Ethambutol (E)|
234679|NCT02459301|Drug|IPH2201|
234680|NCT00172016|Drug|Zoledronic acid|
234681|NCT02459314|Dietary Supplement|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
234682|NCT02459314|Dietary Supplement|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
234683|NCT02459327|Behavioral|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
234684|NCT02459327|Behavioral|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
234685|NCT02459340|Other|therapeutic treatment (inpatient and outpatient setting)|
234686|NCT02459353|Drug|Dapagliflozin|
234687|NCT02459353|Drug|Placebo|
234688|NCT02459379|Radiation|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
234689|NCT02459392|Other|Epiduroscopy|Epiduroscopy has two main uses in the pain clinic:
Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.
Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots.
234690|NCT02459392|Drug|Hyaluronic Acid|
234691|NCT00002466|Radiation|radiation therapy|
234692|NCT00172029|Drug|Zoledronic acid|
239099|NCT02432664|Drug|ODM-108 Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
239100|NCT02432664|Drug|Placebo Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
234378|NCT02463929|Drug|Diphenhydramine|Intravenous Injection
234379|NCT02463929|Drug|normal saline|Intravenous Injection
234380|NCT02463929|Drug|Ketamine|Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
234381|NCT02463929|Drug|Sevoflurane|Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
234382|NCT02465944|Drug|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
234383|NCT02465957|Biological|aNK|A natural killer cell line recovered from a patient with large granular lymphoma
234384|NCT02465970|Device|STARSTIM|Multifocal transcranial direct current stimulation.
CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.
The stimulation is applied during a 60 min session
234385|NCT02465970|Device|sham TDCS|
234386|NCT02465983|Biological|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
234387|NCT02465983|Drug|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
234388|NCT00174382|Drug|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
234389|NCT02465996|Device|pCLE examination|All FD patients received pCLE examination.
234390|NCT02465996|Drug|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
234391|NCT02466009|Drug|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
234392|NCT02466022|Drug|Dexmedetomidine|Bolus dose prior to spinal anesthetic
234393|NCT02466022|Drug|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
234394|NCT02466022|Drug|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
238781|NCT00169221|Drug|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
238782|NCT02440009|Drug|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
238783|NCT02440022|Device|Lutonix DCB|
238784|NCT02440022|Device|Standard Balloon Angioplasty Catheter|
234088|NCT02432898|Device|CT-1P|Tonometry
234089|NCT02432898|Device|TRK-2P|Tonometry, Corneal Topography
234090|NCT02432898|Device|SP-1P|Specular Microscopy
234091|NCT02432898|Device|SL-D701|Slit Lamp Imaging
234092|NCT02432898|Device|MC-4S|Visual Acuity Testing
234093|NCT00002460|Procedure|oophorectomy|
234094|NCT00168480|Biological|Botulinum Toxin Type A|100 U, repeated treatments at > 4 month intervals up to Month 32, over a 36-month study period
234095|NCT02432911|Drug|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
234096|NCT02432911|Drug|low dose cytarabine|cytarabine 20mg bid for 10 days.
234097|NCT02432924|Behavioral|Instant + Multidimensional Physical Activity Feedback|
234098|NCT02432937|Drug|Corever|Corever
234099|NCT02432950|Dietary Supplement|Dietary Intervention|Participate in the PNP
234100|NCT02432950|Other|Educational Intervention|Participate in the PNP
234101|NCT02432950|Other|Laboratory Biomarker Analysis|Correlative studies
234102|NCT02432950|Other|Quality-of-Life Assessment|Ancillary studies
234103|NCT02432963|Other|Laboratory Biomarker Analysis|Correlative studies
234104|NCT02432963|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
234105|NCT02435459|Procedure|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
238514|NCT02444975|Other|No intervention|No intervention
238515|NCT02444988|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
238516|NCT02447146|Other|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
238517|NCT02447146|Other|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
238518|NCT02447159|Behavioral|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
238519|NCT02447172|Drug|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
238520|NCT02447172|Other|Placebo|Matching placebo sponge
238521|NCT02447185|Drug|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.
All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation.
238785|NCT02440035|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 in Group 3.
238786|NCT02440035|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 4.
238787|NCT02440035|Drug|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
238788|NCT02440048|Device|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
238789|NCT02440048|Device|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
238790|NCT02440061|Drug|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 1 μg/kg/hr continuous infusion for 4 hours.
238216|NCT02451631|Device|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
238217|NCT02451644|Device|pedometer|patient will cary pedometer
238218|NCT02451657|Other|No Intervention|No intervention was administered in this study
238219|NCT02451670|Behavioral|Wizard algorithm risk reduction advice|Wizard algorithm risk reduction advice is made available by web-based Clinical Decision Support algorithms estimate the patient's cardiovascular risk and quantify decreases in cardiovascular risk with appropriate management of out-of-control cardiovascular risk factors. The algorithms identify evidence-based treatment options to address each uncontrolled cardiovascular risk factor. Lifestyle treatment recommendations are also provided, when appropriate.
238220|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
238221|NCT02451683|Other|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
238222|NCT00170885|Drug|Everolimus|
238223|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
238224|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
238225|NCT02453802|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
238226|NCT02453802|Drug|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
238227|NCT02453802|Drug|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
238228|NCT02453815|Procedure|non-cardiac surgery|all surgical procedures except cardiac
238229|NCT02453815|Other|arterial catheter|arterial catheter
238230|NCT00171158|Drug|imatinib mesylate|
238522|NCT00170209|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
237606|NCT02465060|Drug|Afatinib|Given PO
237607|NCT02465060|Drug|Crizotinib|Given PO
237608|NCT02465060|Other|Cytology Specimen Collection Procedure|Optional correlative studies
237609|NCT02465060|Drug|Dabrafenib|Given PO
237904|NCT02458417|Device|ReCell|A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
237905|NCT02458417|Device|Full surface CO2 laser 200 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
237906|NCT02458417|Device|Full surface CO2 laser 150 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
237907|NCT00171873|Drug|Placebo|Sodium chloride intramuscularly every 28 days
237908|NCT02458417|Device|Fractional CO2 laser 7.5 mJ, 20%|Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
237909|NCT02458443|Other|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
237910|NCT02458456|Other|Isometric resistance training|Isometric exercise using a hand dynamometer.
237911|NCT02458469|Drug|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
237912|NCT02458469|Drug|Trazodone|100 mg dose before bed-time
237913|NCT02458469|Drug|Placebo|One placebo pill before bed-time
237914|NCT02458482|Device|AccuPAP|With nasal clips on, AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
237915|NCT02458482|Drug|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
237916|NCT02458495|Behavioral|Diabetes MAP Intervention|
237624|NCT02465086|Other|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
237625|NCT00002471|Drug|etoposide|
237626|NCT00174265|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
237627|NCT02465099|Device|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) posterior spinal fusion (PSF)
237628|NCT02465099|Device|Electrocautery Dissection (ED)|Electrocautery dissestion will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) posterior spinal fusion (PSF)
237629|NCT02465112|Drug|In111-Pentetréotide|
237630|NCT02429544|Other|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
237631|NCT02429544|Behavioral|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
237632|NCT02429557|Other|Abdominal compression with inflatable cuff|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
237921|NCT02460536|Behavioral|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
237922|NCT00172172|Drug|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
237923|NCT02460536|Behavioral|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
237924|NCT02460549|Behavioral|therapeutic education program|
237925|NCT02460562|Device|S-PRG filler|Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.
The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567.
237926|NCT02460562|Device|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
237927|NCT02460575|Biological|Lactobacillus reuteri 17938|probiotic
237928|NCT02460588|Drug|Cyclophosphamide|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2
237315|NCT00168688|Dietary Supplement|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
237316|NCT02434549|Drug|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
237317|NCT02434549|Drug|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
237318|NCT02434562|Other|Serum (with or without urine) samples|
237319|NCT02434588|Device|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
237320|NCT02436863|Procedure|Surgical performance|Two different surgical performances
237321|NCT02436876|Drug|MBN-101|MBN-101 is a locally administered, anti-infective drug product
237322|NCT02436876|Other|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
237323|NCT02436889|Drug|Mirabegron|
237324|NCT02436889|Drug|Tolterodine Tartrate|
237325|NCT00168896|Drug|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
237326|NCT02436902|Procedure|TACE|
237327|NCT02436902|Drug|Sorafenib|
237633|NCT02429557|Other|Sham abdominal compression with inflatable cuff|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
237634|NCT02429570|Drug|Meclofenamate|
237635|NCT02429583|Drug|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
237636|NCT02429596|Drug|Experimental|Switch from brand to generic
237637|NCT02429609|Device|Moorfields Acuity Chart|
237638|NCT02429622|Radiation|IMRT simultaneous integrated boost|Radiation: Radical Chemoradiation Radiation: Radical Radiation Drug: Paclitaxel Drug: Nedaplatin Surgery: Radical Surgery
237639|NCT00167947|Drug|Rapamune (Sirolimus)|Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
237008|NCT00169312|Other|internet-based intervention|
237009|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
237010|NCT02441621|Other|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
237011|NCT02441621|Other|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
237012|NCT02441647|Device|KL029 Intimate Lubricant Gel|
237013|NCT02441660|Drug|Capsaicin 8% Patch|Applied topically for 1 hour
237014|NCT02441660|Drug|Low Dose Capsaicin 0.04% gel|
237015|NCT02441673|Drug|Nefopam|
237016|NCT02441673|Drug|Tramadol|
237017|NCT02441673|Drug|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
237018|NCT02441673|Drug|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
237019|NCT00169312|Other|preventative dietary intervention|
237020|NCT02444130|Device|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
237021|NCT02444143|Drug|tacrolimus extended release|
237022|NCT02444156|Other|Indoor rowing|
237023|NCT02444169|Device|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
237024|NCT02444169|Drug|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
237025|NCT02444169|Device|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
237328|NCT02436902|Drug|TACE plus sorafenib|
237329|NCT02436902|Procedure|transarterial chemotherapy plus embolization|
236690|NCT02448732|Drug|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
236691|NCT00170404|Drug|Vitamin A|
236692|NCT02448745|Device|Insecticide treated wall lining|Polypropylene non-woven fabric.
236693|NCT02448771|Drug|Palbociclib|
236694|NCT02448771|Drug|Bazedoxifene|
236695|NCT02448784|Drug|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
236696|NCT02448797|Drug|Icotinib|125 mg three times daily (375 mg per day) orally, until disease progression or untolerable toxicity.
236697|NCT02448797|Drug|Chemotherapy|vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.
cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.
236698|NCT02448810|Biological|BAX69 + infusional 5-FU/LV|Study Part 1: Safety Run-in
Administered weekly as part of a 4 week treatment cycle
Intravenous injection
236699|NCT02448810|Biological|BAX69 + panitumumab|Study Part 1: Safety Run-in
Administered weekly as part of a 4 week treatment cycle
Intravenous injection
236700|NCT02448810|Biological|BAX69 + 5-FU/LV|
236701|NCT02448810|Biological|BAX69 + panitumumab|
236702|NCT00170417|Behavioral|Cognitive Behaviour Therapy|
236703|NCT02448810|Drug|Standard of Care|Investigator's choice
Dose according to drug label
236704|NCT02448810|Biological|Standard of Care|Investigator's choice
Dose according to drug label
Choice includes panitumumab in KRAS &NRAS wt group only
236705|NCT02450955|Other|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
236706|NCT02450955|Other|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
236707|NCT02450968|Drug|Dexamethasone|
236708|NCT02450968|Drug|Placebo|
236061|NCT02459821|Other|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
236062|NCT02459821|Other|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
236063|NCT02459834|Other|Allulose|A double-blind, randomized, multiple-crossover "non-inferiority or equivalence" design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle.
236064|NCT00172094|Drug|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
236065|NCT02459834|Other|Fructose|A double-blind, randomized, multiple-crossover "non-inferiority or equivalence" design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle.
236066|NCT02459834|Other|Control|A double-blind, randomized, multiple-crossover "non-inferiority or equivalence" design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle.
236368|NCT02453295|Behavioral|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
236369|NCT02453308|Drug|ACT|Artemether-lumefantrine for 3 days
Dihydroartemisinin-piperaquine for 3 days.
236370|NCT02453308|Drug|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.
Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.
236371|NCT02453321|Procedure|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
236372|NCT02453321|Procedure|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
236373|NCT02453321|Procedure|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
235774|NCT02464449|Behavioral|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
235775|NCT02464462|Dietary Supplement|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
235776|NCT02464462|Other|Placebo|Rice powder pills
235777|NCT02464475|Other|osteopathic manipulative treatment|
235778|NCT00002471|Drug|dexamethasone|
235779|NCT00173992|Behavioral|Balance and Exercise|
235780|NCT02464475|Other|sham osteopathic treatment|
235781|NCT02464488|Other|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
235782|NCT02464501|Other|Paclitaxel administration using the OPC|
235783|NCT02464514|Other|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
235784|NCT02464514|Other|High fat meal|58% fat, 17% protein, and 25% carbohydrate
235785|NCT02428777|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
235786|NCT02428803|Other|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
235787|NCT02428816|Other|MRI acquisition|MRI acquisitions
235788|NCT02428816|Behavioral|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
235789|NCT02428829|Procedure|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
236067|NCT02459847|Behavioral|Mindfulness Training|
236068|NCT02459847|Behavioral|Sonographic Biofeedback|
236069|NCT02459847|Other|Standard Care|
235470|NCT02433431|Behavioral|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
235471|NCT02433444|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
235472|NCT02433457|Drug|CC-292|
235473|NCT00168545|Biological|Measles vaccine|
235474|NCT02433457|Drug|Oral Omeprazole (OMP)|
235475|NCT02433470|Device|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
235476|NCT02433483|Drug|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
235477|NCT02433483|Drug|Intrathecal Triples|given IT.
235478|NCT02433483|Biological|HPC-A|Given IV.
235479|NCT02433496|Other|Physician coaching|The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.
The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice.
235480|NCT02433509|Other|Human Umbilical Cord Blood mononuclear cells and 20% mannitol|The cord blood need to be infusion within 72 hours after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.
20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion .
235481|NCT02433522|Drug|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
235482|NCT02433522|Drug|Placebo|
235483|NCT02433535|Drug|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
235484|NCT02435979|Other|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
235485|NCT02435992|Drug|RPC1063|
235486|NCT02435992|Drug|Placebo|
235487|NCT02436018|Device|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
234912|NCT02448030|Other|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
234913|NCT02448030|Other|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
235187|NCT00169286|Procedure|Telephone care management|
235188|NCT02440880|Drug|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
235189|NCT02440880|Drug|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
235190|NCT02440880|Other|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
235191|NCT02440893|Other|Corus CAD|Collection of second Corus CAD sample post-metformin exposure
235192|NCT02440906|Behavioral|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
235193|NCT02440906|Behavioral|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
235194|NCT02440919|Other|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
235195|NCT02440919|Other|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
235196|NCT02440919|Other|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
235197|NCT02440919|Other|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
235198|NCT00169286|Procedure|peer-led chronic disease self-management workshop|
235199|NCT02440932|Dietary Supplement|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
235200|NCT02440932|Other|Normal (control) diet|Breakfast, lunch and open buffet dinner
234625|NCT02452528|Drug|ARC-520|
234626|NCT00170989|Drug|valsartan plus hydrochlorothiazide|
234627|NCT02452528|Drug|Placebo|
234628|NCT02452528|Drug|Entecavir|0.5 or 1.0 mg/day orally
234629|NCT02452528|Drug|Tenofovir|300 mg/day orally
234630|NCT02452541|Other|Prognostic tests|Brain CT-Scan on day 1, 3 and 7
Brain MRI on day 7
SomatoSensory Evoked Potentials on day 7
Electroencephalogram on day 7
Serum biomarkers on day 1, 3 and 7
Daily clinical exams
234631|NCT02454608|Drug|Verapamil HCl|Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
234632|NCT02454608|Other|Placebo|Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
234633|NCT02454621|Behavioral|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
234634|NCT02454634|Drug|IDH1 peptide vaccine|
234914|NCT02448043|Drug|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
234915|NCT02448043|Other|placebo: saline|Placebo drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
234916|NCT02448069|Drug|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
234917|NCT02448082|Other|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
234918|NCT02448082|Other|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
234919|NCT02448095|Drug|Ponatinib|Observation of tolerability and safety profiles
234920|NCT02448108|Behavioral|i-IPSRT|internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.
CH will have participated in a two day training about Bipolar Disorder and IPSRT.
234921|NCT02448108|Other|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
235244|NCT02448173|Biological|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
235245|NCT02448173|Procedure|Surgery|Surgical resection of Stage II colon cancer
235246|NCT02448186|Behavioral|ESTEEM|10-session cognitive behavioral treatment
235247|NCT00170326|Device|Device implantation|Conventional Pacing vs biventricular pacing
235248|NCT02448199|Drug|Meloxicam and Glucosamine|Experimental
235249|NCT02448199|Drug|Meloxicam|Active Comparator
235250|NCT02448199|Drug|Glucosamine|Active Comparator
235251|NCT02448212|Drug|TS-121|Oral
235252|NCT02448212|Drug|[11C]TASP0410699|Intravenous radiotracer
235253|NCT02448212|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
235254|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
235255|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FSPG PET/CT
235256|NCT02448225|Radiation|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
235257|NCT02448225|Radiation|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
235258|NCT00002462|Radiation|radiation therapy|
235259|NCT00170352|Procedure|Hyperbaric Oxygen Treatment (HBOT)|
235260|NCT02448225|Other|Laboratory Biomarker Analysis|Correlative studies
235261|NCT02448225|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
235262|NCT02448225|Procedure|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
235550|NCT02441088|Drug|90Y-DOTA-tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used in this a dosimetry-guided theranostics trial for both children and adults with neuroendocrine and other somatostatin receptor positive tumors. Each subject will receive three doses of 90Y-DOTATOC.
235551|NCT02441088|Radiation|Dosimetry-Guided Peptide Receptor Radiotherapy|90Y-DOTATOC delivers radiation to rumor cells that express somatostatin receptors.The dose of 90Y-DOTATOC administered in this dosimetry-guided theranostics trial will be determined by dosimetry that estimates the amount of radiation delivered to the kidneys during treatments one and two.
234693|NCT02459392|Drug|DepoMedrol|
234974|NCT02452697|Biological|NK-DLI + DUK-CPG-001|DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.
On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI.
234975|NCT00171015|Drug|valsartan plus hydrochlorothiazide|
234976|NCT02452710|Other|Placebo|Open-label placebo
234977|NCT02452723|Biological|ISC-hpNSC|
234978|NCT02452736|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
234979|NCT02454777|Other|Questionnaire Administration|Ancillary studies
234980|NCT02454790|Radiation|Radiotherapy|
234981|NCT02454816|Device|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
234982|NCT02454816|Device|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
234983|NCT02454829|Other|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
234984|NCT02454842|Drug|TH-4000|TH-4000 is a hypoxia-activated prodrug
234985|NCT02454855|Drug|melatonin|Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line chemotherapy.
Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg.
234986|NCT02454855|Drug|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line chemotherapy.
234987|NCT00171340|Drug|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
234395|NCT02466022|Drug|Fentanyl|Intrathecal Fentanyl 10ug
234396|NCT02466022|Drug|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
234397|NCT02466035|Dietary Supplement|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
234694|NCT02459405|Procedure|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
234695|NCT02459405|Device|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
234696|NCT02459418|Drug|Afolia|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:
Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
234697|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
234698|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
234699|NCT02461485|Other|Non fermented Milk Product|2 pots/day during 28 days
234700|NCT02461511|Other|Therapeutic Education|participation in a therapeutic education program on diabetes
234701|NCT02461524|Device|Endurant Evo AAA Stent Graft System|
234702|NCT00172445|Procedure|blood sampling, neck lymph node biopsy|
234703|NCT02461524|Procedure|Endovascular aneurysm repair (EVAR)|
234704|NCT02461537|Drug|Cytarabine|high-dose cytarabine 3 g/m2 (days 1-3)/
234705|NCT02461537|Drug|Mitoxantrone|mitoxantrone 10mg/m2 (days 3-5)
234706|NCT02461550|Device|Irreversible Electroporation Ablation|
234707|NCT02461563|Drug|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
234708|NCT02461563|Drug|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
234709|NCT02461563|Drug|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
234710|NCT02461576|Device|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
234106|NCT02435459|Procedure|RMGI cement|placement of lining material under amalgam dental restorations
234107|NCT02435459|Procedure|Resin Bonding Agent|placement of lining material under amalgam dental restorations
234108|NCT00168792|Drug|Tenecteplase|
234109|NCT02435472|Behavioral|Supervised Exercise|This Phase 2, open-label, dual-center, two-arm randomized controlled trial (RCT) will investigate the effects of 24 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance (n=74 will be recruited at MSKCC, for a total of 150 patients across both sites). The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.
234110|NCT02435485|Device|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
234398|NCT02466048|Procedure|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
234399|NCT00174395|Drug|eletriptan|
234400|NCT02466048|Device|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
234401|NCT02466061|Behavioral|Telemedicine Weight Management plus Wi-Fi Scale (Arm A)|Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
234402|NCT02466061|Behavioral|Text for Diet (Text4Diet) Group (Arm B)|Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
234403|NCT02430701|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
234404|NCT02430701|Device|NanoKnife|
234405|NCT02430714|Drug|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
234406|NCT02430740|Drug|recFSH|
234407|NCT00168116|Procedure|radiation alone|
234408|NCT02430753|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
234409|NCT02430753|Device|NanoKnife|
238791|NCT02440061|Drug|Synthetic human DAG|Synthetic human DAG (1.1 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4 hours.
238792|NCT02442284|Drug|Ombitasvir|
238793|NCT02442284|Drug|Paritaprevir|
238794|NCT02442284|Drug|Ritonavir|
238795|NCT02442284|Drug|Dasabuvir|
238796|NCT02442284|Drug|Ribavirin|
238797|NCT02442297|Genetic|HER2-specific T cells|Dose Level 1: 1x10^7 cells
Dose Level 2: 3x10^7 cells
Dose Level 3: 1x10^8 cells*
* due to volume restriction, this dose will be given in two 5x10^7 cells aliquots on two successive days
The initial safety profile will be done at 6 weeks following the HER2-specific T-cell infusion. If the patient has documented stable disease or a response by the RECIST criteria evaluations they are eligible to receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the cell number at the highest safety established dose level.
238798|NCT02442310|Drug|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
238799|NCT02442310|Drug|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
238800|NCT02442323|Behavioral|Walking Intervention|12-week walking program
238801|NCT02442336|Behavioral|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
234111|NCT02435485|Other|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
234112|NCT02435498|Other|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
234113|NCT02435498|Other|Video|The online video will contain the same information within the website.
234114|NCT02435498|Other|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
234115|NCT02435511|Other|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
238523|NCT02447185|Drug|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.
During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.
All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation.
238524|NCT02447211|Drug|Doxepin cream 5%|Patients use doxepin creamtwice daily for one weeks
238525|NCT02447211|Other|Placebo|Patients use cream without doxepin ingredient twice daily for one weeks
238526|NCT02447224|Drug|1 gm IV ertapenem at enrollment|
238527|NCT02447224|Drug|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
238528|NCT02447224|Procedure|Appendectomy|
238529|NCT02447237|Other|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
238530|NCT02447250|Drug|Varied albuterol dose response|Subjects will be evaluated in three sessions. The sessions will occur within a 7 day time span, beginning between 14-28 days of life. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
238531|NCT02447263|Procedure|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
238532|NCT02447276|Drug|REGN475|
238533|NCT00170209|Drug|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
238534|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
238535|NCT02449382|Procedure|continuous venovenous hemofiltration|If the serum sodium concentration >150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
238536|NCT02449382|Drug|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
238537|NCT02449408|Other|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
238538|NCT02449421|Behavioral|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
237917|NCT02460523|Procedure|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
237918|NCT02460523|Procedure|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
237919|NCT02460536|Behavioral|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
237920|NCT02460536|Behavioral|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
238231|NCT02453828|Procedure|Non-cardiac surgery|patients having non-cardiac surgery
238232|NCT02453841|Drug|Oxymetazoline|
238233|NCT02453854|Behavioral|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
238234|NCT02453867|Other|Reduce immunosuppression|Carry on tacrolimus (Advagraf, trough levels > 5ng/ml) Stop steroids at month 3 Stop mycophenolate at month 6
238235|NCT02453867|Drug|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
238236|NCT02453867|Drug|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
238237|NCT02453867|Drug|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
238238|NCT02453880|Behavioral|Web-based Cognitive Behavioral Therapy|Participants will be asked to complete a web-based cognitive behavioral therapy "self-help" program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session.
238239|NCT02453893|Drug|Iloperidone|
238240|NCT02453893|Drug|Risperidone|
238241|NCT00171171|Drug|deferasirox|
238242|NCT02453906|Other|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
238243|NCT02453906|Other|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
238244|NCT02453906|Other|Control 2|stimulation at 5 control points
237929|NCT02460588|Drug|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
237930|NCT02460588|Drug|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
237931|NCT02460601|Drug|Qizhiweitong granule|
237932|NCT02460614|Procedure|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
237933|NCT00172172|Drug|placebo|Placebo injected subcutaneously and 700 mg calcium orally
237934|NCT02460614|Procedure|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
237935|NCT02460614|Other|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
237936|NCT02460627|Drug|Lidocaine adhesive tape|700 mg for 12 hours
237937|NCT02460627|Other|Adhesive tape|For 12 hours
237938|NCT02462785|Behavioral|In-person Carbohydrate Counting Class|An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
238253|NCT02456350|Drug|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
238254|NCT00171561|Drug|valsartan/hydrochlorothiazide|
238255|NCT02456350|Biological|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
238256|NCT02456363|Biological|TNF alpha|Depending on patient need to use different TNF alpha
238257|NCT02456363|Drug|NSAIDs and sulfasalazine|randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
238258|NCT02456376|Procedure|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
238259|NCT02456376|Procedure|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
238260|NCT02456389|Other|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
238261|NCT02456389|Other|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
237640|NCT02429635|Behavioral|My exercise|Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.
Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.
Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan
237641|NCT02429648|Procedure|DCC first then PVI|DCC performed prior to PVI
237642|NCT02429648|Procedure|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
237643|NCT02429661|Behavioral|Peer support groups|
237644|NCT02429674|Behavioral|IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
237645|NCT02429687|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours
237646|NCT02429687|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
237647|NCT02429687|Drug|Bleomycin|Bleomycin 30000IU IV/IM on day 1/8/15 for 12 weeks.
237648|NCT02429687|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles.
237649|NCT02429687|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
237650|NCT02432105|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
237939|NCT02462785|Behavioral|Online Carbohydrate Counting Tutorial|A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
237940|NCT02462798|Other|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
237941|NCT02462798|Other|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
237942|NCT02462811|Drug|CL-108|
237330|NCT02436915|Other|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
237331|NCT02436915|Other|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
237332|NCT02436928|Biological|AT-501 High Dose vaccine|Comparison of each dose of vaccine
237333|NCT02436928|Biological|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
237334|NCT02436928|Biological|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
237335|NCT02436928|Biological|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
237336|NCT00168909|Drug|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
237337|NCT02436941|Radiation|Proton or Photon|
237338|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 8 mmHg|
237339|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 12 mmHg|
237340|NCT02436967|Other|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
237341|NCT02436980|Drug|Tramadol|GROUP T
237342|NCT02436980|Drug|Midazolam|GROUP M
237343|NCT02436993|Drug|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
237344|NCT02436993|Drug|Paclitaxel|80 mg/m^2 IV over 1-3 hours weekly for 12 doses
237345|NCT02436993|Drug|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
237346|NCT02436993|Drug|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
237347|NCT02439333|Device|nasal catheter or Venturi mask|Conventional oxygen therapy
237348|NCT02439346|Drug|BAY1143269|BAY1143269 will be given orally at a starting dose of 5 mg once daily. Each treatment cycle will last 21 days.
237349|NCT02439346|Drug|BAY1143269|BAY1143269 will be given orally at the MTD (to be determined from Arm 1) once daily. Each treatment cycle will last 21 days.
236709|NCT02450981|Drug|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
236710|NCT02450994|Drug|Dexamethasone|
237026|NCT02444169|Device|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
237027|NCT02444182|Dietary Supplement|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
237028|NCT02444182|Dietary Supplement|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
237029|NCT00169676|Other|observation|registry and database for surgery outcomes
237030|NCT02444195|Behavioral|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
237031|NCT02444208|Behavioral|Active Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of cocaine cues.
237032|NCT02444208|Behavioral|Neutral Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of neutral cues.
237033|NCT02444234|Drug|Tedizolid PO/IV|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
237034|NCT02444234|Drug|Tedizolid IV/PO|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
237035|NCT02444247|Other|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
237036|NCT02444247|Other|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
237037|NCT02444247|Other|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
237038|NCT02444247|Other|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
237039|NCT02444260|Drug|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
237040|NCT00169689|Procedure|rTMS, "repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
236374|NCT02453321|Drug|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
236375|NCT02455401|Drug|High dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
236376|NCT02455401|Drug|Low dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
236377|NCT02455401|Drug|No remifentanil|Intervention: no remifentanil will be administrated
236378|NCT02455427|Device|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
236379|NCT02455427|Other|Physical Therapy|Physical therapy will be administered for 60 minutes
236380|NCT02455427|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
236381|NCT00171418|Drug|Tegaserod|
236382|NCT02455440|Drug|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
236383|NCT02455440|Drug|Placebo|
236384|NCT02455440|Drug|Propofol and sevoflurane|
236385|NCT02455453|Drug|FFNP|Positron Emission Tomography / Computed Tomography (PET/CT) Scan
236711|NCT02450994|Drug|Placebo|
236712|NCT02451007|Drug|lurbinectedin (PM01183)|
236713|NCT00170781|Drug|Lumiracoxib|
236714|NCT02451020|Other|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
236715|NCT02451033|Drug|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
236716|NCT02451033|Drug|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
236717|NCT02451033|Drug|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
236070|NCT02459860|Behavioral|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
236071|NCT02459860|Behavioral|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
236072|NCT02459873|Behavioral|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
236073|NCT02459886|Drug|BIIB054|IV infusion
236074|NCT02459886|Drug|Placebo|IV infusion
236075|NCT00172094|Drug|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
236076|NCT02459899|Drug|Placebo|Placebo, once daily, before the first meal of the day
236077|NCT02459899|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
236078|NCT02459899|Drug|Sotagliflozin|Middle dose Sotagliflozin,once daily, before the first meal of the day
236079|NCT02459899|Drug|Sotagliflozin|High dose Sotagliflozin,once daily, before the first meal of the day
236080|NCT02462096|Device|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
236081|NCT02462109|Drug|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.
236082|NCT02462122|Drug|IDP-118 Lotion|
236083|NCT02462135|Behavioral|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
236084|NCT02462135|Behavioral|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
236085|NCT00172653|Procedure|functional tasks|
236386|NCT02455479|Biological|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
235488|NCT02436018|Device|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
235790|NCT02428829|Procedure|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
235791|NCT00167869|Behavioral|dairy peptides|
235792|NCT02428842|Procedure|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
235793|NCT02428842|Procedure|Blood sampling|Blood sampling will be performed before and after treatment.
235794|NCT02428855|Drug|Dasatinib|
235795|NCT02428868|Drug|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
235796|NCT02428868|Drug|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
235797|NCT02428868|Other|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
235798|NCT02428881|Drug|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
235799|NCT02428894|Device|LVAD|
235800|NCT02428907|Behavioral|simulation training|teamtraining of endoscopy staff
235801|NCT02428920|Behavioral|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
235802|NCT00167882|Drug|5-aminosalicylate (Pentasa, Ferring)|
235803|NCT02428933|Drug|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
235804|NCT02428946|Drug|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
235805|NCT02431403|Drug|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
235806|NCT00168298|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
235807|NCT02431416|Drug|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
235808|NCT02431416|Drug|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
235201|NCT02440945|Device|Collection of blood|Blood test on blotting paper DBS (for the patients recruting)
235202|NCT02440958|Drug|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
235203|NCT02440971|Device|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
235204|NCT02443324|Drug|Pembrolizumab|Administered IV
235205|NCT02443337|Drug|LY3023414|Administered orally
235206|NCT02443337|Drug|Necitumumab|Administered IV
235489|NCT02436031|Drug|Desipramine|200 mg administered 2 hour before normal sleep time
235490|NCT02436031|Drug|Placebo|
235491|NCT02436044|Procedure|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
235492|NCT00168831|Drug|Tiotropium Inhalation Solution|
235493|NCT02436044|Drug|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
235494|NCT02436044|Drug|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
235495|NCT02436044|Drug|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
235496|NCT02436057|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|
235497|NCT02436070|Behavioral|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
235498|NCT02436070|Behavioral|General text messages|Subjects received text messages generalized to children with asthma
235499|NCT02436083|Drug|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
235500|NCT02436096|Drug|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
235501|NCT02436096|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
234922|NCT00170313|Device|Conducted AF-Response Algorithm|
234923|NCT02448121|Procedure|Stem Cell Graft Group|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
234924|NCT02448121|Biological|Autologous bone marrow stem cell|Bone marrow ficoll separated mononuclear autologous cells. Autologous bone marrow cells collection under sedation, then processed through a ficoll gradient.
234925|NCT02448134|Behavioral|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
234926|NCT02448147|Behavioral|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
234927|NCT02448147|Behavioral|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
234928|NCT02448160|Device|alfapump|Implantation of alfapump
234929|NCT02450227|Dietary Supplement|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
234930|NCT02450227|Dietary Supplement|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
234931|NCT02450240|Behavioral|standardized diagnostic assessment|
234932|NCT02450240|Behavioral|self-report questionnaires|
235207|NCT02443363|Other|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
235208|NCT02443363|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
235209|NCT02443376|Device|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
235210|NCT02443376|Device|BCM- Body Composition Monitor|BCM - Body Composition Monitor gives information about:
Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)
235211|NCT00169572|Drug|Ondansetron|
235212|NCT02443402|Drug|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) < 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
235213|NCT02443402|Drug|Placebo|One pill daily until discharge
235552|NCT02441088|Drug|Aminosyn II|Aminosyn II is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
235553|NCT00169299|Drug|Black cohosh|
235554|NCT02441101|Device|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
235555|NCT02443467|Other|No intervention|
235556|NCT02443493|Device|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
235557|NCT00169572|Drug|GW679769|
235558|NCT02443493|Device|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
235559|NCT02443493|Radiation|radiotherapy|
235560|NCT02443506|Drug|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
235561|NCT02443506|Drug|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
235562|NCT02443519|Behavioral|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
235563|NCT02443532|Behavioral|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
235564|NCT02443532|Behavioral|Individual education|Usual care (individual consultations as routinely performed)
235565|NCT02443545|Drug|Deferiprone|
235566|NCT02443558|Other|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
235567|NCT02443558|Device|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
235867|NCT02436356|Device|Osteoprobe-RPI|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
235868|NCT02436356|Radiation|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
234988|NCT02454868|Drug|Remifentanil|Remifentanil for intubation without neuromuscular blockade
234989|NCT02454881|Drug|Dexmedetomidine|
234990|NCT02454881|Drug|Oxycodone|
235263|NCT02448238|Other|VSL#3® probiotic|Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special "canari", a commonly used earthenware water container also containing sand that works on the principal of "trans-evaporation" to keep contents at room temperature (~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator
235264|NCT02448251|Drug|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
235265|NCT02448264|Drug|BCX7353|
235266|NCT02448264|Drug|Placebo to match BCX7353|
235267|NCT02448277|Device|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
235268|NCT02448277|Device|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
235269|NCT02448277|Device|Glidescope|the device is to assist the nasotracheal tube into trachea
235270|NCT02450344|Behavioral|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
235271|NCT02450344|Behavioral|Passive health promotion|An electronic package of information related to alcohol
235272|NCT02450357|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
235273|NCT02450357|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
235274|NCT02450370|Behavioral|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
235275|NCT02450370|Behavioral|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
235276|NCT02450383|Procedure|Surgical endosseous dental implant placement with simultaneous buccal autologous subepithelial connective tissue graft|
235277|NCT02450383|Procedure|Surgical endosseous dental implant placement with simultaneous buccal soft tissue allograft (Alloderm®)|
234711|NCT02461589|Drug|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily.
234712|NCT02461589|Drug|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
234713|NCT00172484|Procedure|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
234714|NCT02461589|Drug|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
234991|NCT02454894|Drug|lidocaine|surface anesthesia with lidocaine
234992|NCT02454894|Procedure|postoperative management|lying without the pillow for half an hour after lumbar puncture
234993|NCT02454907|Other|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
234994|NCT02454933|Drug|AZD9291|Once daily tablet 80 mg
234995|NCT02454933|Drug|MEDI4736|10mg/kg q2w (IV) infusion
234996|NCT02454959|Device|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
234997|NCT02454959|Device|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
234998|NCT00002466|Drug|cyclophosphamide|
234999|NCT00171340|Drug|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
235000|NCT02454972|Drug|lurbinectedin (PM01183)|
235001|NCT02457221|Drug|Tacrolimus capsules|oral
235002|NCT02457221|Drug|Cyclophosphamide injections|intravenous injection
235003|NCT02457221|Drug|Prednisone|oral
235004|NCT02457234|Behavioral|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
235005|NCT02457247|Drug|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
235006|NCT02457247|Drug|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
234410|NCT02430766|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
234411|NCT02430766|Device|NanoKnife|
234412|NCT02430779|Procedure|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
234413|NCT02430779|Device|NanoKnife|
234414|NCT02430792|Behavioral|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
234415|NCT02430805|Other|dna extraction and genotyping|blood and urine sample
234416|NCT02430818|Drug|ketamine|
234417|NCT02430818|Drug|morphine|
234715|NCT02461628|Behavioral|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
234716|NCT02461641|Other|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
234717|NCT02461641|Other|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
234718|NCT02461641|Other|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
234719|NCT02461654|Other|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
234720|NCT02461667|Drug|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
234721|NCT02463929|Drug|Bupivacaine|Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
234722|NCT02463942|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
234723|NCT00173758|Procedure|co-culture of embryos and endometrial cells|
234724|NCT02463942|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
234116|NCT02435524|Behavioral|A&T infant and young child feeding intervention|Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:
Increase mother's knowledge about optimal breastfeeding and its benefits
Increase mother's self-efficacy related to breastfeeding
Improve mother's perceptions about social norms relating to breastfeeding
Community mobilisation activities to:
- Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers
Enhanced training of government health workers in infant and young child feeding to:
Improve their ability to support mothers and provide timely information about infant feeding
234117|NCT02435537|Drug|Dexmedetomidine (Precedex)|intrathecal administration
234118|NCT02435537|Drug|Bupivacaine|intrathecal 10 mg bupivacaine
234119|NCT00002461|Drug|carmustine|
234120|NCT00168792|Procedure|PCI|
234121|NCT02435537|Drug|Morphine|intrathecal 0.5mg morphine
234122|NCT02435550|Other|Laboratory Assay for genetic testing|All groups will be asked to donate samples for laboratory assay for genetic testing.
234123|NCT02435563|Drug|ticagrelor 180 mg administrated alone|
234124|NCT02435563|Drug|Ticagrelor adjusted dose + ritonavir 100mg|
234125|NCT02435576|Radiation|Radiotherapy (primary or postoperative)|
234126|NCT02437903|Device|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, and month 6.
234127|NCT02437916|Drug|AMG 228|AMG 228 will be administered intravenously
234128|NCT02437929|Procedure|Mobilization|
234129|NCT02437929|Procedure|Positioning|
234418|NCT00002460|Drug|goserelin acetate|
234419|NCT00168129|Procedure|Helical tomotherapy|
234420|NCT02430831|Dietary Supplement|Nidina|
234421|NCT02430831|Dietary Supplement|Placebo|
234422|NCT02430857|Other|OMT|Manuel osteopathic treatment of the spine
234423|NCT02430870|Drug|TAK-648|TAK-648 administered orally once daily for 15 days.
234424|NCT02430870|Drug|Placebo|Matching placebo to TAK-648 administered orally once daily for 15 or 8 days for part 1 and part 2 respectively.
238802|NCT00169455|Biological|Live attenuated human rotavirus vaccine|
238803|NCT02442349|Drug|AZD9291|Once daily tablet 80 mg
238804|NCT02442362|Drug|paclitaxel+oxaliplatin+fluorouracil|Patients treated with "paclitaxel+oxaliplatin+fluorouracil": paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14.
238805|NCT02442362|Drug|oxaliplatin+S1|Patients treated with "oxaliplatin+S1": oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area < 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14
238806|NCT02442375|Radiation|standard dose prescription|standard elective dose
no intermediate dose-level
visual interpretation of FDG-PET-scan
238807|NCT02442375|Radiation|FDG‐PET guided gradient dose prescription|de-escalation of elective dose
intermediate dose-level
standardized methods to evaluate FDG-PET-scan
238808|NCT02442388|Procedure|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
238809|NCT02442388|Procedure|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
238810|NCT02442388|Procedure|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
238811|NCT02442401|Device|The negative pressure wound therapy|
238812|NCT02442414|Drug|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
238813|NCT00169468|Drug|Rituximab -CHOP plus Velcade|
238814|NCT02442427|Drug|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
238815|NCT02442427|Other|Placebo|An equal volume of 0.9% normal saline
238816|NCT02444988|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
238817|NCT02445001|Procedure|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
238818|NCT02445014|Device|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
238819|NCT00169767|Other|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
238245|NCT02453906|Other|Control 3|no stimulation at 5 control points
238246|NCT02453932|Drug|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
238247|NCT02453932|Drug|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
238248|NCT02456324|Device|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
238249|NCT02456337|Device|Mucograft|
238250|NCT02456337|Device|Emdogain|
238251|NCT02456337|Procedure|Coronally Advanced flap|
238252|NCT02456350|Drug|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
238539|NCT02449421|Behavioral|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
238540|NCT02449447|Behavioral|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
238541|NCT02449447|Other|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
238542|NCT02449473|Biological|Tralokinumab|Subcutaneous Injection
238543|NCT02449473|Other|Placebo|Subcutaneous Injection
238544|NCT02449486|Drug|Ropivacaine|
238545|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
238546|NCT02449525|Procedure|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
238547|NCT02449538|Drug|everolimus|everolimus 10 mg qd daily one cycle is 28days.
238548|NCT02449551|Drug|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
238549|NCT02449564|Drug|sirolimus|sirolimus 1mg daily
238550|NCT02449577|Other|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
238262|NCT02456389|Other|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
238263|NCT02456389|Other|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
238264|NCT02456389|Other|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
238265|NCT00171574|Drug|Valsartan|
238266|NCT02456389|Other|Standard postoperative care|Routine postoperative care, as medically indicated
238267|NCT02456402|Device|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
238268|NCT02456402|Device|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
238269|NCT02456415|Device|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
238270|NCT02456428|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
238560|NCT02451696|Drug|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
238561|NCT02451709|Device|Activated Smartinhaler or Smartturbo|Medication reminder alarms
238562|NCT02451709|Other|Feedback of adherence data|Review of adherence data with action planning
238563|NCT02451709|Device|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
238564|NCT02451722|Device|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
238565|NCT02451735|Behavioral|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
238566|NCT02451735|Behavioral|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
237943|NCT00173511|Device|24 hr Holter monitor|
237944|NCT02462811|Drug|Placebo|
237945|NCT02462811|Drug|Norco|
237946|NCT02462824|Behavioral|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
237947|NCT02462837|Drug|Mirabegron|
237948|NCT02462837|Drug|Placebo|
237949|NCT02462850|Drug|CL-108|
237950|NCT02462863|Dietary Supplement|Arginine and fish oil|Dietary supplements
237951|NCT02462876|Device|GORE® VIABAHN® Endoprosthesis|
237952|NCT02462889|Drug|Eylea|Intravitreal aflibercept injection
237953|NCT02462889|Drug|Placebo|
237954|NCT00002471|Drug|cytarabine|
237955|NCT00173524|Behavioral|PharmacoEconomic Assessment|Collecting PE data.
237956|NCT02462902|Drug|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
237957|NCT02462902|Drug|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
237958|NCT02462915|Device|i-gel|a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.
gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration.
237959|NCT02462915|Device|endotracheal tube|traditional and regularly use in many surgeries for maintaining the airway.
238271|NCT02458521|Device|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
238272|NCT00171886|Drug|Octreotide|
237651|NCT02432118|Procedure|Lumpectomy|Undergo lumpectomy
237652|NCT02432118|Other|Questionnaire Administration|Ancillary studies
237653|NCT02432118|Procedure|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
237654|NCT02432144|Drug|UX003|
237655|NCT00168363|Drug|brimonidine|
237656|NCT02432157|Drug|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
237657|NCT02432157|Drug|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
237658|NCT02432170|Device|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
237659|NCT02432196|Device|Mitral Valve Repair|Harpoon Medical TSD-5
237660|NCT02432209|Other|Caloric Restriction|Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
237661|NCT02432209|Drug|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
237662|NCT02432209|Other|Moderate exercise|Subjects will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
237663|NCT02432222|Behavioral|Visual Arts Training|Visual arts training
237664|NCT02432222|Behavioral|Music Training|Music training
237665|NCT02432235|Drug|ADCT-301|intravenous infusion
237666|NCT00168376|Device|Transcranial Magnetic Stimulation|
237667|NCT02432248|Drug|Dehydroepiandrosterone|75mg/day, PO for 90 days
237668|NCT02432248|Other|placebo(medical starch)|75mg/day, PO for 90 days
237669|NCT02432261|Drug|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
237670|NCT02432261|Drug|Testosterone only gel|Testosterone only gel
237671|NCT02432274|Drug|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
237672|NCT02432274|Drug|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
237041|NCT02444260|Drug|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
237042|NCT02446600|Other|Laboratory Biomarker Analysis|Correlative studies
237043|NCT02446600|Drug|Olaparib|Given PO
237044|NCT02446600|Drug|Paclitaxel|Given IV
237350|NCT02439346|Drug|BAY1143269 + Docetaxel|BAY1143269 will be given orally at the MTD (to be determined from Arm 1) once daily in combination with IV docetaxel at 75 mg/m2 every 3 weeks. Each treatment cycle will last 21 days.
237351|NCT02439359|Drug|CF-301|Dose escalation
237352|NCT02439359|Drug|Placebo|
237353|NCT02439385|Drug|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
237354|NCT02439385|Dietary Supplement|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
237355|NCT02439398|Other|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
237356|NCT00169169|Drug|rituximab|
237357|NCT02439398|Other|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
237358|NCT02439411|Drug|Trametinib|
237359|NCT02439424|Device|Reactive ATP|Reactive ATP turned to "on"
237360|NCT02439437|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
237361|NCT02439450|Biological|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
237362|NCT02439450|Drug|Nivolumab|Patients will receive nivolumab per the package insert for the treatment of NSCLC (3 mg/kg as an i.v. infusion over 60 minutes every two weeks) until disease progression or unacceptable toxicity
237363|NCT02439463|Procedure|Below-knee amputation|Patients with traumatic below-knee amputation.
237364|NCT02439489|Drug|BKM120-CIS|BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.
In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity
236718|NCT02451059|Behavioral|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
236719|NCT02451059|Behavioral|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Investigators will conduct regular booster sessions every 4 months; investigators will also train new providers should there be staff turnover
236720|NCT02451059|Behavioral|Patient Navigator|Peer patient navigators will offer guidance to families with accessing community resources. They will be available at least 1.5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. Navigators will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
236721|NCT02451072|Drug|Placebo|Capsules containing mannitol looking identical to LSD per os
236722|NCT02451072|Drug|LSD|100µg per os, single dose
236723|NCT02451072|Drug|Ketanserin|40mg per os, single dose looking identical to LSD per os
236724|NCT00170794|Drug|Everolimus (RAD001)|
236725|NCT02453334|Drug|Injectafer|
236726|NCT02453334|Other|Normal Saline|
236727|NCT00171080|Drug|irbesartan|
236728|NCT02453347|Device|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
237045|NCT02446600|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
237046|NCT02446600|Other|Pharmacological Study|Correlative studies
237047|NCT02446600|Other|Quality-of-Life Assessment|Ancillary studies
237048|NCT00170027|Device|Magnetocardiograph|
237049|NCT02446613|Other|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
236387|NCT02455479|Biological|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
236388|NCT02455492|Other|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
236389|NCT02455505|Behavioral|background questionnaire|
236390|NCT02455505|Behavioral|bereavement risk screening tool|
236391|NCT02455518|Drug|Oxycodone/acetaminophen|
236392|NCT00171431|Drug|Tegaserod|
236393|NCT02455518|Drug|Hydrocodone/acetaminophen|
236394|NCT02455518|Drug|Codeine/acetaminophen|
236395|NCT02455518|Drug|Ibuprofen/acetaminophen|
236396|NCT02455557|Other|Laboratory Biomarker Analysis|Correlative studies
236397|NCT02455557|Drug|Montanide ISA 51 VG|Given SC
236398|NCT02455557|Biological|Sargramostim|Given SC
236399|NCT02455557|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
236400|NCT02455557|Drug|Temozolomide|Given PO or IV
236401|NCT02455570|Other|No intervention|No intervention
236402|NCT02455583|Behavioral|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
236403|NCT00171444|Behavioral|Medical education|
236404|NCT02457884|Other|Control Group|Leisure reading activities
236405|NCT02457897|Drug|Liothyronine|Oral supplement given every 8 hours
236406|NCT02457910|Other|Biomarker Analysis|Correlative studies
236407|NCT02457910|Drug|Enzalutamide|Given PO
236408|NCT02457910|Other|Pharmacological Study|Correlative studies
236409|NCT02457910|Drug|Taselisib|Given PO
235809|NCT02431429|Drug|Miltefosine|
235810|NCT02431442|Drug|RM-493|
235811|NCT02431442|Drug|Placebo|
236086|NCT02462148|Drug|Dexamethasone|Used in nerve block mixture
236087|NCT02462148|Drug|Bupivacaine|Used in nerve block mixture
236088|NCT02462148|Drug|Epinephrine|Used in nerve block mixture
236089|NCT02462148|Procedure|Saphenous Peripheral Nerve Block|Peripheral nerve block.
236090|NCT02462161|Drug|Insulin aspart|Participants will administer 20 IU insulin aspart bid with an intranasal delivery device.
236091|NCT02462161|Drug|Placebo|Participants will administer placebo bid with an intranasal delivery device.
236092|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
236093|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
236094|NCT02462174|Drug|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
236095|NCT02462174|Drug|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
236096|NCT00002471|Drug|cyclophosphamide|
236097|NCT00172809|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
236098|NCT02462187|Drug|NVN1000|Applied topically, co-administered with hydrogel
236099|NCT02462187|Other|Vehicle Gel|Applied topically, co-administered with hydrogel
236100|NCT02462200|Procedure|Breast-conserving surgery (BCS)|
236101|NCT02462200|Procedure|Cavity shave margins (CSM)|
236102|NCT02462200|Behavioral|BREAST-Q Questionnaire|
236103|NCT02462200|Device|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
236104|NCT02462213|Other|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
235502|NCT02436109|Device|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
235503|NCT00168831|Other|Placebo|
235504|NCT02436135|Drug|Idelalisib|Idelalisib tablets administered orally for 24 weeks
235505|NCT02436135|Drug|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
235506|NCT02436148|Other|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
235507|NCT02436161|Behavioral|Care management program "PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
235508|NCT02436174|Device|novel device|novel device being used to measure shivering
235509|NCT02436200|Device|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
235812|NCT02431455|Device|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
235813|NCT02431455|Device|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
235814|NCT02431468|Drug|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
235815|NCT02431468|Other|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
235816|NCT02431481|Drug|LEE011|400 mg
235817|NCT00168298|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
235818|NCT02431494|Device|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
235819|NCT02431494|Device|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
235820|NCT02431494|Device|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
235214|NCT02443402|Drug|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG > 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
235215|NCT02443402|Drug|Insulin glargine|When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate >2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.
Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day
The basal insulin dose will be adjusted as follow:
If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change
If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day
If fasting and pre-dinner BG is > 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day
If fasting and pre-dinner BG is < 100 mg/dL in the absence of hypoglycemia: stop glargine
235216|NCT02443402|Drug|Supplemental insulin (Insulin lispro)|Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.
For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin lispro
BG between 221-260 mg/dL; 3-5 units of insulin lispro
BG between 261-300 mg/dL; 4-6 units of insulin lispro
BG between 301-350 mg/dL; 5-7 units of insulin lispro
BG between 351-400 mg/dL; 6-8 units of insulin lispro
BG > 400 mg/dL; 7-9 units of insulin lispro
235217|NCT02443402|Drug|Supplemental insulin (Insulin aspart)|Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.
For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin aspart
BG between 221-260 mg/dL; 3-5 units of insulin aspart
BG between 261-300 mg/dL; 4-6 units of insulin aspart
BG between 301-350 mg/dL; 5-7 units of insulin aspart
BG between 351-400 mg/dL; 6-8 units of insulin aspart
BG > 400 mg/dL; 7-9 units of insulin aspart
235218|NCT02443454|Device|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
235219|NCT02443454|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
235510|NCT02438540|Other|Placebo (for acupuncture including electro body acupuncture and auricular acupuncture)|for those points that were located in the abdomen, needles were inserted 0.3cm laterally from the real location and the needling was maximally superficial. Those points that were located on other parts of the body, needles were inserted 0.5 cm up and 0.5cm laterally from the real location and needling was superficial as well. In control group electric lines were connected with some of the needles same way they were connected in case group. EA machine was switched off during 30 minutes of therapeutic time. Ear acupuncture was used on the same location as in the case group however we just used sticky layers without seeds.
235511|NCT02438553|Device|OSTNS Neurostimulator|Non-invasive transcutaneous neurostimulation.
235512|NCT02438553|Device|Placebo OSTNS Neurostimulator|Placebo non-invasive transcutaneous neurostimulation
235513|NCT00002461|Procedure|autologous bone marrow transplantation|
235514|NCT00169104|Drug|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
235869|NCT02436356|Radiation|MRI|Determines bound water and pore water of bone.
235870|NCT02438696|Drug|BI 1060469, TF1, Reference|
235871|NCT02438696|Drug|BI 1060469, TF2, Test|
235872|NCT02438696|Drug|BI 1060469, TF1, Reference|
235873|NCT02438696|Drug|BI 1060469, TF1, Reference|
235874|NCT02438696|Drug|BI 1060469, TF2, Test|
235875|NCT02438696|Drug|BI 1060469, TF2, Test|
235876|NCT02438696|Drug|BI 1060469, iFF, Test|
235877|NCT02438696|Drug|BI 1060469, TF2, Test|
235878|NCT02438696|Drug|BI 1060469, TF1, Reference|
235879|NCT02438709|Drug|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
235880|NCT00169117|Behavioral|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
235881|NCT02438722|Drug|Afatinib Dimaleate|Given PO
235882|NCT02438722|Biological|Cetuximab|Given IV
235883|NCT02438722|Other|Laboratory Biomarker Analysis|Correlative studies
235884|NCT02438748|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
235885|NCT02438761|Drug|PF-05212384|PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections
The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.
235886|NCT02438774|Behavioral|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
235887|NCT02438774|Behavioral|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
235888|NCT02438787|Drug|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
235278|NCT02450383|Device|Alloderm®|
235279|NCT00170716|Device|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
235280|NCT02450383|Device|autologous subepithelial connective tissue graft|
235281|NCT02450409|Procedure|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
235568|NCT00169572|Drug|Dexamethasone|
235569|NCT02443571|Radiation|Fluciclovine (18F)|Not applicable. This is an observational study.
235570|NCT02443584|Other|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
235571|NCT02443597|Other|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
235572|NCT02443623|Biological|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
235573|NCT02443649|Behavioral|Sleep hygiene program|Sleep hygiene program
235574|NCT02443649|Behavioral|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
235575|NCT02443662|Other|Catheterization|Routine catheterization during follow up.
235576|NCT02443688|Drug|CTX-4430|
235577|NCT02443688|Drug|Placebo|
235578|NCT02446184|Procedure|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
235579|NCT00169949|Drug|aripiprazole|
235580|NCT02446184|Procedure|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
235581|NCT02446197|Other|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
235007|NCT02457247|Drug|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
235008|NCT00171717|Drug|Cyclosporine - cyclosporine microemulsion|
235009|NCT02457260|Drug|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
235010|NCT02457273|Drug|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
235011|NCT02457286|Drug|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
235282|NCT02450409|Procedure|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
235283|NCT02450422|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
235284|NCT02450422|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
235285|NCT02450435|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
235286|NCT02450435|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
235287|NCT02450448|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
235288|NCT02450448|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
235289|NCT02450461|Other|no intervention|
235290|NCT00170716|Other|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
235291|NCT02450474|Device|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
235292|NCT02450474|Device|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
235293|NCT02452749|Dietary Supplement|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
235294|NCT02452762|Drug|Vitamin D3|
235295|NCT02452762|Drug|Placebo|
235296|NCT02452775|Biological|OC-L|
235297|NCT02452775|Other|Montanide|
235298|NCT02452775|Other|poly-ICLC (Hiltonol),|
234725|NCT02463942|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
234726|NCT02463955|Device|flexible video endoscope|Thoracoscopy is done using flexible video endoscope
234727|NCT02463955|Device|video-rigid thoracoscope|Thoracoscopy is done using video-rigid thoracoscope
234728|NCT02463968|Procedure|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
234729|NCT02463968|Procedure|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
234730|NCT02463981|Device|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
234731|NCT02463994|Drug|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
234732|NCT02463994|Radiation|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
235012|NCT02457286|Behavioral|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
235013|NCT02457286|Device|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
235014|NCT02457299|Procedure|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
235015|NCT02457299|Procedure|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
235016|NCT02457312|Drug|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
235017|NCT02457312|Drug|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
235018|NCT02457325|Drug|Surgery with 2% articaine|During and after lower third molars surgeries, clinical efficacy of the local anesthetic articaine 2% in association with 1:200,000 adrenaline was study.
235019|NCT00171730|Drug|Pasireotide|
235020|NCT02457325|Drug|Surgery with 4% articaine|During and after lower third molars surgeries, clinical efficacy of the local anesthetic articaine 4% in association with 1:200,000 adrenaline was study.
235021|NCT02457338|Dietary Supplement|Bifidobacterium|
234425|NCT02430883|Procedure|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
234426|NCT02430896|Drug|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
234427|NCT02430896|Drug|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
234428|NCT02430909|Biological|Bimekizumab|Pharmaceutical form: Solution for infusion
Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose
Route of administration: iv infustion
234429|NCT02430909|Biological|Certolizumab Pegol|Pharmaceutical form: Prefilled syringes
Concentration: 200 mg/ml
Route of administration: Subcutaneous injection
234430|NCT00168155|Drug|perioperative chemotherapy|
234431|NCT00168493|Drug|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
234432|NCT02432963|Biological|Pembrolizumab|Given IV
234433|NCT02432976|Drug|Exenatide|Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.
The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .
The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier.
234434|NCT02432976|Drug|Insulin|Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.
The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.
The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al.
234435|NCT02432989|Behavioral|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
234436|NCT02433015|Other|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
234437|NCT02433015|Other|Tobacco Cigarette|Smoke own brand of cigarette as previously
234438|NCT02433041|Drug|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
234733|NCT02464007|Biological|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
234734|NCT00173862|Drug|Gemcitabine, Ifosfamide|
234735|NCT02464020|Drug|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
234736|NCT02464033|Drug|GAD-Alum|
238820|NCT02445027|Device|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
238821|NCT02445040|Device|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
234130|NCT02437929|Procedure|Personal Hygiene Care|
234131|NCT02437929|Procedure|Bladder catheterization|
234132|NCT02437929|Procedure|Wound care|
234133|NCT02437929|Procedure|Subcutaneous drugs administration|
234134|NCT02437942|Other|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
234135|NCT02437955|Other|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
234136|NCT00169065|Drug|Clozapine|
234137|NCT02437955|Other|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
234138|NCT02437955|Other|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
234139|NCT02437955|Other|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
234140|NCT02437968|Behavioral|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
234141|NCT02437981|Drug|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
234142|NCT02437994|Behavioral|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
234143|NCT02438007|Drug|Galeterone|2550 mg galeterone tablets once daily PO
234144|NCT02438007|Drug|Enzalutamide|160 mg enzalutamide capsules once daily PO
234145|NCT02438020|Drug|Metformin|One tablet of 500 mg will be ingested before the main meal
238551|NCT02449577|Other|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
238552|NCT02449577|Other|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
238553|NCT02449577|Other|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
238554|NCT02449577|Other|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
238555|NCT02449577|Other|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
238556|NCT00002463|Drug|Leucovorin Calcium|
238557|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
238558|NCT02451683|Other|Training with non-invasive strategy|
238559|NCT02451683|Other|Training with some stimulation|
238822|NCT02445053|Drug|ivacaftor|
238823|NCT02445066|Dietary Supplement|Vitamin D3|
238824|NCT02445079|Other|This is an observational study only|Observational study only
238825|NCT02445092|Other|washing the insemination catheter with sperm washing media|Intervention: pre-washing of the IUI catheter
Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:
Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.
Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..
Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.
Labeling:
Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter.
238826|NCT02445105|Behavioral|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
238827|NCT02445105|Behavioral|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
238828|NCT02445118|Other|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
238567|NCT02451748|Other|Lab Work|Lab work to measure IL-7 and IL-7R
238568|NCT00170898|Drug|Lumiracoxib|
238569|NCT02451761|Biological|Blood sampling|
238570|NCT02451774|Drug|Pentoxifylline Plus Chemotherapy|Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
238571|NCT02451774|Drug|Placebo Plus Chemotherapy|Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
238572|NCT02451787|Dietary Supplement|Vitamin D|2400 units per day for 3 months
238573|NCT02451800|Other|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
238574|NCT02451800|Other|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
238575|NCT02451800|Other|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
238840|NCT02447315|Drug|Placebo|oral
238841|NCT02447328|Drug|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
238842|NCT00170222|Drug|doxycycline|
238843|NCT02447367|Drug|JLP-1207|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
238844|NCT02447367|Drug|JLP-1207|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
238845|NCT02447380|Drug|AZD6094|
238846|NCT02447380|Drug|Docetaxel|
238847|NCT02447393|Drug|levocetirizine|levocetirizine
238848|NCT02447393|Drug|cetirizine|cetiridine
238273|NCT02458521|Device|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
238274|NCT02458534|Other|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
238275|NCT02458534|Other|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
238276|NCT02458534|Other|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
238277|NCT02458547|Procedure|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8~1.0
238278|NCT02458547|Procedure|Propofol|Total intravenous anesthesia with propofol target controlled infusion
238279|NCT02458547|Procedure|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
238280|NCT02458560|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
238281|NCT02458573|Other|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
238282|NCT02458573|Other|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
238283|NCT00171899|Drug|imatinib mesylate|
238284|NCT02458586|Dietary Supplement|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
238285|NCT02458599|Dietary Supplement|Test product|Whey protein hydrolysate (20 g)
238286|NCT02458599|Dietary Supplement|Reference product 1|Iso-energetic carbohydrate (20 g)
238287|NCT02458599|Dietary Supplement|Reference product 2|Negligible energy placebo (20 g)
238288|NCT02458612|Other|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
238576|NCT02451813|Procedure|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure
238577|NCT02453932|Drug|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
237673|NCT02432274|Drug|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
237674|NCT02432274|Drug|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose).
237960|NCT02462915|Drug|lidocaine, propofol, fentanyl and cisatracurium|
237961|NCT02465112|Other|simple monitoring without active therapy|
237962|NCT02465125|Biological|red blood cell transfusion|
237963|NCT02465138|Drug|Ketorolac|Intravenous ketorolac
237964|NCT02465138|Drug|Placebo|Intravenous saline
237965|NCT02465151|Other|Protein-based beverage|protein-based beverage
237966|NCT02465164|Device|Cook catheter|
237967|NCT02465164|Drug|Oxytocin|
237968|NCT00174265|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
237969|NCT02465203|Drug|Previous treatment in DEB025 study|Follow-up after DEB025 active study
237970|NCT02465216|Other|Placebo|Placebo
237971|NCT02465216|Biological|ID93 + GLA-SE|ID93 + GLA-SE
237972|NCT02465229|Procedure|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
237973|NCT02465255|Drug|Ketorolac|
237974|NCT02465255|Drug|Tramadol|
237975|NCT02465255|Drug|Acetaminophen|
237976|NCT02465268|Biological|pp65 DC with GM-CSF|
237977|NCT02465268|Biological|Influenza DC with GM-CSF|
237978|NCT02465268|Biological|PBMC with GM-CSF|
237979|NCT00174278|Drug|Somatropin|
237980|NCT02465268|Drug|Td|
237365|NCT02439489|Drug|BKM120-CARBO|BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.
In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity
237366|NCT02439502|Device|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
237367|NCT00169169|Procedure|Autologous stem cell transplant|
237368|NCT02439515|Device|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
237675|NCT02432274|Drug|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
237676|NCT02432274|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
237677|NCT02434601|Procedure|Treatment of Dentin Surface|Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.
Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.
Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate.
237678|NCT02434601|Procedure|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
237679|NCT02434601|Procedure|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
237680|NCT02434614|Drug|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
237681|NCT02434614|Radiation|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
237682|NCT02434614|Drug|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
237683|NCT00168688|Dietary Supplement|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
237684|NCT02434627|Drug|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
237685|NCT02434640|Drug|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
237686|NCT02434640|Drug|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
237050|NCT02446626|Procedure|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
237051|NCT02446626|Procedure|Blood draw|Peripheral blood draws will be performed.
237052|NCT02446626|Other|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatchedfrom eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
237053|NCT02446639|Other|Blood collection|
237054|NCT02446652|Drug|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
237055|NCT02446652|Drug|Placebo|Placebo (orally) starting 1 week before the first day of the QT
237056|NCT02446652|Drug|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
237057|NCT02446652|Drug|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
237058|NCT02446665|Device|MR Elastography (MRE) and FibroScan|
237059|NCT00170053|Drug|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
237060|NCT02446678|Device|PillCam ESO2|Capsule endoscopy
237061|NCT02446691|Biological|Menveo|
237062|NCT02446704|Drug|Olaparib|
237063|NCT02446704|Drug|Temozolomide|
237064|NCT02446717|Drug|ABT-493|Tablets
237065|NCT02446717|Drug|ABT-530|Tablets
237066|NCT02446717|Drug|Ribavirin|Tablets
237067|NCT02446717|Drug|ABT-493/ABT-530|Tablets
237369|NCT02441673|Drug|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
237370|NCT02441673|Drug|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
237371|NCT02441673|Drug|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
237372|NCT02441686|Drug|Bortezomib|
236410|NCT02457923|Other|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
236729|NCT02453360|Procedure|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
236730|NCT02453360|Drug|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
236731|NCT02453373|Device|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
236732|NCT02453373|Drug|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
236733|NCT02453373|Drug|tPA|tPA will be administered intravenously if indicated
236734|NCT02453373|Drug|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
236735|NCT02453373|Drug|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
236736|NCT02453386|Drug|tozadenant|
236737|NCT02453386|Drug|placebo|
236738|NCT00171093|Drug|valsartan + simvastatin|
236739|NCT02453399|Device|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
236740|NCT02453412|Device|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
236741|NCT02453425|Other|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
236742|NCT02453425|Other|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
236743|NCT02453425|Other|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
236744|NCT02453438|Other|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
236745|NCT02453451|Other|2D-/3D-TTE|recording of 3 cardiac cycles
236746|NCT02453451|Other|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
236105|NCT02464527|Behavioral|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
236106|NCT02464527|Device|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
236411|NCT02457936|Behavioral|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
236412|NCT02457949|Other|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
236413|NCT02457949|Other|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
236414|NCT00002466|Drug|vincristine sulfate|
236415|NCT00171821|Drug|Deferasirox|
236416|NCT02457988|Device|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
236417|NCT02458001|Behavioral|SAFFRON stepped care|Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.
Assessment Algorithm FSFI Interventions
Level 1:
Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.
Level 2:
A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.
Level 3:
16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)
236418|NCT02458014|Drug|Blinatumomab|In first induction cycle, initial dose of Blinatumomab is 9 μg/day for the first 7 days of treatment by a central venous catheter, which then will be escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 μg/day is the dose for all 4 weeks of continuous treatment.
236419|NCT02458014|Behavioral|Phone Calls|Participants called by study staff 1 time each month for up to 18 months after all participants have been enrolled in the study.
236420|NCT02458027|Dietary Supplement|Hemp Shake|Hemp Protein Shake
236421|NCT02458027|Dietary Supplement|Hemp Shake|Hemp Protein Shake
236422|NCT02458027|Dietary Supplement|Soybean Shake|Soybean Protein Shake
236423|NCT02458027|Dietary Supplement|Soybean Shake|Soybean Protein Shake
236424|NCT02458027|Dietary Supplement|Control|Non-Protein Shake
235821|NCT02431507|Device|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
235822|NCT02431520|Procedure|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
235823|NCT02431520|Procedure|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
235824|NCT02431533|Dietary Supplement|PX0612|PX0612 is a probiotic contained in a veggie capsule.
235825|NCT00168558|Biological|Measles vaccine|The children will be randomised to the following three arms:
Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.
Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.
Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.
V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine
235826|NCT02433548|Procedure|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
235827|NCT02433548|Procedure|Sham injection|subcutaneous of 5 cc of normal saline
236107|NCT02464540|Procedure|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
236108|NCT02464540|Procedure|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
236109|NCT02464553|Other|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
236110|NCT00174161|Behavioral|self-care, health behavior|
236111|NCT02464566|Behavioral|Intensive lifestyle intervention|
236112|NCT02464566|Other|Health Education|
236113|NCT02464592|Procedure|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
236114|NCT02464605|Biological|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
235515|NCT02438566|Drug|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
235516|NCT02438566|Drug|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
235517|NCT02438579|Other|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
235518|NCT02438605|Device|Nellix|
235519|NCT02438618|Procedure|Surgery for Ponto bone anchored hearing aids|
235520|NCT02438657|Procedure|median nerve block|
235521|NCT02438670|Device|PID control algorithm|
235522|NCT02438670|Device|MPC control algorithm|
235523|NCT02438683|Drug|BI 409306|medium dose, single dose, oral administration
235524|NCT02438683|Drug|BI 409306|low dose, single dose, oral administration
235525|NCT00169104|Drug|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
235526|NCT02438683|Drug|Placebo|single dose, oral administration
235527|NCT02438696|Drug|BI 1060469, iFF, Test|
235528|NCT02438696|Drug|BI 1060469, iFF, Test|
235529|NCT02438696|Drug|BI 1060469, TF1, Reference|
235530|NCT02438696|Drug|BI 1060469, TF2, Test|
235531|NCT02438696|Drug|BI 1060469, TF2, Test|
235532|NCT02438696|Drug|BI 1060469, iFF, Test|
235828|NCT02433561|Procedure|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
235829|NCT02433561|Procedure|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
236161|NCT02431637|Biological|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
236162|NCT02431637|Drug|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
236163|NCT02431650|Drug|OZ439|
236164|NCT02431650|Drug|Primaquine|
236165|NCT02431663|Drug|Ketamine|Intravenous administration in continuous
236166|NCT00168584|Drug|Vitamin A|
236167|NCT02433691|Other|stretching and toning|anaerobic stretching and toning followed by memory training.
236168|NCT02433704|Device|New Intraosseous|Intraosseous administration of prophylactic antibiotics
236169|NCT02433704|Drug|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
236170|NCT02433717|Drug|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
236171|NCT02433730|Drug|Testosterone|intramuscular injection
236172|NCT02433730|Drug|placebo|intramuscular injection
236173|NCT02433743|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
236174|NCT02433756|Device|CRTD|
236175|NCT02433769|Device|TOFscan|Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX ("gold standard")
236176|NCT02433769|Drug|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
236177|NCT00168597|Drug|Vitamin A|
236178|NCT02433782|Other|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
235582|NCT02446210|Device|Magstim 200|Transcranial Magnetic Stimulation
235583|NCT02446210|Device|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
235584|NCT02446223|Drug|Inggenol Mebutate 0.015%|
235585|NCT02446236|Drug|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
235586|NCT02446236|Drug|Ibrutinib|560 mg PO daily
235587|NCT02446236|Drug|Rituximab|375 mg/m2 IV Day 1
235588|NCT02446249|Biological|AAV2hAQP1|Infusion of gene therapy
235889|NCT02438787|Drug|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
235890|NCT02438787|Drug|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
235891|NCT00169130|Drug|doxorubicin|
235892|NCT02438787|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
235893|NCT02441101|Device|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
235894|NCT02441114|Drug|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
235895|NCT02441127|Device|diode laser group|the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
235896|NCT02441127|Procedure|scalpel control group|In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
235897|NCT02441140|Procedure|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
235299|NCT02452788|Other|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
235300|NCT00171028|Drug|valsartan|
235301|NCT02452801|Drug|ALKS 5461|Single dose, given orally
235302|NCT02452827|Other|Biomechanical parameters|
235303|NCT02452827|Other|MRI|MRI of cervical spine
235304|NCT02452840|Other|No Intervention|No Intervention
235305|NCT02452853|Procedure|HR|HR:
HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
235589|NCT02446275|Other|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
235590|NCT00002462|Drug|vincristine sulfate|
235591|NCT00169962|Drug|rhDNAse (pulmozyme)|
235592|NCT02446275|Other|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
235593|NCT02446288|Device|TMJ Next Generation|
235594|NCT02446288|Device|DSG Relaxer|
235595|NCT02446301|Drug|Bain®|Nalbuphine HCl 20mg, IM injection
235596|NCT02446301|Drug|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
235597|NCT02446314|Dietary Supplement|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
235598|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
235599|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
235600|NCT00170352|Procedure|Enhanced Oxygen Treatment (Enhanced FiO2)|
235022|NCT02457351|Drug|Roniciclib (BAY 1000394)|Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)
Part 1 & Part 2
Cycle 2 and subsequent 21-day cycles:
Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose
235023|NCT02459418|Drug|US Gonal-f®|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:
Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
235024|NCT02459431|Other|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
235025|NCT02459431|Other|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
235026|NCT02459444|Device|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
235027|NCT02459444|Other|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
235028|NCT02459457|Drug|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
235029|NCT00172042|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
235306|NCT02452853|Drug|FOLFOX4|FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):
4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks
235307|NCT02452866|Drug|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
235308|NCT02452879|Device|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
235309|NCT02452879|Device|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
235310|NCT02452879|Drug|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg / tablet
234737|NCT02464033|Drug|Vitamin D|
234738|NCT02464033|Drug|Etanercept|
234739|NCT02464046|Drug|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
234740|NCT02464046|Drug|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
234741|NCT02464059|Drug|Vitamin D3|The design of the study to complete this aim will be in the format of a baseline and repeat bronchoscopy after oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
234742|NCT02464072|Procedure|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
234743|NCT02428426|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
234744|NCT00167817|Drug|Aripiprazole|
234745|NCT02428439|Drug|fluoxetine or escitalopram|Participants who take the standardized pharmacotherapy (Fluoxetine or Escitalopram) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
234746|NCT02428452|Behavioral|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
234747|NCT02428465|Behavioral|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
234748|NCT02428478|Drug|Desipramine|200 mg administered 2 hour before normal sleep time
234749|NCT02428478|Drug|Placebo|
235030|NCT02459457|Drug|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
235031|NCT02459457|Drug|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
235032|NCT02459457|Radiation|Radiotherapy|
234146|NCT02438020|Other|Placebo|A placebo tablet will be ingested daily before main meal.
234147|NCT00169065|Drug|Olanzapine|
234148|NCT02440386|Behavioral|Conditional economic incentive|Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:
Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and
send a text message to the study team to let us know they have started ART;
Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation.
234439|NCT02433041|Drug|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
234440|NCT02433041|Drug|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
234441|NCT02433041|Drug|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
234442|NCT00168506|Drug|SSRI|
234443|NCT02433054|Device|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
234444|NCT02433067|Other|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
234445|NCT02433067|Other|Control Group|standard oncologic care
234446|NCT02433080|Behavioral|Shape-Up following cancer treatment|The programme is based on "Social Cognitive Theory" and "Control Theory". The focus of the programme lies on self-control, self-efficacy, and relapse prevention.
234447|NCT02433093|Drug|Basimglurant|Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
234448|NCT02433093|Drug|Placebo|Participants will receive 22 days of once-daily oral matching placebo capsules.
234449|NCT02433106|Other|GAA 15|Neuromuscular injury prevention training
234450|NCT02433106|Other|Control|Usual training
234451|NCT02433119|Drug|OROSARTAN® 5/160mg|
234452|NCT02433119|Drug|CODIOVAN® 160/12.5mg|
234453|NCT00168506|Drug|CBT|
238829|NCT02445131|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
238830|NCT00169780|Radiation|High definition helical CT (64 head scanner)|Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone "anatomy" which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs.
238831|NCT02445131|Drug|GA101|Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg
Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg.
238832|NCT02447276|Drug|Placebo|
238833|NCT02447289|Drug|Intranasal ketamine|
238834|NCT02447289|Drug|Oral ketamine|
238835|NCT02447289|Drug|Intranasal midazolam|
238836|NCT02447289|Drug|Oral midazolam|
238837|NCT02447302|Drug|APD334|
238838|NCT02447302|Drug|Placebo|
238839|NCT02447315|Drug|Pilocarpine|oral
234149|NCT02440399|Drug|Tramadol hydrochloride|Please see arm description
234150|NCT02440399|Drug|Morphine|Please see arm description
234151|NCT02440399|Drug|Paracetamol|
234152|NCT02440399|Drug|Diclofenac|
234153|NCT02440399|Drug|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
234154|NCT02440412|Other|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
234155|NCT00169247|Drug|Cisplatin|
234156|NCT02440412|Other|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
234157|NCT02440425|Drug|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
234158|NCT02440425|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
238849|NCT02447393|Drug|placebo|placebo
238850|NCT02447406|Drug|AZD6094|
238851|NCT02447406|Drug|docetaxel|
238852|NCT02447419|Drug|Gefitinib|Gefitinib 250mg will be administered orally daily
238853|NCT00170235|Other|Prehabilitation|Exercise class pre-surgery
238854|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
238855|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
238856|NCT02447432|Biological|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
238857|NCT02447445|Procedure|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men < 27 kg and women <16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
238858|NCT02447458|Drug|MLN3126|MLN3126 tablets
238859|NCT02447458|Drug|MLN3126 Placebo|MLN3126 placebo-matching tablets
238860|NCT02447471|Device|Nexfin|Nexfin cuff placed on finger to measure blood pressure
238861|NCT02449577|Other|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
238862|NCT02449577|Other|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
234168|NCT02442843|Device|Sham tDCS|Participants will complete up to 10 daily sessions of tDCS over two consecutive weeks. Each session will last 1 - 2 hours.
234169|NCT02442856|Device|Thigh Cuff|
234170|NCT02442869|Behavioral|Behavioral therapy (Treatment as usual [TAU])|4-8 weeks of behavioral therapy
234171|NCT00169520|Drug|SB-715992|
234172|NCT02442869|Behavioral|CAMS short|4-8 weeks Collaborative Assessment and Management of Suicidality (CAMS) short course
234173|NCT02442869|Behavioral|CAMS long|4-16 weeks Collaborative Assessment and Management of Suicidality (CAMS) long course
238578|NCT02453945|Device|Adjustable Support Bra|A ClearPoint Medical support bra
238579|NCT02453958|Device|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
238580|NCT02453971|Other|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
238581|NCT00171184|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
238582|NCT02453984|Other|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
238583|NCT02454010|Biological|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
238584|NCT02454023|Device|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
238585|NCT02454023|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
238586|NCT02454036|Behavioral|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
238587|NCT02454049|Dietary Supplement|beetroot juice|6mmol nitrate
238588|NCT02454049|Dietary Supplement|sodium nitrate|6mmol sodium nitrate
238589|NCT02454049|Dietary Supplement|water|plain water
238590|NCT02454062|Drug|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
238591|NCT02454062|Drug|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
238592|NCT00171184|Drug|Placebo|Placebo tablet once daily with sham titration
238593|NCT02454075|Drug|YF476|Gastrin receptor antagonist
238594|NCT02454088|Other|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
238595|NCT02454088|Device|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
238596|NCT02454101|Procedure|cord milking|milking of the cord 5 times toward the neonate
238597|NCT02454101|Procedure|delayed cord clamping|delay clamping of the cord for 120 seconds
237981|NCT02465268|Drug|Saline|
237982|NCT02465281|Other|MRI|
237983|NCT02465294|Dietary Supplement|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
237984|NCT02465294|Behavioral|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
238289|NCT02458612|Other|intervention group|Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to "National Strength and Conditioning Association (NSCA)" protocols. Intensity of exercise is gradually increased 10% bi-weekly.
238290|NCT02458625|Dietary Supplement|Iron sucrose 500 mg|
238291|NCT02460640|Procedure|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
238292|NCT02460640|Procedure|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
238293|NCT02460640|Drug|Morphine|
238294|NCT02460640|Drug|Ropivacaine|
238295|NCT02460653|Device|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
238296|NCT02460666|Behavioral|Tai-Chi-Chih (TCC)|
238297|NCT00172185|Drug|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
238298|NCT02460666|Behavioral|Health Education and Wellness Classes (HEW)|
238299|NCT02460679|Drug|EPI-589|An immediate release film-coated table at a 250 mg dosage strength.
238300|NCT02460692|Drug|placebo cannabis|Administration of vaporized cannabis plus either dronabinol or placebo pill
238301|NCT02460692|Drug|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
238302|NCT02460692|Drug|Vaporized Cannabis 3.5% delta-9-THC|Administration of vaporized cannabis plus either dronabinol or placebo pill
238303|NCT02460705|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
238304|NCT02460718|Behavioral|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
237687|NCT02434640|Drug|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
237688|NCT02434653|Other|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
237689|NCT02434653|Other|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
237690|NCT02434666|Drug|CPC-201|
237691|NCT02434692|Device|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after cataract surgery on day 0 (V01)
237985|NCT02465294|Other|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
237986|NCT02465294|Other|Blood Test|All subjects will have blood tests performed.
237987|NCT02465294|Dietary Supplement|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
237988|NCT02465307|Behavioral|Confusion Assessment Method|Confusion Assessment Method (CAM) score
237989|NCT02465307|Device|Thigh accelerometer|To verify activity level
237990|NCT00174291|Drug|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
237991|NCT00167960|Drug|Piperacillin/tazobactam and other β-lactam/β-lactamase|
237992|NCT02429700|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours
237993|NCT02429700|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
237994|NCT02429700|Drug|Bleomycin|Bleomycin 30000IU IV/IM on day 1/8/15 for 12 weeks.
237995|NCT02429700|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles.
237996|NCT02429700|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
237997|NCT02429713|Procedure|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
237998|NCT02429713|Procedure|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
237373|NCT02441686|Drug|Lenalidomide|
237374|NCT02441686|Drug|Dexamethasone|
237375|NCT02441699|Behavioral|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
237376|NCT02441712|Device|Patterned Electrical Neuromuscular Stimulation administered by the Omnistim® FX² Pro Stimulation device|
237377|NCT02441725|Other|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
237378|NCT02441738|Procedure|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
237379|NCT00169312|Procedure|evaluation of cancer risk factors|
237380|NCT02441738|Procedure|Catheter Ablation|The procedure will be performed following standard of care guidelines.
237381|NCT02441751|Procedure|intra-operative blood loss|surgery in the urology and orthopedics
237382|NCT02441777|Device|Polarization-Sensitive OFDI|
237383|NCT02441790|Behavioral|Early Active Range of Motion|3-9 days
237384|NCT02441790|Behavioral|Standard Immobilization|21-27 days
237385|NCT02441803|Drug|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
237386|NCT02441803|Drug|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
237387|NCT02441803|Drug|Clofarabine|Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.
Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3.
237388|NCT02441803|Radiation|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
237389|NCT02441803|Drug|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
237390|NCT00169325|Procedure|Magnetic resonance imaging|
237391|NCT02441803|Biological|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or >3.0 X 108 marrow mononuclear cells/kg if bone marrow.
237692|NCT02434705|Other|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
236747|NCT02453451|Other|Walking Test|for 6 minutes
236748|NCT02453451|Procedure|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
236749|NCT00171106|Drug|valsartan|
237068|NCT02446730|Device|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
237069|NCT02446730|Drug|Prasugel|
237070|NCT02448823|Other|Mass media and Stylish Events|Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
"Stylish Man/Living Event" (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more "Stylish" are interwoven through the mobilization.
The Stylish Man Van (SMV) accompanies the SMEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP "customers" and where appropriate their spouses.
237071|NCT02448823|Other|Mass Media|1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
237072|NCT02448836|Device|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
237073|NCT02448836|Device|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
237074|NCT02448849|Biological|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
237075|NCT02448849|Other|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
237076|NCT02448862|Device|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
237077|NCT02448875|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. The CyPass Micro-Stent is designed to be permanently implanted in the eye.
237078|NCT00002463|Drug|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
237079|NCT00170430|Drug|Fluconazole|
237080|NCT02448875|Device|CyPass Micro-Stent + 60 ul viscoelastic|In addition to CyPass Micro-Stent implantation, 60 ul of ophthalmic viscoelastic will be used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
237081|NCT02448888|Other|Adapted exercise|2 months, 3 times/week
236425|NCT02458040|Drug|Drug selected in the study|
236426|NCT02459912|Procedure|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
236427|NCT02459912|Device|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
236428|NCT02459925|Behavioral|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
236750|NCT02455596|Drug|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
236751|NCT02455609|Procedure|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
236752|NCT02455609|Drug|Dexmedetomidine|
236753|NCT02455609|Drug|ketamine|
236754|NCT02455609|Drug|Bupivacaine|
236755|NCT02455622|Drug|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
236756|NCT02455635|Procedure|office hystroscopy|Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath & 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
236757|NCT02455648|Procedure|ESD/EMR plus Cell Sheet|Patients receive ESD/EMR plus CellSheet:
Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane ("Cell Sheet") that are inserted 2 weeks later on the occasion of the ESD or EMR
236758|NCT02455648|Procedure|ESD/EMR|only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane ("Cell Sheet") but NOT used for insertion in the patient during/after ESD/EMR two weeks later
236759|NCT02455661|Device|TR Band (TM)|
236760|NCT00171457|Drug|Tegaserod|
236761|NCT02455661|Device|AngioSeal(R)|
236762|NCT02455687|Drug|Intravenous magnesium sulfate|
236763|NCT02455687|Drug|Inhaled budesonide|
236764|NCT02455687|Drug|normal saline|
236115|NCT02464618|Behavioral|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
236116|NCT02464631|Drug|Sofosbuvir + Ribavirin 1|
236117|NCT02464631|Drug|Sofosbuvir + Ribavirin 2|
236118|NCT02464631|Drug|Sofosbuvir + Ribavirin 3|
236119|NCT02464644|Other|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
236120|NCT02464657|Drug|Nivolumab|Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.
Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I.
236121|NCT00174174|Drug|Modafinil|
236122|NCT02464657|Drug|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
236429|NCT02459925|Behavioral|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
236430|NCT02459938|Drug|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
236431|NCT02459938|Drug|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
236432|NCT00172094|Drug|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
236433|NCT02459951|Other|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
236434|NCT02459964|Drug|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
236435|NCT02459964|Drug|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
236436|NCT02459964|Behavioral|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
236437|NCT02459977|Drug|Basiliximab|Basiliximab induction therapy
236438|NCT02459977|Drug|No basiliximab|No basiliximab induction therapy
235830|NCT02433574|Radiation|Neoadjuvant Stereotactic body radiation (SBRT)|Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.
The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments.
235831|NCT02433587|Drug|Aspirin|
235832|NCT02433587|Drug|Clopidogrel|
235833|NCT02433600|Other|Cow's milk-based infant formula|
235834|NCT02433600|Other|Cow milk-based infant formula with enriched protein fractions|
235835|NCT02433626|Drug|COTI2|COTI-2 is a third generation thiosemicarbazone.
235836|NCT00168571|Biological|Measles vaccine|
235837|NCT02433639|Drug|TH-302 monotherapy|TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
235838|NCT02433652|Biological|Recombinant live attenuated trivalent dengue vaccine|Contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10^3.0 PFU of each component.
235839|NCT02433652|Biological|Placebo|
235840|NCT02433652|Biological|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10^3 PFU
235841|NCT02433665|Drug|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
235842|NCT02433665|Device|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
235843|NCT02433678|Drug|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
235844|NCT02433678|Drug|Placebo|
235845|NCT02433691|Other|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
235846|NCT02433691|Other|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
235847|NCT00002461|Biological|filgrastim|
236179|NCT02433795|Drug|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
236180|NCT02433808|Drug|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
236512|NCT02429180|Other|Rehabilitation|ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.
Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals
Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.
Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme
Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression.
236513|NCT02429193|Drug|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
236514|NCT02429193|Drug|Enzalutamide|Enzalutamide (160 mg/day p.o.)
236515|NCT02429206|Other|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
236516|NCT02429206|Other|standard moisturizing cream (Glaxal Base)|
236517|NCT02429219|Drug|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
236518|NCT02429219|Procedure|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
236519|NCT02429219|Procedure|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
236520|NCT00167921|Drug|Premarin® oral tablets|
236521|NCT02429232|Drug|Pioglitazone|Pioglitazone 30mg/tablet once daily
236522|NCT02431676|Drug|Metformin|Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
236523|NCT02431676|Behavioral|Coach Directed Behavioral Weight Loss|Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
236524|NCT00168311|Device|sham TMS|
236525|NCT02431676|Behavioral|Self-control weight loss|
236526|NCT02431689|Procedure|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
235898|NCT02441140|Procedure|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
235899|NCT02441140|Procedure|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
235900|NCT02441140|Procedure|Blood collection|Intravenous blood collection will be drawn from an IV
235901|NCT02441140|Procedure|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
235902|NCT00169299|Drug|Multibotanical preparation|
235903|NCT02441153|Other|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
236181|NCT02433808|Other|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
236182|NCT02433821|Other|Pilates|
236183|NCT02433834|Drug|Glycopyrronium MDI|GP MDI
236184|NCT02433834|Drug|Serevent Diskus 50 μg|
236185|NCT02433834|Drug|Placebo|
236186|NCT02433847|Drug|Mosapride|
236187|NCT02433860|Behavioral|pharmacist nicotine cessation counseling using SCRIPT protocol|Participant will be shown a short DVD "Commit to Quit: During and After Pregnancy. She will be given "a Pregnant Woman's Guide to Quitting" booklet.
Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.
Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.
At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately > 36 weeks gestation or at delivery.
236188|NCT02436369|Dietary Supplement|low fat yogurt enriched with flaxseed|daily intake of low fat yogurt enriched with flaxseed for 8 weeks
236189|NCT02436369|Dietary Supplement|low fat yogurt|daily intake of low fat yogurt for 8 weeks
236190|NCT02436382|Other|change in temperature|increase in ambient room temperature
236191|NCT02436395|Procedure|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
236192|NCT02436395|Procedure|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
235601|NCT02448290|Drug|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
235602|NCT02448303|Drug|Pembrolizumab|
235603|NCT02448303|Drug|ACP-196|
235604|NCT02448316|Procedure|endoscopic surgery|Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.
A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).
Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,
235605|NCT02448316|Drug|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
235606|NCT02448316|Drug|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
235904|NCT02441166|Procedure|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
235905|NCT02441179|Other|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
235906|NCT02441179|Other|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
235907|NCT02441179|Other|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
235908|NCT02441192|Other|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
235909|NCT02441192|Other|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
235910|NCT02443701|Other|Exercise|Warmup program, maximum isometric strengthening, and jump training
235911|NCT00169585|Drug|Levofloxacin oral tablets|
235912|NCT02443701|Other|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
235913|NCT02443701|Other|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
235311|NCT00171041|Drug|valsartan|
235312|NCT02452892|Device|LFMS|Low field magnetic stimulation (1 kHz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
235313|NCT02452905|Drug|Nitazoxanide|
235314|NCT02452905|Drug|Placebo (for Nitazoxanide)|
235315|NCT02454998|Other|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
235316|NCT02455011|Biological|REMD-477|
235317|NCT02455037|Other|Neck Strengthening|Targeted neck strengthening exercises
235318|NCT02455050|Drug|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops [New Eye Drop Formula] in each eye.
235319|NCT02455050|Drug|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
235320|NCT02455050|Drug|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
235321|NCT02455076|Drug|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
235607|NCT02448316|Behavioral|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
235608|NCT02448329|Drug|AZD1775|AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1~3
235609|NCT02448329|Drug|paclitaxel|paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
235610|NCT02448342|Device|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
235611|NCT00170365|Behavioral|Restorative Yoga|
235612|NCT02448355|Device|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
235613|NCT02448368|Drug|RDEA3170, 5mg|
235614|NCT02448368|Drug|RDEA3170,10 mg|
235033|NCT02459470|Procedure|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
235034|NCT02459483|Behavioral|Nurse phone call|
235035|NCT02459496|Behavioral|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines (with or without specific focus on BCAA and PUFA)
235036|NCT02459509|Drug|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
235037|NCT02459522|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
235038|NCT02459535|Other|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
235039|NCT02459535|Other|oral stimulation saccharin|
235040|NCT00172055|Drug|Zoledronic acid|
235041|NCT02459535|Other|oral stimulation aspartame|
235042|NCT02459535|Other|oral stimulation sucralose|
235043|NCT02459548|Other|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
235044|NCT02459548|Other|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
235045|NCT02459561|Device|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
235046|NCT02461667|Drug|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
235047|NCT02461667|Drug|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
235048|NCT02461680|Procedure|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
235049|NCT00172484|Procedure|nursing program|To establish a systemic stroke prevention, education protocol
235050|NCT02461680|Procedure|suture|
235051|NCT02461693|Drug|Caffeine|200mg delivered as pill; one-time dose
234454|NCT02435589|Other|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
234455|NCT02435589|Other|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
234456|NCT02435602|Procedure|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
234457|NCT02435602|Procedure|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions >= 5 mm diameter Pathologic examination of all biopsy tissue specimens
234458|NCT02435615|Device|SaniSal Oral Fluid Collector|Sanisal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
234750|NCT02428491|Biological|DTaP-IPV-Hep B-PRP-T combined vaccine (Hexaxim™)|0.5 mL, Intramuscular
234751|NCT02428491|Biological|DTaP-IPV-Hep B-PRP-T combined vaccine (Hexaxim™)|0.5 mL, Intramuscular
234752|NCT02428517|Procedure|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
234753|NCT02428517|Procedure|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
234754|NCT02428517|Procedure|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
234755|NCT00167830|Behavioral|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
234756|NCT02428517|Procedure|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
234757|NCT02428530|Other|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
234758|NCT02428543|Drug|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
234759|NCT02428556|Other|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
234760|NCT02428556|Other|promising language|Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs ("promising drug")
234159|NCT02440438|Biological|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
234160|NCT02440451|Device|Neurofeedback (BCI using neuroimaging)|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
234161|NCT02440464|Procedure|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
234162|NCT02440464|Drug|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -5 through Day -2.
234163|NCT02440464|Drug|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -3 and -2.
234164|NCT02440464|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Days -2, +1, +4 and +7.
234165|NCT02440464|Drug|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
234166|NCT00169247|Procedure|Radiotherapy 70 Gy, 35 fractions|
234167|NCT02442843|Device|Active tDCS|Participants will complete up to 10 daily sessions of tDCS over two consecutive weeks. Each session will last 1 - 2 hours.
234459|NCT00168805|Drug|enoxaparin|40 mg once daily
234460|NCT02435628|Other|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
234461|NCT02435641|Other|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
234462|NCT02435654|Drug|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
234463|NCT02435667|Other|Resistance Exercise Training|Aerobic Exercise
a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.
Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.
a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises
Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises
234174|NCT02442869|Behavioral|Dialectical Behavioral Therapy (DBT) long|4-16 weeks of Dialectical Behavioral Therapy (DBT) long course
234175|NCT02442908|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
234176|NCT02442908|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
234177|NCT02442921|Drug|Colchicine|up to 2mg of Colchicine daily
234178|NCT02442921|Drug|Placebo|Daily placebo
234179|NCT02442934|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
234180|NCT02442934|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
234181|NCT02442934|Other|Targeted interventions in each ICU to reduce discomforts|These targeted interventions are implemented through the coordination of two local champions.
The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.
The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures.
234182|NCT00169533|Drug|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
234183|NCT02442947|Other|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment [charcoal base], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
234184|NCT02442960|Drug|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
234185|NCT02442973|Procedure|Control group (CG): standard practice|Standard practice group
234186|NCT02442973|Procedure|Ultrasound group (UG):|SpineView3D™ anatomical "scouting" approach
234477|NCT02438085|Other|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
234478|NCT02438098|Drug|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
234479|NCT02438111|Genetic|metagenome|metagenome
234480|NCT02438124|Behavioral|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
238863|NCT02449577|Other|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
238864|NCT02449577|Other|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
238865|NCT02449577|Other|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
238866|NCT02449590|Dietary Supplement|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
238867|NCT02449590|Dietary Supplement|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
238868|NCT02449603|Drug|Exenatide|
238869|NCT02449603|Drug|Biphasic insulin Aspart 30|
238870|NCT02449616|Drug|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
238871|NCT00170573|Drug|Caelyx|Caelyx 40 mg/ m2biweekly
238872|NCT02449655|Drug|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
238873|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
238874|NCT02449655|Drug|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
238875|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
238876|NCT02449668|Device|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
238877|NCT02449668|Device|Sham Acupuncture|
238878|NCT02449681|Drug|TH-4000|
238879|NCT02449694|Device|OCS Liver|OCS Liver will be used to preserve the donor liver
238880|NCT02449707|Procedure|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
238881|NCT02449707|Device|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
238882|NCT00170586|Device|Underglove coating (skin barrier)|
238305|NCT02460731|Other|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors] Solution for intravenous infusion
238306|NCT02460744|Radiation|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
238307|NCT02460757|Other|Laryngoscopy|Observation of glottic width in different arms
238308|NCT00000367|Drug|Treatment of depression|
238309|NCT00002470|Drug|fluorouracil|
238310|NCT00172185|Drug|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
238598|NCT02454114|Other|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
238599|NCT02456428|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
238600|NCT02456428|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
238601|NCT02456428|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
238602|NCT02456428|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
238603|NCT02456428|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
238604|NCT00171574|Drug|Valsartan plus HCTZ|
238605|NCT02456428|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
238606|NCT02456428|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
237999|NCT02429726|Drug|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
238000|NCT02429726|Drug|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
238001|NCT02429726|Drug|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
238002|NCT00167986|Drug|vancomycin-resistant enterococci and ESBL|
238003|NCT02429739|Behavioral|Working memory Training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
Other name: Cogmed RoboMemo
238004|NCT02429752|Other|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
238311|NCT02460770|Drug|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
238312|NCT02460783|Dietary Supplement|Boost A|Supplement providing 530 Kcal/Bottle
238313|NCT02460783|Behavioral|Healthy Living Diet|Counseling and educational material on diet portion, consistency
238314|NCT02460796|Other|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
238315|NCT02460809|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
238316|NCT02462928|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
238317|NCT02462928|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
238318|NCT02462928|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
238319|NCT02462941|Drug|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
238320|NCT02462941|Procedure|Cardiac catheterization|(non-experimental) standard procedure
238321|NCT00173537|Procedure|for BMPR II study|
237693|NCT02434718|Drug|BIIB037 (aducanumab)|As described in the treatment arm
237694|NCT00002461|Biological|sargramostim|
237695|NCT00168701|Drug|BG00012|
237696|NCT02434718|Drug|Placebo|IV administration of 0.9% sodium chloride
237697|NCT00002461|Drug|cyclophosphamide|
237698|NCT00168909|Drug|placebo|placebo once daily, oral, for 3 years
237699|NCT02436993|Drug|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
237700|NCT02437006|Other|exercise|cycle ergometry
237701|NCT02437019|Drug|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
237702|NCT02437032|Drug|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
237703|NCT02437032|Drug|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
237704|NCT02437032|Drug|hMG|Controlled ovarian stimulation with 150-300 UI hMG
237705|NCT02437045|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
237706|NCT02437045|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
237707|NCT02437058|Other|preidictive model|
237708|NCT02437071|Drug|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
237709|NCT00168922|Drug|Bendamustin/Ribomustin|
237710|NCT02437071|Radiation|Radiotherapy|
237711|NCT02437071|Procedure|Radiofrequency ablation|
237712|NCT02437084|Drug|Atorvastatin|study subjects divided into 2 groups as described earlier and both receiving atorvastatin 40 mg for 8 weeks.
238005|NCT02429765|Drug|ACL/FOR|
238006|NCT02429765|Drug|Placebo|
237082|NCT02448888|Other|General exercise recommendations|2 months, 3 times/week
237083|NCT02448901|Drug|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
237084|NCT02448914|Drug|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
237085|NCT02448914|Drug|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
237392|NCT02441803|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
237393|NCT02441803|Drug|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
237394|NCT02441803|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
237395|NCT02441803|Drug|Decitabine|20 mg/m2 by vein on Days 1 - 5.
237396|NCT02441803|Drug|Cytarabine|1 g/m2 by vein on Days 6 - 10.
237397|NCT02444260|Drug|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
237398|NCT02444260|Drug|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
237399|NCT02444273|Procedure|Exercise|Subjects will be given and individualized exercise program.
237400|NCT02444299|Device|Shoulder hemi-arthroplasty|
237401|NCT02444312|Behavioral|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
237402|NCT02444312|Behavioral|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
237403|NCT02444325|Behavioral|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
237404|NCT02444338|Device|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
237405|NCT02444338|Other|standard of care|
237406|NCT00169689|Other|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
237407|NCT02444351|Drug|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
236765|NCT02455700|Device|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
236766|NCT02455713|Device|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
236767|NCT02455726|Dietary Supplement|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
236768|NCT02455726|Dietary Supplement|Fructose|Oral fructose 10 g twice a day
236769|NCT02455726|Drug|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
236770|NCT02455726|Drug|Pregabalin|Pregabalin 25 mg at 8 pm
236771|NCT00002466|Drug|doxorubicin hydrochloride|
237086|NCT02448927|Device|balloon aortic valvuloplasty|
237087|NCT02448927|Device|Transcatheter Aortic Valve Implantation|
237088|NCT02448940|Dietary Supplement|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
237089|NCT02448940|Dietary Supplement|lactose|2 capsule a day containing lactose
237090|NCT00170430|Drug|Metronizadole|
237091|NCT02448953|Procedure|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
237092|NCT02451085|Behavioral|training with video therapy|training with video therapy
237093|NCT02451085|Behavioral|conventional exercise|training in conventional way
237094|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
237095|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
237096|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
237097|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
237098|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
237099|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
237100|NCT02451111|Drug|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
236439|NCT02459977|Procedure|Kidney transplantation|kidney transplantation
236440|NCT02460003|Behavioral|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
236441|NCT02460003|Other|Home exercise program|Home exercise program
236442|NCT02460016|Drug|AK0529|AK0529 pellets for oral administration
236443|NCT00172107|Drug|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
236444|NCT02460029|Other|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
236445|NCT02460042|Procedure|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
236446|NCT02460042|Device|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
236447|NCT02460055|Device|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
236448|NCT02460055|Drug|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
236449|NCT02462213|Other|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
236772|NCT00171470|Drug|Tegaserod|
236773|NCT02455739|Other|chewing gum|postoperative gum chewing to improve gastrointestinal function
236774|NCT02455752|Procedure|LE-TME|Retroperitoneal approach for total mesorectal excision
236775|NCT02455765|Other|Rice and Amino Acid mixtures|Rice and amino acid mixture
236776|NCT02455778|Dietary Supplement|Cinnamon|
236777|NCT00171834|Drug|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
236778|NCT02458053|Behavioral|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
236779|NCT02458053|Behavioral|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
236123|NCT02428959|Drug|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
236124|NCT02428972|Drug|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
236125|NCT02428972|Drug|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
236126|NCT02428985|Drug|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
236127|NCT02428998|Dietary Supplement|Korean Red Ginseng|
236128|NCT02428998|Dietary Supplement|Placebo|
236129|NCT02429011|Device|fMRI|a baseline pretreatment scan and (2) a post-treatment scan at 24 hours after participants receive either IV ketamine or IV midazolam in a randomized, double-blind manner
236130|NCT02429011|Drug|ketamine or midazolam|
236131|NCT00167895|Procedure|Adding platelet concentrate to the wound|
236132|NCT02429024|Device|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
236133|NCT02429024|Device|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
236134|NCT02429037|Drug|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10^12 viral particles (VP) in a 21-days cycle.
236135|NCT02429037|Radiation|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
236136|NCT02429037|Drug|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
236137|NCT02429050|Drug|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
236138|NCT02429050|Drug|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
236527|NCT02431702|Drug|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
236528|NCT02431702|Drug|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
236529|NCT02431702|Drug|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
236530|NCT02431702|Drug|Paliperidone ER|Paliperidone Extended Release (ER) tablets 3 to 12 milligram (mg) per day will be administered by orally.
236836|NCT02462408|Procedure|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
236837|NCT02462408|Procedure|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
236838|NCT02462421|Drug|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
236839|NCT00173082|Procedure|Glucose tolerance test|
236840|NCT02462434|Behavioral|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
236841|NCT02462447|Drug|11C-sarcosine|Radiotracer injection for PET/CT scan
236842|NCT02462447|Drug|11C-choline|Radiotracer injection for PET/CT scan
236843|NCT02462460|Device|MRI|
236844|NCT02462473|Drug|Aripiprazole|Participants will receive aripiprazole 5 milligram (mg) oral formulation once daily for 12 weeks as part of participant treatment.
236845|NCT02462473|Drug|Olanzapine|Participants will receive olanzapine 5 mg oral formulation once daily for 12 weeks as part of participant treatment.
236846|NCT02462473|Drug|Paliperidone|Participants will receive paliperidone 3 mg oral formulation once daily or 39 mg once every 4 weeks for 12 weeks as part of participant treatment.
236847|NCT02464774|Radiation|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
236193|NCT00168857|Drug|telmisartan|
236194|NCT02436408|Drug|Vismodegib|
236195|NCT02436421|Other|Best Practice Alert based in the Electronic Medical Record|
236196|NCT02436434|Device|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
236197|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
236198|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
236199|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
236200|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
236531|NCT02431702|Drug|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
236532|NCT02431702|Drug|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
236533|NCT02431702|Drug|Risperidone|Risperidone will be administered in accordance with the label or Investigator's discretion
236534|NCT02431702|Drug|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92.
236535|NCT00168324|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
236536|NCT02431702|Drug|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92. Dose will be increased based on Investigator's discretion.
236537|NCT02431715|Drug|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|All patients will have their weight and baseline vital signs recorded.
The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.
The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.
Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.
Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians.
236538|NCT02431728|Dietary Supplement|Melatonin|5 mg capsule p.o. at bedtime daily
236539|NCT02431728|Dietary Supplement|Matched Placebo|5 mg capsule p.o. at bedtime daily
236540|NCT02431741|Device|Mepilex Transfer Ag|
235914|NCT02443714|Device|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
235915|NCT02443714|Device|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
235916|NCT02443727|Drug|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
235917|NCT02443727|Other|Placebo|Dosage and details described in arm.
235918|NCT02443740|Drug|PF-05251749|Single ascending doses of PF-05251749 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
235919|NCT02443740|Drug|PF-05251749|Single ascending doses of PF-05251749 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
235920|NCT02443740|Drug|PF-05251749|Single dose (Maximum Tolerated Dose) of PF-05251749 as extemporaneously prepared solution/suspension
236201|NCT02436460|Other|Laboratory Biomarker Analysis|Correlative studies
236202|NCT02436460|Biological|Neihulizumab|Given IV
236203|NCT02436460|Other|Pharmacological Study|Correlative studies
236204|NCT00168857|Drug|losartan|
236205|NCT02436473|Drug|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
236206|NCT02436473|Other|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
236207|NCT02436473|Drug|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
236208|NCT02436473|Drug|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
236209|NCT02436486|Drug|Placebo|Capsules, orally, single dose
236210|NCT02436486|Drug|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
236211|NCT02436486|Drug|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
236212|NCT02436486|Drug|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
236213|NCT02436499|Drug|Botulinum Toxin-A|
236214|NCT02436512|Drug|Inhaled Nitric Oxide|The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:
(Dose 1): 5 ppm inhaled nitric oxide for 15 minutes
(Dose 2): 40 ppm inhaled nitric oxide for 15 minutes
235615|NCT02448368|Drug|RDEA3170, 2.5 mg|
235616|NCT02448381|Drug|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
235617|NCT02448381|Drug|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
235618|NCT02448394|Other|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
235619|NCT02448407|Biological|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
235620|NCT02448407|Drug|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
235621|NCT02450487|Drug|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
235622|NCT02450500|Behavioral|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
235623|NCT02450513|Drug|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
235921|NCT02443753|Device|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
235922|NCT00169598|Procedure|positron emission tomography|
235923|NCT02443766|Other|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
235924|NCT02443792|Procedure|Unicirc with tissue adhesive|As above
235925|NCT02443792|Procedure|Open Surgical|As above
235926|NCT02443805|Biological|300 IR|300 IR tablet of HDM Allergen Extracts
235322|NCT02455076|Drug|Glargine|Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.
FBG >180 mg/dL, no hypoglycemia; glargine increased by 4 IU.
FBG >140 mg/dL, no hypoglycemia; glargine increased by 2 IU.
FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.
FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.
FBG or RBG < 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.
FBG or RBG < 40 mg/dl, decrease dose of glargine by 30%.
235323|NCT02455076|Drug|Oral antidiabetic drugs|The dose of oral antidiabetic drugs will be adjusted based on the blood glucose levels.
235324|NCT00171353|Drug|valsartan|
235325|NCT02455076|Drug|Rapid-acting insulin analogs|If the BG levels are >140 mg/dL, rapid acting insulin analogs will be administered following the "supplemental/sliding scale" protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the "usual" dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the "sensitive" dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG> 400 mg/dL, the insulin will be 8,12 or 16 units.
235326|NCT02455089|Other|GADD34 RNA level measurement.|Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.
A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months.
235327|NCT02455102|Other|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
235328|NCT02455115|Other|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
235329|NCT02455115|Drug|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
235330|NCT02455115|Drug|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
235331|NCT02455128|Other|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
235332|NCT02455141|Drug|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
235333|NCT02457351|Drug|Itraconazole (Sporanox)|Part 1 & Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
235334|NCT02457377|Procedure|laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
234761|NCT02428556|Other|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
234762|NCT02430909|Other|Placebo|Pharmaceutical form: Solution for infusion
Concentration: 0.9% saline
Route of administration: Intravenous infusion
234763|NCT02430922|Device|iVolution nitinol stent|
234764|NCT02430935|Behavioral|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
234765|NCT02430935|Behavioral|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
235052|NCT02461693|Drug|Placebo|
235053|NCT02461706|Drug|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
235054|NCT02461706|Other|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
235055|NCT02461719|Drug|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
235056|NCT02461719|Drug|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
235057|NCT02461732|Behavioral|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|Topics covered include:
drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings
235058|NCT02461732|Behavioral|Cognitive-Behavioral Therapy for Substance Dependence|Topics covered include:
drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities
235059|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
234464|NCT02435667|Radiation|DEXA bone scan|A DEXA scan that provides bone density measures.
234465|NCT02435667|Other|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
234466|NCT02435667|Other|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
234467|NCT02435667|Other|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
234468|NCT02435667|Other|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
234469|NCT02435680|Drug|MCS110|taken by I.V
234470|NCT00168805|Drug|dabigatran etexilate|150 mg once daily
234471|NCT02435680|Drug|carboplatin|taken by I.V
234472|NCT02435680|Drug|gemcitabine|taken by I.V
234473|NCT02438033|Device|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
234474|NCT02438046|Procedure|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
234475|NCT02438059|Behavioral|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
234476|NCT02438072|Drug|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
234766|NCT02430948|Other|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
234767|NCT02430948|Other|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
234768|NCT02430948|Other|Standard support|Screening recommendations presented in standard format
234769|NCT02430948|Other|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
234770|NCT02430974|Drug|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
234771|NCT02430987|Other|questionnaire|will be applied questionnaire about sexuality
234481|NCT02438137|Drug|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Subjects will be instructed to take the medication with food, in the morning and at dinnertime. If subjects miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
234482|NCT02438137|Drug|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Subjects will be instructed to take the placebo with food, in the morning and at dinnertime. If subjects miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
234483|NCT00169078|Drug|Chloroquine|
234484|NCT02438150|Behavioral|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
234485|NCT02438150|Behavioral|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
234486|NCT02438163|Device|Theta Burst Stimulation|During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.
During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session.
234487|NCT02438176|Procedure|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
234488|NCT02438176|Procedure|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
234489|NCT02438189|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
234490|NCT02440464|Drug|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
234785|NCT02433171|Procedure|Standard of Care FDG-PET Imaging|[11C]Methionine [11]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. [11C]PBR28 [12]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
234786|NCT02433184|Drug|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
234787|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
238883|NCT02449707|Device|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
234187|NCT02442973|Device|Accuro SpineView3D™|
234188|NCT02442999|Other|Screening for obstructive sleep apnea|
234189|NCT02442999|Device|CPAP - continuous positive airway pressure|
234190|NCT02445586|Drug|Pertuzumab|The initial dose (Cycle 1, Day 1) will be 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.
234191|NCT02445586|Drug|Trastuzumab|Initial dose of trastuzumab was 8 mg/kg administered as a 90-minute intravenous infusion, followed every 3 weeks by a dose of 6 mg/kg administered as an intravenous infusion over 30 to 90 minutes.
234192|NCT02445599|Drug|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
234193|NCT02445599|Drug|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
234194|NCT02445599|Drug|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
234195|NCT02445599|Drug|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
234196|NCT02445599|Drug|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
234197|NCT02445599|Drug|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
234198|NCT02445599|Drug|Metamizole-sodium|Additional rescue analgetic 2g intravenously
234199|NCT02445599|Drug|Tramadol|Additional rescue analgetic 100mg intravenously
234200|NCT00169845|Other|Placebo|Alpha-Tocopherol placebo and Beta-Carotene placebo (the Beta-Carotene placebo was stopped during the trial)
234201|NCT02445612|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
234202|NCT02445625|Device|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
234203|NCT02445638|Other|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
234204|NCT02445638|Other|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
234205|NCT02445651|Dietary Supplement|Intravenous and Oral n—acetyl cysteine|
238607|NCT02456441|Other|Intervention group|The device current generator TENS used was " Neurodyn Portable Tens / Fes " of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 "microseconds" and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes
238608|NCT02456441|Other|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
238609|NCT02456454|Drug|Risperidone|Liquid risperidone
238610|NCT02456454|Drug|Valproic Acid|Liquid valproic acid
238611|NCT02456454|Drug|Placebo Valproic Acid|PCB
238612|NCT02456480|Drug|CLS001|topical gel
238884|NCT02449707|Device|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
238885|NCT02449707|Device|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
238886|NCT02451826|Drug|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
238887|NCT02451852|Drug|AZD9291|AZD9291 80mg tablet once daily, open label
238888|NCT00170911|Drug|AAE581|
238889|NCT02451865|Drug|Binimetinib|Given PO
238890|NCT02451865|Drug|Docetaxel|Given IV
238891|NCT02451865|Other|Laboratory Biomarker Analysis|Correlative studies
238892|NCT02451878|Device|E-Couch|
238893|NCT02451891|Biological|MVA-EBO Z|
238894|NCT02451891|Biological|ChAd3-EBO Z|
238895|NCT02451904|Other|Observation|
238896|NCT02451917|Drug|Glargine|Comparison of Glargine Insulin versus NPH on glucose levels.
238897|NCT02451917|Drug|NPH insulin|
238898|NCT02451930|Drug|Necitumumab|Administered IV
238322|NCT02462954|Device|ContraGel|
238323|NCT02462954|Device|HEC Universal Placebo gel|
238324|NCT02462967|Drug|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
238325|NCT02462967|Drug|Placebo|Placebo for GR-MD-02
238326|NCT02462993|Drug|Aloe Vera|Local drug delivery of aloe vera gel
238327|NCT02463006|Drug|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
238328|NCT02463006|Drug|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
238329|NCT02463019|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
238330|NCT02463032|Drug|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
238331|NCT02463045|Drug|TOP1288|
238332|NCT00173537|Genetic|BMPRII|
238613|NCT02456480|Drug|Vehicle|topical gel
238614|NCT02456506|Radiation|Hyperfractionated IMRT|
238615|NCT00002466|Drug|etoposide|
238616|NCT00171574|Drug|Lisinopril|
238617|NCT02456506|Radiation|Conventional Fraction IMRT|
238618|NCT02456519|Other|PaedQoR-15 questionnaire|Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
238619|NCT02456532|Drug|placebo|
238620|NCT02456532|Drug|Zolpidem CR|
238621|NCT02458625|Dietary Supplement|Iron bisglycinate 60 mg|
238622|NCT02458638|Drug|Atezolizumab|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
238623|NCT02458651|Other|No intervention|No intervention administered in this study
238624|NCT00002466|Procedure|conventional surgery|
238007|NCT02429778|Behavioral|Diaphragmatic Breathing|Deep or diaphragmatic breathing is taught prior to relaxation.
238008|NCT02429778|Behavioral|Progressive Muscle Relaxation|Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
238009|NCT02429791|Drug|DTG 50 mg|Participants will take one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet will contain 52.62 mg dolutegravir sodium salt, which is equivalent to 50 mg dolutegravir free acid.
238010|NCT02429791|Drug|RPV 25 mg|Participants will take one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet will contain 27.5 mg of rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.
238011|NCT02429791|Drug|CAR|CAR will include following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
238012|NCT02429804|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
238013|NCT00167999|Drug|piperacillin-tazobactam|
238014|NCT02429804|Radiation|Fludeoxyglucose F-18|Given IV
238015|NCT00002460|Procedure|ablative endocrine surgery|
238016|NCT00168389|Drug|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
238017|NCT02432274|Drug|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
238018|NCT02432274|Drug|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
238019|NCT02432274|Drug|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
238020|NCT02432287|Drug|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
238021|NCT02432287|Drug|Placebo|
238022|NCT02432300|Behavioral|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
238023|NCT02432313|Drug|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
238024|NCT02432326|Drug|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3.
238025|NCT02432326|Drug|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
237408|NCT02444351|Other|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
237409|NCT02444364|Drug|Sitagliptin|
237410|NCT02444377|Behavioral|Interval training|
237411|NCT02444390|Procedure|Biopsy|biopsy of a metastasis
237713|NCT02437097|Other|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
237714|NCT02437097|Other|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
237715|NCT02437097|Other|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
237716|NCT02437097|Other|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
237717|NCT02437110|Drug|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
237718|NCT02439515|Device|Balance|Balance control exercises with visual biofeedback
237719|NCT02439515|Other|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
237720|NCT02439528|Genetic|Genetic analysis|One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.
The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.
237721|NCT02439541|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10^7)
237722|NCT02439567|Device|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
237723|NCT02439580|Dietary Supplement|Annona muricata extract|ethanol-soluble fraction of water extract
237101|NCT02451111|Drug|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
237102|NCT00170820|Drug|Everolimus|
237103|NCT02451124|Device|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
237104|NCT02451124|Other|Questionnaire Administration|Ancillary studies
237105|NCT02451124|Other|Laboratory Biomarker Analysis|Correlative studies
237106|NCT02451124|Procedure|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
237107|NCT02451137|Drug|INSULIN GLARGINE (U300)|Pharmaceutical form: solution
Route of administration: subcutaneous
237108|NCT02451137|Drug|INSULIN GLARGINE (U100)|Pharmaceutical form: solution
Route of administration: subcutaneous
237412|NCT02444403|Behavioral|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).
A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3).
237413|NCT02444416|Procedure|blood sample|
237414|NCT02444429|Drug|Corticosteroid boluses Methylprednisolone|Intensification of the corticotherapy in accordance with the validated protocol for the treatment of "classic" and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.
An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.
The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered
237415|NCT02444429|Other|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
237416|NCT02444429|Other|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
236780|NCT02458053|Behavioral|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
236781|NCT02458053|Behavioral|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
236782|NCT02458053|Other|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
236783|NCT02458053|Behavioral|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
236784|NCT02458066|Other|IRS: bendiocarb|carbamate insecticide
236785|NCT02458066|Other|IRS: deltamethrin|Pyrethroid insecticide
236786|NCT02458079|Drug|Pentoxiphylline|
236787|NCT02458079|Drug|Stool microbiota transplantation|
236788|NCT00171847|Drug|Letrozole|
236789|NCT02458092|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
236790|NCT02458092|Biological|Rabipur|Rabipur is a licensed rabies vaccine.
236791|NCT02458105|Behavioral|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
236792|NCT02458105|Behavioral|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
236793|NCT02458118|Drug|Secretin|Secretin 1 IU/kg over 3 min
237109|NCT02451137|Drug|Insulin detemir (Levemir)|Pharmaceutical form: solution
Route of administration: subcutaneous
237110|NCT02451150|Drug|TAK-536 5 mg|TAK-536 tablets
237111|NCT02451150|Drug|TAK-536 10 mg|TAK-536 tablets
237112|NCT02451163|Dietary Supplement|wheat polysaccharides|Consumed once daily for 12 weeks.
237113|NCT00170833|Drug|Everolimus|
237114|NCT02451163|Dietary Supplement|maltodextrin|Consumed once daily for 12 weeks.
237115|NCT02451176|Device|Davol Bard Soft Mesh synthetic|soft mesh synthetic
237116|NCT02451176|Device|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
236139|NCT02429063|Device|Bright White Light|The light will be administered via a Litebook Elite (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
236450|NCT02462226|Behavioral|The-Optimal-Lymph-Flow|The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes "what to do," rather than "what to avoid." It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.
236451|NCT02462226|Behavioral|Arm Precaution|The webpage also has a section entitled "Arm Precautions," representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb.
236452|NCT00172809|Drug|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
236453|NCT02462239|Other|Whole-body FDG PET-CT|
236454|NCT02462252|Drug|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
236455|NCT02462252|Drug|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
236456|NCT02462252|Drug|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
236457|NCT02462252|Drug|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
236458|NCT02462265|Drug|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) & Oshadi R (180mg TID) will be administrated;
236459|NCT02462265|Drug|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
236460|NCT02462278|Device|TempuRing|
236461|NCT02462291|Other|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
236462|NCT02462304|Procedure|End-Point-Management grid laser|
236463|NCT00172939|Procedure|foreskin from healthy adults|
236464|NCT02462304|Drug|ranibizumab|
236848|NCT02464787|Dietary Supplement|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
236849|NCT02464800|Procedure|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
236850|NCT02464813|Drug|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
236851|NCT02464813|Drug|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
236852|NCT00174226|Drug|Atomoxetine|
236853|NCT02464813|Drug|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
237168|NCT02458183|Biological|DTaP-IPV combination vaccine|0.5-mL IM
237169|NCT02458183|Biological|DTaP vaccine and IPV vaccine|0.5-mL IM
237170|NCT02458196|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
237171|NCT02458196|Drug|Prednisone and Mycophenolate mofetil|Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months.
237172|NCT02458209|Biological|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
237173|NCT02458209|Biological|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
237174|NCT02458209|Biological|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
237175|NCT02458222|Other|language game therapy|participants will take part in 3 different types of game therapy, differentiated by type of language facilitation offered, or no facilitation
237176|NCT02458222|Other|standard therapy|usual clinical care
237177|NCT00171847|Drug|Letrozole|
237178|NCT02458235|Drug|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
237179|NCT02458235|Biological|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
236541|NCT02431754|Drug|Tadalafil|Administered orally
236542|NCT02431754|Drug|Placebo|Administered orally
236543|NCT02431754|Drug|Alpha1 Blocker|Administered orally
236544|NCT00168610|Drug|Vitamin A|
236545|NCT02433873|Dietary Supplement|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
236546|NCT02433886|Procedure|Gamma Ventral Capsulotomy|
236547|NCT02433899|Procedure|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
236548|NCT02433899|Procedure|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
236549|NCT02433899|Drug|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
236550|NCT02433899|Drug|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
236854|NCT02464826|Drug|Nailprotex|Nailprotex apply to the abnormal nail twice daily
236855|NCT02464852|Behavioral|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
236856|NCT02464852|Behavioral|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
236857|NCT02464852|Device|Sheffield Support Snood|
236858|NCT02464852|Device|sEMG|
236859|NCT02464865|Drug|Thiamine 1|If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.
Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks
236860|NCT02464865|Other|no intervention|no symptoms and signs of thiamine deficiency
236861|NCT02464865|Drug|Thiamine 2|If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.
If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks
236862|NCT02464878|Drug|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
236863|NCT00174226|Drug|Buspirone|
236215|NCT02438800|Behavioral|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
236216|NCT02438813|Other|No Intervention|
236217|NCT02438826|Drug|LY2951742|Administered SQ
236218|NCT02438826|Drug|Placebo|Administered SQ
236219|NCT02438852|Other|Placebo|Given IV
236220|NCT02438852|Other|Questionnaire Administration|Ancillary studies
236221|NCT02438852|Drug|Ropivacaine Hydrochloride|Given IV
236222|NCT02438865|Drug|Immediate instillation of intravesical chemotherapy-Epirubicin-|
236223|NCT02438865|Drug|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
236224|NCT00169130|Drug|cyclophosphamide|
236225|NCT02438878|Behavioral|Baby Behavior|
236551|NCT02433899|Drug|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
236552|NCT02433912|Procedure|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
236553|NCT02433912|Procedure|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
236554|NCT02433912|Drug|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
236555|NCT00168623|Drug|Vitamin A|
236556|NCT02433912|Drug|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
236557|NCT02433925|Dietary Supplement|Resveratrol|
236558|NCT02433925|Dietary Supplement|Placebo|
236559|NCT02433938|Procedure|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
236560|NCT02433938|Procedure|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
235927|NCT02443805|Biological|Placebo|Placebo tablet
235928|NCT02443818|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
235929|NCT02443831|Procedure|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19 CAR T-cells
235930|NCT02443831|Drug|Lymphodepletion with fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19CAR T-cell infusion.
235931|NCT02443831|Drug|Lymphodepletion with cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19CAR T-cell infusion.
235932|NCT02443831|Biological|CD19 CAR T-cells|A single dose of 3 x 106/kg CD19CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
235933|NCT00169611|Drug|methylphenidate|
235934|NCT02446314|Dietary Supplement|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
235935|NCT02446327|Other|Blood sampling for biomarker assessment|
235936|NCT00169975|Device|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
235937|NCT02446340|Drug|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
235938|NCT02446340|Drug|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
235939|NCT02446353|Drug|Apetrol ES / Megace|Sequences of administered drugs
235940|NCT02446366|Other|Laboratory Biomarker Analysis|Correlative studies
236226|NCT02438891|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
236227|NCT02438904|Biological|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
236228|NCT02438930|Behavioral|Motivational interviewing intervention during HIV testing|
236229|NCT02438930|Behavioral|Standard-of-care counseling during HIV testing|
235335|NCT02457390|Procedure|CE-LUS|To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.
The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure.
235624|NCT02450526|Drug|Dysport|
235625|NCT02450526|Drug|Botox|
235626|NCT02450526|Other|AbobotulinumtoxinA Placebo|50 Units
235627|NCT02450526|Other|OnabotulinumtoxinA Placebo|20 Units
235628|NCT02450539|Drug|Abemaciclib|Administered orally
235629|NCT00170729|Drug|Prednisolone acetate|
235630|NCT02450539|Drug|Docetaxel|Administered IV
235631|NCT02450552|Drug|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
235632|NCT02450552|Drug|Placebo|Matched placebo
235633|NCT02450565|Other|Questionnaire|
235634|NCT02450578|Drug|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
235635|NCT02450578|Drug|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
235636|NCT02450578|Biological|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
235637|NCT02450578|Drug|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
235638|NCT02450591|Drug|Erlotinib|
235639|NCT02450591|Other|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
235640|NCT00170742|Drug|Octreotide, 30 mg i.m. LAR formulation|
235641|NCT02450604|Genetic|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
235642|NCT02450617|Behavioral|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
235643|NCT02450617|Behavioral|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
235060|NCT00172484|Procedure|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
235061|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
235062|NCT02461758|Biological|Influenza vaccine|40 patients will be enrolled in the TNF Monotherapy Group and randomized in a 1:1 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.
235063|NCT02461771|Drug|APL-2|On treatment day, subjects will be administered a single 100 μL IVT injection of APL-2 at the dose corresponding to their treatment assignment.
235064|NCT02464072|Procedure|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
235065|NCT02464072|Procedure|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
235066|NCT00173875|Drug|Iressa|
235336|NCT02457403|Device|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
235337|NCT02457403|Other|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
235338|NCT02457416|Other|Peanut|Treatment with peanut in increasing doses until a maintenance dose
235339|NCT02457429|Device|Experiemental diagnostic procedure: Dx-pH measurement system|The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.
The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
235340|NCT00171743|Drug|Cyclosporine microemulsion|
235341|NCT02457429|Other|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
235342|NCT02457429|Other|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
234772|NCT00168168|Drug|G-CSF/Filgrastim|
234773|NCT02431000|Procedure|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
234774|NCT02431013|Drug|Simvastatin|Simvastatin 40 mg on Day 1 & Day 8.
234775|NCT02431013|Drug|Pravastatin|Pravastatin 20 mg on Day 1 & Day 8.
234776|NCT02431013|Drug|Cilostazol|Cilostazol 100 mg twice a day for 6 days & on Day 8 with statin.
234777|NCT02431026|Device|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
234778|NCT02431039|Device|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
234779|NCT02431039|Device|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
234780|NCT02431052|Drug|DRM01|
234781|NCT02431052|Other|Vehicle|
234782|NCT02431065|Procedure|Rectus sheath block|Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:
Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.
Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
234783|NCT02433132|Other|Nasal brushing|The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
234784|NCT02433158|Drug|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses. Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg. Subjects 6 to 11 years of age or subject who weighs 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
235067|NCT02464085|Other|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
235068|NCT02464111|Other|Treatment 1: Control|No supplement provided.
235069|NCT02464111|Dietary Supplement|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
235070|NCT02464111|Dietary Supplement|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
234788|NCT02433184|Drug|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
234789|NCT02433184|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
234790|NCT02433184|Drug|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
234791|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
234792|NCT02433197|Device|Aerobic program|The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.
In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression.
234793|NCT00168506|Drug|CBT/SSRI|
234794|NCT02433210|Device|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
234795|NCT02433210|Device|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
234796|NCT02433210|Device|Optiflux 160NR|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
234797|NCT02433236|Drug|Fostamatinib Disodium tablet 100 mg|
234798|NCT02433236|Drug|Fostamatinib Disodium tablet 150 mg|
234799|NCT02433249|Behavioral|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
234800|NCT02435693|Other|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
235086|NCT02428556|Other|breakthrough with "may" warning|Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): "Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
235087|NCT02428556|Other|breakthrough with "is" warning|Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: "Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
234206|NCT02445664|Behavioral|Educational video|Video: Information on osteoporosis and alendronate treatment.
234491|NCT02440477|Other|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
234492|NCT02440490|Behavioral|Computerised cognitive training|
234493|NCT02440490|Behavioral|Video watching|
234494|NCT02440516|Other|Early treatment group|Physical- and occupational Therapy
234495|NCT02440516|Other|Late treatment group|Waiting list - then Physical- and occupational Therapy
234496|NCT02440529|Behavioral|Verbal+Visual Aid|Detailed Discussion of how cigarette smoke impacts Orthopaedic Management plus Powerpoint Presentation.
234497|NCT02440529|Behavioral|Verbal Group|Detailed Discussion of how cigarette smoke impacts Orthopaedic Management
234498|NCT02440542|Other|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
234499|NCT02440555|Other|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
234500|NCT00169260|Behavioral|motivational counseling|behavioral motivational counselling
234501|NCT02440568|Drug|Omacetaxine|Omacetaxine (at assigned dose level) administered subcutaneously Q12 hours Days 1 to 7. Dose levels include: 0.625, 1.25, 2.0, 3.0, and 4.2 mg/m^2
234502|NCT02440568|Drug|Cytarabine|Cytarabine (100mg/m2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
234503|NCT02440568|Drug|Idarubicin|Idarubicin (12 mg/m2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
234504|NCT02440581|Drug|Alendronate|
234505|NCT02440581|Drug|Teriparatide|
234506|NCT02440581|Drug|Cinacalcet|
234507|NCT02440594|Behavioral|Enhanced BHL Program|Subjects or the caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard Clinical Monitoring Module.
234508|NCT02440607|Other|Electronic Cognitive Aid|
234509|NCT02440607|Other|Static Cognitive Aid|
238899|NCT00170924|Drug|Valsartan|
238900|NCT02451930|Drug|Pembrolizumab|Administered IV
238901|NCT02451943|Drug|Olaratumab|Administered IV
238902|NCT02451943|Drug|Doxorubicin|Administered IV
238903|NCT02451943|Drug|Placebo|Administered IV
238904|NCT02451956|Drug|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
238905|NCT02451956|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
238906|NCT02451969|Biological|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
238907|NCT02451969|Biological|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
238908|NCT02451982|Drug|Cyclophosphamide|200 mg/m2
238909|NCT02451982|Biological|GVAX pancreatic cancer|5x10^8 cells
234207|NCT02445677|Device|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
234208|NCT02445677|Device|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
234209|NCT02445703|Biological|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
234210|NCT02445703|Biological|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
234211|NCT00169858|Biological|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
234212|NCT02447783|Dietary Supplement|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
234213|NCT02447783|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
234214|NCT00170274|Device|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
238625|NCT00171912|Drug|imatinib mesylate|
238626|NCT02458664|Genetic|Genetic analysis on tumor kept in tumor bank|
238627|NCT02458677|Drug|PRX003|
238628|NCT02458677|Other|Placebo|
238629|NCT02458690|Behavioral|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
238630|NCT02458690|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
238631|NCT02458690|Drug|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. The depression clinical specialist (DCS) will work with the patient's primary care provider to develop a plan that follows the IMPACT algorithm. Primary care providers will manage prescriptions. To optimize eIMPACT for CVD risk reduction, we will restrict the list of antidepressants to SSRIs (except paroxetine) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
238910|NCT00170937|Drug|valsartan plus hydrochlorothiazide|
238911|NCT02451982|Drug|Nivolumab|3 mg/kg
238912|NCT02451995|Device|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
238913|NCT02451995|Device|Conventional AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of activation mapping and entrainment
238914|NCT02452008|Drug|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
238915|NCT02452008|Drug|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
238916|NCT02452034|Drug|Posaconazole IV solution|Posaconazole 300 mg IV solution (sterile)
238917|NCT02454114|Other|Standard Hospital Care|No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.
SF-12 (physical and mental function) [performed twice in total] - at recruitment (day 0) and 6 weeks
CAP-SYM [performed 3 times in total] - at recruitment day 0 (twice including day minus 30) and 6 weeks
Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor.
238918|NCT02454127|Behavioral|Atkins Diet|Dietary counseling for 1 year
238333|NCT02463058|Other|exercise under hot and humid conditions protocol|acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously
experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously.
238334|NCT02463071|Drug|AZD0585|1g soft capsule
238335|NCT02463071|Drug|AZD0585 placebo|1g soft capsule
238336|NCT02463084|Other|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
238337|NCT02463084|Other|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
238338|NCT02463097|Device|Insulin Pump|Closed Loop Algorithm
238339|NCT02463097|Other|i-STAT blood testing|Intravenous i-STAT blood testing is used for reference validation
238340|NCT02463097|Other|Blood Glucose Meter testing|Frequent finger stick blood glucose testing using a Blood Glucose meter is required
238341|NCT02463110|Drug|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
238342|NCT02463110|Drug|No treatment|
238343|NCT02465307|Device|Kinect for Windows sensor|red, green, blue (RGB) capture
238344|NCT02465320|Drug|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
238345|NCT02465320|Drug|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
238346|NCT02465333|Procedure|Heel Fat Grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the heel fat pad using specialized injection cannulas.
Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity.
238347|NCT02465333|Drug|Local anesthetic|To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.
Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot.
237724|NCT02439580|Dietary Supplement|Placebo|maltose
237725|NCT02439593|Other|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
237726|NCT02439593|Other|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
237727|NCT00169182|Drug|DOCETAXEL|
237728|NCT02439606|Device|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
238026|NCT02432339|Drug|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
238027|NCT00168389|Other|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
238028|NCT02432339|Drug|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
238029|NCT02432352|Behavioral|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
238030|NCT02432365|Drug|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
238031|NCT02432365|Drug|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
238032|NCT02432365|Procedure|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
238033|NCT02432378|Biological|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
238034|NCT02432378|Biological|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
238035|NCT02432391|Behavioral|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
238036|NCT02432404|Drug|NuvaRing|
238037|NCT02432417|Drug|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
238038|NCT02434731|Device|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
238039|NCT02434744|Drug|KD026|Dosed in combination with Metformin
237417|NCT00170079|Behavioral|Smoking Cessation Intervention|A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of "step care." The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:
Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;
Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and
Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition.
237418|NCT02446730|Drug|Clopidogrel|
237419|NCT02446743|Biological|Meningococcal Group B (rDNA Component adsorbed)|Boost dose of Meningococcal Group B (rMenB+OMV NZ) at 4 to 7.5 years after last dose.
4 blood samples at: -Baseline (prior to boost dose), at 3, 7 and 30 days after boost dose
237420|NCT02446743|Biological|Meningococcal Group B (rDNA Component adsorbed)|2 doses of Meningococcal Group B (rMenB+OMV NZ) at 0,1-month schedule 4 blood samples at: Baseline (prior to first dose), at 30 days post first dose, at 3, 7 and 30 days post second dose
237421|NCT02446756|Other|acupuncture|
237422|NCT02446756|Other|physiotherapy|
237423|NCT02446769|Device|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
237424|NCT02446782|Drug|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
237425|NCT02446782|Other|saline|100 mL normal saline 15-30 minutes before the start of the procedure
237729|NCT02439606|Device|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
237730|NCT02439619|Other|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
237731|NCT02439632|Drug|prulifloxacin|
237732|NCT02439632|Drug|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
237733|NCT02439632|Drug|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
237734|NCT02439632|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
237735|NCT02439658|Drug|Dofetilide and/or sotalol|This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
237117|NCT02451189|Dietary Supplement|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
237118|NCT02451189|Dietary Supplement|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
237119|NCT02453464|Drug|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
237120|NCT02453464|Drug|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
237121|NCT02453464|Drug|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
237122|NCT02453464|Drug|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
237123|NCT02453477|Genetic|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
237124|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
237125|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
237126|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
237127|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
237128|NCT02453503|Drug|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
237129|NCT00171119|Drug|valsartan|
237426|NCT02446795|Drug|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
237427|NCT02446795|Drug|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
237428|NCT00000363|Drug|Antihistamine|
237429|NCT00002462|Radiation|low-LET cobalt-60 gamma ray therapy|
237430|NCT00170118|Behavioral|motivational interviewing|
237431|NCT02446795|Drug|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
236465|NCT02462304|Drug|Bevacizumab|
236466|NCT02462317|Drug|botulinum A toxin|botulinum toxin injection
236467|NCT02462317|Drug|Baclofen|baclofen oral tablet
236468|NCT02462317|Drug|Placebo toxin|placebo injection
236469|NCT02462317|Drug|placebo baclofen|placebo oral tablet
221294|NCT02278224|Behavioral|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
221295|NCT02278224|Behavioral|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
221296|NCT02278237|Behavioral|Video Module Education (VME)|
221297|NCT02278250|Drug|VX-803|
221298|NCT02278250|Drug|Carboplatin|
221299|NCT02278263|Drug|Tranexamic Acid|Given intravenously or topically
221300|NCT00148863|Drug|Ribavirin (drug)|
221301|NCT02278263|Drug|Normal saline (0.9% NaCl)|Administered in all 3 groups
221302|NCT02278276|Drug|sodium polysulthionate|Bioavailable composition of α-sulfur
221303|NCT02278276|Drug|Placebo|400 mg capsules containing placebo
221304|NCT02280486|Drug|Saxagliptin|5 mg qd
221305|NCT02280486|Drug|Glimepiride|1mg/d, up titrated 1mg if FPG ＞6.1 mmol/L (110mg/dL) till 6 mg
221306|NCT02280499|Device|standard PROMOS prosthesis|
221307|NCT02280512|Device|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
221308|NCT02280525|Drug|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
221309|NCT02280525|Drug|Rituximab|375 mg/m2 by vein on Day -5.
221310|NCT02280525|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to -3.
237180|NCT02458248|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
237181|NCT02458274|Other|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
237182|NCT02458287|Biological|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
237183|NCT00172107|Drug|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
237184|NCT02460185|Behavioral|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
237185|NCT02460198|Biological|Pembrolizumab|
237186|NCT02460211|Dietary Supplement|Vitamin D3|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
237493|NCT02453581|Drug|OZ439|OZ439 Powder for Oral Suspension
237494|NCT02453594|Biological|pembrolizumab|
237495|NCT02453607|Drug|Infliximab|
237496|NCT02453607|Drug|thiopurine|
237497|NCT02453620|Drug|Entinostat|Given PO
237498|NCT00000129|Procedure|Radial Keratotomy|
237499|NCT00000363|Drug|Corticosteroid|
237500|NCT00002463|Procedure|Conventional Surgery|
237501|NCT00171132|Drug|atenolol|
237502|NCT02453620|Biological|Ipilimumab|Given IV
237503|NCT02453620|Other|Laboratory Biomarker Analysis|Correlative studies
237504|NCT02453620|Biological|Nivolumab|Given IV
237505|NCT02453620|Other|Pharmacological Study|Correlative studies
236864|NCT02464878|Procedure|Islet Transplantation|
236865|NCT02464878|Drug|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
236866|NCT02464878|Drug|Basiliximab|Basiliximab will be used for subsequent transplants.
236867|NCT02464878|Drug|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
236868|NCT02464891|Drug|CCX168|
236869|NCT02429232|Drug|Linagliptin|Linagliptin 5mg/tablet once daily
236870|NCT02429245|Other|Retrospective study|
236871|NCT02429258|Drug|Farxiga|Farxiga 10mg/day
236872|NCT02429258|Drug|Placebo|Placebo
236873|NCT02429258|Drug|Metformin|Metformin background therapy >/= 1500mg/day
236874|NCT02429258|Drug|Insulin|Insulin >/= 30 units
236875|NCT02429271|Drug|Ticagrelor|
236876|NCT02429271|Drug|Clopidogrel|
236877|NCT02429271|Procedure|Percutaneous Coronary Intervention (PCI)|
237187|NCT02460211|Dietary Supplement|Placebo|Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
237188|NCT02460224|Drug|LAG525|study drug 1
237189|NCT02460224|Drug|PDR001|study drug 2
237190|NCT02460237|Procedure|Disease Screening|Complete HPV self-test
237191|NCT02460237|Other|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
237192|NCT02460237|Other|Informational Intervention|Receive standard instructions and information sheet
237193|NCT02460237|Other|Laboratory Biomarker Analysis|Correlative studies
237194|NCT00172120|Drug|ALX1-11|
237195|NCT02460237|Other|Survey Administration|Ancillary studies
236561|NCT02433951|Other|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
236562|NCT02433964|Other|Grupo LED|
236563|NCT02433964|Other|Placebo|ledterapia off + price
236564|NCT02433977|Dietary Supplement|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
236565|NCT02433977|Drug|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
236566|NCT00168636|Drug|Vitamin A|
236567|NCT02433977|Drug|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
236568|NCT02434029|Drug|Budesonide effervescent 1mg tablet twice daily|
236569|NCT02434029|Drug|Placebo effervescent tablet twice daily|
236570|NCT00168870|Drug|Gemcitabine|
236571|NCT02436525|Device|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
236572|NCT02436525|Device|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
236573|NCT02436525|Device|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
236878|NCT00002458|Biological|monoclonal antibody 3F8|
236879|NCT00167934|Drug|Valproate|Depakote ER 500 mg to 3000 mg taken every night
236880|NCT02429271|Procedure|Coronary Angiography|
236881|NCT02429297|Other|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
236882|NCT02429297|Other|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
236883|NCT02429310|Device|Revitive IX|This is a neuromuscular electrical stimulation device
236884|NCT02429323|Drug|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
236885|NCT02429349|Procedure|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
236230|NCT02438943|Other|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
236231|NCT02438943|Other|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
236232|NCT02438956|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
236233|NCT02438956|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
236234|NCT02438982|Drug|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 4-7 ng/ml.
236235|NCT00169130|Procedure|Autologous stem cell transplantation|
236236|NCT02438982|Drug|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3 (CD 19% >1), it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
236237|NCT02438995|Drug|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
236238|NCT02439008|Procedure|Blood samples collection before radiotherapy|Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.
Before radiotherapy:
Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy
236239|NCT02441192|Other|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
236240|NCT02441205|Behavioral|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
236241|NCT02441218|Drug|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
236242|NCT00169299|Drug|Multibotanical preparation + dietary soy counseling|
236243|NCT02441218|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
236244|NCT02441231|Drug|Visbiome|Visbiome probiotic
236574|NCT02436538|Other|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
236575|NCT02436551|Other|Observation|
235644|NCT02452918|Drug|Oritavancin|a single 1200 mg IV dose of Orbactiv (oritavancin)
235645|NCT02452931|Drug|Leuprolide Acetate 45 mg|Subcutaneous injection
235646|NCT02452944|Device|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
235647|NCT02452944|Device|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
235941|NCT02446366|Other|Quality-of-Life Assessment|Ancillary studies
235942|NCT02446366|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
235943|NCT02446379|Drug|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
235944|NCT02446379|Device|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
235945|NCT02446379|Device|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
235946|NCT02446392|Other|No intervention.|
235947|NCT00169988|Drug|risperidone|
235948|NCT02446405|Drug|Enzalutamide|
235949|NCT02446405|Drug|NSAA|
235950|NCT02446405|Drug|LHRHA or Surgical Castration|
235951|NCT02446418|Drug|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
235952|NCT02446418|Drug|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
235953|NCT02446418|Drug|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
235954|NCT02446418|Drug|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
235955|NCT02446418|Drug|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
235956|NCT02446418|Drug|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
235957|NCT02448420|Drug|Palbociclib|oral dose of 200 mg/day for 2 weeks, followed by 1 week off.Number of Cycles: until progression or unacceptable toxicity develops.
235343|NCT02457442|Drug|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
235344|NCT02457442|Drug|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
235345|NCT02457442|Drug|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
235346|NCT02457442|Drug|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
235347|NCT02457442|Drug|SPR 1|Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.
SPR 1: Changing Propofol for skin incision.
235348|NCT02457442|Drug|SPR2|Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.
Changing Sevoflurane for skin incision.
235349|NCT02457468|Device|coflex|
235350|NCT02457481|Device|Embryo Culture medium|Two step sequential embryo culture medium system
235351|NCT00171756|Drug|valsartan/atenolol|
235352|NCT02459561|Other|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
235353|NCT02459574|Procedure|AVATAR-AF ablation|Experimental ablation protocol
235648|NCT02452970|Drug|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
235649|NCT02452970|Drug|Gemcitabine and cisplatin|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
235650|NCT02452983|Drug|Sertraline|
235651|NCT00171054|Drug|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
235652|NCT02452983|Procedure|Bone Marrow Aspirate/Biopsy|
235653|NCT02452996|Drug|GNbAC1|Single dose of IMP, IV infusion
235654|NCT02453009|Drug|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
235655|NCT02453009|Drug|Prednisone|Pharmaceutical form:tablet Route of administration: oral
235656|NCT02453009|Drug|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
235071|NCT02464124|Drug|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
235072|NCT02464124|Drug|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
235073|NCT02464137|Radiation|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
235074|NCT02464150|Dietary Supplement|Gluten challenge|Challenge done in the form of a once daily muesli bar in participants in both substudies (celiac disease and non celiac gluten sensitivity
235075|NCT02464150|Dietary Supplement|FODMAP-challenge|Challenge done in the form of a muesli bar in participants with non celiac gluten sensitivity
235076|NCT02464150|Dietary Supplement|Placebo|Challenge done in the form of a muesli bar in participants with non celiac gluten sensitivity
235077|NCT00173888|Drug|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
235078|NCT02464163|Biological|Panblok|Intramuscular injection
235079|NCT02464163|Biological|rHA adjuvant|Intramuscular injection
235080|NCT02464176|Drug|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
235081|NCT02464176|Drug|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
235082|NCT02464176|Drug|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
235083|NCT02464176|Procedure|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
235084|NCT02464176|Drug|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
235085|NCT02464189|Other|Q-Kap|
235354|NCT02459574|Drug|Anti-Arrhythmic therapy|Group 2 will be prescribed medication listed below:
Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.
You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed.
235355|NCT02459574|Procedure|Conventional AF ablation|Conventional ablation procedure
235088|NCT02428569|Behavioral|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
235089|NCT02428582|Device|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
235090|NCT00002456|Procedure|allogeneic bone marrow transplantation|
235091|NCT00167830|Behavioral|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
235092|NCT02428582|Device|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
235093|NCT02428595|Device|Eclipse™ System|The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the "Eclipse Insert") and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System.
235094|NCT02428608|Biological|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
235095|NCT02428621|Device|Twicare® appliance|Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.
The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night).
235096|NCT02428621|Device|Removable Herbst appliance|Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.
The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night).
235097|NCT02428634|Behavioral|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
235098|NCT02428634|Behavioral|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
235099|NCT02428647|Dietary Supplement|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
235100|NCT02428647|Dietary Supplement|preventive zinc supplement|7 mg zinc daily as dispersible tablet
234510|NCT02440633|Drug|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
234511|NCT00169260|Behavioral|placebo|
234512|NCT02440646|Radiation|Coronary computed tomography angiography|The coronary arteries will be visualized with the 128-slice CT scan Aquilion CX (Toshiba, Tokyo, Japan).
234801|NCT02435693|Other|Without PHARMACEUTICAL CARE programe|
234802|NCT02435706|Procedure|Flapless immediate implant placement|No elevation of flap prior to immediate implant placement
234803|NCT02435706|Procedure|Flap assisted immediate implant placement|Flap will be elevated prior to immediate implant placement
234804|NCT02435706|Device|Implant and temporary crown|Standard intervention/procedure (non-experimental)
234805|NCT02435732|Drug|Placebo saline solution|
234806|NCT02435732|Drug|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
234807|NCT02435732|Drug|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
234808|NCT00168805|Drug|dabigatran etexilate|220 mg once daily
234809|NCT02435758|Procedure|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
234810|NCT02435771|Drug|Ergocalciferols|Treatment 1- 400,000 IU
234811|NCT02435771|Drug|Ergocalciferols|Treatment 2- 800,000 IU
234812|NCT02435784|Other|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
234813|NCT02435784|Other|Treatment as usual|Patients will attend a psychiatric consultation as usual.
234814|NCT02435797|Drug|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
234215|NCT02447796|Drug|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
234216|NCT02447796|Drug|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
234217|NCT02447809|Drug|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)* 12 month.
234218|NCT02447809|Drug|acetylsalicylic acid (ASA)|
234219|NCT02447822|Drug|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
234220|NCT02447835|Drug|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)[1,5]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
234221|NCT02447848|Drug|Sufentanil tablet 30 mcg|Sufentanil tablet 30 mcg
234222|NCT02447874|Drug|Arginine|Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.
Loading dose: 200 mg/kg once
Continuous IV: 300 mg/kg/24 hours
234223|NCT02447874|Drug|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 200 mg/kg once
234513|NCT02440646|Radiation|Quantitative coronary angiography|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich, Germany).
234514|NCT02440672|Device|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
234515|NCT02443012|Drug|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
234516|NCT02443012|Procedure|Laser|Grid/Focal Laser Photocoagulation
234517|NCT02443025|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
234518|NCT00169546|Drug|Salmeterol/fluticasone propionate|
234519|NCT02443038|Other|Yoga|16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.
The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups.
234520|NCT02443051|Behavioral|Attention Bias Modification|Computer delivered modification in 80% of trials
238919|NCT02454127|Behavioral|Zone Diet|Dietary counseling for 1 year
238920|NCT02454127|Behavioral|Weight Watchers Diet|Dietary counseling for 1 year
238921|NCT00171210|Drug|Deferasirox|Tablets taken orally once a day.
238922|NCT02454127|Behavioral|Ornish Diet|Dietary counseling for 1 year
238923|NCT02454140|Radiation|SBRT|Fixed five-fraction stereotactic radiotherapy
238924|NCT02454153|Device|REMStar Postive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
238925|NCT02454153|Behavioral|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
238926|NCT02454166|Other|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
238927|NCT02454166|Other|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
238928|NCT02454179|Drug|pembrolizumab|
238929|NCT02454179|Drug|ACP-196|
238930|NCT02454192|Behavioral|CHAMPS|
238931|NCT02454205|Drug|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
238932|NCT00171223|Drug|imatinib mesylate|
234224|NCT02447874|Drug|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
234225|NCT00170287|Procedure|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
234226|NCT02447887|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
234227|NCT02447887|Drug|Pegylated IFN-alpha 2b|Weekly injection
234228|NCT02447900|Device|BioXmark|
234229|NCT02447913|Behavioral|Voucher|Introduction of vouchers will improve uptake of family method as well as child immunization.
Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method
238348|NCT02465346|Device|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
238349|NCT02465346|Device|Control stroke management|Conventional stroke management
238632|NCT02458690|Other|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis and are encouraged to follow-up with their primary care provider, who also receives a letter indicating that their patient has a depressive disorder and was randomized to usual care. Our letter provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received.
238633|NCT02458703|Other|Cardiopulmonary exercise test|Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are "cooling down", they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis.
238634|NCT02458716|Procedure|Robotic Assisted Radical Prostatectomy|Undergo RARP
238635|NCT02458716|Procedure|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
238636|NCT00171925|Drug|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance > 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg*hr/l).
238637|NCT02458716|Other|Laboratory Biomarker Analysis|Correlative studies
238638|NCT02460822|Device|MyChemoCare iPad application|
238639|NCT02460835|Radiation|Adaptive Radiation Therapy|
238640|NCT02460848|Other|Outpatient therapeutic program, counseling and cash transfer|Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.
The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption.
238641|NCT02460848|Other|Outpatient therapeutic program and counseling|
238642|NCT02460861|Procedure|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
238643|NCT00172198|Drug|Omegaven 10%|
238644|NCT02460861|Procedure|RPVE|Open Radical prostatovesiculectomy in Magdeburg
238040|NCT02434744|Drug|Placebo|Dosed in combination with Metformin
238041|NCT02434744|Drug|Metformin|Drug prescribed by each subject's prescribing physician
238042|NCT02434757|Drug|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
238043|NCT02434770|Biological|TiantanBio bOPV lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
238044|NCT02434770|Biological|TiantanBio bOPV lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
238045|NCT02434770|Biological|Bivalent Type 1 & 3 Oral Poliomyelitis Vaccine (BioFarma)|Each dose of tOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 and 105.8 infective units per dose, respectively
238350|NCT02465359|Drug|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
238351|NCT02465372|Behavioral|CSPAP|Comprehensive School Physical Activity Program.
238352|NCT02465385|Drug|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
238353|NCT00174304|Drug|Amlodipine/atorvastatin single pill|
238354|NCT02465398|Procedure|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
238355|NCT02465411|Device|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
238356|NCT02465424|Other|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
238357|NCT02465437|Drug|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
238358|NCT02465437|Drug|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
238359|NCT02465450|Drug|JBT-101|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
238360|NCT02465450|Other|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
238361|NCT02465463|Procedure|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
238362|NCT02465463|Device|flexible sigmoidoscopy|
237736|NCT02439671|Behavioral|McGill Transition Support Program|The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:
Social communication (e.g. listening, perspective taking)
Self-determination (e.g. problem-solving, self-advocacy)
Working with others (e.g. knowing your context, teamwork)
Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.
The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages.
237737|NCT02441803|Drug|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
237738|NCT02441816|Drug|Aflibercept|
237739|NCT02441816|Other|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
237740|NCT02441829|Drug|Eleclazine|Eleclazine tablets administered orally in morning with food
237741|NCT00169338|Procedure|Deep brain stimulation|internal pallidal deep brain stimulation
237742|NCT02441842|Drug|atenolol|administered 60 minutes pre procedure
237743|NCT02441842|Drug|lisinopril|administered 60 minutes pre procedure
237744|NCT02441842|Other|glucose|administered 60 minutes pre procedure
237745|NCT02441855|Device|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
238046|NCT02434796|Behavioral|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
238047|NCT00168714|Drug|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
238048|NCT02434796|Behavioral|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
238049|NCT02434809|Procedure|Bronchoscopic Implantation|Calypso transponders
237432|NCT02446808|Device|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
237433|NCT02446821|Device|VeraCept|IUD placement of VeraCept
237434|NCT02446834|Behavioral|intensive lifestyle intervention|3 months low GI diet and exercise
237435|NCT02446834|Drug|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
237436|NCT02446834|Drug|Metformin|Use metformin 3 months to treat PCOS
237437|NCT02446834|Drug|Acarbose|Use acarbose 3 months to treat PCOS
237438|NCT02446847|Drug|3BNC117|3BNC117 infusions
237439|NCT02446847|Other|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
237440|NCT02448953|Procedure|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
237441|NCT02448966|Procedure|open esophagectomy|
237442|NCT02448966|Procedure|Minimally invasive esophagectomy|
237443|NCT02448979|Procedure|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
237444|NCT02448979|Procedure|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
237445|NCT02448992|Radiation|hippocampal-sparing WBRT|
237446|NCT02449005|Genetic|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
237447|NCT02449005|Other|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
237448|NCT02449005|Procedure|Open flap debridement|Group C will receive open flap debridement retaining the soft tissue wall of the pocket and no use of grafting materials
237746|NCT02441868|Behavioral|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
237747|NCT02441881|Device|Venefit|Endovenous radiofrequency device
221311|NCT02280525|Drug|Cyclophosphamide|200 mg/m2 by vein on Days -5 to -3.
221312|NCT02280525|Procedure|NK Cells|Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 107 NK cells/kg given by vein on Day 0.
NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase.
221313|NCT00002372|Drug|Nelfinavir mesylate|
221314|NCT00149162|Drug|proleukin|One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)
1 cycle of treatment each month during 12 months
221315|NCT02280538|Device|Intra-Articular Hyaluronic Acid|
221316|NCT02280538|Device|Placebo|
221623|NCT02312557|Other|Laboratory Biomarker Analysis|Correlative studies
221624|NCT00152698|Drug|Irbesartan|
221625|NCT02312557|Biological|Pembrolizumab|Given IV
221626|NCT02312570|Device|Eclipse PRP™ Wound Biomatrix|Administration of Eclipse PRP™ Wound Biomatrix to wound in addition to usual and customary care
221627|NCT02312570|Other|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
221628|NCT02312583|Behavioral|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
221629|NCT02312583|Behavioral|iFightDepression online programme|iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
Participants will complete the modules of a structured online programme for depression
221630|NCT02312596|Device|Eclipse PRP™ Wound Biomatrix|Application of Eclipse PRP™ Wound Biomatrix in addition to usual and customary practice
221631|NCT02314871|Drug|Piritramide|see Arm/group description
221632|NCT00152854|Drug|acetaminophen|acetaminophen 1g po qid for 7 days
221633|NCT02314871|Drug|Morphine|see Arm/group description
221634|NCT02314884|Drug|Cafusertib Hydrochloride|
221635|NCT02314897|Device|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
221636|NCT02314897|Device|RV pacing|Conventional right ventricular pacing.
221637|NCT02314910|Other|Sample histology|
237506|NCT02453633|Other|Emotional SMS text|SMS appointment reminder with the following text (translated from Norwegian):
Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.
tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.
No-show fee: Kr. 640.
Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS.
237507|NCT02453633|Other|Standard SMS text|SMS appointment reminder with the following text (translated from Norwegian):
Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS.
237508|NCT02453646|Device|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
237509|NCT02453659|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
237510|NCT02453659|Behavioral|Health Education (HE)|
237511|NCT02453659|Behavioral|Smoking Cessation counseling|
237512|NCT00171132|Drug|hydrochlorothiazide|
237513|NCT02453659|Drug|Transdermal Nicotine Patch|
237514|NCT02453672|Biological|SB8|SB8, proposed bevacizumab biosimilar
237515|NCT02453672|Biological|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
237516|NCT02453672|Biological|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
237807|NCT02446990|Drug|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
237808|NCT00170157|Biological|MDX-010 therapy|MDX-010 3 mg/kg one time dose (Ipilimumab)
237809|NCT02449161|Drug|MPA|
237810|NCT02449161|Drug|placebo|
237811|NCT02449174|Biological|Frozen Microbiota|Frozen Mcirobiota will be delivered via enema route.
237812|NCT00170469|Biological|AVA|
237813|NCT02449174|Biological|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
237814|NCT02449187|Drug|JLP-1310, Fasted followed by fed|In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition.
237815|NCT02449187|Drug|JLP-1310, Fed followed by fasted|In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition.
237196|NCT02460250|Procedure|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
237197|NCT02460263|Device|Tablo Hemodialysis System|
237198|NCT02460276|Drug|Lenalidomide|
237199|NCT02460276|Drug|Ibrutinib|
237200|NCT02460276|Drug|Rituximab|
237201|NCT02460289|Drug|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
237202|NCT02460302|Drug|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
237203|NCT02460315|Procedure|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
237204|NCT02460315|Procedure|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
237205|NCT00172133|Drug|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
237206|NCT02460341|Drug|ondansetron|Ondansetron 8mg, 16mg, 24mg
237207|NCT02460341|Drug|placebo|placebo pill
237208|NCT02460354|Drug|Metformin|Metformin 500 mg pill dispensed once orally
237209|NCT02462473|Drug|Quetiapine|Participants will receive quetiapine 150 mg oral formulation once daily for 12 weeks as part of participant treatment.
237517|NCT02453685|Drug|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
237518|NCT02455973|Behavioral|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
237519|NCT02455973|Behavioral|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
237520|NCT02455986|Behavioral|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
236886|NCT02429375|Drug|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
236887|NCT02429388|Drug|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
236888|NCT02429401|Behavioral|Non-adapted brief motivational interview|1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
236889|NCT02429401|Behavioral|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
236890|NCT00167934|Drug|Placebo|Placebo given at same frequency as Valproate
236891|NCT02431767|Biological|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
236892|NCT02431767|Biological|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
236893|NCT00168324|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
236894|NCT02431767|Biological|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
237210|NCT02462473|Drug|Risperidone|Participants will receive risperidone 1 mg oral formulation once daily or 12.5 mg injection once every 2 weeks for 12 weeks as part of participant treatment.
237211|NCT02462486|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
237212|NCT00173108|Behavioral|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
237213|NCT02462486|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
237214|NCT02462486|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
237215|NCT02462499|Drug|Inspra (eplerenone)|
236576|NCT02436564|Genetic|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
236577|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
236578|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
236579|NCT02436577|Drug|Ticagrelor IR tablet (90 mg) administered with 200 mL of water|Ticagrelor 90 mg IR tablet, single dose
236580|NCT02436590|Device|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
236581|NCT00168870|Drug|Treosulfan|
236582|NCT02436603|Behavioral|Nutrition/Mind-Body Coaching|Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
236583|NCT02436616|Device|microEEG|microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).
If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation.
236584|NCT02436629|Dietary Supplement|Nitrate-rich concentrated red beetroot juice|
236585|NCT02436629|Dietary Supplement|Nitrate-depleted concentrated red beetroot juice|
236586|NCT02436642|Device|AVERT Plus System|
236587|NCT02436655|Procedure|surgical aortic valve replacement|open heart aortic valve replacement
236588|NCT02436668|Drug|Ibrutinib|
236589|NCT02436668|Drug|Gemcitabine|
236590|NCT02436668|Drug|Nab-paclitaxel|
236591|NCT02436681|Device|MIROMESH|
236592|NCT00168883|Drug|Carboplatin|
236593|NCT02436694|Drug|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
236594|NCT02436694|Drug|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
235958|NCT00170378|Drug|Enoxaparin|
235959|NCT02448420|Drug|Trastuzumab|8 mg/kg in the first dose, followed by 6 mg/kg every 3 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
235960|NCT02448420|Drug|Letrozole|daily oral dose of 2.5 mg. Number of Cycles: until progression or unacceptable toxicity develops.
236245|NCT02441231|Other|Placebo|Placebo
236246|NCT02441244|Drug|Visbiome|Visbiome probiotic
236247|NCT02441244|Other|Placebo|Placebo
236248|NCT02441257|Procedure|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
236249|NCT02441257|Procedure|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
236250|NCT02441270|Drug|Cyclophosphamide|
236251|NCT02441270|Radiation|Stereotactic body radiotherapy|
236252|NCT02441283|Drug|ABT-493|Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.
236253|NCT00169299|Drug|Conjugated equine estrogen +/- medroxyprogesterone acetate|
236254|NCT02441283|Drug|ABT-530|Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.
236255|NCT02441296|Other|Formula with lactose|
236256|NCT02441296|Other|Formula with maltodextrins|
236257|NCT02441309|Drug|Mifamurtide|
236258|NCT02441309|Drug|Ifosfamide|
236259|NCT02441322|Device|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
236260|NCT02441348|Behavioral|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
236261|NCT02441361|Other|Exercise training|Exercise training will comprise aerobic and strength exercises
236262|NCT02441374|Device|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
235657|NCT02453022|Drug|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
235658|NCT02453022|Drug|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
235659|NCT02453022|Drug|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
235660|NCT02453035|Device|PTCA - Desolve Scaffold|Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
235661|NCT02453048|Biological|BPZE1|Intranasal live, attenuated vaccine
235662|NCT00002463|Drug|Vincristine Sulfate|
235663|NCT00171054|Drug|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
235664|NCT02453048|Other|Placebo|Diluent
235665|NCT02453061|Drug|Triheptanoin oil|Triheptanoin oil orally administered at 1g/kg/day
235666|NCT02453061|Drug|Placebo|Safflower oil orally administered at 1g/kg/day
235667|NCT02453074|Other|Online survey - Follow up for Better Care|
235668|NCT02453087|Drug|DCDS0780A|
235669|NCT02453087|Drug|Rituximab|
235670|NCT02453100|Behavioral|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
235961|NCT02448433|Device|Phototherapy light-emitting glasses|The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m^2) upon awakening and progressive shift to earlier wake-up times.
Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.
During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls.
235962|NCT02448446|Drug|ranibizumab 0.3mg|intravitreally administered
235963|NCT02448459|Drug|COOL-COS|Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.
Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.
The triggering will be performed using leuprorelin 1 mg (subcutaneous).
235964|NCT02448472|Other|Observational study, none intervention|
235356|NCT02459587|Behavioral|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
235357|NCT00172068|Drug|Zoledronic acid + Calcium/Vitamin D|
235358|NCT02459600|Other|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
235359|NCT02459613|Other|99mTc-Annexin V-128 SPECT|
235360|NCT02459626|Other|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis
235361|NCT02459639|Other|Anthroposophic integrative care rehabilitation program|The programme for chronic pain at AIC consists of two phases:
A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.
Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups.
235362|NCT02459639|Other|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
235363|NCT02459652|Drug|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
235364|NCT02459652|Radiation|Radiation Therapy|Radiation therapy is delivered with >6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
235365|NCT02459665|Biological|Vaginal probiotics for prevention of BV recurrence (Ecologic Femi vaginal capsule)|Vaginal probiotics to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
235366|NCT02459665|Drug|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
235367|NCT02459665|Biological|Vaginal probiotics for prevention of BV recurrence (Gynophilus vaginal tablet)|
235368|NCT00172081|Drug|placebo|Daily subcutaneous injection with placebo
235671|NCT02455141|Drug|Paclitaxel|Paclitaxel: 80mg/m2, d1, qw*12
235369|NCT02461784|Procedure|Semen & Data Collection|If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.
Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project.
235370|NCT02461797|Other|healthy controls|biopsy of nasal mucosa for healthy controls
235371|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
235372|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
235373|NCT02461810|Device|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
235374|NCT02461810|Procedure|Balloon Kyphoplasty|
235375|NCT02461823|Device|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
235376|NCT00172510|Procedure|blood drawing|
235377|NCT02461823|Device|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
235378|NCT02461836|Drug|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
235379|NCT02461836|Radiation|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
235380|NCT02461849|Drug|Imatinib|Imatinib 400mg qd daily
235381|NCT02461862|Behavioral|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
235382|NCT02461862|Procedure|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
235383|NCT02461862|Procedure|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
235384|NCT02461875|Drug|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
235385|NCT02461875|Drug|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
234815|NCT02435797|Drug|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
234816|NCT02435823|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
234817|NCT02435836|Drug|Aripiprazole|
234818|NCT02435849|Genetic|Single dose of CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
234819|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
235101|NCT02428647|Dietary Supplement|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
235102|NCT00167830|Behavioral|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
235103|NCT00168181|Procedure|Submandibular gland Transfer|
235104|NCT02431065|Drug|Ropivacaine|Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:
Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.
Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
235105|NCT02431065|Other|Normal saline|Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:
Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.
Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
235106|NCT02431078|Procedure|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
235107|NCT02431091|Other|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
235108|NCT02431104|Device|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|
235109|NCT02431130|Other|low-fidelity instructor driven simulation training|
235110|NCT02431143|Drug|Miltefosine|
234521|NCT02443064|Drug|Vancomycin|Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.
Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on.
234522|NCT02443077|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
234523|NCT02443077|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
234524|NCT02443077|Drug|Carmustine|Given IV
234525|NCT02443077|Drug|Cyclophosphamide|Given IV
234526|NCT02443077|Drug|Cytarabine|Given IV
234527|NCT02443077|Drug|Etoposide|Given IV
234528|NCT02443077|Drug|Ibrutinib|Given PO
234529|NCT00002462|Drug|mechlorethamine hydrochloride|
234530|NCT00169546|Drug|Fluticasone propionate|
234531|NCT02443077|Other|Laboratory Biomarker Analysis|Correlative studies
234532|NCT02443077|Drug|Melphalan|Given IV
234533|NCT02443077|Other|Placebo|Given PO
234534|NCT02443090|Drug|fispemifene|
234820|NCT02435862|Drug|1.0mg Luminate®|
234821|NCT02438202|Device|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
234822|NCT02438215|Drug|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
234823|NCT02438228|Other|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
234824|NCT02438241|Procedure|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
234230|NCT02449915|Drug|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
234231|NCT02449915|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
234232|NCT02449928|Drug|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
234233|NCT02449928|Drug|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
234234|NCT00170664|Drug|Paclitaxel|
234235|NCT02449941|Drug|PPI(proton pump inhibitor)|Pre ESD (endoscopic submucosal dissection)
Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
Use of Proton Pump Inhibitor(PPI) for 2 months
Post ESD 1 (After 2 months)
Assess the distribution of helicobacter pylori after using PPI.
Stop of Proton Pump Inhibitor(PPI)
Post ESD 2 (After 4 months)
Assess the distribution of helicobacter pylori after stop of PPI.
234236|NCT02449954|Drug|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
234237|NCT02449954|Drug|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
234238|NCT02449954|Drug|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
234239|NCT02449967|Procedure|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
234240|NCT02449980|Procedure|Primary Surgery Group|Patients will received immediate surgical intervention, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
234241|NCT02449980|Procedure|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
234535|NCT02443090|Other|Placebo|
234536|NCT02443103|Drug|Guanabenz acetate|
234537|NCT02443116|Biological|NGM282|
234538|NCT02443116|Other|Placebo|
234539|NCT02443129|Device|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
234540|NCT02443142|Drug|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
238645|NCT02460861|Procedure|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
238646|NCT02460861|Procedure|CE|Open cystectomy in Magdeburg/Gronau
238647|NCT02460861|Procedure|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
238648|NCT02460874|Drug|Glyburide|1.25mg, twice a day
238933|NCT02454205|Drug|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
238934|NCT02454205|Drug|Levofloxacin|750mg (<50kg) 1000mg (>50kg)
238935|NCT02454205|Drug|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
238936|NCT02454205|Drug|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
238937|NCT02454205|Drug|Ethionamide|15mg/kg (max 900mg)
238938|NCT02454205|Drug|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
238939|NCT02454205|Drug|Moxifloxacin|400mg po daily.
238940|NCT02454205|Drug|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
238941|NCT02454218|Device|Transcranial Direct Current Stimulation|The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.
The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions.
238942|NCT02456532|Drug|Eszopiclone|
238943|NCT02456545|Other|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
238944|NCT02456545|Other|depressive syndrome|in- and outpatients with depressive syndrome
238945|NCT02456545|Other|ADHD|in- and outpatients with ADHD
238946|NCT02456558|Drug|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
238947|NCT02456558|Drug|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
238363|NCT02429804|Radiation|Fluorine F 18 Sodium Fluoride|Given IV
238364|NCT02429804|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
238365|NCT02429804|Procedure|Positron Emission Tomography|Undergo PET/MRI
238366|NCT02429817|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
238367|NCT02429817|Device|Aeroneb Solo|
238368|NCT02429817|Device|Jet Nebulizer|
238369|NCT02429817|Other|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
238370|NCT02429817|Other|Spirometry|FEV1, FVC assessment
238371|NCT02429830|Device|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
238372|NCT00168012|Drug|Immunoglobulins Intravenous (Human)|
238649|NCT02460874|Other|Placebo|1.25mg, twice a day
238650|NCT02460887|Drug|Gemcitabine|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
238651|NCT02460887|Drug|cisplatin|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
238652|NCT02460887|Drug|cisplatin|Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
238653|NCT02460887|Radiation|Intensity-modulated Radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
238654|NCT00172211|Drug|Physioneal|
238655|NCT02460900|Drug|Varenicline|
238656|NCT02460900|Behavioral|Positively Smoke Free|
238657|NCT02460900|Drug|Placebo|
238658|NCT02460900|Behavioral|Standard of Care|
238659|NCT02460913|Procedure|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
238050|NCT02434809|Device|Cone-Beam CT-Guided|
238051|NCT02434809|Radiation|stereotactic body radiation treatments|
238052|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
238053|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
238054|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
238055|NCT02434835|Drug|[14C]KWA-0711|
238056|NCT02434848|Drug|Engerix B|Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular
Prescription and administration:
The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.
Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years.
238057|NCT02437110|Drug|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100 mg twice daily.
238058|NCT02437110|Drug|Raltegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 400mg twice daily.
238059|NCT00168935|Drug|Fresubin protein energy Drink (CAVE! nutritional intervention)|
238060|NCT02437110|Drug|Zidovudine|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 300mg twice daily.
238061|NCT02437123|Behavioral|The Cedar Project mHealth intervention|
238062|NCT02437136|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACs)
238063|NCT02437136|Drug|pembrolizumab|A selective humanized monoclonal antibody (mAb)
238373|NCT02429843|Drug|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
238374|NCT02429856|Device|SCORPIO™|subjects randomized at surgery to receive 1 of the 2 specified implants
238375|NCT02429869|Drug|everolimus|
238376|NCT02429882|Drug|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
238377|NCT02429882|Drug|Placebo|Placebo will be administered subcutaneously
238378|NCT02429895|Drug|ABT-122|Injection
237748|NCT02441881|Device|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
237749|NCT02441881|Device|Endovenous Radiofrequency|Endovenous radiofrequency device
237750|NCT02441894|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
237751|NCT02441894|Drug|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
237752|NCT00169364|Device|positron emission tomography|
237753|NCT02441894|Drug|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
237754|NCT02441894|Drug|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
237755|NCT02441894|Drug|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
237756|NCT02441894|Drug|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
237757|NCT02441894|Drug|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
237758|NCT02441907|Drug|aflibercept|
237759|NCT02441933|Drug|taxane plus carboplatin|Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.
Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles
Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles
237760|NCT00169702|Behavioral|weight management program|12 sessions, psychoeducation
237761|NCT02444442|Device|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
237762|NCT02444442|Other|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
237763|NCT02444455|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10^5/kg) once a day,a total of three times.
237764|NCT02444468|Device|Flowtron ACS800|Flowtron ACS800 and bandage
237765|NCT02444468|Other|Bandage|Bandage only
237766|NCT02444481|Drug|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
238064|NCT02437149|Behavioral|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
221638|NCT02314923|Biological|BPSC-1001 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^3, 3x10^4, 3x10^5, 3x10^6, 9x10^6, 2x10^7, or 1x10^8 pfu.
221639|NCT02314923|Other|Placebo|0.9% Saline
221640|NCT02314936|Dietary Supplement|Litesse powder containing 12 g polydextrose|12 g polydextrose
221641|NCT02314936|Dietary Supplement|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
221642|NCT02314936|Dietary Supplement|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
221643|NCT00152854|Drug|placebo, sugar pill|
221644|NCT02314936|Dietary Supplement|Placebo|12 g Maltodextrin
221645|NCT02314949|Procedure|intestinal transplantation|
221646|NCT02314975|Device|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
221949|NCT02307448|Procedure|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
221950|NCT02307448|Procedure|Standard of Care|Patients will receive weekly standard of care.
221951|NCT02307461|Drug|IPI-145 (duvelisib)|High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
221952|NCT02307461|Drug|IPI-145|Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose
221953|NCT02307461|Drug|IPI-145|High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
221954|NCT02307474|Radiation|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
221955|NCT00152204|Drug|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
221956|NCT02309879|Drug|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
221957|NCT02309892|Drug|L-DOS47|A treatment cycle will be 21 days, with patients receiving L DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
221958|NCT00152386|Drug|Certolizumab pegol (CDP870)|
221959|NCT02309905|Device|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
237816|NCT02449200|Other|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
237817|NCT02449239|Biological|Vicinium|Intravesical administration
237818|NCT02449252|Radiation|Consolidation involved-site radiotherapy (ISRT)|six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.
Involved-site radiotherapy (ISRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week.
237819|NCT02449252|Radiation|Consolidation involved-field radiotherapy (IFRT)|six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
Involved-field RT (IFRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week.
237820|NCT02449252|Drug|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
237821|NCT02449252|Drug|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
237822|NCT02449252|Drug|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
237823|NCT00170469|Biological|rPA vaccine containing alhydrogel|
237824|NCT02449252|Drug|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
237825|NCT02449265|Radiation|Consolidation involved-site radiotherapy (ISRT)|6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR).
238120|NCT02442063|Drug|Radium Ra 223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
238121|NCT02444650|Device|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
238122|NCT02444650|Device|tonometer|
238123|NCT02444663|Radiation|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
238124|NCT02444663|Radiation|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
238125|NCT02444663|Radiation|Device Valgus|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
238126|NCT02444663|Radiation|Device Varus|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
238127|NCT02444676|Other|Stratification and outcomes|
237521|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
237522|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
237523|NCT02455999|Drug|Placebo|Placebo eye drops administration for 10 consecutive days
237524|NCT02456012|Drug|oral esomeprazole 20 mg twice daily|for 36 weeks
237525|NCT02456012|Drug|oral esomeprazole 20 mg once daily|for 36 weeks
237526|NCT00171496|Drug|Tacrolimus|
237527|NCT02456025|Drug|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
237528|NCT02456038|Drug|Asfotase Alfa (ALXN1215)|
237529|NCT02456064|Behavioral|Lifestyle counseling|Group medical visits
Telephone medical consultations
Expert patient
Training workshops
237530|NCT02456077|Behavioral|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
237531|NCT02456103|Drug|Ataluren|
237532|NCT02456116|Device|acupuncture/PCA/NSAID|standard program with defined points:
Ear acupuncture needles bitten once (day 0-5)
Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released
237533|NCT02456116|Device|sham acupuncture/PCA/NSAID|standard program with defined points:
Ear acupuncture needles bitten once (day 0-5)
Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5
237534|NCT02456116|Other|PCA/NSAID|standard boli of morphine by pressing a button of PCA
237535|NCT02456129|Drug|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
237826|NCT02449265|Radiation|Consolidation involved-field radiotherapy (IFRT)|6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15~18 fractions of 2 Gy 5 days per week for partial response (PR).
237827|NCT02449265|Drug|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
237828|NCT02449265|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
237829|NCT02449265|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy.
237216|NCT02462525|Drug|ABBV-838|Varying doses of ABBV-838
237217|NCT02462538|Drug|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
237218|NCT02462538|Drug|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
237219|NCT02462551|Device|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
237220|NCT02462577|Drug|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
237221|NCT02462590|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
237222|NCT02462590|Drug|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
237223|NCT00173251|Procedure|obtain surgical specimen for analysis|
237224|NCT02462603|Drug|EPI-589|EPI-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
237225|NCT02462616|Other|not intervention|This is a cross-sectional study, no intervention was performed.
237226|NCT02462629|Drug|BLZ-100|
237227|NCT02462642|Dietary Supplement|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
237228|NCT02462642|Other|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
237229|NCT02462642|Dietary Supplement|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
237536|NCT02456129|Drug|[14C] Vilaprisan|an intravenous microtracer dose of [14C]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
237537|NCT00171509|Drug|Cyclosporine microemulsion|
237538|NCT02456129|Other|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
237539|NCT02456142|Drug|caudal bupivacaine|
237540|NCT02456142|Drug|intravenous morphine|
236895|NCT02431780|Device|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
236896|NCT02431793|Behavioral|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated inbox message and (c-3) pharmacists prompted to counsel via request printed on prescription.
236897|NCT02431793|Behavioral|SMS Texting Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
236898|NCT02431806|Drug|Placebo|
236899|NCT02431806|Drug|Levomilnacipran ER|
236900|NCT02431806|Drug|Fluoxetine|
236901|NCT02431819|Device|contention socks|Patients wear contention socks during 15 days.
236902|NCT02431832|Drug|Augmentin tab|
236903|NCT02431845|Drug|SSRIs|usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40~80 mg dose equivalents
236904|NCT00168324|Other|Sham Injection|Sham injection on Day 0.
236905|NCT02431858|Device|E-Catheter (Pajunk)|
236906|NCT02431858|Device|Sonolong Catheter (Pajunk)|
236907|NCT02431884|Procedure|collect body fluids/tissues & med history|collect tissues/fluids & history
236908|NCT02431897|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 6-8 weeks before surgery, then 2x/week for 1 year after surgery.
236909|NCT02431897|Drug|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for 6-8 weeks before surgery, then 2x/week for 1 year after surgery.
236910|NCT02431910|Other|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
236911|NCT02431910|Other|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
236912|NCT02431936|Drug|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
236913|NCT02431936|Drug|Placebo|Sugar pill made to look identical to Prazosin intervention.
236914|NCT02431949|Other|Admission to BCPP|There is no intervention associated with this study.
236263|NCT02441374|Other|Classical kinesiotherapy.|Appliying classical kinesiotherapy in upper limb post stroke.
236264|NCT00169312|Behavioral|behavioral dietary intervention|
236265|NCT02443844|Procedure|Transurethral Resection|Endoscopic treatment of bladder cancer
236266|NCT02443844|Drug|Tamsulosin|Medical treatment for benign prostate hyperplasia
236267|NCT02443857|Device|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
236595|NCT02439008|Procedure|Blood samples collection during radiotherapy|Sample T1: within 15 minutes after the administration of the first fraction,
Sample T2: within 15 minutes after the administration of the second fraction,
Sample T3: within 15 minutes after the administration of the third fraction
236596|NCT02439008|Procedure|Blood samples collection after radiotherapy|Sample T4: one week after the end of the radiotherapy,
Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy.
236597|NCT02439008|Radiation|Radiotherapy|
236598|NCT02439021|Device|COBRA|
236599|NCT02439021|Device|LMA|
236600|NCT02439034|Drug|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
236601|NCT02439034|Drug|Ketoprofen|Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
236602|NCT00169143|Drug|Rituximab + ACVBP regimen plus Pegfilgrastim|
236603|NCT02439047|Procedure|Biological samples collection|-Peritoneal samples : will be collected during abdominal surgery
A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum
- Adipose tissue samples : will be collected during surgery for breast reconstruction
236604|NCT02439060|Other|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
236605|NCT02439073|Behavioral|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
236606|NCT02439086|Device|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
235965|NCT02448485|Procedure|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
235966|NCT02448498|Behavioral|Exercise Intervention|
235967|NCT02448511|Other|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
235968|NCT02448511|Device|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
235969|NCT00170391|Behavioral|Quarter of an Hour rule|
235970|NCT02448511|Other|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
235971|NCT02448524|Device|MiStentTM|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
235972|NCT02448524|Device|TIVOLI|
235973|NCT02448537|Drug|PM01183|
235974|NCT02448537|Drug|Doxorubicin|
235975|NCT02448537|Drug|Gemcitabine|
235976|NCT02448550|Drug|Bivalirudin|
235977|NCT02448550|Drug|Unfractionated heparin|
235978|NCT02448563|Behavioral|Nutrition and physical activity education|Eight weekly in-person groups
235979|NCT02450617|Behavioral|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
236268|NCT02443857|Device|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
236269|NCT02443857|Device|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
236270|NCT02443857|Device|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
236271|NCT02443857|Device|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
235672|NCT02455141|Drug|Paclitaxel plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w*4 Carboplatin AUC=2, d1,d8,d15, q4w*4
235673|NCT00171366|Drug|amlodipine/benazepril|
235674|NCT02455154|Drug|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
235675|NCT02455154|Drug|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
235676|NCT02455154|Drug|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
235677|NCT02455167|Drug|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
235678|NCT02455167|Drug|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
235679|NCT02455167|Drug|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
235680|NCT02455180|Drug|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
235681|NCT02455193|Behavioral|Exercise|
235682|NCT02455193|Behavioral|Diet|
235683|NCT02455206|Behavioral|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
235684|NCT00171379|Drug|Enteric-Coated Mycophenolate Sodium|
235685|NCT02455206|Behavioral|Usual care|
235686|NCT02455219|Device|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
235687|NCT02455232|Procedure|upper limb muscle block|
235688|NCT02455232|Drug|4cc of lidocaïne®|
235689|NCT02455245|Drug|Carboplatin|
235690|NCT02455245|Drug|Vincristine|
235691|NCT02455258|Other|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
235386|NCT02461888|Drug|Ixazomib|
235692|NCT02455258|Other|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
235693|NCT02455271|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
235694|NCT02457507|Dietary Supplement|Vitamin B12|2 tablets
235695|NCT02457507|Dietary Supplement|Placebo|2 tablets
235696|NCT02457520|Drug|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
235697|NCT02457533|Behavioral|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
235698|NCT02457546|Biological|EVICEL Fibrin Sealant|
235699|NCT02457546|Device|Hydrogel sealant|
235700|NCT02457559|Drug|ONO/GS-4059|ONO/GS-4059 capsules administered orally
235701|NCT02457572|Procedure|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
235702|NCT02457572|Other|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
235703|NCT02457585|Drug|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
235704|NCT00171769|Drug|Certoparin|
235705|NCT02457598|Drug|ONO/GS-4059|ONO/GS-4059 capsules administered orally
235706|NCT02457598|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
235707|NCT02457598|Drug|Entospletinib|Entospletinib tablets administered orally
235708|NCT02457611|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
235709|NCT02457624|Behavioral|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
235710|NCT02457637|Other|standard treatment|
235111|NCT02431156|Other|Assessment of visual capacity|Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.
VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC
235112|NCT02431182|Behavioral|Memory Training Workshop|Presentation of the workshop: Objectives and Methodology
Explanation of the different types of memory and its implication in normal life
Strategies for gathering and codification of the information
Strategies for selection and storage the information
Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory
Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences
Strategies for recuperation according to the individual profile. Improving self-esteem
Strategies for recuperation Social skills.
Personal and social skills
New contexts and opportunities
Evaluation of the workshop
235113|NCT02431208|Drug|Atezolizumab|Participants will receive 1200 mg intravenous (IV) atezolizumab administered on Day 1 of each 21-day cycle until symptomatic deterioration attributed to progressive disease (PD), unacceptable toxicity, or loss of clinical benefit.
235114|NCT00168181|Drug|Salagen|
235387|NCT00172536|Behavioral|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
235388|NCT02461888|Drug|Cyclophosphamide|
235389|NCT02461888|Drug|Dexamethasone|
235390|NCT02464202|Other|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
235391|NCT02464215|Procedure|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
235392|NCT00173888|Drug|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
235393|NCT02464215|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
235394|NCT02464228|Drug|Tipifarnib|twice daily, oral
235395|NCT02464241|Other|only examination|
235396|NCT02464254|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
234825|NCT00169091|Drug|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
234826|NCT02438241|Procedure|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
234827|NCT02438241|Procedure|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
234828|NCT02438280|Device|AcceleDent, Vibrational Device|
234829|NCT02438293|Other|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
234830|NCT02438306|Biological|Autologous cell therapy|
234831|NCT02438306|Device|CardiAMP cell therapy|
234832|NCT02438306|Other|Sham|Optimal medical/device therapy
234833|NCT02438319|Other|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
234834|NCT02438319|Other|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
234835|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
234836|NCT00169091|Drug|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
234837|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
235115|NCT02431208|Drug|Lenalidomide|Lenalidomide will be administered orally (PO) on Days 1 to 14 of each 21-day cycle. Participants in Cohort B1 will receive ascending-dose lenalidomide beginning at 10 milligram (mg; Level 1) and increasing to 15 mg (Level 2) and 25 mg (Level 3). A reduced dose of 5 mg (Level -1) will be used if Level 1 exceeds the maximum tolerable dose (MTD). Participants in Cohort B2 will receive lenalidomide at the MTD as determined in Cohort B1.
235116|NCT02431221|Drug|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
235117|NCT02431221|Drug|Placebo|
234541|NCT00169559|Drug|GW590735|1µg to 20µg daily doses of GW590735
234542|NCT02445716|Drug|Testosterone|It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.
Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit.
234543|NCT02445716|Drug|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
234544|NCT02445729|Other|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
234545|NCT02445729|Other|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
234546|NCT02445742|Drug|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
234547|NCT02445768|Device|3T scanner|Neurocognitive therapeutic
234548|NCT02445768|Device|Inactive transcutaneous electrical nerve stimulation (TENS)|
234549|NCT02445768|Other|The exercises with the robot|
234550|NCT02445781|Device|Glucose clamp|Different levels of hypoglycemia
234551|NCT02445794|Drug|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
234552|NCT00169884|Behavioral|cognitive-behavioural therapy|
234553|NCT02445794|Drug|RT001 comparator|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
234554|NCT02445807|Drug|DFD06-Cream|Twice daily topical application for 14 days.
234555|NCT02445807|Drug|Vehicle Cream|Twice daily topical application for 14 days.
234556|NCT02445820|Drug|HES|2500 mL of balanced HES 130/0.4
234838|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
234839|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
234840|NCT02438345|Biological|PRO 140|Humanized monoclonal antibody to CCr5
238948|NCT00171587|Drug|PTK787/ZK 222584 (vatalanib)|
238949|NCT02456571|Device|CTC biomarker expression prevalence|
238950|NCT02456584|Drug|DMPA 150|injectable contraceptive
238951|NCT02456584|Drug|DMPA 300|injectable contraceptive
238952|NCT02456584|Drug|DMPA 104|injectable contraceptive
238953|NCT02456597|Drug|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
238954|NCT02456597|Drug|Isotonic Saline|Isotonic saline injected through the novel Catheter
234242|NCT02449993|Device|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
234243|NCT02450019|Procedure|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
234244|NCT02450019|Procedure|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
234245|NCT00170664|Drug|Carboplatin|
234246|NCT02450032|Biological|G17DT|
234247|NCT02450045|Procedure|Continuous femoral nerve block|
234248|NCT02450045|Drug|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
234249|NCT02450058|Drug|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
234250|NCT02450058|Drug|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
234251|NCT02452320|Drug|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
234252|NCT02452333|Procedure|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
234253|NCT02452333|Procedure|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
234254|NCT02452333|Other|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
238660|NCT02460913|Drug|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
238661|NCT02460926|Procedure|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
238662|NCT00173550|Procedure|Hysterectomy and Bilateral salpingo-oophorectomy|
238663|NCT02463110|Drug|Placebo|
238664|NCT02463123|Device|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
238665|NCT02463136|Behavioral|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
238666|NCT02463136|Device|Functional magnetic resonance imaging w neurofeedback|The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).
Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014).
238667|NCT02463149|Behavioral|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
238668|NCT02463162|Other|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
238955|NCT02456610|Biological|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
238956|NCT02456623|Behavioral|Intervention|Home-based session targeting the parent
238957|NCT02456623|Behavioral|Attention Control|Attention condition with newsletters and support phone calls
238958|NCT02456636|Behavioral|Fee-for-Service Model|To be performed by participant's doctor or other healthcare professional in their doctor's office.
238959|NCT00171600|Drug|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
238960|NCT02456636|Behavioral|Patient Centered Medical Home|To be performed by a registered dietitian, a nurse or other healthcare professional.
238961|NCT02456636|Behavioral|Disease Management|To be preformed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling
238379|NCT02429908|Device|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
238380|NCT02429921|Dietary Supplement|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
238381|NCT02429921|Dietary Supplement|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
238382|NCT02429934|Drug|abatacept|125mg injected subcutaneously weekly for 16 weeks
238383|NCT00168025|Drug|Immunoglobulins Intravenous (Human)|
238384|NCT02429934|Drug|Placebo|
238385|NCT02429960|Device|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
238386|NCT02429960|Device|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
238387|NCT02429960|Device|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
238388|NCT02429960|Drug|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
238389|NCT00168402|Drug|Botulinum Toxin Type A|
238390|NCT02432430|Behavioral|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
238391|NCT02432430|Behavioral|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
238669|NCT02463175|Drug|Plasmalyte|Boluses of 5ml/kg of plasmalyte
238670|NCT02463175|Procedure|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
238671|NCT02463188|Behavioral|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
238672|NCT02463201|Behavioral|Weight loss|
238673|NCT00173615|Procedure|Extracorporeal membrane oxygenation|
238065|NCT02437149|Behavioral|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
238066|NCT02437149|Behavioral|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
238067|NCT02437162|Drug|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1
238068|NCT02437162|Drug|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
238069|NCT02437162|Drug|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
238070|NCT00168948|Drug|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
238071|NCT02437162|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
238072|NCT02437175|Dietary Supplement|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
238073|NCT02437175|Dietary Supplement|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
238074|NCT02437188|Behavioral|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
238075|NCT02437201|Behavioral|Liberty Program|
238076|NCT02439697|Other|Darbepoetin alfa|Conversion from Aranesp® to NESP®
238077|NCT00169195|Drug|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
238078|NCT02439710|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
238079|NCT02439723|Drug|Regorafenib|
238080|NCT02439736|Other|Blood draw within 12 hours of head injury|
221960|NCT02309918|Drug|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
221961|NCT02309931|Procedure|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
221962|NCT02309931|Procedure|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
221963|NCT02309944|Procedure|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if >2 cm deep, followed by staple or suture closure of the skin.
221964|NCT02309944|Device|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
221965|NCT02309957|Device|BioMatrix CRD|
221966|NCT02309970|Drug|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
221967|NCT02309970|Drug|alteplase|subject in this group will receive intravenous tPA
221968|NCT02309970|Procedure|endovascular|
222263|NCT02181764|Drug|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
222264|NCT02181777|Behavioral|GRASP|GRoup trAining for Social skills in Psychosis
222265|NCT00137540|Device|RF ablation|
222266|NCT02181777|Behavioral|Standard care|Treatment as usual
222267|NCT02181790|Device|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
222268|NCT02181803|Drug|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 14 mg, 16 mg, 20 mg, or 40 mg
222269|NCT02184273|Drug|Magnesium metamizol|
222270|NCT02184273|Drug|Placebo|
222271|NCT02184286|Drug|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
222272|NCT02184286|Drug|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
222273|NCT00137865|Genetic|EGEN-001 (phIL-12-005/PPC)|
222274|NCT02184299|Drug|Nevirapine|
238128|NCT02444689|Behavioral|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
238129|NCT00002462|Drug|procarbazine hydrochloride|
238130|NCT00169728|Biological|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
238131|NCT02444689|Behavioral|Standard of care education|
238132|NCT02444715|Behavioral|Standard care|Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
238133|NCT02444715|Behavioral|CAPSYS|In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
238134|NCT02444728|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
238135|NCT02444728|Drug|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
238136|NCT02444728|Drug|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
238137|NCT02444728|Drug|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
238138|NCT02444741|Drug|Pembrolizumab|Phase I: Starting dose of Pembrolizumab (MK-3475) 100 mg by vein on Day 1 of each 3-week cycle.
Phase II: Starting dose of Pembrolizumab at the maximum tolerated dose from Phase I.
238139|NCT02444741|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) delivered at 50 Gy in 4 daily fractions.
238140|NCT02444741|Radiation|Wide-Field Radiation Therapy|Wide-field radiation therapy (WFRT) delivered at 45 Gy in 15 daily fractions.
238141|NCT00169728|Biological|heptavalent pneumococcal conjugate vaccine, Prevenar|
238443|NCT02437357|Other|Positivity Training|8 group sessions á 60 min
238444|NCT02437370|Drug|Pembrolizumab|Given IV
238445|NCT02437370|Drug|Docetaxel|Given IV
238446|NCT02437370|Drug|Gemcitabine Hydrochloride|Given IV
238447|NCT02439853|Behavioral|Monthly Check-in Session|Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
238448|NCT02439866|Drug|placebo|gelatinous capsules filled with sugar as placebo
238449|NCT00169208|Drug|fludarabine|
237830|NCT02449265|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy.
237831|NCT02451332|Biological|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
237832|NCT02451345|Behavioral|Personalized coaching intervention|A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.
The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care.
237833|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (2 injections 28 days apart for participants aged 6 to 35 months )
237834|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
237835|NCT00170846|Drug|Mycophenolate acid (MPA)/Azathioprine (AZA)|
237836|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2 injections 28 days apart for participants aged 3 to 8 years)
237837|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
237838|NCT02451371|Device|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
237839|NCT02451384|Procedure|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
237840|NCT02451384|Procedure|no-touch surgery|
237841|NCT02451384|Procedure|laparoscopic surgery|
237842|NCT02451410|Other|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
237843|NCT02451423|Drug|MPDL3280A Dose Level 1|1200 mg x 1 dose
238142|NCT02444754|Other|Medical Chart Review|Obtain medical data
238143|NCT02444754|Other|Questionnaire Administration|Complete demographics questionnaires
238144|NCT02444754|Other|Survey Administration|Complete surveys
238145|NCT02444767|Drug|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
237541|NCT02458287|Biological|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
237542|NCT02458287|Biological|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
237543|NCT02458287|Biological|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
237544|NCT02458300|Other|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
237545|NCT02458300|Other|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
237546|NCT00171860|Drug|imatinib mesylate|
237547|NCT02458300|Other|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
237548|NCT02458300|Other|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
237549|NCT02458300|Other|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
237550|NCT02458313|Drug|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
237551|NCT02458313|Other|Placebo|Placebo capsules b.i.d. for 12 weeks
237552|NCT02458326|Other|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
237553|NCT02458326|Other|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
237554|NCT02458339|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
237844|NCT02451423|Drug|MPDL3280A Dose Level 2|1200 mg every 3 weeks x 2 doses
237845|NCT02451423|Drug|MPDL3280A Dose Level 3|1200 mg evert 3 weeks x 3 doses
237846|NCT00170846|Drug|Steroids|
237847|NCT02451436|Behavioral|Sleep and Media Use Intervention|
236915|NCT02434042|Dietary Supplement|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
237230|NCT02462642|Other|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
237231|NCT02462655|Other|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
237232|NCT02464904|Device|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
237233|NCT02464904|Other|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
237234|NCT02464917|Device|Device: simple facemask to administer supplemental oxygen|
237235|NCT02464943|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
237236|NCT02464969|Drug|Apixaban|Tablet or Solution
237237|NCT00174239|Drug|cabergoline|
237238|NCT02464969|Drug|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist.
237239|NCT02464982|Procedure|Tattoo|tattoo device with EC standards, and sterile single-use only needle
237240|NCT02464995|Device|Bronchial thermoplasty with the Alair System|
237241|NCT02465008|Drug|Levobupivacaine|
237242|NCT02465008|Drug|Placebo|
237243|NCT02465021|Other|Dietary intervention|All arms are given to all participants, in a randomized order
237244|NCT02465034|Device|Transcranial Magnetic Stimulation (Magstim)|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 Hz) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
236607|NCT02439112|Other|Exercise|8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly >65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.
Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)
236608|NCT02439125|Drug|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
236609|NCT02439125|Drug|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
236610|NCT02439125|Drug|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
236611|NCT02439125|Drug|Placebo|b.i.d. orally for 3 weeks
236612|NCT02439138|Drug|GS-1101|
236613|NCT00169143|Procedure|Autologous stem cell transplant|
236916|NCT02434042|Other|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
236917|NCT02434055|Device|AVERT PLUS|
236918|NCT02434068|Other|CT|followup
236919|NCT02434081|Drug|Nivolumab|
236920|NCT02434094|Behavioral|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
236921|NCT02434107|Procedure|Completion Lymphadenectomy|
236922|NCT00168649|Drug|Vitamin A|
236923|NCT02434107|Procedure|Clinical Monitoring (Palpation and node ultrasound)|
236924|NCT02434133|Procedure|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
236925|NCT02434146|Drug|Topical Phenylephrine Solution|Given topically via spray
236926|NCT02434159|Other|Heart scan|
236927|NCT02434172|Other|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
236928|NCT02434211|Other|Questionnaire and focus group|
236272|NCT02443857|Device|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
236273|NCT02443883|Drug|Ramucirumab|Administered IV
236274|NCT02443896|Procedure|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
236275|NCT00002462|Drug|prednisone|
236276|NCT00169624|Drug|Metformin|
236277|NCT02443896|Procedure|No sealant of permanent molars|No sealant applied to permanent molars.
236278|NCT02443909|Procedure|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
236279|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
236280|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
236281|NCT02443909|Device|Holmium laser device|
236282|NCT02443922|Drug|Glimepiride|Glimepiride 2mg qam
236283|NCT02443922|Drug|Sitagliptin|Sitagliptin 100mg qam
236284|NCT02443922|Drug|Metformin|Metformin as prescribed
236285|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 4 weeks
236286|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 24 weeks
236287|NCT00169624|Drug|Gliclazide|
236288|NCT02443948|Other|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
236289|NCT02443961|Biological|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
236614|NCT02439151|Device|New lung ventilation strategy|New ventilation strateg: PCV molel; FiO2 0.3; regulate the PC allows transpulmonary pressure at the end of inspiration less than 20cmH2O; Ti 1s; frequency 10bpm; regulate the PEEP allows transpulmonary pressure at the end of expiration greater than 0cmH2O and less than 5cmH2O.
236615|NCT02439151|Device|Conventional ventilation strategy|Conventional ventilation strategy: PCV molel; FiO2 0.3; PC 10cmH2O; Ti 1s; frequency 10bpm; PEEP 10cmH2O.
236616|NCT02439164|Drug|Midazolam|
235980|NCT02450630|Behavioral|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated & severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
235981|NCT02450643|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
235982|NCT02450643|Other|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
235983|NCT02450656|Drug|Afatinib|Tablet
235984|NCT02450656|Drug|Selumetinib|Capsule
235985|NCT02450656|Drug|Capecitabine|
235986|NCT00170755|Drug|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
235987|NCT02450656|Drug|Irinotecan|
235988|NCT02450656|Drug|Docetaxel|
235989|NCT02450682|Drug|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
235990|NCT02450682|Drug|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
235991|NCT02450695|Device|rTMS|
235992|NCT02450708|Genetic|KIR genotyping|
235993|NCT02450708|Genetic|HLA genotyping|
235994|NCT02450721|Other|Biomarkers serum level measurement|Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- "Cloud-CloneCorp." (USA); PAPP-A ELISA- "IBL" (Germany); Lp (a) ELISA Kit-"AssayPro" (USA ), ADMA ELISA Kit- "ImmunDiagnostik" ( Germany); hsCRP ELISA- "Biomerica" (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader "Bio-Tek" (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO.
235995|NCT02450734|Procedure|Ultrasound-guided intermediate cervical plexus block|
235996|NCT02450747|Device|1-Day ACUVUE® MOIST® MULTIFOCAL|Subjects will wear the test lens for four weeks.
235997|NCT00170768|Drug|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
235998|NCT02450760|Other|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
227370|NCT02157883|Drug|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
227371|NCT02157883|Drug|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
227372|NCT02157909|Device|Lotrafilcon B sphere modified design contact lenses|
227373|NCT02157909|Device|Lotrafilcon B sphere contact lenses|
227374|NCT00134784|Drug|[123I]B-CIT SPECT imaging|To assess [123I]B-CIT SPECT imaging
227375|NCT02157922|Drug|alginate oligosaccharide|Inhalation
227376|NCT02157935|Drug|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
227377|NCT02157935|Drug|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
227378|NCT02157935|Other|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
227379|NCT02157935|Other|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
227380|NCT02157948|Drug|Denosumab (CP2)|Subjects will receive denosumab CP2 (60 mg every 6 months) for 12 months, via a pre-filled syringe.
227381|NCT02157948|Drug|Denosumab (CP4)|Subjects will receive denosumab CP4 (60 mg every 6 months) for 12 months, via a pre-filled syringe.
227382|NCT02157987|Drug|bevacuzimab spray|
227708|NCT00138671|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
227709|NCT02191527|Device|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
227710|NCT02191540|Drug|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
227711|NCT02191553|Behavioral|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
227712|NCT02191553|Behavioral|Loving-kindness meditation|Following Kristin Neff protocol
227713|NCT02191553|Behavioral|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
227714|NCT02191553|Behavioral|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
226751|NCT02170337|Drug|Placebo|Contains no active drug
227059|NCT02163005|Drug|Gadolinium|-agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents.
227060|NCT02163018|Drug|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
227061|NCT02163018|Drug|Placebo|Subcutaneous administration of increasing doses of placebo
227062|NCT02163031|Device|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
227063|NCT02165566|Drug|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
227064|NCT02165566|Drug|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
227065|NCT02165579|Other|1 cohort, standard care, observational|
227066|NCT02165605|Drug|HylaCare|cream
227067|NCT02165605|Drug|Placebo|placebo
227068|NCT02165618|Other|Medication review, based on but not limited to the RASP list|Systematic approach:
Medication reconciliation
Applying the RASP list
Expert review (not based on the RASP list)
Multidisciplinary discussion
227069|NCT00135694|Drug|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
227070|NCT02165644|Drug|Acetazolamide|Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration.
227071|NCT02165644|Drug|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
227072|NCT02165657|Device|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
227073|NCT02165670|Device|Coronary stenting with CE-marked stent|
227074|NCT02165696|Other|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
227075|NCT02165696|Other|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
227076|NCT02165709|Procedure|Salpingectomy|
226457|NCT02178163|Other|laboratory biomarker analysis|Correlative studies
226458|NCT02180841|Dietary Supplement|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
226459|NCT02180854|Other|Control group|
226460|NCT02180854|Other|Increased monitoring frequency|
226461|NCT00137436|Drug|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
226752|NCT02170350|Procedure|Meditation therapy|Use brief mindful meditation practice
226753|NCT02172768|Other|daily dosing|micafungin daily for 8 days
226754|NCT02172768|Drug|micafungin|
226755|NCT02172781|Drug|Ipratropium - unit dose vial|
226756|NCT02172781|Drug|Tiotropium - inhalation capsule|
226757|NCT02172781|Drug|Placebo matching tiotropium|
226758|NCT02172781|Drug|Placebo matching ipratropium|
226759|NCT02172794|Drug|Tiotropium|
226760|NCT00136513|Drug|SB-743921|
226761|NCT02172794|Drug|Placebo to tiotropium|
226762|NCT02172794|Drug|Salmeterol|
226763|NCT02172794|Drug|Placebo to salmeterol|
226764|NCT02172807|Drug|Tiotropium low|Tiotropium 18 µg inhalation capsule
226765|NCT02172807|Drug|Tiotropium high|Tiotropium 36 µg inhalation capsule
226766|NCT02172807|Drug|Placebo MDI|Placebo metered dose inhaler (MDI)
226767|NCT02172807|Drug|Placebo inhalation capsule|
226768|NCT02172807|Drug|Oxitropium|Oxitropium MDI (100 µg/puff)
226769|NCT02172820|Behavioral|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
226770|NCT02172846|Radiation|Proton beam radiation therapy (PBT)|
226187|NCT02188511|Other|Electronic cigarette (nicotine/placebo) - Days 6 through 8|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
226188|NCT02188511|Other|Electronic cigarette (nicotine/placebo)- Days 5 through 8|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
226462|NCT02180867|Drug|Doxorubicin Hydrochloride|Given IV
226463|NCT02180867|Drug|Ifosfamide|Given IV
226464|NCT02180867|Other|Laboratory Biomarker Analysis|Correlative studies
226465|NCT02180867|Drug|Pazopanib Hydrochloride|Given PO
226466|NCT02180867|Other|Pharmacological Study|Correlative studies
226467|NCT02180867|Radiation|Radiation Therapy|Undergo radiation therapy
226468|NCT02180867|Procedure|Therapeutic Conventional Surgery|Undergo surgery
226469|NCT02180880|Drug|Pregabalin and Oxcarbazepine|Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.
Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.
226470|NCT02180893|Other|Paravertebral Block|Paravertebral nerve block injection
226471|NCT02180893|Other|Placebo Comparator|No block
Patients who did not receive PVB
226472|NCT00137436|Drug|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
226473|NCT02180919|Device|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
226474|NCT02180932|Biological|periodontal pocket samples|
226475|NCT02180971|Procedure|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
226476|NCT02180971|Procedure|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
225862|NCT02157207|Dietary Supplement|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
225863|NCT02157207|Other|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
225864|NCT02157220|Device|Fixed bearing prosthesis|
225865|NCT02157220|Device|Mobile bearing prosthesis|
225866|NCT02157233|Behavioral|Rest|
225867|NCT02157233|Behavioral|Exercise|
225868|NCT02157246|Other|Pimonidazole|
225869|NCT02157246|Other|F-MISO scan|
225870|NCT02157272|Drug|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
225871|NCT02157285|Behavioral|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
225872|NCT00134719|Biological|M-M-R®II|One subcutaneous dose at 12-15 months of age
225873|NCT02157298|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
225874|NCT02157298|Drug|Placebo tablet|Placebo tablet. Oral dose
225875|NCT02157311|Drug|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
225876|NCT02157324|Drug|ACP-196 and ACP-319|
226189|NCT02188511|Other|Electronic cigarette (nicotine/placebo) - Days 4 through 8|On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine.
226190|NCT02188524|Other|Exercise|Tai Chi and Compensatory Stepping
226191|NCT02190617|Behavioral|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
225539|NCT02167542|Device|CPAP valve (Boussignac)|Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.
Oxygen flow will be titrated by the investigator to ensure SpO2>92%.
225540|NCT02167555|Dietary Supplement|Active Comparator|Wild Blueberry Beverage
225541|NCT02167555|Dietary Supplement|Placebo Comparator|Placebo Beverage
225542|NCT02167568|Genetic|Genetic|
225543|NCT02167594|Drug|18F-AV-1451|
225544|NCT02167594|Drug|florbetapir F18|
225545|NCT02167607|Dietary Supplement|Active Comparator|Purple Potato
225546|NCT02167607|Dietary Supplement|Placebo Comparator|Placebo Comparator
225547|NCT02167620|Drug|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
225548|NCT02167620|Drug|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
225549|NCT00135889|Drug|Femoral perineural infusion|
225550|NCT02167633|Procedure|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
225551|NCT02167633|Radiation|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
225552|NCT02167633|Radiation|Fractionated Radiotherapy|Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.
Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume.
225553|NCT02167633|Drug|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
225554|NCT02167633|Drug|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
225555|NCT02167646|Procedure|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
224899|NCT02180165|Drug|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
224900|NCT02180165|Drug|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
224901|NCT02180178|Other|observational only- no intervention|
224902|NCT02180191|Other|Comparison of the gut microbiota composition|
224903|NCT02180204|Drug|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
224904|NCT02180204|Drug|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
224905|NCT02180217|Drug|LCI699|
224906|NCT02180230|Device|NobelSpeedy Shorty implant|
224907|NCT02180230|Device|Brånemark System Mk III Shorty implants|
224908|NCT00137358|Drug|Cisplatin|
224909|NCT02180243|Behavioral|Yoga/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
224910|NCT02182830|Drug|Empagliflizon low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
224911|NCT00137709|Drug|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
225217|NCT02175069|Drug|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
225218|NCT02175069|Procedure|Shoulder Surgery|As per individual requirement (patient-dependent)
225219|NCT02175082|Other|Cycling at Forced rate|
225220|NCT02175082|Other|Cycling at self-selected rate|
225221|NCT02175095|Drug|Regorafenib|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy).
225222|NCT02175121|Drug|Placebo|Tablet, once daily for 28 days
225223|NCT02175121|Drug|PF-06291874|Tablet, 15 mg, once daily for 28 days
225224|NCT02175121|Drug|PF-06291874|Tablet, 35 mg, once daily for 28 days
230612|NCT02396056|Other|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
230613|NCT00163319|Drug|Ciclesonide|
230614|NCT02396069|Drug|JPI-289|PARP-1 inhibitor
230615|NCT02396069|Drug|Placebo|Placebo
230616|NCT02396082|Behavioral|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
230617|NCT02396082|Other|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
230618|NCT02396108|Drug|Paclitaxel + Carboplatin + ASLAN001|Phase I
IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle
IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle
PO ASLAN001 daily continuously (starting dose 500mg BID)
Phase II
•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks
Followed by:
IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles
IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles
PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks
230619|NCT02396121|Dietary Supplement|Oral nutritional supplement : Renutryl® Booster|
230620|NCT02396134|Biological|CMVpp65-A*0201 peptide vaccine|Given SC
230621|NCT02396134|Other|Placebo|Given SC
230622|NCT02396134|Other|Laboratory Biomarker Analysis|Correlative studies
230623|NCT02396147|Drug|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
230624|NCT00163332|Drug|Ciclesonide|
230625|NCT02396147|Drug|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
230626|NCT02396147|Drug|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
230627|NCT02396160|Dietary Supplement|Urox|Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
230038|NCT02407119|Drug|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
230039|NCT02407119|Drug|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
230323|NCT02400840|Procedure|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
230324|NCT02400840|Drug|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
230325|NCT02400853|Device|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
230326|NCT02400853|Procedure|Cord blood analysis|Cord blood will be collected during deliverance and analysed
230327|NCT02400866|Drug|Olanzapine|
230328|NCT00164112|Drug|Azithromycin plus Cooperstown 5+1|
230329|NCT02400879|Drug|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
230330|NCT02400879|Drug|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
230331|NCT02403050|Device|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
230332|NCT02403063|Drug|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
230333|NCT02403063|Drug|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
230334|NCT02403063|Drug|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
230335|NCT00164385|Behavioral|Adolescent Impact|
230336|NCT02403089|Other|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
230337|NCT02403089|Other|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
230338|NCT02403115|Other|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
230339|NCT02403128|Drug|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
229750|NCT02411565|Drug|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
229751|NCT02411565|Procedure|Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
229752|NCT02411565|Other|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
229753|NCT00165295|Drug|Sildenafil citrate (Viagra)|
229754|NCT02411578|Drug|G-Pen Mini™ (glucagon injection)|1st BG check, 1st treatment
BG is 50-69 mg/dl, treatment is 150 µg of glucagon
BG is 40-49 mg/dl, treatment is 300 µg of glucagon
15 min later, 2nd BG check, 2nd treatment
BG is 60-69 mg/dl, no treatment
BG is 50-59 mg/dl, treatment is 150 µg of glucagon
BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
30 minutes later, 3rd BG check, 3rd treatment
(1) BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
(150 µg of glucagon per syringe)
229755|NCT02413528|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
229756|NCT02413541|Procedure|Polymyxin-B Hemoperfusion|Endotoxin removal
229757|NCT02413541|Procedure|Standard treatment|
230040|NCT02407132|Behavioral|Family Model DSME|Participants assigned to this arm will received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
230041|NCT02407145|Other|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
230042|NCT02407158|Device|SonarMed Airwave Device|Measure the concordance of chest x-ray and the Airwave device for measuring the change of position of an endotracheal tube.
230043|NCT02407171|Drug|MK-3475|200 mg every 2 weeks by IV infusion
230044|NCT02407171|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
230045|NCT00164931|Drug|Intravenous omeprazole infusion|
230046|NCT02407184|Other|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
230047|NCT02407210|Drug|azilsartan|
230048|NCT02407210|Drug|Olmesartan medoxomil|
224679|NCT02195453|Drug|Yangzhengxiaoji Capsule|Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.
Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.
Yangzhengxiaoji Capsule four granules t.i.d po.
224680|NCT02195453|Drug|Placebo Capsule|Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.
Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.
Placebo Capsule four granules t.i.d po.
224681|NCT02195466|Drug|Tipranavir (TPV)|500 mg bid on days 7-14
224682|NCT02195466|Drug|Ritonavir (RTV)|200 mg bid on days 7-14
224683|NCT00139230|Drug|Cisplatin|
224684|NCT02195466|Drug|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
224685|NCT02156531|Behavioral|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
224686|NCT02156531|Behavioral|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
224687|NCT02156544|Drug|CKD-519|
224688|NCT02156544|Drug|placebo|
224689|NCT02156557|Biological|Colon KCC Heptapeptide|Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.
The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then "injected" into a special, single-use "sprayer", like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.
The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.
We will obtain copies of your endoscopy report and any pathology reports.
224690|NCT02156570|Drug|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
224691|NCT00134706|Drug|Docetaxel|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
224989|NCT02190045|Other|Wii-Fit exercises|Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks
224990|NCT02190045|Other|Cognitive remediation exercises|Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
224991|NCT02190058|Drug|DS-1971a|suspension
224036|NCT02169271|Other|Placebo|Given PO
224037|NCT02169284|Drug|Erlotinib Hydrochloride|Given PO
224038|NCT02169284|Other|Laboratory Biomarker Analysis|Correlative studies
224365|NCT02162069|Device|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
224366|NCT02162082|Device|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
224367|NCT02162121|Procedure|Continuous lumbar plexus: stimulating catheter|Perinervous stimulating catheter ("Stimulong", "Pajunk", Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia.
224368|NCT02162121|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
224369|NCT02162121|Procedure|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
224370|NCT02162121|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times a day
224371|NCT02162121|Procedure|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS>4
224372|NCT02162121|Drug|Mepivacaine 1%|
224373|NCT02162121|Drug|Levobupivacaine 0,5%|
224374|NCT02162121|Drug|Ropivacaine 0,2%|
224375|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
224376|NCT02162121|Drug|Ketorolac 30mg|
224377|NCT02162121|Drug|Buprenorphine 0,2mg|
224378|NCT02162121|Device|Stimulong, Pajunk, Germany.|
224379|NCT02162121|Procedure|Continuous lumbar plexus: non-stimulating catheter|
224380|NCT02164357|Procedure|EVT (endovascular treatment )|
224381|NCT02164357|Procedure|IVT (intravenous thrombolytic therapy)|
224382|NCT02164383|Drug|Nicotine patch|4-week starter kit of nicotine patch
224383|NCT00002269|Drug|Zidovudine|
228909|NCT02397785|Device|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
228910|NCT00163592|Drug|Tissucol®|
228911|NCT02397785|Device|Sham Device|
228912|NCT02397798|Behavioral|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
228913|NCT02397798|Behavioral|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
228914|NCT02397811|Dietary Supplement|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
228915|NCT02397811|Dietary Supplement|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
228916|NCT02397811|Dietary Supplement|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
228917|NCT02397811|Dietary Supplement|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
224039|NCT00136097|Device|Placement of a silver impregnated central venous catheter|
224040|NCT02169284|Other|Pharmacological Study|Correlative studies
224041|NCT02169284|Other|Placebo|Given PO
224042|NCT02169284|Procedure|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
224043|NCT02169297|Procedure|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter [maximum pump infusion rate]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
224044|NCT02169297|Procedure|PCA only|Patients received intravenous PCA post-operatively
224045|NCT02169323|Other|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
224046|NCT02169336|Drug|Intranasal Dexmedetomidine|
224047|NCT02169336|Other|Intranasal Placebo|
228635|NCT02404532|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
228636|NCT02404545|Device|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
228637|NCT02404558|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
228638|NCT02404558|Drug|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
228639|NCT02404571|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
228640|NCT02404584|Genetic|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
228641|NCT02404584|Biological|Blood drawn for pharmacokinetic measures|Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.*
*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
228642|NCT02404597|Device|NICOM (non-invasive cardiac output monitor)|The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure <100 or mean arterial pressure <65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.
The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined.
228918|NCT02397811|Dietary Supplement|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
228919|NCT02397811|Dietary Supplement|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
228920|NCT02397824|Other|Salivary and blood samples|
228921|NCT00163592|Procedure|Control: Conventional treatment, i.e. compression with swabs|
228922|NCT02397837|Drug|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
228923|NCT02397837|Drug|Placebo|placebo match study drug
228333|NCT02408627|Device|EEG|
228334|NCT02408640|Behavioral|Cannabishjalpen.se|
228335|NCT02408653|Device|EEG|
228336|NCT02408666|Other|Interview|
228337|NCT00165087|Procedure|cranial radiation (once daily fractionation)|
228338|NCT02408679|Procedure|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
228339|NCT02408679|Other|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
228340|NCT02408692|Drug|Levonorgestrel (LNG)-based Emergency Contraception|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of <25 kg/m2 will have completed study participation.
228341|NCT02410837|Procedure|Electromagnetic Navigation Bronchoscopy|
228342|NCT02410850|Device|Oral Appliance|Mandibular Advancement Splints
228343|NCT02410863|Drug|Dabrafenib|150 mg twice daily
228344|NCT02410863|Drug|Trametinib|2 mg daily
228345|NCT00165217|Drug|Capecitabine|
228346|NCT02410876|Procedure|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
228347|NCT02410876|Procedure|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
228348|NCT02410889|Other|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
228349|NCT02410902|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
228350|NCT02410902|Drug|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
228351|NCT02410915|Device|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
227701|NCT02191462|Dietary Supplement|Niagen 1000mg|
227702|NCT02191475|Drug|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
227703|NCT02191475|Drug|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
227704|NCT02191488|Drug|5-aminolevulinic acid|
227705|NCT02191501|Device|The Apollo Overstitch Suturing|The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.
However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested.
227706|NCT02191527|Device|PIMA® for quantitative analysis of CD4-count|
227707|NCT02191527|Device|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
228012|NCT02184195|Drug|Placebo|Match Olaparib 100mg placebo
228013|NCT02184195|Drug|Placebo|Match Olaparib 150mg placebo
228014|NCT02184221|Device|High frequency stimulation|The parameter of DMS: alpha frequency
228015|NCT00137852|Procedure|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
228016|NCT02184221|Device|Low frequency stimulation|The parameter of DMS: 0.5Hz
228017|NCT02184234|Drug|Antistax film coated tablets|
228018|NCT02184247|Drug|anhydrous theophylline, 350 mg|
228019|NCT02184247|Drug|anhydrous theophylline, 300 mg|
228020|NCT02184260|Drug|Metamizole|
228021|NCT02184260|Drug|Placebo|
228022|NCT02186483|Drug|Rosuvastatin|Rosuvastatin, 20 mg, once daily
228023|NCT02186483|Drug|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
228024|NCT02186496|Drug|CKD-330 8/5mg|
228025|NCT02186496|Drug|Candesartan 8mg and Amlodipine 5mg|
228026|NCT02186509|Radiation|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
227715|NCT00139048|Behavioral|Decision Aid|
227716|NCT02194023|Drug|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
227717|NCT02194023|Drug|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
227718|NCT02194036|Behavioral|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
227719|NCT02194036|Behavioral|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
227720|NCT02194049|Drug|BKM120|Given PO
227721|NCT02194049|Drug|cisplatin|Given IV
227722|NCT02194049|Drug|etoposide|Given IV
227723|NCT02194062|Drug|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
227724|NCT02194062|Drug|Budesonide|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
227725|NCT02194062|Drug|Budesonide|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
227726|NCT00139061|Drug|Torcetrapib/Atorvastatin|
227727|NCT02194075|Drug|Fluvoxamine+Methylphenidate hydrochloride|
227728|NCT02194075|Drug|Fluvoxamine+sugar pill|
228037|NCT02186587|Device|Off-the-shelf total knee implant|
228038|NCT02186600|Drug|Calcium carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
228039|NCT02186600|Drug|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
228040|NCT02186600|Drug|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
228041|NCT00138060|Drug|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
228042|NCT02186600|Behavioral|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
227077|NCT02165709|Procedure|Traditional sterilization|
227383|NCT02158000|Other|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
227384|NCT02158013|Other|Levorag Emulgel|
227385|NCT00134810|Drug|Botulinum type A toxin (Dysport®)|
227386|NCT02158013|Drug|Diltiazem|
227387|NCT02158039|Drug|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
227388|NCT02158039|Drug|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
227389|NCT02158052|Drug|Tacrolimus|Tacrolimus starting on Day -1
227390|NCT02158052|Drug|Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
227391|NCT02158052|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques.
227392|NCT02160548|Drug|Standard care|Standard management for OP poisoning
227393|NCT02160548|Drug|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
227394|NCT02160548|Drug|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
227395|NCT02160561|Other|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
227396|NCT02160574|Drug|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
227397|NCT02160574|Drug|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
227398|NCT02160574|Drug|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
227399|NCT00135213|Behavioral|training in smoking cessation|
227400|NCT02160574|Other|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
227401|NCT02160587|Drug|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
227402|NCT02160587|Drug|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
226771|NCT00136526|Drug|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
226772|NCT02172846|Drug|Paclitaxel|
226773|NCT02172846|Drug|Carboplatin|
226774|NCT02172859|Dietary Supplement|lumiVida™|
226775|NCT02172859|Dietary Supplement|Placebo|
227078|NCT02165722|Behavioral|4 Pillars Toolkit|Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit [chronic and acute] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).
Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).
Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).
Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback).
227079|NCT02165735|Other|Patient Empowerment and Autonomy Training|Participants will be given supports to address patient autonomy, competence and development of provider-patient relationships.
227080|NCT00135694|Procedure|liver transplant|Occurs at study entry
227081|NCT02165735|Behavioral|Patient Empowerment and Autonomy Training|
227082|NCT02165761|Device|GORE® Hybrid Vascular Graft|
227083|NCT02165761|Device|Non-heparin bonded synthetic graft|
227084|NCT02168062|Drug|Luteinizing hormone releasing hormone agonists|
227085|NCT02168075|Drug|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
227086|NCT02168075|Drug|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
227087|NCT02168075|Drug|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
227088|NCT02168075|Drug|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
226477|NCT02180984|Device|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
226478|NCT02180997|Drug|Tamsulosin|Tamsulosin 0.4mg, once daily
226479|NCT02180997|Drug|Solifenacin|Solifenacin 10 mg, once daily
226480|NCT02180997|Drug|Tamsulosin and solifenacin|Tamsulosin 0.4mg, once daily Solifenacin 10 mg, once daily
226481|NCT02183428|Drug|BI 1356|
226482|NCT02183428|Drug|Glyburide|
226776|NCT02172872|Drug|standard combination chemotherapy|Cycle 1
daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days
cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
Cycle 2
daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days
cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
Cycle 3 (mini-ICE)
idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
etoposide (100 mg/m²) infusion (1 hr) for 3 days
Cycle 4 (mini-ICE) (optional)
idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
etoposide (100 mg/m²) infusion (1 hr) for 3 days
226777|NCT02172872|Drug|decitabine|Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 2
if bone marrow (BM) blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 3
if BM blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days
Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days
Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available.
226778|NCT02172885|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
226779|NCT02175732|Behavioral|'OnTrack'|Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.
During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine.
226780|NCT02175745|Drug|fluorine F 18 fluorodopa|Given IV
226781|NCT02175745|Procedure|positron emission tomography|Undergo 18F FDOPA PET/CT or PET/MRI
226782|NCT02175745|Procedure|computed tomography|Undergo 18F FDOPA PET/CT or PET/MRI
226783|NCT02175745|Procedure|magnetic resonance imaging|Undergo 18F FDOPA PET/CT or PET/MRI
226784|NCT02175758|Drug|SOF (oral tablets)|SOF tablets administered orally once daily
226785|NCT02175758|Drug|RBV|RBV administered as capsules or oral solution
226192|NCT02190630|Device|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
226193|NCT02190643|Behavioral|Cessation counseling with adherence focus|
226194|NCT00138593|Drug|vildagliptin|
226195|NCT02190643|Behavioral|Cessation counseling without adherence focus|
226196|NCT02190669|Other|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
226197|NCT02190695|Drug|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
226198|NCT02190695|Drug|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
226199|NCT02190695|Drug|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
226200|NCT02190708|Drug|PQ912|from day2 up to day6 twice daily oral dose of PQ912
226201|NCT02190708|Drug|Midazolam|single oral dose on day1 and day 6
226202|NCT02190708|Drug|Omeprazole|single oral dose on day1 and day6
226203|NCT02190721|Drug|tbo-filgrastim|5 μg/kg
226204|NCT02190734|Other|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
226205|NCT00002295|Drug|Inosine pranobex|
226206|NCT00138606|Drug|vildagliptin|
226207|NCT02190734|Other|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
226208|NCT02190734|Other|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
226209|NCT02190747|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
226210|NCT02190747|Drug|Placebo|
226483|NCT02183428|Drug|BI 1356 + Glyburide|
226484|NCT02183441|Drug|BI 1356|
226485|NCT02183441|Drug|Ritonavir|
225556|NCT02167659|Device|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥10 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and <10% above pre-surgical baseline.
225557|NCT02167685|Drug|CMX001|
225877|NCT02157337|Drug|Atorvastatin|80 mg (PO) once daily for 6 days
225878|NCT02157337|Drug|placebo|80 mg (PO) once daily for 6 days
225879|NCT02159963|Other|Control|8 weeks of control period. Participants are doing daily living.
225880|NCT02159976|Drug|Pantoprazole|
225881|NCT02159976|Drug|Amoxicillin|
225882|NCT02159976|Drug|Clarithromycin|
225883|NCT00135135|Drug|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
225884|NCT02159976|Drug|Metronidazole|
225885|NCT02159976|Drug|Tetracycline|
225886|NCT02159976|Drug|Bismuth|
225887|NCT02159989|Other|Laboratory Biomarker Analysis|Correlative studies
225888|NCT02159989|Drug|Sapanisertib|Given PO
225889|NCT02159989|Biological|Ziv-Aflibercept|Given IV
225890|NCT02160002|Procedure|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
225891|NCT02160002|Procedure|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
225892|NCT02160015|Drug|Ibrutinib|Given PO
225893|NCT02160015|Other|Laboratory Biomarker Analysis|Correlative studies
225894|NCT00135135|Procedure|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
225895|NCT02160015|Drug|Lenalidomide|Given PO
225896|NCT02160015|Biological|Rituximab|Given IV
225225|NCT02175121|Drug|PF-06291874|Tablet, 75 mg, once daily for 28 days
225226|NCT02175121|Drug|PF-06291874|Tablet, 150 mg, once daily for 28 days
225227|NCT00136760|Drug|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
225228|NCT02175134|Other|Blood and Ascites ELISPOT|
225229|NCT02175160|Other|Braking and functionality|
225230|NCT02175173|Drug|Rufinamide|Administration of Inoveron 100mg or 200mg Tablets
225231|NCT02175186|Drug|ALBIS|
225232|NCT02175186|Drug|Placebo|
225233|NCT02175199|Device|Lotrafilcon B contact lenses with color printing|
225234|NCT02175199|Device|Phemfilcon A contact lenses with color printing|
225235|NCT02175212|Drug|Goserelina 4 months and Bicalutamida|Goserelina 10,8 mg by subcutaneous injection for 4 months Bicalutamida 50 mg tablet every day for 2 months
225236|NCT02175212|Drug|Goserelina|Goserelina 10,8 mg by subcutaneous injection for 4 months Goserelina 10,8 mg by subcutaneous injection every 3 months for 2 years at the end of the radiotherapy.
225237|NCT02175225|Drug|Deferoxamine Mesylate|
225238|NCT00136773|Drug|amlodipine/benazepril|
225239|NCT02175225|Drug|Placebo (for Deferoxamine Mesylate)|
231541|NCT02416700|Procedure|immediate implant surgery|Surgery of dental implants in one side of the mouth.
231542|NCT02416700|Device|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
231543|NCT02418715|Other|Water Aerobics Training|
231544|NCT02418728|Other|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
231545|NCT02418741|Other|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
231546|NCT02418754|Drug|REGN2176-3|
231547|NCT02418754|Drug|Intravitreal Aflibercept Injection (IAI)|
231548|NCT02418767|Drug|MOD-4023|
230910|NCT02426931|Device|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
230911|NCT02426944|Drug|apixaban|Medical arm, patients will be treated by apixaban.
230912|NCT02426944|Device|Left atrial appendage closure - Watchman device preferentially|The patients will be treated by interventional closure of the left atrial appendage.
230913|NCT02426957|Behavioral|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
230914|NCT02426983|Device|Direct Current Stimulation|Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).
Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks.
230915|NCT02426983|Drug|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
230916|NCT02426996|Procedure|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
230917|NCT02427009|Other|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
230918|NCT00167622|Procedure|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
230919|NCT02427009|Procedure|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
230920|NCT02393625|Drug|Nivolumab|
230921|NCT02393638|Other|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
230922|NCT02393638|Other|Lecture|Lecture
230923|NCT02393651|Device|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
230340|NCT02403141|Other|Questionnaire|
230341|NCT02403154|Device|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
230342|NCT02403154|Device|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
230343|NCT02403180|Device|Nelfilcon A Contact Lenses|
230628|NCT02396173|Other|Risk Score for non-return to work|The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation ("1. With a probability score over 50% (not to return to work), patient's allocation to the "Evaluation Pathway" should be considered" "2. With a probability score over 70% (not to return to work), the "Evaluation Pathway" is probably the most suitable choice").
230629|NCT02396186|Device|PTCA Balloon Angioplasty|
230630|NCT02398422|Behavioral|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
The non-filtered music intervention will consist of the same music as the filtered-music intervention.
230631|NCT02398435|Biological|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients will receive the treatment three times a week subcutaneously.
230632|NCT00163709|Procedure|BNP test|
230633|NCT02398448|Drug|Zyloprim® 300 mg|
230634|NCT02398448|Drug|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
230635|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
230636|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 3|
230637|NCT02398461|Drug|rHIgM22|Administered via IV infusion
230638|NCT02398461|Drug|Placebo|
230639|NCT02398474|Drug|TFP block ropivacaine|
230640|NCT02398474|Drug|ropivacaine infiltration of the iliac crest bone|
230049|NCT02407223|Drug|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
230050|NCT02407223|Drug|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
230051|NCT02407223|Drug|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
230052|NCT02407236|Drug|Placebo IV|Placebo will be administered as intravenous infusion.
230053|NCT02409316|Drug|[18F]FES|[18F]FES PET/CT scan
230054|NCT02409329|Behavioral|Text Messaging|The intervention consists of daily, tailored text messaging addressing and assessing medication adherence, as well as a weekly text message that provides adherence feedback. Participants will receive a text message at each time point when A1c results are ready with instructions on how to access their results. Participants also have access to the REACH Helpline for research-, technical-, and/or medication-related questions.
230344|NCT02403180|Device|Omafilcon A Contact Lenses|
230345|NCT02403193|Drug|PBF-509|PBF-509: 80 mg, PO, twice daily (BID)
1 capsule of PBF-509 formulated in 80 mg gelatin capsules will be administered orally, twice daily, during 28-day cycle.
Subjects will enter follow-up either after confirmation of progressive disease (PD) or completion of 12 months of treatment.
230346|NCT00164398|Behavioral|HIP: HIV Intervention for Providers|
230347|NCT02403193|Drug|PBF-509|PBF-509: 160 mg, PO, twice daily (BID)
2 capsules of PBF-509 formulated in 80 mg gelatin capsules will be administered orally, twice daily, during 28-day cycle.
Subjects will enter follow-up either after confirmation of progressive disease (PD) or completion of 12 months of treatment.
230348|NCT02403193|Drug|PBF-509|PBF-509: 320 mg, PO, twice daily (BID)
4 capsules of PBF-509 formulated in 80 mg gelatin capsules will be administered orally, twice daily, during 28-day cycle.
Subjects will enter follow-up either after confirmation of progressive disease (PD) or completion of 12 months of treatment.
230349|NCT02403193|Drug|PBF-509|PBF-509: 640 mg, PO, twice daily (BID)
8 capsules of PBF-509 formulated in 80 mg gelatin capsules will be administered orally, twice daily, during 28-day cycle.
Subjects will enter follow-up either after confirmation of progressive disease (PD) or completion of 12 months of treatment.
224992|NCT02190058|Drug|placebo|placebo matching DS-1971a
224993|NCT00138541|Drug|vildagliptin|
224994|NCT02190084|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
224995|NCT02190097|Other|Paleolithic diet|see procedures section for more details
224996|NCT02190097|Other|American Diabetes Association diet|see procedures section
224997|NCT02190123|Drug|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
224998|NCT02190136|Other|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
224999|NCT02192892|Dietary Supplement|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
225000|NCT00138866|Drug|Risedronate|
225001|NCT02192892|Dietary Supplement|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
225002|NCT02192892|Dietary Supplement|Commercial porridge flour|Porridge from commercial porridge flour
225003|NCT02192892|Dietary Supplement|Commercial porridge bar|Porridge from commercial porridge bar
225004|NCT02192892|Dietary Supplement|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
225005|NCT02192905|Behavioral|Diabetes Prevention Program Lifestyle Intervention|
225006|NCT02192918|Behavioral|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
225007|NCT02192918|Behavioral|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
225008|NCT02192918|Behavioral|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
225323|NCT02185495|Behavioral|Observer nodule detection|Radiologists will detect the nodules.
224384|NCT00135564|Biological|Hib-MenC-TT|
224385|NCT02164383|Behavioral|Cessation Counseling|5 brief counseling sessions
224386|NCT02164383|Device|Mobile Games|
224387|NCT02164396|Device|Spectacle Lens|
224388|NCT02164396|Device|Habitual Soft Contact Lens|
224389|NCT02164396|Device|Test Lens|ACUVUE OASYS or ACUVUE TruEye
224692|NCT02156596|Drug|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
224693|NCT02156596|Drug|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
224694|NCT02156596|Drug|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
224695|NCT02156596|Drug|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
224696|NCT02156609|Device|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
224697|NCT02156635|Device|Transcranial direct current stimulation|
224698|NCT02156635|Behavioral|Constraint-Induced Movement Therapy|
224699|NCT02156635|Other|Placebo|
224700|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
224701|NCT02156661|Drug|Oxytocin|
224702|NCT00134706|Drug|Carboplatin|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
224703|NCT02156674|Drug|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
224704|NCT02156687|Device|Y mesh|Y mesh
224705|NCT02156687|Device|Dual flat mesh|Dual flat mesh
224706|NCT00135057|Drug|insulin glargine|
224707|NCT02159456|Other|Continuous enteral feeding via infusion pump|
224048|NCT02169349|Other|laboratory biomarker analysis|
224049|NCT02171520|Drug|Dabigatran etexilate generation II|
224050|NCT02171533|Drug|dabigatran|
224051|NCT02171533|Drug|Verapamil|
224052|NCT02171533|Drug|Verapamil ER|
224053|NCT02171546|Drug|Dabigatran etexilate capsules|
224054|NCT02171546|Drug|Quinidine sulfate tablets|
224055|NCT02171546|Drug|Fexofenadine tablets|
224056|NCT00136435|Drug|vincristine|Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.
CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle
224057|NCT02171559|Drug|Enoxaparin prefilled syringes|
224058|NCT02171559|Drug|Dabigatran etexilate capsules|
224059|NCT02171572|Drug|Dabigatran etexilate low|
224060|NCT02171572|Drug|Dabigatran etexilate high|
224061|NCT02171585|Drug|Dabigatran etexilate|
224062|NCT02171585|Drug|Clarithromycin|
224063|NCT02171598|Drug|Clopidogrel|
224390|NCT02164409|Procedure|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
224391|NCT02164422|Drug|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
224392|NCT02164422|Drug|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
224393|NCT02164422|Drug|Placebo|
224394|NCT02164435|Procedure|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
224395|NCT00135577|Drug|alvimopan|
228924|NCT02400138|Other|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle five times per week over eight weeks, divided into three five-minute sessions of inspiratory training and the same doses of expiratory training, totaling 30 minutes of training. The training program will follow previously employed protocols for stroke survivors and will be carried-out with the threshold regulated at 40% of the subjects' maximal inspiratory and expiratory pressure values.
228925|NCT02400138|Other|Control|The control/sham group will underwent exactly the same protocol and bi-weekly monitoring at home, but the participants will receive the threshold devices with the minimum resistance of the spring.
228926|NCT02400151|Drug|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
228927|NCT00163995|Drug|urotensin II|
228928|NCT02400151|Drug|Placebo|Patients randomized to this group will receive placebo for 90 days.
228929|NCT02400151|Other|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
228930|NCT02400151|Other|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
228931|NCT02400164|Device|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
228932|NCT02400177|Behavioral|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
228933|NCT02400190|Other|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
228934|NCT02400203|Other|Control|
228935|NCT02400203|Other|Hemp foods|
228936|NCT02400229|Procedure|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
224064|NCT02171598|Drug|Dabigatran high dose|
224065|NCT02171598|Drug|Dabigatran low dose|
224066|NCT02171611|Drug|Dabigatran etexilate pellets|
224067|NCT00136435|Drug|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
228643|NCT00164593|Behavioral|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
228644|NCT02404610|Procedure|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
228645|NCT02404610|Procedure|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
228646|NCT02404610|Drug|propofol|
228647|NCT02404623|Dietary Supplement|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
228648|NCT02406508|Drug|Sorafenib|
228649|NCT02406521|Drug|Pazopanib|
228650|NCT02406521|Drug|Sorafenib|
228651|NCT02406521|Drug|Radium-223|
228652|NCT02406534|Behavioral|HRQoL surveys|
228653|NCT02406547|Device|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
228654|NCT02406547|Device|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
228655|NCT00164827|Device|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
228656|NCT02406560|Drug|tafamidis|fasted
228657|NCT02406560|Drug|tafamidis|high fat meal
228658|NCT02406560|Drug|tafamidis|
228659|NCT02406573|Device|Crest® Sensi-Stop™ Strips|
228660|NCT02406586|Drug|Salsalate|Salsalate 750 mg
228661|NCT02406586|Drug|Carvedilol|Carvedilol 3.125 mg
228662|NCT02406586|Drug|Placebo|One tablet
228663|NCT02406586|Drug|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
228027|NCT02186509|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
228028|NCT02186509|Drug|Alisertib|Given PO
228029|NCT02186509|Procedure|Quality-of-life assessment|Ancillary studies
228030|NCT00138047|Drug|zinc supplementation|
228031|NCT02186535|Dietary Supplement|Vitamin D and Calcium|
228032|NCT02186548|Procedure|Closed surgical technique|Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone
The bone covering the canine is being removed
Attachment with a chain is bonded to the exposed tooth
The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery
The canine is orthodontically moved beneath the palatal mucosa
228033|NCT02186548|Procedure|Open surgical technique|Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth
Pack/filling material is applied on the tooth
Spontaneous eruption of the palatally impacted canine is allowed expected
The canine is orthodontically moved above the mucosa
228034|NCT02186561|Device|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
228035|NCT02186574|Drug|Tenofovir disoproxil|
228036|NCT02186587|Device|ConforMIS custom total knee|
228352|NCT02410915|Other|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
228353|NCT02410928|Device|direct laringoscope|the vocal cords will be visualized after extubation with direct laringoscopy
228354|NCT02410928|Device|fiberoptic nasal laringoscope|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
228355|NCT02410928|Device|video laringoscope|the vocal cords will be visualized after extubation with fiberoptic video laringoscopy
228356|NCT00165217|Drug|Thalidomide|
228357|NCT02410928|Device|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
228358|NCT02410941|Behavioral|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
228043|NCT02186613|Behavioral|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
228044|NCT02186626|Biological|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
228045|NCT02186626|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
228046|NCT02186652|Drug|Pantoprazole|
228047|NCT02186665|Drug|calcitriol ointment|
228048|NCT02188940|Other|Stretching and Breathing exercise|Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.
*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups.
228049|NCT00138281|Biological|Fluzone|
228050|NCT02188953|Drug|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
228051|NCT02188953|Drug|Calcium carbonate placebo|
228052|NCT02188966|Device|Geographic Information System|GIS data is delivered by "SimaTech Enterprise System" communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform
228053|NCT02189005|Dietary Supplement|Study dietary supplement (PreCrea 600 mg capsules)|Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
228054|NCT02189005|Dietary Supplement|Placebo|
228055|NCT02189018|Other|Active Exercise|Active exercise on a treadmill
228056|NCT02189018|Other|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
228367|NCT02413021|Drug|Deferasirox|20 mg/kg ,oral, per day
228368|NCT02413034|Drug|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
228369|NCT02413047|Drug|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
228370|NCT02413047|Drug|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
227403|NCT02160587|Other|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
227404|NCT02160600|Other|Standard multiphase CT|
227405|NCT02160600|Other|split bolus Dual energy CT|
227729|NCT02194088|Drug|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
227730|NCT02194088|Drug|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
227731|NCT02194101|Procedure|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
227732|NCT02194114|Other|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
227733|NCT02194127|Drug|Anthocyan capsules|
227734|NCT02194127|Drug|Placebo|
227735|NCT02194140|Other|oral iodinated contrast material|diluted in water
227736|NCT02194153|Drug|Metalyse weight-adjusted|
227737|NCT00139061|Drug|Fenofibrate|
227738|NCT02194166|Drug|trastuzumab IV|Loading dose 8 mg/kg at Day 1 Cycle 1, followed by 6 mg/kg trastuzumab administered intraveneously (IV) every 3 weeks
227739|NCT02194166|Drug|trastuzumab SC vial|Fixed dose 600 mg SC trastuzumab assisted administration in hospital setting
227740|NCT02196662|Drug|IBD98-M:|single adiministration
227741|NCT02196662|Drug|IBD98-M without HA|single adiministration
227742|NCT02196662|Drug|Delzicol|single adiministration
227743|NCT02196675|Device|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
227744|NCT02196688|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
227089|NCT02168101|Drug|MLN9708|Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy.
Cohort 1: 2.3mg single weekly dose
Cohort 2: 3mg single weekly dose
Cohort 3: 4mg single weekly dose
Expansion Phase: An additional 20 patients will receive MLN9708 at the MTD
227090|NCT02168114|Other|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
227091|NCT02168114|Procedure|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
227092|NCT02168127|Drug|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
227093|NCT02168127|Drug|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
227406|NCT02160613|Procedure|Open flap debridement|an access flap
227407|NCT02160626|Drug|A-101 Vehicle|Placebo control
227408|NCT02160626|Drug|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
227409|NCT02160626|Drug|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
227410|NCT00135226|Drug|aspirin|
227411|NCT02160639|Other|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
227412|NCT02160652|Procedure|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
227413|NCT02160665|Drug|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
227414|NCT02160665|Drug|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
227415|NCT02160665|Drug|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
227416|NCT02160678|Drug|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
227417|NCT02160678|Drug|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
227418|NCT02160678|Drug|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
227419|NCT02163057|Biological|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device|Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 (VGX-3100 and INO-9012) via IM+EP with CELLECTRA®-5P. All subjects will receive a total of 4 doses of immunotherapy
226786|NCT02175758|Drug|SOF (oral granules)|SOF oral granule capsules administered orally once daily
226787|NCT00136851|Drug|amlodipine besylate/benazepril hydrochloride|
226788|NCT02175771|Drug|Fluticasone propionate Multidose Dry Powder Inhaler (Fp MDPI)|100 mcg, 200 mcg
226789|NCT02175771|Drug|Fluticasone propionate /salmeterol MDPI (FS MDPI)|100/12.5 mcg, 200/12.5 mcg
226790|NCT02175771|Drug|Fluticasone propionate HFA Inhalation Aerosol|110 mcg, 220 mcg
226791|NCT02175771|Drug|Fluticasone propionate/salmeterol dry powder formulation|250/50 mcg, 500/50 mcg
226792|NCT02175784|Drug|ipragliflozin|oral
226793|NCT02175784|Drug|placebo|oral
227094|NCT00135967|Drug|prednisone 0,5 mg/kg orally on alternate days|
227095|NCT02168140|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
227096|NCT02168140|Drug|bendamustine hydrochloride|Given IV
227097|NCT02168153|Other|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
227098|NCT02168153|Other|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
227099|NCT02168166|Behavioral|Executive Function Training|
227100|NCT02168166|Behavioral|Placebo|Placebo version of executive function training
227101|NCT02168179|Procedure|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
227102|NCT02168179|Other|questionnaire administration|Ancillary studies
227103|NCT02170350|Other|Quality-of-life assessment|Ancillary studies
227104|NCT00136292|Drug|daptomycin|
227105|NCT02170350|Other|Questionnaire administration|Ancillary studies
226486|NCT02183454|Device|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
226487|NCT00137787|Drug|cefepime|
226488|NCT02183467|Drug|BI 1356, low dose|
226489|NCT02183467|Drug|BI 1356, high dose|
226490|NCT02183467|Drug|Placebo|
226491|NCT02183467|Drug|Moxifloxacin|
226492|NCT02183480|Drug|Linagliptin, low dose|
226493|NCT02183480|Drug|Linagliptin, medium dose|
226494|NCT02183480|Drug|Linagliptin, high dose|
226495|NCT02183493|Drug|BI 1356|
226496|NCT02183506|Drug|Metformin|
226497|NCT02183506|Drug|BI 1356 BS|
226498|NCT00137800|Drug|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
226499|NCT02183519|Drug|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of reflex cough sensitivity.
226500|NCT02183519|Other|Healthy Older Adults|For this study all participants will receive reflex and voluntary cough testing. This will include coughing on command and reflex cough sensitivity testing. Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand reflex and voluntary cough more fully.
226501|NCT02183519|Other|Parkinson's Disease|For this study all participants will receive reflex and voluntary cough testing. This will include coughing on command and reflex cough sensitivity testing. Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand reflex and voluntary cough more fully.
226502|NCT02183532|Drug|BI 1356 BS|single dose
226503|NCT02183532|Drug|BI 1356 BS|multiple doses
226504|NCT02183545|Drug|BI 1060469|single rising doses given as tablet
226505|NCT02183545|Drug|Placebo|given as tablet (matching placebo of BI 1060469)
226506|NCT02183558|Other|OGTT by randomization|
225897|NCT02160028|Other|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
225898|NCT02160028|Other|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
225899|NCT02160041|Drug|BGJ398|BGJ398 will be dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
225900|NCT02160054|Drug|Graceptor®|oral
225901|NCT02160067|Drug|Second generation BTDS patch|
226211|NCT02190760|Drug|Dexamethasone|
226212|NCT02190760|Drug|Bupivacaine|
226213|NCT02190786|Drug|KUX-1151|
226214|NCT02190799|Biological|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
226215|NCT02190812|Device|Forearm supporter|The forearm supporter be use in tennis elbow.
226216|NCT02190812|Device|Grip ball|
226217|NCT00138619|Drug|vildagliptin|
226218|NCT02190825|Device|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
226219|NCT02193399|Other|Physiotherapy in patients with stem cell transplantation|The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.
The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient.
226220|NCT02193412|Procedure|noxious stimulus|standardized noxious stimulus with tetanic stimulation
226221|NCT02193412|Procedure|change in operating table slope: head-down tilt position|-30°
226222|NCT02193412|Procedure|change in operating table slope: head-up tilt position|+30°
226223|NCT00138957|Procedure|Laparoscopic parastomal hernia repair with mesh|
226224|NCT02193425|Drug|F-18FDG|Participants will be tested with FDG-PET once to map glucose metabolism
226225|NCT02193425|Device|MRI|To assess the short term test-retest reliability of the FC measures
231549|NCT02418767|Drug|Placebo|
231550|NCT00166257|Drug|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
231551|NCT02418780|Other|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
231552|NCT02418793|Drug|MOD-5014|Long Acting Factor VIIa
231553|NCT02418806|Behavioral|Psychotherapy groups|
231554|NCT02418806|Behavioral|Self-help groups|
231555|NCT02418819|Drug|PF-06412562 3mg BID|PF-06412562
231556|NCT02418819|Drug|PF-06412562 9mg BID|PF-06412562
231557|NCT02418819|Drug|PF-06412562 45mg BID|PF-06412562
231558|NCT02418819|Other|Placebo|Placebo
231559|NCT02418832|Procedure|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
231560|NCT02418845|Drug|SYM-1219|
231561|NCT00002449|Drug|Aldesleukin|
231562|NCT00166270|Device|ExAblate 2000|
231563|NCT02418845|Drug|Placebo|
231564|NCT02418858|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
231565|NCT02418871|Device|FluidVisionTM accommodating intraocular lens|
231566|NCT02418884|Drug|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
231863|NCT02412319|Drug|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
231864|NCT02412319|Other|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
231865|NCT02414464|Other|35% hydrogen peroxide|Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.
Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session.
230924|NCT00163020|Drug|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
231222|NCT02422641|Drug|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
231223|NCT02422654|Drug|eliglustat|Pharmaceutical form:liquid formulation
Route of administration: oral without ingestion
231224|NCT00166946|Procedure|foreskin from healthy adults for organotypic culture|
231225|NCT02422667|Other|Patient Registry|Orthopedic Data Registry
231226|NCT02422680|Procedure|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
231227|NCT02422693|Other|Aquatic Exercises|Exercises performed in the water.
231228|NCT02422693|Other|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
231229|NCT02422706|Drug|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
231230|NCT02422706|Drug|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
231231|NCT02422706|Drug|Omeprazole|Omeprazole 20 twice daily
231232|NCT02422706|Drug|Clarithromycin|KLacid twice daily
231233|NCT02422706|Drug|Levofloxacin|Tavanic. Tavacin
231234|NCT02422706|Drug|Doxicycline|Vibramycin 100 mg twice daily
231235|NCT00167011|Procedure|CT|
231236|NCT02422719|Drug|Radotinib|Radotinib 400mg bid
231237|NCT02422732|Other|Neuropsychological assessments|IQ (WISC-IV)
Reading tests (reading accuracy, reading speed, reading comprehension and strategy):
Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)
231238|NCT02422732|Radiation|morphological and functional MRI (fMRI)|The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a "Flair" to allow UBO location.
231239|NCT02422732|Genetic|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
230641|NCT02398487|Device|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
230642|NCT02398487|Device|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
230643|NCT00163722|Other|Culture and histology|
230644|NCT02398500|Biological|LMG324|IVT injection
230645|NCT02398500|Biological|Ranibizumab 0.5 mg|IVT injection
230646|NCT02398500|Biological|Sham|Fake injection used for masking purposes
230647|NCT02398513|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
230925|NCT02393664|Drug|propofol, bupivacaine|Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
230926|NCT02393664|Drug|sevoflurane, rocuronium|Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
230927|NCT02393677|Drug|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
230928|NCT02393677|Drug|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
230929|NCT02393690|Radiation|Iodine I-131|Given PO
230930|NCT02393690|Other|Laboratory Biomarker Analysis|Correlative studies
230931|NCT02393690|Other|Placebo|Given PO
230932|NCT02393690|Drug|Selumetinib|Given PO
230933|NCT02393716|Device|Endurant Evo AAA Stent Graft System|
230934|NCT02393716|Procedure|Endovascular aneurysm repair (EVAR)|
230935|NCT00163033|Drug|estetrol|
230936|NCT02393729|Behavioral|Neuropsychological assessment|The neuropsychological assessment will include an assessment of:
Intellectual ability
Laterality
Reading Skills
Motor skills
Oral Language
Attention
Child's behaviour
230937|NCT02393729|Other|MRI Study|It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes
Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.
Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task).
230350|NCT02403206|Device|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
230351|NCT02403206|Procedure|Continuous Curvilinear Capsulorhexis|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
230352|NCT02403219|Drug|Botulinum toxin type A injection|Injection of botulinum toxin type A
230353|NCT02405078|Procedure|FDG PET/CT Imaging|With day 1 designated as start of chemotherapy, FDG PET/CT scans performed sequentially between day -21 - day 0 (baseline PET), day 4 (interim PET1, after completion of 1st high dose chemotherapy), day 21 (interim PET2, after completing 1st cycle of chemotherapy), and day 42 (end of therapy PET).
230354|NCT02405078|Procedure|Blood Draws|Blood draws on day -5 - 0, day 4, day 8, day 21 and day 42.
230355|NCT02405091|Drug|NBI-98854|
230356|NCT00164671|Behavioral|POWER|
230357|NCT02405104|Drug|chlorzoxazone|ATC-code: M03BB03
230358|NCT02405104|Drug|Placebo|Placebo
230359|NCT02405104|Procedure|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
230360|NCT02405104|Procedure|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
230361|NCT02405117|Behavioral|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
230362|NCT02405130|Other|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
230648|NCT02398526|Drug|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
230649|NCT02398539|Drug|Silver Nitrate|Silver Nitrate Sticks
230650|NCT02398539|Drug|Triamcinolone|0.5% cream
230651|NCT02398552|Drug|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
230652|NCT02398565|Other|No intervention|
230653|NCT02398578|Device|Amphora OAB Device|Cystoscopic procedure to treat OAB
230654|NCT00163722|Other|Aspergillus galactomannan and PCR|
225324|NCT00137995|Drug|Carboplatine|max 800mg D2
225325|NCT02185495|Device|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
225326|NCT02185521|Other|patient assessmen|Patient clinician status assessment based on HII trend. The HII indicator combines existing data such as physiologic parameters (HR, BP), laboratory measurements (Albumin, HCT, Bicarbonate, WBC, BUN), and ADT information (age). HII will be displayed on charting workstation (WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
225327|NCT02185534|Drug|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
225328|NCT02185547|Drug|Zoloft|Sertraline treatment 25 mg
225329|NCT02185547|Behavioral|ICBT|Internet behavioral cognitive therapy only
225330|NCT02185560|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
225331|NCT02185573|Procedure|Bulk fill|This is one of the composite restoration application techniques
225332|NCT02185573|Procedure|SonicFill|This is the recent intervention under evaluation
225333|NCT02185586|Procedure|laparoscopic cholecystectomy|
225334|NCT02185599|Device|DySIS|Colposcopy performed with the DySIS digital colposcope
225335|NCT00137995|Drug|Ifosfamide + Mesna|5 g/m² from D2 to D13
225336|NCT02187939|Other|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
225337|NCT02187952|Behavioral|Behavioral feeding intervention|Behavioral feeding intervention will include escape extinction.
225338|NCT02187978|Other|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
225339|NCT02187978|Other|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
225340|NCT02187991|Drug|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
225341|NCT00138203|Other|laboratory biomarker analysis|Correlative studies
224708|NCT02159456|Other|Intermittent enteral feeding via gravity-based infusion|
224709|NCT02159469|Drug|Testosterone enanthate auto-injector|Dose Adjustment 100 mg / 75 mg / 50 mg
224710|NCT02159482|Drug|Interferon Alfa-2a|
224711|NCT02159495|Drug|cyclophosphamide|Given IV
224712|NCT02159495|Biological|anti CD123-CAR/CD28-costimulatory, lentiviral vector-transduced autologous T lymphocytes|Given IV
224713|NCT02159495|Other|laboratory biomarker analysis|Correlative studies
224714|NCT02159495|Drug|Etoposide|Given IV
224715|NCT02159495|Drug|Fludarabine Phosphate|Given IV
225009|NCT02192931|Drug|Creatine monohydrate|
225010|NCT02192944|Drug|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
225011|NCT00138892|Procedure|Waiting time (access time to Total joint replacement)|See Detailed Description.
225012|NCT02192944|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
225013|NCT02192957|Device|Lifepak 20E Defibrillator, Licence No: 61944|Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.
Ottawa AF Cardioversion
225014|NCT02192970|Drug|Bevacizumab|
225015|NCT02192996|Dietary Supplement|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
225016|NCT02193009|Behavioral|SipSmarter|6-month behavioral trial
225017|NCT02193009|Behavioral|MoveMore|6 month behavioral trial
225018|NCT02193022|Drug|Miltefosine|
225019|NCT02193035|Other|Microparticle levels|Microparticle levels will be evaluated before and after the TAVR procedure.
225020|NCT02193048|Other|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
225021|NCT02193061|Biological|Rotarix|
224396|NCT02164448|Drug|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
224397|NCT02164448|Drug|the control group|saline infusion from induction of anesthesia to end of surgery
224398|NCT02164461|Biological|ADXS11-001|
224399|NCT02164474|Behavioral|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at ~85-90% peak oxygen uptake [VO2peak] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at ~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
224400|NCT02164500|Drug|Ruxolitinib|
224401|NCT02164513|Drug|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
224402|NCT02164513|Drug|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
224403|NCT02164513|Drug|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
224404|NCT02164526|Other|Routine therapy|Routine therapy
224405|NCT02167048|Drug|Psychostimulants|Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).
To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions.
224406|NCT02167061|Drug|DA-1229_01|complex single administration
224407|NCT02167061|Drug|E+M|co-administration of 2 drugs
224408|NCT02167061|Drug|DA-1229_01 fast|
224716|NCT02159495|Biological|Therapeutic Allogeneic Lymphocytes|Given allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes IV
224717|NCT00135070|Drug|Detemir|
224718|NCT02159508|Behavioral|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
224719|NCT02159521|Device|EkoSonic Endovascular System|ultrasound catheter directed thrombolysis
224720|NCT02159534|Other|NOBEPPI|NOBEPPI stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
224068|NCT02171611|Drug|Dabigatran etexilate powder|
224069|NCT02171611|Drug|Dabigatran etexilate capsule|
224070|NCT02171624|Drug|dabigatran etexilate|
224071|NCT02171624|Drug|quinidine|
224072|NCT02171637|Drug|BIBW 2992|escalating doses
224073|NCT02171650|Drug|BIBW 2992|
224074|NCT02171663|Drug|BIBW 2992|
224075|NCT02171676|Drug|Docetaxel|
224076|NCT02171676|Drug|BIBW 2992|
224077|NCT02171689|Drug|[14C]- BIBW 2992 MA2|
224078|NCT00136435|Drug|asparaginase|Induction: Given into the muscle on day 5
224079|NCT02171702|Drug|BIBW 2992|
224080|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
224081|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
224082|NCT00136734|Drug|Methylphenidate|
224083|NCT02174575|Drug|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
224084|NCT02174588|Drug|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
224085|NCT02174588|Drug|propofol|propofol are used for sedation drug
224086|NCT02174614|Behavioral|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
224087|NCT02174614|Behavioral|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
224409|NCT02167061|Drug|DA-1229_01 fed|
224410|NCT02167074|Device|25G FNA needle|
228664|NCT02406599|Device|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
228937|NCT02400229|Procedure|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
228938|NCT00164008|Drug|zoledronic acid vs pamidronate|
228939|NCT02400242|Drug|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
228940|NCT02400242|Drug|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
228941|NCT02400242|Drug|Dexamethasone|40 mg qd on days 1, 8, 15, 22
228942|NCT02400255|Drug|crenolanib besylate|80 mg PO TID
228943|NCT02400268|Other|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
228944|NCT02400268|Other|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
228945|NCT02400281|Drug|crenolanib besylate|Crenolanib besylate 100 mg PO TID on Days 1-28 of Induction or Consolidation.
228946|NCT02402491|Drug|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
228947|NCT02402491|Drug|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
228948|NCT02402491|Drug|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
228949|NCT02402504|Other|Control|Non pulse extruded snack
228950|NCT00164294|Behavioral|Brief intervention|
228951|NCT02402504|Other|Small particle size pea flour|Pulse extruded snack
228952|NCT02402504|Other|Large particle size pea flour|Pulse extruded snack
228953|NCT02402504|Other|Lentil flour|Pulse extruded snack
228954|NCT02402504|Other|Navy bean flour|Pulse extruded snack
228955|NCT02402504|Other|Pinto bean flour|Pulse extruded snack
228956|NCT02402517|Other|Control|Non pulse extruded snack
228359|NCT02410954|Device|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
228360|NCT02410967|Behavioral|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
228361|NCT02412995|Other|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
228362|NCT02412995|Other|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
228363|NCT00165464|Drug|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
228364|NCT02413008|Drug|estriol|
228365|NCT02413008|Drug|Placebo|
228366|NCT02413021|Drug|Cytarabine|20 mg/m^2 , SC, two times a day for 10 days every 30 days for 1 cycle
228665|NCT02406599|Other|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
228666|NCT00164840|Drug|Esomeprazole|
228667|NCT02406612|Device|X-Seal 6F Vascular Closure Device|
228668|NCT02406625|Behavioral|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
228669|NCT02406638|Other|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
228670|NCT02406651|Drug|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
228371|NCT02413047|Drug|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
228372|NCT02413060|Other|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
228373|NCT02413060|Behavioral|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
228374|NCT00165464|Drug|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
228375|NCT02413073|Procedure|Whole Body Vibration|We wil use vibration in patients with kidney disease
228376|NCT02413086|Procedure|Early-stage amputation|Individuals with DFU were given early-stage amputation.
228377|NCT02413086|Procedure|Amputation|Individuals with DFU were given amputation.
228378|NCT02413086|Other|External herbs chitosan|Wound was given external herbs chitosan after amputation.
228379|NCT02413086|Other|Traditional gauze|Wound was given traditional gauze after amputation.
228380|NCT02413099|Drug|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
228381|NCT00165698|Drug|alfacalcidol|0.25 μg twice a day orally for 12 months
228382|NCT02415387|Biological|typhoid vaccine|Given IM
228383|NCT02415387|Other|Placebo|Given IM
228384|NCT02415400|Drug|Apixaban|
228385|NCT02415400|Drug|vitamin K antagonist|
228386|NCT02415400|Drug|Acetylsalicylic acid|
228387|NCT02415400|Other|Acetylsalicylic acid placebo|
228388|NCT02415413|Drug|carfilzomib|
228389|NCT02415413|Drug|Lenalidomide|
228684|NCT00165087|Procedure|cranial radiation (twice-daily fractionation)|
228685|NCT02408757|Procedure|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
227745|NCT02196688|Drug|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
227746|NCT02196701|Drug|Adalimumab|
227747|NCT02196701|Drug|Methotrexate|
227748|NCT00139321|Device|Force platform and electromyography|
227749|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
228057|NCT02189018|Other|Weight loss and active exercise|Weight loss and active exercise on a treadmill
228058|NCT02189018|Other|Ad lib activity at home|Ad lib activity at home
228059|NCT02189031|Device|Tactor array|
228060|NCT00002293|Drug|Nystatin|
228061|NCT00138294|Biological|influenza vaccine|live attenuated influenza vaccine (FluMist); 0.2 ml intranasal dose inactivated influenza vaccine, 0.5 ml intramuscular injection
228062|NCT02189031|Device|Bypass Tactor|
228063|NCT02189044|Other|Pilates Exercise|The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.
During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.
In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.
In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall.
228064|NCT02189057|Other|AssureRx GeneSight genotyping results|
228065|NCT02189057|Other|Treatment as usual|
228066|NCT02189083|Drug|TSD|TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.
High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks.
228067|NCT02189096|Other|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
228068|NCT02191566|Drug|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
228069|NCT02191566|Drug|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
227420|NCT02163070|Dietary Supplement|whey drink,|consumption of 220 milliliters of whey drink three times a week,
227421|NCT02163070|Dietary Supplement|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
227422|NCT00135434|Drug|Atazanavir/Ritonavir/Lopinavir/ritonavir|
227423|NCT02163070|Dietary Supplement|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
227424|NCT02163083|Procedure|ICG|Improvement of detection of positive lymphnodes
227425|NCT02163122|Procedure|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
227426|NCT02163122|Other|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
227427|NCT02163122|Biological|Cat allergen (FelD1)|
227750|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
227751|NCT02196714|Drug|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
227752|NCT02196714|Drug|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
227753|NCT02196740|Drug|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
227754|NCT02196740|Drug|creosote|Pulp removal,Root canal irrigation and disinfection
227755|NCT02196753|Other|PET CT|All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient`s weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.
In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV> 40% of the background.
227756|NCT02196766|Other|Bioclean First Care EX / comfilcon A|Subjects dispensed either Bioclean First Care EX / comfilcon A combination or Aosept Clearcare / comfilcon A combination and then crossover to the alternate combination.
227757|NCT02196766|Other|Aosept Clearcare / comfilcon A|Subjects dispensed either Bioclean First Care EX / comfilcon A combination or Aosept Clearcare / comfilcon A combination and then crossover to the alternate combination.
227758|NCT02196792|Device|Total Hip Arthroplasty|
227106|NCT02170363|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
227107|NCT02170376|Drug|BIA 9-1067: 25, 50 or 75 mg|Dosage regimen:
From Day 1 to Day 11(once-daily, evening administration):
- 25, 50 or 75 mg OPC or placebo for Groups 2, 3, and 4.
227108|NCT02170376|Drug|Placebo|Placebo for Group 1 from Day 1 to Day 11(once-daily, evening administration) and Placebo three times per day for Groups 2, 3 and 4 on Day 12.
227109|NCT02170376|Drug|100/25 mg levodopa/carbidopa|On Day 12:
- 100/25 mg levodopa/carbidopa three times per day for all groups (1, 2, 3 and 4).
227110|NCT02170376|Drug|200 mg ENT|On Day 12:
- 200 mg ENT or placebo three times per day for Group 1.
227111|NCT02170389|Biological|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
227112|NCT02170389|Procedure|Therapeutic Conventional Surgery|Undergo partial or radical nephrectomy
227113|NCT02170389|Other|Laboratory Biomarker Analysis|Correlative studies
227114|NCT02170402|Biological|Octocog alfa (recombinant human coagulation factor VIII)|Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants
Part 2: On-demand treatment regimen
Part 3: Prophylaxis treatment regimen
227428|NCT02163148|Behavioral|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
227429|NCT02163161|Drug|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
227430|NCT02163161|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
227431|NCT02163161|Drug|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
227432|NCT02163174|Drug|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
227433|NCT00135460|Drug|nucleoside analogue sparing HAART regimen|
227434|NCT02163174|Drug|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
227435|NCT02163187|Device|Implantation of the InterStimTM|
227436|NCT02163187|Behavioral|MSK BFI questionnaires|
227437|NCT02163187|Behavioral|The Low Anterior Resection Score (LARS) questionnaires|
227438|NCT02163187|Behavioral|The EuroQOL5D questionnaires|
226794|NCT02175797|Device|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
226795|NCT02175888|Dietary Supplement|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
226796|NCT02175888|Dietary Supplement|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
226797|NCT02175901|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
226798|NCT00136864|Procedure|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
226799|NCT02175901|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
226800|NCT02175901|Drug|Amoxicillin|antibiotic of each quadruple therapy
226801|NCT02175901|Drug|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
226802|NCT02175901|Drug|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
226803|NCT02175914|Drug|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
226804|NCT02175927|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
226805|NCT02178176|Behavioral|Education, encouragement, card sort|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process.
226806|NCT02178176|Behavioral|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
226807|NCT02178189|Other|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
226808|NCT02178189|Other|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
226809|NCT02178202|Behavioral|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
226810|NCT02178202|Device|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
226811|NCT02178215|Other|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
226226|NCT02193438|Other|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
226227|NCT02193438|Other|Placebo|Tomato juice intake
226228|NCT02193451|Procedure|Urodynamics|Diagnostic test for urinary storage and voiding function
226229|NCT02193451|Procedure|Usual care|
226230|NCT02193477|Device|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
226231|NCT02193477|Device|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
226232|NCT02193490|Drug|DNase|DNase 0.1% eye drops four times a day for 8 weeks
226507|NCT02183558|Other|OGTT by indication|
226508|NCT02183571|Drug|Merck Glucophage® high dose|Part I: Treatment A
226509|NCT00137813|Drug|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
226510|NCT02185859|Drug|Saline|the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
226511|NCT02185872|Other|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
226512|NCT02185872|Other|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
226513|NCT02185885|Procedure|Increased bloodpressure during CPB.|
226514|NCT02185898|Other|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
226515|NCT02185898|Other|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
226516|NCT02185898|Other|Electronic cigarette #1|Electronic cigarette
226517|NCT02185898|Other|Electronic cigarette #2|Electronic cigarette
226518|NCT02185898|Other|Electronic cigarette #3|Electronic cigarette
231866|NCT02414464|Other|20% hydrogen peroxide|Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.
Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session.
231867|NCT02414477|Drug|Deuterated NNN|
231868|NCT00165607|Drug|MENATETRANONE|
231869|NCT02414490|Drug|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
231870|NCT02414503|Drug|8IU intranasal oxytocin|
231871|NCT02414503|Drug|24IU intranasal oxytocin|
231872|NCT02414503|Drug|Placebo|
231873|NCT02414503|Device|OptiNose Breath Powered Bi|
231874|NCT02414516|Drug|OBP-801|OBP-801 will be administered IV
231875|NCT02414529|Drug|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
231876|NCT02414529|Drug|Placebo|
231877|NCT02414542|Device|MINIMA stem|
231878|NCT02414555|Drug|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
231879|NCT00165620|Drug|Iomeprole|
231880|NCT02414555|Drug|fluid bolus|
231881|NCT02414555|Device|oesophagus doppler (CardioQ)|
231882|NCT02414555|Drug|Normal Saline|
231883|NCT02414555|Device|arterial cannulation|
231884|NCT02414555|Device|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
232174|NCT02410252|Device|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature
232175|NCT00165178|Drug|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
231240|NCT02422745|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 600 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
231241|NCT02422745|Dietary Supplement|Multivitamin|Multivitamin
231242|NCT02422745|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
231567|NCT02418923|Other|Procedure: Blood specimen collection|Blood specimen collection
231568|NCT02418936|Device|gene diagnostic kit|
231569|NCT02418949|Drug|Cyproheptadine|Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.
Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug
231570|NCT02420717|Drug|Dasatinib|Starting dose of Dasatinib: 100 mg by mouth once daily.
231571|NCT02420717|Drug|Rituximab|375 mg/m2 days 1 and 11 for cycles 1 and 3, and days 1 and 8 for cycles 2 and 4.
231572|NCT02420717|Drug|G-CSF|5 mcg/kg/day within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher for Hyper-CVAD chemotherapy all courses.
231573|NCT02420717|Drug|Pegfilgrastim|6 mg subcutaneously for one dose approximately 24 hours after completion of the chemotherapy may be substituted for G-CSF at the discretion of the treating physician for Hyper-CVAD chemotherapy all courses.
231574|NCT02420717|Drug|Methotrexate|12 mg (6 mg via Ommaya reservoir) day 2 of each of the first 4 cycles of Hyper-CVAD chemotherapy.
200 mg/m2 by vein over 2 hours followed by 800 mg/m2 by vein over 22 hours day 1 of Hyper-CVAD chemotherapy Courses 2, 4, 6, 8.
20 mg/m2 by mouth weekly for maintenance phase chemotherapy (POMP maintenance). Treatment cycle is 28 days.
231575|NCT02420717|Drug|Cytarabine|100 mg day 7 of each of the first 4 cycles of Hyper-CVAD chemotherapy during cycles 1 and 3 of Hyper-CVAD Courses 1, 3, 5, 7.
3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Hyper-CVAD Courses 2, 4, 6, 8.
231576|NCT02420717|Drug|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for Hyper-CVAD (Courses 1, 3, 5, 7).
231577|NCT00002451|Drug|Ritonavir|
231578|NCT00166582|Behavioral|parent-adolescent communication and problem-solving skills|
231579|NCT02420717|Drug|Mesna|600 mg/m2/d by vein continuous infusion daily for 24 hours days 1 - 3 for Hyper-CVAD (Courses 1, 3, 5, 7).
231580|NCT02420717|Drug|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4, after last dose of Cyclophosphamide given for Hyper-CVAD (Courses 1, 3, 5, 7).
231581|NCT02420717|Drug|Vincristine|2 mg by vein on day 4 and day 11 for Hyper-CVAD (Courses 1, 3, 5, 7).
2 mg by vein approximately every 28 days for maintenance phase chemotherapy (POMP maintenance).
230938|NCT02393742|Drug|Sodium nitrite|
230939|NCT02393742|Drug|Placebo|
230940|NCT02393755|Drug|Capecitabine|Given PO
230941|NCT02393755|Other|Laboratory Biomarker Analysis|Correlative studies
230942|NCT02393755|Drug|Nintedanib|Given PO
230943|NCT02393755|Other|Pharmacological Study|Correlative studies
230944|NCT02393794|Drug|Romidepsin|Histone deacetylase inhibitor
230945|NCT02393794|Drug|Cisplatin|Platinum compound
230946|NCT00163046|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
231243|NCT02422745|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
231244|NCT02422758|Device|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative & Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
231245|NCT02422758|Other|Passive Prewarming|
231246|NCT02424812|Behavioral|Lifebuoy School of Five Handwashing Intervention|
231247|NCT02424825|Behavioral|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
231248|NCT02424838|Procedure|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
231249|NCT02424838|Device|22 gauge needle|
231250|NCT02424838|Device|25 gauge needle|
231251|NCT02424851|Drug|Bortezomib|1.3 mg/m2 subcutaneously* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).
*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib
231252|NCT02424851|Drug|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
231253|NCT00167375|Drug|eszopiclone 3 mg qHS|
231254|NCT02424851|Drug|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
230655|NCT02398591|Drug|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
230656|NCT02400892|Other|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
230657|NCT02400905|Device|BioMimics 3D Stent System|Femoropopliteal stenting
230658|NCT02400918|Other|The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)|An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
230659|NCT02400931|Procedure|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
230660|NCT02400931|Procedure|no mask ventilation|
230661|NCT02400931|Drug|Rocuronium|
230662|NCT02400944|Behavioral|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
230663|NCT02400944|Other|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
230664|NCT00164112|Drug|Telithromycin plus Cooperstown 5+1|
230665|NCT02400957|Other|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
230666|NCT02400957|Other|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
230947|NCT02396199|Device|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
230948|NCT02396212|Biological|Canakinumab|Canakinumab 4mg/kg every 4 weeks
230949|NCT02396225|Drug|Voriconazole|
230950|NCT02396238|Device|Celution Device|ADRCs prepared using the investigational Celution Device
225342|NCT02187991|Drug|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
225653|NCT02177695|Drug|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
225654|NCT02177695|Drug|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
225655|NCT02177721|Other|Collection of samples|Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to GSK for determination of raxibacumab concentrations.
Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to GSK for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for TNA or ADA. If serum, pleural fluid, ascitic fluid, CSF, and BAL sample volume remains following analyses by GSK, the remaining sample may be sent to CDC for investigational analyses. Any such analyses performed by CDC will be reported separately, by the CDC.
225656|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
225657|NCT00137111|Drug|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
225658|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
225659|NCT02177734|Biological|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
225660|NCT02177747|Other|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
225661|NCT02177747|Device|Smartphone|
225662|NCT02177760|Drug|Sirolimus|
225663|NCT02177773|Drug|DOTA-TOC PET/CT|Single Gallium-68 DOTA-TOC PET/CT in patients with somatostatin receptor positive malignancies.
225664|NCT02177786|Drug|GS-4997|GS-4997 tablets administered orally once daily
225665|NCT02177786|Drug|Placebo to match GS-4997|Placebo to match GS-4997 tablets administered orally once daily
225666|NCT02177812|Drug|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
225667|NCT02180412|Biological|Panhematin|
225668|NCT02180412|Other|Placebo|
225022|NCT02195479|Drug|Velcade|Participants will receive velcade 1.3 mg/m^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
225023|NCT02195479|Drug|Melphalan|Participants will receive melphalan 9 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
225024|NCT02195479|Drug|Prednisone|Participants will receive prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
225025|NCT02195479|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or study end.
225026|NCT02195492|Drug|Synvisc®|
225027|NCT02195518|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
225028|NCT02195531|Behavioral|Education and feedback|The education leaflets are information concerning OSA and CPAP treatment. The feedback reports are CPAP usage patterns.
225029|NCT02195544|Drug|Synvisc®|
225343|NCT02188017|Drug|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
225344|NCT02188030|Other|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
225345|NCT02188030|Other|Individual Exercise Program|The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.
During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
225346|NCT02188043|Behavioral|Relay Model|The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.
Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+.
225347|NCT02188082|Drug|IvabRadine hemisulfate Sustained-release Tablets|
225348|NCT02188082|Drug|placebo|
225349|NCT02188108|Other|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
224721|NCT02159547|Drug|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
224722|NCT02159547|Other|Normal Saline|50 ml normal saline
224723|NCT02159560|Device|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
224724|NCT02159573|Biological|natalizumab|Administered as per routine clinical practice
224725|NCT02159573|Drug|dimethyl fumarate|Administered as per routine clinical practice
224726|NCT02159599|Drug|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
224727|NCT02159599|Drug|Lamivudine|Lamivudine (300mg) : QD
224728|NCT00135083|Drug|insulin glulisine|Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.
Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.
Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below.
224729|NCT02159599|Drug|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
224730|NCT02159612|Other|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
224731|NCT02162134|Other|sugar free chewing gum|Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
224732|NCT02162134|Other|sugared chewing gum|Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
224733|NCT02162134|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
224734|NCT02162134|Drug|Inj. Midazolam 0.7mg/kg 45 min before surgery|Inj . Midazolam 0.7 mg/kg given as premedication.
225030|NCT02195557|Drug|Synvisc®|
225031|NCT00139230|Drug|5-Fluorouracil|
225032|NCT02195570|Other|Quit Smoking Now (QSN)|The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's "Best Practices for Comprehensive Tobacco Control", and the U.S. Department of Health and Human Services' "Treating Tobacco Use and Dependence Clinical Guidelines" with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse.
224411|NCT00135811|Drug|MMF and Dexamethasone|MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.
Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg
224412|NCT02167074|Device|20G ProCore FNB needle|
224413|NCT02167087|Procedure|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
224414|NCT02167126|Device|Kinesio Taping|using the "V" technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity.
224415|NCT02167126|Device|Placebo Tape|Micropore tape was applied using the "V" technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella.
224416|NCT02167139|Drug|Humira (adalimumab)|
224417|NCT02167139|Drug|SB5 (proposed biosimilar to adalimumab)|
224418|NCT02167152|Device|Blood Pressure Cuff|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
224419|NCT02167165|Drug|Digoxin|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
224420|NCT02167178|Other|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
224421|NCT02167178|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
224422|NCT00135824|Drug|Povidone K25 eye drops (povidone)|
224423|NCT02167178|Other|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
224424|NCT02167178|Other|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
224425|NCT02169349|Other|Next Generation Sequencing|
224426|NCT00136110|Drug|Sodium Valproate|
224427|NCT02169349|Genetic|DNA Analysis|
228957|NCT02402517|Other|Small particle size pea flour|Pulse extruded snack
228958|NCT02402517|Other|Large particle size pea flour|Pulse extruded snack
228959|NCT02402517|Other|Lentil flour|Pulse extruded snack
228960|NCT02402517|Other|Navy bean flour|Pulse extruded snack
228961|NCT00002440|Drug|Indinavir sulfate|
224088|NCT02174614|Behavioral|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
224089|NCT02174627|Drug|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
224090|NCT02174627|Drug|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
224091|NCT02174640|Dietary Supplement|Coffee|Coffee Beverage
224092|NCT02174640|Dietary Supplement|Water|Water
224093|NCT00136734|Other|placebo|placebo
224094|NCT02174653|Drug|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
224095|NCT02174653|Drug|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
224096|NCT02174666|Dietary Supplement|Red clover extract|Aglycone isoflavones 80mg/d
224097|NCT02174666|Dietary Supplement|Supplementation (placebo)|
224098|NCT02174679|Drug|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
224099|NCT02174692|Other|Exercise|One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum
2 mins rest between sets
224100|NCT02174705|Drug|Sucrose|Sucrose 24% orally prior to vaccine injections
224101|NCT02174705|Drug|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
224102|NCT02174718|Dietary Supplement|Transdermal D Patch|
224103|NCT02174718|Dietary Supplement|Oral vitamin D3|
228671|NCT02406651|Drug|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
228672|NCT02406664|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
228673|NCT02406677|Other|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
228674|NCT02406690|Other|Estradiol Valerate, Progesterone in Oil, Leuprolide|Patients will undergo an endometrial preparatory cycle using the above medications and once completed will have a uterine aspiration and biopsy performed.
228675|NCT02406703|Drug|Chloroprocaine|
228676|NCT02406703|Drug|Mepivacaine|
228677|NCT02408692|Drug|Levonorgestrel (LNG)-based Emergency Contraception|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
228678|NCT02408705|Drug|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
228679|NCT02408705|Drug|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
228680|NCT02408705|Drug|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
228681|NCT02408718|Behavioral|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
228682|NCT02408731|Drug|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
228683|NCT02408744|Drug|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
228962|NCT00164307|Behavioral|Parent assisted social skills training|
228963|NCT02402517|Other|Pinto bean flour|Pulse extruded snack
228964|NCT02402530|Drug|Placebo|Matching placebo administered as intravenous infusion.
228965|NCT02402530|Drug|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
228966|NCT02402543|Drug|Gabapentin|
228686|NCT02408770|Drug|ulipristal acetate|selective progesterone receptor modulator
228687|NCT02408796|Drug|OTO-201|
228688|NCT02408809|Behavioral|Standard of Care|This group receives the standard of care for patients who smoke are receive orthopaedic management. This is a generic statement that smoking negatively impacts patient health.
228689|NCT02408809|Behavioral|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a novel orthopaedic related smoking cessation discussion 10 minutes in length and based on content from OrthoInfo, systematic reviews and randomized control trials that evaluated the effects of smoking cigarettes during orthopaedic management. A visual aid is also utilized in the discussion to reinforce the points made to the orthopaedic patient.
228690|NCT02408822|Device|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
228691|NCT02408822|Device|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
228692|NCT02408835|Device|PICO™|Negative pressure wound therapy device for closed surgical wounds.
228693|NCT02408848|Other|Observational|This is an observational study. There is no intervention.
228694|NCT02408861|Biological|Ipilimumab|Given IV
228695|NCT00165087|Procedure|Intrathecal chemotherapy without radiation|
228696|NCT02408861|Other|Laboratory Biomarker Analysis|Correlative studies
228697|NCT02408861|Biological|Nivolumab|Given IV
228698|NCT02408887|Procedure|Total Thyroidectomy (TT)|Total removal of thyroid
228699|NCT02410967|Behavioral|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
228700|NCT02410980|Device|Optical Imaging|Assessment of the skin change
228701|NCT02410980|Drug|Tretinoin cream 0.1%|Assessment of the skin change
228702|NCT02410980|Device|Skin Smoothing Laser|Assessment of the skin change
228703|NCT02410993|Procedure|CABG surgery|
228704|NCT02411006|Behavioral|Prediction mailing|Ask people to predict their upcoming medication adherence
228705|NCT00165230|Drug|Thalidomide|
228070|NCT02191579|Biological|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
228071|NCT02191579|Drug|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
228072|NCT00002296|Drug|Inosine pranobex|
228073|NCT00138684|Procedure|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
228074|NCT02191605|Behavioral|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
228390|NCT02415413|Drug|Dexamethasone|
228391|NCT02415413|Drug|Melphalan|
228392|NCT00165711|Drug|Mecobalamin|
228393|NCT02415426|Behavioral|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek & Steffen Moritz, http://clinical-neuropsychology.de/metacognitive_training_for_depression.html).
228394|NCT02415439|Drug|VBP15|
228395|NCT02415439|Drug|Placebo|
228396|NCT02415452|Procedure|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
228397|NCT02415465|Procedure|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
228398|NCT02415465|Procedure|General|General Intraoperative Anesthesia
228399|NCT02415465|Procedure|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
228400|NCT02415465|Procedure|Spinal|Spinal Intraoperative Anesthesia
228401|NCT02415478|Other|endoscopic lung volume reduction by valves|Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.
Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust.
227759|NCT00002302|Drug|Epoetin alfa|
227760|NCT00139334|Biological|Rotavirus|
227761|NCT02196805|Drug|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
227762|NCT02196805|Drug|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
227763|NCT02158052|Drug|Bone marrow transplant from a related donor|Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
227764|NCT02158052|Radiation|Total body irradiation 400 centigray (200 cGy X 2)|on day -1
227765|NCT02158065|Other|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
227766|NCT02158078|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
228075|NCT02191605|Behavioral|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
228076|NCT02191618|Device|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
228077|NCT02191631|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
228078|NCT02191644|Dietary Supplement|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
228079|NCT02191644|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
228080|NCT02191657|Drug|Deferiprone|Oral iron chelator
228081|NCT02191670|Drug|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
228082|NCT02191696|Device|IMED-4 recording|
228083|NCT02191709|Drug|Dextromethorphan syrup|
228084|NCT00138697|Drug|IVIG-L|
227439|NCT02163187|Behavioral|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
227440|NCT02163213|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
227441|NCT02163226|Radiation|Hypofractionated Radiation Treatment|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
227442|NCT02163226|Radiation|One Radiation Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
227443|NCT02165774|Device|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
227444|NCT02165774|Device|Turning ON the neuromodulator|
227445|NCT02165800|Procedure|L-PANP-TME|
227446|NCT02165800|Procedure|O-PANP-TME|
227447|NCT02165813|Drug|Nitazoxanide|
227448|NCT02165813|Drug|Placebo|
227449|NCT02165826|Drug|Roflumilast|Roflumilast tablets
227767|NCT00134823|Other|weight based dosing decision support|weight based dosing decision support
227768|NCT02158091|Drug|IPI-145|oral PI3K delta/gamma inhibitor
227769|NCT02158091|Drug|Fludarabine|intravenous chemotherapy
227770|NCT02158091|Drug|Cyclophosphamide|intravenous chemotherapy
227771|NCT02158091|Drug|Rituximab|intravenous immunotherapy
227772|NCT02158104|Procedure|Deep dry needling|
227773|NCT02158117|Drug|nasal naloxone|one puff in one nostril with the subject is lying down
227774|NCT02158143|Dietary Supplement|vitamin D3|
227775|NCT02158156|Behavioral|Exercise|Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
227776|NCT02158182|Drug|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
226812|NCT02178215|Other|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
226813|NCT02178241|Drug|Eribulin Mesylate|Given IV
227115|NCT00136305|Behavioral|Pictorial asthma action plan|
227116|NCT02170415|Drug|Protective analgesia|Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.
For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day.
227117|NCT02170415|Other|Pain education|Participant will receive a pain education leaflet
227118|NCT02170415|Behavioral|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
227119|NCT02170415|Procedure|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
227120|NCT02170415|Other|Daily visits from pain team whilst in hospital|
227121|NCT02170454|Procedure|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
227122|NCT02170467|Other|assessment of the intestinal permeability|
227123|NCT02170506|Device|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
227124|NCT02170519|Drug|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
227125|NCT02170532|Drug|levalbuterol|0.5 ml. levalbuterol
227126|NCT00136305|Behavioral|Written asthma action plan|
227127|NCT02170532|Drug|saline|0.5ml saline
227128|NCT02172911|Biological|1.1 mL of INO-3112 delivered via IM EP|Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 in the deltoid followed immediately by EP with CELLECTRA®-5P.
227129|NCT02172924|Biological|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
227130|NCT02172924|Biological|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
227131|NCT00136539|Drug|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
227132|NCT02172937|Biological|Decidual Stromal Cells thawed in plasma|
226519|NCT00137995|Drug|BCNU|300mg/m² on D-6
226520|NCT02185898|Other|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
226521|NCT02185924|Drug|Parecoxib|
226522|NCT02185924|Drug|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
226523|NCT02185924|Drug|N/S 0.9%|
226524|NCT02185937|Dietary Supplement|cola|imatinib intake with coca-cola
226525|NCT02185950|Device|ultrasound|
226526|NCT02185950|Device|paraffin|
226527|NCT02185950|Device|endermotherapy|
226528|NCT02185963|Drug|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
226529|NCT02185976|Other|cartoon|5 different cartoons which will be recorded on a tablet PC.
226814|NCT00137137|Procedure|Placement of the mini-screw|
226815|NCT02178241|Drug|Gemcitabine Hydrochloride|Given IV
226816|NCT02178254|Drug|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
226817|NCT02178254|Drug|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
226818|NCT02178267|Dietary Supplement|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
226819|NCT02178280|Other|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
226820|NCT02178293|Drug|Benzidamine hydrochloride|
226821|NCT02178293|Drug|Ketoprofen lysine salt|
226822|NCT02178306|Drug|Telmisartan low dose|
226823|NCT02178306|Drug|Telmisartan high dose|patients switch to high dose if mean SBP >= 85 mmHg after 4 weeks of treatment
226824|NCT02178306|Drug|Placebo|Run-in phase
232176|NCT02410265|Behavioral|Lantern: Guided self-help program|Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an "e-coach" who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call.
232177|NCT02410265|Behavioral|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
232178|NCT02410278|Drug|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
232179|NCT02410278|Drug|montelukast|As described in the treatment arm
232180|NCT02410278|Drug|Placebo|Matched placebo
232181|NCT02410291|Other|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
232182|NCT02410304|Device|Xrays|Clinical evaluation
232183|NCT02410304|Device|Ultrasound (B mode )|
232184|NCT02410304|Device|Ultrasound (D mode)|
232185|NCT02410317|Drug|Ropivacaine|
232186|NCT00165178|Drug|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
232187|NCT02410317|Drug|Morphine|
232188|NCT02410330|Procedure|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
232189|NCT02410330|Procedure|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
232190|NCT02410343|Drug|TV-1106|Starting dose titrated to normal range for insulin-like growth factor 1 (IGF-I)
232191|NCT02410343|Drug|Placebo|Placebo treatment will be administered in a blinded fashion
232192|NCT02410356|Drug|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
232193|NCT02410356|Drug|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
231582|NCT02420717|Drug|Dexamethasone|40 mg by vein or mouth daily days 1 - 4 and days 11 - 14 for Hyper-CVAD (Courses 1, 3, 5, 7).
231583|NCT02420717|Drug|Solumedrol|50 mg by vein over 2 hours approximately every 12 hours for 6 doses days 1 - 3 for Hyper-CVAD chemotherapy Courses 2, 4, 6, 8.
231584|NCT02420717|Drug|6-mercaptopurine|50 mg tablets by mouth 3 times daily for maintenance phase chemotherapy (POMP maintenance). Treatment cycle is 28 days.
231585|NCT02420717|Drug|Prednisone|200 mg by mouth daily days 1 to 5 approximately every 28 days, starting with vincristine (if given) for maintenance phase chemotherapy (POMP maintenance).
231885|NCT02414555|Drug|Elo-Mel Isoton (balanced acetat-based infusate)|
231886|NCT02414568|Drug|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
231887|NCT02414568|Drug|Prednisone|Prednisone 40 mg/m² PO
231888|NCT02414568|Drug|Vinblastine|Vinblastine 6 mg/m² IV
231889|NCT02414568|Drug|Doxorubicin|Doxorubicin 40 mg/m² IV
231890|NCT00002447|Drug|Ritonavir|
231891|NCT00165633|Drug|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
231892|NCT02414581|Drug|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine-based solution
231893|NCT02416713|Device|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
231894|NCT02416713|Other|Education Only|No active intervention, educational materials will be provided
231895|NCT02416726|Device|Illumina MiSeq panel|The investigators used this panel to detect the gene mutations of the samples obtained from patients
231896|NCT02416739|Drug|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
231897|NCT02416752|Drug|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
231898|NCT02416752|Drug|choice of intra-operative opioids were left to the discretion of anesthesiologist|
231899|NCT02416765|Other|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
231900|NCT00165971|Procedure|BIS monitoring|
231255|NCT02424851|Drug|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
231256|NCT02424864|Other|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
231257|NCT02424877|Procedure|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
231258|NCT02424890|Other|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
231259|NCT02424916|Biological|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
231260|NCT02424929|Procedure|Sedation|Propofol anesthesia administered during entire surgery.
231261|NCT02424929|Drug|Propofol|
231262|NCT02424942|Drug|placebo|Pharmaceutical form:solvent for parenteral use
Route of administration: intraarticular
231586|NCT02420717|Drug|Leucovorin|50 mg by vein followed by 15 mg by vein every 6 hours for 8 doses (or until MTX cleared) beginning 12 hours post MTX completion for courses 2, 4, 6, 8.
231587|NCT02420730|Drug|AGN-232411|AGN-232411 topical ophthalmic solution
231588|NCT02420730|Drug|AGN-232411 Vehicle|Vehicle for AGN-232411 topical ophthalmic solution.
231589|NCT00166595|Drug|Risperidone|
231590|NCT02420743|Procedure|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
231591|NCT02420743|Procedure|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
231592|NCT02420756|Device|PET Scan|
231593|NCT02420782|Drug|ASP6282|oral
231594|NCT00167089|Behavioral|Treadmill Training|Partian body weight support treadmill training, 30 min/day * 3 days /week
231595|NCT02422771|Other|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
231596|NCT02422784|Dietary Supplement|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
226298|NCT02160158|Drug|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
226299|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
226300|NCT00135148|Procedure|Sex steroid analysis|
226301|NCT02160158|Drug|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
226302|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
226303|NCT02160158|Drug|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
226304|NCT02160158|Drug|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
226305|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
226306|NCT02160158|Drug|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
226307|NCT02160171|Device|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
226308|NCT02160184|Device|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
226309|NCT02160197|Device|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
226310|NCT02160197|Device|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
226311|NCT00135161|Procedure|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
226312|NCT02160210|Device|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
226313|NCT02160223|Drug|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
226314|NCT02160223|Drug|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
226315|NCT02160236|Drug|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
226607|NCT02196116|Other|PET|PET Scan with [18F]-Flutemetamol
226608|NCT02196116|Other|MRI|
226609|NCT02196116|Other|neuropsychological tests|
225669|NCT02180425|Drug|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
225670|NCT02180425|Drug|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
225976|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
225977|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
225978|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
225979|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
225980|NCT00136240|Behavioral|Computer Assisted Education for Behavior Change|
225981|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
225982|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
225983|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
225984|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
225985|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
225986|NCT02170025|Drug|Riociguat (Adempas, BAY63-2521)|The patients will receive a lower dose of treatment (0.5 mg in Part 1 or 1 mg in Part 2) for the initial 14 days and a higher dose (1 mg in Part 1 or 2 mg in Part 2 respectively) for the second 14 days of BAY63-2521(Riociguat) tablet, three times a day for duration of 28 days
225987|NCT02170025|Drug|Placebo|Placebo tablet, three times a day for duration of 28 days
225988|NCT02170038|Drug|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
225989|NCT02170038|Drug|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
225990|NCT02170051|Behavioral|CBSST-CCT|
225991|NCT00136253|Behavioral|Help dietitians and patients address specific nutritional barriers|
225992|NCT02170051|Behavioral|Goal focused supportive contact|
225993|NCT02170064|Drug|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
225350|NCT02188121|Drug|Simvastatin|
225351|NCT02188121|Drug|Losartan|
225352|NCT00138216|Drug|irinotecan hydrochloride|
225353|NCT02188147|Device|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
225354|NCT02188160|Drug|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
225355|NCT02190136|Other|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
225356|NCT02190136|Other|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
225357|NCT02190149|Biological|ADVATE (Antihemophilic Factor [Recombinant])|
225358|NCT02190149|Biological|RIXUBIS (Coagulation Factor IX [Recombinant])|
225359|NCT02190162|Drug|Tantum Verde® mouthwash|
225360|NCT00138554|Drug|vildagliptin|
225671|NCT02180438|Drug|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
225672|NCT02180464|Drug|LAS41004|
225673|NCT02180464|Drug|control|
225674|NCT02180477|Drug|UHAC 62 XX - TF1 tablet|
225675|NCT02180477|Drug|UHAC 62 XX - TF2 tablet|
225676|NCT02180477|Drug|UHAC 62 XX - capsules|
225677|NCT00137371|Drug|PVC (twice weekly)|
225678|NCT02180490|Drug|UHAC 62 XX tablet|
225679|NCT02180490|Drug|UHAC 62 XX capsule|
225680|NCT02180503|Drug|BI 1356 BS PIB - low dose|
225681|NCT02180503|Drug|BI 1356 BS tablet - low dose|
225682|NCT02180503|Drug|BI 1356 BS PIB - high dose|
225033|NCT02195570|Behavioral|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
225034|NCT02195583|Drug|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
225035|NCT02195583|Drug|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
225036|NCT02195583|Drug|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
225037|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
225038|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
225039|NCT02195583|Drug|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
225040|NCT02195596|Other|High intensity aerobic exercise+strength|The program consist in a "Continuous High aerobic exercise and moderate intensity intervals" (ShoshanaB et al, 2012) combined with "muscular strength exercises and joint mobility". Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse.
225041|NCT02195596|Other|Low intensity aerobic exercise+strength|Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.
225042|NCT00139230|Drug|Leucovorin|
225043|NCT02195609|Dietary Supplement|Omega-3|600 mg oral twice a day
225044|NCT02156700|Procedure|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
225045|NCT02156713|Behavioral|CIMT Camp|
225046|NCT02156726|Drug|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
225047|NCT02156739|Drug|Gadoxetate|Participants undergoing a follow-up MR with initial administration of Gadoxetate 0.025mmol/kg by vein over about 1 minute.
225048|NCT02156739|Drug|Gadopentetate Dimeglumine|Participants undergoing a follow-up MRI receive Gadopentetate Dimeglumine 0.1mmol//kg by vein over about 1 minute, 20 minutes after receiving Gadoxetate.
225049|NCT02156752|Behavioral|ACT|Treatment is based on Acceptance and Commitment Therapy
225361|NCT02190188|Device|Wedge Insole 5mm|
225362|NCT02190188|Device|Knee Brace|
225363|NCT02190201|Device|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
224735|NCT02162134|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
224736|NCT02162134|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia.
224737|NCT00002267|Drug|Rifabutin|
224738|NCT00135356|Drug|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
224739|NCT02162134|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
224740|NCT02162134|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
224741|NCT02162134|Drug|Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
224742|NCT02162134|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
224743|NCT02162160|Device|probiotic creme|Probiotic creme applied
224744|NCT02162160|Drug|Placebo|Creme without probiotics applied in same manner
224745|NCT02162173|Procedure|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
224746|NCT02162199|Drug|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
224747|NCT02162199|Drug|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
224748|NCT02162212|Other|Optimized Shoulder Movement Program|A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured "activity count" at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity.
224749|NCT00135356|Drug|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor [PI] combination + 2 NRTIs
224750|NCT02164539|Drug|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
224104|NCT00136747|Drug|Memantine|Two capsules of Memantine twice daily for 12 days.
224105|NCT02174718|Dietary Supplement|Placebo patch|
224106|NCT02174718|Dietary Supplement|Oral placebo|
224107|NCT02177214|Procedure|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
224108|NCT02177227|Device|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
224109|NCT02177240|Device|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
224428|NCT02169362|Device|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
224429|NCT02169375|Other|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
224430|NCT02169388|Drug|Probiotic|Microbial composition using probiotic
224431|NCT02169388|Drug|placebo（for probiotic）|microbiota modulation using placebo
224432|NCT02169401|Device|Implantation with the commercially available Axium Neurostimulator|
224433|NCT02169414|Drug|BIA 9-1067 5 mg|OPC, Opicapone
224434|NCT02169414|Drug|BIA 9-1067 25 mg|OPC, Opicapone
224435|NCT02169414|Drug|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
224436|NCT02169414|Drug|Placebo|PLC, Placebo
224437|NCT00136123|Procedure|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
224438|NCT02169414|Drug|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
224439|NCT02169427|Drug|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
224440|NCT02169440|Drug|BIA 9-1067|BIA 9-1067 25 mg
224441|NCT02169440|Drug|Warfarin|Warfarin 25 mg
228967|NCT02402543|Drug|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
228968|NCT02402543|Drug|Acetaminophen|
228969|NCT02402543|Drug|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
228970|NCT02402543|Drug|Placebo|
228971|NCT02402556|Behavioral|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
228972|NCT02402569|Device|32 channels Deep Brain Stimulator|
228973|NCT00164320|Behavioral|TEAM|
228974|NCT02404636|Other|Interview|Brief structured interview
228975|NCT02404649|Device|Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants (Zimmer) after Staged Sinus Bone Augmentation Procedures|Comparing conventional implant versus trabecular metal implant biological behavior in a sinus bone augmentation environment.
228976|NCT02404649|Device|Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants (Zimmer) after Staged Sinus Floor Elevation Procedures|Comparing conventional implant versus trabecular metal implant biological behavior in a sinus elevation only environment.
228977|NCT02404649|Procedure|sinus bone augmentation|
228978|NCT02404649|Procedure|sinus elevation only|
228979|NCT02404662|Other|Supportive text messages intervention|The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: "Monitor changes in your mood; develop a list of personal warning signs." An example message targeting abstinence is: "Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot.
228980|NCT00002440|Drug|Amprenavir|
228981|NCT00164606|Behavioral|Positive Parenting Program (Triple-P)|
228982|NCT02404662|Other|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
224110|NCT02177240|Device|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
224111|NCT02177253|Drug|Ipratropium bromide / Salbutamol|
224112|NCT02177253|Drug|Placebo Inhalation solution|
228983|NCT02404675|Drug|icotinib|
228984|NCT02404688|Drug|Active delta-9-THC|Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or "joint". Administered over 20 minutes.
228985|NCT02404688|Drug|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
228986|NCT02404688|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
228987|NCT02404688|Drug|Placebo|Control: no alcohol, administered for a total of 80 minutes.
228988|NCT02404701|Dietary Supplement|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
228989|NCT02404701|Dietary Supplement|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
228990|NCT00164853|Procedure|endoscopic balloon dilatation|Refer to description under arms
228991|NCT02406716|Other|Biospecimen retention|
228992|NCT02406729|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
228993|NCT02406729|Other|Placebo|Route:subcutaneous
228994|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
228995|NCT02406742|Drug|Rituximab|
228996|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 2 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
228997|NCT02406742|Drug|Ibrutinib|
228998|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 9 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
228402|NCT02417402|Other|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
228403|NCT02417415|Other|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at ~44ºC continuously for 2 hr.
228404|NCT02417415|Other|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
228405|NCT02417428|Dietary Supplement|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
228706|NCT02411006|Behavioral|Commitment mailing|Ask people to commit to their upcoming medication adherence
228707|NCT02411006|Behavioral|Reminder|Remind people to take their medicine
228708|NCT02411006|Behavioral|Anonymity|Keep patient predictions and commitment anonymous
228709|NCT02411006|Behavioral|Identification|Ask patients to report their predictions and commitments
228710|NCT02411019|Biological|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
228711|NCT02411032|Behavioral|Reminder|Customer gets mailing that reminds them to take their medication.
228712|NCT02411032|Behavioral|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
228713|NCT02411032|Behavioral|Fresh start framing|The fresh start event will be highlighted in the mailings.
228714|NCT02411045|Behavioral|Take and send a selfie|Direction to take and send a selfie.
228715|NCT02411045|Behavioral|Workout gears|Direction to wear workout gears.
228716|NCT00002443|Drug|Zidovudine|
228717|NCT00165230|Drug|Temodar|
228718|NCT02411045|Behavioral|Exercise|Direction to complete a 30 minute workout.
228719|NCT02411058|Behavioral|Uninformed|Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
228085|NCT02191709|Drug|Dextromethorphan soft pastilles|
228086|NCT02191722|Behavioral|reading comics booklet|
228087|NCT02191735|Device|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
228088|NCT02191735|Device|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
228089|NCT02191748|Procedure|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
228090|NCT02194166|Drug|trastuzumab SID|Fixed dose 600 mg SC trastuzumab using SID, self-administration after initial injection and instructions by HCP in hospital setting
228091|NCT02194179|Drug|NVP XR 400 mg (KCR 25%)|
228092|NCT02194179|Drug|NVP XR 400 mg (KCR 20%)|
228093|NCT02194179|Drug|NVP XR 300 mg (KCR 25%)|
228094|NCT02194179|Drug|NVP XR 300 mg (KCR 20%)|
228406|NCT02417428|Other|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
228407|NCT02417428|Behavioral|Exercise|Participants will also take part in twelve weeks of walking training at 60-75% of maximal heart rate (HR max). 3 times/ week during 50 continuous minutes or 5 times/ week during 30 continuous minutes. Each period are monitored using polar system.
228408|NCT00166114|Drug|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
228409|NCT02417428|Other|without exercise|No exercise program (walking training) will be assigned to participants.
228410|NCT02417441|Device|EEVA™|Embryos of consented subjects will be assessed with EEVA™ System and morphological assessment and will be followed up after Embryo Transfer until achievement of implantation and confirmation of pregnancy.
228411|NCT02417454|Dietary Supplement|ProbioStick|One sachet daily, without or without meals (3 x 10^9 CFU per sachet)
(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)
228412|NCT02417454|Other|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
228413|NCT02417467|Other|Nicotine E-Cigarette|
227777|NCT02158182|Drug|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
227778|NCT00002263|Drug|Zidovudine|
227779|NCT00134836|Behavioral|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
227780|NCT02158182|Drug|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
227781|NCT02158182|Drug|Placebo|Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.
Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.
Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days.
227782|NCT02158195|Biological|blood samples|
227783|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
227784|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
227785|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube|
227786|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes|
227787|NCT02158221|Drug|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
227788|NCT02160691|Device|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
227789|NCT02160704|Drug|Enclomiphene citrate|25 mg daily for 16 weeks
227790|NCT00135226|Drug|Omega-3-acid Ethyl Esters|
228095|NCT02194179|Other|high-fat breakfast|
228096|NCT02194179|Drug|NVP IR 200 mg (Viramune®)|
228097|NCT02194192|Drug|Placebo|Normal saline 10 ml
228098|NCT00139074|Drug|Quetiapine fumarate|oral variable dose
228099|NCT02194192|Drug|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
228100|NCT02194192|Drug|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
228101|NCT02194205|Drug|COMBIVENT HFA|
228102|NCT02194205|Drug|Placebo HFA|
227133|NCT02172937|Biological|Decidual Stromal Cells thawed in human albumin|
227134|NCT02172950|Biological|rVIII‑SingleChain|Recombinant single-chain coagulation factor VIII
227135|NCT02172963|Biological|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10^6 cells/kg.
227136|NCT02172976|Drug|Gemcitabine|
227450|NCT00135694|Drug|corticosteroids|3-month course of corticosteroids
227451|NCT02165826|Drug|Roflumilast Placebo|Roflumilast placebo-matching tablets
227452|NCT02165826|Drug|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
227453|NCT02165839|Behavioral|Brief Behavioral Therapy for Insomnia (BBT-I)|
227454|NCT02165839|Behavioral|Healthy Eating Education Learning (HEAL)|
227455|NCT02165852|Procedure|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
227456|NCT02165852|Procedure|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
227457|NCT02165865|Procedure|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
227458|NCT02165891|Drug|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
227459|NCT02165891|Procedure|primary video-assisted thorascopic surgery|
227460|NCT02165904|Biological|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
227461|NCT00135694|Other|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
227462|NCT02165917|Procedure|Excision plus hyaluronic acid gel|Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
227463|NCT02165917|Procedure|Excision only|Excision of endometriosis foci by laparoscopic standard methods only.
227464|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
226825|NCT00137150|Procedure|Placement of implants|
226826|NCT02178319|Procedure|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
226827|NCT02181010|Behavioral|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
226828|NCT02181023|Drug|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
226829|NCT00137436|Drug|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
226830|NCT02181023|Drug|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
226831|NCT02181036|Other|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
226832|NCT02181062|Behavioral|Walking Intervention|
227137|NCT02172976|Drug|Oxaliplatin|
227138|NCT02172976|Drug|5-Fluorouracil|
227139|NCT02172976|Drug|Irinotecan|
227140|NCT02172976|Drug|Natriumfolinate|
227141|NCT02173002|Other|myIBDcoach|
227142|NCT00136539|Drug|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
227143|NCT02173002|Other|Standard care|
227144|NCT02173015|Other|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
227145|NCT02173041|Other|Prevention Awareness Groups (PAG)|
227146|NCT02173041|Other|Standard Care|
232503|NCT02404038|Drug|Triphasil|Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
Composition:
The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.
The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.
The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.
The seven red tablets are inert
232504|NCT02405897|Device|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
232505|NCT02405910|Drug|Nab-paclitaxel|
232506|NCT02405910|Drug|Gemcitabine|
232507|NCT02405923|Other|HRF|The subject will take the formula for a period of 12 months.
232508|NCT02405923|Other|eHF|The subject will take the formula for a period of 12 months.
232509|NCT02405936|Procedure|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
232510|NCT00164749|Drug|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
232511|NCT02405949|Genetic|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
232512|NCT02405962|Behavioral|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). Parents will learn to (1) increase acceptance of subjective experiences, (2) learn mindfulness of the present rather than an over-attachment to the past or future; (3) clarify personally held values and (4) move on in an effort to promote asthma care and parenting.
232513|NCT02405962|Behavioral|An educational talk|One session of educational talk about pediatric asthma care, as usual practice.
232514|NCT02405975|Other|SCRIPT|An online tool designed to train doctors in all areas of prescribing
232515|NCT02405988|Drug|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
232516|NCT02405988|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
232517|NCT02406001|Device|Tigran PTG|Open Flap Debridement
232518|NCT02406001|Procedure|Surgical intervention|Open Flap Debridement
232519|NCT02406014|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
231901|NCT02416765|Drug|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
231902|NCT02416765|Drug|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
231903|NCT02416765|Other|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
231904|NCT02416778|Drug|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
231905|NCT02416791|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
232194|NCT02410369|Drug|S-588410|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
232195|NCT02410369|Drug|Placebo|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
232196|NCT02410382|Drug|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
232197|NCT02412332|Procedure|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
232198|NCT02412332|Procedure|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
232199|NCT02412345|Procedure|Extracorporeal shockwave therapy|
232200|NCT02412345|Procedure|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
232201|NCT02412345|Other|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
232202|NCT02412358|Device|toothbrush|
232203|NCT02412371|Drug|Veliparib|Oral capsule of varying doses
232204|NCT00165399|Drug|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
232205|NCT02412371|Drug|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week/cycle.
232206|NCT02412371|Drug|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week/cycle.
231597|NCT02422784|Dietary Supplement|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
231598|NCT02422784|Dietary Supplement|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
231599|NCT02422797|Drug|DTG 50 mg|Participants will take one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet will contain 52.62 mg dolutegravir sodium salt, which is equivalent to 50 mg dolutegravir free acid.
231600|NCT02422797|Drug|RPV 25 mg|Participants will take one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet will contain 27.5 mg of rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.
231601|NCT02422797|Drug|CAR|CAR will include following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
231602|NCT02422823|Drug|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
231603|NCT02422823|Drug|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
231604|NCT02422823|Drug|Epinephrine|
231906|NCT02416791|Device|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
231907|NCT02416791|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
231908|NCT02416791|Other|Physical Therapy|Physical therapy will be administered for 40 minutes.
231909|NCT02416791|Other|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
231910|NCT02416804|Drug|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -> 10 μg/hr -> 15 (5+10) μg/hr -> 20 μg/hr
231911|NCT00166010|Drug|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
231912|NCT02416804|Drug|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -> 200 mg/d -> 250 mg/d -> 300 mg/d
231913|NCT02416817|Other|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
226610|NCT02196129|Drug|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
226611|NCT02196129|Drug|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
226612|NCT02196142|Drug|Cortisol 20mg|Drug: Cortisol 20mg
226613|NCT02196142|Drug|Placebo Mannitol|Drug: Placebo Mannitol
226614|NCT02196155|Drug|Botulinum toxin A|Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.
In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc..
226615|NCT00139269|Drug|Docetaxel|
226616|NCT02196155|Drug|cortisone|
226617|NCT02196155|Drug|Saline|
226618|NCT02196168|Drug|Cisplatin|Given IV
226619|NCT02196168|Other|Laboratory Biomarker Analysis|Correlative studies
226620|NCT02196168|Other|Pharmacological Study|Correlative studies
226621|NCT02196168|Other|Placebo|Given PO
226622|NCT02196168|Drug|WEE1 Inhibitor AZD1775|Given PO
226623|NCT02196181|Drug|Dabrafenib|Given PO
226624|NCT02196181|Other|Laboratory Biomarker Analysis|Correlative studies
226625|NCT02196181|Drug|Trametinib|Given PO
226626|NCT00139269|Drug|Cisplatin|
226627|NCT02196194|Drug|Tiotropium|
226628|NCT02196207|Drug|Long-acting recombinant factor VIII Fc fusion protein|Eloctate (50 IU/kg weekly) will be administered prophylactically in previously untreated children with severe hemophilia A before the first bleed.
226629|NCT02157506|Drug|Placebo|
225994|NCT02170077|Drug|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
225995|NCT02170077|Drug|Placebo|Placebo tablets administered orally
225996|NCT02170090|Drug|Gemcitabine|Gemcitabine 1000mg/m2
225997|NCT02172430|Drug|Tersigan®|2 puffs of oxitropium three times daily via MDI
225998|NCT02172443|Drug|tiotropium inhalation powder capsules|
226316|NCT02162628|Procedure|Total Native Tissue Repair|
226317|NCT02162641|Procedure|Sentinel lymph node biopsy|
226318|NCT02162654|Procedure|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
226319|NCT00135395|Drug|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
226320|NCT02162654|Procedure|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
226321|NCT02162667|Drug|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
226322|NCT02162680|Drug|1% lidocaine|
226323|NCT02162680|Drug|bacteriostatic normal saline (BNS)|
226324|NCT02162693|Biological|Mesenchymal progenitor cells|Administrated for intra-articular injection
226325|NCT02162693|Biological|Sodium Hyaluronate|
226326|NCT02162719|Drug|Ipatasertib|Administered orally 400 mg daily Days 1-21 of each 28-day cycle
226327|NCT02162719|Drug|Paclitaxel|80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each cycle
226328|NCT02162719|Drug|Placebo|Administered orally daily Days 1-21 of each 28-day cycle
226329|NCT02162732|Device|Guided Therapy|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
226330|NCT00135408|Drug|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
225683|NCT02180503|Drug|BI 1356 BS tablet - high dose|
225684|NCT02180503|Drug|BI 1356 BS tablet - high dose with food|
225685|NCT02180516|Drug|Meloxicam|
225686|NCT02180516|Drug|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
225687|NCT02180529|Drug|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
225688|NCT00137397|Drug|Tolterodine ER|
225689|NCT02180529|Drug|Placebo|
225690|NCT02180555|Other|Oral glucose tolerance test|
225691|NCT02180568|Procedure|Lipiodol|Lipiodol-guided lung localization technique
225692|NCT02180568|Procedure|Hookwire|Hookwire-guided lung localization technique
225693|NCT02180568|Drug|Lipiodol|
225694|NCT02180581|Dietary Supplement|Probiotic (2 * 10^9 cfu/day)|
225695|NCT02180620|Other|No exericse|
225696|NCT02180633|Other|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
225697|NCT02180646|Other|high protein breakfast|
225999|NCT02172443|Drug|Atrovent|
226000|NCT02172443|Drug|placebo to Atrovent|
226001|NCT02172443|Drug|placebo to tiotropium inhalation capsules|
226002|NCT02172456|Drug|99mTc-radiolabelled tiotropium|
226003|NCT00000328|Drug|Opioid-Related Disorders|
226004|NCT00002277|Drug|Fluconazole|
226005|NCT00136461|Drug|All-trans retinoic acid|
226006|NCT02172456|Drug|non-radiolabelled tiotropium|
226007|NCT02172469|Drug|Tiotropium inhalation powder capsule|
225364|NCT02190201|Device|Direct laryngoscope|A kind of traditional laryngoscopes
225365|NCT02190227|Device|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
225366|NCT02190279|Drug|18F DCFBC|Each subject will receive a single i.v. dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
225367|NCT02190305|Device|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
225368|NCT02190318|Drug|Losartan|
225369|NCT02190318|Drug|spirolactone|
225370|NCT02190318|Other|blank control|
225371|NCT00138554|Drug|pioglitazone|pioglitazone 45 mg qd
225372|NCT02190331|Other|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
225373|NCT02190331|Other|Control Group physical education classes|Only performed the physical education classes
225374|NCT02190344|Device|8-channel paddle coil|MRI Coil
225375|NCT02190357|Drug|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
225376|NCT02190370|Behavioral|Resources activation|
225377|NCT02190383|Behavioral|Habit Reversal Training|awareness training, competing response training
225378|NCT02190409|Device|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
225379|NCT02190435|Device|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
225380|NCT02190448|Dietary Supplement|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
225381|NCT02190448|Dietary Supplement|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
225382|NCT00002298|Drug|Ribavirin|
225383|NCT00138905|Device|UMTS mobile basestation radiation|
225698|NCT02183129|Drug|Diclofenac|
224751|NCT00135577|Drug|placebo|
224752|NCT02164539|Drug|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
225050|NCT02156752|Behavioral|SR|Treatment is based on Self-Regulation theory.
225051|NCT00134719|Biological|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
225052|NCT02156752|Behavioral|WLO|Treatment is based on cooking tips and demonstrations.
225053|NCT02156778|Behavioral|Active Comparator: Extended Standard Care (Stroke Card)|Standard Care plus
extended training with access to weekly educational lectures (education of patients and relatives), implementation of "My Stroke Card" containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.
3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.
6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.
12-Mo clinical visit and outcome assessment.
225054|NCT02156778|Behavioral|Active Comparator: Standard Care|In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).
Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.
Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).
Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.
AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).
3-Mo telephone interview and 12-Mo clinical visit and outcome assessment.
225055|NCT02156791|Biological|gpASIT+TM|
225056|NCT02156804|Drug|Nivolumab (BMS-936558)|
225057|NCT02156817|Other|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
225058|NCT02156843|Drug|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
225059|NCT02156843|Drug|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
225060|NCT02156869|Other|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
225061|NCT02156895|Drug|Axitinib|based on Axitinib approval
224442|NCT02169453|Drug|BIA 9-1067|OPC, Opicapone
224443|NCT02169453|Drug|Placebo|PLC, Placebo
224444|NCT02169453|Drug|Sinemet® CR 100/25|Controlled-release levodopa/carbidopa 100/25 mg
224445|NCT02169466|Drug|BIA 9-1067|OPC, Opicapone
224446|NCT02169466|Drug|Placebo|PLC, Placebo
224447|NCT02169466|Drug|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
224448|NCT00136136|Procedure|Registration of the bispectral index and spectral edge frequency|Registration of the bispectral index and spectral edge frequency
224449|NCT02169479|Drug|BIA 9-1067|OPC, Opicapone
224450|NCT02169479|Drug|Placebo|PLC, Placebo
224451|NCT02169479|Drug|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
224753|NCT02164539|Drug|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
224754|NCT02164552|Dietary Supplement|Vitamin D3 pills|Dietary supplement
224755|NCT02164552|Other|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
224756|NCT02164565|Drug|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
224757|NCT02164565|Drug|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
224758|NCT02164578|Drug|Rivaroxaban|
224759|NCT02164578|Drug|Aspirin|
224760|NCT02164604|Drug|intravitreal injection of 0.03ml ranibizumab|
224761|NCT02164617|Other|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
224762|NCT00135590|Dietary Supplement|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
224763|NCT02164630|Behavioral|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
224113|NCT02177253|Drug|Ipratropium bromide|
224114|NCT02177253|Drug|COMBIVENT Inhalation Aerosol|
224115|NCT02177253|Drug|Placebo Inhalation Aerosol|
224116|NCT02177266|Drug|Colchicine|
224117|NCT00137033|Drug|Naproxen|
224118|NCT02177266|Drug|Placebo|
224119|NCT02177279|Other|Visit A high wheat bran|
224120|NCT02177279|Other|Visit B normal wheat bran|
224121|NCT02177279|Other|Follow up normal (8days) and high (1day) bran consumption|
224122|NCT02177292|Radiation|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
224123|NCT02177305|Drug|0.02 mcg tiotropium solution|
224124|NCT02177305|Drug|0.04 mcg tiotropium solution|
224125|NCT02177305|Drug|0.08 mcg tiotropium solution|
224126|NCT02177305|Drug|0.16 mcg tiotropium solution|
224127|NCT02177305|Drug|0.28 mcg tiotropium solution|
224128|NCT00137033|Drug|ASA|
224129|NCT02177305|Drug|0.40 mcg tiotropium solution|
224130|NCT02177305|Drug|Placebo solution|
224131|NCT02177318|Drug|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
224132|NCT02177331|Drug|Lacidipine|
224133|NCT02177344|Drug|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
224134|NCT02177344|Drug|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
224135|NCT02177344|Drug|Atrovent|Two puffs, 4 times daily by oral inhalation
224136|NCT02177344|Drug|Placebo|
228999|NCT02406742|Drug|Obinutuzumab|
229000|NCT02406755|Other|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
224137|NCT02177357|Drug|Pramipexole|
224138|NCT02179762|Behavioral|moderate exercise intervention|Perform moderate exercise therapy
224139|NCT02179762|Behavioral|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
224140|NCT02179762|Other|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
224141|NCT02179762|Other|laboratory biomarker analysis|Correlative studies
224142|NCT02179762|Behavioral|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
224143|NCT02179762|Behavioral|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
224144|NCT02179762|Behavioral|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
224145|NCT00137319|Device|Impedance threshold device|
224146|NCT02179762|Behavioral|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
224147|NCT02179775|Drug|propranolol|
224148|NCT02179775|Drug|Quince's oxymel|
224149|NCT02179775|Drug|placebo|
224150|NCT02179788|Behavioral|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
224151|NCT02179788|Drug|Metformin|The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:
Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)
Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)
Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)
Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.
The trial duration is 28 days (with a +/- 3 day cushion)
228720|NCT02411058|Behavioral|Informed|Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
228721|NCT02411084|Biological|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
228722|NCT02413112|Behavioral|Resistance training|Whole-body resistance training in the University gym that is supervised by researchers.
Training once per week, Training twice per week, Training thrice per week.
228723|NCT02413125|Device|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
228724|NCT02413125|Drug|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
229001|NCT00164853|Procedure|Standard sphincterotomy|Refer to under arms
229002|NCT02406755|Other|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
229003|NCT02406755|Other|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
229004|NCT02406781|Drug|Combination of MK3475 with Metronomic CP|Combination of MK3475 with Metronomic CP CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.
MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
229005|NCT02406794|Drug|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
229006|NCT02406807|Other|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
229007|NCT02406807|Other|Sham Spinal lumbar manipulation|Sham manipulation
229008|NCT02406820|Device|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
229009|NCT02406833|Drug|TGF-β2 antisense oligonucleotide|intravitreal injection
228414|NCT02417467|Other|Non-Nicotine E-Cigarette|
228415|NCT02417467|Behavioral|Counseling|
228416|NCT02417480|Behavioral|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
228417|NCT02417480|Behavioral|Follow usual diet|Participants will be asked to consume their habitual, usual diet.
228418|NCT02417493|Behavioral|Simulation of epinephrine self-injection|
228419|NCT00166114|Drug|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
228420|NCT02417506|Other|E-OA-07 (Lanconone)|
228421|NCT02417506|Drug|Ibuprofen|
228422|NCT02417519|Other|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
228423|NCT02417519|Other|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
228424|NCT02419599|Other|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
228425|NCT02419612|Drug|Saxagliptin|
228426|NCT02419612|Drug|Dapagliflozin|
228427|NCT02419612|Drug|Glimepiride|
228725|NCT02413138|Drug|VRS-317|
228726|NCT00002446|Drug|Posaconazole|
228727|NCT00165464|Drug|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
228728|NCT02413151|Behavioral|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
228729|NCT02413151|Device|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
228103|NCT02194205|Drug|COMBIVENT CFC|
228104|NCT02194205|Drug|Placebo CFC|
228105|NCT02194218|Drug|Nevirapine, low dose|50 mg
228106|NCT02194218|Drug|Nevirapine, high dose|100 mg
228107|NCT02194231|Drug|Trabectedin|Trabectedin 1.3 mg/m2 Continuous intravenous infusion in 5% glucose (preceded by dexamethasone 20 mg) via central venous catheter over 3 hours every 21 days.
228108|NCT02194244|Drug|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
228109|NCT00139074|Drug|sodium valproate|oral
228110|NCT02194244|Drug|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
228111|NCT02194257|Drug|[14C]-cyclohexane ambroxol oral solution|
228112|NCT02194257|Drug|[14C]-benzyl ambroxol oral solution|
228113|NCT02194257|Drug|Ambroxol lozenge|
228114|NCT02194270|Drug|Ambroxol hydrochloride - soft pastille|
228115|NCT02194270|Drug|Ambroxol hydrochloride - syrup - low dose|
228116|NCT02194270|Drug|Ambroxol hydrochloride - syrup - high dose|
228117|NCT02194283|Drug|Ambroxol - in single rising doses|
228118|NCT02194283|Drug|Placebo|
228119|NCT02194296|Drug|Ambroxol hydrochloride - lozenge|
228120|NCT00139087|Behavioral|Telephone Outreach for Therapy|
228121|NCT02194296|Drug|Ambroxol hydrochloride - syrup|
228428|NCT02419612|Other|Placebo|
228429|NCT02419625|Behavioral|questionnaires|questionnaires , serum samples will be used
228430|NCT02419638|Drug|Rebif (IFN β-1a subcutaneous three times per week)|
228431|NCT02419638|Drug|Tecifdera (dimethyl fumarate)|
228432|NCT00166400|Drug|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
227465|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
227466|NCT02168192|Behavioral|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
227467|NCT02168192|Behavioral|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
227468|NCT00135967|Drug|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
227469|NCT02168205|Drug|Pomalidomide|Capsules
227791|NCT02160704|Other|Placebo|placebo daily for 16 weeks
227792|NCT02160730|Drug|R-roscovitine|See Arm Description
227793|NCT02160743|Dietary Supplement|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
227794|NCT02160756|Drug|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
227795|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
227796|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
227797|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
227798|NCT02160782|Drug|LUM001|
227799|NCT02160782|Drug|Placebo|
227800|NCT02160808|Drug|Secretin|Drug to stimulate pancreatic secretion
227801|NCT00135226|Drug|Placebo Aspirin|
227802|NCT02160808|Drug|Placebo|
227803|NCT02160821|Procedure|Caudal Epidural|Ultrasound Guided Caudal Block
227804|NCT02160821|Procedure|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
227805|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (3-min break)|Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in "real time."
227147|NCT02173054|Other|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
227148|NCT02173054|Other|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
227149|NCT02173054|Other|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
227150|NCT02173080|Other|PLD-Q|polycystic liver disease questionnaire
227151|NCT02173093|Biological|IL-2|Given SC
227152|NCT02173093|Biological|GD2Bi-aATC|Given IV
227153|NCT00136539|Drug|Adriamycin|Given every three weeks for 12 weeks after surgery.
227154|NCT02173093|Biological|GM-CSF|Given SC
227155|NCT02175927|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
227156|NCT02175927|Drug|Metronidazole|antibiotic of each quadruple therapy
227157|NCT02175927|Drug|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
227158|NCT02175927|Drug|Tetracycline|antibiotic of classical quadruple therapy
227159|NCT00136877|Procedure|(adeno)tonsillectomy|
227470|NCT02168205|Other|Caffeine|Capsules
227471|NCT02168205|Other|Tobacco|Cigarettes
227472|NCT02168218|Other|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
227473|NCT02168231|Procedure|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
227474|NCT02168244|Other|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
227475|NCT02168244|Other|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
227476|NCT02168257|Device|RAM Cannula|
227477|NCT02168257|Device|Binasal Prong CPAP|
227478|NCT02168270|Dietary Supplement|ascorbic acid|Given IV
232520|NCT02406014|Drug|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
232521|NCT00164749|Drug|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
232785|NCT02401802|Dietary Supplement|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
232786|NCT02401815|Drug|PLX9486|PLX9486 tablets, 50mg
232787|NCT00002439|Drug|Alitretinoin|
232788|NCT00164203|Behavioral|activity control condition|weekly games & activities x 12 weeks
232789|NCT02401815|Drug|PLX3397|PLX3397 capsules, 200mg
232790|NCT02401828|Drug|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
232791|NCT02401841|Drug|Two different types of drug for resolution of neuro-muscular blockade|
232792|NCT02401880|Drug|Linagliptin|22 subjects will receive Linagliptin for 30 days
232793|NCT02401880|Other|Placebo|22 subjects will receive Placebo for 30 days
232794|NCT02401880|Drug|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
232795|NCT02401893|Biological|Influenza Vaccine|Everyone immunized as recommended by current guidelines
232796|NCT02401906|Other|MRI|
232797|NCT02401919|Behavioral|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
232798|NCT02401932|Other|Hemophagocytosis|Best supportive care and immunosuppressive treatments
232799|NCT00164216|Drug|mefloquine plus artesunate|
232800|NCT02401945|Drug|DE-120|
232801|NCT02401945|Drug|Aflibercept|
232802|NCT02401958|Other|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
232803|NCT02401971|Drug|Thalidomide|Given orally
232207|NCT02412371|Radiation|Radiotherapy|Radiation treatment administered on Day 1 through Day 5 of each week for approximately 30-34 visits.
232208|NCT02412371|Other|Placebo for Veliparib|Oral capsule of varying doses
232209|NCT02412384|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
232210|NCT02412384|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
232211|NCT02412397|Procedure|Total Shoulder Arthroplasty|
232212|NCT02412410|Behavioral|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
232213|NCT02412423|Drug|post-transplantation cyclophosphamide|
232214|NCT02412436|Drug|depot medroxyprogesterone acetate|At study entry/week 0, participants will receive DMPA 150 mg administered intramuscularly (IM) as a single-dose.
232522|NCT02406027|Drug|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2*5 mg), orally, once daily.
232523|NCT02406027|Drug|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
232524|NCT02406027|Drug|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
232525|NCT02406040|Other|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
232526|NCT02408068|Drug|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
232527|NCT00165048|Drug|Vioxx (Rofecoxib)|
232528|NCT02408068|Drug|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
232529|NCT02408068|Drug|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
232530|NCT02408081|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
231914|NCT02418949|Drug|Placebo for Cyproheptadine|Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.
Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug
231915|NCT02418949|Other|Active Movement Practice (AMP)|Participants will alternate between active training with a custom video game and a robot active-assistive Voice and EMG-Driven Actuated (VAEDA) glove during active training occupational therapy.
231916|NCT02418949|Other|Passive Cyclical Stretching|Participants will wear the actuated device/glove for the duration of the training sessions (2 20-min stints followed by 10 min of rest) during which time the actuated glove will cyclically stretch the joints of the digits in the hand between flexion and extension while remaining passive/relaxed.
231917|NCT00166283|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
231918|NCT02418962|Biological|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
231919|NCT02418962|Other|Normal Saline|0.9% Sodium chloride solution for injection
231920|NCT02418975|Other|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
231921|NCT02418975|Other|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
231922|NCT02418988|Drug|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
232215|NCT00165412|Procedure|breast MRI|Repeated once a year for three years
232216|NCT02412449|Drug|AKB-6548 tablet, reference formulation given in the fasted state|
232217|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fasted state.|
232218|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fed state|
232219|NCT02412462|Drug|AB-16B5|
232220|NCT02412475|Drug|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
232221|NCT02412475|Drug|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
232222|NCT02412475|Drug|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
226923|NCT02188719|Procedure|Leukapheresis|Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.
Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level >/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level </=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis.
226924|NCT02188719|Procedure|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
226925|NCT02188719|Procedure|Liver biopsies|Subjects will be followed for 40 weeks after transplant, during which liver biopsy samples will be collected and analyzed per protocol.
226926|NCT00138632|Drug|PTK787|Visudyne® + PTK787 1000 mg/day
226927|NCT02191033|Behavioral|Smoking counseling|
226928|NCT02191033|Behavioral|Text messaging|
226929|NCT02191033|Drug|Nicotine patch|
226930|NCT02191046|Device|squeezable bottle|nasal irrigation twice daily for 2 weeks period
226931|NCT02191046|Device|syringe 20 ml|nasal irrigation twice daily for 2 weeks
226932|NCT02191059|Drug|Icotinib|
226933|NCT02191059|Drug|Docetaxel|
226934|NCT02191072|Drug|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
226935|NCT02191085|Procedure|Fast Track|In the "Fast Track" arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the "Fast Track" clinic to assist with the assessment of patients who appear unwell. As in the "Standard Management" arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP.
226936|NCT02191098|Drug|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
226937|NCT00138632|Drug|Placebo|Visudyne® + Placebo
226938|NCT02191111|Behavioral|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
226331|NCT02162745|Drug|Isotonic solution (NaCl 0.9%)|
226332|NCT02162745|Drug|Hypertonic solution (NaCl 3%)|
226333|NCT02162758|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules
226334|NCT02162758|Drug|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
226335|NCT02162771|Biological|rituximab|
226336|NCT02162771|Biological|CT-P10|
226337|NCT02162784|Drug|Budesonide/Procaterol, 180/10mcg X1|one puff
226338|NCT02162784|Drug|Budesonide/procaterol 180/10 mcg X 2|2 puffs
226630|NCT02157519|Other|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
226631|NCT02157532|Procedure|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
226632|NCT02157532|Drug|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
226633|NCT02157558|Drug|Fexofenadine|All subjects will receive 180 mg fexofenadine
226634|NCT00134732|Biological|Live attenuated human rotavirus vaccine|
226635|NCT02157558|Drug|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
226636|NCT02157571|Drug|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
226637|NCT02157571|Drug|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
226638|NCT02157571|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
226639|NCT02157571|Drug|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
226640|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
226641|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
226008|NCT02172469|Drug|Placebo Metered Dose Inhaler|
226009|NCT02172469|Drug|Ipratropium Bromide Metered Dose Inhaler|
226010|NCT02172469|Drug|Placebo inhalation powder capsule|
226011|NCT02172482|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
226012|NCT02172495|Drug|Tiotropium bromide|Tiotropium bromide 18 micrograms
226013|NCT02172508|Drug|Tiotropium Inhalation Capsule|
226014|NCT02172508|Drug|Placebo Lactose Capsule|
226015|NCT02172521|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
226016|NCT00136461|Drug|Bryostatin 1|
226017|NCT02172534|Drug|Tiotropium bromide low|
226018|NCT02172534|Drug|Tiotropium bromide medium|
226019|NCT02172534|Drug|Tiotropium bromide high|
226020|NCT02172534|Drug|Placebo|
226021|NCT02172547|Drug|Spiriva|
226022|NCT02172560|Drug|Tiotropium|
226023|NCT02172573|Drug|Pramipexole|
226024|NCT02172573|Drug|Bromocriptine|
226025|NCT02172573|Drug|Placebo pramipexole|
226026|NCT02172573|Drug|Placebo bromocriptine|
226339|NCT02162784|Drug|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
226340|NCT02162797|Dietary Supplement|Zinc supplementation|Intervention group A: Patients who will orally receive zinc for 3 months.
226341|NCT00135408|Drug|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
226342|NCT02165267|Biological|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
225699|NCT02183129|Drug|Meloxicam|
225700|NCT02183142|Drug|Mobic, China, 7.5 mg|
225701|NCT02183142|Drug|Mobic, Germany, 7.5 mg|
225702|NCT02183155|Drug|Meloxicam - low|
225703|NCT02183155|Drug|Meloxicam - medium|
225704|NCT00137748|Drug|CMV-Ig|Drug: CMV-Ig
225705|NCT02183155|Drug|Meloxicam - high|
225706|NCT02183155|Drug|Placebo|
225707|NCT02183155|Drug|Extended-release indomethacin|
225708|NCT02183168|Drug|Meloxicam suppository|
225709|NCT02183168|Drug|Meloxicam tablet|
225710|NCT02183168|Drug|Indomethacin|
225711|NCT02183181|Drug|Meloxicam capsule|
225712|NCT02183181|Drug|Meloxicam tablet|
225713|NCT02183194|Device|Lutonix Paclitaxel Drug Coated Balloon|
225714|NCT02183207|Procedure|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
225715|NCT00137761|Drug|ZD 1839|Taken orally once daily
225716|NCT02183220|Drug|Metamizol|
225717|NCT02183220|Drug|Acetylsalicylic acid (ASA)|
225718|NCT02183220|Drug|Metamizol placebo|
225719|NCT02183220|Drug|ASA placebo|
225720|NCT02183233|Drug|Eschscholtzia Californica|
225721|NCT02183233|Drug|Eschscholtzia Californica Placebo|
225722|NCT02183246|Drug|Porfiromycin|
225723|NCT02183246|Drug|Placebo|
225724|NCT02183246|Radiation|Radiotherapy|
225062|NCT02159625|Device|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
225384|NCT02193061|Biological|RotaTeq|
225385|NCT02193074|Drug|IONIS-SMN Rx|Administered by intrathecal injection
225386|NCT02193074|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
225387|NCT02193087|Drug|Study Drug 1|
225388|NCT02193087|Drug|TDV Study Drug 2|
225389|NCT02193087|Drug|Study Drug 3|
225390|NCT02193087|Drug|TDV Placebo|Takeda's tetravalent dengue placebo-matching vaccine
225391|NCT02193113|Drug|KVD001 Injection|A novel plasma kallikrein inhibitor
225392|NCT02193126|Other|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
225393|NCT02193139|Drug|WL8713, 6 mg|
225394|NCT00138918|Biological|OGX-011|See Detailed Description, Treatment Plan
225395|NCT02193139|Drug|WL8713, 12 mg|
225396|NCT02193139|Drug|WL8713, 18 mg|
225397|NCT02193139|Drug|WL8713, 24 mg|
225398|NCT02193139|Drug|Placebo|
225399|NCT02193152|Drug|Pazopanib|
225400|NCT02193165|Drug|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
224764|NCT02164630|Other|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
224765|NCT02164643|Drug|Flutemetamol (18F)|
224766|NCT02164643|Drug|Florbetapir (18F)|
224767|NCT02164656|Behavioral|mindfulness for smokers|
224768|NCT02164682|Procedure|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
224769|NCT02164682|Procedure|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
224770|NCT02164695|Procedure|Remote ischemic perconditioning (RIPC)|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
224771|NCT02167191|Behavioral|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
224772|NCT02167204|Radiation|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
224773|NCT02167204|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET/CT
225063|NCT02159638|Device|Guardian Enlite sensor|Sensor insertion
225064|NCT02159638|Device|Dexcom G4 platinum sensor|Sensor insertion
225065|NCT02159651|Drug|Prograf|oral
225066|NCT02159664|Other|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
225067|NCT02159677|Device|EIM Measurements|
225068|NCT02159690|Drug|Enzalutamide|160mg
225069|NCT02159690|Drug|Abiraterone acetate|1000mg
225070|NCT00135096|Drug|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
225071|NCT02159690|Drug|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
225072|NCT02159690|Drug|Dutasteride|0.5mg
225073|NCT02159690|Drug|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
224452|NCT02169505|Drug|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
224453|NCT02171715|Drug|BIBW 2992 MA2|powder for oral solution
224454|NCT02171728|Drug|BIBW 2992|
224455|NCT02171741|Drug|BIBW 2992|continuous daily dosing for 20 or 13 days
224456|NCT02171741|Drug|Docetaxel|single infusion on day 1
224457|NCT02171754|Drug|BIBW 2992|
224458|NCT02171754|Drug|Ritonavir|
224459|NCT02171767|Drug|BIBW 2992 MA2 - single rising dose|
224460|NCT00002276|Drug|Zidovudine|
224461|NCT00136435|Drug|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
224462|NCT02171780|Drug|BI 1744 CL|
224463|NCT02171780|Drug|Placebo|
224464|NCT02171793|Drug|BI 1744 CL|
224465|NCT02171793|Drug|Placebo|
224466|NCT02171806|Drug|BI 1744 CL|
224467|NCT02171806|Drug|Placebo|
224468|NCT02171819|Biological|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1 is formulated to contain 7.5 mcg or 15 mcg hemagglutinin (HA) and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose, and filled in single dose vials. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 0.02%) and sucrose (not more than 2.0%).
IVACFLU-A/H5N1 is a sterile, slightly opalescent suspension after shaking well. Antibiotics are not used in the manufacture of IVACFLU-A/H5N1. IVACFLU-A/H5N1 does not contain latex.
224469|NCT02171819|Biological|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1 is formulated to contain 7.5 mcg or 15 mcg hemagglutinin (HA) and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose, and filled in single dose vials. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 0.02%) and sucrose (not more than 2.0%).
IVACFLU-A/H5N1 is a sterile, slightly opalescent suspension after shaking well. Antibiotics are not used in the manufacture of IVACFLU-A/H5N1. IVACFLU-A/H5N1 does not contain latex.
224470|NCT02171819|Biological|Placebo Comparator|Placebo (PBS) will be manufactured by IVAC. PBS, pH 7.2, will also be in 0.5 mL single-dose vials. Every vial contain : Nacl 4.500mg;Na2HPO4.2H2O: 0.685 mg; NaH2PO4.2H2O:0.186 mg and Water For Injection (qs):0.5 mL
224471|NCT02171832|Drug|BI 1744 CL, low dose|
224472|NCT00136435|Radiation|cranial radiation|Given in 10 daily treatments during CNS therapy phase
224152|NCT02179788|Drug|Placebo|The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:
Days 1-7, take 1 capsule with evening meal
Days 8-14, take 3 capsules with evening meal
Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal
Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.
224153|NCT02179814|Drug|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
224475|NCT02171871|Other|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
224476|NCT02171884|Other|Sample of cord blood|
224477|NCT02171884|Other|Sample of placenta|
224478|NCT02171897|Procedure|Osteosynthesis|
224479|NCT02171897|Procedure|Total hip replacement|
224480|NCT02174731|Drug|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
224481|NCT02174731|Drug|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
224482|NCT02174744|Other|numeric pain rating scale|
224483|NCT02174757|Drug|Inersan|Probiotic
224484|NCT02174757|Drug|Doxycycline|Antibiotic
224485|NCT02174770|Other|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
224486|NCT02174770|Other|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
224487|NCT02174783|Other|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
224488|NCT00002279|Drug|Zalcitabine|
224489|NCT00136747|Drug|bupropion|
229010|NCT02406833|Procedure|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
229011|NCT02406846|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
229012|NCT00002441|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
229013|NCT02408887|Procedure|Prophylactic central neck lymph node dissection(pCND)|Lymph node dissection
229014|NCT02408913|Biological|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
229015|NCT02408913|Biological|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
229016|NCT02408926|Biological|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
229017|NCT02408926|Biological|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
229018|NCT02408926|Biological|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
224154|NCT02179814|Drug|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
224155|NCT02179814|Drug|Placebo|Placebo at the second, third and fourth medication intake time point
224156|NCT00137332|Drug|GAP-486 (ZP-123)|
224157|NCT02182479|Drug|Placebo MDI|
224158|NCT02182492|Drug|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
224159|NCT02182492|Drug|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
224160|NCT02182505|Drug|Berodual® Respimat®, low dose|
224161|NCT02182505|Drug|Berodual® Respimat®, high dose|
224162|NCT02182505|Drug|Berodual® MDI|
224163|NCT02182518|Drug|Epinastine|
224164|NCT00137670|Device|Video-based HIV/STD prevention intervention|
224165|NCT02182518|Drug|Pseudoephedrine|
224166|NCT02182518|Drug|Placebo|Placebo during run-in period
228730|NCT02413164|Other|A multimodal physiotherapy programme|Intervention group: One-hour sessions will be conducted two times per week during 12 weeks, consisting of An individualised Multimodal Physiotherapy Programme (MMPP) of therapeutic exercises combined with education healthy-style-of-life based.
Each session will be comprised of 60 min of land-based exercise. Land-based exercise included 10 minute of warm up, 25 minutes of a individual aerobic circuit-training, 15 min of full-body mobility and strecthing exercises and 10 minutes of warm-down.
Control group: care as usual
228731|NCT02413177|Behavioral|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
228732|NCT02413177|Behavioral|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
228733|NCT02413203|Drug|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
228734|NCT02413203|Drug|Placebo|Blood and urine collections before and 3 hours after placebo administration.
228735|NCT02413216|Behavioral|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
229019|NCT02408926|Biological|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
229020|NCT00165100|Procedure|Dynamic Area Telethermometry (DAT)|
229021|NCT02408939|Drug|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
229022|NCT02408952|Behavioral|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
229023|NCT02408952|Behavioral|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
229024|NCT02408965|Drug|Methergine|
229025|NCT02408965|Drug|Placebo|
229026|NCT02408978|Drug|OXP005|
229027|NCT02408978|Drug|Naproxen|
228433|NCT02419651|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
228434|NCT02419651|Drug|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
228435|NCT02419651|Drug|Placebo|Women will receive a placebo 1 hour before the procedure
228436|NCT02419664|Procedure|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
228437|NCT02419677|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
228438|NCT02419677|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
228439|NCT02419690|Behavioral|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
228440|NCT02419703|Device|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
228441|NCT02419716|Device|Cologuard|Prescription of Cologuard for at-home stool collection
228442|NCT02419729|Device|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
228443|NCT00166413|Drug|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
228444|NCT02419729|Drug|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
228445|NCT02419729|Drug|Placebo of Estrogen|Placebo of topical estrogen cream.
228446|NCT02419729|Device|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
228447|NCT02419742|Drug|Carboplatin|Carboplatin Dose=Area Under Curve [AUC], 6 mg*mL/min X (Glomerular Filtration Rate [GFR] + 25) administered I.V. over 1 hour every 3 weeks for 6 cycles.
228448|NCT02419742|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m^2 administered as a 5 to 60 minute I.V. bolus injection every 3 weeks for 4 cycles.
227806|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (6-min break)|Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in "real time."
227807|NCT02160847|Behavioral|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
227808|NCT02160873|Other|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
227809|NCT02160873|Other|flavor-matched placebo|
227810|NCT02160886|Behavioral|child-goal|The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.
The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.
The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.
The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions.
228122|NCT02194309|Drug|Telmisartan low|
228123|NCT02196818|Device|Mpact Acetabular Shell|Total Hip Replacement
228124|NCT02196831|Drug|tesamorelin|
228125|NCT02196831|Drug|Placebo|inactive substance that looks like tesamorelin
228126|NCT02196844|Behavioral|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
228127|NCT02196844|Behavioral|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
228128|NCT02196844|Other|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
228129|NCT02196857|Drug|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
228130|NCT02196857|Drug|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
228131|NCT00139347|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
228132|NCT02196883|Procedure|Transforaminal Epidural Steroid Injection|
228133|NCT02196896|Other|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
228134|NCT02196896|Other|Information|The patients receive online information about depression once a week for 90 days.
227479|NCT00135980|Behavioral|professional audit and feedback|
227480|NCT02168270|Drug|temozolomide|Given PO
227481|NCT02168270|Other|quality-of-life assessment|Ancillary studies
227482|NCT02168270|Other|laboratory biomarker analysis|Correlative studies
227483|NCT02168283|Procedure|treatment arm|The regular PD fluid regimen will be changed from 1.5% to 2.5% in one or two of the daily bag-exchange.
227484|NCT02168283|Behavioral|Control arm|Dietary counseling
227485|NCT02168296|Dietary Supplement|Plant-based ingredient added to starchy meal|
227486|NCT02168296|Dietary Supplement|Plant-based ingredient added to liquid|
227487|NCT02168296|Dietary Supplement|No Plant-based ingredient|
227488|NCT02168309|Drug|Labetalol|Titrate up for blood pressure control
227489|NCT02168309|Drug|Nifedipine|Titrate up to achieve blood pressure control
227490|NCT00135980|Behavioral|integrated care programmes|
227491|NCT02168322|Device|collagen membrane|bovine collagen membrane used for selective tissue regeneration
227492|NCT02168322|Device|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
227493|NCT02168335|Other|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
227494|NCT02168335|Other|Sea salt|Unmedicated sea salt
227811|NCT02163226|Behavioral|Questionnaire|Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
227812|NCT00135473|Drug|10% Hemohes® (10% Hydroxyethyl starch)|
227813|NCT02163239|Device|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
227814|NCT02163252|Behavioral|Standard|
227815|NCT02163252|Behavioral|Early Intervention|
227816|NCT02163265|Procedure|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
232804|NCT02401971|Drug|CPT-11|Given Ivgtt
232805|NCT02401984|Other|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
232806|NCT02401997|Behavioral|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
232807|NCT02402010|Behavioral|Adjunctive Yoga|
233097|NCT02397148|Radiation|Computed Tomography|imagery with ionizing radiation
233098|NCT02397148|Radiation|Cone Beam Computed Tomography|imagery with ionizing radiation
233099|NCT02397161|Other|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
233100|NCT02397161|Other|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
233101|NCT02397161|Other|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
233102|NCT02397174|Other|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
233103|NCT02397174|Other|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
233104|NCT02397187|Behavioral|LOOP|The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the "place" where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes.
233105|NCT02397200|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
233106|NCT00163488|Drug|Ciclesonide|
233107|NCT02397200|Dietary Supplement|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
233108|NCT02397213|Drug|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
233109|NCT02397213|Drug|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
233110|NCT02397226|Procedure|Radiofrequency ablation|
232531|NCT02408107|Behavioral|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
232532|NCT02408120|Drug|Insulin glargine|Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.
Daily insulin dose will be adjusted as follow:
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day
If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day
If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.
232533|NCT02408120|Drug|Insulin aspart|Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.
Daily insulin dose will be adjusted as follow:
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day
If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day
If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.
232808|NCT02402010|Behavioral|Enhanced Treatment as Usual|
232809|NCT02402023|Behavioral|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
232810|NCT02404051|Drug|Everolimus|10 mg daily tablets
232811|NCT02404051|Drug|Exemestane|25 mg daily tablets
232812|NCT02404051|Drug|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
232813|NCT02404064|Drug|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
232814|NCT00164528|Behavioral|Positive Behavior Support|
232815|NCT02404064|Drug|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
232816|NCT02404064|Drug|Placebo|No perioperative antibiotics
232817|NCT02404077|Drug|Clonidine|
232818|NCT02404090|Radiation|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
232819|NCT02404103|Drug|Flunisolide HFA|
232223|NCT02414581|Drug|Ethyl Alcohol 7%|Mouth rinse with Ethyl Alcohol 7%-based solution
232224|NCT02414594|Drug|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
232225|NCT02414594|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
232226|NCT02414607|Biological|Elderberry Juice|
232227|NCT02414607|Other|Placebo|
232228|NCT02414620|Device|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
232229|NCT02414646|Biological|Trastuzumab Emtansine|Given IV
232230|NCT02414646|Other|Questionnaire Administration|Ancillary studies
232231|NCT02414646|Other|Laboratory Biomarker Analysis|Correlative studies
232232|NCT00165633|Drug|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
232233|NCT02414646|Other|Quality-of-Life Assessment|Ancillary studies
232234|NCT02414659|Procedure|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
232235|NCT02414672|Behavioral|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
232236|NCT02414685|Drug|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
232237|NCT02414685|Drug|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
232534|NCT02408120|Drug|Supplemental insulin aspart|Insulin aspart will be administered following the supplemental insulin scale protocol.
For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:
BG >141-180 mg/dL; 2-4 units of insulin aspart
BG between 181-220 mg/dL; 3-6 units of insulin aspart
BG between 221-260 mg/dL; 4-8 units of insulin aspart
BG between 261-300 mg/dL; 5-10 units of insulin aspart
BG between 301-350 mg/dL; 6-12 units of insulin aspart
BG between 351-400 mg/dL; 7-14 units of insulin aspart
BG > 400 mg/dL; 8-16 units of insulin aspart
For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:
BG between 261-300 mg/dL; 5-10 units of insulin aspart
BG between 301-350 mg/dL; 6-12 units of insulin aspart
BG between 351-400 mg/dL; 7-14 units of insulin aspart
BG > 400 mg/dL; 8-16 units of insulin aspart
226939|NCT02191124|Drug|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
227250|NCT02183792|Drug|Furosemide|
227251|NCT02183805|Drug|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
227252|NCT02183831|Device|Insertion of the capsular tension ring|
227253|NCT02183844|Behavioral|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
227254|NCT02183857|Device|Ultrasound|
227255|NCT02183857|Other|Landmark|
227256|NCT02183870|Drug|Crizotinib|250mg crizotinib bid until end of treatment
227257|NCT02183883|Drug|Afatinib|40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.
EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade > 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg.
227258|NCT00002287|Drug|Zidovudine|
227259|NCT00137852|Drug|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
227260|NCT02186210|Device|prewarming|recovery slope StO2
227261|NCT00138008|Drug|endocrine therapy|Drug: endocrine therapy
227262|NCT02186223|Device|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
227263|NCT02186249|Drug|Nivolumab|
227264|NCT02186249|Drug|Ipilimumab|
227265|NCT02186275|Drug|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|Weight at inclusion < 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.
Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.
227266|NCT02186275|Drug|Vitamin D3 800 UI/day then 800 UI/day|Weight < 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance
Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance
226642|NCT02157597|Other|NIRS based management|Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair
Deepen anesthesia with volatile or intravenous agent.
Consider Extra-Corporeal Membrane Oxygenation (ECMO).
226643|NCT02157597|Other|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
226644|NCT02157610|Behavioral|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
226645|NCT00134745|Drug|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
226646|NCT02157610|Drug|Nicotine Patch|Participants receive a 6-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke >10 cigarettes/day receive 4 weeks of 21 mg, 1 week of 14 mg, and 1 week of 7 mg patches. Those who smoke 5-10 cigarettes/day receive 4 weeks of 14 mg and 2 weeks of 7 mg patches. Participants who smoke < 5 cigarettes/day given 6 weeks of 7 mg patches.
226647|NCT02157610|Behavioral|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
226648|NCT02157610|Procedure|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
226940|NCT02191124|Drug|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
226941|NCT02191137|Drug|Riociguat (Adempas,BAY63-2521)|Oral riociguat titrated from 0.5 mg to 2.5mg (max. dose) TID for 24 weeks
226942|NCT02191163|Drug|Antistax®|
226943|NCT02191163|Drug|Placebo|
226944|NCT02191176|Drug|Dextromethorphan syrup - low dose|
226945|NCT02191176|Drug|Dextromethorphan syrup - high dose|
226946|NCT02191176|Drug|Placebo|
226947|NCT02191189|Drug|Nevirapine suspension, into Enterion™ capsule|
226948|NCT00138645|Behavioral|MicroDiet|MicroDiet
226949|NCT02191189|Drug|Nevirapine suspension|
226950|NCT02191202|Drug|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
226951|NCT02191215|Drug|Nevirapine (Viramune®)|
226952|NCT02193750|Dietary Supplement|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
226343|NCT02165267|Biological|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
226344|NCT02165280|Behavioral|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
226345|NCT00135642|Procedure|Venepuncture: 20 ml blood sample taken on 2 separate visits|
226346|NCT02165293|Drug|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
226347|NCT02165306|Behavioral|Motivational Interviewing (MI)|A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.
Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.
Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure
226348|NCT02165306|Behavioral|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
226349|NCT02165319|Device|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
226350|NCT02165319|Device|Tapered|Tapered-shaped tube will be used during general anesthesia.
226351|NCT02165332|Drug|Part 1: SAD RO7033877|Single dose
226352|NCT02165332|Drug|Part 1: SAD placebo|Single dose
226353|NCT02165332|Drug|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
226354|NCT02165332|Drug|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
226355|NCT02165332|Drug|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
226356|NCT00135655|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
226357|NCT02165332|Drug|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
226649|NCT02157610|Behavioral|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
226650|NCT02157623|Drug|Levulan|Levulan application followed by Red or Blue light PDT on randomized treatment fields
226651|NCT02160236|Drug|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
225725|NCT02183259|Drug|ESR 1150 CL, Capsule, oral|
225726|NCT00137761|Drug|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
226027|NCT00136474|Drug|Amifostine|Given 30-60 minutes prior to daily radiation therapy
226028|NCT02172586|Drug|Telmisartan|
226029|NCT02172586|Drug|Losartan|
226030|NCT02172586|Drug|Hydrochlorothiazide|
226031|NCT02175381|Drug|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
226032|NCT02175381|Drug|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
226033|NCT00136812|Behavioral|Tobacco Use Cessation|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
226034|NCT02175394|Drug|Microgynon®|
226035|NCT02175394|Drug|BI 1356|
226036|NCT02175407|Drug|ASP1707|oral
226037|NCT02175407|Drug|itraconazole|oral
226038|NCT02175420|Biological|BCG|
226039|NCT02175420|Biological|TFV|
226040|NCT02175433|Drug|AGS67E|intravenous (IV) infusion
226041|NCT02175446|Drug|Bevacizumab and eribulin|In this study, Bevacizumab and Eribulin are considered to be the "investigational study drugs". Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water
226042|NCT02175472|Device|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
226043|NCT02175472|Device|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
226044|NCT00002280|Drug|Didanosine|
226045|NCT00136825|Drug|N-Acetylcysteine|
225401|NCT02193165|Drug|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
225402|NCT02193165|Drug|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
225403|NCT02193191|Drug|Plerixafor|
225727|NCT02183259|Drug|ESR 1150 CL, solution, intravenous|
225728|NCT02183272|Drug|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
225729|NCT02183272|Drug|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
225730|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 soft gelatine capsules|
225731|NCT02185612|Behavioral|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
225732|NCT02185625|Device|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
225733|NCT02185638|Other|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
225734|NCT02185651|Drug|Zavesca® Prescription|Following baseline evaluation, Zavesca® prescription is given.
Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.
225735|NCT02185664|Procedure|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
225736|NCT02185664|Device|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
225737|NCT02185677|Other|Clinical evaluation|
225738|NCT02185677|Other|neuropsychological battery test|
225074|NCT02159703|Procedure|TORS|
225075|NCT02159703|Radiation|Adjuvant Radiation Therapy|
225076|NCT02159716|Biological|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
225077|NCT02159729|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
225078|NCT02159729|Drug|ATX-101 (1 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
225079|NCT02159729|Drug|ATX-101 (2 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
225080|NCT02159729|Drug|ATX-101 (4 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
225081|NCT00135096|Drug|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
225082|NCT02159742|Other|Data Collection|
225083|NCT02159755|Drug|Ibrutinib|Given PO
225084|NCT02159755|Other|Laboratory Biomarker Analysis|Correlative studies
225085|NCT02159755|Drug|Palbociclib|Given PO
225086|NCT02159755|Other|Pharmacological Study|Correlative studies
225404|NCT02193204|Behavioral|Personal Stress Imagery|The stress imagery script will be based on participants' description of a recent personal event experienced as "most stressful", and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
225405|NCT00138931|Procedure|Blood draw (genetic testing)|Blood draw (genetic testing)
225406|NCT02195609|Dietary Supplement|Soy Isoflavones|54.4 mg oral twice a day
225407|NCT02195622|Device|Lumenis VersaCut Morcellator|
225408|NCT02195622|Device|Wolf Piranha Morcellator|
225409|NCT02195635|Drug|Telotristat etiprate|500 mg telotristat etiprate
225410|NCT02195635|Drug|Octreotide acetate|200 µg octreotide acetate three times daily
224473|NCT02171832|Drug|BI 1744 CL, high dose|
224474|NCT02171845|Other|surgical biopsies|
224774|NCT02167204|Procedure|Computed Tomography|Undergo 18F-FLT PET/CT
224775|NCT02167217|Drug|Prednisolone|Prednisolone (5mg per kg )will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
224776|NCT02167230|Procedure|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
224777|NCT02167230|Procedure|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
224778|NCT02167243|Behavioral|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
224779|NCT00135837|Drug|Verteporfin for injection|
224780|NCT02167243|Other|Standard of care|
224781|NCT02167256|Drug|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
224782|NCT02167256|Drug|AZD0530 125mg daily|Patients with plasma drug level <70ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
224783|NCT02167256|Drug|Placebo|50% of patients will receive placebo treatment for the duration of the study.
224784|NCT02167269|Device|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
224785|NCT02167308|Device|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
224786|NCT02167321|Drug|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
224490|NCT02174783|Other|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
224491|NCT02174783|Other|Protein-Sparing Modified Fast (PSMF)|Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.
Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.
Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards.
224492|NCT02174796|Procedure|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
224493|NCT02174796|Procedure|orthopedic treatment|orthopedic treatment by vacuum bell.
224789|NCT02169531|Drug|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
224790|NCT02169544|Drug|Abatacept|
224791|NCT02169557|Drug|Fexinidazole|
224792|NCT02169570|Dietary Supplement|Vitamin D|
224793|NCT02169570|Dietary Supplement|Calcium|
224794|NCT02169570|Dietary Supplement|Placebo Vit D|
224795|NCT00136149|Procedure|Immediate implants|Immediate implants are used.
224796|NCT02169570|Dietary Supplement|Placebo Calcium|
224797|NCT02169583|Drug|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
224798|NCT02169583|Drug|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
224799|NCT02169583|Drug|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
224800|NCT02169583|Drug|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
224801|NCT02169596|Other|Blood Test|Blood tests taken for flow cytometry
224802|NCT02169596|Other|EndoPAT - endothelial assessment|
224803|NCT02169609|Drug|Dinutuximab. Immunotherapy|Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.
Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy.
224167|NCT02182531|Drug|Epinastine|
224168|NCT02182531|Drug|Pseudoephedrine|
224169|NCT02182531|Drug|Epinastine + Pseudoephedrine combination|
224170|NCT02182544|Drug|WAL801CL dry syrup|
224171|NCT02182544|Drug|Ketotifen fumarate dry syrup|
224172|NCT02182544|Drug|Ketotifen fumarate dry syrup placebo|
224173|NCT02182544|Drug|WAL 801 CL dry syrup placebo|
224174|NCT02182557|Drug|WAL 801 CL Dry Syrup|
224175|NCT00137683|Behavioral|one-on-one education, group education, small media|
224176|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup|
224177|NCT02182557|Drug|WAL 801 CL Dry Syrup placebo|
224178|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup placebo|
224179|NCT02182570|Drug|WAL 801 CL dry syrup|
224180|NCT02182583|Drug|Ba253MDI|
224181|NCT02182583|Drug|Ba253BINEB|
224494|NCT02174809|Behavioral|Use of 5As to discuss gestational weight gain|
224495|NCT02174809|Behavioral|Usual care|
224496|NCT02174822|Drug|AVP-786|
224497|NCT02174822|Drug|Paroxetine|
224498|NCT02174822|Drug|Duloxetine|
224499|NCT02174835|Drug|AVP-786|
224500|NCT00136747|Drug|placebo|
224501|NCT02174835|Drug|AVP-923|
224502|NCT02174848|Drug|Deferiprone oral solution|Oral iron chelator
224503|NCT02174848|Drug|Deferiprone|Deferiprone oral solution up to 15 mg per kilogram of body weight, twice a day
229028|NCT02408991|Drug|Neupogen|Neupogen is given as an injection in your skin every three days for a total of 5 doses.
229029|NCT02408991|Device|Art-Assist Device|The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
229030|NCT02409004|Drug|Ataluren|
229031|NCT00002442|Drug|Lamivudine|
229032|NCT00165126|Procedure|Radiation therapy|Given as standard therapy
229033|NCT02409004|Drug|Rifampin|
229034|NCT02409017|Procedure|Insulin drip|
229035|NCT02409043|Other|Blood draw|Blood drawn for comparison with other groups
229036|NCT02409043|Other|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
229037|NCT02409056|Behavioral|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
229038|NCT02409056|Behavioral|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
224182|NCT02182596|Drug|Mylotarg|Dose level study
224183|NCT02182609|Drug|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
224184|NCT02182622|Drug|Docetaxel|
224185|NCT02182622|Drug|Prednisone|
224186|NCT00137696|Biological|Vaccination with inactivated polio vaccine|
224187|NCT02182622|Drug|LDE225|
224188|NCT02182635|Drug|Ba253BINEB|
224189|NCT02182648|Drug|etomidate|intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.
infusion of etomidate at 2 minutes before anesthesia induction
224190|NCT02185053|Drug|CPC-201|
224191|NCT02185066|Drug|Atorvastatin 20mg and Metformin XR 500mg (Reference)|Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.
Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.
228736|NCT02415491|Other|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.
Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.
Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency.
228737|NCT00165724|Drug|Donepezil Hydrochloride|
228738|NCT02415504|Behavioral|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
228739|NCT02415504|Behavioral|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
228740|NCT02415517|Behavioral|Cognitive training|Cognitive training on computer. Six sessions with different tasks: "Tiere merken" & "Räumlich visuelles Training" (application BrainTwister) and "Taskswitching" (programmed with eprime)
228741|NCT02415517|Behavioral|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
228742|NCT02415530|Behavioral|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3~6 months
228743|NCT02415543|Procedure|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
228744|NCT02415543|Procedure|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
228745|NCT02415556|Drug|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
228746|NCT02415556|Drug|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
228747|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
228748|NCT00165737|Drug|Donepezil Hydrochloride|
228135|NCT02196909|Other|motor function and strength assessment|
228136|NCT02196909|Other|NMR assessment|
228137|NCT02196909|Other|24h urine and serum collection|
228138|NCT02196922|Device|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
228139|NCT02196922|Other|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
228140|NCT02196935|Other|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
228141|NCT02196948|Other|Electrolysis Percutaneous Therapeutic (EPTE)|
228142|NCT00139360|Drug|Bevacizumab|Anti angiogenesis treatment
228143|NCT02196948|Other|Eccentric exercise|
228144|NCT02196961|Drug|Ipilimumab|adjuvant treatment of completely resected Merkel cell carcinoma
228449|NCT02421523|Procedure|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of ~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
228450|NCT02421523|Procedure|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of ~30% of the subject's MVC. Subjects will be asked to perform ~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (~50% MVC). Similarly, if no damage has occurred at ~50% MVC, four more subjects exercise at ~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
228451|NCT02421523|Procedure|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
228452|NCT02421536|Other|Vibrogent Smartphone Application|
228453|NCT02421549|Device|Unpaired remote monitoring transmitter|
227817|NCT02163278|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
227818|NCT02163278|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
227819|NCT02163291|Drug|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
227820|NCT02163304|Other|Sucrose|
227821|NCT02163304|Other|Artificial Sweetner|
227822|NCT02163304|Other|Tasteless Solution|
227823|NCT00135473|Drug|Sterofundin® (Ringer lactate solution)|
227824|NCT02163317|Radiation|stereotactic radiosurgery|Undergo MRI-guided focal SRS
227825|NCT02163317|Procedure|magnetic resonance imaging|Undergo staging MRI with contrast
227826|NCT02163317|Other|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
227827|NCT02163317|Procedure|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
227828|NCT02163317|Procedure|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
227829|NCT02163317|Behavioral|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
227830|NCT02163330|Drug|Acetazolamide|
227831|NCT02163330|Drug|sugar pill|
227832|NCT02163356|Drug|Fenretinide/LXS Oral Powder|Oral Powder
228145|NCT02196974|Procedure|cryobiopsy|
228146|NCT02196987|Other|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
228147|NCT02196987|Other|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
228148|NCT02197000|Dietary Supplement|DIM-Avail 100mg|DIM 100 mg*1 daily for 2 years
233111|NCT02397226|Procedure|High ligation/stripping|
233112|NCT02397226|Device|Radiofrequency ablation catheter|
233113|NCT02397226|Procedure|Tumescent anesthesia|
233114|NCT02397226|Procedure|General anesthesia|
233115|NCT02397226|Device|Vein stripping catheter|
233116|NCT02397252|Device|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
233117|NCT00163501|Drug|Ciclesonide|
233399|NCT02427802|Other|Placebo|Matching collagen sponge
233400|NCT02427815|Behavioral|Intervention Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer Educator.
233401|NCT02427828|Device|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
233402|NCT02427841|Drug|Fluorouracil|Given IV
233403|NCT02427841|Drug|Gemcitabine Hydrochloride|Given IV
233404|NCT02427841|Radiation|Image Guided Radiation Therapy|Undergo IG-IMRT
233405|NCT02427841|Radiation|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
233406|NCT02427841|Other|Laboratory Biomarker Analysis|Correlative studies
233407|NCT02427841|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
233408|NCT02427841|Procedure|Therapeutic Conventional Surgery|Undergo surgery
233409|NCT00002456|Drug|methotrexate|
233410|NCT00167700|Dietary Supplement|Prebiotics|
233411|NCT02427854|Behavioral|Education by animated training video|Training performed by watching an animated educational video.
233412|NCT02427854|Procedure|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
233413|NCT02427867|Other|Remote ischemic preconditioning|
233414|NCT02427867|Other|no ischemic preconditioning|
232820|NCT02404116|Other|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
232821|NCT02404116|Other|Wait List|Individuals are on a waiting list
232822|NCT02404129|Other|Turn 180 test|The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed "Up and Go" test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor.
232823|NCT02404142|Drug|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
232824|NCT02404142|Drug|saline isotonic solution|
232825|NCT00164541|Behavioral|Arts Based Program|
232826|NCT02404155|Drug|Clozapine|
232827|NCT02404168|Drug|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
232828|NCT02404168|Drug|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
233118|NCT02397252|Device|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
233119|NCT02397252|Procedure|Physician-collected sampling|Routine colposcopy sample collected by a physician.
233120|NCT02399488|Device|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
233121|NCT02399501|Procedure|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
233122|NCT02399501|Device|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
233123|NCT02399501|Device|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
232535|NCT02408133|Other|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
232536|NCT00165178|Drug|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
232537|NCT02410382|Drug|Placebo|oral placebo
232538|NCT02410395|Procedure|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
232539|NCT02410395|Procedure|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
232540|NCT02410408|Device|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
232541|NCT02410408|Other|information package|Information on PSC and RCA
232542|NCT02410421|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
232543|NCT02410434|Other|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
232544|NCT02410447|Device|Defocused shock wave therapy (DUOLITH® SD1)|
232545|NCT02410460|Drug|clonidine|
232546|NCT02410460|Drug|glycopyrrolate|
232547|NCT00165178|Drug|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
232548|NCT02410460|Drug|propofol|
232549|NCT02410460|Drug|ketamine|
232550|NCT02410460|Drug|marcaine|
227267|NCT02186288|Other|High-flow nasal cannula oxygen|
227268|NCT02186301|Drug|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
227269|NCT02186301|Drug|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
227594|NCT02178553|Drug|Epidural|
227595|NCT02178553|Drug|Intercostal Bupivicaine (Exparel)|
227596|NCT02178566|Drug|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
227597|NCT02178592|Drug|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
227598|NCT00137189|Procedure|Standard care|
227599|NCT02178592|Drug|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
227600|NCT02178605|Procedure|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
227601|NCT02178618|Device|Deployment of Partially covered biliary self expandable metal stent|
227602|NCT02178618|Device|Deployment of uncovered biliary self expandable metal stent|
227603|NCT02178631|Behavioral|Deprexis|Online self-help
227604|NCT02178631|Other|CAU|Care as usual
227605|NCT02178644|Drug|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
227606|NCT02178657|Drug|Autologous bone marrow mononuclear cell intra-arterial injection|
227607|NCT02178670|Biological|CSC-DC|
227608|NCT02178683|Drug|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
227609|NCT00137202|Drug|Ondansetron (Zofran)|
227610|NCT02178696|Other|Placebo|Placebo responses will be compared against results of neuroimaging studies with fMRI and PET
226953|NCT00138996|Device|automated direct feedback on CPR from defibrillator|
226954|NCT02193750|Dietary Supplement|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
226955|NCT02193750|Dietary Supplement|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
226956|NCT02193763|Procedure|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
226957|NCT02193776|Drug|Pa-824|oral
226958|NCT02193776|Drug|bedaquiline|oral
226959|NCT02193776|Drug|moxifloxacin|oral
226960|NCT02193776|Drug|pyraziminide|oral
226961|NCT02193776|Drug|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
226962|NCT02193789|Procedure|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
227270|NCT02186314|Device|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
227271|NCT02186314|Device|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
227272|NCT00138008|Procedure|radiotherapy|Procedure/Surgery: radiotherapy
227273|NCT02186327|Behavioral|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
227274|NCT02186340|Procedure|Inspiratory muscle training|
227275|NCT02186353|Behavioral|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
226652|NCT02160236|Drug|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
226653|NCT02160249|Behavioral|Community-based rehabilitation|
226654|NCT02160249|Other|Facility based care|
226655|NCT02160262|Drug|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
226656|NCT02160275|Device|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
226657|NCT00135187|Drug|VELCADE|VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days
1, 4, 8, and 11) followed by a 1-week break.
226658|NCT02160275|Device|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
226659|NCT02160288|Drug|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
226660|NCT02160288|Drug|Normal Saline|Dispensed in a 5 cc syringe
226661|NCT02160301|Drug|Gabapentin|
226662|NCT02160301|Drug|Acetaminophen|PO
226663|NCT02160301|Drug|Acetaminophen|IV
226664|NCT02160301|Drug|Celecoxib|
226665|NCT02160301|Drug|Dexamethasone|IV
226666|NCT02160301|Drug|Oxycodone|PO
226667|NCT02160314|Device|pessary|disposable, single-use pessary
226668|NCT00135187|Drug|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
226669|NCT02160314|Device|Absorbent pad|
226670|NCT02160353|Drug|Abiraterone acetate, Prednisolone|
226671|NCT02160366|Other|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
226672|NCT02160379|Other|standard test meal|
226963|NCT02193789|Device|Covered Self-expandable Metallic Stents|
226964|NCT00002299|Drug|Interferon beta-1b|
226046|NCT02175485|Drug|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
226047|NCT02175498|Drug|Homoeopathic medicines|4 pills once a week of the indicated Similimum
226048|NCT02175511|Device|Cloud-based home BP monitoring|a sphygmomanometer-style BP measurement device (Microlife®, "WatchBP Home") that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network.
226358|NCT02165345|Drug|Tocilizumab|162 mg will be administered by subcutaneous injection at the following intervals: pJIA participants < 30 kg: every 3 weeks; pcJIA participants >/= 30 kg: every 2 weeks; sJIA participants < 30 kg: every 2 weeks; sJIA participants >/= 30 kg: once weekly
226359|NCT02165371|Behavioral|Sinovuyo Caring Families Programme|Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.
Program activities will be delivered over 14 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.
The program is manualized in isiXhosa.
226360|NCT02165384|Device|Ear tube placement with the Hummingbird TTS|Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
226361|NCT02165397|Drug|Ibrutinib|Subjects will receive 420 mg of Ibrutinib orally. Other Name: PCI-32765
226362|NCT00135941|Drug|insulin glargine|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
226363|NCT02167841|Behavioral|Knee-Chest Position|
226364|NCT02167854|Drug|BYL719|
226365|NCT02167854|Drug|LJM716|
226366|NCT02167854|Drug|TRASTUZUMAB|
226367|NCT02167867|Device|ZERONA Z6|20 minutes of treatment to the front side of the waist, hips and thighs and 20 minutes of treatment to the back side of the waist, hips and thighs.
226368|NCT02167893|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
226369|NCT02167906|Other|arterial stiffness measurement|
226370|NCT02167919|Device|Prostatic artery embolization|Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
225739|NCT02185677|Other|MRI|
225740|NCT02185677|Other|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
225741|NCT00137995|Drug|Cisplatine|100 mg/m² from D1 to D13
225742|NCT02185690|Drug|Binimetinib|Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.
MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule.
225743|NCT02185690|Drug|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
225744|NCT02185690|Drug|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
226049|NCT02175537|Behavioral|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
226050|NCT02175550|Device|NR CC|
226051|NCT02175563|Device|Audiovisual feedback from smartphone based app|
226052|NCT02175576|Device|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
226053|NCT02175576|Device|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
226054|NCT02175589|Other|Colchicine Cessation|Colchicine Cessation
226055|NCT02177825|Drug|Imatinib Mesylate|oral administration
226056|NCT00137111|Drug|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
226057|NCT02177838|Biological|cetuximab|Given IV
226058|NCT02177838|Drug|cisplatin|Given IV
226059|NCT02177838|Radiation|external beam radiation therapy|Undergo EBRT
226060|NCT02177838|Other|laboratory biomarker analysis|Correlative studies
226061|NCT02177851|Dietary Supplement|Single oral iron dose of 120 mg per day for 3 consecutive days|
226062|NCT02177851|Dietary Supplement|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
226063|NCT02177864|Dietary Supplement|Fiber|
225411|NCT02195648|Other|Experimental: Treatment of sub-occipital muscle inhibition|Experimental: Sub-occipital muscle inhibition
The intervention will last for 4 weeks with 2 days of treatment at week.
Each of the interventions will consist in application of sub-occipital muscle inhibition technique associated with interferential electrotherapy.
225412|NCT02195661|Dietary Supplement|Melatonin|
225413|NCT02195661|Drug|Chloral Hydrate|
225414|NCT02195687|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
225415|NCT00139230|Drug|G-CSF|
225416|NCT02195687|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
225417|NCT02195700|Drug|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
225418|NCT02195700|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks.
225419|NCT02195713|Device|Accuryn|Accuryn is a novel electronic urine output monitor
225420|NCT02195726|Procedure|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
225421|NCT02195726|Procedure|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
225422|NCT02195752|Other|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
225423|NCT02195765|Drug|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
225424|NCT02195765|Procedure|Open flap debridement|Open flap debridement
225745|NCT02185703|Device|Chordate System S020 in treatment mode|
225746|NCT02185703|Device|Chordate System S020 in placebo mode|
225747|NCT02185716|Drug|Levobupivacaine 0.25 %|
225748|NCT02185716|Drug|Levobupivacaine 0.5%|
225749|NCT02185729|Drug|Intralipid|Infusion of Intralipid (soybean-derived fat)
225750|NCT02185729|Drug|ClinOleic|Infusion of ClinOleic (olive oil-based)
225751|NCT02185729|Drug|Dextrose|Infusion of dextrose (sugar) without fat
224787|NCT02167321|Drug|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
224788|NCT02167334|Device|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
225087|NCT02159768|Device|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
225088|NCT02162212|Other|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c < 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is <130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
225089|NCT02162225|Drug|beet juice (Unbeetable)|Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.
On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28.
225090|NCT02162238|Device|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
225091|NCT02162251|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
225092|NCT02162264|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
225093|NCT02162277|Device|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
225094|NCT02162290|Other|Interval exercise training|Exercise bouts in low and high intensities
225095|NCT02162290|Other|Continuous exercise training|
225096|NCT02162303|Drug|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
225097|NCT02162303|Drug|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
225098|NCT00135369|Drug|stavudine extended-release, lamivudine, efavirenz|
225099|NCT02162316|Drug|Motilitone®|
224804|NCT02169635|Procedure|macular buckle|macular buckle with a three-armed silicone capsule
224805|NCT02169648|Drug|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
224806|NCT00136175|Drug|Paclitaxel|
224807|NCT02169661|Other|Burger and Beetroot Study|50% fat, 10% beetroot extract
224808|NCT02169687|Device|HIFU|High Intensity focalized Ultrasounds
225103|NCT02162329|Procedure|Magnetic Resonance Imaging (fMRI|Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.
Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit.
225104|NCT02162329|Behavioral|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
225105|NCT02164708|Behavioral|Mindfulness Meditation|The program progressively trained students in "mindfulness of breathing", a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice.
225106|NCT02164721|Device|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
225107|NCT00135590|Dietary Supplement|Spread diet|Dietary protein was spread over the four meals.
225108|NCT02164734|Device|Endotracheal intubation|
225109|NCT02164734|Device|Laryngeal mask airway|
225110|NCT02164747|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
225111|NCT02164760|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
225112|NCT02164773|Drug|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
225113|NCT02164773|Drug|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
225114|NCT02164812|Drug|Moxifloxacin|
225115|NCT02164812|Drug|Placebo|
225116|NCT02164812|Drug|Efavirenz|
224504|NCT02177357|Drug|Placebo|
224505|NCT00137046|Drug|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
224506|NCT02177370|Drug|Fenoterol MDI|
224507|NCT02177370|Drug|DSCG MDI|
224508|NCT02177383|Dietary Supplement|Docosahexaenoic acid diet supplementation|Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.
One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells.
224509|NCT02177383|Dietary Supplement|Placebo supplementation|Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.
One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells.
224510|NCT02177396|Drug|Telmisartan|
224511|NCT02177396|Drug|Valsartan|
224512|NCT02177396|Drug|Placebo|
224513|NCT02177409|Drug|Telmisartan|
224514|NCT02177409|Device|Amlodipine|
224515|NCT02177409|Drug|Placebo|
224809|NCT02169700|Procedure|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
224810|NCT02169713|Drug|Mirabegron|Oral
224811|NCT02169713|Drug|Solifenacin succinate|Oral
224812|NCT02169713|Drug|Tamsulosin HCl|Oral
224813|NCT02169713|Drug|Placebo|Oral
224192|NCT02185066|Drug|CJ-30056 20/500mg (Test)|Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.
Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.
224193|NCT02185079|Behavioral|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
224194|NCT02185079|Behavioral|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
224195|NCT02185092|Dietary Supplement|Lactobacillus GG|probiotic supplement
224196|NCT02185118|Drug|oxygen|Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.
Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
224197|NCT02185118|Drug|Sevoflurane|Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.
Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
224198|NCT02185118|Drug|Isoflurane|Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.
Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
224199|NCT02185131|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
224200|NCT00137969|Drug|Acetaminophen|
224516|NCT00137046|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
224517|NCT02177422|Drug|Telmisartan|telmisartan 80 mg once daily
224518|NCT02177422|Drug|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure < 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
224519|NCT02177435|Drug|Telmisartan|
224520|NCT02177435|Drug|Telmisartan/Hydrochlorothiazide|
224521|NCT02177435|Drug|Placebo|
224522|NCT02177448|Drug|BIBR277 low dose|
224523|NCT02177448|Drug|BIBR277 medium dose|
224524|NCT02177448|Drug|BIBR277 high dose|
228749|NCT02415569|Drug|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
229039|NCT02411084|Biological|Conventional Second-line Treatment|There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with "best conventional second-line treatments" which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab.
229040|NCT02411097|Procedure|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
229041|NCT02411110|Device|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
229042|NCT02411110|Device|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
229043|NCT02411123|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
229044|NCT02411136|Drug|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
229045|NCT00165243|Procedure|Tangential radiation|Radiation given over 6 1/2 weeks
229046|NCT02411136|Drug|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
229047|NCT02411149|Drug|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
229048|NCT02411149|Drug|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
229049|NCT02411149|Drug|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
229050|NCT02411162|Drug|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm^2 of skin.
229051|NCT02411162|Drug|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
228454|NCT02421562|Procedure|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
228455|NCT02421575|Drug|Hydroxychloroquine|Given PO
228456|NCT00166712|Drug|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
228457|NCT02421575|Other|Laboratory Biomarker Analysis|Correlative studies
228458|NCT02421588|Drug|Lurbinectedin (PM01183)|
228459|NCT02421588|Drug|Pegylated liposomal doxorubicin (PLD)|
228460|NCT02421588|Drug|Topotecan|
228461|NCT02421601|Drug|Condoliase|1.25 U, intradiscal injection, one time
228462|NCT02421614|Other|high-protein low-carbohydrate diet with high olive oil|
228463|NCT02421614|Other|high-protein low-carbohydrate diet with high sunflower oil|
228464|NCT02421627|Device|moxibustion|Mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin, keeping the spot warm and making it reddened, but not burnt.The temperature maintained at 43 ± 1℃。
228465|NCT02421627|Device|Placebo moxibustion|Placebo mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin (farther than the real moxibustion), keeping the temperature maintained at 37 ± 1℃。
228750|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
228751|NCT02415582|Other|Aerobic exercise|Aerobic exercise on treadmill
228752|NCT02417519|Other|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
228753|NCT02417532|Device|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
228754|NCT02417558|Behavioral|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
228755|NCT02417558|Behavioral|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
228149|NCT02158234|Drug|Cisplatin|Cisplatin 15 mg/m^2 prior to each fraction
228150|NCT02158234|Radiation|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
228151|NCT00134875|Drug|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
228152|NCT02158260|Behavioral|Position changing|
228153|NCT02158273|Drug|Sugar Pill|145 mg/day, oral pill, 9 days
228154|NCT02158273|Drug|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
228155|NCT02158286|Other|Measuring emptying rate from the gastric tube|
228156|NCT02158299|Drug|Avitene|
228157|NCT02158299|Drug|Sapylin|
228158|NCT02158299|Behavioral|axillary drainage|
228159|NCT02158299|Other|reexamine|
228160|NCT02158312|Device|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
228161|NCT02158325|Procedure|anterior capsulorhexis sizes|Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0~3.9, 4.0~5.0, 5.1~6.0 mm in diameter)
228162|NCT00134888|Drug|Buprenorphine/naloxone|
228163|NCT02158338|Other|Asthma|mothers who have children that have been diagnosed with respiratory issues
228164|NCT02158338|Other|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
228165|NCT02158351|Procedure|liver and white adipose tissue biopsies|
228166|NCT02158364|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
228167|NCT02158377|Device|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
228466|NCT02421640|Drug|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
228467|NCT00166725|Drug|Octreotide LAR|
233415|NCT02427880|Drug|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
233416|NCT02427880|Drug|Furosemide and Hydrochlorothiazide Followed by Furosemide|
233417|NCT02427893|Drug|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
233418|NCT02427893|Drug|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
233419|NCT02427919|Drug|G-CSF|Comparison of the effect of G-CSF use
233420|NCT02427932|Drug|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
233421|NCT00167713|Drug|Ibuprofen|
233422|NCT02427932|Drug|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
233704|NCT02421510|Drug|Placebo|Placebo, once daily, before the first meal of the day
233705|NCT02423681|Device|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
233706|NCT00002452|Drug|Indinavir sulfate|
233707|NCT00167206|Procedure|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
233708|NCT02423681|Device|Without ThermoSmart|ThermoSmart is switched off
233709|NCT02423694|Device|electro-acupuncture|8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.
Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5~1.0 mA
233710|NCT02423694|Drug|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
233711|NCT02423707|Drug|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.
The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use.
233712|NCT02423707|Drug|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
233713|NCT02423720|Behavioral|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
233124|NCT02399501|Device|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
233125|NCT02399514|Other|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
233126|NCT02399540|Device|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
233127|NCT00002437|Drug|Cidofovir|
233128|NCT00163891|Behavioral|Chest physiotherapy|
233129|NCT02399540|Device|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
233130|NCT02399540|Device|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
233131|NCT02399540|Device|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
233132|NCT02399553|Other|Soccer boot intervention|
233133|NCT02399566|Drug|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
233134|NCT02399579|Other|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
233423|NCT02427932|Drug|Gentamicin|Prescribed to non-pregnant participants
233424|NCT02427945|Behavioral|Provision of information on safe water|A promoter from Evidence Action will visit the household and provide information on safe water.
233425|NCT02394782|Device|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
233426|NCT02394782|Device|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
233427|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
233428|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|
233429|NCT02394821|Drug|Polihexanide 2%|
233430|NCT00163163|Procedure|Echographic measurements|
232829|NCT02404194|Behavioral|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
232830|NCT02404194|Behavioral|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
232831|NCT02404207|Other|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
232832|NCT02404207|Other|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
232833|NCT02406053|Genetic|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
232834|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
232835|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
232836|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
232837|NCT02406066|Drug|Placebo|Each cohort will have 2 subjects receiving placebo
232838|NCT02406079|Procedure|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
232839|NCT00002440|Drug|Saquinavir|
232840|NCT00164749|Drug|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
232841|NCT02406092|Drug|Rituximab|Rituximab sub-cutaneous (SC), 1400
232842|NCT02406105|Radiation|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
232843|NCT02406105|Drug|CyberKnife|
232844|NCT02406118|Procedure|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
227611|NCT02181283|Behavioral|W+P|Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored "change plan".
Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support.
227612|NCT02181296|Drug|ropivacaine|
227613|NCT00137475|Procedure|Intensity-Modulated Radiation Therapy|
227614|NCT02181309|Drug|Meloxicam, low dose|
227615|NCT02181309|Drug|Meloxicam, medium dose|
227914|NCT02173405|Drug|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
227915|NCT02173418|Drug|Phrenic nerve block with Ropivacaine|
227916|NCT02173444|Other|Blood test|
227917|NCT02173457|Drug|Chiglitazar|Take orally
227918|NCT02173457|Drug|Sitagliptin|Take orally
227919|NCT00136578|Drug|Ispinesib|
227920|NCT02173470|Other|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
227921|NCT02173483|Procedure|Quadriceps graft|
227922|NCT02173496|Other|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
227923|NCT02173509|Other|Multidisciplinary and multifaceted educational intervention.|Outreach visits (40 minutes) which included a PowerPoint presentation and impress materials: poster; flyers; participation certificate and articles mentioned in the presentation. This outreach visit aimed to change the knowledge-attitudes previously identified in a previous study as being associated with poor prescribing of antibiotics in the case of physicians and propensity to dispense antibiotics without medical prescription in the case of pharmacists.
227924|NCT02173522|Device|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
227925|NCT02173548|Drug|Anakinra|
227926|NCT02173548|Drug|Placebo|
227927|NCT02173561|Behavioral|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
227276|NCT02186366|Other|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
227277|NCT02186366|Drug|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
227278|NCT02188719|Procedure|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
227279|NCT02188732|Behavioral|CBHH+AT|Community Based Health Home + Automated Telehealth (CBHH+AT):
Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk.
227280|NCT02188732|Behavioral|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
227281|NCT00138242|Drug|docetaxel|
227282|NCT02188732|Behavioral|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
227616|NCT02181309|Drug|Meloxicam, high dose|
227617|NCT02181322|Drug|Meloxicam - low dose|
227618|NCT02181322|Drug|Meloxicam - medium dose|
227619|NCT02181322|Drug|Meloxicam - high dose|
227620|NCT02181335|Drug|Respimat® Budesonide low dose|
227621|NCT02181335|Drug|Respimat® Budesonide high dose|
227622|NCT02181335|Drug|Turbohaler® Budesonide|
227623|NCT02181335|Drug|Placebo|
227624|NCT00137488|Device|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
226965|NCT00139009|Drug|Cyclosporine A|
226966|NCT02193802|Device|PillCam® SB3 capsules|Patient preparation for PillCam® SB3 capsule procedure:
Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.
Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator.
226967|NCT02193815|Drug|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
226968|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 4% solution
226969|NCT02193815|Drug|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
226970|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 2% Ointment
226971|NCT02193815|Drug|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
226972|NCT02193815|Drug|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
226973|NCT02193828|Biological|Collagenase clostridium histolyticum|Single injection into nodule
226974|NCT02193828|Biological|Placebo|Single injection into nodule
226975|NCT02193841|Procedure|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
226976|NCT00139022|Device|Continuous Positive Airway Pressure|
226977|NCT02196259|Drug|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
226978|NCT02196272|Behavioral|Nurse-led reminder program through email|Both groups will receive an educational program and usual care. The educational program will consist of:
- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form.
226979|NCT02196285|Biological|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
226980|NCT02196298|Device|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
226981|NCT02196298|Other|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
226982|NCT02196324|Drug|VPD-737|NK1 receptor antagonist
226983|NCT02196324|Drug|Placebo|
226371|NCT02167932|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
226372|NCT02167945|Drug|ABT-450/r/ABT-267|tablet
226373|NCT00135941|Drug|insulin glulisine|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
226374|NCT02167945|Drug|ABT-333|tablet
226673|NCT02160392|Procedure|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
226674|NCT02160405|Dietary Supplement|native potato|
226675|NCT02160418|Behavioral|Financial Incentives|
226676|NCT02160418|Behavioral|Cognitive Incentives|
226677|NCT02160418|Behavioral|Financial and Cognitive Incentives|
226678|NCT02160431|Behavioral|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
226679|NCT02162797|Dietary Supplement|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
226680|NCT02162810|Drug|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
226681|NCT02162810|Drug|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
226682|NCT02162823|Procedure|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
226683|NCT02162836|Drug|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
226684|NCT02162849|Drug|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
226685|NCT02162849|Drug|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
226686|NCT02162849|Drug|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
226064|NCT02177890|Device|Transcutaneous vagal nerve stimulation|
226065|NCT02177890|Device|Sham vagal nerve stimulation|
226066|NCT02177903|Device|Bair Paws Patient Adjustable Warming System|Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
226067|NCT00137111|Drug|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
226068|NCT02177916|Other|Education|
226069|NCT02177929|Other|adapted canoeing, hadbike and conventional physiotherapy|The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.
The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.
Individuals in the conventional physiotherapy group will make stretching and strengthening exercises.
226070|NCT02177942|Other|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
226375|NCT02167945|Drug|Ribavirin (RBV)|tablet
226376|NCT02167958|Drug|Fludarabine|Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).
For decreased creatinine clearance (< 61 mL/min) determined by the Cockcroft Formula:
Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr)
Fludarabine dosage should be reduced per standard of care.
226377|NCT02167958|Drug|Cyclophosphamide|Pre-transplant
Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW
Post-transplant
Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.
Cyclophosphamide [50mg/kg] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.
226378|NCT02167958|Drug|Mesna|Pre-transplant
Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.
Post-transplant
Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.
226379|NCT02170090|Drug|Cisplatin|Cisplatin 25mg/m2
226380|NCT02170090|Other|Observation|clinical, laboratory and imaging evaluation every 3 months
226381|NCT02170103|Procedure|percutaneous intervention (PCI)|
225752|NCT00137995|Drug|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
225753|NCT02185729|Other|Saline (control)|Infusion of 0.9% normal saline
225754|NCT02188173|Drug|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
225755|NCT02188186|Drug|Triple combination|
225756|NCT02188212|Device|NobelProcera Crown Shaded Zirconia|
225757|NCT02188225|Procedure|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
225758|NCT02188225|Drug|fluoxetine|10 mg/ daily
225759|NCT02188238|Other|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
225760|NCT02188251|Dietary Supplement|Activamp|
225761|NCT02188251|Other|Placebo|
225762|NCT00138216|Drug|temozolomide|
225763|NCT02188264|Drug|Cyclosporine|Given PO
225764|NCT02188264|Other|Laboratory Biomarker Analysis|Correlative studies
225765|NCT02188264|Other|Pharmacological Study|Correlative studies
225766|NCT02188264|Drug|Selumetinib|Given PO
225767|NCT02188277|Drug|Xeomin|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
225768|NCT02188277|Drug|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
226071|NCT02177942|Other|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
226072|NCT02177955|Drug|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
226073|NCT02177955|Drug|10 mg diazepam|10 mg midazolam 45 minutes before surgery
226074|NCT02177968|Other|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
225100|NCT02162316|Drug|A-Cilin®, Clari® and Pantoline®|
225101|NCT02162329|Behavioral|Questionnaires|Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.
Meditation Group and Wait-List Group also complete questionnaires at follow up visit.
225102|NCT02162329|Procedure|Electroencephalography (EEG)|Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.
Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.
225425|NCT02195791|Drug|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
225426|NCT00139230|Drug|Ciprofloxacin|
225427|NCT02195791|Drug|Placebo|Placebo (oral) 1 tab once daily for 7 days
225428|NCT02195804|Drug|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
225429|NCT02195804|Drug|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
225430|NCT02195804|Drug|Ranitidine hydrochloride|
225431|NCT02195817|Other|Selincro® 18 mg with continuous psychosocial support: Cohort A|
225432|NCT02195817|Other|Initial psychosocial support: Cohort B|
225433|NCT00134719|Biological|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
225434|NCT02156908|Drug|D-serine|D-serine 60 mg/kg
225435|NCT02156908|Drug|Placebo|
225436|NCT02156921|Other|App-based training|
225437|NCT02156934|Biological|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
225438|NCT02156947|Procedure|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
225439|NCT02156960|Drug|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
225440|NCT02156960|Drug|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
225441|NCT02156960|Drug|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
225117|NCT02164825|Drug|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
225118|NCT00135603|Drug|amoxicillin/clavulanate potassium|1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
225119|NCT02164825|Drug|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
225120|NCT02164838|Drug|Axitinib|
225121|NCT02164864|Drug|Dabigatran Etexilate 110mg|Active treatment
225122|NCT02164864|Drug|Warfarin 3mg|Active comparator
225123|NCT02164864|Drug|Aspirin|Active comparator
225124|NCT02164864|Drug|Dabigatran Etexilate 150mg|Active treatment
225448|NCT02157038|Device|Pedometer|
225449|NCT02157038|Device|MRI|
225450|NCT02157051|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
225451|NCT02157051|Other|Laboratory Biomarker Analysis|Correlative studies
225452|NCT02157077|Drug|Aflibercept|Intravitreal Injection
225453|NCT02157090|Other|Herpes Patch SOS (Hansaplast®)|
225454|NCT02157090|Other|Herpes vesicle patch of Compeed®|
225455|NCT00134719|Biological|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
225456|NCT02157103|Drug|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
225457|NCT02157116|Drug|cisplatin|
225458|NCT02157116|Drug|Docetaxel|
225459|NCT02157116|Drug|Pegfilgrastim|
225460|NCT02157129|Device|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
225461|NCT02159781|Procedure|periodontal treatment - scaling and root planning|
225462|NCT02159794|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
224814|NCT02171910|Drug|Doxapram|
224815|NCT02171910|Drug|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
224816|NCT02171936|Other|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
224817|NCT00136435|Drug|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
224818|NCT02171949|Biological|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
224819|NCT02171962|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
224820|NCT02171975|Procedure|pre-procedure ultrasound guided paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
224821|NCT02171975|Procedure|Conventional landmark guided midline spinal anaesthetic|Spinal anaesthesia was administered based on conventional landmark based midline approach.
224822|NCT02171988|Drug|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
224823|NCT02171988|Drug|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
224824|NCT02171988|Drug|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
224825|NCT02171988|Drug|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
224826|NCT02172001|Drug|Iron isomaltoside 1000|
225125|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
225126|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active treatment
225127|NCT02164864|Drug|Warfarin 5mg|Active comparator
225128|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active treatment
225129|NCT00135603|Procedure|appendectomy|ablation of the appendix by laparotomy or laparoscopy
225130|NCT02164864|Drug|Warfarin 1mg|Active comparator
224525|NCT02177448|Drug|Enalapril low dose|
224526|NCT02177448|Drug|Enalapril medium dose|
224527|NCT00137059|Drug|acetaminophen sustained-release|
224528|NCT02177448|Drug|Enalapril high dose|
224529|NCT02177448|Drug|Placebo matching BIBR277|
224530|NCT02179840|Procedure|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
224531|NCT02179853|Drug|Anakinra|First two doses IV followed by SQ dosing
224532|NCT02179866|Drug|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) [14C]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
224533|NCT02179879|Other|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
224534|NCT02179892|Drug|Bupivacaine Extended-Release Liposome Injection (Exparel)|266mg/30mL of Exparel will be injected via unilateral TAP block
224535|NCT02179892|Drug|Bupivacaine and Dexamethasone Injection|28 ml of Bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block
224536|NCT02179918|Drug|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
224537|NCT02179918|Drug|MK-3475|2 mg/kg q3wks, IV
224538|NCT02179931|Drug|Flupentixol/melitracen film-coated tablet|
224827|NCT02172014|Drug|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
224828|NCT00136435|Drug|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
224829|NCT02172014|Drug|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
224830|NCT02172027|Device|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
224831|NCT02172040|Drug|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
229052|NCT02411175|Other|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
229053|NCT02411175|Drug|20% ethanol|
229054|NCT02411188|Behavioral|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
224201|NCT02185131|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
224202|NCT02185144|Behavioral|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
224203|NCT02185144|Behavioral|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
224204|NCT02185157|Other|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
224205|NCT02185157|Other|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
224206|NCT02187471|Drug|150mg pregabalin capsule|
224207|NCT00138151|Drug|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
224208|NCT02187471|Drug|placebo tablet|matching DS-5565 tablet
224209|NCT02187471|Drug|placebo capsule|matching pregabalin capsule
224210|NCT02187471|Drug|75mg pregabalin capsule|
224211|NCT02187484|Drug|BIBR 277|
224212|NCT02187497|Drug|Low dose of BIBR 277|
224213|NCT02187497|Drug|Medium dose of BIBR 277|
224214|NCT02187497|Drug|High dose of BIBR 277|
228756|NCT02417558|Behavioral|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
228757|NCT02417558|Behavioral|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
228758|NCT00166127|Drug|Levosimendan|
228759|NCT02417571|Device|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A&D Company, Tokyo, Japan)
228760|NCT02417584|Device|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
228761|NCT02417597|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
228762|NCT02417610|Device|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
228763|NCT02417610|Device|Hyaluronic acid - HA - Ialart|Hyaluronic acid
228764|NCT02417623|Behavioral|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
228765|NCT02417636|Other|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 24months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
229055|NCT02411201|Drug|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
229056|NCT00165256|Procedure|Wide Excision of DCIS|Wide excision of DCIS and a minimum of 1cm histologically negatic breast tissue
229057|NCT02411214|Other|survey|questionnaire survey sent by regular mail for 3 groups
229058|NCT02413216|Other|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
229059|NCT02413229|Drug|DSXS|DSXS (Taro Pharmaceuticals Inc.)
229060|NCT00165477|Drug|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
229061|NCT02413229|Drug|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
228468|NCT02421640|Drug|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
228469|NCT02423798|Device|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
228470|NCT02423811|Dietary Supplement|Fursultiamine|Use of Fursultiamine in addition to CCRT
228471|NCT02423824|Biological|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
228472|NCT02423837|Drug|Rituximab, bendamustine|
228473|NCT02423850|Device|3D photooptical camera|
228474|NCT02423863|Biological|Hiltonol|Priming treatment course, which consists of a total of 6 IT injections of 0.5 mg poly-ICLC followed by boosting treatment course, consisting of IM injections of Poly-ICLC twice weekly for 3 treatment cycles and a 6 week maintenance cycle with administration of 1 mg IM Poly-ICLC twice weekly. Study subject's response will be defined as Disease Control (CR, PR, SD) or PD
228475|NCT02423876|Drug|Epidural analgesia|Receive epidural placement. Standard epidural medications and dosage are as follows:
0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate
3 mL/hr RN bolus, to be used as needed based on pain ratings
3 mL/30 minutes patient bolus, which is available on patient demand.
228476|NCT00167219|Procedure|Stem Cell Transplant|As part of the stem-cell transplant process, patients receive high doses of chemotherapy to treat their underlying disease, such as cancer. This treatment also kills the healthy stem cells already in the marrow. The transplanted cells from a donor replace the patient's bone marrow and allow the blood counts to recover. Subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day.On the day of transplantation, cells from the donor will arrive to the bone marrow transplant unit and be transfused via venous line.
228477|NCT02423876|Other|Intraoperative Complication Management and Prevention|Undergo ERP
228478|NCT02423876|Procedure|Pain Therapy|Undergo ERP
228479|NCT02423889|Radiation|Radiotherapy|
228480|NCT02423902|Biological|Ad-RTS-hIL-12|Approximately 1.0x10^12 viral particles (vp) per injection
228481|NCT02423902|Drug|Veledimex|7 oral doses of veledimex
228482|NCT02423915|Drug|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
233714|NCT02423733|Other|The Journal|"The Journal" is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care.
233715|NCT02423746|Behavioral|Family Check Up Behavioral Parenting Training Program (BPT)|The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.
Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention.
233716|NCT02423746|Behavioral|Behavioral Placebo|The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.
Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention.
233717|NCT02423759|Drug|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
233718|NCT00167206|Drug|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
234009|NCT02463630|Procedure|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
234010|NCT02463643|Drug|Z-215 10mg|Z-215 10mg, capsules
234011|NCT00173693|Behavioral|exercise for strength, balance, health education|
234012|NCT02463643|Drug|Z-215 20mg|Z-215 20mg, capsules
234013|NCT02463643|Drug|Z-215 Placebo|Z-215 placebo-matching capsules
234014|NCT02463643|Drug|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
234015|NCT02463643|Drug|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
233431|NCT02394821|Drug|Metronidazole 0.8%|
233432|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
233433|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
233434|NCT02394847|Drug|propofol|
233435|NCT02394860|Other|echo Doppler lower limbs|
233436|NCT02394873|Biological|ALLO-ASC-DFU|Dressing for second-degree burn wound.
233437|NCT02394886|Biological|ALLO-ASC-DFU|
233438|NCT02394899|Behavioral|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
233439|NCT02394899|Other|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
233440|NCT02394912|Device|vena cava filter implantation (LUMIFI with Crux VCF System)|
233441|NCT00163163|Procedure|Blood samples|
233719|NCT02423759|Drug|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
233720|NCT02423759|Drug|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
233721|NCT02423772|Behavioral|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
233722|NCT02425787|Behavioral|Interview|This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be solely conducted by the study PI. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.
In order to ensure that the PI does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences.
232845|NCT02406131|Other|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
232846|NCT02406144|Drug|MLN9708|
233135|NCT02399592|Drug|Bevacizumab|10 mg/kg q3w
233136|NCT02399592|Drug|Tocotrinol|300 mg tid
233137|NCT02399605|Other|Stimulation|Subcutaneous abdominal electrical stimulation
233138|NCT02399618|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
233139|NCT00163904|Behavioral|High mono-unsaturated fat/low carbohydrate diet|
233140|NCT00164229|Behavioral|math|
233141|NCT02402023|Behavioral|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
233142|NCT02402036|Drug|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
233143|NCT02402049|Drug|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
233144|NCT02402049|Drug|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
233145|NCT02402049|Drug|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
233146|NCT02402049|Drug|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
233147|NCT02402049|Drug|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
233148|NCT02402049|Drug|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
233149|NCT02402049|Drug|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
233150|NCT02402049|Drug|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
233151|NCT00164229|Behavioral|behavior regulation|
233152|NCT02402049|Drug|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
233153|NCT02402049|Drug|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
227928|NCT02176330|Other|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
227929|NCT02176330|Other|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
227930|NCT02176356|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
227931|NCT00002281|Drug|Filgrastim|
228245|NCT02168491|Drug|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
228246|NCT02168530|Drug|placebo|matching placebo administered daily orally
228247|NCT02168530|Drug|vismodegib|vismodegib 150 mg administered daily orally
228248|NCT02168543|Drug|Alendronate|
228249|NCT02168543|Drug|Placebo|
228250|NCT02168556|Behavioral|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
228251|NCT00136019|Drug|SPM 927|
228252|NCT02168556|Behavioral|Video|Subject watches an informational video prior to undergoing urodynamic testing.
228253|NCT02168556|Other|Standard of care|Standard of care
228254|NCT02168569|Drug|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to <15kg, two tablets per dose for those 15 to <25kg, and three tablets per dose for those 25 to <35kg.
228255|NCT02168569|Drug|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children <9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
227625|NCT02181348|Drug|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
227626|NCT02181348|Drug|placebo (edible oil)|
227627|NCT02181361|Drug|aspirin plus hirudin|hirudin two tables, three times a day and aspirin 100mg, once daily.
227628|NCT02181361|Drug|Warfarin|An initial dose of Warfarin is 1.5mg,once daily. 3 days later,we check the international normalized ratio(INR) values and adjust the warfarin dose make INR between 2-3 steady.Then, we maintain this warfarin dose.
227629|NCT02181387|Drug|Acetaminophen|administered every 6 hours by mouth up to 4 doses
227630|NCT02181387|Drug|Placebo|
227631|NCT02181400|Device|Ellex Integre NIR laser|Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.
The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period.
227632|NCT02181413|Drug|Ixazomib Citrate|Ixazomib citrate capsules
227633|NCT02181413|Drug|Placebo|Ixazomib citrate placebo-matching capsules
227634|NCT02181426|Drug|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
227635|NCT02183896|Biological|Platelet-rich plasma (PRP)|
227636|NCT02183896|Drug|Saline|
227637|NCT02183909|Other|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
227932|NCT00136916|Drug|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
227933|NCT02176356|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
227934|NCT02176356|Device|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
227935|NCT02176356|Device|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
227936|NCT02176356|Device|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
227283|NCT02188745|Drug|17B-estradiol|Anti-estrogen
227284|NCT02188745|Drug|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
227285|NCT02188745|Drug|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
227286|NCT02188745|Drug|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
227287|NCT02188758|Other|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
227288|NCT02188771|Device|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
227289|NCT02188784|Drug|Polysaccharide Iron Complex 150 mg|Oral Iron
227290|NCT02188784|Drug|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
227291|NCT02188797|Behavioral|Group MI risk reduction program|
227292|NCT00138242|Procedure|adjuvant therapy|
227293|NCT02188810|Biological|PAL|Single dose administered intramuscularly.
227294|NCT02188810|Biological|TIV|Single dose administered intramuscularly .
227295|NCT02188823|Behavioral|Low carbohydrate diet|
227296|NCT02191228|Drug|Linagliptin - single dose|
227297|NCT02191228|Drug|Linagliptin - Multiple dose|
227298|NCT02191241|Drug|Red Vine Leaf Extract|
227299|NCT02191254|Drug|Antistax®|
227300|NCT02191254|Drug|Placebo|
227301|NCT02191267|Radiation|[F18]-T807|[F18]-T807 PET Scan to measure tau deposition in the brain.
227302|NCT02191267|Radiation|[F18]-Florbetapir|[F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
226687|NCT02162849|Drug|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
226688|NCT02162849|Behavioral|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
226689|NCT00002268|Drug|Sevirumab|
226690|NCT00135421|Drug|Pexacerfont|Tablets & Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
226691|NCT02162849|Behavioral|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
226984|NCT02196350|Behavioral|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
226985|NCT00139269|Drug|5-Fluorouracil|
226986|NCT02196350|Behavioral|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
226987|NCT02196350|Behavioral|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
226988|NCT02196376|Other|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
226989|NCT02196376|Other|Physical|the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.
Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis
226990|NCT02196376|Other|blood draw|blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers
no more than 15 ml (1 TBSP) will be drawn.
226991|NCT02196376|Behavioral|Questionnaires|The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.
The following questionnaires will be conducted:
RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31
226992|NCT02196389|Device|Nasal dilator Nasanita|Nasal Dilator
226993|NCT02196389|Device|Nasal dilator Nozovent|
226994|NCT02196389|Device|Nasal dilator Breath Right|
226995|NCT02196389|Device|Nasal dilator Airmax|
226996|NCT00139282|Drug|Squalamine Lactate|
226382|NCT02170103|Drug|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
226383|NCT02170103|Procedure|Ultrasound|Intermittent high MI (Mechanical Index) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MHz;pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
226384|NCT00136266|Drug|Ferrous sulphate drops with vitamins A, D, and C|
226385|NCT02170116|Drug|BIBR 1048 MS dose 1|
226386|NCT02170116|Drug|BIBR 1048 MS dose 2|
226387|NCT02170116|Drug|BIBR 1048 MS dose 3|
226388|NCT02170116|Drug|BIBR 1048 MS dose 4|
226389|NCT02170116|Drug|BIBR 1048 MS dose 5|
226390|NCT02170116|Drug|Placebo to BIBR 1048 MS|
226692|NCT02162849|Other|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
226693|NCT02162849|Other|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
226694|NCT02162862|Behavioral|Behavioral Counseling|
226695|NCT02162862|Drug|bupropion-SR|
226696|NCT02162875|Drug|Praziquantel|Six different treatment strategies with praziquantel
226697|NCT02162888|Drug|Test Product (Bendamustine)|
226698|NCT02162901|Behavioral|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
226699|NCT02165397|Drug|Placebo|Subjects will receive placebo capsules orally.
226700|NCT02165397|Drug|Rituximab|Drug: rituximab Subjects will receive rituximab 375mg/m2 intravenously Other Name: Rituxan
226075|NCT02177981|Procedure|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
226076|NCT02177981|Procedure|Control|The cuff will be placed around the arm but not inflated.
226077|NCT02177994|Drug|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
226078|NCT00137111|Procedure|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
226079|NCT02178020|Device|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
226080|NCT02178020|Device|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
226081|NCT02180646|Other|high carbohydrate breakfast|
226082|NCT00137397|Drug|Placebo|
226083|NCT02180659|Drug|sublingual buprenorphine tablets|
226084|NCT02180659|Drug|Buprenorphine implant|
226085|NCT02180659|Drug|placebo implants|
226086|NCT02180659|Drug|sublingual placebo tablets|
226087|NCT02180672|Drug|Nasal Fluticasone|One spray per nostril, per day.
226088|NCT02180672|Drug|Placebo|One spray per nostril, per day.
226089|NCT02180685|Other|Anchor fixation|
226090|NCT02180698|Other|Laboratory Biomarker Analysis|Correlative studies
226091|NCT02180698|Radiation|Radiation Therapy|Undergo radiation therapy
226092|NCT02180698|Drug|TLR4 Agonist GLA-SE|Given intratumorally
226093|NCT00137410|Drug|Celebrex|
226094|NCT02180711|Drug|ACP-196|
226095|NCT02180711|Drug|rituximab (IV)|
225442|NCT02156973|Other|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
225443|NCT02156999|Device|Ibandronic acid, vitamin D|
225444|NCT00134719|Biological|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
225445|NCT02157012|Drug|The effectiveness of Xeljanz in rheumatoid arthritis patients|
225446|NCT02157025|Device|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
225447|NCT02157025|Other|Usual Care procedures during Humphrey perimetry for children|
225769|NCT02188303|Drug|LY2944876|Administered SC
225770|NCT02188303|Drug|Placebo|Administered SC
225771|NCT02188316|Device|Jumbo forceps|comparison of different polypectomy devices
225772|NCT02188316|Device|Hot biopsy forceps|comparison of different polypectomy devices
225773|NCT00138216|Drug|vincristine sulfate|
225774|NCT02188342|Behavioral|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
225775|NCT02188368|Drug|POM|
225776|NCT02188368|Drug|Steroids|
225777|NCT02188368|Drug|PLD|
225778|NCT02188368|Drug|CFZ|
225779|NCT02188368|Drug|BTZ|
225780|NCT02188368|Drug|CLA|
225781|NCT02188368|Drug|Other drugs|
225782|NCT02188381|Other|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
225783|NCT02188394|Drug|Anesthetic blockades with bupivacaine|
225784|NCT00138567|Drug|vildagliptin|
225785|NCT02190461|Procedure|Early Respiratory Rehabilitation Program|
225463|NCT02159807|Drug|Bupivacaine|These groups relate to the dose of bupivacaine that will be administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy containing one of the three doses of bupivacaine being identified only by a syringe number. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal
225464|NCT02159820|Drug|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
225465|NCT00002264|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
225466|NCT00135109|Drug|SPM 927|
225467|NCT02159820|Drug|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve [AUC] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
225468|NCT02159833|Other|Intranasal challenge with active substance (food protein)|
225469|NCT02159833|Other|Intranasal challenge with placebo|
225470|NCT02159859|Drug|Ertapenem|Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
225793|NCT02190539|Other|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
225794|NCT02190552|Device|EmboTrap® Revascularization Device|
225795|NCT00138580|Drug|vildagliptin|
225796|NCT02190565|Dietary Supplement|Food supplement|Randomized double-blind, placebo-controlled
225797|NCT02190578|Device|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
225798|NCT02190591|Device|Peanut Labor Ball|
225799|NCT02190604|Drug|Placebo|Capsule- oral dose
225800|NCT02190604|Drug|QBW251|Capsule - oral dose
225131|NCT02164877|Drug|pectin|Patients allocated to experiment group will receive 15g pectin each day
225132|NCT02167334|Procedure|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
225133|NCT00135850|Genetic|VEGF-A165 plasmid|
225134|NCT02167347|Behavioral|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
225135|NCT02167360|Drug|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
225136|NCT02167373|Other|Cogito Companion Intervention|
225137|NCT02167373|Device|mobile phone application|
225138|NCT02167386|Behavioral|Enhanced PrEP Adherence|
225139|NCT02167386|Behavioral|Standard PrEP Adherence|
225140|NCT02167412|Device|Abdominal and lower extremity compression|POTS patients will have a repeat HUT test while wearing the Zoex compression suit.
225141|NCT02167425|Other|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
225142|NCT02167438|Device|Hem-Avert Perianal Stabilizer|
225143|NCT02167451|Drug|Maraviroc|
225144|NCT00135863|Drug|tinzaparin|
225145|NCT02167464|Drug|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
225146|NCT02167464|Other|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
225147|NCT02167464|Drug|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
225471|NCT02159872|Drug|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
225472|NCT02159885|Other|Telemonitoring|
225473|NCT02159898|Device|EndoMAXX EVT|
225474|NCT02159898|Device|EndoMAXX|
224832|NCT02172040|Drug|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
224833|NCT02172040|Drug|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
224834|NCT02172040|Drug|Matched placebo tablet for over-encapsulated amlodipine besylate tablet|Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks
224835|NCT02174861|Drug|AMG 334|All subjects will receive AMG 334 periodically for 13 months followed by a safety follow up visit .The subjects who complete the 12-week double-blind treatment phase of the AMG 334 20120295 parent study and meet all AMG 334 20130255 eligibility criteria will be enrolled into this study. Enrollment should occur within 14 days after the week 12 visit of the parent study.
224836|NCT02174887|Drug|Nab-paclitaxel + Gemcitabine|Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days
The patients will receive 2 cycles of treatment every 28 days:
224837|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
224838|NCT02174900|Drug|Artemether-Lumefantrine (AL) combination|
224839|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
224840|NCT02174913|Device|bispectral index|Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
224841|NCT02174926|Procedure|Elective laparoscopic sigmoid resection|
224842|NCT00136760|Drug|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
224843|NCT02174926|Dietary Supplement|Conservative treatment|Written lifestyle guidance and fiber supplements
224844|NCT02174939|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
224845|NCT02174939|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
224846|NCT02174952|Behavioral|Self-help version of the New Forest Parenting Programme|
225148|NCT02167477|Device|Macintosh laryngoscopy|Tracheal intubation
225149|NCT02167477|Device|Storz C-MAC, standard blade|Tracheal intubation
225150|NCT02167477|Device|Storz C-MAC, D-BLADE|Tracheal intubation
225151|NCT02167490|Procedure|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
225152|NCT02167516|Drug|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
224215|NCT02187510|Procedure|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
224216|NCT02187510|Procedure|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
224217|NCT02187523|Drug|Hydrochlorothiazide|
224218|NCT00002291|Drug|Pentamidine isethionate|
224219|NCT00138164|Biological|denileukin diftitox|
224220|NCT02187523|Drug|Telmisartan|
224539|NCT02179931|Drug|Flupentixol/melitracen coated tablet (Deanxit®)|
224540|NCT00000329|Drug|Opioid-Related Disorders|
224541|NCT00002283|Drug|Trimethoprim|
224542|NCT00137332|Drug|0.9% Sodium Chloride, USP|
224543|NCT02179970|Drug|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
224544|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
224545|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
224546|NCT02179996|Biological|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
224547|NCT02179996|Biological|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
224548|NCT02180022|Drug|Placebo|After randomization, placebo was treated for 12 weeks
224549|NCT02180022|Drug|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
224550|NCT02180035|Dietary Supplement|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
224551|NCT02180035|Dietary Supplement|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
229062|NCT02413242|Other|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
229063|NCT02413255|Drug|TAK-020|TAK-020 oral solution
229064|NCT02413255|Drug|TAK-020 Placebo|TAK-020 placebo-matching oral solution
229065|NCT02413268|Drug|Nitroglycerin|
229066|NCT02413281|Drug|ALKS 5461|Sublingual tablets, single administration
229067|NCT02413281|Drug|Buprenorphine|Sublingual tablets, single administration
229068|NCT02413281|Drug|Placebo|Sublingual tablets, single administration
229069|NCT02413294|Device|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
229070|NCT02413307|Other|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
229071|NCT00165477|Radiation|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
229072|NCT02413320|Drug|Paclitaxel|
229073|NCT02413320|Drug|Carboplatin|
229074|NCT02413320|Drug|Doxorubicin|
229075|NCT02413320|Drug|Cyclophosphamide|
229076|NCT02413320|Drug|Docetaxel|
229077|NCT02413333|Device|Clear Care® Plus contact lens cleaning and disinfecting solution|Hydrogen peroxide 3% solution for cleaning, disinfection and overnight storage of contact lenses
224221|NCT02187523|Drug|Telmisartan/HCTZ FDC|
224222|NCT02187536|Drug|Telmisartan|
224223|NCT02187536|Drug|Simvastatin|
224224|NCT02187536|Drug|Telmisartan placebo|
224225|NCT02187549|Device|HYMOVIS|Intra-articular injection
224226|NCT02187549|Device|Placebo|Intra-Articular Injection
224227|NCT02187562|Drug|Meloxicam|
228766|NCT02417649|Biological|Placebo|The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.
Three months of rest, according to the indications, will be allowed.
A second cycle (the same as point 1.) will be performed
A second three month rest (according to point 2.) will be provided.
228767|NCT02417649|Biological|Ismigen|The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.
Three months of rest, according to the indications, will be allowed.
A second cycle (the same as point 1.) will be performed
A second three month rest (according to point 2.) will be provided.
228768|NCT02417662|Radiation|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
228769|NCT00166153|Drug|Mycophenolate Mofetil|
228770|NCT02419742|Drug|Docetaxel 100 mg/m^2|Docetaxel 100 mg/m^2 (at investigator's discretion or Paclitaxel) will be administered as a 1-hour I.V. infusion every 3 weeks for four cycles, beginning on Day 1 of Cycle 5.
228771|NCT02419742|Drug|Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2 as a 60-minute I.V. bolus injection every 3 weeks.
228772|NCT02419742|Drug|Doxorubicin|Doxorubicin 60 mg/m^2 administered as a 5 to 15 minute intravenous (I.V.) bolus injection every 3 weeks for 4 cycles.
228773|NCT02419742|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 (at investigator's discretion or docetaxel 100 mg/m^2) will be administered as a 1-hour I.V. infusion every 3 weeks for four cycles, beginning on Day 1 of Cycle 5.
228774|NCT02419742|Drug|Trastuzumab (Anthracycline based therapy (AC-TH))|Trastuzumab loading dose 4 mg/kg body weight administered as a 90 minute intravenous infusion followed by a weekly dose 2 mg/kg body weight administered as a 30 minute infusion or 8 mg/kg (Loading dose) followed by 6 mg/kg every 3 weeks.
228775|NCT00166426|Drug|Exisulind|
228776|NCT02419742|Drug|Trastuzumab (Non-anthracycline based therapy (TCH))|Trastuzumab loading dose 4 mg/kg body weight administered as a 90 minute intravenous infusion followed by a weekly dose 2 mg/kg body weight administered as a 30 minute infusion or 8 mg/kg (Loading dose) followed by 6 mg/kg every 3 weeks.
228777|NCT02419755|Drug|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
228778|NCT02419755|Drug|Vorinostat|Vorinostat should be taken orally (PO) with food.
228779|NCT02419755|Drug|Mitoxantrone|Given by intravenous (IV) injection.
228780|NCT02419755|Drug|Cytarabine|Given by intravenous (IV) injection.
228781|NCT02419755|Drug|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
234016|NCT02463669|Device|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
234017|NCT02463682|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
234018|NCT02463682|Device|Closed-Loop Control System|The devices that will be used in the Closed-Loop Control System include the following components:
DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)
234019|NCT02463695|Procedure|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
234020|NCT02463708|Behavioral|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
234021|NCT02463721|Other|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
234022|NCT00002471|Drug|daunorubicin hydrochloride|
234023|NCT00173706|Drug|L-Carnitine Injection|
229393|NCT02411357|Behavioral|WHO contraception protocol|World Health Organization's contraception protocol
229394|NCT02411357|Behavioral|Incentives|Financial incentives contingent on follow-up visit attendance
229395|NCT02411370|Behavioral|phonetic tests|
229396|NCT02411383|Device|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
229397|NCT02411396|Other|Patient Centered Outcomes|Comparison of treatment in patients with SCD in VOC in acute care settings
229398|NCT00165282|Behavioral|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
229399|NCT02411409|Behavioral|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
233723|NCT00002455|Biological|Corynebacterium granulosum P40|
233724|NCT00167492|Drug|Myfortic|720 mg by mouth every 12 hours
233725|NCT02425800|Other|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
233726|NCT02425800|Other|Laboratory Biomarker Analysis|Correlative studies
233727|NCT02425813|Drug|Budesonide|Given PO
233728|NCT02425813|Drug|Methylprednisolone Sodium Succinate|Given IA and IV
233729|NCT02425826|Drug|Apremilast|
233730|NCT02425826|Drug|Placebo|
233731|NCT02425839|Device|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
233732|NCT02425839|Device|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
233733|NCT02425852|Drug|Azathioprine|Azathioprine alone versus Azathioprine and IFX
233734|NCT02425852|Drug|Infliximab|
233735|NCT00167505|Behavioral|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
233736|NCT02425852|Drug|Prednisolone|
233737|NCT02425852|Drug|Hydrocortisone|
233738|NCT02425865|Drug|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
233739|NCT02425878|Drug|Ulipristal Acetate|
234024|NCT02463747|Drug|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
234025|NCT02463747|Drug|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
234026|NCT02463747|Drug|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
234027|NCT02465840|Procedure|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
233154|NCT02402049|Drug|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
233155|NCT02402049|Drug|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
233156|NCT02402062|Drug|TH-302 + Sunitinib|Combination of the two drugs in cycles of 28 days, described as follows:
Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.
TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.
233442|NCT02394925|Device|Multifocal Test Contact lens|Used in a daily wear modality
233443|NCT02394938|Other|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
233444|NCT02394951|Drug|Pregabalin|Anticonvulsant
233445|NCT02394951|Drug|Placebo|Identical, matching inactive substance
233446|NCT02397265|Device|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
233447|NCT02397265|Device|Standard opened loop pump|Using a standard opened loop pump
233448|NCT02397278|Drug|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
233449|NCT02397291|Drug|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
233450|NCT02397291|Drug|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
233451|NCT02397291|Drug|Placebo|placebo
233452|NCT02397304|Other|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
233453|NCT02397317|Radiation|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
233454|NCT00163514|Drug|Ciclesonide|
233455|NCT02397330|Drug|bupivacaine|
233456|NCT02397330|Device|ultrasound|ultrasound guided nerve blocks
228256|NCT02168582|Behavioral|physiotherapy as usual in primary care|
228257|NCT02168595|Drug|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
228258|NCT02168595|Drug|Placebo|
228259|NCT02168608|Other|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
228260|NCT02168608|Other|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
228261|NCT02168621|Procedure|Full-mouth ultrasonic debridement|
228262|NCT00136032|Drug|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
228263|NCT02170818|Other|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
228264|NCT02170831|Drug|BIBR 1048 MS low|
228265|NCT02170831|Drug|BIBR 1048 MS medium 1|
228564|NCT02397577|Other|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
228565|NCT02397590|Drug|Fimasartan|
228566|NCT02397590|Drug|Atorvastatin|
228567|NCT02397603|Drug|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
228568|NCT02397603|Drug|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
228569|NCT02397616|Other|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
228570|NCT02397629|Other|This study has no intervention|
228571|NCT00163566|Drug|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
228572|NCT02397642|Procedure|IVF/ICSI|
228573|NCT02397642|Drug|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
228574|NCT02397668|Device|CorMatrix ECM Tricuspid valve|CorMatrix ECM tricuspid valve to replace a diseased tricuspid valve not amenable to annuloplasty or repair, including tricuspid valve disease secondary to congenital heart disease.
227937|NCT02176369|Drug|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
227938|NCT02176382|Drug|denosumab|denosumab subcutaneous injection
227939|NCT02176382|Drug|teriparatide|teriparatide daily subcutaneous injection
227940|NCT02176382|Drug|Zoledronic acid|zoledronic acid infusion
227941|NCT02176395|Drug|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
227942|NCT02176395|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
227943|NCT00136929|Drug|Thrombolytic therapy|
227944|NCT02176395|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
227945|NCT02176408|Behavioral|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
227946|NCT02178696|Drug|Citalopram, or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated
227947|NCT02178709|Drug|FOLFIRINOX|FOLFIRINOX consists of the following combination of drugs:
Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle
Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle
Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.
5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle.
227948|NCT02178722|Drug|MK-3475|IV infusion
227949|NCT02178722|Drug|INCB024360|Oral daily dosing
228266|NCT02170831|Drug|BIBR 1048 MS medium 2|
228267|NCT02170831|Drug|BIBR 1048 MS high|
228268|NCT00136344|Drug|Cefuroxime|
228269|NCT02170831|Drug|BIBR 1048 MS placebo|
228270|NCT02170844|Drug|BIBR 1048 MS|
227303|NCT00138645|Behavioral|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
227638|NCT02183909|Behavioral|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
227639|NCT02183909|Other|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
227640|NCT02183909|Drug|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
227641|NCT02183922|Dietary Supplement|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
227642|NCT02183922|Dietary Supplement|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
227643|NCT02183922|Dietary Supplement|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
227644|NCT02183935|Device|Duodena-jejunal liner|
227645|NCT00137852|Drug|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
227646|NCT02183948|Drug|Oxytocin|
227647|NCT02183948|Drug|Placebo|
227648|NCT02183961|Other|Restech|
227649|NCT02183961|Other|Peptest|
227650|NCT02183961|Other|Detection of pepsin in adenoid specimen|
227651|NCT02183974|Procedure|Peptest|
227652|NCT02183987|Other|Active Knowledge Translation Intervention|Access to CSN guidelines, & provider- & patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space & disseminated to patients.
Educational whiteboard video will be made available as a resource for clinic staff & patients.
Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (>3 months) starting dialysis early (eGFR >10.5 ml/min), for all incident dialysis patients from the clinic, with provincial & national average comparisons. These reports, & the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.
Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines & evidence supporting an intent-to-defer strategy, & will receive follow-up.
227653|NCT02184013|Procedure|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
226997|NCT02196415|Device|Biplanar Radiography|standard biplanar radiography of the foot
226998|NCT02157623|Other|Red Light Photodynamic Therapy|Aktilite™ (red lamp) after Levulan application on randomized treatment field
226999|NCT02157623|Other|Blue Light Photodynamic Therapy|Blu-U® (blue lamp) after Levulan application on randomized treatment field
227000|NCT02157636|Drug|CPI-0610|
227001|NCT02157649|Drug|IR Tablet under Fasted conditions|Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
227002|NCT02157649|Drug|ER Tablet under Fed Conditions|Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
227003|NCT00134758|Drug|Ursodeoxycholic acid|During 2 years :
between 40 and 50 kg : 500 mg/day
between 51 and 75 kg : 750 mg/day
between 76 and 100 kg : 1000 mg/day
227304|NCT02191267|Device|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
227305|NCT02191267|Genetic|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
227306|NCT02191280|Drug|Antistax®, low dose|
227307|NCT02191280|Drug|Antistax®, high dose|
227308|NCT02191280|Drug|Placebo|
227309|NCT02191293|Drug|Viramune® tablets|
227310|NCT02191319|Drug|Viramune®|
227311|NCT02191332|Drug|Viramune|
227312|NCT02191345|Behavioral|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
227313|NCT02191371|Drug|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
227314|NCT00138658|Drug|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
226701|NCT02165410|Procedure|ASL-MRI|ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
226702|NCT02165410|Procedure|Diffusion tensor imaging (diffusion MRI)|Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
226703|NCT02165410|Procedure|Eye-tracking|Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
226704|NCT00135668|Drug|nitroprusside|nitroprusside IV infusion 0.3-3 mcg/kg/ min
226705|NCT02165410|Procedure|Cognitive profile|Children will be asked to perform certain tasks, adapted for their age.
226706|NCT02165423|Behavioral|myFAMI iPad application|
226707|NCT02165436|Other|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
226708|NCT02165436|Other|Control|No intervention will be assessed for this group.
227004|NCT02157649|Drug|ER Tablet under Fasted Conditions|Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
227005|NCT02157675|Dietary Supplement|Polyherbal capsule|
227006|NCT02157675|Dietary Supplement|Placebo capsule|
227007|NCT02157688|Other|no intervention : case control study|
227008|NCT02157701|Dietary Supplement|Polyherbal capsule|
227009|NCT02157701|Dietary Supplement|Placebo capsule|
227010|NCT02157714|Drug|PRX002|
227011|NCT02157714|Other|Placebo|
227012|NCT02157727|Device|Infants hospitalized in health facilities performing Tele-expertise|
227013|NCT02157740|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
227014|NCT00134758|Drug|Placebo|During 2 years :
between 40 and 50 kg : 2 tabs/day
between 51 and 75 kg : 3 tabs/day
between 76 and 100 kg : 4 tabs/day
227015|NCT02157766|Behavioral|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
226391|NCT02170129|Device|50% AAB plus 50% autologous bone|All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).
A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.
Both groups received tapered implants with an anodised surface.
226392|NCT02170129|Device|100% AAB|All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).
A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface.
226393|NCT02170142|Device|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
226394|NCT02170168|Other|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
226395|NCT00136266|Drug|Ferrous fumarate sprinkles with vitamins and minerals|
226396|NCT02170181|Radiation|SBRT|SBRT to Oligometastases
226397|NCT02170194|Behavioral|Resilience Enhancement Training via Smart Phone|
226398|NCT02170194|Behavioral|Daily Text Messages|
226399|NCT02170207|Drug|Lansoprazole|Lansoprazole 30 mg injection
226400|NCT02172599|Behavioral|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
226401|NCT02172612|Other|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
226402|NCT02172625|Dietary Supplement|Protandim Dietary Supplement|
226403|NCT02172638|Procedure|Fast-Track Protocol|
226404|NCT02172638|Procedure|Usual management|
226405|NCT02172651|Drug|Vitamin D3|
225786|NCT02190461|Procedure|Conventional Respiratory Rehabilitation Program|
225787|NCT02190474|Behavioral|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
225788|NCT02190500|Other|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
225789|NCT02190526|Drug|Mesalazine(asacol 800 mg)|
225790|NCT02190526|Drug|Amitriptyline|
225791|NCT02190526|Drug|placebo like asacol|
225792|NCT02190526|Drug|placebo like amitriptyline|
226096|NCT02180724|Drug|ACP-196|
226097|NCT02180737|Drug|Dexmeditomedine|
226098|NCT02180750|Other|Memory Work Therapy|
226099|NCT02180750|Other|Standard care|Pediatric clinic, ART
226100|NCT02180763|Biological|Gammanorm|Sub-Q IgG
226101|NCT02180776|Other|Summit 456 TLSO|Thoracolumbarsacral orthosis
226102|NCT02180789|Drug|Tamsulosin OCAS|oral
226103|NCT02180802|Behavioral|motivational interviewing|
226104|NCT00002283|Drug|Sulfamethoxazole|
226105|NCT00137423|Drug|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
226106|NCT02180802|Behavioral|motivational interviewing with parental involvement|
226107|NCT02180802|Behavioral|Control group|
226108|NCT02180815|Device|ReVENT Sleep Apnea System|
226109|NCT02180828|Drug|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
226110|NCT02180828|Drug|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
225801|NCT02190617|Behavioral|Enhanced Clinic+ Unified Plan + CHW|Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.
Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.
Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign.
225802|NCT02190617|Behavioral|Enhanced Clinic+ Unified Management Plan|Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.
Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign.
225803|NCT02193204|Behavioral|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
225804|NCT02193217|Drug|MT-1303-Low|
225805|NCT02193217|Drug|MT-1303-High|
225806|NCT02193217|Drug|Fingolimod|
225807|NCT02193217|Drug|Placebo|
225808|NCT02193256|Drug|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
225809|NCT02193256|Drug|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
225810|NCT02193256|Drug|Placebo|
226122|NCT02183311|Drug|BI 1356 BS - multiple rising dose|
226123|NCT02183311|Drug|Placebo|
226124|NCT02183324|Drug|Low dose of BI 1356 BS|
226125|NCT02183324|Drug|Medium dose of BI 1356 BS|
226126|NCT02183324|Drug|High dose of BI 1356 BS|
226127|NCT02183324|Drug|Placebo|
226128|NCT02183337|Drug|BI 1356|
226129|NCT02183337|Drug|BI 1356 + Pioglitazone|
226130|NCT02183337|Drug|Pioglitazone|
225475|NCT02159911|Drug|Misoprostol administered orally one hour before surgery|Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.
The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient.
225476|NCT02159937|Other|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
225477|NCT00135122|Drug|prednisolone|Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
225478|NCT02159950|Other|Laboratory Biomarker Analysis|Correlative studies
225479|NCT02159950|Biological|Sipuleucel-T|Given IV
225480|NCT02159950|Drug|Tasquinimod|Given PO
225481|NCT02159963|Other|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
225482|NCT02159963|Other|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
225483|NCT02159963|Other|Optional training|8 weeks of optional home based, unsupervised training.
225484|NCT02162342|Other|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
225485|NCT02162355|Drug|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
225486|NCT02162355|Drug|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
225487|NCT02162355|Drug|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
225488|NCT00135382|Drug|Videx EC|
225489|NCT02162355|Drug|Placebo|1 or 2 matching placebo tablets once daily for 10 days
225490|NCT02162381|Drug|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
225491|NCT02162381|Other|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
225492|NCT02162394|Device|Observational ambulatory ECG monitoring|
225811|NCT02193269|Drug|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
225812|NCT02193269|Drug|Minocycline|you will receive 200 mg as a single daily dose for 4 days
225153|NCT02167516|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
225154|NCT02167542|Device|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
225155|NCT00135876|Drug|dalteparin|
225156|NCT02169726|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
225157|NCT02169739|Device|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
225158|NCT02169752|Drug|Ambrisentan|Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either "placebo" or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner.
225159|NCT00136175|Drug|Carboplatin|
225160|NCT02169765|Other|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
225161|NCT02169765|Other|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
225162|NCT02169778|Behavioral|Intermittent energy restricted diet|
225163|NCT02169778|Behavioral|Continuous energy restricted diet|
225164|NCT02169791|Drug|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
225165|NCT02169804|Drug|Androxal 25 mg|
225166|NCT02169817|Drug|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
225167|NCT02169817|Drug|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
225168|NCT02169830|Drug|nortriptyline|
225493|NCT02162407|Drug|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
225494|NCT02162407|Drug|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
225495|NCT02162420|Drug|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
224552|NCT02182648|Drug|propofol|intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.
infusion of propofol at 2 minutes before anesthesia induction
224553|NCT02182648|Drug|sevoflurane|intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.
inhale sevoflurane for anesthesia induction and maintenance
224554|NCT02182661|Drug|Ba253BINEB|
224555|NCT02182674|Drug|Placebo Combivent HFA|
224556|NCT02182674|Drug|Combivent HFA|
224557|NCT02182674|Drug|Combivent (CFC)|
224558|NCT02182674|Drug|Placebo Combivent (CFC)|
224559|NCT00137696|Procedure|Collection of serum|
224560|NCT02182687|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
224847|NCT02174965|Device|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
224848|NCT02174965|Device|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
224849|NCT02174978|Biological|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
224850|NCT02174978|Other|P falciparum Controlled Human Malaria Infection (CHMI)|
224851|NCT02174991|Drug|Rho-Kinase Inhibitor (AR-12286)|
224852|NCT02175004|Drug|IONIS-TTR Rx|300 mg IONIS-TTR Rx administered once weekly
224853|NCT00136760|Drug|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
224854|NCT02175017|Drug|ONO-4538|
224855|NCT02175030|Drug|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
224856|NCT02175030|Drug|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
224857|NCT02175043|Procedure|atrial electrogram and liner ablation|The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
224228|NCT02187562|Drug|Aspirin|
224229|NCT02187575|Drug|UHAC 62 XX tablet|
224230|NCT00138177|Drug|oxaliplatin|Given IV
224231|NCT02187575|Drug|UHAC 62 XX capsule|
224232|NCT02187588|Drug|Eschscholtzia Californica - low dose|
224233|NCT02187588|Drug|Eschscholtzia Californica - high dose|
224234|NCT02187588|Drug|Ibuprofen|
224235|NCT02187588|Drug|Eschscholtzia Californica - low dose Placebo|
224236|NCT02187588|Drug|Eschscholtzia Californica - high dose Placebo|
224237|NCT02187588|Drug|Ibuprofen Placebo|
224238|NCT02187614|Drug|Diclofenac|
224239|NCT02189759|Other|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
224240|NCT02189759|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
224561|NCT02182687|Procedure|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
224562|NCT02182687|Drug|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
224563|NCT02182700|Drug|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
224564|NCT02182713|Drug|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
224565|NCT02182713|Drug|Salbutamol|Salbutamol 100 mcg per puff
228782|NCT02419755|Drug|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
228783|NCT02419755|Drug|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
229078|NCT02413333|Device|PeroxiClear™ contact lens cleaning and disinfecting solution|Hydrogen peroxide 3% solution for cleaning, disinfection and overnight storage of contact lenses
229079|NCT02413333|Device|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per subject's habitual brand
229080|NCT02413346|Drug|Sarecycline|Administered based on patient body weight.
229081|NCT02413372|Drug|BMS-986036|
229082|NCT00165490|Drug|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
229083|NCT02413372|Drug|BMS-986036|
229084|NCT02413372|Drug|Placebo|
229085|NCT02413372|Drug|BMS-986036|
229086|NCT02415582|Other|Combined exercises|Combined resistance and aerobic exercise
229087|NCT02415582|Other|Control|45 minutes resting sitting
229088|NCT02415595|Drug|BMS-955176|HIV Maturation Inhibitor
229089|NCT02415595|Drug|EFV|
229090|NCT02415595|Drug|TDF/FTC|
229091|NCT02415608|Drug|Ibrutinib|Given PO
229092|NCT02415608|Other|Quality-of-Life Assessment|Ancillary studies
229093|NCT00165750|Drug|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
229094|NCT02415608|Other|Laboratory Biomarker Analysis|Correlative studies
229095|NCT02415608|Other|Pharmacological Study|Correlative studies
229096|NCT02415621|Drug|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
229400|NCT02411422|Device|Conventional endotracheal tube|Conventional endotracheal tube
229401|NCT02413372|Drug|Placebo|
229402|NCT02413385|Behavioral|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
229403|NCT02413398|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
229404|NCT02413398|Drug|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
229405|NCT02413411|Behavioral|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
229406|NCT02413411|Behavioral|an educational program (an NIH-developed booklet)|
229407|NCT02413424|Dietary Supplement|Sucralose|60 ml of 2mM sucralose
229408|NCT00165490|Drug|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
229409|NCT02413424|Other|Water|60 ml of water
229410|NCT02413424|Dietary Supplement|glucose load|
229411|NCT02413437|Other|contrast-enhanced ultrasound guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided.
229703|NCT02407028|Drug|Oxygen|HBO Oxygen; 1.5 ATA, with NBH twice per day X five days or until patient following commands or brain dead
229704|NCT02407028|Other|Usual and customary care for severe traumatic brain injury|Will be treated with usual and customary care for severe traumatic brain injury
229705|NCT02407041|Drug|GR-MD-02|IV infusion
229706|NCT02407054|Drug|LY3023414|Administered orally
229707|NCT02407054|Drug|Enzalutamide|Administered orally
229708|NCT02407054|Drug|Placebo|Administered orally
229709|NCT02407067|Device|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
234028|NCT02465840|Procedure|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
234029|NCT02465840|Other|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
234030|NCT02465853|Drug|Hyaluronic Acid|Injection Hyaluronic Acid in the experimental group
234031|NCT00174356|Drug|CARBOPLATIN|
234032|NCT02465853|Drug|Physiological saline solution|Injection 0.9% Physiological saline solution<1.0 ml
234033|NCT02465853|Other|physical therapy and occupational therapy|rehabilitation
234034|NCT02465866|Drug|CL-108 (Fasted)|Subjects will be randomized to receive either Treatment A, Treatment B, Treatment C or Treatment D during the first study period with 14 day washout periods and subsequent crossovers to alternative treatments.
234035|NCT02465866|Drug|CL-108 (Fed)|Subjects will be randomized to receive either Treatment A, Treatment B, Treatment C or Treatment D during the first study period with 14 day washout periods and subsequent crossovers to alternative treatments.
234036|NCT02465866|Drug|Vicoprofen, Ultracet and Phenegran (Fasted)|Subjects will be randomized to receive either Treatment A, Treatment B, Treatment C or Treatment D during the first study period with 14 day washout periods and subsequent crossovers to alternative treatments.
234037|NCT02465866|Drug|Vicoprofen, Ultracet and Phenegran (Fed)|Subjects will be randomized to receive either Treatment A, Treatment B, Treatment C or Treatment D during the first study period with 14 day washout periods and subsequent crossovers to alternative treatments.
234038|NCT02465879|Other|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
234039|NCT02465892|Behavioral|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
234040|NCT02465905|Other|raw milk|
234041|NCT02465905|Other|Heated milk|
234042|NCT00174369|Drug|PD-0325901|15 mg BID
234043|NCT02465918|Device|motor cortex stimulation (Change of Stimulation Timing)|
229412|NCT02413437|Other|conventional ultrasound guided biopsy|Biopsy was operated under conventional ultrasound-guided.
229413|NCT02413437|Device|Ultrasound|
229414|NCT02413463|Procedure|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
233457|NCT02397330|Drug|morphine|
233458|NCT02397343|Drug|Hyperbaric oxygen|
233459|NCT02397356|Drug|Ketamine first AB|Nebulised ketamine 1mg/kg
233460|NCT02397356|Drug|Placebo first BA|Nebulised saline 1-2ml
233461|NCT02397369|Other|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
233740|NCT02425878|Drug|Placebo|
233741|NCT02425891|Drug|Atezolizumab|An engineered anti-PDL1 antibody; Day 1 and Day 15 of every cycle, participants will receive atezolizumab 840 mg administered by IV infusion every two weeks (every 14 (+/-3) days)
233742|NCT02425891|Drug|Nab-Paclitaxel|Administered alone intravenously on days 1, 8, and 15 of each 28-day cycle, with a starting dose of 100 mg/m2
233743|NCT02425891|Drug|Placebo|On Day 1 and Day 15 of every cycle, participants will receive 840 mg placebo administered by IV infusion every 14 (+/- 3) days
233744|NCT02425904|Drug|Clofarabine|Evaluation of response to clofarabine
233745|NCT02425917|Device|geko|neuromuscular electrostimulator
233746|NCT02427945|Behavioral|Provision of information on safe water and child nutrition|A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
233747|NCT02427958|Drug|Leuprorelin|Suspension for injection
233748|NCT02427984|Other|Metal ions dosage and evaluation of local/systemic reaction|Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.
Determination of local/systemic reaction
233749|NCT02427984|Other|Noise registration and metal ions determination|Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.
Determination of range of noise
233750|NCT02427984|Other|Metal ions dosage, evaluation of local/systemic reaction, noise registration|Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.
Determination of local/systemic reaction
233751|NCT02427997|Behavioral|Treadmill training with Virtual Reality|VR is defined in general as a "high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels". The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components.
228575|NCT02397681|Other|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
228576|NCT02397694|Drug|GS-9883|GS-9883 75 mg tablet administered orally once daily
228577|NCT02397694|Drug|FTC/TAF|FTC/TAF (200/25 mg) FDC tablet administered orally once daily
228578|NCT02397694|Drug|DTG|DTG 50 mg tablet administered orally once daily
228579|NCT02397694|Drug|GS-9883 Placebo|GS-9883 placebo tablet administered orally once daily
228580|NCT02397694|Drug|DTG Placebo|DTG placebo tablet administered orally once daily
228581|NCT02397694|Drug|GS-9883/F/TAF|GS-9883/F/TAF (50/200/25 mg) FDC tablet administered orally once daily
228582|NCT00163579|Drug|Bryophyllum|
228583|NCT02397707|Drug|GS-9857|GS-9857 100 mg tablet administered orally
228584|NCT02399982|Other|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
228860|NCT02428270|Drug|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
228861|NCT00167791|Drug|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
228862|NCT02428270|Drug|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
228863|NCT02428283|Drug|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
228864|NCT02428283|Drug|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
228865|NCT02428283|Drug|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
228866|NCT02428296|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
228867|NCT02428309|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
228868|NCT02428322|Dietary Supplement|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
228869|NCT02428322|Dietary Supplement|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
228271|NCT02170844|Drug|Placebo of BIBR 1048 MS|
228272|NCT02170857|Drug|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
228273|NCT02170870|Drug|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
228274|NCT02170870|Drug|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
228275|NCT02170870|Drug|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
228276|NCT02170883|Other|Interactive SMS|
228277|NCT02170883|Other|Usual care|
228278|NCT02170896|Drug|BIBR 1048 MS Capsule A|
228279|NCT00136344|Drug|Levofloxacin|
228280|NCT02170896|Drug|BIBR 1048 MS Capsule B|
228281|NCT02170896|Drug|BIBR 1048 MS Capsule C|
228282|NCT02170896|Drug|BIBR 1048 MS Capsule D|
228283|NCT02170896|Drug|BIBR 1048 MS tartaric acid solution|
228284|NCT02170896|Drug|Pantoprazole|
228285|NCT02170909|Drug|BIBR 1048 MS low dose|
228286|NCT02170909|Drug|BIBR 1048 MS medium dose|
228287|NCT02170909|Drug|BIBR 1048 MS high dose|
228288|NCT02170922|Drug|BIBR 1048 MS tablet|
228289|NCT02170922|Drug|BIBR 1048 MS solution|
228290|NCT00136357|Behavioral|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
228291|NCT02170935|Drug|BIBR 1048 capsule|
228585|NCT02399982|Other|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
227654|NCT02184026|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
227655|NCT02184052|Drug|Meloxicam|7.5 mg or 15 mg
227950|NCT02178735|Procedure|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
227951|NCT02178735|Procedure|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
227952|NCT02178748|Biological|MVA85A|Single dose of 1x10^8pfu MVA85A intramuscular vaccination
227953|NCT02178761|Device|drug-eluting balloon|angioplasty completed with drug-eluting balloons
227954|NCT02178761|Device|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
227955|NCT00137202|Drug|Diphenhydramine (Benadryl)|
227956|NCT02178761|Device|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
227957|NCT02178761|Device|Stent System|stenting with either bare-metal stents or drug-eluting stents
227958|NCT02178800|Drug|GSK1265744 Tablets|30-mg tablets, taken orally
227959|NCT02178800|Drug|Injectable GSK1265744|Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections
Cohort 2: 600-mg injection, administered as one IM gluteal injection
227960|NCT02178800|Drug|Placebo for GSK1265744 Tablets|Taken orally
227961|NCT02178800|Drug|Injectable Placebo for GSK1265744|Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections
Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection
227962|NCT02178813|Drug|Administration of minocycline|Administration of minocycline with the following schedule:
Day prior to procedure: 800mg p.o., 700mg p.o.
Day of procedure: 600mg i.v., 500mg p.o.
Day after procedure: 400mg p.o., 400mg p.o.
227963|NCT02178826|Device|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
227964|NCT02178826|Device|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
227965|NCT02178839|Dietary Supplement|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
227966|NCT00137215|Device|Silverlon|dressing for donor site mamagement
227315|NCT02191371|Drug|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
227316|NCT02191384|Drug|Orcinoside|oral, twice per day
227317|NCT02191397|Drug|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
227318|NCT02191397|Drug|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
227319|NCT02191397|Drug|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
227320|NCT02193841|Device|Curette|A small surgical instrument with a rounded edge designed for scraping
227321|NCT02193841|Device|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
227656|NCT02186379|Behavioral|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
227657|NCT02186379|Behavioral|Usual Care Control|Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including "What's on Your Plate" and "My Plate for Kids" mini-posters.
227658|NCT02186392|Device|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
227659|NCT02186405|Drug|LEVOTHYROXINE|administration of levothyroxine
227660|NCT02186418|Genetic|Gene transfer|Gene transfer using a gamma-globin lentivirus vector
227661|NCT00138021|Device|Computerized cognitive training program|The cognitive training model used in the McGurk et al. (2005) study is referred to as the "Thinking Skills for Work" program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk & Mueser, unpublished training manual) and a computer-based cognitive training program (described below).
227662|NCT02186431|Device|senofilcon A|
227663|NCT02186444|Other|Personalized Health Information Navigator (PHIN)|The application (or "app") titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs.
227016|NCT02157766|Behavioral|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
227017|NCT02157766|Behavioral|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
227018|NCT02157779|Behavioral|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
227019|NCT02157779|Behavioral|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
227020|NCT02157792|Drug|VX-970|
227021|NCT02157792|Drug|gemcitabine|
227022|NCT02157792|Drug|cisplatin|
227023|NCT02157792|Drug|etoposide|
227024|NCT02157805|Other|beef meat|Meat cooking conditions
st condition : beef meat cooked during 5 minutes at 55°C
nd condition : beef meat cooked during 30 minutes à 90°C
227025|NCT00134771|Drug|Nutrient enriched infant formula|
227026|NCT00135187|Drug|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
227322|NCT02193854|Device|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
227323|NCT02193867|Drug|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with Lysosomal Acid Lipase Deficiency. Dosing will occur once weekly for up to three years.
227324|NCT02193880|Device|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
227325|NCT02193893|Other|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
227326|NCT02193893|Other|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
226406|NCT02172664|Procedure|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
226407|NCT00136474|Radiation|Radiation Therapy|Daily radiation therapy
226709|NCT02165449|Drug|Ketamine|Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a single subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes to patients with Major Depression while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
226710|NCT02165462|Other|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
226711|NCT02165475|Behavioral|Biofeedback|
226712|NCT02165475|Drug|Loperamide|
226713|NCT02165475|Drug|Stool bulking agent (stericulia or isphagula husk)|
226714|NCT02165475|Other|Combination of biofeedback and medical treatment|
226715|NCT00135681|Drug|nedocromil budesonide|
226716|NCT02165514|Procedure|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
226717|NCT02165527|Procedure|Lunar iXDA scan|Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
226718|NCT02165540|Other|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
226719|NCT02165553|Dietary Supplement|Hibiscus sabdariffa calyces extract as a cold drink|
226720|NCT02167958|Radiation|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
226721|NCT02167958|Other|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
226111|NCT02180841|Dietary Supplement|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
226112|NCT02180841|Dietary Supplement|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
226113|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 film-coated tablets|
226114|NCT02183285|Dietary Supplement|Placebo film-coated tablets (fct)|
226115|NCT02183285|Dietary Supplement|Placebo soft gelatine capsules|
226116|NCT02183298|Drug|BI 1356 BS - intravenous|
226117|NCT02183298|Drug|BI 1356 BS - Tablet|
226118|NCT02183298|Drug|Placebo|
226119|NCT00002286|Drug|Zidovudine|
226120|NCT00137774|Drug|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
226121|NCT02183311|Drug|BI 1356 BS - single rising dose|
226408|NCT02172664|Procedure|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
226409|NCT02172664|Device|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
226410|NCT02172677|Behavioral|Episodic memory task|
226411|NCT02172677|Device|fMRI|
226412|NCT02172690|Procedure|Laparoscopic Staging|Laparoscopic Staging
226413|NCT02172703|Device|Non-invasive ICP measurement device|The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.
The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
226414|NCT02172716|Procedure|Nonsurgical periodontal treatment|All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.
Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed.
226415|NCT02172729|Drug|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
226131|NCT00137774|Drug|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
226132|NCT02183350|Drug|BI 1356 BS - single rising dose|
226133|NCT02183350|Drug|Placebo|
226134|NCT02183363|Drug|BI 1356 - Tablet TFII|
226135|NCT02183363|Drug|BI 1356 - Tablet iFF|
226136|NCT02183363|Drug|BI 1356 - Tablet TFIIb|
226137|NCT02183376|Drug|BI 1356|
226138|NCT02183389|Drug|Warfarin|
226139|NCT02183389|Drug|BI 1356|
226140|NCT02183402|Drug|Digoxin|
226141|NCT02183402|Drug|BI 1356|
226142|NCT00137787|Drug|ciprofloxacin|
226143|NCT02183415|Drug|BI 1356 BS, low dose|
226144|NCT02183415|Drug|BI 1356 BS, medium dose|
226145|NCT02183415|Drug|BI 1356 BS, high dose|
226146|NCT02183415|Drug|Placebo|
226147|NCT02185742|Behavioral|Strength Based Case Management|
226148|NCT02185755|Other|Internet-Based Glucose Monitoring System|
226149|NCT02185755|Drug|Normal Medication Positive Control|
226150|NCT02185768|Drug|idarubicin|
226427|NCT02175628|Device|Acoustic Angiography|Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.
Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient.
225813|NCT00138944|Drug|placebo|od
225814|NCT02193282|Drug|Erlotinib Hydrochloride|Given PO
225815|NCT02193282|Other|Laboratory Biomarker Analysis|Correlative studies
225816|NCT02193282|Other|Placebo|Given PO
225817|NCT02193295|Behavioral|Dietary consultations|Dietary consultations and caloric restriction to reduce liver and intra myocellular fat content and improve tissue specific insulin sensitivity
225818|NCT02193308|Drug|Telmisartan/Amlodipine FDC|
225819|NCT02193308|Drug|Telmisartan|
225820|NCT02193308|Drug|Amlodipine|
225821|NCT02193321|Biological|Amniotic Membrane Patch|
225822|NCT02193334|Drug|KP-100IT|
225823|NCT02193334|Drug|Placebo|
225824|NCT00138944|Drug|eplerenone|50mg od
225825|NCT02193347|Biological|PEPIDH1M vaccine|Tetanus Pre-conditioning will consist of a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered to the RIGHT groin area 12-24 hours prior to receiving PEPIDH1M vaccine intradermally in the same groin.
225826|NCT02193360|Drug|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
225827|NCT02193373|Other|Osteopathic Manual Medicine|Osteopathic Manual Medicine
225828|NCT02193373|Other|Sham|Osteopathic Manual Medicine
225829|NCT02193386|Other|No intervention, no follow-up, only registration|Usual Care
225830|NCT02193386|Other|Intervention period|Predefined intervention program
225831|NCT02195830|Other|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
225832|NCT02195843|Other|Electrical optimization by RVLV Conduction Time with VectSelect|VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.
The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode .
225496|NCT02162420|Drug|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
225497|NCT02162420|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
225498|NCT02162420|Radiation|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
225499|NCT00135382|Drug|Epivir|
225500|NCT02162420|Biological|Stem Cell Transplant|Stem cell transplant on day 0.
225501|NCT02162420|Drug|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
225502|NCT02162433|Drug|Normal Saline|to arms 2,4. Serves as the placebo.
225503|NCT02162433|Drug|Dexmedetomidine|to arms 1,3
225504|NCT02162446|Drug|68Ga-OPS202|
225505|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler|
225506|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler with charcoal|
225507|NCT02162485|Drug|Seretide Diskus|
225508|NCT02162485|Drug|Seretide Diskus with charcoal|
225509|NCT02162498|Behavioral|Feeding buddies|The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.
The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations.
225510|NCT00135382|Drug|Sustiva|
225511|NCT02162511|Device|CliniMACS CD34+ cell enrichment and T-cell depletion|
225512|NCT02164890|Other|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
225513|NCT02164903|Other|QoL Survey Booklet|
225514|NCT02164916|Biological|cetuximab|Given IV
225515|NCT02164916|Drug|irinotecan hydrochloride|Given IV
225516|NCT02164916|Drug|vemurafenib|Given PO
224858|NCT02175056|Biological|HL2351|Dose-escalation For 5 level dose groups A ~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
224859|NCT02175056|Biological|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
224860|NCT02177448|Drug|Placebo matching enalapril|
224861|NCT02177461|Drug|Telmisartan|
224862|NCT02177461|Drug|Enalapril|
224863|NCT02177461|Drug|Clonidine|
224864|NCT02177474|Behavioral|Telephone based peer support|
224865|NCT02177487|Drug|Telmisartan/hydrochlorothiazide|
224866|NCT02177500|Drug|Telmisartan + hydrochlorothiazide|
224867|NCT02177500|Drug|Telmisartan|
224868|NCT00137072|Drug|Viagra (Sildenafil Citrate) 100 mg|
224869|NCT02177500|Drug|Placebo|
225169|NCT02169830|Drug|Topiramate|
225170|NCT00136175|Drug|Gemcitabine|
225171|NCT02169843|Drug|Sevoflurane|inhale Sevoflurane
225172|NCT02169843|Drug|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
225173|NCT02169843|Drug|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
225174|NCT02169856|Behavioral|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
225175|NCT02169856|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
225176|NCT02169856|Drug|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
225177|NCT02169856|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
225178|NCT02169856|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
224566|NCT02182726|Drug|MOBEC|
224567|NCT02182739|Drug|Meloxicam|tablets or injectable solution
224568|NCT02182752|Drug|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
224569|NCT02182752|Drug|Ropivacaine|Interscalene block using ropivacaine
224570|NCT00002285|Drug|Zidovudine|
224571|NCT00137709|Drug|Sodium valproate|Week 1 & 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
224572|NCT02182765|Drug|Nevirapine|
224573|NCT02182765|Drug|Amprenavir|
224574|NCT02182765|Drug|Abacavir|
224575|NCT02182778|Drug|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
224576|NCT02182778|Drug|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
224577|NCT02182791|Drug|Nevirapine|
224578|NCT02182791|Drug|EE/NET|
224579|NCT02182804|Device|Olympus|narrow band imaging with magnification
224580|NCT02182804|Device|Cellvizio|probe-based confocal laser endomicroscopy
224581|NCT02185170|Procedure|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
224582|NCT02185170|Device|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
224583|NCT02185170|Device|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
224584|NCT02185183|Drug|Alequel|Alequel
224870|NCT02177513|Drug|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
224871|NCT02177513|Drug|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
224872|NCT02177513|Drug|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
229097|NCT02415634|Other|RECAP|Patients will receive an information pack at ICU discharge called the RECAP. This pack will include
Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)
Part 2: A rehabilitation goal setting care plan
Part 3: A patient communication forum
Part 4: Useful supports and contact information
Part 5: Tailored exercise programme
The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.
The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care.
229098|NCT02415634|Other|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
229099|NCT02415660|Procedure|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
224241|NCT02189759|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
224242|NCT02189772|Drug|Metadoxine extended release|MG01CI
224243|NCT02189772|Drug|Placebo|Inactive drug
224244|NCT02189798|Device|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
224245|NCT02189798|Device|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
224246|NCT02189811|Biological|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
224247|NCT00002294|Drug|Fluconazole|
224248|NCT00138476|Drug|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
224249|NCT02189811|Biological|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
224250|NCT02189811|Biological|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
224251|NCT02189811|Biological|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
224252|NCT02189811|Biological|tOPV|tOPV till 22 weeks of age
229710|NCT02407067|Device|Easy Listener FM system (Phonic Ear Corp.)|A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
Personal Communication System
229711|NCT02407080|Drug|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
229712|NCT02407080|Drug|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
229713|NCT00164918|Device|nasogastric tube|
229714|NCT02407093|Behavioral|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
229715|NCT02409238|Drug|Metformin|Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
229716|NCT02409238|Behavioral|Intensive Lifestyle Intervention|The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.
This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises.
229717|NCT00165139|Drug|Adriamycin|Described under detailed description
229718|NCT02409238|Behavioral|Standard LIfestyle Recommendation|The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
229719|NCT02409251|Behavioral|Education and feedback|
230006|NCT02403011|Other|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
230007|NCT00164372|Behavioral|Peer Education Intervention|
230008|NCT02403011|Other|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
229415|NCT02413463|Procedure|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
229416|NCT02413476|Procedure|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
229417|NCT02413476|Procedure|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
229418|NCT02413489|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
229419|NCT00165490|Drug|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
229420|NCT02413502|Biological|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10^8 CFUs.
229421|NCT02413515|Drug|Nifedipine(Adalat_BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
229422|NCT02413528|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
229423|NCT02415673|Device|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
229424|NCT02415699|Drug|Fluorouracil|
229425|NCT02415699|Drug|Oxaliplatin|
229426|NCT02415699|Drug|Leucovorin|
229427|NCT02415699|Biological|DC-CIK|
229428|NCT02415712|Drug|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
229429|NCT02415725|Drug|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
229430|NCT02415738|Procedure|Prone positioning|
229431|NCT02415751|Behavioral|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
229432|NCT00165776|Drug|BOTULINUM TOXIN TYPE B|
233752|NCT02427997|Behavioral|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
233753|NCT00167739|Drug|Quinine plus sulfadoxine-pyrimethamine|
233754|NCT02428010|Device|TMVR Implant|Implantation of the Twelve TMVR System
233755|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^6 TCID50/mL.
233756|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^7 TCID50/mL.
233757|NCT02428049|Radiation|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
234044|NCT02465931|Other|Paper-Based Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacCAT Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
234045|NCT02465931|Device|Tablet-Based Consent|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
234046|NCT02465944|Drug|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
234047|NCT02430519|Procedure|Furcation Treatment with Allograft and GTR|Allograft and GTR placed into furcation after flap elevation and debridement
234048|NCT02430519|Device|allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)|
234049|NCT02430519|Device|autologous platelet-rich fibrin|
234050|NCT02430532|Drug|dimethyl fumarate|capsule (blue-white)
234051|NCT02430532|Other|Placebo|Matched placebo capsule (blue-white)
234052|NCT02430545|Drug|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
234053|NCT02430545|Drug|Rifampin|Subjects receive rifampin 600 mg oral dose daily [Day -6 to day 4]
234054|NCT02430558|Biological|OD-PHOENIX|dellelularized, freeze-dried, irradiated osteochondral allograft
228870|NCT02428348|Other|Interview about prototype EEG-cap|
228871|NCT02428361|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
228872|NCT00167804|Behavioral|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
228873|NCT02428374|Drug|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
228874|NCT02428374|Drug|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
228875|NCT02428374|Drug|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
228876|NCT02428374|Drug|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
228877|NCT02428387|Behavioral|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
228878|NCT02428400|Biological|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
228879|NCT02428400|Biological|Placebo|Placebo: adenovirus reference material (ARM) buffer
228880|NCT02428413|Device|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
228881|NCT02428413|Device|Standard oxygen mask|Provide supplemental oxygen
228882|NCT02395250|Biological|anti-GPC3 CAR T|
224004|NCT02164305|Other|Neuromuscular group|Closed-chain exercise for shoulder muscles
224005|NCT02164305|Other|Control|No exercise training
224006|NCT02164318|Other|Handgrip training|
224007|NCT02164318|Drug|Nitroglycerin ointment|
224008|NCT02164331|Behavioral|JNC guideline training|Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
224009|NCT02164344|Dietary Supplement|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
228586|NCT02399995|Behavioral|HRQoL questionnaires.|Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:
Baseline sociodemographic and clinical variable data sheet (RSA)
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS
Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS
Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS
Post surgical follow up disease status and treatment assessment questionnaire
At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone.
228587|NCT00163969|Drug|ketamine|
228588|NCT02400008|Procedure|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
228589|NCT02400021|Drug|Prometrium|
228590|NCT02400034|Other|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
228591|NCT02400047|Drug|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
228592|NCT02400047|Drug|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
228593|NCT02400047|Drug|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
228594|NCT02400060|Behavioral|Telephone-Based Intervention|Receive text messaging
228595|NCT02400060|Other|Survey Administration|Ancillary studies
228596|NCT02400060|Other|Laboratory Biomarker Analysis|Correlative studies
228597|NCT02400073|Device|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
228598|NCT00163982|Drug|Norfloxacin|
228599|NCT02400099|Dietary Supplement|High-protein low calorie diet|
228600|NCT02400099|Dietary Supplement|Control low calorie diet|
228601|NCT02400099|Other|Anthropometrical measurements|
228602|NCT02400099|Other|Body composition|
228603|NCT02400099|Other|8-h metabolic profile|
228604|NCT02400099|Other|Liver biopsy|
227967|NCT02178839|Dietary Supplement|Maltodextrin|8.5 g/d Maltodextrin
227968|NCT02178852|Device|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
228292|NCT02170948|Drug|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
228293|NCT02170948|Drug|No Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine with NO Dexmedetomidine will be provided via a series of anesthetic injections related to the ankle block procedure
228294|NCT02173561|Behavioral|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
228295|NCT02173574|Drug|DEB025|
228296|NCT00136578|Drug|carboplatin|
228297|NCT02173574|Drug|EDP239|
228298|NCT02173587|Dietary Supplement|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
228299|NCT02173587|Dietary Supplement|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
228300|NCT02173600|Behavioral|Group-level Intensive dietary Counselling|
228301|NCT02173600|Behavioral|Individual-level Intensive Dietary Counselling|
228302|NCT02173613|Other|procalcitonine|The recommendations will be based on the level of PCT: 4 levels of advice will be given:
It is highly recommended to stop antibiotics if PCT <0.1ng/ml, and the recommended stop if 0.1ng/ml <PCT <0.25 ng / ml.
It is recommended to continue treatment if 0.25 ng / ml <PCT ng / ml.
Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level.
228303|NCT02173626|Behavioral|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
228304|NCT02173639|Drug|BI 1356/metformin|fixed dose combination tablet
228305|NCT02173639|Drug|BI 1356|
228306|NCT02173639|Drug|Metformin|
227664|NCT02186444|Other|NCI Information Booklets (IB)|Participants will receive a packet of information booklets ("What You Need to Know About Prostate Cancer"; "Taking Time: Support for People with Cancer"; and "Facing Forward, Life After Cancer Treatment") that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks.
227665|NCT02186457|Drug|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
227666|NCT02186457|Other|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
227667|NCT02186470|Radiation|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
227668|NCT02186470|Radiation|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
227669|NCT02186470|Radiation|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
227670|NCT02186470|Procedure|therapeutic conventional surgery|Undergo lumpectomy
227671|NCT02186470|Other|questionnaire administration|Ancillary studies
227969|NCT00137501|Drug|Nifedipine|Arm A:
Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.
Arm B:
Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks.
227970|NCT02181439|Device|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
227971|NCT02181465|Biological|G17DT|
227972|NCT02181478|Drug|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
227973|NCT02181478|Drug|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
227974|NCT02181478|Radiation|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
227975|NCT02181478|Drug|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
227976|NCT02181478|Drug|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
227977|NCT02181478|Procedure|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
227327|NCT02193906|Other|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
227328|NCT02193906|Other|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
227329|NCT02193932|Other|EEG Triggered fMRI using Micro Maglink|
227330|NCT00139035|Drug|cyclosporine A|
227331|NCT02193958|Drug|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
227332|NCT02193971|Device|Everolimus-eluting stenting|
227333|NCT02193971|Device|biodegradable polymer biolimus-eluting stent|
227334|NCT02193971|Drug|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
227335|NCT02193984|Behavioral|Peer support|
227336|NCT02193997|Other|Fiber|
227337|NCT02193997|Other|Fiber|
227338|NCT02193997|Other|Placebo|
227339|NCT02194023|Drug|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
227672|NCT00138034|Procedure|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
227673|NCT02186470|Other|laboratory biomarker analysis|Correlative studies
227674|NCT02186483|Drug|Metformin|Metformin,1000mg, once daily
227675|NCT02188836|Device|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
227676|NCT02188836|Device|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
226722|NCT02167958|Drug|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
227027|NCT02160444|Behavioral|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
227028|NCT02160457|Other|Intervention with IGA|Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis
The instrumented gait analysis consists of four steps:
Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)
Impairment-Focused Interpretation
Recommendation for interdisciplinary interventions
Dissemination of recommendations
The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group.
227029|NCT02160470|Behavioral|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
227030|NCT02160470|Behavioral|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
227031|NCT02160470|Behavioral|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
227032|NCT02160470|Behavioral|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
227033|NCT02160483|Other|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
227034|NCT02160496|Behavioral|Weight loss interventional study with 20% protein-diet|
227035|NCT02160496|Behavioral|Weight loss interventional study with 27% protein-diet|
227036|NCT02160496|Behavioral|Weight loss interventional study with 35% protein-diet|
227037|NCT00002265|Drug|Zalcitabine|
226416|NCT02172742|Drug|BIA 2-093|BIA 2-093 1200 mg once-daily
226417|NCT02172742|Drug|Placebo|matching placebo
226418|NCT00136487|Drug|Celecoxib|
226419|NCT02172742|Drug|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
226420|NCT02172755|Drug|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
226421|NCT02172768|Other|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
226422|NCT02175602|Drug|Escitalopram|10 milligrams administered each morning
226423|NCT00136825|Drug|Placebo|
226424|NCT02175602|Drug|Sertraline|50 milligrams administered each morning
226425|NCT02175602|Drug|DCV 3DAA FDC|Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
226426|NCT02175602|Drug|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
226723|NCT02167958|Drug|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
226724|NCT02167958|Drug|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is > 1,000/mm3 for three consecutive days.
226725|NCT00135954|Drug|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
226726|NCT02167971|Other|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
226727|NCT02167971|Other|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
226728|NCT02168010|Drug|Analgecine|Analgesic drug under test
226729|NCT02168010|Drug|Neurotropin|Analgesic drug as positive control
226730|NCT02168010|Drug|Placebo|Blank tablet as placebo.
226428|NCT02175641|Behavioral|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
226429|NCT02175641|Behavioral|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
226430|NCT02175654|Drug|Regorafenib|
226431|NCT02175667|Procedure|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
226432|NCT02175680|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
226433|NCT02175706|Device|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
226434|NCT00136838|Behavioral|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
226435|NCT02175706|Device|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
226436|NCT02175732|Behavioral|'KnowIt'|Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.
During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine.
226437|NCT02178033|Drug|Split dose low-volume PEG solution|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the "control arm" the whole colonoscopy preparation is administered the day before colonoscopy; in the " active comparator " arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure.
226438|NCT02178046|Device|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
226439|NCT02178059|Drug|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate delivered dose per inhalation, 3 inhalations comprise a single dose (for a total of 1.2 mg delivered dose)
225833|NCT02195843|Other|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
226151|NCT02185768|Device|Dc- Beads 300-500µm|
226152|NCT02185781|Other|Autologous NK cells infusions|Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.
The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance.
226153|NCT02185794|Drug|GS-9857|GS-9857 tablets administered orally once daily
226154|NCT02185794|Drug|Placebo to match GS-9857|Placebo to match GS-9857 tablets administered orally once daily
226155|NCT02185794|Drug|SOF/GS-5816|Sofosbuvir (SOF) 400 mg/GS-5816 100 mg FDC tablet administered orally once daily
226156|NCT00137995|Drug|Dexamethasone|40 mg From D1 to D4
226157|NCT02185807|Procedure|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
226158|NCT02185807|Procedure|control group|The control patients receive verbal information and discussion from their physicians.
226159|NCT02185820|Drug|Carfilzomib|
226160|NCT02185820|Drug|Pomalidomide|
226161|NCT02185820|Drug|Dexamethasone|
226162|NCT02185833|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
226163|NCT02185833|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
226164|NCT02185846|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
226165|NCT02185846|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
226166|NCT02185859|Drug|Lidocaine|The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
226167|NCT00137995|Procedure|Autologous Stem Cell Transplantation|
225834|NCT02195843|Device|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
225835|NCT00139243|Drug|Taxotere|
225836|NCT02195856|Dietary Supplement|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
225837|NCT02195856|Dietary Supplement|Placebo|
225838|NCT02195869|Drug|Ibrutinib|
225839|NCT02195882|Procedure|Exercise program of the scapular muscle stabilizers|
225840|NCT02195895|Drug|Alendronate|Weekly oral alendronate 70 mg for 12 months
225841|NCT02195895|Dietary Supplement|Calcium|1000 mg Calcium PO QD
225842|NCT02195895|Dietary Supplement|Vitamin D|1000 IU PO QD
225843|NCT02195908|Other|single point Neiguan(PC6) plus antiemetic drug|
225844|NCT02195908|Other|single point Zhongwan(CV12) plus antiemetic drug|
225845|NCT02195908|Other|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
225846|NCT00139243|Drug|Cisplatin|
225847|NCT02195908|Drug|only antiemetic drug|
225848|NCT02195921|Other|single point Neiguan(CV12) plus antiemetic drug|
225849|NCT02195921|Other|single point Zusanli(ST36) plus antiemetic drug|
225850|NCT02195921|Other|matching points Zusanli(ST36)and Neiguan(CV12) plus antiemetic drug|
225851|NCT02195921|Drug|only antiemetic drug|
225852|NCT02195934|Other|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
225853|NCT02195934|Other|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
225854|NCT02195947|Drug|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
225179|NCT02169856|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
225180|NCT02169856|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
225181|NCT00136188|Drug|Folic Acid|oral administration of folic acid 5mg /d for 4 weeks
225182|NCT02172053|Other|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
225183|NCT02172053|Other|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
225184|NCT02172066|Behavioral|Narrative Exposure Therapy (NET)|
225185|NCT02172079|Other|Real mobilization-with-movement (MWM)|
225186|NCT00136435|Drug|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
225187|NCT02172079|Other|Sham mobilization-with-movement (MWM)|
225188|NCT02172092|Drug|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
225189|NCT02172105|Drug|BI 1744 CL|
225517|NCT02164929|Procedure|Transversus Abdominis Plane (TAP) block with ropivacaine|
225518|NCT02164929|Drug|epidural hydromorphone|Thoracic Epidural Anesthesia (TEA)
225519|NCT02164929|Procedure|Paravertebral Block (PVB)|
225520|NCT00135616|Device|surgical placement of a suburethral sling tvt or tvt-o|
225521|NCT02164929|Drug|ropivacaine 0.25%|
225522|NCT02164929|Drug|bupivacaine 0.25%|
225523|NCT02164929|Drug|Midazolam up to 2 mg. Ppropofol 1-2.5 mg/kg. Dexamethasone 4 mg IV . Isevoflurane|
225524|NCT02164929|Drug|Acetaminophen 1g IV|
225525|NCT02164955|Drug|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
224873|NCT02177513|Drug|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
224874|NCT02177513|Drug|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
224875|NCT02177526|Device|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
224876|NCT02177539|Drug|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
224877|NCT02177539|Drug|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
224878|NCT02177552|Drug|Carboplatin|
224879|NCT00137085|Drug|ketamine|
224880|NCT02177552|Drug|Docetaxel|
224881|NCT02177552|Drug|Capecitabine|
224882|NCT02177552|Drug|Epirubicin|
224883|NCT02177552|Drug|Oxaliplatin|
224884|NCT02177565|Biological|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
224885|NCT02180035|Behavioral|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
224886|NCT00137345|Drug|sirolimus|
224887|NCT02180048|Dietary Supplement|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
224888|NCT02180048|Dietary Supplement|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
225190|NCT02172105|Drug|Placebo|
225191|NCT02172118|Drug|BI 1774 CL|
225192|NCT02172131|Drug|BI 1744 CL|
224253|NCT02189824|Biological|Partially HLA-matched unrelated donor cells|
224254|NCT02189837|Biological|Evolocumab (AMG 145)|Biological
224255|NCT02189837|Drug|Atorvastatin|Atorvastatin
224256|NCT02189837|Drug|Placebo|Placebo
224257|NCT02192541|Drug|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for VEGF-A, VEGF-B, and PIGF and thius confers anti-angiogenic activity
224258|NCT02192541|Drug|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
224259|NCT02192567|Drug|DS-5573a|Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.
Step 2: 30 subjects will use the dose determined in Step 1.
224585|NCT02185196|Drug|Vitamin D3|20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
224586|NCT00137969|Drug|Diphenhydramine|
224587|NCT02185196|Drug|Placebo|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
224588|NCT02185209|Drug|Placebo|Place capsule to mimic antibiotics
224589|NCT02185209|Drug|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
224590|NCT02185209|Drug|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
224591|NCT02185209|Drug|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
224592|NCT02185222|Drug|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
224593|NCT02185222|Drug|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
224594|NCT02185235|Device|Electrical Stimulation|The Chartered Society of Physiotherapy recommends the following standard for electrical devices.
Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.
Treatment time: 5 minutes initially, gradually increasing to 20 minutes.
224595|NCT02185235|Device|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
230009|NCT02403024|Behavioral|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
230010|NCT02403024|Behavioral|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
230011|NCT02403037|Device|True auricular acupressure (Auricular tape with vaccaria seeds)|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
230012|NCT02403037|Device|Sham auricular acupressure (Auricular tape with Junci Medulla)|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
230013|NCT02403037|Drug|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists (such as Granisetron 3 mg, IV) and/or Dexamethasone (8-10 mg, IV) will be administered 30-60 minutes before chemotherapy to prevent acute nausea and vomiting. Dexamethasone (4-5 mg, IV) will be provided in the following 2-3 days to control delayed nausea and vomiting.
230014|NCT02404870|Drug|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
230015|NCT02404883|Other|Online Decision-Aid Tool|
230016|NCT02404896|Drug|Metreleptin|Metreleptin open-label treatment
230017|NCT00164645|Behavioral|Problem Solving intervention|
230018|NCT02404909|Other|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
230019|NCT02404922|Drug|CTP-730|
230020|NCT02404922|Drug|Placebo for CTP-730|
230021|NCT02404935|Drug|Cetuximab|
230022|NCT02404935|Drug|FOLFIRI and cetuximab|
230307|NCT02398396|Biological|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
230308|NCT02398409|Behavioral|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|Randomized trial to evaluate the efficacy of the telephone intervention "Acquiring New Skills While Enhancing Remaining Strengths"in informal caregivers of Veterans with stroke and TBI.
229720|NCT02409264|Other|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
229721|NCT02409277|Other|Experimental: Standard e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the eAT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
229722|NCT02409290|Drug|Regimen A locally-used WHO-approved MDR-TB regimen|Drug: Locally-used WHO-approved MDR-TB regimen
229723|NCT02409290|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
229724|NCT02409290|Drug|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-sopropyliminophenazine.
229725|NCT02409290|Drug|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
229726|NCT02409290|Drug|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
229727|NCT02409290|Drug|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
229728|NCT00165139|Drug|Etoposide (VP-16)|Described under detailed description
229729|NCT02409290|Drug|Prothionamide|Prothionamide has a bacteriostatic action.
229730|NCT02409290|Drug|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
229731|NCT02409290|Drug|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
229732|NCT02409290|Drug|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
229733|NCT02409303|Behavioral|Screen-Refer-Treat Intervention|
229734|NCT02411422|Device|Reinforced endotracheal tube|Reinforced endotracheal tube
229735|NCT02411435|Drug|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
229736|NCT02411435|Drug|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
229737|NCT02411448|Drug|Ramucirumab|Administered IV
234055|NCT02430571|Device|Kangaroo Feeding Tube with IRIS Technology|all subjects will undergo feeding tube placement with IRIS feeding tube
234056|NCT02430584|Other|Observational - no intervention|
234057|NCT00168103|Biological|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
234058|NCT02430597|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
234059|NCT02430597|Device|NanoKnife|
234060|NCT02430610|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
234061|NCT02430610|Device|NanoKnife|
234062|NCT02430623|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
229433|NCT02415764|Other|Behavioral/Attitudinal OnTrack Role-Playing Game|
229434|NCT02415777|Drug|Ursodeoxycholic acid, thiamine, riboflavin|
229435|NCT02415790|Drug|E2027|E2027 capsules will be administered orally in doses of 10 mg to 400 mg.
229436|NCT02415790|Drug|E2027 matching placebo|E2027 matching placebo capsule will be administered.
229437|NCT02415803|Drug|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
229438|NCT02415803|Drug|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
229439|NCT02415803|Drug|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
229440|NCT02415816|Procedure|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
229441|NCT02415829|Drug|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
229442|NCT02415842|Other|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in 3 adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
224010|NCT00135798|Drug|LADR Treatment|PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:
Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was <0.5 ug/kg, PEGIFN was permanently discontinued.
224011|NCT02166944|Drug|tamoxifen 40 mg daily for one year|both arms with riluzole daily
224012|NCT02166957|Procedure|Recanalization|All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.
The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.
The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance.
224013|NCT02166970|Device|Metallic stent deployment in hilar obstruction|
224014|NCT02166983|Other|computer-assisted cognitive training|Complete Lumosity cognitive exercises
224015|NCT02166983|Other|cognitive intervention|Complete Active Journaling cognitive exercises
224016|NCT02166983|Procedure|mind-body intervention procedure|Complete relaxation exercises
224017|NCT02166983|Other|memory intervention|Complete compensatory strategies
224018|NCT02166983|Other|questionnaire administration|Ancillary studies
224019|NCT02166996|Procedure|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
224020|NCT02166996|Procedure|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
224347|NCT00135057|Drug|insulin glulisine|
224348|NCT02159352|Drug|Ritonavir|
224349|NCT02159352|Drug|Lopinavir/Ritonavir|
224350|NCT02159365|Drug|Elotuzumab|
224351|NCT02159365|Drug|Lenalidomide|
224352|NCT02159365|Drug|Dexamethasone|
224353|NCT02159378|Other|Fructosamines|
228883|NCT02395263|Drug|Yuxintine|
228884|NCT02395276|Device|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
228885|NCT02395289|Behavioral|Cognitive-Based Compassion Training (CBCT)|Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day "at home" and will be given a meditation diary to record amount of time spent meditating per week.
228886|NCT02395289|Behavioral|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
228887|NCT02395302|Device|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
228888|NCT02395315|Device|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
228889|NCT02395315|Device|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
228890|NCT02395328|Behavioral|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
228891|NCT02395354|Device|Placing a self-expanding metallic stent|Income on short stay unit (SSU) post-procedure
Light sedation by the endoscopist vs anesthetist by center
Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion
Clips can be placed at the distal end of the prosthesis according to the endoscopist.
Prosthesis removal time in 4 weeks.
228892|NCT00163241|Drug|celecoxib|
228893|NCT02395354|Device|A balloon dilatation|Income on short stay unit (SSU) post-procedure
Light sedation by the endoscopist vs anesthetist by center.
Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion
Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion
It shall be deemed failure to expansion if required> 2 expansions.
228894|NCT02395367|Procedure|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
228895|NCT02395367|Radiation|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
228896|NCT02395367|Drug|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
228307|NCT00136591|Drug|Bortezomib|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
228308|NCT02173652|Drug|BI 1356, high dose|
228309|NCT02173652|Drug|BI 1356, low dose|
228310|NCT02173665|Drug|BI 1356 BS - Powder in bottle (PIB)|
228311|NCT02173665|Drug|BI 1356 BS - Tablet|
228605|NCT02400112|Drug|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
228606|NCT02402296|Other|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
228607|NCT02402309|Drug|Active topical NS2 1% dermatologic cream|
228608|NCT02402309|Drug|Vehicle placebo 0.0% NS2 dermatologic cream|
228609|NCT02402322|Behavioral|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
228610|NCT02402322|Behavioral|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
228611|NCT02402348|Drug|Metformin|
228612|NCT02402374|Device|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
228613|NCT02402374|Device|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
228614|NCT00164268|Behavioral|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
228615|NCT02402387|Procedure|Neutral head position|
228616|NCT02402387|Procedure|Flexed head position|
228617|NCT02402387|Procedure|Extended head position|
228618|NCT02402387|Procedure|Rotated head position|
228619|NCT02402387|Device|Air-Q SP Airway|
228620|NCT02402400|Drug|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
227978|NCT02181478|Procedure|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10^6cells/kg (+/-20%).
227979|NCT02181491|Other|[11C]-P943|
227980|NCT00002283|Drug|Dapsone|
227981|NCT00137514|Drug|chloroquine|
227982|NCT02181504|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
227983|NCT02181504|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
227984|NCT02181504|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
227985|NCT02181517|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
227986|NCT02181517|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
227987|NCT02181517|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
227988|NCT02181530|Other|No Intervention|No treatment (intervention) is being administered as part of this study.
228312|NCT02173665|Drug|Placebo|
228313|NCT02173678|Drug|COMBIVENT® HFA-MDI|
228314|NCT02173678|Drug|COMBIVENT® CFC-MDI|
228315|NCT02173678|Drug|Placebo HFA-MDI|
228316|NCT02173691|Drug|Tiotropium inhalation powder capsules|
228317|NCT02173691|Drug|Salmeterol inhalation aerosol|
228318|NCT00136591|Drug|Bortezomib|Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
228319|NCT02173691|Drug|Placebo inhalation aerosol|
228320|NCT02408549|Drug|Lasosamide Oral Solution|Active substance: Lacosamide
Pharmaceutical form: Oral solution
Concentration: 10 mg/ml
Route of Administration: Oral administration
228321|NCT02408562|Other|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
227677|NCT02188849|Other|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
227678|NCT02188849|Drug|Creatine|Creatine powder 5 g day
227679|NCT02188875|Behavioral|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
227680|NCT02188875|Behavioral|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
227681|NCT02188888|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
227682|NCT00138281|Biological|FluMist|
227683|NCT02188901|Other|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) [GE healthcare]
227684|NCT02188914|Radiation|Positron emission tomography scan|
227685|NCT02188914|Other|Magnetic resonance imaging|
227686|NCT02188927|Other|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
227687|NCT02188927|Behavioral|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
227688|NCT02188940|Behavioral|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
227689|NCT02188940|Behavioral|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
227989|NCT02181543|Drug|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
227990|NCT02181556|Drug|FOLFIR + Aflibercept|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
227991|NCT02181582|Drug|Emapunil|Single peroral administration
227992|NCT00137514|Drug|amodiaquine|
227038|NCT00135200|Drug|Iodine I 131 Tositumomab|The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the "dosimetric" infusion and the "therapeutic" infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose.
227039|NCT02160509|Device|IPhone based realtime remote ultrasound interpretation|
227040|NCT02160522|Device|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
227340|NCT02194023|Drug|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
227341|NCT02196428|Other|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
227342|NCT02196441|Drug|2% tetracaine local anaesthetic drops|topical anaesthetic drops
227343|NCT02196441|Drug|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
227344|NCT02196454|Other|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
227345|NCT02196467|Biological|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
227346|NCT02196467|Procedure|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
227347|NCT02196480|Biological|anti-TNF|Anti-tumor necrosis factor therapy
227348|NCT02196493|Drug|Azithromycin|250mg azithromycin three times per week for 12 weeks
227349|NCT02196506|Drug|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
227350|NCT00139295|Device|Hylastan|
227351|NCT02196506|Drug|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
226731|NCT02168023|Device|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
226732|NCT02168023|Device|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
226733|NCT02168049|Device|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
226734|NCT02168049|Device|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
226735|NCT02168049|Device|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
226736|NCT00135967|Drug|mycophenolate mofetil orally 1000 mg twice a day (BID)|
226737|NCT02170220|Drug|Vortioxetine|Vortioxetine tablets
226738|NCT02170246|Drug|Telmisartan|
227041|NCT02160535|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
227042|NCT02162901|Behavioral|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
227043|NCT02162901|Behavioral|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
227044|NCT00135421|Drug|Escitalopram|Tablets & Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
227045|NCT02162901|Behavioral|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
227046|NCT02162901|Behavioral|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
227047|NCT02162914|Drug|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
226739|NCT02170259|Other|The suboccipital technique|The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it "hangs" from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements
226740|NCT02170259|Other|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
226741|NCT02170259|Other|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
226742|NCT02170272|Behavioral|Home-based Lymphedema Care Program|Undergo HBLCP
226743|NCT00136279|Behavioral|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
226744|NCT02170285|Device|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
226745|NCT02170285|Device|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
226746|NCT02170298|Drug|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
226747|NCT02170311|Drug|Z-213|
226748|NCT02170324|Drug|Exenatide|
226749|NCT02170324|Drug|Placebo|
226750|NCT02170337|Drug|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
226168|NCT02185859|Drug|Magnesium Sulfate|the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
226169|NCT00002292|Drug|Pentamidine isethionate|
226440|NCT02178059|Drug|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate metered dose per inhalation, 3 inhalations comprise a single dose (for a total of 1.2 mg delivered dose)
226441|NCT02178072|Drug|5-Azacitadine|
226442|NCT02178085|Other|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
226443|NCT02178098|Drug|ETC-1002|ETC-1002 capsules taken once daily
226444|NCT02178098|Drug|Placebo|Placebo capsules taken once daily
226445|NCT00137111|Procedure|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
226446|NCT02178111|Other|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
226447|NCT02178111|Procedure|episiotomy|
226448|NCT02178124|Drug|Donepezil|
226449|NCT02178124|Drug|placebo|
226450|NCT02178137|Drug|Diacerien|
226451|NCT02178137|Drug|Glucosamine/Chondroitin|
226452|NCT02178137|Drug|Placebo|
226453|NCT02178150|Dietary Supplement|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
226454|NCT02178150|Dietary Supplement|Placebo|
226455|NCT02178163|Other|cytology specimen collection procedure|Correlative studies
226456|NCT00137124|Drug|L-Arginine|oral administration of L-arginine for 4 weeks
225855|NCT02195960|Dietary Supplement|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
225856|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
226170|NCT00138229|Biological|aldesleukin|
226171|NCT02188394|Drug|Isotonic saline injection|
226172|NCT02188407|Drug|Sevoflurane|MAC 3-5 V% during surgery
226173|NCT02188407|Drug|Propofol|Propofol group (P group)- The group anaesthesied with propofol
226174|NCT02188420|Device|Transcranial Magnetic Stimulation (Magstim)|
226175|NCT02188433|Behavioral|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
226176|NCT02188446|Behavioral|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
226177|NCT02188459|Drug|Bupropion|A total of 300 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
226178|NCT02188459|Drug|Placebo|
226179|NCT02188472|Drug|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
226180|NCT02188472|Drug|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
226181|NCT00138229|Biological|filgrastim|
226182|NCT02188472|Drug|Placebo|Placebo: 2 tablets should be taken twice daily
226183|NCT02188485|Behavioral|ENGAGE|Up to 10 sessions delivered in the home.
226184|NCT02188498|Procedure|Polysomnography|
226185|NCT02188511|Other|Electronic cigarette (nicotine/placebo)- Day 8|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to < 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
226186|NCT02188511|Other|Electronic cigarette (nicotine/placebo)- Days 7 and 8|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
225526|NCT02164981|Drug|sodium nitroprusside|intravenous
225527|NCT02164981|Other|Placebo|Placebo
225528|NCT02165007|Drug|peripheral blood stem cell graft that are CD34+ selected|Before transplant patients will undergo reduced intensity preparatory regimen consisting of Hydroxyurea, ATG, Fludarabine, Thiotepa, Melphalan. Hydroxyurea will be given at Day -50 to -10, rabbit ATG day -9 to -7 (test dose ATG on day -10), Fludarabine day -8 to -4, Thiotepa Day -4, Melphalan day -3, -2, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year
225529|NCT02165020|Device|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.
The injection is performed under local anesthesia (with "Lidocaine") and ultrasound guidance, using a 16 gauge needle.
225530|NCT02165033|Drug|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
225531|NCT00135629|Biological|Sublingual Alutard SQ grass pollen tablets (Phleum pratense)|
225532|NCT02165046|Drug|Budesonide|
225533|NCT02165046|Drug|Procaterol|
225534|NCT02165098|Drug|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
225535|NCT02165098|Drug|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
225536|NCT02165098|Drug|Cariprazine capsule|Cariprazine capsule - fasted
225537|NCT02165098|Drug|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
225538|NCT02165098|Drug|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
225857|NCT02157142|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
225858|NCT02157155|Biological|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
225859|NCT02157168|Behavioral|Community health worker|Community health workers (CHWs) in Hispanic communities, often referred to as "promotoras," are members of the community who use "resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health" of their communities.
The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months.
225860|NCT02157181|Drug|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
225861|NCT00134719|Biological|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
225193|NCT02172131|Drug|Placebo|
225194|NCT02172144|Drug|BI 1744 CL solution for inhalation|
225195|NCT02172144|Drug|Placebo matching BI 1744 CL|
225196|NCT02172144|Drug|Moxifloxacin (Avalox®)|
225197|NCT00136435|Drug|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
225198|NCT02172157|Drug|BI 1744 CL i.v.|
225199|NCT02172157|Drug|BI 1744 CL oral|
225200|NCT02172170|Drug|BI 10773 single rising dose|
225201|NCT02172170|Drug|Placebo|
225202|NCT02172183|Drug|Psychopharmacological treatment|methylphenidate or atomoxetine
225203|NCT02172183|Behavioral|CBT group|
225204|NCT02172196|Drug|BI 10773|
225205|NCT02172196|Drug|Sitagliptin|
225206|NCT02172209|Drug|BI 10773|
225207|NCT02172222|Drug|BI 10773|
225208|NCT00136435|Drug|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
225209|NCT02172222|Drug|Linagliptin|
225210|NCT02172235|Drug|Pioglitazone|
225211|NCT02172235|Drug|Pioglitazone - low dose|
225212|NCT02175069|Procedure|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
225213|NCT02175069|Drug|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
225214|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
225215|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
225216|NCT00136760|Drug|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
224596|NCT02185235|Other|Pelvic Floor Training|First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.
Repeat this exercise to 20 minutes each session.
224597|NCT00137982|Procedure|Treatment of ectopic pregnancy|
224598|NCT02185248|Behavioral|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
224599|NCT02185261|Drug|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
224600|NCT02185300|Drug|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
224601|NCT02187614|Drug|Morphine|
224602|NCT02187614|Drug|Paracetamol|
224603|NCT00138177|Drug|leucovorin calcium|Given IV
224604|NCT02187614|Drug|Placebos|
224889|NCT02180048|Dietary Supplement|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
224890|NCT02180061|Biological|pembrolizumab|
224891|NCT02180087|Drug|Ketoprofen|
224892|NCT02180100|Drug|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
224893|NCT02180100|Drug|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
224894|NCT02180113|Device|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
224895|NCT02180126|Other|Follow-up|Follow-up of of patients with borderline positive ANCA test results
224896|NCT02180139|Device|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
224897|NCT00137358|Procedure|Radiation Therapy|
224898|NCT02180152|Behavioral|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
230309|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
230310|NCT02400736|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) Competitive Employment: The IPS intervention assists participants to enter into competitive jobs; 2) Eligibility Based on Client Choice, i.e. "zero exclusion;" 3) Integration of IPS and Treatment Team, i.e. the PACT; 5) Personalized Benefits Counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) Rapid Job Search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) Systematic Job Development: IPS specialists build an employer network based on Veterans' interests; 8) Time-Unlimited and Individualized Support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study.
230311|NCT02400736|Other|Transitional Work Program (TWP)|Transitional Work Program (TWP) involves 1) Time-limited Set-Aside Employment: short-term transitional work experiences in a brokered or set-aside work setting; 2) Eligibility Criteria: no strict entrance criteria other than general medical clearance; 3) Limited Integration of TWP and Clinical Services: not integrated within PACT; 4) Less Patient-Centered: TWP jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) Personalized Benefits Counseling: TWP specialists help Veterans obtain information about their VA, Social Security, Medicaid, and government entitlements; 6) Job Search: The TWP specialists provide variable and limited guidance for competitive job search; 7) Limited Job Development: TWP specialists do not engage in community based job development for a specific Veteran; 8) Time Limited Support: The TWP specialist does not provide long-term follow-up after the first job is obtained.
230312|NCT02400749|Drug|Apremilast|Apremilast tablets will be provided to sites in blister cards.
Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid.
230313|NCT02400749|Drug|Placebo|Placebo tablets will be provided to sites in blister cards.
230314|NCT02400775|Drug|Azilsartan|Azilsartan tablets
230315|NCT02400788|Drug|Resminostat|
230316|NCT02400788|Drug|Sorafenib|
230317|NCT00164112|Drug|Cooperstown 5+1 alone|
230318|NCT02400801|Drug|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
230319|NCT02400801|Drug|ethinylestradiol + dienogest|oral oestroprogestogen
230320|NCT02400814|Drug|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
230321|NCT02400814|Radiation|Stereotactic Body Radiation Therapy|Undergo SAR
230322|NCT02400827|Other|malignant cells|
230610|NCT02393625|Drug|Ceritinib (LDK378)|
230611|NCT02396056|Other|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
229738|NCT02411448|Drug|Placebo|Administered IV
229739|NCT02411448|Drug|Erlotinib|Administered orally
230023|NCT02404948|Other|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
230024|NCT02404961|Other|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
230025|NCT02404974|Behavioral|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
230026|NCT02404987|Other|Nutritional Supplement|
230027|NCT02405000|Other|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
230028|NCT00164658|Behavioral|Familial risk assessment and personalized prevention messages|
230029|NCT02405013|Drug|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 1 (24-week course) , 2 (12-week course) , or 4 (24-week course) in West and Central Africa
230030|NCT02405013|Drug|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 1 (24-week course) , 2 (12-week course) , or 4 (24-week course) in West and Central Africa
230031|NCT02405039|Drug|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
230032|NCT02405039|Drug|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
230033|NCT02405052|Other|No intervention|Validation of the Panic Screening Score
230034|NCT02405065|Drug|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
230035|NCT02405078|Drug|18F-fluorodeoxyglucose|Participants injected with 18F-fluorodeoxyglucose intravenously with a typical dose range of 7-12 mCi (259 - 444 MBq) before each FDG-PET scan.
230036|NCT02407093|Behavioral|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
230037|NCT02407106|Dietary Supplement|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
229443|NCT00165789|Drug|E2007|
229444|NCT02415855|Drug|Dabigatran|
229445|NCT02415881|Drug|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
229446|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
229447|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
229448|NCT00166166|Drug|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
229449|NCT02417870|Biological|aldesleukin|
229450|NCT02417883|Drug|Furosemide|Evaluate urinary excretion rate fo furosemide
229451|NCT02417896|Drug|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
229740|NCT02411500|Drug|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
229741|NCT02411513|Device|CEFALY|
229742|NCT00165282|Behavioral|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
229743|NCT02411526|Drug|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
229744|NCT02411526|Drug|Risperdal Consta|Risperdal Consta administered as a IM injection
229745|NCT02411526|Drug|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
229746|NCT02411539|Biological|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
229747|NCT02411539|Biological|Placebo|Administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
229748|NCT02411552|Behavioral|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
229749|NCT02411565|Drug|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
224354|NCT02159391|Behavioral|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
224355|NCT02159404|Biological|Immunotherapy|
224356|NCT02159417|Other|Therapeutic Education|Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:
Knowledge of the disease
Food
Physical Activity and care of feet
The therapeutics
224357|NCT02159430|Other|Clinical and psychopathological assessment of HAE patients|
224358|NCT02161991|Drug|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
224359|NCT02162004|Procedure|Continuous Correction|
224360|NCT02162017|Other|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
224361|NCT02162017|Other|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
224362|NCT02162030|Behavioral|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
224363|NCT02162056|Device|implantation of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffolds for coronary artery disease.
224364|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
224677|NCT02195414|Device|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
224678|NCT02195440|Drug|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
228897|NCT02395380|Other|C-reactive protein dosage|
224021|NCT00135811|Drug|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
224022|NCT02167009|Device|Embosphere Microspheres|
224023|NCT02167022|Other|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
224024|NCT02167035|Drug|Combigan BID|
224025|NCT02167035|Drug|Simbrinza TID|
224026|NCT02169219|Drug|Glucocorticoids|Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.
Prednisone will be tapered over 8 weeks as follows:
60mg for 2 weeks
40mg for 2 weeks
30mg for 1 week
20mg for 1 week
10mg for 1 week
5mg for 1 week
224027|NCT00002274|Drug|Didanosine|
224028|NCT00136084|Drug|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
224029|NCT02169219|Drug|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
224030|NCT02169232|Device|Videolaryngoscope|
224031|NCT02169232|Device|Fiberoptic|
224032|NCT02169245|Other|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
224033|NCT02169258|Procedure|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis > 70% of the major epicardial vessels and bypass graft vessel or their major branches (> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
224034|NCT02169271|Drug|Aspirin|Given PO
224035|NCT02169271|Other|Laboratory Biomarker Analysis|Correlative studies
228621|NCT02402413|Procedure|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
228622|NCT02402413|Procedure|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
228623|NCT02402413|Device|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
228624|NCT02402439|Drug|Islet cells|Transplantation of islets into the gastrointestinal submucosa
228625|NCT00164281|Drug|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
228626|NCT02402439|Procedure|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
228627|NCT02402452|Drug|GS-9857|GS-9857 100 mg tablet administered orally
228898|NCT02395393|Device|Alveoflex Confocal MiniprobeTM|
228899|NCT02395406|Device|Orotracheal intubation with Totaltrack|
228900|NCT02395406|Device|Orotracheal intubation with Airtraq|
228901|NCT02397720|Drug|5-azacytidine|Dose Escalation Phase Starting Dose: 75 mg/m2 subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 of every 28 day cycle.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
228902|NCT02397720|Drug|Nivolumab|Dose Escalation Phase Starting Dose: 3.0 mg/kg by vein on Day 1 and day 14 of each 5-azacytidine cycle for the first 4 cycles or until complete response (CR) (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on day 1 of each cycle of 5-azacytidine).
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
228903|NCT02397720|Behavioral|Phone Call|Participant called about 30 days after end-of-study visit. If disease appears to be getting better while taking study drugs, participant called every 3-6 months for up to 5 years.
228904|NCT02397733|Radiation|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
228905|NCT02397733|Radiation|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
228906|NCT02397746|Device|total hip arthroplasty implant|
228907|NCT02397759|Other|Blood draw and cerebrospinal fluid draw|
228908|NCT02397772|Drug|albendazole|Single dose of albendazole (400 mg)
228322|NCT02408562|Other|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
228323|NCT02408575|Device|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
228324|NCT02408575|Device|No filtering (placebo)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3
No notched filtering
228325|NCT02408588|Other|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
228326|NCT00165087|Drug|doxorubicin|
228327|NCT02408601|Other|Helioseal - F|Helioseal -F ( Resin based sealant)
isolate the tooth surface
etch the fissure anatomy with 37% phosphoric acid for 20 seconds
wash the tooth surface and dry it. No salivary contamination is accepeted
using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.
light cure the sealant
check for high points and the occlusion
228328|NCT02408601|Other|ART sealant|Fuji IX extra strength
isolate the tooth surface
condition the fissure anatomy using a GC conditioner for 10 seconds
wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.
dry the tooth surface
mix the GIC according to the standard powder: liquid ratio
place the mix onto the fissures using a plastic spatula
apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)
apply pressure for 10-15 sec and withdraw the finger in a sideways motion
scrap out the excess material
check for the high points and the occlusion
apply petroleum jelly onto the GIC mix
advice patient not to eat or drink for 30 minutes.
228329|NCT02408614|Other|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
228330|NCT02408614|Other|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
228628|NCT02402465|Drug|Placebo|Patients will be treated by placebo
228629|NCT02402465|Drug|Fluticasone propionate|Patients will receive fluticasone nasal spray
228630|NCT02402465|Drug|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
228631|NCT02402465|Procedure|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
228632|NCT00164580|Behavioral|Community-Level Intervention|
228633|NCT02404519|Dietary Supplement|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
228634|NCT02404519|Dietary Supplement|Placebo|1 tablet without MK-7 taken orally every day during 1 year
227993|NCT00137852|Drug|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
227994|NCT02184065|Drug|Meloxicam|
227995|NCT02184078|Drug|Nevirapine|
227996|NCT02184078|Drug|Rifabutin|
227997|NCT02184091|Drug|Nevirapine|
227998|NCT02184104|Dietary Supplement|Caffeine|
227999|NCT02184117|Drug|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
228000|NCT02184117|Drug|Contrast Media|Intracoronary injection of contrast medium to induce hyperemia for "contrast FFR"
228001|NCT02184117|Drug|Resting conditions|Baseline measurement of aortic and coronary pressures
228002|NCT02184130|Other|transcranial magnetic stimulation and motion stimuli|
228003|NCT02184143|Behavioral|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
228004|NCT00137852|Procedure|Radiation Therapy|5 days a week for 5-6 weeks
228005|NCT02184143|Other|Education|Patient education
228006|NCT02184156|Biological|Ampion <5 kDa ultrafiltrate of 5% human serum albumin|4 mL intra-articular injection of Ampion
228007|NCT02184169|Device|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
228008|NCT02184169|Device|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
228009|NCT02184182|Procedure|VLS ablation/portal ligation/hepatectomy|Step1:
exploratory laparoscopy to exclude extrahepatic disease
right portal vein ligation if surgically feasible
RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)
radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible
CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1
Step 2: only if FRL/body weight > 0.5
- laparoscopic/laparotomic right trisectionectomy
228010|NCT02184195|Drug|Olaparib|Tablet -100mg
228011|NCT02184195|Drug|Olaparib|Tablet-150mg
228331|NCT02408614|Other|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
228332|NCT02408614|Device|Treadmill|
227352|NCT02196519|Device|Sylys Surgical Sealant|
227353|NCT02196532|Device|Device: Optical coherence tomography|
227354|NCT02196545|Behavioral|Exercise|
227355|NCT02196558|Drug|E6011|
227356|NCT02196571|Other|Structured Exercise|
227357|NCT02196610|Other|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
227358|NCT02196623|Other|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
227690|NCT02188940|Behavioral|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
227691|NCT02188940|Other|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
227692|NCT02191397|Drug|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
227693|NCT02191410|Procedure|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio > 0.3, RR 60 breaths min-1 and a FGF of < 2 L min-1, using a second identical ventilator with low compliant internal circuit
227694|NCT02191410|Procedure|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
227695|NCT02191423|Drug|Oxytocin|administered pre-fMRI assessment
227696|NCT02191423|Drug|placebo|administered pre-fMRI assessment
227697|NCT00138671|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
227698|NCT02191423|Behavioral|Dyadic psychotherapy|
227699|NCT02191462|Dietary Supplement|Niagen 100mg|
227700|NCT02191462|Dietary Supplement|Niagen 300mg|
227048|NCT02162914|Drug|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
227049|NCT02162927|Dietary Supplement|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
227050|NCT02162927|Dietary Supplement|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
227051|NCT02162940|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
227052|NCT02162940|Other|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
227053|NCT02162966|Drug|High Dose Colistin|High Dose Colistin
227054|NCT02162966|Drug|Standard Dose Colistin|Standard Dose Colistin
227055|NCT00135421|Drug|Placebo|Tablets & Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
227056|NCT02162979|Drug|sildenafil|sildenafil 50mg BID for 2 weeks
227057|NCT02162979|Drug|Placebo|
227058|NCT02162992|Other|No intervention|Observational
227359|NCT02196623|Other|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
227360|NCT02196636|Drug|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
227361|NCT00139308|Device|high frequency stimulation|
227362|NCT02196636|Drug|RO6806127|Administered orally with approximately 240 mL of buffer
227363|NCT02196649|Device|Endoscopic Clip|
227364|NCT02157818|Drug|midazolam|
227365|NCT02157818|Drug|Dexmedetomidine|
227366|NCT02157831|Biological|CP-870,893|
227367|NCT02157870|Biological|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
227368|NCT02157870|Drug|Paclitaxel|80 mg/m^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
227369|NCT02157883|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
242872|NCT02516904|Drug|Placebo|normal saline
242873|NCT02516917|Behavioral|Attention Training Technique|
242874|NCT02516930|Behavioral|crowdsourced video|video promoting condom use
242875|NCT02516930|Behavioral|social marketing video|
243177|NCT02510066|Device|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
243178|NCT02510079|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
243179|NCT02510105|Device|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
243180|NCT02512393|Device|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
243181|NCT02512393|Other|X-Ray|Both groups will have x-rays done of their knees.
243182|NCT00180401|Behavioral|CRT-P and CRT-D devices|
243183|NCT02512393|Other|Walking Test|A 6-minute walking test will be performed. The test will consist of walking on a flat, hard surface in a period of 6 minutes at a fast pace without help from an assistive device (cane or walker) or another person.
243184|NCT02512393|Other|Assessment of sensitivity to heat|Heat pain sensitivity will be tested using a commercially available thermal sensory testing machine.
243185|NCT02512393|Other|Assessment of Sensitivity to Pressure|A handheld device with a small (less than ½ inch wide) rubber tip to apply pressure to the skin.
243186|NCT02512393|Other|Assessment of Sensitivity to Mechanical Stimulation|A handheld probe that has a small nylon tip to tap skin.
243187|NCT02512393|Other|Blood Test|Blood will be used for biomarkers and hormones.
243188|NCT02512393|Other|Assessment of balance, chair stand, and gait speed|A short physical performance battery will be performed. The test will compose of the gait speed, chair stand, and balance tests.
243189|NCT02512393|Other|Assessment of conditioned pain modulation|Conditioned pain modulation will be done by using a cold pressor procedure on the skin.
242554|NCT02523469|Biological|ALT-803|ALT-803: The dose level for ALT-803 will be based on the recommended dose from the Phase Ib part of the study. ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles.
During week 6, no treatment will be administered.
242555|NCT02523469|Biological|Nivolumab|Nivolumab: The dose level for Nivolumab is 3 mg/kg. Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).
After 4 cycles, patients will be treated with Nivolumab alone following the same schedule.
During week 6, no treatment will be administered.
242556|NCT02523508|Behavioral|Experimental group|Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
242557|NCT02523508|Other|Control group|Passive limb mobilization which did not involve the spine
242558|NCT02523521|Behavioral|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
242559|NCT02523534|Procedure|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
242560|NCT02523534|Procedure|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
242561|NCT02523547|Drug|Cavir|0.5mg/day
242876|NCT02516943|Other|Control|The patient's ABGs were test according to a 4 - hour routine
242877|NCT02516943|Other|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
242878|NCT02518971|Drug|Placebo|one capsule daily
242879|NCT02518997|Other|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
242880|NCT02519010|Drug|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
242881|NCT02519010|Drug|Exforge|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
242882|NCT02519023|Drug|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
242883|NCT02519023|Drug|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
242884|NCT00181597|Drug|Trilostane|Taken orally once a day for three days then twice daily thereafter.
242885|NCT02519023|Device|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
242252|NCT02530385|Biological|FMT Capsules|Capsules will be generated as per FDA-approved procedures
242253|NCT02530398|Drug|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
242254|NCT02530411|Drug|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
242255|NCT00002494|Radiation|low-LET cobalt-60 gamma ray therapy|
242256|NCT00183001|Drug|Vitamin K|
242257|NCT02530411|Drug|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
242258|NCT02530424|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
242259|NCT02530424|Drug|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
242260|NCT02530424|Drug|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
242261|NCT02530424|Drug|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
242562|NCT00182260|Drug|Proton Pump Inhibitors|
242563|NCT02523547|Drug|Baraclude|0.5mg/day
242564|NCT02523560|Other|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
242565|NCT02525770|Device|radiostereometric analysis (RSA)|
242566|NCT02525796|Drug|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
242567|NCT02525796|Drug|amiloride|amiloride, titrated up to a maximum of 10mg BID
242568|NCT02525796|Drug|Placebo|
242569|NCT02525796|Drug|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
242570|NCT02525809|Device|Novae E®|
241949|NCT02537444|Drug|ACP-196|
241950|NCT02537444|Drug|ACP-196 and pembrolizumab combination|
241951|NCT02537457|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
241952|NCT02537457|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
241953|NCT02537470|Drug|Biphasic Remogliflozin Etabonate|Experimental Drug
241954|NCT02537470|Other|Placebo|Placebo Comparator
241955|NCT02537483|Drug|IDP-120 Gel|Investigational Product: IDP-120 Gel
241956|NCT00183651|Behavioral|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
241957|NCT02537483|Drug|IDP-120 Component A|Comparator Product: IDP-120 Component A
241958|NCT02537483|Drug|IDP-120 Component B|Comparator Product: IDP-120 Component B
241959|NCT02537483|Drug|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
241960|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
241961|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
241962|NCT02537509|Drug|Cholecalciferol|
241963|NCT02537509|Drug|Placebo of cholecalciferol|
241964|NCT02537522|Device|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
241965|NCT02537522|Device|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
242262|NCT02530437|Drug|LY2940680|Phase IB: 400 mg by mouth daily for 38 days, starting on first chemoradiation day.
Phase II: Step 1 - (First 27 participants): As determined in Phase Ib mg (fixed dose) by mouth daily for 7 days followed by LY2940680 plus chemoradiation.
Phase II: Step 2 - (Second set of 27 participants): As determined in Phase Ib mg (fixed dose) by mouth daily for 38 days, starting on first chemoradiation day.
242263|NCT02530437|Drug|Paclitaxel|50 mg/m2/week by vein on first radiation day of each week for 5 doses.
242264|NCT02530437|Drug|Carboplatin|AUC 2mg/ml/min by vein on first radiation day of each week for 5 doses.
241647|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Spiritual-Existential Group
241648|NCT02507076|Procedure|quality-of-life assessment|Ancillary studies
241649|NCT02507089|Behavioral|Tailored Sleep Health Education|This study features an online website to promote awareness about sleep health and sleep disorders. The website will be a culturally and linguistically tailored peer-based sleep health intervention designed to increase adherence to recommended sleep apnea screening and treatment among blacks.
241650|NCT02507102|Device|Voyager|Non-invasive RFE therapy
241651|NCT02507115|Behavioral|TMAP|Text messages for Alcohol Risk Reduction
241652|NCT02507115|Behavioral|Mojo Texts|Motivational texts not alcohol related
241653|NCT02507128|Drug|liraglutide|Liraglutide were taken 30 min before PCI.
241654|NCT02507128|Drug|placebo|Placebo were taken 30 min before PCI.
241655|NCT02507141|Device|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
241656|NCT02507154|Drug|Cetuximab + NK cells|
241657|NCT00179712|Drug|topotecan|
241658|NCT02507167|Dietary Supplement|mixed meal|250 ml Fortimel compact (chocolate)
241659|NCT02507167|Drug|Rifampin|oral rifampin administration (600 mg EREMFAT®)
241660|NCT02507180|Other|LEFt clinical decision rule|The LEFt rule
Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1
Clinical probability Unlikely: 0 or 1 point Likely: > 1 point
241661|NCT02507193|Procedure|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
241662|NCT02507193|Procedure|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
241663|NCT02507206|Drug|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
241664|NCT02507206|Drug|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
241041|NCT02516150|Drug|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
241042|NCT02516150|Drug|Xeris Glucagon|injection of 100 micrograms of glucagon
241043|NCT02516163|Device|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
241044|NCT02516176|Behavioral|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
241045|NCT02516189|Other|Strength training program|Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.
Relaxation: 5 minutes of stretching.
241046|NCT02516202|Drug|Vagifem|
241344|NCT02509494|Biological|Ad26.ZEBOV|Ebola Zaire vaccine, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles.
241345|NCT02509494|Biological|MVA-BN-Filo|MVA‐BN‐Filo‐ is a live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit (Inf. U.).
241346|NCT02509494|Biological|Menveo|Menveo WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
241347|NCT02509494|Biological|Placebo|0.9% saline for injection
241348|NCT02511678|Procedure|Cryoablation|Cryoablation is an FDA-cleared technology for selective ablation and treatment of different kinds of benign and malignant conditions. For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study.
241349|NCT02511691|Drug|18F-PSS232|Diagnostic PET Tracer
241350|NCT02511704|Drug|Nicotine|Multiple dose nicotine
241351|NCT00180310|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
241352|NCT02511704|Drug|Nicotine|Multiple dose nicotine
241353|NCT02511717|Other|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
240711|NCT02522676|Procedure|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
240712|NCT02522676|Procedure|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
240713|NCT02522689|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
240714|NCT02522689|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
240715|NCT02522702|Other|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
240716|NCT02522715|Drug|Cabazitaxel|Given IV
240717|NCT02522715|Drug|Enzalutamide|Given PO
240718|NCT02522715|Other|Laboratory Biomarker Analysis|Correlative studies
240719|NCT00182104|Drug|Warfarin vs ASA|
240720|NCT02522715|Other|Pharmacological Study|Correlative studies
240721|NCT02522715|Drug|Prednisone|Given PO
240722|NCT02522728|Device|Triathlon CR|Implantation of Knee Prosthesis
240723|NCT02522728|Device|Triathlon PS|Implantation of Knee Prosthesis
240724|NCT02522741|Behavioral|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
241047|NCT02516202|Drug|Replens|
241048|NCT02516202|Other|Placebo|
241049|NCT02516215|Other|No intervention|
241050|NCT00180908|Drug|Doxorubicin, Methotrexate|
241051|NCT02516228|Device|GeodesicTranscranial Electrical Neuromodulation (GTEN 100)|In this feasibility study, patients will be randomly assigned to receive either continuous direct current stimulation or a slow-pulsed electrical current. Stimulation will be focused on the seizure generating cortex.
All patients enrolled in the study will have a one-month, pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.
During this baseline period, two three-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone.
240416|NCT02529631|Drug|orlistat 60 mg|In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.
Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets.
240417|NCT02529631|Device|polyglucosamine|In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.
Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening).
240418|NCT00002494|Drug|vincristine sulfate|
240419|NCT00182819|Radiation|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
240420|NCT02529644|Behavioral|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
240421|NCT02529644|Behavioral|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
240422|NCT02529657|Radiation|Low Level Laser Therapy|In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).
240725|NCT02522754|Biological|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
240726|NCT02522754|Biological|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
240727|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
240728|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
240729|NCT02522767|Drug|Mesalamine|
240730|NCT00182130|Procedure|Quality Initiative in Rectal Cancer (QIRC) strategy|
240105|NCT02534116|Procedure|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
240106|NCT02534129|Drug|Difinsa53|Difinsa53 cream is applied to one half of radiation field
240107|NCT02536508|Drug|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
240108|NCT02536508|Drug|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
240109|NCT02536508|Drug|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate
240110|NCT00183599|Behavioral|5 Minutes of Simple Advice|
240111|NCT02536534|Other|Correlation assessment|
240112|NCT02536547|Device|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
240113|NCT02536573|Other|Radlink Surgical Positioning Software|
240114|NCT02536586|Drug|LY3023414|LY3023414 administered orally.
240115|NCT02536612|Other|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
240116|NCT02536612|Other|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
240117|NCT02536625|Other|prospective study|
240118|NCT02536638|Other|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
240119|NCT02536651|Procedure|Ankle surgery|Plastic or orthopedic surgery of the ankle
240120|NCT02536664|Drug|Rituximab|
240121|NCT00183599|Behavioral|Motivational Enhancement Therapy (MET)|
240122|NCT02536690|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
240123|NCT02536690|Drug|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
240124|NCT02536690|Drug|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
240125|NCT02536703|Device|Lotus Valve System|Lotus Valve System
239514|NCT02440295|Device|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
239515|NCT02440295|Drug|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
239516|NCT02440308|Radiation|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Receive 68Ga-DOTA-Bombesin IV
239517|NCT02440308|Procedure|Magnetic Resonance Imaging|Undergo 68Ga-DOTA-Bombesin PET/MRI
239518|NCT02440308|Procedure|Positron Emission Tomography|Undergo 68Ga-DOTA-Baombesin PET/MRI
239519|NCT02440321|Behavioral|Parent-child interactive program|
239520|NCT02440321|Other|written materials|
239521|NCT02440334|Drug|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
239522|NCT02440347|Device|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
239820|NCT02503982|Drug|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
239821|NCT02503995|Behavioral|Physical Exercise Participation|
239822|NCT02504008|Drug|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
239823|NCT02504008|Drug|Placebo|Once weekly for 6 weeks
239824|NCT02506322|Behavioral|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
239825|NCT02506335|Drug|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
239826|NCT02506348|Drug|Diclofenac|
239827|NCT00179621|Drug|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
256836|NCT02242097|Drug|ibrutinib|Given PO
256837|NCT02242097|Other|laboratory biomarker analysis|Correlative studies
256838|NCT00144586|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
256839|NCT02242110|Behavioral|Exposure, Relaxation, and Rescripting Therapy for Bipolar Disorder|Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
256840|NCT02242136|Behavioral|FORNET|
256841|NCT02242149|Drug|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
256842|NCT02242149|Drug|Placebo|Sugar pill manufactured to mimic Diacerein
256843|NCT02242162|Procedure|phrenic nerves magnetic stimulations|
257171|NCT02276066|Other|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.
257172|NCT02276066|Other|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.
257173|NCT02276079|Behavioral|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 − 0.7 × age).
257174|NCT02276079|Behavioral|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
257175|NCT02276092|Other|antimicrobial stewardship|A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
257176|NCT02276105|Other|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
257177|NCT02276118|Device|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
257178|NCT02276118|Device|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
257179|NCT00148668|Drug|Navelbine|Weekly injections given starting week 3 and ending week 14
257180|NCT02276131|Device|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
256513|NCT02249507|Other|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
256514|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
256515|NCT00145509|Drug|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
256516|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
256517|NCT02249533|Other|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
256518|NCT02249546|Drug|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
256519|NCT02249546|Drug|PPI-amoxicillin-clarithromycin|Triple therapy
256520|NCT02249572|Radiation|gamma knife radiosurgery|Leksell Perfection model gamma knife.
256521|NCT02249585|Device|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
256844|NCT02242175|Device|hydrogen breath test|Hydrogen breath test is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
256845|NCT02242188|Drug|Iron|Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.
The intervention will last from 4 months to 9 months of age.
256846|NCT02242188|Dietary Supplement|Placebo|Maltodextrin (packed in identical sachets as active products)
256847|NCT02242201|Drug|Posterior Lumbar Plexus Block with Bupivacaine|
256848|NCT02242201|Drug|Intra articular injection with Ropivacaine|
256849|NCT00144599|Drug|MRA(Tocilizumab)|
256850|NCT02242201|Drug|Intra articular injection with liposomal bupivacaine (Exparel)|
256851|NCT02242214|Drug|Misoprostol|
256852|NCT02242227|Drug|Salmeterol xinafoate|
256853|NCT02242227|Drug|Serevent® Diskus®|
256203|NCT02254109|Drug|BEA 2180 BR - rising dose|
256204|NCT02254109|Drug|Placebo|
256205|NCT02254122|Drug|BEA 2180 BR|
256206|NCT02254122|Drug|Placebo|
256207|NCT02254122|Device|Respimat®|
256208|NCT02254135|Drug|BEA 2180 BR - rising dose|
256209|NCT02254135|Drug|Placebo|
256210|NCT00146107|Behavioral|Diet|10 percent weight loss through diet and behavioral modification
256211|NCT02256358|Drug|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
256212|NCT00146380|Behavioral|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
256213|NCT02256358|Drug|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
256214|NCT02256371|Behavioral|Hypnosis sessions|1 session per week during 8 weeks
256215|NCT02256371|Behavioral|Relaxation group|1 relaxation session per week during 8 weeks
256216|NCT02256384|Device|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
256217|NCT02256397|Other|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
256522|NCT02249585|Device|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
256523|NCT02249585|Drug|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
256524|NCT02249585|Drug|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
256525|NCT02249598|Biological|lactamica|
256526|NCT00145522|Drug|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
256527|NCT02249598|Biological|Placebo|
256528|NCT02249611|Device|Mobile physical activity promotion tool|Mobile activity sensor
Smartphone with APP
Interactional webpage of internet
Evidence based health information
Individualized reminding messages according to the data from activity recording system
Personal counseling from professional personnel
255564|NCT02265679|Drug|BIIL 284 BS, high dose, pediatric patients|
255565|NCT02265679|Drug|BIIL 284 BS, low dose, adult patients|
255566|NCT02265679|Drug|BIIL 284 BS, medium dose, adult patients|
255567|NCT02265679|Drug|BIIL 284 BS, high dose, adult patients|
255568|NCT00002363|Drug|Peptide Construction 3, Synthetic|
255569|NCT00147537|Drug|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
255570|NCT02267850|Device|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
255571|NCT02267863|Drug|APTO-253 HCl|APTO-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate dose is reached. Patients will be treated on APTO-253 HCl for at least 1 cycle (28 days) for safety evaluation.
255572|NCT02267876|Device|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
255573|NCT02267876|Procedure|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
255574|NCT02267889|Procedure|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
255575|NCT02267889|Device|D-SPECT dedicated cardiac nuclear camera|
255576|NCT02267902|Drug|DA-1229|
255577|NCT02267915|Drug|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
255578|NCT00000340|Drug|Pemoline|
255579|NCT00002366|Drug|Ritonavir|
255580|NCT00147836|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
255900|NCT02260817|Drug|11C-choline Injection|Choline C11 Injection for PET/CT Imaging Protocol:
15 - millicuries (mCi) 11C-choline IV Injection
PET images skull base to mid thigh with 3 min per bed position
Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol
Fusion of PET and CT images
Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:
No IV contrast
High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs
Fusion of coronal and PET images
255901|NCT02260830|Drug|Lu AF11167|
255902|NCT02260843|Other|Generic Fitness|Subjects in this groups will receive three fitness lessons in a weeks while each session last for 1 hour throughout the 12 weeks experimental period
254949|NCT02241005|Other|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
254950|NCT02241018|Drug|CD25 monoclonal antibody|
254951|NCT02241018|Drug|calcineurin inhibitors|
254952|NCT02241018|Biological|MSCs|
254953|NCT02241031|Biological|MPs|MPs are generated from cord blood using a combination of cytokines.
254954|NCT02241031|Drug|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
254955|NCT02241044|Device|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
254956|NCT02241044|Device|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
254957|NCT00144495|Drug|recombinant human erythropoietin|36000IU(s.c.)/week for 12 weeks
254958|NCT02241057|Device|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
254959|NCT02241070|Behavioral|mindulness-based intervention|A number of mindfulness techniques, including both "formal" and "informal" practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance.
254960|NCT02241083|Drug|Dopamine|
254961|NCT02241083|Drug|Norepinephrine|
254962|NCT02241083|Other|no medication|
254963|NCT02241096|Drug|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
254964|NCT02241109|Other|no intervention|progression monitoring by echocardiography
254965|NCT02241122|Procedure|prostate biopsy|
254966|NCT02241135|Biological|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
255261|NCT02272712|Behavioral|Cognitive Behavioural Therapy|
243448|NCT02505529|Other|Mental Imagery|Behavioral intervention of mental imagery
243734|NCT02535754|Behavioral|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
243735|NCT02538159|Device|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
243736|NCT02538159|Device|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
243737|NCT02538172|Other|T-Track® CMV assay|
243738|NCT02538185|Device|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
243739|NCT02538185|Device|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
243740|NCT00183729|Drug|Placebo|Placebo distribution is planned to mimic the active drug.
243741|NCT02538185|Device|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
243742|NCT02538185|Drug|Vaccin rabique Pasteur®|
243743|NCT02538185|Drug|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
243744|NCT02538198|Drug|Lenalidomide|
243745|NCT02538211|Biological|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
243746|NCT02538224|Drug|2.5%ketoprofen gel + 3 % doxycycline|GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.
Intervention category Treatment: drugs
243747|NCT02538224|Drug|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
243190|NCT02512406|Other|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
243191|NCT02512406|Other|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
243449|NCT02505542|Biological|Certolizumab Pegol|Active substance: Certolizumab Pegol
Pharmaceutical form: Prefilled syringe
Concentration: 200 mg / ml
Route of Administration: Subcutaneous injection
243450|NCT02505542|Other|Placebo|Active substance: Placebo
Pharmaceutical form: Prefilled syringe
Concentration: 0.9 % Saline
Route of Administration: Subcutaneous injection
243451|NCT02505555|Device|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
243452|NCT02505568|Drug|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
243453|NCT00179504|Behavioral|Relaxation Response|Relaxation training
243454|NCT02507882|Biological|miRNA quantification|RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.
The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).
cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen).
243455|NCT02507895|Device|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
243456|NCT02507934|Device|Lubricin|Lubricin 150 µg/ml eye drops
243457|NCT02507934|Device|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
243458|NCT02507960|Device|The Gamma Pod|Immobilization of breast during radiation.
243459|NCT02507960|Device|CT simulation|See arm description
243460|NCT02507973|Other|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
242886|NCT02519023|Drug|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
242887|NCT02519023|Drug|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
242888|NCT02519023|Drug|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
242889|NCT02519023|Drug|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
242890|NCT02519036|Drug|IONIS HTTRx|
242891|NCT02519036|Drug|Placebo|
242892|NCT02519049|Other|No intervention|This is an observational study
242893|NCT02519062|Other|No intervention|This is a retrospective study
242894|NCT02519075|Other|No intervention|Observational study
242895|NCT00181597|Drug|Hydrocortisone|Taken orally with trilostane.
242896|NCT02519101|Device|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
242897|NCT02519114|Procedure|Donor Bone Marrow stem cell transplantation|haploidentical Bone Marrow stem cell transplantation
243192|NCT02512406|Other|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
243193|NCT00180414|Device|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
243194|NCT02512406|Other|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
243195|NCT02512406|Other|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
243196|NCT02514655|Other|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
243197|NCT00180687|Drug|Normal Saline|Nebulised Normal Saline
243198|NCT02514668|Drug|SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
242571|NCT02525809|Device|Sunfit®|
242572|NCT02525809|Device|Quartz®|
242573|NCT02525822|Drug|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
242574|NCT00182572|Drug|buprenorphine|
242575|NCT02525822|Drug|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
242576|NCT02525822|Drug|Vehicle Cream|Comparator Product: Vehicle Cream
242577|NCT02525822|Drug|Vehicle Lotion|Comparator Product: Vehicle Lotion
242578|NCT02525835|Dietary Supplement|Low Sodium|Participants will be provided a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days)
242579|NCT02525835|Dietary Supplement|High Sodium|Participants will be provided a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days)
242580|NCT02525848|Drug|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
242581|NCT02525848|Drug|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
242582|NCT02525848|Drug|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
242583|NCT02525861|Biological|GLASSIA|60 mg/kg BW administered at a rate of 0.2 mL/kg/min
242584|NCT02525874|Drug|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
242585|NCT00182572|Drug|naltrexone|
242586|NCT02525887|Other|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
242898|NCT02519127|Other|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
242899|NCT02519127|Other|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
242900|NCT02519140|Drug|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
242901|NCT02519153|Drug|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
242902|NCT02519166|Biological|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
242265|NCT02530437|Radiation|Radiation Therapy|1.8 Gy per weekday for 5 1/2 weeks.
242266|NCT02532556|Device|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
242267|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
242268|NCT02532569|Biological|Inactivated Japanese encephalitis vaccine (Beijing-Handai strain, cell-cultured)|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
242269|NCT02532595|Procedure|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
242270|NCT02532595|Procedure|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
242271|NCT02532608|Other|Acute sleep deprivation|Participants will stay awake for 36 hours
242272|NCT02532634|Drug|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
242273|NCT02532634|Drug|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
242274|NCT02532647|Drug|Remimazolam|
242275|NCT02532647|Drug|Midazolam|
242276|NCT02532647|Drug|Placebo|
242277|NCT02532660|Drug|Escitalopram 10mg|Escitalopram 10mg is administered for both groups (Experimental: A and Placebo Comparator: B)
242278|NCT00183274|Drug|Venlafaxine XR|All participants will take venlafaxine for 6 months. After this initial 6 months, participants who are not randomized to placebo will continue to take venlafaxine.
242279|NCT02532660|Drug|LABCAT TCJUSS|GROUP A: Escitalopram 10mg + LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
242280|NCT02532660|Drug|LABCAT TCJUSS Placebo|GROUP B: Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night).
242281|NCT02532686|Drug|DAAOI-2|500-2000mg/d, oral, for 6 weeks
242282|NCT02532686|Drug|placebo|oral, for 6 weeks
242587|NCT02525900|Procedure|Wound Infiltration with 0.25% Bupivacine|
242588|NCT02525900|Procedure|bilateral TAP block with 0.25% Bupivacaine|
241665|NCT02507219|Drug|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
241666|NCT02507232|Device|NovoTTF-100A|12 cycles
241966|NCT02537535|Other|survey|This is a cross-sectional study without specific intervention
241967|NCT00183664|Drug|Fluoxetine|Fluoxetine 10 to 40 mg/day for 8 months
241968|NCT02537548|Other|Laboratory Biomarker Analysis|Correlative studies
241969|NCT02537548|Procedure|Retroperitoneal Lymph Node Dissection|Undergo RPLND
241970|NCT02537561|Drug|Cisplatin|
241971|NCT02537561|Drug|Gemcitabine|
241972|NCT02502487|Drug|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
241973|NCT02502487|Drug|Tetracaine|1% Tetracaine gel instilled into urethra
241974|NCT02502500|Drug|Celecoxib|
241975|NCT02502500|Drug|AKB-6548|
241976|NCT02502513|Behavioral|Brief computerized intervention|Computer game "Tetris"
241977|NCT02502526|Device|Centurion® Vision System, 45° Balanced Tip|
241978|NCT00179088|Behavioral|Patient may be able to put weight on the operated leg|
241979|NCT02502526|Device|Centurion® Vision System, 45° MFK Tip|
241980|NCT02502526|Device|lnfiniti® Vision System, 45° MFK Tip|
241981|NCT02502526|Device|INTREPID® Ultra infusion sleeve|
241982|NCT02502526|Device|Ultra infusion sleeve|
241983|NCT02502539|Procedure|Controlled physical activity|
241984|NCT02502552|Other|blood specimen|blood specimen
241985|NCT02502565|Other|Uric acid level|
241354|NCT02511717|Other|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
241355|NCT02511730|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
241356|NCT02511730|Device|FFDM|FujiFilm Aspire Cristalle System
241357|NCT02511743|Other|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
241358|NCT02511756|Device|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
241359|NCT02511769|Behavioral|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
241667|NCT02507232|Drug|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
241668|NCT00179725|Drug|CC-5013|
241669|NCT02507245|Drug|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
241670|NCT02507258|Device|PROFEMUR® Am Femoral Stem and PROCOTYL® O HA Coated Acetabular Component|
241671|NCT02509507|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into liver tumors, with ultrasound or computerised tomography guidance. The initial dose of talimogene laherparepvec is 10^6 PFU/mL up to 4 mL in cohorts 1 and 2 and up to 8 mL in cohort 3 of Group A and Group B of Part 1. Subsequent doses of talimogene laherparepvec are up to 4 mL of 10^7 PFU/mL in cohort 1, up to 4 mL of 10^8 PFU/mL in cohort 2, and up to 8 mL of the maximum tolerated concentration from cohorts 1 and 2 (either 10^7 or 10^8 PFU/mL) in cohort 3 of Group A and Group B of Part 1. Subsequent doses of talimogene laherparepvec to be administered for the expansion cohorts of Group A and B of Part 2 will be the maximum tolerated dose (ie, maximum tolerated concentration multiplied by maximum tolerated volume) of talimogene laherparepvec determined in Group A and Group B of Part 1, respectively.
241672|NCT02509520|Procedure|MPR + HPRO|The MPR provides functional strength and cardiopulmonary endurance training. Muscular strength and endurance training will be closed kinetic chain to promote function movements. Intensity will be based upon the patient's hemodynamic response and subjective reporting using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a safe, appropriate physiological response, with a goal to train patients to achieve physiological benefit. The HPRO intervention is based on caloric needs and will be calculated based on the Pennsylvania State Equation to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids 3 times a day and in a bolus to deliver ~15g of essential amino acids (~5g Leucine) per serving. The goal is to achieve a total protein Intake of 1.6 g/kg of protein. This dosage has been used in bed rest studies of adults of varying ages to prevent muscle loss.
241052|NCT02516241|Drug|MEDI4736|IV infusion
241053|NCT02516241|Drug|Tremelimumab|IV infusion
241054|NCT02516241|Drug|Cisplatin|IV infusion
241055|NCT02516241|Drug|Carboplatin|IV infusion
241056|NCT02518438|Drug|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
241057|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
241058|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
241059|NCT02518464|Drug|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. PRU testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
241060|NCT02518477|Other|exercise|progressive resistance training
241061|NCT02518503|Drug|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241062|NCT02518503|Drug|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241063|NCT02518503|Drug|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241064|NCT02518503|Drug|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241360|NCT02511769|Behavioral|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
241361|NCT02511782|Device|D-SQUAME Skin Sampling Discs|A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
240731|NCT02522767|Drug|Placebo|
240732|NCT02522780|Drug|Mesalamine|
240733|NCT02522780|Drug|Placebo|
240734|NCT02522806|Procedure|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
240735|NCT02522819|Device|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
240736|NCT02522832|Other|Titre 1|Virus infection
240737|NCT02525094|Biological|MEDI9929|Subcutaneous (under the skin) injections administered on Day 1, weeks 2, 4, 6, 8, 10.
240738|NCT02525094|Biological|Placebo|Subcutaneous (under the skin) injections administered on Day 1, weeks 2, 4, 6, 8, 10.
240739|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients on Hydroxyurea
240740|NCT02525107|Dietary Supplement|Placebo|SCD patients on Hydroxyurea
240741|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients not on Hydroxyurea
240742|NCT02525107|Dietary Supplement|Placebo|SCD patients not on Hydroxyurea
240743|NCT02525120|Device|Triojection|Triojection is system intended to deliver an specific amount of ozone to a herniated disc.
240744|NCT02525120|Procedure|Surgical discectomy|Patients will receive surgery to remove the herniated disc material.
240745|NCT02525133|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
240746|NCT00182481|Drug|inhaled corticosteroids and other asthma drugs|
240747|NCT02525133|Other|Placebo|Plain collagen implant (vehicle)
240748|NCT02525146|Other|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
240749|NCT02525159|Dietary Supplement|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
241065|NCT02518503|Drug|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241066|NCT00181363|Device|Mamma board|
240126|NCT02536716|Procedure|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
240127|NCT02536716|Procedure|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
240423|NCT02529657|Procedure|Placebo|In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
240424|NCT02529670|Procedure|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
240425|NCT02529670|Procedure|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
240426|NCT02531854|Drug|Pemetrexed|
240427|NCT02531867|Biological|Asfotase Alfa|
240428|NCT02531880|Drug|Mangafodipir|A contrast agent previously approved for liver imaging with MRI, which contains manganese.
240429|NCT02531906|Drug|Gabapentin|Given PO
240430|NCT00183209|Behavioral|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
240431|NCT02531906|Drug|Methadone Hydrochloride|Given PO
240432|NCT02531906|Drug|Oxycodone Hydrochloride|Given PO
240433|NCT02531906|Other|Quality-of-Life Assessment|Ancillary studies
240434|NCT02531906|Other|Questionnaire Administration|Ancillary studies
240435|NCT02531919|Drug|Sodium Bicarbonate|Given PO
240436|NCT02531932|Drug|Carboplatin|Carboplatin will be administered if ANC > 1.5 and platelets are >75k
240437|NCT02531932|Drug|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
240438|NCT02531945|Device|Use of Biomod device|
240439|NCT02531958|Other|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
240440|NCT02531971|Drug|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
239828|NCT02506348|Drug|Nepafenac|
239829|NCT02506387|Device|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
239830|NCT02506413|Other|MamaToto Package|The MamaToto Package is an MNH intervention that builds upon a prior successes in Uganda and will be adapted to meet the needs of the Misungwi District in Tanzania. The intervention includes low-cost programming that builds upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers.
239831|NCT02506426|Procedure|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
239832|NCT02506426|Procedure|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
239833|NCT02506439|Dietary Supplement|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
239834|NCT02506439|Dietary Supplement|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
239835|NCT02506439|Dietary Supplement|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
239836|NCT02506439|Dietary Supplement|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
239837|NCT02506452|Other|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
239838|NCT00179621|Drug|Placebo|Placebo, matching to active study drug arms
240128|NCT02536729|Drug|Oral Sodium Phosphate - Normal preparation|
240129|NCT02536729|Drug|Oral sodium phosphate - Modified Preparation|
240130|NCT02536729|Drug|polyethylene glycol + Electrolytes|
240131|NCT02536742|Drug|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
240132|NCT00183599|Behavioral|Cognitive Behavioral Therapy (CBT)|
240133|NCT02536742|Drug|Placebo|orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
240134|NCT02538926|Biological|Rituximab|Given IV
240135|NCT00183872|Drug|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
257181|NCT02276144|Other|Liver ultrasound|For evaluate whether fatty liver is exist or not
257182|NCT02276183|Dietary Supplement|Nutrition intervention, test formula|
257183|NCT02276183|Behavioral|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
257184|NCT02276196|Drug|Lixisenatide|GLP-1 receptor agonist
257185|NCT02239770|Drug|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
257186|NCT02239783|Device|total hip arthroplasty implant|
257478|NCT02467946|Drug|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
257479|NCT00174642|Drug|Metformin|At same dosages as the previous treatment
257480|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
257481|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
257482|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
257483|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
257484|NCT02467985|Procedure|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
257485|NCT02467998|Device|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
257486|NCT02468011|Other|vibration|vibration will be applied at 35 Hz
257487|NCT02468024|Procedure|Lung Surgery|Sublobar Lung Resection
256854|NCT02242227|Drug|Placebo (HandiHaler®)|
256855|NCT02242227|Drug|Placebo (Diskus®)|
256856|NCT02244671|Device|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
256857|NCT02244710|Drug|Ticagrelor vs Clopidogrel|
256858|NCT02244723|Other|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
256859|NCT02244749|Other|skin specimen|skin specimen
256860|NCT02244762|Drug|20 mg HC-ER|1-72 hours
256861|NCT02244762|Drug|20 mg HC-ER|1-72 hours
256862|NCT02244762|Drug|20 mg HC-ER|1-72 hours
256863|NCT02244775|Device|SR™MCP|
256864|NCT02244788|Device|SR™ PIP|
257187|NCT02239796|Device|NeuroTrac continence stimulators|Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.
Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators.
257188|NCT02239796|Device|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
257189|NCT02239809|Procedure|Stimulation of the trigeminal nerve (active stimulation)|Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks.
257190|NCT02239809|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks.
256529|NCT02249611|Other|Standard care|Counseling on lifestyles with health education material
256530|NCT02249637|Procedure|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
256531|NCT02249650|Drug|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
256532|NCT02249663|Drug|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
256533|NCT02249663|Drug|Dymista™|137/50 mcg Nasal Spray
256534|NCT00145743|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
256535|NCT02251821|Other|Laboratory Biomarker Analysis|Correlative studies
256536|NCT02251821|Drug|Melphalan|Given IV
256537|NCT02251821|Drug|Methotrexate|Given IV
256538|NCT02251821|Drug|Mycophenolate Mofetil|Given IV or PO
256539|NCT02251821|Drug|Tacrolimus|Given IV or PO
256540|NCT02251821|Radiation|Total-Body Irradiation|Undergo TBI
256541|NCT02251821|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
256865|NCT02244801|Drug|darTreg infusion|The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.
Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects.
256866|NCT00144924|Procedure|pyloromyotomy|laparoscopic pyloromytomy
256867|NCT02244814|Behavioral|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
255903|NCT02260843|Other|Tai Chi Intervention|Subjects in this groups will receive three tai chi lessons in a weeks while each session last for 1 hour throughout the 12 weeks experimental period
255904|NCT02260856|Device|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
255905|NCT02260856|Procedure|Percutaneous Drill Epiphysiodesis|
255906|NCT02260856|Procedure|Percutaneous Screw Epiphysiodesis|
255907|NCT00146913|Drug|Imatinib mesylate 600mg/day|
255908|NCT02263105|Drug|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
255909|NCT02263118|Other|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
255910|NCT02263118|Device|Feature phone|Participants were given a feature phone.
255911|NCT02263118|Other|Virtual communities|Exposure to virtual community communication via SMS
255912|NCT02263118|Other|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
255913|NCT02263131|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
255914|NCT02263131|Biological|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
255915|NCT02263144|Procedure|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
255916|NCT02263170|Other|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
255917|NCT02263170|Other|US (ultra sound)|Assessment of the sphincter morphology
255918|NCT00147264|Behavioral|Low-Glycemic Index Diet vs. Control Diet|
256218|NCT02256397|Other|enhanced comprehensive care|standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:
If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller
5 and above--> will receive home-centered comprehensive care with propeller and PIKO
255262|NCT02272725|Drug|Ibuprofen|Ibuprofen
255263|NCT02272725|Drug|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
255264|NCT02272738|Drug|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
255265|NCT02272738|Drug|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
255266|NCT02272751|Behavioral|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
255267|NCT02275260|Device|Transesophageal Echocardiography|Patients undergo a Transesophageal Echocardiography prior to the ablation itself
255268|NCT02275260|Other|Paperbased neurocognitive testing|To assess the impact of PVI on the patient's neurocognitive status
255269|NCT02275286|Drug|Trabectedin|Escalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks. Cohort A: unlimited cycles Cohort B: 3 cycles
255270|NCT02275286|Radiation|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction) Cohort B: 45Gy in 25 fractions (1.8Gy/fraction)
255271|NCT02275299|Drug|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
255272|NCT02275299|Drug|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
255273|NCT02275299|Drug|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
255274|NCT02275325|Other|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
255275|NCT02275338|Drug|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
255276|NCT00148564|Drug|Ziprasidone|treatment with either Olanzapine or Ziprasidone
255277|NCT02275351|Drug|SM04554|Topical solution, applied once a day
255278|NCT02275351|Drug|Vehicle|Topical solution, applied once a day
255279|NCT02275364|Device|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
255280|NCT02275364|Device|Placebo strip|Placebo strip
255281|NCT02275364|Other|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
243748|NCT02538237|Drug|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
243749|NCT02538237|Drug|Ibuprofen 2% mouthwash|
243750|NCT02538250|Dietary Supplement|Nutricomp Drink Plus|Oral nutritional supplementation
244051|NCT02533193|Procedure|Conventional perioperative cares|No Patient's preoperative counseling & education before surgery
Bowel preparation
No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery
Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)
Conventional Mobilization
Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)
IV PCA
Postoperative Nausea Control if needed
No Thromboembolism prophylaxis
No or Low Content Oxygen therapy
Drainage tube insertion if needed
244052|NCT02533206|Procedure|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
244053|NCT02533206|Procedure|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
244054|NCT02533219|Drug|18 F-DOPA|Subjects will undergo PET imaging with [18F]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of [18F]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
244055|NCT00183339|Drug|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
244056|NCT02533232|Drug|Minocycline|Minocycline 200mg per day
244057|NCT02533245|Other|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
244058|NCT02533245|Other|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
244059|NCT02533245|Other|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
244060|NCT02533271|Radiation|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
244061|NCT02533271|Radiation|Long-term chemoradiotherapy|Standard chemoradiotherapy
244062|NCT02533284|Drug|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
244063|NCT02533284|Drug|bupevecaine|US guided TAP using Bupevecaine 0.25 %
244064|NCT02533284|Drug|saline|US guided TAP using placebo (saline)
244065|NCT02533297|Other|Providing clinical skills conditions|
243461|NCT02507973|Other|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
243462|NCT02507986|Device|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
243463|NCT00179803|Procedure|Stem Cell Transplant|Group A: recurrent medulloblastoma, recurrent germ cell tumor
Cytoxan treatment
Stem cell autologous harvest
Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET
Carboplatin and Etoposide treatment
Autologous stem cell harvest
The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to >1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue.
243751|NCT00183742|Drug|liposomal doxorubicin and docetaxel|
243752|NCT02538263|Device|Volume-targeted noninvasive ventilation|
243753|NCT02538289|Behavioral|Teaching talks|Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
243754|NCT02538302|Drug|Minirin|Minirin 5 to 10 mg daily for 6 months
243755|NCT02538302|Drug|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
243756|NCT02538315|Drug|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by [18F]FDOPA PET/CT imaging
243757|NCT02538328|Device|Harmonic scapel|different surgical devices used in the obesity surgery
243758|NCT02503163|Drug|KCT-0809 ophthalmic solution|
243759|NCT02503176|Drug|KCT-0809 ophthalmic solution|
243760|NCT02503189|Drug|KCT-0809 ophthalmic solution|
243761|NCT00179179|Drug|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
243762|NCT02503189|Drug|Placebo|
243763|NCT02503202|Biological|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
243764|NCT02503202|Biological|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
243199|NCT02514681|Drug|Trastuzumab|
243200|NCT02514681|Drug|Pertuzumab|
243201|NCT02514681|Drug|Docetaxel|
243202|NCT02514681|Drug|Paclitaxel|
243203|NCT02514681|Drug|Nab-paclitaxel|
243204|NCT02514681|Drug|Vinorelbine|
243205|NCT02514681|Drug|Eribulin|
243206|NCT02514694|Drug|LEO32731|
243207|NCT02514694|Other|Placebo|
243208|NCT00180687|Drug|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
243209|NCT02514720|Other|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
243210|NCT02514746|Biological|SA-14-14-2 live, attenuated JE vaccine|0.5 ml (single dose), Subcutaneous
243211|NCT02514759|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
243212|NCT02514772|Biological|GP2013 - A Proposed biosimilar rituximab|
243213|NCT02514772|Biological|Originator rituximab - Rituxan ® or MabThera ®|
243464|NCT02507986|Device|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
243465|NCT02507999|Device|Flotrac|Flotrac guided intervention
243466|NCT02508012|Other|Immuno monitoring|treatment optimization
243467|NCT02508025|Other|Functional Capacity Evaluation|Assessment of work related physical capacity
243468|NCT02508038|Procedure|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients will undergo a reduced-intensity conditioning regimen prior to transplant with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells using the CliniMACS System.
243469|NCT02508038|Drug|Zoledronate|Given IV. Patients (except those in Cohort A) will receive two doses of Zoledronate (at a 28 day interval) following transplant. Dose and post-transplant timing of Zoledronate administration is dependent upon patient Cohort.
243470|NCT02508051|Behavioral|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
242903|NCT02521376|Drug|Entospletinib|Entospletinib 100 mg tablet administered orally twice daily
242904|NCT02521389|Drug|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
242905|NCT02521402|Biological|Biovance|decellularized, dehydrated human amniotic membrane
242906|NCT02521415|Drug|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
242907|NCT02521415|Drug|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
242908|NCT02521415|Drug|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
242909|NCT00181935|Drug|olanzapine (Zyprexa)|
242910|NCT02521428|Other|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
242911|NCT02521441|Biological|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
242912|NCT02521441|Biological|Filgrastim|Filgrastim at dose of μg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
242913|NCT02521441|Drug|Epirubicin and Cyclophosphamide|Epirubicin, 100 mg/me and Cyclophosphamide, 600 mg/m2 administrated in vein on Day 1 of each cycle for 4 cycles.
242914|NCT02521454|Behavioral|MBRT|
242915|NCT02521467|Biological|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
242916|NCT02521467|Other|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
243214|NCT02514785|Device|Artificial Pancreas using the Zone-Model Predictive Control|Artificial pancreas (AP) system using the Zone-Model Predictive Control (MPC) algorithm on the Diabetes Assistant (DiAs) platform
243215|NCT02514798|Other|Esophageal and gastric balloons|Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.
242589|NCT02525900|Procedure|bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine|
242590|NCT02525913|Device|RFA Applicator|
242591|NCT02525926|Procedure|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
242592|NCT02528123|Drug|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
242593|NCT02528123|Drug|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
242594|NCT02528136|Drug|Carbetocin|
242595|NCT02528136|Drug|Oxytocin|
242596|NCT00002494|Drug|prednisone|
242597|NCT00182741|Drug|mitoxantrone hydrochloride|
242598|NCT02528149|Procedure|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
242599|NCT02528149|Other|blood sample|
242600|NCT02528162|Behavioral|education|Evaluation of education for GDM
242601|NCT02528175|Device|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
242602|NCT02528175|Radiation|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
242603|NCT02528175|Drug|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
242604|NCT02528188|Drug|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
242605|NCT02528188|Biological|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
242606|NCT02528188|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
242607|NCT02528201|Drug|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
242608|NCT00182741|Drug|prednisone|
242609|NCT02528201|Drug|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
241986|NCT02502578|Drug|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
241987|NCT02502591|Drug|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
241988|NCT02502604|Behavioral|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
241989|NCT00179101|Procedure|Deep Brain Stimulation|
242283|NCT02532699|Dietary Supplement|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
242284|NCT02532699|Dietary Supplement|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
242285|NCT02532712|Drug|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
242286|NCT02532712|Drug|Placebo|Placebo with same shape and size
242287|NCT02535039|Drug|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg * d for application to the third day after surgery
242288|NCT02535039|Other|Physiological saline|The same volume of physiological saline will be given in Placebo group
242289|NCT02535052|Biological|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
242290|NCT00183469|Drug|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
242291|NCT02535065|Device|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
242292|NCT02535078|Drug|IMCgp100|soluble gp100-specific T cell receptor with anti-CD3 scFV
242293|NCT02535078|Drug|durvalumab|anti-PD-L1 monoclonal antibody
241673|NCT02509520|Procedure|MPR + NMES|The MPR exercise intervention will be combined with the NMES intervention which includes daily treatment with NMES. The NMES protocol requires that large (7.6 x 12.7 cm) self-adhesive surface electrodes be placed on quadriceps muscles specifically on the vastus lateralis, vastus medialis and rectus femoris and the gastrocnemius of both legs. This protocol is developed based upon previous NMES protocols used to acutely stimulate muscle protein synthesis rates in older type 2 diabetic patients preserve and restore muscle mass in intensive care patients and increase strength in older adults recovering from total knee replacement. Treatments will be twice daily.
241674|NCT00179959|Drug|Water|Water baths twice weekly for three months
241675|NCT02509520|Procedure|MPR + NMES + HPRO|This is a combination of three above MPR, NMES, and HPRO interventions.
241676|NCT02509533|Device|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
241677|NCT02509533|Device|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
241678|NCT02509546|Other|Laboratory Biomarker Analysis|Correlative studies
241679|NCT02509546|Other|Pharmacological Study|Correlative studies
241680|NCT02509546|Drug|8-chloro-adenosine|Given IV
241681|NCT02509559|Drug|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
241990|NCT02502617|Dietary Supplement|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
241991|NCT02502630|Device|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
241992|NCT02502643|Drug|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
241993|NCT02502643|Drug|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
241994|NCT02502669|Drug|Finasteride 23.5 mg tablets|
241995|NCT02504671|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
241362|NCT00180310|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
241363|NCT02511795|Drug|AZD1775|AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10, then combined with olaparib PO BID on Days 1-14.
241364|NCT02511795|Drug|Olaparib|Olaparib PO BID dosing will commence in Cycle 1 with a Day-3 lead-in period, then administered in combination with AZD1775 on Days 1-14.
241365|NCT02514005|Device|Dry needling|Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
241366|NCT02514018|Biological|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
241367|NCT02514031|Drug|ARQ-761|Dose Level 1:
ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15
Dose Level 2:
ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15
Dose Level 3:
ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15
Expansion Dose Level:
ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15
241368|NCT00180622|Procedure|Blood test|
241369|NCT02514031|Drug|Gemcitabine|Therapy after lead in Phase:
You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression.
241370|NCT02514031|Drug|nab-paclitaxel|Therapy after lead in phase:
You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression.
241371|NCT02514044|Drug|Dexedrine|10 mg immediate release of Dexedrine
241372|NCT02514044|Device|Active tDCS|1.5 mA tDCS anodal tDCS
241373|NCT02514044|Behavioral|Speech Therapy|60 min of speech therapy
241374|NCT02514044|Drug|Placebo|
241375|NCT02514044|Device|Sham tDCS|
241376|NCT02514057|Other|Questionnaire|Form filling only
241377|NCT02514070|Dietary Supplement|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
241682|NCT02509559|Drug|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
241067|NCT02518503|Drug|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241068|NCT02518503|Drug|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for <10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241069|NCT02518503|Drug|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241070|NCT02518503|Drug|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
241071|NCT02518516|Drug|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed >120 days of the index date (i.e. no exposure within 120 days of the index date).
241072|NCT00181766|Drug|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
241073|NCT02520648|Other|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
241074|NCT02520648|Other|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
241075|NCT02520661|Behavioral|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
241076|NCT02520674|Other|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
241077|NCT02520687|Dietary Supplement|Beetroot juice|200mls daily for seven days
241078|NCT02520687|Dietary Supplement|Nitrate-depleted beetroot juice|200mls daily for seven days
241079|NCT02520700|Device|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
241080|NCT02520726|Drug|Sertraline|< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
241378|NCT02514070|Dietary Supplement|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
240441|NCT00183222|Drug|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
240442|NCT02531971|Drug|Duragesic®|TDDS dosage is 25 micrograms/hour
240443|NCT02531971|Drug|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour
240444|NCT02531984|Drug|Azithromycin|
240750|NCT02525159|Other|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
240751|NCT02525172|Drug|Rituximab|
240752|NCT02525172|Drug|intravenous immune globulin|
240753|NCT02525172|Drug|Bortezomib|
240754|NCT02525172|Drug|Methotrexate|
240755|NCT02525185|Other|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
240756|NCT02525198|Dietary Supplement|fatty acid/flavonoid blend|see arm description
240757|NCT00182494|Behavioral|Modified diabetes prevention protocol & Metformin|
240758|NCT02525198|Dietary Supplement|Placebo|see arm description
240759|NCT02525211|Drug|Ropivacaine|a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
240760|NCT02525211|Drug|physiological saline|a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
240761|NCT02525224|Dietary Supplement|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
240762|NCT02525224|Radiation|Minimal Erythema Dose (MED)|1, 2, and 3 MED of solar simulated radiation on the right or left sun protected buttock conducted at baseline visit and week 8 visit
240763|NCT02525237|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
240764|NCT02525237|Drug|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
240765|NCT02527356|Behavioral|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
240136|NCT02538926|Drug|Vincristine Sulfate|Given IV
240137|NCT02538939|Drug|Sodium thiosulfate|
240138|NCT02538952|Device|Xpert device|Interventions in the "Experimental phase" of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device.
240139|NCT02538952|Other|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
240140|NCT02538965|Drug|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Subjects will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
240141|NCT02538978|Biological|Autologous Bone Marrow Concentrate (aBMC)|Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.
Device: SurgWerks-CLI Kit
Device: VXP System
240142|NCT02538978|Biological|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
240143|NCT02538991|Procedure|Bulkamid|Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations "ten, two and five and seven o'clock" within 0.5 to 1 cm from the bladder - urethra junction.
Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The treatment will include prophylactic antibiotic of Cefuroxime 1.5 g x1 i.v. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation.
240445|NCT02531997|Behavioral|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
240446|NCT02531997|Behavioral|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
240447|NCT02532010|Drug|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nM and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit JAK1.
257488|NCT02468024|Radiation|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
257489|NCT02468037|Procedure|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
257490|NCT00174642|Drug|insulin secretagogue|sulfonylurea or glinide
257491|NCT02468050|Behavioral|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
257492|NCT02470091|Other|Pharmacological Study|Correlative studies
257493|NCT02470104|Biological|Breastmilk|A registered dietician will supervise milk provision.
If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician.
257494|NCT02470117|Drug|Alginate-based reflux suppressant|
257495|NCT02470117|Drug|magnesium-aluminium antacid gel|
257496|NCT02470130|Behavioral|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
257786|NCT02499367|Drug|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
257787|NCT02499367|Drug|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
257788|NCT02499367|Drug|Cisplatin|40 mg/m2, weekly for 2 weeks
257789|NCT00178620|Drug|Retavase 10 U IV Bolus|Retavase IV Bolus, 10 U, one dose at time of myocardial infarction
257790|NCT02499380|Device|PneumRx Coil System|
257791|NCT02499393|Drug|Magnesium Sulfate|intravenous infusion of magnesium sulphate
257792|NCT02499406|Behavioral|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
257793|NCT02499432|Behavioral|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
257794|NCT02499445|Drug|Remifentanil|administering remifentanil for anesthesia maintenance
257795|NCT02499445|Drug|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
257796|NCT02499445|Drug|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
257797|NCT02499445|Drug|propofol|administering propofol for anesthesia maintenance
257191|NCT02239822|Procedure|Stimulation of the trigeminal nerve (active stimulation)|Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks.
257192|NCT02239822|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks.
257193|NCT02239835|Drug|Tipranavir (TPV) low dose|
257194|NCT02239835|Drug|Tipranavir (TPV) high dose|
257195|NCT00144352|Drug|sulfadoxine-pyrimethamine|
257196|NCT02239835|Drug|Ritonavir low dose|
257197|NCT02239835|Drug|Ritonavir high dose|
257198|NCT02239835|Drug|Saquinavir|
257199|NCT02242240|Drug|Formoterol twice daily|
257200|NCT02242240|Drug|Formoterol once daily|
257497|NCT02470143|Behavioral|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
257498|NCT02470156|Behavioral|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
257499|NCT02470156|Behavioral|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
257500|NCT00174889|Drug|Pregnenolone|
257501|NCT02470169|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
257502|NCT02470169|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
256868|NCT02244814|Behavioral|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
256869|NCT02244827|Drug|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
256870|NCT02244840|Device|Electronic bidet|commercial electronic bidet
256871|NCT02244840|Device|Sitz bath|Conventional sitz bath
256872|NCT02244866|Drug|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
256873|NCT02244866|Drug|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
256874|NCT02244879|Dietary Supplement|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
256875|NCT02244905|Behavioral|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
256876|NCT02244905|Other|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
256877|NCT00144937|Drug|Stepwise therapy for dyslipidemia, hypertension and diabetes|
256878|NCT02244918|Drug|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
256879|NCT02247271|Behavioral|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
256880|NCT02247284|Device|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
256881|NCT02247297|Procedure|Blood collection|Diagnostic blood collection
256882|NCT02247310|Drug|Betaferon, (BAY 86-5046)|Patients will be treated with Betaferon
257201|NCT02242240|Drug|Tiotropium once daily|
257202|NCT02242240|Drug|Placebo|
257203|NCT00144599|Drug|placebo|
257204|NCT02242253|Drug|Tiotropium|administered via HandiHaler®
257205|NCT02242253|Drug|Salmeterol|administered via metered dose inhaler (MDI)
256219|NCT02256410|Device|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
256220|NCT02256410|Other|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
256221|NCT02256423|Drug|REFERENCE 1: Nurofen® 200 mg tablet|
256222|NCT02256423|Drug|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
256223|NCT00146393|Behavioral|People with Arthritis Can Exercise program|
256224|NCT02256423|Drug|ibuprofen 200 mg soft gel capsule|
256225|NCT02256436|Biological|pembrolizumab|IV infusion
256226|NCT02256436|Drug|paclitaxel|IV infusion
256227|NCT02256436|Drug|vinflunine|IV infusion
256228|NCT02256436|Drug|docetaxel|IV infusion
256229|NCT02256462|Drug|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (> 40kg 160/80/40 mg every 2 weeks or < 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
256230|NCT02256475|Drug|NBI-98854|
256231|NCT02256488|Biological|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
256232|NCT02256488|Biological|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
256233|NCT02256488|Biological|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
256234|NCT00146406|Behavioral|Project Connect|
256235|NCT02258581|Drug|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
256236|NCT00146627|Drug|Nifurtimox|
256237|NCT02258581|Drug|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
255581|NCT02267928|Other|Check Symptoms|Symptoms are "Checked"
255582|NCT02267928|Other|Uncheck Symptoms|Symptoms are "Un-checked"
255583|NCT02267928|Other|Experienced|Focus of instructions is on symptoms the participant has experienced
255584|NCT02267928|Other|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
255585|NCT02267941|Other|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
255586|NCT02267954|Other|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
255587|NCT02267967|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
255588|NCT02267980|Drug|Sevoflurane|Inhalation anesthetic agent
255589|NCT02267980|Drug|Ketamine|Intravenous anesthetic agent
255590|NCT02267980|Drug|Saline|Isotonic solution for placebo group
255591|NCT00147836|Other|Pre-meal|
255592|NCT02267993|Drug|recombinant human thrombopoietin|Patients received subcutaneous injection of rhTPO at a dose of 300 U/kg body weight once daily at a platelet count of < 50×109/L, and rhTPO treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
255593|NCT02268006|Radiation|IMRT-SIB|
255594|NCT02268006|Drug|Capecitabine|
255595|NCT02268006|Procedure|Surgery|
255596|NCT02268019|Procedure|tourniquet application|
255597|NCT02268019|Drug|epinephrine injection|
255598|NCT02270398|Behavioral|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
255599|NCT02270398|Behavioral|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
255600|NCT02270424|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
255601|NCT02270424|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
244066|NCT00183365|Behavioral|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
244067|NCT02533310|Other|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
244068|NCT02533310|Other|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
239327|NCT02458872|Behavioral|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
239328|NCT02458898|Behavioral|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
239329|NCT02458911|Device|Paclitaxel-eluting balloon|
239330|NCT00171951|Drug|Pasireotide|
239331|NCT02458924|Biological|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
239332|NCT02458937|Other|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
239333|NCT02458937|Other|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
239334|NCT02458937|Other|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
239335|NCT02458963|Procedure|IVF|Women will undergo one IVF cycle
239336|NCT02458963|Drug|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
239337|NCT02458976|Device|PDL|
239338|NCT02458989|Procedure|Scalpel|Use of a scalpel as a first incision during thyroid operation
239339|NCT02458989|Procedure|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
243765|NCT02503202|Biological|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
243766|NCT02503202|Biological|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
243767|NCT02503202|Biological|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
243768|NCT02503215|Device|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
243769|NCT02503228|Other|Receiving MOPS-Preserved Cartilage|The Missouri Osteochondral Allograft Preservation System (MOPS) preserves donated cartilage tissue that is meant to be transplanted from the time it is obtained from the donor to the time it is transplanted into the recipient. The MOPS is a different media formulation from the standard media that is usually used to preserve the cartilage tissue.
243770|NCT02503241|Procedure|Recruitment maneuver|Progressive increase in airway pressure to open lungs atelectatic regions.
244069|NCT02533323|Drug|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
244070|NCT02533323|Drug|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
244071|NCT02533323|Drug|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
244072|NCT02533336|Drug|abamectin and fenpyroximate|
244073|NCT02535754|Behavioral|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
244074|NCT02535767|Drug|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
244075|NCT02535780|Procedure|Transcranial magnetic stimulation|
244076|NCT02535780|Procedure|Transcranial direct current stimulation|
244077|NCT02535793|Other|blood test (four dry tubes 7ml) and prick tests|
244078|NCT02535806|Drug|Velcade|4 doses of study drug will be given.
244079|NCT02535806|Drug|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
244080|NCT00183547|Behavioral|Depression-prevention education and support|Weekly therapy sessions offering general depression-prevention education and support
244081|NCT02535806|Drug|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
243471|NCT02510105|Device|CT scan|
243472|NCT02510105|Device|Servo-i|
243473|NCT02510105|Device|- Intubation|
243474|NCT00180063|Drug|L-NMMA(drug)|
243475|NCT02510105|Device|Ventilation ( with an ICU conventional ventilator)|
243476|NCT02510118|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
243477|NCT02510118|Drug|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks
243478|NCT02510118|Drug|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
243479|NCT02510118|Drug|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
243480|NCT02510131|Behavioral|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
243481|NCT02510144|Drug|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
243482|NCT02510144|Drug|Skin Prep Benzoyl Peroxide|
243483|NCT02510157|Drug|Dexamethasone|active comparator
243484|NCT02510157|Drug|Normal Saline|placebo controlled intervention
243485|NCT00180076|Drug|Budesonide|
243771|NCT02503241|Procedure|PEEP titration|PEEP will be decreased at consecutive steps. Static compliance of the respiratory system will be measured at each step. The optimal PEEP value for the patient will be chosen as the lowest PEEP level at witch the compliance of the respiratory system will be the best.
243772|NCT00179179|Behavioral|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
243773|NCT02503254|Other|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
243774|NCT02503254|Other|CC|Subject's own preferred brand of CC ad libitum for 5 days in confinement
243775|NCT02503267|Other|none intervention|
243216|NCT02514798|Other|RIP system|Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
243217|NCT02514798|Other|Sentec transcutaneous monitoring system|The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.
243218|NCT02514811|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
243219|NCT00002492|Drug|isolated limb perfusion|
243220|NCT00181038|Device|Peri-Neuronal Catheter|
243221|NCT02516956|Other|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
243222|NCT02516956|Other|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
243223|NCT02516956|Other|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
243224|NCT02516956|Other|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
243225|NCT02516956|Other|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
243226|NCT02516969|Radiation|Stereotactic Body Radiotherapy|Radiation
243486|NCT02510157|Drug|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
243487|NCT02510170|Other|no intervention|
243488|NCT02510183|Device|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
243489|NCT02510183|Device|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
243490|NCT02510196|Behavioral|reminder|
242917|NCT02521480|Device|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
242918|NCT02521480|Device|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
242919|NCT02521493|Drug|Asparaginase|Given IM or IV
242920|NCT00181948|Drug|atomoxetine (Strattera)|
242921|NCT02521493|Drug|Asparaginase Erwinia chrysanthemi|Given IM or IV
242922|NCT02521493|Drug|Cytarabine|Given IT and IV
242923|NCT02521493|Drug|Daunorubicin Hydrochloride|Given IV
242924|NCT02521493|Drug|Etoposide|Given IV
242925|NCT02521493|Other|Laboratory Biomarker Analysis|Correlative studies
242926|NCT02521493|Drug|Mitoxantrone Hydrochloride|Given IV
242927|NCT02521493|Drug|Thioguanine|Given PO
242928|NCT02523573|Procedure|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
242929|NCT02523586|Device|Simple mask|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
242930|NCT02523599|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
242931|NCT02523599|Other|Placebo|Plain collagen implant (vehicle)
242932|NCT02523612|Procedure|Biopsy|
242933|NCT02523612|Procedure|Blood sample|
242934|NCT02523625|Device|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
242294|NCT02535078|Drug|tremelimumab|anti-CTLA-4 monoclonal antibody
242295|NCT02535091|Drug|YKP3089|
242296|NCT02535104|Drug|Ranpirnase|Topical application by subject
242297|NCT02535104|Drug|Vehicle|Vehicle control
242298|NCT02535117|Procedure|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
242610|NCT02528201|Drug|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
242611|NCT02528214|Drug|Dupilumab SAR231893 (REGN668)|Pharmaceutical form:solution Route of administration: subcutaneous
242612|NCT02528214|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
242613|NCT02528214|Drug|asthma controller therapies (including prednisone/prednisolone)|Pharmaceutical form:aerosol, capsules, tablets Route of administration: inhaled, oral
242614|NCT02528227|Other|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
242615|NCT02528227|Other|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
242616|NCT02528227|Other|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
242617|NCT02528227|Other|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
242618|NCT02528227|Other|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
242619|NCT00182754|Drug|octreotide acetate|Given subcutaneously
242620|NCT02530437|Procedure|Endoscopy|Upper endoscopy performed on day 8 to obtain pictures of the tumor for comparison with the baseline and to obtain tumor tissue for biomarker assessment.
242621|NCT00183014|Behavioral|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
242622|NCT02530450|Device|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
241996|NCT02504684|Device|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
241997|NCT02504684|Device|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
241998|NCT02504710|Device|Kinematic Real Time Feedback|
241999|NCT02504710|Other|Traditional systems of manual therapy teaching|
242000|NCT02504723|Drug|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure >90 mm Hg.
242001|NCT02504723|Drug|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
242002|NCT02504749|Procedure|general anasthesia,spinal anasthesia|Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.
450-pregnant women with an indication for caesarean section were randomly allocated .
242003|NCT02504762|Procedure|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
242004|NCT02504762|Procedure|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
242299|NCT02535117|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
242300|NCT02535130|Device|Positive expiratory pressure|
242301|NCT00183469|Drug|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
242302|NCT02535130|Drug|Amikacine nebulization|
242303|NCT02535143|Other|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
242304|NCT02535143|Drug|Taurine|250 ml of commercially avaible taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
241683|NCT02509559|Device|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
241684|NCT02509559|Device|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
241685|NCT02511808|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
241686|NCT02511808|Behavioral|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
241687|NCT02511808|Behavioral|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
241688|NCT02511821|Other|Computer-Assisted Intervention|Complete online surveys
241689|NCT02511821|Device|Vivofit watch|Wear Vivofit watch
241690|NCT02511821|Other|Quality-of-Life Assessment|Ancillary studies
241691|NCT02511821|Other|Questionnaire Administration|Ancillary studies
241692|NCT02511834|Device|VEST External Support|
241693|NCT00180323|Device|Renewal|Renewal is a CRT-D device for cardiac resynchronization therapy
241694|NCT02511834|Procedure|Coronary Artery Bypass Surgery|
241695|NCT02511847|Drug|Afatinib|Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not
Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course.
241696|NCT02511860|Dietary Supplement|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
241697|NCT02511860|Dietary Supplement|Placebo|Methylcellulose (inert) tablet taken as placebo
241698|NCT02511873|Drug|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
241699|NCT02511873|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
241379|NCT00180622|Procedure|St Georges Questionnaire|
241380|NCT02514083|Drug|Ibrutinib|Ibrutinib
241381|NCT02514083|Drug|Fludarabine|Fludarabine
241382|NCT02514109|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
241383|NCT02514122|Drug|Ketamine|Patients will receive a subcutaneous injectio (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
241384|NCT02514135|Other|No intervention|
241385|NCT02514148|Behavioral|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
241386|NCT02514148|Other|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
241387|NCT02514148|Other|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
241388|NCT02516241|Drug|Gemcitabine|IV infusion
241389|NCT02516254|Dietary Supplement|fortified bread|50 g of fortified bread + placebo daily
241390|NCT02516254|Dietary Supplement|supplement|vitamin D supplement+ plain bread
241391|NCT02516254|Dietary Supplement|placebo|plain bread+placebo
241392|NCT02516267|Device|Multiplate ADP®|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG
241393|NCT00002492|Drug|doxorubicin hydrochloride|
241394|NCT00180921|Drug|Imatinib|
241395|NCT02516280|Device|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
240766|NCT02527369|Device|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
240767|NCT02527382|Procedure|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
240768|NCT02527395|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
240769|NCT02527395|Other|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
241081|NCT02520739|Dietary Supplement|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
241082|NCT02520739|Dietary Supplement|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
241083|NCT00181779|Drug|aripiprazole (Abilify)|
241084|NCT02520739|Dietary Supplement|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
241085|NCT02520752|Drug|INC280|
241086|NCT02520752|Drug|Midazolam|
241087|NCT02520752|Drug|Caffeine|
241088|NCT02520778|Other|Laboratory Biomarker Analysis|Correlative studies
241089|NCT02522832|Other|Titre 2|Virus infection
241090|NCT02522832|Other|Titre 3|Virus infection
240448|NCT02532010|Drug|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
240449|NCT02534129|Drug|Aquaphor|Aquaphor is applied to one half of radiation field
240450|NCT02534155|Device|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
240451|NCT00183417|Behavioral|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
240452|NCT02534155|Procedure|Mitral valve Surgery|Repair or replace mitral valve
240453|NCT02534168|Device|Skin conductance monitor for measuring skin conductance|The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.
The device records sympathetic autonomous nervous system through its effect on skin.
The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor.
240454|NCT02534181|Drug|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
240455|NCT02534194|Other|Image acquisition|Images of baby's face (including ear) and feet
240456|NCT02534207|Drug|RO5186582|Single oral dose: RO5186582 doses between 20 mg and 960 mg may be used in this study. The planned doses for the first two subjects are 160 and 480 mg, respectively. The RO5186582 dose for subsequent subjects will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
240457|NCT02534220|Device|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter & Gamble, Cincinnati, OH
240458|NCT02534220|Device|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter & Gamble, Cincinnati, OH
240459|NCT02534233|Device|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
240770|NCT02527395|Other|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
240771|NCT00002494|Drug|methotrexate|
240772|NCT00182702|Other|laboratory biomarker analysis|Correlative studies
240773|NCT02527421|Drug|DFD01 Spray|
240774|NCT02527421|Drug|Comp01 Lotion|
240775|NCT02527434|Biological|Tremelimumab monotherapy|IV infusion
240776|NCT02527434|Biological|MEDI4736 monotherapy|IV infusion
257798|NCT02499445|Drug|sufentanil|administering sufentanil for anesthesia maintenance
257799|NCT02499458|Other|None- observational study|
257800|NCT00002482|Biological|muromonab-CD3|
257801|NCT00178620|Procedure|Angioplasty/Heart Catheterization|Candidates will receive all the approved standard therapy for heart attacks patients and will go directly for emergent heart catheterization.
Following local anesthesia, a small flexible tube (catheter) will be inserted in an artery of your leg and advanced to the arteries of your heart. By injecting x-ray contrast through the catheter, any blockage in the artery can be seen. If your heart attack artery is still blocked by blood clot or cholesterol deposits, it will be opened up by angioplasty ("balloon surgery" procedure to open the blocked artery) and stenting (placement of a slotted metal tube in the artery to prevent it from closing on itself).
257802|NCT02499471|Other|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
257803|NCT02499484|Drug|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
257804|NCT02499484|Other|Placebo Patch|Topical placebo patch will be used in combination with a eccentric home exercise program
258074|NCT02495233|Drug|ASP2215|oral
258075|NCT02495233|Drug|Erlotinib|oral
258076|NCT02495246|Biological|ChAd3-EBO-Z|
258077|NCT00177983|Behavioral|(relapse rate)|
258078|NCT02495246|Biological|Ad26.ZEBOV|
258079|NCT02495259|Device|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
258080|NCT02495259|Device|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
258081|NCT02495259|Device|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
257503|NCT02470169|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
257504|NCT02470169|Device|shepherd catheter|
257505|NCT02470169|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
257506|NCT02470195|Behavioral|workshop|workshop for procedural simulation for education in difficult airway situation
257507|NCT02470221|Device|Flo-Trac monitoring system|Applying Flo-Trac monitoring system to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
257508|NCT02470221|Device|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
257509|NCT02470234|Drug|Methylphenidate HCl ER Capsules|Methylphenidate Hydrochloride Extended-Release Capsules administered once daily in the morning
257510|NCT02470247|Other|Remote Ischemic Preconditioning (RIPC)|RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.
RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes.
257511|NCT00174902|Drug|inderal (drug), acetylsalicylic acid (drug)|
257512|NCT02470247|Other|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|The SHAM Remote Ischemic Preconditioning ("SHAM" RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol).
257513|NCT02472522|Drug|Ropivacaine + Dexmedetomidine|Addition of Dexmedetomidine 1 micrograms/kg (to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml ) for the TAP block
257805|NCT02501746|Other|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
257806|NCT02501746|Other|Group Medical Visits|The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute "breakout time". The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic.
257206|NCT02242253|Drug|Placebo-MDI|
257207|NCT02242253|Drug|Placebo HandiHaler®|
257208|NCT02242266|Drug|Tiotropium low dose|inhalation powder, hard PE capsule
257209|NCT02242266|Drug|Tiotropium medium dose|inhalation powder, hard PE capsule
257210|NCT02242266|Drug|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
257211|NCT02242266|Drug|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
257212|NCT02242266|Drug|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
257213|NCT02242279|Drug|BEA 2180 BR|
257214|NCT00144612|Drug|MRA(Tocilizumab)|8mg/kg/2weeks
257215|NCT02242279|Drug|Tiotropium|
257216|NCT02242279|Drug|Placebo|
257217|NCT02242292|Drug|Hyoscine butylbromide|
257218|NCT02242292|Drug|Placebo|
257219|NCT02242305|Drug|Hyoscine Butylbromide - Tablet|
257220|NCT02242305|Drug|Hyoscine Butylbromide - Capsule|
257221|NCT02242305|Drug|Placebo|
257222|NCT02242318|Drug|Telmisartan|
257223|NCT02242318|Drug|Valsartan|
257224|NCT02242318|Drug|Placebo|
257225|NCT00144625|Drug|MRA(Tocilizumab)|8mg/kg/4weeks
257226|NCT02242331|Drug|Micardis®|
257227|NCT02242344|Drug|Telmisartan|
257228|NCT02242344|Drug|Placebo|
257514|NCT02472522|Other|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
256542|NCT02251834|Behavioral|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
256543|NCT02251834|Other|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
256544|NCT02251847|Drug|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
256545|NCT00145756|Drug|low sodium high potassium salt substitute|
256546|NCT02251873|Drug|TPV + RTV (low dose)|
256547|NCT02251873|Drug|TPV + RTV (high dose)|
256548|NCT02251873|Drug|ddl|
256549|NCT02251886|Other|Moxibustion in primiparae|Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
256550|NCT02251886|Other|Moxibustion in multiparae|Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
256551|NCT02251899|Behavioral|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
256552|NCT02251912|Drug|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
256553|NCT02251912|Drug|Placebo|6 insufflations (same solution as active treatment minus oxytocin) given twice daily for 12 weeks
256554|NCT02251925|Biological|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
256555|NCT02251925|Drug|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
256556|NCT00145769|Drug|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
256557|NCT02254148|Drug|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
256558|NCT02254148|Drug|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
256559|NCT02254148|Drug|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
255602|NCT00148018|Drug|Dexamethasone|
255603|NCT02270424|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
255919|NCT02263170|Other|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
255920|NCT02263170|Other|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
255921|NCT02263183|Dietary Supplement|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
255922|NCT02263183|Dietary Supplement|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
255923|NCT02263196|Other|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
255924|NCT02263196|Other|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
255925|NCT02263209|Device|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
255926|NCT02263209|Device|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
255927|NCT02263222|Drug|MDT-10013|
255928|NCT02263235|Biological|administration of stable isotope-labelled leucine-|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
255929|NCT00147277|Device|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
255930|NCT02265679|Drug|Placebo|
255931|NCT02265705|Drug|Baricitinib|Administered orally
255932|NCT02265705|Drug|Placebo|Administered orally
255933|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
255934|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
255935|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
255936|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
239340|NCT02459002|Behavioral|QOL Questionnaire|Participant outcomes assessed with survey
239341|NCT00171964|Drug|Zoledronic acid in combination with therapy|
239342|NCT02459002|Behavioral|Caregiver Satisfaction Questionnaire|Caregiver satisfaction with quality of care assessed with surveys
239343|NCT02459015|Device|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
239344|NCT02459028|Behavioral|Positive Psychology intervention|Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on "bad" days (defined as days with higher than average levels of pain intensity or feeling "down in the dumps") for 8 weeks.
239648|NCT02524652|Drug|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
239649|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
239650|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
239651|NCT02524665|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
239652|NCT02524665|Other|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
239653|NCT00182429|Drug|Metronidazole and Rifampin|
239654|NCT02524665|Other|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
239655|NCT02524665|Other|Skin Perfecting Lotion|Available over the counter.
239656|NCT02524678|Drug|Placebo|
239657|NCT02524678|Drug|URC102|
239658|NCT02524691|Device|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
239659|NCT02524704|Device|CT scan|Applied only when part of the patient's standard care
239660|NCT02524717|Drug|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
239661|NCT02524730|Device|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
244082|NCT02535806|Drug|Dexamethasone|Days 1-5 and 15-19
244083|NCT02535806|Drug|Mitoxantrone|Days 1 and 2
244084|NCT02535806|Drug|Vincristine|Days 1, 8, 15, 22
244085|NCT02535806|Drug|Pegaspargase|Days 3 and 17
244086|NCT02535819|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
244087|NCT02535819|Procedure|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
244088|NCT02535832|Other|Active Comparator|CT Scan DXA scan Needle muscle biopsy
244089|NCT02535832|Drug|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
244090|NCT02535832|Drug|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
244091|NCT00183560|Behavioral|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
239345|NCT02459028|Behavioral|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
239346|NCT02461082|Other|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
239347|NCT02461095|Other|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
239348|NCT02461095|Other|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
239349|NCT02461108|Behavioral|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
239350|NCT02461108|Behavioral|Tax|Frame the price difference as a 10% tax on less nutritious food items.
239351|NCT00172328|Biological|Hepatitis B vaccine|
239352|NCT02461108|Behavioral|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
243776|NCT02503280|Drug|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs.
243777|NCT02503280|Drug|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
243778|NCT02503280|Drug|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).
243779|NCT02505581|Drug|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
243780|NCT02505581|Procedure|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
243781|NCT02505581|Drug|Cefuroxime 750mg oral|An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.
243782|NCT02505581|Drug|Metronidazole 250mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
243783|NCT02505581|Drug|Metronidazole 1,5gr Intravenous|An intravenous antibiotic pattern of cefuroxime 1g during anesthetic induction.
243784|NCT02505581|Drug|Cefuroxime 1g Intravenous|An intravenous antibiotic pattern of metronidazole 1,5gr during anesthetic induction.
243785|NCT02505607|Other|Overactive Bladder Care Plan counseling|Use of a printed "Overactive Bladder Plan of Care" information sheet.
243786|NCT02505620|Procedure|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
243787|NCT02505620|Procedure|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
243788|NCT02505633|Device|Stimuplex insulated needle|2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.
1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL.
243789|NCT00179517|Drug|Arimidex|
244092|NCT02535845|Behavioral|Project Voice|Project Voice tablet-based intervention plus informational video
244093|NCT02535845|Behavioral|HPV Informational Video|Informational video only
244094|NCT02535858|Device|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
244095|NCT02535858|Device|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
243491|NCT02510209|Behavioral|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
243492|NCT02510222|Dietary Supplement|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
243493|NCT02510235|Device|Lubricin|Lubricin 150 µg/ml eye drops
243494|NCT02512406|Other|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
243495|NCT02512419|Behavioral|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
243496|NCT02512419|Behavioral|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
243497|NCT02512419|Device|Actigraph GT3X|
243498|NCT02512432|Device|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
243499|NCT02512445|Behavioral|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
243500|NCT02512445|Behavioral|Supportive Care Therapy|Supportive therapy
243501|NCT02512458|Drug|Cabazitaxel|
243502|NCT00180427|Device|ICD|
243503|NCT02512471|Drug|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
243504|NCT02512484|Procedure|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
243790|NCT02505633|Drug|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
243791|NCT02505646|Other|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
242935|NCT02523638|Drug|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
242936|NCT00182260|Procedure|Laparoscopic Nissen Fundoplication|
243227|NCT02516982|Other|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
243228|NCT02516982|Other|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
243229|NCT02516995|Device|Functional magnetic resonance imaging|
243230|NCT02516995|Device|Ultrasound|
243231|NCT00181051|Device|Alaris AEP monitor|
243232|NCT02517008|Other|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
243233|NCT02517021|Drug|Pro-netupitant/Palonosetron|
243234|NCT02517021|Drug|Netupitant/Palonosetron|
243235|NCT02517021|Drug|Dexamethasone|
243236|NCT02517034|Other|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
243237|NCT02517034|Other|Quality-of-Life Assessment|Ancillary studies
243238|NCT02517034|Other|Questionnaire Administration|Ancillary studies
243239|NCT02519179|Behavioral|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
243240|NCT02519179|Behavioral|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
243241|NCT02519192|Device|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
242623|NCT02530463|Drug|Nivolumab|3 mg/kg by vein every 2 weeks.
242624|NCT02530463|Drug|Ipilimumab|3 mg/kg by vein every 3 weeks.
242625|NCT02530463|Drug|5-azacitidine|75 mg/m2 by vein for 5 days every 4 weeks.
242626|NCT02530476|Drug|Selinexor|Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.
242627|NCT02530476|Drug|Sorafenib|Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.
242628|NCT02530489|Drug|MPDL3280A|1200 mg by vein every 3 weeks for 12 weeks before surgery.
Within 4 weeks after surgery, participants start another 4 cycles of MPDL3280A.
242629|NCT02530489|Drug|Nab-paclitaxel|100 mg/m2 by vein weekly for 12 weeks before surgery.
242630|NCT02530502|Other|Laboratory Biomarker Analysis|Correlative studies
242937|NCT02523651|Genetic|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
242938|NCT02523651|Other|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
242939|NCT02523664|Drug|Hydrocortisone|effects of hydrocortisone on memory while fMRI
242940|NCT02523664|Drug|Placebo|
242941|NCT02523690|Drug|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
242942|NCT02523690|Drug|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
242943|NCT02523703|Biological|glutamate and aspartate|
242944|NCT02523716|Other|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
242945|NCT02523716|Other|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
242946|NCT02523729|Dietary Supplement|Anke Malz|non-alcoholic malt drink
242947|NCT00182273|Procedure|Canalith repositioning maneuver (CRM)|
242948|NCT02523742|Device|IMRf|
242305|NCT02535143|Other|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
242306|NCT02535156|Drug|Risperidone|1 mg Risperidone
242307|NCT02535156|Drug|Placebo|Lactose Placebo
242308|NCT02537561|Drug|Talazoparib|
242309|NCT02537574|Drug|NTX/BUP|Daily doses
242310|NCT02537574|Drug|NTX/PBO-B|Daily doses
242311|NCT02537574|Drug|PBO-N/PBO-B|Daily doses
242312|NCT02537587|Other|Control 1|67g of control bar
242313|NCT02537587|Other|Control 2|86g of control bar
242314|NCT00183664|Behavioral|Cognitive therapy (CT)|All participants will receive 16 to 20 individual sessions of CT for 3 months. Participants assigned to continuation phase will receive additional sessions every other week for 8 weeks and then monthly for 6 months.
242315|NCT02537587|Other|15/0|66g of experimental bar 15/0
242316|NCT02537587|Other|15/0LS|84g of experimental bar 15/0LS
242317|NCT02537587|Other|15/5|75g of experimental bar 15/5
242318|NCT02537587|Other|10/5|72g of experimental bar 10/5
242319|NCT02537587|Other|10/10|80g of experimental bar 10/10
242320|NCT02537600|Drug|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
242631|NCT02530502|Biological|Pembrolizumab|Given IV
242632|NCT00183014|Behavioral|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
242633|NCT02530502|Radiation|Radiation Therapy|Undergo focal RT
242634|NCT02530502|Drug|Temozolomide|Given PO
242635|NCT02530515|Drug|Rituximab|375 mg/m2 by vein on Day -5.
242636|NCT02530515|Drug|Cyclophosphamide|250 mg/m2 by vein on Days -5, -4, and -3 per treating physician decision.
242005|NCT00179400|Drug|Pioglitazone/EPA|
242006|NCT02504775|Drug|Mejoral® 500 Tablets|500 mg tablet of paracetamol
242007|NCT02504775|Drug|Tylenol® Caplets|500 mg tablet of paracetamol
242008|NCT02504788|Radiation|hippocampal-sparing WBRT|
242009|NCT02504801|Drug|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
242010|NCT02504814|Device|Nasal Highflow (NHF)|changes in breathing physiology in NHF
242011|NCT02504827|Drug|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
242012|NCT02504866|Other|Excercise|Exercise training of different intensity
242013|NCT02504892|Drug|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
242014|NCT02504931|Drug|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
242015|NCT02504931|Drug|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
242016|NCT00179413|Drug|PEG interferon Alfa-2b; Colchicine|
242017|NCT02507271|Other|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
242018|NCT02507271|Other|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
242019|NCT02507284|Drug|SRX246|
242020|NCT02507284|Drug|Placebo|
242021|NCT02507297|Device|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
242022|NCT02507310|Other|thermostat|ambient temperature as modified by thermostat
242023|NCT02507323|Drug|ticagrelor|A platelet aggregation inhibitor
242024|NCT02507323|Drug|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
241396|NCT02516280|Device|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
241700|NCT02511886|Drug|Arbaclofen Placarbil|Arbaclofen Placarbil
241701|NCT02511886|Drug|Placebo|Placebo matched tablets
241702|NCT02511899|Dietary Supplement|Mango fruit powder|Dietary supplement; Mango fruit powder
241703|NCT02511912|Procedure|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
241704|NCT00180336|Device|CRT-D|
241705|NCT02511925|Other|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
241706|NCT02511925|Other|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
241707|NCT02511925|Other|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
241708|NCT02514148|Other|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
241709|NCT02514161|Other|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
241710|NCT00180622|Procedure|Bodypletysmography|
241711|NCT02514161|Other|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
241712|NCT02514174|Drug|Afatinib|afatinib starting at 40 mg daily dose
241713|NCT02514187|Drug|Cyclotron-produced 99mTc|Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.
All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.
241091|NCT02522845|Device|Class II Compression Stockings (no specific device used)|This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
241092|NCT02522858|Drug|Atropine|To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.
During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group.
241093|NCT00182143|Drug|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
241094|NCT02522858|Drug|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
241095|NCT02522858|Drug|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
241397|NCT02516293|Behavioral|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
241398|NCT02516306|Drug|EV06 (Lipoic Acid Choline Ester, 1.5%)|A 1.5% topical ophthalmic solution administered twice a day intended to treat presbyopia by reversing age-related changes in the crystalline lens that result in diminished lens elasticity.
241399|NCT02516306|Drug|Placebo|A topical ophthalmic solution administered twice a day
241400|NCT02516319|Drug|ICG Dye|
241401|NCT02516332|Drug|Lexapro|
241402|NCT02516332|Drug|Placebo|
241403|NCT02516332|Behavioral|Supervised Aerboic Exercise|
241404|NCT02516345|Device|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
241405|NCT00180934|Procedure|Reirradiation with concomitant chemotherapy|
241406|NCT02516345|Behavioral|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
241407|NCT02516371|Other|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
258377|NCT02488395|Other|visual psychophysics test|This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
258378|NCT02488408|Drug|BGB324|
258379|NCT02488408|Drug|Cytarabine|Low dose cytarabine will be administered with BGB324 at a dose selected dose from Part A of the study
258380|NCT02488434|Device|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
258381|NCT02488460|Behavioral|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
258382|NCT02488473|Drug|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
258383|NCT02490540|Drug|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
258663|NCT02484001|Drug|ESL 800 mg|one (1) tablet of 800 mg (QD).
258664|NCT02484001|Drug|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
258665|NCT00176592|Drug|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
258666|NCT02484001|Drug|ESL 1600 mg|two (2) tablets of 800 mg (QD).
258667|NCT02484001|Drug|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
258668|NCT02484014|Other|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
258669|NCT02484014|Other|SEHER Intervention|The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:
Awareness generation activities for all stakeholders in school
Wall-magazine
Speak-out box
Competitions
School Health Promotion Committee
School health policies
Peer groups of students of standard IX
Workshops and talks for all the students from standard IX, and for teachers
Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year.
258670|NCT02484027|Drug|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
258082|NCT02495259|Device|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
258083|NCT02495259|Device|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
258084|NCT02495272|Drug|Oxytocin|Oxytocin 10IU Administered intramuscularly.
258085|NCT02495285|Drug|Gelofusine 4%|
258086|NCT02495285|Drug|Gelaspan 4%|
258087|NCT02495298|Procedure|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
258088|NCT02497326|Drug|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
258089|NCT02497326|Drug|Topical Heparin|Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by "#27" needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval
258384|NCT02490540|Drug|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
258385|NCT00177294|Behavioral|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
258386|NCT02490540|Drug|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
258387|NCT02490553|Other|heteroevaluation scale by a nurse or doctor|
258388|NCT02490566|Other|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
257807|NCT02501746|Other|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
257808|NCT00178945|Drug|Botulinum Toxin Type A|
257809|NCT02501759|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
257810|NCT02501759|Radiation|Gadodiamide|Given IV
257811|NCT02501759|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
257812|NCT02501759|Procedure|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
257813|NCT02501759|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
257814|NCT02501772|Device|acupressure by ankle band|
257815|NCT02501785|Behavioral|Caregiver Reaction Assessment (CRA)|
257816|NCT02501785|Behavioral|The Caregiver Quality of Life - Cancer (CQOLC)|
257817|NCT02501798|Drug|Methylphenidate|Drug: Methylphenidate
257818|NCT02501798|Drug|Placebo|Drug: Placebo
257819|NCT00178958|Device|Holter Monitor|
257820|NCT02501811|Biological|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
257821|NCT02501811|Biological|Cardiac Stem Cells (CSC)|15 transendocardial injections of 0.4ml CSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
258090|NCT02497326|Drug|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score >4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
258091|NCT02497339|Behavioral|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
258092|NCT00178269|Drug|docetaxel|
258093|NCT02497352|Dietary Supplement|flaxseed|
258094|NCT02497352|Behavioral|lifestyle modification|
257515|NCT02472535|Other|Run-In Period: Placebo|2 capsules, once a day for two weeks
257516|NCT02472535|Drug|MBX-8025 50 mg (Dose Escalation Period 1)|1 capsule once a day for 4 weeks
(MBX-8025 50 mg capsule)
257517|NCT02472535|Drug|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|1 capsule once a day for 4 weeks
(MBX-8025 50 mg or 100 mg capsule)
257518|NCT02472535|Drug|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|1 or 2 capsules once a day for 4 weeks
(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)
257519|NCT02472548|Biological|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
257520|NCT02472548|Biological|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
257521|NCT00175097|Other|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
257522|NCT02472548|Other|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
257523|NCT02472561|Other|Fitbit Physical Activity Monitor|Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4, 8 and 12.
257524|NCT02472561|Other|iHealth Glucometer|Blood Glucose: The participant will monitor their fasting blood glucose once per week by using the iHealth Glucometer and mobile app.
257525|NCT02472561|Other|Withings Blood Pressure|Blood Pressure: The participant will monitor their blood pressure once per week by using a blood pressure cuff and the Withings mobile app.
257526|NCT02472574|Device|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
257527|NCT02472574|Drug|rt-PA|Up to 4 doses of 0.3~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
257528|NCT02472587|Other|Questionnaire|
257529|NCT02472600|Drug|Colistin|
257530|NCT02472600|Drug|Neomycin|
257531|NCT02472600|Drug|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
256560|NCT02254148|Drug|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
256561|NCT02254148|Drug|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
256883|NCT02247310|Device|BETACONNECT|Auto-injector device to support the injection of Betaferon
256884|NCT00145262|Procedure|Autologous Bone Marrow Mononuclear Cell Implantation|
256885|NCT02247323|Other|Risk of malignancy index|Calculation of RMI before sugery.
256886|NCT02247336|Behavioral|MeTree|Participants will enter their family health history information into MeTree, patients and providers will receive a decision support document and pedigree
256887|NCT02247349|Biological|BMS-986012 (anti-fucosyl-GM1)|
256888|NCT02247362|Biological|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
256889|NCT02247362|Other|Placebo|Vaccine Diluent
256890|NCT02247375|Drug|Low dose of BIIL 284 BS tablets|
256891|NCT02247375|Drug|High dose of BIIL 284 BS tablets|
256892|NCT02247375|Drug|Placebo|
256893|NCT02247388|Behavioral|Computerized Alcohol Screening|iPad based automated alcohol screening
256894|NCT02247388|Behavioral|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
256895|NCT00145275|Drug|zoledronic acid|
256896|NCT02247401|Drug|2 DAA|ABT-450/r/ABT-267 tablets
256897|NCT02247401|Drug|RBV|Ribavirin tablets
256898|NCT02247414|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
256899|NCT02247414|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
256900|NCT02247414|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
256901|NCT02247414|Drug|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
256902|NCT02247427|Device|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
255937|NCT02265731|Drug|venetoclax|Step-up doses of venetoclax to the designated cohort dose
255938|NCT02265744|Drug|BMS-931699|
255939|NCT02265744|Drug|Placebo matching BMS-931699|
255940|NCT00147550|Drug|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
256238|NCT02258581|Drug|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
256239|NCT02258594|Other|Web-Based Patient Centered Toolkit (PCTK)|The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via "patient-facing" tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The "provider-facing" PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the "patient thread"; and 5) discussing patient's plan of care with other providers via the "provider thread".
256240|NCT02258594|Behavioral|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
256241|NCT02258607|Drug|MMB|Momelotinib (MMB) tablet(s) administered orally once or twice daily
256242|NCT02258607|Drug|Trametinib|Trametinib tablet administered orally once daily
256243|NCT02258620|Drug|dinitrate isosorbide|dinitrate isosorbide (cedocard*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard*) 5 mg by intra arterial direct in the sheat
256244|NCT02258620|Drug|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
256245|NCT02258633|Other|Interactive interview and tailored family centered seatbelt safety intervention|
256246|NCT02258646|Behavioral|Exercise training at home|
256247|NCT00146640|Drug|Prednisone|
256248|NCT02258646|Behavioral|Telemonitoring and education/self-management|
256249|NCT02258659|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
256250|NCT02258659|Drug|carboplatin|Given IV
239662|NCT02524743|Drug|acetaminophen|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
239663|NCT02524743|Drug|Lidocaine|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated lidocaine (20 mg and 40 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
239664|NCT00182442|Drug|Olanzapine & Quetiapine|
239966|NCT02518126|Other|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
239967|NCT02518139|Drug|TD-4208|
239968|NCT00181285|Device|High Frequency Chest Wall Oscillator|High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
239969|NCT02520154|Drug|Carboplatin|AUC 6 by vein on Day 1 every 21 days for a total of 3 cycles of therapy. After participants undergo interval cytoreductive surgery, they receive same dose and schedule of Carboplatin for three more cycles.
239970|NCT02520154|Drug|Paclitaxel|80 mg/m2 by vein on Days 1,8,15 every 21 days for a total of 3 cycles of therapy. After participants undergo interval cytoreductive surgery, they receive same dose and schedule of Paclitaxel for three more cycles.
239971|NCT02520154|Drug|Pembrolizumab|200 mg by vein on Day 1 every 21 days for a total of 3 cycles. After participants undergo interval cytoreductive surgery, Pembrolizumab maintenance therapy 200 mg by vein every 21 days for a total of 20 cycles or until progression.
239972|NCT02520167|Behavioral|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
239973|NCT02520180|Device|Firehawk™ stent system|MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
239974|NCT02520180|Device|Abbott Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
239975|NCT02520193|Procedure|Protocolized early mobilization in ICU|
239976|NCT02520219|Drug|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,>1h,d1; or DDP25 mg/m2,ivgtt,>1h,d1-3.
239977|NCT02520219|Biological|Endostar|Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.
Repeated every 21 days.
239353|NCT02461121|Genetic|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
239354|NCT02461121|Genetic|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
239355|NCT02461121|Drug|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
239356|NCT02461121|Drug|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
239357|NCT02461121|Drug|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
239358|NCT02461121|Drug|fludarabine|30 mg/m2/d for 5days
239359|NCT02461121|Drug|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
239360|NCT02461121|Drug|cyclophosphamide|40 mg/kg/d for 2 days
239361|NCT02461134|Drug|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
239362|NCT00172341|Drug|Staloral TM|
239363|NCT02461147|Procedure|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
239364|NCT02461160|Drug|TAK-915|TAK-915 oral suspension
239665|NCT02524743|Other|Placebo|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated 5 ml iv normal saline before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
239666|NCT02526953|Drug|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
239667|NCT02526953|Radiation|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
239668|NCT02526966|Biological|blood sample|dosage of anti-hinge region antibodies
239669|NCT02526979|Drug|mirabegron|oral
239670|NCT02526992|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
239671|NCT02527005|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
244096|NCT02535871|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
244097|NCT02535871|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
244098|NCT02538328|Device|Ligasure|Bipolar vessel sealing system used in obesity surgery
244099|NCT02538341|Biological|Herpes Zoster Vaccine|
244100|NCT02538341|Drug|Placebo|
244101|NCT02538354|Dietary Supplement|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
244102|NCT00183768|Behavioral|Cognitive Behavioral Therapy|
244103|NCT02538367|Drug|YH12852 IR(Immediate Release) 0.3mg|Subjects will receive one of the randomized treatments
244104|NCT02538367|Drug|YH12852 IR(Immediate Release) 0.5mg|Subjects will receive one of the randomized treatments
244105|NCT02538367|Drug|YH12852 IR(Immediate Release) 1mg|Subjects will receive one of the randomized treatments
244106|NCT02538367|Drug|YH12852 IR(Immediate Release) 2mg|Subjects will receive one of the randomized treatments
244107|NCT02538367|Drug|YH12852 IR(Immediate Release) 3mg|Subjects will receive one of the randomized treatments
244108|NCT02538367|Drug|Prucalopride 2mg|Subjects will receive one of the randomized treatments
244109|NCT02538367|Drug|Placebo|Subjects will receive one of the randomized treatments
244110|NCT02538367|Drug|YH12852 DR(Delayed Release)1 4mg|Subjects will receive one of the randomized treatments
244111|NCT02538367|Drug|YH12852 DR(Delayed Release)2 8mg|Subjects will receive one of the randomized treatments
244112|NCT02538367|Drug|YH12852 DR(Delayed Release)1 2mg|Subjects will receive one of the randomized treatments
244113|NCT00183768|Behavioral|Psychopharmacology|
244114|NCT02538367|Drug|YH12852 DR(Delayed Release)2 4mg|Subjects will receive one of the randomized treatments
239365|NCT02461160|Drug|Midazolam|Midazolam oral solution
239366|NCT02461160|Drug|Placebo|Placebo-matching TAK-915 suspension
239367|NCT02461173|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
243792|NCT02505659|Behavioral|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
243793|NCT02505672|Radiation|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
243794|NCT02505711|Behavioral|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
243795|NCT02505724|Behavioral|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
243796|NCT02505724|Behavioral|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
243797|NCT02508051|Behavioral|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
243798|NCT02508064|Drug|BMS-663068|
243799|NCT02508077|Drug|Fluorouracil|Given IV
243800|NCT00179816|Drug|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
243801|NCT02508077|Drug|Irinotecan Hydrochloride|Given IV
243802|NCT02508077|Other|Laboratory Biomarker Analysis|Correlative studies
243803|NCT02508077|Drug|Leucovorin Calcium|Given PO
243804|NCT02508077|Biological|Panitumumab|Given IV
243805|NCT02508103|Drug|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
243806|NCT02508103|Drug|Placebo|Intranasal placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
244115|NCT02538380|Procedure|EUS-B-FNA followed by EUS-FNA for LAG analysis|
243242|NCT00181610|Drug|Recombinant Human Prolactin|60 mcg/kg every 12 hours
243243|NCT02519192|Procedure|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
243244|NCT02519192|Procedure|ostomy bag applications|Non Vac Arm will receive ostomy bag applications.
243245|NCT02519192|Procedure|wet to dry dressing changes|Non Vac arm will receive wet to dry dressing changes.
243505|NCT02512497|Drug|Romidepsin|Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.
Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle for 1 year.
243506|NCT02512497|Drug|Busulfan|Part 1: The first two doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
243507|NCT02512497|Drug|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
243508|NCT02512497|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
243509|NCT02512510|Drug|TD-4208|
243510|NCT02512523|Drug|Teneligliptin|
243511|NCT02512523|Drug|Sitagliptin|
243512|NCT02512536|Drug|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
243513|NCT00180440|Device|ICD|all models of Guidant/Bsc ICD's
243514|NCT02512549|Other|Pulmonary Rehabilitation|
243515|NCT02512562|Drug|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
243516|NCT02512562|Drug|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
243517|NCT02512562|Drug|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
243518|NCT00180687|Other|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
243519|NCT02514824|Drug|MLN0128|Investigational mTOR kinase inhibitor
242949|NCT02523742|Other|language task and a reference task (rest and Tamil)|
242950|NCT02523755|Drug|Epidural analgesia Ropivacaine|Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
242951|NCT02525926|Procedure|sham procedure|Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a " sham " procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.
Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study.
242952|NCT02525939|Drug|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
242953|NCT02525939|Drug|Placebo|matching placebo tablets
242954|NCT02525952|Procedure|Hepatectomy|Surgical removal of all lesions
242955|NCT00182572|Procedure|behavior therapy|
242956|NCT02525952|Procedure|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
242957|NCT02525965|Procedure|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
243246|NCT02519205|Other|Survey|
243247|NCT02519218|Device|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
243248|NCT02519231|Drug|Naproxen|Naproxen 440mg 1x pid
243249|NCT02519231|Drug|Placebo|Placebo tablet 440mg 1x pid
243250|NCT02519244|Device|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
243251|NCT02519257|Procedure|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
243252|NCT02519257|Procedure|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
243253|NCT00181610|Biological|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
243254|NCT02519270|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein.
242637|NCT02530515|Drug|Fludarabine monophosphate|25 mg/m2 by vein on Day -5, -4, and -3.
242638|NCT02530515|Drug|Bendamustine|30 mg/m2 by vein on Days -5, -4, and -3 per treating physician decision.
242639|NCT02530515|Biological|Activated T-Cell Infusion|Activated T-cell infusion, approximately 1 x 1010, by vein on Day 0.
242640|NCT02530515|Drug|Lenalidomide|5 mg by mouth 1 time each day for about 6 months after blood counts are high enough after activated T-cell infusion.
242641|NCT02530515|Behavioral|Phone Calls|Study staff calls participant starting about a year and a half after the activated T-cell infusion every 6 months for up to 5 years.
242642|NCT02530528|Drug|CHG|Varied application times
242643|NCT00183027|Behavioral|Dietary composition and energy intake|
242644|NCT02530541|Drug|CHG|Varied application times
242645|NCT02532725|Procedure|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
242646|NCT02532725|Procedure|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
242647|NCT00183274|Drug|Placebo|After initial treatment with venlafaxine, some participants will be randomized to take placebo for 6 months in the second phase of the study and then to switch back to venlafaxine or continue with placebo for an additional 6 months.
242648|NCT02532725|Procedure|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
242649|NCT02532725|Procedure|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
242650|NCT02532738|Drug|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
242958|NCT02525965|Procedure|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin <1cm
242959|NCT02525978|Behavioral|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
242025|NCT00179725|Drug|liposomal doxorubicin|
242026|NCT02507323|Drug|Placebo|placebo
242321|NCT02537613|Drug|Obinutuzumab|Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
242322|NCT02537613|Drug|Ibrutinib|Ibrutinib given once daily by mouth
242323|NCT02537626|Device|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
242324|NCT02537626|Device|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
242325|NCT00183664|Drug|Placebo|Placebo daily for 8 months
242326|NCT02537639|Device|Transesophageal echocardiography simulator|
242327|NCT02537652|Other|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
242328|NCT02537665|Other|heating precondition|
242329|NCT02537678|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
242330|NCT02502669|Drug|Finasteride 33.5 mg tablets|
242331|NCT02502669|Drug|Placebo tablets|
242332|NCT02502682|Drug|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
242333|NCT02502695|Other|VATS-associated best practices|
242334|NCT02502708|Drug|Indoximod|
242335|NCT00179114|Drug|Botulinum Toxin Type A|
242336|NCT02502708|Drug|Temozolomide|
242337|NCT02502708|Radiation|Conformal Radiation|
241714|NCT02514187|Drug|Generator-produced 99mTc|Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.
All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.
241715|NCT02514200|Procedure|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
242027|NCT02507336|Drug|Thalidomide|
242028|NCT02507336|Other|Clinical/Laboratory Evaluations|Annual Clinical/Laboratory evaluations will include Physical Exam, Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), Lactate dehydrogenase (LDH)
242029|NCT02507336|Other|Survival|Patient will be followed for survival by annual telephone contact or in-person visit.
242030|NCT02507349|Behavioral|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
242031|NCT02507349|Behavioral|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
242032|NCT02507362|Radiation|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
242033|NCT02507362|Radiation|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
242034|NCT02507362|Drug|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
242035|NCT02507362|Procedure|epithelial debridement|corneal epithelium will be removed by a cottons swab
242036|NCT00179738|Drug|CC5013|
242037|NCT02507375|Drug|Erlotinib|Erlotinib will be administered as oral tablets.
242038|NCT02507375|Drug|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
242039|NCT02507388|Drug|RTH258 Lower Dose|Administered as an intravitreal injection
242040|NCT02507388|Drug|RTH258 Higher Dose|Administered as an intravitreal injection
242041|NCT00179959|Drug|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
241408|NCT02516384|Biological|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (>18 year old) patients with active ulcerative colitis (UC).
241409|NCT02518516|Drug|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
241410|NCT02518516|Drug|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
241411|NCT02518516|Drug|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
241412|NCT02518516|Drug|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
241716|NCT02514200|Procedure|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
241717|NCT02514200|Drug|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
241718|NCT02514200|Device|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
241719|NCT02514213|Biological|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
241720|NCT02514213|Biological|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
241721|NCT00002490|Drug|mitomycin C|
241722|NCT00180635|Procedure|Inhalation of aminoguanidine and oral intake and inhalation of L-arginine|
241723|NCT02514213|Biological|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
241724|NCT02514213|Biological|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
258671|NCT02484040|Radiation|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
258672|NCT02484040|Drug|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
258673|NCT02484053|Drug|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
258674|NCT02484066|Device|VBN (DirectPath; Olympus)|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
258675|NCT02484066|Device|EBUS-GS (Olympus)|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
258676|NCT00176605|Drug|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
258677|NCT02486432|Drug|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
258678|NCT00176839|Drug|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
258679|NCT02486445|Drug|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
258972|NCT02479529|Drug|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
258973|NCT02479529|Drug|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
258974|NCT00176176|Device|EEG|
258975|NCT02479542|Other|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
258976|NCT02479542|Device|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
258389|NCT02490579|Behavioral|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
258390|NCT02490579|Behavioral|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
258391|NCT02490579|Behavioral|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
258392|NCT02490592|Other|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
258393|NCT02490592|Other|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
258394|NCT02490605|Procedure|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
258395|NCT02490605|Procedure|therapeutic exercises|The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the "roof of the mouth" 3 times per day with each period consists of of 3 sets with 15 repetitions
258396|NCT00002478|Drug|etoposide|
258397|NCT00177294|Behavioral|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
258398|NCT02490618|Other|Probiotic tablet- Biogaia|
258399|NCT02490618|Other|Placebo tablet|
258400|NCT02490631|Drug|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
258680|NCT02486458|Drug|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
258681|NCT02486458|Drug|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
258682|NCT02486471|Procedure|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
258683|NCT02486471|Other|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
258684|NCT02486484|Drug|ziv-aflibercept|zaltrap injection
258685|NCT02486497|Biological|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
258095|NCT02497365|Drug|Besifloxacin|
258096|NCT02497365|Drug|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
258097|NCT02497378|Drug|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
258098|NCT02497378|Drug|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
258099|NCT02497378|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
258100|NCT02497391|Drug|Evacetrapib|administered orally
258101|NCT02497404|Drug|5-Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irriadiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,
-8 and -7. This will be administered on an outpatient basis if possible.
258102|NCT02497404|Drug|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fluddarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
258103|NCT00178269|Procedure|Radiation Therapy|
258104|NCT02497404|Drug|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
258105|NCT02497404|Drug|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 20 mg subcutaneously on days -6, -5, -4, -3, -2 for unrelated donors, and on days -4, -3, -2 for related donors.
258106|NCT02497443|Biological|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
258401|NCT02492880|Device|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
258402|NCT02492893|Other|Hatha yoga|
258403|NCT02492906|Other|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
258404|NCT02492906|Other|Healthy|Healthy and non-symptomatic volunteers.
257822|NCT02501811|Biological|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
257823|NCT02501824|Other|anthroposophic therapeutic speech|anthroposophic therapeutic speech
257824|NCT02468050|Behavioral|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
257825|NCT02468063|Drug|Low dose terlipressin|Terlipressin-2mg (low dose )
257826|NCT02468063|Drug|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
257827|NCT02468063|Drug|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
257828|NCT02468076|Device|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
257829|NCT02468089|Drug|Carbepenem|
257830|NCT02468089|Drug|Albumin|
257831|NCT02468089|Drug|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
257832|NCT02468102|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).
Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban [od], tablets).
Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).
Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid]).
257833|NCT00174655|Drug|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
257834|NCT02468102|Drug|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
257835|NCT02468115|Drug|VIS410|Single fixed IV dose of VIS410
257836|NCT02468115|Drug|Placebo|Single IV dose of placebo
257837|NCT02468128|Drug|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
257838|NCT02468128|Drug|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
257839|NCT02468141|Drug|SJDBT|Sipjeondaebo-tang
256903|NCT02247440|Drug|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
256904|NCT02249663|Other|Placebo|Nasal spray with no pharmaceutically active content
256905|NCT02249676|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
256906|NCT02249689|Other|Definitive 65|
257229|NCT02242357|Drug|Micardis®|
257230|NCT02242357|Drug|Micardis® Plus|
257231|NCT02242370|Drug|Low dose of telmisartan|
257232|NCT02242370|Drug|High dose of telmisartan|
257233|NCT02242383|Drug|Telmisartan|
257234|NCT02244918|Behavioral|Smoking Cessation Counseling|
257235|NCT02244931|Device|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
257236|NCT02244931|Device|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
257237|NCT02244931|Device|Standard manual Wheelchair|Standard manual Wheelchair
257238|NCT02244944|Drug|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
257239|NCT02244957|Device|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations <88% while on stable bi-level settings.
257240|NCT02244957|Drug|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
257241|NCT02244970|Other|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
257242|NCT02244970|Other|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
257243|NCT00144937|Behavioral|Dietary recommendations|
257244|NCT02244983|Other|Patients History|History taking and drawing of a blood sample
256251|NCT02258659|Radiation|radiation therapy|Undergo radiation therapy
256252|NCT02258659|Drug|paclitaxel|Given IV
256253|NCT02258659|Drug|fluorouracil|Given IV
256254|NCT02258659|Drug|hydroxyurea|Given PO
256255|NCT02258659|Drug|cisplatin|Given IV
256256|NCT02258659|Other|laboratory biomarker analysis|Correlative studies
256257|NCT02258659|Procedure|quality-of-life assessment|Ancillary studies
256562|NCT02254148|Drug|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
256563|NCT02254148|Drug|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
256564|NCT02254161|Drug|Matching placebo|Tablet
256565|NCT02254161|Drug|BI 1181181 healthy elderly|Tablet
256566|NCT02254161|Drug|BI 1181181 Healthy young|Tablet
256567|NCT00146107|Other|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
256568|NCT02254174|Drug|Tiotropium/Salmeterol|Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
256569|NCT02254174|Drug|Serevent® Diskus®|
256570|NCT02254174|Drug|Spiriva®|
256571|NCT02254187|Drug|Salmeterol capsule - low|
256572|NCT02254187|Drug|Salmeterol capsule - high|
256573|NCT02254187|Drug|Salmeterol via Serevent® Diskus®|
256574|NCT02254200|Other|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
256575|NCT02254200|Other|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of ~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
256576|NCT02254213|Other|EEG recording|A short EEG recording is performed 10 times over the span of three months.
239978|NCT00181740|Drug|atomoxetine (Strattera)|
239979|NCT02520232|Behavioral|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
239980|NCT02520232|Behavioral|Stretching and balance exercise program|Stretching and balance exercise program
239981|NCT02520245|Drug|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
239982|NCT02520258|Other|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily, followed by 21 days washout, and 7 days rechallenge; Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
239983|NCT02520271|Behavioral|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
240265|NCT02513602|Procedure|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
240266|NCT02513641|Device|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of ~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
240267|NCT00180856|Procedure|Radiofrequency ablation|
240268|NCT02515812|Device|Anger Camera|
240269|NCT02515825|Device|CADence System|Obtain CADence data under normal conditions of use for comparison of results with those of coronary angiogram
240270|NCT02515838|Drug|Sevuparin|The Drug Product sevuparin solution for IV infusion
240271|NCT02515838|Other|Placebo|Placebo for IV infusion
240272|NCT02515851|Drug|Exparel|
240273|NCT02515864|Drug|FYU-981|
240274|NCT02515864|Drug|Placebo|
240275|NCT02515864|Drug|Moxifloxacin|
240276|NCT02515864|Drug|Moxifloxacin Placebo|
240277|NCT02515877|Radiation|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
239672|NCT02527005|Drug|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
239673|NCT02527018|Device|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
239674|NCT00182650|Drug|fludarabine phosphate|
239675|NCT02527031|Other|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
239676|NCT02527031|Other|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
239677|NCT02527044|Procedure|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
239678|NCT02527057|Device|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
239679|NCT02527070|Device|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
239680|NCT02527070|Device|Quantum Warp10 (Red LED)|
239681|NCT02527070|Device|Omnilux new-U (Near Infrared LED)|
239682|NCT02527070|Other|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
239683|NCT02527083|Drug|Propofol|
239684|NCT02527083|Drug|Sevoflurane|
239984|NCT02520271|Behavioral|Motivational Interview|Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.
MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems.
239985|NCT02520284|Biological|GS-5745|GS-5745 150 mg administered subcutaneously
239986|NCT02520284|Biological|Placebo|Placebo to match GS-5745 administered subcutaneously
239987|NCT02520297|Drug|TRV130|Drug
239988|NCT02520310|Device|AVJ-514|Patients receiving AVJ-514 device
239989|NCT00002493|Drug|doxorubicin hydrochloride|
239368|NCT02461173|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
239369|NCT02461173|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
239370|NCT02463461|Device|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
239371|NCT02463461|Device|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
239372|NCT02463461|Device|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
239373|NCT02463461|Device|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
239374|NCT02463474|Behavioral|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
239375|NCT02463487|Device|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
239376|NCT02463487|Device|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
239377|NCT02463500|Other|DFU|Standard care.
239378|NCT02463513|Dietary Supplement|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
239379|NCT02463513|Dietary Supplement|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
239380|NCT00173667|Drug|Nifedipine 30 mg GITS|
239381|NCT02463513|Dietary Supplement|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
239382|NCT02463526|Other|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
239685|NCT00182663|Drug|clarithromycin|Given PO
239686|NCT02527083|Drug|Remifentanil|
239687|NCT02527083|Drug|Ketamine|
244116|NCT02538393|Drug|Sorafenib (BAY43-9006)|Oral administration once for each treatment arm, 400 mg sorafenib tablets for oral suspension (4 x 100 mg), fed with high-fat,high-calorie breakfast
244117|NCT02538393|Drug|Sorafenib (BAY43-9006)|Oral administration once for each treatment arm, 400 mg sorafenib tablets for oral suspension (4 x 100 mg), fasting
244118|NCT02538393|Drug|Sorafenib (BAY43-9006)|Oral administration once for each treatment arm, 200 mg sorafenib tablets for oral suspension (2 x 100 mg), fasting
244119|NCT02538393|Drug|Sorafenib (Nexavar, BAY43-9006)|Oral administration once for each treatment arm, 400 mg sorafenib marketed tablets (2 x 200 mg), fasting
244120|NCT02538406|Other|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
244121|NCT02538419|Behavioral|Peer Support|
244122|NCT02538419|Behavioral|Individual Education|
244123|NCT02538432|Drug|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
244124|NCT00183781|Behavioral|FITT: Family Intervention - Telephone Tracking|
244125|NCT02503293|Device|Chrono Super PID then Generic Syringe-Gammanorm|Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
• pump and then syringe
The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).
Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection
244126|NCT02503293|Device|Generic Syringe then Chrono Super PID-Gammanorm|Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
• syringe and then pump.
The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).
Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection
244127|NCT02503306|Drug|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
244128|NCT02503306|Drug|placebo|Pharmaceutical form:tablets Route of administration: oral
244129|NCT00179192|Procedure|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
244130|NCT02503319|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)
243520|NCT02514837|Device|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
243521|NCT02514850|Drug|Biochaperone Combo|Injection of BioChaperone Combo
243522|NCT02514850|Drug|Humalog Mix25|Injection of Humalog Mix25
243523|NCT02514850|Drug|Humalog|Injection of Humalog
243524|NCT02514850|Drug|Lantus|Injection of Lantus
243525|NCT02514850|Drug|Placebo|Injection of saline 0.9% solution
243526|NCT02514876|Device|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
243807|NCT02508116|Genetic|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 *2, *3, and *17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
243808|NCT02508129|Behavioral|Brief Behavioral Treatment for Insomnia|BBTI distills efficacious behavioral strategies for treating insomnia, including stimulus control and sleep restriction. To enhance the low-cost, pragmatic nature of BBTI, interventionist contact will occur by telephone and web conferencing rather than in person. BBTI will be administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times. The treatment emphasizes four behavioral recommendations: 1. Reduce your time in bed; 2. Get up at the same time every day of the week, regardless of how long you slept; 3. Do not go to bed unless you're sleepy; 4. Do not stay in bed unless you're asleep. The 3 follow-up sessions will be used to review progress, address questions and concerns, and establish rules for future adjustment of sleep wake times.
243809|NCT02508129|Behavioral|Sleep Healthy Using the Internet|SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a "sleep restriction" window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I, and follows the same structure: 1) Core objectives, 2) Review of homework and sleep diary data, 3) New intervention material, 4) Assignment of homework, and 5) Summary. Intervention content is enhanced through interactive features including personalized goal-setting, graphical feedback, animations/ illustrations, quizzes, patient vignettes, and video-based expert explanation. Automated emails encourage program adherence.
243810|NCT02508129|Behavioral|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
243811|NCT00179829|Procedure|WT 1 Testing|
243812|NCT02510235|Device|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
243255|NCT02519283|Behavioral|GUIDED-HF|Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator (TNC).
Disease education: Brief health literacy screen will identify literacy barriers to understanding discharge and medication instructions.
Lifestyle interventions: Smokers will receive smoking cessation information. Participants will be instructed to track their daily weights.
Guideline recommendations for medications and device referral: Participants' HF characteristics and GWTG:HF recommendations will determine the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.
Outpatient follow-up appointment: TNC will provide a scheduled appointment within 7 days of ED discharge and will conduct a home visit within 48 hours of ED discharge to further tailor the participant's plan to their environment.
243256|NCT02519283|Behavioral|Standard of Care|Those in the standard care arm will receive structured ED discharge assessment to include:
discharge instructions;
medication reconciliation
encourage follow-up.
243257|NCT02519296|Behavioral|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
243258|NCT02519296|Behavioral|Observation|fMRI.
243259|NCT02519296|Device|fMRI|Functional Magnetic Resonance Imaging of the brain
243260|NCT02521506|Device|Verio Pattern Alert® activated|
243261|NCT02521506|Device|Verio Pattern Alert® deactivated|
243262|NCT02521519|Other|Medial branch block in one side|MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
243263|NCT00181961|Drug|Maca Root|
243527|NCT02514889|Behavioral|Calorie-counting|The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.
Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls.
243528|NCT02514889|Behavioral|MyPlate|The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.
Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits & vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls.
243529|NCT00002490|Radiation|radiation therapy|
243530|NCT00180700|Behavioral|Self-hypnosis|
242960|NCT02525978|Other|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
242961|NCT02525991|Device|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
242962|NCT02526004|Drug|Ceftazidime|
242963|NCT02526004|Drug|Tobramycin|
242964|NCT02526017|Drug|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes in the monotherapy and after a 30-minute interval post nivolumab infusion in combination therapy every 2 weeks.
242965|NCT02526017|Drug|Nivolumab|Nivolumab at 3 mg/kg fixed dose will be administered by IV infusion over approximately 30 minutes every 2 weeks in the combination therapy.
242966|NCT00002494|Drug|leucovorin calcium|
242967|NCT00182572|Procedure|voucher-based contingency management|
242968|NCT02526030|Drug|Aripiprazole|
242969|NCT02526030|Drug|Quetiapine|
242970|NCT02526030|Drug|Ziprasidone|
242971|NCT02526043|Procedure|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
242972|NCT02526043|Procedure|Open hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
242973|NCT02526056|Other|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
242974|NCT02528227|Other|Feeding Safety|Part of Health and Safety Curriculum
242975|NCT02528227|Other|Car Seat Safety|Part of Health and Safety Curriculum
242976|NCT02528227|Other|Bath Safety|Part of Health and Safety Curriculum
242977|NCT02528227|Other|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
242978|NCT02528227|Other|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
242338|NCT02502721|Drug|DWC20151|
242339|NCT02502721|Drug|DWC20152|
242340|NCT02502734|Drug|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
242651|NCT02532738|Biological|MSC treatment 01|Injection of 3×10E6/kg of MSC
242652|NCT02532738|Biological|MSC treatment 02|Injection of 6×10E6/kg of MSC
242653|NCT02532738|Other|NS|Injection of NS
242654|NCT02532764|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
242655|NCT02532764|Drug|Placebo|Normal Saline
242656|NCT02532777|Drug|Prednisone|
242657|NCT02532777|Drug|Cyclophosphamide(CTX)|
242658|NCT00183300|Behavioral|Prolonged Exposure Therapy|
242659|NCT02532777|Drug|Mycophenolate mofetil(MMF)|
242660|NCT02532777|Drug|Leflunomide(LEF)|
242661|NCT02532777|Drug|Angiotensin-converting enzyme inhibitor(ACEI)|
242662|NCT02532777|Drug|Methylprednisolone|
242663|NCT02532790|Drug|Prednisone|1.5mg/kg/d
242664|NCT02532790|Drug|ACEI|0.2-0.3mg/kg/d
242665|NCT02532803|Other|Pelvic MRI scan|
242666|NCT02532816|Dietary Supplement|Nutrient dense complementary foods|Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).
Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements
242667|NCT02532829|Other|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
242668|NCT02532855|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet
242669|NCT02535169|Behavioral|Health Education and Coaching Strategy|Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
242042|NCT02509559|Device|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
242043|NCT02509559|Device|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
242044|NCT02509559|Device|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
242045|NCT02509559|Procedure|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
242341|NCT02502734|Drug|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
242342|NCT02502734|Drug|Salbutamol|Salbutamol will be provided as a inhaler.
242343|NCT02502747|Drug|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
242344|NCT02502747|Drug|optimal standard of care|Optimal standard of care
242345|NCT02502747|Procedure|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
242346|NCT00179114|Drug|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
242347|NCT02502760|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
242348|NCT02502760|Dietary Supplement|Whey Protein Isolate Powder|Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.
Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses
242349|NCT02502760|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
242350|NCT02502773|Drug|Hydroxethyl starch|
242351|NCT02502786|Biological|humanized anti-GD2 antibody|
242352|NCT02502786|Drug|GM-CSF|
242353|NCT02502799|Behavioral|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
242354|NCT02502799|Behavioral|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
241725|NCT02514213|Device|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
241726|NCT02516397|Dietary Supplement|Omnia|12weeks of treatment
241727|NCT02516397|Dietary Supplement|Placebo|12weeks of treatment
241728|NCT02516410|Drug|VX-661|
241729|NCT02516410|Drug|ivacaftor|
241730|NCT02516410|Drug|placebo|
241731|NCT02516423|Drug|ixazomib|oral
241732|NCT02516423|Drug|lenalidomide|oral
241733|NCT00180947|Drug|Vinorelbine, cyclofosfamide|
241734|NCT02516423|Drug|dexamethasone|oral
241735|NCT02516423|Drug|zoledronic acid|IV
241736|NCT02516436|Drug|BEMA Buprenorphine NX|Buprenorphine with naloxone
241737|NCT02516436|Drug|Buprenorphine|Buprenorphine
241738|NCT02516449|Other|Patient decision aid|The patient decision aid is a 12-page A3 size color-printed booklet entitled "Should I take asthma inhaled controller medication to optimize asthma control?"
242046|NCT02509572|Behavioral|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
242047|NCT02509585|Drug|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered peritumorally approximately 1-2 hours before surgery
242048|NCT02509598|Drug|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 1-2 hours before surgery
242049|NCT02509598|Drug|Vital Blue Dye|A single dose 1-3 ml of vital blue dye (1%) administered intradermally at the start of or during surgery
242050|NCT02509611|Other|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
242051|NCT02509624|Drug|GS-4997|GS-4997 6 mg tablet administered orally in a fed state
258977|NCT02479555|Drug|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and "Investigational Drug".
"Investigational Drug" will be administered via Bullfrog Micro-Infusion Device.
258978|NCT02479568|Dietary Supplement|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
258979|NCT02479568|Dietary Supplement|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
258980|NCT02479568|Dietary Supplement|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
258981|NCT02479581|Procedure|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
258982|NCT02479581|Procedure|ERAS group|No routine bowel preparation;
Normal eating 1 days before the operation;
No drinking 2h and solid food 6h before the operation;
Drink 10% glucose 250ml 3h before operation ;
Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);
258983|NCT02479581|Procedure|ERAS group|Emphasize the preoperative psychological preparation for patients.
258984|NCT02479581|Procedure|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
258985|NCT00176189|Device|All ceramic FPDs|
258986|NCT02479581|Procedure|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
258987|NCT02479581|Procedure|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
258988|NCT02481817|Procedure|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
259260|NCT02475161|Drug|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
259261|NCT02475161|Drug|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
259262|NCT02475174|Other|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
259263|NCT00175461|Procedure|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
259264|NCT02475174|Other|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
259265|NCT02475200|Device|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
258686|NCT02486510|Drug|Maraviroc|Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.
Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours
258687|NCT02486523|Behavioral|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
258688|NCT02486523|Device|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
258689|NCT00002476|Radiation|low-LET photon therapy|
258690|NCT00176839|Drug|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
258691|NCT02486523|Behavioral|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
258692|NCT02486523|Behavioral|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
258693|NCT02486523|Procedure|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
258694|NCT02486536|Drug|polyethylene glycol|
258695|NCT02486536|Device|capsule endoscopy|
258696|NCT02486549|Procedure|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
258697|NCT02488473|Drug|Ropivacaine|20 ml Ropivacaine 5mg/ml
258698|NCT02488473|Drug|Isotonic Saline|Placebo
258989|NCT02481817|Procedure|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
258990|NCT02481817|Procedure|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
258991|NCT00176462|Drug|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
258992|NCT02481830|Drug|Nivolumab|
258405|NCT02492919|Device|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
258406|NCT00177567|Drug|venlafaxine|
258407|NCT02492932|Device|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
258408|NCT02492945|Drug|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
258409|NCT02492945|Drug|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
258410|NCT02492958|Biological|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
258411|NCT02492958|Biological|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
258412|NCT02492984|Drug|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
258413|NCT02492997|Device|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
258414|NCT02492997|Other|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
258415|NCT02493010|Device|Arousal-based biofeedback system|
258416|NCT02493023|Device|navigated bronchoscopy|
258417|NCT00177567|Drug|tranylcypromine|
258418|NCT02493036|Drug|SYN-010|
258419|NCT02493049|Drug|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
258420|NCT02493062|Device|Sonohysterogram|The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
258699|NCT02488486|Device|Automated postoperative sedation|
258700|NCT02488486|Drug|propofol|
258701|NCT00002477|Drug|cisplatin|
257840|NCT02468141|Drug|Placebo|Placebo
258107|NCT02499484|Other|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
258108|NCT02499497|Drug|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
258109|NCT02499497|Drug|Placebo|The participants will receive pills containing no active drug.
258110|NCT02499510|Device|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
258111|NCT02499523|Procedure|THR with conventional technique|THR with conventional technique.
258112|NCT02499523|Procedure|THR with Acetabular Cup Orientation Guides (ACOG)|THR with the ACOG System.
258113|NCT02499536|Device|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
258114|NCT00178620|Device|Drug eluting stent placed in heart attack related artery|Stents will be placed (if needed) during the end of the angioplasty/heart catheterization.
258115|NCT02499549|Drug|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
258116|NCT02499562|Drug|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
258117|NCT02499562|Drug|Placebo|
258118|NCT02499562|Drug|Entecavir|
258119|NCT02499575|Drug|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
258120|NCT02499575|Drug|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
258121|NCT02499588|Device|Esteem Plus with ConvaTec Moldable Technology|
258122|NCT02499588|Device|Natura with ConvaTec Moldable Technology|
258123|NCT02499588|Device|Natura Accordion with ConvaTec Moldable Technology|
258124|NCT02499588|Device|Esteem synergy Plus with ConvaTec Moldable Technology|
258125|NCT00178633|Procedure|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
257245|NCT02244996|Dietary Supplement|Lycium Barbarum|Traditional Chinese Herbs
257246|NCT02244996|Dietary Supplement|Placebo|Placebo
257247|NCT02245009|Procedure|Cardioversion|
257248|NCT02245022|Drug|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
257249|NCT02245022|Drug|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
257532|NCT02474524|Behavioral|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
257533|NCT00175396|Procedure|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
257534|NCT02474524|Behavioral|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
257535|NCT02474537|Drug|INC280|Single 200 mg dose INC280
257536|NCT02474563|Drug|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
257537|NCT02474563|Drug|Melphalan|Participants receiving Melphalan 9 mg/m^2 will be observed in this study.
257538|NCT02474563|Drug|Prednisone|Participants receiving Prednisone 60 mg/m^2 will be observed in this study.
257539|NCT02474576|Procedure|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
257540|NCT02474589|Drug|tecovirimat|
257541|NCT02474589|Drug|Placebo|
256577|NCT02254226|Drug|Salmeterol Diskus low|
256578|NCT00146107|Other|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
256579|NCT02254226|Drug|Salmeterol Diskus high|
256580|NCT02254226|Drug|Salmeterol MDI low|
256581|NCT02254226|Drug|Salmeterol MDI high|
256582|NCT02254239|Drug|Brentuximab Vedotin|Given IV
256583|NCT02254239|Drug|Everolimus|Given PO
256584|NCT02254239|Other|Laboratory Biomarker Analysis|Correlative studies
256585|NCT02254239|Other|Pharmacological Study|Correlative studies
256586|NCT02256488|Biological|TIVf|Single IM administration dose of 0.5 mL of TIVf
256907|NCT00145522|Drug|Tibolone|2,5 mg/day for 12 cycles of 28 days
256908|NCT02249689|Other|Definitive 74|
256909|NCT02249702|Drug|gemcitabine + docetaxel|
256910|NCT02249702|Drug|trabectedin|
256911|NCT02249715|Device|Brainsway Multiway deep TMS device (two channels)|
256912|NCT02249728|Drug|IV PBT2 microtracer and oral PBT2 single dose|
256913|NCT02249728|Drug|oral 14C-PBT2|
256914|NCT02249741|Drug|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
256915|NCT02249754|Behavioral|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
256916|NCT02249754|Behavioral|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
256917|NCT02249767|Drug|Tretinoin|Treatment of acne once daily in evening
240278|NCT00180869|Procedure|transfusion of allogeneic red blood cell concentrate|
240279|NCT02515877|Drug|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
240280|NCT02515877|Drug|Carboplatin|AUC= 2,5 (Calvert formula)
240281|NCT02515890|Drug|Dexmedetomidine|Subjects will receive this drug during a portion of the study
240282|NCT02515890|Drug|Midazolam|Subjects will receive this drug during a portion of the study
240283|NCT02515890|Device|Peripheral nerve stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the auditory experimental cues.
240284|NCT02515903|Procedure|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
240285|NCT02515903|Procedure|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
240286|NCT02515916|Other|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
240581|NCT02509143|Procedure|High-dose acupuncture with intravenous infusion of ramosetron|Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).
An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group.
240582|NCT02509143|Device|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
240583|NCT02509143|Drug|Intravenous infusion of ramosetron|Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.
When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea.
240584|NCT02509156|Biological|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
240585|NCT02509156|Biological|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
240586|NCT02509169|Drug|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
240587|NCT00180258|Device|Cardiac Resynchronization Therapy with & without defibrillator|
239990|NCT02522390|Other|Research activities|Measurements are primarily based on "do-it-yourself" non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.
The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts.
239991|NCT02522403|Procedure|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
239992|NCT02522403|Device|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
239993|NCT02522416|Device|Central corneal thickness measurement|
239994|NCT02522429|Device|Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
239995|NCT00182078|Drug|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
239996|NCT02522442|Device|CPAP|Continuous positive airway pressure
239997|NCT02522442|Device|Auto BiLevel|AUto Bilevel positive airway pressure with Flex
239998|NCT02522455|Other|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
239999|NCT02522455|Other|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
240287|NCT02515929|Dietary Supplement|Oligomeric Proanthocyanidins|
240288|NCT02515929|Dietary Supplement|Placebo|
240289|NCT00180869|Procedure|transfusion of leuko-reduced red blood cell concentrate|
240290|NCT02515942|Drug|CLG561|
240291|NCT02515942|Drug|LFG316|
240292|NCT02515942|Drug|Sham injection|Empty syringe (without a needle) placed against the eye
239688|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
239689|NCT02527096|Drug|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
239690|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
239691|NCT02527109|Drug|Nifedipine|
239692|NCT02529280|Behavioral|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
239693|NCT00182793|Radiation|radiation therapy|After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.
Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy.
239694|NCT02529293|Drug|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
239695|NCT02529293|Drug|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
239696|NCT02529319|Procedure|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
239697|NCT02529319|Procedure|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
239698|NCT02529332|Dietary Supplement|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
239699|NCT02529345|Device|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
239700|NCT02529358|Behavioral|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
239701|NCT02529358|Behavioral|Personalized text messages|Patients write their own messages
239702|NCT02529358|Behavioral|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
240000|NCT02522468|Procedure|Radioactive Seed Localization|
239383|NCT02463526|Other|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
239384|NCT02463552|Drug|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
239385|NCT02463565|Other|no intervention|
239386|NCT02463591|Drug|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
239387|NCT02463604|Procedure|Coronary Angiography|Coronary angiography is performed following usual site standards
239388|NCT02463617|Other|magnetic resonance imaging|
239389|NCT02465736|Drug|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
239390|NCT02465736|Drug|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
239391|NCT02465749|Drug|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
239392|NCT02465749|Device|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
239393|NCT02465749|Drug|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
239394|NCT02465749|Drug|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
239395|NCT02465749|Drug|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
239396|NCT02465749|Drug|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
239397|NCT00002471|Drug|leucovorin calcium|
239398|NCT00174356|Drug|CI 1033|
239399|NCT02465762|Device|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
239400|NCT02465775|Device|ultrashape treatments for fat reduction|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
239401|NCT02465788|Device|Helos|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
243813|NCT02510248|Drug|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
243814|NCT00180089|Drug|Budesonide|
243815|NCT02510248|Drug|Placebo|Placebo to match AL-704
243816|NCT02510261|Drug|Patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
243817|NCT02510274|Drug|ASP3325|oral
243818|NCT02510287|Drug|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
243819|NCT02510287|Drug|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
243820|NCT02510287|Drug|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
239101|NCT02432664|Drug|ODM-108-Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
239102|NCT02432664|Drug|Placebo Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
239103|NCT02432664|Drug|ODM-108 Part III|Oral capsules 1 - 4 times daily for 7 to 10 days
239104|NCT02432664|Drug|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
239105|NCT00168441|Drug|Botulinum Toxin Type A|
239106|NCT02432677|Drug|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
239107|NCT02432677|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
239108|NCT02432677|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
239109|NCT02432677|Drug|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
239110|NCT02435121|Drug|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
243531|NCT02514902|Device|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
243532|NCT02514915|Radiation|Stereotactic Radiosurgery|Radiation therapy
243533|NCT02514928|Procedure|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
243534|NCT02514928|Procedure|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
243535|NCT02514941|Drug|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
243536|NCT02514941|Drug|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
243537|NCT02517047|Device|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
243538|NCT02517086|Other|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
243539|NCT02517086|Other|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
243540|NCT00181064|Behavioral|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
243821|NCT02510287|Drug|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
243822|NCT02510287|Drug|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
243823|NCT02510300|Drug|Sofosbuvir (SOF)|Exposure of interest for participants who received a sofosbuvir-based regimen in previous Gilead-Sponsored Chronic Hepatitis C Infection Trials
243824|NCT02510300|Drug|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a Ledipasvir/Sofosbuvir-based regimen in previous Gilead-Sponsored Chronic Hepatitis C Infection Trials
243825|NCT00180102|Drug|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
243264|NCT02521519|Other|paravertebral deep intramuscular (PDI) injection|injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
243265|NCT02521532|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
243266|NCT02521532|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
243267|NCT02521545|Drug|BIIB061|Capsule
243268|NCT02521558|Behavioral|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
243269|NCT02521558|Behavioral|Control Group|The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.
A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.
Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning.
243270|NCT02521571|Behavioral|Resiliance Alliance|The intervention is 6 months long & is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs & Supervisors/Managers separately.
Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week.
243271|NCT02521571|Behavioral|Secondary traumatic stress training|These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a "summary" version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent "treatment as usual," as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff.
243272|NCT02521597|Device|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
243273|NCT02521597|Device|Traditional otoscope|Use of a regular otoscope
243274|NCT02523755|Drug|Absence of epidural analgesia|Measurement of regional distribution as assessed by EIT before and after delivery
242670|NCT02535169|Behavioral|Dietary consult|A routine clinic-based dietary consult will be performed (approximately 1-hour).
242671|NCT02535182|Other|Blood Draw|Lab will draw one tube of blood to be stored in 8 mL BD Vacutainer CPT tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.
Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells.
242672|NCT02535195|Dietary Supplement|Ginger supplement|
242979|NCT02528227|Other|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
242980|NCT02528240|Procedure|EMS|
242981|NCT02528240|Device|+ occlusive membrane|
242982|NCT02528240|Device|conebeam CT|
242983|NCT02528253|Biological|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
242984|NCT00182754|Other|placebo|Given subcutaneously
242985|NCT02528253|Biological|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
242986|NCT02528253|Biological|Tanezumab 5 mg SC|Tanezumab 5 mg SC
242987|NCT02528253|Biological|Tanezumab 10 mg SC|Tanezumab 10 mg SC
242988|NCT02528253|Biological|Tramadol PR oral|Tramadol PR oral
242989|NCT02528266|Device|Nerve Capping Device|
242990|NCT02528279|Drug|Coartem|Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:
Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food.
242991|NCT02528292|Procedure|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
242992|NCT02528292|Drug|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
242993|NCT02528305|Other|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 110rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 6 sprints in sessions 1-3, 8 sprints in sessions 4-6 and 10 sprints in sessions 7-12.
242355|NCT02502799|Drug|Methylphenidate|Adolescents will receive methylphenidate.
242356|NCT02502812|Drug|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
242357|NCT02504944|Drug|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
242358|NCT02504957|Procedure|Photodynamic therapy using polyhematoporphyrin|
242359|NCT02504983|Drug|sorafenib|sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
242360|NCT02504983|Procedure|TACE|Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
242673|NCT00183482|Behavioral|Family Cognitive Behavioral Therapy (CBT)|
242674|NCT02535195|Dietary Supplement|Placebo (starch)|
242675|NCT02535208|Other|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR < 0.73.
242676|NCT02535208|Other|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
242677|NCT02535221|Drug|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
242678|NCT02535221|Drug|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
242679|NCT02535247|Drug|MK-3475|
242680|NCT02535273|Drug|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
242681|NCT02535273|Drug|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
242682|NCT02535273|Drug|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
242683|NCT02535273|Drug|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
242052|NCT00179972|Device|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
242053|NCT02509637|Device|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
242054|NCT02509637|Other|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
242055|NCT02509637|Other|Control|
242056|NCT02509637|Other|Impulse Oscillometric|For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth "free-flow", which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks.
242057|NCT02509637|Other|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
242058|NCT02511938|Other|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
242059|NCT02511938|Other|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
242361|NCT02504996|Drug|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
242362|NCT02504996|Drug|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
242363|NCT02504996|Drug|Placebo|Intravenous 100 ml normal saline
242364|NCT02505009|Drug|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
242365|NCT02505009|Drug|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
242366|NCT02505009|Drug|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
242367|NCT00179439|Procedure|nasal potential difference testing|
259266|NCT02475213|Biological|MGA271|MGA271 is administered by IV infusion once per week for up to 51 doses.
259267|NCT02475213|Biological|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
259268|NCT02475226|Other|type of the brain injury|epidural hematoma
259269|NCT02475226|Other|type of the brain injury|subdural hematoma
259270|NCT02475226|Other|type of the brain injury|subarachnoid hematoma
259271|NCT02475226|Other|type of the brain injury|intraparenchymal hematoma
259272|NCT02475226|Other|type of the brain injury|scull fracture
259273|NCT02475226|Other|type of the brain injury|brain contusion
259274|NCT00175474|Procedure|knee surgery|Unspecified
259275|NCT02475239|Behavioral|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
259276|NCT02475239|Behavioral|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
259277|NCT02475252|Procedure|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
259278|NCT02475265|Drug|estradiol 0.045 mg/levonorgestrel 0.015mg|
259279|NCT02475278|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
259280|NCT02475304|Drug|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
259281|NCT02475304|Drug|Placebo|
254521|NCT00148538|Behavioral|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
254522|NCT02275078|Device|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
254523|NCT02275078|Other|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
258993|NCT02481830|Drug|Topotecan|
258994|NCT02481830|Drug|Amrubicin|
258995|NCT02481843|Other|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
258996|NCT02481856|Drug|SQ tree SLIT-tablet|
258997|NCT02481856|Drug|Placebo|
258998|NCT02481869|Biological|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
258999|NCT02481869|Drug|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
259000|NCT02481882|Device|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
259001|NCT02481882|Device|Thornhill RespirAct|A gas blender and delivery system used to modulate arterial blood gas content.
259002|NCT00176462|Drug|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
259003|NCT02481882|Drug|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
259004|NCT02481895|Behavioral|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
259005|NCT02481908|Device|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
259006|NCT02481921|Behavioral|Group medical visits|Or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and medication management join to manage heart failure in addition to and in support of, the patient's regular physician visits.
259007|NCT02481934|Procedure|NKAE cells infusion|Expanded and activated autologous NK cells infusion.
Following a dose escalation schema of 3 patients/cohort , each patient will receive:
Cohort 1: two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
Cohort 2: three infusions of 7.5 x 106 expanded and activated autologous NK cells /kg/cycle.
Cohort 3: four infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
259282|NCT02477254|Biological|Vaccination|A quadrivalent HPV vaccine
259283|NCT02477267|Drug|SL spray|
259284|NCT02477267|Drug|SL film|
259285|NCT02477280|Drug|Methylphenidate|Cross-over
258702|NCT00176995|Drug|15% Eflornithine Hdyrochloride|
258703|NCT02488486|Drug|remifentanil|
258704|NCT02488499|Behavioral|Coping Power|15 sessions of concurrent parent and child group treatment
258705|NCT02488499|Behavioral|Individualized Treatment|15 sessions of individualized child and parent treatment
258706|NCT02488512|Drug|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) [45-46], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
258707|NCT02488525|Drug|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
258708|NCT02488538|Drug|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
258709|NCT02488538|Drug|Fluoxetine|women will receive oral fluoxetine 20 mg daily
258710|NCT02488538|Drug|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
258711|NCT02488538|Drug|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
258712|NCT02488538|Procedure|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
258713|NCT00177008|Drug|Aripiprazole|
258714|NCT02488551|Device|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
258715|NCT02488551|Other|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
258716|NCT02488564|Drug|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
258717|NCT02488564|Drug|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
258718|NCT02488564|Drug|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
258719|NCT02488564|Drug|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
258126|NCT02499601|Device|CORolla™ TAA device|
258127|NCT02499614|Drug|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
258421|NCT02493075|Behavioral|The operator blinded to the contact force data or not.|CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of "appropriate CF", which has been defined in phase I. Circumferential PV ablation will be performed orderly, "isolated segment"," acute reconnected segment ", and "unisolated segment" will be also identified as described in phase I.
Usual ablation group:
Operator will be blinded to CF data, the procedure performance is the same as described in phase I.
258422|NCT00177996|Drug|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
258423|NCT02495298|Procedure|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
258424|NCT02495311|Procedure|myomectomy or adenomyomectomy|
258425|NCT02495324|Drug|Placebo|2 weeks of placebo PO daily
258426|NCT02495324|Drug|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
258427|NCT02495324|Drug|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
258428|NCT02495324|Drug|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
258429|NCT02495337|Other|Tissue Collection|
258430|NCT02495350|Other|Questionarie|Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.
At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.
Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment.
258431|NCT02495363|Procedure|Pectoral Block 2|Ultrasound guided PECS II Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .
The concentration is determined by the upper dose limit to 2 mg / kg 11
258432|NCT02495363|Drug|Bupivacaine 0.25-0.5%|Ultrasound guided PECS II Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .
The concentration is determined by the upper dose limit to 2 mg / kg 11
258433|NCT00178009|Behavioral|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
257542|NCT02474602|Device|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
257543|NCT02474615|Procedure|ENDODONTIC SURGERY|ENDODONTIC SURGERY
257544|NCT00175396|Procedure|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
257545|NCT02474628|Dietary Supplement|sodium bicarbonate|
257546|NCT02474628|Dietary Supplement|calcium carbonate|
257547|NCT02474641|Radiation|Standard Radiation|Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or
Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or
Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially
257841|NCT02468154|Device|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
257842|NCT02468154|Other|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
257843|NCT02468167|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
257844|NCT00174655|Drug|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
257845|NCT02470286|Drug|SA001|
257846|NCT02470286|Drug|Placebo|
257847|NCT02470299|Drug|Ketorolac|Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds
Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:
Patients < 65 years of age: Daily dose of 30 mg for three doses.
Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses
Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose
257848|NCT02470299|Other|Placebo|Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:
Patients < 65 years of age: Daily dose of 30 mg for three doses.
Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.
Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose
256918|NCT00145535|Device|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, ~50 spots over 180°
256919|NCT02249780|Procedure|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
256920|NCT02249780|Procedure|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
256921|NCT02249780|Procedure|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
256922|NCT02249780|Drug|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
256923|NCT02249806|Other|PH target therapy according to physician|Patients receiving PH target therapy
256924|NCT02249819|Device|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
256925|NCT02249832|Device|MIT Anklebot|
256926|NCT02249858|Procedure|Cranial Vault Hold|
256927|NCT02249858|Procedure|Cervical HVLA|
241551|NCT02532361|Device|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
241552|NCT02532361|Procedure|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
241553|NCT02532374|Other|Nicorette inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
241554|NCT02532374|Other|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
241555|NCT00000371|Drug|D-cycloserine|50 mg/daily by mouth
241556|NCT00002495|Drug|vinblastine|6 mg/m^2 on days 1 and 15
241557|NCT00183248|Procedure|Kidney transplant|Occurs at study entry
241558|NCT02532387|Other|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
241559|NCT02532400|Drug|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d*7 plus exemestane: 25mg, po, qd*24w, or anastrozole: 1mg, po, qd*24w
240588|NCT02511353|Drug|placebo|Placebo for ivermectin.
240589|NCT02511353|Drug|dihydroartemisinin-piperaquine|
240590|NCT02511366|Other|Ileal infusion of casein|Intraileal infusion of casein
240591|NCT02511366|Other|Ileal infusion of tap water|Intraileal infusion of tap water
240592|NCT02511379|Other|Propylene Glycol 0.6% eye drops|
240593|NCT02511392|Procedure|rTMS-1Hz|
240594|NCT02511392|Procedure|rTMS-10 Hz|
240595|NCT02511392|Procedure|Sham rTMS|
240596|NCT02511405|Drug|VB-111 + bevacizumab|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months
Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
240597|NCT02511405|Drug|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
240598|NCT00180271|Device|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
240599|NCT02511418|Drug|Simvastatin|
240919|NCT02504359|Other|Laboratory Biomarker Analysis|Correlative studies
240920|NCT02504359|Drug|Melphalan|Given BEAM chemotherapy
240921|NCT02504359|Drug|Methotrexate|Given IV
240922|NCT02504359|Biological|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
240923|NCT00179348|Procedure|Quality-of-Life Assessment|Ancillary studies
240924|NCT02504359|Other|Quality-of-Life Assessment|Ancillary studies
240925|NCT02504359|Drug|Tacrolimus|Given IV or PO
240926|NCT02504372|Biological|pembrolizumab|
240927|NCT02504372|Other|Placebo|
240928|NCT02504385|Device|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
240929|NCT02504385|Other|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
240293|NCT02515955|Drug|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
240294|NCT02515955|Drug|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
240295|NCT02515955|Drug|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
240296|NCT02518152|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
240297|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
240298|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
240299|NCT02518165|Dietary Supplement|Proprietary spearmint extract|Water extracted spearmint extract
240300|NCT02518165|Other|Placebo|Microcrystalline Cellulose
240301|NCT02518178|Device|NFC Necklace|
240302|NCT02518178|Device|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
240303|NCT02518178|Device|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
240304|NCT02518191|Drug|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
240305|NCT02518204|Other|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
240306|NCT00181298|Drug|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
240307|NCT02518204|Other|NP|Conventional in-person Neuropsychological Assessments (NP)
Subtests from:
HRB: Halstead-Reitan Battery
MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia
WAIS-IV: Weschler Adult Intelligence Scale - IV
240308|NCT02518217|Behavioral|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
240600|NCT02511431|Drug|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
240601|NCT02511431|Drug|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost ritonavir as they both use the same CYP system. Will be administered at 100 mg daily.
240602|NCT02511431|Other|Placebo|Placebo
240001|NCT02522468|Procedure|Wire Localization|
240002|NCT02522481|Drug|sulphur hexafluoride lipid-type A microspheres|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent will be administered as 2 single 2-mL IV injections during rest and stress echocardiography
240003|NCT02522494|Behavioral|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
240004|NCT02522494|Behavioral|Video|An educational intervention delivered prior to patients' visits with primary care providers.
240005|NCT02522507|Behavioral|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
240006|NCT00182078|Drug|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
240007|NCT02524756|Procedure|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
240008|NCT02524756|Procedure|laparoscopic radical hysterectomy (type III/C2).|
240009|NCT02524769|Drug|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
240010|NCT02524782|Biological|MEDI-4166|MEDI-4166 administered subcutaneously
240011|NCT02524782|Biological|Placebo|Placebo administered subcutaneously
240012|NCT02524795|Dietary Supplement|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
240013|NCT02524821|Device|Gelesis100|3 capsules each containing 0.75 mg
240014|NCT02524821|Drug|Metformin|1 tablet of 850 mg
240015|NCT02524834|Procedure|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
240016|NCT00182455|Drug|Topiramate|25 - 400 mg/day x 12 weeks
240017|NCT02524834|Device|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
240018|NCT02524847|Drug|UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System|
239402|NCT02465801|Drug|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
239403|NCT02465801|Drug|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
239703|NCT02529371|Device|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
239704|NCT00182806|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
239705|NCT02529384|Other|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
239706|NCT02529397|Behavioral|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
239707|NCT02529397|Behavioral|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
239708|NCT02529410|Procedure|Cardiac Resynchronisation Therapy|
239709|NCT02529423|Dietary Supplement|Multi‐nutrient supplement|Omega 3 fatty acids
Folic acid
Calcium
Selenium
Vitamin D3
239710|NCT00183183|Behavioral|Screening and Brief Intervention|
239711|NCT02531594|Behavioral|SBIRT|The Social Worker will provide caregivers with the brief (10-15 minute) "Advise, Assess, Assist" intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials.
239712|NCT02531594|Behavioral|HHC|The Social Worker will provide caregivers with the brief (10-15 minute) "Lets Go! 5-2-1-0" intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials.
239713|NCT02531607|Other|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
239714|NCT02531620|Other|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
239715|NCT02531620|Other|Routine Care|Usual care for your disease process
239716|NCT02531633|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
239111|NCT02435134|Other|no intervention|
239112|NCT02435147|Drug|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
239113|NCT02435160|Biological|Fecal Microbiota Transplantation|
239114|NCT00168766|Drug|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
239115|NCT02435173|Drug|CDZ173|up to 140 mg per day
239116|NCT02435186|Drug|p53 gene|p53 gene will be given intraperitoneally.
239117|NCT02435186|Drug|Cisplatin|150 mg/m^2 cisplatin will be given intraperitoneally.
239118|NCT02435186|Drug|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
239119|NCT02435199|Drug|EMA401 600mg|
239120|NCT02435199|Drug|Placebo|
239121|NCT02435212|Drug|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use.
239404|NCT02465801|Drug|GCSF|GCSF 5 mcg/kg/day
239405|NCT02465814|Drug|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
239406|NCT02465814|Drug|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
239407|NCT02465814|Drug|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
239408|NCT02465814|Drug|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
239409|NCT00174356|Drug|PACLITAXEL|
239410|NCT02465814|Drug|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
239411|NCT02465814|Drug|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
239412|NCT02465814|Drug|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
239413|NCT02465827|Drug|nerve block with ropivacaine|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
239414|NCT02465827|Drug|nerve block with ropivacaine and with saline|nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
243826|NCT02510313|Other|FSI/ECD|The Family Strengthening Intervention: Early Childhood Development is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning.
243827|NCT02510313|Other|VUP Family-Friendly Cash-for-Work|Eligible families receive a cash transfer in exchange for work
243828|NCT02510339|Other|Observation|Administration of two questionnairs during post operative visits.
243829|NCT02510365|Device|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
243830|NCT02510378|Radiation|Short course radiotherapy|Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.
After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy.
243831|NCT02510391|Behavioral|PIPA|Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
243832|NCT02512575|Drug|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
243833|NCT02512575|Drug|Placebo oral suspension|Matching placebo
243834|NCT02512588|Drug|BTD-001|
243835|NCT02512588|Drug|Placebo|
243836|NCT02512601|Drug|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
243837|NCT02512601|Other|Compression therapy|Compression:
With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.
With a bandage: 7-10 m long and 10 cm wide.
Both strategies (orthosis vs bandage) are equally applicable.
243838|NCT00180453|Device|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
243839|NCT02512614|Other|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
239122|NCT02435212|Drug|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use
239123|NCT02435225|Behavioral|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
239124|NCT02435251|Device|dual energy X-ray absorptiometry|
239125|NCT00168779|Drug|telmisartan 80 mg / hydrochlorothiazide 25 mg|
243275|NCT02523768|Drug|ATG-F|
243276|NCT02523768|Drug|Simulect|
243541|NCT02517086|Other|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
243542|NCT02517099|Drug|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
243543|NCT02517099|Drug|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
243544|NCT02517099|Drug|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
243545|NCT02517112|Other|Parabolic flight|
243546|NCT02517112|Other|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
243547|NCT02517112|Device|3D-BCG sensor|
243548|NCT02517125|Device|Transoral robotic-assisted surgery with Da Vinci Xi|
243549|NCT02517138|Other|Parabolic flight|
243550|NCT02517138|Other|Measurements of eye movements and perception|
243551|NCT00181077|Drug|2% buffered hypertonic saline administration|
243552|NCT02517151|Drug|Ferric carboxymaltose|
243553|NCT02517151|Drug|Placebo|
243554|NCT02517164|Other|Measurement of serum 25-hydroxyvitamin D|
243555|NCT02517164|Other|Analysis of global cognitive efficiency score assessed by the "Montreal Cognitive Assessment" (MoCA).|
243556|NCT02517177|Other|Parabolic flight|
243557|NCT02517177|Other|Cardiovascular parameters measurements|
243558|NCT02517190|Other|Parabolic flight|
243559|NCT02517190|Other|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
243560|NCT02517190|Other|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
242994|NCT02528318|Drug|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
242995|NCT00182767|Drug|ixabepilone|Given IV
242996|NCT02528318|Device|nCPAP alone|nCPAP therapy
242997|NCT02528331|Device|Transcranial magnetic stimulation|
242998|NCT02528331|Behavioral|Cognitive behavioral therapy|
242999|NCT02528344|Behavioral|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
243000|NCT02530554|Drug|CHG|Varied application times
243277|NCT02523781|Other|information pamphlet|The intervention group receives the information pamphlet
243278|NCT02523794|Other|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
243279|NCT02523794|Other|Placebo|Purified Drinking Water
243280|NCT02523820|Drug|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
243281|NCT00182286|Behavioral|Assessment of continuity of care from the patient perspective|
243282|NCT02523820|Drug|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
243283|NCT02523833|Drug|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
243284|NCT02523846|Drug|morphine|Investigators use the formula that was published by Pamela Macintyre in her paper entitled "Age is the Best Predictor of Postoperative Morphine Requirements." The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).
So, half of the total 24-hour morphine requirement will be infused over 24 hours.
e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)
243285|NCT02523846|Behavioral|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
243286|NCT02523859|Drug|Propofol|Hypnotic drug used for anesthesia
243287|NCT02523859|Drug|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
243288|NCT02523898|Drug|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
243289|NCT02523898|Drug|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
242684|NCT00183482|Behavioral|Depression Education|
242685|NCT02535273|Drug|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
242686|NCT02535273|Drug|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
242687|NCT02535286|Drug|Pembrolizumab|IV immunotherapy for cancer
242688|NCT02535286|Drug|TGR-1202|A once daily oral agent
242689|NCT02535286|Biological|ublituximab|IV anti-CD20 monoclonal antibody
242690|NCT02537678|Behavioral|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
242691|NCT02537691|Other|Laboratory biomarker analysis|
242692|NCT02537704|Behavioral|Group Lifestyle Balance Program|
243001|NCT02530567|Procedure|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
243002|NCT02530580|Drug|20 mg AZD7325|A single 20 mg oral dose of AZD7325
243003|NCT02530580|Drug|Placebo|A single oral dose
243004|NCT02530593|Behavioral|There is no intervention, only observation|
243005|NCT02530606|Procedure|Photoacoustic Imaging|Undergo PAI
243006|NCT02530619|Drug|Alisertib|Given PO
243007|NCT02530619|Other|Laboratory Biomarker Analysis|Correlative studies
243008|NCT02530619|Other|Pharmacological Study|Correlative studies
243009|NCT00183040|Drug|Topical testosterone|
243010|NCT02530632|Drug|Propofol|General anesthesia maintained with intravenous propofol infusion
243011|NCT02530632|Drug|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
243012|NCT02530632|Procedure|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
243013|NCT02530645|Behavioral|OnTrack|
242368|NCT02505022|Drug|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
242369|NCT02505022|Behavioral|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
242370|NCT02505035|Behavioral|Default ordering of palliative consult|
242371|NCT02505048|Drug|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
242372|NCT02505061|Behavioral|Hospital-based Program|The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the child‟s natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team.
242373|NCT02505061|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child‟s natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase
242374|NCT02505074|Procedure|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
242375|NCT02505087|Drug|N-Acetylcysteine followed by Placebo|Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
Treatment periods are separated by a 2 month washout.
242376|NCT02507414|Other|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
242377|NCT02507414|Other|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
242693|NCT02537730|Device|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system for all available Soft Contact Lenses
242694|NCT02537730|Device|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system for all available Soft Contact Lenses
242695|NCT02537730|Device|comfilcon A contact lens|contact lens
242696|NCT00183677|Drug|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
242697|NCT02537756|Behavioral|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
254524|NCT02275104|Device|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
254525|NCT02238509|Drug|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
254526|NCT02238522|Drug|ZEN003365|
254527|NCT02238535|Drug|Ventavis|
254528|NCT02238535|Drug|Warfarin|
254529|NCT02238548|Biological|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
254530|NCT00002336|Drug|Clarithromycin|
254531|NCT00144222|Drug|Telmisartan 40 mg|
254532|NCT02238548|Other|Raw milk|
254533|NCT02238574|Procedure|surgery|excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity
254534|NCT02238574|Other|follow up|Intensified outpatient follow up (16 visits in 5 years)
254535|NCT02238587|Other|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
254536|NCT02238587|Dietary Supplement|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
254537|NCT02238613|Device|radioactive stent|radioactive stent carrying seed iodine 125
254538|NCT02238613|Device|plastic stent|common plastic stent without carrying seed iodine 125
254539|NCT02238626|Drug|Placebo (for MN-166)|
254540|NCT02238626|Drug|MN-166|
254870|NCT02270216|Procedure|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
259286|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 7-week Treatment period
259287|NCT02477280|Drug|Placebo|Medikinet
259288|NCT02477293|Drug|Hyeonggaeyeongyo-tang|
259289|NCT02477306|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
259290|NCT02477306|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
259291|NCT02477319|Other|Observational|
259292|NCT02477332|Biological|QGE031|
259293|NCT02477332|Biological|Omalizumab|
259294|NCT02477332|Other|Placebo|
259295|NCT02477345|Drug|Omegaven IV|Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to
1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day.
259296|NCT02477358|Procedure|Platelet Rich Fibrin endodontic revascularization therapy|An in vivo model utilizing mature teeth previously treatment planned for extraction, treating in accordance to the procedure documented by Johns et al. (2013), reimplanting teeth and following for three to four months before extracting and performing histological analysis.
259297|NCT00175838|Drug|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
259298|NCT02477358|Biological|Platelet Rich Fibrin|Biological from patients own blood. No additives.
259299|NCT02477371|Procedure|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values > 0,8 are deferred.
259300|NCT02477371|Procedure|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
259301|NCT02477384|Procedure|8mm-TIPS|
259302|NCT02477384|Procedure|Endoscopic variceal ligation|
259303|NCT02477384|Drug|Propranolol|
259008|NCT02481934|Drug|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
259009|NCT02481934|Drug|Bortezomib|bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
259010|NCT02481947|Drug|BLI400 Laxative|Oral laxative
259011|NCT02484066|Device|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
259012|NCT02484079|Procedure|Polypectomy|
259013|NCT02484092|Genetic|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
259014|NCT02484105|Behavioral|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
259015|NCT02484105|Behavioral|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
259016|NCT02484118|Procedure|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
259017|NCT02484131|Behavioral|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
259018|NCT02484131|Behavioral|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
259019|NCT02484144|Other|patient with sheduled coronarography|information by video for coronarography
259020|NCT02484157|Device|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
259021|NCT00176605|Drug|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
259022|NCT02484157|Device|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
259023|NCT02484170|Drug|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
259024|NCT02484170|Drug|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
258434|NCT02495376|Behavioral|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
258435|NCT02495389|Drug|mirabegron|All study participants will be given mirabegron, 25 mg by mouth once a day for 12 weeks.
258720|NCT02488577|Procedure|Transanal minimally invasive total mesorectal excision|
258721|NCT02488577|Procedure|transanal minimally invasive locoregional resection|
258722|NCT02490644|Procedure|Blood sampling|Blood sampling 5ml
258723|NCT02490657|Drug|Inhaled iloprost|Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.
Enrolled patients were received 25 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb.
258724|NCT02490657|Drug|normal saline (Saline 0.9%)|
258725|NCT02490670|Drug|Cephalexin|Administered orally
258726|NCT02490683|Dietary Supplement|Luna Rich X|
258727|NCT02490683|Dietary Supplement|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
258728|NCT02490683|Dietary Supplement|Reliv Now|
258729|NCT00177307|Drug|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
258730|NCT02490696|Device|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
258731|NCT02490696|Device|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
258732|NCT02490709|Procedure|Local excision|Local excision for rectal cancer with good response
258733|NCT02490722|Other|Patient education|Four times two hours group based patient education
258734|NCT02490735|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
258735|NCT02490748|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
257849|NCT02470312|Procedure|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
257850|NCT02470312|Device|MediGuide|
257851|NCT02470312|Procedure|EP|
257852|NCT02470325|Drug|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
257853|NCT02470325|Drug|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
257854|NCT00174915|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
257855|NCT02470338|Procedure|MBP plus arthroscopy (Group A)|
257856|NCT02470338|Procedure|MBP alone (Group B)|
257857|NCT02470377|Device|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
257858|NCT02470390|Drug|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
257859|NCT02470403|Drug|LIK066|LIK066 25 mg tablets
258128|NCT02499627|Drug|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
258129|NCT02499627|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
258130|NCT02499640|Other|immersion cold water|immersion cold water at different temperatures and exposure times
258131|NCT02499653|Behavioral|Psychological Intervention|
258132|NCT02276495|Other|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
258133|NCT02276495|Drug|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
258134|NCT02276495|Drug|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|100 mLs of a solution containing:
Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)
258135|NCT02276508|Drug|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
258136|NCT02276521|Biological|Cervarix®|All groups will received one dose of Cervarix® vaccine
258137|NCT02276534|Behavioral|SENSE Theatre|A peer-mediated, theatre-based intervention.
241560|NCT02534623|Drug|propofol|
241561|NCT02534623|Drug|sevoflurane|
241562|NCT02534636|Drug|BMS-986165|
241563|NCT02534636|Drug|Interferon alpha-2a recombinant|
241564|NCT02534636|Drug|Ustekinumab|
241565|NCT00183443|Drug|Quetiapine|Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
241566|NCT02534636|Drug|Famotidine|
241567|NCT02534636|Other|Placebo|
241568|NCT02534649|Procedure|Newly obtained biopsy and Blood samples collection|For each patient:
Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling
Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.
Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.
All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report.
241569|NCT02534662|Device|ENDOMINA|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
241866|NCT02527876|Behavioral|Delayed Control|Delayed Control
241867|NCT02527876|Device|FitBit Flex|Use to measure increase in Physical Activity
241868|NCT02527889|Other|Exercise training|8-week resistive exercise training
241869|NCT02527902|Device|Holter|measure of ANS in IgAN patients
241870|NCT02527915|Other|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
241871|NCT02527915|Other|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
241872|NCT02527928|Other|None intervention|
241873|NCT02527941|Drug|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
240930|NCT02504398|Other|Fast injection speed by immunizer|
240931|NCT02504398|Other|Slow injection speed by immunizer|
240932|NCT02504411|Device|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
240933|NCT02504411|Device|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
240934|NCT00002488|Drug|cyclophosphamide|
240935|NCT02506790|Drug|metformin|
240936|NCT02506790|Drug|Melatonin|
240937|NCT02506790|Drug|Toremifene|
240938|NCT02506803|Drug|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
240939|NCT02506816|Drug|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
240940|NCT02506829|Behavioral|Smoking cessation counseling (Quitline)|
240941|NCT02506829|Behavioral|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
240942|NCT02506829|Behavioral|Financial incentives|
240943|NCT02506842|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
241238|NCT02537197|Drug|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
241239|NCT02537210|Drug|Mesalazine|Patients will be prescribed Asacol 2g daily for 12 months
241240|NCT02537210|Drug|Placebo|Patients will be prescribed placebo 5 capsules daily for 12 months
241241|NCT02537223|Drug|BYL719|
241242|NCT00183638|Behavioral|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
241243|NCT02537223|Drug|Cisplatin|
241244|NCT02537223|Radiation|Intensity modulated radiation therapy (IMRT)|
240603|NCT02511444|Other|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
240604|NCT02511470|Other|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
240605|NCT02511470|Other|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
240606|NCT02511483|Drug|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
240607|NCT02511483|Drug|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
240608|NCT02511483|Drug|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
240609|NCT00180271|Device|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
240610|NCT02511483|Procedure|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
240611|NCT02511483|Other|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
240612|NCT02511483|Genetic|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
240613|NCT02513654|Drug|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
240614|NCT02513667|Drug|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
240615|NCT02513667|Radiation|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
240616|NCT02513680|Device|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
240617|NCT02513680|Device|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
240944|NCT00002489|Biological|filgrastim|
240945|NCT00179673|Drug|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
240309|NCT02518217|Behavioral|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
240310|NCT02518217|Behavioral|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
240311|NCT02518230|Device|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
240312|NCT02518230|Device|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
240313|NCT02518243|Other|Patient's answer with non pharmacological therapeutic|Installation at patient's home of :
aromatherapy
music therapy
cognitive training in multimedia application offering cognitive games
240314|NCT02518256|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
240315|NCT02518269|Procedure|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
240316|NCT02518282|Other|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
240317|NCT00000370|Behavioral|Performance-based exposure therapy|
240318|NCT00002492|Radiation|brachytherapy|
240319|NCT00181753|Drug|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for > 3 days before we conduct stable isotope tracer measurements.
240320|NCT02520323|Other|Blood draw|
240321|NCT02520323|Procedure|Bronchoscopy|
240322|NCT02520323|Behavioral|Questionnaires|
240323|NCT02520336|Behavioral|Reminder|
240324|NCT02520349|Device|MarkTen and e-Go e-cigarettes|
240325|NCT02520362|Drug|denosumab|subcutaneous injection
240326|NCT02520362|Drug|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate [Fosamax®], risedronate [Actonel®], ibandronate [Boniva®/Bonviva®] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate [Reclast®/Aclasta®].
240327|NCT02520375|Other|Prebiotic mouthrinse and toothpaste|This group will be asked to rinse with a prebiotic mouthrinse and toothpaste.
239717|NCT02531633|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
239718|NCT02531633|Drug|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
240019|NCT02524860|Device|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
240020|NCT02524873|Device|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
240021|NCT02524886|Device|GPi DBS with Medtronic electorde and Activa PC pulsegenerator|The electric stimulation of 2 leads implanted in the Globus Pallidus internus
240022|NCT02524899|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
240023|NCT02524899|Drug|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
240024|NCT02524899|Drug|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
240025|NCT02524925|Procedure|fast track protocol|Evaluation of postoperative stress
240026|NCT02524938|Dietary Supplement|Chlorogenic Acid (CGA) enriched coffee|Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.
Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)
240027|NCT02527122|Biological|MM09-I|The subjects will receive 4 doses of MM09-I in different concentrations.
240028|NCT02527122|Biological|MM09-II|The subjects will receive 4 doses of MM09-II in different concentrations.
240029|NCT02527122|Other|Histamine dihydrochloride|The subjects will receive 2 doses for positive control
240030|NCT02527122|Other|Glycerinated phenol saline solution|The subjects will receive 2 doses for negative control
240031|NCT00182663|Drug|thalidomide|Given PO
239415|NCT02465827|Drug|nerve block with saline|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
239416|NCT00168077|Drug|Prothrombin Complex Concentrate|
239417|NCT02430337|Behavioral|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
239418|NCT02430337|Behavioral|SafeCare|SafeCare, an evidence-based home visiting program
239419|NCT02430350|Drug|Compound Edaravone Injection|
239420|NCT02430350|Drug|Edaravone Injection|
239421|NCT02430363|Drug|MK - 3475|Administered Intravenously
239422|NCT02430363|Biological|Suppressor of the PI3K/Akt pathways|Capsules orally with food
239423|NCT02430389|Drug|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
239424|NCT02430389|Drug|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
239425|NCT02430402|Other|Rehabilitation in warm climate|
239426|NCT02430415|Device|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
239719|NCT02531633|Drug|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
239720|NCT02531672|Drug|11C-choline|
239721|NCT00183196|Drug|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
239722|NCT02531672|Device|PET/CT Scan|
239723|NCT02531685|Other|Placebo|Placebo: 0.9% Sodium Chloride injection. 3 subjects in each cohort receive placebo injection intradermally on days 1, 22 and 43.
239724|NCT02531685|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral entertoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose. Cohorts 1-4 receive doses of 0.1, 0.3, 1.0 and 2.0 mcg respectively, intradermally on days 1, 22 and 43. Cohort 5 receives a TBD dose on days 1, 22, and 43
239725|NCT02531698|Biological|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
239726|NCT02531698|Biological|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
239126|NCT02435264|Other|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
239127|NCT02435277|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
239128|NCT02435277|Drug|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
239129|NCT02435277|Drug|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
239130|NCT02435277|Drug|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
239131|NCT02435290|Behavioral|determine the incidence , type , and severity of prescribing errors in the oncology department|patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.
the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.
239132|NCT02435303|Drug|Sildenafil|
239133|NCT02435303|Drug|Placebo|
239134|NCT02437591|Drug|fidaxomicin|oral
239135|NCT00169013|Drug|Gabapentin|
239136|NCT02437604|Drug|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
239137|NCT02437604|Drug|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
239138|NCT02437604|Drug|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
239139|NCT02437604|Drug|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
239140|NCT02437617|Procedure|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
239141|NCT02437630|Procedure|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
239427|NCT00168090|Drug|Blood coagulation Factor VIII and vWF, human|
239428|NCT02430415|Device|traditional lightwand intubation|traditional lightwand intubation
243561|NCT02517190|Other|cellular energy metabolism measurements|purines, lactate
243562|NCT00181090|Behavioral|Modified Atkins diet|
243563|NCT02519309|Other|Virta Program|In-person administration vs Virtual administration of dietary intervention
243564|NCT02519322|Drug|Nivolumab 1mg/kg|Group B Neoadjuvant Phase: Nivolumab 1 mg/kg by vein every 3 weeks on weeks 1, 4 and 7 prior to surgical excision.
243840|NCT02512627|Behavioral|Cognitive training|
243841|NCT02512627|Behavioral|Physical exercise|
243842|NCT02512627|Behavioral|Sequential training|
243843|NCT02512627|Behavioral|Dual-task training|
243844|NCT02512640|Procedure|Volume-controlled ventilation|a tidal volume of 8 ml/kg
243845|NCT02512640|Procedure|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
243846|NCT02512653|Biological|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
243847|NCT02512666|Device|AM4113-N5UT Dino-Lite|
243848|NCT02512679|Drug|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
243849|NCT00180453|Device|Coronary artery stent placement|Coronary artery stent placement
243850|NCT02512679|Drug|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
243851|NCT02512679|Drug|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
243852|NCT02512679|Drug|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
243853|NCT02512692|Device|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
243854|NCT02512692|Drug|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
243855|NCT02512692|Drug|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
243856|NCT02512705|Device|Pinel Restraints|
243857|NCT02512705|Behavioral|Seclusion Room|
243290|NCT02523898|Drug|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
243291|NCT02523911|Drug|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
243292|NCT00002494|Drug|doxorubicin hydrochloride|
243293|NCT00182286|Behavioral|Relationship between continuity of care, patient outcomes, and costs|
243565|NCT02519322|Drug|Ipilimumab|Group B Neoadjuvant Phase: Ipilimumab 3 mg/kg by vein every 3 weeks on weeks 1, 4 and 7 prior to surgical excision.
243566|NCT02519322|Drug|Nivolumab 3 mg/kg|Group A Neoadjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks on weeks 1, 3, 5 and 7 prior to surgical excision.
Group A Adjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks postoperatively for 6 months.
Group B Adjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks postoperatively for 6 months.
243567|NCT00181610|Biological|Normal Saline|twice per day
243568|NCT02519335|Drug|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
243569|NCT02519348|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
243570|NCT02519348|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
243571|NCT02519348|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
243572|NCT02519374|Drug|Placebo (including Maltodextrin)|
243573|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 1
243574|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 2
243575|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 3
243576|NCT02519387|Drug|Buprenorphine Transdermal Patch|
243577|NCT02519400|Drug|Amitriptyline|Single oral dosing
243578|NCT00181623|Drug|Recombinant Human Prolactin|
243579|NCT02519413|Drug|dimethyl fumarate|delayed release capsules
243014|NCT02530645|Behavioral|Treatment as Usual|
243015|NCT02530645|Behavioral|Brief Motivational Interviewing|
243016|NCT02530658|Other|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, study introduction materials will be provided. Participants will also complete assessment questionnaires.
243017|NCT02530658|Other|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, the study team will collect demographic, medical, family and physical examination information. All interviews will be audio-taped for later analysis. Participants will complete assessment questionnaires.
243018|NCT02530658|Other|Informed Consent Follow-Up Visit|Within 2-4 weeks following the Informed Consent Visit, participants will complete questionnaires. A subset of participants (30-40) will participate in semi-structured interviews.
243019|NCT02530658|Other|Return of Results Conversation|Depending on the availability of genomic results and preference of the participant and parents, audio-taped interviews will be conducted. Participants will complete the assessment questionnaires.
243020|NCT00183040|Drug|Recombinant human growth hormone|
243021|NCT02530658|Other|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, and the second within 32±8 weeks of the Return of Results Conversation. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
243294|NCT02523911|Drug|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
243295|NCT02526056|Other|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
243296|NCT02526069|Behavioral|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
243297|NCT02526082|Other|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
243298|NCT02526108|Other|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
243299|NCT00182585|Procedure|computer-based HIV, STD & Hepatitis Education|
243300|NCT02526121|Procedure|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
243301|NCT02526121|Behavioral|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
242698|NCT02537769|Device|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
242699|NCT02537769|Procedure|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
242700|NCT02537782|Device|Cardiac resynchronisation therapy|
242701|NCT02537782|Other|Echocardiography|
242702|NCT02537782|Other|Magnetic Resonance Imaging|
242703|NCT02537782|Other|Positron Emission Tomography|
242704|NCT02537795|Device|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
242705|NCT02537795|Procedure|anterior capsulotomy|
242706|NCT02537834|Drug|Tofogliflozin|
242707|NCT00002496|Radiation|low-LET electron therapy|
242708|NCT00183690|Procedure|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
242709|NCT02537834|Drug|GLP-1 analogue|
242710|NCT02537847|Drug|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
242711|NCT02537847|Drug|Ertapenem|Control group will be given ertapenem only for 10 days.
242712|NCT02537860|Other|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
242713|NCT02537860|Other|Placebo at T11 and L3|Two injections that contain saline are performed
242714|NCT02537860|Other|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
242715|NCT02537860|Procedure|Herniorrhaphy|Unilateral inguinal hernia repair
243022|NCT02530658|Procedure|Tissue Sample|For patients who do not have a tissue sample in the St. Jude Tissue Bank and who give consent, a tumor and/or normal tissue sample will be obtained by biopsy as part of routine diagnostic evaluation for use in WGS, WES and RNA sequence analysis.
243023|NCT02530658|Procedure|Blood Sample|A sample of blood will be obtained as a source of germline DNA.
254871|NCT02270216|Procedure|cycling exercise|The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.
Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes.
254872|NCT00148005|Drug|Anticholinergic therapy|
254873|NCT02270242|Drug|Aspirin|
254874|NCT02270242|Drug|Placebo|
254875|NCT02270242|Drug|ticagrelor|
254876|NCT02270255|Procedure|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
254877|NCT02270255|Drug|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
254878|NCT02270255|Procedure|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
254879|NCT02270255|Drug|1% Xylocaine|5ml of 1% Xylocaine
254880|NCT02270268|Dietary Supplement|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
254881|NCT02270268|Dietary Supplement|maltodextrin|
254882|NCT02272478|Drug|Ganetespib|Small molecule comparison
254883|NCT02272491|Device|ZrO2 (Straumann CARES)|Straumann CARES Variobase Abutment RN
Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)
254884|NCT02272491|Device|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
254885|NCT02272517|Drug|Vortioxetine 10-20 mg|
254886|NCT00148265|Drug|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
254887|NCT02272517|Drug|Escitalopram 10-20 mg|
255191|NCT02265432|Other|online map|
254541|NCT02238639|Procedure|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.
If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation.
254542|NCT00144235|Drug|Pharmaton PHL 00749|
254543|NCT02238652|Behavioral|Communication|A preparation process before the patient become incapable of participating in life prolonging decisions
254544|NCT02238652|Behavioral|Systematic Pain Assessment and Treatment|Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
254545|NCT02238652|Behavioral|Medication Review|An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
254546|NCT02238652|Behavioral|Occupational therapy|Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
254547|NCT02238652|Behavioral|Safety|Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
254548|NCT02238665|Device|Endomicroscopy|
254549|NCT02238691|Procedure|Mask ventilation with PEEP via a face mask device|15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.
15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask.
254550|NCT02238704|Dietary Supplement|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
254551|NCT02240875|Biological|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
254552|NCT02240875|Biological|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
254553|NCT02240888|Biological|0,5 mg Prevenar i.m.|
254554|NCT02240888|Biological|0,5 mg seasonal influenza vaccine i.m.|
254555|NCT02240901|Device|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
254556|NCT02240901|Device|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
254557|NCT02240927|Drug|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
254558|NCT00144482|Drug|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
259025|NCT02484183|Device|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher & Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer & Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer & Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
259304|NCT02477384|Device|8mm ePTFE-covered stent|
259305|NCT02477397|Drug|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
259306|NCT02479581|Procedure|ERAS group|Apply Transesophageal Echocardiography（TEE）after anesthesia induction;
Goal-directed fluid management.
259307|NCT02479581|Procedure|ERAS group|Infusion of Human Albumin Grifol®20% 50ml;
Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));
259308|NCT02479581|Procedure|ERAS group|Monitor urine volume closely, over 1ml/kg·h.
259309|NCT02479581|Procedure|ERAS group|Protective ventilation strategy(Low tidal volume about 6~7ml/kg, joint use of PEEP)
259310|NCT02479581|Procedure|ERAS group|Bilateral thoracic paravertebral block before induction of anesthesia;
Fast channel anesthesia:
Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1~0.4ug/kg·min, Propofol Injection 2~6mg/kg·h, Sevoflurane 0.5~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over.
259311|NCT02479581|Procedure|ERAS group|Drink water after 6h, 200ml once, 2~3 times / day.;
early ambulation;
Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；
Intravenous the lansoprazole 30mg q12h.
259312|NCT02479581|Procedure|Conventional control group|Routine preoperative psychological preparation for patients.
259313|NCT02479581|Procedure|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.07ug/kg·h combine with Ketamine 40ug/kg·h).
259314|NCT00176202|Drug|Divalproex Sodium|Divalproex sodium is a mood stabilizer
259315|NCT02479581|Procedure|Conventional control group|Routine bowel preparation;
Liquid food eating 2 days before the operation;
259316|NCT02479581|Procedure|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
259317|NCT02479581|Procedure|Conventional control group|Induction use Sufentanil 0.5~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2~0.6mg/kg,Midazolam0.05~0.1mg/kg ;
Maintain use Sufentanil 1~2ug/kg·h, Propofol 4~12mg/kg·h, Sevoflurane 1~3(minimal alveolar concentration)， Vecuronium 0.06~0.12mg/kg·h;
258736|NCT02490748|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
258737|NCT02490774|Drug|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
258738|NCT02490774|Drug|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
258739|NCT02490774|Drug|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
259026|NCT02484196|Behavioral|Questionnaires|
259027|NCT02484209|Drug|Metformin|Metformin 1500 mg daily for 16 weeks
259028|NCT02484209|Drug|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
259029|NCT02484209|Drug|Metformin|metformin 1500 mg daily for 16 weeks
259030|NCT02484222|Drug|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
259031|NCT02484235|Other|HIIT|Group training with HIIT 3 times per week during 10 sessions
259032|NCT02486549|Procedure|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
259033|NCT02486549|Drug|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
259034|NCT02486549|Device|Ultrasound|The Ultrasound will be used for brachial plexus visualization
259035|NCT02486575|Other|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
259036|NCT00176839|Drug|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
259037|NCT02486575|Other|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
259038|NCT02486588|Other|Messaging|See detailed study description for overview of the different messaging interventions in this study
259039|NCT02486588|Other|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
259040|NCT02486601|Drug|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
259041|NCT02486601|Drug|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
258138|NCT02276534|Behavioral|Delayed Intervention|
258139|NCT02276547|Device|Mitral valve replacement|Transcatheter mitral valve replacement
258140|NCT02276560|Drug|Neoadjuvant Cisplatin, nab-paclitaxel|Cisplatin (75mg/m2) D1, nab-paclitaxel 125 mg/m2) D1, 8, 15; repeat each 28 D cycle x 2 then surgery
258141|NCT00148681|Drug|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
258142|NCT02276560|Drug|Adjuvant Cisplatin,nab-paclitaxel|Cisplatin 75mg/m2 D1,nab-paclitaxel 125mg/m2 D1, 8, 15, repeat each 28D cycle x 2
258143|NCT02276560|Drug|Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine|Cisplatin 75mg/m2 D1 + pemetrexed 500mg/m2 D1 or Gemcitabine 1000 mg/m2 D1, 8 (if SqCC) repeat each 21 D Cycle x 4
258144|NCT02276573|Biological|buccal cavity sample|
258145|NCT02276586|Procedure|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
258146|NCT02276586|Procedure|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
258147|NCT02276599|Procedure|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
258148|NCT02276612|Drug|E/C/F/TAF|Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (E/C/F/TAF) administered orally once daily with food
258436|NCT02495402|Behavioral|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
258437|NCT02495415|Drug|Fenretinide|Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
258438|NCT02495428|Procedure|Kinesio Tape Method|
258439|NCT02497456|Behavioral|Follow-up counselling|
258440|NCT02497469|Drug|Vedolizumab|Vedolizumab infusion
258441|NCT02497469|Drug|Adalimumab placebo|Adalimumab placebo-matching injection
258442|NCT02497469|Drug|Adalimumab|Adalimumab injection
258443|NCT02497469|Drug|Vedolizumab placebo|Vedolizumab placebo-matching infusion
258444|NCT02497495|Other|immersion cold water|immersion cold water at different temperatures and exposure times
258445|NCT02497508|Drug|nivolumab|
241874|NCT02527980|Other|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
241875|NCT00182728|Procedure|therapy|neoadjuvant
241876|NCT02527993|Drug|Glucobay (acarbose)|Se arm description
241877|NCT02527993|Drug|Januvia (sitagliptin)|Se arm description
241878|NCT02527993|Drug|Verapamil HEXAL (verapamil)|Se arm description
241879|NCT02530151|Other|Normal saline|see arm description
241880|NCT00182936|Behavioral|Delirium Abatement Program|
241881|NCT02530164|Device|Transcranial direct current stimulation (tDCS)|active/sham tDCS as adjunctive treatment with a SSRI
241882|NCT02530177|Other|Clinical Assessments|
241883|NCT02530177|Behavioral|Questionnaires|
241884|NCT02530177|Other|Saliva sample|
241885|NCT02530190|Device|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
241886|NCT02530190|Procedure|massage|20 minutes of massage to lower extremities
242182|NCT02523313|Drug|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
242183|NCT02523313|Drug|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
242184|NCT02523313|Drug|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
242185|NCT02523326|Device|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
242186|NCT02523352|Procedure|Non-Invasive Mechanical ventilation - Recruitment maneuver|Progressive increase in airway pressure to open lungs atelectatic regions.
241245|NCT02537236|Dietary Supplement|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
241246|NCT02537236|Behavioral|TLC nutritional intervention|nutritional orientation.
241247|NCT02537236|Dietary Supplement|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
241248|NCT02537249|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
241249|NCT02502188|Drug|CC-90005|
241250|NCT02502188|Drug|Placebo|
241251|NCT02502201|Other|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
241252|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
241253|NCT02502201|Other|six-minute walk study outdoors|Performance of a six-minute walk test.
241254|NCT02502227|Behavioral|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
241255|NCT02502253|Drug|grape seed polyphenolic extract, resveratrol, Concord grape juice|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of three nutraceutical preparations (grape seed polyphenolic extract [GSE], resveratrol, and Concord grape juice) that contain abundant concentrations of polyphenols.
241256|NCT02502266|Drug|Cediranib Maleate|Given PO
241257|NCT02502266|Other|Laboratory Biomarker Analysis|Correlative studies
241570|NCT02534688|Drug|LNG-IUS|
241571|NCT02534688|Drug|DMPA|
241572|NCT02534701|Device|ERIC® and SOFIA™|a self-expanding clot retrieval system
241573|NCT02534740|Drug|tafamidis|relative bioavailability
241574|NCT02534740|Drug|tafamidis|fasted
241575|NCT02534740|Drug|tafamidis|fed
241576|NCT00002496|Drug|cisplatin|
240946|NCT02506842|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
240947|NCT02506842|Drug|oxaliplatin|Patients receive oxaliplatin 85 mg/m^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
240948|NCT02506842|Drug|folinic acid|Patients receive folinic acid 200 mg/m^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
240949|NCT02506842|Drug|fluorouracil|Patients receive fluorouracil 2000 mg/m^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
240950|NCT02506855|Drug|Ropivacaine|
240951|NCT02506855|Other|Placebo|
240952|NCT02506855|Procedure|Transversus Abdominis Plane Block|
240953|NCT02506868|Drug|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
240954|NCT02506881|Drug|Darbepoetin alfa|
240955|NCT02506894|Drug|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
240956|NCT00179686|Drug|CC-5013|
240957|NCT02506894|Other|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
240958|NCT02506920|Dietary Supplement|Six different types of fat in a meal in random order|Oral fat tolerance test
240959|NCT02506933|Other|Laboratory Biomarker Analysis|Correlative studies
240960|NCT02506933|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
240961|NCT02506933|Other|Placebo|Given IM
240962|NCT02509169|Other|TAE|Trans-catheter embolization
240963|NCT02509182|Drug|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
240964|NCT02509182|Drug|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
240965|NCT02509195|Drug|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
240328|NCT02520375|Other|Placebo|This group will be asked to rinse with a placebo mouthrinse and toothpaste.
240329|NCT02520388|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
240618|NCT02513693|Drug|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
240619|NCT00180622|Procedure|Exhaled Nitric Oxide and Carbon Monoxide|
240620|NCT02513693|Drug|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
240621|NCT02513719|Device|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
240622|NCT02513732|Device|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
240623|NCT02513745|Device|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
240624|NCT02513745|Device|Verion|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
240625|NCT02513758|Other|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
240626|NCT02513771|Drug|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
240627|NCT02513771|Drug|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
240628|NCT02513784|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
240629|NCT02513797|Device|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
240630|NCT00180622|Procedure|Exhaled Breath Condensate|
240631|NCT02513797|Device|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
240632|NCT02513810|Device|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
240633|NCT02513810|Device|BioMatrix Flex with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
240032|NCT02527135|Behavioral|Weekly HIV sensitization text messages|Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase "Get tested for HIV".
240033|NCT02527148|Device|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
240034|NCT02527148|Device|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
240330|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant infusion
240331|NCT02520388|Drug|Placebo|
240332|NCT02520401|Other|Probiotic - BioGaia|Use of a probiotic tablet
240333|NCT02520401|Other|Placebo|Use of a placebo tablet
240334|NCT02520414|Device|Symphion® Bipolar Hysteroscopic Tissue Resection System|
240335|NCT02520427|Drug|AMG 330|0.5-960 µg/day cIV infusion in cycles from 14 to 28 days
240336|NCT02520440|Biological|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
240337|NCT02520440|Device|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
240338|NCT02520440|Biological|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
240339|NCT02520453|Drug|MEDI 4736|
240340|NCT02520453|Drug|Placebo|
240341|NCT00181753|Dietary Supplement|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
240342|NCT02520466|Dietary Supplement|flavanol-rich drink vs flavanol-free drink|
240343|NCT02520479|Drug|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
240344|NCT02520479|Radiation|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
239727|NCT02531698|Other|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
239728|NCT02531711|Other|Diet A|Experimental analgesic dietary intervention
239729|NCT02531711|Other|Diet B|Healthy comparator diet
239730|NCT02531724|Drug|Levosimendan|
239731|NCT02533856|Other|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
239732|NCT02533869|Radiation|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
239733|NCT02533869|Procedure|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
239734|NCT02533882|Behavioral|Movement to Music|
239735|NCT02533882|Behavioral|Adapted Yoga|
239736|NCT02533895|Biological|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
239737|NCT02533895|Other|Data evaluation|For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.
Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc
240035|NCT02527148|Procedure|Total Knee Replacement|
240036|NCT02527148|Device|Stryker Triathlon® Total Knee System|Prosthetic components to be implanted including
Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;
Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;
Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon.
240037|NCT02527161|Device|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
240038|NCT02527174|Drug|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
240039|NCT02527174|Drug|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
240040|NCT02527174|Drug|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
239429|NCT02430428|Device|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
239430|NCT02430454|Behavioral|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
239431|NCT02430467|Behavioral|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
239432|NCT02430467|Behavioral|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
239433|NCT02430480|Drug|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
239434|NCT02430480|Procedure|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
239435|NCT02430506|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
239436|NCT02430506|Biological|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
239437|NCT02430519|Procedure|Furcation treatment with PRF|PRF Placed into the furcation after flap elevation and debridement
239438|NCT00168103|Biological|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
239439|NCT02432690|Drug|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
239440|NCT02432703|Drug|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
239441|NCT02432703|Drug|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
239442|NCT02432716|Drug|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
239443|NCT02432716|Drug|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
239444|NCT02432742|Device|Restylane Perlane|Intradermal injection
239445|NCT00168454|Biological|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
243858|NCT02512718|Drug|Omegaven|comparison of FOLE vs. SOLE
243859|NCT02512718|Drug|soybean oil lipid emulsion|comparison of FOLE vs. SOLE
243860|NCT00002489|Procedure|conventional surgery|
243861|NCT02514941|Drug|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
243862|NCT02514941|Procedure|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
243863|NCT02514941|Procedure|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
239142|NCT02437630|Procedure|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
239143|NCT02437630|Other|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
239144|NCT02437630|Procedure|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
239145|NCT02437630|Procedure|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
239146|NCT00169026|Drug|Clozapine versus typical (conventional) and atypical antipsychotic medications|
239147|NCT02437630|Other|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
239148|NCT02437643|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
239149|NCT02437643|Dietary Supplement|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
239150|NCT02437643|Behavioral|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
239151|NCT02437656|Drug|Metformin|J3 - J10 (7 days minimum) : 850 mg 2 times / day
J10 - 48h before surgery : 850 mg 3 times / day
243580|NCT02519426|Procedure|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
243581|NCT02519439|Drug|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
243582|NCT02519452|Drug|Daratumumab Subcutaneous (SC) infusion|Participants will receive Daratumumab sc infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
243583|NCT02519452|Drug|Recombinant Human Hyaluronidase [rHuPH20]) SC infusion|Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) along with Daratumumab by SC infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
243584|NCT02519452|Drug|Daratumumab Intravenous (IV) infusion|Participants will receive Daratumumab 1200 mg IV infusion once weekly in Cycles 1 (each cycle 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
243864|NCT02514941|Procedure|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
243865|NCT00180700|Behavioral|Johrei - a Japanese stress management system|
243866|NCT02514954|Drug|Biochaperone® Combo|Subcutaneous injection of an individualized dose
243867|NCT02514954|Drug|Humalog® Mix25|Subcutaneous injection of an individualized dose
243868|NCT02514967|Drug|Blisibimod|Administered via subcutaneous injection once per week
243869|NCT02514967|Drug|Placebo|Administered via subcutaneous injection once per week
243870|NCT02514980|Drug|Bupivacaine|Infraorbital nerve block using 1 ml bupivacaine 0.25% on each side.
243871|NCT02514980|Drug|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
243872|NCT02515006|Other|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
243873|NCT02515019|Device|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
243874|NCT02515032|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
243875|NCT02515032|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
243876|NCT00180713|Drug|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
243302|NCT02526134|Device|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
243303|NCT02526147|Other|Cash|
243304|NCT02526147|Other|Voucher|
243305|NCT02526147|Other|Food|
243306|NCT02526160|Biological|KRN23|KRN23 is a recombinant human immunoglobulin G isotype 1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
243307|NCT02526160|Other|Placebo|Subjects may be randomized 1:1 to receive placebo administered subcutaneously (SC) every 4 weeks (Q4W). The placebo group will cross over to receive KRN23 treatment at Week 24.
243308|NCT02526173|Procedure|RALP using full nerve sparing technique|RALP using full nerve sparing technique
243309|NCT02526173|Other|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
243310|NCT00182585|Procedure|educator-delivered HIV, STD and Hepatitis education|
243311|NCT02526186|Device|Battlefield Auricular Acupuncture|
243312|NCT02526199|Drug|Bupivacaine|Sciatic nerve block
243313|NCT02526199|Drug|Epinephrine|Adjuvant to perinerual block
243314|NCT02526199|Drug|Dexamethasone|Adjuvant to perinerual block
243585|NCT02519465|Other|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 10l/min
243586|NCT00181974|Drug|Tisseel Fibrin Sealant|
243587|NCT02521610|Drug|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
243588|NCT02521610|Drug|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
243589|NCT02521623|Device|SurgiMend® Acellular Dermal Matrix|See arm description.
243590|NCT02521623|Device|Strattice™ Acellular Dermal Matrix|See arm description.
243591|NCT02521636|Other|Antibiotic therapy randomization|
243592|NCT02521636|Other|Serum PCT dosage|
243024|NCT02530658|Procedure|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
243025|NCT00183313|Behavioral|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
243026|NCT02532855|Drug|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
243027|NCT02532855|Drug|Metformin|Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
243028|NCT02532855|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
243029|NCT02532855|Drug|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
243030|NCT02532868|Drug|MK-0457|
243031|NCT02532881|Other|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
243032|NCT02532881|Other|Treatment as usual|Treatment as usual
243033|NCT02532894|Device|Electronic cigarette|Inhaling e-cigarette vapor
243034|NCT02532907|Procedure|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
243035|NCT02532933|Device|DePuy Synthes Attune PS RP|
243036|NCT00183313|Behavioral|Usual care|Usual care includes standard mental health services.
243037|NCT02532946|Behavioral|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
243038|NCT02532959|Device|Diagnostic Breath Analysis|Conduct exhaled breath samples
243039|NCT02532972|Device|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
255192|NCT00147537|Drug|carboplatin|Phase 2 Arm A:
Carboplatin AUC 6, IV over 15‑60 minutes up to 6 cycles
Phase 2 Arm B:
Carboplatin AUC 6, IV over 15‑60 minutes up to 6 cycles
255193|NCT02265432|Other|Personalized text messages|
255194|NCT02265445|Drug|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
255195|NCT02265445|Drug|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
255196|NCT02265458|Behavioral|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
255197|NCT02265484|Drug|Lactulose+Rifaximin +Bromocriptine|
255198|NCT02265497|Other|Observational, non-intervention|Observational, non-intervention
255199|NCT02265510|Drug|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
255200|NCT02265510|Drug|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
255201|NCT02265510|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
255202|NCT02265510|Drug|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
255203|NCT00147537|Drug|CP-751,871|Phase 1b Dose Escalation/Expansion: CP‑751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP‑751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
255204|NCT02265510|Drug|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
255205|NCT02265510|Drug|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
255206|NCT02265510|Drug|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
255207|NCT02265510|Drug|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
255208|NCT02265510|Drug|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
255209|NCT02267785|Other|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
254559|NCT02240927|Drug|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
254888|NCT02272543|Dietary Supplement|Fish surimi peptide|
254889|NCT02272556|Other|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
254890|NCT02272556|Other|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
254891|NCT02272569|Device|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotics.
254892|NCT02272582|Device|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
254893|NCT02272582|Other|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
254894|NCT02272595|Other|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
254895|NCT02272595|Other|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
254896|NCT02272608|Other|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
254897|NCT00148278|Drug|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
254898|NCT02272621|Procedure|Minimally invasive aortic valve replacement|
254899|NCT02272621|Procedure|Full sternotomy aortic valve replacement|
254900|NCT02272634|Drug|YPL-001 low dose|twice daily [BID]
254901|NCT02272634|Drug|YPL-001 high dose|twice daily [BID]
254902|NCT02272634|Drug|placebo|twice daily [BID]
259318|NCT02479581|Procedure|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
259319|NCT02479581|Procedure|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
259320|NCT02479581|Procedure|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g during the operation
259321|NCT02479594|Behavioral|competence-feedback|competence-feedback
259322|NCT02479594|Other|control|control group without competence-feedback
259323|NCT02479607|Device|Smartphone or tablet|
254560|NCT02240927|Drug|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
254561|NCT02240927|Drug|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
254562|NCT02240940|Device|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
254563|NCT02240953|Drug|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
254564|NCT02240953|Drug|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
254565|NCT02240953|Drug|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
254566|NCT02240953|Drug|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
254567|NCT02240979|Device|cardiac MRI|cardiac MRI
254568|NCT02240992|Biological|PBSC|
254569|NCT00144495|Drug|recombinant human erythropoietin|3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
254570|NCT02240992|Biological|MSCs|
254571|NCT02241005|Other|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
259042|NCT02486614|Procedure|CRRT|citrate based continuous renal replacement therapy
259043|NCT02486627|Drug|plazomicin|
259044|NCT02486627|Drug|meropenem|
259045|NCT02486627|Drug|levofloxacin (oral)|Oral switch after completion of study drug when clinically appropriate
259046|NCT02486640|Drug|Interferon beta-1b (Betaferon, BAY86-5046)|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.
259047|NCT00176839|Drug|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
259324|NCT02479620|Drug|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and "Investigational Drug".
"Investigational Drug" administered via Bullfrog Micro-Infusion Device.
259325|NCT00176202|Drug|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
259326|NCT02481947|Drug|Lubiprostone|Oral laxative
259327|NCT02481960|Procedure|CM-BC2 Irinotecan drug-eluting bead|
259328|NCT00176462|Drug|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
259329|NCT02481973|Other|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
259330|NCT02481986|Behavioral|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
259331|NCT02481986|Behavioral|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
259332|NCT02482012|Other|Survey|This was a survey
259333|NCT02482025|Other|MHV|My HealtheVet registration and enrollment
259334|NCT02482025|Dietary Supplement|SMMRT|Secure Messaging for Medication Reconciliation Tool
259335|NCT02482038|Device|geko|neuromuscular electrostimulator
259336|NCT02482064|Other|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
258446|NCT00178282|Procedure|Pelvic Floor Muscle exercises|
258447|NCT02497547|Drug|Oxytocin|
258448|NCT02497547|Drug|Placebo|
258449|NCT02497560|Dietary Supplement|proprietary formula|
258450|NCT02497573|Procedure|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
258451|NCT02497586|Radiation|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
258452|NCT02497599|Drug|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
258453|NCT02497599|Radiation|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
258454|NCT02497599|Procedure|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
258455|NCT02497612|Drug|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
258456|NCT02497612|Drug|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
258457|NCT00178295|Radiation|Radiation Therapy|standard of care for the cancer being treated
258740|NCT00177307|Drug|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
258741|NCT02490787|Drug|Concizumab|Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
258742|NCT02490787|Drug|placebo|Administered subcutaneously (s.c., under the skin)
258743|NCT02490800|Drug|Oral daily administration of BAL101553|oral administration
258744|NCT02490813|Dietary Supplement|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
258745|NCT02493088|Other|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
258746|NCT02493127|Other|Standard PCS|Subject completes the standard version of the PCS Questionnaire
242187|NCT02523352|Procedure|Non-Invasive Mechanical Ventilation - Decremental PEEP trial|PEEP will be decreased at consecutive steps. Static compliance of the respiratory system will be measured at each step. The optimal PEEP value for the patient will be chosen as the lowest PEEP level at witch the compliance of the respiratory system will be the best.
242188|NCT02523352|Procedure|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
242189|NCT02523365|Procedure|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
242190|NCT02523378|Behavioral|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
242191|NCT00182234|Behavioral|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
242192|NCT02523378|Behavioral|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
242193|NCT02523391|Drug|TA-8995|Capsule
242194|NCT02525601|Device|Triathlon CR cemented|Implantation of Knee Prosthesis
242195|NCT02525601|Device|Triathlon CR uncemented|Implantation of Knee Prosthesis
242196|NCT00182546|Procedure|Two diagnostic management strategies|
242197|NCT02525614|Device|Triathlon Standard Keel|Implantation of Knee Prosthesis
242198|NCT02525614|Device|Triathlon Short Keel|Implantation of Knee Prosthesis
242199|NCT02525627|Device|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
242496|NCT02518880|Other|Parabolic flight|
242497|NCT02518880|Other|plasma volume measurements|
242498|NCT02518893|Other|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
242499|NCT00181584|Drug|Zoledronic acid|Given intravenously once.
242500|NCT02518893|Other|Interview|Up to 30 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
242501|NCT02518906|Behavioral|Adolescent Identity Treatment|
241577|NCT00183456|Behavioral|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
241578|NCT02534753|Drug|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
241579|NCT02534779|Other|Placebo Vaginal Insert|Placebo insert
241580|NCT02534792|Other|Revalvulation|
241581|NCT02534818|Drug|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
241582|NCT02534818|Drug|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
241583|NCT02534831|Procedure|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
241584|NCT02537249|Drug|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
241585|NCT02537262|Dietary Supplement|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM~MN) the day before the surgery and 200ml three hours before the surgery.
241586|NCT02537262|Dietary Supplement|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
241587|NCT02537275|Device|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
241588|NCT00183638|Behavioral|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
241589|NCT02537275|Device|EyeLIKe Shine, Koryo Eyetech Co|clear lens
241590|NCT02537288|Drug|Fedovapagon|
241591|NCT02537288|Drug|Moxifloxacin|
241887|NCT02530203|Device|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
241888|NCT02530203|Device|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
241258|NCT02502266|Drug|Olaparib|Given PO
241259|NCT02502266|Drug|Paclitaxel|Given IV
241260|NCT02502266|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
241261|NCT02502266|Other|Questionnaire Administration|Ancillary studies
241262|NCT02502266|Drug|Topotecan Hydrochloride|Given IV
241263|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
241264|NCT02502279|Device|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
241265|NCT02502279|Device|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
241266|NCT02502292|Behavioral|Fotonovela|Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.
The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet.
241267|NCT02502305|Behavioral|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
241268|NCT02502318|Procedure|Video-thoracoscopy|
241269|NCT02502318|Procedure|thoracotomy|
241270|NCT02502331|Biological|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
241271|NCT00179348|Procedure|Yoga|Undergo a yoga-based rehabilitation program
241272|NCT02504424|Device|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
241273|NCT02504437|Biological|BMMSCs|
241274|NCT02504450|Drug|Adasuve|Inhaled medication to treat acute agitation in the emergency department
241275|NCT02504450|Drug|Alternative medications|Medication given to treat acute agitation in the emergency department
240634|NCT02515955|Drug|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
240635|NCT02515955|Drug|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
240636|NCT02515968|Drug|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
240966|NCT00179933|Behavioral|Newborn Individualized Assessment Program|
240967|NCT02509208|Device|SurgiClot haemostatic dressing|haemostatic dressing
240968|NCT02509234|Drug|Combined chemotherapy with trabectedin followed by irinotecan|Day 1:
Trabectedin 1,1 - 1,5 mg/m²/day i.v.
Day 3-5 and 10-12:
Irinotecan 30- 90 mg/m²/day p.o. or i.v.
240969|NCT02509247|Device|Telemonitoring|Wireless telemonitoring
240970|NCT02509260|Device|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
240971|NCT02509273|Drug|Clonidine|
240972|NCT02509273|Drug|Midazolam|
240973|NCT02509286|Drug|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
240974|NCT02509286|Drug|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
240975|NCT02509286|Drug|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
240976|NCT02509286|Drug|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
240977|NCT00179946|Procedure|HLA typing|
240978|NCT02509286|Drug|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
240979|NCT02509286|Drug|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
240980|NCT02509286|Radiation|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
240981|NCT02509299|Other|Physiotherapy program 1|the standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include daily resistance lower limbs exercises.
240982|NCT02509299|Other|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included daily controlled breathing exercises and active mobilization.
240345|NCT02522520|Behavioral|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
240346|NCT02522520|Behavioral|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
240347|NCT02522520|Device|Omron Walking Style pro. 20|
240348|NCT02522533|Other|Physical Therapy|6 weeks of an exercise program.
240349|NCT02522546|Other|nasopharyngeal swab|nasopharyngeal swab
240350|NCT02522559|Other|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
240351|NCT02522572|Drug|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
240352|NCT02522572|Drug|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
240637|NCT02515968|Drug|Propofol|
240638|NCT00180882|Drug|rituximab|
240639|NCT02515981|Behavioral|NH Medicaid Incentives Program|
240640|NCT02516020|Drug|Global|Embryos are cultured in single step culture from day 1 to day 5
240641|NCT02516020|Drug|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
240642|NCT02516046|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451. Some subjects may receive a second injection after 6 months have passed since the first injection.
240643|NCT02516059|Drug|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
240644|NCT02516059|Drug|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
240645|NCT02516059|Drug|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
240646|NCT02516059|Device|epidural catheter|
240647|NCT02516072|Other|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
240648|NCT02516085|Drug|Metformin|
240649|NCT00180895|Drug|Rituximab|
240041|NCT02527187|Biological|T502|The subjects will receive 4 doses of T502 in different concentrations.
240042|NCT00182663|Drug|dexamethasone|Given PO
240043|NCT02527187|Other|Histamine dihydrochloride|The subjects will receive 1 dose for positive control
240044|NCT02527187|Other|Glycerinated phenol saline solution|The subjects will receive 1 dose for negative control
240045|NCT02527200|Drug|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
240046|NCT02527200|Drug|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
240047|NCT02529423|Behavioral|Behavioral Activation|21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood‐related snacking) and helpful food‐related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.
240048|NCT02529423|Other|Placebo|Placebo pills identical in look and taste but including no active ingredients
240049|NCT02529449|Drug|Placebo|Oral
240050|NCT02529449|Drug|ASP1941|Oral
240051|NCT02529462|Genetic|NEUROPHARMAGEN|NEUROPHARMAGEN is a genetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs.
240052|NCT00182806|Drug|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
240353|NCT02522572|Other|plasmapheresis|Plasmapheresis will be administered based on group assignment.
240354|NCT02522585|Other|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
240355|NCT00182091|Drug|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
240356|NCT02522598|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
240357|NCT02522598|Drug|Placebo|water for injection
240358|NCT02522611|Drug|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
239738|NCT00183391|Drug|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
239739|NCT02533908|Drug|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
239740|NCT02533908|Drug|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
239741|NCT02533921|Other|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
239742|NCT02533921|Other|Standard of Care|Usual care defined as including both a PCP and neurologist
239743|NCT02533934|Drug|Harvoni|Treatment of Hepatitis C with Harvoni
239744|NCT02533947|Behavioral|Exercise|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
239745|NCT02533960|Other|not applicable (observational study)|Observational study without study related intervention.
239746|NCT02533973|Drug|Xamiol® gel|
239747|NCT02533973|Drug|Daivonex® scalp solution|
239748|NCT02533986|Dietary Supplement|Berry peel drink|
239749|NCT00002496|Drug|chemotherapy|
239750|NCT00183404|Drug|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
239751|NCT02533986|Dietary Supplement|Control drink|
239752|NCT02533999|Device|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
239753|NCT02536313|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857(400/100/100 mg) FDC tablet administered orally once daily with food
239754|NCT02536313|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
239755|NCT02536326|Device|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
239756|NCT02536339|Drug|Pertuzumab|Participants will receive an 840-mg loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
239152|NCT02437669|Drug|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
239153|NCT02437708|Procedure|REP with L-PRF|
239154|NCT00002461|Procedure|peripheral blood stem cell transplantation|
239155|NCT00169221|Radiation|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
239156|NCT02440061|Drug|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4 hours.
239157|NCT02440074|Other|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
239158|NCT02440087|Dietary Supplement|Refill Bypass|Dietary supplement
239446|NCT02432742|Device|Restylane|Intradermal injection
239447|NCT02432755|Behavioral|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
239448|NCT02432755|Behavioral|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
239449|NCT02432755|Behavioral|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
239450|NCT02432768|Drug|Triheptanoin|Anaplerotic dietary oil
239451|NCT02432768|Other|Placebo oil|Safflower oil
239452|NCT02432781|Dietary Supplement|Carbohydrate-rich drink|
239453|NCT02432781|Dietary Supplement|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
239454|NCT02432794|Procedure|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
243877|NCT02515045|Drug|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
243878|NCT02515045|Drug|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
243879|NCT02515045|Drug|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
243880|NCT02515045|Drug|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
243881|NCT02515058|Device|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
243882|NCT02515058|Device|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
243883|NCT02515071|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
243884|NCT02515071|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
239159|NCT02440100|Drug|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
239160|NCT02440100|Drug|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
239161|NCT02440100|Drug|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
239162|NCT02440113|Device|Nellix|Nellix Implantation
239163|NCT02440139|Device|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
239164|NCT02440152|Device|PINS® DBS System|
239165|NCT02440165|Behavioral|Nursing nutrition intervention|The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:
Information and advice;
Examples of energy and protein rich meals;
patients will be asked to register their nutritional intake for two days at home;
after a week, the nurse will call the patients to answer questions and to give advice.
This nutrition care plan will be tailored to the individual patient requirements.
Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care.
239166|NCT00169234|Biological|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
243593|NCT02521649|Drug|G17DT|
243594|NCT02521662|Drug|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
243595|NCT02521662|Device|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
243596|NCT02521662|Drug|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
243597|NCT00002494|Drug|cyclophosphamide|
243598|NCT00181987|Drug|methylphenidate HCl (Concerta)|
243599|NCT02521662|Behavioral|Behavioural support|Withdrawal-oriented behavioural support
243600|NCT02521675|Behavioral|Usual algorithm|The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey
The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :
Moderate activity 3 hours after lunch
Intense activity 3 hours after lunch
Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible
243601|NCT02521675|Behavioral|Diabrasport algorithm|The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey
The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week "test algorithms usual" and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:
Moderate activity 3 hours after lunch
Intense activity 3 hours after lunch
Moderate activity 90min after lunch These activities shall not exceed one hour
243602|NCT02521675|Behavioral|Rest|The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.
The patient goes home and he will not perform any physical activity during the week
243603|NCT02521675|Device|Holter Glycemic Ipro2, Medtronic|
243885|NCT02517203|Other|sensorimotor performance|
243886|NCT02517203|Other|Parabolic flight|
243887|NCT02517216|Other|parabolic flight|
243888|NCT02517216|Device|MRI|
243889|NCT02517229|Other|Parabolic flight|
243890|NCT02517229|Other|balance control measurements|
243891|NCT02517229|Device|electromagnetic maneuverable postural platform|
243892|NCT02517242|Device|Pens Device|
243893|NCT02517242|Device|Syringe|
243315|NCT02526212|Behavioral|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
243316|NCT02526212|Behavioral|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
243317|NCT02526212|Drug|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
243318|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection|5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
243319|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection simulation|5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
243320|NCT02528357|Drug|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to <=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
243321|NCT02528357|Drug|Pembrolizumab|Pembrolizumab as 100 mg/4 mL solution or as 50 mg lyophilized powder reconstituted to a dose of 200 mg to be given as IV infusion for 30 min, Q3W
243322|NCT02528370|Device|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
243323|NCT02528383|Behavioral|Vagifem|Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:
Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.
Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.
Impact of treatment on quality of life
243324|NCT02528396|Drug|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
243325|NCT02528396|Drug|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
243326|NCT00182767|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
243327|NCT02528409|Drug|Vortioxetine|Medication currently approved for major depression.
243328|NCT02528409|Drug|Placebo|
243329|NCT02528422|Drug|Acyl-Ghrelin|
243330|NCT02528448|Drug|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
255501|NCT02260661|Drug|AZD8835|AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
255502|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
255503|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
255504|NCT02260674|Drug|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
255505|NCT00000339|Drug|Risperidone|
255506|NCT00002360|Drug|Didanosine|
255507|NCT00146900|Procedure|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
255508|NCT02260674|Drug|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
255509|NCT02260674|Drug|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
255510|NCT02260687|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
255511|NCT02260700|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
255512|NCT02260700|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
255513|NCT02260700|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
255514|NCT02260713|Biological|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
255515|NCT02260726|Procedure|Magnetic resonance imaging|
255516|NCT02260726|Procedure|Ultrasound|
255517|NCT02260739|Other|Blood samples|
255518|NCT00146900|Drug|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
254903|NCT02275104|Device|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
255210|NCT02267785|Other|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
255211|NCT02267785|Other|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
255212|NCT02267798|Other|conventional therapy|The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.
The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors.
255213|NCT02267798|Device|arm training combined with FES|Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.
Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles.
255214|NCT02267811|Other|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
255215|NCT02267811|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
255216|NCT02267824|Device|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
255217|NCT02267824|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
255218|NCT02267837|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
255219|NCT00147836|Drug|Human Insulin (Novolin-R, Novo Nordisk)|
254572|NCT02243657|Drug|ASP3652|oral
254573|NCT02243657|Drug|Placebo|oral
254574|NCT02243670|Device|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
254575|NCT02243683|Drug|AX-024.HCl|
254576|NCT02243683|Other|Placebo|
254577|NCT02243709|Drug|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
254578|NCT02243735|Drug|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
254904|NCT02275104|Device|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
254905|NCT02275104|Device|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
254906|NCT02275104|Procedure|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
254907|NCT02275117|Biological|ALD403|
254908|NCT02275117|Biological|Placebo|
254909|NCT02275130|Procedure|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
254910|NCT00148551|Drug|Triamcinolone Acetonide|
254911|NCT02275130|Device|Radiesse Voice (Calcium Hydroxyapatite)|
254912|NCT02275143|Radiation|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
254913|NCT02275156|Biological|Evolocumab|Administered by subcutaneous injection
254914|NCT02275169|Drug|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
259337|NCT02482077|Drug|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
259338|NCT02482077|Drug|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
259339|NCT00000368|Behavioral|Cognitive behavior therapy|
259340|NCT00002476|Biological|bleomycin sulfate|
259341|NCT00176462|Drug|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
259342|NCT02482077|Drug|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
259343|NCT02482090|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
259344|NCT02482090|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
254579|NCT00144807|Procedure|autologous stem cell transplantation|
254580|NCT02243735|Drug|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
254581|NCT02243748|Other|Palliative Therapy|Receive individualized palliative care
254582|NCT02243748|Other|quality-of-life assessment|Ancillary studies
254583|NCT02243748|Other|questionnaire administration|Ancillary studies
254584|NCT02243761|Other|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
254585|NCT02243774|Behavioral|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
254586|NCT02243774|Behavioral|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
254587|NCT02243774|Behavioral|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
258747|NCT02493127|Other|Grip Strength|Research Assistant takes Grip Strength Measurements
258748|NCT02493127|Other|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
258749|NCT02493140|Dietary Supplement|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
258750|NCT02493140|Dietary Supplement|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
258751|NCT00177567|Drug|mirtazapine|
258752|NCT02493153|Procedure|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
258753|NCT02493166|Other|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
258754|NCT02493179|Drug|Serodase 5 mg|Serodase 5mg two tablets three times per day
258755|NCT02493179|Drug|Placebo|Placebo two tablets three times per day
258756|NCT02493192|Drug|pethidine and haloperidol injection|
258757|NCT02493192|Other|birth ball|
258758|NCT02493218|Behavioral|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
258759|NCT02493218|Behavioral|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
258760|NCT02493231|Drug|Nefopam|
259048|NCT02486640|Device|Betaconnect Autoinjector|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.
259049|NCT02486653|Drug|Tamsulosin|Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.
Outline of schedule:
Day 1-7: tamsulosin 0.4mg in the evening
Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol
Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.
259050|NCT02486653|Drug|Placebo|Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.
Outline of schedule:
Day 1-7: placebo in the evening
Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol
Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.
242502|NCT02518906|Behavioral|Dialectic Behavioral Treatment for Adolescents|
242503|NCT02518919|Other|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
242504|NCT02518919|Other|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
242505|NCT02518932|Drug|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
242506|NCT02518932|Drug|placebo saline|
242507|NCT02518945|Drug|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
242508|NCT02518945|Drug|Insulin|
242509|NCT02518945|Drug|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
242510|NCT00181584|Other|Placebo|Given intravenously once.
242511|NCT02518945|Drug|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
242512|NCT02518958|Drug|RRx-001|
242513|NCT02518958|Drug|Nivolumab|
242514|NCT02518971|Drug|Tamsulosin|0.4 mg daily
242515|NCT02521220|Dietary Supplement|L-citrulline|
242516|NCT00181909|Behavioral|Smoking cessation counseling delivered by telephone|
242517|NCT02521220|Dietary Supplement|Placebo|
242518|NCT02521233|Drug|Candesartan + Chlorthalidone (8mg+12,5mg)|
242519|NCT02521233|Drug|Candesartan + Chlorthalidone (8 mg + 25 mg)|
242520|NCT02521233|Drug|losartan+hydrochlorothiazide|
242840|NCT02514538|Drug|Non- effervescent Paracetamol kern|1g
242841|NCT02514538|Drug|Effervescent paracetamol termalgin|1 g
242842|NCT02514551|Drug|Ramucirumab|Administered IV
242843|NCT02514551|Drug|Paclitaxel|Administered IV
241889|NCT02530216|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized "education prescription" which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS "fingerprint."
241890|NCT02530242|Device|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
241891|NCT00182962|Behavioral|Geriatric Resources for Assessment & Care of Elders (GRACE)|
241892|NCT02530242|Device|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
241893|NCT02530255|Dietary Supplement|cycloastragenol|Oral telomerase activator - cycloastragenol.
241894|NCT02530255|Dietary Supplement|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
241895|NCT02530281|Drug|DRM04 Topical Wipes|Topical wipes containing DRM04
241896|NCT02530281|Other|Placebo|Placebo (vehicle) wipes, do not contain DRM04
241897|NCT02530294|Drug|DRM04 Topical Wipes|Topical wipes containing DRM04
241898|NCT02530294|Other|Placebo|Placebo (vehicle) wipes, do not contain DRM04
241899|NCT02530307|Drug|HT-3951|
241900|NCT02530307|Drug|Placebo|
241901|NCT02530320|Drug|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
241902|NCT00182975|Drug|DHEA replacement|
241903|NCT02532400|Drug|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w*6, Epirubicin 75mg/m2, d1, q3w*6 and Cyclophosphamide: 500mg/m2, d1, q3w*6
241904|NCT02532413|Drug|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
241905|NCT02532413|Drug|Entecavir|Entecavir can inhibit the replication of HBV.
241906|NCT02532426|Procedure|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
242200|NCT02525627|Device|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
242201|NCT02525627|Device|Symax stem|Orthopaedic implant
241276|NCT02504463|Drug|Samidorphan IV|Single IV administration
241277|NCT02504463|Drug|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
241592|NCT02537288|Drug|Placebo (for fedovapagon)|
241593|NCT02537301|Other|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
241594|NCT02537314|Drug|benzocaine|
241595|NCT02537314|Other|placebo|
241596|NCT02537353|Device|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
241597|NCT02537353|Drug|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
241598|NCT02537353|Procedure|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
241599|NCT00183651|Behavioral|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
241600|NCT02537353|Drug|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
241601|NCT02537366|Drug|Dexmedetomidine|
241602|NCT02537366|Drug|Placebo|
241603|NCT02537379|Drug|SOF|SOF 400 mg tablets administered orally once daily
241604|NCT02537379|Drug|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
241605|NCT02537392|Dietary Supplement|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
241606|NCT02537392|Dietary Supplement|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
241607|NCT02537392|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid.
241608|NCT02537405|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
240983|NCT02509299|Drug|Standard medical treatment|The standard medical treatment consists on:
Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).
Glucocorticoids:
Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.
- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β‐lactamase inhibitor and fluoroquinolones.
240984|NCT02509312|Drug|Ketorolac|Patients in experimental arm will receive ketorolac at time of cord clamp and then for 3 more doses every 6 hours
240985|NCT02511509|Device|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
241278|NCT02504463|Drug|[14c]-Samidorphan oral|Single oral administration containing radiolabel
241279|NCT02504476|Drug|AMG 581|Active drug
241280|NCT02504476|Drug|Placebo|Placebo
241281|NCT02504476|Drug|Midazolam|Interaction
241282|NCT00179374|Behavioral|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
241283|NCT02504489|Drug|Docetaxel + Plinabulin (DP)|Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
241284|NCT02504489|Drug|Docetaxel (D)|Docetaxel 75 mg/m2 IV
241285|NCT02504502|Other|Enhanced Genomic Report|Routine clinical care vs. enhanced genomic report
241286|NCT02504502|Other|Routine Clinical Care|Participants will receive routine clinical care. After 6 months the participants will also receive the enhanced genomic report.
241287|NCT02504515|Other|World Health Organization Quality of Life Bref Questionnaire|The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.
The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials.
241288|NCT02504528|Other|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
241289|NCT02504541|Drug|Testosterone enanthate auto-injector|Dose Adjustment 100 mg / 75 mg / 50 mg
241290|NCT02504554|Drug|oral Vancomycin|an antibiotic
241291|NCT02504554|Drug|MoviPrep|a bowel cleanse
241292|NCT02504554|Drug|Prilosec|a stomach acid suppressan
241293|NCT00179374|Behavioral|Print educational intervention|diabetes educational materials by mail
240650|NCT02516085|Drug|L-Arginine|
240651|NCT02516098|Drug|hyoscine butylbromide|
240652|NCT02516111|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
240653|NCT02516111|Biological|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
240654|NCT02516111|Drug|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
240655|NCT02516111|Drug|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
240656|NCT02516124|Procedure|Autologous HSCT|1st AHSCT
240657|NCT02516137|Procedure|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
240986|NCT02511509|Device|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
240987|NCT02511522|Other|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
240988|NCT02511522|Radiation|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
240989|NCT02511535|Biological|TBE booster vaccination|
240990|NCT02511548|Other|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
240991|NCT02511561|Drug|OTO-201 (ciprofloxacin)|
240992|NCT00180284|Device|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
240993|NCT02511574|Drug|natural progesterone|
240994|NCT02511574|Device|cervical pessary|
240995|NCT02511587|Biological|FSME-Immune vaccination|booster vaccination with FSME-Immune
240996|NCT02511600|Other|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
240997|NCT02511600|Other|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
240359|NCT02522624|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
240360|NCT02522637|Other|Exercise training|The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. (2008). Each training session will begin with three minutes of warm-up and cool-down with a low load.
At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each < 5 ).
The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%.
240361|NCT02522650|Drug|Amiloride|5mg twice a day for 8 weeks
240362|NCT02522650|Drug|Triamterene|50mg twice a day for 8 weeks
240363|NCT02522663|Other|24/7-telephone support|ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
240364|NCT02522676|Procedure|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
240365|NCT02522676|Procedure|Endoscopic kidney stone surgery|Mini PCNL will be performed.
240366|NCT00182091|Drug|Saline|To maintain study-subject blinding, doses were sham adjusted.
240367|NCT02522676|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
240368|NCT00182455|Drug|Placebo|25 - 400 mg/day x 12 weeks
240369|NCT02524938|Dietary Supplement|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
240370|NCT02524951|Drug|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
240371|NCT02524964|Drug|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
240658|NCT00181298|Drug|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
240659|NCT02518282|Other|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
240660|NCT02518282|Other|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
240661|NCT02518295|Other|Positive control|200ml milk containing 18g lactose
239757|NCT02536339|Drug|Trastuzumab|Participants will receive trastuzumab at a dose of 6 mg/kg once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
240053|NCT02529475|Drug|Gadoteric acid|Comparison with patients with Meniere's disease
240054|NCT02529488|Device|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
240055|NCT02529514|Drug|Baclofen|25 mg for 7 days at 10 pm every day
240056|NCT02529514|Drug|Placebo|Placebo for 7 days at 10 pm every day
240057|NCT02529527|Behavioral|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
240058|NCT02529540|Other|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
240059|NCT02529540|Other|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
240060|NCT02529540|Other|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
240061|NCT02529553|Drug|LY3076226|Administered IV
240062|NCT02529579|Other|iAPA-DC/CTL adoptive cellular immunotherapy|twice DC cell infusion and CTL cell infusion for 6 times
240063|NCT00182819|Drug|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
240064|NCT02529579|Drug|Gemcitabine|standard Gemcitabine therapy
240065|NCT02529592|Biological|Endotoxin|
240066|NCT02529592|Biological|Placebo|
240067|NCT02529605|Dietary Supplement|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
240068|NCT02529605|Dietary Supplement|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
240069|NCT02529618|Device|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
240070|NCT02531724|Drug|Placebo|Sodium chloride
240071|NCT00002495|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15
239455|NCT02432807|Drug|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
239456|NCT00168454|Drug|Placebo|Placebo (normal saline) injected into detrusor on Day 1
239457|NCT02432807|Drug|Placebo|Placebo
239458|NCT02432833|Drug|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
239459|NCT02432833|Drug|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
239460|NCT02435316|Other|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
239461|NCT02435316|Other|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
239462|NCT00168779|Drug|valsartan 160 mg / hydrochlorothiazide 25 mg|
239758|NCT02536352|Dietary Supplement|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 16-20 weeks gestation until delivery.
239759|NCT00183586|Behavioral|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
239760|NCT02536352|Dietary Supplement|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 16-20 weeks gestation until delivery.
239761|NCT02536365|Behavioral|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
239762|NCT02536365|Behavioral|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
239763|NCT02536391|Drug|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
239764|NCT02536391|Drug|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
239765|NCT02536404|Drug|APD334|
239766|NCT02536404|Drug|Placebo|
239767|NCT02536417|Drug|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
239768|NCT02536417|Drug|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
239167|NCT02440178|Drug|Micafungin|
239168|NCT02440191|Radiation|3DCRT|conventional radiotherapy
239169|NCT02440204|Procedure|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
239170|NCT02440204|Drug|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
239171|NCT02440204|Drug|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
239172|NCT02440230|Drug|OFS + Anastrozole|Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
Patients will take anastrozole 1mg qd.
239173|NCT02442440|Drug|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
239174|NCT02442453|Drug|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
239463|NCT02435329|Other|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
239464|NCT02435342|Drug|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
239465|NCT02435342|Drug|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
239466|NCT02435355|Behavioral|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
239467|NCT02435368|Drug|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
239468|NCT02435381|Drug|Carisbamate|600mg Orally on days 2-4
239469|NCT02435381|Drug|Placebo|Placebo treatment only
239470|NCT02435394|Behavioral|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
243894|NCT02517242|Other|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
243895|NCT00181116|Drug|Levetiracetam|
243896|NCT02517255|Device|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
243897|NCT02517268|Procedure|Pancreaticoduodenectomy|
243898|NCT02517281|Procedure|Biopsy|
243899|NCT02517294|Device|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
243900|NCT02517294|Device|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
243901|NCT02517307|Drug|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
243902|NCT02517307|Drug|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
243903|NCT02517307|Drug|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
243904|NCT02517320|Drug|MT-3995 Low|
243905|NCT02517320|Drug|MT-3995 Middle|
243906|NCT00181129|Behavioral|home based self paced walking program|
243907|NCT02517320|Drug|MT-3995 High|
243908|NCT02517320|Drug|Placebo|
239175|NCT02442453|Drug|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
239176|NCT02442466|Drug|Endothelin Receptor B inhibitor BQ788|
239177|NCT02442466|Drug|PBS|
239178|NCT02442479|Behavioral|resistance training|
239179|NCT02442492|Drug|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
239180|NCT02442492|Drug|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
243331|NCT02528448|Drug|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
243332|NCT02528461|Drug|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
243604|NCT02521688|Procedure|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
243605|NCT02521701|Drug|NFL101|Level 1: 100 µg
50 µg per injection (in each arm), two injections at day 1 and two injections at day 29
The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.
Level 2: 200 µg
100 µg per injection (in each arm), two injections at day 1 and two injections at day 29
The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL.
243606|NCT02521714|Drug|Lenalidomide|
243607|NCT02523911|Drug|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
243608|NCT02523924|Drug|18F-DCFPyL|18F-DCFPyL PET/CT
243609|NCT02523937|Other|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
243610|NCT02523950|Procedure|Staged phacoemulsification and DMEK|Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
Stage 2. DMEK is performed secondarily according to the corneal status of patients.
243611|NCT02523950|Procedure|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
243612|NCT02523950|Device|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
243613|NCT02523963|Other|family work shop|The family work shop has 5 courses, with 6 families in one course.
One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods
243614|NCT02523976|Drug|Dasatinib|Second-generation tyrosine kinase inhibitor
243615|NCT02523976|Drug|prednisone|
243616|NCT00182299|Procedure|porcine small intestine submucosa (SIS)|
243617|NCT02523976|Drug|cyclophosphamide|
243618|NCT02523976|Drug|daunorubicin|
243619|NCT02523976|Drug|vincristine|
255519|NCT02260752|Procedure|hysterectomy|surgical removal of the uterus
255844|NCT02253953|Drug|Ritonavir|
255845|NCT02253966|Drug|Methylprednisoloneacetate|
255846|NCT02256202|Other|Interview|Monitoring interviews to show medical and economic advantages of given therapy
255847|NCT02256215|Drug|Vitamin D|
255848|NCT02256228|Drug|Ropivacaine|Active Group
255849|NCT02256228|Drug|Saline|Placebo Comparator
255850|NCT02256254|Drug|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
255851|NCT02256254|Drug|Placebo|2 placebo capsules every evening for 14 days
255852|NCT02256267|Drug|LY2835219|Administered orally
255853|NCT02256267|Drug|Rifampin|Administered orally
255854|NCT02256280|Drug|Sugammadex|Sugammadex will be diluted in a saline water solution in a 10 mL syringe.
Administration will be according to the neuromuscular blockade:
If Post tetanic count = 1-15: 4 mg/kg
If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg
255855|NCT02256280|Drug|Neostigmine|Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.
Administration will be according to the neuromuscular blockade:
If Post tetanic count = 1-15: 0.07 mg/kg
If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage.
255856|NCT00146380|Drug|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum
ARVs continued for those that meet WHO treatment criteria
255857|NCT02256293|Behavioral|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
255858|NCT02256306|Other|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
255220|NCT02267850|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
255221|NCT02267850|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
255222|NCT02270281|Drug|Dexmedetomidine|CIF 0.3 and 0.6 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
255520|NCT02260752|Procedure|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
255521|NCT02260752|Procedure|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
255522|NCT02262988|Procedure|Autologous cells and total knee arthroplasty|
255523|NCT02262988|Procedure|Standard total knee arthroplasty surgery|
255524|NCT02263001|Other|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
255525|NCT02263001|Other|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
255526|NCT02263014|Behavioral|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
255527|NCT02263027|Biological|Vaccine|Licensed trivalent inactivated influenza vaccine
255528|NCT02263040|Biological|Fluzone High-Dose|Influenza vaccine
255529|NCT00147251|Drug|FDA approved drugs to treat blood pressure and cholesterol|
255530|NCT02263040|Biological|Fluzone (standard dose)|Influenza vaccine
255531|NCT02263053|Procedure|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
255532|NCT02263053|Procedure|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
255533|NCT02263066|Biological|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
255534|NCT02263079|Drug|Lamivudine|Lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100g), given alone for 8 weeks then in combination with Pegasys for 48 weeks
254915|NCT02275169|Other|Placebo|Placebo ampoules administered three times a week for three months
254916|NCT02275182|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
254917|NCT02275182|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
254918|NCT02275208|Procedure|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
254919|NCT02275234|Other|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
254920|NCT02275247|Drug|Stellate Ganglion Block|stellate ganglion block will be administered using either 8 mL saline (Group 1) or 0.25% ropivacaine 8mL (Group 2)
254921|NCT00148564|Drug|olanzapine|treatment with either Olanzapine or Ziprasidone
254922|NCT02275260|Device|Cerebral Diffusion-Weighted Magnetic Resonance Imaging|Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
255223|NCT00148005|Behavioral|Micturition clock|
255224|NCT02270294|Other|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
255225|NCT02270294|Other|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
255226|NCT02270307|Drug|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
255227|NCT02270307|Biological|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
255228|NCT02270320|Behavioral|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
255229|NCT02270333|Device|Inspiratory muscle training|Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).
The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.
The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
255230|NCT02270333|Device|Sham inspiratory muscle training|Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).
The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
254588|NCT02243774|Behavioral|Core letter signed by SG + enhanced implementation prompt|The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to "decide now" - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated.
254589|NCT02243787|Drug|COVA322|
254590|NCT00144820|Drug|Injection of Hyaluronan or Saline|
254591|NCT02243787|Other|Placebo|
254592|NCT02243800|Other|cholecalciferol versus placebo|
254593|NCT02246413|Behavioral|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
254594|NCT02246426|Other|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
254595|NCT02246426|Other|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
254923|NCT02238704|Dietary Supplement|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
254924|NCT02238717|Drug|PF-06372865 (65mg)|single oral dose (65 mg)
254925|NCT00144235|Drug|Placebo|
254926|NCT02238717|Drug|PF-06372865 (15mg)|single oral dose (15mg)
254927|NCT02238717|Drug|Pregabalin|single oral dose (300mg)
254928|NCT02238717|Drug|Placebo|matching oral placebo
254929|NCT02238730|Device|Ultrabrief Right Unilateral|The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
254930|NCT02238730|Device|Brief Pulse Bitemporal|The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
254931|NCT02238756|Biological|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
254932|NCT02238756|Biological|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
254933|NCT02238756|Biological|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
259051|NCT02486666|Drug|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES WITH THROMBOSIS (FiXET)
259052|NCT02486679|Drug|Prostin (PGE2) tablets|
259053|NCT02488590|Drug|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
259054|NCT02488590|Drug|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
259055|NCT00177021|Drug|Aldara Cream 5%|
259056|NCT02488590|Drug|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
259057|NCT02488590|Drug|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
259058|NCT02488590|Drug|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
259059|NCT02488603|Behavioral|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
259060|NCT02488603|Drug|tamoxifen|
259345|NCT02482090|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
259346|NCT02482090|Drug|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
259347|NCT02482103|Procedure|Renal denervation|Catheter based renal nerve ablation
259348|NCT02482116|Other|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
259349|NCT02482129|Drug|LME636 60 mg/mL ophthalmic solution|
259350|NCT00002476|Drug|methotrexate|
242844|NCT02514564|Behavioral|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
242845|NCT02514577|Drug|IDP-122 Lotion|
242846|NCT02514590|Device|Freedom SCS System - High Frequency|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 10kHz therapy.
242847|NCT02514590|Device|Freedom SCS System - Low Frequency|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 therapy.
242848|NCT02514603|Drug|LY2606368|Administered IV
242849|NCT02514616|Procedure|Laparoscopic IPG and lead implant procedure|EST placement
242850|NCT00180687|Drug|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
242851|NCT02514616|Device|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
242852|NCT02514616|Device|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
242853|NCT02514629|Drug|Placebo|
242854|NCT02514629|Drug|Metformin|
242855|NCT02514629|Drug|Testosterone Undecanoate|
242856|NCT02514629|Drug|Metformin + Testosterone Undecanoate|
242857|NCT02514642|Drug|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
242858|NCT02514642|Drug|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
242859|NCT02514655|Device|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
243159|NCT02507882|Biological|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
243160|NCT02509975|Device|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
243161|NCT00180037|Drug|Placebo|
242202|NCT02525627|Device|Accolade TMZF stem|Orthopaedic implant
242203|NCT02525640|Device|Hearing Aid|Hearing aid comparison
242204|NCT02525653|Drug|albumin-bound paclitaxel|
242205|NCT02525653|Drug|gemcitabine|
242206|NCT02525679|Drug|BI 655130|
242207|NCT00182559|Drug|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
242208|NCT02525679|Drug|Placebo|
242209|NCT02525692|Drug|ONC201|
242210|NCT02525705|Biological|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
242211|NCT02525718|Drug|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
242212|NCT02525718|Drug|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.
(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively.
242213|NCT02525744|Biological|LY900014|Administered SC
242214|NCT02525744|Biological|Insulin Lispro|Administered SC
242215|NCT02525757|Drug|MPDL3280A|1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.
Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.
Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation.
242216|NCT02525757|Drug|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
242217|NCT02525757|Drug|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
242218|NCT00182559|Drug|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
242219|NCT02525757|Radiation|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
242220|NCT02527993|Drug|Victoza (liraglutide)|Se arm description
242221|NCT02527993|Drug|Signifor (pasireotide)|Se arm description
241609|NCT02502331|Biological|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
241610|NCT02502344|Behavioral|healthy lifestyle|food control and intensive exercise to lose weight
241611|NCT02502344|Drug|Metformin|use metformin to reduce insulin resistance
241612|NCT00179023|Drug|Pseudoephedrine|30mg tablet,VO. Single dose.
241907|NCT02532439|Device|HR-pQCT|Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.
For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.
241908|NCT02532439|Device|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
241909|NCT02532452|Biological|Viral Specific CTL Infusion|3rd party donor derived CTL's will be infused into immunocompromised patients who have evidence of viral infection or reactivation defined as any of the following:
Blood adenovirus PCR ≥1,000
Blood CMV PCR ≥ 1,000
Blood EBV PCR ≥ 3,000
Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites.
Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis
Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven by biopsy or probable by an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation.
241910|NCT02532465|Device|Air-Q|
241911|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
241912|NCT02532465|Device|i-gel|
241913|NCT02532491|Drug|Aripiprazole|Initial dose: 10 mg.
241914|NCT02532491|Drug|Risperidone|Initial dose: 2 mg.
241915|NCT02532504|Other|CBT|8 sessions of CBT based intervention called "change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;
Five Areas vicious circle
Bad thought spotter
Amazing Bad thought Busting Programme (ABTPB)
Easy 4 Step plan
Things you do that mess you up/Confidence sheet
Happy List/ Things you do that boost how you feel sheet
Planner and Review sheets
241916|NCT02532530|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
241917|NCT02532543|Biological|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
241294|NCT02504554|Biological|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
241295|NCT02504554|Biological|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
241296|NCT02504567|Device|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
241297|NCT02506946|Other|There is no intervention|
241298|NCT02506959|Drug|Busulfan|Busulfan 32 mg/m2 by vein Test Dose before admission if outpatient, and Day -10 if inpatient. Busulfan AUC 4,000 by vein on Days -8 to -5.
241299|NCT02506959|Drug|Palifermin|60 microgram/kg by vein on Days -12, -11, -10, 0, +1 and +2, or -14, -13, -12, 0,+1 and +2.
241613|NCT02502357|Other|Healing Statements|Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:
"Following this operation, [the participant] will feel very comfortable and [the participant] will heal very well."
Toward the end of the surgery, the study staff member will say 5 times:
"The operation has gone very well." "Following the operation, [the participant] will be hungry. [The participant] will be thirsty and urinate easily."
241614|NCT02502370|Drug|observation alone|
241615|NCT02502370|Drug|LV5FU2|
241616|NCT02502370|Drug|FOLFOX|
241617|NCT02502383|Behavioral|ACTION PAC|Adolescents enrolled in ACTION PAC will meet with SBHC providers. SBHC providers will use Motivational Interviewing to motivate students to adopt strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI results discussion with providers. Overweight/Obese adolescents will meet with providers for 16 sessions over 2 years.
241618|NCT02502383|Behavioral|Comparison|Annual BMI results will not be discussed with participants in comparison schools; however, a letter containing BMI results and obesity prevention recommendations will be sent to parent/guardians.
241619|NCT02502396|Other|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to January 6, 2015 at MD Anderson Cancer Center in Houston, Texas.
241620|NCT02502409|Other|Standard care with blood and urine sample collection|
241621|NCT02502422|Device|Classic laryngeal mask airway|measurement of head and neck
Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip~sternal notch), modified mallampati classification under sitting position, thyromental distance.
laryngeal mask airway insertion and measuring cuff pressure by pressure transducer
# 4.0 for female, #5.0 for male
initial cuff volume(air) : maximum volume recommended by the manufacturer
check pressure : if it exceed 60cmH20, we will remove air until 60cmH20
remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured.
241622|NCT02502448|Procedure|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
240998|NCT02511600|Behavioral|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
240999|NCT02511613|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
241000|NCT02511613|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
241001|NCT02511613|Drug|ranibizumab|ranibizumab intravitreal injection
241002|NCT02511639|Drug|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
241003|NCT00180297|Device|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
241004|NCT02511639|Drug|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
241005|NCT02511652|Device|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
241006|NCT02511652|Device|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
241007|NCT02511652|Procedure|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
241300|NCT02506959|Drug|Panobinostat|Panobinostat 20 mg by mouth on Days -9 to -2.
241301|NCT02506959|Drug|Gemcitabine|Gemcitabine 1,875 mg/m2 by vein on Days -8 and -3.
241302|NCT00179699|Drug|CC-5013|
241303|NCT02506959|Drug|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
241304|NCT02506959|Drug|Dexamethasone acetate|Dexamethasone 8 mg by vein 2 times a day on Days -9 through Day -2.
241305|NCT02506959|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day from day -9 until discharge.
241306|NCT02506959|Drug|Glutamine|Glutamine 15 g four times a day, swished, gargled and spit started on day -9 until discharge.
241307|NCT02506959|Drug|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
241308|NCT02506959|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
241309|NCT02506972|Other|Classic Quaker Quick Oats|Various doses of oats without or with sugar
241310|NCT02506972|Other|Cream of Rice Cereal|Various doses of cereal without sugar
240662|NCT02518295|Other|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
240663|NCT02518295|Other|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
240664|NCT02518295|Other|Negative control|200 ml of UHT Lactose free milk
240665|NCT02518308|Behavioral|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
240666|NCT02518321|Device|Technology-Assisted Toileting|
240667|NCT02518334|Other|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
240668|NCT02518347|Dietary Supplement|FDS-Strawberry|Natural frozen and dried strawberries
240669|NCT00181311|Procedure|hysterectomy|
240670|NCT02518347|Dietary Supplement|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
240671|NCT02518360|Other|Osteopathic|Body adjustment in three sessions (20 minutes/session).
240672|NCT02518360|Other|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
240673|NCT02518373|Biological|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
240674|NCT02518373|Drug|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
240675|NCT02518386|Other|No intervention|No intervention is planned
240676|NCT02518399|Other|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
240677|NCT02518399|Other|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
241008|NCT02511665|Drug|Metformin|Given metformin
241009|NCT02511665|Radiation|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
241010|NCT02511665|Drug|Placebo|Given placebo
240072|NCT00183196|Drug|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
240073|NCT02531737|Drug|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
240074|NCT02531737|Drug|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
240372|NCT02524964|Other|control|equivalent volume of sodium chloride solution
240373|NCT02524977|Behavioral|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
240374|NCT02524977|Behavioral|Educational Intervention Only|Educational conference series
240375|NCT02524990|Behavioral|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
240376|NCT02525003|Dietary Supplement|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
240377|NCT02525003|Dietary Supplement|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
240378|NCT02525003|Other|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
240379|NCT00182468|Other|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
240380|NCT02525016|Biological|Blood sampling|
240381|NCT02525016|Drug|Lidocaine|
240382|NCT02525029|Drug|Pregnyl®|ARM 1: High-Risk aGVHD
Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for 4 doses through day 7:
If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.
If no response, the patient will be taken off study treatment
ARM 2: Steroid-Refractory aGVHD
Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for 7 doses through day 14:
If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.
If no response, the patient will be taken off study treatment
Doses for both arms:
Phase 1: up to 5 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.
Phase II: the dose of Pregnyl will be that identified as the MTD during phase I.
240383|NCT02525055|Biological|Infectious titre 1 (H3N2)|Infectious titre 1
240384|NCT02525055|Biological|Infectious titre 2 (H3N2)|Infectious titre 2
240385|NCT02525055|Biological|Infectious titre 3 (H3N2)|Infectious titre 3
240386|NCT02525055|Biological|Infectious titre 4 (H3N2)|Infectious titre 4
239769|NCT02536430|Drug|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
239770|NCT00183586|Behavioral|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
239771|NCT02536430|Drug|Placebo|buccal infiltration of Normal Saline.
239772|NCT02536469|Drug|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
239773|NCT02536482|Dietary Supplement|Amix|Treat the children with cow`s milk allergy for 5 months.
239774|NCT02536495|Drug|Docetaxel|Given IV
239775|NCT02536495|Other|Laboratory Biomarker Analysis|Correlative studies
239776|NCT02536495|Other|Pharmacological Study|Correlative studies
239777|NCT02536495|Drug|Selinexor|Given PO
239778|NCT02538835|Behavioral|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel & Segal.
239779|NCT00183846|Procedure|radiation therapy|
240075|NCT02531750|Other|Immobilization due to an Achilles tendon rupture|
240076|NCT02531763|Behavioral|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
240077|NCT02531776|Device|Subcutaneous insertions of needles|Various types of needles with different designs and mechanical properties.
Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson & Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).
Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.
Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.
No drugs are injected. Only the needle insertion is evaluated.
240078|NCT02531789|Other|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
240079|NCT02531802|Biological|ETVAX|Varying dosages of liquid ETVAX via the oral route administered on Day 0 and 14
240080|NCT02531802|Biological|dmLT|Varying dosages of dmLT via the oral route administered on Day 0 and 14
240081|NCT02531802|Other|Sodium Bicarbonate Buffer|bicarbonate buffer dissolved in 150 ml of potable water
239471|NCT02435394|Behavioral|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
239472|NCT02435394|Behavioral|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
239473|NCT00168779|Drug|placebo|
239474|NCT02435407|Behavioral|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
239475|NCT02435407|Other|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
239476|NCT02435420|Device|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
239477|NCT02435433|Drug|Ramucirumab|Administered IV
239478|NCT02435433|Drug|Placebo|Administered IV
239479|NCT02435446|Device|Cone-beam computed tomography|Cone-beam computed tomography
239480|NCT02435459|Procedure|No lining|No lining material placed under amalgam dental restorations
239481|NCT02437708|Procedure|REP|
239780|NCT02538835|Behavioral|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
239781|NCT02538848|Drug|HTD4010|injectable solution
239782|NCT02538861|Radiation|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
239783|NCT02538861|Radiation|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
239784|NCT02538861|Radiation|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
239785|NCT02538874|Drug|BMS-986171|
239786|NCT02538874|Other|Placebo|
239787|NCT02538887|Device|Radio Frequency Surgical Detection|
239181|NCT00169481|Biological|Pneumococcal (vaccine)|
239182|NCT02442505|Device|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
239183|NCT02442518|Procedure|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
239184|NCT02442531|Drug|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
239185|NCT02442544|Dietary Supplement|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
239186|NCT02442544|Dietary Supplement|Placebo|maltodextrin 3.3g orally/day
239187|NCT02442557|Biological|recombinant human alpha B-crystallin|intravenous injection
239188|NCT02442557|Other|placebo comparator|intravenous injection
239189|NCT02442570|Biological|recombinant human alpha B-crystallin|intravenous injections
239190|NCT02442570|Other|Placebo comparator|intravenous injection
239191|NCT02442583|Other|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
239192|NCT00169494|Biological|HPV-16/18 L1/AS04|
239193|NCT02442609|Other|questionaire|questionaire before surgery
239194|NCT02442622|Other|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
239482|NCT02437708|Biological|stem and progenitor cells|
239483|NCT02437721|Other|infant formula containing folic acid|
239484|NCT00002461|Drug|etoposide|
239485|NCT00169039|Drug|Clozapine|
239486|NCT02437721|Other|infant formula containing MTHF|
243620|NCT02523976|Drug|cytarabine|
243621|NCT02523976|Drug|mercaptopurine|
243622|NCT02523976|Drug|methotrexate|
243623|NCT02523976|Drug|dexamethasone|
243624|NCT02523976|Drug|mitoxantrone|
243909|NCT02517333|Other|EPIC Club|Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
243910|NCT02517346|Other|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
243911|NCT02517346|Other|Telemonitoring|Follow up by telemonitoring system during 3 months
243912|NCT02519465|Other|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 30l/min.
243913|NCT02519465|Other|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 50l/min.
243914|NCT02519478|Behavioral|Helmetless Tackling Training (HuTT)|see previous sections
243915|NCT00181636|Drug|Galantamine-CR|
243916|NCT02519491|Other|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
243917|NCT02519491|Other|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
243918|NCT02519517|Procedure|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
255859|NCT02256319|Drug|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
255860|NCT02256319|Drug|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
256152|NCT02249494|Other|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
256153|NCT02249494|Other|nutritional counseling|Performing routine nutritional counseling in their clinical practice
256154|NCT02249494|Device|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
256155|NCT02251717|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
256156|NCT02251730|Behavioral|Smoking cessation|Refer for smoking cessation
256157|NCT00145717|Drug|Plant sterol enriched milk tea|
256158|NCT02251743|Device|Neurofeedback treatment|Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:
The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)
Average voltage of theta waves
Average voltage of beta
Average ratio of theta to beta power (TBR)
256159|NCT02251756|Device|Actinica, 0.8 mg/cm2, 1 application|
256160|NCT02251756|Device|Actinica, 0.8 mg/cm2, 2 applications|
256161|NCT02251756|Device|Actinica, 2 mg/cm2, 1 application|
256162|NCT02251756|Device|Actinica, 2 mg/cm2, 2 applications|
256163|NCT02251769|Drug|Tipranavir|
256164|NCT02251769|Drug|Ritonavir|
256165|NCT02251769|Drug|Clarithromycin|
255535|NCT02263079|Drug|peginterferon alfa-2a [Pegasys]|Starting at Week 8, Pegasys administered subcutaneously once weekly for 48 weeks, with dosing based on body surface area
255536|NCT02263092|Behavioral|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
255861|NCT02256332|Dietary Supplement|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
255862|NCT02256332|Dietary Supplement|High dose plant based ingredient|Reference food with high dose of plant based ingredient
255863|NCT02256332|Dietary Supplement|Reference food format|Reference food without plant-based ingredient
255864|NCT02256345|Drug|Potassium Nitrate|
255865|NCT02256345|Drug|KCl|Placebo Comparator
255866|NCT02258451|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body
255867|NCT02258451|Drug|Placebo (saline)|Up to 6 cycles of saline injection
255868|NCT00146614|Procedure|Stem Cell Transplantation|
255869|NCT02258451|Drug|Exemestane|25 mg once daily with or without food Dosage and administration of exemestane must be in compliance with the local labels in each of the participating countries and in line with standard practice guidelines.
255870|NCT02258451|Drug|Everolimus|10 mg tablet once daily after a meal Dosage and administration of everolimus must be in compliance with the local labels in each of the participating countries and in line with standard practice guidelines.
255871|NCT02258464|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body
255872|NCT02258464|Drug|Placebo (saline)|Up to 6 cycles of saline injection
255873|NCT02258464|Other|Background hormonal therapy|Prescribed by PI and is provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
255874|NCT02258477|Dietary Supplement|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
255875|NCT02258477|Dietary Supplement|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
255876|NCT02258477|Dietary Supplement|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
255231|NCT02270346|Device|Inspiratory muscle training|Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).
The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.
The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
255232|NCT02270346|Device|Sham inspiratory muscle training|Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.
The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
255233|NCT02270359|Device|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
255234|NCT00148018|Drug|Bortezomib|
255235|NCT02270359|Procedure|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
255236|NCT02270359|Drug|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
255237|NCT02270372|Biological|ONT-10, Varlilumab combination|ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.
Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27.
255238|NCT02270385|Behavioral|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
255537|NCT02263092|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
255538|NCT02263092|Behavioral|Rest|15 or 30 minutes seat without move the legs
255539|NCT02263105|Drug|CDDP|
255540|NCT00147264|Drug|Telmisartan (Micardis®) vs. Placebo|
255541|NCT02265523|Other|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
255542|NCT02265536|Drug|LY3022855|Administered IV.
255543|NCT02265562|Drug|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
255544|NCT02265562|Drug|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
254934|NCT02238769|Device|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
254935|NCT02238782|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
254936|NCT00144248|Drug|nevirapine|
254937|NCT02238782|Other|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of [14C] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
254938|NCT02238808|Drug|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 14 days pre-surgery.
254939|NCT02238834|Drug|FP-025|Subjects will receive single doses of 200 to up to 2000 mg of FP-025 (capsule) in a dose escalation format.
254940|NCT02238834|Drug|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
254941|NCT02238834|Drug|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
254942|NCT02238834|Drug|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
254943|NCT02238847|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
254944|NCT02238860|Drug|Entacavir|Entacavir-0.5 mg ,OD,for
255239|NCT02270385|Behavioral|Usual PU prevention care|Usual PU prevention care including is a series of basic nursing care activities including repositioning of residents, moisturization , change of napkins to keep buttock dry.
255240|NCT02270398|Behavioral|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
255241|NCT02272647|Drug|IM Saline Placebo (0.25 ml)|
255242|NCT02272647|Drug|IM Estradiol valerate (2.5 mg)|
255243|NCT02272647|Drug|IM Saline Placebo (0.5 ml)|
255244|NCT02272647|Drug|IM Estradiol valerate (5.0 mg)|
255245|NCT02272647|Drug|Oral Micronized Progesterone|
255246|NCT00148278|Drug|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
255247|NCT02272647|Drug|Oral Placebo|
259351|NCT00176618|Drug|sulindac|Sulindac 150 mg po BID
259352|NCT02484235|Other|Strength|Group training with strength exercises 3 times per week during 10 sessions
259353|NCT02484248|Drug|Ketotifen|Ketotifen is a anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
259354|NCT02484248|Drug|Placebo|
259355|NCT02484261|Drug|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
259356|NCT02484261|Drug|Pravastatin|10 mg for age < 8 years, 20 mg for age 8-<13 years, 40 mg for ages >14 years
259357|NCT02484274|Biological|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
259358|NCT02484287|Device|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
259359|NCT02484287|Device|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
259360|NCT02484287|Device|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
259361|NCT02484300|Dietary Supplement|Melatonin|
259362|NCT00176618|Drug|curcumin|Curcumin 250 mg po BID
259363|NCT02484300|Other|Placebo|
259364|NCT02484313|Other|dietary treatments|commercially available food products
254596|NCT02246439|Drug|RHB-102|RHB-102, Bimodal Release Ondasetron Tablets
254597|NCT02246465|Drug|RXI-109|
254598|NCT02246478|Drug|TAS-205|Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals
Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals
254599|NCT02246478|Drug|Placebo|Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals
Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals
243162|NCT02509988|Dietary Supplement|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
243163|NCT02509988|Dietary Supplement|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
243164|NCT02510001|Drug|Crizotinib|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
243165|NCT02510001|Drug|PD-0325901|
243166|NCT02510014|Drug|SUBOXONE sublingual film|Suboxone sublingual film used for induction therapy. Participants to take sublingual film for 4-14 days at doses from 8mg-24mg
243167|NCT02510014|Drug|high dose RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose can be adjusted to low dose based on the medical judgment of the Investigator
243168|NCT02510014|Drug|low dose RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose can be adjusted to high dose based on the medical judgment of the Investigator
243169|NCT02510027|Other|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
243170|NCT02510040|Device|Prism|Ground-in or Fresnel prism
243171|NCT02510040|Other|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
243172|NCT00180050|Drug|Budesonide|
243173|NCT02510040|Procedure|Eye Muscle Surgery|Bilateral medial rectus muscle resection surgery
Single medial rectus muscle resection surgery
Recess lateral rectus muscle resection medial rectus muscle surgery
Bilateral lateral rectus muscle recession surgery
Single lateral rectus muscle recession surgery
Bilateral lateral rectus muscle resection surgery
Single lateral rectus muscle resection surgery
Recess medial rectus muscle resection lateral rectus muscle surgery
Bilateral medial rectus muscle recession surgery
Single medial rectus muscle recession surgery
Vertical rectus muscle recession surgery
Vertical rectus muscle mini-tenotomy (snip) surgery
243174|NCT02510040|Procedure|Botox Injection|Botulinum toxin injection
243175|NCT02510053|Drug|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
243176|NCT02510066|Device|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
242521|NCT02521246|Drug|Candesartan + Chlorthalidone|
242522|NCT02521246|Drug|Candesartan + Chlorthalidone|
242523|NCT02521246|Drug|Losartan+hydrochlorothiazide|
242524|NCT02521259|Device|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
242525|NCT02521272|Other|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
242526|NCT02521272|Device|air pocket|Zero air pocket or one-liter air pocket in the snow.
242527|NCT00181922|Drug|ziprasidone (Geodon)|
242528|NCT02521285|Drug|Aspirin|Given PO
242529|NCT02521285|Other|Laboratory Biomarker Analysis|Correlative studies
242530|NCT02521285|Other|Placebo|Given PO
242531|NCT02521285|Other|Questionnaire Administration|Ancillary studies
242532|NCT02521298|Other|Strength Training|
242533|NCT02521298|Procedure|Placebo|
242534|NCT02521298|Drug|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
242535|NCT02521298|Procedure|Dry Needling|
242536|NCT02521311|Drug|Clemastine|12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
242537|NCT02521311|Drug|Placebo|Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
242538|NCT00181935|Drug|risperidone (Risperdal)|
242539|NCT02521324|Device|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
242540|NCT02521337|Other|observation|observation
242541|NCT02521363|Device|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for ~24 hours.
241918|NCT02532543|Biological|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
241919|NCT02532543|Biological|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
241920|NCT02532543|Biological|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
241921|NCT02534844|Drug|VTS-270|Lumber intrathecal infusion of VTS-270 (dose to be selected after Part A)
241922|NCT02534844|Drug|Sham Procedure Control|No experimental drug administered to patients. All intrathecal administrations are simulated.
242222|NCT02527993|Device|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
242223|NCT02527993|Dietary Supplement|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
242224|NCT02528006|Device|Type 2 Thyroplasty using Titanium Bridges|
242225|NCT02528019|Drug|DPP-4 inhibiotors|
242226|NCT02528019|Drug|SGLT2 inhibitors|
242227|NCT00182728|Radiation|radiation therapy|intraoperative
242228|NCT02528019|Drug|Glimepiride|
242229|NCT02528032|Other|Echographic evaluation of heart function|Echocardiographic data collection and analysis, not fully exploited at present
242230|NCT02528045|Procedure|Vitrectomy with scleral shortening|
242231|NCT02528058|Procedure|Vitrectomy with internal limiting membrane peeling|
242232|NCT02528071|Other|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
242233|NCT02528084|Procedure|yoga|patients watch and follow an online yoga video.
242234|NCT02528084|Procedure|standard exercises|patients watch and follow an online standard exercises video.
242235|NCT02528097|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
242236|NCT02528097|Drug|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline)
241623|NCT00002487|Drug|dipyridamole|
241624|NCT00179062|Drug|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
241625|NCT02502448|Drug|hydroxyethyl starch (HES 130/0.6)|
241626|NCT02502461|Procedure|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
241627|NCT02502474|Other|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
241628|NCT02502487|Procedure|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
241629|NCT02504567|Device|RF ablation|Pulmonary vein isolation using the RF ablation catheter
241630|NCT02504580|Drug|HTX-011-19|
241923|NCT02534857|Procedure|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
241924|NCT02534870|Drug|ABT-450/r/ABT-267|Tablet
241925|NCT00183456|Behavioral|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
241926|NCT02534870|Drug|ABT-333|Tablet
241927|NCT02534883|Drug|Misoprostol|To be place vaginally
241928|NCT02534883|Drug|Placebo|
241929|NCT02534896|Drug|Nanocort 75 mg|Nanocort 75 mg + Placebo
241930|NCT02534896|Drug|Nanocort 150 mg|Nanocort 150 mg +Placebo
241931|NCT02534896|Drug|Depo Medrol|Depo Medrol + Placebo
241932|NCT02534909|Biological|LFG316|LFG316 will be administered to all patients enrolled in the study
241933|NCT02534922|Biological|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
241934|NCT02534935|Biological|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
241935|NCT02534935|Biological|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
241311|NCT02506985|Drug|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
241312|NCT02506985|Drug|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
241313|NCT00179699|Drug|pemetrexed|
241314|NCT02506998|Biological|DLE|Adjuvant treatment
241315|NCT02506998|Other|Second generation anti histamines + Nasal corticosteroids|Standard treatment
241316|NCT02507011|Drug|carvedilol|
241317|NCT02507011|Drug|Placebo|
241318|NCT02507024|Other|Online questionnaire|
241319|NCT02507037|Dietary Supplement|gum+PEG|chew sugarless gum
241320|NCT02507037|Drug|polyethylene glycol|2L PEG
241321|NCT02507050|Drug|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
241322|NCT02507063|Procedure|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
241323|NCT02507076|Drug|isolated limb perfusion|Undergo ILP with melphalan
241324|NCT00179712|Drug|CC-5013|
241631|NCT02504580|Drug|Placebo|
241632|NCT02504593|Device|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
241633|NCT02504606|Drug|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
241634|NCT02504606|Drug|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
241635|NCT02504619|Biological|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
241636|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Psycho-educational group
241011|NCT02513823|Dietary Supplement|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
241012|NCT02513836|Other|no intervention|
241013|NCT02513849|Drug|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
241014|NCT02513862|Device|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
241015|NCT02513875|Dietary Supplement|vitamin D|60,000 IU per week for 8 weeks
241016|NCT02513875|Dietary Supplement|Placebo|placebo +diet and lifestyle
241017|NCT02513888|Dietary Supplement|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
241018|NCT00180622|Procedure|Induced Sputum|
241019|NCT02513888|Dietary Supplement|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
241020|NCT02513901|Drug|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
241021|NCT02513914|Procedure|Dural Venous Sinus Stenting|See Dural Venous Sinus Stenting arm.
241022|NCT02513914|Procedure|Cerebrospinal Fluid Shunting|See Cerebrospinal Fluid Shunting arm.
241023|NCT02513927|Drug|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
241024|NCT02513927|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
241025|NCT02513940|Drug|Testosterone|
241026|NCT02513940|Drug|Progesterone|
241027|NCT02513940|Drug|Placebo|
241028|NCT02513940|Drug|Ibutilide|Following 7 days of testosterone, progesterone and placebo (in 3 different phases), subjects will come to the Clinical Research Center and receive ibutilide 0.003 mg/kg intravenously as a single dose. QT interval response to ibutilide will be determined
241029|NCT00180622|Procedure|CT Scan|
241030|NCT02513953|Procedure|Laparoscopic|Four Port Laparoscopic cystectomy
241325|NCT02507076|Drug|melphalan|Undergo ILP with melphalan
240387|NCT02525068|Drug|AZD5363|Until confirmed disease progression.
240388|NCT02525068|Drug|Enzalutamide|Until confirmed disease progression.
240389|NCT02525081|Drug|Ramipril (ACE-inhibitor)|up to 10 mg
240390|NCT00182481|Procedure|Induced sputum cell counts|
240391|NCT02525081|Drug|placebo|up to 10 mg
240678|NCT02518412|Other|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
240679|NCT02518412|Other|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
240680|NCT00181350|Device|Relocatable fixation system|
240681|NCT02520479|Drug|P-CHOP|Two "consolidation" cycles of P-CHOP are given after radiotherapy
240682|NCT02520492|Device|noninvasive method of ICP measurements (Elios)|
240683|NCT02520505|Drug|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
240684|NCT02520505|Behavioral|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
240685|NCT02520505|Procedure|Intrauterine Insemination|Intrauterine insemination will be performed ~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
240686|NCT02520518|Drug|Dapagliflozin|
240687|NCT02520518|Drug|Placebo|
240688|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
240689|NCT02520518|Behavioral|Weight maintenance|
240690|NCT02520518|Behavioral|Ad libitum dietary intake|
240691|NCT02520518|Behavioral|Dietary restriction|
240692|NCT02520531|Device|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
240693|NCT02520531|Device|Scorpio NRG PS|Implantation of total knee prosthesis
240694|NCT02520544|Device|Accolade stem|Total hip replacement
240082|NCT02531815|Biological|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
240083|NCT00183196|Other|Inactive Placebo|Placebo
240084|NCT02531815|Drug|Placebo|Placebo for PF-06741086, single dose
240085|NCT02531828|Device|Application of dressings for surgical correction.|Dressing for surgical correction
240086|NCT02531828|Device|POLYSHAFT®|
240087|NCT02531841|Drug|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):
Rituximab 375 mg/m²/d i.v. (d0)
Dexamethasone 40 mg/d i.v. (d1-3)
Etoposide 100 mg/m²/d i.v. (d1-3)
Ifosfamide 1500 mg/m²/d i.v. (d1-3)
Carboplatin 300 mg/m² i.v. (d1)
240088|NCT02531841|Drug|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4) Consolidation
High-dose chemotherapy (HDT-ASCT):
Carmustine* 400 mg/m² i.v. (d-6)
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
* if carmustine is not available at the investigation site, busulfan can be administered instead:
Busulfan 3,2 mg/kg/d (d-8-(-7))
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
240089|NCT02531854|Drug|ADXS11-001|
240090|NCT02533999|Device|Electrocautery|Surgical method for tonsillectomy and adenoidectomy.
240392|NCT02527213|Drug|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
240393|NCT02527213|Drug|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
240394|NCT02527226|Behavioral|Facial exercises|A series of self-administered facial movements and expressions.
240395|NCT02527239|Other|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
240396|NCT02527252|Other|Craniosacral therapy|
240397|NCT02527252|Other|Classic Massage|
240398|NCT00182689|Drug|sorafenib tosylate|Given orally
240399|NCT02527265|Drug|Insulin human SAR439065|Pharmaceutical form:powder
Route of administration: inhalation
240400|NCT02527278|Procedure|Laparoscopic tubal ligation|Female permanent birth control method performed via a surgical procedure
239788|NCT02538900|Behavioral|Exercise|Participants randomized to low-intensity exercise will be advised to walk at a low, self-paced intensity that feels comfortable, maintaining a leg pain level of < 2 on the 1-5 Likert claudication pain scale, where '1' indicates no pain and '5' indicates maximum, severe pain. Participants randomized to high-intensity exercise will be asked to maintain a pain level of 4-5 on the 1-5 Likert pain scale. These participants are told that to benefit from exercise training they must exercise at a level inducing moderate to high levels of ischemic pain. Both groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
239789|NCT02538900|Other|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
239790|NCT00183859|Drug|irinotecan|Intraperitoneal Irinotecan given every three weeks
239791|NCT02538913|Behavioral|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
239792|NCT02538913|Procedure|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
239793|NCT02538926|Drug|Asparaginase|Given IM or IV
239794|NCT02538926|Drug|Cyclophosphamide|Given IV
239795|NCT02538926|Drug|Doxorubicin Hydrochloride|Given IV
239796|NCT02538926|Drug|Etoposide|Given IV
239797|NCT02538926|Drug|Imatinib Mesylate|Given PO
239798|NCT02538926|Other|Laboratory Biomarker Analysis|Correlative studies
240091|NCT02534012|Drug|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
240092|NCT02534012|Drug|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
240093|NCT02534012|Procedure|Major abdominal surgery|
240094|NCT02534025|Procedure|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
239487|NCT02437734|Procedure|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
239488|NCT02437747|Drug|SRP + Aloe|Scaling and root planing along with aloe vera application was done
239489|NCT02437747|Procedure|SRP|Scaling and root planing was done
239490|NCT02437760|Other|serum and pleural effusion CA-125 level|serum and pleural effusion(if exist) CA-125 are collected:
at time of diagnosis
every 3 month during treatment
stop at the progression or after 12 months
239491|NCT02437773|Behavioral|Cognitive Behavioral Therapy|A therapy which gradually yet repeatedly exposes patients to their obsessive compulsive-relevant "error" cues during a task performance until their anxiety habituates.
239492|NCT02437773|Behavioral|Stress Management Therapy|An active control therapy with minimal effects on OCD symptoms.
239493|NCT02437773|Behavioral|Optional CBT|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
239494|NCT02437786|Drug|GRAZAX|GRAZAX
239495|NCT02437799|Other|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
239496|NCT00169039|Drug|Chlorpromazine|
239497|NCT02437812|Drug|Metformin|Metformin with standard chemotherapy
239498|NCT02437812|Drug|Paclitaxel|Standard chemotherapy
239499|NCT02437812|Drug|Carboplatin|Standard chemotherapy
239500|NCT02437825|Drug|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
239501|NCT02437825|Other|placebo|placebo ( saline) act as comperator in this study.
239502|NCT02437838|Other|No Intervention|No Intervention
239503|NCT02437851|Procedure|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
239504|NCT02437864|Device|Supplemental oxygen via nasal cannula|
239799|NCT02538926|Drug|Prednisone|Given PO
239800|NCT02503852|Procedure|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
243919|NCT02519530|Behavioral|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
243920|NCT02519543|Drug|Placebo|placebo to be given twice daily, once with breakfast and once with supper
243921|NCT02519543|Drug|Metformin|active experimental drug to be given twice a day, 500 mg with breakfast and 1,000 mg with supper.
243922|NCT02519556|Drug|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
239195|NCT02445131|Drug|CAL-101|Induction: Cycle 2-6: d1-28: 150 mg p.o.
Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o.
239196|NCT02445157|Other|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
239197|NCT02445170|Procedure|Amputation|Transmetatarsal or below-knee amputation
239198|NCT02445183|Other|None, N/A|
239199|NCT02445196|Behavioral|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
239200|NCT02445196|Device|Smartphone|All participants must have a smartphone, either apple or android.
239201|NCT02445209|Other|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
239202|NCT02445209|Other|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
239203|NCT02445222|Genetic|Previously treated CART CD 19 patients|Lentiviral-based CD19 directed CART cell therapy
239204|NCT00169793|Other|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
239205|NCT02445235|Other|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
239206|NCT02445248|Genetic|CTL019|Single arm
239207|NCT02445261|Radiation|mobile phone|Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
239208|NCT02445274|Procedure|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
256166|NCT02251769|Other|High-Fat Test Meal|
256167|NCT02251782|Device|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
256168|NCT00145730|Drug|Ibuprofen|
256478|NCT02244632|Drug|Oxaliplatin|85 mg/m2 infusion on day 1 of each 14-day cycle. 4 cycles in total.
256479|NCT02244632|Drug|Irinotecan|180 mg/m2 infusion on day 1 of each 14-day cycle. 4 cycles in total.
256480|NCT02244645|Behavioral|passive modality|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
256481|NCT02244645|Behavioral|Yoga treatment|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
256482|NCT02244658|Drug|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
256483|NCT02244671|Procedure|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
256484|NCT02244671|Drug|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
256485|NCT00002343|Drug|Ethambutol hydrochloride|
256486|NCT00144911|Drug|Fluticasone Propionate/Salmeterol Combination Product|
256487|NCT02247089|Other|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
256488|NCT02247102|Dietary Supplement|Isomaltulose|Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.
Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg).
256489|NCT02247102|Dietary Supplement|Sucrose|Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.
Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg).
256490|NCT02247128|Drug|Aspirin + clopidogrel|
256491|NCT02247128|Drug|Aspirin monotherapy|
256492|NCT02247128|Drug|OAC + clopicogrel|
256493|NCT02247128|Drug|OAC monotherapy|
255877|NCT02258477|Dietary Supplement|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
255878|NCT02258490|Biological|G-CSF mobilized CD34+ selected cells for transplantation|Mobilization of Donor: Following screening and enrollment after informed consent, the donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using the standard National Marrow Donor Program (NMDP) guidelines.
CD34+ selection with CliniMACS device: CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs). If the donor's plasma is not available, CliniMACS buffer will be used.
The Day of CD34+ cell infusion: Immediately after the release tests have been performed and the product passes the release criteria, the patient will receive the final product. No conditioning regimen will be administered prior to cell infusion.
255879|NCT00146627|Drug|Eflornithine|
255880|NCT02258503|Other|pain in elderly patients|
256169|NCT02251782|Device|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
256170|NCT02251795|Drug|Tipranavir|
256171|NCT02251795|Drug|Ritonavir|
256172|NCT02251795|Drug|Darunavir|
256173|NCT02251795|Drug|Aspirin|single dose on day 2
256174|NCT02251821|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
256175|NCT02251821|Drug|Busulfan|Given IV
256176|NCT02251821|Drug|Cyclophosphamide|Given IV
256177|NCT02251821|Drug|Enzyme Inhibitor Therapy|Receive JAK-2 inhibitor
256178|NCT02251821|Drug|Fludarabine Phosphate|Given IV
256179|NCT02253966|Drug|Lidocaine|
256180|NCT02253966|Other|sodium chloride|
256181|NCT02253979|Device|Standard double lumen tube|Endotracheal left side double lumen tube
256182|NCT02253979|Device|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
256183|NCT02253992|Biological|Urelumab|
255545|NCT02265575|Drug|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
255546|NCT00147537|Drug|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
255547|NCT02265588|Behavioral|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
255548|NCT02265601|Other|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
255549|NCT02265601|Other|standard care|paper/pencil living will form
255550|NCT02265614|Genetic|PGS|
255551|NCT02265627|Drug|BIIL 284 BS|
255552|NCT02265640|Drug|BIIL 284 BS boli|
255553|NCT02265640|Drug|BIIL 284 BS tablet C|
255554|NCT02265640|Other|standard breakfast|
255555|NCT02265653|Drug|BIIL 284 BS tablet C|
255556|NCT02265653|Drug|BIIL 284 BS tablet D|
255881|NCT02258516|Behavioral|CHIME 3-M|behavioral intervention for self-management in heart failure
255882|NCT02258516|Behavioral|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
255883|NCT02258529|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
255884|NCT02258529|Biological|Rituximab|Rituximab administered intravenously according to prescribing information
255885|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
255886|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
255887|NCT02258555|Drug|GS-9901|GS-9901 tablets administered orally
255888|NCT02258568|Behavioral|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
255889|NCT02260752|Drug|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
255248|NCT02272647|Drug|Ghrelin (0.3 ug/kg)|
255249|NCT02272647|Drug|Medroxyprogesterone - Acetate|
255250|NCT02272647|Drug|Oral Placebo|(in lieu of Medroxyprogesterone)
255251|NCT02272660|Drug|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
255252|NCT02272660|Drug|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
255253|NCT02272673|Dietary Supplement|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
255254|NCT02272686|Drug|Ibrutinib|560 mg by mouth daily.
255255|NCT02272699|Drug|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
255256|NCT02272699|Drug|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
255257|NCT00148291|Drug|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
255258|NCT02272699|Drug|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
255259|NCT02272699|Radiation|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
255260|NCT02272699|Procedure|Surgery|Esophagectomy
255557|NCT00147537|Drug|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
255558|NCT02265653|Drug|BIIL 284 BS WIF tablet|
255559|NCT02265666|Drug|BIIL 284 BS Tablet FF|
255560|NCT02265666|Drug|BIIL 284 BS tablet C|
255561|NCT02265666|Other|standard breakfast|
255562|NCT02265679|Drug|BIIL 284 BS, low dose, pediatric patients|
255563|NCT02265679|Drug|BIIL 284 BS, medium dose, pediatric patients|
254600|NCT02246491|Other|with gene correction|
254601|NCT02246491|Other|without gene correction|
254602|NCT02246504|Device|HIFU treatment|
254603|NCT00145106|Drug|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
254604|NCT02246517|Drug|N2O|
254605|NCT02246517|Drug|Oxygen|
254606|NCT02246530|Procedure|PRP injection into PTRCT|Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.
PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug.
254607|NCT02246530|Drug|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
254608|NCT02246543|Dietary Supplement|Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
254609|NCT02246543|Dietary Supplement|HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
254610|NCT02246543|Dietary Supplement|LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
254611|NCT02246543|Dietary Supplement|HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
254612|NCT02246543|Dietary Supplement|LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
254613|NCT02246556|Device|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
254614|NCT00145132|Procedure|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
254615|NCT02246556|Other|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
254945|NCT02238860|Drug|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
254946|NCT02238873|Drug|Pegfilgrastim|
254947|NCT00144261|Drug|nevirapine|
254948|NCT02238886|Dietary Supplement|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
243434|NCT02503150|Drug|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
243435|NCT02505425|Behavioral|Behavioral Support|ENABLE CHF-PC includes:
In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.
Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.
The PNC uses the manualized curriculum: "Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families".
Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
243436|NCT02505425|Behavioral|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
243437|NCT02505438|Behavioral|Exercise|
243438|NCT02505451|Drug|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
243439|NCT02505477|Drug|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
243440|NCT02505477|Other|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
243441|NCT02505490|Other|Television|The purpose is to determine whether television impacts liking of food.
243442|NCT00179491|Behavioral|Intercessory Prayer|14 days of intercessory prayer from 3 sites
243443|NCT02505490|Other|No Television|The purpose is to determine whether the lack of television impacts liking of food.
243444|NCT02505503|Device|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
243445|NCT02505503|Device|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
243446|NCT02505516|Other|metformin|
243447|NCT02505529|Other|Resistance Exercise Training|Behavioral interventions of resistance exercise
242542|NCT02521363|Drug|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
242543|NCT02523391|Drug|TA-8995|Tablet
242860|NCT02516839|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
242861|NCT02516839|Behavioral|Behavioral Weight Loss (BWL)|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
242862|NCT02516839|Behavioral|BWL + ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.
242863|NCT02516839|Behavioral|Nutrition Education|In order to equate for contact time received by participants in the other three intervention arms, the AC will be matched on number of meetings and incentive components. Topics included will be stress management/relaxation, social support, and nutrition education.
242864|NCT02516852|Other|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
242865|NCT02516852|Behavioral|Community nutrition education|Establishment of a behavior change communication campaign (nutrition education) promoting healthy maternal, infant, and young child diets and eating behaviors
242866|NCT02516865|Device|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
242867|NCT00181025|Drug|Melphalan|
242868|NCT02516865|Device|Ankle weights|Worn during typical daily activities.
242869|NCT02516878|Procedure|Acupuncture|Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.
Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated.
242870|NCT02516891|Device|Drug-Eluting Stents implantation in bifurcation lesions|
242871|NCT02516904|Drug|CD101 IV|antifungal
242237|NCT02528110|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
242238|NCT00182741|Dietary Supplement|calcitriol|
242239|NCT02528110|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
242240|NCT02528110|Other|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
242241|NCT02528110|Other|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
242242|NCT02528123|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
242544|NCT02523404|Procedure|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
242545|NCT02523417|Procedure|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
242546|NCT02523430|Procedure|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
242547|NCT02523443|Other|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
242548|NCT02523443|Other|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
242549|NCT02523456|Behavioral|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
242550|NCT02523456|Behavioral|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
242551|NCT00182247|Procedure|venogram|
242552|NCT02523469|Biological|ALT-803|ALT-803: The starting dose level for ALT-803 is 6 microgram (µg)/kilogram (kg); the second dose level is 10 µg/kg; and the third dose level is 15 µg/kg. ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles.
During week 6, no treatment will be administered.
242553|NCT02523469|Biological|Nivolumab|Nivolumab: The dose level for Nivolumab is 3 mg/kg. Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).
After 4 cycles, patients will be treated with Nivolumab alone following the same schedule.
During week 6, no treatment will be administered.
241936|NCT00183469|Drug|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
241937|NCT02534948|Behavioral|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
241938|NCT02534961|Drug|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
241939|NCT02534974|Device|NOSTEN|
241940|NCT02534987|Other|iCPR2|clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
241941|NCT02535000|Drug|Duloxetine|duloxetine 60 mg
241942|NCT02535000|Drug|Placebo|placebo
242243|NCT02528123|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
242244|NCT02528123|Drug|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
242245|NCT02530333|Other|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
242246|NCT02530346|Drug|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
242247|NCT02530346|Drug|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
242248|NCT02530359|Drug|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
242249|NCT02530359|Drug|Placebo equivalent|Placebo equivalent per mouth
242250|NCT02530372|Device|UriCap-F|non-invasive urine collection device for women
242251|NCT02530385|Other|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
241637|NCT02504632|Other|test|Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.
The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.
Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates.
241638|NCT02504632|Other|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
241639|NCT02504645|Drug|IPP-201101|
241640|NCT02504645|Drug|Placebo|
241641|NCT02504645|Other|Standard of Care|
241642|NCT02504658|Behavioral|Lifestyle text messages|Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional "goal status update message" on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status ("still working on it" or "completed it"). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website.
241643|NCT02504658|Behavioral|Attention Control Group|Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK "A Guide for Teenagers: Take Charge of Your Health!" to take home to read over.
241644|NCT02504671|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
241645|NCT02504671|Drug|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
241646|NCT02504671|Drug|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
241943|NCT02535013|Device|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
241944|NCT02537405|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
241945|NCT00183651|Behavioral|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
241946|NCT02537418|Drug|durvalumab|
241947|NCT02537418|Drug|tremelimumab|
241948|NCT02537431|Biological|KRN23|KRN23 is a recombinant human immunoglobulin G isotype 1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
241326|NCT02509312|Drug|Epidural Morphine|All patients, including those in both the experimental and control groups, in this study will receive epidural morphine prior to removal of epidural catheter as part of routine obstetric care for cesarean delivery.
241327|NCT02509312|Drug|Hydromorphone|Post-operatively all patients patients will have intravenous hydromorphone on an as needed basis to control their pain, as part of routine obstetric care for cesarean delivery.
241328|NCT02509325|Device|Parkinson's Kinetigraph|
241329|NCT00179959|Drug|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
241330|NCT02509338|Device|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
241331|NCT02509351|Drug|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
241332|NCT02509351|Drug|placeboo|women will recive 2 identical tablets as placeboo
241333|NCT02509364|Other|No intervention|
241334|NCT02509377|Procedure|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
241335|NCT02509390|Procedure|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
241336|NCT02509403|Drug|Essential oils infused Perineal Hygiene wipe|Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
241337|NCT02509429|Device|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
241338|NCT02509429|Device|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
241339|NCT02509442|Procedure|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
241340|NCT00179959|Drug|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
241341|NCT02509468|Drug|Sirolimus|each patient will be followed during a 12-month-period
each patient will start by an observational period and end being treated by sirolimus
at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period
241342|NCT02509481|Drug|Ivermectin|
241343|NCT02509481|Drug|Albendazole|
240695|NCT02520544|Device|Accolade II stem|Total hip replacement
240696|NCT02520544|Device|Trident/Tritanium cup|Total hip replacement
240697|NCT02520557|Other|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
240698|NCT02520570|Drug|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
240699|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
240700|NCT02520583|Dietary Supplement|Lactic acid bacteria and bifidobacteria|
240701|NCT02520583|Other|Placebo|
241031|NCT02513979|Drug|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
241032|NCT02513992|Procedure|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
241033|NCT02513992|Drug|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
241034|NCT02513992|Device|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
241035|NCT02513992|Device|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
241036|NCT02514005|Other|Manual therapy|- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
241037|NCT02516137|Procedure|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
241038|NCT02516137|Procedure|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
241039|NCT00180908|Drug|Etoposide, Ifosfamide, Methotrexate|
241040|NCT02516137|Other|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
240401|NCT02527278|Procedure|Hysteroscopic sterilization|Female permanent birth control method performed via placement of a device
240402|NCT02527291|Other|Blood test|Blood test for CMV PCR and IL28
240403|NCT02527304|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
240404|NCT02527304|Other|Quality-of-Life Assessment|Ancillary studies
240405|NCT02527304|Other|Questionnaire Administration|Ancillary studies
240406|NCT02527304|Radiation|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
240407|NCT02527317|Drug|Lipegfilgrastim|Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
240408|NCT02527330|Other|MR T2* imaging|Cardiac magnetic resonance imaging with T2* imaging
240409|NCT00182702|Drug|ixabepilone|Given IV
240410|NCT02527343|Drug|volanesorsen|
240411|NCT02527343|Drug|Placebo|
240412|NCT02527356|Behavioral|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-mintue break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
240702|NCT02520596|Other|Bioavailability of Raspberry polyphenols|
240703|NCT02520622|Behavioral|Digital photographs loaded onto a mobile device|
240704|NCT02520622|Behavioral|Skin exam reminders|
240705|NCT02520622|Behavioral|Social support network|
240706|NCT02520635|Drug|supra-early TEMODAL® chemotherapy|
240707|NCT02520635|Drug|standard TEMODAL® chemotherapy|
240708|NCT02520635|Radiation|Radiotherapy 60Gy|
240709|NCT02520648|Other|Soft treatment|The physical therapist is situated to the patient's left and applies three soft touches from the transverse apophysis of D1 to the transverse apophysis of D12.
240710|NCT02522676|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
240095|NCT02534038|Drug|AVP-786|d6-DM/Q
240096|NCT02534038|Drug|Placebo|matching placebo
240097|NCT02534051|Other|Clinical Care Pathway|The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth & well-being, counselling about birth risks, and discussion of breastfeeding, intrapartum: consideration of venous thromboembolism prophylaxis is suggested and if a cesarean, higher levels of antibiotics (e.g. 3 gm Ancef), and postpartum: advice re OGTT if GDM, encouragement of a healthy weight and folic acid 1 mg preconception and appropriate contraception.
240098|NCT00183417|Behavioral|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
240099|NCT02534064|Dietary Supplement|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
240100|NCT02534064|Dietary Supplement|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
240101|NCT02534077|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
240102|NCT02534077|Drug|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
240103|NCT02534077|Drug|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
240104|NCT02534116|Procedure|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
240413|NCT02527356|Behavioral|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
240414|NCT02529618|Device|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
240415|NCT02529618|Device|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
239801|NCT02503852|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
239802|NCT02503865|Drug|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
239803|NCT02503865|Dietary Supplement|"Analimentary detoxication"|Vegetable and salt diet
239804|NCT02503878|Device|Masimo Sedline brain function monitors|Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of "sedation" based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing
239805|NCT02503891|Device|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
239806|NCT00179257|Drug|sertraline (Zoloft)|
239807|NCT02503904|Procedure|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
239808|NCT02503904|Device|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
239809|NCT02503904|Drug|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
239810|NCT02503930|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
239811|NCT02503930|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
239812|NCT02503943|Drug|"Liraglutide" and "Mitiglinide"|"Liraglutide"(1.2mg/d) and "Mitiglinide" (50mg, 3/d)
239813|NCT02503943|Drug|"Metformin" and "Mitiglinide"|"Metformin"(500mg, 3/d) and "Mitiglinide"(50mg, 3/d)
239814|NCT02503943|Drug|"Mitiglinide"|"Mitiglinide" (50mg, 3/d)
239815|NCT02503956|Device|Perforated Punctal plugs|Perforated punctal plugs
239816|NCT02503956|Procedure|Crawford tube insertion|
239817|NCT00179283|Drug|sertraline|
239818|NCT02503956|Device|Crawford lacrimal tube|
239819|NCT02503969|Other|Exposure to having a long-term condition.|Long-term conditions are self-reported: twelve named conditions are recorded, along with an "other" condition - these shall all be considered with the exception of the named condition "cancer".
239209|NCT02445300|Other|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
239210|NCT02445300|Other|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
239211|NCT02445313|Device|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
239212|NCT02445326|Drug|OTX-DP treatment|
239213|NCT02445326|Device|Placebo Plug with no drug|
239505|NCT02437890|Biological|ALX-0061|
239506|NCT02437890|Biological|Placebo|
239507|NCT00169052|Behavioral|Health Care Management and Supported Rehabilitation|
239508|NCT02440230|Drug|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
239509|NCT02440243|Drug|Purethal|prerseasonal course of SCIT - three years
239510|NCT02440243|Drug|Purethal -placebo|preseasonal course of SCIT - three years
239511|NCT02440256|Other|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
239512|NCT00169234|Biological|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
239513|NCT02440295|Procedure|Lower Extremity Amputation|
256494|NCT02247141|Biological|Subgam® (Human Normal Immunoglobulin Solution)|
256495|NCT02247154|Biological|Vigam® (Human Normal Immunoglobulin)|
256496|NCT00145249|Drug|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
256497|NCT02247167|Procedure|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
256498|NCT02247180|Behavioral|cognitive rehabilitation|
256499|NCT02247180|Behavioral|standardized cognitive training|
256500|NCT02247193|Drug|Botulinum Toxin Type A|Injection of toxin at the time of surgery at cleft lip repair site
256824|NCT02239744|Behavioral|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
256825|NCT02239757|Procedure|Left radial approach|Primary PCI performed through left radial approach.
256826|NCT02239757|Procedure|Right radial approach|Primary PCI performed through right radial approach.
256827|NCT02239770|Drug|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
256828|NCT00144339|Drug|placebo|
256829|NCT02242019|Device|Erchonia LUNULA|
256830|NCT02242032|Drug|P-321 Ophthalmic Solution|
256831|NCT02242032|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
256832|NCT02242045|Drug|Idelalisib|Idelalisib tablet administered orally
256833|NCT02242058|Other|Quantitative sensory testing|
256834|NCT02242071|Biological|Stem Cell|
256835|NCT02242084|Drug|Intravenuse Alteplase|
256184|NCT02253992|Biological|Nivolumab|
256185|NCT02254005|Drug|bivatuzumab mertansine|
256186|NCT00146081|Behavioral|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
256187|NCT02254018|Drug|bivatuzumab mertansine|
256188|NCT02254031|Drug|bivatuzumab mertansine|
256189|NCT02254044|Drug|bivatuzumab mertansine|
256190|NCT02254057|Drug|BIBT 986 BS - single rising dose|
256191|NCT02254057|Drug|Placebo|
256501|NCT02247193|Drug|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair.
256502|NCT02247206|Behavioral|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
256503|NCT02247219|Behavioral|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
256504|NCT02247232|Drug|Z-100|
256505|NCT02247232|Drug|Placebo|
256506|NCT02247245|Drug|Ivabradine|Ivabradine 7.5mg
256507|NCT00145249|Drug|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
256508|NCT02247245|Other|Atrial fibrillation|Pacemaker base rate alteration
256509|NCT02247258|Drug|Azathioprine|See arm/group descriptions
256510|NCT02247258|Drug|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
256511|NCT02247258|Procedure|Ileocolonoscopy|See arm/group descriptions
256512|NCT02247258|Procedure|Small bowel follow trough|See arm/group descriptions
255890|NCT02260752|Procedure|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
255891|NCT02260752|Procedure|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
255892|NCT02260752|Procedure|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
255893|NCT02260765|Device|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
255894|NCT02260778|Behavioral|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
255895|NCT02260791|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
255896|NCT00146900|Other|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
255897|NCT02260791|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
255898|NCT02260804|Biological|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
255899|NCT02260804|Biological|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
256192|NCT02254070|Drug|BIBT 986 BS|
256193|NCT02254083|Drug|BIBT 986 BS - low|
256194|NCT02254083|Drug|BIBT 986 BS - high|
256195|NCT02254083|Drug|Placebo|
256196|NCT02254096|Drug|BIRT 1696 BS|
256197|NCT00000338|Drug|Lisuride|
256198|NCT00002352|Drug|Lobucavir|
256199|NCT00146094|Procedure|BMD Measurement|
256200|NCT02254096|Drug|Placebo|
256201|NCT02254096|Other|Grapefruit juice (GFJ)|
256202|NCT02254096|Other|High fat meal (HFM)|
251777|NCT02263976|Drug|Spiriva|
251778|NCT02263989|Drug|Telmisartan film coated tablet|
251779|NCT02263989|Drug|Telmisartan conventional tablet|
251780|NCT02264002|Drug|Cilobradine low dose 1|
251781|NCT02264002|Drug|Cilobradine low dose 2|
251782|NCT02264002|Drug|Cilobradine medium dose|
251783|NCT00147368|Drug|intravenous (IV) arginine|
251784|NCT02264002|Drug|Cilobradine high dose 1|
252083|NCT02257008|Drug|Ritonavir|
252084|NCT02257021|Drug|BILR 355 BS|
252085|NCT02257021|Drug|Tipranavir|
252086|NCT02257021|Drug|Low dose of ritonavir|
252087|NCT02257021|Drug|High dose of ritonavir|
252088|NCT02257034|Other|Taichi|
252089|NCT02257034|Other|Dance|
252090|NCT00146523|Drug|placebo|
252091|NCT02257047|Dietary Supplement|Tea|
252092|NCT02257047|Dietary Supplement|RYR|red yeast rice
252093|NCT02257060|Procedure|Endocardial Ablation|
252094|NCT02257073|Behavioral|Cognitive-behavioral treatment|
252095|NCT02257073|Behavioral|Waiting List|
252096|NCT02257112|Device|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
252097|NCT00146731|Drug|SP + amodiaquine|
252098|NCT02259348|Drug|Fludarabine|Given IV
252099|NCT02259348|Biological|G-CSF|Given IV or subcutaneously (SQ)
251428|NCT02268851|Drug|TGR-1202|Capsules taken whole daily with water and with food
251429|NCT02268851|Drug|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
251430|NCT02268864|Drug|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
251431|NCT02268864|Drug|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
251432|NCT02268877|Other|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
251433|NCT02268877|Device|Ultrasound|
251434|NCT02268890|Drug|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
251435|NCT02268903|Drug|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
251436|NCT02268903|Drug|Placebo|Placebo in one single direct intra venous injection
251437|NCT00147875|Drug|Doxorubicin (Adriamycin)|
251438|NCT02268916|Behavioral|Counseling|OT led counseling
251439|NCT02268916|Behavioral|Usual education|Usual diabetes lifestyle education
251440|NCT02268929|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
251441|NCT02268929|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
251442|NCT02268942|Device|HeartWare HVAD|
251443|NCT02271100|Device|palpation guidance|use of palpation for position estimation
251444|NCT02271113|Drug|GMI-1271|
251445|NCT02271113|Drug|Placebo|
251785|NCT02264002|Drug|Cilobradine high dose 2|
251786|NCT02264002|Drug|Metoprolol succinate tablets|
251787|NCT02264002|Drug|Placebo|
251788|NCT02264015|Drug|Cilobradine, low, film-coated tablets|
251789|NCT02264015|Drug|Cilobradine, high, film-coated tablets|
250833|NCT02204475|Drug|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
251121|NCT00139659|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
251122|NCT02199405|Other|Cervical traction|
251123|NCT02199418|Drug|Paclitaxel|
251124|NCT02199418|Drug|Cisplatin|
251125|NCT02199431|Drug|Lu AF11167|
251126|NCT02199431|Drug|Itraconazole|
251127|NCT02199444|Drug|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
251128|NCT02199444|Drug|Placebo|
251129|NCT02199457|Device|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
251130|NCT02199457|Device|SVSS and reference devices|Body temperature taken with infrared thermometer
251131|NCT02199457|Device|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
251132|NCT00139659|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
251133|NCT02199457|Device|SVSS and reference devices|Measurement of respiration rate
251134|NCT02199496|Biological|Ustekinumab|Ustekinumab is an IL-12 and IL-23 antagonist biologic drug that is FDA approved to treat psoriasis. Ustekinumab may offer a specific and welltolerated new treatment for CVID-related enteropathy.
251135|NCT02199509|Drug|Levetiracetam|Anticonvulsant
251136|NCT02199522|Procedure|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
251137|NCT02199548|Other|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
251138|NCT02199561|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
251139|NCT02199574|Drug|EXPAREL|
250521|NCT02211937|Drug|BI 44847 solution, low dose|
250522|NCT02211937|Drug|BI 44847 suspension, high dose|
250523|NCT02211937|Drug|BI 44847 tablet, low dose|
250524|NCT02211937|Drug|BI 44847 tablet, high dose|
250525|NCT02211937|Other|high fat breakfast|
250526|NCT00141219|Drug|pregabalin|150-600mg/day, BID
250527|NCT02211950|Drug|BI 44847|
250834|NCT02204488|Procedure|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
250835|NCT02204488|Procedure|Trapeziectomy|Trapeziectomy
250836|NCT02206945|Behavioral|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
250837|NCT00140647|Drug|Ramipril|
250838|NCT02206958|Behavioral|Behavioral Urinary Incontinence Treatment|12 week program with 3 components
Continence program administered by a registered nurse during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.
Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor.
Recommendations for improving toilet access (i.e., lighting, toileting and dressing devices, grab bars, raised toilet seats, clearing path to toilet).
250839|NCT02206971|Other|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
250840|NCT02206984|Drug|Tamoxifen|
250841|NCT02206984|Drug|Anastrozole|
250842|NCT02206984|Drug|Fulvestrant|
250843|NCT02207010|Biological|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
250844|NCT02207023|Behavioral|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
250845|NCT02207036|Behavioral|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
250222|NCT02219321|Drug|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
250223|NCT02219321|Drug|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
250224|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
250225|NCT02219334|Device|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
250226|NCT02219347|Drug|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
250227|NCT02219373|Drug|Gabapentin|
250228|NCT02219373|Drug|Oxcarbazepine|
250229|NCT02219373|Other|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
250528|NCT02211950|Drug|Acarbose|
250529|NCT02211950|Other|Japanese diet|
250530|NCT02211963|Drug|BI 44847|
250531|NCT02211963|Drug|Placebo|
250532|NCT02211976|Drug|Bisacodyl|
250533|NCT02211976|Drug|Simeticone|
250534|NCT02214368|Other|Early application of NIV|Device:BiPAP Vision.
NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization.
250535|NCT00141479|Drug|Bifeprunox|
250536|NCT02214368|Device|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
250537|NCT02214368|Drug|Propofol|Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).
NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).
In the conventional treatment group: No intervention.
249904|NCT00142844|Drug|Naltrexone|
249905|NCT02226328|Drug|Midazolam and Fentanyl sedation|
249906|NCT02226341|Drug|CellCept|For both arms:
CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144
249907|NCT02226341|Drug|ACTHar gel|Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
249908|NCT02226341|Drug|ACTHar gel|Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
249909|NCT02226354|Dietary Supplement|Ahiflower oil|9.73 ml per day for 28 days
249910|NCT02226354|Dietary Supplement|Flaxseed oil|9.73ml per day for 28 days
249911|NCT02226367|Drug|prazosin hydrochloride|study drug arm prazosin
249912|NCT02226367|Drug|placebo|study drug arm placebo
249913|NCT02226380|Drug|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
249914|NCT02226393|Behavioral|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
249915|NCT00142844|Drug|Disulfiram|
249916|NCT02226393|Behavioral|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
249917|NCT02226406|Other|A: Chair - Leg Cycle ergometer|
249918|NCT02226406|Other|B: Chair - Arm Cycle ergometer|
250230|NCT02219386|Other|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
250231|NCT02219386|Other|group 2. Passive analitical stretch (performed in both groups)|
249608|NCT02231346|Drug|Berodual® Respimat® - inhaler|
249609|NCT02231359|Drug|Berodual® Respimat® solution for inhalation|
249610|NCT02231372|Drug|Berodual® Respimat® solution for inhalation|
249611|NCT02231385|Drug|Acetic Acid|Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.
Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time.
249612|NCT02233790|Drug|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
249613|NCT02233803|Drug|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
249614|NCT02233803|Drug|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
249615|NCT00143689|Drug|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
249616|NCT02233803|Drug|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
249617|NCT02233803|Drug|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
249618|NCT02233816|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
249619|NCT02233816|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
249620|NCT02233816|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
249621|NCT02233816|Biological|Placebo|A single dose of placebo
249622|NCT02233829|Drug|Brain Dopamine Reactivity|Methylphenidate
249623|NCT02233829|Drug|Brain Dopamine Receptor|C-11 Raclopride
249624|NCT02233868|Device|MRI|Functional Connectivity Magnetic Resonance Imaging (fcMRI) of connectivity in brain
249625|NCT02233868|Drug|C-11PBR28|PET brain imaging of neuroinflammation using the radiotracer [11C]PBR28
249626|NCT00143702|Drug|d4T|See Detailed Description.
254165|NCT00002339|Drug|Fluconazole|
254166|NCT00144482|Drug|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
249293|NCT02198846|Drug|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
249294|NCT02198859|Drug|Lithium Carbonate|
249295|NCT02198872|Other|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
249296|NCT02198872|Other|Land Group|Patients of this group perform physical training on bicycle.
249297|NCT02198898|Device|GUARDIX-SG|
249298|NCT02198911|Other|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
249299|NCT02198911|Other|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
249300|NCT02201420|Drug|Tc 99m tilmanocept|
249301|NCT02201459|Drug|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
249302|NCT00139945|Drug|Human acylated ghrelin|5 pmol/kg body weight per min
249303|NCT02201459|Drug|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and
Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation.
249304|NCT02201472|Device|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
249305|NCT02201485|Device|Stent|
249306|NCT02201485|Device|Balloon|
249307|NCT02201498|Procedure|Pulpotomies with Formocresol/OZE and Biodentine|
249308|NCT02201511|Drug|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
249309|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
253858|NCT02248506|Other|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
253859|NCT02248519|Procedure|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
253860|NCT02248519|Procedure|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
253861|NCT02248532|Biological|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes >1.9 mV, and linear shortening <6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
253862|NCT02248558|Behavioral|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
253863|NCT00145418|Drug|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
254167|NCT02240875|Biological|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
254168|NCT02240875|Biological|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
254169|NCT02240875|Biological|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
254170|NCT02243501|Behavioral|Behavioural intervention|The intervention program will be conceptually consistent across age groups in terms of the focus of each session; however, age-specific information will be included for each of the three targeted age groups: toddlers (1-2 years), preschoolers (3-5 years) and school-aged children (6-10 years). Parents of toddlers, however, will also receive information about the role of sleep hygiene specific to naptime, while parents of school-aged children will learn about the negative impacts on children's sleep of permitting a television in the child's bedroom. Each session will provide strategies to help support parents in their implementation of the information provided (e.g., confirmation and discussion of the challenges faced in implementing these strategies, self-help tips, etc.).
254171|NCT02243527|Other|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
254172|NCT02243527|Other|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
254173|NCT00144807|Drug|rituximab|
254174|NCT02243553|Drug|Tipranavir capsule|
254175|NCT02243553|Drug|Tipranavir solution|
254176|NCT02243553|Drug|Ritonavir capsule|
254177|NCT02243553|Drug|Caffeine|
253551|NCT02255240|Behavioral|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
253552|NCT02255253|Drug|Telmisartan|capsule,40mg per day,2 months
253553|NCT02255253|Drug|Hydrochlorothiazide|tablet, 25mg per day, 2 months
253554|NCT02255266|Drug|liraglutide|No treatment given.
253555|NCT02255279|Biological|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
253556|NCT00146237|Drug|phenytoin|
253557|NCT02255279|Biological|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
253558|NCT02255292|Drug|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study
253559|NCT02255305|Biological|FMT|Patients in the FMT group will receive ~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.
253560|NCT02255305|Drug|Antimicrobials|Patients randomized to the control group will receive antimicrobials targeting C. difficile.
253561|NCT02255318|Device|Taurolock|
253562|NCT02255318|Drug|Placebo|
253563|NCT02255357|Drug|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
253564|NCT02255357|Drug|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
253864|NCT02248558|Behavioral|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
253865|NCT02248571|Drug|Bevacizumab|administered as combined therapy with Capecitabine
253866|NCT02248571|Drug|Capecitabine|administered as combined therapy with Bevacizumab
253867|NCT02250924|Behavioral|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
248063|NCT02230579|Drug|MMV390048 20mg|Supplied as "powder in bottle" formulation for reconstitution pre-dose.
248064|NCT02230579|Drug|MMV390048 60mg|Supplied as "powder in bottle" formulation for reconstitution pre-dose
248065|NCT02230579|Drug|MMV390048 120mg|Supplied as "powder in bottle" formulation for reconstitution pre-dose
248066|NCT02230579|Drug|MMV390048 220mg|Supplied as "powder in bottle" formulation for reconstitution pre-dose
248067|NCT02230579|Drug|MMV390048 340mg|Supplied as "powder in bottle" formulation for reconstitution pre-dose
248068|NCT02230579|Drug|MMV390048 475mg|Supplied as "powder in bottle" formulation for reconstitution pre-dose
248069|NCT02230579|Drug|Placebo to match MMV390048|Supplied as "powder in bottle" formulation for reconstitution pre-dose
248070|NCT02230579|Drug|MMV390048 x mg|dose to be determined based on emerging data
248071|NCT02230605|Other|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
248072|NCT00143364|Drug|varenicline (CP-526,555)|
248073|NCT02230605|Other|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
248074|NCT02230605|Other|Geriatric Depression Scale|To be completed at the Screening Visit
248075|NCT02230605|Other|Charlson Comorbidity Index|To be completed at the Screening Visit
248076|NCT02230605|Other|Short Form 36 Health Survey|To be completed at the Screening Visit
248077|NCT02230605|Other|Confusion Assessment Method|To be completed at the Day 0 (Per-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:00 A.M. and 6:00 P.M. (or until hospital discharge)
248078|NCT02230605|Other|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Per-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:00 A.M. and 6:00 P.M. (or until hospital discharge)
248394|NCT02223598|Drug|CB-5083|
248395|NCT02223598|Drug|Dexamethasone|
248396|NCT02223611|Drug|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)＜1.25 m2 40mg twice a day, 1.25 m2≤BSA＜1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
247447|NCT02203097|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
247751|NCT00143936|Behavioral|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
247752|NCT02235701|Drug|ifosfamide|
247753|NCT02235727|Drug|GBR 900|
247754|NCT02235727|Drug|Placebo|
247755|NCT02235740|Drug|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
247756|NCT02235740|Drug|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
247757|NCT02197975|Drug|Placebo MDI|Placebo MDI. Administered as 2 inhalations
247758|NCT02197988|Drug|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
247759|NCT02197988|Drug|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
247760|NCT02198001|Drug|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|BPs per os< 3ans: amoxicillin- clavulanate J-1 à J+10
BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):
amoxicillin- clavulanate J-3 à J+10
In case of allergy:
BPs per os: clindamycine J-1 à J+10
BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):
clindamycine J-3 à J+10
247761|NCT02198001|Procedure|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
247762|NCT02198014|Other|Manual Therapy|5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.
10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.
10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.
10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.
10 minutes. Local cryotherapy with ice pack.
247763|NCT02198014|Other|Educational Physiotherapy|Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.
Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique.
247764|NCT02198027|Drug|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
247765|NCT02198027|Other|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
253314|NCT02269605|Other|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
253315|NCT02269605|Drug|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
253316|NCT00147953|Procedure|Total nodal irradiation|
253317|NCT02269605|Drug|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
253318|NCT02269618|Other|Home-based telehealth program|Home-based telehealth program
Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.
Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms
Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor
Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need
Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises.
253631|NCT02262208|Device|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
253632|NCT02262221|Other|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
253633|NCT02262234|Other|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
253634|NCT02262234|Other|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
253635|NCT00147160|Drug|Temozolomide, Cisplatinum|
253636|NCT02262260|Drug|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
253637|NCT02262260|Drug|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
253003|NCT02237950|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
253004|NCT02237950|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
253005|NCT02237950|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
253006|NCT02237963|Procedure|Posterolateral thoracotomy|
253007|NCT02237963|Procedure|Axillary thoracotomy|
253008|NCT02237976|Behavioral|Self-hypnosis|
253009|NCT02237976|Behavioral|Routine practice|
253010|NCT02237989|Drug|paracetamol|1500 mg
253011|NCT02237989|Drug|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
253012|NCT02238002|Procedure|cataract surgery|The patients of both groups underwent cataract surgery
253013|NCT00144170|Drug|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
253319|NCT02269618|Other|Home-based rehabilitation|Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer
Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)
Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient.
253320|NCT02269618|Other|Usual care|Usual care All patients will be followed also in usual care manner by their GPs.
253321|NCT02269631|Behavioral|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
253322|NCT02269631|Behavioral|Control diet group|no legumes in lunch or dinner meals
253323|NCT02269631|Device|Smartpill|to assess how long food takes to pass through the digestive system
253324|NCT02271919|Drug|Varenicline|Phase I (VAR) Group Weeks 1 - 6: Varenicline dosing follows recommended dosing schedule (i.e., 0.5 mg/day Varenicline for Days 9 - 11; 0.5 mg twice a day for Days 12 - 15; and 1 mg twice a day thereafter).
Phase II Weeks 7 - 12 Group 3: If participant previously on Varenicline, will continue same dosage and schedule. Group 4: If participant previously on Placebo, will now start Varenicline. Group 5: If participant previously taking Varenicline in Phase I, will now continue same regimen, but take 1 extra dose in the evening.
253325|NCT02271919|Other|Placebo Patch|Phase I (VAR) Group Weeks 1 - 6: Placebo patch placed daily.
Phase II - Assigned Groups: Placebo patch per physicians instruction.
252704|NCT02243072|Other|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
252705|NCT02245529|Drug|Tamsulosin|
252706|NCT02245542|Drug|ALNA®OCAS®|
252707|NCT02245555|Drug|Tamsulosin|
252708|NCT02245568|Drug|TRx0237|All subjects will initially be given 200 mg/day of TRx0237 (one 100-mg tablet in the morning and one 100-mg tablet in the evening). Thereafter, dosing is flexible (100 mg/day to 300 mg/day).
252709|NCT02245581|Procedure|SVV-guided fluid management|
252710|NCT02245581|Procedure|CVP-guided fluid management|
252711|NCT00144989|Drug|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
252712|NCT02245607|Behavioral|Compensatory Cognitive Training|
252713|NCT02245607|Behavioral|Recreational Therapy|
252714|NCT02245620|Drug|MTP-131 (Bendavia™)|MTP-131 (Bendavia™; 0.25 mg/kg/hour) administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
252715|NCT02245620|Drug|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
252716|NCT02245659|Device|CPAP|Continuous Positive Airway Pressure
253014|NCT02238015|Procedure|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
253015|NCT02238028|Other|Particulate filtering respirator|particulate filtering respirators are required to wear for continuous 48 hours except the necessary daily life needs to get rid of it. Each subject will act the control of himself/herself since they all need to accomplish wearing the particulate filtering respirator or not wearing.
253016|NCT02238041|Device|GlucoClear System|
253017|NCT02238106|Drug|Salmeterol medium dose|
253018|NCT02238106|Drug|Salmeterol low dose|
253019|NCT02238106|Drug|Salmeterol high dose|
253020|NCT02238106|Drug|Serevent® Diskus®|
253021|NCT02238106|Drug|Placebo HandiHaler®|
253022|NCT02238106|Drug|Placebo Diskus®|
252380|NCT02250326|Drug|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
252381|NCT02250326|Drug|CC-486|Oral CC-486
252382|NCT02250339|Other|LAKU family program|Multi-systemic and multicomponent family-based intervention program
252383|NCT02250339|Other|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
252384|NCT02250339|Other|Family therapy|Treatment as usual (TAU)
252385|NCT02250352|Other|cytology specimen collection procedure|Correlative studies
252386|NCT02250365|Other|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
252387|NCT00145587|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
252388|NCT02250365|Other|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
252389|NCT02250378|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
252390|NCT02250378|Procedure|therapeutic conventional surgery|Undergo wedge resection
252391|NCT02250378|Other|laboratory biomarker analysis|Correlative studies
252392|NCT02250378|Other|quality-of-life assessment|Ancillary studies
252393|NCT02250391|Drug|NPB-06|5 days continuous-infusion
252394|NCT02252328|Drug|Placebo|
252395|NCT02252341|Dietary Supplement|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
252396|NCT02252354|Drug|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
252397|NCT00145782|Behavioral|Life style|
252398|NCT02252354|Drug|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
252399|NCT02252354|Drug|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
252400|NCT02252367|Drug|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
252100|NCT02259348|Biological|Interleukin-2|Given SQ
252101|NCT02259348|Drug|Melphalan|Given IV
252102|NCT02259348|Drug|Thiotepa|Given IV
252103|NCT02259348|Drug|Rituximab|Given IV
252104|NCT02259348|Biological|Natural killer cell therapy|Given IV
252105|NCT02259348|Biological|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
252106|NCT02259348|Biological|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
252107|NCT02259361|Drug|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
252108|NCT00146731|Drug|AQ + artesunate|
252109|NCT02259361|Drug|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
252403|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with IUD
252404|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with EUD
252405|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with IUD
252406|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with EUD
252407|NCT02252393|Other|quality-of-life assessment|Ancillary studies
252408|NCT00145795|Drug|Kaletra + Current Dual NRTI Backbone|
252409|NCT02252406|Drug|Ranolazine|Ranolazine 500 mg up to 1000 mg daily for 24 weeks.
252410|NCT02252406|Drug|Placebo|Matching placebo tablets daily for 24 weeks.
252411|NCT02252419|Drug|Dexamethasone|Dexamethasone will be administered.
252412|NCT02252419|Drug|Paracetamol|Paracetamol will be administered.
252413|NCT02252432|Drug|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
252414|NCT02252432|Drug|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
251790|NCT02264015|Drug|Placebo, film-coated tablets|
251791|NCT02264015|Drug|Moxifloxacin, film-coated tablets|
251792|NCT02264028|Drug|[14C]-DK-AH 269 CL, solution for infusion|
251793|NCT02264028|Drug|[14C]-DK-AH 269 CL, drinking solution|
251794|NCT00147381|Drug|Alemtuzumab|Day 0: Campath-1H 20 mg IV infusion over 3-6 hours
Day 1: Campath-1H 20 mg IV infusion over 3-6 hours
251795|NCT02264041|Drug|Cilobradine, low dose|
251796|NCT02264041|Drug|Cilobradine, high dose|
251797|NCT02264041|Drug|Itraconazole|
251798|NCT02266459|Device|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is < 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
251799|NCT02266472|Drug|metformin|single dose of metformin given as tablets
251800|NCT00002364|Drug|Abacavir sulfate|
251801|NCT00147654|Drug|Tamsulosin 0.4 mg QD|
251802|NCT02266472|Drug|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
251803|NCT02266472|Drug|empagliflozin|single dose of empagliflozin given as tablet
251804|NCT02266485|Drug|BIBB 515 BS|
251805|NCT02266485|Drug|Pravastatin|
251806|NCT02266485|Drug|Placebo|
251807|NCT02266498|Drug|BIBB 515 BS|
251808|NCT02266498|Other|Standard breakfast (40 g fat)|
251809|NCT02266511|Drug|Flomax®, Norman II facility|
251810|NCT02266511|Drug|Flomax®, Nishine facility|
251811|NCT02266524|Drug|Tamsulosin hydrochloride, very low dose|
252110|NCT02259374|Procedure|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
251140|NCT02199587|Behavioral|Presence of medical clown during endocrine test|
251141|NCT02199600|Device|GMK Sphere Knee Replacement|
251142|NCT02199613|Drug|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
251446|NCT02271113|Drug|Enoxaparin Sodium (Lovenox®)|
251447|NCT02271126|Device|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
251448|NCT02271126|Device|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
251449|NCT02271126|Drug|Heparin|Anticoagulation provided to patients in ECMO
251450|NCT02271139|Drug|Alectinib|Alectinib 600 mg (four 150-mg capsules) administered orally twice daily with food
251451|NCT00148083|Behavioral|Social Skills Training|
251452|NCT02271152|Procedure|FAST mapping and ablation|
251453|NCT02271152|Procedure|PVI|
251454|NCT02271165|Drug|Immunoglobulin (Hizentra)|
251455|NCT02271178|Other|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
251456|NCT02271178|Other|Conventional therapy|Usual therapy
251457|NCT02271191|Drug|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
251458|NCT02271204|Drug|Ibandronic acid|As prescribed by physician
251459|NCT02271217|Drug|Placebo|
251460|NCT02271217|Drug|dalfampridine-ER 7.5mg|
251461|NCT02271217|Drug|dalfampridine-ER 10mg|
251462|NCT00148096|Device|Mechanical Heat Recovery Ventilation|De-humidification without loss of heat
251463|NCT02271230|Drug|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
251464|NCT02271230|Dietary Supplement|Fish oil (EPA/DHA) alone|1 g/d fish oil
250846|NCT02207036|Behavioral|Smokefree.gov|referral to the NCI Smokefree.gov website
250847|NCT02207049|Behavioral|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
250848|NCT00140647|Drug|Rosiglitazone|
250849|NCT02207049|Behavioral|No Snacking|Caloric needs will be provided to preschoolers within three meals
250850|NCT02207062|Drug|Ibrutinib|Given PO
250851|NCT02207062|Other|Laboratory Biomarker Analysis|Correlative studies
250852|NCT02207075|Radiation|[C11]PK-1195 PET scan|
250853|NCT02207088|Drug|ombitasvir/paritaprevir/ritonavir|tablet
250854|NCT02207088|Drug|dasabuvir|tablet
251143|NCT02202135|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
251144|NCT02202135|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
251145|NCT02202135|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
251146|NCT02202161|Drug|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
251147|NCT02202161|Drug|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
251148|NCT00140049|Drug|Cosopt|
251149|NCT02202161|Drug|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
251150|NCT02202161|Drug|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
251151|NCT02202174|Device|Supraglottic Airway Device|
251152|NCT02202187|Drug|GSK2140944|Investigational Study Drug
251153|NCT02202187|Other|Placebo|Placebo
251154|NCT02202200|Drug|PD- 0332991|PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg
All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients
250538|NCT02214368|Other|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2> 0.5 or breathing at least 10 L/min oxygen.
250539|NCT02214381|Drug|Myocet|
250540|NCT02214381|Drug|Cyclophosphamide|
250541|NCT02214381|Drug|Paclitaxel|
250542|NCT02214394|Other|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
250543|NCT02214394|Device|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
250544|NCT02214407|Drug|Decitabine|Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.
Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.
250545|NCT02214407|Drug|HYDROXYUREA|Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.
Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.
250546|NCT00141492|Drug|Androgel (testosterone gel)|
250547|NCT02214420|Drug|Simeprevir|
250855|NCT02207088|Drug|Ribavirin|tablet
250856|NCT02207101|Dietary Supplement|E-OJ-01 (OXYJUN)|
250857|NCT02207101|Dietary Supplement|Placebo|
250858|NCT02207114|Other|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
250859|NCT00140660|Drug|rituximab|
250860|NCT02207127|Procedure|MRI, DISE, and Surgery|
250232|NCT02219399|Dietary Supplement|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
250233|NCT02221648|Drug|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
250234|NCT00142415|Drug|177-Lu-DOTA-cG250|At day 8, every patient received the cG250 at a dose of 10 mg coupled to DOTA and labeled with a dose of 177-Lutetium (177-Lu) that started at 10 mCi by square meter for the patients of the 1st cohort.
250235|NCT02221674|Drug|Tapentadol|Participants aged 6 months to less than 23 months.
250236|NCT02221674|Drug|Tapentadol|Participants aged 1 month to less than 6 months.
250237|NCT02221674|Drug|Tapentadol|Participants aged from birth (must be ≥37 weeks gestational age) to less than 1 month.
250238|NCT02221687|Dietary Supplement|Synbiotic formula|
250239|NCT02221700|Other|Massage|Two groups receive massage three times a week for 4 weeks.
Two groups receive massage two times a week for 6 weeks.
250240|NCT02221700|Behavioral|Questionnaires|3 symptom questionnaires completed at baseline, at weeks 4, 6, 8, 10, and at follow up visit. Questionnaires take about 15-30 minutes to complete in total.
250241|NCT02221700|Other|Leg Function and Balance Tests|Participants complete tasks such as walking and standing on 1 leg at baseline, at weeks 4, 6, 8, 10, and at follow up visit. Tests should take about 20 minutes to complete.
250242|NCT02221726|Drug|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
250243|NCT02221726|Drug|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 44 cm^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
250244|NCT02221739|Drug|Ipilimumab|
250245|NCT00142428|Drug|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
250246|NCT02221739|Radiation|Radiotherapy (IMRT or 3-D CRT)|
250247|NCT02221752|Dietary Supplement|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
250548|NCT02214420|Drug|Sofosbuvir|
250549|NCT02214420|Drug|Ribavirin|
249919|NCT02226406|Other|C: Walk in place|
249920|NCT02226419|Dietary Supplement|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
249921|NCT02226432|Procedure|- Postoperative Antagonistic Peripheral Magnetic Stimulation|Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.
Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.
Comparision of both groups will be statistified
249922|NCT02226432|Device|Selected Peripheral Magnetic Stimulation|Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with "eight saped" bovine, of 30 minutes, aplied on antagonistic muscles, twice a week.
249923|NCT02228863|Other|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
249924|NCT02228889|Procedure|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
249925|NCT00143156|Drug|pregabalin|
249926|NCT02228889|Other|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
249927|NCT02228889|Other|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
249928|NCT02228889|Other|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
249929|NCT02228889|Other|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
249930|NCT02228889|Other|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
249931|NCT02228889|Other|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
249932|NCT02228889|Other|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
249933|NCT02228889|Other|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
249934|NCT02228889|Other|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
249935|NCT02228889|Other|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
249936|NCT00143169|Drug|Parecoxib and placebo|
249937|NCT02228889|Other|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
249310|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
249311|NCT02201511|Drug|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
249312|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
249313|NCT00002305|Drug|Amphotericin B|
249627|NCT02233868|Drug|F-18FDG|PET brain imaging of neurofunction using the radiotracer F-18FDG
249628|NCT02233881|Drug|Atrovent® - inhalets|
249629|NCT02233894|Drug|Atrovent® - inhalets|
249630|NCT02233907|Drug|Ventilat® - metered dose inhaler|
249631|NCT02233920|Drug|Ventilat® - metered dose inhaler|
249632|NCT02233933|Other|Hemospray|hemospray is used after argon coagulation to stop bleeding
249633|NCT02233946|Behavioral|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
249634|NCT02233972|Drug|Midazolam|
249635|NCT02233972|Drug|Ginkgolides Meglumine Injection|
249636|NCT02233972|Drug|placebo|
249637|NCT00143702|Drug|Abacavir|See Detailed Description.
249638|NCT02236338|Device|EVLT 980nm diode laser system|
249639|NCT02236351|Device|Pinched Patch|
249640|NCT02236364|Device|Contour, Bayer Healthcare, LLC|Blood glucose measurement
249641|NCT02236377|Behavioral|Exposure, Relaxation, and Rescripting Therapy|Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
249642|NCT02236390|Behavioral|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
249643|NCT02236390|Behavioral|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
254178|NCT02243553|Drug|Warfarin sodium|
254179|NCT02243553|Drug|Vitamin K|
254180|NCT02243553|Drug|Omeprazole|
254181|NCT02243553|Drug|Dextromethorphan hydrobromide|
254182|NCT02243553|Drug|Midazolam injection|
254183|NCT02243553|Drug|Midazolam oral solution|
254184|NCT00144807|Drug|doxorubicin|
254185|NCT02243553|Drug|Digoxin tablet|
254186|NCT02243553|Drug|Digoxin injection|
254187|NCT02243566|Drug|MicardisPlus®|
254188|NCT02243579|Other|Laboratory Biomarker Analysis|Correlative studies
254189|NCT02243579|Biological|Pembrolizumab|Given IV
254190|NCT02243592|Other|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
254191|NCT02243605|Drug|Cabozantinib S-malate|Given PO
249314|NCT00139971|Drug|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
249315|NCT02201524|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
249316|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
249317|NCT02201524|Other|Placebo|Subjects will receive placebo for 4 weeks
249318|NCT02201537|Device|renal echography|Renal biopsy will be performed at 3 and 12 months.
The functional imaging examinations will be held as follows:
Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS
249319|NCT02201563|Drug|Minocycline|Oral minocycline (100mg twice a day) for 3 months
249320|NCT02201576|Drug|Bortezomib|Five plasma exchanges +0.1 g/kg of intravenous globulins at the end of each course
two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)
four courses of polyclonal intravenous globulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)
249321|NCT02201576|Drug|Plasma exchanges and intravenous immunoglobulins|Five plasma exchanges +0.1 g/kg of intravenous globulins at the end of each course
four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)
oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11 of the two first intravenous immunoglobulins courses)
253868|NCT00002347|Drug|Zalcitabine|
253869|NCT00145613|Drug|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
253870|NCT02250937|Drug|Busulfan|Arm 1 - Busulfan 80 mg/m2 (PK Studies) on Day -13 and Day -12.
Arm 2 - Busulfan 80 mg/m2 (PK Studies) on Day - 20 and Day -13.
Both Arms - Busulfan administered after Cladribine at dose calculated to achieve a total (including first two doses) systemic exposure of 20,000 ± 12% µMol-min based on pharmacokinetic studies on Days -6 to -3.
253871|NCT02250937|Drug|Fludarabine|Arm 1 and 2 - Fludarabine 10 mg/m2 on Days -6 through -3.
253872|NCT02250937|Drug|Cladribine|Both Arms - Cladribine 10 mg/m2 administered after Fludarabine on Days -6 through -3.
253873|NCT02250937|Procedure|Stem Cell Transplant|Both Arms - Stem cell transplant on Day 0.
253874|NCT02250937|Drug|G-CSF|Both Arms - G-CSF 5 mcg/kg/day subcutaneously on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.
253875|NCT02250937|Drug|Methotrexate|Both Arms - Methotrexate 5 mg/m2 on Days +1, +3, +6, and +11 post bone marrow transplant.
253876|NCT02250950|Behavioral|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
253877|NCT02250950|Behavioral|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
253878|NCT02250976|Drug|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
253879|NCT02250976|Drug|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
253880|NCT00145626|Drug|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
253881|NCT02250976|Drug|Livaro tab. 2mg|Pitavastatin Ca 2mg
254192|NCT02243605|Other|Laboratory Biomarker Analysis|Correlative studies
254193|NCT02243618|Drug|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
254194|NCT02243618|Drug|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
254195|NCT00144807|Drug|cyclophosphamide|
248397|NCT02223611|Drug|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
248398|NCT02223624|Other|walking and light weights|
248399|NCT00142558|Drug|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
248400|NCT02223624|Other|eccentric aerobic exercise|
248401|NCT02223624|Other|concentric aerobic exercise|
248402|NCT02225691|Device|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
248403|NCT02225704|Drug|Radium-223 and enzalutamide|
248404|NCT02225717|Procedure|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
248405|NCT02225743|Other|Observation Of Temperature|Participants temperature will be recorded perioperatively.
248406|NCT00142779|Drug|Fluoxetine|
248407|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
248408|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
248409|NCT02225756|Drug|Placebo|Oral administration for a short time of placebo
248410|NCT02225769|Other|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
248411|NCT02225769|Other|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
248412|NCT02225782|Drug|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
248717|NCT02218606|Drug|Abiraterone acetate 1000 mg po daily|
248718|NCT02218606|Drug|Cabazitaxel 25 mg/m2 IV|
248719|NCT00142038|Drug|Capecitabine|
248720|NCT02218606|Drug|prednisone 5 mg po BID|
247766|NCT00139516|Behavioral|self-help|
248079|NCT02230618|Other|No treatment given|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
248080|NCT02230631|Other|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
248081|NCT02230644|Other|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
248082|NCT02230644|Other|Other distraction|Such as newspaper, magazine or the news on television
248083|NCT00143377|Drug|tolterodine SR, overactive bladder|
248084|NCT02230657|Procedure|Same day discharge|
248085|NCT02230657|Procedure|Next day discharge|
248086|NCT02230670|Drug|IDN-6556|25 mg BID
248087|NCT02233114|Other|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
248088|NCT02233140|Device|Extra-corporeal pulsed-activated therapy or shockwave therapy|
248089|NCT02233153|Other|Elder-Friendly Surgical Unit|
248090|NCT02233179|Device|Removable cast walker|Offloading device that can be removed by patients.
248091|NCT02233179|Device|Irremovable cast walker|Offloading device that cannot be removed by patients.
248092|NCT02233205|Device|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
248093|NCT02233205|Drug|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
248094|NCT02233218|Drug|Telmisartan|
248095|NCT02233218|Drug|Amlodipine|
248096|NCT00002332|Drug|Thymopentin|
248097|NCT00143637|Other|clean air|Clean air
248098|NCT02233218|Drug|Rosuvastatin|
248099|NCT02233231|Drug|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
253638|NCT02262273|Other|Data Collection|Colleciton of data from medical records only
253639|NCT02262299|Drug|Pirfenidone|Receive tablets with pirfenidone
253640|NCT02262299|Drug|Placebo|Recieve tablets with placebo
253641|NCT02264678|Drug|Administration of AZD6738 in combination with carboplatin|An oral formulation of AZD6738 will be used. In Part A, patients will receive a single dose of AZD6738 on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Part B, patients will receive AZD6738 and carboplatin at the dose, frequency and schedule recommended from Part A.
253642|NCT02264678|Drug|Administration of AZD6738 in combination with olaparib|Oral formulations of AZD6738 and olaparib will be used. In Part A2, patients will receive a single dose of AZD6738 followed by 4 to 6 days washout, before multiple dosing with AZD6738 and olaparib. In Part B, patients will receive AZD6738 and olaparib at the dose, frequency and schedule recommended from Part A2.
253643|NCT02264678|Drug|Administation of AZD6738 in combination with MEDI4736|An oral formulation of AZD6738 will be used. MEDI4736 is given via IV infusion. In part A patients will receive and initial single dose of AZD6738 on Day 1, followed by multiple dosing in combination with MEDI4736. In part B expansion cohorts will receive AZD6738 at the dose, frequency and schedule recommended from part A, in combination with MEDI4736.
253946|NCT02257710|Device|Orsiro|
253947|NCT02257723|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
253948|NCT02257723|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
253949|NCT02257723|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
253950|NCT02257723|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
253951|NCT02257723|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
253952|NCT02257736|Drug|JNJ56021927|Participants will receive 240 milligram (mg) tablet of JNJ56021927 once daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
253953|NCT00146575|Device|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
253326|NCT02271919|Drug|Nicotine Patch|Phase I - (NPL) Group: Nicotine 21 mg patch applied to upper arm starting on Day 12.
Phase 2 Assigned Groups: Nicotine patch applied per physician's instruction.
253327|NCT02271919|Other|Placebo Lozenges|Phase I (VAR) Group: Placebo lozenge used as needed.
Phase II Assigned Groups: Placebo lozenge used as needed.
253328|NCT02271919|Drug|Nicotine Lozenge|Phase I (NPL) Group: Nicotine 2 mg lozenge used as needed.
Phase II Assigned Group: Nicotine 2 mg lozenge used as needed.
253329|NCT02271919|Behavioral|Questionnaires|Questionnaire completion at baseline, and on Days 8, 17, 24, 38, 52, 59, 73, and 94. Questionnaires also completed at follow up visit 9 and 10.
253330|NCT00148148|Drug|liposomal amphotericin B|
253331|NCT02271919|Behavioral|Counseling|Counseling about quitting smoking conducted on Days 8, 17, 24, 38, 52, 59, 73, and 94. Some sessions may be audio/video recorded.
253332|NCT02271919|Behavioral|Phone Calls|Study staff conducts visits over the phone for Visits 2, 3, 4, 6, and 7 (on Days 17, 24, 38, 69, and 73). Each call should take about 25-45 minutes.
Study staff calls participant 1 day before quit date and 3 days after quit date to check on participant's progress in quitting smoking. Each call should take about 10-15 minutes.
253333|NCT02271932|Other|Non-operative management with antibiotics alone|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
253644|NCT02264678|Drug|Administration of AZD6738|An oral formulation of AZD6738 will be used. In Part A1, patients will receive a single dose of AZD6738 on Day 1, followed by 4 to 6 days washout, before multiple dosing. Treatment will be given until disease progression.
253645|NCT02264704|Other|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
253646|NCT02264704|Other|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
253647|NCT02264717|Procedure|SPECT|Patients are randomized to either SPECT or Cardiac MRI
253648|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
253649|NCT02264717|Procedure|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
253650|NCT02264730|Drug|ClotFoam|Patient has not received blood products between screenings
253651|NCT02264743|Drug|Femoston Conti|Ultra-low-dose oral E2/D [Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg] oral Femoston Conti 0.5mg Estradiol&Dydrogesterone vs Oestradiol&Norethisterone acetate
253652|NCT02264743|Drug|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
253023|NCT02238119|Drug|Tiotropium + formoterol combination|
253024|NCT00144183|Drug|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
253025|NCT02238119|Drug|Tiotropium|
253026|NCT02238119|Drug|Formoterol|
253027|NCT02240407|Drug|Rapamycin|Patients will receive Rapamycin (dose 0.6-1 mg/m^2/day, adjusted to maintain a trough serum sirolimus level of 12-20 ng/mL.) every day starting from 3 days before first injection of AAV9 until one month after second injection.
253028|NCT02240407|Other|Lactated Ringer's|Same volume as rAAV9-DES-hGAA injection will be used.
253029|NCT02240407|Drug|Rituxan|Patients will receive Rituxan (dose: 750 mg/m^2 twice) 15 and 1 day prior first AAV9 injection. Rituxan will be repeated at 2nd injection only if B cells counts are detectable. The maintenance dose of Rituxan will be 750 mg/m^2 once.
253030|NCT00144443|Behavioral|Basic home repair|
253031|NCT02240407|Drug|Diphenhydramine|25-50mg will be provided before each rituximab dose.
253032|NCT02240407|Drug|Acetaminophen|We will provide 650 mg of tylenol before each dose of rituximab.
253033|NCT02240407|Drug|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
253034|NCT02240420|Behavioral|Life Style Counseling (Star-Mama)|Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated "out of range," a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their "out of range" reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources
253334|NCT02271945|Drug|MEDI-551 and MEDI0680 (AMP-514)|3 to 6 subjects with relapsed or refractory aggressive B-cell lymphomas will be enrolled per cohort in the dose-escalation portion, starting with a MEDI0680 (AMP-514) medium dose every 2 weeks for 12 months of therapy (thirteen 28-day cycles). If a patient experiences PD after completing first year therapy, combination treatment may be resumed for up to 12 additional months.
Provided the MTD is not exceeded at the starting dose level, MEDI0680 (AMP-514) dosing will also be explored at a higher dose level. Subjects will receive MEDI0680 (AMP-514) on Days 2 and 15 of Cycle 1 and Days 1 and 15 of each subsequent 28-day cycle. Subjects will receive medium dose of MEDI-551 on Days 1 and 8 of Cycle 1 and on Day 1 of all subsequent 28-day cycles. Once an MTD is identified is reached, 20 additional subjects with DLBCL will be enrolled and treated at the selected dose of MEDI-551 in combination with MEDI0680 (AMP-514)
253335|NCT02271958|Drug|Mifepristone|
253336|NCT02271958|Drug|PLACEBO|
253337|NCT02271971|Dietary Supplement|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
253338|NCT02271971|Dietary Supplement|Placebo|A daily placebo capsule during 6 weeks.
252401|NCT02252367|Other|Placebo|Placebo tablet once daily for 12 weeks.
252402|NCT02252380|Device|Transcranial ExAblate System|MR Guided Focused Ultrasound
252717|NCT02245659|Other|Nasal dilator strip|Nasal dilator strip to be worn nightly
252718|NCT02245672|Drug|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
252719|NCT02245672|Drug|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
252720|NCT02245672|Drug|Placebo|Placebo administered via the CRC749 and Diskus devices
252721|NCT02245698|Biological|Stem cell|
252722|NCT00144989|Drug|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
252723|NCT02245711|Biological|Stem Cell|
252724|NCT02245724|Biological|Stem Cell|
252725|NCT02245737|Drug|LY3314814|Administered orally
252726|NCT02245737|Drug|Placebo|Administered orally
252727|NCT02245750|Device|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
252728|NCT02245763|Device|Leaflet Clip|
252729|NCT02245776|Biological|Stem Cell|
252730|NCT02245789|Procedure|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
252731|NCT02245789|Drug|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
252732|NCT02247921|Other|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
252733|NCT02247960|Drug|Ciprofloxacin|
252415|NCT02252432|Drug|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
252416|NCT02252445|Drug|Propofol|Propofol will be administered.
252417|NCT02252445|Drug|Sevoflurane|Sevoflurane will be administered.
252418|NCT02252458|Drug|Fentanyl|
252419|NCT00145795|Drug|Current Regimen|
252420|NCT02252471|Behavioral|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
252421|NCT02252484|Other|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
252422|NCT02252484|Other|Standard of Care|Standard of Care for this patient population.
252423|NCT02254798|Other|no intervention|this is a non interventional study
252424|NCT02254811|Biological|Fecal Microbiota Transplant|
252425|NCT02254824|Drug|Xuezhikang|Xuezhikang
252426|NCT02254824|Drug|Atorvastatin|Atorvastatin
252427|NCT00146172|Drug|neratinib|HKI-272
252738|NCT02248025|Other|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
252739|NCT02248038|Procedure|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
252740|NCT02248038|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
252741|NCT02248051|Drug|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
252742|NCT00145340|Drug|pioglitazone|30 Mg/day
252743|NCT02248064|Device|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
252744|NCT02248077|Device|AutoloGel|
252111|NCT02259374|Procedure|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
252112|NCT02259400|Device|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)< 0.3.
252113|NCT02259400|Device|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 < 0.3.
252114|NCT02259413|Behavioral|Exercise Rehabilitation|This intervention will consist of group classes incorporating education about resistance exercise techniques and the benefit of exercise in end-stage renal disease; stationary cycling during hemodialysis sessions and additional one-to-one education sessions. Duration of the intervention will be 12 weeks.
252115|NCT02259426|Drug|Dihydroartemisinin-piperaquine combination (Artekin)|
252116|NCT02259426|Drug|Primaquine|Single-dose 0.25mg/kg
252117|NCT02259452|Procedure|SPECT Lung Perfusion Scan|
252118|NCT02259452|Procedure|SPECT Heart Perfusion Scan|
252119|NCT00002358|Drug|Sorivudine|
252120|NCT00146731|Drug|chlorproguanil-dapsone|
252121|NCT02259452|Procedure|Pulmonary Function Tests|
252122|NCT02261649|Device|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
252123|NCT00147043|Procedure|Infusion of stem cells via image guided scan|
252124|NCT02261649|Other|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and maybe stopped at any time.
252125|NCT02261662|Drug|Ribavirin|A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
It will be used along with Topical steroids; Betamethasone
252126|NCT02261662|Drug|Betamethasone|Topical Steroids alone will be used; Betamethasone
252127|NCT02261675|Drug|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
251465|NCT02271230|Drug|Vitamin D alone|2000 IU vitamin D
251466|NCT02271230|Other|Placebo|Vitamin D placebo and fish oil placebo
251467|NCT02271256|Device|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
251812|NCT00147667|Drug|Erythromycin|
251813|NCT02266524|Drug|Tamsulosin hydrochloride, low dose|
251814|NCT02266524|Drug|Tamsulosin hydrochloride, medium dose|
251815|NCT02266524|Drug|Tamsulosin hydrochloride, high dose|
251816|NCT02266537|Drug|Tamsulosin|
251817|NCT02266537|Drug|Alfuzosin|
251818|NCT02266537|Drug|Doxazosin|
251819|NCT02266537|Drug|Placebo|
251820|NCT02266550|Drug|[14C] BILL 284 BS|
251821|NCT02266563|Drug|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
251822|NCT02266563|Drug|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
251823|NCT00147680|Drug|Paclitaxel, Carboplatin|
251824|NCT02266576|Behavioral|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the Indian Health Center is the Group Lifestyle Balance DPP, which has previously been tailored for the urban American Indian/Alaskan Natives (AIAN). The Standard DPP consists of 16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator. The intervention will occur over the course of 20 weeks.
251825|NCT02268955|Drug|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
251826|NCT02268955|Drug|Saline|Saline will be administered to the placebo group
251827|NCT02268968|Drug|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
251828|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
251155|NCT02202213|Drug|Placebo|
251156|NCT02202213|Drug|Lu AF11167|
251157|NCT02202226|Drug|Lu AF35700|
251158|NCT02202226|Drug|Placebo|
251159|NCT00000331|Drug|Placebo Drug|
251160|NCT00002306|Drug|Fluconazole|
251161|NCT00140062|Drug|latanoprost 0.005% (Xalatan)|
251162|NCT02202239|Drug|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
251163|NCT02202239|Drug|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
251164|NCT02202239|Drug|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
251165|NCT02202239|Drug|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
251468|NCT02271269|Behavioral|Value Pricing Subsidies|Usual care for glaucoma
Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.
Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points.
251469|NCT02271282|Drug|Toremifene|
251470|NCT02271282|Drug|Placebo|
251471|NCT02273518|Drug|Asasantin ER, new formulation I|
251472|NCT02273518|Drug|Asasantin ER, new formulation II|
251473|NCT00148395|Drug|Carboplatin|
251474|NCT02273518|Drug|Asasantin ER, present commercial formulation|
251475|NCT02273531|Drug|Asasantin ER, new formulation|
251476|NCT02273531|Drug|Asasantin ER, present commercial formulation|
251477|NCT02273544|Drug|Asasantin ER (new formulation - low)|
251478|NCT02273544|Drug|Asasantin ER (new formulation - medium)|
251479|NCT02273544|Drug|Asasantin ER (new formulation - high)|
250861|NCT02209350|Procedure|Recanalization and stenting of aorta-iliac segment|Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.
Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often "mixed") artery recanalization is performed. Tomaximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter).
250862|NCT02209350|Drug|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
250863|NCT00140959|Drug|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
250864|NCT02209363|Device|auto-adjusting positive airway pressure|nightly use for 6 months
250865|NCT02209363|Other|Nasal dilator strips|nightly use for 6 months
250866|NCT02209376|Biological|CART-EGFRvIII T cells|
250867|NCT02209389|Device|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
250868|NCT02209402|Behavioral|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
250869|NCT02209415|Behavioral|standard follow-up|Outpatient clinic visits
250870|NCT02209415|Procedure|PET/CT and EUS|PET/CT and EUS
250871|NCT02209428|Drug|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
250872|NCT02209441|Drug|Phase I Dose-finding Study of Sorafenib Study|
250873|NCT02209454|Drug|Enantyum® oral solution|One dose of 25 mg DKP oral solution
250874|NCT00000332|Drug|Nimodipine|
250875|NCT00002313|Drug|Didanosine|
251166|NCT02202239|Drug|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
251167|NCT02202239|Drug|Cisatracurium Besilate|Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.
During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation.
251168|NCT02202239|Drug|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
250550|NCT02214433|Drug|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
250551|NCT02214433|Drug|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
250552|NCT02214433|Drug|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
250553|NCT02214433|Drug|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
250554|NCT02214433|Drug|Debio 1450 Capsule|Debio 1450 40 mg capsules
250555|NCT02214433|Drug|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
250556|NCT02214433|Drug|Pantoprazole|Pantoprazole 40 mg orally
250557|NCT02216864|Procedure|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
250558|NCT02216877|Drug|Mablet 360 mg|
250559|NCT02216877|Drug|Placebo|
250560|NCT02216890|Drug|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
250561|NCT02216916|Drug|HM781-36B|
250562|NCT02216942|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
250563|NCT02216942|Drug|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
250564|NCT02216968|Behavioral|Increase vegetable intake in pre-school children|6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate "increase vegetable intake in pre-school children".
250565|NCT02216981|Behavioral|Cognitive Behavioural Therapy (CBT)|
250566|NCT02216994|Drug|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
250567|NCT00141791|Drug|Etanercept|
250876|NCT00140959|Drug|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
249938|NCT02228889|Other|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
250248|NCT02221752|Dietary Supplement|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
250249|NCT02221765|Drug|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
250250|NCT02221765|Drug|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
250251|NCT02221778|Radiation|SBRT|SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:
Prescription dose(Gy) / (MLD) (Gy)
50 / 13
45 / 15
40 / 15
35 / 15.5
30 / 16
27.5 / 17
If the dose constraints cannot be met, prescription will be according to the level immediately bellow.
Treatment will be delivered in 5 fractions in consecutive working days
250252|NCT02221791|Dietary Supplement|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
250253|NCT02221791|Dietary Supplement|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
250254|NCT02224183|Behavioral|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
250255|NCT02224196|Other|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
250256|NCT02224196|Other|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
250257|NCT02224209|Device|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|Standard method of endovascular interventional treatment:
Method of stage-1 angioplasty
The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;
Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.
Method of stage-2:
The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);
Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;
After the placement of stent, the angioplasty is a success when residual stenosis is <30%.
249644|NCT02236403|Drug|Ivermectin 0.1% Metronidazole 1%|
249645|NCT02236416|Behavioral|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
249646|NCT00002334|Drug|Zidovudine|
249647|NCT00143988|Behavioral|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
249648|NCT02236416|Behavioral|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
249649|NCT02236429|Biological|vaginal flora transplant|
249939|NCT02228889|Other|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
249940|NCT02228889|Other|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
249941|NCT02228889|Other|Assess overall complications at 30 days postoperatively|
249942|NCT02228889|Other|Assess overall complications at 1 year postoperatively|
249943|NCT02228889|Procedure|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
249944|NCT02228889|Device|Strattice|Strattice mesh
249945|NCT02228889|Device|XenMatrix|Xenmatrix mesh
249946|NCT02228902|Drug|Ferrous fumarate|one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
249947|NCT00143182|Drug|Asenapine|Asenapine , 9 weeks
249948|NCT02228902|Drug|Ferrous gluconate|One group receives ferrous fumarate and one group receives ferrous fumarate.
249949|NCT02231411|Procedure|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
249950|NCT02231411|Procedure|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
249951|NCT02231411|Procedure|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
249952|NCT02231424|Drug|Drug: Berodual®|
249953|NCT02231437|Drug|Berodual®|
249954|NCT02231450|Drug|Lu AE58054 encapsulated film-coated tablets|
249322|NCT02201589|Device|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
249323|NCT02203734|Procedure|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
249324|NCT02203747|Other|Administration of patient self-assessment|
249325|NCT02203760|Drug|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
249326|NCT02203760|Drug|Pazopanib|Pazopanib 800 mg orally once daily
249327|NCT02203773|Drug|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
249328|NCT02203773|Drug|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
249329|NCT02203773|Drug|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
249330|NCT02203773|Drug|Posaconazole|Posaconazole will be administered twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
249331|NCT02203786|Drug|Haloperidol|Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).
Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol.
249650|NCT02236442|Other|Recommendation to use global headache treatment protocol|The global treatment protocole is :
Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor
Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.
Provide a sound-proof helmet to the patient.
Provide a ligth-blocking google to the patient.
If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.
If judged necesary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :
Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidial anti inflamatory or paracetamol or triptan.
Tension headache : nonsteroidial anti inflamatory or paracetamol. Avoid methylmorphine or tramadol if possible.
Cluster headache : Intraveinous or nasal spray sumatriptan and oxygen therapy.
Other etiology : Treatment left at the discretion of the physician in charge of the patient.
249651|NCT02236455|Behavioral|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
249652|NCT02236455|Behavioral|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
249653|NCT02236455|Behavioral|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
254196|NCT02243631|Drug|Probenecid|Treatment
254197|NCT02243644|Drug|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
254198|NCT02243644|Drug|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
254199|NCT02246244|Drug|Escitalopram|
254200|NCT02246257|Other|Simvastatin|LDL > 2.5 is treated with 40 mg
254201|NCT02246257|Other|Losartan|BT > 140/90 mmHg treated with 100 mg OD
254202|NCT00145067|Behavioral|Disease Management Assessment|
254203|NCT02246257|Other|Losartan|DM BT > 130/80 mmHg treated with 100 mg OD
254204|NCT02246257|Other|Losartan|Microalbuminuria (urinary albumin creatinin ratio > 30 mg) treated with 100 mg OD
254205|NCT02246257|Other|Metformin|HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
254206|NCT02246257|Other|Outpatient rheumatology department|(4 times yearly)
254207|NCT02246257|Other|Refered to general practice|
254208|NCT02246270|Drug|Intravescial Heparin|
254209|NCT02246270|Other|Placebo|Intravesical saline
254210|NCT02246296|Dietary Supplement|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
254211|NCT02246296|Dietary Supplement|Modified F75 Milk|This is the experimental group
254212|NCT02246309|Device|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
254213|NCT00002344|Drug|Azithromycin|
254214|NCT00145080|Behavioral|Disease Management Assessment|
254215|NCT02246309|Device|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
249332|NCT02203786|Drug|Fluphenazine|Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).
Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine.
249333|NCT00140283|Procedure|Educational interactive intervention|
248721|NCT02218619|Drug|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
248722|NCT02218619|Drug|Sugar Pill (placebo)|Placebo
248723|NCT02218632|Other|lactose-free diet|standard diet
248724|NCT02218632|Dietary Supplement|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
248725|NCT02218645|Drug|WE 941 OD tablets|
248726|NCT02218645|Drug|Brotizolam|
248727|NCT02218658|Drug|WE941 OD tablets|
248728|NCT02218658|Drug|Brotizolam|
248729|NCT02218671|Drug|WE 941 OD tablets|
248730|NCT00142051|Drug|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
248731|NCT02218684|Drug|Telmisartan|
248732|NCT02218684|Drug|Lacidipine|
248733|NCT02218684|Drug|Placebo|
248734|NCT02218697|Biological|Influsplit™ Tetra (Fluarix™ Tetra)|1 dose administered intramuscularly in deltoid of dominant arm on Day 0.
248735|NCT02221076|Device|Confocal Laser Endomicroscopy (CLE)|
248736|NCT02221089|Drug|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
248737|NCT02221089|Dietary Supplement|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
248738|NCT02221089|Other|Placebo|Placebo capsules identical in appearance to Retaron capsules
248739|NCT02221102|Drug|Aspirin|non-steroidal anti-inflammatory drugs
248740|NCT00142337|Drug|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
248741|NCT02221102|Drug|edoxaban|orally active direct factor Xa inhibitor
248742|NCT02221102|Drug|placebo|
249059|NCT02213757|Drug|Premarin vaginal estrogen cream|
248100|NCT02233231|Drug|Placebo|
248101|NCT02233244|Drug|CTX-4430|
248102|NCT02233244|Drug|Midazolam|
248103|NCT02233257|Drug|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
248413|NCT02225795|Other|Hematopoietic stem cell transplantation|Immuno-ablative regimen for HSCT:
Day Treatment
6 r-ATG 2 mg/kg
5 r-ATG3 2 mg/kg
4 r-ATG3 2 mg/kg
3 Cyclophosphamide with Mesna
2 Cyclophosphamide with Mesna
1 REST 0 PBSC infusion
3 Cyclophosphamide with Mesna
4 Cyclophosphamide with Mesna
6 Start GCSF
248414|NCT02225808|Behavioral|CBT for anxiety in autism|
248415|NCT02225821|Drug|Cephalozin|1000 mg Cephalozin
248416|NCT02225821|Other|Sodium chloride|10 cc of NaCl 0.9%
248417|NCT00142792|Device|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
248418|NCT02225834|Drug|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
248419|NCT02225847|Other|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
248420|NCT02225847|Procedure|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
248421|NCT02225847|Behavioral|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
248422|NCT00143065|Drug|Rituximab|On Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr).
On Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician.
248423|NCT02228239|Drug|Esketamine|Esketamine 84 milligram (mg) [3*1 of spray in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
253954|NCT02257736|Drug|Abiraterone acetate|Participants will receive 1000 mg (four 250 mg tablets) of abiraterone acetate (AA) once daily on an empty stomach until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
253955|NCT02257736|Drug|Prednisone|Participants will receive 5 mg tablet prednisone twice daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
253956|NCT00146809|Drug|Minocyline|
253957|NCT02259985|Drug|Itasetron tablet|
253958|NCT02259985|Drug|Itasetron infusion|
253959|NCT02259985|Other|high fat breakfast|
253960|NCT02259998|Drug|Persantin® new formulation|
253961|NCT02259998|Drug|Persantin® commercial formulation|
253962|NCT02260011|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
253963|NCT02260011|Drug|Atrovent® CFC inhalation aerosol|
253964|NCT02260011|Drug|Placebo|
254283|NCT02253212|Drug|Carboplatin|Carboplatin : 6 cycles - individual dose determination according to renal function and AUC
254284|NCT02253225|Other|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
254285|NCT00145938|Drug|sildenafil|
254286|NCT02253238|Behavioral|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
254287|NCT02253238|Behavioral|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
254288|NCT02253238|Other|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
254289|NCT02253238|Behavioral|Symptoms Surveys|Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.
Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.
254290|NCT02253238|Behavioral|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
254291|NCT02253251|Genetic|KRAS-variant|Participant in these studies will be tested for the KRAS-variant
254292|NCT02253264|Drug|Rituximab|
253653|NCT02264756|Other|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
253654|NCT02264769|Drug|Carbetocin|
253655|NCT02264782|Behavioral|PreView, the Video Doctor Plus Provider Alert|PRE-VIEW is a multimedia program utilizing laptop computers to assess whether or not primary care patients are up to date with cancer screening, assess their stage of change and personal barriers to screening. The Video Doctor, portrayed by an actor, delivers brief, individually tailored stage and barrier specific messages that simulate the ideal physician-patient cancer screening conversation, using a library of digital video clips and complex branching logic. The program then provides the individualized information to the patient's physician in the form of a cue sheet or "Provider Alert."
253656|NCT02264782|Behavioral|Healthy Lifestyles|Individuals in the Control Group will watch a video about healthy lifestyles, including information about exercise and healthy eating. This video was obtained from the Patient Education Institute. There will be no Provider Alert generated for participants in the control group.
253657|NCT02264795|Drug|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
253658|NCT02264808|Other|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
253659|NCT02267174|Behavioral|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
253660|NCT02267187|Procedure|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
253965|NCT02260024|Other|High fat, high caloric meal|
253966|NCT02260024|Drug|Pramipexole IR tablets|
253967|NCT00146822|Device|ENDOTAK RELIANCE G lead|
253968|NCT02260024|Drug|Pramipexole SR C|
253969|NCT02260024|Drug|Pramipexole SR C2|
253970|NCT02260024|Drug|Pramipexole SR C2A|
253971|NCT02260024|Drug|Pramipexole SR C2B|
253972|NCT02260037|Drug|Epinastine nasal|
253973|NCT02260037|Drug|Placebo|
253974|NCT02260050|Drug|WAL 801 CL dry syrup new formulation|
253975|NCT02260050|Drug|WAL 801 CL dry syrup conventional formulation|
253339|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 20 milligram per kilogram (mg/kg) single dose orally dispersed in water after meal.
253340|NCT02271984|Drug|Cysticide|Cysticide tablet 40 mg/kg given with water orally after a meal.
253341|NCT00148174|Behavioral|Intensive telephone followup|Telephone calling
253342|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 10 mg/kg single dose orally dispersed in water after meal.
253343|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 30 mg/kg single dose orally dispersed in water after meal.
253344|NCT02274389|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
253345|NCT02274402|Biological|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
253346|NCT02274415|Biological|Vaccination with the combined vaccine (Prevenar13 ®)|
253347|NCT02274415|Biological|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
253348|NCT02274428|Drug|Pneumostem|human umbilical cord blood derived mesenchymal stem cells
253349|NCT02274454|Drug|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
253350|NCT02274454|Drug|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
253351|NCT02274467|Device|Trans-catheter electric stimulation test|
253352|NCT02274480|Device|cardiac MRI with DWI|
253353|NCT00148473|Drug|Misoprostol|
253661|NCT02267187|Drug|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
253662|NCT02267187|Device|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
253663|NCT02267187|Other|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
253664|NCT02267213|Drug|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.|
253665|NCT02267226|Drug|Octafibrin|
252734|NCT02247973|Biological|mesenchymal stem cells|Intravenous administration of up to 1~2x10^6 MSCs per kg,for 2 times,d0 and d14
252735|NCT02247973|Biological|mesenchymal stem cells|bone marrow derived mesenchymal stem cells from related donors.
252736|NCT02247986|Drug|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
252737|NCT02248012|Drug|Everolimus , temozolomide|
253035|NCT02240433|Drug|LY2157299|LY2157299 administered orally
253036|NCT02240433|Drug|Sorafenib|Sorafenib administered orally
253037|NCT02240446|Device|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
253038|NCT02240446|Device|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
253039|NCT02240459|Drug|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
253040|NCT02240459|Drug|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
253041|NCT00144443|Behavioral|Asthma Trigger Education|
253042|NCT02240459|Drug|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
253043|NCT02240459|Drug|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
253044|NCT02240472|Procedure|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
253045|NCT02240485|Behavioral|Couple therapy|The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the "Alcohol Behavior Couple Therapy" from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors imcompatibles with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support).
253046|NCT02240485|Behavioral|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
253047|NCT02240498|Drug|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
253048|NCT02243098|Drug|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
252745|NCT02248077|Other|Usual and Customary Care (UCC)|
252746|NCT02248090|Drug|AZD9496|AZD9496
252747|NCT02248090|Drug|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
252748|NCT02248103|Procedure|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
252749|NCT02248103|Biological|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
252750|NCT02248116|Drug|Talsaclidine|
252751|NCT02248129|Drug|Telmisartan and hydrochlorothiazide|
252752|NCT02248142|Drug|Pramipexole|
252753|NCT00145353|Drug|Insulin NovoRapid versus Actrapid|
252754|NCT02248155|Drug|Pramipexole|
252755|NCT02248168|Drug|Pramipexole|
252756|NCT02250391|Drug|Placebo|5 days continuous-infusion
252757|NCT02250404|Other|cytology specimen collection procedure|Correlative studies
252758|NCT02250404|Other|laboratory biomarker analysis|Correlative studies
252759|NCT02250417|Other|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
253054|NCT02243137|Drug|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
253055|NCT00144755|Drug|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
253056|NCT02243137|Drug|prasugrel|Administration: one loading dose (60mg)
253057|NCT02243137|Drug|lysine acetylsalicylate|Administration: one dose (450mg iv)
253058|NCT02243150|Drug|G1T28-1 (CDK 4/6 Inhibitor)|
253059|NCT02243150|Drug|Placebo|
253060|NCT02243163|Behavioral|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
253061|NCT02243176|Drug|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
252428|NCT02254824|Behavioral|Lifestyle modification|Lifestyle modification
252429|NCT02254837|Device|Zilver PTX Drug-Eluting Stent|
252430|NCT02254850|Procedure|Flow Mediated Dilation|Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and "software" calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel.
252431|NCT02254850|Drug|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
252432|NCT02254850|Drug|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
252433|NCT02254850|Drug|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
252434|NCT02254850|Drug|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
252435|NCT02254863|Biological|DUOC-01|Intrathecal administration of DUOC-01
252436|NCT02254876|Other|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
252437|NCT02254876|Other|NeuroMuscular Taping (NMT)|The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.
In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus.
252438|NCT00146185|Drug|ALGRX 3268|
252439|NCT02254889|Drug|proton pump inhibitor|). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
252440|NCT02254902|Behavioral|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
252441|NCT02254915|Device|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
252442|NCT02254915|Drug|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
251829|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
251830|NCT00147875|Drug|Gemcitabine|
251831|NCT02268981|Device|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
251832|NCT02268994|Drug|ferric citrate|1 gr ferric citrate containing approximately 210 mg of ferric iron
251833|NCT02268994|Drug|Placebo|Matching placebo
251834|NCT02269007|Biological|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
252128|NCT02261688|Dietary Supplement|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
252129|NCT02261688|Dietary Supplement|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
252130|NCT02261688|Dietary Supplement|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
252131|NCT02261701|Other|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
252132|NCT02261701|Other|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
252133|NCT02261714|Biological|TG01|TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.
Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.
TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.
Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes
252134|NCT00147056|Device|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
252135|NCT02261714|Biological|TG01|For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.
TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.
Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes
252136|NCT02261727|Drug|Theophylline|Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
252137|NCT02261727|Drug|Prednisone|Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
251480|NCT02273544|Drug|Asasantin ER - commercial formulation|
251481|NCT02273557|Drug|Asasantin ER (new formulation I - low)|
251482|NCT02273557|Drug|Asasantin ER (new formulation III - medium)|
251483|NCT02273557|Drug|Asasantin ER (new formulation II - high)|
251484|NCT00148395|Drug|Cisplatin|
251485|NCT02273557|Drug|Asasantin ER (present commercial formulation)|
251486|NCT02273570|Drug|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
251487|NCT02273570|Drug|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
251488|NCT02273583|Drug|continuous oral cyclophosphamide and methotrexate|
251489|NCT02273596|Drug|WTX101|Dosage Form: 15 mg Tablets
251490|NCT02273609|Drug|Vitamin K antagonists (acenocoumarol or warfarin)|INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.
No specific recommendation about treatment will be provided by sponsor.
251835|NCT02269020|Procedure|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
251836|NCT02269033|Behavioral|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
251837|NCT02269033|Behavioral|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
251838|NCT02269046|Other|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
251839|NCT02269046|Drug|Simvastatin|10mg/d,p.o,12 weeks.
251840|NCT02269046|Other|Therapeutic Lifestyle Change|Reduced intakes of saturated fats (<7% of total calories) and cholesterol (<200 mg per day)
Therapeutic options for enhancing LDL lowering
Weight reduction
Increased physical activity
251169|NCT02202239|Drug|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
251170|NCT02204501|Drug|Midazolam 5mg Syrup|All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.
On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.
On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B.
251171|NCT02204501|Drug|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
251172|NCT02204501|Drug|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
251173|NCT02204514|Procedure|Surgery for external snapping hip|
251174|NCT00140374|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
251175|NCT02204527|Dietary Supplement|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
251176|NCT02204527|Dietary Supplement|placebo pill|Placebo
251177|NCT02204540|Behavioral|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
251178|NCT02204553|Drug|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
251179|NCT02204566|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
251180|NCT02204579|Drug|NPSP795|
251181|NCT02204605|Behavioral|Video-based Consensus Opinion|
251182|NCT02204618|Device|cochlear implantation|
251183|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
251184|NCT02204631|Other|Head and Neck Educational Handbook|
251185|NCT00140387|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
251491|NCT02273622|Dietary Supplement|hydroxytyrosol|Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.
251492|NCT02273622|Dietary Supplement|placebo|
250877|NCT02209454|Drug|Keral® tablet|One dose of 25 mg DKP tablet
250878|NCT02209467|Other|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
250879|NCT02209480|Behavioral|Alexander Technique|
250880|NCT02209480|Device|Heat pad application|
250881|NCT02209480|Behavioral|guided imagery|
250882|NCT02209493|Behavioral|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
250883|NCT02209493|Behavioral|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
250884|NCT02209506|Drug|MLN3126|MLN3126 tablets
250885|NCT02209506|Drug|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
250886|NCT02209519|Drug|Metronidazole (male partner)|500 mg PO BID for 7 days
250887|NCT02211989|Drug|BI 14332 CL|
250888|NCT02211989|Drug|Placebo|
250889|NCT02212002|Drug|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
250890|NCT00141219|Drug|Placebo|Placebo
250891|NCT02212015|Drug|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
250892|NCT02212028|Drug|prasugrel|the effects of whole tablets versus crushed tablets will be compared
250893|NCT02212041|Other|disposable electronic cigarettes|Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.
During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained.
250894|NCT02212054|Behavioral|conservative|anal dilatation; colonic lavage; oral probiotic
250895|NCT02212054|Procedure|operative|one stage pull through radical colectomy
250896|NCT02212067|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
250258|NCT02224209|Device|a balloon, stent|Routine stenting procedure:
The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);
Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;
After the placement of stent, the angioplasty is a success when residual stenosis is <30%.
250568|NCT02216994|Behavioral|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
250569|NCT02216994|Drug|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
250570|NCT02217007|Drug|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
250571|NCT02217020|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
250572|NCT02217033|Other|'R' (Electro-kinetically altered beverage)|
250573|NCT02217033|Other|Placebo (water)|
250574|NCT02217046|Procedure|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
250575|NCT02217072|Behavioral|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
250576|NCT02219399|Dietary Supplement|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
250577|NCT02219399|Dietary Supplement|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
250578|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
250579|NCT02219412|Drug|ticagrelor|90 mg bid for 2 weeks
250580|NCT02219412|Drug|Aspirin|100mg Qd for 2 weeks.
250581|NCT02219425|Procedure|endometrial biopsy|
250582|NCT02219438|Drug|ropivacaine|
249955|NCT00143468|Behavioral|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
249956|NCT02231463|Other|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
249957|NCT02231463|Other|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
249958|NCT02231463|Other|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
249959|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
249960|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
249961|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
249962|NCT02231476|Drug|Zoledronic acid|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions
Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
250259|NCT02224235|Drug|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
250260|NCT02224235|Device|Resolute Integrity DES|Resolute Integrity DES
250261|NCT02224235|Device|COBRA PzF|
250262|NCT00000334|Drug|Buprenorphine|
250263|NCT00002324|Drug|Nevirapine|
250264|NCT00142649|Behavioral|diet|
250265|NCT02224235|Drug|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
250266|NCT02224248|Behavioral|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
250267|NCT02224248|Behavioral|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
250268|NCT02224261|Other|Physical Therapy protocol|
250269|NCT02224261|Other|Control|
250270|NCT02226432|Other|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
249654|NCT02236455|Behavioral|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
249655|NCT02236468|Other|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
249656|NCT02236468|Behavioral|WASH/malaria behavior change|WASH/malaria behavior change communication
249657|NCT02236468|Dietary Supplement|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
249658|NCT00144014|Drug|V10153|Single acute intravenous bolus dose up to 10 mg/kg
249659|NCT02236468|Other|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
249660|NCT02198911|Other|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
249661|NCT02198924|Drug|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
249662|NCT02198924|Drug|placebo|control patients are supplied with the corresponding placebo with the same instructions.
249663|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
249664|NCT02198937|Other|Blood sample|
249665|NCT02198963|Drug|Hypochlorous acid solution 106 mg/L|test product
249666|NCT02198963|Drug|0.1% (w/v) Sodium Lauryl Sulfate|positive control
249667|NCT02198963|Drug|0.9% Physiological Saline, USP|negative control
249963|NCT02231489|Drug|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
249964|NCT02231489|Drug|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
249965|NCT02231489|Drug|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
249966|NCT00143481|Drug|Tolterodine ER 4mg QD|
249967|NCT02231502|Other|Vegetable-based convenience food|
249968|NCT02231502|Other|Vegetable meal|
249334|NCT02203786|Drug|Dexedrine|Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.
Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine.
249335|NCT02203786|Drug|Placebo|Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.
Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1.
249336|NCT02203786|Behavioral|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
249337|NCT02203799|Biological|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
249338|NCT02203812|Drug|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
249339|NCT02203812|Drug|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
249340|NCT02203825|Biological|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
249341|NCT02206165|Drug|Candesartan 8mg|Once a day, 8 weeks
249342|NCT02206165|Drug|Candesartan 16mg|Once a day, 8 weeks
249343|NCT02206165|Drug|Amlodipine 5mg|Once a day, 8 weeks
249344|NCT02206165|Drug|Amlodipine 10mg|Once a day, 8 weeks
249345|NCT02206178|Drug|N-acetylcysteine combination with acetaminophen|
249346|NCT02206178|Drug|Placebo|
249347|NCT02206204|Drug|selexipag|
249348|NCT02206204|Drug|placebo for selexipag|
249349|NCT00140569|Procedure|CHOP + TBI and autotransplant|
249350|NCT02206204|Drug|moxifloxacin|
249351|NCT02206204|Drug|moxifloxacin-matching placebo|
249668|NCT02198989|Behavioral|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
249060|NCT02213757|Drug|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
249061|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
249062|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
249063|NCT00141440|Procedure|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
249064|NCT02213796|Drug|Meropenem|
249065|NCT02213809|Behavioral|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
249066|NCT02213809|Behavioral|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
249067|NCT02213822|Other|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
249068|NCT02213835|Other|Specific Carbohydrate diet (SCD)|
249069|NCT02213848|Drug|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
249070|NCT02213848|Drug|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
249071|NCT02213861|Drug|SHAPE|topical gel
249072|NCT02216227|Drug|Chlorhexidine gluconate|Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.
Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery.
249073|NCT02216227|Drug|Cefazolin|All patients will receive Cefazolin during surgery
249074|NCT02216227|Drug|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
249075|NCT02216240|Other|Paramedic|
248424|NCT02228239|Drug|Mirtazapine|Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
248425|NCT02228239|Drug|Placebo (Matched to Esketamine)|Placebo [3*1 in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
248426|NCT02228239|Drug|Placebo (Matched to Mirtazapine)|Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
248427|NCT02228252|Other|Whey protein|
248428|NCT02228252|Other|Casein|
248743|NCT02221115|Device|Google Glass|
248744|NCT02221115|Device|iPad|
248745|NCT02221154|Dietary Supplement|Inofolic®|
248746|NCT02221154|Other|Gonadotropins; Folic Acid|standard ovarian stimulation
248747|NCT02221167|Other|Donor Milk|breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk "comes in."
248748|NCT02221180|Drug|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
248749|NCT02221180|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
248750|NCT02221180|Drug|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
248751|NCT00142337|Drug|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight >60 kg) once daily, starting at the onset of labor and for one month postpartum
248752|NCT02221193|Other|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
248753|NCT02221206|Device|Mini-Screw implant|Mini-screw implants (VectorTASTM8*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
248754|NCT02221219|Drug|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
248755|NCT02221219|Procedure|delay in umbilical cord clamp at birth|provision of a 45 second delay of umbilical cord clamping at birth in preterm infants
254293|NCT02253277|Drug|Nilotinib|Nilotinib will be supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib will not be dosed by weight or body surface area. Medication labels will be in German and comply with the legal requirements of Germany. They will include storage conditions for the drug but no information about the patient. The investigator must emphasize compliance and will instruct the patient to take nilotinib exactly as prescribed.
254294|NCT02253277|Drug|Ruxolitinib|Ruxolitinib will be supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels will be in German and comply with the legal requirements of Germany. They will include storage conditions for the drug but no information about the patient. The investigator must emphasize compliance and will instruct the patient to take ruxolitinib exactly as prescribed.
254295|NCT02253303|Other|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
254296|NCT00145951|Behavioral|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
254297|NCT02253316|Biological|Ixazomib|
254298|NCT02253316|Drug|Lenalidomide|
254299|NCT02253316|Drug|Dexamethasone|
254300|NCT02253329|Procedure|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
254301|NCT02253329|Procedure|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
254302|NCT02253342|Drug|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
249413|NCT02211352|Drug|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
249414|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
249415|NCT02213887|Drug|Pantoprazole|40 mg PO QAM
249416|NCT00141453|Drug|olmesartan medoxomil|Tablets 10, 20, or 40 mg
249417|NCT02213887|Drug|Pantoprazole|0 mg PO QAM
249418|NCT02213900|Drug|Haloperidol|0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
249419|NCT02213900|Drug|Placebo|
249420|NCT02213913|Drug|lenalidomide|Given PO
253976|NCT02260063|Drug|Epinastine syrup|
253977|NCT02260063|Drug|Epinastine tablets|
253978|NCT00146835|Biological|Pediarix|1 or more injections
253979|NCT02260076|Drug|PEG 400|
253980|NCT02260076|Drug|Placebo|
253981|NCT02260089|Drug|Low dose of telmisartan|
253982|NCT02260089|Drug|High dose of telmisartan|
253983|NCT02260089|Drug|Placebo|
253984|NCT02260102|Drug|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations [no change due to enrollment in the study]).
253985|NCT02260115|Device|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
253986|NCT02260115|Procedure|Surgical Control|Surgery only
253987|NCT02260128|Other|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
253988|NCT02260141|Dietary Supplement|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
253989|NCT02262312|Other|Transient elastography|All patients will have a transient elastography performed as a measure of liver stiffness.
253990|NCT02262325|Radiation|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
254303|NCT02253355|Device|Deep Brain Stimulation|
254304|NCT02255500|Drug|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
254305|NCT02255500|Drug|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
254306|NCT02255513|Drug|HLD200|methylphenidate hydrochloride (MPH) Capsules
254307|NCT02255526|Device|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
254308|NCT02255552|Drug|eteplirsen injection|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
253666|NCT02267239|Drug|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (I-EO).
253667|NCT02267239|Drug|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
253668|NCT00002365|Drug|LXR015-1|
253669|NCT00147745|Drug|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
253670|NCT02267239|Drug|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (M-EO).
253671|NCT02267239|Drug|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
253672|NCT02267239|Procedure|professional oral cleaning|scaling and polishing teeth of the volunteers
253673|NCT02267239|Procedure|Plaster cast|Taking a plaster cast of the volunteers' mouth
253674|NCT02267239|Device|IDODS|Specific intraoral device which carries six glass disks
253675|NCT02267252|Other|Antibody-sperm binding|
253676|NCT02267265|Other|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
253677|NCT02267265|Other|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
253678|NCT02267278|Drug|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
253679|NCT02267278|Drug|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
253680|NCT00147745|Drug|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
253991|NCT02262325|Drug|cisplatin|Given IV
253992|NCT02262325|Drug|etoposide|Given IV
253993|NCT02262325|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
253994|NCT00147186|Device|Hylan G-F 20|
253995|NCT02262325|Other|laboratory biomarker analysis|Correlative studies
253049|NCT02243098|Drug|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
253050|NCT02243098|Drug|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
253051|NCT02243111|Radiation|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
253052|NCT02243124|Drug|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
253053|NCT02243124|Drug|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
253354|NCT02274493|Device|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
253355|NCT02274493|Procedure|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
253356|NCT02274493|Procedure|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
253357|NCT02274506|Drug|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
253358|NCT02274506|Drug|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
253359|NCT02274506|Procedure|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
253360|NCT02274519|Other|Tai Chi|Arm 1
253361|NCT02274519|Other|Education|Arm 2
253362|NCT02274532|Device|SoftHand|Biomechanical, ADL, and functional testing.
253363|NCT02274545|Biological|H7N9 Anhui 2013/AA ca|10^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
253364|NCT00148486|Drug|NS 2330|
253365|NCT02274545|Biological|Inactivated subvirion H7N9 vaccine|30 mcg
253366|NCT02274558|Drug|NBI-98854|NBI-98854 40 mg capsules
253367|NCT02274558|Drug|Placebo|NBI-98854 placebo capsules
253368|NCT02274571|Drug|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
253369|NCT02274571|Other|Placebo|non active
253062|NCT02243176|Drug|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
253063|NCT02243189|Drug|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
253064|NCT02243189|Drug|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
253065|NCT02243189|Drug|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
253066|NCT00002341|Drug|Itraconazole|
253067|NCT00144768|Drug|laronidase|dose of 0.58mg/kg body weight IV every week
253068|NCT02243202|Drug|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
253069|NCT02243202|Drug|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
253070|NCT02243202|Drug|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
253071|NCT02243202|Drug|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
253072|NCT02243215|Other|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
253073|NCT02243228|Drug|GM-CSF|
253074|NCT02245815|Dietary Supplement|use probiotics Boucardii|group A will be administered the lactobacillus boucardii probiotic (1x109 colonies forming units (UFC) per day for 3 weeks). The diagnosis of NEC will be made using the Bell criteria by the attending physician. Gastric tolerance will be measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) will be measured at the beginning and at the end of treatment.
253075|NCT00145002|Drug|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
253380|NCT02238223|Drug|Alesion®|
253381|NCT02238236|Drug|Alesion®|Dry Syrup
253382|NCT02238249|Drug|Alesion®|Dry Syrup
253383|NCT02238262|Drug|Telmisartan|
253384|NCT02238275|Drug|Micardis® plus|
253385|NCT02238288|Drug|Aminocaproic acid|Crushed tablet in the dental socket
252443|NCT02257125|Behavioral|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
252760|NCT00145587|Drug|Systemic chemotherapy and antibodies|Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease
Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis.
252761|NCT02250430|Drug|SB204|SB204 2% and 4% to left and right cheeks
252762|NCT02250443|Drug|BYM338 (Bimagrumab)|
252763|NCT02250456|Procedure|Echo doppler|vascular ultrasound explorations
252764|NCT02250469|Device|Treatment with the Axium SCS system|
252765|NCT02250469|Device|Treatment with the Medtronic SCS System|
252766|NCT02250482|Biological|Optivate® (Human Coagulation Factor VIII)|
252767|NCT02250495|Device|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
252768|NCT02250508|Biological|Optivate® (Human Coagulation Factor VIII)|
252769|NCT02250508|Biological|Haemate P® (Human Coagulation Factor VIII)|
252770|NCT02250521|Device|McGrath MAC enhanced direct laryngoscope|The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct larygnoscopy with an inline video camera for an enhanced view. The rugged, portable design and low cost per use make the McGRATH® MAC EDL the laryngoscope to choose for everyday use. McGRATH® MAC enhanced direct laryngoscopes augment patient safety with an intuitive design.
252771|NCT00145600|Drug|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
252772|NCT02250534|Other|Very low nicotine content cigarettes|
252773|NCT02250560|Biological|Replenine®-VF (High Purity Factor IX)|
252774|NCT02250573|Biological|Replenine®-VF (High Purity Factor IX)|
252775|NCT02250586|Behavioral|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
252776|NCT02250599|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
252777|NCT02250599|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
252138|NCT02261727|Drug|Placebo (for prednisone)|Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily
Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily
252139|NCT02261727|Drug|Placebo (for Theophylline)|One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
252140|NCT02264054|Drug|[14C]talsaclidine, oral|
252141|NCT02264054|Drug|[14C]talsaclidine, iv|
252142|NCT02264067|Drug|Talsaclidine|
252143|NCT02264067|Drug|Placebo|
252144|NCT02264080|Drug|WAL2014|
252145|NCT02264080|Drug|Placebo|
252146|NCT02264093|Drug|Propranolol|
252444|NCT02257125|Behavioral|low incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game does not include visual effects or monetary rewards.
252445|NCT02257138|Drug|Ruxolitinib|Phase I starting dose of Ruxolitinib: 10 mg by mouth twice a day for a 28 day cycle.
Phase II starting dose of Ruxolitinib: MTD from Phase I.
252446|NCT02257138|Drug|Decitabine|Phase I and II: Decitabine 20 mg/m^2 by vein on Days 1 - 5 of each 28 day cycle.
252447|NCT00146549|Drug|Trastuzumab|
252448|NCT02257151|Drug|BMS-986142|
252449|NCT02257151|Drug|Placebo|
252450|NCT02257164|Procedure|Femoral nerve block|2 mg/ml
252451|NCT02257164|Procedure|obturator nerve block|
252452|NCT02257164|Procedure|intraarticular injection|
252453|NCT02257177|Drug|Inhaled TD139|DPI Galectin-3 inhibitor
252454|NCT02257177|Drug|Placebo|DPI placebo
252455|NCT02257190|Behavioral|Control|One hour of rest.
252456|NCT02257190|Behavioral|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
252457|NCT02257190|Behavioral|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
251841|NCT00147888|Procedure|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
251842|NCT02269059|Drug|MK-7680|MK-7680 10 mg and 100 mg capsules
251843|NCT02269072|Drug|Testosterone|Testosterone cream applied daily for two weeks
251844|NCT02269072|Drug|Nesiritide|Administered IV once during the study
251845|NCT02269072|Drug|Leuprolide|Administered twice during the study by injection
251846|NCT02269072|Drug|Anastrozole|Daily pill for 8 weeks
251847|NCT02269072|Drug|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
251848|NCT02269085|Drug|Ibrutinib|Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.
Phase II Starting Dose: MTD from Phase I.
251849|NCT02271282|Drug|GHRH/Ghrelin combined Injection|
251850|NCT02271295|Drug|Enoxaparine|Enoxaparine 4000UI/day during 24 months
251851|NCT00148109|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
251852|NCT02271308|Behavioral|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
251853|NCT02271321|Other|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
252147|NCT00147381|Drug|Tacrolimus|Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.
till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months.
252148|NCT02264093|Drug|Talsaclidine|
252149|NCT02264106|Drug|Lefradafiban tablet|
252150|NCT02264106|Drug|Lefradafiban double chamber sachet|
252151|NCT02264106|Drug|Pantoprazole|
252152|NCT02264119|Drug|Lefradafiban tablet|
252153|NCT02264119|Drug|Pantoprazole tablet|
251493|NCT02273635|Drug|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
251494|NCT02273635|Drug|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
251495|NCT00148395|Drug|Mitomycin|
251496|NCT02273648|Device|Drug Eluting Stent (DES)|
251497|NCT02273661|Drug|Liposomal amphotericin B (Ambisome®)|
251498|NCT02273674|Device|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
251499|NCT02276196|Drug|Insulin glulisine|Insulin analogue
251500|NCT02276209|Drug|Dasotraline|Dasotraline 4 mg once daily
251501|NCT02276209|Drug|Dasotraline|Dasotraline 6 mg once daily
251502|NCT02276209|Other|Placebo|Placebo once daily
251503|NCT02276222|Drug|Glycopyrrolate (SUN-101 )|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID)
251504|NCT00002371|Drug|Indinavir sulfate|
251505|NCT00148668|Drug|Taxotere|Given every three weeks starting week 3 and ending on week 14
251506|NCT02276222|Drug|tiotropium (Spiriva®)|Spiriva (tiotropium) 18 mcg once daily (QD)
251507|NCT02276235|Device|Catgut embedding group|An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.
Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)
251508|NCT02276235|Device|sham catgut embedding group|The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.
Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)
251509|NCT02276248|Radiation|Intensity-modulated radiation therapy|total dose: 50 to 56 grays per fraction: 2 grays
251510|NCT02276248|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
251511|NCT02276261|Procedure|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
250897|NCT02212067|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
251186|NCT02204644|Drug|Flumatinib 600mg qd|
251187|NCT02204644|Drug|Imatinib 400mg qd|
251188|NCT02204657|Device|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
251189|NCT02204670|Other|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
251190|NCT02204683|Drug|Aflibercept|Intravitreal aflibercept
251191|NCT02204696|Procedure|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
251192|NCT02204709|Other|2N Trout|Diploid/2N trout source
251193|NCT02207140|Dietary Supplement|HOWARU Restore|
251194|NCT02207179|Device|LumaScan Image Guided Surgery|
251195|NCT02207192|Other|Postural change in lung volumes: sitting to Supine|Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.
Pulmonary function tests were performed both in the sitting and then in the supine position.
251196|NCT02207205|Drug|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
251197|NCT02207218|Drug|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
251198|NCT02207231|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 148 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 148 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 148 (Group III).
251199|NCT02207231|Drug|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
251200|NCT02207231|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
251201|NCT02207231|Drug|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
251202|NCT00140660|Drug|doxorubicin|
250583|NCT02219451|Other|exercise training|exercise training
250584|NCT02219464|Device|Nasopharyngeal catheter|
250585|NCT02219464|Device|Nasal Cannula|
250586|NCT02219464|Procedure|Oxygen Supplementation|Initially set at 3 liters/minute
250898|NCT02212080|Drug|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
250899|NCT02212080|Drug|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
250900|NCT02212106|Biological|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
250901|NCT00141232|Drug|Atorvastatin and Omega-3 fatty acids|
250902|NCT02212106|Biological|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
250903|NCT02212119|Drug|Botulinum Toxin|
250904|NCT02212119|Drug|Saline|
250905|NCT02212132|Other|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
250906|NCT02212158|Behavioral|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
250907|NCT00141505|Drug|Bifeprunox|
250908|NCT02214459|Behavioral|DASH Mobile mhealth enhanced coaching|
250909|NCT02214472|Behavioral|Biofeedback|
250910|NCT02214472|Drug|Placebo|
250911|NCT02214485|Behavioral|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
250912|NCT02214485|Behavioral|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
250271|NCT02226445|Other|Combined ADHD medication and psychosocial counseling|The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.
ADHD medication:
First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.
When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.
If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.
If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine.
250272|NCT02226458|Drug|EPI-743|
250273|NCT00002326|Drug|Adefovir|
250274|NCT00142844|Drug|Placebo|
250275|NCT02226484|Drug|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
250276|NCT02226497|Device|Health Telemonitoring|Use home telemonitoring device
250277|NCT02226497|Other|Quality-of-Life Assessment|Ancillary studies
250278|NCT02226497|Other|Questionnaire Administration|Ancillary studies
250279|NCT02226497|Procedure|Supportive Care|Receive standard outpatient supportive care
250587|NCT02219464|Procedure|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
250588|NCT02219477|Drug|ABT-450/ritonavir/ABT-267|tablet
250589|NCT00142103|Drug|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
250590|NCT02219477|Drug|ABT-333|tablet
250591|NCT02219477|Drug|Ribavirin|tablet
250592|NCT02219490|Drug|ABT-450/r/ABT-267|tablet
250593|NCT02219490|Drug|ABT-333|tablet
250594|NCT02219490|Drug|Ribavirin (RBV)|tablet
250595|NCT02219503|Drug|ombitasvir/ABT-450/ritonavir|tablet
250596|NCT02219503|Drug|dasabuvir|tablet
250597|NCT02219516|Drug|RDEA3170|
250598|NCT02219529|Device|MCE|
249969|NCT02231515|Device|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
249970|NCT02231515|Device|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
249971|NCT02231528|Device|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
249972|NCT02231528|Device|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
249973|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
249974|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is turned off.
249975|NCT02233985|Drug|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
249976|NCT02233985|Drug|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
249977|NCT02233998|Other|Mouth Rinse 1|
249978|NCT02233998|Other|Mouth Rinse 2|
249979|NCT02233998|Other|Mouth Rinse 3|
249980|NCT02234011|Drug|Ketamine|
249981|NCT02234011|Drug|Placebo|
249982|NCT02234024|Dietary Supplement|Supplementation of dairy-derived concentrated gangliosides.|
249983|NCT02234037|Other|Decitabine and Exercise|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise > 10 minutes of muscle strengthening, > 10 minutes of aerobic exercise (treadmill walking or cycling), > 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
250280|NCT02226510|Drug|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
250281|NCT02226510|Drug|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
244610|NCT02517554|Behavioral|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
244611|NCT02517554|Behavioral|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
244612|NCT00002492|Procedure|conventional surgery|
244613|NCT00181168|Drug|Recombinant thyrotropin|
244614|NCT02517554|Behavioral|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
244615|NCT02517567|Device|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
244616|NCT02517567|Device|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
244617|NCT02517567|Device|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
244618|NCT02517567|Other|No intervention|
244619|NCT02517580|Dietary Supplement|Vitamin K2 (MK7)|
244620|NCT02519751|Dietary Supplement|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
244621|NCT02519764|Other|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
244622|NCT02519764|Other|Not hydration when thirsty|Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a "hydration when thirsty" protocol.
244623|NCT02519777|Drug|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
244624|NCT02519777|Drug|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
244625|NCT02519777|Drug|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
244626|NCT00181688|Drug|Iressa (ZD1839)|
244627|NCT02519777|Drug|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
244911|NCT02513069|Behavioral|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
249076|NCT00141713|Drug|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
244320|NCT02524197|Drug|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
244321|NCT02524197|Drug|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
244322|NCT02524197|Drug|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
244323|NCT00182351|Procedure|Serial Compression Ultrasound|
244324|NCT02524197|Drug|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
244325|NCT02524210|Drug|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
244326|NCT02524210|Drug|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
244327|NCT02524210|Drug|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
244328|NCT02524223|Other|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
244329|NCT02524223|Other|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
244330|NCT02524223|Other|systematic HPV Status in newborns in case of pregnancy|
244331|NCT02524236|Drug|Botox injection in the prostate|transrectal access of prostatic injection
244332|NCT02524249|Drug|Caffeine|
244333|NCT02524249|Drug|Placebo (dextrose)|
244334|NCT00182364|Drug|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
244335|NCT02524262|Dietary Supplement|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
244336|NCT02524275|Drug|Capecitabine|Given PO
244337|NCT02526563|Procedure|ropivicaine|Blood draws to measure serum ropivicaine
244338|NCT02526576|Biological|Stromal Vascular Fraction|The SVF obtained from adipose tissue will be added to the graft
248756|NCT02221232|Drug|Chloraprep|ZuraPrep Config 1, ZuraPrep Config 2, Vehicle Product and Reference Product Chloraprep are applied.
248757|NCT02221232|Drug|ZuraPrep Config 1|ZuraPrep with ~70% Isopropyl Alcohol - First configuration
248758|NCT02221232|Drug|ZuraPrep Config 2|ZuraPrep with ~70% Isopropyl Alcohol - Second configuration
248759|NCT02223637|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
248760|NCT02223650|Device|Overminus treatment|2.50D overminus spectacles
248761|NCT02223650|Device|Non-overminus treatment|spectacles without overminus or no spectacles
248762|NCT02223676|Procedure|Clinical pharmacists conduct medication history|pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
249077|NCT02216240|Other|Standard care|
249078|NCT02216253|Drug|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
249079|NCT02216253|Other|Placebo|Placebo tablet twice a day 7 days before and after surgery
249080|NCT02216266|Drug|Physostigmine|
249081|NCT02216266|Other|Sodium Chloride solution|
249082|NCT02216279|Drug|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
249083|NCT02216292|Other|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
249084|NCT02216292|Other|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
249085|NCT02216305|Procedure|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorroidal base with absorbable suture
249086|NCT02216305|Procedure|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorroid. Other procedures will not be associated.
249087|NCT00141726|Drug|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
249421|NCT02213913|Drug|etoposide|Given IV
249422|NCT02213913|Drug|prednisone|Given PO
249423|NCT02213913|Drug|vincristine sulfate|Given IV
249424|NCT02213913|Drug|doxorubicin hydrochloride|Given IV
249425|NCT02213913|Drug|cyclophosphamide|Given IV
249426|NCT02213913|Biological|rituximab|Given IV
249427|NCT00002317|Drug|Trimetrexate glucuronate|
249428|NCT00141453|Drug|Placebo Tablets|Matching placebo tablets
249429|NCT02213913|Other|quality-of-life assessment|Ancillary studies
249430|NCT02213913|Other|laboratory biomarker analysis|Correlative studies
249431|NCT02213926|Drug|ACP-196|
249432|NCT02213952|Drug|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
249433|NCT02213952|Other|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
249745|NCT02206503|Drug|Dexamethasone|
249746|NCT02206516|Device|Transcranial Direct Current Stimulation|
249747|NCT02206529|Behavioral|Social Network Engagement+Std Treatment|
249748|NCT02206529|Behavioral|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
249749|NCT00140595|Drug|doxorubicin|
249750|NCT00140907|Drug|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
249751|NCT02208843|Drug|Afatinib|Afatinib tablet once daily until progression
249752|NCT02208856|Drug|BIBR 796 BS|
254309|NCT02255565|Drug|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
254310|NCT00146289|Drug|MICARDIS® (telmisartan)|
254311|NCT02255565|Drug|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
254312|NCT02255565|Drug|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
254313|NCT02255578|Device|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
254314|NCT02255578|Drug|clomiphene citrate treatment|
254315|NCT02255591|Drug|Lidocaine-adrenaline added gadolinium.|
254316|NCT02255604|Drug|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
254317|NCT02255604|Drug|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
254318|NCT02255604|Drug|0.1 ml Isoton saline|4 injection into a lymphnode
254319|NCT02255617|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
254320|NCT02255630|Other|Cycling Exercise|
254321|NCT00146302|Biological|Bacille Calmette Guerin (BCG)|
254322|NCT02255643|Device|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
254323|NCT02255656|Drug|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
254324|NCT02255669|Device|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
254325|NCT02255669|Device|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
249434|NCT02213965|Device|Peripheral IV catheter|Intravenous access according to Instructions For Use
249435|NCT02213991|Device|Intraoperative radiotherapy using Intrabeam®|Operation day
Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.
Purse string suture pulles up tissues and wraps up the applicator.
Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.
After IORT, applicator was out of the operative field, and usual wound closure will be done.
Postoperative period
Chemotherapy WBRT (46 Gy) for 4~5 weeks
Endocrine therapy or target therapy
249436|NCT02214004|Drug|Trastuzumab|- Eight times IV administration of trastuzumab per 3 weeks
Trastuzumab 8mg/kg on Day 1 of Cycle 1
Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8
253996|NCT02262338|Biological|AGT-182|
253997|NCT02262351|Other|30 Second Pulse Check|To detect atrial fibrillation
253998|NCT02262351|Device|Watch BP Home A|Blood pressure device that detects atrial fibrillation
253999|NCT02262351|Device|HeartCheck Hand-held ECG device|To detect atrial fibrillation
254000|NCT02262364|Biological|APS|See above
254001|NCT02262377|Behavioral|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
254002|NCT02262390|Procedure|Partner Notification Reminders|For all 3 arms, the following will be done:
All participants will have an antenatal clinic visit every 4 weeks until delivery.
All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.
Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test.
254003|NCT02262403|Other|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
254004|NCT02262416|Drug|leuprolide|normal saline
254005|NCT00147199|Drug|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
254006|NCT02262429|Other|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
254007|NCT02262429|Other|ONS Standard Feeding|Standard of care
254008|NCT02262442|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
254009|NCT02262442|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
254010|NCT02262455|Drug|STM 434|STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
254011|NCT02262455|Drug|Liposomal doxorubicin|Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial (cohorts 8 and 9). Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
254326|NCT02255682|Drug|Simvastatin|
254327|NCT02255682|Dietary Supplement|Q10|
253370|NCT02274584|Genetic|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
253371|NCT02238132|Drug|ATROVENT® inhalets|
253372|NCT02238145|Drug|Atrovent® Inhaletten|
253373|NCT02238158|Drug|Atrovent® inhalets|
253374|NCT02238171|Drug|Atrovent® inhalets|
253375|NCT02238184|Drug|Atrovent®|
253376|NCT02238184|Drug|Ventilat®|
253377|NCT02238197|Drug|Atrovent® Inhalation Solution|
253378|NCT02238210|Drug|Atrovent®|
253379|NCT00144183|Drug|Zidovudine (ZCV)|
253681|NCT02269631|Other|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
253682|NCT02269644|Drug|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
253683|NCT02269644|Drug|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
253684|NCT00147966|Drug|rituximab|treatment with rituximab
253685|NCT02269644|Drug|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
253686|NCT02269644|Drug|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
253687|NCT02269657|Device|EOS® imaging system|Intervention includes adjusting the arm position in full spinal radiography
253688|NCT02269670|Drug|everolimus|Given PO
253689|NCT02269670|Drug|anastrozole|Given PO
253690|NCT02269670|Drug|letrozole|Given PO
253691|NCT02269670|Drug|tamoxifen citrate|Given PO
253692|NCT02269670|Drug|fulvestrant|Given IM or PO
253693|NCT02269670|Drug|megestrol acetate|Given PO
253694|NCT02269683|Procedure|Robot-assisted distal pancreatectomy|
253386|NCT02238288|Other|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
253387|NCT02238288|Drug|lidocaine and epinephrine|2%
253388|NCT02238288|Drug|Paracetamol|750 mg
253389|NCT02238301|Other|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
253390|NCT00144183|Drug|3TC|
253391|NCT02238301|Other|Bold sequence|A first sequence BOLD will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.
Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation.
253392|NCT02238314|Drug|Tipranavir low dose|
253393|NCT02238314|Drug|Tipranavir high dose|
253394|NCT02238314|Drug|Ritonavir|
253395|NCT02238314|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
253396|NCT02238314|Drug|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
253397|NCT02238327|Procedure|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
253398|NCT02238327|Procedure|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
253399|NCT02238327|Procedure|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
253400|NCT02240498|Drug|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
253704|NCT02269735|Drug|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
253705|NCT02269735|Biological|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
253706|NCT00147979|Device|Bridging by PTFE without bounded heparin|Bridging by PTFE without bounded heparin
252778|NCT02250599|Drug|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
252779|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose A|
252780|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose B|
253076|NCT02245815|Dietary Supplement|use probiotics Multi-species|Group B will be administered multi-species probiotic (1x109 colonies forming units (UFC) per day for 3 weeks). The diagnosis of NEC will be made using the Bell criteria by the attending physician. Gastric tolerance will be measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) will be measured at the beginning and at the end of treatment.
253077|NCT02245828|Drug|QCC374|Single and multiple ascending doses of QCC374
253078|NCT02245828|Drug|Placebo|Placebo comparator
253079|NCT02245841|Drug|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
253080|NCT02245854|Device|Exacto™|Cold snare polypectomy
253081|NCT02245867|Drug|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
253082|NCT02245880|Device|Glidescope|videolaryngoscope
253083|NCT02245880|Device|ILMA|handling of the device till the optimal ventilation achieved
253084|NCT02245893|Procedure|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
253085|NCT02245906|Dietary Supplement|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
253086|NCT00145002|Drug|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
253087|NCT02245906|Dietary Supplement|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
253088|NCT02245906|Dietary Supplement|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
253089|NCT02245919|Other|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
252458|NCT00146549|Drug|Vinorelbine|
252459|NCT02257203|Behavioral|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
252460|NCT02257203|Behavioral|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
252461|NCT02257216|Other|Vayarin®|Medical Food
252462|NCT02257216|Other|Placebo|Cellulose
252463|NCT02257229|Procedure|Surgical|Surgery only
252464|NCT02257229|Procedure|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
252465|NCT02257229|Procedure|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
252466|NCT02257242|Drug|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
252467|NCT02257242|Drug|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
252781|NCT02252497|Drug|Active comparator : Tranexamic Acid (Exacyl)|1g Exacyl Intra Venous, just before surgery
Then infusion of 1g of Exacyl over eight hours .
252782|NCT02252497|Drug|Placebo comparator : physiologic serum|1g Intra Venous just before surgery
Then infusion of 1g of physiologic serum over eight hours
252783|NCT02252510|Other|HALOSPERM|
252784|NCT02252523|Drug|Dexmedetomidine|
252785|NCT02252536|Drug|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
252786|NCT02252536|Drug|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
252787|NCT02252549|Device|SPIES+WLI assisted TURB|
252788|NCT00145808|Device|Given® Diagnostic System|
252789|NCT02252549|Device|WLI assisted TURB|
252790|NCT02252562|Device|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
252791|NCT02252575|Device|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
252154|NCT02264119|Device|Lefradafiban double chamber sachet|
252155|NCT02264132|Drug|Pramipexole ER tablet|
252156|NCT02264132|Drug|Pramipexole IR tablet|
252157|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - low|
252158|NCT00147381|Drug|Alemtuzumab|Day 0: Campath-1H 30 mg IV infusion over 3-6 hours
Day 1: Campath-1H 30 mg IV infusion over 3-6 hours
252159|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - medium|
252160|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - high|
252161|NCT02264145|Drug|Ethanolic Solution From Respimat®|
252162|NCT02264158|Drug|Telmisartan high|
252163|NCT02264158|Drug|Telmisartan low|
252164|NCT02264158|Drug|Lacidipine high|
252165|NCT02264158|Drug|Lacidipine low|
252166|NCT02264158|Drug|Placebo|
252167|NCT02264171|Drug|Tamsulosin HCl|
252168|NCT02264171|Drug|Ketoconazole|
252169|NCT00002362|Drug|Emtricitabine|
252170|NCT00147394|Drug|Risperidone|
252171|NCT02264184|Drug|Tamsulosin|
252172|NCT02264184|Drug|Paroxetine|
252468|NCT02257242|Drug|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
252469|NCT00002356|Drug|Fomivirsen sodium|
252470|NCT00146549|Drug|Paclitaxel|
252471|NCT02259465|Behavioral|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
252472|NCT02259465|Dietary Supplement|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
251854|NCT02271334|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
251855|NCT02271334|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
251856|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
251857|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
251858|NCT02271347|Drug|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
251859|NCT02271360|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
251860|NCT02271360|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 21 days
251861|NCT02271373|Behavioral|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
251862|NCT00148109|Drug|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
251863|NCT02271386|Behavioral|Supporting Practice for ADHD (SPA)|The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.
3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period.
251864|NCT02271399|Drug|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
251865|NCT02271399|Drug|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
251866|NCT02271412|Drug|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
251867|NCT02271412|Drug|Placebo|Placebo
251868|NCT02271425|Drug|Evacetrapib Tablet|Oral administration
251869|NCT02271425|Drug|Evacetrapib Intravenous|Intravenous administration
251870|NCT02271438|Drug|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6*140 mg capsules) of ibrutinib in Treatment B.
251203|NCT02207244|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 148 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 148 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 148 depending upon PASI response (Group III).
251204|NCT02207244|Drug|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
251512|NCT02276261|Procedure|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
251513|NCT02276274|Drug|SYR-322-MET|Oral administration of SYR-322-MET
251514|NCT02276300|Drug|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
251515|NCT02276300|Drug|Sargramostim|Sargramostim is part of Her2 vaccination
251516|NCT00148668|Drug|Carboplatin|Given every three weeks starting week 3 and ending on week 14
251517|NCT02276300|Drug|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
251518|NCT02276300|Drug|Imiquimod|Imiquimod is part of Her2 vaccination
251519|NCT02276313|Device|Passeo-18 Lux|Endovascular Therapy
251520|NCT02276326|Dietary Supplement|VSL#3 sachets|4 sachets a day for 4 months
251521|NCT02276339|Other|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
251522|NCT02276352|Drug|Treatment 1|
251523|NCT02276352|Drug|Treatment 2|
251524|NCT02276352|Drug|Treatment 3|
251525|NCT02239861|Biological|TAA-Specific CTLs|Patients may be pre-medicated with diphenhydramine (Benadryl) up to 1 mg/kg IV (max 50 mg) and acetaminophen (Tylenol) 10 mg/kg po (max 650 mg), though this is not mandatory.
Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
If patients with active disease have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals, each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.
251526|NCT02239874|Dietary Supplement|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
251527|NCT02239874|Dietary Supplement|Fish oil and vitamin D placebo|840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
250913|NCT02214498|Drug|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
250914|NCT02214498|Drug|Placebo|
250915|NCT02214511|Behavioral|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
250916|NCT02214511|Behavioral|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
251205|NCT02207244|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
251206|NCT02207244|Drug|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
251207|NCT02207257|Drug|PER977|Reversal of edoxaban-induced anticoagulation
251208|NCT02207257|Drug|Placebo|Reversal of edxoaban-induced anticoagulation
251209|NCT02207270|Procedure|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
Patients randomized to ON will receive usual overnight care and will be discharged the following morning. Costs and outcomes will be identified in-hospital by study personnel. They will receive a follow up phone call from a study coordinator at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
251210|NCT02207283|Drug|Tadalafil|
251211|NCT02207283|Drug|Placebo|
251212|NCT02207296|Device|Plethysmographic variability index|
251213|NCT00002312|Drug|Delavirdine mesylate|
251214|NCT00140660|Drug|cyclophosphamide|
251215|NCT02207309|Drug|Pazopanib|
251216|NCT00140972|Drug|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
251217|NCT02209519|Other|Placeob (male partner)|matching placebo capsules PO BID for 7 days
251218|NCT02209532|Device|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
251219|NCT02209545|Drug|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
251220|NCT02209545|Drug|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
250599|NCT02219529|Device|Standard gastroscopy|
250600|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
250601|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
250602|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
250603|NCT02219555|Drug|NaCl and lidocaine placebo/salt water|1ml of 0.9% NaCl and 2 ml of 1% lidocaine placebo/salt water injection at the time of enrollment into the study. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
250604|NCT02221791|Dietary Supplement|Placebo|Participants will consume 70g white chocolate + placebo capsules
250605|NCT02221804|Behavioral|14 days of voluntary step count reduction to no more than 1500 steps/day.|
250606|NCT00142441|Device|Pulsed dye laser|
250607|NCT02221817|Procedure|Trochanter bursa injections|
250608|NCT02221817|Device|Ultrasound|
250609|NCT02221830|Drug|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
250610|NCT02221856|Procedure|SureSmile|SureSmile, a type of orthodontic treatment, is a custom wire system which uses three dimensional models to create virtual treatment plans and fabricate customized, robot-bent arch wires.
250917|NCT02214524|Device|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
250918|NCT00141518|Drug|Levodopa-carbidopa in an intestinal gel formulation|should be kept within a range of 0.5-10 ml/hour (1--200 mg levodopa/hour) and is usually 2-6 ml/hour (40-120 mg levodopa/hour)
250919|NCT02214537|Other|MACS|
250920|NCT02214550|Drug|microgestin 1/20|Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
Continuous OC use - Pills containing hormones will be taken every day for 1 year
250921|NCT02214563|Dietary Supplement|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
250922|NCT02214563|Dietary Supplement|Olive oil|
250923|NCT02214589|Other|Oral glucose, facilitated tucking, NNS|
250924|NCT02214589|Other|Oral glucose and NNS|
250282|NCT02226536|Behavioral|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
250283|NCT02226549|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
250284|NCT02226549|Drug|VDV|VDV 80 mg tablet administered orally once daily
250285|NCT00142870|Drug|Bupropion|150 mg, twice a day
250286|NCT02226549|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
250287|NCT02226562|Drug|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
250288|NCT02226562|Drug|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
250289|NCT02226575|Behavioral|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
250290|NCT02226588|Drug|Misoprostol|
250291|NCT02228928|Drug|CAPNP, 50 ug/cm2 capsaicin patch|
250292|NCT02228928|Drug|CAPNP, 100 ug/cm2 capsaicin patch|
250293|NCT02228928|Drug|0.075% capsaicin cream|
250294|NCT02228954|Procedure|Molecular imaging|
250295|NCT02228967|Behavioral|SBIRT|SBIRT is an "opportunistic" approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a "teachable moment," are delivered a brief, motivational intervention matched to their level of risk.
250296|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
250297|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
250298|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
250299|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
244912|NCT02513069|Drug|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
244913|NCT02513069|Drug|Nicotine lozenge|Participants will be prescribed one form of nicotine replacement "rescue" treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred "rescue" treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings.
244914|NCT02513069|Device|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
244915|NCT02513069|Device|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
244916|NCT02513082|Procedure|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
244917|NCT02513095|Drug|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
244918|NCT00180531|Device|Renewal TR2|
244919|NCT02513108|Procedure|same day discharge|same day discharge after PCI for stable CAD
244920|NCT02513121|Other|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
244921|NCT02513147|Drug|Dolutegravir + 2 NRTI|
244922|NCT02513147|Drug|PI + 2 NRTI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir, if the 2 NRTIs are abacavir + Lamivudine
244923|NCT02513160|Drug|Beclomethasone Dipropionate|Beclomethasone Dipropionate 320 BAI & MDI and 640 mcg BAI & MDI
244924|NCT02513160|Drug|Placebo|Matching Placebo BAI & MDI
244925|NCT02515383|Behavioral|Questionnaires|Part 1: Participants complete the EQ-5D and a single-item quality of life (QOL) questionnaire.
Part 2: Participants complete the EQ-5D and a single item quality of life question only after first MDASI (adolescent version) completion.
244926|NCT00180778|Drug|Low dose steroids|
244927|NCT02515396|Drug|MMI-0100|
244928|NCT02515396|Drug|Placebo|
244929|NCT02515409|Device|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
244930|NCT02515409|Device|CPAP|CPAP, as a first line treatment in OSAS.
244339|NCT02526576|Biological|Biopsy|a subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
244340|NCT02526602|Procedure|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
244341|NCT02526602|Procedure|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
244628|NCT02519816|Other|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
244629|NCT02519829|Procedure|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
244630|NCT02519829|Procedure|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
244631|NCT02519829|Procedure|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
244632|NCT02519829|Procedure|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
244633|NCT02519842|Drug|Fosaprepitant|
244634|NCT02519842|Drug|Placebo for fosaprepitant|
244635|NCT02519842|Drug|Ondansetron|
244636|NCT02519842|Drug|Dexamethasone|
244637|NCT00181688|Drug|Arimidex (Anastrozole)|
244638|NCT02519842|Drug|5-HT3 antagonist|
244639|NCT02519855|Biological|Zostavax™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
244640|NCT02519855|Biological|Placebo to Zostavax™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
244641|NCT02519855|Biological|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
244642|NCT02519868|Device|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
244643|NCT02519868|Device|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
244644|NCT02519881|Procedure|Microfracture|simple microfracture of ankle
244645|NCT02521987|Procedure|8mm port|Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
249088|NCT02216318|Other|blue light|
249089|NCT02216331|Drug|TMC207|This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under "Arms" description.
249090|NCT02216331|Drug|rifapentine|
249091|NCT02216331|Drug|rifampicin|
249092|NCT02216357|Drug|Ifetroban, Oral Capsule|
249093|NCT02216357|Drug|Placebo, Oral Capsule|
249094|NCT02216383|Drug|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
249095|NCT02218697|Biological|Pneumovax 23/Pneumovax|1 dose administered intramuscularly in deltoid of non-dominant arm on Day 0 (Co-Ad group) and Day 28 (Control group).
249096|NCT02218697|Biological|Placebo|1 dose intramuscularly in deltoid of non-dominant arm on Day 0 (Control group) and Day 28 (Co-Ad group).
244342|NCT02526615|Drug|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
244343|NCT02526615|Drug|Metformin|Patients received either placebo, metformin or rosiglitazone
244344|NCT02526615|Drug|Placebo|Patients received either placebo, metformin or rosiglitazone
244345|NCT02526641|Procedure|Functional Hepatic Nitrogen Clearance (FHNC)|
244346|NCT02526641|Procedure|Galactose Elimination Capacity (GEC)|
244347|NCT00182611|Procedure|conventional surgery|
244348|NCT02526641|Procedure|Liver vein catheterization|
244349|NCT02526654|Device|Heidelberg Edge Perimeter|All glaucoma subjects and controls are tested on HEP machine to see how well the machine can detect glaucoma
244350|NCT02526654|Device|Octopus Visual Field|All glaucoma subjects and controls are tested on OVF machine to see how well the machine can detect glaucoma
244351|NCT02526654|Device|Optical Coherence Tomography|Patients obtain imaging of the optic nerve head by OCT.
244352|NCT02526667|Drug|Chlorhexidine Gluconate|comparison with other CHG products
244353|NCT02526667|Other|Vehicle|Cloth with Excipients no CHG
249753|NCT02208856|Drug|Placebo|
249754|NCT02208856|Other|high fat standardized breakfast|
249755|NCT02208882|Drug|BMS-986120|
249756|NCT02208882|Drug|Placebo|
249757|NCT02208882|Drug|Midazolam|
249758|NCT02208908|Other|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
249759|NCT02208934|Drug|PBF-999|5, 10, 20 and 40 mg of PBF-999
249760|NCT02208934|Drug|Placebo|Placebo for all dosis of PBF-999
249761|NCT00140920|Drug|MK0966; rofecoxib|
249762|NCT02208947|Behavioral|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
249763|NCT02208947|Behavioral|PREPARE|PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or "played" like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library).
249764|NCT02208960|Device|Neonatal Kit|Contents of the neonatal kit:
Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.
4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.
Sunflower oil emollient (50 mL)
ThermoSpot
Mylar infant sleeve
Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.
Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker.
250060|NCT02201914|Drug|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
250061|NCT02204033|Drug|unlabelled hMAb BIWA 4 - high dose|
250062|NCT02204046|Drug|BIWA 4|
250063|NCT00140322|Behavioral|Exercise, fall risk reduction|
250064|NCT02204059|Drug|hMAb BIWA 4|
250065|NCT02204072|Drug|BI 836845|
250066|NCT02204072|Drug|Enzalutamide|
250067|NCT02204072|Drug|Enzalutamide|
249437|NCT02216383|Drug|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
249438|NCT02216383|Drug|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
249439|NCT02216409|Drug|Hu5F9-G4|
249440|NCT00141739|Drug|Etanercept|Etanercept 0.4 mg/kg per dose [maximum dose 25 mg] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.
Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant.
249441|NCT02216422|Drug|ABT-450/r/ABT-267|Tablet
249442|NCT02216422|Drug|ABT-333|Tablet
249443|NCT02216422|Drug|Ribavirin (RBV)|Tablet
249444|NCT02216448|Other|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
249445|NCT02216448|Other|OR Training|Training on diagnostic knee arthroscopy in the OR
249446|NCT02216461|Drug|Low dose of BIBW 2948 BS for oral inhalation|
249447|NCT02216461|Drug|Medium dose of BIBW 2948 BS for oral inhalation|
249448|NCT02216461|Drug|High dose of BIBW 2948 BS for oral inhalation|
249449|NCT02216461|Drug|Placebo|
249450|NCT02216474|Other|Transcranial direct current stimulation|
249451|NCT00141752|Device|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
249452|NCT02216487|Drug|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
249453|NCT02216500|Dietary Supplement|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
249454|NCT02216513|Drug|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
249765|NCT02208960|Behavioral|Neonatal Stimulation|A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:
Eye contact and talking to children
Responsive feeding and caregiving
Singing songs, including those with gentle touch
254328|NCT02257736|Drug|Placebo|Participants will receive matching placebo to JNJ56021927 once daily until study drug discontinuation.
254329|NCT02257749|Other|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
254330|NCT02257749|Other|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
254331|NCT02257762|Dietary Supplement|LNS|Compact, stockcube-sized snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
254332|NCT02257762|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
254333|NCT02257762|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet.
254334|NCT02257775|Genetic|n/a - observational|
254335|NCT02257788|Biological|PRO 140|Humanized monoclonal antibody to CCR5
254336|NCT00146575|Device|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
254337|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
254338|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
254339|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
254340|NCT02257814|Behavioral|Incredible Years Teacher Training|
254341|NCT02257814|Behavioral|Preschool PATHS|
254342|NCT02257814|Behavioral|Tools of the Mind|
254343|NCT02257827|Radiation|IMRT|The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.
The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy.
254344|NCT02257853|Other|Stress Reduction|Gentle chair yoga and breath work
254345|NCT02257918|Drug|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
253695|NCT00147979|Device|Bridging by PTFE with bounded heparin|Bridging by PTFE with bounded heparin
253696|NCT02269683|Procedure|Laparoscopic distal pancreatectomy|
253697|NCT02269696|Drug|Metoprolol|Intraoperative metoprolol infusion.
253698|NCT02269696|Drug|Normal saline|Equal of volume compared to metoprolol.
253699|NCT02269709|Device|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI), a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
253700|NCT02269722|Device|Vascular compression device- RADAR TM-Short clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
253701|NCT02269722|Device|Vascular compression device RADAR TM-Long clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
253702|NCT02269735|Drug|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
253703|NCT02269735|Biological|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
254012|NCT02262468|Radiation|x ray|
254013|NCT02262481|Drug|dydrogesterone|
254014|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
254015|NCT02264821|Drug|ropivacaine infiltration|wound infiltration
254016|NCT02264821|Drug|intrathecal morphine|100 µg added to the spinal anaesthesia
254017|NCT02264821|Drug|placebo|placebo in spinal anaesthesia and in wound infiltration
254018|NCT02264834|Drug|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
254019|NCT02264834|Drug|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
254020|NCT02264834|Procedure|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
254021|NCT02264847|Drug|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
254022|NCT02264847|Drug|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
253707|NCT02269735|Drug|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
253708|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 20 mg/kg single dose orally dispersed in water without meal.
253709|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 20 mg/kg single dose directly disintegrated orally without water after meal.
253710|NCT02271997|Drug|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
253711|NCT02271997|Drug|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
253712|NCT02271997|Drug|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
253713|NCT02272010|Other|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
253714|NCT02272010|Other|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
253715|NCT02272023|Behavioral|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
253716|NCT00148226|Behavioral|Decision Aid|
253717|NCT02272023|Behavioral|Single session of Motivational Interviewing|
253718|NCT02272036|Procedure|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
253719|NCT02272036|Device|mobile phone|SMS received by mobile phone
253720|NCT02272049|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
253721|NCT02272062|Other|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
253722|NCT02272075|Device|Mobile OCT M3 scope|
253723|NCT02272088|Behavioral|physical activity-moderate|cross -over of moderate and intense physical activity
254033|NCT02264951|Dietary Supplement|Olive oil|a triglyceride containing mostly three oleic acids
254034|NCT02264951|Dietary Supplement|Carrot|mainly water and glucose
253090|NCT02245932|Dietary Supplement|Resveratrol|12 weeks of 150 mg resveratrol (2 times 75mg/day)
253091|NCT02245932|Dietary Supplement|Placebo|12 weeks of placebo supplementation (two doses per day)
253092|NCT02245945|Drug|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
253093|NCT02248181|Drug|Pramipexole|
253401|NCT02240498|Device|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
253402|NCT02240498|Device|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
253403|NCT02240498|Device|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
253404|NCT00144456|Drug|ED-71|0.75μg/day(p.o.)for 144 weeks
253405|NCT02240498|Device|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
253406|NCT02240498|Device|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
253407|NCT02240498|Device|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
253408|NCT02240498|Device|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
253409|NCT02240511|Dietary Supplement|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
253410|NCT02240511|Other|Resistance Exercise|
253411|NCT02240524|Procedure|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
253412|NCT02240524|Procedure|Systemic chemotherapy|
253413|NCT02240524|Procedure|HIPEC|
252792|NCT02252588|Drug|Chlorhexidine|Oral Rinse
252793|NCT02252588|Other|Placebo|Oral Rinse
252794|NCT02252614|Drug|naproxen sodium codein|Pain intensity, contramal consumption
252795|NCT02252614|Drug|paracetamol codein|Pain intensity, contramal consumption
252796|NCT02252614|Drug|Placebo|Pain intensity, contramal consumption
252797|NCT02252627|Drug|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
252798|NCT02252627|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
252799|NCT00145834|Behavioral|community based trial|
252800|NCT02252627|Other|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
252801|NCT02252627|Drug|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
252802|NCT02252640|Biological|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
252803|NCT02252640|Biological|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
253094|NCT02248194|Device|Tactile electrosurgical ablation probe|
253095|NCT02248194|Device|Hysteroscopic endometrial ablation|
253096|NCT02248207|Drug|Pramipexole|
253097|NCT02248220|Drug|Pramipexole|
253098|NCT02248233|Drug|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
253099|NCT02248233|Drug|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
253100|NCT02248246|Device|Harmonic ACE®+7 Shears|Vessel sealing performance assessed for transection and sealing of the following named vessels:
Inferior mesenteric artery (IMA)
Inferior mesenteric vein (IMV) (if identified)
253101|NCT00145366|Drug|Recombinant human thyrotropin (Thyrogen)|
253102|NCT02248259|Drug|BI 409306|Oral single dose of BI 409306
252473|NCT02259465|Dietary Supplement|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
252474|NCT02259491|Drug|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
252475|NCT02259504|Device|HyperSoft® 3D|HyperSoft® 3D or any other bare metal coil but must finish the remainder of the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils
252476|NCT02259517|Drug|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
252477|NCT02259530|Behavioral|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
252478|NCT02259543|Other|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
252479|NCT02259556|Biological|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
252480|NCT00146744|Biological|Mtb72F/AS02A|
252481|NCT02259569|Other|Pressure-controlled ventilation|
252482|NCT02259569|Other|Volume-controlled ventilation|
252483|NCT02259582|Drug|Pemetrexed|
252484|NCT02259582|Drug|Carboplatin|
252485|NCT02259582|Drug|demcizumab|
252486|NCT02259595|Drug|HPN-07|500-1,500 mg oral capsules administered in a single dose
252487|NCT02259595|Drug|NAC|1,200mg NAC administered via oral capsule in single dose
252488|NCT02259595|Drug|Placebo|placebo oral capsule
252804|NCT02252640|Biological|ChAd63 ME-TRAP (5 x 10^10 vp)|
252805|NCT02252640|Biological|MVA ME-TRAP (2 x 10^8 pfu)|
252806|NCT02252666|Device|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
251871|NCT02273674|Device|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
252173|NCT02266576|Behavioral|Enhanced DPP|The Enhanced Diabetes Prevention Program (DPP) will include all components of the Standard DPP [16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator] delivered by the Indian Health Center and additional components to address psychosocial issues. The Enhanced DPP components include 4 visits with a mental health counselor, active referrals to mental health services, and traditional healing workshops, such as the use of talking circles to address specific psychosocial issues that are a result of historical trauma, stress, and grief. The intervention will occur over the course of 20 weeks.
252174|NCT02266589|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
252175|NCT02266602|Radiation|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
252176|NCT02266615|Genetic|Biobanking of biomaterial for future genetic research.|
252177|NCT02266628|Biological|RSV-F Vaccine|
252178|NCT02266628|Biological|Saline Placebo|
252179|NCT02266641|Behavioral|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
252180|NCT02266641|Dietary Supplement|multivitamin supplement|
252181|NCT02266654|Other|IV fluids|Normal Saline 0.9%
252182|NCT00147693|Behavioral|Diagnosis of caregivers' problems|
252183|NCT02266654|Other|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
252184|NCT02266667|Device|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
252185|NCT02266667|Device|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
252186|NCT02266680|Behavioral|Yoga Treatment Group|The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
252187|NCT02266693|Behavioral|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
251528|NCT02239874|Dietary Supplement|Vitamin D placebo and fish oil placebo|placebo
251529|NCT02239874|Dietary Supplement|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
251530|NCT02239887|Device|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
251531|NCT02239900|Drug|Ipilimumab|Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.
Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.
Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4
251872|NCT02273687|Device|Vivid S6 GE Ultrasound|Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.
The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe.
251873|NCT02273700|Drug|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
251874|NCT02273713|Drug|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
251875|NCT02273726|Drug|Epoetin Alfa|Epoetin alfa will be dosed intravenously three times a week.
251876|NCT02273726|Drug|FG-4592|Roxadustat will be dosed orally three times a week.
251877|NCT02273739|Drug|AG-221|AG-221 administered orally on every day of 28 day cycles until disease progression or unacceptable toxicities. Multiple doses.
251878|NCT00002369|Drug|Stavudine|
251879|NCT00148395|Drug|Ifosfamide|
251880|NCT02273752|Drug|everolimus|Given PO
251881|NCT02273765|Drug|Tenofovir + lamivudine + raltegravir|In this arm, patients will receive the following medications :
Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)
Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)
Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)
Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food
251882|NCT02273765|Drug|Tenofovir + lamivudine + efavirenz|In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:
Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)
OR:
• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)
Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight.
251883|NCT02273778|Procedure|MRI Scan|
251221|NCT02209558|Behavioral|Visual Sternal Precautions|Visual depiction of SPs in addition to "standard of care" written precautions
251222|NCT02209571|Other|Venous blood markers|Routine venous blood sampling
251223|NCT02209597|Drug|Wellbutrin XL® 300mg|
251224|NCT02209597|Drug|300mg bupropion XL 1|
251225|NCT02209597|Drug|300mg bupropion XL 2|
251226|NCT02209597|Drug|300mg bupropion XL 3|
251227|NCT00140972|Drug|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
251532|NCT00144365|Drug|Antiretroviral therapy|
251533|NCT02239900|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
251534|NCT02239913|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
251535|NCT02239913|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
251536|NCT02239913|Drug|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
251537|NCT02239913|Drug|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
251538|NCT02239926|Drug|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
251539|NCT02239926|Drug|Placebo|
251540|NCT02239939|Device|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
251541|NCT02239939|Behavioral|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
251542|NCT02239952|Drug|Sunitinib|50 mg once daily, oral use for 14 days
251543|NCT00144378|Drug|Irinotecan|
251544|NCT02239952|Drug|vandetanib|300 mg, once daily, oral use for 14 days
250925|NCT02214589|Other|Facilitated tucking and NNS|
250926|NCT02214602|Drug|Epirubicin|Experimental: Study group(Epirubicin)
in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
250927|NCT02214615|Drug|Carbamazepine|Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.
Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days.
250928|NCT02214615|Drug|Placebo|
250929|NCT02217072|Behavioral|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
250930|NCT02217098|Procedure|GIC Restorations|Restorations using Glass Ionomer Cement
250931|NCT00141804|Drug|Sirolimus|
250932|NCT02217098|Procedure|Carbomer Restorations|Restorations using Glass Carbomer
250933|NCT02217098|Procedure|Compomer Restorations|Restorations using Compomer
250934|NCT02217111|Behavioral|Adventures in Voice: Pediatric Voice Therapy|
250935|NCT02217124|Other|dried apples|120 calories
250936|NCT02217124|Other|muffin|120 calories
251228|NCT02209610|Device|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
251229|NCT02209610|Drug|Intrathecal Fentanyl|Mu-opioid receptor agonist
251230|NCT02209636|Drug|Lanthanum carbonate|Non-calcium containing phosphorus binder
251231|NCT02209636|Drug|placebo|Table identical to lanthanum carbonate but with no active ingredient
251232|NCT02209636|Drug|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
251233|NCT02209636|Drug|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
250611|NCT02221856|Procedure|Insignia|Insignia, a type of orthodontic treatment, is a custom appliance system which uses digital intra-oral scans to create a virtual model of the desired final occlusion, and then fabricates reverse-engineered brackets.
250612|NCT02221856|Procedure|Invisalign|Invisalign, a type of orthodontic treatment, is a custom aligner system which uses a series of aligners fabricated according to the desired final outcome for each individual.
250613|NCT02221856|Procedure|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
250614|NCT02221869|Drug|Xyrem|
250615|NCT02221882|Drug|LY3164530|Administered IV.
250616|NCT02221895|Other|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
250617|NCT00142454|Biological|NY-ESO-1 protein|
250618|NCT02221895|Other|Postpartum follow up 6-8wk after delivery|control arm
250619|NCT02221908|Device|Mespere Venus 1000 CVP System|
250620|NCT02221921|Device|MicroPort's Transcatheter Aortic Valve and Delivery System|
250621|NCT02221934|Device|Altius|Electrical signal
250622|NCT02221947|Drug|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
250623|NCT02221947|Drug|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
250624|NCT02221960|Biological|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
250625|NCT02221960|Biological|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
250626|NCT02221973|Dietary Supplement|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
250627|NCT02221986|Behavioral|Interdisciplinary rehabilitation|
250628|NCT00002322|Drug|Zidovudine|
250629|NCT00142454|Drug|Imiquimod|
250630|NCT02221999|Drug|Paclitaxel|
250631|NCT02221999|Drug|Cisplatin|
250632|NCT02221999|Drug|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
245209|NCT00179881|Procedure|External Beam Radiation Therapy|
245210|NCT02508545|Other|perceived egocentric distance (PED) measurements|
245211|NCT02508545|Other|Parabolic flight|
245212|NCT02508558|Other|motion perception and locomotor operation performance measurements|
245213|NCT02508558|Other|parabolic flight|
245214|NCT02508571|Other|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. This training is provided once a day, 5 days a week. And it is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
245215|NCT02508571|Other|Oral sensorimotor stimulation (OSMS)|The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier.
In combined DST and OSMS group, each intervention is provided once a day, 5 days a week. And it is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
245216|NCT02508584|Biological|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
245217|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
245218|NCT02508623|Drug|Rifaximin|Rifaximin 550 mg tablet BID for 60 days
245219|NCT02508623|Drug|Placebo|Placebo 1 tablet BID for 60 days
245220|NCT00179894|Behavioral|Physician training|Physicians are trained in guidelines for medication management.
245221|NCT02508636|Drug|Enzalutamide|
245222|NCT02508636|Drug|Leuprolide|
245223|NCT02508649|Drug|selepressin|
245224|NCT02508649|Drug|placebo|
245225|NCT02508662|Other|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
245226|NCT02508688|Procedure|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
244646|NCT02521987|Procedure|12mm port|Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
244647|NCT02522013|Drug|Aminophylline|
244648|NCT00182013|Drug|Quetiapine|Open treatment with Quetiapine
244649|NCT02522013|Drug|isotonic saline|
244650|NCT02522039|Drug|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
244931|NCT02515422|Drug|Ketamine|Subcutaneous infiltration of ketamine
244932|NCT02515422|Drug|Bupivacaine|Subcutaneous infiltration of bupivacaine
244933|NCT02515422|Drug|Placebo (0.9% saline solution)|
244934|NCT02515435|Drug|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 750mg Qd, p.o, continue until disease progression
244935|NCT02515448|Drug|gentamicin|
244936|NCT02515461|Device|Low energy shockwave therapy|Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.
Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).
Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG.
244937|NCT00180791|Drug|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
244938|NCT02515474|Device|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
244939|NCT02515474|Device|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
244354|NCT02526667|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
244355|NCT02526680|Device|OrCam|All thirteen glaucoma subjects in study used the OrCam low vision aid
244356|NCT02526693|Device|RAPDx Pupillography|The Konan RAPDx (Konan Medical USA, Irvine, CA) utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify the pupillary response to light
244357|NCT02526706|Other|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
244358|NCT00182611|Procedure|neoadjuvant therapy|
244359|NCT02526719|Procedure|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
244360|NCT02528825|Drug|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
244651|NCT02522039|Drug|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
244652|NCT02522039|Drug|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
244653|NCT02522052|Other|Blue mussel diet|5 meals a week containing blue mussels
244654|NCT02522052|Other|Meat/Control diet|5 meals a week containing meat
244655|NCT02522078|Drug|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
244656|NCT02522078|Drug|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
244657|NCT02522091|Device|functional brain MRI|
244658|NCT02522091|Other|Neuropsychology tests|
244659|NCT00182026|Behavioral|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
244660|NCT02522104|Drug|Siklos|
250068|NCT02204085|Drug|GO-203-2c|
250069|NCT02204098|Biological|Mammaglobin-A DNA Vaccine|
250070|NCT02204098|Drug|Anastrozole|Anastrozole is in a class of drugs called nonsteroidal aromatase inhibitors and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive.
250071|NCT02204098|Drug|Letrozole|Letrozole is in a class of drugs called nonsteroidal aromatase inhibitors and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive.
250072|NCT02204098|Drug|Tamoxifen|Tamoxifen is in a class of drugs called selective estrogen receptor modulators and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive.
250073|NCT02204098|Drug|Exemestane|Exemestane is in a class of drugs called aromatase inhibitors and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive.
250074|NCT00140335|Behavioral|handwashing|
250075|NCT02204098|Drug|Goserelin|Letrozole is in a class of drugs called gonadotropin-releasing hormone (GnRH) agonists and is considered endocrine therapy. This drug is given to women who are pre-menopausal.
The treating physician will decide what type and dose of endocrine therapy the participant will receive.
250076|NCT02204111|Other|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
250077|NCT02204124|Device|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
250078|NCT02204124|Device|EnSeal|
250079|NCT02204137|Other|Falls Risk Questionnaire|
250080|NCT02204137|Other|Cancer and Aging Research Group Geriatric Assessment|
250081|NCT02204137|Other|Falls Efficacy Scale-International (FES-1)|
250378|NCT02236754|Drug|18F-FP-DTBZ|The drug, no carrier added [18F]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce [18F]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 mCi of [18F]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
250379|NCT02236754|Radiation|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
250380|NCT02199184|Drug|Ofatumumab|300 mg by vein on day 1 (before infusions) and 2,000 mg on days 2 and 11 during Cycle 1 only. Starting with Cycle 2, participants receive Ofatumumab 2,000 mg by vein on days 1 and 8 of Cycles 2 and 4, and day 1 and 11 of Cycle 3 for a total of 8 injections of ofatumumab. Cycles are 21 - 28 days.
250381|NCT02199184|Drug|Etoposide|50 mg/m2/day by vein days 1- 4 of a 21 - 28 day cycle.
249766|NCT02208973|Drug|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
249767|NCT02208973|Drug|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
249768|NCT02208986|Drug|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
249769|NCT02208999|Device|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
249770|NCT02209012|Drug|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
249771|NCT02209012|Drug|Topical Solution Vehicle|Vehicle PDT given in CP0108
249772|NCT00140920|Drug|Comparator: diclofenac 2x 75 mg|
249773|NCT02211378|Other|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
249774|NCT02211378|Other|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
249775|NCT02211391|Other|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
249776|NCT02211391|Other|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
249777|NCT02211417|Drug|DS107G|
249778|NCT00141154|Drug|Placebo|
249779|NCT02211417|Drug|Placebo|
249780|NCT02211430|Behavioral|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
249781|NCT02211430|Behavioral|Best Practice (BC) Control|For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current "best practice" guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4).
250082|NCT02204137|Other|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
254346|NCT02257918|Drug|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
249455|NCT02216513|Drug|placebo|normal saline IV for 4 hours for 5 consecutive days
249456|NCT02216526|Other|Cetaphil® Restoraderm|
249457|NCT02216526|Other|Excipial|
249458|NCT02216539|Behavioral|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
249459|NCT02216539|Procedure|Lung transplantation|
249460|NCT02216539|Other|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
249461|NCT02216552|Dietary Supplement|Resveratrol, Lifestyle Counseling, Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
249462|NCT02218905|Behavioral|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
249463|NCT02218918|Behavioral|Ground walk training|3 times a week and 6 weeks
249464|NCT02218918|Behavioral|Supervised Treadmill Walk training|3 times a week and 6 weeks
249465|NCT02218931|Behavioral|Targeted ESTEEM diet|The key components of the diet are:
High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)
The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants
249466|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
249467|NCT02218944|Behavioral|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
249468|NCT02218957|Procedure|Extended Pouch RYGB|
249469|NCT00142077|Device|Electronic health record and messaging system|
249470|NCT02218957|Procedure|Standard RYGB|
254023|NCT02264860|Dietary Supplement|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
254024|NCT02264873|Drug|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
254025|NCT00147498|Drug|CP-690,550|30 mg BID for 6 weeks
254026|NCT02264886|Radiation|MRI-guided stereotactive body radiation therapy|
254027|NCT02264899|Other|in Memento-VASCOD|Pulse wave velocity assessment
Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences
Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement
Neuropsychological testing and behaviorial and mood scales
Urinary albumin excretion measurement
254028|NCT02264912|Drug|antiplatelet drugs - P2Y12 antagonists|
254029|NCT02264925|Device|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
254030|NCT02264938|Dietary Supplement|Antioxidant|Oral supplemmentation with antioxidants
254031|NCT02264951|Dietary Supplement|Tributyrin|a triglyceride containing three C4-acids
254032|NCT02264951|Dietary Supplement|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
254347|NCT00146588|Drug|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
254348|NCT02257944|Behavioral|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
254349|NCT02257944|Other|Treatment as Usual|treatment as usual
254350|NCT02257957|Drug|PRP injection|
254351|NCT00146835|Biological|Licensed DTPa containing vaccine|1 or more injections
254352|NCT02260154|Drug|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
254353|NCT02260167|Other|A mix of natural treatments and medications|
254354|NCT02260180|Drug|A-101|Topical Solution
254355|NCT02260193|Drug|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
254035|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
254036|NCT00002362|Drug|Stavudine|
254037|NCT00147498|Other|Placebo|Placebo tablets
254038|NCT02267278|Behavioral|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
254039|NCT02267291|Other|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
254040|NCT02267304|Drug|50 mL of sodium chloride (0,9%)|
254041|NCT02267304|Drug|Morphine 0,05mg/kg|
254042|NCT02267304|Drug|Naloxone 10mg|
254043|NCT02267317|Drug|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
254044|NCT02267317|Other|D5W|5% Dextrose Water = Vehicle
254045|NCT02267330|Procedure|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
254046|NCT02267343|Drug|ONO-4538|
254047|NCT02267343|Drug|Placebo|
254048|NCT00147758|Drug|Colesevelam hydrochloride|
254049|NCT02267356|Drug|VT-1161|
254050|NCT02267356|Drug|Placebo|
254051|NCT02267369|Behavioral|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
254052|NCT02267369|Behavioral|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
254053|NCT02267369|Behavioral|Basic fitness program|Participants can register workshops online and track program participation.
254054|NCT02267382|Drug|VT-1161|
254055|NCT02267382|Drug|Placebo|
254056|NCT02267395|Other|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
253414|NCT02240537|Drug|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
253415|NCT00144456|Drug|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
253416|NCT02240537|Drug|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
253417|NCT02240537|Drug|Montanide|Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.
Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration.
253418|NCT02240550|Device|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
253724|NCT02272088|Behavioral|Intense physical activity|cross -over of moderate and intense physical activity
253725|NCT02272101|Dietary Supplement|Vitamin D versus placebo|Cross-over design
253726|NCT02272127|Drug|icotinib|
253727|NCT00148239|Behavioral|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
253728|NCT02272153|Other|Egg refined grain|
253729|NCT02272153|Other|Egg Whole Grain|
253730|NCT02272153|Other|Cereal Refined grain|
253731|NCT02272166|Drug|propofol|
253732|NCT02272166|Drug|Sevoflurane|
253733|NCT02274597|Device|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
253734|NCT02274610|Drug|Docetaxel-PNP|Docetaxel Polymeric Nanoparticle Formulation
253735|NCT02274610|Drug|Taxotere|Docetaxel
253736|NCT02274623|Drug|CTAP101 Capsules|escalating doses
253737|NCT00002369|Drug|Zidovudine|
253738|NCT00148499|Drug|Ambroxol hydrochloride (Mucoangin?)|
253103|NCT02248259|Drug|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
253104|NCT02248259|Drug|BI 409306|Oral single dose
253105|NCT02248272|Other|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
253106|NCT02248272|Other|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
253107|NCT02248285|Device|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
253108|NCT02248298|Drug|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
253109|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose C|
253419|NCT02240550|Device|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
253420|NCT02243241|Drug|HYD|Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg [(1) 40 mg tablet + (1) 120 mg tablet] (day 15) extended-release tablets administered orally every 24 hours.
253421|NCT02243241|Drug|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
253422|NCT02243241|Drug|Placebo for HYD|Placebo to match HYD tablets administered orally every 24 hours.
253423|NCT02243241|Drug|Placebo for moxifloxacin|Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
253424|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
253425|NCT02243254|Drug|high dose remifentanil|high dose remifentanil
252807|NCT02252692|Drug|Enalapril|oral administration
252808|NCT02254928|Drug|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
252809|NCT02254941|Drug|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
252810|NCT02254941|Biological|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
252811|NCT02254954|Drug|Macitentan in combination with RT and TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
252812|NCT02254967|Drug|Fidaxomicin|oral
252813|NCT02254967|Drug|Vancomycin|oral
252814|NCT00146198|Drug|ALGRX 4975|
252815|NCT02254980|Device|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
252816|NCT02254980|Device|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
252817|NCT02254993|Drug|C16G2|antimicrobial peptide
252818|NCT02255006|Device|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
252819|NCT02255006|Device|Sham acupuncture|For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
Volunteers undergo FMD measurement and acupuncture like above methods.
252820|NCT02255006|Drug|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
253110|NCT00145600|Drug|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
253111|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose D|
252188|NCT02266706|Drug|ceftolozane/tazobactam|
252489|NCT02259608|Biological|BCG vaccine SSI|BCG vaccination
252490|NCT02259621|Drug|Nivolumab|Anti-PD-1 Therapy
252491|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
252492|NCT02259634|Behavioral|Patient Navigation|Motivational Interviewing
252493|NCT02259647|Drug|Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
252494|NCT02259647|Drug|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo|Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
252495|NCT02261740|Behavioral|Yoga Therapy|A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).
Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice.
252496|NCT02261753|Dietary Supplement|Classical ketogenic diet|A high fat low carbohydrate, low protein diet.
252497|NCT02261766|Device|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
252498|NCT02261779|Drug|Tranylcypromine|
252499|NCT02261779|Drug|Tretinoin|
252500|NCT00147108|Device|ExAblate 2000|
252501|NCT02261792|Procedure|24 hours Trendelenburg position|Trendelenburg position
252502|NCT02261792|Procedure|24 hours bed rest|24 hours bed rest after EBP
252503|NCT02261792|Procedure|EBP|Autologous Epidural Blood Patch
252504|NCT02261805|Drug|Ganetespib and doxorubicin|IV ganetespib and doxorubicin
252505|NCT02261818|Behavioral|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
252506|NCT02261831|Other|obese patients|collection of blood sampling and biopsies
252507|NCT02261831|Other|diabetic patients|collection of blood sampling and biopsies
252508|NCT02261831|Other|patients free of obesity and diabetes|collection of blood sampling and biopsies
251884|NCT02273778|Procedure|PET-CT Scan|
251885|NCT02273778|Other|No intervention|
251886|NCT02273791|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
251887|NCT02273791|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
252189|NCT02266719|Device|CMD|The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft, except as noted below.
In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used. Only in rare situations in which large accessory renal arteries or separate visceral arteries may exist, the device may include more than 4 fenestrations to accommodate these additional vessels.
Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms.
252190|NCT02266732|Device|Stimuplex HNS 12|
252191|NCT02266745|Drug|PT-112 Injection|
252192|NCT02269085|Drug|Carfilzomib|Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.
Phase II Starting Dose: MTD from Phase I.
252193|NCT02269085|Behavioral|Phone Calls|Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
252194|NCT02269098|Other|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
252195|NCT00147901|Drug|Fludarabine|
252196|NCT02269111|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
252197|NCT02269111|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
252198|NCT02269111|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
252199|NCT02269111|Procedure|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
251545|NCT02242383|Drug|Telmisartan in combination with hydrochlorothiazide|
251546|NCT02242396|Drug|Telmisartan|
251547|NCT00144651|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
251548|NCT02242396|Drug|Telmisartan hydrochlorothiazide|
251549|NCT02242409|Drug|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
251550|NCT02242435|Biological|Ampion <5 kDa ultrafiltrate of 5% human serum albumin|4 mL intra-articular injection of Ampion
251551|NCT02242461|Drug|Rhodiola placebo capsules|Corn starch
251552|NCT02242461|Drug|Rhodiola Crenulata|Rhodiola Crenulata
251553|NCT02242474|Drug|Anti-TNF suspended perioperatively|
251888|NCT02276365|Drug|BI 10773|
251889|NCT02276365|Drug|Pioglitazone|
251890|NCT00148681|Drug|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
251891|NCT02276378|Drug|Telmisartan low|
251892|NCT02276378|Drug|Telmisartan high|
251893|NCT02276378|Drug|Hydrochlorothiazide (HCTZ)|
251894|NCT02276378|Other|Japanese meal|
251895|NCT02276391|Drug|Telmisartan/HCTZ combination|
251896|NCT02276391|Drug|Telmisartan|
251897|NCT02276404|Behavioral|relaxation training|The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: "Body Scan", mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes.
251898|NCT02276404|Other|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
251899|NCT02276417|Other|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
251234|NCT02209636|Procedure|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
251235|NCT02209636|Procedure|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
251236|NCT02209636|Procedure|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
251237|NCT02209649|Drug|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
251238|NCT00140985|Drug|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
251239|NCT02209649|Drug|Lacidipine|
251240|NCT02209649|Drug|Telmisartan|
251241|NCT02209662|Device|APIC-PRP|APIC-PRP
251242|NCT02209662|Other|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
251243|NCT02209675|Other|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
251244|NCT02212171|Other|TRIAP|The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.
Administrative staff:
Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.
Nursing staff:
They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.
GP:
They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc.
251245|NCT02212184|Other|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
251554|NCT02242474|Drug|Anti-TNFα continued perioperatively|
251555|NCT02242487|Drug|CVT-301|
251556|NCT02242500|Procedure|Coronally Advanced Flap|
251557|NCT02242500|Device|Mucograft|
251558|NCT00002340|Drug|Pentamidine isethionate|
250633|NCT02224274|Drug|Clopidogrel|
250634|NCT02224274|Drug|Ticagrelor|
250635|NCT02224287|Procedure|Technologist control of fluoroscopy|Technologist control of fluoroscopy
250937|NCT02217163|Drug|Carfilzomib, Cyclophosphamide, Dexamethasone|Carfilzomib is administered over 30 minutes as an infusion. For cycle 1 only, Carfilzomib is administered at 20mg/m2 IV on days 1 and 2, followed by escalation to 56mg/m2 on days 8,9,15 and 16 on a 28 day cycle. Patients who tolerate 56mg/m2 dose are kept at this dose for the subsequent cycles on Days 1,2,8,9,15,16 on a 28 day cycle. Dose and schedule modifications for intolerable side effects are detailed in the protocol. Additionally Cyclophosphamide is given a fixed dose of 500mg once per week orally, along with dexamethasone is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib.
250938|NCT02217189|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
250939|NCT02217215|Device|CNDS Advanced Cervical Scan|Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, "Cervical Cytology Enrollment Targets". After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated.
250940|NCT02217228|Device|Sebacia microparticles and laser|
250941|NCT02217228|Device|Vehicle suspension and laser|
250942|NCT00141817|Drug|pantoprazole for approximately 9 weeks.|
250943|NCT02217228|Device|Sebacia microparticles without laser|
250944|NCT02217241|Other|Handoff Workshop|
250945|NCT02217254|Procedure|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
250946|NCT02217254|Device|Cryoballoon catheter ablation|
250947|NCT02217267|Drug|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
250948|NCT02217267|Drug|Placebo|
250949|NCT02217280|Drug|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
250950|NCT02219555|Drug|triamcinolone acetonide, lidocaine|a mixture of one ml of triamcinolone acetonide, 240 mg/ml, and 2 ml of 1% lidocaine, active medication injection. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
245227|NCT02508701|Behavioral|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
245523|NCT02237144|Other|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
245524|NCT02237144|Behavioral|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
245525|NCT02237157|Drug|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
245526|NCT00002334|Drug|Zalcitabine|
245527|NCT00144079|Procedure|external beam radiotherapy|
245528|NCT02237183|Drug|Iloprost|Given via inhalation
245529|NCT02237183|Other|Laboratory Biomarker Analysis|Correlative studies
245530|NCT02237183|Other|Placebo|Given via inhalation
245531|NCT02237183|Other|Quality-of-Life Assessment|Ancillary studies
245532|NCT02237183|Other|Questionnaire Administration|Ancillary studies
245533|NCT02237196|Biological|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
245534|NCT02237196|Biological|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
245535|NCT02237196|Biological|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
245536|NCT02237196|Biological|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
245537|NCT02237209|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
245538|NCT00144092|Procedure|stem cell source|
245539|NCT02237209|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
245540|NCT02237222|Other|Gait rehabilitation|
245541|NCT02237235|Drug|Magnesium threonate|Magnesium L-Threonate (There is approximately 78 milligrams of elemental magnesium in 1 gram of Magtein). Total daily amount of elemental magnesium is 156 mg. Inactive ingredients: rice protein
245542|NCT02237235|Drug|Placebo|
244940|NCT02515487|Other|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
244941|NCT02515500|Behavioral|Gradual Cessation|
244942|NCT02515500|Behavioral|Gradual Cessation w/ Quitbit|
244943|NCT02517593|Genetic|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40%).
244944|NCT02517606|Other|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
245228|NCT02510885|Device|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
245229|NCT02510898|Behavioral|6-week Writing to Heal course|During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.
Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways.
245230|NCT02510911|Drug|Caffeine (100 mg)|Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.
First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.
Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
245231|NCT00180128|Drug|daunorubicin|
245232|NCT02510911|Drug|Caffeine (200 mg)|Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.
First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.
Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
245233|NCT02510911|Drug|corn starch (250 mg approx.)|Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.
First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.
Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
244661|NCT02522117|Drug|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
244662|NCT02522117|Drug|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
244663|NCT02522130|Drug|Lidocaine|intracervical injection
244664|NCT02522130|Drug|oral misoprostol|oral treatment
244665|NCT02522130|Drug|naproxen|oral treatment
244666|NCT02522130|Other|placebo|oral treatment
244667|NCT02522143|Behavioral|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
244668|NCT02522143|Behavioral|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
244669|NCT02522156|Behavioral|Looming Vulnerability Induction|guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.
244670|NCT02524275|Drug|Docetaxel|Given IV
244671|NCT02524275|Other|Quality-of-Life Assessment|Ancillary studies
244945|NCT02517606|Other|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
244946|NCT02517619|Drug|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
244947|NCT00181181|Drug|atorvastatin|Atorvastatin 80 mg daily for 3 months
244948|NCT02517619|Drug|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
244949|NCT02517632|Behavioral|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
244950|NCT02517632|Behavioral|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
250382|NCT02199184|Drug|Doxorubicin|10 mg/m2/day by vein days 1 - 4 of a 21 - 28 day cycle.
250383|NCT02199184|Drug|Vincristine|0.5 mg by vein days 1 - 4 of a 21 - 28 day cycle.
250384|NCT02199184|Drug|Cyclophosphamide|750 mg/m2 by vein on day 5 of a 21 - 28 day cycle.
250385|NCT02199184|Drug|Prednisone|60 mg by mouth twice a day on days 1 - 5 of a 21 - 28 day cycle.
250386|NCT02199184|Drug|Rituximab|375 mg/m2 by vein on days 1 and 11 of Cycle 1 and 3 and days 2 and 8 of Cycle 2 and 4 of a 21 - 28 day cycle. Rituximab replaces ofatumumab if insurance does not approve ofatumumab.
250387|NCT00002304|Drug|Fluconazole|
250388|NCT00139633|Drug|carboplatin, 5FU, Taxol and radiation|
250389|NCT02199184|Drug|Pegfilgrastim|6 mg within 72 hours after completion of chemotherapy.
250390|NCT02199184|Drug|G-CSF|10 µg/kg/day until neutrophil recovery 1 x 109/L or higher, can be substituted or can be added to Pegfilgrastim if neutrophils have not recovered to 1 x 109/L by day 21.
250391|NCT02199184|Behavioral|Phone Calls|Participant receives phone calls from study staff every 3 months for 1 year after receiving the study drugs. These calls should last about 5 minutes each time.
250392|NCT02199197|Drug|Radium Ra 223 dichloride with Enzalutamide|
250393|NCT02199197|Drug|Enzalutamide|
250394|NCT02199210|Other|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
250395|NCT02199223|Drug|regorafenib + panitumumab|
250396|NCT02199236|Radiation|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
250719|NCT00143520|Drug|Rivoglitazone|
250720|NCT02231749|Drug|Sunitinib|
250721|NCT02231762|Drug|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
250722|NCT02231762|Drug|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
250723|NCT02231775|Drug|Dabrafenib|Starting Dose: 150 mg by mouth twice a day.
250083|NCT02204150|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
250084|NCT02204163|Drug|Eutropin|
250085|NCT00140348|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
250086|NCT02204163|Drug|Genotropin|
250087|NCT02204176|Other|Exercise info|Discussion:
benefits of exercise
types of exercise
exercise guidelines
components of an exercise session
how to reduce risk of injuries
250088|NCT02206542|Device|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
250089|NCT02206542|Other|Physical therapy|
250090|NCT02206542|Device|Electroacupuncture|
250091|NCT02206555|Drug|emtricitabine/tenofovir disoproxil fumarate|
250092|NCT02206568|Drug|URAL|
250093|NCT02206581|Device|Hydration Monitor|
250094|NCT02206594|Procedure|Descemetorhexis|
250095|NCT02206607|Drug|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
250096|NCT02206607|Drug|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
250097|NCT02206607|Drug|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
250098|NCT00140595|Drug|cyclophosphamide|
250099|NCT02206607|Drug|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
250100|NCT02206620|Drug|Donepezil|
250101|NCT02206633|Device|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
250102|NCT02206646|Drug|Metalyse|
250103|NCT02206659|Drug|Telmisartan|
250104|NCT02206659|Drug|Placebo|
249471|NCT02218970|Behavioral|strength training|
249472|NCT02218970|Behavioral|no training (control)|
249473|NCT02218983|Device|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
249474|NCT02218983|Other|Usual care|
249782|NCT02211443|Biological|Recombinant full human Anti-EGFR Monoclonal Antibody|
249783|NCT02211456|Procedure|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
249784|NCT02211469|Drug|BMS-986104|
249785|NCT02211469|Drug|Placebo|
249786|NCT02211482|Drug|dolutegravir, lamivudine|single arm
249787|NCT02211495|Device|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
249788|NCT02211495|Other|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
249789|NCT00141154|Drug|Loxoprofen|
249790|NCT02211508|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
249791|NCT02211521|Biological|PRP|3ml of PRP
249792|NCT02211521|Drug|Hyaluronic acid|3ml hyaluronic acid
249793|NCT02214004|Drug|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
249794|NCT02214017|Device|A videotelephone, TandBerg E20,|
249795|NCT00141466|Behavioral|Education for professionals|
249796|NCT02214017|Behavioral|Behavioral motivation|Optimization of medical care in diabetes
249797|NCT02214030|Device|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
249798|NCT02214056|Other|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
254356|NCT02260193|Drug|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
254357|NCT02260193|Drug|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
254358|NCT02260206|Drug|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
254359|NCT02260219|Procedure|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
254360|NCT02260232|Other|exercise training|
254361|NCT02260245|Behavioral|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
254362|NCT00146835|Biological|Prevnar®: (Wyeth)|Concomitant vaccination
254363|NCT02260258|Drug|Rocuronium|Neuromuscular Blockade
254364|NCT02260258|Drug|Normal Saline|Normal Saline
254365|NCT02260271|Other|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
254366|NCT02260284|Other|Acupotome(needle knife)|patients under the treatment of acupotome(needle knife)
254367|NCT02260284|Other|Control|patients under the treatment of general acupuncture,but not acupotome (needle knife)
254368|NCT02260297|Device|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
254369|NCT02260310|Other|Weizhong and Huantiao|
249475|NCT02218996|Other|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
249476|NCT02219009|Device|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
249477|NCT02219022|Other|Control group|
249478|NCT02219022|Other|Experimental group|
249479|NCT02219048|Drug|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
249480|NCT00002320|Drug|Lamivudine|
249481|NCT00142090|Drug|3% Hypertonic saline|
254057|NCT02267395|Other|(2) scapular dyskinesis test|Test to determine scapular control
249174|NCT02226094|Device|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
249175|NCT02226107|Behavioral|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
249176|NCT02226107|Behavioral|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
249177|NCT02226120|Drug|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
249178|NCT02226133|Device|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
249179|NCT02226146|Biological|Bertilimumab|
249180|NCT02226159|Drug|Lidocaine|
249181|NCT02226159|Drug|Lidocaine with Dexamethasone|
249182|NCT02228486|Behavioral|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
249183|NCT02228499|Other|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
249184|NCT00143091|Drug|Sertraline|
249185|NCT02228512|Drug|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
249186|NCT02228512|Drug|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
249187|NCT02228512|Drug|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
249188|NCT02228512|Drug|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
249189|NCT02228512|Drug|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
249190|NCT02228512|Drug|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
253739|NCT02274636|Dietary Supplement|Xylitol|A comparison between discs and gel
253740|NCT02274649|Behavioral|one-to-one peer mentoring|
253741|NCT02274649|Behavioral|general peer support|
253742|NCT02274662|Biological|Thymus Transplantation|Subjects receive thymus transplantation. Subjects may receive pre and/or post-transplantation immunosuppression.
Potential thymus recipient subjects are screened for eligibility. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue is transplanted into the subject's quadriceps. Two to three months post-transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, skin biopsy conducted. Subjects undergo laboratory testing for approximately one year post-transplantation. At year 2 post-transplantation, subjects are contacted for data collection.
253743|NCT02274662|Procedure|Blood Draw|Biological Mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow for testing of T cell identity in the thymus recipient subjects. If blood is not obtainable, then a buccal swab may be done.
253744|NCT02274662|Drug|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
253745|NCT02274675|Device|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
254058|NCT02267395|Other|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
254059|NCT00147771|Drug|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
254060|NCT02267408|Other|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
254061|NCT02267408|Other|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
254062|NCT02267421|Behavioral|Home based Aerobic exercise training|
254063|NCT02267434|Biological|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
254064|NCT02269748|Procedure|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
254065|NCT02269748|Procedure|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
254066|NCT02269748|Drug|Analgesic Therapy|Ibuprofen 600 mg TID
253426|NCT02243254|Drug|Ibuprofen|intravenous ibuprofen
253427|NCT02243254|Drug|low dose remifentanil|low dose remifentanil
253428|NCT02243267|Other|sample collection|
253429|NCT02243280|Drug|ABT-493|Tablets
253430|NCT02243280|Drug|ABT-530|Tablets
253431|NCT02243293|Drug|ABT-493|Tablet
253432|NCT02243293|Drug|ABT-530|Tablet
253433|NCT02243293|Drug|Ribavirin (RBV)|Tablet
253434|NCT02243293|Drug|ABT-493/ABT-530|Tablet
253435|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
253436|NCT02243306|Drug|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
253437|NCT02243319|Drug|HGP1201|
253438|NCT02243319|Drug|HGP0904|
253439|NCT02243319|Drug|HGP0904 and HGP1201 co-administraion|
253440|NCT02243332|Device|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
253441|NCT02243358|Drug|Folfox6|
253442|NCT02243358|Drug|Gemcitabine|
253746|NCT02274675|Other|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
253747|NCT02274688|Behavioral|Stepped Care Management|Case management, information technology, psychopharmacology, and psychotherapy.
253748|NCT02274701|Other|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
253749|NCT00148499|Drug|benzocaine|
253112|NCT02250612|Drug|1 drop of timolol maleate|0.5 %
253113|NCT02250638|Other|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
253114|NCT02250651|Drug|Bimatoprost sustained-release|Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
253115|NCT02250651|Other|Sham|Sham administered on Day 1, Week 16, and Week 32, as per protocol.
253116|NCT02250651|Drug|Timolol|Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
253117|NCT02250651|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
253118|NCT02250664|Other|Very low nicotine content cigarettes|Very low nicotine content cigarettes
253119|NCT02250690|Device|experimental group - tDCS|
253120|NCT02250690|Device|Control group (tDCS sham)|
253121|NCT00145600|Drug|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
253122|NCT02250703|Drug|oral midazolam syrup|oral midazolam 0.5mg/kg upto maximum dose of 15mg
253123|NCT02250703|Drug|Intranasal dexmedetomidine|intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
253124|NCT02250703|Procedure|dental surgery|
253125|NCT02250703|Drug|N2O and Sevoflurane|
253126|NCT02250703|Drug|Fentanyl and Propofol|
253127|NCT02250703|Drug|Morphine and Toradol|
253128|NCT02250716|Procedure|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
253129|NCT02250729|Other|intradermal pholcodine allergy test in cases|
253130|NCT02250729|Other|Blood sampling|
253131|NCT02250742|Other|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
253443|NCT02243358|Radiation|Radiation Therapy|
252509|NCT02261831|Other|patients free type 2 diabetes|collection of blood sampling and biopsies
252510|NCT02261844|Dietary Supplement|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
252511|NCT00147121|Drug|Rituximab + Standard CHOP|Rituximab + Standard CHOP
252821|NCT02255006|Drug|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
252822|NCT02255032|Drug|4 mg CLS-TA|4 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
252823|NCT02255032|Drug|0.8 mg CLS-TA|0.8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
252824|NCT02255045|Drug|Meloxicam|meloxicam in vaginal ring
252825|NCT00146211|Drug|Ethyl-EPA (Miraxion™)|
252826|NCT02255045|Drug|Potassium Diclofenac|oral pill
252827|NCT02255058|Other|No intervention|The study is a Prospective observational cohort study
252828|NCT02257255|Procedure|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
252829|NCT02257255|Procedure|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
252830|NCT02257268|Behavioral|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
252831|NCT02257281|Device|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
252832|NCT02257281|Device|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
252833|NCT02257294|Drug|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
252834|NCT02257294|Other|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
252200|NCT02269124|Device|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
252201|NCT02269150|Biological|fecal microbiota transplantation (FMT)|
252202|NCT02269150|Other|No fecal microbiota transplantation (FMT), routine management|
252203|NCT02269163|Biological|Immune Globulin (Human) Intravenous|ProMetic BioTherapeutics Immune Globulin Intravenous is a 10% liquid formulation of human IgG in 50 mL vials containing 100 mg/mL of IgG.
252204|NCT02269163|Biological|Commercial Immune Globulin Intravenous|
252205|NCT02269176|Drug|Low dose of telmisartan|
252206|NCT00147901|Drug|Cyclophosphamide|
252207|NCT02269176|Drug|High dose of telmisartan|
252512|NCT02261844|Drug|Placebo|Placebo 1 pill daily X 10 days
252513|NCT02261857|Device|Personalized continuous positive airway pressure (CPAP) mask|Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
252514|NCT02261870|Device|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
252515|NCT02261883|Drug|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
252516|NCT02261883|Drug|Placebo|matching placebo
252517|NCT02261896|Drug|Placebo|Evaluate usefullness of antibiotic prophylaxis
252518|NCT02261896|Drug|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
252519|NCT02261922|Drug|ticagrelor|
252520|NCT02261922|Drug|prasugrel|
252521|NCT02264197|Drug|BIBX 245 CL - fed|
252522|NCT02264197|Drug|BIBX 245 CL- fasted|
252523|NCT02264210|Drug|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
252524|NCT02264223|Dietary Supplement|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
251900|NCT02276417|Other|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
251901|NCT00148681|Drug|Navelbine|Intravenously every week for 12 weeks
251902|NCT02276417|Other|Ultrasound|Ultrasound will be administered to the patient at baseline and weekly until week 6 as long as the patient is still hospitalized. Ultrasound will also be obtained at the one year appointment.
251903|NCT02276417|Other|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
251904|NCT02276417|Other|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
251905|NCT02276417|Other|Physical Function Tests|Physical function tests will be administered at 3, 6 and 12 months.
251906|NCT02276430|Other|Vena punction|Once 90 ml
251907|NCT02276443|Drug|Anthracycline Based Chemotherapy|Participants receive standard-of-care chemotherapy for 4 cycles. A cycle of treatment may be given once every 2 or 3 weeks depending upon doctor's decision.
251908|NCT02276443|Procedure|Ultrasound|Ultrasound performed at baseline, and after 2 and 4 cycles of chemotherapy.
251909|NCT02276456|Behavioral|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
252208|NCT02269176|Drug|Low dose of losartan|
252209|NCT02269176|Drug|High dose of losartan|
252210|NCT02269189|Drug|BIIL 284 BS, high dose|
252211|NCT02269189|Drug|BIIL 284 BS, low dose|
252212|NCT02269189|Drug|Placebo|
252213|NCT02269202|Drug|Midazolam, tablet|
252214|NCT02269202|Drug|Crobenetine, i.v. infusion|
252215|NCT02269202|Drug|Placebo|
252216|NCT02269215|Drug|BIII 890 CL|
252217|NCT00147901|Drug|Alemtuzumab|
252218|NCT02269215|Drug|Placebo|
252219|NCT02269228|Drug|Asasantin ER|
251559|NCT00144664|Drug|MRA(Tocilizumab)|
251560|NCT02242513|Device|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
251561|NCT02242513|Drug|Xylocaine|
251562|NCT02242526|Device|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
251563|NCT02242526|Device|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
251564|NCT02242539|Behavioral|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
251565|NCT02242539|Behavioral|Community-based monitoring|Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of "Yummy Soy" powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day.
251566|NCT02242565|Device|ShangRing|ShangRing device for male circumcision
251567|NCT02242578|Device|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
251568|NCT02242578|Device|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
251569|NCT02242591|Drug|Ropivacaine 7,5 mg/ml|
251570|NCT00144677|Drug|sirolimus|
251571|NCT02245126|Drug|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
251572|NCT02245126|Drug|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
251573|NCT02245152|Dietary Supplement|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
251910|NCT02276469|Behavioral|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
251911|NCT02276482|Drug|Tedizolid Phophate 200 mg, IV to oral for 6 days|
250951|NCT02219568|Procedure|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
250952|NCT02219568|Device|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
251246|NCT02212184|Other|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
251247|NCT02212197|Drug|leuprolide acetate|
251248|NCT02212210|Drug|Methylprednisolone|
251249|NCT00141245|Drug|Pregabalin|
251250|NCT02212210|Drug|Normal saline|
251251|NCT02212223|Dietary Supplement|Vitamin D3|
251252|NCT02212236|Other|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
251253|NCT02212249|Biological|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
251254|NCT02212275|Drug|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
251255|NCT02212288|Other|Blood sample|Blood samples are for metabolic and genetic and biological investigation
251256|NCT02212288|Other|Urine sample|Urine sample for biological investigation
251257|NCT02212301|Device|senofilcon A|
251258|NCT02212301|Device|AIR OPTIX® AQUA|
251259|NCT02212314|Behavioral|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
251260|NCT00141258|Drug|pregabalin|
251261|NCT02212340|Drug|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
251262|NCT02212340|Drug|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
245543|NCT02237261|Drug|Bendamustine, Bortezomib, Prednisone|Cycle 1 (d1-42) - Induction:
Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4
Cycle 2-9 (d1-28) - Consolidation:
Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4
245544|NCT02237274|Other|High altitude exposition|High altitude exposition
245855|NCT02227277|Drug|Peg-IFN-α2b|Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL > 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).
Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks.
245856|NCT02227290|Drug|Naftin Cream|
245857|NCT02227290|Drug|Placebo Cream|
245858|NCT02227303|Behavioral|lifestyle modification instructional and motivational sessions|
245859|NCT02229656|Drug|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
245860|NCT02229669|Procedure|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
245861|NCT02229669|Procedure|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
245862|NCT02229682|Radiation|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
245863|NCT02229708|Behavioral|Healthy Lifestyle Group|
245864|NCT02229721|Drug|Syntocinon Nasalspray|Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.
245865|NCT02229721|Drug|Placebo Nasalspray|Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.
245234|NCT02510911|Other|Radiopaque marker|On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .
On day 4 after surgery an abdominal X-ray will be performed to localize the markers.
Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%).
245235|NCT02510924|Device|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
245236|NCT02510937|Drug|CC-90001|
245237|NCT02510950|Biological|Personalized peptide vaccine|
245238|NCT02510950|Drug|Poly-ICLC|
245239|NCT02510950|Drug|Temozolomide|
245240|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 24week of gestation
245241|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 28week of gestation
245242|NCT00180128|Drug|cytarabine|
245243|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 32week of gestation
245244|NCT02510976|Drug|prucalopride|
245545|NCT02237287|Other|wound dressing with VAC and sNAG without antiaggregation|
245546|NCT00139672|Drug|PD-217,014|
245547|NCT02199626|Device|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
245548|NCT02199652|Drug|Prazosin|
245549|NCT02199652|Drug|Placebo|
245550|NCT02199665|Drug|selinexor|Given PO
245551|NCT02199665|Drug|carfilzomib|Given IV
245552|NCT02199665|Drug|dexamethasone|Given PO or IV
245553|NCT02199665|Other|laboratory biomarker analysis|Correlative studies
245554|NCT02199665|Other|pharmacological study|Correlative studies
245555|NCT02199665|Other|questionnaire administration|Ancillary studies
245556|NCT02199678|Drug|Placebo|placebo
245557|NCT00139685|Drug|Depo-Provera Contraceptive Injection - DP150CI|
244951|NCT02517658|Other|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
244952|NCT02517658|Other|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
244953|NCT02517671|Device|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
244954|NCT02517684|Drug|Infliximab|
244955|NCT02517684|Drug|Prednisolone|
244956|NCT02517684|Other|Exclusive enteral nutrition|
244957|NCT02517684|Drug|Azathioprine|
244958|NCT00181181|Other|placebo|placebo daily
244959|NCT02517697|Drug|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
244960|NCT02517697|Drug|Placebo|oral formulation of matching placebo three times daily for 12 weeks
244961|NCT02517710|Procedure|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
244962|NCT02517723|Behavioral|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.
NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.
244963|NCT02519881|Device|CartiFill|add collagen when doing microfracture
245245|NCT02510976|Drug|placebo|
245246|NCT02511028|Drug|Ferumoxytol|510mg (17mL) IV
245247|NCT02513186|Drug|SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
245248|NCT02513186|Drug|bortezomib|Pharmaceutical form:lyophilized powder for subcutaneous injection Route of administration: subcutaneous
245249|NCT02513186|Drug|cyclophosphamide|Pharmaceutical form:tablet Route of administration: oral
245250|NCT02513186|Drug|dexamethasone|Pharmaceutical form:tablet or solution for infusion Route of administration: oral or intravenous
250724|NCT02231775|Drug|Trametinib|Starting Dose: 2 mg by mouth once daily.
250725|NCT02231775|Procedure|Surgery|Group A: Surgical resection of gross disease within 4 weeks after enrolling in study. Participant then treated with standard care for the disease after surgery per study doctor.
Group B: Participant has MRI and/or CT scans of brain to check status of disease after taking study drugs for 8 weeks. Participant also has CT scans of the chest, abdomen, and pelvis. If scans show disease has not spread or grown, surgical resection of gross disease is scheduled.
250726|NCT02231788|Drug|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
250727|NCT00143741|Drug|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
250728|NCT02234336|Procedure|Contrast Echocardiography|
250729|NCT02234336|Procedure|Cardiac magnetic resonance imaging|
250730|NCT02234349|Procedure|pancreas kidney transplantation|
250731|NCT02234349|Procedure|kidney transplantation|
250732|NCT02234362|Drug|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
250733|NCT02234375|Drug|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
250734|NCT02234388|Other|Observation|There are no interventions associated with this registry as it is purely observational.
250735|NCT02234401|Device|Bi level pressure support|
250736|NCT02234401|Other|Standard Care|
250737|NCT02234427|Drug|Aspirin|2-week aspirin therapy (81mg/day)
250738|NCT00143754|Procedure|Hydration|
250739|NCT02234440|Drug|Metformin|
250740|NCT02234440|Drug|Insulin|
251022|NCT02226952|Drug|BILN 2061 W, low dose|
251023|NCT02226952|Drug|BILN 2061 W, medium dose|
251024|NCT02226952|Drug|BILN 2061 W, high dose|
251025|NCT02226952|Drug|Placebo|
250105|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
250397|NCT02199236|Drug|concurrent capecitabine or 5-FU|Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.
Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days.
250398|NCT02199236|Behavioral|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
250399|NCT00139646|Drug|Parecoxib|
250400|NCT00140010|Drug|erythropoietin beta|30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
250401|NCT02201914|Drug|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
250402|NCT02201927|Device|galvanic vestibular stimulation|
250403|NCT02201940|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
250404|NCT02201940|Drug|Placebo to match SOF/VEL|Placebo to match SOF/VEL tablet administered orally once daily
250405|NCT02201953|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
250406|NCT02201953|Drug|SOF|SOF 400 mg tablet administered orally once daily
250407|NCT02201953|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
250408|NCT02201979|Procedure|Vertical breast lift with implants|
250409|NCT02201992|Drug|Crizotinib|Given PO
250410|NCT02201992|Other|Laboratory Biomarker Analysis|Correlative studies
250411|NCT00140023|Drug|Azithromycin microspheres 2.0 single dose|
250412|NCT02201992|Other|Placebo|Given PO
250413|NCT02202005|Drug|Nevirapine|Nevirapine 400mg PR tablet
249799|NCT02214056|Procedure|Mobile team exam|Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:
questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).
At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations.
249800|NCT02214082|Other|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
249801|NCT02214095|Drug|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
249802|NCT02214095|Drug|lactose capsules|
250106|NCT02206685|Drug|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
250107|NCT02206685|Drug|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
250108|NCT02206711|Drug|BMS-955176|Single dose of drug on Day 1
250109|NCT00140608|Device|Seprapack Sinus Dressing|
250110|NCT02206724|Radiation|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
250111|NCT02206737|Device|No nicotine e-cigarette|
250112|NCT02206737|Device|Low dose nicotine e-cigarette|
250113|NCT02206737|Device|High dose nicotine e-cigarette|
250114|NCT02206750|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
250115|NCT02209012|Device|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
250116|NCT02209025|Dietary Supplement|Theobromine|Theobromine a compound for cocoa
250117|NCT02209025|Dietary Supplement|Placebo drink|
250118|NCT02209038|Behavioral|Expanded AD Choice|
250119|NCT02209038|Behavioral|Expanded Life-sustaining Therapy Choice|
250120|NCT02209051|Other|AMNIOEXCEL|Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.
249482|NCT02219048|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
249483|NCT02219074|Device|Sebacia microparticle and laser treatment|
249484|NCT02219074|Device|Vehicle and laser treatment|
249485|NCT02219087|Drug|Liposomal bupivacaine|
249486|NCT02219087|Drug|ropivacaine, morphine ,ketorolac, methylprednisolone|Standard of care analgesia
249487|NCT02219100|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
249488|NCT02221401|Drug|Linagliptin|
249489|NCT02221401|Drug|Metformin|
249490|NCT02221414|Drug|Linagliptin/Metformin FDC|
249491|NCT02221414|Drug|Linagliptin|
249492|NCT02221414|Drug|Metformin|
249493|NCT02221427|Other|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
249494|NCT00142389|Biological|pneumococcal polysaccharide and protein conjugate vaccines|
249495|NCT02221427|Other|Static labour progression curve (F)|
249496|NCT02221440|Device|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
249497|NCT02221453|Drug|Triamcinolone Acetonide|
249498|NCT02221479|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
249803|NCT02214108|Other|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
249804|NCT02214121|Drug|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
249805|NCT02214121|Drug|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
249806|NCT00141466|Behavioral|Distribution of educational materials|
249191|NCT02228512|Drug|Cyclophosphamide|Part B: 750 mg/m2 Day 5
249192|NCT02228525|Drug|selinexor (KPT-330)|
249193|NCT02228538|Device|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system & off-the-shelf standard knee implant system from various manufacturers
249499|NCT02221479|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
249500|NCT02221492|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
249501|NCT02221492|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
249502|NCT02221505|Drug|LOP628|
249503|NCT02221518|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
249504|NCT02221531|Drug|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
249505|NCT00142402|Drug|Modafinil|
249506|NCT02221531|Drug|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
249507|NCT02221544|Device|Low-frequency repetitive Transcranial Magnetic Stimulation|Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.
The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain.
249508|NCT02221544|Device|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
249509|NCT02221544|Device|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
249510|NCT02221544|Device|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
249511|NCT02221557|Device|easy-graft (beta-Tricalcium Phosphate)|
249512|NCT02223962|Behavioral|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
249513|NCT02223988|Procedure|subglottic secretion removal|
254067|NCT02269761|Device|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
254068|NCT02269774|Procedure|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
254069|NCT02269787|Behavioral|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
254070|NCT02269800|Drug|Benzalkonium chloride solution|Tid, 7 days
254071|NCT02269800|Drug|Normal saline|Tid, 7 days
254072|NCT02269813|Other|MammaPrint|
254073|NCT00147992|Procedure|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
254074|NCT02269813|Other|BluePrint|
254075|NCT02269813|Other|TargetPrint|
254076|NCT02269826|Device|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
249194|NCT02228551|Other|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
249195|NCT00143104|Drug|Inhaled insulin|
249196|NCT02228564|Device|PTA followed by LIFESTREAM™ covered stent|Implant of the LIFESTREAM™ covered stent after balloon angioplasty.
249197|NCT02228564|Device|Device: PTA followed by LIFESTREAM™ covered stent|Balloon angioplasty followed by implant of the LIFESTREAM™ covered stent.
249198|NCT02228590|Drug|APL-130277|
249199|NCT02228603|Behavioral|high-intensity exercise training|
249200|NCT02228603|Behavioral|web-based follow-up program|
249201|NCT02228603|Behavioral|usual care|
253750|NCT02274714|Other|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
253751|NCT02274740|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
253752|NCT02274740|Drug|metformin|Pharmaceutical form:tablet Route of administration: oral
253753|NCT02274766|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
253754|NCT02274766|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
253755|NCT02238327|Procedure|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to <88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
253756|NCT00144196|Drug|tiotropium (Spiriva)|
253757|NCT02238327|Radiation|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
253758|NCT02238327|Procedure|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
253759|NCT02238327|Procedure|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
253760|NCT02238327|Procedure|Glycocalyx|Participants may have a handheld camera placed under the tongue to capture an image of the blood vessels for blood vessel identification and measurement. This is a non-invasive test taking approximately 10 minutes.
253761|NCT02238340|Drug|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
254077|NCT02269826|Device|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
254078|NCT02269839|Device|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
253444|NCT02243358|Procedure|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
253445|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6 (Arm A) or Day 1 of Cycles 3-6 (Arm B)
253446|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
253447|NCT02243371|Biological|GVAX|5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2 (Arm A and B)
253448|NCT02243371|Drug|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6 (Arm A only)
253449|NCT02245945|Drug|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
253450|NCT02245958|Other|No Intervention|No treatment (intervention) was administered.
253451|NCT02245971|Procedure|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
253452|NCT02245971|Procedure|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
253453|NCT00145015|Behavioral|Increased dietary intake of salmon or cod|
253454|NCT02245984|Other|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
253455|NCT02245984|Other|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
253456|NCT02245997|Radiation|External beam radiotherapy|
253457|NCT02246010|Dietary Supplement|Lactose- free milk|Lactose- free milk
253458|NCT02246023|Device|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
253459|NCT02246023|Device|Oxygen saturation|Continuous measurement of oxygen saturation;
253460|NCT02246023|Device|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
253461|NCT02246023|Device|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
252835|NCT02257307|Procedure|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
252836|NCT02257320|Device|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
253132|NCT00145600|Drug|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
253133|NCT02250755|Other|MRI T1 T2 sequences|MRI
253134|NCT02250768|Biological|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
253135|NCT02250781|Drug|Oral ONC201|Given PO
253136|NCT02252718|Other|Stool Assessment|After passing a stool by the child participating in the study, within a short-time interval (<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the "in vivo" stool appraisal and child condition.
253137|NCT02252731|Drug|Warfarin|Oral
253138|NCT00145847|Drug|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
253139|NCT02252731|Drug|FG-4592|Oral
253140|NCT02252744|Other|No intervention|
253141|NCT02252757|Device|CoVa|
253142|NCT02252770|Dietary Supplement|Nitric oxide supplement|Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
253143|NCT02252770|Dietary Supplement|Placebo|Placebo will not contain nitric oxide supplement.
253144|NCT02252783|Drug|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
253145|NCT02252796|Radiation|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
253146|NCT02252796|Drug|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
252525|NCT02264223|Dietary Supplement|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
252526|NCT02264236|Biological|P10s-PADRE vaccine|P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Subcutaneous injection at weeks 1, 2, 3, and 8
252527|NCT02264236|Biological|Placebo|Subcutaneous injection at weeks 1, 2, 3, and 8
252528|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy.
252529|NCT00147420|Drug|Zhi Byed 11|
252530|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy.
252531|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy.
252532|NCT02264262|Other|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
252533|NCT02264275|Behavioral|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
252837|NCT02257346|Drug|Lidocaine|Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
252838|NCT00146549|Drug|Docetaxel|
252839|NCT02257346|Drug|Normal Saline|Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
252840|NCT02257359|Drug|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
252841|NCT02257372|Drug|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
252842|NCT02257372|Drug|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
252843|NCT02257372|Drug|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
252220|NCT02271438|Drug|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
252221|NCT02271438|Drug|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
252222|NCT00148122|Drug|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
252223|NCT02271438|Drug|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
252224|NCT02271451|Device|Q collar|collar worn around neck
252225|NCT02271464|Drug|Maintenance:BEVACIZUMAB|Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:
BEVACIZUMAB 5 mg/kg over 30 minutes, day 1
IRINOTECAN 165 mg/sqm IV over 1-h, day 1
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1
L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1
5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1
with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):
- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)
252226|NCT02271464|Drug|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:
BEVACIZUMAB 5 mg/kg over 30 minutes, day 1
IRINOTECAN 165 mg/sqm IV over 1-h, day 1
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1
L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1
5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1
with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):
BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),
CAPECITABINE 500 mg/tid orally, continuously,
CYCLOPHOSPHAMIDE 50 mg/day orally, continuously.
252534|NCT02264288|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
252535|NCT02264288|Biological|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
252536|NCT02264288|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
252537|NCT02264288|Other|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
252538|NCT02264301|Drug|Puerarin injection 400 mg|
252539|NCT02264301|Drug|Qingkailing injection 40 ml|
252540|NCT00147446|Behavioral|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
251912|NCT00148681|Drug|Doxorubicin|Every 3 weeks for 12 weeks
251913|NCT02276482|Drug|Antibiotic comparator|
251914|NCT02239952|Drug|Erlotinib|150 mg, once daily, oral use for 14 days
251915|NCT02239978|Behavioral|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
251916|NCT02239991|Procedure|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
251917|NCT02240004|Device|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
251918|NCT02240017|Drug|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
251919|NCT02240017|Drug|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
251920|NCT02240017|Drug|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
251921|NCT02240030|Drug|CVT-301|
251922|NCT02240043|Other|growth hormone secretion|The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
251923|NCT00144391|Drug|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
251924|NCT02240069|Behavioral|Education (Tx1)|Education on best burn practices
251925|NCT02240069|Device|Air Filtration Unit Treatment (Tx2)|A 20" x 18" Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove
251926|NCT02240069|Device|Placebo Intervention (Tx3)|A 20" x 18" Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter.
251927|NCT02240082|Behavioral|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
251263|NCT02212353|Other|Observational study, not interventional|
251264|NCT00141518|Device|CADD-Legacy® 1400|Ambulatory infusion pump
251265|NCT02214628|Drug|Fovista® (anti-PDGF BB) plus anti-VEGF|
251266|NCT02214641|Behavioral|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
251574|NCT02245152|Behavioral|Child's health and nutrition topics|After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).
Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children.
251575|NCT02245152|Behavioral|National policy well-baby visits|
251576|NCT02245165|Biological|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
251577|NCT02245165|Biological|saline|
251578|NCT00144937|Behavioral|Smoking cessation|
251579|NCT02245178|Procedure|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
251580|NCT02245178|Other|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
251581|NCT02245191|Drug|Ephedrine|5mg after Spinal Anesthesia
251582|NCT02245191|Drug|Phenylephrine|100mcg after Spinal Anesthesia
251583|NCT02245191|Drug|Metaraminol|200mcg Metaraminol after Spinal Anesthesia
251584|NCT02245204|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
251585|NCT02245217|Device|PET/CT scan to assess treatment efficacy|
251586|NCT02245230|Drug|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
251587|NCT02245230|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
245866|NCT02229734|Radiation|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
245867|NCT00143234|Drug|Amlodipine/atorvastatin single pill|
245868|NCT02229734|Drug|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
245869|NCT02229747|Drug|Meloxicam|
245870|NCT02229747|Drug|Diclofenac|
246154|NCT02220114|Drug|Vigabatrin: Vigabatrin new ST formulation then Sabril®|first "treatment" phase (V1/D1-V3/D84), in which patients already under Sabril® "granules for oral solution" and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.
second "treatment" phase (V3/D84-V4/D98) in which the patient is switched to Sabril® "granules for oral solution" (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.
Dose and treatment regimen should be maintained as in first treatment phase.
- At V4/D98, patients who received Sabril® "granules for oral solution" (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision).
246155|NCT02220127|Radiation|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
246156|NCT02220127|Radiation|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
246157|NCT02220140|Behavioral|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
246158|NCT02220153|Biological|UCB7665 Intravenous 1|Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion
246159|NCT02222441|Drug|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
246160|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
246161|NCT02222441|Drug|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
246162|NCT02222454|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
246163|NCT02222467|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
246164|NCT02222480|Drug|Fimasartan|
246165|NCT02222480|Drug|Hydrochlorothiazide|
245558|NCT02199678|Drug|ketamine 25 mg|ketamine
245559|NCT02199678|Drug|ketamine 35 mg|ketamine
245560|NCT02199678|Drug|ketamine 50 mg|ketamine
245561|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
245562|NCT02199691|Biological|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197Conjugate Vaccine|0.5 mL, IM
245563|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
245564|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
245565|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
245566|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
245567|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
245568|NCT00139698|Drug|olmesartan alone or in combination with hydrochlorothiazide|
245569|NCT02199704|Other|Self Directed Positive Parenting Program|Individuals with psychosis who are parents will receive a copy of the "Every Parent's Self Help Workbook" (Markie-Dadds, Sanders & Turner, 1999) and up to ten sessions of support. This is a case series study.
245871|NCT02229747|Drug|Nimesulide|
245872|NCT02229760|Drug|Tipranavir capsules|
245873|NCT02229760|Drug|Ritonavir capsules|
245874|NCT02229773|Drug|BIBB 1464 MS low dose|
245875|NCT02229773|Drug|Placebo|
245876|NCT02229773|Drug|Pravastatin|
245877|NCT02229773|Drug|BIBB 1464 MS medium dose|
245878|NCT00143247|Drug|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
245879|NCT02229773|Drug|BIBB 1464 MS high dose|
245880|NCT02229786|Drug|Buscopan® plus|
245251|NCT00180544|Device|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
245252|NCT02513199|Radiation|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
245253|NCT02513199|Drug|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
245254|NCT02513212|Device|Potassium Oxalate|Professionally applied liquid
245255|NCT02513212|Drug|Stannous fluoride paste|SnF2 Paste
245256|NCT02513212|Device|Manual toothbrush|Marketed manual toothbrush
245257|NCT02513212|Device|Power toothbrush|Marketed power toothbrush
245258|NCT02513225|Behavioral|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
245259|NCT02513225|Other|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
245260|NCT02513238|Drug|Mesenchymal stem cell|Stemcells injected into submandibularis
245261|NCT02513238|Drug|Isotonic NaCl|
245262|NCT00180557|Device|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
245263|NCT02513251|Other|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
245264|NCT02513290|Drug|Bilastine|
245265|NCT02513290|Drug|Loratadine|
245266|NCT02513303|Drug|Sirolimus|Subjects in the treatment group will receive a single prophylactic dose of sirolimus delivered locally to the vessel wall at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery. Control group subjects will have surgery for creation of the AV fistula but will not receive the drug.
251676|NCT02254616|Behavioral|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
251677|NCT02254616|Behavioral|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
251026|NCT02226965|Drug|PNT2258|
251027|NCT02226978|Drug|Tipranavir|
251028|NCT02226978|Drug|Ritonavir|
251029|NCT02226978|Drug|Valaciclovir|
251030|NCT00142896|Drug|Morphine|
251031|NCT02226991|Drug|Tipranavir|
251032|NCT02229305|Behavioral|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
251033|NCT02229305|Behavioral|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita & Weisz, 2010).
251034|NCT02229318|Dietary Supplement|FruitiVits|
251035|NCT02229331|Other|Gait analysis|
251036|NCT00143195|Procedure|Exercise Stress Test|
251037|NCT02229344|Other|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
251038|NCT02229357|Biological|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
251039|NCT02229383|Drug|Exenatide|2 mg weekly suspension injection
251040|NCT02229383|Drug|Exenatide matching placebo|Once weekly Placebo injection
251041|NCT02229396|Drug|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
251042|NCT02229396|Drug|Exentide|2 mg
251043|NCT02229396|Drug|Dapagliflozin|10 mg once daily Dapagliflozin
251044|NCT02229409|Behavioral|Walkadoo|Walkadoo is a MeYou Health, LLC product.
251045|NCT02229422|Drug|GA101/HDMP|All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.
On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.
On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.
On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:
•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.
251345|NCT00146705|Procedure|blood samples are taken once|
250414|NCT02202005|Drug|Viramune®|Viramune® 400 mg Retardtabletten
250741|NCT02234453|Device|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
250742|NCT02234466|Drug|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
250743|NCT02234466|Drug|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
250744|NCT02234466|Other|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
250745|NCT02234479|Biological|Hydrophor (Group A)|Rehydrates dry, chapped or chafed skin
May be used alone as a skin lubricant or protectant
250746|NCT02234479|Biological|MediHoney (Group B)|It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:
Maintain a balanced environment for healing.
Aids in reducing dermatitis.
Reduce affected area pH.2-3
250747|NCT02234492|Drug|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
250748|NCT02234505|Procedure|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
250749|NCT00143780|Biological|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
250750|NCT02234518|Other|High quantity fiber|The intervention type is food product
250751|NCT02234518|Other|Low quantity fiber|The intervention type is food product
250752|NCT02234518|Other|Placebo|
250753|NCT02236767|Device|TMS Neurostar Therapy System|Treatment will entail daily (5 days/week) sessions of rTMS for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
250754|NCT02236793|Drug|BioChaperone PDGF-BB|
250755|NCT00144053|Drug|Cisplatin+Vindesine+MMC/ concurrent radiation|
250756|NCT02236793|Other|Standard of Care|
250757|NCT02236806|Drug|Bisoprolol|5 mg daily
250758|NCT02236806|Drug|Ramipril|5 mg daily
250759|NCT02236806|Drug|Placebo|1 capsule daily
250121|NCT02209051|Other|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
250122|NCT02209064|Device|Pericardial access|Access to the pericardium to enable further treatments.
250123|NCT02209077|Device|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
250124|NCT02209090|Procedure|maternal modified sims position|Maternal Modified Sims position during at least 40 minutes for each 60 minutes
250125|NCT00140933|Drug|MK0966; rofecoxib|
250126|NCT02209090|Procedure|maternal free positions|At least 40 minutes each hour during labour
250127|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid|
250128|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid formulation|
250129|NCT02209103|Dietary Supplement|Identical looking placebo|
250415|NCT02202018|Other|Active KT intervention|Provider & patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space
Educational white board presentations promoting home dialysis
Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial & national averages
A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.
Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic.
250416|NCT02202031|Behavioral|Paced Respiration|
250417|NCT02202031|Behavioral|Music Therapy|
250418|NCT02202044|Device|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
250419|NCT02202057|Other|Respiratory resistive load on inhalation|The participant will be seated in a chair, and will be instructed to "relax and breathe" through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in.
250420|NCT02202057|Other|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
250421|NCT02202070|Drug|onabotulinumtoxinA|
250422|NCT00140036|Procedure|Blood draw|
249807|NCT02214134|Genetic|Tumour markers testing|
249808|NCT02214147|Drug|Alisertib|Alisertib will be supplied as enteric coated tablets.
249809|NCT02214160|Drug|UX007|Subjects will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
249810|NCT02214173|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
249811|NCT02214173|Dietary Supplement|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
249812|NCT02214186|Other|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
249813|NCT02214199|Other|Manipulative Therapy Techniques|
249814|NCT02214199|Other|Home Exercises|
249815|NCT00141765|Procedure|Myeloablative Chemotherapy|High dose chemotherapy (carboplatin and thiotepa) transplant rescue
249816|NCT02216565|Other|Hospitalization in specialized neuro-vascular unit|
249817|NCT02216565|Drug|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
249818|NCT02216565|Other|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
249819|NCT02216565|Procedure|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
249820|NCT02216578|Drug|cabozantinib|
249821|NCT02216591|Device|Active Cognitive Training (ACT)|
249822|NCT02216591|Device|Control (CON)|
249823|NCT02216604|Behavioral|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
250130|NCT02209116|Other|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
250131|NCT02209142|Other|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
250132|NCT02209142|Other|psychometric data collection|
249514|NCT02224001|Procedure|The Flag Technique|A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts
The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result.
249515|NCT02224014|Drug|Lendormin D tablets|
249516|NCT02224027|Device|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
249517|NCT02224027|Device|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
249824|NCT02216617|Drug|Taxotere, Cisplatin, Afatinib|
249825|NCT02216630|Drug|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
249826|NCT00141765|Procedure|Stem Cell Rescue|autologous stem cell transplantation
249827|NCT02216643|Procedure|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with the approved stentriever stentriever Solitaire FR® versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire FR device. No additional treatment will be allowed either with IA tPA, mechanical devices or angioplasty/stenting.
249828|NCT02216643|Device|stentriever Solitaire FR®|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with the approved stentriever stentriever Solitaire FR® versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire FR device. No additional treatment will be allowed either with IA tPA, mechanical devices or angioplasty/stenting.
249829|NCT02216656|Drug|Placebo|Oral administration
249830|NCT02216656|Drug|KHK7580 low dose|Oral administration
249831|NCT02216656|Drug|KHK7580 middle dose|Oral administration
249832|NCT02216656|Drug|KHK7580 high dose|Oral administration
249833|NCT02216656|Drug|KRN1493|Oral administration
249834|NCT02216669|Drug|2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide or DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
249835|NCT02216708|Other|Rapid dehydration|
249836|NCT02216708|Other|Slow rehydration|
249837|NCT00141778|Drug|Placebo|Matching placebo taken once a day
249838|NCT02219113|Procedure|Arthroscopic surgery|
249202|NCT02228616|Drug|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
249203|NCT02228616|Drug|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 14 weeks.
249204|NCT02228616|Drug|Lactulose|Optimized dose of Lactulose will be administrated for 14 weeks.
249205|NCT02228629|Device|CrocsRx Medical Silver cloud clogs|
249206|NCT00143117|Drug|UK-390,957|
249207|NCT00143416|Drug|Pegvisomant|
249208|NCT02231073|Behavioral|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
249209|NCT02231086|Procedure|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
249210|NCT02231086|Drug|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
249211|NCT02231086|Procedure|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
249518|NCT02224027|Device|i-gel|In i-gel group, i-gel is inserted by novices.
249519|NCT02224040|Drug|ceftriaxone|
249520|NCT00142597|Device|Acupuncture|Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.
Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.
All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional.
249521|NCT02224040|Drug|ceftriaxone and azithromycin|
249522|NCT02224040|Drug|azithromycin|
249523|NCT02224040|Drug|azithromycin and cefixime|
249524|NCT02224053|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
249525|NCT02224053|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
254079|NCT02269852|Biological|trivalent seasonal influenza vaccine|Infants: 0.25 ml/ dose;
Adults: 0.5 ml/ dose;
Seniors: 0.5 ml/ dose;
254080|NCT02269891|Dietary Supplement|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
254081|NCT02269891|Other|Placebo|
254082|NCT02269904|Drug|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
254083|NCT02269904|Drug|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
254084|NCT00148005|Procedure|Questionnaire and micturition and drinking diaries|
254085|NCT02269917|Drug|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
254086|NCT02272179|Behavioral|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention to be initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, My Safety Space (MSS); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
254087|NCT02272179|Behavioral|MySafety Space|MySafetSpace (MSS) is a HIPAA-compliant web-based application designed to provide the participants with guidance, social support, and convenient access to their safety plan via the patients' phone.
254088|NCT02272179|Behavioral|Treatment as Usual|Participants will receive usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which will include a paper safety plan.
254089|NCT02272192|Behavioral|Play-based|The Early Start Denver Model (ESDM) is a comprehensive behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures used to deliver this content. The teaching format focuses on natural activities involving play or daily routines, though structure is added for children who need more structure to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches. Discrete Trial Teaching is not used in this group.
254090|NCT02272192|Behavioral|Discrete Trial Teaching|Discrete trial training (DTT) is a one-to-one instructional approach used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
249212|NCT02231099|Procedure|Prolift + M|prolapse surgery with mesh
249213|NCT02231099|Procedure|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
249214|NCT02231112|Radiation|Whole breast RT on prone position|
253462|NCT02246023|Device|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
253762|NCT02238340|Drug|Extended- release Oxycodone|
253763|NCT02238340|Drug|ketoprofen|
253764|NCT02238340|Drug|dipirone|
253765|NCT02238340|Drug|dexametasone|
253766|NCT02238340|Drug|Morphine IV (rescue)|
253767|NCT00144209|Drug|pramipexole|
253768|NCT02238353|Drug|azelastine + fluticasone|
253769|NCT02238353|Drug|Placebo|
253770|NCT02238366|Drug|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
253771|NCT02238379|Drug|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
253772|NCT02238379|Other|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
253773|NCT02238392|Procedure|Adenosine test|Testing dormant conduction after PVI
253774|NCT02238392|Procedure|Termination of AF|Testing AF iducibility and ermination of
253775|NCT02240563|Procedure|Low-level laser therapy|
253776|NCT02240563|Procedure|Non laser ordinary red light|
253777|NCT02240589|Drug|Memantine|Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
253778|NCT02240589|Drug|Placebo|Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
253779|NCT02240602|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
253780|NCT02240602|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
253781|NCT00144456|Drug|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
253782|NCT02240602|Drug|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
253147|NCT02252796|Drug|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
253148|NCT02252796|Radiation|Image-guided IMRT|Given during chemo-radiation phase
253149|NCT00002350|Biological|APL 400-003|
253150|NCT00145873|Drug|nesiritide, continuous infusion|
253151|NCT02252809|Drug|adalimumab|
253152|NCT02252809|Drug|methylprednisolone|
253153|NCT02252822|Behavioral|Overcoming Bulimia Online Programme|
253154|NCT02252835|Drug|Arhalofenate|800 mg once daily orally for four weeks
253463|NCT02246036|Device|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
253464|NCT00145028|Drug|Carboplatin|
253465|NCT02246049|Biological|Bevacizumab|Given IV
253466|NCT02246049|Drug|5-fluorouracil|Given IV
253467|NCT02246049|Drug|Irinotecan hydrochloride|Given IV
253468|NCT02246049|Drug|Leucovorin calcium|Given IV
253469|NCT02246049|Drug|Oxaliplatin|Given IV
253470|NCT02246062|Behavioral|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
253471|NCT02246062|Behavioral|smartphone|the child received smartphone application immediately before entering the operating room
253472|NCT02246075|Drug|EVP-6124|
253473|NCT02248298|Drug|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
252844|NCT02259660|Device|Respiratory muscle strength training|Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
252845|NCT02259660|Device|Sham respiratory muscle strength training|The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
252846|NCT02259673|Other|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
252847|NCT02259673|Other|fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises
(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
252848|NCT02259686|Drug|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
252849|NCT02259686|Drug|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
252850|NCT02259686|Drug|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
252851|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
252852|NCT02259686|Drug|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
252853|NCT02259686|Drug|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
253155|NCT02252835|Drug|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
253156|NCT02252835|Drug|Arhalofenate|600 mg once daily orally for four weeks
253157|NCT02252835|Drug|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
253158|NCT02252835|Drug|Colchicine|0.6 mg daily
253159|NCT02252848|Drug|Clonidine|Determining the maximum-tolerated dose (MTD) of clonidine and secondarily, explore the efficacy of clonidine for reducing shivering in infants who are undergoing therapeutic hypothermia for treatment of HIE
253160|NCT02252848|Drug|Clonidine|Characterizing population PK/PD of clonidine using non-linear mixed effects analysis to estimate the exposure-response relationship of clonidine on changes in cardiovascular parameters (heart rate and blood pressure), core body temperature, and cerebrovascular autoregulation during the cooling and rewarming phases of therapeutic hypothermia.
253161|NCT02255071|Device|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
252541|NCT02264314|Behavioral|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
252542|NCT02266758|Other|GDM Screening Methods|
252543|NCT00147693|Behavioral|Professional service: treatment of problems by counseling or practical support|
252544|NCT02266771|Device|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
252545|NCT02266771|Device|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
252546|NCT02266784|Behavioral|Contingency Management (CM)|
252547|NCT02266784|Drug|Transdermal nicotine skin patches (i.e. Habitrol)|
252548|NCT02266784|Other|Supportive Counseling|
252549|NCT02266797|Drug|Dexamethasone|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
252550|NCT02266797|Other|Saline|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
252551|NCT02266810|Device|PROPEL Mini or Nova Sinus Implant.|Placement of sinus implant following frontal sinus surgery
252552|NCT02266810|Procedure|Sinus Surgery only.|Sinus surgery only, without implant placement
252553|NCT02266823|Behavioral|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
252854|NCT02259699|Other|Decision Aid|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
252855|NCT02259712|Other|Hipopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
252856|NCT02259712|Behavioral|Therapeutic education.|The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.
In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant.
252227|NCT02271477|Device|Ultrasound-guided volemic repletion|After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
252228|NCT02271490|Other|Acrosome Reaction induction|
252229|NCT02271490|Other|capacitation in incubation medium prior to ICSI|
252230|NCT02271503|Drug|carbidopa and levodopa|Symptomatic treatment of Parkinsons disease
252231|NCT02271516|Radiation|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
252232|NCT02271529|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
252233|NCT00148122|Drug|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
252234|NCT02271542|Drug|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
252235|NCT02271555|Drug|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
252236|NCT02273804|Drug|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
252237|NCT02273804|Drug|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
252238|NCT00148408|Drug|Montelukast|
252239|NCT02273817|Drug|Ciclesonide nasal spray, 50 μg per actuation.|During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.
During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:
Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.
252240|NCT02273830|Drug|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
252241|NCT02273843|Drug|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
251588|NCT02245230|Drug|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
251589|NCT00144950|Drug|insertion of a chest drain with urokinase instillation|
251590|NCT02245243|Drug|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
251591|NCT02245256|Drug|Precedex|infusion of 0.1mcg/kg/hr of precedex
251592|NCT02245256|Drug|placebo control|placebo
251593|NCT02245269|Drug|Tipranavir|
251594|NCT02245269|Drug|Ritonavir|
251928|NCT02240095|Behavioral|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
251929|NCT02240095|Behavioral|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
251930|NCT02240095|Behavioral|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
251931|NCT02240108|Drug|Rifaximin DR|
251932|NCT02240108|Drug|Placebo|
251933|NCT02240121|Drug|Rifaximin DR|
251934|NCT02242591|Drug|Saline|
251935|NCT02242604|Other|Multidimensional Geriatric Assessment (MGA)|The MGA contains the following tests:
Barthel Katz Index (activity of daily living, ADL)
Mini Mental State Test (MMST)
DemTec (dementia detection test)
Clock Test
Geriatric Depression Scale (GDS)
Tinetti Test
TUG (timed up-and-go Test)
Esslinger Transfer Scale (ETS)
Handgrip Test
Mini Nutritional Assessment (MNA)
251936|NCT02242617|Device|CPAP|Continuous or Auto-adjusting Positive Airway Pressure (CPAP/APAP here described as PAP), a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through the patient's airway during sleep to keep the airway open
251937|NCT02242617|Device|Mandibular Advancement Splint|Mandibular Advancement Splints (MAS), which are dental splints used to keep the mandible in an advanced position, opening the upper airway during sleep
251938|NCT02242630|Drug|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
251939|NCT02242630|Drug|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
246166|NCT02222480|Drug|Placebo|
246167|NCT00142480|Procedure|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
246168|NCT02222493|Biological|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
246169|NCT02222493|Biological|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
246170|NCT02222506|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
246462|NCT00141284|Drug|Lamivudine 150 mg twice daily|
246463|NCT02212756|Drug|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
246464|NCT02212769|Drug|Losartan 50mg|Losartan 50mg once daily for 7 days
246465|NCT02212769|Drug|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
246466|NCT02212782|Drug|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
246467|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
246468|NCT02215239|Behavioral|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
246469|NCT02215252|Drug|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
246470|NCT02215252|Drug|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
246471|NCT00141596|Drug|Cardura XL 4 mg bd|
246472|NCT02215252|Drug|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
246473|NCT02215252|Drug|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
246474|NCT02215265|Drug|Cisplatin|Chemotherapy
246475|NCT02215265|Radiation|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
246476|NCT02215278|Dietary Supplement|10 x 55 g/ bean per arm|
245881|NCT02232165|Other|Hypotension avoidance|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP >= 65 mmHg is not inferior to induced hypertension.
245882|NCT02232165|Other|Induced hypertension|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
245883|NCT02232178|Drug|2 100mg Xaracoll implants|
245884|NCT02232178|Drug|3 100mg Xaracoll implants|
245885|NCT02232178|Drug|150mg Bupivacaine HCl injection|
245886|NCT02232191|Biological|Pneumovax-23|
245887|NCT02232204|Behavioral|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
245888|NCT02232217|Behavioral|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
245889|NCT02232217|Other|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
245890|NCT00143559|Procedure|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
245891|NCT02232230|Drug|Provenge|
245892|NCT02232243|Drug|Hydroxychloroquine|Hydroxychloroquine (400 mg/d, 800 mg/d or 1200 mg/d) will be given to subjects for up to 14 days prior to surgery
246171|NCT02222519|Drug|Rocuronium|Rocuronium 0.6mg/kg iv single dose
246172|NCT02222532|Drug|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
246173|NCT02222532|Drug|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
246174|NCT02222545|Biological|OMS721|
246175|NCT02222558|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
246176|NCT02222571|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
246177|NCT02222571|Behavioral|Supervision for Safety|group-based safety intervention for parents
251678|NCT02254616|Behavioral|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
251679|NCT02254616|Behavioral|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
251680|NCT02254629|Drug|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
251681|NCT02254629|Drug|Laxative Polyethylene Glycol|laxative：2000 ml.
251682|NCT02254642|Procedure|Ischemic preconditioning during aortic clamping|
251683|NCT02254642|Procedure|Procedure/Surgery: usual surgery|
251684|NCT02254655|Drug|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
251685|NCT00002353|Biological|P3C541b Lipopeptide|
251686|NCT00146146|Drug|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
251687|NCT02254655|Drug|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
251688|NCT02254668|Other|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
251689|NCT02256813|Drug|Caffeine|
251690|NCT02256813|Drug|Midazolam hydrochloride|
251691|NCT02256813|Drug|Vitamin K1|
251692|NCT02256826|Drug|BILR 355 BS|
251693|NCT02256826|Drug|Ritonavir (RTV)|NORVIR®
251694|NCT02256826|Drug|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
251695|NCT02256839|Device|CST_001|
251696|NCT02256852|Biological|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
251697|NCT02256865|Drug|Ketoconazole|Ketoconazole is taken 4 times a day
251346|NCT02259114|Drug|OTX015/MK-8628|OTX105/MK-8628 10, 20 and/or 40 mg capsules
251347|NCT02259127|Drug|DTG|
251348|NCT02259140|Procedure|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
251349|NCT02259140|Procedure|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
251350|NCT02259153|Behavioral|Changes in cholesterol metabolism|
251351|NCT02261298|Drug|ONO-4538|
251352|NCT02261311|Other|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
251353|NCT02261350|Dietary Supplement|Food fortification|
251354|NCT02261350|Dietary Supplement|Oral Nutritional Supplements|
251355|NCT02261376|Drug|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
251356|NCT02261389|Other|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
251357|NCT02261402|Other|Medisinstart|"Medisinstart" is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.
251358|NCT02261415|Drug|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
251359|NCT02261415|Drug|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
251360|NCT02261428|Device|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
251361|NCT00147004|Drug|Placebo|
251362|NCT02261428|Device|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
251363|NCT02261441|Other|No treatment|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
250760|NCT02236832|Device|transcranial magnetic stimulation|
250761|NCT02236832|Other|MRI imaging|
250762|NCT02236832|Other|EEG recording|
250763|NCT02236832|Behavioral|Neuropsychological examination|
251046|NCT02229461|Drug|Aleve(Naproxen Sodium,BAY117031)|Naproxen sodium 220 mg qd
251047|NCT00002329|Drug|Celgosivir hydrochloride|
251048|NCT00143208|Drug|Xalacom|
251049|NCT02229461|Drug|Aspirin (Acetylsalicylic Acid, BAYE4465)|ASA 81 mg qd
251050|NCT02229474|Behavioral|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
251051|NCT02229487|Other|Mixed meal test|
251052|NCT02229500|Dietary Supplement|Inulin|
251053|NCT02229500|Dietary Supplement|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
251054|NCT02229500|Dietary Supplement|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
251055|NCT02231788|Drug|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
251056|NCT02231801|Behavioral|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
251057|NCT02231814|Dietary Supplement|Crohns Disease Exclusion Diet + PEN|
251058|NCT00143520|Drug|Pioglitazone|
251059|NCT02231814|Other|Crohns Disease Exclusion Diet|
251060|NCT02231827|Other|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
251061|NCT02231853|Biological|MVST|MVST Infusion
251062|NCT02231866|Biological|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
250423|NCT02204176|Other|Implementation intentions|Discussion of:
barriers to exercise and how to address/overcome barriers
how to create detailed exercise plans
250424|NCT02204176|Other|Industriousness|Discussion of:
realistic monitoring of efforts related to exercise
reaching and pushing past thresholds for sustained effort for exercise
250425|NCT02204176|Device|pedometer|
250426|NCT02204189|Drug|TongFuSan|TongFuSan 1g
250427|NCT02204202|Drug|[18F]FDG|10 millicuries (mCi) of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
250428|NCT02204202|Drug|[18F]ISO-1|8 mCi of [18F]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
250429|NCT02204215|Device|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
250430|NCT02204215|Other|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
250431|NCT00140361|Drug|Sulfadoxine-pyrimethamine|
250432|NCT02204228|Device|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
250764|NCT02236845|Device|Lacrima Medical Device and sham comparator|
250765|NCT02236858|Device|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
250766|NCT00144053|Drug|Irinotecan+Carboplatin/concurrent radiation|
250767|NCT02236858|Device|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
250768|NCT02236871|Behavioral|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
250769|NCT02236871|Behavioral|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
250770|NCT02236884|Procedure|no-scar transanal total mesorectal excision(TME)|
250771|NCT02236897|Other|PET Scanning|
250772|NCT02236910|Other|Lu-DOTA-TATE|
250133|NCT02209155|Drug|R-verapamil 75 mg tablet|
250134|NCT02209155|Drug|Placebo|
250135|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
250136|NCT00140933|Drug|Comparator: diclofenac, placebo|
250137|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
250138|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
250139|NCT02209181|Drug|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
250140|NCT02209194|Device|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
250141|NCT02211534|Device|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
250142|NCT02211534|Device|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
250143|NCT02211547|Device|Epic 10 Diode Laser by Biolase Inc.|
250144|NCT02211547|Other|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
250145|NCT02211560|Other|Phosphatidylserine|
250146|NCT02211560|Other|Placebo|
250147|NCT02211573|Other|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
250148|NCT00002315|Drug|Acyclovir|
250149|NCT00141167|Drug|varenicline|
250433|NCT02204241|Drug|Carfilzomib|
249839|NCT02219113|Procedure|Liposuction|
249840|NCT02219113|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
249841|NCT02219113|Other|Intraarticular administration of autologous ADRC|
249842|NCT00142090|Drug|Placebo|Normal saline
249843|NCT02219126|Other|Dietary intervention|
249844|NCT02219139|Device|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
249845|NCT02219152|Drug|tranexamic acid|
249846|NCT02219152|Drug|saline|
250150|NCT02211586|Drug|Insulin Glargine or LY2605541|When initiating LY2605541, the patient will administer their basal insulin dose of LY2605541 in addition to a tapered dose of insulin glargine. On Day -2, the patient will administer the determined dose of LY2605541 plus 50% of the determined dose of insulin glargine. On Day -1, the patient will administer the determined dose of LY2605541 plus 25% of the determined dose of insulin glargine. On Day 1, the patient will administer the determined dose of LY2605541 only (no insulin glargine). Stable doses of LY2605541 will be administered for a minimum period of 4 weeks.
250151|NCT02211599|Other|15% protein|Meal to provide 15%en from protein.
250152|NCT02211599|Other|30% protein|Meal to provide 30%en from protein.
250153|NCT02211599|Other|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
250154|NCT02211612|Dietary Supplement|PUFA-group|
250155|NCT02211612|Dietary Supplement|SFA-group|
250156|NCT02211625|Drug|Open-label TRV734 125 mg|125 mg
250157|NCT02211625|Drug|TRV734 blinded|blinded, multiple ascending dose
250158|NCT02211625|Drug|Oxycodone IR 10 mg|
250159|NCT02211625|Drug|Placebo|TRV734-matched and oxycodone placebo
250160|NCT00141180|Drug|CP-481,715|
250161|NCT02211638|Drug|Candesartan Cilexetil|Candesartan Cilexetil tablet
250162|NCT02211664|Device|Passeo-18 balloon|
250163|NCT02211664|Device|Passeo-18 Lux drug releasing balloon|
249526|NCT02224053|Drug|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
249527|NCT02224053|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
249528|NCT02224066|Drug|Ticagrelor 90 mg twice per day during three months following TAVI|
249529|NCT02224066|Drug|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
249530|NCT02224079|Drug|BIIB 722 CL|
249531|NCT00142597|Other|Sham treatment|Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.
All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional.
249532|NCT02224079|Drug|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
249533|NCT02224092|Dietary Supplement|multivitamin multimineral with phytonutrient supplementation|The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two "Vitamin" tablets, a "Mineral" tablet, and a "Phytonutrient" tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo.
249534|NCT02224105|Drug|BI 653048 BS|
249535|NCT02224105|Drug|Prednisolone low|
249536|NCT02226172|Drug|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
249537|NCT00142818|Drug|Placebo|400 mg and/or 100-150 mg placebo pills
249538|NCT02226172|Drug|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
249539|NCT02226185|Drug|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 3 years
249847|NCT02219165|Drug|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
249848|NCT02219165|Drug|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
249849|NCT02219178|Drug|lenalidomide|25mg days 1 - 14 of 21 day schedule
249850|NCT02219178|Drug|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
249851|NCT02219178|Drug|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
249215|NCT02231125|Drug|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
249216|NCT02231125|Drug|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
249217|NCT02231138|Drug|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
249218|NCT00143429|Drug|Xalatan|
249219|NCT02231151|Behavioral|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
249220|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
249221|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
249222|NCT02231164|Drug|placebo|oral placebo
249223|NCT02231164|Drug|nintedanib|oral experimental therapy
249224|NCT02231177|Drug|BI 1744 CL|
249225|NCT02231177|Drug|BI 1744 CL/Tiotropium FDC|
249226|NCT02231177|Drug|Tiotropium|
249227|NCT02231190|Drug|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
249228|NCT02231190|Drug|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
249229|NCT00143442|Drug|[S,S]-Reboxetine|
249230|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
249231|NCT02233660|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
249232|NCT02233660|Procedure|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
249540|NCT02226198|Drug|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
253783|NCT02240615|Device|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
253784|NCT02240628|Device|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
253785|NCT02240628|Drug|Saline|Patients in arm 2 will receive Saline with the Propofol.
254091|NCT00148239|Behavioral|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
254092|NCT02272205|Other|Retrospective analysis of records|
254093|NCT02272218|Procedure|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
254094|NCT02272244|Behavioral|Decision Support & Navigation|
254095|NCT02272244|Behavioral|Standard|
254096|NCT02272257|Behavioral|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
254097|NCT02272257|Behavioral|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
254098|NCT02272270|Drug|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
254099|NCT02272283|Device|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
254100|NCT02272296|Device|jet injector|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
254101|NCT02272296|Device|Conventional pen (NovoPen IV)|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
254102|NCT00148239|Behavioral|Control|Participants given written educational materials at beginning of study; no treatment beyond this
254103|NCT02272309|Procedure|EEG and EP measurement|
254104|NCT02274779|Drug|ELIGARD|Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.
Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical.
254105|NCT02274792|Drug|Etanercept|Etanercept 50 mg twice weekly for 12 weeks followed by 50 mg once weekly (for additional 12 weeks). During the first 12 weeks of the study, subjects will receive 2 doses of etanercept per week (eg, on Monday and Thursday). During the second 12 weeks of the study, subjects will receive 1 dose of etanercept per week (scheduled approximately 7 days apart).
253474|NCT02248298|Drug|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
253475|NCT02248337|Drug|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
253476|NCT00145379|Drug|Tablet Metformin 500 mg|
253477|NCT02248350|Behavioral|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
253478|NCT02248350|Behavioral|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
253786|NCT02240628|Drug|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
253787|NCT02240641|Drug|Lacidipine|
253788|NCT02240641|Drug|Diuretics|
253789|NCT02240641|Drug|antihypertensive drugs|
253790|NCT02240641|Drug|alpha blockers|
253791|NCT02240641|Drug|Angiotensin-Converting Enzyme Inhibitors|
253792|NCT00144456|Drug|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
253793|NCT02240641|Drug|beta blockers|
253794|NCT02240667|Drug|Dabigatran etexilate|150 mg or 110 mg capsules twice daily
253795|NCT02240667|Drug|Phenprocoumon|International Normalized Ratio (INR) 2-3
253796|NCT02240680|Drug|placebo|placebo matching linagliptin 5 mg
253797|NCT02240680|Drug|linagliptin|5 mg once a day
253798|NCT02240693|Drug|BI 409306|
253799|NCT02240693|Drug|Placebo|
253800|NCT02240693|Drug|BI 409306|
253801|NCT02240693|Drug|Placebo|
253162|NCT02255071|Device|Sham wristband|A wristband over wrist but no acupressure for seven days.
253163|NCT02255084|Behavioral|Group 1 remove self sample kit at gp consulting room or perform pap smear|Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.
Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
253164|NCT02255084|Behavioral|Group 2 perform self sample at home or pap smear|Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.
When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
253165|NCT02255097|Biological|pembrolizumab|
253166|NCT02255110|Drug|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
253167|NCT02255110|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
253168|NCT02255136|Other|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
253169|NCT00146224|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
253170|NCT02255136|Other|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
253171|NCT02255149|Device|Bone/Mesh|
253479|NCT02248363|Other|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
253480|NCT02248376|Drug|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
253481|NCT02248389|Device|Sonatherm 600i ablation system|HIFU ablation of tumor.
253482|NCT02248402|Biological|Vax-DC/MM|
253483|NCT02248415|Other|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
252857|NCT02259712|Other|Pelviperineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
252858|NCT02259712|Other|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
252859|NCT02259725|Drug|regorafenib|Given PO
252860|NCT02259725|Other|laboratory biomarker analysis|Correlative studies
252861|NCT02261935|Other|Existing home care nursing practice|Home care nurses in this comparator group will provide "care as per usual" to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done.
252862|NCT00147121|Drug|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
252863|NCT02261935|Other|Practice support tool intervention|The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.
The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.
252864|NCT02261948|Drug|Levosimendan|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
252865|NCT02261948|Drug|Placebo|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
252866|NCT02261961|Biological|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
252867|NCT02261961|Other|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
252868|NCT02261961|Other|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
253172|NCT02255162|Drug|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
253173|NCT02255162|Genetic|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
253174|NCT02255162|Drug|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
253175|NCT02255175|Drug|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
252242|NCT02273843|Drug|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
252243|NCT02273895|Drug|Scopolamine|0.3 mg/mL, intravenously, once
252554|NCT00147706|Procedure|Tailored Healthmedia programs on EHR Patient Portal|
252555|NCT02266836|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non‐damaged pathways of the central nervous system.
252556|NCT02266849|Drug|Loperamide|12 mg Loperamide each day for three days
252557|NCT02266849|Drug|Placebo|6 tablets daily for three days
252558|NCT02266862|Radiation|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
252559|NCT02266875|Drug|hypertonic saline|
252560|NCT02266875|Drug|standard saline|
252561|NCT02266888|Biological|Rituximab (Rituxan®)|2 Doses: 375 mg/m2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/‐2 days).
252562|NCT02266888|Biological|Placebo for Rituximab (Rituxan®)|2 Doses: 375 mg/m2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/‐2 days).
252563|NCT02266901|Procedure|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
252564|NCT02269228|Drug|Placebo|
252565|NCT02269241|Drug|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
252566|NCT02269254|Device|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
252567|NCT02269254|Device|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
252568|NCT02269267|Other|Stopping their TKI|Patients with CML patients who are on imatinib, dasatinib, nilotinib, or bosutinib and have had deep molecular response is defined as BCR-ABL < 0.01%, (> MR4 i.e. > 4 log reduction) by PCR for at least 2 years will stop their TKI. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
251940|NCT02242630|Drug|Triamcinolone, 20 mg|Compared with methylprednisolone
251941|NCT02242630|Drug|Triamcinolone, 40 mg|Compared with methylprednisolone
251942|NCT02242643|Biological|FluLaval Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
251943|NCT02242643|Biological|Fluzone Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
251944|NCT00144677|Drug|tacrolimus|
251945|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
252244|NCT02273908|Other|No intervention|The study is observational
252245|NCT02273921|Other|EEG recording|EEG is recorded once for each participant
252246|NCT02273934|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
252247|NCT02273934|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
252248|NCT02273947|Drug|BMS-955176|
252249|NCT00148408|Behavioral|Education|
252250|NCT02273960|Drug|BMS-986004|
252251|NCT02273973|Drug|GDC-0032|GDC-0032 will be administered orally at 4 mg daily on 5 days-on/2 days-off schedule for up to 16 weeks.
252252|NCT02273973|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 16 weeks.
252253|NCT02273973|Other|Placebo|Placebo matched to GDC-0032 will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
252254|NCT02273986|Drug|Digoxin|
252255|NCT02273986|Drug|K-877|
252256|NCT02273999|Device|RecoveryRx™|Appliance of the device after surgery
252257|NCT02274012|Drug|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
246477|NCT02215304|Dietary Supplement|Bifidobacterium longum ssp infantis R0033|12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)
246478|NCT02215304|Dietary Supplement|Lactobacillus helveticus R0052|12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)
246479|NCT02215304|Dietary Supplement|Bifidobacterium bifidum R0071|12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)
246480|NCT02215304|Dietary Supplement|Placebo|12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)
246796|NCT02207946|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
246797|NCT02207946|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
246798|NCT02207959|Drug|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
246799|NCT02207959|Procedure|White-light examination|standard white light examination
246800|NCT00140764|Drug|Metronidazole gel versus placebo gel|
246801|NCT02207959|Procedure|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
246802|NCT02210234|Dietary Supplement|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
246803|NCT02210247|Drug|EXPAREL|
246804|NCT02210260|Procedure|Spinal and infusion of local anaesthetic|Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.
PLUS
Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
246805|NCT02210260|Procedure|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
246806|NCT02210260|Drug|Bupivacaine|
246178|NCT00142493|Drug|Propofol|1.2ug/ml
246179|NCT02222597|Device|infrascanner|
246180|NCT02222610|Drug|0.5 mg ranibizumab|
246181|NCT02222610|Procedure|Targeted Retinal Photocoagulation|TRP to areas of retinal ischemia
246182|NCT02222623|Drug|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
246183|NCT00142701|Behavioral|stress management|
246184|NCT02224833|Behavioral|Pharmacist intervention|Systematic review of treatments:
Identification of reasons for PPI.
Determination of recommended pharmacotherapeutic alternatives.
Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.
After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP.
246185|NCT02224846|Drug|Tadalafil|Administered orally
246186|NCT02224859|Device|HCP will place the Invictus Cranial Support Device (CSD) on the patient|There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.
The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient.
246187|NCT02224859|Other|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
246188|NCT02224872|Procedure|Bone marrow transplant|Day 0
246189|NCT02224872|Drug|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
246190|NCT02224872|Drug|Fludarabine|30 mg/M2 IV on days -6 to -2
246481|NCT02215330|Drug|Eplerenone|
246482|NCT00141596|Drug|Amiloride 5 mg bd|
246483|NCT02215330|Drug|Maltodextrin|
246484|NCT02215343|Dietary Supplement|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R&D Centre Europe).
246485|NCT02215343|Dietary Supplement|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
252003|NCT02250079|Device|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
252004|NCT02250092|Device|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
252005|NCT02250092|Device|Placebo Comparator|
252006|NCT00145574|Drug|colesevelam HCl|Tablets
252007|NCT02250105|Drug|ARI-3037MO|Lipid lowering
252008|NCT02250105|Drug|Placebo|Inactive
252009|NCT02250118|Drug|Bevacizumab|Intrapleural Bevacizumab
252010|NCT02250131|Procedure|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery > 280 mL/min/m2
252011|NCT02250144|Device|Foot orthoses|
252012|NCT02250157|Drug|Oratecan|
252013|NCT02250170|Drug|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
252014|NCT02250183|Device|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
252015|NCT02250183|Device|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
252016|NCT02250196|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
252017|NCT00002347|Drug|Zidovudine|
252018|NCT00145574|Drug|placebo|Matching Tablets
252019|NCT02250196|Drug|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
251364|NCT02261454|Other|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
251698|NCT00146497|Drug|Budesonide-Surfactant|
251699|NCT02256865|Drug|Hydrocortisone|Hydrocortisone is taken 3 times a day
251700|NCT02256865|Drug|Testosterone|Testosterone gel is applied once a day
251701|NCT02256865|Drug|Placebo|Placebo for ketoconazole
251702|NCT02256865|Drug|Placebo|Placebo for hydrocortisone
251703|NCT02256865|Drug|Placebo|Placebo for testosterone
251704|NCT02256878|Drug|BIRT 2584 XX|
251705|NCT02256878|Drug|Amitriptyline|
251706|NCT02256891|Device|PRFM|
251707|NCT02256891|Procedure|Double Row|
251708|NCT02256904|Procedure|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
251709|NCT00146510|Behavioral|HealtheLifestyle Program|
251710|NCT02256904|Procedure|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
251711|NCT02256917|Biological|Human cl rhFVIII|
251712|NCT02256930|Drug|M518101|
251713|NCT02256930|Drug|M518101 Vehicle|
251714|NCT02256930|Other|Sodium lauryl sulfate|
251715|NCT02256930|Other|Saline|
251716|NCT02256943|Drug|Amitriptyline|100 mg single dose
251717|NCT02256943|Drug|Tolterodine|Placebo 1 mg single dose
251718|NCT02256956|Drug|Amitriptyline|25 mg / day for 10 days
251063|NCT02231866|Biological|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
251064|NCT02231879|Drug|Plerixafor|Plerixafor (Mozobil ) is a specific antagonist of the chemokine receptor CXCR4. It is FDA approved since 2008 for use in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin s lymphoma (NHL) and multiple myeloma (MM). CXCR4 is the gene mutated in WHIM syndrome and is hyperfunctional in this disorder. Our previous studies have demonstrated that low dose treatment of WHIM patients with this agent is safe and suggested efficacy at reducing infection frequency and improving wart burden.
251365|NCT02261467|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
251366|NCT02261467|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
251367|NCT02261480|Other|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
251368|NCT02261480|Other|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
251369|NCT02261493|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
251370|NCT02261493|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
251371|NCT02261506|Other|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
251372|NCT00147030|Procedure|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
251373|NCT02263690|Procedure|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
251374|NCT02263703|Biological|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
251375|NCT02263729|Drug|Losartan|
251376|NCT02263729|Drug|placebo|
251377|NCT02263742|Behavioral|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
251378|NCT02263742|Behavioral|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
250773|NCT02236936|Dietary Supplement|Standard care of parenteral nutrition|Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
250774|NCT02236936|Dietary Supplement|ZentroOLIMEL 5.7% parenteral over night|
250775|NCT02236936|Biological|Cetuximab|Weekly during radiotherapy; not given if cisplatin is given during radiotherapy
Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)
250776|NCT02236936|Drug|Cisplatin|Cisplatin 100 mg/m² on day 1, 22 and 43 (during radiotherapy; in total 3 cycles à 21 days); not given in combination with cetuximab
250777|NCT00144053|Drug|Paclitaxel+Carboplatin/concurrent radiation|
250778|NCT02236936|Radiation|Radiotherapy|First 18 irradiations once daily with single dose of 1.8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days (1.5 Gy per day with at least 5 hours interval to 1.8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
250779|NCT02199249|Device|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
250780|NCT02199249|Device|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
250781|NCT02199262|Other|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
250782|NCT02199262|Other|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
251065|NCT02231879|Drug|G-CSF|G-CSF (NeupogenTM) is FDA-licensed and the standard of care for severe chronic neutropenia, and will be used as the control or comparator drug in this study. G-CSF is a recombinant human protein produced in E. coli that is identical in amino acid sequence with the exception of an additional N-terminal methionine to a naturally occurring cytokine made by human monocytes, fibroblasts, and endothelial cells. G-CSF acts on specific receptors to regulate the proliferation and differentiation of neutrophil progenitors, and augments the bone marrow release and function of mature neutrophils. It has minimal effects on other hematopoietic cell types. Its effect on bone marrow release of neutrophils is mediated in part by interfering with CXCL12 availability at CXCR4.
251066|NCT02231892|Device|TMS|HAC coil (real rTMS or sham rTMS)
251067|NCT02231905|Drug|BI-Sifrol®|
251068|NCT02231918|Drug|MIRAPEX® - low|
251069|NCT00143520|Drug|Placebo|
251070|NCT02231918|Drug|MIRAPEX® - medium|
251071|NCT02231918|Drug|MIRAPEX® - high|
250434|NCT02204241|Drug|Cyclophosphamide|
250435|NCT02204241|Drug|Dexamethasone|
250436|NCT02204254|Device|Radiofrequence|Associated to arm radiofrequence
250437|NCT02204254|Drug|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
250438|NCT02204267|Other|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
250439|NCT02204267|Device|ECG|
250440|NCT02204293|Drug|Canakinumab|Canakinumab will be injected subcutaneously in a dose of 4mg/kg body weight up to a maximum of 300 mg every 4 weeks.
250441|NCT02204293|Drug|Placebo|
250442|NCT00002308|Drug|Stavudine|
250443|NCT00140361|Drug|sulfadoxine-pyrimethamine plus artesunate|
250444|NCT02204306|Genetic|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
250445|NCT02204319|Device|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 mW, 635 nm red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
250446|NCT02204332|Drug|Cabazitaxel|
250447|NCT02204332|Other|Best Supportive Care|
250448|NCT02204345|Drug|RO5479599|Administered by intravenous infusion of every 3 weeks (q3w)
250449|NCT02206750|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
250450|NCT02206763|Drug|MMB|Momelotinib (MMB) tablet(s) administered orally once or twice daily
250451|NCT02206763|Drug|Erlotinib|Erlotinib tablet(s) administered orally once daily.
250452|NCT02206776|Drug|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
250453|NCT02206776|Drug|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
250454|NCT00140621|Drug|Agalsidase beta|
250164|NCT02211664|Device|Pulsar-18 stent|
250165|NCT02211690|Drug|dolutegravir 50 mg (one tablet daily)|
250166|NCT02211690|Drug|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
250167|NCT02211716|Device|BeGraft Peripheral Stent Graft System|
250168|NCT02214212|Device|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
250169|NCT02214212|Device|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
250170|NCT00141466|Behavioral|Feedback for professionals|
250171|NCT02214225|Biological|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
250172|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
250456|NCT02206789|Drug|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
250457|NCT02206802|Drug|5% minoxidil topical foam|5% minoxidil topical foam
250458|NCT02206815|Drug|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
250459|NCT02206815|Drug|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
250460|NCT02206841|Procedure|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
250461|NCT02206841|Device|ARFI|ARFI imaging will be performed for evaluate fibrosis of liver.
250462|NCT02206841|Device|SWE|SWE (supersonic shearwave elastography) will be performed for evaluate fibrosis of liver.
250463|NCT02206841|Device|Transient elastography (Fibroscan)|Transient elastography will be performed for evaluate fibrosis of liver.
250464|NCT02206854|Drug|R-flurbiprofen|200 mg gelatine capsule once orally
250465|NCT00140634|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
250466|NCT02206867|Biological|LBAL|Anti-inflammatory agents
249852|NCT02219191|Drug|puerarin tablet 50 mg|
249853|NCT00142103|Drug|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
249854|NCT02219191|Drug|Atorvastatin tablet 20 mg|Approval No.: H19990258
249855|NCT02219204|Procedure|Acupuncture|
249856|NCT02219204|Other|Herbal treatment|
249857|NCT02219217|Drug|Dolutegravir, Elvitegravir and Cobicistat|
249858|NCT02219230|Device|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
249859|NCT02219230|Device|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
249860|NCT02219230|Device|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
249861|NCT02219243|Behavioral|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
249862|NCT02219243|Behavioral|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
249863|NCT02219256|Drug|TAK-079|TAK-079 solution
249864|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
249865|NCT02219256|Drug|Placebo to TAK-079|Placebo to TAK-079 solution
249866|NCT02221570|Drug|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
250173|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
250174|NCT02214238|Device|PAP device|
250175|NCT02214251|Device|PK-16CH EXG system|
250176|NCT02214264|Behavioral|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
250177|NCT02214264|Behavioral|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
249541|NCT02226198|Drug|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
249542|NCT02226211|Device|Air-Q intubation laryngeal airway|The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.
After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.
After successful intubation, the device will be removed according to the manufactures guides using removal stylet .
249543|NCT02226211|Device|Ambu-Aura i laryngeal mask|The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (> 100kg).
After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.
After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.
After successful intubation, the device will be removed according to the manufactures guides using another ETT.
249544|NCT02226237|Procedure|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
249545|NCT02226237|Procedure|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
249546|NCT02226250|Dietary Supplement|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
249547|NCT02226263|Dietary Supplement|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 [CFU] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
249548|NCT00142831|Drug|Pharmacotherapies for Smoking Cessation|Bupropion-SR or Identical Placebo
249549|NCT02226276|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
249550|NCT02226276|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
249551|NCT02226276|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
249552|NCT02226276|Biological|trastuzumab|Given IV
249553|NCT02226276|Radiation|copper Cu 64-DOTA-trastuzumab|Given IV
249554|NCT02226276|Procedure|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
249555|NCT02228655|Drug|FMX-8|
254106|NCT02274805|Procedure|Adults presenting for surgery in the neck area|
254107|NCT02274818|Behavioral|Flexible Duty Hour Schedule|IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:
No more than 80 hours of work per week
1 day off in 7 (when averaged over 4 weeks)
In-house call no more frequently than every 3rd night (when averaged over 4 weeks)
254108|NCT02274831|Other|Email Reminder of need to follow up with primary physician|
254109|NCT00148512|Drug|1. Tesofensine (NS 2330)|
249233|NCT02233673|Behavioral|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
249234|NCT02233686|Drug|XEN-D0501|
249235|NCT02233686|Drug|Placebo|
249236|NCT02233699|Drug|XEN-D0501|
249237|NCT02233699|Drug|Placebo|
249238|NCT02233712|Biological|G17DT|
249239|NCT02233725|Device|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
249240|NCT02233738|Behavioral|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
249241|NCT00143676|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
249242|NCT02233738|Behavioral|Control Treatment Condition (CT)|Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., "How do I talk to my family about my alcohol problem?"), money management with feedback (2 sessions), and cooking-home maintenance.
249243|NCT02233751|Drug|Testosterone enanthate auto-injector|Randomization of Treatment A; or Treatment B
249244|NCT02233764|Other|FeZnPM|Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
249245|NCT02233764|Other|CtrlPM|Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
253802|NCT02240693|Drug|Placebo|
253803|NCT00144469|Drug|peginterferon alfa-2a|
253804|NCT02240693|Drug|BI 409306|
253805|NCT02240693|Drug|Placebo|
253806|NCT02240693|Drug|Placebo|
253807|NCT02243371|Drug|CY|200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2 (Arm A and B)
253808|NCT02243384|Procedure|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
253809|NCT02243384|Procedure|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
253810|NCT02243423|Procedure|SUPINE|Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.
A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline.
254110|NCT02274844|Behavioral|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
254111|NCT02274857|Procedure|Standard PVI Ablation|Standard PVI procedure without FIRMap.
254112|NCT02274857|Procedure|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
254113|NCT02274870|Drug|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
254114|NCT02274870|Drug|Bupivicaine HCl|Administered via femoral nerve block
254115|NCT02274883|Dietary Supplement|Enriched Protein Fractions|Enriched protein fractions
254116|NCT02274883|Dietary Supplement|Protein Fractions|Protein fractions
254117|NCT02274896|Device|PD Catheter group|PD catheter
254118|NCT02274909|Other|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
254119|NCT02274935|Other|Exercise|Balance and gait exercise twice a week for an hour
253484|NCT02248415|Other|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
253485|NCT02248415|Other|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
253486|NCT02248415|Other|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
253487|NCT00145379|Drug|Placebo|
253488|NCT02248415|Other|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
253489|NCT02248415|Other|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
253490|NCT02250794|Drug|metformin and sitagliptin|metformin 750 mg PO twice daily
253491|NCT02250794|Drug|insulin glargine and insulin lispro|insulin glargine given once daily
253492|NCT02250794|Drug|metformin and sitagliptin|sitagliptin 100 mg PO once daily
253493|NCT02250794|Drug|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
253494|NCT02250807|Drug|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
253495|NCT02250807|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
253496|NCT02250820|Drug|Dexmedetomidine|Nasal administration
253497|NCT00145613|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
253498|NCT02250820|Drug|Pentobarbital|Oral administration
253811|NCT02243423|Procedure|TILT|Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.
A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline.
253812|NCT02243436|Drug|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
253813|NCT02243436|Drug|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
253814|NCT02243436|Drug|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
253815|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
253176|NCT02255175|Drug|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
253177|NCT02255188|Procedure|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
253178|NCT02255201|Dietary Supplement|Master Performance Blend Dose 1|Caffeine content: 200 mg
253179|NCT02255201|Dietary Supplement|Master Performance Blend Dose 2|Caffeine content: 400 mg
253180|NCT02257372|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
253181|NCT02257385|Drug|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
253182|NCT02257385|Drug|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
253183|NCT02257385|Drug|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
253184|NCT02257385|Drug|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
253185|NCT00146562|Drug|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
253186|NCT02257385|Drug|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
253187|NCT02257385|Drug|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
253188|NCT02257385|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
253499|NCT02250820|Other|Oral Placebo|Oral placebo will be cherry syrup
253500|NCT02250820|Other|Nasal Placebo|Nasal placebo will be nasally atomized saline
253501|NCT02250833|Drug|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
252569|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
252570|NCT02269280|Drug|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
252571|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
252869|NCT02261961|Other|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
252870|NCT02261961|Dietary Supplement|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
252871|NCT02261961|Dietary Supplement|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
252872|NCT02261974|Device|Active Treatment Viveve|Application of Radiofrequency Energy to the vaginal introitus
252873|NCT00147134|Procedure|open colectomy|Procedure/Surgery: open colectomy
252874|NCT02261974|Device|Sham Treatment Viveve|Subject will receive less than one (1) Joule of radiofrequency energy to the vaginal introitus
252875|NCT02261987|Other|Autogenic drainage (AD)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
252876|NCT02261987|Other|Resistive inspiratory manoeuvre (RIM)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
252877|NCT02261987|Other|Resistive inspiratory manoeuvre+autogenic drainage|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
252878|NCT02262000|Radiation|Image Guided Stereotatic Ablative Radiotherapy|
252879|NCT02262013|Behavioral|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
252880|NCT02264327|Behavioral|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
252258|NCT02274012|Drug|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
252259|NCT02274038|Drug|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
252260|NCT02237573|Other|Written medical report and standardized medical advices|The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:
a detailed report of the consultation (motive, case history, clinical examination, conclusion)
written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients.
252261|NCT02237573|Other|Control|Other:
Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator.
252262|NCT02237586|Biological|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
252263|NCT02237612|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
252264|NCT02237612|Other|laboratory biomarker analysis|Correlative studies
252572|NCT00147914|Drug|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
252573|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
252574|NCT02269293|Drug|Paclitaxel|
252575|NCT02269293|Drug|Carboplatin|
252576|NCT02269293|Drug|Selinexor|
252577|NCT02269306|Drug|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
252578|NCT02269319|Drug|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
252579|NCT02269319|Drug|Linezolid|Oral linezolid 600mg given twice a day for 10 days
252580|NCT02269332|Other|Screening Colonoscopy|we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
252581|NCT02269345|Other|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
252582|NCT02269345|Other|Standard Treatment|Standard Treatment alone.
252583|NCT00147914|Drug|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
246807|NCT02210260|Drug|Diamorphine|500mcg
246808|NCT02210260|Device|A Painbuster® catheter|
246809|NCT02210260|Device|25G Whitacre needle|
246810|NCT00141037|Drug|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
246811|NCT02210273|Device|Solace Bladder Control Balloon|Subjects may undergo treatment every 12 months until study completion.
246812|NCT02210273|Device|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control Balloon
246813|NCT02210286|Dietary Supplement|Magtein|
246814|NCT02210299|Other|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
247096|NCT02202980|Drug|SOF/GS-5816|Sofosbuvir (SOF) 400 mg/GS-5816 100 mg fixed-dose combination (FDC) tablets administered orally once daily
247097|NCT02205281|Behavioral|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
247098|NCT02205294|Other|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
247099|NCT02205307|Device|PINPOINT|
247100|NCT02205307|Device|SPY Elite|
247101|NCT02205320|Biological|DRL_PG|
247102|NCT00140478|Drug|Mifepristone|200mg orally once daily
247103|NCT02205320|Biological|Pegfilgrastim Form A|
247104|NCT02205320|Biological|Pegfilgrastim Form B|
247105|NCT02205333|Biological|MEDI6469/tremelimumab|MEDI6469 in combination with tremelimumab
247106|NCT02205333|Biological|MEDI6469/MEDI4736|MEDI6469 in combination with MEDI4736
247107|NCT02205333|Biological|MEDI6469/rituximab|MEDI6469 in combination with rituximab
247108|NCT02205333|Biological|MEDI6469|MEDI6469 monotherapy
246486|NCT02215356|Drug|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
246487|NCT02215356|Drug|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
246488|NCT02217800|Drug|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
246489|NCT02217800|Drug|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
246490|NCT02217813|Drug|Tafamidis|20 mg of current commercial formulation
246491|NCT02217813|Drug|Tafamidis|20 mg of new formulation
246492|NCT00141895|Drug|Misoprostol|2 tablets 200 micrograms Vaginal route
246493|NCT02217826|Drug|DG3173|
246494|NCT02217826|Drug|Saline|
246495|NCT02217826|Drug|Octreotide|
246496|NCT02217839|Drug|DG3173|
246497|NCT02217839|Drug|DG3173+Octreotide|
246498|NCT02217839|Drug|Octreotide|
246499|NCT02217839|Drug|DG3173 Placebo|
246500|NCT02217839|Drug|DG3173 Placebo+Octreotide Placebo|
246501|NCT02217839|Drug|Octreotide+DG3173 Placebo|
246502|NCT02217852|Drug|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
246503|NCT00141895|Drug|Misoprostol|2 tablets of 200 micrograms Sublingual route
246815|NCT02210325|Drug|solithromycin|
246816|NCT02210325|Drug|ceftriaxone|
246817|NCT02210325|Drug|azithromycin|
246818|NCT02210338|Device|Karl Storz C-MAC|
252020|NCT02250209|Drug|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14~16 cycles.
252021|NCT02250209|Drug|Capecitabine|Capecitabine 800~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.
Number of cycles: 8 cycles.
252327|NCT02242903|Drug|LY3079514|Administered IV
252328|NCT02242903|Drug|Placebo|Administered SC
252329|NCT02242903|Drug|Placebo|Administered IV
252330|NCT02242916|Radiation|Photon therapy versus proton therapy|
252331|NCT00144703|Drug|Tacrolimus|
252332|NCT02245399|Behavioral|A canola oil enriched mediterranean diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
252333|NCT02245399|Behavioral|A high wheat fiber diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
252334|NCT02245412|Biological|ALXN1007|8 IV doses of 10 mg/kg of ALXN1007 once weekly
252335|NCT02245425|Other|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
252336|NCT02245425|Other|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
252337|NCT02245438|Drug|Tipranavir low dose|
252338|NCT00144963|Drug|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
252339|NCT02245438|Drug|Tipranavir high dose|
252340|NCT02245438|Drug|Ritonavir low dose|
252341|NCT02245438|Drug|Ritonavir high dose|
252342|NCT02245438|Drug|Norethindrone-Ethinyl Estradiol|
252343|NCT02245451|Drug|Tipranavir|
252344|NCT02245451|Drug|Ritonavir|
252345|NCT02245451|Drug|Methadone|
251719|NCT02256956|Drug|Tolterodine|Placebo 1 mg / day for 10 days
251720|NCT02259153|Other|Lean red meat diet|
251721|NCT02259153|Other|Fat red meat diet|
252022|NCT02252211|Drug|DS-8895a|Cohort Number: 1; No. Pts: 3-6; DS-8895a dose rest of cycle: 1 mg/kg
Cohort Number 2; No. Pts.: 3-6; DS-8895a dose rest of cycle: 3 mg/kg
Cohort Number 3; No. Pts.: 3-6; DS-8895a dose rest of cycle: 10mg/kg
Cohort Number 4; No. Pts.: 3-6; DS-8895a dose rest of cycle: 20 mg/kg
Patients will receive an initial 89Zr trace labelled infusion of DS-8895a. DS-8895a will then be infused on Day 8, and second weekly infusions of DS-8895a, for a further two infusions, will subsequently occur. The day 36 infusion of DS-8895a will also be trace labelled with 89Zr, with subsequent PET imaging and pharmacokinetic sampling. Four dose levels (1, 3, 10 and 20mg/kg) will be evaluated, with 3-6 patients entered at each dose level.
252023|NCT00145769|Drug|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
252024|NCT02252237|Biological|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at two following visits. Buccal cell collection swab
252025|NCT02252250|Procedure|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
252026|NCT02252250|Procedure|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
252027|NCT02252263|Drug|Elotuzumab|
252028|NCT02252263|Drug|Lirilumab|
252029|NCT02252263|Drug|Urelumab|
252030|NCT02252276|Procedure|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
252031|NCT02252276|Procedure|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
252032|NCT02252302|Other|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
252033|NCT02252302|Other|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 55% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
252034|NCT00145769|Procedure|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
251379|NCT02263768|Procedure|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
251380|NCT00147355|Drug|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
251381|NCT02263781|Procedure|Blood draw|Blood draw
251382|NCT02263781|Procedure|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
251383|NCT02263794|Procedure|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
251722|NCT02259166|Other|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
251723|NCT02259179|Drug|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
251724|NCT02259179|Drug|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
251725|NCT00146718|Drug|Amodiaquine and Sulphadoxine/Pyrimethamine|
251726|NCT02259192|Device|MED-EL Maestro Cochlear Implant|cochlear implant
251727|NCT02259205|Other|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
251728|NCT02259205|Other|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
251729|NCT02259218|Other|laboratory biomarker analysis|Correlative studies
251730|NCT02259231|Drug|Omaveloxolone Capsules (2.5 mg/capsule)|
251731|NCT02259231|Drug|Ipilimumab (3 mg/kg)|
251732|NCT02259231|Drug|Nivolumab (3 mg/kg)|
251733|NCT02259244|Behavioral|Weight reduction program|
251734|NCT02259270|Other|Record review|Record review. No intervention with patient or physician. No effect on outcome.
251735|NCT02259270|Other|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
251736|NCT00146731|Drug|SP|
251737|NCT02259283|Device|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
251072|NCT02231931|Drug|Digoxin|single dose, fasted
251073|NCT02231931|Drug|Rosuvastatin|single dose, fasted
251074|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
251075|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
251076|NCT02231931|Drug|Metformin hydrochloride|single dose, fasted
251077|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
251078|NCT02231931|Drug|Furosemide|single dose, fasted
251079|NCT02234531|Device|EVER TEACHER|The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called "virtual teacher" will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment.
251080|NCT02234531|Device|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
251081|NCT02234544|Drug|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
251082|NCT02234544|Drug|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
251384|NCT02263794|Procedure|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
251385|NCT02263807|Procedure|Arthroscopy and MPFL-surgery|MPFL reconstruction or standard treatment follewed by physiotherapy
251386|NCT02263807|Procedure|Rehabilitation|Arthroscopy followed by active rehabilitation
251387|NCT02263859|Device|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
251388|NCT02263872|Drug|Minocycline|Minocycline 200mg perday
250455|NCT02206789|Drug|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
250783|NCT02199262|Other|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
250784|NCT02199301|Procedure|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
250785|NCT02199314|Procedure|Intraoperative Neurophysiologic Monitoring|transcranial motor evoked potentials are collected prior to the administration of desflurane (under intravenous anesthesia) and again after desflurane is added for at least 5 minutes and is at 3%.
250786|NCT02199314|Drug|Desflurane|
250787|NCT02199327|Drug|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
250788|NCT02199327|Drug|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
250789|NCT00139646|Drug|Diclofenac|
250790|NCT02199340|Other|iStep exercise test|
250791|NCT02199340|Other|CPET exercise test|
250792|NCT02199353|Other|Stimulation of Activities Daily Living|Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.
The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks.
250793|NCT02199353|Other|Conventional ADLOccupational Therapy|Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.
The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks.
250794|NCT02199366|Procedure|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
250795|NCT02199379|Drug|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
250796|NCT02199392|Drug|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
250467|NCT02206867|Biological|Humira|Anti-inflammatory agents
250468|NCT02206893|Behavioral|Self-monitoring via Smartphone|
250469|NCT02206893|Behavioral|Peer support via Smartphone|
250470|NCT02206893|Behavioral|Professional support via Smartphone|
250471|NCT02206893|Behavioral|Self-monitoring via Web (Static)|
250472|NCT02206906|Behavioral|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
250473|NCT02206932|Drug|Sofosbuvir + Simeprevir|
250474|NCT02206945|Behavioral|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
250475|NCT02209207|Device|Treadmill|
250476|NCT02209207|Other|walking training|
250477|NCT02209220|Device|Positive airway pressure for the treatment of OSA|
250478|NCT02209233|Other|Massage Therapy|
250799|NCT02202096|Other|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
250800|NCT02202096|Other|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
250801|NCT02202096|Other|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
250802|NCT02202096|Other|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
250803|NCT02202096|Other|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
250804|NCT02202096|Other|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a "walk-in" basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline.
250178|NCT02214264|Behavioral|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
250179|NCT02214264|Behavioral|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
250180|NCT02214277|Device|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
250181|NCT00141466|Behavioral|Reminders for professionals|
250182|NCT02214277|Device|TAVR|
250183|NCT02214290|Drug|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
250184|NCT02214290|Drug|Placebo|A 750 gram placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
250185|NCT02214290|Dietary Supplement|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
250186|NCT02214316|Other|Hypertonic Saline|
250187|NCT02214316|Other|Normal Saline|
250188|NCT02214329|Device|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
250189|NCT02214329|Other|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
250190|NCT02214342|Other|Balance Training|Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as "ankle reaching" and "obstacle crossing" using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
250191|NCT02216734|Behavioral|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
250479|NCT02209246|Other|PROMIS CAT Pain Interference|
250480|NCT02209246|Other|PROMIS CAT Pain Behavior|
250481|NCT00140946|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
250482|NCT02209246|Other|PROMIS CAT Physical Function|
249556|NCT02228681|Drug|Everolimus|10mg daily by mouth
249867|NCT02221583|Drug|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
249868|NCT02221583|Drug|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
249869|NCT02221583|Drug|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
249870|NCT00142415|Drug|111-In-DOTA-cG250|At day 1, every patient received the cG250 at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of 111-Indium (111-In).
249871|NCT02221596|Dietary Supplement|vitamin D|50,000IU/wk of vitamin D3
249872|NCT02221596|Other|aerobic training|7 days of treadmill training during the 13th week of study
249873|NCT02221609|Other|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
249874|NCT02221609|Other|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
249875|NCT02221622|Drug|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
249876|NCT02221622|Drug|Placebo injection (intravenous solution)|Placebo intravenous infusion
249877|NCT02221635|Procedure|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
249246|NCT02233777|Drug|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
249247|NCT02233777|Drug|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
249248|NCT02233790|Drug|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
249249|NCT00143975|Drug|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
249250|NCT02236169|Drug|Atrovent CFC inhalation aerosol|
249557|NCT02228681|Drug|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
249558|NCT02228681|Drug|Letrozole|2.5mg twice a day by mouth
249559|NCT02228681|Drug|Medroxyprogesterone Acetate|200 mg daily by mouth
249560|NCT02228707|Drug|BIIB061|Participants receive BIIB061
249561|NCT02228707|Other|Placebo|Matched placebo
249562|NCT02228733|Drug|KBP-5074|Comparisons of different doses of study drug
249563|NCT02228746|Dietary Supplement|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
249564|NCT02228759|Procedure|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
249565|NCT00002328|Drug|Azithromycin|
249566|NCT00143130|Drug|Pregabalin|Pregabalin
249567|NCT02228772|Drug|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
249568|NCT02228772|Drug|Vincristine|Standard chemotherapy dosage and duration
249569|NCT02228772|Drug|Cytarabine|Standard chemotherapy dosage and duration
249570|NCT02228772|Drug|Doxorubicin|Standard chemotherapy dosage and duration
249571|NCT02228772|Drug|Mercaptopurine|Standard chemotherapy dosage and duration
249572|NCT02228772|Drug|Cyclophosphamide|Standard chemotherapy dosage and duration
254120|NCT00148525|Behavioral|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
254121|NCT02274948|Drug|Metformin|
254122|NCT02274961|Drug|S-pantoprazole 10mg|
254123|NCT02274961|Drug|Placebo|
254124|NCT02274974|Drug|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
254125|NCT02274974|Drug|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
254126|NCT02274987|Other|Specialized tumor board recommendation|Feasibility of a specialized tumor board to come up with treatment recommendations no later than 21 business days from surgery.
254127|NCT02238405|Other|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
249251|NCT02236182|Drug|Ipratropium Bromide low dose|
249252|NCT02236182|Drug|Placebo|
249253|NCT02236182|Drug|Ipratropium Bromide high dose|
249254|NCT02236195|Drug|Mocetinostat|
249255|NCT02236234|Biological|HPV vaccine|HPV vaccine
249256|NCT02236247|Drug|ivabradine|5 mg oral twice daily
249257|NCT02236247|Drug|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
249258|NCT02236260|Procedure|Electroacupuncture|Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.
249259|NCT02236260|Drug|Local Anesthesia (lidocaine hydrochloride)|All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
249260|NCT00143975|Drug|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
249261|NCT02236273|Behavioral|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
253816|NCT02243436|Drug|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
253817|NCT02243436|Drug|Ara C|Intravenous use, 2g/m2, day 5
253818|NCT02243449|Procedure|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
253819|NCT02243449|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
253820|NCT02243462|Device|Forced Air Warmer|A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable "blanket". The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket.
253821|NCT02243462|Other|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
253822|NCT02243488|Device|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
253823|NCT02246088|Procedure|MT + NE|Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.
The content and pictures of the neuroscience education (NE) will be based on the text "Explicando el dolor" (Spanish version of "Explain Pain").
253824|NCT02246088|Procedure|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
254128|NCT02238418|Drug|Cholecalciferol vial (100 000 UI)|VISIT 1:
Patient > 60 kg and initial 25OHD serum concentration < 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration < 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient < 20 kg and initial 25OHD serum concentration < 75 nmol/L: prescription of 1 single vial
A local lab will performed urinary dosage of calciuria and creatininuria:
at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial
at days 0, 2 and 4 after other intakes (when applicable)
VISIT 2:
25OHD serum concentration will then be dosed at month 2 after visit 1
254129|NCT02238431|Drug|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
253502|NCT02250833|Drug|Telmisartan|- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
253503|NCT02250833|Drug|S-amlodipine|- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
253504|NCT02250846|Drug|EGFR-TKI|egfr-TKI treatment
253505|NCT02250859|Drug|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
253506|NCT02250872|Drug|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
253507|NCT02250872|Drug|Placebo|100mg in 2 divided doses plus cisplatin
253508|NCT00145613|Device|Miltenyi Biotec CliniMACS|stem cell selection device
253509|NCT02250872|Drug|Cisplatin|All patients will receive intravenous cisplatin
253510|NCT02250885|Drug|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
253511|NCT02250898|Other|Myofascial Massage Therapy|Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
253512|NCT02250898|Other|Global Relaxation Massage|Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
253513|NCT02250911|Other|webcasts|
253514|NCT02250911|Behavioral|Assessments|
253515|NCT02250911|Other|Usual care|
253516|NCT02250924|Dietary Supplement|Caffeine|
253517|NCT02250924|Other|Gum|Chewing gum
253518|NCT00145886|Drug|rhPTH|Subjects will be treated with rhPTH for 12 months.
253519|NCT02252861|Other|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
253520|NCT02252874|Behavioral|Slow-paced action video game|20 hours slow-paced action video games
253521|NCT02252874|Behavioral|Fast-paced action video game|20 hours fast-paced action video games
253825|NCT00145041|Drug|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
252881|NCT02264327|Behavioral|Motivational Interviewing eBook (eBook)|The Phase I research team developed a 69-page eBook as a "credible online comparator" that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills.
252882|NCT02264327|Behavioral|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
252883|NCT02264340|Behavioral|Relaxation technique Autogenic Training|Autogenic Training
253189|NCT02257398|Drug|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
253190|NCT02257398|Drug|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
253191|NCT02257398|Drug|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
253192|NCT02257398|Drug|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
253193|NCT02257411|Device|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
253194|NCT02257424|Drug|Trametinib 2mg daily|
253195|NCT02257437|Dietary Supplement|LNS|Compact, stockcube-sized snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
253196|NCT00146562|Drug|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
253197|NCT02257437|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
253198|NCT02257437|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet.
253199|NCT02257437|Other|Borbor|White rice porridge
253200|NCT02257463|Drug|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
253201|NCT02259738|Drug|Human Urinary Kallidinogenase|
253202|NCT00146770|Biological|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
253203|NCT02259738|Drug|Shuxuening injection|
253204|NCT02259751|Drug|KUC 7483 CL|
252584|NCT02269358|Drug|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
252585|NCT02269371|Other|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
252586|NCT02269371|Other|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
252587|NCT02269384|Procedure|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
252588|NCT02271555|Drug|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
252589|NCT02271555|Drug|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
252590|NCT02271568|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
252591|NCT02271568|Other|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
252884|NCT02264340|Behavioral|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
252885|NCT02264353|Drug|Donepezil|Donepezil 10mg before sleep
252886|NCT02264353|Drug|placebo|One piece of placebo before sleep
252887|NCT02264366|Behavioral|Motivational Communication for Health Behavior management|An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of "best self", goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, "rolling with resistance", and supporting self-efficacy. (Rubak 2005, Knight 2006).
252888|NCT02264379|Radiation|normal fractionated irradiation|25*2 Gy (once a day, 5 days a week)
252889|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
252890|NCT02264379|Radiation|hypo fractionated irradiation|3*10 Gy (once a day, 2-3 days a week)
252891|NCT02264392|Procedure|Ultrasound Guided Incision and Drainage|Ultrasound guidance of the abscess drainage
252892|NCT02264392|Procedure|Blind Incision and Drainage|Incision and drainage of abscess guided by physical exam alone
247109|NCT02205359|Device|aCRT ON|CRT device with AdaptivCRT enabled
247110|NCT02205359|Device|aCRT OFF|CRT device with AdaptivCRT disabled
247111|NCT02205372|Drug|MT-3995|
247112|NCT02205372|Drug|Placebo|
247113|NCT00140491|Device|Vision Restoration Therapy (NOVAVISION)|
247114|NCT02205385|Procedure|Targeted Muscle Reinnervation|
247115|NCT02205385|Procedure|Traction Neurectomy|
247116|NCT02205398|Drug|INC280|
247117|NCT02205398|Drug|cetuximab|
247118|NCT02205411|Device|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
247119|NCT02205411|Device|Control VAD|The HeartMate II® VAD or HVAD®
247120|NCT02205450|Drug|Recombinant Somatropin|
247406|NCT00139802|Device|Coronary Stent Implantation|
247407|NCT02200536|Other|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
247408|NCT02200536|Other|Infant oral health pamphlet|Infant oral health pamphlet
247409|NCT02200549|Device|Control group|Neither cycle training nor inspiratory muscle training.
247410|NCT02200549|Device|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
247411|NCT02200549|Device|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
247412|NCT02200562|Drug|ipilimumab and dabrafenib|
247413|NCT02200575|Drug|Telmisartan|
247414|NCT02200601|Device|Seipher Wellness|
247415|NCT02200614|Drug|BAY1841788 (ODM-201)|BAY1841788 (ODM-201) tablets 2 x 300mg bid
246819|NCT02210338|Device|Bonfils Intubation Fibrescope|
246820|NCT02210351|Device|MRI test|
246821|NCT00141037|Drug|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40 kg and 1.5 mg/kg/day in subjects weighing >40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
246822|NCT02210364|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
246823|NCT02210364|Drug|capecitabine|capecitabine 150 mg tablets
246824|NCT02210377|Other|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
246825|NCT02212782|Drug|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
246826|NCT02212795|Drug|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
246827|NCT02212795|Drug|Levofloxacin 250mg|Levofloxacin 250mg single dose
246828|NCT02212795|Drug|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
246829|NCT02212808|Other|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
246830|NCT02212808|Other|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
246831|NCT00141297|Drug|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
246832|NCT02212821|Drug|Erythromycin|
246833|NCT02212821|Drug|Placebo|physiological saline
247121|NCT02205463|Drug|KD019|
247122|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
252346|NCT02245464|Drug|Telmisartan|
252347|NCT02245477|Device|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
252650|NCT02237924|Drug|DDP|DDP:80mg/m2 for 2-3 cycles
252651|NCT00002335|Drug|Emtricitabine|
252652|NCT00144157|Drug|3TC|
252653|NCT02237924|Radiation|IMRT|IMRT:70-74Gy for 2-3 cycles
252654|NCT02237937|Drug|Paroxetine|
252655|NCT02237937|Drug|Sertraline|
252656|NCT02237937|Drug|Citalopram|
252657|NCT02240238|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
252658|NCT02240251|Other|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
252659|NCT02240264|Dietary Supplement|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
252660|NCT00002338|Drug|Raluridine|
252661|NCT00144417|Drug|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
252662|NCT02240264|Dietary Supplement|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
252663|NCT02240290|Drug|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
252664|NCT02240290|Drug|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
252665|NCT02240303|Procedure|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
252666|NCT02240303|Procedure|Physical Performance|Participants in both groups will have a Physical Performance test.
252667|NCT02240303|Procedure|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
252035|NCT02252302|Drug|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
252036|NCT02252302|Drug|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
252037|NCT02252302|Other|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
252038|NCT02252302|Other|Filtered air|Participants will be breathing filtered air
252348|NCT02245477|Other|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
252349|NCT00002343|Drug|Rifabutin|
252350|NCT00144976|Drug|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
252351|NCT02245490|Drug|Tamsulosin HCl controlled release capsules|
252352|NCT02245490|Drug|Matching placebo capsule|
252353|NCT02245503|Drug|Tamsulosin|
252354|NCT02245516|Drug|KPI-121|KPI-121 drug product will be supplied in two strengths: 0.25% and 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
252355|NCT02247843|Genetic|βAS3-FB vector transduced BM CD34+ cells|BM CD34+ from SCD patients are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
252356|NCT00002346|Drug|Adefovir dipivoxil|
252357|NCT00145327|Drug|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
252358|NCT02247856|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
252359|NCT02247856|Device|Jet Nebulizer|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a "T" piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min
251738|NCT02259296|Procedure|Lower eGFR for AVF construction|Lower eGFR patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
251739|NCT02259296|Procedure|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
251740|NCT02259309|Drug|Misoprostol - buccal|buccal administration
251741|NCT02259309|Drug|Misoprostol - vaginal|vaginal administration
251742|NCT02259322|Behavioral|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
251743|NCT02259322|Behavioral|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
252039|NCT02252315|Other|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
252040|NCT02252315|Other|Verbal education module|A structured in-person education module about mild traumatic brain injury.
252041|NCT02252328|Drug|Simvastatin|Simvastatin 80mg once daily
252042|NCT02254668|Other|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
252043|NCT02254681|Drug|Gemcitabine|
252044|NCT02254681|Drug|Cisplatin|
252045|NCT02254681|Radiation|Low dose whole liver and portal lymph node basin radiotherapy|
252046|NCT02254694|Other|high heeled shoes|see detailed study description
252047|NCT02254707|Drug|BILB 1941 ZW|
252048|NCT02254707|Drug|Placebo|
252049|NCT02254720|Drug|BEA 2180 BR solution for infusion|
252050|NCT00146146|Drug|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
252051|NCT02254720|Drug|Placebo|Intravenous infusion
252052|NCT02254720|Drug|BEA 2180 BR solution for inhalation|
252053|NCT02254720|Device|Respimat®|
251389|NCT02263885|Device|ExAblate Transcranial System|Transcranial MRgFUS
251390|NCT02263898|Drug|Raf kinase inhibitor LGX818|Given PO
251391|NCT00147355|Drug|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
251392|NCT02263898|Drug|binimetinib|Given PO
251393|NCT02263898|Other|laboratory biomarker analysis|Correlative studies
251394|NCT02263911|Drug|Baricitinib|Administered orally
251395|NCT02263924|Dietary Supplement|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
251396|NCT02263924|Dietary Supplement|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
251397|NCT02266303|Other|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
251398|NCT02266316|Device|Air warming mask|Mask that warms air at the mouth
251399|NCT02266329|Drug|prazosin hydrochloride|Orally capsules of prazosin titrated to optimum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
251400|NCT02266329|Drug|placebo|Oral capsules of placebo titrated in the same manner as prazosin.
251401|NCT02266342|Device|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
251402|NCT02266355|Drug|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
251403|NCT02266368|Device|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
251404|NCT02266381|Procedure|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
251744|NCT02259322|Behavioral|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
251745|NCT02259335|Device|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
251746|NCT02259348|Drug|Cyclophosphamide|Given intravenously (IV)
251747|NCT02261506|Other|14 days of adequate antibiotic treatment durations|
250797|NCT02202083|Other|Cook Balloon|There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.
This group is term gestaion,with bishop score less than 6.
250798|NCT02202096|Other|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
251083|NCT02234544|Other|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
251084|NCT02234557|Behavioral|Tai Chi|6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.
Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).
Practice will consist of warm up, followed by practice of selected pieces of the form.
Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention).
251085|NCT02234570|Other|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
251086|NCT00143780|Biological|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
251087|NCT02234570|Drug|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
251088|NCT02234583|Drug|15mg DS-5565|
251089|NCT02234596|Drug|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
251090|NCT02234609|Device|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
251091|NCT02234622|Behavioral|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention
251092|NCT02234622|Behavioral|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity physical activity with didactics about wellness topics.
251093|NCT02236949|Behavioral|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
251094|NCT02236962|Drug|Placebo|
251095|NCT02236962|Drug|Ephedrine, pioglitazone|
250805|NCT02202096|Other|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
250806|NCT02202096|Other|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
250807|NCT00140049|Drug|Xalacom|
250808|NCT02202096|Other|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
250809|NCT02202096|Other|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
250810|NCT02202109|Behavioral|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
250811|NCT02202109|Behavioral|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
250812|NCT02202122|Other|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
251100|NCT02237027|Biological|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
251101|NCT02237027|Biological|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
251102|NCT00144066|Drug|platinum-based chemotherapy alone (up to six cycles)|
251103|NCT02237040|Procedure|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
251104|NCT02237053|Drug|Glucagon|
251105|NCT02237053|Drug|Octreotide|
251106|NCT02237053|Behavioral|Placebo|
250483|NCT02209246|Other|MISS-21|
250484|NCT02209259|Other|PROMIS Upper Extremity Function|
250485|NCT02209259|Other|Pain intensity|
250486|NCT02209259|Other|PROMIS depression|
250487|NCT02209259|Other|Positive affect negative affect scale (PANAS)|
250488|NCT02209259|Other|standard PCS|
250489|NCT02209259|Other|positively-adjusted version of the PCS|
250490|NCT02209272|Drug|bacteriostatic saline|
250491|NCT02209272|Drug|buffered lidocaine|
250492|NCT00140946|Drug|Comparator: placebo / Duration of Treatment: 16 weeks|
250493|NCT02209285|Behavioral|Community Navigation and Rehabilitation Intervention|Individuals in the Community Navigation and Rehabilitation group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
250494|NCT02209298|Device|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
250495|NCT02209311|Procedure|Oral mucosa biopsy|
250496|NCT02209311|Procedure|Sinus lift with implantation of tissue engineered construction|
250497|NCT02209311|Device|Dental implant|
250498|NCT02209324|Drug|ASP2151|
250499|NCT02209337|Device|SRS|
250500|NCT02209350|Procedure|Aorta-femoral bypass|Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.
Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of "end-to-side" in the reconstruction by shunting.
After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of "end-to-side". If antegrade flow is absent, anastomosis is formed in the sort of "end to end".
250813|NCT02204345|Drug|carboplatin|AUC 6 mg/mL x min dose given by IV infusion q3w for at least 4 to 6 21-day cycles
249878|NCT02221635|Drug|Risperidone|Risperidone (2-4 mg) was took orally.
249879|NCT02221648|Drug|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
250192|NCT02216747|Drug|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
250193|NCT02216747|Drug|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
250194|NCT02216747|Drug|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
250195|NCT02216760|Device|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
250196|NCT02216760|Device|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
250197|NCT02216773|Procedure|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
250198|NCT02216773|Procedure|Portal vein embolization (PVE)|
250199|NCT02216786|Drug|AZD2014|Oral tablet
250200|NCT02216786|Drug|Everolimus|Oral tablet
250201|NCT00141778|Drug|Ramipril|Taken orally, once a day
250202|NCT02216786|Drug|Fulvestrant|Im injection
250203|NCT02216799|Drug|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
250204|NCT02216799|Drug|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
250205|NCT02216812|Drug|500 mg vitamin c, 1 pill per day for 6 weeks|
250206|NCT02216812|Drug|1 placebo pill for 6 weeks|
250207|NCT02216825|Dietary Supplement|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
250208|NCT02216825|Dietary Supplement|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
250209|NCT02216838|Drug|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
250210|NCT02216838|Other|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
249573|NCT02228772|Drug|Methotrexate|Standard chemotherapy dosage and duration
249574|NCT02228785|Biological|G17DT|
249575|NCT02228811|Drug|DCC-2701 tablet|
249576|NCT02228824|Drug|Very low nicotine content cigarettes|0.07 mg nicotine delivery
249577|NCT00143143|Drug|Pregabalin|
249578|NCT02228824|Drug|Normal nicotine content cigarettes|0.8 mg nicotine delivery
249579|NCT02228837|Dietary Supplement|Pear|
249580|NCT02228837|Dietary Supplement|Placebo|
249581|NCT02228850|Drug|Alprostadil|
249582|NCT02228850|Other|Placebo|
249880|NCT02224105|Drug|Prednisolone high|
249881|NCT02224105|Drug|Placebo|
249882|NCT02224105|Drug|sodium chloride infusion|
249883|NCT02224105|Drug|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
249884|NCT02224118|Drug|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
249885|NCT02224118|Drug|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
249886|NCT00142610|Dietary Supplement|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
249887|NCT02224118|Drug|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
249888|NCT02224118|Drug|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
249889|NCT02224118|Drug|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
249890|NCT02224131|Drug|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
249262|NCT02236273|Behavioral|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
249263|NCT02236286|Behavioral|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
249264|NCT02236299|Procedure|Right Coronary Artery Percutaneous Coronary Intervention|
249265|NCT02236299|Other|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
249266|NCT02236299|Other|GLP-1 Infusion|30 minute infusion GLP-1
249267|NCT02236312|Drug|Botulinum Toxin Type A|
249268|NCT02236312|Drug|Placebo|
249269|NCT02236325|Behavioral|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
249270|NCT02236325|Behavioral|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
249271|NCT00143988|Behavioral|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
249583|NCT02228863|Other|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
249584|NCT02228863|Other|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
249585|NCT02228863|Other|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
249586|NCT02231203|Drug|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
249587|NCT02231203|Drug|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
249588|NCT02231216|Procedure|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
249589|NCT02231216|Procedure|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
249590|NCT02231216|Procedure|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
254130|NCT00144209|Drug|levodopa in combination with benserazide|
254131|NCT02238431|Drug|OCP|to schedule the start of the artificial cycle
254132|NCT02238431|Other|Natural|to use the normal menstrual period to schedule treatment start
254133|NCT02238444|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
254134|NCT02238444|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
254135|NCT02238444|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
254136|NCT02238444|Drug|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
254137|NCT02238457|Drug|Low dose losartan|25 mg losartan bid for 10 weeks
254138|NCT02238457|Drug|High dose losartan|50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
254139|NCT02238470|Drug|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
254140|NCT02238483|Drug|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
254141|NCT00144222|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
254142|NCT02238483|Drug|Placebo|Inhaled placebo solution
254143|NCT02238496|Procedure|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
254144|NCT02238496|Drug|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
254145|NCT02238496|Drug|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
254146|NCT02238509|Drug|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
254147|NCT02240693|Drug|BI 409306|
249272|NCT02236338|Procedure|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
249273|NCT02236338|Device|ClosureFAST radiofrequency catheter|
253826|NCT02246114|Device|piCO+ Smokerlyzer and text messages|Arm B: will be given a piCO+ Smokerlyzer® monitor, will receive daily text messages, and will receive feedback about the relative level of carbon monoxide.
253827|NCT02246114|Other|Text messages|Arm A: not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
253828|NCT02246127|Drug|Drug: Everolimus|10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
253829|NCT02246127|Drug|STZ-5FU|0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).
Number of Cycles: until progression or unacceptable toxicity develops.
253830|NCT02246140|Other|Cerebral MRI and MRA|
253831|NCT02246153|Procedure|Laparoscopic gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy.
253832|NCT02246153|Procedure|Open gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience.
253833|NCT02246166|Drug|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
253834|NCT02246166|Other|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
253835|NCT02246179|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
253836|NCT00145054|Behavioral|MoodHelper Internet program for Depression Self-Help|
253837|NCT02246179|Drug|AHES|Topical application at test region 1 and 3 under occlusion for 10 minutes
253838|NCT02246179|Drug|EMLA cream|Topical application at test region 2 and 4 under occlusion for 10 minutes
253839|NCT02246192|Procedure|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
253840|NCT02246192|Procedure|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
253841|NCT02246205|Procedure|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
253842|NCT02246218|Drug|RAVICTI|
253843|NCT02246231|Device|MR imaging|
253205|NCT02259751|Drug|Placebo|
253206|NCT02259764|Drug|KUC 7483 CL - single rising dose|
253207|NCT02259764|Drug|Placebo|
253208|NCT02259764|Other|standardized high fat meal|
253209|NCT02259777|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
253210|NCT02259777|Other|high fat, high caloric meal|
253211|NCT02259790|Drug|Telmisartan/amlodipine fixed-dose combination tablet|
253212|NCT02259790|Drug|Telmisartan|
253522|NCT02252874|Behavioral|Control|20 hours leisure activities
253523|NCT02252887|Drug|Gemcitabine|
253524|NCT02252887|Drug|Trastuzumab|
253525|NCT02252887|Drug|Pertuzumab|
253526|NCT02252900|Other|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
253527|NCT02252913|Drug|Volitinib|oral administration
253528|NCT02252913|Drug|Docetaxel|intravenous injection
253529|NCT00145912|Behavioral|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
253530|NCT02252926|Drug|Bupivacaine|25 mg bupivacaine lozenge
253531|NCT02252926|Drug|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
253532|NCT02252939|Radiation|X-Ray|X-ray as part of standard care
253533|NCT02252952|Other|Beverage Consumption|
253534|NCT02252965|Drug|Metformin XR|Metformin XR tablets will be administered orally once daily at a dose of 500 milligram (mg) for 1 week, followed by 1000 mg for 1 week, then 1500 mg for next 2 weeks, and then 2000 mg orally once daily for subsequent 12 weeks.
253535|NCT02252965|Drug|Metformin IR|Metformin IR tablets will be administered orally at a dose of 500 mg once daily for 1 week, followed by 500 mg twice daily for 1 week, then 500 mg three times daily for next 2 weeks, and then 2000 mg daily for subsequent 12 weeks.
253536|NCT02252978|Drug|ciprofloxacin|Given PO
252893|NCT02264405|Procedure|Autologous HSCT|1st AHSCT
252894|NCT02264418|Drug|ODM 203|ODM 203
252895|NCT02264444|Other|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
252896|NCT02264457|Device|T-flex Aspheric Toric IOL|
252897|NCT02264457|Device|AT TORBI toric IOL|
252898|NCT02264470|Other|Not relevant|Not relevant
252899|NCT02264496|Behavioral|Exercise|
252900|NCT02266914|Device|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
252901|NCT00147719|Drug|Colesevelam hydrochloride|
252902|NCT02266927|Drug|Flovent HFA|
252903|NCT02266927|Drug|OPTINOSE™ FLUTICASONE|
252904|NCT02266940|Drug|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
253213|NCT00146770|Biological|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
253214|NCT02259790|Drug|Amlodipine|
253215|NCT02259803|Drug|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
253216|NCT02259803|Drug|Telmisartan|
253217|NCT02259803|Drug|Amlodipine|
253218|NCT02259816|Drug|Telmisartan|
253219|NCT02259816|Drug|Amlodipine|
253220|NCT02259829|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
253221|NCT02259829|Drug|Telmisartan|
253222|NCT02259829|Drug|Amlodipine|
253223|NCT02259842|Drug|BI 34021 FU2 solution|
253224|NCT00146770|Biological|placebo|Placebo for 26 weeks
247416|NCT02200614|Drug|Placebo|Matching placebo tablets x 2 bid
247417|NCT00139815|Drug|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
247418|NCT02200640|Drug|High dose of Micardis®, once daily|
247419|NCT02200640|Drug|Low dose of Micardis®, once daily|
247420|NCT02200640|Drug|Low dose of COZAAR®, once daily|
247421|NCT02200640|Drug|High dose of COZAAR®, once daily|
247422|NCT02200640|Drug|Placebo|
247423|NCT02200653|Drug|High dose of MICARDIS®, once daily|
247424|NCT02200653|Drug|Low dose of MICARDIS®, once daily|
247425|NCT02200653|Drug|Low dose of COZAAR® / LORZAAR®, once daily|
247426|NCT02200653|Drug|High dose of COZAAR® / LORZAAR®, once daily|
247427|NCT02200653|Drug|Placebo|
247428|NCT00139815|Drug|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
247429|NCT02200705|Device|Ice-Sense3TM|
247729|NCT02233101|Drug|Intravenous Tranexamic Acid|Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
247730|NCT00143637|Other|Office dust|airborne office dust spiked with glucan
247731|NCT02233114|Other|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
247732|NCT02235571|Behavioral|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
247733|NCT02235584|Drug|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
247734|NCT02235610|Procedure|EVLP Group|EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.
Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
247735|NCT02235623|Procedure|Single-stage Fowler-Stephens orchidopexy (FSO)|
247123|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
247124|NCT00140504|Other|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
247125|NCT02205489|Drug|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
247126|NCT02207972|Device|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
247127|NCT02207972|Procedure|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
247128|NCT02207985|Procedure|Allogeneic hematopoietic stem cell transplantation|
247129|NCT02207998|Drug|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
247130|NCT02207998|Drug|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
247131|NCT02208024|Radiation|Stereotactic Body Radiation Therapy|
247132|NCT02208037|Drug|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
247133|NCT02208037|Drug|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
247134|NCT02208037|Drug|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
247135|NCT00002312|Drug|Zidovudine|
252668|NCT02240303|Procedure|Blood Sample|Participants in both groups will have blood samples taken.
252669|NCT02240329|Behavioral|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
252670|NCT02240329|Behavioral|Respiratory measures|We will collect measures of cough airflow and breathing strength.
252671|NCT02240329|Drug|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
252968|NCT02271880|Other|Medication as usual + STAR|Physicians will prescribe medication and adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
252969|NCT02271893|Drug|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
252970|NCT02271906|Drug|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
252971|NCT02274168|Procedure|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
252972|NCT00148447|Drug|escitalopram|
252973|NCT02274181|Drug|Androxal|
252974|NCT02274194|Other|Nasal CPAP|use of nasal mask to titrate CPAP - after titration 30 days of nasal CPAP
252975|NCT02274194|Other|Oronasal CPAP|use of oronasal mask to titrate CPAP - after titration 30 days of nasal CPAP
252976|NCT02274207|Device|NPWT application|NPWT mode is cyclic mode : -125~-50 mmHg
252977|NCT02274220|Dietary Supplement|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
252978|NCT02274233|Drug|SP-420|
252979|NCT02274246|Drug|gadobutrol|Gadobutrol administration in healthy volunteers
252980|NCT02274259|Drug|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
252981|NCT02274259|Drug|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
252360|NCT02247856|Device|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
252361|NCT02247869|Drug|dose dense ABVD|dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen
Doxorubicin 25 mg/m2 i.v. day 1 and 8
Bleomycin 10 mg/m2 i.v. day 1 and 8
Vinblastine 6 mg/m2 i.v. day 1 and 8
Dacarbazine 375 mg/m2 i.v. day 1 and 8
Granulocyte colony-stimulating factor (G-CSF): days 9 to 14
252362|NCT02247882|Other|Patient Education|The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.
The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain.
252672|NCT00144430|Drug|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
252673|NCT02240342|Drug|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
252674|NCT02240355|Drug|RO6885247|oral solution
252675|NCT02240355|Drug|placebo|oral solution
252676|NCT02240381|Procedure|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
252677|NCT02240381|Procedure|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
252678|NCT02240381|Other|laboratory biomarker analysis|Correlative studies
252679|NCT02240407|Genetic|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose for vector injections will be 5 x 10^9 vg per TA mg diluted in 1.5 ml Lactated Ringer's Solution.
252680|NCT02242916|Radiation|Photon therapy versus C-ion therapy|
252681|NCT02242929|Drug|Imiquimod 5% cream with prior curettage|
252682|NCT02242929|Procedure|Standard surgical excision|
252683|NCT02242942|Drug|Chlorambucil|Chlorambucil, administered orally: 0.5 mg/kg at Day 1 and Day 15 for Cycle 1-12
252684|NCT02242942|Drug|GDC-0199|GDC-0199, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12
252685|NCT02242942|Drug|Obinutuzumab|Obinutuzumab, intravenous (IV) infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
252054|NCT02254733|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
252055|NCT02254733|Other|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
252056|NCT02254746|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
252057|NCT02254759|Drug|Midazolam, IV|2 mg/ml midazolam solution for intravenous (IV) administration. For a 1 mg dose, the midazolam solution (0.5 ml of 2 mg/ml) will be injected at 2 mg/min.
252058|NCT02254759|Drug|Midazolam, oral|0.1 mg/ml midazolam for oral administration. For a 5 mg dose, subjects will receive 50 ml of 0.1 mg/ml midazolam.
252059|NCT02254759|Drug|RG1662|Oral tablet
252363|NCT02247882|Other|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
252364|NCT02247895|Device|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
252365|NCT02247895|Device|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
252366|NCT02247908|Other|Surgeon General's Warning|Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:
SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.
SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.
SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.
SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide.
252367|NCT02247908|Other|Graphic Warning|Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:
Text: "WARNING: Cigarettes are addictive." Image: Man smoking through tracheotomy hole.
Text: "WARNING: Cigarettes causes fatal lung disease." Image: Healthy lungs next to diseased lungs.
Text: "WARNING: Cigarettes cause cancer." Image: Mouth with cancerous lesion on lip.
Text: "WARNING: Smoking can kill you." Image: Woman dying from cancer.
252368|NCT00145327|Drug|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
252369|NCT02250209|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.
Number of cycles: 8 cycles.
251748|NCT02261519|Drug|NaBen®|500 mg twice daily (1000 mg total)
251749|NCT02261519|Other|Placebo|0 mg twice daily (0 mg total)
251750|NCT02261532|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
251751|NCT02261545|Dietary Supplement|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
251752|NCT02261545|Dietary Supplement|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
251753|NCT02261558|Other|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
251754|NCT02261558|Other|Clinical Vocal Improvisation|* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
251755|NCT02261571|Other|Moxibustion|In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.
The moxibustion will be removed when the patient feel hotness and require remove them
251756|NCT02261584|Device|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
251757|NCT00147043|Procedure|Leukapheresis|
251758|NCT02261584|Device|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
251759|NCT02261597|Behavioral|Cold Pressor Test|Repeated immersion of hand in ice-cold water
251760|NCT02261610|Procedure|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
251761|NCT02261623|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
252060|NCT02254772|Biological|ipilimumab|Given via intratumoral injection
252061|NCT00146159|Drug|Mitoxantrone|dosage
252062|NCT02254772|Drug|TLR9 agonist SD-101|Given via intratumoral injection
251096|NCT02236975|Device|BuMA Supreme Biodegradable drug coating coronary stent system|
251097|NCT02236975|Device|Resolute Integrity durable polymer stent system|
251098|NCT02236988|Drug|Apremilast|
251099|NCT02237001|Device|Suture-based meniscal repair|Suture-based meniscal repair
251405|NCT02266381|Procedure|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
251406|NCT00147654|Drug|Tolterodine ER 4 mg QD|
251407|NCT02266381|Procedure|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
251408|NCT02266394|Drug|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
251409|NCT02266394|Procedure|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
251410|NCT02266407|Procedure|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
251411|NCT02266420|Procedure|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
251412|NCT02266433|Drug|Ketorolac|The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders.
251413|NCT02266433|Drug|Dexamethasone|Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.
In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites.
251414|NCT02266446|Behavioral|Attention & Interpretation Modification|
251415|NCT00147875|Drug|Prednisone|
251416|NCT02268760|Drug|BILN 2061 ZW single rising doses|
251107|NCT02237053|Drug|Insulin|
251108|NCT02237066|Device|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
251109|NCT02237066|Device|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
251110|NCT02237079|Drug|DUAVEE|
251111|NCT02237079|Drug|PLACEBO|
251112|NCT02237092|Procedure|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
251113|NCT00144066|Drug|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
251114|NCT02237105|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
251115|NCT02237118|Device|Mepitel One|
251116|NCT02237118|Device|UrgoTul|
251117|NCT02237131|Drug|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
251118|NCT02199405|Other|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
251119|NCT02199405|Other|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
251120|NCT02199405|Other|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
251423|NCT02268786|Other|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
251424|NCT02268825|Drug|MK-3475|MK-3475 in combination with mFOLFOX6 in a 14 day cycle
Phase 1 and Phase 2 Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV
MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)
Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks
Phase 2: MK-3475 at highest tolerated dose
251425|NCT02268838|Drug|E6007|
251426|NCT00147875|Drug|Vinblastine|
251427|NCT02268838|Drug|E6007 matching placebo|
250814|NCT02204345|Drug|paclitaxel|200 mg/m2 given by IV infusion q3w for at least 4 to 6 21-day cycles
250815|NCT02204358|Procedure|autologous bone marrow stem cells|Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.
If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits.
250816|NCT02204371|Drug|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
250817|NCT02204371|Drug|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
250818|NCT00140361|Drug|lumefantrine plus artemether|
250819|NCT02204384|Other|Meal A: Food sources of fiber|
250820|NCT02204384|Dietary Supplement|Meal B: Fiber supplement|
250821|NCT02204384|Other|Meal C: control|
250822|NCT02204397|Drug|INGAP Peptide, Ustekinumab|
250823|NCT02204410|Dietary Supplement|Omega-3 Fatty Acid|
250824|NCT02204410|Drug|Stimulant Medication|
250825|NCT02204423|Procedure|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
250826|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
250827|NCT02204449|Behavioral|Cardiac Rehabilitation Peer Mentorship|
250828|NCT02204462|Drug|FBnTP|A PET imaging radiotracer
250829|NCT00140361|Behavioral|Sleeping under insecticide-treated bednet|
250830|NCT02204475|Drug|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
250831|NCT02204475|Drug|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
250832|NCT02204475|Drug|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
250211|NCT02216851|Device|Restylane Perlane|Intradermal injection
250212|NCT00000333|Drug|Benztropine|
250213|NCT00002318|Drug|Vincristine sulfate|
250214|NCT00141778|Drug|Spironolactone|Taken orally, once a day
250501|NCT02211729|Drug|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
250502|NCT02211729|Drug|suplhadoxine-pyrimethemine + amodiaquine + placebo azithromycin|suplhadoxine-pyrimethemine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
250503|NCT02211742|Drug|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
250504|NCT00141193|Drug|Celecoxib|
250505|NCT02211755|Drug|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
250506|NCT02211768|Procedure|MRI, FDG-PET/CT scans|Per standard of care
250507|NCT02211768|Procedure|[18F]-FLT-PET/CT scans|Per research study
250508|NCT02211794|Other|data collection|
250509|NCT02211833|Drug|BI 2536|
250510|NCT02211833|Drug|Pemetrexed|
250511|NCT02211846|Drug|Mirabegron|oral
250512|NCT02211859|Drug|BI 2536|
250513|NCT02211872|Drug|BI 2536 BS, intravenous|
250514|NCT02211885|Drug|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
250515|NCT00141206|Drug|varenicline (CP-526,555)|
250516|NCT02211898|Drug|BNS003|
250517|NCT02211911|Drug|Bisacodyl|
250518|NCT02211911|Drug|Sodium picosulfate|
250519|NCT02211924|Drug|BI 44847|
250520|NCT02211924|Drug|Placebo|
249891|NCT02224131|Drug|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
249892|NCT02224144|Drug|Vitamin D3 plus Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
249893|NCT02224144|Drug|Vitamin D3 plus Placebo|Placebo (sugar pill) 1 pill per day for 12 months
249894|NCT02224157|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
249895|NCT02224157|Drug|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
249896|NCT02224170|Drug|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
249897|NCT00142623|Behavioral|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
249898|NCT02224170|Drug|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
250215|NCT02219282|Other|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
250216|NCT02219295|Dietary Supplement|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
250217|NCT02219295|Dietary Supplement|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
250218|NCT02219295|Dietary Supplement|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
250219|NCT02219295|Other|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
250220|NCT02219308|Procedure|Paracervical Block (PCB)|Drug: 1% Lidocaine Hydrochloride
Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.
IUD placement then proceeds
250221|NCT02219308|Procedure|No Paracervical Block (Sham PCB)|Drug: 1% Lidocaine Hydrochloride
Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blancing, indentation, or pain.
IUD placement then proceeds
249591|NCT02231229|Other|PCR-based strategy|Treatment based on the results of detection of resistance to INH and RIF with PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (HRZ) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
249592|NCT02231229|Drug|isoniazid (INH or H)|Initiation of a standard 4 drug combination (HRZE) until the results of DST are available.
249593|NCT02231229|Drug|rifampicin (RIFor RMP or R)|
249594|NCT02231229|Drug|pyrazinamide (PZA or Z)|
249595|NCT02231229|Drug|ethambutol (EMB or E)|
249596|NCT00143455|Drug|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
249597|NCT02231242|Biological|Autologous Stem Cell Transplantation|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.
Intrathecal Autologous Bone Marrow TNC
249598|NCT02231255|Drug|Sifrol®|
249599|NCT02231268|Drug|Gladem|
249600|NCT02231281|Drug|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
249601|NCT02231281|Procedure|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
249602|NCT02231294|Drug|Sifrol®|
249603|NCT02231307|Drug|SUBLIVAC FIX Birch|
249604|NCT02231320|Drug|Berodual® Respimat® - inhaler|
249605|NCT02231333|Drug|S-adenosylmethionine (SAMe)|
249899|NCT02224183|Behavioral|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
249900|NCT02226276|Biological|ado-trastuzumab emtansine|Given IV
249901|NCT02226276|Other|laboratory biomarker analysis|Correlative studies
249902|NCT02226289|Drug|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
249903|NCT02226328|Drug|Propofol sedation|
249274|NCT02198729|Procedure|Endoscopic Submucosal Dissection|
249275|NCT02198729|Procedure|Endoscopic Mucosal Resection|
249276|NCT02198742|Device|Miller blade|To participate in the study the subjects must have >500 intubations with the miller blade.
249277|NCT02198742|Device|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
249278|NCT02198742|Device|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
249279|NCT02198755|Device|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
249280|NCT02198755|Device|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
249281|NCT00139568|Drug|Tegaserod|
249282|NCT02198794|Drug|SD-809|SD-809 tablets dose titrated for 6 weeks until optimal dose is reached. The dose is maintained for the duration of the study.
249283|NCT02198807|Drug|Fosmidomycin-Piperaquine|
249284|NCT02198820|Drug|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
249285|NCT02198820|Drug|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
249286|NCT02198833|Biological|Urine Culture|Obtain urine culture every third day
249287|NCT02198833|Device|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
249288|NCT02198833|Device|Scanning Electron Microscopy|Houston Site Only
249289|NCT02198833|Procedure|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
249290|NCT02198833|Procedure|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
249291|NCT02198846|Device|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
249292|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
249606|NCT02231333|Drug|pentoxiphylline (PTX)|
249607|NCT00143455|Drug|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
254148|NCT02240706|Procedure|Best Supportive Care|At Discretion of the Investigator (Transfusions)
254149|NCT02240706|Drug|BI 836858|Monotherapy with BI 836858
254150|NCT02240719|Drug|everolimus|Given PO
254151|NCT02240719|Drug|bendamustine hydrochloride|Given IV
254152|NCT02240745|Other|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
254153|NCT02240758|Procedure|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
254154|NCT00144469|Drug|rivavirin|
254155|NCT02240771|Procedure|Transarterial chemotherapy|Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.
Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.
The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes.
254156|NCT02240771|Drug|Oral chemotherapy|Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.
Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD
Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count & Platelet count would be monitored every 15 days
254157|NCT02240797|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
254158|NCT02240810|Device|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
254159|NCT02240823|Other|adipose derived stem cells|
254160|NCT02240836|Other|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
254161|NCT02240849|Device|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
254162|NCT02240849|Device|Placebo general pillow|
254163|NCT02240862|Device|Carotid Artery Stent|Placement of a stent within the carotid artery
254164|NCT02240875|Biological|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
253537|NCT02252978|Other|placebo|Given PO
253538|NCT02252978|Other|quality-of-life assessment|Ancillary studies
253539|NCT02252978|Other|laboratory biomarker analysis|Correlative studies
253540|NCT00145912|Behavioral|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
253541|NCT02252991|Other|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
253542|NCT02253004|Drug|Cilostazol|Single oral administration of active or placebo one week apart
253543|NCT02253004|Drug|Placebo|
253544|NCT02253017|Other|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
253844|NCT02248428|Drug|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
253845|NCT02248428|Drug|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
253846|NCT02248428|Drug|Cyclophosphamide|300mg/m^2 intravenously daily on day 1-3,repeated every 28 days
253847|NCT02248428|Drug|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
253848|NCT02248441|Other|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
253849|NCT02248454|Drug|Lispro|Increasing insulin doses
253850|NCT02248480|Drug|Duloxetine|Administered orally
253851|NCT02248480|Drug|Placebo|Administered orally
253852|NCT00145405|Drug|Lanreotide Autogel and Octreotide LAR|
253853|NCT02248493|Drug|Paracetamol|
253854|NCT02248493|Drug|Placebo (for paracetamol)|
253855|NCT02248493|Drug|Ketoprofen|
253856|NCT02248493|Drug|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
253857|NCT02248493|Drug|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
253225|NCT02259842|Drug|BI 34021 FU2 tablet|dose group 4 only
253226|NCT02259842|Drug|Placebo|
253227|NCT02259842|Other|High fat, high calorie breakfast|only for dose groups 3 and 5
253228|NCT02259855|Drug|Tipranavir|
253229|NCT02259855|Drug|Ritonavir|
253230|NCT02259855|Drug|Pegylated interferon|
253231|NCT02259855|Drug|Ribavirin|
253232|NCT02259868|Drug|BILR 355 BS /1B, current low dose formulation|
253233|NCT02259868|Drug|BILR 355 BS /1B, current high dose formulation|
253234|NCT02259868|Drug|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
253235|NCT02262013|Behavioral|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
253236|NCT02262026|Drug|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
253237|NCT02262026|Drug|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
253238|NCT02262026|Drug|Placebo|Placebo
253239|NCT00002361|Drug|Ritonavir|
253240|NCT00147134|Procedure|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
253545|NCT00146224|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
253546|NCT02255201|Dietary Supplement|Performance Energy Blend|Caffeine content: 175 mg
253547|NCT02255201|Dietary Supplement|Energy Blend|Caffeine content: 200 mg
253548|NCT02255201|Dietary Supplement|Placebo|Caffeine content: 0 mg
253549|NCT02255227|Biological|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
253550|NCT02255227|Biological|Pneumo 23|one dose
247736|NCT02235623|Procedure|Two-stage Fowler-Stephens orchidopexy (FSO)|
247737|NCT02235649|Behavioral|Social Cognition therapy ( Psychological Therapy)|
247738|NCT02235662|Drug|TFV IVR|
247739|NCT00143923|Other|usual care|usual care
247740|NCT02235662|Drug|TFV/LNG IVR|
247741|NCT02235662|Other|Placebo IVR|
247742|NCT02235675|Device|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
247743|NCT02235688|Drug|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
247744|NCT02235688|Drug|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
247745|NCT02235688|Drug|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
247746|NCT02235688|Drug|gemcitabine|
247747|NCT02235701|Drug|aldoxorubicin|administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
247748|NCT02235701|Drug|aldoxorubicin|administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
247749|NCT02235701|Drug|aldoxorubicin|administered 350 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
247750|NCT00002334|Drug|Saquinavir|
248057|NCT02228200|Behavioral|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
248058|NCT02228213|Biological|MIS416|Intravenous administration weekly for 52 weeks
248059|NCT02228213|Drug|Saline|Intravenous administration weekly for 52 weeks
248060|NCT02230566|Drug|UX003|UX003 is a sterile liquid buffered saline formulation of rhGUS
248061|NCT00143351|Drug|Ziprasidone|
248062|NCT02230579|Drug|MMV390048 5mg|Supplied as "powder in bottle" formulation for reconstitution pre-dose
247430|NCT02200718|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
247431|NCT02200718|Biological|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
247432|NCT02200731|Behavioral|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
247433|NCT02202993|Drug|Mibefradil with Radiation|Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.
This will be given concurrently with hypofractionated radiation therapy.
247434|NCT02203006|Biological|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
247435|NCT02203019|Drug|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
247436|NCT02203019|Drug|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
247437|NCT02203019|Drug|Fentanyl|Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention "of interest".
247438|NCT00140153|Drug|testosterone gel (Androgel)|
247439|NCT02203032|Drug|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
247440|NCT02203032|Drug|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
247441|NCT02203032|Drug|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
247442|NCT02203032|Drug|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
247443|NCT02203045|Other|Total Knee Arthroplasty|
247444|NCT02203058|Other|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
247445|NCT02203058|Other|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
247446|NCT02203084|Other|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
252982|NCT02274272|Other|ADR-1|two ADR-1 capsules, once daily, QD
252983|NCT00148460|Drug|TNK-tPA|
252984|NCT02274272|Other|GMNL-263|two GMNL-263 capsules, once daily, QD
252985|NCT02274272|Other|placebo|two placebo capsules, once daily, QD
252986|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
252987|NCT02274285|Biological|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
252988|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
253299|NCT00147745|Drug|Colesevelam|Colesevelam 3.8g for 12 weeks
253300|NCT02267161|Other|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
253301|NCT02269514|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
253302|NCT02269514|Other|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
253303|NCT02269514|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
253304|NCT02269527|Other|Live music|Providing 1-hour live music 5 days/ week.
253305|NCT00147953|Drug|Rituximab|
253306|NCT02269540|Drug|Sertraline|selective serotonin reuptake inhibitor
253307|NCT02269540|Drug|Citalopram|selective serotonin reuptake inhibitor
253308|NCT02269540|Drug|N-acetylcysteine (NAC)|natural health product
253309|NCT02269553|Device|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
253310|NCT02269553|Device|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
253311|NCT02269566|Drug|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
253312|NCT02269566|Drug|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
253313|NCT02269579|Drug|CPX-351|
252686|NCT02242955|Drug|Diazepam|40 mg per day.
252687|NCT02242981|Drug|LY2623091|Administered orally
252688|NCT02242994|Device|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
252689|NCT02242994|Device|Experimental App|Participant receives experimental app to test speed and error rate of communication.
252690|NCT00144716|Device|Insect Repellent plus Insecticide Treated Net|
252691|NCT02243007|Drug|FOLFIRINOX|
252692|NCT02243007|Drug|Gemcitabine/nab-Paclitaxel|
252693|NCT02243007|Radiation|Radiation therapy|
252694|NCT02243007|Drug|Capecitabine|
252989|NCT02274298|Behavioral|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
252990|NCT02274311|Drug|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
252991|NCT02274324|Dietary Supplement|different diets|3 different diets: A\B\C
252992|NCT02274337|Drug|Avitinib|patients take avitinib orally once per day at different dose
252993|NCT02274350|Radiation|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
252994|NCT00148460|Drug|rt-PA|
252995|NCT02274363|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque‐type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
252996|NCT02237937|Drug|Venlafaxine|
252997|NCT02237937|Drug|Amitriptyline|
252998|NCT02237937|Drug|Escitalopram|
252999|NCT02237937|Drug|Amitriptylinoxide|
253000|NCT02237937|Drug|Nortriptyline|
253001|NCT02237937|Drug|Trimipramine|
253002|NCT00144170|Drug|Tipranavir (with low dose ritonavir)|
252370|NCT02250222|Drug|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex [β-cyclodextrin] sulfobutylether sodium, NF)
252371|NCT02250222|Drug|Placebo (Captisol ®)|betadex [β-cyclodextrin] sulfobutylether sodium, NF
252372|NCT02250235|Other|Health risk information|
252373|NCT02250248|Biological|AttraX Putty|
252374|NCT02250248|Other|Iliac Crest Bone Graft (ICBG)|
252375|NCT02250261|Behavioral|KÄPY|
252376|NCT00145587|Procedure|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
252377|NCT02250274|Biological|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
252378|NCT02250274|Biological|IIV|A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.
[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.]
252695|NCT02243020|Device|Vagus Nerve Stimulation (VNS)|
252696|NCT02243033|Device|MR-guided laser interstitial thermal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
252697|NCT02243046|Drug|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
252698|NCT02243046|Drug|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
252699|NCT02243046|Drug|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
252700|NCT02243059|Drug|Gadofosveset trisodium (Ablavar™ )|
252701|NCT00144729|Procedure|Bone marrow transplant|
252702|NCT02243059|Device|MRI|
252703|NCT02243072|Behavioral|Fit Families plus Standard Medical Care|Adolescents will receive twice weekly home-based, family psychotherapy from a CHW for 6 months
252063|NCT02254772|Radiation|radiation therapy|Undergo radiation therapy
252064|NCT02254772|Other|laboratory biomarker analysis|Correlative studies
252065|NCT02254785|Drug|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
252066|NCT02254785|Drug|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
252067|NCT02254785|Drug|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
252068|NCT00146510|Behavioral|step counters with monthly feedback on logs|
252069|NCT02256969|Drug|Blephamide|
252070|NCT02256969|Drug|GenTeal PM Night-Time|
252071|NCT02256969|Procedure|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) will be applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine will be injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) will be used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients will initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
252072|NCT02256969|Procedure|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) will be applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine will be injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin will be touched with the probes without actual probing of the meibomian gland orifices.
252073|NCT02256982|Drug|Gemcitabine|
252074|NCT02256982|Drug|Cisplatin|
252075|NCT02256982|Procedure|Surgery|Surgical Resection and Lymphadenectomy
252076|NCT02256982|Radiation|Radiation|Radiation Therapy
252077|NCT02256995|Device|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
252078|NCT02257008|Drug|BILR 355 BS|
252079|NCT00146523|Drug|Mifepristone|
252080|NCT02257008|Other|Grapefruit juice|
252081|NCT02257008|Drug|Nelfinavir|
252082|NCT02257008|Drug|Atazanavir|
252379|NCT02250300|Drug|MLN9708|
251417|NCT02268760|Drug|Placebo|
251418|NCT02268760|Drug|BILN 2061 ZW fixed dose|
251419|NCT02268760|Other|Standardized breakfast|
251420|NCT02268773|Drug|Asasantin®|
251421|NCT02268773|Drug|Acetylsalicylic acid low dose|
251422|NCT02268773|Drug|Acetylsalicylic acid high dose|
251762|NCT02261623|Device|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
251763|NCT02261623|Device|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
251764|NCT02261636|Drug|mesalazine|
251765|NCT02261649|Device|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
251766|NCT02261649|Procedure|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
251767|NCT02263937|Procedure|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
251768|NCT02263937|Procedure|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
251769|NCT02263950|Drug|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
251770|NCT02263963|Drug|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
251771|NCT02263963|Procedure|TAP Block|no intervention will be done to this arm.
251772|NCT00147355|Drug|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
251773|NCT02263976|Drug|BEA 2180 BR|
251774|NCT02263976|Drug|Placebo|
251775|NCT02263976|Device|Respimat® A 4|
251776|NCT02263976|Drug|Methacholine Chloride|methacholine challenge test
255649|NCT00000341|Drug|Buprenorphine|
255650|NCT00002370|Drug|Itraconazole|
255651|NCT00148590|Drug|Memantine|Daily dose of 10mg memantine Vs. Placebo
255652|NCT02275494|Procedure|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
255653|NCT02275507|Device|Masimo Rainbow Sensor|Non-Invasive Hemoglobin Measurement
255654|NCT02275520|Device|NIO Adult device|IO access-1
255655|NCT02275520|Device|Bone Iniection Gun|IO access-2
255656|NCT02275520|Device|EZ-IO|IO access-3
255657|NCT02275520|Device|Jamshidi Intraosseous Needle|IO access-4
255658|NCT02275520|Device|Cook Intraosseous Needle|IO access-5
255659|NCT02275533|Other|Clinical Observation|Undergo standard of care clinical observation
255660|NCT02275533|Other|Laboratory Biomarker Analysis|Correlative studies
255661|NCT02275533|Biological|Nivolumab|Given IV
255662|NCT00148590|Drug|Placebo|Daily dose of 10mg memantine Vs. Placebo
255663|NCT02239107|Procedure|laparoscopic ovarian drilling|
255975|NCT02270502|Other|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
255976|NCT02270515|Other|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and health promoter to the care team.
255977|NCT02270528|Behavioral|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (~5 minutes)
255978|NCT02270528|Behavioral|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
255979|NCT02270541|Other|Telemedicine|In-ambulance telemedicine
255980|NCT00148031|Behavioral|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
255336|NCT02244073|Drug|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
255337|NCT00144833|Drug|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
255338|NCT02244086|Drug|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
255339|NCT02244099|Other|Controlled Substance|Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
255340|NCT02244112|Drug|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
255341|NCT02244112|Drug|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
255342|NCT02244125|Drug|PCD|STUDY TREATMENT PHASE: All patients
4x 28 days cycles of PCD
[Pomalidomide: 4mg/day oral route on 21 days per cycle]
[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]
[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle]
CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:
Arm A:
Melphalan 200mg/m2 followed by Autologous Transplantation
2x 28 days cycles of PCD, three months post transplantation
Arm B:
5x 28 days cycles of PCD
[Pomalidomide: 4mg/day oral route on 21 days per cycle]
[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]
[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle]
MAINTENANCE PHASE: All patients
- Until progression/relapse or discontinuation for any other reason
[Pomalidomide: 4mg/day oral route on 21 days per cycle]
[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle]
255343|NCT02244125|Procedure|Autologous transplantation (ASCT)|Arm A:
•Melphalan 200mg/m2 followed by Autologous Transplantation
255344|NCT02244138|Behavioral|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
255345|NCT02244151|Drug|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and folicular puncture at 24, 30, 36 or 40 after administration.
255346|NCT02246699|Device|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
255347|NCT02246699|Other|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
255664|NCT02239120|Drug|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
254732|NCT02257983|Drug|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
255046|NCT02251288|Drug|MF59|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
255047|NCT02251288|Biological|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
255048|NCT02251301|Dietary Supplement|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
255049|NCT00145678|Behavioral|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
255050|NCT02251301|Behavioral|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
255051|NCT02251301|Other|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
255052|NCT02251301|Dietary Supplement|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
255053|NCT02251327|Other|investigational Xpert DST test|The Xpert MTB/RIF cartridge detects M. tuberculosis as well as resistance to rifampin, and has been endorsed by the World Health Organization for use in settings of high HIV and/or drug-resistant tuberculosis prevalence.
255054|NCT02251340|Behavioral|Eczema Care Plan|
255055|NCT02251353|Procedure|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
255056|NCT02251353|Drug|systemic treatment|Systemic therapy
255057|NCT02251366|Procedure|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
255058|NCT02251379|Drug|Flovent Diskus|Inhaled corticosteroids
255059|NCT02251379|Other|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
255060|NCT00145990|Device|KoKo Digidoser|
255061|NCT02253563|Behavioral|Resistance Training|
254414|NCT02264990|Drug|Cisplatin|Intravenous infection
254415|NCT02264990|Drug|Pemetrexed|Intravenous infusion
254416|NCT02265029|Other|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
254417|NCT00147511|Drug|linezolid|
254733|NCT02257996|Behavioral|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
254734|NCT02258009|Drug|Ranibizumab|0.5 mg intravitreal injections
254735|NCT00002357|Drug|HBY 097|
254736|NCT00146588|Drug|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
254737|NCT02258009|Drug|Aflibercept|2 mg intravitreal injections
254738|NCT02258022|Device|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™ breath delta value analyzer, that is intended to determine the breath delta value of breath samples collected from critically ill patients. We will use the Isomark Canary™ to determine the breath delta value of breath samples collected during this study.
254739|NCT02258035|Other|Blood draw|Sampling of 100-150 ml of blood
254740|NCT02258061|Procedure|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
254741|NCT02258061|Procedure|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
254742|NCT02258074|Drug|Nicotinamide|
254743|NCT02258074|Drug|Lanthanum Carbonate|
254744|NCT02258074|Drug|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
254745|NCT02258074|Drug|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
254746|NCT02258087|Radiation|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
254747|NCT00146588|Drug|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
259176|NCT02466477|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
259177|NCT02466490|Drug|Fimasartan|Fimasartan tablets
259178|NCT02466490|Drug|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
259179|NCT00174460|Drug|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
259180|NCT02466503|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
259181|NCT02466503|Drug|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
259182|NCT02466516|Drug|GS-4997|GS-4997 tablets administered orally once daily
259183|NCT02466516|Biological|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
259184|NCT02466542|Drug|Placebo group|Patients will receive regular general anesthesia
259185|NCT02466542|Drug|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
259186|NCT02466555|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
259187|NCT02466568|Drug|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
259188|NCT02466568|Biological|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
254418|NCT02265029|Other|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
254419|NCT02265042|Device|Stimulette|electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
254420|NCT02265055|Procedure|transfer early cleavage embryos|transfer early cleavage embryos
254421|NCT02265055|Procedure|transfer non early cleavage embryo|
258606|NCT02477046|Biological|bOPV|administered per protocol
258607|NCT02477046|Biological|IPV|administered per protocol
258891|NCT02470871|Biological|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
258892|NCT02470884|Device|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
258893|NCT02470897|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
258894|NCT02470897|Radiation|Stereotactic Body Radiation Therapy|Undergo moderate dose SBRT with SIB
258895|NCT02470897|Radiation|Stereotactic Body Radiation Therapy|Undergo uniform dose SBRT
258896|NCT00174941|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
258897|NCT02470910|Device|Magnetic Resonance Imaging|
258898|NCT02470923|Drug|Nicotine replacement therapy|
258899|NCT02470923|Behavioral|Intensive counseling|
258900|NCT02472964|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
258901|NCT02472964|Drug|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
258902|NCT02472977|Drug|Ulocuplumab|
258903|NCT02472977|Drug|Nivolumab|
258904|NCT00175149|Drug|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
258905|NCT02472990|Other|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
258906|NCT02473003|Behavioral|high intensity exercise|high intensity exercise 80-90%
258907|NCT02473003|Behavioral|low/medium intensity exercise|low/medium intensity exercise 40-50%
258908|NCT02473003|Behavioral|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
258909|NCT02473016|Drug|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode [ipsilateral nostril].
258327|NCT02483897|Drug|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
258328|NCT02483910|Behavioral|Direct Instruction-Language for Learning (DI-LL)|DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts ("show me" or "point to" or "say the whole thing"), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons.
258608|NCT00175825|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
258609|NCT02477059|Drug|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
258610|NCT02477059|Drug|saline solution|La saline solution is administered by intravenous infusion.
258611|NCT02477072|Procedure|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
258612|NCT02477072|Procedure|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
258613|NCT02477072|Procedure|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
258614|NCT02477072|Procedure|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
258615|NCT02477072|Drug|Heparin|Heparin doses will be administered according to the assigned group.
258616|NCT02477085|Other|all women with an induced labor|all women who have an induced labor
258617|NCT02479334|Other|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
258618|NCT02479334|Other|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
258619|NCT02479334|Other|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
258620|NCT02479347|Drug|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
258029|NCT02490423|Other|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
258030|NCT02490436|Drug|Cetuximab|Randomized cross-over between cetuximab and placebo
258031|NCT02490436|Drug|Placebo|Randomized cross-over between cetuximab and placebo
258032|NCT02490449|Drug|Dexlansoprazole MR|Administration of drug after or before diet
258033|NCT02490462|Other|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
258034|NCT02490462|Other|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
258329|NCT02483910|Behavioral|Treatment as Usual|Usual care including speech therapy in school, community or both
258330|NCT02483923|Drug|Ultrasound guided serratus anterior block with ropivacaine and intravenous PCA|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
258331|NCT02483923|Drug|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
258332|NCT02483936|Drug|Olmesartan medoxomil + chlorthalidone|1 tablet a day
258333|NCT02483936|Drug|Olmesartan medoxomil + chlorthalidone|1 tablet a day
258334|NCT02483936|Drug|Losartan + hydrochlorothiazide (Hyzaar ®)|1 tablet a day
258335|NCT00176592|Drug|Betaseron|Betaseron 250 micrograms injected SQ every other day
258336|NCT02483949|Behavioral|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
258337|NCT02483962|Other|Gelatine capsule|Gelatine capsules containing no active ingredients.
257751|NCT02495103|Drug|Vandetanib|Vandetanib is commercially available under the trade name CAPRELSA, but will be supplied by the manufacturer (AstraZeneca Pharmaceuticals, Wilmington, DE) for the purposes of the study.
257752|NCT02495103|Drug|Metformin|Metformin is commercially available and manufactured by Bristol-Myers Squibb Company (Princeton, NJ) under the trade name GLUCOPHAGE.
257753|NCT02495129|Drug|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
257754|NCT02495129|Drug|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
257755|NCT02495155|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
257756|NCT02495168|Drug|Symbicort|Brand Budesonide/Formoterol fumarate dihydrate
257757|NCT02495168|Drug|Generic Budesonide/Formoterol fumarate dihydrate|Test generic Budesonide/Formoterol fumarate dihydrate
257758|NCT00002481|Drug|dexamethasone|
257759|NCT00177970|Drug|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff vs placebo.
257760|NCT02495168|Drug|Placebo|Placebo
257761|NCT02495181|Drug|IVT Aflibercept; Verteporfin PDT|
257762|NCT00178256|Drug|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
257763|NCT02497235|Drug|TAK-935|TAK-935 oral solution.
257764|NCT02497235|Drug|[18F]MNI-792 (tracer)|[18F]MNI-792 injection.
257765|NCT02497248|Procedure|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
257766|NCT02497261|Procedure|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
257767|NCT02497274|Other|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
258035|NCT02490475|Drug|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
257170|NCT02276066|Drug|Iohexol|Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
257459|NCT02501629|Drug|Placebo|
257460|NCT02501642|Behavioral|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
257461|NCT02501642|Other|Treatment as usual|Treatment as usual
257462|NCT02501655|Device|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
257463|NCT00002485|Procedure|psychosocial assessment and care|
257464|NCT00178932|Procedure|genetic assay|genetic assay of blood sample drawn with patient's consent
257465|NCT02501655|Device|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
257466|NCT02501681|Other|priming solution during cardiovascular surgery|
257467|NCT02501694|Other|Auscultation|Electronic stethoscope
257468|NCT02501720|Procedure|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
257469|NCT02501720|Procedure|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
257470|NCT02501720|Procedure|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
257471|NCT02501733|Device|Medacta GMK Sphere® Medial Knee Prosthesis|There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.
To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices.
257472|NCT02467907|Drug|Paclitaxel|Administration of paclitaxel at a dose of 175 mg/m^2 on day 1 every 3 weeks for at least 6 cycles
257473|NCT02467920|Drug|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
257474|NCT02467920|Drug|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
253245|NCT02262078|Other|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
253246|NCT02262091|Dietary Supplement|Food fibers|
253247|NCT02262091|Dietary Supplement|Maltodextrin|
253248|NCT02262091|Biological|Influenza vaccine (incl. criterion)|
253249|NCT02262104|Behavioral|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
253250|NCT02262104|Behavioral|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
253251|NCT00147147|Procedure|Gastrectomy with D2 or greater lymph node dissection|
253252|NCT02262117|Other|No immune profiling|No specific medical care
253253|NCT02262117|Drug|endometrial immune profiling|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
253254|NCT02262130|Drug|Omalizumab|
253255|NCT02262143|Drug|Rosuvastatin|Rosuvastatin 10 mg, qd, po
253256|NCT02262143|Drug|Fenofibrate|Fenofibrate 160mg, qd, po
253257|NCT02262156|Other|Cognitive behavioral therapy|The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.
The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention
253258|NCT02262156|Drug|SSRI|Patients will receive the "treatment as usual" with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned.
253259|NCT02262169|Drug|Omeprazole|2 Omeprazole capsules 20 mg, once daily
253260|NCT02262169|Drug|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
253261|NCT00147459|Biological|HBV vaccine booster|
253262|NCT02264509|Procedure|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
253565|NCT02255370|Drug|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
252625|NCT02274142|Procedure|ART with powder-liquid material|restoration with powder liquid glass ionomer cement
252626|NCT02274142|Procedure|ART with Encapsulated material|restoration with encapsulated ionomer cement
252627|NCT02274142|Device|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
252628|NCT02274142|Device|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
252629|NCT02274155|Drug|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
252630|NCT02274155|Procedure|Surgical Resection|Surgical Resection of Tumor
252924|NCT02269384|Procedure|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
252925|NCT02269410|Dietary Supplement|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252926|NCT02269410|Dietary Supplement|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252927|NCT02269410|Dietary Supplement|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252928|NCT00002367|Drug|Lamivudine|
252929|NCT00147927|Behavioral|Sequential emails and web support|
252930|NCT02269410|Dietary Supplement|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252931|NCT02269423|Biological|BPSC-1001 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
252932|NCT02269423|Other|Placebo|Normal saline placebo.
252933|NCT02269436|Drug|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
252934|NCT02269449|Device|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
252935|NCT02269449|Device|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
252936|NCT02269449|Procedure|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
252313|NCT02242812|Drug|Telmisartan|
252314|NCT02242812|Drug|Metoprolol succinate|
252315|NCT02242812|Drug|Placebo|
252316|NCT02242825|Drug|Micardis®|
252317|NCT02242825|Drug|MicardisPlus®|
252318|NCT02242838|Drug|Telmisartan|
252319|NCT02242851|Drug|Telmisartan|
252320|NCT00144703|Drug|Sirolimus|
252321|NCT02242864|Drug|Micardis®|
252322|NCT02242864|Drug|MicardisPlus®|
252323|NCT02242877|Drug|Telmisartan|
252324|NCT02242877|Drug|Telmisartan combined with hydrochlorothiazide|
252325|NCT02242890|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
252326|NCT02242903|Drug|LY3079514|Administered SC
252631|NCT02274168|Procedure|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
252632|NCT02237768|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
252633|NCT02237781|Drug|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
252634|NCT02237807|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
252635|NCT02237807|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
252636|NCT02237820|Drug|Dexamethasone|6 mg/day of Oral Dexamethasone
252637|NCT02237820|Drug|Prednisone|40 mg/day of Oral Prednisone
252638|NCT02237846|Biological|Human umbilical cord tissue-derived mesenchymal stem cells|
256932|NCT02251951|Drug|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
256933|NCT02251964|Drug|Rituximab|2 times 1000mg dose at 14 days interval treatment
256934|NCT02251964|Radiation|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
256935|NCT02251977|Drug|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
256936|NCT02251977|Drug|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
256937|NCT02251977|Drug|mFOLFOX6 or XELOX|mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.
XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.
The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient.
256938|NCT02251990|Drug|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
256939|NCT00145769|Drug|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
256940|NCT02251990|Drug|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
256941|NCT02252003|Other|Pain scales testing|
256942|NCT02252016|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
256943|NCT02252016|Drug|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
256944|NCT02252042|Biological|pembrolizumab|
256945|NCT02252042|Drug|methotrexate|
256946|NCT02252042|Drug|docetaxel|
257250|NCT02245048|Other|Carotid Intima-Media Thickness (CIMT)|
257251|NCT02245061|Other|paired pulses cortical electrical stimulation|
257252|NCT02245074|Other|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
257253|NCT02245087|Drug|Atorvastatin|20 mg of atorvastatin daily
256273|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
256274|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
256275|NCT02260934|Drug|Prednisone|Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)
Continue prednisone 10 mg/day to week 96
256587|NCT02256501|Biological|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
256588|NCT02256514|Biological|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
256589|NCT02256527|Other|Observational|compare data
256590|NCT02256540|Drug|Climara|
256591|NCT02256540|Drug|Placebo patch|Placebo patch designed to match active Climara patches.
256592|NCT02256540|Dietary Supplement|Resveratrol|
256593|NCT02256540|Dietary Supplement|Placebo|Placebo tablets designed to match active resveratrol tablets.
256594|NCT02256553|Biological|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
256595|NCT02256553|Biological|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
256596|NCT00146419|Behavioral|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
256597|NCT02256553|Drug|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
256598|NCT02256566|Behavioral|emotional memory training exercise|
256599|NCT02256566|Behavioral|memory training exercise|
256600|NCT02256592|Drug|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
256601|NCT02256605|Dietary Supplement|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D [259OH)D] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
256602|NCT02256618|Other|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
256603|NCT02256631|Biological|VRC01|Administered by subcutaneous injection in the thigh
255969|NCT02268175|Drug|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
255970|NCT02268175|Drug|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
255971|NCT02268175|Drug|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
255972|NCT02268175|Drug|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
255973|NCT02268188|Other|educational intervention|Undergo Harvesting Health program
255974|NCT02270502|Other|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
256276|NCT02260934|Drug|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
256277|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
256278|NCT02263235|Other|collection of CSF, blood, urine, saliva|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
256279|NCT02263248|Drug|venlafaxine|slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
256280|NCT02263248|Drug|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
256281|NCT02263248|Drug|placebo|patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
256282|NCT02263261|Other|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
256283|NCT02263274|Device|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
256284|NCT02263287|Other|LeSCoD scale|LeSCoD is a clinical scale
256285|NCT02263313|Other|EGO-COMBO group|Assess the safety and effectiveness of Combo stent
256286|NCT02263326|Drug|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
255981|NCT02270554|Device|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
255982|NCT02270567|Device|NETest|Non-invasive blood test
255983|NCT02270580|Behavioral|PN+|we will evaluate the efficacy of a culturally tailored PN program ("PN+") on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors
255984|NCT02270580|Behavioral|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
255985|NCT02270606|Radiation|intensity-modulated radiation therapy|Undergo IMRT
255986|NCT02270606|Drug|fluorouracil|Given IV
255987|NCT02270606|Drug|oxaliplatin|Given IV
255988|NCT02270606|Drug|leucovorin calcium|Given IV
255989|NCT02270606|Procedure|therapeutic conventional surgery|Undergo total mesorectal excision
255990|NCT02270619|Biological|Endotoxin|Low dose endotoxin (0.4 ng/kg of body weight) as IV bolus
255991|NCT00148031|Behavioral|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
255992|NCT02270619|Behavioral|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
255993|NCT02270619|Other|Placebo|0.9% saline as IV bolus
255994|NCT02270619|Other|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
255995|NCT02270632|Drug|F8IL10|F8IL10 (30 μg/kg or 160 μg/kg) will be administered once a week for 8 weeks (or until withdrawn from the study).
255996|NCT02270632|Drug|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
256293|NCT02263352|Drug|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
256294|NCT02263352|Device|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
256295|NCT02263365|Drug|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
256296|NCT02263378|Drug|ellagic acid + annona muricata|pills
255665|NCT02239120|Drug|placebo to ASA|placebo to comparator drug
255666|NCT02239120|Drug|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
255667|NCT02239120|Drug|placebo to dabigatran etexilate|placebo
255668|NCT02239120|Drug|ASA 100 mg|active comparator drug
255669|NCT02239120|Drug|dabigatran etexilate|active drug
255670|NCT02239133|Device|ProVATE vaginal pessary|
255671|NCT02239146|Drug|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
255672|NCT02239146|Drug|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
255673|NCT00144300|Drug|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
255674|NCT02239159|Other|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
255675|NCT02239172|Biological|PA83-FhCMB|
255676|NCT02239185|Procedure|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
255677|NCT02239185|Procedure|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
255678|NCT02239198|Other|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
255679|NCT02239211|Drug|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
255680|NCT02239224|Biological|ATYR1940|Patients will enter the double-blind treatment period and will receive 30-minute IV infusions of Study Drug (ATYR1940 or placebo) according to their random treatment assignment.
255681|NCT02239237|Drug|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
255062|NCT02253563|Behavioral|Balance Training|
255063|NCT02253576|Other|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
255348|NCT02246712|Drug|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
255349|NCT00145171|Drug|apomorphine HCl injection|
255350|NCT02246712|Other|CYP2D6 phenotype|Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.
CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato
255351|NCT02246712|Other|CYP3A phenotype|A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.
The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.
The in vivo activity of CYP3A was evaluated by midazolam oral clearance.
255352|NCT02246712|Genetic|CYP2B6 genotype|The single nucleotide polymorphism 516G>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
255353|NCT02246725|Other|Contact with palliative care unit.|
255354|NCT02246738|Other|Blood Collection|
255355|NCT02246751|Device|Targeted Training for trunk control using ORLAU standers (see description below)|Orthotics Research and Locomotor Research Unit (ORLAU) standers will be imported from England for research purposes. These standers are custom fit to help the child train at the segmental level of the trunk where they begin to lose control of posture. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body. The researchers evaluate children every 8 weeks and adjust the stander to lower levels of support as the child gains control.
255356|NCT02246764|Drug|Netarsudil (AR-13324) Ophthalmic Solution q.d.|1 drop daily
255357|NCT02246764|Drug|Netarsudil (AR-13324) Ophthalmic Solution b.i.d.|1 drop twice daily
255358|NCT02246764|Drug|Timolol maleate Ophthalmic Solution b.i.d.|1 drop twice daily
255359|NCT02246777|Device|Ex-PRESS™ Glaucoma Filtration Device, Model P50PL|
255360|NCT00145184|Dietary Supplement|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
255361|NCT02246790|Procedure|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
254748|NCT02258087|Radiation|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
254749|NCT02258100|Other|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
254750|NCT02258113|Device|Ocusweep|A novel reaction-time based visual field device.
254751|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 15g|
254752|NCT02260336|Drug|Celecoxib Capsule 400 mg daily|
254753|NCT02260349|Drug|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
255064|NCT02253576|Other|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
255065|NCT02253589|Behavioral|modified ASSIST-linked Brief Intervention|Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
255066|NCT02253602|Drug|Ferumoxytol|maximum rate of administration 1 ml/sec
255067|NCT02253615|Other|Machines exercises|Resistance training in pneumatic machines.
255068|NCT02253615|Other|Elastic exercises|Resistance training with elastic tubes.
255069|NCT02253628|Other|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255070|NCT02253628|Other|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255071|NCT00145990|Device|Rosethal Dosimeter|
255072|NCT02253628|Other|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255073|NCT02253628|Other|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255074|NCT02253641|Behavioral|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
255075|NCT02253641|Behavioral|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
254422|NCT02265068|Drug|Ticagrelor|Treatment of ACS patients with Ticagrelor
254423|NCT02265081|Procedure|ultrasound|pelvic floor ultrasound
254424|NCT02265081|Procedure|uroflow-meter|uroflow meter: measurement of passed urine volume
254425|NCT02265094|Other|Electroencephalography|EEG recordings during memory tests
254426|NCT02265094|Behavioral|Neuropsychological assessment|patterns of eye gaze during cognitive tests
254427|NCT02265107|Other|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
254428|NCT00147524|Drug|quinapril|
254429|NCT02265120|Behavioral|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
254430|NCT02265159|Procedure|Focal Therapy Using High Intensity Focused Ultrasound|
254431|NCT02265172|Procedure|Physiotherapy screening|Physiotherapy screening.
254432|NCT02267434|Biological|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
254433|NCT02267434|Biological|Adjuvant without active component|s.c. injection
254434|NCT02267460|Biological|AA4500|
254435|NCT02267460|Device|ErecAid® Esteem® Manual Vacuum Therapy System|
254436|NCT02267460|Procedure|Investigator Modeling|
254437|NCT02267486|Other|Standard therapy of Alzheimer Dementia (AD)|
254438|NCT00147784|Drug|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
254439|NCT02267486|Other|Observation|
254754|NCT02260375|Biological|Mesenchymal Stromal Cells|
254755|NCT02260388|Drug|Nortriptyline|
254756|NCT02260388|Drug|Duloxetine|
258910|NCT02473029|Radiation|Vascular tomodensitometry|
258911|NCT02473029|Other|Magnetic resonance angiography|
258912|NCT02473029|Other|Vascular ultrasonography|
258913|NCT02473029|Other|Retinal angiography|
258914|NCT02473029|Other|Retinal optical coherence tomography|
259189|NCT02466581|Drug|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
259190|NCT00174460|Other|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
259191|NCT02466581|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
259192|NCT02466581|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
259193|NCT02466581|Biological|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
259194|NCT02466594|Device|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
259195|NCT02468622|Other|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
259196|NCT02468635|Other|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
259197|NCT02468635|Other|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
259198|NCT02468648|Drug|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
258621|NCT02479347|Drug|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
258622|NCT02479373|Other|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
258623|NCT00176137|Procedure|preoperative radiochemotherapy|
258624|NCT02479373|Other|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
258625|NCT02479373|Other|Biodex dynamometer|To study muscle strength
258626|NCT02479373|Other|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
258627|NCT02479373|Other|Quality of life questionnaires|
258915|NCT00175162|Device|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
258916|NCT02473042|Procedure|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
258917|NCT02473042|Drug|Zofran|4 mg by vein for 1 dose.
258918|NCT02473042|Drug|Dexamethasone|10 mg by vein for 1 dose.
258919|NCT02473042|Drug|Phenergan|6.25 mg by vein for 1 dose.
258920|NCT02473042|Drug|Pepcid|10 mg by vein for 1 dose.
258921|NCT02473042|Behavioral|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
258922|NCT02473055|Other|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
258923|NCT02473068|Device|CPAP|
258924|NCT02473081|Behavioral|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
258925|NCT02473081|Other|Usual care|Usual care was given by their family physicians.
258926|NCT00175175|Behavioral|Allied health professional-run osteoporosis service ("case-management")|
258927|NCT02475031|Device|TAP Catheters|Both groups will have catheters inserted into the TAP area after a single shot TAP block
258338|NCT02483962|Other|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
258339|NCT02483975|Drug|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
258340|NCT02486276|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
258341|NCT02486276|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
258342|NCT02486289|Drug|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
258343|NCT00176826|Drug|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
258344|NCT02486289|Drug|Placebo|NBMI Placebo
258345|NCT02486302|Drug|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
258346|NCT02486315|Device|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
258347|NCT02486328|Drug|Midazolam|Dosage adjustment
258628|NCT02479399|Drug|Suglat|
258629|NCT02479412|Drug|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
258630|NCT02479412|Drug|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
258631|NCT02479412|Drug|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
258632|NCT02479412|Drug|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
258633|NCT02479412|Drug|Salbutamol|Inhalation as needed
258634|NCT00176163|Behavioral|Operant behavioral treatment; Drug: THC|
258036|NCT02490475|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
258037|NCT00177294|Drug|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
258038|NCT02490488|Drug|Masitinib (AB1010)|6 mg/kg/day
258039|NCT02490488|Drug|Gemcitabine|1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion
258040|NCT02490501|Procedure|SC0806 and rehabilitation|
258041|NCT02490501|Other|Rehabilitation only|
258042|NCT02490514|Other|No intervention|No intervention was administered in this study.
258043|NCT02490527|Dietary Supplement|Pure epicatechin capsules (100mg)|Epicatechin is a compound found naturally in dark chocolate.
258044|NCT02490527|Drug|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
258045|NCT02490527|Other|Placebo|A substance that has no therapeutic effect and will act as a control.
258046|NCT02492750|Other|Placebo|Given SC
258047|NCT02492763|Drug|MK-8521|Dose strengths: 180 mcg QD administered subcutaneously; 300 mcg QD administered subcutaneously
258048|NCT02492763|Drug|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 mcg QD administered subcutaneously; matching placebo for MK-8521 180 mcg QD administered subcutaneously
258049|NCT02492763|Drug|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously
258050|NCT02492763|Drug|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
258051|NCT00177567|Drug|bupropion|
258052|NCT02492776|Drug|Omeprazole|20 mg oral capsules administered once daily for 8 days
258053|NCT02492776|Drug|AF-219|AF-219 oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
258054|NCT02492776|Drug|AF-219|AF-219 oral tablet (50 mg tablet) administered twice daily for 8 days
258348|NCT02486328|Drug|Meperidine|Dosage adjustment
258349|NCT02486328|Drug|Remifentanil|Dosage adjustment
257475|NCT02467933|Other|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
257476|NCT02467933|Other|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
257477|NCT02467933|Other|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
257768|NCT02497287|Drug|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 >= 65 years old will start at a dose of 28 mg in Week 5.
257769|NCT02497287|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
257770|NCT02497287|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants >= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
257771|NCT02497287|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
257772|NCT02497287|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants < 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants >= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
257773|NCT00002481|Radiation|radiation therapy|
257774|NCT00178256|Procedure|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
257775|NCT02497300|Drug|Spironolactone|
257776|NCT02497300|Drug|Amiloride|
257777|NCT02497313|Drug|Isotonic saline|
257778|NCT02497313|Drug|Metformin placebo|
257779|NCT02497313|Drug|Cholecystokinin|
253566|NCT02255383|Device|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
253567|NCT00002354|Drug|Indinavir sulfate|
253568|NCT02257463|Other|peripheral muscles exercise training|
253569|NCT02257463|Device|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
253570|NCT02257476|Drug|Carfilzomib|- Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
253571|NCT02257476|Drug|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
253572|NCT02257489|Drug|ACE-083|recombinant fusion protein
253573|NCT02257502|Drug|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
253574|NCT00146562|Drug|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
253575|NCT02257528|Other|Laboratory Biomarker Analysis|Correlative studies
253576|NCT02257528|Biological|Nivolumab|Given IV
253577|NCT02257541|Drug|BGJ398|
253578|NCT02257541|Drug|Imatinib Mesylate|
253579|NCT02257554|Behavioral|education|Discussion of surgical expectations with patients
253580|NCT02257567|Drug|bendamustine|Bendamustine 90 mg/m2 administered intravenously on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles.
253581|NCT02257567|Drug|obinutuzumab|Obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles.
253582|NCT02257567|Drug|polatuzumab vedotin|Polatuzumab vedotin administered intravenously on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles.
253583|NCT02257567|Drug|rituximab|Rituximab standard dose, 375 mg/m2 intravenously on Day 1 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles.
252937|NCT02269449|Procedure|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
252938|NCT02269462|Drug|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
252939|NCT02269462|Drug|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
252940|NCT00147940|Procedure|Acoustic rhinometry (procedure)|
252941|NCT02269475|Drug|MEDI3250|MEDI3250
252942|NCT02269475|Drug|Placebo|Placebo
252943|NCT02269488|Drug|MEDI3250|MEDI3250
252944|NCT02269501|Other|Exercise treatment|
252945|NCT02269514|Other|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
253263|NCT02264522|Other|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
253264|NCT02264522|Other|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
253265|NCT02264522|Other|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
253266|NCT02264522|Other|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
253267|NCT02264535|Drug|0.1mg/ml Ginkgolides Meglumine Injection|
253268|NCT02264535|Drug|1mg/ml Ginkgolides Meglumine Injection|
253269|NCT02264535|Drug|5mg/ml Ginkgolides Meglumine Injection|
253270|NCT02264548|Radiation|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
253271|NCT02264561|Other|Food|Active group
253272|NCT00147472|Other|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
253273|NCT02264561|Other|Food|Control group
253274|NCT02264574|Drug|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
253275|NCT02264574|Drug|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
252639|NCT02237859|Drug|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
252640|NCT00144157|Drug|Zidovudine|
252641|NCT02237859|Dietary Supplement|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
252642|NCT02237885|Device|NeuroSky MindWave Mobile|
252643|NCT02237898|Behavioral|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application & Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
252644|NCT02237898|Behavioral|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the Sensodrone™ CO sensor.
252645|NCT02237898|Device|Sensordrone™ carbon-monoxide sensor|
252646|NCT02237898|Device|MoMba Live Long Smartphone application|
252647|NCT02237911|Other|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
252648|NCT02237911|Other|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
252649|NCT02237924|Drug|endostar|Endostar 7.5mg / m2, 2 cycles of intravenous infusion for ten days,and 2 cycles of maintenance therapy after radiotherapy
252946|NCT02269514|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
252947|NCT02271698|Drug|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
252948|NCT02271698|Other|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
252949|NCT02271711|Biological|Natural Killer (NK) Cells|Starting dose level of NK-cell number per infusion is 10^6/m^2. Infusions given through ommaya reservoir catheter. Participants receive the NK cells 3 times a week (at least 1 day apart) for the first 3 weeks in each 4-week cycle.
252950|NCT02271724|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
252951|NCT02271724|Procedure|Blood sample|Blood sample
257254|NCT00144937|Behavioral|Increase in physical activity|
257255|NCT02245100|Other|Cytology specimen|Correlative studies
257256|NCT02245100|Other|Laboratory biomarker analysis|Correlative studies
257257|NCT02245113|Other|diets|Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
257258|NCT02481089|Other|validation group|
257259|NCT02481128|Procedure|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
257260|NCT02481141|Drug|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
257261|NCT02481141|Drug|Placebo|
257262|NCT02481154|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
257263|NCT02481180|Drug|T0001|injection (SC) T0001 15mg weekly for 12 weeks
257264|NCT02481180|Drug|T0001|injection (SC) T0001 30mg weekly for 12 weeks
257265|NCT02481180|Drug|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
257266|NCT02481180|Drug|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
257267|NCT00176358|Device|PTCA and Stent Implantation|
257268|NCT02481180|Drug|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
257269|NCT02481193|Drug|Cisatracurium|Different doses of cisatracurium pretreatment
257270|NCT02481206|Device|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
257271|NCT02481219|Device|PillCam® COLON 2 procedure-CONT|
257272|NCT02481219|Drug|Senna tablets|
257273|NCT02481219|Drug|PEG|
257548|NCT02474641|Radiation|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
257549|NCT02474654|Drug|Bupivicaine|15mg
256604|NCT02256657|Behavioral|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
256605|NCT02256670|Behavioral|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
256947|NCT02252042|Biological|cetuximab|
256948|NCT02252055|Biological|ATDC_Nantes|ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.
Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)
256949|NCT02252068|Behavioral|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
256950|NCT02254252|Drug|Nicorandil|nicorandil (10mg tablets, two times a day)
256951|NCT02254252|Drug|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
256952|NCT02254265|Drug|OTX-101 0.05%|OTX-101 0.05% Ophthalmic Solution
256953|NCT00146120|Drug|Idarubicin|
256954|NCT02254265|Drug|OTX-101 0.09%|OTX-101 0.09% Ophthalmic Solution
256955|NCT02254265|Drug|Vehicle|Vehicle of OTX-101 Ophthalmic Solution
256956|NCT02254278|Drug|Cisplatin|Given IV
256957|NCT02254278|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
256958|NCT02254278|Other|Laboratory Biomarker Analysis|Correlative studies
256959|NCT02254278|Other|Quality-of-Life Assessment|Ancillary studies
256960|NCT02254291|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
256961|NCT02254291|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after initial dose escalation steps of 0.25 mg once weekly (4 weeks) and 0.5 mg once weekly (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
256962|NCT02254291|Drug|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
256963|NCT02254304|Drug|Rebif®|Rebif® (interferon beta-1a) will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart™ auto-injector three times a week for a total duration up to 12 months.
256287|NCT02263326|Drug|lamivudine|300 mg tablet by mouth once daily for 48 weeks
256288|NCT00147290|Device|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
256289|NCT02263326|Drug|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
256290|NCT02263339|Behavioral|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
256291|NCT02263339|Behavioral|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
256292|NCT02263339|Behavioral|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
256606|NCT02256683|Drug|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
256607|NCT00146432|Procedure|Immunoadsorption of LPS, IL-6 and C5a|
256608|NCT00002357|Drug|Zidovudine|
256609|NCT00146666|Device|Intermittent compression|
256610|NCT02258672|Other|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
256611|NCT02258698|Procedure|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
256612|NCT02258711|Device|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
256613|NCT02258737|Behavioral|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
256297|NCT02263391|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
256298|NCT02265770|Drug|Chemotherapy + Valproate|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses.
256299|NCT02265770|Radiation|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
256300|NCT02265770|Drug|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
256301|NCT00147563|Drug|Eplerenone|
256302|NCT02265770|Drug|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
256303|NCT02265770|Radiation|conformal radiotherapy +/- boost|Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions
256304|NCT02265796|Drug|Ranolazine|Ranolazine 500mg tablet
500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks
256305|NCT02265796|Drug|Sugar pill|500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks
256306|NCT02265809|Drug|Aldesleukin|
256307|NCT02265822|Drug|melatonin in children premedication|
256308|NCT02265822|Drug|midazolam in children premedication|
256309|NCT02265835|Other|no intervention|no intervention
256310|NCT02265848|Other|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
256624|NCT02258802|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
255997|NCT02270632|Drug|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
255998|NCT02272881|Procedure|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
255999|NCT02272881|Procedure|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
256000|NCT02272894|Procedure|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
256001|NCT00148343|Device|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation & use for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
256002|NCT02272907|Other|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
256003|NCT02272920|Procedure|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
256004|NCT02272933|Device|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
256005|NCT02272933|Device|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
256006|NCT02272946|Drug|Canakinumab|150mg Canakinumab received subcutaneously
256007|NCT02272946|Drug|Placebo|150mg Placebo received subcutaneously
256008|NCT02272959|Behavioral|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
256009|NCT02272959|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
256010|NCT02272972|Other|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
255362|NCT02246790|Procedure|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
255363|NCT02246803|Procedure|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
255364|NCT02246803|Procedure|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
255682|NCT02241382|Device|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
255683|NCT02241395|Biological|Intrathecal autologous bone marrow mononuclear cell transplantation|
255684|NCT02241421|Drug|Amoxicillin|
255685|NCT02241421|Drug|Vancomycin|
255686|NCT02241434|Biological|Stem Cell|
255687|NCT00144521|Drug|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
255688|NCT02241447|Other|Nurse based at echo facility will inform referring physician within one week that their Patient was diagnosed with severe aortic Stenosis.|Nurse based at echo facility will inform referring physician within one week that their Patient was diagnosed with severe aortic Stenosis. outcomes and Treatment decision will be documented.
255689|NCT02241460|Drug|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
255690|NCT02241460|Drug|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
255691|NCT02241473|Other|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single‐blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
255692|NCT02241486|Drug|Sublingual Fentanyl Spray|
255693|NCT02241499|Radiation|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
255694|NCT02241499|Drug|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
255695|NCT02241512|Drug|Ibuprofen|
255076|NCT02253654|Drug|Epoetin alfa|The treatment allocation and dose of investigational product will be blinded. The duration of the study for an individual subject is approximately 41 weeks, which consists of a 12-week titration period, 25-week evaluation period, and 4-week safety follow-up period.
255077|NCT02253667|Device|HFONC|
255078|NCT02253667|Device|Conventional oxygen therapy|
255079|NCT02253680|Procedure|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
255080|NCT02253706|Device|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
255081|NCT02253706|Device|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
255082|NCT00146003|Drug|Efalizumab treatment|
255083|NCT02255825|Procedure|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
255365|NCT02249039|Drug|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
255366|NCT02249052|Drug|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
255367|NCT02249052|Drug|placebo|Placebo
255368|NCT02249065|Drug|Brimonidine|
255369|NCT02249078|Drug|E6011|E6011 solution for injection
255370|NCT00145457|Procedure|Radiography|
255371|NCT02249078|Drug|Placebo|Placebo 2-mL vial solution for injection
255372|NCT02249091|Drug|Selinexor|Patients receive Selinexor 40 mg/m2 twice weekly orally
255373|NCT02249091|Drug|Idarubcin|infusion, iv, 10 mg/m2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
255374|NCT02249091|Drug|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m2, iv,
255375|NCT02249104|Drug|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|
255376|NCT02249104|Other|Cetaphil Acne Regimen|
255377|NCT02249117|Drug|BIWH 3|
254757|NCT02260388|Drug|Pregabalin|
254758|NCT00146861|Device|sensor programming|
254759|NCT02260388|Drug|Mexiletine|
254760|NCT02260401|Other|Individualized report|Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
254761|NCT02260414|Drug|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
254762|NCT02260414|Other|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
254763|NCT02260427|Device|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
254764|NCT02260427|Device|Insertion of the air-Q sp|
254765|NCT02260440|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
254766|NCT02260440|Drug|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
254767|NCT02260453|Other|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
254768|NCT02260453|Other|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
254769|NCT00146874|Device|cardiac resynchronization therapy|
254770|NCT02260466|Other|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
254771|NCT02260479|Procedure|Preheated|Skin disinfection solution is preheated in a warming cupboard
254772|NCT02260492|Drug|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
254773|NCT02260492|Drug|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
254774|NCT02260492|Drug|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
254775|NCT02260505|Drug|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
254776|NCT02262624|Drug|Hydrochlorthiazide (HCTZ)|
259199|NCT02468648|Drug|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
259200|NCT02468661|Drug|INC280 single agent|
259201|NCT02468661|Drug|INC280 in combination with erlotinib|
259202|NCT02468661|Drug|Platinum/pemetrexed|
259203|NCT00174694|Drug|Telithromycin|
259204|NCT02468674|Drug|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 45.
259205|NCT02468674|Drug|Placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 45.
254440|NCT02267499|Other|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
254441|NCT02267512|Drug|ATG-F|iv
254442|NCT02267525|Drug|Velusetrag|
254443|NCT02267525|Drug|Placebo|
254444|NCT02267538|Drug|dexmedetomidine hydrochloride for injection|Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).
Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.
At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery.
254445|NCT02267538|Drug|0.9% sodium chloride for injection|Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.
Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.
At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation after surgery.
254446|NCT02267551|Other|Mimic dv-Trainer|
254447|NCT02267551|Other|daVinci Skills Simulator|
254448|NCT02267564|Procedure|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
254449|NCT00147784|Drug|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
254450|NCT02267564|Procedure|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
258928|NCT02475031|Drug|Placebo|Placebo Group (TAP-S) (TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter Both groups will receive single shot TAP block with 30ml 0.5% ropivacaine at the end of case
258929|NCT02475031|Drug|ropivacaine|The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter Both groups will receive single shot TAP block with 30ml 0.5% ropivacaine at the end of case
258930|NCT02475031|Drug|Oxycodone/Acetaminophen|
258931|NCT02475044|Behavioral|Cognitive-Behavioral Therapy|16 Sessions of CBT.
258932|NCT02475057|Drug|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
258933|NCT02475057|Drug|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
258934|NCT02475057|Device|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
258935|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
259206|NCT02468674|Drug|bimagrumab low/moderate/high to placebo switch|Placebo will be administered as an intravenous infusion starting on Day 1 until week 45.
259207|NCT02468674|Drug|Placebo/Placebo switch|Placebo will be administered as an intravenous infusion starting on Day 1 until week 45.
259208|NCT02468687|Drug|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
259209|NCT02468700|Drug|Sustained release dexamethasone, 0.4mg|
259210|NCT02468700|Device|Placebo punctum plug, no drug|
259211|NCT02468713|Drug|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
259212|NCT02468713|Drug|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
259213|NCT02468726|Device|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
259214|NCT00174707|Drug|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
259215|NCT02468726|Drug|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
259216|NCT02470923|Behavioral|Medical advice|
258635|NCT02479425|Procedure|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
258636|NCT02479438|Other|Diagnosed with GERD|Recording of patient outcomes
258637|NCT02479451|Drug|Theophylline|The study medication will be provided by Foundation Care.
258638|NCT02479464|Genetic|Genotyping results|Genotyping results provided in Phase II
258639|NCT02479477|Other|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
258640|NCT00176436|Behavioral|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
258641|NCT02481674|Drug|VX15/2503|VX15/2503 is a humanized IgG4 monoclonal antibody and will be dosed intravenously at 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
258642|NCT02481674|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
258643|NCT02481687|Other|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
258644|NCT02481700|Procedure|Third molar removal|The surgical removal of third molars by local or general anaesthesia
258645|NCT02481713|Behavioral|motivational interviewing|motivational interviewing
258646|NCT02481713|Behavioral|learning style interviews|interview and feedback about learning style
258936|NCT02475070|Drug|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
258937|NCT02475070|Drug|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
258938|NCT02475083|Other|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
258939|NCT02475083|Other|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
258350|NCT02486328|Drug|Propofol|Dosage adjustment
258351|NCT02486341|Drug|Insulin|Continuous glucose monitoring system over 120-hour period.
258352|NCT02486354|Drug|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
258353|NCT02486367|Drug|Clopidogrel|Standard ADP receptor blockade
258354|NCT00176839|Procedure|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
258355|NCT02486367|Drug|Ticagrelor|High potency ADP receptor blockade
258356|NCT02486380|Device|Simplus/Eson|Released product Simplus and Eson masks
258357|NCT02486393|Procedure|Parotid surgery|Surgery of the parotid gland tumours
258358|NCT02486406|Drug|ombitasvir|
258359|NCT02486406|Drug|paritaprevir|
258360|NCT02486406|Drug|ritonavir|
258361|NCT02486406|Drug|dasabuvir|
258362|NCT02486406|Drug|ribavirin|
258363|NCT02486419|Other|Outdoor weather|Seasonal changes in temperature
258364|NCT02488291|Drug|0.1% ropivacaine|0.1% ropivacaine
258365|NCT00176969|Drug|Capsaicin|
258366|NCT02488304|Radiation|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.
An upper airway (UA) scan will be taken on visit 2.
258367|NCT02488317|Other|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
258368|NCT02488330|Drug|Control treatment|Patients on treatment at the completion of the P-trial, defined as when relevant efficacy and safety analyses for the trial are completed by the Sponsor, should be enrolled immediately thereafter into this E-trial. Patients will receive treatment with either the control treatment or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first).
257780|NCT02497313|Drug|Metformin|
257781|NCT02499341|Drug|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
257782|NCT02499354|Drug|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
257783|NCT02499354|Drug|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
257784|NCT02499367|Drug|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
257785|NCT02499367|Radiation|Radiation therapy|20 Gy to metastatic lesion
258055|NCT02492789|Biological|SHR-1210 injection|Part1:SHR-1210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.
Part2:Additional patients (tentatively, 1, 3 and 10 mg/kg dose cohorts. The dose cohorts may be modified, based on the objective data achieved from Part 1, to facilitate RP2D identification and preliminary anti-tumor activities of SHR-1210) will be enrolled in Part 2 , depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of SHR-1210 as well as the other objectives of the study.
258056|NCT02492802|Drug|posaconazole|collection plasma samples for measuring posaconazole drug concentration
258057|NCT02492841|Drug|Mineral trioxide aggregate|Mineral trioxide aggregate
258058|NCT02492841|Drug|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
258059|NCT02492841|Drug|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
258060|NCT02492854|Device|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
258061|NCT02492854|Other|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
258062|NCT00002481|Drug|cisplatin|
258063|NCT00177567|Drug|lamotrigine|
258064|NCT02492867|Radiation|Response-driven Adaptive Radiation Therapy|
258065|NCT02492867|Drug|Carboplatin|
253882|NCT02251015|Procedure|occlusal plate|In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
253883|NCT02251015|Procedure|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
253884|NCT02253030|Device|Optical Coherence Tomography|
253885|NCT02253043|Device|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
253886|NCT02253056|Other|Fasting / Caloric Restriction|
253887|NCT02253056|Other|Healthy Diet|
253888|NCT02253069|Device|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
253889|NCT02253069|Device|Applying Placebo to tie-over dressings|Placebo control
253890|NCT00145925|Drug|Perindopril-indapamide|
253891|NCT02253082|Drug|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
253892|NCT02253082|Biological|Fresh frozen plasma|Standard FFP from the Blood Bank
253893|NCT02253095|Drug|Albendazole|
253894|NCT02253095|Dietary Supplement|Zinc|
253895|NCT02253095|Dietary Supplement|Multiple Micronutrient Supplement|
253896|NCT02253095|Drug|Placebo|
253897|NCT02253108|Device|Everolimus eluting bioresorbable polymer stent|
253898|NCT02253108|Device|Biolimus eluting bioresorbable polymer stent|
253899|NCT02253121|Drug|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
253276|NCT02264574|Drug|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
253277|NCT02264587|Drug|Mosapride|Mosapride 5mg by mouth ,3 times one day for 1 4days.
253278|NCT02264587|Drug|domperidone|Domperidone 10mg by mouth ,3 times one day for 1 4days.
253279|NCT02264613|Drug|ALRN-6924|ALRN-6924 will be administered as an IV infusion over a 1-hour period
253280|NCT02264626|Drug|Remifentanil|infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
253281|NCT02264639|Drug|APL-2|
253282|NCT02264652|Device|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
253283|NCT00147485|Drug|AG-024322|
253284|NCT02264665|Drug|sunitinib|sunitinib 37.5mg/d orally
253285|NCT02264665|Drug|everolimus|everolimus 10mg/d orally
253286|NCT02264665|Drug|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
253584|NCT02257580|Drug|E-Aminocaproic acid|E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
253585|NCT00146562|Drug|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
253586|NCT02257593|Other|Dietary protein|Persons were fed
Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein
253587|NCT02257606|Other|I-TRAVLE training|
253588|NCT02257619|Drug|INCB039110|INCB039110 tablets administered orally at dose defined in the protocol for Part 1 of the study and the dose selected from Part 1 based on the data available for use in Part 2 of the study.
253589|NCT00146783|Drug|Sulphadoxine-pyrimethamine|
253590|NCT02259868|Drug|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
253591|NCT02259868|Drug|BILR 355 BS - Suspension low dose|
252952|NCT02271737|Behavioral|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
252953|NCT02271750|Procedure|lumbar puncture|for spinal fluid
252954|NCT02271763|Other|ultrasound|subjects' neck will be scanned using ultrasound
252955|NCT00148135|Drug|Capecitabine|
252956|NCT02271776|Dietary Supplement|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
252957|NCT02271776|Dietary Supplement|maltodextrin|
252958|NCT02271789|Other|problematic tooth|problematic tooth
252959|NCT02271802|Dietary Supplement|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
252960|NCT02271802|Dietary Supplement|NaCl|
252961|NCT02271815|Other|Oral Hygiene|Oral Hygiene
252962|NCT02271828|Procedure|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
252963|NCT02271841|Device|PVI|Pleth Variability Index
252964|NCT02271854|Drug|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily
252965|NCT02271867|Procedure|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
252966|NCT00148148|Drug|caspofungin|
252967|NCT02271880|Other|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
253287|NCT02267070|Behavioral|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
253288|NCT00147732|Radiation|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
253289|NCT02267070|Behavioral|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
257550|NCT02474654|Drug|Fentanyl|15mcg
257551|NCT02476630|Device|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
257552|NCT02476630|Other|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
257553|NCT00175734|Procedure|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
257554|NCT02476643|Other|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
257555|NCT02476682|Other|blood or stool samples will be collected|blood or stool samples will be collected
257556|NCT02476695|Device|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
257557|NCT02476695|Device|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
257558|NCT02476695|Device|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
257559|NCT02476708|Dietary Supplement|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
257560|NCT02476708|Dietary Supplement|Placebo|oral placebo capsule
257561|NCT02476721|Other|detection of pulmonary embolism|
257562|NCT02476734|Biological|CART-19 autologous T-cells|
257563|NCT02476734|Radiation|FDG-PET/CT|
257564|NCT00175734|Procedure|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
257565|NCT02476747|Other|EMR|performing EMR for patients with small polyp
257566|NCT02476747|Other|CSP|performing CSP for patients with small polyp
257860|NCT02470403|Drug|Placebo|Matching placebo tablets
256964|NCT00146120|Drug|Cytosin-Arabinosid|
256965|NCT02254317|Dietary Supplement|0 mg placebo|Not containing GSE (Placebo)
256966|NCT02254317|Dietary Supplement|300 mg GSE|300 mg GSE
256967|NCT02254317|Dietary Supplement|600 mg GSE|Containing 600 mg of GSE
256968|NCT02254317|Dietary Supplement|900 mg GSE|Containing 900 mg of GSE
256969|NCT02254343|Device|proximal robot-assisted therapy|
257274|NCT02481219|Drug|Metoclopramide|
257275|NCT02481219|Drug|Erythromycin|
257276|NCT02481219|Drug|SUPREP oral sulfate solution|
257277|NCT02481219|Drug|Bisacodyl|
257278|NCT00176358|Behavioral|Exercise Training|
257279|NCT02481219|Drug|SUPREP oral sulfate solution with Gastrografin|
257280|NCT02481232|Biological|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
257281|NCT02481245|Drug|Bezafibrate|30 patients with Bipolar I disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of lithium (.6 to 1.0 meq/L).
257282|NCT02481258|Drug|Ataciguat (HMR1766)|
257283|NCT02481258|Other|Placebo Comparator: Matching Placebo|
257284|NCT02481271|Behavioral|relaxation program|relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises
1 week program, one introductory session and daily home practice
257285|NCT02481271|Behavioral|surgery education|intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery
1 single unit in the week before the surgery
257286|NCT00176527|Genetic|polyacrylamide gel electrophoresis|
257287|NCT02483403|Other|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
257288|NCT02483403|Device|MRI|
256614|NCT02258737|Behavioral|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
256615|NCT02258750|Dietary Supplement|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
256616|NCT02258750|Other|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
256617|NCT02258763|Drug|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
256618|NCT02258763|Drug|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
256619|NCT02258776|Dietary Supplement|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
256620|NCT00146679|Behavioral|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
256621|NCT02258776|Dietary Supplement|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
256622|NCT02258776|Dietary Supplement|Placebo|Placebo will be taken 1/day for 12 weeks.
256623|NCT02258789|Other|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
256970|NCT02254343|Device|distal robot-assisted therapy|
256971|NCT02254343|Behavioral|individualized intensive therapy|
256972|NCT02254356|Device|Zilver Flex Bare Metal Stent|
256973|NCT02254369|Drug|GC021109|
256974|NCT02254369|Other|Placebo|
256975|NCT00146120|Drug|Etoposide|
256976|NCT02254382|Device|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
256977|NCT02254395|Device|Deep Brain Stimulation|
256978|NCT02254408|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
256625|NCT02258815|Drug|ch14.18/CHO|A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.
Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year.
256626|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
256627|NCT00146926|Drug|kétamine 20mg|
256628|NCT02260934|Biological|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
256629|NCT02260947|Drug|PF-06273340|PF-06273340 50 mg
256630|NCT02260947|Drug|PF-06273340|PF-06273340 400 mg
256631|NCT02260947|Drug|Pregabalin|Pregabalin 300 mg
256632|NCT02260947|Drug|Ibuprofen|Ibuprofen 600 mg
256633|NCT02260947|Drug|Placebo|Matching Placebo
256634|NCT02260960|Dietary Supplement|Omega-3 (Triglyceride form)|
256635|NCT02260973|Dietary Supplement|Omega-3 (Triglyceride form)|
256636|NCT02260986|Drug|dupilumab|
256637|NCT02260986|Drug|placebo|
256638|NCT00146926|Drug|ephedrine 3mg|
256639|NCT02261025|Drug|acetylsalicylic acid|75-100mg,per day
256640|NCT02261038|Other|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
256641|NCT02261051|Other|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
256642|NCT02261064|Drug|Telmisartan/Amlodipine low dose|
256643|NCT02261064|Drug|Telmisartan/Amlodipine high dose|
256644|NCT02261064|Other|Japanese meal|
256645|NCT02261077|Drug|Hyoscine butylbromide|
256996|NCT02256722|Drug|Propranolol|
256011|NCT02272985|Other|[15O]H2O PET-CT scan|All participants will undergo 3 [15O]H2O PET-CT scans during the hemodialysis study session
256311|NCT02265848|Other|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
256312|NCT00147576|Drug|CP-866,087|
256313|NCT02265861|Drug|HCG|
256314|NCT02265874|Drug|Habitrol|Patch used daily for 28 weeks
256315|NCT02265874|Drug|Placebo to Habitrol|
256316|NCT02265887|Other|standard of care|No intervention, this a patient registry and is purely an observational study
256317|NCT02265900|Other|Exercise|Vigorous exercise
256318|NCT02265900|Other|Exercise|Light exercise
256319|NCT02265913|Drug|Acyclovir 5 percent (Perrigo)|
256320|NCT02265913|Drug|Acyclovir 5 percent (Reference)|
256321|NCT02265913|Drug|Placebo cream|
256322|NCT00147836|Drug|Gliclazide (Diamicron, Servier)|
256323|NCT02268188|Other|nutritional intervention|Undergo Harvesting Health program
256324|NCT02268188|Behavioral|exercise intervention|Undergo Harvesting Health program
256325|NCT02268188|Other|questionnaire administration|Ancillary studies
256326|NCT02268188|Other|laboratory biomarker analysis|Correlative studies
256327|NCT02268188|Other|quality-of-life assessment|Ancillary studies
256328|NCT02268201|Drug|Advagraf|oral
256329|NCT02268201|Drug|Prograf|oral
256330|NCT02268214|Drug|Dapagliflozin|
256331|NCT02268214|Drug|Placebo for Dapagliflozin|
255696|NCT02241512|Drug|placebo|
255697|NCT02241538|Device|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
255698|NCT00144521|Drug|MTX|8mg/week(p.o.) for 24 weeks
255699|NCT02241538|Device|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
256012|NCT00148343|Other|Conventional Standard of Care|Conventional standard of care (which may include implementation & use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
256013|NCT02272985|Other|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
256014|NCT02272998|Drug|ponatinib hydrochloride|Given PO
256015|NCT02275546|Drug|Placebo vaginal ring|Drug-free placebo vaginal ring
256016|NCT02275546|Device|Single-use, non-sterile applicator|Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
256017|NCT02275559|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
256018|NCT02275559|Behavioral|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
256019|NCT02275572|Procedure|Pharmacist Intervention|
256020|NCT02275585|Other|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
256021|NCT02275598|Drug|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
256022|NCT02275598|Drug|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
256023|NCT02275611|Drug|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
256024|NCT02275611|Drug|Intranasal Placebo Spray|Intranasal Placebo Spray
256025|NCT00148603|Drug|montelukast|
255378|NCT02249117|Drug|Placebo|
255379|NCT02249130|Drug|Tipranavir (TPV)|
255380|NCT02249130|Drug|Ritonavir (RTV)|
255381|NCT00145470|Drug|Asenapine|Asenapine fast dissolving tablets 5 and 10 mg; starting dose 5 mg BID 1 day; 10 mg BID after Day 1
255382|NCT02249130|Drug|Delavirdine (DLV)|
255383|NCT02249130|Drug|Zidovudine (ZDV)|
255384|NCT02249130|Drug|Lamivudine (3TC)|
255385|NCT02249130|Drug|Stavudine (d4T)|
255386|NCT02249143|Device|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
255387|NCT02249156|Behavioral|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
255388|NCT02249182|Drug|LDV/SOF|LDV/SOF FDC tablet(s) administered orally once daily
255700|NCT02241538|Device|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
255701|NCT02241538|Device|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
255702|NCT02244151|Drug|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
255703|NCT02244164|Drug|Incretinomimetics|
255704|NCT00144846|Drug|albuterol sulfate inhalation aerosol|
255705|NCT02244164|Drug|DPP-4 inhibitors|
255706|NCT02244190|Drug|Tipranavir|New oral solution (back up) formulation
255707|NCT02244190|Drug|Tipranavir|
255708|NCT02244190|Drug|Ritonavir|
255084|NCT02255825|Other|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
255085|NCT02255838|Device|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
255086|NCT02255838|Device|Bronchoscope disposable (aScope 3)|Bronchoscopy and alveolar lavage
255087|NCT00146328|Drug|Tipranavir|
255088|NCT02255851|Device|SENTINEL (Cerebral Protection System)|
255089|NCT02255864|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
255090|NCT02255877|Device|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
255091|NCT02255877|Device|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
255092|NCT02255903|Other|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
255093|NCT02255916|Other|Music|live sound-bed music intervention
255094|NCT02255929|Radiation|Gamma Knife Radiosurgery|
255095|NCT02255942|Other|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
255096|NCT02255942|Other|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
255097|NCT02255942|Other|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
255098|NCT00146341|Drug|Telmisartan/HCTZ|
255099|NCT02255942|Other|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
255100|NCT02255955|Drug|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
255101|NCT02255955|Drug|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
255102|NCT02255955|Drug|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
255103|NCT02255968|Drug|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
255104|NCT02255968|Drug|Placebo|Matching placebo capsules. All interventions are given as multiple doses
254451|NCT02267577|Device|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
254452|NCT02267603|Other|Laboratory Biomarker Analysis|Ancillary studies
254453|NCT02267603|Biological|Pembrolizumab|Given IV
254454|NCT02267616|Device|Etonogestrel Implant|Subdermal arm implant
254455|NCT02267629|Drug|GLYX-13|10 mg/kg IV GLYX-13
254456|NCT02267642|Biological|AbGn-168H|monoclonal antibody
254457|NCT02269917|Drug|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) as per current treatment regimen.
254458|NCT02269917|Drug|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
254459|NCT02269930|Drug|peginterferon beta-1a|Administered as subcutaneous injection
254777|NCT02262624|Drug|Telmisartan/HCTZ fixed combination|
254778|NCT02262637|Drug|Micardis®|
254779|NCT02262637|Drug|MicardisPlus®|
254780|NCT02262650|Drug|Telmisartan|
254781|NCT00147225|Drug|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
254782|NCT02262650|Drug|Clopidogrel|
254783|NCT02262663|Drug|Vilaprisan (BAY1002670)|
254784|NCT02262676|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
254785|NCT02262689|Drug|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
254786|NCT02262689|Drug|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
254787|NCT02262702|Drug|Paracetamol 665 mg|Paracetamol 665 mg tablet
254788|NCT02262702|Drug|Paracetamol 500 mg|Paracetamol 500 mg tablet
254789|NCT02262715|Drug|VX-787|Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
259217|NCT02470936|Behavioral|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
259218|NCT02470949|Behavioral|Manipulated Social Status|The participants will be randomized to either the Low Social Status Condition or the High Social Status condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
259219|NCT02470962|Other|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
259220|NCT02470988|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|
259221|NCT02470988|Behavioral|CBASP Without DPI|
259222|NCT02471001|Biological|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
259223|NCT00174941|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
259224|NCT02471014|Drug|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
259225|NCT02471014|Other|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
254460|NCT02269930|Drug|Rebif|Administered as subcutaneous injection
254461|NCT02269943|Drug|CC-486|
254462|NCT02269956|Behavioral|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
254463|NCT02269969|Drug|Tobramycin|
254464|NCT02269982|Device|AR-v7 assays|
254465|NCT02269995|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
254466|NCT00148005|Procedure|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
254467|NCT02270008|Other|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
254468|NCT02270021|Device|Mobile Application (APP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
258940|NCT02475096|Behavioral|Internet-delivered CBT|The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.
Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
258941|NCT02475109|Drug|PAN-90806 Ophthalmic Solution|
258942|NCT02475122|Other|azygos blood flow measurements by MRI|
258943|NCT02475135|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
258944|NCT02475135|Drug|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
258945|NCT02475135|Drug|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
258946|NCT00175448|Procedure|physiotherapy|See Detailed Description.
258947|NCT02475135|Drug|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
258948|NCT02475135|Drug|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
258949|NCT02477098|Drug|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
258950|NCT02477098|Drug|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
258951|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg/day in a double-blinded way for the 7-week Treatment period
258952|NCT02477111|Device|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
258953|NCT02477124|Device|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
259226|NCT02471014|Other|Questionnaires|All participants will answer the following questionnaires:
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.
258647|NCT02481726|Radiation|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
258648|NCT02481739|Other|retrospective study|
258649|NCT02481752|Other|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
258650|NCT02481752|Other|SHAM Training|
258651|NCT00176449|Drug|Bupropion SR|
258652|NCT02481765|Device|High definition transcranial direct current stimulation|
258653|NCT02481778|Other|Blood sampling|
258654|NCT02481791|Drug|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
258655|NCT02481791|Drug|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
258656|NCT02481791|Drug|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
258657|NCT02481804|Other|Dietary intervention|Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.
Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts.
258658|NCT02481804|Other|Standard treatment|Standard treatment will be continued
258659|NCT02483975|Drug|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
258660|NCT02483975|Drug|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
258661|NCT02483975|Drug|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
258066|NCT02492867|Drug|Paclitaxel|40 mg/m^2 IV
258067|NCT02492867|Device|FDG-PET|
258068|NCT02492867|Device|V/Q SPECT|
258069|NCT02495181|Drug|IVT Aflibercept; Sham PDT|
258070|NCT02495194|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
258071|NCT02495207|Device|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
258072|NCT02495220|Drug|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
258073|NCT02495220|Drug|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
258369|NCT02488330|Biological|Onartuzumab|Onartuzumab will be administered intravenously at either a dose of 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks.\nPatients on treatment at the completion of the P-trial, defined as when relevant efficacy and safety analyses for the trial are completed by the Sponsor, should be enrolled immediately thereafter into this E-trial. Patients will receive treatment with either the control treatment or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first).
258370|NCT02488343|Behavioral|Behavioral Intervention|Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
258371|NCT02488356|Dietary Supplement|Litramine|
258372|NCT02488369|Device|PET / CT|
258373|NCT02488382|Drug|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
258374|NCT02488395|Other|fMRI|The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
258375|NCT02488395|Other|Ophthalmologic evaluation|The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
258376|NCT00176982|Drug|Hydroxychloroquine|
253900|NCT02253121|Drug|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
253901|NCT00145925|Drug|Gliclazide MR-based glucose lowering|
254216|NCT02246322|Device|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
254217|NCT02246322|Device|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
254218|NCT02246335|Device|Cemented total hip arthroplasty|
254219|NCT02246335|Device|Cemented hemiarthroplasty|
254220|NCT02246348|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
254221|NCT02246361|Procedure|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
254222|NCT02246374|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
254223|NCT02246387|Procedure|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
254224|NCT02246400|Behavioral|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
254225|NCT00145093|Drug|Baker’s yeast (Bio Chromium)|
254226|NCT02248571|Drug|Everolimus|administered as combined therapy with Exemestane
254227|NCT02248571|Drug|Exemestane|administered as combined therapy with Everolimus
254228|NCT02248571|Other|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
254229|NCT02248584|Dietary Supplement|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
254230|NCT02248597|Drug|fludarabine phosphate|Given IV
254231|NCT02248597|Drug|busulfan|Given IV
254232|NCT02248597|Drug|cyclophosphamide|Given IV
254233|NCT00145431|Drug|torcetrapib/atorvastatin|
253592|NCT02259868|Drug|BILR 355 BS - Suspension high dose|
253593|NCT02259868|Drug|Ritonavir|
253594|NCT02259881|Drug|Low dose of BIBT 986 CL, per i.v. infusion|
253595|NCT02259881|Drug|Medium dose of BIBT 986 CL, per i.v. infusion|
253596|NCT02259881|Drug|High dose of BIBT 986 CL, per i.v. infusion|
253597|NCT02259881|Drug|Placebo|
253598|NCT02259881|Drug|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
253599|NCT02259894|Drug|BIRT 2584 XX|
253600|NCT00146783|Drug|Sulphadoxine-pyrimethamine, amodiaquine|
253601|NCT02259894|Drug|Placebo|
253602|NCT02259907|Drug|KUC 7483 CL|
253603|NCT02259907|Drug|Placebo|
253604|NCT02259907|Other|High fat meal|
253605|NCT02259920|Drug|KUC 7483 CL, immediate release tablet|
253606|NCT02259920|Drug|KUC 7483 CL, particulate formulation|
253902|NCT02253160|Device|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
253903|NCT02253160|Device|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
253904|NCT02253160|Drug|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
253905|NCT02253173|Drug|Estradiol|
253906|NCT02253173|Drug|Placebo|
253907|NCT02253186|Device|Auto-Adjustable MOBIDERM Armsleeve|
253908|NCT00146250|Drug|Nitrous oxide|
253290|NCT02267083|Drug|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
253291|NCT02267096|Behavioral|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
253292|NCT02267096|Behavioral|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
253293|NCT02267109|Biological|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
253294|NCT02267109|Biological|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
253295|NCT02267122|Procedure|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
253296|NCT02267122|Procedure|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
253297|NCT02267135|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
253298|NCT02267135|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
253607|NCT02259920|Drug|KUC 7483 CL, solution formulation|
253608|NCT02259920|Device|Enterion™ capsule|
253609|NCT02259933|Drug|KUC 7483 CL|
253610|NCT02259933|Drug|Placebo|
253611|NCT00146796|Device|Rapid diagnostic test for malaria|
257861|NCT02470416|Device|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
257862|NCT02470429|Device|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
257863|NCT02470429|Device|Hyabak 0.15% eye drops|Preservative-free
257864|NCT02470429|Drug|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
257865|NCT00174915|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
257866|NCT02470442|Drug|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
257867|NCT02470442|Drug|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
257868|NCT02470455|Drug|Atorvastatin|Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
257869|NCT00175097|Other|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
257870|NCT02472600|Drug|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
257871|NCT02472613|Device|acupuncture|Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).
The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.
257872|NCT02472613|Drug|placebo|Placebo was given for 12 consecutive weeks.
257873|NCT02472613|Device|sham-acupoint acupuncture|Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.
• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.
257874|NCT02472613|Drug|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
257875|NCT02472626|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
257289|NCT02483429|Device|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
257290|NCT02483455|Drug|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
257291|NCT02483455|Drug|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
257292|NCT02483468|Behavioral|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
257293|NCT02483468|Device|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
257567|NCT02476760|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
257568|NCT02476760|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
257569|NCT02476760|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
257570|NCT02476760|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
257571|NCT02476760|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
257572|NCT02478866|Drug|BPI9016M|Seven dose cohorts will be evaluated, including 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. BPI9016M will be administered orally to patients once daily for each dose cohort.
257573|NCT02478879|Drug|ZP-PTH|Patch applied daily for 30 minutes, 14 days
257574|NCT02478879|Drug|FORTEO|Subcutaneous injection administration daily for 14 days
257575|NCT02478892|Device|prophylactic endoscopic ultrasound|The patients will be followed up clinically with routine, prophylactic endoscopic ultrasound surveillance every 12 months for a duration of 5 years.
257576|NCT02478905|Other|Influenza|
257577|NCT02478918|Other|Phone call|Automated phone call reminder
257578|NCT00176059|Drug|intravenous immunoglobulins (IVIG)|
256979|NCT02256683|Drug|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
256980|NCT02256696|Drug|PA-824|200 mg QD
256981|NCT02256696|Drug|Rifampin|
256982|NCT02256696|Drug|Rifabutin|
256983|NCT02256696|Drug|Pyrazinamide|
256984|NCT02256696|Drug|Ethambutol|
256985|NCT02256696|Drug|Isoniazid|
256986|NCT02256709|Drug|BIBP 5371 CL tablet|single rising daily doses
256987|NCT02256709|Drug|BIBP 5371 CL solution|
256988|NCT02256709|Other|High fat, high caloric breakfast|
256989|NCT00146445|Behavioral|Peer Mentoring Intervention|
256990|NCT02256709|Drug|Placebo tablet|
256991|NCT02256709|Drug|BIBP 5371 CL tablet high dose|
256992|NCT02256709|Drug|Placebo drinking solution|
256993|NCT02256709|Drug|BIBP 5371 CL tablet low dose|
256994|NCT02256722|Drug|KUC 7483 CL|
256995|NCT02256722|Drug|Bisoprolol|
257294|NCT02483468|Device|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
257295|NCT02483481|Procedure|shear wave ultrasound elastography|
257296|NCT02483494|Other|APN-led Telemedicine|Allocation to experimental or Usual care is 1:1.
The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention.
257297|NCT00002476|Drug|leucovorin calcium|
257298|NCT00176527|Genetic|protein expression analysis|
256997|NCT02256722|Drug|Acipimox|
256998|NCT02256722|Drug|Salmeterol|
256999|NCT02256735|Drug|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
257000|NCT00146458|Procedure|18F-fluorodeoxyglucose positron emission tomography|
257001|NCT02256735|Drug|Treatment B|
257002|NCT02256735|Drug|Treatment C|
257003|NCT02256735|Drug|Treatment D|
257004|NCT02256735|Drug|Placebo|
257005|NCT02256735|Drug|Moxifloxacin|
257006|NCT02256748|Drug|BIRT 2584 XX|
257007|NCT02256748|Drug|Midazolam|
257008|NCT02256761|Drug|BIRT 2584 XX - multiple escalating dose|
257009|NCT02256761|Drug|Placebo|
257010|NCT02256761|Drug|BIRT 2584 XX - single dose|
257011|NCT00002355|Drug|Fomivirsen sodium|
257012|NCT02258828|Drug|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
257013|NCT02258841|Behavioral|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
257014|NCT02258841|Behavioral|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
257015|NCT02258841|Behavioral|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
257016|NCT02258841|Behavioral|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
257017|NCT00146679|Behavioral|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
256332|NCT02268240|Behavioral|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
256333|NCT00147836|Drug|Diamicron and Glucophage|
256646|NCT02261077|Drug|Placebo|
256647|NCT02261090|Drug|Formulation B: Pramipexole Slow release (SR) tablet|
256648|NCT02261090|Drug|Formulation C: Pramipexole Slow release tablet|
256649|NCT00146926|Drug|lidocaine 40mg|
256650|NCT02261090|Drug|Formulation D: Pramipexole Slow release tablet|
256651|NCT02261090|Drug|Formulation E: Pramipexole Slow release tablet|
256652|NCT02261090|Drug|Formulation F: Pramipexole Slow release tablet|
256653|NCT02261090|Drug|Formulation G: Pramipexole Slow release tablet|
256654|NCT02261090|Drug|Formulation H: Pramipexole Slow release tablet|
256655|NCT02261090|Drug|Pramipexole immediate release (IR) tablets|
256656|NCT02261103|Drug|Pramipexole ER tablets|
256657|NCT02261103|Drug|Pramipexole IR tablets|
256658|NCT02263391|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
256659|NCT00147303|Drug|MCI-9042|
256660|NCT02263404|Device|Deep Brain Stimulation|DBS Implant Stimulation
256661|NCT02263417|Device|Deep Brain Stimulation (DBS) of Gpi|
256662|NCT02263417|Device|Deep Brain Stimulation (DBS) of STN|
256663|NCT02263430|Device|Deep Brain Stimulation|
256664|NCT02263443|Procedure|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
256026|NCT02275637|Device|implantable cardioverter defibrillator|
256027|NCT02275650|Radiation|nbUVB|2 SED nbUVB exposure will be given every other week
256028|NCT02275663|Drug|Azacytidine|
256029|NCT02275663|Drug|Fludarabine|
256030|NCT02275663|Drug|Cytarabine|
256031|NCT02275663|Drug|Filgrastim|G-CSF
256032|NCT02275676|Other|bioelectrical impedance analysis|
256033|NCT02275676|Other|indirect calorimetry|
256334|NCT02268253|Drug|SL-401|
256335|NCT02268266|Device|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
256336|NCT02268279|Drug|solithromycin|
256337|NCT02268292|Behavioral|bicycle exercise|All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
256338|NCT02268305|Drug|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
256339|NCT02268305|Other|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
256340|NCT02268318|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
256341|NCT02268318|Other|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
256342|NCT02268331|Other|Active Surveillance|
256343|NCT02268331|Other|Passive Surveillance|
256344|NCT00147849|Behavioral|mailing of printed educational materials|
256345|NCT02270645|Device|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
256346|NCT02270658|Device|CPAP|
256347|NCT02270671|Behavioral|ABMT|Attention Bias Modification Training
255709|NCT02244203|Drug|BI 60732|
255710|NCT02244203|Drug|Placebo|
255711|NCT02244216|Drug|Berotec® N 100 µg Metered-dose Inhaler|
255712|NCT02244229|Drug|Tamsulosin|
255713|NCT02244229|Drug|Finasteride|
255714|NCT02244229|Drug|Placebo|
255715|NCT00144859|Drug|SB681323|
255716|NCT02244242|Drug|Tamsulosin hydrochloride|
255717|NCT02244255|Drug|FLOMAX® capsules|
255718|NCT02244255|Drug|Ascending doses of HYTRIN® capsules|
255719|NCT02244268|Drug|ALNA®|
255720|NCT02244281|Drug|tamsulosin hydrochloride|
255721|NCT02244281|Drug|Placebo|
255722|NCT02244294|Drug|FLOMAX® capsules|
255723|NCT02244294|Drug|Placebo capsules|
255724|NCT02244307|Drug|alpha-adrenergic blocker|
255725|NCT02244320|Drug|Tamsulosin|
255726|NCT00144872|Drug|lamotrigine|
256034|NCT02275689|Procedure|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
256035|NCT02275689|Procedure|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
256036|NCT00148616|Drug|Memantine|Daily dosage of 10mg Memantine vs. Placebo
256037|NCT02275702|Drug|Dexamethasone IV|It will be administered at the induction of the anesthesia
256038|NCT02275702|Drug|Saline solution|
256039|NCT02275715|Behavioral|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
255105|NCT02255981|Other|Traditional Chinese Medicine (TCM) Acupuncture|Treatment consist in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.
255106|NCT02255994|Device|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
255389|NCT02249182|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF FDC tablet administered orally once
255390|NCT02249182|Drug|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
255391|NCT02249208|Device|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
255392|NCT00145470|Drug|placebo|Placebo fast dissolving tablets BID
255393|NCT00145678|Behavioral|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
255394|NCT02251379|Drug|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
255395|NCT02251392|Other|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
255396|NCT02251392|Other|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
255397|NCT02251392|Drug|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
255398|NCT02251405|Behavioral|One bag, stainless container|
255399|NCT02251418|Device|Extracorporeal shockwave therapy|
255400|NCT02251431|Drug|BYDUREON|Exenatide-extended release
255401|NCT02251431|Drug|Placebo|
255402|NCT02251444|Procedure|outpatient rehabilitation program|
255403|NCT02251444|Procedure|physical therapy|
255404|NCT00002348|Drug|Mitoguazone|
255405|NCT00145691|Drug|Oxcarbazepine|
255406|NCT02251457|Drug|Ranolazine|Ranexa is FDA approved for chronic angina
255407|NCT02251470|Other|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
254790|NCT02262715|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
254791|NCT02262715|Other|Placebo|Participants will receive placebo matching to VX-787 either two times a day or or once a day.
254792|NCT00002362|Drug|Abacavir sulfate|
254793|NCT00147225|Drug|Adriamycin|75-90 mg/m^2 IV
254794|NCT02262728|Drug|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
254795|NCT02262728|Drug|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
254796|NCT02262728|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
254797|NCT02262741|Biological|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
254798|NCT02262741|Biological|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
254799|NCT02262754|Drug|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
254800|NCT02262754|Drug|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
254801|NCT02262754|Drug|Naproxen|500 mg BID for 4 weeks
255107|NCT02255994|Procedure|No mesh.|Patients in this arm had subvesical plication without reinforcement.
255108|NCT02256020|Other|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
255109|NCT00146341|Drug|Telmisartan|
255110|NCT02258126|Other|Multidisciplinary intervention program|Exercise group:
The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months.
255111|NCT02258152|Drug|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
255112|NCT02258152|Drug|Placebo|Placebo QD
255113|NCT02258165|Device|PET/CT|PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By "freezing" this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images.
255114|NCT02258178|Biological|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
254469|NCT02270021|Device|Patient-Centered Approach (PCA) + APP|Patient-Centered Approach (PCA): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.
APP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
254470|NCT02270034|Drug|Crizotinib|Crizotinib is added to Stupp method
254471|NCT02270047|Dietary Supplement|Orange nectar|Orange nectar
254472|NCT02270047|Dietary Supplement|Orange Nectar with fibre|
254473|NCT02270060|Other|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
254474|NCT02270060|Other|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
254475|NCT02270073|Behavioral|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
254476|NCT02270112|Device|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
254477|NCT00002367|Drug|Zidovudine|
254802|NCT02262767|Drug|PF-06649751|Experimental Pfizer compound.
254803|NCT02262767|Drug|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
254804|NCT00147225|Drug|Ifosfamide|10 gm/m^2 IV; OR, High dose ifosfamide = 14 gm/m^2.
254805|NCT02265172|Procedure|Standard practice|Orthopaedic surgeon assessment
254806|NCT02265211|Behavioral|Self-Help App|
254807|NCT02265224|Drug|Acetylcysteine|
254808|NCT02265237|Drug|ombitasvir/ABT-450/ritonavir|tablets
254809|NCT02265237|Drug|Ribavirin|tablets
254810|NCT02265250|Other|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
254811|NCT02265250|Other|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
259227|NCT02471027|Procedure|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
259228|NCT02471040|Drug|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
259229|NCT02471040|Other|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
259230|NCT02471053|Other|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
259231|NCT02471066|Device|rTMS|Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham
Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session
259232|NCT02471079|Radiation|Radiotherapy|
259233|NCT02471092|Other|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
259234|NCT00174954|Procedure|MRI|Subjects underwent MRI to evaluate tophi.
259235|NCT02471105|Drug|Preserved Bimatoprost 0.1%|Eye drops solution Topical use Once in the evening 3 months
259236|NCT02473094|Drug|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
259237|NCT02473094|Drug|Metformin|Metformin up to 2500mg/d
259238|NCT02473094|Radiation|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
259239|NCT02473094|Drug|Placebo|Placebo up to 2500mg/d
259240|NCT02473107|Other|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
259241|NCT02473107|Other|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
254478|NCT02272322|Device|cystocele repair with biomesh soft prolaps and endofast reliant|
258662|NCT02483988|Device|NUsurface® Meniscus Implant|The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
258954|NCT02477124|Other|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
258955|NCT02477137|Device|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
258956|NCT02477150|Biological|Zostavax|Vaccination of a zoster vaccine (Zostavax)
258957|NCT02477150|Biological|placebo|placebo administration
258958|NCT02477176|Other|Discectomy|Lumbar discectomy
258959|NCT02477189|Procedure|Silicone Block|
258960|NCT02477202|Device|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into 14 volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) at Memorial Sloan Kettering Cancer Center (MSK). FTF tissue (and ovarian inclusion cyst tissue) collected at the time of RRSO will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
258961|NCT02477215|Drug|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
258962|NCT00175825|Drug|Brivaracetam 20 mg/day|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg/day in a double-blinded way for the 7-week Treatment period
258963|NCT02477215|Drug|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
258964|NCT02477215|Drug|Bendamustine|Bendamustine dose levels:
Dose 1: 70 mg/m2, days 1 and 2 Dose 2: 80 mg/m2. days 1 and 2 Dose 3: 90 mg/m2, days 1 and 2
258965|NCT02477228|Procedure|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
258966|NCT02477228|Procedure|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
258967|NCT02477241|Procedure|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
249669|NCT02199002|Device|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
249670|NCT02199015|Device|Lateral spinal cord surgical implant of electrodes|The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.
A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG).
249671|NCT02199028|Drug|Hyaluronidase|If assigned to hyaluronidase week, subjects will inject 1 milliliter (ml) Hylenex (150 units/ml) into the catheter hub prior to connecting the insulin infusion set. They will then give a catheter fixed prime of 0.7 cc to clear the infusion set of hyaluronidase. On the morning of day 3 during a Hyaluronidase week, a second dose of 1ml Hylenex (150 units/1ml) will be injected through the catheter hub prior to breakfast using the Duo Infusion Set Tubing. They will then reconnect their pump catheter and give a fixed prime of 0.7 cc to clear the infusion set of hyaluronidase.
249672|NCT02199041|Drug|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
249673|NCT02199041|Drug|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
249674|NCT00139594|Drug|licarbazepine|
249675|NCT02199041|Drug|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
249676|NCT02199041|Drug|Melphalan|Given by intravenous infusion as part of the preparative regimen.
249677|NCT02199041|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
249678|NCT02199041|Biological|G-CSF|Given either by intravenous infusion or subcutaneously daily until ANC >2000 for 3 consecutive days.
249679|NCT02199041|Drug|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
249680|NCT02199041|Drug|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
249681|NCT02199041|Drug|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
249682|NCT02201602|Drug|Gliclazide|
249683|NCT02201602|Drug|Glibenclamide|
249684|NCT00139971|Drug|UFT 250mg/m2, daily for 1 year|
249685|NCT02201615|Other|Perineal massage in childbirth|
249686|NCT02201628|Device|Nasopharyngeal and oesophageal temperature probes|
254234|NCT02248597|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
254235|NCT02248597|Drug|tacrolimus|
254236|NCT02248597|Drug|mycophenolate mofetil|
254237|NCT02248610|Other|Non-interventional study|
249352|NCT02206217|Device|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
249353|NCT02206230|Radiation|Hypofractionated radiation therapy|
249354|NCT02206230|Radiation|Standard radiation therapy|
249355|NCT02206243|Drug|Embozene Microspheres|Intraarterial application
249356|NCT02206256|Drug|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
249357|NCT02206256|Behavioral|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
249358|NCT02206269|Device|Alair System|The Alair system is used for doing bronchial thermoplasty.
249359|NCT02206295|Drug|selexipag|
249360|NCT00140582|Drug|Rituximab|one infusion of rituximab (375 mg/m2) every 2 months for 2 years
249361|NCT02206308|Biological|Chimeric anti-CD20 monoclonal antibody|
249362|NCT02206321|Procedure|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
249363|NCT02206321|Procedure|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
249364|NCT02206334|Radiation|Stereotactic Radiosurgery|Undergo SBRT
249365|NCT02206347|Behavioral|attention focus|
249366|NCT02206360|Procedure|Endoscopic Ultrasound|
249367|NCT02206360|Procedure|Magnetic Resonance Imaging (MRI)|
249368|NCT02206386|Other|MHTraining-Net|See Arm Description for more details.
249369|NCT02206386|Other|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
253909|NCT02255396|Other|ESTRADIOL|
253910|NCT02255409|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
253911|NCT02255409|Biological|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
253912|NCT02255422|Drug|Omaveloxolone capsules, 2.5 mg|
253913|NCT02255422|Drug|omaveloxolone capsules, 5 mg|
253914|NCT02255422|Drug|omaveloxolone capsules, 10 mg|
253915|NCT02255422|Drug|Placebo capsules|
253916|NCT02255422|Drug|omaveloxolone capsules, 20 mg|
253917|NCT02255422|Drug|omaveloxolone capsules, TBD mg|
253918|NCT02255435|Drug|Omaveloxolone Capsules, 2.5 mg|
253919|NCT00146263|Behavioral|computerized cognitive training|
253920|NCT02255435|Drug|Omaveloxolone Capsules, 5 mg|
253921|NCT02255435|Drug|Omaveloxolone Capsules, 10 mg|
253922|NCT02255435|Drug|Placebo|
253923|NCT02255435|Device|Omaveloxolone Capsules, 20 mg|
253924|NCT02255435|Drug|Omaveloxolone Capsules, TBD mg|
254238|NCT02248636|Drug|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
254239|NCT02248636|Drug|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
254240|NCT02248649|Behavioral|Structured exercise|Walking instruction and encouragement
254241|NCT02248649|Behavioral|Health education|Provision of general information about a variety of health topics
Provision of general information about a variety of health
254242|NCT02248675|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
253612|NCT02259946|Drug|BI 1744 CL|
253613|NCT02259946|Drug|Placebo|
253614|NCT02259946|Drug|Tiotropium bromide|
253615|NCT02259959|Drug|Single rising doses of BI 1744 CL, solution for oral inhalation|
253616|NCT02259959|Drug|Tiotropium, fixed dose, solution for oral inhalation|
253617|NCT02259959|Drug|Placebo|
253618|NCT02259972|Drug|BI 113823 solution|
253619|NCT02259972|Drug|BI 113823 tablet|
253620|NCT02259972|Drug|Placebo|
253621|NCT02259972|Other|High fat, high calorie breakfast|only for dose group 5
253622|NCT00002359|Biological|HIV-1 Immunogen|
253623|NCT02262169|Drug|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
253624|NCT00147147|Drug|Gastrectomy+ chemotherapy|
253625|NCT02262169|Drug|Placebo capsule of Omeprazole|2 placebo capsules of DLBS2411, once daily
253626|NCT02262182|Other|KP group|
253627|NCT02262182|Other|KM group|
253628|NCT02262195|Other|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
253629|NCT02262208|Other|Aerobic Exercises|Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.
Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test.
253630|NCT02262208|Other|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
253925|NCT02255448|Device|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
253926|NCT02255461|Drug|palbociclib isethionate|Given PO
253927|NCT02255461|Other|pharmacological study|Correlative studies
257876|NCT02472626|Drug|Cytarabine|Given IV
258149|NCT02276625|Biological|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
258150|NCT02276638|Device|Specular Microscope|Nidek CEM-530
258151|NCT02276638|Device|Specular Microscope|Konan CELLCHECK XL
258152|NCT00148681|Drug|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
258153|NCT02276664|Behavioral|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
258154|NCT02276664|Behavioral|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
258155|NCT02276677|Drug|Oxytocin|Single dose, intranasal
258156|NCT02276677|Drug|Placebo|Single dose, intranasal
258157|NCT02468167|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
258158|NCT02468167|Drug|N-butyl-2-cyanoacrylate|
258159|NCT02468167|Drug|Lauromacrogol|
258160|NCT02468180|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
258161|NCT02468180|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
258162|NCT02468180|Drug|N-butyl-2-cyanoacrylate|
258163|NCT02468180|Drug|Lauromacrogol|
258164|NCT02468193|Drug|Osilodrostat|Osilodrostat will be prescribed by the investigator. Osirodrostat 1 mg, 5 mg, 10 mg, 20 mg in the form of film-coated tablets will be used for oral administration
258165|NCT02468206|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
258166|NCT02468206|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
258167|NCT00174655|Drug|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
258168|NCT02468206|Drug|N-butyl-2-cyanoacrylate|
258169|NCT02468206|Drug|Lauromacrogol|
257579|NCT02478944|Device|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
257580|NCT02478957|Drug|PA101|40 mg PA101 administered via inhalation three times daily for 6 weeks
257581|NCT02478957|Drug|Placebo|matching placebo administered via inhalation three times daily for 6 weeks
257582|NCT02478970|Device|Konan SP4000|current standard of care at Kellogg Eye Center
257583|NCT02478970|Device|NIDEK CEM-350|newly marketed device
257584|NCT02478983|Device|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
257585|NCT02478983|Device|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
257877|NCT02472626|Drug|Daunorubicin Hydrochloride|Given IV
257878|NCT02472639|Device|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
257879|NCT02472652|Drug|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
257880|NCT00175097|Other|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
257881|NCT02472665|Drug|plasma-derived FVIII/VWF concentrate Fanhdi|1 single dose of 80 IU VWF:RCof/kg of Fanhdi will be administered
257882|NCT02472678|Other|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
257883|NCT02472678|Other|Standard care|The control group will receive standard care.
257884|NCT02472691|Drug|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
257885|NCT02472691|Drug|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
257886|NCT02474654|Drug|Epimorphine|150mcg
257299|NCT02483507|Other|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
257300|NCT02483520|Behavioral|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
257301|NCT02483533|Drug|Salmeterol|
257302|NCT02483546|Device|Laerdal®|simulation- based educational intervention
257303|NCT02483546|Behavioral|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
257304|NCT02483546|Behavioral|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
257305|NCT00176800|Drug|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
257306|NCT02485743|Other|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
257307|NCT02485756|Other|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
257308|NCT02485769|Drug|PF-06650833|
257309|NCT02485769|Drug|Placebo|
257310|NCT02485782|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
257586|NCT02478996|Other|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
257587|NCT02479009|Device|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
257018|NCT02258841|Behavioral|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
257311|NCT02485782|Device|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
257312|NCT02485782|Device|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
257313|NCT02485795|Other|Observational|This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
257314|NCT02485808|Other|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
257315|NCT02485821|Drug|Estradiol|
257316|NCT00176800|Procedure|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
257317|NCT02485821|Drug|Placebo|
257318|NCT02485821|Drug|Misoprostol|
257319|NCT02485834|Procedure|Positron emission tomography|Undergo FDG-PET
257320|NCT02485834|Procedure|gastrectomy|Undergo surgery
257321|NCT02485834|Drug|5-fluorouracil|200 mg/m^2/day IV
257322|NCT02485834|Drug|capecitabine|oral 800 mg/m^2 BID
257323|NCT02485834|Drug|docetaxel|30 mg/m^2 IV
257324|NCT02485834|Drug|Irinotecan|50 mg/m^2 IV
257325|NCT02485834|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET
257326|NCT02485834|Radiation|3-Dimensional conformal radiation therapy|Undergo 3D-CRT
257327|NCT00176800|Procedure|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
257328|NCT02485834|Radiation|Intensity modulated radiation therapy|Undergo IMRT
257329|NCT02485847|Procedure|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
257330|NCT02485860|Device|Melectis G|
256665|NCT02263443|Procedure|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
256666|NCT02263443|Procedure|No enema|Patients NPO groups will NPO and no bowel preparation.
256667|NCT02263456|Biological|Replenine®-VF (High Purity Factor IX)|
256668|NCT02263469|Biological|Replenine®-VF (High Purity Factor IX)|
256669|NCT02263482|Other|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
256670|NCT00002362|Drug|Efavirenz|
256671|NCT00147316|Drug|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
257019|NCT02258854|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
257020|NCT02258867|Drug|Placebo|Solution for subcutaneous injection
257021|NCT02258867|Drug|Gevokizumab|Solution for subcutaneous injection
257022|NCT02258880|Drug|SUN13837|
257023|NCT02258880|Drug|placebo|
257024|NCT02258893|Other|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
257025|NCT02258893|Other|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
257026|NCT02258893|Other|Control|a "control" filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
257027|NCT02258906|Drug|ulinastatin|
257028|NCT00146679|Behavioral|Usual Care|Usual Care provided by providers
257029|NCT02258919|Procedure|Decompressive craniectomy (DC) and best medical treatment|Decompressive craniectomy:
All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.
Best medical treatment:
Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
257030|NCT02258919|Procedure|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
257031|NCT02258971|Drug|BEA 2180 BR oral|Oral solution
257032|NCT02258971|Drug|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
256348|NCT02270671|Other|Placebo|Placebo Training
256349|NCT00148031|Behavioral|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
256350|NCT02270684|Device|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
256351|NCT02270697|Device|Array|Applications of oligonucleotide array in diagnosis.
256352|NCT02270723|Drug|5% Human Albumin " Behring"|Intravenous infusion of 5% Human Albumin during major surgery
256353|NCT02270723|Drug|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
256354|NCT02270736|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
256355|NCT02270736|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
256672|NCT02263482|Other|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
256673|NCT02263482|Other|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
256674|NCT02263495|Drug|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
256675|NCT02263495|Drug|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
256676|NCT02263495|Drug|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
256677|NCT02263508|Drug|talimogene laherparepvec|Phase 1b: talimogene laherparepvec will be administered by intralesional injection at Day 1, Week -5; then every 2 weeks starting at Day 1, Week -2; Phase 3, Arm 1 talimogene laherparepvec will be administered by intralesional injection at Day 1 Week 0, 3, 5, 7 then every 3 weeks starting at Day 1 Week 9.
256678|NCT02263508|Drug|pembrolizumab (MK-3475)|Phase 1b: pembrolizumab will be administered intravenously every 2 weeks starting at Day 1 Week 0; Phase 3, Arm 1 and Arm 2 pembrolizumab will be administered intravenously on Day 1 Week 0, then every 3 weeks starting at Day 1 Week 3.
256679|NCT02263508|Drug|placebo|Phase 3, Arm 2 placebo will be administered by intralesional injection at Day 1 Week 0, 3, 5, 7 then every 3 weeks starting at Day 1 Week 9.
256680|NCT02263521|Other|No intervention employed. Study is based on a cross-sectional observational design.|
256681|NCT02265926|Device|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
256040|NCT02275728|Other|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
256041|NCT02239250|Device|Water filter and cookstove|The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's "highly protective" standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices.
256042|NCT02239276|Drug|Stiripentol|The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
256043|NCT00144300|Drug|Requip|Standard marketed product dispensed according to manufacturer's guidelines
256044|NCT02239289|Other|Biofeedback|Idem as described in the arm section (above)
256045|NCT02239315|Other|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
256046|NCT02239341|Other|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
256047|NCT02239341|Other|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
256048|NCT02239354|Device|VC-01™ Combination Product|Biologic and Device
256049|NCT02239367|Behavioral|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
256356|NCT02270749|Drug|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
256357|NCT02270749|Drug|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
256358|NCT02270762|Other|Rest in bed|
256359|NCT02270762|Other|Passive verticalization|
255408|NCT02251470|Other|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
255409|NCT02251483|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|
255410|NCT02251483|Other|Placebo|
255411|NCT02251496|Other|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
255727|NCT02244333|Drug|ALNA®|
255728|NCT02244346|Drug|Secotex®|
255729|NCT02244359|Behavioral|Training|
255730|NCT02244359|Behavioral|Usual care|
255731|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 0.76 g|
255732|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.15 g|
255733|NCT02244372|Dietary Supplement|Placebo|
255734|NCT02244385|Other|no intervention|
255735|NCT02244398|Other|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
255736|NCT02244398|Other|FP services|VHTs in the control arm only provide family planning services
255737|NCT02246816|Drug|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
255738|NCT02246829|Procedure|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
255739|NCT02246842|Biological|D-Gam® (human anti-D immunoglobulin)|
255740|NCT02246842|Biological|Rhophylac® (human anti-D immunoglobulin)|
255741|NCT02246855|Biological|Gammaplex® (Human Normal Immunoglobulin)|
255742|NCT02246868|Biological|Optivate® (Human Coagulation Factor VIII)|
255743|NCT00145184|Drug|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
255744|NCT02246881|Biological|Optivate® (Human Coagulation Factor VIII)|
255115|NCT02258191|Device|telemonitoring|
255116|NCT02258191|Device|sham telemonitoring|
255117|NCT00146601|Drug|Fulvestrant|
255118|NCT02258204|Drug|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
255119|NCT02258204|Drug|Placebo|
255120|NCT02258217|Drug|Acthar|Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
255121|NCT02258230|Device|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
255122|NCT02258230|Device|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
255123|NCT02258243|Drug|aminolevulinic acid hydrochloride|Applied topically
255124|NCT02258243|Drug|photodynamic therapy|Undergo PDT using blue light on the left side of the body and red light on the right side of the body
255125|NCT02258243|Drug|photodynamic therapy|Undergo PDT using blue light on the right side of the body and red light on the left side of the body
255126|NCT02258243|Other|laboratory biomarker analysis|Correlative studies
255127|NCT02258243|Other|questionnaire administration|Ancillary studies
255128|NCT00146614|Drug|Sirolimus|
255412|NCT02251496|Other|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
255413|NCT02251509|Drug|Carvedilol|
255414|NCT02251509|Drug|Metoprolol tartrate|
255415|NCT02251535|Device|ATTUNE® Knee System|
255416|NCT00145704|Drug|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
255417|NCT02251535|Device|PFC® SIGMA® Knee System|
255418|NCT02251548|Drug|Ibrutinib|Oral BTK inhibitor
255419|NCT02251548|Drug|Fludarabine|IV purine analogue chemotherapy agent
254812|NCT00147524|Procedure|Laser Doppler imaging|
254813|NCT02265250|Other|Laboratory blood test|Cardiovascular biomarkers
254814|NCT02265276|Drug|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
254815|NCT02265276|Drug|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
254816|NCT02265289|Drug|Lefradafiban|
254817|NCT02265289|Drug|Clopidogrel|
254818|NCT02265302|Drug|BIIL 284 oral solution|
254819|NCT02265302|Drug|BIIL 284 wetability improved formulation (WIF) tablets|
254820|NCT02265302|Drug|Placebo|
254821|NCT02265315|Other|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
254822|NCT02265315|Behavioral|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
254823|NCT00147537|Drug|CP-751,871|Phase 2 Arm A:
CP‑751,871 20 mg/kg IV over 2.5 hours up to 17 cycles
254824|NCT02265328|Dietary Supplement|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
254825|NCT02265328|Dietary Supplement|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
254826|NCT02265328|Other|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. (If Lilli score > 0.45 after 7 days, then prednisolone would be stopped)
255129|NCT02258256|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
255130|NCT02258269|Other|SQ|
255131|NCT02258269|Other|Control|
255132|NCT02258282|Drug|Etanercept|
255133|NCT02258282|Drug|Control|
255134|NCT02258295|Drug|Synvisc|Synvisc consists of Hylan A & B. Synvisc is available with a concentration of 16mg/2cc.
255135|NCT02258295|Drug|Intragel|Intragel has an average molecular weight of 800-1200 KDaltons.
254479|NCT02272335|Behavioral|Group Sessions|10 weekly sessions:
CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.
CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain
254480|NCT02272348|Other|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
254481|NCT02272348|Other|Usual diabetes management.|
254482|NCT02272361|Other|laparoscopic sacrocolpopexy|
254483|NCT02272361|Other|vaginal mesh surgery|
254484|NCT02272374|Procedure|AVF creation|
254485|NCT02272374|Procedure|TCC placement|
254486|NCT02272374|Procedure|AVG creation|
254487|NCT00002369|Drug|Indinavir sulfate|
254488|NCT00148252|Drug|Mycophenolate mofetil withdrawal|
254489|NCT02272387|Dietary Supplement|Vitamin D3 (Cholecalciferol)|
254490|NCT02272387|Other|Placebo|
254491|NCT02272400|Radiation|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
254492|NCT02272413|Drug|Chemotherapy|
254493|NCT02272413|Drug|BI 695502|
254494|NCT02272413|Drug|bevacizumab|
254495|NCT02272413|Drug|Chemotherapy|
254496|NCT02272426|Behavioral|CARET|Combined Aerobic and Resistance Exercise Training
254497|NCT02272426|Behavioral|CTI|Cognitive Training Intervention
254498|NCT02272426|Behavioral|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
254499|NCT00148252|Drug|Cyclosporione A withdrawal|
258968|NCT02477241|Device|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
258969|NCT02479490|Drug|Prednisone + Everolimus|Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.
A treatment cycle consists of 28 days.
258970|NCT02479503|Procedure|Antibiotic prophylaxis in adult heart transplantation|
258971|NCT02479516|Behavioral|Community Health Assessment Program Philippines (CHAP-P)|
259242|NCT02473120|Biological|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
259243|NCT02473133|Radiation|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
259244|NCT02473133|Radiation|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
259245|NCT02473146|Drug|Gemtuzumab ozogamicin (GO)|
259246|NCT00175188|Device|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
259247|NCT02473159|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
259248|NCT02473172|Device|Pressure Support ventilation|Assisted mechanical ventilation
259249|NCT02473172|Device|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
259250|NCT02473185|Drug|Methylphenidate|Cross-over
259251|NCT02473198|Drug|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
259252|NCT02473198|Drug|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
249687|NCT02201641|Radiation|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
249984|NCT02234050|Drug|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
249985|NCT00002333|Drug|Saquinavir|
249986|NCT00143702|Drug|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
249987|NCT02234050|Other|Local standard of care|Left to the discretion of the investigator
249988|NCT02234063|Other|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
249989|NCT02234076|Behavioral|VRET|
249990|NCT02234076|Behavioral|TAU|Treatment as usual offered by the participating mental health care organisations
249991|NCT02234089|Drug|Degarelix|According to medical practice
249992|NCT02234089|Drug|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
249993|NCT02234102|Device|Endoscopically guided laser ablation HeartLight system|
249994|NCT02234115|Drug|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
249995|NCT02234128|Device|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
249996|NCT02234141|Drug|GS-4997|GS-4997 tablet administered orally once daily
249997|NCT00143715|Drug|Phytonadione (Vitamin K1)|1.25 mg given orally
249998|NCT02234141|Drug|Placebo to match GS-4997|Placebo to match GS-4997 tablets administered orally once daily
249999|NCT02236481|Drug|Anakinra|
250000|NCT02236481|Drug|TNF alpha inhibitors|
250001|NCT02236494|Behavioral|Brief Negotiated Interview|As per arm
250002|NCT02236494|Behavioral|General Health Information|As per arm (this is the active comparator)
249370|NCT02206425|Drug|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
249371|NCT00140894|Drug|Comparator: placebo / Duration of Treatment: 24 weeks|
249372|NCT02208687|Behavioral|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
249373|NCT02208687|Other|Control group|Usual care
249374|NCT02208700|Other|Oxepa|Therapeutic nutrition with EPA, GLA< and antioxidants
249375|NCT02208700|Other|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
249688|NCT02201641|Radiation|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
249689|NCT02201641|Device|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
249690|NCT02201641|Device|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
249691|NCT02201654|Other|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
249692|NCT02201667|Drug|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
249693|NCT02201667|Drug|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
249694|NCT02201667|Drug|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
249695|NCT00139984|Device|24 hour blood pressure measurement|
249696|NCT02201667|Procedure|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
249697|NCT02201693|Dietary Supplement|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
249698|NCT02201693|Dietary Supplement|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
249699|NCT02201706|Procedure|Multi-electrocoagulation retinectomy|a modified surgery named "multi-electrocoagulation retinectomy" to re-attach the retina.
All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.
Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process.
254243|NCT02248675|Other|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
254244|NCT00002347|Drug|Saquinavir|
254245|NCT00145431|Drug|atorvastatin|
254246|NCT02248688|Device|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
254247|NCT02248688|Procedure|Left Gastric Artery Embolization|
254248|NCT02248701|Drug|testosterone enanthate, finasteride|Subjects receive testosterone (125 mg/week) by intramuscular injection and finasteride (5 mg/day) orally
254249|NCT02248701|Drug|placebo|Subjects receive weekly placebo injection and placebo pill daily
254250|NCT02248714|Dietary Supplement|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
254251|NCT02251028|Behavioral|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
254252|NCT02251041|Drug|Antithrombin-III|
254253|NCT02251041|Drug|Infliximab|
254254|NCT02251041|Drug|Apotransferrin|
254255|NCT02251041|Drug|Human recombinant erythropoietin|
254256|NCT02251041|Drug|C1-Inhibitor|
254257|NCT02251041|Drug|Glutathione|
254258|NCT00145626|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
254259|NCT02251041|Drug|Alfa-tocopherol|
249376|NCT02208713|Biological|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
249377|NCT02208726|Other|Sucrose pillules|Unmedicated sucrose pillules
249378|NCT02208726|Other|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
253928|NCT02255461|Other|laboratory biomarker analysis|Correlative studies
253929|NCT02255474|Device|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
253930|NCT00146276|Drug|gemcitabine|
253931|NCT02255474|Device|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
253932|NCT02255474|Device|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
253933|NCT02255487|Device|IrriSept System|The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.
Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation.
253934|NCT02255487|Other|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) only surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
253935|NCT02257619|Drug|Placebo|Matching placebo tablets to be administered by mouth at dose defined in the protocol for Part 1 of the study and the dose selected from Part 1 based on the data available for use in Part 2 of the study.
253936|NCT02257619|Drug|docetaxel|Administered as an intravenous infusion in the clinic at the frequency defined in the protocol for Part 1 of the study and the dose selected from Part 1 based on the data available for use in Part 2 of the study.
253937|NCT02257632|Drug|Ranibizumab|0.5 mg intravitreal injections
253938|NCT02257632|Drug|Aflibercept|2 mg intravitreal injections
253939|NCT02257658|Drug|Doxycycyline|
253940|NCT02257658|Behavioral|Incentive|
253941|NCT02257671|Drug|Oral contraceptive|Neovletta
253942|NCT00146562|Drug|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
253943|NCT02257684|Drug|pegcrisantaspase|
253944|NCT02257697|Drug|Mizoribine (MZR)|
253945|NCT02257697|Drug|Cyclophosphamide (CTX)|
254260|NCT02251041|Drug|Melatonin|
254261|NCT02251041|Drug|Epoprostenol|
258170|NCT02468219|Behavioral|cardiovascular rehabilitation program|Phase I - respiratory muscle training and neuromuscular electrical stimulation 7x/week for 6 weeks.
Phase II - 8 weeks of supervised, structured, combined endurance and resistance training.
258171|NCT02468232|Drug|LCZ696|LCZ696 50 mg, 100 mg, 200 mg film-coated tablets
258172|NCT02468232|Drug|Enalapril|Enalapril 2.5 mg, 5 mg, 10 mg film-coated tablets
258458|NCT02497612|Other|Placebo|Capsules Placebo capsules are used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No patient will receive placebo only.
258459|NCT02497625|Behavioral|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
258460|NCT02497625|Behavioral|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
258461|NCT02497625|Other|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
258462|NCT02499653|Behavioral|Videos|
258463|NCT02499666|Procedure|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
258464|NCT02499666|Device|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
258465|NCT02499666|Drug|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
258466|NCT00178646|Drug|Botox|Botox 75-150 units, single treatment only
258467|NCT02499692|Device|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
258468|NCT02499705|Dietary Supplement|Sucralose|2 packets
258469|NCT02499705|Dietary Supplement|Sucrose|equisweet to sucralose
258470|NCT02499705|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
258471|NCT02499718|Device|BiPAP mode|Noninvasive ventilator
257887|NCT02474654|Drug|Normal Saline|0.3 ml
257888|NCT02474654|Drug|Normal Saline|30ml
257889|NCT02474654|Drug|Normal Saline|100 ml
257890|NCT00175409|Procedure|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
257891|NCT02474654|Drug|Ropivicaine|100 ml
257892|NCT02474654|Drug|Epinephrine|600 mcg
257893|NCT02474654|Drug|Ketorolac|30 mg
257894|NCT02474654|Drug|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
257895|NCT02474667|Drug|BB3|
257896|NCT02474667|Other|Placebo|
257897|NCT02474680|Genetic|Pharmacogenetic testing|Psychotropic genotyping panel
257898|NCT02474706|Drug|Cefoxitin|
257899|NCT02474706|Drug|imipenem|
258173|NCT02468232|Drug|Placebo to LCZ696|Placebo to match LCZ696 50 mg, 100 mg and 200 mg film-coated tablets
258174|NCT02468232|Drug|Placebo to Enalapril|Placebo to match enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets
258175|NCT02468245|Behavioral|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
258176|NCT02468245|Behavioral|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
258177|NCT02468258|Procedure|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
258178|NCT00174655|Drug|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
258179|NCT02468284|Drug|degarelix|
257588|NCT02479022|Drug|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
257589|NCT00176059|Procedure|kidney transplantation|
257590|NCT02479022|Drug|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
257591|NCT02479022|Drug|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
257592|NCT02479035|Dietary Supplement|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
257593|NCT02481284|Device|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
257594|NCT02481297|Drug|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
257595|NCT02481297|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
257596|NCT00176371|Behavioral|physical exercise|
257597|NCT02481310|Drug|Cyclophosphamide|Given IV
257598|NCT02481310|Drug|Cytarabine|Given IT or intraventricularly
257599|NCT02481310|Drug|Doxorubicin Hydrochloride|Given IV
257600|NCT02481310|Drug|Etoposide|Given IV
257601|NCT02481310|Drug|Ixazomib Citrate|Given PO
257602|NCT02481310|Other|Laboratory Biomarker Analysis|Correlative studies
257603|NCT02481310|Drug|Methotrexate|Given IT or intraventricularly
257604|NCT02481310|Drug|Prednisone|Given PO
257605|NCT02481310|Biological|Rituximab|Given IV
257606|NCT02481310|Drug|Therapeutic Hydrocortisone|Given IT or intraventricularly
257607|NCT00002475|Drug|cyclophosphamide|
257900|NCT02474719|Other|comparison of two regimens in peritoneal dialysis|Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
257331|NCT02487979|Drug|Glembatumumab Vedotin|Given IV
257332|NCT02487979|Other|Laboratory Biomarker Analysis|Correlative studies
257333|NCT02487979|Other|Pharmacological Study|Correlative studies
257334|NCT02487992|Biological|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
257608|NCT00176384|Behavioral|Aerobic endurance exercise training (ergometer)|
257609|NCT02481310|Drug|Vincristine Sulfate|Given IV
257610|NCT02481323|Drug|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
257611|NCT02481323|Drug|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
257612|NCT02481336|Other|Questionnaires|EORTC CIPN20 and EQ-5D-3L
257613|NCT02481336|Procedure|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
257614|NCT02481336|Genetic|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
257615|NCT02481349|Other|Hatha Yoga|Participants and their caregivers take part in up to 12 sessions of Hatha yoga over the course of radiation therapy (2-3 weekly sessions for usually 5-6 weeks). Most of the yoga sessions may be videotaped.
257616|NCT02481349|Behavioral|Hatha Yoga Questionnaires|During each week of radiation therapy, participant completes a questionnaire about the Hatha yoga sessions.
257617|NCT02481349|Behavioral|Quality of Life Questionnaires|Participant completes about 9 questionnaires before first radiation treatment, and again after completion of radiation treatment schedule (usually 6 weeks later). The questionnaires ask about participant's health, symptoms, mood, level of fatigue, sleeping habits, relationship, and quality of life. It should take about 45 minutes to complete these questionnaires.
257618|NCT02481362|Other|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
257619|NCT00176397|Procedure|Percutaneous coronary intervention (left main)|
257620|NCT02483559|Device|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (~470 nm) to be worn prior to desired sleep onset time.
257621|NCT02483559|Device|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
257033|NCT02261103|Drug|Placebo matching Pramipexole ER tablets|
257034|NCT02261103|Drug|Placebo matching Pramipexole IR tablets|
257035|NCT00146952|Device|Vibrotactile feedback|
257036|NCT02261103|Other|Standard high-fat breakfast|
257037|NCT02261116|Drug|Telmisartan|
257038|NCT02261116|Drug|Candesartan|
257039|NCT02261116|Drug|Placebo|
257040|NCT02261129|Drug|Telmisartan film-coated tablet|
257041|NCT02261129|Drug|Telmisartan uncoated tablet|
257042|NCT02261142|Device|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
257335|NCT02488005|Device|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
257336|NCT02488018|Other|Honey Glycemic Index|25g available carbohydrate provide for each subject after taking fasting blood glucose level, and blood samples will be taken with an interval of 15minuts for 2hr.
257337|NCT00176930|Drug|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
257338|NCT02488031|Behavioral|Error-reduction|During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.
The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed.
257339|NCT02488031|Behavioral|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
257340|NCT02488031|Behavioral|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
257341|NCT02488031|Behavioral|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
257342|NCT02488031|Behavioral|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
256682|NCT00147589|Drug|Eplerenone|
256683|NCT02265939|Drug|NPO-13|
256684|NCT02265952|Drug|REGN1500|
256685|NCT02265965|Drug|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
256686|NCT02265978|Device|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
256687|NCT02265991|Procedure|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
256688|NCT02266004|Device|Transcranial Direct Current Stimulation (tDCS)|anodal Transcranial Direct Current Stimulation (tDCS will be applied for 20 minutes at 2mA with IOMED Phoresor.
256689|NCT02266004|Other|locomotor training|An individualized training exercise for patients with Parkinson's disease.
256690|NCT02266004|Other|sham-tDCS|this is sham Transcranial Direct Current Stimulation (tDCS)
256691|NCT02266017|Behavioral|Pain Coping Skills Training|
256692|NCT02266030|Drug|Cilostazol|Pletaal as an active drug
257043|NCT02261155|Procedure|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
257044|NCT02261168|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
257045|NCT02261181|Device|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
257046|NCT00146978|Procedure|intra-arterial treatment|
257047|NCT02261194|Behavioral|Self-Care Tools|
257048|NCT02261207|Drug|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
257049|NCT02261220|Biological|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
257050|NCT02261220|Biological|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
256360|NCT00148044|Procedure|Blood sampling for determination of uremic toxins|
256361|NCT02270762|Other|Rest in bed|
256362|NCT02270788|Drug|Crenolanib|Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.
All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old.
256363|NCT02270788|Drug|Sorafenib|Days 8-28 of course 1: given orally once each day.
All subsequent courses: given orally on days 1-28 once per day
This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered.
256364|NCT02270788|Drug|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
256365|NCT02272998|Other|laboratory biomarker analysis|Correlative studies
256366|NCT02273011|Procedure|caesarean section|elective caesarean section under regional anesthesia
256367|NCT02273024|Behavioral|Exercise|
256368|NCT02273037|Device|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
256369|NCT02273037|Procedure|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
256370|NCT02273050|Drug|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
256371|NCT02273050|Drug|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
256372|NCT02273050|Drug|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
256373|NCT00002369|Drug|Lamivudine|
256374|NCT00148343|Procedure|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
256693|NCT00147602|Drug|atorvastatin|
256694|NCT02266030|Drug|Aspirin|Aspirin as an active comparator
256695|NCT02266043|Device|Pre-epiglottic baton plate (PEBP)|modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.
This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol.
255745|NCT02246894|Biological|Optivate® (Human Coagulation Factor VIII)|
255746|NCT02246907|Other|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
255747|NCT02246920|Drug|Fluticasone propionate|50 mcg/actuation Nasal Spray
255748|NCT02246920|Drug|Flonase®|50 mcg/actuation Nasal Spray
255749|NCT02246920|Drug|Placebo|Inactive Nasal Spray
256050|NCT02239380|Drug|Lorazepam|intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to < 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.
Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study.
256051|NCT02239393|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.
Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product).
256052|NCT02239419|Procedure|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
256053|NCT02239419|Procedure|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
256054|NCT00144313|Biological|hepatitis B vaccine|
256055|NCT02239445|Drug|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
256056|NCT02241551|Drug|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
256057|NCT02241551|Drug|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
256058|NCT02241564|Other|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
256059|NCT02241564|Drug|Switch from calcineurin inhibitor to an mTOR inhibitor|
255420|NCT02251548|Drug|Cyclophosphamide|IV alkylator chemotherapy agent
255421|NCT02253719|Procedure|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
255422|NCT02253732|Behavioral|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength & aerobic exercises
255423|NCT02253745|Drug|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
255424|NCT02253745|Drug|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
255425|NCT02253758|Drug|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
255426|NCT02253771|Device|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
255427|NCT02253784|Drug|Dexamethasone|
255428|NCT02253784|Drug|Bupivacaine|
255429|NCT02253797|Drug|14C-Tipranavir|
255430|NCT02253797|Drug|Tipranavir|
255431|NCT00146016|Drug|Amantadine|
255432|NCT02253797|Drug|Ritonavir|
255433|NCT02253810|Drug|Tranexamic Acid|
255434|NCT02253810|Drug|Placebo|
255435|NCT02253823|Drug|EFV|
255436|NCT02253823|Drug|TPV/RTV - low dose|
255750|NCT02246933|Other|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
255751|NCT02246933|Other|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
255752|NCT02246946|Device|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
255753|NCT02246946|Other|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
255136|NCT02260518|Behavioral|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
255137|NCT02260518|Behavioral|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
255138|NCT02260531|Drug|Cabozantinib|One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
255139|NCT02260531|Drug|Trastuzumab|For HER2-Positive participants only. Administered by IV on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
255140|NCT00146887|Procedure|coronary catheterization|
255141|NCT02260544|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
255142|NCT02260557|Drug|Selexipag|Selexipag 200 μg tablets administered orally twice daily (b.i.d.).
255143|NCT02260557|Drug|Placebo|Placebo matching selexipag 200 μg tablets will be administered orally b.i.d.
255144|NCT02260570|Drug|Tolcapone|COMT Inhibitor
255145|NCT02260570|Drug|Placebo|A pill that contains no active ingredient
255146|NCT02260583|Device|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
255437|NCT02253823|Drug|TPV/RTV - high dose|
255438|NCT02253836|Drug|Tipranavir|TPV
255439|NCT02253836|Drug|Ritonavir|RTV
255440|NCT02253836|Drug|Atazanavir|TAZ
255441|NCT02253849|Drug|Carbamazepine|
255442|NCT00146042|Drug|Docetaxel|
255443|NCT02253849|Drug|Tipranavir|
254500|NCT02272426|Behavioral|Sham CTI|Sham Cognitive Training Intervention
254827|NCT02265341|Drug|Ponatinib Hydrochloride|Given PO
254828|NCT02265341|Other|Laboratory Biomarker Analysis|Correlative studies
254829|NCT02265341|Other|Questionnaire Administration|Ancillary studies
254830|NCT02265341|Other|Quality-of-Life Assessment|Ancillary studies
254831|NCT02265354|Behavioral|Collective-Intelligence computer tailored health communication|
254832|NCT02265354|Behavioral|Rule-based computer tailored health communication|
254833|NCT02265367|Drug|Levomilnacipran|
254834|NCT00147537|Drug|paclitaxel|Phase 2 Arm A:
Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles
Phase 2 Arm B:
Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles
254835|NCT02267655|Drug|inhaled NO - 30 mcg/kg IBW/hr [4880 ppm]|inhaled NO in 30 mcg/kg IBW/hr doses [cylinder concentration of 4880 ppm (6.0 mg/L)]
254836|NCT02267655|Drug|inhaled NO - 25 mcg/kg IBW/hr [2440 ppm] - Seq 1|inhaled NO in 25 mcg/kg IBW/hr doses [cylinder concentration of 2440 ppm (3.0 mg/L)]
254837|NCT02267655|Drug|inhaled NO - 25 mcg/kg IBW/hr [4880 ppm] - Seq 1|inhaled NO in 25 mcg/kg IBW/hr doses [cylinder concentration of 4880 ppm (6.0 mg/L)]
254838|NCT00147810|Procedure|Telephone outreach to enhance asthma care|
254839|NCT02267655|Drug|inhaled NO - 25 mcg/kg IBW/hr [4880 ppm] - Seq 2|inhaled NO in 25 mcg/kg IBW/hr doses [cylinder concentration of 4880 ppm (6.0 mg/L)]
254840|NCT02267655|Drug|inhaled NO - 25 mcg/kg IBW/hr [2440 ppm] - Seq 2|inhaled NO in 25 mcg/kg IBW/hr doses [cylinder concentration of 2440 ppm (3.0 mg/L)]
254841|NCT02267668|Behavioral|STEP|Physical therapists guide participants through novel set of assigned exercises
254842|NCT02267668|Behavioral|Control|Participants self-guide through standard exercises
254843|NCT02267681|Drug|Fentanyl|Intravenous fentanyl for sedation/analgesia
254844|NCT02267681|Drug|Alfentanil|Intravenous alfentanyl for sedation/analgesia
254845|NCT02267681|Drug|Propofol|Intravenous propofol for sedation
254846|NCT02267694|Drug|Freeze-dried black raspberry powder|
259253|NCT02473198|Drug|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
259254|NCT02473198|Drug|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
259255|NCT02475135|Other|High-fat Breakfast|High-fat breakfast will be administered.
259256|NCT02475135|Other|Standardized Regular Breakfast|Standardized regular breakfast will administered.
259257|NCT02475148|Drug|JNJ 54175446|
259258|NCT02475148|Drug|Placebo|
259259|NCT02475148|Other|High fat/high Calorie Breakfast|
254501|NCT02272452|Device|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
254502|NCT02272465|Other|No intervention|Observational study
254503|NCT02272478|Drug|Arm A Mylotarg|
254504|NCT02272478|Drug|Arm D Cladribine|Arm D - DAC Therapy
254505|NCT02272478|Drug|AC220|Small molecule comparison
254506|NCT02274987|Radiation|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
254507|NCT02275000|Other|5 Day Physiotherapy Programme|The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.
254508|NCT02275000|Other|Physiotherapy|Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
254509|NCT02275013|Drug|Levosimendan|
254510|NCT00148525|Behavioral|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
254511|NCT02275026|Procedure|Functional magnetic resonance imaging|Diffusion tensor imaging
254512|NCT02275039|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
250003|NCT02236507|Device|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
250004|NCT02236520|Drug|Spironolactone|
250005|NCT02236520|Drug|Chlorthalidone|
250006|NCT02236520|Dietary Supplement|Diet|
250300|NCT00143182|Drug|Olanzapine|Olanzapine, 9 weeks
250301|NCT02229006|Radiation|18F-NaF PET-CT|
250302|NCT02229019|Behavioral|Volunteer mealtime assistance|
250303|NCT02229045|Drug|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
250304|NCT02229045|Drug|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
250305|NCT02229058|Drug|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
250306|NCT02229058|Drug|S-1|40mg QD D1-D14,every 3 weeks,for BSA<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA>1.5m2,until disease progress or intolerable toxicity.
250307|NCT02229071|Drug|Donafenib(200mg)|Donafenib 200mg,bid,po
250308|NCT02229071|Drug|Donafenib(300mg)|Donafenib 300mg,bid,po
250309|NCT02229084|Biological|Chemovax|Timing of the vaccination relative to chemotherapy
250310|NCT02229097|Drug|Normal bolus|During the "normal bolus" period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period
250311|NCT00143195|Drug|Amlodipine|
250312|NCT02229097|Drug|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
250313|NCT02229110|Other|Signal|Automatic signal in the electronic medical record
250314|NCT02229123|Drug|Intravenous Levetiracetam|Intravenous Levetiracetam 40 to 60 mg/kg loading dose. 7.5 to 15 mg/kg 8 hourly maintenance as determined by the dose escalation design
250315|NCT02229136|Drug|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
250316|NCT02229136|Drug|Prednisolone|Prednisolone oral solution 15 mg/5 ml
249700|NCT02201732|Procedure|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
249701|NCT02201732|Procedure|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
249702|NCT02201745|Behavioral|Oral hygiene instructions|Participants will be instructed how to brush the palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
249703|NCT02203838|Drug|RBP-7000 - 120-mg dose|120-mg of RBP-7000 dose Patients subject to a one-time down-titration to 90-mg RBP-7000 for tolerability, at the investigator's discretion
249704|NCT02203851|Drug|BI 655066|
249705|NCT02203864|Biological|BIBW2 component A|BIBW2 without IL-2 secreting cell line
250007|NCT02236520|Drug|Placebo|
250008|NCT00144027|Behavioral|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
250009|NCT02236533|Dietary Supplement|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
250010|NCT02236546|Radiation|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
250011|NCT02236546|Other|Molecular assays on biopsied tissue|Correlative studies
250012|NCT02236546|Device|positron emission tomography|Undergo FDG-PET/CT
250013|NCT02236546|Device|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
250014|NCT02236559|Device|Noninvasive positive pressure ventilation (NIPPV)|Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.
FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%.
249379|NCT02208739|Procedure|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
249380|NCT02208739|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
249381|NCT02208752|Other|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
249382|NCT00140907|Drug|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
249383|NCT02208765|Device|Stress Single Photon Emission Computed Tomography|
249384|NCT02208778|Drug|Duloxetine|54 participants will be allocated for duloxetine treatment
249385|NCT02208778|Drug|Remifentanil|27 participants will be allocated to Remifentanil infusion
249386|NCT02208778|Drug|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
249387|NCT02208778|Drug|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
249388|NCT02208791|Drug|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
249389|NCT02208791|Drug|No intervention|
249390|NCT02208804|Device|Holmium-166-poly (L-lactic acid) microspheres|
249391|NCT02208830|Other|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
249392|NCT02208830|Other|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
249393|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
249394|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
249706|NCT00140296|Behavioral|Contraceptive counseling|
254262|NCT02251041|Drug|Sodium chloride solution|
254263|NCT02251054|Other|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
254264|NCT02251054|Other|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
254265|NCT02251067|Drug|VPI-2690B low dose|Comparison of different doses of study drug
254266|NCT02251067|Drug|VPI-2690B medium dose|Comparison of different doses of study drug
254267|NCT02251067|Drug|Placebo to match VPI-2690B|
254268|NCT02251067|Drug|VPI-2690B high dose|Comparison of different doses of study drug
254269|NCT00145626|Procedure|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
254270|NCT02251093|Drug|Lcr Regenerans|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
254271|NCT02251093|Drug|Placebo|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
254272|NCT02251106|Device|Lumbar corset (Quickdraw, Aspen Medical Products)|The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
254273|NCT02251119|Drug|Tipranavir|
254274|NCT02251119|Drug|Ritonavir|
254275|NCT02251119|Drug|Loperamide|
254276|NCT02251132|Drug|TPV low 1|
254277|NCT02251132|Drug|TPV low 2|
254278|NCT02251132|Drug|TPV medium|
254279|NCT02251132|Drug|TPV high 1|
254280|NCT00145639|Drug|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
254281|NCT02253199|Drug|intranasal dexmedetomidine|Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the "Dixon up-and-down method for rescue sedation.
The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg.
254282|NCT02253212|Device|SonoCloud|SonoCloud : dose escalation
258472|NCT02499731|Behavioral|Strong Hearts, Healthy Communities|We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' "social network".
258473|NCT02499731|Behavioral|Strong Hearts, Healthy Women|The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.
Participants will learn and discuss techniques and strategies to improve personal health.
258474|NCT02499744|Device|NIPPV|For infants in the NIPPV-group who "fail"NIPPV (see definition below), need immediate intubation, a invasive "Rescue-Treatment" may be provided. The decision to attempt "Rescue-Treatment", the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
258761|NCT02493231|Drug|Ketamine|
258762|NCT00177580|Drug|Pravastatin|
258763|NCT02493231|Drug|Saline|
258764|NCT02493244|Other|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
258765|NCT02493257|Drug|Capsaicin|
258766|NCT02493257|Drug|Placebo|
258767|NCT02493270|Behavioral|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
258768|NCT02493270|Procedure|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
258769|NCT02495441|Other|Use of Rapid Immunoassay Tests for the Detection of PROM|After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.
The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.
Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®.
258770|NCT02495454|Drug|Ga101|
258771|NCT02495467|Drug|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
258772|NCT02495467|Drug|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
258773|NCT02495480|Device|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
258180|NCT02468297|Device|Electronic Acupunture Shoes|Experiment group receives a one-hour treatment given by "Electronic Acupuncture Shoes" three times a week. 6 weeks of treatment was given.
Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy.
258181|NCT02470468|Biological|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
258182|NCT02470468|Biological|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
258183|NCT02470468|Other|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
258184|NCT02470481|Other|No Intervention|This is an obervational study
258185|NCT02470507|Other|development of AKI|
258186|NCT02470520|Procedure|CRRT|continuous renal replacement therapy
258187|NCT02470533|Radiation|Radiation therapy|6 fractions of 8-9Gy
258188|NCT00174915|Drug|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
258189|NCT02470533|Device|chemoembolization|Up to 4 sessions
258190|NCT02470546|Drug|Metformin|Metformin 1000mg twice a day
258191|NCT02470546|Drug|Placebo|Placebo 1000mg twice a day
258192|NCT02470559|Biological|Aldesleukin|Given SC
258193|NCT02470559|Biological|HER2Bi-Armed Activated T Cells|Given IV and IP
258475|NCT02499744|Device|HHFNC|For infants in the HHFNC-group who "fail"HHFNC (see definition below), need immediate intubation, a invasive "Rescue-Treatment" may be provided. The decision to attempt "Rescue-Treatment", the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
258476|NCT02499757|Device|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
258477|NCT00178659|Other|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
258478|NCT02499757|Device|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
258479|NCT02499757|Device|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
258480|NCT02499757|Device|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
257901|NCT00175409|Procedure|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
257902|NCT02474732|Device|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
257903|NCT02474745|Procedure|- Directed open-glottis pushing|Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:
"After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:
"After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
257904|NCT02474745|Procedure|Directed closed-glottis pushing|Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:
"After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:
"After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
257905|NCT02474797|Device|Diaphragmatic ultrasonography|Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.
Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = [(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100]. Diaphragmatic dysfunction is defined like a DTF < 20% (7).
257906|NCT02476760|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
257907|NCT02476760|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
257908|NCT02476760|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
257909|NCT00175747|Drug|Inhaled Budesonide 800 µg twice daily|
257910|NCT02476773|Biological|Na-GST-1/Alhydrogel plus GLA-AF|
257911|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel|
257912|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
257913|NCT02476773|Biological|Sterile Saline Placebo|
257622|NCT02483572|Behavioral|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
257623|NCT02483585|Drug|AMG 334|AMG 334 Investigational Product
257624|NCT00176527|Other|immunohistochemistry staining method|
257625|NCT02483585|Drug|Placebo|Placebo comparator
257626|NCT02483598|Drug|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
257914|NCT02476786|Device|Oncotype DX® Breast Cancer Assay|The Oncotype DX test is a molecular diagnostic test that analyzes the individual biology of a breast cancer tumor by examining the activity of 21 genes in the tumour tissue. The results of the analysis are fed into a formula that gives a Recurrence Score® result. The Recurrence Score result, a number between 0 and 100, can provide information about how likely breast cancer is to recur within 10 years of diagnosis and the likelihood that the participant will benefit from chemotherapy.
257915|NCT02476786|Behavioral|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
257916|NCT02476786|Drug|Goserelin|
257917|NCT02476786|Drug|Anastrozole|
257918|NCT02476786|Drug|Exemestane|
257919|NCT02476786|Drug|Fulvestrant|
257920|NCT00175760|Procedure|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
257921|NCT02476786|Drug|Tamoxifen|
257922|NCT02476799|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
257923|NCT02476799|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
257924|NCT02476799|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
257925|NCT02476799|Drug|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
257926|NCT02476812|Behavioral|Positive Piggy Bank|Already noted.
257343|NCT02488031|Behavioral|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
257344|NCT02488031|Behavioral|Brief Test of Attention|A cognitive test assessing focus and attention.
257345|NCT02488031|Behavioral|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
257346|NCT02488031|Behavioral|Hand Grip Dynamometer|This tests measures hand grip strength.
257347|NCT02488031|Behavioral|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
257348|NCT00176930|Radiation|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
257349|NCT02488031|Behavioral|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
257350|NCT02488031|Behavioral|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
257627|NCT02483598|Drug|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
257628|NCT02483611|Drug|Magnesium Sulfate|
257629|NCT02483611|Drug|Lidocaine|
257630|NCT02483611|Drug|Isotonic Solution|
257631|NCT02483611|Drug|Cisatracurium|
257632|NCT02483624|Drug|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
257633|NCT02483624|Drug|Placebo|Placebo
257634|NCT02483637|Device|RejuvenAir|Device: RejuvenAir
257635|NCT00176540|Drug|dextromethorphan hydrobromide|
257636|NCT02483663|Device|Functional Magnetic Resonance Imaging|Measure brain activity.
257637|NCT02483663|Radiation|Dual Energy X-ray absorptiometry|Body composition measurements.
257638|NCT02483663|Other|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
257639|NCT02483663|Other|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
257051|NCT02261233|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
257052|NCT02261246|Procedure|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
257053|NCT02261259|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
257054|NCT02261272|Behavioral|CBT for insomnia SHUTi|SHUTi
257055|NCT02261272|Behavioral|passive patient education/sleep hygiene|
257056|NCT02261285|Drug|ONO-4538|
257057|NCT00002361|Drug|Indinavir sulfate|
257058|NCT00147004|Drug|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
257059|NCT02263534|Procedure|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
257060|NCT00147329|Drug|MM-093|
257351|NCT02490098|Other|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
257352|NCT02490098|Other|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
257353|NCT02490098|Other|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
257354|NCT02490098|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
256696|NCT02266056|Drug|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
256697|NCT02266056|Drug|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
256698|NCT02266069|Other|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
256699|NCT02266082|Other|No intervention|There is no intervention in this study.
256700|NCT02266095|Device|Oval-8 Splint|Splinting with Oval-8
256701|NCT02266095|Device|Tee Pee Splint|Splinting with Tee Pee
256702|NCT02266095|Device|Forearm Based Splint|Splinting with Forearm based
256703|NCT02266108|Behavioral|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
256704|NCT00147615|Drug|Eplerenone|
256705|NCT02266121|Device|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
256706|NCT02266134|Behavioral|Measurement Based Care|measurement based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire
256707|NCT02268344|Device|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
256708|NCT02268357|Drug|Propranolol|Oral propranolol capsules
256709|NCT02268370|Drug|Dasatinib|
256710|NCT02268383|Drug|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection
256711|NCT02268396|Drug|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
256712|NCT02268409|Drug|ACE-536|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
256713|NCT02268422|Drug|Buprenorphine|7 day patch
256060|NCT02241577|Procedure|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
256061|NCT02241577|Procedure|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
256062|NCT02241590|Drug|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
256063|NCT00144521|Drug|MTX placebo|0mg/week(p.o.) for 24 weeks
256064|NCT02241590|Drug|Entecavir + Fuzheng Huayu Tablet|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
256065|NCT02241603|Behavioral|Weight loss vs weight maintenance|Obese Veterans will undergo dietary education for weight loss or weight maintenance
256066|NCT02241616|Drug|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
256375|NCT02273050|Drug|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
256376|NCT02273063|Device|Transcranial Magnetic Stimulation|Stimulating DLPFC at 5 Hz for up to 40 treatment sessions overall. 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper over 3 weeks. There will be a post treatment assessment 72 hours after final treatment, and then again 1 month after the final treatment.
256377|NCT02273076|Device|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
256378|NCT02273089|Device|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
256379|NCT02273102|Drug|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
256380|NCT02273102|Drug|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
256381|NCT02273115|Drug|Oxytocin|
256382|NCT02273115|Device|Transcervical Foley catheter|
256383|NCT02273128|Genetic|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
256384|NCT02273141|Drug|NER1006, Day Before-Only Dosing|A 1-day day before-only split-dosage regimen of NER1006.
256385|NCT00148356|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
256386|NCT02273141|Drug|SP+MS, Day Before-Only Dosing|A 1-day day before-only split -dosage regimen of SP+MS.
255754|NCT00145197|Behavioral|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
255755|NCT02246946|Procedure|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
255756|NCT02246959|Behavioral|Process Incentive|Daily sweepstake conditional on daily medication adherence
255757|NCT02249208|Device|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
255758|NCT02249208|Device|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
255759|NCT02249221|Biological|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
255760|NCT02249221|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
255761|NCT02249234|Drug|Botox|
255762|NCT02249247|Drug|Low dose of BIIL 284 BS tablets|
255763|NCT02249247|Drug|Medium dose of BIIL 284 BS tablets|
255764|NCT02249247|Drug|High dose of BIIL 284 BS tablets|
255765|NCT02249247|Drug|Placebo|
255766|NCT02249260|Behavioral|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
255767|NCT00145483|Drug|Sildenafil|
256067|NCT02241629|Drug|placebo|placebo of levo phencynonate hydrochloride
256068|NCT02241629|Drug|levo phencynonate hydrochloride|levo phencynonate hydrochloride
256069|NCT02241642|Device|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
256070|NCT02241655|Device|a pragmatic EEG-guided anesthetic protocol|
256071|NCT02241668|Procedure|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
255444|NCT02253849|Drug|Ritonavir|
255445|NCT02253862|Drug|Tadalafil|administered days 1, 8 and 16
255446|NCT02253862|Drug|Tipranavir|administered days 8-18
255447|NCT02253862|Drug|Ritonavir|administered days 8-18
255448|NCT02253875|Drug|Tipranavir (TPV)|
255449|NCT02253875|Drug|Ritonavir|
255450|NCT02253875|Drug|Omeprazole|
255451|NCT02253888|Drug|TPV - Room condition|
255452|NCT02253888|Drug|TPV - Refrigerated conditions|
255453|NCT00146042|Drug|Trastuzumab|
255454|NCT02256020|Other|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
255455|NCT02256033|Drug|Istradefylline|One 40 mg-tablet administered on Day 1
255456|NCT02256046|Device|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
255457|NCT02256059|Procedure|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
255458|NCT02256072|Other|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
255768|NCT02249273|Other|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
255769|NCT02249286|Behavioral|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
255770|NCT02249286|Other|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
255771|NCT02249299|Drug|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
254847|NCT02267707|Drug|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
254848|NCT02267707|Drug|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
254849|NCT00147823|Device|Vitoss Alone|Synthetic bone graft material
255147|NCT02260609|Other|Grafix®|The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.
Patients will be treated for up to 16 weeks.
Patients will be evaluated at screening and then weekly throughout the study or until wound closure.
255148|NCT02260622|Drug|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
255149|NCT02260622|Drug|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
255150|NCT02260635|Drug|Evacetrapib|Administered orally
255151|NCT00146900|Procedure|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
255152|NCT02260635|Drug|Placebo|Administered orally
255153|NCT02260648|Drug|Evacetrapib|Administered orally
255154|NCT02260648|Drug|Ezetimibe|Administered orally
255155|NCT02260648|Drug|Atorvastatin|Administered orally
255156|NCT02260648|Drug|Placebo|Administered orally
255157|NCT02262780|Drug|Low dose of telmisartan|
255158|NCT02262780|Drug|High dose of telmisartan|
255159|NCT02262780|Drug|HCTZ|
255160|NCT02262793|Drug|telmisartan|
255161|NCT02262793|Drug|ASA/ER-DP|
255162|NCT02262806|Drug|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
255163|NCT02262819|Other|Killed Bacteria|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
255164|NCT02262832|Drug|Metreleptin|
254513|NCT02275039|Drug|gemcitabine hydrochloride|Given IV
254514|NCT02275039|Other|laboratory biomarker analysis|Correlative studies
254515|NCT02275052|Drug|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
254516|NCT02275052|Drug|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
254517|NCT02275052|Drug|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
254518|NCT02275065|Drug|GS-9883|GS-9883 tablet(s) administered orally once daily
254519|NCT02275065|Drug|GS-9883 Placebo|Placebo to match GS-9883 administered orally once daily
254520|NCT02275078|Behavioral|COPD self-management using an action plan|Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.
Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
254850|NCT02267720|Procedure|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
254851|NCT02267720|Procedure|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
254852|NCT02267733|Drug|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
254853|NCT02267746|Drug|Tazarotene (Fabior™)|
254854|NCT02267746|Drug|Tazarotene (Actavis)|
254855|NCT02267746|Drug|Vehicle foam|
254856|NCT02267759|Device|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
254857|NCT02267759|Device|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
254858|NCT02267772|Drug|IV Acetaminophen|IV Acetaminophen
254859|NCT02267772|Drug|IV Morphine|IV Morphine
254860|NCT00147823|Device|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
250317|NCT02231554|Other|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
250318|NCT02231554|Other|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
250636|NCT02224287|Procedure|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
250637|NCT02224300|Behavioral|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
250638|NCT00142649|Behavioral|physical activity|
250639|NCT02224313|Drug|oral estradiol 0.5 mg|
250640|NCT02224313|Drug|oral estradiol 1.0 mg|
250641|NCT02224313|Drug|oral progesterone 100 mg|
250642|NCT02224352|Device|Functional neuromuscular electrical stimulation|
250643|NCT02224365|Dietary Supplement|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
250644|NCT02224365|Dietary Supplement|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
250645|NCT02224378|Procedure|peep induced CVP|
250646|NCT02224378|Procedure|passive leg raising(PLR)|
250647|NCT02224391|Behavioral|Smartphone Training|ABM Group: Participants complete 13 days of attentional bias modification (ABM) training through a smartphone, designed to help in smoking cessation after first lab session.
Sham Group: Participants complete 13 days of smartphone training after first lab session.
250648|NCT02224391|Behavioral|Questionnaires|Questionnaire completion regarding smoking history and behavior completed at baseline, Day 15, Day 70, and daily after Smartphone training.
250649|NCT00142662|Behavioral|diet|
250015|NCT02236559|Device|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%.
250016|NCT02236572|Drug|Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:
Anastrozole 1 mg
Letrozole 2.5 mg
Exemestane 25 mg
250017|NCT02236585|Procedure|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
250018|NCT02199041|Radiation|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
250019|NCT02199041|Biological|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
250020|NCT02199054|Other|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
250021|NCT00139607|Drug|Paracoxib|
250319|NCT00143494|Procedure|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
250320|NCT02231567|Other|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
250321|NCT02231567|Other|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
250322|NCT02231580|Drug|BN82451B|BN82451B capsule
250323|NCT02231580|Drug|Placebo|Placebo capsule
250324|NCT02231593|Other|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
250325|NCT02231606|Other|Free Glasses|Provide free glasses
250326|NCT02231606|Other|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
249707|NCT02203864|Biological|BIBW2 component B|BIBW2 with IL-2 secreting cell line
249708|NCT02203877|Dietary Supplement|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
249709|NCT02203877|Dietary Supplement|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
249710|NCT02203903|Biological|Tumor associated antigen lymphocytes (TAA-CTL)|TAA-CTL may be generated from donors or recipients and will be tested for specificity to 4 tumor antigens commonly found in hematological malignancies (WT1, PRAME, SURVIVIN, and MAGE-A3). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
249711|NCT02203916|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
249712|NCT02203916|Drug|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
249713|NCT02203942|Other|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
249714|NCT02203955|Drug|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
249715|NCT02203955|Drug|Maltodextrin|4 chews (maltodextrin) daily for 12 months
249716|NCT02203968|Drug|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
249717|NCT00140309|Drug|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
249718|NCT02203968|Drug|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
249719|NCT02203994|Device|Duolith® SD 1 "T-Top" (Storz Medical AG, Switzerland)|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
249720|NCT02204007|Device|3D imaging & surrogate bone model|3D imaging & surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
249721|NCT02204020|Drug|5-azacytidine (5-aza) maintenance therapy after transplant|The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
249722|NCT02204033|Drug|99mTc - labelled hMAb BIWA 4|
249723|NCT02204033|Drug|186 Re - labelled hMAb BIWA 4|
249395|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
249396|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
249397|NCT00141141|Drug|Simvastatin|
249398|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
249399|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
249400|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
249401|NCT02211274|Other|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
249402|NCT02211287|Other|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q&A form and can help answer frequent family questions.
249403|NCT02211287|Other|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
249404|NCT02211300|Device|The OptiScanner|treatment of blood glucose per standard of care
249405|NCT02211300|Device|YSI 2300 STAT Plus™|
249406|NCT02211313|Device|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
249407|NCT02211326|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.
249408|NCT00141154|Drug|Celecoxib|
249409|NCT02211326|Behavioral|Standard initiation dose for warfarin|Initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.
249410|NCT02211339|Behavioral|Peer tutor training|Peer tutor training to meet the interaction needs of the group.
249411|NCT02211339|Other|Usual care|Usual care
258774|NCT00178022|Behavioral|Case management and problem solving therapy|
258775|NCT02495493|Drug|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
258776|NCT02495506|Other|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
258777|NCT02495506|Other|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
258778|NCT02495519|Drug|Imatinib|Imatinib 400 mg/day until disease progression
259061|NCT02488616|Other|5-day intervention with single-hormone closed-loop strategy|A sensor will be inserted on the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.
Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days.
259062|NCT02488616|Other|5-day intervention with sensor-augmented pump therapy|A sensor will be inserted on the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.
Participants will have been previously shown how to use the study insulin pump.
259063|NCT02488616|Other|5-day intervention with dual-hormone closed-loop strategy|A sensor will be inserted on the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.
Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days. Participants will have to reconstitute glucagon everyday.
259064|NCT02488616|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
259065|NCT02488616|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
259066|NCT00177034|Drug|Narrow Band UVB Treatment|
259067|NCT02488616|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
259068|NCT02488616|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
259069|NCT02488629|Drug|SCB01A|This study is a single arm, open-label, Phase II trial
259070|NCT02490813|Dietary Supplement|Placebo|Placebo will be starch with colorings
258481|NCT02499770|Drug|G1T28 + carboplatin/ etoposide|G1T28, carboplatin and etoposide.
258482|NCT02499770|Drug|Placebo + carboplatin/ etoposide|Placebo, carboplatin and etoposide.
258483|NCT02499783|Biological|Adalimumab|Subjects will be given subcutaneous injections of adalimumab.
258484|NCT02499783|Other|Placebo|Subjects will be given subcutaneous injections of placebo
258485|NCT02466230|Device|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
258486|NCT02466243|Drug|JBT-101|20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84
258487|NCT02466243|Drug|Placebo|Once daily on Days 1-28, then twice daily on Days 29-84
258488|NCT02466256|Procedure|Intraocular lens implantation|Intraocular lens implantation
258489|NCT02466256|Device|Autosert Injector|Motorised injection device for intraocular lens implantation
258490|NCT02466256|Device|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
258491|NCT02466256|Device|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
258492|NCT02466269|Procedure|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
258493|NCT02466282|Device|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
258779|NCT02495532|Other|Lymph node clearing technique with Carnoy solution|Procedure: lymph node clearing technique with Carnoy solution
(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
258780|NCT02495532|Other|Lymph node clearing technique with GEWF solution|Procedure: lymph node clearing technique with GEWF solution
(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
258781|NCT02495545|Procedure|CSFD and elevation of MAP|Lumbar drain placement with CSFD with elevation of MAP
258194|NCT02470559|Other|Laboratory Biomarker Analysis|Correlative studies
258195|NCT02470559|Biological|Sargramostim|Given SC
258196|NCT02470572|Other|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
258197|NCT02470572|Other|Conventional light microscope|Conventional light microscope
258198|NCT02470585|Other|Placebo|Capsule
258199|NCT00174915|Drug|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
258200|NCT02470585|Drug|Veliparib|Capsule
258201|NCT02470585|Drug|Veliparib|Capsule
258202|NCT02470585|Drug|Carboplatin|Intravenous infusion
258203|NCT02470585|Drug|Paclitaxel|Intravenous infusion
258204|NCT02470598|Other|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
258205|NCT02470611|Drug|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% sodium alendronate gel
258206|NCT02470611|Other|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% placebo gel
258207|NCT02470624|Other|treatment following current guideline|
258208|NCT02472691|Biological|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10^6 CD3/kg (1st DLI), 1-5x10^6 CD3/kg (2nd DLI) and 5-15x10^6 CD3/kg (3rd DLI).
258209|NCT02472704|Dietary Supplement|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
258210|NCT02472704|Dietary Supplement|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
258211|NCT02472717|Drug|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
258212|NCT02472717|Other|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
257927|NCT02476825|Drug|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
257928|NCT02476825|Device|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
257929|NCT02476838|Procedure|microvascular VCA transplant|
257930|NCT02479035|Dietary Supplement|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
257931|NCT02479035|Dietary Supplement|Control meal|0 g red raspberry
257932|NCT02479048|Dietary Supplement|Test meal 1|High fat meal (HF) with ½ avocado (~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
257933|NCT02479048|Dietary Supplement|Test meal 2|High fat meal (HF) with 1 avocado (~136g) matched for energy but not macronutrient content or type.
257934|NCT02479048|Dietary Supplement|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
258214|NCT02472730|Device|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
258215|NCT02472743|Device|Custom-built phototherapy lamp|Described in the arm description
258216|NCT02472756|Drug|Chemotherapy|The treatment received was per local practice and treatment standards and not directed per the protocol.
258217|NCT02472756|Drug|Rituximab|The treatment received was per local practice and treatment standards and not directed per the protocol.
258218|NCT02472769|Drug|IBP-9414|
258219|NCT02472769|Drug|Placebo|Sterile water
258220|NCT02472782|Drug|Teriparatide|The study will include patients from pre‐defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
258221|NCT02472795|Drug|ACT-334441|Selective Sphingosine 1-phosphate (S1P) modulator
258222|NCT02472795|Drug|Placebo|Placebo matching ACT334441 capsules or Experimental doses
258223|NCT02472808|Other|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
258224|NCT00175110|Behavioral|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
258225|NCT02472808|Other|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
257640|NCT02483663|Other|Test Meals|Breakfast, a snack, and lunch provided during study visit.
257641|NCT02483663|Other|Computer Tests|Perform a series of computer tests to determine reaction time.
257642|NCT02483663|Procedure|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
257643|NCT02483676|Device|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
257644|NCT02485873|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
257645|NCT02485873|Drug|Vitamin K antagonists|As prescribed by treating physicians
257646|NCT02485886|Drug|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
257647|NCT02485899|Biological|BMN 190|300 mg ICV infusion administered every other week for up to 240 weeks
257648|NCT02485912|Biological|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
257935|NCT02479074|Drug|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
257936|NCT02479074|Drug|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
257937|NCT00176098|Procedure|Hypnoanalgesia; Hypnotic shielding|
257938|NCT02479074|Drug|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
257939|NCT02479087|Drug|Plasma-derived FVIII/VWF concentrate|The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of > 1: 4.5.
The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.
The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma).
257940|NCT02479100|Procedure|Contrast Enhanced Spectral Mammography|
257941|NCT02479113|Procedure|Blood sampling|At 12 - 32 weeks: All patients need OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need HbA1c + fructosamine
257942|NCT02479139|Biological|Vehicle|formulation without active ingredient
257355|NCT00177255|Drug|Docetaxel|Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.
Cycle 2 will begin on day 22.
257356|NCT02490098|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
257357|NCT02490098|Device|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
257358|NCT02490098|Device|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
257359|NCT02490111|Drug|DWJ1319|
257360|NCT02490111|Drug|Placebo|
257361|NCT02490137|Behavioral|Race Car Video Game|Repeatedly playing a race car video game
257362|NCT02490150|Drug|Corifollitropin alfa|
257363|NCT02490163|Device|Spectra Optia|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.
Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.
The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
257649|NCT02485912|Biological|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
257650|NCT02485925|Device|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
257651|NCT00176813|Drug|Gemcitabine|
257652|NCT02485938|Drug|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
257653|NCT02485951|Procedure|Central air injection|Air was injected inside the trephination site in the central injection group.
257654|NCT02485951|Procedure|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
257655|NCT02485964|Other|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
257656|NCT02485977|Device|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
257657|NCT02485990|Drug|Tremelimumab|
257061|NCT02263534|Procedure|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
257062|NCT02263547|Drug|teriflunomide|
257063|NCT02263547|Drug|Colestipol|
257064|NCT02263560|Behavioral|Kinematic measurements|
257065|NCT02263573|Other|PEP'C-R|Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.
Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.
Session 2 Session 17: increase in the burden of BASE (5 BASE * 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC * 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).
Session 18 = Session 1.
257066|NCT02263573|Other|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
257067|NCT02263586|Behavioral|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
257068|NCT02263638|Drug|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
257069|NCT02263651|Procedure|Quilting suture without drainage|In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.
Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.
The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area.
257070|NCT02263651|Procedure|Conventional closure with drainage|The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent.
257071|NCT00147355|Drug|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
257072|NCT02263677|Drug|Sitagliptin|
257073|NCT02263690|Procedure|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
256387|NCT02273154|Drug|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
256388|NCT02273154|Drug|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
256389|NCT02273167|Drug|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take any mandatory additional clear fluid. Subject will take the second dose together with any required additional clear fluids on the morning of the colonoscopy.
256390|NCT02275728|Other|Eletromyography Biofeedback|
256391|NCT02275741|Biological|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
256392|NCT02275754|Behavioral|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
256393|NCT02275754|Behavioral|PN Only|Participants will be navigated by PN on request
256714|NCT02268435|Drug|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
256715|NCT02268448|Drug|Clonidine|
256716|NCT02268448|Drug|Naltrexone|
256717|NCT00147849|Behavioral|a combination of interactive educational meetings, educational outreach visits, and reminders|
256718|NCT02268461|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
256719|NCT02268461|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
256720|NCT02268474|Device|Excel V 532nm (KTP) Laser or 595nm Pulse Dye Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization.
256721|NCT02268487|Drug|Sertraline|Treatment
256722|NCT02268500|Biological|Influenza vaccine|Influenza vaccine
256723|NCT02268526|Biological|CSJ148|
256724|NCT02268526|Drug|Placebo|
256072|NCT02241668|Drug|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
256073|NCT02241681|Dietary Supplement|Peptamen 1.5|Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
256074|NCT00002340|Drug|Atovaquone|
256075|NCT00144534|Drug|MRA (Tocilizumab)|8mg/kg/4 weeks
256076|NCT02241694|Other|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
256077|NCT02241720|Drug|regorafenib|
256078|NCT02241733|Behavioral|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
256079|NCT02241733|Behavioral|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
256080|NCT02241746|Other|no intervention|
256081|NCT02241759|Drug|TA-8995|
256082|NCT00144885|Behavioral|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
256083|NCT02244411|Behavioral|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
256084|NCT02244411|Behavioral|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
256085|NCT02244411|Behavioral|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
256086|NCT02244411|Other|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
256394|NCT02275767|Device|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
256395|NCT02275767|Device|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
256396|NCT00148629|Drug|multivitamin, mebendazole|
256397|NCT02275767|Device|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
255772|NCT02249299|Drug|Placebo|
255773|NCT02249312|Drug|BIIL 284 BS|
255774|NCT02249312|Drug|Placebo|
255775|NCT02249325|Dietary Supplement|Probiotic dietary supplement|Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
255776|NCT02249338|Drug|BIIL 284 BS|
255777|NCT02249338|Drug|Placebo|
255778|NCT00145496|Drug|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
255779|NCT02249351|Drug|Talsaclidine|
255780|NCT02249351|Drug|Placebo|
255781|NCT02249364|Procedure|Control|Routine practice
255782|NCT02249364|Procedure|Hypnosis|Hypnosis session before induction of anesthesia
255783|NCT02249364|Drug|propofol|Closed-loop administration of propofol for anesthesia induction
255784|NCT02251548|Drug|Rituximab|IV anti-CD20 monoclonal antibody
255785|NCT02251561|Device|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
255786|NCT02251561|Device|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
255787|NCT02251561|Device|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
255788|NCT02251574|Other|Low Calorie Diet|Weight management program designed around a low calorie diet.
255789|NCT02251574|Other|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
255790|NCT00145704|Dietary Supplement|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
256087|NCT02244424|Behavioral|Tools for Teen Moms|The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities ("challenges") for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life.
256088|NCT02244437|Drug|Ibuprofen|
256089|NCT02244437|Drug|Acetaminophen|
255165|NCT02262845|Device|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
255166|NCT02262858|Drug|Telmisartan and HCTZ|
255167|NCT00147238|Drug|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
255168|NCT02262858|Drug|Telmisartan|
255169|NCT02262858|Drug|HCTZ|
255459|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
255460|NCT02256085|Device|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
255461|NCT02256085|Device|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
255462|NCT02256085|Device|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
255463|NCT02256098|Device|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
255464|NCT00002354|Drug|Stavudine|
255465|NCT00146354|Behavioral|Hospitalists Results Manager|
255466|NCT02256098|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
255467|NCT02256111|Drug|Enzalutamide|
255468|NCT02256111|Drug|Androgen deprivation therapy|
255469|NCT02256111|Behavioral|Supervised exercise training|
255470|NCT02256124|Drug|Lamotrigine|
255471|NCT02256124|Drug|Placebo|
255472|NCT02256150|Drug|Mizoribine (MZR)|
255473|NCT02256150|Drug|Cyclophosphamide (CTX)|
255474|NCT02256189|Drug|Sitagliptin|Treatment with sitagliptin 100mg QD for four weeks followed by hyperinsulinemic hypoglycemic clamp
254861|NCT00148005|Behavioral|Adaptation of the drinking scheme|
254862|NCT02270125|Procedure|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
254863|NCT02270138|Behavioral|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
254864|NCT02270151|Device|MyDiagnostick|Diagnostick strategy with MyDiagnostick
254865|NCT02270164|Dietary Supplement|Artichoke Leaf Extract|Capsule
254866|NCT02270164|Other|Placebo|Capsule
254867|NCT02270177|Other|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
254868|NCT02270190|Device|Percutaneous Tibial Nerve Stimulation (PTNS)|
254869|NCT02270203|Radiation|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
255170|NCT02262871|Device|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
255171|NCT02262871|Device|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
255172|NCT02262884|Device|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
255173|NCT02262884|Device|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
255174|NCT02262897|Drug|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
255175|NCT02262910|Biological|MOR209/ES414|MOR209/ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
255176|NCT02262923|Drug|metoclopramide|
255177|NCT02262936|Drug|Desmopressin|
255178|NCT00147238|Procedure|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
255179|NCT02262936|Drug|Fesoterodine|
250650|NCT02224391|Other|Saliva Collection|Saliva collected at baseline, Day 15, and at Day 70 to check cotinine levels.
250651|NCT02224391|Procedure|Electroencephalography (EEG)|Event-related potential (ERP) electroencephalography (EEG) performed at baseline, Day 15, and on Day 70.
250652|NCT02224391|Drug|Nicotine Replacement Therapy|Nicotine Replacement Therapy given to participants on Day 15 consisting of 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg.
250653|NCT02224391|Behavioral|Counseling Sessions|Participants attend counseling sessions on Day 15 in person, and on the phone on Days 28, 42, and 56.
250654|NCT02224404|Device|Fast Gelling Dressing (Exufiber)|
250655|NCT02226601|Drug|Aprepitant|3 days perioperative Aprepitant once a day
250656|NCT02226601|Drug|Placebo|3 days perioperative Placebot once a day
250953|NCT02219581|Drug|Dexamethasone 10 mg|Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
250954|NCT02219581|Drug|Dexamethasone 20 mg|Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
250955|NCT02219581|Drug|Standard multimodal pain management regimen|The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:
Preoperative:
Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)
Intraoperative:
Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)
Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. (15 mg if older patient or CrCl low)
Postoperative
Tylenol: 1000mg po q 8hr (scheduled)
Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid
IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain
Morphine PCA: only for failure of the above
MS Contin: Use as backup prn pain
250956|NCT02219581|Drug|Placebo|Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
250957|NCT00142116|Drug|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
250958|NCT02219594|Device|CT image for patient with suspected in-stent restenosis|Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the "gold standard" of in-stent restenosis.
250959|NCT02219620|Behavioral|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
250960|NCT02219620|Behavioral|Social Control|social conversational group facilitated by care counselor
250961|NCT02219633|Drug|LEO 39652 cream|Applied for 21 days
250962|NCT02219646|Drug|Vardenafil|Vardenafil 10 mg twice daily for six months
250327|NCT02231606|Other|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
250328|NCT02231619|Behavioral|Baseline verbal instruction on LSUPT|
250329|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
250330|NCT00000105|Biological|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
250331|NCT00000126|Procedure|Surgery|
250332|NCT00000335|Drug|Morphine|
250333|NCT00002331|Drug|Clarithromycin|
250334|NCT00143507|Drug|Ivabradine|
250335|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
250336|NCT02231645|Device|STN DBS|The DBS device is turned on and off by the physician.
250337|NCT02231658|Drug|Liraglutide|
250338|NCT02231658|Drug|Lixisenatide|
250339|NCT02234154|Device|TOPS device|Spinal surgery
250340|NCT02234167|Behavioral|Risk behaviour and infectious diseases|through counselling, testing vaccination
250341|NCT02234180|Drug|Regorafenib|
250657|NCT02226614|Device|University of Edinburgh head cooling device|head cooling
250658|NCT02226653|Drug|Evacetrapib|Administered orally
250659|NCT02226666|Other|Survey Questions|
250660|NCT00142883|Drug|Pregabalin|pregabalin compared to placebo
250661|NCT02226666|Other|Oxygen Levels and Respiration|
250662|NCT02226679|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
250663|NCT02226705|Procedure|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
250664|NCT02226718|Other|Administration of questionnaire|
249724|NCT02204033|Drug|unlabelled hMAb BIWA 4 - low dose|
250022|NCT02199054|Other|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
250023|NCT02199054|Other|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
250024|NCT02199080|Other|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
250025|NCT02199093|Other|Functional Rehabilitation of apraxia|The intervention will cover every type of approaches related with upper limb apraxia.
We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.
On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence.
250026|NCT02199093|Other|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
250027|NCT02199106|Device|Left temporal verum cTBS|Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)
Arms: Left temporal verum cTBS
250028|NCT02199106|Device|Left temporal placebo cTBS|Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings
Arms: Left temporal placebo cTBS
250029|NCT02199119|Behavioral|Exercise|30 min of moderate exercise on a treadmill
250030|NCT02199119|Behavioral|TV viewing|watching TV (animated children's programming) for 30 min
250031|NCT02199119|Behavioral|Sitting quietly|Sitting quietly for 30 min
250032|NCT00139620|Drug|Tarceva, erlotinib, OSI-774|
250033|NCT02199145|Procedure|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
250034|NCT02199158|Procedure|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
250035|NCT02199171|Drug|carboplatin|Given via HIPEC
249412|NCT02211352|Drug|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
249725|NCT02204033|Drug|unlabelled hMAb BIWA 4 - medium dose|
249726|NCT00140582|Drug|rituximab|maintenance with rituximab for 2 years
249727|NCT02206425|Drug|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
249728|NCT02206425|Drug|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
249729|NCT02206425|Drug|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
249730|NCT02206425|Dietary Supplement|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
249731|NCT02206425|Drug|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
249732|NCT02206425|Drug|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
249733|NCT02206438|Device|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
249734|NCT02206438|Device|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
249735|NCT02206464|Biological|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
249736|NCT02206464|Biological|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
249737|NCT00002311|Drug|Wobenzym|
249738|NCT00140595|Drug|rituximab|
249739|NCT02206477|Drug|Dimethyl Sulfoxide|
249740|NCT02206477|Drug|Saline 0.9%|
249741|NCT02206490|Drug|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
249742|NCT02206490|Drug|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
259071|NCT02490826|Other|Table-based T2T intervention|Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top matherials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:
Auditory Bombardment;
Auditory and discrimination;
Letter-sound knowledge;
Phoneme identity and phoneme matching;
Blending;
Segmentation;
Rhyme;
Phoneme manipulation.
259072|NCT02490826|Other|Tablet-based T2T intervention|Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital matherials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:
Auditory Bombardment;
Auditory and discrimination;
Letter-sound knowledge;
Phoneme identity and phoneme matching;
Blending;
Segmentation;
Rhyme;
Phoneme manipulation.
259073|NCT02490839|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
259074|NCT02490839|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
259075|NCT02490852|Other|Investigational infant formula|fed ad libitum
259365|NCT02484326|Other|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
259366|NCT02484339|Drug|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 50 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
259367|NCT02484339|Other|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)->->conventional or high dose radiotherapy
259368|NCT02484352|Drug|saline|different dosage of IV oxycodone was given before intubation
259369|NCT02484352|Drug|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
259370|NCT02484352|Drug|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
259371|NCT02484352|Drug|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
259372|NCT02484352|Drug|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
259373|NCT00176631|Dietary Supplement|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
259374|NCT02486679|Device|Foley catheter|
259375|NCT02486692|Other|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and treatment for PTSD.
258782|NCT02495545|Procedure|Maintenance of MAP|Lumbar drain placement without CSFD and with maintenance of MAP
258783|NCT02495558|Other|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
258784|NCT02495571|Other|Cough Assessment in ALS Patients|Volitional Cough assessment by spirometer:
a) Peak Cough Espiratory Flow (PCEF)
Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)
258785|NCT00178035|Drug|paroxetine|
258786|NCT02495584|Dietary Supplement|Fortified milk (10µg vitamin D3)|
258787|NCT02495584|Dietary Supplement|Unfortified milk (placebo)|
258788|NCT02495584|Dietary Supplement|10µg vitamin D3 supplement|
258789|NCT02497638|Drug|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
258790|NCT02497638|Drug|Atorvastatin|Atorvastatin 20 mg once daily until progression.
258791|NCT02497638|Drug|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
258792|NCT02497638|Drug|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
258793|NCT02497651|Dietary Supplement|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
258794|NCT02497651|Other|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
258795|NCT00178321|Device|earplugs|
258796|NCT02497664|Other|Active Breathing Control|
259076|NCT00177307|Drug|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
259077|NCT02490852|Other|Active Comparator: Commercially available Infant formula|fed ad libitum
259078|NCT02490852|Other|Active Comparator: Human milk|fed ad libitum
259079|NCT02490865|Drug|RNS60|RNS60, 4 ml dose nebulized twice daily
259080|NCT02490865|Drug|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
259081|NCT02490878|Drug|bevacizumab|IV
258213|NCT00175097|Other|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
258494|NCT02466282|Device|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
258495|NCT00174434|Drug|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
258496|NCT02466295|Other|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
258497|NCT02466295|Other|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
258498|NCT02466308|Device|SAM Ultrasound Diathermy Device|
258499|NCT02466321|Procedure|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
258500|NCT02466334|Drug|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins on one day compared to IV placebo for 20 mins on another day.
258501|NCT02466347|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
258502|NCT02466347|Drug|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
258503|NCT02466360|Behavioral|Back Belief questionnaire|
258504|NCT02466360|Behavioral|QUEBEC scale|
258505|NCT02466360|Behavioral|Fear Avoidance beliefs questionnaire|
258506|NCT02468297|Drug|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
258507|NCT02468310|Other|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
258508|NCT02468323|Drug|Placebo|Patients will receive regular spinal anesthesia
258509|NCT02468323|Drug|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
258226|NCT02472808|Other|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
258227|NCT02472808|Other|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
258228|NCT02472821|Behavioral|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
258229|NCT02472821|Behavioral|Internet-based educational booster|Visit to an educational Web site focused on hearing health
258230|NCT02474810|Drug|Alteplase|Alteplase for CVC dysfunction.
258231|NCT02474823|Other|polysomnogram|all participants will undergo PSG for assessment of OSA
258232|NCT02474823|Other|home sleep test|all participants will undergo HST for assessment of OSA
258233|NCT02474823|Other|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
258513|NCT02468349|Other|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
258514|NCT00174668|Drug|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
258515|NCT02468362|Procedure|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
258516|NCT02468362|Procedure|open intersphincteric resection|
258517|NCT02468375|Drug|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
258518|NCT02468388|Other|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
258519|NCT02468388|Other|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
258520|NCT02468388|Other|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
258521|NCT02468401|Procedure|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
258522|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
258523|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
257943|NCT02479139|Biological|ANT-1207|formulation containing botulinum toxin
257944|NCT02479152|Device|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
257945|NCT02479165|Drug|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
257946|NCT02479165|Drug|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
257947|NCT02479178|Drug|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
257948|NCT00176111|Procedure|peripheral nerve stimulation (procedure)|
257949|NCT02479191|Device|Ovation Abdominal Stent Graft Platform|
257950|NCT02479204|Drug|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
257951|NCT02479204|Drug|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
257952|NCT02479204|Drug|placebo|ACT-33441-matching placebo
257953|NCT02481362|Other|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
257954|NCT02481375|Dietary Supplement|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
258234|NCT02474836|Biological|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
258235|NCT02474836|Biological|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
258236|NCT00175422|Behavioral|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
258237|NCT02474836|Biological|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
258238|NCT02474849|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
257658|NCT02485990|Drug|Olaparib|
257659|NCT02486016|Drug|Duragesic Reference Fentanyl Patch|25 µg/hour
257660|NCT02486016|Drug|Apotex Generic Fentanyl Patch|25 µg/hour
257661|NCT02486016|Drug|Mylan Generic Fentanyl Patch|25 µg/hour
257662|NCT00176813|Drug|Cisplatin|
257663|NCT02486042|Drug|Omegaven|
257664|NCT02486055|Drug|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
257665|NCT02486068|Device|ABSORB scaffold|
257666|NCT02486068|Device|Xience Prime|
257667|NCT02486081|Device|smart soccer ball or an Adidas miCoach football|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
257668|NCT02486107|Procedure|surgical procedure|
257669|NCT02486133|Drug|Prezista|once daily
257670|NCT02486133|Drug|Norvir|once daily
257671|NCT02486133|Drug|Tivicay|once daily
257672|NCT02486133|Drug|Truvada|once daily
257955|NCT02481375|Dietary Supplement|Iron|12-wk supplementation of iron
257956|NCT02481375|Dietary Supplement|Placebo|12-wk supplementation of placebo
257957|NCT02481388|Other|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
257958|NCT02481401|Behavioral|Intensive Individual Intervention Program|
257959|NCT02481401|Behavioral|Peer-To-Peer Program Intervention|
257960|NCT02481414|Biological|Pepcan+Candin|
257961|NCT02481414|Biological|Candin|
257074|NCT02263690|Procedure|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
257075|NCT02266147|Drug|SD-101|
257364|NCT02490176|Drug|liraglutide|Liraglutide were taken daily for 7 days
257365|NCT02490176|Drug|placebo|Placebo were taken daily for 7 days
257366|NCT00177255|Drug|Capecitabine|Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).
Each cycle will consist of 21 days.
Cycle 2 will begin on day 22.
257367|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
257368|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
257369|NCT00177567|Drug|Depakote-ER|
257370|NCT02492516|Biological|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
257371|NCT02492529|Other|Neuropsychological tests|Scales and tests to evaluate:
Global cognitive performance
Handedness
Memory functions performance
Gestural praxis functions performance
Lexical and semantic functions performance
Executive functions performance
Memory disorders
Way of life
Mood
257372|NCT02492529|Device|A cranial MRI|
257373|NCT02492529|Other|Experimental procedure|
257374|NCT02492542|Device|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
257375|NCT02492555|Other|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
257376|NCT02492555|Other|OD|A screening of FC and DA on demand (OD)
257377|NCT02492568|Drug|pembrolizumab|
257378|NCT02492568|Radiation|Stereotactic Body Radiation Therapy|
257379|NCT02492581|Drug|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
257380|NCT00177567|Drug|risperidone|
256725|NCT02268539|Procedure|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
256726|NCT02268552|Drug|LMI070|
256727|NCT02268565|Drug|Aspirin|81mg aspirin daily at bedtime over a 2 week period
256728|NCT00147849|Behavioral|identification of local opinion leaders and establishment of local consensus processes|
256729|NCT02268565|Drug|Placebo|pill that looks like aspirin without the effects of aspirin
256730|NCT02268578|Device|Transcranial Direct Current Stimulation|2mA tDCS
256731|NCT02268578|Procedure|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
256732|NCT02270801|Drug|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
256733|NCT02270814|Drug|nab-paclitaxel|
256734|NCT02270814|Drug|Cisplatin|
256735|NCT02270814|Drug|Carboplatin|
256736|NCT02270814|Biological|Cetuximab|
257076|NCT02266147|Radiation|Radiation therapy|
257077|NCT02266160|Drug|EMLA cream 5%|the interventional group will spread 2 grams (2 m"l) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days.
257078|NCT02266160|Other|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
257079|NCT02266186|Behavioral|Traditional Cognitive behavioural therapy|Therapist supported live therapy
257080|NCT02266186|Behavioral|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
257081|NCT02266212|Procedure|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
257082|NCT02266225|Other|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
257083|NCT00147628|Drug|sildenafil citrate|
256398|NCT02275780|Drug|Doravirine|Doravirine 100 mg tablet administered orally once daily for 96 weeks.
256399|NCT02275780|Drug|Darunavir|Darunavir 800 mg tablet administered orally once daily for 96 weeks.
256400|NCT02275780|Drug|Ritonavir|Ritonavir 100 mg tablet administered orally once daily for 96 weeks
256401|NCT02275780|Drug|TRUVADA™ or EPZICOM™/KIVEXA™|The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine. Either tablet can be administered orally once daily, or TRUVADA™, can be administered once every 2 days. The length of treatment is 96 weeks.
256402|NCT02275806|Drug|Irinotecan|
256403|NCT02275806|Drug|Cisplatin|
256404|NCT02275832|Drug|3 % Minoxidil lotion|
256405|NCT02275832|Drug|Placebo|
256406|NCT02275845|Drug|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
256407|NCT00148642|Device|silver salts coated endotracheal tube|intubation with silver coated tube
256408|NCT02275845|Other|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
256409|NCT02275858|Device|Stiffening wire|Stiffening wire
256410|NCT02275858|Device|Placebo wire|Placebo wire
256411|NCT02275871|Other|MRI|High risk screening MRI will be performed as part of the patient's routine care.
256412|NCT02275871|Other|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
256413|NCT02239445|Drug|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
256414|NCT02239445|Drug|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
256737|NCT02270827|Drug|Aminophylline|intravenous medication
256738|NCT00002368|Drug|Nevirapine|
256739|NCT00148057|Behavioral|Low-fat diet|
256090|NCT02244450|Biological|SCID screening|
256091|NCT02244463|Drug|MLN0128|This is a non-randomized phase II study to investigate efficacy of MLN0128 in metastatic anaplastic thyroid cancer cases.
256092|NCT02244489|Drug|MMB|Momelotinib (MMB) tablet(s) administered orally once or twice daily
256093|NCT00144898|Procedure|Sentinel Node Resection|Sentinel Node Resection
256094|NCT02244489|Drug|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
256095|NCT02244489|Drug|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
256096|NCT02244502|Device|NovoTTF-100L(O)|Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
256097|NCT02244502|Drug|Paclitaxel|Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
256098|NCT02244515|Drug|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
256099|NCT02244528|Drug|Sildenafil|
256100|NCT02244541|Drug|ANAVEX2-73 Oral|
256101|NCT02244541|Drug|ANAVEX2-73 Intravenous|
256102|NCT02244541|Drug|ANAVEX2-73 Oral|30 mg hard gelatin capsule
256103|NCT02244541|Drug|ANAVEX2-73 Oral|50 mg hard gelatin capsule
256104|NCT00144898|Procedure|Conventional Axillary Dissection|Conventional Axillary Dissection
256105|NCT02244554|Device|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
256106|NCT02246959|Behavioral|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
256107|NCT02246972|Behavioral|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
256415|NCT02239458|Drug|Saxagliptin|
256416|NCT02239484|Drug|Tadalafil|
256417|NCT02239484|Drug|Tamsulosin|
255475|NCT02256189|Drug|Placebo|Treatment with placebo QD for four weeks followed by hyperinsulinemic hypoglycemic clamp
255476|NCT00146367|Behavioral|Active Living Every Day|
255477|NCT02258295|Drug|Depomedrol|DEPOMEDROL Sterile Aqueous Suspension contains methylprednisolone acetate which is the 6-methyl derivative of prednisolone.
255478|NCT02258308|Behavioral|CHW intervention|Home education and support for asthma self management
255479|NCT02258321|Drug|PPI-668 tablet|
255480|NCT00146614|Drug|Tacrolimus|
255481|NCT02258321|Drug|PPI-668 capsule|
255791|NCT02251574|Other|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
255792|NCT02251587|Other|Standard Weight Management Program|Standard Diet program based on diet and exercise.
255793|NCT02251587|Other|Sensible Weigh Program|Weight loss program designed for low income women.
255794|NCT02251600|Drug|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
255795|NCT02251613|Drug|Olopatadine HCl ophthalmic solution, 0.1%|
255796|NCT02251613|Drug|Epinastine HCl ophthalmic solution, 0.05%|
255797|NCT02251626|Dietary Supplement|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
255798|NCT02251639|Behavioral|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
255799|NCT02251639|Device|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
255800|NCT02251639|Procedure|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
255801|NCT00145704|Dietary Supplement|Calcium|calcium supplement given to patients with growth hormone deficiency
255802|NCT02251652|Drug|Ingenol Mebutate|Ingenol mebutate 0.05% gel
255803|NCT02251652|Procedure|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
255804|NCT02251665|Other|No intervention|a single-center prospective observational study
255180|NCT02262949|Device|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
255181|NCT02262962|Other|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthTxt Messaging service.
255182|NCT02265367|Drug|Placebo|
255183|NCT02265380|Device|Placement of IV catheter|
255184|NCT02265393|Drug|OTO-104|
255185|NCT02265393|Drug|Placebo|
255186|NCT02265406|Drug|Anti-Infective Agents|
255187|NCT02265406|Drug|Placebo|
255188|NCT02265419|Device|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
255189|NCT02265432|Behavioral|General physical activity educational materials|
255190|NCT02265432|Device|Wearable activity tracking devices (fitbit)|
255482|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
255483|NCT02258334|Biological|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
255484|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
255485|NCT02258334|Biological|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
255486|NCT02258347|Device|Echopulse|
255487|NCT02258360|Other|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
255488|NCT02258373|Device|CGM+BGM|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter
255489|NCT02258373|Device|CGM Only|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
255490|NCT02258399|Behavioral|Exercise|Moderate intensity exercise
255491|NCT00146614|Drug|Methotrexate|
255492|NCT02258399|Dietary Supplement|Breakfast|Breakfast consumption
250963|NCT02219646|Drug|Placebo|Placebo two tablets daily for 6 months
250964|NCT02219659|Drug|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
250965|NCT02221999|Drug|Letrozole|
250966|NCT02222012|Device|single channel "Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
251267|NCT02214641|Behavioral|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
251268|NCT02214667|Behavioral|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
251269|NCT02214667|Behavioral|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
251270|NCT02214680|Drug|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
251271|NCT02214680|Drug|Timolol|0.5% eye drop
251272|NCT02214693|Drug|DA-1229|
251273|NCT02214706|Drug|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
251274|NCT02214706|Other|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
251275|NCT00002317|Drug|Leucovorin calcium|
251276|NCT00141531|Drug|Apaziquone|Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.
In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis.
251277|NCT02214706|Device|Pulsed Dye Laser|
250665|NCT02226731|Device|Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization.
250666|NCT02226744|Behavioral|Focused Breathing|
250667|NCT02226757|Drug|Paclitaxel-trastzumab|Trastuzumab
Dose:
First dose: 4 mg/kg IV
Subsequent doses: 2 mg/kg every week IV.
The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.
Paclitaxel
- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab
250668|NCT02226770|Device|Implantable Cardioverter Defibrillator (ICD)|
250669|NCT02226783|Drug|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
250670|NCT02226783|Drug|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
250671|NCT00142883|Drug|placebo|sugar pill compared to pregabalin
250672|NCT02226783|Drug|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
250673|NCT02226796|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
250674|NCT02226796|Other|Non-Prime Condition|
250675|NCT02226796|Behavioral|Traditional behavioral treatment|
250676|NCT02226809|Device|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
250967|NCT02222012|Device|Two channels "Multiway stimulator coil®" (Brainsway Ltd.)|During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.
10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
1 Hz protocol:
1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks).
250036|NCT02201758|Dietary Supplement|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
250037|NCT02201771|Drug|Aspirin|
250342|NCT02234180|Drug|Placebo|
250343|NCT02234193|Device|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
250344|NCT02234193|Procedure|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
250345|NCT02234206|Drug|Chandrakanthi Choornam (CKC)|12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration
Preparation from approved sastric book as per drugs & cosmetic act 1940
250346|NCT02234219|Drug|Probiotics|
250347|NCT02234232|Behavioral|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
250348|NCT00143728|Drug|Lamivudine|See Detailed Description.
250349|NCT02234245|Device|Telemedicine System|Telemedicine System is used in remote monitoring group
250350|NCT02234258|Behavioral|Cognitive behavioral social skills|
250351|NCT02234258|Behavioral|Psychoeducation|
250352|NCT02234271|Other|Mobile Health Application|Mobile Health application for contraception information
250353|NCT02234271|Other|Health Educator Counseling|Counseling via health educator
250354|NCT02234284|Behavioral|Health Coaching|Major health coach activities will be:
Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Use of oxygen; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Helping patient obtain prescriptions; Identifying gaps in care, areas where care not in line with care plan; Helping patients to make and keep appointments and obtain needed testing; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers;
250355|NCT02234297|Drug|BLZ-100|
249743|NCT02206503|Drug|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
249744|NCT02206503|Drug|Lenalidomide|
250038|NCT02201771|Drug|Ticagrelor|
250039|NCT00139997|Device|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
250040|NCT02201784|Drug|Levobupivacaine|Comparison of Equipotent doses
250041|NCT02201784|Drug|Ropivacaine|Comparison of equipotent doses
250042|NCT02201797|Other|DCE MRI|
250043|NCT02201810|Behavioral|Rate reduction intervention|
250044|NCT02201810|Behavioral|Recycling Group|
250045|NCT02201810|Behavioral|Choice Group|
250046|NCT02201810|Behavioral|Proactive QL|
250047|NCT02201823|Drug|ABTL0812|ABTL0812. Five cohorts and one extension phase.
250048|NCT02201836|Other|One time music therapy|
250049|NCT02201836|Other|Group music therapy|
250050|NCT00139997|Device|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
250051|NCT02201849|Drug|Study Drug|
250052|NCT02201849|Drug|Active Control|
250053|NCT02201849|Drug|Placebo|
250054|NCT02201888|Behavioral|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
250055|NCT02201888|Other|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
259376|NCT02486705|Behavioral|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
259377|NCT02486705|Behavioral|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
259378|NCT02486718|Drug|Atezolizumab (MPDL3280A)|
259379|NCT00176839|Drug|ATG|ATG will be administered to umbilical cord blood recipients.
259380|NCT02486718|Other|Best Supportive Care (BSC)|
259381|NCT02486744|Drug|ACTHAR|As described.
259382|NCT02486757|Drug|micronized progesterone|
259383|NCT02486757|Drug|transdermal estradiol|
259384|NCT02486770|Biological|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
259385|NCT02486770|Biological|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
259386|NCT02486770|Biological|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
259387|NCT02486796|Biological|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
254616|NCT02248727|Device|somofilcon A|All participants wear habitual enfilcon A lens first then refitted with somofilcon A lens
254617|NCT02248740|Procedure|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
254618|NCT02248753|Drug|Pharmacological cardioversion|
254619|NCT02248753|Procedure|Electrical cardioversion|
254620|NCT02248753|Drug|Metoprolol|
254621|NCT00145431|Drug|fenofibrate|
254622|NCT02248753|Drug|Verapamil|
254623|NCT02248753|Drug|Digoxin|
254624|NCT02248766|Device|somofilcon A|All participants wear habitual enfilcon A lens first and then refitted with somofilcon A lens
254625|NCT02248792|Drug|Methotrexate|
259082|NCT02490878|Drug|corticosteroids|IV
259083|NCT02490878|Other|placebo|IV
259084|NCT02490891|Device|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
259085|NCT02490904|Drug|Eplerenon|Double blinded Eplerenon administrated for 4 days at 25mg each 12 hours
259086|NCT02490904|Drug|Placebo|Double blinded Placebo administrated for 4 days at 25mg each 12 hours
259087|NCT00177333|Drug|Doxycycline|
259088|NCT02490917|Device|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
259089|NCT02490917|Device|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
259090|NCT02490930|Drug|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
259091|NCT02490943|Other|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
259092|NCT02490943|Other|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
259093|NCT02493283|Drug|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
259094|NCT02493283|Drug|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
259095|NCT02493283|Biological|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
259096|NCT02493283|Biological|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
259388|NCT02486796|Drug|Coenzyme Q10|Preparation of coenzyme Q10
259389|NCT02486796|Drug|Melatonin|Preparation of melatonin
259390|NCT00176852|Drug|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
258510|NCT02468323|Drug|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
258511|NCT02468336|Device|AngioDefender|
258512|NCT02468336|Device|Ultrasound|
258797|NCT02497677|Behavioral|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals.
258798|NCT02497677|Behavioral|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
258799|NCT02497690|Behavioral|Telemedicine|Half of subjects will undergo nine months of AVT administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
258800|NCT02497690|Behavioral|In-person AVT|Half of subjects will undergo nine months of AVT administered in person. Therapy will be provided in the usual manner.
258801|NCT02497703|Device|Knee robot|
258802|NCT02497716|Drug|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban dry powder
258803|NCT02497729|Procedure|Written Checklist|Use of a written checklist pre and peri-intubation
258804|NCT02497729|Procedure|Head of Bed Up|Raising the patient's head of bed to 25 degrees
258805|NCT02497742|Other|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
258806|NCT00178347|Radiation|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
258807|NCT02497755|Behavioral|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
258808|NCT02497755|Device|smartphone|
258809|NCT02497768|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
258810|NCT02499796|Device|Hygrovent Gold|
258811|NCT02499796|Device|Heated and moisture exchanger (HME)|
258524|NCT02468427|Other|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
258525|NCT00174668|Drug|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
258526|NCT02468427|Other|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
258527|NCT02468440|Other|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
258528|NCT02468453|Device|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
258529|NCT02470637|Drug|SAR439065|Pharmaceutical form:dry powder insulin
Route of administration: inhalation
258530|NCT02470637|Drug|Insulin lispro|Pharmaceutical form:solution for injection
Route of administration: subcutaneous
258531|NCT00002472|Drug|etoposide|
258532|NCT00174915|Drug|Placebo|Placebo, orally, once daily for up to 28 weeks.
258533|NCT02470650|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
258816|NCT02499822|Drug|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
258817|NCT02499835|Biological|Pembrolizumab|Given IV
258818|NCT02499835|Biological|pTVG-HP Plasmid DNA Vaccine|Given ID
258819|NCT02499848|Drug|PRX302|Single prostate cancer lesion injected with PRX302.
258820|NCT02499861|Drug|Decitabine and Genistein|intravenous Decitabine with oral genistein
258821|NCT02499874|Drug|Efavirenz|oral Efavirenz 400mg
258822|NCT02499874|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
258823|NCT02499874|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
258824|NCT00178672|Procedure|Heart Catheterization -Angioplasty|Standard of care carotid stenting. A catheter is inserted in the femoral vein into the carotid artery where a balloon is inflated and shortly thereafter a stent is placed in the target lesion area.
258825|NCT02499874|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
258239|NCT02474862|Behavioral|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
258240|NCT02474862|Behavioral|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
258241|NCT02474875|Other|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
258242|NCT02474888|Other|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
258243|NCT02474901|Biological|Quadrivalent Live Attenuated Influenza Vaccine|
258244|NCT02474914|Drug|Octreotide|Octreotide will be given after PD
258245|NCT02474914|Drug|Placebo|Octreotide will NOT be given after PD
258246|NCT02474927|Drug|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
258247|NCT00000367|Drug|Suicide prevention treatment|
258248|NCT00002474|Drug|cyclophosphamide|
258249|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
258250|NCT02476851|Device|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
258251|NCT00175812|Drug|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
258534|NCT02470650|Drug|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
258535|NCT02470650|Drug|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
258536|NCT02470650|Drug|Ritonavir|Ritonavir 100 mg recovered tablet once a day
258537|NCT02470650|Drug|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
258538|NCT02470650|Drug|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
258539|NCT02470663|Dietary Supplement|DENSITYTM caplets (marketed as Amorphical)|supplementation
258540|NCT02470663|Dietary Supplement|Calcium carbonate 600 mg once daily|supplementation
257962|NCT02481427|Procedure|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
257963|NCT00176410|Drug|fluvastatin|40mg fluvastatin daily
257964|NCT02481427|Procedure|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
257965|NCT02481440|Biological|Umbilical Cord Mesenchymal Stem Cells|Intrathecal administration of UC-MSCs
257966|NCT02481453|Drug|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
257967|NCT02481453|Drug|Placebo|Comparator: placebo
257968|NCT02481466|Behavioral|Portfolio Plus Diet|Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale). Study visits after randomization will be every 3 months.
Exercise: A physical activity/exercise program encouraging 150 minutes of exercise. This is based on the exercise program developed at the Quebec Heart and Lung Institute.
257969|NCT02481466|Behavioral|DASH-like (high fiber) Diet|Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.
Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided.
257970|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
258252|NCT02476851|Device|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
258253|NCT02476864|Drug|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
258254|NCT02476864|Drug|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
258255|NCT02476890|Drug|AF-219|AF-219 50 mg tablets administered twice daily
258256|NCT02476890|Drug|Matching placebo for AF-219|Matching placebo tablets administered twice daily
257381|NCT02492594|Other|Peripheral blood sampling|Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia, together with blood sampling for routine diagnostic purposes.
257382|NCT02492607|Other|Standard treatment|wide local excision only or wide local excision and radiotherapy or mastectomy.
+/- hormonal therapy
257383|NCT02492607|Device|digital mammography|annual mammography
257384|NCT02492607|Radiation|radiotherapy|
257673|NCT02488031|Behavioral|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
257674|NCT02488031|Behavioral|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
257675|NCT02488044|Drug|AEB1102|modified human arginase I
257676|NCT02488057|Drug|Liraglutide|Active comparator. See arm descriptions.
257677|NCT02488057|Behavioral|Weight loss|Active comparator. See arm descriptions.
257678|NCT02488070|Procedure|Computed Tomography|Undergo PET/CT
257679|NCT02488070|Radiation|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Given IV
257680|NCT02488070|Other|Laboratory Biomarker Analysis|Correlative studies
257681|NCT00176930|Drug|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
257682|NCT02488070|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
257683|NCT02488070|Procedure|Positron Emission Tomography|Undergo PET/CT
257684|NCT02488070|Procedure|Positron Emission Tomography|Undergo PET/MRI
257685|NCT02488083|Device|Ultrashape|circumference reduction
257686|NCT02488096|Device|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
257084|NCT02266238|Device|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
257085|NCT02266238|Device|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
257086|NCT02266238|Procedure|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
257087|NCT02266264|Drug|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
257088|NCT02266277|Other|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
257089|NCT02266277|Other|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
257090|NCT02266277|Other|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
257091|NCT02266277|Other|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
257092|NCT02266290|Procedure|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
257385|NCT02492620|Drug|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
257386|NCT02492633|Behavioral|Control|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
257387|NCT02494947|Behavioral|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
257388|NCT02494947|Other|Usual care|
256740|NCT02270827|Drug|Hydrocortisone|Intravenous medication
256741|NCT02270840|Device|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
256742|NCT02270853|Device|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
256743|NCT02270866|Device|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
256744|NCT02270879|Procedure|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
256745|NCT02270892|Device|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
256746|NCT02270905|Device|dCELL® Meniscus|decellularised porcine xenograft
256747|NCT02270918|Drug|Kcentra|IV infusion
256748|NCT02270918|Drug|Apixaban|
256749|NCT02270918|Drug|Placebo|
256750|NCT00148070|Drug|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
256751|NCT02270931|Device|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
256752|NCT02270944|Biological|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
256753|NCT02270944|Biological|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
256754|NCT02270957|Biological|Abatacept|
256755|NCT02270957|Other|Placebo|
256756|NCT02270970|Biological|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
256757|NCT02270983|Drug|Linaclotide 145 micrograms|
256758|NCT02270983|Drug|Linaclotide 290 micrograms|
257093|NCT02266290|Device|Sport tex® kinesiotape|
256418|NCT02239484|Drug|Tadalafil + Tamsulosin|
256419|NCT02239497|Procedure|Femoral block by ultrasound and neurostimulation|
256420|NCT02239497|Drug|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
256421|NCT02239510|Drug|Senna|1 capsule (50 mg) Senna daily for 12 weeks
256422|NCT00000336|Drug|Selegiline|
256423|NCT00002337|Drug|Vesnarinone|
256424|NCT00144326|Drug|Tiotropium Bromide|
256425|NCT02239510|Drug|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
256426|NCT02239523|Procedure|Recommendation Letter|At time of discharge from the hospital or the emergency room, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment. This will be shown to the patient and they will be asked to give the letter to their primary care physician.
256427|NCT02239523|Procedure|DEXA study arranged|The orthopedic department will be responsible for arranging bone density testing (DEXA). The DEXA study will be arranged for the patient as an inpatient if they are admitted for hospitalization or as an out patient if they are not admitted. The patient will be given the report and asked to discuss further care with their primary care physician.
256428|NCT02239523|Procedure|Endocrine arranged|An endocrinologist with specialty in treatment of osteoporosis will determine appropriate treatment based on patient profile, available DEXA scan, and FRAX score.
256429|NCT02239536|Procedure|removal of eligible polyps using hot snare polypectomy technique|Snare polypectomy using a electrosurgical snare with application of electrocautery
256430|NCT02239536|Procedure|removal of eligible polyps using hot snare polypectomy after saline injection technique|Snare polypectomy after saline injection, using a electrosurgical snare with application of electrocautery
256431|NCT02239549|Device|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
256432|NCT02239549|Device|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
256433|NCT02239562|Drug|sPIF|
256434|NCT02239562|Drug|Placebo|
256435|NCT00144326|Drug|Placebo|
255805|NCT02251678|Dietary Supplement|Elimune Capsules|2 capsules BID for 28 days
255806|NCT02251691|Drug|Advagraf|Compare the drug compliance between once daily or twice daily regimen
255807|NCT02251691|Drug|Prograf|Compare the drug compliance between once daily or twice daily regimen
255808|NCT02251704|Procedure|Blood sampling|Capillary blood samples collected for determination of parasite prevalence at the time of survey.
255809|NCT02251704|Procedure|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
255810|NCT02253888|Drug|Ritonavir (RTV)|
255811|NCT02253901|Drug|BILR 355 BS|
255812|NCT02253901|Drug|Ritonavir|
255813|NCT02253901|Drug|TRUVADA|
255814|NCT02253914|Drug|BILR 355 BS, solution|
256108|NCT02246985|Dietary Supplement|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
256109|NCT02246985|Dietary Supplement|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
256110|NCT02246985|Dietary Supplement|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
256111|NCT02246985|Dietary Supplement|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
256112|NCT02246998|Drug|STB|Stribild (STB; EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily with food
256113|NCT02246998|Drug|TVD|Truvada (TVD; FTC 200 mg/TDF 300 mg) tablet administered orally once daily with food
256114|NCT00000337|Drug|Selegiline|
256115|NCT00002345|Drug|Megestrol acetate|
256116|NCT00145210|Drug|Nebivolol and Atenolol|
256117|NCT02246998|Drug|ATR|Atripla (ATR; EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily on an empty stomach at bedtime
256118|NCT02246998|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily with food
255493|NCT02258412|Drug|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
255494|NCT02258412|Drug|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
255495|NCT02258425|Behavioral|FEM-CARE|
255496|NCT02258425|Behavioral|Health Promotion|
255497|NCT02258438|Behavioral|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
255498|NCT02258438|Behavioral|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
255499|NCT02258438|Behavioral|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
255500|NCT02260661|Drug|AZD8835|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
255815|NCT02253914|Drug|BILR 355 BS, tablet|
255816|NCT02253914|Drug|Ritonavir|
255817|NCT02253914|Drug|Placebo|
255818|NCT02253927|Drug|BILR 355 - D1|
255819|NCT02253927|Drug|BILR 355 - D2|
255820|NCT00146042|Procedure|Erythromycin Breath Test (ERMBT)|
255821|NCT02253927|Drug|BILR 355 - D3|
255822|NCT02253927|Drug|BILR 355 - D4|
255823|NCT02253927|Drug|Ritonavir|
255824|NCT02253927|Other|high fat breakfast|
255825|NCT02253940|Drug|BILR 355 - Treatment A (current tablet formulation)|
251278|NCT02214719|Behavioral|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
251279|NCT02214732|Behavioral|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
251280|NCT02214745|Other|Questionnaire|Questionnaire developed for this purpose by the investigators
251281|NCT02254408|Drug|Placebo|Placebo to match presatovir administered orally or nasogastric tube
251282|NCT02254421|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
251283|NCT02254421|Drug|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
251595|NCT02247453|Other|screening|All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.
Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT.
251596|NCT02247466|Drug|Rocuronium and Sugammadex|
251597|NCT00145301|Drug|Lumiracoxib|
251598|NCT02247479|Drug|Lampalizumab|10-mg dose of lampalizumab administered intravitrally
251599|NCT02247479|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab
251600|NCT02247505|Drug|Harnal-D Cap. 0.2mg|
251601|NCT02247505|Drug|Cialis Tab. 5mg|
251602|NCT02247518|Drug|Cialis Tab. 5mg|
251603|NCT02247518|Drug|Harnal-D Cap. 0.2mg|
251604|NCT02247531|Drug|Lampalizumab|10-mg dose of lampalizumab administered intravitrally
251605|NCT02247531|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab
251606|NCT02247544|Drug|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
250968|NCT02222025|Other|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
250969|NCT02222038|Other|skin biopsy|
250970|NCT02222051|Behavioral|Tai Chi|traditional chinese martial art meditative movement technique
250971|NCT02222051|Behavioral|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
250972|NCT00142467|Drug|Gemcitabine|
250973|NCT02222064|Behavioral|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
250974|NCT02222116|Device|MGuard Prime|
250975|NCT02222116|Device|Control BMS DES|
250976|NCT02222129|Drug|Bupivacaine|
250977|NCT02222129|Drug|liposomal bupivacaine|
250978|NCT02222142|Drug|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
250979|NCT02222155|Drug|CCX168 low dose plus standard of care|
250980|NCT02222155|Drug|CCX168 high dose plus standard of care|
250981|NCT02222155|Other|Placebo BID plus standard of care|
250982|NCT02222168|Drug|BI 409306|medium dose, oral administration
250983|NCT00142467|Drug|Oxaliplatin|
250984|NCT02222168|Drug|BI 409306|medium dose, oral administration
250985|NCT02222168|Drug|BI 409306|medium dose, oral administration
251284|NCT02254434|Drug|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
251285|NCT02254447|Drug|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
250356|NCT02234310|Biological|rFIXFc|Adjustments to the dose and interval of rFIXFc can be made in this study based on investigator discretion using available PK data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There is an option to start study dosing as episodic treatment (on-demand).
250357|NCT02234323|Biological|rFVIIIFc|Administered as specified in the treatment arm
250358|NCT02234336|Procedure|Noncontrast echocardiography|
250677|NCT02226848|Drug|Erythropoeitin|
250678|NCT02226861|Device|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
250679|NCT02229149|Drug|Trastuzumab|Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.
Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.
For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving.
250680|NCT02229149|Drug|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
250681|NCT02229149|Drug|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|physician's choice of chemotherapy:
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
Docetaxel 75 mg/m2 IV every 3 weeks; OR
Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
250682|NCT02229175|Drug|bevacizumab|intravitreal injections of antibodies inhibiting vascular endothelial growth factor
250683|NCT02229175|Device|PASCAL Endpoint Management (EpM) laser treatment|This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
250684|NCT00143195|Drug|iso- 5 - mononitrate|
250685|NCT02229188|Behavioral|Problem Solving Therapy|
250686|NCT02229188|Other|Evolution|
250687|NCT02229201|Drug|Propofol|4-6 mg/kg/h during anaesthesia
250688|NCT02229201|Drug|Sevoflurane|0.8 MAC
250689|NCT02229214|Drug|Qsymia|
250690|NCT02229214|Drug|Placebo|
250691|NCT02229227|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
250056|NCT02201888|Other|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
250057|NCT02201901|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
250058|NCT02201901|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
250059|NCT02201914|Drug|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
250359|NCT02236585|Procedure|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
250360|NCT00144040|Behavioral|Physician & patient education on appropriate antibiotic use|
250361|NCT02236598|Drug|K+ supplement|
250362|NCT02236598|Drug|Placebo|
250363|NCT02236611|Drug|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
250364|NCT02236611|Drug|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
250365|NCT02236624|Behavioral|Aerobic exercise|
250366|NCT02236650|Behavioral|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
250367|NCT02236650|Other|Treatment as Usual|Treatment as Usual for 4 weeks
250368|NCT02236663|Behavioral|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
250369|NCT02236663|Behavioral|Personalized App-Based Safety Decision Aid|Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.
Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.
Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan.
250370|NCT02236676|Behavioral|Nap after rehearsal trials|
250371|NCT00144040|Procedure|Rapid C-reactive protein testing to guide antibiotic treatment|
254626|NCT02248805|Drug|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a dual affinity re-targeting (DART) molecule. MGD007 will be administered as a single agent.
254627|NCT02248818|Drug|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
254628|NCT02248818|Drug|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
254629|NCT02248831|Device|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
254630|NCT02248844|Biological|Botulinum Toxin Type A|Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
254631|NCT02248857|Other|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
254632|NCT00145444|Drug|olanzapine|
254633|NCT02248857|Other|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
254634|NCT02248870|Drug|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
254635|NCT02248870|Drug|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
254636|NCT02248883|Drug|TPV low|
254637|NCT02248883|Drug|Placebo|
254638|NCT02248883|Drug|Moxifloxacin|
254967|NCT02241148|Drug|Acetaminophen 500mg|500 mg, tablets every 8 hours
254968|NCT00144508|Drug|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
254969|NCT02241148|Device|Kinesio taping|Taping will be changed every week.
254970|NCT02241161|Other|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
254971|NCT02241161|Other|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
254972|NCT02241161|Other|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
254973|NCT02243813|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
259391|NCT02486809|Drug|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
259392|NCT02486822|Procedure|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
259393|NCT02486822|Drug|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
259394|NCT02486822|Procedure|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
259395|NCT02486835|Device|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
259396|NCT02486835|Device|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
259397|NCT02486848|Drug|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
259398|NCT02486848|Drug|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
259399|NCT02486861|Other|optical coherence tomography|
259400|NCT02486874|Device|PoreSkin|a human acellular dermal matrix
259401|NCT02488642|Drug|Isosorbide Dinitrate|
259402|NCT02488642|Drug|Misoprostol|
259403|NCT02488642|Drug|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
259404|NCT02488655|Device|Echopulse|HIFU Under ultrasound guidance
259405|NCT02488668|Device|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
259406|NCT02488681|Device|Micra Pacemaker Implant|
259407|NCT02488694|Drug|Afatinib|40 mg/d
259408|NCT00177047|Procedure|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
259409|NCT02488694|Drug|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
254639|NCT02248883|Drug|TPV high|
258812|NCT02499796|Device|Heated humidifier (HH)|
258813|NCT00178672|Device|Angioguard XP distal protection device|Standard of care stenting of carotid arteries protocol is used.
258814|NCT02499809|Other|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
258815|NCT02499822|Drug|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
259097|NCT00177593|Behavioral|behavioral weight loss|
259098|NCT02493296|Other|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
259099|NCT02493309|Other|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
259100|NCT02493309|Other|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
259101|NCT02493322|Drug|Olmesartan Medoxomil + Chlorthalidone|1 tablet a day
259102|NCT02493322|Drug|Olmesartan medoxomil + Chlortalidone|1 tablet a day
259103|NCT02493322|Drug|Losartan + hydrochlorothiazide|1 tablet a day
259104|NCT02493335|Drug|Budesonide effervescent 0.5mg tablet twice daily|
259105|NCT02493335|Drug|Budesonide effervescent 1mg tablet twice daily|
259106|NCT02493335|Drug|Placebo effervescent tablet twice daily|
259107|NCT02493348|Device|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) uses rhythmic sensory cues to induce brain entrainment based on the premise that the spontaneous electrical activity of the brain can synchronize to external periodic auditory, visual, or somatosensory stimuli. RSS can be delivered through sound devices. In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the sound (40 Hz RSS), the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
259108|NCT00177606|Behavioral|withdrawal of life sustaining treatments|
258826|NCT02499887|Drug|beclamethasone dipropionate|Inhaler
258827|NCT02499887|Drug|albuterol|Inhaler
258828|NCT02499887|Drug|Prednisone|Oral corticosteroid
258829|NCT02499900|Drug|Copaxone®|Subcutaneous Injections of 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily
258830|NCT02499913|Behavioral|breath alcohol monitoring|Daily breath alcohol monitoring
258831|NCT02499913|Behavioral|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
258832|NCT02499926|Dietary Supplement|Arginine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
258833|NCT02499939|Behavioral|Standard Care|Education and home exercises
258834|NCT02499939|Other|Ultrasound Therapy|Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.
(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)
258835|NCT00174434|Drug|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
259115|NCT02495623|Drug|SYN-010 42 mg|
259116|NCT02495623|Drug|Placebo|
259117|NCT02495636|Drug|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
259118|NCT00178035|Behavioral|One night of Total Sleep Deprivation|
259119|NCT02495636|Drug|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
259120|NCT02495649|Other|[18F]-DOPA|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
259121|NCT02495649|Device|PET-CT|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
259122|NCT02495662|Drug|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
258541|NCT02470676|Device|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
258542|NCT02470676|Drug|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
258543|NCT00174928|Drug|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
258544|NCT02470689|Drug|Diacerin cream|Diacerin tablet solubule in ultraphil cream
258545|NCT02470702|Drug|Oritavancin|
258546|NCT02470702|Drug|Placebo (D5W)|
258547|NCT02470715|Genetic|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
258548|NCT02470728|Other|New Clinical Pathway|
258549|NCT02470741|Drug|Letrozole|
258550|NCT02470741|Other|Placebo|
258551|NCT02470754|Device|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
258552|NCT02470754|Device|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
258553|NCT02470767|Drug|Direct oral anticoagulants|Treatment pattern following the summary of product characteristics
258554|NCT00174928|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
258555|NCT02470780|Drug|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
258556|NCT02470780|Drug|Placebo|Placebo matching Rifaximin treatment.
258836|NCT02466360|Behavioral|Visual analog scale|
258837|NCT02466360|Behavioral|individual interviews|
258838|NCT02466360|Behavioral|Focus groups|
258839|NCT02466373|Drug|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
258840|NCT02466386|Drug|SPD489|SPD489 will be provided in 5, 10, 15, 20, and 30mg strength capsules. Subjects will be instructed to take 1 capsule daily throughout the study.
258841|NCT02466399|Drug|POLAT-001|Subconjunctival injection
258257|NCT02476903|Drug|Monovisc|
258258|NCT02476916|Drug|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety, tolerability and clinical efficacy. AG-348 will be administered by mouth (orally) each day for a period of 24 weeks.
258259|NCT02476929|Device|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
258260|NCT02476929|Device|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
258261|NCT02476942|Drug|Bypassing Agents|Episodic or prophylactic treatment with bypassing agents such as Factor VIII Inhibitor bypassing activity (FEIBA), an activated prothrombin complex concentrate and recombinant human FVIIa (rFVIIa) for at least last 6 months.
258262|NCT00175812|Drug|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
258263|NCT02476955|Drug|ARQ 092 + carboplatin + paclitaxel|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
258264|NCT02476968|Drug|Olaparib|Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispenses for a 4 weekly visit, with a 2 day overage.
Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.
Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water.
258265|NCT02476981|Drug|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
258266|NCT02476981|Drug|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
258267|NCT02476981|Drug|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
258268|NCT02476981|Drug|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
258269|NCT02476981|Drug|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
258557|NCT02472834|Dietary Supplement|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing ~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
258558|NCT02472847|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
258559|NCT02472847|Drug|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
257687|NCT02488096|Device|MRI + TRUS-Guided Biopsy|A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.
The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy ~ 1 week after the MRI.
257688|NCT02488109|Other|Higher Calorie Refeeding|
257689|NCT02488109|Other|Lower Calorie Refeeding|
257690|NCT02488122|Other|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
257691|NCT02488122|Other|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
257692|NCT00176943|Drug|Aldara Cream 5%|
257971|NCT02483676|Behavioral|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
257972|NCT02483689|Drug|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
257973|NCT00176553|Drug|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
257974|NCT02483689|Other|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
257975|NCT02483689|Drug|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
257976|NCT02483689|Other|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
257977|NCT02483702|Other|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
257978|NCT02483702|Other|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
257979|NCT02483715|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
257980|NCT02483715|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
257389|NCT02494960|Behavioral|The brief smoking cessation AWARD model|Ask whether or not the patient currently smokes
Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.
Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.
Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.
Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again.
257390|NCT02494960|Behavioral|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
257391|NCT02494973|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
257392|NCT02494973|Drug|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
257393|NCT00177879|Behavioral|website comparison|
257394|NCT02494973|Drug|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
257395|NCT02494973|Drug|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
257396|NCT02494986|Drug|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or oral granules for weight adjusted RPV dose, as applicable, in combination with an investigator selected background regimen consisting of 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs).
257397|NCT02494999|Biological|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 1 month interval, a booster dose 9 months after the first dose
257398|NCT02494999|Biological|7-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Wyeth,three doses with 1 month interval, a booster dose 9 months after the first dose
257399|NCT02495012|Drug|placebo|Freeze-dried powder without snake venom will be dissovled in saline
257400|NCT02495012|Drug|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
257693|NCT02488135|Device|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
257694|NCT02488135|Procedure|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
257695|NCT02490189|Behavioral|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
257696|NCT02490189|Behavioral|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
257094|NCT00147628|Drug|placebo for sildenafil citrate|
257095|NCT02266290|Device|Pretape Cramer®|
257096|NCT02268591|Device|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
257097|NCT02268604|Drug|BIIB 722 CL|
257098|NCT02268604|Drug|Placebo|
257099|NCT02268617|Other|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
257100|NCT02268643|Other|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
257101|NCT02268656|Drug|propofol|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
257102|NCT02268669|Other|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
257103|NCT00147862|Drug|Tranexamic Acid|
257104|NCT02268682|Other|Patient-Guided|The "Explore Transplant" education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the "Explore Transplant" program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program.
257105|NCT02268682|Other|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
257106|NCT02268695|Drug|Cisplatin|
257107|NCT02268695|Drug|5-Fluorouracile|
257108|NCT02268695|Drug|Docetaxel|
257109|NCT02268695|Drug|Cetuximab|
256759|NCT02273167|Drug|NER1006,1-Day Morning Split-Dosing|The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take any mandatory additional clear fluid.
After a 1-2 hour break the subject will self-administer the second dose plus any additional clear mandatory fluid.
256760|NCT02273167|Drug|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take any mandatory additional clear fluid. Subject will take the second dose together with any required additional clear fluids on the morning of the colonoscopy.
256761|NCT02273180|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
256762|NCT02273180|Drug|insulin lispro|Pharmaceutical form:solution Route of administration: subcutaneous
256763|NCT02273180|Drug|insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
256764|NCT02273206|Behavioral|Preventive Care Management for Depression|
256765|NCT00148356|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
256766|NCT02273206|Behavioral|Preventive Care Management for Cancer Screening|
256767|NCT02273219|Drug|AEB071|AEB071, oral, 100-400 mg twice daily
256768|NCT02273219|Drug|BYL719|BYL719, oral, 200-350 mg daily
256769|NCT02273232|Other|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
256770|NCT02273232|Other|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
256771|NCT02273232|Other|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
256772|NCT02273245|Radiation|Thoracic aortogram CT|With and without contrast dye
256773|NCT02273258|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
256774|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
256775|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
256776|NCT00148369|Drug|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
256777|NCT02273271|Other|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
256119|NCT02246998|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily with food
256120|NCT02246998|Drug|ABC/3TC|Abacavir/Lamivudine (ABC 600 mg/3TC 300 mg) tablet administered orally once daily with food
256121|NCT02246998|Drug|Iohexol|Iohexol 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
256122|NCT02247037|Other|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines.
256123|NCT02247050|Behavioral|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
256124|NCT02247063|Device|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1that involves sending a weak electrical current into your brain.
256125|NCT02247076|Behavioral|Grazing|
256126|NCT02247076|Behavioral|Time-restricted feeding (early eating)|
256127|NCT00145236|Drug|Nebivolol|
256128|NCT02247089|Other|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
256436|NCT02239588|Other|Oral consumption|Daily oral consumption for 12 weeks:
Placebo;
Pure Canterbury;
Other infant formula milk powder:
Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)
Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)
Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)
Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)
Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)
Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)
256437|NCT02241759|Drug|Moxifloxacin|
256438|NCT02241759|Drug|Placebo|
256439|NCT02241772|Drug|TA-8995|
256440|NCT02241772|Drug|Placebo|
256441|NCT00144547|Drug|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
256442|NCT02241785|Drug|natalizumab|Administered as specified in the treatment arm
256443|NCT02241798|Other|oxygen|O2 by nasal prongs
256444|NCT02241811|Drug|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
256445|NCT02241811|Drug|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
255826|NCT02253940|Drug|BILR 355 - Treatment B (new tablet formulation)|
255827|NCT02253940|Drug|BILR 355 - Treatment C (new capsule formulation)|
255828|NCT02253940|Drug|BILR 355 - Treatment D (current tablet formulation)|
255829|NCT02253940|Drug|BILR 355 - Treatment E (new capsule formulation)|
255830|NCT02253940|Drug|Ritonavir|
255831|NCT00146055|Procedure|Reduced intensity conditioning with allogeneic transplant|
255832|NCT02253953|Drug|BILR 355 BS, D1|
255833|NCT02253953|Drug|BILR 355 BS, D2|
255834|NCT02253953|Drug|BILR 355 BS, D3|
255835|NCT02253953|Drug|BILR 355 BS, D4|
255836|NCT02253953|Drug|BILR 355 BS, D5|
255837|NCT02253953|Drug|BILR 355 BS, D6|
255838|NCT02253953|Drug|BILR 355 BS, D7|
255839|NCT02253953|Drug|BILR 355 BS, D8|
255840|NCT02253953|Drug|BILR 355 BS, D10|
255841|NCT02253953|Drug|Placebo|
255842|NCT00146068|Drug|Avonex/Zocor|
255843|NCT02253953|Other|high-fat breakfast|
256129|NCT02249377|Other|Platelets-Rich-Plasma|Platelet-Rich Plasma
256130|NCT02249377|Drug|Corticosteroid|Corticosteroid
256131|NCT02249403|Drug|Talsaclidine 6 mg|
256132|NCT02249403|Drug|Talsaclidine 12 mg|
256133|NCT02249403|Drug|Talsaclidine 24 mg|
256134|NCT00002347|Drug|Nevirapine|
256135|NCT00145496|Drug|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
251607|NCT02247557|Drug|Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
251608|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
251609|NCT02247557|Drug|BOTOX 200U in normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
251610|NCT02247557|Drug|Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
251611|NCT02247570|Procedure|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
251612|NCT02247596|Drug|Resveratrol|1g tds 2 weeks
251613|NCT02247596|Drug|Placebo|Sugar pill 1g tds for 2 weeks
251614|NCT02247609|Genetic|Anti-CD19 CAR T cells|Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
251946|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
251947|NCT02242682|Other|Child passenger safety video|
251948|NCT02242695|Drug|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
251949|NCT02242695|Drug|Canesten vaginal tablets|one vaginal tablet for 7 days
251950|NCT02242708|Behavioral|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
251951|NCT02242734|Drug|20 mg HC-ER|1-72 hours
251952|NCT02242734|Drug|20 mg HC-ER|1-72 hours
251953|NCT02242734|Drug|20 mg HC-ER|1-72 hours
251954|NCT02242747|Drug|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
251955|NCT00144690|Drug|E2007 (perampanel)|
251956|NCT02242747|Drug|5% 5-FU|two applications a day for four weeks in a pre-determined area
251957|NCT02242760|Drug|SB204 2%|
251958|NCT02245269|Drug|Atorvastatin|
251286|NCT02254447|Drug|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
251287|NCT02254447|Drug|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
251288|NCT00146120|Drug|All-trans Retinoid acid|
251289|NCT02254460|Dietary Supplement|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
251290|NCT02254460|Other|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
251291|NCT02254473|Other|Wedge Insert|
251292|NCT02254473|Other|Flat Insert|
251293|NCT02254486|Drug|NER1006|NER1006:2-Day Split-Dosing Regimen (to commencein the evening of the day before the colonoscopy)
251294|NCT02254486|Drug|Trisulfate solution|Trisulfate solution 2-Day Split-Dosing Regimen (to commencein the evening of the day before the colonoscopy)
251295|NCT02254512|Drug|Metformin|Metformin by mouth twice daily with meals
251296|NCT02254512|Drug|Carboplatin|Carboplatin AUC of 5, IV day 1 of every 21 days times 4 cycles
251297|NCT02254512|Drug|Pemetrexed|Pemetrexed 500 mg/m2, IV day 1 of every 21 days until PD
251298|NCT02254525|Drug|Intravenous ibuprofen|Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.
All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
251299|NCT00146133|Behavioral|diet, exercise|
251300|NCT02254525|Drug|Saline solution|Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.
All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
251301|NCT02254538|Drug|BILR 355 BS|
251302|NCT02254538|Drug|PEG 400|
251303|NCT02254551|Drug|LDE225|Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.
Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.
Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity.
250692|NCT02229227|Drug|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
250693|NCT02229240|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
250694|NCT02229240|Drug|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
250695|NCT00143195|Procedure|Blood tests|
250696|NCT02229253|Drug|degarelix|
250986|NCT02222181|Other|Pharmacotherapy Management|assessment of patient characteristics as alcoholic, smoker, food, drugs
Pharmacotherapy follow-up
to evaluated medication adherence
Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention.
250987|NCT02224417|Behavioral|Diabetes Educational Program (DEP)|Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.
The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic.
250988|NCT02224417|Behavioral|DEP + Process Incentive|Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:
SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.
SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.
SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit.
250989|NCT02224417|Behavioral|DEP + Outcome Incentive|Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.
SGD 2 weekly if one glucose readings falls within the normal range,
SGD 7 weekly if two glucose readings fall within the normal range,
SGD 14 weekly if all three glucose readings fall within the normal range.
250990|NCT02224443|Drug|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
250991|NCT02224443|Drug|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
250992|NCT00142662|Behavioral|financial incentives|
250993|NCT02224443|Drug|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
250994|NCT02224443|Drug|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4~5μg.kg-1 fentanyl,1.0~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
250372|NCT02236689|Procedure|Non operative|no surgical intervention
250373|NCT02236689|Procedure|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
250374|NCT02236702|Other|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
250375|NCT02236715|Drug|Atrovent®|
250376|NCT02236728|Drug|Pramipexole|
250377|NCT02236741|Drug|Mirapexin® (Sifrol®)|
250697|NCT02229266|Biological|NK cells|
250698|NCT02229266|Drug|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
250699|NCT02229279|Device|Teleconsulting|
250700|NCT02229292|Drug|Tranexamic Acid|Active group:
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure.
250701|NCT02229292|Drug|Saline|Placebo group:
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure.
250702|NCT02231671|Drug|ALS-008176|
250703|NCT02231671|Drug|ALS-008112|
250704|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
250705|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
250706|NCT02231697|Other|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
250707|NCT02231710|Biological|BPX-501 and AP1903|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by AP1903 infusion on day 7
250708|NCT00143507|Drug|Placebo|
250709|NCT02231723|Drug|BBI608|Administered continuously twice daily with doses separated by 12 hours
250710|NCT02231723|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
254974|NCT02243826|Drug|50:50 mixture of nitrous oxide/oxygen|
254975|NCT02243839|Drug|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
254976|NCT02243839|Procedure|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
254977|NCT02243852|Drug|Growth Hormone Replacement Therapy|An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
254978|NCT02243865|Device|Chordate System S200 + CT100 (active treatment)|
254979|NCT02243865|Device|Chordate System S200 + CT100 (placebo treatment)|
254980|NCT02243878|Radiation|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
254981|NCT00002342|Drug|Tecogalan sodium|
254982|NCT00144833|Drug|fosamprenavir/ritonavir (700mg/100mg BID)|
254983|NCT02243878|Drug|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
254984|NCT02243891|Procedure|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
254985|NCT02243891|Procedure|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
254986|NCT02243917|Drug|CB-5083|
254987|NCT02243930|Device|Disposable distal attachment|
254988|NCT02243943|Drug|Sugammadex|
254989|NCT02243943|Drug|Neostigmine|
255282|NCT02275377|Other|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
255283|NCT02275377|Other|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
254640|NCT02248883|Drug|RTV|
254641|NCT02248896|Drug|Telmisartan|
254642|NCT02248896|Drug|Other angiotensin-receptor blockers (ARBs)|
254643|NCT00145444|Drug|ziprasidone|
254644|NCT02251132|Drug|TPV high 2|
254645|NCT02251132|Drug|RTV low|
254646|NCT02251132|Drug|Ritonavir high|
254647|NCT02251132|Drug|Radiolabelled erythromycin|
254648|NCT02251145|Drug|Tipranavir low dose|
254649|NCT02251145|Drug|Tipranavir high dose|
254650|NCT02251145|Drug|Ritonavir low dose|
254651|NCT02251145|Drug|Ritonavir high dose|
254652|NCT02251145|Drug|Tenofovir disoproxil fumarate|
254653|NCT02251158|Drug|Tipranavir oral solution|
254654|NCT00145639|Procedure|Limb Sparing|See Detailed Description for treatment plan.
254655|NCT02251158|Drug|Tipranavir capsules|
254656|NCT02251158|Drug|Ritonavir oral solution|
254657|NCT02251158|Drug|Ritonavir soft gel capsules|
254658|NCT02251158|Other|High fat breakfast|
254659|NCT02251171|Drug|Tipranavir|
254660|NCT02251171|Drug|Ritonavir|
254661|NCT02251171|Drug|Rifabutin|
254662|NCT02251184|Drug|Aggrenox|
254663|NCT02251184|Drug|Dipyridamole|
254664|NCT02251184|Drug|Aspirin|
254665|NCT00145652|Drug|Neo-Recormon and Venofer|
259109|NCT02493361|Drug|Pembrolizumab|
259110|NCT02493361|Drug|pIL-12|
259111|NCT02495584|Dietary Supplement|Placebo supplement|
259112|NCT02495597|Other|no intervention - just observational|
259113|NCT02495610|Other|Gait analysis and MRI:|Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; Zebris medical GmbH), study-specific, but routine procedures.
MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage.
259114|NCT02495623|Drug|SYN-010 21 mg|
259410|NCT02488707|Procedure|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
259411|NCT02488707|Procedure|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
259412|NCT02488733|Procedure|Laparoscopic Sleeve Gastrectomy plus conventional medical therapy|
259413|NCT02488733|Drug|Conventional medical therapy|
259414|NCT02488746|Device|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
259415|NCT02488759|Drug|Nivolumab|
259416|NCT02488772|Device|Sleep mask|
259417|NCT02488772|Other|Standard of care|Standard of care as decided by treating emergency physician
259418|NCT02488772|Device|Ear Plugs|
259419|NCT00177047|Drug|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
259420|NCT02488785|Behavioral|Virtual Diabetes Self-Care and Education Program|Participants will be able to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
259421|NCT02488785|Device|Fitbit|
259422|NCT02488785|Device|Smartphone|
259123|NCT02495662|Drug|Placebo|0.9% normal saline
259124|NCT02495675|Device|High flow nasal cannulas|Comparison of different flow levels
259125|NCT02495675|Device|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
259126|NCT02495688|Procedure|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
259127|NCT02495688|Procedure|General anesthesia|Standard procedure.
259128|NCT02495701|Procedure|Hip arthroscopic surgery|Hip arthroscopic surgery
259129|NCT00178048|Drug|paroxetine|
259130|NCT02495714|Behavioral|Active learning|Physical activity one hour a day as part of academic learning
259131|NCT02495714|Behavioral|Dietary councelling|Teaching children and parents about a healthy diet
259132|NCT02495727|Behavioral|Step-reduction|Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
259133|NCT02495727|Behavioral|Pre-training|Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
259134|NCT02495727|Behavioral|Exercise snacking|Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
259135|NCT02495740|Behavioral|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
259136|NCT02497781|Drug|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
259429|NCT02491008|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
259430|NCT00177346|Device|CAS with cerebral protection|
259431|NCT02491008|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
258842|NCT02466399|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
258843|NCT02466412|Other|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
258844|NCT02466412|Other|mCC|Single use of of subject's own menthol conventional cigarette (mCC)
258845|NCT02466425|Drug|SHP465|12.5mg and 25mg capsules (one capsule daily)
258846|NCT00002471|Drug|methotrexate|
258847|NCT00174447|Drug|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
258848|NCT02466425|Drug|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
258849|NCT02466438|Drug|Piperacillin-tazobactam|Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion
Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours
Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours
Acute Kidney injury : Dosing as prescribed by treating physician
258850|NCT02466451|Other|Questionnaires|For not collaborative patients, under the age of 4 years:
Standardized questionnaire collecting anamnestic-clinical data
Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).
For collaborative patients, over the age of 4 years:
Standardized questionnaire collecting anamnestic-clinical data
Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )
Spirometry
6-minutes walk test (WT 6')
Prick tests
Children Quality of life questionnaire (KINDL questionnaire)
Psychological test (Raven Matrices)
Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)
258851|NCT02466464|Device|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
258852|NCT02466464|Device|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
258853|NCT02466477|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
259137|NCT02497781|Drug|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
259138|NCT02497794|Other|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
258560|NCT02472860|Behavioral|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
258561|NCT02472860|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition
258562|NCT00002472|Radiation|radiation therapy|
258563|NCT00175123|Drug|Botulinum A toxin|Intravesical injection. 12 IE/kg b.w.
258564|NCT02472873|Procedure|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
258565|NCT02472873|Procedure|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
258566|NCT02472873|Drug|Ethanol|
258567|NCT02472886|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
258568|NCT02472886|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
258569|NCT02472899|Other|Blood sample|Non-interventional study based on blood samples taken at a single study visit
258570|NCT02472912|Biological|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
258571|NCT02472912|Biological|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
258572|NCT02472912|Biological|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
258573|NCT02472925|Other|GlowCap|Glowcap bottles will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm
258574|NCT00175136|Device|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
258575|NCT02472938|Drug|dimethyl fumarate|dimethyl fumarate 120 mg capsules
258576|NCT02472938|Other|Placebo|Placebo for BG00012
258854|NCT02466477|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
257981|NCT02483728|Other|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
257982|NCT02483741|Biological|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
257983|NCT02483767|Drug|goserelin|Gonadotropin-Releasing Hormone Agonist
257984|NCT00176566|Drug|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
257985|NCT02483767|Drug|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
257986|NCT02483780|Behavioral|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
257987|NCT02483793|Drug|Tamsulosin|
257988|NCT02483793|Drug|Oxybutynin|
258270|NCT02476994|Drug|Clinolipid|
258271|NCT02479204|Drug|atenolol|film-coated tablet containing atenolol at a strength of 50 mg
258272|NCT02479204|Drug|diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
258273|NCT02479217|Drug|Docetaxel|
258274|NCT02479217|Drug|Xeloda|
258275|NCT02479230|Biological|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
258276|NCT02479230|Drug|gemcitabine hydrochloride|Given IV
258277|NCT00002475|Biological|recombinant interferon alfa|
258278|NCT00176124|Procedure|leukocyte depletion of whole blood|
258279|NCT02479256|Drug|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
258280|NCT02479256|Drug|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
257697|NCT02490202|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
257698|NCT02490202|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
257699|NCT02490228|Procedure|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
257700|NCT02490241|Drug|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
257701|NCT02490254|Other|Surveillance card|
257702|NCT02490267|Other|Quality of Life questionnaire|
257703|NCT02490280|Behavioral|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
257704|NCT02490293|Drug|Cephalosporin|During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.
After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days.
257705|NCT00177268|Other|Blood draw or skin biopsy|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
257706|NCT02490293|Drug|Placebo|During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.
After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days.
257707|NCT02490306|Device|Strokefinder MD100 prehospital measurement|A prehospital microwave measurement will be performed with the patient lying on the ambulance stretcher or another suitable surface.
257708|NCT02490306|Device|Strokefinder MD100 hospital measurement|A follow-up microwave measurement will be performed at the hospital in conjunction with a Computed Tomography (CT) scan, if this is performed as part of the standard of care within 48 hours of stroke onset.
257709|NCT02490332|Device|Ventilation tube treatment|Tympanostomy
257710|NCT02490345|Drug|gabapentin|gabapentin usage as adjunctive treatment for pain control
257711|NCT02490345|Drug|Placebo|Identical placebo
257989|NCT02483806|Procedure|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0->5->10, 0->10->5, 5->10->0, 5->0->10, 10->5->0, 10->0->5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
257990|NCT00176813|Drug|Celecoxib|
257991|NCT02486133|Drug|Kivexa|once daily
257110|NCT02268695|Drug|granulocyte colony-stimulating factor (G-CSF)|
257401|NCT02495025|Behavioral|Telephone-based developmental screening and care coordination|
257402|NCT02495038|Drug|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
257403|NCT02495038|Drug|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
257404|NCT00177892|Procedure|sleep disruption|experimentally-induced Sleep Fragmentation
257405|NCT02495051|Procedure|esophageal biopsies|
257406|NCT00178217|Behavioral|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
257407|NCT02497118|Drug|Endostatin|Endostatin,7.5mg/m^2,intravenous, d1-14;
257408|NCT02497118|Drug|Vinorelbine|vinorelbine,25mg/m^2,intravenous, d1, d8;
257409|NCT02497118|Drug|Cisplatin|Cisplatin，75mg/m^2 intravenous,divide into d1-3
257410|NCT02497131|Drug|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
257411|NCT02497144|Other|NMES Group|Neuromuscular electrical stimulation
257412|NCT02497144|Other|Control Group|Breathing exercises
257413|NCT02497157|Drug|Oxaliplatin (L-OHP)|
257414|NCT02497157|Drug|Irinotecan hydrochloride hydrate (CPT-11)|
257415|NCT02497157|Drug|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
257416|NCT02497157|Drug|Levofolinate calcium (l-LV)|
257417|NCT00178243|Procedure|3D Conformal Radiation Therapy and Radiosurgery|
257418|NCT02497157|Drug|Bevacizumab (Bmab)|
256778|NCT02273284|Device|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
256779|NCT02273297|Other|Maternal factors|
257111|NCT02268708|Procedure|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
257112|NCT02268721|Device|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
257113|NCT02268747|Drug|Dacomitinib|The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).
If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction.
257114|NCT00002367|Drug|Saquinavir|
257115|NCT02270983|Drug|Placebo|Matching placebo
257116|NCT02270996|Other|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
257117|NCT00148070|Procedure|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
257118|NCT02271009|Drug|AllerT|Ultrafast immunotherapy
257119|NCT02271009|Drug|Placebo|placebo control
257120|NCT02271022|Other|Non-Interventional Study|Non-Interventional Study
257121|NCT02271035|Drug|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
257122|NCT02271035|Drug|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
257123|NCT02271048|Device|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
256446|NCT02241824|Device|In-elastic lumbar brace|
256447|NCT02241824|Device|Elastic abdominal binder|
256448|NCT02241850|Other|High intensity training|9 weeks of supervised high intensity training
256449|NCT02241863|Behavioral|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
256450|NCT02241863|Behavioral|Routine counseling|
256451|NCT02241876|Drug|N-acetylcysteine|
256452|NCT00144560|Drug|MRA(Tocilizumab)|
256453|NCT02241889|Device|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
256454|NCT02241889|Device|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
256455|NCT02241915|Procedure|Open Colorectal Surgery|
256456|NCT02241915|Procedure|Laparoscopic Surgery|
256457|NCT02241928|Biological|Stem Cell|
256780|NCT02273310|Behavioral|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
256781|NCT02273323|Other|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
256782|NCT02275884|Dietary Supplement|Dark chocolate (85% cocoa)|
256783|NCT02275884|Dietary Supplement|White chocolate (0% cocoa)|
256784|NCT02275897|Procedure|Slow Speed of spinal injection|Speed of injection over 60 seconds
256785|NCT02275897|Procedure|Fast Speed of spinal injection|Speed of injection over 15 seconds
256786|NCT02275910|Drug|E7090|
256787|NCT00148642|Device|uncoated endotracheal tube|intubation
256136|NCT02249403|Drug|Talsaclidine 36 mg|
256137|NCT02249403|Drug|Placebo|
256138|NCT02249416|Drug|Tipranavir (TPV) low|
256139|NCT02249416|Drug|Ritonavir (RTV) low|Norvir®
256140|NCT02249416|Drug|Tipranavir (TPV) high|Retrovir®
256141|NCT02249416|Drug|Ritonavir (RTV) high|
256142|NCT02249416|Drug|Zidovudine|
256143|NCT02249429|Drug|PQR309|60 mg or 80 mg PQR309 per oral (p.o.) once daily until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
256144|NCT02249442|Drug|Tipranavir (TPV)|
256145|NCT02249442|Drug|Ritonavir (r)|
256146|NCT00145509|Drug|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
256147|NCT02249455|Device|Acapella|Treatment time for 20 min twice daily
256148|NCT02249455|Other|ELTGOL|ELTGOL technique 20 min twice daily
256149|NCT02249455|Other|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
256150|NCT02249481|Procedure|Adductor Canal catheter delivering 0.0625% L- Bupivacaine|Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
256151|NCT02249481|Procedure|Femoral nerve catheter delivering 0.0625% L- Bupivacaine|Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
256458|NCT02241941|Drug|Daptomycin|
256459|NCT02241954|Device|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
256460|NCT02241967|Device|Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current delivered by electrodes attached to the scalp.
256461|NCT02241980|Other|Patient survey|
256462|NCT02241980|Other|Physician survey|
251959|NCT02245269|Drug|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
251960|NCT02245295|Procedure|Sedation for EBUS-TBNA|EBUS-TBNA was performed either in general anaesthesia by one of the thoracic surgeons (D.S., P.K.) or by one of the pulmonologists in moderate sedation (D.F., M.K.). The first 116 consecutive patients undergoing EBUS-TBNA in deep sedation were compared with the first 116 consecutive patients with EBUS-TBNA in moderate sedation. On this basis, there was a pseudo-randomization to one of the groups.
251961|NCT02245308|Drug|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
251962|NCT02245308|Behavioral|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
251963|NCT00144950|Procedure|primary video-assisted thorascopic surgery|
251964|NCT02245308|Behavioral|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
251965|NCT02245308|Drug|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
252265|NCT02237638|Biological|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
252266|NCT02237651|Device|topical anesthesia multi-use device|
252267|NCT02237651|Device|topical anesthesia Intranasal Mucosal Atomization|
252268|NCT00144144|Drug|Angiotensin II receptor antagonists, Calcium channel blocker|
252269|NCT02237664|Procedure|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
252270|NCT02237664|Procedure|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
252271|NCT02237677|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
252272|NCT02237690|Drug|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
251615|NCT02247635|Behavioral|Healthy lifestyle and adherence|Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care
251616|NCT02247648|Drug|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
251617|NCT02247648|Drug|Placebo|Patients from control group received a "shame" tramadol pill on day one, two, and 3
251618|NCT00145535|Device|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, ~50 spots over 180°
251619|NCT02249871|Drug|Omeprazole|Will be given daily with oral semaglutide.
251620|NCT02249884|Drug|Urea Dose A|Urea cream for topical use.
251621|NCT02249884|Drug|Urea Dose B|Urea cream for topical use.
251622|NCT02249884|Drug|Urea Dose C|Urea cream for topical use.
251623|NCT02249884|Drug|Chamomile Dose A|Chamomile gel for topical use.
251624|NCT02249884|Drug|Chamomile Dose B|Chamomile gel for topical use.
251625|NCT02249884|Drug|Chamomile Dose C|Chamomile gel for topical use.
251626|NCT02249897|Drug|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
251627|NCT02249910|Drug|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
251628|NCT02249910|Drug|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
251629|NCT00145548|Device|Intra Bronchial Valve|
251630|NCT02249910|Drug|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
251631|NCT02249910|Drug|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
251632|NCT02249936|Drug|AZD1722|
251633|NCT02249936|Drug|Omeprazole|
250995|NCT02224443|Drug|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05~0.1mg.kg-1.h-1cisatracurium besylate,4~8mg.kg-1.h-1propofol,0.1~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%~1.0%
250996|NCT02224456|Drug|Tenofovir disoproxil fumarate|White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with "GILEAD" and "4331" on one side of the tablet.
250997|NCT02224469|Device|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
250998|NCT02224482|Behavioral|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
250999|NCT02224495|Behavioral|Structured exercise training|
251000|NCT02224521|Drug|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
251304|NCT00146471|Drug|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
251305|NCT02256761|Other|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
251306|NCT02256774|Drug|BILR 355 BS|
251307|NCT02256774|Drug|Combivir®|
251308|NCT02256774|Drug|Ritonavir|
251309|NCT02256787|Drug|BILB 1941 ZW - single rising dose part|
251310|NCT02256787|Drug|Placebo|
251311|NCT02256787|Drug|BILB 1941 ZW - solution|
251312|NCT02256787|Drug|BILB 1941 ZW - tablet|
251313|NCT02256787|Other|standardized breakfast|
251314|NCT02256800|Genetic|UGT1A1 genotyping (6,6)|The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2.
251315|NCT00146471|Drug|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
251316|NCT02256800|Genetic|UGTIA1 genotyping (6,7)|The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2.
250711|NCT02231723|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
250712|NCT02231723|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
250713|NCT02231723|Drug|Leucovorin|Arm C, D: Leucovorin 400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
250714|NCT02231723|Drug|Irinotecan|Arm B: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
250715|NCT02231723|Drug|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m^2 I.V. bolus followed by 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
250716|NCT02231723|Drug|MM-398|MM-398 70 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
250717|NCT02231749|Biological|Nivolumab|
250718|NCT02231749|Biological|Ipilimumab|
251001|NCT02224521|Drug|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
251002|NCT02224521|Drug|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
251003|NCT00142675|Behavioral|Physical Activity|
251004|NCT02224521|Drug|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
251005|NCT02226887|Procedure|MESH|Pre-operative :
It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .
Surgical technique:
Peristomal incision with electrocautery
Release the handle of ileum
Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).
Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.
We add the mesh between the edges of the defect during fascia closure.
The skin is sutured "purse string" style.
Post-Op
Hospital discharge after verification of normal digestive transit.
251006|NCT02226887|Procedure|NO MESH|Pre-operative :
It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .
Surgical technique:
Peristomal incision with electrocautery
Release the handle of ileum
Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).
Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.
The skin is sutured "purse string" style.
Post-Op
- Hospital discharge after verification of normal digestive transit
251007|NCT02226887|Radiation|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
251008|NCT00142896|Drug|Tramadol|
251009|NCT02226887|Radiation|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
255284|NCT02275390|Behavioral|Nurse-led Psycho-education|The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).
255285|NCT02275390|Behavioral|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
255286|NCT02275403|Procedure|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
255287|NCT02238912|Drug|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
255288|NCT02238925|Drug|CPX-351|
255289|NCT02238938|Procedure|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
255290|NCT02238938|Procedure|piecemeal resection|Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.
After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done.
255291|NCT02238951|Other|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
255292|NCT02238951|Other|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
255293|NCT02238964|Device|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
255294|NCT02238964|Procedure|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
255295|NCT02238977|Drug|Fluoxetine|Antidepressant
255604|NCT02270424|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
255605|NCT02270424|Drug|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
254666|NCT02251184|Drug|Lansoprazole|
254667|NCT02251197|Drug|BIII 890 CL|
254990|NCT02243956|Other|Flavanol rich food product|polyphenol rich test product
254991|NCT02243969|Dietary Supplement|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
254992|NCT02243969|Dietary Supplement|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
254993|NCT00144833|Drug|fosamprenavir/ritonavir (1400mg/100mg BID)|
254994|NCT02243982|Other|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
254995|NCT02243995|Other|Physical training|
254996|NCT02243995|Behavioral|Physical training|
254997|NCT02244008|Other|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
254998|NCT02246556|Device|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
254999|NCT02246582|Device|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
255000|NCT02246582|Device|Guardian Mobile App|
255001|NCT02246582|Device|640G Insulin Pump|
255002|NCT02246595|Biological|CaCP29|
255003|NCT02246595|Biological|Placebo|
255004|NCT02246608|Device|Routine NPWT plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
255005|NCT02246608|Device|Routine NPWT plus foam wound product|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
255006|NCT02246621|Drug|Abemaciclib|Administered orally
259423|NCT02488798|Procedure|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
259424|NCT02488798|Procedure|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
259425|NCT02490956|Biological|Verorab® (PVRV; Purified Vero Cell Vaccine)|Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363
259426|NCT02490969|Procedure|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
259427|NCT02490982|Drug|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
259428|NCT02490995|Other|Movie|Besides the anesthesist explanations the children will have a movie explanation.
254668|NCT02251197|Drug|Placebo|
254669|NCT02251210|Drug|BIIL 284 BS low dose|
254670|NCT02251210|Drug|BIIL 284 BS medium dose|
254671|NCT02251210|Drug|BIIL 284 BS high dose|
254672|NCT02251210|Drug|Placebo|
254673|NCT02251223|Drug|Tipranavir low dose|
254674|NCT02251223|Drug|Tipranavir medium dose|
254675|NCT02251223|Drug|Tipranavir high dose|
254676|NCT00145665|Procedure|FLT-PET scan|PET scan using FLT
254677|NCT02251223|Drug|Ritonavir low dose|
254678|NCT02251223|Drug|Ritonavir high dose|
254679|NCT02251236|Drug|Stribild|To be administered orally, once daily with food.
254680|NCT02253368|Other|sleep|
254681|NCT02253381|Procedure|Right|Right lateral decubitus position during spinal anesthesia
254682|NCT02253381|Procedure|Left|Left lateral decubitus position during spinal anesthesia
254683|NCT00145977|Drug|Alendronate 70mg|
254684|NCT02253394|Drug|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
259432|NCT02491021|Other|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
259433|NCT02491034|Behavioral|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
259434|NCT02491047|Device|BonyPid-1000TM|BonyPid-1000TM implantation concomitantly to standard of care (SOC) treatment
259435|NCT02491047|Procedure|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
259436|NCT02491060|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
259437|NCT02491060|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
259438|NCT02491073|Other|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
259439|NCT02491086|Drug|Nicotine replacement therapy (NRT) sampling|1-week free NRT
259440|NCT02491086|Behavioral|Smoking cessation counseling|Smoking cessation counseling
259441|NCT00177346|Device|CAS without cerebral protection|
259442|NCT02491099|Drug|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
259443|NCT02491112|Drug|Luliconazole Cream 1%|Application of Luliconazole Cream 1% once daily for 7 days
259444|NCT02491112|Drug|Vehicle Cream|Application of Vehicle Cream once daily for 7 days
259445|NCT02491125|Dietary Supplement|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
259446|NCT02491125|Dietary Supplement|Placebo|12 weeks daily intake of 15g of maltodextrin
259447|NCT02491138|Behavioral|Appearance-based intervention|
254692|NCT02253446|Drug|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
254693|NCT02253459|Drug|UTD1 Injection plus capecitabine|
254694|NCT00145990|Drug|methacholine|
254695|NCT02253459|Drug|Capecitabine|
254696|NCT02253472|Device|Deep Brain Stimulation|
259139|NCT02497820|Drug|Aspirin|Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).
Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.
The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place.
259140|NCT02497833|Dietary Supplement|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
259141|NCT02497833|Other|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
259142|NCT02497846|Device|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity [I]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
259143|NCT00178360|Behavioral|Music Therapy|During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.
Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:
Group singing
Group drumming
Music assisted relaxation
Group song writing
Lyric analysis
Improvisation
Music with art
259144|NCT02497859|Behavioral|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
259145|NCT02497859|Behavioral|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
259146|NCT02497859|Behavioral|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
259147|NCT02497859|Behavioral|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
254370|NCT02260310|Other|A-shi point|
254371|NCT02260323|Other|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
254372|NCT02260323|Other|patient-tailored DMARDs|patient use tailored disease-modifying antirheumatic drugs
258855|NCT02468466|Behavioral|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
258856|NCT02468466|Behavioral|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
258857|NCT02468479|Other|No relevant intervention.|No relevant intervention.
258858|NCT02468492|Biological|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
258859|NCT02468492|Other|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
258860|NCT02468505|Behavioral|STEPS|time-limited behavioral counseling, online materials, training
258861|NCT02468518|Drug|Vitamin E capsule|Capsules will be distributed to each participant free of cost
258862|NCT00002471|Drug|thiotepa|
258863|NCT00174668|Drug|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
258864|NCT02468531|Drug|oxygen|50% oxygen inhalation during the the whole perioperative period
258865|NCT02468531|Drug|Xenon|50% Xenon inhalation during the the whole perioperative period
258866|NCT02468544|Other|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
258867|NCT02468557|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
258868|NCT02468557|Drug|Nab-paclitaxel|Nab-paclitaxel administered intravenously on Days 1, 8 and 15 of each 28 day cycle
258869|NCT02468557|Drug|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 mg/m^2 or racemic leucovorin 400 mg/m^2, oxaliplatin 85 mg/m^2, bolus 5-fluorouracil 400 mg/m^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m^2.
258870|NCT02468570|Other|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
258871|NCT02468583|Drug|FX006|Experimental
258281|NCT02479256|Drug|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
258282|NCT02479256|Drug|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
258283|NCT02479269|Other|Aerobic exercise|Aerobic exercise for 8 weeks
258284|NCT02479282|Procedure|natural cesarean section|
258285|NCT02479282|Procedure|traditional cesarean section|
258286|NCT02479295|Device|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
258287|NCT02479308|Drug|Moxifloxacin|Single administration
258288|NCT02479308|Drug|ALKS 5461|Daily administration for a total of 12 dosing days
258289|NCT00176124|Other|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
258290|NCT02479308|Drug|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
258577|NCT02472951|Other|Low carbohydrate meals|Meal macronutritional energy composition:
Carbohydrate 30% Protein 30% Fat 40%
258578|NCT02472951|Other|Standard carbohydrate meals|Meal macronutritional energy composition:
Carbohydrate 55% Protein 15% Fat 30%
258579|NCT02472964|Biological|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
258580|NCT02472964|Biological|HERMyl 1401O Trastuzumab|HERMyl 1401O Trastuzumab 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
258581|NCT02474940|Behavioral|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
257992|NCT02486159|Drug|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
257993|NCT02486159|Procedure|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
257994|NCT02486172|Behavioral|Peer support program|Peer support program as an additional service to the routine clinical service
257995|NCT02486185|Other|SCREENING TEST|Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).
Muscle force will be measured using a hydraulic dynamometer
Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)
257996|NCT02486198|Drug|placebo|For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.
For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)
257997|NCT02486198|Drug|GM|For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.
For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)
257998|NCT02486198|Drug|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
257999|NCT02486211|Drug|Amantadine|100mg BID for 7 days at 0600 and 1200
258000|NCT02486211|Drug|Placebo|Placebo comparitor
258001|NCT00176826|Procedure|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
258002|NCT02486224|Dietary Supplement|Kona Deep|Subjects will receive Kona Deep post exercise
258003|NCT02486224|Dietary Supplement|Spring Water|Subjects will receive Spring Water post exercise
258004|NCT02486224|Dietary Supplement|Sports Drink|Subjects will receive Sports Drink post exercise
258291|NCT02479321|Other|PGDT based on noninvasive monitoring|Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based PGDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.
In the intra and postoperative period (4 hours), hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. In case of instability a Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders.
257419|NCT02497170|Behavioral|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
257420|NCT02497183|Device|ultrasound|A repeat ultrasound exam following oral contrast material consumption
257712|NCT02490371|Device|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
257713|NCT02490371|Behavioral|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
257714|NCT02490384|Procedure|Physical exam indicated cerclage|Cervical cerclage
257715|NCT02490397|Other|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
257716|NCT00177281|Drug|S CKD602|
257717|NCT02492633|Behavioral|Intervention|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:
A web-based smoking cessation intervention via Facebook
Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.
A behavioral "nudge" designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable "pledge" program.
257718|NCT02492646|Procedure|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
257719|NCT02492646|Procedure|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
257720|NCT02492659|Procedure|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
257721|NCT00177567|Drug|olanzapine|
257722|NCT02492659|Procedure|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
257723|NCT02492685|Device|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
257724|NCT02492698|Dietary Supplement|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
257124|NCT02271061|Device|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
257125|NCT02271061|Device|Control tape|Apply tape in same technique without tension.
257421|NCT02497183|Other|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
257422|NCT02497196|Device|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
257423|NCT02497196|Device|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
257424|NCT02497196|Device|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
257425|NCT02497196|Device|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
257426|NCT02497222|Drug|RNS60|
257427|NCT02497222|Drug|Normal Saline|
257428|NCT02499198|Other|[D4]Nornicotine - 10% Lowest|Level equal to 10% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
257429|NCT02499198|Other|[D4]Nornicotine - 5% Lowest|Level equal to 5% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
257430|NCT02499198|Other|13C6-NNN|0.5µg/g - below traditional levels found in moist snuff
257431|NCT02499198|Other|Herbal Snuff|A tobacco-free herbal snuff, such as Smokey Mountain or similar
256788|NCT02275923|Device|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
256789|NCT02275936|Drug|N91115|S Nitrosoglutathione Reductase Inhibitor
256790|NCT02275949|Device|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
256791|NCT02275949|Device|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
256792|NCT02275949|Device|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
256793|NCT02275949|Device|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
256794|NCT02275949|Device|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
256795|NCT02275962|Drug|K-877|
256796|NCT02275962|Drug|Rifampin|
256797|NCT02275975|Drug|K-877|
256798|NCT00148655|Device|Decision Board|Decision board that explains the risks and benefits of treatment options
256799|NCT02275975|Drug|Fluconazole|
256800|NCT02275988|Drug|K-877|
256801|NCT02275988|Drug|Clarithromycin|
256802|NCT02276001|Drug|K-877|
256803|NCT02276001|Drug|Cyclosporine|
257126|NCT02271074|Other|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
257127|NCT02271074|Behavioral|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
257128|NCT00148083|Drug|Risperdal Consta (drug)|
256463|NCT00144573|Drug|MRA(Tocilizumab)|
256464|NCT02242006|Other|serial serum sampling for quantification of drug concentration|
256465|NCT02244567|Drug|Metformin 850 mg twice daily for 3 months|This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
256466|NCT02244567|Procedure|Serum uc-oc|Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
256467|NCT02244567|Other|drug|This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
256468|NCT02244580|Device|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
256469|NCT02244593|Other|FAST MRI and mammography screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
256470|NCT02244606|Drug|SCY-078|
256471|NCT02244606|Drug|Fluconazole|
256472|NCT02244606|Drug|Micafungin|
256473|NCT02244619|Drug|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
256474|NCT00144911|Drug|Salmeterol|
256475|NCT02244619|Drug|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
256476|NCT02244632|Drug|Modufolin|30 or 60 mg/m2 IV on day 1and day 2 of each 14-day cycle. 4 cycles in total.
256477|NCT02244632|Drug|Fluorouracil|500 mg/m2 IV on day 1and day 2 of each 14-day cycle. 4 cycles in total.
256804|NCT02276014|Dietary Supplement|Beta-carotene|
256805|NCT02276027|Drug|BYL719|BYL719 will be dosed as 350 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take BYL719 exactly as prescribed.
252273|NCT02237703|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
252274|NCT02237729|Biological|PF-06410293|PF-06410293 will be administered as a single 40 mg, subcutaneous dose
252275|NCT02237729|Biological|Adalimumab-US|Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
252276|NCT02237729|Biological|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
252277|NCT02237742|Drug|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
252278|NCT02237755|Drug|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
252279|NCT00144157|Drug|Nevirapine|
252280|NCT02237755|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
252281|NCT02237768|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
252282|NCT00144404|Drug|Transdermal Testosterone Gel|2.0 mg per pump of testosterone gel (8 pumps, 12 pumps, 16 pumps). Pharmacokinetic study
252283|NCT02240121|Drug|Placebo|
252284|NCT02240134|Behavioral|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
252592|NCT02271594|Behavioral|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
252593|NCT02271607|Device|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
252594|NCT02271620|Procedure|nasal allergen provocation test|nasal allergen provocation test
252595|NCT02271633|Dietary Supplement|Sodium nitrate|
252596|NCT00002368|Drug|Lamivudine|
252597|NCT00148135|Drug|Carboplatin|
252598|NCT02271633|Dietary Supplement|Beetroot juice|
251634|NCT02249949|Drug|efatutazone|oral
251635|NCT02249949|Drug|placebo|oral
251966|NCT02245308|Drug|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
251967|NCT02245321|Dietary Supplement|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
251968|NCT02245321|Dietary Supplement|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
251969|NCT02245321|Other|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
251970|NCT02245321|Other|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
251971|NCT02245321|Dietary Supplement|Placebo|Receive pills to take daily that contain 0 mg iron.
251972|NCT02245334|Drug|Povidone-Iodine|1 pill per biopsy
251973|NCT02245360|Drug|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
251974|NCT00144963|Drug|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
251975|NCT02245360|Drug|placebo|placebo tablet given once daily over 60 days
251976|NCT02245373|Drug|Antidepressants|
251977|NCT02245373|Other|Active Monitoring|
251978|NCT02245386|Radiation|transperineal pelvic floor ultrasound|Transperineal pelvic floor ultrasound applied for the submitted 120 women "primiparae" (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.
251979|NCT02247674|Procedure|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
251980|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
251981|NCT02247687|Drug|Protease inhibitor|Modification in the antiretroviral treatment
•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
251982|NCT02247687|Drug|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
251317|NCT02256800|Genetic|UGTIA1 genotyping (7,7)|The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2.
251318|NCT02256800|Genetic|UGT1A1 non-genotyping|The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
251319|NCT02256800|Drug|bevacizumab (Avastin)|
251320|NCT02256800|Drug|irinotecan|
251321|NCT02256800|Drug|Leucovorin|
251322|NCT02256800|Drug|5-FU|
251323|NCT02256813|Drug|BIRT 2584 XX|
251636|NCT02249975|Device|Coldplay Focal Cryoballoon Ablation System|Ablation of Barrett's Esophagus using the Coldplay Focal CryoBalloon Ablation System. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
251637|NCT02249988|Drug|ABX203 therapeutic Hepatitis B vaccine treatment arm|
251638|NCT02250014|Procedure|cryotherapy|Undergo cryotherapy
251639|NCT02250014|Biological|sargramostim|Given subcutaneously
251640|NCT00145561|Drug|Saquinavir and Ritonavir|
251641|NCT02250027|Drug|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
251642|NCT02250027|Drug|Placebo|2 capsules at once, 3 times a day, for 7 days
251643|NCT02250040|Other|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
251644|NCT02250040|Other|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
251645|NCT02250053|Other|Exercise|
251646|NCT00002349|Drug|Stavudine|
251647|NCT00145769|Radiation|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
251648|NCT02252068|Behavioral|IDC|Individual Drug Counseling manual that has been demonstrated efficacy for the treatment of drug dependence.
251010|NCT02226887|Other|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
251011|NCT02226900|Procedure|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
251012|NCT02226900|Procedure|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
251013|NCT02226913|Drug|Lidocaine|2% lidocaine
251014|NCT02226913|Drug|sodium bicarbonate|8.4% sodium bicarbonate
251015|NCT02226913|Drug|placebo|sterile distilled water
251016|NCT02226926|Drug|Aggrenox|
251017|NCT02226926|Drug|Persantin Retard|
251018|NCT02226926|Drug|Acetylsalicylic acid|
251019|NCT00142896|Drug|Naloxone|
251020|NCT02226939|Drug|BILN 2061 ZW|
251021|NCT02226939|Drug|Placebo|
251324|NCT02256813|Drug|Warfarin sodium|
251325|NCT02256813|Drug|Omeprazole|
251326|NCT00146484|Drug|Twice Daily versus Three Times Daily Insulin Injections|
251327|NCT02256813|Drug|Dextromethorphan hydrobromide|
251328|NCT02258984|Device|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
251329|NCT02259010|Drug|Alisertib|Alisertib tablets
251330|NCT02259010|Drug|Itraconazole|Itraconazole oral solution
251331|NCT02259023|Other|Liquid: Sugar sweetened beverage consumption|Sugar sweetened beverage consumption
251332|NCT02259023|Other|Solid: Grain based desserts and candy consumption|Grain based desserts and candy consumption
255606|NCT02270424|Drug|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
255607|NCT02270424|Drug|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
255608|NCT02270437|Drug|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
255609|NCT02270450|Procedure|therapeutic conventional surgery|Undergo abdominal surgery
255610|NCT02270450|Procedure|gastrointestinal complications management/prevention|Undergo non-surgical management
255611|NCT02270450|Other|quality-of-life assessment|Ancillary studies
255612|NCT02270463|Drug|SL-401|
255613|NCT00148031|Drug|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
255614|NCT02270489|Biological|AFFITOPE® PD01A + Adjuvant|s.c. injection
255615|NCT02270489|Biological|AFFITOPE® PD03A + Adjuvant|s.c. injection
255616|NCT02270489|Biological|Adjuvant without active component|s.c. injection
255617|NCT02270502|Device|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
255618|NCT02272751|Behavioral|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
255619|NCT00148317|Drug|Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin, Cyclophosphamide|Bortezomib 1.3 mg/m2 days 1, 4, 8, 11 (initial cycles) Dexamethasone 40 mg Days 1-4, 8-11, 15-18 (initial cycles) Doxil 30 mg/m2 Day 4 of subsequent cycles
255620|NCT02272764|Drug|Itraconazole|Administered orally in a crossover design
255621|NCT02272764|Drug|ALKS 5461|Administered sublingually in a crossover design
255622|NCT02272777|Drug|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
255623|NCT02272777|Drug|Nilotinib|Nilotinib 300mg BID or 400mg QD
255007|NCT00145145|Biological|MAGE-3.A1 peptide and CpG 7909|
255008|NCT02246621|Drug|Anastrozole|Administered orally
255009|NCT02246621|Drug|Letrozole|Administered orally
255010|NCT02246621|Drug|Placebo|Administered orally
255296|NCT00144274|Drug|Ambroxol Lozenge|
255297|NCT02238977|Drug|Bupropion|Antidepressant
255298|NCT02239003|Drug|DAOIB|
255299|NCT02239003|Drug|Placebo|
255300|NCT02239029|Drug|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
255301|NCT02239029|Drug|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
255302|NCT02239042|Procedure|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
255303|NCT02239081|Drug|CTP-730|
255304|NCT02239081|Drug|Placebo for CTP-730|
255305|NCT02239094|Drug|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
255306|NCT02239107|Drug|N-Acetyl cysteine|
255307|NCT00144287|Drug|Tipranavir/Ritonavir|
255308|NCT02241174|Drug|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
255309|NCT02241187|Drug|PEGPH20|
255310|NCT02241187|Drug|Cetuximab|
255311|NCT02241187|Device|DW & DCE-MRI|
254685|NCT02253394|Drug|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
254686|NCT02253407|Biological|MMR vaccine|
254687|NCT02253420|Drug|Copanlisib (BAY80-6946)|Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose TBD (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose TBD (based on part 1 data)
Part 1 & Part 2
Cycle 2 and subsequent cycles:
Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg
254688|NCT02253420|Drug|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
254689|NCT02253420|Drug|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
254690|NCT02253433|Other|Enhanced in-clinic care and intervention|This arm receives enhanced in-clinic care, as well as a customized home-based environmental exposure assessment and multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
254691|NCT02253446|Drug|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
255011|NCT02246634|Other|Diffusion Weighted MRI scan|Non-contrast diffusion weighted MRI scan of the liver
255012|NCT02246647|Other|saccharides|saccharides will be compared in IBS-C vs healthy participants
255013|NCT02246647|Procedure|esophagogastroduodenoscopy|duodenal biopsies will be collected from IBS-C volunteers and healthy volunteers
255014|NCT02246647|Procedure|flexible sigmoidoscopy|colonic biopsies will be collected from IBS-C volunteers and healthy volunteers
255015|NCT02246660|Drug|Resveratrol|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
OR
The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
255016|NCT02246660|Drug|Placebo|Placebo will be taken orally for 6 months.
255017|NCT02246673|Drug|RDEA3170 15 mg|
255018|NCT00145158|Biological|8 HLA-A2 restricted peptides and Montanide ISA-51|
255019|NCT02246673|Drug|RDEA3170 10 mg|
255020|NCT02246673|Drug|RDEA3170 2.5|
255021|NCT02246673|Drug|RDEA3170 5 mg|
255022|NCT02246673|Drug|Febuxostat 40 mg|
255023|NCT02246673|Drug|Febuxostat 80 mg|
254697|NCT02253485|Drug|telbivudine|in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.
in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV.
254698|NCT02253498|Device|deep brain stimulation (DBS)|
254699|NCT02253511|Drug|Cidan capsule|
254700|NCT02253524|Drug|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
254701|NCT02253524|Drug|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
254702|NCT02253537|Device|CST001|
254703|NCT02253550|Drug|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
254704|NCT02253550|Drug|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
254705|NCT00002351|Drug|Indinavir sulfate|
254706|NCT02255695|Other|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
254707|NCT02255708|Other|Proprioceptive Neuromuscular Facilitation - PNF|
254708|NCT02255721|Behavioral|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
254709|NCT02255721|Behavioral|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
254710|NCT00146315|Behavioral|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
254711|NCT02255734|Drug|Acyclovir|
255032|NCT02248961|Drug|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg
255033|NCT02248974|Other|LVAD Decision Aid|Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.
This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE).
254373|NCT00146848|Device|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|All subjects in this trial receive the same device. For the purpose of this trial, "intervention" is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm.
254374|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 1g|
254375|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 5g|
254376|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 10g|
254377|NCT02262481|Drug|placebo|
254378|NCT02262494|Procedure|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
254379|NCT00147199|Drug|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
254380|NCT02262494|Procedure|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
254381|NCT02262494|Procedure|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
254382|NCT02262507|Device|Q Collar|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins
254383|NCT02262520|Drug|Apixaban|
254384|NCT02262520|Drug|Digoxin|
254385|NCT02262533|Drug|Apixaban|
254386|NCT02262533|Drug|Atenolol|
254387|NCT02262546|Drug|Pramipexole extended-release (ER) tablets|
254388|NCT02262546|Drug|Pramipexole immediate-release (IR) tablets|
254389|NCT02262546|Drug|Moxifloxacin|
254390|NCT00147212|Drug|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
254391|NCT02262546|Drug|Pramipexole Placebo|
254392|NCT02262546|Drug|Moxifloxacin Placebo|
254393|NCT02262559|Drug|BIBR 277 tablet|
254712|NCT02255747|Drug|Lactulose|
259148|NCT02497872|Procedure|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
259149|NCT00178672|Device|stenting|stenting of carotid arteries
259150|NCT02499952|Drug|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
259151|NCT02499965|Drug|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
259152|NCT02499965|Drug|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
259153|NCT02499978|Drug|Darunavir/Cobicistat|Fixed dose combination medication
259154|NCT02499978|Drug|Dolutegravir|single tablet medication
259155|NCT02499991|Behavioral|memory|keep track of social events in diary for memory recall. Used by treatment group
259156|NCT02500004|Radiation|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
259157|NCT02500004|Radiation|DXA scanning|Body composition: DXA scanning, D2O and MRI.
259158|NCT02500004|Procedure|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
259159|NCT02500004|Procedure|Blood sampling|Systemic inflammatory profile: blood sampling.
259160|NCT00178685|Behavioral|Self-determination Intervention for Tobacco Dependence|autonomy supported behavioral intervention for tobacco dependent individuals
259161|NCT02500004|Other|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
259162|NCT02500004|Device|Accelerometry|Physical activity level: accelerometry.
259163|NCT02500004|Other|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
259164|NCT02500017|Dietary Supplement|Melatonin|5mg rapid release melatonin capsule
259165|NCT02500017|Other|Placebo|matching placebo capsule
259166|NCT02500030|Procedure|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
259167|NCT02500030|Procedure|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
258582|NCT02474940|Behavioral|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
258583|NCT02474940|Behavioral|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
258584|NCT02474953|Dietary Supplement|Proprietary Curcumin Formulation|
258585|NCT02474953|Dietary Supplement|Unformulated Comparator Curcumin Product|
258586|NCT02474966|Device|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
258587|NCT02474979|Device|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
258588|NCT02474979|Other|Control|
258872|NCT02468583|Drug|Kenalog®-40|Comparator
258873|NCT02468596|Other|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to a serie of electrical stimulations of the median nerve
258874|NCT00174681|Drug|Insulin Glargine|
258875|NCT02468596|Other|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin Vigorimètre, RT-mISS, T25W, 9 hole peg test, and ataxia scale
258876|NCT02468609|Radiation|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
258877|NCT02470793|Procedure|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
258878|NCT02470793|Procedure|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
258292|NCT02479321|Device|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index. We will also collect hourly diuresis and blood loss.
258293|NCT02479334|Other|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
258294|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
258295|NCT02481479|Drug|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
258296|NCT02481492|Device|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
258297|NCT00176423|Drug|galantamine|
258298|NCT02481492|Device|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
258299|NCT02481505|Drug|Chloroprocaine HCl 1%|Intrathecal Route
258300|NCT02481518|Drug|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
258301|NCT02481518|Other|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
258302|NCT02481531|Other|Previously marketed infant formula|
258303|NCT02481531|Other|Previously marketed formula using a similar protein|
258304|NCT02481544|Behavioral|Gratitude Journaling Plus SOC|
258305|NCT02481544|Behavioral|Memorable Events Journaling Plus SOC|
258306|NCT02481557|Device|Oxalate Salt Solution|Applied by dentist
258307|NCT02481570|Other|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
258308|NCT00176436|Behavioral|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
257725|NCT02492698|Dietary Supplement|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
257726|NCT02492711|Biological|Margetuximab|15 mg/kg via IV (intravenous) infusion over 120 minutes on day 1 of each 21 day cycle, until progression or unacceptable toxicity develops.
257727|NCT02492711|Biological|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion over 30-90 minutes on day 1 of each 21 day cycle, until progression or unacceptable toxicity develops.
258005|NCT02486237|Other|None, observational study|None, it is an observational study
258006|NCT02486250|Other|Validation Study|
258007|NCT02486263|Other|Study|Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)
Total fluid volume restriction (120-140 milliliters/kilogram/day)
Feeding duration over 30 minutes
Infant feeds with right side down
Infant is placed on back following feeds
258008|NCT02486276|Drug|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
258009|NCT02488148|Behavioral|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
258010|NCT02488148|Behavioral|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
258011|NCT02488161|Other|No intervention|
258012|NCT02488174|Other|PROOFcheck|
258013|NCT02488187|Device|ABUS|Automated breast ultrasound
258014|NCT02488200|Other|No intervention|No intervention
258015|NCT02488213|Other|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
258016|NCT02488213|Other|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
257432|NCT02499211|Other|Intervention stores|In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.
Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.
Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them.
257433|NCT02499224|Drug|YYB101|Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.
Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development
257434|NCT00178568|Behavioral|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
257435|NCT02499237|Drug|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
257728|NCT02492711|Drug|Capecitabine|1000 mg/m2 BID for 14 days in a 21-day cycle
257729|NCT02492711|Drug|Eribulin|1.4 mg/m2 on days 1 and 8 of a 21-day cycle
257730|NCT02492711|Drug|Gemcitabine|1000 mg/m2 on days 1 and 8 of a 21-day cycle
257731|NCT02492711|Drug|Vinorelbine|25-30 mg/m2 on days 1 and 8 of a 21-day cycle
257732|NCT00177567|Drug|paroxetine|
257733|NCT02492737|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
257734|NCT02492750|Biological|Anakinra|Given SC
257735|NCT02492750|Drug|Dexamethasone|Given PO
257736|NCT02492750|Other|Laboratory Biomarker Analysis|Correlative studies
257737|NCT02492750|Drug|Lenalidomide|Given PO
257738|NCT02495064|Drug|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
257739|NCT02495077|Biological|Infliximab|A single dose, of 3mg/kg infusion
257740|NCT02495077|Drug|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
257741|NCT02495077|Drug|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
257129|NCT02271074|Other|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
257130|NCT02271100|Device|ultrasound guidance|use of ultrasound for entry position estimation
257131|NCT02273323|Other|Placebo|Placebo: tea flavour, colouring and sugar
257132|NCT02273336|Other|cytology specimen collection procedure|Undergo tissue and blood sample collection
257133|NCT02273336|Other|laboratory biomarker analysis|Correlative studies
257134|NCT02273349|Device|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
257135|NCT02273362|Drug|Erlotinib Hydrochloride|Given PO
257136|NCT00148382|Drug|ATL-962|
257137|NCT02273362|Other|Laboratory Biomarker Analysis|Correlative studies
257138|NCT02273362|Other|Quality-of-Life Assessment|Ancillary studies
257139|NCT02273375|Drug|MEDI4736|
257140|NCT02273375|Drug|Placebo|
257141|NCT02273388|Drug|BI 6727|
257142|NCT02273401|Drug|BI 11054 CL|
257143|NCT02273401|Drug|Placebo|
257144|NCT02273414|Drug|BIIL 284 BS - rising dose|
257145|NCT02273414|Drug|Placebo|
257146|NCT02273427|Drug|BIIL 284 BS|
257147|NCT00148395|Drug|Gemcitabine|
257436|NCT02499237|Drug|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
257437|NCT02499250|Device|remote ischemic conditioning (TDFT-12-A2)|The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the "TDFT-12-A2" device produced by "Shenzhen TDF Tai Smart technology Co., Ltd."
256806|NCT02276027|Drug|INC280|INC280 will be dosed as 600 mg twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to takeINC280 exactly as prescribed.
256807|NCT02276027|Drug|LDK378|LDK378 will be dosed as 750 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take LDK378 exactly as prescribed.
256808|NCT02239601|Other|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program will be provided to continue throughout chemotherapy treatment
256809|NCT02239614|Biological|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
256810|NCT02239614|Biological|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
256811|NCT02239627|Drug|Epidural steroid|
256812|NCT02239627|Drug|Clonidine|
256813|NCT02239653|Behavioral|Physician communication|
256814|NCT02239666|Other|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
256815|NCT02239679|Drug|Aminolevulinic Acid|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
256816|NCT02239679|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
256817|NCT00144339|Drug|tiotropium|
256818|NCT02239679|Device|BLU-U|10 J/cm2 blue light delivered at 10mW/cm2
256819|NCT02239679|Procedure|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable AK lesions at screening.
256820|NCT02239692|Drug|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
256821|NCT02239718|Procedure|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
256822|NCT02239718|Procedure|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
256823|NCT02239731|Drug|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
257148|NCT02273427|Other|high fat meal|
252599|NCT02271633|Dietary Supplement|Spinach|
252600|NCT02271633|Dietary Supplement|Rocket salad|
252601|NCT02271646|Drug|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
252602|NCT02271659|Radiation|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
252603|NCT02271659|Radiation|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
252604|NCT02271672|Device|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
252605|NCT02271672|Device|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
252606|NCT02271685|Other|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
252607|NCT02271685|Other|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
252608|NCT00148135|Drug|Gemcitabine|
252609|NCT02271685|Other|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
252610|NCT02271685|Other|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
252611|NCT00148421|Drug|Darbepoetin alfa and Epoetin alfa|
252905|NCT02266940|Drug|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
252906|NCT02266953|Behavioral|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
252907|NCT02266953|Behavioral|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
252908|NCT02266966|Drug|F2695|
252909|NCT02266992|Biological|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
251983|NCT02247687|Other|Counseling arm|No change of antiretroviral treatment but only counseling
251984|NCT02247726|Drug|Saline Placebo (0.5mL injection)|
251985|NCT02247726|Drug|RSV F vaccine (0.5mL injection)|
252285|NCT02240134|Device|Air Filtration Unit Treatment (Tx2)|A 20" x 18" Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the "high" setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency.
252286|NCT02240134|Device|Placebo Intervention (Tx3)|Similar to Tx1, a 20" x 18" Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter.
252287|NCT02240147|Behavioral|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
252288|NCT02240160|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
252289|NCT02240173|Dietary Supplement|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
252290|NCT02240173|Drug|Haloperidol|Conventional drug normally used for psychotic problems
252291|NCT02240186|Device|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
252292|NCT02240186|Device|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
252293|NCT00144417|Drug|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
252294|NCT02240199|Drug|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
252295|NCT02240199|Drug|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
252296|NCT02240199|Drug|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
252297|NCT02240199|Drug|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
251649|NCT02252081|Drug|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
251650|NCT02252081|Drug|Placebo|placebo pill(s) orally per day for 16 weeks
251651|NCT02252094|Device|Hemolung|Hemolung (Alung technologies, Pittsburgh, PA, USA) is an extracorporeal carbon dioxide removal device. It removes blood through a reinforced double lumen 15.5F catheter, pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by a negative pressure sweep gas through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
251652|NCT02252094|Other|Ultra-protective ventilation|Ventilation with </= 3ml/kg predicted body weight
251653|NCT02252094|Other|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
251654|NCT02252107|Drug|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
251655|NCT02252120|Device|Supreme|
251656|NCT02252120|Device|Laryngeal Tube|
251657|NCT02252133|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear
251986|NCT02247739|Biological|Recombinant human C1 inhibitor|
251987|NCT02247739|Other|Placebo|
251988|NCT02247752|Other|inactive carrier|Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.
Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology.
251989|NCT02247778|Procedure|conventional plate osteosynthesis|Standard incision
251990|NCT02247778|Procedure|mini-incision-type osteosynthesis|Mini-incision
251991|NCT00145314|Drug|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.
Cetuximab weekly.
251992|NCT02247791|Procedure|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
251993|NCT02247791|Procedure|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
251994|NCT02247804|Drug|Bimatoprost sustained-release|Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
251995|NCT02247804|Other|Sham|Sham administered on Day 1, Week 16, and Week 32, as per protocol.
251333|NCT02259036|Other|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
251334|NCT00146692|Behavioral|Free medical treatment|
251335|NCT02259049|Dietary Supplement|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
251336|NCT02259049|Dietary Supplement|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
251337|NCT02259062|Other|Music with brief mindfulness intervention|Music listening with mindfulness therapy
251338|NCT02259062|Other|Music listening alone|
251339|NCT02259062|Other|Audiobook listening|
251340|NCT02259075|Drug|Botulinum Toxin Type A|
251341|NCT02259088|Drug|ranibizumab|intravitreal injections for 3 months then as needed
251342|NCT02259088|Procedure|laser|laser photocoagulation according to ETDRS guidelines
251343|NCT02259101|Behavioral|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
251344|NCT02259101|Behavioral|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
251658|NCT00145769|Radiation|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
251659|NCT02252133|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear
251660|NCT02252146|Drug|IMO-8400 given subcutaneously either weekly or twice weekly|
251661|NCT02252172|Drug|Daratumumab|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 5 years).
251662|NCT02252172|Drug|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
251663|NCT02252172|Drug|Dexamethasone|Dexamethasone 40 mg intravenously or orally (only when intravenous formulation is not available) once in a week.
255941|NCT02265757|Behavioral|Cognitive Rehabilitation|Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.
Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual.
255942|NCT02265757|Behavioral|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
255943|NCT02265757|Behavioral|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
255944|NCT02265757|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
255945|NCT02265757|Behavioral|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
255946|NCT02265770|Drug|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
255947|NCT02265770|Drug|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
255948|NCT02268032|Drug|DHEA|
255949|NCT02268032|Drug|Another Androgenic Agent (VRaA)|
255950|NCT02268032|Drug|Fixed combination of 2 androgenic agents (VR2A)|
255951|NCT02268045|Biological|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
255952|NCT00147836|Drug|Novolin-R|
255953|NCT02268058|Drug|Acetaminophen|routine administration of medication for a 72 hour period
255312|NCT02241187|Other|blood draws|Blood samples will be drawn at various time points.
255313|NCT02241200|Drug|DA3880|
255314|NCT00144508|Other|current treatment|continue current treatment
255315|NCT02241200|Drug|Aranesp|
255316|NCT02241213|Device|Transcranial Magnetic Stimulation (TMS-r)|10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil "placebo" for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI).
255624|NCT02272790|Drug|AZD1775 + carboplatin|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
255625|NCT02272790|Drug|AZD1775 + PLD|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Chemotherapy is a category of cancer treatment that uses chemical substances, especially one or more anti-cancer drugs (chemotherapeutic agents) that are given as part of a standardized chemotherapy regimen.
255626|NCT02272803|Drug|Lenalidomide|
255627|NCT02272803|Drug|Dexamethasone|
255628|NCT02272803|Biological|Elotuzumab (BMS-901608)|
255629|NCT02272816|Drug|Carboplatin AUC-10|Carboplatin will be administered as a day case and doses will be calculated using the Calvert formula as below:
Dose (mg) = (GFR + 25) x 10
Treatment will be repeated every 3 weeks for 3 or 4 cycles depending on the metabolic response after cycle 1 (assessed by PET-CT scan). Patients who display complete response after cycle 1 will have 3 cycles in total. Those who display partial response will have 4 cycles in total. Patients who display no response after cycle 1 but do display a response after cycle 2 will have 4 cycles in total. Those who display no response after cycle 2 will be withdrawn.
255630|NCT00148330|Drug|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia]) was injected into the vitreous under sterile conditions in a minor procedures area.
255631|NCT02272829|Behavioral|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
255632|NCT02272829|Other|Health Education|
255633|NCT02272842|Dietary Supplement|Vitamin B12|Vitamin B12 in a multivitamin paste.
255634|NCT02272855|Biological|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
255024|NCT02246686|Drug|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
255025|NCT02246686|Drug|Placebo|Application over 12 weeks 20 drops three time daily
255026|NCT02248896|Drug|Angiotensin-converting enzyme inhibitors (ACEIs)|
255027|NCT02248896|Drug|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
255028|NCT02248922|Drug|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
255029|NCT02248948|Dietary Supplement|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
255030|NCT02248948|Dietary Supplement|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
255031|NCT02248961|Drug|Fimasartan|Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).
If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).
When possibilities are, the patient should be administrated by the study medication at the same time in the morning.
255317|NCT02241213|Device|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
255318|NCT02241226|Behavioral|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
255319|NCT02241252|Device|iPhone ECG|Please see detailed description for additional information.
255320|NCT02241265|Procedure|Bronchial Thermoplasty|Thermoplasty delivers thermal energy to the airways to reduce bronchial muscle mass and airway reactivity. Each application delivers the energy over 10 seconds to each bronchial segment.
255321|NCT02241278|Drug|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
255322|NCT02241291|Procedure|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
255323|NCT02241330|Dietary Supplement|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
255324|NCT02241330|Dietary Supplement|Fortification|Wheat flour is fortified before testmeal preparation
255034|NCT02248987|Other|patients treated with antipsychotics|
255035|NCT02249000|Device|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
255036|NCT00145457|Procedure|Blood sample|
255037|NCT02249013|Procedure|Cytoreductive Surgery (CRS)|CRS will be performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
255038|NCT02249013|Procedure|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC will be performed according to the closed-abdomen technique using cisplatin (25 mg/L of perfusate/m2, total limit of 240mg) for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 3L to 6L) will be circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
255039|NCT02249013|Drug|combination of carboplatin and paclitaxel|Systemic chemotherapy will include the standard combination of carboplatin and paclitaxel as adjuvant or neo-adjuvant plus adjuvant regimens.
255040|NCT02249026|Drug|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
255041|NCT02249026|Drug|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
255042|NCT02251249|Drug|Paracetamol concentration time curve from 0 to 120 min|It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
255043|NCT02251262|Other|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
255044|NCT02251275|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
255045|NCT02251288|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
255335|NCT02244060|Other|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
254713|NCT02255760|Drug|MEDI3902|MEDI3902
254714|NCT02255760|Drug|Placebo|Placebo
254715|NCT02255773|Behavioral|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
254716|NCT02255773|Behavioral|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
254717|NCT02255786|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
254718|NCT02255799|Drug|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
254719|NCT02255799|Drug|Placebo|Placebo capsule once daily for 70 days.
254720|NCT02255812|Dietary Supplement|Single intragastric instillation of 200 mL tap water via nasogastric tube|
254721|NCT00146315|Behavioral|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
254722|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
254723|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
254724|NCT02255812|Dietary Supplement|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
254725|NCT02255812|Dietary Supplement|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
254726|NCT02255812|Dietary Supplement|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
254727|NCT02255825|Genetic|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
254728|NCT02257957|Drug|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
254729|NCT02257970|Drug|oral anti-inflammatory drug|1 capsule, three times a day, for four months
254730|NCT02257970|Drug|Placebo|1 capsule, three times a day, for four months
254731|NCT02257983|Drug|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
259168|NCT02500043|Drug|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
259169|NCT02500043|Drug|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
254394|NCT02262559|Drug|BIBR 277 capsule|
254395|NCT02262572|Drug|Telmisartan /HCTZ - compression tablet (DC)|
254396|NCT02262572|Drug|Telmisartan /HCTZ - dry granulation tablet (DG)|
254397|NCT02262572|Drug|Telmisartan /HCTZ - present commercial formulation|
254398|NCT02262585|Drug|BIBR 277 tablet|
254399|NCT02262585|Drug|BIBR 277 capsule|
254400|NCT02262598|Drug|Telmisartan|
254401|NCT00147225|Drug|AMG 531|Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).
1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)
254402|NCT02262598|Drug|Hydrochlorthiazide (HCTZ)|
254403|NCT02262598|Drug|Telmisartan/HCTZ fixed dose|
254404|NCT02262611|Drug|Micardis®|
254405|NCT02262611|Drug|MicardisPlus®|
254406|NCT02262624|Drug|Telmisartan|
254407|NCT02264964|Procedure|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
254408|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
254409|NCT02264964|Procedure|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
254410|NCT02264977|Device|Branched TAG® Device|
254411|NCT02264990|Drug|Veliparib|Oral Capsule
254412|NCT02264990|Drug|Carboplatin|Intravenous infusion
254413|NCT02264990|Drug|Paclitaxel|Intravenous infusion
258879|NCT02470806|Device|PICO - Negative Pressure Wound Therapy (NPWT)|PICO - Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
258880|NCT02470806|Device|ActiV.A.C.®|NPWT from -25 mmHg to -200 mmHg; intensity settings of low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
258881|NCT02470819|Genetic|Genetic profiling|genetic profiling
258882|NCT02470832|Drug|RG1662|
258883|NCT02470832|Drug|itraconazole|
258884|NCT02470845|Drug|Tian Jiu Treatment formula|The powder of eight Chinese herbal medicine, which include 30g Bai Jie Zi, 15g Yan Hu Suo, 15g Zhi Gan Sui, 15g Xi Xin, 15g Sheng Ma Huang 15g, Zhi Fu Zi, 15g Rou Gui, 15g Ding Xiang, will be mixed with Ginger Juice. They will be made of mixed herbal patches, and each will be weighted as 2g and 1cm*1cm round size. Each patch will be applied on one acupoint.
258885|NCT00174941|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
258886|NCT02470845|Drug|Sham Tian Jiu Treatment|Sham Tian Jiu formula will be made by brown-colored flour and mixed by water with the same weight and size, which seems to be the same at the appearance.
258887|NCT02470858|Drug|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
258888|NCT02470858|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
258889|NCT02470858|Drug|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
258890|NCT02470871|Biological|Eptacog alfa (activated) or pdFVII|Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.
Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study.
259170|NCT02500056|Device|Optilene LP mesh|Lichtenstein hernioplasty
259171|NCT00178698|Other|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
259172|NCT02500056|Device|Ultrapro mesh|Lichtenstein hernioplasty
259173|NCT02500069|Other|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
259174|NCT02500069|Other|Casein (in duodenum)|infusion of protein in duodenum
259175|NCT02500069|Other|Casein (in jejunum)|infusion of protein in jejunum
258589|NCT02474992|Behavioral|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
258590|NCT02475005|Behavioral|pain self management app on smartphone|
258591|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
258592|NCT02475018|Dietary Supplement|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
258593|NCT02475018|Dietary Supplement|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
258594|NCT02476994|Drug|Intralipid|
258595|NCT02477007|Drug|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
258596|NCT00002474|Procedure|bone marrow ablation with stem cell support|
258597|NCT00175812|Drug|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
258598|NCT02477007|Drug|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg). Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
258599|NCT02477007|Drug|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
258600|NCT02477007|Drug|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
258601|NCT02477020|Drug|TAK-063 20 mg|TAK-063 tablets.
258602|NCT02477020|Drug|Placebo|TAK-063 matching-placebo tablets.
258603|NCT02477033|Dietary Supplement|Butyricicoccus pullicaecorum 25-3T|
258604|NCT02477033|Other|Maltodextrin|
258605|NCT02477046|Biological|tOPV|administered per protocol
258017|NCT00176956|Procedure|Skin Biopsy|Skin biopsy.
258018|NCT02488226|Other|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
258019|NCT02488239|Device|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
258309|NCT02481583|Drug|Levosulpiride|different formulations of levosulpiride
258310|NCT02481596|Behavioral|Family-focused components (FFC)|The intervention consists of the individual text messaging intervention plus family-focused phone counseling sessions, goal-focused text messaging, and the option to invite a family member to receive text messages.
258311|NCT02481596|Behavioral|Individual text messaging|The intervention consists of daily, tailored text messaging addressing and assessing medication adherence, as well as a weekly text message that provides adherence feedback (see NCT02409329).
258312|NCT02481609|Drug|N-acetyl cysteine (NAC)|
258313|NCT02481635|Drug|Gemcitabine|
258314|NCT02481635|Drug|Nab-paclitaxel|
258315|NCT02481635|Radiation|Radiation Therapy|
258316|NCT02481635|Procedure|Surgical Resection|
258317|NCT02481648|Other|Exercise|
258318|NCT02481661|Procedure|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
258319|NCT02483832|Behavioral|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
258320|NCT02483845|Drug|Natalizumab|
258321|NCT02483858|Drug|PQR 309|Intervention of this drug may include safety, tolerability, PK and efficacy
258322|NCT02483871|Drug|Rosuvastatin|
258323|NCT02483884|Drug|[68Ga]RM2|[68Ga]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
258324|NCT00176579|Procedure|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
258325|NCT02483884|Procedure|PET/CT|Patients received [68Ga]RM2 undergo PET/CT 60 min p.i. for at least 20 min
258326|NCT02483897|Drug|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
257742|NCT02495077|Drug|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
257743|NCT02495077|Biological|Thymoglobulin|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
257744|NCT02495077|Drug|Acetaminophen|30 to 60 minutes prior to the start of the infusion
Tylenol, 600 to 1000mg by mouth or
Suppository form
257745|NCT02495077|Drug|Loratadine|30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth
257746|NCT02495077|Biological|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
257747|NCT00177892|Procedure|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
257748|NCT02495077|Drug|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
257749|NCT02495077|Drug|Diphenhydramine|30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth
258020|NCT02488252|Drug|Semi-individualised Chinese Medicine treatment|A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction
B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction
C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis
D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb
E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb
258021|NCT02488252|Drug|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
258022|NCT02488265|Other|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
258023|NCT02488265|Other|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
258024|NCT02488278|Device|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
258025|NCT02488291|Drug|0.25 sufentanil|with different dosage
258026|NCT02488291|Drug|0.5µg/ml sufentanil|0.5µg/ml sufentanil
258027|NCT02490397|Other|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
258028|NCT02490410|Dietary Supplement|protein supplement|
257438|NCT02499250|Drug|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
257439|NCT02499276|Device|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
257440|NCT02499302|Behavioral|Mental training|
257441|NCT02499315|Drug|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
257442|NCT02499315|Drug|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
257443|NCT02499328|Drug|AZD9150|AZD9150
257444|NCT02499328|Drug|MEDI4736|MEDI4736
257445|NCT00178581|Drug|Glutamine|
257446|NCT02499328|Drug|AZD5069|AZD5069
257447|NCT02499341|Drug|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
257448|NCT02501551|Drug|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
257449|NCT02501564|Drug|Naproxen Sodium Codeine|One tablet twice a day
257450|NCT02501564|Drug|Placebo|One tablet twice a day
257451|NCT02501577|Device|SAD 1|Placement and fiberoptic control
257452|NCT00178932|Procedure|genetic analysis|genetic assay of blood sample drawn with patient's consent
257453|NCT02501577|Device|SAD 2|Placement and fiberoptic control
257454|NCT02501603|Drug|afatinib|Afatinib 40mg daily oral administration
257455|NCT02501603|Drug|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
257456|NCT02501616|Drug|Metformin|
257457|NCT02501616|Drug|Dapagliflozin|
257458|NCT02501629|Drug|Reslizumab|Reslizumab Subcutaneous Dosing
257750|NCT02495090|Genetic|Exome sequencing|Plain DNA sequencing
257149|NCT02273427|Other|low fat meal|
257150|NCT02273440|Drug|BIIL 284 BS|
257151|NCT02273440|Drug|Theophylline|
257152|NCT02273440|Drug|Placebo|
257153|NCT02273453|Drug|Songha® Night|
257154|NCT02273453|Drug|Oxazepam|
257155|NCT02273453|Drug|Placebo|
257156|NCT02273466|Drug|Desipramine tablet|
257157|NCT02273466|Drug|Crobenetine infusion|
257158|NCT00148395|Drug|Navelbine|
257159|NCT02273466|Drug|Placebo infusion|
257160|NCT02273479|Drug|Asasantin®|Asasantin® extended release (RAD-SP)
257161|NCT02273479|Drug|Placebo|
257162|NCT02273492|Drug|Asasantin ER|
257163|NCT02273492|Other|Standardized breakfast|
257164|NCT02273505|Drug|Asasantin (ER)|
257165|NCT02273505|Drug|Persantin|
257166|NCT02273505|Drug|Acetyl salicylic acid (ASA)|
257167|NCT02276027|Drug|MEK162|MEK162 will be dosed as 45 mg twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take MEK162 exactly as prescribed.
257168|NCT00148668|Drug|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
257169|NCT02276040|Drug|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
252910|NCT02267005|Dietary Supplement|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
252911|NCT02267005|Dietary Supplement|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
252912|NCT00147732|Radiation|Accelerated radiotherapy|68 Gy over 5.5 weeks
252913|NCT02267018|Device|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
252914|NCT02267031|Procedure|mechanical ventilation|Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).
Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg.
252915|NCT02267044|Drug|Ropivacaine|The drug used for the interscalene blocks
252916|NCT02267057|Drug|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
252917|NCT02267057|Drug|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
252918|NCT02267057|Drug|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
252919|NCT02267057|Drug|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
252920|NCT02267070|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
252921|NCT02267070|Behavioral|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
252922|NCT02269384|Behavioral|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
252923|NCT02269384|Behavioral|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
253241|NCT02262039|Device|Airseal insufflation system|10 mmHg target pressure
253242|NCT02262039|Device|Standard insufflation|15 mmHg target pressure
253243|NCT02262052|Other|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
253244|NCT02262078|Drug|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
252298|NCT02240212|Drug|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
252299|NCT02240212|Drug|Paclitaxel|Paclitaxel sourced locally will be administered IV
252300|NCT02240238|Drug|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
252301|NCT02242760|Drug|SB204 4%|
252612|NCT02274038|Drug|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare"|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT "flare".
252613|NCT02274038|Drug|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
252614|NCT02274051|Dietary Supplement|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
252615|NCT02274064|Behavioral|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
252616|NCT02274077|Drug|EXPAREL|
252617|NCT02274077|Drug|Normal Saline|
252618|NCT02274090|Drug|Placebo gel|Placebo gel consist of drug without the active component.
252619|NCT02274090|Drug|1% Metformin gel|Metformin gel consist of active component.
252620|NCT02274103|Behavioral|BFST|Family-based skills training.
252621|NCT02274116|Other|SHAM - Intermittent Room Air - room air mixture|Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment 3 times per week for 4 weeks.
252622|NCT00148434|Behavioral|Patient-held guideline for hypertension|
252623|NCT02274116|Other|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia). Participants will receive treatment 3 times per week for 4 weeks.
252624|NCT02274129|Device|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
251996|NCT02247804|Drug|Timolol|Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
251997|NCT02247804|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
251998|NCT02247817|Device|Hybrid CRT-D/P implantation|
251999|NCT02247830|Other|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
252000|NCT02247830|Drug|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
252001|NCT02250066|Other|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
252002|NCT02250079|Device|polyethylene plastic bag|Inborn neonates with both a gestational age >29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
252302|NCT02242760|Drug|Vehicle Gel|
252303|NCT02242773|Device|Multi-Parametric MRI|Multi-Parametric MRI
252304|NCT02242773|Device|MRI-Guided Biopsy|MRI-Guided Biopsy
252305|NCT02242773|Behavioral|Expanded Prostate Cancer Index Composite Questionnaire|Quality of Life Questionnaire administered 0 to 3 months after enrollments and every 12 months from initial biopsy.
252306|NCT02242773|Behavioral|Memory Anxiety Scale for Prostate Cancer patients|Quality of Life Questionnaire administered 0 to 3 months after enrollments and every 12 months from initial biopsy.
252307|NCT02242773|Behavioral|Food Frequency Questionnaire|Quality of Life Questionnaire administered at baseline
252308|NCT02242786|Radiation|External beam radiation therapy|
252309|NCT00144690|Drug|Placebo|
252310|NCT02242799|Drug|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
252311|NCT02242799|Drug|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
252312|NCT02242799|Drug|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
251664|NCT02252185|Device|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson & Johnson Medical Suzhou Ltd.
251665|NCT02252185|Device|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
251666|NCT02252198|Other|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
251667|NCT02252211|Drug|89Zr-DS-8895a|Cohort Number: 1; No. Pts: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg
Cohort Number 2; No. Pts.: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg
Cohort Number 3; No. Pts.: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg
Cohort Number 4; No. Pts.: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg
251668|NCT02254551|Drug|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
251669|NCT02254577|Drug|Endometrin® Only|
251670|NCT02254577|Drug|Endometrin® plus Progesterone in Oil (PIO)|
251671|NCT02254577|Drug|Progesterone in Oil (PIO) Only|
251672|NCT02254590|Procedure|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
251673|NCT02254603|Device|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
251674|NCT00146146|Drug|testosterone undecanoate alone|1000 mg/12 weeks
251675|NCT02254603|Behavioral|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
256928|NCT02249871|Drug|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
256929|NCT02251925|Drug|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
256930|NCT02251925|Drug|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
256931|NCT02251938|Drug|DE-109|Medium Dose of DE-109
255954|NCT02268058|Drug|Ibuprofen|routine administration of medication for a 72 hour period
256258|NCT02260869|Procedure|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
256259|NCT02260869|Device|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
256260|NCT02260882|Biological|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
256261|NCT02260895|Dietary Supplement|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
256262|NCT02260908|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
256263|NCT02260908|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
256264|NCT02260921|Device|iovera°|
256265|NCT02260921|Device|Sham Comparator|
256266|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
256267|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
256268|NCT00146913|Drug|Peg-Interféron at 90 microg/week|
256269|NCT02260934|Drug|Prednisone|Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)
Continue prednisone 10 mg/day to week 96
256270|NCT02260934|Drug|Methylprednisolone|Week 0 and Week 2:
Solumedrol (100 mg) IV
256271|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
256272|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
255635|NCT02272868|Biological|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
255636|NCT02272868|Drug|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
255637|NCT02272868|Drug|rifaximin+omeprazole+miralax|
255638|NCT00148577|Device|Transcutaneous Electrical Nerve Stimulation|
255639|NCT02275403|Other|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
255640|NCT02275416|Drug|Ipilimumab|
255955|NCT02268071|Drug|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values <135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
255956|NCT02268084|Device|EEG,ECG-guided Transcranial Magnetic Stimulation|A coil delivers a pulsed magnetic field to the cortex of the brain
255957|NCT02268084|Device|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
255958|NCT02268097|Procedure|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
255959|NCT02268097|Procedure|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
255960|NCT02268110|Other|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
255961|NCT02268110|Other|Abdominal binding|Wearing an abdominal binder for 12 weeks
255962|NCT02268136|Drug|BIII 890 CL|
255963|NCT00147836|Drug|Human Insulin NPH (Novolin-N, Novo Nordisk)|
255964|NCT02268136|Drug|Placebo|
255965|NCT02268149|Drug|BIIL 284 BS|
255966|NCT02268149|Drug|Prednisone|
255967|NCT02268149|Drug|Placebo|
255968|NCT02268162|Procedure|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
255325|NCT00144521|Drug|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
255326|NCT02241343|Device|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
255327|NCT02241356|Device|bifocals|bifocal glasses with an addition of 2.5 Dioptres
255328|NCT02241356|Device|single vision glasses|single vision glasses
255329|NCT02241369|Biological|INO-3106, INO-9012|
255330|NCT02241382|Device|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
255331|NCT02244008|Other|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
255332|NCT02244021|Drug|BRENTUXIMAB VEDOTIN|Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment
Growth factors may be used at the discretion of investigators but are not routinely advised.
Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT.
255333|NCT02244047|Drug|Bifidobacterium breve|
255334|NCT02244047|Drug|Placebo (for Bifidobacterium breve)|
255641|NCT02275416|Biological|UV1 vaccine|
255642|NCT02275416|Biological|GM-CSF|
255643|NCT02275429|Procedure|Blood test|blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
255644|NCT02275442|Other|EPICES scale|
255645|NCT02275455|Behavioral|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
255646|NCT02275468|Drug|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
255647|NCT02275481|Drug|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
255648|NCT02275481|Drug|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
246941|NCT02225275|Drug|Obinutuzumab|100 mg by vein on Day 1, 900 mg by vein on Day 2, and 1000 mg on Day 8 and Day 15 for the first cycle, then 1000 mg on Day 1 for cycles 2 - 6 in a 28 day cycle.
246942|NCT00142727|Drug|Partial opioid agonist|
246943|NCT02225288|Drug|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
246944|NCT02225301|Other|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention that takes 1.5-2 hours to complete.
246945|NCT02225314|Behavioral|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
246946|NCT02225314|Behavioral|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
246947|NCT02225314|Behavioral|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
246948|NCT02225327|Biological|Fluad alone|Fluad
246949|NCT02225327|Biological|Fluad and PPV23 on the different arms|Fluad and Prodiax
246950|NCT02225327|Biological|Fluad and PPV23 on the same arm|Fluad and Prodiax
246951|NCT02225327|Biological|PPV23 alone|Prodiax
247233|NCT02220517|Device|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
247234|NCT02220517|Device|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
247235|NCT02220530|Drug|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
247236|NCT02220543|Other|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
247237|NCT02220543|Other|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
247238|NCT02220556|Procedure|Blood sampling|
247239|NCT02220582|Other|MRI|Magnetic Resonance Imaging
246632|NCT02230098|Other|Remote Ischemic Conditioning|
246633|NCT00143585|Procedure|intramyocardial delivery of either VEGF165 or placebo|
246634|NCT02232451|Device|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
246635|NCT02232451|Device|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
246636|NCT02232477|Drug|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
246637|NCT02232490|Biological|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
246638|NCT02232490|Biological|Placebo|
246639|NCT02232503|Genetic|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
246640|NCT02232516|Drug|romidepsin|Given IV
246641|NCT02232516|Drug|lenalidomide|Given PO
246642|NCT02232516|Other|laboratory biomarker analysis|Correlative studies
246643|NCT02232529|Drug|MIN-101|
246644|NCT00143598|Device|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
246645|NCT02232529|Drug|Placebo|
246646|NCT02232542|Drug|Duloxetine - low dose|
246647|NCT02232542|Drug|Duloxetine - high dose|
246648|NCT02232542|Drug|Placebo|
246649|NCT02232555|Drug|Duloxetine|
246650|NCT02232555|Drug|Placebo|
246651|NCT02232568|Behavioral|Feedback|
246652|NCT02232581|Drug|Alovudine - low|
246653|NCT02232581|Drug|Alovudine - medium|
246952|NCT02225353|Drug|Progesterone Cervical Pessary|Progesterone Cervical Pessary: 6.3 g Progesterone Cervical Pessary: 7.7 g
246023|NCT02207478|Procedure|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
246024|NCT02207478|Procedure|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
246025|NCT02207491|Drug|Timolol maleate Ophthalmic Solution|1 drop twice daily
246026|NCT02207491|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily
246027|NCT00140699|Behavioral|Balance|
246028|NCT02207504|Drug|Crizotinib|
246029|NCT02207504|Drug|Enzalutamide|
246030|NCT02207517|Procedure|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
246317|NCT02197351|Procedure|White light biopsy|Endoscopy with biopsies guided by high definition white light
246318|NCT02197351|Procedure|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
246319|NCT02197351|Procedure|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
246320|NCT02197377|Device|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion.
246321|NCT02197377|Device|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.
246322|NCT02197390|Behavioral|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
246323|NCT02197390|Behavioral|Obesity chronic care model|
246324|NCT00139451|Drug|GH|Growth Hormone will be 0.3mg/kg/week, given SC once daily.
246325|NCT02197390|Behavioral|Physical activity, healthy eating, water drinking, healthy sleep promotion|
246326|NCT02199912|Other|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
246327|NCT02199925|Drug|Gammaplex 5%|
245736|NCT02217501|Drug|1 month daily 75 mg plavix|1 month daily dose of 75 mg plavix
245737|NCT02217501|Drug|12 months daily 75 mg plavix|12 months daily 75 mg plavix
245738|NCT02217501|Drug|12 months daily 75-100 mg aspirin|12 months daily 75-100 mg aspirin
245739|NCT02217501|Drug|1 month daily 75-100 mg aspirin|1 month daily 75-100 mg aspirin
245740|NCT02217514|Drug|Midazolam|
245741|NCT02217514|Drug|BI 44370 low dose|
245742|NCT02217514|Drug|BI 44370 medium dose|
245743|NCT02217514|Drug|BI 44370 high dose|
245744|NCT02217527|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
245745|NCT02217527|Drug|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
245746|NCT00141843|Genetic|B-Domain deleted Recombinant Factor VIII|
245747|NCT02217540|Other|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
245748|NCT02217540|Other|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
245749|NCT02217553|Drug|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
246031|NCT02207530|Drug|MEDI4736|MEDI4736 monotherapy
246032|NCT02207543|Other|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
246033|NCT02207556|Drug|Doxycycline|Doxycycline will be continued until one of the following criteria is met:
Patient has completed 1 year of doxycycline therapy
Patient develops any grade 3-4 toxicity related to doxycycline use.
246034|NCT02207569|Device|CoreValve Evolut R TAVR system|
246035|NCT02207582|Device|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
245421|NCT00142688|Behavioral|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
245422|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.
245423|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
245424|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.
245425|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
245426|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 5mg QD
245427|NCT02226991|Drug|Ritonavir|
245428|NCT02226991|Drug|Efavirenz|
245429|NCT02227004|Device|Perform MRI in patients with cardiac devices|Perform MRI in patients with cardiac devices
245430|NCT02227017|Drug|TPV capsule|
245431|NCT02227017|Drug|TPV solution|
245432|NCT02227017|Drug|RTV capsule|
245433|NCT02227017|Drug|RTV solution|
245434|NCT02227017|Other|standard meal|
245435|NCT02227030|Drug|BIIB 722 CL solution|
245436|NCT00142909|Drug|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
245437|NCT02227030|Drug|BIIB 722 CL tablet|
245438|NCT02227030|Drug|Placebo solution|
245439|NCT02227030|Drug|Placebo tablet|
245440|NCT02227056|Drug|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
245441|NCT02227069|Drug|M518101|
244852|NCT02506140|Drug|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
244853|NCT02506140|Drug|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
244854|NCT02506153|Other|Laboratory Biomarker Analysis|Correlative studies
244855|NCT00002489|Biological|dactinomycin|
244856|NCT00179595|Behavioral|relaxation response- meditation|
245127|NCT00183573|Behavioral|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
245128|NCT02536274|Device|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
245129|NCT02536287|Procedure|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
245130|NCT02536287|Procedure|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1*1 *1 mm,and placed into the subcutaneous of the forearm.
245131|NCT02536300|Drug|Idelalisib|Idelalisib tablet administered orally
245132|NCT02538731|Procedure|dilation-assisted stone extraction|
245133|NCT02538731|Device|Spyglass Guided Laser Lithotrips|
245134|NCT02538744|Drug|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
245135|NCT02538744|Drug|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 [placebo], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
245136|NCT02538744|Drug|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
245137|NCT02538744|Drug|Placebo|
245138|NCT02538757|Biological|Herpes Zoster Vaccine|
245139|NCT02538770|Other|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
244558|NCT02512926|Drug|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
244559|NCT02512926|Drug|Cyclophosphamide|
244560|NCT02512926|Drug|Etoposide|
244561|NCT02512939|Procedure|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
244562|NCT02512952|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
244563|NCT02512952|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
244564|NCT00180505|Device|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
244565|NCT02512952|Procedure|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
244566|NCT02512965|Radiation|20 Gy in 5 fractions|
244567|NCT02512965|Radiation|Conventional SBRT: 24 Gy in 2 fractions|
244857|NCT02506153|Biological|Pembrolizumab|Given IV
244858|NCT02506153|Other|Pharmacological Study|Correlative studies
244859|NCT02506153|Other|Quality-of-Life Assessment|Ancillary studies
244860|NCT02506153|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
244861|NCT02506166|Device|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
244862|NCT02508376|Other|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. Group 1 will receive 5 mcg of AP10-602 IM on days 1, 29 and 57. Group 2 will receive 10 mcg IM on days 1, 29 and 57.
244863|NCT02508376|Biological|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). Groups 1-4 will receive 10 mcg ID93 IM on days 1, 29 and 57
244864|NCT02508376|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). Group 3 will receive 5 mcg GLA-SE on days 1, 29 and 57
244865|NCT02508389|Drug|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
244274|NCT02517437|Drug|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
244275|NCT02517450|Behavioral|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
244276|NCT02517450|Other|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
244277|NCT02519608|Drug|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
244278|NCT02519608|Drug|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
244279|NCT02519621|Device|NPWT PRO|NPWT PRO without irrigation.
244280|NCT02519621|Device|NPWT PRO|NPWT PRO with irrigation (saline)
244281|NCT02519621|Device|KCI Ulta|KCI Ulta NPWT without irrigation
244282|NCT02519634|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
244283|NCT00181662|Drug|Curcumin|
244284|NCT02519634|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
244285|NCT02519647|Device|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
244286|NCT02519647|Device|Tracheal intubation with S-guide|Tracheal intubation with S-guide
244287|NCT02519660|Drug|Lidocaine/Tetracaine patch|
244288|NCT02519660|Drug|Lidocaine/Prilocaine cream|
244289|NCT02519673|Device|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
244290|NCT02519699|Drug|norepinephrine|Increase in mean arterial pressure using norepinephrine
244568|NCT02512978|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
248690|NCT02216149|Drug|S-1|S-1 25 mg/m2/day BID d1-14
248691|NCT02216149|Drug|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14
249010|NCT00140894|Drug|MK0966; rofecoxib / Duration of Treatment: 24 weeks|
249011|NCT02208596|Drug|Etomidate|
249012|NCT02208609|Other|Day 1 Maize/Amaranth|Children were fed Maize/Amaranth tortillas on day 1 and common maize tortillas on day 2
249013|NCT02208609|Other|Day 2 Maize/Amaranth|Children were fed common maize tortillas on day 1 and maize/amaranth tortillas on day 2
249014|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
249015|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
249016|NCT02208622|Dietary Supplement|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
249017|NCT02208635|Other|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (~30 µg Zn/g).
249018|NCT02208635|Other|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
249019|NCT02208635|Other|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
249020|NCT02208674|Other|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
249021|NCT00002313|Drug|Nystatin|
249022|NCT00141115|Drug|levetiracetam|Levetiracetam 1500 mg BID
249023|NCT02211157|Other|high fat breakfast|
249024|NCT02211170|Drug|BIBR 796 BS, low dose|
249025|NCT02211170|Drug|BIBR 796 BS, high dose|
249026|NCT02211170|Drug|Placebo|
249027|NCT02211170|Drug|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
249028|NCT02211183|Procedure|Best Repair of torn Rotator Cuff|
249029|NCT02211183|Device|InSpace™ system|
248382|NCT02223494|Drug|Terbogrel|
248383|NCT02223507|Drug|BIIR 561 CL|
248384|NCT02223507|Drug|Placebo|
248385|NCT02223520|Drug|Mupirocin and Chlorhexidine|
248386|NCT02223520|Drug|Placebo ointment and placebo cloths|
248387|NCT00002323|Drug|Zidovudine|
248388|NCT00142558|Drug|MK0663; etoricoxib / Duration of Treatment: 5 Days|
248389|NCT02223533|Device|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
248390|NCT02223533|Drug|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
248391|NCT02223572|Radiation|hip Xray|
248392|NCT02223585|Other|Animal-based protein diet|
248393|NCT02223585|Other|Vegan-based protein diet|
248692|NCT02216162|Other|Arm A: adapted physical activity + enhanced geriatric follow-up|Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.
A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36).
248693|NCT02216162|Other|No intervention|Usual clinical follow-up
248694|NCT02216175|Other|SLIT to cow's milk|
248695|NCT00141700|Drug|Rituximab|
248696|NCT02216175|Other|OIT to cow's milk|
248697|NCT02216188|Biological|AFFITOPE® PD01A|s.c. injection
248698|NCT02216188|Other|Control|Untreated control group
248699|NCT02216214|Drug|Mirabegron|oral
248700|NCT02216214|Drug|Placebo|oral
248701|NCT02216227|Drug|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
219399|NCT02303834|Device|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
219400|NCT02303847|Drug|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
219401|NCT02306343|Device|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
219402|NCT02306356|Behavioral|Internet-delivered Cognitive Behavior Therapy|
219403|NCT02306369|Behavioral|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
219404|NCT02306382|Procedure|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
219405|NCT00152100|Drug|Filgrastim, Alemtuzumab|
219406|NCT02306382|Device|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
219407|NCT02306395|Procedure|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
219408|NCT02306421|Procedure|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
219409|NCT02306421|Procedure|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
219702|NCT02299245|Drug|rosuvastatin|different dose of rosuvastatin treatment
248778|NCT00142571|Drug|Docetaxel|
248779|NCT02223806|Behavioral|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
248780|NCT02223806|Behavioral|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
248781|NCT02223819|Drug|crizotinib|
248782|NCT02223832|Drug|ACT-128800|
248783|NCT02223845|Other|Music|Self-selected music played via headphones
248784|NCT02225860|Behavioral|Diet and water adjustment|
248785|NCT02225873|Other|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
249097|NCT02218723|Drug|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
249098|NCT02218723|Drug|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
249099|NCT02218736|Drug|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
249100|NCT02218736|Drug|placebo|oral dosing of 10 mg placebo daily for 8 weeks
249101|NCT00142051|Drug|oxygen|oxygen fi02 21% (room air)
249102|NCT02218749|Other|Initially triaged to physiotherapist|
249103|NCT02218749|Other|Initially triaged to physician|
249104|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
249105|NCT02218762|Drug|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
249106|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
249107|NCT02218762|Drug|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
248458|NCT02230800|Drug|Tocovid SupraBio plus pentoxifylline|
248459|NCT02230800|Drug|Matching placebos|
248460|NCT00143390|Drug|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
248461|NCT02230839|Behavioral|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
248462|NCT02230839|Behavioral|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (<30% of calories from fat) diet will be used as part of the weight loss intervention.
248463|NCT02230878|Drug|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
248464|NCT02230878|Drug|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
248465|NCT02230878|Drug|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
248466|NCT02230878|Drug|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
248467|NCT02233374|Other|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
248786|NCT02225873|Other|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
248787|NCT02225886|Drug|Ascorbic Acid|300 mg of ntravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
248788|NCT02225912|Other|PrevinC|
248789|NCT02225925|Radiation|Brachytherapy|
248790|NCT00142805|Drug|Ketasyn™ (AC-1202)|
248791|NCT02225951|Dietary Supplement|Nutritional product|
248792|NCT02225951|Other|Standard breakfast according to ADA recommendations|
248793|NCT02225977|Drug|Gilenya|
248144|NCT02198183|Device|Casmed Fore-Sight Elite|
248145|NCT02198183|Device|Non-invasive Cardiac Output Monitor (NICOM)|
248146|NCT02198196|Behavioral|Weight Talk-Mindfulness|
248147|NCT02198209|Drug|Liraglutide|acute study: one injection of 0.6 mg s.c. before IVGTT
chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c).
248148|NCT02198235|Drug|Dexamethasone|
248149|NCT00139516|Behavioral|smoking cessation|
248150|NCT02198235|Drug|Buprenorphine|
248151|NCT02198248|Drug|Rituximab|Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
248152|NCT02198248|Drug|Glucocorticoids|"Low-dose" group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.
"High-dose" group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.
248153|NCT02198261|Drug|5% minoxidil topical foam|5% minoxidil topical foam
248154|NCT02198274|Drug|BIBH 1|100 mg/week
248155|NCT02198287|Drug|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
248156|NCT02198287|Drug|Placebo|
248157|NCT02198300|Procedure|Coronary angioplasty with stent implantation|
248158|NCT02200926|Other|Unloaded breathing training|7 days/week, for 8 weeks
248159|NCT02200926|Other|Placebo|7 days/week, for 8 weeks
248160|NCT02200939|Device|Bioinductive implant|
248161|NCT02200939|Device|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
248162|NCT00139854|Drug|Alprazolam orally disintegrating tablets|
248163|NCT02200952|Drug|recombinant LH|recombinant LH twice/day for 10 days from pick up
248468|NCT02233374|Other|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
247830|NCT00140530|Device|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
247831|NCT02205606|Drug|HCP1306 10/10mg|P.O.
247832|NCT02205606|Drug|HCP1306 20/10mg|P.O.
247833|NCT02205619|Device|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
247834|NCT02205619|Device|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
247835|NCT02205619|Device|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
247836|NCT02205632|Device|MPS II|
247837|NCT02205645|Device|FibroFix™ Meniscus scaffold|The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.
The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
247838|NCT02205671|Behavioral|Building Better Caregivers Small-group Workshop|
247839|NCT02205684|Other|Computer game skills training|Playing Nintendo Wii Sports
247840|NCT02205684|Other|Physical activity|Aerobic High Intensity Training (HIT)
247841|NCT00140530|Device|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
247842|NCT02205697|Behavioral|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
247843|NCT02205710|Other|Computerized cognitive training|
247844|NCT02205710|Other|Computerized games|
247224|NCT02218086|Device|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
247225|NCT02218086|Device|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
247226|NCT02218086|Device|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
247227|NCT00141947|Drug|bexarotene (Targretin)|
247228|NCT02218086|Device|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
247229|NCT02220491|Radiation|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
247230|NCT02220504|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
247231|NCT02220504|Other|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
247232|NCT00142233|Drug|Magnesium (15 mmol/d)|
247530|NCT02213107|Drug|Enzalutamide and Dutasteride|Enzalutamide by mouth daily. Dutasteride by mouth daily.
247531|NCT02213133|Drug|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly.
247532|NCT02213146|Drug|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
247533|NCT00141323|Drug|lasofoxifene|0.25 mg once per day, orally
247534|NCT02213146|Drug|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
247535|NCT02213146|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
247536|NCT02213159|Drug|Dexmedetomidine|
247537|NCT02213159|Drug|Morphine|
247538|NCT02213172|Dietary Supplement|Bifidobacterium longum R0175|
247539|NCT02213172|Dietary Supplement|Lactobacillus paracasei HA-196|
247540|NCT02213172|Other|Placebo|
247541|NCT02213185|Other|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
247240|NCT02220595|Procedure|Carotid endarterectomy vs. carotid stenting|
247241|NCT02220608|Biological|Bortezomib|
247242|NCT02220608|Drug|G-CSF|
247243|NCT00002321|Drug|Aldesleukin|
247244|NCT00142233|Drug|ANTOX (vers.) 1.2 (300 µg organic selenium, 54000 IU beta carotene, 750 mg vitamin C, 540 IU vitamin E, 2700 mg methionine)|
247245|NCT02220621|Device|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
247246|NCT02220621|Device|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
247247|NCT02220634|Drug|Regadenoson|Injection for intravenous administration
247248|NCT02220647|Drug|Linagliptin/Metformin FDC|
247249|NCT02220647|Drug|Linagliptin|
247250|NCT02220647|Drug|Metformin|
247251|NCT02220660|Drug|BI 1744 CL|
247252|NCT02220660|Drug|BI 54903 XX|
247253|NCT02220660|Drug|BI 1744 CL + BI 54903 XX FDC|
247254|NCT02220660|Drug|Placebo|
247551|NCT00141635|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|
247552|NCT02215603|Behavioral|Breaking prolonged sitting with physical activity|
247553|NCT02215616|Drug|Laquinimod|Laquinimod 0.5, 1.0, 1.5 mg
247554|NCT02215616|Drug|Placebo|Placebo
247555|NCT02215629|Drug|VS-4718|
247556|NCT02215655|Behavioral|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
247557|NCT02215668|Procedure|Physical exercise|Exercise muscle stretching and body warming.
247558|NCT02215681|Device|acupuncture|
246953|NCT00142727|Drug|Opioid antagonist|
246954|NCT02225353|Drug|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
246955|NCT02225366|Biological|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
246956|NCT02225366|Other|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
246957|NCT02227589|Behavioral|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
246958|NCT02227589|Other|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
246959|NCT02227602|Dietary Supplement|Mango polyphenolics|Frozen mango pack will be provided (200~400g per day).
246960|NCT02227602|Dietary Supplement|sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
246961|NCT02227615|Dietary Supplement|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
246962|NCT02227615|Dietary Supplement|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
246963|NCT02227628|Dietary Supplement|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
246964|NCT02227628|Dietary Supplement|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
246965|NCT02227641|Biological|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
246966|NCT02227654|Procedure|Abnormal Ovarian Ultrasound|Ultrasound
246967|NCT00142961|Other|placebo|
246968|NCT02227667|Drug|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
246969|NCT02227680|Other|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
246328|NCT02199938|Other|Identification and characterization of molecular markers in musculoskeletal tumors|
246329|NCT02199951|Drug|Dihydroartemisinin and piperaquine|Antimalarial
246330|NCT02199964|Drug|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
246331|NCT02199964|Drug|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
246332|NCT02199977|Other|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
246333|NCT02199977|Other|Conditional ACT voucher|Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a "Green Leaf" approved malaria drug.
246334|NCT02199977|Other|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
246335|NCT00139737|Drug|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
246336|NCT02200003|Behavioral|attention bias modification for anxiety|
246337|NCT02200016|Procedure|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
246654|NCT02232581|Drug|Alovudine - high|
246655|NCT00143598|Device|Knee-length, placebo stocking|Worn daily for two years
246656|NCT02232581|Drug|Placebo|
246657|NCT02232594|Drug|Berodual®|
246658|NCT02232607|Drug|Lacidipine, low dose|
246659|NCT02232607|Drug|Lacidipine, medium dose|
246660|NCT02232607|Drug|Lacidipine, high dose|
246661|NCT02232607|Drug|Placebo|
246662|NCT02232620|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
246663|NCT02232633|Drug|BBI503|
246664|NCT02232646|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
246036|NCT02207582|Device|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
246037|NCT02207595|Drug|UCB5857|Active Substance: UCB5857
Pharmaceutical Form: Capsule
Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg
Route of Administration: Oral Use
246038|NCT00140712|Drug|Ropinirole Immediate Release|
246039|NCT02207595|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Capsule
Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg
Route of Administration: Oral Use
246040|NCT02207608|Drug|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
246041|NCT02207608|Drug|BCG (Immucist®)|Usual BCG treatment
246042|NCT02207621|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily (evening)
246043|NCT02209909|Drug|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
246044|NCT02209909|Drug|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
246045|NCT02209922|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
246046|NCT02209922|Device|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
246047|NCT02209935|Other|Early Rehabilitation Protocol|
246048|NCT00141011|Drug|Placebo|0.6 mL/kg/hr
246049|NCT02209935|Other|Usual care|
246050|NCT02209948|Drug|Temozolomide|
246051|NCT02209974|Drug|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
246338|NCT02200016|Procedure|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
246339|NCT02200016|Device|B Braun Contiplex S catheter|
246340|NCT02200029|Drug|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
245442|NCT02227069|Drug|M518101 Vehicle|
245443|NCT02227069|Other|sodium lauryl sulfate|
245444|NCT02227069|Other|saline|
245750|NCT02217566|Drug|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
245751|NCT02217566|Drug|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
245752|NCT02217566|Drug|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
245753|NCT02217579|Dietary Supplement|Protein|A food containing 5 grams/serving of supplemental protein.
245754|NCT02217579|Dietary Supplement|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
245755|NCT02217579|Dietary Supplement|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
245756|NCT02217579|Dietary Supplement|Control|An isocaloric food not containing the test protein and fiber.
245757|NCT00141843|Genetic|BDDrFVIII|
245758|NCT02217605|Dietary Supplement|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
245759|NCT02219776|Drug|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
245760|NCT02219776|Other|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
245761|NCT02219789|Drug|Alisertib|Given PO
245762|NCT02219789|Drug|Fulvestrant|Given IM
245763|NCT02219789|Other|Laboratory Biomarker Analysis|Correlative studies
245764|NCT00142155|Drug|Rituximab|
245765|NCT02219802|Procedure|Treatment according arm|
245766|NCT02219815|Behavioral|Prehab Intervention|Pre-operative, structured exercise intervention.
245767|NCT02219828|Drug|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
245140|NCT02538770|Other|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
245141|NCT00183846|Drug|irinotecan|
245142|NCT02538783|Behavioral|Financial Incentive|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
245143|NCT02538796|Other|TEA + Grober Test + Task 1 + Grober Test|The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.
245445|NCT02227082|Radiation|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
245446|NCT02227082|Drug|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
245447|NCT00142909|Drug|Placebo|Lofexidine Placebo
245448|NCT02227095|Behavioral|Exercise|Heart rate monitors worn by each child at each session
245449|NCT02227095|Behavioral|After-school program|Supervised recreational program with token economy
245450|NCT02227108|Biological|CAT-8015 (Moxetumomab Pasudotox)|
245451|NCT02227121|Device|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
245452|NCT02227134|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
245453|NCT02227147|Drug|rhNGF 20µg/ml|
245454|NCT02227147|Drug|Placebo Vehicle|
245455|NCT02227160|Behavioral|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
245456|NCT02229513|Procedure|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
245457|NCT02229526|Dietary Supplement|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
244866|NCT02508389|Drug|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
244867|NCT02508389|Drug|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
244868|NCT02508402|Drug|Dexamethasone|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.
All the participants in both groups will randomly be assigned by computer list.
II. After six hours of the initial dose, the labour induction will start via Oxytocin using
244869|NCT02508402|Drug|Placebo|two milliliters of normal saline given to placebo group .
244870|NCT02508415|Other|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
244871|NCT02508428|Device|Total Hip Replacement (Marathon)|Comparison of Marathon and Enduron polyethylene
244872|NCT00179881|Drug|Thalomid|
244873|NCT02508428|Device|Total Hip Replacement (Enduron)|
244874|NCT02508441|Drug|Andes-1537 for Injection|Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle
Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle
244875|NCT02508467|Drug|BLU-554|
245144|NCT02538796|Other|TEA + Grober Test + Task 2 + Grober Test|The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.
245145|NCT02538796|Other|TEA + Grober Test + Implicit Task 3 + Grober Test|The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word ("yes-no" answer).
245146|NCT02538796|Other|TEA + Grober Test + Explicit Task 3 + Grober Test|The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words ("positive-negative" answer).
245147|NCT02538809|Other|measurement of cytokeratin concentration in urine|
245148|NCT02538822|Device|dynamic imaging|In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
245149|NCT02538822|Device|mechanical testing|In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
244569|NCT02512991|Other|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
244570|NCT02513004|Drug|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
244571|NCT02513004|Drug|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
244572|NCT02513017|Behavioral|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
244573|NCT02515240|Biological|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
244574|NCT00180739|Procedure|Magnetic Resonance Guided Focused Ultrasound|
244575|NCT02515253|Other|Bra prescription|
244576|NCT02515253|Other|Standard Care|
244577|NCT02515266|Other|nutrition: protein intake|additional protein fortification of human milk
244578|NCT02515279|Drug|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
244579|NCT02515279|Drug|Ribavirin|1000-1600 mg day orally for 48 weeks.
244580|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel|
244581|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel (Reference)|
244582|NCT02515305|Drug|Placebo gel|
244583|NCT02515318|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
244584|NCT02515318|Drug|Medical standard treatment|The standard medical treatment consists on:
Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).
Glucocorticoids:
Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.
- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β‐lactamase inhibitor and fluoroquinolones.
244585|NCT00180765|Procedure|Up to 100ml blood will be taken by venupuncture.|
244586|NCT02515331|Drug|LHW090|Capsule - oral dose
249030|NCT02211196|Behavioral|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
249031|NCT02211196|Other|survey administration|Ancillary studies
249032|NCT02211196|Other|questionnaire administration|Ancillary studies
249033|NCT00141128|Drug|SS-RBX|
249034|NCT02211209|Drug|volanesorsen|
244291|NCT02519712|Drug|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
244292|NCT02519712|Procedure|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
244293|NCT02519725|Other|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, all the relatives, and the staff. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
244294|NCT00181675|Drug|galantamine HBr|
244295|NCT02519738|Drug|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
244296|NCT02519738|Drug|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
244297|NCT02519738|Other|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
244298|NCT02519751|Dietary Supplement|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
244299|NCT02521896|Device|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
244300|NCT02521909|Device|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
248702|NCT02218528|Dietary Supplement|Plant-based ingredient|
248703|NCT02218528|Dietary Supplement|No Plant-based ingredient|
248704|NCT02218541|Device|abutment margin .5mm subgingival|
248705|NCT02218541|Device|abutment margin 1.5mm subgingival|
248706|NCT02218554|Genetic|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
248707|NCT02218567|Behavioral|questionnaire qualilty of life|
248708|NCT00142038|Drug|Docetaxel|
248709|NCT02218567|Behavioral|psychological interview|
248710|NCT02218567|Behavioral|psychological tests|
248711|NCT02218567|Other|Motor evaluation|
248712|NCT02218567|Behavioral|Behavioral evaluation|
248713|NCT02218567|Behavioral|cognitive tests|
248714|NCT02218580|Other|Massage therapy|
248715|NCT02218580|Other|Standard care|
248716|NCT02218593|Device|WREX orthosis|Upper extremity exoskleton used to assist movement
249035|NCT02211209|Drug|Placebo|
249036|NCT02211222|Drug|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
249037|NCT02211248|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
249038|NCT02211248|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
249039|NCT02211261|Biological|PF-06293620|subcutaneous, single dose 0.3 mg/kg
249040|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
219703|NCT02299258|Device|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
219704|NCT02299258|Device|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
219705|NCT02301403|Drug|Nicotine patch|8 weeks of nicotine patch
219706|NCT00151541|Drug|Dapsone Topical Gel + benzoyl peroxide gel 4%|
219707|NCT02301403|Behavioral|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
219708|NCT02301403|Drug|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
219709|NCT02301403|Drug|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
219710|NCT02301403|Behavioral|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
219711|NCT02301403|Behavioral|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
219712|NCT02301403|Behavioral|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
219713|NCT02301416|Drug|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
219714|NCT02301429|Device|Model 20105|implant and follow-up of study device
219715|NCT02301442|Behavioral|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
219716|NCT02301442|Behavioral|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic & strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers & exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
219717|NCT00151541|Drug|Dapsone Topical Gel + vehicle control|
219718|NCT02301455|Behavioral|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
249108|NCT02218775|Drug|LY2456302|Mood and Anxiety Disorders
249109|NCT02218801|Other|Evaluation of treatment for liver metastasis|
249110|NCT02218814|Procedure|Adductor Canal Block, Bupivacaine|Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.
Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease.
249111|NCT02218814|Procedure|Femoral Nerve Block, Bupivacaine|Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.
Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.
249112|NCT00142064|Behavioral|observed levels of pain|
249113|NCT02218827|Drug|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
249114|NCT02218840|Other|Smoking topography|Evaluation of cigar smoking topography
249115|NCT02218879|Drug|Tecfidera|Oral Tecfidera 240 mg bid
244361|NCT02528851|Procedure|Extubation from endotracheal mechanical ventilation to CPAP|Following randomization, the infants will be extubated to the "higher" CPAP group (CPAP level 2cm H2O higher than extubation EAP) or "equivalent" CPAP group (CPAP level equal to the extubation EAP) based on their allocation.
244362|NCT02528877|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
244363|NCT02528877|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoeitic stem cell transplant
244364|NCT02528877|Drug|Fludarabine Phosphate|Given IV
244365|NCT00182793|Drug|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
244366|NCT02528877|Other|Laboratory Biomarker Analysis|Correlative studies
244367|NCT02528877|Drug|Melphalan|Given IV
244368|NCT02528877|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo hematopoietic stem cell transplant
244369|NCT02528877|Other|Pharmacological Study|Correlative studies
244370|NCT02528877|Drug|Ruxolitinib Phosphate|Given PO
244371|NCT02528877|Drug|Sirolimus|Given PO
244372|NCT02528877|Drug|Tacrolimus|Given IV or PO
248794|NCT02225990|Other|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
248795|NCT02225990|Other|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
248796|NCT02225990|Other|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
248797|NCT02225990|Other|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
248798|NCT02226003|Drug|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
248799|NCT02226003|Drug|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
248800|NCT02226003|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
248801|NCT00142818|Drug|Naltrexone|150 mg daily for males; 100 mg daily for females
248802|NCT02226003|Drug|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
248803|NCT02226003|Drug|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
248804|NCT02226016|Device|FG-5000A|a measuring device for the assessment of levator muscle strength
249116|NCT02221232|Drug|Vehicle Product|Vehicle product is ZuraPrep without Isopropyl Alcohol
249117|NCT02221245|Procedure|Tumor Biospy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
249118|NCT02221258|Biological|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
249119|NCT00002322|Drug|Atevirdine mesylate|
249120|NCT00142350|Drug|continuous infusion of 5-fluorouracil|
249121|NCT02221271|Drug|NPB-01|
249122|NCT02221284|Drug|Alogliptin|Alogliptin tablets
248469|NCT02233387|Other|injection with [18F] HX4 and PET imaging|A standard clinical [18F]FDG PET-CT will be performed for the radiotherapy planning.
After a minimum time interval of 24 hours, baseline [18F]HX4 PET scans will be performed:
Based on the phase I trial1 444 MBq (12 mCi) [18F]HX4 is administrated via a bolus IV injection.
The first image acquisition is started together with the administration of [18F]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i
248470|NCT02233400|Drug|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
248471|NCT02233413|Device|Active LLLT helmet application|LED helmet applied with light activated
248472|NCT02233413|Device|Non-active LLLT helmet application|LED helmet applied without light activated
248473|NCT00143663|Drug|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
248474|NCT02233439|Dietary Supplement|Herbal galactagogue|
248475|NCT02233439|Dietary Supplement|Placebo|
248476|NCT02233452|Drug|Methadone|The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
248477|NCT02233452|Drug|Ketamine|The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.
248478|NCT02233452|Drug|Methadone plus Ketamine|the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
248479|NCT02233465|Procedure|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
248480|NCT02233478|Dietary Supplement|Pomegranate Juice|Pomegranate Juice alone
248481|NCT02233478|Dietary Supplement|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
248482|NCT02233478|Dietary Supplement|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
248483|NCT02233491|Behavioral|Active lifestyle intervention|
248484|NCT00143663|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
248485|NCT02233504|Drug|Exjade® (deferasirox, ICL670)|
248486|NCT02235922|Other|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
247845|NCT02208180|Behavioral|Return of genomic results on cardiovascular disease risk|Experimental group: Participants will receive genomic cardiovascular disease risk information.
Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
248164|NCT02200965|Other|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
248165|NCT02200978|Drug|ATO|Given IV
248166|NCT02200978|Drug|RIF|Given orally
248167|NCT02200978|Drug|ATRA|Given orally
248168|NCT02200978|Drug|mitoxantrone|Given IV
248169|NCT02200978|Drug|Ara-C|Given IV
248170|NCT02200978|Drug|MTX|Given orally
248171|NCT02200978|Drug|6MP|Given orally
248172|NCT02200978|Other|intrathecal injection|Ara-C and dexamethasone
248173|NCT00139867|Drug|PARCOPA|
248174|NCT02200991|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
248175|NCT02200991|Drug|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
248176|NCT02200991|Drug|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
248177|NCT02201004|Drug|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
248178|NCT02201004|Drug|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
248179|NCT02201004|Drug|placebo|Pharmaceutical form:tablet Route of administration: oral
248180|NCT02201030|Biological|NBP606|A single intramuscular injection into the thigh
248181|NCT02201030|Biological|Prevnar13|A single intramuscular injection into the thigh
248182|NCT02201043|Drug|Thalidomide 150mg|
248183|NCT02201043|Drug|Thalidomide 100mg|
247542|NCT02213198|Behavioral|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
247543|NCT02213198|Behavioral|Standard Care|
247544|NCT00002316|Drug|Amphotericin B|
247545|NCT00141336|Drug|Pregabalin|
247546|NCT02213211|Drug|Artemether lumefantrine|School-based diagnosis and treatment of uncomplicated malaria using malaria rapid diagnostic tests (mRDTs) and Artemether lumefantrine as part of Learner Treatment Kits (LTK) used by teachers. All children in the school have access to the service.
247547|NCT02213224|Drug|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
247548|NCT02213224|Drug|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
247549|NCT02213224|Drug|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
247550|NCT02215590|Device|Re-Step|Research Group:
Each session begins with a warm-up exercise, muscle-stretching and strengthening exercises: duration 10 minutes.
Afterwards, walking exercises with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.
At the end of the session 5 min of cool down exercises
20 training sessions of 60 minutes, two/three a week.
247846|NCT02208193|Behavioral|Cognitive and psycho-behavioral effects of an artistic dimension|
247847|NCT02208219|Behavioral|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
247848|NCT02208219|Behavioral|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
247559|NCT02215694|Dietary Supplement|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
247560|NCT02215694|Dietary Supplement|placebo|2g of powder daily without probiotics
247561|NCT02215707|Biological|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
247562|NCT00141648|Drug|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
247563|NCT02215720|Drug|Cetuximab|
247564|NCT02215720|Drug|Temsirolimus|
247565|NCT02215733|Drug|ARB|other than telmisartan
247566|NCT02215733|Drug|ACEI|
247567|NCT02215733|Drug|Beta-blockers|
247568|NCT02215733|Drug|Diuretics|
247569|NCT02215733|Drug|Telmisartan|
247570|NCT02215746|Drug|BI 44370 powder for oral solution|
247571|NCT02215746|Drug|BI 44370 tablet|
247572|NCT02215746|Other|high fat breakfast|
247573|NCT00141648|Radiation|Radiotherapy|Total 45 Gy in 25 fractions
247574|NCT02215759|Drug|BI 44370 TA|
247575|NCT02215759|Drug|Placebo|
247576|NCT02215772|Drug|BI 44370 BS|
247862|NCT02208297|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
247863|NCT02210702|Drug|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
247864|NCT02210715|Drug|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
247865|NCT02210715|Other|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
247255|NCT00142506|Drug|sildenafil citrate and questionaires|Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.
Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
247256|NCT02223000|Drug|BIBV 308 SE solution|
247257|NCT02223000|Drug|BIBV 308 SE capsule 1|
247258|NCT02223000|Drug|BIBV 308 SE capsule 2|
247259|NCT02223013|Drug|BIBV 308 SE solution|
247260|NCT02223013|Drug|BIBV 308 SE capsule L|
247261|NCT02223013|Drug|BIBV 308 SE capsule S|
247262|NCT02223026|Drug|Linagliptin/metformin FDC|
247263|NCT02223026|Other|high-fat, high caloric meal|
247264|NCT02223039|Biological|AbGn-168H|AbGn-168H monoclonal antibody
247265|NCT02223039|Biological|Placebo|Placebo of AbGn-168H
247266|NCT00142506|Drug|placebo tablets and questionaires|Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.
In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.
Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
247267|NCT02223052|Drug|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
247268|NCT02223052|Drug|Vidaza|75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
247269|NCT02223065|Drug|Saxagliptin|
247270|NCT02223065|Drug|Dapagliflozin|
247271|NCT02223078|Biological|G17DT|
247272|NCT02223091|Behavioral|Consultation by a trained physician|
246665|NCT02235077|Drug|Spironolactone|Patients receiving no MRA at home will receive either spironolactone 100 mg or matching placebo (4x25 mg study capsules) once daily for 96 hours.
Patients already receiving low-dose MRA at home will receive spironolactone 100 mg vs. 25 mg (1x25 mg spironolactone and 3 placebo study capsules) in hospital for 96 hours.
246666|NCT02235077|Drug|Placebo|Patients receiving no MRA at home will receive either spironolactone 100 mg or matching placebo (4x25 mg study capsules) once daily for 96 hours.
Patients already receiving low-dose MRA at home will receive spironolactone 100 mg vs. 25 mg (1x25 mg spironolactone and 3 placebo study capsules) in hospital for 96 hours.
246667|NCT02235090|Other|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
246668|NCT02235103|Other|Sperm Chromatin Dispersion Test|
246669|NCT02235116|Other|Survey|
246670|NCT00143858|Device|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
246671|NCT02235129|Other|breath-holding|
246672|NCT02235142|Other|Blood sample|
246673|NCT02235168|Procedure|six minute walking test|
246674|NCT02235181|Device|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
246675|NCT02235194|Dietary Supplement|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
246970|NCT02227680|Other|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
246971|NCT02227693|Drug|avatrombopag|E5501 (avatrombopag) 20-mg tablets
246972|NCT02227693|Drug|Placebo|Placebo matching 20-mg tablets
246973|NCT02227706|Biological|EVICEL® Fibrin Sealant|
246974|NCT02227706|Device|SURGICEL® Absorbable Hemostat|
246975|NCT02227719|Device|CTI|CTI is the titanium mesh
246976|NCT02227719|Device|Collagen membrane|
246341|NCT02200029|Drug|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
246342|NCT02200042|Drug|Cisplatin|Given IV
246343|NCT02200042|Drug|Gemcitabine Hydrochloride|Given IV
246344|NCT02200042|Radiation|Image Guided Radiation Therapy|Undergo image-guided radiation therapy
246345|NCT02200042|Other|Laboratory Biomarker Analysis|Correlative studies
246346|NCT00139750|Drug|CP-526,555 (varenicline)|
246347|NCT02200055|Device|Bodystat Quadscan 4000|Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.
Bioimpedance Assessment
246348|NCT02200068|Other|SANOIA Website|
246349|NCT02200081|Drug|MGN1703|
246350|NCT02200081|Other|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
246351|NCT02200094|Drug|Low dose of Telmisartan, once daily|
246352|NCT02202512|Drug|BI 1060469 high dose|tablets
246353|NCT02202512|Drug|BI 1060469 low dose|tablets
246354|NCT02202512|Drug|Naproxen|
246355|NCT02202512|Drug|BI 1021958|tablets
246356|NCT00140101|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
246357|NCT02202525|Drug|Micardis®|
246358|NCT02202525|Drug|Other hypertensives|
246359|NCT02202538|Device|Indego|Indego
246360|NCT02202551|Drug|ADS-5102|
246361|NCT02202564|Procedure|LT|Orthotopic LT
246362|NCT02202564|Drug|ADV-TK|
246676|NCT02235194|Dietary Supplement|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
245768|NCT02219828|Drug|Placebo|Placebo
245769|NCT02219841|Procedure|radiofrequency catheter ablation|
245770|NCT02219854|Procedure|Laparoscopic gastrectomy|
245771|NCT02219854|Procedure|Open gastrectomy|
245772|NCT02219867|Drug|Ketamine|Drug (including placebo)
246052|NCT02209974|Drug|Inhaled Placebo|
246053|NCT02209987|Drug|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
246054|NCT02209987|Drug|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
246055|NCT02210000|Drug|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
246056|NCT02210000|Drug|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
246057|NCT02210026|Device|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
246058|NCT02210039|Device|SECM Probe|Imaging of the esophagus using SECM probe and system.
246059|NCT00141024|Biological|EP HIV-1043|Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.
The vaccine is provided in single-use 1.1-mL vials.
246060|NCT02210052|Device|Radiofrequency cannula|Patients with spinal hardware that are undergoing radiofrequency ablation procedures will have an addtional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurment only.
246061|NCT02210065|Biological|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|The cytotoxic T cells (CTL) product given as single infusion within 72 hours of cytomegalovirus (CMV) reactivation. CTL dose infused at least 0.6x10e6/m2 but not greater than 6 x 10e6/m2.
246062|NCT02210078|Biological|Cytotoxic T-Lymphocytes (CTL)|CTL dose infused will not be greater than 10e5 viable CD3+ T cells/kg. If patient has a partial response, stable disease or progressive disease, then eligible to receive one additional dose of CTL at a minimum of 2 weeks interval from the first CTL infusion.
246063|NCT02210091|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
246064|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
246065|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
245458|NCT02229526|Dietary Supplement|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
245459|NCT02229526|Dietary Supplement|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
245460|NCT00143221|Drug|Viagra|
245461|NCT02229526|Dietary Supplement|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
245462|NCT02229539|Drug|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
245463|NCT02229539|Drug|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
245464|NCT02229539|Other|Placebo|2.5 mL placebo and 2.5 mL water administered orally
245465|NCT02229565|Device|Biopsy or prostatectomy|
245773|NCT02219880|Dietary Supplement|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
245774|NCT02219880|Dietary Supplement|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
245775|NCT00142155|Drug|monoclonal antibodies|
245776|NCT02219893|Drug|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
245777|NCT02219906|Drug|Resveratrol|1000mg tid
245778|NCT02219906|Drug|Placebo|1000mg tid placebo
245779|NCT02219919|Other|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
245780|NCT02219919|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
245781|NCT02219932|Drug|fampridine|Prolonged-release fampridine administered as specified in the treatment arm
245782|NCT02219932|Drug|Placebo|Matched placebo
245783|NCT02219945|Other|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
245150|NCT02538835|Behavioral|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
245151|NCT02503709|Drug|CDKI AT7519|Given IV
245152|NCT00179218|Behavioral|exercise|leg press exercise; every other day, 3 days per week, for 6 months
245153|NCT02503709|Drug|Hsp90 Inhibitor AT13387|Given IV
245154|NCT02503709|Other|Laboratory Biomarker Analysis|Correlative studies
245155|NCT02503709|Other|Pharmacological Study|Correlative studies
245156|NCT02503722|Other|Laboratory Biomarker Analysis|Correlative studies
245157|NCT02503722|Drug|Osimertinib|Given PO
245158|NCT02503722|Other|Pharmacological Study|Correlative studies
245159|NCT02503722|Drug|Sapanisertib|Given PO
245160|NCT02503735|Drug|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
245161|NCT02503748|Other|Online tutorial|website informing about treatment options in localized prostate cancer
245162|NCT02503761|Drug|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
245163|NCT00179231|Drug|olanzapine vs. clozapine|
245466|NCT02229578|Drug|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
245467|NCT02229578|Drug|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
245468|NCT02229604|Other|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
245469|NCT02229604|Drug|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
244587|NCT02515331|Drug|Placebo|Capsule - oral dose
244876|NCT02508480|Behavioral|Photovoice|The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.
In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination.
244877|NCT02508480|Behavioral|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
244878|NCT02508493|Other|THINC-it Tool|Digitalized cognitive test application administering the following cognitive test components:
Digit Symbol Substitution Test (DSST)
Choice Reaction Time (CRT)
One-back working memory tool
Trail Making Test B (TMT-B)
Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
244879|NCT02510729|Device|Neurostimulation|
244880|NCT02510729|Device|Sham stimulation|
244881|NCT02510742|Device|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
244882|NCT02510742|Device|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
244883|NCT02510755|Other|MRI|
244884|NCT02510768|Device|ELAPR002f|Intradermal implant
244885|NCT02510768|Device|ELAPR002g|Intradermal implant
244886|NCT00180128|Drug|idarubicin|
244887|NCT02510768|Device|Saline|Intradermal implant
244888|NCT02510781|Drug|Epirubicin|75mg/m2 d1 evry 21days
244889|NCT02510781|Drug|Docetaxel|75mg/m2 d1 evry 21days
244890|NCT02510781|Drug|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
244891|NCT02510781|Drug|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
244892|NCT02510794|Drug|Ranibizumab ITV injection|0.5-mg monthly ITV injections of 10-mg/mL formulation
244301|NCT02521909|Device|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
244302|NCT02521909|Device|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
244303|NCT02521922|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
244304|NCT02521922|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
244588|NCT02515344|Other|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
244589|NCT02515344|Other|Providing general information about CRC sreening|
244590|NCT02515357|Behavioral|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
244591|NCT02515357|Behavioral|Standard care|Hypocaloric diet and general written instructions regarding the adoption of a healthy lifestyle.
244592|NCT02515370|Other|Friends for Life Circles (FLCs).|The intervention 'Friends for Life Circles" (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs
244593|NCT02515383|Behavioral|MD Anderson Symptom Inventory (Adolescent Version)|Part 1: Adolescent participants complete the MDASI (adolescent version).
Part 2: MDASI (adolescent version) administered twice, one day apart, to assess test-retest reliability. MDASI (adolescent version) then administered at 5 additional time points, each a week apart.
244594|NCT02515383|Behavioral|Interview|Part 1: Participants are interviewed by study staff regarding the symptom questionnaire.
Part 2: First 20 participants are interviewed by study staff regarding the symptom questionnaire.
244595|NCT02517463|Drug|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
244596|NCT02517476|Dietary Supplement|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
249041|NCT02211261|Biological|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
249042|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
249043|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 3 mg/kg
249044|NCT00141141|Drug|Atorvastatin|
249045|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
249046|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 6 mg/kg
249047|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
249048|NCT02211261|Biological|PF-06293620|Intravenous infusion single dose 1 mg/kg
249049|NCT02211261|Biological|Placebo|Intravenous infusion normal saline single dose
249050|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
249051|NCT02213718|Drug|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
249052|NCT00141427|Drug|Pregabalin|
249053|NCT02213731|Other|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
249054|NCT02213744|Drug|MM-302|
249055|NCT02213744|Drug|Gemcitabine|
249056|NCT02213744|Drug|Capecitabine|
249057|NCT02213744|Drug|Vinorelbine|
249058|NCT02213744|Drug|Trastuzumab|
244305|NCT02521935|Device|Complete traditional dentures|Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):
Appointment 1: Examination & diagnosis & initial impressions.
Appointment 2: Secondary impressions.
Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)
Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.
Appointment 5: Wax-trial denture try-in.
Appointment 6: Insertion and instructions for care of definitive prostheses.
Appointments 7-9 Post adjustments
244306|NCT02521935|Device|Complete CADCAM dentures|Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):
Appointment 1: Exam, diagnosis, & tray selection (begin impressions)
Appointment 2: Definitive impressions and Maxillomandibula relations
Appointment 3: Wax-trial arrangement
Appointment 4: Insertion and instructions for care of definitive prosthesis
Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage
220016|NCT02294565|Drug|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
220017|NCT00002378|Drug|Delavirdine mesylate|
220018|NCT00150839|Drug|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
220019|NCT02294591|Drug|N-acetylcysteine|Add-on treatment of NAC
220020|NCT02294591|Drug|Placebo|Add-on treatment of placebo
220021|NCT02294604|Device|ethyl alcochol, chlorhexidine and moisturizers|
220022|NCT02294604|Device|chlorhexidine|
220023|NCT02294604|Device|povidone-iodine|
220024|NCT02294617|Other|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
220025|NCT02294617|Other|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
220026|NCT00151086|Drug|Vinorelbine|
220027|NCT02296983|Biological|VSV-ZEBOV|VSV-ZEBOV
220028|NCT02296996|Drug|Dabrafenib + Trametinib|
220029|NCT02297009|Procedure|Buccal swab|Buccal swabs will be taken from the volunteers
220030|NCT02297022|Device|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
220031|NCT02297035|Behavioral|Behavioural testing|
220032|NCT02297035|Other|Brain imaging|MRI, PET
220033|NCT02297035|Genetic|Genetic screening|APOE, Progranulin
220034|NCT02297048|Dietary Supplement|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
220035|NCT02297061|Biological|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
244373|NCT02528890|Other|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
244374|NCT02528903|Drug|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
244375|NCT02528903|Drug|Matching placebo|Single intravenous dose
244376|NCT00182793|Drug|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
244377|NCT02528929|Dietary Supplement|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
244378|NCT02528942|Radiation|Radiation therapy|Radiation therapy will be given to study patients.
244379|NCT02528955|Radiation|A: De-Intensification RT primary tumor region|A:
Reduction of radiation dose in the primary tumor region to 56 Gy,
Elective Radiotherapy of both neck sides
244380|NCT02528955|Radiation|B: De-Intensification RT contralateral lymph nodes|B:
No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)
Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation
244672|NCT02524288|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
244673|NCT02524301|Drug|Positron Emission Tomography using [11C]diprenorphine|PET using [11C]diprenorphine
244674|NCT02524314|Device|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
244675|NCT02524327|Other|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
244676|NCT02524327|Other|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
244677|NCT02524353|Other|cardiac surgery|Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
244678|NCT00182377|Drug|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
244679|NCT02524366|Procedure|Artificial Urinary Sphincter|
244680|NCT02524379|Drug|RP-1127|3-day infusion of Glyburide beginning within 6 hours of spinal cord injury.
249123|NCT02221297|Dietary Supplement|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
249124|NCT02221310|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m^2/dose given IV over 2 hours once during conditioning
249125|NCT02221323|Drug|Insulin LISPRO|
249126|NCT02221336|Device|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
249127|NCT02221336|Device|Non-MONARCA II system|Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
249128|NCT02221349|Device|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
249129|NCT02221349|Drug|Sodium fluoride paste|Toothpaste used by subject
249130|NCT02221349|Drug|Stannous fluoride paste|Toothpaste used by subject
249131|NCT00142350|Drug|combination of irinotecan and cisplatin|
249132|NCT02221375|Drug|BHT low|
249133|NCT02221375|Drug|BHT medium|
249134|NCT02221375|Drug|BHT high|
249135|NCT02221375|Drug|BI 54903 XX low|
249136|NCT02221375|Drug|BI 54903 XX medium 1|
249137|NCT02221375|Drug|BI 54903 XX medium 2|
249138|NCT02221375|Drug|BI 54903 XX high|
249139|NCT02221375|Drug|Ciclesonide|
249140|NCT02221388|Drug|BI 671800 HEA, 200 mg tablets|
244381|NCT02528955|Radiation|C. De-Intensification RT primary tumor region AND contralateral lymph nodes|C:
Reduction of radiation dose in the primary tumor region to 56 Gy, AND
Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation
244382|NCT02531165|Drug|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
244383|NCT02531165|Drug|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
244384|NCT02531165|Drug|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
248805|NCT02226029|Other|Lipid emulsion|2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability
Lipid emulsion 1: acid stable, particle size 0.6 µm
Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm
13C-markers will be mixed with emulsions
248806|NCT02228330|Other|Controls|The non-blocked obtorator side of each patient will be used as control
248807|NCT02228330|Drug|Lidocaine 2 %|
248808|NCT00143091|Drug|CP-316,311|
248809|NCT02228343|Other|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
248810|NCT02228356|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
248811|NCT02228369|Drug|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
248812|NCT02228369|Drug|AZD9291|AZD9291 160mg once daily
248813|NCT02228382|Drug|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
248814|NCT02228395|Drug|PF-04958242|Oral capsule, single dose, 0.35 mg, 0.55 mg, 0.75 mg
248815|NCT02228395|Drug|Placebo|Oral capsule, single placebo dose
248816|NCT02228408|Drug|Hydralazine/Isorsorbide Dinitrate|Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
Target Dose:
Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day
Allowable Dosage Forms:
ISD/HY 10 mg/12.5-3x/day ISD/HY 20 mg/37.5mg-3x/day ISD/HY 40 mg/75 mg-3x/day
Dose Titration:
ISD/HY will be administered at a starting dose ISD/HY 10 mg/12.5-3x/day and titrated to ISD/HY 20 mg/37.5mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects.
248817|NCT02228408|Drug|Amlodipine and Placebo|Amlodipine will be administered with a target dose of 10 mg daily and Placebo 2/day. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events. To maintain blinding, a second placebo tablet will be administered twice daily so that each subject takes a total of 2 tablets 3x/day regardless of study arm.
Target Dose:
Amlodipine 10 mg daily and Placebo 2x/day
Allowable Dosage Forms:
Amlodipine 2.5 mg/day & placebo 2x/day Amlodipine 5.0 mg/day & placebo 2x/day Amlodipine 10.0 mg/day & placebo 2x/day
Dose Titration:
Amlodipine will be administered at 2.5 mg daily. Placebo will be administered twice daily. Amlodipine will be increased to 5 mg daily after 4 days and to 10 mg daily at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects.
248818|NCT02228434|Behavioral|Monitoring and Tailored prescription|
248819|NCT00143091|Drug|Placebo|
248820|NCT02228434|Behavioral|Happy 10 program|
248821|NCT02228434|Behavioral|Specified nutrition education|
248184|NCT00139880|Drug|Parcopa|
248185|NCT02201043|Drug|Placebo|
248186|NCT02201056|Drug|TAK-935|TAK-935 oral solution
248187|NCT02201056|Drug|Placebo|TAK-935 placebo-matching oral solution
248487|NCT02235948|Drug|folic acid supplementation|0.8mg folic acid/day
248488|NCT02235961|Drug|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
248489|NCT02235961|Drug|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
248490|NCT02235961|Drug|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
248491|NCT02235974|Behavioral|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
248492|NCT00143949|Drug|losartan|
248493|NCT02235974|Behavioral|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
248494|NCT02235974|Behavioral|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
248495|NCT02235974|Behavioral|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
248496|NCT02235987|Drug|saline|Eligible patients are to receive saline as placebo comparator, followed by 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
248497|NCT02235987|Drug|octreotide|Eligible patients are to receive saline as placebo comparator, followed by 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
248498|NCT02235987|Drug|DG3173|Eligible patients are to receive saline as placebo comparator, followed by 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
248499|NCT02236000|Drug|Neratinib|Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.
Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day
Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy
247849|NCT02208219|Behavioral|Conventional treatment|This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:
Passive mobilization: controlled manipulation of movements to release a joint.
Stretch and progressive resistance training.
Task-specific training: reaching and manipulation of different objects.
Intense physical training: repetition of sequence of movements.
247850|NCT02208232|Procedure|cataract surgery|cataract surgery with implantation of intraocular lens
247851|NCT02208245|Device|Ultrasound: Axillary block|Ultrasound guided axillary block
247852|NCT02208245|Device|Ultrasound: Infraclavicular block|Ultrasound guided infraclvicular block
247853|NCT00140816|Behavioral|Increased intake of dairy products|
247854|NCT02208245|Drug|Ropivacaine|20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
247855|NCT02208258|Device|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
247856|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
247857|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
247858|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
247859|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
247860|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
247861|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
248188|NCT02203331|Drug|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
248189|NCT02203331|Drug|Anastrozole + Levonorgestrel (BAY 98-7196)|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
248190|NCT02203331|Drug|Anastrozole + Levonorgestrel (BAY 98-7196)|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
248191|NCT02203331|Drug|Anastrozole + Levonorgestrel (BAY 98-7196)|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
247866|NCT02210728|Drug|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
247867|NCT02210728|Behavioral|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
247868|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
247869|NCT00141050|Drug|Focalin XR|
247870|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
247871|NCT02210754|Other|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
247872|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
247873|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
247874|NCT02210754|Other|Marlboro Cigarette|cigarettes
247875|NCT02210767|Other|Walnut Diet|2 oz. walnuts/day (2-3% of total calories from ALA)
247876|NCT02210767|Other|Walnut Control Diet|2-3% ALA but no walnuts provided
247877|NCT02210767|Other|Low ALA Diet|ALA replaced by oleic acid
247878|NCT02210780|Drug|Dupilumab|Administered via subcutaneous injection.
247879|NCT02210780|Drug|placebo|An inactive substance containing no medicine administered via subcutaneous injection
247880|NCT00141063|Drug|Focalin XR|
247881|NCT02210793|Procedure|transepithelial PRK|
247882|NCT02210793|Procedure|LASIK|
247883|NCT02210806|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
248209|NCT02203487|Drug|BIIF 1149 BS - single rising dose|
248210|NCT02203487|Drug|Placebo|
248211|NCT02203500|Drug|Lacidipine|
247273|NCT02223091|Behavioral|Consultation by an untrained physician|
247274|NCT02223104|Device|Flexima Active|
247577|NCT02215785|Other|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
247578|NCT02215798|Drug|Cymbalta|
247579|NCT02215811|Biological|Mesenchymal stromal cells|
247580|NCT02218086|Device|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
247581|NCT02218099|Drug|ASP8232|Oral
247582|NCT02218099|Drug|Placebo|Oral
247583|NCT02218112|Procedure|bariatric surgery (gastric bypass)|
247584|NCT02218125|Biological|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
247585|NCT02218125|Biological|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
247586|NCT02218138|Behavioral|Learning 2 BREATHE|Mindfulness-based group program
247587|NCT02218138|Behavioral|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
247588|NCT02218151|Other|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
247589|NCT00141960|Drug|Famotidine|
247590|NCT02218151|Other|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
247591|NCT02218164|Drug|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
246977|NCT02227745|Drug|Dorzolamide hydrochloride (2%)|Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.
Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed
246978|NCT02230111|Behavioral|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
246979|NCT00143273|Drug|Lasofoxifene|0.5 mg tablets
246980|NCT02230111|Behavioral|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
246981|NCT02230124|Device|MRE|
246982|NCT02230137|Behavioral|Text message arm|Text message sent before each injection of insulin
246983|NCT02230150|Behavioral|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
246984|NCT02230163|Biological|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
246985|NCT02230176|Drug|Sunitinib|
247275|NCT02223104|Device|Sensura|
247276|NCT02223117|Biological|Thrombosomes|Freeze-dried platelets
247277|NCT00142519|Drug|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
247278|NCT02223117|Biological|Placebo|
247279|NCT02225379|Device|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
246677|NCT02235207|Behavioral|Neuromuscular exercise|Fustra20 Neck & Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.
The main targets are to
improve movement control in different posture and movements of the neck and back
improve flexibility with active functional movements
improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain
improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities
246678|NCT02235220|Other|Composite resin restoration|Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.
A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted.
246679|NCT02235233|Radiation|Tc 99m MEB|Each subject will be injected with ~2.5 mCi of 99m Technetium-Mebrofenin (Tc 99m MEB).
246680|NCT02235246|Drug|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
246681|NCT00143871|Drug|Rituximab|
246682|NCT02235246|Drug|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
246683|NCT02235259|Drug|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
246684|NCT02197390|Behavioral|Environment, policy, systems changes in clinic setting only|
246685|NCT02197390|Behavioral|No intervention|No intervention.
246686|NCT02197390|Behavioral|Environment, policy, and systems changes in schools, early child care education & recreation|
246687|NCT02197403|Drug|Dexmedetomidine|200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion
246688|NCT02197403|Drug|Propofol|25~75mcg/kg/min continuous infusion
246689|NCT02197416|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
246690|NCT02197429|Other|Acupuncture|
246691|NCT02197442|Drug|Valsartan|
246692|NCT02197455|Drug|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
246693|NCT00002303|Drug|Epoetin alfa|
246066|NCT02212522|Other|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
246067|NCT02212522|Other|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
246068|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
246069|NCT02212535|Drug|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
246070|NCT02212548|Device|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
246363|NCT02202564|Drug|ganciclovir|
246364|NCT02202577|Drug|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
246365|NCT02202577|Drug|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
246366|NCT02202590|Device|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
246367|NCT00140114|Drug|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
246368|NCT02202603|Drug|Teriparatide|single oral tablet
246369|NCT02202603|Drug|Teriparatide|subcutaneous standard injection
246370|NCT02202603|Drug|placebo|Oral placebo
246371|NCT02202616|Drug|Glycopyrronium /Indacaterol maleate|Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
246372|NCT02202629|Other|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
246373|NCT02202642|Procedure|collagenase|Cultured limbal stem cells transplantation
246374|NCT02202668|Device|TRS|TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the "6 and 12" and "3 and 9" ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines.
245784|NCT02219971|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
245785|NCT02219984|Drug|Anticoagulants|
245786|NCT02222324|Drug|E2609|E2609 will be administered as 8 tablets
245787|NCT02222324|Drug|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
245788|NCT02222337|Behavioral|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
245789|NCT02222350|Drug|10mg DS-8500a tablet|
245790|NCT02222350|Drug|75mg DS-8500a tablet|
245791|NCT02222350|Drug|placebo|
246071|NCT02212561|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
246072|NCT00141271|Drug|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
246073|NCT02212561|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 15 through 19. Fludarabine may be given prior to day 15 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
246074|NCT02212561|Drug|Cytarabine|Will be given IV over 4 hours daily on days 15 through 19. Cytarabine may be given prior to day 15 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
246075|NCT02212561|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
246076|NCT02212574|Drug|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
246077|NCT02212574|Drug|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
246078|NCT02212574|Drug|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
246079|NCT02212574|Drug|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
245470|NCT02229617|Drug|Subcutaneous testosterone|
245471|NCT00143221|Drug|Placebo|
245472|NCT02229630|Radiation|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
245473|NCT02229656|Radiation|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
245474|NCT02231944|Biological|Replenine®-VF (High Purity Factor IX)|
245475|NCT00143533|Drug|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
245476|NCT02231957|Other|educational text message reminders|
245477|NCT02231957|Other|conventional text message reminders|
245478|NCT02231970|Procedure|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
245479|NCT02231983|Genetic|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
245480|NCT02232009|Device|Neonatal MRI Scanner|
245481|NCT02232022|Device|Reveal LINQ Insertable Cardiac Monitor|
245482|NCT02232035|Drug|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
245483|NCT02232048|Other|Transthoracic Echocardiogram|
245792|NCT02222363|Drug|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
245793|NCT00142480|Drug|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
245794|NCT02222376|Drug|Pirfenidone|Twice a day topical application
245795|NCT02222376|Procedure|Debridement|Weekly ulcer debridement
244893|NCT02510794|Drug|Ranibizumab through RPDS Implant|Ranibizumab delivered through the implant with three different formulations
244894|NCT02510807|Other|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
245164|NCT02503774|Biological|MEDI9447|Subjects will receive MEDI9447 for 52 weeks
245165|NCT02503774|Biological|MEDI4736 and MEDI9447|Subjects will receive MEDI9447 and MEDI4736 for 52 weeks
245166|NCT02503787|Device|RestoreSensor SureScan MRI Rechargeable Neurostimulator|RestoreSensor SureScan MRI Rechargeable Neurostimulator
245167|NCT02503813|Procedure|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
245168|NCT02503826|Drug|Sufentanil|low dose
245169|NCT02503826|Drug|Sufentanil|moderate dose
245170|NCT02503826|Drug|Sufentanil|high dose
245171|NCT02503826|Drug|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
245172|NCT02503826|Drug|propofol|
245173|NCT02503826|Drug|cisatracurium|
245174|NCT00000369|Drug|Lithium carbonate|
245175|NCT00002488|Drug|cisplatin|
245176|NCT00179244|Drug|Rispridone (drug) and Bupropion ER (drug)|
245177|NCT02503839|Drug|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
245178|NCT02503839|Biological|H56:IC31|Therapeutic and prophylactic TB vaccine
245179|NCT02503852|Device|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
245180|NCT02503852|Device|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
245181|NCT02506192|Drug|Delayed-Release Prednisone|Delayed-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
245182|NCT02506192|Drug|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
245183|NCT02506205|Behavioral|Lee Silverman Voice Treatment (SVLT) LOUD|
244597|NCT02517489|Drug|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
244598|NCT02517489|Drug|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
244599|NCT02517502|Drug|DHA|4 capsules of 400 mg DHA daily
244600|NCT02517502|Drug|Placebo|Matched, blinded placebo
244601|NCT00181155|Drug|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
244602|NCT02517515|Drug|ABT-450/r/ABT-267|Tablet
244603|NCT02517515|Other|Placebo|Placebo for ABT-450/r/ABT-267
244604|NCT02517515|Drug|ABT-333|Tablet
244605|NCT02517515|Other|Placebo|Placebo for ABT-333
244895|NCT02510820|Device|Biofinity (comfilcon A) Soft Contact Lens|Biofinity (comfilcon A) Soft Contact Lens worn daily for use with either the Multipurpose Solution #1 (Synergi) or the Multipurpose Solution #2 (Biotrue Multipurpose Solution)
244896|NCT02510820|Other|Multipurpose Solution #1|Synergi contact lens care for use with Biofinity (comfilcon A) soft contact lens worn daily
244897|NCT00180128|Drug|mitoxantrone|
244898|NCT02510820|Other|Multipurpose Solution #2|Biotrue contact lens care for use with Biofinity (comfilcon A) soft contact lens worn daily
244899|NCT02510833|Behavioral|Exercises oriented, manual and monitoring by phone|Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
244900|NCT02510833|Behavioral|Exercises oriented, manual and without monitoring by phone|Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
244901|NCT02510846|Behavioral|Intensive educative management|5 hours a week
244902|NCT02510859|Other|Systematic nutritional consultation at home|Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled "Dietary own program" will be given to the patient.
244307|NCT00182013|Drug|Olanzapine|Open treatment with Olanzapine
244308|NCT02521948|Device|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.
244309|NCT02521961|Other|Informational Intervention|Watch a Chair-robics DVD
244310|NCT02521961|Other|Informational Intervention|Receive community resource booklet
244311|NCT02521961|Other|Quality-of-Life Assessment|Ancillary studies
244312|NCT02521961|Other|Questionnaire Administration|Ancillary studies
244313|NCT02521961|Procedure|Support Group Therapy|Attend support group sessions
244314|NCT02521974|Biological|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
244315|NCT02524145|Drug|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
244316|NCT02524158|Behavioral|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
244317|NCT02524171|Behavioral|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
244318|NCT02524184|Drug|sildenafil|sildenafil 100 mg per day for 7 days.
244319|NCT02524184|Drug|placebo|an identical placebo per day for 7 days
244606|NCT02517528|Drug|ABT-450/r/ABT-267|Tablet
244607|NCT02517528|Drug|ABT-333|Tablet
244608|NCT02517528|Drug|Ribavirin|Tablet
244609|NCT02517541|Device|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
220036|NCT02297074|Other|Ordinary white bread|The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
220037|NCT00151099|Drug|high caloric drink with protein|
220345|NCT02289872|Device|TruView PCD Video laryngoscope|Video-Laryngoscopy
220346|NCT02289885|Device|SonoScape|Ultrasonography device
220347|NCT02289898|Drug|Demcizumab|administered intravenously
220348|NCT02289898|Drug|Abraxane®|administered intravenously
220349|NCT02289898|Drug|gemcitabine|administered intravenously
220350|NCT00150267|Drug|Xalacom|
220351|NCT02289898|Drug|Placebo|
220352|NCT02292108|Behavioral|dietetic counselling|
220353|NCT00150566|Drug|Lanthanum carbonate|
220354|NCT02292108|Behavioral|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
220355|NCT02292121|Procedure|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
220356|NCT02292121|Other|a solution of mannitol and lactitol|
220357|NCT02292134|Device|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
220358|NCT02292173|Drug|Trametinib|Dose Escalation:
Level 1 - 1 mg daily Level 2 - 1.5 mg daily Level 3 - 1.5 mg daily Level 4 - 2 mg daily
Dose Expansion:
Maximum Tolerated Dose (MTD)
220359|NCT02292173|Drug|Sorafenib|Dose Escalation:
Level 1 - 200 mg twice daily Level 2 - 200 mg twice daily Level 3 - 400 mg twice daily Level 4 - 400 mg twice daily
Dose Expansion:
Maximum Tolerated Dose (MTD)
220360|NCT02292186|Drug|Revusiran (ALN-TTRSC)|
244681|NCT02524392|Other|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
244682|NCT02524405|Other|Flutemetamol PET scan|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Flutemetamol, which is not yet approved for clinical use in Canada, will be performed in all subjects.
244683|NCT02524405|Device|Fluroescent Ligand Eye Scanning (FLES)|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Fluorescent Ligand Eye Scanning will be performed in all subjects using the Sapphire II System (a combination device/ointment system) to assess the presence of amyloid in the ocular lens.
244684|NCT02524418|Procedure|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
244685|NCT02524431|Other|Collection of trabecular meshwork tissue during surgery|Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
244686|NCT02524444|Drug|Mefloquine|Tabs Mefloquine 250mg
244687|NCT02524444|Drug|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
244688|NCT02524457|Other|This is an observational study. There are no interventions|
244964|NCT02519894|Behavioral|Dietary Scanning Calculator|
244965|NCT02519907|Device|Surface Electrical Stimulation|Please see information under 'Detailed description'
244966|NCT00181701|Drug|Paclitaxel|
244967|NCT02519920|Drug|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
244968|NCT02519920|Drug|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
244969|NCT02519920|Drug|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
244970|NCT02519920|Drug|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
244385|NCT02531165|Drug|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
244386|NCT02531165|Procedure|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
244387|NCT00183131|Behavioral|Brief Personalized Feedback|
244388|NCT02531178|Biological|ABBV-257|subcutaneous injection
244389|NCT02531178|Biological|Placebo|Placebo for ABBV-257
244390|NCT02531191|Drug|ASP015K|oral
244391|NCT02531204|Drug|ASP1585|oral
244392|NCT02531217|Biological|ATYR1940|Biological: ATYR1940
244393|NCT02531230|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
244394|NCT02531243|Behavioral|CALMS|Family Therapy; Multi-user Biofeedback Videogames
244395|NCT02531256|Device|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
244396|NCT02531282|Behavioral|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
244397|NCT02531282|Behavioral|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
244398|NCT00183144|Behavioral|Contingency management|
244399|NCT02531295|Drug|Euphorbia kansui extract powder prepared as tea|1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
244400|NCT02531308|Drug|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
244401|NCT02531308|Drug|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
244689|NCT00182390|Procedure|Red blood cell transfusion|
244690|NCT02526732|Other|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
244691|NCT02526745|Biological|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
248822|NCT02228434|Behavioral|General Health Education|
249141|NCT02221388|Drug|BI 671800 HEA EC, 200 mg tablets|
249142|NCT00142350|Drug|oral administration of S-1|
249143|NCT02221388|Drug|BI 671800 HEA, 50 mg tablets|
249144|NCT02221388|Drug|BI 671800 ED, 100 mg capsules|
249145|NCT02221388|Other|Standard meal|
249146|NCT02221401|Drug|Linagliptin/Metformin FDC|
249147|NCT02223858|Behavioral|Positive Activities (PA) Program|This is a 6-week program consisting of at-home activities (1 completed per week) that have been shown to increase positivity. Activities will be delivered using a combination of activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist will orient participants to the booklets and review the first activity at the end of an in-person baseline visit. The booklet contains all instructions patients need to complete the full program. However, the interventionist will conduct weekly telephone calls to provide additional support patients may need. During these calls, the interventionist will assess whether participants completed the previous week's activity, review instructions for the next week's activity, and help participants trouble-shoot anticipated barriers to completing the next activity.
249148|NCT02223858|Behavioral|Attention Control (AC) Program|This is a 6-week program consisting of at-home activities (1 completed per week) that are based on affectively neutral activities from control conditions in prior studies of positive activities interventions. Activities will be delivered using a combination of activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist will orient participants to the booklets and review the first activity at the end of an in-person baseline visit. The booklet contains all instructions patients need to complete the full program. However, the interventionist will conduct weekly telephone calls to provide additional support patients may need. During these calls, the interventionist will assess whether participants completed the previous week's activity, review instructions for the next week's activity, and help participants trouble-shoot anticipated barriers to completing the next activity.
249149|NCT02223871|Drug|ACT-451840|
249150|NCT02223871|Other|Plasmodium falciparum-infected human erythrocytes|Each participant will be inoculated on Day 0 with approximately1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
249151|NCT02223871|Drug|Artemether 20 mg and lumefantrine 120mg combination tablet|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally should be immediately followed by food or drinks rich in fat (e.g., milk).
249152|NCT00142584|Drug|Nebivolol|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
249153|NCT02223871|Drug|Primaquine|Rescue treatment to ensure clearance of Plasmodium falciparum. To be taken as a single, orally administered, 45 mg dose with food. Primaquine rescue medication will be used only if gametocytes are identified after administration of Riamet® rescue medication.
249154|NCT02223884|Drug|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
249155|NCT02223884|Drug|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
248500|NCT02236000|Drug|T-DM1|Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
248501|NCT02236013|Drug|ASP2215|Oral
248502|NCT02236013|Drug|Idarubicin|lyophilized powder administered intravenously
248503|NCT00143962|Behavioral|Low Carbohydrate Diet|
248504|NCT02236013|Drug|Cytarabine|solution administered intravenously
248505|NCT02236026|Drug|Supratherapuetic dose of Nestorone|
248823|NCT02228447|Behavioral|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
248824|NCT02228460|Drug|GZ/SAR402671|Pharmaceutical form: capsule Route of administration: oral
248825|NCT02228473|Drug|Glycopyrrolate|Glycopyrrolate will be administered.
248826|NCT02228473|Drug|Atropine|Atropine will be administered.
248827|NCT02228486|Device|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
248828|NCT02230878|Drug|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
248829|NCT02230891|Drug|Carvedilol|Carvedilol is a non selective beta blocker
248830|NCT02230891|Drug|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
248831|NCT02230904|Drug|Rotigotine (Test product PR 2.3.1)|Pharmaceutical form: Transdermal patch
Concentration: 8 mg/24 hours
Route of administration: Transdermal
248832|NCT00002331|Drug|Ethambutol hydrochloride|
248833|NCT00143403|Drug|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
248834|NCT02230904|Drug|Rotigotine (Reference product PR 2.1.1)|Pharmaceutical form: Transdermal patch
Concentration: 8 mg/24 hours
Route of administration: Transdermal
248835|NCT02230917|Drug|Sotatercept|
248836|NCT02230917|Drug|Placebo|
248192|NCT02203331|Drug|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
248193|NCT02203357|Biological|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
248194|NCT02203370|Device|NIRS - Near-infrared spectroscopy|
248195|NCT02203383|Device|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
248196|NCT02203396|Drug|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
248197|NCT00140192|Drug|creatine|
248198|NCT02203409|Procedure|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
248199|NCT02203422|Drug|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
248200|NCT02203422|Drug|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
248201|NCT02203448|Device|Facet Wedge spinal system|
248202|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
248203|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
248204|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
248205|NCT02203474|Drug|Tiotropium HFA BAI 5 mcg|
248206|NCT02203474|Drug|Tiotropium 18 mcg Capsule|
248207|NCT02203474|Drug|Placebo|Placebo
248208|NCT00140205|Drug|r-metHuLeptin|
248506|NCT02236026|Drug|Placebo|
248507|NCT02236026|Drug|Moxifloxacin|
248508|NCT02198300|Drug|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
248509|NCT02198313|Drug|BIIX 1 XX - D1|
248212|NCT02203500|Drug|Telmisartan|
248213|NCT02205723|Behavioral|Asthma teaching in ER|Asthma teaching
248214|NCT02205723|Behavioral|Smartphone Asthma Control|Smartphone Asthma Control
248215|NCT02205736|Other|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
248216|NCT02205749|Behavioral|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
248217|NCT02205749|Behavioral|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
248218|NCT02205749|Behavioral|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
248219|NCT02205762|Drug|Prednisone|Stratum I
248220|NCT00002310|Drug|Crofelemer|
248221|NCT00140543|Drug|sirolimus versus mycophenolate mofetil|
248222|NCT02205762|Drug|Vinblastine|Stratum I
248223|NCT02205762|Drug|mercaptopurine|Stratum I
248224|NCT02205762|Drug|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
248225|NCT02205762|Drug|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
248226|NCT02205762|Drug|Cytosine Arabinoside|
248227|NCT02205762|Drug|2-chlorodeoxyadenosine|
248228|NCT02205762|Procedure|hematopoietic stem cell transplantation (RIC-HSCT)|
248229|NCT02205762|Biological|Intravenous immunoglobulin|
248230|NCT02205775|Drug|Atorvastatin|80 + 40 mg pre PCI
248231|NCT02205775|Drug|Rosuvastatin|40 + 40 mg before PCI
248232|NCT00140556|Radiation|Chemoradiotherapy|External beam radiation daily (M-F)
248233|NCT02205775|Drug|Rosuvastatin|5 mg twice before PCI (+ 10 mg ezetimibe)
248234|NCT02205775|Drug|Ezetimibe|10 mg twice before PCI (+ 5 mg rosuvastatin)
247592|NCT02218164|Drug|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 1000 mg/m2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
247593|NCT02218177|Drug|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
247594|NCT02218177|Drug|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
247884|NCT02210806|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
247885|NCT02210806|Other|Placebo DPI|Placebo, 1 inhalation
247886|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
247887|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
247888|NCT02210819|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Cohort participants are classified as "rivaroxaban" patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine
247889|NCT02213250|Drug|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
247890|NCT02213263|Biological|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
247891|NCT02213263|Biological|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
247892|NCT02213276|Other|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
247893|NCT02213276|Other|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
247894|NCT02213289|Drug|Trastuzumab|HER2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line) + Trastuzumab
247895|NCT00141349|Drug|UK-369,003|
247896|NCT02213289|Drug|TBD|MET group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ TBD
247897|NCT02213289|Drug|ABT-806|EGFR Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ ABT-806
247898|NCT02213289|Drug|TBD2|FGFR2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ TBD2
247280|NCT02225392|Procedure|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
247281|NCT02225392|Device|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
247282|NCT02225405|Drug|Nintedanib|Run-In Phase Starting Dose of Nintedanib: 150 mg by mouth twice a day every day from Day 2 of Cycle 1 through Day 7 of Cycle 3, except for the days that Cisplatin and Docetaxel given.
Expansion Phase: During expansion phase, participants receive priming therapy with Nintedanib single agent for 28 days (+/- 7 days) at the maximum tolerated dose from Run-In Phase. Then 3 cycles given with Cisplatin and Docetaxel followed by surgery.
247283|NCT02225405|Drug|Cisplatin|Run-In Phase: 75 mg/m2 by vein on Day 1. Cycles repeated every 21 days +7 days/-3 days for a maximum of 3 cycles.
Expansion Phase: Same dose as Run-In Phase.
247284|NCT02225405|Drug|Docetaxel|Run-In Phase: 75 mg/m2 by vein on Day 1. Cycles repeated every 21 days +7 days/-3 days for a maximum of 3 cycles.
Expansion Phase: Same dose as Run-In Phase.
247285|NCT02225418|Drug|Ropivacaine|
247286|NCT00142753|Biological|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
247287|NCT02225418|Drug|saline|
247288|NCT02225431|Drug|sodium chloride infusion|
247289|NCT02225444|Other|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
247290|NCT02225457|Other|Hypercaloric diet|Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a "snack" type, high fat and high carbohydrates diet.
247291|NCT02225457|Dietary Supplement|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
247292|NCT02225457|Dietary Supplement|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
247293|NCT02225470|Drug|E7389 (Eribulin Mesylate)|
247595|NCT02218177|Procedure|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
247596|NCT02218190|Drug|Alvimopan|
247597|NCT02218190|Drug|Placebo|
247598|NCT02218203|Drug|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject
246694|NCT00139477|Drug|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
246986|NCT02230176|Drug|177Lu-DOTA0-Tyr3-Octreotate|
246987|NCT02230189|Biological|Segmental airway allergen challenge|
246988|NCT02230202|Other|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
246989|NCT02230202|Other|single blood draw|single blood draw of approximately 45 mL.
246990|NCT00002330|Drug|Ganciclovir|
246991|NCT00143286|Drug|varenicline (CP-526,555)|
246992|NCT02230215|Device|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
246993|NCT02230228|Drug|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
246994|NCT02230254|Device|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
246995|NCT02230267|Other|High intensity exercise and balance training|
246996|NCT02230267|Other|Usual care arm exercise|
246997|NCT02232659|Device|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
246998|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
246999|NCT02232672|Device|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
247000|NCT02232685|Device|18F-Choline PET/CT|18F-Choline PET/CT
247001|NCT02232698|Device|Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.
247002|NCT02232698|Device|Standard Blood Glucose Monitoring|Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.
247003|NCT02232724|Device|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
246375|NCT02202681|Device|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
246376|NCT02202694|Behavioral|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
246377|NCT00140439|Behavioral|Emergency Department based asthma follow-up clinic|The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:
Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.
Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.
Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks
246378|NCT02205047|Drug|Trastuzumab|
246379|NCT02205047|Drug|Pertuzumab|
246380|NCT02205047|Procedure|gastrectomy|D2 gastrectomy
246695|NCT02197481|Procedure|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
246696|NCT02197481|Device|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
246697|NCT02197494|Drug|Valsartan|320mg tablets
246698|NCT02197507|Device|Digitized sensor|Measure of grip strength of the dominant hand
246699|NCT02197520|Drug|Insulin Peglispro|Administered subcutaneously
246700|NCT02197520|Drug|Insulin Glargine|Administered subcutaneously
246701|NCT02197520|Drug|Insulin Lispro|Administered subcutaneously
246702|NCT02197533|Other|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
246703|NCT02197546|Other|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
246704|NCT02197559|Procedure|DES group|all the participants in this group will be performed with drug -eluting stents
246705|NCT00139477|Behavioral|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
246706|NCT02197559|Procedure|BMS group|all the participants in this group will be performed with bare-metal stents
246080|NCT02212574|Drug|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
246081|NCT02212574|Drug|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
246082|NCT02212587|Drug|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
246083|NCT00141284|Drug|nelfinavir 1,250 mg twice daily|
246084|NCT02212600|Other|Observational|
246085|NCT02212613|Drug|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
246086|NCT02212626|Device|Rotarex S|
246087|NCT02215044|Drug|BI 2536, intravenous|
246088|NCT02215044|Drug|Gemcitabine, intravenous|
246089|NCT02215057|Drug|topical anesthesia|topical anesthetic drops and Group 2
246090|NCT02215057|Drug|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
246381|NCT02205060|Other|virtual reality exposure treatment|
246382|NCT02205060|Other|cognitive and behavioral approaches therapy|
246383|NCT02205073|Drug|Placebo RD + AVP SD|Placebo (matching to study drug) repeat doses + intranasal AVP single dose
246384|NCT02205073|Drug|Placebo RD + Placebo SD|Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
246385|NCT02205073|Drug|RG7314 RD + AVP SD|RG7314 repeat doses + intranasal AVP single dose
246386|NCT02205086|Other|Diagnosis|Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.
Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software.
246387|NCT02205099|Drug|SKL15508|
246388|NCT00002309|Drug|Azithromycin|
246389|NCT00140452|Drug|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
245796|NCT02222389|Behavioral|CM for Alcohol|Escalating reinforcement for alcohol abstinence.
Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say "good job!" or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.
245797|NCT02222389|Behavioral|CM for drugs|Escalating reinforcement for drug abstinence.
Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say "good job!" or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.
245798|NCT02222389|Behavioral|CM for both substances|Escalating reinforcement for drug and alcohol abstinence.
Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say "good job!" or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.
245799|NCT02222389|Behavioral|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
245800|NCT02222402|Behavioral|INTRA-DIALYTIC EXERCISE TRAINING|
245801|NCT02222415|Dietary Supplement|Exercise + Protein drink|
245802|NCT02222428|Drug|BI 1744 CL/BI 54903 XX FDC|
245803|NCT02222428|Drug|BI 54903 XX|
245804|NCT00142480|Drug|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
245805|NCT02222428|Drug|BI 1744 CL|
245806|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
245807|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD
245808|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
245809|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 25 mg QD
245810|NCT02224690|Drug|GWP42003-P|GWP42003-P oral solution
245811|NCT02224690|Drug|Placebo Control|Placebo oral solution
246091|NCT02215070|Drug|Pasireotide + Chemo|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Chemotherapy (Busulfan) will be given 4 days before stem cell transplant.
246092|NCT02215070|Drug|Pasireotide + Total Body Irradiation|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Total Body Irradiation (TBI) will be given 4 days before stem cell transplant.
245184|NCT02506218|Dietary Supplement|10 + 20 g protein consumption|whey isolate
245185|NCT02506218|Other|30 g protein breakfast|30 g mixed meal breakfast
245186|NCT00179608|Drug|CC-5013|
245187|NCT02506218|Other|10 g protein breakfast|10 g mixed meal breakfast
245188|NCT02506231|Drug|Folinic acid|
245484|NCT02232061|Drug|Fingolimod|
245485|NCT02232074|Other|Patient navigation enhanced with legal support|
245486|NCT00143546|Drug|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
245487|NCT02232087|Drug|salmeterol (as salmeterol xinafoate)|2, 6, and 12 inhalations
245488|NCT02232087|Drug|fluticasone propionate|2, 6, and 12 inhalations
245489|NCT02232100|Behavioral|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
245490|NCT02232100|Behavioral|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
245491|NCT02232113|Drug|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
245492|NCT02232126|Other|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
245493|NCT02232139|Drug|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
245494|NCT02232152|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
245495|NCT02232152|Drug|fluorouracil|Given IV
245496|NCT02232152|Other|pharmacological study|Correlative studies
245497|NCT00143559|Drug|Systematic chemotherapy and antibodies|Systemic chemotherapy and antibodies as follows:
Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD
245498|NCT02232152|Other|laboratory biomarker analysis|Correlative studies
244903|NCT02510872|Other|18F-FDG PET combined with CT with iodinated contrast injection|
244904|NCT02510872|Other|18F-FDG PET combined with CT without injection|
244905|NCT02513030|Procedure|Defibrillation testing during ICD replacement|
244906|NCT02513043|Drug|medical abortion|medical abortion
244907|NCT00180518|Device|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System ("RX ACCUNET") and the RX ACCULINK Carotid Stent System ("RX ACCULINK").
The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.
The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients.
244908|NCT02513056|Other|MRI|MRI
244909|NCT02513069|Drug|Nicotine gum|Participants will be prescribed one form of nicotine replacement "rescue" treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred "rescue" treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings.
244910|NCT02513069|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
245189|NCT02506231|Drug|Placebo|
245190|NCT02506244|Device|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
245191|NCT02506244|Device|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
245192|NCT02506257|Drug|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
245193|NCT02506257|Drug|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
245194|NCT02506257|Drug|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
245195|NCT02506257|Drug|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
245196|NCT02506270|Device|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
245197|NCT00179621|Drug|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
245198|NCT02506270|Device|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
220949|NCT02278120|Drug|LEE011|LEE011 600 mg daily oral
220950|NCT02278120|Drug|Tamoxifen|tamoxifen 20 mg daily oral
220951|NCT02278120|Drug|Letrozole|letrozole 2.5 mg daily oral
220952|NCT02280304|Behavioral|Inner Resources for Veterans (IRV)|Meditation therapy which utilizes mindfulness, techniques that encourage non-judgmental attention to oneself in the present moment
220953|NCT02280304|Behavioral|PTSD and mTBI education|Participants will learn about symptoms and triggers of PTSD and mTBI
220954|NCT02280317|Drug|VAL201|VAL201-001 Sub-cutaneous injection.
220955|NCT00149123|Drug|hydrocortisone 200 mg/day|
220956|NCT02280330|Dietary Supplement|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
220957|NCT02280330|Other|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
220958|NCT02280343|Other|evaluated lung function|lung function tests
220959|NCT02280356|Radiation|external beam radiation therapy|
220960|NCT02280356|Radiation|brachytherapy|
220961|NCT02280356|Behavioral|questionnaires|
220962|NCT02280382|Device|Femmeze®|Femmeze Vaginal Trainer
220963|NCT02280395|Drug|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
220964|NCT02280395|Drug|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
220965|NCT02280408|Other|Placebo|Normal saline placebo.
220966|NCT00149136|Drug|imatinib|
220967|NCT02280408|Biological|BPSC-1001 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
220968|NCT02280421|Drug|ASP2151 400mg + 100mg ciclosporin|
220361|NCT02292199|Device|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
220362|NCT02292199|Device|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
220363|NCT02292199|Device|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
220364|NCT00150579|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
220662|NCT02285439|Drug|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
220663|NCT02285452|Drug|Zingiberis Rhizoma plv.|
220664|NCT02285452|Drug|Sinapis nigrea semen|
220665|NCT02285452|Drug|Placebo|
220666|NCT00149721|Procedure|Ventriculo-peritonal shunting|
220667|NCT02285465|Drug|ASP3700|Oral
220668|NCT02285465|Drug|Placebo|Oral
220669|NCT02285491|Drug|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
220670|NCT02285491|Drug|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
220671|NCT02285504|Drug|SAGE-547|Intravenous
220672|NCT02287779|Drug|SHP626|
220673|NCT02287779|Drug|Placebo|
220674|NCT02287792|Procedure|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
220675|NCT02287805|Other|qualitative survey|
220676|NCT02287805|Other|quantitative survey|
244971|NCT02519933|Procedure|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
244972|NCT02519933|Procedure|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
244973|NCT02519946|Other|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
244974|NCT02519959|Drug|(F18)-FAZA injection|Participants will have received pre-study testing that is standard of care (e.g. biopsy, complete blood count, serum electrolytes, urinalysis, liver function tests, beta-hCG testing, etc.) with no incremental testing. Patients will receive a routine MRI and CT. In addition they will receive a FAZA-PET scan 2-3 days prior to surgery.
244975|NCT02519959|Drug|Pimonidazole-HCl|Two to three days prior to surgery participants will be dispensed oral pimonidazole-HCl. On the day before surgery, in addition to typical peri-operative activities (e.g. 24 hour solid fast, only consuming clear fluids) the patient will be instructed to take the prescribed dose of oral pimonidazole-HCl 16-20 hours before surgery. The patient will be admitted for same day surgery which will be carried out in a routine fashion.
244976|NCT02519972|Device|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
244977|NCT00181701|Drug|Carboplatin|
245267|NCT02513329|Drug|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
245268|NCT02513329|Drug|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
245269|NCT02513342|Biological|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
245270|NCT02513342|Drug|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
245271|NCT02515513|Procedure|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
245272|NCT02515526|Drug|Percoffedrinol, Tolbutamide PCH, Omepazol Ratiopharm, Hustenstiller Ratiopharm, Digacin and Midazolam-ratiopharm|
244692|NCT02526745|Biological|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
244693|NCT02526745|Biological|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
244694|NCT02526745|Biological|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
244695|NCT02526745|Biological|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
244696|NCT02526745|Biological|placebo|
244697|NCT02526758|Drug|beclomethasone|
244698|NCT02526758|Drug|formoterol|
244699|NCT00002494|Drug|mesna|
244700|NCT00182637|Drug|bortezomib|
244701|NCT02526758|Drug|budesonide|
244702|NCT02526771|Procedure|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
244703|NCT02526771|Procedure|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
244704|NCT02526784|Drug|degarelix|
244705|NCT02526810|Drug|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
244706|NCT02526810|Drug|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
244707|NCT02526823|Drug|R-CHOP/CHOPE or ABVD chemotherapy regimen|R-CHOP:
Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；
CHOPE:
Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;
ABVD:
Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
244708|NCT02526823|Drug|R-CDOP/CDOPE or DBVD chemotherapy regimen|R-CDOP:
Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；
CDOPE:
PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;
DBVD:
PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
249156|NCT02223897|Drug|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
244402|NCT02531308|Drug|Cyclophosphamide|Interferes with DNA replication
244403|NCT02531308|Drug|Doxorubicin|anthracycline antitumor antibiotic
244404|NCT02531308|Drug|Vincristine|Inhibits cell mitosis causing cell death.
244405|NCT02531308|Drug|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
244406|NCT02531308|Drug|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
244407|NCT02533349|Drug|Motilitone|30mg, 1 tablet, 3 times a day
244408|NCT02533349|Drug|Pantoprazole|40mg, 1 tablet, 1time a day
244409|NCT02533349|Drug|Placebo|30mg, 1 tablet, 3 times a day
244410|NCT02533362|Drug|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
244411|NCT00183365|Behavioral|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
244412|NCT02533375|Drug|Adalimumab|Adalimumab
244413|NCT02533388|Device|electro-acupuncture|Prior to the induction of anesthesia,patients in group E received induction of EA at Neiguan, Shenmen, Lieque, chize, and futu,Renying for 30 min (The stimulus frequency was100Hz),which lasted to the end of the surgery.
244414|NCT02533401|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
244415|NCT02533401|Drug|Fludarabine|Fludarabine will be administered IV at 25 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
244416|NCT02533401|Drug|Rituximab|Rituximab will be administered IV at 375 mg/m^2 on Day 1 of Cycle 1 and then at 500 mg/m^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
244417|NCT02533414|Device|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
244418|NCT02533414|Device|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
244419|NCT02533427|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857 (400/100/100 mg) FDC tablet administered orally once daily
244420|NCT02533427|Drug|GS-9857|GS-9857 100 mg tablet administered orally once daily
248837|NCT02230930|Drug|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
248838|NCT02230930|Device|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
248839|NCT02230930|Drug|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
248840|NCT02230930|Drug|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
248841|NCT02230956|Biological|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
248842|NCT02230956|Drug|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
248843|NCT02230969|Drug|peginterferon beta-1a|Administered as described in the treatment arm
249157|NCT02223897|Drug|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
249158|NCT02223910|Procedure|Neurofeedback training of functional connectivity|
249159|NCT02223923|Drug|AZD6738|
249160|NCT02223923|Radiation|Palliative radiotherapy|
249161|NCT02223936|Other|group exposed|Assessment by Brunet Lezine scale
249162|NCT02223936|Other|Control|Not exposed group
249163|NCT00142584|Drug|Metoprolol|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
249164|NCT02223949|Device|Cook double balloon catheter|
249165|NCT02223949|Drug|PGE1 tablet|
249166|NCT02226042|Behavioral|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
248510|NCT00139529|Behavioral|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
248511|NCT02198313|Drug|BIIX 1 XX - D2|
248512|NCT02198313|Drug|BIIX 1 XX - D3|
248513|NCT02198313|Drug|Placebo|
248514|NCT02198326|Drug|BIBN 4096 BS- in single rising doses|
248515|NCT02198326|Drug|Placebo|
248516|NCT02198339|Drug|BIBN 4096 BS|
248517|NCT02198339|Drug|Placebo|
248518|NCT02198352|Drug|BIBN 4096 BS - in single rising doses|
248519|NCT02198352|Drug|Placebo|
248520|NCT02198378|Drug|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
248521|NCT00002304|Drug|Ketoconazole|
248522|NCT00139529|Behavioral|Educational Intervention|Educational intervention will be completed during pregnancy.
248523|NCT02198378|Drug|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
248524|NCT02198404|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
248525|NCT02198417|Drug|Metformin ER|Treatment with metformin ER for 12 weeks
248526|NCT02198443|Drug|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
248527|NCT02198443|Drug|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
248528|NCT02198469|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
248844|NCT00143403|Drug|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
248845|NCT02230982|Drug|nintedanib|soft gelatin capsule
248529|NCT02198469|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
248530|NCT02198482|Drug|Volasertib|
248531|NCT02198482|Drug|Cytarabine|
248532|NCT02198482|Drug|Daunorubicin|
248533|NCT02201069|Behavioral|health coaching|
248534|NCT02201082|Procedure|Airway clearance technique|
248535|NCT02201082|Drug|Amikacin nebulization|
248536|NCT02201095|Device|Forced air warming|
248537|NCT02201095|Device|Conduction warming mattress|
248538|NCT02201108|Drug|Teriflunomide HMR1726|Pharmaceutical form:film-coated tablet Route of administration: oral
248539|NCT02201108|Drug|Placebo|Pharmaceutical form:tablet Route of administration: oral
248540|NCT00139893|Drug|Reglan ODT|
248541|NCT02201121|Other|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
248542|NCT02201134|Drug|sevoflurane|
248543|NCT02201147|Procedure|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
248544|NCT02201147|Procedure|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
248545|NCT02201147|Device|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
248546|NCT02201147|Device|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
248547|NCT02201160|Dietary Supplement|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
247899|NCT02213289|Drug|Ramucirumab|VEGFR2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ Ramucirumab
247900|NCT02213302|Drug|placebo administration|
247901|NCT02213302|Drug|midazolam intravenous administration|
247902|NCT02213315|Drug|100mg Mavrilimumab|100mg Mavrilimumab
247903|NCT02213315|Drug|150mg mavrilimumab|150mg mavrilmumab
247904|NCT02213315|Other|Placebo|Placebo
247905|NCT02213328|Drug|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
248235|NCT02205775|Drug|placebo|twice before PCI
248236|NCT02205801|Procedure|Superficial Cervical Plexus Block|0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
248237|NCT02205801|Procedure|Local Wound Infiltration|0.25% Marcaine is injected at the site of incision (20mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
248238|NCT02205801|Drug|0.9% saline|
248239|NCT02205801|Drug|Marcaine|
248240|NCT02205814|Drug|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
248241|NCT02205814|Drug|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
248242|NCT02208297|Drug|Vehicle Gel (BID)|One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
248243|NCT00140855|Drug|Anti-CTLA4 (monoclonal antibody MDX-010)|
248244|NCT02208310|Drug|Cholecalciferol 10,000 IU|
248245|NCT02208310|Drug|Cholecalciferol 400 IU|
248246|NCT02208323|Device|Bubble CPAP|Respiratory assistance
248247|NCT02208336|Other|medical chart review|Ancillary studies
248248|NCT02208349|Device|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
247599|NCT02218203|Drug|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
247600|NCT00141986|Dietary Supplement|vitamin D3|2000 IU per day
247601|NCT00142246|Drug|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
247602|NCT02220673|Drug|BHT 0.1%|
247603|NCT02220673|Drug|BHT 0.5%|
247604|NCT02220673|Drug|Placebo for RMT-B|
247605|NCT02220673|Drug|Placebo for HFA-MDI|
247606|NCT02220686|Behavioral|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
247607|NCT02220712|Drug|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
247608|NCT02220725|Biological|Andexanet|
247609|NCT02220725|Other|Placebo|
247610|NCT02220738|Drug|ABT-957|ABT-957 administered twice-daily for 7 days
247611|NCT02220738|Other|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
247612|NCT00142246|Other|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
247613|NCT02220751|Drug|non-surgical periodontal therapy + systemic doxycycline|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group.
247614|NCT02220751|Procedure|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
247906|NCT00141362|Drug|Pregabalin|
247907|NCT02213341|Procedure|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
247908|NCT02213341|Procedure|Blood draw|
247004|NCT02232737|Other|Very low nicotine content cigarettes|
247005|NCT02232763|Drug|Losartan|12 weeks of losartan or placebo with crossover to the other
247006|NCT02232763|Drug|Placebo|12 weeks of losartan or placebo with crossover to the other
247007|NCT02232776|Drug|Losartan|
247294|NCT02225470|Drug|Vinorelbine injection|
247295|NCT02225496|Procedure|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
247296|NCT02225496|Procedure|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
247297|NCT00142753|Biological|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
247298|NCT02225496|Behavioral|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
247299|NCT00142974|Drug|Tegaserod|
247300|NCT02227745|Drug|Placebo Sodium hyaluronate 4mg|Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.
Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed.
247301|NCT02227771|Device|Percutaneous coronary intervention|
247302|NCT02227784|Drug|Evacetrapib|Administered orally
247303|NCT02227784|Drug|Atorvastatin|Administered orally
247304|NCT02227784|Drug|Ezetimibe|Administered orally
247305|NCT02227784|Drug|Placebo|Administered orally
247306|NCT02227797|Drug|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
247307|NCT02227810|Other|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
247308|NCT02227810|Other|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
247309|NCT02227810|Other|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
246707|NCT02197572|Drug|MLN0128|MLN0128 capsules
246708|NCT02197585|Procedure|Inguinal mesh hernioplasty|
246709|NCT02197598|Drug|nalmefene|
246710|NCT02197637|Drug|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
246711|NCT02200094|Drug|High dose of Telmisartan, once daily|
246712|NCT02200107|Behavioral|self management education|
246713|NCT02200133|Other|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
246714|NCT02200146|Drug|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
246715|NCT02200146|Drug|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
246716|NCT00139763|Procedure|Educational Materials|
247008|NCT02232789|Drug|Mephedrone|Single oral dose mephedrone
247009|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
247010|NCT02232789|Drug|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
247011|NCT02232789|Drug|Placebo|Single oal dose placebo
247012|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
247013|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
247014|NCT02232828|Procedure|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
246390|NCT02205099|Drug|Placebo|
246391|NCT02205112|Drug|Nemonoxacin|
246392|NCT02205112|Drug|Levofloxacin|
246393|NCT02205138|Drug|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia.
246394|NCT02205151|Drug|Fimasartan|
246395|NCT02205151|Drug|Amlodipine|
246396|NCT02205151|Drug|Fimasartan/Amlodipine combination|
246397|NCT02205164|Drug|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
246398|NCT02205164|Drug|Palonosetron|Aloxi 0.25mg
246399|NCT02207621|Drug|Timolol maleate Ophthalmic Solution|2 drops daily
246400|NCT02207634|Biological|Evolocumab (AMG 145)|Evolocumab (AMG 145)
246401|NCT02207634|Other|Placebo|Placebo
246402|NCT02207634|Drug|Effective statin therapy|Effective statin therapy defined as greater than or equal to atorvastatin 20 mg or an equivalent statin
246403|NCT02207647|Other|no intervention|
246717|NCT02200159|Drug|Sedation with dexmedetomidine|
246718|NCT02200172|Other|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
246719|NCT02200172|Other|Placebo|
246720|NCT02200185|Drug|IV titrated morphine|Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:
SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times
246721|NCT02200185|Drug|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
246722|NCT02200185|Drug|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
246723|NCT02200198|Other|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
246093|NCT02215083|Dietary Supplement|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
246094|NCT00141583|Drug|Enalapril 20 mg bd|
246095|NCT02215096|Drug|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
246096|NCT02215096|Drug|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
246097|NCT02215122|Drug|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
246098|NCT02215122|Drug|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
246099|NCT02215122|Drug|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
246100|NCT02215135|Drug|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
246101|NCT02215148|Drug|Tolvaptan|
246102|NCT02215161|Drug|Selinexor|
246103|NCT02215174|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
246104|NCT02215187|Behavioral|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
246105|NCT00141583|Drug|Candesartan 8 mg bd|
246106|NCT02215187|Behavioral|Attention Control|Social contact control (health education/no skill training)
246107|NCT02215200|Drug|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
246108|NCT02215200|Drug|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
246109|NCT02215200|Drug|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
246110|NCT02215200|Drug|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
246111|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D
245499|NCT02234635|Other|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
245500|NCT02234648|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
245501|NCT02234648|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
245502|NCT02234661|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
245812|NCT00142701|Behavioral|diet|
245813|NCT02224703|Drug|GWP42003-P|
245814|NCT02224703|Drug|Placebo Control|
245815|NCT02224729|Drug|Bendamustine hydrochloride|Given IV
245816|NCT02224729|Drug|Bortezomib|Given SC
245817|NCT02224729|Drug|Dexamethasone|Given PO
245818|NCT02224742|Device|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
245819|NCT02224742|Other|Usual care|Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.
Components of usual wound care include:
Formal assessment of ulcer and surrounding skin
Provision of any necessary off-loading
Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)
Appropriate dressing products
Appropriate antibiotic therapy
Nutrition and self care
Optimal glycaemic control
Revascularisation if deemed clinically necessary
Continued close observation
245820|NCT02224755|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
245821|NCT02224755|Device|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
245822|NCT02224768|Drug|Ipilimumab|
245823|NCT00142701|Behavioral|physical activity|
245824|NCT02224781|Drug|Dabrafenib|Given PO
245825|NCT02224781|Biological|Ipilimumab|Given IV
245199|NCT02506283|Device|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
245200|NCT02506296|Drug|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
245201|NCT02506296|Device|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
245202|NCT02506309|Device|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
245203|NCT02506309|Device|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
245204|NCT02506322|Behavioral|SEKT - Cognitive-Behavioral-Emotional|This Bipolar Disorder specific psychotherapy has 4 modules:
psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation
Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance
dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods
behavior changes, (social, problem solving) skill training, communication skills, crisis management
245205|NCT02508493|Other|Pencil-and-paper Cognitive Tests|Pencil-and-paper versions of the following cognitive tests:
Digit Symbol Substitution Test (DSST)
Trail Making Test B (TMT-B)
Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Variant of Choice Reaction Time (CRT)
Variant of the One-back working memory tool
245206|NCT02508506|Drug|ALKS 5461|Single dose, given orally
245207|NCT02508519|Procedure|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
245208|NCT02508532|Drug|BLU-285|
245503|NCT00143806|Drug|Transitioning patients from cyclosporine to alefacept|
245504|NCT02234674|Other|Current intensive CDP|Standard Intensive CDP including
manual lymph drainage,
pressotherapy and
bandaging
245505|NCT02234674|Other|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
245506|NCT02234687|Drug|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
245507|NCT02234687|Drug|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
245508|NCT02234687|Drug|Placebo|Placebo, one dose, one time
245509|NCT02234713|Behavioral|Motivational Interview|
245510|NCT02234713|Other|Video Attention Control|
221251|NCT02314741|Procedure|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually ~6cm long & averages 8-10cm. After the myotomy is performed the scope is withdrawn & inserted into the lumen to inspect the mucosa, ensure mucosal integrity & confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, & is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
221252|NCT00002387|Drug|Efavirenz|
221253|NCT00152841|Drug|Vitamin E 800IU|
221254|NCT02314754|Drug|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
221255|NCT02314767|Behavioral|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
221256|NCT02314767|Behavioral|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
221257|NCT02314780|Drug|heme arginate 1mg/kg|
221258|NCT02314780|Drug|heme arginate 3mg/kg|
221259|NCT02314780|Drug|placebo|
221260|NCT02314793|Drug|ASP2205|oral
221261|NCT02314793|Drug|Placebo|oral
221262|NCT02314806|Drug|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
221263|NCT02314806|Drug|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
221264|NCT00152854|Drug|Acetaminophen|acetaminophen 1g po qid
221265|NCT02314806|Drug|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
221266|NCT02314819|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
221267|NCT02314819|Drug|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
221268|NCT02314832|Procedure|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
221269|NCT02314832|Procedure|femoral nerve block|ultrasound guided femoral nerve block
221270|NCT02314845|Other|Optimal PEEP|"Optimal PEEP" determined by EIT during a PEEP titration procedure.
220677|NCT02287818|Drug|Placebo|Placebo twice daily from Day 1 to Week 12
220678|NCT02287818|Drug|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
220679|NCT02287818|Drug|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration <6 mg/dL
220680|NCT02287831|Biological|umbilical cord mesenchymal stem cells|patients were divided into 3 dose treatment groups (6.29 × 107,9.43 × 107 and 14.15 × 107 cells/m2). After 4 and 8 weeks, patients were injected the same number of cells.
220681|NCT02287844|Other|XOS|5 g of XOS everyday for 4 weeks.
220682|NCT00149942|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
220683|NCT02287844|Other|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
220684|NCT02287844|Other|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
220685|NCT02287857|Drug|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
220969|NCT02280421|Drug|ASP2151 1200mg + 100mg ciclosporin|
220970|NCT02280434|Drug|CBP-307|
220971|NCT02280434|Drug|Placebo|
220972|NCT02280447|Biological|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
220973|NCT02280447|Biological|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
220974|NCT02280447|Biological|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
220975|NCT02280447|Biological|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
220976|NCT02280473|Drug|Carboxymethylcellulose Sodium Based Eye Drop|Carboxymethylcellulose sodium based eye drop 1-2 drops in each eye as needed at least 2 times daily for 30 days.
220977|NCT00149149|Drug|Zinc carnosine|
220978|NCT02280473|Drug|Carboxymethylcellulose Sodium 1.0%|Carboxymethylcellulose sodium 1.0% (REFRESH LIQUIGEL®) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
220979|NCT02282891|Drug|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
220980|NCT02282904|Drug|Pre-Transplant Conditioning Medications|Busulfan, Fludarabine, Cyclophosphamide
245273|NCT02515526|Drug|Percoffedrinol, Tolbutamide PCH, Omepazol Ratiopharm, Hustenstiller Ratiopharm, Digacin, Midazolam-ratiopharm and Wodka Gorbatschow 50%|
245274|NCT02515539|Device|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
245275|NCT02515552|Behavioral|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
245276|NCT00180830|Drug|Glivec|
245277|NCT02515565|Drug|cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
245278|NCT02515565|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
245279|NCT02515565|Device|Electrostimulation|
245280|NCT02515578|Other|Enhanced practice transformation support|
245281|NCT02515578|Other|Standard practice transformation support|
245282|NCT02515591|Other|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
245283|NCT02515604|Drug|Misoprostol|
245570|NCT02199717|Device|Accelerometer|
245571|NCT02199743|Drug|Lurasidone|Compare to haloperidol and perphenazine
245572|NCT02199743|Drug|Haloperidol|Compare to lurasidone
245573|NCT02199743|Drug|Perphenazine|Compare to lurasidone
245574|NCT02199769|Other|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
245575|NCT02202252|Procedure|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
245576|NCT02202252|Procedure|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
244978|NCT02519985|Device|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.
The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
244979|NCT00182039|Drug|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
244980|NCT02522156|Behavioral|Control|Neutral guided imagery scenarios making no reference to smoking.
244981|NCT02522169|Drug|Infliximab|This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.
We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A< 6month, group B < 6 month). Observation period is one year.
244982|NCT02522182|Behavioral|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
244983|NCT02522182|Behavioral|Usual Treatment|Information related to intervention description have been already included in arm/group description
244984|NCT02522208|Drug|BiDil XR|fixed combination capsule
244985|NCT02522208|Drug|BiDil Immediate Release (IR)|fixed combination tablet
244986|NCT02522221|Drug|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
244987|NCT02522221|Drug|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
244988|NCT02522234|Biological|F-627|F-627 administrated by s.c. injection on Day 2 of each cycle for up to 6 cycles.
244989|NCT02522234|Drug|TAC regimen|Chemotherapy (docetaxol, doxorubicin and cyclophosphamide, 75 mg/m2, 50 mg/m2 and 500 mg/m2, respectively) administrated in vein on Day 1 of each cycle for up to 6 cycles.
244421|NCT02533427|Drug|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
244422|NCT00183378|Behavioral|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
244709|NCT02526836|Procedure|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
244710|NCT02526836|Procedure|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
244711|NCT00182650|Biological|aldesleukin|
244712|NCT02526849|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
244713|NCT02528968|Behavioral|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
244714|NCT02528981|Drug|Probiotic|Lactobacillus GR-1 and RC-14
244715|NCT02528981|Drug|Placebo|
244716|NCT02528994|Dietary Supplement|L-serine|Participants will take dietary serine supplementation daily
244717|NCT02529007|Device|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
244718|NCT00182793|Procedure|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
244719|NCT02529007|Other|Standard colonoscopy|Standard colonoscopy without end-cuff
244720|NCT02529020|Device|Mouthguard|Condition of wearing mouthguard
244721|NCT02529020|Device|No mouthguard|Condition without mouthguard
244722|NCT02529033|Device|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
244723|NCT02529046|Dietary Supplement|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
244724|NCT02529046|Behavioral|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
244725|NCT02529059|Drug|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
249167|NCT02226055|Device|Arterial Stiffness Assessment|The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).
We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated.
249168|NCT02226068|Drug|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
249169|NCT02226068|Other|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
249170|NCT02226094|Device|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
249171|NCT02226094|Device|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
249172|NCT00142818|Drug|Modafinil|400 mg daily
249173|NCT02226094|Device|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
244423|NCT02533440|Procedure|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
244424|NCT02533440|Procedure|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
244425|NCT02533453|Biological|Bydureon|exenatide once weekly
244426|NCT02533466|Drug|Test Product|Participants will apply a full ribbon of dentifrice to the study toothbrush and brush their teeth for 1 timed minute using their assigned study toothpaste (wetted toothbrush), swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
244427|NCT02533466|Other|Reference Product|Participants will apply a full ribbon of dentifrice to the study toothbrush and brush their teeth for 1 timed minute using their assigned study toothpaste (wetted toothbrush), swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
244428|NCT02533479|Other|Caloric restriction|three alternate days weekly along 4 weeks.
244429|NCT02533492|Device|vicryl|wound closure with vicryl suture
248846|NCT02230995|Drug|metformin|single dose of metformin given as tablets
248847|NCT02230995|Drug|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
248848|NCT02230995|Drug|empagliflozin|single dose of empagliflozin given as tablet
248849|NCT02231008|Drug|tasimelteon|
248850|NCT02231021|Drug|alogliptin|alogliptin 25 mg add-on background medication metformin
248851|NCT02231021|Drug|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
248852|NCT02231021|Drug|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
248853|NCT02231047|Dietary Supplement|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
248854|NCT02231047|Other|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
248855|NCT02233517|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
248856|NCT02233517|Behavioral|Present Centered Therapy|Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the "here-and-now" to support patients in their efforts to improve functioning.
248857|NCT02233530|Behavioral|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
248858|NCT02233543|Drug|QVA149|Delivered once daily via single-dose dry powder inhaler
248859|NCT02233543|Drug|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
248860|NCT02233556|Drug|Memantine|Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:
Mismatch negativity(MMN)
P50
248861|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
248862|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
248548|NCT02201173|Behavioral|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
248549|NCT02201186|Other|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
248863|NCT02233569|Device|Ventralight ST implant|
248864|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
248865|NCT02233569|Device|ETHICON PHYSIOMESH®|
248866|NCT02233582|Drug|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
248867|NCT02233595|Radiation|Chemoradiation|
248868|NCT02233608|Behavioral|Advanced Pelvic Floor Muscle Exercise (APFX)|
248869|NCT02233621|Other|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with [18F]FES before coelioscopy
248870|NCT02233634|Drug|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
248871|NCT02233634|Other|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
248872|NCT02233634|Other|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
248873|NCT02233647|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
248874|NCT02233647|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
248875|NCT02236039|Procedure|Bronchoscopy|Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
248876|NCT02236052|Biological|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
248877|NCT02236052|Biological|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
248878|NCT02236052|Biological|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
248879|NCT02236052|Biological|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
248249|NCT02208349|Device|traditional direct laryngoscopy (DL)|
248250|NCT02208362|Biological|IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes|Given via intratumoral or intracavitary or intraventricular catheter
248251|NCT02208362|Other|laboratory biomarker analysis|Correlative studies
248252|NCT02208362|Other|quality-of-life assessment|Ancillary studies
248253|NCT02208375|Drug|Olaparib|Dose Escalation Starting Dose of Olaparib: 100 mg by mouth twice a day, or 300 mg by mouth twice a day if in Group 3.
Dose Expansion Starting Dose of Olaparib: MTD from Dose Escalation Phase.
248254|NCT00140868|Device|Luminal stents|
248255|NCT02208375|Drug|AZD2014|Dose Escalation Starting Dose of AZD2014: 25 mg by mouth twice a day for Olaparib + AZD2014 (continuous dosing) group, and 125 mg by mouth twice a day for Olaparib + AZD2014 (intermittent dosing) group.
Dose Expansion Starting Dose of AZD2014: MTD from Dose Escalation Phase.
248256|NCT02208375|Drug|AZD5363|Dose Escalation Starting Dose of AZD5363: 320 mg by mouth twice a day.
Dose Expansion Starting Dose of AZD5363: MTD from Dose Escalation Phase.
248550|NCT02201199|Drug|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
248551|NCT00139906|Drug|Bifeprunox|
248552|NCT02201199|Drug|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
248553|NCT02201199|Drug|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
248554|NCT02201212|Drug|Everolimus|
248555|NCT02201225|Dietary Supplement|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
248556|NCT02201225|Dietary Supplement|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
248557|NCT02201238|Drug|Diclofenac sodium|Diclofenac sodium
248558|NCT02201238|Drug|Menthol|Menthol
248559|NCT02203513|Drug|LY2606368|105 mg/m2 IV once every 14 days of a 28 day cycle
248560|NCT02203526|Drug|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 3 weeks for up to six cycles for second cohort and 5 cycles (cycles 2-6) for first cohort.
248561|NCT02203526|Biological|Rituximab|Rituximab given with TEDD and TEDDI every 3 weeks for up to 6 cycles
247909|NCT02213354|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
247910|NCT02213354|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
247911|NCT02213367|Drug|Bilastine|20mg (8 weeks)
247912|NCT02213367|Drug|Bilastine|40mg
247913|NCT02213367|Drug|Bilastin|80mg
247914|NCT02215824|Drug|BIWH 3|
247915|NCT02215824|Drug|Placebo|
247916|NCT02215837|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
247917|NCT02215837|Biological|Ag-D-CIK|8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
247918|NCT00141661|Drug|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
247919|NCT02215850|Drug|SLC-0111|
247920|NCT02215863|Biological|Fluad and Prevenar13|
247921|NCT02215863|Biological|Fluad|
247922|NCT02215863|Biological|Prevenar13|
247923|NCT02215876|Drug|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
247924|NCT02215876|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
247925|NCT02215876|Drug|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
247926|NCT02215889|Procedure|Liver transplantation|
247927|NCT02215902|Device|Affinity plasmapheresis|
247928|NCT02215915|Procedure|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
248257|NCT02208388|Device|computed tomography perfusion guided treatment|
247310|NCT00142987|Drug|Tegaserod|
247311|NCT02227823|Drug|Pyridostigmine Bromide|
247312|NCT02227836|Device|Allergy Patch Testing|Patient will undergo APT testing per the following protocol:
2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.
Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits
The patches will be removed at 48 hours, and results read at 72 hours after application.
Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles).
247313|NCT02227849|Drug|Canagliflozin (TA-7284) ＋GLP-1 analogue|The patients will receive Canagliflozin orally for 52 weeks
247615|NCT02220764|Device|Teeth abutment|
247616|NCT02220764|Device|Implant abutments|
247617|NCT02220777|Drug|ASP8477|oral
247618|NCT02220777|Drug|omeprazole|oral
247619|NCT02220777|Drug|Placebo|oral
247620|NCT02220803|Drug|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
247621|NCT02220803|Device|nasal Continuous Positive Airway Pressure (nCPAP)|
247622|NCT02220816|Behavioral|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
247623|NCT00142259|Device|Deep brain stimulation of the internal globus pallidus|
247624|NCT02223130|Behavioral|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
247625|NCT02223169|Dietary Supplement|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
247626|NCT02223182|Biological|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
247627|NCT02223182|Biological|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
247628|NCT02223182|Biological|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
247015|NCT02232828|Procedure|Stepwise removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described.
247016|NCT02235259|Drug|Placebo|
247017|NCT02235272|Drug|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
247018|NCT02235272|Drug|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
247019|NCT02235285|Procedure|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
247020|NCT02235298|Drug|Dapagliflozin|Dapaglifozin causes a rapid and significant reduction of epicardial fat in type 2 diabetic patients
247021|NCT02235298|Drug|Metformin|
247022|NCT02235311|Drug|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
247023|NCT02235324|Biological|ziv-aflibercept|Given IV
247024|NCT00143884|Procedure|Reduced intensity conditioning|
247314|NCT02227862|Drug|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
247315|NCT02227862|Drug|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
247316|NCT02227875|Drug|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
246724|NCT02200198|Other|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
246725|NCT02200198|Other|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
246726|NCT02200211|Device|iPad®|Binocular therapy on iPad®
246727|NCT00139776|Drug|Celecoxib|24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.
Placebo used as flare medication when directed.
246728|NCT02200211|Other|Patching 2 hours per day, 7 days per week|
246729|NCT02200224|Other|Rapid Testing|
246730|NCT02200237|Biological|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
246731|NCT02200237|Biological|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
246732|NCT02200263|Dietary Supplement|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
246733|NCT02200263|Dietary Supplement|Placebo|two softgels once-daily with a meal
246734|NCT02200276|Biological|Influenza|
246735|NCT02200315|Other|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
246736|NCT02202707|Drug|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
246737|NCT00140140|Drug|ABI-007|Weekly intravenous infusions over 30 minutes.
246738|NCT02202720|Drug|Sevoflurane|Short term sedation with sevoflurane in ICU
247025|NCT02235324|Drug|leucovorin calcium|Given IV
247026|NCT02235324|Drug|fluorouracil|Given IV
247027|NCT02235324|Other|laboratory biomarker analysis|Correlative studies
247028|NCT02235337|Drug|Riboflavin 400mg daily|
246404|NCT02207660|Drug|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
246405|NCT00140725|Drug|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
246406|NCT02207673|Procedure|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
246407|NCT02207699|Drug|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
246408|NCT02207699|Drug|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
246409|NCT02207699|Drug|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
246410|NCT02207699|Drug|Placebo|8 placebo perles given by mouth once
246411|NCT02207712|Device|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
246412|NCT02207712|Drug|Ranibizumab|Standard ranibizumab treatment only
246413|NCT02207725|Biological|Andexanet|
246414|NCT02207725|Other|Placebo|
246415|NCT02207738|Device|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
246416|NCT00140725|Drug|Lamivudine|
246417|NCT02207738|Device|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
246418|NCT02207764|Behavioral|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
246419|NCT02207777|Procedure|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose 16-18% of their body weight.
246420|NCT02207777|Behavioral|Low-calorie diet|Subjects will meet with a dietitian over 4-6 months to lose 16-18% of their body weight.
246421|NCT02207777|Procedure|BPD|Bilopancreatic Diversion with duodenal switch (BPD) is a surgical procedure to help subjects lose 16-18% of their body weight.
246422|NCT02207777|Procedure|SG|Sleeve Gastrectomy (SG) is a surgical procedure to help subjects lose 16-18% of their body weight.
246423|NCT02207777|Procedure|LAGB|Laparoscopic Adjustable Gastric Banding is a surgical procedure to help subjects lose 16-18% of their body weight.
245826|NCT02224781|Other|Laboratory Biomarker Analysis|Correlative studies
245827|NCT02224781|Biological|Nivolumab|Given IV
245828|NCT02224781|Other|Quality-of-Life Assessment|Ancillary studies
245829|NCT02224781|Drug|Trametinib|Given PO
245830|NCT02224794|Device|Ovation® Abdominal Stent Graft Platform|
245831|NCT02224807|Behavioral|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
245832|NCT02224807|Behavioral|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
245833|NCT02224820|Biological|IdeS|
246112|NCT02217618|Drug|LY2409021|Administered orally
246113|NCT02217631|Drug|BI 653048 BS H3PO4|
246114|NCT02217631|Drug|Prednisolone low dose|
246115|NCT02217631|Drug|Prednisolone high dose|
246116|NCT02217631|Drug|Placebo|
246117|NCT02217644|Drug|BI 653048 H3PO4 solution|
246118|NCT02217644|Drug|BI 653048 H3PO4 low dose capsule|
246119|NCT02217644|Drug|BI 653048 H3PO4 high dose capsule|
246120|NCT02217644|Drug|Placebo|
246121|NCT00141856|Behavioral|Telephone care|
246122|NCT02217657|Device|Thermocool Smart Touch Catheter|Physician informed to contact force
246123|NCT02217670|Drug|Metformin 1000 mg granules|
246124|NCT02217670|Drug|Metformin 1000 mg film-coated tablets|
246125|NCT02217683|Drug|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
246126|NCT02217696|Other|Computerized reading training|
246127|NCT02217709|Drug|phenelzine sulfate|Given by mouth
245511|NCT02234726|Behavioral|Early Childhood Development Program|A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.
CDAs meet with staff at referral health centers on a regular basis. When a CDA refers a child to a health center, the officer-in-charge at the health center receives an SMS message to make them aware of the child and their provisional diagnosis. Once the referred child has been attended to at the facility, health center staff members will then send an SMS back to the CDA to make them aware of the final diagnosis and management plan.
245512|NCT02234739|Drug|Voriconazole|2-week long intravenous instillation of voriconazole
245513|NCT02234752|Drug|Galantamine ER|
245514|NCT00143819|Drug|Neuroskin Forte|Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
245515|NCT02234752|Drug|Memantine XR|
245516|NCT02234765|Other|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
245517|NCT02234765|Other|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
245518|NCT02234778|Device|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
245519|NCT02234804|Device|Xience Prime Stent|
245520|NCT02237131|Drug|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
245521|NCT02237144|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
245522|NCT02237144|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
245834|NCT02227160|Behavioral|Outpatient counseling and support groups|Usual mental health care
245835|NCT02227173|Drug|BMS-986020|
245836|NCT00142922|Behavioral|Breaking Down Barriers|completed
245837|NCT02227173|Drug|Montelukast|
245838|NCT02227173|Drug|Flurbiprofen|
245839|NCT02227173|Drug|Digoxin|
221271|NCT02314845|Other|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
221607|NCT02309853|Other|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
221608|NCT02309866|Genetic|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
221609|NCT02309879|Drug|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
221610|NCT02309879|Drug|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
221611|NCT02309879|Drug|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
221612|NCT02312492|Other|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
221613|NCT00152685|Drug|human serum albumin|
221614|NCT02312492|Other|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
221615|NCT02312492|Other|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
221616|NCT02312505|Device|COPFX|cardiac Output by semi-invasive pulse contour analysis
221617|NCT02312518|Device|Eclipse PRP™ Wound Biomatrix|Eclipse PRP™ Wound Biomatrix in addition to usual and customary practice
221618|NCT02312518|Other|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
221619|NCT02312531|Drug|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
220981|NCT02282904|Other|Haploidentical Cellular Infusion|The infusion of the collected and donated haploidentical family member's cells to serve as a graft for the patient recipient
220982|NCT02282904|Drug|Post-Trasnplant Medications|Sirolimus, Cyclophosphamide
220983|NCT02282904|Radiation|Total Body Irradiation|Total body irradiation as part of the conditioning regimen, this is within clinical scope of practice for pre-transplant treatment
220984|NCT02282917|Drug|AR-42|AR-42 will be administered in a total of ten oral doses, + 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+ 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
220985|NCT02282930|Drug|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
220986|NCT00149422|Device|NT-proBNP measurements|
220987|NCT02282943|Device|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
220988|NCT02282943|Device|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
220989|NCT02282956|Drug|Ropivacaine 0,75%|Ropivacaine injection
220990|NCT02282956|Procedure|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
221272|NCT02314858|Behavioral|Brief risk augmentation intervention|We conducted a pilot (n=11) in which patients observed themselves having apneas via video recording. These recordings are routinely obtained as a part of clinical sleep studies. Patients watched themselves struggle to breathe and saw the associated drop in blood oxygen levels. Brief education about apnea and its treatment was also delivered. Increasing perception of risk is, however, not sufficient; believing that risk can be attenuated by treatment is also important in predicting behavior change (precaution effectiveness). Our patients also saw a second video of themselves sleeping while using PAP. Their personalized improvement in oxygen saturation was noted as well as the potential short and long-term benefits of treating their sleep apnea.
221273|NCT02314871|Other|Epidural analgesia|see Arm/group description
221274|NCT02278120|Drug|Anastrozole|anastrozole 1 mg daily oral
221275|NCT02278120|Drug|Goserelin|Goserelin 3.6 mg subcutaneous injection
221276|NCT02278120|Drug|LEE011 Placebo|LEE011 placebo 600 mg daily oral
221277|NCT02278133|Drug|WNT974|
221278|NCT00148850|Drug|Pioglitazone|
221279|NCT02278133|Drug|LGX818|
221280|NCT02278133|Biological|Cetuximab|
245577|NCT00140075|Drug|Epirubicin with Cyclophosphamide, followed by a Taxane|Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2
Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
245578|NCT02202252|Procedure|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
245579|NCT02202265|Dietary Supplement|Olive oil|30ml a day of olive oil
245580|NCT02202265|Dietary Supplement|Nuts|30g a day of nuts
245581|NCT02202265|Dietary Supplement|Control diet|Diet based on standard guidelines
245582|NCT02202291|Genetic|Demonstration of genetic mutations causing Raynaud's phenomenon|Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.
Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.
In the centers of Nantes and La Roche- sur- Yon , the investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family.
245583|NCT02202304|Drug|Chlorhexidine/Thymol varnish (Cervitec varnish)|
245584|NCT02202317|Device|PET/CT Scan|Subjects will receive a PET/CT Scan, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
245585|NCT02202330|Other|Video Arm|5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)
Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.
Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions.
245586|NCT02202343|Behavioral|school based health and nutrition education|
245587|NCT02202356|Drug|ALS-008176|
245588|NCT00140075|Drug|Epirubicin with a Taxane|Epirubicin = 75 mg/m2 per cycle
Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
245893|NCT02232256|Drug|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
245894|NCT02232269|Other|Black Coffee|
245895|NCT02232269|Other|Grapefruit Juice|
245896|NCT02232269|Other|Water|
245897|NCT02232269|Drug|Felodipine|
244990|NCT00182039|Drug|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
245284|NCT02515617|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
245285|NCT02515617|Device|Endotracheal tubes allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
245286|NCT02515630|Drug|MMB|Momelotinib (MMB) tablet administered orally once daily
245287|NCT00002492|Drug|cisplatin|
245288|NCT00180830|Drug|Gleevec|
245289|NCT02515643|Other|Endothelial dysfunction|One month before surgery and one year after, the following procedures will be performed in donors and recipients:
Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.
Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.
Ambulatory blood pressure monitoring with overnight-automated ABPM monitor
Estimation of glomerular filtration rate by Iohexol method
245290|NCT02515656|Drug|POLYGYNAX®|
245291|NCT02517723|Behavioral|Dialectical Behavior Therapy|Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.
Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings.
245292|NCT02517723|Behavioral|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
245293|NCT02517723|Other|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
245294|NCT02517736|Drug|Sorafenib at a dose of 800 mg / day|
245295|NCT02517749|Device|Chest Drain Insertion and Talc Pleurodesis|
245296|NCT02517749|Device|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
245297|NCT00181194|Device|Asthma Control and Communication Instrument|
244726|NCT02529072|Drug|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
244991|NCT02522247|Procedure|UPP|surgery with cold steel in general anesthesia
244992|NCT02522260|Other|strength/aerobic exercise, weight, bike or treadmill|Group 1) includes strength exercise of the large muscle groups (2 set, 8-12 repetitions on an intensity of 80 % of 1-RM) and aerobic exercise (80 % of HR-max) on an exercise bike or treadmill twice a week for 16 weeks
244993|NCT02522260|Other|aerobic exercise|Group 2) includes aerobic exercise on an exercise bike or treadmill (intensity 70 % of HR-Max) twice a week during 16 weeks
244994|NCT02522260|Other|Standard supportive care|Standard supportive care
244995|NCT02522273|Device|EKF Diagnostics 'SensPoint' Lactate Meter|
244996|NCT02524470|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
244997|NCT02524470|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
244998|NCT02524483|Behavioral|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
244999|NCT02524483|Behavioral|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
245000|NCT02524522|Device|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
245001|NCT02524522|Device|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
245002|NCT02524535|Other|Therapeutic alliance|
245003|NCT02524548|Other|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
245004|NCT02524561|Drug|CEE pill|Conjugated equine estrogens 0.45 mg/day
245005|NCT02524561|Drug|Estradiol patch|Climara 50 mcg/day
245006|NCT00182403|Drug|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
244430|NCT02535884|Device|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
244431|NCT02535897|Dietary Supplement|Flavoured water|
244432|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate|
244433|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate + protein|
244434|NCT00183560|Drug|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
244435|NCT02535910|Dietary Supplement|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
244436|NCT02535910|Dietary Supplement|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
244437|NCT02535910|Dietary Supplement|Control|Subjects are asked to consume a breakfast without vitamin D
244438|NCT02535923|Behavioral|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
244439|NCT02535923|Behavioral|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
244727|NCT02529072|Biological|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
244728|NCT02529085|Other|blood samples|blood samples for the bank
244729|NCT00182793|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
244730|NCT02529098|Other|fMRI|functional magnetic resonance imaging
244731|NCT02529111|Device|"Echonavigator" software|
244131|NCT02503319|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
244132|NCT02503319|Drug|Oxytocin|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
244133|NCT02503332|Drug|APL-2|
244134|NCT02503332|Other|Sham Procedure|
244135|NCT02503345|Drug|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
244136|NCT02503345|Drug|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
244137|NCT02503345|Drug|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
244138|NCT02503345|Drug|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
244139|NCT02503358|Other|Laboratory Biomarker Analysis|Correlative studies
244140|NCT00179192|Procedure|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
244141|NCT02503358|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
244142|NCT02503358|Other|Pharmacological Study|Correlative studies
244143|NCT02503358|Drug|Selumetinib|Given PO
244144|NCT02505737|Behavioral|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
244145|NCT02505737|Other|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
244146|NCT02505750|Radiation|3D conformal EBRT|External Beam Radiation Therapy
244147|NCT00179530|Behavioral|Relaxation Response|Relaxation training
244148|NCT02505750|Device|Contact X-ray brachytherapy 50 kV|
244149|NCT02505750|Drug|Capecitabine|
244150|NCT02505763|Procedure|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
244151|NCT02505776|Drug|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
248880|NCT02236052|Biological|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
248881|NCT00143975|Drug|Cytarabine|3 g/m2 bid. i.v day 1-3
248882|NCT02236052|Biological|Placebo|A single dose of placebo
248883|NCT02236065|Procedure|Umbilical cord blood therapy|
248884|NCT02236065|Biological|Filgrastim|
244153|NCT02505802|Drug|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
244154|NCT02505815|Procedure|Surgery|
244155|NCT02505815|Procedure|Cortisol Level Measurement|
244156|NCT02505815|Procedure|Neurocognitive Testing|
244157|NCT02505828|Procedure|Articular punction, salivary samples, blood sample|
244158|NCT00179543|Behavioral|Relaxation response|
244159|NCT02505841|Other|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
244160|NCT02505841|Drug|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
244161|NCT02505854|Dietary Supplement|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
244162|NCT02505854|Dietary Supplement|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
244163|NCT02505854|Dietary Supplement|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
244164|NCT02505867|Device|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
244165|NCT02505880|Other|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
244166|NCT02505880|Drug|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
244167|NCT02505893|Biological|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
248562|NCT02203526|Drug|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on Day 1 and day 5 of Cycles 2-6 for both cohorts.
248563|NCT02203526|Drug|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle for first cohort.
248564|NCT02203526|Drug|Ibrutinib|Ibrutinib given on Day -14 to Day -1 on Cycle 1 for both groups.
248565|NCT00140218|Drug|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
248566|NCT02203539|Other|exposure to normal light|exposure for 60 minutes in duration
248567|NCT02203539|Other|exposure to bright light|exposure to bright light for 60 minutes of duration
248568|NCT02203539|Other|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
248569|NCT02203552|Drug|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
248570|NCT02203552|Other|placebo|Placebo given by mouth for 9 weeks
248571|NCT02203552|Other|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
248572|NCT02203552|Other|Questionnaire administration|The CES-D and STAI will be administrated weekly.
248885|NCT02236078|Drug|Capreomycin|See arm Description
248886|NCT02236078|Drug|High dose isoniazid|See arm description
248887|NCT02236078|Drug|Rifampicin|see arm description
248888|NCT02236078|Drug|Rifabutin|see arm description
248889|NCT02236078|Drug|Moxifloxacin|see arm description
248890|NCT02236104|Device|Plethysmography opto electronic|
248891|NCT02236104|Procedure|respiratory parameters|
248892|NCT00143975|Drug|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
248893|NCT02236117|Other|Aerobic Training|Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week−1; intensity, >80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
248894|NCT02236130|Procedure|Regional block|Single shot peripheral nerve block
248258|NCT02208388|Device|Fractional flow reserve guided treatment|
248259|NCT02208401|Procedure|conventional cold snare polypectomy|conventional cold snare polypectomy
248260|NCT02208401|Procedure|Cold snare polypectomy with suction|Cold snare polypectomy with suction
248261|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
248262|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
248263|NCT02208427|Drug|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
248264|NCT02208427|Drug|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
248265|NCT00140868|Procedure|Minimally Invasive Surgical Bowel Diversion|
248266|NCT02208440|Procedure|Best Repair of torn Rotator Cuff|
248267|NCT02208440|Device|InSpace™ system|
248268|NCT02210819|Drug|Recommended VTE pharmacological treatments according to international guidelines|Cohort participants are classified as "Standard of care" patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine.
248269|NCT02210832|Behavioral|Best practices|
248270|NCT00141076|Behavioral|low vs high glycemic index diet|
248271|NCT02210832|Behavioral|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
248272|NCT02210845|Behavioral|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
248273|NCT02210845|Behavioral|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
248274|NCT02210858|Other|Laboratory Biomarker Analysis|Correlative studies
248275|NCT02210858|Drug|Tipifarnib|Given PO
248276|NCT02210871|Drug|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
248277|NCT02210884|Dietary Supplement|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
247629|NCT02223182|Biological|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
247630|NCT02223208|Drug|Ro-CHOEP-21 (PHASE I)|Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8
Dose modification according to toxicity:
14mg/ms day +1 and +8
10mg/ms day +1 and +8
8mg/ms day +1 and +8
CHOEP-21
Doxorubicin 50 mg/ms iv day +1,
Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,
Cyclophosphamide 750 mg/ms iv day +1,
Etoposide 100mg/ms iv from day +1 to +3
Prednisone100 mg/ms orally from days +1 to +5
PR or CR:Ro-CHOEP-21 for 3 additionalcycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)
247631|NCT02223208|Drug|Ro-CHOEP-21 (PHASE II)|Ro-CHOEP-21 x 3 cycles
Romidepsin dose according to phase I iv day +1 and +8
Doxorubicin 50 mg/ms iv day +1,
Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,
Cyclophosphamide 750 mg/ms iv day +1,
Etoposide 100mg/ms iv from day +1 to +3
Prednisone100 mg/ms orally from days +1 to +5
PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)
247632|NCT02223221|Procedure|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
247929|NCT00141661|Drug|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
247930|NCT02215915|Procedure|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
247931|NCT02215915|Procedure|DES implantation|
247932|NCT02215928|Genetic|mutation analysis|Correlative studies
247933|NCT02215928|Other|cytology specimen collection procedure|Correlative studies
247934|NCT02215928|Other|laboratory biomarker analysis|Correlative studies
247935|NCT02215941|Drug|TV-45070|TV-45070 8% ointment
247936|NCT02215941|Drug|Placebo|Placebo
247937|NCT02215954|Drug|FE 999169|
247938|NCT02215954|Drug|Niflec|
247939|NCT02215967|Drug|Cyclophosphamide|300 mg/m2 IV over 30 minutes on days -5, -4, and -3
247940|NCT00141661|Drug|Placebo Comparator|Matching placebo.
247941|NCT02218203|Drug|Placebo (Dextromethorphan)|0mg Dextromethorphan
247942|NCT02218203|Drug|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
247943|NCT02218216|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
247317|NCT02227875|Drug|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
247318|NCT02227888|Drug|N91115|GSNORi
247319|NCT02230280|Other|A community navigation and rehabilitation intervention that includes a mobile health solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual home care services: 3 in-home visits by a Community Care Access Centre (CCAC) Case Manager, 4 in-home visits by a Registered Nurse, 4 in-home visits by a Physiotherapist or Occupational Therapist, and 4 in-home visits by a Personal Support Worker. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
247320|NCT02230293|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
247321|NCT02230293|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
247322|NCT02230306|Drug|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
247323|NCT02230306|Drug|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
247324|NCT00143299|Drug|varenicline (CP-526,555)|
247325|NCT02230319|Other|Cryotherapy|
247326|NCT02230319|Drug|Paclitaxel|
247327|NCT02230332|Drug|Alendronate|
247328|NCT02230332|Drug|Placebo|
247329|NCT02230345|Dietary Supplement|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
247633|NCT00142519|Drug|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
247634|NCT02223221|Genetic|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
247635|NCT02223221|Other|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
247636|NCT02223234|Behavioral|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
247637|NCT02223234|Behavioral|Control|Monthly emails on child health
247029|NCT02235350|Other|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
247030|NCT02235350|Other|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
247031|NCT02235363|Procedure|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
247032|NCT02235376|Other|weaning trial of mechanical ventilation|
247033|NCT02235389|Drug|Alteplase (Actilyse)|
247034|NCT02235389|Drug|Standard therapy|
247035|NCT00143884|Procedure|Prophylactic donor leukocyte infusions|
247036|NCT02235402|Drug|Lacidipine|
247037|NCT02197650|Drug|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
247038|NCT02197663|Procedure|acupuncture(44mm in length and 32-gauge)|The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
247039|NCT02197676|Drug|SGI-110 administration|SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.
A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle.
247040|NCT02197689|Device|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
247330|NCT02230345|Dietary Supplement|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
247331|NCT02230358|Procedure|Regional anesthesia|Regional anesthesia
246424|NCT02207790|Drug|E2609|
246425|NCT02210104|Drug|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
246739|NCT02202733|Other|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
246740|NCT02202746|Drug|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
246741|NCT02202759|Drug|MLN0264|MLN0264 IV infusion
246742|NCT02202772|Drug|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
246743|NCT02202772|Drug|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
246744|NCT02202772|Drug|Cisplatin|Intravesical installation of Cisplatin for 2hours
246745|NCT02202785|Drug|MLN0264|MLN0264 IV infusion
246746|NCT02202798|Device|Syringe device|
246747|NCT02202811|Behavioral|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
246748|NCT00140140|Drug|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
246749|NCT02202824|Other|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
246750|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
246751|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
246752|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
246753|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
246754|NCT02202863|Dietary Supplement|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
246755|NCT02202876|Drug|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
246128|NCT02217709|Other|laboratory biomarker analysis|Correlative studies
246129|NCT02217709|Other|questionnaire administration|Ancillary studies
246130|NCT02217722|Other|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
246131|NCT02217722|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
246132|NCT00002318|Drug|Doxorubicin hydrochloride|
246133|NCT00141882|Drug|memantine|
246134|NCT02217735|Behavioral|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
246135|NCT02217748|Other|Survey questionnaire|
246136|NCT02217774|Device|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
246426|NCT02210104|Drug|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
246427|NCT02210104|Biological|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10^10 cells/m^2 on Day 0.
246428|NCT02210117|Drug|Nivolumab|Arms A + B: 3 mg/kg by vein every 2 weeks for 6 weeks.
Arm C: 3 mg/kg by vein every 3 weeks for 6 weeks.
246429|NCT00141024|Biological|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
246430|NCT02210117|Drug|Bevacizumab|Arm B: 10 mg/kg by vein every 2 weeks for 6 weeks.
246431|NCT02210117|Drug|Ipilimumab|Arm C: 1 mg/kg by vein every 3 weeks for 6 weeks.
246432|NCT02210156|Dietary Supplement|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
245840|NCT02227186|Other|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
245841|NCT02227199|Drug|Brentuximab Vedotin|Given IV
245842|NCT02227199|Drug|Carboplatin|Given IV
245843|NCT02227199|Drug|Etoposide|Given IV
245844|NCT02227199|Drug|Ifosfamide|Given IV
245845|NCT02227199|Other|Laboratory Biomarker Analysis|Correlative studies
245846|NCT02227212|Drug|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
245847|NCT00002326|Drug|Zidovudine|
245848|NCT00142935|Behavioral|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
245849|NCT02227238|Drug|DTG|DTG is supplied as 50 mg tablets
245850|NCT02227238|Drug|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
245851|NCT02227238|Drug|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
245852|NCT02227251|Drug|Selinexor|Fixed milligram dose of either 60 mg or 100 mg selinexor orally twice weekly.
245853|NCT02227264|Drug|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
245854|NCT02227264|Procedure|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
246137|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
246138|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
246139|NCT02217800|Drug|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
221620|NCT02312544|Drug|OTX-TP|OTX-TP and placebo drops
221621|NCT02312544|Drug|Timolol|Timolol drops and placebo punctum plug
221622|NCT02312557|Drug|Enzalutamide|Given PO
221924|NCT02304913|Other|Sham acupuncture|
221925|NCT02304913|Behavioral|Dietary recommendations|
221926|NCT02304926|Drug|Simvastatin|simvastatin (40 mg/day) for 4 weeks
221927|NCT02304926|Drug|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
221928|NCT02304926|Drug|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
221929|NCT02307396|Drug|Perphenazine|
221930|NCT02307396|Drug|Sulpiride|
221931|NCT02307396|Drug|bromperidol|
221932|NCT00002384|Drug|Cidofovir|
221933|NCT00152191|Drug|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
221934|NCT02307396|Drug|Zuclopenthixol|
221935|NCT02307396|Drug|Thioridazine|
221936|NCT02307396|Drug|Paliperidone|
221937|NCT02307396|Drug|Ziprasidone|
221938|NCT02307396|Drug|Benperidol|
221939|NCT02307396|Drug|Fluspirilene|
221940|NCT02307396|Drug|Pimozide|
221941|NCT02307396|Drug|Perazine|
221942|NCT02307396|Drug|Fluphenazine|
221943|NCT02307396|Drug|Flupentixole|
221944|NCT00152191|Drug|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
221945|NCT02307396|Drug|Sertindole|
221281|NCT02278146|Device|ParaPatch|A device for the treatment of urinary incontinence
221282|NCT02278159|Procedure|Peritoneal dialysis|
221283|NCT02278159|Procedure|Home hemodialysis|
221284|NCT02278172|Dietary Supplement|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
221285|NCT02278172|Dietary Supplement|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
221286|NCT02278185|Drug|Enzalutamide|Given PO
221287|NCT02278185|Drug|leuprolide acetate|Given SC or IM
221288|NCT02278185|Drug|goserelin acetate|Given SC or IM
221289|NCT00148863|Drug|Peg-interferon alpha 2a (drug)|
221290|NCT02278185|Drug|histrelin acetate|Given SC or IM
221291|NCT02278185|Drug|triptorelin|Given SC or IM
221292|NCT02278185|Drug|degarelix|Given SC or IM
221293|NCT02278198|Drug|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
246504|NCT02217852|Drug|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
246505|NCT02217852|Drug|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
246506|NCT02217852|Drug|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
246507|NCT02217865|Behavioral|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
246508|NCT02217865|Behavioral|Questionnaire|Questionnaire completion asking general health and demographic questions.
246509|NCT02217865|Behavioral|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
246510|NCT02217865|Behavioral|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
246511|NCT02217878|Drug|Morphine|IV bolus injection
245898|NCT02232282|Device|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
245899|NCT02232282|Device|Control Sham/Minimal Acupuncture|Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including "minimal acupuncture", therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints.
245900|NCT02232295|Device|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
245901|NCT02234804|Device|Medtronic Resolute Integrity stent|
245902|NCT02234804|Procedure|Angiography|
245903|NCT02234804|Procedure|OCT|
245904|NCT02234817|Other|Tai Chi|Tai Chi 3 times per week for 6 months
245905|NCT02234817|Other|Multi modal exercise|center-based exercise three times per week for 6 months
245906|NCT00143819|Drug|Placebo Application|Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
245907|NCT02234830|Device|Exoseal closure device|Closure device for femoral artery access closure
245908|NCT02234830|Device|Angioseal closure device|Closure device for femoral artery access closure
245909|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg equivalent of rivaroxaban, once daily, as tablets
245910|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg equivalent of rivaroxaban, twice daily, as oral Suspension
245911|NCT02234843|Drug|Standard of Care|LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.
dose : as per standard of care
246191|NCT02224872|Drug|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
246192|NCT02224872|Radiation|TBI|200 cGy on day -1
246193|NCT02224872|Drug|Mesna|40 mg/kg IV on days 3, 4
246194|NCT00002324|Drug|Zidovudine|
245298|NCT02517762|Behavioral|Physical activity|
245299|NCT02517775|Dietary Supplement|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
245300|NCT02517775|Dietary Supplement|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
245301|NCT02517775|Dietary Supplement|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
245589|NCT02202356|Drug|Placebo|
245590|NCT02202369|Other|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
245591|NCT02202369|Other|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
245592|NCT02202382|Drug|Korean Red Ginseng, Varicocelectomy|
245593|NCT02202382|Drug|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
245594|NCT02202382|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
245595|NCT02202395|Drug|LTS 0.25mg|use LTS 0.25mg/d
245596|NCT02204709|Other|3N Trout|Triploid/3N trout source
245597|NCT02204709|Other|Tilapia|Tilapia/control fish source
245598|NCT02204722|Drug|600mg/day of Imatinib|
245599|NCT00140400|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
245600|NCT02204722|Drug|400mg/day of Imatinib|
245601|NCT02204735|Behavioral|Eat majority of calories in the morning|
245602|NCT02204735|Behavioral|Eat the majority of calories in the evening|
245603|NCT02204748|Device|DePuy Attune posterior stabilizing fixed bearing knee system|
245604|NCT02204761|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
245605|NCT02204787|Device|transcranial direct current stimulation|
245007|NCT02524561|Drug|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
245008|NCT02524561|Other|Placebo tablet|Placebo tablet
245009|NCT02524561|Other|Placebo patch|placebo patch
245010|NCT02524561|Other|Placebo progesterone|placebo progesterone
245011|NCT02524574|Procedure|cardiac Rehabilitation|
245302|NCT02517775|Dietary Supplement|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
245303|NCT02517775|Dietary Supplement|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
245304|NCT02517775|Dietary Supplement|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
245305|NCT02517788|Drug|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
245306|NCT02517788|Drug|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
245307|NCT02517788|Drug|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
245308|NCT00181207|Device|pneumatic vest|
245309|NCT02517801|Dietary Supplement|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
245310|NCT02517801|Dietary Supplement|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
245311|NCT02517814|Dietary Supplement|Vitamin D|
245312|NCT02517827|Device|Paclitaxel-coated balloon angioplasty|paclitaxel-coated balloon angioplasty (optional with atherectomy and stentimplantation) of the common femoral artery
245313|NCT02517827|Procedure|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
245314|NCT02214758|Other|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
244732|NCT02529124|Dietary Supplement|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
244733|NCT02531321|Drug|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
244734|NCT02531334|Dietary Supplement|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
244735|NCT00183157|Behavioral|Brief Motivational Intervention|One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
244736|NCT02531347|Behavioral|Telemedical home blood pressure measurements|
244737|NCT02531347|Behavioral|Conventional blood pressure monitoring|
244738|NCT02531360|Drug|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an [18F]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo [18F]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
244739|NCT02531373|Biological|V114 Medium Dose|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
244740|NCT02531373|Biological|V114 High Dose|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
244741|NCT02531373|Biological|V114 Medium Dose with Alternative Carrier Protein|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
245012|NCT02524574|Other|Tomography Positron Emission|
245013|NCT02524587|Device|standard polyethylene acetabular irradiated at 3 Mrad|
245014|NCT02524587|Other|radio stereometric analysis (RSA) of the acetabular|
245015|NCT02524587|Device|acetabular polyethylene vitamys®|
245016|NCT02524600|Device|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
245017|NCT00002494|Drug|etoposide|
245018|NCT00182416|Device|pacemaker|
244152|NCT02505789|Other|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
244440|NCT02535936|Procedure|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
244441|NCT02535949|Drug|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
244442|NCT02535949|Other|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
244443|NCT02535962|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
244444|NCT02535962|Other|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
244445|NCT00183560|Drug|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
244446|NCT02535975|Drug|Metformin|Tablets metformin 500 mg PO three times a day for 24 weeks
244447|NCT02535975|Drug|Placebo|Tablets placebo PO three times a day for 24 weeks
244448|NCT02535988|Radiation|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
244449|NCT02535988|Drug|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
244450|NCT02538432|Drug|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
244451|NCT02538445|Other|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
244452|NCT02538445|Other|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
244453|NCT02538445|Other|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
244454|NCT02538445|Other|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
244455|NCT02538458|Drug|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
244168|NCT02508142|Drug|Hyoscine-N-Butylbromide|Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)
Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute
244169|NCT02508155|Biological|MEDI7352 for IV infusion|MEDI7352 for IV infusion
244170|NCT02508155|Biological|Placebo for IV infusion|IV Placebo infusion
244171|NCT02508155|Biological|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
244172|NCT02508155|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
244173|NCT02508168|Drug|Alogliptin|Alogliptin 12.5 mg tablets
244458|NCT02538471|Drug|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
244459|NCT02538484|Drug|Letrozole|Aromatase inhibitor
244460|NCT00002496|Radiation|low-LET photon therapy|
244461|NCT00183794|Drug|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
244462|NCT02538484|Dietary Supplement|Fish Oil|Omega-3 free fatty acid
244463|NCT02538497|Behavioral|The Newborn Behavioral Observation (NBO)|The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.
The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old.
244464|NCT02538497|Behavioral|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
244465|NCT02538510|Other|Laboratory Biomarker Analysis|Correlative studies
244466|NCT02538510|Biological|Pembrolizumab|Given IV
244467|NCT02538510|Drug|Vorinostat|Given PO or via PEG
244468|NCT02538536|Drug|PBI4050|
244469|NCT02538549|Behavioral|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
244470|NCT02538575|Other|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
248895|NCT02236130|Procedure|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
248896|NCT02236130|Drug|Local Anesthetic Ropivacaine|0.5% Ropivacaine
248897|NCT02236130|Drug|Opioids Morphine|Morphine
248898|NCT02236130|Drug|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
248899|NCT02236156|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
248900|NCT02236156|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
248901|NCT02236156|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
248902|NCT02236169|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
248903|NCT00139542|Other|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
248904|NCT02198482|Drug|Mitoxantrone|
248905|NCT02198495|Drug|Supplementation of ferric carboxymaltose|
248906|NCT02198495|Drug|Supplementation of iron sucrose|
248907|NCT02198508|Drug|DFX(Deferasirox)|
248908|NCT02198508|Drug|DFP(Deferiprone)|
244174|NCT02508168|Drug|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
244175|NCT02508168|Drug|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
244176|NCT02508181|Device|I-gel|supraglottic airway device without cuff
244177|NCT02508181|Device|LMA Supreme|supraglottic airway device with cuff
244178|NCT00179842|Procedure|Stem Cell Transplant|
244179|NCT02508194|Biological|MEDI7510|RSV sF antigen plus adjuvant
244180|NCT02508194|Biological|IIV|Marketed Inactivated Influenza Vaccine
244181|NCT02508194|Other|Placebo|Sterile Saline
244182|NCT02508207|Drug|VX-661/ivacaftor|
248278|NCT02210910|Device|InSpace™ system over repair|
248279|NCT02210910|Procedure|Best Repair of torn Rotator Cuff|
248573|NCT02203565|Drug|Dakin's solution|Applied topically
248574|NCT02203565|Radiation|radiation therapy|Undergo radiation therapy
248575|NCT02203565|Other|questionnaire administration|Ancillary studies
248576|NCT00140231|Drug|r-metHuLeptin|
248577|NCT02203565|Other|laboratory biomarker analysis|Optional correlative studies
248578|NCT02203578|Drug|romidepsin|Given IV
248579|NCT02203578|Other|laboratory biomarker analysis|Correlative studies
248580|NCT02203591|Drug|3M CHG/IPA Prep C|Apply topically.
248581|NCT02203591|Drug|3M CHG/IPA Prep CH|Apply topically.
248582|NCT02203591|Drug|ChloraPrep Clear|Apply topically.
248583|NCT02203591|Drug|Normal Saline|Apply topically.
248584|NCT02203604|Biological|aldesleukin|Given IV
248585|NCT02203604|Biological|ipilimumab|Given IV
248586|NCT02203604|Other|laboratory biomarker analysis|Correlative studies
248587|NCT00002307|Drug|Zidovudine|
248588|NCT00140244|Drug|r-metHuLeptin|
248589|NCT02205814|Drug|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
248590|NCT00140556|Drug|Cisplatin|Cisplatin week 1 and 5 of radiation
248591|NCT02205814|Drug|Placebo comparator|Single intra-articular injection of placebo
248592|NCT02205827|Other|Single-arm|collection of blood for assessment of whole blood clotting time
248593|NCT02205840|Drug|SI-614|1 drop in each eye
248594|NCT02205840|Drug|Vehicle|1 drop in each eye
247944|NCT02218229|Device|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
247945|NCT02218242|Device|Intraoperative ultrasound|Intraoperative ultrasound
247946|NCT02218255|Device|Eeva™ results|
247947|NCT02218268|Other|Radial tonometry|A meal replacement drink (Boost) and will be randomized (like flipping a coin) to bolus insulin for the "meal" or to not bolus insulin using their standard insulin dose. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring. This is a crossover study and all participants will take place in this arm after 3 months of their visit.
247948|NCT02218268|Dietary Supplement|Boost|Subjects will drink a meal replacement drink (Boost) at the initial study visit and at the visit 3 months later.
247949|NCT02218281|Behavioral|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
248280|NCT02210936|Other|Educational Intervention|The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.
We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers).
248281|NCT00002315|Drug|Netivudine|
248282|NCT00141089|Drug|Tegaserod|
248283|NCT02210949|Drug|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
248284|NCT02210962|Dietary Supplement|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
248285|NCT02210962|Dietary Supplement|olive oil|Yellow capsules containing olive oil (placebo)
248286|NCT02210975|Device|LES-Stimulation Device|
248287|NCT02210988|Other|acupuncture|
248288|NCT02210988|Device|acupuncture|experimental
248289|NCT02210988|Device|Acupuncture|
248290|NCT02211001|Other|Pilates Group|The exercises were applied once a week during eight weeks.
248291|NCT02211001|Other|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
247638|NCT02223234|Behavioral|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
247639|NCT02223247|Drug|TVB-2640|
247640|NCT02223260|Drug|dabigatran|Experimental dose chosen based on age and weight
247641|NCT02223273|Behavioral|Multifaceted Strategy|Simulation Based Team Training
Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions
Reminders -
Check lists - decision support algorithm
Distribution of educational materials: guidelines and recommendations for best practices
247642|NCT02223299|Dietary Supplement|L-tyrosine|6g/d daily for 30 days
247643|NCT02223299|Dietary Supplement|L-Tryptophan|2g/d daily for 30 days
247644|NCT02225509|Procedure|FNA biopsy for thyroid nodule(s)|The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.
The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit.
247645|NCT02225522|Other|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
247646|NCT02225535|Other|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
247647|NCT02225535|Other|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
247648|NCT02225535|Other|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
247649|NCT02225548|Drug|Selegiline|
247650|NCT02225548|Drug|Tadalafil|
247950|NCT02218281|Behavioral|NCI's QuitSTART app|NCI's smoking cessation app
247951|NCT00002319|Drug|Doxorubicin hydrochloride (liposomal)|
247952|NCT00141986|Dietary Supplement|vitamin D3|400 IU per os once daily
247953|NCT02218281|Behavioral|Written smoking cessation materials only|Receipt of written smoking cessation materials
247954|NCT02218294|Drug|BCX4161|
247332|NCT02230358|Procedure|General anesthesia|General anesthesia
247333|NCT02230358|Device|Transcranial Doppler ultrasonography|6x for 4 hours
247334|NCT02230358|Procedure|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
247335|NCT00143312|Drug|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
247336|NCT02230358|Procedure|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
247337|NCT02230358|Procedure|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
247338|NCT02230358|Behavioral|Neurological Control|perioperative, 2-3 days, as done in clinical routine
247339|NCT02230358|Behavioral|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
247340|NCT02230358|Device|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
247341|NCT02230371|Drug|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
247342|NCT02232841|Device|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
247343|NCT02232841|Device|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
247344|NCT02232854|Behavioral|Depression training/supervision program|The intervention will be composed of:
Training of Primary Health Care teams to ensure compliance to the "Clinical Guidelines of the Ministry of Health for the Treatment of Depression". Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.
After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.
Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.
Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment.
247345|NCT02232867|Behavioral|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
247346|NCT00143611|Drug|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
247347|NCT02232880|Drug|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
246756|NCT02202876|Other|High Glycemic Index Meal|isocaloric breakfasts - set the high glycemic index to 80
The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat
246757|NCT02202876|Other|Low Glycemic Index Meal|isocaloric breakfasts - set the low glycemic index to 30
The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat
247041|NCT02197702|Dietary Supplement|vitamin D bolus|
247042|NCT00139477|Behavioral|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
247043|NCT02197702|Dietary Supplement|placebo|
247044|NCT02197715|Behavioral|Computer-adaptive SAFE|
247045|NCT02197715|Behavioral|Face-to-face SAFE|
247046|NCT02197715|Behavioral|Usual Care|
247047|NCT02197728|Device|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
247048|NCT02197741|Drug|opiate with bolus|
247049|NCT02197754|Other|Controlled diet|Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.
The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives.
247050|NCT02197767|Drug|rituximab|After successful enrollment, patients will be treated with an infusion dose of rituximab at Day 1 and at Day 15. CD 20+ cell count will be drawn pre and post infusion at Day 1, Day 28, Day 181, and Day 365. Patients will be retreated with a second dose of rituximab at 6 months independently of CD 20+ cell count.
247051|NCT02197793|Behavioral|Community Mobilization Program|
247052|NCT02197806|Drug|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
247053|NCT00139490|Behavioral|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
246433|NCT02210156|Other|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
246434|NCT02210169|Drug|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
246435|NCT02210182|Drug|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
246436|NCT02210182|Other|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
246437|NCT02210195|Drug|aprepitant|125 mg daily
246438|NCT02210195|Drug|Placebo|Placebo daily
246439|NCT02210195|Behavioral|Standardized behavioral therapy|8 weeks of individual cognitive behavioral therapy
246440|NCT00002314|Drug|Ro 24-7429|
246441|NCT00141037|Drug|Daclizumab|Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)
Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)
246442|NCT02210208|Device|Mepitel Ag|
246758|NCT02205177|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
246759|NCT00140465|Drug|Clopidogrel|after PCI
246760|NCT02205190|Drug|Fimasartan|
246761|NCT02205190|Drug|Rosuvastatin|
246762|NCT02205190|Drug|Fimasartan/Rosuvastatin combination|
246140|NCT00142168|Drug|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
246141|NCT02219997|Device|Clear clip-on glasses|Clip-on glasses with no light filtering properties used as a placebo
246142|NCT02219997|Device|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
246143|NCT02219997|Device|ACRYSOF® IQ IOL|IOL with blue light filtering properties, previously implanted
246144|NCT02219997|Device|Clear IOL|Clear IOL, previously implanted
246145|NCT02220010|Device|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
246146|NCT02220023|Drug|INOmax Inhalation|
246147|NCT02220036|Dietary Supplement|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
246148|NCT02220049|Drug|Bortezomib|
246149|NCT02220062|Procedure|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5~10cc ethanol would be performed as bilateral injections at the celiac trunk.
246150|NCT02220062|Procedure|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
246151|NCT00142168|Drug|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
246152|NCT02220088|Procedure|TACE|Retreatment with TACE: an embolization suspension consisting of mitomycin C, lobaplatin , epirubicin, iodized-oil (Lipiodol; Guerbet, Aulnay-sous-Bois, France), and gelatin-sponge particles.
246153|NCT02220088|Other|non-TACE|Accept treatments other than TACE,such as sorafenib,radiotherapy,Best support conservative treatment and so on.
246443|NCT02210234|Dietary Supplement|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
246444|NCT02212639|Drug|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
246445|NCT02212652|Dietary Supplement|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
221946|NCT02307409|Other|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
221947|NCT02307422|Genetic|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
221948|NCT02307435|Biological|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
222242|NCT02179086|Radiation|photon beam radiation therapy|Undergo dose-escalated and -intensified photon IMRT
222243|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo dose-escalated and -intensified photon IMRT
222244|NCT02181582|Device|PET|Positron emission tomography, which creates images by detecting radioactivity.
222245|NCT02181595|Other|Group reading and discussion|
222246|NCT02181621|Device|Iodosorb|Cadexomer iodine gel
222247|NCT02181621|Device|Solosite gel|Hydrogel
222248|NCT02181634|Drug|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
222249|NCT02181647|Behavioral|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
222250|NCT02181660|Drug|ASP2215|oral
222251|NCT02181673|Drug|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
222252|NCT02181673|Drug|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
222253|NCT02181699|Drug|KHK2823|single agent KHK2823
222254|NCT00137527|Device|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
222255|NCT02181712|Biological|Mesenchymal stem cell|
246512|NCT02217878|Drug|Placebo|IV bolus injection
246513|NCT02217878|Drug|Ticagrelor|180 mg loading dose
246514|NCT02220153|Biological|UCB7665 Intravenous 2|Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion
246515|NCT02220153|Biological|UCB7665 Intravenous 3|Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion
246516|NCT02220153|Biological|UCB7665 Intravenous 4|Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion
246517|NCT00142181|Drug|Campath-1H|Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
246518|NCT02220153|Biological|UCB7665 Intravenous 5|Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion
246519|NCT02220153|Biological|UCB7665 Subcutaneous 1|Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: subcutaneous infusion
246520|NCT02220153|Biological|UCB7665 Subcutaneous 2|Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: subcutaneous infusion
246521|NCT02220153|Biological|Intravenous Placebo|Active substance: Placebo
Pharmaceutical form: solution
Concentration: 0.9 % saline
Route of Administration: intravenous infusion
246522|NCT02220153|Biological|Subcutaneous Placebo|Active substance: Placebo
Pharmaceutical form: solution
Concentration: 0.9 % saline
Route of Administration: subcutaneous infusion
246523|NCT02220166|Dietary Supplement|Triticum monococcum|
246834|NCT02212847|Other|vestibular stimulation|
246835|NCT02212860|Radiation|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (single dose, 21 Gy) followed by lumpectomy for stage I and IIA early stage breast carcinoma
246836|NCT02212873|Other|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
246837|NCT02212886|Drug|GA Depot 80 mg|Recruitment to this arm completed
246838|NCT02212886|Drug|GA Depot 40 mg|Recruiting
246195|NCT00142701|Behavioral|smoking cessation|
246196|NCT02224872|Drug|Tacrolimus|Starting dose of 1 mg IV on day 5 for patients 18 years or older; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
246197|NCT02224872|Drug|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
246198|NCT02224885|Device|Ceiling-mounted Artis Zee imaging system with Syngo DynaCT and Syngo iGuide from Siemens|Standard interventional radiology procedure
246199|NCT02224885|Drug|Novartis sodium fluorescein|Sodium fluorescein contrast agent administration for endomicroscopy imaging
246200|NCT02224885|Device|Cellvizio with AQ-Flex confocal mini probe (Mauna Kea Technologies)|Needle-based confocal laser endomicroscopy imaging of the lesion
246201|NCT02224898|Behavioral|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
246202|NCT02224911|Device|Laser Interstitial Thermal Therapy|
246203|NCT02224924|Other|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
246204|NCT00142935|Behavioral|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
246205|NCT02227316|Drug|IV Ibuprofen|
246206|NCT02227316|Drug|IV Acetaminophen|
246207|NCT02227316|Drug|IV Placebo|
246208|NCT02227329|Drug|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
246209|NCT02227329|Drug|Heparin Lock|
246210|NCT02227329|Drug|Normal Saline|
246211|NCT02227342|Biological|Fecal Microbiota Transplant|serial FMT
246212|NCT02227368|Drug|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
246524|NCT02220179|Behavioral|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
245606|NCT02204813|Drug|Placebo|A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours.
245607|NCT02204813|Drug|Lo-Xenin|A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours.
245608|NCT02204813|Drug|Hi-Xenin|A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours.
245609|NCT02204813|Drug|Extra Hi-Xenin|A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours.
245912|NCT02234856|Procedure|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
245913|NCT02234869|Drug|Interferon Beta|Subcutaneous injection
245914|NCT02234869|Drug|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
245915|NCT02234882|Drug|Rosuvastatin|
245916|NCT02234882|Drug|BMS-663068|
245917|NCT00002333|Drug|Zalcitabine|
245918|NCT00143845|Procedure|Reduced intensity conditioning|Busulfan and Fludarabine regimen
245919|NCT02234895|Device|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
245920|NCT02234895|Device|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
245921|NCT02234908|Behavioral|Contacts|Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.
245922|NCT02234908|Behavioral|Index|Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
245315|NCT02214771|Drug|Fidaxomicin|oral
245316|NCT02214771|Drug|Treatment for CDI other than fidaxomicin Type|Oral
245317|NCT02214784|Device|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
245318|NCT02214784|Device|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
245319|NCT02214797|Device|Etafilcon A, Lotrafilcon B , Senofilcon A|
245320|NCT00141544|Drug|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
245610|NCT00140413|Drug|Nutropin AQ|Daily injection. Dosage dependent on weight.
245611|NCT02204826|Drug|Korean Red Ginseng (KRG)|The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.
KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.
245612|NCT02204826|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
245613|NCT02204839|Drug|Basal insulin dose|
245614|NCT02204852|Drug|Iloprost+eptifibatide|
245615|NCT02204852|Drug|Placebo|
245616|NCT02204865|Device|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
245617|NCT02204878|Drug|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
245618|NCT02204891|Dietary Supplement|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
245619|NCT02207309|Drug|Placebo (for Pazopanib)|
245620|NCT02207322|Other|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
245621|NCT02207335|Drug|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
245622|NCT02207335|Drug|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
245019|NCT02524600|Device|scintigraphic imaging|
245020|NCT02524613|Other|Pelvis CT scan|
245021|NCT02524626|Procedure|Sham stimulation|
245022|NCT02524626|Procedure|Vagus stimulation|
245023|NCT02526849|Drug|Vancomycin|An initial vancomycin regimen (500 mg orally two times per day for 3 days)
245024|NCT02526849|Drug|Placebo|An initial placebo (maltodextrin) regimen (500 mg orally two times per day for 3 days)
245025|NCT02526862|Device|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
245026|NCT02526862|Device|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
245027|NCT02526862|Device|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
245028|NCT02526875|Drug|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
245029|NCT02526888|Drug|ACT-541468|Oral capsule (25 mg) as single dose
245030|NCT02526888|Drug|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
245031|NCT02526901|Other|No intervention|
245032|NCT00182650|Biological|rituximab|
245033|NCT02526914|Drug|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
245321|NCT02214810|Drug|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
245322|NCT02214823|Device|FES-Cycling|
244456|NCT02538458|Drug|3 % hypertonic saline up to 24H|Treatment by inhalation of 3 % hypertonic saline, up to 24H.
followed by 48h of placebo : isotonic saline inhalation. Placebo control group.
244457|NCT02538471|Radiation|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
244742|NCT02531373|Biological|V114 High Dose with Alternative Carrier Protein|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
244743|NCT02531373|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
244744|NCT02531386|Device|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
244745|NCT02531399|Device|FDOCT|Measurement of retinal blood velocities
244746|NCT00183157|Behavioral|Assessment and list of resources|One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
244747|NCT02531399|Device|LDV|Measurement of retinal blood velocities
244748|NCT02531399|Device|DVA|Measurement of retinal vessel diameters
244749|NCT02531412|Drug|Spironolactone|After a major surgery event a time 0, 24h and 48h
244750|NCT02531412|Drug|Placebo|After a major surgery event a time 0, 24h and 48h
244751|NCT02533492|Device|Vicryl plus|wound closure with vicryl plus suture
244752|NCT02533505|Drug|Budesonide 160 mcg and formoterol fumarate dehydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
244753|NCT02533505|Drug|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
244754|NCT00183378|Behavioral|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
244755|NCT02533518|Procedure|Rigid bronchoscopy with ultraviolet transmission|
244756|NCT02533518|Other|Biopsy|
244757|NCT02533531|Device|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
244471|NCT02503371|Other|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
244472|NCT02503397|Device|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
244473|NCT02503410|Behavioral|Home-based exercises|Subjects will receive a combination of physical therapy and home exercise program during 8 to 12 weeks. Home exercise will be recommended at least two times a week. Usual Care of LBP provided in SRH consists of exercises and manual therapy in various combinations according to the needs of the subject. Subjects will fill out a questionnaire about their pain and how much time they spent doing the home exercises every two weeks.
244761|NCT02533570|Drug|Brentuximab vedotin|
244762|NCT02533570|Drug|Placebo|
244763|NCT02533583|Device|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
244764|NCT02533635|Dietary Supplement|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
244765|NCT00183378|Behavioral|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
244766|NCT02533648|Drug|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
244767|NCT02533648|Drug|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
244768|NCT02533661|Other|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
244769|NCT02533674|Drug|Gemcitabine plus PM060184|
244770|NCT02533687|Procedure|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
244771|NCT02533687|Procedure|Bipolar TURP-2|Bipolar TURP
244772|NCT02533687|Procedure|Monopolar TURP|Monopolar TURP
244183|NCT02508207|Drug|ivacaftor|
244184|NCT02508207|Drug|VX-661/ ivacaftor matching placebo|
244185|NCT02508207|Drug|ivacaftor matching placebo|
244186|NCT02508220|Drug|Syntocinon|Oxytocin nasal spray
244187|NCT02508220|Drug|Placebo|distilled water in nasal spray
244188|NCT02508246|Drug|Cisplatin|Given IV
244189|NCT00002489|Drug|cyclophosphamide|
244190|NCT00179855|Procedure|Extracorporeal Photopheresis|ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.
ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician.
244191|NCT02508246|Drug|Docetaxel|Given IV
244192|NCT02508246|Other|Laboratory Biomarker Analysis|Correlative studies
244193|NCT02508246|Other|Pharmacological Study|Correlative studies
244194|NCT02508246|Procedure|Therapeutic Conventional Surgery|Undergo surgery
244195|NCT02508246|Drug|WEE1 Inhibitor MK-1775|Given PO
244196|NCT02510404|Biological|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
244474|NCT02503410|Behavioral|Interactive gaming home-based exercises|Subjects will receive a combination of physical therapy (during 8 to 12 weeks) and at least two sessions of interactive exercises program at home with the Valedo® System (Hocoma AG). Subjects will fill out a questionnaire about their pain every two weeks during the treatment period.
244475|NCT02503410|Device|Valedo® System (Hocoma AG)|
244476|NCT02503423|Drug|ASTX660|described above
244477|NCT02503462|Drug|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
248595|NCT02205853|Other|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
248596|NCT02205853|Other|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
248597|NCT02205866|Other|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
248598|NCT02205879|Drug|Pregabalin|
248909|NCT02198534|Device|Methodology of visual acuity assessment|
248910|NCT02198547|Drug|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
248911|NCT02198547|Drug|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
248912|NCT02198560|Device|RS-3000 Lite|
248913|NCT02198599|Procedure|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
248914|NCT00139542|Other|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
248915|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
248916|NCT02198625|Other|Moderate FiO2 and Protective Lung Ventilation Using|
248917|NCT02198638|Biological|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
248918|NCT02198651|Drug|Adalimumab|Subcutaneously
248919|NCT02198651|Other|Placebo|Subcutaneously in the double blind period
248920|NCT02198664|Biological|Peanut protein capsule|characterized peanut allergen provided in break apart capsules for oral immunotherapy
248921|NCT02198677|Procedure|Anterior to posterior pressures|Anterior to posterior pressures
248922|NCT02198677|Procedure|Lateral glide|Lateral glide
248292|NCT02211001|Other|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
248293|NCT02213380|Procedure|method of anesthesia|Method of anesthesia includes: general anesthesia and regional anesthesia.
General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.
Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA
248294|NCT02213393|Dietary Supplement|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
248295|NCT02213393|Dietary Supplement|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
248296|NCT00141375|Drug|Pregabalin|
248297|NCT02213406|Dietary Supplement|yogurt|Subjects will receive yogurt with varying fat concentrations
248298|NCT02213419|Drug|Endoscopic ultrasonography-guided double ethanol lavage|A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.
The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes.
248599|NCT02205879|Drug|Placebo|
248600|NCT02205892|Drug|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
248601|NCT00140556|Drug|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
248602|NCT02205892|Drug|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
248603|NCT02205905|Drug|14C PER977|Open-label, single dose
248604|NCT02205918|Other|Active TMS|There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz "active" TMS. Tics and urges will be monitored immediately before and after TMS.
248605|NCT02205918|Other|Sham TMS|There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive ("sham") TMS. Tics and urges will be monitored immediately before and after TMS.
248606|NCT02205931|Other|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
248607|NCT02205931|Drug|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
247955|NCT02218307|Drug|Mupirocin|
247956|NCT02218307|Drug|Placebo|
247957|NCT02218320|Drug|Raltegravir|
247958|NCT02218320|Drug|Dolutegravir|
247959|NCT02218320|Procedure|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
247960|NCT02218333|Dietary Supplement|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
247961|NCT02218333|Dietary Supplement|Placebo|
247962|NCT02218346|Drug|AG221|AG221 in fed and fasted conditions
247963|NCT00141999|Biological|hepatitis B vaccine|
247964|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
247965|NCT02218359|Drug|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
247966|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
247967|NCT02220816|Behavioral|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
247968|NCT02220829|Drug|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
247969|NCT02220829|Drug|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
247970|NCT02220842|Drug|Atezolizumab|Following a 21-day obinutuzumab run-in period, 1200 mg Atezolizumab IV administered every 3 weeks.
247971|NCT02220842|Drug|Obinutuzumab|1000 mg obinutuzumab IV administered on Days 1 (the first dose will be split and administered over 2 days), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 8.
247972|NCT02220855|Drug|BKM120|
247973|NCT02220868|Drug|Sofosbuvir, Ribavirin, and Stribild|
248299|NCT02213432|Biological|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
247651|NCT02225561|Drug|Sodium nitroprusside enhanced cardiopulmonary resuscitation (SNPeCPR)|As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 1.96 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 0.98 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:
Using a "pomping needle" and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.
The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.
Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect.
13ml of 5% glucose solution will be add (50 mg in 17ml).
The syringe will be empty to keep only 1 ml (2.94 mg in 1 ml).
5 ml of 5% glucose solution will be add (2.94 mg in 6 ml).
4 ml (1.96 mg) will be injected in bolus for the first injection.
Then 2 ml (0.98 mg) will be injected in bolus for the second injection.
247652|NCT02225561|Drug|placebo|Using a "pomping needle" and the provided syringe 6 ml of 5% glucose solution will be take.
4 ml will be injected in bolus for the first injection.
Then 2 ml will be injected in bolus for the second injection.The preparation of the drug will be done by the nurse in a room different of the one where the CPR will be conducted. The nurse will not be allowed to tell the rest of the team which drug he had prepared.
247653|NCT00142753|Biological|Recombivax|Dosage at entry and week 24; non-responders ((<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
247654|NCT02225574|Drug|MEK-162|Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.
Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.
Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.
Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle.
247655|NCT02225574|Drug|Nilotinib|Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.
Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.
247656|NCT02225574|Behavioral|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
247657|NCT02227901|Drug|Tipifarnib|Given PO
247658|NCT02227901|Radiation|External Beam Radiation Therapy|Undergo EBRT
247659|NCT00143000|Drug|Peginterferon alfa-2a 40KD and Ribavirin|
247660|NCT02227901|Drug|Temozolomide|Given PO
247661|NCT02227901|Other|Laboratory Biomarker Analysis|Correlative studies
247662|NCT02227914|Drug|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
247663|NCT02227914|Drug|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
247664|NCT02227927|Drug|Domperidone|10-30mg oral dose, four times daily.
247665|NCT02227940|Drug|Ceritinib|Given PO
247054|NCT02200328|Drug|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
247055|NCT02200328|Drug|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
247056|NCT00139776|Drug|Celecoxib|24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.
Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.
247057|NCT02200341|Behavioral|MBCT|
247058|NCT02200341|Behavioral|PRT-PsyEd|
247348|NCT02232880|Drug|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
247349|NCT02232893|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.
247350|NCT02232893|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.
247351|NCT02232906|Drug|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation >20%)
247352|NCT02232919|Device|Deep Brain Stimulation|If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.
Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.
The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline.
247353|NCT02232932|Procedure|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
247354|NCT02232932|Procedure|RESECTION|Intent-to-treat R0 liver resection
247355|NCT02232945|Drug|placebo of oseltamivir phosphate|
247356|NCT02232945|Drug|oseltamivir phosphate|
247357|NCT00143624|Drug|Rosiglitazone maleate|See Detailed Description.
247358|NCT02232945|Drug|Banlangen (Radix Isatidis) granules|
247359|NCT02235402|Drug|Bendrofluazide|
247360|NCT02235402|Drug|Placebo|
246763|NCT02205203|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
246764|NCT02205203|Other|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
246765|NCT02205216|Device|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
246766|NCT02205216|Device|Sham tDCS|anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary "tingling" sensation without effects on the brain.
246767|NCT02205216|Behavioral|Rehabilitation Therapy|All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:
cognitive training: attentional strategies (mental counting, mental obstacle)
transfer training: everyday activities
motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory).
246768|NCT02205229|Drug|Multi-ingredient, topical compounded medications|
246769|NCT02205242|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
246770|NCT00140465|Drug|Clopidogrel|after PCI
246771|NCT02205242|Device|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
246772|NCT02205242|Drug|Placebo|
247059|NCT02200354|Drug|pemetrexed with bevacizumab|
247060|NCT02200367|Behavioral|e-mental health collaborative programme|
247061|NCT02200367|Other|Usual Care|
247062|NCT02200380|Drug|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
247063|NCT02200380|Drug|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
246446|NCT02212652|Other|Placeboe|Gummy button placebo, which will appear very similar to the vitamin D supplement.
246447|NCT02212652|Other|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
246448|NCT02212665|Behavioral|High intense interval training|
246449|NCT02212665|Behavioral|Increased daily activity detected by the pedometer|
246450|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+HIIT|
246451|NCT00141284|Drug|Zidovudine 300 mg twice daily|
246452|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+group intervention|
246453|NCT02212678|Drug|N-acetylcysteine capsule|N-acetylcysteine capsule
246454|NCT02212704|Other|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
246455|NCT02212704|Other|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
246456|NCT02212704|Other|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
246457|NCT02212717|Procedure|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
246458|NCT02212717|Procedure|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
246459|NCT02212730|Drug|Pembrolizumab|Up to 3 doses of 200 mg, administered by IV, every 3 weeks
246460|NCT02212730|Procedure|Surgical Resection|Standard of care surgical resection of RCC tumor
246461|NCT02212756|Drug|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
246773|NCT02205255|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
246774|NCT02205255|Drug|Placebo|
222256|NCT02181725|Behavioral|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
222257|NCT02181725|Behavioral|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
222258|NCT02181738|Drug|Nivolumab|
222259|NCT02181738|Drug|Doxorubicin|
222260|NCT02181738|Drug|Vinblastine|
222261|NCT02181738|Drug|Dacarbazine|
222262|NCT02181751|Other|Trauma Focused Cognitive Behavioural Therapy Group|Throughout the length of a year children will participate in trauma focused cognitive behavioural group therapy (TF-CBT) with 7 other children in his/her cohort. The group will take place either on site at the Be Brave Ranch, or via skype in their own homes with their parent or caregiver present. In total children will receive over 200 hours of TF-CBT group therapy.
222585|NCT02174003|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
222586|NCT02174016|Dietary Supplement|Ketogenic diet|
222587|NCT02174029|Procedure|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
222588|NCT02176551|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
222589|NCT02176564|Drug|inhaled bronchodilator|
222590|NCT02176577|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
222591|NCT02176590|Behavioral|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
222592|NCT02176590|Other|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
222593|NCT02176616|Procedure|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
222594|NCT02176616|Procedure|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
246839|NCT02212912|Behavioral|improvement intervention|Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.
The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters.
246840|NCT02212912|Behavioral|no intervention|No intervention indicated that the physicians among control hospital provide routine
246841|NCT02212925|Drug|BI 14332 CL|
246842|NCT00141310|Drug|Sildenafil citrate|
246843|NCT02212925|Drug|Placebo|
246844|NCT02212938|Drug|BI 14332 CL|
246845|NCT02215369|Device|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit. Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to this study schedule.
246846|NCT02215382|Drug|sugammadex|sugammadex 2 mg/kg
246847|NCT02215382|Drug|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
246848|NCT02215395|Drug|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
246849|NCT02215408|Behavioral|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS will follow each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
246850|NCT00002318|Drug|Doxorubicin hydrochloride (liposomal)|
246851|NCT00141596|Drug|Furosemide 40 mg bd|
247136|NCT00140790|Drug|valsartan|valsartan 40 or 160 (80) mg per day
247137|NCT02208037|Drug|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
247138|NCT02208037|Drug|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
246525|NCT02220192|Procedure|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
246526|NCT02220205|Other|PelvicSim|
246527|NCT02220205|Device|Manufacturer model|
246528|NCT00142207|Drug|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
246529|NCT02220218|Drug|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
246530|NCT02220218|Drug|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
246531|NCT02220218|Drug|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
246532|NCT02220231|Procedure|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
246533|NCT02220244|Drug|MD1003 100mg capsule|
246534|NCT02220270|Device|ASD and PDA closure|
246535|NCT02220296|Drug|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
246536|NCT02220296|Drug|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
246537|NCT02222623|Drug|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
246538|NCT02222636|Drug|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
246539|NCT02222636|Drug|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
246540|NCT02222636|Drug|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
246541|NCT02222636|Drug|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
246542|NCT02222636|Drug|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
246543|NCT00142493|Drug|Thiopental Sodium|2.0ug/ml
245923|NCT02234921|Drug|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
245924|NCT02237287|Procedure|wound dressing with VAC|
245925|NCT02237287|Drug|wound dressing with VAC and sNAG under Antiaggregation|
245926|NCT02237300|Behavioral|VR based cue-exposure booster sessions|Comparison of VR based cue-exposure booster sessions and Cognitive-behavioral booster sessions
245927|NCT00144105|Drug|TPV500mg/RTV200mgBID|
245928|NCT02237300|Behavioral|Cognitive-behavioral booster sessions|Comparison of VR based cue-exposure booster sessions and Cognitive-behavioral booster sessions
245929|NCT02237313|Behavioral|psychological support and therapeutic education program|
246213|NCT02227368|Drug|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
246214|NCT02227394|Drug|Z7200|Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).
At visit 2 or 3 (cross-over design)
246215|NCT00142935|Behavioral|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
246216|NCT02227394|Drug|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
246217|NCT02227394|Drug|Placebo of Test product|Single dose of 2 puffs
Z7200 inhalation powder placebo is filled in size 3 hydroxypropyl methylcellulose (HPMC) capsules.
At visit 2 or 3 (cross-over)
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
246218|NCT02227394|Drug|Placebo of Reference Drug|Single dose of 2 puffs
Symbicort placebo does not contain any drug substances, (Budesonide and Formoterol fumarate), or excipients (Lactose monohydrate).
At visit 2 or 3 (cross-over)
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
246219|NCT02227394|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose.
246220|NCT02227407|Device|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
246221|NCT02227420|Drug|Anakinra|Anakinra 100mg s.c. x 5
246222|NCT02227433|Drug|Brentuximab Vedotin|
246223|NCT02227446|Drug|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
245623|NCT02207348|Drug|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
245624|NCT02207361|Drug|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
245625|NCT02207361|Drug|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
245626|NCT02207374|Drug|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
245627|NCT02207374|Drug|Other OAD|Subjects will receive one other OAD (oral anti-diabetic drug) in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
245628|NCT00140673|Biological|Rotavirus|
245629|NCT02207387|Drug|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
245930|NCT02237326|Procedure|Visual Inspection with Acetic Acid|Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
245931|NCT02237326|Procedure|Visual Inspection with Lugol's Iodine|Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
245932|NCT02237339|Drug|Allopurinol|Uric acid lowering medication.
245933|NCT02237339|Drug|Placebo|
245934|NCT02237365|Drug|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
245935|NCT02237365|Drug|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
245936|NCT02237365|Drug|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
245937|NCT02237378|Radiation|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
245938|NCT00144105|Drug|TPV500mg/RTV100mgBID|
245939|NCT02237391|Other|CIPAP Program|
245940|NCT02237391|Other|Treatment as Usual (TAU)|Control group
245323|NCT02214823|Other|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
245324|NCT02214836|Device|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
245325|NCT02214849|Behavioral|LATCH Intervention|
245326|NCT02214862|Drug|[F18]-FDDNP|radiopharmaceutical tracer
245327|NCT02214875|Other|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
245328|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
245329|NCT02214888|Drug|BIRB 796 BS, low dose|
245330|NCT02214888|Drug|BIRB 796 BS, high dose|
245331|NCT00141544|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
245332|NCT02214888|Drug|Placebo|
245333|NCT02217293|Device|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
245334|NCT02217319|Drug|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
245335|NCT02217319|Drug|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
245336|NCT00141830|Drug|Methotrexate plus ERB-041 for 12 weeks|
245337|NCT02217332|Drug|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
245630|NCT02207387|Behavioral|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
245631|NCT02207387|Other|Music|
244758|NCT02533544|Drug|tenofovir disoproxil fumarate|
244759|NCT02533557|Device|stimuplex insulated needle|2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.
1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time.
244760|NCT02533557|Drug|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
245034|NCT02526914|Drug|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
245035|NCT02526914|Drug|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
245036|NCT02526927|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
245037|NCT02526927|Device|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
245038|NCT02526927|Other|Blood samples|
245039|NCT02526940|Procedure|rectal biopsies|6 rectal biopsies
245040|NCT02526940|Other|Blood samples|Blood samples
245041|NCT02526953|Drug|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
245042|NCT02526953|Drug|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
245043|NCT00182650|Biological|therapeutic autologous lymphocytes|
245044|NCT02526953|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
245045|NCT02526953|Drug|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
245046|NCT02529124|Dietary Supplement|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
245047|NCT02529124|Behavioral|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
244773|NCT02536001|Device|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
244774|NCT02536001|Device|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
244775|NCT02536014|Drug|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
244776|NCT02536014|Drug|Saline|Saline infusion during the same time period
244777|NCT02536027|Procedure|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
244778|NCT02536040|Drug|38% diammine silver fluoride|treatment of cavity with study agent
244779|NCT00183573|Behavioral|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
244780|NCT02536040|Other|Water|Fluoride free, distilled water
245050|NCT02529163|Other|Treatment as Usual|The TAU group will be offered non-pharmacological interventions such as (but not limited to):
metabolic monitoring
skin hygiene
pain management
nutritional counseling
family counselling
Financial/housing support
Group CBT (Cognitive Behavioral Therapy)
Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.
Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:
Risperidone
Aripiprazole
Quetiapine
Olanzapine
Paliperidone
Clozapine
Ziprasidone
Max dosing and the time to reach the target dose is done at the discretion of the treating physician.
245051|NCT02529176|Behavioral|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
245052|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
245053|NCT00182793|Procedure|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
245054|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
245055|NCT02529202|Drug|Dexmedetomidine|Dexmedetomidine infusion
245056|NCT02529215|Behavioral|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
245057|NCT02529228|Other|Meal (Eating) Frequency|Dividing meal intake into 2 or 6 meals with equal energy content
244478|NCT00179205|Drug|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
244479|NCT02503462|Drug|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
244480|NCT02503462|Drug|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
244481|NCT02503475|Other|Real-Time fMRI|Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:
(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements.
244482|NCT02503475|Behavioral|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
244483|NCT02503475|Device|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
244484|NCT02503488|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
244485|NCT02503488|Behavioral|Treatment as Usual|See arm description
244486|NCT02503501|Drug|Insulin glulisine|
244487|NCT02503501|Drug|Placebo|Bacteriostatic 0.9% Sodium Chloride
244488|NCT02505893|Drug|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
244489|NCT00179556|Drug|Isoflavone supplement|
244490|NCT02505893|Drug|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
244491|NCT02505893|Drug|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
244492|NCT02505906|Radiation|Simultaneous Integrated Boost Technique|
244781|NCT02536053|Procedure|Limb salvage|
244782|NCT02536066|Behavioral|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
244783|NCT02536079|Drug|NeuroAiD|
248923|NCT02198690|Other|Mammography decision aid|
248924|NCT02198690|Other|Home safety pamphlet|
248925|NCT00139555|Drug|amlodipine/benazepril|
248926|NCT02198703|Dietary Supplement|Probiotics bacterial strains|
248927|NCT02198716|Procedure|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
248928|NCT02198716|Procedure|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
248929|NCT02201251|Drug|Topiramate|Topiramate weight based dosing for participants 2 to < 10 years of age not to exceed 350 mg/day, as tolerated; 400 mg/day in participants 10-15 years of age. brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.
244197|NCT02510417|Biological|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
244198|NCT02510430|Behavioral|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
244199|NCT02510430|Behavioral|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
244200|NCT00180102|Procedure|early allogeneic PBSCT within induction therapy|
244201|NCT02510430|Behavioral|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
244202|NCT02510443|Device|ESS305 (BAY1454033)|Bilateral insert placement
244203|NCT02510456|Device|Diffuse Optical Spectroscopy Imaging (DOSI)|Subjects will have up to seven DOSI scans at 7 different time points during the course of their chemotherapy. The time course of chemotherapy may vary between 39 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 7 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-45 minutes, although scans at infusion timepoint will take longer in total due to repeated or continuous measurements.
244204|NCT02510469|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
244205|NCT02510482|Other|No intervention|
244206|NCT02510495|Procedure|30" group|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
248608|NCT02205944|Other|Progressive Handgrip Exercise|Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg & Borg, 2001).
Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet.
248609|NCT02205970|Device|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
248610|NCT02205970|Device|TENS (placebo)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
248611|NCT02208453|Device|InSpace Implantation|InSpace device Implantation
248612|NCT02208466|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
248613|NCT02208466|Drug|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
248614|NCT02208466|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
248615|NCT02208466|Drug|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
248616|NCT02208479|Other|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
248930|NCT02201251|Drug|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
248931|NCT02201277|Device|Option IVC Filter|Option brand IVC Filter will be placed in patients randomized to Option Arm.
248932|NCT00139919|Drug|Bifeprunox|
248933|NCT02201277|Device|Denali IVC Filter|Denali brand IVC Filter will be placed in patients randomized to Denali Arm.
248934|NCT02201290|Drug|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
248935|NCT02201290|Drug|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
248936|NCT02201303|Drug|Danirixin|Powdered form for in-vitro administration to blood sample
248937|NCT02201303|Other|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
248300|NCT02213458|Behavioral|Navigated Care|Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a "dashboard" functions as a patient care management system used by Care Team Navigators (CTNs).
248301|NCT02213497|Radiation|18F-FDG (Fluorodeoxyglucose) PET|
248302|NCT02213497|Drug|Carboplatin|
248303|NCT02213497|Drug|Paclitaxel|
248304|NCT02213510|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
248305|NCT02213510|Device|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
248306|NCT02213523|Dietary Supplement|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
248307|NCT00141388|Drug|Pregabalin|
248308|NCT02213523|Dietary Supplement|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
248309|NCT02213523|Dietary Supplement|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
248310|NCT02213523|Dietary Supplement|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
248311|NCT02213536|Radiation|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
248312|NCT02213549|Dietary Supplement|Placebo|
248313|NCT02215967|Drug|Fludarabine|30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
248314|NCT02215967|Biological|Anti-BCMA CAR T cells|0.3x106- 15.0x106 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
248315|NCT02215980|Drug|Lenalidomide|
248316|NCT02215980|Drug|Dexamethasone|
248317|NCT02215993|Drug|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
247666|NCT02227940|Drug|Cisplatin|Given IV
247667|NCT02227940|Drug|Gemcitabine Hydrochloride|Given IV
247974|NCT02220881|Device|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
247975|NCT02220881|Other|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
247976|NCT02220894|Biological|pembrolizumab|
247977|NCT00142272|Drug|Ciprofloxacin|
247978|NCT02220894|Drug|carboplatin|
247979|NCT02220894|Drug|paclitaxel|
247980|NCT02220894|Drug|pemetrexed|
247981|NCT02220907|Drug|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
247982|NCT02220920|Drug|Canagliflozin (TA-7284) ＋insulin|The patients will receive Canagliflozin orally for 16 weeks
247983|NCT02220920|Drug|Placebo＋insulin|The patients will receive Placebo orally for 16 weeks
247984|NCT02220933|Drug|MD1003 100mg capsule|
247985|NCT02220933|Drug|Placebo|
247986|NCT02220946|Device|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
247987|NCT02220959|Other|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
247988|NCT00142285|Drug|Zinc sulphate (20 mg)|
247989|NCT02220972|Drug|Perampanel|
247990|NCT02220972|Drug|Placebo|
247991|NCT02220985|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
247992|NCT02220985|Drug|Cyclophosphamide|Given IV
247993|NCT02220985|Drug|Fludarabine Phosphate|Given IV
247361|NCT02235415|Drug|Motens® (lacidipine)|
247362|NCT02235428|Drug|Ipratropium bromide|
247363|NCT02235428|Drug|Placebo|
247364|NCT02235428|Drug|Salbutamol|
247365|NCT02235441|Other|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
247366|NCT02235454|Device|SDOCT-GMPE software|Noninvasive imaging of the optic nerve in patients with existing glaucoma
247668|NCT02227940|Other|Laboratory Biomarker Analysis|Correlative studies
247669|NCT02227940|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
247670|NCT00002327|Drug|Cidofovir|
247671|NCT00143026|Drug|carbidopa, levodopa, entacapone|
247672|NCT02227940|Other|Pharmacological Study|Correlative studies
247673|NCT02227953|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
247674|NCT02227953|Device|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
247675|NCT02227966|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
247676|NCT02227966|Device|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
247677|NCT02227979|Behavioral|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
247678|NCT02227979|Behavioral|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
247679|NCT02227992|Biological|EVARREST™ Sealant Matrix|
247680|NCT02227992|Device|SURGICEL®|
247064|NCT02200393|Device|Abdominal FES|Stimulation intensity was adjusted on a channel by channel basis until a strong visible contraction of the abdominal muscles is observed. During the session, manual adjustment of both the stimulation intensity (to compensate for fatigue) and the duty cycle is possible.
Four pairs of surface electrodes were placed on the participant's abdomen. One pair will be placed on both the right and left side of the rectus abdominis around the naval. One pair of electrodes will also be placed on both the right and left side of the external oblique muscles with one electrode being placed just below the participant's bottom rib and the other below this with a separation of around 3cm.
247065|NCT02200406|Drug|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
247066|NCT02200419|Other|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
247067|NCT00139789|Drug|Kemstro|
247068|NCT02200432|Other|PERSPeCT Recommender System|PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.
"Patient Experience Recommender System for Persuasive Communication Tailoring." PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient.
247069|NCT02200445|Drug|Interleukin-2 (aldesleukin).|Description of intervention is covered in "Arm", above.
247070|NCT02200458|Device|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
247071|NCT02200471|Device|VeinViewer|
247072|NCT02200484|Behavioral|Combined parent training and obesity prevention program|
247073|NCT02200484|Behavioral|Wellness program (active contact control)|
247074|NCT02200510|Behavioral|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
247075|NCT02200510|Behavioral|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
247076|NCT02200523|Device|SARA electrode|
247077|NCT02200523|Device|Gold cup|
247078|NCT02202889|Behavioral|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
247367|NCT02235467|Behavioral|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
247368|NCT00143910|Other|observation|
247369|NCT02235480|Drug|Experimental Tazarotene Gel|
246775|NCT02205268|Procedure|Near infrared spectroscopy neurofeedback training|
246776|NCT02207790|Drug|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
246777|NCT02207803|Behavioral|Transition Assistance Program|
246778|NCT00140738|Biological|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
246779|NCT02207816|Procedure|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
246780|NCT02207829|Drug|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
246781|NCT02207829|Drug|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
246782|NCT02207829|Drug|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
246783|NCT02207829|Drug|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
246784|NCT02207855|Drug|Chloroprocaine|
246785|NCT02207881|Drug|VDO gel|VDO gel
246786|NCT02207881|Drug|placebo|matching placebo gel
246787|NCT02207907|Drug|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
246788|NCT02207907|Drug|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
246789|NCT00140751|Drug|Lopinavir/ritonavir (drug)|
246790|NCT02207920|Biological|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
246791|NCT02207920|Biological|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
246792|NCT02207920|Biological|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
246793|NCT02207920|Biological|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
246794|NCT02207933|Procedure|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
246795|NCT02207933|Procedure|Gait training|Gait training only for 3 times a week for 6 weeks.
222595|NCT00136955|Drug|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
222596|NCT02176629|Other|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
222597|NCT02176629|Other|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
222598|NCT02176642|Drug|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
222599|NCT02176642|Device|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
222600|NCT02176642|Drug|Placebo|Tablet taken by mouth daily for 6 weeks
222601|NCT02176655|Drug|Sumatriptan succinate 12.5 mg/acetylsalicylic acid 325 mg|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
222602|NCT02176655|Drug|Placebo|
222603|NCT02176668|Drug|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
222604|NCT02176668|Drug|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
222912|NCT02168907|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
222913|NCT02168907|Drug|bendamustine hydrochloride|Given IV
222914|NCT02168907|Biological|rituximab|Given IV
222915|NCT02168907|Other|laboratory biomarker analysis|Correlative studies
222916|NCT02168920|Drug|2 mg/day|Once daily for 10 weeks
222917|NCT02171104|Drug|Mycophenolate Mofetil (MMF)|Osteopetrosis patient receiving haploidentical graft: Begin Day +5 through Day +30
All other diagnoses receiving any graft other than UCB: Begin Day -2 through Day +30
Dosing: 15 mg/kg (maximum 1 gram), three times daily
222918|NCT02171104|Drug|Granulocyte-Colony Stimulating Factor (G-CSF)|Patients with IMD and males with Rett syndrome:
UCB Recipients Only: 5 mcg/kg IV once daily. Begin day +1 and continue through ANC > 2,500 /μL x 2 consecutive days
222919|NCT02171104|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Patients with Osteopetrosis:
Recipients of Haploidentical Grafts: 250 mcg/m2 IV once daily. Begin day +5. Continue GM-CSF through ANC > 2,500 /μL x 2 consecutive days
Recipients of any graft other than a Haploidentical Graft: 250 mcg/m2 IV once daily. Begin day +1. Continue GM-CSF through ANC > 2,500 /μL x 2 consecutive days
222920|NCT00002276|Drug|Ibuprofen|
222921|NCT00136370|Procedure|sterile water external genital wipe|
247139|NCT02208037|Drug|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
247140|NCT02210377|Other|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
247141|NCT02210390|Behavioral|Psycho education|Psycho-education Sessions will be offered weekly basis
247142|NCT02210403|Device|transcranial direct current stimulation (tDCS)|
247143|NCT02210416|Procedure|inguinal hernia surgery|
247144|NCT02210429|Procedure|Elbow Fracture Fixation|
247145|NCT02210442|Behavioral|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
247146|NCT02210442|Other|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
247147|NCT00141037|Drug|Tacrolimus|Taken orally from immediately preoperatively to those>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects <age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) &5-7 ng/mL >= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 & 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
247148|NCT02210455|Behavioral|Strongest Families FASD intervention|
247149|NCT02210455|Other|Psychoeducation|
247150|NCT02210468|Device|APIC-CF, 4 cc|
247151|NCT02210468|Device|APIC-CF, 2 cc|
247152|NCT02210468|Other|Placebo Comparator: Saline|Placebo Comparator: Saline
247153|NCT02210494|Drug|Secretrol|
247154|NCT02210507|Other|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
247448|NCT02203097|Drug|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
247449|NCT00140166|Drug|niacinamide|
247450|NCT02203123|Device|Ultrasound|
246544|NCT02222649|Dietary Supplement|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
246852|NCT02215421|Behavioral|Mommio|The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, "Totally Frobisher" (providing backstory to the game), and play a game called Mommio (a "casual" video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store.
246853|NCT02215434|Drug|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
246854|NCT02215434|Drug|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
246855|NCT02215447|Drug|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
246856|NCT02215447|Drug|Carboplatin|
246857|NCT02215460|Procedure|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
246858|NCT02215460|Procedure|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
246859|NCT02215460|Drug|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
246860|NCT02215460|Drug|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
246861|NCT02215460|Drug|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
246862|NCT00141609|Drug|Slow Sodium|
246863|NCT00141908|Drug|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
246224|NCT02227459|Drug|ND-L02-s0201 Injection|
246225|NCT02227472|Other|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
246226|NCT00142948|Drug|Naltrexone|naltrexone
246227|NCT02229786|Drug|Buscopan®|
246228|NCT02229786|Drug|Paracetamol|
246229|NCT02229786|Drug|Placebo|
246230|NCT02229799|Drug|Actilyse|
246231|NCT02229812|Drug|alteplase|
246232|NCT02229825|Drug|Duloxetine high|
246233|NCT02229825|Drug|Duloxetine low|
246545|NCT02222649|Dietary Supplement|Placebo|Capsules of starch, no therapeutic action
246546|NCT02222662|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
246547|NCT02222662|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
246548|NCT02222675|Procedure|Sonography assisted breast surgery|
246549|NCT02222675|Procedure|Conventional breast surgery|
246550|NCT02222688|Drug|cirmtuzumab|
246551|NCT02222714|Biological|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
246552|NCT02222714|Drug|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
246553|NCT02222727|Drug|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
246554|NCT00002323|Drug|Nevirapine|
246555|NCT00142493|Drug|Dexmedetomidine Hydrochloride|0.5ng/ml
245941|NCT02237404|Device|Telemedicine System|Telemedicine System is used in remote monitoring group
245942|NCT02237417|Drug|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
245943|NCT02237417|Drug|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
245944|NCT02237417|Other|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
245945|NCT02237430|Device|MynxGrip|Closure device for femoral artery access closure
245946|NCT02199782|Other|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
245947|NCT02199795|Device|Contralaterally Controlled Neuromuscular Electrical Stimulation|
245948|NCT02199795|Device|Cyclic Neuromuscular Electrical Stimulation|
246234|NCT02229838|Drug|BIBB 1464 MS tablet|
246235|NCT00143260|Drug|Viagra (Sildenafil Citrate) 100 mg|
246236|NCT02229838|Drug|BIBB 1464 MS solution|
246237|NCT02229838|Drug|BIBB 1464 MS placebo|
246238|NCT02229838|Other|Standard dinner|
246239|NCT02229851|Drug|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
246240|NCT02229851|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
246241|NCT02229851|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Switch to NNC0195-0092 treatment in the extension period.
246242|NCT02229864|Device|Coronary artery stenting: ABSORB BVS|Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm
246243|NCT02229877|Drug|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
246244|NCT02229877|Drug|AF-219|AF-219 oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
245632|NCT02207400|Drug|Sodium bicarbonate plus sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
245633|NCT02207400|Drug|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
245634|NCT02207413|Biological|FLU-D-QIV IP|Quadrivalent influenza vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
245635|NCT02207413|Biological|FLU-D-QIV LP|Quadrivalent influenza vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups
245636|NCT02207426|Drug|Tobramycin|
245637|NCT02207439|Drug|Nelfinavir (Viracept®) 1250 mg|
245638|NCT02207452|Device|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
245639|NCT00140686|Biological|Rotavirus (vaccine)|
245640|NCT02207452|Drug|Salbutamol|Salbutamol 5mg nebulised single dose
245641|NCT02207452|Drug|Ipratropium|Ipratropium 500mcg nebulised single dose
245642|NCT02207452|Device|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
245643|NCT02209688|Drug|ESR 1150 CL|
245644|NCT02209688|Drug|Placebo|
245645|NCT02209701|Drug|Porfiromycin|
245646|NCT02209714|Drug|BIIF 1149 BS|
245647|NCT02209714|Drug|Placebo|
245648|NCT00140985|Drug|Comparator: amlodipine / Duration of Treatment: 20 weeks|
245649|NCT02209727|Drug|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
245650|NCT02209740|Other|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
245651|NCT02209753|Drug|BIRB 796 BS, low dose|
245652|NCT02209753|Drug|BIRB 796 BS, medium dose 1|
245048|NCT02529150|Behavioral|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
245049|NCT02529163|Other|Late-life Schizophrenia ICP|The ICP medication algorithms first trial begins with:
Risperidone titrated to a max dose
Failure to Risperidone will lead to a second trial with either:
Quetiapine OR Aripiprazole
If subject refuses or if this trial does not work, then offer:
Ziprasidone or Loxapine
Failure of 2 anti-psychotic trials results in:
Clozapine trial
If subject refuses a Clozapine trial then:
Olanzapine offered
titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E
If compliance is an issue then a depot preparation:
Paliperidone
Risperidone
Flupentixol
Aripiprazole
Physicians will be prompted for non-pharmacological interventions
245338|NCT02217345|Drug|Growth hormone|
245339|NCT02217345|Drug|Placebo|
245340|NCT02217358|Device|NBI endoscopy|see in "detail description of the study" part of the protocol
245341|NCT02217371|Other|Neuropsychological tests|The tests are :
Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT
These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h).
245342|NCT02217397|Device|OA, CPAP, combination therapy|
245343|NCT02217410|Biological|CFZ533|
245344|NCT02217410|Drug|Tacrolimus (Tac)|
245345|NCT02217410|Drug|Mycophenolic acid (MPA)|
245346|NCT02217410|Drug|Corticosteroids (CS)|
245347|NCT00141830|Drug|Placebo for 12 weeks|
245348|NCT02217410|Biological|anti-IL2 Induction|
245349|NCT02217423|Other|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
245350|NCT02217423|Other|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
245351|NCT02217436|Device|iPad|iPad with age-appropriate applications, videos, and music
245352|NCT02217436|Other|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
245353|NCT02217449|Other|Prediction of histology|
245058|NCT02529228|Other|Protein Composition|Consuming meals with higher or lower protein.
245059|NCT02529241|Drug|Group 1:LCB01-0371|Period:LCB01-0371 Tablet 400 mg
Period: LCB01-0371 Tablet 400 mg
245060|NCT02529241|Drug|Group 2:LCB01-0371|Period:LCB01-0371 Tablet 800 mg
Period: LCB01-0371 Tablet 1200 mg
245061|NCT02529254|Behavioral|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
245062|NCT02529267|Other|Standard of care|
245063|NCT02531425|Biological|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
245064|NCT02531438|Drug|Omadacycline|Injection for IV; Oral tablets
245065|NCT02531438|Drug|Moxifloxacin|IV solution; Oral tablets
245066|NCT02531451|Drug|Ibuprofen|
245067|NCT02531451|Drug|Acetylsalicylic acid|
245068|NCT02531464|Other|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
245359|NCT02219659|Drug|Fentanyl Push First|Fentanyl 25 mcg IVP every 5 min up to 4 doses hourly PRN to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
245360|NCT02219672|Drug|Triplitode|Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir .
245361|NCT00142116|Drug|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
245362|NCT02219672|Drug|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
245363|NCT02219685|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
245364|NCT02219685|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF tablet administered orally once daily
245365|NCT02219698|Drug|Ibuprofen|
244784|NCT02536092|Device|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
244785|NCT02536105|Drug|Methylphenidate HCl ER tablets 1|
244786|NCT02536105|Drug|Placebo|
244787|NCT02536105|Drug|Methylphenidate HCl ER tablets 2|
244788|NCT02536105|Drug|Methylphenidate HCl ER for suspension|
244789|NCT02536118|Device|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
244790|NCT00183573|Behavioral|Brief Informational Intervention|15 minute informational DVD on safer sex
244791|NCT02536131|Other|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
244792|NCT02536144|Procedure|magnetic-controlled capsule endoscopy system|A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.
The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.
While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.
The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus.
244793|NCT02536144|Procedure|Colonoscopy|Bowel preparation should be well done before the examination.
A tube with illumination and camera system would insert into colon from anus.
From the pictures captured by the camera ,the doctor would see the mucous of the colon.
244794|NCT02536157|Device|Thermoplastic splinting|
244795|NCT02538588|Device|Nebulizer 1|
244796|NCT00183807|Drug|irinotecan, cisplatin, celecoxib|
244797|NCT02538588|Device|Nebulizer 2|
244798|NCT02538601|Behavioral|CBT-A|CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., "I will lose control."); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking).
244207|NCT02510495|Procedure|60" group|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
244208|NCT02510495|Procedure|180" group|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
244209|NCT02510495|Procedure|300" group|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
244493|NCT02505919|Device|Aquablation|To utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue using the AQUABEAM system, which is a personalized image-guided tissue removal system.
244494|NCT02505919|Procedure|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
244495|NCT02505932|Procedure|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
244496|NCT02505932|Procedure|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
244497|NCT02505945|Drug|Omeprazole|
244498|NCT02505945|Device|LINX Reflux Management System|
244499|NCT02505958|Other|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing ~ 6000 Kcal/24 h.
244500|NCT00179569|Behavioral|Relaxation response|8 weeks of relaxation response training
244501|NCT02505958|Other|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (~333 calories each) totaling ~ 1,000 calories/24 hours.
244502|NCT02505971|Drug|Nadolol|Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.
S/he will be monitored until Week 52.
248938|NCT02201316|Drug|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
248939|NCT02201316|Drug|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
248940|NCT02201316|Drug|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
248941|NCT02201329|Drug|Azacitidine|Azacitidine (subcutaneous)
248942|NCT02201329|Drug|Volasertib|Volasertib escalating doses (intravenous)
248943|NCT00139932|Drug|formoterol fumarate|
248944|NCT02201342|Drug|Udenafil|Drug
248945|NCT02201355|Radiation|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
248946|NCT02201368|Drug|Triheptanoin (SpezialölÒ 107®)|Randomization: Treatment with Triheptanoin for 6 months
Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months
Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months
248947|NCT02201368|Dietary Supplement|MCT (Medium-Chain Triglycerides)|Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months
Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months
Crossover: Treatment with Triheptanoin for 6 months
248948|NCT02201394|Drug|Loading dose|Single loading doses of Ticagrelor (180 mg)
248949|NCT02201394|Drug|Loading dose|AS 325mg
244210|NCT00180479|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
244211|NCT02512731|Device|Esophageal Doppler Monitor|Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
244212|NCT02512744|Procedure|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
244213|NCT02512744|Device|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
244214|NCT02512770|Procedure|endoscopic dilatation|
244215|NCT02512783|Drug|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
248617|NCT02208492|Drug|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
248618|NCT02208492|Drug|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
248619|NCT00140881|Drug|MK0476; montelukast sodium|
248620|NCT02208505|Drug|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil 10 min before end of the surgery (TCI 1 ng/ml)
248621|NCT02208505|Drug|Remifentanil-high dose|maintain the infusion of remifentanil 10 min before end of the surgery (TCI 2 ng/ml)
248622|NCT02208518|Procedure|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
248623|NCT02208518|Device|EUS-elastography|
248624|NCT02208531|Behavioral|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
248625|NCT02208544|Procedure|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
248626|NCT02208544|Device|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
248627|NCT02208544|Radiation|FDG-PET/CT|Head and Neck FDG-PET/CT
248628|NCT02208557|Procedure|Reinforcement with Absorbable Mesh|
248629|NCT02208557|Radiation|Control CT|At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.
The radiologist is blinded to the patient's history and the technique used for midline fascial closure.
248630|NCT00140881|Drug|Comparator: placebo|
248631|NCT00141102|Drug|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
248632|NCT02211014|Drug|ACP-196|
248950|NCT02201394|Drug|Maintenance dose|Ticagrelor 90 mg BID x 3-7 days
247994|NCT02220985|Other|Laboratory Biomarker Analysis|Correlative studies
247995|NCT00142532|Procedure|Acupuncture and Questionnaires|Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.
Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.
Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory
248318|NCT02215993|Drug|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
248319|NCT02216006|Procedure|Control group, conventional ventilatory settings|Handling of the airway during induction and intubation is performed in a conventional manner.
Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
248320|NCT02216006|Procedure|High fresh gas flow, high minute ventilation|Handling of the airway during induction and intubation is performed in a conventional manner.
Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
248321|NCT02216019|Other|Whole blood|preoparatoire whole blood and postoperative whole blood
248322|NCT02216032|Other|TMW Curriculum|
248323|NCT00141674|Procedure|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
248324|NCT02216032|Other|Nutrition Curriculum|
248325|NCT02216045|Drug|Peginterferon, Ribavirin, camel milk|Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.
Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .
camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks.
248326|NCT02216045|Drug|Peginterferon, Ribavirin|Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.
Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks.
248327|NCT02216058|Device|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
247681|NCT02228005|Drug|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
247682|NCT00143039|Procedure|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
247683|NCT02228018|Device|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
247684|NCT02228031|Drug|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
247685|NCT02230371|Drug|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
247686|NCT02230384|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
247687|NCT02230384|Drug|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
247688|NCT02230397|Other|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
247996|NCT02223299|Drug|deplin|15mg daily for 30 days
247997|NCT02223299|Other|Placebo A|a sugar-pill that looks like a real medication
247998|NCT02223299|Other|Placebo B|a sugar-pill that looks like a real medication
247999|NCT02223312|Biological|TAPA-pulsed DC vaccine|
248000|NCT02223338|Drug|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
248001|NCT02223338|Drug|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
248002|NCT02223351|Drug|ASP2151|
248003|NCT02223351|Drug|ritonovir|
248004|NCT02223364|Drug|Peripheral nerve blocks with Bupivacaine|
248005|NCT02223364|Drug|Intra articular injection with Ropivacaine|
247370|NCT02235480|Drug|Placebo|
247371|NCT02235493|Biological|Retrospective Case Only|
247372|NCT02235506|Procedure|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
247373|NCT02235506|Procedure|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
247374|NCT02235506|Device|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
247375|NCT02235506|Device|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
247376|NCT02235519|Drug|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
247377|NCT02235519|Drug|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
247378|NCT02235532|Other|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
247379|NCT00143923|Behavioral|Nutrition, Exercise, Stress Management Counseling|Individualized advice
247380|NCT02235532|Other|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
247381|NCT02235545|Device|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
247382|NCT02235558|Drug|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
247383|NCT02197806|Drug|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
247384|NCT02197806|Drug|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
247385|NCT02197819|Device|Sling|
247386|NCT02197819|Device|External Rotation Brace|
247689|NCT00143325|Drug|varenicline (CP-526,555)|
247690|NCT02230397|Other|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
247691|NCT02230410|Device|CryoBalloon Focal Ablation|
247079|NCT00140140|Drug|Trastuzumab|Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.
Trastuzumab is commercially available and was not supplied by the Sponsor.
247080|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
247081|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
247082|NCT02202915|Behavioral|Behavioral Checklist|
247083|NCT02202928|Biological|DC-CIK|8×10^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
247084|NCT02202928|Radiation|Radiotherapy|45~50 Gy in 25-28 fractions.
247085|NCT02202928|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
247086|NCT02202941|Other|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
247087|NCT02202941|Other|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
247088|NCT02202954|Other|Guided Self-rehabilitation Contract|In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.
The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary.
247089|NCT02202967|Drug|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
247090|NCT00002307|Drug|Stavudine|
247091|NCT00140140|Biological|G-CSF|During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.
In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was >20,000/mm^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.
G-CSF is commercially available and was not supplied by the Sponsor.
247092|NCT02202967|Drug|Placebo|Placebo contains lactose granules
247093|NCT02202980|Drug|LDV/SOF|Ledipasvir 90 mg/sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
222922|NCT02171104|Drug|N-acetylcysteine|Cerebral Adrenoleukodystrophy (c-ALD) Patients Only (as part of a mandatory randomized 4 arm sub-study of anti-oxidant and anti-inflammatory supportive care):
Standard-Risk, Regimen A: Beginning after the preparative regimen (day +1), 70 mg/kg/dose IV, every 6 hours (while inpatient) and 3 times daily (once outpatient), through day +28
Standard-Risk, Regimen B: Beginning after the preparative regimen (day +1), 70 mg/kg/dose IV, every 6 hours (while inpatient) and 3 times daily (once outpatient), through day +56
High-Risk, Regimen C: Beginning just prior to the preparative regimen (day -8 or -5, depending upon the graft source), 70 mg/kg/dose IV, every 6 hours (while inpatient) and 3 times daily (once outpatient), through day +100
High-Risk, Regimen D: Beginning just prior to the preparative regimen (day -8 or -5, depending upon the graft source), 70 mg/kg/dose IV, every 6 hours (while inpatient) and 3 times daily (once outpatient), through day +100
222923|NCT02171104|Drug|Celecoxib|Cerebral Adrenoleukodystrophy (c-ALD) Patients Only (as part of a mandatory randomized 4 arm sub-study of anti-oxidant and anti-inflammatory supportive care):
High-Risk, Regimen C and D: Beginning at the start of the preparative regimen (day -8 or - 5, depending upon the graft source) and continuing through day +100 Patients >25 kg: 100 mg PO twice daily Patients ≥ 10 kg and ≤ 25 kg: 50 mg PO twice daily
222924|NCT02171104|Drug|Vitamin E|Cerebral Adrenoleukodystrophy (c-ALD) Patients Only (as part of a mandatory randomized 4 arm sub-study of anti-oxidant and anti-inflammatory supportive care):
High-Risk, Regimen D: 300 mg PO daily, beginning at the start of the preparative regimen (day -8 or -5, depending upon the graft source) and continuing through day +100
222925|NCT02171104|Drug|Alpha Lipoic Acid|Cerebral Adrenoleukodystrophy (c-ALD) Patients Only (as part of a mandatory randomized 4 arm sub-study of anti-oxidant and anti-inflammatory supportive care):
High-Risk, Regimen D: 200 mg PO twice daily, beginning at the start of the preparative regimen (day -8 or -5, depending upon the graft source) and continuing through day +100
222926|NCT02171117|Procedure|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
222927|NCT02171117|Biological|HLA-mismatched donor peripheral stem cell infusion|
222928|NCT02171130|Drug|3 mg glucagon powder|3 mg glucagon powder
223238|NCT02163954|Drug|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
223239|NCT00135538|Device|Noninvasive positive pressure ventilation|
223240|NCT02163967|Device|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
223241|NCT02163980|Drug|Caudal ropivacaine + normal saline|
223242|NCT02163980|Drug|Caudal ropivacaine + dexmedetomidine|
223243|NCT02163993|Drug|LY2951742|Administered SQ
223244|NCT02163993|Drug|Placebo|Administered SQ
223245|NCT02164006|Drug|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
247451|NCT02203123|Drug|normal saline|
247452|NCT02203136|Procedure|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
247453|NCT02203136|Procedure|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
247454|NCT02203149|Drug|Grazoprevir|
247455|NCT02203149|Drug|Elbasvir|
247456|NCT02203149|Drug|Placebo|
247457|NCT02205489|Drug|cetirizine|Pharmaceutical form:tablet Route of administration: oral
247458|NCT02205489|Drug|ranitidine|Pharmaceutical form:tablet Route of administration: oral
247459|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
247460|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
247461|NCT02205489|Drug|aciclovir|Pharmaceutical form:tablet Route of administration: oral
247462|NCT02205489|Drug|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
247463|NCT02205489|Drug|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
247464|NCT02205489|Drug|paracetamol|Pharmaceutical form:tablet Route of administration: oral
247465|NCT02205502|Drug|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
247466|NCT00140517|Drug|sulphadoxine-pyrimethamine|
247467|NCT02205502|Drug|Normal saline|
247468|NCT02205515|Drug|Everolimus|Everolimus is a novel derivative of rapamycin.
247469|NCT02205528|Drug|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
247470|NCT02205528|Drug|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
247471|NCT02205528|Drug|Placebo|Matching placebo to RO6811135 will be self-administered daily via SC injection.
246864|NCT02217891|Behavioral|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, & qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits & harms of tumor genomic profiling; 2) interest in & perceived benefits & harms of incidental findings arising from tumor genomic profiling; 3) anticipated process & needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, & those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; & 6) implications of & concerns about incidental findings for family.
246865|NCT02217904|Drug|10 mg MK-8591|Single oral dose of 10 mg MK-8591
247155|NCT02210507|Other|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
247156|NCT02210507|Other|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
247157|NCT02210520|Device|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
247158|NCT00141037|Drug|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
247159|NCT02210520|Device|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
247160|NCT02210520|Device|laser|1 W/cm², 2 minutes in 6 points around the back spine
247161|NCT02210546|Other|Magnetic Resonance Imaging (MRI)|
247162|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|
247163|NCT02210559|Drug|FG-3019|FG-3019 is administered in TREATMENT ARM A ONLY on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion. The dose level is 35 mg/kg.
247164|NCT02212938|Other|high fat breakfast|
247165|NCT02212951|Drug|BIOD-531|
247166|NCT02212951|Drug|Humalog Mix 75/25|
247167|NCT02212951|Drug|Humulin R U-500|
247168|NCT02212977|Device|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
247169|NCT02212977|Procedure|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
247170|NCT02212990|Drug|Acetaminophen Arm|Blinded Therapy
246556|NCT02222740|Drug|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
246557|NCT02222740|Drug|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
246558|NCT02222766|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
246559|NCT02222766|Behavioral|Control|Minimal attention control- 9 weekly mailed information on general child development
246560|NCT02222805|Procedure|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
246561|NCT02222805|Procedure|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
246562|NCT02224924|Device|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
246563|NCT02224937|Drug|Melatonin|
246564|NCT00142714|Procedure|Sympathetic manipulation on sexual arousal in women|
246565|NCT02224937|Drug|Placebo|
246566|NCT02224950|Device|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
246866|NCT02217904|Drug|100 mg MK-8591|Single oral dose of 100 mg MK-8591
246867|NCT02217904|Drug|<100 mg MK-8591|Single oral dose of <100 mg MK-8591
246868|NCT02217917|Drug|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
246869|NCT02217917|Drug|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
246870|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
246871|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
246872|NCT02217917|Drug|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
246873|NCT02217930|Drug|WCK 2349|
246245|NCT02229877|Drug|AF-219|AF-219 oral tablet (50 mg tablet) administered twice daily for 8 days
246246|NCT00143273|Drug|lasofoxifene|0.05 mg tablets
246247|NCT02229877|Drug|AF-219|AF-219 oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
246248|NCT02229890|Drug|alteplase|
246249|NCT02229903|Device|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
246250|NCT02229903|Device|Sham Treatment|29 treatments over 6 weeks.
246251|NCT02229929|Drug|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
246252|NCT02229929|Drug|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
246253|NCT02229929|Drug|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
246254|NCT02229929|Drug|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
246255|NCT00143559|Device|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
246256|NCT02232295|Device|Mirror Box|A resource used for many pain and disability states of the hands and feet.
246567|NCT02224950|Other|Non-medicated Emollient plus Cotton Sleeve|
246568|NCT02224963|Behavioral|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
246569|NCT02224963|Behavioral|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
246570|NCT02224976|Behavioral|Intensified Training|Volunteers will increase exercise training by 30% from baseline
246571|NCT02224989|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
246572|NCT02225002|Drug|CP-870,893|
246573|NCT02225015|Behavioral|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
245949|NCT02199821|Dietary Supplement|Formula with soybean oil, medium-chain triglycerides|
245950|NCT00139711|Drug|Irinotecan|
245951|NCT02199821|Dietary Supplement|Soybean oil formula commonly used in the hospital|
245952|NCT02199834|Behavioral|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
245953|NCT02199834|Behavioral|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
245954|NCT02199847|Drug|Pharmaton® Caplets|
245955|NCT02199847|Drug|Placebo|
245956|NCT02199860|Drug|SD I|
245957|NCT02199860|Drug|SD II|
245958|NCT02199860|Drug|Placebo|
245959|NCT02199873|Drug|BIIX 1 XX - single rising dose|
245960|NCT02199873|Drug|Placebo|
245961|NCT00139711|Drug|Docetaxel|
245962|NCT02199886|Drug|BIBH 1|labeled with eight to ten millicurie of 131I
245963|NCT02199899|Drug|BIIF 1149 BS - single rising doses|
245964|NCT02199899|Drug|Placebo|
245965|NCT02199912|Procedure|Biopsy of adipose and muscular tissue|
245966|NCT02199912|Other|Blood sampling|
245967|NCT02199912|Other|Calorimetry|
245968|NCT02199912|Other|Impedance measure|Evaluation of physical composition (non-invasive method)
245969|NCT02199912|Other|Evaluation of nutritional status|Nutritional status will be assessed by using the "Mini Nutritional Assessment" (MNA) questionnaire and a scale that evaluates anorexia
245970|NCT02199912|Other|Evaluation of physical performance|This will be assessed by using a "tiredness scale" named "Echelle Visuelle Analogique" (EVA) in french
245354|NCT02217475|Drug|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food
245355|NCT02217475|Drug|Placebo|Placebo administered orally once daily and taken every morning with food
245356|NCT02217488|Drug|DG3173|
245357|NCT02217488|Drug|Placebo|
245358|NCT02219659|Drug|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is porformed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
245653|NCT02209753|Drug|BIRB 796 BS, medium dose 2|
245654|NCT02209753|Drug|BIRB 796 BS, high dose|
245655|NCT02209753|Drug|Placebo|
245656|NCT02209766|Drug|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
245657|NCT02209766|Drug|Placebo|st cohort: Dose 1(2g) D5884(n=3) in Japanese
nd cohort: Dose 2(4g) D5884(n=3) in Japanese
245658|NCT02209779|Drug|BIBR 796 BS|
245659|NCT00140998|Drug|17 beta estradiol|
245660|NCT02209779|Drug|Placebo|
245661|NCT02209792|Drug|Placebo|
245662|NCT02209792|Drug|BIBR 796 BS, 5 mg|
245663|NCT02209792|Drug|BIBR 796 BS, 20 mg|
245664|NCT02209805|Drug|BIRB 796 BS, low dose|
245665|NCT02209805|Drug|BIRB 796 BS, high dose|
245666|NCT02209805|Drug|Placebo|
245667|NCT02209818|Radiation|Laser Irradiation One dose|
245668|NCT02209818|Radiation|Laser Irradiation Two doses|
245669|NCT02209831|Device|BIBR 796 BS|single dose
245366|NCT02219698|Drug|Paracetamol|
245367|NCT02219711|Drug|MGCD516|MGCD516 capsules will be taken with water.
245368|NCT02219724|Drug|MOXR0916|MOXR0916 administered intravenously
245369|NCT02219737|Drug|Carboplatin|Given IVPB
245370|NCT02219737|Drug|Etoposide|Given IVPB
245371|NCT02219737|Drug|Ibrutinib|Given PO
245372|NCT00002320|Drug|Zidovudine|
245373|NCT00142129|Drug|Bortezomib (Velcade)|
245374|NCT02219737|Drug|Ifosfamide|Given IV
245375|NCT02219737|Other|Laboratory Biomarker Analysis|Correlative studies
245376|NCT02219737|Other|Pharmacological Study|Correlative studies
245377|NCT02219737|Biological|Rituximab|Given IV
245378|NCT02219750|Drug|switch twice-daily insulin|compare two different insuiln regimen in basal insuln base and premixed insulin.
NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin
245379|NCT02222207|Drug|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
245679|NCT02212392|Drug|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
245680|NCT02212405|Device|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
245681|NCT02212405|Other|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
245682|NCT02212418|Other|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
245683|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
245684|NCT02212431|Drug|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
245685|NCT02212444|Device|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
245069|NCT00183157|Behavioral|Referral to Community Resources|All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
245070|NCT02531477|Drug|propofol|intracarotid propofol as an anesthetic agent
245071|NCT02531490|Drug|Labetalol|
245072|NCT02531490|Drug|Nifedipine|
245073|NCT02531490|Drug|Methyldopa|
245074|NCT02531503|Other|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
245075|NCT02531516|Drug|JNJ-56021927|
245076|NCT02531516|Drug|Bicalutamide|
245077|NCT02531516|Drug|Bicalutamide Placebo|
245078|NCT02531516|Drug|JNJ-56021927 Placebo|
245079|NCT02531516|Drug|GnRH (agonist)|
245080|NCT00183170|Drug|Beer (alcohol)|
245081|NCT02531516|Radiation|74-80 Grays (units of radiation)|
245082|NCT02531529|Drug|dexmedetomedine|intraoperative infusion
245083|NCT02531529|Drug|Fentanyl|
245084|NCT02531542|Device|Echocardiography according to the READ method.|Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.
A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels.
245085|NCT02531555|Device|810 Nanometer Wavelenght GaAlAs Diode Laser|FDA approved 810 nanometer GaAlAs Diode Laser
245086|NCT02531555|Device|Gracey curettes|
245087|NCT02531568|Drug|Warfarin|
245088|NCT02531568|Drug|MT-3995|
245089|NCT02531581|Drug|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output <500cc
244503|NCT02505971|Drug|Propranolol|Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.
In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.
S/he will be monitored until Week 52.
244504|NCT02505984|Drug|Oxytocin|Study participants will be randomized to a placebo or drug group.
244505|NCT02505984|Drug|Placebo|Study participants will be randomized to a placebo or drug group.
244506|NCT02505997|Drug|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
244507|NCT02505997|Drug|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
244508|NCT02506023|Drug|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
244509|NCT02508259|Drug|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
244510|NCT02508259|Drug|Saline|50 ml IV over 30 minutes
244799|NCT02538601|Behavioral|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
244800|NCT02538614|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
244801|NCT02538614|Drug|BI 836826|BI 836826 will be administered intravenously from Week 2 through Week 46.
244802|NCT02538627|Drug|MM-151|MM-151
244803|NCT02538627|Drug|MM-121|MM-121
244804|NCT02538640|Other|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
244805|NCT02538640|Other|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
244806|NCT02538653|Other|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
244807|NCT00183820|Drug|paclitaxel, gemcitabine, and oxaliplatin|Paclitaxel 170 mg/m2 IV d 1 14 days
Gemcitabine 800 mg/m2 IV d 1 14 days
Oxaliplatin 100 mg/m2 IV d 1 14 days
244808|NCT02538653|Other|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
244216|NCT02512783|Drug|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
244217|NCT02512783|Drug|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
244218|NCT02512796|Drug|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
244219|NCT02512809|Drug|Isoflurane|
244220|NCT02512809|Drug|Dexmedetomidine|
244221|NCT00180479|Device|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
244222|NCT02512822|Procedure|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
244223|NCT02512835|Other|Community vital signs|We will present clinicians with information about their patients' communities
244224|NCT02512861|Drug|Bupivacaine|Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:
Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs
244225|NCT02512861|Drug|Placebo|Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:
Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients > 50 kgs
244226|NCT02512874|Other|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
244227|NCT02512874|Device|Dynamometer|Grip Test
244228|NCT02512874|Radiation|DEXA|Body Composition Testing
244229|NCT02512874|Other|Gait Speed Test|15 foot walk test
244511|NCT02508298|Procedure|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
244512|NCT02508298|Drug|Indocyanine Green Retention test|As decribed in arm descriptions
244513|NCT02508298|Device|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
248951|NCT02201394|Drug|Maintenance dose|ASA 81 mg OD x 3-7 days
248952|NCT02203617|Behavioral|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
248953|NCT02203617|Behavioral|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
248954|NCT02203630|Drug|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
248955|NCT02203630|Drug|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
248956|NCT02203643|Drug|Carfilzomib|
248957|NCT02203643|Drug|Cyclophosphamide|
248958|NCT02203643|Drug|Lenalidomide|
248959|NCT02203643|Drug|Dexamethasone|
248960|NCT02203656|Drug|Placebo|placebo supplement
248961|NCT02203656|Dietary Supplement|Nutritional Supplement|protein supplement
248962|NCT00140257|Drug|Escitalopram|
248963|NCT02203656|Behavioral|In-home exercise|In-home exercise program
248964|NCT02203656|Drug|Testosterone|Testosterone injection
248965|NCT02203669|Other|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
248966|NCT02203669|Other|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
248967|NCT02203682|Drug|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
248968|NCT02203682|Drug|placebo|Tablet placebo for 12 weeks
248969|NCT02203695|Drug|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
248970|NCT02203695|Radiation|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
248328|NCT02216071|Drug|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
248329|NCT02216071|Drug|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
248330|NCT02218372|Drug|Fidaxomicin|Oral suspension to be given to patients from Birth (only in Europe and Canada) to < 6 years; oral tablets to be given to patients with ages ≥ 6 years to < 18 years
248331|NCT02218372|Drug|Vancomycin|Oral liquid to be given to patients from Birth (only in Europe and Canada) to < 6 years; oral capsules to be given to patients with ages ≥ 6 years to < 18 years
248633|NCT02211027|Biological|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.
Patients will have vaccinations administered at 4 different sites as follows:
Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site.
248634|NCT02211040|Behavioral|My Plan|The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.
Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.
In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.
Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.
In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans.
248635|NCT02211053|Drug|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
248636|NCT02211053|Drug|placebo|
248637|NCT02211066|Drug|Clopidogrel|
248638|NCT02211066|Drug|Ticagrelor|
248639|NCT02211079|Drug|JNJ-54861911|JNJ-54861911, 50 mg (2*25 mg tablets) orally once daily from Day 2 to Day 9.
248640|NCT02211079|Drug|Caffeine|Single oral dose of caffeine 100 mg (2*50 mg tablets), on Day 1, 2, and 9.
248641|NCT02211079|Drug|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
248642|NCT00141102|Drug|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
248643|NCT02211079|Drug|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
248644|NCT02211092|Behavioral|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
248645|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
248006|NCT00142532|Procedure|Placebo Acupuncture, Questionnaires|The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.
Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked "no pain" at one end and "worst pain" at the other.
248007|NCT02223364|Drug|Intra articular injection with liposomal bupivacaine (Exparel)|
248008|NCT02223377|Drug|Morphine|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
248009|NCT02223377|Drug|Hydromorphone|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
248010|NCT02223390|Behavioral|Improving AIDS Care after Trauma (ImpACT)|
248011|NCT02223403|Dietary Supplement|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
248012|NCT02223403|Dietary Supplement|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
248013|NCT02223416|Drug|RGB-10|
248014|NCT02223416|Drug|Teriparatide|
248332|NCT02218385|Device|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
248333|NCT02218398|Drug|Albuterol|
248334|NCT02218411|Other|Exercise training|Exercises routine based on the Otago exercise programme
248335|NCT02218424|Drug|Magnesium|
248336|NCT02218424|Drug|Normal saline|
248337|NCT00142012|Behavioral|Nutrition Intervention|
248338|NCT02218437|Drug|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
248339|NCT02218463|Drug|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
248340|NCT02218463|Drug|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
247692|NCT02230423|Procedure|Nasal surgery|
247693|NCT02230436|Other|Early drain removal|Removing drain(s) on postoperative day 3
247694|NCT02230436|Other|Late drain removal|Removing drain(s) on postoperative day 4 or later
247695|NCT02230462|Other|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
247696|NCT02230488|Other|Intensive Diabetes Case Management|A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
247697|NCT02230501|Dietary Supplement|stringent diet regimen|
247698|NCT02230501|Dietary Supplement|moderate diet regimen|
247699|NCT02230514|Drug|XCEL-MT-OSTEO-ALPHA|"ex-vivo" expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery
247700|NCT00143338|Drug|Inhaled insulin|
247701|NCT02230514|Other|autologous iliac crest|Autologous iliac crest in association with surgery
247702|NCT02230514|Procedure|Surgery|Standard surgery for non-union fractures
247703|NCT02230527|Drug|Ticagrelor|
247704|NCT02230527|Drug|Clopidogrel|Clopidogrel
247705|NCT02230540|Device|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
247706|NCT02230540|Device|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
247707|NCT02230540|Device|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
247708|NCT02230553|Drug|Lapatinib|
247709|NCT02230553|Drug|trametinib|
247710|NCT02232945|Drug|placebo of Banlangen(Radix Isatidis) granules|
248015|NCT02225587|Biological|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm, alternating arms for each study vaccine or placebo dose, if possible.
247094|NCT02202980|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
247095|NCT02202980|Drug|GS-9857|GS-9857 tablets administered orally once daily with food
247387|NCT02197832|Procedure|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
247388|NCT02197832|Procedure|control procedure|Using pipelle catheter without entering the uterine cavity.
247389|NCT02197832|Device|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
247390|NCT02197845|Behavioral|Patient Navigator|Patient navigators will encourage use and/or adherence to hydroxyurea. PNs will make at minimum weekly contacts including at minimum monthly home visits for the initial six months, and at minimum bi-weekly contacts for the second six months.
247391|NCT02197845|Behavioral|HU Offer and Dosing to MTD|Participants are offered and/or prescribed up to maximum tolerated dose of hydroxyurea.
247392|NCT02197871|Dietary Supplement|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
247393|NCT00139490|Behavioral|Basic Group|The basic information and referral intervention will deliver key "just-in-time" information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay.
247394|NCT02197884|Drug|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
247395|NCT02197884|Drug|Itraconazole 200 mg|Itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
247396|NCT02197884|Drug|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
247397|NCT02197897|Drug|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
247398|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
247399|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
247400|NCT02197923|Procedure|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
247401|NCT02197923|Procedure|endometrial biopsy|transcervical endometrial biopsy
223246|NCT02166684|Device|Do-it-yourself devices|Medisana Vifit is worn every day all-day by each subject
Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.
Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks
Subjects use Medisana BS 440 BT scale daily
In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.
Subjects self-measure fasting blood glucose twice per week for 13 weeks.
Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120.
223247|NCT02166697|Drug|candesartan cilexetil|candesartan cilexetil tablets
223248|NCT00135759|Drug|naltrexone|0.250 mg capsule/day for 6 days
223249|NCT02166710|Device|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
223250|NCT02166710|Device|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
223251|NCT02166723|Device|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
223573|NCT02159040|Drug|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
223574|NCT02159040|Drug|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
223575|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
223576|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
223577|NCT02159053|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
223578|NCT02159066|Drug|LGX818|Combination of LGX818 and MEK162 (Part I)
223579|NCT02159066|Drug|MEK162|Combination of LGX818 and MEK162 (Part I)
223580|NCT02159066|Drug|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
247767|NCT02198040|Other|Manual Therapy|5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.
15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.
15 minutes. Passive muscle stretching (within the limits of mobility). Compression technique, passive muscle stretching and relaxation in biceps and triceps.
15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder with extension of elbow and dorsal flexion of wrist, to adduction, internal rotation of shoulder with flexion of elbow and palmar flexion of wrist and fingers.
10 minutes. Local cryotherapy with ice bag and protection between it and the skin
247768|NCT02198040|Other|Educational group|Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.
Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique.
247769|NCT02198066|Other|Dry Sterile Dressing|Described in Arm Description.
247770|NCT02198066|Other|Metallic Silver Dressing|Described in Arm Description.
247771|NCT02198066|Other|Ionic Silver Dressing|Described in Arm Description.
247772|NCT02198079|Biological|Sputum|
247773|NCT02200757|Drug|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
247774|NCT02200757|Drug|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
247775|NCT02200770|Biological|MEDI-551|
247776|NCT02200770|Other|Placebo|Matching placebo
247777|NCT02200783|Device|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
247778|NCT02200783|Device|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
247779|NCT00002305|Drug|Fluconazole|
247780|NCT00139828|Drug|human coagulation Factor IX|
247781|NCT02200783|Device|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
247782|NCT02200796|Other|Control Meal|High carbohydrate meal
247783|NCT02200796|Other|Low Protein Meal|Omelet with 15 g of protein
247171|NCT02212990|Drug|Placebo Arm|Blinded Therapy
247172|NCT00141323|Drug|lasofoxifene|0.5 mg once per day, orally
247173|NCT02212990|Drug|Ibuprofen Arm|Open Label Therapy
247174|NCT02213003|Biological|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight into the Omentum.
247175|NCT02213016|Device|Transcranial Magnetic Stimulation|
247176|NCT02213016|Device|Sham Transcranial Magnetic Stimulation|
247177|NCT02213029|Drug|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
247178|NCT02213029|Drug|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
247472|NCT02205528|Drug|RO6811135|RO6811135 solution will be self-administered in daily doses of 1.8 mg via SC injection.
247473|NCT02205541|Drug|Eculizumab|According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.
ECZ or placebo will be administrated intravenously as a 30-minute injection
247474|NCT02205541|Drug|Placebo|According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.
ECZ or placebo will be administrated intravenously as a 30-minute injection
247475|NCT02205554|Drug|Omnitram|Nine 20 mg doses administered every 6 hours
247476|NCT02205554|Drug|Tramadol|Nine 50 mg doses administered every 6 hours.
247477|NCT00140517|Drug|chloroquine|
247478|NCT02205554|Drug|Placebo|Nine doses administered every 6 hours.
247479|NCT02205567|Dietary Supplement|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
247480|NCT02205580|Drug|continuous intravenous sufentanil 0.02μg•kg－1•h－1 infusion|
247481|NCT02205580|Drug|continuous intravenous sufentanil 0.03μg•kg－1•h－1 infusion|
247482|NCT02205580|Drug|continuous intravenous sufentanil 0.04μg•kg－1•h－1 infusion|
247483|NCT02208037|Drug|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
246874|NCT00141908|Drug|Castor oil|weekly IM injections
246875|NCT02217930|Drug|Placebo|
246876|NCT02217930|Drug|Moxifloxacin|
246877|NCT02217943|Procedure|Roux-en-Y gastric bypass|
246878|NCT02217943|Procedure|Sleeve gastrectomy|
246879|NCT02217956|Drug|Cisplatin|
246880|NCT02217956|Drug|Bevacizumab|
246881|NCT02217969|Behavioral|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
246882|NCT02217982|Drug|Simethicone|
246883|NCT02217982|Drug|Loperamide|
246884|NCT02217982|Other|Peanut Butter|
246885|NCT00141921|Drug|Etanercept|open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given QW SC in 1 or 2 injections
246886|NCT02220296|Drug|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
246887|NCT02220296|Drug|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
246888|NCT00142207|Device|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
247179|NCT02213029|Drug|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
247180|NCT02213029|Drug|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson & Johnson
247181|NCT02213042|Drug|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm are to receive 1000 mg per day of Lapatinib, so will be instructed to take 4 x 250 mg tablets per day. Lapatinib should be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
247182|NCT02213042|Biological|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab will be administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab will be administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab can be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg)
247183|NCT00141323|Other|placebo|placebo
246574|NCT02225028|Behavioral|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
246575|NCT00142727|Drug|Methadone|
246576|NCT02225054|Drug|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
246577|NCT02225054|Drug|Ropivacaine|15 ml 0.5%
246578|NCT02225054|Drug|Normal Saline|1 mL 0.9%
246579|NCT02225067|Drug|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
246580|NCT02225093|Drug|Caffeine|Oral
246581|NCT02225093|Drug|Dextromethorphan|Oral /.L
246582|NCT02225093|Drug|Enzalutamide|Oral
246583|NCT02225093|Drug|Enzalutamide Placebo to Match (PTM)|Oral
246584|NCT02225106|Drug|Methylphenidate|
246585|NCT02225132|Drug|Hydroxyurea|
246586|NCT00142727|Drug|Full opioid agonist|
246587|NCT02225197|Radiation|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
246588|NCT02227472|Other|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
246889|NCT02220335|Procedure|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
246890|NCT02220335|Drug|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
246891|NCT02220348|Drug|linaclotide|
246892|NCT02220361|Drug|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
245971|NCT02199912|Other|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
245972|NCT00002305|Drug|Flucytosine|
245973|NCT00139724|Drug|tolterodine extended release capsule|
246257|NCT02232308|Drug|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
246258|NCT02232308|Drug|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
246259|NCT02232308|Drug|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
246260|NCT02232321|Other|PsA MDA|
246261|NCT02232334|Other|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
246262|NCT02232347|Drug|Ketamine|
246263|NCT02232347|Drug|Sufentanil|
246264|NCT02232360|Drug|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
246265|NCT02232360|Drug|Rosuvastatin alone|Rosuvastatin 10mg per day
246266|NCT00002331|Drug|Clofazimine|
246267|NCT00143572|Drug|Magnesium Pidolate, Hydroxyurea|Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
246268|NCT02232373|Behavioral|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
246269|NCT02232373|Dietary Supplement|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
246270|NCT02232373|Dietary Supplement|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
246271|NCT02232386|Drug|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
246272|NCT02232386|Drug|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
245670|NCT00141011|Drug|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
245671|NCT02209831|Drug|Pantoprazole|5 days
245672|NCT02209844|Drug|BI 44847|
245673|NCT02209844|Drug|Placebo|
245674|NCT02209870|Behavioral|E-checklist Group|The patient group after E-checklist system deployed
245675|NCT02209896|Device|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
245676|NCT02212366|Device|Active TDCS|Active Stimulation
245677|NCT02212366|Device|Sham TDCS|Sham Stimulation
245678|NCT02212379|Drug|raltegravir and etravirine|Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.
Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal.
245974|NCT02199912|Other|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
245975|NCT02202395|Drug|LTS 0.5mg|use LTS 0.5mg/d
245976|NCT02202395|Drug|LTS 1.0mg|use LTS 1.0mg/d
245977|NCT02202395|Drug|Placebo|use placebo once daily
245978|NCT00140088|Drug|ALGRX 3268|
245979|NCT02202408|Drug|SKI2670|Oral, Single Dose
Dosing Group 1: SKI2670 20mg*1cap
Dosing Group 2: SKI2670 20mg*2cap
Dosing Group 3: SKI2670 80mg*1cap
Dosing Group 4: SKI2670 80mg*2cap
245980|NCT02202408|Drug|Placebo|Same shape as the experimental drug
Dosing Group 1: placebo*1cap
Dosing Group 2: placebo*2cap
Dosing Group 3: placebo*1cap
Dosing Group 4: placebo*2cap
245981|NCT02202421|Behavioral|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
245982|NCT02202434|Device|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System
245983|NCT02202434|Device|CoreValve Transcatheter Aortic Valve Replacement System|Transcatheter aortic valve replacement (TAVR) with CoreValve Transcatheter Aortic Valve Replacement System
245686|NCT02212444|Device|Off -the-shelf triplanar orthoses|
245687|NCT02212457|Biological|rMenB+OMV|
245688|NCT02212457|Other|Placebo|
245689|NCT02212457|Biological|Hep A|
245690|NCT02212457|Biological|ABCWY|
245691|NCT02212470|Device|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
245692|NCT02212470|Device|Nitinol stenting|Nitinol stent deployment
245693|NCT02212483|Other|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
245694|NCT00002316|Drug|Lobradimil|
245695|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
245696|NCT02212483|Other|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
245697|NCT02212483|Other|Final home visit|Final home visit at the end of the study after 12 months, with sampling and home audit.
For the "intervention group", checking of the advice compliance. For the both comparative groups, delivery of advices.
245698|NCT02212522|Other|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
245991|NCT02202499|Other|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
245992|NCT02202512|Drug|Placebo|tablets
245993|NCT02202512|Drug|Cimetidine|
245994|NCT02202512|Drug|Placebo|tablets
245995|NCT02202512|Drug|Placebo|tablets
245996|NCT02204891|Dietary Supplement|Probiotics|One capsule twice daily for 30 days
245090|NCT02531581|Drug|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
245380|NCT02222207|Procedure|Sham IVT|Sham injections
245381|NCT02222207|Drug|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
245382|NCT02222207|Drug|Placebo|Placebo eye drops
245383|NCT02222220|Drug|Metoclopramide|30 mg/day during 4 weeks
245384|NCT02222220|Drug|placebo|
245385|NCT02222233|Drug|BI 671800 HEA delayed release (enteric coated) tablet|
245386|NCT00142467|Drug|Bevacizumab|
245387|NCT02222233|Drug|BI 671800 HEA solution|
245388|NCT02222233|Drug|BI 671800 HEA particulate|
245389|NCT02222246|Drug|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
245390|NCT02222246|Drug|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
245391|NCT02222246|Drug|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
245392|NCT02222246|Drug|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
245393|NCT02222259|Procedure|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
245394|NCT02222285|Other|Medical Food : PS_005|
245395|NCT02222285|Other|Placebo|
244809|NCT02538666|Biological|Nivolumab|
244810|NCT02538666|Biological|Ipilimumab|
244811|NCT02538666|Other|Placebo|
244812|NCT02538679|Drug|bupivacaine|bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
244813|NCT02538679|Procedure|Transversus abdominis plane block, ultrasound guided|
244814|NCT02538679|Procedure|Transversus abdominis plane block, laparoscopic guided|
244815|NCT02538692|Drug|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
244816|NCT02538705|Drug|Neovasculgen|
244817|NCT02538718|Drug|MgSO4|
244818|NCT00183833|Drug|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
244819|NCT02538718|Drug|YTP(Ritodrine)|
244820|NCT02503527|Other|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
245091|NCT02533700|Drug|CEOP/IVE/GDP chemotherapy regimen|CEOP:
Cyclophosphamide 750mg/m2, ivgtt D1 Pharmorubicin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2,PO,D1-D5
IVE:
Fosfamide 2000mg/m2,ivgtt D1-D3 Pharmorubicin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3
GDP:
Gemcitabine 1g/m2,ivgtt D1,D8
Cis-platinum 25mg/m2, ivgtt D1-D3
Dexamethasone 40mg, ivgtt D1-D4
245092|NCT02533700|Drug|CEOP chemotherapy regimen for 6 cycles|CEOP:
Cyclophosphamide 750mg/m2, ivgtt D1 Pharmorubicin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2,PO,D1-D5 every 21 days for total 6 courses
245093|NCT02533713|Device|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
245094|NCT00183378|Behavioral|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
245095|NCT02533726|Other|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
245096|NCT02533726|Other|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
244514|NCT00179868|Behavioral|C-Reactive Protein levels|Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:
Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.
Acute GVHD > grade II defined according to the Seattle criteria
VOD- defined according to the modified Seattle criteria
244515|NCT02508298|Device|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
244516|NCT02508311|Drug|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first 4 weeks. The remaining 12 weeks subjects will receive extended release Albuterol, 8mg twice daily.
244517|NCT02508311|Drug|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
244518|NCT02508324|Biological|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
244519|NCT02508324|Biological|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 NBC/kg
244520|NCT02508337|Drug|XG-102|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
244521|NCT02508337|Drug|Placebo|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
244522|NCT02508350|Drug|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
244523|NCT02508350|Other|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
244524|NCT02508363|Behavioral|questionnaires|
244821|NCT00179205|Drug|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
244822|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
244230|NCT02512874|Device|Activity Monitor|Measures energy expenditure and activity
244231|NCT02512874|Other|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
244232|NCT00180492|Device|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
244233|NCT02515084|Device|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
244234|NCT02515084|Device|MRI imaging|
244235|NCT00180713|Drug|Placebo|Placebo tablet once daily.
244236|NCT02515097|Drug|IDP-122 Lotion|
244237|NCT02515110|Radiation|External Beam Radiation Therapy|Undergo hypofractionated RNI
244238|NCT02515110|Other|Questionnaire Administration|Ancillary studies
244239|NCT02515110|Other|Laboratory Biomarker Analysis|Correlative studies
244240|NCT02515123|Device|E-Motion System|E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.
E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.
By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding.
244241|NCT02515123|Device|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
244242|NCT02515136|Behavioral|Stimulus-response|See summary
244243|NCT02515149|Device|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
244244|NCT02515162|Procedure|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
244245|NCT02515162|Procedure|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
244246|NCT00180726|Procedure|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
244247|NCT02515175|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
248646|NCT02211118|Drug|Intranasal dexemdetomidine (IN-DEX)|
248647|NCT02211131|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
248648|NCT02211131|Procedure|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
248649|NCT02211144|Drug|BIBR 796 BS|
248650|NCT02211144|Drug|Placebo|
248971|NCT02203708|Other|Supportive Program for Mother with BPD (SuPMother-B).|The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.
Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids.
248972|NCT02203734|Procedure|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
248973|NCT00140270|Behavioral|PEP program|
248974|NCT02205983|Drug|Oral hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
248975|NCT00140556|Drug|Erlotinib|Erlotinib daily during radiation
248976|NCT02205983|Drug|Buprenorphine|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
248977|NCT02205996|Drug|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
248978|NCT02205996|Device|Euglycaemic Hypoglycaemic Insulin clamp|
248979|NCT02206009|Device|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
248980|NCT02206022|Drug|Remifentanil|Pain's evaluation for Remifentanil Group
248981|NCT02206022|Drug|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
248341|NCT02218476|Drug|CoQ10|
248342|NCT02218476|Drug|Placebo|
248343|NCT02218489|Drug|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
248344|NCT02218489|Drug|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain LE. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
248345|NCT02218502|Other|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
248346|NCT02218502|Other|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
248347|NCT02218502|Other|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
248348|NCT00142025|Drug|Oxcarbazepine|
248349|NCT02218502|Other|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
248350|NCT02218515|Procedure|Open Flap Debridement|Open Flap Debridement (Control Group)
248351|NCT02218515|Biological|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
248651|NCT02211157|Drug|BIBR 796 BS|
248652|NCT02211157|Drug|Placebo|
248653|NCT02213549|Dietary Supplement|Ume paste and ginger powder|
248654|NCT02213562|Dietary Supplement|200 mg of chrysanthemum flower oil|
248655|NCT02213562|Dietary Supplement|300 mg of chrysanthemum flower oil|
248656|NCT02213562|Dietary Supplement|400 mg of chrysanthemum flower oil|
248657|NCT02213575|Other|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
248658|NCT00141401|Drug|Pregabalin|
248016|NCT02225587|Biological|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm, alternating arms for each study vaccine or placebo dose, if possible.
248017|NCT02225587|Biological|Placebo|Injections are to be administered into the deltoid muscle of the upper arm, alternating arms for each study vaccine or placebo dose, if possible
248018|NCT02225600|Drug|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
248019|NCT02225600|Drug|Placebo|Intranasal Placebo
248020|NCT02225600|Drug|24 IU intranasal Oxytocin|
248021|NCT02225613|Other|Usual protocol|
248022|NCT00142753|Biological|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
248023|NCT02225613|Other|Spa protocol|
248024|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
248025|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
248026|NCT02225626|Drug|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
248027|NCT02225639|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
248028|NCT02225639|Drug|Placebo|Oral placebo capsule
248029|NCT02225639|Drug|PRC-063 35 mg|Oral 35 mg capsule - active
248030|NCT02225639|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
248031|NCT02225639|Drug|PRC-063 55 mg|Oral 55 mg capsule - active
248032|NCT02225639|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
248033|NCT00002325|Drug|Fluconazole|
248034|NCT00142766|Behavioral|Nurse Implemented Goal-Directed Comfort Algorithm|See description
248035|NCT02225639|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
248036|NCT02225639|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
248037|NCT02225652|Drug|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
247402|NCT02197962|Device|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or placebo radial shockwaves per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
247403|NCT02197975|Drug|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
247404|NCT00139490|Behavioral|Control Group|Usual Care
247405|NCT02197975|Drug|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
247711|NCT02232958|Other|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
247712|NCT02232971|Drug|Glucagon|Glucagon is given in three different doses according to three research days.
247713|NCT02232971|Other|Isotonic saline solution|Placebo
247714|NCT02232997|Other|Long Hydration|The hydration with sodium chloride was set 12 hours before the procedure (before contrast exposure during coronary angiography), continued for the duration of the procedure, and for 12 hours post-procedure at the speed of 1ml/kg/hr (0.5ml/kg/hr for patients with congestive heart failure, New York Heart Association class III or LVEF<35%). For patients who weighed more than 80 kg, the bolus and infusion rate were limited to those calculated for patients weighing 80 kg.
247715|NCT02232997|Other|Short Hydration|The hydration with sodium chloride was set 1 hour before the procedure (before contrast exposure during coronary angiography), continued for the duration of the procedure, and for 4 hours post-procedure at the speed of 3ml/kg/hr (1.5ml/kg/hr for patients with congestive heart failure, New York Heart Association class III or LVEF<35%). For patients who weighed more than 80 kg, the bolus and infusion rate were limited to those calculated for patients weighing 80 kg.
247716|NCT02233010|Other|The level of NGAL after pre op,post op 4hr, post op 12hr|
247717|NCT02233023|Drug|Pramipexole|
247718|NCT02233023|Drug|Bromocriptine and other dopamine agonists|
247719|NCT00143624|Drug|Placebo|See detailed description.
247720|NCT02233049|Drug|Erlotinib|
247721|NCT02233049|Drug|Everolimus|
247722|NCT02233049|Drug|Dasatinib|
247723|NCT02233062|Dietary Supplement|Exclusive Enteral Nutrition Therapy|
247724|NCT02233075|Drug|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
223581|NCT00135018|Drug|celecoxib and chemotherapy|
223582|NCT02159066|Drug|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
223583|NCT02159066|Drug|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
223584|NCT02161601|Procedure|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
223585|NCT02161614|Drug|Estradiol valerate|
223586|NCT02161614|Drug|Placebo|
223587|NCT02161627|Device|Automatic Control|Saluda Medical External Trial System
223588|NCT02161627|Device|Manual Control|Saluda Medical External Trial System
223589|NCT02161653|Drug|Prednisone plus Metadoxine|
223590|NCT02161653|Drug|Pentoxifylline plus Metadoxine|
223591|NCT00135304|Drug|Sensipar®|Cinacalcet hydrochloride
223592|NCT02161679|Drug|IMMU-132 infusion is administered to participants in one arm for the study|
223593|NCT02161679|Drug|IMMU-132 plus Carboplatin infusion|
223594|NCT02161692|Drug|Cyclophosphamide|
223595|NCT02161692|Drug|Etoposide|
223596|NCT02161692|Drug|Cisplatin|
223597|NCT02161692|Drug|Bleomycin|
223598|NCT02161692|Drug|Carboplatin|High dose carboplatin
223912|NCT00139191|Procedure|C-11 acetate PET scan|
223913|NCT02194998|Drug|Ribavirin|RBV, supplied as 200-mg tablets, will be given in two divided doses (one dose in the morning and one dose in the evening) by mouth each day with food, for a total daily dose of 1000 mg or 1200 mg based on participant's body weight.
223914|NCT02195011|Device|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
223915|NCT02195011|Drug|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
223916|NCT02195024|Procedure|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
247784|NCT02200796|Other|Moderate Protein Meal|Omelet with 30 g of protein
247785|NCT02200796|Other|High Protein Meal|Omelet with 45 g of protein
248104|NCT02233283|Other|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
248105|NCT02233283|Other|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
248106|NCT02233283|Other|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
248107|NCT02233283|Other|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
248108|NCT00143650|Behavioral|House dust|
248109|NCT02233296|Drug|Lasmiditan|2 discrete doses separated by 6 days.
248110|NCT02233309|Other|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
248111|NCT02233322|Dietary Supplement|Iron|All subjects will receive iron supplementation based on iron levels in the blood
248112|NCT02233361|Behavioral|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
248113|NCT02235753|Behavioral|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
248114|NCT02235753|Behavioral|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
248115|NCT02235766|Other|Echocardiographic assessment|
248116|NCT02235779|Other|Transbronchial lung cryobiopsy|
247484|NCT02208037|Drug|Cyclophosphamide|Hydration prior to cyclophosphamide may be given according to institutional standards.
Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.
Cyclophosphamide [50 mg/kg ideal body weight (IBW); if ABW < IBW, use ABW] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
247485|NCT02208050|Drug|Fampridine|
247486|NCT02208050|Drug|Placebo|
247487|NCT02208063|Drug|Telavancin|
247488|NCT02208063|Drug|Vancomycin|
247489|NCT02208063|Drug|Daptomycin|
247490|NCT00140803|Drug|Visudyne|
247491|NCT02208063|Drug|Synthetic penicillin|
247492|NCT02208063|Drug|Cefazolin|
247786|NCT02200809|Device|MR-guided focal laser ablation|
247787|NCT02200822|Drug|beta blockers|
247788|NCT02200822|Drug|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
247789|NCT02200848|Drug|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
247790|NCT02200900|Other|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
247791|NCT00139841|Drug|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
247792|NCT02200900|Other|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
247793|NCT02200900|Other|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
247794|NCT02200900|Other|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
247795|NCT02200913|Other|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
247184|NCT02213055|Drug|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
247185|NCT02213055|Drug|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products. After a baseline scalp exam for lice count and preexisting signs of irritation,Parents who agree to the comparison arm may choose and purchase any other head lice treatment of their choice. All treatments (investigational and comparison) are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any of these examinations, the school nurse will instruct the parent/guardian to retreat.
247186|NCT02215460|Drug|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
247187|NCT02215460|Drug|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
247188|NCT02215460|Drug|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
247189|NCT02215460|Drug|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
247190|NCT02215460|Drug|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
247493|NCT02208076|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
247494|NCT02208089|Procedure|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
247495|NCT02208089|Procedure|Corneal Collagen Cross-Linking (CXL)|Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.
UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
247496|NCT02208102|Procedure|Radio-frequency catheter ablation|
247497|NCT02208115|Dietary Supplement|Meal composition - Low versus high GI.|
246893|NCT02220361|Drug|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
246894|NCT02220361|Drug|high dose dexmedetomidine|received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.
The infusion was completed in 30 minutes
246895|NCT02220374|Other|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
246896|NCT02220387|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
246897|NCT02220387|Other|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
246898|NCT02220400|Drug|Ketamine|
246899|NCT00142220|Drug|Defined percentage of omega-3-fatty acids|
246900|NCT02220426|Drug|Xenon|Inhalation of hyperpolarized xenon gas
246901|NCT02220452|Other|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
246902|NCT02220452|Other|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
246903|NCT02220465|Behavioral|PA+ Smoking Cessation (LMPA)|
246904|NCT02220465|Behavioral|Standard Care Smoking Counseling (SCC)|
246905|NCT02220478|Device|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
246906|NCT02220491|Radiation|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
246907|NCT02222818|Device|Conducted AF Response Plus (CAFRPlus)|
247191|NCT02215473|Drug|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
247192|NCT02215473|Procedure|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
247193|NCT02215486|Other|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
246273|NCT02232399|Drug|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
246274|NCT02232399|Drug|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
246275|NCT02232425|Drug|IX-01|
246276|NCT02232425|Drug|Placebo|
246589|NCT02227472|Other|Home Observation Measure|To measure the quality and quantity of stimulation and support available to a child in the home environment, the Home Observation Measurement of Environment (HOME) Inventory and the Early Childhood (EC) HOME Inventory will be completed during a semi-structured interview and observation period of 45 to 90 minutes in the participant's home.
246590|NCT02227485|Drug|Punica granatum Plenifora (Golnaar) mouth rinse|All the patient in intervention group use 10 ml of "Golnaar" mouth rinse for 2 minutes every night for 2 weeks.
246591|NCT02227485|Drug|Chlorhexidine (2%)|All the patient in control group use 10 ml of chlorhexidine (2%) for 2 minutes every night for 2 weeks.
246592|NCT02227485|Procedure|Tooth bleaching|Tooth bleaching for both groups one time afterusing mouth rinses.
246593|NCT02227498|Device|Argus II Retinal Prosthesis System|
246594|NCT02227511|Dietary Supplement|Fruits|Randomization to extra fruit or nuts as snacks
246595|NCT02227511|Dietary Supplement|Nuts|
246596|NCT02227524|Other|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
246597|NCT02227524|Device|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
246598|NCT00142948|Drug|Placebo|placebo
246599|NCT02227524|Device|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
246600|NCT02227524|Device|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
246601|NCT02227537|Device|Providence Nighttime Bracing System|Providence Nighttime Bracing System
246602|NCT02227537|Device|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
246603|NCT02227550|Drug|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
245984|NCT02202447|Drug|EC1169|Dose dependent on cohort, IV (in the vein) on days 3, 5, 7, 15, 17, and 19 of each 21 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
245985|NCT02202473|Drug|Lamivudine|
245986|NCT02202473|Drug|Lamivudine+Oxymatrine Capsules|
245987|NCT02202486|Other|Brain MRI|Brain MRI with gadolinium contrast
245988|NCT02202499|Drug|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
245989|NCT00140101|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
245990|NCT02202499|Other|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
246277|NCT02232438|Behavioral|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
246278|NCT02234921|Biological|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
246279|NCT02234921|Biological|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
246280|NCT02234921|Drug|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
246281|NCT02234934|Biological|Lentiviral G1XCGD Gene Therapy|The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.
The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then infused into the patient. The cell/product dose will consist of at least 1 x 10^6 cells per kg of body weight transduced ex vivo with 1 x 10^8 IG/ml of lentiviral vector to achieve > 0.3 integrated copies per cell.
246282|NCT02234947|Procedure|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
246283|NCT00143845|Procedure|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
246284|NCT02234960|Drug|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
246285|NCT02234986|Drug|ENMD-2076|250 mg oral dose, QD for 28 day cycles
245997|NCT02204904|Genetic|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
245998|NCT00140426|Drug|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
245999|NCT02204917|Drug|OPTISON|Contrast-enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. VCUG examination as part of the standard care.
246000|NCT02204930|Drug|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
246001|NCT02204943|Other|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy samples
246002|NCT02204943|Drug|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
246003|NCT02204956|Behavioral|Extended Care|
246004|NCT02204956|Behavioral|Brief Education|
246005|NCT02204969|Dietary Supplement|Lithia water|Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water
Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels
246006|NCT02204969|Device|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
246007|NCT02204982|Drug|IPI-145 (duvelisib)|IPI-145 (25 mg BID) administered orally in 28-day continuous treatment cycles
246008|NCT02204982|Drug|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
246294|NCT00143845|Procedure|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
246295|NCT02235051|Other|laboratory biomarker analysis|Correlative studies
246296|NCT02235051|Other|questionnaire administration|Ancillary studies
246297|NCT02235051|Other|quality-of-life assessment|Ancillary studies
246298|NCT02235064|Drug|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
246299|NCT02235064|Drug|Placebo|Capsule containing cellulose powder of same color as experimental arm
245396|NCT02222298|Procedure|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
245397|NCT00142480|Drug|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
245699|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
245700|NCT02214901|Drug|BIBW 2948 BS for oral inhalation|
245701|NCT02214901|Drug|Placebo|
245702|NCT02214914|Drug|BI 11634 drinking solution|
245703|NCT02214914|Drug|BI 11634 tablet|
245704|NCT02214914|Drug|Placebo|
245705|NCT02214927|Drug|BI 11634 tablet|
245706|NCT02214927|Drug|BI 11634 drinking solution|
245707|NCT02214940|Drug|BI 11634|
245708|NCT02214940|Drug|Placebo|
245709|NCT00141557|Drug|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
245710|NCT02214953|Drug|BI 11634 ER formulation A|
245711|NCT02214953|Drug|BI 11634 ER formulation B|
245712|NCT02214953|Drug|BI 11634 ER formulation M|
245713|NCT02214953|Drug|BI 11634 ER formulation C|
245714|NCT02214953|Drug|BI 11634 IR tablet|
245715|NCT02214966|Drug|Telmisartan/Ramipril, fixed dose combination tablet|
245716|NCT02214966|Other|high fat, high caloric meal|
245717|NCT02214979|Drug|Telmisartan/Ramipril|fixed dose combination tablet
245097|NCT02533726|Other|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
245098|NCT02533739|Behavioral|Cognitive and neuropsychological assesment|
245099|NCT02533765|Drug|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
245100|NCT02533778|Device|Penumbra system, TREVO, or Solitaire|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
245101|NCT02533791|Biological|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10^10vp/1ml per dose
245102|NCT02533791|Biological|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10^11vp/1ml per dose, with one dose to each arm at the same time
245103|NCT02533791|Biological|placebo|
245104|NCT02533817|Dietary Supplement|Dietary sugar|This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
245105|NCT00183391|Drug|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
245106|NCT02533830|Biological|sugarless gum|One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)"S.A.E." , for 15 Minutes Every 2 hours After Surgery Tell Defecation
245398|NCT02222298|Procedure|Bascom Cleft lift procedure|
245399|NCT02222311|Other|Blood Samples|
245400|NCT02222324|Drug|Placebo|8 placebo tablets matching E2609
245401|NCT02224521|Drug|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
245402|NCT02224521|Drug|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
245403|NCT02224534|Drug|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
245404|NCT02224534|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
245405|NCT02224547|Radiation|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
244823|NCT02503540|Drug|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
244824|NCT02503553|Behavioral|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
244825|NCT02503553|Behavioral|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
244826|NCT02503566|Device|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
244827|NCT02503579|Behavioral|physical training|physical activity program, 30 minutes
244828|NCT02503592|Other|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
244829|NCT02503605|Drug|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
244830|NCT02503605|Drug|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
244831|NCT02503631|Device|Stool Sample Collection Kit|Stool sample collection kit
244832|NCT00179218|Drug|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
244833|NCT02503644|Drug|IVA337|Capsules of 200mg IVA337
244834|NCT02503644|Drug|Placebo|Identical capsules without active substance
244835|NCT02503657|Drug|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
244836|NCT02503657|Drug|Placebo|Excipients of MN-001/tipelukast
244837|NCT02503670|Behavioral|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
244838|NCT02503670|Other|Control Group|Continue with standard care.
244839|NCT02503683|Drug|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
245107|NCT02533830|Other|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
244248|NCT02515175|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
244249|NCT02515175|Drug|Placebo|0.9% Normal Saline
244525|NCT00179881|Drug|Carboplatin|
244526|NCT02510508|Behavioral|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
244527|NCT00002489|Drug|leucovorin calcium|
244528|NCT00180102|Procedure|autologous PBSCT|
244529|NCT02510508|Behavioral|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
244530|NCT02510508|Other|Non-intervention|Non-intervention
244531|NCT02510521|Device|acute muscle exercise by NMES|
244532|NCT02510521|Device|daily workout sequence with NMES in one week|
244533|NCT02510521|Other|rest situation|
244534|NCT02510534|Drug|Menopur 150 international units|Menopur 150 international units given x 1 dose
244535|NCT02510534|Drug|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
244536|NCT02510547|Procedure|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
244537|NCT02510547|Procedure|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
244538|NCT02510560|Drug|NTRA-2112|NTRA-2112 is an Insulin based drug product, orally administered in preterm infant nutrition, aiming to reduce intestinal malabsorption by assisting with the maturation and functionality of premature infants' gastrointestinal (GI) system.
244539|NCT00180115|Drug|Cytarabine Dosage|
244540|NCT02510560|Drug|Placebo|
244541|NCT02510586|Drug|Sevoflurane|administer 1.0 MAC (1.7~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
244542|NCT02510599|Drug|solithromycin|
244543|NCT02510612|Drug|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
248982|NCT02206035|Drug|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant
248983|NCT02206035|Drug|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11
248984|NCT02206035|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
248985|NCT02206048|Drug|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
248986|NCT00140569|Procedure|CHVP + interferon|
248987|NCT02206061|Behavioral|School-Based Asthma Care for Teens (SB-ACT)|
248988|NCT02206061|Behavioral|Directly Observed Therapy|
248989|NCT02206061|Behavioral|Asthma Education|
244250|NCT02515188|Drug|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
244251|NCT02515188|Drug|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
244252|NCT02515201|Drug|Taurolidine|taurolidine in central catheter lumen
244253|NCT02515201|Drug|Heparin|heparin in central venous catheter lumen
244254|NCT02515227|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
244255|NCT02515227|Drug|Pembrolizumab|Humanized monoclonal antibody (mAb) specific for PD-1.
244256|NCT02517359|Drug|RV6153 single dose|Safety and tolerability of single doses
244257|NCT02517359|Drug|RV6153 matching placebo single dose|Safety and tolerability of single doses
244258|NCT02517359|Drug|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
244259|NCT02517359|Drug|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
244260|NCT02517359|Drug|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
244261|NCT00181142|Drug|Zenapax|
244262|NCT02517359|Drug|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
244263|NCT02517372|Drug|CRD007|
248659|NCT02213588|Dietary Supplement|AOX blend|Antioxidant supplement
248660|NCT02213588|Dietary Supplement|Placebo|
248661|NCT02213601|Behavioral|Yoga|
248662|NCT02213614|Dietary Supplement|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
248663|NCT02213614|Dietary Supplement|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
248664|NCT02213614|Other|natural spring water|A group will drink natural spring water for 4 months
248665|NCT02213627|Drug|Corifollitropin alfa|
248666|NCT02213627|Drug|Recombinant FSH|
248667|NCT02213627|Drug|HP-hMG|
248668|NCT02213640|Device|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
248669|NCT00141414|Drug|Pregabalin|
248670|NCT02213640|Device|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
248671|NCT02213653|Drug|ARM A : IV iron + epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously
Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).
Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1.
248672|NCT02213653|Drug|ARM B: IV iron + epoietin zeta sequence|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7
carboxymaltose ferric (Ferinject ®) at week 1
Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).
Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1.
248990|NCT02206074|Dietary Supplement|Beetroot|
248991|NCT02206087|Drug|PER977|Reversal of heparin-induced anticoagulation
248992|NCT02206087|Drug|Placebo|Reversal of heparin-induced anticoagulation
248993|NCT02206100|Drug|PER977|reversal of edoxaban-induced anticoagulation
248994|NCT02206100|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
248995|NCT02206113|Behavioral|Standing workstation|
248352|NCT02218515|Biological|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
248353|NCT02220985|Drug|Methotrexate|Given IV
248354|NCT02220985|Drug|Mycophenolate Mofetil|Given IV and PO
248355|NCT02220985|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
248356|NCT02220985|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
248357|NCT00142298|Drug|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
248358|NCT02220985|Drug|Tacrolimus|Given IV or PO
248359|NCT02220985|Drug|Thiotepa|Given IV
248360|NCT02220985|Radiation|Total-Body Irradiation|Undergo TBI
248361|NCT02220998|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
248362|NCT02220998|Drug|SOF|SOF 400 mg tablet administered orally once daily
248363|NCT02220998|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
248364|NCT02221011|Device|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.
Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
248365|NCT02221024|Procedure|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
248366|NCT02221024|Drug|Normal saline|
248367|NCT02221024|Device|MicroClave ICU Medica|
248368|NCT00142324|Drug|Donepezil|
248369|NCT02221037|Drug|GSK2862277|It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using "Pari eFlow with s30 mesh" device.
247725|NCT02233088|Behavioral|ELM Group|ELM participants are trained to portion their meals according to the "Perfect Plate" method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity.
247726|NCT02233088|Other|ELM Classes|ELM classes will be administered through Rush Generations program and focus on health education.
247727|NCT02233088|Other|ELM Individual|ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
247728|NCT02233101|Drug|Oral Tranexamic Acid|patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
248038|NCT02225665|Genetic|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
248039|NCT02225665|Genetic|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
248040|NCT02225665|Drug|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
248041|NCT02228044|Behavioral|Prevention program|
248042|NCT02228070|Device|strabismus video goggles|
248043|NCT02228083|Drug|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
248044|NCT02228096|Biological|CTL019 T-cells|
248045|NCT02228109|Device|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
248046|NCT02228109|Device|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
248047|NCT02228109|Device|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
248048|NCT02228122|Device|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
248049|NCT00143065|Drug|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2, 6, 10, 14, 18, and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
248050|NCT02228135|Drug|Dexamethasone|
248051|NCT02228148|Device|NFS|Cochlear Nucleus Fitting Software
248052|NCT02228148|Device|CSS|Cochlear Nucleus Custom SoundTM Suite
223917|NCT02195076|Other|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
223918|NCT02195089|Drug|BLS_ILS_E710c 500mg|- 2 capsules per day for 20 days (week 1,2,4 & 8)
223919|NCT02195089|Drug|BLS_ILB_710c 1000mg|- 4 capsules per day for 20 days (week 1,2,4 & 8)
223920|NCT02195089|Drug|BLS_ILS_E710c 1500mg|- 6 capsules per day for 8 weeks (week 1,2,4 & 8)
223921|NCT02195102|Device|Transcatheter aortic valve Replacement|
223922|NCT02195115|Procedure|Laparoscopic Cholecystectomy|
223923|NCT00139204|Procedure|C11 Methionine PET scan|
223924|NCT02195115|Drug|amitriptyline|
223925|NCT02195115|Other|low-fat and low cholesterol diet|
223926|NCT02156141|Other|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
223927|NCT02156154|Drug|Intravenous Acetaminophen|
223928|NCT02156167|Device|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
223929|NCT02156193|Procedure|Prophylactic clip|Prophylactic clipping
223930|NCT02156193|Procedure|No prophylactic management|No prophylaxis
223931|NCT02156206|Behavioral|123 women emergency phone line in Medellin, Colombia|123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.
When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday.
219076|NCT02311413|Drug|Cat-PAD|
219077|NCT00152542|Drug|Placebo|No iNO given for days 1-7
219078|NCT02311413|Drug|Placebo for Cat-PAD|
219079|NCT02311426|Other|Observational study|
248117|NCT02235792|Device|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
248118|NCT00143936|Behavioral|Low Calorie Diet|Maintain a low calorie diet
248119|NCT02235805|Dietary Supplement|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
248120|NCT02235805|Dietary Supplement|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
248429|NCT02228252|Other|Gluten protein|
248430|NCT02228265|Other|Cytology Specimen Collection Procedure|Correlative studies
248431|NCT02228265|Drug|Enzalutamide|Given PO
248432|NCT02228265|Other|Laboratory Biomarker Analysis|Correlative studies
248433|NCT00143065|Drug|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2, 6, 10, 14, 18, and 22).
248434|NCT02228278|Behavioral|Text message|Text message arm will receive daily texts for 12 weeks.
248435|NCT02228278|Other|Control Group|Controls will receive current standard care - clinic visits every three months with anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.
248436|NCT02228291|Dietary Supplement|Capsule containing citrus flavonoid|
248437|NCT02228291|Dietary Supplement|Placebo|
248438|NCT02228304|Drug|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
248439|NCT02228304|Drug|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
248440|NCT02228317|Device|Telemedicine consultation|Telemedicine consultation done by telephone or video
248441|NCT02228330|Procedure|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
248442|NCT02230670|Drug|Placebo|
247796|NCT02200913|Other|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
247797|NCT02200926|Other|Loaded breathing training|7 days/weeks, for 8 weeks
247798|NCT02203162|Device|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
247799|NCT02203175|Drug|saline|Before the anesthesia induction, 5 ml isotonic saline
247800|NCT02203175|Drug|fentanyl|before the anesthesia induction 50 mcgr fentanyl
247801|NCT00140166|Drug|pyridoxine|
247802|NCT02203175|Drug|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
247803|NCT02203188|Procedure|Lid debridgement scaling|
247804|NCT02203214|Device|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
247805|NCT02203227|Dietary Supplement|Placebo|
247806|NCT02203227|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
247807|NCT02203227|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
248121|NCT02235818|Device|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
248122|NCT02235818|Device|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
248123|NCT02235831|Device|Nelfilcon A MF contact lenses (DACP MF)|Multifocal contact lenses in Low, Medium, High Add
248124|NCT02235831|Device|Nelfilcon A single vision contact lenses (DACP)|
248125|NCT02235844|Biological|Umbilical Cord Mesenchymal Stem Cells|
248126|NCT02235857|Device|Liposorber® LA-15 System|Liposorber® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
248127|NCT02235896|Behavioral|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
248128|NCT02235909|Drug|Azilsartan Medoxomil|
248129|NCT00143949|Drug|enalapril|
247498|NCT02208128|Drug|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
247499|NCT02208154|Drug|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
247500|NCT02208154|Drug|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10^5 units. SOD will be applied to the mouth 4 times daily until extubation.
247501|NCT00140803|Drug|Kenalog|
247502|NCT02208154|Drug|Selective Digestive Decontamination (SDD)|SDD consists of both:
SOD (described elsewhere)
AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u, to be administered via the nasogastric tube.
The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)
247503|NCT02208167|Biological|HXTC infusion|
247504|NCT02210559|Drug|Gemcitabine|Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 1000 mg/m2.
247505|NCT02210559|Drug|Nab-paclitaxel|Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 125 mg/m2.
247506|NCT02210572|Dietary Supplement|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
247507|NCT02210572|Dietary Supplement|Low- FODMAPs diet|
247508|NCT02210585|Other|Rehabilitation|12 weeks : 5 sessions per week (1 supervised session at home every month)
92 weeks : spontaneous training (supervised by phone every month)
247509|NCT00141037|Drug|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
247510|NCT02210598|Device|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
247808|NCT02203227|Dietary Supplement|MaQxan|
247809|NCT02203240|Other|Cocoa|
247810|NCT02203253|Drug|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
247811|NCT02203253|Drug|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
247812|NCT00140166|Drug|ascorbate|
247813|NCT02203253|Drug|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
247194|NCT02215486|Other|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
247195|NCT02215499|Drug|Placebo|
247196|NCT00141622|Drug|Slow sodium|
247197|NCT02215499|Drug|Sodium Oxybate|
247198|NCT02215499|Drug|JZP-386|
247199|NCT02215512|Drug|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
247200|NCT02215525|Device|UVA|device uses UVA
247201|NCT02215525|Dietary Supplement|Herbal|Herbal tablets, 1000 mg every 6 hours daily for 6 months
247202|NCT02215538|Drug|OROS methylphenidate|
247203|NCT02215538|Drug|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
247204|NCT02215577|Procedure|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
247205|NCT02215577|Procedure|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
247206|NCT02217995|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual ("automatic") dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams & Teasdale, 2002).
247207|NCT02218008|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
247208|NCT02218008|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
247209|NCT02218021|Drug|Samidorphan|
247210|NCT02218021|Drug|Placebo|
247211|NCT02218021|Drug|Oxycodone|
247511|NCT02210598|Device|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
246604|NCT02227550|Drug|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine >= 1.5 mg/dl (133mM), <= 60 kg body weight or age >= 80 years.
246605|NCT02227563|Device|Active tDCS|repetitive daily tDCS sessions for a period of one week
246606|NCT02227563|Device|control|
246607|NCT02227576|Drug|Romiplostim|
246608|NCT02227589|Behavioral|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
246908|NCT02222818|Device|Conducted AF Response (CAFR)|
246909|NCT02222831|Procedure|Day 0 denudation and time lapse culture on IVF-oocytes.|
246910|NCT02222844|Other|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
246911|NCT00142493|Drug|Midazolam Hydrochloride|60ng/ml
246912|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
246913|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2014-2015 formulation)
246914|NCT02222883|Genetic|Testing of BRCA status regarding germline and somatic mutation|
246915|NCT02222896|Drug|Chlorhexidine Gluconate|comparison with other CHG products
246916|NCT02222896|Other|Vehicle|Cloth with Excipients no CHG
246917|NCT02222896|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
246918|NCT02222909|Other|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
246919|NCT02222922|Drug|PF-06647020|Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.
246920|NCT02222922|Drug|PF-06647020|Part 2: Patients with triple negative breast cancer (unselected for PTK7 expression) or non small cell lung cancer (pre-selected with moderate to high PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.
246921|NCT02222922|Drug|fluconazole|combination drug used for drug-drug interaction sub-study
246922|NCT00142493|Drug|placebo|intralipid, saline, saline with multi-Vit solution
246286|NCT02234999|Drug|CC-122|3mg [14C]-CC-122 will be administered as a single dose
246287|NCT02235012|Drug|Ketamine|KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :
Initial rapid infusion of 0,23 mg/kg
Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
246288|NCT02235012|Drug|Placebo|CHLORURE DE SODIUM 0,9 % MACOPHARMA :
Initial rapid infusion of 0,23 mg/kg
Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
246289|NCT02235025|Other|Cardio-pulmonary exercise testing|
246290|NCT02235038|Behavioral|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
246291|NCT02235038|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
246292|NCT02235038|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
246293|NCT02235051|Behavioral|exercise intervention|Undergo Curves exercise program
246609|NCT00142961|Drug|Atomoxetine|atomoxetine
246610|NCT02229929|Drug|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
246611|NCT02229929|Drug|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
246612|NCT00143273|Drug|Placebo|0 mg
246613|NCT02229942|Drug|Rituximab|Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).
Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months.
246614|NCT02229942|Drug|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
246615|NCT02229955|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
246616|NCT02229968|Drug|Amicar (ε-aminocaproic acid)|
246617|NCT02229968|Drug|normal saline|
246618|NCT02229981|Drug|ABC294640|
246619|NCT02229994|Other|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|Evaluation will be performed on a group of 200 patients deriving from 4 samples.
From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).
From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment.
246300|NCT02197247|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
246301|NCT02197247|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
246302|NCT00139438|Behavioral|Disease Management Assessment|
246303|NCT02197247|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
246304|NCT02197247|Procedure|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
246305|NCT02197247|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
246306|NCT02197260|Drug|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
246307|NCT02197273|Drug|Liposomal bupivacaine|
246308|NCT02197273|Drug|Standard of care analgesia|
246309|NCT02197286|Drug|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
246310|NCT02197286|Drug|Placebo|Daily dose of a single gelatin placebo capsule.
246311|NCT02197299|Dietary Supplement|L-carnitine|
246312|NCT02197299|Dietary Supplement|Placebo|
246313|NCT00139451|Drug|Pediasure|With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.
246314|NCT02197312|Device|NobelProcera Bridge Shaded Zirconia|
246315|NCT02197325|Device|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
246316|NCT02197338|Other|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
246629|NCT02230059|Other|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
246630|NCT02230072|Device|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
246631|NCT02230085|Other|Administration of the questionnaire and monitoring of CPAP adherence|
245718|NCT02214979|Drug|Telmisartan|
245719|NCT02214979|Drug|Ramipril capsule|
245720|NCT00141557|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
245721|NCT02214979|Drug|Ramipril tablet|
245722|NCT02214992|Drug|Telmisartan/Ramipril|Fixed dose combination tablet
245723|NCT02214992|Drug|Telmisartan|
245724|NCT02214992|Drug|Ramipril capsule|
245725|NCT02214992|Drug|Ramipril tablet|
245726|NCT02215005|Drug|Telmisartan|
246009|NCT00140426|Drug|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
246010|NCT02204982|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
246011|NCT02204995|Procedure|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
246012|NCT02204995|Procedure|Trapeziectomy|Trapeziectomy
246013|NCT02205008|Procedure|surgery|Total or subtotal gastrectomy with D2
246014|NCT02205008|Drug|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
246015|NCT02205008|Drug|Early postoperative intraperitoneal chemothgerapy|operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2
1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq
246016|NCT02205021|Other|No intervention|
246017|NCT02205034|Drug|oxytocin|Intranasal administration
246018|NCT02205047|Drug|Cisplatin|
246019|NCT02205047|Drug|5-fluorouracil or Capecitabine|
246020|NCT02207465|Radiation|Radiotherapy|
246021|NCT02207465|Drug|Gemcitabine 1000 mg|
246022|NCT02207465|Drug|nab-paclitaxel 125 mg|
245406|NCT02224560|Drug|GWP42003-P|
245407|NCT02224560|Drug|Placebo control|
245408|NCT02224573|Drug|GWP42003-P|
245409|NCT02224586|Device|light treatment|clinical routine treatment according to the doctor's advice
245410|NCT00142688|Behavioral|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
245411|NCT02224599|Biological|TAPA-pulsed DC vaccine|
245412|NCT02224612|Device|Medline Pediatric Face Masks|Medline Face Masks
245413|NCT02224612|Device|KC Childs Mask|
245414|NCT02224625|Drug|2% CHG Cloth|
245415|NCT02224625|Device|Vehicle Cloth|
245416|NCT02224625|Drug|DynaHex Solution|Cholorhexidine gluconate solution
245417|NCT02224625|Other|Saline|
245418|NCT02224625|Other|SLS|Provides a slight irritation for a positive control
245419|NCT02224638|Device|TheraHoney HD|Honey
245420|NCT02224638|Device|SkinTegrity|Hydrogel
245727|NCT02215005|Drug|Ramipril|
245728|NCT02215018|Drug|BI 44370 TA solution|
245729|NCT02215018|Drug|BI 44370 TA tablet|
245730|NCT02215018|Drug|Placebo solution|
245731|NCT00141570|Drug|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
245732|NCT02215018|Drug|Placebo tablet|
245733|NCT02215031|Drug|BI 44370|
245734|NCT02215031|Drug|Placebo|
245735|NCT00141843|Genetic|ReFacto AF|
245108|NCT02533843|Procedure|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
245109|NCT02536170|Drug|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
245110|NCT02536170|Drug|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
245111|NCT02536170|Other|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
245112|NCT02536183|Device|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
245113|NCT02536183|Drug|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
245114|NCT02536196|Device|Embolic Protection Device|Embolic protection
245115|NCT00183573|Behavioral|Intensive Informational Intervention|4-hour, information-only intensive group workshop
245116|NCT02536196|Procedure|ranscatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
245117|NCT02536209|Drug|MT-8554 low dose|
245118|NCT02536209|Drug|MT-8554 high dose|
245119|NCT02536209|Drug|Oxycodone hydrochloride|
245120|NCT02536209|Drug|Placebo|
245121|NCT02536222|Other|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
245122|NCT02536235|Other|heat|activated heating pad to lower abdomen
245123|NCT02536248|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
245124|NCT02536248|Drug|Placebo|Placebo for 6 weeks
245125|NCT02536274|Device|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
245126|NCT00002496|Procedure|conventional surgery|
244544|NCT02510612|Drug|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
244545|NCT02510625|Procedure|Anatomic Glenoid Reconstruction|Distal tibia bone graft
244546|NCT02510625|Procedure|Arthroscopic bankart Repair|Arthroscopic bankart Repair
244547|NCT02510651|Procedure|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
244840|NCT02503683|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
244841|NCT02503696|Device|Stool Collection Kit|Stool Collection Kit.
244842|NCT02506036|Other|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
244843|NCT02506049|Device|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
244844|NCT00179582|Drug|VSL#3|
244845|NCT02506062|Device|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
244846|NCT02506075|Device|Transcranical direct current stimulator|approved by Conformity European as safe treatment device for stroke patients
244847|NCT02506075|Behavioral|Visual inattention training|
244848|NCT02506088|Behavioral|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
244849|NCT02506101|Device|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
244850|NCT02506114|Biological|PROSTVAC V/F|PROSTVAC-V/F is a PSA (prostate-specific antigen)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
244851|NCT02506114|Drug|Ipilimumab|
244264|NCT02517385|Drug|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
244265|NCT02517398|Drug|MSB0011359C|Subjects will receive intravenous infusion of MSB0011359C once every 2 weeks until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or IMP occurs.
244266|NCT02517411|Other|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
244267|NCT02517411|Other|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
244268|NCT02517411|Device|electrostimulation|
244269|NCT02517424|Drug|High THC/Low CBD Cannabis|
244270|NCT02517424|Drug|High THC/High CBD Cannabis|
244271|NCT02517424|Drug|Low THC/Low CBD Cannabis|
244272|NCT00181155|Drug|Allopurinol|intravenous infusion of allopurinol (300mg)
244548|NCT02510664|Behavioral|Diabetes Strengths Study|
244549|NCT02510677|Other|myocardial perfusion scintigraphy|
244550|NCT00180128|Drug|all-trans retinoid acid|
244551|NCT02510703|Other|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
244552|NCT02510716|Behavioral|SGR|
244553|NCT02510716|Behavioral|Support message only|
244554|NCT02512887|Drug|Caudal Block Anesthesia (bupivacaine without epinephrine)|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
244555|NCT02512887|Drug|Dorsal Penile Block Anesthesia (bupivacaine without epinephrine)|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
244556|NCT02512900|Drug|MEDI9929 (AMG 157)|MEDI9929 (AMG 157) (Investigational Product) - single dose
244557|NCT02512913|Behavioral|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
248996|NCT02206126|Behavioral|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
248997|NCT00140569|Drug|fludarabine|
248998|NCT02206152|Drug|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
248999|NCT02206152|Drug|Placebo|
249000|NCT02208557|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
249001|NCT02208570|Other|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
249002|NCT02208570|Drug|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
249003|NCT02208570|Other|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
249004|NCT02208583|Drug|Docetaxel & Prednisone|Docetaxel & Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
249005|NCT02208583|Drug|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
249006|NCT02208583|Drug|cisplatin & Etoposide|cisplatin & Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
249007|NCT02208583|Drug|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
249008|NCT02208596|Drug|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
249009|NCT02208596|Drug|propofol|
244273|NCT02517437|Drug|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
248370|NCT02221037|Drug|Placebo|It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using "Pari eFlow with s30 mesh" device.
248673|NCT02213653|Drug|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
248674|NCT02213666|Device|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
248675|NCT02213679|Dietary Supplement|Guanidinoacetic acid|Guanidinoacetic acid is a highly bio-available natural precursor of creatine
248676|NCT02213705|Biological|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
248677|NCT02213718|Drug|Desflurane|desflurane (7%-8% end-tidal concentration)
248678|NCT02213718|Drug|propofol|propofol (TCI:3.5-4.0μg/min)
248679|NCT02216084|Drug|Recombinant ADAMTS13|rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.
Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3).
248680|NCT02216097|Drug|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
248681|NCT02216097|Drug|Placebo|Matching placebo tablet taken once daily for 7 days.
248682|NCT02216110|Procedure|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
248683|NCT00002318|Drug|Bleomycin sulfate|
248684|NCT00141687|Procedure|External cephalic version|Informaton not available at this time.
248685|NCT02216123|Drug|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
248686|NCT02216123|Drug|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
248687|NCT02216123|Drug|Chloroquine|One of two formulations of commercially available generic chloroquine may be utilized in this study:
tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,
tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base).
248688|NCT02216123|Drug|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
248689|NCT02216123|Drug|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
248053|NCT02228161|Behavioral|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
248054|NCT02228174|Device|Intrauterine Ultrasound-Guided Radiofrequency Ablation System|The VizAblate System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. VizAblate is suitable in an inpatient or outpatient setting, and is intended to provide focal treatment of symptomatic fibroids responsible for heavy menstrual bleeding (HMB).
248055|NCT02228187|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
248056|NCT02228200|Behavioral|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
248371|NCT02221063|Other|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
248372|NCT02221063|Other|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
248373|NCT02221063|Other|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
248374|NCT02223429|Drug|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
248375|NCT02223429|Drug|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
248376|NCT00142545|Drug|apomorphine HCl injection|
248377|NCT02223429|Drug|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
248378|NCT02223455|Other|Hand Hygiene Compliance Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
248379|NCT02223481|Drug|Terbogrel low dose|
248380|NCT02223481|Drug|Terbogrel high dose|
248381|NCT02223481|Drug|Placebo|
219080|NCT02311439|Drug|FOLFIRINOX + CRT|Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.
In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.
Radiotherapy :
A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator.
219081|NCT02311452|Device|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
219082|NCT02311465|Other|Palliative Care|Components of the palliative care service intervention are expected to include:
Establishment of a palliative care plan
Care coordination by palliative care team
Informational, patient friendly materials supporting Palliative Care
Communication by palliative care team to all providers and teams involved in patient's care
Systematic collection of information, including identification of surrogate or health care proxy and advance care planning
Questionnaires capturing health related quality of life at regular intervals throughout the intervention period
219083|NCT02311478|Device|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
219084|NCT02311491|Device|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
219085|NCT02311504|Device|OCT examination|
219086|NCT02311517|Drug|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
219087|NCT02311517|Drug|Normal Saline|
219088|NCT00152555|Behavioral|Physical Therapy or Relaxation Therapy|
219089|NCT02311530|Drug|Felodipine|Extended Release Tablets, 10mg
219090|NCT02311530|Drug|Felodipine (Plendil®)|
219091|NCT02311543|Drug|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
219092|NCT02311556|Device|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
219093|NCT02311569|Drug|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
219094|NCT02311582|Biological|MK-3475|
219398|NCT02303821|Drug|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
248443|NCT02230683|Drug|IDN-6556|25 mg BID
248444|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
248445|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
248446|NCT02230696|Drug|Placebo nasal spray|
248447|NCT02230709|Other|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
248448|NCT02230709|Other|TENS plus dry needling|Application of TENS current after dry needling technique
248763|NCT02223689|Procedure|Skin Affix|
248764|NCT02223702|Drug|Amoxicillin|500 mg, 3 times per day for 7 days
248765|NCT02223702|Drug|Metronidazole|500 mg, 3 times per day, for 7 days
248766|NCT02223702|Drug|Moxifloxacin|400 mg, once in a day for 7 days.
248767|NCT00142571|Drug|Gemcitabine|
248768|NCT02223715|Other|CDI Pts|
248769|NCT02223728|Behavioral|Lifestyle|
248770|NCT02223728|Behavioral|Health Education|
248771|NCT02223741|Other|Korean medical treatment|acupuncture and herbal drugs
248772|NCT02223767|Device|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
248773|NCT02223767|Device|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
248774|NCT02223780|Other|early palliative care|the patients will benefit from an early palliative care consultation
248775|NCT02223793|Behavioral|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
248776|NCT02223793|Behavioral|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
248777|NCT02223793|Behavioral|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
248130|NCT02235909|Drug|Losartan|
248131|NCT02235909|Drug|Placebo for Azilsartan Medoxomil|
248132|NCT02235909|Drug|Placebo for Losartan|
248133|NCT02235922|Other|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
248134|NCT02198092|Other|Epi proColon Testing|Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.
For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.
248135|NCT02198105|Device|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|Interventional procedure:
PTA with Cutting-Balloon (60-120 seconds).
PTA with DC-Balloon (60 seconds).
Technical success is defined as
no recoil >30%
no dissection >Type B
no stenting >30% of lesion length.
248136|NCT02198118|Other|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
248137|NCT02198131|Procedure|laser therapy|Undergo pulsed dye laser
248138|NCT00139516|Drug|nicotine replacement therapy|
248139|NCT02198131|Other|questionnaire administration|Ancillary studies
248140|NCT02198144|Other|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
248449|NCT00143390|Drug|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
248450|NCT02230722|Behavioral|Motivational Interviewing|
248451|NCT02230722|Behavioral|Attention Control|
248452|NCT02230735|Drug|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
248453|NCT02230735|Drug|Normal Saline|(placebo for bupivacaine)
248454|NCT02230761|Drug|XOPH5 Ointment|
248455|NCT02230761|Drug|Placebo|
248456|NCT02230787|Device|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
248457|NCT02230787|Device|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
247814|NCT02203266|Device|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
247815|NCT02203266|Behavioral|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
247816|NCT02203279|Other|Rebase II Fast|It is going to be used a direct relining material
247817|NCT02203279|Other|Flexacryl|This is going to be used as a second direct relining material
247818|NCT02203279|Other|Vertex|This is going to be used as an indirect relining material
247819|NCT02203292|Behavioral|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb < 9.0 g/dL
247820|NCT02203292|Behavioral|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb < 7.0 g/dL
247821|NCT02203305|Device|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
247822|NCT02203305|Other|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
247823|NCT00140179|Drug|valnoctamide|
247824|NCT02203331|Drug|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
247825|NCT02205593|Behavioral|Haut Tief patient education|the intervention consists of the educational program (patient education on disease, therapy management, stress reduction by yoga, sport, meditation, psychological education) for 2h twice a week for 9 weeks. Additionally, patients receive regular follow-up visits.
247826|NCT02205606|Drug|HGP0816 5mg|P.O.
247827|NCT02205606|Drug|HGP0816 10mg|P.O.
247828|NCT02205606|Drug|HGP0816 20mg|P.O.
247829|NCT02205606|Drug|HCP1306 5/10mg|P.O.
248141|NCT02198157|Other|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
248142|NCT02198170|Drug|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
248143|NCT02198170|Drug|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
247512|NCT02210598|Drug|Oxytocin|When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement.
247513|NCT02210611|Procedure|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
247514|NCT02210611|Procedure|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
247515|NCT02210624|Biological|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
247516|NCT02210650|Procedure|Ureteral stone removal|Ureteral stone removal by the surgical procedure called Ureteroscopy
247517|NCT02210650|Procedure|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and Ureteral stone removal by the surgical procedure called Ureteroscopy
247518|NCT02210663|Drug|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
247519|NCT02210676|Other|PROMIS Upper Extremity|
247520|NCT00141037|Drug|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
247521|NCT02210676|Other|Likert Pain Scale|
247522|NCT02210676|Other|Mallet Finger Extensor Lag Measurement|
247523|NCT02210689|Drug|clindamycin phosphate vaginal cream 2%|
247524|NCT02210702|Drug|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
247525|NCT02213068|Drug|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
247526|NCT02213068|Drug|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
247527|NCT02213068|Drug|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
247528|NCT02213081|Drug|Ulipristal|Patients will take 15mg every other day, or every 4 days per week.
247529|NCT02213094|Drug|Nicotinamide|Nicotinamide daily for up to 14 days or to delivery, which occurs first
246923|NCT02222935|Behavioral|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
246924|NCT02222935|Behavioral|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
246925|NCT02222948|Drug|Vatelizumab SAR339658|Pharmaceutical form:solution for infusion Route of administration: intravenous
246926|NCT02222948|Drug|Placebo|Pharmaceutical form:solution for infusion Route of administration: intravenous
246927|NCT02222961|Drug|BIIR 561 CL|
246928|NCT02222961|Drug|Placebo|
246929|NCT02222974|Drug|BIIR 561 CL|
247212|NCT02218034|Drug|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
247213|NCT02218034|Drug|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
247214|NCT02218034|Drug|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
247215|NCT02218034|Drug|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
247216|NCT00141934|Drug|AD 452|
247217|NCT02218047|Drug|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
247218|NCT02218060|Procedure|Coronary CT angiography on SOMATOM Force|
247219|NCT02218060|Procedure|Previous coronary CT angiography on 2nd generation CT scanner|
247220|NCT02218073|Drug|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
247221|NCT02218073|Drug|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
247222|NCT02218073|Drug|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
247223|NCT02218086|Device|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
246620|NCT02230007|Drug|MEOPA|3 sessions of reeducation using MEOPA
246621|NCT02230020|Device|Nasal High Flow|
246622|NCT02230033|Drug|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
246623|NCT00143273|Drug|Lasofoxifene|0.25 mg tablets
246624|NCT02230033|Drug|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
246625|NCT02230033|Drug|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
246626|NCT02230046|Drug|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
246627|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
246628|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
246930|NCT02222974|Drug|Placebo|
246931|NCT02222987|Drug|Terbogrel|
246932|NCT02222987|Drug|Clopidogrel|
246933|NCT02225210|Drug|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
246934|NCT02225210|Drug|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
246935|NCT02225210|Drug|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
246936|NCT02225223|Device|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
246937|NCT02225223|Device|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
246938|NCT02225236|Behavioral|Classroom Intervention|
246939|NCT02225262|Radiation|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
246940|NCT02225275|Drug|Lenalidomide|5 mg by mouth per day from day 9 until day 56, and at 10 mg per day from day 57 until progression or excessive toxicity.
278038|NCT02702765|Procedure|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
278039|NCT02702778|Drug|Delayed-Release (DR) Prednisone|delayed release prednisone
278040|NCT02702778|Drug|Immediate Release (IR) Prednisone|standard prednisone
278041|NCT02702791|Behavioral|Telecoaching|Pedeometer based goals and telecoaching support
278042|NCT02702791|Other|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
278043|NCT02702804|Other|High Intensity Interval Training|High Intensity Interval Training
278044|NCT02702817|Drug|Naproxen|pale blue oval tablets
278045|NCT02704923|Drug|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
278046|NCT02704949|Radiation|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
278047|NCT02704949|Radiation|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
278337|NCT02698449|Procedure|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
278338|NCT02698449|Procedure|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
278339|NCT02698449|Radiation|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
278340|NCT02698462|Other|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
278341|NCT02698475|Drug|Ustekinumab 0.75 mg/kg|Participants weighing less than (<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40.
278342|NCT02698475|Drug|Ustekinumab 45 mg|Participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40.
278343|NCT02698475|Drug|Ustekinumab 90 mg|Participants weighing >100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40.
278344|NCT02698488|Procedure|Morphology|
277761|NCT02709057|Behavioral|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
277762|NCT02709070|Procedure|resection|hepatectomy for HCC
277763|NCT00203203|Other|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
277764|NCT02709070|Procedure|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
277765|NCT02709083|Drug|Dasatinib|Given PO
277766|NCT02709083|Drug|Imatinib Mesylate|Given PO
277767|NCT02709083|Other|Laboratory Biomarker Analysis|Correlative studies
277768|NCT02709083|Drug|Nilotinib|Given PO
277769|NCT02709083|Other|Questionnaire Administration|Ancillary studies
277770|NCT02709096|Drug|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
277771|NCT02709096|Drug|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
277772|NCT02709109|Drug|VX-371|
277773|NCT02709109|Drug|Saline|
278048|NCT02704962|Drug|full-dose olanzapine|trifluoperazine 5mg/d
278049|NCT02704975|Device|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
278050|NCT02704975|Device|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
278051|NCT02704988|Procedure|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
278052|NCT02704988|Procedure|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
277492|NCT02715115|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
277493|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
277494|NCT02715115|Drug|Placebo|Strawberry flavored solution and Water for Injection
277495|NCT02715128|Device|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
277496|NCT02715141|Behavioral|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
277497|NCT02715154|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
277498|NCT02715154|Drug|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
277499|NCT02715167|Drug|Budesonide novolizer|
277500|NCT02715167|Drug|Placebo|
277501|NCT02715180|Radiation|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
277502|NCT02715193|Biological|REMD-477|
277503|NCT02715193|Biological|Placebo Comparator|
277504|NCT00203918|Behavioral|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
277505|NCT02715206|Behavioral|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
277506|NCT02715206|Behavioral|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
277507|NCT02715206|Behavioral|control|control group continues to teach whatever prevention curriculum they were using prior to study
277197|NCT02683967|Procedure|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
277198|NCT02683980|Device|Lumenis Pulse P120H and Xpeeda side firing fiber|
277199|NCT02683993|Device|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
277200|NCT02686242|Procedure|general anesthesia|general anesthesia with intubation
277201|NCT02686255|Other|complete blood count|complete blood count during follow up in the heart institute
277202|NCT02686281|Drug|GMC-252-L-Lysine|
277203|NCT02686281|Other|Placebo|
277204|NCT02686294|Drug|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
277205|NCT02686294|Drug|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
277206|NCT00200447|Drug|carbidopa/l-dopa|
277207|NCT02686307|Procedure|ICD Implant|Implantation of an implantable cardioverter/defibrillator
277208|NCT02686333|Other|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
277209|NCT02686346|Drug|Brentuximab Vedotin|Phase I:
Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)
Phase II:
BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I
277210|NCT02686346|Drug|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
277211|NCT02686346|Drug|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
277212|NCT02686346|Drug|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
277213|NCT02686359|Biological|sample|
277214|NCT02686372|Other|Biological: HBV antigen specific TCR redirected T cell|Subjects will receive escalating doses of HBV antigen specific TCR redirected T cell infusion.
277215|NCT02686385|Drug|Prednisolone|
277216|NCT02686385|Drug|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
277217|NCT00200447|Drug|carbidopa/l-dopa/entacapone|
276590|NCT02695810|Drug|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
276591|NCT02695810|Behavioral|Exercise|Interval training, 5 times per week, 30 min per session
261781|NCT02485314|Other|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
261782|NCT02485327|Drug|Technosphere Insulin SAR439065 Afrezza®|Pharmaceutical form: dry powder
Route of administration: oral inhalation
261783|NCT02485340|Drug|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
261784|NCT02485340|Drug|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
261785|NCT02485340|Drug|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
261786|NCT02485353|Drug|Vosaroxin and Cytarabine|
261787|NCT02485366|Drug|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
261788|NCT02485366|Procedure|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
261789|NCT00176774|Drug|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
261790|NCT02485379|Procedure|Prostate biopsy|Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of "clinically significant cancer" will be considered as negative for the TB strategy.
261791|NCT02487589|Other|Telephone support, telemonitoring and tele-exercise|The care model will provide 24/24 h assistance for six months and include:
Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .
Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.
Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist.
261792|NCT02487602|Device|Gelesis100|Gelesis100 capsules
261793|NCT02487602|Other|Placebo|Sucrose (sugar) capsules
261794|NCT02487628|Device|HQ® Matrix Soft Tissue Mesh|
261795|NCT02487628|Device|ULTRAPRO® Partially Absorbable Lightweight Mesh|
261183|NCT00178165|Procedure|Skill Training Condition – problem solving training|
261184|NCT02496546|Drug|LEO 32731 cream vehicle|Applied for 3 weeks
261185|NCT02496559|Procedure|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
261471|NCT02489526|Drug|VVZ-149 Injections|A novel analgesic drug candidate, VVZ-149 Injections shows dual antagonistic activity with moderate potency on glycine transporter type 2 (GlyT2, IC50=0.86 μM) and serotonin receptor 2A (5HT2A, IC50=1.3 μM), which are therapeutic targets for pain. GlyT2 inhibitors have been studied by many pharmaceutical companies as a well-known and promising analgesic candidate because of their role in inhibitory (glycine) modulation and regional specificity.
261472|NCT02489526|Drug|Placebo|Same formulation and appearance with VVZ-149 Injections
261473|NCT02489539|Device|GORE® EXCLUDER® Conformable AAA Endoprosthesis|
261474|NCT00177177|Drug|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
261475|NCT02489565|Other|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
261476|NCT02489578|Other|other|retrospective cohort study
261477|NCT02489591|Device|Oral appliance|Patients will bring their prescribed oral appliance.
261478|NCT02489591|Device|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
261479|NCT02489604|Drug|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
261480|NCT02489604|Drug|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
261481|NCT02489617|Other|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
261482|NCT02491957|Other|LOFT Therapy|LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.
The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement.
261483|NCT02491970|Drug|Fluticasone/Formoterol|
260912|NCT02467036|Behavioral|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
260913|NCT02467049|Device|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
260914|NCT02467049|Device|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
261186|NCT02496572|Drug|Short course MDR-TB treatment regimen|Intensive phase:
Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.
Continuation phase:
Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration.
261187|NCT02496585|Drug|Nintedanib|
261188|NCT02496585|Drug|Prednisone|
261189|NCT02496585|Other|Placebo|
261190|NCT02496598|Procedure|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
261191|NCT02496598|Drug|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
261192|NCT02496611|Drug|Exenatide extended-release for injectable suspension (BYDUREON™)|
261193|NCT02496611|Dietary Supplement|Meal Replacement Therapy|A short-term meal replacement induction period designed to achieve >5% BMI reduction in 1, 2, or 3 months.
261194|NCT00178165|Procedure|REACH for TLC (Telephone Linked Computer) system|
261195|NCT02496624|Other|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
261196|NCT02496637|Behavioral|Appetite Awareness|
261197|NCT02496637|Behavioral|Nutrition Education|
261198|NCT02496650|Drug|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
261199|NCT02498496|Drug|Placebo|Administration of 100 mL of Normal Saline
261200|NCT02498509|Drug|CKD-342|treatment for 4 weeks after randomization
260630|NCT02471755|Device|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
260631|NCT02473523|Other|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
260632|NCT02473523|Other|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
260633|NCT02473536|Radiation|Stereotactic ablative radiation therapy|SABR
260634|NCT02473549|Device|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
260635|NCT02473549|Device|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
260636|NCT02473549|Device|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
260915|NCT02467062|Device|MRI|MRI measurement to evualuate for 4D blood flow pattern
260916|NCT02467075|Drug|Iopamidol 300|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
260917|NCT02467075|Drug|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
260918|NCT02467088|Other|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
260919|NCT02467101|Other|Corticosteroid/Saline|Corticosteroid/Saline
Two groups were defined: group A and group B.
Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head
Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.
Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.
Each patient will be injected on half-head.
260920|NCT02467114|Device|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
260921|NCT00002471|Drug|methylprednisolone|
260922|NCT00174525|Drug|AAB-001|
260923|NCT02467114|Device|Sham coil stimulation|Stimulation with a sham coil as a comparison
260360|NCT02477748|Drug|Placebo|Tablet PO, taken once daily for 10 weeks.
260361|NCT02477761|Dietary Supplement|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
260362|NCT02477774|Device|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
260363|NCT02477787|Biological|allogeneic, donor-derived NK cells|Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.
For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.
Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions.
260364|NCT00175890|Other|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
260365|NCT02477800|Drug|Aducanumab (BIIB037)|Low dose
260366|NCT02477800|Drug|Aducanumab (BIIB037)|High dose
260367|NCT02477800|Drug|Placebo|Placebo
260368|NCT02477813|Drug|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
260369|NCT02477826|Drug|Nivolumab|
260370|NCT02477826|Drug|Ipilimumab|
260371|NCT02477826|Drug|Carboplatin|
260372|NCT02477826|Drug|Cisplatin|
260373|NCT02477826|Drug|Gemcitabine|
260374|NCT02477826|Drug|Pemetrexed|
260375|NCT00175903|Drug|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
260376|NCT02477839|Drug|Lacosamide|Active Substance: Lacosamide; Pharmaceutical Form: Syrup; Concentration: 10 mg/mL; Route of Administration: oral
260377|NCT02477839|Other|Placebo|Active Substance: Placebo; Pharmaceutical Form: Syrup; Concentration: N/A; Route of Administration: oral
260378|NCT02477852|Drug|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
260379|NCT02479828|Drug|Placebo|
259774|NCT00177060|Drug|hydromorphone|
259775|NCT02491138|Other|Pamphlets|
260068|NCT02484495|Other|Program evaluation (impact assessment)|The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.
Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day.
260069|NCT02484508|Drug|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
260070|NCT02484508|Drug|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
260071|NCT02484521|Device|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
260072|NCT02484521|Other|Questionnaires|Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.
Questionnaires what would be used are:
GAF- Global assessment of functioning
PANSS- Positive and negative syndrome scale
SANS- Scale for the Assessment of Negative Symptoms
The Calgary Depression Scale for schizophrenia
Demographic Questionnaire
Hamilton Anxiety scale
260073|NCT02484547|Drug|Aducanumab (BIIB037)|Low dose
260074|NCT02484547|Drug|Aducanumab (BIIB037)|High dose
260075|NCT02484547|Drug|Placebo|Placebo
260076|NCT00176657|Drug|HEMOBAG Assessment|
260077|NCT02484560|Drug|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
260078|NCT02484573|Drug|Propanolol|The patients going to receive propanolol, then different measures are going to do, pre and posttreatment
260079|NCT02484586|Device|Etafilcon A|Prototype lens material
260080|NCT02484586|Device|Etafilcon A|Control lens for presbyope group
260081|NCT02484586|Device|Nelfilcon A|Control lens for presbyope group
260082|NCT02484586|Device|Nesofilcon A|Control lens for presbyope group
260083|NCT02484586|Device|Nelfilcon A|Control lens for non-presbyope group
260084|NCT02484586|Device|Etafilcon A|Control lens for non-presbyope group
260085|NCT02484586|Device|Somofilcon A|Control lens for presbyope group
276406|NCT02714595|Drug|Best Available Therapy|Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
276407|NCT02714608|Drug|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
276408|NCT02714608|Drug|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
276409|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
276410|NCT02714608|Drug|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
276731|NCT02710669|Drug|Placebo|
276732|NCT00203385|Drug|Divalproex sodium|
276733|NCT02710682|Procedure|Mini-open surgery|This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.
Skin disinfection; Local anesthesia (lidocaine 1%).
Skin incision, slightly anterior to lateral epicondyle.
Exposure of the plane between the tendon and fascia.
Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.
Excision of diseased tissue of the ECRB tendon.
ECRL tendon is sutured back to the fascia. The skin is closed.
Patient is monitored for 30 minutes after procedure.
276734|NCT02710682|Device|Ultrasound-guided Tendon fenestration|This treatment will be administered by a fellowship-trained MSK radiologist.
Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.
Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.
Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.
Patient monitored for 30 minutes, before being discharged.
276735|NCT02710695|Behavioral|Verbal|This group will receive a 10 minute discussion about the common causes of shoulder pain.
276736|NCT02710695|Behavioral|Verbal + Video|This group will receive a standardized 10 minute discussion aided with a shoulder anatomy video that will be orated by the research staff.
276737|NCT02710695|Behavioral|Verbal + Model|This group will receive a standardized 10 minute discussion aided with a shoulder anatomic model. Each participant will touch the shoulder model while the discussion is given by the interviewer.
276738|NCT02710708|Drug|EE20/DRSP (YAZ, BAY86-5300)|
276739|NCT02710721|Other|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
276740|NCT02710721|Other|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
276741|NCT02710734|Drug|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
276104|NCT02683486|Device|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
276105|NCT02683486|Device|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
276106|NCT00200096|Procedure|placebo acupuncture|During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.
Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure.
276107|NCT02683499|Procedure|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
276108|NCT02683512|Other|No intervention|This is an observational study that consists of data abstraction.
276109|NCT02683525|Drug|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
276110|NCT02683538|Device|Separable cluster electrode|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
276111|NCT02683551|Procedure|Sutureless Thyroidectomy|Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Device which will be used is decided according to current availability in the operating room. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
276112|NCT02683564|Drug|BOW015|monoclonal antibody against TNF-alpha
276113|NCT02685774|Drug|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
276411|NCT02714621|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
276412|NCT02714634|Drug|Methotrexate + biologic administration|Methotrexate + adalimumab or
Methotrexate + certolizumab or
Methotrexate + etanercept or
Methotrexate + golimumab or
Methotrexate + infliximab or
Methotrexate + abatacept or
Methotrexate + rituximab or
Methotrexate + tocilizumab
276413|NCT02714634|Drug|methotrexate + salazopyrine + hydroxychloroquine administration|
276414|NCT02714647|Behavioral|Attentional prime|
276415|NCT02714647|Behavioral|Sham prime|
276416|NCT02714660|Other|none, observational study|
275810|NCT02690402|Behavioral|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
275811|NCT02690415|Procedure|Antibiotics Given|Patients who's treating physician prescribed antibiotics
275812|NCT02690415|Procedure|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
275813|NCT02690428|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
275814|NCT00200954|Dietary Supplement|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
275815|NCT02690441|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
275816|NCT02690441|Behavioral|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
275817|NCT02690441|Behavioral|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
275818|NCT02690467|Device|Insupen G34x3,5mm|
275819|NCT02690467|Device|Insupen G32x4mm|
275820|NCT02690480|Drug|PD-0332991 (Palbociclib)|Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first
275821|NCT02690480|Drug|Fulvestrant|Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)
Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first
275822|NCT02690480|Drug|Placebo|Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs
275823|NCT02690493|Procedure|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
275824|NCT02690493|Other|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
275239|NCT02699385|Drug|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
275240|NCT02699385|Drug|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
275241|NCT00202007|Drug|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
275242|NCT02699398|Behavioral|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
275243|NCT02699398|Behavioral|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
275244|NCT02699411|Device|Dry needling|dry needling Travell and Simons
275245|NCT02701582|Device|FloTrac Sensor|
275246|NCT02701595|Drug|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients >70kg)
275247|NCT02701595|Procedure|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
275248|NCT02701608|Drug|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients >70kg)
275249|NCT02701608|Drug|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients >70kg)
275250|NCT02701608|Procedure|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
275251|NCT02701621|Other|MIRT-AT|Aquatic therapy
275252|NCT02701621|Other|MIRT|Land-based Therapy
275253|NCT02701634|Drug|Entospletinib|Entospletinib tablet(s) administered orally twice daily under fasted conditions
275254|NCT00202306|Drug|lithium carbonate|
275255|NCT02701634|Drug|Placebo|Placebo to match entospletinib tablet(s) administered orally twice daily under fasted conditions
275256|NCT02701634|Drug|Systemic Corticosteroids|Systemic corticosteroids may include prednisone or prednisone equivalent.
274398|NCT02713971|Other|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
274399|NCT02715999|Procedure|Quadratus Lumborum Block|0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
274671|NCT02710019|Other|Back to Reality Series video games|Back to Reality Series are a psycho-educational video games that address the emotional harms associated with underage substance use. They also help youth learn how and where to seek help for mental health and addictions problems.
274672|NCT02710019|Other|Control video games|The control video game will consist of digital puzzles and memory mini-games. The control games will not have any content related to mental health and addictions problems
274673|NCT02710032|Behavioral|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
274674|NCT02710032|Behavioral|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
274675|NCT02710045|Biological|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
274676|NCT02710045|Biological|Diphtheria-tetanus-whole cell pertussis vaccine at 9 months of age|Single intramuscular (i.m.) dose of DTP (Serum Institute of India Ltd.) into the thigh at 9 months of age
274677|NCT02710045|Biological|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
274678|NCT02710058|Behavioral|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
274679|NCT00203307|Drug|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
274680|NCT02710071|Drug|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
274681|NCT02710071|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
274682|NCT02710084|Drug|Oxytocin|Intranasal oxytocin
274683|NCT02710084|Drug|Saline|Placebo
278653|NCT00201136|Behavioral|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
278654|NCT02691871|Drug|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
278655|NCT02691871|Drug|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
278656|NCT02691871|Drug|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
278657|NCT02691884|Procedure|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
278934|NCT02687074|Device|NIV|patients treated with noninvasive ventilation
278935|NCT02687087|Device|Visco-ease|19.6 mg/mL of LMS-611
278936|NCT02687087|Device|Placebo|Physiological Saline
278937|NCT02687100|Drug|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
278938|NCT02687100|Drug|Placebo|patients will receive 8 mL of saline without any drug
278939|NCT02687113|Device|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
278940|NCT02687126|Device|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
278941|NCT02687139|Drug|18F-DCFPyL|
278942|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
278943|NCT02687139|Procedure|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
278944|NCT02687152|Other|N-hydroxy-nor-L-arginine|
278945|NCT02687165|Drug|Milnacipran and D-cycloserine|
278946|NCT02687178|Drug|Canrenone 50 vs canrenone 100 mg|
278947|NCT02687191|Biological|PF-05230907|PF-05230907 IV bolus injection
278948|NCT02687204|Drug|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
278345|NCT00201890|Procedure|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
278346|NCT02698488|Procedure|Morphology and Mass Spectroscopy|
278347|NCT02698501|Drug|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
278348|NCT02698501|Drug|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
278349|NCT02698514|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
278350|NCT02698514|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
278351|NCT02700724|Procedure|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
278352|NCT02700737|Other|Image-based simulation modelling|The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as "limited dataset").
278353|NCT02700737|Other|Imaging parameters currently recommended by clinical practice guidelines|The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as "image-based modelling dataset").
278658|NCT02694198|Other|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
278659|NCT02694211|Behavioral|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
278660|NCT00201448|Biological|Hepatitis A Vaccine|Single dose give IM
278661|NCT02694224|Drug|vismodegib|Smo inhibitor
278662|NCT02694224|Drug|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
278663|NCT02694224|Drug|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
278664|NCT02694224|Drug|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
278053|NCT02705001|Other|all admissions except accident and emergency|No additional intervention, retrospective study
278054|NCT02705014|Drug|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
278055|NCT00202813|Device|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
278056|NCT02705027|Device|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
278057|NCT02705040|Other|Normal|bone mineral density T>=-1.0
278058|NCT02705040|Other|Osteopenia|bone mineral density -1.0>T>=-2.5
278059|NCT02705040|Other|Osteoporosis|bone mineral density T<-2.5
278060|NCT02705053|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
278061|NCT02705053|Device|Closed-Loop Control System|The devices that will be used in the Closed-Loop Control System include the following components:
DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)
278062|NCT02705066|Dietary Supplement|Citicoline supplement|
278063|NCT02705066|Dietary Supplement|Placebo supplement|Cellulose
278064|NCT02705079|Other|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
278065|NCT02705092|Other|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
278066|NCT00202826|Procedure|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
278354|NCT00202189|Drug|Budesonide|Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
278355|NCT02700750|Device|OCT exam|OCT exam
278356|NCT02700763|Other|[18F]dabrafenib molecular imaging|A [18F]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
278357|NCT02700776|Other|Phlebotomy - Blood sampling for GP88 at MM|Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
278358|NCT02700776|Procedure|SOC Tissue biopsy|standard of care tissue biopsy if clinically indicated.
277774|NCT00203216|Drug|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
277775|NCT02711020|Behavioral|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
277776|NCT00203450|Drug|Placebo|Placebo pill
277777|NCT02711020|Behavioral|Personal Construct Therapy|Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a "dilemma" and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives.
277778|NCT02711033|Procedure|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
277779|NCT02711033|Procedure|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
277780|NCT02711046|Procedure|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
277781|NCT02711059|Procedure|parathyroidectomy|surgical treatment of hyperparathyroidism
277782|NCT02711072|Drug|control group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
277783|NCT02711072|Drug|infiltration group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
277784|NCT02711085|Other|No intervention|No intervention - observational study
277785|NCT02711098|Biological|Inflammatory biomarkers dosage "Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
277786|NCT02711098|Biological|Inflammatory biomarkers dosage "Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
277787|NCT00203463|Drug|topiramate|
277788|NCT02711111|Device|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
277218|NCT02686398|Biological|Fluad|
277219|NCT02686398|Biological|Agrippal|
277508|NCT02715219|Other|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
277509|NCT00204165|Procedure|MRI of the small bowel|
277510|NCT02717364|Drug|Yervoy|
277511|NCT02717377|Behavioral|physical activity|
277512|NCT02717390|Behavioral|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
277513|NCT02717390|Behavioral|Safe N' Sound (SNS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Safe 'N Sound [SNS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
277514|NCT02717403|Behavioral|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
277515|NCT02717403|Behavioral|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
277516|NCT02717403|Behavioral|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
277517|NCT02717403|Behavioral|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
277518|NCT02717416|Drug|Endo-Clot(TM)|The patients who enrolled this study will undergo endoscopic hemostasis using hemostatic powder, Endo-clot. This is a single arm study.
277519|NCT02717429|Behavioral|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
277520|NCT00204178|Behavioral|Oxidative stress in kidney transplant recipients|
261796|NCT02487654|Procedure|Pulmonary vein isolation|Catheter ablation within the left atrium that electrically disconnects these veins from the rest of the left atrium (pulmonary vein isolation)- Current standard of treatment.
261797|NCT02487654|Procedure|Ganglionic plexi ablation|Catheter ablation around the nerve supplying the heart and destroying the collection of these nerve endings(ganglionic plexi ablation).
262092|NCT02480647|Drug|Levonorgestrel|20μg/day.
262093|NCT02480647|Drug|Etonogestrel|20μg/day.
262094|NCT02480660|Behavioral|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
262095|NCT00176293|Drug|dexamethasone|oral dexamethasone, 12mg BID on days 1, 2, 3, 4, & 5 of each 28-day cycle
262096|NCT02480673|Dietary Supplement|Chia|The subject will eat 25 gr of chia in 2 oatmeal cookies at day
262097|NCT02480673|Dietary Supplement|Oatmeal|The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.
262098|NCT02480673|Behavioral|Normocaloric diet|The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
262099|NCT02480686|Drug|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
262100|NCT02480699|Biological|Recurring blood sample|
262101|NCT02480699|Other|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
262102|NCT02483143|Drug|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
262103|NCT02483156|Drug|single tablet of EHCV containing Sofosbuvir, Ribavirin, and Natural anti-hemolytic|The fixed dose EHCV combinations of SOF (400 mg)/RBV (100 mg)/AH (400 mg) in single tablet. Subjects will take 1 tablet with food for 12-24 weeks
262104|NCT02483156|Drug|Sofosbuvir tablet (SOF)|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
262105|NCT00176527|Biological|recombinant interferon alfa-2b|
261484|NCT02491970|Drug|Fluticasone/Salmeterol|
261485|NCT02491983|Drug|Palbociclib|
261486|NCT02491983|Drug|Letrozole|
261487|NCT02491983|Drug|Fulvestrant|
261488|NCT02491996|Behavioral|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
261798|NCT00176904|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
261799|NCT02487667|Device|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
261800|NCT02487680|Dietary Supplement|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
261801|NCT02487680|Dietary Supplement|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
261802|NCT02487693|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
261803|NCT02487693|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
261804|NCT02487706|Drug|Dolutegravir|Dolutegravir 50mg/day per 5 days
261805|NCT02487719|Drug|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
261806|NCT02487732|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
261807|NCT02487732|Drug|Prasugrel|Prasugrel 10mg once daily for 5 weeks
261808|NCT02487745|Behavioral|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
261809|NCT02489630|Drug|Ketamine|0.1mg/kg ketamine IV
261810|NCT02489630|Drug|Normal Saline|1ml/kg normal saline placebo
261201|NCT02498509|Drug|Mometasone furoate|treatment for 4 weeks after randomization
261202|NCT02498509|Drug|Levocabastine HCL|treatment for 4 weeks after randomization
261203|NCT02498522|Drug|Metformin|83 patients will continue metformin until end of 1st trimester
261204|NCT02498535|Drug|Nitric Oxide 160 ppm|
261205|NCT02498548|Behavioral|Trained SCI Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control, members of this group will be trained at moderate gait speeds,
261206|NCT00178464|Drug|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
261489|NCT02492009|Behavioral|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
261490|NCT00177489|Other|Control arm|Caregivers in the control group received 2 brief "check-in" telephone calls during the 6-month intervention.
261491|NCT02492009|Behavioral|Patient Decision Aid|The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.
261492|NCT02492022|Dietary Supplement|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
261493|NCT02492022|Dietary Supplement|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
261494|NCT02492022|Other|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
261495|NCT02492035|Behavioral|Lifestyle intervention|
261496|NCT02492048|Device|Cellutome Epidermal Harvesting System|
261497|NCT02492048|Procedure|Split Thickness Skin Graft|
261498|NCT02492061|Behavioral|Demand creation for couples' HCT|The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
261499|NCT02492074|Drug|Delta-9-tetrahydrocannabinol|
261500|NCT02492074|Drug|Cannabidiol|
260924|NCT02467114|Other|Control without stimulation|
260925|NCT02467127|Dietary Supplement|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
260926|NCT02467140|Device|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
260927|NCT02467140|Device|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
260928|NCT02469285|Dietary Supplement|Pork and berries|Pork with normal fat composition and Finnish berries
260929|NCT00174772|Drug|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
260930|NCT02469298|Drug|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
260931|NCT02469298|Drug|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
260932|NCT02469298|Drug|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
260933|NCT02469298|Drug|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
261207|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
261208|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
261209|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
261210|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
261211|NCT02498574|Device|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
261212|NCT02498574|Behavioral|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
261213|NCT02498600|Biological|Ipilimumab|Given IV
260637|NCT02473549|Device|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
260638|NCT02473562|Drug|Varenicline|Tablet 1 mg BID
260639|NCT02473562|Drug|Placebo (for varenicline)|Tablet 1 mg BID
260640|NCT00175253|Procedure|islet transplant|
260641|NCT02473575|Dietary Supplement|caffeine gum|Gum is consumed 30 minutes before commencement of run
260642|NCT02473575|Dietary Supplement|placebo gum|Gum is consumed 30 minutes before commencement of run
260643|NCT02473588|Device|Retia Medical Long Time Interval Analysis|Retia Medical "Long Time Interval Analysis" will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter
260644|NCT02473601|Drug|Mivacurium Chloride|Anesthesia induction:
Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.
Anesthesia maintenance:
Two groups of sevoflurance 1%~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 ~ 60. PetCO2 was 30 ~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane.
260645|NCT02473614|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
260646|NCT02473614|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
260647|NCT02473627|Drug|DS-1971a|200mg tablet
260648|NCT02473627|Drug|midazolam hydrochloride|2.5mg oromucosal liquid
260649|NCT02473627|Drug|Omeprazole|20mg gastro-resistant capsule
260650|NCT02473627|Drug|Pioglitazone hydrochloride|15mg tablet
260651|NCT00175266|Drug|alemtuzumab|
260652|NCT02473627|Drug|Buproprion|150mg Prolonged release tablet
260653|NCT02475759|Dietary Supplement|optimal caloric formula|nutritional intervention received two weeks before surgical intervention
260654|NCT02475759|Dietary Supplement|sub-optimal caloric formula|nutritional intervention received one weeks before surgical intervention
260086|NCT02484599|Behavioral|Computerized attention training (CAT)|Three sessions of active computerized attention training.
260087|NCT00176670|Drug|midazolam or GameBoy or parental presence|
260088|NCT02484599|Behavioral|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
260380|NCT02479841|Other|Self management program|
260381|NCT02479854|Drug|Asmakast|1 chewable tablet contains 5 mg montelukast
260382|NCT02479854|Drug|Singulair|1 chewable tablet contains 5 mg montelukast
260383|NCT02479867|Drug|Cefadroxil|1 tablet from test vs 1 tablet from reference
260384|NCT02479880|Drug|Tenofovir DF|Tenofovir DF 300 mg tablet administered orally once daily for up to 96 weeks
260385|NCT02479880|Radiation|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
260386|NCT02479893|Procedure|polypectomy|Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
260387|NCT02479906|Device|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
260388|NCT02479906|Device|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
260389|NCT00176241|Drug|paclitaxel|150 mg/m2 IV on days 1 & 15
260390|NCT02479919|Device|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
260391|NCT02479919|Device|Magstim® Sham TBS|Sham stimulation
260392|NCT02479932|Other|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
260393|NCT02479932|Other|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
260394|NCT02479945|Other|Obtaining biospecimen|
260395|NCT02479958|Procedure|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
260396|NCT02479958|Procedure|Tooth drying|The tooth was dried with air jet.
276742|NCT02710734|Drug|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
276743|NCT00203411|Drug|Capecitabine (Xeloda)|1000mg/m2 administered orally twice daily for two weeks followed by one week rest period
276744|NCT02710734|Drug|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
276745|NCT02710734|Drug|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
276746|NCT02710734|Radiation|Intensity modulated radiation therapy|
276747|NCT02710734|Procedure|Maximal Transurethral Resection|Performed at baseline, after chemotherapy, and after chemoradiation
276748|NCT02710734|Drug|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 of radiation
276749|NCT02710734|Drug|Mitomycin C|Intravenous on day 1 of radiation
277042|NCT02704611|Device|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
277043|NCT02706808|Dietary Supplement|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
277044|NCT02706808|Dietary Supplement|cross-over period|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
277045|NCT02706821|Dietary Supplement|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
277046|NCT02706821|Dietary Supplement|Placebo|Placebo, crossover design
277047|NCT02706834|Drug|Group A1= TAK-828 0.1 mg+TAK-828 3 mg +TAK-828 20 mg +Placebo|TAK-828 oral solution, fasted.
277048|NCT02706834|Drug|Group B1= TAK-828 0.1 mg+TAK-828 3 mg+Placebo+TAK-828 100 mg|TAK-828 oral solution, fasted.
277049|NCT00202930|Drug|anti-CD20 (Rituximab)|
277050|NCT02706834|Drug|Group C1= TAK-828 0.1 mg+Placebo+TAK-828 20 mg+TAK-828 100 mg|TAK-828 oral solution, fasted.
277051|NCT02706834|Drug|Group D1= Placebo+TAK-828 3 mg+TAK-828 20 mg+TAK-828 100 mg|TAK-828 oral solution, fasted.
277052|NCT02706834|Drug|Group A2: TAK-828 0.5 mg+TAK-828 10 mg+TAK-828 40 mg+Placebo|TAK-828 oral solution, fasted.
276417|NCT02714673|Drug|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
276418|NCT02714686|Behavioral|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
276419|NCT02714699|Drug|diclofenac potassium|patients will take oral diclofenac potassium; one tablet (cataflam 50 mg) and one tablet placebo 30 minutes before the procedure
276420|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
276421|NCT02714699|Drug|hyoscine butyl bromide|patients will take oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
276422|NCT02714699|Drug|placebo|patients will take oral placebo; 2 tablets 30 minutes before the procedure
276423|NCT02714712|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
276424|NCT02714725|Drug|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion ranged from 0.1-0.7 mcg/kg/hr
276425|NCT02714725|Drug|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
276426|NCT02714725|Drug|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
276427|NCT02714738|Procedure|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
276428|NCT02714751|Behavioral|Daily asynchronies information|
276429|NCT02716909|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
276430|NCT02716922|Procedure|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
276750|NCT02710747|Genetic|CYP2C9;VKORC1|
276751|NCT02712671|Procedure|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
276752|NCT02712671|Other|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
275825|NCT00200954|Dietary Supplement|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
276114|NCT02685787|Behavioral|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
276115|NCT00200356|Drug|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
276116|NCT02685787|Behavioral|Educational Intervention on AD|The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.
Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions.
276117|NCT02685826|Drug|Durvalumab|
276118|NCT02685826|Drug|Lenalidomide|
276119|NCT02685826|Drug|Dexamethasone|
276120|NCT02685839|Device|Intelligent POWER Rehabilitation Cluster Machine|
276121|NCT02685839|Other|general physical therapy|
276122|NCT02685852|Drug|Exenatide|Exenatide at a dose of 5 mcg
276123|NCT02685852|Drug|Acarbose|Acarbose at a dose of 25 mg
276124|NCT02685852|Drug|Placebo|Placebo
276125|NCT02685865|Device|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
276126|NCT00200369|Device|MEMS cap|
276127|NCT02685865|Device|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
276128|NCT02685891|Other|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
276129|NCT02685891|Other|sham condition|in the sham condition, no tones will be played
276130|NCT02685904|Biological|ENIA11|
276131|NCT02685904|Biological|Placebo|
275257|NCT02701647|Device|repetitive transcranial magnetic stimulation|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric filed in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim 200 magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
275541|NCT02695277|Device|Repeated Endocardial ablation(s)|
275542|NCT02695290|Drug|Afatinib|
275543|NCT02695303|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
275544|NCT00201630|Drug|Uroxatrol (drug)|
275545|NCT02695316|Other|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
275546|NCT02695316|Other|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
275547|NCT02697227|Drug|Nicotine Patch|Participants receive 8 weeks of 21 mg NRT patch therapy. Therapy initiated on the scheduled quit day (just prior to Visit 4). Patch dispensation occurs at visit 3 and visit 8.
275548|NCT02697227|Behavioral|Cotinine Level Testing|Saliva collected to check Cotinine level at Visits 1,9, and 10.
275549|NCT00201773|Other|Correlative studies|
275550|NCT02697227|Procedure|Lab Session|Participants take part in a lab session at or before Visit 1 to test brain activity. Participants asked to watch a series of slides.
During the lab session, participant's brain electrical activity checked with an electroencephalogram (EEG).
Participant to complete computer tasks, including questionnaires that measure emotions and attention level.
Lab session may last up to 2 hours total.
275551|NCT02697240|Drug|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
275552|NCT02697253|Drug|Exendin 9-39|Infusion of exendin 9 at the rate of 600 pmol/kg/min, infusion time 60 minutes. An average of 12.1 ml will be infused in a forearm vein during an oral glucose (50 g) preload.
275553|NCT02697253|Drug|Placebo|Infusion of 0.9% saline solution for 60 minutes. An average of 12.1 ml will be infused in a forearm vein during an oral glucose (50 g) preload.
275554|NCT02697266|Other|No intervention|This is an observational study.
275555|NCT02697279|Procedure|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I&D technique with or without packing utilizing a standard I&D kit.
275556|NCT02697279|Procedure|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I&D kit and the cuff of a sterile glove for a loop device.
274684|NCT02710097|Drug|Active inhaled cannabis|~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or "joint". Administered over 20 minutes via a vaporizer.
274685|NCT02711878|Behavioral|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
274686|NCT02711878|Behavioral|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
274978|NCT02705976|Other|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
274979|NCT02705989|Drug|BMS-986195|Specified dose on specified day
274980|NCT02705989|Other|Placebo|Specified dose on specified day
274981|NCT02706002|Device|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
274982|NCT02706002|Procedure|hip prosthesis|all patients in the study will undergo hip prosthesis
274983|NCT02706015|Drug|Cefaliv® (Dihydroergotamine mesylate+ dipyrone sodium + caffeine)|The subject must manage 02 tablets of Cefaliv®+ 02 placebo tablets right after a light to moderate migraine.
274984|NCT02706015|Drug|Neosaldina® (Isometheptene mucate + dipyrone sodium + anhydrous caffeine)|The subject must manage 02 Neosaldina® tablets + 02 placebo tablets right after a light to moderate migraine.
274985|NCT02706015|Drug|Placebo|
274986|NCT02706028|Device|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
274987|NCT00202878|Drug|Placebo for simvastatin 40 mg|one or two tablets orally daily
274988|NCT02706028|Device|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
274989|NCT02706041|Procedure|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
274990|NCT02706041|Procedure|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
274991|NCT02706054|Other|saline|The patients received an IM injection of saline near the nerve root (periradicular)
278949|NCT02687204|Drug|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
278950|NCT02687217|Drug|oxygen|Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
278951|NCT02687230|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
278952|NCT02689388|Other|Femoral Nerve Block|Use of femoral nerve block as part of general anaesthesai
278953|NCT02689401|Drug|Ferumoxytol|
278954|NCT00200863|Device|Monochromatic visible light exposure|Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
278955|NCT02689401|Device|MRI 3T scanner|
274400|NCT00203996|Procedure|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
274401|NCT02715999|Procedure|Transversus Abdominis Plane Block|0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
274402|NCT02716012|Drug|MTL-CEBPA|Intravenous administration into a vein (peripheral or central) on day 1, 8 and 15 of each 28-day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
274403|NCT02716025|Procedure|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
274404|NCT02716038|Drug|MPDL3280A|MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
274405|NCT02716038|Drug|Carboplatin|Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin AUC=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
274406|NCT02716038|Drug|Nab-paclitaxel|Nab-paclitaxel is a Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
274407|NCT02716051|Device|MRI|Whole body MRI with cardiac and pulmonary synchronization
274408|NCT02716051|Device|PET|
278665|NCT02694237|Behavioral|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
278666|NCT02694237|Behavioral|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
278667|NCT02694237|Behavioral|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
278668|NCT02694250|Device|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
278669|NCT02694263|Drug|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
278670|NCT02694263|Drug|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
278671|NCT00201448|Biological|Towne CMV Vaccine|Single dose given subcutaneously
278672|NCT02694263|Drug|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
278673|NCT02694263|Drug|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
278674|NCT02694263|Drug|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
278956|NCT02689414|Procedure|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
278957|NCT02689414|Procedure|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
278958|NCT02689427|Drug|Enzalutamide|160 mg by mouth every day for 12 study cycles. Each cycle is 7 days (1 week).
278959|NCT02689427|Drug|Paclitaxel|80 mg/m^2 by vein on Day 1 of each 7 day cycle.
278960|NCT02689440|Drug|Dasatinib|50 mg by mouth once daily.
278961|NCT02689453|Biological|IL-15 plus alemtuzumab|rhIL-15 by s.c. injection Monday-Friday over two weeks; followed by alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
278962|NCT02689479|Procedure|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
278359|NCT02700789|Procedure|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
278360|NCT02700802|Other|Feed1st+|Informal caregivers suffering from household food insecurity will be connected to a community health information specialist to help access food and other resources in their community to meet their health and social needs. Informal caregivers will be recruited within 48 hours of their child's hospital admission.
278361|NCT02700815|Drug|Diclofenac|
278362|NCT02700815|Drug|Capsaicin|
278363|NCT02700815|Drug|Placebo|
278364|NCT02700828|Drug|Hydrocortisone|4 * 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
278365|NCT00202202|Procedure|consultation format|
278366|NCT02700828|Drug|Placebo|4 * 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
278367|NCT02700841|Other|Laboratory Biomarker Analysis|Correlative studies
278368|NCT02700841|Drug|Melphalan|Given IV
278369|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
278370|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
278371|NCT02700841|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
278372|NCT02700841|Biological|Tetanus Toxoid Vaccine|Given IM
278373|NCT02700841|Biological|Therapeutic Autologous Lymphocytes|Via infusion
278374|NCT02700841|Biological|Trivalent Influenza Vaccine|Given IM
278375|NCT02700841|Biological|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|Given SC
278376|NCT00202215|Behavioral|Chrysalis Day Program|
278675|NCT02694276|Behavioral|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
277789|NCT02711111|Device|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
278067|NCT02707107|Drug|Intravenous infusions of WCK 5222|
278068|NCT02707107|Drug|Placebo|
278069|NCT02707120|Drug|PRGF-Endoret|
278070|NCT02707120|Drug|Artificial tears eye-drops|
278071|NCT02707133|Other|No intervention|
278072|NCT00202982|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
278073|NCT02707146|Behavioral|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
278074|NCT02707146|Other|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
278075|NCT02707146|Device|iPad|
278076|NCT02707159|Drug|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
278077|NCT02707172|Behavioral|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
278078|NCT02707172|Behavioral|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
278079|NCT02707185|Behavioral|Simulation-Based Training|An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
278080|NCT02707198|Drug|kefir|4 ounces of kefir 3 times a day, with or without food.
278081|NCT02707211|Biological|Anti-oxLDL IgM antibody|Immunization
278082|NCT02707224|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
278083|NCT00202982|Drug|glatiramer acetate 40 mg|glatiramer acetate 40 mg
278084|NCT02707224|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
278085|NCT02707224|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
278086|NCT02707237|Other|Verbal counseling|Verbal counseling done by physician
277521|NCT02717429|Behavioral|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
277522|NCT02717442|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
277523|NCT02717442|Drug|Placebo|Single intratympanic injection of placebo
277790|NCT02711137|Drug|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts.
277791|NCT02711150|Device|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
277792|NCT02711163|Dietary Supplement|Extensively Hydrolyzed formula|
277793|NCT02711163|Dietary Supplement|Amino acid formula|
277794|NCT02713074|Drug|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
277795|NCT02713074|Drug|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
277796|NCT02713087|Behavioral|Ephedrine or Phenylephrine|
277797|NCT02713100|Behavioral|level of agitation|psychological pain
277798|NCT02713113|Drug|sugammadex reversal of neuromuscular blockade|
277799|NCT02713126|Drug|Placebo Solution|Placebo solution (normal saline), administered by inhalation over 10-15 minutes using a nebulizer, taken every 4 hours or 3 times per day during waking hours for 12 weeks
277800|NCT02713126|Drug|Sodium Nitrite Inhalation Solution|Sodium Nitrite Inhalation Solution, 80 mg administered by inhalation over 10-15 minutes using a nebulizer, taken every 4 hours or 3 times per day during waking hours for 12 weeks
277801|NCT02713126|Device|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
277802|NCT02713126|Other|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
277803|NCT02713139|Drug|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
277804|NCT00203710|Device|Concentric Retriever Device|
262106|NCT02483156|Drug|Ribavirin (RBV)|RBV (1000 mg.) orally once daily in the morning with SOF and with food for 12-24 weeks.
262107|NCT02483169|Drug|cilostazol|Cilostazol 100mg bid
262108|NCT02483169|Drug|Probucol|Probucol 250mg bid
262109|NCT02483169|Drug|Aspirin|Aspirin 100mg qd
262110|NCT02483169|Drug|placebo of cilostazol|same shape and size of active cilostazol
262406|NCT02476435|Device|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
262407|NCT02476448|Drug|Normal saline|Used to distend the bladder for cystoscopic evaluation
262408|NCT02476448|Drug|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
262409|NCT02476448|Drug|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
262410|NCT02476448|Drug|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
262411|NCT02476461|Drug|xiapex|
262412|NCT02476461|Procedure|percutaneous needle fasciotomy|
262413|NCT02476474|Procedure|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
262414|NCT02476474|Procedure|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
262415|NCT02478528|Device|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
262416|NCT02478528|Device|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
262417|NCT02478528|Other|control condition|No exposure of the subject to any light sources (control condition)
262418|NCT02478541|Other|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
262419|NCT00176007|Procedure|Hypoxia|
262420|NCT02478554|Other|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
262421|NCT02478567|Other|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
261811|NCT02489630|Drug|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
261812|NCT00177203|Behavioral|Brief Behavioral Treatment of Insomnia or Information|The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.
In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information.
261813|NCT02489643|Procedure|Individualized practical training|
261814|NCT02489656|Device|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
262111|NCT02483169|Drug|Placebo of aspirin|same size and shape of active aspirin 100mg
262112|NCT02483169|Device|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
262113|NCT02483182|Drug|ZEP-3 ointment 1.0%|
262114|NCT02483182|Drug|Acyclovir cream 5%|
262115|NCT02483195|Drug|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
262116|NCT00176527|Drug|docetaxel|
262117|NCT02483195|Drug|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
262118|NCT02483195|Drug|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
262119|NCT02483195|Other|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
262120|NCT02483208|Drug|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
262121|NCT02483208|Drug|Advate|Advate infusion to analyze pharmacokinetics.
262122|NCT02483221|Drug|Hydromorphone|Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
262123|NCT02483221|Drug|Morphine|Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
262124|NCT02483234|Drug|secukinumab|
261501|NCT00177502|Behavioral|behavioral exercise intervention|
261502|NCT02492074|Drug|Placebo|
261503|NCT02492087|Drug|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
261504|NCT02494388|Procedure|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
261505|NCT02494401|Other|Internet-based self-management program|
261506|NCT02494401|Other|Scleroderma book|
261507|NCT02494414|Other|Long-term follow-up|Vital and neurological follow-up
261508|NCT00177762|Behavioral|behavior weight loss|
261815|NCT02489669|Device|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
261816|NCT02489682|Other|Long-form written Informed consent information|
261817|NCT02489682|Other|Short-form written Informed consent information|
261818|NCT02489682|Other|Video Informed consent information|
261819|NCT02489695|Drug|axitinib|
261820|NCT02489708|Behavioral|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
261821|NCT02489721|Device|PICC and Midline|Peripherally inserted central venous catheter
261822|NCT02489734|Drug|sevoflurane|extubation when end-tidal concentration of sevoflurane < 0.5%
261823|NCT00177216|Drug|Escitalopram|Antidepressant, escitalopram, treatment for insomnia
261824|NCT02489734|Drug|Sevoflurane|extubation when end-tidal concentration of sevoflurane >= 0.5%
261825|NCT02489747|Dietary Supplement|WBE|wheat bran extract (3 g/day)
261214|NCT02498600|Other|Laboratory Biomarker Analysis|Correlative studies
261215|NCT02498600|Biological|Nivolumab|Given IV
261216|NCT02498613|Other|18F-Fluoromisonidazole|Correlative studies
261217|NCT00178477|Procedure|MRI with breath-holding|Breath holding for diminished tumor motion.
261218|NCT02498613|Drug|Cediranib Maleate|Given PO
261219|NCT02498613|Other|Laboratory Biomarker Analysis|Correlative studies
261220|NCT02498613|Drug|Olaparib|Given PO
261221|NCT02498613|Procedure|Positron Emission Tomography|Correlative studies
261222|NCT02498626|Other|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
261223|NCT02500758|Procedure|Preoperative surgical scrubbing|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
261224|NCT00178763|Other|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
261509|NCT02494427|Device|CAD/CAM manufactured fixed unitary dental prostheses|
261510|NCT02494427|Device|Conventionally manufactured unitary dental prostheses|
261511|NCT02494453|Procedure|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this observational study, treatment will not be altered based on the data collected from these MRIs.
260655|NCT02475772|Drug|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
260934|NCT02469311|Other|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
260935|NCT02469311|Other|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
260936|NCT02469324|Behavioral|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
260937|NCT02469324|Behavioral|Compassionate Mind Training|see above
260938|NCT02469337|Drug|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
260939|NCT02469337|Dietary Supplement|Carbohydrate drinks|preoperative carbohydrate drinks
260940|NCT00174785|Drug|dronedarone (SR33589)|oral administration (tablets)
260941|NCT02469337|Behavioral|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
260942|NCT02469350|Other|Serious game|Rehabilitation with serious game
260943|NCT02469363|Device|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
260944|NCT02469363|Device|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
260945|NCT02469363|Device|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
260946|NCT02469363|Device|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
260947|NCT02469376|Drug|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
260948|NCT02471768|Procedure|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
260397|NCT02479958|Procedure|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
260398|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
260656|NCT00175565|Drug|inhaled fluticasone 500 mcg b.i.d.|
260657|NCT02475772|Procedure|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
260658|NCT02475785|Device|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
260659|NCT02475785|Device|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
260660|NCT02475798|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
260661|NCT02475811|Radiation|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
260662|NCT02475824|Drug|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
260663|NCT02475824|Drug|"Meperidine" (pethidine®)|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
260664|NCT02475824|Drug|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
260665|NCT02475824|Drug|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
260666|NCT02475837|Drug|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
260667|NCT00175591|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
260668|NCT02475837|Drug|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
260669|NCT02475850|Other|Evidence-based tailored fall prevention|
277053|NCT02706834|Drug|Group B2: TAK-828 0.5 mg+TAK-828 10 mg+Placebo+TAK-828 200 mg|TAK-828 oral solution, fasted.
277054|NCT02706834|Drug|Group C2: TAK-828 0.5 mg+Placebo+TAK-828 40 mg+TAK-828 200 mg|TAK-828 oral solution, fasted.
277055|NCT02706834|Drug|Group D2: Placebo+TAK-828 10 mg+TAK-828 40 mg+TAK-828 200 mg|TAK-828 oral solution, fasted.
277056|NCT02706834|Drug|Group A3: TAK-828 3 mg +TAK-828 20 mg +Placebo|TAK-828 oral solution, fasted.
277057|NCT02706834|Drug|Group B3: TAK-828 3 mg+Placebo+TAK-828 100 mg|TAK-828 oral solution, fasted.
277058|NCT02706834|Drug|Group C3: Placebo+TAK-828 20 mg+TAK-828 100 mg|TAK-828 oral solution, fasted.
277059|NCT02706847|Drug|ABT-494|ABT-494 oral tablet
277060|NCT00202943|Procedure|TCRFVR and LAUP|
277061|NCT02706847|Drug|Placebo|Oral tablet
277062|NCT02706860|Drug|Atorvastatin|
277063|NCT02706873|Drug|ABT-494|Oral Tablet
277350|NCT02700386|Radiation|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
277351|NCT02702362|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
277352|NCT02702375|Other|Fructose-containing Sugars|
277353|NCT02702388|Drug|Lenvatinib|
277354|NCT02702388|Drug|Lenvatinib matching placebo|
277355|NCT02702401|Biological|Pembrolizumab|IV infusion
277356|NCT02702401|Drug|Placebo|0.90% w/v sodium chloride IV infusion
277357|NCT02702401|Other|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
277358|NCT00202436|Procedure|Phlebotomy|Removal of 500 ml whole blood
277359|NCT02702414|Biological|Pembrolizumab|
277360|NCT02702427|Biological|virus-specific T-Cells|infusion
276753|NCT02712671|Procedure|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
276754|NCT02712684|Procedure|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
276755|NCT02712697|Drug|WM (Shentong Granules)|Shentong Granules with Prednisone
276756|NCT00203619|Device|Wireless capsule endoscopy|wire less capsule endoscopy
276757|NCT02712697|Drug|Hormone (prednisone)|Oral prednisone
276758|NCT02712710|Device|functional knee brace|The functional knee brace for OA can decrease abnormal varus torque by external force.
276759|NCT02712723|Drug|Letrozole|Nonsteroidal aromatase inhibitor
276760|NCT02712723|Drug|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
276761|NCT02712723|Drug|Placebo|Placebo for ribociclib
276762|NCT02712736|Other|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
276763|NCT02712749|Device|Sound with Binaural Beats|Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
276764|NCT02712749|Device|Sound without Binaural Beats|Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
276765|NCT02712762|Other|Cross-sectional study|
276766|NCT02712775|Drug|Minocycline (yes/no)|
276767|NCT00203619|Other|standard care|standard diagnostic evaluation as decided by treating physician
276768|NCT02712775|Drug|Placebo|Saline
277064|NCT02706873|Drug|Methotrexate|Oral capsule
277065|NCT02706873|Drug|ABT-494 matching placebo|Oral tablet
277066|NCT02706873|Drug|Methotrexate matching placebo|Oral capsule
276132|NCT02685917|Procedure|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
276133|NCT02685917|Procedure|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
276431|NCT02716935|Dietary Supplement|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
276432|NCT02716935|Dietary Supplement|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
276433|NCT02716948|Other|Laboratory Biomarker Analysis|Correlative studies
276434|NCT00204113|Device|Multi-purpose rehabilitation frame|
276435|NCT02716948|Biological|Nivolumab|Given IV
276436|NCT02716948|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
276437|NCT02716961|Drug|Gemcitabine, cisplatin|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
276438|NCT02716974|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
276439|NCT02716974|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
276440|NCT02716974|Drug|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
276441|NCT02716974|Procedure|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
276442|NCT02716974|Radiation|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
276443|NCT02716987|Drug|TAK-831|TAK-831 Suspension
276444|NCT02716987|Drug|[18F]PGM299|[18F]PGM299 Injection
276445|NCT00204113|Device|Surface Functional Electrical Stimulation|
276446|NCT02717013|Dietary Supplement|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
276447|NCT02717013|Dietary Supplement|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
276448|NCT02717026|Device|Optical coherence tomography|Sections including the retinal vasculature will be taken.
275557|NCT02697292|Drug|Intravenous Immunoglobulin|GAMUNEX-C is the brand name for Intravenous Immunoglobulin, and is clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration.
275558|NCT02697292|Drug|Placebo/Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents.
275559|NCT02697305|Dietary Supplement|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
275826|NCT02690493|Other|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
275827|NCT02690506|Drug|Placebo|
275828|NCT02690506|Drug|Pregabalin|
275829|NCT02693002|Drug|Placebo|inactive ingredient
275830|NCT02693028|Drug|Probiotic lozenges|The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
275831|NCT02693028|Drug|Placebo lozenges|The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
275832|NCT02693028|Drug|Probiotic capsules|The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
275833|NCT02693028|Drug|Placebo capsules|The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
275834|NCT02693028|Drug|Probiotic chewing gum|The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
275835|NCT02693041|Drug|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
275836|NCT02693041|Drug|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
275837|NCT02693054|Device|HALO|Laser Treatment
275838|NCT02693067|Drug|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
275839|NCT00201279|Drug|13-cis Retino Acid|
274992|NCT02706054|Drug|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
274993|NCT02706067|Drug|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent [%] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
274994|NCT02707965|Drug|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
274995|NCT00203060|Drug|placebo|tablet, once daily, 58 weeks
275258|NCT02701647|Other|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Maximum achieved speed will be maintained followed by 0.5 km/h decrements. Participants will maintain the rest of the treadmill session with this speed or further adjustment will be made if participants are unable to maintain. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
275259|NCT02701660|Device|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
275260|NCT02701673|Drug|Busulfan|Busulfan "test dose" administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
275261|NCT02701673|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
275262|NCT02701673|Drug|Glutamine|Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
275263|NCT02701673|Drug|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
275264|NCT02701673|Drug|Belinostat|Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
275265|NCT02703727|Behavioral|Extended polymedication check|Behavioral: Medication review
Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps
The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.
As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.
275266|NCT02703740|Device|Hyaluronic acid dermal filler with lidocaine 0.3%|
274409|NCT02716064|Behavioral|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
274410|NCT02716077|Radiation|FDG PET/CT imaging|
274411|NCT00204009|Behavioral|Disease Surveillance, Family Studies, Questionnaire Followup|
274412|NCT02716090|Drug|Adapalene and Benzoyl peroxide Dalap Duo®|
274413|NCT02716090|Drug|Adapalene and Benzoyl peroxide Epiduo®|
274414|NCT02716103|Other|blood collection|
274415|NCT02716103|Other|bone marrow collection|
274416|NCT02716116|Drug|AP32788|AP32788 capsules
274417|NCT02716129|Drug|Morphine|35 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
274687|NCT02711891|Drug|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
274688|NCT02711891|Drug|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
274689|NCT02711904|Drug|Extubation U|Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:
20 years old - 6.0 mcg/Kg/h
30 years old - 5.7 mcg/Kg/h
40 years old - 5.3 mcg/kg/h
50 years old - 5.0 mcg/kg/h
60 years old - 4.6 mcg/kg/h
70 years old - 4.3 mcg/kg/h
80 years old - 4.0 mcg kg/h.
274690|NCT02711904|Drug|Extubation T|Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:
The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.
The remifentanil dose was adjusted according to the randomization:
20 years old - 9.0 mcg/Kg/h
30 years old - 8.5 mcg/Kg/h
40 years old - 8.0 mcg/kg/h
50 years old - 7.5 mcg/kg/h
60 years old - 7.0 mcg/kg/h
70 years old - 6.5 mcg/kg/h
80 years old - 6.0 mcg kg/h.
274691|NCT02711917|Drug|MAC 0.5|0.5 MAC Sevoflurane
274692|NCT00203554|Genetic|Poly methylmetacrylate, PMMA|
274693|NCT02711917|Drug|MAC 0.75|0.75 MAC Sevoflurane
278963|NCT02689479|Biological|11C-5-HTP|150-400 MBq [11C]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
278964|NCT02689479|Procedure|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
278965|NCT00200876|Drug|Hypertonic saline|
278966|NCT02689479|Procedure|Mixed-Meal Tolerance Test (MMTT)|
278967|NCT02689479|Procedure|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
278968|NCT02689479|Procedure|Glomerular Filtration Rate Testing|
278969|NCT02689479|Procedure|Blood draw|
278970|NCT02689505|Drug|BI 836880|
278971|NCT02689518|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
278972|NCT02689544|Other|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
278973|NCT02689544|Other|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
278974|NCT02689544|Other|Control|The control group volunteers no received intervention
274418|NCT02716129|Drug|Morphine plus Nalbuphine|35 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
274419|NCT00204334|Drug|darbopoeitin|
274420|NCT02718287|Behavioral|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
274421|NCT02718300|Drug|INCB050465|Up to 3 oral once a day (QD) doses of INCB050465.
274422|NCT02718300|Drug|INCB050465|Two recommended oral QD doses of INCB050465.
274423|NCT02718300|Drug|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of INCB050465.
278676|NCT02696460|Procedure|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
278677|NCT02696473|Dietary Supplement|Carrot|
278678|NCT02696486|Behavioral|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
278679|NCT02696499|Drug|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
278680|NCT02696499|Drug|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
278681|NCT02696512|Drug|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
278682|NCT00201721|Drug|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
278683|NCT02696512|Device|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
278684|NCT02696512|Dietary Supplement|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
278685|NCT02696512|Other|Standard of Care|Standard of Care treatment
278686|NCT02696538|Other|Functional Gait Assessment|Balance assessment
278687|NCT02696538|Other|mini-Balance Evaluation Systems Test|Balance assessment
278688|NCT02696538|Other|Berg Balance Scale|Balance assessment
278689|NCT02696551|Other|Medical education|
278690|NCT02696564|Drug|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
278691|NCT02696564|Drug|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
278692|NCT02696577|Drug|Low dose aspirin|
278975|NCT02691897|Drug|Melatonin|Melatonin 3mg once daily at bedtime
278976|NCT02691897|Drug|Placebo|Placebo 1 tablet once daily at bedtime
278087|NCT02707237|Other|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
278088|NCT02707250|Drug|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
278089|NCT02707250|Drug|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
278377|NCT00202475|Procedure|eythrocytapheresis|machinal collection of erythrocytes
278378|NCT02702817|Drug|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
278379|NCT02702830|Other|Cardiopulmonary Exercise Testing|Undergo CPET
278380|NCT02702830|Procedure|Magnetic Resonance Imaging|Undergo MRI
278381|NCT02702843|Procedure|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
278382|NCT02702843|Procedure|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
278383|NCT02702856|Other|ExoIntelliScore Prostate|
278384|NCT02702869|Procedure|cleft lip repair|
278385|NCT02702869|Procedure|cleft palate repair|
278386|NCT02702869|Procedure|oronasal fistula repair|
278387|NCT02702869|Procedure|pharyngoplasty|
278388|NCT00202475|Procedure|whole blood collection|collection of whole blood
278389|NCT02702869|Procedure|gingivoperiosteoplasty|
278390|NCT02702869|Procedure|LeFort-1 maxillary repositioning|
278391|NCT02702869|Procedure|rhinoplasty|
278392|NCT02702869|Procedure|myringotomy and tympanostomy tube placement|
278393|NCT02702869|Other|speech therapy|
278394|NCT02702869|Procedure|orthodontia|
278395|NCT02702869|Procedure|presurgical orthopedics|
278396|NCT02702882|Dietary Supplement|Fenugreek Seeds Extract|Furosap one caps OD
277805|NCT02713139|Drug|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
277806|NCT02713139|Drug|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
277807|NCT02713165|Other|Raisins|Participants will consume 84g of raisins per day for 14 days.
277808|NCT02713178|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
277809|NCT02713178|Drug|Placebo|Normal saline.
277810|NCT02713191|Drug|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
278090|NCT02707250|Drug|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
278091|NCT02707250|Drug|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
278092|NCT02707263|Drug|intravenous continuous infusion of heparin (IV UFH)|
278093|NCT02707263|Drug|Subcutaneous Heparin|
278094|NCT00202995|Drug|Glatiramer Acetate|20 mg s.c. daily
278095|NCT02709109|Drug|Placebo|
278096|NCT02709109|Drug|Orkambi|
278097|NCT02709122|Device|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
278098|NCT02709148|Device|Activa PC+S|DBS
278099|NCT02709161|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
278100|NCT02709161|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
278101|NCT02709174|Procedure|blood draw|blood draw
278102|NCT02709187|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
278103|NCT02709187|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
262422|NCT02478567|Other|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
262423|NCT02478580|Drug|Nuvigil|Patients will receive Nuvigil before the surgery
262424|NCT02478580|Drug|Placebo|Placebo will be given before surgery
262425|NCT02478593|Behavioral|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
262698|NCT00175084|Behavioral|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
262699|NCT02472483|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
262700|NCT02472509|Drug|Ursodeoxycholic Acid|Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.
Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose.
262701|NCT02474394|Device|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
262702|NCT00175370|Drug|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
262703|NCT02474407|Drug|diazepam nasal spray|
262704|NCT02474407|Drug|diazepam rectal gel|
262705|NCT02474420|Drug|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
262706|NCT02474420|Drug|Deferasirox|Deferasirox administered per standard of care by the treating physician
262707|NCT02474433|Drug|Misoprostol (Cytotec)|
262708|NCT02474446|Dietary Supplement|Vitamin D|150,000 IU of Vitamin D3 Oral solution
262125|NCT02483247|Drug|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
262126|NCT02483247|Drug|Capecitabine|Capecitabine 1000 mg/m^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
262127|NCT02485392|Device|Da Vinci Single Site Robot-Assisted Cholecystectomy|
262128|NCT02485392|Device|Single Incision Laparoscopic Cholecystectomy|
262129|NCT02485405|Other|Trier social stress test|Volunteers perform Trier social stress test
262130|NCT02485418|Drug|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 20 minutes, followed by an increase to 30 mcg/kg/min for 20 minutes and then by an increase to 40 mcg/kg/min for 20 minutes.
262131|NCT02485431|Drug|Deflazacort|
262132|NCT02485444|Drug|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
262426|NCT02478606|Other|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
262427|NCT02478619|Other|IMT group|Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.
They will also receive the routine physical therapy in the post operative period.
262428|NCT02478619|Other|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
262429|NCT02478632|Drug|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
262430|NCT00176020|Drug|nicotinic acid|
262431|NCT02478645|Drug|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
262432|NCT02478645|Drug|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
262433|NCT02478645|Drug|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
262434|NCT02478658|Other|exercise training|high-intensity resistance training
262435|NCT02478671|Device|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
261826|NCT02489747|Dietary Supplement|Placebo|Placebo
261827|NCT02489760|Biological|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
261828|NCT02489760|Biological|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
261829|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except friday|
261830|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except thursday and friday|
261831|NCT02489786|Drug|patients take 0.125 mg of digoxin daily|
261832|NCT02489786|Drug|digoxin dose is calculated using Jusko-Koup method and given daily|
261833|NCT02492087|Drug|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
261834|NCT02492100|Behavioral|Multi-modality sexual dysfunction intervention|
261835|NCT02492113|Procedure|Positive end-expiratory pressure (PEEP)|Optimal PEEP. After recruitment maneuver and decremental WOB trial, the optimal WOB PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at optimal WOB PEEP, with the PSV=0 and FiO2 unchanged.
262133|NCT02485457|Procedure|Volume loading|Volume loading with Ringer Lactate
262134|NCT02485457|Drug|Ringer solution|
262135|NCT02485470|Other|MPACT|Maintaining Physical Activity during Cancer Treatment
262136|NCT00176787|Drug|Capecitabine|
262137|NCT02485496|Device|Endovascular abdominal repair|
262138|NCT02485509|Drug|VM-1500/Placebo|VM-1500 or Placebo
262139|NCT02485535|Other|Laboratory Biomarker Analysis|Correlative studies
262140|NCT02485535|Drug|Selinexor|Given PO
262141|NCT02485548|Drug|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
262142|NCT02485548|Drug|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
262143|NCT02485548|Drug|Cisplatin|All patients will receive concurrent cisplatin.
262144|NCT02485548|Radiation|IMRT|All patients will receive IMRT
261512|NCT02494453|Procedure|Biomarkers|Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.
All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this observational study, treatment will not be altered based upon the data collected from these samples.
261513|NCT02494466|Drug|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
261514|NCT02494479|Drug|Prurisol|50mg tablet
261515|NCT02494479|Drug|Placebo|Sugar pill designed to match Purisol tablet
261516|NCT02494492|Other|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
261517|NCT02494505|Drug|Mycophenolate Mofetil|2g/day per os
261518|NCT02494505|Drug|placebo|
261519|NCT00002481|Drug|cytarabine|
261520|NCT00177775|Drug|MucoMilk product|
261521|NCT02494518|Behavioral|Forced Exercise & Upper Extremity Repetitive Task Practice|
261522|NCT02494518|Behavioral|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
261523|NCT02494518|Behavioral|Stroke Education & Upper Extremity Repetitive Task Practice|
261524|NCT02494531|Radiation|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
261525|NCT02496663|Other|Laboratory Biomarker Analysis|Correlative studies
261526|NCT02496663|Biological|Necitumumab|Given IV
261527|NCT02496663|Drug|Osimertinib|Given PO
261528|NCT02496663|Other|Pharmacological Study|Correlative studies
261836|NCT02492113|Procedure|ZEEP|After recruitment maneuver and decremental WOB trial, the optimal WOB PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0 cmH2O, with the PSV=0 and FiO2 unchanged.
261837|NCT02492126|Other|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
261838|NCT02492139|Device|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
260949|NCT02471781|Device|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
260950|NCT02471794|Behavioral|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
261225|NCT02500758|Procedure|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
261226|NCT02500771|Behavioral|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
261227|NCT02500784|Drug|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
261228|NCT02500784|Drug|Formoterol B|2mL, BID inhaler for 12 months
261229|NCT02500797|Biological|Ipilimumab|Given IV
261230|NCT02500797|Other|Laboratory Biomarker Analysis|Correlative studies
261231|NCT02500797|Biological|Nivolumab|Given IV
261232|NCT02500797|Other|Quality-of-Life Assessment|Ancillary studies
261233|NCT02500810|Drug|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
261234|NCT02500836|Drug|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
261235|NCT00002484|Radiation|radiation therapy|
261236|NCT00178776|Behavioral|Transtheoretical Model Group Therapy|
261237|NCT02500836|Drug|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
261238|NCT02500836|Drug|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
261239|NCT02500849|Genetic|SB-728mR-HSPC Infusion 3 days following busulfan conditioning|
261240|NCT02500875|Device|PTNiA|
260670|NCT02475850|Other|Usual care|
260671|NCT02475863|Device|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
260672|NCT02475863|Other|Standard Practice|Warfarin dose adjustments according to standard unit protocol
260673|NCT02477852|Drug|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
260674|NCT02477852|Drug|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
260675|NCT02477852|Drug|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
260951|NCT02471807|Device|EW Transcatheter Tricuspid Repair System|
260952|NCT02471820|Drug|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
260953|NCT02471820|Drug|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
260954|NCT02471820|Drug|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
260955|NCT02471833|Drug|Telmisartan 20mg|Subjects will be given 20 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 20mg for a duration of 8 months.
260956|NCT02471833|Drug|Telmisartan 40mg|Subjects will be given 40 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 40mg for a duration of 8 months.
260957|NCT00175006|Other|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
260958|NCT02471833|Drug|Placebo|Subjects will be given placebo to be taken orally once a day before bedtime. Subjects will be on placebo for a duration of 8 months.
260959|NCT02471846|Drug|Atezolizumab (MPDL3280A)|Participants will receive Atezolizumab at a fixed dose of 1200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle.
260960|NCT02471846|Drug|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, and 400 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
260961|NCT02471859|Drug|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
260962|NCT02471859|Drug|Placebo|Placebo at various doses, depending on the cohort and treatment period
277361|NCT02702440|Other|Liquid calories from sugars|
277362|NCT02702453|Behavioral|Focus Group|An evaluation of the effect of the intervention with 142 couples in a pilot trial on a number of outcomes important to patients with localized prostate cancer and partners, as compared to usual care. Primary outcome will be Global Satisfaction with Sex Life; secondary outcomes will include participants' knowledge about rehabilitation for the sexual side-effects of prostate cancer treatment, survivors' and partners' sexual function, complicated grief about the loss of sexual function and couple coping. Longer term outcomes will additionally include depression, anxiety and quality of life. We anticipate that the intervention group participants will experience greater global satisfaction with their sex lives, will be more knowledgeable, will grieve more successfully and cope more closely as a couple. The study team also anticipate that they will be less anxious and depressed and will have higher quality of life.
277363|NCT02702466|Other|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
277364|NCT02702479|Other|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
277365|NCT02702479|Other|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
277366|NCT02702492|Drug|KCP-9274|
277367|NCT02702505|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
277368|NCT02702505|Other|ProRoot MTA|Control group
277369|NCT00202436|Procedure|Erythrocytapheresis|machinal removal of erythrocytes
277650|NCT02696213|Other|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
277651|NCT02696213|Other|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
277652|NCT02696226|Drug|Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
277653|NCT02698176|Drug|MK-8628 40 mg|40 mg administered as an oral capsule, in a fasted state, twice a day (BID) continuously for 21 days per cycle
277654|NCT02698189|Drug|MK-8628 20 mg|20 mg administered as an oral capsule, in a fasted state, twice a day (BID) continuously for 21 days per cycle
277655|NCT00201864|Drug|Exemestane|25 mg orally per day
277656|NCT02698189|Drug|MK-8628 30 mg|30 mg administered as an oral capsule, in a fasted state, BID continuously for 21 days per cycle
277067|NCT02706886|Drug|ALN-GO1|Single or multiple doses of ALN-GO1 by subcutaneous (sc) injection
277068|NCT02706886|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
277069|NCT02706899|Drug|vadastuximab talirine|
277070|NCT02706899|Drug|Azacitidine|azacitidine 75 mg/m2 given intravenously or subcutaneously x 7 days every 4 weeks
277071|NCT00002547|Drug|cyclophosphamide|
277072|NCT02708810|Device|Unframed Virtual Cone|If a face mask (unframed) is used, it will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
277073|NCT02708810|Radiation|80 Gy of Radiation|
277074|NCT02708823|Other|Delirium Risk Profile (DRP) application|The DRP application is administered once to all study participants.
277075|NCT02708836|Procedure|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
277076|NCT02708836|Device|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
277077|NCT02708836|Device|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
277078|NCT02708836|Procedure|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
277079|NCT00203177|Drug|rasagiline mesylate|0.5 rasagiline mesylate
277080|NCT02708836|Procedure|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
277081|NCT02708836|Procedure|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
277082|NCT02708836|Procedure|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
277083|NCT02708836|Procedure|Emergence from anesthesia|At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as "open your eyes" or "squeeze my hand").
276449|NCT02717026|Device|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
276450|NCT02717026|Device|Fundus photography|30 and 50 degree fundus images
276451|NCT02717039|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
276769|NCT02712788|Drug|Milrinone|
276770|NCT02712788|Drug|Placebo|
276771|NCT02712801|Drug|Zidovudine|Dose will be adjusted according to the child's weight.
276772|NCT02712801|Drug|Nevirapine|Dose will be adjusted according to the child's weight.
276773|NCT02712801|Drug|Lamivudine|Dose will be adjusted according to the child's weight.
276774|NCT02714777|Device|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
276775|NCT02714803|Behavioral|"Connective tissue massage" and "Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
276776|NCT00203892|Biological|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
276777|NCT02714803|Behavioral|"Classic massage group" and "Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
276778|NCT02714803|Behavioral|"Sham massage group" and "Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
276779|NCT02714829|Device|Inject BMP|
276780|NCT02714829|Device|ExcelOS Inject|
276781|NCT02714842|Drug|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
276782|NCT02714842|Drug|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
276783|NCT02714842|Drug|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
276784|NCT02714842|Drug|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
276785|NCT02714855|Drug|Apixaban|
275840|NCT02693080|Radiation|Computed Tomography Perfusion Imaging|Undergo perfusion CT
275841|NCT02693080|Other|Laboratory Biomarker Analysis|Correlative studies
275842|NCT02693093|Drug|NI-03|
275843|NCT02693093|Drug|Placebo|
275844|NCT02693106|Dietary Supplement|Dietary supplement|Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated (5 g of leucine, 3.6 g of butyrate, 7.2 g of butyrate, 5 g of octanoate, 10 g of octanoate, 1.95 g of carnitine or 65 g of butter fraction rich in MCT) follow by a period of 4-hour with multiple blood sampling.
276134|NCT02685930|Behavioral|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
276135|NCT02685943|Behavioral|Psychotherapy|
276136|NCT02685956|Device|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
276137|NCT02688231|Other|Task-oriented upper limb training|Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.
The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.
The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks.
276138|NCT02688231|Other|Control intervention|The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).
The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks.
276139|NCT02688244|Procedure|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
276140|NCT02688244|Procedure|No irrigation|Suction only, using suction device
276141|NCT02688257|Other|MRI|Functional magnetic resonance imaging
276142|NCT00200681|Drug|Velcade|
276143|NCT02688257|Other|Ultrasound|Optoacoustic imaging
276144|NCT02688270|Drug|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
276145|NCT02688270|Drug|Vehicle (placebo)|Vehicle administered topically
275267|NCT02703753|Behavioral|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
275268|NCT00202644|Drug|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
275269|NCT02703766|Behavioral|overfeeding induced weight gain|
275270|NCT02703779|Drug|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
275271|NCT02703779|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
275272|NCT02703779|Drug|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
275560|NCT00201786|Drug|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
275561|NCT02697305|Dietary Supplement|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
275562|NCT02697305|Other|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
275563|NCT02697318|Drug|Timolol maleate 0.5% ophthalmic solution|
275564|NCT02697331|Drug|Progesterone|women will receive progesterone capsules containing 100mg of progesterone per tablet . it will be used by the patient as one tablet per vagina twice per day .
women will be showed how to use tablets . medication will be started at 20 weeks and stopped at the end of 34 weeks
275565|NCT02697331|Other|Placebo|omen will receive placebo tablets twice a day . it will be used by the patient as one tablet per vagina twice per day .
women will be showed how to use tablets . medication will be started at 20 weeks and stopped at the end of 34 weeks
275566|NCT02697344|Drug|Dexamethasone|Given PO
275567|NCT02697344|Other|Laboratory Biomarker Analysis|Correlative studies
275568|NCT02699411|Other|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
275569|NCT02699424|Radiation|External radiation therapy|
275570|NCT02699437|Other|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
275571|NCT02699450|Drug|RO6867461|Participants will receive 6 injections of 1.5 mg or 6 mg RO6867461 IVT every 4 weeks up to Week 20.
274694|NCT02711917|Drug|MAC 1.0|1.0 MAC Sevoflurane
274695|NCT02711917|Drug|Propofol|Propofol consumption
274696|NCT02711917|Drug|Etomidate|Etomidate consumption
274697|NCT02711917|Drug|Rocuronium|Consumption of Rocuronium
274698|NCT02711943|Drug|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
274699|NCT02711956|Drug|ZEN003694|
274700|NCT02711956|Drug|Enzalutamide|
274701|NCT02711969|Drug|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
274702|NCT02711982|Procedure|Optic canal and optic nerve sheath decompression|within 5 days from trauma
274703|NCT00203567|Drug|carbamazepine ER|Active study drug, no comparator
274704|NCT02711982|Drug|methylprednisolone|within 5 days from trauma
274705|NCT02713984|Biological|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
274996|NCT02707978|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
274997|NCT02707991|Behavioral|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
274998|NCT02708004|Drug|AC-080|Formulated in capsules in 2 different strengths; 2 capsules per day
274999|NCT02708004|Other|Placebo|Matching active drug
275000|NCT02708017|Procedure|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
274424|NCT02718326|Drug|Intravitreal aflibercept injection [IAI]|
274425|NCT02718326|Drug|Sham|
274426|NCT02718339|Behavioral|Intensive counseling|
274427|NCT02718352|Other|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
274428|NCT02718365|Procedure|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
274429|NCT02718365|Procedure|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
274430|NCT00204347|Drug|risperidone|
274431|NCT02718378|Drug|estetrol|
274432|NCT02718378|Drug|placebo|
274433|NCT02718391|Biological|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
274434|NCT02718404|Procedure|MR-HIFU Treatment|The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.
At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.
274435|NCT02718404|Drug|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
274436|NCT02718404|Procedure|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
274706|NCT02713997|Drug|etanercept|50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
274707|NCT02713997|Drug|Alpha 1-Antitrypsin|90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
274708|NCT02714010|Drug|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
274709|NCT02714010|Radiation|whole brain radiotherapy|30Gy/10F
274710|NCT02714023|Procedure|Laproscopic or Open Appendectomy|Laparoscopic or open appendectomy was performed on each patient.
274711|NCT02714023|Procedure|Irrigation with Normal Saline|Intra-operative irrigation with normal saline
278977|NCT02691910|Drug|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
278978|NCT02691910|Drug|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
278979|NCT02691923|Drug|Fluorescein|
278980|NCT02691923|Drug|Fluorescein + ALA|
278981|NCT00201136|Behavioral|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
278982|NCT02691936|Device|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
278983|NCT02691936|Drug|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
278984|NCT02691949|Drug|Mycophenolate sodium|mycophenolate sodium 1# BID-2# BID
278985|NCT02691962|Device|XenMatrix AB|XenMatrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
278986|NCT02691975|Drug|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
278987|NCT02691988|Other|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
278988|NCT02691988|Other|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
278989|NCT02692001|Other|Intervention MealTrain menu|Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled "Eat like a superhero" was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls.
278990|NCT02692027|Other|Same-day ART initiation|Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.
In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation.
274437|NCT02718417|Drug|carboplatin|Given Q3W during chemotherapy phase
278397|NCT02702895|Behavioral|Phase 1: In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
278398|NCT02702895|Behavioral|Phase 2: In-depth Interview (IDI)|
278399|NCT00202488|Drug|H. pylori treatment|
278400|NCT02702908|Other|Unspecified|Historical Reference group.
278401|NCT02702921|Device|Surgeon's 'standard of care' stapler|
278402|NCT02702921|Device|Ethicon Powered Vascular Stapler|
278693|NCT00201721|Drug|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
278694|NCT02696577|Drug|Omega 3|
278695|NCT02696590|Dietary Supplement|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
278696|NCT02696603|Behavioral|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
278697|NCT02696603|Behavioral|Phonation|Participants are asked to record themselves saying "Aaah" for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative.
278698|NCT02698527|Drug|Non-Buffered Lidocaine|Active comparator
278699|NCT02698527|Drug|Buffered Lidocaine|Experimental, additIon of Sodium Bicarbonate to Lidocaine
278700|NCT02698540|Other|Nutritional Supplement|High calorie, high protein peptide based
278701|NCT02698553|Drug|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
278702|NCT02698553|Drug|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
278703|NCT00201916|Procedure|5250 cGy/20 fractions over 28 days|see above
278704|NCT02698566|Drug|Lucentis PFS|Participants will receive ITV injection of Lucentis dose level 1 delivered via PFS.
278705|NCT02698579|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
278104|NCT02709187|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
278105|NCT00203216|Procedure|Transcranial Magnetic Stimulation|
278106|NCT02709200|Drug|Dexmedetomidine|
278107|NCT02709213|Other|Diagnostic|
278108|NCT02709226|Radiation|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD (provided no DLT) with a maximum of 21 evaluable patients enrolled.
278109|NCT02709239|Dietary Supplement|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
278110|NCT02709239|Dietary Supplement|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
278403|NCT02702934|Other|Test meal|Participants received in random order two test meals (900Kcal, 100g carbohydrates) that differed only in the carbohydrate source: rusks prepared with amylose-rich wheat flour or regular wheat flour (control). Blood samples were taken at fasting and over 4 hours after the meal for glucose and insulin evaluation. In addition we evaluated satiety, by visual analogue scale , and intestinal fermentation, by H2-breath test.
278404|NCT02702947|Dietary Supplement|Prunus domestica extract|Prosman 1 capsule twice a day
278405|NCT02702960|Procedure|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for >3 wks
278406|NCT02705092|Other|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
278407|NCT02705105|Biological|Mogamulizumab + Nivolumab|i.v. administration
278408|NCT02705118|Device|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
278409|NCT02705118|Device|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
278410|NCT02705131|Device|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
262709|NCT02474459|Device|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
262710|NCT02474459|Other|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
262711|NCT02474472|Drug|bupivacaine hydrochloride|
262712|NCT02474472|Drug|bupivacaine liposomal injectable suspension|
262713|NCT00175383|Drug|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
262714|NCT02474485|Device|BVS Absorb implantation.|Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
262715|NCT02474485|Device|DEB Sequent Please inflation.|Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
263008|NCT02392819|Dietary Supplement|Placebo|
263009|NCT02392832|Biological|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.
Starts from 2016, fourteen sites in each of the two study districts will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, the investigators will perform a cross over and switch the control and treatment sites. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs.
263010|NCT02392845|Drug|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
263011|NCT02356757|Behavioral|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
263012|NCT02356770|Device|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
263013|NCT02356770|Procedure|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
262436|NCT02480712|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
262437|NCT02480725|Procedure|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
262438|NCT02480738|Behavioral|Computerized Cognitive Training Apparatus|CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.
Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process.
262439|NCT02480751|Drug|Beraprost|
262440|NCT00176293|Drug|doxorubicin|Doxorubicin 50mg/m^2 I.V. on day 5
262441|NCT02480751|Drug|Placebo|
262442|NCT02480764|Drug|Azilsartan medoxomil|azilsartan medoxomil tablets
262443|NCT02480764|Drug|Valsartan|Valsartan 80 mg capsules
262444|NCT02480764|Drug|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
262716|NCT02474485|Procedure|Control coronary angiography.|Control coronary angiography will be performed at 9 month follow-up.
262717|NCT02474485|Procedure|OCT visualization.|OCT visualization will be performed during index procedure and at 9 month follow-up.
262718|NCT02474485|Other|Clinical observation.|Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
262719|NCT02474498|Drug|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
262720|NCT02474498|Device|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
262721|NCT02474498|Procedure|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
262722|NCT02474511|Other|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
262723|NCT00175695|Drug|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
262145|NCT02485561|Behavioral|Health communication intervention|This study will compare the effects of adding personal experiences with colon cancer screening to educational information to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
262146|NCT02485561|Behavioral|Education information|CDC Screen for Life campaign materials are used to present educational information to participants about colon cancer and screening tests.
262147|NCT00176787|Procedure|Radiation|
262148|NCT02485574|Procedure|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in left side of disc space and anterior bridging cages augmented with auto bone in rt side of disc space in transforaminal lumbar interbody arthrodesis.
262149|NCT02485587|Behavioral|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
262150|NCT02485587|Behavioral|Treatment as usual|counseling, psychoeducation
262151|NCT02485613|Drug|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
262152|NCT02485626|Procedure|2D tissue doppler echocardiography|
262153|NCT00176904|Drug|Busulfan, Cyclophosphamide, Antithymocyte Globulin|Subjects will receive BUSULFAN intravenously (IV)- patients < or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow "take" and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
262445|NCT02480764|Drug|Valsartan Placebo|Valsartan placebo-matching capsules
262446|NCT02480777|Biological|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
262447|NCT02480803|Drug|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
262448|NCT02480803|Device|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
262449|NCT02480816|Dietary Supplement|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
262450|NCT02480829|Device|Amphora OAB Device 3.0 mm|Treatment with the Amphora OAB Device
262451|NCT00176306|Drug|Levofloxacin 750 mg IV|PK in obesity
262452|NCT02480842|Other|Alloplastic free ROM|
261839|NCT02492139|Device|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
261840|NCT02492152|Device|Study group|Dianatal
261841|NCT00002480|Radiation|radiation therapy|
261842|NCT00177515|Behavioral|"video doctor," computer module|computerized counseling about emergency contraception and peri-conception folate
261843|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
261844|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
261845|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
261846|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
261847|NCT02492178|Drug|Intrarectal artesunate|
261848|NCT02492178|Drug|Intravenous artesunate|
261849|NCT02492178|Drug|Intravenous quinine|
261850|NCT02492191|Device|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
261851|NCT02492217|Drug|Adalimumab|
261852|NCT02492230|Device|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
261853|NCT00177528|Drug|venlafaxine-XR|
261854|NCT02492230|Drug|Warfarin|Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.
All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0.
261855|NCT02492243|Device|PCI|
261856|NCT02492243|Device|ILR implantation|
261241|NCT02500875|Device|PTNiB|
261242|NCT02500875|Device|PTN|
261243|NCT02500888|Radiation|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
261244|NCT02500901|Drug|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
261245|NCT02500901|Drug|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
261529|NCT02496676|Drug|Magnesium L-threonate|Following an initial washout of magnesium-containing supplements, patients with XMEN syndrome will be randomized into 2 arms. Arm 1 will receive 12 weeks of oral magnesium supplementation followed by 12 weeks of placebo. Arm 2 will receive 12 weeks of placebo followed by 12 weeks of oral magnesium supplementation. Magnesium supplementation will consist of escalating doses of daily, orally self-administered magnesium Lthreonate. Dose escalation for oral magnesium L-threonate will be based on patients weight and tolerance of the supplement. Intolerance is defined as gastrointestinal symptoms (eg, diarrhea, nausea) after any dose. Patients experiencing intolerance will revert to the last tolerated dose. Oral magnesium L-threonate capsules will be purchased from commercial sources.
261530|NCT02496676|Drug|Placebo|Dose escalation for placebo will be based on patients weight and tolerance of the formulation (i.e., absence of gastrointestinal symptoms). The Clinical Center s Pharmaceutical Development Section will formulate matching placebo capsules using clear, unmarked 00 vegetable (hydroxypropyl methyl cellulose) capsules containing lactose. The tablets and packaging for magnesium L-threonate and placebo will be identical in appearance.
261531|NCT00000369|Behavioral|Individual psychotherapy|
261532|NCT00002481|Procedure|autologous bone marrow transplantation|
261533|NCT00178178|Device|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
261534|NCT02496676|Drug|Magnesium Sulfate (MgSO)|After 24 weeks of study, patients who show & lt; 0.5 log reduction in the number of EBVinfected B cells on oral magnesium as compared to placebo (oral treatment failure) will begin a 2-week washout and proceed to Part II. Such patients will be hospitalized to receive 3 days of IV MgSO4 administered 3 times per day for a total daily dose of 30/mg/kg/day. Then they will restart escalating doses of orally self-administered magnesium L-threonate and continue for the remaining 24 weeks of the study.
261535|NCT02496689|Biological|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
261536|NCT02496702|Device|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
261537|NCT02496715|Drug|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
261538|NCT02496715|Drug|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
277936|NCT02691442|Drug|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
277937|NCT02691455|Device|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
277938|NCT02691455|Procedure|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
277939|NCT02691455|Device|Ahmed Model FP7 Flexible Plate|
277940|NCT00201110|Behavioral|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
277941|NCT02691455|Device|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
277942|NCT02691468|Device|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
277943|NCT02691468|Device|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
277944|NCT02691481|Dietary Supplement|Oatmeal breakfast|
278221|NCT02684357|Drug|placebo to BI 655066|
278222|NCT02684357|Drug|placebo to ustekinumab|
278223|NCT02686671|Other|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
278224|NCT02686684|Drug|Dimethyl fumarate|
278225|NCT02686697|Drug|L-Carnosine|
278226|NCT00200473|Drug|Nebivolol|
278227|NCT02686697|Drug|Placebo|
278228|NCT02686697|Behavioral|Cognitive Training|Cognitive Training for 2 weeks
278229|NCT02686710|Drug|Sevoflurane|
278230|NCT02686710|Drug|Propofol|
278231|NCT02686723|Other|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
278232|NCT02686736|Behavioral|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
277657|NCT02698202|Device|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
277658|NCT02698215|Drug|Varenicline|Varenicline 1 mg twice daily
277659|NCT02698215|Drug|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
277660|NCT02698228|Drug|Bupivacaine (femoral nerve block)|0.5% bupivacaine
277661|NCT02698228|Drug|Morphine|Intravenous injection of 0.1mg/kg of morphine
277662|NCT02698228|Device|Ultrasound|
277663|NCT02698241|Device|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
277664|NCT02698254|Radiation|Re-Irradiation Therapy (RRT) to Brain|Participants may receive up to 6 weeks of radiation therapy. Dose of radiation decided by participant's radiation oncologist.
277665|NCT02698254|Behavioral|Questionnaires|Quality of life and symptom questionnaires completed at baseline, and at months 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, and 25 after radiation therapy.
277666|NCT00201864|Drug|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
277667|NCT02698267|Drug|BIIB074 (raxatrigine)|Administered as specified in the treatment arm
277668|NCT02698267|Drug|Itraconazole|200 mg twice daily [BID] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
277669|NCT02698280|Drug|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
277670|NCT02698280|Drug|Nimustine|Nimustine is administered intravenously at 90mg/m^2 to 110mg/m^2 every 6 weeks.
277945|NCT02691481|Dietary Supplement|Glucerna formula|
277946|NCT02691481|Dietary Supplement|Ultra Glucose Control formula|
277947|NCT02691494|Drug|Placebo|Placebo for 6-month Treatment
277948|NCT02691494|Drug|Elagolix|Elagolix for 6-month Treatment
277949|NCT02693938|Device|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
277950|NCT02693951|Drug|Cefotiam|Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
277951|NCT02693964|Other|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
277370|NCT02702518|Drug|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
277371|NCT02702518|Drug|Vehicle|Drug vehicle 4 times a day for 8 weeks
277372|NCT02702531|Device|FloShield Defogging and Cleaning System|
277373|NCT02702544|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
277374|NCT02702544|Device|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
277375|NCT02702557|Other|Elastic Band Exercises|
277376|NCT02704624|Dietary Supplement|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
277377|NCT02704624|Other|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
277378|NCT02704637|Device|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
277379|NCT02704650|Procedure|fluid sample|taking a vaginal fluid sample
277380|NCT02704663|Procedure|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
277381|NCT00002546|Procedure|adjuvant therapy|
277382|NCT00202774|Drug|(capecitabine, oxaliplatin, 5-fluorouracil)|
277383|NCT02704663|Procedure|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
277384|NCT02704676|Other|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
277385|NCT02704689|Device|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
277386|NCT02704702|Drug|Fimasartan|
277387|NCT02704702|Drug|Rosuvastatin|
277388|NCT02704702|Drug|Fimasartan + Rosuvastatin|
277389|NCT02704715|Procedure|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
277390|NCT02704728|Other|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
276786|NCT02714868|Behavioral|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
276787|NCT00203892|Biological|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
276788|NCT02714868|Behavioral|Matched Comparison|Participants set goal to try a new activity in the community
277084|NCT02708849|Drug|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
277085|NCT02708849|Drug|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
277086|NCT02708849|Drug|Placebo|oral dose placebo
277087|NCT02708862|Device|Simple mask at 60 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
277088|NCT02708862|Device|Non-rebreather at 15 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
277089|NCT02708862|Device|Non-rebreather at 60 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
277090|NCT00203177|Drug|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
277091|NCT02708862|Device|Bag valve mask at 15 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
277092|NCT02710760|Other|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
277093|NCT02710760|Other|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
277094|NCT02710773|Other|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
277095|NCT00203411|Drug|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
276146|NCT02688283|Other|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
276147|NCT02688296|Device|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
276148|NCT02688309|Drug|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
276149|NCT02688309|Procedure|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
276452|NCT02717052|Drug|(S)-ketamine|Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)
276453|NCT02683564|Drug|Remicade|monoclonal antibody against TNF-alpha
276454|NCT02683577|Drug|telotristat etiprate|
276455|NCT02683590|Device|Ceramic Implant|The replacement of the sternum by a ceramic implant
276456|NCT02683603|Drug|AS colistin and "imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
276457|NCT00200109|Device|Occipital Nerve Stimulation|Each group had a different plan
276458|NCT02683603|Drug|IV colistin " and "imipenem" .|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
276459|NCT02683603|Drug|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
276460|NCT02683603|Drug|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
276461|NCT02683603|Drug|AS colistin and imipenem|IV imipenem 1 g three times per day.
276462|NCT02683603|Drug|IV colistin and imipenem|IV imipenem 1 g three times per day
276463|NCT02683616|Device|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
276464|NCT02683629|Biological|NTCELL Implantation|NTCELL Implantation
276465|NCT02683629|Other|Sham Surgery|Sham Surgery
275572|NCT02699450|Drug|Ranibizumab|Participants will receive 7 injections of 0.3 mg ranibizumab IVT every 4 weeks upto Week 24.
275573|NCT02699450|Drug|Sham|Participants will receive 1 sham administration, mimicking the action of an injection, at Week 24.
275574|NCT02699463|Device|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
275575|NCT00202007|Drug|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
275576|NCT02699463|Other|Control Group|Standard sleep hygiene counseling as per published guidelines
275577|NCT02699476|Behavioral|Psycho-Social Therapy|
275578|NCT02699476|Device|Cognitive Behavioral Computer Training|
275579|NCT02699476|Behavioral|Interactive Trainer-Subject Sessions|
275580|NCT02699476|Device|Active Control Games|
275845|NCT02693119|Drug|MTP-131 1% ophthalmic solution|
275846|NCT02693119|Drug|Vehicle topical ophthalmic solution|
275847|NCT02693132|Behavioral|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
275848|NCT02693132|Behavioral|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
275849|NCT02693132|Behavioral|Step-based (STEP)|Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 "brisk" steps/day.
275850|NCT00002540|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
275851|NCT02695316|Other|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
275852|NCT02695316|Other|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
275853|NCT02695329|Device|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
275854|NCT02695342|Behavioral|Home balance exercise program|
275001|NCT02708017|Procedure|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
275002|NCT02708030|Other|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
275003|NCT02708030|Other|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
275004|NCT02708030|Other|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
275005|NCT02708043|Other|Flexible-Laryngeal Mask Airway|
275006|NCT00203073|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
275007|NCT02708056|Drug|Sugammadex|
275008|NCT02710097|Drug|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
275273|NCT02703805|Other|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
275274|NCT02703805|Other|Standard YMCA membership|A 12 week standard YMCA membership.
275275|NCT02703818|Device|Senza|Spinal Cord Stimulation
275276|NCT02703831|Procedure|Dual attending|Two attending spine surgeons perform surgery
275277|NCT02703831|Procedure|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
275278|NCT02703844|Device|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
275279|NCT00202644|Drug|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
275280|NCT02703844|Device|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
274712|NCT02714023|Procedure|Irrigation with Sterile Water|Intra-operative irrigation with sterile water
274713|NCT02714036|Drug|ibudilast|
274714|NCT00203788|Behavioral|Skills training group|Group social skills training that did not focus primarily on work situations
274715|NCT02714049|Behavioral|sex therapy|60 minutes each time, in person or on the telephone
274716|NCT02714049|Drug|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
274717|NCT02714062|Drug|Placebo|Placebo, po once daily
274718|NCT02714062|Drug|VI-0521 Mid Dose|phentermine 7.5 mg and topiramate 46 mg, po once daily
274719|NCT02714062|Drug|VI-0521 Top Dose|phentermine 15 mg and topiramate 92 mg, po once daily
274720|NCT02714075|Other|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
274721|NCT02714075|Other|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
274722|NCT02714075|Other|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
274723|NCT02714075|Other|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
274724|NCT02714075|Other|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
274725|NCT00203801|Drug|Sulfadoxine-pyrimethamine|
274726|NCT02714075|Other|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
274727|NCT02714088|Other|Novel high-intensity interval training|
275009|NCT02710097|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
275010|NCT02710097|Drug|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
275011|NCT02710110|Device|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
274438|NCT02718417|Drug|paclitaxel|Investigator choice of weekly or Q3W during chemotherapy phase
274439|NCT02718417|Drug|Avelumab|Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
274440|NCT02718417|Drug|Avelumab|Given as single agent in maintenance portion Q2W
274441|NCT00204373|Drug|Lansoprazole (Prevacid)|Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
274442|NCT02718430|Drug|VXM01|Oral immunotherapy targeting VEGFR2
274443|NCT02685046|Drug|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
274444|NCT02685059|Drug|MEDI4736 (Anti PD-L1)|MEDI4736 1.5g total i.v. every 4 weeks
As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:
MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by
MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).
274445|NCT02685059|Drug|Placebo|Placebo i.v. every 4 weeks
As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:
Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by
MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).
274446|NCT02685059|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
274447|NCT02685059|Drug|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
274448|NCT02685059|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
274449|NCT02685072|Drug|Progesterone (200 mgs BID)|
274450|NCT02685072|Drug|Placebo|
274451|NCT00200304|Behavioral|Internet weight loss with SlimFast and human counseling|
274452|NCT02685072|Drug|Transdermal Nicotine Patch (TNP)|TNP will be tapered after 4-6 weeks. Participants who smoke more than 10 cigarettes per day will receive the following dose of TNP: 21mg/24 hours for 4 weeks, 14mg for weeks 5 and 6 and 7 mg for weeks 7 and 8. Participants that smoke between 5-10 cigarettes per day will receive the following dose of TNP: 14mg/24 hours for 6 weeks, 7mg for weeks 7 and 8.
274453|NCT02685072|Behavioral|Brief counseling for smoking cessation|
274454|NCT02685085|Drug|Misoprostol ( Prostaglandin E2)|
274455|NCT02685085|Device|Foley's catheter|
274456|NCT02685098|Biological|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2 and/or gender mismatched allogeneic MSCs into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective BKA 3-21 days before surgery.
278706|NCT02698592|Device|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
278707|NCT02698592|Device|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
278708|NCT02698592|Device|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
278991|NCT02692027|Other|Standard of care|Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.
Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis.
278992|NCT02694289|Drug|Metformin|Treatment/continuation of metformin therapy during admission
278993|NCT02694289|Drug|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
278994|NCT02694302|Device|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
278995|NCT02694302|Device|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
278996|NCT02694315|Other|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
278997|NCT02694315|Other|cervical length|measuring cervical length by trans-vaginal ultrasound
278998|NCT00201461|Device|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
278999|NCT02694328|Drug|ALKS 3831|Daily dosing
279000|NCT02694328|Drug|Olanzapine|Daily dosing
279001|NCT02694341|Procedure|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
278411|NCT02705131|Device|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
278412|NCT02705144|Other|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
278413|NCT02705157|Procedure|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
278414|NCT02705157|Radiation|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
278415|NCT02705170|Procedure|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
278416|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
278417|NCT02705183|Radiation|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
278418|NCT02705196|Biological|LOAd703|oncolytic virus
278419|NCT02705196|Drug|Gemcitabine|chemotherapy
278420|NCT02705196|Drug|nab-paclitaxel|chemotherapy
278709|NCT02698605|Device|Usability test study of the MirrorPath|The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.
A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch.
278710|NCT02698618|Procedure|Diagnostic|Pre-PCI and treatment:
At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.
At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured.
278711|NCT02698618|Drug|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence [Body Mass Index (BMI) ≥30 kg/m2] with the implementation of a dedicated randomization list.
263014|NCT02356783|Device|Pedometer|Wireless pedometer
263015|NCT02356796|Other|Multidisciplinary group treatment|Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.
The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months.
263016|NCT02356796|Other|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
263017|NCT02356809|Drug|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
263018|NCT02356822|Other|Patient registry|Oncology data registry
263019|NCT00158587|Drug|primaquine|
263304|NCT02388243|Behavioral|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
263305|NCT02388243|Behavioral|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
263306|NCT02388243|Behavioral|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
263307|NCT02390453|Behavioral|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
263308|NCT02390453|Behavioral|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
262724|NCT02476487|Procedure|FDG PET CT|FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.
2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal.
262725|NCT02476500|Procedure|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
262726|NCT02476526|Drug|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
262727|NCT02476526|Drug|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
262728|NCT02476526|Drug|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
262729|NCT02476526|Procedure|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
262730|NCT02476539|Drug|Hemay022|
262731|NCT02476552|Drug|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
262732|NCT02476552|Drug|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of [14C]-niraparib)
263020|NCT02356835|Device|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
263021|NCT02356835|Device|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
263022|NCT02356848|Behavioral|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
263023|NCT02356848|Behavioral|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
263024|NCT02356861|Device|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|The LED helmet from Photomedex, Montgomeryville, PA will be used.
18 LED pods are in the helmet. Each LED pod:
Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2
20 NIR diodes, 830 nm and 4 red diodes, 633 nm.
1 J/cm2 = 30.4 sec
263025|NCT00158821|Drug|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
263026|NCT02359162|Radiation|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
263027|NCT02359175|Drug|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
262453|NCT02480842|Other|Alloplastic limited ROM|
262454|NCT02480842|Other|Oncoplastic free ROM|
262455|NCT02480842|Other|Oncoplastic limited ROM|
262456|NCT02480855|Other|Questionnaire and feedback|
262457|NCT02480881|Drug|BMS-663068|Investigational product
262458|NCT02480881|Drug|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
262459|NCT02480881|Drug|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
262460|NCT02480894|Drug|BMS-663068|
262461|NCT02480894|Drug|Maraviroc|
262462|NCT00176319|Behavioral|Aerobic endurance exercise training (ergometer)|
262463|NCT00176527|Drug|estramustine phosphate sodium|
262464|NCT02483247|Drug|Doxorubicin|Doxorubicin 60 mg/m^2 body surface area is administered intravenously once every three weeks (21-days).
262465|NCT02483247|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
262466|NCT02483247|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
262467|NCT02483247|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
262468|NCT02483247|Drug|Sunitinib|Sunitinib 37.5 mg is administered once daily.
262733|NCT02476552|Drug|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
262734|NCT00175721|Procedure|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
262735|NCT02476565|Device|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
262736|NCT02476565|Device|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
262154|NCT02487745|Behavioral|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
262155|NCT02487758|Procedure|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
262156|NCT02487771|Drug|DHA|600 mg DHA capsule
262157|NCT02487771|Drug|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
262158|NCT02487784|Procedure|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
262159|NCT02487784|Procedure|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
262160|NCT02487797|Drug|Oxytocin|
262161|NCT02487797|Other|Sodium Chloride 0.9%|
262162|NCT02487810|Behavioral|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
262163|NCT02487810|Behavioral|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
262164|NCT00002477|Drug|carboplatin|
262165|NCT00176917|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
262166|NCT02487823|Drug|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
262167|NCT02487836|Device|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
262168|NCT02487849|Procedure|HIPEC|secondary cytoreductive operation
262169|NCT02487849|Drug|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
262170|NCT02487862|Behavioral|Stress Reduction Protocol|Stress Reduction Protocol
262171|NCT02487875|Other|rehabilitation|
262172|NCT02487888|Other|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
261539|NCT02496715|Drug|Placebo|Placebo inhaler
261540|NCT02496728|Behavioral|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
261541|NCT02496728|Behavioral|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
261542|NCT02496728|Behavioral|Social Support|Participants may interact with each other through Facebook and Instagram.
261543|NCT02496728|Behavioral|Educational Materials|Educational materials regarding healthy behaviors.
261544|NCT00178178|Drug|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
261857|NCT02494531|Radiation|Florbetapir-PET|Florbetapir-PET performed within 2 months
261858|NCT02494544|Device|Total Knee Replacement|Comparing patient satisfaction and functional testing between the iTotal (patient-specific jigs AND implants) to off the shelf (only patient-specific jigs).
261859|NCT02494570|Drug|ABI-009|
261860|NCT02494583|Biological|pembrolizumab|
261861|NCT02494583|Drug|cisplatin|
261862|NCT02494583|Drug|5-FU|
261863|NCT00177840|Procedure|acupuncture|
261864|NCT02494583|Drug|capecitabine|
261865|NCT02494596|Drug|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
261866|NCT02494596|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
261867|NCT02494609|Drug|sotagliflozin|400 mg sotagliflozin
261868|NCT02494609|Drug|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
261869|NCT02494609|Drug|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
261870|NCT02494635|Other|Laboratory Biomarker Analysis|Biomarker analysis
261871|NCT02494648|Device|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
278233|NCT02686749|Device|Catheter Ablation|During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which "disconnects" the pathway of the AF.
278234|NCT02686762|Drug|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
278235|NCT02686762|Drug|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
278236|NCT02686762|Drug|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
278237|NCT00002537|Radiation|radiation therapy|
278238|NCT00200499|Drug|Nebivolol|
278239|NCT02686775|Behavioral|Patient coach|
278240|NCT02686775|Behavioral|Standard care|
278241|NCT02686788|Drug|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
278242|NCT02686814|Device|17mm MDT-2215 aortic valve bioprosthesis|
278532|NCT02715674|Device|BIPAP VISION|
278533|NCT00203970|Behavioral|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
278534|NCT02715674|Device|Plasti-med oxygen therapy mask|
278535|NCT02717728|Procedure|Control group sham nerve block|Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.
Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.
Device: Dressing
Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.
278536|NCT02717741|Drug|tafetinib|
278537|NCT02717754|Drug|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg IV BID for 5 days.
278538|NCT02717754|Drug|Placebo|Oseltamivir matched placebo will be administered IV for 5 days.
278539|NCT02717767|Other|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
278540|NCT02717780|Drug|Fentanyl and sevoflurane|
277952|NCT02693977|Procedure|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
277953|NCT02693990|Radiation|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
277954|NCT02694003|Behavioral|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
277955|NCT02694016|Procedure|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
277956|NCT02694029|Device|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing.
277957|NCT02694029|Device|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry.
277958|NCT02694042|Behavioral|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
277959|NCT00201435|Drug|Paclitaxel weekly in combination with capecitabine|
278243|NCT02686827|Drug|Paricalcitol|Vitamin D3 analogue
278244|NCT02686827|Drug|Placebo (for paricalcitol)|Injection fluid to mimic paricalcitol injection
278245|NCT02686840|Drug|sublingual misoprostol|All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.
Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).
Paracetamol, eight hourly, will be provided as analgesic or antipyretic.
A specimen bottle to collect the POC if passed out.
Two pairs of disposable gloves.
Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
278246|NCT02689037|Procedure|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
278247|NCT02689037|Drug|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
277391|NCT02704728|Other|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
277671|NCT02698293|Drug|Gliolan|orally, 40 mg/kg
277672|NCT02698306|Drug|Dexamethasone|Dexamethasone
277673|NCT02698306|Drug|Diclofenac Sodium|Diclofenac Sodium
277674|NCT02698319|Behavioral|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
277675|NCT02698332|Device|Algorithm for UTI|The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
277676|NCT02698345|Device|drug-eluting balloon (In.PACT Admiral, Medtronic)|
277677|NCT00201877|Drug|Velcade|Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 & 14.
Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23.
277678|NCT02698358|Device|Epic stent (Boston Scientific)|
277679|NCT02700399|Device|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
277680|NCT02700399|Device|Traditional tilt table from Rehab-Care|Traditional tilt table
277681|NCT02700412|Drug|Epidiolex|The titration of CBD will start with a dose of 5 mg/kg/day given in two divided doses and titrated by 5 mg/kg/2 weeks up to 25 mg/kg/day; in some patients additional titration by 5mg/kg/day every 2 weeks up to 50mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI
277682|NCT02700425|Device|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
277683|NCT00202150|Behavioral|Application of a management action plan|
277684|NCT02700438|Drug|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
277685|NCT02700438|Procedure|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
277686|NCT02700451|Drug|Ketorolac|Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
277096|NCT02710773|Other|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
277097|NCT02710786|Procedure|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
277098|NCT02710799|Other|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
277099|NCT02710799|Other|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
277392|NCT02704741|Device|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
277393|NCT00202787|Drug|FOLFOX-4+cetuximab|Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);
FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
277394|NCT02704754|Drug|suvorexant|First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
277395|NCT02704754|Other|placebo|Pill with inactive ingredients
277396|NCT02704767|Drug|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
277397|NCT02704767|Drug|Tarceva|
277398|NCT02704767|Drug|Placebo|
277399|NCT02704780|Drug|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
277400|NCT02704793|Other|Bilateral 1 Hz Cerebellar rTMS|900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
277401|NCT00202956|Drug|Bugusan|
277402|NCT02706899|Drug|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A
277403|NCT02706912|Behavioral|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
277404|NCT02706925|Drug|BI 443651|
277405|NCT02706925|Drug|Placebo|
276466|NCT02683655|Drug|Apatinib|Apatinib 500mg qd p.o.
276467|NCT02683655|Drug|Apatinib|Apatinib 750mg qd p.o.
276468|NCT00200122|Device|Spinal Cord Stimulation|
276469|NCT02683668|Device|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
276470|NCT02683668|Device|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
276471|NCT02683668|Device|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
276472|NCT02683694|Device|iOCT|the number of subjects that can be peeled without dye are assessed
276473|NCT02683707|Other|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
276474|NCT02683707|Drug|Fentanyl|IV peri-procedural analgesia
276789|NCT02714881|Drug|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
276790|NCT02714881|Radiation|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
276791|NCT02714894|Drug|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
276792|NCT02714907|Device|Cortrium C3 device|Data is read from Cortrium C3 monitor
276793|NCT02714907|Device|Holter device|Date is read from Holter device
276794|NCT02714920|Other|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
276795|NCT02714933|Other|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
276796|NCT02717052|Drug|(S)-ketamine|Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes.
276797|NCT02717052|Drug|(R,S)-ketamine|Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes.
276798|NCT02717052|Drug|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
275855|NCT02695355|Drug|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
275856|NCT02695368|Device|Air cleaner with plasma-filter turned on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through.
275857|NCT02695368|Device|Air-cleaner with plasma-filter turned off|
275858|NCT02695368|Device|Air-cleaner with plasma-filter turned on or turned off|
275859|NCT00201643|Drug|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
275860|NCT02695381|Drug|Etodolac-lidocaine topical patch|Once daily
275861|NCT02695381|Drug|Placebo|Once daily
275862|NCT02695407|Other|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
275863|NCT02695407|Other|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
275864|NCT02695420|Drug|25 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID
276150|NCT02688309|Procedure|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
276151|NCT02688322|Drug|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
276152|NCT02688335|Device|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
276153|NCT00002539|Biological|filgrastim|
276154|NCT02690519|Drug|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
276155|NCT02690519|Drug|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
276156|NCT02690545|Biological|ATLCAR.CD30 cells|For Phase Ib two doses will be investigated: 1x10^8 cells/m^2 and 2x10^8 cells/m^2. Phase II patients will receive the dose level decided upon in Phase I.
275281|NCT02703857|Drug|cefoxitin|Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing
275282|NCT02703870|Device|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
275283|NCT02703870|Device|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
275284|NCT02703870|Behavioral|VRT|Vision restoration training, 10 sessions, 20 minutes
275285|NCT02703883|Device|BWST|BWST (six weeks, 3 times/week)
275286|NCT02706080|Other|emergency|
275287|NCT02706093|Other|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at ~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
275288|NCT02706093|Other|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
275289|NCT02706093|Other|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax [25min; ~150kcals; 4d/wk]
275290|NCT00202878|Drug|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
275291|NCT02706093|Other|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax [15min; ~90kcals; 4d/wk]
275292|NCT02706106|Device|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
275581|NCT02699489|Procedure|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
275582|NCT02699489|Procedure|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
275583|NCT02699502|Other|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
275584|NCT02699515|Drug|MSB0011359C|Subjects with metastatic or locally advanced solid tumors will receive intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
275585|NCT02699528|Drug|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
275012|NCT02710110|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
275013|NCT00203307|Drug|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
275014|NCT02710110|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
275015|NCT02710110|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
275016|NCT02710110|Other|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
275017|NCT02710110|Device|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
275018|NCT02710110|Drug|Capsaicin|A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction "cough if you need to" prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
275019|NCT02710123|Other|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
275020|NCT02710123|Other|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
275021|NCT02710136|Biological|Glycerinated German Cockroach Allergenic Extract|Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).
Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data).
275022|NCT02710149|Biological|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
275293|NCT02706119|Drug|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
275294|NCT02706119|Drug|Regular insulin within TPN reservoir|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
275295|NCT02706132|Biological|Mesenchymal Stem Cells(MSCs)|Six doses of 1*10^6/kg body weight MSCs are given, intravenously.
274728|NCT02714101|Other|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
274729|NCT02714114|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
274730|NCT02714114|Other|Blood draw|One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
274731|NCT02716142|Drug|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
274732|NCT02716142|Drug|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
274733|NCT02716168|Other|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
274734|NCT00204022|Drug|Mycophenolate mofetil|Mycophenolate mofetil
274735|NCT02716181|Device|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
274736|NCT02716181|Device|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
274737|NCT02716194|Biological|BAX 826|
274738|NCT02716194|Biological|Octocog alfa|
274739|NCT02716207|Device|CyberKnife|Radiation Therapy
274740|NCT02716220|Device|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
274741|NCT02716233|Drug|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
274742|NCT02716233|Drug|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
274743|NCT02716246|Genetic|scAAV9.U1a.hSGSH|Self-complementaty adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
274744|NCT02716259|Procedure|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
274745|NCT00204022|Drug|Azathioprine|Azathioprine
274746|NCT02716259|Procedure|Supragingival prophylaxis|Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
279002|NCT02694341|Device|Bakri Balloon|
279003|NCT02694354|Drug|BI 685509|
279004|NCT02694354|Drug|Placebo|
279005|NCT02694367|Other|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
279006|NCT02694393|Drug|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
279007|NCT02694406|Device|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
279008|NCT02694419|Device|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
274457|NCT02685111|Drug|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
274458|NCT02685111|Drug|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
274459|NCT02685124|Dietary Supplement|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
274460|NCT02685137|Drug|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
274461|NCT02685137|Other|Sham Injection|nothing
274462|NCT00200304|Behavioral|Internet weight loss with SlimFast and computer counseling|
274463|NCT02685150|Device|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
274464|NCT02687464|Drug|Non-operative treatment|will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement for a minimum of 12 hours (a total course of 10 days of antibiotics (intravenous and oral)). They will be discharged home once they meet a standardized set of criteria to be used in all centers.
The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results.
278712|NCT02700854|Other|5% carbon-dioxide inhalation|5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE > -5 mmol/L in arterial blood gas samples
278713|NCT02700867|Device|NIO|Intraosseous access device NIO (Defibtech)
278714|NCT02700880|Device|LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
278715|NCT02700893|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
278716|NCT02700893|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
278717|NCT02700906|Drug|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
278718|NCT02700906|Drug|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
278719|NCT02700919|Drug|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
278720|NCT02700919|Drug|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
278721|NCT02700932|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
278722|NCT00202228|Drug|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
279009|NCT00201461|Drug|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
279010|NCT02694432|Behavioral|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
279011|NCT02694432|Behavioral|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
279012|NCT02694445|Other|observation|The study is non-interventional.
279013|NCT02694458|Other|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
279014|NCT02694458|Other|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
263309|NCT02390453|Behavioral|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
263310|NCT02390453|Behavioral|Control|Control modules provide social contact for group discussion and instruction in health self-management and successful aging.
263311|NCT02390466|Biological|VAC-3S|Administered via intra-muscular injection in the arm
263312|NCT00162604|Drug|Cefuroxime|
263313|NCT02390479|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of four clinical visits
Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
263314|NCT02390492|Drug|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous [14C]-ipatasertib on Day 1 of study
263315|NCT02390492|Drug|Period 2 treatment|200-mg/100-mcCi oral [14C]-ipatasertib on Day 15 of study
263316|NCT02390505|Drug|Vitamin C|
263317|NCT02390505|Drug|Placebo|
263603|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
263604|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
263605|NCT02383511|Drug|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
263606|NCT02383524|Procedure|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
263607|NCT02383537|Other|Diabetes|the trial is observational with no intervention
263608|NCT02383550|Other|Observational Cognitive assessments|Observational
263609|NCT02383563|Drug|metformin extended release|
263610|NCT00161655|Drug|Methotrexate|
263611|NCT02385851|Drug|CHS-1701|
263612|NCT02385851|Drug|Pegfilgrastim|
263613|NCT02385877|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
263028|NCT02359175|Drug|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
263029|NCT02359175|Drug|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
263030|NCT02359175|Drug|Oral Paracetamol|Paracetamol to be given orally
263031|NCT02359175|Drug|Oral NSAID|NSAID to be given orally
263032|NCT02359175|Drug|Oral opioids|Opioids to be given orally
263033|NCT02359175|Drug|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
263034|NCT02359188|Device|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
263035|NCT02359201|Drug|V0018|Oromucosal - Single dose
263036|NCT00158834|Drug|Salmeterol/Fluticasone propionate combination product|
263037|NCT02359201|Drug|Placebo|Oromucosal - Single dose
263038|NCT02359214|Dietary Supplement|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
263039|NCT02359214|Other|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
263040|NCT02359227|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
263318|NCT02390518|Radiation|Stereotactic Radiosurgery|Patients with 1-5 brain metastases will be treated. If a patient has multiple brain metastases, one of these lesions will be chosen at random to receive the experimental dose, as determined by size of that lesion (see Table 1).
Table 1: Dose Escalation Schema Cohort Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1: < 20 mm 26 Gy 28 Gy 30 Gy n/a Cohort 2: 21-30 mm 20 Gy 22 Gy 24 Gy n/a Cohort 3: 31-40 mm 17 Gy 19 Gy 21 Gy 23 Gy
Dose escalation will proceed in increments of 2 Gy per fraction up to a maximum dose of 30 Gy, 24 Gy, and 23 Gy for metastases < 20 mm, 21-30 mm, and 31-40 mm respectively.
Cohorts 1, 2 and 3 may be enrolled simultaneously; however, 5 patients must be enrolled to each dose level and complete the 12 week DLT (Dose Limiting Toxicity) period before escalation can occur within a cohort.
263319|NCT02390531|Drug|Bevacizumab|Varying dosages in 10µl
263320|NCT02390544|Drug|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
263321|NCT02390557|Other|PDQMI|Intervention Arm
263322|NCT02390570|Other|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
263323|NCT00162617|Drug|Red blood cell transfusion|
262737|NCT02476578|Other|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
262738|NCT02476591|Behavioral|Charge Transparency|Providers caring for patients in the "Charge Transparency" cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs
262739|NCT02476604|Behavioral|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
262740|NCT02476617|Drug|ombitasvir/ABT-450/ritonavir|ombitasvir/ABT-450/ritonavir tablets
262741|NCT02476617|Drug|dasabuvir|dasabuvir tablets
262742|NCT02476617|Drug|ribavirin|ribavirin tablets
262743|NCT02478684|Other|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
262744|NCT02478684|Other|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
262745|NCT02478697|Behavioral|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
262746|NCT02478710|Drug|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
262747|NCT02478710|Drug|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
262748|NCT00176046|Drug|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
262749|NCT02478723|Device|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
263041|NCT02359240|Procedure|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
263042|NCT02359240|Procedure|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
262173|NCT02487888|Other|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
262469|NCT02483260|Drug|Ribavirin|Loading dose, 33 mg/kg (maximum dose: 2.64 g)
Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)
Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses).
262470|NCT02483286|Behavioral|ICG|Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.
The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
Subjects are encouraged to practice study home exercise program at least twice weekly.
262471|NCT02483286|Behavioral|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
262472|NCT02483286|Behavioral|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
262473|NCT02483299|Drug|Metformin|
262474|NCT00176527|Drug|isotretinoin|
262475|NCT02483299|Drug|Glucophage tablets and Victoza|
262476|NCT02483312|Biological|IL-12|
262477|NCT02483325|Drug|Allogeneic transplant conditioning|Allogeneic transplant
262478|NCT02483338|Behavioral|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
262479|NCT02483351|Other|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
262480|NCT02483351|Other|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of <=80g/L
262481|NCT02483364|Other|HC-SVT-1001|A single application in the context of a single surgical intervention.
262482|NCT02483377|Other|Quality-of-Life Assessment|Ancillary studies
262483|NCT02483377|Other|Questionnaire Administration|Complete questionnaires
262484|NCT02483390|Other|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
261872|NCT02494648|Other|Control|
261873|NCT02494661|Behavioral|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
261874|NCT00177853|Drug|celecoxib|Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
261875|NCT02494661|Behavioral|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
261876|NCT02494674|Behavioral|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
261877|NCT02494687|Drug|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
261878|NCT02494687|Drug|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
262174|NCT02487901|Device|Bone removal with ultrasonic osteotome|making gutter with ultrasonic osteotome
262175|NCT02489799|Behavioral|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
262176|NCT00002477|Drug|doxorubicin hydrochloride|
262177|NCT00177216|Drug|Zolpidem|Benzodiazepine receptor agonist (BzRA), zolpidem, treatment for insomnia
262178|NCT02489799|Behavioral|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
262179|NCT02489812|Behavioral|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
262180|NCT02489825|Procedure|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
262181|NCT02489825|Procedure|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
262182|NCT02489851|Procedure|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
262183|NCT02489851|Procedure|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
262184|NCT02489864|Drug|Terlipressin|
278541|NCT02717780|Drug|Remifentanil and desflurane|
278542|NCT02717793|Other|Strength testing|isometric muscle strength
1RM measurement of muscle strength
278543|NCT02717806|Behavioral|PATHway|Patients will use the PATHway platform for 6 months
278544|NCT02717819|Dietary Supplement|Protein|Daily intake of supplement
278545|NCT00204243|Drug|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
278546|NCT02717819|Dietary Supplement|Placebo|Daily intake of supplement
278547|NCT02717819|Other|Resistance training|Resistance training (daily while hospitalized, and 4 x/week after discharge)
278548|NCT02717832|Drug|hyperinsulinemic-euglycemic clamp|
278549|NCT02717845|Other|CT scan Ellipse|diagnostic CT scan imaging
278550|NCT02717845|Other|CT scan tomofix|diagnostic CT scan imaging
278551|NCT02717858|Drug|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
278552|NCT02717858|Drug|placebo|Injected s.c./subcutaneously (under the skin) once daily.
278846|NCT02711527|Other|Acupunture group B|Subjects in Group B will receive 14 needles based on the TCM theory "Soothing liver-qi stagnation" and "Tonifying the heart and the spleen"and "Invigorating the Yang Qi", all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) "特定電磁波譜" will be applied to Group B immediately after the needle insertion.
278847|NCT02711540|Procedure|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
278848|NCT02711553|Drug|Ramucirumab|Administered IV
278849|NCT02711553|Drug|Merestinib|Administered orally
278850|NCT02711553|Drug|Cisplatin|Administered IV
278851|NCT02713464|Behavioral|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
278852|NCT02713477|Drug|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|Pharmaceutical form: solution
Route of administration: subcutaneous
278853|NCT02713477|Drug|Insulin glargine HOE901|Pharmaceutical form: solution
Route of administration: subcutaneous
278248|NCT02689050|Device|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
278249|NCT02689063|Drug|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
278250|NCT02689063|Drug|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
278251|NCT02689063|Drug|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
278252|NCT02689063|Drug|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
278253|NCT00200824|Drug|Soy Isoflavone Nutritional Supplements|
278254|NCT02689076|Other|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
278255|NCT02689076|Other|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
278256|NCT02689089|Drug|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
278257|NCT02689102|Device|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
278258|NCT02689115|Other|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
278259|NCT02689141|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
278260|NCT02689141|Drug|Ofatumumab|Induction:
Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.
Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.
Cycle 1-8: Day 1 1000 mg i.v.
278553|NCT02717871|Device|PACK-CXL|Local anesthesia
- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times
Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer
Corneal scrape
Hypo-osmolaric riboflavin solution
- Apply one drop every 2 minutes for 20 minutes
UV-A irradiation
3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)
Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.
Additional postoperative treatment
Homatropin or Scopolamin, if anterior chamber reaction
Systemic NSAID/NSAR, if substantial pain
Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching
278554|NCT02717871|Drug|Cefazolin in combination with either tobramycin or gentamicin|Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.
Initial empiric topical antibiotic therapy (eye drops or ocular ointment):
1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).
277687|NCT02700451|Drug|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
277688|NCT02700451|Drug|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
277960|NCT02694055|Other|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to a CCM service delivery package.
277961|NCT02694055|Other|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to a CCM service delivery package to patients that visit them at their work post.
277962|NCT02694055|Other|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
277963|NCT02694055|Other|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
277964|NCT02696226|Drug|Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
277965|NCT02696226|Drug|Warfarin and clopidogrol|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
277966|NCT02696226|Drug|Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
277967|NCT02696239|Device|V-lock suture|
277968|NCT02696239|Device|Vicryl Suture|
277969|NCT02696239|Device|Lapra-Ty II|
277970|NCT02696265|Procedure|CFAE guided ablation|CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation, according to methods by Nademanee. PVI will be checked before and after ablation using a mapping catheter.
277971|NCT00201708|Drug|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
277972|NCT02696265|Procedure|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
277973|NCT02696278|Other|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
277406|NCT02706938|Other|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
277407|NCT02706938|Other|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
277408|NCT02706951|Drug|ABT-494|Oral tablet
277409|NCT02706951|Drug|Methotrexate|Oral capsule
277410|NCT02706951|Drug|ABT-494 matching placebo|Oral tablet
277411|NCT02706951|Drug|Methotrexate matching placebo|Oral capsule
277412|NCT00202969|Drug|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
277689|NCT02700464|Device|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
277690|NCT02700464|Procedure|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
277691|NCT02700477|Dietary Supplement|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
277692|NCT02700477|Other|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
277693|NCT02700490|Behavioral|Psychotherapy|
277694|NCT00202163|Drug|DHEA|
277695|NCT02700503|Behavioral|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
277696|NCT02700529|Drug|ubenimex|
277697|NCT02700529|Other|placebo|
277698|NCT02700542|Other|Integrated Pest Management|One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
277699|NCT02702570|Behavioral|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
277700|NCT02702596|Other|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
276799|NCT00204126|Device|Treadmill with partial body weight support|
276800|NCT02717052|Other|PILOT Study: PET1|[11C]DASB PET
276801|NCT02717052|Other|PILOT Study: PET2|[11C]DASB PET
276802|NCT02717052|Other|Main Study: PET1|[11C]DASB PET
276803|NCT02717052|Other|Main Study: PET2|[11C]DASB PET
276804|NCT02717065|Other|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
276805|NCT02717065|Other|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
276806|NCT02717078|Other|Diet Therapy|The intervention for both study groups will be a change in diet.
276807|NCT02717091|Drug|FOLFIRINOX|
276808|NCT02717091|Drug|gemcitabine + nab-paclitaxel|
276809|NCT02717117|Other|Soup meal|Soup meal as above
276810|NCT00204126|Device|Surface Functional Electrical Stimulation|
277100|NCT02710812|Procedure|Local Excision or Wait-and-See|Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).
The following principles should be respected:
A gross margin of at least 0.5 cm;
full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;
determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist.
277101|NCT02710825|Other|Osteopathy|The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.
When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality.
277102|NCT02710825|Other|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
277103|NCT02710838|Device|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
277104|NCT02710851|Biological|low dosage HPV Vaccine(1:1)|Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month.
276157|NCT02690558|Drug|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pebrolizumab with gemcitabine and cisplatin prior to cystectomy
276158|NCT02690571|Other|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
276159|NCT02690584|Behavioral|Metacognitive therapy|
276160|NCT02690597|Other|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
276161|NCT00002539|Procedure|conventional surgery|
276162|NCT00200967|Drug|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
276163|NCT02690610|Procedure|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
276164|NCT02690623|Other|Pediatric hospitalist program|In-house hospitalists available at all hours
276165|NCT02690623|Other|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
276166|NCT02690636|Radiation|radiotherapy|daily fractions, five fractions per week.
276167|NCT02690649|Other|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
276475|NCT02683707|Drug|Lidocaine|Local Anesthetic
276476|NCT02683707|Drug|Midazolam|IV sedation
276477|NCT02683720|Dietary Supplement|ONS|randomized clinical trial involving different ONS strategies
276478|NCT02683733|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
276479|NCT00000380|Drug|GHRH|
276480|NCT00002536|Drug|vincristine sulfate|
276481|NCT00002537|Drug|topotecan hydrochloride|
276482|NCT00200382|Drug|PS-341 (Velcade-drug)|
276483|NCT02685969|Procedure|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
275586|NCT00202020|Drug|Cilostazol 200mg/day Oral|
275587|NCT02699541|Behavioral|Diabetes Self-Management Education|This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.
Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight.
275588|NCT02699554|Procedure|Single-event multilevel surgery|
275589|NCT02699567|Other|No intervention|
275590|NCT00202319|Procedure|Sedation management protocol|
275591|NCT02701673|Drug|Azacitidine|Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
275592|NCT02701673|Drug|Gemcitabine|Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
275593|NCT02701673|Drug|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
275594|NCT02701673|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
275595|NCT02701686|Behavioral|quit immediately (QI)|advise to quit immediately using the AWARD model
275596|NCT02701686|Behavioral|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
275597|NCT02701699|Biological|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
275598|NCT02701712|Radiation|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
275599|NCT02701725|Device|CRI status|Measurement of CRI
275865|NCT02695420|Drug|Placebo|Drug: n/a Subjects will receive Placebo BID
275866|NCT02695420|Drug|37.5 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID up to week 4 or week 8 and 25 mg or 37.5 mg BID after week 4 or week 8, based on week 2 PK
275867|NCT02695420|Drug|50 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID up to week 4 or week 8 and 25 mg or 50 mg BID after week 4 or week 8, based on week 2 PK
275868|NCT02695433|Dietary Supplement|Active|Active Treatment Diet Plan
275869|NCT02695433|Dietary Supplement|Control|Control Diet Plan
275870|NCT00201643|Drug|Placebo|Course of Placebo (NS)
275296|NCT02706145|Other|Social norming campaign|community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
275297|NCT02706158|Dietary Supplement|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
275298|NCT02706158|Behavioral|balanced diet|participants will get a balanced diet according to pregnancy stage
275299|NCT02706171|Radiation|CyberKnife|
275300|NCT02706184|Drug|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
275301|NCT00000382|Behavioral|Child Protective Services|
275302|NCT00002547|Drug|busulfan|
275303|NCT00202891|Drug|sisomicin|
275304|NCT02706184|Drug|Placebo|Placebo
275305|NCT02706197|Device|OxyChip|The OxyChip is an investigational device
275306|NCT02706223|Other|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
275307|NCT02706236|Drug|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
275308|NCT02706236|Drug|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
275309|NCT02706249|Drug|Enoxaparin|
275310|NCT02708069|Other|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
275311|NCT02708069|Other|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
275312|NCT02708082|Device|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
275313|NCT02708095|Drug|Baricitinib|Administered orally
275600|NCT02701738|Dietary Supplement|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
274747|NCT02716272|Drug|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
274748|NCT02716272|Drug|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
275023|NCT02711995|Drug|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
275024|NCT02711995|Drug|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
275025|NCT02712008|Drug|REGN910-3|
275026|NCT02712008|Drug|Intravitreal Aflibercept Injection (IAI)|
275027|NCT02712021|Other|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
275028|NCT02712021|Other|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
275029|NCT02712034|Behavioral|MAT + A-CHESS|Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:
Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.
The latest information about addiction and recovery support, monitoring prompts, and peer and family support.
Advice on where to go for help and on how to make the best use of health and human services; and
A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.
A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects).
275030|NCT02712034|Other|MAT|Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. "Appropriate pharmacology" may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care.
275031|NCT02712047|Drug|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
275032|NCT00203580|Drug|Tinzaparin sodium|
275033|NCT02712047|Drug|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
275034|NCT02712047|Drug|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
275035|NCT02712060|Other|No intervention|
274465|NCT02687464|Procedure|Appendectomy|will undergo laparoscopic appendectomy within 12 hours of randomization and will receive intravenous antibiotics from the time of randomization and post-operatively according to a defined and standardized treatment regime based on consensus for this trial.
children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and a minimum total course for 5 days (intravenous and oral). The type of antibiotics used in each center will be identical to those used in the non-operative treatment group.
274466|NCT02687477|Procedure|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
274467|NCT02687477|Procedure|Sham procedure|patient in the sham group will receive sham procedure
274468|NCT02687490|Drug|Abraxane|125 mg/m2, D1, D8, D15
274469|NCT02687503|Dietary Supplement|Probiotic|
274749|NCT02716285|Drug|Tempocol-ColoPulse® (Peppermint oil)|Peppermint oil, menthae piperitae aetheroleum
274750|NCT02716285|Drug|Placebo|Placebo capsule, containing microcrystalline cellulose
274751|NCT02716285|Drug|Tempocol® (Peppermint oil)|Peppermint oil, menthae piperitae aetheroleum
274752|NCT02716311|Drug|Afatinib|
274753|NCT02716311|Drug|Cetuximab|
274754|NCT02716324|Behavioral|Care Manager|The CM is an individual responsible for communicating and coordinating ADHD care. The CM establishes rapport with families and communicates with them weekly to every 3 months to assess treatment use, identify new concerns, and help problem-solve. The CM also communicates with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
274755|NCT02718443|Drug|VXM01|Oral immunotherapy targeting VEGFR2
274756|NCT02718456|Behavioral|Expedited CD4 testing|
274757|NCT02718456|Behavioral|Supplemental peer counseling|
274758|NCT02718469|Biological|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
274759|NCT02718469|Biological|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
274760|NCT02718469|Biological|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
274761|NCT02718469|Biological|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
279015|NCT02696603|Behavioral|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
279016|NCT02696603|Behavioral|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test [Corsi, P.M. (1972)] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
279017|NCT02696603|Behavioral|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
279018|NCT02696603|Behavioral|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
279019|NCT02696603|Other|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
279020|NCT02696616|Drug|BI 655088|
279021|NCT00201734|Drug|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
279022|NCT02696616|Drug|Placebo|
279023|NCT02696629|Procedure|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
279024|NCT02696629|Device|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
279025|NCT02696629|Behavioral|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
274470|NCT02687516|Behavioral|Family-based behavioral social facilitation therapy|Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the "Traffic light diet" in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities.
274471|NCT02687516|Behavioral|TAU - Treatment as usual|This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a "contract" is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic.
274472|NCT02687529|Device|CST001|
263614|NCT02385877|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
263615|NCT02385890|Other|Control|Non pulse ingredient bagel
263616|NCT02385890|Other|Pea flour|Pulse ingredient bagel
263617|NCT02385890|Other|Pea fibre|Pulse ingredient bagel
263618|NCT00161993|Drug|Gammagard S/D (Solvent/Detergent)|
263619|NCT02385890|Other|Pea flour + pea fibre|Pulse ingredient bagel
263620|NCT02385890|Other|Pea flour + pea protein|Pulse ingredient bagel
263621|NCT02385890|Other|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
263622|NCT02385903|Other|Flammacerium|
263623|NCT02385903|Other|Standard dressing procedure|
263624|NCT02385916|Other|EstroSense®/MD|A natural product already approved by Health Canada
263625|NCT02385916|Other|Placebo|Placebo
263915|NCT02378727|Device|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
263916|NCT02378727|Device|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
263917|NCT02378740|Drug|Saline|The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:
0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion
263918|NCT02378740|Drug|Ketamine|The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:
0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion
263919|NCT02378753|Biological|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
263920|NCT02378766|Behavioral|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).
TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change.
263324|NCT02390583|Behavioral|CBT treatment of internet dependence|CBT treatment of internet dependence
263325|NCT02390583|Behavioral|CBT treatment of sleep disorders|CBT treatment of sleep disorders
263326|NCT02390596|Drug|Anakinra|The dose of Anakinra will be 2mg/kg. If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra (4mg/kg) at day 3 instead of 2mg/kg. Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
263327|NCT02392858|Other|Control group|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
263328|NCT02392871|Radiation|Palliative radiotherapy|
263329|NCT00002432|Drug|Foscarnet sodium|
263330|NCT00162916|Drug|citalopram|20mg or 40mg, once daily, for 40 weeks
263331|NCT02392871|Drug|Dabrafenib and trametinib (combination)|Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
263332|NCT02392884|Behavioral|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
263333|NCT02392897|Behavioral|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
263334|NCT02392897|Behavioral|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
263626|NCT02385929|Behavioral|Swallowing therapy & resistance training|i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.
iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards.
263627|NCT02385942|Device|Smart phone|measure the Live assessed wound size and the transmitted Smart phone-based wound size
determine dressing materials using Smart phone-based tele-consultation
263628|NCT02385955|Procedure|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
263629|NCT00162006|Drug|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
263630|NCT02385981|Device|Stivax|
263043|NCT02359253|Other|Arm|During the hour of Active Training the subject will actively move their arm while supported in the IntelliArm to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
263044|NCT02359253|Other|Hand|During the hour of active training the subject will actively open and close their hand while participating in task oriented occupational therapy focused on grasp and release tasks.
263045|NCT02359253|Other|Arm and Hand|Each visit subject alternates between interventions (a) and (b):
During the hour of Active Training the subject will actively move their arm while supported in the IntelliArm to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance
During the hour of active training, the subject will actively open and close their hand while participating in task oriented occupational therapy focused on grasp and release tasks.
263046|NCT02359266|Dietary Supplement|Vitamin D|Given to patients with existing vitamin D deficiency
263047|NCT02361684|Other|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
263048|NCT02361697|Other|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
263049|NCT02361710|Procedure|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
263050|NCT00159146|Drug|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
263051|NCT02361723|Drug|BGB-290|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
263052|NCT02361736|Drug|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
263053|NCT02361736|Drug|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
263054|NCT02361749|Drug|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
263055|NCT02361749|Procedure|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
263335|NCT02392910|Drug|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
263336|NCT02392910|Drug|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
262485|NCT02485639|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants will receive vaccine IM on day 1.
262486|NCT02485652|Drug|HM61713 (BI 1482694)|800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigator‟s opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
262750|NCT02478736|Other|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
262751|NCT02478749|Procedure|arm retraction|gently pulling through the ipsilateral arm to the knee
262752|NCT02478762|Procedure|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
262753|NCT02478762|Procedure|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
262754|NCT02478775|Drug|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
262755|NCT02478775|Drug|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
262756|NCT02478788|Drug|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
262757|NCT02478788|Drug|Placebo|Pills with no medication in it
262758|NCT02478801|Dietary Supplement|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
262759|NCT00176046|Drug|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
262760|NCT02478814|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
262761|NCT02478827|Behavioral|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
262762|NCT02478840|Drug|Lamazym|recombinant human alpha-mannosidase
262763|NCT02478853|Other|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
262764|NCT02480907|Behavioral|Workshop Group|Workshop support group
262185|NCT02489890|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
262186|NCT02489903|Drug|RRx-001|
262187|NCT02489903|Drug|Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane)|To be dosed after RRx-001
262188|NCT00177216|Drug|Placebo|Placebo control
262189|NCT02489903|Drug|cisplatin/carboplatin plus etoposide|To be dosed after RRx-001
262190|NCT02489916|Drug|CM4307|CM4307 300mg bid, each 4 week cycle
262191|NCT02489929|Other|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
262192|NCT02489929|Drug|azacytidine|
262193|NCT02489942|Drug|Jardiance|Empagliflozin
262194|NCT02489955|Drug|Amikacin|
262487|NCT02485665|Device|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
262488|NCT02485678|Other|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
262489|NCT02485678|Other|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
262490|NCT00176787|Procedure|Surgery|
262491|NCT02485678|Other|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
262492|NCT02485691|Drug|cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: intravenous
262493|NCT02485691|Drug|enzalutamide|Pharmaceutical form:capsule Route of administration: oral
278854|NCT02713477|Drug|Placebo|Pharmaceutical form: solution
Route of administration: subcutaneous
278855|NCT02713490|Drug|EXPAREL|EXPAREL and bupivacaine HCl
278856|NCT00203749|Behavioral|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
278857|NCT02713490|Drug|Bupivacaine|Single dose of bupivacaine HCl 0.5%
278858|NCT02713503|Other|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
278859|NCT02713503|Other|VisionCoach|Visual field evaluation using VisionCoach
278860|NCT02713516|Device|Virtual Reality|Use of virtual reality to deliver exposure therapy
278861|NCT02713529|Biological|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
278862|NCT02713542|Device|ACP|Autologous Conditioned Plasma
278863|NCT02713542|Other|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
278864|NCT02713555|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
274308|NCT02705729|Device|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
274309|NCT02705729|Device|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
274310|NCT02705742|Biological|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
274311|NCT02705755|Drug|TD-9855|
274312|NCT02705755|Drug|Placebo|
274313|NCT02705768|Drug|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
274314|NCT02705768|Drug|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
278555|NCT02717871|Drug|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
278556|NCT00204256|Drug|Iron sucrose|
278557|NCT00200200|Drug|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
278558|NCT02684370|Drug|BI 655066|
278559|NCT02684370|Drug|placebo to ustekinumab|
278560|NCT02684370|Drug|ustekinumab|
278561|NCT02684370|Drug|placebo to BI 655066|
278562|NCT02684370|Drug|placebo to BI 655066|
278563|NCT02684370|Drug|placebo to ustekinumab|
278564|NCT02684383|Biological|rDEN3∆30|10^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
278565|NCT02684383|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
278566|NCT02684396|Drug|TAK-648|TAK-648 Solution
278567|NCT02684396|Drug|TAK-648 Placebo|TAK-648 placebo-matching solution
278568|NCT00002536|Procedure|surgical procedure|
278569|NCT00200213|Behavioral|portion or unportioned food|
278570|NCT02684409|Drug|PROT-CL-NP101-015.01|
278571|NCT02684422|Other|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
278572|NCT02684435|Drug|Perflutren lipid microsphere|Dosing per approved package label
278573|NCT02684448|Procedure|Inguinal Hernia Repair|Inguinal (unilateral or bilateral) hernia repair
278865|NCT02713555|Procedure|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
277974|NCT02696278|Other|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
277975|NCT02696278|Other|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
277976|NCT02696291|Drug|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
278261|NCT02689141|Drug|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
278262|NCT02689154|Device|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
278263|NCT02689167|Drug|Sunitinib|
278264|NCT00200850|Biological|Hose Dust Mite SLIT|low dose SLIT 143 AU/ml daily
278265|NCT02689180|Drug|Placebo|Replacement of furosemide by placebo
278266|NCT02689180|Drug|Furosemide|Maintenance of furosemide on usual doses
278267|NCT02691494|Drug|Elagolix + Estradiol/Norethindrone Acetate|Elagolix + Estradiol/Norethindrone Acetate for 6-month Treatment
278268|NCT02691507|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
278269|NCT00201110|Behavioral|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
278270|NCT02691507|Drug|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
278271|NCT02691533|Drug|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
278272|NCT02691533|Drug|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
278273|NCT02691546|Other|blood sample collection|
278274|NCT02691559|Device|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
278275|NCT02691572|Procedure|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
277701|NCT02702596|Behavioral|Depression Education Fotonovela|Depression education that uses a unique, culturally adapted depression fotonovela titled "Secret Feelings" developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues
277702|NCT02702596|Behavioral|Standard Education|The the use of a pamphlet to educate people about depression.
277703|NCT00202449|Drug|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
277704|NCT02702609|Device|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
277705|NCT02702609|Device|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
277706|NCT02702622|Other|Provitamin A-biofortified transgenic bananas|
277707|NCT02702635|Procedure|DCE MRI of the brain|An MRI of the brain including a DCE sequence
277977|NCT02696291|Drug|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
277978|NCT02696291|Drug|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
277979|NCT02696291|Drug|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
277980|NCT02696291|Drug|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
277981|NCT02696291|Drug|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
277982|NCT00002542|Drug|epirubicin hydrochloride|
277983|NCT00201708|Drug|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
277984|NCT02696304|Other|Adipose tissu repartition|absorptiometry,
277985|NCT02696304|Other|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
277986|NCT02696304|Other|Preadipocyte quantification and adipose tissue inflamation|biopsy
277105|NCT02710851|Biological|low dosage HPV Vaccine(1:2)|Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month.
277106|NCT00002548|Biological|recombinant interferon alfa|3 million units/m2 SQ Monday-Wednesday
-Friday (3 times a week)
277107|NCT00203424|Drug|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
277108|NCT02712801|Drug|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
277109|NCT02712814|Drug|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
277110|NCT02712814|Procedure|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
277111|NCT02712814|Procedure|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
277112|NCT00203632|Drug|rosiglitazone/placebo|
277113|NCT02712827|Procedure|Progrip|Self-fixating mesh
277114|NCT02712827|Procedure|Non-Progrip|Non self-fixating mesh with the use of glue
277115|NCT02712840|Procedure|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
277116|NCT02712840|Procedure|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
277413|NCT02706964|Device|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
277414|NCT02706964|Device|Magnetic resonance imaging|A brain MRI will be performed.
277415|NCT02706964|Device|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
277416|NCT02706977|Drug|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
277417|NCT02706977|Drug|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
277418|NCT02706977|Device|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
276484|NCT02685982|Device|Rhythmic Sensory Stimulation|The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.
In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation.
276485|NCT02685995|Device|VectorFlow TDC|TDC insertion, either VectorFlow or Palindrome, will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
276486|NCT02685995|Device|Palindrome TDC|TDC insertion, either VectorFlow or Palindrome, will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
276487|NCT02686008|Drug|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
276488|NCT02686021|Drug|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
276489|NCT02686021|Drug|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
276490|NCT02686021|Drug|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
276811|NCT02717130|Drug|Aripiprazole|
276812|NCT02717156|Procedure|Computed Tomography|Correlative studies
276813|NCT02717156|Other|Laboratory Biomarker Analysis|Correlative studies
276814|NCT02717156|Biological|Pembrolizumab|Given IV
276815|NCT02717156|Procedure|Positron Emission Tomography|Correlative studies
276816|NCT02717156|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
276817|NCT02717169|Device|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
275871|NCT02695446|Drug|Minocycline|Oral extended release minocycline
275872|NCT02695459|Drug|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
275873|NCT02695472|Drug|80 Milligrams NSI-189|Orally Administered
275874|NCT02695472|Drug|Placebo|Orally administered
275875|NCT02695472|Drug|40 Milligrams NSI-189|Orally Administered
275876|NCT02697344|Drug|Lenalidomide|Given PO
275877|NCT02697344|Other|Pharmacological Study|Correlative studies
275878|NCT02697344|Drug|R-(-)-Gossypol Acetic Acid|Given PO
275879|NCT00201799|Drug|Infliximab|A total of 6 doses of Infliximab will be administered as follows:
Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42
275880|NCT02697357|Behavioral|Psychosocial Instruments|
275881|NCT02697357|Behavioral|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
275882|NCT02697370|Drug|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
275883|NCT02697383|Drug|Ixazomib (MLN9708)|
275884|NCT02697383|Drug|Dexamethasone|
275885|NCT02697396|Behavioral|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
275886|NCT02697396|Other|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
276168|NCT02690662|Behavioral|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
276169|NCT02690675|Dietary Supplement|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
276170|NCT02690688|Device|determination of dynamic preload variables|
275601|NCT00202332|Procedure|Coronary artery bypass|
275602|NCT02701751|Other|Exercise session|A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
275603|NCT02701764|Drug|Pregabalin|
275604|NCT02701764|Drug|Placebo|
275605|NCT02701777|Drug|Seromycin|100mg pill of Seromycin by mouth will be administered
275606|NCT02701777|Device|STDP|noninvasive magnetic or electrical stimulation will be applied to the brain
275607|NCT02701777|Other|Training|following the directions of the researcher the participant will be asked to perform specific repetitive movements using their hand, arm or leg .
275608|NCT02701777|Drug|Dextromethorphan|150mg of DExtromethorphan pill will be administered
275609|NCT02701777|Drug|Seromycin Placebo|placebo pill will be administered
275610|NCT02701777|Drug|Dextromethorphan Placebo|placebo pill will be administered
275611|NCT02701777|Device|Sham STDP|noninvasive magnetic or electrical sham stimulation will be applied to the brain
275612|NCT00202345|Drug|Iron sucrose|
275613|NCT02701790|Device|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
275614|NCT02701790|Device|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
275615|NCT02701790|Other|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
275616|NCT02701790|Other|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
275617|NCT02703896|Drug|Drug either PPIS or H2RA and prokinetics|Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups
Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )
Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)
Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)
Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)
Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)
Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)
Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)
Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)
Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)
Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
275618|NCT02703896|Procedure|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
275036|NCT02712073|Other|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
275037|NCT02712086|Other|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
275038|NCT02712112|Drug|Imatinib Mesylate|
275039|NCT02712125|Drug|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
275314|NCT02708095|Drug|Placebo|Administered orally
275315|NCT02708108|Behavioral|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
275316|NCT02708108|Behavioral|Activity and Exercise Intervention|Beginning at the time of diagnosis, the exercise and activity component uses an "activity menu" to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy.
275317|NCT02708121|Behavioral|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to a commercial weight loss treatment.
275318|NCT02708121|Other|Comparator Intervention|Participants informed that they have free access to a commercial weight loss treatment.
275319|NCT00203073|Drug|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
275320|NCT02708147|Other|Physioteraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
275321|NCT02708160|Drug|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
275322|NCT02708160|Drug|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
275323|NCT02708160|Drug|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
275324|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
275325|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
274762|NCT02718482|Drug|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
274763|NCT02718482|Drug|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
274764|NCT00204386|Drug|Topiramate|
274765|NCT02718495|Drug|PTI-428|
274766|NCT02718495|Drug|Placebo|
274767|NCT02718508|Behavioral|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
274768|NCT02718521|Procedure|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
274769|NCT02718521|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
274770|NCT02718521|Drug|0.9% sodium chloride ﬂuid administration|
275040|NCT02712125|Drug|Placebo|placebo vaginal tablets once daily until delivery
275041|NCT02712151|Procedure|Abdominal Wall Block|bilateral TAP and RS blocks.
275042|NCT02712151|Procedure|Surgical infiltration|distributed between the 4 laparoscopic port sites.
275043|NCT02714127|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
275044|NCT02714127|Other|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
275045|NCT02714140|Behavioral|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select those 2 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the two options over all existing testing options. In addition, the investigators will offer a default option which combines the most common feature levels currently found in the study area.
275046|NCT02714140|Behavioral|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and 2 PB-HCT options that are less preferred than the default option and whose utility differential to the default option is comparable to that of the more-preferred (PB-HCT +) options. In addition, the investigators will offer the same default option as in the PB-HCT + intervention, which combines the most common feature levels currently found in the study area.
274473|NCT02687542|Drug|Placebo|Placebo
274474|NCT00002538|Procedure|laparoscopic surgery|
274475|NCT00200590|Drug|acetaminophen and reduced dosage of prostaglandin|
274476|NCT02687542|Drug|PF-06649751 low dose|PF-06649751 low dose
274477|NCT02687542|Drug|PF-06649751 middle dose level 1|PF-06649751 middle dose level 1
274478|NCT02687542|Drug|PF-06649751 middle dose level 2|PF-06649751 middle dose level 2
274479|NCT02687542|Drug|PF-06649751 high dose|PF-06649751 high dose
274480|NCT02687555|Behavioral|Cognitive Bias Modification of Appraisals (CBM-App)|
274481|NCT02687555|Behavioral|Peripheral Vision Task (control condition)|
274482|NCT02689804|Drug|Ulipristal acetate 30mg|The investigators plan to enroll women with normal BMI and obese women of reproductive age in order to compare LNG-EC and UPA-EC PK parameters between the two groups of women. A research coordinator will randomly assign the order in which women receive the two drugs at the enrollment visit. Women will be admitted to CUMC for two 24-hour periods separated by at least 5 half-lives (~ 8 days). During this admission, the women will receive a single dose of an FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg and have serial 13 blood specimens collected. The woman will be discharged from CUMC after her 24-hour blood collection and will return to CUMC the following day for a 48-hour blood collection. This blood collection will conclude participation in this arm of the study.
274483|NCT02689817|Device|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
274484|NCT02689830|Device|Bead Block|Prostate embolization
274485|NCT02689843|Drug|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
274486|NCT02689843|Drug|Metformin|Metformin 500mg three times daily
274487|NCT02689843|Drug|Pioglitazone|Pioglitazone 30mg once daily
274771|NCT02718521|Drug|isosorbide dinitrate|
274772|NCT02718547|Drug|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
274773|NCT02718560|Behavioral|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
274774|NCT02718599|Drug|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
263921|NCT02380963|Behavioral|Colorado Diet with monetary payments|Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.
Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.
Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.
Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend.
263922|NCT02380976|Drug|combination drug: DW330SR, DW1030|
263923|NCT02380976|Drug|DW340|
263924|NCT02380989|Device|Ayurveda|Ayurveda combinations in the form of gel and patches were applied on acute pain site.
263925|NCT02380989|Device|Placebo|
263926|NCT02381002|Other|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
263927|NCT02381015|Genetic|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
263928|NCT02381015|Genetic|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
263929|NCT02381015|Behavioral|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
263930|NCT02381015|Behavioral|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
264231|NCT02374437|Drug|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
264232|NCT02374437|Drug|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
264233|NCT02376296|Drug|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
264234|NCT02376296|Other|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
264235|NCT02376309|Behavioral|Inactivity|Inactivity
264236|NCT02376309|Drug|ND|1 nandrolone decanoate injection
264237|NCT02376309|Dietary Supplement|Leu|Leucine supplements
263631|NCT02385994|Device|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
263632|NCT02386007|Drug|DW-3101_150mg|
263633|NCT02386007|Drug|DW-3101_300mg|
263634|NCT02386007|Drug|DW-3101_600mg|
263635|NCT02386007|Drug|Placebo|
263636|NCT02386020|Drug|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
263637|NCT02386020|Drug|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
263638|NCT02386033|Drug|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
263639|NCT00162292|Drug|BMS-582949 and Methotrexate|
263640|NCT02388256|Device|acupuncture|Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).
Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience.
263641|NCT02388256|Other|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
263642|NCT02388269|Device|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
263643|NCT02388282|Device|diaphragm ecography|recording of diaphragm ecography
263931|NCT00161395|Behavioral|Preconception advice|Preconception advice for diet and frequency of intercourse.
263932|NCT02381028|Other|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
263933|NCT02381028|Other|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
263934|NCT02381067|Other|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
263935|NCT02381080|Drug|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
263337|NCT02392936|Procedure|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
263338|NCT02392949|Behavioral|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
263339|NCT02392949|Other|Placebo|The shoulders will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
263340|NCT02392962|Procedure|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
263341|NCT00162916|Drug|Placebo|Cornstarch
263342|NCT02392962|Procedure|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
263343|NCT02392975|Procedure|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
263344|NCT02392988|Other|acupuncture treatment|acupuncture treatment
263345|NCT02392988|Other|Placebo Comparator|Placebo Comparator
263346|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
263347|NCT02393001|Other|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
263348|NCT02356874|Behavioral|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
263349|NCT02356887|Other|IJV Flow in the sitting position|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions. The volunteers will be scanned initially in the sitting position at rest followed by the 2 conditions mimicking venous occlusion, one with internal jugular compression using neck collar and Valsalva maneuver.. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
263350|NCT02356900|Procedure|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
263644|NCT02388295|Drug|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
263645|NCT02388295|Drug|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
262765|NCT02480907|Behavioral|Internet-based support group|Internet based support group with E-mail coaching
262766|NCT02480933|Procedure|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
262767|NCT02480933|Other|Biopsy|Biopsy of BI-RADS 3 and superior lesions
262768|NCT02480946|Drug|MBS2320|As described in the arm descriptions
262769|NCT02480946|Drug|Placebo|As described in the arm descriptions
262770|NCT02480946|Drug|Methotrexate|Background therapy as described in the arm descriptions
263056|NCT02361762|Behavioral|Computerized executive control training|Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.
Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.
A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks.
263057|NCT02361775|Device|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
263058|NCT02361775|Device|opioid iv pca|opioid pca consisting of hydromorphone
263059|NCT02361775|Drug|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
263060|NCT02361775|Device|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
263061|NCT00159159|Drug|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
263062|NCT02361801|Drug|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
263063|NCT02361801|Drug|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output < 2 mL/Kg/h despite adequate fluid replacement.
263064|NCT02361814|Procedure|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
263065|NCT02361827|Procedure|Embryo transfer|For patients in each group, they will have embryo transferred 3 or 5 days after oocyte retrieval.
263066|NCT02361853|Other|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
263067|NCT02361853|Other|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
262494|NCT02485691|Drug|abiraterone acetate|Pharmaceutical form:tablet Route of administration: oral
262495|NCT02485691|Drug|prednisone|Pharmaceutical form:tablet Route of administration: oral
262496|NCT02485704|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
262497|NCT02485704|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
262498|NCT02485717|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
262499|NCT02485717|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
262500|NCT02485743|Other|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
262501|NCT00002476|Radiation|low-LET cobalt-60 gamma ray therapy|
262502|NCT02487901|Device|Bone removal with drill|
262771|NCT02480959|Procedure|Surgical treatment for recurrent patellar instability|Either medial plication or MPFL reconstructuion surgery
262772|NCT02480972|Procedure|magnetic resonance imaging|multiparametric MRI as follows:
diffusion weighted imaging using multiple b-values
Fat quantification sequence
perfusion MRI using ECCM agent
MR elastography
routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)
262773|NCT02480985|Other|Pituitary function evaluation|Pituitary function evaluation performed at hospital discharge, 6 and 12 months
Thyroid-stimulating hormone, free T4 and T3
Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone
Adrenocorticotropic hormone stimulation test
Glucagon test (growth hormone deficit)
Risk factors evaluation of pituitary dysfunction
Demographic data
Daily data (clinical exam, secondary brain injuries)
Hormone levels on day 1, 3 and 7
Biomarkers on day 1, 3 and 7
Brain CT-Scan on day 1
Pituitary MRI on day 7
Outcome measures at 6 and 12 months
Neurological recovery (GOSe)
Independent functioning (FIM)
Quality of life (EQ-5D-5L)
Life satisfaction (LISAT-11)
Depression (PHQ-9)
262774|NCT00176332|Drug|rosuvastatin|
262775|NCT02480998|Biological|IL-YANG Flu Vaccine QIV 0.5mL|
262776|NCT02480998|Biological|IL-YANG Flu Vaccine TIV 0.5mL|
262777|NCT02481011|Drug|antithrombotic drugs|
262778|NCT02481037|Other|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
274315|NCT02705781|Device|smARTrack Feeding Tube System|
274316|NCT02705807|Drug|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen [pH] 10.2 - 10.8 diluent) for Injection.
274317|NCT02707757|Drug|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
274318|NCT02707757|Drug|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
274319|NCT02707770|Other|Pulmonary Rehabilitation|
274320|NCT02707783|Device|Bioresorbable vascular scaffold (BVS) implantation|
274321|NCT00203047|Drug|Placebo|Placebo for prednisone given daily
274322|NCT02707796|Procedure|Hemicolectomy|
274323|NCT02707809|Drug|Dexmedetomidine|Dexmedetomidine infusion
274324|NCT02707822|Other|Clinical and genetic factors|
274325|NCT02707835|Other|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
274326|NCT02707835|Other|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
274327|NCT02707835|Other|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
274328|NCT02707848|Other|No intervention|
274329|NCT02707861|Drug|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
274604|NCT02701400|Biological|Durvalumab|Given IV
274605|NCT02701400|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
274606|NCT02701400|Other|Laboratory Biomarker Analysis|Correlative studies
274607|NCT02701400|Other|Pharmacological Study|Correlative studies
274608|NCT02701400|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
274609|NCT00202293|Drug|Olanzapine|
274610|NCT02701400|Biological|Tremelimumab|Given IV
278866|NCT02713568|Other|Ultrasound examination|Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.
Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.
For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin.
278867|NCT00002548|Drug|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
278868|NCT00203762|Behavioral|Public sector antiretroviral treatment programmes|
278869|NCT02715687|Drug|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
278870|NCT02715687|Drug|Placebo|Will receive 30 days treatment with oral placebo of 200mg
278871|NCT02715700|Drug|Methadone|Methadone 20 - 200 mg (10 mg/mL if oral solution concentrate) oral tablets once daily. Participants will receive their stable maintenance methadone at their usual clinic for at least 2 weeks before Day 1. Beginning on Day 1, participants will receive the same formulation and dose of methadone (after an overnight fast) at the study site. On Day 6, participants will be discharged from the study site and resume their maintenance methadone therapy at their usual clinic.
278872|NCT02715700|Drug|MK-1439|MK-1439 100 mg oral tablet once daily after an overnight fast from Day 2 to Day 6
278873|NCT02715726|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
278874|NCT02715726|Drug|placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
278875|NCT02715726|Drug|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
278876|NCT02715726|Drug|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
278877|NCT02715726|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
278878|NCT00002548|Drug|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
278879|NCT00203996|Device|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
278880|NCT02715726|Drug|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
278881|NCT02715726|Drug|simvastatin|Pharmaceutical form:tablet Route of administration: oral
278882|NCT02715739|Other|No intervention|
278883|NCT02715752|Dietary Supplement|Gene-Eden-VIR/Novirin|
278276|NCT02691572|Drug|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
278277|NCT02691572|Drug|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
278278|NCT02691572|Procedure|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
278279|NCT02691572|Procedure|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
278280|NCT00201123|Drug|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
278281|NCT02691572|Procedure|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients` abdomen.
278574|NCT02684461|Drug|Pembrolizumab|Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.
Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.
278575|NCT02684474|Biological|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
278576|NCT02684487|Drug|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
278577|NCT02684487|Drug|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
278578|NCT02684500|Device|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
278579|NCT02684513|Dietary Supplement|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
278580|NCT00200226|Drug|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
278581|NCT02684513|Dietary Supplement|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
278582|NCT02684526|Procedure|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
278583|NCT02686840|Drug|vaginal misoprostol|All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.
Paracetamol, eight hourly, will be provided as analgesic or antipyretic
278584|NCT02686853|Drug|Liposomal amphotericin B|
277987|NCT02698371|Device|G1-Control: Futurabond®DC-SE|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G1 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
277988|NCT02698371|Device|G2-Control: Futurabond®DC pre-etching|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G2 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
277989|NCT02698371|Device|G3: Futurabond® U - ER|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G3 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
278282|NCT02691572|Procedure|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
278283|NCT02691572|Drug|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
278284|NCT02691572|Drug|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
278285|NCT02691572|Procedure|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
278286|NCT02691585|Other|Music Intervention|A raga will be played for 10 minutes & data collected.
278287|NCT02691598|Drug|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
278288|NCT02691663|Dietary Supplement|Oral bicarbonate supplementation|
278289|NCT02691663|Dietary Supplement|Placebo|
278290|NCT02691676|Drug|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
277419|NCT02706977|Other|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
277420|NCT02706977|Other|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
277421|NCT02706990|Device|Physica KR|Kinematic retaining total knee implant
277422|NCT02706990|Device|Physica PS|Posterior stabilized total knee implant
277423|NCT02708875|Other|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
277424|NCT02708875|Other|Glucose Challenge|Glucose drink (50g glucose)
277425|NCT02708888|Other|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
277426|NCT02708888|Other|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
277427|NCT02708901|Dietary Supplement|VSL#3|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
277428|NCT02708901|Dietary Supplement|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
277429|NCT02708914|Biological|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
277430|NCT02708914|Biological|Eprex|Eprex® is chosen as the comparator.
277708|NCT02702648|Drug|AC-082|Hard gelatin capsules for oral administration
277709|NCT02702648|Drug|Placebo|Matched placebo capsules for oral administration
277710|NCT02702661|Procedure|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
277711|NCT02702661|Procedure|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
277712|NCT02702661|Drug|Levobupivacaine|Levobupivacaine 0.125% - 40ml
277713|NCT02702674|Drug|propranolol|propranolol 20 mg given before induction of labor
277714|NCT00002545|Radiation|low-LET photon therapy|
277715|NCT00202449|Drug|paroxetine|20 mg taken at 10a for duration of the study
276818|NCT02717182|Other|interviews|interviews
276819|NCT02717195|Drug|Risperidone|4-6 mg/day, encapsulated tablets, orally
276820|NCT02717195|Drug|Olanzapine|15-20 mg/day, encapsulated tablets, orally
276821|NCT00002548|Procedure|autologous bone marrow transplantation|day 0
276822|NCT00204139|Procedure|Routine midtrimester pregnany ultrasound scan|
276823|NCT00200148|Procedure|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
276824|NCT02683733|Drug|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
276825|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
276826|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
276827|NCT02683746|Drug|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
276828|NCT02683746|Drug|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
277117|NCT02712853|Other|Saliva collection|Collection of saliva via swab for miRNA processing
277118|NCT02712853|Other|Vineland Adaptive Behavior Scale-II Assessment|
277119|NCT02712866|Drug|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
277120|NCT02712892|Genetic|Non Interventional Study|
277121|NCT02712905|Drug|INCB059872|Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.
INCB059872 tablets to be administered by mouth.
276171|NCT02690701|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring on days of study visits will be done by the patients (or caregivers) at home.
276172|NCT02690701|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients will be switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring on days of study visits will be done by the patients (or caregivers) at home.
276173|NCT00200967|Drug|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
276174|NCT00201305|Drug|Gemcitabine+5FU+Leucovorin|
276175|NCT02693145|Other|Anti-Retroviral Treatment and Access to Services (ARTAS)|Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
276176|NCT02693171|Drug|Dinutuximab|Unituxin will be administered along with cytokines according to the prescribing information (see FDA-approved Unituxin Package Insert, March 2015; SmPC, August 2015).
276177|NCT02693184|Other|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
276178|NCT02693184|Other|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
276179|NCT02693197|Drug|T-817MA|A single oral dose of 448 mg
276180|NCT02693210|Drug|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
276181|NCT02693210|Drug|Methotrexate|Participants will receive >= 10 mg/week methotrexate orally up to 24 weeks
276182|NCT02693210|Other|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
276183|NCT02693210|Other|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
276184|NCT02693210|Other|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
276491|NCT02686034|Device|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
275887|NCT02697396|Other|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
275888|NCT02697409|Behavioral|Education Against Tobacco intervention|
275889|NCT02697422|Other|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
275890|NCT00201812|Drug|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
275891|NCT02697435|Other|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
275892|NCT02697435|Other|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
275893|NCT02697448|Drug|propofol|Participant receives propofol as anesthetic for cardiac ablation.
275894|NCT02697448|Drug|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
275895|NCT02697461|Other|Intrinsic Foot Strengthening|Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and "toe yoga" maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises.
275896|NCT02699580|Device|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
275897|NCT02699580|Procedure|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
275898|NCT02699593|Device|Test Contact Lens|
275899|NCT02699593|Device|Control Contact Lens|
275900|NCT02699606|Drug|JNJ-42756493|Participants will receive 10 mg of JNJ-42756493, once daily for 7 consecutive days on Days 1-7 and Days 15-21 of a 28-day cycle.
275901|NCT02699619|Device|Pinloc|3 hook pins interlocked in plate.
275902|NCT02699619|Device|2 Hansson pins|2 isolated hook pins.(Without plate)
275903|NCT00202020|Drug|Aspirin 100mg/day Oral|
275904|NCT02699645|Drug|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|
275326|NCT02708186|Drug|Nelotanserin|once daily, oral, 20-mg tablets
275327|NCT02708186|Drug|Placebo|once daily, oral, matching tablets
275328|NCT02708212|Procedure|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
275329|NCT02710162|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
275330|NCT00203320|Drug|etanercept given by perispinal administration|
275619|NCT02703909|Drug|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
275620|NCT02703909|Device|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
275621|NCT00002546|Drug|ifosfamide|
275622|NCT00202657|Procedure|echocardiography|
275623|NCT02703922|Other|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
275624|NCT02703935|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
275625|NCT02703935|Behavioral|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
275626|NCT02703948|Device|Restylane Silk with Lidocaine|
275627|NCT02703961|Drug|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
275628|NCT02703961|Drug|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
275629|NCT02703961|Radiation|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
275630|NCT02703961|Radiation|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
275047|NCT02714140|Behavioral|Economic incentive|Six months after the offer of testing options, all participants will be re-contacted. The date and location of participants' most recent HIV test will be ascertained; participants who did not test using either the more-preferred, less-preferred, or default options, will be asked if they had tested elsewhere. If they had not, they will be reminded of the options, and offered an incentive of 5,000 Tanzanian Shilling (~$3) to present for testing using any of the options; the incentive will be paid at the testing location.
275048|NCT00203801|Drug|Artesunate plus sulfadoxine-pyrimethamine|
275049|NCT02714153|Device|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
275050|NCT02714166|Other|Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
275051|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
275052|NCT02714179|Drug|Paracetamol was given intravenously in both group at different times|
275053|NCT02714192|Other|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
275054|NCT02714205|Drug|transdermal nitroglycerin|
275055|NCT02714205|Drug|Placebo|
275056|NCT02714218|Biological|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
275331|NCT02710162|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
275332|NCT02710162|Device|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
275333|NCT02710162|Drug|Capsaicin|A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction "cough if you need to" prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
275334|NCT02710162|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
275335|NCT02710162|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
274775|NCT00204399|Behavioral|Telephone counseling support|
274776|NCT02718599|Drug|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
274777|NCT02718625|Biological|Santyl|Collagenase ointment applied topically
274778|NCT02718625|Biological|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
274779|NCT02685150|Drug|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
274780|NCT02685150|Other|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
274781|NCT02685163|Other|Antioxidant ice-cream|Narutal Antioxidant ice-cream
274782|NCT02685163|Other|Control Ice-cream|Natural Control Ice-cream
274783|NCT02685176|Device|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)|A heater (STK Heatpac) will be used in the active warming arms of the study.
274784|NCT02685176|Other|No heat|No active heating provided post cooling
274785|NCT02685189|Other|Previous exposure to stannsoporfin|No intervention in this protocol
274786|NCT02685202|Device|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
274787|NCT02685228|Drug|Decitabine|decitabine 5mg/m2,d1-d5;
274788|NCT00002536|Radiation|radiation therapy|
274789|NCT00200304|Behavioral|Internet weight loss program with SlimFast|
274790|NCT02685228|Drug|Gemcitabine|gemcitabine 1.0g/m2, d8,d15,d22
275057|NCT02714218|Biological|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
275058|NCT02714218|Biological|Nivolumab 1 mg/kg IV|
275059|NCT00203801|Drug|Artemether-lumefantrine|
275060|NCT02714218|Biological|Ipilimumab 3 mg/kg IV|
275061|NCT02714231|Drug|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
264238|NCT02376322|Radiation|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
264239|NCT02376335|Biological|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
264240|NCT02376335|Other|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
264241|NCT00160745|Drug|Rosuvastatin|
264242|NCT02376348|Behavioral|Control full WHO package for VMMC, as well as awareness activities developed by Jhpiego|Outreach sites randomized to the control arm will receive the full WHO package for VMMC, as well as awareness activities developed by Jhpiego (including mass media and community outreach activities prior to, and during, the outreach service provision).
264243|NCT02376348|Behavioral|Intervention full WHO package for VMMC, as well as awareness activities developed by Jhpiego plus additional demand-creation communication messages|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
264244|NCT02376361|Device|Transonic|Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines
Recirculation, access flow will be performed according to HD03 Manual.
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.
264245|NCT02376374|Other|Controlling vaccination rates in communities|
264246|NCT02376400|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29 or 57.
259673|NCT02479659|Other|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
259674|NCT02479659|Other|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
259675|NCT00176215|Procedure|survival failure of more than 20 %|
263936|NCT02381080|Drug|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
263937|NCT02381080|Drug|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
263938|NCT02381093|Other|Modified BLS course|BLS using CI
263939|NCT02381093|Other|Standard BLS Course|Usual BLS teaching
263940|NCT02381119|Behavioral|Personalized Dietary Advice Services|This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).
This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories.
263941|NCT02383589|Other|MMF placebo|Divided dose given orally daily
263942|NCT02383589|Drug|mycophenolate mofetil|1 g will be given orally in divided doses at start. Dose wil be increased gradually to 1 g twice daily.
263943|NCT02383589|Drug|rituximab [MabThera/Rituxan]|1000 mg rituximab given by intravenous infusion on Day 1 and 15, with repeat rituximab administration on Day 168 and 182 provided specific safety criteria have been met
263944|NCT02383589|Other|rituximab placebo|Matching rituximab placebo given intravenously on Day 1 and 15, with repeat matching placebo administration on Day 168 and 182 provided specific safety criteria have been met
263945|NCT02383615|Procedure|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
263946|NCT02383654|Procedure|Autologous Adipose-Tissue Derived Stem Cells|Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells
Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.
Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation .
263947|NCT02383667|Device|Electrocardiogram holter|
263948|NCT02383680|Biological|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
264247|NCT02376400|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29 or 57.
264248|NCT02376400|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
264249|NCT02376413|Procedure|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
264250|NCT02376413|Drug|Chemotherapy or endocrine therapy or Trastuzumab therapy|
263646|NCT02388308|Device|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
263647|NCT02388321|Drug|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
263648|NCT02388321|Drug|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
263649|NCT02388334|Other|to develop a standardized questionnaire|to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).
The development of this standardized tool will also :
identify the specific support needs of the caregivers
study the links between the quality of care as perceived by the professionals, patients and caregivers
identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results.
263650|NCT00162305|Drug|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
263651|NCT02388347|Drug|Placebo SC|Liquid formulation
263652|NCT02388347|Biological|MEDI7836 SC Cohort 1|Liquid Formulation
263653|NCT02388347|Biological|MEDI7836 SC Cohort 2|Liquid Formulation
263654|NCT02388347|Biological|MEDI7836 SC Cohort 3|Liquid Formulation
263655|NCT02388347|Biological|MEDI7836 SC Cohort 4|Liquid Formulation
263656|NCT02388360|Drug|topical prostaglandin analogs|
263657|NCT02388373|Drug|Fluticasone 250/formoterol 10|
263658|NCT02388373|Drug|Fluticasone 250/salmeterol 25|
263659|NCT02388373|Drug|Fluticasone 125/formoterol 5|
263660|NCT02390609|Drug|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
263661|NCT02390609|Drug|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
263662|NCT02390609|Drug|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
263663|NCT02390609|Drug|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
263664|NCT02390609|Drug|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
263068|NCT02364427|Device|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
263069|NCT02364440|Device|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
263070|NCT02364453|Drug|PACAP38|Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
263071|NCT02364479|Drug|etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
263072|NCT02364479|Drug|etanercept (half dose)|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
263073|NCT02364479|Drug|placebo|
263074|NCT02364492|Drug|MAG-TN3 + AS15|
263351|NCT02356900|Procedure|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
263352|NCT02356900|Drug|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
263353|NCT00158600|Biological|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
263354|NCT02356913|Drug|Nicotine gum|
263355|NCT02356939|Device|intraductal removable stent custom-made segment (2 cm) of a 8 French T-tube|: In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.
In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.
In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 6th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1.
263356|NCT02356939|Procedure|stent extraction by endoscopic retrograde cholangio-pancreatography (ERCP)|
263357|NCT02356952|Behavioral|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
263358|NCT02356952|Behavioral|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
263359|NCT02356952|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
263360|NCT02356965|Drug|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
263361|NCT02356965|Drug|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
262779|NCT02481037|Other|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
262780|NCT02481050|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
262781|NCT02481063|Other|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
262782|NCT02481063|Other|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
262783|NCT02481076|Device|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
262784|NCT02481076|Other|Braun frame|The leg is elevated on a Braun frame
262785|NCT00176345|Behavioral|Exercise Training|
262786|NCT02481076|Device|compression bandage|application of flowtron hydroven boot and compression bandage
262787|NCT02371525|Behavioral|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
262788|NCT02371538|Biological|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
262789|NCT02371551|Other|Blood/urine sampling|Routine chemistry profile
263075|NCT02364505|Behavioral|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
263076|NCT02364505|Behavioral|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
263077|NCT00159380|Procedure|Saliva|
263078|NCT02364518|Procedure|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
263079|NCT02364531|Other|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
263080|NCT02364544|Behavioral|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
274611|NCT02701413|Device|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
274612|NCT02701413|Device|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
274613|NCT02703532|Behavioral|CARE-CITE Education Program|CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.
If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.
Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.
Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete.
274614|NCT02703532|Behavioral|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
274615|NCT02703532|Behavioral|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.
Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete.
274616|NCT02703558|Drug|Phenazopyridine|
274617|NCT02703558|Drug|Fluorescein|
274618|NCT02703571|Drug|ribociclib|
274619|NCT02703571|Drug|Trametinib|
274620|NCT02703584|Drug|Buseralin|
274906|NCT02697071|Drug|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
274907|NCT02697071|Drug|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
274908|NCT02697084|Other|anal cancer|Anal cancer patients with TEP TDM
274909|NCT02697110|Behavioral|Edutainment based intervention|Edutainment intervention package
274330|NCT02707861|Drug|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
274331|NCT02707874|Drug|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
274332|NCT00203047|Drug|Prednisone|Prednisone 1250 mg taken daily
274333|NCT02707874|Drug|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
274334|NCT02707887|Behavioral|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
274335|NCT02707887|Behavioral|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
274336|NCT02707887|Behavioral|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
274337|NCT02707900|Drug|Vorinostat|At Step 2 - subjects receive a single oral dose of Vorinostat (VOR) 400 mg. Step 3 - Paired VOR dosing. If there are no clinically significant adverse events and a statistically significant increase in the rca-RNA after the first VOR dose is observed, two paired doses of VOR 400 mg PO will be administered to subjects.
Step 6 - VOR dosing. Approximately 7- 10 days after the 4th dose of AGS-004 in Step 5 (Visit 13), ten (10) doses of VOR 400 mg PO will be administered at the same interval at which rca-RNA induction was observed in paired dosing (Step 3).
Steps 7 & 8 - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 7) followed by 10 doses of VOR 400 mg PO (Step 8).
274338|NCT02709915|Other|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
274339|NCT02709915|Other|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
274340|NCT02709928|Drug|TD-0714|
274341|NCT02709928|Drug|Placebo|
274342|NCT02709941|Other|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
278585|NCT02686866|Device|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
278586|NCT00200512|Drug|apomorphine HCl injection|
278587|NCT02686866|Device|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
278588|NCT02686866|Device|hand grip strength|
278589|NCT02686879|Device|Multifocal contact lenses|
278590|NCT02686879|Device|Single vision contact lenses|
278591|NCT02686905|Dietary Supplement|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
278592|NCT02686905|Dietary Supplement|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
278884|NCT02715765|Device|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
278885|NCT02715765|Device|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
278886|NCT02717871|Drug|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
278887|NCT02717871|Drug|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
278888|NCT02717884|Drug|tranylcypromine|TCP p.o., daily either 20, 40**, 60**, 80** mg/day, (28d/cycle)
**TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)
278291|NCT00201123|Drug|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
278292|NCT02694055|Other|Training of primary health centre staff|Health center staff will receive targeted training in
Integrated management of childhood illness
Diagnosis and treatment of simple and severe cases of malaria
Helping babies breathe
Managing post-partum haemorrhage
Gestational dating using frontal height, last menstrual period and ultrasound
Family planning counselling and administration of long-acting contraceptives
Pharmacy stock management
Health center management
278293|NCT02694068|Other|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
278294|NCT02694068|Other|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
278295|NCT02694081|Procedure|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
278296|NCT02694081|Procedure|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
278297|NCT02694094|Dietary Supplement|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for > 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
278298|NCT00201435|Drug|Docetaxel every 3 week in combination with capecitabine|
278299|NCT02694107|Other|Proprioceptive exercises|
278300|NCT02694107|Other|Control|
278593|NCT02686905|Dietary Supplement|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
278594|NCT02686905|Dietary Supplement|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
278595|NCT02686905|Dietary Supplement|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
278596|NCT02686905|Dietary Supplement|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
278597|NCT00200525|Drug|apomorphine HCl injection|
277716|NCT02702674|Drug|placebo|starch tablet containing no active drug material given before induction of labor
277717|NCT02702674|Drug|Oxytocin|intravenous infusion of oxytocin
277718|NCT02702687|Behavioral|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
277719|NCT02702687|Behavioral|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
277720|NCT02702700|Drug|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
277721|NCT02702700|Drug|Verteporfin|Visudyne® IV 3 mg/m2
277722|NCT02704793|Other|Sham (electrical stimulation)|900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
277723|NCT02704819|Other|Decision Support System (DSS)|The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:
Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.
Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own.
277724|NCT02704819|Other|Specialist Audiovestibular Consultation|After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a "Gold Standard" diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor.
277725|NCT00202787|Drug|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
277990|NCT02698371|Device|G4: Futurabond® U - SE|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G4 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
277991|NCT02698371|Device|G5: Adhese® Universal - ER|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G5 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
277122|NCT02712918|Behavioral|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
277123|NCT00000382|Behavioral|Psychoeducational Home Visitation|
277124|NCT00002548|Drug|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
277125|NCT00203645|Behavioral|Self-help treatment|Workbook "Becoming a Winner",
277126|NCT02712918|Other|Standard Care|Treatment as usual at the ward
277127|NCT02712944|Drug|Testosterone|Testosterone
277128|NCT02712944|Drug|Saline|Placebo
277129|NCT02712957|Drug|NEO6860|TRPV1 antagonist
277130|NCT02712957|Drug|NEO6860 placebo|Inactive substance
277131|NCT02712957|Drug|Naproxen|NSAID
277132|NCT02712957|Drug|Naproxen placebo|inactive substance
277133|NCT02712970|Procedure|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of <1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
277134|NCT02714946|Device|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
277135|NCT02714946|Device|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
277136|NCT00203892|Biological|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
277431|NCT02708927|Other|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
277432|NCT00002547|Drug|methotrexate|
277433|NCT00203190|Drug|Topiramate|
276492|NCT02686034|Device|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
276493|NCT00200395|Drug|Erlotinib (drug)|
276494|NCT02686047|Device|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
276495|NCT02686047|Device|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
276496|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day,|
276497|NCT02688348|Other|Quality-of-Life Assessment|Ancillary studies
276498|NCT02688348|Other|Questionnaire Administration|Ancillary studies
276499|NCT02688361|Drug|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
276500|NCT02688361|Drug|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
276501|NCT02688374|Other|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
276502|NCT02688374|Other|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
276503|NCT02688374|Other|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
276504|NCT02688387|Drug|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
276505|NCT02688387|Drug|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
276506|NCT02688400|Drug|Diacerein|
276507|NCT00200694|Drug|ramipril 10 mg + valsartan 160 mg/day,|
276508|NCT02688400|Drug|Celecoxib|
276509|NCT02688400|Drug|Placebo|
275905|NCT02699645|Drug|Placebo|
275906|NCT02699658|Drug|Levofloxacin|
276185|NCT00201318|Drug|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
276186|NCT02693210|Drug|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
276187|NCT02693223|Other|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
276188|NCT02693236|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
276189|NCT02693262|Device|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
276190|NCT02693262|Device|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
276191|NCT02693275|Device|Quotient® System iPad Test|See arm/group description
276192|NCT02693288|Procedure|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
276193|NCT02693301|Other|Exercise program|
276194|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
276195|NCT02695485|Procedure|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
276196|NCT02695498|Other|Mindfulness Based Stress Reduction|MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a "mindfulness retreat day" (approximately 6 hours) after the 6th class [9 total classes.] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief.
276197|NCT02695498|Other|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
276198|NCT02695511|Other|Caloric restriction|25% caloric restriction below baseline energy requirement
276199|NCT02695524|Other|Strengthening exercises|
276200|NCT00201656|Procedure|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
276201|NCT02695524|Other|Neuromuscular exercises|
275631|NCT02703961|Drug|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
275632|NCT02703974|Behavioral|Early handwashing station|A handwashing station will be a dedicated location for handwashing in each selected school and will include:
A raised concrete platform (built to child height)
A plastic container with a lid and spigot
Soap
The early handwashing stations will be constructed in weeks 3 and 4 of the study, after the baseline observations (Phase I) are complete.
275633|NCT00202696|Drug|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
275634|NCT02703974|Behavioral|Late handwashing station|A handwashing station will be a dedicated location for handwashing in each selected school and will include:
A raised concrete platform (built to child height)
A plastic container with a lid and spigot
Soap
The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 6.
275635|NCT02706262|Other|Metabolically abnormal obese - Mediterranean diet|The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.
275907|NCT02699671|Device|Bioresorbable Vascular Scaffold|
275908|NCT02699697|Radiation|External Beam Radiation Therapy|Undergo EBRT
275909|NCT02699697|Radiation|Palliative Radiation Therapy|Undergo EBRT
275910|NCT02699697|Other|Quality-of-Life Assessment|Ancillary studies
275911|NCT02699697|Other|Questionnaire Administration|Ancillary studies
275912|NCT02699710|Drug|Folic Acid|Participants will be administered single 5 mg doses of folic acid.
275913|NCT02699710|Drug|GDC-0853|Participants will be administered single or multiple doses of GDC-0853 tablets or capsules.
275914|NCT00202033|Behavioral|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
275915|NCT02699710|Drug|Methotrexate|Participants will be administered single doses of 7.5 mg methotrexate tablets.
275916|NCT02699710|Drug|Rabeprazole|Participants will receive multiple doses of rabeprazole.
275917|NCT02699723|Drug|Arsenic Trioxide|Given PO
275918|NCT02699723|Drug|Itraconazole|Given PO
275919|NCT02699723|Other|Laboratory Biomarker Analysis|Correlative studies
275336|NCT02710162|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
275337|NCT02710162|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
275338|NCT02710162|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
275339|NCT02710162|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
275340|NCT02710162|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
275341|NCT00002547|Procedure|syngeneic bone marrow transplantation|
275342|NCT00203333|Device|Medtronic REVEAL|
275343|NCT02710162|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
275344|NCT02710175|Other|serum TSH level|
275345|NCT02710188|Drug|HTL0009936 modified release|HTL0009936 modified release
275346|NCT02710188|Drug|HTL0009936 immediate release|HTL0009936 immediate release
275347|NCT02710201|Behavioral|Descriptive Social Norm|
275348|NCT02710201|Behavioral|Descriptive-plus-Injunctive Social Norm|
275349|NCT02710214|Drug|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
275636|NCT02706262|Other|Metabolically abnormal obese - Low carbohydrate ketogenic diet|The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.
275637|NCT02706262|Other|Metabolically abnormal obese - Plant-based, very-low-fat diet|The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
275638|NCT02706262|Other|Metabolically normal lean - Low-protein diet|The effect of consuming a low-protein (0.5 g protein/kg body weight/day) diet for 12 weeks in the weight stable state will be examined, with all meals provided.
275062|NCT02716324|Other|ADHD Portal|The ADHD portal is a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment are measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents are encouraged to consult with their children when completing the tool.
275063|NCT00204035|Behavioral|Evaluation (behavior)|TEACH is a precollege enrichment program for highschool students to encourage and promote these students towards careers in clinical research. To accomplish this, instruments designed to evaluate the knowledge, attitudes, and behaviors are administered during their participation in the TEACH program.
275064|NCT02716337|Dietary Supplement|Addition of human milk fortifiers according to human milk analysis|
275065|NCT02716350|Dietary Supplement|B-GOS|comparison versus placebo
275066|NCT02716350|Dietary Supplement|Maltodextrin|placebo
275067|NCT02716363|Device|Rotational Atherectomy by Rotablator|
275068|NCT02716376|Device|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
275069|NCT02716389|Other|Zebris CMS 70|
275070|NCT02716389|Other|3-D Bulls Eye Spirit Meter|
275071|NCT02716402|Radiation|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
275072|NCT02716415|Drug|Calmoseptine Ointment|A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.
The regimen includes:
regular diaper changing,
gentle cleansing
application of the trial ointment
275073|NCT02716415|Drug|Destin Maximum Strength 40% Zinc|A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.
The regimen includes:
regular diaper changing,
gentle cleansing
application of the trial ointment
275074|NCT00204048|Behavioral|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
275350|NCT00203593|Behavioral|Exercise|
275351|NCT02712151|Drug|Sterile saline|Placebo injection
275352|NCT02712151|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
259676|NCT02479672|Device|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
259677|NCT02479672|Procedure|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
259678|NCT02479672|Device|VividTrac®|
259679|NCT02482129|Drug|Dexamethasone 0.1% ophthalmic solution|
259680|NCT02482129|Drug|LME636 Vehicle|Inactive ingredients used for masking purposes
259681|NCT00176462|Drug|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
259682|NCT02482142|Dietary Supplement|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
259683|NCT02482155|Drug|Ibuprofen|ibuprofen 400 mg single dose oral solution
259684|NCT02482168|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
259685|NCT02482194|Biological|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
259686|NCT02482207|Drug|Rosuvastatin|
259687|NCT02482207|Behavioral|Life style modification|
259688|NCT02482220|Behavioral|Physical activity intervention|
259689|NCT02482233|Behavioral|ENDD (NJOY)|As described above.
259690|NCT02482233|Drug|NRT (NicoDerm CQ)|As described above.
259691|NCT02482233|Behavioral|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
259994|NCT02475538|Device|Electroacupuncture with gradual tapering|Gradual Tapering Benzodiazepines will be tapered off over four weeks. The blinded researcher will explain the discontinuation plan to the patient and to set clear reduction goals. The subjects will be told to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.
Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). "De qi" is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min.
264251|NCT02376413|Radiation|Radiation therapy|
264252|NCT00160758|Procedure|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
264253|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
264254|NCT02378779|Other|Questionary SF12 and PEDT|12 questions are asking to the patients 5 questions are asking to the patients
264255|NCT02378779|Other|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
264256|NCT00161070|Drug|anticoagulation|
264257|NCT02378779|Other|Humour|Use the humour to approach the subject of premature ejaculation
264258|NCT02378779|Other|Take the drama out|Take the drama out to approach the subject of premature ejaculation
264259|NCT02378779|Other|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
264260|NCT02378779|Other|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
264261|NCT02378779|Other|Help to verbalize|Help for the patient to speak about premature ejaculation
264262|NCT02378792|Device|Vagus Nerve Stimulation|Vagus Nerve Stimulator
264263|NCT02378805|Drug|ACE-inhibitor|observational study!
264264|NCT02378805|Drug|AT1-inhibitor|observational study!
264265|NCT02378805|Drug|HMG-Coenzyme inhibitor (statin)|observational study!
264266|NCT02378805|Drug|Spironolactone|observational study!
264267|NCT00161070|Drug|aspirin and dipyridamole|
264268|NCT02378805|Drug|Paricalcitol|observational study!
264269|NCT02378818|Behavioral|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
259692|NCT00176462|Drug|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
263949|NCT02383693|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
263950|NCT02383706|Device|ApneaLink Air|Overnight, home polysomnography device
263951|NCT00161668|Drug|Mylotarg|
263952|NCT02383706|Behavioral|Berlin Quesionnaire|OSA screening questionnaire
263953|NCT02383706|Behavioral|Epworth Sleepiness Scale|OSA screening questionnaire
263954|NCT02383706|Behavioral|STOP-BANG questionnaire|OSA screening questionnaire
263955|NCT02383706|Other|Physical exam|Physical exam of neck, mouth and upper airway
263956|NCT02383719|Device|Oro-nasal Mask|
263957|NCT02383732|Behavioral|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention & Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
263958|NCT02383732|Behavioral|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
263959|NCT02386033|Drug|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
263960|NCT00162019|Drug|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
263961|NCT02386046|Other|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
263962|NCT02386059|Drug|PLACEBO|received normal saline, intravenously
263963|NCT02386059|Drug|Dexamethasone|4 mg, intravenously, at the start of surgery
263964|NCT02386059|Drug|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
263965|NCT02386059|Drug|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
263966|NCT02386072|Drug|mirabegron|oral
263967|NCT02386072|Drug|antimuscarinic medication|oral
263362|NCT02356978|Device|Arm1 homemade phototherapy treatment|session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the "DRAP" device during the next nights.
263363|NCT02356978|Device|DRAP|
263364|NCT00002412|Drug|Stavudine|
263365|NCT00158600|Drug|Placebo|Placebo Comparator; qow for 78 weeks.
263366|NCT02356991|Drug|Famitinib|
263367|NCT02356991|Drug|Placebo|
263368|NCT00158834|Drug|Fluticasone propionate|
263369|NCT02359279|Device|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
263370|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI|
263371|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI|
263372|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
263665|NCT02390609|Drug|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
263666|NCT02390622|Other|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
263667|NCT00002430|Drug|Lamivudine|
263668|NCT00162630|Procedure|Fascia Iliaca Compartment Blockade|
263669|NCT02390635|Drug|18F-FDG|Participants receive an injection of 18F-FDG prior to whole body magnetic resonance imaging.
263670|NCT02390635|Procedure|Whole Body Magnetic Resonance Imaging (MRI)|Participants receive whole body MRI.
263671|NCT02390635|Drug|Gadolinium|Participants receive injection of gadolinium contrast agent 2 mL/sec and 0.1 mmol/kg of body weight during whole body MRI.
263672|NCT02390635|Procedure|Positron Emission Tomography/ Computed Tomography (PET/CT)|PET/CT performed following whole body MRI.
263673|NCT02390648|Drug|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
263674|NCT02390648|Drug|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
263675|NCT02390661|Device|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
263081|NCT02364544|Behavioral|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
263082|NCT02364544|Behavioral|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
263083|NCT02364544|Behavioral|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
263084|NCT02364544|Other|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
263085|NCT02364557|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
263086|NCT02364557|Procedure|Therapeutic Conventional Surgery|Undergo surgery
263087|NCT02364557|Other|Laboratory Biomarker Analysis|Correlative studies
263088|NCT02366728|Biological|Group I unpulsed DCs|Given intradermally 12-24 hours before the fourth vaccine
263089|NCT00159653|Drug|Timolol|
263090|NCT02366728|Biological|Group II Td|Given intradermally 12-24 hours before the fourth vaccine
263091|NCT02366728|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|Human CMV pp65-LAMP mRNA-pulsed autologous DCs is the name of the study drug given with every vaccine.
263373|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
263374|NCT02359292|Drug|Placebo pMDI|
263375|NCT02359305|Drug|Acetaminophen|Acetaminophen given either IV or rectally
263376|NCT02359318|Device|Icon|Resin infiltration as described in manufacture´s documentation prior bonding of new brackets
263377|NCT02359318|Procedure|Debonding|debonding of brackest and bonding of new ones
263378|NCT02359331|Procedure|H. pylori culture and antimicrobial susceptibility testing|This intervention will be performed in 7 days tailored therapy group.
All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method
263379|NCT00158847|Drug|fluticasone 500 mcg|
274910|NCT02697123|Other|antepartum and postpartum|This is a prospective observational cohort study.
274911|NCT02697136|Drug|CER-001|Recombinant human apoA-I/phospholipid complexes
274912|NCT02697136|Drug|Placebo|0.9% Sodium Chloride Injection, USP
274913|NCT02699099|Biological|Stamaril|Intramuscular injection of a yellow fever vaccine (1 dose)
274914|NCT02699112|Other|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
274915|NCT02699125|Drug|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
274916|NCT02699125|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
274917|NCT02699138|Drug|Trazodone|100mg of trazodone to be administered orally once.
274918|NCT00201968|Other|Conventional Exercise|An aerobic and resistance training program.
274919|NCT02699138|Drug|Placebo|Compounded sugar pill
274920|NCT02699138|Device|Epiglottic catheter|Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
274921|NCT02699151|Drug|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
274922|NCT02699151|Procedure|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
274923|NCT02699151|Other|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
274924|NCT02699164|Device|non-surgical spinal decompression therapy|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
274925|NCT02699164|Device|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
275182|NCT02694952|Biological|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
275183|NCT02694952|Biological|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
274343|NCT02709941|Other|Placebo|
274621|NCT00202618|Drug|Valsartan|
274622|NCT02703584|Other|Placebo|
274623|NCT02703584|Drug|pregnyl|
274624|NCT02703597|Behavioral|Surveys|Baseline survey includes questions related to smoking behavior and attitude toward smoking, as well as demographic questions. Psychosocial surveys and social network surveys also completed.
274625|NCT02703597|Behavioral|Focus Group|Participants engage in audio recorded group discussions that work to improve upon the online health programs.
274626|NCT02703597|Behavioral|ASPIRE|Participants engage in four 40-minute sessions of A Smoking Prevention Interactive Experience (ASPIRE) spread over a period of 4 weeks. During ASPIRE use, participants face a laptop computer and individually watch videos and engage in computer-based activities related to the negative effects of smoking.
274627|NCT02703597|Behavioral|GSA-ASPIRE|Participants engage in four 45-minute sessions of ASPIRE conducted over a period of four weeks. During each session, after every 9 minutes of ASPIRE use, participants engage in a 3-minute game-based social activities (GSA), for a total of 5 GSAs. During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSA activities contain games about the effects of smoking.
274628|NCT02703610|Drug|Oxycodone/acetaminophen|
274629|NCT02703610|Drug|Hydrocodone/acetaminophen|
274630|NCT02703610|Drug|Codeine/acetaminophen|
274631|NCT02703610|Drug|Ibuprofen/acetaminophen|
274632|NCT00202618|Drug|Amlodipine|
274633|NCT00202865|Biological|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
274634|NCT02705807|Drug|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
274635|NCT02705820|Drug|Pembrolizumab|Switch maintenance pembrolizumab treatment
274636|NCT02705859|Drug|Copanlisib|Copanlisib is a novel small molecule PI3K inhibitor being evaluated for the treatment of a wide variety of advanced and refractory malignancies either as a single agent or in combination with other investigational agents.Copanlisib has potent and selective activity against all four Class I PI3K isoforms with IC50s of 0.5-6.4nM in biochemical assays. Notably, copanlisib shows excellent anti-tumour activity in pre-clinical models with an up-regulated PI3Kα pathway suggesting a particular role for it in PIK3CA mutated cancers.
274637|NCT02705859|Drug|Trastuzumab|A humanised IgG1 monoclonal antibody
278889|NCT02717884|Drug|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
278890|NCT02717884|Drug|cytarabine|40mg s.c. (days 1-10)
278891|NCT02717897|Other|No intervention|This study is not interventional
278892|NCT02717910|Behavioral|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
278893|NCT02717910|Behavioral|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
278894|NCT02717923|Drug|capecitabine plus cetuximab|
274344|NCT02709954|Drug|Active inhaled delta-9-THC|Low dose THC (~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or "joint". Administered over 20 minutes via a vaporizer.
274345|NCT00203294|Drug|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
274346|NCT02709954|Drug|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
274347|NCT02709954|Drug|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
274348|NCT02709954|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
274349|NCT02709967|Other|Material support|Writing materials
274350|NCT02709967|Other|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
274351|NCT02709967|Behavioral|Community dialogue|Community dialogue (youth club meetings, community meetings and parent meetings)
278598|NCT02686918|Other|Advanced Practice Nurse consultation|
278599|NCT02686944|Biological|Intuvax (suspension for intratumoral injection)|Therapeutic vaccine: allogeneic, proinflammatory dendritis cells
278600|NCT02686983|Drug|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
278601|NCT02686996|Dietary Supplement|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
278602|NCT02686996|Other|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
278603|NCT02687009|Drug|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
278604|NCT02689193|Other|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
278605|NCT02689206|Drug|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
278606|NCT02689206|Drug|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
278607|NCT02689219|Drug|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
278608|NCT02689232|Biological|Fresh Frozen Plasma|
278609|NCT02689232|Biological|Platelets Concentrate|
278610|NCT02689232|Biological|Cryo Precitipitate|
278611|NCT02689245|Drug|Tenofovir|
278612|NCT00200850|Biological|High dose SLIT|House Dust Mite SLIT- 10,000 AU/ml daily
278895|NCT02717936|Procedure|Immunohistochemistry using Pancytokeratin Staining|
278896|NCT00002548|Procedure|peripheral blood stem cell transplantation|day 0
278897|NCT00204269|Drug|Testosterone Gel Wolff|
278898|NCT02717949|Drug|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
278899|NCT02717949|Drug|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
278900|NCT02717949|Drug|Ribavirin|ribavirin 1200 mg given orally in divided dose for those >75kg and 1000 mg in divided dose for those <75 kg.
277992|NCT02698371|Device|G6: Adhese® Universal - SE|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G6 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
277993|NCT02700568|Drug|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
277994|NCT02700581|Procedure|low PEEP conventional ventilation|
277995|NCT02700581|Procedure|moderate PEEP conventional ventilation|
277996|NCT02700581|Procedure|low PEEP protective ventilation|
277997|NCT02700581|Procedure|moderate PEEP protective ventilation|
277998|NCT02700594|Other|Joint mobilization|Mobilization and manipulation are manual therapy techniques" comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement."16 The term joint mobilization, or nonthrust mobilization, often refers to slow, "rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
277999|NCT00202163|Drug|Testosterone|
278000|NCT02700607|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
278001|NCT02700607|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
278002|NCT02700620|Behavioral|Internet-delivered CBT|Guided internet treatment
278301|NCT02694133|Procedure|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
278302|NCT02694133|Procedure|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
278303|NCT02694146|Drug|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
277434|NCT02708927|Other|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
277435|NCT02708940|Other|Participatory technology development|Creating mobile support tools by patients and their therapists
277436|NCT02708940|Other|Usual Care|Usual care as part of the UCLA PHP and IOP programs
277437|NCT02708953|Procedure|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
277438|NCT02708953|Procedure|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
277439|NCT02708966|Drug|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
277440|NCT02708966|Drug|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
277441|NCT02708979|Other|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
277442|NCT02708979|Other|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
277443|NCT02708992|Drug|Azithromycin|
277444|NCT00203203|Device|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
277445|NCT02708992|Drug|Cefixime|
277446|NCT02710851|Biological|high dosage HPV Vaccine(1:1)|Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month.
277447|NCT02710851|Biological|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
277448|NCT02710877|Device|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
277449|NCT02710877|Other|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
277450|NCT02710877|Drug|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
276829|NCT02683759|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug
276830|NCT02683759|Drug|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
276831|NCT02683785|Drug|GSK3196165|GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
276832|NCT02683785|Drug|Placebo|Matching placebo will be administered as above.
276833|NCT02683798|Dietary Supplement|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
276834|NCT00200148|Procedure|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
276835|NCT02683798|Dietary Supplement|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
276836|NCT02683811|Behavioral|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
276837|NCT02683824|Procedure|Computed Tomography|Undergo [18F] FP-R01-MG-F2 PET/CT scan
276838|NCT02683824|Other|Laboratory Biomarker Analysis|Correlative studies
276839|NCT02686060|Device|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
276840|NCT02686086|Device|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
276841|NCT02686086|Device|Standard hospital jet nebuliser|The "standard hospital jet nebuliser" refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications
276842|NCT02686086|Drug|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
276843|NCT02686099|Device|SternaLock 360|Sternal closure with SternaLock 360
276202|NCT02695537|Drug|Epidiolex|In some patients additional titration by 5 mg/kg/day every 2 weeks up to 50 mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI
276203|NCT02695550|Drug|CT-707|
276204|NCT02695563|Drug|Lactoferrin|
276205|NCT02695576|Procedure|Lumbar Fusion Surgery|Interbody fusion with fixation
276510|NCT02688413|Device|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
276511|NCT02688413|Other|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
276512|NCT02688426|Device|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
276513|NCT02688426|Device|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
276514|NCT02688439|Other|Sciatic Nerve block|
276515|NCT02688439|Other|Leg raised 30°|
276516|NCT02688439|Other|Distal tourniquet placed on the lower part of the leg|
276517|NCT02688439|Other|Leg in a neutral position|
276518|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
276519|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
276520|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
276521|NCT02690714|Biological|Plasminogen (human) intravenous|ProMetic Plasminogen(human) intravenous
276522|NCT02690727|Drug|RP6530|Single oral dose
276523|NCT02690740|Other|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|see information in "arm/group descriptions"
276524|NCT02690753|Procedure|A protocol tailored to individual risk factors|
276525|NCT02690753|Device|The Prevalon® Turn and Position System 2.0|
276526|NCT02690753|Device|Comfort Shield® barrier cream cloths|
275920|NCT02699749|Drug|TAK-931|TAK-931 oral capsules.
275921|NCT02699762|Other|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
275922|NCT02701803|Device|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
275923|NCT02701816|Device|innova stent (Boston scientific)|
275924|NCT02701829|Other|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
275925|NCT02701829|Other|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
275926|NCT02701829|Other|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
275927|NCT02701842|Device|ImPACT Online/Paper Pencil Tests|
276206|NCT02695576|Other|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
276207|NCT02695576|Other|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
276208|NCT02695602|Procedure|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
276209|NCT02695602|Procedure|Submucous Resection with non powered instrument|
276210|NCT02695628|Radiation|18F-Fluoromisonidazole|Undergo [18F] FMISO PET/CT
276211|NCT00002542|Drug|doxorubicin hydrochloride|
276212|NCT00201656|Procedure|Removal of Cerclage|Immediate removal of Cerclage following randomization
276213|NCT02695628|Procedure|Arterial Embolization|Undergo transcatheter arterial embolization
276214|NCT02695628|Procedure|Computed Tomography|Undergo [18F] FMISO PET/CT
276215|NCT02695628|Procedure|Positron Emission Tomography|Undergo [18F] FMISO PET/CT
275639|NCT00202904|Drug|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
275640|NCT02706262|Other|Metabolically normal lean - Moderate-protein diet|The effect of consuming a moderate-protein (0.8 g protein/kg body weight/day) diet for 12 weeks in the weight stable state will be examined, with all meals provided.
275641|NCT02706262|Other|Metabolically normal lean - High-protein diet|The effect of consuming a high-protein (1.4 g protein/kg body weight/day) diet for 12 weeks in the weight stable state will be examined, with all meals provided.
275642|NCT02706275|Other|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
275643|NCT02706288|Other|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose 7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 80% of energy from carbohydrate, 10% from protein, and 10% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
275644|NCT02706301|Behavioral|Telephone-Based Coping Skills Training (CST)|
275645|NCT02706327|Device|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
275646|NCT02706327|Device|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
275647|NCT02708225|Behavioral|medical clown|a medical clown will assist the child during the performance of pulmonary function test
275928|NCT00202358|Drug|atenolol|
275929|NCT02701842|Device|ImPACT Online|
275930|NCT02701855|Behavioral|Cognitive tests|Cognitive tests include:
The MMSE (Mini Mental State Examination)
Free and Cued Selective Recall Reminding Test (FCSRT).
Executive functions (fluencies, TMT A and B, span).
Tests of verbal fluency (literal and category)
Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)
The Clinical Dementia Rating Scale
The IADL scale evaluates autonomy.
Geriatric Depression screening Scale (GDS)
275931|NCT02701855|Biological|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
275353|NCT02712151|Device|Ultrasound|For nerve localization
275354|NCT02712151|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
275355|NCT02712164|Device|Modified NPWT dressing|
275356|NCT02712164|Device|Tegaderm|Standard of care for STSG donor sites.
275357|NCT02712177|Biological|4CMenb|
275358|NCT02712177|Biological|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
275359|NCT02712177|Biological|conjugated pneumococcal vaccine|
275360|NCT02712177|Biological|MMRV|
275361|NCT00002548|Drug|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
275362|NCT00203593|Device|Blood volume|
275363|NCT02712190|Device|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
275364|NCT02712203|Biological|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
275365|NCT02712216|Procedure|Laparoscopy|Determine best port sites to insert bariatric trocars
275366|NCT02712229|Behavioral|CONNECT|CONNECT is a primary palliative care - care management intervention led by existing oncology nurses. CONNECT is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs, and choosing a surrogate decision maker. Subsequent visits include an additional focus on treatment preferences and future goals.
CONNECT visits are guided by patient-reported outcomes. During every CONNECT encounter, the nurse will work with patients and caregivers to complete and update individualized Shared Care Plans. After every CONNECT visit, the nurse will discuss patients' symptoms, preferences, and goals with their oncologists via a mandatory check-in session and conduct a follow-up call with the patient and/or caregiver.
275367|NCT02712242|Other|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
275368|NCT02712242|Other|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
275369|NCT02712242|Other|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
275648|NCT00002547|Drug|cytarabine|
275649|NCT00203099|Drug|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
259995|NCT02475538|Device|Placebo acupuncture with gradual tapering|Gradual Tapering The gradual tapering procedure will be the same as in the "Electroacupuncture combined with gradual tapering" group.
Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the "Electroacupuncture combined with gradual tapering" group.
259996|NCT02475551|Drug|IdeS|Intravenous infusion
259997|NCT02475564|Drug|Placebo|40mg of starch
259998|NCT02475564|Drug|Resveratrol|40mg of resveratrol (powder)
259999|NCT02477540|Drug|Cellgram-CLI|Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip
Main ingredient: Autologous bone marrow-derived mesenchymal stem cells
Dosage: 50,000,000 cells/10ml, 2-time injection
Storage: An airtight container, 20~25℃
Injection Method: Intramuscular
260000|NCT02477553|Behavioral|DA - Quantitative|
260001|NCT00175864|Drug|Seletracetam (ucb 44212)|
260002|NCT02477553|Behavioral|DA - Verbal|
260003|NCT02477566|Drug|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
260004|NCT02477566|Drug|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
260005|NCT02477579|Device|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
260006|NCT02477592|Procedure|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
260007|NCT02477592|Procedure|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
260008|NCT02477605|Device|CONSTELLATION 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS Valved Entry System comprised of 3 trocar/cannulas and related accessories.
260302|NCT02471521|Drug|Rucoronium|Rocuronium 6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
260303|NCT02471534|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
259693|NCT02482233|Behavioral|brief advice|Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): "The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
259694|NCT02482233|Behavioral|brochure|A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.
Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf
259695|NCT02482272|Drug|Lamivudine|Lamivudine 100mg/day orally
259696|NCT02482272|Drug|Adefovir|Adefovir 10mg/day orally
259697|NCT02482272|Drug|Entecavir|Entecavir 1mg/day orally
259698|NCT02482298|Drug|Ticagrelor|ticagrelor 10 mg+ ticagrelor placebo OR ticagrelor 45 mg + ticagrelor placebo, oral, twice a day (morning and evening at least 12 hours apart) from randomization to end of treatment
259699|NCT02482298|Drug|Placebo|ticagrelor placebo + ticagrelor placebo, oral, twice a day (morning and evening at least 12 hours apart) from randomization to end of treatment
259700|NCT02482298|Drug|Analgesic|opioid or non-opioid as needed for pain from randomization to end of treatment
259701|NCT02482311|Drug|AZD 1775|AZD1775 dose A will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.
AZD1775 should be taken approximately 2 hours before or 2 hours after food.
259702|NCT02484365|Other|No treatment|Attach adhesive probe on thumb or index finger
259703|NCT02484378|Drug|CER-001|Engineered pre-beta HDL particle
259704|NCT02484378|Drug|Placebo|Normal saline
259705|NCT02484391|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
259706|NCT02484391|Drug|Cytarabine|Given IV
259707|NCT02484391|Procedure|Hematopoietic Cell Transplantation|Undergo stem cell transplant
259708|NCT02484391|Drug|Mitoxantrone Hydrochloride|Given IV
259709|NCT02484404|Drug|Olaparib|Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days.
MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID)
Ph II - MEDI4736 + Olaparib at RP2D
259710|NCT02484404|Drug|Cediranib|Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days.
MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily)
Ph II - MEDI4736 + Cediranib at RP2D
263968|NCT02386085|Procedure|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study.
263969|NCT02386098|Drug|BMS-955176|HIV Maturation Inhibitor
264270|NCT02378844|Device|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
264271|NCT02378844|Device|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
264272|NCT02378870|Drug|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
264273|NCT02378870|Drug|Placebo|
264274|NCT02378883|Device|Apollo™ Onyx™ Delivery Micro Catheter|
264275|NCT02378896|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
264276|NCT02378896|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
264277|NCT02381119|Behavioral|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
264278|NCT00161408|Behavioral|cognitive behavioural therapy|
264279|NCT02381132|Drug|Norco 7.5mg/325|
264280|NCT02381132|Drug|MNK155|
264281|NCT02381145|Dietary Supplement|EGCG+RSV-supplementation|Teavigo (~300mg/d) Resveratrol (~80mg/d)
264282|NCT02381158|Drug|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
264283|NCT02381171|Device|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
264284|NCT02381171|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
264285|NCT02381171|Device|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
264286|NCT02381171|Device|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
263676|NCT02390674|Drug|Ciclosporin|Comparison between ciclosporin and placebo
263677|NCT02390674|Drug|Saline|
263678|NCT02390687|Drug|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
263679|NCT00162643|Drug|zidovudine+lamivudine+lopinavir/ritonavir|
263680|NCT02390687|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
263681|NCT02390700|Biological|Golimumab Intravenous|This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
263682|NCT02390713|Device|MID-AVR|Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.
Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography.
263683|NCT02354547|Genetic|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
263970|NCT02386098|Drug|Atazanavir(ATV)|
263971|NCT00162032|Drug|Sestamibi|Sestamibi
263972|NCT02386098|Drug|Ritonavir(RTV)|
263973|NCT02386098|Drug|Dolutegravir(DTG)|
263974|NCT02386098|Drug|Tenofovir(TDF)|
263975|NCT02386111|Drug|Combination of varlilumab and sunitinib|During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.
Phase ll Dose: The planned varlilumab dose will be established from the outcome of the Phase 1 portion of the study.
All patients will receive sunitinib at a dose of 50 mg.
263976|NCT02386124|Other|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
263977|NCT02386137|Device|Contrast-enhancement ultrasound with Sonovue|
263380|NCT02359331|Drug|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|Giving the 14 days PBMT regimen as 2nd rescue therapy
Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.
263381|NCT02359331|Drug|Metronidazole|
263382|NCT02359331|Drug|Tetracycline|
263383|NCT02359331|Drug|tripotassium dicitrate bismuthate|
263384|NCT02359331|Drug|7 days tailored therapy Proton Pump Inhibitor|
263385|NCT02359331|Drug|Moxifloxacin|
263386|NCT02359331|Drug|Amoxicillin|
263387|NCT02359344|Drug|CNV1014802|
263388|NCT02359344|Drug|Placebo|
263389|NCT02359357|Drug|FDL169|
263390|NCT00158847|Drug|fluticasone 500 mcg + salmeterol 50 mcg|
263391|NCT02359357|Drug|Placebo|
263392|NCT02359370|Drug|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
263393|NCT02359370|Drug|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
263394|NCT02359383|Other|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
263395|NCT02361853|Other|Exposure: abundance of Immature monocytes counts in blood samples|
263684|NCT02354547|Drug|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
263685|NCT02354547|Drug|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
263686|NCT02354560|Drug|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
275184|NCT02694965|Other|observational|
275185|NCT02694978|Drug|Ferumoxytol|
275186|NCT02694978|Drug|Ferric carboxymaltose|
275187|NCT02694991|Other|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
275188|NCT02695004|Drug|DKF-310|
275189|NCT02695004|Drug|Placebo|
275190|NCT00201552|Drug|Statin|
275191|NCT02695017|Device|Iso inertial|
275192|NCT02695017|Device|Conventional machine|
275193|NCT02695030|Device|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
275194|NCT02695043|Behavioral|RRTBIMS|TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
275195|NCT02695043|Behavioral|Multimedia Multicultural Educational Program for TBI (MMEPT)|
275196|NCT02695069|Procedure|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
275197|NCT02695108|Other|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
275198|NCT02695108|Other|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
275199|NCT02695134|Other|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
275200|NCT02695147|Procedure|TAVI|
275481|NCT02690168|Behavioral|Fasting|72 hour fasting
275482|NCT02690181|Biological|GBS Trivalent Vaccine|Lyophilized formulation of a vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197
274638|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
274639|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
274926|NCT02699164|Procedure|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
274927|NCT02699177|Device|CBF measurements|CBF measurements
274928|NCT02699190|Other|Whole Genome Sequencing (WGS)|
274929|NCT00201981|Drug|Rebamipide|OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks
OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks
274930|NCT02699190|Other|Standard Clinical Care and Diagnostic Approaches|
274931|NCT02699203|Behavioral|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
274932|NCT02699203|Behavioral|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
274933|NCT02699216|Device|Nova Oculus™|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
274934|NCT02699242|Device|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
274935|NCT02701426|Behavioral|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
274936|NCT02701439|Device|Small membrane filtration|Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
Abbreviated demographic and clinical evaluation
TB history and evaluation
Obtain three sputum samples - one early morning sample and two spot samples
HIV testing (and CD4 if positive)
Chest radiograph
Small membrane filtration intervention will be administered to both arms
274937|NCT02701452|Other|COAGO|blood samples for haemostasis and hormonal data
274938|NCT02701465|Other|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
274352|NCT02709980|Behavioral|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
274353|NCT02709980|Behavioral|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
274354|NCT02709993|Biological|TAPA-pulsed DC vaccine|A total of six vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered every 14 days.
274355|NCT02711800|Drug|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
274356|NCT02711813|Drug|TAB08|biologic
274357|NCT02711813|Other|Placebo|
274358|NCT02711826|Biological|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 400 ±100 x 10^6 polyTregs.
274359|NCT02711826|Biological|Donor-Alloantigen-Reactive Regulatory T Cells|Participants randomized to darTregs group will receive a single infusion of 400 ±100 x 10^6 darTregs.
274360|NCT02711826|Drug|Everolimus|
274640|NCT02705885|Dietary Supplement|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
274641|NCT02705885|Dietary Supplement|Placebo IgY|Placebo IgY
274642|NCT02705898|Behavioral|LPA+Fitbit|
274643|NCT02705898|Behavioral|HEC|
274644|NCT00202878|Drug|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
274645|NCT02705911|Other|Isometric handgrip exercise|Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
274646|NCT02705911|Other|Aerobic endurance training|To perform 150 minutes extra/week at moderate aerobic intensity
278901|NCT02717962|Drug|VAL-083|The dosing regimen for patients will be VAL-083 (40 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation. In patients who demonstrate response or stable disease and tolerate therapy, permission to continue treatment beyond 12 cycles will be considered, but will require consent of the Sponsor.
278902|NCT02717962|Drug|Lomustine|The dosing regimen for patients will be lomustine (90 mg/m2, with an option to escalate to 110 mg/m2) orally on day 1 at the beginning of each 42-day treatment cycle. Patients will continue to receive lomustine for up to 6, 42-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
278903|NCT02684526|Procedure|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
278904|NCT02684539|Device|tilt table Erigo®|tilting table with onset of syncope
278905|NCT02684552|Device|Non invasive ventilation|Training on treadmill with Non invasive ventilation
278906|NCT02684552|Device|Oxygen|Training on treadmill with oxygen
278907|NCT02684565|Dietary Supplement|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
278908|NCT02684565|Dietary Supplement|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
278909|NCT02684578|Drug|Metformin|
278910|NCT02684591|Drug|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
278911|NCT00200226|Drug|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
278912|NCT02684591|Drug|Placebo|Placebo
278913|NCT02684617|Biological|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35
274361|NCT02711826|Drug|Tacrolimus|
274362|NCT02711826|Drug|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
274363|NCT00203528|Drug|risperidone|
274364|NCT02711826|Drug|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
274365|NCT02711826|Drug|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
278304|NCT02694146|Drug|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
278305|NCT02694172|Other|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
278306|NCT02694185|Other|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
278307|NCT02696304|Other|Inflamation blood markers quantification|blood drawn,
278308|NCT02696317|Device|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
278309|NCT02696317|Device|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
278310|NCT02696330|Drug|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
278311|NCT02696330|Drug|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
278312|NCT02696330|Drug|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
278313|NCT02696343|Device|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
278314|NCT00201708|Drug|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
278315|NCT02696343|Device|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
278316|NCT02696356|Biological|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
278317|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:200,000|
278613|NCT02689245|Drug|Fecal Microbiota Transplantation (FMT)|
278614|NCT02689258|Drug|HTX-011|
278615|NCT02689258|Drug|Placebo|
278616|NCT02689271|Other|MRI|VERDICT diffusion-weighted microstructure imaging sequence
277726|NCT02704819|Other|DSS Customised Vestibular Physiotherapy|Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.
Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.
Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement.
277727|NCT02704819|Other|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
277728|NCT02704819|Other|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
277729|NCT02704832|Other|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
277730|NCT02704858|Drug|Perillyl alcohol|Intranasal administration
277731|NCT02704871|Other|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
277732|NCT02704884|Dietary Supplement|probiotic soy milk|
277733|NCT02704897|Other|Wound Questionnaire|A set of questions relating to the symptoms of wound infection
277734|NCT02704910|Behavioral|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
277735|NCT02704923|Drug|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
277736|NCT00202800|Drug|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
277737|NCT00202969|Drug|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
277738|NCT02707016|Other|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
277739|NCT02707016|Other|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
276844|NCT02686099|Device|Wire Cerclage|Sternal closure with standard wire cerclage
277137|NCT02714959|Drug|Proleukin|
277138|NCT02714972|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
277139|NCT02714998|Drug|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
277140|NCT02714998|Procedure|salpingectomy|Laparoscopic unilateral salpingectomy
277141|NCT02715011|Drug|JNJ-63709178|Intravenous infusion of JNJ-63709178 once every 2 weeks. The duration of each treatment cycle is 28 days.
277142|NCT02715024|Drug|Tamsulosin|Oral
277143|NCT02715024|Drug|Solifenacin|Oral
277144|NCT02715037|Other|Throat swabbing|
277145|NCT02715050|Device|Active or Placebo Phototherapy (MR4)|
277146|NCT02715063|Behavioral|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
277147|NCT00002548|Drug|prednisone|40 mg/m2 PO days 1-7 q 35 days
277148|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
277149|NCT02715063|Behavioral|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
277150|NCT02715063|Behavioral|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
277151|NCT02715063|Other|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
277152|NCT02715076|Other|Ambient Temperature 19°C|Ambient Temperature 19°C
277153|NCT02715076|Other|Ambient Temperature 21°C|Ambient Temperature 21°C
277154|NCT02715076|Other|Ambient Temperature 23°C|Ambient Temperature 23°C
277155|NCT02715076|Device|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
276527|NCT02690766|Behavioral|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
276528|NCT02690779|Other|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
276529|NCT02690779|Other|Routine Care Instructions|patients will follow routine care and instructions
276530|NCT02690792|Other|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
276845|NCT02686125|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
276846|NCT02686138|Drug|Tenapanor|
276847|NCT00200421|Drug|Nebivolol and Atenolol|
276848|NCT02686138|Drug|Placebo|
276849|NCT02686151|Drug|Letrozole|used after oocyte retrieval
276850|NCT02686151|Drug|Polygeline|used after oocyte retrieval
276851|NCT02686151|Drug|Sodium Chloride|used after oocyte retrieval
276852|NCT02686151|Drug|dexamethasone|used after oocyte retrieval
276853|NCT02686164|Drug|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
276854|NCT02686164|Drug|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
276855|NCT02686177|Drug|Liraglutide|
276856|NCT02686177|Drug|Metformin or sulfonylurea|
276857|NCT02686190|Other|Luxtherapy|
276858|NCT00200434|Drug|Nebivolol|
276859|NCT02686203|Device|B-Cure Laser Pro and needles|Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).
The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment
276216|NCT02695641|Drug|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
276217|NCT02695641|Drug|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
276218|NCT02695654|Drug|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
276219|NCT02695654|Drug|Clonidine|Clonidine 100 mcg
276220|NCT02697461|Other|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
276221|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
276222|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
276223|NCT02697487|Other|No treatment|This is an observational study with no intervention.
276224|NCT02697513|Behavioral|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
276225|NCT00201812|Drug|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
276226|NCT02697526|Other|Terumo|
276531|NCT00200993|Behavioral|physical activity|
276532|NCT02690792|Dietary Supplement|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
276533|NCT02690805|Device|MR-compatible scinti-mammography (MRI-SMM) system|
276534|NCT02690818|Behavioral|Regularly scheduled LTBI medication reminder text messages|
276535|NCT02690831|Other|Inspiratory Muscle training (IMT)|Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
276536|NCT02690831|Other|IMT + Manual Therapy and Motor Control Exercise|IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
276537|NCT02690831|Device|Powerbreathe|
275932|NCT02701855|Radiation|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
275933|NCT02701855|Other|Adaptative optics|The retina adaptative optic imaging will be performed at the "Unité de prevention des maladies cardiovasculaires" Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging.
275934|NCT02701881|Device|Long stenting using drug-eluting stent (Zilver PTX)|Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
275935|NCT02701881|Device|Spot stenting using drug-eluting stent (Zilver PTX)|Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
275936|NCT02701894|Dietary Supplement|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
275937|NCT02701920|Device|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
275938|NCT02701920|Device|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
275939|NCT00002545|Drug|carmustine|
275940|NCT00202358|Drug|placebo|
275941|NCT02701920|Device|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
275942|NCT02701920|Device|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
275943|NCT02701920|Other|parental feedback|Questionnaire
275944|NCT02703974|Behavioral|Nudge|A nudge will be built in each randomly selected school and will consist of:
Connecting latrines to the handwashing station via paved pathways that are painted bright colors
Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations
The nudges will be constructed at the end of week 5 and 6, after Phase II data collection is complete within each randomly assigned nudge school.
276227|NCT02697526|Other|Tensoplast|
276228|NCT02697539|Other|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
276229|NCT02697539|Other|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
276230|NCT02697552|Drug|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly [BIW].
276231|NCT02697565|Behavioral|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
275650|NCT02708238|Dietary Supplement|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
275651|NCT02708238|Dietary Supplement|Lactobacillus reuteri DSM 17938 (108 CFU)|
275652|NCT02708238|Drug|Simethicone|
275653|NCT02708251|Drug|glyceryl trinitrate cream|
275654|NCT02708251|Drug|lidocaine cream|
275655|NCT02708251|Drug|placebo cream|
275656|NCT02708264|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
275657|NCT02708277|Device|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
275658|NCT02708277|Device|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
275659|NCT02708290|Other|MITA visual puzzles - Each game adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.
275660|NCT00203112|Drug|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
275661|NCT02708303|Other|Mayo Clinic Foregut Surgery Report Card Questionnaire|Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
Data collected from the questionnaire will be entered into a database that will be maintained for future research.
275662|NCT02708316|Genetic|sequencing faecal metagenome|sequencing faecal metagenome in not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
275663|NCT02708329|Procedure|T-provisional stenting|Standard endovascular T-provisional stenting technique
275664|NCT02708329|Procedure|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
275945|NCT02703974|Behavioral|Education|Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:
Importance of handwashing
Method of handwashing
Critical times of handwashing
Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.
The Hand hygiene education-based program will begin at the beginning of weeks 6 and 7, after Phase II data collection is complete in each randomly assigned education school.
260304|NCT02471547|Other|BWT with Mitomycin-C prior TURBT|Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The "Elmedical" BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes
260305|NCT02471560|Drug|dimethyl fumarate|As per the prevailing local label.
260306|NCT02471560|Drug|injectable MS DMT|As described above.
260307|NCT02471573|Procedure|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
260308|NCT00174980|Drug|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
260309|NCT02471573|Procedure|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
260310|NCT02471586|Procedure|Coronary PCI guided by IVUS|Imaging type
260311|NCT02471586|Procedure|Coronary PCI guided by OCT|Imaging type
260312|NCT02471586|Procedure|Coronary PCI guided by Angiography|Imaging type
260313|NCT02473458|Drug|Licorice whole extract|Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:
Starch-filled capsules (as placebo)
450 mg whole licorice extract capsules
900 mg whole licorice extract capsules
260314|NCT00002473|Procedure|conventional surgery|
260315|NCT00175240|Behavioral|Evidence summaries endorsed by local opinion leaders|
260316|NCT02473458|Drug|Placebo|
260317|NCT02473471|Procedure|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
260318|NCT02473497|Drug|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
260319|NCT02473510|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
260320|NCT02473510|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
260009|NCT02477605|Device|CONSTELLATION 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
260010|NCT02477605|Procedure|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
260011|NCT02477618|Drug|SAGE-547|
260012|NCT00175877|Biological|Certolizumab Pegol|Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.
Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.
Duration: Until end of study.
260013|NCT02477618|Drug|Placebo|Placebo
260014|NCT02477631|Drug|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
260015|NCT02477644|Drug|Olaparib|tablets per os 300 mg twice daily
260016|NCT02477644|Drug|Placebo|tablets per os 300 mg twice daily
260017|NCT02477657|Procedure|Paracentesis|
260018|NCT02477657|Device|Tunneled Intraperitoneal Drain (IPD)|
260019|NCT02477657|Device|Peritoneal-Venous shunts (PVS)|
260020|NCT02477670|Drug|AVP-786|
260021|NCT02477670|Drug|Placebo|
260022|NCT02477696|Drug|ACP-196|
260023|NCT00002475|Biological|allogeneic tumor cell vaccine|
260024|NCT02479685|Procedure|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
260025|NCT02479698|Biological|Cytotoxic T lymphocytes (CTLs)|CTL dose infused will not be greater than 2 x 105 cells/kg BKV-specific CD3+ T cell line as a single infusion. If participant has a partial response, stable disease or progressive disease, they will be eligible to receive one additional dose of CTL at a minimum of 2 weeks interval from the first CTL infusion.
260026|NCT02479711|Other|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
264287|NCT02381184|Drug|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
264288|NCT02381184|Procedure|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
264289|NCT00161408|Behavioral|psychoeducation|
264290|NCT02381197|Device|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
259711|NCT02484404|Drug|MEDI4736|Ph I - MEDI4736 will be administered once every 2 weeks for 12 months.
259712|NCT00176631|Drug|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
259713|NCT02484417|Biological|RSV A2 Study Agent|Each adult volunteer will receive a single intranasal inoculation with RSV A2 with subsequent sampling of nasal secretions and blood draws.
259714|NCT02484430|Other|Laboratory Biomarker Analysis|Correlative studies
259715|NCT02484430|Other|Pharmacological Study|Correlative studies
259716|NCT02484430|Drug|Sapanisertib|Given PO
259717|NCT02484443|Biological|Dinutuximab|Given IV
259718|NCT02484443|Other|Laboratory Biomarker Analysis|Correlative studies
259719|NCT02484443|Other|Pharmacological Study|Correlative studies
259720|NCT02484443|Biological|Sargramostim|Given SC
259721|NCT02484456|Drug|AV 101 (4-Chlorokynurenine)|Glycine Receptor Antagonist
259722|NCT02484456|Other|Placebo|Placebo pill
259723|NCT00176644|Drug|Transdermal Estradiol|application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.
The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed.
259724|NCT02484469|Device|The Virtual Human Project|Virtual Human educational videos about leprosy
259725|NCT02484482|Drug|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
259726|NCT00176852|Drug|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC >2500 x 2 days.
263978|NCT02386150|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
263979|NCT02386163|Biological|MSC from synovial membrane and infrapatellar Fat Pad|
263980|NCT02386189|Behavioral|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
263981|NCT02386202|Other|No intervention|No interventions
263982|NCT00162045|Drug|Technetium Tc99m Sestamibi|Rest and/or stress SPECT imaging study
263983|NCT02388386|Device|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
263984|NCT00162305|Drug|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
263985|NCT02388399|Procedure|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex> cap thickness, spotty calcification)
263986|NCT02388399|Procedure|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
263987|NCT02388438|Device|Bongener|
263988|NCT02388451|Device|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
264291|NCT02381210|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
264292|NCT02381236|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
264293|NCT02381249|Drug|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
264294|NCT02381249|Drug|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
264295|NCT02381262|Behavioral|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
264296|NCT02381275|Drug|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
264297|NCT02381288|Drug|TAK-448|TAK-448 solution for subcutaneous injection
263687|NCT02354573|Drug|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
263688|NCT02354586|Drug|Niraparib|
263689|NCT02354599|Drug|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
263690|NCT02354599|Drug|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
263691|NCT02354599|Drug|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
263692|NCT00002411|Drug|Didanosine|
263693|NCT00158405|Drug|Ritonavir (NRV)|
263694|NCT02354612|Drug|TRC105|
263695|NCT02354612|Drug|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
263696|NCT02354612|Drug|Axitinib|companion therapy selection depends on companion therapy used in the parent study
263697|NCT02354612|Drug|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
263698|NCT02354612|Drug|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
263699|NCT02354625|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
263700|NCT02354638|Behavioral|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
263701|NCT02354638|Drug|Pharmacotherapy|Pharmacotherapy will also be prescribed as per the need assessment consisting of:
Nicotine Chewing Gums:
Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months
Nicotine Transdermal patches:
Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks
263702|NCT02354651|Other|Pulmonary function testing|Measure the breathing muscles ability to move gases in and out
263989|NCT02388464|Drug|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
263990|NCT02388464|Drug|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
263991|NCT02388464|Drug|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
263992|NCT02388464|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
275483|NCT02690194|Device|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
275484|NCT02690194|Device|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
275485|NCT00200928|Biological|BCG|
275486|NCT02690207|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
275487|NCT02690220|Device|TiLOOP® PRO A (surgical mesh implant)|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginal using the TiLOOP® Application Set to place the mesh arms.
275488|NCT02690233|Procedure|Elective Surgery|Elective laparoscopic inguinal hernia repair
275489|NCT02690246|Other|questionnaire|a questionnaire based study
275490|NCT02690259|Procedure|Sentinel node procedure|Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
275491|NCT02690272|Behavioral|Psychic processes|Quantitative and qualitative aprroche of the psychic process
275492|NCT02690285|Drug|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
275493|NCT02690285|Other|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
275494|NCT02690298|Device|ExSpiron|Non-Invasive respiratory volume monitoring
275495|NCT02690311|Device|smartphone display|
275496|NCT00200941|Drug|Topiramate|
275497|NCT02690324|Behavioral|cognitive stress (serial 7)|
275498|NCT02690337|Drug|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
275499|NCT02690350|Drug|U3-1784|All doses of U3-1784 will be administered every 2 weeks (q2w) as a 250 mL IV infusion of 5% dextrose.
275500|NCT02690376|Device|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
275501|NCT02690389|Drug|Flumazenil|used alone or with acupuncture
275502|NCT02690389|Procedure|Acupuncture|used alone or with flumazenil
274939|NCT02701465|Other|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
274940|NCT02701478|Drug|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
274941|NCT02701491|Dietary Supplement|Ginger|ginger
274942|NCT00202293|Drug|Lithium|
274943|NCT02701491|Other|Placebo|Placebo
275201|NCT00201591|Behavioral|Exercise training for 10 weeks|
275202|NCT02695160|Genetic|SB-FIX|A single dose of each of the 3 components of SB-FIX (ZFN1, ZFN2, and cDNA Donor) administered via IV infusion
275203|NCT02695160|Genetic|SB-FIX|A single dose of each of the 3 components of SB-FIX (ZFN1, ZFN2, and cDNA Donor) administered via IV infusion
275204|NCT02697149|Radiation|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
275205|NCT00201773|Drug|Exemestane|25 mg orally once per day for 16 weeks.
275206|NCT02697149|Radiation|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
275207|NCT02697162|Device|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
275208|NCT02697162|Device|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
275209|NCT02697162|Drug|Octenidine chloride|Antiseptic
275210|NCT02697175|Device|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
275211|NCT02697175|Other|No Live Video-Colposcopy|The TV will be shut off during colposcopy
275212|NCT02697188|Drug|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
275213|NCT02697188|Drug|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
275214|NCT02697201|Drug|Intralipid|0.55 ml/kg/h
274647|NCT02705924|Behavioral|psychoeducation|Participants will attend conferences where experts present the state of the art in various domains:
Latest knowledge in oncogenetics
Recommendations and morbidity of prophylactic breast surgeries and annexectomy
Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits
How to perform the periodic breast screening
Assisted medical procreation and embryo selection
Importance of nutrition and physical activity as risk modulator
Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?
Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.
The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist.
274648|NCT02705937|Other|Dairy product|
274649|NCT02705937|Device|Aequasyal mouth spray|
274650|NCT02705950|Drug|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
274651|NCT02705950|Other|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
274652|NCT02707900|Biological|AGS-004|Step 5 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.
Steps 7 & 8 - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 7) followed by 10 doses of VOR 400 mg PO (Step 8).
274653|NCT02707913|Drug|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
274654|NCT02707913|Drug|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
274655|NCT02707926|Drug|Anti-HIV Agents|
274656|NCT02707939|Other|Observation|Patients will be observed before and after they receive anesthesia
274657|NCT00203060|Drug|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
274658|NCT02707952|Drug|ABT-493/ABT-530|Tablet
274944|NCT02701517|Drug|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
274945|NCT02701517|Drug|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
274946|NCT02701530|Behavioral|Targeted smoking cessation|Smoking cessation program developed in cooperation with and aimed at smokers with low education.
274947|NCT02701543|Device|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
274948|NCT02701543|Device|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
274366|NCT02711826|Drug|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
274367|NCT02711826|Procedure|Biopsy, Kidney|
274368|NCT02711826|Procedure|Blood Draw|
274369|NCT02711826|Procedure|Leukapheresis|
274370|NCT02711826|Procedure|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
274371|NCT02711839|Dietary Supplement|Commercial diabetic formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
274372|NCT02711839|Dietary Supplement|White sweet potato formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
274373|NCT02711852|Drug|Duvelisib|Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg. Subjects will take duvelisib until disease progression or unacceptable toxicity.
274374|NCT00203541|Device|TELFA™ A.M.D. Island dressing|
274375|NCT02711865|Biological|IGF1R antibody MK0646|
274376|NCT02711865|Other|Saline solution|
274377|NCT02711878|Behavioral|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
274378|NCT02713828|Drug|Glembatumumab Vedotin|Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).
Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs.
274379|NCT02713828|Drug|Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response [PR] or Complete Response [CR]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
274659|NCT02707952|Drug|Ombitasvir/paritaprevir/ritonavir|Tablet
274660|NCT02707965|Drug|Oxcarbmazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
278617|NCT02689284|Drug|margetuximab in combination with pembrolizumab|Combination treatment is administered once every 21-day cycle
278618|NCT02689297|Other|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
278619|NCT02689297|Other|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
278620|NCT02689310|Other|Leptospermum scoparium honey|
278621|NCT02689310|Other|Standard of Care Treatment|
278622|NCT02689323|Device|repeated transcranial magnetic stimulation|
278623|NCT00200850|Biological|Placebo SLIT|Placebo SLIT daily
278624|NCT02689336|Biological|Erlotinib|
278625|NCT02689336|Drug|Temozolomide|
278626|NCT02689349|Device|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
278627|NCT02689362|Drug|Evogliptin|
278628|NCT02689362|Drug|Sitagliptin|
278629|NCT02689362|Drug|Placebo Evogliptin|
278630|NCT02689362|Drug|Placebo Sitagliptin|
278631|NCT02689375|Device|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
278632|NCT02691676|Drug|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
278633|NCT02691689|Other|Genetic testing|Genetic testing by DNA sequencing on blood samples after DNA extraction
278634|NCT02691702|Drug|PF-05251749|Multiple ascending doses of PF-05251749 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
278635|NCT02691702|Drug|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
278914|NCT02684617|Drug|dinaciclib|dinaciclib 7 mg/m^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35
277740|NCT02707042|Drug|Amoxicillin|Amoxicillin (Amoxil (Registered Trademark)): Each capsule of Amoxil, with royal blue opaque cap and pink opaque body, contains 500 mg amoxicillin as the trihydrate. The cap and body of the 500-mg capsule are imprinted with the product name AMOXIL and 500.
278003|NCT02700633|Device|Pacemaker|
278004|NCT02700646|Behavioral|Developmental recommendations|
278005|NCT02700646|Behavioral|Standard care|standard care
278006|NCT02700659|Other|Cxbladder|Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
278007|NCT02700672|Other|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
278008|NCT02700685|Dietary Supplement|Pycnogenol|
278009|NCT02700685|Drug|Methylphenidate|
278010|NCT00002544|Drug|docetaxel|
278011|NCT00202176|Drug|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
278012|NCT02700685|Other|Placebo|
278013|NCT02700711|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
278014|NCT02700711|Drug|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
278015|NCT02700711|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
278016|NCT02700711|Drug|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
278017|NCT02700724|Other|Immediate Surgery|
278018|NCT02700724|Other|Observation|
278019|NCT02702700|Device|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of <10mWcm2.
278020|NCT02702713|Dietary Supplement|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
278021|NCT02702713|Dietary Supplement|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
277156|NCT02715076|Other|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
277157|NCT02717195|Drug|Lu AF35700|10 mg/day, encapsulated tablets, orally
277158|NCT02717195|Drug|Lu AF35700|20 mg/day, encapsulated tablets, orally
277159|NCT02717208|Biological|HL036|
277451|NCT02710877|Drug|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
277452|NCT02710877|Drug|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
277453|NCT02710890|Drug|Lacosamide|Pharmaceutical form: solution for infusion
Concentration: 10 mg/ml
Route of Administration: intravenous
277454|NCT02710903|Procedure|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
277455|NCT02710916|Device|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
277456|NCT00203450|Drug|Zonegran|zonisamide
277457|NCT02710942|Behavioral|SPHERE|
277458|NCT02710942|Behavioral|PRISM|
277459|NCT02710955|Dietary Supplement|Thickened infant formula|
277460|NCT02710968|Device|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed at 26-30 weeks gestation using above devices and reversed after 4-5 weeks.
277461|NCT02710981|Drug|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
277462|NCT02710981|Drug|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
277463|NCT02710994|Drug|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
276860|NCT02686216|Drug|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
276861|NCT02686229|Other|no interventions|
276862|NCT02686242|Procedure|spinal anesthesia|bupivacaine injected by spinal puncture
276863|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
276864|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
276865|NCT02688465|Drug|Apomorphine|
276866|NCT02688478|Other|Phthalate|Delivered by inhalation on day 1 of the triad
276867|NCT02688478|Other|Filtered Air|Delivered by inhalation on day 1 of the triad
277160|NCT02717208|Biological|Vehicle|
277161|NCT02717221|Other|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
277162|NCT02717234|Other|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
277163|NCT02717247|Device|Active tRNS|The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).
100Hz-650Hz, 2mA, 30min, twice daily, 5 days
277164|NCT02717247|Device|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
277165|NCT02717260|Device|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
277166|NCT02717273|Drug|standard|peri-operative antibiotic regimen only
277167|NCT00204152|Behavioral|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
277168|NCT02717273|Drug|extended|extended three-day course of antibiotics
277169|NCT02717273|Drug|steroids|500mg methylprednisolone intravenously
277170|NCT02717273|Other|liver transplant|orthotopic liver transplantation
276538|NCT02690844|Drug|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
276539|NCT02690844|Drug|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
276540|NCT02690844|Drug|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
276541|NCT02690857|Drug|Docosahexaenoic acid|
276542|NCT00201006|Behavioral|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
276543|NCT02690857|Drug|Sunflower Oil|
276544|NCT02690870|Drug|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
276545|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
276546|NCT00201331|Drug|leucovorin+5-FU|
276547|NCT02693314|Dietary Supplement|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
276548|NCT02693327|Other|Biological Sample|A one time sample will be collected.
276549|NCT02693327|Other|Blood Sample|A one time blood sample will be collected.
276550|NCT02693340|Biological|sampling|• Sampling period(s):
Blood: W0, W6, W14, W30 and W52 and relapse.
Biopsies and fecal: W0, W14 and M52 and relapse.
276551|NCT02693366|Biological|Autologous Cell Transplantation|Endovascular infusion of bone marrow derived cells in both renal arteries.
276868|NCT02688478|Other|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
276869|NCT02688491|Drug|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
276870|NCT02688517|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
276871|NCT00200707|Procedure|Intracoronary injection of autologous bone marrow mononuclear cells|
276872|NCT02688517|Other|Laboratory Biomarker Analysis|Correlative studies
276873|NCT02688530|Drug|IV Saline|
276232|NCT02697565|Behavioral|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
276233|NCT02697591|Drug|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
276234|NCT02697617|Drug|Pioglitazone|Pioglitazone
276235|NCT02697617|Drug|Placebo|Placebo
276236|NCT00002542|Drug|methotrexate|
276237|NCT00201812|Drug|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
276238|NCT02697630|Drug|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
276239|NCT02697630|Drug|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
276240|NCT02697643|Behavioral|BHCDS-based recommendations|
276241|NCT02697643|Behavioral|Non-tailored recommendations|
276242|NCT02697656|Behavioral|IPS|Individualized job support provided by an employment specialist
276243|NCT02699775|Other|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
276244|NCT02699788|Device|Multifunction Cardiogram|
276245|NCT02699801|Drug|propofol|propofol for post-sternal closure sedation
276246|NCT00202059|Drug|Zoledronic acid|
276247|NCT02699801|Drug|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
276248|NCT02699814|Behavioral|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
276552|NCT02693379|Device|D-VIA|D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.
Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment.
275946|NCT02703987|Other|Fermented infant milk formula|
275947|NCT02703987|Other|Non-fermented infant milk formula|
275948|NCT02704000|Behavioral|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
275949|NCT02704013|Drug|Oxybutynin|Anticholinergic
275950|NCT02704026|Other|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
275951|NCT02704052|Drug|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
275952|NCT02704052|Drug|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
275953|NCT00202696|Other|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
275954|NCT02704078|Device|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
275955|NCT02704078|Device|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
275956|NCT02704091|Drug|Smecta|
275957|NCT02704091|Drug|Smecta placebo|
275958|NCT02704104|Device|Application of AC5 Hemostatic agent|Application of the hemostatic agent will be applied to the skin lesion directly as prescribed
275959|NCT02704104|Device|Standard application of water resistant dressing|Application of a water resistant dressing to the skin lesion as prescribed
275960|NCT02704117|Device|Transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device).
275961|NCT02704130|Procedure|Transarterial Chemoembolization|In transarterial chemoembolization, a concentrated dose of chemotherapeutic agents is delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery. The delivery of chemotherapy is in conjunction with or followed by embolization using either permanent or temporary particulate materials.
276249|NCT02699827|Drug|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
276250|NCT02699827|Drug|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
260584|NCT02467023|Procedure|Muscle Biopsy|This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4" long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding.
260585|NCT02467023|Drug|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
260586|NCT02467023|Drug|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
260587|NCT02467023|Drug|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
260588|NCT02469129|Drug|[18F]FluorThanatrace|For the Dosimetry Studies, 10 mCi of [18F]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.
For the Kinetic Studies, 10 mCi of [18F]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection.
260589|NCT02469142|Procedure|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
260590|NCT00174759|Drug|Clopidogrel|
260591|NCT02469155|Drug|ITI-007|
260592|NCT02469155|Drug|Risperidone|
260593|NCT02469155|Drug|Placebo|
260594|NCT02469168|Device|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
260595|NCT02469168|Procedure|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
260596|NCT02469194|Other|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
260597|NCT02469207|Other|Removal of tissue post-mortem|
260598|NCT02469220|Other|Low FODMAP diet|
260321|NCT02473523|Other|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
260322|NCT02473523|Other|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
260323|NCT02473523|Device|Biodex System 3 Dynamometer|The "Biodex System 3 Dynamometer" will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete.
260324|NCT02473523|Device|Jamar Hydraulic Hand Dynamometer|A calibrated "Jamar" hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete.
260325|NCT02473523|Other|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
260326|NCT00175253|Drug|alemtuzumab|
260327|NCT02473523|Other|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
260328|NCT02475577|Device|Peripherals with HealthInterlink technology|home remote monitoring
260329|NCT02475590|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
260330|NCT02475590|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
260331|NCT02475603|Procedure|Total knee arthroplasty|Total knee arthroplasty
260332|NCT02475616|Drug|PCO371|
260333|NCT00002474|Drug|mitoxantrone hydrochloride|
260334|NCT00175539|Behavioral|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
260335|NCT02475616|Drug|Placebo|
259727|NCT02486887|Device|telemonitoring of weight, pulse and blood pressure|
259728|NCT02486900|Device|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
259729|NCT02486913|Other|Enhanced Health Check|National Health Service Health Check enhanced by risk report
259730|NCT02486926|Other|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
260027|NCT02479711|Other|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
260028|NCT02479724|Device|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
260029|NCT02479737|Device|Blood drainage post cardiac surgery using PleuraFlow System|
260030|NCT02479750|Device|ColdZyme® mouth spray|
260031|NCT00176228|Drug|Lamotrigine|It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.
The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg.
260032|NCT02479750|Device|Placebo|
260033|NCT02479763|Procedure|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
260034|NCT02479776|Biological|stem cell injection|Injection of autologous bone marrow derived stem cells
260035|NCT02479789|Drug|Lidocaine|
260036|NCT02479789|Drug|Placebo|
260037|NCT02479802|Biological|Albumin|27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:
three weeks of intensive treatment with two plasma exchanges per week
twenty-one weeks of maintenance treatment with one weekly plasma exchange
260038|NCT02479815|Dietary Supplement|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
264298|NCT02381288|Drug|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
264299|NCT02381301|Biological|Venous blood sampling prior to CCTA.|
264300|NCT00161421|Drug|Oral Testosterone|200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
264301|NCT02383732|Behavioral|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
264302|NCT02383745|Other|Acute EEG with fast EEG electrode|
264303|NCT02383758|Drug|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
264304|NCT00161681|Drug|Levonorgestrel/Ethinyl Estradiol|
264305|NCT02383758|Drug|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
259731|NCT02486926|Drug|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
259732|NCT02486926|Drug|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
259733|NCT02486926|Drug|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
259734|NCT02486926|Drug|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
259735|NCT02486939|Drug|CHS-0214|Open label
259736|NCT02486952|Drug|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
263993|NCT02388477|Drug|Doxycycline|antibiotic used to treat infection
263994|NCT02388477|Drug|sugar pill|placebo with no pharmacologic effect
263995|NCT00162305|Drug|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
263996|NCT02388490|Drug|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
263997|NCT02388503|Dietary Supplement|no added fruit extract|
263998|NCT02388503|Dietary Supplement|fruit extract|
263999|NCT02388503|Dietary Supplement|fruit extract|
264000|NCT02388503|Dietary Supplement|fruit extract|
264001|NCT02388503|Dietary Supplement|fruit extract|
264002|NCT02388516|Dietary Supplement|Vitamin D3|
264003|NCT02388516|Dietary Supplement|Placebo|
264004|NCT02388529|Drug|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
264005|NCT02388529|Drug|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
264006|NCT00000359|Behavioral|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
264007|NCT00002429|Drug|Didanosine|
264008|NCT00162305|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
264009|NCT02388529|Drug|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
264010|NCT02390726|Biological|Fecal Microbiota Transplant|
264011|NCT02390726|Biological|Placebo|
264012|NCT02390739|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
259448|NCT02493387|Other|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
275768|NCT02685683|Drug|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers patients the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating rest periods for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period
275769|NCT02685696|Device|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
275770|NCT02685696|Device|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
275771|NCT02685709|Drug|Octreotide capsules|Octreotide capsules 40mg/day, 60mg/day, 80mg/day
275772|NCT02685709|Drug|Injectable Somatostatin Analogs (octreotide or lanreotide)|Octreotide - 10, 20, 30mg. Lanreotide 60,90, 120mg.
275773|NCT02685709|Drug|Cabergoline|Cabergoline - 3.5mg/week
275774|NCT02685722|Biological|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
275775|NCT02685722|Other|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
275776|NCT00200356|Drug|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
275777|NCT02685735|Drug|Gabapentin|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
275778|NCT02685735|Drug|Placebo|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
275779|NCT02685748|Drug|Aspirin|1000 mg pd in two doses
275780|NCT02685748|Drug|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
275781|NCT02685748|Drug|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
275782|NCT02685761|Procedure|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
275783|NCT02685761|Procedure|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
275215|NCT02697201|Drug|Saline|0.55 ml/kg/h for
275216|NCT00201773|Drug|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
275217|NCT02697214|Device|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device.
275218|NCT02697214|Device|Apple Watch|Apple Watch heart rate monitoring device.
275219|NCT02697214|Device|Mio Fuse|Mio Fuse heart rate monitoring device.
275220|NCT02697214|Device|Basis Peak|Basis Peak heart rate monitoring device.
275221|NCT02697227|Behavioral|Questionnaires|Questionnaires completed at Baseline, at Study Visits, and at Follow Up Visit.
275222|NCT02697227|Behavioral|CO Level Testing|CO level measured at Baseline, Visit 1, Visit 9, and at Visit 10. Participants asked to blow air through a CO-measuring device.
275503|NCT02692768|Other|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
275504|NCT02692768|Other|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
275505|NCT02692768|Other|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
275506|NCT02692781|Drug|MOD-6031|
275507|NCT02692781|Other|Placebo control|
275508|NCT02692807|Procedure|Arthroscopic surgical procedures|See arm/group description
275509|NCT02692820|Dietary Supplement|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
275510|NCT02692820|Other|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
275511|NCT02692833|Other|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
274949|NCT02701556|Device|Complete Multi-Purpose Solution|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
274950|NCT02701556|Device|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
274951|NCT02701569|Other|Rebound exercise|Repeated jumping on a mini trampoline was administered
274952|NCT02701582|Other|Goal-Directed Therapy (GDT) group + Visible FloTrac Algorithm|The anesthesiologist WILL be able to see the dynamic indicators, and will be given a study algorithm to follow based on the trending data for the duration of the surgery
274953|NCT00202293|Drug|Chlorpromazine|
274954|NCT02701582|Other|FloTrac Algorithm Not Visible|Although FloTrac will be connected to the monitor, the anesthesiologist will not be able to see the dynamic indicators on the monitor and will not receive a study algorithm to follow based the on trending data (that they cannot see) for the duration of the surgery, but the FloTrac data will be collected by the computer and stored for subsequent analysis
274955|NCT02703623|Drug|Abiraterone acetate|1000 mg by mouth daily in a 21 day cycle.
274956|NCT02703623|Drug|Prednisone|5mg by mouth twice daily in a 21 day cycle.
274957|NCT02703623|Drug|ARN509|240 mg by mouth daily in a 21 day cycle.
274958|NCT02703623|Drug|Ipilimumab|3 mg/kg by vein every 3 weeks for 4 weeks starting Day 1 of Cycles 4, 5, 6, and 7. Study cycle is 21 days.
274959|NCT02703623|Drug|Cabazitaxel|25 mg/m2 by vein once every 3 weeks for 4 weeks starting on Day 1 of Cycles 4, 5, 6, and 7. Study cycle is 21 days.
274960|NCT02703623|Drug|Carboplatin|AUC4 by vein once every 3 weeks for 4 weeks starting on Day 1 of Cycles 4, 5, 6, and 7. Study cycle is 21 days.
274961|NCT02703636|Drug|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
275223|NCT02697227|Behavioral|Behavior Activation Treatment (BAT)|Smokers assigned to the BATS treatment complete 8, 45-minute individual treatment sessions. Treatment consists of 15 minutes of Standard Cessation (SC) strategies as well as 30 minutes of Behavioral Activation (BA) strategies. The BA strategies focus on encouraging the smoker to structure a variety of reinforcing activities to promote a more rewarding smoke-free lifestyle through daily activity monitoring, assessment of values and life goals to facilitate choice of rewarding activities, scheduling of specific activities related to quit preparation and abstinence, and weekly homework assignments.
275224|NCT02697227|Behavioral|Standard Cessation (SC)|Smokers assigned to the SC condition receive 8, 45-minute individual behavioral treatment sessions. Sessions initially consist of 15 minutes of behavioral treatment strategies for smoking cessation. Treatment involves preparation for quitting, identification of high risk situations for smoking, development of coping skills and direct support before and after the quit date, motivational intervention 91 for keeping or resetting a quit date, management of withdrawal symptoms, stress management, relaxation, relapse prevention, and medication compliance.
274661|NCT02707965|Drug|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
274662|NCT02707965|Drug|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
274663|NCT02707965|Drug|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
274664|NCT02707965|Drug|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
274665|NCT02707965|Drug|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
274666|NCT02707965|Drug|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
274667|NCT02709993|Drug|Cyclophosphamide|Administration of low dose CYP (100 mg/day) starting 7 days prior to TAPA-pulsed DC vaccine administration.
274668|NCT00203294|Drug|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
274669|NCT02709993|Other|Granulocyte Macrophage Colony Stimulating Factor|Granulocyte Macrophage Colony Stimulating Factor 50 micrograms/day of GM-CSF will be administered for 5 days following each TAPA-pulsed DC vaccine.
274670|NCT02710006|Procedure|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
274962|NCT02703649|Drug|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
274963|NCT02703662|Device|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
278915|NCT02684630|Device|Trima Accel System|Platelet Apheresis Procedure
278916|NCT02684643|Other|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
278917|NCT02684643|Other|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
278918|NCT02684643|Other|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
278919|NCT02684656|Procedure|Hemodialysis|Hemodialysis >/=4h
278920|NCT02684656|Procedure|Hemodiafiltration|Hemodiafiltration >/=4h, > 20l convection
278921|NCT02684669|Drug|Naloxone|active drug infusion
278922|NCT00200239|Behavioral|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
278923|NCT02684669|Drug|Normal saline|placebo comparator
278924|NCT02684682|Behavioral|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
278925|NCT02684682|Behavioral|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
278926|NCT02684682|Behavioral|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
278927|NCT02687022|Device|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
278928|NCT02687022|Device|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
278929|NCT02687035|Device|TAVR with SAPIEN S3 valve|Transcatheter aortic valve replacement
278930|NCT02687048|Behavioral|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
278931|NCT00200538|Drug|memantine|
278932|NCT02687048|Behavioral|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
278022|NCT02702713|Dietary Supplement|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
278023|NCT00202449|Drug|Placebo|Placebo
278024|NCT02702713|Dietary Supplement|Bakery placebo|Bakery placebo: Biscuits without enrichment
278025|NCT02702713|Dietary Supplement|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
278318|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:80,000|
278319|NCT02696382|Behavioral|Progressive High Intensity Therapy (PHIT)|Participants in the "Progressive High Intensity Therapy" (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program.
278320|NCT02696382|Behavioral|Usual Care (UC)|Participants in the "Usual Care" group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program.
278321|NCT02696395|Device|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
278322|NCT02696395|Device|DePuy Corail® femoral stem + Deltamotion® acetabular component|
278323|NCT02696408|Device|Laser treatment|Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by athermal laser of treating by daily scanning the entire oral cavity by scanning lips, inner cheeks, palate and sides of the tongue, for 2 minutes with an output of 250 mW, starting with packaging and J1 until the onset of mucositis of grade 1.
278324|NCT02696408|Device|Placebo|
278325|NCT00201721|Drug|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
278326|NCT02696434|Drug|Naltrexone|daily dosing
278327|NCT02696434|Drug|Placebo|daily dosing
278328|NCT02696434|Drug|Buprenorphine|daily dosing
278329|NCT02696460|Procedure|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
278330|NCT02698410|Drug|Lanreotide (Autogel formulation) and Temozolomide|
278331|NCT02698423|Device|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
278332|NCT02698423|Other|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
277464|NCT02710994|Drug|Losec|Losec 40 mg
277465|NCT02711007|Drug|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
277466|NCT02712970|Procedure|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
277741|NCT02707042|Drug|Azithromycin|Azithromycin (Zithromax (Registered Trademark)): Tablets for oral administration are provided as red film-coated, oval-shaped tablets that contain 250 mg of azithromycin as the monohydrate. The tablets are engraved with Pfizer and 306 .
277742|NCT02707055|Drug|PF-05190457|Ghrelin Receptor Inverse Agonist
277743|NCT02707055|Behavioral|MI-VF|Motivational Interviewing with Video
277744|NCT02707055|Other|Placebo|Placebo
277745|NCT02707055|Other|Counseling|Counselling Support
277746|NCT02707068|Behavioral|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
277747|NCT02707081|Drug|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
277748|NCT00202969|Drug|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
277749|NCT02707081|Drug|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
277750|NCT02707081|Drug|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
277751|NCT02707081|Drug|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
277171|NCT02717286|Procedure|restorative|It was performed direct restoration using two kinds of adhesive system (total-eatching adhesive and self-eatching adhesive)
277172|NCT02717299|Device|Verasense|Verasense will collect balancing data on all patients in this trial.
277173|NCT02717325|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
277174|NCT02717338|Behavioral|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
277175|NCT02717338|Behavioral|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
277176|NCT02717338|Behavioral|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
277177|NCT02717351|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
277467|NCT02712970|Procedure|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
277468|NCT00203658|Drug|Tinzaparin sodium|
277469|NCT02712970|Procedure|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
277470|NCT02712983|Drug|TIP|TIP dose regimen
277471|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
277472|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
277473|NCT02712983|Drug|TIP|TIP dose regimen
277474|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
277475|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
277476|NCT02712983|Drug|TIP|TIP dose regimen
277477|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
277478|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
276874|NCT02688530|Drug|IV Dexamethasone 4mg|
276875|NCT02688530|Drug|IV Dexamethasone 6mg|
276876|NCT02688530|Drug|IV Dexamethasone 8mg|
276877|NCT02688543|Procedure|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
276878|NCT02688543|Radiation|radiofrequency ablation|
276879|NCT02688543|Device|ultrasound|
276880|NCT02688556|Drug|cyclosporine|
276881|NCT02688556|Drug|vehicle of OTX-101|
276882|NCT00200720|Behavioral|Atkins diet (low carbohydrate diet)|
276883|NCT02688569|Behavioral|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
276884|NCT02688582|Other|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
276885|NCT02688595|Device|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
276886|NCT02688608|Drug|Pembrolizumab|200 mg IV once every 3 weeks
276887|NCT02688621|Behavioral|Internet Only|18 month behavioral weight loss intervention delivered online
276888|NCT02688621|Behavioral|Internet + Incentives|18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
277178|NCT02683824|Procedure|Positron Emission Tomography|Undergo [18F] FP-R01-MG-F2 PET/CT scan
277179|NCT02683824|Drug|[18F]FP-R01-MG-F2|
277180|NCT02683824|Drug|[18F]-FDG|
277181|NCT02683837|Drug|Remifentanil|
277182|NCT02683837|Device|Pupillometry|Pupillary diameter measured every 5 minutes
276553|NCT02693392|Drug|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|Patients receiving either of the following oral hypoglycemic agents
Sulfonylurea based oral hypoglycemic agents
Metformin based oral hypoglycemic agents
Metformin plus Sulfonylurea based oral hypoglycemic agents
276554|NCT02693392|Dietary Supplement|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
276555|NCT02693405|Other|Executive functions|measures of executive functioning with tasks
276556|NCT02693405|Other|social cognition|measures of socio-cognitive functioning with tasks
276557|NCT00201344|Drug|Cisplatin,5-FU,Leucovorin|
276558|NCT02693405|Other|quality of life|measures of quality of life with questionnaires
276559|NCT02693418|Drug|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
276560|NCT02693418|Drug|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
276561|NCT02693418|Drug|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
276562|NCT02693418|Drug|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
276563|NCT02693431|Other|Non interventional Study|Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.
The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.
At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires.
276564|NCT02693444|Drug|Lidocaine|
276565|NCT02693444|Drug|Saline|
276566|NCT02693457|Procedure|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
276567|NCT02695693|Behavioral|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
276568|NCT02695693|Behavioral|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
276569|NCT02695693|Behavioral|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
276889|NCT02690870|Drug|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
276251|NCT02699827|Drug|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
276252|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
276253|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
276254|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
276255|NCT02699853|Other|Questionnaire Administration|Ancillary studies
276256|NCT02699853|Procedure|Radical Cystectomy|Undergo RRC
276257|NCT00002543|Drug|gallium nitrate|
276258|NCT00202059|Behavioral|Physical activity intervention|
276259|NCT02699853|Procedure|Radical Cystectomy|Undergo ORC
276260|NCT02699866|Device|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
276261|NCT02699879|Drug|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
276262|NCT02699892|Drug|Rituximab|Participants will receive rituximab as per investigator discretion according to approved indication.
276263|NCT02699905|Other|phlebotomy|phlebotomy
276264|NCT02699918|Procedure|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
276265|NCT02699931|Device|Electric3D|Oral-B 3D with orthodontic head
276266|NCT02699931|Device|Manual|Oral-B orthodontic
276267|NCT02699944|Device|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
276268|NCT02699957|Procedure|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
276269|NCT02701920|Other|healthcare provider feedback|Questionnaire
276270|NCT02701933|Drug|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
276271|NCT02701933|Drug|Saline|Saline, intravenous infusion
260599|NCT02469233|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
260600|NCT02469246|Drug|F/TAF|Emtricitabine/tenofovir alafenamide (F/TAF) fixed dose combination (FDC) tablets administered orally once daily
260883|NCT02498431|Device|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
260884|NCT02498444|Drug|Treprostinil|Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
260885|NCT02498457|Other|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
260886|NCT00178451|Drug|Abciximab|
260887|NCT02498470|Procedure|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
260888|NCT02498483|Drug|Acetaminophen|
260889|NCT02498496|Drug|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
260890|NCT02500641|Drug|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration > 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
260891|NCT02500641|Drug|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
260892|NCT02500641|Drug|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
260893|NCT02500641|Drug|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
260894|NCT02500641|Drug|Omeprazole|Omeprazole 20 mg capsules
260895|NCT02500654|Device|Emdogain®|Surgery and Emdogain®
260896|NCT02500654|Device|Surgery alone|Surgery alone
260897|NCT02500667|Drug|N91115|200 mg BID
260898|NCT02500667|Drug|Rifampin|600 mg QD
260336|NCT02475629|Biological|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
260601|NCT00002471|Drug|vincristine sulfate|
260602|NCT00174772|Drug|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
260603|NCT02469246|Drug|ABC/3TC|Abacavir/lamivudine (ABC/3TC) FDC tablets administered orally once daily
260604|NCT02469246|Drug|ABC/3TC Placebo|Placebo to match ABC/3TC tablets administered orally once daily
260605|NCT02469246|Drug|F/TAF Placebo|Placebo to match F/TAF tablets administered orally once daily
260606|NCT02469246|Drug|Third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC, efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
260607|NCT02469259|Drug|Oxytocin|
260608|NCT02469259|Other|Placebo|
260609|NCT02469272|Drug|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
260610|NCT02469285|Dietary Supplement|Modified pork|Pork with modified fatty acid composition
260611|NCT02469285|Dietary Supplement|Pork|Pork with normal fat composition
260612|NCT02471599|Procedure|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
260613|NCT02471599|Other|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
260614|NCT02471625|Device|ClearView Scanning|
260615|NCT02471651|Drug|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
260616|NCT02471651|Drug|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
260617|NCT02471664|Device|Mitral Loop Cerclage Annuloplasty|
260039|NCT02479828|Drug|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
260040|NCT02479828|Drug|Ropivacaine|
260041|NCT02479828|Device|ultrasound|
260042|NCT00002475|Biological|recombinant interferon gamma|
260043|NCT00176241|Drug|gemcitabine|2000-3000mg/m2 IV on days 1 & 15
260044|NCT02482324|Drug|ALZT-OP1a|Mast cell stabilizer
260045|NCT00176462|Drug|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
260046|NCT02482324|Drug|ALZT-OP1b|anti-inflammatory
260337|NCT02475629|Drug|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
260338|NCT02475642|Other|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
260339|NCT02475642|Other|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
260340|NCT02475655|Drug|Ruxolitinib|10 mg orally twice daily for 5 weeks
260341|NCT02475668|Device|Pulse oximeter|Hypoxia
260342|NCT02475681|Drug|ACP-196|
260343|NCT02475681|Drug|Obinutuzumab|
260344|NCT02475681|Drug|Chlorambucil|
260345|NCT00175552|Behavioral|Psychotherapy Training|
260346|NCT02475694|Other|No intervention|No treatment
260347|NCT02475707|Biological|MultiTAA-specific T cells|The 3 dose levels are:
Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2
The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.
If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions every 4-6 weeks.
259737|NCT00176852|Drug|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
259738|NCT02486952|Drug|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
259739|NCT02486952|Drug|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
259740|NCT02486952|Drug|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
259741|NCT02486952|Drug|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
259742|NCT02486965|Device|thermode (TSA-II model)|thermal stimulation with test thermode
259743|NCT02486965|Other|Adapted Physical Activity|
259744|NCT02486965|Other|Physical activity|
259745|NCT02486978|Other|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
259746|NCT02486978|Dietary Supplement|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
259747|NCT02488798|Procedure|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
259748|NCT02488824|Procedure|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95° F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
259749|NCT02488850|Procedure|Surgery|
259750|NCT02488850|Radiation|SABR|
259751|NCT02488863|Other|MRI Neuroimaging|MRI scans to be use to measure the structural and functional integrity of the brain.
260047|NCT02482324|Device|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
260048|NCT02482337|Procedure|POEM|POEM procedure in the OR
260049|NCT02482350|Behavioral|Reading Training|Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called "Times Square" presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text.
260050|NCT02482363|Radiation|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
259449|NCT02493387|Other|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
259450|NCT02493426|Drug|Intranasal Oxytocin|
259451|NCT02493439|Behavioral|Best Possible Self|
259452|NCT02493439|Behavioral|Daily Activities|
259453|NCT02493452|Drug|Plecanatide|
259454|NCT02493452|Drug|Placebo|
259455|NCT02493465|Drug|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
259456|NCT00177619|Drug|Alendronate|
259457|NCT02493504|Drug|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
259458|NCT02493517|Drug|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection.
259459|NCT02493517|Drug|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection.
259460|NCT02493530|Drug|TGR-1202|Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.
Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.
Expansion will commence after proper combination doses of both agents is established.
259461|NCT02493530|Drug|ruxolitinib|
259462|NCT02493543|Other|Blood collection|Blood collection from the subject's arm
259463|NCT02493556|Device|LLLT before muscle damage|
259464|NCT02493556|Device|Placebo LLLT before muscle damage|
259465|NCT02493556|Device|LLLT after muscle damage|
259466|NCT02493556|Device|Placebo LLLT after muscle damage|
259467|NCT00177632|Behavioral|behavioral weight loss|
259468|NCT02493569|Procedure|The radical mastectomy of breast cancer|The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
259469|NCT02493582|Biological|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
275784|NCT02685774|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
275785|NCT02688114|Procedure|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
276079|NCT02716779|Drug|Ribavirin|Participants with chronic hepatitis C, genotype 1 will receive ribavirin monotherapy, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]), in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, orally daily for 6 weeks. Thereafter, all participants will receive combination therapy with PEG-INF alfa-2a (40KD) plus ribavirin (1000 to 1200 mg PO) for 12 weeks which may be followed further for 36 weeks depending on initial virological response.
276080|NCT02716792|Drug|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
276081|NCT02716805|Drug|Tremelimumab|
276082|NCT02716805|Drug|Durvalumab|
276083|NCT02716818|Drug|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
276084|NCT02716818|Drug|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
276085|NCT02716831|Behavioral|Nutritional Counseling And Acceptance-based Therapy (N-CAAT)|
276086|NCT02716831|Behavioral|Cognitive Behavioral Therapy for Eating Disorders (CBT)|
276087|NCT02716844|Other|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
276088|NCT02716857|Drug|Oxycodone extended-release|
276089|NCT00204100|Device|Surface Functional Electrical Stimulation|
276090|NCT02716857|Drug|Placebo of oxycodone extended-release|
276091|NCT02716870|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
276092|NCT02716883|Procedure|AMT|The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.
In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed.
276093|NCT02716896|Radiation|Radiation and chemotherapy|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
276094|NCT02716896|Procedure|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
275512|NCT02692859|Biological|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose
275513|NCT00201253|Other|Bronchoalveolar lavages and venipunctures only|
275514|NCT02692937|Procedure|Neurolysis|
275515|NCT02692937|Other|Traditional neck-specific exercise program|
275516|NCT02692950|Other|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
275517|NCT02692950|Behavioral|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
275518|NCT02692963|Biological|BCG vaccination|BCG vaccine SSI
275519|NCT02692976|Biological|mDC vaccination|Intranodal mDC vaccination
275520|NCT02692976|Biological|pDC vaccination|Intranodal pDC vaccination
275521|NCT02692976|Biological|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
275786|NCT02688114|Procedure|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, confocal laser endomicroscopy, and biopsies.
275787|NCT02688114|Procedure|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, confocal laser endomicroscopy, and biopsies.
275788|NCT02688114|Procedure|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, confocal laser endomicroscopy, and biopsies.
275789|NCT02688127|Drug|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
275790|NCT02688140|Drug|Arsenic trioxide|
275791|NCT02688140|Drug|Idarubicin|
275792|NCT02688140|Drug|Cytarabine|
275793|NCT00200655|Drug|Placebo|
275794|NCT02688140|Drug|Tretinoin|
275795|NCT02688140|Drug|Mitoxantrone|
275796|NCT02688140|Drug|Mercaptopurine|
275797|NCT02688140|Drug|Methotrexate|
275225|NCT02699268|Other|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
275226|NCT02699281|Drug|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
275227|NCT02699281|Drug|Placebo|um-PEA like placebo twice a day
275228|NCT02699294|Other|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
275229|NCT02699294|Other|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
275230|NCT00201994|Drug|Tolvaptan|
275231|NCT02699294|Other|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
275232|NCT02699307|Behavioral|Counseling|OT led counseling
275233|NCT02699320|Other|Complications|Not involved
275234|NCT02699346|Device|HS-1000 recording|
275235|NCT02699359|Device|HS-1000 recording|
275236|NCT02699372|Drug|Placebo|
275522|NCT02692989|Procedure|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
275523|NCT02693002|Drug|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
275524|NCT00201266|Procedure|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
274964|NCT02703662|Device|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
274965|NCT00202631|Device|Surface Functional Electrical Stimulation|
274966|NCT02703675|Device|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
274967|NCT02703688|Behavioral|Healthy Homes|The HHBI will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
274968|NCT02703688|Other|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
274969|NCT02703701|Behavioral|Physician at triage|A physician embedded at triage
274970|NCT02703701|Other|Usual Care|No physician at triage
274971|NCT02703714|Drug|Pembrolizumab|
274972|NCT02703714|Drug|Sargramostim|
274973|NCT02705963|Drug|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
274974|NCT02705963|Drug|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
274975|NCT02705963|Drug|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
274976|NCT00202878|Drug|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
274977|NCT02705976|Other|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
275237|NCT02699372|Drug|RO6889450|
275238|NCT02699385|Other|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
278933|NCT02687074|Device|HFNC|patients treated with high flow nasal cannula
274380|NCT02713841|Drug|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
274381|NCT02713841|Drug|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
274382|NCT02713854|Procedure|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
274383|NCT02713867|Biological|Nivolumab|
274384|NCT02713893|Drug|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
274385|NCT02713893|Drug|Placebo plus Econazole nitrate 1% intravaginal cream|
274386|NCT00203788|Behavioral|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
274387|NCT02713893|Drug|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
274388|NCT02713893|Drug|Placebo intravaginal cream|
274389|NCT02713906|Device|X-Ray Knee Guide group|
274390|NCT02713919|Behavioral|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
274391|NCT02713932|Device|Transcatheter aortic valve implantation|
274392|NCT02713945|Drug|Simvastatin|Experimental drug administrated orally
274393|NCT02713945|Drug|Placebo|Treatment for the control group
274394|NCT02713958|Other|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
274395|NCT02713958|Other|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
274396|NCT02713971|Device|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
274397|NCT00203788|Drug|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
278333|NCT00002542|Drug|tamoxifen citrate|
278334|NCT00201877|Drug|Rituximab|Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.
Maintenance: 375 mg/m2 day 1 weekly x 4 weeks.
278335|NCT02698449|Procedure|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
278336|NCT02698449|Procedure|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
278636|NCT02691715|Procedure|Endometrial saline plus curettage|
278637|NCT02691715|Procedure|Endometrial curettage|
278638|NCT02691728|Drug|LDV/SOF FDC|
278639|NCT02691754|Other|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
278640|NCT02691767|Drug|pazopanib|
278641|NCT02691780|Drug|Sorafenib|
278642|NCT00201123|Other|Placebo|
278643|NCT02691793|Drug|sunitinib|
278644|NCT02691806|Other|experimental protocol|first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.
second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors.
278645|NCT02691819|Device|single stent and embedded balloon angioplasty|
278646|NCT02691832|Device|"Dräger" double sensor|The "Dräger" Double Sensor is a novel non-invasive device for assessing core body temperature.
278647|NCT02691845|Behavioral|BA (brief advice)|
278648|NCT02691845|Behavioral|SHE (supervised and home-based exercise)|
278649|NCT02691845|Behavioral|HE (health education)|
278650|NCT02691845|Behavioral|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
278651|NCT02691858|Drug|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
278652|NCT02691858|Drug|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
277752|NCT02707094|Device|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
277753|NCT02707094|Other|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
277754|NCT02709005|Drug|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
278026|NCT02702713|Dietary Supplement|Egg placebo|Egg placebo: Frozen pancakes without enrichment
278027|NCT02702726|Other|Congee and juice with coconut gel|25g coconut oleogel
278028|NCT02702726|Other|Congee and juice with coconut oil|25g coconut oil
278029|NCT02702726|Other|Congee and juice with sunflower gel|25g sunflower oleogel
278030|NCT02702726|Other|Congee and juice with sunflower oil|25g sunflower oil
278031|NCT02702739|Drug|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
278032|NCT02702752|Other|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
278033|NCT02702765|Procedure|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
278034|NCT00202462|Drug|Testosterone gel|Testosterone gel 7.5 gm qd
278035|NCT02702765|Procedure|Ultrasound|Ultrasound is a non-invasive procedure
278036|NCT02702765|Drug|Galactose|Galactose elimination capacity is performed to evaluate metabolic liver function.
The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
278037|NCT02702765|Procedure|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
277479|NCT00203684|Drug|Flunisolide-HFA|
277480|NCT02712996|Drug|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
277481|NCT02712996|Drug|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
277482|NCT02713009|Dietary Supplement|Pregnancy multi-vitamin (including 10μg vitamin D3)|
277483|NCT02713009|Dietary Supplement|10μg vitamin D3|
277484|NCT02713009|Dietary Supplement|0μg vitamin D (placebo)|
277485|NCT02713022|Device|DEXA Scan|
277486|NCT02713022|Behavioral|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
277487|NCT02713035|Behavioral|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
277488|NCT02713048|Other|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
277489|NCT02713061|Drug|TAK-850|TAK-850 injection
277755|NCT02709005|Other|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
277756|NCT02709018|Drug|losartan|Angiotensin receptor blocker (ARB)
277757|NCT02709018|Drug|Placebo|Placebo
277758|NCT02709031|Drug|Cicletanine + magnesium|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses.
277759|NCT02709031|Drug|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
277760|NCT02709044|Drug|Ringer lactate|
277183|NCT02683837|Drug|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
277184|NCT00200161|Drug|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
277185|NCT02683850|Dietary Supplement|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
277186|NCT02683863|Drug|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
277187|NCT02683889|Drug|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
277188|NCT02683902|Device|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
277189|NCT02683902|Behavioral|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
277190|NCT02683902|Device|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
277191|NCT02683915|Procedure|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
277192|NCT02683928|Biological|GBR 830|
277193|NCT02683928|Biological|Placebo|
277194|NCT02683941|Drug|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression
277195|NCT00200161|Drug|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
277196|NCT02683941|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
277490|NCT00203697|Drug|minocycline|
277491|NCT02715089|Genetic|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
276890|NCT02690883|Drug|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
276891|NCT02690883|Drug|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG <10.0mmol/L.
276892|NCT02690896|Behavioral|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
276893|NCT02690896|Behavioral|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
276894|NCT02690909|Device|Redy™ Renal Denervation System|Renal Denervation System
276895|NCT02690922|Drug|Dasatinib|100mg (d1-d84)
276896|NCT02690922|Drug|prednisone|60mg/m2 d1-24
276897|NCT00201006|Behavioral|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
276898|NCT02690922|Drug|dexamethasone|10mg/d 3-7days
276899|NCT02690922|Drug|methotrexate|3g/m2 1day
276900|NCT02690935|Drug|2LALERG|Homeopathic drug
276901|NCT02690935|Drug|Placebo|Placebo
276902|NCT02690948|Other|Laboratory Biomarker Analysis|Correlative studies
276903|NCT02690948|Biological|Pembrolizumab|Given IV
276904|NCT02690948|Drug|Vismodegib|Given PO
276905|NCT02690961|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
276906|NCT02690961|Drug|placebo multiple doses|
276907|NCT02690974|Drug|LCZ696 (sacubitril/valsartan)|All patients will be treated with the LCZ696 (sacubitril and valsartan) tablets
276908|NCT00201006|Other|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
276909|NCT02690987|Drug|Exenatide|Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.
The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of ~130-190 pg/mL.
276570|NCT00201656|Procedure|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
276571|NCT02695693|Behavioral|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
276572|NCT02695706|Device|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
276573|NCT02695719|Drug|Lubiprostone|Lubiprostone capsules
276574|NCT02695719|Drug|Placebo|Lubiprostone placebo-matching capsules
276575|NCT02695732|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
276576|NCT02695732|Device|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
276577|NCT02695745|Drug|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
276578|NCT02695745|Drug|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
276579|NCT02695745|Drug|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
276580|NCT02695745|Drug|Capsaicin|1% administered topically
276581|NCT00201669|Drug|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
276582|NCT02695758|Procedure|Interscalene brachial plexus block|
276583|NCT02695758|Procedure|bupivacaine extended-release liposome injection|
276584|NCT02695771|Drug|Mitomycin C|Cancer chemotherapeutic agent
276585|NCT02695771|Drug|Gemcitabine|Cancer chemotherapeutic agent
276586|NCT02695784|Dietary Supplement|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
276587|NCT02695797|Other|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
276588|NCT02695797|Drug|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
276589|NCT02695810|Drug|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
260899|NCT00178763|Other|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
260900|NCT02500680|Biological|MER4101|
260901|NCT02500680|Biological|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
261170|NCT02494336|Procedure|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
261171|NCT02494336|Drug|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
261172|NCT02494349|Drug|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
261173|NCT02494349|Drug|Solifenacin 5mg + Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
261174|NCT02494362|Other|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
261175|NCT02494375|Other|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
261176|NCT02496507|Other|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
261177|NCT02496520|Biological|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
261178|NCT02496520|Procedure|Surgery as needed by the patient´s tumor and stage|
261179|NCT02496520|Drug|Chemotherapy as needed by the patient´s tumor and stage|
261180|NCT02496520|Radiation|Radiation therapy as needed by the patient´s tumor and stage|
261181|NCT02496533|Procedure|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
261182|NCT02496546|Drug|LEO 32731 cream|Applied for 3 weeks
260618|NCT00174993|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
260619|NCT02471677|Drug|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
260620|NCT02471677|Drug|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
260902|NCT02500693|Biological|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
260903|NCT02500706|Drug|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
260904|NCT02500706|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted.
260905|NCT02500706|Drug|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
260906|NCT02500719|Other|Fitted Q Learning Algorithm|A reinforcement learning algorithm, fitted Q learning, will be applied to fMRI and skin conductance response (SCR) data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory. The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
260907|NCT02500732|Drug|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
260908|NCT02500732|Drug|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
260909|NCT02467023|Other|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
260910|NCT00174512|Drug|Moxifloxacin|
260911|NCT02467023|Other|Passive Range of Motion treatment|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
260348|NCT02475733|Drug|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
260349|NCT02475733|Drug|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
260350|NCT02475733|Drug|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
260351|NCT02475746|Drug|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
260352|NCT02475746|Drug|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
260353|NCT00175890|Drug|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
260354|NCT02477696|Drug|ibrutinib|
260355|NCT02477709|Drug|AF-219|AF-219 oral tablet (150 mg administered as three 50 mg tablets) - single dose only
260356|NCT02477722|Other|EFP-NF|
260621|NCT02471690|Drug|Oritavancin|IV - Single dose 1200 mg Oritavancin
260622|NCT02471690|Drug|Dextrose|D5W 5% in Water
260623|NCT02471703|Device|Total hip arthroplasty|Total hip arthroplasty
260624|NCT02471716|Drug|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes every 2 weeks
260625|NCT02471729|Device|EnligHTN™ Renal Denervation System|The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
260626|NCT02471742|Procedure|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
260627|NCT02471742|Procedure|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
260628|NCT02471755|Device|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
260629|NCT00174993|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
260051|NCT02482363|Radiation|Sham Control|20 minutes of sham control exposure
260052|NCT02482376|Radiation|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
260053|NCT02482389|Radiation|Single fraction of 10Gy|All subjects will receive a single 10Gy fraction of radiotherapy to the intact tumor prior to surgery.
260054|NCT02482402|Drug|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
260055|NCT02482402|Drug|Placebo|inhalation solution placebo
260056|NCT00176462|Drug|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
260057|NCT02482415|Other|Psycho-educational|
260058|NCT02482428|Drug|LFX453|The cream will be applied twice daily for up to 12 weeks
260059|NCT02482428|Drug|Aldara®|Cream will be applied 3 times a week for 16 weeks
260060|NCT02482441|Drug|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
260061|NCT02482441|Drug|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
260062|NCT02482454|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
260063|NCT02482454|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
260064|NCT02482467|Other|Hormonal analysis, pelvic US|
260065|NCT02482480|Other|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
260066|NCT02482480|Other|Control|Dietary and general recommendations
260067|NCT00176462|Drug|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
260357|NCT02477722|Other|Sham|
260358|NCT02477735|Device|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
260359|NCT02477748|Drug|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
259752|NCT00177047|Drug|Melphalan|Administered intravenously 200 mg/m^2
259753|NCT02488863|Other|Quantitative Sensory Testing|Vibratory Detection Thresholds, Tactile Detection Thresholds and Temporal Summation, Thermal Detection Thresholds, Pain Thresholds and Temporal Summation, Allodynia and Temporal Summation, and Punctate Pain Testing and Temporal Summation
259754|NCT02488863|Other|Questionnaires|RAND 36-item Health Survey (SF-36), Multidimensional Pain Inventory (MPI), the Pittsburgh Sleep Quality Index (PSQI), the trait version of the State-Trait Anxiety Inventory (STAI), the trait version of the Positive and Negative Affect Schedule (PANAS) and the Pain Disability Index (PDI), NIH Cognition toolbox Dimensional Card Sort test, the Stroop Interference test, the Ruff Figural Fluency test, The Montreal Cognitive Assessment (MoCA), and the Center for Epidemiologic Studies Depression Scale (CES-D).
259755|NCT02488863|Other|Physical Function Testing|Upper Limb Isometric Strength, Short physical performance battery (SPPB), 400 Meter Walk, and Knee Extension Isokinetic Strength
259756|NCT02488889|Drug|Varenicline|
259757|NCT02488889|Drug|Placebo pill (for varenicline)|
259758|NCT02488889|Drug|Alcohol|
259759|NCT02488889|Drug|placebo beverage (for alcohol)|
259760|NCT02488902|Drug|Placebo|Placebo
259761|NCT02488902|Drug|Tafenoquine 25mg|Tafenoquine 25mg
259762|NCT02488902|Drug|Tafenoquine 50mg|Tafenoquine 50mg
259763|NCT00177047|Biological|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
259764|NCT02488902|Drug|Tafenoquine 100 mg|Tafenoquine 100 mg
259765|NCT02488902|Drug|Tafenoquine 200 mg|Tafenoquine 200 mg
259766|NCT02488902|Drug|Mefloquine 250 mg|Mefloquine 250 mg
259767|NCT02488915|Device|EmboTrap® Revascularization Device|
259768|NCT02488954|Other|Probiotics in the form of cheese portion|
259769|NCT02488967|Drug|Carboplatin|Given IV
259770|NCT02488967|Drug|Cyclophosphamide|Given IV
259771|NCT02488967|Drug|Doxorubicin Hydrochloride|Given IV
259772|NCT02488967|Other|Laboratory Biomarker Analysis|Correlative studies
259773|NCT02488967|Drug|Paclitaxel|Given IV
276095|NCT00200096|Procedure|Acupuncture and questionnaires|Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.
On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated "posttreatment" values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation.
276391|NCT02712580|Device|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
276392|NCT02712580|Device|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
276393|NCT02712580|Device|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
276394|NCT02712580|Device|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
276395|NCT02712593|Dietary Supplement|Niagen™ 100|
276396|NCT02712593|Dietary Supplement|Niagen™ 300|
276397|NCT02712593|Dietary Supplement|Niagen™ 1000|
276398|NCT02712593|Other|Placebo|
276399|NCT02712619|Drug|Metformin|
276400|NCT00203606|Drug|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
276401|NCT02712658|Drug|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
276402|NCT02712658|Drug|Placebo|
276403|NCT02712671|Radiation|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
276404|NCT02712671|Procedure|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
276405|NCT02712671|Procedure|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
275798|NCT02688153|Device|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR & CABG.
275799|NCT02688153|Device|Stented aortic bioprostheses|In comparison to control valves available on the market.
275800|NCT02688166|Other|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
275801|NCT02688192|Behavioral|Exercise Intervention|Participate in fitness program
275802|NCT02688192|Behavioral|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
275803|NCT02688192|Device|Monitoring Device|Wear an electronic accelerometer
275804|NCT00200668|Drug|FDG = fluorodeoxyglucose|
275805|NCT02688192|Other|Quality-of-Life Assessment|Ancillary studies
275806|NCT02688205|Other|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
275807|NCT02688205|Device|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
275808|NCT02688218|Behavioral|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
276096|NCT02683395|Drug|PLX51107|
276097|NCT02683408|Other|placebo|inactive placebo
276098|NCT02683408|Dietary Supplement|diosmiplex|diosmiplex is an FDA regulated medical food product
276099|NCT02683421|Drug|tilmanocept|
276100|NCT02683434|Device|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
276101|NCT02683447|Other|CRM Simulation and Debrief|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
276102|NCT02683460|Procedure|Patella resurfacing|
276103|NCT02683460|Procedure|Patella retention|
275525|NCT02695160|Genetic|SB-FIX|A single dose of each of the 3 components of SB-FIX (ZFN1, ZFN2, and cDNA Donor) administered via IV infusion
275526|NCT02695186|Procedure|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
275527|NCT02695199|Procedure|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
275528|NCT02695199|Procedure|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
275529|NCT02695212|Drug|Apremilast|Investigational Product: Apremilast
Doses: Period A:
10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6
Period B:
30mg Twice per day, day #7 through week #24
Period C:
Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral
275530|NCT02695225|Behavioral|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
275531|NCT02695225|Behavioral|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
275532|NCT02695238|Procedure|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
275533|NCT00201617|Device|Bone-anchored hearing aid|
275534|NCT02695251|Other|low AGE meal|Patients will receive a low AGE (eggs) meal
275535|NCT02695251|Other|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
275536|NCT02695264|Device|HS-1000 recording|
275537|NCT02695277|Device|AtriCure Bipolar System|
275538|NCT02695277|Device|Standard Endocardial Ablation with Catheter|
275539|NCT02695277|Device|AtriClip® PRO LAA Exclusion System|
275540|NCT02695277|Device|Endocardial Ablation with Catheter|
275809|NCT02688218|Behavioral|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
265791|NCT02386917|Behavioral|Very low calorie diet|Non-surgical weight loss procedure
265792|NCT02386930|Behavioral|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
265793|NCT02386943|Drug|Sitagliptin|100mg po once.
265794|NCT02386943|Drug|Saxagliptin|5mg po once.
265795|NCT00162123|Drug|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
265796|NCT02386943|Drug|Blank control|No medication is taken.
265797|NCT02386956|Other|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
265798|NCT02386956|Other|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
265799|NCT02386956|Other|Control|10 minutes with the patient lying on a machine off of magnetotherapy
265800|NCT02389127|Device|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
265801|NCT02389140|Other|Trigger point release|Trigger point therapy
265802|NCT02389140|Other|Ultrasound|sham ultrasound
266067|NCT02379559|Behavioral|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
266068|NCT02379559|Behavioral|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
266069|NCT02379572|Device|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
266070|NCT02379572|Drug|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
266071|NCT02379585|Drug|Doxorubicin|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
265478|NCT02355210|Dietary Supplement|galactooligosaccharide|5 g galactooligosaccharide
265479|NCT00158457|Drug|Efavirenz (EFV)|
265480|NCT02355210|Dietary Supplement|Placebo|lactose powder, 5 grams
265481|NCT02355223|Other|FAST|See information in arm description
265482|NCT02355236|Drug|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
265483|NCT02355236|Drug|Celecoxib 200mg|Capsule, o.d.
265484|NCT02355236|Drug|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
265485|NCT02355236|Drug|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
265486|NCT02355249|Procedure|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
265487|NCT02355249|Procedure|OE|Patients will be treated with traditional three incisions esophagectomy.
265488|NCT02355262|Other|Informational Intervention|Receive CATCH-UP intervention
265489|NCT02355275|Procedure|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
265490|NCT00002412|Drug|Emivirine|
265491|NCT00158470|Drug|efavirenz|
265492|NCT02355288|Procedure|Minimally Invasive Coronary Bypass (MICS CABG)|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
265493|NCT02355288|Procedure|Percutenous Coronary Intervention with Drug Eluting Stent (PCI/DES)|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
265494|NCT02355301|Procedure|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
265495|NCT02355314|Other|Doppler-based renal|Doppler-based renal : day 0 and day 3
265496|NCT02355314|Biological|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
265497|NCT02357966|Drug|Standard IV antibiotic therapy|standard antibiotic therapy will be determined by the attending physician and will be guided by the results of cultures with sensitivities.
270761|NCT02345304|Drug|Midazolam|
270762|NCT02345304|Drug|Omeprazole|
270763|NCT02345304|Drug|BI 1181181|
270764|NCT02345304|Drug|Midazolam|
270765|NCT02345304|Drug|Midazolam|
270766|NCT00157196|Other|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
270767|NCT02345304|Drug|Warfarin|
270768|NCT02345304|Drug|BI 1181181|
271051|NCT02338739|Behavioral|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
271052|NCT02338739|Behavioral|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
271053|NCT02338752|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
271054|NCT02338752|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
271055|NCT00156208|Drug|Asoprisnil|25 mg Tablet, oral Daily for 18 months
271056|NCT02338765|Behavioral|mHealth Physical Activity|
271057|NCT02338765|Behavioral|Buddy-partnered exercise|
271058|NCT02340949|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
271059|NCT02340949|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
271060|NCT02340962|Drug|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
270475|NCT02352363|Other|Observational cohort|
270476|NCT02352376|Other|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
270477|NCT02352376|Other|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
270478|NCT00158236|Drug|Buprenorphine and Naloxone|
270479|NCT02352389|Other|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
270480|NCT02352389|Other|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
270481|NCT02352389|Other|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
270482|NCT02352389|Other|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
270483|NCT02352389|Other|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
270484|NCT02352402|Drug|Ticagrelor|
270485|NCT02352402|Drug|Placebo|
270769|NCT02345304|Drug|Digoxin|
270770|NCT02345304|Drug|Digoxin|
270771|NCT02345330|Biological|Plasmid interleukin-12|Patients will receive intratumoral injection(s) of pIL-12.
270772|NCT02345330|Device|Intratumoral electroporation|Immediately following intratumoral injection of pIL-12, electroporation will follow by electrical discharge around the tumor site using the OMS system.
270773|NCT02345343|Drug|Apixaban|
270774|NCT02345356|Genetic|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
270775|NCT02345356|Other|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
270776|NCT02345369|Device|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
270777|NCT00157209|Biological|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
270185|NCT02318797|Behavioral|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
270186|NCT02318810|Drug|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
270187|NCT02318810|Drug|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
270188|NCT02318810|Drug|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
270189|NCT02318810|Drug|Placebo|Patients receive saline
270190|NCT02318823|Other|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
270191|NCT02318823|Other|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
270192|NCT00153127|Drug|polyethyleneglycol3350|
270193|NCT02321150|Procedure|Sutures|Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.
Conjunctiva undermined at the recipient site.
Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures
270194|NCT02321163|Device|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
270195|NCT02321163|Device|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
270196|NCT00153478|Behavioral|Brief Motivational Counseling|
270197|NCT02321163|Device|NMES no stimulation|Placebo, electrode pad on, no stimulation
270198|NCT02321176|Drug|trans-resveratrol|patients received 100mg Longevinex everyday,total of three days
1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient
270199|NCT02321189|Drug|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
270200|NCT02321189|Drug|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
270201|NCT02321202|Drug|Omega-3 Fatty Acid-Based Parenteral Nutrition|Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid [FA] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
270486|NCT02352428|Other|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
269886|NCT02326194|Biological|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
269887|NCT02326194|Biological|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
269888|NCT02326194|Biological|placebo (one dose)|placebo, one doses
269889|NCT02326194|Biological|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
269890|NCT00153985|Procedure|Stem Cell Transfusion|Performed three days after the end of chemotherapy
269891|NCT02326207|Device|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
269892|NCT02326220|Drug|Alirocumab|
269893|NCT02326220|Drug|Placebo|
269894|NCT02326233|Biological|Pen of SB5|
269895|NCT02326233|Biological|PFS of SB5|
269896|NCT02326246|Other|multi-parametic MRI|
269897|NCT02326259|Other|Initiation of treatment of diabetes|Treatment of diabetes according to the standard of care.
269898|NCT02326272|Biological|Certolizumab Pegol|Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use
269899|NCT02326272|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use
269900|NCT02326285|Drug|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
269901|NCT00153998|Drug|Cetuximab|
269902|NCT02326285|Drug|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
269903|NCT02326285|Drug|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
269904|NCT02326285|Procedure|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
269905|NCT02326298|Biological|Certolizumab Pegol|Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use
269302|NCT02338076|Drug|Petrolatum application under occlusion|Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)
1 well will be empty and the other well will contain petrolatum
Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch
1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)
269303|NCT00156143|Procedure|Blood sample|
269304|NCT02338089|Drug|Oxytocin|Oxytocin, 100 micromolar solution
269598|NCT02333214|Other|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
269599|NCT02333227|Dietary Supplement|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
269600|NCT02333240|Other|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
269601|NCT02333253|Drug|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach >12 mm
269602|NCT02333266|Other|Candidemia|
269603|NCT02333292|Drug|Telaprevir|Initiation of a regimen containing TVR
269604|NCT02333292|Drug|Boceprevir|Initiation of a regimen containing BOC
269605|NCT02333292|Drug|Sofosbuvir|Initiation of a regimen containing SOF
269606|NCT00154895|Drug|intrapleural minocycline instillation|
269607|NCT02333292|Drug|SMV|Initiation of a regimen containing SMV
269608|NCT02333292|Drug|DCV|Initiation of a regimen containing DCV
269609|NCT02333292|Drug|LED|Initiation of a regimen containing LED
269610|NCT02333292|Drug|PTV/OTV|Initiation of a drug combination of PTV/OTV
269611|NCT02333292|Drug|DBV|Initiation of a regimen containing DBV
269612|NCT02333305|Dietary Supplement|CoQ10|• 2 dosages according to patient weight: Weight < 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
273995|NCT02346383|Device|preset program|Change to different present program using epidural and peripheral lead to cover pain
273996|NCT02346396|Device|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
273997|NCT02346409|Device|tACS of the cerebellum|tACS of the cerebellum
273998|NCT02346422|Genetic|MYDICAR Phase 1|Single dose of MYDICAR
273999|NCT02346422|Genetic|MYDICAR Phase 2|Single dose of MYDICAR
274000|NCT02346422|Genetic|Placebo Phase 2 only|Single dose of placebo
274001|NCT02346448|Procedure|endoscopic sphincterotomy|sphincterotomy during ERCP
274002|NCT02346448|Procedure|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
274003|NCT00157339|Drug|injected insulin|patient specific dose, injected, before meals, 12 months.
274004|NCT02346448|Procedure|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
274005|NCT02346461|Drug|ManNac.|At doses of 3,000 mg and 6,000 mg twice daily for a total dose of 6,000 and 12,000 mg per day
274006|NCT02346461|Drug|ManNac|At doses of 6,000 mg twice daily (12,000 mg per day).
269305|NCT02340208|Drug|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
269306|NCT02340221|Drug|fulvestrant|500 mg fulvestrant administered by intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle.
269307|NCT02340221|Drug|placebo|placebo to taselisib taken orally once a day
269308|NCT02340221|Drug|taselisib|4 mg taselisib tablet formulation taken orally once a day
269309|NCT02340234|Drug|Lebrikizumab|Lebrikizumab 3 dose groups administered by SC injection
269310|NCT02340234|Drug|Placebo|Placebo administered by SC injection
269311|NCT02340247|Other|Water|
269312|NCT02340247|Drug|Ursodeoxycholic Acid|
269313|NCT00156520|Drug|aprotonin; epsilon aminocaproic acid|
269314|NCT02340247|Drug|Chenodeoxycholic Acid|
273708|NCT02351544|Other|Migraine Disability Assessment Test (MIDAS)|
273709|NCT02351544|Other|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
273710|NCT02351544|Other|Migraine-Specific Quality of Life Questionnaire (MSQ)|
273711|NCT02353702|Drug|NaCl|
273712|NCT02353715|Drug|Enzalutamide|
273713|NCT02353715|Drug|Abiraterone acetate|
273714|NCT02353715|Drug|Sipuleucel-T|
273715|NCT00002411|Drug|Zidovudine|
273716|NCT00158353|Behavioral|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
273717|NCT02353728|Drug|Nilotinib|
273718|NCT02353741|Drug|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
273719|NCT02353741|Radiation|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
274007|NCT02346487|Drug|LPV/RTV pellets and AZT/3TC or ABC/3TC|Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:
Between 3 and 5.9kg: 2 capsules twice a day
Between 6 and 9.9kg: 3 capsules twice a day
Between 10 and 13.9kg: 4 capsules twice a day
Between 14 and 19.9kg: 5 capsules twice a day
Between 20 and 24.9kg: 6 capsules twice a day
Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:
Between 3 and 5.9kg: 1 tablet twice a day
Between 6 and 9.9kg: 1.5 tablets twice a day
Between 10 and 13.9kg: 2 tablets twice a day
Between 14 and 19.9kg: 2.5 tablets twice a day
Between 20 and 24.9kg: 3 tablets twice a day
274008|NCT02346500|Device|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
274009|NCT02346513|Device|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
274010|NCT02346513|Device|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
274011|NCT02346526|Procedure|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
274012|NCT02346526|Procedure|CT scan and bone scan|Standard CT and bone scans will be carried out prior to treatment, week 9, and week 25.
274013|NCT02346526|Procedure|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
273401|NCT02320201|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
273402|NCT02320240|Drug|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273403|NCT00002391|Drug|Lamivudine|
273404|NCT00153322|Behavioral|Nurtition and Physical Activity Education|
273405|NCT02320240|Drug|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273406|NCT02320240|Drug|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273407|NCT02320240|Drug|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273408|NCT00153634|Drug|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
273409|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
273410|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
273411|NCT02322619|Drug|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
273412|NCT02322632|Drug|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
273413|NCT02322645|Drug|Eszopiclone Tablets 3 mg|
273414|NCT02322658|Drug|Eszopiclone Tablets 3 mg|
273415|NCT02322671|Drug|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
273416|NCT02322671|Drug|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
273417|NCT02322671|Drug|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
273720|NCT02353754|Drug|Intrathecal morphine injection|0.2 mg
273721|NCT02353754|Drug|EXPAREL|266 mg
273722|NCT02353767|Procedure|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
267784|NCT02375425|Other|no intervention|no intervention-specimen collection study only
267785|NCT02375451|Other|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
267786|NCT02375464|Drug|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
268099|NCT02368808|Behavioral|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief. Primary caregivers of Abangane participants will participate in a parallel caregiver-only group that will focus on key parenting skills for building positive child-caregiver relationships, including: understanding adolescents' behavior and feelings, building adolescent's self-esteem, discipline, communication, assertiveness, cooperation and problem solving.
268100|NCT02371187|Drug|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
268101|NCT02371200|Device|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
268102|NCT02371213|Other|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
268103|NCT02371226|Drug|AGT-181 (HIRMAb-IDUA)|invtravenous infusion over 3-4 hours
268104|NCT02371239|Behavioral|Physical activity intervention|
268105|NCT02371252|Drug|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
268106|NCT00160147|Drug|Placebo|Placebo
268107|NCT02371265|Other|Adherence and retention package|Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:
Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;
Adherence and retention package: 1) Creation of "Adherence Committees" at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision.
268108|NCT02371278|Dietary Supplement|Leucine|5 g leucine with sucrose and maltodextrin
268109|NCT02371278|Dietary Supplement|Placebo|5 g glycine with sucrose and maltodextrin
268110|NCT02371291|Behavioral|Memory Flexibility Training|As in experimental arm description.
267481|NCT02382562|Behavioral|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
267482|NCT02382575|Drug|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
267483|NCT02382575|Drug|Tacrolimus|Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
267484|NCT02382588|Drug|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
267485|NCT02382588|Drug|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
267486|NCT02382601|Radiation|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
267487|NCT00161538|Device|Selection 9000 prevent AF an Diagnose AF|
267787|NCT02375477|Other|Educational Intervention|Given educational presentation
267788|NCT02375490|Behavioral|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal (ex: eating and physical activity behaviour of children), interpersonal (ex: educators and parents), organizational (ex. child care centres), community (ex: community organization involvement), and physical environment and political levels (ex: built environment and policies). These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
267789|NCT02375503|Dietary Supplement|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
267790|NCT00160641|Biological|Certolizumab Pegol|Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.
Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.
Duration: Until end of study.
267791|NCT02375503|Dietary Supplement|Placebo|
267792|NCT02377830|Other|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
267187|NCT02387489|Behavioral|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
267188|NCT02387489|Behavioral|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
267189|NCT02387502|Device|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
267190|NCT02387502|Device|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
267191|NCT02387502|Device|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
267192|NCT00162201|Drug|Abatacept|Parenteral, IV, 500 mg if < 60 kg; 750 mg if > 60 & < 100 kg; 1000 mg if > 100 kg, Monthly, 4 months.
267193|NCT02387515|Other|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
267194|NCT02389751|Drug|Paclitaxel|50 mg/m2 weekly by vein during radiation therapy.
267195|NCT02389751|Radiation|Radiotherapy|Radiotherapy administered once-daily, 5 days a week, for 5.5 weeks, or a total of 28 treatments. Total dose 50.4 Gy (@ 1.8 Gy/fx/day) prescribed to the periphery of the planning target volume (PTV).
267196|NCT02389764|Drug|BIBF 1120|Initial dose is 200 mg twice daily orally for a 28 day cycle.
267197|NCT00162474|Drug|Warfarin|
267198|NCT02389764|Behavioral|Phone Call|Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
267199|NCT02389777|Biological|Amnion-derived Cellular Cytokine Solution|ACCS will be applied to the UV light burn wound topically by spray twice per day
267200|NCT02389790|Drug|MT-1303|
267201|NCT02389803|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
267488|NCT02382601|Radiation|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
266607|NCT00159302|Procedure|Spirometry|
266608|NCT02363452|Drug|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup)
266899|NCT02355873|Device|AN69ST hemofilter|
266900|NCT02355873|Device|AN69 hemofilter|
266901|NCT02355886|Drug|Gabapentin|Given PO
266902|NCT00158535|Procedure|liver transplantation|
266903|NCT02355886|Other|Placebo|Given PO
266904|NCT02355886|Other|Questionnaire Administration|Ancillary studies
266905|NCT02355899|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
266906|NCT02355912|Device|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
266907|NCT02355925|Drug|intrauterine injection of uhCG|500 IU of uhCG (0.5ml) is injected intrauterine before embryo transfer
266908|NCT02355925|Drug|Placebo|
266909|NCT02355938|Drug|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
266910|NCT02355938|Drug|Placebo|1 dose of placebo every 6 hours x 2 doses
266911|NCT02355938|Drug|Vancomycin|Vancomycin 125 mg every 6 hours
266912|NCT02355951|Other|blood draw|
266913|NCT00158548|Drug|SP, chloroquine, amodiaquine, primaquine, artesunate|
266914|NCT02355964|Behavioral|Exercise|Aerobe exercise 3 times a week in 8 weeks
266915|NCT02355964|Behavioral|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
266916|NCT02355977|Drug|minocycline|Periocline dental ointment
266917|NCT02355977|Procedure|surface and root planning|surface and root planning
266918|NCT02358538|Drug|Ganaxolone|oral suspension or capsules
266919|NCT02358551|Device|Placement of electrode lead through axillary vein puncture|
266920|NCT00158756|Biological|Tetanus|
266316|NCT02370511|Device|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
266317|NCT02370524|Drug|[18F]T807|All enrolled subjects will undergo an [18F]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
266318|NCT02370537|Drug|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
266319|NCT02370537|Drug|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
266320|NCT02370550|Drug|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
266609|NCT02363465|Other|Echographic measurement of skin thickness|(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.
The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.
266610|NCT02363478|Drug|buspirone|buspirone 10 mg X2 for 4 weeks
266611|NCT02363491|Drug|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
266612|NCT02363504|Other|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
266613|NCT02363517|Drug|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
266614|NCT02363530|Device|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
266615|NCT02363530|Device|BSS|Balanced Salt Solution including normal saline and glucose
266616|NCT02363543|Device|Hyalomatrix|
266617|NCT02363543|Device|Integra|
266618|NCT00159315|Procedure|Inhalation Challenge with ATP|
266619|NCT02363556|Procedure|Misoprostol administered vaginally|
266620|NCT02363556|Procedure|Misoprostol administered buccally|
266621|NCT02363556|Procedure|Misoprostol administered vaginally with Dilapan|
266622|NCT02363556|Procedure|Misoprostol administered buccally with Dilapan|
266623|NCT02363582|Other|formula|An infant formula contains prebiotics and lactoferrin
266058|NCT02379481|Dietary Supplement|NS 550mg|
266059|NCT02379481|Dietary Supplement|NS 1100mg|
266060|NCT02379481|Dietary Supplement|placebo|
266061|NCT00161213|Drug|gemcitabine hydrochloride|
266062|NCT02379507|Other|DEC033 Study Product|Apply twice daily
266063|NCT02379520|Genetic|HPV Specific T Cells|This is a dose escalation study. Three dose levels are being evaluated, namely 1×10^7 cells/m2, 3×10^7 cells/m2, and 1×10^8 cells/m2.
HPVSTs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
If the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies) and no significant toxicities, he or she may receive up to 5 repeat infusions (for a max total of 6 infusions) of HPVSTs at or below the same dose level.
266064|NCT02379533|Other|Aerobic exercise|
266065|NCT02379546|Drug|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
266066|NCT02379546|Device|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
266321|NCT02372994|Other|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
266322|NCT02373007|Procedure|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
266323|NCT02373020|Other|colonoscopic biopsies|
266324|NCT02373033|Other|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
266325|NCT02373033|Other|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
266326|NCT02373033|Other|Apple juice|Received apple juice containing no folate or folic acid.
266327|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
266328|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
266329|NCT00002420|Drug|Didanosine|
266072|NCT00161213|Drug|imatinib mesylate|
266073|NCT02379585|Drug|cyclophosphamide|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
266074|NCT02379585|Drug|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
266075|NCT02379585|Drug|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
266076|NCT02382042|Behavioral|Intensive Referral Intervention|
266077|NCT02382055|Behavioral|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
266078|NCT02382055|Behavioral|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
266079|NCT02382055|Behavioral|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
266080|NCT02382068|Drug|Dexamethasone|Given via intratympanic injection
266081|NCT02382068|Other|Placebo|Given via intratympanic injection
266082|NCT02382068|Drug|Cisplatin|Standard of care treatment with the following treatment course criteria:
Dose: > 50 mg/m2
Frequency: q3 -q4 weeks
Cycles: 7 maximum
266342|NCT02373124|Drug|infusion of NMDA antagonist|52 minute infusion
266343|NCT02373137|Procedure|DSAEK|
266344|NCT02373137|Procedure|DMEK|
266345|NCT02373137|Device|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
266346|NCT02374788|Behavioral|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
266347|NCT02374788|Behavioral|Group meetings|Participants receive 12 group meetings over two years' time.
271673|NCT02329587|Other|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
271674|NCT02329587|Other|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
271675|NCT02329600|Drug|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
271676|NCT02329600|Drug|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
271677|NCT00154310|Drug|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
271678|NCT02329613|Other|Standard evening meals.|Patients will receive usual evening meals.
271679|NCT02329613|Other|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
271680|NCT02331589|Drug|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
271681|NCT00154661|Drug|pentoxifylline|
271682|NCT02331589|Drug|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
271683|NCT02331602|Drug|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
271684|NCT02331602|Drug|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
271685|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
271686|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
271687|NCT02331615|Device|SHAM|no meaningful stimulation will be given
271688|NCT02331628|Device|ESWT - Extracorporeal Shockwave Therapy|Patients will receive:
Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\52 from baseline until and including week 14\52, one dose every two weeks ± 3 days), administered by the principal investigator.
Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.
The energy flux density (EFD) will be 'high level'
All participants will be supplied with headphones to reduce the noise level emitted by the machine.
271689|NCT02331641|Procedure|Hepatectomy|Removal of a part of the liver
271061|NCT02340962|Drug|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
271062|NCT02340962|Drug|Interferon Alfa-2a|IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.
Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5.
271063|NCT00156637|Behavioral|Team-Based Quality Improvement Intervention|Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
271064|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
271065|NCT02340975|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
271066|NCT02340975|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
271362|NCT02333981|Device|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
271363|NCT02333994|Device|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
271364|NCT02333994|Other|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
271365|NCT02334007|Drug|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
271366|NCT02336347|Drug|AVP-786|
271367|NCT02336347|Drug|AVP-923|
271368|NCT02336360|Drug|18F-AV-1451|370 megabecquerel (MBq) (10 millicurie [mCi]) administered in a separate Avid-sponsored study. No drug will be administered in this study.
270778|NCT02345369|Device|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
270779|NCT02345382|Drug|BAY1143572|The starting dose will be 20 mg BAY 1143572. Maximum dose escalation between dose levels will be 2 fold.The dose-escalation part of each dosing schedule may be followed by an expansion part.
270780|NCT02347462|Other|Standard care|Standard care according to the hospital severe asthma protocol
270781|NCT02347475|Other|Observational Study|Ultrasound and NIRS
270782|NCT02347488|Device|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard.
270783|NCT00157625|Behavioral|Automatic stop order|
270784|NCT02347501|Drug|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
270785|NCT02347514|Behavioral|Diabetes group visit|
270786|NCT02347527|Behavioral|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
270787|NCT02347527|Behavioral|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
270788|NCT02347553|Other|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
271067|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab
271068|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
271069|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
271070|NCT02341001|Other|Daily text message of support|
271071|NCT02341014|Drug|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient regardless of dose level must be 20mg/m2 . All subsequent doses of carfilzomib will be based on the patient's dose level.
271072|NCT02341014|Drug|Romidepsin|
271073|NCT02341014|Drug|Lenalidomide|
271074|NCT00156637|Behavioral|Opinion Leader Intervention|Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
270487|NCT02352441|Other|Implementation Intentions(II)|Implementation Intention training will include:
Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals.
270488|NCT02352454|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
270489|NCT00158236|Drug|Hydromorphone|
270490|NCT02352467|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
270491|NCT02352480|Device|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
270492|NCT02352493|Drug|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
270493|NCT02352493|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
270494|NCT02352506|Other|Blood draw for measurement of MIF|Observational study, no intervention
270495|NCT02316067|Other|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
270496|NCT02316080|Other|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
270497|NCT02316080|Other|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
270498|NCT02316093|Other|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
270499|NCT02316106|Drug|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. Treatment cycles are 8 weeks in length.
270500|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20. Treatment cycles are 8 weeks in length.
270501|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
269906|NCT02328703|Other|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
270202|NCT02321202|Drug|Structolipid|Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
270203|NCT02321215|Other|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
270204|NCT02321228|Procedure|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
270205|NCT02321228|Procedure|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
270206|NCT02321241|Drug|Aflibercept (EYLEA, BAY-86-5321)|st year: 3 monthly injections followed by 1 injection every two months
nd year and following: injection according the visual and anatomical results observed the 1st year
270207|NCT00153491|Drug|artemether-lumefantrine|
270208|NCT02321254|Device|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
270209|NCT02321254|Behavioral|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
270210|NCT02321267|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
270211|NCT02321280|Drug|Denosumab|Single dose subcutaneous administration
270212|NCT02321293|Dietary Supplement|CurcuVIVA™|80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
270213|NCT02321293|Drug|Tyrosine Kinase Inhibitor gefitinib (Iressa)|250 mg PO daily until progression
270214|NCT02323698|Dietary Supplement|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 60min after consumption to mimic the caffeine drug protocol.Throughout the 60min wait time and experimentation, blood pressure and heart rate will be monitored.
270215|NCT02323711|Device|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
270216|NCT02323724|Genetic|BRAF V600E mutation by pyrosequencing technique|
269613|NCT02333305|Other|Sanomit Placebo|• according to patient weight: Weight < 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
269614|NCT02333318|Drug|VVZ-149 injection|Colorless, transparent liquid in water for injection
269615|NCT02333318|Other|Placebo|water for injection
269616|NCT02333331|Drug|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
269617|NCT00002400|Drug|Delavirdine mesylate|
269618|NCT00154986|Procedure|immunohistochemical staining, transfection, invasion assay|
269619|NCT02333331|Other|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
269907|NCT02328716|Procedure|Cytoreduction|Cytoreduction
269908|NCT02328716|Drug|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
269909|NCT00154232|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
269910|NCT02328729|Procedure|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
269911|NCT02328729|Procedure|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
269912|NCT02328729|Procedure|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
269913|NCT02328729|Procedure|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
269914|NCT02328729|Procedure|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
269915|NCT02328729|Procedure|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
269916|NCT02328742|Biological|Hysteroscopy + endometrial biopsy|The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.
This intervention is required for the observational needs of this study.
269917|NCT02328742|Other|Telephone call|Patients will be contacted via telephone 6 months after first hysteroscopy.
This intervention is required for the observational needs of this study.
269918|NCT02328742|Biological|Resection + endometrial biopsy|If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.
This intervention is required for the observational needs of this study.
269315|NCT02340260|Behavioral|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
269316|NCT02340260|Behavioral|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
269317|NCT02340273|Device|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
269318|NCT02340273|Device|Placebo therapeutic ultrasound|Patients receive "sham" therapeutic ultrasound daily for 4 hours.
269319|NCT02340299|Device|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
269320|NCT02340299|Device|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
269321|NCT02340312|Procedure|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
269322|NCT02340312|Other|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
269323|NCT02340325|Drug|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
269324|NCT00156533|Drug|Zolpidem|10 mg of Zolpidem
269620|NCT02335450|Device|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
269621|NCT02335489|Device|Implantation with the commercially available Axium neurostimulator|
269622|NCT02335502|Device|Implantation with the commercially available Axium neurostimulator|
269623|NCT02335515|Device|Soctec|Gastroretentive Drug Delivery System
269624|NCT02335528|Behavioral|SimCoach|
269625|NCT02335554|Behavioral|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
269626|NCT02335554|Behavioral|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
269627|NCT00002401|Drug|Indinavir sulfate|
269628|NCT00155675|Drug|GUSUIBU|
274014|NCT00157378|Drug|Risperidone, Haloperidol|
274015|NCT02346539|Drug|Nicotine polacrilex|Single Acute dose
274016|NCT02346552|Device|AutoLap|
274017|NCT02346565|Procedure|Exercise ECG|
274018|NCT02346565|Procedure|Stress Echocardiography|
274019|NCT02348879|Drug|AMG 403|AMG 403 is for treatment of subjects with chronic pain
274020|NCT02348879|Drug|Placebo|contains no active drug
274021|NCT02348892|Other|Coordinator|Patients in complex situation taken care by coordinator
274022|NCT02348892|Other|Classic plan|Patients in complex situation taken care by classic plan
274023|NCT02348905|Drug|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
274024|NCT02348905|Drug|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
274025|NCT00157807|Procedure|bipolar radiofrequency ablation of persistent and permanent AF|
274026|NCT02348918|Drug|Luminate 1.0mg|
274027|NCT02348918|Drug|Luminate 2.0mg|
274028|NCT02348918|Drug|Luminate 3.0mg|
269325|NCT02340325|Drug|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
269326|NCT02342522|Device|Sham control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
269327|NCT02342535|Behavioral|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
269328|NCT02342548|Drug|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
269329|NCT02342561|Device|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
269330|NCT02342574|Drug|F901318|Administration of active compound
273723|NCT02353780|Drug|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
273724|NCT02353780|Drug|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
273725|NCT02353780|Drug|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
273726|NCT02353793|Device|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
273727|NCT00158353|Behavioral|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
273728|NCT02353793|Device|Cotton wool blanket|Using cotton wool blanket for patient warming
273729|NCT02353806|Drug|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
273730|NCT02353819|Radiation|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
273731|NCT02353832|Device|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
273732|NCT02353858|Other|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
273733|NCT02353858|Radiation|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
273734|NCT02353858|Drug|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
273735|NCT02353871|Drug|Clostridium Botulinum Toxin Type A|
273736|NCT02353871|Drug|Placebo|
273737|NCT02353910|Procedure|Ultrasound|
273738|NCT02317640|Other|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
273739|NCT02317640|Device|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
274029|NCT02348918|Drug|Avastin|
274030|NCT02348918|Device|Focal laser photocoagulation|
268111|NCT02371291|Behavioral|Psychoeducation|As in experimental arm description.
268112|NCT02371304|Radiation|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
268113|NCT02371304|Procedure|Additional TME surgery|
268114|NCT02371304|Drug|capecitabine|
268115|NCT02371317|Behavioral|Mindfulness-Based Stress Reduction|Patients are randomized to an intervention
268411|NCT00159380|Procedure|Nasal Lavage|
268412|NCT02364414|Device|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
268413|NCT02366598|Other|Hemp shake|Hemp protein shake
268414|NCT02366598|Other|Soybean shake|Soybean protein shake
268415|NCT02366598|Other|Control|Non-protein shake
268416|NCT02366611|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
268417|NCT00159653|Drug|Xalacom|
268418|NCT02366637|Drug|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
268419|NCT02366637|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
268420|NCT02366663|Radiation|Yttrium Y 90 Ibritumomab tiuxetan|0.4 mCi/kg given IV
268421|NCT02366663|Drug|Carmustine|Given IV
268422|NCT02366663|Drug|Etoposide|Given IV
268423|NCT02366663|Drug|Cytarabine|Given IV
268424|NCT02366663|Drug|Melphalan|Given IV
268425|NCT02366663|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
268426|NCT02366663|Biological|Rituximab|Given IV
268427|NCT02366663|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
268428|NCT00159653|Drug|Xalatan|
267793|NCT02377843|Behavioral|Participatory|The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:
Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine
Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making
Practice using the communication strategy via role play
Discussion on applying the communication strategy to medical practice
267794|NCT00160927|Drug|sodium nitroprusside|
267795|NCT02377843|Behavioral|Efficient|The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:
Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine
Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines
Practice using the communication strategy via role play
Discussion on applying the communication strategy to medical practice
267796|NCT02377856|Drug|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
267797|NCT02377869|Other|No intervantion|
267798|NCT02377895|Drug|Nasapaque Nasal Solution|
267799|NCT02377895|Drug|Placebo Saline Nasal Solution|
267800|NCT02377908|Other|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
267801|NCT02377921|Drug|Sialic Acid Tablets|
267802|NCT02377921|Drug|Placebo Tablets|
268116|NCT02371317|Behavioral|Stress Management Education|Patients are randomized to an intervention
268117|NCT00160160|Drug|eprosartan/HCTZ|
268118|NCT02371317|Other|American Heart Association Recommended Self-Care|All Patients receive AHA Recommended Self-Care
268119|NCT02371343|Dietary Supplement|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
268120|NCT02371343|Dietary Supplement|Sunflower Oil|
268121|NCT02371369|Drug|PLX3397 capsule|Each capsule of PLX3397 will contain 200 mg of PLX3397 HCl
268122|NCT02371369|Drug|Placebo capsule matching PLX3397 capsule|Placebo capsule matching PLX3397 capsule
268123|NCT02371382|Device|Arthroplasty hip|Hip replacement
267489|NCT02382601|Procedure|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
267490|NCT02382601|Behavioral|Neurological Function Assessment|Neurological development tests called a Bayley exam and Pediatric Stroke Outcome Measure (PSOM) will be performed.
267491|NCT02382601|Procedure|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
267492|NCT02382601|Procedure|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
267493|NCT02382614|Device|Spiration Valve System|
267494|NCT02382640|Drug|Febuxostat XR|Febuxostat extended-release (XR) capsules
267495|NCT02382640|Drug|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
267496|NCT02382653|Drug|oral perixicam|Oral adminstration of buccal perixicam
267497|NCT02382666|Drug|Rolapitant|
267498|NCT00161551|Device|Vitatron T70 DR|
267499|NCT02382679|Dietary Supplement|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
267500|NCT02385058|Drug|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
267501|NCT02385058|Drug|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
267502|NCT02385058|Drug|Placebo|Placebo tablet orally once starting on Day 21.
267503|NCT00161863|Biological|FSME-IMMUN NEW 0.25 ml|
267504|NCT02385071|Drug|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
267505|NCT02385071|Drug|Treatment B|Treatment B (3*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
267506|NCT02385071|Drug|Treatment C|Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions).
267507|NCT02385071|Drug|Treatment D|*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions.
267508|NCT02385071|Drug|Treatment E|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
266921|NCT02358551|Device|Placement of electrode lead through subclavian vein puncture|
266922|NCT02358564|Procedure|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
266923|NCT02358564|Procedure|Upper Endoscopy|You will have an upper endoscopy
266924|NCT02358564|Procedure|Rectal Barostat and Infusion of Fats|Feeding tube will be placed as well as a small balloon in the rectum
267202|NCT02389803|Dietary Supplement|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
267203|NCT02389816|Drug|Placebo|Placebo tablets
267204|NCT02389816|Drug|Lu AA21004|Lu AA21004 tablets
267205|NCT02389829|Drug|Hydromorphone|
267206|NCT02389829|Drug|Prochlorperazine|
267207|NCT02389829|Drug|Diphenhydramine|
267208|NCT00162474|Drug|Phenytoin|
267209|NCT02389842|Drug|Palbociclib + Taselisib / Pictilisib|
267210|NCT02389855|Procedure|NeuroBlate® System Therapy|
267211|NCT02389868|Drug|Lovastatin|
267212|NCT02389881|Drug|TAK-058 25 mg|TAK-058 25 mg administered orally.
267213|NCT02389881|Drug|TAK-058 75 mg|TAK-058 75 mg administered orally.
267214|NCT02389881|Drug|TAK-058 150 mg|TAK-058 150 mg administered orally.
267215|NCT02389881|Drug|Matching Placebo to TAK-058|Matching placebo to TAK-058 administered orally.
267216|NCT02389881|Drug|TAK-058 300 mg|TAK-058 300 mg administered orally.
267217|NCT02389894|Device|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
267218|NCT02389894|Device|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
267219|NCT00162487|Drug|Albuterol (1,200 μg) through metered-dose inhaler|
267220|NCT02389920|Drug|Nilotinib|
266624|NCT02363608|Other|standard post surgery care|
266625|NCT02363608|Behavioral|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
266626|NCT02363608|Behavioral|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
266627|NCT02363621|Drug|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
266628|NCT02363621|Drug|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
266629|NCT00159315|Procedure|Inhalation Challenge with AMP|
266630|NCT02363634|Dietary Supplement|magnesium threonate|nutritional product
266925|NCT02358577|Device|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
266926|NCT02358577|Other|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
266927|NCT02358590|Behavioral|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
266928|NCT02358590|Behavioral|Standard care|The treating physician will advice participants to take vitamin D
266929|NCT02358616|Behavioral|Focus Group Discussions and In-Depth Interviews|All participants in this study participated in interviews. 88 participants participated in Phase 1 of the study. 131 participants participated in Phase 2.
266930|NCT02358629|Device|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
266931|NCT00000356|Drug|LAAM|
266932|NCT00002413|Drug|Emivirine|
266933|NCT00158756|Biological|Pertussis|
266934|NCT02358642|Drug|Angiotensin converting enzyme inhibitor (Lisinopril)|
266935|NCT02358642|Drug|Placebo|
266330|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
266331|NCT02373059|Other|Diabetes Issue Cards Decision Aids|
266332|NCT02373059|Other|Usual Pharmaceutical Care|
266333|NCT02373072|Drug|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
266334|NCT02373072|Drug|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
266335|NCT02373072|Drug|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
266336|NCT02373085|Other|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
266337|NCT02373098|Drug|Fingolimod 0.5 mg|60 relapsing remitting MS (RRMS) patients will be recruited.Patients who meet all inclusion and none of the exclusion criteria will be treated by Fingolimod 0.5 mg
266338|NCT02373111|Dietary Supplement|Isoflavone|
266339|NCT02373111|Dietary Supplement|Astaxanthin|
266340|NCT02373111|Dietary Supplement|Placebo|
266341|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
266631|NCT02363647|Other|Tumor Genomic Analysis|A sequential Bayesian approach will be used to assess the efficacy of treatment with a personalized therapeutic treatment plan.
266632|NCT02365766|Procedure|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
266633|NCT02365779|Procedure|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
266634|NCT02365779|Device|endomicroscopy Cellvizio® system|
266635|NCT02365792|Procedure|Clinical Decision Support Tool for Prehospital Care|A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: "Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care".
266636|NCT02365805|Drug|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
266348|NCT02374788|Behavioral|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
266349|NCT02374801|Device|SonR automatic optimization feature turned ON ("AV+VV").|
266350|NCT02374814|Drug|Rabies vaccine|Compare dose schedule and route of administration
266351|NCT02374814|Drug|Placebo|Placebo
266352|NCT02374827|Procedure|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
266353|NCT02374827|Procedure|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
266354|NCT00160537|Drug|Levocetirizine|
266355|NCT02374853|Drug|Vancomycin|Topical prophylactic antibiotic
266356|NCT02374866|Other|closer monitoring|
266357|NCT02374879|Device|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
266358|NCT02374892|Behavioral|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
266359|NCT02374905|Device|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
266360|NCT02374905|Behavioral|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
266361|NCT02374918|Device|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
266362|NCT02374918|Device|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
266651|NCT02365935|Procedure|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
266652|NCT02365935|Drug|Cisplatin|
266653|NCT02365935|Drug|Paclitaxel|
266654|NCT02365948|Biological|Certolizumab Pegol|Active Substance: Certolizumab Pegol
Pharmaceutical Form: Prefilled syringes
Concentration: 200 mg/mL
Route of Administration: Subcutaneous injection
271690|NCT02331654|Other|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
271691|NCT02331654|Other|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
271988|NCT02324543|Drug|Cisplatin|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
271989|NCT02324543|Drug|Irinotecan|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
271990|NCT02324569|Drug|SYR-472|SYR-472 tablets
271991|NCT02324569|Drug|Placebo|Placebo tablets
271992|NCT02324582|Drug|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembroluzimab.
271993|NCT02324595|Procedure|Laparoscopic interval debulking surgery|Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm "flexible tip" videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered
271994|NCT02324608|Biological|cetuximab|Given IV
271995|NCT00153816|Drug|placebo|placebo; two tablets per day
271996|NCT02324608|Other|laboratory biomarker analysis|Correlative studies
271997|NCT02324621|Drug|Oral ONC201|Given PO
271998|NCT02324621|Other|pharmacological study|Correlative studies
271999|NCT02327130|Device|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
272000|NCT02327143|Drug|LY2835219|Administered orally
272001|NCT02327143|Drug|^13C-LY2835219|Administered IV
272002|NCT02327156|Drug|dexmedetomidine|adding dexmedetomidine to the local anesthetic
272003|NCT02327169|Drug|MLN2480|MLN2480
272004|NCT02327169|Drug|MLN0128|MLN0128
272005|NCT02327169|Drug|Alisertib|Alisertib
271369|NCT02336373|Drug|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
271370|NCT02336386|Drug|CDD|Chemotherapy
271371|NCT02336386|Drug|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
271372|NCT02336412|Other|SMS reminder|Daily SMS medication reminder
271373|NCT02336425|Drug|QGE031|QGE031 120 mg per 1 mL liquid in vial
271374|NCT00000353|Drug|Buprenorphine/naloxone|
271375|NCT00002401|Drug|Delavirdine mesylate|
271376|NCT00156000|Device|Fetal Fibronectin|fFN test done during pregnancy
271377|NCT02336425|Drug|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
271378|NCT02336438|Dietary Supplement|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
271379|NCT02336451|Drug|LDK378|LDK378 (ceritinib) 750 mg once daily, orally administered
271692|NCT00154674|Device|ICY catheter, Thermoguard device|
271693|NCT02331667|Other|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
271694|NCT02331667|Other|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
271695|NCT02331680|Drug|OPC-41061|
271696|NCT02331680|Drug|OPC-41061|
271697|NCT02331680|Drug|Placebo|
271698|NCT02331693|Biological|anti-EGFR CAR T|
271699|NCT02331706|Drug|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
271700|NCT02331732|Behavioral|Virtually Observed Treatment|
271701|NCT02331732|Other|Directly Observed Treatment|
271702|NCT02331745|Drug|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
271075|NCT02341027|Device|Jadelle|within 5 days of delivery and before discharge from hospital
271076|NCT02341027|Device|Jadelle|6-8 weeks (42-56 days) postpartum
271077|NCT02341053|Other|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
271078|NCT02341066|Device|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
271079|NCT02343263|Biological|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
271080|NCT02343276|Drug|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
271081|NCT02343276|Other|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
271082|NCT00156910|Other|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
271083|NCT02343289|Drug|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
271084|NCT02343289|Drug|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
271085|NCT02343302|Device|Suctioning Drainage|A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled "suction drain"
271380|NCT02336477|Drug|Mexiletine|Blisters of 10 capsules of 200 mg mexiletine hydrochloride.
Patients will receive gradual dose of the treatment as it would be done in clinical practice.
Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.
The duration of each treatment period is 18 days minimum (maximum 22 days).
271381|NCT02336477|Drug|placebo|
271382|NCT02336490|Other|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
271383|NCT02336503|Drug|BBI-4000 Low Concentration|BBI-4000 Low Dose
271384|NCT02336503|Drug|BBI-4000 Middle Concentration|BBI-4000 Middle Dose
271385|NCT02336503|Drug|BBI-4000 High Concentration|BBI-4000 High Dose
271386|NCT02336503|Drug|Placebo|Vehicle
270789|NCT02347566|Behavioral|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
270790|NCT02347566|Other|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
270791|NCT02347592|Device|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
270792|NCT02347592|Device|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
270793|NCT02347605|Drug|Nicotine lozenge 4 mg|
270794|NCT00157638|Behavioral|integration of pharmacist into primary care|
270795|NCT02347605|Drug|Placebo lozenge|
270796|NCT02347618|Radiation|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
270797|NCT02347631|Device|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1|Soft contact lens - Daily wear disposable to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over project where both lenses will be worn by participant over the course of the study. The order of randomization will differ for each participant. There is a washout period in between earch contact lens wearing schedule.
270798|NCT02347631|Device|Acuvue TruEye|
270799|NCT02347644|Behavioral|Brief Motivational Interview|Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:
No perception of any alcohol consumption problem
Realization of alcohol consumption problem with no corresponding action
270800|NCT02347657|Drug|VX-661/ ivacaftor|
270801|NCT02347657|Drug|ivacaftor|
270802|NCT02349958|Device|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
270803|NCT02349958|Device|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
270804|NCT02349971|Device|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
270805|NCT02349997|Other|no interventions|This is an observational study and no intervention applied.
270217|NCT02323737|Drug|Irinotecan and cisplatin|
270218|NCT02323737|Drug|Etoposide and cisplatin|
270219|NCT02323763|Other|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
270220|NCT02323776|Other|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
270502|NCT02316132|Drug|Stress|Corticotropin-Releasing Hormone
270503|NCT00152971|Drug|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
270504|NCT02316132|Drug|Control|Saline 0.9%
270505|NCT02316145|Behavioral|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
270506|NCT02316158|Other|Web-based support|Comparison between the efficacy between webb-based support and informational support
270507|NCT02316171|Biological|CAVATAK|CAVATAK is a purified preparation of CVA21
270508|NCT02316171|Drug|Mitomycin C|Chemotherapy
270509|NCT02316184|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
270510|NCT02316184|Behavioral|Brief Advice|
270511|NCT02316197|Drug|MSC2490484A|Initial starting dose at 100 mg (oral administration), once daily, subsequent doses and treatment regimens will be determined by the SMC (once or twice daily). MSC2490484A will be administered in continuous 21-day cycles in dose escalation or dose expansion cohorts, as long as they do not experience unacceptable toxicity or disease progression.
270512|NCT02316210|Device|electrical stimulation|
270513|NCT02316223|Behavioral|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
270514|NCT02318836|Drug|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
270515|NCT02318849|Behavioral|Web intervention|interactive website using social media and gamification
269919|NCT02328742|Biological|Follow-up hysteroscopy + endometrial biopsy|For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.
This intervention is required for the observational needs of this study.
269920|NCT00154245|Drug|Enteric-Coated Mycophenolate sodium (EC-MPS)|
269921|NCT02328755|Drug|peg-IFN-α|
269922|NCT02328755|Procedure|Hematopoietic Cell Transplant (HCT)|
269923|NCT02328755|Drug|Calcineurin Inhibitor|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
269924|NCT02328755|Drug|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
269925|NCT02328768|Drug|Omegaven|
269926|NCT02328781|Device|Drug-eluting stent|
269927|NCT02328794|Behavioral|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
270221|NCT02323789|Drug|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
270222|NCT02323802|Behavioral|educational group intervention|
270223|NCT02323802|Behavioral|prescriptive diet|
270224|NCT00153751|Drug|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
270225|NCT02323815|Dietary Supplement|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
270226|NCT02323815|Behavioral|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
270227|NCT02323828|Dietary Supplement|High RS cookies|High RS cookies ingestion in healthy young adults
270228|NCT02323828|Dietary Supplement|Placebo|Placebo cookies ingestion in healthy young adults
270229|NCT02323841|Procedure|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
270230|NCT02323854|Procedure|Ablation and Surgical Resection|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated.
The antenna will be removed and the planned surgical resection will be conducted as scheduled.
269629|NCT02335567|Other|there is no intervention|
269630|NCT02335580|Drug|Somatostatin and its analogs|
269631|NCT02335580|Procedure|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|
269632|NCT02335593|Dietary Supplement|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
269633|NCT02335593|Other|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
269634|NCT02335593|Drug|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
269635|NCT02335593|Drug|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
269636|NCT02335619|Behavioral|Early pain and symptom/palliative care referral|
269637|NCT02335632|Drug|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
269638|NCT02335632|Drug|Placebo|For probiotics
269639|NCT00155714|Drug|type-5 phosphodiesterase Inhibitor (Sildenafil)|
269640|NCT02335645|Other|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.
The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.
Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.
At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture.
269928|NCT02328794|Behavioral|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
269929|NCT02330926|Drug|Ibuprofen|
269930|NCT02330939|Other|Low fat- Low glycemic index meal|
269931|NCT02330939|Other|MUFA- Low glycemic index meal|
269932|NCT02330939|Other|SAFA- Low glycemic index meal|
269933|NCT02330939|Other|Low fat- High glycemic index meal|
269934|NCT02330939|Other|MUFA- High glycemic index meal|
269935|NCT02330939|Other|SAFA- High glycemic index meal|
269331|NCT02342574|Drug|Placebo|Administration of placebo
269332|NCT00156819|Drug|montelukast|Montelukast (5 or 10 mg each night).
269333|NCT02342587|Drug|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
269334|NCT02342600|Drug|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
269335|NCT02342600|Drug|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
269336|NCT02342613|Biological|Activated PTCy-MILs|
269337|NCT02342626|Behavioral|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
269338|NCT02342639|Drug|Rifaximin|550mg pills
269339|NCT02342639|Drug|Placebo|Placebo pill
269340|NCT02342652|Drug|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
269341|NCT02342652|Drug|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
269342|NCT02342665|Drug|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
269343|NCT00156819|Drug|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
269344|NCT02342678|Behavioral|Yoga Therapy|
269641|NCT02335658|Drug|DSP-5423P|40-80mg/day
269642|NCT02335671|Procedure|Intra-operative Magnetic Resonance Imaging (MRI)|
269643|NCT02335671|Other|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
269644|NCT02335684|Other|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
269645|NCT02338102|Other|Saline mixture|premeasured salt packets mixed with distilled water
269646|NCT02338115|Drug|Paclitaxel 80mg/m2 weekly x 12 weeks|
274031|NCT02348931|Device|Use of customized nasal brace (Nasella) for nose deformities|
274032|NCT02348931|Procedure|corrective surgery|
274033|NCT02348944|Other|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
274034|NCT02348970|Device|ONIRIS®|sleeping test
274035|NCT02348970|Device|TALI|sleeping test
274036|NCT00157820|Device|Implantable Cardioverter Defibrillator (ICD)|Single Chamber (SC) and Dual Chamber (DC) ICD
274037|NCT02348983|Behavioral|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
274038|NCT02348996|Other|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
274039|NCT02348996|Other|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
274040|NCT02349009|Drug|C-82 Topical Gel, 1%|active
274041|NCT02349009|Drug|C-82 Topical Gel, Placebo|placebo
274042|NCT02349022|Radiation|[89Zr]Df-IAB2M|
274043|NCT02349035|Device|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
274044|NCT02351583|Device|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
274045|NCT02351583|Device|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
274046|NCT02351596|Other|Physiotherapy Core Stability Group Programme|The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.
Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this.
268429|NCT02366663|Other|Laboratory Biomarker Analysis|
268430|NCT02366676|Drug|IALURIL|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd~5th month:once a month)
268431|NCT02366689|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
268432|NCT02366689|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
268433|NCT02366689|Drug|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
268434|NCT02366689|Drug|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
268748|NCT02318147|Procedure|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
268749|NCT02318147|Other|The traditional treatment|the traditional treatments according to associated guidelines
268750|NCT02318160|Other|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
268751|NCT02320526|Behavioral|Control|
268752|NCT02320526|Behavioral|Continuous walking|
268753|NCT02320526|Behavioral|Interval walking|
268754|NCT02320552|Other|No intervention|no intervention
268755|NCT02320565|Procedure|3D Laparoscopy|3D Laparoscopy approach
268756|NCT02320565|Procedure|Standard Laparoscopy|Standard laparoscopy approach
268757|NCT02320578|Procedure|3D Laparoscopy|3D Laparoscopy approach
268758|NCT02320578|Procedure|Standard Laparoscopy|Standard laparoscopy approach
268759|NCT02320591|Other|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
268760|NCT00153374|Behavioral|Women's health|
268124|NCT02373553|Other|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
268125|NCT02373553|Other|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
268126|NCT02373566|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
268127|NCT02373579|Drug|Omega-3 Fatty Acids|study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .
Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day .
268128|NCT00160368|Behavioral|Potassium supplementation|
268129|NCT02373579|Drug|Methotrexate|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
268130|NCT02373592|Behavioral|SMS and voice messaging|This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.
During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.
Hereafter, for the remaining 50 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care).
268131|NCT02373592|Device|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
268132|NCT02373605|Other|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
268133|NCT02373605|Other|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
268134|NCT02373618|Other|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
268435|NCT02366689|Drug|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
268436|NCT02366702|Device|Lower Limb Powered Knee-Ankle Prosthesis|
268437|NCT02366715|Device|HeatedHumidifiedHighFlowNasalCannula|We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. [3] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.
Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016.
268438|NCT02368834|Behavioral|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
267803|NCT02377934|Radiation|Cardiac Magnetic Resonance Imaging (MRI)|
267804|NCT02377960|Behavioral|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
267805|NCT00160953|Procedure|Endorectal Coil Magnetic Resonance Images|
267806|NCT02377960|Behavioral|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
267807|NCT02377960|Behavioral|Usual care|Usual care
267808|NCT02377986|Behavioral|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
267809|NCT02377986|Behavioral|In-Home Decluttering|In-home decluttering practice
267810|NCT02377999|Drug|Picato|
267811|NCT02378012|Other|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
267812|NCT02378012|Other|Computer-Assisted Intervention|Receive iPad and instruction manuals.
267813|NCT02380287|Drug|humanized monoclonal antibody against human IL-17|
267814|NCT02380313|Drug|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
267815|NCT02380313|Drug|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
267816|NCT02380313|Drug|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
267817|NCT02380313|Drug|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
267818|NCT02380326|Procedure|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
267819|NCT02380339|Behavioral|Psych-Educational session and virtual reality|
267820|NCT02380339|Behavioral|Psych-Educational and BF sessions|
267821|NCT02380352|Drug|Amoxicillin|
267822|NCT00161317|Behavioral|Living with Hope Program|
267221|NCT02389933|Drug|LCZ696|immediate release film coated tablet in different strengths for oral administration.
267222|NCT02392104|Drug|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
267223|NCT02392117|Drug|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
267224|NCT02392130|Drug|Clobetasol propionate 0.05% ointment|
267225|NCT02392130|Drug|LEO 130852A gel 1%|
267226|NCT02392130|Drug|LEO 130852A placebo gel|
267509|NCT02385071|Drug|Treatment F|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
267510|NCT02385084|Drug|LY2409021|Administered orally
267511|NCT02385097|Drug|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
267512|NCT02385097|Drug|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
267513|NCT02385110|Drug|Alemtuzumab|Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks.
267514|NCT00161876|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
267515|NCT02385110|Drug|Etoposide|Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.
Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide.
267516|NCT02385110|Drug|Dexamethasone|Induction Phase: 20 mg/m2 by vein daily for 1 week followed by 10 mg/m2 by mouth for 1 week followed by 5 mg/m2 by mouth for 2 weeks followed by 2.5 mg/m2 by mouth for 2 weeks followed by 1.25 mg/m2 by mouth for 2 weeks.
Maintenance Phase: 1.25 mg/m2 by mouth three times for 16 weeks.
267517|NCT02385110|Drug|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
267518|NCT02385110|Behavioral|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
267519|NCT02385123|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
267520|NCT02385136|Drug|Temozolomide|
266936|NCT02358655|Other|Retrospective review of OAC prescription|
266937|NCT02358655|Other|Prescription of OAC in ED|
266938|NCT02358655|Other|Community AF clinic|
266939|NCT02358668|Drug|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
266940|NCT02358668|Drug|BTI320 matching placebo|Placebo
266941|NCT02358681|Drug|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
266942|NCT02360761|Procedure|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
266943|NCT02360774|Drug|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
266944|NCT02360774|Drug|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
267227|NCT02392143|Other|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test [18]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
267228|NCT02392143|Other|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
267229|NCT02392143|Other|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
267230|NCT00002431|Drug|Chlorhexidine gluconate|
267231|NCT00162773|Drug|omalizumab|
267232|NCT02392156|Biological|rFVIIIFc|As described in the treatment arm
267233|NCT02392156|Biological|rFIXFc|As described in the treatment arm
267234|NCT02392156|Drug|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
266637|NCT00159536|Drug|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
266638|NCT02365805|Drug|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
266639|NCT02365805|Drug|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
266640|NCT02365818|Drug|CG0070|
266641|NCT02365831|Other|Observation of treatment management|Group/cohort
266642|NCT02365857|Drug|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine & Bupivacaine.
266643|NCT02365857|Drug|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
266644|NCT02365870|Drug|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
266645|NCT02365870|Drug|placebo|Participants will receive a placebo transdermal patch to be worn daily
266646|NCT02365896|Procedure|TLDG or LADG|
266647|NCT02365909|Drug|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
266648|NCT00159536|Drug|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
266649|NCT02365909|Drug|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
266650|NCT02365935|Procedure|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
266945|NCT02360787|Behavioral|Energy restriction|
266946|NCT02360787|Behavioral|Almonds (15% kcal/day)|
266947|NCT02360800|Procedure|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
266948|NCT02360800|Procedure|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
266949|NCT02360813|Behavioral|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
266950|NCT02360813|Other|Treatment as usual|Keep getting usual care.
266655|NCT02368002|Behavioral|Enhanced behavioral weight loss therapy|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
266656|NCT02368015|Other|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
266657|NCT02368015|Drug|cefazolin|
266658|NCT02368028|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
266659|NCT02368041|Device|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology INC. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
266660|NCT02368054|Drug|Bupivacaine|Infiltration anesthesia
266661|NCT02368054|Drug|Adrenaline|Infiltration anesthesia
266662|NCT00159796|Drug|Placebo|placebo, 3 weeks
266663|NCT02368067|Procedure|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
266664|NCT02368067|Procedure|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
266665|NCT02368080|Device|Comparison of two MBWN2 devices : "EasyOne Pro Lab" versus "Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
266666|NCT02368093|Drug|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
266667|NCT02368106|Radiation|Radiation Therapy|targeted radiation treatment
266668|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
266669|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
266965|NCT02363673|Other|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
272006|NCT02327169|Drug|Paclitaxel|Paclitaxel
272007|NCT02327169|Drug|Cetuximab|Cetuximab
272008|NCT00154076|Drug|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
272009|NCT02327169|Drug|Irinotecan|Irinotecan
272010|NCT02327182|Drug|MT-4666|
272296|NCT02319720|Procedure|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
272297|NCT02319733|Device|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
272298|NCT00153595|Drug|EWO1|
272299|NCT02322112|Other|Acacia Gum Supplementation|Fifty five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
272300|NCT02322112|Other|Corn Arabinoxylan Supplementation|Fifty five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AX (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
272301|NCT02322112|Other|Resistant Starch Type 4 Supplementation|Fifty five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
272302|NCT02322125|Device|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
272303|NCT02322138|Other|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
272304|NCT02322138|Other|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
272305|NCT02322138|Other|Reference Group|Breast fed ad libitum
272306|NCT02322190|Procedure|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment
272307|NCT02322190|Drug|Methoxsalenused in conjuction with photopheresis procedure|Used in conjuction with photopheresis procedure
272308|NCT02322203|Dietary Supplement|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
271703|NCT00154687|Drug|Paclitaxel, Cisplatin, 5-Fluorouracil|
271704|NCT02331745|Drug|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
271705|NCT02334007|Other|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
271706|NCT02334020|Other|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
271707|NCT02334033|Other|other|
271708|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
271709|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
271710|NCT02334046|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
271711|NCT00002400|Drug|Lamivudine|
271712|NCT00155337|Procedure|photodynamic therapy|
271713|NCT02334059|Drug|Ketamine|Ketamine infusion plus placebo infusion of normal saline
271714|NCT02334059|Drug|Ketamine plus magnesium|Ketamine plus magnesium infusion
272011|NCT02327195|Drug|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
272012|NCT02327195|Drug|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
272013|NCT02327208|Dietary Supplement|Control|
272014|NCT02327208|Dietary Supplement|Protein|
272015|NCT02327208|Dietary Supplement|Carbohydrate|
272016|NCT02327221|Drug|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
272017|NCT02327221|Drug|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
272018|NCT02327234|Drug|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
271387|NCT00156000|Device|Salivary Estriol|Salivary Estriol done during pregnancy
271388|NCT02336516|Drug|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
271389|NCT02336516|Drug|Placebo (glucose solution 10%)|
271390|NCT02336529|Drug|Bupivacaine|
271391|NCT02336529|Drug|NaCl|
271392|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
271393|NCT02338778|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
271394|NCT02338778|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
271395|NCT02338791|Device|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
271396|NCT02338804|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
271715|NCT02334059|Other|Placebo|2 placebo infusions
271716|NCT02334072|Device|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
271717|NCT02334072|Device|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
271718|NCT02334072|Device|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
271719|NCT02334072|Device|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
270806|NCT02350010|Device|CT Angiography|CTA Scan with the specified sequences below:
120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.
Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s.
271086|NCT02343302|Device|Non-suctioning drainage|A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled "gravity drain"
271087|NCT02343315|Device|TENS|Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
Equipment- TENS (CEFAR Basic TENS Machine)
Electrodes- Four channel electrode to cover the site of pain
Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.
Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.
Frequency- 5 Hertz
Duration- 30 minutes
271088|NCT02343315|Other|SMCE|Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.
Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities.
271089|NCT02343315|Other|UHEP|All the participants will receive the following treatments:
Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.
Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.
Participants will not be asked to not take the "over the counter" analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen).
271090|NCT02343328|Biological|Fecal Microbiota Transplant|
271091|NCT02343328|Biological|Placebo|
271092|NCT02343341|Behavioral|Preschool Health Promotion Education Program|
271093|NCT00156923|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
271094|NCT02343354|Behavioral|Nutrition/physical activity intervention|Please see arm description
271095|NCT02345382|Drug|BAY1143572|As soon as the MTD has been determined for the once-daily continuous dosing schedule (i.e. Study Arm 1), Study Arm 2 will be opened, testing a 3 days on / 4 days off dosing schedule. The starting dose for Study Arm 2 will be the MTD of BAY1143572 determined in Study Arm 1.
Maximum dose escalation between dose levels will be 2 fold. The dose-escalation part of each dosing schedule may be followed by an expansion part.
271096|NCT02345395|Procedure|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
270516|NCT02318862|Procedure|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
270517|NCT02318875|Dietary Supplement|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
270518|NCT02318875|Other|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
270519|NCT02318888|Procedure|Surgery|
270520|NCT02318888|Drug|Icodextrin|
270521|NCT02318901|Drug|Pembrolizumab|
270522|NCT02318901|Drug|Trastuzumab|
270807|NCT00157937|Drug|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
270808|NCT02350023|Drug|Topical latanoprost 0.005%|Local application of the drug on affected skin/scalp
270809|NCT02350023|Drug|Topical betamethasone 0.05%|Local application of the drug on affected skin/scalp
270810|NCT02350036|Other|ultrasound monitoring|Uterine artery Doppler assessment
270811|NCT02350075|Procedure|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
270812|NCT02350075|Device|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
270813|NCT02350088|Drug|probiotics|probiotics
270814|NCT02350088|Drug|placebo|placebo
270815|NCT02350101|Device|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
270816|NCT02350114|Procedure|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
270817|NCT02350127|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLI is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
270818|NCT00002410|Drug|Lamivudine|
270819|NCT00157950|Biological|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
270231|NCT02323867|Device|Alpha Beta T cell depletion|
270232|NCT02323880|Drug|Selinexor|
270233|NCT02323893|Drug|[18F]F-AraG|
270234|NCT02323906|Drug|CC-122|Investigational new drug
270235|NCT00153751|Drug|Holopon|holopon
270236|NCT02323906|Drug|Sorafenib|Kinase inhibitor
270237|NCT02326298|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use
270238|NCT02326311|Drug|imatinib|Tyrosin kinase inhibitor
270239|NCT02326311|Drug|nilotinib|Tyrosin kinase inhibitor
270240|NCT02326311|Drug|dasatinib|Tyrosin kinase inhibitor
270241|NCT02326337|Device|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
270523|NCT02318901|Drug|ado-trastuzumab emtansine|
270524|NCT00153140|Drug|polyethyleneglycol3350|
270525|NCT02318901|Drug|Cetuximab|
270526|NCT02318914|Drug|gevokizumab|
270527|NCT02318927|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
270528|NCT02318940|Device|central venous catheter|installation of Central venous catheter ultrasound guided
270529|NCT02318940|Device|central venous catheter|installation of Central venous catheter landmark guided
270530|NCT02318953|Device|Mobile app follow-up care|The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
270531|NCT02318953|Other|Conventional, in-person follow-up care|This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
269936|NCT00154492|Drug|activated recombinant human factor VII|
269937|NCT02330952|Drug|Prednisone|40mg/day per os for 5 days
269938|NCT02330952|Drug|Placebo|40mg/day per os for 5 days
269939|NCT02330965|Procedure|Blood Draw|Blood draws (65 mLs [~4 tablespoons] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
269940|NCT02330965|Procedure|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
269941|NCT02330978|Procedure|Intravitreal transplantation of mesenchymal stem cell|
269942|NCT02330978|Biological|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
269943|NCT02330991|Drug|Temozolomide|
269944|NCT02331004|Other|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
269945|NCT02331004|Other|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
269946|NCT02331017|Behavioral|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
269947|NCT00154505|Device|Lateral trunk support of wheelchair seating|
269948|NCT02331030|Procedure|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
269949|NCT02331030|Procedure|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
270242|NCT02326337|Device|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
270243|NCT00153998|Procedure|Liver resection|
270244|NCT02326350|Drug|Aspirin 75mg|Active treatment
270245|NCT02326350|Drug|Lactose powder|Placebo
269647|NCT02338141|Device|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
269648|NCT02338141|Device|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
269649|NCT02338167|Procedure|Blood sampling|A blood sample will be taken during a routine blood draw
269650|NCT02338180|Other|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
269651|NCT02338180|Other|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
269652|NCT02338193|Drug|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
269653|NCT02338193|Drug|DAPA|10 mg dapagliflozin QD for 20-24 weeks
269654|NCT00156143|Procedure|Radiography|
269655|NCT02338193|Drug|MET XR|1000 mg Metformin XR BID for 20-24 weeks
269656|NCT02338206|Drug|Growth hormone|
269657|NCT02338219|Other|postpartum female pelvic floor muscle affection|transperineal pelvic floor ultrasound applied for the submitted 120 women "primiparae" (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.
269658|NCT02338219|Other|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
269659|NCT02338232|Drug|Telmisartan|
269950|NCT02331030|Procedure|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
269951|NCT02331030|Drug|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
269952|NCT02331030|Drug|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
269953|NCT02331043|Dietary Supplement|Plant stanol ester|
269345|NCT02342678|Behavioral|Physical Conditioning|
269346|NCT02342691|Drug|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
269347|NCT02342691|Drug|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
269348|NCT02342704|Drug|natalizumab|Administered as specified in the treatment arm
269349|NCT02342704|Drug|fingolimod|Administered as specified in the treatment arm
269350|NCT02344784|Drug|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
269351|NCT00157092|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
269352|NCT02344797|Procedure|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures >185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
269353|NCT02344810|Drug|c-Met inhibitor AMG 337|Given PO
269354|NCT02344810|Other|placebo|Given PO
269355|NCT02344810|Drug|oxaliplatin|Given IV
269356|NCT02344810|Drug|leucovorin calcium|Given IV
269357|NCT02344810|Drug|fluorouracil|Given IV
269358|NCT02344810|Other|pharmacological study|Correlative studies
269359|NCT02344810|Other|laboratory biomarker analysis|Correlative studies
269360|NCT02344823|Drug|Vardenafil|per oral intake of 10mg Vardenafil once daily
269361|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
269362|NCT00157105|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
269363|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
269364|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
268761|NCT02320591|Other|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
268762|NCT02320591|Other|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
268763|NCT02320604|Drug|Pre-surgery dose of AmBisome 2 mg/kg|First 8 patients receiving 2 mg/kg
268764|NCT02320604|Drug|Pre-surgery dose of AmBisome 3 mg/kg|Patients 9-16 receiving 3 mg/kg
268765|NCT02320617|Procedure|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
268766|NCT02320630|Drug|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
268767|NCT02320630|Drug|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
269071|NCT02351895|Other|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
269072|NCT02351908|Drug|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
269073|NCT02351908|Drug|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
269074|NCT02351908|Drug|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
269075|NCT02351921|Device|Transcranial magnetic stimulation|Continuous theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. CTBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (~1 hour) in neural activity in the brain. The delivery of cTBS requires ~ 40 seconds in total.
269076|NCT02351934|Drug|Furosemide|
269077|NCT02351947|Other|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
269078|NCT02351960|Drug|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg orally once daily for 4 weeks.
269079|NCT00158184|Drug|oxycodone|Placebo, 15 mg/70 kg oxycodone, and 30 mg/70 kg oxycodone are administered once per day
269080|NCT02354144|Other|Control gel|A gel not containing carrageenan
268439|NCT02368847|Device|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
268440|NCT02368847|Device|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
268441|NCT02368860|Drug|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
268442|NCT02368873|Procedure|Application of IPOM mesh|
268443|NCT02368886|Drug|Clobetasol Propionate|Given topically
268444|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight >20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight >45 kg: 40 mg 3 times a day (tid)
268445|NCT02368886|Other|Pharmacological Study|Correlative studies
268446|NCT02368886|Other|Quality-of-Life Assessment|Ancillary studies
268447|NCT02368886|Drug|Regorafenib|Given PO
268448|NCT02368899|Other|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
268449|NCT02368899|Other|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
268450|NCT02368912|Drug|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
268451|NCT02368912|Drug|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
268452|NCT02368912|Drug|ASP1707 single dose fasted|Oral, healthy young male
268768|NCT02320630|Drug|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
268769|NCT02320643|Device|Seratom® PA mesh|Partially absorbable mesh
268770|NCT02320656|Other|Blood sampling|Longitudinal (3 stages of the disease)
268771|NCT00153387|Behavioral|Women's health|
267823|NCT02380352|Drug|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
267824|NCT02380365|Device|Electrocardiography|Duration of intervention per patient/subject:
5 min, observation 6 months
268135|NCT02373618|Other|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
268136|NCT02373631|Other|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
268137|NCT02373631|Other|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
268138|NCT02373644|Other|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
268139|NCT00000358|Drug|Lofexidine|
268140|NCT00002422|Drug|HE2000|
268141|NCT00160381|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
268142|NCT02373644|Other|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
268143|NCT02373657|Behavioral|instruction in soap-making and hygiene education|
268144|NCT02375516|Behavioral|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
268145|NCT02375529|Procedure|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
268146|NCT02375529|Procedure|Four Ports Laparoscopic Cholecystectomy (4PLC)|An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.
Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation .
267521|NCT02385149|Other|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
267522|NCT02387528|Behavioral|MIndfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and ilness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
267523|NCT02387528|Behavioral|Control Group meetings|Eight meetings where the participants will practice relaxation techniques.
267524|NCT02387554|Drug|HGP0904|
267525|NCT02387554|Drug|HGP0608|
267526|NCT02387554|Drug|HGP1405|
267825|NCT02380404|Procedure|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
267826|NCT02380417|Procedure|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
267827|NCT02380417|Drug|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
267828|NCT02380417|Device|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
267829|NCT02380430|Other|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
267830|NCT02380443|Biological|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
267831|NCT02380443|Procedure|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
267832|NCT02380456|Other|dHACM|dHACM is a composite of dehydrated amniotic membrane graft layers designed to be a natural barrier that protects the collagen matrix and optimize surgical performance. The product is processed from human tissue according to the American Association of Tissue Banks (AATB) standards and is regulated as a tissue product under Section 361 of the Public Health Service Act.
267833|NCT00161330|Drug|oral amoxicilline/clavulanic acid|
267834|NCT02382679|Dietary Supplement|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
267235|NCT02392156|Drug|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
267236|NCT02392169|Drug|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
267237|NCT02392182|Other|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
267238|NCT02392195|Other|Non-interventional|Observational
267239|NCT02392208|Drug|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
267240|NCT02392208|Procedure|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
267241|NCT02392234|Drug|VX-661/ivacaftor|
267242|NCT00162786|Drug|Rupatadine|
267243|NCT02392234|Drug|ivacaftor|
267244|NCT02392234|Drug|VX-661/ ivacaftor placebo|
267245|NCT02355990|Procedure|Minimally Invasive Micro Sclerostomy|Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
267527|NCT02387567|Drug|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
267528|NCT02387567|Drug|Sham Lidocaine|Sham injection, without lidocaine.
267529|NCT02387567|Other|Standard treatment|Standard treatment only, without lidocaine or sham injection.
267530|NCT02387580|Drug|OZ439 + TPGS|
267531|NCT00162214|Drug|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
267532|NCT02387580|Drug|OZ439 Prototype 1|
267533|NCT02387580|Drug|OZ439 Prototype 3|
267534|NCT02387580|Drug|PQP|
267535|NCT02387593|Device|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
267536|NCT02387606|Drug|Placebo|Participants will receive placebo once daily.
266951|NCT02360826|Drug|Pravastatin|
266952|NCT00158990|Drug|sertraline|
266953|NCT02360826|Drug|Simvastatin|
266954|NCT02360852|Drug|A4250|A4250 once daily
266955|NCT02360865|Other|Exercise|
266956|NCT02360878|Device|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
266957|NCT02360891|Other|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
266958|NCT02360904|Other|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
266959|NCT02360917|Other|Emerging from the Haze|A 6 week psycho-educational class
266960|NCT02360943|Other|4 blood samples|PK and / or PD measurements during hospitalization
266961|NCT02360956|Drug|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
266962|NCT02360956|Drug|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
266963|NCT00159016|Drug|Glivec|
266964|NCT02363660|Biological|GINI|
267246|NCT02356003|Device|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
267247|NCT02356016|Behavioral|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
267248|NCT02356016|Behavioral|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
266966|NCT02363686|Procedure|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
266967|NCT02363686|Procedure|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
266968|NCT02363699|Drug|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
266969|NCT02363699|Drug|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
266970|NCT02363712|Device|APOS shoe|It consists of two shoes each with two large convex rubber balls called "Pertupods" screwed into the plantar surface of the sole so that a person walks on these balls.
266971|NCT02363712|Device|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
266972|NCT00159328|Procedure|Magnetic Resonance Guided Focused Ultrasound|
266973|NCT02363725|Drug|Colchimax®|
266974|NCT02363725|Drug|Conventional treatment|
266975|NCT02363738|Drug|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
266976|NCT02363738|Other|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
266977|NCT02363751|Drug|Bevacizumab|Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinium salt+bevacizumab).
In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up.
266978|NCT02363764|Procedure|Nasal swab|Will be obtained by the physiotherapist in:
Expectorating CF patients
Non-expectorating CF patients
Bronchoscopy CF patients
266979|NCT02363764|Procedure|Cough swab|Will be obtained by the physiotherapist in:
Expectorating CF patients
Non-expectorating CF patients
Bronchoscopy CF patients
266980|NCT02363764|Procedure|Spontaneous expectorated sputum|Will be obtained by the physiotherapist in:
- Expectorating CF patients
272309|NCT00153608|Biological|WT1 126-134 peptide|
272310|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
272311|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
272312|NCT02322216|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
272313|NCT02322229|Drug|Ocriplasmin 0.125 mg in a 0.1 mL volume|
272314|NCT02322242|Drug|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
272315|NCT02322242|Drug|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
272595|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, after cooking|
272596|NCT02353338|Procedure|Surgical intervention|Surgical management of radial fracture
272597|NCT02353338|Procedure|Conservative management|Immobilized/cast for 6 weeks
272598|NCT02353338|Device|cast|
272599|NCT00158314|Behavioral|Cognitive behavioral self-help manual|
272600|NCT02353351|Device|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
272601|NCT02353364|Other|PGS|Embryos screened by the validated NGS technology CNV-Seq
272602|NCT02317120|Genetic|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
272603|NCT00153049|Drug|Telmisartan + Hydrochlorothiazide|
272604|NCT02317133|Biological|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
272605|NCT02317133|Biological|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
272606|NCT02317146|Drug|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
272607|NCT02317159|Drug|Imatinib|400mg imatinib qd PO
272019|NCT00154089|Drug|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
272020|NCT02327234|Drug|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
272021|NCT02327247|Drug|Felodipine|Extended Release Tablets, 10mg
272022|NCT02327247|Drug|PLENDIL®|Extended Release Tablets, 10mg
272023|NCT02327260|Behavioral|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
272024|NCT02327260|Behavioral|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
272025|NCT02327273|Drug|BMS-963272|
272026|NCT02327273|Drug|Placebo|
272027|NCT02329626|Device|PET CT 18 FDG|Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography.
This intervention is required for the observational needs of the study.
272028|NCT02329639|Genetic|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
272029|NCT02329652|Device|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
272030|NCT02329665|Device|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
272031|NCT02329678|Procedure|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
272316|NCT02322268|Dietary Supplement|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
272317|NCT02322281|Drug|Rociletinib|
272318|NCT02322281|Drug|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
272319|NCT02322294|Dietary Supplement|Glucodia™|
272320|NCT00153634|Drug|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
272321|NCT02322294|Other|Placebo|
271720|NCT02334072|Device|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
271721|NCT02334098|Dietary Supplement|Omega-3 supplemented drink|The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.
1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment.
271722|NCT02334098|Dietary Supplement|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
271723|NCT00155350|Drug|pioglitazone|
271724|NCT02334111|Behavioral|RESPECT - Plus|A RESPECT-Plus family specialist (FS) will deliver intervention to subjects randomized into the study's intervention arm. During infant's hospital stay, FS will schedule a convenient time to meet these subjects to educate them on infant soothing techniques. All Babies Cry consists of an 11-minute video program, a DVD for families to take home, a 28-page booklet, and social media. The 5 S's provides methods that can be used to calm a crying infant. FS will join infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between subjects and FS. The American Academy of Pediatrics recommends 7 routine visits during the first year of life (1 wk;1,2,4,6,9,12 mos); FS will attend subject to availability and parent wishes.
271725|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
271726|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
271727|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
271728|NCT02336555|Drug|MK-8291|MK-8291 10 mg tablet orally, once daily, on days 1,2 and 28; and twice daily, on days 3 to 27
271729|NCT02336555|Drug|Placebo|Placebo for MK-8291 tablet orally, once daily on days 1,2, and 28; and twice daily, on days 3 to 27
271730|NCT00156013|Drug|CLOFARABINE|4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles
271731|NCT02336568|Drug|Oxytoine|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
272032|NCT02329704|Procedure|Diff-Quik staining for morphology evaluation|Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).
Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm.
272033|NCT02329704|Procedure|Motility Evaluation for grade A and B|The better separation method will insure more progressive sperms after processing.
Grading using A and B scale scored by (WHO 2010) references.
271097|NCT02345408|Drug|CCX872-B|Tablets (oral administration)
271098|NCT02345434|Other|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
271099|NCT02345447|Drug|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
271397|NCT02338804|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
271398|NCT02338817|Device|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
271399|NCT02338830|Drug|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
271400|NCT02338843|Drug|LJPC-501|Treatment arm
271401|NCT00156234|Behavioral|One-knee extension ergometer|
271402|NCT02338843|Drug|Placebo|PBO
271403|NCT02338856|Drug|MB12066 200mg|100mg bid (multiple dose, day 8)
271404|NCT02338856|Drug|Placebo|100mg bid (multiple dose, day 8)
271405|NCT02338869|Behavioral|Dialogue-based psychosocial rehabilitation|
271406|NCT02338882|Device|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
271407|NCT02338882|Device|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
271408|NCT02338895|Device|Ultrasound|Ultrasound of inferior vena cava and kidneys
271409|NCT02338908|Other|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
271410|NCT02338908|Other|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
271411|NCT02338921|Drug|Sitagliptin|100mg qd per oral during 24months
compared with other treatment groups
271412|NCT02341079|Drug|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
270820|NCT02350127|Behavioral|Usual Care Control|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the adult day center, which include a combination of daily physical, mental and social activities.
270821|NCT02350140|Other|Text messaging from beginning|Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free "call back" text message to the designated clinic phone at any time.
270822|NCT02352519|Procedure|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
270823|NCT02352519|Procedure|Local Infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
271100|NCT02345447|Drug|Placebo|Aqueous ethanol solution non-distinguishable from verum
271101|NCT02345460|Drug|Irinotecan Hydrochloride|Given IV
271102|NCT02345460|Drug|Oxaliplatin|Given IV
271103|NCT00157209|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
271104|NCT02345460|Drug|Leucovorin Calcium|Given IV
271105|NCT02345460|Drug|Fluorouracil|Given IV
271106|NCT02345460|Other|Laboratory Biomarker Analysis|Correlative studies
271107|NCT02345473|Genetic|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
271108|NCT02345486|Other|0.9% sodium chloride|
271109|NCT02345486|Other|Physiologically balanced fluid|
271110|NCT02345499|Procedure|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
271111|NCT02345499|Procedure|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
271112|NCT02345512|Device|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
270532|NCT02318966|Dietary Supplement|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
270533|NCT02318979|Device|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
270534|NCT02318979|Device|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
270535|NCT00153153|Drug|polyethyleneglycol3350|
270536|NCT02321293|Drug|Tyrosine Kinase Inhibitor erlotinib (Tarceva)|150 mg PO daily until progression
270537|NCT02321306|Drug|LUM001|LUM001 administered orally once each day.
270538|NCT02321319|Drug|Hydromorphone HCl ER Tablets|
270539|NCT02321332|Procedure|bilateral simultaneous endoscopic thoracic symapthectomy|Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
270540|NCT00153504|Behavioral|Housing and Health Study housing rental assistance|
270541|NCT02321332|Procedure|unilateral sequential endoscopic thoracic symapthectomy.|Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
270824|NCT02352532|Other|Dry Needling|The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a "pistoning" (in and out) technique.
270825|NCT02352532|Other|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
270826|NCT02352545|Drug|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
270827|NCT00158249|Drug|citicoline|2 gm/day, 8 weeks treatment
270828|NCT02352558|Drug|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
270246|NCT02326363|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
270247|NCT02326363|Behavioral|Twelve-Step Facilitation Intervention (TSF)|The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a "take home" summary and homework assignment.
270248|NCT02326376|Drug|anakinra (Kineret)|
270249|NCT02326389|Behavioral|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
270250|NCT02326389|Behavioral|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
270251|NCT02326402|Device|TandemHeart System|Percutaneous insertion of TandemHeart System
270252|NCT02326415|Other|Clinical Pathway with "Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
270253|NCT02326415|Other|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
270254|NCT00153998|Drug|Cetuximab and FOLFIRI|Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:
Cetuximab 250 mg/m² (1.0 h i.v.) weekly
Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)
270255|NCT02326428|Device|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, preSET, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
270256|NCT02326428|Drug|Intravenous thrombolysis by alteplase (Actilyse)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
270257|NCT02326441|Drug|KX2-361|
270258|NCT02328794|Behavioral|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
270542|NCT02321345|Other|Palliative Care Support|Palliative care meetings Quality of Life Assessments
270543|NCT02321358|Behavioral|Two-time implementation intention|Will be given intervention and booster at six weeks
270544|NCT02321358|Behavioral|One-time implementation intention|Will only be given the intervention once
269954|NCT02331043|Dietary Supplement|Placebo|
269955|NCT02333344|Drug|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
269956|NCT02333357|Behavioral|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
269957|NCT02333357|Behavioral|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
269958|NCT02333370|Drug|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
269959|NCT02333370|Drug|Letrozole|25mg
269960|NCT02333396|Other|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
269961|NCT02333396|Other|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
269962|NCT02333409|Procedure|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
269963|NCT02333422|Other|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
269964|NCT00155064|Drug|captopril, Losartan (drug)|
269965|NCT02333435|Dietary Supplement|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
269966|NCT02333435|Dietary Supplement|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
269967|NCT02333448|Biological|Blood sample taken on the day the treatment is initiated|
270259|NCT02328794|Behavioral|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
270260|NCT00154258|Drug|Clozapine|
264407|NCT02354833|Drug|Phenylephrine|
264408|NCT02354833|Drug|Norepinephrine|
264409|NCT02354859|Drug|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
264410|NCT02354859|Drug|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
264411|NCT02354872|Drug|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
264697|NCT02386566|Drug|natalizumab|As described in the treatment arm
264698|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
264699|NCT02386579|Procedure|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
264700|NCT02386592|Drug|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
264701|NCT02388698|Biological|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
264702|NCT02388711|Other|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
264703|NCT02388724|Drug|Vonoprazan|Vonoprazan tablets
264704|NCT02388724|Drug|Lansoprazole|Lansoprazole capsules
264705|NCT02388724|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
264706|NCT02388724|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
264707|NCT02388737|Drug|Vonoprazan|Vonoprazan tablets
264708|NCT00162344|Drug|Technetium Tc99m Sestamibi|
264709|NCT02388737|Drug|Lansoprazole|Lansoprazole capsules
264710|NCT02388737|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
264711|NCT02388737|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
269081|NCT02354157|Other|no intervention|no intervention
269082|NCT02354170|Drug|Mifepristone|
269083|NCT02354170|Drug|Placebo|
269084|NCT02354183|Behavioral|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
269085|NCT02354196|Procedure|CCTA|CT of heart to assess coronary disease
269086|NCT02354222|Drug|Canagliflozin|
269087|NCT02354222|Drug|Teneligliptin|
269088|NCT02354222|Drug|Placebo|
269089|NCT02354235|Drug|Teneligliptin|
269090|NCT00158405|Procedure|Structured Treatment Interruption|
269091|NCT02354235|Drug|Canagliflozin|
269092|NCT02354235|Drug|Placebo|
264412|NCT02354872|Behavioral|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
264413|NCT02357368|Drug|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
264414|NCT02357368|Device|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
264415|NCT02357381|Device|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
264416|NCT00158652|Procedure|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
264417|NCT02357407|Drug|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
264418|NCT02357407|Drug|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
268772|NCT02320656|Other|Bone marrow aspirate|Longitudinal (3 stages of the disease)
268773|NCT02320656|Other|Skin biopsy|Single biopsy (optional)
268774|NCT02320656|Other|Buccal swab|Single sampling.
268775|NCT02320669|Drug|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
268776|NCT02320669|Drug|Placebo|Bolus of Placebo followed by infusion for 48 hours
268777|NCT02323126|Drug|EGF816|
268778|NCT02323126|Drug|INC280|
268779|NCT00153660|Drug|Celecoxib(drug)|Celecoxib 100 mg bd
268780|NCT02323126|Drug|Nivolumab|
268781|NCT02323139|Drug|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
268782|NCT02323152|Behavioral|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
268783|NCT02323152|Other|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
268784|NCT02323165|Other|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
268785|NCT02323178|Drug|eltrombopag|initial dose of 100 mg once daily, then the dose can be sequentially increased every 2 weeks by 100 mg steps up to a maximum dose of 300mg/day
268786|NCT02323191|Drug|MPDL3280A|MPDL3280A administered intravenously every 3 weeks
268787|NCT02323191|Drug|RO5509554|RO5509554 administered intravenously every 3 weeks
268788|NCT02323204|Behavioral|Link for Injured Kids|Psychological First Aid
268789|NCT02323204|Other|So you've been in an accident|Educational materials
268790|NCT00153660|Drug|Naproxen(drug)|Naproxen 500 mg bd
268147|NCT02375555|Drug|Lenalidomide|
268148|NCT02375555|Drug|Elotuzumab|
268149|NCT02375555|Drug|Bortezomib|
268150|NCT02375555|Drug|Dexamethasone|
268151|NCT02375555|Procedure|Stem Cell Mobilization|
268453|NCT02368912|Drug|ASP1707 single dose fed|Oral, healthy young male
268454|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
268455|NCT00159887|Drug|Sildenafil citrate|
268456|NCT02368912|Drug|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
268457|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
268458|NCT02368912|Drug|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
268459|NCT02368912|Drug|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
268460|NCT02368912|Drug|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
268461|NCT02371395|Other|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
268462|NCT02371408|Drug|ravidasvir hydrochloride|200 mg
268463|NCT02371408|Drug|sofosbuvir|400 mg
268464|NCT02371408|Drug|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
268465|NCT00160173|Drug|Estradiol|
268466|NCT02371421|Drug|Allopurinol|
268467|NCT02371434|Biological|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 106, 1 x 106, and 3 x 106 cells/kg body weight in cohorts of three patients each.
268468|NCT02371447|Drug|VPM1002BC|Phase 1:
Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)
Phase 2:
Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)
267835|NCT02382718|Biological|FAST fish mCyp c 1|Subcutaneous immunotherapy
267836|NCT02382718|Biological|Placebo|Subcutaneous immunotherapy
267837|NCT02382731|Behavioral|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4, 20, 44 weeks post-MI procedure.
267838|NCT02382731|Behavioral|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained peer health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the peer health worker. Peer health workers will not provide clinical advice.
267839|NCT02382744|Device|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
267840|NCT02382744|Device|Ultrasound guidance and nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
267841|NCT02382757|Drug|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
268152|NCT02375568|Other|103024-F|mesenchymal stem cell isolation
268153|NCT00160654|Drug|Levetiracetam|
268154|NCT02375581|Drug|Icotinib|125mg, Po, TID during RT
268155|NCT02375581|Radiation|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
268156|NCT02375594|Other|Exercise in park equipment|
268157|NCT02375607|Device|Algometer|Algometer performed patients
268158|NCT02375620|Biological|PEG-somatropin|
268159|NCT02375633|Drug|DW-330SR2|
268160|NCT02375633|Drug|Pelubiprofen|
268161|NCT02375646|Drug|Warfarin|
268162|NCT02375646|Drug|LMW Heparin|
268163|NCT02375659|Other|Focus Group Discussion|Each focus group will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
267537|NCT02387606|Drug|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
267538|NCT02387619|Drug|Rosuvastatin|Drug: Rosuvastatin once daily for 9 days
267539|NCT02387619|Drug|Telmisartan/Amlodipine|Drug: Telmisartan/Amlodipine once daily for 9 days
267540|NCT02387619|Drug|Rosuvastatin and Telmisartan/Amlodipine|Drug: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
267541|NCT02387645|Procedure|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
267542|NCT00162227|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
267543|NCT02387658|Procedure|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
267544|NCT02389946|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
267545|NCT02389946|Device|Xience DES|
267546|NCT02389959|Drug|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
267842|NCT02382770|Procedure|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
267843|NCT00161564|Drug|Rituximab|
267844|NCT02382783|Other|FLARE Intervention Group|Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...
The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says "yes" to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported.
267845|NCT02382796|Drug|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
267846|NCT02382809|Drug|DC071|Mouthwash, twice daily
267249|NCT02356016|Other|control (dietary counseling)|Monthly dietary counseling only
267250|NCT02356042|Other|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
267251|NCT00002412|Drug|Hydroxyurea|
267252|NCT00158561|Drug|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
267253|NCT02356055|Behavioral|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
267254|NCT02356068|Other|ROTEM analysis|3 blood samples for ROTEM analysis
267255|NCT02356081|Other|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
267256|NCT02356094|Procedure|Pentacam|Corneal topography using Scheimpflug Pentacam examination
267257|NCT02356107|Drug|5-hydroxytryptophan and Creatine monohydrate|
267258|NCT02356120|Other|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
267259|NCT02356146|Drug|Tacrolimus C12|
267260|NCT02356159|Biological|Rituximab|Rituximab: 375 mg/m2 IV, day 1 for patients with CD20-positive disease
267261|NCT02356159|Drug|Conditioning Chemotherapy|Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3
267262|NCT02356159|Drug|TMS|Tacrolimus: 0.02 mg/kg , start day 3. Continue IV or PO. Taper will begin at day +60 if no acute GVHD then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.
267263|NCT00158574|Drug|sulphadoxine-pyrimethamine|
267547|NCT02389959|Drug|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
267548|NCT02389972|Drug|Dasatinib|
267549|NCT02389985|Drug|CRLX101 and weekly paclitaxel|
266981|NCT02363764|Procedure|Induced sputum|Will be obtained by the physiotherapist in:
Non-expectorating CF patients
Bronchoscopy CF patients
267264|NCT02356159|Drug|FLAG|Fludarabine:25 mg/m2 per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m2 IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy
267265|NCT02358681|Drug|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
267266|NCT02358681|Drug|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
267267|NCT00158756|Biological|Hepatitis B vaccine|
267268|NCT02358681|Drug|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
267269|NCT02358694|Dietary Supplement|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
267270|NCT02358694|Other|Placebo|Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.
Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID).
267271|NCT02358707|Other|Ibuprofen phonophoresis|
267272|NCT02358720|Radiation|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
267273|NCT02358720|Radiation|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
267274|NCT02358733|Procedure|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
267275|NCT02358733|Procedure|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
267276|NCT02358746|Other|combined endo/epicardial approach|
267277|NCT02358746|Other|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
267278|NCT00158769|Drug|Intravenous GR270773 - Phospholipid emulsion|
267279|NCT02358759|Procedure|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
267280|NCT02358772|Other|thrombolysis in a pre-hospital setting (STEMO concept)|
267281|NCT02358785|Device|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
272608|NCT02317172|Other|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
272609|NCT02317185|Device|genex bone graft with bone graft|
272610|NCT02317185|Other|autogenous bone graft|
272611|NCT02317198|Drug|Clopidogrel|
272612|NCT02317198|Drug|Ticagrelor or Prasugrel|
272613|NCT02317211|Dietary Supplement|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
272614|NCT00002389|Drug|Lamivudine|
272615|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
272616|NCT02317211|Dietary Supplement|placebo|starch
272617|NCT02317224|Procedure|"3-Hole" subxiphorid and subcostal approach|"3-Hole" subxiphorid and subcostal approach anterior mediastinum tumor resection
272902|NCT02348476|Other|No Intervention|No study drug is administered in this study.
272903|NCT02348489|Drug|SGI-110 (guadecitabine)|Investigational Medicinal Product
272904|NCT00157742|Procedure|Percutaneous Myocardial Laser Revascularisation (PMR)|
272905|NCT02348489|Drug|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
272906|NCT02348515|Procedure|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
272907|NCT02348515|Procedure|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
272908|NCT02350998|Drug|OTO-201|
272909|NCT02351011|Biological|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
272910|NCT02351011|Biological|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
272911|NCT00158080|Procedure|hemofiltration|
272912|NCT02351011|Biological|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
272913|NCT02351024|Drug|OXP005|
272914|NCT02351024|Drug|Naprosyn®|
272322|NCT02324621|Other|laboratory biomarker analysis|Correlative studies
272323|NCT02324634|Device|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
272324|NCT02324660|Other|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
272325|NCT02324673|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
272326|NCT02324686|Drug|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
272327|NCT02324699|Drug|Prednisone|
272328|NCT02324699|Drug|Placebo|
272329|NCT00153829|Behavioral|Multifaceted outreach facilitation for chronic illness care|
272330|NCT02324699|Drug|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
272331|NCT02324712|Device|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
272332|NCT02324712|Device|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
272333|NCT02324725|Drug|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
272334|NCT02324738|Drug|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
272335|NCT02324738|Other|Wash-out period|
272336|NCT02324738|Drug|Mefloquine|2 tablets of Mefloquine single dose
272618|NCT02317224|Procedure|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
272619|NCT02317224|Procedure|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
272620|NCT02317237|Procedure|Local anesthesia|Conscious sedation
272621|NCT02317250|Procedure|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
272034|NCT02329704|Procedure|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
272035|NCT00154310|Drug|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
272036|NCT02329704|Procedure|24 H half life|percentage of active motile to non motile sperms.
Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.
272037|NCT02329704|Procedure|48 H half life|percentage of active motile to non motile sperms.
Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.
272038|NCT02329704|Procedure|HBA Testing|The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).
By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm.
272039|NCT02329704|Biological|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
272040|NCT02329717|Drug|PBI 05204|PBI 05204 daily dosing
272041|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
272042|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
272043|NCT02331758|Behavioral|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
272044|NCT02331771|Drug|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
272045|NCT02331771|Drug|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
272046|NCT02331784|Behavioral|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
272337|NCT02324751|Biological|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
272338|NCT02324751|Biological|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
271413|NCT02341079|Drug|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
271414|NCT02341092|Behavioral|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
271415|NCT02341105|Procedure|Catheter ablation|Pulmonary vein isolation by catheter ablation
271416|NCT02341105|Drug|Amiodarone|antiarrhythmic therapy using Amiodarone
271417|NCT02341118|Genetic|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
271732|NCT02336568|Drug|PLACEBO|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
271733|NCT02336581|Behavioral|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
271734|NCT02336581|Behavioral|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
271735|NCT02336594|Drug|RDEA3170 10 mg|
271736|NCT02336594|Drug|RDEA3170 2.5 mg|
271737|NCT02336607|Drug|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
271738|NCT02336607|Drug|Felodipine tablet (Plendil)+Hydrochlorothiazide|Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.
If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
271739|NCT02336607|Drug|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.
If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
271740|NCT02336607|Drug|Felodipine tablets (Plendil)+Lisinopril (Zestril)|Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.
If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
271113|NCT02345525|Behavioral|mCIMT|This intervention is based on 3 main aspects:
intensive training of functional tasks with the affected arm (massed practice)
constraint of the un-affected hand through a mitt
shaping techniques designed to transfer gains to the real world activities
The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT.
271114|NCT00157209|Other|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
271115|NCT02347657|Drug|VX-661/ ivacaftor placebo|
271116|NCT02347657|Drug|ivacaftor placebo|
271117|NCT02347670|Behavioral|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
271118|NCT00157638|Drug|optimizing therapeutic treatments|
271418|NCT00156637|Behavioral|Team Based Quality Improvement|Intervention to increase appropriate use of clozapine through a team based quality intervention.
271419|NCT02341131|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
271420|NCT02341131|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
271421|NCT02341144|Procedure|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
271422|NCT02341144|Procedure|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
271423|NCT02341144|Drug|Ropivacaine|
271424|NCT02341170|Radiation|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
271425|NCT02341183|Device|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
271426|NCT02341183|Device|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
270829|NCT02352558|Drug|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
270830|NCT02352558|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
270831|NCT02352558|Drug|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
270832|NCT02352558|Drug|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
270833|NCT02352571|Biological|GC1118|For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.
For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.
Both Part A and Part B participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease.
270834|NCT02352584|Biological|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
270835|NCT02352584|Biological|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
270836|NCT02352584|Biological|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
270837|NCT02352597|Drug|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
270838|NCT00152971|Drug|Enoxaparin|30 mg subcutaneously twice daily
271119|NCT02347670|Behavioral|Office-Based Usual Care|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.
This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital.
271120|NCT02347696|Behavioral|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
271121|NCT02347696|Behavioral|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
271122|NCT02347696|Behavioral|Endurance Activity (EA)|Subject will follow a program of endurance activity as follows:
Frequency: 3 times/week Duration: 60 minutes
Intensity:
weeks 1-4: 14.2 kcal*kg-1*week-1;
weeks 5-8: 18.9 kcal*kg-1*week-1;
weeks 9-12: 23.6 kcal*kg-1*week-1.
270545|NCT02321358|Behavioral|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
270546|NCT02321358|Behavioral|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
270547|NCT02321371|Drug|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
270548|NCT02321371|Drug|Lactulose|Continuation of Lactulose therapy for further 48 hours.
270549|NCT02321384|Drug|Placebo|Matching placebo to RO6889678 administered orally
270550|NCT02321384|Drug|RO6889678|RO6889678 administered orally
270551|NCT00153504|Behavioral|Standard local practice housing assistance|
270552|NCT02321384|Drug|midazolam|100 µg midazolam solution administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678
270553|NCT02321397|Drug|Oxycodone|
270554|NCT02321397|Drug|Naloxone|Prolonged Release Tablets
270555|NCT02321410|Other|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
270556|NCT02321410|Other|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
270557|NCT02321436|Drug|AbobotulinumtoxinA|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
270558|NCT02321436|Drug|Placebo|Placebo administered intramuscularly in the targeted upper limb.
270559|NCT02321462|Drug|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
270560|NCT02321462|Drug|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
270561|NCT02321475|Drug|EGb761®|
270562|NCT00153517|Drug|oral versus vaginal metronidazole|
270839|NCT02316236|Drug|dexmedetomidine|an alpha-2 receptor agonist
270840|NCT02316236|Other|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
270841|NCT02316236|Other|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
270261|NCT02328794|Behavioral|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
270262|NCT02328807|Procedure|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
270263|NCT02328820|Other|Percutaneous coronary intervention (PCI)|For lesions with both FFR<=0.8 and CFR<2.0
270264|NCT02328820|Other|Optimal medical therapy (OMT)|For lesions with FFR>0.8 or CFR>=2.0 or both
270265|NCT02328833|Other|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
270266|NCT02328859|Other|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
270267|NCT02328859|Other|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
270268|NCT02328872|Device|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
270269|NCT02328872|Device|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
270270|NCT02328885|Other|DLI of the 20 fraction of the UCBT|
270271|NCT00000352|Drug|Dextromethorphan|
270272|NCT00002397|Drug|Stavudine|
270273|NCT00154271|Drug|Valsartan, Valsartan HCT|
270274|NCT02328898|Device|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
270275|NCT02328898|Device|Resolute Integrity stent|
270276|NCT02328911|Device|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
264712|NCT02388750|Drug|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
264713|NCT02388750|Radiation|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
264714|NCT02388763|Device|Stenfilcon A contact lenses|
264715|NCT02388763|Device|Narafilcon A contact lenses|
264716|NCT02388776|Device|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
264717|NCT02388789|Other|active movement|same as arm description
265021|NCT02381613|Other|Baked herring|A meal based on baked herring
265022|NCT02381613|Other|Pickled herring|A meal based on pickled herring
265023|NCT02381626|Device|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
265024|NCT02381626|Behavioral|questionnaires|
265025|NCT02381626|Other|Log-book|PM and biological measurements
265026|NCT02381626|Other|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
265027|NCT00161447|Drug|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
265028|NCT02384044|Device|Crest® Sensi-Stop™ Strips|
265029|NCT02384044|Device|Colgate® Sensitivity Relief Pen|
265030|NCT02384057|Other|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
265031|NCT02384057|Other|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
265032|NCT02384070|Procedure|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
264419|NCT02357420|Drug|RM-131|Double blind RM-131 given subcutaneously at three BID doses: 10, 30 and 100 μg for 12 weeks.
264420|NCT02357420|Drug|Placebo|Placebo given subcutaneously for 12 weeks.
264421|NCT02357433|Device|High Doses CPFA|
264422|NCT02357459|Drug|FX006|Single intra-articular injection
264423|NCT02357459|Drug|Normal Saline|Single intra-articular injection
264424|NCT02357459|Drug|TCA IR|Single intra-articular injection
264425|NCT02357472|Drug|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
264426|NCT02357485|Biological|ADSC|Single injection of ADSC
264427|NCT00158652|Procedure|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
264428|NCT02357498|Procedure|transsphenoidal surgery|
264429|NCT02357511|Device|Study Monitor used|
264430|NCT02357524|Drug|Oritavancin|
264718|NCT02388802|Procedure|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
264719|NCT00162357|Drug|Technetium Tc99m Sestamibi|
264720|NCT02388802|Procedure|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
264721|NCT02388802|Procedure|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
264722|NCT02388802|Drug|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
264723|NCT02388802|Procedure|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
264724|NCT02388802|Procedure|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
264725|NCT02390986|Drug|LON002|Extension study to provide continuing access to LON002 medication.
264726|NCT02390999|Procedure|48 hours of therapeutic hypothermia|
269093|NCT02354248|Procedure|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
269094|NCT02354261|Drug|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
269095|NCT02354274|Radiation|Escalated: Inhomogene dose plan|
269096|NCT02354274|Radiation|Standard: Homogene dose plan|
269097|NCT02354287|Procedure|Cold forceps polypectomy with pre lift|Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..
These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.
The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue.
269098|NCT02354300|Device|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
269099|NCT02354313|Drug|Lenalidomide|Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).
Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation.
269100|NCT02354326|Radiation|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
269101|NCT00158405|Drug|Zidovudine (ZDV)|
269102|NCT02354326|Radiation|computed tomography|Undergo CT without VNC
269103|NCT02354339|Dietary Supplement|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
269104|NCT02318173|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix
269105|NCT02318199|Procedure|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
269106|NCT02318212|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
269107|NCT02318225|Drug|Misoprostol|Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
268469|NCT02371460|Dietary Supplement|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
268470|NCT02371460|Dietary Supplement|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
268471|NCT02371473|Drug|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
268472|NCT02371473|Drug|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
268473|NCT02371486|Procedure|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
268791|NCT02323217|Radiation|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
268792|NCT02323217|Drug|Idazoxan|Idazoxan block of [11C]BU99008
268793|NCT02323217|Drug|Isocarboxazid|Isocarboxazid block of [11C]BU99008
268794|NCT02323230|Biological|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
268795|NCT02323230|Drug|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
268796|NCT02323243|Device|Allium " Bulbar Urethral Stent " (BUS) system|
268797|NCT02323256|Other|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
268798|NCT02323256|Other|Speech-ABR|
268799|NCT02323256|Other|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
268800|NCT02323256|Other|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
268801|NCT00153673|Drug|celecoxib|Celecoxib 200mg bd
268802|NCT02323269|Drug|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
268803|NCT02323282|Drug|ropivacaine|
268804|NCT02325544|Behavioral|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
268164|NCT00160667|Drug|Placebo|Daily oral dose of two equal intakes, morning and evening of placebo in a double-blinded way for the 4-week treatment period
268165|NCT02378012|Other|Questionnaire Administration|Ancillary studies
268166|NCT02378025|Behavioral|Yoga Group|A 10-week yoga course designed to treat pain.
268167|NCT02378025|Behavioral|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
268168|NCT00160966|Drug|CsA + MMF|according to the Giessen protocol
268169|NCT02378038|Drug|PNT2258|
268170|NCT02378051|Behavioral|Staying Strong with Schools Intervention|On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.
Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her.
268171|NCT02378064|Drug|6-month treatment|
268172|NCT02378077|Procedure|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
268173|NCT02378077|Procedure|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
268474|NCT02371486|Procedure|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
268475|NCT02371486|Procedure|Ultrasound Scan|Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.
The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina.
268476|NCT00160186|Drug|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
268477|NCT02371486|Procedure|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
268478|NCT02371499|Dietary Supplement|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
268479|NCT02371499|Dietary Supplement|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
267847|NCT02382809|Drug|Placebo|Mouthwash, twice daily
267848|NCT02382822|Other|No intervention.|
267849|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
267850|NCT02382848|Drug|Placebo|Placebo (sugar pill) is used for 3 weeks.
267851|NCT02382861|Device|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
267852|NCT02385149|Other|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
267853|NCT02385175|Other|Different objective clinical tests of Eustachian tube function|
267854|NCT02385175|Other|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
267855|NCT00161889|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
267856|NCT02385188|Drug|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
267857|NCT02385188|Drug|paracetamol|
267858|NCT02385188|Drug|lidocaine in Vaseline ointment|
267859|NCT02385201|Device|Senza|Spinal Cord Stimulation
267860|NCT02385214|Procedure|Wide Local Excision = 1cm Margin|A wide local excision involves removing an extra "safety margin" of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.
268174|NCT02378077|Dietary Supplement|Fish Oil Supplement|Fish Oil supplementation for three months.
268175|NCT02378116|Procedure|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
268176|NCT02378129|Drug|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
268177|NCT02378129|Drug|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
268178|NCT02378142|Drug|Pazopanib|
267550|NCT02389998|Other|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
267551|NCT02389998|Drug|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
267552|NCT00002430|Drug|Nelfinavir mesylate|
267553|NCT00162500|Biological|Peptide Vaccine (MUC-1)|
267554|NCT02390011|Procedure|MRI|
267555|NCT02390024|Device|Invasive Mechanical Ventilation|Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:
Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840
267556|NCT02390050|Drug|Bexagliflozin tablets|Bexagliflozin tablets, 5 mg, 10 mg, 20 mg, and placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
267557|NCT02390063|Biological|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
267558|NCT02390063|Biological|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
267559|NCT02390063|Drug|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
267560|NCT02390076|Device|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
267561|NCT02390076|Other|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
267562|NCT02392234|Drug|ivacaftor placebo|
267563|NCT02392247|Procedure|Blood specimen collection|
267861|NCT02385214|Procedure|Wide Local Excision = 2cm Margin|A wide local excision involves removing an extra "safety margin" of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.
267282|NCT02358798|Other|3 years-assessment of respiratory function|
267283|NCT02358811|Device|Magnetic resonance imaging (MRI)|The acquisition of the image will last 45 minutes with 6 sequences.
Before any examination, the manipulator will check the absence of contraindication to MRI.
During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.
Throughout the examination, a physician will always be present.
267564|NCT02392260|Device|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
267565|NCT02392273|Drug|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
267566|NCT02392286|Drug|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
267567|NCT02392312|Drug|ATF-Fresenius S|intravenous
267568|NCT02392325|Biological|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10^3.0 plaque-forming units (PFU)
267569|NCT02392325|Biological|Placebo|Administered subcutaneously in 0.5 mL
267570|NCT00162786|Drug|Hydroxyzine|
267571|NCT02392325|Biological|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10^3.0 PFU
267572|NCT02392338|Procedure|Eletrophysiologic study|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isloation lesion and box lesions in left atrium
267573|NCT02392351|Device|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
267574|NCT02392351|Device|Renal Angiography|Percutaneous renal angiography
267575|NCT02392364|Drug|Intravitreal Aflibercept Injection|
267576|NCT02392377|Drug|Paclitaxel|Given IV or IVPB
267577|NCT02392377|Drug|Carboplatin|Given IV or IVPB
267578|NCT02392377|Drug|Oxaliplatin|Given IV
267579|NCT02392377|Drug|Leucovorin Calcium|Given IV
267580|NCT02392377|Drug|Fluorouracil|Given IV
267581|NCT00162786|Drug|Placebo|
267582|NCT02392377|Radiation|Radiation Therapy|Undergo radiation therapy
272915|NCT02351037|Drug|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
272916|NCT02351037|Drug|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
272917|NCT02351037|Drug|Ibrutinib + Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
272918|NCT02351050|Device|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
272919|NCT02351050|Other|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
272920|NCT02351063|Drug|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
272921|NCT02351089|Dietary Supplement|Capsules placebo|Capsules
272922|NCT00158093|Drug|Nebivolol|
272923|NCT02351089|Dietary Supplement|Capsules probiotic powder and corn starch|
272924|NCT02351102|Drug|Valacyclovir|
272925|NCT02351102|Drug|Placebo|
273245|NCT02344212|Behavioral|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
273246|NCT02344225|Drug|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
273247|NCT02344225|Drug|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
273248|NCT02344225|Drug|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
273249|NCT02344238|Other|ID Cap|Capsule-encased computer chip
273250|NCT02344238|Dietary Supplement|Riboflavin|50mg
273251|NCT02344238|Behavioral|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
273252|NCT02344251|Device|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
273253|NCT00157014|Drug|Cyclosporine|Oral
272622|NCT02317250|Procedure|FDG-PET|[F-18] FDG-PET brain scans are administered once to all arms.
272623|NCT02317263|Drug|testosterone|Apply 3 pump actuations to each thigh each morning (60mg).
272624|NCT02317263|Drug|placebo gel|Apply 3 pump actuations to each thigh each morning.
272625|NCT02317276|Drug|Triamcinolone 0.1%|Topical ointment
272626|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
272627|NCT02317289|Device|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
272628|NCT02317302|Device|FDG-PET/MR|
272629|NCT02319746|Behavioral|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
272630|NCT02319746|Behavioral|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
272631|NCT00153244|Drug|Lamotrigine|
272632|NCT02319759|Drug|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
272633|NCT02319759|Drug|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
272634|NCT02319759|Drug|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
272635|NCT02319772|Drug|BCX4430|
272636|NCT02319772|Drug|Placebo|
272637|NCT02319785|Behavioral|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
272638|NCT02319785|Behavioral|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
272926|NCT02351115|Drug|Staccato® Alprazolam, 0.5 mg|
272927|NCT02351115|Drug|Staccato® Alprazolam, 1 mg|
272339|NCT02324751|Biological|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
272340|NCT00153842|Drug|Bexarotene (targretin)|Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
Level 1: 300mg Level 2: 400mg
272341|NCT02324764|Device|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
272342|NCT02324764|Device|standard 6- French radial sheath|
272343|NCT02324777|Drug|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
272344|NCT02327286|Behavioral|Promote and support healthy behaviors|Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.
Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.
Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.
A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices.
272345|NCT02327299|Dietary Supplement|Bouillon fortified with FePP|
272346|NCT02327299|Dietary Supplement|Bouillon fortified with FePP + Stabilizer|
272347|NCT00002397|Drug|Saquinavir|
272348|NCT00154102|Drug|Cetuximab|Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Number of Cycles: until progression or unacceptable toxicity develops
272349|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4|
272350|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4 + Stabilizer|
272351|NCT02327312|Device|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
272352|NCT02327312|Procedure|Laser|Laser Trabeculoplasty
272353|NCT02327312|Device|Laser Trabeculoplasty|
272354|NCT02327325|Behavioral|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
272355|NCT02327325|Behavioral|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
271741|NCT00156247|Drug|acitretin|Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
271742|NCT02338921|Drug|Dapagliflozin|10mg qd per oral during 24months
compared with other treatment groups
271743|NCT02338921|Drug|Lobeglitazone|0.5mg qd per oral during 24months
compared with other treatment groups
271744|NCT02338921|Drug|Glimepirde|
271745|NCT02338921|Drug|Metformin|
272047|NCT02331784|Behavioral|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
272048|NCT02331797|Device|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
272049|NCT02331797|Device|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
272050|NCT02331810|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
272051|NCT02331810|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
272052|NCT00154700|Drug|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
272053|NCT02331823|Drug|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
272054|NCT02331823|Drug|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
272055|NCT02331836|Device|Arc Endocuff (AEC 110, 120, 130, 140)|
272056|NCT02331836|Device|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
272057|NCT02331836|Device|Standard colonoscope|
272058|NCT02331849|Device|High resolution manometry (HRM)|High resolution manometry of the esophagus
272059|NCT02331862|Drug|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
271427|NCT02341196|Procedure|CEA|Patients in both groups received an intra-operative angiography
271428|NCT02341209|Drug|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
271429|NCT00156650|Drug|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
271430|NCT02341222|Device|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
271431|NCT02343367|Behavioral|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
271432|NCT02343367|Other|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
271433|NCT02343367|Behavioral|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
271746|NCT02338934|Drug|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
271747|NCT02338947|Procedure|OPCAB|Surgical access to the heart will be gained through a median sternotomy in all of the patients. Patients will be heparinized with 100 IU/kg intravenously to achieve activated clotting time >200s. The proximal anastomoses of the grafts, when performed in the aorta, shall be by the Heartstring Proximal Seal System device to prevent clamping of the aorta (http://www.maquet.com/int/product/HEARTSTRING-III-Proximal-Seal-System--with-Aortic-Cutter). The distal anastomoses will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
271748|NCT02338947|Procedure|CABG|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 300 IU/kg to achieve an activated clotting time >480 s. Heparin will be neutralized with 1 mg protamine sulfate per 100 IU given.
271749|NCT02338960|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
271750|NCT02338960|Drug|Placebo|Placebo
271751|NCT02338973|Drug|Interferon gamma-1b|
271752|NCT00156260|Procedure|Ductal lavage|
271753|NCT02338999|Radiation|PET/CT|The combined PET/CT scans provide
271123|NCT02347696|Behavioral|EA+Resistance Training (RT)|Subject will follow a program of endurance activity as follows:
Frequency: 3 times/week Duration: 60 minutes
Intensity (for Endurance activity):
weeks 1-4: 14.2 kcal*kg-1*week-1;
weeks 5-8: 18.9 kcal*kg-1*week-1;
weeks 9-12: 23.6 kcal*kg-1*week-1.
Resistance activity:
Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);
Progression: increase of 1-2.5 kg*week-1
Training of all muscle groups in the same session
271124|NCT02347696|Behavioral|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
271125|NCT02347696|Behavioral|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
271126|NCT02347709|Procedure|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
271127|NCT02347709|Other|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
271128|NCT02347709|Other|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
271129|NCT00157638|Behavioral|optimizing processes of care|
271130|NCT02347709|Other|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
271131|NCT02347735|Other|No interventions, only data collection|Only data is collected from the subjects in both groups.
271132|NCT02347748|Behavioral|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
271133|NCT02350140|Other|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
271134|NCT02350166|Procedure|laparoscopic surgery|laparoscopic-assisted small-incision surgery
271434|NCT02343367|Behavioral|Text messages|regularly scheduled cell phone text messages for 12 months
271435|NCT02343367|Behavioral|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
271436|NCT02343367|Behavioral|Newsletters|12 monthly newsletters mailed to participant homes
271437|NCT02343380|Other|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
270842|NCT02316249|Drug|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
270843|NCT02316249|Other|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
270844|NCT02316262|Procedure|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves—after excision of end-neuromas—are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
270845|NCT02316275|Other|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
270846|NCT02316275|Other|Standard post-operative activity restriction|
270847|NCT02316288|Behavioral|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
270848|NCT02316288|Behavioral|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
270849|NCT00152984|Drug|Tiotropium inhalation capsules|
270850|NCT02316301|Drug|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
270851|NCT02316301|Drug|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
270852|NCT02316314|Procedure|Cardiac magnetic resonance imaging (CMR)|CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called "contrast" to get a better picture of the heart.
270563|NCT02323919|Behavioral|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
270564|NCT02323919|Behavioral|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
270565|NCT02323919|Behavioral|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
270566|NCT02323932|Behavioral|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
270567|NCT02323945|Other|AIH|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
270568|NCT02323945|Other|SHAM|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment on 5 consecutive days.
270569|NCT02323945|Other|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
270570|NCT02323945|Other|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
270571|NCT02323958|Other|acupoint stimulation|stimulation is given at acupoints
270572|NCT00153751|Other|placebo|placebo
270573|NCT02323958|Other|non-acupoint stimulation|stimulation is given at acupoints
270574|NCT02323958|Drug|Mannitol|mannitol is given at 1h before the end of surgery
270575|NCT02323958|Other|electrode attached|electrodes are attached to skin
270576|NCT02323958|Device|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
265033|NCT02384070|Drug|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
265034|NCT00161733|Drug|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
265035|NCT02384070|Drug|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
265036|NCT02384070|Drug|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
265037|NCT02384083|Drug|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
265038|NCT02384096|Device|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
265039|NCT02384096|Device|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
265343|NCT02379182|Device|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sesions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
265344|NCT02379182|Device|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sesions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
265345|NCT02379195|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
265346|NCT00161122|Biological|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
265347|NCT02379195|Drug|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
265348|NCT02379195|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
265349|NCT02379195|Drug|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
264727|NCT02391012|Biological|Fecal microbial l transplantation|infusion of preparation of fecal preparation from a healthy donor to a colitis patient
264728|NCT02391025|Procedure|Gallium-68 citrate PET|
264729|NCT00162656|Drug|LMB B|
264730|NCT02391038|Drug|MLN0264|MLN0264 IV.
264731|NCT02391051|Radiation|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
264732|NCT02391064|Behavioral|Cognitive evaluation|Questionnaires for assessment of confounding factors
Cognitive evaluation
Walking tests and 9 Hole Peg Test
264733|NCT02391064|Behavioral|Expanded Disability Status Scale (EDSS) score|- EDSS score
264734|NCT02391077|Other|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
264735|NCT02391077|Other|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
264736|NCT02391077|Other|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
264737|NCT02391090|Device|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
264738|NCT02391090|Device|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
264739|NCT02391090|Procedure|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
264740|NCT00162656|Drug|LMB C|
265040|NCT02384109|Behavioral|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
265041|NCT02384109|Other|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
265042|NCT02384122|Drug|Octreotide|Two injections of 20 mg will be given monthly.
265043|NCT02384135|Other|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
265044|NCT02384148|Other|Circadian rhythm measurement|
265045|NCT00161733|Drug|TISSEEL VH fibrin sealant|
264431|NCT02357537|Behavioral|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
264432|NCT02357550|Drug|ketone|3-OHB is infused intravenously.
264433|NCT02357550|Drug|placebo|Saline infusion.
264434|NCT02357563|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
264435|NCT02357563|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
264436|NCT02357576|Drug|Intralipid 20% I.V. Fat Emulsion|
264437|NCT02357589|Procedure|2D laparoscopic cholecystectomy|
264438|NCT00158652|Drug|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
264439|NCT02359656|Procedure|surgical treatment|C1-C1 arthrodesis
264440|NCT02359656|Other|non operative treatment for odontoid non unions|specific non operative treatment protocol
264441|NCT02359669|Behavioral|StimuLearn Intervention|StimuLearn apps
Cognitive questionnaires
264442|NCT02359669|Behavioral|Without StimuLearn intervention|Cognitive Questionnaires
264443|NCT02359682|Other|No intervention|No Intervention
264444|NCT02359695|Drug|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
264445|NCT02359708|Procedure|Surgical hand disinfection.|Bacterial recolonization
264446|NCT02359721|Drug|tablet clarithromycin 500 mg (Clarino-500) orally|orally
264447|NCT00158873|Drug|morphine|
264448|NCT02359734|Other|Intervention bundle for improving smart pump practice|The safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
264449|NCT02359734|Device|smart pump|
264450|NCT02359747|Genetic|Polymerase Chain Reaction and Whole Genome Amplification|
268805|NCT02325557|Drug|ADXS31-142|starting at 1x10^9 cfu IV
268806|NCT02325557|Drug|ADXS31-142 + Pembrolizumab (MK-3475)|starting at dose from Part A + 200mg of Pembrolizumab
268807|NCT02325570|Device|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
268808|NCT02325570|Procedure|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
268809|NCT02325583|Drug|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
268810|NCT02325583|Drug|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
268811|NCT02325596|Genetic|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
268812|NCT02325635|Other|Educational Training|Intervention/Training offered to endoscopists only.
269108|NCT02318225|Drug|Placebo|Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
269109|NCT02318238|Other|6 minutes walking test|
269110|NCT00153075|Device|Berodual HFA-MDI|
269111|NCT02318238|Other|6 minutes step test|
269112|NCT02318238|Other|4 meters gait speed|
269113|NCT02318251|Other|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
269114|NCT02318251|Other|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
269115|NCT02318264|Device|Kinesio Tape|Elastic tape placed over the skin
269116|NCT02318277|Drug|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
269117|NCT02318277|Drug|INCB024360|INCB024360: Oral daily dosing
268480|NCT02371512|Device|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
268481|NCT02371512|Procedure|Reconstructive mitral valve surgery|Reconstructive mitral valve surgery will be performed according to routine clinical practice
268482|NCT02332798|Drug|Placebo|Oral capsule, placebo, twice a day dosing for 14 days
268483|NCT02332798|Drug|PF-04958242|Oral capsule, 0.35 mg, twice a day dosing for 14 days
268484|NCT02332798|Drug|Placebo|Oral capsule, placebo, twice a day dosing for 14 days
268485|NCT02332811|Drug|sevelamer carbonate 800mg|Pharmaceutical form:tablet
Route of administration: oral
268486|NCT02332811|Drug|sevelamer carbonate 2.4 g|Pharmaceutical form:powder
Route of administration: oral
268487|NCT02332824|Drug|TAK-272 tablets|
268488|NCT00154817|Procedure|radiotherapy|
268489|NCT02332824|Drug|Placebo tablets|
268490|NCT02332824|Drug|Candesartan cilexetil tablets|
268491|NCT02332837|Behavioral|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
268492|NCT02332837|Behavioral|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
268493|NCT02332837|Behavioral|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
268494|NCT02332850|Drug|SAR650984|
268813|NCT02325648|Drug|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
268814|NCT00153959|Behavioral|acute psychiatric day care|
268815|NCT02325661|Other|cognitive interviewing|For the individual cognitive interviews we are using the two techniques "to think aloud" and the "verbal probing". "To think aloud" means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the "verbal probing" technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation.
268179|NCT00160966|Drug|Tacr + MMF|according to Giessen protocol
268180|NCT02378155|Device|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
268181|NCT02378168|Other|no intervention; retrospective study|
268182|NCT02378181|Behavioral|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
268183|NCT02378181|Behavioral|Treatment-as usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
268184|NCT02378194|Drug|Placebo|24 weeks, once daily oral administration
268185|NCT02378194|Drug|HD-003 (800mg/day)|24 weeks, once daily oral administration
268186|NCT02378194|Drug|HD-003 (1600mg/day)|24 weeks, once daily oral administration
268187|NCT02378207|Biological|H4:IC31|
268188|NCT02380469|Behavioral|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
268189|NCT02380482|Other|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
268190|NCT02380482|Other|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
268191|NCT02380495|Other|Data Collection|
268192|NCT02380508|Drug|BCG SSI|Intradermal injection
268193|NCT02380508|Other|No vaccination|
268194|NCT02380508|Drug|BCG Sii|intradermal injection
268495|NCT02332850|Drug|Carfilzomib|
268496|NCT02332863|Device|Back-loaded Needle (Device)|Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:
total length of procedure
how many markers are successfully deployed
technical success
Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation.
267862|NCT02385227|Other|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
267863|NCT02385227|Other|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
267864|NCT02385227|Other|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
267865|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
267866|NCT00161902|Drug|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
267867|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
267868|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
267869|NCT02385227|Other|Nicotine product cessation C|Nicotine cessation
267870|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
267871|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Reference)|
267872|NCT02385240|Drug|Placebo gel|
267873|NCT02385253|Behavioral|Educational training program|The educational training program (intervention) consists of four sequential phases:
Knowledge Acquisition
Skills Assessment
Deliberate Practice
Clinical Proficiency
267874|NCT02385266|Drug|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
267875|NCT02385266|Drug|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
267876|NCT02385279|Device|MiStent|Percutaneous Coronary Intervention
267877|NCT00161915|Drug|Fibrin Sealant|
267878|NCT02387671|Behavioral|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
267879|NCT02387671|Behavioral|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
267880|NCT02387671|Behavioral|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
267583|NCT02392377|Procedure|Therapeutic Conventional Surgery|Undergo esophagectomy
267584|NCT02392377|Other|Laboratory Biomarker Analysis|Correlative studies
267585|NCT02392390|Procedure|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
267586|NCT02392390|Drug|Metvixia cream|
267587|NCT02392403|Device|Nucleus CI532 cochlear implant|
267881|NCT02387671|Behavioral|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue & dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
267882|NCT02387697|Device|Edwards Sapien XT Valve|The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
267883|NCT02387710|Drug|Tiagabine|GABA reuptake inhibitor
267884|NCT02387710|Drug|Placebo|Placebo comparator
267885|NCT02387723|Biological|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
267886|NCT02387736|Behavioral|Dialectical Behaviour Therapy (6 months)|Modification of behaviours achieved with reframing thoughts and impulses
267887|NCT00162240|Drug|Muraglitazar|
267888|NCT02387736|Behavioral|Dialectical Behaviour Therapy (12 months)|Modification of behaviours achieved with reframing thoughts and impulses
267889|NCT02387749|Genetic|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
267890|NCT02387762|Drug|ACP-196|
267891|NCT02387762|Drug|Placebo|
267892|NCT02387762|Drug|Methotrexate|
273254|NCT02344251|Device|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
273255|NCT02344251|Dietary Supplement|Riboflavin|50 mg
273256|NCT02344264|Drug|Ropivacaine|Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).
Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.
273257|NCT02344264|Drug|Saline|Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).
Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.
273258|NCT02346084|Drug|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.
Each treatment regimen will be followed by a washout period of 14 to 21 days.
Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling).
273259|NCT02346097|Device|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to ""Arm descriptions"
273260|NCT02346110|Drug|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
273261|NCT02346110|Drug|Dexamethasone|4 mg
273262|NCT02346110|Other|Sodium chloride|1 mL of sodium chloride solution as placebo
273263|NCT00157300|Drug|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
273577|NCT00156351|Behavioral|Physical activity promotion|
273578|NCT02339701|Radiation|IMRT|
273579|NCT02339701|Radiation|SBRT|
273580|NCT02339714|Device|acupuncture combined moxibustion|Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).
Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether.
273581|NCT02339714|Drug|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
273582|NCT02339727|Dietary Supplement|Preterm infants formula|The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
273583|NCT02339740|Drug|Arsenic Trioxide|Given IV
272928|NCT02351115|Drug|Staccato® Alprazolam, 2 mg|
272929|NCT02351115|Drug|Staccato® Placebo (a)|
272930|NCT02351115|Drug|Staccato® Placebo (b)|
272931|NCT02351128|Drug|Lanreotide|
272932|NCT02351141|Other|Hyperpolarized Noble Gas MRI|Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.
Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
272933|NCT00158093|Drug|Atenolol|
272934|NCT02351154|Other|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
272935|NCT02351167|Drug|Combination NRT (Nicotine patch, Nicotine lozenge)|
272936|NCT02351167|Drug|Varenicline|
272937|NCT02353390|Other|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
272938|NCT02353403|Other|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
272939|NCT02353403|Other|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
272940|NCT02353416|Behavioral|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
272941|NCT02353416|Other|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
272942|NCT02353429|Drug|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
272943|NCT02353442|Procedure|Posterior shoulder mobilizations|The subjects will be randomized to Experimental or control group.
272944|NCT02353455|Procedure|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
273264|NCT02346123|Genetic|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
273265|NCT02346136|Behavioral|Tai Chi training|
272639|NCT02319785|Behavioral|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
272640|NCT02319785|Behavioral|Unilateral RAT|This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.
The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System.
272641|NCT02319785|Behavioral|Bilateral RAT|This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.
The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
272642|NCT00153257|Device|Ugytex|
272643|NCT02319785|Behavioral|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
272644|NCT02319798|Other|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
272645|NCT02319798|Other|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
272646|NCT02319811|Procedure|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
272647|NCT02319824|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
272648|NCT02319824|Other|Laboratory Biomarker Analysis|Correlative studies
272649|NCT02319824|Radiation|Palliative Radiation Therapy|Undergo palliative radiation therapy
272650|NCT02322307|Other|HealthPROMISE users|Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.
Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings.
272651|NCT02322307|Other|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
272652|NCT02322320|Drug|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
272060|NCT02331875|Drug|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
272061|NCT02331875|Procedure|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
272062|NCT02331875|Radiation|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
272063|NCT00002399|Drug|Fluconazole|
272064|NCT00154713|Biological|CEA pulsed dendritic cells|
272065|NCT02334124|Other|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
272356|NCT02327338|Device|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
272357|NCT02327338|Drug|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
272358|NCT02327351|Other|Biological: TCR alfa beta T cell depletion|
272359|NCT00154102|Drug|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops
272360|NCT02327377|Behavioral|Online Cognitive Behavior Therapy|
272361|NCT02327377|Behavioral|Online Education|
272362|NCT02327390|Procedure|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
272363|NCT02327390|Biological|X-ACT|Administered as an IV infusion
272364|NCT02327403|Drug|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
272365|NCT02327416|Drug|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
272366|NCT02327416|Drug|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
272367|NCT02327416|Drug|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
271754|NCT02338999|Drug|Pioglitazone|Increases insulin sensitivity in muscle.
271755|NCT02338999|Procedure|Vascular function studies|Non-invasive
271756|NCT02339038|Drug|Ledipasvir and Sofosbuvir Combined|Lepipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination a per treatment guidelines
271757|NCT02339051|Behavioral|Jumping on one leg|
271758|NCT02339064|Drug|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
271759|NCT02339090|Drug|somavaratan|long acting growth hormone therapy
271760|NCT02339090|Drug|Daily rhGH|daily growth hormone therapy
271761|NCT02339103|Other|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
271762|NCT02339103|Other|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
271763|NCT00156286|Drug|Gleevec|
271764|NCT02339116|Drug|fluoruracil|
272066|NCT02334124|Other|Ward|Admission to a hospital based ward
272067|NCT02334124|Drug|ceftriaxone|50mg/kg once daily
272068|NCT02334124|Drug|flucloxacillin|50mg/kg 6 hourly
272069|NCT02334137|Behavioral|iPad app|Provided by the Patient Education Institute, the "X-plain" iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others.
272070|NCT02334137|Behavioral|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
272071|NCT02334137|Behavioral|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
272072|NCT02334150|Drug|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
272073|NCT02334163|Drug|Nitazoxanide|500 mg nitazoxanide tablets twice daily
272074|NCT00155363|Device|conventional artificial kidney (AK) vs. high flux AK|
271438|NCT02343393|Drug|Hydralazine|
271439|NCT02343393|Drug|Isosorbide Dinitrate|
271440|NCT00156923|Drug|Medisorb naltrexone 190 mg|Administered via IM injection once every 4 weeks for up to 3.5 years.
271441|NCT02343406|Drug|ABT-414|ABT-414 will be administered by intravenous infusion over approximately 30-40 minutes.
271442|NCT02343406|Drug|Lomustine|Lomustine will be administered orally.
271443|NCT02343406|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally.
271444|NCT02343419|Other|Methacholine Challenge Test|Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.
In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes.
271445|NCT02343432|Drug|Triamcinolone|Triamcinolone
271446|NCT02343432|Drug|Epidural Volume|Epidural Volume
271447|NCT02343432|Drug|Bupivacaine|Bupivacaine
271448|NCT02343445|Drug|P-1037|P-1037 is a novel ENaC inhibitor
271449|NCT02343445|Drug|Hypertonic Saline|4.2% saline solution
271450|NCT02343445|Drug|Saline|0.17% saline solution
271451|NCT00156936|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
271452|NCT02343458|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
271453|NCT02343458|Drug|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
271765|NCT02341222|Device|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
271135|NCT02350179|Drug|Tranexamic Acid|This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.
The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.
Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
271136|NCT02350179|Drug|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
271137|NCT02350192|Behavioral|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
271138|NCT02350205|Biological|Self assembled skin substitute (SASS)|Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.
271139|NCT02350205|Procedure|Split-thickness autograft|Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.
271140|NCT02350218|Drug|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
271141|NCT00157950|Biological|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
271142|NCT02350231|Drug|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
271143|NCT02350231|Drug|Tonics group|Those patients will receive only tonics
271144|NCT02350244|Behavioral|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
271145|NCT02350257|Behavioral|Internet-based CBT|12 weeks of internet-based CBT
271146|NCT02350270|Other|gait and cognitive testing|
271147|NCT02350283|Device|Interventional treatment with Solitaire|Interventional treatment with Solitaire: The first group will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
271148|NCT02350283|Other|Standard Medical Management|Standard Medical Management:Treated with standard medical management.
271149|NCT02350296|Drug|KSL 40 mg|Ketoprofen lysine salt oral immediate release tablets 40 mg
271150|NCT02350296|Drug|OKi® 80 mg|Ketoprofen lysine salt granules for oral solution 40 mg (half of a bipartite sachet)
271151|NCT02350309|Drug|E2006 5 mg|E2006 5 mg tablet
270577|NCT02323971|Drug|Ticagrelor|
270853|NCT02316314|Procedure|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
270854|NCT02316314|Procedure|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
270855|NCT02318979|Device|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
270856|NCT02318992|Biological|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
270857|NCT02319005|Drug|Revusiran (ALN-TTRSC)|
270858|NCT02319005|Drug|Sterile Normal Saline (0.9% NaCl)|
270859|NCT02319018|Drug|Alisertib|Given PO
270860|NCT02319018|Drug|Fluorouracil|Given IV
270861|NCT02319018|Other|Laboratory Biomarker Analysis|Correlative studies
270862|NCT02319018|Drug|Leucovorin Calcium|Given IV
270863|NCT02319018|Drug|Oxaliplatin|Given IV
270864|NCT02319031|Drug|Daclatasvir|
270865|NCT00153166|Drug|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
270866|NCT02319031|Drug|Sofosbuvir|
270867|NCT02319031|Drug|Ribavirin|
270868|NCT02319044|Drug|MEDI4736|MEDI4736 monotherapy
270869|NCT02319044|Drug|Tremelimumab|Tremelimumab monotherapy
270870|NCT02319044|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
270871|NCT02319057|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
270872|NCT02319057|Drug|ORM-12741 IR|Immediate release formulation of ORM-12741
270873|NCT02319057|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
265350|NCT02379195|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
265351|NCT02379221|Drug|lidocaine-epinephrine|2% lidocaine 1:100k epinephrine nerve block injection
265352|NCT02379221|Drug|Topicaine gel|4% Topicaine gel
265353|NCT02379234|Other|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
265354|NCT02379247|Drug|BYL719|Oral PI3K inhibitor
265355|NCT02379247|Drug|Nab-paclitaxel|IV taxane
265356|NCT02379260|Other|Interview with a sociologist|
265357|NCT00161148|Drug|Probiotics|
265358|NCT02379273|Device|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
265359|NCT02379286|Other|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
265658|NCT02374567|Drug|Doxepin|
265659|NCT02374567|Drug|Maprotiline|
265660|NCT02374567|Drug|Amitriptyline oxide|
265661|NCT02374567|Drug|Fluoxetine|
265662|NCT02374567|Drug|Citalopram|
265663|NCT02374567|Drug|Paroxetine|
265664|NCT02374567|Drug|Sertraline|
265665|NCT02374567|Drug|Fluvoxamine|
265666|NCT00002423|Drug|Abacavir sulfate|
265667|NCT00160485|Drug|Glyburide|dosage required to obtain adequate glucose control
265668|NCT02374567|Drug|Escitalopram|
265669|NCT02374567|Drug|Tranylcypromine|
265670|NCT02374567|Drug|Moclobemide|
265046|NCT02384148|Procedure|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
265047|NCT02384161|Other|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
265048|NCT02384174|Dietary Supplement|Resistant starch|
265049|NCT02386592|Behavioral|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
265050|NCT02386592|Behavioral|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
265051|NCT02386592|Other|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
265052|NCT02386605|Behavioral|Motivational Interviewing|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
265053|NCT02386605|Behavioral|Relaxation Skills|Relaxation skills training group for comparison condition for negative symptoms of schizophrenia
265054|NCT02386618|Procedure|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN < 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN > 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN > 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
265055|NCT02386631|Device|Custom Made Orthotic|Provides longitudinal arch support
265056|NCT02386644|Other|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
265057|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
265360|NCT02379299|Device|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
265361|NCT02379299|Device|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
265362|NCT02379312|Dietary Supplement|Very low energy aerated beverage|
265363|NCT02381639|Behavioral|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
264451|NCT02359760|Procedure|Piezocision|Flapless corticotomies
264741|NCT02391090|Other|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
264742|NCT02391090|Procedure|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
264743|NCT02391090|Procedure|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
264744|NCT02391090|Procedure|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
264745|NCT02391103|Device|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
264746|NCT02391103|Device|sham-stimulation|no electricity applied
264747|NCT02391116|Drug|BAY 80-6946 / Copanlisib|Starting dose: 60 mg (Dose reduction due to toxicities to 45 mg is allowed.), will be administered as a slow bolus IV injection on Days 1, 8 and 15 of each 28-day treatment cycle till patient disease progression is observed or patient withdraw treatment for any reason
264748|NCT02391129|Procedure|Operation for Periprosthetic fractures of the hip with stem loosening|
264749|NCT02391142|Drug|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
264750|NCT02391155|Procedure|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
264751|NCT02354872|Behavioral|5Rs Motivation Counseling|The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
264752|NCT02354872|Behavioral|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
264753|NCT02354872|Other|No Treatment|No Treatment
264754|NCT00158431|Other|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
269118|NCT02318290|Drug|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
269119|NCT02318303|Drug|GSP 301-1 NS|
269120|NCT02318303|Drug|GSP 301-2 NS|
269121|NCT00153088|Drug|Telmisartan capsule 40 mg|
269122|NCT02318303|Drug|Placebo nasal spray|
269123|NCT02318303|Drug|Olopatadine hydrochloride NS-1|
269124|NCT02318303|Drug|Olopatadine hydrochloride NS-2|
269125|NCT02318303|Drug|Mometasone furoate NS-1|
269126|NCT02320682|Device|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
269127|NCT02320695|Drug|Saline|
269128|NCT02320695|Drug|Isopropyl Alcohol|
264452|NCT02359799|Device|Intelligent Stretcher|The impaired ankle of the participants are trained 3 sessions a week for 6 weeks in lab/at home. The participants use the portable robot in passive mode to increase range of motion (ROM), then subjects use their gained ROM immediately in the active movement to train their impaired ankle in controlling game play and improve motor control.
264453|NCT02359825|Drug|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
264454|NCT02359838|Other|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
264455|NCT02359838|Other|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
264456|NCT02359851|Biological|Pembrolizumab|Given IV
264457|NCT02359851|Other|Laboratory Biomarker Analysis|Correlative studies
264458|NCT00002415|Drug|Tenofovir disoproxil fumarate|
264459|NCT00158873|Drug|remifentanil|
264460|NCT02359877|Drug|BCD-054|
268816|NCT02325687|Procedure|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
268817|NCT02325700|Procedure|Aortic repair|Aortic bypass
268818|NCT02325713|Drug|ODT-PZQ|ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal
268819|NCT02325713|Drug|Cysticide|Cysticide tablet at a single dose of 40 mg/kg given with water orally after a meal
268820|NCT02325713|Drug|ODT-PZQ|ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal
268821|NCT02325713|Drug|ODT-PZQ|ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal
268822|NCT02325713|Drug|ODT-PZQ|ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal
268823|NCT00154180|Drug|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
268824|NCT02328300|Drug|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
268825|NCT02328313|Behavioral|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
268826|NCT02328326|Other|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
268827|NCT02328326|Other|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
268828|NCT02328339|Other|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
269129|NCT02320695|Drug|Pain Relieving Cream|
269130|NCT02320695|Drug|Antibiotic/Pain Relieving Ointment|
269131|NCT00153400|Behavioral|Women's health|
269132|NCT02320695|Drug|Original Ointment|
269133|NCT02320695|Drug|Pain Relief Ointment|
269134|NCT02320708|Drug|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
268497|NCT02332863|Device|Preloaded Needle (Device)|Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:
total length of procedure
how many markers are successfully deployed
technical success
Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation.
268498|NCT02332876|Behavioral|Exercise|
268499|NCT00154830|Behavioral|cerebral palsy|
268500|NCT02332876|Behavioral|Control|
268501|NCT02332889|Biological|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be > 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
268502|NCT02332889|Drug|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
268503|NCT02332902|Drug|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
268504|NCT02332915|Behavioral|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
268505|NCT02332928|Drug|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
268506|NCT02335008|Dietary Supplement|Sucrose|equisweet to sucralose
268507|NCT02335021|Dietary Supplement|Sucralose|2 packets per 12 fl oz
268508|NCT02335021|Dietary Supplement|Sucrose|equisweet to sucralose
268509|NCT00155493|Procedure|obtain surgical specimen for analysis|
268510|NCT02335021|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
268511|NCT02335034|Behavioral|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
268512|NCT02335034|Behavioral|Control Group only make evaluations / consultations with all professional teams|Evaluations and consultations with all professional teams without classes for 2 years.
At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years.
268829|NCT02328339|Other|Placebo|Placebo matched to tea with respect to taste and appearance
268195|NCT02380521|Drug|Exenatide once weekly (BYDUREON™)|Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.
Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.
Subjects will follow a fixed dose of 2 mg
268196|NCT02380534|Procedure|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
268197|NCT02380547|Other|Sonographic diaphragmatic measurements|
268198|NCT00161330|Drug|iv ceftriaxone|
268199|NCT02380560|Device|Ultrasonographic examination|An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:
a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.
(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker.
268200|NCT02380573|Drug|Methylene Blue|
268201|NCT02380573|Drug|FD&C Blue # 2|
268202|NCT02380573|Drug|Phenazopyridine hydrochloride|
268203|NCT02380586|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
268204|NCT02380599|Other|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
268205|NCT02380599|Other|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
268206|NCT02380599|Other|Sham Ultrasound|Sham ultrasound to T3-5 region
268207|NCT02380612|Device|ReCell Treatment|
268208|NCT02380612|Procedure|Skin Graft|
268209|NCT00161343|Behavioral|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
268210|NCT02382861|Device|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
268211|NCT02382874|Biological|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
267893|NCT02387775|Device|Esophageal temperature control|Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.
All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit.
267894|NCT02387788|Drug|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
267895|NCT02387801|Drug|Ixekizumab|Administered SC
267896|NCT02387814|Drug|Abemaciclib|Administered Orally
267897|NCT02387827|Behavioral|Diet+ short term versus long -term physical activity|
267898|NCT00002429|Drug|Stavudine|
268214|NCT02382887|Device|Airtraq|
268215|NCT02382887|Device|fiberscope|
268216|NCT02382900|Biological|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
268217|NCT02382913|Biological|aP booster|Acellular pertussis vaccine:
Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
268218|NCT02382913|Biological|TdaP booster|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
Other: Saline solution Subjects received one injection of saline solution at one month after vaccination.
268219|NCT02382913|Biological|Licensed TdaP booster (Boostrix®)|Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
Other: Saline solution Subjects received one injection of saline solution at one month after vaccination.
268220|NCT02382926|Other|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
268221|NCT02382939|Drug|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
268222|NCT02382939|Drug|somatropin|Administered subcutaneously (s.c., under the skin) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
268223|NCT00161577|Other|Placebo|Placebo Comparator
273584|NCT02339740|Drug|Cytarabine|Given IV
273585|NCT02339740|Drug|Dexamethasone|Given PO or IV
273586|NCT02339740|Drug|Idarubicin|Given IV
273587|NCT02339740|Other|Laboratory Biomarker Analysis|Correlative studies
273588|NCT00156377|Drug|Mupirocin|
273589|NCT02339740|Drug|Mitoxantrone Hydrochloride|Given IV
273590|NCT02339740|Other|Questionnaire Administration|Ancillary studies
273591|NCT02339740|Drug|Tretinoin|Given PO
273592|NCT02339753|Drug|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
273593|NCT02339766|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
273594|NCT02342002|Drug|Mifepristone|Mifepristone for treatment of missed abortion
273595|NCT02342002|Drug|Misoprostol|Misoprostol for treatment of missed abortion
273596|NCT02342015|Drug|Atorvastatin|Atorvastatina 40mg/day for three months
273597|NCT00156715|Drug|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
273889|NCT02334865|Drug|Lenalidomide|Given PO
273890|NCT02334865|Biological|Sargramostim|Given SC
273891|NCT02334865|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
273892|NCT02334878|Biological|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
273893|NCT02334878|Procedure|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra & through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted & the remaining tape cut off at the level of the skin.
273266|NCT02346136|Behavioral|Educational Control|
273267|NCT02346149|Other|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
273268|NCT02346149|Device|Bold-MRI|performance of a renal MRI in both groups
273269|NCT02346162|Behavioral|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI </=25, and when pregnant, weight gain within IOM guidelines.
273270|NCT02346162|Other|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
273271|NCT02346175|Drug|SHR3824|
273272|NCT02346175|Drug|Placebo|
273273|NCT02346188|Dietary Supplement|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
273274|NCT00157313|Behavioral|Integrated treatment, family involvement|
273275|NCT02346188|Dietary Supplement|Zinc oxide|Tablet formulated from 30 mg zinc oxide
273276|NCT02346188|Dietary Supplement|Placebo|
273277|NCT02346201|Drug|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
273278|NCT02346201|Drug|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
273279|NCT02346227|Drug|AV2|The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).
It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution.
273280|NCT02346227|Drug|Placebo|The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.
It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix.
273281|NCT02348515|Procedure|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
273282|NCT02348515|Procedure|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
273283|NCT02348515|Procedure|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
273284|NCT02348528|Drug|Lenalidomide|
273285|NCT02348528|Drug|Dexamethasone|
272653|NCT02322333|Drug|MLD10|
272654|NCT02322333|Drug|Placebo|
272945|NCT00158327|Behavioral|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
272946|NCT02353468|Drug|Bortezomib|Given IV
272947|NCT02353468|Drug|Lenalidomide|Given PO
272948|NCT02353468|Drug|Dexamethasone|Given PO or IV
272949|NCT02353481|Other|Heart Failure Management|
272950|NCT02353494|Drug|Dihydroartemisinin-Piperaquine|Treatment according to national guidelines with follow up.
272951|NCT02353507|Device|Opticell Ag+|
272952|NCT02353507|Device|Aquacel Ag+|
272953|NCT02353520|Other|motricity index strength assessment|
272954|NCT02353533|Device|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
272955|NCT02353533|Device|EMR|Standard endoscopic mucosal resection using a resection snare
272956|NCT00158327|Behavioral|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
272957|NCT02353546|Behavioral|CALM|
272958|NCT02353559|Behavioral|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
272959|NCT02353572|Drug|Melphalan|Given IV
272960|NCT02317302|Device|FDG-PET/CT|
272961|NCT02317341|Drug|Ketamine|Single intravenous dose
272962|NCT02317341|Drug|Placebo (saline)|Given intravenously over 40 minutes
272963|NCT02317341|Drug|Ketamine|Single intravenous dose given over 40 minutes
272368|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
272369|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
272370|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
272371|NCT00002398|Drug|Levocarnitine|
272372|NCT00154323|Drug|Oxcarbazepine|
272373|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
272655|NCT02322346|Other|Group S|Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.
During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
272656|NCT02322346|Drug|Group LL|Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.
During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
272657|NCT02322346|Drug|Group HL|Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.
During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
272658|NCT02322372|Drug|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
272659|NCT00153634|Drug|PO azithromycin|250 mg once daily
272660|NCT02322372|Drug|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
272661|NCT02322398|Drug|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
272075|NCT02334163|Drug|Oral lactulose|Oral lactulose (65%)
272076|NCT02334163|Drug|Metronidazole|250 mg metronidazole tablets every 8 hours
272077|NCT02334163|Drug|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
272078|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
272079|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
272080|NCT02334176|Drug|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
272081|NCT02334189|Behavioral|Letter|Patients receive an information letter following an avoidable visit to the Emergency Department.
272082|NCT02334202|Behavioral|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
272374|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
272375|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
272376|NCT02329743|Drug|RX-10045|topical therapy
272377|NCT02329756|Drug|Tranexamic Acid|
272378|NCT02329756|Drug|Sodium Chloride 0.9%|
272379|NCT02329769|Drug|PRO044 SC 6 mg/kg|
272380|NCT02329769|Drug|PRO044 IV 6 mg/kg|
272381|NCT02329769|Drug|PRO044 IV 9 mg/kg|
271766|NCT02341235|Behavioral|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
271767|NCT02341235|Behavioral|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
271768|NCT02341248|Other|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
271769|NCT02341261|Behavioral|Standard Care Counseling|
271770|NCT02341261|Behavioral|Supervised Exercise and Counseling|
271771|NCT02341274|Drug|Tacrolimus|Bioequivalence study
271772|NCT02341287|Device|Warming hydrogel device|
271773|NCT02341287|Device|Non thermal hydrogel device|
271774|NCT00156650|Drug|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
271775|NCT02341300|Device|Cast Iron Pot|Cast iron pot
271776|NCT02341339|Procedure|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
271777|NCT02341352|Drug|fluoride varnish|Sodium fluoride 50mg/ml
271778|NCT02341352|Biological|Immunoglobulin Yolk|anti—Streptococcus mutans IgY
271779|NCT02341352|Dietary Supplement|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
271780|NCT02341365|Other|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
271781|NCT02341378|Biological|TissueGene-C(Low dose)|TissueGene-C at 6.0x10^6 cells
271782|NCT02341378|Biological|TissueGene-C(High dose)|TissueGene-C at 1.8x10^7 cells
271783|NCT02341391|Biological|TissueGene-C(Low dose)|3.0 x 10^6 cells
271784|NCT02341391|Biological|TissueGene-C(Medium dose)|1.0 x 10^6 cells
271785|NCT00156650|Drug|Depo-Medroxyprogesterone|300 mg IM every 3 months
272083|NCT00156026|Procedure|loop electrosurgical excision procedure (LEEP)|1. loop electrosurgical excision procedure
271152|NCT00157963|Drug|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
271454|NCT02345525|Behavioral|hCIMT|This intervention is based on 3 main aspects:
intensive training of functional tasks with the affected arm (massed practice)
constraint of the un-affected hand through a mitt
shaping techniques designed to transfer gains to the real world activities
In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.
In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week).
271455|NCT02345551|Behavioral|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
271456|NCT02345564|Device|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
271457|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
271458|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
271459|NCT02345590|Drug|Eplerenone|25mg of eplerenone
271460|NCT02345603|Procedure|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
271461|NCT02345616|Drug|Nitric oxide|
271462|NCT02345629|Procedure|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
271463|NCT02345629|Behavioral|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
271464|NCT00157235|Drug|Tiotropium bromide|
271465|NCT02345629|Procedure|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
271466|NCT02345629|Procedure|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
271467|NCT02345642|Device|ActiveCare+SFT Supine|
271468|NCT02345642|Device|VenaFlow Elite Supine|
271469|NCT02345642|Device|ActiveCare+SFT Standing|
270874|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
270875|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
270876|NCT00153166|Drug|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
271153|NCT02350309|Drug|E2006 10 mg|E2006 10 mg tablet
271154|NCT00158249|Drug|placebo|matched for physical appearance
271155|NCT02352597|Drug|estradiol valerate|2mg from cycle day 7 to day 11
271156|NCT02352597|Drug|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
271157|NCT02352610|Procedure|LRTI|
271158|NCT02352610|Device|Biotenodesis Screw|
271159|NCT02352623|Radiation|DXA scan|DXA scan
271160|NCT02352623|Procedure|Clinical examination|Clinical examination
271161|NCT02352636|Other|magnetotherapy|The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
271162|NCT02352636|Device|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
271163|NCT02352636|Other|Placebo|Subjects will serve as a placebo control, and will receive LAT at "power off" mode (i.e. deactivated laser) for acupoint "stimulation" before the application of plaster without magnetic pellets that mimic MAT treatment.
271164|NCT02352649|Drug|Neovasculgen|
271165|NCT00158262|Drug|Propranolol|long-acting 240 mg/day
271166|NCT02352662|Other|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
271167|NCT02352675|Other|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
271168|NCT02352688|Procedure|Enhanced Colorectal Geriatric Care|
271169|NCT02352701|Drug|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
265671|NCT02374567|Drug|Mianserin|
265672|NCT02374567|Drug|Trazodone|
265673|NCT02374567|Drug|Mirtazapine|
265674|NCT02374567|Drug|Bupropion|
265675|NCT02374567|Drug|Venlafaxine|
265676|NCT02374567|Drug|Reboxetine|
265677|NCT02374567|Drug|Duloxetine|
265678|NCT00160485|Drug|Insulin|variable dosage to obtain glucose control
265679|NCT02374567|Drug|Agomelatine|
265680|NCT02374567|Drug|Pyritinol|
265681|NCT02374567|Drug|Piracetam|
265682|NCT02374567|Drug|Donepezil|
265683|NCT02374567|Drug|Rivastigmine|
265684|NCT02374567|Drug|Galantamine|
265685|NCT02374567|Drug|Memantine|
265686|NCT02374567|Drug|Nicergoline|
265687|NCT02374567|Drug|Acamprosate|
265957|NCT02367794|Drug|Carboplatin|Area under the concentration curve (AUC) 6 on Day 1 of each 21-day cycle for 4 to 6 cycles
265958|NCT02367794|Drug|Nab-paclitaxel|100 mg/m^2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 to 6 cycles
265959|NCT02367794|Drug|Paclitaxel|200 mg/m^2 on Day 1 of each 21-day cycle for 4 or 6 cycles
265960|NCT02367807|Drug|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
265961|NCT02367820|Drug|NKTR-181|
265962|NCT02367833|Drug|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
265364|NCT02381652|Device|Cingal®|Injection into the knee
265365|NCT02381665|Device|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
265366|NCT02381665|Device|Flexstim IF faked|Patient enrolled will receive a sham device.
265367|NCT02381691|Other|maternal breast milk odor|
265368|NCT02381691|Other|no odor|
265369|NCT02381717|Other|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
265370|NCT02381717|Drug|bupivacaine|
265371|NCT02381717|Drug|morphine|
265372|NCT02381730|Drug|Intravitreal aflibercept|Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
265373|NCT00161447|Drug|Testosterone Gel|Testosterone Gel (10 g daily
265374|NCT02381743|Behavioral|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
265375|NCT02381743|Behavioral|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
265376|NCT02381756|Device|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
265377|NCT02381769|Other|polymeric blenderized kitchen based liquid diet|
265378|NCT02381769|Other|soft/ solid diet|
265379|NCT02381795|Drug|Nasal Carbon Dioxide|
265380|NCT02381821|Other|ultrasound examination|All patients will undergo 3D transvaginal ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
265381|NCT02381834|Procedure|Bladder stimulation technique|
265688|NCT02374567|Drug|Lithium|
265689|NCT00160498|Drug|Lercanidipine|
265690|NCT02374593|Drug|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
265691|NCT02374593|Device|Ultrasound|
264755|NCT02354885|Drug|Tranexamic Acid|Coagulation Management / Efficiency
264756|NCT02354898|Drug|BBI503|
264757|NCT02354898|Drug|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
265058|NCT02386644|Device|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
265059|NCT02386644|Device|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
265060|NCT02386644|Other|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
265061|NCT02386644|Other|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
265062|NCT02386657|Other|Satisfaction|Satisfaction questionnaire to be filled in
265063|NCT02386657|Other|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
265064|NCT02386657|Other|Pain management|Validated pain scale questionnaire to be filled in
265065|NCT02386670|Other|tDCS + CR|First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).
tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. per session.
CR sessions will follow the tDCS session and last 2 hours in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. "Strategic monitoring and bridging discussions" will promote transfer of cognitive gains to everyday tasks.
265066|NCT02388815|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.
During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed.
265067|NCT02388828|Biological|lentiviral-based CART meso therapy|
265068|NCT02388841|Radiation|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
265069|NCT02388854|Genetic|Real Time- Polymerase Chain Reaction|Research of frequency of SNPs in women affected by endometriosis
265070|NCT02388867|Procedure|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
265071|NCT00162370|Drug|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
264461|NCT02359877|Drug|Rebif|
264462|NCT02359877|Drug|Avonex|
264463|NCT02359890|Device|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
264464|NCT02362360|Device|Coloplast Test Product|A new 2-piece ostomy appliance developed by Coloplast A/S
264465|NCT02362360|Device|Comparator (Hollister)|Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
264466|NCT02362373|Drug|levonorgestrel IUS|placement of levonorgestrel intrauterine system
264467|NCT00002417|Drug|Amprenavir|
264468|NCT00159250|Drug|AVI-4658 (PMO)|morpholino antisense oligonucleotide
264469|NCT02362386|Device|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
264470|NCT02362399|Drug|sildenafil citrate|single oral dose of 50 mg
264471|NCT02362399|Other|placebo|single oral dose of placebo tablet
264472|NCT02362412|Drug|FK949E|oral
264473|NCT02362425|Drug|N-acetylcysteine|
264758|NCT02354911|Biological|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (~10 million cells/injection).
264759|NCT02354911|Other|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
264760|NCT02354937|Drug|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
264761|NCT02354950|Drug|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
264762|NCT02354963|Procedure|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
264763|NCT02354976|Drug|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
264764|NCT02354976|Drug|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
269135|NCT02320708|Drug|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
269136|NCT02320708|Drug|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
269137|NCT02320708|Drug|Placebo|2 placebo caplets for acetaminophen taken orally one time
269138|NCT02320708|Drug|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
269139|NCT02320708|Drug|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
269140|NCT02320721|Drug|Insulin glargine U300 HOE901|Pharmaceutical form:solution for injection
Route of administration: subcutaneous
269141|NCT02320721|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection
Route of administration: subcutaneous
269142|NCT00153413|Behavioral|Women's health|
269143|NCT02320734|Drug|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
269144|NCT02320747|Other|Tai Chi|
269145|NCT02320760|Behavioral|Physical activity on prescription|
269146|NCT02320773|Drug|Betmiga®|Oral
269147|NCT02320786|Behavioral|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
269148|NCT02320799|Behavioral|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
269149|NCT02320799|Behavioral|treatment as usual|Clinic psychosocial treatment as usual
269150|NCT02320812|Biological|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
269151|NCT02320825|Radiation|single-fraction SRS|
264474|NCT02362438|Drug|Intrathecal Delivery of scAAV9/JeT-GAN|This is a non-randomized, phase I, single dose study to assess the safety of the gene transfer vector scAAV9/JeT-GAN through intrathecal delivery to the brain and spinal cord of patients with Giant Axonal Neuropathy (GAN, OMIM #256850).
264475|NCT02362451|Biological|Autologus elutriated monocyte placebo vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
264476|NCT02362451|Biological|ME TARP vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
268830|NCT02328352|Procedure|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
268831|NCT02328352|Procedure|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
268832|NCT02328352|Procedure|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
268833|NCT02328352|Procedure|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
268834|NCT00154180|Drug|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
268835|NCT02328365|Other|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
268836|NCT02328378|Procedure|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
268837|NCT02328404|Drug|50.000IU Vitamin D3|50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months
268838|NCT02328404|Drug|placebo|placebo coated tablet by oral route
268839|NCT02328417|Other|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
268840|NCT02328430|Device|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
268841|NCT02328443|Drug|Midazolam|
268842|NCT02328443|Drug|itraconazole|
268843|NCT02328443|Drug|rifampicin|
268844|NCT02330575|Behavioral|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
268845|NCT02330575|Behavioral|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
268212|NCT00161577|Drug|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
268213|NCT02382887|Procedure|tracheal intubation|tracheal intubation with the Airtraq
268513|NCT02335047|Other|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
268514|NCT02335060|Drug|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
268515|NCT02335060|Drug|N-acetylcysteine|A pill given orally.
268516|NCT02335060|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
268517|NCT02335060|Drug|Placebo|Placebo "sugar" pill given orally with no N-acetylcysteine.
268518|NCT02335073|Other|Venous blood|
268519|NCT02335099|Drug|ticagrelor|ticagrelor 90 mg twice a day for 6 months
268520|NCT00155532|Procedure|3 mm-punch biopsies of the skin|
268521|NCT02335099|Drug|Placebo|1 pill twice a day for 6 months
268522|NCT02335112|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
268523|NCT02335112|Device|NanoKnife|
268524|NCT02335125|Behavioral|Motivational Interviewing|
268525|NCT02335125|Behavioral|Cognitive Behavioral Therapy Elements|
268526|NCT02335125|Drug|Psychotropic Drugs|
268527|NCT02335125|Other|Care Management|
268528|NCT02335138|Behavioral|Couples Voluntary Counseling and Testing|Male couples randomized to the experimental group (Couples Voluntary Counseling and Testing) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
268529|NCT02335138|Behavioral|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
268530|NCT02335151|Drug|Desflurane|Apply desflurane as anesthetic
268224|NCT02382952|Device|Differential Dissector|
268225|NCT02382952|Other|Standard Dissection|
268226|NCT02382965|Device|transcranial focused ultrasound|
268227|NCT02382978|Other|nurse-provided well child visit|
268228|NCT02382991|Device|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
268229|NCT02382991|Device|NMPK-3C60|1 month with NMPK - 3 months with 3C60
268230|NCT02383004|Other|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
268231|NCT02385279|Device|XIENCE EES|Percutaneous Coronary Intervention
268534|NCT02337608|Drug|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
268535|NCT02337608|Drug|Placebo|placebo daily dosing in the morning daily for 12 weeks
268536|NCT02337621|Other|No intervention|
268537|NCT02337634|Drug|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
268538|NCT02337634|Drug|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
268539|NCT02337647|Other|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
268540|NCT00156104|Other|Placebo arm|
268541|NCT02337660|Procedure|Liver biopsy|One ultrasound guided liver biopsy
268542|NCT02337660|Other|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
268543|NCT02337686|Drug|Pembrolizumab|Up to 2 doses of 200 mg IV prior to surgery (Day -21 and Day -1, prior to the surgery on Day 0); continued after recovery from surgery (approximately 2-3 weeks) every 3 weeks until disease progression or development of unacceptable toxicities.
268544|NCT02337686|Procedure|Surgery|Routine care surgery (reoperation) performed Day 0 for tumor progression.
268545|NCT02337699|Device|Implantation with the commercially available Axium neurostimulator|
273894|NCT02334891|Other|Standard|Standard management
273895|NCT02334904|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
273896|NCT02334904|Drug|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
273897|NCT02334917|Procedure|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
273898|NCT02334930|Other|Biopsy|
273899|NCT00155480|Procedure|computed tomography|
273900|NCT02334943|Biological|Blood test|Blood test
273901|NCT02334956|Other|Brain MRI|
273902|NCT02334969|Drug|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
273903|NCT02334969|Drug|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
273904|NCT02334982|Drug|TAK-137|TAK-137 tablets
273905|NCT02334982|Drug|Placebo|TAK-137 placebo-matching tablets
273906|NCT02335008|Dietary Supplement|Sucralose|2 packets per 12 fl oz
273907|NCT02337413|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
273908|NCT02337413|Behavioral|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
273909|NCT02337426|Drug|Dimethyl Fumarate|Given PO
274194|NCT00002398|Drug|Adefovir dipivoxil|
274195|NCT00154440|Drug|proton pump inhibitor|
274196|NCT02330471|Procedure|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
274197|NCT02330471|Procedure|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
274198|NCT02330484|Behavioral|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
273598|NCT02342028|Biological|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
273599|NCT02342041|Drug|SUVN-G3031|
273600|NCT02342041|Drug|Placebo|
273601|NCT02342054|Radiation|MRI-TRUS fusion guided Single Frac HDR|
273602|NCT02342067|Drug|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
273603|NCT02342067|Drug|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
273604|NCT02342080|Other|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
273605|NCT02342080|Device|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
273606|NCT02342093|Drug|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
273607|NCT02342093|Drug|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
273608|NCT00156728|Device|Vitatron biventricular pacemaker|
273609|NCT02342119|Other|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
273610|NCT02342119|Other|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
273910|NCT02337426|Drug|Temozolomide|Given PO
272964|NCT02317341|Drug|Midazolam|Given intravenously over 40 minutes
272965|NCT02317341|Drug|Midazolam(placebo)|Given intravenously over 40 minutes
272966|NCT02317393|Other|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
272967|NCT02317393|Other|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
273286|NCT02348541|Device|CollaGUARD|
273287|NCT02348554|Behavioral|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
273288|NCT00002409|Drug|Abacavir sulfate|
273289|NCT00157755|Device|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
273290|NCT02348554|Behavioral|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
273291|NCT02348567|Other|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
273292|NCT02348567|Other|announced hospital surveys|
273293|NCT02348580|Behavioral|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
273294|NCT02348593|Drug|JZP-110|
273295|NCT02348606|Drug|JZP-110|
273296|NCT02348619|Drug|JZP-110|
273297|NCT02348632|Drug|JZP-110|
273298|NCT02348645|Procedure|Spinal fusion|
273299|NCT02348645|Procedure|Spinal decompression|
273300|NCT00157768|Device|Implantable cardioverter defibrillator|
273301|NCT02348658|Drug|TAK-536TCH|TAK-536TCH tablets
272662|NCT02322398|Drug|hMG|150-300 IU/d hMG
272663|NCT02322411|Device|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
272664|NCT02322411|Behavioral|Compensatory approaches|
272665|NCT02324777|Device|Volcano® Medic Vapourizer|Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).
The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique.
272666|NCT02324790|Device|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
272667|NCT02324803|Drug|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
272668|NCT02324816|Device|The Zeltiq System|CoolSculpting treatment.
272968|NCT00153062|Drug|Clopidogrel placebo|placebo
272969|NCT02317406|Drug|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
272970|NCT02317406|Drug|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
272971|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
272972|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
272973|NCT02317419|Drug|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
272974|NCT02317419|Drug|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
272975|NCT02317432|Behavioral|Comparison of a combined CBT + exercise intervention and enhanced usual care|
272976|NCT02317458|Biological|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
272977|NCT02317458|Biological|Sham comparator|One arm with standard of care undergoing a sham procedure
272382|NCT02329782|Behavioral|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
272383|NCT00154336|Drug|Imatinib in combination with methotrexate|
272384|NCT02329795|Radiation|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
272385|NCT02329795|Drug|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
272386|NCT02329808|Procedure|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
272387|NCT02329821|Other|hartmann solution|hartmann solution infusion in patients for hepatic resection
272388|NCT02329834|Drug|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
272389|NCT02331888|Device|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
272390|NCT02331914|Procedure|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
272391|NCT02331914|Procedure|Tumor biopsy|Tumor biopsy after disease progression
272669|NCT02324842|Drug|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
272670|NCT02324842|Drug|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
272671|NCT02324855|Other|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
272672|NCT00153868|Drug|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
272673|NCT02324868|Device|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
272084|NCT02336620|Drug|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
272085|NCT02336620|Drug|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
272086|NCT02336633|Dietary Supplement|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
272087|NCT02336633|Other|Placebo|
272088|NCT02336646|Drug|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
272089|NCT02336646|Drug|Normal saline|
272090|NCT02336659|Drug|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
272091|NCT02336659|Drug|sitagliptin|DPP-4 Inhibition
272092|NCT02336672|Device|Cryothermal ablation|The procedures will be performed in the Endoscopic Room. Patients will be sedated by the anaesthesiologist. Device settings and application times will be set and recorded on a computer that will analyze the changes of the properties of the tissue.
The setting of the maximal application time will be based on the results of the described ex-vivo and in-vivo studies and will be adjusted to the size of the tumour. This ensures a reduction of HybridTherm related complications which may occur if the applica-tion time would not be limited. The application of Power Doppler will make the procedure safer.
The probe will be guided under real time EUS into the tumour. The success of the placement of the HTP into the tumour will be an index of the feasibility of the treatment. The system will analyse the effects on the tissue, and EUS will record the changes of the tissues, the growing edema around the treated area, and tissue devita-lisation, with attention to the complications.
272093|NCT02336685|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
272094|NCT00156039|Behavioral|Follow-up Strategy for Breast Cancer|
272095|NCT02336685|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
272096|NCT02336685|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
272097|NCT02336698|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
272098|NCT02336698|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
272099|NCT02336698|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
272100|NCT02336711|Radiation|dose escalation|molecular imaging based radiotherapy dose escalation
272101|NCT02336724|Drug|Famitinib|
271470|NCT02345642|Device|VenaFlow Elite Standing|
271471|NCT02345655|Procedure|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
271786|NCT02341391|Biological|TissueGene-C(High dose)|3.0 x 10^7 cells
271787|NCT02341404|Drug|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
271788|NCT02343458|Drug|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
271789|NCT02343458|Drug|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
271790|NCT02343471|Dietary Supplement|20 g whey protein|
271791|NCT02343484|Drug|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
271792|NCT02343484|Drug|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
271793|NCT02343497|Dietary Supplement|Astaxanthin|
271794|NCT02343497|Dietary Supplement|Placebo|
271795|NCT02343510|Other|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
271796|NCT00156936|Drug|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
271797|NCT02343536|Drug|Oral Azacitidine|
271798|NCT02343536|Drug|Rituximab|
271799|NCT02343536|Drug|cyclophosphamide|
271800|NCT02343536|Drug|Vincristine|
271801|NCT02343536|Drug|Prednisone|
271802|NCT02343549|Device|bevacizumab, NovoTTF100A, temozolomide|
271803|NCT02343562|Dietary Supplement|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
271170|NCT02352701|Drug|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
271171|NCT02352701|Drug|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
271172|NCT02352714|Drug|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
271173|NCT02352714|Drug|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
271174|NCT02352740|Dietary Supplement|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
271472|NCT02345655|Other|no test|normal procedure decided by the general practitioner
271473|NCT02347748|Behavioral|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
271474|NCT02347748|Behavioral|Reading 2 scripts|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.
Patients will be read a comfort talk script before extubation
271475|NCT02347761|Drug|SUN101|SUN-101 50 mcg twice daily (BID)
271476|NCT02347761|Drug|SUN101|SUN-101 25 mcg BID
271477|NCT02347761|Drug|Placebo|Placebo BID
271478|NCT02347774|Drug|SUN-101|SUN-101 50 mcg twice daily (BID)
271479|NCT02347774|Drug|SUN-101|SUN-101 25 mcg BID
271480|NCT00157651|Drug|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
271481|NCT02347774|Drug|Placebo|Placebo BID
271482|NCT02347787|Behavioral|IMPaCT|The IMPaCT intervention has three stages:
Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.
Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.
Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group.
271483|NCT02347813|Drug|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
271484|NCT02347839|Procedure|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
271485|NCT02347852|Drug|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
271486|NCT02347865|Drug|AMG 162 - Prolia|500 patients
265963|NCT02367833|Drug|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Ortho Evra) on the GH/IGF-1 axis.
265964|NCT02367833|Drug|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
265965|NCT02367846|Drug|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
265966|NCT00159783|Drug|Olanzapine|Olanzapine, 40 weeks
265967|NCT02367846|Drug|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
265968|NCT02367859|Drug|Dabrafenib|Given PO
265969|NCT02367859|Other|Laboratory Biomarker Analysis|Correlative studies
265970|NCT02367872|Drug|TAK-272|TAK-272 tablet
265971|NCT02367885|Drug|TAK-850 0.5 mL injection|TAK-850 intramuscular injection for 13-19 year olds
265972|NCT02367885|Drug|TAK-850 0.5 mL injection (3-12 year olds)|Two intramuscular injections of TAK-850 0.5 mL in 3-12 year old participants
265973|NCT02367885|Drug|TAK-850 0.25 mL injection (age 6-35 months)|Two intramuscular injections of TAK-850 0.25 mL in 6-35 month old participants
266227|NCT02360592|Drug|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
266228|NCT02360592|Drug|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
266229|NCT02360592|Drug|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
266230|NCT02360605|Behavioral|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
265692|NCT02374619|Dietary Supplement|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement [Resoferon Ferrous Sulfate 125 (37) mg]
265693|NCT02376933|Procedure|Vertebroplasty|Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
265694|NCT02376933|Radiation|Radiotherapy|Radiotherapy of metastatic lesions to the spine.
265695|NCT00160823|Procedure|Self-administered leaflet|
265696|NCT02376946|Device|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
265697|NCT02376946|Device|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
265698|NCT02376959|Behavioral|Spiritist "passe"|For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.
The applied intervention will consist of placing both hands in the classic Spiritist "passe" position for the stipulated 5-min period. Spiritist "passe" will be applied by volunteers with training and experience of more than two years with the technique.
265699|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
265700|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
265701|NCT02376972|Drug|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
265702|NCT02376972|Drug|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
265703|NCT02376985|Procedure|Oral management|
265704|NCT02376985|Drug|Everolimus|
265705|NCT02376998|Device|Valiant™ endoluminal procedure|Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:
The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.
After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak.
265706|NCT00160836|Device|Tissue sampling ("G.I.U.M." catheter)|
265707|NCT02377011|Behavioral|Problem solving cognitive behaviour therapy (PS CBT)|
265708|NCT02377024|Dietary Supplement|TF 600mg|
265974|NCT02370251|Drug|Omegaven + Intralipid|Infants who experience resolution of cholestasis and continue to require IV lipids will have Intralipid added back at a dose of 0.5 g/kg/day (if enteral intake is 50-99 ml/kg/day) or 1 g/kg/day (if enteral intake is 0-49 ml/kg/day) three times weekly. Essential fatty acid profiles will be monitored.
265072|NCT02388867|Procedure|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
265073|NCT02388880|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
265074|NCT02388906|Drug|Ipilimumab|
265382|NCT02381847|Procedure|intraperitoneal chemoperfusion|HIPEC with cisplatin at the time of D2 radical surgery
265383|NCT02381860|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
265384|NCT00161447|Drug|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 & month 3
265385|NCT02381860|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
265386|NCT02381886|Drug|IDH305|
265387|NCT02381899|Drug|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
265388|NCT02384174|Dietary Supplement|Dietary fibre (arabinogalactan, gum guar, pectin)|
265389|NCT02384187|Drug|Gabapentin as premedication|Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
265390|NCT02384187|Drug|placebo|Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
265391|NCT02384200|Drug|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
265392|NCT02384200|Drug|ampicillin|IV (2 g)
265393|NCT02384200|Drug|gentamicin|IV (5 mg/kg)
265394|NCT02384200|Drug|vancomycin|IV (1 g)
265395|NCT00161746|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
265396|NCT02384200|Drug|ceftriaxone|IV (2 g)
265397|NCT02384239|Drug|Palbociclib|
265398|NCT02384252|Other|functional tissu atrial analysis|
264765|NCT00158444|Procedure|insertion of the HemiCAP™ Femoral Resurfacing Prosthesis|
264766|NCT02354976|Drug|Fenofibrate 200mg|200mg capsule administered once daily
264767|NCT02354976|Drug|Placebo|Placebo matching to fenofibrate 200mg
264768|NCT02354989|Device|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
264769|NCT02354989|Device|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
264770|NCT02357589|Procedure|3D laparoscopic cholecystectomy|
264771|NCT02357602|Drug|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
264772|NCT02357615|Drug|nifedipine CR tablets (Xin Ran)|
264773|NCT02357615|Drug|Adalat|
264774|NCT02357628|Device|Wound treatment with RO-NPT|
264775|NCT02357628|Device|Wound Irrigation|
264776|NCT02357641|Other|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
264777|NCT02357654|Drug|GnRH|single shot of GnRH agonist
264778|NCT02357654|Drug|placebo|placebo
265075|NCT02388906|Drug|Nivolumab|
265076|NCT02388906|Other|Placebo matching Ipilimumab|
265077|NCT02388906|Other|Placebo matching Nivolumab|
265078|NCT02388919|Drug|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
265079|NCT02388919|Drug|Placebo|Basic dosage, take once when limosis in the morning.
265080|NCT02388932|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
265081|NCT02388932|Procedure|Positron Emission Tomography|Undergo PET/CT
265082|NCT00162383|Drug|Debrisoquine|
264477|NCT02362464|Biological|ME TARP vaccine|Dose of 20 x 10^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally every 3 weeks at weeks 3, 6, 9, 12, 15 and 24.
264478|NCT02362477|Behavioral|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
264479|NCT00159263|Procedure|Induced Sputum|
264480|NCT02362477|Behavioral|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
264481|NCT02362490|Drug|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
264482|NCT02362503|Drug|BMS-663068|
264483|NCT02362503|Other|Placebo|
264484|NCT02362516|Drug|BI 425809|
264485|NCT02362529|Drug|Minocycline|50 mg and 100 mg capsule, oral administration
264486|NCT02362529|Drug|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
264487|NCT02362529|Drug|Celecoxib|100 mg and 200 mg capsules, oral administration.
264488|NCT02362542|Device|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
264489|NCT02362555|Other|no intervention was used in this observational study|
264490|NCT02364973|Other|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
264491|NCT02364986|Drug|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
264492|NCT02364999|Drug|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles
264493|NCT02364999|Drug|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
264494|NCT02364999|Drug|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle.
264779|NCT02357680|Other|Diary|The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.
The diary contains a written description on how to use the diary during and after the patients stay in the ICU.
269152|NCT02320825|Radiation|high-dose hypofractionated SRS|
269153|NCT02323295|Radiation|Radiation|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
269154|NCT02323295|Procedure|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
269155|NCT02323308|Other|blood sampling|
269156|NCT02323321|Device|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
269157|NCT02323334|Drug|LY3202626|administered orally
269158|NCT02323334|Drug|Placebo (Part A, B, C)|administered orally
269159|NCT02323334|Drug|Itraconazole|administered orally
269160|NCT02323347|Other|Progesterone|Progesterone level
269161|NCT00002393|Drug|Efavirenz|
269162|NCT00153673|Drug|Dologesics|Dologesics 2 tablets bd
269163|NCT02323360|Radiation|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
269164|NCT02323360|Procedure|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
269165|NCT02323373|Drug|Tranexamic Acid - topical|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
269166|NCT02323373|Drug|Placebo|100 ml of saline solution administered with anesthesia during 10 minutes
269167|NCT02323373|Drug|Tranexamic Acid - intravenous|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
269168|NCT02323386|Device|Primary Total Knee Arthroplasty (ATTUNE Knee System)|The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.
The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected.
268531|NCT02337582|Other|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
268532|NCT02337582|Other|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
268533|NCT02337595|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
268846|NCT02330588|Behavioral|Chow Down! (Injunctive Feedback)|Our nutrition-based brief intervention (Chow Down!) includes two questions for parents to answer regarding perceptions of their children's diet; one question relates to portion sizes of grain products and another queries intake of sugar-sweetened beverages. Parents' responses to the intervention questions will be compared to injunctive data; for example, national recommendations (e.g., Canada's Food Guide).
268847|NCT02330588|Behavioral|Chow Down! (Normative Feedback)|Our nutrition-based brief intervention (Chow Down!) includes two questions for parents to answer regarding perceptions of their children's diet; one question relates to portion sizes of grain products and another queries intake of sugar-sweetened beverages. Parents' responses to the intervention questions will be compared to normative data from the Canadian pediatric population (e.g., Canadian Health Measures Survey).
268848|NCT02330588|Behavioral|Move It! (Injunctive Feedback)|Our physical activity-based brief intervention (Move It!) includes two questions for parents to answer regarding children's physical activity; one question relates to the duration of daily moderate-to-vigorous physical activity and another queries the amount of daily screen time. Parents' responses to the intervention questions will be compared to injunctive data; for example national recommendations (e.g., Canadian Physical Activity Guidelines for Children and Youth).
268849|NCT02330588|Behavioral|Move It! (Normative Feedback)|Our physical activity-based brief intervention (Move It!) includes two questions for parents to answer regarding children's physical activity; one question relates to the duration of daily moderate-to-vigorous physical activity and another queries the amount of daily screen time. Parents' responses to the intervention questions will be compared to normative data from the Canadian pediatric population (e.g., Canadian Health Measures Survey).
268850|NCT02330588|Behavioral|Heads Up!|Parents assigned to the control group will be presented with information about healthy lifestyle behaviors for children in general, but intervention questions will not be delivered.
268851|NCT02330601|Procedure|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
268852|NCT00154440|Drug|amoxicillin|
268853|NCT02330614|Other|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
268854|NCT02330614|Other|Nothing - control group|Only NEO-FFI test , data used as control
268855|NCT02330627|Behavioral|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
268546|NCT02337699|Procedure|QST Testing|
268547|NCT02337712|Radiation|q.d. RT|65 Gy in 26 fractions
268548|NCT02337712|Radiation|b.i.d.RT|45 Gy in 30 fractions
268549|NCT02337725|Drug|TVP-1012|TVP-1012 Tablets
268550|NCT02337725|Drug|Placebo|Placebo tablets.
268551|NCT00156117|Drug|asenapine|5 mg BID or 10mg BID
268552|NCT02337738|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
268553|NCT02337738|Drug|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
268554|NCT02337738|Drug|Placebo|Placebo Tablets
268555|NCT02337751|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
268556|NCT02337764|Drug|TVP-1012 1mg with levodopa|TVP-1012 1mg Tablets with levodopa, A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period.
268557|NCT02337803|Behavioral|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
268859|NCT02332928|Drug|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
268860|NCT02332941|Drug|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
268861|NCT02332954|Drug|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
268862|NCT02332967|Other|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
268863|NCT00154830|Behavioral|crouch gait|
268864|NCT02332967|Other|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
268865|NCT02332967|Other|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
268866|NCT02332980|Drug|Ibrutinib|Given PO
268867|NCT02332980|Drug|Idelalisib|Given PO
274199|NCT02330484|Behavioral|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
274200|NCT02330497|Procedure|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
274201|NCT02330523|Device|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
274202|NCT02330523|Device|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
274203|NCT02330536|Device|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or sixteen L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
274204|NCT02330549|Drug|Cenicriviroc 150 mg|CVC 150 mg, administered orally once daily and taken every morning with food
274205|NCT02330549|Drug|Matching placebo|Matching placebo administered orally once daily and taken every morning with food
274206|NCT00154440|Drug|clarithromycin|
274207|NCT02330562|Drug|Marizomib|Dosing to start at 0.55 mg/m2 and increase with each cohort.
Dose Escalation: The dose of marizomib will be escalated per schema in a 3+3 fashion.
274208|NCT02330562|Drug|Bevacizumab|Bevacizumab IV infusion dosing to be at 10 mg/kg for all cohorts.
274209|NCT02332694|Device|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
269525|NCT02323516|Drug|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
269526|NCT02323529|Drug|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
269527|NCT02323542|Other|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
273911|NCT02337426|Radiation|Radiation Therapy|Undergo radiation therapy
273912|NCT00156104|Drug|Asenapine|5 mg BID
273913|NCT02337439|Behavioral|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
273914|NCT02337439|Behavioral|Active Control Training|Commercially available educational software
273915|NCT02337452|Behavioral|Family History Questionnaire|Participants complete a family history questionnaire online or hardcopy, which should take about 20 minutes to complete.
273916|NCT02337452|Behavioral|Web-Based Family Outreach Registry|Participants taught how to use the Web-Based Family Outreach Registry. They will be given a secure log-in username and password for the web site.
273917|NCT02337465|Procedure|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
273918|NCT02337465|Radiation|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
273919|NCT02337478|Drug|Vincristine Sulfate Liposome|Given via injection
273920|NCT02337478|Other|Laboratory Biomarker Analysis|Correlative studies
273921|NCT02337491|Drug|Pembrolizumab|Administered intravenously
273922|NCT02337491|Drug|Bevacizumab|Administered Intravenously
273923|NCT00156104|Drug|Asenapine|10 mg BID
273924|NCT02337504|Other|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
273925|NCT02337517|Other|Laboratory Biomarker Analysis|Correlative studies
273926|NCT02337517|Drug|Vismodegib|Given PO
273927|NCT02337530|Drug|Selumetinib|
273928|NCT02337530|Drug|Pemetrexed|
273929|NCT02337530|Drug|Cisplatin|
273930|NCT02337543|Drug|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
273931|NCT02337543|Drug|Placebo|Placebo
273932|NCT02337556|Other|Peptamen Bariatric|Commercially available enteral diet
273933|NCT02337556|Other|Replete|Commercially available enteral diet
273302|NCT02348671|Other|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
273303|NCT02348684|Radiation|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
273304|NCT02348697|Biological|NOVOCART 3D|Autologous Chondrocyte Implantation
273305|NCT02351167|Drug|Placebo|
273306|NCT02351180|Drug|Inhaled beclomethasone|
273307|NCT02351180|Drug|Placebo|
273611|NCT02344277|Device|S-ICD System (implantable defibrillator)|The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.
Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system.
273612|NCT02344290|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
273613|NCT02344290|Drug|Placebo|One tablet taken once daily, orally with or without food
273614|NCT02344303|Drug|TRV130|
273615|NCT02344303|Drug|Moxifloxacin|
273616|NCT02344303|Drug|Placebo|
273617|NCT00157014|Drug|Mycophenolate mofetil|Intravenous and Oral
273618|NCT02344316|Drug|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
273619|NCT02344316|Other|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
273620|NCT02344329|Device|Topical wound dressing|Topical Wound Dressing
273621|NCT02344329|Biological|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
273622|NCT02344329|Other|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
273623|NCT02344342|Device|Telemonitoring|The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.
273624|NCT02344342|Other|Flexible Diuretic Regimen|Patients will have a prescribed diuretic regimen specified by specific weight ranges.
272978|NCT02317471|Biological|autologous gp96 vaccination|Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.
gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion.
272979|NCT00153062|Drug|Clopidogrel placebo|placebo
272980|NCT02317471|Drug|Oxaliplatin+S-1|Treatment will be start at the 5th week after the surgery.
S-1: 40~60mg bid，d1~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.
272981|NCT02317484|Drug|Ipragliflozin (SGLT2 inhibitor)|
272982|NCT02317497|Other|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
272983|NCT02319837|Drug|Enzalutamide|
272984|NCT02319837|Drug|Placebo|Sugar pill to mimic enzalutamide
272985|NCT02319837|Drug|Leuprolide|
272986|NCT00153270|Drug|Sodium Valproate|
273308|NCT02351193|Other|transvaginal Ultrasound|
273309|NCT02351206|Radiation|x-ray, MRI|
273310|NCT02351219|Drug|FOLFOXIRI|
273311|NCT02351232|Drug|Liraglutide|
273312|NCT00158093|Drug|Moxifloxacin|
273313|NCT02351232|Drug|Placebo|
273314|NCT02351245|Other|observation|
273315|NCT02351258|Device|70% isopropyl alcohol embedded caps|protective cap on central lines
273316|NCT02351271|Device|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
273317|NCT02351271|Device|Manual capsulorhexis and lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
272674|NCT02324868|Device|Conventional IV catheter protection|No Shower patch will be provided during study period
272675|NCT02324881|Behavioral|Telephone-Based Intervention|Use PSMA
272676|NCT02324881|Other|Questionnaire Administration|Ancillary studies
272677|NCT02324894|Procedure|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
272678|NCT02324907|Device|Procedure/ Surgery:|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
272679|NCT02324920|Device|DDD-CLS|
272680|NCT02324920|Device|ODO|
272681|NCT02324933|Drug|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
272682|NCT02324946|Other|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
272683|NCT00002395|Drug|Topotecan|
272684|NCT00153881|Drug|Capecitabine (Xeloda)|Neoadjuvant Chemotherapy:
Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.
Concomitant chemotherapy and radiation:
Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles).
272685|NCT02327429|Behavioral|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
272686|NCT02327442|Radiation|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
272987|NCT02319850|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
272988|NCT02319863|Procedure|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
272989|NCT02319863|Procedure|hepatectomy (rapid ligating)|
272990|NCT02319889|Radiation|Stereotactic Body Radiotherapy|Undergo SBRT
272991|NCT02319889|Drug|Carboplatin|Given IV
272992|NCT02319889|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
272102|NCT02336737|Device|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
272392|NCT02331927|Biological|Aflibercept|Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.
compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression.
272393|NCT02331940|Drug|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
272394|NCT02331940|Device|Handihaler|Inhalation via the HandiHaler once daily
272395|NCT02331940|Device|Respimat|Inhalation via the Respimat once daily
272396|NCT02331979|Device|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
272397|NCT02331992|Behavioral|Adherence program|Participants will receive supportive messages while enrolled in the program.
272398|NCT02332005|Drug|diepalrestat choline|aldose reductase inhibitor
272399|NCT00154726|Drug|Paclitaxel-HDFL|
272400|NCT02332005|Drug|Placebo|Placebo
272401|NCT02332018|Radiation|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
272402|NCT02332031|Drug|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
272403|NCT02332031|Drug|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
272404|NCT02332044|Drug|Erdos|capsule, 300mg
272405|NCT02332044|Drug|Talion|tablet, 10mg
272406|NCT02332044|Drug|Erdos, Talion|capsule 300mg and tablet 10mg
272407|NCT02332057|Drug|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
272408|NCT02332057|Drug|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
271804|NCT02343562|Dietary Supplement|Placebo|Multivitamin off-the-counter.
271805|NCT02343575|Drug|Valproic Acid|1.
Start:
VPA PO/NGT 500 mg BID
2.
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS
3.
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS
4.If need to increase in 24 or more hours:
VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
271806|NCT02343575|Drug|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
272103|NCT02336737|Drug|Radioisotope|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
272104|NCT02336737|Drug|Blue dye|Injection of a single dose of isosulfan blue dye
272105|NCT00156052|Radiation|Conventional whole breast radiation schedule|
272106|NCT02336750|Drug|Aprepitant|125mg D1, 80mg D2-3
272107|NCT02339116|Drug|Oxaliplatin|
272108|NCT02339116|Drug|Irinotecan|
272109|NCT02339116|Drug|Bevacizumab|
272110|NCT02339129|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
272111|NCT02339129|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
272112|NCT02339142|Radiation|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
272113|NCT02339142|Drug|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
272114|NCT02339155|Biological|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
272115|NCT02339155|Biological|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
272116|NCT00156299|Drug|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
272117|NCT02339155|Drug|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
272118|NCT02339168|Drug|Enzalutamide|Given PO
272119|NCT02339168|Drug|Metformin Hydrochloride|Given PO
272120|NCT02339168|Other|Laboratory Biomarker Analysis|Correlative studies
271487|NCT02347865|Drug|AMG 162 - Prolia|250 patients, one year later
271488|NCT02347878|Drug|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
271489|NCT02347891|Drug|Belimumab/Placebo + standard of care (randomized phase)|monthly infusions (week 0 - week 36)
271490|NCT02347904|Drug|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
271491|NCT00002409|Drug|Lamivudine/Zidovudine|
271492|NCT00157651|Drug|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
271493|NCT02347917|Drug|BBI608|480 mg orally twice daily (960 mg total daily dose)
271807|NCT00156949|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
271808|NCT02343575|Drug|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
271809|NCT02343588|Behavioral|The Health Lifestyles Interventions|Creating supportive school and family environment, whole intervention periods;
Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;
Instruct and promote school physical education, whole intervention periods;
The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor
271810|NCT02343601|Device|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
271811|NCT02345668|Behavioral|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
271812|NCT02345668|Drug|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
271813|NCT00002407|Drug|Stavudine|
271814|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
271815|NCT02345668|Behavioral|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
271816|NCT02345681|Drug|Furosemide|
266231|NCT00158964|Device|EASYTRAK 4 STEERABLE LV lead|
266232|NCT02360605|Behavioral|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
266233|NCT02363322|Other|Treatment A|Optimized standard of care for Ebola virus infection
266234|NCT00002418|Drug|Emivirine|
266235|NCT00159302|Procedure|24hr Urine Samples|
266236|NCT02363335|Drug|Placebo|
266237|NCT02363335|Drug|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin
266238|NCT02363335|Drug|Sitagliptin|
266239|NCT02363335|Drug|Roflumilast|
266240|NCT02363348|Dietary Supplement|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
266241|NCT02363348|Other|Placebo|calcined magnesia
266242|NCT02363361|Drug|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
266243|NCT02363374|Drug|Induction Chemotherapy arm A|Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:
Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
After a break of two weeks, radiotherapy starts combined with:
5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71
266244|NCT02363374|Radiation|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
266527|NCT02391831|Other|Electrophysiology measurements|
266528|NCT02391831|Other|Blood sampling for biomarker analysis|
266529|NCT02391844|Drug|Oxycodone|Oxycodone with Acetaminophen Extended Release
266530|NCT02391857|Procedure|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
265975|NCT02370264|Procedure|Quality-of-Life Assessment|Ancillary studies
265976|NCT02370264|Other|Questionnaire Administration|Ancillary studies
265977|NCT02370264|Other|Medical Chart Review|Ancillary studies
265978|NCT02370277|Other|Cytology Specimen Collection Procedure|Undergo collection of stool samples
265979|NCT02370277|Other|Laboratory Biomarker Analysis|Correlative studies
265980|NCT00160030|Drug|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
265981|NCT02370277|Other|Questionnaire Administration|Ancillary studies
265982|NCT02370290|Other|Medical Chart Review|Clinical and imaging information collected
265983|NCT02370290|Other|Informational Intervention|Clinical and imaging data collected
265984|NCT02370316|Behavioral|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
265985|NCT02370316|Behavioral|Clinical Structured Treatment|structured case management and symptom-targeted medication
265986|NCT02370329|Other|Laboratory Biomarker Analysis|Correlative studies
265987|NCT02370329|Biological|PEG-Proline-Interferon Alfa-2b|Given SC
265988|NCT02370329|Other|Quality-of-Life Assessment|Ancillary studies
265989|NCT02370342|Procedure|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
265990|NCT02370342|Procedure|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
265991|NCT00160030|Drug|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
265992|NCT02370342|Procedure|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
265993|NCT02370355|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
265994|NCT02370355|Other|Laboratory Biomarker Analysis|Correlative studies
265995|NCT02370368|Device|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
265399|NCT02384265|Behavioral|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
265400|NCT02384278|Behavioral|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
265401|NCT02384291|Device|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
265402|NCT02384291|Device|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
265403|NCT02384304|Behavioral|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
265404|NCT02384304|Behavioral|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
265709|NCT02377024|Dietary Supplement|TF 1200mg|
265710|NCT02377024|Dietary Supplement|placebo|
265711|NCT02377037|Other|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
265712|NCT02377050|Other|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
265713|NCT02377063|Dietary Supplement|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
265714|NCT02377076|Dietary Supplement|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
265715|NCT02377076|Dietary Supplement|Control|Control (Whey protein, vitamin D, sugar and salt)
265716|NCT02379312|Dietary Supplement|Normal energy aerated beverage 1|
265717|NCT02379312|Dietary Supplement|Normal energy aerated beverage 2|
265718|NCT02379312|Dietary Supplement|Normal energy aerated beverage 3|
265719|NCT02379325|Behavioral|Lets Quit|Five tracks were created including "Not Ready", "Beginner", "Advance", "Relapse", and "Distraction". The "Distraction" track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling.
265720|NCT02379325|Behavioral|pamphlets material|Given pamphlets material on smoking and complication
265721|NCT00161187|Biological|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
265083|NCT02388932|Procedure|Computed Tomography|Undergo PET/CT
265084|NCT02388932|Other|Quality-of-Life Assessment|Ancillary studies
265085|NCT02388945|Other|APD|PDGO APD machines used in the PD patients for 8 weeks
265086|NCT02388945|Other|CAPD|CAPD used in the PD Patients for 8 weeks
265087|NCT02388971|Drug|MLN1202|MLN1202 solution
265088|NCT02388971|Drug|Placebo|MLN1202 placebo-matching solution
265089|NCT02388984|Drug|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
265090|NCT02388984|Drug|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
265091|NCT00162669|Drug|bevacizumab|
265092|NCT02391155|Procedure|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
265093|NCT02391181|Drug|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
265094|NCT02391181|Drug|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
265095|NCT02391194|Drug|AVB-620|
265096|NCT02391207|Procedure|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
265405|NCT02384304|Behavioral|Self help|A self help program consisting of 8 modules
265406|NCT00161759|Drug|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
265407|NCT02384317|Drug|CCX168|BID for 84 days
265408|NCT02384343|Drug|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
265409|NCT02384343|Drug|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
264780|NCT00158665|Biological|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
264781|NCT02357693|Drug|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
264782|NCT02357706|Device|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
264783|NCT02357706|Device|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
264784|NCT02357719|Device|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
264785|NCT02357732|Drug|Nivolumab|
264786|NCT02357732|Drug|Trametinib|
264787|NCT02357732|Drug|Dabrafenib|
264788|NCT02357745|Procedure|Non surgical periodontal therapy|scaling and root planing
264789|NCT02357758|Drug|Antibiotic Prophylaxis|
264790|NCT02357771|Drug|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
264791|NCT00158678|Procedure|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
264792|NCT02357771|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
264793|NCT02357784|Device|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
264794|NCT02359903|Drug|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
264795|NCT02359903|Drug|Infliximab (Remicade)|
264796|NCT02359916|Other|Time delays on delivery of less healthy snacks|
264797|NCT02359916|Other|25%/$0.25 discount on healthy snacks|
264798|NCT02359916|Other|25%/$0.25 tax on less healthy snacks|
264495|NCT02364999|Drug|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cycle.
264496|NCT02365012|Drug|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
264497|NCT02365025|Other|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
264498|NCT02365038|Other|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
264499|NCT00159432|Drug|Capecitabine|
264500|NCT02365038|Other|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
264501|NCT02365051|Behavioral|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
264502|NCT02365064|Device|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
264503|NCT02365090|Other|patching|covering the sound eye with a patch for 2 hours each day to force use of the amblyopic eye
264504|NCT02365090|Other|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
264505|NCT02365103|Other|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
264506|NCT02365103|Other|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
264507|NCT02365103|Other|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
264508|NCT02365103|Other|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
264509|NCT02365116|Behavioral|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
264510|NCT00159445|Drug|gemcitabine, capecitabine|
268856|NCT02330640|Drug|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
268857|NCT02330640|Drug|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
268858|NCT02330640|Drug|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
269169|NCT02323399|Drug|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level]; each initial treatment group will have two PK sampling schedules.
269170|NCT02323412|Drug|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
269171|NCT02323412|Drug|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
269172|NCT02325713|Drug|Cysticide|Cysticide crushed tablets at a single dose of 40 mg/kg given with water orally after a meal
269173|NCT02325726|Procedure|Renal Resistive Index compared with NephroCheckTM|
269174|NCT00002396|Drug|Tenofovir disoproxil fumarate|
269175|NCT00153972|Drug|Cabergoline|
269176|NCT02325739|Drug|FGF401|FGF401 is a FGFR4 inhibitor.
269177|NCT02325752|Other|Intervention|A multidisciplinary team delivered the transitional care program.
Our transitional care program focused on four key areas:
Post discharge surveillance of the patient to ensure adherence to care plans.
Coordination of follow-up visits with specialist care providers.
Patent education and care giver training.
Activation of community and social services.
Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge.
269178|NCT02325778|Procedure|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
269179|NCT02325791|Drug|REGN2222|
269180|NCT02325791|Drug|Placebo|
269181|NCT02325804|Behavioral|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
269182|NCT02325817|Device|drug-eluting balloon|
268868|NCT02332980|Other|Laboratory Biomarker Analysis|Correlative studies
268869|NCT02332980|Biological|Pembrolizumab|Given IV
268870|NCT02332993|Dietary Supplement|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
268871|NCT02333006|Other|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
268872|NCT02333019|Behavioral|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
268873|NCT02333019|Behavioral|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
268874|NCT00154843|Drug|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
268875|NCT02333032|Other|Inclined treadmill training|
268876|NCT02333045|Drug|Truvada qd|Truvada 1 tablet PO daily for 7 days
268877|NCT02333045|Drug|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
268878|NCT02333058|Drug|Treosulfan|Treosulfan dose per day is to be calculated by using BSA:
One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.
Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.
Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2.
269188|NCT02325869|Device|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
269189|NCT02325882|Drug|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
269190|NCT02325882|Drug|Fentanyl 1|conventional fentanyl-based epidural PCA
269191|NCT02325882|Drug|Fentanyl 2|conventional fentanyl based intravenous PCA
269192|NCT02325895|Other|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
269528|NCT02323555|Other|Paramedic telephone consultation|
269529|NCT02323568|Other|Gynecological consultation|
269530|NCT02323581|Device|Endovascular treatment of Thoracoabdominal Aortic Aneurysm|A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.
This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called "fenestrations") that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm.
269531|NCT02323594|Drug|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
269532|NCT02325934|Drug|Stribild, crushed|Crushed Stribild tablet
269533|NCT02325947|Device|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
269534|NCT00153985|Drug|Busulfex|Given once daily for 4 days
269535|NCT02325947|Device|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
269536|NCT02325960|Drug|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
269537|NCT02325960|Drug|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
269538|NCT02325973|Device|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
269539|NCT02325986|Drug|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
269540|NCT02325986|Drug|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
269541|NCT02325986|Radiation|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
269542|NCT02325999|Procedure|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
269829|NCT02318589|Drug|Irinotecan + Eribulin|Patients receive Oral Irinotecan on days 1-5 and IV Eribulin on days 1 and 8 of a 21 day cycle in the absence of disease progression or unacceptable toxicity.
269830|NCT00153101|Drug|Combination of Telmisartan and Ramipril|
273934|NCT00156104|Drug|Haloperidol|4 mg BID
274210|NCT02332707|Drug|Grazoprevir|One grazoprevir 100 mg tablet (Part A), or two MK-3682B tablets each containing grazoprevir 50 mg (Part B), taken once daily by mouth.
274211|NCT02332707|Drug|MK-3682|Two or three MK-3682 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or two MK-3682B tablets each containing MK-3682 225 mg (Part B), taken once daily by mouth.
274212|NCT02332707|Drug|Elbasvir|One elbasvir 50 mg tablet (Part A), taken once daily by mouth.
274213|NCT02332707|Drug|MK-8408|Six MK-8408 10 mg (60 mg total daily dose) capsules (Part A), or two MK-3682B tablets each containing MK-8408 30 mg (Part B), taken once daily by mouth.
274214|NCT00002400|Drug|Indinavir sulfate|
274215|NCT00154791|Drug|5-FU/LV|
274216|NCT02332707|Drug|MK-3682B|Two FDC tablets, each containing grazoprevir 50 mg + MK-3682 225 mg + MK-8408 30 mg (Part B), taken once daily by mouth.
274217|NCT02332707|Drug|Ribavirin|Ribavirin (RBV) 200 mg capsules taken twice-daily at a total daily dose of 800-1400 mg based on participant body weight.
274218|NCT02332720|Drug|Grazoprevir|One grazoprevir 100 mg tablet (Part A), or two MK-3682B tablets each containing grazoprevir 50 mg (Part B), taken q.d. by mouth.
274219|NCT02332720|Drug|MK-3682|Two or three MK-3682 150 mg (300 or 450 mg total daily dose) tablets (Part A), or two MK-3682B tablets each containing MK-8742 225 mg (Part B), taken q.d. by mouth.
274220|NCT02332720|Drug|MK-8742|One MK-8742 50 mg tablet (Part A), taken q.d. by mouth.
274221|NCT02332720|Drug|MK-8408|Six MK-8408 10 mg (60 mg total daily dose) capsules (Part A), or two MK-3682B tablets each containing MK-8408 30 mg (Part B), taken q.d. by mouth.
274222|NCT02332720|Drug|MK-3682B|Two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + MK-8408 30 mg (Part B), taken q.d. by mouth.
274223|NCT02332720|Drug|RBV|RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
274224|NCT02332733|Biological|TV003|10^3 plaque forming units (PFU) of rDEN1 delta 30, 10^3 PFU of rDEN2/4 delta 30(ME), 10^3 PFU of rDEN3 delta 30/31-7164, and 10^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
274225|NCT02332733|Biological|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
274226|NCT00154804|Drug|Paclitaxel, Cisplatin,Surgery, CCRT|
274227|NCT02332759|Device|Materna Medical|
273625|NCT02344355|Drug|Temozolomide|oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.
Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.
For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.
If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.
273626|NCT02344355|Radiation|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
273627|NCT02344355|Drug|Ascorbic Acid|Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.
After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.
273628|NCT00157014|Drug|Methylprednisolone|Intravenous
273629|NCT02344368|Other|sucrose 25% 0,2 ml|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
273935|NCT02337569|Drug|NPC-02|
273936|NCT02339766|Procedure|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
273937|NCT02339766|Drug|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
273938|NCT02339766|Drug|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
273939|NCT02339779|Procedure|autologous fat transfer|Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.
Typically three separate procedures are needed for a complete breast reconstruction:
First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.
Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.
Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast.
273940|NCT02339779|Procedure|breast implant|Implant-based reconstruction typically will occur as follows:
During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.
The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.
When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.
(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)
273941|NCT00156390|Device|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
273942|NCT02339792|Other|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
273943|NCT02339805|Other|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
273944|NCT02339805|Device|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
273945|NCT02339831|Device|CAMOPED|Camoped given after surgery
273318|NCT02351284|Other|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
273319|NCT02351297|Dietary Supplement|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
273320|NCT02351297|Dietary Supplement|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
273321|NCT02351297|Dietary Supplement|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
273322|NCT02351310|Drug|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
273323|NCT00158106|Procedure|Speech and Language therapy for dysarthria and/or aphasia|
273324|NCT02351310|Genetic|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
273325|NCT02351323|Drug|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
273326|NCT02351323|Behavioral|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
273327|NCT02351336|Device|Ultrasound imaging|- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)
- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )
- CL measurement using 2D ultrasound ( in cm)
273328|NCT02351349|Other|multidisciplinary intervention|multidisciplinary intervention
273329|NCT02351349|Other|NO intervention|NO intervention
273330|NCT02351362|Behavioral|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
273630|NCT02344368|Other|sucrose 25% 0,5 ml|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
273631|NCT02344381|Dietary Supplement|Sucrose|
273632|NCT02344381|Dietary Supplement|Glucose|
273633|NCT02346240|Biological|Certolizumab Pegol|Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/ mL
Route of Administration: Subcutaneous use
273634|NCT02346240|Biological|Etanercept|Active Substance: Etanercept
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 50 mg / mL
Route of Administration: Subcutaneous use
273635|NCT02346240|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use
272993|NCT02319902|Device|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
272994|NCT02319902|Device|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
272995|NCT02319915|Drug|Tranexamic Acid|
272996|NCT02319915|Drug|Adrenalin|
272997|NCT00153283|Drug|Gabapentin|
272998|NCT02319928|Procedure|Colonoscopy|
272999|NCT02319941|Drug|ticagrelor|
273000|NCT02319941|Drug|clopidogrel|
273001|NCT02319954|Procedure|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
273002|NCT02319967|Behavioral|CAPE|Structured patient-centered ED discharge template completed prior to ED discharge.
273003|NCT02319967|Behavioral|Home|Home visits led by community-health workers to reinforce CAPE and guide environmental remediation.
273004|NCT02319980|Procedure|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
273005|NCT02319993|Drug|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
273006|NCT02319993|Drug|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
273007|NCT02319993|Drug|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
273008|NCT00153296|Drug|Carbamazepine|
273331|NCT02351375|Other|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
273332|NCT02351375|Device|IntelliCap® system|
273333|NCT02353572|Drug|Bortezomib|Given IV
273334|NCT02353572|Drug|Dexamethasone|Given IV
273335|NCT02353572|Procedure|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
272409|NCT02332070|Procedure|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
272410|NCT00154739|Drug|Gemcitabine|
272687|NCT00154115|Drug|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
272688|NCT02327455|Procedure|Stress Dobutamine Echocardiographic using 4DE System|
272689|NCT02327468|Biological|INO-1400|
272690|NCT02327468|Biological|INO-9012|
272691|NCT02327481|Procedure|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
272692|NCT02327481|Procedure|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
272693|NCT02327494|Drug|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
272694|NCT02327507|Behavioral|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
272695|NCT02327520|Other|Colitis with CDI treatment|All patients will be treated with standard treatment
272696|NCT02327546|Drug|AKB-6548|
272697|NCT02327546|Drug|Ferrous Sulfate|
272698|NCT00154115|Drug|placebo|Placebo
272699|NCT02327559|Behavioral|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
272700|NCT02327559|Behavioral|Treatment as usual (TAU)|The treatment as usual "TAU" active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis).
272701|NCT02327585|Behavioral|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
272121|NCT02339194|Procedure|Denture fabrication technique|Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the "traditional protocol" group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied.
272122|NCT02339207|Drug|AL-335 matching placebo|=
272123|NCT02339207|Drug|AL-335|
272411|NCT02334202|Other|Health Education|The health education group will follow the "HEY-Durham" health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
272412|NCT02334215|Drug|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
272413|NCT00155376|Drug|morphine and glucagon|
272414|NCT02334215|Behavioral|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
272415|NCT02334215|Behavioral|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
272416|NCT02334228|Behavioral|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
272417|NCT02334228|Behavioral|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
272418|NCT02334241|Device|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
272419|NCT02334241|Device|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
272420|NCT02334254|Drug|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
272421|NCT02334254|Drug|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
272422|NCT02334267|Drug|GranuFlow|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.
271817|NCT02345694|Device|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
271818|NCT02345694|Device|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
271819|NCT02345707|Drug|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
271820|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
271821|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
271822|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
271823|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
272124|NCT02339220|Behavioral|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
272125|NCT02339220|Behavioral|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
272126|NCT02341417|Drug|Cinacalcet|Subjects will receive cinacalcet daily for up to 28 weeks in addition to standard therapy. Sites to receive 5mg capsules and 30mg tablets. Protocol specified doses: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, 180mg. Subjects completing treatment in 20130356 and up to week 26 in 20110100 will be eligible to receive cinacalcet in this study. For subjects enrolling from 20130356, the maximum dose of cinacalcet at any time during the study will be 2.5 mg/kg/day based on baseline dry weight/ 180 mg daily, whichever is lower. For subjects enrolling from 20100100, the maximum dose of cinacalcet at any time will be 2.5 mg/kg/day based on baseline dry weight/ 60 mg daily, whichever is lower.
272127|NCT02341430|Device|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
272128|NCT02341443|Procedure|Implants|Experimental arm: Rigid
Surgical treatment using arch bars and according to the following fixation:
Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).
Active comparator: Non-rigid
Surgical treatment using arch bars and according to the following fixation:
Non-rigid fixation on both fracture sides.
Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate.
266531|NCT02391870|Behavioral|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
266532|NCT02391883|Drug|Clopidogrel|
266533|NCT00162747|Drug|Aquaphor|
266534|NCT02391896|Device|Dual energy and tomosynthesis xray|
266535|NCT02391909|Biological|Vivotif|
266536|NCT02391922|Behavioral|First aid course|
266537|NCT02355639|Drug|Petrolatum ointment|
266538|NCT02355652|Device|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
266539|NCT02355652|Device|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
266540|NCT02355665|Drug|Nicotine|Novel Nicotine Replacement Therapy
266541|NCT02355665|Drug|Placebo|Placebo to match novel Nicotine Replacement Therapy
266542|NCT00158496|Drug|ribavirin|
266543|NCT02355678|Drug|dexamethasone|IV 0.5 mg/kg
266544|NCT02355678|Drug|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
266545|NCT02355678|Drug|General anesthesia|Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).
Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%.
266546|NCT02355678|Procedure|Tonsillectomy|Mono-polar electrocautery or cold dissection
266547|NCT02355678|Procedure|gastric content suction|By orogastric tube
266548|NCT02355678|Drug|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
266549|NCT02355678|Drug|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
266837|NCT02387346|Device|Magstim Rapid 2 Sham Stimulation|
266838|NCT02387359|Drug|Plecanatide|
266839|NCT02387359|Drug|Placebo|
266245|NCT02363374|Radiation|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
266246|NCT00159302|Procedure|Exhaled Breath Condensate|
266247|NCT02363374|Drug|Chemotherapy arm B|chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.
After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:
Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
266248|NCT02363374|Procedure|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
266249|NCT02363387|Behavioral|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
266250|NCT02363387|Behavioral|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
266251|NCT02363400|Drug|MEP|Adjuvant Chemotherapy
266252|NCT02363413|Other|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
266253|NCT02363413|Other|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
266254|NCT02363426|Device|INVOcell Culture Device|INVOcell is a vaginal culture device
266255|NCT02363426|Device|IVF Incubation|IVF Incubator
266256|NCT02365662|Drug|ABBV-221|ABBV-221 wll be given every 3 weeks by intravenous infusion over 30-40 minutes. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
266257|NCT02365675|Device|Cotton gauze with petrolatum|
266258|NCT02365675|Device|Cellulose acetate with petrolatum|
266259|NCT02365675|Device|Nanocrystalline silver (Acticoat)|
266260|NCT02365675|Device|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
266261|NCT02365688|Procedure|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
266262|NCT02365701|Drug|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
265722|NCT02379338|Drug|[18F]Fluortriopride|All subjects will receive a [18F]Fluortriopride PET/CT scan
265723|NCT02379351|Device|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
265724|NCT02379364|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
265725|NCT02379377|Radiation|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET scan
265726|NCT02379377|Radiation|Carbon-11 Acetate|Undergo 11C-acetate PET scan
265727|NCT02379377|Device|Positron Emission Tomography|Undergo 18F-FSPG PET
265728|NCT02379377|Procedure|Positron Emission Tomography|Undergo 11C-acetate PET
265729|NCT02379377|Other|Laboratory Biomarker Analysis|Correlative studies
265996|NCT02370394|Behavioral|ROSE Program|The ROSE Program will be specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It will also be tailored on the current IPV risk assessment, pregnancy or postpartum status of each participant, will be designed to reach participants across levels of motivation for change. The content of ROSE will be theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
265997|NCT02370407|Device|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
265998|NCT02372799|Drug|Fluoxetine|
265999|NCT02372812|Drug|dexamethasone|12 mg of dexamethasone
266000|NCT02372812|Drug|Placebo|
266001|NCT02372825|Procedure|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
266002|NCT02372838|Procedure|Microvascular fibula bone transfer|Reconstructive surgery with a microvascular bone flap
266003|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
266004|NCT02372851|Device|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
265410|NCT02384369|Drug|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
265411|NCT02384382|Drug|Enzalutamide|
265412|NCT02384395|Drug|DTG/3TC/ABC FDC|DTG/3TC/ABC FDC as initial therapy for AHI
265413|NCT02384408|Procedure|Endometrial Biopsy|Histological assessment
265414|NCT02384408|Device|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
265415|NCT02386670|Other|sham tDCS + sham CR|First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).
tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes.
CR sessions will follow the tDCS session and last 2 hours in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.
265416|NCT02386683|Other|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
265417|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
265418|NCT02386696|Other|Ultrasound|Lung ultrasound examination on healthy volunteers
265419|NCT02386709|Device|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
265420|NCT02386722|Device|Smartinhaler/POEMS with audio reminders and additional support calls|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, which will sound every 30 seconds over a period of 60 minutes after the time predesigned for inhalation. The alarm will stop as soon as the inhaler is used, or if it is not used after 60 minutes. The devices will be programmed to emit an alarm one to two times daily, depending on inhalation prescriptions.
265421|NCT02386735|Drug|Placebo|Three days prednisone 40mg, two days placebo
265422|NCT02386735|Drug|Prednisone|Five days prednisone 40mg.
265423|NCT02386748|Dietary Supplement|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
265730|NCT02379390|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
265731|NCT02379390|Drug|Enzalutamide|Pharmaceutical form:Tablet Route of administration: Oral
265732|NCT00161200|Drug|Ranitidine & Pantoprazole|
265733|NCT02379390|Drug|Abiraterone acetate|Pharmaceutical form:Capsule Route of administration: Oral
265097|NCT02391220|Other|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
265098|NCT02391220|Other|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
265099|NCT02391233|Behavioral|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
265100|NCT02391233|Behavioral|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
265101|NCT02391246|Other|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
265102|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
265103|NCT02391259|Drug|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
265104|NCT02391259|Drug|Placebo|contains no active drug
265105|NCT02391272|Drug|rhTPO|
265106|NCT02355002|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects. See attached Rossi et. al. 2009 as a reference to safety guidelines for TMS.
265107|NCT02355028|Drug|LHA510 ophthalmic suspension|
265108|NCT02355028|Drug|LHA510 vehicle|Inactive ingredients used as a placebo comparator
265109|NCT02355028|Drug|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
265110|NCT02355041|Behavioral|Meal Replacement-based Weight Loss Diet|
265111|NCT02355041|Behavioral|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
264799|NCT02359929|Biological|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
264800|NCT00158873|Drug|propofol|
264801|NCT02359942|Drug|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
264802|NCT02359955|Device|zero degree teeth|zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
264803|NCT02359955|Device|anatomic teeth|when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
264804|NCT02359968|Drug|FOLFOX|radiochemotherapy before surgery
264805|NCT02359968|Drug|CarboP-pacliT|radiochemotherapy before surgery
264806|NCT02359981|Behavioral|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
264807|NCT02359981|Behavioral|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
264808|NCT02359981|Device|Smartphone|An Android Smartphone with operating system version higher than 2.2
264809|NCT02359994|Device|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot or the control device. Randomization will be conducted by a designated individual (randomization designee) at the investigational site. The prescribed hemostatic agent will be applied according to the respective product Instructions for Use.
264810|NCT02359994|Device|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot or the control device. Randomization will be conducted by a designated individual (randomization designee) at the investigational site. The prescribed hemostatic agent will be applied according to the respective product Instructions for Use.
264811|NCT00158886|Drug|Hycamtin|
264812|NCT02360007|Drug|Interim Buprenorphine Treatment (IBT)|The Interim Buprenorphine Treatment (IBT) includes:
Buprenorphine (BUP)
Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.
Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support
Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs
HIV+Hepatitis Education delivered via iPad
264813|NCT00159263|Drug|Symbicort, Formoterol, Budesonide and Placebo|
269183|NCT02325830|Device|CARILLON Mitral Contour System|Percutaneous mitral valve repair
269184|NCT02325843|Other|human bone marrow MSC|the arms of active comparator :human bone marrow MSC subconjunctival injection once per week,adminstered for 4 weeks
269185|NCT02325856|Device|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
269186|NCT00153972|Drug|Levodopa|
269187|NCT02325856|Behavioral|Clinical judgement|
264511|NCT02367170|Procedure|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
264512|NCT02367170|Device|Inspiratory Muscle Strength Training (IMST)|Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve without"valve flutter"noise.
264513|NCT02367170|Device|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
264514|NCT02367170|Procedure|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
264515|NCT02367170|Other|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
264516|NCT02367183|Drug|GED-0301|
264517|NCT02367183|Drug|Placebo|
264518|NCT02367196|Drug|CC-90002|
269193|NCT02325921|Device|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences (including diffusion tensor imaging), but without contrast enhancement.
269194|NCT02325934|Drug|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
269195|NCT02328456|Other|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
269196|NCT00154193|Drug|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
269197|NCT02328469|Drug|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
269198|NCT02328469|Drug|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
269199|NCT02328469|Other|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
269200|NCT02328469|Drug|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
269201|NCT02328482|Drug|Cabaletta 30gr|Cabaletta 30 g for IV infusion administered every week over an additional 52 weeks
269202|NCT02328495|Drug|Misoprostol|Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
264524|NCT02367248|Drug|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
264525|NCT02369627|Device|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
264526|NCT02369627|Other|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
269831|NCT02318602|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
269832|NCT02318615|Procedure|Immediate Axillary Plasty|Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
269833|NCT02318628|Device|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.
CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability.
269834|NCT02318641|Device|oximetry|Retinal oximetry will be performed with Oxymap.
269835|NCT02318654|Other|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
269836|NCT02318654|Drug|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
269837|NCT02320981|Procedure|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
269838|NCT02321020|Procedure|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
269839|NCT00153452|Behavioral|perpetration of intimate partner violence|
269840|NCT02321020|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
269841|NCT02321033|Dietary Supplement|soft drinks|soft drinks with palatinose and maltodextrin
269842|NCT02321059|Device|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
269843|NCT02321072|Drug|Oxygen|
269844|NCT02321085|Procedure|Sinus Rhythm control|
269845|NCT02321085|Procedure|Pulse Rate control|
269846|NCT02321098|Drug|Loceryl Nail Lacquer|Once weekly application of Loceryl Nail Lacquer during 3 months (12 applications) in combination with cosmetic varnish
274228|NCT02332772|Other|Data Collection|Data collected from endoscopy procedures.
274229|NCT02332785|Other|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
274230|NCT02332798|Drug|PF-04958242|Oral capsule, 0.20 mg, twice a day dosing for 14 days
269543|NCT02326012|Behavioral|Emotion Regulation Individual Therapy for Adolescents|
269544|NCT02326025|Drug|Olaratumab|Administered IV
269545|NCT00153985|Drug|Fludarabine|Given intravenously once daily for 4 days
269546|NCT02326025|Drug|Doxorubicin|Administered IV
269547|NCT02326038|Drug|Methylphenidate|single oral administration of 20 mg tablet
269548|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
269549|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
269550|NCT02326077|Other|Ultrasound|Monitoring of the mechanism of labor
269551|NCT02326090|Drug|cis-UCA ophthalmic solution 1.0%|
269552|NCT02326090|Drug|cis-UCA ophthalmic solution 2.5%|
269553|NCT02326090|Drug|Placebo ophthalmic solution|
269554|NCT02326103|Drug|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
269555|NCT02326103|Drug|Placebo|
269556|NCT00153985|Drug|Alemtuzumab|One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.
269557|NCT02326116|Other|Trachael Preparation Education|
269558|NCT02326142|Drug|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
269559|NCT02328547|Drug|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
269560|NCT02328547|Drug|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
269561|NCT02328573|Behavioral|Communal singing|
273946|NCT02339831|Device|CPM passive motion device|
273947|NCT02339844|Drug|Aripiprazole|6 weeks of individual doses of aripiprazole
273948|NCT02339857|Procedure|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
273949|NCT02339870|Other|Psychosocial Support for Caregiver|Complete expressive disclosure writing
273950|NCT02339870|Other|Psychosocial Support for Caregiver|Complete benefit finding writing
273951|NCT02339870|Other|Questionnaire Administration|Ancillary studies
273952|NCT00156390|Other|LV lead placement as per standard of care (without echo guidance)|
273953|NCT02339870|Other|Sham Intervention|Complete writing on an emotionally neutral topic
273954|NCT02339896|Biological|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
274231|NCT02698917|Other|Low normal PaCO2|4.5-4.7 kPa
274232|NCT02698917|Other|High normal PaCO2|5.8-6.0 kPa
274233|NCT02698917|Other|Low normal PaO2|10-15 kPa
274234|NCT02698917|Other|High normal PaO2|20-25 kPa
274235|NCT02698917|Other|Low normal MAP|65-75 mmHg
274236|NCT00201942|Procedure|PET scan|
274237|NCT02698917|Other|High normal MAP|80-100 mmHg
274238|NCT02698930|Drug|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
274239|NCT02698930|Drug|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
274240|NCT02698943|Procedure|Phacoemulsification|Phacoemulsification for cataract extraction with Envista MX-60 implantation
274241|NCT02698956|Device|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
274242|NCT02698969|Drug|Sugammadex|
273636|NCT02346253|Radiation|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
273637|NCT00157313|Behavioral|Social skills training|
273638|NCT02346253|Drug|Bicalutamide|Given PO
273639|NCT02346253|Drug|Leuprolide Acetate|Given IM or SC
273640|NCT02346253|Drug|Goserelin Acetate|Given SC
273641|NCT02346253|Drug|Triptorelin Pamoate|Given IM
273642|NCT02346253|Drug|Degarelix|Given SC
273643|NCT02346253|Other|Laboratory Biomarker Analysis|Correlative studies
273644|NCT02346253|Other|Quality-of-Life Assessment|Ancillary studies
273645|NCT02346266|Other|SMART Education|
273646|NCT02346279|Other|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
273647|NCT02346305|Device|Non-invasive ventilation|Home NIV installation
273648|NCT00002407|Drug|Didanosine|
273649|NCT00157326|Drug|tadalafil|
273650|NCT02346318|Drug|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
273651|NCT02346331|Other|WHO algorithm of fluid boluses guided by physical examination|
273652|NCT02346331|Other|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
273653|NCT02346331|Other|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
273955|NCT02339909|Behavioral|Fixed financial incentive|Participants receiving the "fixed financial incentive" intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment.
273956|NCT02339909|Behavioral|Probabilistic financial incentive|Participants receiving the "probabilistic financial incentive" intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment.
273336|NCT02353598|Drug|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
273337|NCT02353598|Drug|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
273338|NCT02353598|Drug|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
273339|NCT02353598|Drug|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
273340|NCT00158340|Behavioral|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
273341|NCT02353611|Other|peroxide hydrogen 6% compound catalyzed by titanium oxide nanoparticles and activated by blue hybrid light and an infrared laser|
273342|NCT02353611|Other|35% peroxide gel tooth bleaching|conventional peroxide whitening compound acted like control
273343|NCT02353624|Behavioral|Cycling|Cycling distance of 2880 km in 14 days
273344|NCT02353637|Dietary Supplement|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
273345|NCT02353650|Dietary Supplement|Q10|
273346|NCT02353650|Dietary Supplement|placebo|
273347|NCT02353663|Other|Echocardiography|Echocardiography examination
273348|NCT02353676|Drug|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
273349|NCT02353676|Other|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
273350|NCT02353689|Dietary Supplement|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
273351|NCT00158340|Behavioral|Usual clinical care|Control group participants receive treatment as usual.
273352|NCT02353689|Dietary Supplement|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
273654|NCT02346331|Other|Oxygen delivery|
273655|NCT02346331|Other|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
273656|NCT02346331|Other|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
272702|NCT02327611|Drug|Custodiol|
272703|NCT02327611|Drug|Enriched Ringer's lactate solution|
272704|NCT02327624|Drug|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
272705|NCT02329834|Drug|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
273009|NCT02320006|Other|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
273010|NCT02322424|Procedure|pancreaticoduodenectomy|
273011|NCT02322437|Other|Home treatment|Patients are treated at home whenever possible and appropriate
273012|NCT02322437|Other|Treatment As Usual|Patients are treated at a mental hospital
273013|NCT02322450|Drug|QGC001|
273014|NCT02322450|Drug|Placebo|
273015|NCT00153634|Drug|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
273016|NCT02322463|Drug|Arab children|Treatment with Oxycodone
273017|NCT02322476|Other|No intervention will be performed|No intervention will be performed
273018|NCT02322489|Device|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
273019|NCT02322489|Device|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
273020|NCT02322502|Drug|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
273021|NCT02322502|Drug|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
273022|NCT02322502|Drug|propofol|intravenous injection to maintain anaesthesia
273023|NCT02322515|Other|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
273024|NCT02322515|Other|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
272423|NCT02334267|Drug|NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.
272424|NCT00155389|Drug|Helicobacter pylori eradication|For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.
The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013.
272706|NCT02329847|Drug|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
272707|NCT02329847|Drug|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
272708|NCT02329860|Drug|Apatinib|
272709|NCT02329860|Drug|Placebo|
272710|NCT00154349|Drug|Imatinib Mesylate|
272711|NCT02329873|Behavioral|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
272712|NCT02329899|Other|Second step of investigations|Second step according to results of the first step:
exploration of coagulation factors;
factor XIII and fibrinolysis investigations;
investigation of platelet function;
investigation of thrombocytopenia.
272713|NCT02329912|Device|SmartPill|Application of the SmartPill at the end of surgery
272714|NCT02329925|Device|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
272715|NCT02329938|Procedure|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
272716|NCT02329938|Procedure|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
272717|NCT02329951|Procedure|Injection|Injection of steroids and local anesthetic / radiofrequency denervation for those with a positive facet block
272718|NCT02329964|Drug|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
272719|NCT02329964|Drug|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
272129|NCT02341456|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
272130|NCT02341456|Drug|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
272131|NCT02341456|Drug|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
272132|NCT02341469|Other|integrated ediagnostic approach (IeDA)|IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:
REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.
The training of nurses on IMCI and REC.
A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.
A supervision system conducted implemented by district managers to provide support and guidance to health centres.
A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres.
272133|NCT02341482|Drug|PF-04958242|PF-04958242 will be provided in a capsule. subjects will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.
272134|NCT00156663|Behavioral|Caring for Women Veterans|
272425|NCT02334280|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
272426|NCT02336750|Drug|Mirtazapine|15mg D2-4
272427|NCT02336763|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
272428|NCT02336763|Other|Laboratory Biomarker Analysis|Correlative studies
272429|NCT02336776|Other|Functional electrical stimulation|Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.
Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session.
272430|NCT02336789|Other|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
272431|NCT02336789|Other|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
272432|NCT02336802|Behavioral|Avoidance experiment|Participants complete an avoidance task
266840|NCT00162175|Drug|Muraglitazar|
266841|NCT02387372|Drug|Ceftolozane/Tazobactam - Multiple Doses|4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:
Participants with CLCR > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours
Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours
Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours
266842|NCT02387372|Drug|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
266843|NCT02389582|Drug|Enoxaparin|Use for 5 days
266844|NCT02389595|Other|HIV positive subjects|This group will provide a blood sample.
266845|NCT02389595|Other|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
266846|NCT02389608|Device|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
266847|NCT02389608|Device|Functional electrical stimulation (FES)|
266848|NCT02389608|Device|Sham stimulation|
266849|NCT00162448|Drug|Placebo|Oral Solution, Oral, 0 mg, Single dose, 1 day.
266850|NCT02389621|Drug|Lusutrombopag|Tablets for oral administration
266851|NCT02389621|Drug|Placebo|Tablets for oral administration
266852|NCT02389660|Behavioral|Blended Cognitive Behavioural Therapy (CBT)|
266853|NCT02389660|Behavioral|Treatment as usual|
266854|NCT02389673|Device|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
266855|NCT02389686|Device|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
266856|NCT02389699|Radiation|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
266857|NCT02389699|Radiation|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
266858|NCT02389712|Drug|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
266263|NCT02365701|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
266264|NCT00159523|Dietary Supplement|Probiotic|
266550|NCT02355678|Drug|Paracetamol Suppository|If Visual Analogue Scale was less than 4
266551|NCT02355691|Device|PREVENA|The device is a sealed negative pressure wound therapy tool. The details of the device can be found at http://www.kci1.com/KCI1/prevena.
266552|NCT02355704|Drug|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
266553|NCT00158509|Drug|Valacyclovir|
266554|NCT02355704|Drug|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
266555|NCT02355717|Other|Observational Study|
266556|NCT02355730|Procedure|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
266557|NCT02355743|Drug|rtPA lock therapy|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as "lock therapy" in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion.
266558|NCT02355756|Drug|Maxadilan|
266559|NCT02355756|Drug|Placebo|
266560|NCT02355782|Biological|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
266561|NCT02355795|Behavioral|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 13% and 67%, respectively
266562|NCT02358343|Drug|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
266563|NCT02358356|Drug|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
266564|NCT00158743|Other|sodium chloride|
266565|NCT02358356|Drug|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
266005|NCT02372864|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
266006|NCT02372877|Device|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
266007|NCT02372903|Drug|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
266008|NCT02372916|Drug|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
266009|NCT02372929|Procedure|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
266010|NCT02372942|Drug|Lattoferrin|RCT using lattoferrin and progesteron to assess, which of the two drugs will prevent preterm delivery
266011|NCT02372942|Drug|Progesterone|randomized controlled clinical trial administring to pregnant women with risk of preterm delivery lattoferrin or progesteron
266265|NCT02365714|Radiation|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
266266|NCT02365727|Drug|Liposomal bupivacaine|
266267|NCT02365727|Drug|Ropivacaine|
266268|NCT02365727|Drug|Epinephrine|
266269|NCT02365727|Drug|Clonidine|
266270|NCT02365727|Drug|Saline|
266271|NCT02365740|Other|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
266272|NCT02365740|Other|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
266273|NCT02365740|Other|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
266274|NCT02365740|Drug|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
265734|NCT02379390|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
265735|NCT02379416|Drug|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
265736|NCT02379442|Biological|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
265737|NCT02379455|Other|Comprehensive drug review|1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
265738|NCT02379468|Drug|Pedyphar Ointment|
265739|NCT02379468|Drug|Panthenol|Ointment
265740|NCT02381912|Other|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
265741|NCT02381938|Behavioral|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
265742|NCT02381938|Other|Healthy Finances|6-month intervention to educate and improve financial health
265743|NCT02381951|Device|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
265744|NCT02381964|Dietary Supplement|Supradyn® (1RDA+CoQ10)|
265745|NCT02381964|Dietary Supplement|Supradyn® (3RDA)|
265746|NCT02381964|Dietary Supplement|Placebo|
265747|NCT00161460|Behavioral|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
265748|NCT02381977|Other|No intervention|
265749|NCT02381990|Procedure|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic "cryoprobes/devices" are employed to freeze and all "circuled or noted" cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins
266012|NCT02372955|Drug|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
266013|NCT02372955|Drug|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
265112|NCT00158457|Drug|Tenofovir (TDF)|
265424|NCT02386748|Dietary Supplement|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
265425|NCT02386748|Other|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
265426|NCT02386761|Drug|Single Ascending Dose (SAD)|
265427|NCT02386761|Drug|Multiple Ascending Dose (MAD)|
265428|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
265429|NCT02386774|Device|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
265430|NCT02386774|Device|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|used for Multifluorescence IVCM
anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)
Fluorescein 0,5%, Rose Bengal , Infracyanine
265431|NCT02386774|Procedure|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
265432|NCT02386787|Device|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
265433|NCT02386800|Drug|Ruxolitinib|
265434|NCT02386826|Drug|INC280|Dose Escalation Phase: INC280 will be administered orally twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:
Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)
Dose Expansion Phase: INC280 will be administered orally twice daily at the MTD determined in the dose escalation phase
265435|NCT02388997|Drug|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
265436|NCT02388997|Biological|Rhinovirus (strain 16)|This strain of pooled rhiovirus has been approved for use in experiemental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
265437|NCT00162383|Drug|Mephenytoin|
265438|NCT02389010|Biological|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
265439|NCT02389010|Other|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
264814|NCT02362568|Procedure|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
265113|NCT02355054|Drug|C-11 Choline PET Imaging|Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
265114|NCT02355067|Behavioral|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
265115|NCT02355067|Behavioral|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
265116|NCT02355080|Behavioral|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
265117|NCT02355080|Behavioral|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
265118|NCT02355093|Procedure|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
265119|NCT02355093|Procedure|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
265120|NCT02355093|Drug|ropivacaine|
265121|NCT02355106|Device|PolarStart System|Atrial flutter Ablation
265122|NCT02355119|Drug|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
265123|NCT00158457|Drug|Emtricitabine (FTC)|
265124|NCT02355119|Drug|Gemcitabine|
265125|NCT02355132|Other|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
265126|NCT02355158|Drug|clonidine hydrochloride topical gel, 0.1%|
265127|NCT02357797|Drug|Vortioxetine|
265128|NCT02357797|Other|Placebo|
265129|NCT02357810|Drug|Pazopanib Hydrochloride|Given PO
264519|NCT00159744|Drug|Asenapine|Asenapine, 3 weeks
264520|NCT02367222|Other|Exposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
264521|NCT02367222|Other|Unexposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
264522|NCT02367235|Procedure|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
264523|NCT02367235|Procedure|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
264815|NCT02362581|Other|prophylaxis treatment, on demand treatment|
264816|NCT02362594|Biological|pembrolizumab|
264817|NCT02362594|Other|placebo|Locally sourced placebo
264818|NCT02362607|Behavioral|Integrated Diabetes Management Protocol|
264819|NCT02362607|Behavioral|Standard Diabetes Management Protocol|
264820|NCT02362633|Device|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
264821|NCT02362633|Device|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
264822|NCT02362646|Biological|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
264823|NCT02362646|Drug|Control Solution|
264824|NCT00159276|Procedure|Induced Sputum|
264825|NCT02362672|Drug|NKTR-181|
264826|NCT02362672|Drug|Placebo|
264827|NCT02362685|Device|functional test|subjects perform a metabolic exercise testing
264828|NCT02362685|Genetic|matching genotype with phenotype|
264527|NCT02369640|Procedure|Error-management training vs error-avoidance training. Defined by training instructions.|. Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.
Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as "the more errors you make, the more you learn!" or "you have made an error? Great! Because now you can learn something new!"
264528|NCT00159952|Procedure|intensive insulin therapy|control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.
treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL
264529|NCT02369653|Drug|Apixaban|
264530|NCT02369653|Other|No systemic anticoagulant prophylaxis|
264531|NCT02369666|Dietary Supplement|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
264532|NCT02369666|Dietary Supplement|Placebo|Contains MCT oil.
264533|NCT02369679|Device|Precast Adjustable Compression Wrap (Circaid)|A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.
After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days).
264534|NCT02369679|Device|Multilayer Compression Bandages|A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.
After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days).
264535|NCT02369692|Device|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
264536|NCT02369718|Other|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
264835|NCT02365116|Behavioral|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
264836|NCT02365129|Other|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
264837|NCT02365142|Biological|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
270137|NCT02352324|Other|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
270138|NCT00002411|Drug|Lamivudine|
270139|NCT00158236|Drug|Buprenorphine|
270140|NCT02352337|Drug|FOLFIRINOX|
270141|NCT02352337|Drug|LV5FU2|
270142|NCT02352337|Drug|FOLFIRI|
270143|NCT02315833|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
270144|NCT02315872|Drug|ACTH|ACTH injections twice weekly for 28 weeks.
270145|NCT02315872|Drug|Placebo|Placebo injections twice weekly for 28 weeks.
270146|NCT02315885|Other|Alcohol administration|
270147|NCT02315898|Drug|Inhaled tissue plasminogen activator (tPA)|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment
270148|NCT02315911|Procedure|ATE|surgical removal of adenoids and tonsils
270149|NCT02315911|Procedure|APP|surgical removal of adenoids and tonsils and suturing of palatal pillars
270150|NCT02315924|Other|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
270151|NCT00152971|Drug|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
270152|NCT02315924|Other|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
270153|NCT02315937|Procedure|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
270154|NCT02315950|Other|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
269562|NCT02328586|Other|Group Acupuncture|
269563|NCT02328599|Procedure|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
269564|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
269565|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
269847|NCT02321098|Drug|Loceryl Nail Lacquer|Once weekly application of Loceryl Nail Lacquer during 3 months (12 applications)
269848|NCT02321098|Drug|Loceryl Nail Lacquer follow up period|Once weekly application of Loceryl Nail Lacquer during 15 additional months
269849|NCT02321098|Other|Cosmetic varnish|Once weekly application of cosmetic varnish during 3 months (12 applications) in combination with Loceryl Nail Lacquer
269850|NCT00153465|Behavioral|Motivational intervention, parent training|
269851|NCT02321111|Drug|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
269852|NCT02321111|Drug|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water
269853|NCT02321124|Other|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
269854|NCT02321124|Behavioral|life style advice|We will apply life style advice for four weeks.
269855|NCT02321137|Procedure|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
269856|NCT02321137|Procedure|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
269857|NCT02321150|Procedure|Cautery|Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.
Conjunctiva undermined at the recipient site.
Relaxing incisions placed at the corners of the recipient site.
Graft is slid into place
Graft / host interface is gently dried with a Qtip
Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.
Power setting: 25.
Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.
Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off
Cautery is applied at the 4 apices of the graft then in between these points.
269858|NCT02323594|Drug|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
269859|NCT00153699|Drug|Topiramate|
274243|NCT02698969|Device|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
274244|NCT02698969|Drug|Neostigmine|
274245|NCT02698969|Drug|Atropine|
274246|NCT02698969|Device|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
274247|NCT00201955|Drug|Rebamipide|
274248|NCT02698969|Drug|Rocuronium|Rocuronium will be administered 0.6 mg*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
274249|NCT02698969|Drug|Fentanyl|Fentanest will be administered 2 mcg*kg-1 at the induction of general anesthesia and titrated 0.5 mcg*kg-1 every 30 minutes
274250|NCT02698969|Drug|Propofol|Propofol will be administered 2 mg*kg-1 at the induction of general anesthesia
274251|NCT02698969|Drug|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
274252|NCT02698982|Device|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
274253|NCT02698982|Procedure|moderate risk surgery|
269566|NCT00154219|Drug|Lumiracoxib (drug)|
269567|NCT02328612|Other|Intravenous infusion of cells|The treatment administration will be infused intravenously to the subjects after randomization:
An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator.
269568|NCT02328638|Behavioral|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
269569|NCT02328638|Behavioral|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
269570|NCT02328651|Drug|Ribavirin plus Xiao'er jiebiao oral liquid|For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.
For moderate (Phase II) patients:
recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg,iv, Bid~tid）
273957|NCT02342132|Device|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
273958|NCT02342132|Device|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
273959|NCT02342132|Device|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
273960|NCT02342145|Drug|Basiliximab,|Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
273961|NCT02342145|Drug|cyclosporine A|Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
273962|NCT02342145|Drug|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
273963|NCT02342145|Drug|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
273964|NCT02342158|Procedure|biopsy or surgical sampling|
273965|NCT00156741|Device|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
273966|NCT02342158|Other|blood sampling|
273967|NCT02342171|Other|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
273968|NCT02342184|Drug|GB-0998|
273969|NCT02342197|Drug|Decapeptyl|half the dose of Gn agonist
274254|NCT02698995|Drug|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
274255|NCT02698995|Drug|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
273657|NCT02346357|Procedure|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% [local anesthetic]) 30 minutes prior to induction of anesthesia.
273658|NCT02346357|Drug|Ropivacaine|
273659|NCT02346357|Drug|Placebo Saline|
273660|NCT00157339|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
273661|NCT02348710|Behavioral|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
273662|NCT02348710|Behavioral|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
273663|NCT02348723|Drug|Warfarin|Patients receiving Warfarin to keep INR between 2.0 - 3.0
273664|NCT02348723|Drug|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg BID
273665|NCT02348736|Device|Time for tracheal intubation|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
273666|NCT02348749|Radiation|18F-MFBG (meta-fluoro benzylguanidine)|Adult patients: about 8-12 mCi of 18F-MFBG will be administered intravenously. Pediatric patients: 12 mCi/1.7m2 IV (up to a maximum of 12mCi).
273667|NCT00157781|Device|Medtronic AT500|
273668|NCT02348749|Device|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
273669|NCT02348749|Other|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration.
273670|NCT02348762|Dietary Supplement|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
273671|NCT02348775|Dietary Supplement|Cysteine (as n-acetylcysteine) and glycine|HIV patients will be studied before and after receiving cysteine and glycine
273672|NCT02348788|Drug|Artemether-lumefantrine + Primaquine|
273673|NCT02348788|Drug|Chloroquine + Primaquine|
273025|NCT02322528|Drug|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
273026|NCT00002393|Drug|Indinavir sulfate|
273027|NCT00153634|Drug|PO ciprofloxacin|500 mg every 12 hours if weight <50 kg 750 mg every 12 hours if weight ≥50 kg
273028|NCT02322541|Other|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
273029|NCT02322554|Biological|Cellular and tissue based products|Procedure: Application of device or biological to wounds
273030|NCT02322567|Other|medical records|review of medical records
273353|NCT02353689|Dietary Supplement|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
273354|NCT02353702|Procedure|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
273355|NCT02353702|Drug|Infusion of Ropivacaine during 48 hours|20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.
20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %.
273356|NCT02353702|Device|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
273357|NCT02353702|Drug|Infusion of placebo during 48 hours|
273358|NCT02317497|Drug|Vasopressors to maintain normal blood pressure values, if needed|
273359|NCT02317497|Drug|Osmotherapeutics to lowr intracranial pressure, if needed|
273360|NCT02317497|Procedure|Endovascular stroke care to treat brain vessel occlusions, if needed|
273361|NCT02317497|Procedure|Decompressive neurosurgery, if needed|
273362|NCT02317510|Procedure|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
273363|NCT02317510|Procedure|general anesthesia|General anesthesia for laparoscopic cholecystectomy
273364|NCT02317523|Behavioral|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
273365|NCT00153062|Drug|Micardis|80 mg micardis
273366|NCT02317523|Behavioral|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
272720|NCT02329977|Other|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
272721|NCT00154362|Drug|Oxcarbazepine|
272722|NCT02329990|Dietary Supplement|phosphorus|phosphorus supplement
272723|NCT02330003|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
272724|NCT02330003|Biological|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
272725|NCT02330016|Device|Voluma XC|Voluma XC
273031|NCT02322580|Drug|etanercept|
273032|NCT02322593|Drug|TAS-118 plus Oxaliplatin|
273033|NCT02322593|Drug|S-1 plus Cisplatin|
273034|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
273035|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
273036|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
273037|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
273038|NCT02324959|Device|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
273039|NCT02324959|Device|Acupuncture|The affected meridian group is treated by needling on Baihui (GV20/DU20) and Shenting (GV24/DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices).
273040|NCT02324972|Drug|AQX-1125|Synthetic SHIP1 activator
273041|NCT02324972|Drug|Placebo|
273042|NCT02324985|Drug|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
273043|NCT02324985|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
273044|NCT02324998|Drug|Olaparib|PARP Inhibitor
273045|NCT02324998|Drug|Degarelix|Gonadotrophin releasing hormone blocker
272433|NCT02336815|Drug|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
272434|NCT02336815|Drug|Dexamethasone|20 mg will be given with each dose of Selinexor.
272435|NCT00156052|Radiation|Hypofractionated whole breast radiation schedule|
272436|NCT02336841|Other|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
272437|NCT02336841|Other|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
272438|NCT02336854|Drug|Tacrobell tab. 2mg|
272439|NCT02336854|Drug|Prograf cap. 2mg|
272440|NCT02336867|Device|Closure clip (OTSC® Proctology)|
272441|NCT02336880|Behavioral|Internet-delivered cognitive behavioural therapy|
272442|NCT02336893|Behavioral|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
272726|NCT02330029|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
272727|NCT02330029|Device|Atractylodes|Atractylodes (~10-15g)
272728|NCT02330029|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
272729|NCT02332083|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
272730|NCT02332083|Device|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
272731|NCT02332083|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
272732|NCT02332083|Device|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
272733|NCT02332096|Device|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
267151|NCT02382523|Drug|Acthar 80 unit injection|Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.
If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.
If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed.
267152|NCT00161538|Device|Pacing leads to be implanted according randomization.|
267153|NCT02382536|Device|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
267154|NCT02382536|Device|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
267155|NCT02384928|Drug|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
267156|NCT02384928|Procedure|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
267157|NCT02384928|Behavioral|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
267158|NCT02384941|Drug|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
267159|NCT02384941|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
267160|NCT02384941|Drug|Placebo|Placebo, once daily, before the first meal of the day
267161|NCT02384954|Biological|Rituximab|Intravenous infusion; Patients will receive a 4-week induction cycle consisting of Rituximab given on Day 1, 8, 15, 22. Eligible patients will receive a consolidation treatment consisting of Rituximab given on Day 78, 134, 190, 246.
267162|NCT02384954|Biological|ALT-803|Intravenous infusion for cohort 1, 2 and 3; subcutaneous injection for cohort 4, 5, 6 and 7; Patients will receive a 4-week induction cycle consisting of ALT-803 given on Day 2, 8, 15, 22. Eligible patients will receive a consolidation treatment consisting of ALT-803 given on Day 78, 134, 190, 246.
267163|NCT02384967|Drug|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
266566|NCT02358356|Drug|Temozolomide|temozolomide 75mg/m2 b.i.d.
266567|NCT02358369|Drug|Bimatoprost|Bimatoprost sustained release
266568|NCT02358369|Drug|Timolol|BID drops OU, 0.5% ophthalmic solution
266569|NCT02358382|Drug|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
266859|NCT02389712|Drug|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed > 40mg.
266860|NCT00162461|Drug|Phenytoin single dose (300 mg)|
266861|NCT02389725|Device|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
266862|NCT02389725|Device|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
266863|NCT02389738|Drug|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
266864|NCT02389738|Drug|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
266865|NCT02389738|Device|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
266866|NCT02389751|Drug|Ganetespib|Starting dose of Ganetespib 80 mg/m2 by vein once a week during radiotherapy.
266867|NCT02389751|Drug|Carboplatin|AUC=2 weekly by vein during radiation therapy.
266868|NCT02391922|Behavioral|First aid instructions by mobile phone|
266869|NCT02391935|Drug|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
266870|NCT02391935|Drug|Placebo|Cryomedium
266871|NCT02391935|Device|Sham injection|skin penetration of the needle without injection of liquid
266872|NCT02391961|Drug|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
266873|NCT02391961|Drug|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
266275|NCT00159523|Biological|placebo|
266276|NCT02365740|Drug|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
266277|NCT02365753|Device|SofPulse|Pulsed Electomagnetic Field Therapy Device. Selectively inhibits cytokines to inhibit pain.
266278|NCT02365766|Drug|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
266279|NCT02365766|Drug|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
266280|NCT02365766|Drug|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
266281|NCT02367898|Other|Lumosity Cognitive Training|adaptive online cognitive training
266282|NCT02367898|Other|Crossword Puzzles|timed online crossword puzzles
266283|NCT02367911|Drug|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
266284|NCT00159796|Drug|Asenapine|Asenapine, 3 weeks
266285|NCT02367911|Drug|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
266570|NCT02358395|Drug|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
266571|NCT02358395|Drug|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
266572|NCT02358408|Device|Blood glucose monitoring systems for self-testing|
266573|NCT02358434|Device|Cruciate Retaining, Fixed Bearing ATTUNE TM Knee System|
266574|NCT02358447|Procedure|TKR|non-navigated versus computer-navigated total knee replacement
266575|NCT00158756|Biological|Diphtheria|
266576|NCT02358460|Device|Ventilation delivered by SLE5000 ventilator|In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.
In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits.
266577|NCT02358473|Biological|mogamulizumab|Mogamulizumab will be administered by IV infusion.
266578|NCT02358473|Drug|Docetaxel|Docetaxel will be administered by IV infusion.
266014|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
266015|NCT02372968|Other|Full body composition and of plasma and urine metabolites|Full body composition in lean, fat and bone mass will be assessed from DXA scans.
Plasma and urine metabolites will be measured using metabolomics
266016|NCT02372981|Device|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
266017|NCT02374619|Dietary Supplement|Placebo|
266018|NCT02374632|Other|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
266019|NCT02374632|Other|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
266020|NCT02374632|Other|Sham feeding|
266021|NCT02374645|Drug|Volitinib|600mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
266022|NCT02374645|Drug|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
266023|NCT02374645|Drug|Volitinib|800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
266024|NCT00160511|Drug|Levetiracetam|
266025|NCT02374658|Behavioral|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
266026|NCT02374671|Device|VisAbility Implant Model SGP-046|The VisAbility implant is a curved scleral implant segment that is injection molded from PMMA ( polymethyemethacrylate), a material with an extensive history of long-term implantation in the human eye, including intraocular lenses (IOLs). Four (4) VisAbility Implant segments are placed in a single presbyopic eye to improve near vision.
266027|NCT02374684|Drug|Methosulide|Tolerability Study:
Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)
Pharmacokinetic Study:
Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg
,group 2:depending on the adverse drug reaction,150mg/250mg)
Food Effect on the Pharmacokinetics:
single dose(100mg),two status(Feeding and fasting), washout period(7 days)
266028|NCT02374684|Drug|Placebo|Placebo to match with experimental groups
266029|NCT02374697|Device|During tele-expertise|
265440|NCT02389023|Other|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
265750|NCT02382003|Behavioral|Positive Cognitive Bias Modification - Interpretation|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.
265751|NCT02382003|Behavioral|50/50 Cognitive Bias Modification - Interpretation Control|This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment. Thus, there will not be a contingency trained with regards to how ambiguous situations are resolved.
265752|NCT02382003|Behavioral|Neutral Cognitive Bias Modification - Interpretation Control|This control condition follows the same format as the training scenarios (i.e., 3 sentence stories that end with a word fragment), but scenarios are neutral throughout and do not resolve any emotional ambiguity will be used. In this way, the neutral condition will match the other conditions for task demands, such as attention, time, format, and other nonspecific factors.
265753|NCT02382003|Behavioral|Anxious Imagery Prime|We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime prior to each training session will enhance training effects.
265754|NCT02382003|Behavioral|Neutral Imagery Prime|Prior to each training session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
265755|NCT02382016|Drug|Macitentan|Macitentan film-coated tablet 10 mg once daily.
265756|NCT02382016|Other|Placebo|Matching placebo tablet once daily.
265757|NCT02382029|Drug|Clonazepam|Active medical treatment for burning mouth syndrome
265758|NCT00161473|Drug|prazosin|Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.
Duration was 8 weeks.
265759|NCT02382029|Other|acupuncture|Traditional chinese acupuncture
265760|NCT02384408|Procedure|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
265761|NCT02384421|Device|Adaptive DBS (Activa PC+S Neurostimulator)|
265762|NCT00161772|Biological|Tick-borne Encephalitis Vaccine|
265763|NCT02384421|Device|Continuous DBS (Activa PC+S Neurostimulator)|
265764|NCT02384434|Device|Low Level Laser Therapy|Red Light Therapy
265765|NCT02384460|Drug|SD-101-6.0 cream|applied topically once a day for 90 days
265130|NCT02357810|Drug|Oral Topotecan Hydrochloride|Given PO
265131|NCT02357810|Other|Laboratory Biomarker Analysis|Correlative studies
265132|NCT02357823|Other|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
265133|NCT02357823|Other|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
265441|NCT02389023|Other|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
265442|NCT02389036|Drug|SDD Paste|A six-hourly topical application of 0.5g paste, containing colistin 2%, tobramycin 2% and nystatin 2%,
265443|NCT02389036|Drug|SDD Suspension|A six-hourly administration of 10 ml of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 106 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
265444|NCT02389036|Drug|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
265445|NCT02389062|Other|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
265446|NCT02389075|Procedure|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
265447|NCT02389075|Procedure|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
265448|NCT00162383|Drug|Dapsone|
265449|NCT02389088|Drug|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
265450|NCT02389101|Other|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
265451|NCT02389114|Other|Soy Protein|Soy protein is commonly consumed in Asian diet.
265452|NCT02389114|Other|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
264829|NCT02362698|Other|electro-acupuncture|13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.
HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour.
264830|NCT02362698|Other|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
264831|NCT02362711|Drug|NPC-16 Standard Dosing Regimen Group|
264832|NCT02362711|Drug|NPC-16 Continuous Dosing Regimen Group|
264833|NCT02362711|Drug|Placebo Group|
264834|NCT02362737|Behavioral|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be ~16 weekly meetings of ~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
265134|NCT02357836|Drug|Itraconazole|Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, "Post-treatment" assessments will include a skin biopsy, blood draw for the PK analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure.
265135|NCT00002412|Drug|Didanosine|
265136|NCT00158678|Procedure|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
265137|NCT02357849|Drug|Aripiprazole|see arm description
265138|NCT02357849|Drug|Fluoxetine|see arm description
265139|NCT02357862|Procedure|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
265140|NCT02357888|Drug|V0018|Oromucosal - Single dose
265141|NCT02357888|Drug|Placebo|Oromucosal - Single dose
265142|NCT02357901|Drug|Sublingual Film buprenorphine|Sublingual film is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization
265143|NCT02357901|Drug|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either High dose or Low dose
264838|NCT02365142|Biological|Platelet Rich plasma (PRGF)|3 injections of PRGF
264839|NCT02365155|Other|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
264840|NCT02365155|Other|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
264841|NCT02365155|Other|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
264842|NCT02365155|Other|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
264843|NCT02365155|Other|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
264844|NCT02365155|Other|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
264845|NCT00159458|Drug|Gemcitabine and oxaliplatin|
264846|NCT02365168|Other|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
264847|NCT02365168|Other|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
264848|NCT02365168|Other|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
264849|NCT02365168|Other|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
264850|NCT02365181|Procedure|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
265153|NCT02360033|Behavioral|Systemic Therapy for Social Anxiety Disorder|
265154|NCT02360033|Behavioral|Cognitive Behavioral Therapy for Social Anxiety Disorder|
265155|NCT02360046|Drug|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
265156|NCT02360046|Drug|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
270155|NCT02315963|Other|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
270156|NCT02315976|Drug|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
270443|NCT02347423|Biological|IPV Vaccine SSI|
270444|NCT02347436|Procedure|24-hr ambulatory blood pressure measurement|
270445|NCT02347449|Other|Questionnaires, Oncotype Dx Assay|Physician pre-assay questionnaire
Patient pre-assay questionnaire
Oncotype DX® Assay
Physician post- assay questionnaire
Patient post-assay questionnaire
270446|NCT02347462|Device|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
270447|NCT02349841|Drug|Meropenem|To administer 2g daily 8 hourly for 14 days
270448|NCT02349841|Drug|Faropenem|To adminster 600mg 8 hourly daily for 14 days
270449|NCT02349841|Drug|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
270450|NCT02349841|Drug|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
270451|NCT02349854|Procedure|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm & 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
270452|NCT02349867|Drug|Gemcitabine Hydrochloride|Given IV
270453|NCT02349867|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
270454|NCT00157924|Drug|atorvastatin|atorvastatin 10mg
270455|NCT02349867|Drug|Sorafenib Tosylate|Given PO
270456|NCT02349867|Drug|Vorinostat|Given PO
270457|NCT02349867|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
270458|NCT02349867|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
269860|NCT02323594|Drug|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
269861|NCT02323594|Drug|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
269862|NCT02323607|Drug|Pacritinib|Given PO
269863|NCT02323607|Drug|Cytarabine|Given IV
269864|NCT02323607|Drug|Daunorubicin Hydrochloride|Given IV
269865|NCT02323607|Drug|Decitabine|Given IV
269866|NCT02323607|Other|Laboratory Biomarker Analysis|Correlative studies
270157|NCT02315989|Radiation|proton therapy|proton therapy
270158|NCT02316002|Drug|Pembrolizumab 200 mg every 3 weeks|
270159|NCT02316015|Dietary Supplement|Infatrini® or Infatrini Peptisorb®|
270160|NCT02316028|Drug|Decitabine|administration of decitabine by hepatic arterial infusion
Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.
Proposed dose levels:
10 mg/m2 per course
15 mg/m2 per course
20 mg/m2 per course
270161|NCT02316041|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
270162|NCT00152971|Drug|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
270163|NCT02316041|Device|ReLEx® (SMILE)|
270164|NCT02316054|Device|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
270165|NCT02318667|Biological|Golimumab|Golimumab is a fully human anti-TNFalpha monoclonal antibody that will be administered SC.
270166|NCT02318680|Other|Review of follow home visits after discharge from Nykøbing Falster Hospital|The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
270167|NCT02318693|Drug|Sitagliptin|Sitagliptin 50 mg orally, once a day before breakfast for 14 days
270168|NCT02318693|Drug|Glibenclamide|Glibenclamide, 1.25 mg orally, twice a day (2.5 mg/day) for 14 days
270169|NCT00153101|Drug|Ramipril|
270170|NCT02318706|Drug|DS-5565|
269571|NCT02328651|Drug|Ribavirin|For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.
For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg, iv, Bid~tid）
269572|NCT02328664|Procedure|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
269573|NCT02328690|Other|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz [Hz]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
269574|NCT02330770|Drug|GnRHa then HCG|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
269575|NCT02330770|Drug|GnRHa then HCG|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
269576|NCT02330783|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
269577|NCT02330783|Drug|Sorafenib|400mg twice daily by oral of each 4-week cycle
269578|NCT02330796|Drug|Bucillamine|Bucillamine Tablets
269579|NCT02330796|Drug|Colchicine|
269580|NCT02330809|Other|Daily extra water intake|Amount of extra daily water intake to consume
269867|NCT02323607|Other|Pharmacological Study|Correlative studies
269868|NCT02323620|Procedure|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
269869|NCT02323633|Device|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
269870|NCT00153725|Drug|Aspirin and Pantoloc|
269871|NCT02323633|Device|Sham|No transcranial Pulsed Current Stimulation (tPCS)
269872|NCT02323646|Drug|Placebo Comparator|Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids
274256|NCT02698995|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
274257|NCT02701231|Device|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
274258|NCT02701244|Radiation|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
274259|NCT02701257|Device|iPhone-based bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
274260|NCT02701257|Device|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
274261|NCT02701257|Drug|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
274262|NCT00202267|Device|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
274263|NCT02701257|Drug|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
274264|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
274265|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
274266|NCT02701270|Dietary Supplement|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
274267|NCT02701270|Dietary Supplement|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
274268|NCT02701283|Device|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
274269|NCT02701283|Device|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
274270|NCT02701296|Drug|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
274271|NCT02701296|Drug|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
269581|NCT02330809|Other|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
273970|NCT02342210|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
273971|NCT02342223|Device|Voluma|
273972|NCT02342236|Device|cemented or cementless type of hip prothesis|
273973|NCT02344394|Device|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
273974|NCT02344394|Device|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
273975|NCT02344394|Device|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
273976|NCT02344407|Biological|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
273977|NCT02344407|Biological|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
273978|NCT02344407|Drug|Placebo|
273979|NCT00002407|Drug|Nevirapine|
273980|NCT00157014|Drug|Prednisone|Oral
273981|NCT02344420|Procedure|Echocardiography|The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.
Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization.
273982|NCT02344420|Behavioral|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
273983|NCT02344420|Procedure|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
273367|NCT02317536|Dietary Supplement|Carnipure Product 1|
273368|NCT02317536|Dietary Supplement|Carnipure Product 2|
273369|NCT02317536|Other|Placebo|Placebo
273370|NCT02317549|Drug|LB1148|
273371|NCT02317549|Drug|Placebo|
273372|NCT02317562|Drug|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
273373|NCT02317575|Biological|LY900014|Administered SC
273374|NCT02317575|Biological|Insulin Lispro|Administered SC
273375|NCT02317588|Dietary Supplement|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
273376|NCT00153062|Drug|Micardis|80 mg micardis
273674|NCT02348801|Behavioral|Weight loss and Exercise|Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.
Exercise sessions of ~90 min duration 15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and, after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months.
273675|NCT02348801|Behavioral|Healthy lifestyle|Diabetes support and education
273676|NCT02348827|Behavioral|Family psychoeducation|
273677|NCT02348827|Behavioral|Social support group|
273678|NCT00157794|Device|Search AV+ algorithm|
273679|NCT02348840|Device|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
273680|NCT02348853|Behavioral|Healthy Weight for Living (HWL)|
273681|NCT02348853|Behavioral|Current Best Practice (CBP)|
273682|NCT02348866|Other|method of laundering and donning scrubs|
273683|NCT02351388|Device|Transcranial Direct Current Stimulation|
273684|NCT00158119|Behavioral|InVEST (Increased Velocity Exercise Specific to Task)|
273046|NCT02325011|Drug|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
273047|NCT02325011|Drug|Sativex® and fluconazole concomitantly (Treatment B)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose.
273048|NCT00153894|Behavioral|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
273049|NCT02325024|Drug|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
273050|NCT02325037|Drug|GLPG1837 single ascending doses|Single dose, oral suspension
273051|NCT02325037|Drug|Placebo single dose|Single dose, oral suspension matching placebo
273377|NCT02317588|Dietary Supplement|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
273378|NCT02317601|Drug|methylprednisolone sodium succinate|Single dose Intravenous
273379|NCT02317601|Drug|placebo saline|
273380|NCT02317614|Behavioral|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
273381|NCT02317627|Drug|KD025|
273382|NCT02317640|Drug|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
273383|NCT02320019|Drug|Placebo|Placebo matching YH14618
273384|NCT02320019|Drug|YH14618|
273385|NCT02320032|Drug|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
273386|NCT02320045|Drug|ITCA 650 (Exenatide in osmotic mini pump)|
273387|NCT02320058|Drug|Ipilimumab|
273388|NCT02320058|Drug|Nivolumab|
272734|NCT02332109|Device|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
272735|NCT02332122|Procedure|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is >= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
272736|NCT02332122|Procedure|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of >= 3mm is a positive result.
272737|NCT02332122|Other|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
272738|NCT02332135|Procedure|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
272739|NCT00154739|Drug|Cisplatin|
272740|NCT02332135|Drug|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
273052|NCT02325037|Drug|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
273053|NCT02325037|Drug|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
273054|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
273055|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp).
273056|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
273057|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 1*10^11 viral particles (vp).
273058|NCT02325050|Other|Placebo|One 0.5 mL IM injection of 0.9% saline.
267450|NCT02377817|Device|PrenaBelt|The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.
The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side.
267451|NCT02377817|Device|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
267452|NCT02377830|Device|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
267453|NCT02380027|Procedure|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
267454|NCT02380040|Device|PPG|
267455|NCT00161278|Procedure|Gene expression profiling (analysis) of tumor samples|
267456|NCT02380053|Drug|Bisoprolol|2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
267457|NCT02380053|Drug|Celiprolol|2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
267458|NCT02380066|Drug|Anyu Peibo|
267459|NCT02380079|Drug|SCD-101|Administered as gelatin capsules
267460|NCT02380092|Device|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
267461|NCT02380105|Behavioral|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
267462|NCT02380105|Device|Interocclusal Appliances|Patients were treated using interocclusal appliances
267463|NCT02380118|Drug|Olanzapine|Intramuscular injection
267464|NCT02380118|Drug|Haloperidol|Intramuscular injection
267465|NCT02380118|Drug|Midazolam|Intramuscular injection
267466|NCT00161291|Drug|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
266874|NCT02391974|Device|PERIOSYAL FILL|Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.
Touch-up treatment provided at 3 and 6 weeks.
266875|NCT00162747|Drug|Sunflower Seed Oil|
266876|NCT02391987|Device|Tele-monitoring and health coaching|Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.
Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management.
266877|NCT02392000|Device|WatchPAT sleep monitor|Self-management of insomnia using a mobile sleep device
267164|NCT02384980|Device|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
267165|NCT00161850|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
267166|NCT02384993|Behavioral|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
267167|NCT02385006|Biological|Blood sample|
267168|NCT02385019|Biological|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|Regulatory T cells selected by a sequential 2 step procedure:
- Negative selection of CD8 and CD19 cells
- Positive selection of CD25 cells
267169|NCT02385032|Drug|Ursodiol|
267170|NCT02385032|Drug|URSO Forte|
267171|NCT02385045|Device|i-scan|i-scan function is located on the head of the Pentax endoscopes
267172|NCT02385045|Device|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
267173|NCT02387385|Device|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
267174|NCT02387398|Procedure|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
267175|NCT02387411|Other|High-intensity interval exercise training|High-intensity interval exercise training [4 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)]
266579|NCT02358486|Device|Acupuncture|Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)
Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 ~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea
266580|NCT02358486|Device|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
266581|NCT02358499|Drug|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
266582|NCT02358512|Other|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
266583|NCT02358525|Behavioral|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
266584|NCT02360605|Behavioral|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
266585|NCT02360618|Drug|Metformin|See Group Description
266586|NCT02360618|Drug|Simvastatin|See Group Description
266587|NCT02360631|Drug|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
266878|NCT02392000|Behavioral|CBT-i Coach mobile app|Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
266879|NCT02392013|Other|Home Modification|Removal of home barriers or hazards.
266880|NCT02392026|Drug|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
266881|NCT02392039|Drug|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
266882|NCT02392039|Drug|Loratadine|Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
266883|NCT02392039|Other|Placebo|Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
266286|NCT02367924|Drug|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
266287|NCT02367937|Drug|PRC-4016 (icosabutate)|Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under "Study description"
266288|NCT02367950|Behavioral|Exercise|10 exercise sessions with a personal trainer
266289|NCT02367963|Behavioral|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
266290|NCT02367963|Behavioral|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
266291|NCT02367976|Drug|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
266292|NCT02367989|Dietary Supplement|0g of barley β-glucan|
266293|NCT02367989|Dietary Supplement|2g of barley β-glucan|
266294|NCT02367989|Dietary Supplement|4g of barley β-glucan|
266295|NCT00159796|Drug|Olanzapine|Olanzapine, 3 weeks
266296|NCT02367989|Dietary Supplement|8g of barley β-glucan|
266297|NCT02368002|Behavioral|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
266298|NCT02368002|Behavioral|Meal replacements|Participants continue with behavioral weight loss therapy, but this is augmented with meal replacements (MR). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. MRs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. MRs also serve as a "teaching tool" regarding the amount and type of food people should eat in order to produce weight loss.
266299|NCT02370407|Device|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
266300|NCT02370420|Biological|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
265766|NCT02384460|Drug|SD-101-0.0 cream|applied topically once a day for 90 days
265767|NCT02384473|Procedure|Real-Time CEUS|Undergo real-time CEUS
265768|NCT02384473|Procedure|SWE|Undergo SWE
266030|NCT02374710|Procedure|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
266031|NCT02374710|Procedure|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
266032|NCT02374723|Device|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
266033|NCT02374723|Device|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
266034|NCT02374736|Drug|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).
Privigen will be provided in vials containing 10 g IgG in 100 mL.
266035|NCT00160524|Biological|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
266036|NCT02374749|Behavioral|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
266037|NCT02374749|Behavioral|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
266038|NCT02377089|Device|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
266039|NCT00160849|Drug|Lopinavir/r|
266040|NCT02377089|Device|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
266041|NCT02377102|Procedure|Physical Therapy|12 weeks of supervised physical therapy.
266042|NCT02377115|Other|Tablet computer-based clinical screening tool.|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing postoperative delirium.
266043|NCT02377128|Procedure|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
265453|NCT02391285|Device|dynamometer (Auckland vaginal elastometer)|The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.
I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.
II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.
III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings.
265454|NCT02391298|Behavioral|Mindfulness Meditation|
265455|NCT02391311|Device|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
265769|NCT02384486|Behavioral|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
265770|NCT02384486|Other|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
265771|NCT02384499|Biological|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
265772|NCT02384499|Drug|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
265773|NCT00161785|Biological|FSME-IMMUN 0.5ml|
265774|NCT02384512|Drug|Azilect®|AZILECT® 1mg Tablets
265775|NCT02384525|Procedure|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
265776|NCT02384525|Procedure|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
265777|NCT02384538|Biological|ABT-981|ABT-981
265778|NCT02384538|Other|Placebo|Placebo
265144|NCT02357901|Drug|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen expect volumes matching the experimental drug at either the Low dose or High dose
265145|NCT02357927|Behavioral|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
265146|NCT02357927|Behavioral|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
265147|NCT00158678|Drug|concomitant cisplatin|100 mg/m2 D1, D22, D43
265148|NCT02357940|Drug|Experimental Product|1% Colloidal Oatmeal Balm
265149|NCT02357953|Other|Measurement of cardiac index|
265150|NCT02357966|Biological|514G3|True Human Monoclonal Antibody
265151|NCT02357966|Drug|Placebo|
265152|NCT02360020|Device|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
265456|NCT02391324|Procedure|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
265457|NCT02391324|Procedure|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
265458|NCT02391324|Procedure|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
265459|NCT02391337|Drug|Bisoprolol|
265460|NCT00002430|Drug|Stavudine|
265461|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
265462|NCT02391337|Drug|Digoxin|
265463|NCT02391350|Behavioral|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
265464|NCT02391350|Procedure|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
265465|NCT02391363|Behavioral|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
265157|NCT02360059|Drug|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
265158|NCT02360059|Other|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
265159|NCT02360059|Behavioral|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
265160|NCT02360059|Other|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
265161|NCT00158899|Drug|GW501516 oral tablets|
265162|NCT02360098|Other|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
265163|NCT02360111|Drug|Cyclophosphamide|
265164|NCT02360124|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
265165|NCT02360150|Radiation|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
265166|NCT02360163|Procedure|Traditional Landmark Technique (TLT)|
265167|NCT02360163|Device|ultrasound guided peripheral intravenous access (USGPIVA)|
265168|NCT02360176|Procedure|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
265169|NCT02360176|Procedure|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
265170|NCT02360202|Procedure|Impedance analysis|Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.
impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle
265171|NCT02360202|Drug|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
265476|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
265477|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
270459|NCT02349867|Other|Laboratory Biomarker Analysis|Correlative studies
270460|NCT02349880|Behavioral|shared decision making training|
270461|NCT02349893|Device|RFA treatment|RFA treatment using CelonProSleep plus system
270462|NCT02349906|Drug|Treosulfan|
270463|NCT02349906|Drug|Busilvex|
270746|NCT00156910|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
270747|NCT02343237|Procedure|Osteopathic treatment|osteopathic sessions of 20 minutes
270748|NCT02343237|Procedure|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
270749|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
270750|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
270751|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
270752|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
270753|NCT02343263|Drug|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
270754|NCT02345278|Other|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
270755|NCT00157196|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
270756|NCT02345291|Drug|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
270757|NCT02345291|Drug|Placebo to match NRD135S.E1|
270758|NCT02345304|Drug|Omeprazole|
270759|NCT02345304|Drug|Warfarin|
270760|NCT02345304|Drug|BI 1181181|
270171|NCT02318706|Drug|placebo|
270172|NCT02318719|Drug|placebo|placebo
270173|NCT02318719|Drug|DS-5565|
270174|NCT02318732|Behavioral|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
270175|NCT02318745|Behavioral|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
270176|NCT02318745|Behavioral|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
270177|NCT02318758|Drug|UT-15C|sustained release oral treprostinil
270178|NCT02318758|Other|ethanol|Absolut 100 vodka
270179|NCT02318771|Radiation|Radiation Therapy (RT)|Undergo RT
270464|NCT02349919|Drug|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
270465|NCT00157937|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
270466|NCT02349919|Drug|Placebo|Placebo twice daily for 4 weeks
270467|NCT02349932|Other|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
270468|NCT02349945|Drug|follitropin alpha|All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.
Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage > 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle.
270469|NCT02349958|Device|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
270470|NCT02349958|Device|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
270471|NCT02352337|Drug|Gemzar|
270472|NCT02352350|Other|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
270473|NCT02352350|Other|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
270474|NCT02352363|Drug|CVT-301|
269873|NCT02323646|Drug|Proellex 6 mg|Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids
269874|NCT02323646|Drug|Proellex 12 mg|Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids
269875|NCT02323659|Drug|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
269876|NCT02323659|Drug|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
269877|NCT02323685|Biological|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
269878|NCT02323698|Dietary Supplement|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 60min after consumption to approximately coincide with peak plasma concentrations.Throughout the 60min wait time and experimentation, blood pressure and heart rate will be monitored.
269879|NCT02323698|Other|AIH|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia).
269880|NCT02323698|Other|SHAM|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia).
269881|NCT00153738|Drug|phytosterol|
269882|NCT02326142|Drug|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
269883|NCT02326168|Drug|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
269884|NCT02326181|Device|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
269885|NCT02326181|Device|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
270180|NCT00002390|Drug|Abacavir sulfate|
270181|NCT00153114|Drug|polyethyleneglycol3350|
270182|NCT02318771|Drug|MK-3475|Given IV
270183|NCT02318784|Drug|Carfilzomib|
270184|NCT02318797|Behavioral|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
269582|NCT00154453|Procedure|obtain surgical specimen for analysis|
269583|NCT02330822|Drug|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
269584|NCT02330835|Behavioral|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
269585|NCT02330835|Behavioral|School bus driver training videos|Basic bus driving safety videos
269586|NCT02330848|Dietary Supplement|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
269587|NCT02330848|Dietary Supplement|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
269588|NCT02330861|Device|combowire and IVUS|
269589|NCT02330887|Other|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
269590|NCT02330887|Other|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
269591|NCT02330900|Other|Study group|Exposure to cell phone interference of the ICD
269592|NCT02330913|Procedure|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
269593|NCT00154466|Behavioral|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
269594|NCT02330926|Other|standard care|
269595|NCT02330926|Other|nutritional supplements and advice|
269596|NCT02330926|Other|home-based self-assisted exercise program|
269597|NCT02333214|Other|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
273984|NCT02344420|Behavioral|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
273985|NCT02344433|Behavioral|VICKY|Relational agent/virtual counselor
269283|NCT02337985|Drug|Etoposide|Given IV
269284|NCT02337985|Drug|Doxorubicin Hydrochloride|Given IV
269285|NCT02337985|Drug|Vincristine Sulfate|Given IV
269286|NCT02337985|Drug|Cyclophosphamide|Given IV
269287|NCT02337985|Biological|Filgrastim|Given SC
269288|NCT02337985|Biological|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
269289|NCT02337998|Other|load carriage|
269290|NCT02338011|Drug|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
269291|NCT02338011|Radiation|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
269292|NCT00156130|Radiation|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
269293|NCT02338024|Behavioral|Modified Antiretroviral Treatment Access Study intervention|
269294|NCT02338037|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
269295|NCT02338037|Procedure|Biopsy|Undergo biopsy
269296|NCT02338037|Drug|Eribulin Mesylate|Given IV
269297|NCT02338037|Procedure|Microdialysis|Undergo intracerebral microdialysis
269298|NCT02338037|Other|Pharmacological Study|Correlative studies
269299|NCT02338050|Biological|Moxetumomab Pasudotox|
269300|NCT02338063|Behavioral|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
269301|NCT02338063|Behavioral|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
273685|NCT02351388|Other|Sham Stimulation|
273686|NCT02351401|Behavioral|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
273687|NCT02351414|Device|Total Knee Arthroplasty (EVOLUTION®)|
273688|NCT02351427|Drug|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
273689|NCT02351427|Drug|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
273690|NCT02351440|Drug|duloxetine|patients will be randomized to receive either duloxetine or placebo
273691|NCT02351440|Drug|placebo|placebo
273692|NCT02351466|Other|Observational|
273693|NCT02351479|Behavioral|Hula|
273694|NCT02351492|Procedure|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
273695|NCT00158132|Drug|Propranolol|Propranolol 100mg/day in 3 divided doses
273986|NCT02344433|Behavioral|MFHP|US Surgeon General's family history tool
273987|NCT02344446|Other|Skilled Therapy|Active physical therapy treatment
273988|NCT02344459|Device|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
273989|NCT02344472|Drug|pertuzumab|HER2 targeted Therapy
273990|NCT02344472|Drug|Trastuzumab|HER2 targeted Therapy
273991|NCT00157027|Procedure|Extracorporeal photochemotherapy with UVADEX|Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.
The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient.
273992|NCT02344472|Drug|Capecitabine|Chemotherapy
273993|NCT02346370|Drug|PEGPH20|
273994|NCT02346370|Drug|Docetaxel|
273389|NCT02320071|Other|Examination of abdominal wall strength changes over time|
273390|NCT02320084|Drug|Nitisinone|Nitisinone according to prescription
273391|NCT02320097|Other|Foot pressure measurement|Description of the foot pressure measurement:
The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.
The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions.
273392|NCT00153309|Behavioral|People with Arthritis Can Exercise|
273393|NCT02320123|Behavioral|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
273394|NCT02320136|Behavioral|cognitive testing|patients perform simple tasks like watching a video or memorizing items
273395|NCT02320149|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating
273396|NCT02320149|Drug|Placebo|Dose-matched placebo taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating.
273696|NCT02351492|Procedure|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
273697|NCT02351492|Device|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
273698|NCT02351492|Device|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
273699|NCT02351505|Drug|Selinexor|Given PO
273700|NCT02351505|Other|Laboratory Biomarker Analysis|Correlative studies
273701|NCT02351505|Other|Pharmacological Study|Correlative studies
273702|NCT02351518|Other|No intervention|There will be no interventions in this study
273703|NCT02351531|Dietary Supplement|Extensively Hydrolyzed formula|
273704|NCT02351544|Drug|Botulinum Toxin Type A|
273705|NCT02351544|Procedure|Surgery|
273706|NCT00158132|Drug|Amantadine|Amantadine 100mg three times daily
273707|NCT02351544|Other|Daily headache diary|
273059|NCT00153894|Behavioral|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
273060|NCT02325063|Drug|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
273061|NCT02327624|Drug|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
273062|NCT02327624|Drug|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
273063|NCT02327637|Behavioral|Moderate Activity|Ambulation 150 feet, two times per day
273064|NCT02327650|Procedure|The examinations for bones in joints of OA and RA patients|
273065|NCT00154128|Device|occlusal appliance|
273066|NCT02327663|Drug|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
273067|NCT02327676|Drug|Emtricitabine|emtricitabine were given to each patients for 48 weeks
273068|NCT02327689|Drug|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
273069|NCT02327702|Drug|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
273070|NCT02327715|Drug|Emtricitabine|emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
273071|NCT02327728|Procedure|Botulinum toxin A injection (5 sites: 12.5U)|
273072|NCT02327728|Procedure|Botulinum toxin A injection (4 sites: 10U)|
273073|NCT02327728|Drug|Botulinum toxin A 12.5U|
273074|NCT02327728|Drug|Botulinum toxin A 10U|
273075|NCT02327741|Drug|plavix|taking plavix more than 12 months
273397|NCT02320162|Behavioral|Experiential learning oral health education|
273398|NCT02320175|Behavioral|Communication Bundle|Communication bundle to improve patient and family experience and patient safety
273399|NCT02320188|Other|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
273400|NCT02320188|Other|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
267467|NCT02380131|Drug|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
267767|NCT02373501|Procedure|Intra-abdominal repair|Intra abdominal repair of uterine incision
267768|NCT02373501|Procedure|Extra-abdominal repair|Extra abdominal repair of uterine incision
267769|NCT02373514|Drug|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
267770|NCT02373514|Drug|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
267771|NCT02373527|Other|No Fasting prior to catheterization|No restriction for oral intake
267772|NCT02373540|Device|Algovita Spinal Cord Stimulation system|
267773|NCT02375347|Other|Chickpea Enhanced Diet (Short term)|Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.
Stool Samples collected at Day 1, Day 9, and Day 14.
267774|NCT02375360|Other|Oral immunotherapy|
267775|NCT02375373|Other|Observational Chickpea Diet|Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.
Fecal samples collected monthly.
267776|NCT02375386|Procedure|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
267777|NCT02375386|Procedure|Therapeutic touch|Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of "hands-on" contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
267778|NCT02375386|Procedure|fMRI|Both groups will receive an fMRI.
267779|NCT00160628|Drug|Levetiracetam|
267780|NCT02375386|Behavioral|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
267781|NCT02375386|Other|Questionnaires|Both groups will receive Questionnaires
267782|NCT02375386|Behavioral|Physical Impairment|Both groups will receive testing on physical impairment.
267783|NCT02375412|Procedure|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
267176|NCT02387411|Other|Combined exercise training|High intensity [2 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
267177|NCT02387424|Behavioral|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
267178|NCT02387424|Behavioral|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
267179|NCT02387437|Behavioral|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
267180|NCT02387437|Behavioral|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
267181|NCT00162188|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
267468|NCT02380131|Drug|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
267469|NCT02380144|Other|Fresh orange fruit and pasteurized fruit juice|
267470|NCT02380157|Drug|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
267471|NCT02380157|Drug|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
267472|NCT02380183|Device|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
267473|NCT02380209|Other|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
267474|NCT02380222|Other|Interview|Single interview lasting approximately one hour
267475|NCT02380235|Biological|PEG-somatropin|0.20mg/kg/w
267476|NCT02380248|Other|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
267477|NCT00161304|Drug|Testosterone Enanthate|
267478|NCT02380261|Other|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
267479|NCT02382549|Drug|vemurafenib|Braf inhibitor
267480|NCT02382549|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
266884|NCT02392039|Behavioral|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
266885|NCT02392052|Behavioral|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
266886|NCT00162760|Drug|Thalidomide|
266887|NCT02392052|Behavioral|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
266888|NCT02392078|Device|NeuroBlate System|
266889|NCT02355795|Behavioral|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 13% and 57%, respectively
266890|NCT02355795|Behavioral|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 13% and 47%, respectively
266891|NCT00158522|Drug|pegylated interferon alpha2a|
266892|NCT02355808|Behavioral|Tailored Leaflet|
266893|NCT02355808|Behavioral|GP visit|
266894|NCT02355821|Drug|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
266895|NCT02355821|Drug|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
266896|NCT02355834|Other|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
266897|NCT02355847|Other|Lectures|Lectures
266898|NCT02355860|Behavioral|assessment|assessment
267182|NCT02387437|Behavioral|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
267183|NCT02387450|Drug|Sildenafil|100 mg per day
267184|NCT02387450|Drug|Placebo|Placebo with same presentation as the active drug
267185|NCT02387476|Device|FRESCA Nasal Mask|FRESCA nasal mask
267186|NCT02387476|Device|CPAP Nasal Mask|CPAP nasal pillow and nasal mask
266301|NCT02370420|Behavioral|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
266588|NCT02360631|Drug|Placebo|Health education counseling will be provided to all participants.
266589|NCT02360644|Dietary Supplement|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
266590|NCT02360657|Drug|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2*5 mg tablet) orally once daily for 4 weeks.
266591|NCT02360657|Drug|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
266592|NCT02360657|Drug|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
266593|NCT00002416|Drug|Emtricitabine|
266594|NCT00158977|Device|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
266595|NCT02360670|Other|control imaging|
266596|NCT02360670|Other|additional multimodal imaging|
266597|NCT02360683|Other|patients with Parkinson's disease|
266598|NCT02360709|Device|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
266599|NCT02360722|Other|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
266600|NCT02360722|Other|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
266601|NCT02360735|Other|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
266602|NCT02360735|Other|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
266603|NCT02360748|Dietary Supplement|Plant based high protein food items|Patients will add high protein plant based food items to their diet
266604|NCT02360761|Procedure|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
266605|NCT00158990|Drug|triiodothyronine|
266606|NCT02363439|Drug|IMO-8400|IMO-8400 at 0.6, 1.2 or 2.4 mg/kg/wk as defined per Protocol 8400-401
266044|NCT02377128|Procedure|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
266045|NCT02377141|Procedure|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
266046|NCT02377141|Procedure|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
266302|NCT02370433|Drug|Intravenous Neostigmine and Glycopyrrolate|
266303|NCT00160043|Drug|SH T00268C|1250 mg experimental drug od
266304|NCT02370433|Drug|Transdermal Neostigmine and Glycopyrrolate|
266305|NCT02370446|Other|personalized medication log|
266306|NCT02370446|Other|standard of care|
266307|NCT02370446|Behavioral|questionnaires|
266308|NCT02370446|Behavioral|Cognitive Interview|
266309|NCT02370459|Other|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
266310|NCT02370459|Other|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
266311|NCT02370472|Device|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
266312|NCT02370485|Drug|LY2801653|Administered orally
266313|NCT02370498|Biological|pembroliziumab|
266314|NCT00160043|Drug|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
266315|NCT02370498|Drug|paclitaxel|
265779|NCT02384551|Other|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
265780|NCT02386826|Biological|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks.
265781|NCT02386839|Other|Mecasermin rinfabate|
265782|NCT02386852|Drug|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
265783|NCT02386852|Drug|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
265784|NCT00162110|Drug|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
265785|NCT02386852|Drug|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
266047|NCT02377154|Device|Slit lamp|Examination of cornea
266048|NCT02377154|Device|Autorefractor|Measurement of refraction
266049|NCT02377154|Device|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
266050|NCT00160862|Drug|SLV317|
266051|NCT02377154|Device|Pentacam HR|Measurement of white-to-white distance; Keratometry
266052|NCT02377154|Device|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
266053|NCT02377154|Device|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
266054|NCT02377167|Procedure|Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
266055|NCT02377180|Procedure|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
266056|NCT02377180|Procedure|Suprascapular nerve block|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.
Evaluates the diagnostic validity of suprascapular nerve block for muscle pain.
266057|NCT02377180|Procedure|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
265466|NCT02391363|Behavioral|Information and referral|Resource counseling and follow-up for mental health and basic needs
265467|NCT02391376|Other|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
265468|NCT02391376|Other|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
265469|NCT02391376|Other|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
265470|NCT02391389|Procedure|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
265471|NCT02391402|Behavioral|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
265472|NCT02355184|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
265473|NCT02355197|Drug|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
265474|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1|packet containing 10^9 cells of Bifidobacteria adolescentis BD1
265475|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10^9 cells of Bifidobacteria animalis subsp. lactis BB-12
265786|NCT02386878|Behavioral|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
265787|NCT02386878|Behavioral|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
265788|NCT02386891|Other|Thermal Environment|
265789|NCT02386904|Drug|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
265790|NCT02386917|Procedure|Gastric bypass|Weight loss surgery
270400|NCT02345187|Dietary Supplement|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
270693|NCT02338609|Drug|Everolimus|Blood sample and Tanner Stage assessment
270694|NCT02338609|Drug|Envirolimus drug class as prescribed by Physician|At the discretion of the investigator, patients may be treated with commercially available everolimus, as per local product information/ standard of care.
270695|NCT00156195|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 months
270696|NCT02338622|Drug|olaparib|olaparib BD
270697|NCT02338622|Drug|AZD5363|AZD5363 BD
270698|NCT02338635|Drug|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
270699|NCT02338648|Drug|SUN-131 1.5% TDS|Active transdermal patch
270700|NCT02338648|Drug|Placebo TDS|Placebo transdermal patch for blinding
270701|NCT02338661|Device|SBG hip stem|
270702|NCT02338674|Drug|Telbivudine and Tenofovir|Telbivudine and Tenofovir administered at least 64 weeks
270703|NCT02338687|Dietary Supplement|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
270704|NCT02338687|Behavioral|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
270705|NCT02338700|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
270706|NCT00002402|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
270707|NCT00156195|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
270708|NCT02338700|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
270709|NCT02338713|Drug|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
270710|NCT02338726|Other|Gynecological examination|Comparison of questionnaires and gynecological examination
270114|NCT02349776|Other|Providing testimonies from survivors of transplants to patients|Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.
Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant.
270115|NCT02349802|Drug|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
270116|NCT00157924|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
270401|NCT00157183|Device|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
270402|NCT02345187|Dietary Supplement|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
270403|NCT02345200|Procedure|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
270404|NCT02345200|Procedure|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
270405|NCT02345213|Drug|E2020|E2020 tablets will be orally administered once daily after breakfast
270406|NCT02345213|Drug|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
270407|NCT02345226|Drug|FTC/RPV/TAF|Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg (FTC/RPV/TAF) FDC tablets administered orally once daily
270408|NCT02345226|Drug|Placebo to match EFV/FTC/TDF|Placebo to match EFV/FTC/TDF tablets administered orally once daily
270409|NCT02345226|Drug|EFV/FTC/TDF|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF) FDC tablets administered orally once daily
270410|NCT02345226|Drug|Placebo to match FTC/RPV/TAF|Placebo to match FTC/RPV/TAF tablets administered orally once daily
270411|NCT02345239|Drug|Pantoprazole|proton pump inhibitor
270412|NCT00157196|Biological|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
270413|NCT02345252|Drug|FTC/RPV/TAF|Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg (FTC/RPV/TAF) FDC tablets administered orally once daily
270414|NCT02345252|Drug|Placebo to match FTC/RPV/TDF|Placebo to match FTC/RPV/TDF tablets administered orally once daily
269819|NCT00153101|Drug|Telmisartan|
269820|NCT02318511|Device|ReNu amniotic allograft|
269821|NCT02318511|Device|placebo saline|
269822|NCT02318511|Device|Hyaluronic Acid|
269823|NCT02318537|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
269824|NCT02318537|Drug|Placebo Solution|A matching oral solution containing no cannabidiol.
269825|NCT02318550|Other|MRI Scan|The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:
Normal operating mode
SAR ≤ 2.0 W/kg per patient.
269826|NCT02318563|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
269827|NCT02318563|Drug|Placebo Solution|A matching oral solution containing no cannabidiol
269828|NCT02318576|Other|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
270117|NCT02349802|Drug|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
270118|NCT02349815|Drug|Jaydess (Levonorgestrel,BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
270119|NCT02349828|Drug|Acyclovir|
270120|NCT02352194|Other|Rehabilitation|Physiotherapy and physical activity
270121|NCT02352207|Other|identification of a pulmonary malformation in the fetus|
270122|NCT02352233|Procedure|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
270123|NCT02352246|Procedure|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
270124|NCT02352246|Procedure|Physical activity programs high intensity intermittent exercise (HIIE)|
270125|NCT02352259|Procedure|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
279034|NCT02698631|Procedure|Conventional AF ablation|Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).
Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins.
279035|NCT00201916|Procedure|6600 cGy/33 fractions over 45 days|see above
279036|NCT02698631|Procedure|LGE-MRI guided AF ablation|Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).
Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.
In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed.
279037|NCT02698644|Drug|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
279038|NCT02698657|Drug|ASP5094|Intravenous (IV)
279039|NCT02698657|Drug|Placebo|Intravenous (IV)
279040|NCT02698670|Device|Rhythmia mapping system|A 3-D Cardiac Mapping system
274488|NCT02689856|Drug|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
274489|NCT00200889|Device|acupuncture|different forms of acupuncture and sensory stimulation will be used
274490|NCT02689856|Drug|Placebo control|Vehicle cream alone
274491|NCT02689856|Drug|Hydrocortisone acetate|hydrocortisone alone
274492|NCT02689856|Drug|Lidocaine hydrochloride|lidocaine alone
274493|NCT02689869|Drug|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
274494|NCT02689869|Drug|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
274495|NCT02689882|Dietary Supplement|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
274496|NCT02689895|Other|modified directly administered anti-retroviral therapy (mDAART)|As described before
274497|NCT02689908|Radiation|computed tomography|low dose protocol of thorax ct
278751|NCT02703064|Dietary Supplement|Furocyst|Furocyst caps BD
278752|NCT02703077|Procedure|Spyglass|Endoscopic direct view of the bile ducts
278753|NCT02703077|Procedure|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
278754|NCT02703077|Procedure|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
278755|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
278756|NCT02705274|Procedure|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
278757|NCT02705287|Other|Pregnant|tracer dose of deuterated vitamin D3
278758|NCT02705287|Other|Non-pregnant|tracer dose of deuterated vitamin D3
278759|NCT02705300|Drug|Irinotecan 165 mg/m2 iv|Max. 4 months
278760|NCT02705300|Drug|Oxaliplatin 85 mg/m2 iv|Max. 4 months
278761|NCT02705300|Drug|Calcium folinate 200 mg/m2 iv|Max. 6 months
278762|NCT02705300|Drug|5-fluorouracil 3200 mg/m2|Max. 6 months
279041|NCT02698670|Device|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
279042|NCT02698683|Other|lymphocyte count|lymphocyte count
279043|NCT02698696|Other|ECo program|
279044|NCT02698696|Other|CRT program|
279045|NCT02698696|Other|Supportive psychotherapy|
279046|NCT00201929|Procedure|Standard Decision Board|
279047|NCT02698709|Other|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
279048|NCT02698722|Other|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
279049|NCT02698735|Drug|Gentamicin|
279050|NCT02698735|Drug|Placebo|
278463|NCT02709447|Behavioral|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
278464|NCT02709447|Behavioral|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
278465|NCT02709460|Procedure|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
278466|NCT02709460|Procedure|Cervical occlusion|Cervical occlusion of the uterine artery
278467|NCT00203242|Drug|Depacon IV and Depakote ER|
278468|NCT02709473|Drug|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
278469|NCT02709473|Drug|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
278470|NCT02711267|Drug|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
278471|NCT02711267|Drug|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
278472|NCT02711267|Drug|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
278473|NCT02711267|Drug|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
278474|NCT00203476|Drug|Ezetimibe|
278475|NCT02711267|Drug|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
278476|NCT02711267|Procedure|OFM|Sampling method for interstitial fluid
278763|NCT02705300|Dietary Supplement|Tocotrienol|Max. 2 years or at the discretion of the investigator
278764|NCT02705300|Drug|Placebo|Max. 2 years or at the discretion of the investigator
278765|NCT02705313|Drug|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
278766|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
278767|NCT02705326|Device|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
277882|NCT02686593|Drug|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
278171|NCT02715453|Other|Intervention on frailty|Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):
Nutritional evaluation and intervention after randomization and regularly during follow-up
Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year
Psychiatrist or psychologist assistance for 1 year after discharge
278172|NCT02715466|Drug|Gelaspan 4%|Gelaspan combined with Sterofundin ISO
278173|NCT02715466|Drug|Sterofundin ISO|
278174|NCT02715479|Drug|Dolutegravir|
278175|NCT02715479|Drug|BMS955176|
278176|NCT02715492|Drug|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
278177|NCT02715492|Procedure|TACE|Trans arterial chemoembolization
278178|NCT02715505|Drug|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
278179|NCT02715518|Device|PCI using drug-eluting stent|Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.
FFR-guided strategy arm
Angiography-guided strategy arm
278180|NCT02715531|Drug|5-FU|5-FU (400 mg/m^2) will be administered as an IV bolus, followed by 2400 mg/m^2 by continuous IV infusion over 46 (± 1) hours, q2w.
278181|NCT00203944|Behavioral|Behavioral, Development|
278182|NCT02715531|Drug|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg (Arm A) q3w or 840 mg q2w (Arms B and C).
278183|NCT02715531|Drug|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A) or 10 mg/kg q2w (Arm B).
278184|NCT02715531|Drug|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
278185|NCT02715531|Drug|Leucovorin|Leucovorin 200 mg/m^2 or 400 mg/m^2 will be administered IV over 120 (± 15) minutes, q2w.
278186|NCT02715531|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
277604|NCT00201058|Behavioral|Generic web-based asthma education|4 computer sessions over a period of 180 days
277605|NCT02691325|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
277606|NCT02691325|Drug|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
277607|NCT02691338|Other|EEG|EEG analysis
277608|NCT02691338|Other|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
277609|NCT02691351|Other|Prospective Registry|Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment
Regimen
Response Evaluation
SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection
277610|NCT02691364|Procedure|Blood withdrawal|
277611|NCT02693769|Drug|Indacaterol maleate / glycopyrronium bromide capsules|
277612|NCT02693782|Dietary Supplement|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
277613|NCT02693782|Dietary Supplement|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
277614|NCT02693795|Other|Baduanjin exercise|A detailed description of a standardized Baduanjin exercise protocol complied with the "Health Qigong Baduanjin Standard" enacted by the General Administration of Sports in 2003.
277883|NCT02686606|Dietary Supplement|Vital 1.5|Oral nutritional supplement
277884|NCT02686606|Dietary Supplement|Ensure Plus|Oral nutritional supplement
277885|NCT02686606|Dietary Supplement|elemental 028|Oral nutritional supplement
277886|NCT02686606|Other|water|water
277887|NCT02686619|Drug|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
277888|NCT02686619|Drug|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
277889|NCT02686619|Drug|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2*500mg tablets or 4*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
277313|NCT02698033|Other|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
277314|NCT02698046|Dietary Supplement|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
277315|NCT02698046|Dietary Supplement|Placebo starch|200mg of placebo starch three times a day for 4 months
277316|NCT02698059|Device|iNAP® Sleep Therapy System (iNAP)|The iNAP Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
277317|NCT02698072|Other|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
277318|NCT02698072|Device|Dry needling|Dry needling needle AGUPUNT®
277319|NCT02698072|Device|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
277320|NCT02698085|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
277321|NCT02698085|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
277322|NCT00201851|Procedure|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
277323|NCT02698098|Drug|Methadone|
277324|NCT02698111|Drug|Donafenib|donafenib 200mg，bid
277325|NCT02698124|Drug|Decitabine|
277326|NCT02698150|Device|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
277327|NCT02698163|Device|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
277328|NCT02698163|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
277329|NCT02698176|Drug|MK-8628 20 mg|20 mg administered as an oral capsule, in a fasted state, twice a day (BID) continuously for 21 days per cycle
276729|NCT02710669|Drug|(R)-propafenone|
276730|NCT02710669|Drug|(S)-Propafenone|
277021|NCT02704507|Drug|Emollient|topical application nightly to half the face for 4 weeks
277022|NCT02704520|Drug|Capecitabine|Coated tablet. Systemic chemotherapy
277023|NCT02704520|Drug|Oxaliplatin|Concentrate for Solution for Infusion. Systemic chemotherapy
277024|NCT02704520|Drug|5-fluorouracil|Infusion. Systemic chemotherapy
277025|NCT02704520|Drug|Folinic Acid|Solution for infusion.
277026|NCT00202748|Behavioral|Increase in activity to control weight.|
277027|NCT02704533|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
277028|NCT02704533|Biological|PfSPZ Challenge (NF54)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
277029|NCT02704533|Biological|PfSPZ Challenge (7G8)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
277030|NCT02704533|Other|Normal saline|0.9% sodium chloride
277031|NCT02704546|Drug|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
277032|NCT02704546|Drug|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
277033|NCT02704559|Drug|DWC20155|
277034|NCT02704559|Drug|DWC20156|
277035|NCT02704572|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection.
277036|NCT02704585|Device|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
277037|NCT00202761|Behavioral|PIH|Intensified training
277038|NCT02704585|Device|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
277039|NCT02704598|Drug|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
272758|NCT02334345|Drug|Trixiera|Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
272759|NCT02334358|Device|YVOIRE Classic s|
272760|NCT02334371|Radiation|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
273076|NCT00154141|Drug|Fibrin sealant (FS2)|
273077|NCT02327741|Drug|plavix|taking plavix less than 12 months
273078|NCT02327754|Drug|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
273079|NCT02327754|Drug|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
273080|NCT02327767|Device|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
273081|NCT02327780|Other|FODMAP diet|
273082|NCT02327793|Drug|Nitroglycerin|
273083|NCT02327793|Drug|Labetalol|
273084|NCT02327806|Device|pulsed electromagnetic field therapy|
273085|NCT02327819|Dietary Supplement|Branched-chain amoni acids (BCAA)|
273086|NCT02327819|Dietary Supplement|non-BCAA protein supplement|
273087|NCT00154154|Behavioral|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
273088|NCT02327832|Procedure|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
273089|NCT02327832|Drug|bone marrow-derived mesenchymal stem cells|
273090|NCT02330029|Device|Tangerine Peel|Tangerine Peel (~10g)
273091|NCT02330029|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
273092|NCT02330029|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
273093|NCT00154375|Drug|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
272474|NCT02341560|Drug|QPI-1007 Injection - single low dose|QPI-1007 Injection, single low dose
272475|NCT02341560|Drug|QPI-1007 Injection - single high dose|QPI-1007 Injection, single high dose
272476|NCT02341560|Drug|QPI-1007 Injection - multiple low dose|QPI-1007 Injection, multiple low dose
272477|NCT02341560|Drug|QPI-1007 Injection - multiple high dose|QPI-1007 Injection, multiple high low dose
272478|NCT02341560|Other|Sham Injection Procedure|Sham Procedure
272479|NCT02341573|Drug|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
272480|NCT02341573|Drug|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
272481|NCT00002404|Drug|Valacyclovir hydrochloride|
272482|NCT00156676|Device|Lokomat|
272761|NCT02334384|Biological|Antimicrobial TheraGauze|In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.
In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess.
272762|NCT02334397|Behavioral|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
272763|NCT02334410|Device|Whole body vibration (WBV)|Side-alternating WBV
272764|NCT02334423|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
272765|NCT02334436|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
272766|NCT02334449|Drug|LML134|LML134 will be administered first as single doses and then as multiple doses
272767|NCT00155415|Behavioral|Different timing of taking polyethylene glycol(PEG)|
272768|NCT02334449|Drug|Placebo|All study cohorts (except food effect cohort) are placebo controlled
272769|NCT02334462|Biological|Pfs230D1M-EPA/Alhydrogel|
272770|NCT02334462|Biological|Pfs25M-EPA/Alhydrogel|
272771|NCT02336919|Behavioral|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
272182|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the day the last infusion is completed.
272183|NCT02345850|Drug|Cyclophosphamide|Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.
Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
272184|NCT02348164|Other|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
272185|NCT02348177|Drug|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
272186|NCT02348177|Drug|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
272187|NCT02348190|Other|Lipid/heparin|32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.
Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs.
272188|NCT00157690|Drug|Alendronate|70 mg 1x weekly for 12 months
272189|NCT02348203|Drug|Aspirin|Given PO
272190|NCT02348203|Other|Laboratory Biomarker Analysis|Correlative studies
272191|NCT02348203|Other|Placebo|Given aspirin placebo PO
272192|NCT02348203|Other|Placebo|Given zileuton placebo PO
272193|NCT02348203|Drug|Zileuton|Given PO
272483|NCT02341586|Other|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
272484|NCT02341586|Dietary Supplement|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
272485|NCT02341586|Other|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
271885|NCT02352948|Drug|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
271886|NCT02352948|Drug|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
271887|NCT02352948|Drug|MEDI4736 in combination with tremelimumab (anti-CTLA4)|MEDI4736 in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
271888|NCT02352948|Drug|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
271889|NCT02352961|Other|Exclusive Intervention Strategy|The "Exclusive Intervention Strategy" aimed at men aged 25 - 49 years and "Active Follow-up strategy"
271890|NCT02352974|Drug|GAD-Alum|
271891|NCT02352974|Drug|Vitamin D|
271892|NCT00002411|Drug|Stavudine|
271893|NCT00158288|Behavioral|LAAM|
271894|NCT02352987|Drug|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
271895|NCT02352987|Drug|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
271896|NCT02353000|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
271897|NCT02353000|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
271898|NCT02353013|Dietary Supplement|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
271899|NCT02353013|Dietary Supplement|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
271900|NCT02353026|Drug|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
271901|NCT02353039|Drug|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
271902|NCT02353039|Drug|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
271903|NCT02353039|Drug|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
271904|NCT02316782|Device|Blinded IVUS assessment|Only the angiogram is used for stent placement
271273|NCT02324322|Other|Muscle Biopsies|Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.
To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking.
271274|NCT02324322|Other|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
271275|NCT02324335|Drug|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
271276|NCT02324335|Other|Placebo|
271277|NCT02324348|Procedure|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
271278|NCT02326766|Dietary Supplement|KRG|5g Korea red ginseng (KRG)
271279|NCT02326766|Dietary Supplement|Placebo|5g placebo
271280|NCT02326779|Drug|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
271281|NCT00154037|Drug|Pioglitazone (drug) and/or candesartan (drug)|
271583|NCT02319330|Behavioral|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
271584|NCT02319330|Behavioral|Treatment as Usual|Routine HIV clinic-based counseling
271585|NCT02319343|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
271586|NCT02319343|Drug|Isotonic Sodium Chloride|Placebo
271587|NCT02319356|Dietary Supplement|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
271588|NCT00153179|Drug|placebo|matching placebo
271589|NCT02319356|Dietary Supplement|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
271590|NCT02319369|Drug|DS-3032b|DS-3032b will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg DS-3032b
271591|NCT02319382|Radiation|PET with the tracer 18F-DPA-714|
270982|NCT02331329|Device|Cardiac MRT cardiac output measurement|
270983|NCT02331342|Device|NICOM cardiac output measurement|
270984|NCT00154622|Behavioral|work hardening program|
270985|NCT02331342|Device|Innocor cardiac output measurement|
270986|NCT02331368|Procedure|Autologous Stem Cell Transplant|
270987|NCT02331368|Drug|Melphalan|140-200 mg/m^2
270988|NCT02331368|Drug|Lenalidomide|5-15 mg/day starting 100-120 days post-transplant
270989|NCT02331368|Drug|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses or 180 days
270990|NCT02331381|Device|Magnetic resonance imaging|
270991|NCT02331394|Dietary Supplement|Chinese herbs formula: Shu Yu Wan|The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
270992|NCT02331407|Device|Robotic arm therapy|Training with the ReoGo device
270993|NCT02331420|Procedure|Gastric bypass|A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.
270994|NCT02331420|Behavioral|Medical therapy|Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);
Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;
Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;
Programs for diet and lifestyle modification, including reduced overall energy and fat intake (<30% total fat, <10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);
low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids).
270995|NCT00154635|Drug|DCB-AD1|
270996|NCT02331433|Drug|APN1125|APN1125 orally at ascending doses
271282|NCT02326792|Other|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
271283|NCT02326805|Other|Laboratory Biomarker Analysis|Correlative studies
270711|NCT02338739|Behavioral|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
270712|NCT02338739|Behavioral|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
270997|NCT02333721|Procedure|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
270998|NCT02333734|Other|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces ~ 90% of the maximum heart rate. The time spent per session is expected to last ~ 25 minutes.
270999|NCT02333747|Device|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
271000|NCT02333760|Genetic|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
271001|NCT00155272|Drug|Thalidomide|
271002|NCT02333773|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
271003|NCT02333786|Other|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
271004|NCT02333786|Other|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
271005|NCT02333799|Drug|Bedaquiline|100mg tablets
271006|NCT02333799|Drug|PA-824|200mg tablets
271007|NCT02333799|Drug|Linezolid|Scored 600mg tablets
271008|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
271009|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
271010|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
271011|NCT02333825|Procedure|Medial patellofemoral ligament reconstruction surgery|
270415|NCT02345252|Drug|FTC/RPV/TDF|Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg (FTC/RPV/TDF) FDC tablets administered orally once daily
270416|NCT02345252|Drug|Placebo to match FTC/RPV/TAF|Placebo to match FTC/RPV/TAF tablets administered orally once daily
270417|NCT02345265|Drug|Cediranib Maleate|Given PO
270418|NCT02345265|Other|Laboratory Biomarker Analysis|Correlative studies
270419|NCT02345265|Drug|Olaparib|Given PO
270420|NCT02345265|Other|Pharmacological Study|Correlative studies
270713|NCT02338739|Behavioral|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
270714|NCT02340806|Device|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. The bolus rate will be 300 mL/h in the high-rate bolus group, and 100 mL/h in the low-rate bolus group. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
270715|NCT02340819|Drug|Teduglutide|0.05mg/kg/day
270716|NCT02340845|Biological|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
270717|NCT02340858|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
270718|NCT02340871|Genetic|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
270719|NCT02340884|Behavioral|Promoting Resilience In Stress Management (PRISM)|The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person "booster" sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding.
270720|NCT02340910|Other|Whole Body Vibration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. Different frequencies of WBV (35 Hz or 50 Hz) and different treatment times (180 sec or 360 sec) will be used in each of the 4 WBV treatment sessions. Exposure periods include 45-sec bouts with 1 minute intervening rests.
270126|NCT02352259|Device|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
270127|NCT00158223|Drug|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
270128|NCT02352259|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
270129|NCT02352272|Other|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
270130|NCT02352285|Drug|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
270131|NCT02352285|Drug|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
270132|NCT02352298|Device|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
270133|NCT02352298|Device|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
270134|NCT02352311|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
270135|NCT02352311|Drug|AVODART|Dutasteride 0.5 mg
270136|NCT02352311|Drug|CIALIS|Tadalafil 5 mg
270421|NCT02345278|Drug|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
270422|NCT02347280|Procedure|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
270423|NCT02347280|Procedure|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
270424|NCT02347293|Other|High levels of indigestible carbohydrates|
270425|NCT02347293|Other|Low levels of indigestible carbohydrates|
270426|NCT02347306|Other|Telephone interview|
270427|NCT02347319|Drug|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
270428|NCT00157599|Procedure|various diagnostic measures for DVT (e.g., CUS)|
274498|NCT02689921|Drug|Exemestane|Aromatase inhibitor
274499|NCT02689921|Drug|Letrozole|Aromatase inhibitor
274500|NCT00200902|Drug|venlafaxine (Effexor)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
274501|NCT02689921|Drug|Anastrozole|Aromatase inhibitor
274502|NCT02692235|Dietary Supplement|carnitine & leucine|500 mg/d l-carnitine-l-tartrate and 500 mg/d l-leucine
274503|NCT02692248|Drug|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
274504|NCT02692248|Drug|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
274505|NCT02692248|Drug|Gemcitabine|Gemcitabine 1000 mg/msq IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
274506|NCT02692248|Drug|Oxaliplatine|Oxaliplatine 100 mg/msq (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
274791|NCT02685254|Behavioral|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
274792|NCT02685254|Other|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
274793|NCT02685267|Drug|Docetaxel|
274794|NCT02685267|Drug|Enzalutamide|
274795|NCT02685267|Drug|Prednisone|
274796|NCT02685280|Device|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
274797|NCT02685293|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
274798|NCT02685293|Drug|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
279051|NCT02698748|Drug|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
279052|NCT02698748|Drug|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
279053|NCT02701010|Behavioral|Structured training and leaflet|The patients who were given both "explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB" by continence nurse and the educational leaflet were included in this group.
279054|NCT02701010|Behavioral|Structured training|The patients who were given only "explanatory verbal instructions of the educational leaflet on the structured behavioural therapy" by continence nurse were included in this group.
279055|NCT02701010|Behavioral|Leaflet|The patients who were given "only educational leaflet" were included in this group.
279056|NCT00202241|Procedure|testosterone injection|
279057|NCT02701010|Behavioral|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
279058|NCT02701023|Drug|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
279059|NCT02701049|Other|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
274507|NCT02692248|Drug|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
274508|NCT02692261|Procedure|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
274509|NCT02692261|Procedure|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
274510|NCT02692287|Device|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
274511|NCT00201188|Behavioral|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
274512|NCT02692300|Procedure|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram
274513|NCT02692313|Drug|Epinephrine|Dose response of epinephrine infusion
278768|NCT02705339|Drug|Rociletinib|
278769|NCT02705339|Procedure|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
278770|NCT02705339|Procedure|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
278771|NCT02705352|Drug|5-Fluorouracil|Treatment medication
278772|NCT02705352|Other|Normal saline|Placebo
278773|NCT02705365|Other|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
278774|NCT02705365|Other|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
278775|NCT02705378|Drug|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
278776|NCT02705378|Drug|naloxegol|Intervention would be given by OG or NG tube
278777|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
278778|NCT02705404|Genetic|Multifocal Tissue Banking|
278779|NCT00202995|Drug|Rebif|44 ug 3 times a week
278780|NCT02707393|Biological|bone marrow or peripheral blood stem cells|infusion
278781|NCT02707406|Other|NEOX®CORD 1K|use of human tissue product wound covering
278782|NCT02707406|Other|standard of care|standard wound coverings
278783|NCT02707419|Device|Experimental group|Video of the exercises
278784|NCT02707419|Device|Control group|video of nature scenes
278785|NCT02707419|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
279060|NCT02701062|Device|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
279061|NCT02701062|Drug|Anticoagulation Therapy (No AtriClip®)|Anticoagulation Therapy - Standard of Care at the discretion of the Investigator.
279062|NCT02701075|Device|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
278187|NCT02717598|Procedure|cold snare polypectomy|CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.
278477|NCT02711267|Device|OFM Probe|Sampling probe used during OFM
278478|NCT02711267|Device|OFM Pump|Pump used to operate OFM probes
278479|NCT02711280|Drug|Sevoflurane|
278480|NCT02711280|Drug|Propofol|
278481|NCT02711293|Other|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home every four weeks to provide a one-month's supply of ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count >350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been >350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than six months ago.
278482|NCT02711293|Other|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice).
278483|NCT02711306|Other|Placebo|The placebo diet was composed of well-cooked noodle through 200 g/piece twice daily to substitute the daily carbohydrate for 4 weeks.
278484|NCT02711306|Other|konjac glucomannan noodle|The KGN diet was composed of well-cooked noodle with 2 g of konjac glucomannan in a dosage of 200 g/piece twice daily to substitute the daily carbohydrate for 4 weeks.
278485|NCT00203489|Device|KERLIX A.M.D. Gauze|
278486|NCT02711319|Device|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
278487|NCT02711319|Device|sham rTMS|Sham Comparator: sham rTMS (SHAM GROUP)
For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
278488|NCT02711332|Other|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
278489|NCT02711332|Other|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
278490|NCT02711345|Drug|LTT462|ERK Inhibitor
277890|NCT02686619|Drug|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
277891|NCT02686619|Drug|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
277892|NCT00200460|Drug|Nebivolol|
277893|NCT02686632|Behavioral|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
277894|NCT02686645|Biological|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
277895|NCT02686645|Drug|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
277896|NCT02686645|Drug|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
277897|NCT02686645|Drug|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
277898|NCT02686658|Drug|Zimura®|
277899|NCT02686658|Drug|Sham|
277900|NCT02688933|Drug|Insulin lispro|Pharmaceutical form:Solution Route of administration: subcutaneous
277901|NCT02688946|Other|Not provided|
277902|NCT02688959|Behavioral|Tai Chi|
277903|NCT02688959|Behavioral|Exercise|
278188|NCT02717598|Procedure|hot snare polypectomy|HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
278189|NCT02717611|Drug|ACP-196 (acalabrutinib)|
278190|NCT02717624|Drug|ACP-196 in combination with BR|
278191|NCT02717650|Other|A-STEP|Study A) Study A) Observational Feasibility Study (no comparator). Externally paced incremental step test without breath-by-breath analysis. Standardised step height.
277330|NCT02698176|Drug|MK-8628 30 mg|30 mg administered as an oral capsule, in a fasted state, twice a day (BID) continuously for 21 days per cycle
277331|NCT02700243|Behavioral|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
277615|NCT02693795|Other|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
277616|NCT02693808|Procedure|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
277617|NCT02693808|Procedure|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
277618|NCT02693821|Drug|Gabapentin|gabapentin 300 mg per day, orally during 30 days
277619|NCT00201409|Drug|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
277620|NCT02693821|Other|Placebo|Placebo 300 mg per day, orally during 30 days
277621|NCT02693834|Device|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
277622|NCT02693834|Device|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
277623|NCT02693860|Drug|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute.
277624|NCT02693860|Drug|89Zr−J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO−huJ591 with 89Zr is achieved by the addition of 89Zr−oxalate to the DFO−huJ591 in ammonium acetate buffer.
277625|NCT02693873|Behavioral|GLA:D Canada (education and neuromuscular exercise program)|EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.
EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions).
277626|NCT02693886|Other|doctor experience|
277627|NCT02693899|Other|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
277628|NCT02693912|Procedure|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
277040|NCT02704598|Drug|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
277041|NCT02704611|Device|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
277332|NCT02700256|Behavioral|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
277333|NCT00202137|Behavioral|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
277334|NCT02700269|Other|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
277335|NCT02700282|Behavioral|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
277336|NCT02700295|Device|Orthokeratology lens|
277337|NCT02700308|Device|Kyphoplasty|Placement and inflation of balloon prior to cement injection
277338|NCT02700308|Device|Conventional vertebroplasty|Conventional vertebroplasty
277339|NCT02700321|Device|OPTIFLOW/ AIRVO|Patients randomized in "HFNC" group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction.
277340|NCT02700321|Procedure|STANDARD Face Mask|Patients randomized in "STANDARD Face Mask" group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction.
277341|NCT02700334|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
277342|NCT02700334|Drug|Placebo|one per day before breakfast during 12 weeks.
277343|NCT02700347|Drug|Pyrazinamide|
277344|NCT00202137|Behavioral|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
277345|NCT02700347|Drug|Allopurinol|
273094|NCT02330029|Drug|Radix curcumae|Radix curcumae (~10g)
273095|NCT02330029|Drug|Fingered citron|Fingered citron (~10g)
273096|NCT02330029|Drug|Tuckahoe|Tuckahoe (15g)
273097|NCT02330029|Drug|Placebo|Placebo is blindly given to patients.
273098|NCT02330055|Procedure|Forty-five degrees elevated upper body position|
273099|NCT02330055|Procedure|non-elevated upper body position|
273100|NCT02330055|Device|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
273418|NCT02322684|Device|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
273419|NCT00153634|Drug|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
273420|NCT02322697|Drug|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
273421|NCT02322710|Device|Urgotul: Low-adherent dressing|
273422|NCT02322710|Device|TulleGras M.S.: Vaseline gauze|
273423|NCT02322749|Drug|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
273424|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
273425|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
273426|NCT02322775|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
273427|NCT02322775|Biological|Placebo|Placebo administered subcutaneously every 4 weeks
273428|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M2
273429|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M3
273430|NCT00153634|Drug|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
273431|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
272772|NCT02336945|Device|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
272773|NCT02336958|Drug|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
272774|NCT02336958|Drug|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
272775|NCT02336958|Drug|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
272776|NCT02336958|Drug|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
272777|NCT02336971|Behavioral|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
272778|NCT02336971|Behavioral|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
272779|NCT02336984|Biological|HER-2 pulsed DC1|
272780|NCT02336984|Drug|trastuzumab|
272781|NCT00156065|Drug|Asenapine|5 or 10 mg BID
272782|NCT02336984|Drug|pertuzumab|
273101|NCT02330055|Other|Stop-Bang questionnaire|The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.
The investigators will ask the patient to answer the questionnaire and measure the neck circumference.
273102|NCT02330055|Other|Epworth Sleepiness Scale|The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.
The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition.
273103|NCT02330055|Other|P-SAP Score|The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.
The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance.
273104|NCT00154375|Drug|Hydroxyurea|
273105|NCT02330055|Other|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
273106|NCT02330068|Drug|citalopram|Cases
272486|NCT02341599|Drug|CB-238,618 Group A|Subjects in Group A will participate in one treatment period and will receive a single IV dose of 1000 mg CB-238,618.
272487|NCT02341599|Drug|CB-238,618 Group B|Subjects in Group B will participate in one treatment period and will receive a single IV dose of 1000 mg CB-238,618.
272488|NCT02341599|Drug|CB-238,618 Group C|Subjects in Group C will participate in one treatment period and will receive a single IV dose of 500 mg CB-238,618.
272489|NCT02341599|Drug|CB-238,618 Group D|Subjects in Group D will participate in one treatment period and will receive a single IV dose of 500 mg CB-238,618.
272490|NCT02341599|Drug|CB-238,618 Group E|Subjects in Group E will participate in two treatment periods, Treatment Period 1 and Treatment Period 2. These patients will receive a single IV dose of 250 mg CB-238,618 per treatment period, once before the hemodialysis (HD) session and once following the HD session.
272491|NCT02341612|Other|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
272492|NCT02343757|Device|PET/MRI|
272493|NCT02343770|Other|blood sample for identifying biomarkers|
272494|NCT02343783|Other|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
272495|NCT02343796|Other|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
272496|NCT02343796|Device|everStick|GC, Belgium
272497|NCT02343809|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
272498|NCT02343809|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
272783|NCT02336997|Procedure|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
272784|NCT02336997|Procedure|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1*10e6 cells/cm2.
272785|NCT02336997|Procedure|PLACEBO|Saline will be injected into expanded skin.
271905|NCT02316782|Device|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
271906|NCT02316795|Procedure|Sentinel lymph node biopsy|
272194|NCT02348216|Biological|KTE-C19|
272195|NCT02348229|Procedure|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
272196|NCT02348229|Procedure|ERAS protocols|No bowel preparation
272197|NCT02348229|Procedure|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
272198|NCT02348229|Procedure|ERAS protocols|Vasoactive drugs used if need be
272199|NCT00157690|Drug|Placebo|70 mg 1 x weekly for 12 months
272200|NCT02348229|Procedure|ERAS protocols|Temperature management
272201|NCT02348229|Procedure|ERAS protocols|Intra-abdominal drains not to be used
272202|NCT02348229|Procedure|ERAS protocols|Intraperitoneal Ropivicaine infusion
272203|NCT02348229|Procedure|ERAS protocols|On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.
Oral non‐opioid analgesia/Drinking 0.5L liquid. Active mobilisation
272204|NCT02348229|Procedure|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
272205|NCT02348229|Procedure|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
272206|NCT02348229|Procedure|ERAS protocols|On the5-6th postoperative day Check discharge criteria
272207|NCT02348229|Procedure|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
272208|NCT02348229|Procedure|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
272209|NCT02350686|Drug|capecitabine|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
272210|NCT02350686|Drug|oxaliplatin|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
272211|NCT02350699|Device|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
272212|NCT00158041|Drug|Amifostine administered subcutaneously|
271592|NCT02319382|Radiation|PET with the tracer 11C-PE2I|
271593|NCT02319382|Other|MRI|Magnetic field
271594|NCT02319395|Genetic|Blood Sampling and DNA collection|One blood sampling during the study. A small number (1 to 5) of markers type "tag SNPs" or "coding SNP" " (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate.
271595|NCT02319408|Radiation|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
271596|NCT02319421|Other|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
271597|NCT02319434|Device|Ostom-i Alert Sensor|Sensor on ostomy bag.
271598|NCT02321800|Drug|S-649266|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function and body weight)
271599|NCT02321800|Drug|Imipenem/cilastatin|1000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function and body weight)
271600|NCT02321813|Behavioral|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
271601|NCT02321813|Other|placebo control|Quality of life measurement
271907|NCT02316795|Device|Goggle-based device with light-emitting diodes (LED)|
271908|NCT02316795|Drug|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
271909|NCT02316808|Dietary Supplement|Plant stanol ester|Smoothie that contains plant stanol ester
271910|NCT02316808|Dietary Supplement|placebo|Smoothie that contains placebo
271911|NCT02316821|Drug|RTA 402|
271912|NCT00153023|Drug|Valsartan|
271913|NCT02316821|Drug|Placebo|
271914|NCT02316834|Drug|BMN 673|1 mg by mouth once daily.
271915|NCT02316847|Drug|diazepam nasal spray|
271284|NCT02326805|Other|Placebo|Given SC
271285|NCT02326805|Biological|Rilimogene-galvacirepvec|Given SC
271286|NCT02326818|Procedure|BoNT injection|
271287|NCT02326818|Procedure|US guidance|
271288|NCT02326818|Procedure|E-stim Guidance|
271289|NCT02326844|Drug|BMN 673 (talazoparib)|1 mg p.o. once daily on 28-day cycles until disease progression
271290|NCT02326870|Device|AutoLap|
271291|NCT02326883|Behavioral|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
271292|NCT00154050|Drug|candesartan (drug) or quinapril (drug)|
271293|NCT02326883|Behavioral|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
271294|NCT02326883|Behavioral|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
271295|NCT02326909|Device|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
271296|NCT02326909|Device|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
271297|NCT02326922|Device|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
271298|NCT02326935|Biological|Autologous adipose derived mesenchymal cells|Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
271299|NCT02326961|Device|Celution Device|ADRCs Prepared using the Celution Device
271300|NCT02326961|Other|Placebo|Inactive Placebo
271301|NCT02326974|Drug|T-DM1|Participants will receive Trastuzumab emtansine (T-DM1) by IV every 3 weeks for 6 doses; for a total of 18 weeks of treatment.
271302|NCT02329262|Behavioral|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
271012|NCT00155285|Procedure|computed tomography|
271013|NCT02333825|Other|Physical therapy and rehabilitation|
271014|NCT02333838|Drug|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)
271015|NCT02333838|Drug|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
271016|NCT02333838|Drug|IV Busulfan|(Busilvex 3.2 mg/kg/day for 3 days) (Day-5, -4 and -3)
271303|NCT02329262|Behavioral|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
271304|NCT02329275|Procedure|Testicular biopsy|
271305|NCT02329288|Drug|Triamcinolone Acetonide|
271306|NCT02329288|Drug|placebo|
271307|NCT02329301|Drug|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
271308|NCT02329301|Drug|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
271309|NCT02329327|Biological|Andexanet|
271310|NCT00154297|Drug|Everolimus (RAD001)|
271311|NCT02329340|Behavioral|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
271312|NCT02329340|Behavioral|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
271313|NCT02329353|Drug|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
271314|NCT02329366|Other|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
271315|NCT02329379|Drug|Levothyroxine|
271316|NCT02329405|Drug|Rifampicin|
271317|NCT02329405|Drug|Placebo|
271318|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
271319|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
270721|NCT02340910|Other|Transcutaneous Spinal Cord Stimulation (tSCS)|There is evidence that Transcutaneous Spinal Cord Stimulation (tSCS) has effects on spasticity and spinal reflex activity that are similar to those of WBV. The effects of tSCS will be tested during 1 of the 6 sessions for comparison to the effects of WBV. The tSCS stimulation will be applied with charge balanced-biphasic waveforms and stimulation frequencies of 50 Hz.
270722|NCT02340910|Other|Sham Electrical Stimulation|1 of the 6 sessions will include sham electrical stimulation to compare the effects of standing alone to WBV and tSCS. Stimulation intensity will be increased to sensory threshold and then reduced until the subject does not feel it. This will be applied while subjects are standing on the WBV device and during resting breaks between standing.
270723|NCT02340936|Drug|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
270724|NCT00156624|Drug|Balloon Angioplasty with or without drug administration|
270725|NCT02340936|Drug|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
271017|NCT02333838|Drug|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
271018|NCT02333851|Drug|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
271019|NCT02333851|Drug|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
271020|NCT02333864|Device|POGO® BGMS|SMBG
271021|NCT02336217|Other|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
271022|NCT02336230|Drug|remestemcel-L|Subjects will be treated with intravenous (IV) remestemcel-L at a dose of 2 x 10e6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart and no more than 5 days apart for any infusion.
271023|NCT02336243|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
271024|NCT02336243|Dietary Supplement|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
271025|NCT02336256|Procedure|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
271026|NCT00155974|Biological|Community-based vaccine outreach intervention|
271027|NCT02336282|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level < 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
270429|NCT02347319|Drug|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
270430|NCT02347319|Drug|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
270431|NCT02347332|Drug|vinflunine|
270432|NCT02347332|Drug|Methotrexate|
270433|NCT02347345|Drug|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni, one pill daily x 12 weeks
270434|NCT02347358|Device|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
270435|NCT02347358|Drug|IV r-tPA|intravenous recombinant human tissue plasminogen activator
270436|NCT02347384|Device|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
270437|NCT02347384|Device|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem
270438|NCT02347397|Device|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head & SL-TWIN Stem
270439|NCT00157612|Procedure|a clinical pathway for the management of nursing home acquired pneumonia|
270440|NCT02347397|Device|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head & SL-PLUS Stem
270441|NCT02347410|Device|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
270442|NCT02347423|Biological|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
270726|NCT02340936|Drug|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
270727|NCT02340936|Drug|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
270728|NCT02340949|Drug|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
270729|NCT02340949|Drug|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
270730|NCT02343094|Drug|PBA 15g/d|Treatment for 14 days with PBA
270731|NCT02343107|Behavioral|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
274799|NCT02685306|Biological|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
274800|NCT00200317|Behavioral|Internet and print-based interventions|
274801|NCT02685306|Drug|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
274802|NCT02685319|Procedure|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
274803|NCT02687568|Other|EEG monitoring|Value of EEG monitoring as adjunct to standard monitoring
274804|NCT02687581|Device|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
274805|NCT02687581|Device|patch|6-hour of eye patch on the fellow eye
274806|NCT02687594|Drug|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
274807|NCT00200603|Device|calcium phosphate macroporous bioceramics|
274808|NCT02687607|Device|WEB Aneurysm Embolization System|
274809|NCT02687633|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
275075|NCT02716428|Drug|Faldaprevir|
275076|NCT02716428|Drug|TD-6450|
275077|NCT02716428|Drug|Ribavirin|
275078|NCT02716441|Device|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
275079|NCT02716454|Procedure|Ileocecal resection|laparoscopic ileocecal resection with primary anastomosis
275080|NCT02716467|Other|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
275081|NCT02716467|Radiation|Radiotherapy|All participants will receive treatment by radiotherapy
275082|NCT02646163|Drug|REP 2055|(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.
(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks.
274514|NCT02692313|Other|Saline infusion|Placebo
274515|NCT02692326|Procedure|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies < 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
274516|NCT02692339|Drug|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
274517|NCT02692339|Drug|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
274518|NCT02692352|Other|Goal Management Training|Goal Management training, 8 sessions of 2 hours
274519|NCT02692352|Other|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
274520|NCT02692365|Procedure|Magnetic Resonance + hemodynamic + infusion of gadolinium|
274521|NCT02692378|Drug|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
274522|NCT00201201|Other|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
274523|NCT02692391|Drug|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
274524|NCT02692391|Drug|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
274525|NCT02694640|Behavioral|Reach Plus Phone|In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or "coaches" will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff.
274810|NCT02687646|Drug|Adult Allogeneic Mesenchymal cells from adipose tissue.|Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.
Subjects will receive four sequential IV dose of Mesenchymal stem cells.
Sequential doses:
Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg
274811|NCT02687659|Device|TEMIS system|Wearing TEMIS system over the day during one week
274812|NCT02687672|Biological|Stem Cell Transplantation|Transplantation of autologous stem cells
274813|NCT02687685|Other|Skin to skin contact immediate|
274814|NCT02687685|Other|skin to skin contact early|
279063|NCT02701075|Device|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
279064|NCT02701088|Drug|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
279065|NCT02701088|Radiation|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
279066|NCT02701101|Device|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
279067|NCT00202254|Behavioral|Physiotherapy|
279068|NCT02701101|Other|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
279069|NCT02701114|Procedure|Proximal Adductor Canal Block|Continuous Nerve Block
279070|NCT02701114|Procedure|Distal Adductor Canal Block|Continuous Nerve Block
279071|NCT02701127|Drug|Oral niacinamide, 1 gram daily|
279072|NCT02701127|Drug|Oral niacinamide, 3 gram daily|
279073|NCT02701127|Drug|Placebo|
279074|NCT02701140|Procedure|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
279075|NCT02703077|Procedure|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
279076|NCT00202527|Device|Nasal continuos positive airway pressure|
279077|NCT02703090|Drug|Remifentanil|
279078|NCT02703090|Drug|Normal saline|
279079|NCT02703103|Other|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
279080|NCT02703103|Device|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
279081|NCT02703116|Behavioral|eSBI for Alcohol Use|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
278491|NCT02711358|Drug|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
278492|NCT02711358|Drug|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
278493|NCT02713386|Drug|Paclitaxel|Given IV
278494|NCT02713386|Drug|Ruxolitinib Phosphate|Given PO
278495|NCT02713386|Procedure|Therapeutic Conventional Surgery|Undergo TRS
278496|NCT02713399|Device|Optical Coherence Tomography|
278786|NCT02707432|Behavioral|Heart Matters|"Heart Matters" is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at three different stages.
278787|NCT02707445|Drug|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
278788|NCT02707458|Drug|Probucol|Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike "statin" drugs used widely in Canada and the US.
278789|NCT02707471|Behavioral|SM-AET|
278790|NCT00203021|Drug|Glatiramer acetate|Glatiramer acetate 20mg and mannitol 40mg contained in same pre-filled syringe; subcutaneous injection once daily.
278791|NCT02707471|Behavioral|general health education|
278792|NCT02707484|Drug|Thalidomide (100mg)|Patients were randomly assigned to receive a four-month course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
278793|NCT02707484|Drug|Thalidomide (50mg)|Patients were randomly assigned to receive a four-month course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
278794|NCT02707484|Drug|placebo|Patients were randomly assigned to receive a four-month course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
278795|NCT02707497|Drug|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
278796|NCT02707497|Drug|Placebo|The control group will not use any platelet-increased drugs.
278192|NCT00204230|Drug|mycophenolate mofetil (drug)|
278193|NCT02717650|Other|A-STEPmax|Study B) Crossover Validity Study (random allocation). Externally paced incremental step test with breath-by-breath gas analysis. Standardized step height anticipated. Test may be repeated with modified step height.
278194|NCT02717650|Other|Comparator: CPET Godfrey Protocol|Study B) Crossover Validity Study (random allocation). Incremental progressive exercise test with breath-by-breath gas analysis. The "gold standard" cardiopulmonary exercise test (CPET) on a cycle ergometer. Test wattage and design as per the Godfrey Protocol.
278195|NCT02717663|Behavioral|Adaptive Goals|Prescribed goals change daily based on participant's performance
278196|NCT02717663|Behavioral|Static Goals|Prescribed goals remain the same throughout study
278197|NCT02717663|Behavioral|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
278198|NCT02717663|Behavioral|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
278199|NCT02717676|Procedure|Episiotomy|episiotomy will be done after crowning of the fetal head
278200|NCT02717689|Other|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
278201|NCT02717715|Behavioral|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
278202|NCT02717728|Procedure|Drug group Fascia iliaca nerve block|Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.
Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.
Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.
278203|NCT00204243|Drug|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
278204|NCT02684279|Drug|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
278205|NCT02684292|Biological|pembrolizumab|IV infusion
278497|NCT02713412|Other|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
278498|NCT02713412|Other|Water|300ml water
278499|NCT02713425|Device|Entertaining Video Game|
277629|NCT02693938|Device|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
277630|NCT00002542|Drug|CMF regimen|
277631|NCT00201422|Drug|Omeprazole,Amoxicillin,Clarithromycin|
277904|NCT02688972|Other|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
277905|NCT02688972|Other|Control group|The volunteers stayed in rest about 10 minutes
277906|NCT02688985|Drug|Ocrelizumab|Participants with RMS will receive two 300 mg i.v. infusions on Days 1 and 15 then as single infusions of 600 mg every 24 weeks thereafter for a total of three doses.
277907|NCT00200785|Dietary Supplement|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
277908|NCT02688998|Device|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
277909|NCT02689011|Procedure|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
277910|NCT02689011|Procedure|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
277911|NCT02689024|Drug|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
277912|NCT02689024|Drug|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
277913|NCT02689024|Drug|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
277914|NCT02689024|Drug|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
277915|NCT02689024|Drug|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
277916|NCT02689024|Drug|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
277917|NCT02689024|Drug|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
277918|NCT00002539|Drug|cisplatin|
277346|NCT02700360|Dietary Supplement|high-fat diet|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.
277347|NCT02700360|Drug|EC-18|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
277348|NCT02700373|Drug|PDC-APB|
277349|NCT02700373|Drug|Placebo|
277632|NCT02696122|Procedure|General anesthesia via laryngeal mask|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg.
277633|NCT02696122|Procedure|Local anesthesia|For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
277634|NCT02696122|Procedure|Intrathecal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
277635|NCT02696122|Drug|propofol|
277636|NCT02696122|Drug|alfentanyl|
277637|NCT02696122|Drug|ropivacaive|
277638|NCT00201695|Drug|Dexamethasone|40 mg PO days 1-4
277639|NCT02696122|Drug|hyperbaric bupivacaine|
277640|NCT02696122|Device|laryngeal mask|
277641|NCT02696122|Device|27G disposable Quincke needles (B. Braun, Meisungen, AG)|
277642|NCT02696148|Drug|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
277643|NCT02696148|Drug|placebo|For subcutaneous (s.c., under the skin) injection once daily.
277644|NCT02696161|Other|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
273432|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
273433|NCT02322814|Drug|cobimetinib|60 mg/day cobimetinib orally administered once a day (QD), on Day 3 through Day 23 of each 28-day treatment cycle
273434|NCT02325063|Drug|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
273435|NCT02325063|Drug|Corticoid injection|Patients will be treated with an injection of Corticoids.
273436|NCT02325076|Device|Spirodoc|A device to detect the physical condition of the lungs
273437|NCT02325089|Device|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
273438|NCT02325089|Device|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
273439|NCT02325102|Other|No intervention|As this is an observational study, no intervention was conducted.
273740|NCT02317666|Procedure|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
273741|NCT02317679|Drug|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
273742|NCT00153062|Drug|Aggrenox placebo|placebo
273743|NCT02317679|Device|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
273744|NCT02317692|Behavioral|Parent training|
273745|NCT02317705|Drug|OTL38|
273746|NCT02317718|Other|monitor reproductive outcome|
273747|NCT02317731|Other|Straw|Bowel preparation ingestion with a straw
273748|NCT02317744|Drug|Naltrexone and bupropion combination|
273749|NCT02317744|Other|Pill Placebo|
273750|NCT02317770|Drug|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
273107|NCT02330081|Device|Mirasol treatment of whole blood|Subject will be infused with two products at the same time:
radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.
radio-labeled platelets derived from subject's untreated fresh whole blood.
273108|NCT02330094|Drug|Gabapentin|Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.
Both groups will receive other standard of care pain medications.
273109|NCT02330094|Drug|Placebo|Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.
Both groups will receive other standard of care pain medications.
273110|NCT02330107|Other|MAT & LAT|For MAT, the magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.
For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear.
273111|NCT02330120|Drug|propofol|
273112|NCT02332200|Other|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
273113|NCT02332213|Procedure|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
273114|NCT02332213|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
273115|NCT00154739|Drug|Epirubicin|
273116|NCT02332213|Procedure|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
273440|NCT02325128|Behavioral|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
273441|NCT02325141|Procedure|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
273442|NCT02325154|Device|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
273443|NCT00153907|Drug|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
273444|NCT02325167|Behavioral|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
272786|NCT02337010|Device|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
272787|NCT02337010|Device|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
272788|NCT02337010|Drug|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
272789|NCT02337010|Drug|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
272790|NCT02337023|Radiation|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
272791|NCT02337036|Other|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
272792|NCT00156065|Drug|Asenapine|5 or 10 mg BID
272793|NCT02337036|Other|Pharmacogenetic|Pharmacogenetic study
272794|NCT02339376|Device|High-frequency repetitive transcranial magnetic stimulation|
272795|NCT00002402|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
272796|NCT00156312|Drug|Capecitabine|
272797|NCT02339376|Device|Sham repetitive transcranial magnetic stimulation|
272798|NCT02339389|Other|Maternal ventilation|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
272799|NCT02339415|Drug|Edoxaban 30mg daily|
272800|NCT02339415|Drug|Matching placebo|
272801|NCT02339428|Drug|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
272802|NCT02339428|Drug|Placebo|Inactive pill manufactured to mimic diclofenac tablet
272803|NCT02339441|Drug|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
273117|NCT02332213|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
273118|NCT02332213|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
272213|NCT02350712|Drug|patritumab|The initial loading dose of patritumab is given at 18mg/kg, IV, over 60-minutes. Subsequent doses are given every 3-weeks, at 9mg/kg, IV, over 60-minutes.
272214|NCT02350712|Drug|Cetuximab|The initial dose of cetuximab is given at 400mg/m^2, IV, as a 2-hour infusion. Subsequent weekly infusions of cetuximab are given at 250mg/m^2 over 60-minutes.
272215|NCT02350712|Drug|Cisplatin|Cisplatin is given at 100mg/m^2, over 1-hour, once every 3 weeks for a maximum of 6-cycles of treatment
272499|NCT02343809|Other|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
272500|NCT02343822|Other|Platelet Rich Plasma Injection|Plasma component of blood rich in growth factors
-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing
272501|NCT00156975|Drug|Capecitabine|
272502|NCT02343822|Other|Saline Injection|Saline
-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing
272503|NCT02343835|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
272504|NCT02343848|Device|smart bracelet.|Physical activity will be evaluated using smart bracelet.
272505|NCT02343861|Behavioral|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
272506|NCT02343861|Behavioral|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
272507|NCT02343874|Other|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
272508|NCT02343887|Other|neuropsychological tests|
272509|NCT02343887|Other|STAI-Y scale for anxiety|
272510|NCT02343887|Other|Beck scale for depression|
272511|NCT02343887|Other|without intervention|
272512|NCT00156975|Drug|Oxaliplatin|
271916|NCT02316860|Other|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
271917|NCT02316873|Behavioral|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
271918|NCT02316873|Behavioral|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
271919|NCT02316886|Device|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold + Optimal Medical treatment
271920|NCT02316886|Drug|Optimal Medical treatment|
271921|NCT02316899|Drug|ASP0456|
271922|NCT02316899|Drug|Placebo|
271923|NCT00153036|Drug|rt-PA 0.9 mg/kg verum or placebo Intravenous|
271924|NCT02316912|Drug|ATX2417|Randomised double blind parallel group ascending dose assessment
271925|NCT02316912|Drug|Placebo|Randomised double blind parallel group ascending dose assessment
271926|NCT02316925|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning
271927|NCT02316925|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning
271928|NCT02316938|Drug|Everolimus and reduced CNI|MTORi inhibitor, given as part of the core CRAD001A2433 study.
271929|NCT02316938|Drug|Calcineurin Inhibitor and MPA|Will either be cyclosporine or tacrolimus. Used as standard of care in this patient population, but at a lower dose in the everolimus arm and at a standard dose in the comparator arm. Treatment given as part of the core CRAD001A2433 stud.
272216|NCT02350712|Drug|Carboplatin|Carboplatin is given at area under the curve [AUC 5], as an IV-bolus, over 30-60 minutes, every 3- weeks, for a maximum of 6-cycles
272217|NCT02350725|Drug|Furosemide injection solution for subcutaneous administration (80 mg)|
272218|NCT02350725|Drug|Oral Furosemide tablets (80 mg)|
272219|NCT02350738|Other|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
272220|NCT02350738|Other|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
272221|NCT02350738|Other|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
271602|NCT02321826|Behavioral|Music|Participants choice among 4 genres of music matched on music characteristics
271603|NCT02321826|Behavioral|Audiobook|Participants choice among 4 types of audiobooks
271604|NCT02321839|Drug|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
271605|NCT02321852|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
271606|NCT02321852|Drug|Placebo|Once daily oral administration of placebo mannitol for 7 days
271607|NCT02321865|Drug|NPC-02|
271608|NCT00153556|Biological|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
271609|NCT02321878|Drug|liraglutide|Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.
No treatment given.
271610|NCT02321891|Device|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
271611|NCT02321904|Procedure|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
271612|NCT02321904|Procedure|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
271613|NCT02321904|Procedure|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
271614|NCT02321904|Procedure|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
271615|NCT02321904|Procedure|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
271616|NCT02321917|Device|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
271617|NCT02321930|Drug|tofacitinib 5mg po bid|
271618|NCT02321956|Device|Ultrasound guide|
271619|NCT00153569|Biological|Tyrosinase, MAGE-3, GnTV|
271620|NCT02321969|Dietary Supplement|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate [EGCG]).
271320|NCT02329431|Behavioral|activation curriculum|psychosocial activation curriculum
271321|NCT00154310|Drug|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
271322|NCT02329431|Behavioral|support group|parent directed support group
271323|NCT02329444|Procedure|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
271324|NCT02329444|Procedure|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
271325|NCT02329457|Biological|Zostavax|varicella zoster vaccine
271622|NCT02324348|Procedure|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
271623|NCT02324361|Device|Physical Activity Monitor|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
271624|NCT00153803|Drug|Placebo|Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 5 years of therapy.
271625|NCT02324361|Behavioral|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
271626|NCT02324374|Procedure|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
271627|NCT02324374|Device|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
271628|NCT02324387|Procedure|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
271028|NCT02336282|Device|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
271029|NCT02336282|Other|Cognitive Assessment|Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.
The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.
The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture.
271030|NCT02336282|Other|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
271031|NCT02336295|Other|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
271032|NCT02336308|Drug|Ketamine|
271326|NCT02329457|Biological|Normal Saline|normal saline placebo vaccine
271327|NCT02329470|Procedure|Withdrawal of CPAP treatment|Withdrawal of CPAP treatment
271328|NCT02329496|Device|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System
271329|NCT02331433|Drug|Placebo|Matching Placebo
271330|NCT02331446|Behavioral|Physical exercise intervention|
271331|NCT02331459|Other|Multicomponent training intervention|Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)
Legend:
min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching
271332|NCT02331459|Other|Nutritional intervention|Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.
Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.
Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)
271333|NCT02331485|Device|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
271334|NCT02331498|Drug|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
271335|NCT02331511|Drug|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
270732|NCT02343120|Drug|BGB-3111|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the safety, schedule and efficacy expansion part, patients will be assigned to different cohorts based on histology type.
270733|NCT02343133|Biological|HemaMax|Recombinant human interleukin-12 [rHuIL-12]
270734|NCT02343133|Biological|Placebo|Placebo
270735|NCT00156897|Drug|Orlistat|
270736|NCT02343146|Behavioral|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
270737|NCT02343159|Drug|dimethyl fumarate|120 mg and 240 mg delayed release capsules
270738|NCT02343159|Device|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
270739|NCT02343172|Drug|HDM201|
270740|NCT02343172|Drug|LEE011|
270741|NCT02343185|Other|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
270742|NCT02343185|Other|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
270743|NCT02343198|Device|Custom-built research muscle stimulator|Muscle stimulator
270744|NCT02343211|Drug|Immunoglobulin|
270745|NCT02343224|Drug|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
271033|NCT02336308|Drug|Placebo, Normal Saline|
271034|NCT02336321|Device|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
271035|NCT02336334|Device|Positioning measurement|Logging of posturing informations
271036|NCT02336334|Device|Patient feedback|Evaluation of patients questionary
271037|NCT00155987|Procedure|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
271038|NCT02336334|Procedure|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
275083|NCT02646176|Behavioral|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
275084|NCT02646189|Drug|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
275085|NCT02646189|Drug|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
275086|NCT02646189|Drug|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
275087|NCT00002529|Drug|tamoxifen citrate|Tamoxifen 20 mg daily.
275088|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
275089|NCT02646202|Procedure|Sclerotherapy|Injection of varices
275090|NCT02646202|Procedure|Band ligation|endoscopic banding of varices
275091|NCT02646202|Procedure|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
275092|NCT02646215|Procedure|inspiratory muscle training by inspiratory threshold|
275093|NCT02646228|Other|molecular profiling, patient derived cells|molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.
Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer.
275094|NCT02646241|Procedure|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
275370|NCT02712255|Behavioral|Individual Planning|CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter.
275371|NCT02714231|Drug|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
275372|NCT02714231|Drug|lidocaine-prilocaine cream|The patients in the study group before tenaculum placement, a syringe filled with 3 ml of prilocaine cream will be applied to the ectocervix at the planned tenaculum site (1 ml), followed by 2 ml will be placed in the cervix up to the level of the internal os then we will wait 3 minutes before intrauterine device insertion
275373|NCT02714244|Other|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
274815|NCT02687698|Other|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
274816|NCT02687724|Drug|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
274817|NCT02687737|Procedure|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
274818|NCT00200616|Procedure|Antimicrobial prophylaxis|
274819|NCT02687737|Procedure|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
274820|NCT02687737|Procedure|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
274821|NCT02687737|Behavioral|Swallowing Tasks|These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium "hard" swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP.
274822|NCT02687750|Device|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
274823|NCT02689921|Drug|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
274824|NCT02689921|Drug|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
274825|NCT02689921|Drug|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
274826|NCT02689934|Dietary Supplement|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
274827|NCT02689934|Dietary Supplement|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
274828|NCT02689947|Device|Restylane Silk|
274829|NCT02689960|Drug|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
275095|NCT02646241|Procedure|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB & unroofing biopsy.
275096|NCT02646254|Other|blood cardioplegia|
275097|NCT02646254|Other|del nido cardioplegia|
274526|NCT02694640|Behavioral|Reach Plus Message|In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or "coaches" will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff.
274527|NCT02694653|Drug|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
274528|NCT02694653|Drug|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
274529|NCT02694666|Device|Controlled whole-body vibration by Galileo Med L|Device name: Galileo Med L
274530|NCT02694679|Behavioral|CBNH|The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
274531|NCT02694692|Procedure|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
274532|NCT00201513|Behavioral|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
274533|NCT02694692|Behavioral|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
274534|NCT02694705|Device|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
274535|NCT02694705|Device|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
274536|NCT02694705|Device|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
274537|NCT02694718|Drug|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m^2 bid orally on Days 1-14, and at a dose of 825mg/m^2 bid on Days 22-35 and 43-56.
274538|NCT02694718|Drug|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m^2/d on intravenously on day 1 and 50mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
274539|NCT02694731|Behavioral|Mobile application intervention|Consists of the app described in the arm description.
274540|NCT02694744|Drug|patiromer|8.4 g/day starting dose, administered orally
274541|NCT02694757|Device|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
278797|NCT02707510|Other|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
278798|NCT02707523|Drug|Azithromycin 10 mg|
278799|NCT02707523|Drug|Azithromycin 20mg|
278800|NCT02707523|Drug|Placebo|
278801|NCT00002547|Drug|cyclosporine|
278802|NCT00203034|Drug|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
278803|NCT02709473|Drug|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
278804|NCT02709486|Drug|Tanezumab|2.5 mg
279082|NCT02703116|Behavioral|Nutrition Intervention for Health Promotion|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
279083|NCT02703129|Other|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
279084|NCT02703142|Procedure|Patients after esophagectomy|postoperative endoscopic evaluation
279085|NCT02703155|Device|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
279086|NCT02703181|Drug|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
279087|NCT00202540|Drug|S18986|
279088|NCT02703181|Drug|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
279089|NCT02703194|Drug|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
279090|NCT02703194|Drug|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
279091|NCT02703207|Device|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
278500|NCT00203749|Behavioral|Community-Based HIV VCT|COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.
EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.
POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission.
278501|NCT02713438|Behavioral|Individual Planning|CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter.
278502|NCT02713438|Behavioral|Dyadic Planning|CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads).
278503|NCT02713438|Behavioral|Collaborative Planning|CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity.
278504|NCT02713438|Behavioral|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.
The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners.
278505|NCT02713451|Drug|Modulation of Inspired Fraction of Oxygen (FiO2)|In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).
This management of FiO2 will be done until extubation of the patient.
278506|NCT02715531|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 will be administered IV over 120 (± 5) minutes q2w.
278805|NCT02709486|Drug|Tanezumab|5 mg
278806|NCT02709486|Drug|Placebo|Placebo
277919|NCT00200785|Dietary Supplement|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
277920|NCT02689024|Drug|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
277921|NCT02689024|Drug|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
277922|NCT02689024|Drug|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
278206|NCT02684292|Biological|brentuximab vedotin|IV infusion
278207|NCT02684305|Drug|Administration of Propess|History taking and physical examination including cervical length
Eligibility assessment
Explanation regarding the study protocol
Signed informed consent (at VAS<3)
Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.
Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum.
278208|NCT02684305|Device|balloon|History taking and physical examination including cervical length
Eligibility assessment
Explanation regarding the study protocol
Signed informed consent (at VAS<3)
Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.
Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum.
278209|NCT02684305|Drug|Intravenous oxytocin infusion|History taking and physical examination including cervical length
Eligibility assessment
Explanation regarding the study protocol
Signed informed consent (at VAS<3)
Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.
Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum.
278210|NCT02684318|Drug|PM01183 + olaparib|
278211|NCT02684331|Other|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
278212|NCT00200200|Drug|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
278213|NCT02684331|Other|Echocardiography|Standard measurements and strain.
277645|NCT02696161|Other|5% Dextrose|Ultrasound-guided 3cc 5% Dextrose injection between proximal carpal tunnel and median nerve.
277646|NCT02696174|Other|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
277647|NCT02696187|Behavioral|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
277648|NCT02696200|Device|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
277649|NCT00201695|Drug|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
277923|NCT02691377|Device|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
277924|NCT02691377|Device|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
277925|NCT02691390|Device|dTMS|dTMS to ACC
277926|NCT02691403|Drug|levo-bupivacaine|
277927|NCT00000381|Drug|Fluoxetine|
277928|NCT00002540|Other|Laboratory Biomarker Analysis|Correlative studies
277929|NCT00201084|Behavioral|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
277930|NCT02691403|Drug|normal saline|
277931|NCT02691416|Drug|propofol|0.5%-2% sevoflurane and 1.2mg/L propofol (TCI)
277932|NCT02691416|Drug|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
277933|NCT02691429|Other|Acai dye 10%|dye to be used during chromovitrectomy in humans
277934|NCT02691442|Drug|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
277935|NCT02691442|Drug|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
273751|NCT02317770|Drug|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
273752|NCT02317783|Drug|FDG-PET, [18F]Flutemetamol|
273753|NCT00153062|Drug|Aggrenox placebo|placebo
273754|NCT02317796|Drug|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
273755|NCT02317809|Drug|Liquid pergoveris®|Pergoveris (recombinant human follicle-stimulating hormone [r-hFSH]/recombinant human luteinizing hormone [r-hLH]) liquid formulation will be administered as a single dose of 900 international units (IU) r-hFSH/450 IU r-hLH as subcutaneous injection using a disposable pen-injector.
273756|NCT02317809|Drug|Freeze-dried pergoveris®|Pergoveris (r-hFSH/r-hLH) freeze-dried power will be administered as a single dose of 150 IU r-hFSH/75 IU r-hLH as subcutaneous injection.
273757|NCT02317822|Drug|ASA (75-100 mg) + clopidogrel 75 mg: 12m treatment intervention|ASA (75-100 mg) + clopidogrel 75 mg: 12m (treatment arm)
273758|NCT02317822|Drug|ASA (75-100 mg) + clopidogrel: 1m (control arm)|ASA (75-100 mg) + clopidogrel: 1month (control arm)
273759|NCT02317835|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
274047|NCT02351596|Other|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
274048|NCT02351609|Behavioral|Intervention|Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.
Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation.
274049|NCT02351609|Other|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
274050|NCT00158132|Drug|Placebo|Placebo pills
274051|NCT02351622|Drug|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
274052|NCT02351622|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
274053|NCT02351622|Drug|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
274054|NCT02351635|Other|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
273445|NCT02325167|Behavioral|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
273446|NCT02325180|Drug|Dihydroartemisinin-Piperaquine|
273447|NCT02325180|Drug|Artemether-lumefantrine|
273448|NCT02325193|Device|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
273449|NCT02325206|Drug|dapagliflozin|one administration in the morning
273450|NCT02325206|Drug|Placebo|one administration in the morning
273451|NCT02325219|Drug|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
273452|NCT02325219|Drug|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
273453|NCT02325219|Drug|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
273454|NCT00153907|Drug|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
273455|NCT02325219|Drug|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
273456|NCT02325232|Device|Capsule endoscopy, double balloon enteroscopy sequential use|Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
273457|NCT02327858|Other|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months and then daily supportive text messages for the next three months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
273760|NCT02320240|Drug|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273761|NCT02320240|Drug|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273762|NCT02320240|Drug|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273763|NCT02320240|Drug|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273764|NCT02320240|Drug|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
273119|NCT02332213|Procedure|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
273120|NCT02332226|Behavioral|Representational approach|Representational approach to patient education
273121|NCT02332239|Behavioral|iDOVE Intervention (ED+text)|In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention
Eight-week longitudinal tailored text-message program
273122|NCT02332239|Behavioral|Control (EUC)|In-ED brief session, discussing home safety & nutrition
Eight-week longitudinal home safety & nutrition text-message program
273123|NCT02332252|Device|Scalpel|Skin incision performed with a scalpel during cesarean section.
273124|NCT02332252|Device|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
273125|NCT02332252|Procedure|Skin incision|
273126|NCT00154752|Procedure|CCRT, Pelvic lymphadenoectomy.|
273127|NCT02332265|Other|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed & implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, & Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission & partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices & sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings & Loans Groups, 3) building capacity of local governance structures & 4) integrating HIV education & gender empowerment into programs through training & education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
273128|NCT02332278|Procedure|Early feeding|Fluid diet four hours after cesarean section
273129|NCT02332278|Procedure|Late feeding|Fluid diet 12 hours after cesarean section
273130|NCT02332291|Drug|Escitalopram|Escitalopram 10-20mg daily
273131|NCT02332291|Drug|Bupropion XL|Bupropion XL 150-450mg daily
273132|NCT02332304|Procedure|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
273133|NCT02334462|Drug|TWINRIX|
273134|NCT02334462|Drug|Menactra|
273135|NCT02334475|Biological|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
272513|NCT02345850|Drug|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
272514|NCT02345850|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
272515|NCT02345863|Drug|Bendamustine|Debulking:
2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated.
272804|NCT02339441|Drug|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
272805|NCT02339441|Drug|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
272806|NCT02339454|Device|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
272807|NCT00156325|Drug|Escitalopram (Lexapro)|
272808|NCT02339454|Device|Placebo group|Placebo Applicator
272809|NCT02339467|Other|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
272810|NCT02339467|Other|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
272811|NCT02339480|Other|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
272222|NCT02350751|Drug|MEDI8852|
272223|NCT00158054|Behavioral|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
272224|NCT02350751|Drug|Placebo|
272225|NCT02350764|Drug|nivolumab|
272226|NCT02350764|Drug|pilimumab|
272227|NCT02350777|Procedure|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
272228|NCT02350777|Device|CliniMACS Cell Selection System|
272229|NCT02350790|Procedure|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
272230|NCT02350790|Procedure|Robotic excision|Robotic excision of endometriosis
272231|NCT02350803|Device|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
272232|NCT02350816|Drug|HGT-1410|
272233|NCT00158301|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
272234|NCT02353039|Drug|Placebo|Administer placebo t.i.d for 2 weeks
272235|NCT02353052|Other|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
272236|NCT02353065|Procedure|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
272516|NCT02345863|Drug|GA101|Induction
GA101 iv infusion:
Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg
Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.
GA101: Cycle 1-8 Day 1 1000 mg
272517|NCT02345863|Drug|Ibrutinib|Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.
Cycle 2-6: Day 1 420 mg daily
Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.
Ibrutinib: Cycle 1-8 420 mg daily
272518|NCT02345876|Other|no intervention|
271621|NCT02321982|Other|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
271930|NCT02316951|Device|single-arm study group|Study participants will wear a small motion detection wrist band and have a KINECT-based video set up in their hospital room. Study participants will be questioned about their sociodemograhic, pain, and health history.
271931|NCT02316964|Drug|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
271932|NCT02319447|Behavioral|Additional education|Our Intervention includes a 60-90 minute educational seminar, entitled "Destination: Transplant", featuring "live" speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about CKD, transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar.
271933|NCT00002391|Drug|Abacavir sulfate|
271934|NCT00153192|Drug|Marinol (dronabinol)|
271935|NCT02319460|Biological|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
271936|NCT02319460|Biological|Plasma|
271937|NCT02319473|Other|JAC Registry|patients who received reperfusion therapy
271938|NCT02319486|Drug|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
271939|NCT02319486|Drug|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
271940|NCT02319499|Dietary Supplement|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
271941|NCT02319499|Dietary Supplement|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
271942|NCT02319499|Dietary Supplement|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
271943|NCT02319499|Other|Placebo|Placebo group received no minerals/vitamin
271944|NCT02319512|Other|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
271945|NCT00153205|Device|computerized physician order entry|
271946|NCT02319512|Other|Glucose|12ml glucose solution (13,6g) per day
271947|NCT02319525|Other|computerized patient decision guide|this guide contains information that patients prefer regarding benefits and harms
271629|NCT02324387|Drug|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
271630|NCT02324400|Device|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
271631|NCT02324400|Device|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
271632|NCT02324413|Drug|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
271633|NCT02324413|Drug|Placebo|
271634|NCT02324426|Drug|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
271635|NCT00153816|Drug|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
271950|NCT02319538|Drug|medical hormone treatment (Thyroxine)|Medical hormon treatment with individual dosage
271951|NCT02319564|Drug|Clenil Compositum 250mcg +100mcg|
271952|NCT02319564|Drug|Beclomethasone 250mcg|
271953|NCT02319564|Drug|Placebo|
271954|NCT02319577|Drug|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
271955|NCT02319577|Drug|Gefitinib|EGFR tyrosine kinase inhibitor
271956|NCT00153231|Device|IVS|Infracoccygeal sacropexy
271957|NCT02322008|Biological|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
271958|NCT02322021|Drug|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
271959|NCT02322021|Drug|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
271960|NCT02322034|Other|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
271961|NCT02322047|Drug|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 15-49: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
271336|NCT02331511|Drug|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
271337|NCT02331511|Drug|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
271338|NCT00154648|Procedure|CE-MRA|
271339|NCT02331524|Behavioral|Activity Feedback and Encouragement|The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to "Continue what you are doing. You are doing great!"
271340|NCT02331524|Other|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
271341|NCT02331537|Behavioral|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
271636|NCT02324439|Drug|Omega Nutrition cold-milled flaxseeds|Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
271637|NCT02324452|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
271638|NCT02326974|Drug|Pertuzumab|Participants will receive a loading dose of pertuzumab by IV on Cycle 1 Day 1 followed by maintenance dose of pertuzumab by IV every 3 weeks for a total of 6 doses; for a total of 18 weeks of treatment.
271639|NCT00154063|Drug|E2007|
271640|NCT02326974|Procedure|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
271641|NCT02326987|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
271642|NCT02326987|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
271643|NCT02327000|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
271644|NCT02327000|Drug|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
271039|NCT02336334|Device|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
271040|NCT02338739|Behavioral|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
271041|NCT02338739|Behavioral|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
271042|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
271043|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
271044|NCT00156208|Drug|Asoprisnil|10mg Tablet, oral Daily for 18 months
271045|NCT02338739|Behavioral|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
271046|NCT02338739|Behavioral|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
271047|NCT02338739|Behavioral|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
271048|NCT02338739|Behavioral|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
271049|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
271050|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
271342|NCT02331550|Procedure|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
271343|NCT02331550|Procedure|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
271344|NCT02331563|Drug|Dexmedetomidine|ultrasound guided transvers abdominis plane block
271345|NCT02331563|Drug|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
275374|NCT02714257|Behavioral|Enhanced Usual Care plus Exercise Coaching|For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.
Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.
For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation.
275375|NCT02714270|Procedure|modified partograph|
275376|NCT02714270|Procedure|paperless partograph|
275377|NCT02714283|Drug|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
275378|NCT02714283|Drug|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
275379|NCT00002548|Drug|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
275380|NCT00203814|Drug|Sulfadoxine-pyrimethamine|
275381|NCT02714296|Dietary Supplement|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
275382|NCT02714296|Dietary Supplement|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
275383|NCT02714309|Dietary Supplement|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
275384|NCT02714309|Other|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
275385|NCT02714309|Other|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
275665|NCT02708329|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
275666|NCT02708355|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
275667|NCT02710214|Drug|Placebo|Once-daily dosing of placebo for 8 weeks
275098|NCT02646267|Drug|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
275099|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
275100|NCT02646267|Drug|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
275101|NCT02646267|Drug|dabigatran etexilate|110mg, twice a day, oral
275102|NCT02646280|Other|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
275103|NCT02646280|Other|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
275104|NCT02685332|Radiation|Stereotactic Radiation|Stereotactic Body Partial Breast irradiation Cohort 1: 22.5 Gy Cohort 2: 25 Gy Cohort 3: 27.5 Gy Cohort 4: 30 Gy
275105|NCT02685345|Drug|DS-8500a 25 mg|
275106|NCT02685345|Drug|DS-8500a 75 mg|
275107|NCT02685345|Drug|placebo|
275108|NCT02685358|Behavioral|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
275109|NCT02685358|Behavioral|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
275110|NCT02685371|Behavioral|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
275111|NCT02685384|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
275112|NCT00200330|Behavioral|Behavioral weight loss treatment|
275113|NCT02685397|Drug|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
275114|NCT02685397|Drug|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
275386|NCT02714309|Other|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
275387|NCT02714322|Biological|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
274542|NCT02694770|Biological|Neihulizumab Treatment|Monoclonal antibody
274543|NCT00002542|Drug|cyclophosphamide|
274830|NCT02689973|Behavioral|Self-Efficacy|The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).
Group and individual components were included. Setting: secondary and high schools.
274831|NCT02689973|Behavioral|Planning|The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).
Group and individual components were included. Setting: secondary and high schools.
274832|NCT00200902|Drug|duloxetine (Cymbalta)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
274833|NCT02689973|Behavioral|Education|Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.
The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.
Group and individual components were included. Setting: secondary and high schools.
274834|NCT02689986|Drug|Bendamustine, Rituximab|Bendamustine, Rituximab
274835|NCT02689999|Drug|Dexrabeprazole 10 mg Enteric-Coated Tablets|
274836|NCT02690012|Other|Magnesium Oxide|Magnesium Oxide
274837|NCT02690012|Other|Magnesium Citrate|Magnesium Citrate
274838|NCT02690025|Drug|ZP1848|
274839|NCT02690038|Drug|Intravenous immunoglobulin (IVIG)|Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.
Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization
274840|NCT02690038|Drug|Normal Saline|Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.
Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization
279092|NCT02703207|Device|PAP combined with oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
279093|NCT02703220|Other|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
279094|NCT02703220|Drug|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
279095|NCT02703220|Drug|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
279096|NCT02705417|Procedure|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
274544|NCT00201539|Drug|single dose Morphine|
274545|NCT02696850|Drug|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
274546|NCT02696850|Other|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
274547|NCT02696863|Behavioral|questionnaire|
274548|NCT02696876|Device|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
274549|NCT02696876|Procedure|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
274550|NCT02696889|Procedure|ROSE Protocol|Laparoscopy followed by injection of BMSC fraction in right ovary
274551|NCT00201747|Drug|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
274552|NCT02696902|Drug|MEDI3902|Active
274553|NCT02696902|Other|Placebo|Placebo
278807|NCT02709499|Device|0J LLLT|perform with the machine off
278808|NCT02709499|Device|6J LLLT|irradiation will be perform with 4J
278809|NCT02709512|Drug|ADI-PEG 20 plus Pem Cis|Investigational Drug in combination approved standard of care treatment for this indication
278810|NCT02709512|Other|Placebo plus Pem Cis|Placebo in combination approved standard of care treatment for this indication
278811|NCT00203255|Drug|Soy Isoflavones|
278812|NCT02709525|Drug|hyaluronic acid|
278813|NCT02709525|Other|Placebo|
278814|NCT02709538|Drug|GSP 301 NS|2 spray in each nostril twice daily for 52 weeks
278815|NCT02709538|Drug|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
278816|NCT02709538|Drug|GSP 301 Placebo NS pH 7|2 spray in each nostril twice daily for 52 weeks
278817|NCT02709551|Behavioral|HRV_Bfb|
278818|NCT02709551|Behavioral|MBI|
278819|NCT02709551|Behavioral|MBI_HRV_Bfb|
278820|NCT02709564|Drug|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
278821|NCT02709564|Drug|Misoprostol 200 sublingual|patients will take 1 tablet of sublingual misoprostol 200 microgram 1 hour before the surgery
278822|NCT00203268|Drug|dihydroergotamine mesylate|1.0 mg. intramuscularly
278823|NCT02709577|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
278824|NCT02709577|Other|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
278825|NCT02709590|Drug|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
278826|NCT02709590|Drug|placebo|patients will have of oral placebo tablet 30 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
278827|NCT02709603|Drug|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
278214|NCT02684331|Other|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
278215|NCT02684344|Drug|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
278216|NCT02684344|Other|Education|Education about signs and symptoms of urinary retention
278217|NCT02684357|Drug|BI 655066|
278218|NCT02684357|Drug|placebo to ustekinumab|
278219|NCT02684357|Drug|USTEKINUMAB|
278220|NCT02684357|Drug|placebo to BI 655066|
278507|NCT02715544|Other|Healthy lifestyle|The families will receive a designed for these purposes intervention
278508|NCT02715544|Other|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
278509|NCT02715557|Behavioral|Arise|Arise is an an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
278510|NCT02715570|Drug|PC945 - single doses|Safety and tolerability of single doses
278511|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
278512|NCT02715570|Drug|Placebo - single doses|Safety and tolerability of single doses
278513|NCT02715570|Drug|PC945 - repeat doses|Safety and tolerability of repeat doses
278514|NCT02715570|Drug|Placebo - repeat doses|Safety and tolerability of repeat doses
278515|NCT02715583|Drug|11C-Acetate|
278516|NCT02715583|Drug|Ra-223 therapy|
278517|NCT02715596|Dietary Supplement|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
278518|NCT02715596|Other|Placebo|placebo in 15 cc emulsion stick-pack
278519|NCT02715609|Drug|Disulfiram|
278520|NCT02715609|Drug|Copper Gluconate|
278521|NCT02715609|Procedure|Surgery|
269365|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
269366|NCT02344823|Drug|Placebo intake once daily|
269660|NCT02338245|Drug|ASLAN001|ASLAN001 400mg BID
269661|NCT02338245|Drug|Lapatinib|Lapatinib 1250mg QD
269662|NCT02338245|Drug|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
269663|NCT02338258|Device|Anti-rotational plate|
269664|NCT02338258|Device|Exchanged Intramedullary nailing|
269665|NCT00156156|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
269666|NCT02338271|Other|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
269667|NCT02340338|Biological|rTSST-1 Variant Candidate Vaccine|In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.
Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of < 20 to > 40 or a 4-fold increase in TSST-1 Ab titer .
Patients 3 µg or more will be randomized.
269668|NCT02340351|Device|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
269669|NCT02340351|Procedure|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
269670|NCT02340364|Behavioral|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
269671|NCT02340364|Behavioral|Self-care Education|208 patients randomized to self-care education alone.
269672|NCT02340377|Device|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
274055|NCT02351648|Other|a transitional care model|Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge
Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge
Intervention after discharge:
Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients
274056|NCT02351648|Other|Control|Patients receive usual standard of care from the internal medicine team
274057|NCT02351661|Other|There was no intervention|observational study, no intervention
274058|NCT02351687|Dietary Supplement|Lipid Nutrient Supplement|
274059|NCT02351687|Drug|Sulfadoxine-pyrimethamine|
274060|NCT02351687|Drug|Albendazole|
274061|NCT00158366|Behavioral|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
274062|NCT02353923|Dietary Supplement|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
269367|NCT02344836|Behavioral|Podcast + mobile diet app|Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
269368|NCT02344836|Behavioral|Podcast + theory-based mobile diet app|Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
269369|NCT02344849|Drug|mesenchymal stem cell (Cellgram-ED)|Patients will receive single injection of Cellgram-ED( 30,000,000 MSC) intracavernously.
269370|NCT02344862|Drug|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
269371|NCT02344862|Drug|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
269372|NCT02344862|Drug|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
269373|NCT00157118|Drug|Protein C Concentrate (Human) Vapor Heated|
269374|NCT02344862|Drug|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
269375|NCT02346903|Drug|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
269376|NCT02346916|Drug|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
273765|NCT02320253|Behavioral|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
273766|NCT02320253|Behavioral|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
273767|NCT00153335|Behavioral|patient-provider interaction|
273768|NCT02320253|Behavioral|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
273769|NCT02320279|Device|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
273770|NCT02320292|Biological|Rituximab|Given IV
273771|NCT02320292|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
273772|NCT02320292|Other|Quality-of-Life Assessment|Ancillary studies
273773|NCT02320292|Other|Questionnaire Administration|Ancillary studies
273774|NCT02320292|Other|Laboratory Biomarker Analysis|Correlative studies
273775|NCT02320305|Biological|MART-1 Antigen|Given IM
273776|NCT02320305|Drug|TLR4 Agonist GLA-SE|Given IM
273777|NCT02320305|Other|Laboratory Biomarker Analysis|Correlative studies
273778|NCT00153348|Behavioral|Women's health|
273779|NCT02320318|Drug|Ibodutant 10 mg|Oral tablet, once daily.
274063|NCT02353936|Drug|BIBW2992|International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH & Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).
Route of administration: Orally (Take by swallowing) Dosage: Once daily
274064|NCT02353949|Drug|Flutemetamol|PET-MR Scan using the radiotracer Flutemetamol for diagnostic purpose
273458|NCT02327871|Device|Esophageal cooling device (and usual standard procedure)|Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
273459|NCT02327910|Other|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
273460|NCT02327910|Other|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
273461|NCT02327923|Drug|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
273462|NCT02327923|Drug|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
273463|NCT02327923|Drug|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
273464|NCT02327923|Drug|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
273465|NCT00154154|Behavioral|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
273466|NCT02327923|Drug|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
273467|NCT02327923|Drug|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
273468|NCT02327923|Drug|Vecuronium|Inj Veccuronium 0.1mg/kg will be given at induction and for maintenance.
273469|NCT02327923|Drug|Atropine|Inj Atropine 0.4 mg IV will be given for bradcardia (HR < 50/min)
273470|NCT02327923|Drug|Ephedrine|
273471|NCT02327923|Drug|Morphine|
273472|NCT02327923|Drug|Ketorolac|
273473|NCT02327923|Drug|Ondansetron|
273474|NCT02327923|Drug|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
273475|NCT02327923|Drug|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
273476|NCT00154167|Drug|NV-101 (phentolamine mesylate solution)|
272812|NCT02339493|Other|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
272813|NCT02339506|Drug|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
272814|NCT02341612|Other|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
272815|NCT00156676|Device|Body-weight supported treadmill|
272816|NCT02341612|Other|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
272817|NCT02341612|Other|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
272818|NCT02341612|Other|passive recovery|The control group was exposed to treatment after the EIMD protocol.
272819|NCT02341625|Drug|BMS-986148|
273136|NCT02334475|Biological|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
273137|NCT02334488|Drug|Everolimus|Active Comparator
273138|NCT02334488|Drug|Tacrolimus|Active Comparator
273139|NCT02334488|Drug|Mycophenolate sodium|Experimental Arm
273140|NCT00155428|Procedure|rapid prototyping|
273141|NCT02334501|Drug|Lansoprazole|
273142|NCT02334501|Drug|Neratinib|
273143|NCT02334527|Drug|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
273144|NCT02334540|Dietary Supplement|purses|food intake
273145|NCT02334540|Dietary Supplement|a calorie/protein matched smoothie|
273146|NCT02334553|Drug|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
273147|NCT02334553|Drug|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
272519|NCT02345889|Device|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
272520|NCT02345889|Device|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
272521|NCT00157261|Drug|tenecteplase|
272522|NCT02345889|Device|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
272523|NCT02345889|Device|Standard Colonoscopy|Current standard of care colonoscopy
272524|NCT02345902|Drug|Haloperidol|haloperidol 1.25 mg P.O q.d
272525|NCT02345902|Other|Placebo|placebo 1.25 mg P.O q.d
272526|NCT02345902|Other|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
272527|NCT02345915|Other|Blood sample|
272528|NCT02345915|Other|Electrocardiogram|
272529|NCT02345928|Drug|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
272530|NCT02345928|Drug|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
272531|NCT02345928|Drug|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
272532|NCT00157274|Drug|alemtuzumab|
272533|NCT02348229|Procedure|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
272534|NCT00157703|Drug|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
272535|NCT02348229|Procedure|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
272820|NCT02341638|Drug|BMS-986141|
272821|NCT02341638|Drug|Placebo|
272822|NCT02341638|Drug|Aspirin|
271948|NCT02319525|Other|usual care|patient gets the standard handout from non-profit organization regarding lupus and its treatments, that explains risks and benefits of various treatments
271949|NCT02319538|Procedure|Absolute total thyroidectomy performed|Surgery combined with standard thyroxine treatment
272237|NCT02353065|Radiation|Bedside x-ray|Portable x-ray of fracture post-reduction
272238|NCT02353078|Drug|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
272239|NCT02353078|Procedure|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
272240|NCT02353078|Device|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
272241|NCT02353091|Device|Personal FM system|
272242|NCT02353104|Dietary Supplement|Onion-Pumpkin Extract|
272243|NCT02353117|Behavioral|Congenital Syphilis Intervention Group|
272244|NCT00158301|Drug|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
272245|NCT02353130|Drug|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
272246|NCT02353143|Drug|MEN1112|One-hour intravenous infusion of MEN1112 pro/Kg body weight dose on days 1, 8, 15 of a 21-day cycle. Two induction cycles followed by a 3 week End of induction period. Post-induction/Maintenance Visits every 4 weeks with or without maintenance treatment administration, whilst clinical benefit is maintained as per Investigator's judgement. The individual treatment/observation period is six months.
272247|NCT02353156|Other|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
272248|NCT02353156|Other|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
272249|NCT02353169|Drug|Dexmedetomidine|
272250|NCT02353169|Other|normal saline solution|
272251|NCT02353182|Drug|Dexmedetomidine|Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
272252|NCT02353182|Drug|Remifentanil|Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
271962|NCT02322047|Drug|Naltrexone|Naltrexone Dosing Days 1-49: 50mg @ 9PM
271963|NCT02322047|Drug|Placebo|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 15-49: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
271964|NCT02322047|Drug|Placebo|Placebo Dosing Days 1-49: 50mg @ 9PM
271965|NCT00153582|Biological|WT1 126-134 peptide|
271966|NCT02322060|Procedure|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
271967|NCT02322060|Procedure|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
271968|NCT02322060|Procedure|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
272257|NCT02316964|Biological|aldesleukin|Given SC
272258|NCT00153049|Drug|Telmisartan|
272259|NCT02316964|Other|laboratory biomarker analysis|Correlative studies
272260|NCT02317003|Behavioral|Intervention PPIL|
272261|NCT02317003|Behavioral|Control OR|
272262|NCT02317016|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
272263|NCT02317016|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
272264|NCT02317016|Drug|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
272265|NCT02317016|Procedure|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
272266|NCT02317016|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
272267|NCT02317029|Device|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
272268|NCT02317029|Procedure|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
272269|NCT00153049|Drug|Hydrochlorothiazide|
271645|NCT02327013|Drug|vortioxetine 10 mg tablet|Oral tablets, once daily
271646|NCT02327013|Drug|vortioxetine 20 mg tablet|Oral tablets, once daily
271647|NCT02327013|Other|Placebo tablet|Oral tablets, once daily
271648|NCT02327026|Procedure|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
271649|NCT02327026|Procedure|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
271650|NCT00154063|Other|Placebo|
271651|NCT02327039|Drug|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
271652|NCT02327039|Drug|Placebo|Tables of Dapagliflozin placebo
271653|NCT02327052|Other|No intervention was performed.|No intervention was performed.
271654|NCT02327065|Device|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
271655|NCT02327065|Device|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
271969|NCT02322073|Procedure|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
271970|NCT02322086|Drug|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
271971|NCT02322099|Drug|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
271972|NCT02322099|Drug|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
271973|NCT02322099|Dietary Supplement|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
271974|NCT02322099|Drug|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
271975|NCT02322112|Other|Microcrystalline Cellulose Supplementation|Fifty five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
271346|NCT02331576|Drug|rocaine|
271347|NCT02331576|Drug|Fentanyl|
271348|NCT02333877|Other|Skinlink|suture using Skinlink
271349|NCT02333877|Other|Nylon|conventional suture using nylon
271350|NCT00155311|Procedure|orthodontic treatment|
271351|NCT02333890|Drug|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
271352|NCT02333890|Drug|Placebo|
271353|NCT02333903|Other|Personalized Physical Activity|1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.
Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises.
271354|NCT02333916|Other|overfeeding + exercise pre-training|
271355|NCT02333916|Behavioral|fitness training|
271356|NCT02333916|Other|overfeeding + exercise post-training|
271357|NCT02333929|Device|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
271358|NCT02333942|Device|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
271359|NCT02333955|Drug|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
271360|NCT02333968|Behavioral|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
271361|NCT00155324|Device|Extracorporeal Shock Wave Therapy (Device)|
271656|NCT02327078|Drug|Nivolumab + Epacadostat|Epacadostat: Oral daily dosing; Nivolumab: IV infusion
271657|NCT02327091|Drug|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
271658|NCT02327104|Behavioral|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
275668|NCT02710227|Other|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
275669|NCT02710240|Drug|Indocyanine Green (ICG)|
275670|NCT00203346|Procedure|Greater Occipital Nerve Block|
275671|NCT02710240|Radiation|intraoperative near-infrared (NIR)|
275672|NCT02710253|Radiation|Radiation Therapy|Radiation treatment consists of standard doses to 50 Gy in 4 fractions with stereotactic radiation or 30-45 Gy in 3-6 Gy fractions with conventional external beam radiation. The radiation dose, fractionation, and target at discretion of the treating radiation oncologist.
275673|NCT02710266|Drug|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
275674|NCT02710266|Drug|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
275675|NCT02710266|Drug|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
275676|NCT02710279|Behavioral|Trier Social Stress Test (TSST)|For the TSST the participants are instructed to imagine having applied for their "dream job" and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days.
275677|NCT02710279|Device|smartphone|
275678|NCT02710292|Device|Delefilcon A contact lenses|
275679|NCT02710292|Device|Narafilcon A contact lenses|
275680|NCT02710305|Drug|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
275681|NCT00203359|Drug|etanercept given by perispinal administration|
275962|NCT02704130|Procedure|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
275963|NCT02706327|Other|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
275964|NCT02706340|Other|No intervention - observational study only|
275388|NCT02714322|Biological|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
275389|NCT02714348|Other|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
275390|NCT02714361|Dietary Supplement|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
275391|NCT02716480|Behavioral|Mobility coaching|The intensive follow-up for the patients of "Mobility Coaching " arm will consist on a monthly remote coaching of 20 to 30 minutes led by a "Mobility" coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used.
275392|NCT02716480|Behavioral|Diet coaching|The intensive follow-up for the patients of "Diet Coaching " arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery.
275393|NCT02716493|Behavioral|Telerehabilitation program|The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.
Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.
In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions
275394|NCT00002548|Procedure|allogeneic bone marrow transplantation|day 0
275395|NCT00204061|Behavioral|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
275396|NCT02716506|Procedure|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
275397|NCT02716519|Biological|Santyl|Collagenase ointment applied topically once per day for up to six weeks
275398|NCT02716519|Other|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
275399|NCT02716532|Dietary Supplement|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
275400|NCT02716545|Device|balloon assisted enteroscopy|Patients with recurrent bleeding (>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
275401|NCT02716558|Other|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
275682|NCT02710305|Drug|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
274841|NCT02692417|Device|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
274842|NCT02692430|Other|No intervention is studied|
274843|NCT02692443|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
275115|NCT02685397|Drug|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
275116|NCT02685397|Drug|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
275117|NCT02685397|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
275118|NCT02685410|Other|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
275119|NCT02685423|Behavioral|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
275120|NCT02685423|Behavioral|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
275121|NCT02685423|Behavioral|Binocular deprivation 5 days|Research participants will be asked to live 5 days in an experimentally-controlled dark environment.
275122|NCT02685436|Drug|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
275123|NCT00200330|Behavioral|Behavioral and home environment weight loss treatment|
275124|NCT02685449|Drug|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
275125|NCT02685449|Drug|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
275126|NCT02687763|Biological|ProQuad|2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:
to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.
to participate in the three (3) antibody titer blood draws.
275127|NCT02687789|Other|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
275128|NCT02687789|Other|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
274554|NCT02696915|Drug|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
274555|NCT02696915|Drug|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
274556|NCT02696915|Device|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
274557|NCT02696915|Drug|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
274558|NCT02696928|Drug|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
274559|NCT02696928|Drug|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
274560|NCT02696928|Drug|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
274561|NCT02696941|Drug|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
274562|NCT00002542|Drug|fluorouracil|
274563|NCT00201760|Drug|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
274564|NCT02696941|Drug|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
274565|NCT02696954|Drug|Artemether-lumefantrine combination|Regimen 1 (Artemether-lumefantrine on Day 0, 1 and 2) Washout period: 4 weeks
274844|NCT02692443|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
274845|NCT02692456|Device|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
274846|NCT02692456|Device|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
274847|NCT02692469|Procedure|Duodenal Switch|Bariatric procedure
274848|NCT02692469|Procedure|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
274849|NCT00201201|Other|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
274850|NCT02692482|Device|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
274272|NCT02701309|Other|no intervention|
274273|NCT00002544|Drug|mitoxantrone hydrochloride|
274274|NCT00202267|Device|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
274275|NCT02701322|Behavioral|Medical clown|
274276|NCT02701335|Device|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
274277|NCT02703363|Drug|Celecoxib|
274278|NCT02703363|Drug|Placebo|
274279|NCT02703376|Drug|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
274280|NCT02703389|Behavioral|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
274281|NCT02703389|Behavioral|Pamphlet|Contains same information as video.
274282|NCT02703402|Other|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
274283|NCT02703402|Other|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
274284|NCT00202592|Drug|Perindopril|
274285|NCT02703415|Drug|Bupivacaine group|caudal block with bupivacaine (0.25%) 1mg/kg alone
274286|NCT02703415|Drug|Ketamine|caudal block with bupivacaine (0.25%) 1mg/kg plus ketamine 0.5 mg/kg
274287|NCT02703415|Drug|Tramadol|caudal block with bupivacaine (0.25%) 1mg/kg plus tramadol 1 mg/kg
274288|NCT02703441|Other|Tablet computer|Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
278522|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
278523|NCT02715609|Radiation|Radiation|
278524|NCT02715609|Drug|Temozolomide|
278525|NCT02715622|Procedure|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
278526|NCT02715635|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
278527|NCT02715635|Dietary Supplement|Concentrate beetroot Juice|140 ml containing ~8 mmol of inorganic nitrate
278528|NCT02715635|Dietary Supplement|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
278529|NCT02715648|Drug|Phenazopyridine|
278530|NCT02715661|Other|exercise|six-month interval of exercise
278531|NCT02715674|Device|Plasti-med TRIFLO|
278828|NCT02709603|Drug|diclofenac potassium|oral diclofenac potassium; one tablet (cataflam 50 mg) 30 minutes before the procedure
278829|NCT02711371|Other|fMRI|
278830|NCT02711397|Other|Observational study|Comparison excretion levels of gluten immunogenic peptides
278831|NCT02711410|Drug|Clopidogrel|
278832|NCT00203502|Drug|Bevacizumab|IV 15mg/kg 21 days
278833|NCT02711423|Drug|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
278834|NCT02711423|Drug|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
278835|NCT02711436|Device|Computed Tomography Scan|
278836|NCT02711436|Device|Fast Magnetic Resonance Imaging|
278837|NCT02711449|Drug|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
278838|NCT02711449|Drug|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
278839|NCT02711462|Drug|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
269673|NCT02340390|Device|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
269674|NCT02340390|Device|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
269968|NCT02333448|Biological|Blood sample taken on day 3 after initiation of treatment|
269969|NCT02333448|Biological|Blood sample taken on day 5 after initiation of|
269970|NCT02333448|Biological|Blood sample taken on day 7 after initiation of treatment|
269971|NCT02333448|Biological|Blood sample taken on day 10 after initiation of treatment|
269972|NCT02333461|Dietary Supplement|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
269973|NCT02333461|Dietary Supplement|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
269974|NCT02333461|Dietary Supplement|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
269975|NCT00155220|Device|Low Stretch Bandage and Kinesio Tape|
269976|NCT02335684|Other|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
269977|NCT02335697|Behavioral|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
269978|NCT02335697|Other|No intervention|
269979|NCT02335710|Device|Journey II BCS TKA|
269980|NCT02335723|Device|Alteco LPS Adsorber|Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.
Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species.
269377|NCT02346929|Other|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
269378|NCT02346955|Biological|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1-intravenous administration
269379|NCT02346968|Other|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
269380|NCT00157534|Drug|Celgosivir|
269381|NCT02346981|Behavioral|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
269382|NCT02346994|Dietary Supplement|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
269383|NCT02346994|Dietary Supplement|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
269675|NCT02340403|Procedure|NMR Spectroscopy|
269676|NCT00156533|Drug|Sugar Pill|
269677|NCT02340416|Device|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
269678|NCT02340429|Device|DE500 Digital Video Otoscope|
269679|NCT02340442|Other|Obstetrical care parameters|
269680|NCT02340442|Other|DVA measurements|
269681|NCT02340442|Other|Fundus photographs|
269682|NCT02340455|Drug|Pregabalin_male|Pregabalin 150mg bid 1day Men
269683|NCT02340455|Drug|Pregabalin_female|Pregabalin 150mg bid 1day Women
269684|NCT02340455|Drug|Placebo_Men|Placebo durg
269685|NCT02340455|Drug|Placebo_Women|Placebo_Women
269686|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
274065|NCT02353962|Other|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
274066|NCT02353975|Drug|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
274067|NCT02353988|Drug|Bicalutamide|Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.
Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade >= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity.
274068|NCT02353988|Other|Physician's Choice|The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.
The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.
Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance.
274069|NCT02354001|Drug|Raloxifene hydrochloride|
274070|NCT02354001|Drug|Placebo|
274071|NCT02354014|Drug|Bedaquiline (TMC207)|Bedaquiline (TMC207) tablet formulation administered orally as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1 and Bedaquiline (TMC207)tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. Dose administered in cohort 3 and 4 will depend upon the review of safety and pharmacokinetic data from Cohort 1 and 2 by internal safety monitoring group.
274072|NCT00158366|Behavioral|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
274073|NCT02354014|Drug|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
274074|NCT02354027|Drug|SHR3824 metformin|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
Drug: SHR3824 + Metformin
274075|NCT02317848|Other|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
274076|NCT02317861|Drug|RDEA3170|Oral Treatment
269384|NCT02347007|Dietary Supplement|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
273477|NCT02327923|Drug|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
273478|NCT02327923|Drug|Glycopyrrolate|10 mcg/kg with neostigmine
273780|NCT02320318|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
273781|NCT02322814|Drug|paclitaxel|Paclitaxel administered at a dose of 80 mg/m2 by IV infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information
273782|NCT02322814|Drug|placebo|matching placebo to cobimetinib, orally administered once a day (QD), on Day 3 through Day 24 of each 28-day treatment cycle
273783|NCT02322853|Drug|Tamoxifen|hormonotherapy
273784|NCT02322853|Drug|Ralimetinib (LY2228820 dimesylate)|
273785|NCT02322866|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating
273786|NCT02322866|Drug|Placebo|Dose-matched placebo, taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating
273787|NCT02322879|Drug|Acetaminophen|Daily administration of 4 grams of acetaminophen.
273788|NCT00153634|Drug|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
273789|NCT02322879|Drug|Acetaminophen/Propelyne Glycol|Daily administration of 4 grams of acetaminophen and 70 mg/kg propylene glycol.
273790|NCT02322892|Drug|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
273791|NCT02322892|Drug|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
273792|NCT02322905|Behavioral|Emotion Regulation Therapy|8 sessions of ERT
273793|NCT02322918|Genetic|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
273794|NCT02322931|Procedure|Intra-operative C-arm CT imaging|Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.
Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.
One Cine loop C-arm scan in the sagittal plane while retracting the probe.
One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down).
273148|NCT02334566|Behavioral|NET TX|Intervention procedures are a behavioral intervention (NET & KIDNET) with 8-12 sessions administered on a weekly basis.
273149|NCT02334579|Radiation|CyberKnife Stereotactic Radiosurgery|Five treatments given over about one week.
273150|NCT02334592|Radiation|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
273151|NCT00155428|Procedure|computed tomography|
273152|NCT02334605|Other|cold dry air|Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.
Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%.
273153|NCT02334605|Device|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
273154|NCT02334605|Device|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
273155|NCT02334631|Drug|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
273156|NCT02334631|Drug|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
273479|NCT02327936|Drug|Fesoterodine|Administer medication to patients with overactive bladder
273480|NCT02330120|Drug|dexmedetomidine|
273481|NCT02330133|Behavioral|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
273482|NCT02330133|Behavioral|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
273483|NCT00154388|Drug|Imatinib mesylate|
273484|NCT02330146|Drug|RCT-01|
273485|NCT02330146|Drug|Placebo|
273486|NCT02330159|Procedure|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
272823|NCT02341638|Drug|Itraconazole|
272824|NCT02341651|Other|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
272825|NCT02341677|Procedure|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
272826|NCT00156676|Device|Lokomat|
272827|NCT02341690|Other|Interval walking training|Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.
IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger
272828|NCT02341690|Other|control|Standard care at the promotion centre in the municipality
272829|NCT02341703|Drug|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
272830|NCT02341703|Drug|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
272831|NCT02341703|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
272832|NCT02341703|Other|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
272833|NCT02341716|Procedure|WA|Walk advice with Nordic Poles and best medical treatment
272834|NCT02341716|Procedure|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
272835|NCT02341716|Procedure|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
272836|NCT02341729|Drug|ticagrelor|crushed tablets and non-crushed tablets
272837|NCT00156689|Drug|levetiracetam|
272838|NCT02341742|Device|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
272839|NCT02343913|Device|PAC checklist|
272840|NCT02343926|Drug|GEMIGLIPTIN LS15-0444|Pharmaceutical form:tablet
Route of administration: oral
272841|NCT02343926|Drug|vildagliptin|Pharmaceutical form:tablet
Route of administration: oral
272253|NCT02353182|Drug|Bupivacaine|Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
272254|NCT02353182|Drug|Ropivacaine|Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
272255|NCT00158314|Behavioral|Referral to Gamblers Anonymous|
272256|NCT02316964|Biological|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
272536|NCT02348229|Procedure|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
272537|NCT02348229|Procedure|conventional pathway group|5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.
Drains removed
272538|NCT02348242|Device|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
272539|NCT02348242|Device|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
272540|NCT02348242|Device|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
272541|NCT02348255|Procedure|Electric Field Therapy|Undergo NovoTTF-100A
272542|NCT02348255|Biological|Bevacizumab|Given IV
272543|NCT02348255|Drug|Carmustine|Given IV
272544|NCT02348255|Other|Quality-of-Life Assessment|Ancillary studies
272545|NCT00157716|Drug|(MC-1) Pyridoxal-5’-phosphate|
272546|NCT02348268|Other|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
272547|NCT02348268|Other|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
272548|NCT02348268|Device|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
272549|NCT02348281|Drug|Bicalutamide|150mg, po, qd, d1-28
272550|NCT02348294|Other|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
272270|NCT02317029|Device|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
272271|NCT02317029|Procedure|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
272272|NCT02317055|Other|imaging|
272273|NCT02317068|Device|HBR|
272274|NCT02317068|Device|DD|
272275|NCT02317081|Device|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
272276|NCT02317094|Other|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
272277|NCT02317094|Drug|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
272278|NCT02317120|Genetic|NGS BRCA 1 and BRCA 2 full sequencing|
272556|NCT02350829|Other|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
272557|NCT00158054|Behavioral|Referred depression care|Physician notified of depression symptoms, usual care followed.
272558|NCT02350842|Device|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
272559|NCT02350842|Device|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
272560|NCT02350855|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
272561|NCT02350855|Other|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
272562|NCT02350855|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
272563|NCT02350868|Drug|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
271976|NCT02324465|Device|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
271977|NCT02324465|Device|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
271978|NCT02324478|Procedure|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
271979|NCT02324491|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
271980|NCT02324491|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
271981|NCT02324504|Device|C3 Wave ECG-based PICC Tip Confirmation System|The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
271982|NCT02324504|Radiation|Chest radiograph|Chest radiograph will be performed as a second measure to confirm catheter tip placement.
271983|NCT02324530|Device|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
271984|NCT00153816|Drug|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
271985|NCT02324543|Drug|Gemcitabine|IV over 40 minutes; Days 4 and 11 of a 21 day cycle
271986|NCT02324543|Drug|Taxotere|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
271987|NCT02324543|Drug|Xeloda|orally, twice daily; Days 1 through 14 of a 21 day cycle
272279|NCT02319603|Drug|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
272280|NCT02319603|Drug|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
272281|NCT02319616|Drug|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
272282|NCT02319629|Drug|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
272283|NCT02319629|Drug|Placebo|
272284|NCT02319642|Drug|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
272285|NCT02319655|Procedure|Air tamponade|Air tamponade
271659|NCT02327104|Other|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
271660|NCT02327117|Drug|Tranexamic Acid|
271661|NCT00154076|Drug|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
271662|NCT02327117|Drug|Normal saline|
271663|NCT02329509|Procedure|two stage palate surgical repair|two stage palate surgical repair with a hard palate closure at 3 to 4 years old
271664|NCT02329509|Procedure|One stage Palate Surgical repair|One stage palate repair at the age of 9 to 24 months old
271665|NCT02329522|Device|Ultrasonic Cardiac Output Monitor|An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).
USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow.
271666|NCT00154310|Drug|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
271667|NCT02329522|Device|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
271668|NCT02329535|Drug|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
271669|NCT02329548|Other|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
271670|NCT02329561|Drug|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
271671|NCT02329561|Behavioral|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
271672|NCT02329561|Drug|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
276592|NCT02697656|Behavioral|Self-help|Self-help resources on obtaining employment and coping with chronic pain
276593|NCT02697656|Behavioral|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
275965|NCT02706353|Drug|APX005M|Dose Escalation Phase Starting Dose Level of APX005M: 1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected. Up to 0.5 ml injected into tumors 0.5 to 1.5 cm, up to 1 ml into tumor 1.5 to 2.5 cm and up to 2 ml into tumors >2.5 cm.
Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase.
275966|NCT00202904|Drug|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
275967|NCT02706353|Drug|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
275968|NCT02706379|Other|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
275969|NCT02706392|Other|Laboratory Biomarker Analysis|Correlative studies
275970|NCT02706392|Biological|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
275971|NCT02706405|Biological|JCAR014|Given IV
275972|NCT02706405|Drug|Cyclophosphamide|Given IV
275973|NCT02706405|Biological|Durvalumab|Given IV
275974|NCT02706405|Drug|Fludarabine Phosphate|Given IV
275975|NCT02706405|Other|Pharmacological Study|Correlative studies
275976|NCT02706418|Procedure|Clinical Massage Therapy|
275977|NCT00202917|Drug|Fludarabine|
275978|NCT02706431|Procedure|Hyperventilation|
275979|NCT02706444|Device|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
275980|NCT02706444|Device|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
275981|NCT02706457|Other|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
275683|NCT02710318|Behavioral|Electronic immunization alert|Immunization alert in the electronic health record
275684|NCT02710331|Drug|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally.
275685|NCT02710331|Drug|Placebo|Control: no alcohol, administered for ~80 minutes.
275686|NCT02710331|Drug|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
275687|NCT02710331|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
275688|NCT02710344|Behavioral|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
275689|NCT02712255|Behavioral|Dyadic Planning|CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
The plan focuses on physical activity of only one person in the dyad: the patient.
275690|NCT02712255|Behavioral|Collaborative Planning|CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity.
275691|NCT00203593|Procedure|VO2max test|
275692|NCT02712255|Behavioral|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
275693|NCT02712268|Other|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
275694|NCT02712281|Behavioral|Autism MEAL Plan|The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.
The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.
275129|NCT02687802|Other|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
275130|NCT02687815|Drug|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
275131|NCT02687815|Drug|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
275132|NCT00200629|Procedure|Adenosine SPECT myocardial perfusion imaging|
275402|NCT02716558|Other|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
275403|NCT02716571|Other|Leukapheresis or Plasmapheresis|Leukapheresis: Donate 5x10^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.
Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE).
275404|NCT02716584|Behavioral|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
275405|NCT02716584|Behavioral|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
275406|NCT00204061|Drug|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
275407|NCT02683161|Drug|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
275408|NCT02683161|Behavioral|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
275409|NCT02683161|Behavioral|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
275410|NCT02683174|Device|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
275411|NCT02683174|Biological|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
274851|NCT02692482|Procedure|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
274852|NCT02692521|Dietary Supplement|Human Milk|
274853|NCT02692534|Other|Urine cocaine negative|Preoperative urine cocaine negative
274854|NCT02692534|Other|Urine cocaine positive|Preoperative urine cocaine positive
274855|NCT02692547|Device|Hybrid-logic closed loop system|All patients get to wear the pump
274856|NCT02692560|Behavioral|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
274857|NCT02692560|Other|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Group Health Cooperative enrollees.
274858|NCT02692573|Other|positioning|prone positioning for the initial 5 minutes of life
274859|NCT02692573|Other|positioning|supine positioning for the initial 5 minutes of life
274860|NCT00201214|Drug|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
274861|NCT02692586|Device|FlowTriever System|
274862|NCT02692599|Biological|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
274863|NCT02692599|Biological|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
275133|NCT02687841|Drug|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
275134|NCT02687841|Drug|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
275135|NCT02687854|Drug|Apixaban|As prescribed by treating physicians
275136|NCT02687854|Drug|Vitamin K antagonist|As prescribed by treating physicians
275137|NCT02687867|Drug|Dabigatran (Pradaxa)|As prescribed by treating physicians
275138|NCT02687867|Drug|Vitamin K antagonist|As prescribed by treating physicians
274289|NCT02703454|Procedure|FIRM-guided RF ablation|
274290|NCT02703454|Procedure|Conventional RF ablation|
274566|NCT02696954|Drug|Amodiaquine|Regimen 2 (Amodiaquine on Day 0, 1 and 2) Washout period: 6 weeks
274567|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine|Regimen 3 (Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2) Washout period: 6 weeks
274568|NCT02696954|Drug|Primaquine|Regimen 4 (Primaquine on Day 0) Washout period: 1 week
274569|NCT02696954|Drug|Artemether-lumefantrine combination + Primaquine|Regimen 5 (Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0) Washout period: 4 weeks
274570|NCT02698995|Drug|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
274571|NCT00201968|Device|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
274572|NCT02698995|Drug|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
274573|NCT02699008|Drug|Clopidogrel|Antiplatelet agent
274574|NCT02699008|Drug|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
274575|NCT02699034|Procedure|ablation for typical atrial flutter|
274576|NCT02699034|Device|Vision-MR ablation catheter|
274577|NCT02699047|Dietary Supplement|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
274578|NCT02699047|Dietary Supplement|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
274579|NCT02699060|Procedure|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|The procedure should be performed on an empty stomach standard technique of anesthesia;10% lidocaine solution). The examination includes analysis of esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects (erosions, ulcers, strictures, hemorrhages), as well as the appearance of the gastric and duodenal mucosa. . The modified Savary-Miller classification of esophagitis will be used to characterize changes in the esophageal mucosa. For morphological research and monocyte/macrophage phenotype assessment biopsy sampling of distal esophagus will be performed.
278840|NCT02711462|Drug|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
278841|NCT02711488|Behavioral|Intervention group|The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.
The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager.
278842|NCT02711501|Procedure|Laser-assisted surgery.|laser-assisted surgery
278843|NCT00203502|Drug|Cyclophosphamide|500mg per meter squared, IV every 21 days
278844|NCT02711501|Procedure|conventional surgery by blade|conventional surgery
278845|NCT02711527|Other|Acupunture group A|Subjects in Group A will receive 14 needles based on the TCM theory "Soothing liver-qi stagnation", all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14).
274291|NCT02703480|Biological|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
274292|NCT02703480|Biological|Ti-mesh|Titanium mesh
274293|NCT02703493|Radiation|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
274294|NCT02703506|Other|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
274295|NCT00202605|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
274296|NCT02703506|Other|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
274297|NCT02703519|Procedure|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
274298|NCT02705664|Drug|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
274299|NCT02705664|Drug|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
269981|NCT00155766|Biological|HPV16 E7 peptide-pulsed autologous DCs|
269982|NCT02335723|Device|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
269983|NCT02335736|Drug|Gonadotropins releasing hormone antagonist|
269984|NCT02335749|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
269985|NCT02335788|Device|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
269986|NCT02335814|Drug|FLX925|
270277|NCT02328911|Device|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
270278|NCT02328924|Other|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
270279|NCT02331056|Other|fluid loading|Fluid loading at defined period
500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records.
270280|NCT02331056|Procedure|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
270281|NCT02331056|Procedure|thoracotomy|the patient group for scheduled open pulmonary lobectomy
270282|NCT00154518|Procedure|Orthodontic treatment|
270283|NCT02331069|Drug|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
270284|NCT02331069|Other|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
270285|NCT02331082|Other|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
269687|NCT02342717|Drug|Itraconazole|multiple doses of Itraconazole capsules
269688|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
269689|NCT02342730|Behavioral|Weight Loss Specialist|Referred to a weight loss specialist
269690|NCT00156845|Procedure|AI-700 contrast-enhanced echocardiography|
269691|NCT02342730|Other|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
269692|NCT02342730|Other|Medical Chart Review|Chart reviews are performed
269693|NCT02342743|Device|CEFALY|
269694|NCT02342756|Device|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
269695|NCT02342769|Drug|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
269696|NCT02342782|Biological|Yttrium Y 90 Basiliximab|Given IV
269697|NCT02342782|Drug|Carmustine|Given IV
269698|NCT02342782|Drug|Etoposide|Given IV
269699|NCT02342782|Drug|Cytarabine|Given IV
269700|NCT02342782|Drug|Melphalan|Given IV
269987|NCT02335827|Procedure|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
269988|NCT02335840|Other|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
269989|NCT02335840|Other|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
269990|NCT02335840|Other|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
269991|NCT02335840|Other|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
269992|NCT00155870|Behavioral|questionnaires|
269993|NCT02335866|Procedure|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
269385|NCT02347007|Dietary Supplement|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
269386|NCT02347020|Behavioral|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
269387|NCT02347020|Behavioral|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
269388|NCT02349308|Device|CentrosFLO Long Term Hemodialysis Catheter|
269389|NCT00002410|Drug|Indinavir sulfate|
269390|NCT00157872|Drug|Comparator: naproxen tablet 500 mg|
269391|NCT02349321|Behavioral|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
269392|NCT02349321|Behavioral|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
269393|NCT02349334|Device|Percutaneous Tibial Nerve Stimulation|
269394|NCT02349347|Drug|Melphalan|
269395|NCT02349347|Drug|Lenograstim|
269396|NCT02349360|Biological|L. johnsonii N6.2|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks (n=15)
269397|NCT02349360|Biological|Placebo|Encapsulated starch placebo administered for 8 weeks (n=15)
269398|NCT02349373|Behavioral|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
269399|NCT02349373|Behavioral|16 week training period|Receipt of a weekly running schedule through an online training diary.
269701|NCT00156858|Drug|intravenous busulfan|
273795|NCT02322944|Behavioral|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
274077|NCT02317861|Drug|Febuxostat|Oral Treatment
274078|NCT02317861|Drug|Benzbromarone|Oral Treatment
274079|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
274080|NCT02317874|Drug|Carboplatin|Given IV
274081|NCT02317874|Other|Laboratory Biomarker Analysis|Correlative studies
274082|NCT02317874|Drug|Paclitaxel|Given IV
274083|NCT02317874|Other|Pharmacological Study|Correlative studies
274084|NCT02317874|Drug|Talazoparib|Given PO
274085|NCT02317887|Biological|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
274086|NCT02317900|Biological|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10^3 plaque forming units (PFUs) of each component (10^3.3 PFUs/mL of rDEN1∆30, 10^4.3 PFU/mL of rDEN2/4∆30(ME), 10^3.3 PFU/mL of rDEN3∆30/31-7164 and 10^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
274087|NCT02317900|Biological|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
274088|NCT02317900|Biological|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
274089|NCT02317926|Drug|Levothyroxine|
274090|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
274091|NCT02317926|Drug|Levothyroxine Plus Liothyronine|
274092|NCT02317926|Drug|Desiccated Thyroid Extract|
274093|NCT02317939|Other|instruction|online instruction tutorials at followup visits
274094|NCT02317939|Other|standard baseline instruction|self-guidance at followup visits
274095|NCT02317952|Other|Experimental Extensively Hydrolyzed Formula|
274096|NCT02317952|Other|Active Comparator Formula|
273487|NCT02330172|Other|Injection of neostigmine or sugammadex|At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected.
273488|NCT02330185|Device|ultrasonography|spinal anesthesia guided with ultrasonography
273489|NCT02330211|Biological|Fecal Microbiota Transplant|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standards by the Microbiome Health Research Institute Inc. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
273490|NCT02330211|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
273491|NCT02330224|Other|Hypertension Management Intervention|The multifaceted intervention consists of three main components:
Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients
Motivational conversation by nurses and nurse practitioners for high risk patients at baseline
Telephone based follow-up for all patients by nurses
273492|NCT02330237|Drug|natural gels|whole fruits and vegetables
273493|NCT02330237|Drug|Placebo|
273494|NCT00154401|Drug|liraglutide|
273495|NCT02330250|Other|Pharmaceutical Care|The patients assigned for the intervention group will receive guidance from a pharmacist ("pharmaceutical consultation") in addition to the medical care habitually delivered by the hospital.
The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners.
273796|NCT02322944|Behavioral|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
273797|NCT02322957|Drug|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
273798|NCT02322970|Device|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
273799|NCT02325245|Drug|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
273800|NCT02325245|Drug|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
273157|NCT02334644|Dietary Supplement|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
273158|NCT02337036|Drug|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
273159|NCT02337062|Drug|APD421|
273160|NCT02337062|Drug|Placebo|
273161|NCT02337075|Behavioral|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
273162|NCT02337075|Device|Activity Mentor|
273163|NCT02337088|Procedure|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
273164|NCT02337088|Procedure|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
273165|NCT02337101|Other|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
273166|NCT02337101|Behavioral|EUC + Early intervention programme|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.
Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion.
273167|NCT00002401|Drug|Lamivudine|
273168|NCT00156078|Drug|pregabalin|
273169|NCT02337114|Behavioral|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
273170|NCT02337114|Behavioral|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
273171|NCT02337127|Drug|Lamivudine|Lamivudine, 100mg/day, per os
273172|NCT02337140|Device|Pacemaker SORIN Group KORA DR|
273173|NCT02337140|Procedure|transcatheter aortic valve implantation (TAVI)|
273174|NCT02337166|Device|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
272551|NCT02348307|Drug|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
272552|NCT02348307|Drug|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
272553|NCT02348320|Biological|Personalized polyepitope DNA vaccine|
272554|NCT02348333|Drug|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
272555|NCT02348333|Drug|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
272842|NCT02343926|Drug|metformin|Pharmaceutical form:tablet
Route of administration: oral
272843|NCT02343939|Drug|Entospletinib|Entospletinib tablets administered orally
272844|NCT02343939|Drug|Daunorubicin|Daunorubicin 60 mg/m^2 administered intravenously daily on Days 1 to 3 of each 14 day cycle
272845|NCT02343939|Drug|Cytarabine|Cytarabine 100 mg/m^2 administered intravenously daily on Days 1 to 7 of each 14 day cycle
272846|NCT02343939|Drug|Decitabine|Decitabine 20 mg/m^2 administered intravenously
272847|NCT02343952|Drug|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
272848|NCT02343965|Other|Touch-massage|
272849|NCT00156988|Drug|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
272850|NCT02343978|Drug|KWA-0711|
272851|NCT02343991|Device|Transcranial ExABlate|MR Guided Focused Ultrasound
272852|NCT02344004|Drug|Liposomal Amikacin for Inhalation|
272853|NCT02344017|Drug|ODM-204|co-administered with prednisone, orally daily
272854|NCT02344017|Drug|Prednisone|ODM-204 is co-administered with oral prednisone
272855|NCT02344030|Device|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
272856|NCT02344030|Device|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
272857|NCT02344043|Device|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
272564|NCT02350881|Device|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
272565|NCT02350920|Behavioral|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
272566|NCT02350933|Procedure|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a Storz Hopkins II 10020 ATA 0° endoscope.
272567|NCT02350933|Device|Storz Hopkins II 10020 ATA 0° endoscope|
272568|NCT00000355|Drug|Buprenorphine|
272569|NCT00002410|Drug|Zidovudine|
272570|NCT00158067|Device|external Responsive Neurostimulator (eRNS) System|
272571|NCT02350946|Drug|Oxytocin|
272572|NCT02350946|Drug|Placebo|
272573|NCT02350959|Drug|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
272574|NCT02350959|Drug|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
272865|NCT02344095|Drug|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
272866|NCT02345928|Drug|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
272867|NCT02345941|Other|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
272868|NCT02345941|Other|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
272869|NCT02345954|Procedure|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
272870|NCT02345954|Procedure|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
272871|NCT02345967|Device|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
272872|NCT02345980|Drug|Sildenafil|Patients in this arm will receive Sildenafil 50 tablet daily from fixation of the stent for 2 weeks
272286|NCT02319655|Procedure|Balanced salt solution filling|BSS filling
272287|NCT02319668|Drug|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
272288|NCT02319668|Drug|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
272289|NCT00153231|Procedure|Sacrospinofixation|
272290|NCT02319681|Behavioral|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
272291|NCT02319681|Behavioral|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
272292|NCT02319707|Drug|Oxytocin|The study group: divided into two groups:
• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
272293|NCT02319707|Drug|Oxytocin in 100 ml NaCl 0.9%|The control group:
pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
272294|NCT02319720|Biological|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
272295|NCT02319720|Biological|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
272575|NCT02350972|Biological|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
272576|NCT02350985|Drug|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
272577|NCT02350985|Drug|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
276594|NCT02697669|Other|18F-FDG PET|Imaging
276595|NCT02697682|Biological|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
276596|NCT02697695|Other|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
276597|NCT00201825|Drug|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
276598|NCT02697708|Dietary Supplement|Potassium (control diet)|See arm/group description.
276599|NCT02697708|Dietary Supplement|Potassium (supplement diet)|See arm/group description.
276600|NCT02697708|Dietary Supplement|Potato Diet|See arm/group description.
276601|NCT02697708|Dietary Supplement|French Fries Diet|See arm/group description.
276602|NCT02697721|Behavioral|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
276603|NCT02697721|Other|Control with delayed intervention|Control with delayed intervention
276604|NCT02697734|Drug|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg. Each strength has a unique size and color. The osilodrostat 1 mg, 5 mg, 10 mg and 20 mg film coated tablets are approximately 6 mm, 7 mm, 9 mm, and 11 mm respectively in diameter and pale yellow, yellow, pale orange brown and light brown respectively in color.
276605|NCT02697734|Drug|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg. Each strength has a unique size and color.
276606|NCT02697747|Other|Education|Educational intervention in the use of ultrasound to identify landmarks
276607|NCT02697760|Radiation|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
276608|NCT00201825|Drug|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
276609|NCT02697773|Other|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
276610|NCT02697773|Biological|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
276272|NCT02701946|Procedure|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
276273|NCT02701946|Procedure|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
276274|NCT02701959|Dietary Supplement|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (300ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~530 mg nitrate derived).
276275|NCT02701959|Dietary Supplement|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (50ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~3 mg nitrate derived).
276276|NCT00202371|Procedure|Red Blood Cell transfusion|
276277|NCT02701972|Device|BACE Device|Implanted BACE device
276278|NCT02701985|Drug|Matching Placebo|Two matching placebo 50-mg capsules, taken orally, twice daily
276279|NCT02701985|Drug|RO5459072|Two 50-mg capsules, taken orally, twice daily
276280|NCT02701998|Behavioral|mHealth-Enhance Physical Activity Intervention|
276281|NCT02701998|Other|Physical Activity Intervention|
276282|NCT02702011|Drug|empagliflozin medium dose|
276283|NCT02702011|Drug|empagliflozin low dose|
276284|NCT02702011|Drug|empagliflozin high dose|
276285|NCT02702011|Drug|placebo|
276286|NCT02702024|Procedure|Double uterine incision technique in uterus preserving surgery for placenta percreta|
276287|NCT00202397|Drug|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
276288|NCT02702037|Dietary Supplement|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
276289|NCT02702037|Other|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
275982|NCT02706470|Drug|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
275983|NCT02706470|Drug|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
275984|NCT02706483|Drug|Plecanatide|
275985|NCT02706509|Drug|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
275986|NCT02708355|Drug|Placebo|Placebo capsules
275987|NCT02708368|Other|blood withdrawal|3 times
275988|NCT02708381|Other|Screening|Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
275989|NCT02708394|Drug|olanzapine|atypical antipsychotic
275990|NCT00203112|Drug|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
275991|NCT02708394|Drug|placebo|placebo control
275992|NCT02708407|Procedure|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
275993|NCT02708420|Device|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
275994|NCT02708420|Device|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
275995|NCT02708433|Drug|Lidocaine|Lidocaine
275996|NCT02708446|Drug|Mifepristone|200mg oral mifepristone to both study arms
275997|NCT02708446|Drug|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
275998|NCT02708446|Drug|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
275999|NCT02708459|Device|surgically inserted Transversus abdominus plane catheter|at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
275412|NCT02683187|Drug|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
275413|NCT00200057|Device|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
275414|NCT02683187|Drug|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
275695|NCT02712281|Behavioral|Parent Education|The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.
Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial.
275696|NCT02712294|Other|Neuromuscular Electrical Stimulation|
275697|NCT02712307|Drug|Phenoxymethylpenicillin|
275698|NCT02712320|Drug|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
275699|NCT02712333|Behavioral|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
275700|NCT02712333|Behavioral|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
275701|NCT00203814|Drug|Artesunate plus sulfadoxine-pyrimethamine|
275702|NCT02714361|Other|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
275703|NCT02714374|Drug|GL-ONC1|Dose and Regimen:
Single dose group: Cohort 1 dose is 1 × 109 pfu
Multiple dose groups: (1) Cohort 2 dose is 1 × 109 pfu × 5 consecutive days; (2) Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days; or (3) Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.
Route: GL-ONC1 is delivered as a bolus IV injection.
275139|NCT02687880|Procedure|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
275140|NCT02687893|Behavioral|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
275141|NCT02687893|Behavioral|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
275142|NCT02687906|Drug|Carbavance|Carbavance (meropenem-vaborbactam) for IV injection
275143|NCT00200629|Procedure|Combined adenosine / exercise SPECT myocardial perfusion imaging|
275144|NCT02687919|Other|Modified Paleo diet|Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
275145|NCT02687932|Drug|LCZ696|
275146|NCT02687932|Drug|Valsartan|
275147|NCT02687945|Procedure|Outpatient physiotherapy|
275148|NCT02690051|Device|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
275149|NCT02690064|Dietary Supplement|Acute Antioxidant Cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
275150|NCT00200902|Drug|escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
275415|NCT02683200|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
275416|NCT02683200|Radiation|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
275417|NCT02683213|Drug|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
275418|NCT02683213|Drug|Placebo|Matching placebo.
274580|NCT02699060|Procedure|24-h esophageal pH-impedance test with manometry-control of pH-transducer|Procedure of pH impedancemetry includes intranasal introduction of a probe into oesophagus and connection of the probe with the recording device and 24-hour wearing of the probe.
Installation of the probe is carried out on an empty stomach. 24-h pH-impedance monitoring will be done in both distal oesophagus and in the stomach according to standard of practice. Esophageal pH sensor will be positioned 5 cm above the manometrically located border of the lower esophageal sphincter. Measurement with a second pH sensor in the stomach, 10cm below the lower esophageal sphincter in order to monitor intragastric acidity will be done as a standard routine procedure.
Standard measuring parameters will be collected: percent of time when pH is less than 4, total number of reflux episodes, number of acid and alkaline reflux episodes, duration of longest reflux episode.
274581|NCT02699073|Drug|regorafenib|160mg once daily during 3 weeks followed by 1 week off therapy.
Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity.
274864|NCT02694770|Biological|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
274865|NCT02694783|Biological|PyVST|ex vivo generated
274866|NCT02694796|Behavioral|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
274867|NCT02694809|Drug|Conjugated Estrogens/Bazedoxifene|Given PO
274868|NCT02694809|Other|Cytology Specimen Collection Procedure|Correlative studies
274869|NCT02694809|Other|Laboratory Biomarker Analysis|Correlative studies
274870|NCT02694809|Other|Pharmacological Study|Correlative studies
274871|NCT02694809|Other|Placebo|Given PO
274872|NCT02694809|Procedure|Quality-of-Life Assessment|Ancillary studies
274873|NCT02694809|Other|Questionnaire Administration|Ancillary studies
274874|NCT00201539|Drug|double dose Morphine|
274875|NCT02694822|Drug|AGEN1884|anti-CTLA-4 antibody
274876|NCT02694848|Drug|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
274877|NCT02694848|Drug|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
274300|NCT02705664|Drug|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
274301|NCT02705690|Device|iOS Balance Application|We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:
The phone is kept stable against the lower back of the participant using the belt.
The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.
These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)
274302|NCT02705703|Biological|TAPA-pulsed DC vaccine|A total of six vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered every 14 days.
274303|NCT02705703|Drug|Cyclophosphamide|Administration of low dose CYP (100 mg/day) starting 7 days prior to TAPA-pulsed DC vaccine administration.
274304|NCT02705703|Other|Granulocyte Macrophage Colony Stimulating Factor|50 micrograms/day of GM-CSF will be administered for 5 days following each TAPA-pulsed DC vaccine.
274305|NCT02705716|Other|Test Dentifrice|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
274306|NCT00202865|Biological|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
274307|NCT02705716|Other|Control Dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
274582|NCT00000382|Behavioral|Infant-Parent Psychotherapy|
274583|NCT00002542|Radiation|radiation therapy|
274584|NCT00201968|Device|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
274585|NCT02699086|Drug|PDC-1421 Capsule|
274586|NCT02699086|Drug|placebo|
274587|NCT02699099|Dietary Supplement|Vitamin A|Oral administration of Vitamin A (1 dose)
274588|NCT02699099|Biological|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
274589|NCT02699099|Biological|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
274590|NCT02701335|Device|Gloreha device|Robotic assisted passive mobilization.
274591|NCT02701335|Device|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
270286|NCT02331082|Other|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
270287|NCT02331082|Device|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
270288|NCT02331082|Device|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
270289|NCT02331082|Behavioral|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
270578|NCT02323984|Other|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
270579|NCT02324010|Drug|Sitagliptin|100mg mane for 2 days
270580|NCT02326454|Drug|talaporfin sodium|1 mg/kg
270581|NCT02326454|Drug|Saline|
270582|NCT02326454|Device|Drug Activator 100 J/cm|Light Dose: 100 J/cm
270583|NCT02326454|Device|Drug Activator 200 J/cm|Light Dose: 200 J/cm
270584|NCT02326467|Drug|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
270585|NCT02326480|Other|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
270586|NCT02326493|Device|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
270587|NCT00153998|Drug|Cetuximab and FOLFOX|Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:
Cetuximab 250 mg/m² (1.0 h i.v.) weekly
Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)
269994|NCT02335866|Procedure|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
269995|NCT02335879|Biological|Gonal-F|
269996|NCT02335905|Drug|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
269997|NCT02338284|Other|ultrasound of globe|A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.
A value > 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS.
269998|NCT02338297|Procedure|TACE|Transarterial chemoembolisation (TACE)
269999|NCT02338297|Drug|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
270000|NCT02338297|Drug|Gelfoam|Occlude arterioportal shunts(APS) with gelfoam
270001|NCT02338310|Drug|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
270002|NCT02338323|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
270003|NCT02338323|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
270004|NCT02338336|Drug|Nowarta110|
270005|NCT02338336|Drug|Placebo|
270006|NCT00156156|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
270290|NCT02331082|Other|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
270291|NCT02331095|Drug|Atorvastatin|Atorvastatin belongs to the "statin" class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP).
270292|NCT02331095|Drug|Warfarin|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
270293|NCT00002399|Drug|Posaconazole|
270294|NCT02333461|Dietary Supplement|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
269702|NCT02342782|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
269703|NCT02342782|Other|Laboratory Biomarker Analysis|Correlative studies
269704|NCT02342782|Other|Pharmacological Study|Correlative studies
269705|NCT02342795|Other|e-cigarette|
269706|NCT02342795|Other|cigarette substitute|
269707|NCT02342808|Behavioral|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
269708|NCT02342808|Behavioral|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
269709|NCT02342834|Dietary Supplement|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
269710|NCT02342847|Other|N/A (non-interventional study)|
269711|NCT02344875|Drug|FYU-981, (Oral single dosing)|
269712|NCT02344888|Drug|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of cycle)
269713|NCT02344888|Drug|Clomiphene citrate|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of cycle)
269714|NCT02344914|Device|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire.
269715|NCT02344927|Other|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
269716|NCT02344927|Other|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
269717|NCT02344940|Drug|Toremifene|patients will take toremifene 60 mg qd.
269718|NCT02344940|Drug|Tamoxifen|patients will take tamoxifen 10 mg bid.
269719|NCT02344992|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
274097|NCT02317965|Other|Maternal Blood Draw|Maternal Blood Draw
274098|NCT02317978|Procedure|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
274099|NCT02317991|Drug|nab-paclitaxel|nab-paclitaxel 125 mg/m2 IV
274100|NCT02317991|Biological|ramucirumab|Ramucirumab 8 mg/kg IV
269400|NCT02349386|Drug|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
269401|NCT00157885|Drug|Amodiaquine plus artesunate; Artekin|
269402|NCT02349386|Drug|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
269403|NCT02349399|Drug|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
269404|NCT02349412|Other|Early palliative care|
269405|NCT02349425|Drug|AF-219|
269406|NCT02349425|Drug|Placebo (for AF-219)|
269407|NCT02349438|Device|senofilcon A Soft Contact Lens|A soft spherical contact lens
269408|NCT02349438|Device|Air Optix Aqua|
269409|NCT02349451|Biological|adalimumab|Double-blind Every Other Week (EOW)
269410|NCT02349451|Biological|ABT-122|Double-Blind every week (EW)
269411|NCT02349464|Other|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
269412|NCT00157898|Drug|MK0826; ertapenem sodium|
269413|NCT02349477|Drug|Gabapentin|gaba potentiating medication
269414|NCT02349477|Drug|Placebo|a pill that looks exactly like the active medication but does not contain medication
269415|NCT02349490|Device|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
269416|NCT02349503|Drug|NBI-77860|
269417|NCT02351960|Drug|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg orally once daily for 8 weeks.
273801|NCT02325258|Other|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
273802|NCT02325271|Other|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
273803|NCT02325284|Device|Pressure Algometer Testing|
273804|NCT02325297|Other|Letter of condolence|
273805|NCT02325310|Biological|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
273806|NCT02325336|Device|BCMA (bar-code-assisted medication administration)|Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.
In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification.
273807|NCT00153920|Drug|bortezomib|
273808|NCT02325349|Drug|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
273809|NCT02325362|Drug|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
273810|NCT02325362|Drug|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
274101|NCT00002389|Drug|Zidovudine|
274102|NCT00153062|Drug|Micardis placebo|placebo
274103|NCT02318004|Other|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
273175|NCT02337166|Procedure|Periodontal flap surgery|
273176|NCT02337179|Procedure|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
273496|NCT02330250|Other|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
273497|NCT02330263|Dietary Supplement|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
273498|NCT02332317|Behavioral|Palliative rehabilitation|12-week individually customized, specialized palliative rehabilitation program
273499|NCT02332330|Device|VEST|
273500|NCT02332343|Other|No intervention - Natural history study|
273501|NCT02332356|Drug|azathioprine or adalimumab and infliximab|
273502|NCT00154765|Device|sling suspension exercises|
273503|NCT02332369|Device|Capsular Tension Ring|
273504|NCT02332408|Radiation|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
273505|NCT02332408|Radiation|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
273506|NCT02332421|Device|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
273507|NCT02332434|Other|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
273508|NCT02332447|Drug|naloxone|A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.
The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS.
272858|NCT02344056|Other|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
272859|NCT02344056|Other|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
272860|NCT00157001|Procedure|Photopheresis Post Angioplasty|
272861|NCT02344069|Drug|Fibrinogen|Human fibrinogen concentrate as a injection
272862|NCT02344069|Drug|Placebo|Saline 0.9% as a injection
272863|NCT02344082|Other|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
272864|NCT02344095|Drug|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
273177|NCT02337192|Drug|Curcumin|
273178|NCT02337192|Device|LED|
273179|NCT00156091|Drug|Olanzapine|5- 20 mg QD
273180|NCT02337192|Drug|Surfactant|
273181|NCT02337192|Drug|DMSO + water|
273182|NCT02337192|Drug|Chlorhexidine gluconate|
273183|NCT02339506|Drug|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
273184|NCT02339519|Device|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
273185|NCT02339519|Device|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
273186|NCT02339519|Device|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
273187|NCT00156338|Procedure|fluid management|volume and sodium restriction
273188|NCT02339532|Drug|FEC100|3 cycles of FEC 100 administered IV q3w
5-Fluorouracil (5-FU) 500 mg/m2
Epirubicin 100 mg/m2
Cyclophosphamide 500 mg/m2
273189|NCT02339532|Drug|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m2 IV escalading at 100 mg/m2 IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m2 IV
272873|NCT02345993|Drug|Extra fine Formoterol/Beclomethasone|standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation
+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes
272874|NCT02346006|Behavioral|More physical activity.|Subjects receiving more physical activity in school.
272875|NCT02346019|Procedure|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
272876|NCT00157287|Procedure|Evidence based weaning protocol|
272877|NCT02346032|Drug|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
272878|NCT02346045|Procedure|Renal sympathetic denervation|In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed
After femoral puncture guiding catheter is engaged in renal artery
Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery
4-5 ablations are applied in each renal artery.
In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed
272879|NCT02346058|Drug|Esarin Gel|
272880|NCT02346071|Behavioral|Acceptance and Commitment Therapy|All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.
The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy.
273201|NCT02339571|Biological|Sargramostim|Given SC
273202|NCT02339584|Drug|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
273203|NCT02339584|Drug|Brinzolamide 10 mg/mL eye drops, suspension|
273204|NCT02339584|Drug|Brimonidine 2 mg/mL eye drops, solution|
273205|NCT02339584|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
273206|NCT02339597|Procedure|Automatic Positive Airway Pressure (APAP) initiation|
273207|NCT02339610|Device|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
273208|NCT02339623|Device|Ultrasound imaging|- Fetal adrenal gland volume calculation using 3D ultrasound
- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound
- CL measurement using 2D ultrasound
272578|NCT02353195|Other|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
272579|NCT02353208|Other|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
272580|NCT02353208|Other|Placebo|Participants will not be asked to chew bacon bits
272581|NCT02353234|Other|Bread|In each arm subjects consume bread
272582|NCT02353247|Drug|Norethindrone acetate|
272583|NCT02353260|Device|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
272584|NCT02353260|Drug|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
272585|NCT02353273|Drug|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
272586|NCT02353299|Drug|Silenor 6 mg|Silenor 6 mg single nighttime dose.
272587|NCT02353299|Drug|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
272588|NCT00158314|Behavioral|Cognitive behavioral therapy|
272589|NCT02353312|Drug|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
272590|NCT02353325|Dietary Supplement|non-encapsulated FeSO4|
272591|NCT02353325|Dietary Supplement|encapsulated FeSO4, before cooking|
272592|NCT02353325|Dietary Supplement|encapsulated FeSO4, after cooking|
272593|NCT02353325|Dietary Supplement|non-encapsulated FeSO4 + ascorbic acid|
272594|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, before cooking|
272881|NCT02346071|Other|Enhanced Usual Care (EUC)|All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.
The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services.
276910|NCT02690987|Biological|Desacyl ghrelin|Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. GMP-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).
The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of ~13-19 ng/mL.
276911|NCT02690987|Biological|Saline|The placebo visit will involve an intravenous infusion of normal saline.
276912|NCT02691000|Device|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
276913|NCT02691000|Device|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
276914|NCT02693457|Procedure|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
276915|NCT00201357|Drug|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
276916|NCT02693470|Drug|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
276917|NCT02693483|Drug|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
276918|NCT02693496|Other|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
276919|NCT02693509|Other|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
276920|NCT02693522|Drug|somatropin|Subcutaneous injection
276921|NCT02693522|Drug|Eutropin|Subcutaneous injection
276922|NCT02693535|Drug|Erlotinib|drug
276923|NCT02693535|Drug|Axitinib|drug
276924|NCT02693535|Drug|Bosutinib|drug
276925|NCT02693535|Drug|Crizotinib|drug
276926|NCT00201383|Drug|cisplatin|
276927|NCT02693535|Drug|Palbociclib|drug
276928|NCT02693535|Drug|Sunitinib|drug
276290|NCT02702050|Other|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
276611|NCT02697773|Biological|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
276612|NCT02697786|Device|Transcranial doppler|Prolonged de airing to decrease the number of MES
276613|NCT02697799|Behavioral|High-level recruitment strategy consent form|Patients will be exposed to a consent for that includes supplemental information describing a high-level recruitment strategy
276614|NCT00202098|Procedure|Variable ventilation|Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and "traditional" CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system.
276615|NCT02699983|Behavioral|Behavioral Dietary Intervention|Undergo SparkPeople program
276616|NCT02699983|Behavioral|Exercise Intervention|Undergo SparkPeople program
276617|NCT02699983|Device|Monitoring Device|Wear health monitoring device
276618|NCT02699983|Procedure|Psychosocial Assessment and Care|Undergo SparkPeople program
276619|NCT02699983|Other|Quality-of-Life Assessment|Ancillary studies
276620|NCT02699983|Other|Questionnaire Administration|Correlative studies
276621|NCT02699996|Other|Educational Intervention|Receive tailored survivorship educational materials from the Children's Oncology Group patient education "Health Links"
276622|NCT02699996|Other|Informational Intervention|Receive a self-management strategies brochure and general health tips via text message
276623|NCT02699996|Other|Questionnaire Administration|Complete interview
276624|NCT02699996|Behavioral|Telephone-Based Intervention|Complete the PSST peer mentoring intervention with videoconferencing and text messages
276625|NCT00202111|Procedure|Laparoscopic-assisted colectomy|
276626|NCT02700009|Behavioral|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
276627|NCT02700009|Other|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
276000|NCT02708459|Drug|Intravenous morphine|Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
276001|NCT00203125|Drug|rasagiline mesylate|0.5 or 1 mg oral, once-daily
276291|NCT02704143|Other|combination of Cyberknife with S-1|Radiation therapy combined with chemotherapy
276292|NCT00202709|Behavioral|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
276293|NCT02704156|Device|Cyberknife|Radiation therapy
276294|NCT02704169|Other|Spatially registered endoscopy|
276295|NCT02704182|Device|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
276296|NCT02704182|Device|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
276297|NCT02704195|Device|Unilateral reduction of STN stimulation|Unilateral 30% decrease of STN stimulation
276298|NCT02704195|Device|Chronic STN stimulation|Chronic STN stimulation condition
276299|NCT02704208|Behavioral|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
276300|NCT02704208|Behavioral|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
276301|NCT02704221|Device|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
276302|NCT02704221|Behavioral|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
276303|NCT00202722|Drug|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
276304|NCT02704221|Behavioral|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
276305|NCT02704234|Device|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
276306|NCT02704234|Device|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
276307|NCT02704247|Device|CARDIOSPACE System|autonomic nervous system test
tilt test
ultrasound exploration at rest (heart / vessels)
laser doppler + iontophoresis test
sub-maximal exercise test
275704|NCT02714374|Drug|Eculizumab|Dose and Regimen: With the exception of Cohorts 3 and 5, eculizumab is administered as a single dose on Week 1/Day 1 at 900 mg 60-90 minutes prior to GL-ONC1. An additional 3 patients may be enrolled into Cohorts -1 to 2 as a control without eculizumab treatment if positive PK of virus in blood is observed, and/or positive VPA of virus is confirmed in excised tumors. In Cohorts 2, 4 and 6, additional patients may receive eculizumab on Week1/Day 2 or Week 1/Day 3 rather than Week 1/Day 1. For patients undergoing surgery (at the discretion of the Principal Investigator (PI) > 10 days following completion of virus treatment, an additional, maintenance dose of Eculizumab (600 mg) is given 14 to 17 days following administration of the initial eculizumab dose.
Route: Eculizumab is administered intravenously.
275705|NCT02714387|Other|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
275706|NCT02714400|Drug|Venlafaxine|Venlafaxine 50mg before sleep
275707|NCT02714400|Drug|Placebo|One piece of placebo before sleep
275708|NCT02714413|Dietary Supplement|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
276002|NCT02708459|Drug|Bupevecaine|
276003|NCT02708459|Drug|Dexmedetomedine|
276004|NCT02708472|Device|synchronized Transcranial Magnetic Stimulation (sTMS)|Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.
The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes.
276005|NCT02708485|Other|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
276006|NCT02710357|Procedure|Mandibular Overdenture|Participants allocated to the intervention group will have an implant placed in the mandible midline and subsequently the denture will be converted to an overdenture.
276007|NCT02710357|Procedure|Mandibular complete denture|Participants allocated to the control group will receive new conventional mandibular dentures.
276008|NCT02710396|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion.
276009|NCT00203372|Drug|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
276010|NCT02710409|Biological|Quadrivalent influenza vaccine|0.5 ml/vial, one dose, intramuscular injection on day 0
275419|NCT02683226|Drug|Vipdomet|
275420|NCT02683226|Drug|Incresync|
275421|NCT02683239|Drug|Fasinumab|Sub-cutaneous (SC) injections of fasinumab
275422|NCT02683239|Drug|Placebo|Sub-cutaneous (SC) injections of placebo
275423|NCT02683252|Other|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
275424|NCT00200070|Device|Spinal Cord Stimulation|
275425|NCT02683265|Drug|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
275426|NCT02683265|Drug|Placebo|Placebo capsules
275427|NCT02683278|Behavioral|Cognitive-behavioral|Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
275428|NCT02685449|Drug|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
275429|NCT02685462|Drug|Rosuvastatin|
275430|NCT02685462|Drug|Atorvastatin|
275431|NCT02685462|Drug|Simvastatin|
275432|NCT02685462|Drug|Digoxin|
275433|NCT02685462|Drug|Caffeine|
275434|NCT02685475|Drug|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
275435|NCT02685488|Device|Transcranial Ultrasound|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
275436|NCT00200343|Drug|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
275437|NCT02685501|Other|no intervention|
275438|NCT02685514|Device|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
275439|NCT02685553|Device|Near-Infrared Technology|
275709|NCT02714413|Dietary Supplement|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
274878|NCT02694874|Drug|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
274879|NCT02694874|Drug|Placebo|This is the placebo control
274880|NCT02694900|Other|Manually chest compressions|Chest compressions performed manually without any device
274881|NCT02694900|Device|Cardiopump|Chest compressions performed with Cardiopump
274882|NCT02694900|Device|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
274883|NCT02694913|Other|Non Interventional|This is a non therapeutic, pilot study.
274884|NCT02694926|Other|Education|During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
275151|NCT02690064|Dietary Supplement|Chronic Antioxidant Cocktail|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
275152|NCT02690064|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
275153|NCT02690077|Procedure|Family-Centered Cesarean|Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
275154|NCT02690077|Procedure|Traditional Cesarean|Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
275155|NCT02690103|Drug|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
275156|NCT02690103|Dietary Supplement|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
275157|NCT02690103|Drug|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
275158|NCT02690116|Other|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 12 weeks, with a recommended home practice time of 2 1/2 hours each week.
275159|NCT02690116|Other|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 12 weeks, with a recommended home practice time of 2 1/2 hours each week.
274592|NCT02701348|Other|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
274593|NCT02701348|Drug|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
274594|NCT02701348|Procedure|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
274595|NCT02701348|Other|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
274596|NCT02701361|Behavioral|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
274597|NCT02701361|Behavioral|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
274598|NCT00202280|Drug|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
274599|NCT02701361|Behavioral|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
274600|NCT02701374|Drug|TRK-700|
274601|NCT02701374|Drug|Placebo|
274602|NCT02701387|Device|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
274603|NCT02701387|Device|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
274885|NCT00201539|Drug|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
274886|NCT02694939|Behavioral|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
274887|NCT02694939|Behavioral|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
274888|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine + Primaquine|Regimen 6 (Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0) Washout period: 6 weeks
274889|NCT02696967|Drug|CLR325|CLR325 Concentrate for solution for infusion
274890|NCT02696967|Other|Placebo|Normal saline
274891|NCT02696980|Device|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
270588|NCT02326506|Device|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
270589|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
270590|NCT02326532|Other|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
270591|NCT02326532|Other|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
270592|NCT02326545|Behavioral|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
270593|NCT02326545|Behavioral|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
270594|NCT02326558|Procedure|laparoscopic microwave ablation-assisted enucleation|
270595|NCT02326558|Procedure|conventional laparoscopic nephron-sparing surgery|
270596|NCT02326558|Device|Microwave generator and ablation antenna|
270597|NCT02326584|Drug|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
270877|NCT02319083|Procedure|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
270878|NCT02319096|Other|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
270879|NCT02319122|Other|High Intensity Interval Training|See arm description
270880|NCT02319122|Other|Progressive Resistance Training|See arm description
270881|NCT02319135|Drug|Azacitadine|
270882|NCT02319135|Drug|Fludarabine|
270883|NCT02319135|Drug|Cytarabine|
270884|NCT02319135|Drug|Lenograstim|
270885|NCT02321488|Behavioral|Survey|Survey related to surveillance practice patterns following curative resection of colorectal cancer patients administered to eligible providers for them to complete.
270886|NCT02321501|Drug|Ceritinib (LDK378)|Dose Escalation Phase Starting Dose of Ceritinib (LDK378) - No ALK Status: 450 mg by mouth once a day in a 28 day cycle.
Dose Expansion Phase Starting Dose of Ceritinib (LDK378) - No ALK Status: MTD from Dose Escalation Phase.
Dose Expansion Phase participants with non small cell lung cancer (NSCLC), with anaplastic lymphoma kinase (ALK+) expression on IHC who have progressed, treated with Ceritinib (LDK378) at MTD from Dose Escalation Phase.
270295|NCT02333461|Dietary Supplement|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
270296|NCT02333474|Biological|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
270297|NCT02333474|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
270298|NCT02333487|Drug|Lu AF35700|5 mg tablets for oral administration once daily, up to 21 days. Dose will be established based on receptor occupancy, safety, tolerability and PK data from previous cohorts. Starting at 10 mg/day and not more than 20 mg/ day
270299|NCT02333500|Other|olfactory workshop|olfactory workshop
270300|NCT02333500|Other|other workshop|other workshop: discussion group, dance and body Expression
270301|NCT02333500|Other|No intervention|control group
270302|NCT02333513|Drug|Lomustine/Vincristine/Procarbazine|
270303|NCT02333539|Behavioral|Pump It Up!|
270304|NCT00155233|Drug|Nalbuphine and morphine|
270305|NCT02333565|Drug|Everolimus|
270306|NCT02333565|Drug|Octreotide|
270307|NCT02333578|Procedure|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
270308|NCT02333591|Drug|Exenatide|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
270598|NCT00002397|Drug|Nelfinavir mesylate|
270599|NCT00154011|Drug|rosiglitazone (drug)|
270600|NCT02326584|Drug|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
270601|NCT02326584|Drug|Daunorubicin|60 mg/m2/day Days 1-3
270602|NCT02326584|Drug|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
269720|NCT00157131|Drug|Fibrin Sealant, Tisseel 4IU/ml VH SD|
270007|NCT02338349|Drug|RAD1901|
270008|NCT02338362|Drug|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
270009|NCT02338362|Drug|Saline placebo inhaler|saline metered dose inhaler
270010|NCT02338375|Biological|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
270011|NCT02338388|Procedure|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
270012|NCT02338401|Dietary Supplement|Omega-3 Complete|Fish Oil Capsules
270013|NCT02338401|Dietary Supplement|Placebo Pill|Olive Oil Capsules
270014|NCT02338414|Drug|Romiplostim|Subcutaneous Romiplostim (weekly injection) -> if titrated with maintaining PLT count between 50-200 x 10^9/L -> Subcutaneous Romiplostim (biweekly injection)
270015|NCT02338427|Other|Immunohistochemistry|
270016|NCT02338427|Other|Proteomic analysis|
270017|NCT00156169|Drug|Dunaliella|
270018|NCT02338440|Drug|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
270019|NCT02340468|Device|diffuse optical spectroscopy|diffuse optical spectroscopy
270020|NCT00156546|Drug|antibiotic to reduce the recurrence of infection|
270021|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
270022|NCT02340481|Drug|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
270023|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
270024|NCT02340481|Drug|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
270025|NCT02340494|Behavioral|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
269418|NCT02351973|Drug|Hydrochlorthiazide|HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.
In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.
In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
269419|NCT02351973|Drug|Amiloride|Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.
In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.
In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
269721|NCT02344992|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
269722|NCT02345005|Device|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
269723|NCT02345018|Procedure|Mechano-chemical ablation|Treatment with mechano-chemical ablation
269724|NCT02345031|Drug|AUT00063|600 mg, orally, once a day, for 4 weeks
269725|NCT02345031|Drug|Placebo|orally, once a day, for 4 weeks
269726|NCT02345044|Drug|CS-3150|
269727|NCT02345044|Drug|placebo|
269728|NCT02345044|Drug|eplerenone|
269729|NCT02345057|Drug|CS-3150|
269730|NCT02345057|Drug|placebo|
269731|NCT00002407|Drug|Lamivudine|
269732|NCT00157157|Biological|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).
The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.
For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.
Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.
rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion.
269733|NCT02345070|Drug|SAR156597|Pharmaceutical form:solution Route of administration: subcutaneous
274104|NCT02320331|Behavioral|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
274105|NCT02320344|Behavioral|Partners in Care|The diabetes self-management intervention is titled, "Partners in Care," emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications.
274106|NCT02320357|Drug|Treatment by clopidogrel|Peripheral blood will be obtained during the study
274107|NCT02320370|Device|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
274108|NCT02320383|Drug|FC+ GA101|FCG regimen:
GA101 iv infusion:
Cycle 1 Day 1 100 mg Day 2 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2 - 6 Day 1 1000 mg Fludarabine iv infusion 25 mg/m2 day 3-5 in cycle 1, respectively day 2-4 q4wks, cycle 2 to 6 Day 3 25 mg/m2 Day 4 25 mg/m2 Cyclophosphamide iv infusion 250 mg/m2 day 3-5 in cycle 1, respectively day 2-4 q4wks, cycle 2 to 6
274109|NCT02320383|Drug|B+ GA101|BG regimen:
GA101 iv infusion:
Cycle 1 Day 1 100 mg Day 2 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2 - 6 Day 1 1000 mg Bendamustine iv infusion 70 mg/m² day 3-4 in cycle 1, respectively day 2-3 q4wks, cycle 2 to 6
274110|NCT02320396|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
274111|NCT02320396|Drug|Placebo|Placebo tablets
274112|NCT00153361|Behavioral|Discussion Group|
274113|NCT02320409|Drug|Sufatinib|250mg Sufatinib ,single dose,oral
274114|NCT02320422|Behavioral|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
274115|NCT02320435|Drug|Pertuzumab|Pertuzumab single agent or in combination with other anti-cancer therapies, at the same dose and schedule at which it was given at the end of the Parent study
274116|NCT02320448|Drug|PIPAC|
274117|NCT02320474|Drug|Aflibercept|
274118|NCT02320487|Drug|Bendamustine|Intravenous repeating dosing
273509|NCT02332447|Drug|Placebo|Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.
The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS.
273510|NCT02332473|Drug|Ypeginterferon alfa-2b|
273511|NCT02332473|Drug|Granulocyte-macrophage colony stimulating factor|
273811|NCT02325375|Procedure|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
273812|NCT02325388|Device|ForeSite PT™ system|XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the "ForeSite PT™ system") continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts.
273813|NCT02325401|Drug|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
273814|NCT02325401|Drug|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
273815|NCT02325401|Radiation|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
273816|NCT02327936|Drug|Oxybutynin XL|Administer medication to patients with overactive bladder
273817|NCT02327949|Device|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
273818|NCT02327949|Device|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
273819|NCT02327975|Other|Training group|The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).
During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax.
273820|NCT02327975|Other|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
273821|NCT02327975|Other|Control group|No received intervention.
273822|NCT02327988|Other|Cryotherapy|
273190|NCT02339532|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
273191|NCT02339532|Drug|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
273192|NCT02339532|Drug|Carboplatin|CARBOPLATIN AUC 6 IV q3w
273193|NCT02339545|Device|Volcano FloWire|Following successful revascularization, Coronary Flow Reserve will be measured for all subjects.
273194|NCT02339558|Other|Laboratory Biomarker Analysis|Correlative studies
273195|NCT02339558|Biological|Nivolumab|Given IV
273196|NCT02339571|Biological|Ipilimumab|Given IV
273197|NCT02339571|Other|Laboratory Biomarker Analysis|Correlative studies
273198|NCT00156338|Procedure|fluid management|volume restriction
273199|NCT02339571|Biological|Nivolumab|Given IV
273200|NCT02339571|Other|Quality-of-Life Assessment|Ancillary studies
273512|NCT02332486|Drug|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
273513|NCT00154778|Drug|Taxol, UFT,Leucovorin|
273514|NCT02332499|Drug|Anlotinib|Anlotinib p.o. qd
273515|NCT02332499|Drug|Placebo|Placebo p.o. qd
273516|NCT02332512|Drug|Apatinib|
273517|NCT02332512|Drug|Placebo|
273518|NCT02334644|Dietary Supplement|Placebo|2 sachets/day x 12 weeks
273519|NCT02334657|Other|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
273520|NCT02334670|Drug|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
273209|NCT02341768|Device|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
273210|NCT02341794|Drug|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
273211|NCT02341807|Biological|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
273212|NCT02341833|Drug|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
273213|NCT02341846|Other|Qualitative interviews|
273214|NCT02341859|Device|stenfilcon A|contact lens
273215|NCT02341859|Device|delefilcon A|contact lens
273216|NCT02341859|Device|narafilcon A|contact lens
273217|NCT02341872|Other|Fluoride varnish|Duraphat fluoride varnish will be applied to the teeth with brush.
273218|NCT00156702|Behavioral|Feedback and Motivational Interviewing|
273219|NCT02341872|Other|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
273220|NCT02341872|Other|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
273221|NCT02341898|Other|Educational programme for all nurses|
273222|NCT02341898|Other|Training and structured support for nominated key nurses|
273223|NCT02341898|Other|Facultative train-the-trainer module for key nurses|
273532|NCT02334787|Drug|1% OPA-15406 Ointment|
273533|NCT00002400|Drug|Zidovudine|
273534|NCT00155454|Procedure|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
273535|NCT02334787|Drug|3% OPA-15406 Ointment|
273536|NCT02334787|Drug|Placebo|
273537|NCT02334800|Drug|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
273538|NCT02334813|Drug|Prednisone|
272882|NCT00157729|Drug|pyridoxal-5'-phosphate with and without ACE inhibitor|
272883|NCT02348346|Other|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
272884|NCT02348359|Drug|X-82|
272885|NCT02348359|Drug|Anti-VEGF|
272886|NCT02348359|Drug|Placebo|
272887|NCT02348372|Drug|GSK1278863A Placebo|Matching size, shape and color
272888|NCT02348372|Drug|GSK1278863A|A round, biconvex, white film coated tablet
272889|NCT02348385|Drug|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
272890|NCT02348398|Drug|Pazopanib|600 mg by mouth daily in a 28 day cycle.
272891|NCT02348398|Drug|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
272892|NCT02348398|Behavioral|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
272893|NCT00157742|Procedure|Spinal Cord Stimulation (SCS)|
272894|NCT02348411|Device|ExAblate|
272895|NCT02348424|Drug|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
272896|NCT02348437|Procedure|Repair|An on-going suture technique with minimum four stitches.
272897|NCT02348437|Procedure|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
272898|NCT02348450|Drug|Irinotecan|
272899|NCT02348450|Drug|Etoposide|
272900|NCT02348450|Drug|Cisplatin|
272901|NCT02348463|Drug|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
273224|NCT02341898|Other|Printed study material|
276929|NCT02693535|Drug|Temsirolimus|drug
276930|NCT02693535|Drug|Trastuzumab and Pertuzumab|drug
276931|NCT02693535|Drug|Vemurafenib and Cobimetinib|drug
277220|NCT02686411|Behavioral|Participant Questionnaires|Participants complete 4 questionnaires about satisfaction and impression of care received in the PCU, how much distress experienced in past week, and level of comfort with being transferred to the PCU. Questionnaires take about 15 minutes to complete.
Two (2) weekdays after completion of first set of questionnaires, 3 questionnaires completed about overall satisfaction and impression of care received in the PCU, and how much distress experienced in the past few days. One (1) questionnaire asks comparison of care received with the palliative care consult, to the care received in the PCU. These questionnaires should also take about 15 minutes to complete.
277221|NCT02686411|Behavioral|Caregiver Questionnaires|Caregiver completes questionnaire about their demographic information. It should take about 5-10 minutes to complete.
Caregiver then completes 4 questionnaires about their overall satisfaction and impression of care their family member or friend received in the PCU, how much distress experienced in past week, and level of comfort felt with family member/friend being transferred to the PCU. These questionnaires should take about 15 minutes to complete.
Two (2) weekdays after completion of first set of questionnaires, same questionnaires completed about overall satisfaction and impression of care their family member or friend received in the PCU and how much distress experienced in the past few days. One (1) questionnaire asks caregiver to compare the care their family member or friend received with the palliative care consult, to the care their family member/friend received in the PCU. These questionnaires should take also about 15 minutes to complete.
277222|NCT02688634|Drug|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
277223|NCT02688647|Drug|KD025|
277224|NCT02688647|Drug|Standard of Care|Treatment/Drug determined by each subject's prescribing physician
277225|NCT02688660|Other|MRI Scans|
277226|NCT00200720|Behavioral|DASH diet (high carbohydrate diet)|
277227|NCT02688673|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
277228|NCT02688686|Biological|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
277229|NCT02688699|Procedure|EndoClot|
277230|NCT02688712|Drug|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
277231|NCT02688712|Drug|Capecitabine|Antimetabolite chemotherapy
277232|NCT02688712|Drug|Fluorouracil|Antimetabolite chemotherapy
277233|NCT02688712|Procedure|Tumor specific mesorectal excision|Tumor specific mesorectal excision
277234|NCT02688725|Device|post mastectomy ultrasound|post mastectomy ultrasound
276628|NCT02700022|Drug|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
276932|NCT02693535|Drug|Vismodegib|drug
276933|NCT02693535|Drug|Cetuximab|drug
276934|NCT02693535|Drug|Dasatinib|drug
276935|NCT02693561|Behavioral|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
276936|NCT02693561|Behavioral|Self-Help Book|Reading the self-help book.
276937|NCT00201396|Radiation|CCRT|Radiation with weekly Cisplatin
276938|NCT02693574|Drug|Clarithromycin|
276939|NCT02693574|Drug|Levofloxacin|
276940|NCT00201682|Drug|Etanercept|25 mg SQ twice weekly weeks 1-5
276941|NCT02695823|Device|Ultrasound|Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.
Search of any neurological complication during the 5 postoperative days.
276942|NCT02695836|Other|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
276943|NCT02695836|Other|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
276308|NCT02704260|Genetic|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
276309|NCT02704286|Behavioral|Internet-Based Osteoarthritis Risk Calculator|The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
276629|NCT02700035|Other|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
276630|NCT02700048|Drug|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
276631|NCT02700048|Drug|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
276632|NCT02700061|Procedure|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
276633|NCT02700061|Procedure|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
276634|NCT02700074|Other|No Intervention|Intervention is not a part of this study.
276635|NCT02702050|Other|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
276636|NCT02702063|Other|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
276637|NCT02702063|Procedure|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
276638|NCT02702063|Other|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
276639|NCT02702076|Drug|Apomorphine|
276640|NCT02702076|Drug|Placebo|
276641|NCT02702089|Procedure|Rectal cancer surgery|Rectal cancer resection
276642|NCT00202397|Other|placebo|capsule-shaped tablet bid for 8 weeks
276643|NCT02702102|Drug|11C-PBR28|Up to 20 millicuries
276011|NCT02710409|Biological|Trivalent influenza vaccine A|0.5 ml/vial, one dose, intramuscular injection on day 0
276012|NCT02710409|Biological|Trivalent influenza vaccine B|0.5 ml/vial, one dose, intramuscular injection on day 0
276013|NCT02710422|Procedure|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
276014|NCT02710422|Behavioral|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and at 3, 6, 9 and 12 months post-RARP.
276015|NCT02710422|Other|PSA Measurement|Measurement of serum PSA levels at baseline, and at 3, 6, 9 and months post-RARP.
276016|NCT02710422|Behavioral|Sexual History Inventory for Men|Sexual History Inventory for Men (SHIM) psychosocial questionnaire administered 3,6, 9 and 12 months post-RARP.
276017|NCT02710435|Device|Neovasc Reducer System|An aid in the management of chronic refractory angina pectoris
276018|NCT02710448|Drug|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
276310|NCT02704286|Behavioral|Generic osteoarthritis information|Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
276311|NCT02704299|Biological|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
276312|NCT02704312|Radiation|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
276313|NCT02706509|Behavioral|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
276314|NCT02706509|Device|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
276315|NCT00202917|Drug|Thiotepa|
276316|NCT02706522|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
276317|NCT02706522|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
276318|NCT02706535|Drug|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
275710|NCT02714413|Other|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
275711|NCT02714426|Behavioral|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) a psychoeducational component, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
275712|NCT00203853|Device|pillbox, wristwatch|
275713|NCT02714426|Other|Testing only|Participants receive 14 weekly sessions of testing
275714|NCT02714439|Drug|Proflavine|Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
275715|NCT02714439|Procedure|High-Resolution Microendoscopy (HRME)|High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
275716|NCT02714452|Behavioral|Person-centred care|Person-centred and thriving promoting care
275717|NCT02714465|Other|hyperbaric oxygen therapy|hyperbaric oxygen therapy
275718|NCT02716597|Drug|25% Albumin|
275719|NCT02716597|Drug|Placebo|
275720|NCT02716610|Drug|INH 69 U (low)|inhaled human insulin
275721|NCT02716610|Drug|INH 69 U (high)|inhaled human insulin
275722|NCT02716610|Drug|INH 139 U|inhaled human insulin
275723|NCT02716610|Drug|INH 208 U|inhaled human insulin
275724|NCT02716610|Drug|LIS 18 U|subcutaneous insulin lispro
275725|NCT02716623|Other|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
275726|NCT02716623|Behavioral|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
275727|NCT02716636|Procedure|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
275160|NCT02690116|Other|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60 minute class per week for the 12 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
275161|NCT00200902|Other|placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
275162|NCT02690129|Drug|Vaginal Progesteron|
275163|NCT02692625|Dietary Supplement|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
275164|NCT02692625|Dietary Supplement|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
275440|NCT02685566|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
275441|NCT02685566|Device|FFDM|FujiFilm Aspire Cristalle System
275442|NCT02685579|Other|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
275443|NCT02685592|Drug|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
275444|NCT02685605|Procedure|Standard surgery (neuronavigation-guided)|
275445|NCT02685605|Radiation|Intraoperative radiotherapy|Dose to applicator surface: 30 Gy; Carl Zeiss INTRABEAM System
275446|NCT02685605|Radiation|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
275447|NCT00200343|Drug|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
275448|NCT02685605|Drug|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
275449|NCT02685618|Drug|Iloprost|
275450|NCT02685618|Drug|Saline|
275451|NCT02685618|Device|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
274892|NCT00201760|Drug|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
274893|NCT02696993|Drug|Nivolumab|Phase I Starting Dose: 3 mg/kg by vein every 2 weeks.
Phase II Starting Dose: Maximum tolerated dose from Phase I, given by vein every two weeks.
274894|NCT02696993|Drug|Ipilimumab|Phase I and Phase II: Ipilimumab 1 mg/kg by vein every 6 weeks.
274895|NCT02696993|Radiation|Stereotactic Radiosurgery (SRS)|Phase I and Phase II:
Stereotactic Radiosurgery (SRS) performed once, at dosage prescribed by treating physician.
274896|NCT02696993|Radiation|Whole Brain Radiation Therapy (WBRT)|Phase I and Phase II: Whole Brain Radiation Therapy (WBRT) delivered to the whole brain 5 days a week. Participants treated to a total dose of 30 Gy in 10 fractions.
274897|NCT02696993|Behavioral|Neurocognitive Exam|Neurocognitive exam completed at baseline and 1 month after radiation treatment.
274898|NCT02697006|Drug|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
274899|NCT02697019|Behavioral|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
274900|NCT02697032|Drug|Bicalutamide|150mg
274901|NCT02697032|Procedure|FDHT PET|PET scan
274902|NCT02697045|Drug|Aripiprazole 400mg LAI|
274903|NCT00201760|Drug|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
274904|NCT02697058|Biological|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
274905|NCT02697058|Drug|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
275165|NCT02692638|Procedure|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
275166|NCT02692638|Procedure|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
275167|NCT02692651|Drug|Fidaxomicin|
275168|NCT02692651|Drug|Vancomycin|
270887|NCT02321501|Drug|Ceritinib (LDK378) 750 mg|Dose Expansion Phase of Non small cell lung cancer (NSCLC) participants with anaplastic lymphoma kinase (ALK+) expression on IHC receive single agent Ceritinib (LDK378) at 750 mg by mouth once a day for a 28 day cycle.
270888|NCT02321501|Drug|Everolimus|Dose Escalation Phase Starting Dose of Everolimus: 5 mg by mouth once a day in a 28 day cycle.
Dose Expansion Phase Starting Dose of Everolimus: MTD from Dose Escalation Phase.
Dose Expansion Phase participants with non small cell lung cancer (NSCLC), with anaplastic lymphoma kinase (ALK+) expression on IHC who have progressed, treated with Everolimus at MTD from Dose Escalation Phase.
270889|NCT02321514|Device|Tendyne Mitral Valve System|Transcatheter mitral valve replacement
270890|NCT02321527|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
270891|NCT02321527|Device|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
270892|NCT02321527|Procedure|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
270893|NCT02321527|Behavioral|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
270894|NCT02321540|Drug|Ibrutinib|Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.
Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily.
270895|NCT00153530|Drug|methotrexate|chemotherapy with radiotherapy
chemotherapy without radiotherapy
271175|NCT02352740|Dietary Supplement|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
271176|NCT00158262|Drug|Placebo|Placebo
271177|NCT02352753|Drug|Denosumab|All subjects will receive denosumab 1 mg/kg (up to a maximum of 60 mg) given subcutaneously every 6 months for 36 months.
271178|NCT02352779|Dietary Supplement|Omega-3 Fatty Acid|Given PO
271179|NCT02352779|Other|Placebo|Given PO
271180|NCT02316314|Procedure|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
271181|NCT02316327|Drug|gemcitabine, cisplatin and bevacizumab|Therapeutic
271182|NCT02316340|Drug|Vorinostat|400mg by mouth daily
271183|NCT02316340|Drug|Hydroxychloroquine|600mg by mouth daily
270603|NCT02326597|Other|Decision Aid|Use of decision aid tool to aid in understanding treatment option and identifying personal values and beliefs accessible via devices: iPad, Smart phone, Computer, Tablet
270604|NCT02326597|Other|Standard Practice|Standard care teaching and discussion in addition to web-based decision aid tool accessible via devices: iPad, Smart phone, Computer, Tablet
270605|NCT02328937|Device|Investigational Soft Contact Lens - etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
270606|NCT02328950|Drug|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
270607|NCT02328963|Drug|Everolimus|Everolimus : 0.75 bid, targeted to 3-8 ng/ml
Cyclosporin A :
CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.
Corticosteroids :
Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study
Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
270608|NCT02328963|Drug|mycophenolic acid|Mycophenolic acid :
1080 mg bid for one month, then 720 mg bid
Cyclosporin A :
CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.
Corticosteroids :
Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study
Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
270609|NCT02328976|Other|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
270610|NCT00154284|Drug|Everolimus (Certican)|
270611|NCT02328989|Device|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
270612|NCT02329002|Device|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
270613|NCT02329015|Behavioral|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
270614|NCT02329015|Behavioral|Physical Education Class|Standard physical education
270896|NCT02321553|Other|Brown rice|brown rice cake
270897|NCT02321553|Other|White rice|white rice cake
270898|NCT02321566|Device|Epidural Motor Cortex Stimulation|
270026|NCT02340507|Other|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
270027|NCT02340507|Other|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
270028|NCT02340520|Drug|Theophylline. Roflumilast|Oral
270309|NCT02333591|Drug|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
270310|NCT02333591|Drug|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
270311|NCT02333591|Drug|Saline|Infused intravenously for 2,5 hours.
270312|NCT02333617|Other|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point [No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
270313|NCT02335918|Drug|Combination of varlilumab and nivolumab|During the treatment phase of the study, eligible patients will receive varlilumab for 3 cycles, with an option for a 4th cycle as determined by study doctors. Treatment cycles are eight weeks each with study drug administered once every two weeks. There is no limit on the number of cycles of nivolumab. Patients may be discontinued from receiving study treatment (nivolumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
Phase I Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.1 mg/kg, 1 mg/kg, or 10 mg/kg.
Phase II Dose: The planned varlilumab dose will be established from the outcome of the Phase I portion of the study.
All patients will receive nivolumab at a dose of 3 mg/kg.
270314|NCT02335944|Drug|INC280|
270315|NCT02335944|Drug|EGF816|
270316|NCT02335957|Radiation|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
270317|NCT02335970|Other|Training group|After 1 week
Chest expansions
Static thoracic extension in prone
Lateral flexion of the spine in standing
Bilateral shoulder flexion
Shoulder external rotation of shoulders
Rotation of the thoracic spine in sitting
Static back extensor strength in prone
After 1 month
Thoracic extension, rotation and flexion abduction
Hand in neck and in back
Bilateral active flexion abduction
Strength training of leg muscles
Static back extensor strength
After 2 months
Strength training of legs and back muscles
Push-ups against a wall
Thoracic extension in sitting and standing
Thoracic rotation in lying
Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise
270318|NCT02335983|Drug|Carfilzomib|
270319|NCT00155883|Drug|Taxteral|
269734|NCT02347020|Behavioral|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
269735|NCT02347020|Behavioral|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
270029|NCT02340533|Procedure|hysteroscopic endo-myometrial biopsy|
270030|NCT02340533|Device|ultrasound|two dimensional trans-vaginal ultrasonography
270031|NCT00156572|Procedure|Sodium supplementation|
270032|NCT02340546|Device|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
270033|NCT02340559|Behavioral|Meta-cognitive Training|
270034|NCT02340559|Behavioral|Psychoeducational group|
270035|NCT02340572|Drug|PRS-080#022-DP|hepcidin antagonist
270036|NCT02340572|Drug|PRS-080-Placebo#001|Placebo treatment
270037|NCT02340585|Device|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
270038|NCT02340598|Other|cold vest|The lowering of body temperature increases basal metabolic rate
270039|NCT02340611|Drug|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
270040|NCT02340611|Drug|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
269420|NCT02351973|Drug|Hydrochlorthiazide and Amiloride|HCTZ 12.5 to 25mg & + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.
In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.
In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
269421|NCT02351986|Procedure|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
269422|NCT02351986|Other|ice pack|
269423|NCT02351999|Device|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
269424|NCT02352012|Other|Autologous blood|Autologous blood was perfused to the target pulmonary segment
269425|NCT02352012|Device|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
269426|NCT02352025|Drug|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
269427|NCT00158197|Behavioral|contingency management voucher|participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
269428|NCT02352038|Device|low-level laser therapy|
269429|NCT02352038|Other|orthodontic treatment|
269430|NCT02352051|Drug|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
269431|NCT02352051|Drug|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
269432|NCT02352064|Procedure|PET (18-FDG)|Every patient will have a PET
269433|NCT02352077|Biological|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
269434|NCT02352090|Drug|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
269435|NCT02352090|Drug|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
269436|NCT02352090|Drug|Dienogest|One tablet orally for 9 weeks, continuous use
269437|NCT02237430|Other|Manual compression|Conventional manual compression
273823|NCT00154180|Drug|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
273824|NCT02327988|Device|Laser therapy|
273825|NCT02328001|Behavioral|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
273826|NCT02328014|Drug|ACP-196 and ACP-319|Dose escalation
273827|NCT02328014|Drug|ACP-196 and ACP-319|Dose expansion
273828|NCT02328027|Drug|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
273829|NCT02328040|Drug|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog
274119|NCT02320487|Drug|Obinutuzumab|Intravenous repeating dosing
274120|NCT02320500|Behavioral|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
274121|NCT02320500|Behavioral|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
274122|NCT02320513|Other|Wearing activty monitoring device (Fitbit Flex)|
274123|NCT00153361|Behavioral|Video Discussion Group|
274124|NCT02320513|Device|Fitbit Flex|
274125|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
274126|NCT02322983|Behavioral|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
274127|NCT02322996|Other|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
274128|NCT02323009|Device|Esophageal Balloon|Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
274129|NCT02323009|Other|Cstat|PEEP was adjusted to achieve the best CStat in this group of patients
274130|NCT02323022|Drug|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
273521|NCT02334683|Device|E-stim|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
273522|NCT00155441|Behavioral|cognitive-behavioral therapy|
273523|NCT02334683|Device|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
273524|NCT02334709|Radiation|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
273525|NCT02334722|Drug|Levetiracetam extended release|
273526|NCT02334735|Biological|DC Vaccine|DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)
10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 106 cells)
273527|NCT02334735|Biological|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
273528|NCT02334735|Biological|Poly-ICLC|1.4 mg
273529|NCT02334748|Drug|canakinumab|canakinumab
273530|NCT02334774|Procedure|Oral Swallowing Care Program|An Oral Swallowing Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
273531|NCT02334787|Drug|0.3% OPA-15406 Ointment|
273830|NCT02328040|Other|placebo and insulin/novolog via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog
273831|NCT02328053|Procedure|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
273832|NCT02328053|Drug|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
273833|NCT02328066|Device|NBI used by trained endoscopists|Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
273834|NCT00002397|Drug|Lamivudine|
273835|NCT00154180|Drug|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
273539|NCT02334813|Drug|Dexamethasone|
273540|NCT02334826|Procedure|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
273541|NCT02334826|Procedure|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
273542|NCT02337205|Drug|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
273543|NCT02337218|Device|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
273544|NCT02337231|Dietary Supplement|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
273545|NCT02337244|Device|Zimmer Persona Total Knee System|No Intervention
273546|NCT02337257|Drug|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
273547|NCT02337257|Drug|Placebo|subjects will receive placebo one pill per day for 16 weeks
273548|NCT02337270|Biological|Ad5Ag85A|
273549|NCT00156091|Drug|Asenapine|5 or 10 mg BID
273550|NCT02337283|Drug|BI 425809|Tablets
273551|NCT02337283|Drug|Placebo|Tablets
273552|NCT02337296|Behavioral|ADHERE|ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.
All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence.
273848|NCT02330354|Behavioral|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
273849|NCT02330367|Drug|Avitinib|Stage1: Avitinib will be administered in escalating dosages in a period of 28-day cycles.
Stage 2: Avitinib will be administered twice-daily at RP2D.
273850|NCT02330380|Drug|Methotrexate|Subjects will receive Methotrexate as detailed in the "Group" description.
273851|NCT02330380|Drug|Ustekinumab|Subjects will receive Ustekinumab as detailed in the "Group" description.
273225|NCT02341898|Other|Supportive material (poster, mugs etc.)|
273226|NCT02341911|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
273227|NCT02341911|Drug|Gemcitabine,carboplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
273228|NCT02341924|Other|Portfolio of functional foods|
273229|NCT00156702|Behavioral|Smoking Prevention Video|
273230|NCT02341924|Other|Control foods|
273231|NCT02341937|Other|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
273232|NCT02341950|Behavioral|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
273233|NCT02341963|Drug|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
273234|NCT02341976|Other|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
273235|NCT02341989|Drug|Bleomycin Etoposide and Cisplatin|
273236|NCT02341989|Drug|Carboplatin|
273237|NCT02344095|Device|oncothermia|Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.
- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W.
273238|NCT02344108|Device|Inspire® Upper Airway Simulation System, Model 3024 IPG, and any subsequent iteration thereof that are approved under P130008 for the treatment of obstructive sleep apnea|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
273239|NCT02344121|Radiation|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
273240|NCT02344134|Biological|NBP607|0.5 mL, intramuscular, a single dose
273241|NCT02344134|Biological|Agrippal S1|0.5 mL, intramuscular, a single dose
273242|NCT00157014|Drug|Tacrolimus|Oral
273243|NCT02344160|Other|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
273244|NCT02344186|Drug|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
277235|NCT02688738|Drug|Doxycycline|
277236|NCT02688751|Radiation|time-resolved CT Angiography|A multi-phase contrast CT
277237|NCT00200746|Drug|Arginine|Amino Acid Arginine
277238|NCT02688751|Procedure|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
277524|NCT02717455|Drug|LBH589|Patients with recurrent/progressive DIPG will be enrolled at the time of progression. Therapy with panobinostat will be administered every other day, 3 times/ week, p.o. preferably on a Monday/Wednesday/Friday schedule for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (total 4 weeks) will constitute one course. Treatment will continue for up to 26 courses (approximately 2 years) barring progressive disease or unacceptable toxicity.
277525|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
277526|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
277527|NCT02717481|Device|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
277528|NCT02684006|Drug|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
277529|NCT02684006|Drug|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
277530|NCT02684006|Drug|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
277531|NCT02684019|Drug|Dexmedetomidine|added to propofol sedation
277532|NCT02684019|Drug|Magnesium Sulphate|added to propofol sedation
277533|NCT02684032|Drug|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
277534|NCT00200174|Drug|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
277535|NCT02684032|Drug|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
277536|NCT02684032|Drug|Letrozole|Letrozole at 2.5 mg daily
277537|NCT02684032|Drug|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
277538|NCT02684045|Procedure|Posterolateral surgical procedure with MAGNIFUSE|
276944|NCT02695836|Other|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
276945|NCT02695836|Other|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
277239|NCT02688764|Drug|PA21 (Velphoro®)|During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.
During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.
277240|NCT02688764|Drug|Calcium Acetate (Phoslyra®)|During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.
During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.
277241|NCT02691013|Drug|Ramelteon|
277242|NCT02691013|Drug|Placebo|
277243|NCT02691026|Drug|Pembrolizumab|
277244|NCT02691052|Other|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
277245|NCT02691065|Drug|Integrase Inhibitor|
277246|NCT00201019|Behavioral|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
277247|NCT02691078|Other|Comparison between 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide to the diagnosis of neuroendocrine tumors|
277248|NCT02691104|Device|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
276644|NCT02702115|Genetic|SB-318|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN)1, ZFN2, and complementary deoxyribonucleic acid (cDNA) Donor] administered via intravenous (IV) infusion.
276645|NCT02702128|Drug|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
276646|NCT02702128|Drug|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
276647|NCT02702141|Drug|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
276648|NCT02702154|Device|High-frequency rTMS|20 Hz active stimulation, twice daily
276946|NCT02695836|Other|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
276947|NCT02695862|Drug|Terlipressin|
276948|NCT02695875|Procedure|Aquatic therapy|Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve "core" muscles and, in this way, improve postural balance.
276949|NCT02695875|Procedure|Land-based therapy|The material is contributed by Faculty of Physiotherapy at University of "A Coruña".
The exercises that will be made during treatment, are designed and developed to improve "core" muscles and, in this way, improve postural balance.
276950|NCT02695888|Behavioral|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
276951|NCT00201682|Drug|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
276952|NCT02695888|Behavioral|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
276953|NCT02695901|Drug|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
276954|NCT02697799|Behavioral|Mid-level recruitment strategy consent form|Patients will be exposed to a consent for that includes supplemental information describing a mid-level recruitment strategy
276955|NCT02697812|Procedure|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
276956|NCT02697825|Procedure|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
276957|NCT02697838|Drug|Apatinib|Apatinib (850 mg qd p.o.) plus paclitaxel (80mg/m2, i.v. d1,d8, d15, q28d)until disease progression or intolerable toxicity
276319|NCT02706535|Drug|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
276320|NCT02706535|Drug|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
276321|NCT02706548|Behavioral|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
276322|NCT02706548|Behavioral|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association & American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
276323|NCT02706561|Behavioral|questionnaires|
276324|NCT02706561|Behavioral|three in-person sessions|
276325|NCT02706561|Behavioral|monthly phone calls|
276326|NCT00202917|Drug|Melphalan|
276327|NCT02706561|Behavioral|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
276649|NCT02702154|Device|Low-frequency rTMS|1 Hz active stimulation, twice daily
276650|NCT02702154|Device|Sham rTMS|Sham stimulation, twice daily
276651|NCT02702167|Device|High-frequency rTMS|20 Hz active stimulation, twice daily
276652|NCT02702167|Device|Low-frequency rTMS|1 Hz active stimulation, twice daily
276653|NCT00202410|Biological|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
276654|NCT02702167|Device|Sham rTMS|Sham stimulation, twice daily
276655|NCT02702180|Drug|molgramostim|molgramostim nebuliser solution
276656|NCT02702180|Drug|placebo|placebo nebuliser solution
275728|NCT00204074|Drug|17-beta-estradiol (drug)|
276019|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|The whole intervention has been divided in 3 treatments A, B and C, performed every 2 weeks. In every treatment, an oral glucose tolerance test (OGTT) will be conducted. Blood samples will be obtained at basal time and at 15-30-60-120 minutes after oral ingestion of a commercial glucose solution (75 g/200 mL). The urine of each subject will be collected from basal time to 180 minutes.
The first treatment (A) will be used as control and will only consist of OGTT. Treatment B is characterized by the administration of 10 g of a mixture of grape and pomegranate pomaces ("product") just before the OGTT. In treatment C the subjects will consume the product 10 hours before the OGTT.
The aim of this procedure is to detect changes at the glucose response (AUC), after the administration of the product at time 0 and 10 hours before (in order to detect possible differential effects of intact polyphenols and microbial-derived metabolites).
276020|NCT00203372|Drug|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
276021|NCT02710474|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
276022|NCT02710474|Behavioral|Standard Care|The standard provided on the NICU floor.
276023|NCT02710487|Behavioral|REMSA|Awakening from REM sleep during the last hour of the sleep period
276024|NCT02712346|Drug|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
276025|NCT00203593|Procedure|Lower body negative pressure|
276026|NCT02712346|Drug|Placebo|One inactive pill daily for twelve weeks
276027|NCT02712359|Procedure|Blood sample collection|A blood sample (~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10)
276028|NCT02712372|Drug|AZD4831|AZD4831 1-50 mg/g oral suspension
276029|NCT02712372|Drug|AZD4831 placebo|AZD4831 placebo oral suspension
276030|NCT02712385|Other|'The Healthy Brain Manual'|The Healthy Brain Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
276031|NCT02712385|Device|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
276032|NCT02712385|Procedure|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
276033|NCT02712398|Device|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
276034|NCT02712411|Drug|HCP1303|
275452|NCT02685618|Device|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
275453|NCT02685631|Other|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
275454|NCT02685644|Procedure|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
275455|NCT02685657|Drug|Drug: Selumetinib|
275456|NCT02687945|Procedure|Self-guided physiotherapy|
275457|NCT02687958|Drug|Everolimus|Maintenance therapy
275458|NCT02687971|Drug|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
275459|NCT02687984|Drug|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
275460|NCT02687997|Other|poligraphy|Sleep study
275461|NCT02688010|Behavioral|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
275729|NCT02716649|Other|No intervention|
275730|NCT02716662|Dietary Supplement|Axona|medical powder, supplement food
275731|NCT02716675|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
275732|NCT02716675|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
275733|NCT02716688|Drug|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 80 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to six cycles.
275734|NCT02716688|Radiation|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8-2.0Gy to a total dose of 54-60Gy.
275735|NCT02716701|Behavioral|Exercise Group|
275736|NCT02716701|Other|Control Group|
275737|NCT02716701|Device|wristband activity tracker|
275169|NCT02692664|Device|Endovascular aorto-iliac repair|
275170|NCT00201227|Other|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
275171|NCT02692677|Drug|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
275172|NCT02692690|Device|Stimulette r4x|
275173|NCT02692703|Drug|ABT-493/ABT-530|Tablet
275174|NCT02692716|Drug|semaglutide|For oral use once daily.
275175|NCT02692716|Drug|placebo|For oral use once daily.
275176|NCT02692729|Procedure|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
275177|NCT02692729|Procedure|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
275178|NCT02692742|Drug|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
275179|NCT02692742|Drug|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
275180|NCT02692755|Drug|Palbo + Letrazole|Palbociclib x 21 D 7 day reast plusd 2.5 mg Letrazole QD (no break) until progression or maximum of 12 months
275181|NCT00201240|Device|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ >5 x 10*6/kg and CD3+ < 1 x 10*5/kg
275462|NCT00200642|Device|Stretta® System|
275463|NCT02688023|Drug|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
275464|NCT02688036|Radiation|hypofractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
275465|NCT02688036|Radiation|conventionally fractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
271184|NCT02316340|Drug|Regorafenib|160 mg by mouth daily
271185|NCT00002389|Drug|Abacavir sulfate|
271186|NCT00152984|Drug|Placebo inhalation capsules|
271187|NCT02316353|Biological|C1-esterase inhibitor|
271188|NCT02316366|Device|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
271189|NCT02316379|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
271190|NCT02316379|Device|MRI|
271191|NCT02316392|Drug|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
271192|NCT02316392|Device|MRI|
271193|NCT02316405|Other|Arm and Leg Cycling Exercise for Walking after Stroke|
271194|NCT02316418|Device|Anchoring system|A single patient use Anchoring System pre-loaded with short fibers connected to a miniature nitinol anchor, each implant is placed in a separate needle within the Anchor System.The Anchoring System is of linear shape and may contain up to 20 implants.
271195|NCT02316444|Biological|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses then their response will be re-assessed.
271196|NCT02316457|Biological|IVAC_W_bre1_uID|vaccination
271197|NCT00152997|Drug|Pramipexole 0.125 mg tablets|
271494|NCT02347917|Drug|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
271495|NCT02347917|Drug|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
271496|NCT02347930|Other|kidney ultrasound|kidney ultrasound
271497|NCT02347956|Procedure|Reduced port robotic distal gastrectomy|
271498|NCT02347969|Dietary Supplement|X34|Dietary supplement named X34
271499|NCT02350309|Drug|E2006-matched placebo|E2006-matched placebo tablet
271500|NCT02350309|Drug|Flurazepam 30 mg|Flurazepam 30 mg capsule
270899|NCT02321579|Dietary Supplement|vitamin B-6|50 mg/d
270900|NCT02321579|Dietary Supplement|Glutathione|500 mg/d
270901|NCT02321579|Dietary Supplement|Dextrins|50 mg/d
270902|NCT02321592|Drug|AFM13|
270903|NCT02321605|Behavioral|e-BPS|Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.
They carry out the exercise in a Positive Technology System called the "Book of Life", which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously.
270904|NCT02324010|Drug|Placebo|Inactive drug (Placebo)
270905|NCT02324023|Device|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
270906|NCT02324036|Device|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
270907|NCT00153764|Drug|Cooper Complete One-A-Day Vitamin Supplement|
270908|NCT02324036|Behavioral|Coached Care|Community health worker provides participation training to patient
270909|NCT02324049|Drug|SBC-103|
270910|NCT02324062|Other|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
270911|NCT02324062|Other|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
270912|NCT02324075|Behavioral|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
270913|NCT02324088|Drug|Docetaxel|
270914|NCT02324088|Drug|Cyclophosphamide|
270915|NCT02324088|Drug|Epirubicin|
270320|NCT02335983|Drug|Lenalidomide|
270321|NCT02335983|Drug|Dexamethasone|
270322|NCT02335996|Biological|Blood samples for measuring adiponectin, leptin and omentin plasma|
270323|NCT02335996|Device|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancreas
270324|NCT02336009|Device|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
270615|NCT02329028|Device|Prehospital mini-EEG|Observational
270616|NCT02329041|Device|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
270617|NCT02329041|Device|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
270618|NCT02329054|Drug|Favipiravir|Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.
Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.
Group C: daily dosages will be adapted to their body weight.
270619|NCT02329067|Other|walnuts|consumption of 43 g walnuts per day
270620|NCT02329080|Drug|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
270621|NCT00154284|Drug|Cyclosporine (Neoral)|
270622|NCT02329080|Drug|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
270623|NCT02329080|Drug|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
270624|NCT00154557|Behavioral|elite judo athletes program|
270625|NCT02331108|Other|Measurement of temperature|Standard anesthesia care will be provided after induction. Temperatures will be monitored every 15 minutes
270626|NCT02331121|Behavioral|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
270627|NCT02331121|Behavioral|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
270628|NCT02331134|Drug|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
270629|NCT02331147|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment
270041|NCT02340624|Behavioral|Referral to SmokeFreeMoms, Quitline or Brief intervention|SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.
The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.
Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer.
270042|NCT02342860|Other|WASH in Schools (WinS) programme|The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:
Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;
Software: operations and maintenance (O&M) training for teachers, hygiene training, and basic hygiene package.
270043|NCT00156871|Behavioral|exercise|
270044|NCT02342873|Procedure|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
270045|NCT02342873|Procedure|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
270325|NCT02336022|Device|Respiratory Motion Inc|
270326|NCT02336035|Procedure|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
270327|NCT02336048|Drug|chlorambucil|0.5 mg/kg chlorambucil oral administration per local prescribing information, on Days 1 and 15 of Cycles 1-6
270328|NCT02336048|Drug|obinutuzumab|1000 mg obinutuzumab as an IV infusion administered as a 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2; and as a single 1000 mg dose administered on Cycle 1 Days 8 and 15 and Day 1 of each subsequent cycle for up to 6 cycles
270329|NCT02336048|Drug|placebo|Matching IV placebo infusion prior to the first dose of obinutuzumab
270330|NCT00155883|Drug|5-Fluorouracil|
270331|NCT02336048|Other|standard premedication|Standard-of-care premedication prior to the first infusion per U.S. Package Insert/Summary of Product Characteristics, consisting of paracetamol, antihistamine, and corticosteroid
270332|NCT02336048|Drug|tocilizumab|IV infusion of 8 mg/kg tocilizumab or adjusted dose (up to a maximum threshold of 20 mg/kg) prior to the first infusion of obinutuzumab
270333|NCT02336061|Behavioral|Evaluation of gender differences on the psychosocial and economic impact.|
269438|NCT02237443|Drug|Rocuronium|Administration of a NMBD
269439|NCT02237443|Drug|Vecuronium Bromide|Administration of a NMBD
269440|NCT00144105|Drug|LPV400mg/RTV100mgBID|
269736|NCT02347033|Drug|Sertraline|Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.
We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks.
269737|NCT00157547|Drug|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
269738|NCT02347033|Behavioral|Cognitive Behavioural Therapy|CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.
Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent.
269739|NCT02347046|Drug|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
269740|NCT02347059|Drug|L-dopa|Antiparkinsonian medication
269741|NCT02347059|Drug|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
269742|NCT02347072|Drug|GFF MDI (PT003)|
269743|NCT02347072|Drug|Placebo MDI|
269744|NCT02347072|Drug|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
269745|NCT02347085|Drug|GFF MDI (PT003)|
269746|NCT02347085|Drug|Placebo MDI|
269747|NCT02347098|Procedure|Percutaneous coronary intervention|Widening of coronary arteries using balloons or stents.
269748|NCT00002408|Drug|Crofelemer|
269749|NCT00157560|Drug|Chemotherapy, multiple agents|
269750|NCT02347098|Procedure|Intravascular ultrasound with virtual histology|IVUS-VH allows for the identification of discrete plaque components using radiofrequency backscatter data. The technology can visualize the coronary artery wall and measure atherosclerosis volume.
274131|NCT02323022|Drug|High-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
274132|NCT02323022|Drug|Intermediate-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 10mg/msq/d (d1-3)
274133|NCT02323035|Device|Headgear|Investigative Headgear with CPAP Mask.
274134|NCT02323048|Drug|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
274135|NCT02323048|Drug|placebo|Placebo (sugar pill)
274136|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
274137|NCT02323061|Procedure|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
274138|NCT02323074|Procedure|Brain Computer Interface|
269441|NCT02237443|Drug|Succinylcholine|Administration of a NMBD
269442|NCT02237456|Procedure|Comparison of OCT scans|
269443|NCT02237456|Procedure|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
269444|NCT02237469|Radiation|Prone and supine simulation|Treatment planning in the two positions.
269445|NCT02237482|Device|Trilogy cup|
269446|NCT02237482|Device|Trabecular metal cup (TM)|
269447|NCT02237482|Device|ZCA cup|
269448|NCT02237495|Drug|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
269449|NCT02237495|Drug|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
269450|NCT02237508|Drug|Z7200|
269451|NCT00144118|Drug|sevoflurane or isoflurane|
269452|NCT02237508|Drug|Symbicort Turbohaler|
269453|NCT02237508|Drug|Z7200 with charcoal|
269454|NCT02237508|Drug|Symbicort Turbohaler with charcoal|
273836|NCT02328079|Drug|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: First group (prednisolone 60 mg /day IM /IV), second group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
273837|NCT02330276|Drug|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
273838|NCT02330289|Behavioral|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers, accompanied by a feedback session with the attending physician.
273839|NCT02330302|Drug|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
273840|NCT02330302|Drug|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
273841|NCT02330315|Device|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
273842|NCT02330315|Device|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
273843|NCT02330328|Other|No Telemetry Monitoring|
273844|NCT00154414|Drug|liraglutide|
273845|NCT02330328|Device|Telemetry Monitoring|
273846|NCT02330341|Dietary Supplement|Artemisia dracunculus|
273847|NCT02330341|Other|Placebo|
274139|NCT02323087|Device|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
274140|NCT02323087|Device|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
273852|NCT02330380|Drug|Etanercept|Subjects will receive Etanercept as detailed in the "Group" description.
273853|NCT02330380|Drug|Adalimumab|Subjects will receive Adalimumab as detailed in the "Group" description.
273854|NCT02330380|Drug|Acitretin|Subjects will receive Acitretin as detailed in the "Group" description.
273855|NCT00154427|Drug|activated recombinant human factor VII|
273856|NCT02330380|Other|UVB Excimer Laser|Subjects will receive UVB Excimer Laser therapy as detailed in the "Group" description.
273857|NCT02330380|Other|Narrowband UVB|Subjects will receive Narrowband UVB as detailed in the "Group" description.
273858|NCT02330406|Drug|Anagliptin|Suiny 100 mg
273859|NCT02330406|Drug|Sitagliptin|Januvia 50 mg Glactiv 50 mg
273860|NCT02330419|Drug|Placebo|
273861|NCT02330419|Drug|Naltrexone|
273862|NCT02332525|Device|Oral Vibrational Stimulation|Oral application of vibratory stimulus
: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place.
273863|NCT02332538|Procedure|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
273864|NCT02332538|Procedure|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
273865|NCT02332538|Procedure|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
273866|NCT02332551|Device|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
273867|NCT02332564|Other|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
273868|NCT00154791|Drug|oxaliplatin|
274159|NCT02325479|Drug|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
274160|NCT02325479|Drug|tissue culture media|intrauterine administration after oocyte pickup as placebo
274161|NCT02325492|Drug|Aramchol|
273553|NCT02337309|Drug|SF1126|SF1126 in IV form with be given to patients on this study.
273554|NCT02337322|Drug|Dolutegravir|
273555|NCT02337322|Drug|Darunavir/r|
273556|NCT02337348|Other|Optical coherence tomography|Preintervention imaging
273557|NCT02337348|Radiation|Coronary angiography|Conventional coronary intervention
273558|NCT02337361|Behavioral|Electronic SBI|Bilingual (English and Spanish) e-SBI with four key components:
1) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies.
273559|NCT02337374|Device|Midurethral sling mesh|
273560|NCT00156091|Other|Placebo|
273561|NCT02337387|Biological|Blosozumab|Administered SC
273562|NCT02337387|Other|Placebo|Administered SC
273563|NCT02337400|Behavioral|Cognitive behavioral smoking reduction program "Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
273564|NCT02337400|Behavioral|15 minute counseling interview|
273565|NCT02337413|Drug|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
273566|NCT00156338|Procedure|fluid management|liberal fluid management
273567|NCT02339636|Other|PDUS examination|
273568|NCT02339649|Procedure|Blood Sample|Blood Sample
273569|NCT02339649|Behavioral|Neurocognitive Assessment|Neurocognitive Assessment
273570|NCT02339649|Other|Resting State EEG|10-20 Minutes of Resting State EEG
273571|NCT02339649|Procedure|Lumbar Puncture|Lumbar Puncture
273572|NCT02339649|Other|MRI|60 Minutes MRI
273573|NCT02339662|Drug|Gabapentin|muscles pain treatment
273574|NCT02339662|Drug|Amitriptyline|muscles pain treatment
277539|NCT02684058|Drug|dabrafenib|dabrafenib oral, twice daily. Patient dose based on weight and age. Patients will receive study drug until they are no longer receiving clinical benefit as determined by investigator, disease progression, death, unacceptable toxicity, start of new anticancer treatment or study is terminated by Sponsor.
277540|NCT02684071|Drug|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
277541|NCT02684084|Drug|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
277542|NCT02684084|Drug|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
277811|NCT02713191|Drug|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
277812|NCT02713191|Other|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
277813|NCT02713191|Drug|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
277814|NCT02713191|Drug|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
277815|NCT00203723|Drug|Risperidone|
277816|NCT02713204|Drug|REGN910-3|
277817|NCT02713204|Drug|Intravitreal Aflibercept Injection (IAI)|
277818|NCT02713217|Other|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
277819|NCT02715232|Drug|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
277820|NCT02715232|Drug|Lynestrenol|2-3 tablets/day, if menstruation still occurs
277821|NCT02715232|Drug|Cyproterone Acetate|25mg daily
277822|NCT02715232|Drug|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
277823|NCT02715232|Drug|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
277824|NCT02715245|Procedure|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
277249|NCT02691104|Device|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
277250|NCT02691117|Drug|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
277251|NCT02691130|Biological|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
277252|NCT02691130|Biological|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
277253|NCT02691130|Biological|Saline|0.9% NaCl in double distilled water
277543|NCT02684097|Drug|Tralokinumab|All groups will receive study drug every two weeks for 24 weeks.
277544|NCT02684097|Drug|Placebo|Matching placebo given every two weeks for 24 weeks
277545|NCT00200174|Drug|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
277546|NCT02684123|Drug|Apremilast|Subjects will get drug or placebo
277547|NCT02684123|Drug|Placebo|
277548|NCT02684136|Drug|suvorexant|suvorexant 20 mg taken before sleep
277549|NCT02684136|Drug|placebo|placebo taken before sleep
277550|NCT02684149|Procedure|relational touch|
277551|NCT02684162|Drug|SGI-110|Starting dose: 40 mg/m2 subcutaneously daily, Days 1 to 5.
277552|NCT02686437|Other|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
277553|NCT02686463|Procedure|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
277554|NCT02686463|Procedure|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
277555|NCT02686476|Drug|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
276958|NCT02697851|Drug|Microgynon 30®|
276959|NCT00201838|Drug|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
276960|NCT02697851|Drug|Evotaz®|
276961|NCT02697864|Drug|tafamidis|
276962|NCT02697877|Drug|Regadenoson|
276963|NCT02697890|Device|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
276964|NCT02697890|Device|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
277254|NCT02691143|Other|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
277255|NCT02691156|Other|Bilirubin Binding Capacity|Laboratory assay of bilirubin binding capacity
277256|NCT02691156|Other|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
277257|NCT00201045|Other|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
277258|NCT02691156|Other|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
277259|NCT02691169|Drug|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
277260|NCT02691182|Drug|SPN-810|
277261|NCT02691195|Drug|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
277262|NCT02691195|Drug|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
277263|NCT02693587|Drug|Misodel and Angusta|
277264|NCT02693600|Procedure|Ligamentoplasty with partial trapeziectomy|
277265|NCT02693600|Procedure|Ligamentoplasty with total trapeziectomy|
277266|NCT02693613|Drug|ASP1517|Oral
276657|NCT02702193|Behavioral|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
276658|NCT02702206|Drug|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
276659|NCT02702206|Drug|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
276660|NCT02704325|Biological|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
276661|NCT00202735|Procedure|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
276662|NCT02704325|Biological|rAAVrh74.MCK.GALGT2 PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
276663|NCT02704338|Biological|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
276664|NCT02704351|Procedure|Surger|Sugammadex to reverse neuromuscular blockade
276665|NCT02704364|Biological|NGM282|
276666|NCT02704364|Other|Placebo|
276667|NCT02704377|Other|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
276668|NCT02704377|Procedure|Dual X-ray Absorptiometry|Undergo iDXA
276669|NCT02704377|Other|Laboratory Biomarker Analysis|Correlative studies
276965|NCT02697903|Dietary Supplement|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
276966|NCT02697903|Dietary Supplement|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
276967|NCT02697916|Drug|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
276968|NCT02697929|Drug|sugammadex|
276035|NCT02712411|Drug|HGP1201|
276036|NCT00203593|Behavioral|Heart Rate|
276037|NCT02712411|Drug|HIP1402|
276328|NCT02706561|Behavioral|Enhanced Monitoring and Education (EME)|
276329|NCT02706587|Device|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
276330|NCT02706587|Device|Sham control|No electrostimulation
276331|NCT02708498|Behavioral|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
276332|NCT02708511|Procedure|Computed Tomography|Undergo PET/CT
276333|NCT02708511|Radiation|Copper Cu 64-DOTA B-Fab|Given IV
276334|NCT02708511|Other|Laboratory Biomarker Analysis|Correlative studies
276335|NCT02708511|Other|Pharmacological Study|Correlative studies
276336|NCT02708511|Procedure|Positron Emission Tomography|Undergo PET/CT
276337|NCT00203125|Other|tyramine|50 mg once daily
276338|NCT02708537|Biological|PRGF in candidates for sperm donors|PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
276339|NCT02708550|Behavioral|Participatory Organizational Intervention|
276340|NCT02708563|Procedure|Immediate intubation|
276341|NCT02708563|Procedure|Immediate resuscitation|
276342|NCT02708576|Biological|NGM313|
276343|NCT02708576|Other|Placebo|
276344|NCT02708589|Dietary Supplement|probiotic|
275738|NCT02716714|Drug|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
275739|NCT00204087|Behavioral|Cognitive behavioral therapy (CBT)|
275740|NCT02716714|Drug|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
275741|NCT02716727|Device|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
275742|NCT02716727|Device|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
275743|NCT02716740|Dietary Supplement|Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week|After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
275744|NCT02716753|Biological|seminal plasma|Physiological NaCL
275745|NCT02683278|Behavioral|Mindfulness-acceptance|Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
275746|NCT02683278|Other|Pain Education|Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
275747|NCT02683291|Drug|sirolimus|
275748|NCT02683291|Drug|tacrolimus|
275749|NCT02683291|Drug|mycophenolate|
275750|NCT02683291|Drug|Prednisone|Prednisone 30mg/day
276038|NCT02712424|Biological|DAR-901|
276039|NCT02712424|Biological|Sterile saline placebo|
276040|NCT02712437|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
276041|NCT02712476|Drug|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
276042|NCT02712476|Drug|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
276043|NCT02712476|Drug|placebo|mannitol alone is compared with placebo
276044|NCT02712489|Other|No intervention|
275466|NCT02688049|Biological|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
275467|NCT02688049|Biological|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
275468|NCT02688062|Device|NeuroRegen Scaffold with BMMCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
275469|NCT02688062|Procedure|Surgical intradural decompression and adhesiolysis|Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
275470|NCT02688075|Other|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
275471|NCT02688088|Drug|Drug Cocktail|Administered orally
275472|NCT02688088|Drug|Abemaciclib|Administered orally
275473|NCT00200655|Drug|Pravastatin|
275474|NCT02688101|Drug|DpC|iron chelator
275475|NCT02688114|Procedure|Baseline surveillance endoscopy|All study participants will undergo endoscopy with confocal laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
275476|NCT02690142|Drug|Placebo|Single dose i.v.
275477|NCT02690142|Drug|ABY-035 i.v.|Single dose i.v.
275478|NCT02690142|Drug|ABY-035 s.c.|Single dose s.c.
275479|NCT02690155|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
275480|NCT02690155|Drug|VKA (Vitamin K antagonist)|As prescribed by treating physicians
275751|NCT02683291|Drug|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
275752|NCT00200083|Device|Transcend II Model 8848|All subjects will be implanted with the IGS device and then randomized to "on" or "off" for 12 months. After 12 months all subjects will be turned "on" through 24 month follow up.
275753|NCT02683291|Drug|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
275754|NCT02683304|Biological|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
271501|NCT02350322|Other|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
271502|NCT02350322|Other|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
271503|NCT02350322|Dietary Supplement|Supplement|Omega-3 capsules three times a week for 12 weeks
271504|NCT02350335|Drug|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
271505|NCT02350361|Drug|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
271506|NCT02350361|Drug|Placebo|Placebo
271507|NCT02350374|Other|carbohydrate counting|patients must fill their logbook with the following data:
cho amount at breakfast, lunch, snack and dinner
insulin amount at breakfast, lunch, snack and dinner
271508|NCT00157976|Drug|Photrex (rostaporfin)|
271509|NCT02350387|Procedure|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
271510|NCT02350387|Procedure|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
271511|NCT02350400|Device|DEBIRI|DEBIRI TACE
271512|NCT02350413|Other|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
271513|NCT02350426|Other|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
271514|NCT02350426|Other|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
271515|NCT02350426|Other|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
271824|NCT02345720|Device|Investigational Multifocal Contact Lens (Vistakon®)|The investigational contact lens must be worn at least six hours daily.
271825|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
271826|NCT02345733|Other|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
271198|NCT02316457|Biological|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
271199|NCT02316470|Biological|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
271200|NCT02316470|Biological|Placebo|phosphate buffered saline (PBS) solution
271201|NCT02316496|Drug|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
271202|NCT02316496|Drug|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
271203|NCT02316509|Drug|SRN-927|oral administration
271204|NCT02316535|Drug|Capecitabine|adjuvant chemotherapy;
271205|NCT02316548|Other|No radiation|No radiation is received by the patient.
271206|NCT02316548|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy (IMRT)
271207|NCT02319135|Drug|Filgastrim|
271208|NCT02319148|Drug|itraconazole|itraconazole dosed at 200 mg
271209|NCT00153166|Drug|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
271210|NCT02319148|Drug|diltiazem|diltiazem dosed at 240 mg
271211|NCT02319148|Drug|SR verapamil|SR verapamil dosed at 240 mg
271212|NCT02319161|Drug|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
271213|NCT02319174|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
271214|NCT02319187|Drug|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
271215|NCT02319187|Drug|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
271216|NCT02319187|Drug|irinotecan|irinotecan 160mg/m2 d1, every 14 days
271217|NCT02319200|Drug|Metformin|1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)
Metformin daily during 36 months
271218|NCT02319200|Drug|placebo tablet|4 tablets per day for 36 months
270630|NCT02331147|Other|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
270631|NCT02331160|Behavioral|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
270632|NCT02331173|Drug|Dorzolamide 2% TID or brinzolamide 1% TID|Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:
Topical dorzolamide 2% three times per day
Topical brinzolamide 1% three times per day
270633|NCT02331186|Procedure|bariatric surgery|bariatric surgery for obese women
270634|NCT02331199|Device|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
270916|NCT02324101|Device|Hsp90|Detect plasma Hsp90α concentration
270917|NCT02324114|Device|Hsp90|Detect plasma Hsp90α concentration
270918|NCT00002394|Drug|Terbinafine hydrochloride|
270919|NCT00153777|Drug|Cellulose Sulfate gel (6%)|
270920|NCT02324127|Device|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
270921|NCT02324140|Other|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
270922|NCT02324153|Drug|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
270923|NCT02324153|Drug|Microcrystalline Cellulose|Placebo Comparator
270924|NCT02324166|Drug|Cefazolin|cephalosporin antibiotic
270925|NCT02324166|Drug|Lidocaine|local anesthetic
270926|NCT02324192|Other|Ultrasonography|imaging findings
270927|NCT02324205|Device|Digital Breast Tomosynthesis|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
270928|NCT02324205|Device|Full-field digital mammogram|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
270929|NCT02326610|Drug|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
270930|NCT02326623|Other|distraction|distraction using an iPad with a selection of child-appropriate games
270334|NCT02338453|Behavioral|Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
270335|NCT02338466|Drug|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
270336|NCT02338466|Drug|tenecteplase|Tenecteplase is under the form of powder and solvent for solution for injection.
The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg).
270337|NCT02338492|Device|Photodynamic Bone Stabilization System (PBSS)|Treatment of impending and actual pathological fractures of the humerus
270338|NCT02338505|Device|Telelap ALF-X|Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.
Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure.
270339|NCT02338518|Drug|oxaliplatin|oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.
Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group.
270635|NCT00154570|Device|EGG, 24 hour esophageal pH monitor|
270636|NCT02331199|Device|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
270637|NCT02331212|Other|Cytology Specimen Collection Procedure|Correlative studies
270638|NCT02331212|Other|Laboratory Biomarker Analysis|Correlative studies
270639|NCT02331225|Other|No intervention given|There is no intervention for this study
270640|NCT02331238|Behavioral|"Coaching Boys into Men" program|"Coaching Boys into Men" program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
270641|NCT02331251|Drug|Pembrolizumab|
269751|NCT02347098|Drug|Atorvastatin or other equivalent dose statin|40-80mg oral daily dose of Atorvastatin or other equivalent dose statin to lower LDL in blood.
269752|NCT02349503|Drug|NBI-77860|
269753|NCT02349503|Drug|NBI-77860|
269754|NCT02349516|Drug|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
269755|NCT02349529|Behavioral|Psychosocial Intervention Group|6 group sessions
270046|NCT02342886|Drug|Moxifloxacin|Oral
270047|NCT02342886|Drug|PA-824|Oral
270048|NCT02342886|Drug|Pyrazinamide|Oral
270049|NCT02342886|Drug|HRZE (Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol combination tablet)|Oral
270050|NCT02342886|Drug|HR (rifampicin plus isoniazid combination tablets)|Oral
270051|NCT02342899|Device|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
270052|NCT02342899|Device|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
270053|NCT02342912|Behavioral|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
270054|NCT00156884|Drug|strontium-89|
270055|NCT02342925|Other|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
269455|NCT02237508|Drug|Symbicort Turbohaler replicate|
269456|NCT02237521|Other|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
269457|NCT02237521|Other|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
269458|NCT02237534|Drug|Lanthanum carbonate|
269459|NCT02237534|Drug|Calcium Carbonate|
269460|NCT02237547|Biological|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
269461|NCT02237560|Behavioral|Cybercycle-Game|Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
269462|NCT00144131|Drug|Aranesp®|
269463|NCT02237560|Behavioral|Cybercyle-Tour|Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
269464|NCT02237560|Behavioral|Game Only|While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
269756|NCT02349529|Other|Waiting list control|Treatment as usual
269757|NCT02349542|Drug|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
269758|NCT00157898|Drug|Comparator: ceftriaxone + metronidazole|
269759|NCT02349555|Dietary Supplement|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
269760|NCT02349568|Procedure|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
269761|NCT02349568|Procedure|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
269762|NCT02349581|Procedure|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
269763|NCT02349581|Drug|Bupivacaine|
274141|NCT02323100|Drug|Ravicti low dose|8 am, 4pm and midnight
274142|NCT02323100|Drug|Ravicti high dose|8 am, 4pm and midnight
274143|NCT02323100|Drug|Placebo|8 am, 4pm and midnight
274144|NCT02323113|Drug|TAK-659|TAK-659 tablets taken orally once daily.
274145|NCT02325414|Drug|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
274146|NCT02325414|Drug|Placebo|Placebo infusion to match zoledronic acid
274147|NCT00153933|Drug|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
274148|NCT02325427|Device|tDCS|tDCS could deliver either real or sham stimulation.
274149|NCT02325440|Drug|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
274150|NCT02325440|Drug|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
274151|NCT02325453|Procedure|Robotic Surgery|Surgical procedure performed with a robotic system.
274152|NCT02325453|Procedure|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
274153|NCT02325453|Procedure|Open Surgery|Traditional approach for gastric cancer.
274154|NCT02325466|Drug|Aspirin|Aspirin 81mg
274155|NCT02325466|Drug|Ticagrelor|ticagrelor 90 mg
274156|NCT02325466|Drug|Aspirin Placebo|
274157|NCT02325466|Drug|Ticagrelor Placebo|
274158|NCT00153933|Drug|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
269465|NCT02318303|Drug|Mometasone furoate NS-2|
269466|NCT02318316|Other|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
269467|NCT02318329|Drug|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
274162|NCT02325492|Drug|Placebo|
274163|NCT02325492|Device|Ultrasound|
274164|NCT02325518|Drug|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
274165|NCT02325518|Drug|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
274166|NCT02325518|Drug|Subject's habitual PGA monotherapy|
274167|NCT02325531|Other|ALL|The ALL Initiative ('ALL') is a population-level management program developed at Kaiser Permanente (KP). It seeks to decrease cardiovascular disease (CVD) morbidity and mortality in patients with diabetes by improving rates of prescribing for guideline-concordant cardioprotective medications.
For SPREAD-NET, we propose to compare the effectiveness of 3 support strategies for optimizing the sustainable implementation of the evidence-based ALL intervention. To do so, we will randomize 30 CHCs to receive 1 of 3 implementation support strategies: Low support (toolkit only), Medium (toolkit, staff training), High (toolkit, training, on-site facilitation). Using a mixed methods approach, we will assess how effectively each strategy supports sustainable implementation of ALL at the practice- and patient-levels, and we will identify clinic characteristics associated with success at each level of support. We will also conduct a cost analysis to compare costs per patient in each study arm.
274168|NCT02325544|Behavioral|Cognitive Behavioral Therapy|12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.
Standardised medical as described in other intervention.
274169|NCT00153946|Drug|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
274170|NCT02328092|Device|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
274171|NCT02328105|Drug|carboplatin plus abraxane|
274172|NCT02328118|Drug|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
274173|NCT02328118|Drug|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
274174|NCT02328144|Drug|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
274175|NCT02328144|Drug|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
269484|NCT02318446|Drug|Folic Acid|Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
273575|NCT02339675|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
273576|NCT02339688|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
273869|NCT02332577|Drug|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
273870|NCT02332577|Drug|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
273871|NCT02332577|Drug|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
273872|NCT02332577|Drug|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
273873|NCT02332590|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
273874|NCT02332590|Drug|adalimumab|Pharmaceutical form:solution Route of administration: subcutaneous
273875|NCT02332603|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
273876|NCT02332603|Drug|Isotonic Sodium Chloride|Placebo
273877|NCT02332616|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
273878|NCT02332616|Drug|Isotonic Sodium Chloride|Placebo
273879|NCT00154791|Drug|gemcitabine|
273880|NCT02332629|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
273881|NCT02332629|Drug|Isotonic Sodium Chloride|Placebo
273882|NCT02332642|Other|Immuno-monitoring|
273883|NCT02332655|Drug|Cannabidiol|Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed.
273884|NCT02332668|Biological|Pembrolizumab|
277825|NCT00203918|Behavioral|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
277826|NCT02715258|Drug|Bexagliflozin|20 mg, tablet
277827|NCT02715258|Drug|Placebo|20 mg tablet to match active comparator
277828|NCT02715271|Procedure|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
277829|NCT02715284|Biological|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
277830|NCT02715297|Radiation|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
278111|NCT02709252|Device|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
278112|NCT02709265|Drug|amikacin/fosfomycin|single aerosolized dose
278113|NCT02709278|Biological|BCG|BCG SSI
278114|NCT02709278|Other|Saline placebo|Saline placebo
278115|NCT02709291|Behavioral|behavioral parent training|
278116|NCT00203229|Drug|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
278117|NCT02709291|Behavioral|interventionist training|
278118|NCT02709304|Drug|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
278119|NCT02711176|Drug|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
278120|NCT02711176|Drug|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
278121|NCT02711176|Drug|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
278122|NCT02711176|Drug|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
278123|NCT00203476|Drug|Niacin|
278124|NCT02711176|Drug|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
277556|NCT02686489|Other|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher & Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
277557|NCT02686489|Other|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
277558|NCT00200447|Drug|Stalevo|
277559|NCT02686502|Behavioral|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
277831|NCT02715323|Other|Cross-sectional study|
277832|NCT02715336|Drug|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
277833|NCT02715349|Behavioral|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
277834|NCT02715362|Drug|TAI-GPC3-CART cells|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
277835|NCT02715375|Device|CREON2000A|
277836|NCT00203931|Drug|Cetuximab|
277837|NCT02715375|Device|Sham|
277838|NCT02715388|Device|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
277839|NCT02715401|Drug|HCP1303|
277840|NCT02717494|Biological|PPV-23|PPV-23 is a polysaccharide PNC vaccine, licensed in Brazil, that is directed against 23 serotypes.
277841|NCT02717494|Biological|PCV-10|PCV-10 is a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
277842|NCT02717494|Other|NaCl|NaCl is the placebo for the study against which the two vaccines will be compared during pregnancy.
277267|NCT02693613|Drug|Kremezin®|Oral
277268|NCT02693626|Behavioral|intensive cessation message|intensive mobile phone-based text message interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
277269|NCT02693652|Biological|CVI-HBV-002|Investigational product: CVI-HBV-002
Dose: 20ug or 40ug
Frequency: 3 or 6 times
Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months
Administration route: Intramuscular injection
277270|NCT02693665|Behavioral|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
277271|NCT00201396|Drug|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
277272|NCT02693678|Other|Massage|
277273|NCT02693678|Device|DIathermy|
277274|NCT02693678|Device|Sham diathermy|
277560|NCT02686515|Device|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
277561|NCT02686515|Device|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
277562|NCT02686528|Other|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
277563|NCT02686528|Other|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
277564|NCT02686541|Device|Atherectomy followed by Drug Eluting Balloon (DEB)|Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.
Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).
During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit.
277565|NCT02686554|Other|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
276969|NCT02697929|Drug|Neostigmine|
276970|NCT00201838|Drug|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
276971|NCT02697942|Other|cognitive training|The investigators will provide participants with tablets to play brain games through Lumosity.
276972|NCT02697942|Other|exercise training|The investigators will provide participants with foot peddlers.
276973|NCT02697955|Drug|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
276974|NCT02697955|Other|Placebo|9 mg sodium chloride pr. ml (0,9 %)
276975|NCT02697968|Device|Electroacupuncture|
276976|NCT02697981|Behavioral|nutrition counseling|nutrition counseling and guidance.
276977|NCT02697994|Other|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
276978|NCT02697994|Other|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
276979|NCT02700087|Drug|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
276980|NCT00202111|Procedure|Conventional open colectomy|
276981|NCT02700087|Drug|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
276982|NCT02700100|Device|Bioabsorbable Pulmonary Valved Conduit (PV-001)|The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.
The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:
Tetralogy of Fallot
Truncus Arteriosus
Pulmonary Atresia
Transposition of Great Arteries with Ventricular Septal Defect (VSD)
Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes
The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits.
277275|NCT02693691|Device|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
277276|NCT02693704|Device|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
277277|NCT02693717|Drug|Pemetrexed|500 mg/m2 by vein on Day 1 of each 21-day cycle.
276345|NCT02708589|Other|Placebo|
276346|NCT02708602|Genetic|β2AR polymorphism|
276347|NCT02708615|Other|insertion type|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
276348|NCT00203138|Drug|rasagiline mesylate|
276670|NCT02704377|Other|Quality-of-Life Assessment|Ancillary studies
276671|NCT02704377|Other|Questionnaire Administration|Ancillary studies
276672|NCT00202735|Procedure|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
276673|NCT02704390|Drug|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
276674|NCT02704403|Drug|Elafibranor|
276675|NCT02704403|Drug|Placebo|
276676|NCT02704416|Procedure|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
276677|NCT02704429|Drug|PRN1008|PRN1008, oral dose, 12 weeks
276678|NCT02704468|Other|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
276679|NCT02704481|Drug|Mifepristone|200mg oral mifepristone
276680|NCT02704481|Drug|Misoprostol|800mcg buccal misoprostol
276681|NCT02704481|Drug|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
276682|NCT02704481|Drug|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
276683|NCT00202748|Behavioral|Increase in activity to control weight|
276684|NCT02704494|Drug|Resveratrol|Resveratrol 500mg daily
276685|NCT02704494|Drug|Placebo|Placebo 1 capsule daily
276686|NCT02704494|Drug|Losartan|Losartan 12.5mg daily
276045|NCT02712502|Drug|Levofloxacin|Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.
Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.
276046|NCT02712502|Drug|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.
• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.
276047|NCT00203593|Procedure|Blood Pressure|
276048|NCT02712515|Procedure|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
276049|NCT02714478|Device|equistasi|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
276050|NCT02714478|Device|placebo|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
276051|NCT02714491|Other|Erigo + Music|The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with "Erigo" (3/week for 5 consecutive weeks) and musical stimulation.
276052|NCT02714491|Other|Erigo + Metronome|The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with "Erigo" (3/week for 5 consecutive weeks) and metronome stimulation.
276053|NCT02714491|Other|Erigo + Silence|The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with "Erigo" (3/week for 5 consecutive weeks), without auditory stimulation.
276054|NCT00203866|Drug|G250 peptide|
276055|NCT02714504|Drug|Voriconazole or posaconazole|Azole with activity against molds
276056|NCT02714517|Other|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
276349|NCT02708628|Drug|extract of allium cepae, allantoin and heparin|prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
276350|NCT02708628|Procedure|Scar excision|Scar excision in second c-section
276351|NCT02708641|Drug|pembrolizumab|200 mg IV given every three weeks
276352|NCT02708654|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
275755|NCT02683304|Device|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
275756|NCT02683317|Dietary Supplement|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
275757|NCT02683317|Dietary Supplement|sunflower oil|Sunflower similar to the excipient used in experimental group
275758|NCT02683330|Behavioral|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
275759|NCT02683356|Other|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
275760|NCT02683356|Other|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
275761|NCT02683369|Dietary Supplement|Blood Builder®/Iron Response®|The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.
One tablet will be taken once a day offering a total daily serving of:
15 mg of Vitamin C
400 mcg of Folate
30 mcg Vitamin of B-12
26 mg of Iron
125 mg of Beet Root
275762|NCT02683382|Device|Moisturizing Eye Product in Liquid Formula|Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
275763|NCT02685657|Drug|Doxorubicin|
275764|NCT02685657|Drug|Cyclophosphamide|
275765|NCT00200343|Drug|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
275766|NCT02685657|Drug|Docetaxel|
275767|NCT02685670|Drug|Ex vivo-expanded autologous T cells modified to express CD19 CAR|
276057|NCT02714517|Other|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
276058|NCT02714530|Drug|Erlotinib|Tarceva daily during radiotherapy course
276059|NCT02714530|Radiation|Radiation|Radiotherapy
276060|NCT02714543|Drug|aloevera juice|aloevera juice to drink twice daily for 3 months.
271827|NCT02345733|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
271828|NCT02345746|Drug|Oxaliplatin|infusion over 12 hours via HAI
271829|NCT02345746|Drug|Folinic Acid|as a 2-hour infusion via HAI on day 2
271830|NCT02345746|Drug|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
271831|NCT02345772|Drug|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
271832|NCT02347995|Other|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein before and after each training session.
271833|NCT02347995|Other|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage before and after each training session.
271834|NCT02348008|Drug|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
271835|NCT02348008|Drug|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
271836|NCT00157677|Procedure|D-dimer testing|Uniform D-dimer use
271837|NCT02348008|Drug|MK-3475|Arm B: Phase II Treatment: 200mg IV
271838|NCT02348008|Drug|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 5mg or 10mg as established in the Phase 1b dose escalation cohort study.
271839|NCT02348021|Procedure|Percutaneous coronary intervention (PCI)|
271840|NCT02348021|Drug|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
271841|NCT02348034|Device|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
271842|NCT02348047|Device|Hamilton T1|
272135|NCT02341482|Drug|Itraconazole|Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17).
272136|NCT02341495|Drug|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
271219|NCT02319213|Other|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
271220|NCT00153166|Drug|placebo/placebo|placebo orally three times daily
271516|NCT02350439|Drug|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
271517|NCT02350452|Procedure|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
271518|NCT02350452|Procedure|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
271519|NCT00157989|Procedure|Controlled tidal volume resuscitation|
271520|NCT02350465|Behavioral|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
271521|NCT02350465|Behavioral|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
271522|NCT02350478|Drug|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
271523|NCT02352779|Other|Questionnaire Administration|Ancillary studies
271524|NCT02352779|Other|Laboratory Biomarker Analysis|Correlative studies
271525|NCT02352792|Radiation|radiochemotherapy with 70 Gy|
271526|NCT02352792|Radiation|radiochemotherapy with 77 Gy|
271527|NCT02352805|Device|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
271528|NCT02352818|Other|no study intervention|
271529|NCT02352831|Drug|Tosedostat|
271530|NCT00158275|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
271531|NCT02352831|Drug|Capecitabine|
271532|NCT02352844|Drug|Everolimus|
271533|NCT02352857|Other|Sugar|100g of sponge cakes made with 24g of dextrose.
271534|NCT02352857|Other|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
270931|NCT02326623|Other|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
270932|NCT02326636|Biological|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
270933|NCT02326649|Device|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
270934|NCT00154024|Drug|atorvastatin|
270935|NCT02326662|Biological|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
270936|NCT02326675|Drug|Stem Cell|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
270937|NCT02326675|Drug|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
271221|NCT02319213|Other|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
271222|NCT02319213|Other|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
271223|NCT02319226|Other|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
271224|NCT02319239|Radiation|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
271225|NCT02319239|Radiation|hypofractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
271226|NCT02319239|Radiation|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
271227|NCT02319252|Device|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
271228|NCT02319252|Device|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
271229|NCT02319265|Drug|Melatonin|Oral liquid
271230|NCT02319278|Drug|Ferumoxytol|Infusion following between paired MRI scans
271231|NCT02321605|Behavioral|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
270642|NCT02331251|Drug|Gemcitabine|
270643|NCT02331251|Drug|Docetaxel|
270644|NCT02331251|Drug|Nab-paclitaxel|
270645|NCT02331251|Drug|Vinorelbine|
270646|NCT00154609|Drug|Gu-Sui-Bu (Davallia Divaricata)|
270647|NCT02331251|Drug|Irinotecan|
270648|NCT02333617|Other|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
270649|NCT02333617|Other|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
270650|NCT00155246|Drug|pentoxifylline (drug)|
270651|NCT02333617|Other|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
270652|NCT02333630|Other|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
270653|NCT02333630|Other|Asthma education|A website with links to written asthma education and videos
270654|NCT02333643|Drug|CLS003|
270938|NCT02326688|Other|Kinematic analysis of trunk compensation|
270939|NCT02326714|Other|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
270940|NCT02326714|Other|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
270941|NCT02326727|Drug|Ropivacaine|Epidural analgesia
270942|NCT02326727|Drug|Fentanyl|General Anesthesia
270056|NCT02342925|Drug|RG1662|Oral administration twice daily
270057|NCT02342925|Drug|metformin|Single 850 mg dose of metformin
270058|NCT02345070|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
270059|NCT02345096|Dietary Supplement|Saccharomyces cerevisiae|
270060|NCT02345096|Dietary Supplement|Placebo|
270061|NCT02345109|Device|Transtek DUT|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.
Measure each participants by Transtek DUT.
270062|NCT02345109|Device|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
270340|NCT02338518|Drug|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
270341|NCT02338518|Drug|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
270342|NCT02338518|Drug|S-1|80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
270343|NCT00156182|Drug|Asoprisnil|10mg Tablet, oral Daily for 6 months
270344|NCT02338531|Drug|PF-03084014|
270345|NCT02338531|Procedure|Breast cancer surgery|
270346|NCT02338544|Drug|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
270347|NCT02338557|Device|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
270348|NCT02338557|Device|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
270349|NCT02338570|Drug|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
270350|NCT02338583|Device|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
270351|NCT00156572|Procedure|Fluid restriction|
269764|NCT02349594|Drug|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
269765|NCT02349594|Drug|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
269766|NCT02349607|Drug|PF-05089771 300mg|PF-05089771 300 mg
269767|NCT02349607|Drug|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
269768|NCT02349607|Drug|Placebo|Placeco
269769|NCT00157911|Drug|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
269770|NCT02349607|Drug|pregabalin 300 mg|pregabalin 300 mg
269771|NCT02349607|Drug|ibuprofen 600 mg|ibuprofen 600 mg
269772|NCT02349620|Biological|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
269773|NCT02349633|Drug|PF-06747775|The study will evaluate PF-06747775 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose of PF-06747775 will be 25 mg PO daily. The escalation/de-escalation of PF-06747775 will follow the Bayesian Model Averaging Continual Reassessment Method (BMA-CRM) approach.
269774|NCT02349646|Device|Implantation with the commercially available Axium neurostimulator|
269775|NCT02349659|Device|Implantation with the commercially available Axium neurostimulator|
270063|NCT02345122|Behavioral|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
270064|NCT02345122|Other|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
270065|NCT02345135|Procedure|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
270066|NCT02345135|Procedure|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
270067|NCT00157170|Behavioral|supervised exercise|
269468|NCT02318342|Drug|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
269469|NCT02318355|Other|normal saline|Crystalloid intravenous solution
269470|NCT02318355|Other|lactated ringers|Crystalloid intravenous solution
269471|NCT00153088|Drug|Placebo|
269472|NCT02318368|Drug|Ficlatuzumab|
269473|NCT02318368|Drug|Erlotinib|
269474|NCT02318368|Drug|placebo|
269475|NCT02318381|Procedure|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
269476|NCT02318394|Biological|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
269477|NCT02318407|Drug|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
269478|NCT02318407|Drug|Placebo|contains no active drug
269479|NCT02318420|Other|The Paper Partogram (pPartogram) System|This includes the WHO paper partogram and a centrally located blackboard with an overview of women in labour.
269480|NCT02318420|Other|The Electronic Partogram (ePartogram) System|This includes an electronic partogram under development by Jhpiego (an international, non-profit health organization affiliated with Johns Hopkins University) with alarms to guide health providers and strengthen timely labour management, and a centrally located digital screen showing an overview of the ePartogram data on all women in labour to promote and enable team work, prioritizing of the work force, and centralized integrated supervision of staff.
269481|NCT02318433|Drug|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
269482|NCT00153088|Drug|Telmisartan capsule 80 mg|
269483|NCT02318433|Drug|Saline|
269776|NCT02352103|Procedure|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
269777|NCT00158210|Drug|Rivastigmine|
269778|NCT02352103|Procedure|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
269485|NCT02318446|Drug|Saccharine|Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
269486|NCT02318459|Other|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
269487|NCT02318459|Other|Traditionnal group rehabilitation|Traditionnal group rehabilitation, 3 times a week, 1 hour duration
269488|NCT00153426|Behavioral|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
269489|NCT02320825|Behavioral|Quality of Life Measures|
269490|NCT02320838|Device|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
269491|NCT02320838|Device|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
269492|NCT02320838|Device|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
269493|NCT02320851|Behavioral|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
269494|NCT02320851|Behavioral|Self-help group (SHG)|(see description of corresponding study arm)
269495|NCT02320864|Procedure|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
269496|NCT02320877|Device|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
269497|NCT02320890|Device|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
269498|NCT02320890|Device|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
269499|NCT00000349|Drug|Flupenthixol|
269500|NCT00002391|Drug|Zidovudine|
269501|NCT00153439|Behavioral|Motivational enhancements, parent training|
269502|NCT02320903|Device|VillageWhere App|
269503|NCT02320916|Procedure|23Gauge|Arterial puncture will be made using a 23Gauge needle
269504|NCT02320916|Procedure|25Gauge|Arterial puncture will be made using a 25Gauge needle
273885|NCT02334839|Other|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
273886|NCT02334865|Biological|Incomplete Freund's Adjuvant|Given SC
273887|NCT02334865|Other|Laboratory Biomarker Analysis|Correlative studies
273888|NCT00155467|Procedure|CT|
274176|NCT02328157|Device|Vitrectomy with cataract surgery and toric IOL|
274177|NCT02328157|Device|Vitrectomy with cataract surgery and common IOL|
274178|NCT02328170|Other|EUROIMMUN Allergy|Immunoblot assay
274179|NCT00154180|Drug|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
274180|NCT02328170|Other|ImmunoCap|Fluoroallergosorbent test
274181|NCT02328183|Drug|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
274182|NCT02328196|Behavioral|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
274183|NCT02328209|Drug|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
274184|NCT02328222|Drug|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
274185|NCT02328235|Other|High Saturated Fat Diet|Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to "lead-in" to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study.
274186|NCT02328248|Procedure|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
274187|NCT02328261|Drug|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
274188|NCT02328274|Procedure|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
278125|NCT02711176|Drug|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
278126|NCT02711189|Drug|Oxytocin|Oxytocin nasal spray given in dose 80
278127|NCT02711189|Other|Placebo|
278128|NCT02711202|Drug|MabCampath,|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
278129|NCT02711202|Drug|Remicade|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
278130|NCT02711202|Drug|Sirolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
278421|NCT02705209|Other|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
278422|NCT02705209|Other|Placebo Cataplasm|Poultice of Kaolin and Water
278423|NCT02705222|Procedure|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
278424|NCT02705222|Procedure|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
278425|NCT02705261|Behavioral|cognitive-behavior therapy|Internet based program to support parents in developing strategies to help their children
278426|NCT02705274|Drug|Bevacizumab|Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met.
278427|NCT02707276|Device|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
278428|NCT02707276|Device|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment.
278429|NCT02707302|Device|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
278430|NCT02707302|Procedure|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
277843|NCT00204191|Drug|tacrolimus|
277844|NCT02717507|Drug|Carvedilol|Given PO
277845|NCT02717507|Other|Laboratory Biomarker Analysis|Correlative studies
277846|NCT02717507|Other|Pharmacological Study|Correlative studies
277847|NCT02717507|Other|Placebo|Given PO
277848|NCT02717507|Other|Quality-of-Life Assessment|Ancillary studies
277849|NCT02717507|Other|Questionnaire Administration|Ancillary studies
278131|NCT02711202|Drug|Tacrolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
278132|NCT02711215|Radiation|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
278133|NCT02711215|Drug|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
278134|NCT00203476|Drug|Colestipol|
278135|NCT02711215|Drug|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
278136|NCT02711215|Drug|Placebo (saline)|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
278137|NCT02711228|Biological|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
278138|NCT02711241|Drug|Dipyrone|1 gram by slow IV infusion
278139|NCT02711241|Drug|Papaverine|80 mg by slow intravenous infusion
278140|NCT02711254|Device|Phantom System|Unloading of medial knee compartment with Phantom System
278141|NCT02713217|Other|Blended Telemedicine-Based Integrated Care|This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and "virtual co-location" of doctoral-level mental health providers with prompt access through tele-video or telephone communication.
278142|NCT02713230|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension, either 133 mg in 10 mL expanded with normal saline to 20 mL or 266 mg in 20 mL
277566|NCT02688777|Behavioral|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
277567|NCT02688790|Drug|Dalbavancin|
277568|NCT02688803|Drug|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
277569|NCT02688803|Drug|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
277570|NCT02688803|Drug|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
277571|NCT02688816|Device|Xpert HPV|Point-of-care HPV DNA PCR test
277572|NCT02688816|Device|OncoE6|Point-of-care E6 oncoprotein test
277573|NCT00200759|Drug|Cranberry juice and capsules|
277850|NCT02717520|Device|EQUIA Forte|The site will be isolated with cotton rolls. A sectional metal matrix system and wedge will be placed. GC cavity conditioner (20% polyacrylic acid, GC) will be applied for 10 sec., rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte (GC) will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 minutes 30 seconds after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat (GC) will be applied to the surfaces using a micro-tip applicator. The coated surface will be light cured with D-light (GC) for 20 seconds.
277851|NCT02717520|Device|Tetric EvoCeram|The site will be isolated with rubber-dam. A sectional metal matrix system will be placed. Enamel will be etched with 37% orthophosphoric acid for 10 sec. (Ivoclar Vivadent, Schaan, Liechtenstein). After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (GC, 1200 mW/cm2, slow mode) for 10 sec. The composite resin (Tetric EvoCeram, Ivoclar Vivadent) will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece, and polished using flexible polishing discs, rubber points (Compo system, Komet) with a diamond particle paste.
277852|NCT02717533|Other|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
277853|NCT02717546|Device|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
277854|NCT00204217|Device|endotracheal intubation|
277855|NCT02717572|Radiation|Fludeoxyglucose F 18|
277856|NCT02717572|Device|Positron Emission Tomography|
277278|NCT02693717|Dietary Supplement|Folic Acid|5 daily doses of Folic Acid 400 µg by mouth taken during the 7-day period preceding the first dose of Pemetrexed; and dosing should continue during the full course of therapy and for 3 weeks after the last dose of Pemetrexed.
277279|NCT02693717|Dietary Supplement|Vitamin B12|1000 μg administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of Pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy.
277280|NCT02693717|Drug|Dexamethasone|4 mg of oral or equivalent by mouth given twice daily taken on the day before, the day of, and the day after each dose of Pemetrexed.
277281|NCT02693743|Device|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
277282|NCT00201409|Drug|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
277283|NCT02693756|Other|Motor imagery|The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:
"Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally" The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks.
277284|NCT02693769|Drug|fluticasone propionate/formoterol fumarate breath actuated inhaler|
277285|NCT02695901|Drug|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
277286|NCT02695914|Drug|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
277287|NCT02695927|Device|Computer rehabilitation glasses|
277288|NCT02695940|Drug|LEO 124249 ointment 30 mg/g|
277289|NCT02695940|Other|LEO 124249 ointment vehicle|
277290|NCT02695966|Procedure|Whipples Surgery|Whipples Surgery
277291|NCT02695992|Drug|Metoprolol|Dosage 100 mg o.d.
277292|NCT02695992|Drug|Diltiazem|Dosage 360 mg o.d.
277574|NCT02688829|Device|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
277575|NCT02688842|Device|Rapamycin target-eluting coronary stent systems (38mm)|
276687|NCT02706600|Behavioral|myCOPD|myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.
Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.
Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.
A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients.
276688|NCT02706600|Behavioral|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
276689|NCT02706613|Behavioral|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
276983|NCT02700113|Other|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
276984|NCT02700139|Device|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
276985|NCT02700152|Device|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
276986|NCT02700165|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments. Cryolipolysis is the technology of the non-invasive treatments.
276987|NCT02700178|Other|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
276988|NCT02700191|Device|uCor|
276989|NCT02700204|Device|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
276990|NCT02700204|Device|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
276991|NCT00202124|Drug|Tryptophan|
276992|NCT02700217|Procedure|Bupivacaine and Diamorphine|
276993|NCT02700217|Procedure|Remifentanil, Propofol and Cistracurium|
276994|NCT02700217|Procedure|Bupivacaine and Rectus Sheath injection|
276353|NCT02708654|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
276354|NCT02708654|Behavioral|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
276355|NCT02710487|Behavioral|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
276356|NCT02710500|Drug|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
276357|NCT02710513|Dietary Supplement|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
276358|NCT02710526|Drug|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
276359|NCT02710539|Drug|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
276360|NCT02710539|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
276361|NCT02710552|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
276362|NCT00203372|Drug|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
276363|NCT02710552|Drug|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
276364|NCT02710565|Other|Cohort|Obtaining additional EBUS TBNA samples for cell culture
276365|NCT02710578|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
276366|NCT02710578|Drug|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
276690|NCT02706613|Behavioral|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
276691|NCT02706626|Drug|brigatinib|Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
276692|NCT02706665|Other|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
276693|NCT00202917|Drug|OKT-3|
276061|NCT02714543|Drug|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
276062|NCT02714543|Drug|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
276063|NCT02714543|Drug|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
276064|NCT02714543|Drug|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
276065|NCT00203866|Drug|IL-2|
276066|NCT02714556|Other|Physiologic measures of lung function|Respiratory function tests:
Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)
276067|NCT02714569|Drug|LY3202328|Administered orally
276068|NCT02714569|Drug|Placebo|Administered orally
276069|NCT02714569|Drug|Atorvastatin|Administered orally
276070|NCT02714569|Drug|Simvastatin|Administered orally
276071|NCT02714582|Behavioral|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson & Mangino 2006).
276072|NCT02714595|Drug|S-649266|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function).
276073|NCT02716766|Drug|Sorafenib|PO
276074|NCT02716766|Drug|Capecitabine|PO
276075|NCT02716766|Drug|Oxaliplatin|IV
276076|NCT02716779|Drug|Pegylated Interferon (PEG-INF) alfa-2a|Participants with chronic hepatitis C, genotype 1 will receive Pegylated Interferon (PEG-INF) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks. Thereafter, all participants will receive combination therapy with PEG-INF alfa-2a (40KD) plus ribavirin (1000 to 1200 milligram [mg] orally [PO]) for 12 weeks which may be followed further for 36 weeks depending on initial virological response.
276077|NCT02716779|Drug|Placebo|Participants with chronic hepatitis C, genotype 1 will receive ribavirin matching placebo PO for 6 weeks.
276078|NCT00204087|Behavioral|Supportive Counselling (SC)|
276367|NCT02710591|Drug|Rimeporide|Cohort 1:
50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight > 30kg at Baseline
Cohort 2:
100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight > 30kg at Baseline
Cohort 3:
150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight > 30kg at Baseline
Cohort 4:
200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight > 30kg at Baseline
272137|NCT02341495|Drug|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
272138|NCT02341495|Drug|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
272139|NCT02341508|Biological|0.5 mg/kg Lpathomab|
272140|NCT02341508|Biological|1.0 mg/kg Lpathomab|
272141|NCT02341508|Biological|3.0 mg/kg Lpathomab|
272142|NCT02341508|Biological|10 mg/kg Lpathomab|
272143|NCT02341508|Biological|20 mg/kg Lpathomab|
272144|NCT02343614|Drug|Celecoxib|
272145|NCT02343627|Drug|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
272146|NCT02343627|Drug|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
272147|NCT02343653|Behavioral|Nutrition and strength training|All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:
Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.
The intervention group will receive supervised training.
272148|NCT02343653|Behavioral|Nutrition|All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:
Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.
272149|NCT02343666|Biological|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
272150|NCT02343666|Drug|Carmustine|Given IV
272151|NCT00000354|Drug|Lofexidine|
272152|NCT00002407|Drug|Indinavir sulfate|
272153|NCT00156962|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
272154|NCT02343666|Biological|Filgrastim|Given SC
272155|NCT02343666|Other|Laboratory Biomarker Analysis|Correlative studies
272156|NCT02343666|Drug|O6-Benzylguanine|Given IV
271535|NCT02352870|Other|Computerised Cognitive Behavioural Therapy|Online treatment sessions are schedules to last approximately one our, completed independently by the participant on a weekly basis
271536|NCT02352870|Other|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
271537|NCT02352883|Procedure|Magnetic Resonance Imaging|Undergo MRI
271538|NCT02352883|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy
271843|NCT02348073|Drug|Vayarin®, supplementation of n-3 PUFA|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product.
271844|NCT02348073|Drug|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
271845|NCT02348099|Other|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
271846|NCT02348112|Device|Altis Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
271847|NCT00157677|Procedure|D-dimer testing|Selective D-Dimer use
271848|NCT02348112|Device|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
271849|NCT02348125|Drug|Mitochondrial Cocktail|
271850|NCT02348138|Other|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
271851|NCT02348151|Other|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
271852|NCT02348151|Other|Corridor|The volunteers will perform the shuttle walk test on the corridor
271853|NCT02348164|Other|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
271854|NCT02350478|Drug|Placebo|The subject will receive placebo orally once daily for 12 weeks.
271855|NCT02350491|Other|Collection of biological samples|
271232|NCT02321618|Behavioral|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
271233|NCT00153530|Radiation|radiotherapy|whole-brain irradiation
271234|NCT02321618|Behavioral|BP educational materials|Exposure to hypertension educational materials
271235|NCT02321631|Dietary Supplement|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
271236|NCT02321631|Dietary Supplement|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
271237|NCT02321644|Drug|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
271238|NCT02321657|Other|iPad app containing art, music and games|An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
271239|NCT02321657|Other|Toys, books and games|Games, books and toys used to distract
271240|NCT02321670|Procedure|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
271539|NCT02352883|Procedure|Therapeutic Surgical Procedure|Undergo wide local excision
271540|NCT02352883|Radiation|Radiation Therapy|Undergo radiation therapy
271541|NCT00158275|Drug|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
271542|NCT02352883|Drug|Endocrine Therapy|Undergo endocrine therapy
271543|NCT02352883|Other|Quality-of-Life Assessment|Ancillary studies
271544|NCT02352883|Other|Laboratory Biomarker Analysis|Correlative studies
271545|NCT02352883|Other|Cytology Specimen Collection Procedure|Correlative studies
271546|NCT02352896|Drug|EPI-743|EPI-743 is a quinone oxidation product of alpha tocotrienol
271547|NCT02352909|Other|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
271548|NCT02352909|Other|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
270943|NCT02326727|Drug|Propofol|General Anesthesia
270944|NCT02326727|Drug|Isoflurane|General Anesthesia
270945|NCT00154024|Drug|irbesartan|
270946|NCT02326727|Drug|Nitrous Oxide|General Anesthesia
270947|NCT02326740|Drug|gevokizumab|
270948|NCT02326740|Drug|Placebo|
270949|NCT02326740|Drug|gevokizumab open-label|
270950|NCT02326753|Device|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
270951|NCT02326753|Device|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
270952|NCT02326753|Device|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
270953|NCT02329080|Drug|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
270954|NCT02329080|Drug|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
270955|NCT02329080|Drug|Etoposide|Etoposide 100 mg/m2/d in 250 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
270956|NCT02329080|Drug|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
270957|NCT02329080|Drug|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL saline sol. in 1-hr infusion on day-6 of conditioning and ASCT
270958|NCT02329080|Radiation|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
270959|NCT02329093|Procedure|To MRI-detecting bone signal changes in radiographic hip OA|
271241|NCT02321670|Procedure|Graft|Incicion of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
271242|NCT02321683|Device|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
271243|NCT02321696|Device|Acupuncture|
271244|NCT00002392|Drug|Thalidomide|
270352|NCT02340637|Behavioral|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
270353|NCT02340637|Behavioral|TAU|Treatment as usual
270354|NCT02340650|Device|High Resolution Microendoscope|
270355|NCT02340663|Device|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
270356|NCT02340663|Device|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
270357|NCT02340676|Procedure|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
270358|NCT02340676|Drug|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
270655|NCT02333643|Drug|Furosemide|
270656|NCT02333643|Drug|Digoxin|
270657|NCT02333643|Drug|Vehicle topical|
270658|NCT02333656|Other|New OA model|The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at "Healthy Living Center" or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist.
270659|NCT02333669|Other|no intervention|no intervention
270660|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
270661|NCT00155259|Drug|Docetaxel , Cisplatin , Capecitabine|
270662|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
270663|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
270664|NCT02333682|Dietary Supplement|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
270665|NCT02333695|Device|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
270068|NCT02345135|Behavioral|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
270069|NCT02345148|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
270070|NCT02345161|Drug|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
270071|NCT02345161|Drug|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
270072|NCT02345161|Drug|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
270073|NCT02345161|Drug|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
270074|NCT02345161|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
270075|NCT02345174|Drug|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
270076|NCT02345174|Drug|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
270077|NCT02347098|Device|LDL-apheresis|The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
270359|NCT02340689|Other|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
270360|NCT02340702|Other|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of <0.7.
270361|NCT02340728|Device|ERCP with SEMS plus radiofrequency ablation|
270362|NCT00156611|Procedure|Balloon Angioplasty|
270363|NCT02340728|Device|ERCP with SEMS alone (standard of care)|
270364|NCT02340741|Procedure|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
269779|NCT02352103|Device|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
269780|NCT02352116|Other|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
269781|NCT02352116|Other|Standard of care management|Current standard of care at a major U.S. teaching hospital.
269782|NCT02352129|Other|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
269783|NCT02352142|Other|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
269784|NCT02352142|Behavioral|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
269785|NCT02352155|Procedure|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
269786|NCT02352155|Other|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
269787|NCT02352168|Drug|Budesonide nasal spray|64mcg/1putt, 1 putt/nostril,b.i.d
269788|NCT00158223|Drug|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
269789|NCT02352168|Drug|Placebo|1 putt/nostril,b.i.d
269790|NCT02352181|Procedure|Conventional coagulation profile Analysis|Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if fibrinogen <1gram per liter
Platelet concentrate :
if platelets <50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.
if platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :
if prothrombin<40% before transfusion at anhepatic phase or in case of bleeding.
if prothrombin<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.
Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.
Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF).
270078|NCT02347111|Drug|Flecainide|
270079|NCT02347111|Drug|Sotalol|
270080|NCT02347124|Behavioral|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
269505|NCT02320929|Procedure|Intraoperative flexor tendon sheath irrigation|
269791|NCT02352181|Procedure|Rotem analysis|Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM <8 mm
Platelet concentrate :
If MCF EXTEM <40mm or A10<35 mm and MCF or A10 FIBTEM >8mm.
If platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding.
2 Fresh frozen plasma if CT EXTEM >100s.
Bolus Tranexamic acid 1g and 3g every 24 hours :
if fibrinolysis in EXTEM
Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes >15%.
Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).
Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.
269792|NCT02315677|Device|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
269793|NCT02315690|Drug|dihydroartemisinin-piperaquine|In the TPE arm, all individuals in the Target Area will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
269794|NCT02315690|Procedure|reactive case detection|Individuals in RACD Target Areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
269795|NCT02315703|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
269796|NCT02315703|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
269797|NCT02315703|Biological|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
269798|NCT02315703|Biological|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
269799|NCT02315703|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
269800|NCT00152958|Drug|Pramipexole|
269801|NCT02315716|Procedure|ASCT|Randomisation to melphalan conditioned autologous stem cell transplant
269802|NCT02315716|Drug|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
269803|NCT02315742|Behavioral|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
274189|NCT02328287|Drug|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
274190|NCT02330432|Biological|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
274191|NCT02330432|Other|Best standard care|Antibiotics as early as possible; Norepinephrine > vasopressin > epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
274192|NCT02330445|Drug|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
274193|NCT02330458|Procedure|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall >3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
269506|NCT02320929|Procedure|Postoperative flexor tendon sheath irrigation|
269507|NCT02320942|Other|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
269508|NCT02320955|Procedure|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
269509|NCT02320968|Device|MedclineTM Sleep Assist Device|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
269510|NCT02323425|Device|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
269511|NCT00153686|Procedure|capsule endoscopy|capsule endoscopy of small intestine
269512|NCT02323438|Other|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
269513|NCT02323438|Other|Electronic Cigarette #1|Electronic cigarette
269514|NCT02323438|Other|Electronic Cigarette #2|Electronic cigarette
269515|NCT02323438|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
278431|NCT02707315|Drug|Gemcitabine|
278432|NCT02707315|Radiation|Stereotactic Radiosurgery|
278433|NCT02707328|Drug|Gemcitabine|
278434|NCT02707328|Drug|nab-paclitaxel|
278435|NCT02707328|Radiation|CyberKnife|
278436|NCT02707354|Device|Probe based confocal laser endomicroscopy (Cellvizio)|The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a "live virtual biopsy", that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data.
278437|NCT00202995|Drug|Betaseron|250 mg every other day
278723|NCT02700945|Device|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
278724|NCT02700958|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
278725|NCT02700958|Procedure|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
278726|NCT02700971|Procedure|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
278727|NCT02700984|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of uncomplicated cataract surgery.
278728|NCT02700984|Procedure|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
278729|NCT02700997|Device|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
278730|NCT02702960|Radiation|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
278731|NCT02702960|Procedure|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
278143|NCT02713230|Drug|Placebo|Normal saline in 20 mL.
278144|NCT02713243|Drug|LJN452|Capsules containing LJN452
278145|NCT02713243|Drug|Placebo to LJN452|Capsules containing placebo to LJN452
278146|NCT02713256|Drug|CFZ533|Patients will receive CFZ533 intravenously over approximately one hour
278147|NCT02713269|Procedure|Thermal Ablation Procedure|Thermal ablation procedure performed before spine stereotactic radiosurgery. Thermal ablation heats tumor tissue using a laser, and helps to shrink the tumor by destroying tumor cells.
278148|NCT00203736|Drug|Sulfadoxine-pyrimethamine|
278149|NCT02713269|Radiation|Stereotactic Spine Radiosurgery (SSRS)|Treatment delivered in 1 or 3 fractions per treating physician. One fraction: Gross tumor volume (GTV) prescribed to 24 or 18 Gy in a single fraction depending on the tumor histology. Radioresistant histologies such as renal cell carcinoma, sarcoma and melanoma treated to 24 Gy, and radiosensitive tumor such as breast cancer and non-small lung cancer treated to 18 Gy. Clinical target volume (CTV) prescribed to 16 Gy in a single fraction. Three fractions: GTV prescribed to 24 or 27 Gy in 3 fractions, and the CTV prescribed to 21 Gy in 3 fractions.
278438|NCT02707367|Behavioral|Recovery Roadmap (RR)|A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. Participants in the RR intervention will use the tool in Year 2, Quarter 1 (Y2Q1), Y2Q2, and Y2Q3. There are 3 components:
Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.
Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.
Coaching & Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library.
278439|NCT02707367|Behavioral|Illness Management and Recovery (IMR)|IMR is an established evidence-based practice that helps people set meaningful goals for themselves, acquire information and skills to develop more mastery over their psychiatric illness, and make progress towards their own personal recovery. For this study, the IMR intervention will arise from established use of the intervention in enrolled programs.
278440|NCT02707380|Other|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
278441|NCT02707380|Other|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
278442|NCT02707393|Drug|Fludarabine|infusion
278443|NCT02707393|Drug|Thiotepa|infusion
278444|NCT02707393|Drug|Melphalan|infusion
278445|NCT02707393|Drug|ATG|infusion
278446|NCT02707393|Drug|Cyclosporine A|infusion, orally if possible
278447|NCT02707393|Drug|Mycophenolate mofetil|infusion
278448|NCT02709304|Drug|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
277857|NCT02717572|Device|Computerized Tomography|
277858|NCT02717572|Device|Magnetic Resonance Imaging|
277859|NCT02717585|Device|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
277860|NCT02684162|Procedure|Donor Lymphocyte Infusion|On Day 6 of Cycles 2, 4, and 6, participants receive a donor lymphocyte infusion by vein over about 10-30 minutes.
277861|NCT02684175|Device|Remote CI Counseling|The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
277862|NCT02684175|Other|In-Person CI Counseling|The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
277863|NCT02684188|Other|Enhanced Transitions Planning|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
277864|NCT00200187|Procedure|low venous pressure general anesthesia|
277865|NCT02684201|Device|Boston Scientific Stimulator Lead|A Boston Scientific PMA P030017 spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
278150|NCT02713269|Behavioral|Symptom Questionnaires|Symptom questionnaires completed at baseline and at follow up months 1, 3, 6, 9, 12, then every 6 months.
278151|NCT02713282|Drug|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
278152|NCT02713308|Other|Device programming|
278153|NCT02713334|Behavioral|survey|
278154|NCT02713334|Behavioral|semi-structured interview|
278155|NCT02713347|Behavioral|ADAPT Intervention|The intervention includes 3 components:
nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.
social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.
collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist.
277576|NCT02688855|Device|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
277577|NCT02688855|Device|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|
277578|NCT02688868|Device|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
277579|NCT02688881|Drug|sirolimus|
277580|NCT02688894|Other|No treatment is included in this protocol.|Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.
Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.
277581|NCT02688907|Drug|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first & second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
277582|NCT02688920|Procedure|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
277583|NCT02688933|Drug|Insulin glargine (U300) HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
277584|NCT00200772|Drug|Sutherlandia frutescens, subspecies microphylla (an herb)|
277585|NCT02688933|Drug|Insulin glargine HOE901|Pharmaceutical form:Solution Route of administration: subcutaneous
277586|NCT02688933|Drug|Insulin glulisine HMR1964|Pharmaceutical form:Solution Route of administration: subcutaneous
277587|NCT02688933|Drug|Insulin aspart|Pharmaceutical form:Solution Route of administration: subcutaneous
277588|NCT02691208|Other|Kinesiotherapy|Compare the standard treatment of pain, by kinesioterapy versus kinesioterapy associated with the acupuncture.
277589|NCT02691221|Behavioral|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
277590|NCT02691234|Device|Extracorporeal Shockwave Therapy and debridement|
277591|NCT02691234|Other|debridement and cleaning|
277592|NCT02691247|Biological|CLBS03 Low Dose|
277593|NCT00201058|Behavioral|Tailored Web-based Asthma Management|Web-based asthma management
277594|NCT02691247|Biological|CLBS03 High Dose|
276995|NCT02700230|Procedure|Computed Tomography|Undergo CT scan
276996|NCT02700230|Other|Laboratory Biomarker Analysis|Correlative studies
276997|NCT02700230|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
276998|NCT02700230|Other|Quality-of-Life Assessment|Ancillary studies
276999|NCT02700230|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT imaging
277000|NCT02702206|Drug|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
277001|NCT02702219|Behavioral|Mobility of the hamstrings muscles|
277002|NCT02702232|Other|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
277003|NCT02702245|Dietary Supplement|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
277293|NCT00201695|Drug|Doxil®|40 mg/m2 IV day 1
277294|NCT02696005|Other|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
277295|NCT02696018|Device|Ultrasonography|Ultrasonographic assessment of the diaphragm function
277296|NCT02696031|Drug|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
277297|NCT02696031|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
277298|NCT02696031|Drug|Secukinumab|150 mg Secukinumab s.c. monthly
277299|NCT02696044|Drug|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
277300|NCT02696057|Other|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
277301|NCT02696057|Other|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
277302|NCT02696070|Device|Provant Therapy System|
277303|NCT02696083|Device|Provant Therapy System|
277304|NCT00201695|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
276694|NCT02706678|Drug|Tacrolimus sustained-release capsule|Oral
276695|NCT02706691|Drug|BGJ398|125 mg daily of BGJ398 for 21 days on and 7 days off (28-day cycle)
276696|NCT02706704|Drug|Adalimumab|
276697|NCT02706717|Drug|Visibiome|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
276698|NCT02706717|Drug|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
276699|NCT02706730|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
276700|NCT02706756|Other|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
276701|NCT02706756|Other|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
276702|NCT02706756|Other|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
276703|NCT02706756|Other|Supervised neglect|Monitoring of group without formal intervention.
276704|NCT00202917|Procedure|CD3/CD19 depletion on CliniMACS|
276705|NCT02706769|Drug|Placebo|Study medication contains blinded placebo
276706|NCT02706769|Drug|Paracetamol|Study medication contains blinded paracetamol
276707|NCT02706782|Drug|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
276708|NCT02706795|Biological|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
276709|NCT02708654|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
276710|NCT02708680|Drug|entinostat|An orally available histone deacetylases inhibitor (HDAC)
276711|NCT02708680|Drug|atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
277004|NCT00202410|Other|placebo|subcutaneous administration of physiologic solution
277005|NCT02702245|Dietary Supplement|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
276368|NCT02710604|Drug|CMX157|tablet
276369|NCT02710604|Drug|TDF|300mg tablet
276370|NCT02710617|Device|Blood glucose monitoring systems for point-of-care-testing|
276371|NCT02710630|Drug|Dabigatran etexilate tablet E1|
276372|NCT02710630|Drug|Dabigatran etexilate tablet D1|
276373|NCT00203372|Drug|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
276374|NCT02710630|Drug|Dabigatran etexilate tablet C1|
276375|NCT02710630|Drug|Dabigatran etexilate tablet B1|
276376|NCT02710630|Drug|Dabigatran etexilate tablet A1|
276377|NCT02710630|Drug|Dabigatran etexilate capsule|
276378|NCT02710643|Drug|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
276379|NCT02710656|Device|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
276380|NCT02712515|Device|Ad-Tech Medical Instrumentation Corp. device|Ad-Tech Medical Instrumentation Corp. device is an intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
276381|NCT02712515|Device|FHC Guideline 4000+ system|Brain signals will be recorded using the clinical FHC Guideline 4000+ system, which is capable of recording during stimulation.
276382|NCT02712528|Drug|remifentanil-based|
276383|NCT02712528|Drug|sevoflurane-sufentanil balanced|
276384|NCT02712554|Drug|Treatment A low dose CL-108|Treatment A low dose CL-108
276385|NCT02712554|Drug|Treatment B high dose CL-108|Treatment B high dose CL-108
276386|NCT02712554|Drug|Treatment C low dose M366|M366 Low Dose
276387|NCT02712554|Drug|Treatment D high dose M366|M366 High Dose
276388|NCT02712554|Drug|Placebo|Placebo
276389|NCT00203593|Behavioral|Total Peripheral Resistance|
276390|NCT02712567|Drug|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
272443|NCT02336906|Drug|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
272444|NCT02336906|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
272445|NCT02336906|Behavioral|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
272446|NCT00156065|Drug|Haloperidol|2-8 mg BID
272447|NCT02339220|Behavioral|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
272448|NCT00156299|Drug|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
272449|NCT02339220|Behavioral|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
272450|NCT02339233|Biological|Locomotor Training|Standing and Stepping in a body weight support (BWS) harness on a treadmill with/out EMG evaluation
272451|NCT02339246|Drug|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
272452|NCT02339246|Drug|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
272453|NCT02339259|Other|Observation|
272454|NCT02339272|Other|non interventional|
272455|NCT02339285|Device|tACS (alpha)|
272456|NCT02339285|Device|tACS (gamma)|
272457|NCT02339298|Other|music application|music is applied during anaesthesia using headphones
272458|NCT02339298|Other|only headphones|music is not applied, only headphones are placed
272459|NCT00156312|Drug|Docetaxel|
272460|NCT02339298|Drug|a caudal block|
271856|NCT02350504|Behavioral|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
271857|NCT02350517|Drug|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
271858|NCT02350530|Drug|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
271859|NCT02350530|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
271860|NCT02350543|Drug|Aspirin|
272157|NCT02343666|Drug|Plerixafor|Given SC
272158|NCT02343679|Drug|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
272159|NCT02343692|Procedure|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
272160|NCT02343705|Device|Latella Knee Implant System|
272161|NCT02343718|Drug|Vinblastine|
272162|NCT02343718|Drug|Temsirolimus|
272163|NCT02343731|Other|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
272164|NCT00156962|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
272165|NCT02343744|Drug|Guselkumab|Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined "Very much improved" or "Much improved" in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined "No change" or "Worsened" in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined "Minimally improved" in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary.
272166|NCT02345772|Drug|Docetaxel (T) 75 mg/m2 (Taxotere)|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
272167|NCT02345772|Drug|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
271549|NCT02352909|Other|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
271550|NCT02352922|Drug|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
271551|NCT02316561|Radiation|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
271552|NCT00152997|Drug|Pramipexole 0.125 mg tablets Placebo|
271553|NCT02316574|Behavioral|Cognitive Behavioral Coping Skills Therapy|Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or "cope" with alcohol cravings and other emotions that promote alcohol use.
271554|NCT02316600|Device|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
271555|NCT02316613|Drug|Rituximab|
271556|NCT02316626|Drug|Subcutaneous progesterone|25 mg daily for 14 days
271557|NCT02316626|Drug|Vaginal progesterone|90 mg daily for 14 days
271558|NCT02316639|Other|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
271559|NCT02316652|Procedure|Scaling and root planing|Mechanical instrumentation
271861|NCT00158002|Drug|Topiramate|
271862|NCT02350556|Other|Dynamic Avoidance Task|
271863|NCT02350556|Procedure|physical therapy|
271864|NCT02350556|Device|3D motion on optoelectronic device|
271865|NCT02350569|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally
271866|NCT02350582|Device|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
271867|NCT02350595|Other|Lean fish|
271868|NCT02350595|Other|Fatty fish|
271869|NCT02350608|Device|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
271870|NCT02350621|Procedure|ACDF|
271245|NCT00153543|Biological|Pneumococcal polysaccharide vaccine|
271246|NCT02321696|Other|Physiotherapy and eccentric exercise|
271247|NCT02321696|Other|Watchful waiting and eccentric exercise|
271248|NCT02321696|Other|eccentric exercise|
271249|NCT02321709|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
271250|NCT02321709|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
271251|NCT02321735|Behavioral|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
271252|NCT02321748|Drug|Montelukast|
271253|NCT02321748|Drug|ASP2151|
271254|NCT02321761|Drug|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
271255|NCT02321787|Procedure|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
271256|NCT00153543|Biological|Pneumococcal conjugate vaccine|
271257|NCT02324218|Other|Data collection|Data extraction from CPRD database of UK.
271258|NCT00153790|Drug|PhosphoLean|
271259|NCT02324231|Other|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
271260|NCT02324231|Other|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
271261|NCT02324257|Drug|RO6958688|RO6958688 administered intravenously, once per week (QW) schedule
271262|NCT02324270|Drug|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
271263|NCT02324270|Other|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
271560|NCT02316652|Procedure|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
271561|NCT02316665|Device|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
270666|NCT02333708|Other|Blood sample|
270667|NCT02333721|Procedure|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
270668|NCT02336074|Drug|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
270669|NCT02336074|Drug|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
270670|NCT02336074|Drug|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).
Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
270671|NCT02336074|Biological|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at week 24.
270960|NCT02329106|Device|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
270961|NCT00154284|Drug|Steroid|Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
270962|NCT02329119|Other|electrophysiological recordings|
270963|NCT02329132|Drug|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
270964|NCT02329145|Procedure|renal denervation|
270965|NCT02329158|Drug|6% hydroxyethyl starch|
270966|NCT02329171|Drug|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
270967|NCT02329171|Procedure|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
270968|NCT02329184|Drug|MYK-461|
270969|NCT02329197|Drug|Human Chorionic Gonadotropin (HCG)|intrauterine injection of HCG prior to embryo transfer in an IVF cycle
270365|NCT02340741|Procedure|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
270366|NCT02340741|Procedure|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
270367|NCT02340754|Behavioral|Mindfulness-based Stress Reduction|
270368|NCT02340754|Behavioral|MS Education Control|
270369|NCT02340767|Device|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
270370|NCT02340767|Device|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
270371|NCT02340780|Drug|Buparlisib|
270372|NCT02340793|Dietary Supplement|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of >15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
270373|NCT00002403|Drug|Zintevir|
270374|NCT00156611|Drug|ReoPro|
270375|NCT02342938|Procedure|MEG or fMRI And INtracranial EEG|
270376|NCT02342938|Procedure|fMRI|
270377|NCT02342951|Other|Lung clearance index determination|Lung clearance index determination
270378|NCT02342964|Other|Measure of hepatic elasticity|Measure of hepatic elasticity by four non-invasive methods:
Fibroscan, Fibrotest, SWE, MRE.
270379|NCT02342977|Drug|Placebo|Patients will randomly receive placebo
270380|NCT02342977|Drug|Lacosamide|Patients will randomly receive lacosamide
270672|NCT02336074|Biological|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at week 32 Day 1 (2 prior to start of vorinostat)
270673|NCT02336087|Drug|Gemcitabine Hydrochloride|Given IV
270674|NCT02336087|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
270675|NCT00155883|Drug|Leucovorin|
270676|NCT02336087|Drug|Metformin Hydrochloride|Given PO
270081|NCT02347124|Behavioral|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
270082|NCT02347137|Other|step-reduction|reduce daily physical activity to less than 1500 steps per day
270083|NCT02347137|Other|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
270084|NCT02347163|Drug|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
270085|NCT00157573|Drug|GM-CSF, Leukine|GM-CSF 150 mcg given subcutaneously daily without interruption
270086|NCT02347176|Biological|Subcutaneous Injection 1|Subcutaneous injection with tralokinumab
270087|NCT02347176|Biological|Subcutaneous Injection 2|Subcutaneous injection with tralokinumab
270088|NCT02347176|Biological|Subcutaneous Injection 3|Subcutaneous injection with tralokinumab
270089|NCT02347176|Other|Subcutaneous Injection 4|Subcutaneous injection with placebo
270090|NCT02347189|Device|Melody Transcatheter Pulmonary Valve PB1016|
270091|NCT02347202|Other|Online counseling via Zoom teleconferencing|
270092|NCT02347202|Other|Telephone support as needed|
270093|NCT02347215|Other|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
270094|NCT02347215|Procedure|Stress imaging|Stress imaging
270095|NCT02347228|Drug|OB318 capsule|Oral qd, at least 30 minutes before breakfast
270096|NCT00157586|Drug|Delapril, Delapril-Manidipine Fixed combination|
270097|NCT02347241|Other|Educational intervention|Educational Debriefings and High frequency training and team reflection
270098|NCT02347254|Device|Transcranial ExAblate|Transcranial ExAblate MRgFUS
270099|NCT02347267|Behavioral|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
270100|NCT02347267|Behavioral|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
269804|NCT02315768|Drug|GA101|
269805|NCT02315768|Drug|ibrutinib|
269806|NCT02315781|Device|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
270101|NCT02349672|Procedure|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
270102|NCT02349685|Procedure|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute [amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC > 1.0 μ g / ml; metronidazole (MET), MIC > 8 μ g / ml; tetracycline (TC), MIC > 4 μ g / ml; and moxifloxacin (MOX), MIC > 1 μ g / ml).
270103|NCT02349685|Drug|14 day PBMT group|Rescue therapy using 14 day PBMT regimen [Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d]
270104|NCT02349685|Drug|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
270105|NCT00157911|Drug|Comparator: simvastatin / Duration of Treatment: 12 weeks|
270106|NCT02349698|Biological|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
270107|NCT02349711|Dietary Supplement|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
270108|NCT02349711|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
270109|NCT02349724|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
270110|NCT02349737|Other|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
270111|NCT02349750|Procedure|endometrial scratch injury|ESI using No.8 neonatal feeding tube
270112|NCT02349763|Drug|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
270113|NCT02349763|Drug|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
269516|NCT02323451|Device|Medical Chitosan|intra-articular injection
269517|NCT02323451|Drug|Sodium Hyaluronate Injection|intra-articular injection
269518|NCT02323464|Procedure|Surgery for colorectal cancer|We are investigating patients before and after planned surgery for colorectal cancer.
269519|NCT02323477|Biological|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
269520|NCT02323490|Procedure|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
269521|NCT02323490|Procedure|without microfractures|standard procedure meniscal repair without augmentation.
269522|NCT00153686|Procedure|Mesenteric Angiogram|Mesenteric Angiogram
269523|NCT02323503|Device|CRT-D device replacement|
269524|NCT02323516|Drug|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
269807|NCT02315781|Device|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
269808|NCT02315794|Device|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
269809|NCT02315794|Device|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
269810|NCT02315807|Device|transcranial direct current stimulation|
269811|NCT00152971|Drug|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
269812|NCT02315820|Procedure|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
269813|NCT02315833|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
269814|NCT02318472|Device|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
269815|NCT02318472|Device|Plaster cast|Lower limb plaster cast
269816|NCT02318485|Biological|Limbal epithelial stem cell graft|
269817|NCT02318498|Procedure|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
269818|NCT02318511|Procedure|Knee injection|Injection into knee for the treatment of Osteoarthritis
278732|NCT02702960|Drug|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
278733|NCT02702960|Drug|Mesna|administered on Days 3 and 4 with PTCy
278734|NCT00202501|Device|Nasal CPAP (Continuous Positive Airway Pressure)|
278735|NCT02702960|Drug|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
278736|NCT02702960|Drug|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
278737|NCT02702960|Drug|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
278738|NCT02702960|Drug|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
278739|NCT02702960|Drug|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
279026|NCT02696642|Drug|Anetumab ravtansine (BAY94-9343)|All subjects will receive anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
279027|NCT02696655|Behavioral|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
279028|NCT02696668|Other|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
279029|NCT02696668|Other|Multisensory|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:
Limits of stability training with eyes open / eyes closed
Self induced movement strategies with eyes open / eyes closed
Gaze stability exercises in sitting / standing / walking
Sensory integration
Habituation exercises
279030|NCT02696681|Behavioral|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
279031|NCT02696694|Other|Progesterone 25-75|Impact of serum progesterone concentrations [25-75] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
279032|NCT00201734|Drug|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
279033|NCT02698618|Procedure|PCI|Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated
PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.
Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR).
278449|NCT02709317|Behavioral|Prevention Intervention|
278450|NCT02709317|Behavioral|Brief Intervention|
278451|NCT02709330|Drug|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
278452|NCT02709330|Other|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
278453|NCT02709343|Drug|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
278454|NCT02709343|Drug|Placebo|Placebo product visually very similar to mesenchymal stromal cells
278455|NCT02709356|Dietary Supplement|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
278456|NCT00203229|Drug|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
278457|NCT02709356|Dietary Supplement|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day
278740|NCT02702960|Drug|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
278741|NCT02702973|Other|Observe the fundus characteristics after therapy.|
278742|NCT02702986|Procedure|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
278743|NCT02702986|Device|Laser|
278744|NCT02702999|Device|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
278745|NCT00202514|Drug|divalproex sodium extended release|
278746|NCT02702999|Device|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
278747|NCT02703012|Other|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
278748|NCT02703025|Dietary Supplement|GCB-70|green coffee bean extract
278749|NCT02703051|Drug|GMI-1271|
278750|NCT02703051|Drug|Filgrastim|
278156|NCT02713360|Behavioral|Cognitive Therapy|
278157|NCT02713373|Biological|Cetuximab|Given IV
278158|NCT02713373|Other|Laboratory Biomarker Analysis|Correlative studies
278159|NCT00203736|Drug|Artesunate plus sulfadoxine-pyrimethamine|
278160|NCT02713373|Biological|Pembrolizumab|Given IV
278161|NCT02713386|Drug|Carboplatin|Given IV
278162|NCT02713386|Other|Laboratory Biomarker Analysis|Correlative studies
278163|NCT02715401|Drug|HGP1201|
278164|NCT02715401|Drug|HIP1402|
278165|NCT02715414|Behavioral|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
278166|NCT02715414|Behavioral|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
278167|NCT02715427|Other|Conventional care|
278168|NCT02715427|Other|Enhanced recovery|
278169|NCT02715440|Drug|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
278170|NCT00203931|Drug|Pemetrexed|
278458|NCT02709369|Device|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
278459|NCT02709382|Drug|Cefepime and Tazobactam combination|
278460|NCT02709395|Device|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
278461|NCT02709434|Behavioral|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
278462|NCT02709434|Other|Standard care|Usual IBD management
277866|NCT02684214|Behavioral|Newsletters|Families will receive 6 monthly newsletters.
277867|NCT02684214|Behavioral|Prevention Plus +|Families will meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
277868|NCT02684214|Behavioral|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
277869|NCT02684227|Drug|Enzalutamide|Safety Lead-in Phase (Part A) Starting Dose: 160 mg by mouth daily of a 21 day cycle.
Phase II (Part B) Starting Dose: Maximum tolerated dose (MTD) from Safety Lead-in Phase (Part A). Enzalutamide taken every day by itself during the first cycle (called Cycle 0).
277870|NCT02684227|Drug|Carboplatin|Safety Lead-in Phase (Part A) Starting Dose: AUC= 5 by vein on Day 1 of Cycles 1 - 9 of a 21 day cycle.
Phase II (Part B) Starting Dose: Maximum tolerated dose (MTD) from Safety Lead-in Phase (Part A). Carboplatin given by vein on Day 1 of Cycles 1 - 9.
277871|NCT02684227|Drug|Paclitaxel|Safety Lead-in Phase (Part A) Starting Dose: 175 mg/m2 by vein on Day 1 of Cycles 1 - 9 of a 21 day cycle.
Phase II (Part B) Starting Dose: Maximum tolerated dose (MTD) from Safety Lead-in Phase (Part A). Paclitaxel given by vein on Day 1 of Cycles 1 - 9.
277872|NCT02684240|Drug|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
277873|NCT02684240|Other|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
277874|NCT02684253|Drug|Nivolumab|
277875|NCT00200187|Procedure|combined spinal-epidural anesthesia|
277876|NCT02684253|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
277877|NCT02684266|Drug|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
277878|NCT02686567|Procedure|with TDT|a transanal drainage tube insert from the anus after laparoscopic anterior resection and double-stapling technique anastomosis were finished. And it will be retaind for 5-7days
277879|NCT02686567|Procedure|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
277880|NCT02686580|Biological|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
277881|NCT00200447|Procedure|[123I]-IBZM imaging|
277305|NCT02696096|Other|FMRI|all participants will complete 2 FMRIs
277306|NCT02696096|Drug|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
277307|NCT02696109|Behavioral|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
277308|NCT02696109|Behavioral|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
277309|NCT02698007|Device|Laryngeal Mask Airway|
277310|NCT02698020|Procedure|Room-air|Provision of room-air
277311|NCT00201851|Drug|Tamoxifen|20 mg po daily x 5 years
277312|NCT02698033|Drug|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
277595|NCT02691247|Biological|Placebo|
277596|NCT02691260|Behavioral|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
277597|NCT02691260|Behavioral|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
277598|NCT02691260|Behavioral|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
277599|NCT02691273|Behavioral|cellular application treating diabetes using breathing technique|
277600|NCT02691299|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
277601|NCT02691299|Drug|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
277602|NCT02691312|Device|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
277603|NCT02691325|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
277006|NCT02702245|Other|Placebo Comparator: Control|75 g pure glucose.
277007|NCT02702258|Behavioral|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
277008|NCT02702271|Device|WATCHMAN FLX LAA closure device|
277009|NCT02702284|Behavioral|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
277010|NCT02702284|Behavioral|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
277011|NCT02702297|Other|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
277012|NCT02702310|Other|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
277013|NCT02702310|Other|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
277014|NCT02702323|Drug|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
277015|NCT00202423|Drug|Sativex|
277016|NCT02702323|Procedure|TACE|one times every 4-6 weeks.
277017|NCT02702336|Behavioral|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
277018|NCT02702349|Other|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
277019|NCT02704507|Drug|Triamcinolone|topical application nightly to half the face for 4 weeks
277020|NCT02704507|Drug|Tretinoin|topical application nightly for 8 weeks
276712|NCT02708693|Drug|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort)
276713|NCT00203151|Drug|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
276714|NCT02708693|Device|thermoplastic wrist splint|thermoplastic wrist splint with wrist placed in a neutral position
276715|NCT02708693|Drug|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
276716|NCT02708706|Drug|hyaluronic acid (hyruan)|2cc hyaluronic acid
276717|NCT02708706|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
276718|NCT02708719|Procedure|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
276719|NCT02708745|Behavioral|Intervention Survey|
276720|NCT02708745|Behavioral|Placebo Survey|
276721|NCT02708758|Behavioral|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
276722|NCT02708771|Drug|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
276723|NCT02708771|Drug|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
276724|NCT00203164|Drug|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
276725|NCT02708797|Other|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
276726|NCT02708797|Other|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
276727|NCT02708810|Device|Framed Virtual Cone|If a head frame is used, the patient will be given a local anesthesia to numb their skin and make it easier to position the special head frame. The head frame wil be fixed in place with pins partially extending into the patient's skull. The head frame holds the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. The patient may be given a steroid medicine through an IV in their arm before the radiosurgery to prevent swelling of the brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The head frame will be removed after the treatment.
276728|NCT02710656|Device|Standard PTA|Percutaneous angioplasty performed with a standard balloon
272461|NCT02339311|Other|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
272741|NCT02332148|Drug|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
272742|NCT02332148|Drug|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
272743|NCT02332161|Other|surveys, evaluative tests for leg function|See outcome measures
272744|NCT02332174|Drug|rufinamide|comparison of different doses, sex and medication conditions
272745|NCT02332187|Device|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
272746|NCT02332187|Device|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
272747|NCT02334293|Drug|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
272748|NCT02334306|Biological|AMG 557/MEDI5872|Fixed subcutaneous (SC) dose of AMG 557/MEDI5872 every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.
272749|NCT02334306|Other|Placebo|Fixed SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.
272750|NCT02334319|Drug|Ganetespib|Given IV
272751|NCT02334319|Procedure|Therapeutic Conventional Surgery|Undergo surgery
272752|NCT02334319|Other|Laboratory Biomarker Analysis|Correlative studies
272753|NCT02334332|Other|Educational Intervention|Receive educational brochure
272754|NCT02334332|Procedure|Standard Follow-Up Care|Receive standard post-operative care
272755|NCT02334332|Procedure|Quality-of-Life Assessment|Ancillary studies
272756|NCT00155402|Drug|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
272757|NCT02334345|Drug|Evoskin|Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
272168|NCT02345772|Drug|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
272169|NCT02345785|Other|urologic surgery and caudal block|
272170|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
272171|NCT02345798|Procedure|Standard Follow-Up Care|Undergo usual care
272172|NCT02345798|Other|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
272173|NCT02345798|Other|Educational Intervention|Undergo video-assisted intervention
272174|NCT02345798|Other|Quality-of-Life Assessment|Undergo quality of life assessment
272175|NCT02345798|Other|Questionnaire Administration|Undergo questionnaire administration
272176|NCT02345824|Drug|Ribociclib|CDK4/6 INHIBITOR
272462|NCT02339324|Drug|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
272463|NCT02339337|Other|Abbreviation of treatment duration|
272464|NCT02339350|Drug|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
272465|NCT02339350|Drug|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
272466|NCT02339363|Behavioral|Sitting Meditation|4 weeks Sitting Meditation
272467|NCT02339363|Behavioral|Hatha yoga|4 weeks of Hatha yoga
272468|NCT02339376|Device|Low-frequency repetitive transcranial magnetic stimulation|
272469|NCT02341508|Other|Saline solution for intravenous infusion|
272470|NCT00156676|Device|Body-weight supported treadmill|
272471|NCT02341521|Drug|OC000459|Taken orally for 8 days
272472|NCT02341534|Device|BioMonitor|Patients will be implanted with the BioMonitor and receive best medical treatment according to guidelines.
272473|NCT02341547|Drug|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
271871|NCT02350621|Procedure|minimal invasive Posterior Cervical Foraminotomy|
271872|NCT00158028|Drug|Respiridone|
271873|NCT02350634|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
271874|NCT02350647|Device|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
271875|NCT02350647|Device|Suture anchor Twinfix Ultra HA|
271876|NCT02350660|Dietary Supplement|cow's milk|daily consumption of cow's milk
271877|NCT02350660|Dietary Supplement|peanut powder|peanut oral immunotherapy
271878|NCT02350673|Drug|MPDL3280A|Fixed dose of 800 mg MPDL3280A administered in combination with RO6895882 as an IV infusion every two weeks
271879|NCT02350673|Drug|RO6895882|RO6895882 administered in combination with MPDL3280A as an IV infusion every two weeks
271880|NCT02352922|Drug|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
271881|NCT00158275|Behavioral|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
271882|NCT02352935|Device|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
271883|NCT02352948|Drug|MEDI4736|MEDI4736 treatment by intravenous infusion
271884|NCT02352948|Drug|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
272177|NCT02345837|Device|endometrial sampling|injury to the endometrium
272178|NCT02345837|Drug|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
272179|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the day the last infusion is completed.
272180|NCT02345850|Procedure|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the day the last infusion is completed.
272181|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
271562|NCT02316665|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
271563|NCT00153010|Drug|NS 2330 (Tesofensine)|
271564|NCT02316678|Other|No intervention|There is no intervention
271565|NCT02316704|Device|THA with G7 PPS coted acetabular component|
271566|NCT02316704|Device|THA with G7 OsseoTi coted acetabular component|
271567|NCT02316717|Biological|IMM-124E|IMM-124E
271568|NCT02316717|Other|Placebo|Matched placebo
271569|NCT02316730|Drug|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
271570|NCT02316730|Drug|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
271571|NCT02316743|Drug|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
271572|NCT02316756|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
271573|NCT02316756|Drug|Placebo|Placebo which will be given as oral suspension
271574|NCT00153023|Drug|Telmisartan|
271575|NCT02316769|Device|Intubation with the King Vision video laryngoscope|
271576|NCT02316769|Device|Intubation with the McGrath MAC video laryngoscope|
271577|NCT00153179|Drug|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
271578|NCT02319291|Device|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
271579|NCT02319304|Drug|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
271580|NCT02319304|Radiation|Low dose fractionated radiation therapy (LDFRT)|see arm description
271581|NCT02319317|Behavioral|Risky driving prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
271582|NCT02319317|Behavioral|Control group general health promotion|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
270970|NCT02329223|Biological|Omalizumab|Omalizumab will be supplied as a lyophilized, sterile powder in a single-use vial.
270971|NCT02329223|Other|Placebo|Placebo will be supplied as a lyophilized, sterile powder in a single-use vial without study drug.
270972|NCT00154284|Drug|Basiliximab (Simulect)|
270973|NCT02329249|Behavioral|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
270974|NCT02329249|Other|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
270975|NCT02331251|Drug|Liposomal Doxorubicin|
270976|NCT02331264|Other|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
270977|NCT02331277|Drug|BI 655064|subcutaneous injection
270978|NCT02331277|Drug|Placebo|Placebo
271264|NCT02324283|Drug|desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.
Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.
271265|NCT02324283|Drug|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
271266|NCT02324296|Drug|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
271267|NCT02324309|Drug|BIOD-531|
271268|NCT02324309|Drug|Humalog Mix 75/25|
271269|NCT00153803|Drug|Erlotinib (tarceva)|Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 5 years of therapy.
271270|NCT02324309|Drug|Humulin R U-500|
271271|NCT02324309|Drug|BIOD-531|
271272|NCT02324322|Device|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
270677|NCT02336087|Dietary Supplement|Therapeutic Dietary Intervention|Given PO
270678|NCT02336087|Other|Laboratory Biomarker Analysis|Correlative studies
270679|NCT02336087|Other|Quality-of-Life Assessment|Ancillary studies
270680|NCT02336100|Device|Endoscopy (FICE and pCLE)|FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
270681|NCT02336113|Behavioral|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge
270682|NCT02336126|Behavioral|Biopsychological intervention|
270683|NCT02336139|Drug|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
270684|NCT02336152|Device|Anaesthesia, Teles Pro, Body suit|
270685|NCT02336165|Drug|MEDI4736|Anti-PD-L1
270686|NCT00155935|Procedure|venous puncture|
270687|NCT02336165|Radiation|Radiotherapy|
270688|NCT02336165|Biological|Bevacizumab|
270689|NCT02336178|Drug|Benefix|Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first.
270690|NCT02336191|Procedure|living donor liver transplantation|living donor liver transplantation
270691|NCT02336217|Other|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
270692|NCT02338596|Procedure|Total hip replacement|Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.
Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.
The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups.
270979|NCT02331303|Other|Radium - 223 (Xofigo)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
270980|NCT02331316|Other|Daily extra water intake|Intervention-A: Timing of assigned daily extra water intake specified
Intervention-B: Daily extra water assigned at any time during 24 hour period
270981|NCT02331329|Device|NICOM cardiac output measurement|
270381|NCT02342990|Other|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
270382|NCT00002406|Drug|Indinavir sulfate|
270383|NCT00156884|Drug|cisplatin|
270384|NCT02342990|Other|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
270385|NCT02343003|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
270386|NCT02343003|Drug|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
270387|NCT02343016|Device|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
270388|NCT02343029|Other|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
270389|NCT02343029|Other|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
270390|NCT02343042|Drug|Selinexor|Tablets
270391|NCT02343042|Drug|Dexamethasone|Oral tablets in a multi-dose vial.
270392|NCT02343042|Drug|Lenalidomide|25mg Oral capsule
270393|NCT02343042|Drug|Pomalidomide|4 mg oral tablets
270394|NCT00156897|Drug|ATL-962|
270395|NCT02343042|Drug|Bortezomib|3.5mg for injection supplied as lyophilized powder in single-use viles for subcutaneous injection.
270396|NCT02343055|Other|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
270397|NCT02343081|Drug|Temozolomide|
270398|NCT02343081|Drug|Temozolomide|
270399|NCT02343094|Drug|PBA 7,5g/d|Treatment for 14 days with PBA
266680|NCT02370589|Biological|Base Dose EBOV GP Vaccine|
266681|NCT02370589|Biological|2x Base Dose EBOV GP Vaccine|
266682|NCT02370589|Biological|4x Base Dose EBOV GP Vaccine|
266683|NCT02370589|Biological|8x Base Dose EBOV GP Vaccine|
266684|NCT02370589|Biological|Placebo|
266685|NCT02370589|Biological|Matrix-M Adjuvant|
266686|NCT02370602|Drug|TAK-063|TAK-063 tablets
266687|NCT02370602|Drug|[^11C]T-773|[^11C]T-773 IV solution
266688|NCT02370615|Drug|TAK-272, Itraconazole|TAK-272, ITRIZOLE Oral Solution 1 percent
266689|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
266690|NCT02370615|Drug|TAK-272, Digoxin, Midazolam|TAK-272, DIGOSIN, Midazolam HCl Syrup
266982|NCT02363764|Procedure|Bronchoalveolar lavage|Will be obtained by the pulmonologist in:
- Bronchoscopy CF patients
266983|NCT00159341|Procedure|Nasal lavage|Nasal lavage was carried out at specified timepoints
266984|NCT02365948|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Prefilled syringes
Concentration: 0.9 % Saline
Route of Administration: Subcutaneous injection
266985|NCT02365961|Drug|ropivicaine|
266986|NCT02365961|Drug|clonidine|
266987|NCT02365961|Drug|Epinephrine|
266988|NCT00159549|Behavioral|education and training program|
266989|NCT02365961|Drug|Noropin|
266990|NCT02365974|Device|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
266991|NCT02365974|Device|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
266992|NCT02365987|Dietary Supplement|Un-interesterified palm kernal and palm stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
266372|NCT02377193|Drug|Simulect|Simulect IV 40 mg/day D0 and D4
and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
266373|NCT02377193|Drug|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
266374|NCT02377206|Other|ADAS-Cog evaluation|[18F]DPA-714 PET imaging
266375|NCT00160875|Drug|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
266376|NCT02377219|Other|hormonal and blood analysis|
266377|NCT02377232|Behavioral|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
266378|NCT02377232|Behavioral|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
266379|NCT02377258|Other|Non Interventional|
266380|NCT02377271|Drug|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
266381|NCT02377271|Drug|placebo|treatment by bosentan or placebo is randomized
266382|NCT02377284|Other|Photograph|Add a photograph to a chef card.
266383|NCT02377297|Procedure|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
266384|NCT02377297|Procedure|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
266385|NCT02377297|Procedure|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
266386|NCT00160875|Drug|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
266691|NCT02370628|Procedure|Percutaneous vertebroplasty|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.
In our trial, vertebroplasty shall be performed in two steps:
Step 1: facet block
Step 2: cement infusion
Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention.
266692|NCT02370628|Procedure|Facet block|A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.
All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty.
266693|NCT02370641|Dietary Supplement|PomX|1000 mg POMx daily for 4 weeks
266694|NCT02370654|Behavioral|Tai chi|
266101|NCT02384590|Behavioral|Computerized cognitive behavioral therapy|The "Beating the Blues" computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience.
266102|NCT00161798|Biological|Tick-borne encephalitis vaccine|
266103|NCT02384603|Other|Global postural reeducation|
266104|NCT02384603|Other|Segmental muscle stretching exercises|
266105|NCT02384603|Other|Cognitive behavioral therapy|
266106|NCT02384616|Other|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
266107|NCT02384629|Device|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
266108|NCT02384629|Device|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
266109|NCT02384629|Device|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
266110|NCT02384629|Device|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
266111|NCT02384642|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
266112|NCT02386969|Device|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
265554|NCT02362958|Drug|lapatinib and capecitabine|lapatinib 1250 mg qd; Capecitabine 1000 mg/m2 bid
265555|NCT02362984|Drug|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
265556|NCT02362984|Drug|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
265557|NCT00159302|Procedure|Exhaled Nitric Oxide|
265558|NCT02362997|Drug|Pembrolizumab|Anti-PD-1 monoclonal antibody
265840|NCT02391571|Drug|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
265841|NCT02391571|Drug|Oxycodone|Oxycodone to be taken with stable dose of Methadone
265842|NCT02355327|Device|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
265843|NCT02355327|Behavioral|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
265844|NCT02355340|Other|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
265845|NCT02355340|Other|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
265846|NCT02355353|Other|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
265847|NCT00158470|Drug|didanosine|
265848|NCT02355366|Behavioral|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
265849|NCT02355366|Behavioral|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
265850|NCT02355379|Drug|LV5FU2 or capectitabine|
265234|NCT02369965|Drug|albuvirtide|albuvirtide 320mg administered intravenously once a week
265235|NCT02369965|Drug|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
265236|NCT02369965|Drug|tenofovir|tenofovir 300mg administered orally once daily
265237|NCT02369965|Drug|lamivudine|lamivudine 300mg administered orally once daily
265238|NCT02369978|Drug|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
265239|NCT00159991|Procedure|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
265240|NCT02369978|Drug|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
265241|NCT02369978|Drug|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
265242|NCT02369991|Procedure|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
265243|NCT02370004|Procedure|Resistive Flexibility and Strength Training|RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.
During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions.
265244|NCT02370017|Biological|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
265245|NCT02370030|Dietary Supplement|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
265559|NCT02363010|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
265560|NCT02363010|Behavioral|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
265561|NCT02363010|Behavioral|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
265562|NCT02363023|Procedure|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
265563|NCT02363049|Procedure|Colectomy|
264943|NCT02374567|Drug|Biperiden|
264944|NCT02374567|Drug|Levomepromazine|
264945|NCT02374567|Drug|Fluphenazine|
264946|NCT02374567|Drug|Perphenazine|
264947|NCT02374567|Drug|Perazine|
264948|NCT00160446|Drug|Placebo|Tablet, oral Daily for 12 weeks
264949|NCT02374567|Drug|Thioridazine|
264950|NCT02374567|Drug|Haloperidol|
264951|NCT02374567|Drug|Melperone|
264952|NCT02374567|Drug|Pipamperone|
264953|NCT02374567|Drug|Bromperidol|
264954|NCT02374567|Drug|Benperidol|
264955|NCT02374567|Drug|Sertindole|
264956|NCT02374567|Drug|Ziprasidone|
264957|NCT02374567|Drug|Flupentixol|
264958|NCT02374567|Drug|Chlorprothixene|
264959|NCT00160459|Drug|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
264960|NCT02374567|Drug|Zuclopenthixol|
264961|NCT02374567|Drug|Fluspirilene|
264962|NCT02374567|Drug|Pimozide|
264963|NCT02374567|Drug|Clozapine|
264964|NCT02374567|Drug|Olanzapine|
264965|NCT02374567|Drug|Quetiapine|
264966|NCT02374567|Drug|Sulpiride|
264967|NCT02374567|Drug|Tiapride|
264968|NCT02376608|Dietary Supplement|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
264345|NCT02388529|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
264346|NCT02388542|Behavioral|Educational Intervention|Employees above the age of 35 years will be rise stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
264347|NCT02388555|Procedure|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
264348|NCT02388568|Drug|Lorcaserin|Lorcaserin plus Lifestyle Modification
264631|NCT02381379|Drug|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
264632|NCT02381392|Device|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
264633|NCT02381405|Dietary Supplement|Enterade beverage|
264634|NCT02381418|Biological|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
264635|NCT02381431|Device|FLIR ONE|
264636|NCT00161421|Drug|Leuprolide (Lupron)|7.5 mg injection into muscle (once) (Day -14)
264637|NCT02381470|Drug|Faropenem|400mg Faropenem
264638|NCT02381470|Drug|Amoxicillin/clavulanic acid|500mg Amoxicillin/ 125mg clavulanic acid
264639|NCT02381470|Drug|Pyrazinamide|2g pyrazinamide
264640|NCT02381470|Drug|Isoniazid|300mg isoniazid
264641|NCT02381483|Other|Cold exposure|
264642|NCT02381496|Drug|ACT-453859 1 mg|Capsule
264643|NCT02381496|Drug|ACT-453859 3 mg|Capsule
264644|NCT02381496|Drug|ACT-453859 10 mg|Capsule
264645|NCT02381496|Drug|ACT-453859 30mg|Capsule
264646|NCT02381496|Drug|ACT-453859 100 mg|Capsule
269018|NCT02346825|Behavioral|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
269019|NCT02346825|Behavioral|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
269020|NCT02346825|Behavioral|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
269021|NCT02346838|Dietary Supplement|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
269022|NCT02346838|Dietary Supplement|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
269023|NCT02346851|Procedure|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
269024|NCT00157521|Drug|L-arginine|
269025|NCT02346864|Behavioral|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
269026|NCT02346864|Behavioral|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
264349|NCT02388568|Drug|Placebo|Placebo plus Lifestyle Modification
264350|NCT02388581|Drug|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
264351|NCT02388594|Drug|ZFN Modified CD4+ T Cells|
264352|NCT02388594|Drug|Cyclophosphamide|
264353|NCT02388607|Other|measurements|performance measurements
264354|NCT00162318|Drug|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
264355|NCT02388620|Drug|LEE011|400 mg
264356|NCT02388633|Procedure|Plasmapharesis|Clinically-indicated LDL apheresis
268710|NCT02354066|Device|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
268711|NCT02354066|Device|Retail Shoe|Brake response time measurement before surgery (control run)
268712|NCT02354079|Genetic|hypobetalipoproteinemia genetic and genotypic screening|
268713|NCT02354092|Procedure|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
268714|NCT00158366|Behavioral|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
268715|NCT02354092|Procedure|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
268716|NCT02354092|Procedure|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
268717|NCT02354092|Procedure|Dilator Placement|Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference
Drugs:
Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.
Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter.
268718|NCT02354092|Behavioral|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
268719|NCT02354092|Drug|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
268720|NCT02354118|Other|Heparinized saline catheter flush|
268721|NCT02354118|Other|Saline-only catheter flush|
268722|NCT02354131|Drug|Niraparib|Sequential bevacizumab followed by Niraparib versus Niraparib versus Bevacizumab-Niraparib combo
268723|NCT02354131|Drug|Bevacizumab|
268724|NCT02354144|Other|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
268725|NCT00158379|Drug|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
268393|NCT02364271|Biological|point-of-care test for H-FABP|Patients were tested with an H-FABP point-of-care test according to the instructions of the manufacturer. It is a rapid chromatographic immunoassay designed for quantitative determination of H-FABP in blood samples using a reader QuickSens®Ω100 (8sens.biognostic GmbH, Germany). This test has a limit of detection of 2 µg/L, a 99th percentile cut-off value of 7 µg/L, and a coefficient of variation of less than 10% at 5 µg/L. The test requires a 120 µL blood sample and the result was interpreted at 15 minutes after sample application. The test was invalid if no control line is visible. In such a case, the measurement was repeated immediately. The research assistant performed the H-FABP point-of-care tests, was blinded to the CACS results and TIMI scores.
268394|NCT02364271|Radiation|Coronary CT Angiography|Patients underwent CACS on a 64-slice multidetector CT scanner. Images were acquired during a single breath hold, using prospective ECG gating with imaging triggered at 70% of the R-R interval (collimation 16x2.5 mm, voltage 120 KeV, current 150 mAs). The computer software automatically defined the presence of calcified lesions as those greater than 130 Hounsfield units. A radiologist blinded to the H-FABP results and TIMI scores then calculated the CACS by selecting only calcified lesions specifically located within the coronary arteries, along with a description of whether the scan result is normal (CACS = 0), or shows minimal (1 to 10), mild (11 to 100), moderate (101 to 400), or severe (>400) calcification.
268395|NCT02364271|Other|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
268396|NCT02364271|Biological|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
268397|NCT02364271|Other|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
268398|NCT02364297|Device|Early TIPS|TIPS (first 5 days)
268399|NCT02364310|Device|Baroreceptor stimulation with Barostim Neo TM|
268400|NCT00159380|Procedure|Exhaled Breath Condensate|
268401|NCT02364323|Behavioral|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
268402|NCT02364323|Other|Normal usual care|General education on diabetes and diabetic complications
268403|NCT02364336|Drug|Peginterferon alfa-2a|
268404|NCT02364349|Drug|Bee Venom(BV)|
268405|NCT02364349|Drug|Essential Bee Venom(e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
268406|NCT02364362|Drug|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m^2
268407|NCT02364362|Drug|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m^2
268408|NCT02364362|Drug|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m^2
239218|NCT02447497|Drug|3M CHG/IPA|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
239219|NCT00002462|Radiation|low-LET photon therapy|
239220|NCT00170235|Other|Usual care|Exercise booklet, physiotherapy if needed
239221|NCT02447497|Other|Normal Saline|0.9% sodium chloride applied with foam applicator
239222|NCT02447510|Procedure|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
239223|NCT02447510|Procedure|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
239224|NCT02447510|Procedure|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
239225|NCT02447523|Procedure|Elective abdominal surgery|
239226|NCT02447536|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
239227|NCT02447536|Biological|BCG-Russia-I (Serum Institute of India)|See above
239228|NCT02447549|Radiation|WBRT|One RT plan with whole bladder treated to standard dose.
239229|NCT02447549|Radiation|SART|Three plans (small, medium & large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
239230|NCT02447549|Radiation|DART|Three plans (small, medium & large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
239523|NCT00169247|Drug|cetuximab|
239524|NCT02440347|Device|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
239525|NCT02440360|Behavioral|PSH|Please see arm description.
239526|NCT02440360|Behavioral|Usual Care|Please see arm description.
239527|NCT02442622|Other|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
239528|NCT02442635|Behavioral|Yoga|Yoga breathing and postures
239529|NCT02442648|Drug|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
243950|NCT02521831|Drug|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
243951|NCT02521831|Drug|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
243952|NCT02521844|Drug|ETC-1922159|
243953|NCT02521857|Drug|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
243954|NCT02521870|Drug|SD-101|SD-101 administered intratumorally for up to 11 doses.
243955|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously q 3 weeks from Study Day 1 up to Day 316
243956|NCT00182013|Drug|Risperidone|Open treatment with Risperidone
243957|NCT02521883|Device|Sooma tDCS|2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
243958|NCT02521883|Device|Sham tDCS|sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
243959|NCT02524002|Dietary Supplement|Usual clear diet|Usual clear liquids
243960|NCT02524015|Other|Novel physical therapy|
243961|NCT02524015|Other|Standard physical therapy|
243962|NCT02524041|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
243963|NCT02524041|Other|blood specimen|blood specimen
243964|NCT02524054|Drug|Furosemide|
243965|NCT02524054|Drug|Placebo|
243966|NCT00182325|Behavioral|personalized web-based prenatal information|
243967|NCT02524067|Behavioral|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
243968|NCT02524080|Procedure|Triage to optimal healthcare level|Triage to optimal healthcare level
243969|NCT02524093|Behavioral|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
243376|NCT02535455|Behavioral|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
243377|NCT02535481|Device|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
243378|NCT02535481|Procedure|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
243379|NCT02535494|Other|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
243664|NCT02528526|Drug|OXY111A|OXY111A intravenous infusion
243665|NCT02528539|Other|ITP|The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.
Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points
243666|NCT02528552|Device|LH80 PRO|
243667|NCT02528552|Device|Sham Device|
243668|NCT02528565|Device|Adhesix Bioring|
243669|NCT02528578|Device|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
243670|NCT02528578|Other|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
243671|NCT02528591|Device|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
243672|NCT02528604|Procedure|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
243673|NCT00182793|Biological|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
243674|NCT02528604|Procedure|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
243675|NCT02528604|Procedure|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
243676|NCT02528604|Device|Implantable loop recorder|
243677|NCT02528617|Drug|Velaglucerase alfa|Enzyme replacement therapy
243678|NCT02530814|Other|Blood Collection|Onetime blood collection.
243107|NCT02502994|Drug|GEN0101|
243108|NCT02503007|Dietary Supplement|Placebo|
243109|NCT02503007|Dietary Supplement|HMB-FA|
243110|NCT02503020|Dietary Supplement|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
243111|NCT02503020|Dietary Supplement|Preterm infants formula B|Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.
At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age.
243112|NCT02503033|Drug|HMPL-523|Oral administration, once daily
243113|NCT02503046|Other|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
243114|NCT02503046|Genetic|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
243115|NCT00179153|Dietary Supplement|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
243116|NCT02503072|Behavioral|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
243117|NCT02505269|Drug|Dacarbazine|
243118|NCT02505282|Other|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
243119|NCT02505295|Drug|Selenium|4 vials selenase stat and 2 vials daily for 5 days
243120|NCT00002488|Drug|etoposide|
243121|NCT00179465|Drug|Placebo|Placebo
243122|NCT02505295|Drug|normal saline|
243380|NCT02535507|Drug|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
243381|NCT02535533|Drug|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
243382|NCT02535533|Drug|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
242475|NCT02516774|Drug|Adalimumab|
242798|NCT02509858|Drug|Placebo|treatment with 50μg of placebo, once daily, for two months.
242799|NCT02509858|Other|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
242800|NCT02509871|Other|Body composition measurement|DXA, impedance
242801|NCT02509897|Other|Hypoxic training|Hypoxic training 3 times per week four four weeks
242802|NCT02509897|Other|Hypoxic rest|Resting stay 3 times per week four four weeks
242803|NCT02509897|Other|Normoxic training|Normoxic training 3 times per week four four weeks
242804|NCT00180037|Drug|Coenzyme Q10 Nanodispersion (Nanoquinone)|
242805|NCT02509923|Drug|Z-215 10mg|Z-215 10mg, capsules
242806|NCT02509923|Drug|Z-215 20mg|Z-215 20mg, capsules
242807|NCT02509923|Drug|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
242808|NCT02509923|Drug|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
242809|NCT02509936|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
242810|NCT02509936|Dietary Supplement|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
242811|NCT02509949|Drug|Dexmedetomidine|
242812|NCT02509949|Drug|Saline|
242813|NCT02509962|Dietary Supplement|Slow sodium tablets|6 g sodium chloride per day over 14 days
242814|NCT02512276|Behavioral|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
242815|NCT00180388|Procedure|endoscopic vein harvesting|
242816|NCT02512289|Device|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
242817|NCT02512302|Drug|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
242174|NCT02523274|Drug|Placebo|Vegetable-based cellulose
242175|NCT02523274|Behavioral|Exercise|Multi-modal exercise regimen, 3 days/week
242176|NCT02523287|Biological|Fluad|Randomized assignment
242177|NCT02523287|Biological|Saline|Randomized assignment
242178|NCT02523300|Procedure|TEVAR|The patients will be undertaken TEVAR
242179|NCT02523300|Drug|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
242180|NCT00182221|Procedure|MDA D-Dimer Testing|
242181|NCT02523300|Drug|saline|The other 120 patients will be given saline as control group
242476|NCT02516787|Other|Parabolic flight|
242477|NCT02516787|Other|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
242478|NCT02516787|Other|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
242479|NCT02516813|Drug|MSC2490484A|Phase 1a: Subjects will receive a starting dose of 100 milligram (mg) of MSC2490484A orally once daily 1.5 hours prior each radiotherapy(RT) fraction (3 Gray [Gy]) for up to 10 fractions. Dose escalation will continue from MSC2490484A 100 mg/day up to a maximum dose of MSC2490484A 800 mg/day until one of the following stopping rules apply: a maximum number of 30 subjects are included, more than three cohorts are assigned to the same dose level or the estimate for dose limiting toxicity (DLT) probability of the maximum tolerated dose (MTD) reaches sufficient precision.
Phase 1b: Subjects will receive the assigned dose of MSC2490484A once daily orally.
cPoP Study: Subjects will receive a single oral dose of MSC2490484A (planned doses of 100 mg, 200 mg and 400 mg) on Day 2, 1.5 hours before the start of RT.
242480|NCT02516813|Radiation|Fractionated palliative RT|Phase 1a: Subjects will receive fractionated palliative RT (3 Gy x 10, 5 fractions per week [F/W]).
Phase 1b: Subjects will receive fractionated RT (2 Gy x 30, 5 F/W).
cPoP study: Subjects will receive a single high dose of RT (10-25 Gy) on Day 1 given on Lesion 1 and one dose of MSC2490484A followed by a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2.
242481|NCT02516826|Drug|Rosuvastatin|
242482|NCT02516826|Drug|Olmesartan|
242483|NCT02516826|Drug|Combination|Rosuvastatin/Olmesartan(Combination)
242484|NCT00181025|Drug|Tasonermine (TNFa)|
242485|NCT02516826|Drug|Placebo of Rosuvastatin|
242486|NCT02516826|Drug|Placebo of Olmesartan|
242487|NCT02516826|Drug|Placebo of Rosuvastatin/Olmesartan(Combination)|
266993|NCT02365987|Dietary Supplement|Interesterified palm kernal and palm stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
266994|NCT02366000|Other|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
266995|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
266996|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
266997|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
266998|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
266999|NCT00159562|Behavioral|individual education|individual sessions of psycho-education
267000|NCT02366026|Biological|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
267001|NCT02366052|Behavioral|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
267002|NCT02366052|Dietary Supplement|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
267284|NCT02358811|Behavioral|Cognitive assessment|This cognitive assessment will include the following executive tests :
test of Stroop
left Trail Making Test A and B
verbal fluence test
test of memory of figures direct and inverse in order
completion of matrices
Paced Auditory Serial Addition Test (PASAT)
267285|NCT02358824|Drug|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
(1arm:2period and 4period, 2arm:1period and 3period)
267286|NCT02358824|Drug|Telmisartan|- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
(1arm:1period and 3period, 2arm: 2period and 4period)
267287|NCT02358824|Drug|S-amlodipine|- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
(1arm:1period and 3period, 2arm: 2period and 4period)
267288|NCT02360969|Other|Examination of the eye|Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.
During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.
Pictures of the eye will be performed under general anesthesia.
Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the "top" given by the anesthetist under the following conditions:
Deep anesthesia: BIS <50 Deep anesthesia and muscle relaxation: BIS <50 and TOF 0/4
267289|NCT02360982|Behavioral|propofol and esmeron(rokuronyum)|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
266695|NCT02370654|Behavioral|Conventional exercise|
266696|NCT02370667|Other|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
266697|NCT02370667|Other|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
266698|NCT02373137|Drug|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
266699|NCT02373137|Drug|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
266700|NCT02373137|Drug|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
266701|NCT02373137|Drug|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
266702|NCT02373137|Device|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
266703|NCT02373150|Drug|Imeglimin|
266704|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
266705|NCT02373150|Drug|Placebo|
266706|NCT02373163|Drug|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
266707|NCT02373163|Drug|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
266708|NCT02373163|Drug|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
266709|NCT02373176|Drug|[14C]PRC 4016 (Icosabutate)|Single oral dose
267003|NCT02366052|Other|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
267004|NCT02366065|Drug|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
267005|NCT02366078|Behavioral|SMART|Paced breathing meditation with cognitive training
266113|NCT02386969|Device|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
266114|NCT02386982|Drug|HMS5552|
266387|NCT02377323|Other|MACFIMS|Cognitive evaluation of 50 participants
266388|NCT02377323|Other|MSQoL-54|Quality of life questionnaires
266389|NCT02377336|Drug|GS-6615|GS-6615 tablets administered orally
266390|NCT02377336|Drug|Placebo|Placebo to match GS-6615 tablets administered orally
266391|NCT02377349|Biological|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
266392|NCT02377349|Drug|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
266393|NCT02377362|Drug|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
266394|NCT02377362|Drug|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
266395|NCT02377362|Drug|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
266396|NCT02377362|Drug|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
266397|NCT00160888|Drug|sodium nitroprusside, bradykinin, acetylcholine|
266398|NCT02377362|Drug|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
266399|NCT02379585|Drug|Trastuzumab|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
266400|NCT02379585|Drug|Pertuzumab|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
266401|NCT02379598|Dietary Supplement|Aminoacid based formula|Formula based on aminoacid
265851|NCT02355379|Drug|FOLFOX4 or XELOX|
265852|NCT02355379|Other|Observation|
265853|NCT02355379|Drug|LV5FU2 or capecitabine|
265854|NCT02355392|Other|Telemedical home blood pressure measurements|
265855|NCT02355405|Device|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
265856|NCT02355405|Radiation|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
265857|NCT02355418|Procedure|Mitral valve repair|Standard mitral valve repair surgery
265858|NCT00158470|Drug|lamivudine|
266115|NCT02386995|Device|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
266116|NCT02386995|Device|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
266117|NCT02387008|Biological|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
266118|NCT00162136|Drug|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 & 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
266119|NCT02387008|Biological|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
266120|NCT02387008|Biological|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
266121|NCT02387021|Procedure|Continuous femoral nerve block|
266122|NCT02387021|Procedure|Continuous adductor canal block|
266123|NCT02387021|Procedure|infragluteal Sciatic nerve block|
266124|NCT02387021|Drug|Ropivacaine 0.2%|
266125|NCT02387021|Drug|Saline|
266126|NCT02387034|Behavioral|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
265564|NCT02363049|Drug|Chemotherapy|
265565|NCT02365324|Behavioral|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
265566|NCT02365350|Procedure|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
265567|NCT02365350|Procedure|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
265568|NCT02365363|Other|Control|Non pulse ingredient bagel
265569|NCT00159497|Device|porous coated Trilogy®|THA
265570|NCT02365363|Other|Pea flour|Pulse ingredient bagel
265571|NCT02365363|Other|Pea fibre|Pulse ingredient bagel
265572|NCT02365363|Other|Pea flour and pea fibre|Pulse ingredient bagel
265573|NCT02365363|Other|Pea flour and pea protein|Pulse ingredient bagel
265574|NCT02365363|Other|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
265575|NCT02365389|Drug|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
265576|NCT02365389|Drug|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
265577|NCT02365402|Drug|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
265578|NCT02365415|Drug|Sirolimus|8 weeks oral sirolimus, following drug levels
265859|NCT02355431|Drug|INCB039110|tablets to be administered by mouth once daily at dose selected from safety run-in phase
265860|NCT02355431|Drug|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
265861|NCT02355431|Drug|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
265862|NCT02355444|Dietary Supplement|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
265246|NCT02370043|Drug|KQ-791|Capsules administered orally while fasting, in up to 3 periods
265247|NCT02370043|Drug|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
265248|NCT02370043|Drug|Placebo|Capsules, administered orally, in 1 period
265249|NCT02370056|Device|The Olympus HD 3D Laparoscopic Surgical Video System|
265250|NCT00002420|Drug|Emivirine|
265251|NCT00159991|Procedure|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
265252|NCT02370069|Biological|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
265253|NCT02370082|Device|Localization of breast lesion|localization of breast lesion for removal
265254|NCT02370095|Drug|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
265255|NCT02370095|Drug|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
265256|NCT02370108|Device|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
265257|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
265258|NCT02372526|Other|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
265259|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
265260|NCT02372539|Other|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
265261|NCT02372539|Other|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
265262|NCT02372552|Device|CROMA|Microwave coagulation of small blood vessels
265263|NCT02372565|Behavioral|Facebook and text Message|Culturally-relevant physical activity promotion program
265264|NCT00160303|Drug|Local Corticosteroid Therapy|
265265|NCT02372565|Behavioral|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
265266|NCT02372578|Drug|ASP3662|oral
264647|NCT00161421|Drug|Dutasteride|24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
264648|NCT02381496|Drug|ACT-453859 300 mg|Capsule
264649|NCT02381496|Drug|ACT-453859 800 mg|Capsule
264650|NCT02381496|Other|Placebo|Matching ACT-453859 placebo capsule
264651|NCT02381496|Drug|Setipiprant 500 mg|Capsule
264652|NCT02381496|Drug|Setipiprant 1000 mg|Capsule
264653|NCT02381509|Device|IVC Filter|
264654|NCT02381522|Other|Remote Ischemic Pre-conditioning|
264655|NCT02381522|Other|Sham RIPC|
264656|NCT02383875|Behavioral|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
264969|NCT02376608|Dietary Supplement|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
264970|NCT02376608|Dietary Supplement|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
264971|NCT02376608|Dietary Supplement|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
264972|NCT02376621|Dietary Supplement|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
264973|NCT02376621|Dietary Supplement|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
264974|NCT02376621|Dietary Supplement|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
264975|NCT02376621|Dietary Supplement|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
264357|NCT02388646|Other|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
264358|NCT02388646|Device|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
264359|NCT02388646|Other|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
264360|NCT02388659|Device|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
264361|NCT02388672|Dietary Supplement|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
264362|NCT02388672|Dietary Supplement|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
264363|NCT02388672|Dietary Supplement|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
264364|NCT02388672|Dietary Supplement|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
264365|NCT00162331|Drug|Technetium Tc99m Sestamibi|
264366|NCT02388685|Other|Exercise|Home exercise therapy
264367|NCT02388698|Procedure|Cervical swab|Cervical Swab at baseline.
HPV testing at recurrence, if applicable.
264368|NCT02388698|Radiation|PET-CT|PET-CT will be completed 3 month post chemoradiation.
264369|NCT02390856|Device|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
264370|NCT02390856|Device|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
264657|NCT02383888|Drug|BI 425809|
264658|NCT02383888|Drug|BI 425809|
264659|NCT02383888|Drug|Placebo|
264660|NCT02383888|Drug|BI 425809|
264661|NCT02383901|Drug|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
264662|NCT00161707|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
269027|NCT02346877|Other|Personalized Patient Counselling (Interventional) Cohort|In the interventional cohort all subjects enrolled on the study will receive Enbrel® (Etanercept) therapy and personalized patient counselling using the IMS-model based on the BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
269028|NCT02346890|Drug|AZD1722|
269029|NCT02346890|Drug|Renvela|
269030|NCT02349165|Drug|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
269031|NCT02349165|Drug|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
269032|NCT02349178|Drug|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
269033|NCT00157859|Drug|Chloroquine and sulphadoxine-pyrimethamine|
269034|NCT02349178|Drug|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
269035|NCT02349178|Drug|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
269036|NCT02349191|Procedure|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
269037|NCT02349204|Behavioral|Music - Mozart's sonata for 2 pianos in D-440|
269038|NCT02349217|Behavioral|Mindfulness-Based Relationship Enhancement (MBRE)|Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
269039|NCT02349217|Behavioral|Self-Help Materials|Participants and partner receive self-help materials.
269040|NCT02349217|Behavioral|Pain Assessment|Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
269041|NCT02349217|Behavioral|Questionnaires|Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
269042|NCT02349217|Behavioral|Neurocognitive Tests|Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
269043|NCT02349217|Procedure|Cortisol Tests|Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
269044|NCT00157872|Drug|MK0966; rofecoxib|
269045|NCT02349217|Behavioral|Interviews|Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
268409|NCT02364388|Device|Imagio Scan|The Imagio breast imaging system is indicated for use by a qualified and trained healthcare provider for opto-acoustic (OA) evaluation of breasts in women who are referred for a diagnostic breast ultrasound work-up due to a suspicious mass (including both palpable and non-palpable) or an imaging finding such as mammographic mass, architectural distortion, asymmetry or suspicious calcifications.
268410|NCT02364401|Device|Ablation|Catheter ablation for atrial fibrillation
268726|NCT02318017|Drug|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
268727|NCT02318017|Drug|Placebo|
268728|NCT02318043|Drug|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
268729|NCT02318056|Other|Aquacel® Ag Burn Glove|burn dressing
268730|NCT02318056|Other|Mepilex® Transfer Ag|burn dressing
268731|NCT02318056|Drug|antibiotic|antibiotic burn dressing
268732|NCT02318069|Biological|FSME-immune|0.5 ml im as scheduled in the 5 arms
268733|NCT02318082|Drug|Interleukin-2|
268734|NCT02318095|Drug|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. Restaging will be completed post chemotherapy.
268735|NCT00153062|Drug|Micardis placebo|placebo
268736|NCT02318095|Radiation|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
268737|NCT02318095|Other|Sugical resection|Surgical resection of the pancreas post radiation therapy
268738|NCT02318095|Drug|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
268739|NCT02318108|Other|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
268740|NCT02318108|Other|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
268741|NCT02318121|Procedure|Amniotomy first|rupture of membranes to augment labor
268742|NCT02318121|Procedure|Oxytocin first|Administration of oxytocin to augment labor
239530|NCT02442674|Drug|Tolvaptan|Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.
Dosage: Depending on age, weight and serum sodium response:
Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days
239531|NCT02442674|Other|Placebo|Placebo tablet matching active drug
239532|NCT02442687|Drug|JKB 121|weak TLR4 receptor antagonist
239533|NCT02442687|Drug|Placebo|
239534|NCT02442700|Drug|pitavastatin|give for the first 12 weeks in arm A, and late 12 weeks in arm B
239535|NCT00169507|Biological|Pneumococcal (vaccine)|
239536|NCT02442700|Drug|placebo|give for the first 12 weeks in arm B, and late 12 weeks in arm A
239537|NCT02442713|Drug|fluvoxamine|fluvoxamine: 50-300mg/day
239538|NCT02442726|Device|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
239539|NCT02442739|Drug|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 16 weeks.
239540|NCT02442739|Other|Placebo|Placebo syrup will be given by mouth once a week for 16 weeks.
239541|NCT02442752|Drug|Dexlansoprazole|Dexlansoprazole capsules
239542|NCT02442765|Drug|AVP-786|
239543|NCT02442765|Drug|Placebo|
239544|NCT02442778|Drug|AVP-786|
239545|NCT02442778|Drug|Placebo|
239546|NCT00169520|Drug|docetaxel|
239547|NCT02442791|Drug|Byetta (Lilly, Exenatide)|See description of Arms
239839|NCT02506452|Other|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
239840|NCT02506465|Device|iTIND|Temporary Implantable Nitinol Device (iTIND)
239841|NCT02506465|Procedure|Sham Arm|Foley catheter will be placed and immediately removed.
239231|NCT00170248|Device|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
239232|NCT02447562|Device|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
239233|NCT02447562|Other|Phone-based care group|
239234|NCT02447562|Other|Usual care group|
239235|NCT02447575|Device|Utilization of electronic flowmeter for metered dose inhaler|subject will actuate metered dose inhaler with electronic flowmeter in place before and after short education process to remind subject how they should use the metered dose inhaler
239236|NCT02447588|Other|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
239237|NCT02447588|Other|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
239238|NCT02449707|Procedure|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
239239|NCT02449707|Procedure|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
239240|NCT02449720|Drug|Ropivacaine|Intraperitoneal instillation and infusion
239241|NCT02449720|Drug|0.9% Saline|Intraperitoneal instillation and infusion
239242|NCT02449733|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
239243|NCT02449733|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
239244|NCT02449733|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
239245|NCT00170612|Biological|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
243679|NCT02530827|Drug|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
243680|NCT02530840|Behavioral|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
243681|NCT02530840|Behavioral|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
243682|NCT02530840|Behavioral|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
243683|NCT02530853|Other|Laser acupuncture|Laser acupuncture
243684|NCT02530866|Other|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
243970|NCT02524093|Other|treatment as usual|
243971|NCT02524106|Drug|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
243972|NCT02524106|Drug|Placebo|
243973|NCT02524119|Drug|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
243974|NCT02524119|Procedure|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
243975|NCT02524132|Behavioral|Physical Activity|
243976|NCT02524145|Other|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
243977|NCT00182351|Procedure|D-dimer|
243978|NCT02524145|Drug|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
243979|NCT02524145|Drug|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
243383|NCT02535533|Drug|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
243384|NCT02535533|Drug|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
243385|NCT02535559|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
243386|NCT00002496|Drug|fluorouracil|
243387|NCT00183521|Behavioral|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
243388|NCT02535572|Device|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
243389|NCT02535572|Device|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
243390|NCT02535585|Device|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
243391|NCT02535585|Device|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
243392|NCT02535598|Behavioral|Normal presentation|All the material will be presented as plain text.
243393|NCT02535598|Behavioral|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
243394|NCT02535598|Behavioral|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
243395|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
243396|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
243397|NCT02538016|Drug|Tolvaptan|
243398|NCT02538029|Behavioral|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
243399|NCT02538029|Behavioral|Single Task Group|Performing motor or cognitive tasks alone.
243685|NCT02530879|Drug|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
242818|NCT02512302|Drug|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
242819|NCT02512302|Drug|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
243123|NCT02505308|Other|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
243124|NCT02505321|Other|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
243125|NCT02505321|Procedure|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
243126|NCT02505334|Drug|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
243127|NCT02505347|Other|No splint|Can move arm as tolerated with no restrictions on mobility
243128|NCT02505347|Device|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
243129|NCT02505360|Other|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
243130|NCT02505373|Behavioral|Attempted Suicide Short Intervention Program (ASSIP)|The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.
Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.
Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.
Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.
Regular letters are sent to patients over a period of 2 years.
243131|NCT02505373|Behavioral|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
243132|NCT00179478|Drug|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
243133|NCT02505386|Drug|Ertapenem|
243134|NCT02505399|Drug|ticagrelor|Ticagrelor will be administered orally, according to the following scheme:
180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
90 mg the following morning (D Day before rotational atherectomy and angioplasty),
90 mg the following evening (D Day after rotational atherectomy and angioplasty),
90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).
242488|NCT00181571|Drug|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
242489|NCT02518828|Other|High SpO2|Oxygen delivery up to 97%
242490|NCT02518828|Other|Low SpO2|Oxygen delivery up to 91%
242491|NCT02518841|Device|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
242492|NCT02518841|Other|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
242493|NCT02518867|Other|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
242494|NCT02518867|Other|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
242495|NCT02518867|Other|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
242820|NCT02512302|Drug|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
242821|NCT02512302|Drug|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
242822|NCT02512315|Drug|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
242823|NCT02512315|Drug|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
242824|NCT02512315|Radiation|Concurrent chemoradiation (CRT)|The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).
The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly.
242825|NCT02512328|Device|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
242826|NCT00180388|Procedure|open vein harvesting|
242827|NCT02512341|Device|Computer Aided Auscultation (CAA)|
242828|NCT02512354|Other|Sample of a fragment of fetal tissue|
242829|NCT02512354|Other|Blood samples|
242830|NCT02512367|Other|Dental care education program|
267290|NCT02360982|Behavioral|marcaine and fentanyl|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
267291|NCT02360995|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
267292|NCT02360995|Drug|stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration). Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
267293|NCT02360995|Drug|fluoride toothpaste + fluoride mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration). Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
267294|NCT02361008|Device|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
267295|NCT02361008|Procedure|Surgery repair with CBP|Traditional surgery repair under the CBP.
267296|NCT02361021|Other|- Weaning from mechanical ventilation|
267297|NCT02361034|Drug|GRC 27864|
267298|NCT00159055|Biological|CMV vaccine|
267299|NCT02361034|Drug|Placebo|
267588|NCT02392429|Drug|Chemotherapy|Given anthracycline IV
267589|NCT02392429|Procedure|Computed Tomography|Undergo FLT PET/CT
267590|NCT02392429|Drug|Cytarabine|Given IV
267591|NCT02356159|Drug|EPOCH-F|Fludarabine:25 mg/m2 per day IV infusion over 30 minutes, daily on days 1-4. Etoposide :50 mg/m2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin:10 mg/m2/day CIV, days 1-4. Vincristine: 0.4 mg/m2 per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide: 750 mg/m2 IV infusion over 30 minutes on day 5 Prednisone:60 mg/m2 per day PO daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV.
267592|NCT02356159|Procedure|Hematopoietic Stem Cell Transplant|Hematopoietic stem cell transplant
267593|NCT02356159|Drug|Palifermin|Escalating doses of palifermin given during transplant phase
267594|NCT02356198|Drug|EXPAREL|transversus abdominis plane injection
267595|NCT02356198|Drug|Intrathecal hydromorphone|Intrathecal opioid administration
267006|NCT02366091|Drug|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
267007|NCT02368132|Behavioral|Group Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
267008|NCT02368158|Other|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
267009|NCT02368171|Other|measure exhaled carbon monoxide and nitric oxide|
267010|NCT02368197|Drug|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
267011|NCT02368197|Device|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
267012|NCT02368210|Drug|122-0551 Foam|Topical Foam
267013|NCT02368210|Drug|Vehicle Foam|Topical Foam
267014|NCT02368223|Device|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
267015|NCT02368236|Behavioral|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
267016|NCT02368249|Drug|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
267017|NCT00159822|Drug|Voriconazole|Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.
Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours
267300|NCT02361047|Behavioral|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
267301|NCT02361060|Drug|Neostigmine|40mcg/kg
267302|NCT02361060|Drug|Sugammadex|4mg/kg
266402|NCT02379598|Dietary Supplement|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
266403|NCT02379611|Procedure|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
266710|NCT02373189|Device|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
266711|NCT02373202|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
266712|NCT02373202|Drug|non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin)|
266713|NCT02373202|Drug|sulfasalazine|Pharmaceutical form: tablet Route of administration: oral
266714|NCT02373202|Drug|leflunomide|Pharmaceutical form: tablet Route of administration: oral
266715|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
266716|NCT02373202|Drug|bucillamine|Pharmaceutical form: tablet Route of administration: oral
266717|NCT02373202|Drug|tacrolimus|Pharmaceutical form: capsule Route of administration: oral
266718|NCT02373202|Drug|mizoribin|Pharmaceutical form: tablet Route of administration: oral
266719|NCT02373215|Drug|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
266720|NCT02373228|Other|Audio signal processing (applied offline before playback)|
266721|NCT02373241|Drug|Losartan|Standard dosing
266722|NCT02374970|Other|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
266723|NCT02374970|Other|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
266127|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
266128|NCT02387060|Drug|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
266129|NCT00002429|Drug|Nelfinavir mesylate|
266130|NCT00162149|Drug|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
266131|NCT02387060|Drug|Fentanyl|Intrathecal administration of fentanyl 25 mcg
266132|NCT02387073|Other|Electrical version patient reported outcome questionnaire|Assess satisfaction of patients with "electrical version patient reported outcome questionnaire".
266133|NCT02387086|Drug|Thalidomide|
266134|NCT02387086|Drug|placebo|
266135|NCT02387086|Drug|Gefitinib|
266136|NCT02387086|Drug|Aspirin|
266404|NCT02379624|Drug|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
266405|NCT02379637|Drug|N-acetylcysteine|
266406|NCT00161226|Device|Levonorgestrel intrauterine system|
266407|NCT02379637|Drug|Placebo|
266408|NCT02379650|Drug|Hydroxychloroquine (HCQ)|
266409|NCT02379650|Drug|Placebo|
266410|NCT02379663|Drug|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
266411|NCT02379663|Drug|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
266412|NCT02379663|Other|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
266413|NCT02379676|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
266414|NCT02379676|Drug|Clopidogrel|Clopidogrel 75mg once daily for 30 days
266415|NCT02379689|Drug|Injectable placental tissue extract called BioDGenesis (Active Product)|
265863|NCT02358109|Behavioral|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
265864|NCT02358122|Other|Wholegrain rye|A variety of cereal foods providing >100g/day wholegrain from rye
265865|NCT02358122|Other|Wholegrain wheat|A variety of cereal foods providing >100g/day wholegrain from wheat
265866|NCT02358122|Other|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
265867|NCT00158717|Drug|Hepsera|
265868|NCT02358135|Other|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
265869|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
265870|NCT02358161|Drug|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
265871|NCT02358174|Procedure|Hemorrhoidectomy|Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.
All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation
265872|NCT02358174|Other|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
265873|NCT02358174|Other|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
266137|NCT02389309|Drug|Cyclophosphamide|Cyclophosphamide by mouth once daily for 21 days of a 28 day course.
266138|NCT02389309|Drug|Temsirolimus|Temsirolimus by vein once weekly for 3 consecutive weeks of a 28 day course.
266139|NCT02389322|Biological|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
265267|NCT02372578|Drug|pregabalin|oral
265268|NCT02372578|Drug|ASP3662 placebo|oral
265579|NCT02365428|Behavioral|Physical activity text messages|
265580|NCT00159497|Device|Trilogy Calcicoat®|THA
265581|NCT02365441|Drug|Regorafenib|
265582|NCT02365441|Drug|imatinib|
265583|NCT02365454|Device|Stent Graft Placement (Nexus)|The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via "surgical bypass grafting", either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.
This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system.
265584|NCT02365467|Device|Valiant Mona LSA Thoracic Stent Graft System|
265585|NCT02365480|Drug|Berberine Chloride|Given PO
265586|NCT02365480|Other|Laboratory Biomarker Analysis|Correlative studies
265587|NCT02365480|Other|Placebo|Given PO
265588|NCT02365493|Drug|Beta-Lactam|
265589|NCT02365506|Drug|GS-6615|GS-6615 tablets administered orally
265590|NCT02365506|Drug|Placebo|Placebo to match GS-6615 tablets administered orally
265591|NCT02367638|Biological|MG1111|2000, 8000, 25000 Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
265592|NCT02367638|Biological|VARIVAX|VARIVAX is administered by subcutaneous injection
265593|NCT00002419|Drug|Amprenavir|
265594|NCT00159770|Behavioral|Panss , CGI-C, UKU-SERS-Pa|
265595|NCT02367651|Drug|Pazopanib 800 mg|Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
265596|NCT02367651|Drug|Placebo|Tablets matching the 200 mg and 400 mg pazopanib tablets
265597|NCT02367664|Biological|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
264976|NCT00160784|Procedure|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
264977|NCT02376621|Dietary Supplement|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
264978|NCT02376634|Behavioral|Hypnosis|Patients will be taught self-hypnosis.
264979|NCT02376647|Other|Driving pressure limited ventilation|Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.
Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment.
264980|NCT02376647|Other|Conventional ventilation|Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
264981|NCT02376660|Other|Oats|
265269|NCT02372578|Drug|pregabalin placebo|oral
265270|NCT02372591|Drug|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
265271|NCT02372591|Drug|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
265272|NCT02372591|Drug|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
265273|NCT02372604|Drug|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)
the evening : placebo capsule
Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)
the evening : 10 mg of levocetirizine (capsule))
265274|NCT02372604|Drug|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)
the evening : 10 mg of levocetirizine(tablet)
Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)
the evening : placebo tablet
265275|NCT00160316|Drug|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
265276|NCT02372617|Procedure|periacetabular osteotomy|
265277|NCT02372630|Drug|Linagliptin|
265278|NCT02372630|Drug|Placebo|
264663|NCT02383927|Drug|Tipifarnib|FTase inhibitor
264664|NCT02383940|Drug|Sotagliflozin|Sotagliflozin high dose, once daily before the first meal of the day
264665|NCT02383940|Drug|Placebo|Placebo, once daily before the first meal of the day
264666|NCT02383966|Drug|Cetuximab|Cetuximab will be administered on a weekly basis until disease progression. The initial dose will be 400 milligrams per square meter (mg/m^2) as an intravenous infusion. The subsequent doses will be 250 mg/m^2.
264667|NCT02383966|Drug|Cisplatin/Carboplatin|Cisplatin (or carboplatin at an equivalent dose in case of intolerability of cisplatin) will be administered at a dose of 75 mg/m^2 as a 60-minute intravenous infusion on Day 1 of each 21-day treatment cycle, to a maximum of 6 chemotherapy cycles.
264668|NCT02383966|Drug|5-fluorouracil|5-fluorouracil (5-FU) will be administered after cisplatin or carboplatin, at a dose of 750 mg/m^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle, to a maximum of 6 chemotherapy cycles.
264669|NCT02383979|Device|Sham (Comparator) Plasma Ball|will consist of undergoing a sham therapy with a 22" plasma globe involving contralateral limb interaction with the sphere.
264670|NCT02383979|Device|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
264671|NCT02383992|Drug|3% H2O2 solution|
264672|NCT02383992|Drug|0.9% normal saline|
264673|NCT00002427|Drug|Didanosine|
264674|NCT00161720|Drug|Protein C Concentrate (Human) Vapor Heated|
264675|NCT02384005|Other|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
264676|NCT02384018|Biological|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
264982|NCT02376673|Other|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
264983|NCT02379065|Device|Phillips Respironic© mask|
269046|NCT02349230|Other|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
264371|NCT02390869|Drug|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
264372|NCT02390869|Drug|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
264373|NCT02390882|Drug|Tamsulosin|Placebo
264374|NCT02390882|Drug|Tamsulosin|Tamsulon low dose
264375|NCT00162656|Drug|without COPADM3|
264376|NCT02390882|Drug|Tamsulosin|Tamsulosin high dose
264377|NCT02390895|Procedure|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
264378|NCT02390895|Procedure|Postnatal Myelomeningocele Repair Surgery|repair of myleomeningocele after birth
264379|NCT02390908|Behavioral|PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
264380|NCT02390908|Behavioral|Enhanced treatment as usual (eTAU) wait-list condition|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
264381|NCT02390921|Drug|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
264382|NCT02390921|Drug|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
264383|NCT02390934|Radiation|Radium 223|
264384|NCT02390947|Drug|Famitinib|25 mg p.o. qd
264385|NCT02390947|Drug|Placebo|25 mg p.o. qd
264386|NCT00162656|Drug|mini CYVE, without 3 maintenance courses|
264387|NCT02390960|Drug|Sildenafil|patients will be instructed to apply the pre-weighed IP to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
264388|NCT02390960|Drug|Placebo|patients will be instructed to apply the pre-weighed IP to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
268743|NCT02318121|Procedure|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
268744|NCT02318121|Drug|Oxytocin|
268745|NCT02318134|Procedure|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
268746|NCT00153075|Device|Berodual Respimat|
268747|NCT02318134|Other|The traditional treatment|the traditional treatments according to associated guidelines
269047|NCT02349243|Drug|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
269048|NCT02349243|Drug|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
269049|NCT02349282|Dietary Supplement|Calcifediol 10ug/day|
269050|NCT02349282|Dietary Supplement|Vitamin D3 20ug/day|
269051|NCT02349282|Dietary Supplement|Placebo|
269052|NCT02349295|Drug|Ixekizumab|Administered SC
269053|NCT02349295|Drug|Placebo|Administered SC
269054|NCT02351791|Other|Patch 6, Leakage pocket|
269055|NCT02351791|Other|Patch 6, Adhesive|
269056|NCT02351804|Drug|Ropivacaine + dexamethasone|Adductor canal block, single bolus
269057|NCT00158171|Drug|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
269058|NCT02351804|Drug|Ropivacaine + placebo|Adductor canal block, single bolus
269059|NCT02351817|Device|Test A|Ostomy appliance
269060|NCT02351817|Device|Test B|Ostomy appliance
269061|NCT02351817|Device|Baseline|Ostomy appliance
269062|NCT02351830|Other|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
269063|NCT02351830|Procedure|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
269064|NCT02351843|Device|MECTA Spectrum 5000Q|
239842|NCT02506478|Other|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
239843|NCT02506491|Other|Pilates exercise|2 sessions/week, 1 hour/session during 22 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
239844|NCT02506491|Other|Muscular exercise|2 sessions/week, 1 hour/session during 22 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
239845|NCT02508714|Device|Orsiro|stents will be implanted in case of significant coronary artery disease
239846|NCT02508714|Device|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
239847|NCT02508727|Other|MRI|
239848|NCT00179907|Procedure|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors < 20 mm, 21-25 mm and 26-40 mm respectively
239849|NCT02508727|Other|3D cardiac ultrasound|
239850|NCT02508740|Drug|bevenopran|Single oral dose
239851|NCT02508753|Drug|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
239852|NCT02508753|Drug|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
239853|NCT02508753|Drug|Moxifloxacin|400 mg tablet
239854|NCT02508753|Drug|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
239855|NCT02508766|Procedure|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
239856|NCT02508779|Behavioral|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
239857|NCT02508779|Other|Routine Care|Participants will continue to receive care from their clinician.
239246|NCT02449733|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).
For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit.
239247|NCT02449733|Other|HIV Testing|Rapid HIV testing at multiple time points
239548|NCT02442791|Other|20% Human Albumin|See description of Arms
239549|NCT02442804|Dietary Supplement|POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
239550|NCT02442804|Other|Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
239551|NCT02442817|Drug|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
239552|NCT02442830|Device|Early Video Capsule Endoscopy|The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.
Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue.
239553|NCT02445352|Drug|Rosuvastatin 5mg|
239554|NCT02445352|Drug|DP-R207 5/10mg|
239555|NCT02445352|Drug|Rosuvastatin 10mg|
239556|NCT02445352|Drug|DP-R207 10/10mg|
239557|NCT02445352|Drug|Rosuvastatin 20mg|
239558|NCT02445352|Drug|DP-R207 20/10mg|
239559|NCT02445352|Drug|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
239560|NCT02445352|Drug|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
239561|NCT02445352|Drug|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
239562|NCT02445365|Device|AutoRIC device|
239563|NCT00169806|Other|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
243980|NCT02526446|Behavioral|Self-administered acupressure|This intervention included total 30-hr self-administered acupressure training and practice over 8 weeks: (i) Group learning and practice: A 1-hr introduction of self-administered acupressure followed by a 1-hour training session twice a week for two weeks (4 hours), (ii) Self-practice: A total of 21-hr self-practice at home, 15-minute twice a day for 6 weeks following the completion of the 2-week training session, (iii) Home visit: A 4-hr home visit, 1-hour twice a week for 2 weeks to reinforce learning and self-practice, and (iv) Monitoring for compliance: twice a week phone calls will be made during the 5th to 8th week of the intervention, by a senior year TCM student to remind the participant to perform the self-administered acupressure with feedback for any questions or concerns.
243981|NCT02526446|Other|Health education|The control group will receive monthly general health education sessions unrelated to acupressure, commencing at the point when the intervention group starts. Once the intervention group has completed the entire intervention program, the participants in the control group will receive the same self-administered acupressure program.
243982|NCT02526459|Behavioral|Birth plan|Patient will receive a birth plan
243983|NCT02526472|Procedure|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
243984|NCT02526472|Procedure|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
239248|NCT02449733|Other|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
239249|NCT02449733|Procedure|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
239250|NCT02449733|Behavioral|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
239251|NCT02449746|Biological|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
239252|NCT02452034|Drug|Posaconazole powder for oral suspension|Posaconazole 300 mg powder for oral suspension
239253|NCT02452047|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
243686|NCT00183092|Drug|Quinacrine|100mg by mouth three times a day
243687|NCT02530879|Behavioral|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
243688|NCT02530879|Other|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
243689|NCT02530892|Procedure|EmbryoHug|An embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity.
243690|NCT02530905|Drug|SRP-4045|
243691|NCT02530905|Drug|Placebo|
243692|NCT02530918|Drug|DS-7080a|1.0, 2.0, or 4.0 mg by intravitreal (IVT) injection of a 50 μL of solution administered every 4 weeks for 12 weeks.
243693|NCT02530918|Drug|Ranibizumab|0.5 mg by IVT injection of a 50μL of solution administered every 4 weeks for 12 weeks.
243694|NCT02530931|Drug|Gadolinium|diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
243695|NCT02530957|Device|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
243696|NCT02530957|Device|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
243697|NCT00183092|Drug|Placebo|100mg by mouth three times a day
243698|NCT02530983|Other|Mayo Clinic Conduit Report Card Questionnaires|Patients will be asked to complete the Mayo Clinic Conduit Report Card Questionnaires at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
243699|NCT02530996|Drug|BH4|BH4 is between 5-20 mg/kg/day given to a total of 32 SSc patients (16 complicated, 16 uncomplicated)
243700|NCT02533076|Device|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
243701|NCT02533089|Other|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
243135|NCT02505399|Drug|clopidogrel|Clopidogrel will be administered orally, according to the following scheme:
300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
75 mg the following morning (D Day before rotational atherectomy and angioplasty),
0 mg the following evening (D Day after rotational atherectomy and angioplasty),
75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).
243136|NCT00179764|Radiation|CNS prophylaxis radiation|Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.
Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant.
243400|NCT00183716|Behavioral|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
243401|NCT02538042|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking <10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked <10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
243402|NCT02538042|Drug|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
243403|NCT02538042|Behavioral|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
243404|NCT02538042|Behavioral|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
243405|NCT02538055|Behavioral|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
243406|NCT02538055|Behavioral|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
243407|NCT02538068|Behavioral|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
243408|NCT02538068|Behavioral|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
243409|NCT02538081|Drug|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
243410|NCT02538081|Drug|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
243411|NCT00183729|Drug|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
243412|NCT02538094|Device|Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes or sham stimulation using Eldith Neuro-Conn stimulator
242831|NCT02512367|Other|Surveillance|
242832|NCT02512380|Drug|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
242833|NCT02512380|Drug|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
242834|NCT02512393|Device|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
242835|NCT02514486|Behavioral|Questionnaire|
242836|NCT02514499|Other|Questionnaires|
242837|NCT02514512|Device|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
242838|NCT02514525|Device|CryoBalloon Ablation System|A balloon-based cryotherapy device provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
242839|NCT00180674|Drug|Warfarin|
243137|NCT02507700|Drug|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
243138|NCT02507700|Device|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
243139|NCT02507700|Other|Plaster cover|Plaster cover will be used to control group for sham procedure
243140|NCT02507700|Drug|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
243141|NCT02507700|Other|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
243142|NCT02507726|Device|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
243143|NCT02507739|Other|no possibility to walk during labor|
243144|NCT02507739|Other|possibility to walk during labor|
243145|NCT02507765|Other|Laboratory Biomarker Analysis|Correlative studies
243146|NCT02507765|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
267596|NCT02356211|Other|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIACTRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
267597|NCT02356211|Other|Falls e-consult|Electronic medical record review for falls assessment (Falls e-consult) was also available to primary care physicians during the time of the study. Recommendations were made based on information available in the EMR, but without the benefit of a history and physical targeted at falls assessment.
267598|NCT02356224|Drug|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
267599|NCT02356224|Drug|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
267600|NCT00158574|Drug|mefloquine|
267601|NCT02356237|Other|No episiotomy|Avoidance of episiotomy
267602|NCT02356276|Procedure|D2 lymphadenectomy|
267603|NCT02356276|Procedure|HIPEC|HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.
267604|NCT02356276|Drug|Systemic chemotherapy (XELOX)|Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine:
1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/ intolerance.
267605|NCT02356289|Drug|Placebo|
267606|NCT02356289|Drug|MYK-461|
267607|NCT02356302|Device|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|Contains 182 mg vicriviroc (MK-4176).
267608|NCT02356302|Device|MK-2048 IVR|Contains 30 mg MK-2048.
267899|NCT02390076|Device|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
267900|NCT02390076|Device|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
267901|NCT00162513|Biological|Allogeneic tumor cell vaccine|
267902|NCT02390089|Drug|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
267303|NCT02361060|Drug|Atropine|10 mcg/kg
267304|NCT02361086|Drug|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
267305|NCT02361099|Other|Monitoring by SENTINEL application|Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
267306|NCT02361112|Drug|pyrotinib combined with capecitabine|
267307|NCT02361125|Drug|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
267308|NCT02363764|Other|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients >6 years of age
267309|NCT02363777|Procedure|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic infusion is run postoperatively
267310|NCT02363777|Procedure|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
267311|NCT02363790|Procedure|LVHR PFC|Information included in arm description
267312|NCT02363790|Procedure|Bridging LVHR|Information included in arm description
267313|NCT02363803|Drug|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
267314|NCT02363803|Drug|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
267315|NCT02363829|Drug|Nelfinavir|
267316|NCT02363829|Biological|Cisplatin|
267317|NCT02363842|Device|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
267318|NCT00159341|Procedure|Nasal filter paper|Nasal filter paper was placed at specified timepoints
267319|NCT02363842|Other|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
267609|NCT02356302|Device|MK-2048A IVR|Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
267610|NCT02356302|Device|Placebo IVR|
267611|NCT00158574|Drug|Chlorproguanil-dapsone|
266724|NCT02374983|Other|Gamma knife radiosurgery re-planning with convolution algorithm|The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.
Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms.
266725|NCT02375009|Procedure|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
266726|NCT00160563|Drug|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
267018|NCT02368249|Drug|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
267019|NCT02368262|Other|Questionnaire and micturition and drinking diaries|Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.
Diaries: 24-hour voiding chart
267020|NCT02368262|Procedure|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
267021|NCT02368288|Drug|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
267022|NCT02368301|Drug|Elotuzumab|
267023|NCT02368314|Drug|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
267024|NCT02368327|Biological|Fluad|
267025|NCT02368327|Biological|Fendrix|
267026|NCT02368327|Biological|Placebo|
267027|NCT02370667|Other|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
267028|NCT02370680|Drug|Aspirin|steady-state run-in prior to Durlaza treatment
267029|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
267030|NCT02370680|Drug|Durlaza™|comparison of different numbers of capsules
267031|NCT02370693|Drug|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 48 weeks
267032|NCT02370693|Drug|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 48 weeks
266416|NCT02379689|Drug|Placebo|
266417|NCT00161239|Drug|Doxil, Methotrexate, L-Asparaginase, Prednisone|
266418|NCT02379702|Other|Metabolic Syndrome|This study will provide important information on the social and economic dimensions of metabolic syndrome
266419|NCT02379715|Drug|Remifentanil|
266420|NCT02382224|Behavioral|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
266421|NCT02382224|Behavioral|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
266422|NCT02382237|Device|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
266423|NCT02382250|Behavioral|Survey|Survey will be given to all participants
266424|NCT02382263|Drug|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
266425|NCT02382263|Drug|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
266727|NCT02375022|Drug|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
266728|NCT02375035|Device|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
266729|NCT02375048|Radiation|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
266730|NCT02375048|Radiation|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
266731|NCT02375061|Behavioral|e-BPS|
266732|NCT02375061|Behavioral|Daily Activities|
266733|NCT02375074|Behavioral|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
266734|NCT02375074|Behavioral|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
266140|NCT02389322|Biological|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
266141|NCT02389322|Biological|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
266142|NCT02389322|Biological|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
266143|NCT02389348|Drug|DSM265|Single oral doses of DSM265
266144|NCT02389348|Drug|OZ439|Single oral doses of OZ439
266145|NCT00162409|Drug|Folic acid|
266146|NCT02389361|Drug|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
266147|NCT02389361|Drug|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
266148|NCT02389374|Drug|chloroquine|standard dose
266149|NCT02389374|Drug|Artemether-lumefantrine combination|standard dose
266150|NCT02389374|Drug|Primaquine|single dose
266151|NCT02389374|Drug|Primaquine|14 days
266152|NCT02389387|Other|Behavioral Interventions for Dialysis Facilities|Educational seminars and monthly educational webinars
Peer-to-peer mentoring program
Bulletin boards about transplantation
Facility-specific feedback reports detailing transplant referral data for their center compared to state average
Formulate a facility-specific improvement plan to increase transplant referrals.
Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.
Monthly monitoring and reporting of patient referrals to ESRD Network
Conduct a patient and family education session about transplantation
Host a movie day to show Living ACTS (About Choices in Transplantation & Sharing) video
266153|NCT02389400|Drug|methotrexate|Single Group Assignment
266154|NCT02389413|Drug|PQ912 oral|
266155|NCT02389413|Other|Placebo|
266156|NCT00162422|Drug|albuterol|
266426|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
265598|NCT02367664|Biological|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
265599|NCT02367664|Biological|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
265874|NCT02358187|Biological|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
265875|NCT02358200|Drug|BMN-673|
265876|NCT02358200|Drug|Carboplatin|
265877|NCT02358200|Drug|Paclitaxel|
265878|NCT00158730|Drug|AmBisome|
265879|NCT02358213|Procedure|Ultrasound|Ultrasound examinations are done 5 times
265880|NCT02358226|Behavioral|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
265881|NCT02360384|Drug|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
265882|NCT02360384|Dietary Supplement|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
265883|NCT02360397|Drug|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
265884|NCT02360410|Behavioral|Check Yourself App with Feedback|
265885|NCT02360423|Device|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
265886|NCT02360423|Device|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
265279|NCT02372643|Other|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
265280|NCT02372656|Drug|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
265281|NCT02374567|Drug|Amisulpride|
265282|NCT02374567|Drug|Prothipendyl|
265283|NCT00160459|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
265284|NCT02374567|Drug|Risperidone|
265285|NCT02374567|Drug|Aripiprazole|
265286|NCT02374567|Drug|Paliperidone|
265287|NCT02374567|Drug|Diazepam|
265288|NCT02374567|Drug|Oxazepam|
265289|NCT02374567|Drug|Lorazepam|
265290|NCT02374567|Drug|Bromazepam|
265291|NCT02374567|Drug|Clobazam|
265292|NCT02374567|Drug|Alprazolam|
265600|NCT02367677|Other|Method comparison|
265601|NCT02367690|Drug|Selinexor|Topical gel
265602|NCT02367690|Other|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
265603|NCT02367690|Other|Vehicle Gel|Topical vehicle gel with no active ingredients.
265604|NCT02367703|Procedure|laparoscopic hysterectomy|
265605|NCT00159770|Procedure|Blood tests|
265606|NCT02367716|Device|CRT|Quartet™ left heart leads or any newer St. Jude Medical quadripolar CRT systems including CRT-P systems that CFDA might approve in the future
265607|NCT02367729|Device|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
265608|NCT02367729|Device|Sham|Inactive neurostimulator device programmed to turn off after 5 min of use. To be worn for 5 days each week x 4 weeks.
264984|NCT02379078|Other|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
264985|NCT02379078|Other|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
264986|NCT02379078|Other|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
264987|NCT02379091|Drug|Namilumab|Namilumab subcutaneous injection
264988|NCT02379091|Drug|Placebo|Namilumab placebo-matching subcutaneous injection
264989|NCT02379091|Drug|Methotrexate|Methotrexate
264990|NCT02379091|Drug|Folic/folinic acid|Folic/folinic acid
264991|NCT02379104|Device|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
264992|NCT02379130|Behavioral|Family Nurture Intervention|The child will be asked to sit on the mother's lap during a five minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will remain on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached to further engage the child with soothing and calming. Should the child will become dysregulated at some point during the visit, the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
264993|NCT00002424|Drug|Lamivudine|
264994|NCT00161122|Biological|trivalent inactivated influenza vaccine|
264995|NCT02379130|Behavioral|Play and Nutrition Intervention|The intervention begins with the Welch Lap test. The child will be asked to sit on the mother's lap during a five minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
264996|NCT02379143|Other|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
264997|NCT02379156|Drug|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
265293|NCT02374567|Drug|Hydroxyzine|
265294|NCT00160459|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
265295|NCT02374567|Drug|Buspirone|
264389|NCT02390973|Procedure|Sleeve Gastrectomy|
264390|NCT02390973|Procedure|Roux-en-Y Gastric Bypass|
264391|NCT02390973|Procedure|Biliopancreatic Diversion with Duodenal Switch|
264392|NCT02390973|Other|Medical management|
264677|NCT02384031|Device|Traumatic needle|Lumbar puncture is performed with a traumatic needle
264678|NCT02384031|Device|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
264679|NCT02386436|Drug|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
264680|NCT02386436|Drug|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume [w/v] Sodium Chloride) administered as single dose s.c.
264681|NCT02386449|Drug|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
264682|NCT02386449|Drug|mannitol|
264683|NCT02386449|Drug|Bisacodyl|
264684|NCT02386462|Drug|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
264685|NCT02386462|Drug|Propofol|
264686|NCT02386475|Other|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
264687|NCT00162084|Drug|apadenoson|
264688|NCT02386475|Drug|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
264689|NCT02386475|Drug|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
264690|NCT02386488|Drug|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
264691|NCT02386488|Drug|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
264692|NCT02386488|Drug|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
269065|NCT02351856|Drug|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
269066|NCT02351869|Drug|Nitrous Oxide|
269067|NCT02351869|Drug|Placebo|
269068|NCT00158171|Dietary Supplement|Folic Acid|400 mg
269069|NCT02351882|Drug|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
269070|NCT02351882|Drug|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
264393|NCT02354729|Other|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
264394|NCT00158418|Procedure|Uncemented Humeral Stem|
264395|NCT02354742|Other|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
264396|NCT02354742|Other|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
264397|NCT02354755|Device|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
264398|NCT02354768|Drug|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
264399|NCT02354768|Drug|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
264400|NCT02354781|Biological|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
264401|NCT02354794|Dietary Supplement|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
264402|NCT02354794|Dietary Supplement|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
264403|NCT02354807|Drug|Mirabegron|One-time dose of 100mg of Mirabegron
264404|NCT02354807|Other|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
264405|NCT00158431|Procedure|Arthroscopy plus Medical Management|Arthroscopic Surgery
264406|NCT02354820|Other|Evidence Based Constipation Reminders|
240144|NCT02538991|Procedure|Tension-free Vaginal Tape|TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
240145|NCT02539004|Other|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
240146|NCT00183885|Drug|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
240147|NCT02539017|Drug|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
240148|NCT02539017|Biological|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
240149|NCT02539030|Procedure|Microfracture|simple microfracture
240150|NCT02539030|Device|CartiFill|add collagen when doing microfracture
240151|NCT02504021|Behavioral|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
240152|NCT02504034|Procedure|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
240153|NCT02504034|Device|6-French sheath|
240154|NCT02504034|Device|22-gauge chiba needle|
240155|NCT00179283|Drug|venlafaxine XR|
240156|NCT02504034|Device|260-cm-long stiff shaft wire|
240157|NCT02504034|Device|Balloon catheter|
240158|NCT02504034|Device|Bare metal stent|
240159|NCT02504034|Device|Covered stent|
240160|NCT02504047|Procedure|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 & 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
239564|NCT02445378|Procedure|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
239565|NCT02445378|Other|Placebo|Undergo placebo intervention using rose water
239566|NCT02445378|Other|Questionnaire Administration|Ancillary studies
239567|NCT02445391|Drug|Carboplatin|Given IV
239568|NCT02445391|Drug|Cisplatin|Given IV
239569|NCT02445391|Other|Laboratory Biomarker Analysis|Correlative studies
239570|NCT02445391|Other|Quality-of-Life Assessment|Ancillary studies
239858|NCT02508792|Device|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
239859|NCT00179920|Drug|Carboplatin|
239860|NCT02508792|Device|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
239861|NCT02508805|Drug|Neuromultivit|
239862|NCT02508805|Drug|Voltaren|
239863|NCT02508805|Drug|Sirdalud|
239864|NCT02508818|Other|Parabolic flight|
239865|NCT02508818|Other|Cardiovascular measurements|
239866|NCT02508831|Procedure|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
239867|NCT02508844|Dietary Supplement|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
239868|NCT02508844|Dietary Supplement|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
239869|NCT02511041|Drug|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- & lt;=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
239870|NCT02511041|Drug|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
239254|NCT02452047|Drug|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (~180 to 360 mg CMS), depending on renal function, once every 12 hours
239255|NCT02452047|Drug|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
239256|NCT00170950|Drug|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
239257|NCT02452047|Drug|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
239258|NCT02452060|Drug|Ketamine|0.4mg/kg infusion
239259|NCT02452060|Other|Placebo Comparator|0.4mg/kg infusion
239260|NCT02452073|Other|Thyroid function tests|
239261|NCT02452086|Device|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
239262|NCT02452086|Procedure|Placebo|LLLT with zero intensity
239263|NCT02452099|Procedure|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
239264|NCT02452099|Procedure|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
239571|NCT02445404|Drug|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
239572|NCT02445404|Drug|fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
239573|NCT02445443|Device|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
239574|NCT00169819|Drug|Abciximab|
239575|NCT02445456|Drug|Sienna+ injection|Endoscopic injection of magnetic tracer
239576|NCT02445456|Other|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
239577|NCT02445456|Procedure|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
239578|NCT02445456|Device|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
239579|NCT02445469|Other|MRI exam of the brain|MRI exam of the brain
243985|NCT02526485|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
243986|NCT02526498|Radiation|Accelerated Partial Breast Irradiation|Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
243987|NCT02526498|Radiation|High-Dose Rate Brachytherapy|Undergo APBI using HDR brachytherapy
243988|NCT02526498|Other|Laboratory Biomarker Analysis|Correlative studies
243989|NCT00182611|Drug|tegafur-gimeracil-oteracil potassium|
243990|NCT02526498|Other|Questionnaire Administration|Ancillary studies
243991|NCT02526511|Procedure|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
243992|NCT02526511|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
243993|NCT02526511|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
243994|NCT02526511|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
243995|NCT02526524|Drug|Met DR|metformin delayed-release tablets
243996|NCT02526524|Drug|Met IR|metformin immediate-release tablets
243997|NCT02526524|Drug|Placebo|
243998|NCT02526550|Biological|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
243999|NCT02526550|Biological|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
244000|NCT00182611|Procedure|adjuvant therapy|
244001|NCT02528630|Other|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
244002|NCT02528630|Other|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
244003|NCT02528643|Drug|enzalutamide|oral
244004|NCT02528643|Drug|placebo|oral
244005|NCT02528656|Device|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
243413|NCT02538107|Drug|Methoxy-polyethyleneglycol epoetin beta|
243414|NCT02538120|Other|Microvascular assessment|Microvascular assessment
243415|NCT02538133|Biological|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
243416|NCT02538146|Dietary Supplement|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
243417|NCT02503072|Behavioral|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
243702|NCT02533102|Drug|E7050|100 mg tablet administered orally
243703|NCT02533115|Drug|CPX-351|CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC.
243704|NCT02533128|Drug|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 60 mmHg
243705|NCT02533128|Drug|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 75 mmHg
243706|NCT02533141|Device|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
243707|NCT02533141|Device|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
243708|NCT02533141|Drug|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
243709|NCT00002495|Radiation|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
243710|NCT00183339|Drug|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
243711|NCT02533154|Drug|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
243712|NCT02533154|Drug|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
243713|NCT02533154|Other|Bacterial culture|bacterial cultures obtained with conjunctival swabs
243147|NCT00179777|Dietary Supplement|hydrolysed vs nonhydrolysed infant formula vs breast feeding|hydrolysed vs nonhydrolysed infant formula vs breast feeding
243148|NCT02507765|Procedure|Transarterial Chemoembolization|Undergo TACE
243149|NCT02507778|Device|CellCollectorTM (Gilupi, Germany) needle|
243150|NCT02507791|Other|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
243151|NCT02507804|Other|Patient diary PROMs|
243152|NCT02507804|Other|Counselling|
243153|NCT02507817|Other|blood sample and tissue sample|Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.
A small sample of the placenta will be examined in order to assess the level of ACTH protein
243154|NCT02507843|Drug|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
243155|NCT02507843|Drug|Placebo|Placebo will be administered in placebo group monthly for 6 months.
243156|NCT02507869|Behavioral|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
243157|NCT02507869|Behavioral|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
243158|NCT00179790|Procedure|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
243418|NCT02503085|Drug|Ibuprofen Suspension|
243419|NCT02503098|Behavioral|Recovery Record adaptive smartphone application|
243420|NCT02503098|Behavioral|Recovery Record standard smartphone application|
243421|NCT02503111|Device|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
243422|NCT02503111|Device|Infrared Coagulator by Redfield Corporation|Treatment with the Infrared Coagulator by Redfield Corporation involves the delivery of light in ghd infrared spectrum to dysplastic areas, thus fulgurating the superficial layers of the mucosa.
243423|NCT02503111|Other|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
243424|NCT02503124|Behavioral|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
267903|NCT02390089|Other|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
267904|NCT02390089|Radiation|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
267905|NCT02390089|Device|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
267906|NCT02390102|Drug|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
267907|NCT02390102|Drug|Placebo|Saline solution 0.9%
267908|NCT02390115|Other|Elastic tape application in shoulder|
267909|NCT02390128|Other|observational only|
267910|NCT02390141|Drug|ZP4207|
267911|NCT02390141|Drug|Placebo|
267912|NCT00162526|Drug|Tocopherol|
267913|NCT02390154|Drug|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of [14C] roniciclib solution
267914|NCT02390154|Drug|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
267915|NCT02390180|Other|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
267916|NCT02390193|Procedure|Hemodialysis|Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.
The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.
The patients who required a change in medication for medical reasons were subsequently excluded from the study.
267917|NCT02390219|Drug|Lumacaftor|
268232|NCT02385292|Device|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
268233|NCT02385305|Device|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
267612|NCT02356315|Other|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
267613|NCT02356328|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
267614|NCT02356341|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
267615|NCT02358850|Drug|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
267616|NCT00158782|Drug|GW786034|
267617|NCT02358850|Drug|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
267618|NCT02358850|Drug|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
267619|NCT02358850|Drug|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
267620|NCT02358863|Drug|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
267621|NCT02358863|Drug|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
267622|NCT02358863|Drug|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
267623|NCT02358863|Drug|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
267624|NCT02358863|Drug|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
267625|NCT02358863|Drug|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
267626|NCT02358863|Drug|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
267627|NCT00158782|Drug|lapatinib|
267628|NCT02358863|Drug|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
267629|NCT02358889|Biological|hI-con1|Intravitreal injection of hI-con1 0.3 mg
267630|NCT02358889|Biological|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
267631|NCT02358889|Other|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
267033|NCT02370693|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 48 weeks
267034|NCT02370706|Drug|PIM447|pan-pim inhibitor
267035|NCT02370706|Drug|Ruxolitinib|JAK1/JAK2 inhibitor
267036|NCT02370706|Drug|LEE011|CDK4/6 inhibitor
267037|NCT02370719|Behavioral|Mobile application for diabetes self-management|
267038|NCT02370732|Other|Alcohol|A weight based dose of alcohol will be administered during each study day.
267039|NCT02370745|Drug|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
267040|NCT00002420|Drug|Hydroxyurea|
267320|NCT02363855|Drug|BAY 1841788|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
267321|NCT02363920|Device|HOF|the addition of high oxygen flow to patients breathing spontaneously
267322|NCT02363920|Device|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
267323|NCT02363933|Drug|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
267324|NCT02363946|Drug|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
267325|NCT02363946|Other|Placebo|0.9 % normal saline
267326|NCT02363959|Drug|Hyperbaric Oxygen Therapy|2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
267327|NCT02363959|Procedure|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
267328|NCT02363972|Device|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
267329|NCT00159341|Procedure|Blood sampling|Blood sampling was performed as a routine safety check
267330|NCT02366091|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
266735|NCT02375100|Procedure|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
266736|NCT02375100|Procedure|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
266737|NCT00160563|Other|Placebo|Oral drops, bid for 18 months
266738|NCT02375100|Procedure|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
266739|NCT02375100|Drug|Bupivacaine %0.5 (hyperbaric)|
266740|NCT02375100|Drug|Bupivacaine %0.25 (isobaric)|
266741|NCT02377362|Drug|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
266742|NCT02377375|Procedure|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
266743|NCT02377375|Procedure|Standard technique|Medtronic DBS lead 3391-28cm
266744|NCT02377388|Drug|saxagliptin|saxagliptin tablets, 48(+-12) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
266745|NCT02377388|Drug|placebo|placebo tablets, 48(+-12) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
267041|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
267042|NCT02370745|Drug|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
267043|NCT02370745|Dietary Supplement|Oral amino acids|Oral amino acids containing 15 g of amino acids
267044|NCT02370745|Drug|GIP|This will be co infused with GLP-1 and intravenous amino acids
267045|NCT02370745|Drug|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
267046|NCT02370758|Drug|Valganciclovir or Ganciclovir|
267047|NCT02370771|Procedure|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
267048|NCT02370771|Procedure|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
266427|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
266428|NCT02382276|Drug|Nalmefene hydrochloride|
266429|NCT00161486|Drug|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
266430|NCT02382289|Procedure|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
266431|NCT02382302|Device|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
266432|NCT02382315|Behavioral|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
266433|NCT02382328|Drug|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
266434|NCT02382341|Device|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
266435|NCT02382354|Drug|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
266436|NCT02382354|Device|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
266437|NCT02382354|Device|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
266438|NCT02382354|Drug|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
266439|NCT02382367|Other|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
266440|NCT00002427|Drug|Hydroxyurea|
266441|NCT02384642|Behavioral|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
266442|NCT00161811|Biological|Vero Cell-derived Influenza Vaccine|
266443|NCT02384655|Drug|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
265887|NCT02360449|Behavioral|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
265888|NCT02360462|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
265889|NCT02360462|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
265890|NCT00158951|Device|CONTAK RENEWAL 2/4/4HE CRT-D|
266157|NCT02389426|Device|TCD baseline|Measurement of cerebral circulation parameters with transcranial doppler baseline.
This examination will be performed in patients with multiple sclerosis and in healthy controls.
266158|NCT02389426|Device|TCD after bosentan administration|Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.
This examination will only be performed in patients with multiple sclerosis.
266159|NCT02391571|Drug|Placebo|2 day placebo run in prior to test and active drug phase of study
266160|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
266161|NCT02391584|Device|XprESS Device|Balloon dilation
266162|NCT02391610|Other|No intervention|
266163|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
266164|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
266165|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
266166|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
266167|NCT02391636|Drug|Carbetocin|at delivery of anterior shoulder
266168|NCT02391636|Drug|Oxytocin|at delivery of anterior shoulder
266169|NCT02391649|Behavioral|bibliotherapy program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the [psychosocial] effects of the illness; and Module 5:Dealing with [physical and mental health] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
265609|NCT02367742|Behavioral|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
265610|NCT02367742|Behavioral|EA + Resistance Training (RT)|Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:
Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%.
265611|NCT02367755|Drug|Propofol|Propofol use during therapeutic hypothermia
265612|NCT02367755|Drug|Lorazepam|Lorazepam use during therapeutic hypothermia
265613|NCT02367781|Drug|Atezolizumab (MPDL3280A)|1200 mg intravenous (IV) infusion on Day 1 of each 21-day cycle
265614|NCT02370121|Drug|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
265615|NCT02370121|Drug|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
265616|NCT02370134|Device|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
265617|NCT02370134|Device|sham glove|
265618|NCT02370147|Behavioral|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
265619|NCT00160004|Behavioral|Intensive Controlled Exercise|
265891|NCT02360475|Biological|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
265892|NCT02360475|Biological|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
265893|NCT02360475|Biological|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
265894|NCT02360475|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
265895|NCT02360488|Device|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
265896|NCT02360488|Behavioral|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
265296|NCT02374567|Drug|Chloral Hydrate|
265297|NCT02374567|Drug|Flurazepam|
265298|NCT02374567|Drug|Nitrazepam|
265299|NCT02374567|Drug|Triazolam|
265300|NCT02374567|Drug|Lormetazepam|
265301|NCT02374567|Drug|Temazepam|
265302|NCT02374567|Drug|Midazolam|
265303|NCT02374567|Drug|Brotizolam|
265304|NCT02374567|Drug|Zopiclone|
265305|NCT00160459|Drug|Placebo|Tablet, oral Daily for 12 weeks
265306|NCT02374567|Drug|Zolpidem|
265307|NCT02374567|Drug|Zaleplon|
265308|NCT02374567|Drug|Melatonin|
265309|NCT02374567|Drug|Clomethiazole|
265310|NCT02374567|Drug|Diphenhydramine|
265311|NCT02374567|Drug|Promethazine|
265312|NCT02374567|Drug|Imipramine|
265313|NCT02374567|Drug|Clomipramine|
265314|NCT02374567|Drug|Opipramol|
265315|NCT02374567|Drug|Trimipramine|
265316|NCT00160472|Procedure|removal of ovarian vessels|
265317|NCT02374567|Drug|Amitriptyline|
265318|NCT02376673|Other|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
265319|NCT02376686|Other|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
265320|NCT02376699|Drug|SEA-CD40|Given intravenously at least every 3 weeks. Number of cycles: until progression or unacceptable toxicity develops.
264693|NCT02386488|Drug|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
264694|NCT02386501|Drug|ADXS31-164|
264695|NCT02386540|Behavioral|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
264696|NCT02386553|Drug|ISIS SMNRx (ISIS 396443)|Solution for intrathecal injection
264998|NCT02379156|Other|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
264999|NCT02379169|Dietary Supplement|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
265000|NCT02379169|Dietary Supplement|Placebo|Triglycerides of medium chain fatty acids
265001|NCT02379182|Behavioral|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
265002|NCT02381535|Drug|Cisplatin|Given IV
265003|NCT02381535|Drug|Hsp90 Inhibitor AT13387|Given IV
265004|NCT00002426|Drug|Adefovir dipivoxil|
265005|NCT00161434|Drug|valacyclovir|1 gram daily for 8 weeks
265006|NCT02381535|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
265007|NCT02381535|Other|Laboratory Biomarker Analysis|Correlative studies
265008|NCT02381535|Other|Pharmacological Study|Correlative studies
265009|NCT02381548|Drug|Belinostat|Given IV
265010|NCT02381548|Other|Laboratory Biomarker Analysis|Correlative studies
265011|NCT02381548|Other|Pharmacological Study|Correlative studies
265012|NCT02381548|Drug|WEE1 Inhibitor AZD1775|Given PO
265013|NCT02381561|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
240777|NCT02527434|Biological|MEDI4736 + tremelimumab combination therapy|IV infusion
240778|NCT02527460|Drug|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
240779|NCT02527473|Other|Dispatcher-Assisted Basic Life Support CPR Education|The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.
The one hour training session is split into four parts:
Video self-instruction manikin practice (30 min), including a brief introduction to AED.
Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer
Debriefing (15 min): Questions, answers and reflection
Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone
240780|NCT02527499|Behavioral|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
240781|NCT02527499|Behavioral|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
240782|NCT02529670|Procedure|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
240783|NCT02529683|Drug|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
240784|NCT02529696|Device|Accelerometer|Measures patient movement
240785|NCT02529709|Other|High-Protein Condition|The participants will be fed a high-protein meal
240786|NCT00182832|Behavioral|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
240787|NCT02529709|Other|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
241096|NCT02522871|Device|OCS™ Liver System|
241097|NCT02522871|Other|Control|
241098|NCT02522884|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
241099|NCT02522897|Drug|Ranibizumab|
241100|NCT02522897|Device|Laser|
240161|NCT02504060|Drug|Starch Placebo|
240162|NCT02504060|Drug|N-acetyl-D-glucosamine|
240460|NCT02534246|Device|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) from single lesion.
240461|NCT02534246|Device|Ultrasound biopsy needle SharkCore|
240462|NCT00183417|Behavioral|Bibliotherapy|Participants will be given a book on how to increase their mood.
240463|NCT02534259|Other|Force monitoring of external fixator struts|
240464|NCT02534272|Other|Stool sampling and sequencing of gut microbiota.|
240465|NCT02534285|Device|hearing protection|Attenuation of hearing during surgery
240466|NCT02534298|Other|functional magnetic resonance imaging|functional magnetic resonance imaging
240467|NCT02534311|Drug|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
240468|NCT02534324|Drug|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
240469|NCT02534337|Drug|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
240470|NCT02534337|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
240471|NCT02536742|Drug|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
240472|NCT02536755|Drug|eliglustat|Pharmaceutical form:capsule
Route of administration: oral
240473|NCT02536768|Behavioral|Minimum package of interventions to improve ART adherence|Package of 5 interventions to improve ART adherence
240474|NCT02536781|Drug|Anthocyanin|Anti-inflammation gel
240475|NCT02536781|Drug|Placebo|Blank gel
240476|NCT02536794|Biological|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
240477|NCT02536794|Other|Laboratory Biomarker Analysis|Correlative studies
239871|NCT02511054|Drug|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
239872|NCT02511054|Drug|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
239873|NCT02511054|Biological|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
239874|NCT02511067|Drug|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
240163|NCT02504073|Other|Exploratory sequential design|Building from qualitative data to quantitative data.
240164|NCT02504086|Behavioral|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
240165|NCT02504099|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; Ombitasvir coformulated with Paritaprevir and ritonavir
240166|NCT00179309|Drug|Docetaxel|35 mg/m^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
240167|NCT02504099|Drug|Dasabuvir|Tablet
240168|NCT02504099|Drug|Ribavirin|Tablet
240169|NCT02504112|Other|there is no intervention|
240170|NCT02504125|Drug|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
240171|NCT02504125|Drug|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
240172|NCT02504138|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
240173|NCT02504138|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
240174|NCT02504151|Drug|Cannabidiol|
240175|NCT02504151|Drug|Placebo|
239580|NCT02445482|Procedure|Biopsy|archival tissue or fresh biospsy
239581|NCT02445495|Device|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
239582|NCT02445508|Drug|Sevelamer|
239583|NCT02517853|Device|Posterior tibial nerve stimulation|
239584|NCT02517853|Device|Sham posterior tibial nerve stimulation|
239585|NCT02517866|Drug|Azilsartan Medoxomil|Azilsartan medoxomil tablets
239586|NCT02517879|Other|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
239587|NCT02517879|Other|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
239588|NCT00181220|Drug|valproic acid|
239589|NCT02517892|Procedure|Biopsy|
239590|NCT02517905|Drug|Bupivacaine liposome|Local administration
239591|NCT02517905|Drug|Placebo|Local administration
239592|NCT02517918|Drug|Sirolimus combined with CP, MT and ZA|Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established.
239875|NCT00180141|Drug|Elidel-Creme|
239876|NCT02511067|Drug|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
239877|NCT02511080|Device|Spot-On|use of active hot measures
239878|NCT02511093|Behavioral|TBC intervention|A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:
BP measurements;
an educational and counselling intervention on patient adherence;
an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback.
239879|NCT02511106|Drug|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
239880|NCT02511106|Drug|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
244006|NCT02528656|Device|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
244007|NCT00182793|Drug|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
239265|NCT02452099|Procedure|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
239266|NCT02452112|Drug|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
239267|NCT00170950|Drug|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
239268|NCT02452112|Drug|Placebo|Placebo patch to be placed on the site of pain
239269|NCT02452125|Dietary Supplement|Nicotine gum|Nicotine chewing gum
239270|NCT02452138|Other|Severe sepsis management|
239271|NCT02452151|Drug|Infliximab-Biosimilar|
239272|NCT02452151|Drug|Infliximab-Innovator|
239273|NCT02452164|Other|Teaching|
239274|NCT02452164|Device|(CellScopeOTO)|
239275|NCT02452177|Drug|Vitamin D|
239276|NCT02452190|Drug|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
239277|NCT02452190|Drug|Placebo|Matching Placebo
239278|NCT00170950|Drug|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
239279|NCT02454231|Biological|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
239280|NCT00002465|Drug|megestrol acetate|
239281|NCT00171236|Drug|Fluvastatin|
239282|NCT02454231|Biological|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
243714|NCT02533167|Other|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
243715|NCT02533180|Procedure|Immunosuppression withdrawal|Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.
CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.
If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-NI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued.
243716|NCT02533193|Procedure|ERAS perioperative cares|Patient's preoperative counseling & education before surgery
No Bowel preparation
Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery
Drug: methylprednisolone (Pfizer Manufacturing Belgium). 500mg intravenous injection before operation
Fluid restriction & Management by pulse contour analysis or transesophageal doppler
Early mobilization
Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)
Intravenous patient controlled analgesics (no opioids analgesics)
Postoperative Nausea Active Control
No nasogastric tube
No drain insertion
Patients will be discharged at POD#4 if there's no problem
243717|NCT02535598|Behavioral|Enhanced support|Participants are offered daily support through the internet from trained therapists.
244008|NCT02528669|Device|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
244009|NCT02528682|Biological|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
244010|NCT02528695|Radiation|18F-FDG PET/CT|18F-FDG PET/CT
244011|NCT02528695|Device|euglycemic clamp|euglycemic clamp
244012|NCT02528695|Device|hypoglycemic clamp|hypoglycemic clamp
244013|NCT02528708|Drug|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
244014|NCT02528708|Drug|Placebo|0.9% saline solution
244015|NCT02528760|Drug|Metaclopramide|23. Metoclopromide to be given 10mg iv 8 hourly
244016|NCT02528760|Drug|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
244017|NCT02528760|Other|Placebo|
244018|NCT00002494|Drug|therapeutic hydrocortisone|
244019|NCT00182793|Drug|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
243425|NCT02503124|Device|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
243426|NCT00002487|Drug|methotrexate|
243427|NCT00179166|Drug|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
243428|NCT02503124|Other|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
243429|NCT02503124|Other|Informative meeting|A short sleep hygiene consultation.
243430|NCT02503124|Drug|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
243431|NCT02503137|Drug|Topical SM04554 solution|
243432|NCT02503137|Drug|Topical Vehicle solution|
243433|NCT02503150|Biological|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
243718|NCT02535611|Drug|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
243719|NCT02535611|Drug|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
243720|NCT00183521|Behavioral|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
243721|NCT02535624|Procedure|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
243722|NCT02535624|Procedure|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
243723|NCT02535637|Other|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
243724|NCT02535650|Drug|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
268234|NCT02385318|Drug|Ingenol Mebutate (Perrigo)|
268235|NCT02385318|Drug|Ingenol Mebutate (Reference)|
268236|NCT02385318|Drug|Placebo gel|
268237|NCT02385344|Device|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
268238|NCT02385357|Dietary Supplement|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
268239|NCT02385370|Drug|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
268240|NCT02385370|Drug|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
268241|NCT00161928|Biological|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
268242|NCT02385383|Drug|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
268243|NCT02385383|Other|Standard Care|Standard Care in a historical control cohort
268244|NCT02385396|Dietary Supplement|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
268245|NCT02385422|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
268246|NCT02385422|Drug|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
268247|NCT02385435|Drug|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
268248|NCT02385435|Drug|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
268249|NCT02385435|Drug|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
268250|NCT02385448|Drug|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
268251|NCT02385448|Drug|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
268558|NCT02339909|Behavioral|Control|Participants receiving the "active comparator", (i.e. "control") intervention, will be sent the standard diabetic retinopathy screening appointment letter.
268559|NCT02339922|Drug|Ixazomib Citrate|Given PO
267918|NCT02390219|Drug|Ivacaftor|
267919|NCT02390232|Biological|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
267920|NCT02390232|Biological|collection of stools|collection of stools
267921|NCT02390232|Biological|blood sample|collection of blood sample
267922|NCT02392429|Other|Fluorothymidine F-18|Undergo FLT PET/CT
267923|NCT00162799|Drug|Triflusal (DCI)|
267924|NCT02392429|Other|Laboratory Biomarker Analysis|Correlative studies
267925|NCT02392429|Procedure|Positron Emission Tomography|Undergo FLT PET/CT
267926|NCT02392442|Other|Saline|180 of normal saline instilled in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total)
267927|NCT02392442|Biological|Endotoxin|4 ng/kg in final volume of 2 ml
267928|NCT02392455|Drug|treatment|Docetaxel plus nintedanib until progression or intolerability
267929|NCT02392468|Drug|BI 409306 matching placebo|placebo
267930|NCT02392468|Drug|BI 409306 matching placebo|placebo
267931|NCT02392468|Drug|BI 409306|low dose
267932|NCT02392468|Drug|BI 409306|high dose
267933|NCT02392481|Procedure|Biofluid sampling|
267934|NCT00162812|Drug|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
267935|NCT02392494|Drug|MK-1075|MK-1075 will be supplied as 10 mg or 100 mg tablets for oral administration.
267936|NCT02392507|Drug|Necitumumab|Administered IV
267937|NCT02392507|Drug|Nab-Paclitaxel|Administered IV
267938|NCT02392507|Drug|Carboplatin|Administered IV
267939|NCT02392520|Drug|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
267940|NCT02392520|Drug|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
267331|NCT02366091|Drug|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
267332|NCT02366117|Behavioral|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
267333|NCT00159562|Behavioral|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
267334|NCT02366130|Drug|Ra-223 dichloride|50 kBq/kg body weight by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
267335|NCT02366130|Drug|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
267336|NCT02366130|Drug|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
267337|NCT02366143|Drug|Atezolizumab (MPDL3280A)|1200 mg intravenous infusion (IV) on day 1 of each 21-day cycle
267338|NCT02366143|Drug|Bevacizumab|15 mg/kg IV on Day 1 of each 21-day cycle
267339|NCT02366143|Drug|Carboplatin|Area under the concentration curve (AUC) 6 on Day 1 of each 21-day cycle for 4 or 6 cycles
267632|NCT02358902|Device|tDCS|tDCS - DC stimulator, Neurocom, Germany
267633|NCT02358902|Procedure|active intervention of aerobic exercise|different types of aerobic exercise
267634|NCT02358902|Device|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
267635|NCT02358902|Procedure|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
267636|NCT02358915|Device|FastStart neuromuscular electrical stimulator|
267637|NCT02358928|Other|Diet Intervention|
267638|NCT00158795|Biological|Haemophilus Influenza type b vaccine|
267639|NCT02358941|Behavioral|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
267640|NCT02361125|Behavioral|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
267641|NCT00159081|Drug|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
267642|NCT02361138|Drug|SHR3824|
267049|NCT02370784|Drug|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
267050|NCT02370784|Drug|Placebo|oral drug of similar appearance to atorvastatin
267051|NCT02370797|Radiation|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
267052|NCT00160082|Drug|Xepol|
267053|NCT02373241|Drug|Losartan|Experimental dosing
267054|NCT02373254|Drug|Ibuprofen|Ibuprofen 400 mg and 800 mg
267055|NCT02373254|Drug|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
267056|NCT02373267|Biological|Technozyme|determination of ADAMTS13 activity
267057|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
267058|NCT02373280|Drug|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
267059|NCT02373280|Procedure|7 day tailored therapy based on antimicrobial susceptibility testing|The participants will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. The resistance to amoxicillin, clarithromycin, metronidazole, tetracycline and moxifloxacin will be evaluated. Based on antimicrobial susceptibility testing, the participants received PPI based triple therapy[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)] or moxifloxacin triple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)].
267340|NCT02366143|Drug|Paclitaxel|200 mg/m^2 IV, Day 1 of each 21-day cycle for 4 or 6 cycles
267341|NCT02366156|Dietary Supplement|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
267342|NCT02366156|Dietary Supplement|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
267343|NCT02366156|Dietary Supplement|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
267344|NCT00159575|Drug|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
266444|NCT02384668|Dietary Supplement|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
266746|NCT02377401|Drug|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
266747|NCT02377414|Drug|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
266748|NCT02377414|Drug|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
266749|NCT02377427|Drug|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
266750|NCT00160901|Drug|two complex naturopathic add-on therapies, leaflet 5-a-day|
266751|NCT02377466|Drug|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
266752|NCT02377466|Drug|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
266753|NCT02377479|Drug|Clomiphene|Taken for controlled ovarian hyperstimulation.
266754|NCT02377479|Drug|Letrozole|Taken for controlled ovarian hyperstimulation
266755|NCT02377492|Drug|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
266756|NCT02377505|Procedure|Deep Brain Stimulation|Surgical electrode implantation in target 1 (mPFC) or target 2 (NAcc), and implantation of the DBS pulse generating device (Kinetra, Medtronic Inc)
266757|NCT02377505|Device|DBS pulse generating device Kinetra, Medtronic|
266758|NCT02377518|Radiation|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
266759|NCT02377531|Other|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
266760|NCT02377531|Other|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
266761|NCT00002424|Drug|L-756423|
266170|NCT02391649|Behavioral|Psycho-education program|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
266171|NCT00162708|Drug|CDDP, 5 Fu|
266172|NCT02391662|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
266173|NCT02391688|Drug|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
266174|NCT02391688|Drug|Bupropion|
266175|NCT02391688|Drug|Fexofenadine|
266176|NCT02391701|Behavioral|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
266445|NCT02384668|Dietary Supplement|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
266446|NCT02384681|Other|Exposure to auditory fatigue|12-hour auditory exposure
266447|NCT02384694|Other|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
266448|NCT02384707|Other|allegic food|Reintroduction procedure for small doses :
Administration of the first dose
Clinical monitoring for 45 minutes
Administration of the second dose
266449|NCT02384707|Other|Placebo|
266450|NCT02384720|Other|Age: 20-40years|
266451|NCT02384720|Other|Age: 41-64years|
266452|NCT02384720|Other|Age: ≥65years|
266453|NCT00161811|Biological|Egg cell-derived Influenza Vaccine|
266454|NCT02384733|Radiation|Loco-regional RT|
266455|NCT02384746|Drug|Fulvestrant|500 mg intramuscular every 28 days
266456|NCT02384746|Drug|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
266457|NCT02384759|Drug|aflibercept|
266458|NCT02384759|Drug|LV5FU2|
266459|NCT02384772|Other|Survey|
265897|NCT02360501|Drug|Docetaxel|75mg/㎡,d1
265898|NCT02360501|Drug|Cisplatin|25mg/㎡,d1-3
265899|NCT02360501|Drug|Capecitabine|2000mg/㎡,d1-14
265900|NCT02360514|Drug|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
265901|NCT00158951|Device|EASYTRAK 2 Lead|
265902|NCT02360540|Other|Gestalt estimation|
265903|NCT02363075|Drug|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
265904|NCT02363075|Drug|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
265905|NCT02363088|Other|Neutral text message reminder|"Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
265906|NCT00159302|Procedure|Nasal Nitric Oxide|
265907|NCT02363088|Other|Messenger text message reminder|"<GP NAME>: Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
265908|NCT02363088|Other|Social Norms A reminder|"Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
265909|NCT02363088|Other|Social Norms B reminder|"Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
265910|NCT02363088|Other|Framed Gain text reminder|"Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
265911|NCT02363088|Other|Framed Loss text reminder|"Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
265912|NCT02363127|Drug|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
266177|NCT02391714|Procedure|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
266178|NCT02391714|Drug|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
266179|NCT02391714|Drug|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
265620|NCT02370147|Behavioral|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
265621|NCT02370160|Biological|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, and 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
265622|NCT02370173|Device|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
265623|NCT02370173|Device|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
265624|NCT02370199|Device|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
265625|NCT02370199|Drug|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
265626|NCT02370212|Dietary Supplement|Creatine|
265627|NCT02370212|Dietary Supplement|Placebo|
265628|NCT02370212|Other|High intensity interval training|
265629|NCT02370225|Other|aerobic exercise|Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).
The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end.
265630|NCT00160017|Behavioral|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
265631|NCT02370238|Drug|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
265632|NCT02370238|Drug|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
265633|NCT02370238|Drug|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
265634|NCT02370251|Drug|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB <2 mg/dL) occurs.
265635|NCT02372656|Drug|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
265636|NCT02372656|Drug|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
265014|NCT02381561|Other|Laboratory Biomarker Analysis|Correlative studies
265015|NCT02381561|Other|Pharmacological Study|Correlative studies
265016|NCT00161434|Drug|placebo|matching placebo for 8 weeks
265017|NCT02381561|Drug|Ropidoxuridine|Given PO
265018|NCT02381587|Other|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
265019|NCT02381600|Drug|Vitamin D|Experimental :
Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.
Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.
At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.
265020|NCT02381613|Other|Baked beef|A meal based on baked beef
265321|NCT02376725|Procedure|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
265322|NCT00002423|Drug|Lamivudine|
265323|NCT00160784|Other|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
265324|NCT02376725|Procedure|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
265325|NCT02376751|Drug|sebelipase alfa|
265326|NCT02376764|Procedure|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
265327|NCT02376777|Other|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
265328|NCT02376790|Drug|Etanercept + Oral Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 20 mg weekly.
265329|NCT02376790|Drug|Etanercept + Placebo for Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral placebo for methotrexate.
265330|NCT02376790|Drug|Oral Methotrexate + Placebo for Etanercept|Oral methotrexate 20 mg weekly plus placebo for etanercept.
265331|NCT02376803|Drug|Warfarin|Morning vs Evening administration
241101|NCT02522910|Drug|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
241102|NCT02522923|Other|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
241103|NCT02522923|Other|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
241104|NCT00182143|Drug|Unfractionated Heparin|5000 IU BID
241105|NCT02522936|Drug|Biotene oral spray|Biotene oral spray will be provided to participants.
241106|NCT02522949|Device|ColdZyme® mouth spray|
241107|NCT02522949|Device|Placebo|
241108|NCT02522962|Behavioral|GroupCoreSIT|Each group session lasts for 60 minutes. The physiotherapist will chose from an "exercises bank" of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training.
241109|NCT02525250|Procedure|Realization of 3 Blood samples during study during treatment with lenalidomide|
241110|NCT02525263|Biological|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
241111|NCT02525276|Behavioral|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
241112|NCT00182507|Drug|Olanzapine|
241113|NCT02525276|Drug|Hormone treatment|Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.
Including:
Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat
241413|NCT02518516|Drug|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
241414|NCT00181506|Procedure|dose escalation (radiotherapy treatment schedule)|
240478|NCT02536794|Other|Pharmacological Study|Correlative studies
240479|NCT02536794|Biological|Tremelimumab|Given IV
240480|NCT00183612|Drug|Olanzapine|
240481|NCT02536807|Drug|Hyaluronan|HA gel injection
240788|NCT02529735|Other|efficiency study|Blood pressure values measured for comparative lower limb and arm
240789|NCT02529748|Other|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
240790|NCT02529748|Other|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
240791|NCT02529748|Other|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
240792|NCT02529761|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
240793|NCT02529761|Procedure|TACE|The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated "on demand" depending on the radiological response.
240794|NCT02529774|Drug|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|Hepatic Artery Infusion for four cycles:
Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion
In combination with Systemic Chemotherapy CapeOX for 8 cycles:
Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14
Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:
Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1
240795|NCT02529774|Drug|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|Systemic Chemotherapy CapeOX alone for 8 cycles:
Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14
Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:
Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1
240796|NCT02529787|Drug|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
240797|NCT00182832|Behavioral|Standard Care|Standard care for hospitalized older patients with cognitive impairment
240798|NCT02529787|Drug|Dexilant|1 capsule contains 60 mg Dexlansoprazole
240799|NCT02529800|Drug|HIP1402|Tamsulosin HCl 0.4mg
240800|NCT02529800|Drug|HGP0412|Tamsulosin HCl 0.2mg
240176|NCT02506491|Other|Control Group|No exercise
240177|NCT02506504|Device|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
240178|NCT02506504|Device|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
240179|NCT02506517|Drug|Afatinib|
240180|NCT00179634|Behavioral|Visualization relaxation|
240181|NCT02506530|Procedure|intensive decongestive treatment|intensive decongestive treatment
240182|NCT02506530|Device|Cellu M6|Use of Cellu M6
240183|NCT02506543|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
240482|NCT02536820|Behavioral|psychoneuroimmune therapy|
240483|NCT02536820|Drug|Conventional treatment|Actual diabetes treatment in each participant
240484|NCT02536833|Drug|SM04690|
240485|NCT02536833|Drug|Placebo|
240486|NCT02536846|Drug|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
240487|NCT02536859|Drug|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
240488|NCT02536859|Drug|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
240489|NCT02536872|Other|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
240490|NCT02536885|Procedure|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
240491|NCT00183625|Behavioral|Individual Placement and Support (Supported Employment)|
239881|NCT02511132|Biological|Vigil|
239882|NCT02511132|Drug|gemcitabine and docetaxel|gemcitabine 675 mg/m2 IV at 10 mg/m2/min D1 and D8 and docetaxel 75 mg/m2 IV D8 every 21 days
239883|NCT02511145|Other|occlusive bandage|
239884|NCT02511145|Device|ablative fractional CO2 laser pretreatment|
239885|NCT02511145|Device|Microneedles pretreatment|
239886|NCT00180167|Drug|randomization between two established Chemotherapies|
239887|NCT02511145|Drug|METVIXIA Cream|
239888|NCT02511158|Procedure|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
239889|NCT02513342|Drug|Cisplatin|d4，cisplatin，75（mg/m2），iv；
239890|NCT02513355|Biological|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
239891|NCT00180570|Device|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
239892|NCT02513355|Drug|Changchun marina|25mg/m2,d1 and d8,q21d×4
239893|NCT02513355|Drug|cisplatin|80mg/m2,d1, q21d×4
239894|NCT02513355|Drug|Taxol|135-175mg/m2,d1,q21d×4
239895|NCT02513355|Drug|parapl|AUC=5-6,d1,q21d×4
239896|NCT02513368|Device|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
239897|NCT02513368|Procedure|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
239898|NCT02513381|Other|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
240184|NCT02506543|Behavioral|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
240185|NCT02506556|Drug|BYl719|Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.
Dose reductions (two levels) are allowed. Each cycle is 28 days
240186|NCT02506569|Device|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
240187|NCT02506569|Other|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
239283|NCT02454244|Behavioral|ART with Mindfulness|Introduction of ART with Mindfulness. Visualization of 100% recovery
Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation
The ART. Breaking the negative thoughts related to the illness. Walking meditation
Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation
Mindfulness and self-compassion. Kindly awareness meditation
The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation
Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities
Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values
The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self
Return to regular life. Mindfulness practice
239593|NCT02517931|Procedure|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
239594|NCT02517931|Procedure|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
239595|NCT02517957|Drug|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
239596|NCT02517957|Drug|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
239597|NCT02517957|Drug|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
239598|NCT02517957|Drug|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
239599|NCT00181246|Drug|Transdermal Fentanyl|
239600|NCT02517970|Behavioral|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
239601|NCT02517983|Other|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
239602|NCT02519998|Other|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
239603|NCT02520011|Drug|Alvocidib|
239604|NCT02520011|Drug|Cytarabine|
239605|NCT02520011|Drug|Mitoxantrone|
244020|NCT02528786|Other|No Intervention|No study drug will be administered in this study.
244021|NCT02528799|Biological|Nexvax2|Nexvax2 intra-dermal injections twice weekly
244022|NCT02528799|Biological|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
244023|NCT02528812|Device|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
244024|NCT02528812|Other|Manual Massage|A massage therapist massaged the participant
244025|NCT02530996|Other|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
244026|NCT02530996|Drug|Placebo|This will be given to a total of total of 32 SSc patients (16 complicated, 16 uncomplicated)
244027|NCT02531022|Behavioral|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
244028|NCT02531022|Behavioral|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
239284|NCT02454244|Behavioral|Mindfulness Compassion|Introduction.Definition of Compassion
Self-Esteemed and Compassion
Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions
Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability
Love,affection and self-compassion.How participants connect with the suffering of others
Equanimity
Forgiveness
Interdependence. Gratitude.Affection to unknown people
Developing affection and empathy.Empathy and burn out
Review of the practices and meditations
239285|NCT02454244|Behavioral|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
239286|NCT02454270|Drug|Part 1 (Dose Escalation): JNJ-64052781|Per dose level during the accelerated dose titration, a single participant will be exposed to JNJ-64052781 starting at 0.5 nanogram per kilogram (ng/kg). The dose will be increased by half-logarithmic steps in the subsequent dose level. The half-logarithmic increase will not exceed 4 times increases from the prior to the next higher JNJ-64052781 dose level. After there is evidence of biologic activity based on tumor response or depletion of B cells, the safety evaluation team (SET) may decide to transition to 3+3 design. Dose escalation will continue until the Maximum-tolerated Dose attain. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. Participants will receive intravenous infusion of JNJ-64052781 once in 2 weeks in each 28 day treatment cycles.
239287|NCT02454270|Drug|Part 2 (Dose Expansion): JNJ-64052781|Participants will receive intravenous infusion of JNJ-64052781 at the recommended Phase 2 dose (RP2D) once in 2 weeks in each 28 day treatment cycles.
239288|NCT02454283|Drug|Vanoxerine HCl|
239289|NCT02454283|Drug|Placebo|
239290|NCT02454296|Drug|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
243725|NCT02535663|Dietary Supplement|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
243726|NCT02535663|Dietary Supplement|Placebo|Same product without RG
243727|NCT02535676|Device|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
243728|NCT02535689|Drug|Tofacitinib|Oral administration of tofacitinib, 5 mg
243729|NCT02535689|Drug|Placebo|
243730|NCT02535715|Drug|ORMD-0801 capsules|ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
243731|NCT00183547|Behavioral|"Living in Harmony" depression prevention program|Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support
243732|NCT02535741|Device|Triathlon CR Total Knee System|Primary total knee replacement
243733|NCT02535754|Behavioral|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
244029|NCT02531035|Drug|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
244030|NCT02531035|Drug|Placebo|Placebo, once daily, before the first meal of the day
244031|NCT02531048|Device|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
244032|NCT02531048|Device|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
244033|NCT00002494|Radiation|low-LET photon therapy|
244034|NCT00183105|Behavioral|Brief Intervention (adaptation of motivational interviewing)|
244035|NCT02531048|Device|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
244036|NCT02531048|Device|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
268560|NCT02339922|Other|Laboratory Biomarker Analysis|Correlative studies
268561|NCT02339922|Other|Quality-of-Life Assessment|Ancillary studies
268562|NCT02339935|Behavioral|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
268563|NCT02339935|Other|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
268564|NCT00156403|Drug|amlodipine (drug)|
268565|NCT02339948|Radiation|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
268566|NCT02339961|Radiation|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
268567|NCT02339974|Device|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava|
268568|NCT02340000|Drug|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
268569|NCT02340000|Drug|high dose amoxicillin/clavulanate|amoxicillin/clavulanate 1000/62.5 two tablets (different manufacturers) bid x 7 days
268570|NCT02340013|Drug|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
268571|NCT02340026|Other|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
268572|NCT02340026|Other|Conventional Therapy|No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing "typical" movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child
268573|NCT02340039|Dietary Supplement|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
268574|NCT02340052|Drug|Pain treatment|Registration af actual analgesic treatment and outcomes
267941|NCT02392533|Other|Education|Education
267942|NCT02392546|Drug|elobixibat|
267943|NCT02392546|Drug|placebo|
268252|NCT00002428|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
268253|NCT00161954|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
268254|NCT02385461|Drug|Low Molecular Weight Heparins (LMWHs)|
268255|NCT00162253|Drug|BMS 587101|
268256|NCT02387840|Device|Magnetic Resonance Imaging|Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
268257|NCT02387840|Device|Magnetic Resonance Fingerprinting|Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
268258|NCT02387853|Drug|LEO 90100|
268259|NCT02387866|Drug|AG-221|
268260|NCT02387892|Dietary Supplement|Cheese & yogurt + Vitamin D|cheese & yogurt with added 420 IU cholecalciferol
268261|NCT02387892|Dietary Supplement|Cheese & yogurt|Cheese & yogurt without added vitamin D
268262|NCT02387905|Radiation|Stereotactic Spinal Radiosurgery (SSRS)|Participants receive CT-guided spinal stereotactic radiosurgery using intensity modulated radiation therapy. Treatment planning based on group's current standards for organ-at-risk dose constraints; however, final target volume and treatment plan at discretion of attending physician.
268263|NCT02387905|Procedure|Prophylactic Cement Augmentation|Participants receive prophylactic cement augmentation to spine within 4 weeks (before or after) radiosurgery treatment.
268264|NCT02387905|Behavioral|Brief Pain Inventory Assessment Form|Assessment form completed at months 3, 6, 9, 12, 18, and 24.
268265|NCT02387905|Behavioral|MD Anderson Symptom Inventory - Spine Tumor (MDASI-SP)|Assessment form completed at months 3, 6, 9, 12, 18, and 24.
268266|NCT00162266|Drug|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
268267|NCT02387918|Drug|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
268268|NCT02387918|Device|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
267643|NCT02361138|Drug|Placebo|
267644|NCT02361151|Behavioral|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
267645|NCT02361151|Behavioral|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
267646|NCT02361177|Drug|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
267647|NCT02361190|Drug|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
267648|NCT02361190|Drug|Placebo|Administration of 1ml aqueous saline spray
267649|NCT02361203|Behavioral|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
267650|NCT02361216|Drug|Ingenol Mebutate|
267651|NCT02361242|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
267652|NCT00159094|Drug|Doxil and Vinorelbine|
267653|NCT02361255|Other|no intervention|
267944|NCT02392559|Drug|Evolocumab|Dose of subcutaneous Evolocumab every 4 weeks
267945|NCT00162851|Drug|alemtuzumab|
267946|NCT02392559|Drug|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
267947|NCT02392572|Drug|ONC201|Phase I Starting dose of ONC201: 125 mg by mouth once every 3 weeks.
Phase II Starting dose of ONC201: MTD from Phase I.
267948|NCT02392585|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
267949|NCT02356354|Procedure|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
267950|NCT02356367|Other|telemonitoring|
267951|NCT02356380|Other|Mobilization Type|Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.
Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae.
267345|NCT02366169|Device|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
267346|NCT02366195|Drug|Talimogene Laherparepvec|Open label Single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 10^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10^8 PFU/mL.
267347|NCT02366208|Drug|PEG-Tα1|1.6 mg/ml, once a week, taken subcutaneously
267348|NCT02366208|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
267349|NCT02366208|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
267350|NCT02366221|Other|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
267351|NCT02366221|Other|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
267352|NCT02366247|Drug|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
267353|NCT02368340|Other|Pulmonary function test|Pulmonary function testing performed
267354|NCT00159835|Drug|atorvastatin|
267355|NCT02368340|Other|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
267356|NCT02368340|Other|Sample collection|Blood and urine sample collections
267357|NCT02368353|Other|Cognitive behavioral therapy|
267358|NCT02368353|Other|Supportive therapy|
267359|NCT02368366|Behavioral|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
267654|NCT02361268|Behavioral|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
267655|NCT02361268|Behavioral|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
267656|NCT02361294|Other|Blood samples|
266762|NCT00160914|Behavioral|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
266763|NCT02379715|Drug|Desflurane|
267060|NCT02373280|Drug|PPI based triple therapy [Esomeprazole, amoxicillin, clarithromycin]|
267061|NCT02373280|Drug|bismuth quadruple therapy [Esomeprazole, Tri potassium dicitrate bismuthate, Metronidazole, Tetracycline]|
267062|NCT02373280|Drug|moxifloxacin triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|
267063|NCT02373306|Procedure|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
267064|NCT02373319|Behavioral|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
267065|NCT02373319|Behavioral|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
267066|NCT02373319|Behavioral|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
267067|NCT02373319|Behavioral|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
267068|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
267069|NCT02373332|Other|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
267070|NCT02373358|Behavioral|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
267071|NCT02373371|Drug|Metvix®|
267072|NCT02375100|Device|25G Quincke needle|
267073|NCT02375100|Device|Echogenic Needle with 30° bevel|
267074|NCT02375100|Drug|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
266460|NCT02384785|Device|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
266461|NCT02384798|Other|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
266462|NCT02384798|Other|interval training|interval training
266463|NCT02384811|Radiation|radiation|A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.
The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes.
266464|NCT00002428|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
266465|NCT00161824|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
266466|NCT02384824|Procedure|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
266764|NCT02379728|Device|PrenaBelt|The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time she spends in this position via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.
The PrenaBelt is worn at the level of the waist or thorax. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back of the user when she lies on her back, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back.
266765|NCT02379728|Device|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
266766|NCT02379728|Device|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
266767|NCT02379741|Biological|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
266768|NCT02379754|Drug|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
266769|NCT02379767|Device|Electroconvulsive therapy|
266770|NCT02379767|Other|Positron emission tomography of the brain using [11C]harmine|
266771|NCT00161265|Procedure|tissue procurement|tissue procurement
266180|NCT02391714|Other|Oxygen|100% oxygen via nasal mask.
266181|NCT02391714|Other|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
266182|NCT02355444|Dietary Supplement|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
266183|NCT02355470|Behavioral|GIFTSS|Universal education and brief counseling regarding sexual violence
266184|NCT02355470|Behavioral|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
266185|NCT02355483|Device|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
266186|NCT02355496|Other|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
266187|NCT02355509|Drug|Acarbose|Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.
The treatment for three months
266188|NCT00158483|Drug|Acyclovir (ACV)|
266189|NCT02355509|Drug|Placebo|Placebo pills are given instead of acarbose in this group
266190|NCT02355522|Drug|Intrauterine lidocaine|
266191|NCT02355522|Drug|Lidocaine gel|
266192|NCT02355522|Drug|KY jelly|
266193|NCT02355522|Drug|Intrauterine normal saline|
266194|NCT02355535|Drug|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
266195|NCT02355548|Other|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
266196|NCT02355561|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
266467|NCT02387099|Drug|3 weeks Dose Induction of Everolimus|Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.
All patients will be treated within the approved indication of everolimus in combination with exemestane.
Patients will be randomized in a 1:1 ratio
265637|NCT02372669|Device|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
265913|NCT02363127|Drug|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
265914|NCT02363140|Other|Will undergo a single MRI assessment with intravenous dye|
265915|NCT02363140|Other|pre and post surgery MRI scan|
265916|NCT02363153|Other|Diet and Exercise|Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.
Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates.
265917|NCT00159302|Procedure|Blood Tests|
265918|NCT02363166|Other|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
265919|NCT02363179|Behavioral|Live preferential music|Live preferential music will be performed for patients in the emergency department.
265920|NCT02363192|Behavioral|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
265921|NCT02363205|Behavioral|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
265922|NCT02363218|Radiation|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
265923|NCT02363270|Procedure|Ketamine|IV Push or or IV Drip
265924|NCT02363283|Drug|Glembatumumab Vedotin|Given IV
265925|NCT02363283|Other|Laboratory Biomarker Analysis|Correlative studies
265926|NCT02363322|Drug|ZMApp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
265927|NCT00159510|Drug|Methylene blue|Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
265928|NCT02365519|Biological|LME636 ophthalmic solution|
265929|NCT02365519|Biological|LME636 Vehicle|Inactive ingredients used as a placebo comparator
265930|NCT02365532|Drug|GS-6615|GS-6615 tablets administered orally
265931|NCT02365532|Drug|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
265332|NCT02376816|Biological|rAAVrh74.MCK.micro-Dystrophin|Recombinant adeno-associated virus carrying a truncated "micro" dystrophin transgene under control of a muscle specific MCK promoter.
265333|NCT02376829|Device|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
265334|NCT00160797|Device|MIS™ Minimally Invasive Solutions™ TKA System|
265335|NCT02376842|Behavioral|Severe sepsis early warning best practice alert|
265336|NCT02376842|Behavioral|Standard care|
265337|NCT02376855|Other|eConsult|An electronic consultation or "eConsult" is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit.
265338|NCT02376868|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
265339|NCT02376868|Device|iVue|OCT machines used for diagnostic purposes
265340|NCT02376881|Drug|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
265341|NCT02376881|Other|placebo|100 ml normal saline in 2 hr for 3 successive days
265342|NCT02376907|Procedure|Biliary drainage|EUS-BD or ERCP
265638|NCT02372669|Procedure|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
265639|NCT02372682|Device|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
265640|NCT00160329|Drug|Atazanavir|300 mg with ritonavir boosting or 400 mg without
265641|NCT02372695|Drug|Paricalcitol|
265642|NCT02372708|Drug|dinitrophenyl(DNP)|
265643|NCT02372708|Radiation|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
265644|NCT02372734|Other|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
265645|NCT02372747|Procedure|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
265646|NCT02372747|Procedure|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
241415|NCT02518516|Drug|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
241416|NCT02518516|Drug|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
241417|NCT02518529|Biological|G17DT|
241418|NCT02518542|Procedure|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
241419|NCT02518542|Procedure|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
241420|NCT02518542|Procedure|Endoscopic intervention C|Endoscopic balloon dilatation
241421|NCT02518542|Procedure|Laparoscopic Surgery|Laparoscopic Heller myotomy
241422|NCT02518555|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
241423|NCT02518555|Drug|Ibrutinib|Given PO
241424|NCT02518555|Other|Laboratory Biomarker Analysis|Correlative studies
241425|NCT00181532|Drug|Celecoxib|
241426|NCT02518555|Other|Pharmacological Study|Correlative studies
241427|NCT02520778|Drug|Navitoclax|Given PO
241428|NCT02520778|Drug|Osimertinib|Given PO
241429|NCT02520778|Other|Pharmacological Study|Correlative studies
241430|NCT02520791|Biological|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
241431|NCT02520791|Other|Laboratory Biomarker Analysis|Correlative studies
241432|NCT00181818|Drug|bupropion SR (sustained-release)|
241433|NCT02520791|Other|Pharmacological Study|Correlative studies
241739|NCT02516462|Device|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
240801|NCT02529813|Drug|Fludarabine monophosphate|25 mg/m2 by vein on Days -5 to -3.
240802|NCT02532010|Drug|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
240803|NCT02532023|Dietary Supplement|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
240804|NCT02532023|Dietary Supplement|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
240805|NCT00183235|Drug|aripiprazole (up to 15 mg/day) for 8 days|
241114|NCT02525289|Other|Bed Rotation Group|Patients received continuous lateral rotation by a mechanical device (Hill Rom Bed Rotation), consecutive cycles of to left and right side, plus supine position during 30 seconds for pause, in the first postoperative day until 48 hours. Additional breathing exercises.
241115|NCT02525289|Other|Orthostatic Group|Patients were seated on the bed 6 hours post extubation for two hours. After, sitting in the bed with their feet on the floor for two minutes; standing up and walking in the place for two minutes, in the first 24 hours and 48 hours postoperative. Additional breathing exercises.
241116|NCT02525302|Drug|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
241117|NCT02525315|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
241118|NCT02525328|Other|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
241119|NCT02525341|Other|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
241120|NCT02525341|Other|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
241121|NCT02525341|Other|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
241122|NCT02525367|Behavioral|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
241123|NCT00000130|Drug|Intravitreal Antibiotics|
241124|NCT00000370|Behavioral|Psychosocial intervention|
240492|NCT02536885|Procedure|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
240493|NCT02536898|Other|Fracture Liaison Service|
240494|NCT02536898|Other|Current treatment|
240495|NCT02536911|Drug|eliglustat|Pharmaceutical form: capsule
Route of administration: oral
240496|NCT02536924|Behavioral|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
240497|NCT02466061|Behavioral|Enhanced Usual Care Group (Arm C)|Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
240498|NCT02466074|Drug|Acetazolamide|see arm description
240499|NCT02466074|Drug|Placebo|Placebo arm
240500|NCT02466087|Drug|Magnesium chloride|Four supplements a day for 6 weeks.
240806|NCT02532023|Dietary Supplement|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
240807|NCT02532023|Dietary Supplement|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
240808|NCT02532036|Biological|Aerosol inhaled MVA85A|
240809|NCT02532036|Biological|Intramuscular MVA85A|
240810|NCT02532036|Biological|Intramuscular Saline placebo|
240811|NCT02532036|Biological|Aerosol inhaled Saline placebo|
240812|NCT02532049|Biological|ChAd63 Pfs25-IMX313|
240813|NCT02532049|Biological|MVA Pfs25-IMX313|
240814|NCT02532062|Dietary Supplement|Cholecalciferol|4,000 IU, oral, once a day for one year
240815|NCT02532062|Dietary Supplement|multivitamin|oral, once a day for one year
240816|NCT00183248|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
240817|NCT02532062|Dietary Supplement|Placebo|oral, once a day for one year
240188|NCT02506582|Dietary Supplement|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
240189|NCT02506582|Dietary Supplement|placebo|40 g powdered rice flour
240190|NCT02506595|Behavioral|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
240191|NCT00179634|Device|Visual Milieu Enhancement (Fine art photograph)|
240192|NCT02506608|Procedure|Operation of sensorized hand prosthesis|Four TIME-4H electrodes will be implanted in the median and ulnar nerves of he amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.
The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.
The use of the prosthesis during different tasks will be considered the intervention.
240193|NCT02506621|Device|R test|
240194|NCT02506621|Device|Nuubo|
240195|NCT02506621|Device|TECHNOMED pocket ECG|
240196|NCT02506621|Device|ZIO xt patch|
240197|NCT02506621|Device|MoMe|
240198|NCT02508857|Drug|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
240199|NCT00179920|Drug|VP-16|
240200|NCT02508857|Drug|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
240201|NCT02508857|Drug|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
240202|NCT02508870|Drug|Atezolizumab|1200 mg Atezolizumab intravenously (IV) every 3 weeks on Day 1 of each 21-day cycle
240203|NCT02508870|Drug|Atezolizumab|840 mg Atezolizumab IV every 2 weeks on Days 8 and 22 of each 28-day cycle
240501|NCT02466100|Behavioral|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
239606|NCT02520024|Behavioral|self-directed care|
239607|NCT02520050|Dietary Supplement|Diabetes-specific nutritional formula|
239608|NCT02520050|Behavioral|MNT plan|
239609|NCT02520050|Behavioral|Weekly coaching by a registered dietitian|
239610|NCT02520063|Drug|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
239899|NCT02513381|Other|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
239900|NCT02513394|Drug|Palbociclib|
239901|NCT02513394|Drug|Standard Adjuvant Endocrine Therapy|
239902|NCT00180583|Device|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
239903|NCT02513407|Behavioral|Behavioral Dietary Intervention|Attend healthy nutritional education session
239904|NCT02513407|Other|Educational Intervention|Attend EML educational session
239905|NCT02513407|Behavioral|Exercise Intervention|Attend exercise educational session
239906|NCT02513407|Behavioral|Exercise Intervention|Receive fitness tracker
239907|NCT02513407|Other|Laboratory Biomarker Analysis|Correlative studies
239908|NCT02513407|Other|Questionnaire Administration|Ancillary studies
239909|NCT02513420|Behavioral|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
239910|NCT02513433|Drug|Bupivacaine|Local anesthetic
239911|NCT02513433|Drug|Levobupivacaine|Local anesthetic
239912|NCT02513433|Drug|Ropivacaine|Local anesthetic
239913|NCT00002490|Biological|BCG vaccine|
239914|NCT00180596|Device|Contak heart failure devices|
239915|NCT02513446|Drug|BI 1026706|Single dose of BI 1026706 on Day 1
239916|NCT02513446|Drug|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
239291|NCT02454296|Drug|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
239292|NCT00171249|Drug|imatinib mesylate|
239293|NCT02454309|Dietary Supplement|Cranberry concentrate|
239294|NCT02454309|Dietary Supplement|Placebo|
239295|NCT02454322|Drug|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
239296|NCT02454335|Procedure|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
239297|NCT02456675|Drug|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
239298|NCT02456675|Drug|INCB039110|The dose of INCB039110 will be given orally once daily (QD).
239299|NCT02456688|Drug|Imrecoxib|
239300|NCT02456701|Biological|KTN3379|IV every 2 weeks
239301|NCT00171613|Drug|Octreotide|
239302|NCT02456701|Drug|vemurafenib|960 mg po bid
239611|NCT00181714|Drug|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
239612|NCT02520063|Drug|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
239613|NCT02520063|Drug|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
239614|NCT02520076|Drug|Alpha-1 Antitrypsin|Subjects will receive their islets treated with Aralast NP during islet isolation process.
Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:
Pre-transplant Day -1
Post-transplant Day 3
Post-transplant Day 7
Post-transplant Day 14
239615|NCT02520089|Procedure|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
239616|NCT02520089|Procedure|Platelet Rich Plasma|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
239617|NCT02520102|Drug|sargramostim GZ402664|Pharmaceutical form: lyophilized powder in vial
Route of administration: subcutaneous
244037|NCT02531061|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.
For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes.
244038|NCT02531074|Behavioral|Mobile Application|
244039|NCT02531074|Behavioral|Food Journal|
244040|NCT02531074|Behavioral|Usual Care|
244041|NCT02531100|Device|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
244042|NCT02531100|Procedure|SOC treatment only|SOC treatment includes: Manual and ultrasonic debridement, and surface decontamination
244043|NCT02531113|Drug|RPC1063|
244044|NCT02531126|Drug|RPC1063|
244045|NCT00183118|Behavioral|Adapted Enhanced-RESPECT (HIV prevention intervention)|
244046|NCT02531139|Other|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
244047|NCT02531139|Other|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
244048|NCT02531152|Drug|Latanoprost|
244049|NCT02531152|Drug|SAR366234|
244050|NCT02531165|Drug|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
239303|NCT02456714|Drug|FOLFIRINOX|
239304|NCT02456727|Procedure|Group/Community Acupuncture|Acupuncture treatment in a group setting.
239305|NCT02456727|Procedure|Individual Acupuncture|Acupuncture treatment in an individual setting.
239306|NCT02456740|Drug|AMG 334|Investigational Product
239307|NCT02456740|Drug|AMG 334|Investigational Product
239308|NCT02456740|Drug|Placebo|Placebo Comparator
239309|NCT02456753|Device|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
239310|NCT02456766|Device|FibroTouch|
268879|NCT02333071|Drug|bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
268880|NCT02333071|Other|Placebo|Placebo
268881|NCT02333084|Dietary Supplement|PRN Joint Health Formula|
268882|NCT02333084|Dietary Supplement|placebo|
268883|NCT00155545|Behavioral|Motion analysis of patients|
268884|NCT02335164|Biological|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
268885|NCT02335164|Biological|Advax1|Delta inulin adjuvant formulation 1
268886|NCT02335164|Biological|Advax2|Delta inulin adjuvant formulation 2
268887|NCT02335177|Behavioral|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
268888|NCT02335190|Procedure|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
268889|NCT02335190|Procedure|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
268890|NCT02335190|Drug|Lidocaine|
268891|NCT02335203|Drug|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
268892|NCT02335203|Other|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
268893|NCT02335216|Device|Implantation with the commercially available Axium neurostimulator|
268894|NCT00155558|Drug|5-Fluorouracil, Leucovorin|
268895|NCT02335229|Device|Implantation with the commercially available Axium Neurostimulator|
268896|NCT02335242|Drug|Sildenafil 20 mg tablets|
268897|NCT02335242|Other|Placebo tablets (resembling Revatio)|
268269|NCT02387931|Dietary Supplement|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
268270|NCT02387931|Dietary Supplement|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
268271|NCT02387957|Drug|Fovista®|
268272|NCT02387957|Drug|bevacizumab|
268273|NCT02387957|Drug|ranibizumab|
268575|NCT00002402|Biological|Aluminum hydroxide|
268576|NCT00156416|Behavioral|Mindfulness Meditation|8 weeks of meditation training
268577|NCT02340065|Procedure|standard colonoscopy|examination of the colon with a conventional colonoscope
268578|NCT02342249|Drug|VX-787 and oseltamivir|Subjects will receive 10 doses of blinded study drug or placebo, administered at 12 hour intervals, over 5 to 6 days.
268579|NCT02342262|Dietary Supplement|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
268580|NCT02342262|Other|Placebo|similar appearance as the probiotic product, but without bacteria
268581|NCT00156741|Procedure|Required pacemaker setting|
268582|NCT02342275|Drug|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
268583|NCT02342275|Drug|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
268584|NCT02342288|Procedure|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
268585|NCT02342288|Procedure|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
268586|NCT02342301|Behavioral|Standing Desk|Participants will be provided with a standing desk for 3 months
268587|NCT02342301|Behavioral|Traditional Desk|Participants will use a traditional seated desk for 3 months
267952|NCT02356406|Radiation|Celiac Plexus Radiosurgery|5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.
It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis.
267953|NCT02356419|Drug|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
267954|NCT02356445|Other|Cytotoxic drug|Observe patients versus treatment type
267955|NCT02356458|Drug|Ibrutinib|Combination therapy:
Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I
Maintenance therapy:
p.o daily: 560 mg
267956|NCT00158574|Drug|Placebo|Placebo
267957|NCT02356458|Drug|bortezomib|Combination therapy:
Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11
267958|NCT02356471|Device|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
267959|NCT02356471|Other|Questionnaire Administration|Ancillary studies
267960|NCT02356471|Other|Quality-of-Life Assessment|Ancillary studies
267961|NCT02356510|Procedure|Primary PCI|
267962|NCT02356536|Device|Agilitas|WCD trial
268274|NCT02387957|Drug|aflibercept|
268275|NCT02387970|Device|Immediate provisionalization|Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
268276|NCT02387970|Device|Delayed provisionalization|Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
268277|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
268278|NCT02387983|Drug|Posaconazole|
268279|NCT02387996|Drug|Nivolumab|
268280|NCT02390245|Other|Use of patient navigation and social worker|This arm will include phoning patients to schedule appointments; confirming appointments by mailings, emails and/or text messaging; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and scheduling trained medical interpreters.
267657|NCT02361307|Procedure|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
267658|NCT02361307|Procedure|Conventional ADL training|The control group receive the conventional ADL training programme
267659|NCT02361320|Procedure|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
267660|NCT02361320|Behavioral|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
267661|NCT02361333|Behavioral|Teaching Intervention|Patients will be taught how to install and use a remote monitor
267662|NCT02361346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
267663|NCT00159107|Drug|Acamprosate|Acamprosate
267664|NCT02361359|Other|Psychological questionnaires|
267665|NCT02363985|Dietary Supplement|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
267666|NCT02363998|Drug|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
267667|NCT02364037|Behavioral|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
267668|NCT02364037|Behavioral|Clinic Provider Training|Clinicians at the recruitment sites will undergo a training session to discuss interuterine device and implant eligibility and same-day insertion considerations in an attempt to increase the number of patients who are receiving these methods, if desired.
267669|NCT02364037|Device|Cost support for IUDs and implants|For women in phase II of the study, women who desire an IUD or implant and can receive one through the study at no cost. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
267670|NCT02364063|Other|urotherapy with or without pharmacotherapy|Individualized
267671|NCT02364076|Drug|MK-3475|Administration of 200 mg MK-3475 once every 3 weeks
267963|NCT02356549|Behavioral|Tailored Health Message|Tailored messages will be developed using guidelines presented in the health communication literature. Many tailoring interventions are based on the input of data collected by means of a comprehensive survey, to produce messages that are matched to an individual's needs and preferences. However, patient data to inform tailoring can also be generated by accessing patient data through Electronic Medical Records (EMR). Interested to explore the impact of different "depths" of tailoring we will use both approaches to generate patient data to produce two types of tailored messages.
267075|NCT02375100|Drug|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
267076|NCT02375113|Dietary Supplement|soy supplementation|Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.
Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone.
267360|NCT02368366|Behavioral|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
267361|NCT02368366|Behavioral|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
267362|NCT02368379|Other|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
267363|NCT02368379|Other|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
267364|NCT02368392|Other|Exposure for cardiac arrests|There is no particular intervention. This study merely observes the occurrence of cardiac arrests
267365|NCT00002419|Drug|Efavirenz|
267366|NCT00159835|Drug|simvastatin|
267367|NCT02368405|Behavioral|Control|Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
267368|NCT02368405|Behavioral|Eat Right, Live Better|Intervention participants will participate a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
267369|NCT02368418|Procedure|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
266772|NCT02379767|Other|Structural magnetic resonance imaging|
266773|NCT02379780|Procedure|USG guided Subcostal TAP block|Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71*50 mm 22G*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.
we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time.
266774|NCT02379780|Procedure|USG guided Paravertebral Block|Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71*50 mm 22 G* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.
we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time.
266775|NCT02379793|Drug|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
266776|NCT02379806|Drug|Enoxaparin|
266777|NCT02379806|Drug|Placebo|
267077|NCT02375126|Procedure|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
267078|NCT02375139|Drug|DA-1229_01|complex single administration
267079|NCT00160576|Drug|Levetiracetam|
267080|NCT02375139|Drug|E+M|co-administration of 2 drugs
267081|NCT02375152|Procedure|Anterior Capsulotomy|
267082|NCT02375165|Procedure|tissue sampling|skin punch biopsy of affected and unaffected tissue (upper/lower limb) phlebotomy for collection of plasma and serum, ~30 cc
267083|NCT02375178|Drug|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
267084|NCT02375178|Drug|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
266468|NCT02387099|Drug|3 weeks Conventional Everolimus Dosing|Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.
All patients will be treated within the approved indication of everolimus in combination with exemestane.
Patients will be randomized in a 1:1 ratio
266469|NCT02387099|Drug|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
266470|NCT02387099|Drug|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
266471|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
266472|NCT02387112|Device|Early VAD implantation|Implantation of a left ventricular assist device
266473|NCT02387125|Biological|CMB305|
266474|NCT02387138|Drug|S-1|S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.
The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).
266475|NCT02387138|Drug|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
266476|NCT02387138|Drug|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
266477|NCT02387138|Other|G-csf|G-csf : d8 to d13 systematically
266478|NCT02387151|Drug|mesenchymal stromal cells|2 doses of 1-2x10^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
266479|NCT02387164|Drug|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
266480|NCT02387164|Drug|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
266481|NCT02387177|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
266482|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
266483|NCT02387177|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
266484|NCT02387190|Other|Telenursing monitoring|The telenursing program protocol is based on:
Contact the patient by telephone, weekly;
Distribution and explanation of the educational booklet;
Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
265932|NCT02365532|Drug|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
265933|NCT02365532|Drug|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
265934|NCT02365558|Drug|Evacetrapib|Administered orally
266197|NCT02355561|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
266198|NCT02355561|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
266199|NCT00158496|Drug|pegylated interferon alpha2a|
266200|NCT02355600|Other|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
266201|NCT02355613|Radiation|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
266202|NCT02355613|Radiation|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
266203|NCT02355639|Drug|Clobetasol propionate 0.05 % ointment|
266204|NCT02355639|Drug|Betamethasone dipropionate 0.064 % ointment|
266205|NCT02358226|Behavioral|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place at Khayelitsha College for a period of 6 months with assessments at the halfway mark. If participants demonstrate near-perfect attendance, and a pass rating of at least 50% in math, engineering, and trade theory and practice, their names will be listed in a national artisan database with guaranteed work placement by recruiting companies. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
266206|NCT02358239|Procedure|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
266207|NCT02358265|Drug|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
266208|NCT02358265|Drug|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
266209|NCT02358265|Drug|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
265647|NCT02372760|Device|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
265648|NCT02372760|Other|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
265649|NCT02372760|Drug|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
265650|NCT02372786|Drug|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
265651|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
265652|NCT02372786|Drug|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
265653|NCT02372786|Device|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
265654|NCT02372786|Device|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
265655|NCT02372799|Drug|Vilazodone|
265656|NCT02372799|Drug|Placebo|
265657|NCT02374567|Drug|Nortriptyline|
265935|NCT02365558|Drug|Omeprazole|Administered orally
265936|NCT02365571|Drug|LY3154207|Administered orally
265937|NCT02365571|Drug|Placebo|Administered orally
265938|NCT00002418|Drug|Stavudine|
265939|NCT00159510|Drug|Nitric oxide|An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
265940|NCT02365571|Drug|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
265941|NCT02365584|Drug|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
241740|NCT02516462|Drug|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
241741|NCT02516475|Dietary Supplement|zinc sulfate|1 zinc sulfate capsule for 15 weeks
241742|NCT02516475|Other|corn starch|1 corn starch capsule for 15 weeks
241743|NCT02516501|Dietary Supplement|Ketogenic breakfast|The breakfast consisting of increasing doses up to 250 ml of betaquick plus MAP will be taken directly after each RT fraction.
241744|NCT00180960|Drug|Oxaliplatin and irinotecan|
241745|NCT02516501|Dietary Supplement|Ketogenic diet|MAP will be used as a supplement for the ketogenic diet. MAP has a net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
241746|NCT02516501|Radiation|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
241747|NCT02516514|Procedure|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
241748|NCT02516527|Drug|Ipilimumab|
241749|NCT02516540|Behavioral|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
241750|NCT02516553|Drug|BI 894999|day 1 to day 21 in 3-week cycles
241751|NCT02516566|Other|PEEP|Mechanical ventilation with PEEP 8 cmH2O
241752|NCT02516579|Drug|Siklos|
241753|NCT02516592|Drug|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
241754|NCT02516592|Drug|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
241755|NCT02518555|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
241756|NCT02518555|Other|Quality-of-Life Assessment|Ancillary studies
241757|NCT02518555|Biological|Trivalent Influenza Vaccine|Given IM
241758|NCT02518568|Drug|V0355|Oral administration (2 tablets)
241759|NCT02518581|Procedure|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
241125|NCT00002494|Drug|ifosfamide|
241126|NCT00182520|Drug|Topiramate|25 mg - 400 mg/day x 12 weeks
241127|NCT02527499|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
241128|NCT00182715|Biological|cetuximab|
241129|NCT02527512|Drug|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
241130|NCT02527512|Other|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
241131|NCT02527525|Behavioral|Stepped Care|
241434|NCT02520804|Drug|sterofundin|sterofundin for shock patients in the first 72 hours
241435|NCT02520804|Drug|normal saline|Normal saline for shock patients in the first 72 hours
241436|NCT02520817|Dietary Supplement|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
241437|NCT02520817|Dietary Supplement|Lactulose|
241438|NCT02520830|Dietary Supplement|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
241439|NCT02520830|Dietary Supplement|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
241440|NCT02520843|Drug|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
241441|NCT02520856|Other|blood sample|
241442|NCT02520869|Procedure|swim-up technique|swim-up technique used
241443|NCT00181831|Device|Proton Magnetic Resonance Spectroscopy|
241444|NCT02520869|Procedure|zeta test technique|zeta test technique used
241445|NCT02520882|Drug|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
241446|NCT02520882|Device|PET/CT|
240818|NCT02532075|Other|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
240819|NCT02532075|Other|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
240820|NCT02532075|Other|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
240821|NCT02532075|Other|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
240822|NCT02532088|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
240823|NCT02532088|Dietary Supplement|Placebo|Placebo
240824|NCT02532101|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
240825|NCT02532114|Drug|Enzalutamide|Given PO
240826|NCT02532114|Other|Laboratory Biomarker Analysis|Correlative studies
240827|NCT00183248|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
240828|NCT02532114|Drug|Niclosamide|Given PO
240829|NCT02532114|Other|Pharmacological Study|Correlative studies
241132|NCT02527538|Device|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
241133|NCT02527551|Other|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
241134|NCT02527564|Drug|Suvorexant|
241135|NCT02527564|Drug|Placebo|
241136|NCT02527577|Drug|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
241137|NCT02527577|Drug|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
241138|NCT02527590|Other|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
241139|NCT00182715|Drug|capecitabine|
241140|NCT02527590|Other|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
240502|NCT02466113|Other|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
240503|NCT02466113|Other|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and <12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
240504|NCT00174408|Drug|Genotropin|
240505|NCT02466126|Behavioral|bCBT|The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to "emotional health" (e.g., depression) but may also address "physical health" concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health).
240506|NCT02466152|Drug|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram [mg/g]) and 1.0% (10 mg/g)
240507|NCT02466165|Behavioral|Physical exercise|
240508|NCT02466178|Device|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
240509|NCT02466191|Drug|Memantine|
240510|NCT02466191|Drug|Gabapentin|
240511|NCT02466204|Drug|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
240512|NCT02466204|Drug|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
240513|NCT02466217|Other|1: AID groups|Clinical and Biological investigations
240514|NCT02466217|Other|2: Control groups|Clinical and Biological investigations
240515|NCT00174421|Drug|Treatment with Genotropin in different dosages|
240516|NCT02504164|Drug|midazolam 0.02mg/kg|
240830|NCT02534350|Drug|Presatovir|Presatovir tablets administered orally once daily
239917|NCT02513459|Drug|BI 655066|dose regimen 1
239918|NCT02513459|Drug|BI 655066|dose regimen 2
239919|NCT02515656|Drug|GYNODAKTARIN®|
239920|NCT02515656|Drug|Placebo|
239921|NCT02515669|Biological|BMS-986089|
239922|NCT02515669|Biological|Placebo|
239923|NCT02515682|Dietary Supplement|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
239924|NCT02515682|Dietary Supplement|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
240204|NCT02508870|Drug|Azacitidine|75 mg/m2 azacitidine subcutaneously (SC) or IV daily on Days 1-7 (or on Days 1-5 and Days 8-9, depending on site preference) of each 28-day cycle
240205|NCT02508896|Biological|AFFITOPE® AT04A+adjuvant|subcutaneous injection
240206|NCT02508896|Biological|AFFITOPE® AT06A+adjuvant|subcutaneous injection
240207|NCT02508896|Biological|Adjuvant without active component|subcutaneous injection
240208|NCT02508909|Procedure|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
240209|NCT02508922|Dietary Supplement|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
240210|NCT00179920|Procedure|Local Surgery|
240211|NCT02508922|Dietary Supplement|Placebo|Matching placebo drops will be taken daily for 20 weeks
240212|NCT02508935|Drug|XARTEMIS XR|XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets
240213|NCT02508961|Behavioral|Exercise|web-based physio exercise programme
240214|NCT02509000|Other|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
240215|NCT02509026|Biological|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
240216|NCT02509039|Drug|CC-122|5 continuous days out of 7 days per week intermittent dosing
240217|NCT02509052|Other|Laboratory Biomarker Analysis|Correlative studies
239618|NCT02520115|Drug|Dexamethasone|Given PO
239619|NCT02520115|Other|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
239620|NCT02520115|Drug|Valproic Acid|Given PO
239621|NCT02520128|Radiation|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
239622|NCT00181727|Drug|divalproex sodium extended release|
239623|NCT02520141|Drug|Ramucirumab|8 mg/kg by vein on Day 1 of each 14 day cycle.
239624|NCT02522286|Behavioral|Ask 3 Questions|Participants were asked to bring an "Ask 3" questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare.
239625|NCT02522286|Behavioral|Open Communication|Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.
2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.
3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow.
239925|NCT02515682|Dietary Supplement|Placebo|Participants will be give placebo for 24 weeks.
239926|NCT02515695|Drug|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
239927|NCT00180843|Drug|salbutamol + ipratropium bromide nebules|
239928|NCT02515708|Device|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
239929|NCT02515721|Device|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
239930|NCT02515721|Device|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
239931|NCT02515734|Drug|fluorouracil|
239932|NCT02515734|Drug|Leucovorin|
239311|NCT02456766|Procedure|Liver Biopsy|
239312|NCT00171626|Drug|Diclofenac Topical Sodium Gel 1%|
239313|NCT02456779|Other|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
239314|NCT02456779|Other|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
239315|NCT02456779|Other|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
239316|NCT02456792|Procedure|IVF|Women will undergo one IVF cycle
239317|NCT02456792|Procedure|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
239318|NCT02456805|Other|Infant Formula 1|Feed ab libitum
239319|NCT02456805|Other|Infant Formula 2|Feed ab libitum
239320|NCT02456831|Other|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
239321|NCT02456831|Other|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
239322|NCT02456831|Other|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
239323|NCT00171639|Drug|zoledronic acid|
239324|NCT02456831|Other|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
239325|NCT02456844|Drug|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose
Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose
Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose
Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose
Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose
BMS-986142: On Days 6 through 12.
239326|NCT02458859|Device|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
239626|NCT02522299|Drug|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device
239627|NCT02522299|Drug|Placebo|Lactose will be administered using a DISKUS dry powder inhaler device
239628|NCT02522299|Device|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
239629|NCT00182052|Drug|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
268898|NCT02335255|Drug|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
268899|NCT02335255|Drug|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
269203|NCT02328495|Other|Bladder Filling|Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used.
269204|NCT02328508|Device|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
269205|NCT02328521|Drug|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
269206|NCT02328521|Drug|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
269207|NCT00154206|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
269208|NCT02328534|Behavioral|Blastocyst Formation Rate|Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.
The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
269209|NCT02328534|Procedure|Blastocyst Rate|Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.
The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.
269210|NCT02328534|Procedure|Pregnancy Rate|All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.
The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
269211|NCT02330653|Biological|Fecal Microbiota Transplant|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standards by the Microbiome Health Research Institute Inc. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
269212|NCT02330653|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
269213|NCT02330666|Behavioral|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
268588|NCT02342314|Drug|LY3143753 (Part A)|Administered via SC injection
268589|NCT02342314|Drug|LY3185643 (Part B)|Administered via SC injection
268590|NCT02342314|Drug|Normal Saline|Administered via SC injection
268591|NCT02342327|Other|switch to non-menthol cigarettes prior to cessation attempt|
268592|NCT00002405|Drug|Amprenavir|
268593|NCT00156780|Drug|AI-700|
268594|NCT02342327|Other|continue smoking menthol cigarettes prior to cessation attempt|
268900|NCT02335255|Drug|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
268901|NCT02335268|Drug|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
268902|NCT02335281|Procedure|FMT|Standardized FMT once
268903|NCT02335281|Drug|Mesalazine|2g Po perday
268904|NCT02335294|Drug|TRV130|Rescue: Ibuprofen, oxycodone
268905|NCT00155597|Behavioral|home physical therapy|
268906|NCT02335294|Drug|Morphine|Rescue: Ibuprofen, oxycodone
268907|NCT02335294|Drug|Placebo|Rescue: Ibuprofen, oxycodone
268908|NCT02337803|Behavioral|Usual Care|Will continue daily physical activity and complete surveys online
268909|NCT02337816|Procedure|laparoscopic surgery, obtainment of biological samples|
268910|NCT02337829|Drug|ACP-196|
268911|NCT02337842|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
268912|NCT00156117|Drug|Placebo|Placebo
268913|NCT02337842|Biological|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units.
268281|NCT00162539|Other|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
268282|NCT02390258|Drug|10mg XEN-D0103|
268283|NCT02390258|Drug|Placebo|
268284|NCT02390258|Drug|30mg XEN-D0103|
268285|NCT02390258|Drug|60mg XEN-D0103|
268286|NCT02390258|Drug|120mg XEN-D0103|
268287|NCT02390258|Drug|200mg XEN-D0103|
268288|NCT02390258|Drug|150mg XEN-D0103|
268289|NCT02390271|Other|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
268290|NCT02390284|Drug|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
268291|NCT02390284|Drug|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
268292|NCT00162552|Drug|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
268293|NCT02390284|Drug|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
268294|NCT02390284|Drug|Timolol|Lower intraocular pressure by decreasing production of fluid
268295|NCT02390284|Drug|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
268296|NCT02390284|Drug|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
268595|NCT02342340|Other|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
268596|NCT02342340|Other|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
268597|NCT02342340|Other|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
268598|NCT02342340|Other|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
268599|NCT02342340|Other|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
268600|NCT02342340|Other|White Rice|One time consumption of 3/4 cup of cooked white rice.
268601|NCT02342353|Drug|Pacritinib|
267964|NCT02356562|Drug|Ombitasvir/ABT-450/r|Tablet
267965|NCT02356562|Drug|Dasabuvir|Tablet
267966|NCT02356562|Drug|Sofosbuvir|Tablet
267967|NCT00158574|Drug|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
267968|NCT02356562|Drug|Ribavirin|Tablet
267969|NCT02356575|Other|Acupuncture|
267970|NCT02356588|Drug|Sufentanil Tablet 30 mcg|
267971|NCT02356588|Drug|Placebo Tablet|
267972|NCT02358941|Behavioral|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
267973|NCT02358954|Procedure|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
267974|NCT02358954|Procedure|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
267975|NCT02358954|Procedure|3D Turntable|
267976|NCT02358954|Procedure|Vection stimulation|
267977|NCT02358967|Dietary Supplement|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
267978|NCT02358967|Dietary Supplement|Placebo|2 x 150 mg capsules
267979|NCT02358980|Device|KIDNEY therapy|
267980|NCT02358993|Drug|methenamine hippurate|A urinary antiseptic used for prevention of UTI
267981|NCT00158808|Biological|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
267982|NCT02358993|Drug|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
267983|NCT02359006|Drug|Minocycline|Minocycline will be compared with placebo
267984|NCT02359006|Drug|Placebo|Placebo will be compared with minocycline
267985|NCT02359019|Biological|Pembrolizumab|Given IV
267370|NCT02368418|Procedure|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
267371|NCT02370810|Behavioral|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
267372|NCT02370823|Procedure|Regenexx SD - Same Day Bone Marrow Concentrate Injection|Regenexx®SD (Same Day) is a bone marrow based stem cell procedure. Spinning down bone marrow in a bedside machine produces a set amount of stem cells to be injected.
267373|NCT02370836|Other|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
267672|NCT02364089|Procedure|Laparoscopic surgical removal of the adrenal tumor|
267673|NCT02364089|Drug|Standardized medical treatment of hypertension by SAHR|Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:
step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )
step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)
step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg
step 4: Add-on of Indapamide LP 1.5 mg
step 5: Add-on of Spironolactone 25 mg
step 6: Add-on of Bisoprolol 10 mg
step 7: Add-on of Prazosine LP 5mg/day.
267674|NCT02364115|Radiation|Stereotactic Body Radiotherapy|
267675|NCT00159354|Drug|predisolone|
267676|NCT02364128|Behavioral|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
267677|NCT02364141|Other|Trunk restraint therapy|Reaching training with trunk restraint by a harness that limited the trunk movements.
Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks.
267678|NCT02364141|Other|Trunk unrestraint therapy|Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks
267679|NCT02364154|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
267680|NCT02364154|Other|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
267681|NCT02366247|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
267085|NCT02375178|Drug|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
267086|NCT02375191|Drug|fentanyl|
267087|NCT02375191|Drug|dexmedetomidine|
267088|NCT02375191|Drug|Ropivacaine|
267089|NCT02375204|Drug|paclitaxel|IV
267090|NCT00002423|Drug|Amprenavir|
267091|NCT00160589|Drug|Levocetirizine|
267092|NCT02375204|Drug|ifosfamide|IV
267093|NCT02375204|Drug|cisplatin|IV
267094|NCT02375204|Drug|pegylated G-CSF|IV
267095|NCT02377544|Dietary Supplement|Probiotic|
267096|NCT02377544|Other|Placebo|
267097|NCT02377557|Drug|Topical Steroids|
267098|NCT02377570|Device|THERANOVA 400 dialyzer prototype AA|Hemodialysis
267099|NCT02377570|Device|THERANOVA 400 dialyzer prototype BB|Hemodialysis
267374|NCT02370849|Drug|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
267375|NCT02370849|Drug|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
267376|NCT02370849|Drug|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
267377|NCT02370862|Drug|Neostigmine and Glycopyrrolate|
267378|NCT02370875|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
267379|NCT02370875|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
267380|NCT02370888|Drug|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
267381|NCT00160108|Behavioral|dietary intervention|
266778|NCT02379819|Device|Nucleus Hybrid L24 Implant|
266779|NCT02379845|Device|NBTXR3|One intratumor implantation by injection
266780|NCT00161486|Drug|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
266781|NCT02382380|Drug|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
266782|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
266783|NCT02382393|Other|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
266784|NCT02382393|Other|Computerized Assessment|a validated, computerized cognitive assessment tool
266785|NCT02382406|Drug|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
266786|NCT02382406|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
266787|NCT02382406|Drug|MK-3475 (Phase I)|MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)
Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
266788|NCT02382406|Drug|MK-3475 (Phase II)|MK-3475 2 mg/kg IV at RP2D and schedule (cycle = 21 days)
Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
266789|NCT02382419|Drug|carrageenan-containing gel|Applied vaginally
266790|NCT02382419|Other|Placebo|Applied vaginally
266791|NCT00161486|Drug|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
266792|NCT02382419|Other|Laboratory Biomarker Analysis|Correlative studies
266793|NCT02382419|Other|Questionnaire Administration|Ancillary studies
266794|NCT02382432|Drug|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
266795|NCT02382432|Drug|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
266796|NCT02382445|Device|Anesthesia depth monitor|
266210|NCT02358265|Drug|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
266211|NCT02358291|Procedure|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
266212|NCT02358291|Procedure|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
266485|NCT02387203|Drug|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
266486|NCT02387216|Drug|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
266487|NCT02389426|Device|NIRS baseline|Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.
This examination will be performed in patients with multiple sclerosis and in healthy controls.
266488|NCT02389426|Device|NIRS after bosentan administration|Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.
This examination will only be performed in patients with multiple sclerosis.
266489|NCT02389439|Drug|Pyronaridine-artesunate|
266490|NCT02389452|Drug|Synvisc-One|intraarticular injection
266491|NCT02389465|Drug|Escitalopram|
266492|NCT02389465|Drug|Placebo|
266493|NCT02389478|Procedure|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
266494|NCT02389478|Procedure|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
266495|NCT00162435|Drug|Warfarin|
266496|NCT02389491|Dietary Supplement|normal density formula (Necocate)|In control group,there are 32 infants
266497|NCT02389491|Dietary Supplement|high density formula(Infatrini)|In intervention group,there are 32 infants
266498|NCT02389504|Other|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
265942|NCT02365597|Drug|JNJ-42756493, 10 mg|10 mg (two 5-mg tablets) will be taken orally, once daily for 7 consecutive days on Days 1-7 and Days 15-21 of a 28-day cycle.
265943|NCT02365597|Drug|JNJ-42756493, 6 mg|6 mg (two 3 mg tablets) will be taken orally (by mouth), once daily for 28-day cycles.
265944|NCT02365610|Drug|GWP42006|
265945|NCT02365610|Drug|Placebo Control|
265946|NCT02365623|Drug|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
265947|NCT02365623|Drug|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS], para-aminosalicylic acid [PAS], amikacin [AMK], levofloxacin [LVFX] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
265948|NCT02365636|Drug|TV-45070|TV-45070 4%, 8%
265949|NCT02365636|Drug|Placebo|
265950|NCT00159510|Drug|Methylene blue & nitric oxide|See the dosage in the previous arms
265951|NCT02365649|Drug|ABT-494|Oral Dosing
265952|NCT02365649|Drug|Placebo|Oral Dosing
265953|NCT02367781|Drug|Carboplatin|Area under the concentration curve (AUC) 6 on Day 1 of each 21-day cycle for 4 or 6 cycles
265954|NCT02367781|Drug|Nab-paclitaxel|100 mg/m2 IV on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles
265955|NCT00159783|Drug|asenapine|Asenapine, 40 weeks
265956|NCT02367794|Drug|Atezolizumab (MPDL3280A)|1200 mg intravenous infusion (IV) on day 1 of each 21-day cycle
266213|NCT00158743|Drug|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
266214|NCT02358291|Procedure|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
266215|NCT02358304|Drug|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
266216|NCT02358304|Drug|Placebo|
242060|NCT02511951|Procedure|pancreaticojejunostomy|To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.
Two layer anatomosis with "Duct-to-Mucosa" pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.
242061|NCT02511964|Behavioral|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
242062|NCT02511964|Behavioral|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
242063|NCT02511977|Other|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
242064|NCT02511990|Biological|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
242065|NCT00180349|Device|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
242066|NCT02511990|Biological|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
242067|NCT02511990|Biological|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
242068|NCT02512003|Device|Fantom Scaffold|
242069|NCT02512016|Other|Study Procedures|Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)
Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.
Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.
Measures of strength and body habitus:
8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index
1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod
Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings.
242070|NCT02512029|Drug|18F-AV-1451|
242071|NCT02512042|Drug|Test-Brinzolamide 1% Ophthalmic suspension|
242072|NCT02512042|Drug|Reference-Brinzolamide 1% Ophthalmic suspension|
242073|NCT02512055|Drug|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
242074|NCT02512068|Drug|SYR-472 25 mg|SYR-472 25 mg Tablets
242075|NCT02512068|Drug|Placebo + SYR-472 25 mg|Placebo Tablets + SYR-472 25 mg Tablets
242076|NCT00002489|Drug|vincristine sulfate|
241447|NCT02520895|Biological|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
241448|NCT02520908|Procedure|HSCT|Hematopoietic stem cell transplantation
241449|NCT02520908|Other|Standard Care|
241450|NCT02520921|Drug|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
241451|NCT02520921|Drug|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
241452|NCT02520934|Drug|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
241453|NCT02522962|Behavioral|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
241760|NCT02518594|Drug|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
241761|NCT02518594|Drug|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
241762|NCT02518594|Device|Arabin Pessary|Placement management from randomization to < 35 wks
241763|NCT02518607|Drug|MGB-BP-3|Treatment of CDI
241764|NCT00181545|Procedure|escalation of dose (radiotherapy treatment)|
241765|NCT02518607|Other|Placebo|Placebo
241766|NCT02518620|Biological|ALX-0061|Multicenter open-label extension study
241767|NCT02518633|Device|Continuous positive airway pressure devices|overnight use of CPAP device
241768|NCT02518659|Dietary Supplement|Inulin|This is the Intervention
241769|NCT02518672|Dietary Supplement|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
241770|NCT02518672|Dietary Supplement|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
241771|NCT02518685|Device|TransPyloric Shuttle|
241772|NCT02518685|Behavioral|lifestyle counseling|
241141|NCT02527590|Other|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
241142|NCT02527590|Other|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
241143|NCT02527590|Other|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
241144|NCT02527603|Procedure|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
241145|NCT02527603|Procedure|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
241146|NCT02527603|Drug|Anti-Inflammatory Agents, Non-Steroidal|All patients will be administered a dose of NSAI intra-muscular or orally ("Dexketoprofen", "Enantyum®") it is part of the normal treatment of these patients to cope with pain.
241147|NCT02527616|Device|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
241148|NCT02527629|Other|Decellularized human heart valves|Decellularized human aortic heart valves
241149|NCT02527642|Other|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
241150|NCT00182715|Drug|fluorouracil|
241151|NCT02529813|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 by vein on Days -5 to -3 or Cyclophosphamide 300 mg/m2 by vein every 12 hours x2 doses on Days -5 to -3 at discretion of treating physician.
241454|NCT02522975|Drug|EPIAO®|Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.
Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
241455|NCT02522975|Drug|EPREX®|Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.
Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
241456|NCT02522988|Behavioral|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
241457|NCT02523014|Drug|vismodegib|oral
241458|NCT02523014|Drug|GSK2256098|oral
240831|NCT02534350|Drug|Placebo|Presatovir placebo tablets administered orally once daily
240832|NCT00183430|Drug|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
240833|NCT02534363|Drug|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
240834|NCT02534363|Drug|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
240835|NCT02534363|Drug|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
240836|NCT02534363|Behavioral|Cognitive battery|Completed in the following standardized sequence: 1—the Rey Auditory Verbal Learning Test (RAVLT); 2—WAIS-III digit symbol subtest; 3—Grooved Pegboard Test; 4—The Zoo Map Test; 5—Tower of London Test (ToL); 6—Rey Complex Figure (RCF); 7—Trail Making Test (TMT); 8—WAIS-III digits forward and backward subtests; 9—WAIS-III letter-number sequencing subtest; 10—WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11—Stroop Test; 12—letter (FAS) and semantic (animal) fluency tests; 14—Eyes Task; 15—Continuous Performance Test (CPT).
240837|NCT02534376|Drug|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
240838|NCT02534389|Dietary Supplement|omega-3 fish oil|2,4g of EPA + DHA
240839|NCT02534402|Drug|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
240840|NCT02534415|Drug|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
240841|NCT02534415|Drug|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
240842|NCT02534415|Drug|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
240843|NCT00183430|Drug|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
240844|NCT02534428|Other|wool clothing|superfine merino wool ensembles for baby wear
240845|NCT02534441|Other|Skin patch test|
240846|NCT02534454|Behavioral|Active Retraining|
240847|NCT02534454|Behavioral|Sham Retraining|
240848|NCT02534454|Device|Active transcranial direct current stimulation (TDCS)|
240849|NCT02534454|Device|Sham transcranial direct current stimulation (TDCS)|
240218|NCT02509052|Drug|Leflunomide|Given PO
240219|NCT02509052|Other|Pharmacological Study|Correlative studies
240220|NCT02509065|Device|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm will deliver insulin and glucagon. The 115 mg/dl arm will deliver insulin and glucagon. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
240221|NCT00002489|Drug|doxorubicin hydrochloride|
240222|NCT00179920|Procedure|Cryotherapy|
240223|NCT02509065|Other|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
240224|NCT02511171|Other|Cranial osteopathic manipulative therapy|
240225|NCT02511184|Drug|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
240226|NCT02511184|Drug|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
240517|NCT00179309|Biological|PANVAC-V|2 x 10^8 PFU
240518|NCT02504164|Drug|No premedication|No premedication before sedation for endoscopic submucosal dissection
240519|NCT02504177|Drug|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
240520|NCT02504177|Drug|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
240521|NCT02504203|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
240522|NCT02504216|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2.5 mg, twice daily, orally, tablet
240523|NCT02504216|Drug|Rivaroxaban-Placebo|matching placebo, twice daily, orally, tablet
240524|NCT02504229|Biological|autologous dendritic cells co-cultured with cytokine-induced killer cells|
240525|NCT02504229|Drug|Gimeracil and Oteracil Porassium Capsules|
240526|NCT02504229|Drug|Oxaliplatin|
240527|NCT02504242|Device|Inject BMP|
240528|NCT00179309|Biological|PANVAC-F|1 x 10^9 PFU
239933|NCT02515734|Drug|irinotecan|
239934|NCT02515734|Drug|oxaliplatin|
239935|NCT02515734|Biological|bevacizumab|
239936|NCT02515734|Biological|cetuximab|
239937|NCT02515747|Procedure|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
239938|NCT00180843|Drug|nebulized saline|
239939|NCT02515747|Procedure|coronary artery bypass grafting|elective surgical myocardial revascularisation
239940|NCT02515760|Procedure|Bone marrow aspiration from the iliac crest|
239941|NCT02515760|Device|Illinois bone marrow aspiration neddle|
239942|NCT02515773|Drug|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
239943|NCT02515773|Behavioral|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
239944|NCT02515786|Other|oxygen humidification|humidification for oxygen delivered by nasal catheter
239945|NCT02515799|Drug|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
239946|NCT02515799|Other|Placebo|Inhaled Placebo
239947|NCT02515812|Drug|I-123-MIBG|
239948|NCT02515812|Device|CZT Camera (D-SPECT)|
240227|NCT02511197|Drug|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
240228|NCT02511197|Device|PET/CT|
240229|NCT02511210|Behavioral|regional anesthesia|preoperative anxiety
240230|NCT02511210|Behavioral|general anesthesia|preoperative anxiety
240231|NCT02511223|Drug|OLAPARIB|Olaparib 300 MG twice a day per os given every day until disease progression or toxicity
240232|NCT00180206|Device|Birmingham Hip Resurfacing|
239630|NCT02522312|Other|No Intervention|No drug is administered in this study
239631|NCT02522325|Drug|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
239632|NCT02522325|Drug|Cocaine|Intranasal cocaine will be administered during experimental sessions.
239633|NCT02522325|Drug|Placebo|Placebo capsules will contain only cornstarch.
239634|NCT02522338|Drug|iohexol|10 ml de l'iohexol (300 mgI/ml)
239635|NCT02522351|Other|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
239636|NCT02522351|Other|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
239637|NCT02522351|Other|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
239638|NCT02522351|Other|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
239639|NCT02522351|Other|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
239640|NCT00002494|Drug|cytarabine|
239641|NCT00182052|Other|Placebo|Given orally twice daily.
239642|NCT02522351|Other|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
239643|NCT02522364|Device|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
239644|NCT02522364|Other|Standard|Clinical and intermittent electrocardiographic follow-up of patients
239645|NCT02522377|Drug|Ketamine|inter venous injections
239646|NCT02522377|Drug|Midazolam|inter venous injections
239647|NCT02524639|Drug|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
269214|NCT02330679|Drug|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
269215|NCT00154440|Drug|metronidazole|
269216|NCT02330679|Drug|Placebo|
269217|NCT02330692|Other|No intervention|
264537|NCT02369718|Other|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR*2 coding strategies*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
264538|NCT02369731|Drug|Translarna|
264539|NCT00159965|Drug|sertraline|flexible dose sertraline
264540|NCT02372266|Other|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
264541|NCT02372279|Other|Embryo observation|In EO group, conventional observations will be made.
264542|NCT02372292|Drug|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
264543|NCT02372305|Biological|FlexHD|
264544|NCT02372305|Biological|Alloderm|
264545|NCT02372318|Drug|Nalmefene|18mg of Nalmefen will be administered orally
264546|NCT02372318|Drug|Placebo|Placebo tablet
264547|NCT00002420|Drug|Stavudine|
264548|NCT00160277|Drug|Moxonidine|
264549|NCT02372331|Other|ERAS perioperative management|Preop Counseling
Preop biliary drainage (X) when Serum Total bilirubin < 14.62mg/dl and cholangitis (-)
Preop enteral nutrition
Oral bowel preparation (mechanical bowel preparation ) (X)
Preop fasting < 6 hours
Prevention of postoperative nausea and vomiting (PONV) (O)
Nasogastric intubation (X)
Near-zero fluid balance
Somatostatin analogues (X)
Postop routine artificial nutrition (X), soft diet at POD #2
Audit
Other items are same as conventional
264550|NCT02372344|Drug|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
264551|NCT02372357|Drug|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
264552|NCT02372357|Procedure|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
268914|NCT02337855|Biological|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
268915|NCT02337855|Other|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
268916|NCT02337855|Biological|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
268917|NCT02337868|Other|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
268918|NCT02337868|Biological|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
268919|NCT02337881|Drug|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
269218|NCT02330705|Drug|HCG|Women will undergo IUI at the time of HCG administration
269219|NCT02330705|Drug|HCG|Women will undergo IUI 12 hours after HCG administration
269220|NCT02330705|Drug|HCG|Women will undergo IUI 34-36 hours after HCG administration
269221|NCT02330718|Other|No intervention|
269222|NCT02330731|Procedure|injection sclerotherapy for gastric varices|The intravariceal technique of injection
269223|NCT02330744|Behavioral|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
269224|NCT02330744|Behavioral|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
269225|NCT02330757|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
269226|NCT00154440|Procedure|radiation therapy|
269227|NCT02330757|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
268602|NCT02344472|Drug|Paclitaxel|Chemotherapy
268603|NCT02344472|Drug|Vinorelbine|Chemotherapy
268604|NCT02344472|Drug|Docetaxel|Chemotherapy
268605|NCT02344472|Drug|Exemestane|endocrine therapy
268606|NCT02344472|Drug|Letrozole|endocrine therapy
268607|NCT02344472|Drug|Anastrozole|endocrine therapy
268608|NCT02344472|Drug|Fulvestrant|endocrine therapy
268609|NCT02344472|Drug|Tamoxifen|endocrine therapy
268610|NCT02344485|Procedure|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
268611|NCT00157040|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
268612|NCT02344498|Drug|Tenofovir disoproxil|
268613|NCT02344511|Drug|Dalbavancin|Drug
268614|NCT02344511|Drug|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
268615|NCT02344524|Device|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
268616|NCT02344537|Behavioral|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
268617|NCT02344550|Drug|Everolimus(afinitor)|Everolimus 10mg p.o. daily
268618|NCT02344550|Drug|Letrozole|Letrozole 2.5 mg p.o. daily
268619|NCT02344550|Drug|Leuprolide|Leuprorelin 3.75 mg SC in every 4 weeks
268920|NCT02337881|Drug|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
268921|NCT02337894|Dietary Supplement|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
268922|NCT02337894|Dietary Supplement|Placebo|Flavored drink without essential amino acids plus arginine.
268923|NCT00002401|Drug|Zidovudine|
268297|NCT02390284|Drug|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
268298|NCT02390284|Drug|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
268299|NCT02390297|Genetic|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
268300|NCT02390310|Device|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
268301|NCT02390310|Drug|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
268302|NCT02390310|Drug|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
268303|NCT00162552|Drug|PLACEBO|Patients with severe cirrhosis treated with a placebo
268304|NCT02390323|Procedure|Lumbar Sympathetic Block|A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The "lumbar sympathetic nerves" are a small bundle of nerves that carries "sympathetic" nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system.
268305|NCT02392585|Procedure|Triple tourniquet|Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary.
268306|NCT02392611|Drug|GS-5829|GS-5829 tablet administered orally
268307|NCT02392624|Drug|Omalizumab|
268308|NCT02392637|Drug|Abraxane (Nab-Paclitaxel)|125 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
268309|NCT02392637|Drug|Cisplatin|25 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
268310|NCT02392637|Drug|Gemcitabine|1000 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
268311|NCT02392637|Behavioral|Phone Calls|Participant receives phone call from study staff 30 days after last dose of study drugs, and every 12 weeks thereafter.
268312|NCT00162864|Drug|montelukast sodium|
268313|NCT02392663|Other|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
267682|NCT02366247|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
267683|NCT00000357|Drug|Buprenorphine|
267684|NCT00002418|Drug|Didanosine|
267685|NCT00159588|Drug|Betablockers or other preventive drugs|Several preventive drugs based on each individual
267686|NCT02366273|Other|PASI and HOMA index|
267687|NCT02366299|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
267688|NCT02366299|Drug|Propofol|Treatment of delirium by Propofol i.v. infusion
267689|NCT02366312|Drug|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
267986|NCT02359019|Other|Laboratory Biomarker Analysis|Correlative studies
267987|NCT02359032|Drug|ASP6858|Oral tablets
267988|NCT02359032|Drug|Placebo|Oral tablets
267989|NCT02359045|Drug|D1400147|Treatment A
267990|NCT02359045|Drug|D14000136|Treatment B
267991|NCT02359045|Drug|D14000137|Treatment C
267992|NCT00158821|Drug|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
267993|NCT02359045|Drug|Epanova®|Treatment D
267994|NCT02359058|Drug|Ramucirumab|Administered IV
267995|NCT02359058|Drug|Capecitabine|Administered orally
267996|NCT02359058|Drug|Cisplatin|Administered IV
267997|NCT02359058|Drug|S-1|Administered orally
267998|NCT02359058|Drug|Oxaliplatin|Administered IV
267999|NCT02359071|Other|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
268000|NCT02359084|Behavioral|Family Navigation|
267382|NCT02370901|Device|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
267383|NCT02370901|Behavioral|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
267384|NCT02370914|Device|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
267385|NCT02370927|Other|Control|Non pulse extruded cereal
267386|NCT02370927|Other|Pea protein|Pulse extruded cereal
267387|NCT02370927|Other|Pea Starch|Pulse extruded cereal
267388|NCT02370927|Other|Pea fibre + pea starch|Pulse extruded cereal
267389|NCT02370927|Other|Pea protein + pea starch|Pulse extruded cereal
267390|NCT02370927|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
267391|NCT02370940|Other|High phytate intake|
267392|NCT00160121|Drug|Lanthanum carbonate|
267393|NCT02370940|Other|Low phytate intake|
267394|NCT02370953|Device|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
267395|NCT02373371|Procedure|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
267690|NCT02366325|Drug|EPO-018B|
267691|NCT02366351|Drug|SHR3824|Once daily, 12 weeks
267692|NCT02366351|Drug|Placebo|Once daily, 12 weeks
267693|NCT02366364|Drug|Placebo|Single oral administration of placebo consumption on Day 1
267694|NCT02366364|Drug|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
267695|NCT02366364|Drug|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
266797|NCT02382445|Device|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
266798|NCT02382445|Drug|propofol and sevoflurane|
267100|NCT02377570|Device|THERNOVA 400 dialyzer prototype CC|Hemodialysis
267101|NCT02377570|Device|FX CorDiax 80 dialyzer|Hemodialysis
267102|NCT02377609|Drug|Tacrolimus|oral
267103|NCT02377622|Device|THERANOVA 400 dialyzer prototype AA|
267104|NCT02377622|Device|THERANOVA 400 dialyzer prototype BB|
267105|NCT00160927|Device|local heating|
267106|NCT02377622|Device|FX CorDiax 80 Dialyzer|
267107|NCT02377622|Device|FX CorDiax 800 Dialyzer|
267108|NCT02377635|Dietary Supplement|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
267109|NCT02377635|Dietary Supplement|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
267110|NCT02377648|Device|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS <70%) associated with concomitant signs or symptoms of myocardial ischemia.
267111|NCT02377661|Drug|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of < 140/90 mmHg is not reached at the respective follow-up
267112|NCT02377674|Device|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
267113|NCT02377687|Other|observational study|
267114|NCT02377700|Device|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
266499|NCT02389504|Other|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
266500|NCT02389517|Drug|Ixazomib Citrate|Given PO
266501|NCT02389517|Drug|Lenalidomide|Given PO
266502|NCT02389517|Drug|Dexamethasone|Given PO
266503|NCT02389530|Drug|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
266504|NCT02389543|Drug|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
266505|NCT02389543|Drug|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
266799|NCT02382458|Behavioral|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
266800|NCT02382458|Behavioral|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
266801|NCT02382471|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
266802|NCT02384837|Device|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
266803|NCT02384850|Drug|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
266804|NCT02384850|Drug|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
266805|NCT02384850|Drug|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
266806|NCT02384850|Drug|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
266807|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
266808|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
266809|NCT02384889|Drug|Difluoromethylornithine|Active Therapy with DFMO
266810|NCT02384889|Drug|Placebo|Placebo Comparitor
266811|NCT00161837|Biological|Vero Cell-derived Influenza Vaccine|
266217|NCT02358317|Behavioral|Video Game Motor Training|
266218|NCT02358317|Behavioral|Sedentary Video Game Training|
266219|NCT02358330|Other|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
266220|NCT02358343|Behavioral|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
266221|NCT02358343|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
266222|NCT02360553|Behavioral|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
266223|NCT02360553|Behavioral|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
266224|NCT02360566|Behavioral|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
266225|NCT02360579|Biological|LN-144|A tumor sample is resected from each patient and cultured with IL-2 in vitro to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are reinfused with the autologous TIL (LN-144) followed by IL-2.
lymphodepletion chemotherapy followed by high dose IL-2 therapy starting the morning on the next day after infusion.
266226|NCT02360592|Drug|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
266506|NCT00162448|Drug|BMS-394136|Oral Solution, Oral, 100 mg, Single dose, 1 day.
266507|NCT02389543|Drug|Dexamethasone|Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.
For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24.
266508|NCT02389569|Procedure|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
242077|NCT00180362|Device|procedure|
242078|NCT02512081|Other|No intervention applied|No intervention applied
242378|NCT02507414|Other|Head down tilt|At three different time points the participants will be head down tilted in 20 degrees.
End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)
242379|NCT02507427|Device|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
242380|NCT02507440|Drug|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
242381|NCT02507440|Drug|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
242382|NCT00179751|Drug|CC-5013|
242383|NCT02507440|Drug|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
242384|NCT02507453|Other|parabolic flight|
242385|NCT02507453|Other|mass/weight perception estimation|estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
242386|NCT02507453|Device|ESA short-arm human centrifuge (SAHC)|
242387|NCT02507466|Behavioral|exercise|Variable conditions of stepping practice
242388|NCT02507479|Drug|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
242389|NCT02507492|Drug|RM-493|
242390|NCT02507505|Procedure|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
242391|NCT02507505|Procedure|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
242392|NCT02507518|Device|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
242393|NCT00002489|Drug|carboplatin|
242394|NCT00179751|Drug|gemcitabine|
242395|NCT02507544|Drug|TRX-818 capsules|
241773|NCT02518685|Device|Sham procedure|
241774|NCT02518698|Drug|Xofigo (Radium-223 dichloride, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
241775|NCT00181558|Drug|Atrasentan|
241776|NCT02518711|Behavioral|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
241777|NCT02518724|Procedure|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
241778|NCT02518724|Procedure|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
241779|NCT02518737|Other|Meal Test|
241780|NCT02518750|Drug|Dexamethasone|Given orally (PO).
241781|NCT02518750|Drug|Panobinostat|Given PO.
241782|NCT02520934|Drug|ERT|enzyme replacement therapy
242079|NCT02514226|Procedure|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
242080|NCT02514226|Procedure|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
242081|NCT02514226|Procedure|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
242082|NCT02514226|Other|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
242083|NCT02514239|Drug|BI 836909|
242084|NCT02514252|Drug|Fentanyl Sublingual Spray (FSS)|Stage 1: Participant receives single dose of FSS that is equivalent to 16-24% of their morphine equivalent daily dose (MEDD) 1 - 4 hours after intravenous opioid as rescue for first episode of breakthrough pain. Participant may receive up to 4 doses of FSS for subsequent episodes of breakthrough pain while in hospital.
Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks.
241459|NCT00182169|Drug|Human recombinant growth hormone|
241460|NCT02523027|Dietary Supplement|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
241461|NCT02523027|Dietary Supplement|Oral nutritional supplement|(List No- P968/Z0)
241462|NCT02523027|Other|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
241463|NCT02523040|Drug|Lenalidomide|
241464|NCT02523053|Procedure|Hepatectomy|Surgical removal of all lesions
241465|NCT02523053|Procedure|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
241466|NCT02523066|Device|Magna Ease|This study is non-intervention
241467|NCT02523079|Behavioral|Cognitive Behavioral Group Therapy for Insomnia|
241468|NCT02523079|Behavioral|Cognitive Behavioral Self-help Therapy for Insomnia|
241469|NCT02523079|Behavioral|Sleep Hygiene Guidance|
241470|NCT00002494|Drug|dexamethasone|
241471|NCT00182182|Behavioral|Primary care based disease management strategy|
241472|NCT02523092|Drug|Acthar gel|Acthar gel given IM or SQ as per package insert
241473|NCT02523105|Device|EEG monitoring|EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).
EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises.
241783|NCT00181844|Drug|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children <12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
241784|NCT02520947|Device|BIS|Bispectral index monitoring
241785|NCT02520947|Drug|Desflurane|volatile agent for maintenance of anesthesia
241786|NCT02520973|Other|Sputum sample|
241787|NCT02520986|Device|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
240850|NCT02534454|Drug|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
241152|NCT02529813|Procedure|T Cell Infusion|Patient (Autologous)-derived CAR T cells infused for active disease following lymphodepleting chemotherapy.
Donor (Allogeneic)-derived CAR T cells infused 6-12 weeks following allogeneic hematopoietic stem-cell transplant (HSCT)
Starting level dose: > 1 x 105/kg but ≤ 1 x 106/kg
241153|NCT02529826|Procedure|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
241154|NCT02529839|Procedure|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
241155|NCT02529839|Drug|Fludarabine|30mg/m2 on days -6 through -3
241156|NCT02529839|Drug|Cyclophosphamide|50mg/kg on days -5 through -4
241157|NCT00182845|Drug|Donepezil|
241158|NCT02529839|Drug|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
241159|NCT02529852|Drug|Lenalidomide|Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.
Phase II Starting Dose Level: Maximum tolerated dose from Phase I.
241160|NCT02529852|Drug|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
241161|NCT02529852|Drug|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
241162|NCT02529852|Drug|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
241163|NCT02529852|Drug|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
241164|NCT02529852|Drug|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
241165|NCT02529865|Biological|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
241166|NCT02529878|Drug|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
241167|NCT02529891|Other|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
241168|NCT00182871|Drug|testosterone|
241169|NCT02529904|Biological|MF59 - ATIV|All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.
Adult participants will receive one dose of MF59-ATIV.
240529|NCT02504242|Procedure|Locally Harvested Bone|
240530|NCT02504255|Biological|Biological samplings|Blood, urine and faecal sampling every 3 months
240531|NCT02504255|Other|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
240532|NCT02504268|Drug|Abatacept|
240533|NCT02504268|Drug|Methotrexate|
240534|NCT02504268|Other|Abatacept Placebo|
240535|NCT02504268|Other|Methotrexate Placebo|
240536|NCT02504294|Drug|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 5 erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
240537|NCT02504294|Other|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 protocol and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
240538|NCT02504307|Device|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
240851|NCT02534467|Drug|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
240852|NCT02534480|Drug|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
240853|NCT02534493|Device|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
240854|NCT02536924|Behavioral|Treatment as usual.|The patient will receive treatment as usual.
240855|NCT02536937|Drug|eliglustat|Pharmaceutical form: capsule
Route of administration: oral
240856|NCT02536950|Device|Fixed set point|Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.
240857|NCT02536950|Device|Variable set point|Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
240858|NCT02536976|Drug|mirabegron|
240233|NCT02511236|Behavioral|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
240234|NCT02511236|Behavioral|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
240235|NCT02511236|Drug|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
240236|NCT02511262|Device|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
240237|NCT02511275|Procedure|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
240238|NCT02511301|Device|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.
240239|NCT02511314|Device|TENA Identifi|
240240|NCT02511327|Drug|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
240241|NCT02511340|Drug|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
240242|NCT02511353|Drug|ivermectin|
240243|NCT00000370|Behavioral|Cognitive behavior therapy|
240244|NCT00002489|Drug|methotrexate|
240539|NCT00179309|Biological|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
240540|NCT02504307|Device|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
240541|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
240542|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
239949|NCT02517996|Drug|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
239950|NCT02517996|Drug|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
239951|NCT02518009|Other|Genetic men treated with estrogen|Observational during estrogen treatment
239952|NCT02518009|Other|Genetic women treated with androgen|Observational during androgen treatment
239953|NCT02518022|Drug|Insulin|Insulin for beer
239954|NCT02518035|Drug|Silicone Gel|Silicone gel will be applied twice per day in the experimental group
239955|NCT02518048|Drug|LEO 90100 Aerosol foam|
239956|NCT02518048|Drug|Betesil® 2.25 mg|
239957|NCT00181272|Drug|azithromycin|
239958|NCT02518061|Other|No intervention|This is a retrospective study
239959|NCT02518074|Other|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
239960|NCT02518087|Device|OXIRIS®|OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [OXIRIS® (Baxter Gambro)].
PrismafleX eXeed™ II (Hospal) with OXIRIS® set will be irrigated with saline during preparation and irrigation of CPB circuit. PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.
OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time.
239961|NCT02518100|Device|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
239962|NCT02518100|Device|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
239963|NCT02518113|Drug|LY3039478|Administered orally
239964|NCT02518113|Drug|Dexamethasone|Administered orally
264553|NCT02372370|Procedure|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
264554|NCT02372370|Procedure|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
264555|NCT02372370|Procedure|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
264851|NCT02365181|Procedure|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
264852|NCT02365181|Drug|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
264853|NCT02365194|Behavioral|Prehabilitation|information included in arm description
264854|NCT02365194|Behavioral|Standard counseling|information included in arm description
264855|NCT02367248|Drug|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
264856|NCT02367248|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
264857|NCT02367261|Device|SPI implant|SPI implant - the original spiral implant
264858|NCT02367274|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
264859|NCT02367300|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
264860|NCT00159744|Drug|Olanzapine|Olanzapine, 3 weeks
264861|NCT02367313|Drug|Vapendavir|Vapendavir 264 mg twice daily
264862|NCT02367313|Drug|Vapendavir|Vapendavir 528 mg twice daily
264863|NCT02367313|Drug|Placebo|Placebo twice daily
264864|NCT02367326|Other|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
264865|NCT02367339|Other|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
269228|NCT02330770|Drug|GnRHa and HCG|Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM
269229|NCT02333084|Dietary Supplement|PRN Flex Omega Benefits® combination|
269230|NCT02333110|Radiation|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
269231|NCT00154856|Behavioral|Detect the variation of limb lengthening|
269232|NCT02333123|Drug|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
269233|NCT02333123|Drug|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
269234|NCT02333136|Device|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
269235|NCT02333149|Dietary Supplement|Melatonin|Children <40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.
Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime.
269236|NCT02333149|Drug|Placebo|Placebo frequency and volume are identical to the experimental arm
264556|NCT02372370|Procedure|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
264557|NCT02372370|Procedure|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
264558|NCT02372370|Drug|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
264559|NCT00160290|Drug|Lactulose|15 mL / 12 hours
264560|NCT02372370|Other|Untreated Control|Untreated control. No interventions.
264561|NCT02374450|Procedure|Lumbar puncture|Optimal sample collection of at least 500 µL (5-10 drops) of cerebrospinal fluid (CSF) for diagnosis of meningitis and neurological AESI
264562|NCT00160446|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
264563|NCT02374450|Procedure|Venous blood sample|Approximately 0.5 mL of whole blood will be collected from all enrolled children at hospital suspected of having a protocol-defined disease specified as an AESI and SAE. This concerns only Passive surveillance group.
268924|NCT00156117|Drug|olanzapine|olanzapine 15 mg QD
268925|NCT02337907|Drug|Placebo|for blinding purposes
268926|NCT02337907|Drug|Placebo|
268927|NCT02337907|Drug|BI 409306|
268928|NCT02337907|Drug|Donepezil|
268929|NCT02337933|Drug|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
268930|NCT02337933|Drug|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
268931|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
268932|NCT02340065|Procedure|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
268933|NCT02340078|Device|HA IDF II plus|
268934|NCT02340078|Device|HA IDF II|
268935|NCT02340091|Device|HA IDF plus|
268936|NCT02340091|Device|HA IDF|
268937|NCT02340104|Drug|Baricitinib|Administered orally
268938|NCT02340104|Drug|[^13C4D3^15N]-baricitinib|Administered IV
268939|NCT02340117|Genetic|SGT-53|The starting dose of SGT-53 in week 1 will be 2.4 mg DNA/infusion. If the combination therapy of SGT-53 and gemcitabine/nab-paclitaxel is tolerated, starting in week 2, the dose of SGT-53 will be escalated to 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 1.2 mg DNA/infusion (dose level -1) or 0.6 mg DNA/infusion (dose level -2) in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
268940|NCT02340117|Drug|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 75 or 100 mg/m² when appropriate.
268941|NCT00156468|Behavioral|Provider Prompt|
269237|NCT02333162|Drug|Fludarabine Phosphate|Given IV
269238|NCT02333162|Drug|Melphalan|Given IV
269239|NCT02333162|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMTMI
269240|NCT02333162|Radiation|Total Marrow Irradiation|Undergo IMTMI
268314|NCT02392663|Other|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
268620|NCT02344563|Drug|Meropem|
268621|NCT02344563|Drug|Mepem|
268622|NCT00157053|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
268623|NCT02344576|Behavioral|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
268624|NCT02344589|Drug|Lidocaine|used for the active blocks
268625|NCT02344589|Drug|Saline|used for the placebo-block
268626|NCT02344602|Drug|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
268627|NCT02344615|Procedure|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
268628|NCT02346578|Drug|Enzalutamide|
268629|NCT02346578|Drug|Flutamide|
268630|NCT02346591|Behavioral|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
268631|NCT02346591|Behavioral|Online stress management information|Online educational information about stress management
268632|NCT02346617|Biological|IFN-γ positive selected T-cells|
268633|NCT02346630|Drug|Placebo|Placebo capsules daily for 3 weeks.
268634|NCT00157482|Drug|Ezetimibe|
268635|NCT02346630|Drug|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
268636|NCT02346630|Device|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
268637|NCT02346643|Device|Implantation with the commercially available Axium Neurostimulator|
268638|NCT02346656|Device|Implantation with the commercially available Axium neurostimulator|
268639|NCT02346669|Procedure|gastroscopy|as detailed in arm description
268001|NCT02361372|Other|Placebo|Placebo daily for 6 months
268002|NCT02361372|Other|CaCO3|CaCO3 daily for 6 months
268003|NCT02361372|Other|Kefir|Kefir daily for 6 months
268004|NCT02361385|Other|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
268005|NCT02361398|Other|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
268006|NCT02361424|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
268007|NCT02361424|Drug|placebo|
268008|NCT02361437|Dietary Supplement|Vasculera|Vasculera 630 mg b.i.d.
268009|NCT02361450|Device|Retrograde Colonic Irrigation|
268010|NCT00159107|Behavioral|Integrative behavior therapy|Integrative behavior therapy
268011|NCT02361450|Other|Usual Care|
268315|NCT02392663|Other|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
268316|NCT02392676|Drug|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
268317|NCT02392676|Drug|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
268318|NCT02392689|Other|Procalcitonin|Procalcitonin guided antibiotic therapy
268319|NCT02392702|Drug|C-10355|
268320|NCT02392702|Drug|C-10358|
268321|NCT02392702|Drug|Kalydeco|
268322|NCT02392715|Device|Inspiratory muscle training with Threshold by respironics|Inspiratory muscle training
15 minutes, 3x/weeks, 36 sessions
Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax.
267696|NCT00159601|Behavioral|General child psychiatric interventions|Usual daily child psychiatric treatment
267697|NCT02366364|Drug|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
267698|NCT02366377|Drug|SHR3824|
267699|NCT02366377|Drug|Placebo|
267700|NCT02366377|Drug|Metformin|
267701|NCT02366390|Behavioral|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
267702|NCT02366403|Behavioral|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
267703|NCT02366403|Behavioral|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
267704|NCT02366416|Behavioral|Exercise training|Physical activity
267705|NCT02366429|Behavioral|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
267706|NCT02366429|Other|TAU|Treatment as usual provided at antenatal clinics and other health care instances
267707|NCT02368431|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
267708|NCT02368431|Drug|Placebo|Placebo
267709|NCT02368444|Behavioral|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
267710|NCT02368457|Drug|Pentoxifylline and Tocopherol|pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
268012|NCT02361463|Device|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
268013|NCT02361463|Device|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
268014|NCT02361476|Drug|Clonidine|Injection - during surgery
268015|NCT02361476|Drug|Placebo|Injection - during surgery
267115|NCT02377713|Drug|KHK6640|Single ascending dose administration
267116|NCT00160927|Device|iontophoresis|
267117|NCT02377713|Drug|Placebo|Single ascending dose administration
267118|NCT02379845|Device|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
267396|NCT02373371|Procedure|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
267397|NCT02373384|Drug|Oral alkalinization (Potassium citrate, Allopurinol)|Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy
Potassium citrate 20 mEq three times daily
Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:
Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.
267398|NCT02373384|Behavioral|Life style modification|Eligible patients, who fulfilled the study criteria, will be also instructed for;
Adequate fluid intake in order to maintain urine volume between 2-3 L per day.
267399|NCT02373384|Dietary Supplement|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
267400|NCT02373397|Device|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
267401|NCT02373397|Device|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
267402|NCT00160355|Procedure|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
267403|NCT02373410|Procedure|Umbilicus|Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.
The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus
267404|NCT02373410|Procedure|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
267405|NCT02373410|Procedure|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
267406|NCT02373410|Procedure|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
267407|NCT02373410|Drug|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
267408|NCT02373410|Drug|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
266812|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
266813|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
266814|NCT02384902|Other|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
266815|NCT02384915|Drug|prilocaine|
266816|NCT02384915|Drug|mepivacaine|
266817|NCT02384915|Procedure|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
266818|NCT02384915|Procedure|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
266819|NCT02384915|Device|Sonoplex, Pajunk|
267119|NCT02379858|Drug|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
267120|NCT00002424|Drug|Stavudine|
267121|NCT00161278|Drug|Carboplatin|
267122|NCT02379858|Drug|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
267123|NCT02379871|Other|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
267124|NCT02379871|Other|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
267125|NCT02379897|Other|Diet|
267126|NCT02379910|Drug|AM1030-CREAM or placebo|
267127|NCT02379923|Device|Revascularization of Coronary Artery Chronic Total Occlusion (Corsair, Gaia, Asahi Guide Wires)|Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.
Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.
266509|NCT02389569|Procedure|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
266510|NCT02389582|Drug|Dabigatran|Use for 5 days
266511|NCT00162721|Drug|doxorubicin, ifosfamide, cisplatin|
266512|NCT02391727|Biological|SYN004|subjects who have received effective treatment for their cancers are eligible
266513|NCT02391740|Other|Questionnaire|
266514|NCT02391753|Device|Transperineal 3D Ultrasound|Imaging was performed with women in lithotomy position with empty bladder. The probe was covered with a sterile film and placed on the perineum in the sagittal plane. The field of view angle was set to a maximum of 70° in the sagittal plane and the volume acquisition angle to 85° in the axial plane. Analysis of stored volumes was conducted offline by another experienced investigator blinded to clinical and delivery data.
266515|NCT02391766|Behavioral|empowerment|The groups of 10 participants meet once a week for eight weeks. last for four hours
topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions.
266516|NCT02391766|Behavioral|usual care|
266517|NCT02391779|Dietary Supplement|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
266518|NCT02391779|Behavioral|Walking training|30-60 minutes walking training, 5 days/week.
266519|NCT02391779|Behavioral|Flexibility training|5 days/week; e.g. stretching training at home
266520|NCT02391779|Dietary Supplement|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
266521|NCT02391779|Behavioral|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
266522|NCT00162734|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
266523|NCT02391805|Drug|Placebo|
266524|NCT02391805|Drug|RO6864018|
266525|NCT02391831|Other|Strength, function and activity measurements|
266526|NCT02391831|Other|Muscle MRI|
266820|NCT02384928|Procedure|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
242396|NCT02507570|Drug|Enzalutamide|used concomitantly
242397|NCT02507570|Radiation|Radium ra 223 dichloride|
242398|NCT02507583|Drug|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.|
242716|NCT00179127|Drug|glargine|0.3u/kg of glargine, subq, once
242717|NCT02502812|Drug|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
242718|NCT02502812|Drug|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
242719|NCT02502825|Other|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
242720|NCT02502825|Device|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
242721|NCT02502825|Device|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
242722|NCT02502851|Device|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
242723|NCT02502851|Device|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
242724|NCT02502864|Drug|Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
242725|NCT02502864|Drug|Cyclophosphamide|Cycle 1: 600 mg/m^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
242726|NCT02502864|Other|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
242727|NCT00179127|Drug|saline|0.3cc/kg of saline, subq, once
242728|NCT02502877|Drug|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
242729|NCT02502877|Drug|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
242730|NCT02502877|Drug|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
242085|NCT02514252|Behavioral|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
242086|NCT00180635|Procedure|Exhaled Breath Condensate|
242087|NCT02514252|Behavioral|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
242088|NCT02514252|Behavioral|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
242089|NCT02514278|Drug|Neoadjuvant chemotherapy Folfirinox, 4 cycles|oxaliplatin: 85 mg/m2
irinotecan: 180 mg/m²
folinic acid: 400 mg/m2
5FU: 2400 mg/m2
242090|NCT02514278|Radiation|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
242091|NCT02514278|Procedure|Local excision in good responders|If local excision:
Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)
Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1.
242092|NCT02514278|Procedure|Rectal excision in bad responders|
242093|NCT02514278|Drug|Capecitabine|1600 mg/m2 daily 5 days/7
242094|NCT02514291|Behavioral|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
242095|NCT02514317|Procedure|percutaneous treatment|
242096|NCT02514317|Device|Ultrasound|
242399|NCT02507583|Drug|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
242400|NCT02509637|Other|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
242401|NCT02509637|Device|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
242402|NCT02509637|Other|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
242403|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
242404|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery using rigide instrumentation|FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.
The procedure works by cutting to remove bone and tissue to enlarge the sinus opening.
241788|NCT02520986|Device|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
241789|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
241790|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
241791|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
241792|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
241793|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
241794|NCT00002493|Radiation|low-LET photon therapy|
241795|NCT00181870|Drug|carbamazepine ER (Equetro)|
241796|NCT02521012|Dietary Supplement|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
241797|NCT02521012|Dietary Supplement|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
241798|NCT02521025|Other|Intermittent feeding pattern|Intermittent feeding
241799|NCT02521025|Other|Continuous feeding pattern|Continuous feeding
241800|NCT02521038|Drug|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
241801|NCT02521051|Drug|Alectinib|
241802|NCT02521051|Drug|Bevacizumab|
241803|NCT02521064|Dietary Supplement|Exclusive Enteral Nutrition (EEN)|Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
242097|NCT00180635|Procedure|Nasal Nitric Oxide|
242098|NCT02514330|Other|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
242099|NCT02514330|Other|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
242100|NCT00180973|Drug|Hydroxyurea|
241170|NCT02529917|Dietary Supplement|Hemp powder|Hemp powder supplement
241171|NCT02529917|Dietary Supplement|Soy Powder|Soy powder supplement
241172|NCT02529930|Biological|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
241474|NCT02525367|Behavioral|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
241475|NCT02525380|Procedure|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
241476|NCT02525393|Device|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
241477|NCT02525393|Device|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
241478|NCT02525393|Device|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
241479|NCT02525406|Other|All surgeries performed from Jan 01, 2010 to Dec 31, 2014|
241480|NCT02525419|Behavioral|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
241481|NCT02525419|Behavioral|HP-IF|High Protein, Intermittent Fast
241482|NCT02525419|Behavioral|HH|Heart Healthy
241483|NCT02525432|Biological|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
241484|NCT00182520|Drug|placebo|25 - 400 mg/day x 12 weeks
241485|NCT02525432|Biological|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
241486|NCT02525445|Procedure|acupuncture|acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
240859|NCT00183625|Behavioral|Social Skills Training|
240860|NCT02536976|Drug|Placebo|
240861|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
240862|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
240863|NCT02537002|Drug|PF-05230907|A single intravenous dose of 3 μg/kg
240864|NCT02537002|Drug|PF-05230907|A single intravenous dose of 5 μg/kg
240865|NCT02537002|Drug|Placebo|A single intravenous dose of matched placebo
240866|NCT02537015|Drug|Bimatoprost Ocular Insert|ForSight VISION5 product (Bimatoprost Ocular Insert) used continuously for 12 weeks, then replaced with a new ForSight VISION5 product and used continuously for another 24 weeks.
240867|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
240868|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
240869|NCT02537028|Drug|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
240870|NCT00183625|Drug|Olanzapine|
240871|NCT02537041|Procedure|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
240872|NCT02537041|Procedure|MRI|
241173|NCT02529943|Procedure|Surgical Decompression|
241174|NCT02529956|Drug|UCB4940|Active Substance: UCB4940
Pharmaceutical Form: Solution for infusion
Concentration: 80 mg/ml
Route of Administration: Intravenous use
241175|NCT02532127|Other|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
241176|NCT02532140|Drug|WCK 5107 250 mg to 2000 mg|
241177|NCT02532140|Drug|Cefepime 2000 mg|
241178|NCT02532140|Drug|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
241179|NCT02532140|Drug|Placebo|
241180|NCT02532153|Drug|Ketamine Hydrochloride|Single open-label infusions
240543|NCT02506634|Drug|Esomeprazole MUPS, 20 mg|The treatment period would be 4 to 8 weeks according to the findings under upper endoscopy. For patients with esophagitis, this period would be 8 weeks(Esomeprazole MUPS, 20 mg bid); for patients with normal findings, this period would be 4 weeks(Esomeprazole MUPS, 20 mg bid).
240544|NCT02506647|Drug|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan & Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
240545|NCT02506647|Drug|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan & Lee insulin glargine injection SC,
240546|NCT02506660|Drug|Bupivacaine|
240547|NCT00179647|Drug|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
240548|NCT02506660|Drug|Perineural dexamethasone|Dexamethasone in nerve block
240549|NCT02506660|Drug|Intravenous dexamethasone|
240550|NCT02506660|Drug|Intravenous saline|
240551|NCT02506660|Drug|Perineural saline|Saline in nerve block
240552|NCT02506673|Device|Zeiss, Cinema ProMED (audiovisual equipment)|
240553|NCT02506673|Drug|Midazolam|
240554|NCT02506673|Device|Skin Conductance Monitor|
240555|NCT02506686|Drug|Meropenem|Meropenem i.v.
240556|NCT02506699|Other|analgesic effect of rTMS|
240557|NCT02506712|Device|SmartDrive assisting device|oxygen consumption
240558|NCT00179647|Drug|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
240559|NCT02506712|Device|Standard manuel wheelchair|oxygen consumption
240560|NCT02506725|Other|prenatal in groups|We will do prenatal care in groups using centering care pregnancy methodology
240561|NCT02506738|Device|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
240873|NCT02537054|Drug|Aflibercept|Intravitreal injection
240874|NCT02537067|Drug|CHONDRON|Harvesting of ankle or knee cartilage
The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
239965|NCT02518113|Drug|Placebo|Administered orally
240245|NCT02513472|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 IV (intravenous) infusion on Day 1 and Day 8 of each 21 day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the subject withdraws consent.
240246|NCT02513472|Drug|Pembrolizumab|Pembrolizumab will be administered as a 200 mg IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit in intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the subject withdraws consent.
240247|NCT02513485|Drug|Levodopa+carbidopa|Sinemet is a combination of 100mg levodopa and 25 mg carbidopa. Sinemet will be administered orally at Visit 2 (within 1 week of Screening) or at Visit 3 (within 2-4 weeks of Screening).
240248|NCT02513485|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 2 (within 1 week of Screening) or at Visit 3 (within 2-4 weeks of Screening).
240249|NCT02513498|Drug|Ixazomib Citrate|Given PO
240250|NCT02513498|Other|Laboratory Biomarker Analysis|Correlative studies
240251|NCT00180609|Device|Automatic threshold test in Insignia Pacemakers from Guidant|
240252|NCT02513498|Other|Quality-of-Life Assessment|Ancillary studies
240253|NCT02513498|Other|Questionnaire Administration|Ancillary studies
240254|NCT02513511|Procedure|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
240255|NCT02513524|Procedure|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
240256|NCT02513550|Drug|Ixekizumab|Administered SQ
240257|NCT02513550|Drug|Placebo|Administered SQ
240258|NCT02513563|Drug|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
240259|NCT02513563|Drug|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
240260|NCT02513563|Drug|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
240261|NCT02513576|Other|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
240262|NCT00180622|Procedure|Spirometry|
264866|NCT02367352|Drug|Alisertib|Alisertib tablets
264867|NCT02367352|Drug|Paclitaxel|Paclitaxel intravenous solution
264868|NCT02367365|Other|No Intervention|No intervention
264869|NCT02367365|Other|No Intervention|No intervention
264870|NCT02367391|Behavioral|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
264871|NCT00159744|Drug|Placebo|placebo, 3 weeks
264872|NCT02367391|Behavioral|Control|Usual Care. All participants receive the active medication, Varenicline.
264873|NCT02367404|Drug|Duloxetine|Duloxetine 60mg OD for 3 months
265172|NCT00158912|Device|Implantable Cardioverter Defibrillator|
265173|NCT00159289|Procedure|Inhalation of LPS|
265174|NCT02362750|Other|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
265175|NCT02362750|Other|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
265176|NCT02362750|Other|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
265177|NCT02362750|Other|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
265178|NCT02362750|Other|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
265179|NCT02362750|Other|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
265180|NCT02362750|Other|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
265181|NCT02362763|Procedure|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
264564|NCT02374463|Behavioral|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
264565|NCT02374463|Behavioral|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
264566|NCT02374476|Device|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
264567|NCT02374489|Drug|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
264568|NCT02374502|Behavioral|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
264569|NCT02374515|Device|EndoCuff-assisted colonoscopy|Adenoma detection rate
264570|NCT02374515|Device|Standard Colonoscopy|
264874|NCT02367404|Behavioral|Pelvic Floor Muscle Training|PMFT weekly for 3 months
264875|NCT02367430|Behavioral|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
264876|NCT02367430|Behavioral|Buried in Treasures Workshop|
264877|NCT02367443|Radiation|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
264878|NCT02367456|Drug|PF-04449913|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
264879|NCT02367456|Drug|Azacitidine|75mg/m2 on Days 1-7 of a 28 day cycle or on Days 1-5, 8-9 of a 28 day cycle
264880|NCT02367456|Drug|PF-04449913 Placebo|Daily dose of the Placebo for PF-04449913 100 mg tablet in a continuous regimen of 28 day cycles.
264881|NCT02367495|Device|PCB|PCB with Citrate-based excipient
264882|NCT02369744|Drug|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
264883|NCT02369744|Drug|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
269241|NCT02333162|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
269242|NCT00154869|Drug|Peginterferon Alfa-2a plus Ribavirin|
269243|NCT02333162|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
269244|NCT02333162|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
269245|NCT02333162|Drug|Tacrolimus|Given IV or PO
269246|NCT02333162|Drug|Mycophenolate Mofetil|Given IV or PO
269247|NCT02333162|Other|Laboratory Biomarker Analysis|Correlative studies
269248|NCT02333175|Other|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
269249|NCT02333188|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
269250|NCT02333188|Drug|Leucovorin Calcium|Given IV
269251|NCT02333188|Drug|Irinotecan Hydrochloride|Given IV
269252|NCT02333188|Drug|Fluorouracil|Given IV
269253|NCT00154882|Drug|Paclitaxel (Phyxol) , Cisplatin|
269254|NCT02333188|Other|Laboratory Biomarker Analysis|Correlative studies
269255|NCT02335307|Genetic|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
269256|NCT02335307|Other|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
269257|NCT02335307|Other|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
269258|NCT02335333|Other|No treatment|
269259|NCT02335346|Drug|Duloxetine|Administered orally
269260|NCT02335359|Drug|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
269261|NCT02335359|Drug|tranexamic acid undiluted (continous infusion)|
269262|NCT02335359|Drug|Placebo|Saline
268640|NCT02346669|Drug|Fecal Microbiota Transplantation|
268641|NCT02346682|Drug|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
268642|NCT02346708|Device|Real TMS|real treatment
268942|NCT02340117|Drug|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 750 mg/m² when appropriate.
268943|NCT02340130|Biological|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
268944|NCT02340130|Biological|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
268945|NCT02340143|Other|Control|Marketed partially hydrolyzed cow's milk protein infant formula
268946|NCT02340143|Other|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
268947|NCT02340156|Genetic|SGT-53|In both Parts A and B, SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
268948|NCT02340156|Drug|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
268949|NCT02340169|Drug|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
268950|NCT02340182|Drug|Vancomycin|250mg 3dd2
268951|NCT02340182|Drug|Ciprofloxacin|500mg 2dd1
268952|NCT00156507|Behavioral|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
268953|NCT02340182|Drug|Metronidazole|500mg 3dd1
268954|NCT02340195|Drug|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
268955|NCT02342353|Drug|Erlotinib|
268956|NCT02342366|Drug|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
268957|NCT00156793|Procedure|AI-700 contrast-enhanced echocardiography|
268323|NCT00162877|Drug|Rabeprazole vs. Esomeprazole|
268324|NCT02392715|Device|Sham Inspiratory muscle training|with Threshold by respironics
15 minutes, 3x/weeks, 36 sessions
Intensity: 5 centimeters of water (cmH20)
268325|NCT02356627|Other|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
268326|NCT02356640|Procedure|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
268327|NCT02356640|Procedure|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson &Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
268328|NCT02356640|Device|Olympus UM 2000|
268329|NCT02356640|Device|B-D Quincke Type Point|
268330|NCT02356640|Drug|Levobupivacaine|
268331|NCT00158574|Drug|IPTi mefloquine|IPTi doses 1 & 2 at ages 2 & 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
268643|NCT02346708|Device|Sham TMS|placebo treatment
268644|NCT02346721|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
268645|NCT00157482|Drug|Simvastatin|
268646|NCT02346734|Device|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
268647|NCT02346747|Biological|Vigil|bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
268648|NCT02346747|Biological|Placebo|"freeze" media.
268649|NCT02346760|Drug|UB-621|100 mg/ml, subcutaneous injection
268650|NCT02346773|Dietary Supplement|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
268016|NCT02361489|Device|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
268017|NCT02361502|Drug|mirabegron|
268018|NCT02361502|Drug|placebo|
268019|NCT02361515|Radiation|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
268020|NCT02361515|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
268021|NCT00159107|Drug|Placebo|Placebo
268022|NCT02361528|Drug|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
268023|NCT02361528|Drug|Placebo|placebo subcutaneously, for 5 days
268024|NCT02361541|Procedure|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
268025|NCT02361554|Device|Medtronic Activa Deep Brain Stimulation System|
268026|NCT02361567|Drug|Tramacet|Pain medication commonly used post-operatively
268027|NCT02361567|Drug|Percocet|Pain medication commonly used post-operatively
268028|NCT02361580|Other|Diary|Subject keeps diary of recovery
268029|NCT02364167|Drug|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
268030|NCT02364167|Device|Verum acupuncture|Verum acupuncture will be performed using indwelling permanent acupuncture needles "New Pyonex" with 1,5 mm length, manufactured by Seirin Corp. Japan
268031|NCT02364167|Other|Placebo acupuncture|Placebo acupuncture will be performed using the placebo "New Pyonex" adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan
268032|NCT02364193|Device|MRI|Cardiac MRI for LVEF and segmentation.
Phase-contrast MRI for CO in aorta and each pulmonary vein.
DCE-MRI for bolus kinetic parameter analysis.
268033|NCT02364193|Drug|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
268332|NCT02356653|Device|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
267409|NCT02373410|Drug|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
267410|NCT02373410|Drug|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
267411|NCT02373423|Other|Advocacy|See above for description
267412|NCT02375204|Drug|G-CSF|IV
267413|NCT02375204|Drug|carboplatin|IV
267711|NCT02368470|Drug|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
267712|NCT02368470|Drug|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
267713|NCT00159848|Behavioral|Treatment Optimization Program (educational material)|
267714|NCT02368483|Other|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
267715|NCT02368496|Device|HR-pQCT|
267716|NCT02368509|Other|Perform sensory tests|
267717|NCT02368535|Other|Survey|25-item questionnaire on pereception of interdisciplinary rounds
267718|NCT02368548|Other|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
267719|NCT02368548|Other|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
267720|NCT02368561|Drug|Injection of Hyaluronic Acid -" SYNVISC" (hylan G-F 20)|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
267721|NCT02368574|Procedure|Class II hysterectomy|Class II hysterectomy
267722|NCT02368587|Biological|WJMSCs Vs. placebo|WJMSCs Vs. placebo
267723|NCT02368587|Biological|Placebo|WJMSCs Vs. placebo
267724|NCT00159861|Drug|Sildenafil citrate|
267128|NCT02379936|Device|The Neo Hilda|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
Point of care method
267129|NCT02379936|Procedure|Traditional evaluation|Traditional way of evaluation
267130|NCT02379936|Device|iPhone 4S|
267131|NCT02379949|Behavioral|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
267132|NCT00161278|Drug|Paclitaxel|
267133|NCT02379949|Behavioral|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
267134|NCT02379962|Other|no intervention|
267135|NCT02379975|Procedure|Non-surgical Periodontal Therapy|
267136|NCT02379988|Radiation|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
267137|NCT02380001|Drug|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
267414|NCT02375204|Drug|etoposide phosphate|IV
267415|NCT02375204|Procedure|stem cell reinfusion|surgical procedure
267416|NCT02375217|Drug|Sugammadex|half dose
267417|NCT02375217|Drug|Sugammadex|full dose
267418|NCT02375217|Drug|Neostigmine|IV = 50mcg/kg
267419|NCT00160602|Drug|Certolizumab Pegol|
267420|NCT02375217|Drug|glycopyrrolate|
267421|NCT02375230|Procedure|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
267422|NCT02375230|Procedure|MR SOPA|Health care provider randomized to the "MR SOPA" group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift.
267423|NCT02375243|Drug|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
266821|NCT02384928|Device|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
266822|NCT00161837|Biological|Egg-derived Influenza Vaccine|
266823|NCT02387216|Drug|Docetaxel|approved chemotherapy treatment for NSCLC
266824|NCT02387216|Drug|Pemetrexed|approved chemotherapy treatment for NSCLC
266825|NCT02387229|Drug|Rivaroxaban|15 mg
266826|NCT02387229|Drug|Acetylsalicylic acid|100 mg
266827|NCT02387242|Drug|Rifampicin|Single oral dose of rifampicin
266828|NCT02387255|Device|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
266829|NCT00162149|Drug|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
266830|NCT02387268|Device|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
266831|NCT02387294|Biological|ntervention: Vaccination with Fluval AB Novo.|vaccination
266832|NCT02387307|Drug|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
266833|NCT02387320|Other|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
266834|NCT02387333|Procedure|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.
A preferred rectal muscle splitting approach is preferred for IC exteriorization.
Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.
Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.
The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.
The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.
A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.
The stoma is then everted and fixed to the skin.
266835|NCT02387333|Procedure|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
266836|NCT02387346|Device|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
242731|NCT02502877|Device|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
242732|NCT02502903|Drug|TNT009|
242733|NCT02502903|Other|Placebo|
242734|NCT02502929|Behavioral|Enhanced standard care|
242735|NCT02502929|Behavioral|Lifestyle|
242736|NCT02502929|Behavioral|Lifestyle Plus Medication Therapy Management|
243040|NCT02532985|Other|Negative Control|No added fiber beverage
243041|NCT02532985|Other|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
243042|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
243043|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
243044|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
243045|NCT02532998|Drug|AZD9977 oral suspension|AZD9977 oral suspension, single dose
243046|NCT02532998|Drug|AZD9977 placebo oral suspension|oral suspension, single dose
243047|NCT02535299|Drug|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
243048|NCT02535312|Drug|Cisplatin|Given IV
243049|NCT02535312|Other|Laboratory Biomarker Analysis|Correlative studies
243050|NCT02535312|Drug|Methoxyamine|Given PO
243051|NCT02535312|Drug|Pemetrexed Disodium|Given IV
243052|NCT00183508|Behavioral|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
243053|NCT02535312|Other|Pharmacological Study|Correlative studies
243054|NCT02535325|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
243055|NCT02535325|Drug|Cisplatin|Given IV
243056|NCT02535325|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
242405|NCT00179998|Drug|Recombinant Human DNase (Pulmozyme)|Comparison of 2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
242406|NCT02509663|Device|Sinuplasty balloon|
242407|NCT02509663|Device|Endoscope|
242408|NCT02509676|Other|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
242409|NCT02509689|Behavioral|Global Z-Score Neurofeedback Training|The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.
Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions.
242410|NCT02509702|Behavioral|Connected to Care|mHealth messages sent on month -12, -10, -6, -5, -3. mHealth quizzes sent on month -9, -4, -2. Sms-reminders of check-up appointment sent on days -30, -7 days, -1, +1, +7.
242411|NCT02509715|Procedure|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
242412|NCT02509728|Dietary Supplement|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
242413|NCT02509728|Dietary Supplement|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
242414|NCT02509728|Dietary Supplement|standard nutrition|standard nutrition
242415|NCT02509741|Behavioral|Education|
242416|NCT00002489|Drug|etoposide|
242737|NCT02502942|Behavioral|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
242738|NCT00179140|Drug|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
242739|NCT02505087|Drug|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
242740|NCT02505100|Other|Touching relaxant|
242741|NCT00179452|Behavioral|Yoga|
242742|NCT02505100|Other|Hypnoses|
242101|NCT02516605|Drug|LJN452|LJN452 capsules administered once daily for 28 days
242102|NCT02516605|Drug|Placebo|Matching placebo capsules administered once daily for 28 days
242103|NCT02516618|Drug|Fasinumab|
242104|NCT02516618|Drug|Placebo|
242105|NCT02516631|Drug|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
242106|NCT02516631|Drug|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
242107|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
242108|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
242109|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
242110|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
242111|NCT00180986|Procedure|Platelet concentrates|
242112|NCT02516644|Behavioral|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
242113|NCT02516644|Behavioral|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
242114|NCT02516657|Drug|Liraglutide|Liraglutide 0.6 mg
242115|NCT02516670|Dietary Supplement|Ascorbic Acid|Given IV
242116|NCT02516670|Drug|Docetaxel|Given IV
242117|NCT02516670|Other|Laboratory Biomarker Analysis|Correlative studies
242118|NCT02516670|Other|Pharmacological Study|Correlative studies
242119|NCT02516670|Other|Placebo|Given IV
242120|NCT02516670|Other|Quality-of-Life Assessment|Ancillary studies
242417|NCT00180011|Drug|Omalizumab|injectable medication
242418|NCT02509741|Dietary Supplement|Food replacement|
241487|NCT02525445|Procedure|sham acupuncture|sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle [20]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no "needle sensation" occurred, and then lifted the needles up from the skin.
241488|NCT02525445|Procedure|positive communication|During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: "Many acupuncture studies have shown excellent results concerning relaxation effects", "Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension".
241489|NCT02525445|Procedure|neutral communication|During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: "During treatment you will just lie down and rest and I will not talk so much to you", "We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study",
241804|NCT02521064|Drug|Prednisone|Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
241805|NCT02521077|Drug|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
241806|NCT00181883|Drug|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
241807|NCT02521077|Other|Normal Saline|Saline 0.9%
241808|NCT02523131|Other|FlorenceM|The automated closed loop system (FlorenceM) will consist of:
Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.
An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
241809|NCT02523131|Other|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
241810|NCT02523144|Drug|Chloral Hydrate|70mg/kg chloral hydrate
241811|NCT02523144|Drug|Dexmedetomidine|2mcg/kg
241812|NCT02523144|Drug|Dexmedetomidine|3mcg/kg
241813|NCT02523144|Drug|Placebo|Flavored placebo syrup
241814|NCT02523157|Other|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
241815|NCT02523157|Other|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
241816|NCT00182195|Procedure|Control Ventilation Strategy|
241181|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
241182|NCT02532179|Biological|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
241183|NCT00183248|Drug|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
241184|NCT02532192|Drug|Belinostat|Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.
Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
241185|NCT02532192|Drug|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
241186|NCT02532192|Drug|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
241187|NCT02532192|Drug|Cytarabine|Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.
Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours.
241188|NCT02532192|Drug|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
241189|NCT02532192|Drug|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
241190|NCT02532192|Drug|Fluconazole|100 mg by mouth daily for 10 days.
241191|NCT02532218|Drug|ARI-3037MO|Lipid lowering treatment
241192|NCT02532231|Drug|Nivolumab|3 mg/kg by vein on Days 1 and 15 of a 28 day treatment cycle.
241193|NCT02532244|Other|sample collection|collection of blood, saliva and buccal cells
241194|NCT00183248|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
241490|NCT02525458|Device|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
241491|NCT02525458|Device|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
241492|NCT02527655|Behavioral|Choice-Based Physical Activity and Active Transportation|
241493|NCT02527668|Dietary Supplement|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
241494|NCT02527668|Dietary Supplement|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
241495|NCT02527668|Other|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
240875|NCT02537080|Drug|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
240876|NCT02537080|Drug|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
240877|NCT02537093|Behavioral|Psychiatric Consultation|
240878|NCT02537106|Procedure|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
240879|NCT02501954|Radiation|Radiation Therapy|Undergo Radiation Therapy
240880|NCT02501967|Other|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
240881|NCT02501980|Biological|Biomarker testing and Ultrasonography|
240882|NCT02502006|Drug|Celecoxib|
240883|NCT02502006|Drug|Naproxen|
240884|NCT02502006|Drug|Placebo|
240885|NCT02502019|Device|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
240886|NCT00179010|Drug|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
240887|NCT02502032|Drug|Cisatracurium|Different groups received different pretreatments of cisatracurium.
240888|NCT02502045|Device|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
240889|NCT02502045|Device|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
240890|NCT02502058|Device|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
240891|NCT02502071|Drug|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
240892|NCT02502084|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
240893|NCT02502097|Drug|AF-219|
240263|NCT02513589|Drug|18F-PBR06|innovative molecular imaging technique
240264|NCT02513589|Device|PET-CT|
240562|NCT02506751|Drug|liothyronine|All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
240563|NCT02506764|Device|Artificial Pancreas using the Zone-Model Predictive Control|Artificial pancreas (AP) system using the Zone-Model Predictive Control (MPC) algorithm on the Diabetes Assistant (DiAs) platform
240564|NCT02506764|Device|Dexcom G4P sensor|Subjects will wear a Dexcom G4P sensor for continuous glucose monitoring, these blood glucose values will not be used to make treatment decisions.
240565|NCT02506777|Drug|metformin|
240566|NCT02506777|Drug|Fluoruracil|
240567|NCT02506777|Drug|Doxorubicin|
240568|NCT02506777|Drug|Cyclophosphamide|
240569|NCT00179660|Drug|Lenalidomide|Capsules for oral administration.
240570|NCT02506777|Drug|melatonin|
240571|NCT02509078|Drug|cisastracurium besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisastracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
240572|NCT02509091|Drug|Bronchoalveolar Lavage and Local Amikacin Injection|injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
240573|NCT02509104|Drug|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
240574|NCT02509104|Drug|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
240575|NCT02509117|Drug|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 3 mg, 12 mg, 40 mg, 125 mg (these are subject to change based on emerging data).
240576|NCT02509117|Drug|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
240577|NCT02509117|Drug|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are 5 mg, 15 mg, 50 mg, 70 mg (these are subject to change based on emerging data).
265182|NCT02362776|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
265183|NCT02362789|Biological|Secukinumab 300 mg|
265184|NCT00159289|Procedure|Placebo|
265185|NCT02362802|Device|Implantable Cardioverter Defibrillator|
265186|NCT02362815|Other|Apple juice|Intervention consists in allowing drinks during labour
265187|NCT02362854|Procedure|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
265188|NCT02362854|Device|DL application in peri-implantitis|Diode laser application in the diseased implants.
265189|NCT02362867|Device|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
265498|NCT02357979|Device|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
265499|NCT02357979|Other|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
265500|NCT02357992|Radiation|Stereotactic Body Radiotherapy (SABR)|Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.
50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor.
265501|NCT02358005|Procedure|Extracorporeal shock wave therapy 60mj|
265502|NCT02358005|Procedure|Extracorporeal shock wave therapy 120mj|
265503|NCT00158691|Drug|Ethyol|
265504|NCT02358005|Procedure|non extracorporeal shock wave therapy|
265505|NCT02358018|Drug|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately ~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
265506|NCT02358031|Biological|Pembrolizumab|
265507|NCT02358031|Drug|Cisplatin|
265508|NCT02358031|Drug|Carboplatin|
264884|NCT02369757|Behavioral|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
264885|NCT02369770|Device|IntelliStretch rehabilitation robot|A portable rehabilitation robot will be used to move the impaired joint back and forth and the subject is asked to relax during the movement. The subject will also be asked to move the joint back and forth with the robot.
264886|NCT02369783|Other|Questionnaire and interview|The aim is to detect social fragility.
264887|NCT02369796|Drug|TAK-448|TAK-448 solution for subcutaneous injection
264888|NCT02369809|Drug|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
264889|NCT02369822|Dietary Supplement|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
264890|NCT02369835|Drug|Dakin's solution|Apply modified Dakin's solution (0.005%) topically
264891|NCT02369835|Other|Placebo|Applied topically
264892|NCT00159965|Drug|placebo|flexible dose placebo
264893|NCT02369835|Other|Questionnaire Administration|Ancillary studies
264894|NCT02369848|Device|Shockwave Lithoplasty System|
264895|NCT02369861|Drug|ACCS|Topical ocular application 4 times per day
264896|NCT02369861|Drug|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
265190|NCT02362880|Radiation|Florbetaben|single dose of Florbetaben followed by PET scan
265191|NCT02362893|Other|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
265192|NCT02362906|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
265193|NCT02365207|Drug|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
265194|NCT00159471|Drug|capecitabine, gemcitabine, docetaxel|
265195|NCT02365220|Behavioral|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
264571|NCT02374528|Procedure|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
264572|NCT02374528|Procedure|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
264573|NCT00160446|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
264574|NCT02374541|Behavioral|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
264575|NCT02374554|Device|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
264576|NCT02374554|Device|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
264577|NCT02374567|Drug|Phenobarbital|
264578|NCT02376426|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.
264579|NCT02376426|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.
264580|NCT02376426|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
264581|NCT02376439|Other|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
264582|NCT02376452|Drug|Raltitrexed|2mg/m2 iv gtt, d1
264583|NCT02376452|Drug|Irinotecan|180 mg/m2 iv gtt, d1
264584|NCT02376452|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
264585|NCT02376452|Drug|Leucovorin|400mg/m2 iv gtt,d1
264586|NCT02376465|Drug|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
264587|NCT02376465|Drug|PEG based bowel preparation|Oral bowel preparation for colonoscopy
264588|NCT00160771|Behavioral|Joint Motion Analysis|Joint motion will be recorded for analysis.
264589|NCT02376478|Drug|TNF-alpha inhibitors|therapy for at least 6 months
268958|NCT02342366|Drug|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
268959|NCT02342379|Drug|Bevacizumab|10mg/kg
268960|NCT02342379|Drug|TH-302|670mg/m2
268961|NCT02342392|Drug|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
268962|NCT02342405|Other|80% oxygen|
268963|NCT02342405|Other|30% oxygen|
269263|NCT00155610|Device|intravesical current perception test|
269264|NCT02335372|Procedure|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
269265|NCT02335372|Drug|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
269266|NCT02335372|Drug|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
269267|NCT02335372|Procedure|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
269268|NCT02335385|Procedure|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
269269|NCT02335385|Procedure|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
269270|NCT02335398|Drug|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
269271|NCT02335411|Biological|pembrolizumab|
269272|NCT02335411|Drug|cisplatin|
269273|NCT02335411|Drug|5-FU|
269274|NCT00155662|Behavioral|work-hardening program|
269275|NCT02335411|Drug|capecitabine|
269276|NCT02335424|Biological|pembrolizumab|IV infusion
268651|NCT02346773|Other|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
268652|NCT02346786|Dietary Supplement|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
268653|NCT02349035|Procedure|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
268654|NCT02349048|Drug|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
268655|NCT02349048|Drug|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
268656|NCT00157833|Drug|Artekin / Coartemther|
268657|NCT02349048|Drug|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
268658|NCT02349061|Drug|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
268659|NCT02349061|Drug|Placebo Infusion|Placebo intravenously at Week 0.
268660|NCT02349061|Drug|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
268964|NCT02342418|Drug|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
268965|NCT02342431|Device|Forced air warming compressible|Warming with a compressible forced air mattress
268966|NCT02342431|Device|Forced air non-compressible|Warming with a non-compressible forced air mattress
268967|NCT02342444|Drug|Enoxaparin Sodium Injection 30 mg BID|
268968|NCT00156806|Procedure|Aloe barbadensis topical application in a moisturizing cream vehicle.|
268969|NCT02342444|Drug|Enoxaparin Sodium Injection 40 mg QD|
268970|NCT02342457|Device|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
268333|NCT02356679|Drug|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
268334|NCT02356679|Drug|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
268335|NCT02356692|Device|enfilcon A|Daily disposable contact lens worn in a daily wear, daily disposable mode
268336|NCT02356692|Device|senofilcon A|Daily disposable contact lens worn in a daily wear, daily disposable mode
268337|NCT02356705|Drug|Midazolam|midazolam 0.2 mg/kg given intranasally
268338|NCT02356705|Drug|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
268339|NCT02356705|Drug|saline placebo|intranasal saline given as placebo
268340|NCT02356718|Behavioral|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
268341|NCT02356718|Behavioral|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
268342|NCT00158574|Drug|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
268343|NCT02356744|Other|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
268344|NCT02356757|Behavioral|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
268345|NCT02359084|Behavioral|Conventional Care Management|
268346|NCT02359097|Drug|gadoteridol|Given IV
268347|NCT00158821|Drug|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
268348|NCT02359097|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
268349|NCT02359097|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC-CBV mapping
268350|NCT02359097|Procedure|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
268351|NCT02359110|Drug|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
268352|NCT02359123|Other|Cannabics capsules|Cannabis extract in an oil formulation
267725|NCT02368600|Behavioral|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
267726|NCT02368613|Drug|DW-3102|
267727|NCT02368626|Device|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
267728|NCT02368639|Device|F&P modified CPAP|The device is a modified version of the Fisher & Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
267729|NCT02368652|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
268034|NCT00002418|Drug|Hydroxyurea|
268035|NCT00159367|Device|Repetitive magnetic stimulation to the quadriceps|
268036|NCT02364193|Device|BIS ImpediMed™ SFB7|BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).
Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.
Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds.
268037|NCT02364193|Device|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
268038|NCT02364206|Drug|LY2228820|
268039|NCT02364206|Drug|Temozolomide|
268040|NCT02364206|Radiation|radiation therapy|
268041|NCT02364219|Other|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
268042|NCT02364219|Device|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
268043|NCT02364232|Behavioral|bilateral training with and without mirror feedback|
268044|NCT02364245|Device|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
268045|NCT02364245|Other|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
268046|NCT00159380|Procedure|Inhalation of aminoguanidine and oral intake and inhalation of L-arginine|
267424|NCT02375256|Biological|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
267425|NCT02375256|Biological|Placebo|Identical buffer solution in which AERAS-402 is formulated.
267426|NCT02375256|Biological|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
267427|NCT02375269|Device|RIPC with a tourniquet|
267428|NCT02375282|Procedure|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
267429|NCT02375295|Drug|Approved antibiotics for use: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin|Approved antibiotics used routinely will be given at the physician discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
267430|NCT00160615|Drug|levetiracetam|
267431|NCT02375308|Behavioral|HDT|20 sessions, individual psychotherapy
267432|NCT02375308|Behavioral|ACDT|20 sessions, individual psychotherapy
267433|NCT02375321|Behavioral|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
267730|NCT02370953|Procedure|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
267731|NCT02370966|Dietary Supplement|Berry powder|Berry and gingivitis trial
267732|NCT02370979|Biological|Blood samples|
267733|NCT02370992|Radiation|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
267734|NCT02371005|Radiation|Cone Beam Computed Tomography (CBCT)|
267735|NCT02371018|Dietary Supplement|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
267138|NCT02380001|Drug|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
267139|NCT02380027|Device|MRI|This will be a multi-parametric MRI of the prostate
267140|NCT02380027|Procedure|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
267141|NCT00161525|Procedure|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
267142|NCT02382471|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
267143|NCT02382484|Device|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
267144|NCT02382497|Device|AN Active tDCS|The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.
tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.
The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.
Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
267145|NCT02382497|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
267146|NCT02382497|Device|BED Active tDCS|The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.
tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.
For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.
Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
267147|NCT02382497|Device|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
267148|NCT02382510|Drug|TRN-157|
267149|NCT02382510|Other|Placebo|
267150|NCT02382510|Drug|Tiotropium|
267434|NCT02375334|Other|Medical Chart Review|Medical chart review by the Cancer Center ORIS and EPIC based systems
243057|NCT02535325|Other|Laboratory Biomarker Analysis|Correlative studies
243058|NCT02535325|Drug|Methoxyamine|Given PO
243059|NCT02535325|Drug|Pemetrexed Disodium|Given IV
243060|NCT02535338|Drug|Erlotinib Hydrochloride|Given PO
243061|NCT02535338|Drug|Hsp90 Inhibitor AT13387|Given IV
243062|NCT02535338|Other|Laboratory Biomarker Analysis|Correlative studies
243063|NCT00183508|Behavioral|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
243064|NCT02535338|Other|Pharmacological Study|Correlative studies
243065|NCT02535351|Drug|sunitinib or pazopanib|First-line treatment
243333|NCT02528461|Procedure|Gastroscopy|
243334|NCT02528461|Procedure|Liver biopsy|
243335|NCT02528461|Procedure|Fibroscan|
243336|NCT02528461|Procedure|Liver vein catheterization|
243337|NCT00182780|Dietary Supplement|American ginseng|
243338|NCT02528461|Drug|Sofosbuvir|
243339|NCT02528474|Device|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
243340|NCT02528474|Device|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
243341|NCT02528500|Device|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
243342|NCT02530671|Device|Toothbrushing with manual toothbrush|
243343|NCT02530671|Device|Toothbrushing with power toothbrush|
243344|NCT02530684|Other|insole|Insoles available on the market without prescription
242743|NCT02505113|Drug|Montelukast|Montelukast (10mg, q.d., p.o.)
242744|NCT02505126|Device|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
242745|NCT02505126|Device|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
242746|NCT02505139|Other|the number of circulating tumor cells|
242747|NCT02505152|Procedure|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
242748|NCT02505165|Behavioral|PUMI|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist and a nurse.
242749|NCT02505165|Other|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist and a nurse.
242750|NCT02505178|Other|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
242751|NCT02505191|Drug|St. John's wort prolonged-release tablet 500 mg|
242752|NCT00179465|Drug|Tiagabine|Up to 36 mg daily
243066|NCT02535351|Procedure|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
243067|NCT02535364|Biological|JCAR015 (CD19-targeted CAR T cells)|Part A: Following leukapheresis and concurrent with generation of JCAR015, participants will receive, at the Investigator's discretion, either one cycle of cytoreductive chemotherapy based on the Investigator's choice of regimens, or supportive care.
Part B: Participants who are eligible for treatment in Part B will receive two IV doses of JCAR015 CAR T cells. JCAR015 infusion will be preceded by lymphodepleting chemotherapy.
243068|NCT02535377|Other|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
243069|NCT02535390|Behavioral|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
242419|NCT02509741|Behavioral|IOT monitoring|
242420|NCT02509754|Procedure|Atrial fibrillation catheter ablation|
242421|NCT02509754|Procedure|Rate control|Composite of optimal medical therapy and device implantation
242422|NCT02512107|Dietary Supplement|Juice Plus+|Dried fruit and vegetable juice capsule.
242423|NCT02512107|Other|Placebo|Placebo capsule
242424|NCT02512120|Device|volume controlled ventilation|After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).
- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used.
242425|NCT02512120|Device|autoflow-volume controlled ventilation|After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).
- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used.
242426|NCT02512133|Device|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
242427|NCT02512133|Procedure|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
242428|NCT02512146|Procedure|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
242429|NCT02512159|Procedure|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
242430|NCT02512159|Procedure|Healing|Were handled as follows:
Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.
healing of skin ulcers were performed every 24 hours.
the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables.
242431|NCT00180375|Device|Prizm, Vitality, Renewal|
242432|NCT02512172|Drug|Oral CC - 486|
242433|NCT02512172|Drug|Romidepsin|
242434|NCT02512172|Drug|MK - 3475|
241817|NCT02523170|Device|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
241818|NCT02523183|Drug|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
241819|NCT02523196|Device|HepQuant-SHUNT|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
241820|NCT02523196|Device|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
241821|NCT02523209|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
241822|NCT02523209|Device|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( <15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
241823|NCT02523222|Dietary Supplement|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
242121|NCT02516683|Other|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
242122|NCT00180999|Drug|Erythropoiétine|
242123|NCT02516696|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
242124|NCT02516696|Drug|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
242125|NCT02516696|Drug|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
242126|NCT02516709|Radiation|Linear LDR Source|
242127|NCT02518750|Drug|Liposomal vincristine|For intravenous (IV) use only.
242128|NCT02518750|Drug|Mitoxantrone|Given IV.
242129|NCT02518750|Drug|Peg-asparaginase|Given IV or intramuscularly (IM).
In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection.
242130|NCT02518750|Drug|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
242131|NCT00181558|Drug|Zoledronic Acid (Zometa)|
242132|NCT02518750|Drug|Intrathecal Triples|Given IT as ITMHA.
242133|NCT02518750|Drug|High-dose methotrexate|Given intrathecally (IT) or IV.
241496|NCT02527681|Drug|ceftobiprole|single dose of ceftobiprole at 15 mg/kg body weight, given as a 4-hour constant-rate infusion of ceftobiprole medocaril
241497|NCT02527694|Device|Flexible EMS stretcher cart|The flexible stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
241498|NCT02527694|Device|mechanical CPR|
241499|NCT02527707|Drug|lonafarnib|antiviral farnesyltransferase inhibitor
241500|NCT02527707|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
241501|NCT02527720|Behavioral|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at ~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
241502|NCT00182715|Drug|leucovorin calcium|
241503|NCT02527733|Drug|Ranibizumab|
241504|NCT02527733|Drug|Ranibizumab and laser|
241505|NCT02527746|Biological|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
241506|NCT02527746|Drug|EC regimen|Epirubicin 100 mg/m2 (in vein) and Cyclophosphamide 600 mg/m2 (in vein) on Day 1 of each cycle for 4 cycles.
241507|NCT02527759|Behavioral|Survey|
241508|NCT02527772|Drug|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
241509|NCT02527772|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
241824|NCT02523222|Dietary Supplement|Placebo|
241825|NCT02523235|Drug|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
241826|NCT02523248|Procedure|tonsillectomy|Tonsillectomy with cold steel
241827|NCT00182208|Device|Veno-device (Venowave)|
241195|NCT02532257|Drug|Lenalidomide|15 mg by mouth on Days 1-21 of Cycle, and 20 mg on Days 1 - 21 of Cycles 2 - 12.
241196|NCT02532257|Drug|Rituximab|375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1, and Day 1 of Cycles 2 through 12.
241197|NCT02532257|Drug|Ibrutinib|560 mg by mouth daily, starting on Day 1 of Cycle 1 and continued through 12 cycles.
241198|NCT02532270|Drug|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
241199|NCT02532283|Drug|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
241200|NCT00183430|Behavioral|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
241201|NCT02534506|Drug|Urelumab|
241202|NCT02534506|Drug|Nivolumab|
241203|NCT02534519|Other|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
241204|NCT02534532|Other|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
241205|NCT02534545|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
241206|NCT02534545|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
241207|NCT02534558|Biological|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
241208|NCT02534571|Device|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 <=150g once
241209|NCT02534571|Device|Hemo-clipping|Hemo-clipping <=20 clips
241210|NCT02534571|Drug|Epinephrine|epinephrine injection endoscopically <20 mls
241211|NCT00183443|Drug|Divalproex-extended release (DVP-ER)|Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
241212|NCT02534571|Device|heater-probe application|contact thermo-coagulation < = 4 pulses
241213|NCT02534597|Behavioral|Promotores Training|
240578|NCT02509117|Drug|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
240579|NCT02509117|Drug|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The planned dose level is 70 mg (this is subject to change based on emerging data).
240580|NCT00179920|Procedure|Laser hyperthermia|
240894|NCT02502097|Drug|Placebo (for AF-219)|
240895|NCT02502110|Drug|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
240896|NCT02502123|Other|No Intervention|No intervention was administered in this study.
240897|NCT00179010|Drug|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
240898|NCT02502136|Procedure|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
240899|NCT02502136|Procedure|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
240900|NCT02502149|Biological|rFVIIIFc|As per arm description
240901|NCT02502162|Drug|LDN|
240902|NCT02502162|Drug|Placebo|Sugar pill
240903|NCT02502175|Drug|opium|
240904|NCT02502175|Drug|methadone|
240905|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
240906|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
240907|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
240908|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
240909|NCT02504333|Drug|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
240910|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
240911|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
240912|NCT00179335|Procedure|Blood drawing to determine drug levels|
265509|NCT02358031|Drug|5-FU|
265510|NCT02358031|Biological|Cetuximab|
265511|NCT02358044|Drug|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
265512|NCT02358044|Biological|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
265513|NCT02358044|Drug|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
265514|NCT00158704|Drug|Hepsera|
265515|NCT02358044|Drug|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
265516|NCT02358057|Drug|Dexmedetomidine|
265517|NCT02358057|Drug|Alfentanil|
265518|NCT02358083|Behavioral|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
265519|NCT02358096|Drug|ASP8232|oral capsule
265803|NCT02389153|Behavioral|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
265804|NCT02389166|Device|Optiflow|Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.
High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%.
265805|NCT02389166|Device|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
265806|NCT00162383|Drug|Caffeine|
265807|NCT02389179|Drug|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
265808|NCT02389192|Drug|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
265809|NCT02389205|Other|kinesio group|kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.
The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc.
265196|NCT02365220|Behavioral|Prospective expectancy|Prospective expectancy instruction ("Training will have an effect on...") with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
265197|NCT02365220|Behavioral|Retrospective expectancy|Retrospective expectancy instruction ("Training already had an effect on...") with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
265198|NCT02365220|Behavioral|Prospective and retrospective expectancy|Prospective ("Training will have an effect on...") and retrospective ("Training already had an effect on...") expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
265199|NCT02365233|Drug|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
265200|NCT02365233|Drug|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
265201|NCT02365233|Drug|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
265202|NCT02365246|Device|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
265203|NCT02365259|Device|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
265204|NCT02365272|Drug|Amikacin|Amikacin administered in a single dose for critical care patients
265205|NCT00159484|Drug|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
265206|NCT02365285|Drug|Galantamine|16 mg po acute intervention prior to the infusion of intralipids
265207|NCT02365285|Drug|Placebo|Placebo po acute intervention prior to the infusion of intralipids
265208|NCT02365298|Device|Marketed Investigational Soft Contact Lens|etafilcon A soft contact lens
265209|NCT02365298|Device|Dailies AquaComfort Plus|nelfilcon A
265520|NCT02358096|Drug|Placebo|oral capsule
265521|NCT02360215|Other|Cognitive Assessment|Ancillary studies
265522|NCT02360215|Radiation|Intensity-Modulated Radiation Therapy|Undergo HA-WBRT using IMRT
265523|NCT02360215|Drug|Memantine Hydrochloride|Given PO
265524|NCT02360215|Other|Quality-of-Life Assessment|Ancillary studies
264590|NCT02376478|Drug|Alternative/no medication|therapy for at least 6 months or no therapy
264591|NCT02376478|Other|Alternative/no medication|phototherapy for at least 6 months
264897|NCT02369874|Drug|MEDI4736|MEDI4736 Monotherapy
264898|NCT02369874|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
264899|NCT02369874|Drug|Standard of Care|Standard of Care
264900|NCT02369900|Drug|Esmolol|
264901|NCT02369913|Other|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
264902|NCT02369926|Procedure|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
264903|NCT00159978|Procedure|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
264904|NCT02369926|Procedure|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
264905|NCT02369939|Radiation|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
264906|NCT02369939|Drug|Mitomycin C|MMC w1, w5
264907|NCT02372383|Drug|Ethambutol|Anti-mycobacterial oral drug
264908|NCT02372383|Drug|Rifampin|Anti-mycobacterial oral drug
264909|NCT02372383|Drug|Azithromycin|Anti-mycobacterial oral drug
264910|NCT02372383|Drug|Pancrelipase|Pancreatic enzyme replacement therapy
264911|NCT02372396|Behavioral|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
264912|NCT02372396|Behavioral|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
264913|NCT02372409|Procedure|MRI-guided laser ablation|
269277|NCT02335450|Behavioral|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
269278|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
269279|NCT02337972|Drug|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
269280|NCT02337985|Drug|Prednisone|Given PO
269281|NCT00156130|Radiation|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
269282|NCT02337985|Biological|Rituximab|Given IV
264592|NCT02376478|Drug|Purine/folic acid analogues|therapy for at least 6 months
264593|NCT02376491|Device|Transcranial magnetic stimulation|
264594|NCT02376504|Behavioral|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
264595|NCT02376517|Behavioral|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
264596|NCT02376543|Device|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
264597|NCT02376543|Device|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
264598|NCT02376582|Biological|DNA|DNA co-administered with protein at month 0, 1 and 6
264599|NCT00160784|Procedure|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
264600|NCT02376582|Biological|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
264601|NCT02376595|Drug|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
268971|NCT02342470|Drug|Placebo|Drug : Placebo
268972|NCT02342470|Drug|PMK-S005 1|Drug : PMK-S005 1 (50mg)
268973|NCT02342470|Drug|PMK-S005 2|Drug : PMK-S005 2 (100mg)
268974|NCT02342470|Drug|PMK-S005 3|Drug : PMK-S005 3 (150mg)
268975|NCT02342483|Dietary Supplement|MSM|
268976|NCT02342496|Dietary Supplement|Placebo|Powder
268977|NCT02342496|Dietary Supplement|Active, only probiotics|Powder
268978|NCT02342496|Dietary Supplement|Active, blend of berries and probiotics|Powder
268979|NCT00156819|Drug|fluticasone|fluticasone (100 microgram twice daily) treatment
268980|NCT02342509|Drug|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
268981|NCT02342509|Drug|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
268982|NCT02342509|Drug|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
268983|NCT02342522|Device|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total. For patients presenting with a systolic blood pressure (SBP)≥175mmHg, a manual blood pressure cuff will be used and inflated to 25 mmHg above systolic blood pressure.
268984|NCT02344615|Procedure|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
268985|NCT02344628|Drug|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
264306|NCT02383758|Drug|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
264307|NCT02383771|Drug|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
264308|NCT02383771|Drug|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
264309|NCT02383771|Drug|Control|No Anti-platelet Therapy
264310|NCT02383771|Drug|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
268661|NCT02349061|Drug|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40.
268662|NCT02349061|Other|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, with safety follow-up through Week 56.
268663|NCT02349074|Procedure|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
268664|NCT02349087|Device|Acute EEG with fast applicable EEG electrode|
268665|NCT02349100|Device|Nellix Endoprosthesis|Implantation of Nellix
268666|NCT02349113|Drug|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
268667|NCT00157846|Device|Upgrade of old device to CRT-device during exchange|
268668|NCT02349126|Drug|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
268669|NCT02349139|Drug|ASN001: Escalating dose Part A|Androgen inhibitor
268670|NCT02349139|Drug|ASN001: Dose 1 Part B|Androgen inhibitor
268671|NCT02349139|Drug|ASN001: Dose 2 Part B|Androgen inhibitor
268672|NCT02349152|Drug|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.2-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
268673|NCT02349152|Drug|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
268674|NCT02349165|Procedure|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
268675|NCT00002411|Drug|Nelfinavir mesylate|
268676|NCT00158158|Drug|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
268677|NCT02351687|Drug|Zinc|
268678|NCT02351687|Other|Insecticide-treated bednet|
268679|NCT02351700|Drug|IV Caldolor (IV Ibuprofen)|Compare addition of IV Caldolor (IV ibuprofen) intraoperatively and postoperatively against IV ibuprofen placebo added intraoperatively and postoperatively.
268680|NCT02351700|Drug|IV Ibuprofen placebo|Compare addition of IV ibuprofen placebo intraoperatively and postoperatively against IV Caldolor (IV ibuprofen) added intraoperatively and postoperatively.
268047|NCT02364245|Other|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
268048|NCT02364258|Drug|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
268049|NCT02364258|Drug|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
268050|NCT00159614|Drug|KW-3902IV|
268051|NCT02366442|Other|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
268052|NCT02366455|Procedure|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
268053|NCT02366455|Procedure|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
268054|NCT02366468|Drug|0.5 mg ranibizumab|
268353|NCT02359136|Procedure|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
268354|NCT02359136|Procedure|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
268355|NCT02359136|Procedure|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
268356|NCT02359149|Procedure|intravitreal injections given by a nurse|
268357|NCT02359149|Procedure|intravitreal injections given by a physician|
268358|NCT00158821|Drug|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
268359|NCT02359149|Procedure|Intravitreal injections|
268360|NCT02359149|Drug|Anti-VEGF agents|
268361|NCT02359162|Drug|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
268362|NCT02359162|Drug|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
267736|NCT02371031|Drug|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
267737|NCT02371031|Device|PET/MRI|
267738|NCT00160134|Drug|SLV320|
267739|NCT02371031|Procedure|Surgical resection (standard of care)|
267740|NCT02371083|Other|Extended timing of pessary care|
267741|NCT02371096|Drug|MabThera (rituximab)|
267742|NCT02371096|Drug|RGB-03|
267743|NCT02371109|Other|selftaken versus clinically taken swabs|
267744|NCT02371122|Device|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
267745|NCT02371122|Device|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
267746|NCT02371122|Device|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
267747|NCT02371122|Device|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
267748|NCT02371135|Genetic|colonic biopsies|
267749|NCT00160147|Drug|bifeprunox|One week titration with dose adjustments
267750|NCT02371135|Genetic|questionnaires|
267751|NCT02371148|Drug|Bortezomib-Rituximab-Bendamustine|Bortezomib 1.3 mg/mq sc days 1, 8, 15, 22*
Rituximab: 375 mg/sqm i.v. day 1**
Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice
Repeat cycles every 28 days for a total of 6 cycles
*In case of toxicity is omitted
**In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8
268055|NCT02366468|Drug|0.5 mg ranibizumab|
268056|NCT02366481|Dietary Supplement|Placebo|Four placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
268057|NCT02366481|Dietary Supplement|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|Two 45-mcg vitamin K2 softgel capsules and two placebo softgel capsules (containing no vitamin K2) everyday for 8 weeks.
268058|NCT02366481|Dietary Supplement|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Four 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
268059|NCT02366494|Drug|Bicalutamide|ANDROGEN BLOCKADE
268060|NCT02366494|Drug|Leuprolide|ANDROGEN BLOCKADE
267435|NCT02377726|Behavioral|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
267436|NCT02377726|Behavioral|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
267437|NCT02377726|Behavioral|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
267438|NCT02377739|Other|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
267439|NCT02377752|Biological|Olaratumab|Administered IV
267440|NCT02377752|Drug|Doxorubicin|Administered IV
267441|NCT02377765|Device|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
267442|NCT02377765|Procedure|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
267443|NCT02377778|Drug|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
267444|NCT00160927|Drug|actylcholine|
267445|NCT02377778|Drug|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
267446|NCT02377791|Genetic|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5*1/*1 vs CYP3A5*1/*3 or CYP3A5*3/*3
267447|NCT02377804|Other|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
267448|NCT02377804|Other|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
267449|NCT02377804|Device|stainless steel needles (0.3mm x 50mm)|
267752|NCT02371161|Drug|R-DHAP/R-ICE|R-DHAP/R-ICE 3 cycles every 21 days:
R-DHAP
Rituximab 375 mg/m2, e.v. day 1
Desamethasone 40 mg days 1-4
cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)
Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)
R-ICE
Rituximab 375 mg/m2, e.v. day 1
Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)
Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)
Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)
Conditioning BEAM or FEAM
243345|NCT02530697|Drug|Miltefosine and Pentoxifylline|
243346|NCT02530697|Drug|Meglumine antimoniate|
243347|NCT02530710|Drug|Q203|
243348|NCT00183053|Device|BedEx Patient Occupancy Monitoring System|
243349|NCT02530710|Drug|Placebo|
243350|NCT02530723|Other|power training|Resistance training machines with CAM devices will be used for training.
243351|NCT02530736|Other|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
243352|NCT02530762|Other|Novel Fiber|novel fiber supplemented beverage provided in one serving
243353|NCT02530762|Other|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
243354|NCT02530762|Other|Negative Control|No added fiber beverage
243625|NCT02523976|Drug|etoposide|
243626|NCT02523976|Procedure|allogeneic hematopoietic stem cell transplantation|
243627|NCT00182312|Drug|Caffeine citrate injection|Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.
Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.
Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
243628|NCT02523976|Procedure|autologous hematopoietic stem cell transplantation|
243629|NCT02523989|Other|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
243630|NCT02524002|Dietary Supplement|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
243631|NCT02526238|Device|TMS and trunk rotation|TMS and trunk rotation
243632|NCT00182598|Procedure|computer-based psychoeducational intervention|
243633|NCT02526238|Device|Sham TMS and trunk rotation|Sham TMS and trunk rotation
243070|NCT02535390|Behavioral|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
243071|NCT02535403|Behavioral|ICBT|
243072|NCT02535416|Drug|ARC-520|
243073|NCT02535429|Other|massage|
243074|NCT02537860|Drug|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
243075|NCT02537860|Drug|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
243076|NCT02537873|Drug|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
243077|NCT00183690|Procedure|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
243078|NCT02537873|Drug|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
243079|NCT02537873|Drug|Placebo comparator|Dextrose in gelatin capsule
243080|NCT02537886|Device|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
243081|NCT02537899|Drug|NeuroAiD|
243082|NCT02537912|Dietary Supplement|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
243355|NCT02530775|Procedure|instrumented spinal fusion with laminectomy|Once determined that a patient has single level "static" degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach.
243356|NCT02530775|Procedure|non-instrumented spinal fusion with laminectomy|Once determined that a patient has single level "static" degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach.
242753|NCT02505191|Drug|St. John's wort film coated tablets 250 mg|
242754|NCT02505204|Other|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
242755|NCT02505204|Other|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
242756|NCT02505230|Behavioral|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
242757|NCT02505256|Other|No intervention|
242758|NCT02505269|Drug|Brentuximab Vedotin|
242759|NCT02505269|Drug|Adriamycin|
242760|NCT02507583|Drug|IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.|
242761|NCT02507583|Drug|IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
242762|NCT02507596|Biological|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
242763|NCT02507596|Biological|Bone allograft|it is a type of bone graft from human cadavers.
242764|NCT02507596|Procedure|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
242765|NCT00179764|Procedure|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
242766|NCT02507609|Other|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
242767|NCT02507609|Other|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
242768|NCT02507622|Other|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
242769|NCT02507622|Other|Parabolic flight|
242770|NCT02507635|Drug|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
242771|NCT02507635|Drug|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
242772|NCT02507648|Drug|Oseltamivir|1 tablet contains 75 mg oseltamivir
242134|NCT02518750|Drug|6-Mercaptopurine|Given PO at consistent time each day.
242135|NCT02518750|Drug|High-dose cytarabine|Given IT or IV.
242136|NCT02518750|Drug|Nelarabine|Given IV
242137|NCT02518750|Drug|Cyclophosphamide|Given IV.
242138|NCT02518750|Drug|Etoposide|Given IV.
In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used.
242139|NCT02518750|Drug|Clofarabine|Given IV.
Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II.
242140|NCT02518763|Drug|Vitamin D3, 100 000 IU weekly, 4 times|
242141|NCT02518763|Biological|25 OH vitamin D serum concentration measurements|
242142|NCT00181571|Drug|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
242143|NCT02518776|Behavioral|Neuropsychological tests|Neuropsychological tests
242144|NCT02518789|Drug|Low-dose Dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
242435|NCT02512198|Behavioral|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
242436|NCT02512224|Device|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
242437|NCT02512224|Device|Enteral nutrition|Participants are retrospectively selected with propensity score matching
242438|NCT02512237|Drug|ARX788|ARX788, an antibody drug conjugate
242439|NCT02512250|Other|Registry|
242440|NCT02512263|Procedure|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
242441|NCT02514343|Drug|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
242442|NCT02514343|Drug|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
242443|NCT02514356|Behavioral|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
241828|NCT02523248|Procedure|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
241829|NCT02523261|Procedure|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
241830|NCT02523261|Procedure|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
241831|NCT02525471|Drug|RNS60|RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 24 weeks.
241832|NCT02525484|Drug|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
241833|NCT02525497|Device|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
241834|NCT00182533|Drug|Sertraline|25 - 200 mg/day x 16 weeks
241835|NCT02525497|Device|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
241836|NCT02525510|Other|Normothermia and Pulsatile Perfusion|Deceased Donors will be kept normothermic until organ recovery is completed. Kidneys then will be placed on machine perfusion based on the respective OPO's protocol
241837|NCT02525510|Other|Hypothermia and Cold Storage|Deceased Donors will be kept hypothermic (34-35 degrees) until organ recovery is completed.
Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation.
241838|NCT02525510|Other|Normothermia and Cold Storage|Deceased Donors will be kept normothermic until organ recovery is completed. Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation
241839|NCT02525510|Other|Hypothermia and Pulsatile Perfusion|Hypothermia and Pulsatile Perfusion Hypothermia in deceased donors (34-35 degrees) until organ recovery is completed.
Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol
241840|NCT02525523|Drug|Alicaforsen|
241841|NCT02525523|Drug|Placebo|
241842|NCT02525536|Drug|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
241843|NCT02525536|Drug|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
241844|NCT02525536|Drug|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
242145|NCT02518789|Drug|High-dose dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
242146|NCT02518789|Drug|normal saline|Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
241214|NCT02534597|Behavioral|Delayed Promotores training|
241215|NCT02534597|Behavioral|Caregiver training|
241216|NCT02534597|Behavioral|Delayed caregiver training|
241510|NCT02527785|Drug|Oxaliplatin, Irinotecan, S-1(OIS)|Treatment will be delivered every 2 weeks
oxaliplatin 65 mg/m2 iv on day 1
irinotecan 135 mg/m2 iv on day 1
S-1 80 mg/m2/day po on day 1-7
241511|NCT02527798|Drug|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
241512|NCT02527798|Drug|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
241513|NCT00182715|Drug|oxaliplatin|
241514|NCT02529956|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Solution for infusion
Concentration: 0.9 % sodium chloride aqueous solution
Route of Administration: Intravenous use
241515|NCT02529969|Dietary Supplement|curcumin|
241516|NCT02529969|Dietary Supplement|Placebo|
241517|NCT02529982|Dietary Supplement|Curcumin|
241518|NCT00182884|Drug|Donepezil|
241519|NCT02529982|Dietary Supplement|Placebo|
241520|NCT02529995|Drug|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
241521|NCT02529995|Drug|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
241522|NCT02530021|Other|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
241523|NCT02530034|Drug|Hu8F4|Phase I Starting dose of Hu8F4: 1 mg by vein over about 30 minutes on Days 0, 7, 14, and 21 of each 28-day cycle.
Phase II Starting dose of Hu8F4 is the maximum tolerated dose (MTD) from Phase I.
241524|NCT02530047|Genetic|MSC-INFβ|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.
Starting dose: 10^5 MSC/kg once a week for 4 treatments.
241525|NCT02530047|Behavioral|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
240913|NCT02504346|Drug|AZD9291|
240914|NCT02504359|Biological|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
240915|NCT02504359|Drug|Carmustine|Given BEAM chemotherapy
240916|NCT02504359|Drug|Cytarabine|Given BEAM chemotherapy
240917|NCT02504359|Drug|Etoposide|Given BEAM chemotherapy
240918|NCT02504359|Drug|Ixazomib Citrate|Given PO
241217|NCT02534597|Behavioral|Materials support|
241218|NCT02534597|Behavioral|Delayed materials support|
241219|NCT02534597|Behavioral|Technical assistance|
241220|NCT02534597|Behavioral|Delayed technical assistance|
241221|NCT02534610|Drug|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
241222|NCT00183443|Drug|Lithium|Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
241223|NCT02534610|Drug|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
241224|NCT02534623|Procedure|Spinal anesthesia|
241225|NCT02534623|Procedure|General anesthesia|
241226|NCT02534623|Drug|bupivacaine|
241227|NCT02534623|Drug|fentanyl|
241228|NCT02537106|Procedure|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
241229|NCT02537119|Procedure|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
241230|NCT00002496|Radiation|low-LET cobalt-60 gamma ray therapy|
241231|NCT00183625|Drug|Risperidone|
241232|NCT02537119|Procedure|Massage therapy|Rubbing on hamstrings
265810|NCT02389218|Device|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
265811|NCT02389218|Drug|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
265812|NCT02389231|Drug|Interleukine-2|Four courses of IL2 ( [Proleukin, Novartis]) will be administered subcutaneously for 5 days.
The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.
The other courses of 3 million IU per day will be initiated after a 16 day wash-out.
265813|NCT02389244|Drug|Regorafenib|4 tablets once daily until progression or innaceptable toxicity
265814|NCT02389244|Drug|Placebo|4 tablets once daily and switch to regorafenib after confirmed progression
265815|NCT02389257|Device|MINIMAG / MEG|
265816|NCT02389257|Device|MINIMAG / ECG|
265817|NCT00002430|Drug|Indinavir sulfate|
265818|NCT00162396|Drug|Albuterol|
265819|NCT02389296|Other|Questionnaire|Questionnaires will be distributed to nursing staff
265820|NCT02389309|Drug|Dasatinib|Dasatinib given twice daily by mouth for 21 days of a 28 day cycle.
265821|NCT00162695|Drug|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
266083|NCT02382081|Procedure|Patient-initiated shared care|
266084|NCT02382094|Drug|Bicalutamide|
266085|NCT00161473|Drug|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
266086|NCT02382107|Other|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
266087|NCT02382133|Device|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
266088|NCT02382146|Drug|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
266089|NCT02382146|Drug|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
266090|NCT02382172|Behavioral|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
265525|NCT02360215|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
265526|NCT02360215|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT using IMRT
265527|NCT02360228|Device|tACS (alpha)|
265528|NCT02360228|Device|tDCS|
265529|NCT02360241|Device|Robot|Use of the robot to locate the fictional needle
265530|NCT02360254|Drug|Insulin degludec|Once daily injection of insulin degludec
265531|NCT00158925|Device|EASYTRAK EPI lead|EASYTRAK EPI lead
265532|NCT02360280|Drug|ketamine|sedative
265533|NCT02360280|Drug|midazolam|sedative
265534|NCT02360293|Behavioral|Stay Strong|Pts randomly placed in the Stay Strong group receive 52 weeks of an internet-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device during waking hours while participating in the study. Pts will be asked to upload the device data weekly and check for messages weekly. Each week the pt will receive a new individually tailored and automatically calculated physical activity goal. In addition to weekly automatic goal messages, Stay Strong study e-coaches will call pts up to 3 times in the first 6 weeks of the study with information to help pts meet physical activity goals. Pts will also be reminded to follow-up with their healthcare provider as needed for the next 12 months. Pts will be asked to complete a survey at 6 months and 12 months after the date of randomization.
265535|NCT02360306|Procedure|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
265536|NCT02360319|Drug|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
265537|NCT02360319|Drug|aripiprazole long acting injectable formulation|
265538|NCT02360332|Behavioral|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
265539|NCT02360345|Drug|ONX-0801|
265822|NCT02391402|Behavioral|Treatment as Usual|TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to "process" his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need.
264914|NCT02372409|Drug|Doxorubicin|
264915|NCT02372409|Drug|Etoposide|
264916|NCT00160290|Drug|Plantago ovata|3,5 g / 12 hours
264917|NCT02372409|Device|Dynamic contrast-enhanced (DCE) MRI|
265210|NCT02365311|Procedure|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
265211|NCT02365324|Behavioral|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
265212|NCT00159757|Drug|ziprazidone|
265213|NCT02367508|Behavioral|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
265214|NCT02367521|Device|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.
Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength.
265215|NCT02367521|Device|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
265216|NCT02367534|Procedure|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
265217|NCT02367547|Drug|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
265218|NCT02367547|Drug|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
265219|NCT02367547|Drug|Methylaminolevulinate cream|In the study we use Metvix.
264602|NCT02378909|Device|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
264603|NCT00161070|Drug|aspirin alone|
264604|NCT02378922|Other|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
264605|NCT02378922|Biological|gene-modified HIV-protected hematopoietic stem cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
264606|NCT02378922|Other|Laboratory Biomarker Analysis|Correlative studies
264607|NCT02378935|Drug|GS-9857|GS-9857 100 mg tablet administered orally once daily with food
264608|NCT02378935|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily with food
264609|NCT02378935|Drug|RBV|RBV tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
264918|NCT02372409|Device|Dynamic susceptibility contrast (DSC) MRI|
264919|NCT02372422|Other|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
264920|NCT02372422|Other|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
264921|NCT02372435|Procedure|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
264922|NCT02372448|Other|ALK analysis on CTCs detected by ISET|
264923|NCT02372461|Drug|Placebo|This is an non inferiority trial, the intervention is a placebo
264924|NCT02372461|Drug|Amoxicillin|Amoxicillin Liquid
264925|NCT02372474|Biological|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
264926|NCT02372487|Drug|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
264311|NCT02383784|Dietary Supplement|Low GI index diet|Low glycemic index diet
264312|NCT02383784|Dietary Supplement|High GI diet|High glycemic index diet
264313|NCT02383797|Biological|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
264314|NCT02383810|Drug|Elsiglutide|
264315|NCT00161694|Dietary Supplement|sucrose solution|
264316|NCT02383810|Drug|Placebo|
264317|NCT02383823|Drug|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
264318|NCT02383823|Other|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
264319|NCT02383862|Other|Feedback Group|The intervention will consist of physicians receiving PROMIS scores, reflecting patients SPADE symptoms, at the time of their patients' visits.
264320|NCT02386215|Behavioral|HIV self-test|Two self-test kits will be distributed to women, each containing the following:
One standard OraQuick ADVANCE I/II test kit
Written pre-test information including test instructions in written and pictorial form
A phone number that participants can call to obtain additional information
Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing
264321|NCT02386228|Genetic|collection of CSF and blood|collection of CSF and blood
264322|NCT02386241|Other|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
264323|NCT02386267|Drug|L-leucine|L-leucine pills per os for 6 months
264324|NCT02386280|Behavioral|Motivational Interviewing for Change of Parenting Styles|
264325|NCT02386280|Behavioral|Psicoeducation|
264326|NCT02386293|Drug|Irbesartan|Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
264327|NCT02386293|Drug|Placebo|Sugar pill made to look identical to irbesartan intervention.
264328|NCT02386306|Drug|GC021109|
264610|NCT02378948|Dietary Supplement|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
264611|NCT02378961|Drug|GS-9857|GS-9857 100 mg tablet administered orally once daily with food
264612|NCT02378961|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily with food
268681|NCT02351713|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
268986|NCT02344641|Drug|Exenatide|
268987|NCT02344654|Drug|Indocyanine green|
268988|NCT02344654|Device|Near-infrared illumination|To see the fluorescence from indocyanine green
268989|NCT00157066|Drug|Ergocalciferol|
268990|NCT02344654|Drug|Urografin|
268991|NCT02344654|Radiation|X-ray|
268992|NCT02344667|Radiation|Stereotactic Body Radiotherapy|
268993|NCT02344680|Drug|Anti-HIV Agents|
268994|NCT02344706|Device|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
268995|NCT02344719|Drug|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
268996|NCT02344719|Procedure|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
268997|NCT02344719|Procedure|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
268998|NCT02344719|Drug|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
268999|NCT02344732|Drug|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
269000|NCT00157079|Biological|Immune Globulin Intravenous (Human), 10%|
269001|NCT02344732|Drug|Homatropine 2% eye drops thrice daily|
269002|NCT02344732|Drug|Oxygen gas|
269003|NCT02344745|Other|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
269004|NCT02344745|Other|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
269005|NCT02344758|Device|Non-invasive lateral flow test for monitoring gluten intake|
268363|NCT02359162|Drug|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
268364|NCT02359162|Drug|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
268365|NCT02359162|Drug|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
268366|NCT02359162|Drug|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
268367|NCT02359162|Drug|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
268368|NCT02359162|Drug|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
268369|NCT00002414|Drug|CPI-1189|
268370|NCT02361593|Procedure|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
268371|NCT02361593|Procedure|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
268372|NCT02361606|Behavioral|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
268682|NCT02351726|Device|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
268683|NCT02351739|Drug|pembrolizumab|
268684|NCT02351739|Drug|ACP-196 in combination with pembrolizumab|
268685|NCT02351752|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR>60)
268686|NCT02351765|Drug|Acelarin|First-in-class nucleotide analogue
268687|NCT00158158|Other|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
268688|NCT02351765|Drug|Cisplatin|Platinum-compound chemotherapy drug
268689|NCT02351791|Other|Patch 1, Center|
268690|NCT02351791|Other|Patch 1, Leakage pocket|
268691|NCT02351791|Other|Patch 1, Adhesive|
268692|NCT02351791|Other|Patch 2, Center|
268693|NCT02351791|Other|Patch 2, Leakage pocket|
268061|NCT00159627|Drug|KW-3902IV|
268062|NCT02366494|Drug|Goserelin|ANDROGEN BLOCKADE
268063|NCT02366494|Drug|Triptorelin|ANDROGEN BLOCKADE
268064|NCT02366494|Drug|Docetaxel|Chemo hormonal therapy
268065|NCT02366520|Device|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
268066|NCT02366546|Drug|TBI-1301|TBI-1301(5*10^8 or 5*10^9) is administered.
268067|NCT02366546|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
268068|NCT02366546|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
268069|NCT02366559|Device|Hyfrecator|
268070|NCT02366559|Device|532 nm Q-switched Nd:YAG laser|
268071|NCT02366572|Other|Control|Non pulse extruded cereal
268072|NCT00159640|Drug|PD-217,014|
268073|NCT02366572|Other|Pea protein|Pulse extruded cereal
268074|NCT02366572|Other|Pea starch|Pulse extruded cereal
268075|NCT02366572|Other|Pea fibre + pea starch|Pulse extruded cereal
268076|NCT02366572|Other|Pea protein + pea starch|Pulse extruded cereal
268077|NCT02366572|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
268078|NCT02366585|Drug|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
268079|NCT02368652|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
268373|NCT00002416|Drug|Lamivudine|
268374|NCT00159120|Other|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
268375|NCT02361619|Drug|Caffeine|probe
268376|NCT02361619|Drug|Diclofenac|probe
267753|NCT02371187|Drug|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
267754|NCT02373436|Other|Constraint Induced Therapy|They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.
The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.
The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:
The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.
The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.
The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal.
267755|NCT00160355|Device|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
267756|NCT02373436|Other|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
267757|NCT02373449|Other|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
267758|NCT02373449|Drug|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
267759|NCT02373462|Drug|Olmesartan|
267760|NCT02373462|Drug|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
267761|NCT02373475|Other|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
267762|NCT02373475|Other|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
267763|NCT02373488|Other|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
267764|NCT02373488|Other|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
267765|NCT02373488|Other|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
267766|NCT00160355|Drug|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
268080|NCT02368665|Drug|Amlodipine 5mg|- Daily oral administration for 8 weeks
243634|NCT02526251|Other|observational|No intervention
243635|NCT02526264|Other|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
243636|NCT02526277|Device|MMF07 Foot Massager|
243637|NCT02526277|Device|Heat Therapy|
243638|NCT02526290|Device|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
243639|NCT02526303|Drug|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
243640|NCT02526316|Biological|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
243641|NCT02526316|Biological|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
243642|NCT02526329|Biological|donor regulatory T lymphocytes|Given IV
243643|NCT00182598|Procedure|community-based substance abuse counseling|
243644|NCT02526329|Other|laboratory biomarker analysis|Correlative studies
243923|NCT02519556|Drug|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
243924|NCT02519569|Other|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
243925|NCT02519582|Drug|Niclosamide|2 g per day orally
243926|NCT00002493|Drug|cisplatin|
243927|NCT00181649|Drug|Recombinant human prolactin|
243928|NCT02519595|Drug|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
243929|NCT02519595|Drug|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
243930|NCT02519595|Drug|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
243931|NCT02519608|Drug|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
243932|NCT02521740|Other|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
243357|NCT02530788|Drug|Selenium Supplement (sodium selenite)|On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.
After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD).
243358|NCT02530788|Drug|Placebo|On the evening before operation the patient receives the first dosage of placebo orally as a pill.
After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD).
243359|NCT00183079|Behavioral|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
243360|NCT02530801|Drug|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
243361|NCT02530801|Drug|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
243362|NCT00183326|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
243363|NCT02532998|Drug|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
243364|NCT02532998|Drug|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
243365|NCT02533011|Other|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
243366|NCT02533024|Other|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
243645|NCT02526342|Device|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
243646|NCT02526355|Behavioral|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
243647|NCT02526368|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
243648|NCT02526381|Drug|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
242773|NCT02507648|Drug|Tamiflu®|1 tablet contains 75 mg oseltamivir
242774|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
242775|NCT02507661|Procedure|no-preservation of alveolar ridge - 2 months|
243083|NCT02537912|Dietary Supplement|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
243084|NCT02537925|Drug|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
243085|NCT02537925|Drug|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
243086|NCT02537925|Radiation|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68~74 Gy for primary tumor (2.0~2.3 Gy/f/day, 5 day/ week, /6~7 weeks), and 50~54 Gy for lymphatic positive area (1.8 ~ 2 Gy/f/day, 5 day/week, /5.0~5.5 weeks).
243087|NCT02537938|Drug|NGP 555|NGP is designed to a be a preventative therapy for Alzheimer's disease.
243088|NCT00183716|Behavioral|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
243089|NCT02537951|Device|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
243090|NCT02537951|Device|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
243091|NCT02537951|Device|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
243092|NCT02537964|Other|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
243093|NCT02537977|Biological|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
243094|NCT02502942|Behavioral|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
243095|NCT02502955|Procedure|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
243096|NCT02502968|Drug|Cytarabine|
243097|NCT02502968|Drug|BL-8040|
242444|NCT02514356|Behavioral|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
242445|NCT02514382|Drug|Bortezomib|Given SC or IV
242446|NCT02514382|Drug|Dexamethasone|Given PO, IV, or IM
242447|NCT02514382|Other|Laboratory Biomarker Analysis|Correlative studies
242448|NCT02514382|Other|Pharmacological Study|Correlative studies
242449|NCT00180635|Procedure|Nasal Lavage|
242450|NCT02514382|Biological|Wild-type Reovirus|Given IV
242451|NCT02514395|Other|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2[32] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
242452|NCT02514408|Procedure|Catheter Management|Insertion of venous catheter under ultrasound guidance
242453|NCT02514408|Other|Cytology Specimen Collection Procedure|Collection of blood samples
242454|NCT02514408|Other|Laboratory Biomarker Analysis|Correlative studies
242455|NCT02514421|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
242776|NCT00179764|Procedure|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
242777|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
242778|NCT02507661|Procedure|no-preservation of alveolar ridge - 4 months|
242779|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
242780|NCT02507661|Procedure|no-preservation of alveolar ridge - 9 months|
242781|NCT02507674|Device|ultrasound|
242782|NCT02507687|Drug|Bimatoprost SR|Bimatoprost sustained-release (SR) Dose A administered on Day 4, Weeks 16 and 32.
242783|NCT02507687|Other|Sham Bimatoprost SR|Sham Bimatoprost SR administered on Day 4, Weeks 16 and 32.
242147|NCT02518789|Drug|Etomidate|After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.
-Does not offer any other drugs within 5 min after completion of etomidate.
242148|NCT02518789|Drug|midazolam，fentanyl，rocuronium|Anesthesia induction：Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg
242149|NCT02518789|Drug|propofol，remifentanil，cis atracurium|Anesthesia maintenance：Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg
242150|NCT02518802|Drug|Gefitinib|Gefitinib 250mg per day for 2 years.
242151|NCT02518802|Drug|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
242152|NCT02518815|Device|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
242153|NCT00002492|Radiation|radiation therapy|
242154|NCT02521090|Biological|EGFRBi-Armed Autologous T Cells|Given IT and IV
242155|NCT02521090|Other|Laboratory Biomarker Analysis|Correlative studies
242156|NCT02521103|Device|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
242157|NCT02521116|Other|Dynamic Vessel Analyzer|
242158|NCT02521116|Other|Oxymap T1|
242159|NCT02521129|Device|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
242160|NCT02521142|Other|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
242161|NCT02521142|Other|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
242456|NCT02514421|Drug|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
241526|NCT02530060|Drug|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
241527|NCT02530073|Device|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E LHR < 25%).
241528|NCT02530086|Procedure|Nasogastric tube placement|Placement of a Nasogastric tube
241529|NCT00182897|Behavioral|Skills Building for Caregiver Health and Care-recipient|
241845|NCT00182533|Drug|Placebo|25 - 200 mg/day x 16 weeks
241846|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel|
241847|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel (Reference)|
241848|NCT02525549|Drug|Placebo gel|
241849|NCT02525562|Device|Triathlon Total Knee System with X3 insert|Total knee replacement
241850|NCT02525562|Device|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
241851|NCT02525562|Device|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
241852|NCT02525575|Behavioral|Project Life Force Group Treatment|PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased "belongingness", both key risk factors for suicide.
241853|NCT02525588|Device|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
241854|NCT02527798|Drug|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
241855|NCT02527798|Other|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
241856|NCT02527811|Drug|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
241857|NCT02527824|Drug|Oxaliplatin, Irinotecan, S-1|Treatment will be delivered every 2 weeks
Oxaliplatin 65 mg/m2 iv on day 1
Irinotecan 135 mg/m2 iv on day 1
S-1 80 mg/m2/day on day1-7
241858|NCT02527837|Drug|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
241233|NCT02537132|Other|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
241234|NCT02537158|Drug|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
241235|NCT02537158|Procedure|TACE|TACE group patients will accept TACE therapy once at a month after resection.
241236|NCT02537171|Drug|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
241237|NCT02537184|Procedure|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
241530|NCT02530086|Procedure|No Nasogastric tube use|No placement of a Nasogastric tube
241531|NCT02530099|Procedure|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
241532|NCT02530099|Procedure|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
241533|NCT02530112|Other|Survey|
241534|NCT02530125|Other|Laboratory Biomarker Analysis|Correlative studies
241535|NCT02530125|Biological|Pidilizumab|Given IV
241536|NCT02530138|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
241537|NCT02530138|Dietary Supplement|Placebo|2 placebo capsules per day for 28 weeks
241538|NCT02530151|Drug|Morphine with clonidine|see arm description
241539|NCT02532283|Drug|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
241540|NCT02532283|Drug|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
241541|NCT02532296|Behavioral|Transition Coach (TC)|TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.
Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.
Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care.
266091|NCT02382172|Other|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
266092|NCT02382185|Other|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
266093|NCT02382185|Drug|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
266094|NCT02382185|Device|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
266095|NCT02382198|Drug|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
266096|NCT00161486|Drug|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
266097|NCT02382198|Drug|Placebo|
266098|NCT02384564|Device|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
266099|NCT02384564|Device|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
266100|NCT02384577|Drug|Budesonide, Formoterol Fumarate Dihydrate|
266363|NCT02374918|Device|HC wavelength-1 bright light|30 minutes of light exposure
266364|NCT02374918|Device|HC wavelength-2 bright light|30 minutes of light exposure
266365|NCT00160550|Drug|Levetiracetam|
266366|NCT02374931|Radiation|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
266367|NCT02374931|Procedure|Positron Emission Tomography|Undergo 18F-FES PET/CT
266368|NCT02374931|Procedure|Computed Tomography|Undergo 18F-FES PET/CT
266369|NCT02374931|Other|Laboratory Biomarker Analysis|Correlative studies
266370|NCT02374944|Procedure|Hardware removal|
266371|NCT02374957|Drug|Cilostazol|100 mg twice daily for 90 days
265823|NCT02391415|Biological|VPM1002|Tuberculosis vaccine
265824|NCT02391415|Biological|BCG|commercially available live vaccine BCG
265825|NCT02391415|Biological|VPM1002(Hyg+)|Tuberculosis vaccine
265826|NCT02391428|Procedure|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
265827|NCT02391428|Dietary Supplement|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
265828|NCT02391454|Device|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
265829|NCT02391454|Other|Usual care|
265830|NCT02391480|Drug|ABBV-075|ABBV-075 Oral tablets
265831|NCT02391493|Device|functional magnetic resonance imaging|Stimuli will be presented in 3 language conditions, French, English and "switch" in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word ("to" or "faire" for actions and, "say" or "dire" for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds).
265832|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
265833|NCT02391506|Device|Cartiva|Cartiva Synthetic Cartilage Implant
265834|NCT02391519|Procedure|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
265835|NCT02391532|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
265836|NCT02391532|Dietary Supplement|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
265837|NCT02391545|Drug|IPI-145 (duvelisib)|PI3K Inhibitor
265838|NCT02391545|Drug|Rituximab|
265839|NCT02391545|Drug|Obinutuzumab|
265220|NCT02367560|Procedure|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
265221|NCT02367560|Procedure|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
265222|NCT02367560|Drug|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
265223|NCT00159770|Drug|ziprasidone versus olanzapine , risperidone or quetiapine|
265540|NCT02360358|Drug|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
265541|NCT02360358|Other|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
265542|NCT00158938|Device|EASYTRAK 3 left ventricular pacing lead|
265543|NCT02360371|Drug|Within-subject assessment of double-blind study drug|Participants will receive a double-blinded study drug as part of their daily sessions and will provide feedback regarding the effects of the drug on various measures. Though the study drug is FDA approved, it is being used here for a non-FDA approved purpose (though the FDA has provided permission to use the drug in this study).
265544|NCT02362906|Drug|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
265545|NCT02362906|Drug|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
265546|NCT00159302|Procedure|Induced Sputum|
265547|NCT02362906|Drug|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
265548|NCT02362906|Drug|second generation cephalosporin|
265549|NCT02362906|Drug|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
265550|NCT02362906|Drug|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
265551|NCT02362919|Biological|FLUAD 2014/2015|All participants of the study will be vaccinated intramuscularly with FLUAD 2014/2015, a trivalent, surface antigen, inactivated influenza virus vaccine adjuvanted with MF59C.1.
265552|NCT02362932|Other|Sanitation|Shared sanitation
265553|NCT02362945|Drug|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
264927|NCT00160303|Drug|Prolotherapy|
264928|NCT02372487|Dietary Supplement|fluid therapy|2 liters of fluid per day
264929|NCT02372500|Dietary Supplement|Chewing gum|Sugar free chewing gum
264930|NCT02372526|Other|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
264931|NCT02374567|Drug|Phenytoin|
264932|NCT02374567|Drug|Carbamazepine|
264933|NCT02374567|Drug|Oxcarbazepine|
264934|NCT02374567|Drug|Valproic Acid|
264935|NCT02374567|Drug|Lamotrigine|
264936|NCT02374567|Drug|Topiramate|
264937|NCT00160446|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
264938|NCT02374567|Drug|Gabapentin|
264939|NCT02374567|Drug|Levetiracetam|
264940|NCT02374567|Drug|Pregabalin|
265224|NCT02367560|Device|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
265225|NCT02367573|Procedure|2D laparoscopic TAPP inguinal hernia repair|
265226|NCT02367573|Procedure|3D laparoscopic TAPP inguinal hernia repair|
265227|NCT02367599|Drug|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
265228|NCT02367612|Dietary Supplement|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
265229|NCT02367612|Dietary Supplement|Placebo|Maltodextrin
265230|NCT02367625|Device|CryoPop|The new CryoPop device will be compared to standard cryotherapy
265231|NCT02367625|Device|MedGyn MGC 200|Standard cryotherapy
265232|NCT02369939|Drug|5-Fluorouracil|5-FU w1, w5
265233|NCT02369939|Procedure|Hyperthermia|6x deep regional hyperthermia
264613|NCT02378974|Biological|Cordstem-ST|
264614|NCT00161083|Drug|ursodeoxycholic acid|
264615|NCT02378974|Biological|Placebo|
264616|NCT02379000|Drug|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
264617|NCT02379000|Procedure|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
264618|NCT02379013|Procedure|Volunteer with MRI|functional MRI
264619|NCT02379026|Dietary Supplement|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
264620|NCT02379026|Behavioral|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
264621|NCT02379026|Dietary Supplement|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
264622|NCT02379052|Drug|Dupilumab|
264623|NCT02379052|Drug|Placebo|
264624|NCT02379065|Device|The Aerogen Aeroneb Solo©|
264625|NCT00161096|Drug|pantoprazole 20 mg (drug)|
264626|NCT02381314|Biological|MGA271 plus ipilimumab|MGA271 is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
264627|NCT02381327|Device|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
264628|NCT02381340|Device|ACE stapling procedure|Endoscopic trans-oral gastroplication
264629|NCT02381353|Drug|Bupivacaine|Intraoperative orbital injection of local pain medication
264630|NCT02381366|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:
Dose A: 10 million cells per kg / Dose B: 20 million cells per kg
264941|NCT02374567|Drug|Lacosamide|
264942|NCT02374567|Drug|Clonazepam|
269006|NCT02344758|Behavioral|gluten-free diet (GFD)|
269007|NCT02344758|Behavioral|gluten-containing diet|
269008|NCT02344771|Procedure|Elective colon cancer surgery|
269009|NCT02344784|Device|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
264329|NCT02386306|Other|Placebo|
264330|NCT00002429|Drug|Lamivudine/Zidovudine|
264331|NCT00162058|Drug|Peflutren Lipid Microsphere Injectable Suspension|
264332|NCT02386319|Drug|Melatonin|Gelatin capsules
264333|NCT02386319|Drug|Placebo|Placebo capsules
264334|NCT02386332|Procedure|transplantation|
264335|NCT02386358|Drug|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
264336|NCT02386358|Drug|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
264337|NCT02386371|Procedure|tumorectomy|Tumorectomy will be performed according to the current standards, obtaining "clear" margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.
264338|NCT02386371|Radiation|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
264339|NCT02386397|Drug|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
264340|NCT02386397|Drug|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
264341|NCT02386410|Behavioral|Group parent training for anxious parents|
264342|NCT00162071|Drug|apadenoson|
264343|NCT02386410|Behavioral|Internet delivered parent training for anxious parents|
264344|NCT02386423|Device|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
268694|NCT02351791|Other|Patch 2, Adhesive|
268695|NCT02351791|Other|Patch 3, Center|
268696|NCT02351791|Other|Patch 3, Leakage pocket|
268697|NCT02351791|Other|Patch 3, Adhesive|
268698|NCT00158171|Drug|Nicotine Replacement Therapies|Nicotine gum 2 & 4 mg dependent on baseline smoking rate
268699|NCT02351791|Other|Patch 4, Center|
268700|NCT02351791|Other|Patch 4, Leakage pocket|
268701|NCT02351791|Other|Patch 4, Adhesive|
268702|NCT02351791|Other|Patch 5, Center|
268703|NCT02351791|Other|Patch 5, Leakage pocket|
268704|NCT02351791|Other|Patch 5, Adhesive|
268705|NCT02351791|Other|Patch 6, Center|
268706|NCT02354040|Behavioral|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
269010|NCT02346786|Dietary Supplement|tap water|
269011|NCT02346799|Behavioral|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
269012|NCT02346799|Behavioral|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
269013|NCT00157508|Drug|nitroaspirin|
269014|NCT02346799|Behavioral|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
269015|NCT02346799|Behavioral|Partner Assignment|Participants will be required to have same "workout window" as partners.
269016|NCT02346812|Other|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
269017|NCT02346812|Other|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
268377|NCT02361619|Drug|Esomeprazole|probe
268378|NCT02361619|Drug|Metoprolol|probe
268379|NCT02361619|Drug|Midazolam|probe
268380|NCT02361619|Drug|Dabigatran|probe
268381|NCT02361619|Drug|Clarithromycin|perpetrator
268382|NCT02361632|Dietary Supplement|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
268383|NCT02361645|Drug|Ketorolac 0.5% eyedrops|
268384|NCT02361645|Drug|Indomethacin 0.5% eyedrops|
268385|NCT00159133|Drug|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
268386|NCT02361645|Drug|Bromfenac 0.09% eyedrops|
268387|NCT02361645|Drug|Nepafenac 0.1% eyedrops|
268388|NCT02361658|Other|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
268389|NCT02361658|Other|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
268390|NCT02361658|Other|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
268391|NCT02361671|Other|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
268392|NCT02361684|Behavioral|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
268707|NCT02354053|Drug|Switch to Triumeq|
268708|NCT02354053|Behavioral|Adherence support + current ART|
268709|NCT02354066|Device|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
268081|NCT02368665|Drug|Amlodipine 5mg, Candesartan cilexetil 16mg|- Daily oral administration Amlodipine 5mg for 8 weeks
268082|NCT02368665|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
268083|NCT02368678|Procedure|Scaling and Root Planning (SRP)|Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).
Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.
Oral hygiene instructions were given to all participants.
268084|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight >20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight >45 kg: 80 mg 3 times a day (tid)
268085|NCT02368678|Procedure|Full Mouth Scaling (FMS)|Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.
Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.
Oral hygiene instructions were given to all participants.
268086|NCT02368691|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
268087|NCT02368704|Other|No intervention|
268088|NCT02368717|Drug|Mesalazine Enema|
268089|NCT02368717|Drug|Placebo Enema|
268090|NCT02368730|Drug|desmopressin|
268091|NCT02368743|Drug|mesalazine|
268092|NCT02368756|Drug|Aflibercept|A 2mg dose of intravitreal Aflibercept given as needed with possible laser until end of protocol.
268093|NCT02368769|Device|During Tele-expertise|
268094|NCT02368795|Device|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
268095|NCT00159874|Drug|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight >20 kg
268096|NCT02368795|Drug|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
268097|NCT02368795|Drug|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
268098|NCT02368795|Drug|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
243933|NCT02521753|Drug|Metformin|Intervention also includes weight reduction diet and exercise therapy
243934|NCT00182000|Drug|seromycin|100mg tablet administered 1 hour prior to each therapy session
243935|NCT02521753|Dietary Supplement|Magnesium|Intervention also includes weight reduction diet and exercise therapy
243936|NCT02521753|Dietary Supplement|PUFA|Intervention also includes weight reduction diet and exercise therapy
243937|NCT02521779|Other|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
243938|NCT02521779|Other|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
243939|NCT02521779|Other|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
243940|NCT02521779|Other|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
243941|NCT02521792|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
243942|NCT02521805|Other|Animal protein|
243943|NCT02521805|Other|Vegetable protein|
243944|NCT02521805|Other|Dietary fiber (cereal food matrice)|
243945|NCT00182000|Behavioral|Behavior Therapy|10 weekly hour-long behavior therapy sessions
243946|NCT02521805|Other|Dietary fiber (meat food matrice)|
239214|NCT02445339|Drug|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
239215|NCT00169793|Other|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
239216|NCT02447484|Behavioral|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education & Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
239217|NCT02447484|Behavioral|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
243649|NCT02526381|Drug|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
243650|NCT02526394|Biological|Meningococcal vaccine|Meningococcal vaccination
243651|NCT02526394|Drug|Pertussis containing vaccine|Pertussis containing vaccination
243652|NCT02526407|Behavioral|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
243653|NCT02526407|Behavioral|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
243654|NCT00182611|Drug|cisplatin|
243655|NCT02526420|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
243656|NCT02528513|Drug|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
243657|NCT02528513|Drug|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
243658|NCT02528513|Drug|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
243659|NCT02528513|Drug|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
243660|NCT02528513|Procedure|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
243661|NCT02528513|Procedure|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
243662|NCT00182780|Other|Placebo|
243663|NCT02528513|Drug|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
243947|NCT02521805|Other|Dietary fiber (vegetable food matrice)|
243948|NCT02521818|Other|Modified Atkins Diet|
243949|NCT02521818|Other|NIA Diet for Seniors|
243098|NCT02502968|Drug|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
243099|NCT02502981|Drug|Spironolactone|25mg orally once a day for 40 weeks
243100|NCT02502981|Drug|chlortalidone|25mg orally once a day for 40 weeks
243101|NCT02502981|Device|Ambulatory blood pressure monitor®|24 hour ambulatory blood pressure monitor will be worn by subjects at baseline and week 40
243367|NCT02533037|Other|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
243368|NCT02533037|Other|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
243369|NCT02533050|Device|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
243370|NCT02533063|Device|VibeTech One|Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the "loading + vibration group" (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g.
243371|NCT02533076|Other|Challenge agent: capsaicin|During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.
In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging.
243372|NCT02533076|Other|Challenge agent: placebo|During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.
In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging.
243373|NCT00183326|Behavioral|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
243374|NCT02533076|Device|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
243375|NCT00183521|Behavioral|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
242784|NCT02507687|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
242785|NCT02507687|Other|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
242786|NCT02507700|Procedure|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
242787|NCT02509767|Drug|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
242788|NCT02509780|Other|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
242789|NCT02509793|Drug|Tetrabenazine|Xenazine, pill, dose to effect, three times a day, for 12 weeks
242790|NCT02509806|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
242791|NCT02509819|Device|Heel Cushion Material Bulk (foam)|The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
242792|NCT02509832|Device|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
242793|NCT00180024|Drug|irbesartan (drug)|
242794|NCT02509832|Device|PCI only|Standard of Care for PCI
242795|NCT02509845|Drug|C16G2|Antimicrobial peptide
242796|NCT02509845|Other|Placebo|Placebo
242797|NCT02509858|Drug|thyroxine|treatment with 50μg of thyroxine once daily for two months.
243102|NCT02502981|Device|Carotid femoral pulse wave velocity|Assessment of Carotid femoral pulse wave velocity at baseline and week 40
243103|NCT02502981|Procedure|Cardiac magnetic resonance imaging|Assessment of cardiac function and mass using cardiac MRI at baseline and week 40
243104|NCT00179140|Behavioral|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
243105|NCT02502981|Procedure|Blood tests|Blood tests for renal function, eGFR and potassium level will be performed at baseline, week 1,2,4,8,20 and 40
243106|NCT02502981|Procedure|Spot urine collection for albumin:creatinine ratio|Will be performed at baseline and week 40
242457|NCT02514421|Drug|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
242458|NCT02514434|Radiation|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
242459|NCT02514434|Radiation|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
242460|NCT00180635|Procedure|Spirometry|
242461|NCT02514447|Drug|G1T28 + Topotecan|G1T28, Topotecan
242462|NCT02514460|Device|plaque excision system|
242463|NCT02514460|Device|Stent|
242464|NCT02514473|Drug|VX-809|
242465|NCT02514473|Drug|Placebo|
242466|NCT02514473|Drug|VX-770|
242467|NCT02516722|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.
Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation.
242468|NCT02516735|Device|I-scan with magnification|
242469|NCT02516735|Device|Standard endoscopy|
242470|NCT02516748|Behavioral|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own accuracy of optical diagnosis
242471|NCT02516761|Other|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
242472|NCT02516761|Other|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
242473|NCT00181012|Drug|Lidocaine|
242474|NCT02516761|Other|Control group|With this group no intervention is done, but they are assessed like the other groups.
241859|NCT02527837|Drug|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
241860|NCT02527850|Device|B-cure laser|
241861|NCT02527863|Drug|Tolvaptan|60 mg Tolvaptan pr day for 1 day
241862|NCT02527863|Drug|Placebo|1 tablet Unikalk pr day for 1 day
241863|NCT02527876|Behavioral|High Intensity Interval Training|High Intensity Interval Training
241864|NCT00182728|Procedure|surgery|conventional
241865|NCT02527876|Behavioral|Moderate Intensity|Moderate Intensity Training
242162|NCT02521142|Other|Spectralis OCT and Topcon DRI OCT|The Spectralis OCT (Heidelberg Engineering) and the high definition Topcon DRI OCT (Topcon), will be used. Both are standard OCT devices for non-invasive imaging of retinal and choroidal structures.
242163|NCT00181896|Drug|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
242164|NCT02521142|Other|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
242165|NCT02521155|Behavioral|Safeguard Your Smile an oral health literacy intervention|Safeguard Your Smile intervention will consist of following five components:
i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month.
242166|NCT02521168|Drug|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
242167|NCT02521168|Drug|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
242168|NCT02521181|Drug|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
242169|NCT02521181|Drug|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
242170|NCT02521181|Drug|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
242171|NCT02521194|Behavioral|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
242172|NCT02521207|Drug|Ibuprofen|
242173|NCT02523274|Drug|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
241542|NCT02532296|Behavioral|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
241543|NCT02532309|Drug|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C>1.1mmol/L and <1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
241544|NCT00183248|Procedure|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
241545|NCT02532309|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
241546|NCT02532322|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
241547|NCT02532322|Drug|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
241548|NCT02532335|Drug|Obeticholic acid|active drug
241549|NCT02532335|Drug|Obeticholic acid placebo|matching placebo
241550|NCT02532348|Other|Blood samples|Blood samples
266670|NCT02368119|Biological|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
266671|NCT02368119|Other|Placebo|IM injection injection of Phosphate Buffered Saline
266672|NCT02368132|Behavioral|Individual Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
266673|NCT00159809|Drug|Viagra (Sildenafil citrate)|
266674|NCT02370550|Drug|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
266675|NCT02370550|Drug|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
266676|NCT02370550|Drug|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
266677|NCT02370563|Drug|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
266678|NCT00160056|Procedure|Hypoglycemia|
266679|NCT02370576|Other|rating scale application|Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.
rating scale application
298519|NCT00410722|Dietary Supplement|Whole wheat and bran muffin|
298520|NCT00410722|Dietary Supplement|Mixed tree nuts|
298521|NCT00410735|Drug|Placebo|0 mg BID for 12 weeks
298522|NCT00410735|Drug|Pranlukast hydrate|225 mg BID for 12 weeks
298523|NCT00410748|Drug|OROS hydromorphone HCI CR|
298524|NCT00410761|Drug|ZD6474 (Vandetanib)|once daily oral tablet
298525|NCT00410774|Biological|bevacizumab|
298526|NCT00410774|Drug|gemcitabine hydrochloride|
298527|NCT00410774|Procedure|adjuvant therapy|
298528|NCT00003294|Drug|paclitaxel|
298529|NCT00410787|Drug|OROS hydromorphone HCI (slow release)|
298530|NCT00410813|Drug|dasatinib|given orally
298531|NCT00410826|Drug|erlotinib hydrochloride|Given orally
298532|NCT00410826|Drug|cisplatin|Given IV
298533|NCT00410826|Radiation|3-dimensional conformal radiation therapy|35 fractions
298534|NCT00410826|Radiation|intensity-modulated radiation therapy|35 fractions
298535|NCT00410826|Procedure|quality-of-life assessment|Ancillary studies
298536|NCT00410839|Procedure|ALA rich diet|
298537|NCT00366210|Behavioral|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
298538|NCT00366236|Drug|Nitazoxanide|
298539|NCT00366249|Drug|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
298540|NCT00003087|Procedure|surgical procedure|
298541|NCT00366249|Drug|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
298542|NCT00366262|Drug|PLA-695|
297776|NCT00384033|Drug|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
297777|NCT00384033|Drug|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
297778|NCT00384046|Drug|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
297779|NCT00000146|Drug|Methylprednisolone|
297780|NCT00000493|Drug|propranolol|
298149|NCT00372710|Drug|Zoledronic acid|
298150|NCT00372723|Drug|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
298151|NCT00372736|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
298152|NCT00372736|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
298153|NCT00375882|Procedure|hypothermia|
298154|NCT00375882|Procedure|cochlear implantation with mild hypothermia|
298155|NCT00375895|Drug|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
298156|NCT00375934|Drug|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
298157|NCT00375934|Drug|Placebo|Oral placebo capsule, every 6 hours
298158|NCT00000487|Drug|antihypertensive agents|
298159|NCT00003129|Drug|valrubicin|
298160|NCT00375947|Other|Hand Exercise|
298161|NCT00375947|Other|sham hand cream|placebo intervention
298162|NCT00375960|Drug|V3381|
298163|NCT00375960|Drug|Placebo|
298164|NCT00375973|Drug|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
298165|NCT00375973|Drug|Placebo|Sugar pill dose comparable to duloxetine
297418|NCT00392665|Drug|erlotinib|Given orally once a day
297419|NCT00392665|Drug|Sulindac|Given orally twice a day
297420|NCT00392678|Drug|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
297421|NCT00392678|Drug|Placebo|
297422|NCT00392691|Drug|ibritumomab tiuxetan|185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients > 80kg) for imaging.
297423|NCT00392691|Drug|rituximab|250 mg/m2
297424|NCT00392691|Drug|melphalan|Dose level 1: 100 mg/m2
Dose level 2: 140 mg/m2
Dose level 3: 170 mg/m2
Dose level 4: 200 mg/m2
297425|NCT00392691|Drug|vinorelbine tartrate / G-CSF|on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days
297426|NCT00392691|Procedure|autologous hematopoietic stem cell harvesting and transplantation|Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.
Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils > 0.5x109/l for at least 2 consecutive days.
297427|NCT00392704|Drug|Bevacizumab|Induction Treatment:
Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.
Combined Modality Treatment:
Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy
297428|NCT00003209|Drug|fluorouracil|
297781|NCT00003165|Drug|doxorubicin-HPMA conjugate|
297782|NCT00384046|Drug|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
297783|NCT00384059|Biological|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
297784|NCT00384059|Biological|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
297785|NCT00384059|Biological|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
297786|NCT00384059|Biological|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
297787|NCT00384059|Biological|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
296686|NCT00410020|Behavioral|Alpha-linolenic enriched diet|
297046|NCT00003243|Drug|pegylated liposomal doxorubicin hydrochloride|
297047|NCT00401193|Drug|Placebo tablets|
297048|NCT00401206|Drug|dexmedetomidine|
297049|NCT00401219|Drug|conjugated estrogens/progestin (MPA)|
297050|NCT00401232|Procedure|Blood Collection|Blood Collection
297051|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 100 mg
297052|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 50 mg
297053|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
297054|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg
297055|NCT00401245|Drug|Placebo|Tapering placebo
297056|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
297057|NCT00003245|Drug|irinotecan hydrochloride|
297058|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
297059|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
297060|NCT00401258|Drug|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
297061|NCT00401271|Drug|OPC-67683|
297062|NCT00401271|Drug|Rifafour e-275|
297063|NCT00401284|Drug|EVT 201|
297064|NCT00401310|Drug|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
297065|NCT00401310|Drug|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
297066|NCT00401323|Drug|docetaxel (XRP6976)|
297067|NCT00401323|Drug|cisplatin|
296322|NCT02616614|Drug|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
296323|NCT02616614|Drug|Placebo|Vehicle gel used as a placebo
296324|NCT02616640|Drug|Durvalumab|
296325|NCT02616640|Drug|Pomalidomide|
296326|NCT02616640|Drug|Dexamethasone|
296327|NCT00193141|Drug|5-Fluorouracil|
296328|NCT02616653|Procedure|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
296329|NCT02616666|Drug|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
296330|NCT02616666|Drug|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
296687|NCT00410033|Drug|soluble human insulin|
296688|NCT00410033|Drug|isophane human insulin|
296689|NCT00410033|Drug|insulin aspart|
296690|NCT00410046|Drug|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
296691|NCT00003289|Drug|7-hydroxystaurosporine|
296692|NCT00410059|Drug|Erlotinib|150 mg by mouth daily x 28 days
296693|NCT00410072|Drug|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
296694|NCT00410072|Drug|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
296695|NCT00410085|Drug|L-NMMA (N-mono.methyl-L-arginine)|
296696|NCT00410098|Behavioral|Bikram Yoga|
296697|NCT00410124|Drug|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
296009|NCT02619045|Other|Telephone follow-up nursing device|Telephone follow-up nursing device involving:
telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),
specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),
actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);
296010|NCT02619058|Biological|NKT cells|autologous natural killer T cell
296011|NCT02619071|Procedure|Tumor sampling|Bone marrow aspirate, blood sampling
296012|NCT02619071|Biological|Constiutional DNA sampling|Buccal swab or Hair follicles
296013|NCT02619084|Procedure|STN DBS|Bilateral STN DBS
296014|NCT02621164|Biological|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
296015|NCT02621164|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
296016|NCT02621177|Biological|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
296017|NCT02621177|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
296018|NCT02621190|Drug|cabazitaxel|25mg/m2 q3w
296019|NCT02621229|Behavioral|High calorie refeeding|beginning with 2000 kcal and advanced 200 kcal/d
296020|NCT00193453|Drug|Gemcitabine|1000mg/m2 30min IV, Day 1 & 8
296021|NCT02621229|Behavioral|Low calorie refeeding|beginning at 1400 kcal/d and advanced 200 kcal every other day
296022|NCT02621242|Procedure|Upper endoscopy|Upper endoscopy with biopsies
296023|NCT02621242|Procedure|Anoscopy|Anoscopy with biopsies
296024|NCT02621242|Drug|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
296025|NCT02621255|Drug|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
296026|NCT02621255|Drug|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
295422|NCT02631772|Drug|Sofosbuvir/Ledipasvir|Both ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, both initiated within 90 days after liver transplant, will have equivalent SVR12 and will be better than that expected compared to the natural history of HCV post-transplant.
295423|NCT02631772|Drug|Sofosbuvir/Ledipasvir|Both ledipasvir/sofosbuvir (LDV/SOF) for 12 weeks, both initiated within 90 days after liver transplant, will have equivalent SVR12 and will be better than that expected compared to the natural history of HCV post-transplant.
295424|NCT02631785|Other|Cognitive Behavioral Therapy|Psychologists will deliver the "COPING CAT" treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session.
295425|NCT02631798|Dietary Supplement|Food grade dye mucosal staining|mucosal staining with food grade dye
295426|NCT02631811|Other|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
295427|NCT02631824|Procedure|open reduction and internal fixation|Open reduction and internal fixation using an intramedullary nail
295428|NCT02631824|Device|TFNA|Trochanteric Femoral Nail Advance
295722|NCT02625363|Other|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
295723|NCT02625363|Other|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
295724|NCT02625363|Other|White Bread and 700 ml water|Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.
First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
295725|NCT02625363|Other|White Bread with 125 ml water (twice)|Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
295726|NCT02625376|Dietary Supplement|Resvega|Dietary supplementation with Resvega BD
295727|NCT02625376|Dietary Supplement|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
295728|NCT02625376|Dietary Supplement|placebo|Dietary supplementation with a placebo BD
295729|NCT02625389|Procedure|selective transarterial catheterization using Lipiodol® Ultra Fluid with surgical glues|
295110|NCT02636257|Procedure|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of peiosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured
295111|NCT02636270|Drug|Increlex|Treat PAPP-A2 deficient patients with Increlex
295112|NCT02636283|Drug|np group|Infusion of NP
295113|NCT00195130|Behavioral|There are no interventions in this study|
295114|NCT02636283|Drug|Placebo group|The placebo group will receive an infusion of saline solution
295115|NCT02636296|Other|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
295116|NCT02636296|Other|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
295117|NCT02636309|Behavioral|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
295118|NCT02636322|Drug|Rituximab|Smart Start: Rituximab 375 mg/m2 by vein on Day 1 of a 21 day cycle for 2 cycles.
At completion of Smart Start: Rituximab 375 mg/m2 by vein on Day 1 of a 21 day cycle for 6 cycles.
295119|NCT02636322|Drug|Ibrutinib|Smart Start: Ibrutinib 560 mg by mouth 1 time every day in a 21 day cycle for 2 cycles.
At completion of Smart Start: Ibrutinib 560 mg by mouth 1 time every day in a 21 day cycle for 6 cycles.
295120|NCT02638519|Device|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
295121|NCT02638532|Procedure|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
295122|NCT00195403|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
295123|NCT02638545|Drug|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
295124|NCT02638558|Other|written + oral explanation|
295125|NCT02638558|Other|written explanation|
295429|NCT02631824|Device|Augmentation (Cement)|Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
294509|NCT02611531|Behavioral|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
294510|NCT02611531|Behavioral|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
294511|NCT02611544|Behavioral|Acceptance and Commitment Therapy|6-week ACT intervention group (n=26)
294512|NCT02611544|Behavioral|Survivorship Education|6-week survivorship education group (SE; n=26)
294513|NCT02611544|Behavioral|Usual Care|usual care (UC; n=26)
294514|NCT00192621|Drug|Kaletra (lopinavir [LPVr])|
294515|NCT02611557|Procedure|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
294516|NCT02611583|Device|TENS|Transcutaneous Electrical Nerve Stimulation
294809|NCT02643173|Other|Volatile anesthetics|
294810|NCT02643173|Other|Intravenous anesthetics|
294811|NCT02643186|Drug|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
294812|NCT02643186|Procedure|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
294813|NCT02643212|Drug|Rivaroxaban|
294814|NCT02643212|Drug|Placebo|
294815|NCT02643238|Device|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
294816|NCT02643251|Drug|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
294817|NCT00195988|Drug|tacrolimus, steroids, mycophenolate mofetil|
294818|NCT02643251|Drug|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
294819|NCT02643264|Other|rTMS 10 Hz targeting the insula|Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
294199|NCT02618135|Other|Control Group|Participants will wait for 8 weeks before training intervention begins.
Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
294200|NCT02618148|Drug|ESTROGEN HERBALS 21|Applies to the following strengths:
17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days.
294201|NCT02618148|Drug|ESTROGEN HERBALS 28|Applies to the following strengths:
17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days.
294202|NCT02618161|Radiation|Timing of HDR Brachytherapy to EBRT|The intervention is usage of HDR and the assessment of toxicities during both before and after the EBRT in both arms
294203|NCT02618174|Behavioral|Neutral Control Condition|Message about age of University of Birmingham
294204|NCT00193245|Drug|Topotecan|
294205|NCT02618174|Behavioral|Food-based Control Condition|Message about variety of vegetables in the world
294206|NCT02618174|Behavioral|Health Condition|Message about the health benefits of eating vegetables
294207|NCT02618174|Behavioral|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
294208|NCT02618174|Behavioral|Liking Social Norm|Message suggesting most people like eating vegetables
294209|NCT02618187|Drug|Eubacterial Spores, Purified Suspension, Encapsulated|
294210|NCT02618187|Drug|Placebo|
294211|NCT02618187|Drug|Placebo Pre-Treat|
294212|NCT02618187|Drug|Vancomycin Pre-Treat|
294213|NCT02618200|Device|3D prostate ultrasound|
294214|NCT02618213|Device|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
294215|NCT00193245|Drug|Docetaxel|
294216|NCT02618213|Device|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
296482|NCT00389766|Procedure|radioisotope therapy|
296483|NCT00003195|Procedure|allogeneic bone marrow transplantation|
296484|NCT00389766|Procedure|radionuclide imaging|
296485|NCT00389766|Procedure|radiosensitization|
296486|NCT00389766|Procedure|total-body irradiation|
296855|NCT00381134|Drug|spironolactone 25 mg orally once daily|
296856|NCT00381134|Drug|placebo once orally once daily|
296857|NCT00381147|Drug|Clarithromycin|
296858|NCT00381160|Behavioral|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
296859|NCT00381173|Drug|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
296860|NCT00381186|Behavioral|diet- and exercise intervention|
296861|NCT00381199|Drug|Amitriptyline Hydrochloride|
296862|NCT00381199|Drug|Nabilone|
296863|NCT00381212|Biological|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
296864|NCT00381225|Procedure|Ultra-sound guided radio-frequency ablation|
296865|NCT00003151|Drug|omeprazole|
296866|NCT00381238|Drug|rosiglitazone|Extended Release Tablets
296867|NCT00381251|Drug|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
296868|NCT00381264|Drug|Cesamet™ (nabilone)|
296869|NCT00381277|Drug|Gatorade|
296870|NCT00381277|Drug|Performance|
296871|NCT00381290|Behavioral|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
296175|NCT02636621|Other|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
296176|NCT02636634|Other|imaging|
296177|NCT02636647|Biological|Fecal transplant|
296178|NCT02636673|Procedure|Sigmoid Resection|
296179|NCT02636686|Drug|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
296180|NCT00002525|Drug|leucovorin calcium|
296181|NCT00195195|Drug|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
296182|NCT02636699|Biological|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
296183|NCT02636699|Biological|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
296184|NCT02636712|Device|ImageReady™ MR Conditional Pacing System|
296185|NCT02636725|Drug|Axitinib|Twice daily dosing of axitinib alone for the first 7 days, followed by concurrent axitinib administered twice daily at 5 mg PO twice daily, plus intravenous administration of pembrolizumab every 21 days. Intrapatient dose escalation of axitinib will be performed following an initial safety lead-in of 5 patients.
296487|NCT00389779|Drug|Darusentan|Darusentan capsules administered orally once daily
296488|NCT00389779|Drug|Guanfacine|Guanfacine capsules administered orally once daily
296489|NCT00389779|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
296490|NCT00389792|Drug|ATI-2042|no intervention
296491|NCT00389792|Drug|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
296492|NCT00389805|Drug|bortezomib|
296493|NCT00389805|Drug|pemetrexed disodium|
296494|NCT00003195|Procedure|peripheral blood stem cell transplantation|
296495|NCT00389805|Genetic|gene expression analysis|
296496|NCT00389805|Genetic|mutation analysis|
295856|NCT02638896|Drug|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will take sulfasalazine (2g/d) from week12 to week48.
295857|NCT02638896|Drug|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
295858|NCT02638909|Drug|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
295859|NCT02638922|Drug|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
295860|NCT00195442|Drug|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
295861|NCT02641288|Drug|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
295862|NCT02641288|Drug|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
295863|NCT02641301|Drug|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
295864|NCT02641314|Drug|metronomic therapy|Propranolol 0.5 mg/kgxd p.o. day 1,
mg/kgxd p.o. day 2,
mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day
Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day
Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose
Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose
Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose
295865|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
295866|NCT02641327|Device|EarlySense (Passive monitoring)|Passive contact-free monitoring
295867|NCT02641340|Drug|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
295868|NCT02641340|Drug|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
296186|NCT02636725|Drug|Pembrolizumab|Pembrolizumab 200 mg flat dose shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
296187|NCT02636725|Procedure|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
294942|NCT02620774|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
294943|NCT02620787|Drug|Tedizolid|
295252|NCT02614105|Procedure|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
295253|NCT02614105|Other|Control|Brief information only
295254|NCT02614118|Drug|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
295255|NCT02614118|Drug|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
295256|NCT02614118|Drug|Placebo|placebo 45 minutes before root canal treatment
295257|NCT02614131|Drug|LY2599666|Administered SC
295258|NCT02614131|Drug|Solanezumab|Administered IV
295259|NCT02614131|Drug|Placebo SC|Administered SC
295260|NCT00002521|Radiation|radiation therapy|
295261|NCT00192933|Procedure|NovoSeven treatment according to guideline|
295262|NCT02614131|Drug|Placebo IV|Administered IV
295263|NCT02614157|Procedure|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
295264|NCT02616198|Other|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
295265|NCT02616198|Other|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
294322|NCT02629341|Dietary Supplement|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
294323|NCT02629354|Drug|Ibuprofen|
294324|NCT02629354|Drug|Caffeine|
294325|NCT02631434|Procedure|sit-to-stand test|
294326|NCT02631434|Procedure|six-minutes walking test|
294327|NCT02631447|Drug|LGX818|LGX818 450 mg p.o. od
294328|NCT02631447|Drug|MEK162|MEK162 45 mg p.o. bid
294329|NCT02631447|Drug|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
294625|NCT02625103|Procedure|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
294626|NCT02625103|Drug|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
294627|NCT02625129|Other|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
294628|NCT02625142|Other|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
294629|NCT02625155|Other|Urine diagnostic testing as SOC, drug regimen changes per SOC|
294630|NCT02625155|Other|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
294631|NCT02625168|Drug|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
294632|NCT02625168|Drug|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
294633|NCT02625181|Procedure|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
294634|NCT00193804|Radiation|IMRT|IMRT in cervical cancers
293757|NCT02640365|Drug|MM-398|unresectable Advanced non-colorectal cancer
293758|NCT02640365|Drug|Irinotecan|unresectable metastatic colorectal cancer
293759|NCT02640365|Drug|Leucovorin (LV)|unresectable metastatic colorectal cancer
293760|NCT02640365|Drug|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
293761|NCT02640365|Drug|bevacizumab|unresectable metastatic colorectal cancer
293762|NCT00002527|Drug|acetylsalicylic acid|
293763|NCT00195598|Drug|Paroxetine|
293764|NCT02640365|Drug|MM-398|unresectable metastatic colorectal cancer
293765|NCT02640378|Other|NO intervention|This study was a cross-sectional study. It had no intervention.
293766|NCT02640391|Other|colonoscopy|
293767|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
293768|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular.
293769|NCT02640417|Drug|Nucleotides + B12|Oral treatment with either Nucleotides + Vitamin B12
293770|NCT02640417|Drug|B Vitamins|Oral treatment with vitamins B1, B6, and B12
293771|NCT02640430|Device|standard treatment|20 minutes, twice a day for 10 sessions
293772|NCT02640430|Device|Free Aspire|20 minutes, twice a day for 10 sessions
293773|NCT02640443|Drug|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
293774|NCT00195611|Drug|Prevenar|
294034|NCT02635685|Other|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
294035|NCT02635698|Other|Optifast|medically-supervised weight management program
294036|NCT02635698|Other|Food-Based|low-energy, low-fat diet
294037|NCT02635711|Behavioral|Adapted Taekwondo training|Adapted Taekwondo training for beginners
298543|NCT00366262|Drug|Naproxen|
298544|NCT00366262|Drug|Placebo|
298890|NCT00003267|Procedure|infection prophylaxis and management|
298891|NCT00404794|Drug|prednisolone and tacrolimus|
298892|NCT00404807|Device|CPAP(Continuous Positive Airway Pressure)|
298893|NCT00404820|Drug|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
298894|NCT00404820|Drug|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
298895|NCT00404820|Drug|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
298896|NCT00404833|Drug|prednisolone and mycophenolate mofetil|
298897|NCT00404833|Drug|prednisolone and chlorambucil|
298898|NCT00404846|Procedure|Hyperbaric Oxygenation Therapy|
298899|NCT00404885|Drug|Placebo|PO BID
298900|NCT00404885|Drug|LX211|0.2 mg/kg, twice a day (BID)
298901|NCT00003267|Procedure|management of therapy complications|
298902|NCT00404885|Drug|LX211|0.4 mg/kg, twice a day (BID)
298903|NCT00404885|Drug|LX211|0.6 mg/kg, twice a day (BID)
298904|NCT00404911|Behavioral|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
298905|NCT00404911|Behavioral|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
298906|NCT00404924|Drug|ZD6474 (vandetanib)|once daily oral tablet
298907|NCT00404924|Other|Best Supportive Care|standard of care
298908|NCT00404937|Drug|Tobradex (Antibiotic steroid combination)|
298909|NCT00404963|Drug|placebo|
298166|NCT00375986|Procedure|Manual placental removal at Cesarean delivery|
298167|NCT00375986|Procedure|Spontaneous placental removal at Cesarean delivery|
298168|NCT00375999|Drug|Docetaxel and epirubicin|
298169|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
298170|NCT00003130|Drug|paclitaxel|
298171|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
298545|NCT00366275|Procedure|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 2 and cyclophosphamide 400 mg/m^2 on days 2-6. Courses were started if granulocytes >1.5 · 10^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM [carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m^2 on days +14 and +21 after autotransplant.
298546|NCT00366288|Drug|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
298547|NCT00366301|Drug|Insulin glargine injection|Once daily for 14 weeks
298548|NCT00366301|Drug|metformin|Up to 4 pils per day (2g per day) maximum
298549|NCT00366301|Drug|Placebo pill|Up to 4 pills per day
298550|NCT00366327|Drug|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
298551|NCT00003087|Radiation|radiation therapy|
298552|NCT00366340|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
298553|NCT00366340|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
298554|NCT00366353|Other|Sedation during SBT|
298555|NCT00366353|Other|No sedation|
298556|NCT00366366|Biological|Infanrix-Hexa|
298557|NCT00366379|Drug|GK Activator (2)|25-200mg po bid for 20 weeks
297788|NCT00384072|Drug|bazedoxifene BZA-20|
297789|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
297790|NCT00384085|Drug|Insulin Glargine|Subcutaneous injection once-a-day
297791|NCT00384085|Drug|Premixed Insulin|Subcutaneous injection twice-a-day.
297792|NCT00003166|Drug|bryostatin 1|Given IV
297793|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
297794|NCT00384098|Drug|CTA018 cream|
297795|NCT00384111|Drug|R-CVP + Zevalin Therapeutic Regimen|Standard R-CVP followed by Zevalin Theraeputic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
297796|NCT00384111|Drug|R-CVP|Standard R-CVP
297797|NCT00384124|Drug|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
297798|NCT00384137|Drug|Tacrolimus|Immunosuppression
297799|NCT00384150|Drug|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
297800|NCT00384176|Drug|Cediranib|oral tablet once daily
297801|NCT00384176|Drug|Bevacizumab|intravenous infusion
297802|NCT00384176|Drug|5-fluorouracil ( in FOLFOX)|intravenous infusion
297803|NCT00003166|Drug|vincristine sulfate|Given IV
297804|NCT00384176|Drug|Leucovorin (in FOLFOX)|intravenous infusion
297805|NCT00384176|Drug|Oxaliplatin (in FOLFOX)|intravenous infusion
298172|NCT00376025|Dietary Supplement|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
298173|NCT00376038|Drug|GSK189075 oral tablets|
298174|NCT00376038|Drug|metformin tablets|
298175|NCT00376051|Drug|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
298176|NCT00376064|Drug|Octreotide acetate and cabergoline/Octrotide and Somavert|
297068|NCT00003248|Biological|rituximab|
297069|NCT00401323|Drug|5-fluorouracil (5-FU)|
297070|NCT00401336|Device|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
297071|NCT00401362|Drug|SC Methylnaltrexone|Dose 1
297429|NCT00392704|Drug|Erlotinib|Induction Treatment:
Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.
Combined Modality Treatment:
Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy
297430|NCT00392704|Drug|Paclitaxel|Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22
Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy
297431|NCT00392704|Drug|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
297432|NCT00392704|Radiation|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
297433|NCT00392717|Drug|Atorvastatin|
297434|NCT00392717|Drug|Fish oils|
297435|NCT00392730|Dietary Supplement|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
297436|NCT00392743|Procedure|pet/spect scan|
297437|NCT00392756|Drug|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
297438|NCT00395135|Drug|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
297439|NCT00395148|Drug|rHDL|
297440|NCT00395161|Drug|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
297441|NCT00395161|Drug|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants < or equal to one year of age, and 20 mg/day elemental zinc for patients > 1 year of age)
297442|NCT00395161|Dietary Supplement|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
297443|NCT00395161|Drug|Selenium|one enteral dose daily of selenium (40 μg for infants < 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children > 13 years)
296698|NCT00410124|Drug|Placebo|
296699|NCT00410150|Drug|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
296700|NCT00410150|Drug|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
296701|NCT00410163|Drug|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
296702|NCT00003290|Biological|gonadotrophin releasing hormone|
296703|NCT00410163|Drug|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
296704|NCT00410163|Drug|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
296705|NCT00410163|Drug|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
296706|NCT00410176|Behavioral|sanitation and personal hygiene|
296707|NCT00410189|Drug|ZD6474|300 mg by mouth daily for 28 Days.
296708|NCT00413166|Drug|Idarubicin|12 mg/m2 one dose only (may be given on day 1 to 5 of induction)
If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date.
296709|NCT00413179|Drug|Metformin|
297072|NCT00401362|Drug|SC Placebo|
297073|NCT00401362|Drug|SC Methylnaltrexone|Dose 2
297074|NCT00401375|Drug|Methylnaltrexone|Intravenous MNTX
297075|NCT00401375|Drug|Placebo|Intravenous
297076|NCT00401388|Drug|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
297077|NCT00404066|Drug|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
297078|NCT00404066|Drug|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
297079|NCT00404066|Drug|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
296331|NCT02616692|Drug|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
296332|NCT02616718|Radiation|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
296333|NCT02616731|Drug|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
296334|NCT02616731|Drug|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
296335|NCT02616744|Drug|Ibandronic acid|150 mg per month oral ibandronate
296336|NCT02616744|Drug|Placebo|1 oral capsule of placebo per month
296337|NCT02616757|Device|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
296338|NCT00193154|Drug|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
296339|NCT02616770|Drug|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
296340|NCT02616770|Drug|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
296341|NCT02616770|Drug|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
296342|NCT02619097|Drug|Pegol-sihematide injection|single dose
296343|NCT02619110|Other|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
296344|NCT02619110|Other|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
296345|NCT00193297|Drug|Topotecan|
296346|NCT02619123|Other|Tailored screening according to breast density|Different interval of mammography screening according to breast density
296347|NCT02619123|Other|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
296348|NCT02619136|Procedure|Transfusion|Red Blood Cell Transfusion
296349|NCT02619149|Drug|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
295730|NCT02625402|Behavioral|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
295731|NCT02625402|Behavioral|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
295732|NCT00000375|Behavioral|Continuation ECT|
295733|NCT00002524|Drug|Cyclophosphamide|
295734|NCT00193869|Drug|Dexamethasone|
295735|NCT02627534|Procedure|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
295736|NCT02627547|Behavioral|Normal training|5-10 hours of endurance training each week
295737|NCT02627547|Behavioral|De-training|No training
295738|NCT02627560|Drug|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
295739|NCT02627560|Drug|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
295740|NCT02627573|Procedure|Unrelated allogeneic stem cell transplantation|
295741|NCT02627573|Drug|Busulfan|
296027|NCT02621268|Drug|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
296028|NCT02621281|Device|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
296029|NCT02621281|Device|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
296030|NCT02621294|Other|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-[1-13C] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
296031|NCT00193453|Drug|Docetaxel|30mg/m2, 30min IV, day 1 & 8
296032|NCT02621307|Dietary Supplement|Salba|
296033|NCT02621307|Dietary Supplement|Flax|
295430|NCT02631837|Procedure|vNOTES hysterectomy|Surgical removal of the womb by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
295431|NCT02631837|Procedure|LSC hysterectomy|Surgical removal of the womb by transabdominal laparoscopy
295432|NCT00194753|Drug|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
295433|NCT02631850|Behavioral|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
295434|NCT02631850|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
295435|NCT02631850|Behavioral|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
295436|NCT02631850|Behavioral|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
295437|NCT02631863|Drug|Aminolaevulinic acid|Aminolaevulinic acid with illumination
295438|NCT02631863|Drug|Placebo|Placebo with illumination
295439|NCT02631876|Drug|IMGN853|
295440|NCT02631876|Drug|Paclitaxel|
295441|NCT02631876|Drug|Doxorubicin|
295442|NCT02631876|Drug|Gemcitabine|
295443|NCT00194753|Drug|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
295444|NCT02634060|Device|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
295445|NCT02634073|Drug|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
295446|NCT02634073|Drug|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
295447|NCT02634099|Device|blood measurement|Hemoglobin measurement
295448|NCT02634099|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
295449|NCT02634099|Device|hemoCue|non invasive method of hemoglobin measurement
295450|NCT00194870|Procedure|computer-assisted analysis of the digitally-recorded EEG signals|computer-assisted analysis of the digitally-recorded EEG signals
294820|NCT02643264|Other|Sham rTMS|Sham stimulation with the same regimen as active treatment
294821|NCT02645123|Device|Transcutaneous electrical nerve stimulation|Enraf-Nonius Sonopuls 692
294822|NCT02645123|Procedure|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
294823|NCT02645123|Procedure|swedish type massage|petrissage, effleurage, tapotement
294824|NCT00196183|Procedure|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
294825|NCT02645123|Procedure|muscle stretching|static hamstring stretching
294826|NCT02645123|Procedure|sham treatment|touching of the skin overlying the lumbar area
294827|NCT02645136|Other|Pilates|Pilates exercises
294828|NCT02645136|Other|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
294829|NCT02645136|Other|Control|
295126|NCT02638571|Other|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
295127|NCT02638584|Drug|Ilaprazole|Ilaprazole 10mg 2tablets QD(1 times / day), before breakfast
295128|NCT02638584|Drug|Rabeprazole|Rabeprazole 20mg 1tablets QD(1 times / day), before breakfast
295129|NCT02638597|Drug|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
295130|NCT02638597|Behavioral|smoking cessation counseling|smoking cessation counseling
295131|NCT02638610|Device|Cochet-Bonnet aesthesiometer|The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.
This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface.
295132|NCT02638623|Procedure|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
295133|NCT00195416|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
295134|NCT02638623|Procedure|Placebo|No additional fluids will be administered
294217|NCT02618226|Device|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
294517|NCT02613741|Other|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
294518|NCT02613754|Behavioral|Contingency Management|See arm description.
294519|NCT02613754|Behavioral|Treatment as Usual|See arm description
294520|NCT02613767|Other|Protein meal|Ingestion of protein
294521|NCT02613767|Other|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
294522|NCT02613780|Procedure|Crosslinking|corneal collagen crosslinking with riboflavin
294523|NCT02613780|Procedure|Photorefractive keratectomy|
294524|NCT02613780|Device|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
294525|NCT02613806|Drug|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
294526|NCT02613806|Drug|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
294527|NCT00192842|Drug|curcumin (+ gemcitabine)|
294528|NCT02613819|Radiation|SABR|Renal cell carcinoma (RCC) is conventionally considered "radioresistant" to fully fractionated EBRT. In an effort to overcome the perceived "radioresistance" of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy.
294529|NCT02613832|Other|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
294530|NCT02613832|Other|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
294531|NCT02613845|Other|no intervention|
296872|NCT00381290|Behavioral|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
296873|NCT00381303|Drug|darunavir|600mg bid for 48 wks
296874|NCT00381303|Drug|ritonavir|100mg bid for 48 wks
296875|NCT00381316|Drug|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
296876|NCT00003151|Drug|tetracycline hydrochloride|
296877|NCT00381316|Drug|Thallous Chloride T1-201|Myoview SPECT Imaging
296878|NCT00003163|Biological|sargramostim|
297246|NCT00372411|Device|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
297247|NCT00372411|Other|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
297248|NCT00372411|Other|Usual Care|The usual chronic stroke care as delivered at each participating medical center
297249|NCT00375427|Drug|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
297250|NCT00375440|Drug|Tranexamic Acid|
297251|NCT00375453|Drug|SH U04722|
297252|NCT00375466|Drug|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
297253|NCT00375466|Drug|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
297254|NCT00003127|Drug|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
297255|NCT00375492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
297256|NCT00375492|Drug|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
296497|NCT00389805|Genetic|protein expression analysis|
296498|NCT00389805|Genetic|reverse transcriptase-polymerase chain reaction|
296499|NCT00389805|Other|flow cytometry|
296500|NCT00389805|Other|immunoenzyme technique|
296501|NCT00389805|Other|immunohistochemistry staining method|
296502|NCT00003205|Drug|bryostatin 1|
296503|NCT00392275|Drug|Ciprofloxacin 0.3%|
296504|NCT00392275|Drug|Levofloxacin 0.5%|
296505|NCT00392275|Drug|Ofloxacin 400mg|
296506|NCT00392275|Drug|Ciprofloxacin 400mg|
296507|NCT00392275|Drug|Levofloxacin 250mg|
296508|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
296509|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
296510|NCT00392288|Drug|Placebo|Placebo MDI over twelve weeks
296511|NCT00392314|Other|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
296512|NCT00392327|Radiation|Radiation Therapy|Undergo radiation therapy
296513|NCT00003206|Drug|carboplatin|
296879|NCT00383669|Dietary Supplement|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
296880|NCT00383682|Drug|morphine and mexiletine|
296881|NCT00383695|Biological|cetuximab|
296882|NCT00383695|Drug|capecitabine|
296883|NCT00383695|Drug|oxaliplatin|
296884|NCT00383695|Procedure|adjuvant therapy|
296885|NCT00383695|Procedure|conventional surgery|
296188|NCT02636725|Procedure|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
296189|NCT02636738|Device|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
296190|NCT02636751|Behavioral|12-week rehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
296191|NCT02636751|Device|Walking aid adjustment|Walking aid adjustment
296192|NCT00195208|Drug|Pantoprazole for approximately 9 weeks|
296193|NCT02636751|Behavioral|Information about pain control|General information about pain control, such as ice application and medication usage
296194|NCT02636764|Other|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
296195|NCT02638935|Device|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
296196|NCT02638948|Drug|BMS-986142|
296197|NCT02638948|Drug|Placebo|
296198|NCT02638948|Drug|Methotrexate|
296199|NCT02638961|Other|IMT|Patients allocated to IMT arm will recieve standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
296200|NCT02638961|Other|FES|Patients allocated to FES arm will recieve standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
296514|NCT00392327|Drug|Vincristine Sulfate|Given IV
296515|NCT00392327|Drug|Carboplatin|Given IV
296516|NCT00392327|Drug|Cisplatin|Given IV
295266|NCT02616198|Other|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
295267|NCT02616198|Other|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
295268|NCT00193128|Drug|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
295562|NCT02645487|Radiation|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size <= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy >1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy >2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy >3-4cm: 15 Gy; + 3 Gy incremental escalation up to 21 Gy
295563|NCT02645500|Behavioral|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
295564|NCT02645500|Behavioral|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
295565|NCT02645513|Behavioral|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
295566|NCT02645513|Behavioral|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
295567|NCT02645513|Behavioral|Control|No text message reminders
295568|NCT02645526|Other|Woolen cap|
295569|NCT02611843|Behavioral|Peer-Supported Web CBT|
295570|NCT02611843|Behavioral|Self-Managed Web CBT|
295571|NCT02611869|Procedure|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
295572|NCT02611869|Procedure|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
295573|NCT02611882|Drug|Ga-68 labeled HBED-CC PSMA PET imaging|Patients will be imaged using Ga-68-HBED-CC-PSMA PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
295574|NCT00192660|Drug|Lamivudine|
294635|NCT02627144|Drug|Avastin|Avastin will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
294636|NCT02627144|Drug|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
294637|NCT02627157|Device|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
294638|NCT02627170|Device|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
294639|NCT02627183|Procedure|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
294640|NCT02627183|Behavioral|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
294641|NCT02627196|Device|Barostim Neo System|
294642|NCT00194064|Drug|Olanzapine|
294643|NCT02627209|Other|spectrophotometric assay|measurement of enzyme activity in the serum
294944|NCT02620787|Procedure|Microdiaylsis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
294945|NCT02620800|Drug|5FU|5 fluorouracil (5-FU) (180 mg/m^2/day for 14 days) by CIVI via ambulatory pump
294946|NCT02620800|Drug|nab-paclitaxel|nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
294947|NCT02620800|Drug|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
294948|NCT02620800|Drug|calcium leucovorin|calcium leucovorin (20 mg/m^2) IV bolus, on Days 1, 8, 15
294949|NCT02620800|Drug|oxaliplatin|oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15
294950|NCT02620813|Drug|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
294951|NCT02620813|Drug|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
294952|NCT00002523|Drug|fluorouracil|
294953|NCT00193427|Drug|Carboplatin|AUC = 1.5 weekly x 7
294038|NCT02635711|Behavioral|Control|Daily jogging
294039|NCT02635724|Drug|Peramivir|
294040|NCT00195078|Drug|ZD1839 (IRESSA)|
294041|NCT02635737|Device|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
294042|NCT02635750|Drug|BI 409306|
294043|NCT02635750|Drug|Donepezil|
294044|NCT02635763|Procedure|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
294045|NCT02635763|Procedure|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
294046|NCT02635776|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
294047|NCT02635776|Biological|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
294048|NCT02635789|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
294049|NCT02635789|Drug|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
294050|NCT02635802|Drug|Remifentanil|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time ＞1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.
Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min.
294051|NCT00195078|Drug|Cisplatin|
294052|NCT02635802|Drug|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
294053|NCT02635802|Drug|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time ＞1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
294330|NCT02631447|Drug|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
294331|NCT02631460|Drug|S1 80-120 mg/d|d1, every 3 weeks
298910|NCT00404963|Drug|GSK376501|
298911|NCT00405002|Procedure|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
298912|NCT00003267|Procedure|surgical procedure|
298913|NCT00405015|Drug|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
293775|NCT02640456|Biological|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
293776|NCT02640456|Procedure|Type of surgery|Surgical approach and complications.
293777|NCT02640456|Biological|Biochemistry|Amylase concentration i pus aspirates.
293778|NCT02640456|Biological|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
293779|NCT02642666|Behavioral|Children's Yoga|Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are "ocean yoga adventure", "jungle yoga adventure" and "outer space yoga adventure". The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme.
293780|NCT02642679|Device|Opticell Ag|
293781|NCT02642692|Procedure|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
293782|NCT02642692|Procedure|Hamstring Graft|Acl reconstruction with hamstring graft
293783|NCT02642705|Other|High intensity interval training N|Exercise training and ambient air breathing
293784|NCT02642705|Other|High intensity interval training H|Exercise training and hypoxic breathing
293785|NCT02642705|Other|Constant load exercise training N|Exercise training and ambient air breathing
293786|NCT02642705|Other|Constant load exercise training H|Exercise training and hypoxic breathing
293787|NCT00195871|Drug|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
293788|NCT02642705|Other|Hypoxic conditioning at rest|Hypoxic breathing at rest
293789|NCT02642705|Other|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
293790|NCT02642718|Drug|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
298558|NCT00366392|Device|Optical Aids|
298559|NCT00366418|Drug|Rituximab|
298560|NCT00366431|Drug|MOA-728|
298561|NCT00366444|Drug|diclofenac potassium (XP21L)|25 mg every 6 hours
298562|NCT00003088|Drug|cyclophosphamide|given IV
298563|NCT00366444|Drug|Placebo|Placebo every 6 hours
298564|NCT00369551|Biological|bevacizumab|Given IV
298565|NCT00369551|Drug|carboplatin|Given IV
298566|NCT00369551|Other|laboratory biomarker analysis|Correlative studies
298567|NCT00003101|Procedure|autologous bone marrow transplantation|
298568|NCT00369564|Drug|glutamic acid|Given orally 3 times daily
298914|NCT00405041|Dietary Supplement|Dietary supplement GVG 2|2.670 g/day for 14 days
298915|NCT00405054|Drug|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
298916|NCT00405067|Drug|BMS-201038 (AEGR-733)|
298917|NCT00405067|Drug|Ezetimibe|
298918|NCT00405080|Drug|GW679769 (Casopitant) oral tablets|
298919|NCT00408005|Drug|Doxorubicin Hydrochloride|Given IV
298920|NCT00408005|Other|Laboratory Biomarker Analysis|Correlative studies
298921|NCT00408005|Drug|Leucovorin Calcium|Given PO
298922|NCT00408005|Drug|Mercaptopurine|Given PO
298923|NCT00408005|Drug|Methotrexate|Given IT or PO
298924|NCT00000504|Drug|imipramine|
298925|NCT00003278|Radiation|radiation therapy|
298926|NCT00408005|Drug|Nelarabine|Given IV
298927|NCT00408005|Drug|Pegaspargase|Given IM or IV
298177|NCT00376077|Drug|Methylprednisolone and IVIG|Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
298178|NCT00376077|Drug|Placebo and IVIG|Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
298179|NCT00376090|Biological|MVA-CMDR|10^7 PFU IM, 1.0 mL
298180|NCT00376090|Biological|Placebo|1.0 mL IM
298181|NCT00003131|Drug|chemotherapy|
298182|NCT00378820|Behavioral|Whey with milk minerals|
298183|NCT00378820|Behavioral|Casein without milk minerals|
298184|NCT00003143|Drug|Amifostine|
298185|NCT00378820|Behavioral|Casein with milk minerals|
298186|NCT00378833|Drug|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
298187|NCT00378833|Drug|niacin|Duration of Treatment: 18 Weeks
298188|NCT00378846|Procedure|infrared thermography|
298189|NCT00378859|Behavioral|Skim milk|
298190|NCT00378859|Behavioral|Lean meat|
298191|NCT00378872|Drug|IV Tranexamic acid 10mg/kg pt body weight|
298192|NCT00378872|Drug|Quixil topical sealant|
298193|NCT00378885|Behavioral|Cognitive-behavioral tailored intervention|
298194|NCT00378898|Device|Bravo PH capsule|standard of care egd with bravo placement
298195|NCT00003143|Drug|DHAP|
298196|NCT00378898|Procedure|Fluoroscopy|one time "xray" to determine evacuation of bravo
298197|NCT00378911|Drug|sunitinib malate|Given orally
298569|NCT00369564|Other|placebo|Given orally 3 times daily
298570|NCT00369577|Drug|Loxapine thermal aerosol|
298571|NCT00369590|Biological|ziv-aflibercept|Given IV
297444|NCT00395161|Other|saline|equivalent volume of intravenous saline
297445|NCT00395161|Other|sterile water|equivalent volume of sterile water
297446|NCT00003215|Drug|mitoxantrone hydrochloride|
297447|NCT00395161|Other|selenium|equivalent volume of sterile water
297448|NCT00395161|Dietary Supplement|whey-protein|one enteral dose daily of whey-protein
297449|NCT00395174|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
297806|NCT00003185|Biological|tumor-draining lymph node lymphocyte therapy|
297807|NCT00387322|Drug|erlotinib hydrochloride|Given orally
297808|NCT00387322|Drug|pemetrexed disodium|Given IV
297809|NCT00387335|Drug|sunitinib malate|Given orally
297810|NCT00387348|Drug|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
297811|NCT00387348|Drug|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
297812|NCT00387361|Procedure|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
297813|NCT00387374|Biological|bevacizumab|Given IV
297814|NCT00387374|Drug|paclitaxel|Given IV
297815|NCT00387374|Drug|carboplatin|Given IV
297816|NCT00387374|Radiation|radiation therapy|Undergo radiotherapy
297817|NCT00000495|Behavioral|diet, reducing|
297818|NCT00003185|Drug|cyclophosphamide|
297819|NCT00387387|Drug|pazopanib|
297820|NCT00387400|Drug|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
297821|NCT00387400|Drug|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
297822|NCT00387400|Genetic|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
297080|NCT00404066|Drug|pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
297081|NCT00404066|Drug|filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
297082|NCT00404066|Drug|dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
297083|NCT00003262|Drug|vinblastine sulfate|
297084|NCT00404066|Drug|trastuzumab|loading: 8 mg/kg/then 6 mg/kg, intravenous every 3 weeks for 1 year
297085|NCT00404079|Drug|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
297086|NCT00404079|Drug|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
297087|NCT00404092|Drug|caspofungin|i.v.
297088|NCT00404105|Procedure|PRK|
297089|NCT00404105|Procedure|LASIK|
297090|NCT00404131|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
297091|NCT00404144|Device|Drug Eluting Balloon|PCI of small vessels single arm study
297092|NCT00404157|Drug|Rituximab|
297093|NCT00404170|Drug|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
297094|NCT00003262|Drug|vincristine sulfate|
297095|NCT00404183|Drug|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
297096|NCT00404183|Drug|Placebo|2 tablets BID
297450|NCT00395187|Procedure|Photodynamic Therapy|
297451|NCT00395200|Procedure|MSC Treatment|Intravenous administration of up to 2x10^6 autologous MSCs per kg
297452|NCT00395213|Drug|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
297453|NCT00395226|Drug|zinc sulfate|zinc sulfate 220 mg bis for 90 days
297454|NCT00395226|Drug|placebo|placebo bid for 90 days
297455|NCT00395239|Drug|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
296350|NCT02619149|Drug|Saline solution|Saline iv as placebo control
296351|NCT02619162|Drug|Nintedanib|Tablets of 100 mg. or 150 mg.
296352|NCT02619162|Drug|Letrozole|Tablet of 2.5 mg.
296710|NCT00003309|Drug|cyclophosphamide|
296711|NCT00413179|Drug|Clomiphene citrate|
296712|NCT00413179|Drug|Placebo|
296713|NCT00413192|Drug|E7389|1.4 mg/m^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
296714|NCT00413205|Drug|Placebo|po daily
296715|NCT00413205|Drug|RAR Gamma|5mg po daily
296716|NCT00413218|Drug|Isavuconazole|Drug treatment
296717|NCT00413218|Drug|Caspofungin|Drug treatment
296718|NCT00413218|Drug|Voriconazole|Drug Treatment
296719|NCT00413231|Device|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
296720|NCT00413244|Drug|AndroGel 5 Grams|Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.
Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
296721|NCT00003309|Drug|etoposide|
296722|NCT00413244|Drug|Placebo|Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.
Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
296723|NCT00413257|Drug|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
296724|NCT00413257|Drug|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
296725|NCT00413257|Drug|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
296726|NCT00413270|Drug|nilotinib|
296034|NCT02621307|Dietary Supplement|Control|
296035|NCT02621320|Dietary Supplement|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
296036|NCT02621320|Dietary Supplement|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
296037|NCT02623270|Device|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
296038|NCT02623283|Other|No intervention given|Participants will have a full dental examination but no operative intervention
296039|NCT02623296|Drug|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
296040|NCT00193596|Drug|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
296041|NCT02623296|Drug|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
296042|NCT02623296|Drug|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
296043|NCT02623309|Procedure|Allogeneic (Allo) hematopoietic stem cell transplantation|
296044|NCT02623322|Drug|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
296045|NCT02623322|Drug|Placebo|Placebo will be administered as a single dose by IV administration.
296046|NCT02623335|Other|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
296353|NCT02619175|Device|BalanceTutor|
296354|NCT02619188|Other|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
296355|NCT02619188|Other|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
296356|NCT00193297|Drug|Paclitaxel|
296357|NCT02619188|Other|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
296358|NCT02619188|Other|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
296359|NCT02619201|Drug|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
295451|NCT02634138|Device|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
295742|NCT00002524|Drug|Etoposide|
295743|NCT00194116|Drug|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
295744|NCT02627573|Drug|Fludarabine monophosphate|
295745|NCT02627573|Drug|Tacrolimus|
295746|NCT02627573|Drug|Mycophenolate mofetil|
295747|NCT02627573|Drug|Cyclophosphamide|
295748|NCT02627573|Drug|Thymoglobulin|
295749|NCT02627586|Other|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
295750|NCT02627586|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
295751|NCT02627599|Device|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
295752|NCT02627612|Behavioral|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
295753|NCT02627612|Behavioral|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
295754|NCT00194116|Drug|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
295755|NCT02629835|Other|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
295756|NCT02629835|Other|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
295757|NCT02629848|Drug|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
295135|NCT02638636|Behavioral|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
295136|NCT02638649|Procedure|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
295137|NCT02638649|Device|ultrasound|
295138|NCT02638662|Other|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
295139|NCT02640963|Other|Control|to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
295140|NCT02640976|Drug|Human menopausal gonadotrophin (HMG)|[Merional® 75 IU ampoules, IBSA institut]
295141|NCT00195663|Biological|Adalimumab placebo|
295142|NCT02640976|Drug|GnRH antagonist Cetrorelix|[Cetrotide® 0.25 mg syringes, Merck Serono]
295143|NCT02640976|Drug|Human chorionic gonadotrophin (hCG)|[Choriomon® 5000 IU ampoules, IBSA institut]
295452|NCT02634151|Drug|Gemcabene 300 mg|1-300 mg table, QD, 84 days
295453|NCT02634151|Drug|Gemcabene 600 mg|2-300 mg tablets, QD, 84 days
295454|NCT02634151|Drug|Gemcabene 900 mg|3-300 mg tablets, QD, 84 days
295455|NCT02634151|Drug|Placebo|Placebo, QD, 84 days
295456|NCT02634164|Dietary Supplement|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
295457|NCT02634164|Dietary Supplement|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
295458|NCT02634164|Dietary Supplement|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
294532|NCT02613871|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
294533|NCT02613884|Drug|Treatment|
294534|NCT02613897|Drug|Saxagliptin|Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
294830|NCT02645149|Drug|Standard therapy or clinical trial|Patients with BRAF V600 and NRAS mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
294831|NCT02645149|Drug|Matched targeted therapy|Patients with tumour found to be BRAF and NRAS wild type will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for BRAF / NRAS wild type melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour as listed above.
294832|NCT02645149|Drug|Trametinib and / or supportive care|Patients with BRAF and NRAS wild type tumour for whom there is no actionable genetic aberration in tumour tissue following extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
294833|NCT02645162|Behavioral|Community-based Preschool|Preschool sessions in community-based preschool
Run by trained community youth leaders from the same village.
294834|NCT02645175|Dietary Supplement|TW1025 (LinEase®)|20ml, 3 times per day (daily dose: 60 ml)
294835|NCT00196196|Device|Codman VPV System|Valve Positioning Verification (VPV) System
294836|NCT02645175|Dietary Supplement|Placebo|20ml, 3 times per day (daily dose: 60 ml)
294837|NCT02645188|Other|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
294838|NCT02645201|Dietary Supplement|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
294839|NCT02645201|Other|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
294840|NCT02645214|Other|Non-antiseptic scrubs|
294841|NCT02645214|Other|Antiseptic scrubs|
294842|NCT02645227|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
294843|NCT02645227|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
294844|NCT02645227|Procedure|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
294845|NCT02645240|Drug|Heparin injection|Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
297257|NCT00375505|Drug|Zoledronic acid|
297258|NCT00375505|Drug|Placebo|Placebo
297259|NCT00375518|Drug|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
297260|NCT00375518|Drug|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
297261|NCT00375531|Behavioral|Mindfulness Meditation (MfM)|
297262|NCT00375544|Device|Low level light therapy|
297263|NCT00375557|Drug|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
297264|NCT00375557|Drug|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
297620|NCT00002845|Biological|aldesleukin|
297621|NCT00312156|Drug|insulin aspart|
297622|NCT00312182|Drug|Nelfinavir|
297623|NCT00312195|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
297624|NCT00312195|Drug|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
297625|NCT00312208|Drug|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
297626|NCT00312208|Drug|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
297627|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
297628|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
297629|NCT00312221|Drug|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
297630|NCT00312234|Behavioral|Aerobic exercise|
297631|NCT00002846|Biological|aldesleukin|
296886|NCT00383695|Procedure|neoadjuvant therapy|
296887|NCT00383695|Radiation|radiation therapy|
296888|NCT00383708|Drug|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
296889|NCT00003163|Drug|cyclophosphamide|
296890|NCT00383708|Drug|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
296891|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
296892|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
296893|NCT00383721|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
296894|NCT00383721|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
296895|NCT00383721|Drug|Placebo|Placebo MDI twice a day for 26 weeks
296896|NCT00383734|Device|Newfill|1 to 7 injections of drug
296897|NCT00383734|Device|Eutrophill|1 to 7 injections of drug
296898|NCT00383747|Device|transdermal nicotine patch|14mg transdermal nicotine application
296899|NCT00383747|Device|Transdermal Nicotine Patch|14mg transdermal nicotine application
296900|NCT00003163|Drug|melphalan|
296901|NCT00383760|Drug|eribulin mesylate|Given IV
296902|NCT00383773|Procedure|Retinal endo vascular surgery|
296903|NCT00383786|Drug|NK1 Antagoist (GR205171)|
297265|NCT00003127|Drug|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
297266|NCT00375570|Drug|ME-609|Topical treatment 5 times daily for 5 days
297267|NCT00375583|Drug|DEC/Albendazole|
297268|NCT00375596|Drug|Ketotifen/vasoconstrictor|
297269|NCT00375609|Drug|PRT054021|
296517|NCT00392327|Drug|Cyclophosphamide|Given IV
296518|NCT00392327|Biological|Filgrastim|Given IV or SC
296519|NCT00392327|Drug|Isotretinoin|Given PO
296520|NCT00392327|Other|Laboratory Biomarker Analysis|Correlative studies
296521|NCT00392327|Other|Quality-of-Life Assessment|Ancillary studies
296522|NCT00392340|Biological|filgrastim|
296523|NCT00392340|Drug|doxorubicin hydrochloride|
296524|NCT00003206|Drug|paclitaxel|
296525|NCT00392340|Drug|topotecan hydrochloride|
296526|NCT00392340|Drug|vincristine sulfate|
296527|NCT00392353|Drug|Azacitidine|Given SC
296528|NCT00392353|Other|Laboratory Biomarker Analysis|Correlative studies
296529|NCT00392353|Other|Pharmacological Study|Correlative studies
296530|NCT00392353|Drug|Vorinostat|Given PO
296531|NCT00392366|Device|MR-guided Laser Interstitial Thermal Therapy System|
296532|NCT00392379|Drug|Nicotine Lozenges|Nicotine lozenges, 4 mg
296533|NCT00392379|Drug|Placebo lozenge|Placebo lozenge
296534|NCT00392392|Drug|nab-paclitaxel|ABI-007
296535|NCT00003207|Drug|pegylated liposomal doxorubicin hydrochloride|
296536|NCT00394771|Drug|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
296537|NCT00394771|Drug|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
296538|NCT00394771|Drug|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
296539|NCT00394797|Procedure|mitral valve annuloplasty|
295575|NCT02611895|Biological|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
295576|NCT02611908|Drug|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
295577|NCT02611908|Drug|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
295578|NCT02611921|Drug|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver.
295579|NCT02611921|Drug|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver.
295869|NCT02641353|Drug|Apremilast|30 mg tablet
295870|NCT02641353|Drug|Apremilast Oral Suspension|30 mg oral suspension
295871|NCT02641366|Device|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
295872|NCT02641366|Procedure|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
295873|NCT02641366|Procedure|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
295874|NCT02641379|Drug|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\n
295875|NCT02641379|Drug|Ribavirin|Ribavirin is available as 200 mg tablets
295876|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
295877|NCT02641392|Drug|GED-0301|
295878|NCT02641392|Other|Placebo|
295879|NCT02641405|Device|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
295880|NCT02641405|Device|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
295881|NCT02641418|Other|Supervised exercise programme|supervised exercise programme
295882|NCT00196066|Device|Peripheral Vessel Stenting|
294954|NCT02620826|Procedure|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
294955|NCT02620826|Procedure|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
294956|NCT02620839|Drug|Alpelisib|
294957|NCT02620839|Drug|Cisplatin|
294958|NCT02620852|Other|Complete a health questionnaire|Complete a health history questionnaire.
294959|NCT02622802|Drug|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
294960|NCT02622802|Drug|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
294961|NCT02622802|Drug|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
294962|NCT02622828|Behavioral|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
294963|NCT02622841|Procedure|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
294964|NCT00002523|Radiation|radiation therapy|
294965|NCT00193557|Drug|Bortezomib|
295269|NCT02616224|Other|No intervention|No intervention was administered in this study.
295270|NCT02616237|Behavioral|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
295271|NCT02616250|Drug|Brimonidine 0.33% gel (Br)|
295272|NCT02616250|Other|CD07805/47 (Br) placebo gel|
295273|NCT02616250|Drug|Ivermectin 1% cream (IVM)|
295274|NCT02616250|Other|CD5024 (IVM) placebo cream|
295275|NCT02616263|Other|Foot exercise|
295276|NCT02616263|Other|Shoulder exercise|
295277|NCT02616276|Other|Control breakfast|It consists of 350 ml of water at room temperature.
294332|NCT02631460|Drug|pemetrexed 500 mg/m2|d1, every 3 weeks
294333|NCT02631460|Drug|carboplatin AUC=5|d1, every 3 weeks
294334|NCT02631473|Drug|50mg NANO-efavirenz|OD
294335|NCT00194727|Drug|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
294336|NCT02631473|Drug|400mg NANO-Lopinavir|BID
294337|NCT02631473|Drug|200mg NANO-Lopinavir|BID
294338|NCT02631473|Drug|100mg Norvir|BID
294339|NCT02631473|Drug|600mg Sustiva|OD
294340|NCT02631473|Drug|50-550mg TBC NANO-Efavirenz|OD
294341|NCT02631473|Drug|400mg Sustiva|OD
294342|NCT02631473|Drug|(Lopinavir400mg/Ritonavir100mg) Kaletra|BID
294343|NCT02631473|Drug|100-400mg TBC NANO-Lopinavir|BID
294344|NCT02631473|Drug|25-100mg TBC Norvir|BID
294345|NCT02631486|Other|Physiotherapy|Passive exercises, active exercises, strengthening, stretching
294346|NCT00194727|Drug|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
294347|NCT02631499|Procedure|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
294348|NCT02631499|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
294349|NCT02631499|Drug|lipiodol|lipiodol is a kind of embolization material used in TACE
294350|NCT02631512|Device|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
294351|NCT02631512|Device|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
294352|NCT02631525|Drug|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
294353|NCT02631525|Drug|Propofol|Total intravenous anesthesia based on propofol
294354|NCT02633605|Device|First Sense Medical®|
293791|NCT02642718|Other|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
293792|NCT02642744|Other|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
293793|NCT02642757|Behavioral|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
293794|NCT02642757|Other|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group)
294054|NCT02635802|Drug|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
294055|NCT02635815|Procedure|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
294056|NCT02638142|Drug|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
294057|NCT00002526|Biological|filgrastim|
294058|NCT00195338|Drug|etanercept|
294059|NCT02638142|Drug|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
294060|NCT02638168|Drug|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
294061|NCT02638168|Drug|Placebo|inert placebo ingredient
294062|NCT02638181|Procedure|trabeculectomy|
294063|NCT02638194|Other|Active smoking of Tobacco Hookah for 2 hours|
294064|NCT02638194|Other|Exposure to tobacco hookah second hand smoke|
294065|NCT02638194|Other|Visit a win bar|Participants will visit a wine bar for food and/or drinks
294066|NCT02638207|Drug|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days) followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam) also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
294067|NCT02638233|Drug|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
298928|NCT00408005|Drug|Prednisone|Given IV or PO
298929|NCT00408005|Radiation|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
298930|NCT00408005|Drug|Thioguanine|Given PO
298931|NCT00408005|Drug|Vincristine Sulfate|Given IV
298932|NCT00408018|Drug|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
298933|NCT00408031|Drug|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
298934|NCT00408044|Procedure|cardiac surgery with sternotomy|
298935|NCT00408057|Other|no intervention|no intervenion
298936|NCT00003279|Biological|BCG vaccine|
298937|NCT00408070|Drug|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
298938|NCT00408070|Drug|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
298939|NCT00408070|Drug|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
298940|NCT00408083|Drug|MultiHance|0.5 mmol/kg as a single dose administration
293795|NCT02642770|Device|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
293796|NCT02642783|Behavioral|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
293797|NCT02642783|Behavioral|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
293798|NCT00195871|Procedure|hematopoietic stem cell allograft|conventional procedures
293799|NCT02642796|Device|transcutaneous electric nerve stimulation|The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.
Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound.
293800|NCT02642809|Drug|Pembrolizumab|
293801|NCT02644811|Drug|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
298572|NCT00369590|Other|pharmacological study|correlative studies
298573|NCT00369590|Other|laboratory biomarker analysis|correlative studies
298574|NCT00369603|Drug|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
298575|NCT00369603|Drug|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
298576|NCT00369616|Biological|CYT002-NicQb|
298577|NCT00369629|Drug|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m^2.
298578|NCT00003101|Procedure|peripheral blood stem cell transplantation|
298579|NCT00369629|Drug|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m^2.
298580|NCT00369642|Behavioral|Cognitive-behavioral therapy|
298581|NCT00369655|Biological|ziv-aflibercept|
298582|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
298583|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
298584|NCT00369668|Behavioral|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
298585|NCT00369681|Biological|bleomycin|
298586|NCT00369681|Biological|rituximab|
298587|NCT00369681|Drug|ABVD regimen|
298588|NCT00369681|Drug|dacarbazine|
298589|NCT00003102|Radiation|iodine I 131 chimeric monoclonal antibody G-250|
298941|NCT00408083|Drug|Magnevist|0.5 mmol/kg as a single dose administration
297823|NCT00387400|Other|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
297824|NCT00387413|Drug|Duloxetine|
297825|NCT00387413|Drug|GSK189254|
297826|NCT00387426|Drug|sunitinib malate|Given PO
297827|NCT00387439|Behavioral|standard medical treatment + anoperineal physiotherapy.|
297828|NCT00387439|Behavioral|Standard medical treatment|
297829|NCT00003185|Procedure|conventional surgery|
298198|NCT00378937|Drug|acetaminophen|
298199|NCT00378937|Drug|codeine phosphate|
298200|NCT00378937|Drug|dextropropoxyphene hydrochloride|
298201|NCT00378937|Drug|morphine sulfate|
298202|NCT00378937|Drug|oxycodone hydrochloride|
298203|NCT00378937|Procedure|management of therapy complications|
298204|NCT00378937|Procedure|quality-of-life assessment|
298205|NCT00378950|Behavioral|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
298206|NCT00003144|Drug|amifostine trihydrate|
298207|NCT00378950|Behavioral|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
298208|NCT00378963|Device|ProAdjuster|
298209|NCT00378976|Drug|valacyclovir|500 mg twice-daily oral
298210|NCT00378976|Drug|matching placebo|twice daily as per experimental drug
298211|NCT00378989|Behavioral|Consultation at the occupational health services|Consultation at the occupational health services
298212|NCT00379015|Biological|trastuzumab|
297456|NCT00395252|Drug|Cetuximab (Erbitux®) and Gemcitabine|Cetuximab:
Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)
Gemcitabine:
1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered
Mode of administration:
Intravenous infusion
297457|NCT00003215|Drug|prednisone|
297458|NCT00395291|Drug|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
297459|NCT00395291|Drug|Placebo|Placebo
297460|NCT00395304|Drug|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
297461|NCT00395304|Drug|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
297462|NCT00395304|Drug|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
297463|NCT00395317|Other|Placebo|placebo tablet
297464|NCT00395317|Drug|Firategrast 150 mg|150 mg tablet
297465|NCT00003231|Drug|docetaxel|
297466|NCT00398398|Drug|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
297467|NCT00398411|Drug|moxifloxacin|400 mg p.o. per day
297468|NCT00398411|Drug|placebo|one tablet per day p.o.
297469|NCT00398424|Drug|S-1/Cisplatin|PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.
On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.
Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.
297470|NCT00398437|Biological|trastuzumab|
297830|NCT00387452|Behavioral|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
297831|NCT00387452|Behavioral|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
297832|NCT00387465|Drug|Azacitidine|Given SC
296727|NCT00413283|Biological|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
296728|NCT00413283|Drug|Placebo|Placebo subcutaneous injection.
296729|NCT00413283|Drug|Gemcitabine|Intravenous infusion
296730|NCT00413283|Drug|Carboplatin|Intravenous infusion
296731|NCT00413283|Drug|Cisplatin|Intravenous infusion
296732|NCT00003309|Drug|vincristine sulfate|
297097|NCT00404196|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
297098|NCT00404209|Procedure|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
297099|NCT00404222|Drug|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
297100|NCT00404222|Drug|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
297101|NCT00404222|Drug|Placebo|q 4 hours x 3
297102|NCT00404235|Drug|carboplatin|
297103|NCT00404235|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
297104|NCT00404248|Drug|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
297105|NCT00003263|Biological|recombinant interferon alfa|vaccine
297106|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (120 Units)|incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (120 Units)
297107|NCT00407030|Drug|Placebo|Placebo
297108|NCT00003273|Drug|thiotepa|
297109|NCT00407043|Drug|Lotemax|
297110|NCT00407043|Drug|Restasis|
297111|NCT00407056|Drug|Difluprednate Ophthalmic Emulsion|
297112|NCT00407082|Drug|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
297113|NCT00407082|Drug|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
296360|NCT02619201|Drug|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
296361|NCT02619214|Drug|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
296362|NCT02619214|Drug|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
296363|NCT02619227|Other|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
296364|NCT02619240|Procedure|bronchoscopy|performance of bronchoscopy with BAL
296365|NCT02619253|Drug|Pembrolizumab|
296366|NCT02619253|Drug|Vorinostat|
296367|NCT00193297|Drug|Carboplatin|
296368|NCT02619266|Other|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
296369|NCT02619266|Other|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
296370|NCT02621333|Biological|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
296371|NCT02621333|Drug|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
296372|NCT02621346|Behavioral|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
296373|NCT02621346|Behavioral|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
296374|NCT02621346|Behavioral|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
296733|NCT00413296|Drug|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
296734|NCT00368849|Drug|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
296735|NCT00368849|Drug|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
296736|NCT00368862|Drug|Ebixa (memantine hydrochloride)|
295758|NCT00194467|Drug|valganciclovir|900 mg once a day for 8 weeks
295759|NCT02629848|Drug|Placebo|Motesanib placebo-matching tablets
295760|NCT02629848|Drug|Paclitaxel|Paclitaxel IV
296047|NCT02623348|Behavioral|pedometer|pedometer-based physical activity recommendations
296048|NCT02623361|Drug|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
296049|NCT02623361|Drug|Sham Block|Sham Block by saline injection
296050|NCT02623374|Behavioral|self-help CBT intervention (SHCBT)|See 'Arms' section
296051|NCT00193596|Drug|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
296052|NCT02623387|Procedure|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
296053|NCT02623426|Drug|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
296054|NCT02623426|Drug|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Use of frozen methotrexate preparations are permitted if used within 45 days of preparation and freezing and within 8 hours after thawing
296055|NCT02623426|Drug|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
296056|NCT02623439|Drug|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
296057|NCT02623452|Drug|Insulin Lispro|Administered subcutaneously (SC)
296058|NCT02623465|Drug|Insulin Lispro|Administered subcutaneously (SC)
296059|NCT02625415|Device|Vitamin B6 cream|Topical Vitamin B6 cream
296060|NCT02625415|Device|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
296061|NCT02625428|Drug|Optison|
296062|NCT02625441|Drug|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
295459|NCT02634177|Genetic|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
295460|NCT02634177|Other|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
295461|NCT00194883|Drug|Recombinant Human Growth Hormone|
295462|NCT02634190|Other|Thinprep® LBC|liquid based cytology
295463|NCT02634190|Other|APTIMA® HPV Assay|in vitro diagnostic test
295464|NCT02634190|Other|HR HC2® HPV DNA|in vitro diagnostic test
295465|NCT02634190|Other|Colposcopy|Colposcopy
295466|NCT02634203|Procedure|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
295467|NCT02636322|Drug|Lenalidomide|Smart Start: Lenalidomide 25 mg by mouth 1 time every day on Days 1-10 of each 21 day cycle for 2 cycles.
At completion of Smart Start: Lenalidomide 25 mg by mouth 1 time every day on Days 1 - 10 of each 21 day cycle for 6 cycles.
295468|NCT02636322|Drug|Etoposide|At completion of Smart Start: Etoposide 50 mg/m2 by vein on Days 1 - 4 of each 21 day cycle for 6 cycles.
295469|NCT02636322|Drug|Prednisone|At completion of Smart Start: Prednisone 60 mg/m2 by mouth 2 times each day on Days 1 - 5 of each 21 day cycle for 6 cycles.
295470|NCT02636322|Drug|Vincristine|At completion of Smart Start: Vincristine 0.4 mg/m2 by vein on Days 1 - 4 of each 21 day cycle for 6 cycles.
295471|NCT00195143|Genetic|Surgical infusion of AAV-GAD into the subthalamic nucleus|
295761|NCT02629848|Drug|Carboplatin|Carboplatin IV
295762|NCT02629861|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
295763|NCT02629861|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
295764|NCT02629861|Drug|Placebo|Matching Placebo
295765|NCT02629874|Drug|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
295766|NCT02629874|Drug|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
295767|NCT02629874|Drug|Placebo|
294846|NCT02611596|Drug|Ranolazine|24 weeks of the assigned medication
294847|NCT02611596|Drug|Placebo|Placebo for 24 weeks
294848|NCT02611609|Biological|MultiStem|
294849|NCT02611609|Biological|MultiStem|
294850|NCT02611609|Biological|Placebo|
294851|NCT02611622|Behavioral|LUMA ENT™|
295144|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
295145|NCT02640989|Biological|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
295146|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
295147|NCT02641002|Drug|CC-90002|Monoclonal Ab to CD47
295148|NCT02641028|Drug|CERC-501|CERC-501
295149|NCT02641028|Drug|Placebo|Placebo
295150|NCT02641041|Biological|BIIB033|single or multiple dose
295151|NCT02641041|Other|Placebo|single or multiple dose
295152|NCT00195663|Drug|Methotrexate placebo|
295153|NCT02641054|Drug|CVXL-0107|
295154|NCT02641054|Drug|Placebo|
295155|NCT02641054|Drug|Levodopa|
295156|NCT02641067|Drug|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
295157|NCT02641080|Drug|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
295158|NCT02641080|Device|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
295159|NCT02641093|Drug|Pembrolizumab|Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
297632|NCT00312234|Behavioral|Qigong exercise|
297633|NCT00312260|Drug|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
297634|NCT00312260|Drug|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
297635|NCT00312273|Drug|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
297636|NCT00369200|Other|laboratory biomarker analysis|Correlative study
297637|NCT00369200|Other|pharmacological study|Correlative study
297638|NCT00003101|Drug|busulfan|
297639|NCT00369213|Device|Additional spermicidal lubricant to condoms|
297640|NCT00369226|Drug|Bortezomib (Velcade)|Infusion for a total of 3 doses
297641|NCT00369226|Drug|Tacrolimus|Taken until Doctor determines it is not necessary any more
297999|NCT00404547|Drug|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
298000|NCT00404573|Drug|RGH-188|
298001|NCT00404586|Drug|GW784568X|
298002|NCT00404599|Drug|atrorvastatin 10mg|Atorvastatin 10 mg once a day
298003|NCT00404599|Drug|simvastatin 40mg|simvastatin 40mg once a day
298004|NCT00404612|Drug|Placebo|PO BID
298005|NCT00404612|Drug|LX211|0.2 mg/kg, twice a day (BID)
298006|NCT00003264|Drug|gemcitabine hydrochloride|
298007|NCT00404612|Drug|LX211|0.4 mg/kg, twice a day (BID)
298008|NCT00404612|Drug|LX211|0.6 mg/kg, twice a day (BID)
298009|NCT00407550|Drug|gemcitabine HCL|1250 mg/m^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 & 8 of each cycle (21 days) x6 cycles.
298010|NCT00003274|Biological|gp100 antigen|
297270|NCT00375622|Drug|Tamoxifen|
297271|NCT00375635|Procedure|mFPSA treatment|
297272|NCT00375648|Drug|Zoledronic acid|
297273|NCT00375661|Drug|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
297274|NCT00375674|Drug|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
297275|NCT00375674|Other|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
297276|NCT00378365|Procedure|ATRA|ATRA
297277|NCT00378378|Drug|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
297278|NCT00378378|Drug|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
297279|NCT00378404|Drug|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
297280|NCT00378404|Radiation|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
297281|NCT00378417|Biological|7-valent pneumococcal-CRM197 conjugate vaccine|
297282|NCT00378417|Biological|7-valent pneumococcal-OMPC conjugate vaccine|
297283|NCT00378443|Drug|prednisone + Inhibace/Cozaar|
297284|NCT00003141|Drug|etoposide|Given IV
297285|NCT00378443|Drug|Inhibace/Cozaar|
297286|NCT00378456|Drug|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
297287|NCT00378456|Drug|Folinic acid|
297288|NCT00378456|Drug|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
297289|NCT00378456|Drug|Placebo|
297290|NCT00378469|Behavioral|45 minute exercise on ergocycle|
297642|NCT00369226|Drug|Methotrexate|Infusion for a total of 4 doses
297643|NCT00369226|Procedure|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
296904|NCT00383786|Procedure|Psychophysiology (Trauma Script)|
296905|NCT00383786|Procedure|Psychophysiology (Verbal Threat)|
296906|NCT00383786|Procedure|Psychophysiology (Fear Conditioning)|
296907|NCT00383786|Procedure|Psychophysiology (Affective Modulation)|
296908|NCT00383786|Procedure|Psychophysiology (Heart rate variability)|
296909|NCT00386828|Drug|Bevacizumab:|
296910|NCT00386841|Drug|Escitalopram|Escitalopram 10 mg p.o. per day
296911|NCT00386841|Drug|Placebo|Placebo
296912|NCT00386854|Behavioral|physical training|
296913|NCT00386867|Drug|800 mcg misoprostol via oral or buccal administration|
296914|NCT00386880|Other|Sounds|
296915|NCT00386893|Procedure|simultaneous EEG/fMRI|fMRI/EEG recordings
296916|NCT00386893|Device|fMRI|
296917|NCT00003184|Biological|CD80 breast cancer vaccine|
296918|NCT00386906|Procedure|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
296919|NCT00386919|Procedure|CyberKnife|
296920|NCT00386945|Behavioral|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
296921|NCT00386958|Drug|Povidone-Iodine|
296922|NCT00386971|Dietary Supplement|L-carnitine|3 grams daily in liquid form by mouth
296923|NCT00386971|Other|placebo|1 oz sweet tasting liquid daily by mouth
296924|NCT00386984|Drug|Somatostatin (octreotide)|
296925|NCT00386997|Drug|liposomal amphotericin B (AmBisome®)|
295883|NCT02643511|Radiation|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
295884|NCT02643524|Behavioral|Nutrition and Exercise Counseling|Patients are prescribed CAM boot for a minimum of 6 weeks and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake, seated upper body physical exercises and asked to perform them three days per week and each exercise 3 times per session if able. They will be asked to record number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
295885|NCT02643524|Behavioral|Control|Patients are prescribed CAM boot for a minimum of 6 weeks. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. lbumin lab test will be drawn and their height and weight measured.
296201|NCT02638961|Other|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
296202|NCT02638974|Other|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
296203|NCT02638987|Device|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
296204|NCT02639000|Procedure|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
296205|NCT00195455|Drug|Trimegestone|
296206|NCT02639013|Procedure|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
296207|NCT02639026|Radiation|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
296208|NCT02639026|Drug|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
296209|NCT02639026|Drug|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
296210|NCT02639039|Drug|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
296211|NCT02639039|Procedure|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
295278|NCT02616276|Other|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
295279|NCT00002522|Drug|etoposide|
295280|NCT00193128|Drug|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
295281|NCT02616276|Other|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
295282|NCT02618603|Drug|Triamcinolone Acetonide|
295283|NCT02618616|Drug|ZPL-3893787|
295284|NCT02618616|Drug|Placebo|
295285|NCT02618629|Drug|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
295286|NCT02618642|Radiation|Piler light phototherapy|Piler light + red filter: phototherapy, 10 treatment sessions,10 minutes for one session Piler light + blue filter: phototherapy, 10 treatment sessions,10 minutes for one session Piler light without a filter: phototherapy, 10 treatment sessions, 10 minutes for one session
Piler light + red filter: 10 people Piler light + blue filter: 10 people Piler light without a filter: 10 people
295287|NCT02618655|Other|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
295288|NCT02618668|Drug|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
295289|NCT02618668|Drug|Propofol|2 mg/kg I.V
295580|NCT02611934|Procedure|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
295581|NCT02611947|Radiation|Low-dose chest CT scans|Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)
35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm
295582|NCT02611960|Biological|pembrolizumab|
295583|NCT02611960|Drug|capecitabine|
295584|NCT02611960|Drug|gemcitabine|
295585|NCT00192660|Drug|Stavudine|
294644|NCT02627209|Other|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
294645|NCT02627222|Other|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
294646|NCT02627222|Other|White cassava|Conventional white cassava
294647|NCT02627235|Behavioral|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
294648|NCT02627235|Behavioral|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
294649|NCT02627248|Drug|Huaier Granule|20g tid, orally
294650|NCT02627248|Drug|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
294651|NCT02627248|Drug|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
294652|NCT02627248|Drug|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
294653|NCT00194077|Drug|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
294654|NCT02627261|Biological|blood samples and bone marrow aspirates will be collected|Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
294655|NCT02627274|Drug|RO6874281|Participants will receive RO6874281, starting with 5 mg once weekly (QW) to a maximum of 50 mg QW, as a single administration by intravenous infusion over a minimum of 2 hours (120 minutes) with a maximum infusion rate of 25 mg/hour. Participants will receive RO6874281 until clinical disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
294656|NCT02627287|Device|FlexPen®|For subcutaneously (s.c. under the skin) injection.
294657|NCT02627287|Device|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
294658|NCT02629354|Drug|Ibuprofen|
294659|NCT02629367|Drug|Vorapaxar|
294660|NCT02629367|Drug|Asprin|
294661|NCT02629367|Drug|Clopidogrel|
294662|NCT02629380|Device|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
294068|NCT02638246|Behavioral|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
294069|NCT00195351|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
294070|NCT02638246|Behavioral|Internet-delivered, non-contingent incentives + Motivational Interviewing|
294071|NCT02638259|Drug|GP2015|Enbrel comparator
294072|NCT02638272|Procedure|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
294073|NCT02638285|Drug|LH|
294355|NCT00194805|Behavioral|Telehealth for Diabetes Self Management|
294356|NCT02633618|Biological|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
294357|NCT02633618|Biological|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
294358|NCT02633644|Device|Harmony System|Percutaneous neuromodulation of the aortic wall
294359|NCT02633657|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
294360|NCT02633670|Device|Hemopatch|
294361|NCT02633670|Device|Standard Technique|
294362|NCT02633683|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
294363|NCT02633696|Drug|silybin phosphatidylcholine|
294364|NCT02633696|Drug|Legalón SIL|
294365|NCT02633709|Drug|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
294366|NCT00002524|Drug|Vincristine Sulfate|
294367|NCT00194805|Other|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
294368|NCT02633709|Other|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
294369|NCT02633709|Drug|RO7034067|Single ascending oral doses of RO7034067 will be administered on Day 1 of Part 1. In Part 2 a single dose of RO7034067 will be once administered under fasted and once under fed conditions. In Part 3 a single dose of RO7034067 will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
293802|NCT02644811|Device|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
293803|NCT02644811|Device|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
293804|NCT02644824|Device|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
293805|NCT02644837|Device|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
293806|NCT02644837|Device|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
293807|NCT02644837|Device|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
293808|NCT02644837|Device|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
293809|NCT02644837|Device|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
293810|NCT02644837|Device|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
293811|NCT00196170|Procedure|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
294074|NCT02638285|Drug|HCG|
294075|NCT02638285|Drug|Clomiphene|
294076|NCT02638298|Device|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
294077|NCT02638298|Other|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
294078|NCT02638324|Device|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
294079|NCT02638337|Drug|Ospemifene|60 mg tablet
294080|NCT02640469|Other|Chlorhexidine with water rinse|This procedure will be followed for both the right and left hands and arms:
scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute
298942|NCT00408096|Procedure|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
298943|NCT00408109|Drug|VRC-AVIDNA036-00-VP|
298944|NCT00408122|Procedure|PET/CT scan and EUS|
298945|NCT00408135|Drug|telithromycin (HMR3647)|
298946|NCT00408148|Drug|Placebo|Undistinguishable placebo tablets
298947|NCT00003279|Biological|monoclonal antibody BEC2|
298948|NCT00408148|Drug|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
298949|NCT00408161|Behavioral|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
298950|NCT00410852|Procedure|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
298951|NCT00410852|Procedure|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
298952|NCT00000506|Drug|phentermine|
298953|NCT00003296|Biological|filgrastim|
298954|NCT00410852|Procedure|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
298955|NCT00410865|Genetic|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
298956|NCT00410878|Drug|OROS Hydromorphone HCI (slow release)|
298957|NCT00410891|Drug|gatifloxacin|
298958|NCT00410904|Drug|cediranib maleate|
298959|NCT00410904|Drug|pemetrexed disodium|
298960|NCT00410930|Biological|Subcutaneous immunotherapy - Recombinant birch pollen|
298961|NCT00410943|Drug|OROS Hydromorphone HCI SR (slow release)|
298962|NCT00410956|Biological|bevacizumab|
298213|NCT00379015|Drug|cyclophosphamide|
298214|NCT00381680|Drug|vincristine sulfate|Given IV
298215|NCT00381680|Drug|prednisone|Given PO
298216|NCT00003152|Drug|vincristine sulfate|
298217|NCT00381680|Drug|doxorubicin hydrochloride|Given IV
298218|NCT00381680|Drug|pegaspargase|Given IM
298219|NCT00381680|Drug|cytarabine|Given IT or IV
298220|NCT00381680|Drug|methotrexate|Given IT or IV
298221|NCT00381680|Drug|dexamethasone|Given PO
298222|NCT00381680|Drug|etoposide|Given IV
298223|NCT00381680|Drug|cyclophosphamide|Given IV
298224|NCT00381680|Drug|leucovorin calcium|Given IV or PO
298590|NCT00372736|Genetic|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs > 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs > 5 x ULN1
298591|NCT00372736|Genetic|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
298592|NCT00372736|Other|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
298593|NCT00372736|Other|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
298594|NCT00372736|Other|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
298595|NCT00372736|Other|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
298596|NCT00003116|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
298597|NCT00372749|Behavioral|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
298598|NCT00372762|Drug|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
297833|NCT00387465|Drug|Entinostat|Given PO
297834|NCT00390026|Drug|Verteporfin photodynamic therapy (PDT)|
297835|NCT00390039|Drug|Intranasal Morphine|MNS075 7.5mg q1h PRN
297836|NCT00390039|Drug|Placebo|IN Placebo q1h PRN
297837|NCT00390039|Drug|IV morphine|IV morphine 7.5mg q3h PRN
297838|NCT00000496|Drug|aspirin|
297839|NCT00003196|Drug|mycophenolate mofetil|Given PO
297840|NCT00390039|Drug|Placebo|IV Placebo q3h PRN
297841|NCT00390039|Drug|Intranasal morphine|MNS075 15mg q3h PRN
297842|NCT00390039|Drug|Placebo|IN Placebo q3h PRN
297843|NCT00390052|Drug|triapine|Given IV and orally
297844|NCT00390052|Other|pharmacological study|correlative study
297845|NCT00390052|Procedure|laboratory biomarker analysis|Correlative study
297846|NCT00390065|Drug|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
297847|NCT00390078|Biological|MVA-mBN32|3 immunizations: 1x 10E8_TCID50 MVA-mBN32
297848|NCT00390078|Biological|IMVAMUNE|3 immunizations: 1x 10E8_TCID50 IMVAMUNE
297849|NCT00390091|Drug|abetimus sodium (LJP 394)|
297850|NCT00003196|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
297851|NCT00390117|Drug|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
297852|NCT00390117|Other|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
297853|NCT00390130|Drug|Pentacel (DPTaP+Hib)|
297854|NCT00390130|Drug|Prevnar (conjugated pneumococcal vaccine)|
298225|NCT00381680|Biological|filgrastim|Given IV or SC
298226|NCT00381680|Drug|asparaginase|Given IM
297114|NCT00407095|Drug|Pardoprunox|12-42 mg/day
297115|NCT00407108|Procedure|Vitrectomy|
297116|NCT00407121|Drug|Bevacizumab|
297117|NCT00407121|Procedure|Intravitreal Injection of Bevacizumab|
297118|NCT00407134|Procedure|Different abdominal volumes and different glucose-concentrations during peritoneal dialysis|
297119|NCT00000504|Drug|flecainide|
297120|NCT00003273|Drug|vincristine sulfate|
297121|NCT00407147|Device|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|antibiotic treatment based on clinical decision making with "traditional thought processes" used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection.
297471|NCT00398437|Drug|chemotherapy|
297472|NCT00398437|Procedure|magnetic resonance imaging|
297473|NCT00398450|Biological|recombinant interferon alfa-2b|
297474|NCT00398450|Drug|azacitidine|
297475|NCT00398463|Drug|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
297476|NCT00003231|Procedure|surgical procedure|
297477|NCT00398463|Drug|Placebo|Saline infusion will be administered for 14-24 hours
297478|NCT00398476|Drug|fluticasone propionate|
297479|NCT00398476|Drug|fluticasone furoate|
297480|NCT00398489|Biological|trastuzumab|
297481|NCT00398489|Drug|anastrozole|
297482|NCT00398489|Drug|cyclophosphamide|
297483|NCT00398489|Drug|docetaxel|
297484|NCT00398489|Drug|epirubicin hydrochloride|
297485|NCT00398489|Drug|goserelin acetate|
297486|NCT00398489|Drug|tamoxifen citrate|
296737|NCT00368862|Drug|Cipralex (escitalopram)|
296738|NCT00368875|Drug|vorinostat|Given orally
296739|NCT00368875|Drug|paclitaxel|Given IV
296740|NCT00003099|Drug|Fenretinide|Daily for 14-28 days.
296741|NCT00368875|Biological|bevacizumab|Given IV
296742|NCT00368888|Device|Urine collection bag for infants|
296743|NCT00368901|Drug|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
296744|NCT00368914|Drug|sirolimus|
296745|NCT00368914|Other|laboratory biomarker analysis|
296746|NCT00368914|Other|pharmacological study|
296747|NCT00368914|Procedure|biopsy|
296748|NCT00368927|Drug|sulindac|Given orally
296749|NCT00368927|Other|placebo|Given orally
296750|NCT00368940|Behavioral|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
296751|NCT00003099|Drug|Tamoxifen Citrate|Daily for 14-28 days.
296752|NCT00368940|Behavioral|Supportive Therapy for Cognitively Impaired Older Adults (ST-CI)|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
296753|NCT00368953|Device|Yukon Choice stent system|coronary stent implantation
296754|NCT00368953|Device|Taxus Liberté stent system|coronary stent implantation
296755|NCT00368966|Biological|13-valent Pneumococcal Conjugate Vaccine|
297122|NCT00407173|Drug|HCV-796|HCV-796 1000mg single dose
297123|NCT00407186|Drug|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
296063|NCT02625441|Drug|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
296064|NCT02625454|Drug|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
296065|NCT02625454|Drug|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
296066|NCT02625467|Procedure|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
296067|NCT02625467|Procedure|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
296375|NCT00193453|Drug|Cetuximab|100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 & 15, all subsequent cycles 250mg/m2 IV day 1, 8, & 15
296376|NCT02621359|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily
296377|NCT02621359|Drug|Levofloxacin|Levofloxacin 500 mg once daily
296378|NCT02621359|Drug|Doxycyclin|Doxycyclin 100 mg twice daily
296379|NCT02621359|Drug|Omeprazole|Omeprazole 40 mg twice daily
296380|NCT02621372|Other|platelet count|Correlation of esophageal varices with platelet count
296381|NCT02621385|Drug|tradipitant|test agent
296382|NCT02621385|Drug|Midazolam|substrate for drug-drug interaction assessment
296383|NCT02621398|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
296384|NCT02621398|Drug|Carboplatin|Given IV
296385|NCT02621398|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
296386|NCT00193466|Drug|Rituximab|
296387|NCT02621398|Other|Laboratory Biomarker Analysis|Correlative studies
296388|NCT02621398|Drug|Paclitaxel|Given IV
296389|NCT02621398|Biological|Pembrolizumab|Given IV
296390|NCT02621411|Drug|Substance use|Patients are found use of substances by preoperative screen
296391|NCT02621424|Device|RTMS|stimulation of the brain with magnetic pulses
296392|NCT02621424|Device|sham|sham noise to block the sound of stimulation
295768|NCT02629887|Device|Non-inflatable supraglottic airway with T Piece Resuscitator|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
295769|NCT00194467|Drug|placebo|matching placebo, once a day for 8 weeks
295770|NCT02629887|Device|Standard of Care - Face Mask with T-Piece resuscitator|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
295771|NCT02629900|Behavioral|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
295772|NCT02629913|Device|mementor somnium|
295773|NCT02629913|Other|wait list|delayed access to mementor somnium
295774|NCT02629926|Other|GH Replacement (NutropinAq®)|GH Replacement continued.
295775|NCT02629926|Other|No additional treatment|GH Replacement not continued.
295776|NCT02629939|Behavioral|course for learning CPR|
295777|NCT02629952|Other|Blueberry Tea|Blueberry Tea
295778|NCT02629965|Drug|tiotropium|fixed dose combination
295779|NCT02629965|Drug|olodaterol|fixed dose combination
295780|NCT00194480|Drug|Pegylated Interferon|Weekly injections of pegIntereferon
295781|NCT02629965|Drug|tiotropium|
295782|NCT02629978|Procedure|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
295783|NCT02631876|Drug|Topotecan|
295784|NCT02631889|Device|Transcollation technology|The use transcollation technology for dissection during lung surgery
296068|NCT02625467|Drug|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
296069|NCT00193882|Drug|Cisplatin|80mg/m2 IV day 1
296070|NCT02625480|Biological|KTE-C19|
296071|NCT02625493|Other|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
298393|NCT00398684|Drug|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
298394|NCT00398684|Drug|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
298395|NCT00398684|Drug|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
298396|NCT00398697|Drug|Perifosine|
298748|NCT00387764|Drug|pazopanib|800 mg daily dosing continously until progression
298749|NCT00387777|Drug|Patch with centrally acting analgesic|
298750|NCT00387777|Drug|Transtec(R) PRO (buprenorphine)|
298751|NCT00390364|Drug|everolimus|
298752|NCT00390364|Procedure|antiangiogenesis therapy|
298753|NCT00390364|Procedure|biopsy|
298754|NCT00390364|Procedure|diagnostic procedure|
298755|NCT00390364|Procedure|gene expression analysis|
298756|NCT00390364|Procedure|immunohistochemistry staining method|
298757|NCT00390364|Procedure|laboratory biomarker analysis|
298758|NCT00390364|Procedure|mutation analysis|
298759|NCT00390364|Procedure|protein tyrosine kinase inhibitor therapy|
298760|NCT00390364|Procedure|reverse transcriptase-polymerase chain reaction|
298761|NCT00003199|Drug|tamoxifen citrate|Given orally
298762|NCT00390377|Procedure|Cutting scalp hair|
298763|NCT00390390|Drug|Lansoprazole|
298764|NCT00390403|Drug|R-(-)-gossypol acetic acid|
298765|NCT00390403|Drug|temozolomide|
298766|NCT00390403|Genetic|gene expression analysis|
298011|NCT00407550|Drug|pemetrexed disodium|500 mg/m^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
298012|NCT00407550|Drug|gemcitabine HCL|1500 mg/m^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
298013|NCT00407563|Drug|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
298014|NCT00407563|Drug|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
298015|NCT00407576|Drug|[11C]MeS-IMPY|
298016|NCT00407589|Drug|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
298017|NCT00407602|Device|Argus II Retinal Stimulation System|epiretinal implantation of device
298018|NCT00407615|Device|Flex Pad/Static Magnet|
298019|NCT00407641|Drug|Tinzaparin administration|Patients will receive tinzaparin during the HD session
298020|NCT00407641|Drug|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
298021|NCT00003274|Biological|incomplete Freund's adjuvant|
298022|NCT00407654|Drug|aflibercept|Given intravenously
298023|NCT00407667|Device|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
298397|NCT00000105|Biological|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
298398|NCT00000147|Drug|Methylprednisolone|
298399|NCT00000500|Drug|aspirin|
298400|NCT00003232|Procedure|quality-of-life assessment|
298401|NCT00398697|Drug|Gemcitabine|
298402|NCT00398710|Drug|Perifosine|100 - 150 mg daily
298403|NCT00398723|Device|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
298404|NCT00398736|Procedure|sonographic measurement of inferior caval vein diameter|
297644|NCT00369239|Drug|risperidone long acting injectable|
297645|NCT00369252|Drug|Nimotuzumab (TheraCIM h-R3)|
297646|NCT00369265|Drug|Lansoprazole|Lansoprazole 30mg twice daily
297647|NCT00369265|Dietary Supplement|Sugar pill|placebo twice daily
297648|NCT00369278|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
297649|NCT00000483|Drug|clofibrate|
297650|NCT00003101|Drug|lomustine|
297651|NCT00369291|Biological|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
297652|NCT00369291|Biological|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
297653|NCT00369304|Drug|pharmacokinetic (how the body absorbs and eliminates) interaction|
297654|NCT00369317|Drug|asparaginase|Given IM
297655|NCT00369317|Drug|daunorubicin hydrochloride|Given IV
297656|NCT00369317|Drug|cytarabine|Given IV or IT
297657|NCT00369317|Drug|thioguanine|Given orally
297658|NCT00369317|Drug|etoposide|Given IV
297659|NCT00369317|Other|laboratory biomarker analysis|Correlative studies
297660|NCT00369330|Device|external electrical cardioversion|
297661|NCT00003101|Drug|procarbazine hydrochloride|
297662|NCT00369343|Drug|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
297663|NCT00369343|Drug|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
297664|NCT00369356|Drug|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
297665|NCT00369356|Device|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
297666|NCT00369356|Device|Bare metal coronary stent|Stenting with BMS only
296926|NCT00387010|Drug|Fentanyl Buccal Tablets|Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.
Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.
Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily.
297291|NCT00378482|Drug|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
297292|NCT00378495|Drug|Miltefosine: initially 2.5 mg/kg/day for 28 days|
297293|NCT00378508|Drug|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
297294|NCT00378508|Drug|Placebo Arm|
297295|NCT00003141|Drug|thiotepa|Given IV
297296|NCT00378521|Drug|MQX-503|
297297|NCT00378534|Device|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selectioni and delayed T cell depletion add back
297298|NCT00378534|Drug|Fludarabine|Therapeutic
297299|NCT00378534|Drug|Cyclosporine|Therapeutic
297300|NCT00378534|Drug|Cyclophosphamide|Therapeutic
297301|NCT00378547|Drug|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
297302|NCT00378547|Drug|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
297303|NCT00378547|Drug|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
297304|NCT00378560|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
297305|NCT00381329|Behavioral|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
297306|NCT00381329|Behavioral|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
296212|NCT02641431|Procedure|Mapping|Mapping and ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar diagnostic catheter will be positioned at the right ventricle (RV) apex. High-density detailed endocardial and epicardial electroanatomical maps (EAM) will be performed using the CARTO 3 system with incorporated area calculation software to define areas of low-voltage and delayed fragmented potentials during stable sinus rhythm and during spontaneous or drug-induced type 1 BrS ECG pattern. Either flecainide or aymaline will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms.
296213|NCT02641431|Drug|Flecainide; aymaline|Flecainide 2mg/Kg in 10 minutes, or Ajmaline 1 mg/Kg in 5 minutes. BrS functional substrate identification will be obtained by mapping the entire RV endocardial and epicardial surface under baseline conditions and provocative testing after flecainide or aymaline infusion and epicardial hot saline infusion.
296214|NCT02641431|Procedure|Radiofrequency ablation|Radiofrequency will be delivered over the low voltage area containing the abnormal electrograms. Ablation will be performed using an externally irrigated 3.5-mm tip ablation catheter. Low voltage areas are identified and quantified and abnormal electrograms tagged in order to be targeted for RF delivery. Immediate procedural endpoint will be the elimination of all the abnormal electrograms identified inside the low voltage areas during sinus rhythm.
296540|NCT00003215|Drug|etoposide|
296541|NCT00394810|Drug|Panzem® NCD|suspension, 100 mg/mL, four times daily continuous dosing
296542|NCT00394823|Behavioral|Set of supportive tools/measures vs. standard care|
296543|NCT00394836|Drug|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
296544|NCT00394836|Drug|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
296545|NCT00394849|Procedure|suturing of tonsillar pillars after tonsillectomy|
296546|NCT00394862|Drug|multivitamin|
296547|NCT00394875|Procedure|Treated and educated by nurses specialized in diabetes.|
296548|NCT00394888|Device|MRI|MRI of the spine.
296549|NCT00394888|Device|MRI of head and neck|MRI of head and C-spine
296550|NCT00394888|Other|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
296551|NCT00003215|Drug|leucovorin calcium|
296552|NCT00394888|Other|Cardiac examination|Complete cardiac examination
296553|NCT00394888|Device|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
296554|NCT00394901|Drug|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
295586|NCT02611960|Drug|docetaxel|
295587|NCT02611973|Other|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
295588|NCT02611973|Other|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
295589|NCT02611973|Other|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
295590|NCT02611973|Drug|Hydroxyurea treatment (HU)|HU maintenance
295591|NCT02611986|Device|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
295592|NCT02611986|Device|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
295593|NCT02614157|Device|labeled line|
295594|NCT02614170|Other|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
295595|NCT02614183|Drug|LY2951742|Administered SC
295596|NCT02614183|Drug|Placebo|Administered SC
295597|NCT02614196|Drug|LY2951742|Administered SC
295598|NCT02614196|Drug|Placebo|Administered SC
295599|NCT02614209|Device|In Vitro diagnostic tests|Prospective blood collection
295600|NCT02614222|Device|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
295886|NCT02643550|Biological|IPH2201|Five dose levels of Monalizumab will be tested in the dose escalation part: 0.4, 1, 2, 4 and 10 mg/kg every 2 weeks.The patients will then receive the recommended dose for phase 2.
295887|NCT02643550|Biological|CETUXIMAB|The first dose of Cetuximab will be 400 mg/m2 IV.All subsequent doses will be 250 mg/m2
295888|NCT02643563|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
295889|NCT02643563|Drug|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
295890|NCT02643563|Drug|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
294663|NCT02629380|Procedure|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
294664|NCT00194415|Procedure|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
294966|NCT02622854|Procedure|plasma exchange|see arm description
294967|NCT02622854|Drug|conservative treatment|see arm description
294968|NCT02622867|Other|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
294969|NCT02622867|Dietary Supplement|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
294970|NCT02622880|Dietary Supplement|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
294971|NCT02622880|Dietary Supplement|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an `immune-enhancing` feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
294972|NCT02622893|Drug|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
294973|NCT02622893|Drug|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
294974|NCT02622906|Drug|Pasireotide|60 mg per month of the Pasireotide during 6 months
294975|NCT02622906|Drug|Placebo|Vehicule injection per month during 6 months
294976|NCT00193570|Drug|Topotecan|
294977|NCT02622932|Drug|Anlotinib and 14C-labeled Anlotinib|oral
294978|NCT02622945|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
294979|NCT02622945|Device|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
294370|NCT02633722|Behavioral|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
294371|NCT02633722|Behavioral|Lifestyle Intervention D|Time limiting feeding (12-9pm)
294372|NCT02633735|Behavioral|appy-cds|See description under arm/group section
294373|NCT02633748|Behavioral|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
294374|NCT02633761|Drug|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
294375|NCT02633761|Drug|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
294376|NCT02633761|Drug|Misoprostol 200mcg|Buccal misoprostol 200mcg
294377|NCT02633774|Drug|Propafenone|AAD(antiarrhythmic drug)
294665|NCT02629393|Drug|ALXN1101|
294666|NCT02629406|Other|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
294667|NCT02629419|Drug|Amphotericin B|Lipid crystal nano-particle formulation of amphotericin B
294668|NCT02629445|Device|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
294669|NCT02629458|Procedure|Treatment by Surgical resection|
294670|NCT02629458|Procedure|Stereotactic Ablative Radiotherapy (SABR)|
294671|NCT02629471|Behavioral|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
294672|NCT02629484|Other|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
294673|NCT02629497|Dietary Supplement|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
294674|NCT02629497|Dietary Supplement|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
294675|NCT00194428|Behavioral|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
294081|NCT02640469|Other|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
294082|NCT02640469|Other|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
294083|NCT02640482|Drug|ABT-493/ABT-530|tablet
294084|NCT02640482|Drug|Placebo for ABT-493/ABT-530|tablet
294085|NCT02640495|Drug|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
294086|NCT00195624|Drug|Alemtuzumab (Campath )|
294087|NCT02640508|Drug|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
294088|NCT02640508|Drug|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
294089|NCT02640521|Behavioral|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
294090|NCT02640534|Drug|Enzalutamide|Enzalutamide 160 mg od until disease progression
294091|NCT02640534|Drug|Metformin|850 mg bid until disease progression
294378|NCT00194818|Drug|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
294379|NCT02633774|Drug|Apixaban|anti-coagulation
294380|NCT02635828|Drug|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
294381|NCT02635828|Drug|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
294382|NCT02635828|Drug|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
294383|NCT02635841|Drug|Deferiprone|Deferiprone oral solution (80 mg/mL)
298963|NCT00410956|Drug|dexamethasone|
298964|NCT00003296|Drug|pegylated liposomal doxorubicin hydrochloride|
293812|NCT02644837|Device|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
293813|NCT02644837|Device|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
293814|NCT02644863|Drug|Paclitaxel|Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
293815|NCT02644863|Biological|DC-CIK|Antigen-sensitized DC-CIK 8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
293816|NCT02644863|Drug|Cisplatin|Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
293817|NCT02644876|Drug|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
293818|NCT02644876|Drug|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
293819|NCT02611245|Drug|Indocyanine green|This group of patients accepted intravenous injection of 0.5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
293820|NCT02611258|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
293821|NCT02611271|Other|Monitoring of antibiotic drug removal|
293822|NCT02611284|Procedure|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
298599|NCT00372762|Drug|Bumetanide|Equivalent dose to pre-existing furosemide will be used
298600|NCT00372762|Drug|furosemide|20mg to 80mg orally once or twice daily
298601|NCT00372762|Drug|bumetanide|0.5mg to 2mg orally once or twice daily
298602|NCT00372775|Drug|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
298603|NCT00372788|Drug|AZD6244|oral vial
298604|NCT00372788|Drug|Pemetrexed|oral
298605|NCT00372801|Drug|Ibuprofen|
298606|NCT00372814|Behavioral|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
298607|NCT00003116|Drug|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
298608|NCT00372814|Behavioral|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
298965|NCT00410956|Drug|floxuridine|
298966|NCT00410956|Genetic|protein expression analysis|
298967|NCT00410956|Other|flow cytometry|
298968|NCT00410956|Other|immunoenzyme technique|
298969|NCT00410956|Other|immunohistochemistry staining method|
298970|NCT00410956|Other|immunologic technique|
298971|NCT00410956|Other|laboratory biomarker analysis|
298972|NCT00410956|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
298973|NCT00410969|Device|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
298974|NCT00410982|Drug|Busulfan|Day -10 = 32 mg/m^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m^2 Intravenous
298975|NCT00003297|Drug|mitoxantrone hydrochloride|
298227|NCT00003152|Procedure|autologous bone marrow transplantation|
298228|NCT00381680|Drug|mercaptopurine|Given PO
298229|NCT00381693|Drug|azacitidine|
298230|NCT00381706|Biological|cetuximab|given IV
298231|NCT00381706|Drug|ECF|epirubicin and 5-fluorouracil given IV
298232|NCT00381706|Drug|IC|cisplatin and irinotecan given IV
298233|NCT00381706|Drug|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
298234|NCT00381719|Drug|AGN 203818|3 mg Capsule twice daily for 4 weeks
298235|NCT00381719|Drug|AGN 203818|20 mg Capsule twice daily for 4 weeks
298236|NCT00381719|Drug|AGN 203818|60 mg Capsule twice daily for 4 weeks
298237|NCT00381719|Drug|placebo capsule|Capsule twice daily for 4 weeks
298238|NCT00003152|Procedure|bone marrow ablation with stem cell support|
298239|NCT00381732|Drug|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
298240|NCT00381732|Drug|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
298241|NCT00381758|Drug|Methylphenidate Extended Release Capsules|
298242|NCT00381771|Behavioral|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
298243|NCT00384189|Drug|Ciclesonide|inhaled Ciclesonide
298244|NCT00384189|Drug|Placebo|Placebo
298245|NCT00384202|Drug|Tacrolimus|Immunosuppression
298246|NCT00384215|Drug|insulin glargine [rDNA origin] injection|
298247|NCT00384228|Drug|Nilotinib|
298248|NCT00384241|Behavioral|Induced Stress|Participation in an active coping task by playing a video game against another participant.
297487|NCT00003231|Radiation|radiation therapy|
297488|NCT00398489|Procedure|adjuvant therapy|
297489|NCT00398489|Procedure|conventional surgery|
297490|NCT00398489|Procedure|neoadjuvant therapy|
297491|NCT00398489|Radiation|radiation therapy|
297492|NCT00398502|Drug|MOA-728|
297493|NCT00398515|Drug|lenalidomide|Given orally
297494|NCT00398515|Drug|temsirolimus|Given IV
297495|NCT00398515|Other|pharmacological study|Correlative studies
297496|NCT00401388|Drug|Perifosine|Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
297497|NCT00401401|Drug|zalutumumab|Eight weekly infusions
297498|NCT00003248|Drug|fludarabine phosphate|
297855|NCT00390143|Biological|Meningococcal vaccine 134612|One intramuscular dose during the primary study
297856|NCT00390143|Biological|Mencevax™ ACWY|One subcutaneous dose during the primary study
297857|NCT00390156|Biological|bevacizumab|5 mg/kg
297858|NCT00390156|Drug|cyclophosphamide|Current dose 50 mg
297859|NCT00390156|Drug|imatinib|Current dose 400 mg
297860|NCT00390169|Behavioral|Mindfulness Meditation-Based Stress Reduction|
297861|NCT00003196|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
297862|NCT00390169|Behavioral|Supportive-Expressive Group Therapy|
297863|NCT00390182|Drug|Gemcitabine|Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.
Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.
**Radiation is the experimental part of the study.
297864|NCT00392769|Drug|Cetuximab|Initial Dose = 400 mg/m^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m^2 IV Over 60 Minutes.
297865|NCT00000498|Behavioral|diet, sodium-restricted|
297124|NCT00407186|Radiation|radiotherapy|45 Gy in 25 fracions (5 days/week)
297125|NCT00407186|Drug|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
297126|NCT00407199|Drug|quetiapine|
297127|NCT00407212|Drug|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
297128|NCT00407225|Drug|Difluprednate Ophthalmic Emulsion|
297129|NCT00407238|Device|Multi-purpose solutions (polyquaternium-1 and PHMB)|
297130|NCT00407251|Drug|Patupilone|
297131|NCT00003273|Procedure|autologous bone marrow transplantation|
297132|NCT00407264|Drug|Fluticasone propionate|
297133|NCT00407277|Drug|Nicotine patch|21 mg of nicotine via a dermal patch
297134|NCT00407277|Other|placebo|placebo via a dermal patch
297135|NCT00407277|Behavioral|smoking cessation group therapy|a 9-week group based on the "Freedom From Smoking" program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders
297136|NCT00410202|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
297137|NCT00410202|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily
297138|NCT00410202|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
297139|NCT00410202|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
297140|NCT00410215|Drug|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
297141|NCT00003290|Radiation|radiation therapy|
297142|NCT00410215|Drug|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
297143|NCT00410215|Drug|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
297144|NCT00410228|Drug|AHT956|
297145|NCT00410254|Drug|HCV-796|
297146|NCT00410254|Drug|midazolam|
296393|NCT02621437|Other|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
296394|NCT02621437|Other|phone questionnaires|Six phone questionnaires (D9, D20, D26, D34, D40 and D48):
pain questionnaire with digital scale,
quality of life survey: SF-12
HAD (Hospital and Anxiety Depression) questionnaire
296395|NCT02621450|Biological|standart dialysis|dialysate sodium consentration 140 mEq
296396|NCT02621450|Biological|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
296397|NCT00002523|Drug|leucovorin calcium|
296398|NCT02623478|Drug|Insulin Lispro|Administered subcutaneously (SC)
296399|NCT02623491|Drug|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
296756|NCT00368966|Biological|7-valent Pneumococcal Conjugate Vaccine|
296757|NCT00368979|Drug|Dutasteride|once daily
296758|NCT00368979|Drug|Placebo|once daily
296759|NCT00368992|Biological|cetuximab|Given IV
296760|NCT00368992|Drug|paclitaxel|Given IV
296761|NCT00368992|Biological|bevacizumab|Given IV
296762|NCT00371982|Drug|Fish oil (Maxepa)|
296763|NCT00371995|Drug|Liposomal amphotericin B and Miltefosine|Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.
Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)
296764|NCT00372008|Drug|Testosterone|
296765|NCT00372021|Procedure|optic nerve neurotomy|
296766|NCT00372034|Device|Temporary Collagen Inserts|
296767|NCT00372047|Device|multiphoton laser imaging|
296768|NCT00372060|Drug|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
296769|NCT00372060|Drug|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
296770|NCT00372060|Drug|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
296072|NCT02625506|Drug|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
296073|NCT02625506|Drug|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
296074|NCT02625519|Drug|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
296075|NCT02625519|Drug|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
296076|NCT02625532|Procedure|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
296077|NCT02625532|Procedure|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
296078|NCT02625545|Device|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
296079|NCT02625558|Drug|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
296080|NCT00193882|Radiation|Radiotherapy|35 Gy in 15 fractions
296081|NCT02625558|Drug|Placebo|Placebo given three times a day
296082|NCT02625571|Behavioral|Phase-based treatment of sexual behavior problems of children|
296083|NCT02625584|Behavioral|Reading Together - Pausing for Reading|
296084|NCT02625584|Behavioral|Reading Together - Dialogic Reading|
296085|NCT02625584|Behavioral|Reading Together - Shared Reading Control|
296086|NCT02627625|Drug|Tiotropium|4 inhalations
296087|NCT02627638|Other|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
296088|NCT02627651|Other|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
296089|NCT02627664|Other|observational study|natural history of non dopaminergic signs
296400|NCT02623491|Drug|Placebo|Participants will receive matching placebo.
296401|NCT00193596|Drug|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
298767|NCT00390403|Genetic|mutation analysis|
298768|NCT00390403|Genetic|protein expression analysis|
298769|NCT00390403|Other|laboratory biomarker analysis|
298770|NCT00390403|Other|pharmacological study|
298771|NCT00390403|Procedure|adjuvant therapy|
298772|NCT00003199|Drug|busulfan|Given orally
298773|NCT00390403|Radiation|radiation therapy|
298774|NCT00390416|Drug|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
299132|NCT00003154|Drug|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
299133|NCT00381940|Biological|filgrastim|Given IV or SC
299134|NCT00381953|Drug|Peginterferon alfa-2a|
299135|NCT00381953|Drug|Interferon alfa-2a|
299136|NCT00381953|Drug|Ribavirin|
299137|NCT00381966|Device|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
299138|NCT00381979|Other|Supportive Expressive Therapy|
299139|NCT00382018|Drug|chemotherapy|No administration details available
299140|NCT00382031|Drug|Zalutumumab|Individual dose titration weekly i.v doses
299141|NCT00382031|Other|Control|Best Supportive Care
299142|NCT00382044|Drug|Eprex; Neorecormon; Aranesp|
299143|NCT00003156|Drug|topotecan hydrochloride|
299144|NCT00382057|Drug|Testosterone|
299145|NCT00382057|Drug|Anastrozole|
299146|NCT00382057|Drug|Goserelin|
298405|NCT00398749|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length
298406|NCT00398775|Procedure|antibiotic discontinuation|
298407|NCT00398788|Drug|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
298408|NCT00398814|Drug|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
298409|NCT00398814|Drug|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
298410|NCT00398827|Drug|Dexmedetomidine|
298411|NCT00003234|Drug|vinorelbine tartrate|
298412|NCT00398827|Drug|Placebo|
298413|NCT00398840|Drug|ARQ 171|
298414|NCT00398853|Dietary Supplement|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
298415|NCT00398866|Drug|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
298416|NCT00398866|Drug|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
298417|NCT00401817|Drug|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
298418|NCT00401830|Drug|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
298419|NCT00401830|Other|Placebo|Matching placebo tablet administered twice daily
298775|NCT00390429|Drug|docetaxel|Given IV
298776|NCT00390429|Drug|erlotinib hydrochloride|Given orally
298777|NCT00390442|Device|continuous positive airway pressure|
298778|NCT00390455|Drug|Lapatinib Ditosylate|Given PO
298779|NCT00390455|Drug|Fulvestrant|Given IM
298780|NCT00390455|Other|Placebo|Given PO
298781|NCT00390455|Other|Laboratory Biomarker Analysis|Correlative studies
298024|NCT00407680|Drug|Intensive therapy Valsartan,Fluvastatin|
298025|NCT00407693|Drug|[C-11]PRB28|
298026|NCT00407706|Procedure|blood test|
298027|NCT00407719|Drug|Bevacizumab|
298028|NCT00407732|Behavioral|psychosocial intervention|motivational enhancing case management intervention
298029|NCT00407745|Drug|placebo|Placebo
298030|NCT00407745|Drug|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
298031|NCT00407758|Drug|enzastaurin hydrochloride|
298032|NCT00003274|Biological|sargramostim|
298033|NCT00407771|Drug|Tirofiban|
298034|NCT00407784|Drug|eplerenone|
298035|NCT00407797|Drug|Pregabalin|150 to 600 mg/day during 21 weeks
298036|NCT00407810|Biological|bevacizumab|Given IV
298037|NCT00407810|Biological|cetuximab|Given IV
298038|NCT00407810|Other|laboratory biomarker analysis|Correlative studies
298039|NCT00410566|Drug|rhASM|Single dose of 0.3mg/kg body weight IV
298040|NCT00410566|Drug|rhASM|Single dose of 0.6mg/kg body weight IV
298041|NCT00410566|Drug|rhASM|Single dose of 1.0mg/kg body weight IV
298042|NCT00410579|Other|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
298043|NCT00003293|Drug|leflunomide|
298044|NCT00410592|Drug|Esomeprazole 40mg|
298045|NCT00410592|Drug|Pantoprazole 40mg|
298046|NCT00410592|Drug|Lansoprazole 30mg|
298047|NCT00410605|Biological|bevacizumab|Given IV
297307|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
297308|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
297309|NCT00381342|Drug|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
297310|NCT00381355|Procedure|Written Action Plan for Acute Asthma|
297311|NCT00381368|Drug|Ibandronic acid|
297312|NCT00381381|Drug|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
297667|NCT00372424|Drug|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
297668|NCT00003114|Drug|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
297669|NCT00372424|Drug|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
297670|NCT00372424|Drug|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
297671|NCT00372437|Drug|MGCD0103|MGCD0103 as an oral dose three times per week.
297672|NCT00372437|Drug|Gemcitabine|Gemcitabine 1000mg/m<2> intravenously days 1, 8, 15 of a 28 day cycle.
297673|NCT00372450|Procedure|management of therapy complications|
297674|NCT00372450|Procedure|quality-of-life assessment|
297675|NCT00372463|Behavioral|6-week Online Diabetes Self-Management Educational Program|
297676|NCT00372476|Drug|Imatinib and Vinorelbine|
297677|NCT00372489|Drug|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
297678|NCT00372502|Procedure|Modified EGDT|Early goal directed therapy with lactate clearance
296555|NCT00394901|Drug|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
296556|NCT00394901|Drug|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
296557|NCT00394901|Drug|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
296558|NCT00394914|Drug|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
296559|NCT00394914|Drug|Placebo to Pleconaril|Placebo nasal suspension
296560|NCT00394953|Drug|Darbepoetin alfa|As prescribed, iv.
296561|NCT00394953|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
296562|NCT00003215|Drug|melphalan|
296563|NCT00397956|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
296564|NCT00397969|Other|counseling intervention|
296927|NCT00387023|Drug|Rituximab|250 mg/m^2 IV over 4-6 hours for 2 weeks.
296928|NCT00003184|Biological|sargramostim|
296929|NCT00387023|Drug|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
296930|NCT00387036|Drug|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
296931|NCT00387036|Drug|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
296932|NCT00387049|Behavioral|Anxiety Sensitivity Program for Smoking Cessation|
296933|NCT00387062|Device|Computer-based Cognitive Training|
296934|NCT00389818|Biological|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
296935|NCT00389818|Biological|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
296936|NCT00389818|Biological|rituximab|375 mg/m2 IV Day 1 of each cycle
296937|NCT00003195|Radiation|radiation therapy|
295891|NCT02643576|Behavioral|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
295892|NCT02643576|Behavioral|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
295893|NCT00196079|Device|Coronary stent|
295894|NCT02643576|Behavioral|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
295895|NCT02643589|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
295896|NCT02643602|Other|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
295897|NCT02643602|Other|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
295898|NCT02645552|Drug|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
295899|NCT00196313|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
295900|NCT02645552|Other|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
295901|NCT02645565|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
295902|NCT02645565|Drug|Azathioprine|azathioprine will be given at 2 mg/kg.
295903|NCT02645565|Drug|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
296215|NCT02641431|Procedure|Cryoablation|Substrate area larger than 15 cm will be treated with cryoablation.Ablation will be performed using a 7-Fr cryoablation catheter with a 6-mm-tip electrode. Each cryo-application will last at least 180 seconds, depending on elimination/modification of the delayed components of the targeted electrograms. Its abolition or persistence is checked with the ablation catheter after each application.
296216|NCT02641431|Procedure|BrS Functional Substrate Re-mapping|A re-map focusing on the low voltage area will be obtained after ablation. Re-mapping will be used to confirm the elimination of all the abnormal electrograms.
294980|NCT02625181|Procedure|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
294981|NCT02625181|Procedure|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
294982|NCT02625181|Procedure|Preoperative recommendations: within AIMS|A recommendation on prophylactic intervention that have to be initiated before the start of anesthesia will be presented within the AIMS of the University of Washington Medical Center, thus before the main notification as previously described.
295290|NCT00000375|Drug|Continuation therapy|
295291|NCT00002522|Procedure|peripheral blood stem cell transplantation|
295292|NCT00193271|Drug|Estramustine|
295293|NCT02618694|Procedure|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
295294|NCT02618694|Procedure|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, & Ihara, 2012; Linos, 2005; George & Kavoussi, 2010).
295295|NCT02618707|Other|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
295296|NCT02618720|Drug|ornidazole|
295297|NCT02618720|Drug|Placebo|
295298|NCT02618733|Drug|Ticagrelor|90mg, twice a day
295299|NCT02618733|Drug|Clopidogrel|75mg, once a day
295300|NCT02618746|Other|Telerehabilitation|
295301|NCT02618746|Other|Hospital based Rehabilitation|
294676|NCT02629510|Drug|Tachosil|
294677|NCT02629523|Drug|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
294678|NCT02629536|Drug|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
294679|NCT02629549|Drug|OTL38|Infusion of OTL38 prior to surgery
294680|NCT02629562|Biological|B12019 and Neulasta|GCSF, Growth Colony Stimulating Factor
294681|NCT02629575|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
294682|NCT02629588|Behavioral|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
294683|NCT02629601|Behavioral|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
294684|NCT02631538|Drug|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
294685|NCT02631538|Drug|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
294983|NCT02625181|Procedure|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
294984|NCT02625181|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
294985|NCT02625181|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
294986|NCT02625181|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
294987|NCT02625181|Procedure|Elective surgery|Surgical procedures that are scheduled and not an emergency.
294988|NCT02625181|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
294989|NCT02625181|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
294990|NCT00193817|Procedure|Two field vs Three field lymphadenectomy|
294991|NCT02625181|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
294992|NCT02625181|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
294384|NCT02635854|Biological|Test group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
294385|NCT02635854|Biological|Control group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
294386|NCT00002525|Drug|fluorouracil|
294387|NCT00195078|Procedure|Radiation Therapy|
294388|NCT02635867|Drug|Resin-modified calcium silicate - TheraCal LC|
294389|NCT02635867|Drug|Calcium hydroxide - Dycal|
294390|NCT02635867|Drug|Resin-based dentin bonding agent|
294391|NCT02635880|Device|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
294392|NCT02635893|Drug|D-Cycloserine|100 mg of Seromycin by mouth will be administered
294393|NCT02635893|Drug|Placebo|placebo pill will be administered instead of medication by mouth
294394|NCT02635893|Other|Training|walking around a designated track at different speeds both forward and backward
294395|NCT02635893|Other|Stimulation|magnetic stimulation and electrical stimulation may be applied
294396|NCT02635893|Other|Placebo Stimulation|this is a fake stimulation that is administered but will be unknow to the subject.
294397|NCT02635906|Other|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
294398|NCT00195091|Drug|Tetrathiomolybdate|Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.
Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.
When target Cp window is reached, then the maintenance phase begins.
Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg
Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime.
294399|NCT02635906|Other|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
294686|NCT02631538|Drug|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
294687|NCT00194740|Drug|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
294688|NCT02631538|Drug|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
294689|NCT02631551|Drug|GSP 301 NS|2 spray in each nostril twice daily for 14 days
293823|NCT02611284|Procedure|INSURE|The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.
After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2< 0.35; for a target Oxygen Saturation (SpO2) of >90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients.
293824|NCT02611297|Procedure|Cryoprobe|
294092|NCT02640560|Other|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
294093|NCT02640560|Other|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
294094|NCT02640573|Drug|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
294095|NCT02640586|Device|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
294096|NCT02640599|Other|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
294097|NCT00195637|Drug|Immune Globulin|
294098|NCT02642809|Radiation|Brachytherapy|
294099|NCT02642809|Procedure|Endoscopic biopsy|
294100|NCT02642809|Procedure|Ultrasound-guided biopsy|
294101|NCT02642809|Procedure|Computed tomography-guided biopsy|
294102|NCT02642809|Procedure|Peripheral blood collection|
294103|NCT02642835|Procedure|vaginal wall mesh|retrospective review of case series
294104|NCT02642848|Procedure|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
294105|NCT02642848|Procedure|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
298976|NCT00410982|Drug|Gemcitabine|Day -8 = 75 mg/m^2 Intravenous bolus; Day -3 = 75 mg/m^2 Intravenous bolus.
298977|NCT00410982|Drug|Melphalan|Day -3 and Day -2 = 60 mg/m^2 Intravenous.
298978|NCT00410982|Other|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
298979|NCT00410982|Drug|Rituximab for Patients with B-Cell Malignancies|375 mg/m^2 Intravenous on Days 1 and 8.
298980|NCT00366457|Drug|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
298981|NCT00366457|Drug|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
298982|NCT00366457|Drug|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
298983|NCT00366470|Drug|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
298984|NCT00366470|Other|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
298985|NCT00366483|Drug|Lecozotan SR|
298986|NCT00366496|Device|Acrysof single piece (SA60AT)|
298987|NCT00366496|Device|Acrysof IQ (SN60WF)|
298988|NCT00366522|Drug|LXR-623|
298989|NCT00003088|Drug|doxorubicin hydrochloride|given IV
293825|NCT02611310|Other|No intervention|No intervention administered in this study.
293826|NCT00192595|Drug|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
293827|NCT02611323|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months, until disease progression or unacceptable toxicity.
293828|NCT02611323|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
293829|NCT02611323|Drug|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 400, 600, or 800 mg on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
298249|NCT00384241|Procedure|Buccal Swab|One Buccal swab collected from each parent
298609|NCT00372827|Drug|Brinzolamide 1% added to Travoprost 0.004%|
298610|NCT00372840|Other|educational intervention|
298611|NCT00372840|Procedure|psychosocial assessment and care|
298612|NCT00372840|Procedure|quality-of-life assessment|
298613|NCT00376090|Biological|MVA-CMDR|10^6 PFU ID, 0.1 mL
298614|NCT00376090|Biological|Placebo|0.1 mL ID
298615|NCT00376090|Biological|MVA-CMDR|10^8 PFU IM, 1.0 mL
298616|NCT00376090|Biological|MVA-CMDR|10^7 PFD ID, 0.1 mL
298617|NCT00376103|Drug|temozolomide|75 mg/m2/day
298618|NCT00376103|Procedure|Brachytherapy|60 Gy to 1 cm
298619|NCT00376103|Procedure|External Beam Radiation Therapy|60 Gy
298620|NCT00376116|Device|Cardiac resynchronisation therapy|
298621|NCT00376116|Device|Implantable cardioverter-defibrillator|
298622|NCT00376129|Drug|Alefacept|15 mg i.m. once weekly for 12 weeks
298623|NCT00003131|Drug|gemtuzumab ozogamicin|
298624|NCT00376142|Behavioral|Psychological theory-based behaviour change interventions|
298625|NCT00376155|Drug|sulfadoxine /pyrimethamine plus amodiaquine|
298626|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
298627|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
298628|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
298629|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
298630|NCT00376181|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
297866|NCT00003209|Drug|ifosfamide|
297867|NCT00392782|Biological|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
297868|NCT00392782|Drug|fludarabine phosphate|Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
297869|NCT00392782|Drug|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
297870|NCT00392782|Procedure|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
297871|NCT00392782|Radiation|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
297872|NCT00392808|Biological|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
297873|NCT00392821|Drug|Sorafenib|Sorafenib
297874|NCT00392821|Drug|RAD001|RAD001
297875|NCT00392834|Biological|filgrastim|given subcutaneously
297876|NCT00392834|Biological|pegfilgrastim|given subcutaneously
298250|NCT00384254|Behavioral|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
298251|NCT00003166|Other|laboratory biomarker analysis|Correlative studies
298252|NCT00384254|Behavioral|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
298253|NCT00384280|Drug|Rifampin|
298254|NCT00384293|Drug|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
298255|NCT00384293|Drug|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
298256|NCT00384306|Drug|prednisolone|
298257|NCT00384319|Device|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
297499|NCT00401401|Drug|cisplatin|Infusions
297500|NCT00401401|Procedure|Radiotherapy|Daily in the treatment period
297501|NCT00401414|Drug|Warfarin|2 mg tablets take as directed by study staff (based on INR)
297502|NCT00401427|Drug|trastuzumab|
297503|NCT00401427|Drug|vinorelbine|
297504|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
297505|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
297506|NCT00401453|Behavioral|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
297507|NCT00401466|Device|Implantable Cardioverter Defibrillator|ICD with Biotronik Home Monitoring capability
297508|NCT00401479|Drug|Placebo|
297509|NCT00003249|Drug|carboxyamidotriazole|
297510|NCT00401479|Drug|Solabegron (GW427353)|
297511|NCT00401492|Drug|gemcitabine prolonged continuous infusion|
297512|NCT00401492|Drug|cisplatin|
297513|NCT00401492|Drug|vinorelbine|
297514|NCT00401518|Device|ACADIA® Facet Replacement System|Investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
297515|NCT00401518|Device|Instrumented posterolateral fusion|Control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
297516|NCT00401531|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
297517|NCT00401531|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
297518|NCT00401544|Drug|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
297519|NCT00401544|Drug|IV iron dextran|Administered by intravenous (IV) injection.
297520|NCT00003249|Drug|chemotherapy|
296771|NCT00003113|Drug|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
296772|NCT00372060|Drug|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
296773|NCT00372073|Drug|seliciclib|1200 mg bid x 3 days every 2 weeks
296774|NCT00372073|Drug|placebo|1200 mg bid x 3 days every 2 weeks
296775|NCT00372086|Drug|Rosiglitazone|
296776|NCT00372099|Drug|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
296777|NCT00372112|Drug|GW642444|GW642444H
296778|NCT00372112|Other|Placebo|Placebo administered twice daily
296779|NCT00372125|Drug|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
296780|NCT00372138|Procedure|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
297147|NCT00410280|Biological|IMA-638 is a biologic|
297148|NCT00410293|Procedure|NT-proBNP testing|
297149|NCT00410306|Drug|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
297150|NCT00410319|Behavioral|Fear-reducing Information|
297151|NCT00410319|Behavioral|Symptom-based exercise|
297152|NCT00000506|Drug|fenfluramine|
297153|NCT00003291|Genetic|cytogenetic analysis|
297154|NCT00410332|Drug|Traumeel S|homeopathic remedy
297155|NCT00410332|Drug|Placebo|placebo drug, identical in size, form and taste as treatment remedy
297156|NCT00410345|Drug|Mifepristone|
297157|NCT00410358|Drug|Gimatecan|
297158|NCT00410371|Drug|Lamotrigine|Lamotrigine
297159|NCT00410371|Drug|GI267119|25 mg ODT
296402|NCT02623504|Drug|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
296403|NCT02623504|Drug|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
296404|NCT02623530|Other|Educational intervention|Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.
Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC.
296405|NCT02623543|Device|OrthoK|
296406|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
296407|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
296408|NCT02623569|Drug|Ivabradine|Not Provided
296409|NCT02623569|Drug|Atenolol|Not Provided
296410|NCT02623582|Biological|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
296411|NCT02623582|Drug|Cyclophosphamide|Given IV
296412|NCT00193596|Drug|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
296413|NCT02623595|Radiation|Stereotactic body radiotherapy|Hypofractionated radiation therapy
296414|NCT02623595|Drug|Recombinant Human Granulocyte-macrophage colony stimulating factor|Immune modulating agents
296415|NCT02623608|Other|Reference breakfast|A high fat, high calorie breakfast
296416|NCT02623608|Other|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
296417|NCT02623608|Other|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
296418|NCT02623608|Other|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
296419|NCT02623608|Other|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
296420|NCT02623621|Drug|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
299147|NCT00384644|Device|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
299148|NCT00384657|Drug|iron sucrose|Patients in Group I will receive iv iron sucrose, as described in the study protocol.
Patient in Group II will receive conventional treatment for chronic heart failure.
299149|NCT00384670|Biological|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
299150|NCT00003172|Biological|filgrastim|
299151|NCT00384670|Biological|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
299152|NCT00384696|Behavioral|Nicotine Replacement Therapy|4 Weeks of nicotine patch.
299153|NCT00384696|Behavioral|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
299154|NCT00384722|Device|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
293939|NCT02624947|Biological|Formulation buffer|
293940|NCT02624960|Device|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
293941|NCT02624973|Drug|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
293942|NCT02624973|Drug|Neoadjuvant letrozole (postmenopausal women)|
293943|NCT02624973|Drug|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
293944|NCT00193765|Procedure|Elective Vs Therapeutic neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers
293945|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide|
293946|NCT02624973|Drug|Neoadjuvant docetaxel|
293947|NCT02624973|Drug|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
293948|NCT02626858|Device|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
293949|NCT02626884|Drug|Ibrutinib|
293950|NCT00002524|Drug|Doxorubicin Hydrochloride (DOX)|
293951|NCT00194012|Drug|Aripiprazole|Addressed in arm description
298782|NCT00390468|Drug|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
298783|NCT00003199|Drug|thiotepa|Given IV
298784|NCT00392938|Procedure|radionuclide imaging|
298785|NCT00392938|Radiation|carbon-11 acetate|
298786|NCT00392938|Radiation|fludeoxyglucose F 18|
298787|NCT00392951|Drug|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
298788|NCT00392977|Dietary Supplement|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
298789|NCT00392990|Drug|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
298790|NCT00392990|Drug|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
298791|NCT00393003|Device|Closed-loop anesthesia system|
298792|NCT00393029|Biological|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
298793|NCT00003210|Biological|recombinant interleukin-12|Given subcutaneously
298794|NCT00393029|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
298795|NCT00393029|Biological|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count > 1.0 x 10^9/L x 3 days or > 5.0 x 10^9/L.
298796|NCT00393029|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
298797|NCT00393029|Drug|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
299155|NCT00384748|Behavioral|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
298048|NCT00410605|Drug|lenalidomide|Given orally
298049|NCT00410605|Drug|dexamethasone|Given orally
298050|NCT00410605|Other|laboratory biomarker analysis|Correlative studies
298420|NCT00401843|Biological|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
298421|NCT00401843|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
298422|NCT00401843|Drug|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
298423|NCT00401843|Drug|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
298424|NCT00401856|Drug|Eplerenone|50mg oral route
298425|NCT00401856|Drug|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
298426|NCT00401869|Drug|Epoetin alfa|
298427|NCT00000501|Drug|potassium|
298428|NCT00003251|Drug|cisplatin|
298429|NCT00401882|Drug|Metoprolol|IV metoprolol will be administrated instead of additional doses of epinephrine.
298430|NCT00401895|Device|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
298431|NCT00401921|Drug|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
298432|NCT00401947|Drug|ACH-0137171|
298433|NCT00401960|Drug|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
298434|NCT00401973|Drug|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
298435|NCT00401973|Drug|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
297679|NCT00003114|Drug|lomustine|Patients receive oral lomustine on day 1.
297680|NCT00372502|Procedure|Standard EGDT|Early goal directed therapy
297681|NCT00372515|Drug|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
297682|NCT00372528|Drug|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
297683|NCT00372541|Drug|ceftriaxone|
297684|NCT00372567|Drug|sunitinib malate|37.5 mg daily
297685|NCT00372567|Drug|imatinib mesylate|800mg daily
297686|NCT00372580|Procedure|blood test|
298051|NCT00410618|Procedure|cognitive assessment|
298052|NCT00410618|Procedure|magnetic resonance imaging|
298053|NCT00410618|Procedure|management of therapy complications|
298054|NCT00003293|Drug|procarbazine hydrochloride|
298055|NCT00410631|Biological|filgrastim|
298056|NCT00410631|Drug|carboplatin|
298057|NCT00410631|Drug|cisplatin|
298058|NCT00410631|Drug|cyclophosphamide|
298059|NCT00410631|Drug|dacarbazine|
298060|NCT00410631|Drug|doxorubicin hydrochloride|
298061|NCT00410631|Drug|etoposide phosphate|
298062|NCT00410631|Drug|ifosfamide|
298063|NCT00410631|Drug|isotretinoin|
298064|NCT00410631|Drug|melphalan|
298065|NCT00003294|Biological|filgrastim|
298066|NCT00410631|Drug|topotecan hydrochloride|
296938|NCT00389818|Biological|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
296939|NCT00389818|Drug|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
296940|NCT00389818|Drug|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
296941|NCT00389818|Drug|prednisone|100 mg PO Days 1-5 of each cycle
296942|NCT00389818|Drug|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
296943|NCT00389818|Other|immunohistochemistry staining method|tissue specimen collected at baseline
296944|NCT00389818|Other|laboratory biomarker analysis|tissue specimen collected at baseline
296945|NCT00389831|Drug|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
296946|NCT00389831|Other|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
296947|NCT00389844|Behavioral|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
296948|NCT00003196|Drug|chemotherapy|Undergo cytoreductive chemotherapy
296949|NCT00389844|Behavioral|Plus component (motivation) of the Exercise Plus Program|Motivation only
297313|NCT00381394|Drug|sitamaquine|
297314|NCT00000490|Procedure|jejunoileal bypass|
297315|NCT00003152|Biological|filgrastim|
297316|NCT00381407|Behavioral|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
297317|NCT00381407|Behavioral|Contingency management (CM)|Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired "end" behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal.
297318|NCT00381420|Device|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
297319|NCT00381420|Device|bare-metal stent|un-coated Bx VELOCITY Stent
297320|NCT00381433|Drug|AVI-4065 Injection|
296217|NCT00195702|Drug|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
296218|NCT02641444|Procedure|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
296219|NCT02641444|Procedure|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
296220|NCT02641444|Procedure|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
296221|NCT02641457|Drug|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
296222|NCT02641457|Drug|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
296223|NCT02641470|Dietary Supplement|DA9301 (Vaccinium uliginosum extract)|
296224|NCT02641470|Dietary Supplement|Placebo|
296225|NCT02641483|Other|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
296226|NCT02641496|Behavioral|CBT-OSA|Participants will
296227|NCT02641496|Behavioral|Sleep Education|Participants will
296228|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
296229|NCT02641509|Device|NBI during polypectomy|NBI to perform the polipectomy
296230|NCT02643615|Device|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
296231|NCT02643615|Device|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the blanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
296565|NCT00397969|Procedure|screening colonoscopy|
296566|NCT00397982|Biological|Bevacizumab|Given IV
296567|NCT00003229|Biological|aldesleukin|
295302|NCT02618759|Drug|DSXS|active treatment
295303|NCT02620852|Genetic|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
295304|NCT02620852|Other|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
295305|NCT02620852|Other|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
295306|NCT02620865|Biological|Aldesleukin|Given SC
295307|NCT02620865|Biological|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
295601|NCT00192946|Procedure|Temporary cardiac resynchronization therapy|
295602|NCT02614235|Device|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
295603|NCT02614248|Other|Organic, Unrefined Coconut Oil|
295604|NCT02614248|Other|Medline Remedy Phytoplex Z-Guard Skin Protectant|
295605|NCT02614261|Drug|LY2951742|Administered SC
295606|NCT02614261|Drug|Placebo|Administered SC
295607|NCT02614274|Dietary Supplement|Nutraceutical joint health formulation|A Proprietary Blend
295608|NCT02614287|Drug|LY2951742|Administered SC
295609|NCT02614300|Other|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
295610|NCT02614300|Other|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
295611|NCT02614300|Other|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
295612|NCT00192959|Drug|Xenon vs propofol|
295613|NCT02614313|Procedure|Open breath test with fructose|Open randomised fructose 35g during breath test
295614|NCT02614313|Procedure|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
295615|NCT02614313|Procedure|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
295616|NCT02614313|Procedure|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
294993|NCT02625181|Drug|Scopolamine|Prophylactic antiemetic
294994|NCT02625181|Drug|Droperidol|Prophylactic antiemetic & rescue antiemetic
294995|NCT02625181|Drug|Haloperidol|Prophylactic antiemetic & rescue antiemetic
294996|NCT02625181|Drug|Dexamethasone|Prophylactic antiemetic & rescue antiemetic
294997|NCT02625181|Drug|Promethazine|Prophylactic antiemetic & rescue antiemetic
294998|NCT02625181|Drug|Meclizine|Prophylactic antiemetic & rescue antiemetic
294999|NCT02625181|Drug|Aprepitant|Prophylactic antiemetic & rescue antiemetic
295000|NCT02625181|Drug|Metoclopramide|Rescue antiemetic
295001|NCT00193830|Procedure|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
295002|NCT02625181|Drug|Fentanyl|Analgesic drug / Opioid
295003|NCT02625181|Drug|Sufentanil|Analgesic drug / Opioid
295004|NCT02625181|Drug|Alfentanil|Analgesic drug / Opioid
295005|NCT02625181|Drug|Remifentanil|Analgesic drug / Opioid
295006|NCT02625181|Drug|Morphine|Analgesic drug / Opioid
295308|NCT00193427|Radiation|Radiation|To 63 Gy
295309|NCT02620865|Drug|Fluorouracil|Given IV
295310|NCT02620865|Drug|Gemcitabine Hydrochloride|Given IV
295311|NCT02620865|Drug|Irinotecan Hydrochloride|Given IV
295312|NCT02620865|Other|Laboratory Biomarker Analysis|Correlative studies
295313|NCT02620865|Drug|Leucovorin Calcium|Given IV
295314|NCT02620865|Drug|Oxaliplatin|Given IV
295315|NCT02620865|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
295316|NCT02620865|Biological|Sargramostim|Given SC
295317|NCT02620878|Device|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
294690|NCT02631551|Drug|GOM NS|2 spray in each nostril twice daily for 14 days
294691|NCT02631551|Drug|GMM-2 NS|2 spray in each nostril twice daily for 14 days
294692|NCT02631551|Drug|GSP 301 Placebo NS|2 spray in each nostril twice daily for 14 days
294693|NCT02631577|Drug|Atezolizumab (MPDL3280A)|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
294694|NCT02631577|Drug|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
294695|NCT02631577|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
294696|NCT02631590|Drug|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
294697|NCT02631590|Drug|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
294698|NCT00194740|Drug|Vinorelbine|27.5 mg/m2, IV, days 8 & 15 of each 21 day cycle
294699|NCT02631590|Drug|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
294700|NCT02631603|Other|Placebo|Administer Placebo as anti-inflammatory
294701|NCT02631603|Drug|Prednisolone|Administer Prednisolone as anti-inflammatory
294702|NCT02631616|Drug|Somatostatin|Monthly injections of Somatostatin
294703|NCT02631629|Other|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
294704|NCT02631629|Other|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
294705|NCT02631642|Drug|HMPL-689|selective PI3Kδ inhibitor
294706|NCT02631642|Drug|HMPL-689 placebo|placebo of HMPL-689
295007|NCT02627287|Drug|placebo|For subcutaneously (s.c. under the skin) injection
295008|NCT02627300|Drug|Octanorm 16.5%|
294106|NCT00195884|Behavioral|Aerobic and Resistance Exercise|Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.
Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.
Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.
Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.
Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
294107|NCT02642848|Procedure|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
294108|NCT02642861|Drug|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
294109|NCT02642861|Drug|Calcium Carbonate|Calcium carbonate for 2 weeks
294400|NCT02635919|Device|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
294401|NCT02635932|Device|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
294402|NCT02635932|Device|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
294403|NCT00195351|Drug|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
294404|NCT02638337|Drug|Placebo|Tablet identical to the ospemifene tablet without drug
294405|NCT02638350|Device|Strategy with lung ultrasound|Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.
Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.
At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema.
294406|NCT02638363|Behavioral|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
294407|NCT02638376|Radiation|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
293830|NCT02611336|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
293831|NCT02611349|Drug|IDP-118|Open-label
293832|NCT02611362|Behavioral|IMB Gaming Intervention|
293833|NCT02611375|Device|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 30 minutes after the stimulation stops.
293834|NCT02613455|Drug|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
293835|NCT02613455|Drug|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
293836|NCT02613468|Other|collection of periodontal records|Clinic attachment level
Probing depth
Gingival index
Plaque index
Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester.
293837|NCT02613468|Other|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
293838|NCT02613468|Other|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
293839|NCT02613481|Drug|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
293840|NCT02613494|Drug|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
294110|NCT02642874|Drug|Methocarbamol|Methocarbamol twice daily
294111|NCT02642874|Drug|Calcium Carbonate|Calcium carbonate twice daily
294112|NCT02642887|Procedure|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
294113|NCT02642900|Procedure|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
294114|NCT02642900|Drug|Nystatin 100.000 units|Control group treated with nystatin
298631|NCT00376194|Drug|DMSA|
298632|NCT00376207|Behavioral|Physical exercise|
298990|NCT00366535|Drug|Neurotropin|
298991|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
298992|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
298993|NCT00366574|Device|Amadeus Microkeratome|
298994|NCT00366574|Device|IntraLase|
298995|NCT00366587|Device|Cataract surgery and IOL implantation|
298996|NCT00366600|Drug|neratinib|HKI-272
298997|NCT00366613|Procedure|Cataract surgery with Perfect Capsule and Sodium Chloride|
298998|NCT00366626|Drug|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
298999|NCT00366626|Drug|Placebo|Placebo for 7 days matched to Naltrexone
299000|NCT00003088|Drug|paclitaxel|given IV
299001|NCT00366639|Other|Acute Decompensated Heart Failure|Treatment & outcomes during hospital admission for Acute DHF
299002|NCT00366652|Drug|desvenlafaxine SR|
299003|NCT00366652|Drug|desipramine|
299004|NCT00366652|Drug|duloxetine|
299005|NCT00366665|Device|Legacy 20000|
299006|NCT00366665|Device|Infinit system|
299007|NCT00366678|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
299008|NCT00366678|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
299009|NCT00366678|Drug|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
299010|NCT00369681|Drug|doxorubicin|
299011|NCT00369681|Drug|vinblastine|
298258|NCT00384332|Drug|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
298259|NCT00384332|Drug|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
298260|NCT00384345|Device|Bright Light Therapy|
298261|NCT00384345|Behavioral|Exercise|
298262|NCT00003167|Biological|Ad5CMV-p53 gene|Given intravesically
298263|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
298264|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
298265|NCT00384358|Other|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
298266|NCT00384371|Drug|Botulinum Toxin A|Botulinum Toxin A
298267|NCT00384371|Drug|Placebo|Placebo
298268|NCT00384384|Drug|oral 18B Glycyrrhetinic acid versus placebo|
298269|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
298270|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
298271|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
298272|NCT00387465|Other|Laboratory Biomarker Analysis|Correlative studies
298273|NCT00387465|Other|Pharmacological Study|Correlative study
298633|NCT00376220|Drug|Riluzole|Initially dispensed 50 mg capsules to take BID. At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
298634|NCT00003132|Drug|bryostatin 1|
298635|NCT00376220|Other|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
297521|NCT00401570|Drug|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
297522|NCT00401570|Drug|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
297523|NCT00401583|Drug|GW786034 (pazopanib)|
297877|NCT00003209|Drug|methotrexate|
297878|NCT00392834|Biological|rituximab|given IV
297879|NCT00392834|Drug|cyclophosphamide|given IV
297880|NCT00392834|Drug|cytarabine|given intrathecally
297881|NCT00392834|Drug|doxorubicin hydrochloride|given IV
297882|NCT00392834|Drug|etoposide|given IV
297883|NCT00392834|Drug|ifosfamide|given IV
297884|NCT00392834|Drug|leucovorin calcium|given IV
297885|NCT00392834|Drug|liposomal cytarabine|given intrathecally
297886|NCT00392834|Drug|methotrexate|given intrathecally
297887|NCT00392834|Drug|therapeutic hydrocortisone|given intrathecally
297888|NCT00003209|Drug|mitomycin C|
297889|NCT00392834|Drug|vincristine sulfate|given IV
297890|NCT00392847|Behavioral|Promoting Parental Skills and Enhancing Attachment|The first group will receive routine follow-up as currently provided by national community health and social services.
297891|NCT00392847|Behavioral|had home visits by community workers during pregnancy|had home visits by community workers during pregnancy to the child's second birthday.
297892|NCT00395317|Drug|Firategrast 300 mg|300 mg tablet
297893|NCT00395343|Drug|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
297894|NCT00395343|Drug|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
297895|NCT00003215|Drug|therapeutic hydrocortisone|
297896|NCT00395356|Behavioral|calorie controlled diet|
297160|NCT00410384|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
297161|NCT00410384|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
297162|NCT00410384|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
297163|NCT00410397|Procedure|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
297164|NCT00003291|Genetic|mutation analysis|
297165|NCT00410397|Procedure|Sham Manipulation|Neutral positional, gentle palpation
297166|NCT00413296|Drug|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
297167|NCT00413296|Drug|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
297168|NCT00413309|Procedure|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
297169|NCT00413322|Drug|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
297170|NCT00413322|Drug|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
297524|NCT00401596|Drug|Xolair (omalizumab)|
297525|NCT00401609|Drug|gemcitabine|
297526|NCT00404248|Other|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
297527|NCT00404261|Drug|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
297528|NCT00404274|Drug|Casopitant (GW679769) oral tablets|
297529|NCT00404274|Drug|Warfarin oral tablets|
297530|NCT00404287|Drug|Fluvastatin|
297531|NCT00404300|Drug|Optivate|Plasma-derived Factor VIII
297532|NCT00404313|Drug|MK0633|Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
296781|NCT00372151|Dietary Supplement|L-Theanine|400 mg/day, caps.
296782|NCT00003113|Radiation|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
296783|NCT00372151|Other|Placebo|caps.
296784|NCT00372164|Procedure|American Society of Interventional Pain Physician Guidelines|
296785|NCT00372177|Radiation|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
296786|NCT00372190|Procedure|Tensionfree vaginal mesh (Prolift)|surgery with Prolift mesh
296787|NCT00372190|Procedure|classic vaginal prolapse surgery (fascia plication)|classic surgery, fascia plication
296788|NCT00372203|Procedure|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
296789|NCT00372216|Drug|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
296790|NCT00375128|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
296791|NCT00003125|Biological|vaccinia-CEA vaccine|
296792|NCT00375141|Device|Pulsed dye laser, Intense pulsed light|
296793|NCT00375154|Device|Noninvasive Positive-Pressure Ventilation (NPPV)|
296794|NCT00375167|Behavioral|Recovery Workbook Training (psychoeducational training)|
296795|NCT00375193|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
296796|NCT00375206|Biological|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
296797|NCT00375219|Drug|Omacetaxine mepesuccinate|Induction:
1.25 mg/m^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.
Maintenance:
1.25 mg/m^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years.
296798|NCT00375232|Drug|Administration of montelukast or placebo|
296799|NCT00375245|Drug|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
296800|NCT00375245|Other|Grapefruit Juice|Daily oral doses starting during the second week on study.
293952|NCT02626897|Device|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
293953|NCT02626897|Device|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
293954|NCT02626910|Other|No intervention|No intervention
293955|NCT02626936|Other|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
293956|NCT02626936|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
293957|NCT02626936|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
293958|NCT02626936|Device|Dexcom G4 Platinum glucose sensor|
293959|NCT02626936|Device|Accu Chek Combo insulin pump|
294234|NCT02620579|Behavioral|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
294235|NCT02622516|Other|Control Group (CG)|The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members.
294236|NCT02622529|Other|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
294237|NCT00193531|Drug|Carboplatin|
294238|NCT02622542|Device|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
294239|NCT02622542|Other|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
294240|NCT02622555|Drug|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
294241|NCT02622568|Drug|Veregen or Sinecatechins|
299156|NCT00384748|Behavioral|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
299157|NCT00384748|Behavioral|Usual care|Routine VA care.
299158|NCT00384774|Drug|COL-144|
299159|NCT00384787|Biological|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
299160|NCT00384787|Biological|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
299161|NCT00003172|Biological|recombinant interferon alfa|
299162|NCT00384800|Drug|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
299163|NCT00384813|Behavioral|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
299164|NCT00384813|Behavioral|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
299165|NCT00384826|Drug|erlotinib|Erlotinib 150 mg/day (until progression)
299166|NCT00384826|Drug|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
299167|NCT00384839|Drug|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
299168|NCT00387790|Drug|motexafin gadolinium|Given IV
299169|NCT00387790|Radiation|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
299170|NCT00387803|Device|Cardiac Resynchronization Therapy with Defibrillation|
299171|NCT00387829|Device|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
299172|NCT00387842|Procedure|Laparoscopic surgery|
299173|NCT00003187|Drug|cyclosporine|
299174|NCT00387842|Procedure|Conventional surgery|
298436|NCT00401973|Drug|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
298437|NCT00401973|Drug|zonisamide|Zonisamide, 100-400mg, oral, daily.
298438|NCT00401973|Behavioral|Wellness education|weight management
298439|NCT00003251|Drug|paclitaxel|
298798|NCT00393042|Drug|Dexmethylphenidate XR|10, 20, 25-30 mg.
298799|NCT00393042|Drug|Mixed Amphetamine Salts, ER|10, 20, 25-30
298800|NCT00393042|Drug|placebo|randomized placebo during each period
298801|NCT00393055|Dietary Supplement|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
298802|NCT00393055|Dietary Supplement|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
298803|NCT00393068|Drug|Erlotinib|Erlotinib
298804|NCT00003210|Other|laboratory biomarker analysis|Correlative studies
298805|NCT00393068|Drug|Bevacizumab|Bevacizumab
298806|NCT00393068|Drug|Paclitaxel|Paclitaxel
298807|NCT00393068|Drug|Carboplatin|Carboplatin
298808|NCT00393068|Drug|5-FU|5-FU
298809|NCT00393068|Procedure|Radiation therapy|Radiation therapy
298810|NCT00393068|Procedure|Surgery|Surgery
298811|NCT00395785|Device|Carotid Stent Implantation|
298812|NCT00395785|Device|Embolic Protection|
298813|NCT00395798|Device|Soft or stiff cervical collar(device), neck school(behavior)|
298814|NCT00395811|Procedure|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
298815|NCT00395824|Procedure|anticoagulation procedure|
298816|NCT00395837|Behavioral|Aerobic exercise|
298067|NCT00410631|Drug|vincristine sulfate|
298068|NCT00410631|Drug|vindesine|
298069|NCT00410631|Procedure|autologous hematopoietic stem cell transplantation|
298070|NCT00410631|Procedure|conventional surgery|
298071|NCT00410631|Procedure|peripheral blood stem cell transplantation|
298072|NCT00410631|Radiation|iobenguane I 131|
298073|NCT00365950|Drug|Warfarin duration|
298074|NCT00365963|Device|Comprehensive Health Enhancement Support System|computer based support and education
298075|NCT00365976|Drug|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
298076|NCT00365976|Drug|Placebo|Placebo nightly over duration of double blind study phase
298077|NCT00365989|Device|ExAblate 2000|
298078|NCT00366002|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
298440|NCT00404625|Behavioral|Risk factors for infections due to ESBL+ Enterobacteriaceae|
298441|NCT00404625|Behavioral|Risk factors for inadequate initial antimicrobial therapy|
298442|NCT00404625|Behavioral|Overall and 30-day mortality in bad first antibiotic therapy|
298443|NCT00404638|Drug|Desmopresin|
298444|NCT00404638|Behavioral|Paula Method of Circular Muscle Exercise|
298445|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
298446|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
298447|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
298448|NCT00003266|Drug|methylphenidate hydrochloride|
298449|NCT00404651|Biological|DTaP-HBV-IPV vaccine|0.5 mL, IM
298450|NCT00404664|Behavioral|influenza vaccine, reminders letters, raffle prize|
298451|NCT00404677|Other|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
297321|NCT00381446|Device|Marketed contact lens care products|
297322|NCT00381472|Drug|Ropinirole|
297323|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
297324|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
297325|NCT00381485|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
297326|NCT00003152|Biological|recombinant interferon alfa|
297327|NCT00381511|Drug|low molecular weight heparin|
297328|NCT00381524|Behavioral|Increase condom use|Voluntary increase in condom use
297329|NCT00381537|Drug|phenobarbitone|
297330|NCT00381537|Drug|carbamazepine|
297331|NCT00381550|Drug|fludarabine phosphate|Given IV
297332|NCT00383786|Procedure|Lumbar Puncture|
297333|NCT00383786|Procedure|24-hour plasma sampling|
297334|NCT00003163|Procedure|autologous bone marrow transplantation|
297335|NCT00383786|Procedure|MRI|
297336|NCT00383799|Drug|iv Amiodarone and iv Procainamide|
297337|NCT00383812|Drug|Intravitreal Bevacizumab|
297687|NCT00372593|Drug|asparaginase|Given intramuscularly
297688|NCT00372593|Drug|cytarabine|Given IV
297689|NCT00372593|Drug|daunorubicin hydrochloride|Given IV over 6 hours
297690|NCT00003114|Drug|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
297691|NCT00003128|Biological|filgrastim|
297692|NCT00375687|Drug|Triptorelin|
297693|NCT00375700|Dietary Supplement|Nutritional Supplement|
296568|NCT00397982|Other|Laboratory Biomarker Analysis|Correlative studies
296569|NCT00397982|Drug|Temsirolimus|Given IV
296570|NCT00397982|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
296571|NCT00397995|Procedure|above- or under elbow cast|
296572|NCT00398008|Drug|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
296573|NCT00398008|Drug|Naltrexone|Opioid antagonist medication to treat opiate dependence
296574|NCT00398008|Behavioral|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
296575|NCT00398034|Drug|Testosterone Gel|
296576|NCT00398047|Drug|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
296577|NCT00398060|Behavioral|Cognitive-behavioral life-style counseling|
296578|NCT00000499|Drug|metoprolol|
296579|NCT00003229|Biological|gp100 antigen|
296580|NCT00398073|Biological|mouse gp100 plasmid DNA vaccine|
296581|NCT00398086|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
296582|NCT00398086|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
296583|NCT00398099|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
296584|NCT00398112|Drug|sunitinib malate|Given orally
296585|NCT00398112|Other|pharmacological study|Correlative studies
296586|NCT00398112|Other|laboratory biomarker analysis|Correlative studies
296587|NCT00398125|Drug|GSK364735|
296588|NCT00398138|Biological|WT-1 analog peptide vaccine|
296589|NCT00398138|Biological|incomplete Freund's adjuvant|
296590|NCT00003229|Biological|tyrosinase peptide|
295617|NCT02614326|Behavioral|Autobiographical Memory Flexibility (MemFlex) training|As in experimental arm description
295618|NCT02614326|Behavioral|Psychoeducation|As in experimental arm description
295619|NCT02614339|Drug|metformin|The patients of this group are treated according to NCCN guideline for stage III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 35 months (total 36months including the adjustment period).
295620|NCT02616289|Other|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
295621|NCT02616302|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
295904|NCT02645578|Device|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
295905|NCT02645591|Procedure|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
295906|NCT02645591|Biological|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
295907|NCT02645591|Behavioral|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
295908|NCT02645617|Drug|Varnish|Topical application to the teeth
295909|NCT02645630|Other|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
295910|NCT00196313|Drug|Placebo tablet|1 tablet daily by mouth
295911|NCT02645630|Other|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
295912|NCT02645630|Other|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
295913|NCT02645643|Other|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
295318|NCT02620878|Other|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
295319|NCT00193440|Drug|Rituximab|
295320|NCT02620891|Device|helium oxygen mixture|
295321|NCT02620904|Drug|Mifepristone|
295322|NCT02620904|Drug|placebo|
295323|NCT02620930|Device|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
295324|NCT02620956|Other|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
295325|NCT02620969|Other|Blood and dialysate sampling|Blood and dialysate sampling
295326|NCT02620982|Device|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
295327|NCT02620995|Drug|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
295328|NCT02620995|Other|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
295622|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
295623|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
295624|NCT02616328|Other|No intervention|No intervention administered in this study
295625|NCT02616341|Behavioral|Team ERP (T-ERP) Intervention|
295626|NCT02616341|Behavioral|Treatment as Usual (TAU)|
295627|NCT02616354|Drug|Imipenem|Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
295628|NCT02616367|Drug|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
295629|NCT00193128|Drug|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
295009|NCT02627313|Device|GammaPod Tumour Bed Boost|Single fraction Tumour Bed boost of 8Gy in 1 Fraction
295010|NCT02627326|Procedure|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
295011|NCT02627352|Procedure|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
295012|NCT02627365|Behavioral|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
295013|NCT00194077|Drug|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
295014|NCT02627378|Other|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
295015|NCT02627378|Other|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
295016|NCT02627391|Other|Early surgical aortic valve replacement|
295017|NCT02627391|Other|Delayed Surgical aortic valve replacement|
295018|NCT02627404|Other|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
295019|NCT02627404|Device|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
295020|NCT02627417|Drug|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
295021|NCT02627417|Drug|Prednisone (Cortancyl®) alone followed by monitoring and "standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
295022|NCT02627417|Drug|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
295023|NCT02627430|Drug|Hsp90 Inhibitor AT13387|Given IV
295024|NCT00194090|Drug|celecoxib|
295025|NCT02627430|Other|Laboratory Biomarker Analysis|Correlative studies
295026|NCT02627430|Other|Pharmacological Study|Correlative studies
295027|NCT02627430|Drug|Talazoparib|Given PO
294408|NCT02638376|Procedure|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.
This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.
The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.
A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution.
294409|NCT02638389|Drug|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
294410|NCT02638415|Procedure|HVPG-guided therapy|Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.
Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.
Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails.
294411|NCT02638415|Other|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
294412|NCT02638415|Drug|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
294707|NCT02633787|Biological|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
294708|NCT02633800|Drug|patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed bya maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
294709|NCT02633800|Drug|Cetuximab|400mg/mg/m2 iv loading dose, followed by 250 mg/m2 weekly
294710|NCT02633800|Drug|Cisplatin or carboplatin|Cisplatin at 100 mg/m2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles or Carboplatin: at AUC 5 IV bolus over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
294711|NCT02633800|Drug|placebo|placebo to match patritumab
294712|NCT02633813|Drug|Naftifine hydrochloride 2%|Topical application for two weeks
294713|NCT02633813|Drug|Placebo|Topical application for two weeks
294714|NCT02633813|Drug|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
294715|NCT02633839|Drug|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
294716|NCT00194844|Behavioral|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
294717|NCT02633839|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
294115|NCT02642913|Drug|Enzalutamide|
294116|NCT02642913|Drug|Enzalutamide with Sorafenib|
294117|NCT00195910|Drug|Morphine and Hydromorphone|
294118|NCT02642926|Procedure|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
294119|NCT02642926|Procedure|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
294120|NCT02642939|Drug|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
294121|NCT02644902|Other|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
294122|NCT02644902|Other|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
294123|NCT02644915|Drug|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
294124|NCT00196170|Procedure|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
294125|NCT02644915|Drug|0.9%%NaCl solution|100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.
Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg
294126|NCT02644941|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
294127|NCT02644941|Device|ePTFE graft|Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
294128|NCT02644954|Drug|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
294129|NCT02644954|Drug|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
294413|NCT02638428|Procedure|CancerSCAN™|Targeted deep sequencing
294414|NCT00195364|Drug|Etanercept|
294415|NCT02638428|Drug|Ifosfamide|
294416|NCT02638428|Drug|Carboplatin|
299012|NCT00369681|Genetic|DNA methylation analysis|
299013|NCT00369681|Other|laboratory biomarker analysis|
299014|NCT00369681|Radiation|fludeoxyglucose F 18|
299015|NCT00369694|Drug|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
293841|NCT02613494|Drug|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
293842|NCT00192777|Procedure|External Beam Radiotherapy|
293843|NCT02613494|Other|Placebo|Placebo twice daily, increasing to placebo three times daily
293844|NCT02613507|Drug|Nivolumab|
293845|NCT02613507|Drug|Docetaxel|
293846|NCT02613520|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
293847|NCT02613520|Other|Normal Saline|0.9% Sodium chloride
293848|NCT02613520|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
293849|NCT02613533|Other|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to LPI surgery and IOP is tested every 15 min before and after surgical procedure
293850|NCT02613546|Behavioral|Cognitive behavioral therapy (CBT)|The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:
evaluation session;
sessions of psychoeducation about the CBT model
5 sessions of cognitive restructuring 2 sessions of preventing relapse
293851|NCT02613546|Behavioral|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
293852|NCT02613559|Biological|TK001|Intravitreal Injection
293853|NCT00192803|Drug|candesartan|
293854|NCT02613572|Drug|alpha lipoic acid|
293855|NCT02613572|Drug|Placebo|
293856|NCT02615717|Behavioral|Attention Bias Modification|comparison of treatment versus control
293857|NCT00193089|Drug|Vinorelbine|Vinorelbine
298636|NCT00376246|Drug|Ezetimibe|
298637|NCT00376259|Drug|telbivudine|600mg/day oral tablet for 96 weeks
298638|NCT00376259|Drug|adefovir dipivoxil|10 mg of adefovir by mouth once daily
298639|NCT00379015|Drug|docetaxel|
298640|NCT00379015|Drug|epirubicin hydrochloride|
298641|NCT00379015|Procedure|conventional surgery|
298642|NCT00000488|Drug|cholestyramine|
298643|NCT00003144|Drug|cisplatin|
298644|NCT00379015|Procedure|neoadjuvant therapy|
298645|NCT00379028|Drug|Budesonide/Formoterol Turbuhaler|
298646|NCT00379028|Drug|Salmeterol/Fluticasone Diskus|
298647|NCT00379041|Biological|bleomycin sulfate|
298648|NCT00379041|Drug|doxorubicin hydrochloride|
298649|NCT00379041|Drug|mechlorethamine hydrochloride|
298650|NCT00379041|Drug|prednisone|
298651|NCT00379041|Drug|procarbazine hydrochloride|
298652|NCT00379041|Drug|vinblastine sulfate|
298653|NCT00379041|Drug|vincristine sulfate|
298654|NCT00003144|Drug|gemcitabine hydrochloride|
298655|NCT00379041|Radiation|radiation therapy|
299016|NCT00369694|Drug|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
299017|NCT00369707|Drug|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
297897|NCT00395369|Drug|intraoperative aprotinin administration|
297898|NCT00395382|Drug|Alendronate|70mg weekly orally
297899|NCT00395382|Drug|Placebo|weekly orally
297900|NCT00395395|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
297901|NCT00395408|Drug|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
297902|NCT00395408|Drug|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
298274|NCT00387478|Biological|Tree MATA MPL or Tree MATA|4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:
600 SU/0.5 ml
1600 SU/0.5 ml
4000 SU/0.5 ml
4000 SU/0.6 ml
4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo
298275|NCT00387491|Drug|MOA-728|
298276|NCT00387504|Drug|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
298277|NCT00387504|Other|pharmacological study|samples drawn per protocol
298278|NCT00003186|Drug|isosulfan blue|
298279|NCT00387517|Drug|Aliskiren/HCTZ|
298280|NCT00387530|Drug|oral sodium phenylbutyrate|
298281|NCT00387530|Drug|valganciclovir|
298282|NCT00387530|Genetic|polymerase chain reaction|
298283|NCT00387530|Genetic|protein expression analysis|
298284|NCT00387530|Procedure|biopsy|
298285|NCT00387556|Drug|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
298286|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
298287|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
298288|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
298289|NCT00003186|Procedure|lymphangiography|
297533|NCT00404313|Drug|Comparator: placebo|Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
297534|NCT00404326|Drug|Hydralazine and magnesium valproate|
297535|NCT00404326|Procedure|Punch biopsy of the primary tumor|
297536|NCT00003263|Drug|cisplatin|
297537|NCT00404339|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
297538|NCT00404339|Biological|tetanus toxoid helper peptide|
297539|NCT00404339|Procedure|adjuvant therapy|
297540|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
297541|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
297542|NCT00404352|Drug|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
297543|NCT00404365|Other|counseling intervention|
297544|NCT00404365|Other|screening questionnaire administration|
297545|NCT00404365|Other|study of socioeconomic and demographic variables|
297546|NCT00404365|Procedure|psychosocial assessment and care|
297547|NCT00003263|Procedure|surgical procedure|
297903|NCT00395421|Drug|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
297904|NCT00395434|Drug|Combretastatin A4 Phosphate (CA4P)|
297905|NCT00395434|Drug|Bevacizumab (Avastin)|
297906|NCT00003215|Drug|vincristine sulfate|
297907|NCT00395447|Procedure|Straight-forward Device Replacement|
297908|NCT00395447|Procedure|Device Replacement with Upgrade|
297909|NCT00395460|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
296801|NCT00375258|Drug|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
296802|NCT00003126|Biological|aldesleukin|
296803|NCT00375258|Drug|Sodium Chloride 0.9%|Visual matched placebo
297171|NCT00413335|Drug|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
297172|NCT00413335|Drug|Placebo|Subject receives placebo.
297173|NCT00413348|Drug|Lactobacillus acidophilus NCFM|
297174|NCT00413361|Drug|versus hydroxychloroquine|versus hydroxychloroquine
297175|NCT00000508|Behavioral|diet, reducing|
297176|NCT00003309|Procedure|adjuvant therapy|
297177|NCT00413374|Drug|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
297178|NCT00413387|Drug|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
297179|NCT00413387|Drug|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
297180|NCT00413400|Drug|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
297181|NCT00413400|Drug|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
297182|NCT00413413|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
297183|NCT00413413|Drug|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
297184|NCT00413413|Drug|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
297185|NCT00413426|Drug|Darifenacin (DAR328)|
297186|NCT00413439|Drug|Isavuconazole|Intravenous solution or oral capsules
297187|NCT00003309|Radiation|radiation therapy|
297188|NCT00413452|Drug|Etanercept|50 mg once weekly
297189|NCT00413465|Drug|Escherichia Coli Endotoxin|
294242|NCT02622581|Other|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
294243|NCT02622594|Drug|Aminolevulinic Acid (ALA)|
294244|NCT02622594|Device|Environ Cosmetic Roller|
294245|NCT02622594|Device|BLU-U IIlluminator|
294246|NCT02622607|Drug|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
294247|NCT02622633|Device|Epidural Electrode|
294248|NCT00193531|Drug|Etoposide|
294249|NCT02622646|Drug|Recombinant VIII factor|Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
Describe PK parameters in patients on prophylaxis treatment with Advate®
Analyze differences in PK parameters in non-controlled vs well controlled patients
Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
294552|NCT02616081|Other|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
294553|NCT02616081|Other|Indwelling Catheter|Indwelling catheterization is a standard of care.
294554|NCT02616081|Other|Bladder Surgery|Bladder surgery is a standard of care.
294555|NCT02618252|Device|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
294556|NCT02618252|Device|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
294557|NCT02618265|Procedure|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
294558|NCT02618265|Procedure|traditional management|aspirin or clopidogrel monotherapy or double treatment for
294559|NCT02618265|Procedure|website platform management|second prevention based on website platform management
293960|NCT02626949|Behavioral|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
293961|NCT02626949|Behavioral|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
293962|NCT00194025|Drug|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
293963|NCT02626962|Drug|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
293964|NCT02626962|Drug|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
293965|NCT02629042|Procedure|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
293966|NCT02629042|Drug|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
293967|NCT02629055|Other|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
293968|NCT00194363|Behavioral|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
293969|NCT02629068|Behavioral|PURPOSE|The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.
Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together
293970|NCT02629081|Other|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
298817|NCT00395850|Drug|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
298818|NCT00395863|Drug|Multihance|0.5 M at a single injection
298819|NCT00395863|Drug|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
298820|NCT00395876|Drug|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
298821|NCT00003216|Drug|gemcitabine hydrochloride|
299175|NCT00387855|Behavioral|SOS program|screening and didactic programming to raise awareness of depression suicidality
299176|NCT00387868|Drug|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29&36 Etoposide: 50 mg/m2 - administered on days 1-5 & 29-33
299177|NCT00387868|Procedure|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
299178|NCT00387868|Radiation|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
299179|NCT00387881|Drug|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
299180|NCT00387881|Drug|Placebo|Placebo to match Treximet tablets
299181|NCT00387894|Drug|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
299182|NCT00387907|Drug|larotaxel (XRP9881)|IV infusion
299183|NCT00387907|Drug|trastuzumab|IV infusion
299184|NCT00003187|Drug|cytarabine|
299185|NCT00387920|Drug|sunitinib malate|Given orally
299186|NCT00387920|Other|pharmacological study|Correlative studies
299187|NCT00387920|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
299188|NCT00387920|Other|laboratory biomarker analysis|Correlative studies
299189|NCT00387933|Drug|hydroxyurea|
298452|NCT00404690|Procedure|Bedside Silo|silo placed at bedside on admission
298453|NCT00404690|Procedure|Operative attempt at closure|go the operating room to attempt closure
298454|NCT00404703|Drug|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
298455|NCT00404703|Drug|Platinum-based chemotherapy|As prescribed
298456|NCT00404716|Drug|Cilostazol|
298457|NCT00404729|Drug|Cytidine-5’-diphosphocholine (Citicoline)|
298458|NCT00404742|Drug|Placebo|PO BID
298459|NCT00000503|Procedure|heart catheterization|
298460|NCT00003266|Procedure|quality-of-life assessment|
298461|NCT00404742|Drug|LX211|0.2 mg/kg, twice a day (BID)
298462|NCT00404742|Drug|LX211|0.4 mg/kg, twice a day (BID)
298463|NCT00404742|Drug|LX211|0.6 mg/kg, twice a day (BID)
298464|NCT00404755|Drug|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
298465|NCT00404755|Drug|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
298822|NCT00395876|Drug|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
298823|NCT00395889|Procedure|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
298824|NCT00395889|Procedure|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
298825|NCT00395902|Drug|Sensipar after Post Transplant|
298826|NCT00395915|Drug|aripiprazole|
298827|NCT00395941|Drug|Pioglitazone|
297694|NCT00375713|Drug|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
297695|NCT00375713|Drug|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
297696|NCT00375713|Drug|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
297697|NCT00375713|Drug|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
297698|NCT00375713|Drug|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
297699|NCT00375726|Biological|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
297700|NCT00375726|Biological|Placebo|Placebo for rDEN3/4delta30(ME)
297701|NCT00375739|Drug|PEP005|
297702|NCT00003128|Drug|ifosfamide|
297703|NCT00375752|Drug|Letrozole|2.5 mg.tablet.
297704|NCT00375752|Drug|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
297705|NCT00375765|Drug|Dutasteride|
297706|NCT00375778|Drug|memantine (drug)|
297707|NCT00375791|Drug|perifosine|100 - 150 mg daily
297708|NCT00375791|Drug|dexamethasone|20 mg twice weekly
297709|NCT00375817|Procedure|Myoblasts injection with MyoCath catheter|
297710|NCT00375830|Procedure|F-18 NaF/F-18 FDG PET/CT|Imaging study to detect cancer
297711|NCT00375830|Procedure|Whole-body MRI|Imaging modality to detect cancer
298079|NCT00366015|Procedure|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
298080|NCT00366015|Procedure|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
298081|NCT00366028|Behavioral|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
296950|NCT00389844|Behavioral|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
296951|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
296952|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
296953|NCT00389870|Biological|panitumumab|
296954|NCT00389870|Drug|cyclosporine|
296955|NCT00389870|Drug|irinotecan hydrochloride|
296956|NCT00389883|Drug|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
296957|NCT00389896|Drug|MK0733 / Duration of Treatment: 18 Weeks|
296958|NCT00389896|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
296959|NCT00003196|Radiation|total-body irradiation|Undergo TBI
296960|NCT00389909|Drug|Doxapram|Dosing comparison between fixed scheduled and sex related dosage.
Dosing related to weight only versus chart taking into account weight, age and gender.
296961|NCT00392392|Drug|Bevacizumab|Bevacizumab
296962|NCT00392392|Drug|Trastuzumab|Trastuzumab
296963|NCT00392405|Drug|3 amps of sodium bicarbonate mixed in one liter of D5W|
296964|NCT00392418|Drug|Multiple micronutrient supplement (iron)|
296965|NCT00392431|Drug|amiodarone|
296966|NCT00392444|Drug|sunitinib malate|Given orally
296967|NCT00392457|Drug|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
296968|NCT00392457|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
296969|NCT00392470|Biological|cetuximab|
296970|NCT00392470|Drug|irinotecan hydrochloride|
296971|NCT00003207|Drug|PSC 833|
296972|NCT00392470|Procedure|conventional surgery|
295914|NCT02645656|Drug|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
295915|NCT02645669|Procedure|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
295916|NCT02645669|Procedure|Control site|Only Scaling and Root planing was done.
295917|NCT02645682|Device|anti-infection CVC|
295918|NCT02645682|Device|normal CVC|
295919|NCT02611999|Behavioral|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
295920|NCT02611999|Behavioral|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
295921|NCT02612012|Radiation|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
296232|NCT02643615|Drug|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
296233|NCT02643615|Drug|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the blanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be ins
296234|NCT02643628|Procedure|Microneedling|
296235|NCT02643628|Device|Microneedling followed by Bellafill treatment|
296236|NCT00196092|Device|Roll-in|Proctored entry.
296237|NCT02643641|Biological|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
296238|NCT02643641|Biological|Placebo|Placebo contains aluminum hydroxide only
296239|NCT02643654|Drug|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
296240|NCT02643654|Drug|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
296241|NCT02643667|Drug|Ibrutinib|
295630|NCT02616367|Drug|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
295631|NCT02616393|Drug|Tesevatinib|
295632|NCT02616406|Device|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
295633|NCT02616419|Device|Buzzy®|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
295634|NCT02616419|Drug|Maxilene® (Lidocaine® 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
295635|NCT02616432|Device|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
295636|NCT02616445|Drug|UE2343|UE2343
10mg, 20, 35mg
twice daily for 9 days
295637|NCT02616445|Drug|Placebo|10mg, 20, 35mg
twice daily for 9 days
295638|NCT02616445|Drug|Placebo|Cross-over study
single dose administered twice (on day 1 and day 8)
study duration 17 days
295639|NCT02616445|Drug|UE2343|Cross-over study
UE2343
single dose administered twice (on day 1 and day 8)
study duration 17 days
295640|NCT00193128|Radiation|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
295641|NCT02616445|Drug|UE2343|UE2343
twice daily for 3 days
single dose on day 4
295642|NCT00193284|Drug|Gefitinib|
295643|NCT02618759|Drug|Placebo|placebo treatment
295922|NCT00002521|Procedure|bone marrow ablation with stem cell support|
295923|NCT00192660|Drug|Didanosine|
295924|NCT02612025|Behavioral|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
295925|NCT02612038|Device|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
295926|NCT02612038|Device|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
295927|NCT02612051|Drug|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
295028|NCT02627443|Drug|ATR Kinase Inhibitor VX-970|Given IV
295329|NCT02622958|Drug|PH94B|PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).
Dosing is sex-specific:
Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg
Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg
295330|NCT02622958|Other|Placebo|Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).
Dosing is sex-specific:
Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg
Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg
295331|NCT02622971|Other|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
295332|NCT02622971|Other|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
295333|NCT02622984|Behavioral|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
295334|NCT02622984|Behavioral|SBIRT|Face to face standard intervention considered "treatment as usual."
295335|NCT02622997|Other|Refrigerated|Self-sample taken and refrigerated immediately then stored in laboratory at -20oC until testing
295336|NCT00193570|Drug|Docetaxel|
295337|NCT02622997|Other|Incubated at 25oC for 1 week|Self-sample taken and refrigerated immediately then incubated at 25oC for 1 week in laboratory then at -20oC until testing
295338|NCT02622997|Other|Incubated at 25oC for 2 weeks|Self-sample taken and refrigerated immediately then incubated at 25oC for 2 weeks in laboratory then at -20oC until testing
295339|NCT02623010|Drug|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
295340|NCT02623023|Drug|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
295341|NCT02623023|Other|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
295342|NCT02623036|Drug|Equivalent dose enalapril|Chronotherapy with enalapril.
295343|NCT02623036|Drug|Equivalent dose lisinopril|Chronotherapy with lisinopril
295344|NCT02623049|Other|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
295345|NCT02623062|Drug|Compound Sodium Alginate Oral Suspension sachet|Contents of 2 sachets taken four times daily for 7 days
294718|NCT02633852|Drug|Aflibercept|
294719|NCT02633878|Drug|Chinese herbal medicine granules|
294720|NCT02633878|Drug|Micronized progesterone|
294721|NCT02633878|Drug|Chinese herbal medicine granules placebo|
294722|NCT02633878|Drug|Micronized progesterone placebo|
294723|NCT02633891|Behavioral|Balance exercise|tailored balance exercise program
294724|NCT02633891|Behavioral|Standard care|general health education and fall prevention classes
294725|NCT02633904|Procedure|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
294726|NCT02633904|Procedure|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
294727|NCT00194844|Behavioral|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
294728|NCT02633917|Behavioral|Motor control exercises|exercises to strength the lumbar musculature and control the posture
295029|NCT02627443|Drug|Carboplatin|Given IV
295030|NCT02627443|Drug|Gemcitabine Hydrochloride|Given IV
295031|NCT02627443|Other|Laboratory Biomarker Analysis|Correlative studies
295032|NCT02627443|Other|Pharmacological Study|Correlative studies
295033|NCT02629601|Behavioral|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
295034|NCT02629601|Behavioral|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
295035|NCT00194428|Behavioral|Low fat caloric diet|Low fat caloric diet
295036|NCT02629601|Behavioral|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
295037|NCT02629601|Behavioral|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
295038|NCT02629627|Drug|Conjugated linoleic acid/Leucine + metformin|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal + Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 8 weeks.
294417|NCT02638428|Drug|Etoposide|
294418|NCT02638428|Drug|Fludarabine|
294419|NCT02638428|Drug|Cytarabine|
294420|NCT02638428|Drug|Pazopanib|
294421|NCT02638428|Drug|Sorafenib|
294422|NCT02638428|Drug|Axitinib|
294423|NCT02640599|Other|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
294424|NCT02640612|Drug|BI 695501|
294425|NCT02640625|Dietary Supplement|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
294426|NCT02640638|Behavioral|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
294427|NCT02640651|Device|DC-Stimulator (PLUS version)|transcranial direct current stimulation
294428|NCT02640664|Drug|Ranibizumab|0.2 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
294429|NCT02640664|Drug|Ranibizumab|0.1 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
294430|NCT02640677|Biological|4CMenB|This study is strictly observational; Administration of Bexsero, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
294431|NCT02640690|Behavioral|Trauma Sensitive Yoga Intervention|(10) 1-hour sessions of trauma sensitive yoga
294432|NCT02640690|Behavioral|Cognitive Processing Therapy-Cognitive Only|(12) 1.5 hour sessions of cognitive processing therapy
294433|NCT00195650|Biological|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
294434|NCT02640703|Biological|Infanrix + Prevenar 13|Different time of application
294729|NCT02633917|Behavioral|Standard exercises|general exercises
294730|NCT02633930|Drug|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
293858|NCT02615730|Drug|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD. Dosing will be conducted in 28-day treatment cycles. Combination (GSK2636771 + paclitaxel) dosing will be initiated on Day 1 of Cycle 1. Decisions for dose determination for subsequent cohorts will be documented and maintained by the site. The maximum dose level planned is GSK2636771 400 mg once daily and paclitaxel 80 mg/m2 administered on Days 1, 8, and 15 of a 28-day treatment cycle.
293859|NCT02615730|Drug|Paclitaxel|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD. Dosing will be conducted in 28-day treatment cycles. Combination (GSK2636771 + paclitaxel) dosing will be initiated on Day 1 of Cycle 1. Decisions for dose determination for subsequent cohorts will be documented and maintained by the site. The maximum dose level planned is GSK2636771 400 mg once daily and paclitaxel 80 mg/m2 administered on Days 1, 8, and 15 of a 28-day treatment cycle.
294130|NCT02644954|Drug|Topical Coal tar|Topical coal tar to be applied once daily
294131|NCT02644954|Drug|Topical calcipotriol|Topical calcipotriol to be applied once daily
294132|NCT02644967|Drug|IMO-2125|Intratumoral injection weekly in Cycle 1, and then once every 3 weeks for Cycle 2, 3, and 4.
294133|NCT02644967|Drug|Ipilimumab|Administered intravenously over 90 minutes at 3 mg/kg
294134|NCT02644980|Drug|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
294135|NCT00196170|Procedure|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
294136|NCT02644980|Drug|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
294137|NCT02644980|Device|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
294138|NCT02644980|Drug|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
294139|NCT02644980|Drug|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
294140|NCT02644980|Other|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
294141|NCT02644993|Radiation|Proton therapy|
294142|NCT02611375|Device|peripheral nerve somatosensory stimulation|Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called "peripheral nerve somatosensory stimulation"). Parameters will vary per participant but should be between 40-55Hz, 200-250uS, and 1-10mA. Stimulation will be applied for 20 minutes. Functional task practice will be completed concurrent with the stimulation and for approximately 30 minutes thereafter.
299018|NCT00369707|Drug|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
299019|NCT00369720|Procedure|Titration of oxygen in delivery room|
299020|NCT00003103|Biological|oblimersen sodium|
299021|NCT00369733|Drug|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
299022|NCT00369746|Drug|citalopram|tablets, 60 mg maximum, daily, 12 weeks
299023|NCT00369759|Other|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
299024|NCT00369772|Drug|darbepoetin alfa|
299025|NCT00369785|Drug|donepezil hydrochloride|Given orally
299026|NCT00369785|Other|placebo|Given orally
299027|NCT00369798|Procedure|PET scan|
299028|NCT00369798|Drug|Rolipram|
299029|NCT00369811|Drug|Oxycodone, fentanyl|
299030|NCT00369824|Biological|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
299031|NCT00003103|Drug|docetaxel|
299032|NCT00369824|Biological|Menactra TM|One dose of vaccine administered intramuscularly
299033|NCT00369824|Biological|Boostrix TM|One dose of vaccine administered intramuscularly
299034|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
299035|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
299036|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
293860|NCT02615743|Behavioral|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
298290|NCT00387582|Drug|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
298291|NCT00387582|Procedure|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
298292|NCT00387608|Drug|veliparib|
298293|NCT00387608|Other|pharmacological study|
298294|NCT00387608|Procedure|biopsy|
298295|NCT00387621|Drug|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
298296|NCT00387621|Drug|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
298297|NCT00387621|Drug|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
298656|NCT00379054|Behavioral|telephone based skills training intervention|
298657|NCT00379067|Drug|Tamsulosin OCAS|Adrenoceptor antagonist
298658|NCT00379067|Drug|Placebo|placebo
298659|NCT00379080|Procedure|conventional surgery|Undergo surgery
298660|NCT00379080|Drug|tandutinib|Given orally
298661|NCT00379080|Other|pharmacological study|Correlative studies
298662|NCT00379080|Other|biopsy|Correlative studies
298663|NCT00379093|Behavioral|Brief advice|The intervention will have the following components:
A) At the time of the recruitment visit, all intervention group patients will receive:
A personalized risk report;
An educational booklet titled "Healthy Drinking as You Age";
A drinking diary;
Brief advice to reduce their drinking by their physicians;
B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.
Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician.
298664|NCT00379106|Procedure|Arm exercises.|Basic active exercise program at home.
298665|NCT00003145|Drug|Fludarabine Phosphate|Given IV
298666|NCT00379106|Procedure|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
298667|NCT00379119|Other|diagnostic laboratory biomarker analysis|
298668|NCT00379119|Other|flow cytometry|
297910|NCT00395460|Drug|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
297911|NCT00395473|Drug|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
297912|NCT00395486|Drug|Rosuvastatin|10mg
297913|NCT00395486|Drug|Atorvastatin|10mg
297914|NCT00395499|Drug|Risperidone|
297915|NCT00395512|Drug|Alogliptin|Alogliptin tablets.
297916|NCT00395512|Drug|Pioglitazone|Pioglitazone tablets.
297917|NCT00000499|Drug|chlorthalidone|
297918|NCT00003215|Procedure|bone marrow ablation with stem cell support|
297919|NCT00395512|Drug|Placebo|Matching placebo tablets.
297920|NCT00395538|Drug|PTH 1-34|Given twice daily by subcutaneous
297921|NCT00395551|Drug|ranibizumab|0.5mg intravitreal injection
297922|NCT00395577|Drug|VX-702|
297923|NCT00395603|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
297924|NCT00398515|Other|laboratory biomarker analysis|Correlative studies
297925|NCT00398528|Drug|Glatiramer acetate, (Copaxone®)|
297926|NCT00003232|Drug|clodronate disodium|
297927|NCT00398528|Drug|IFN-β-1a, (Avonex®)|
297928|NCT00398541|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
298298|NCT00387634|Biological|TBE vaccine for adults|Serology blood draw.
298299|NCT00387647|Drug|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
298300|NCT00003186|Procedure|sentinel lymph node biopsy|
298301|NCT00390195|Drug|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
297190|NCT00413478|Drug|5-Azacytidine|Starting dose level: 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
297191|NCT00413491|Procedure|MR mammography|MR mammography
297192|NCT00413491|Procedure|MR|MR
297193|NCT00413504|Drug|Fondaparinux|
297194|NCT00003099|Other|Placebo|Daily for 14-28 days
297195|NCT00369005|Procedure|Red blood cell transfusion guidelines|
297548|NCT00404378|Drug|ketoconazole|
297549|NCT00404378|Drug|casopitant|
297550|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|1 tablet every 12 hours
297551|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets every 12 hours
297552|NCT00404391|Drug|Placebo|2 tablets every 12 hours
297553|NCT00404404|Biological|bevacizumab|
297554|NCT00404404|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
297555|NCT00407290|Drug|neostigmine|
297556|NCT00407303|Drug|Obatoclax mesylate (GX15-070MS)|obatoclax at various doses in combination with bortezomib
297557|NCT00407303|Drug|Obatoclax|obatoclax in combo with bortezomib
297558|NCT00407329|Procedure|transurethral resection of the prostate|resection of prostate
297559|NCT00407342|Drug|Alefacept (drug)|alefaceptgiven iv
297560|NCT00407342|Procedure|Narrowband UVB phototherapy|
297561|NCT00003273|Procedure|peripheral blood stem cell transplantation|
297562|NCT00407355|Drug|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
297563|NCT00407355|Drug|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
297564|NCT00407368|Procedure|Blood Sample|
294560|NCT02618278|Other|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
294561|NCT02618291|Other|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
294562|NCT00193258|Drug|Bevacizumab|10mg/kg IV infusion every 2 weeks
294563|NCT02618291|Other|Usual care|No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the "usual care" arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit.
294564|NCT02618304|Drug|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
294565|NCT02618317|Drug|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
294566|NCT02618317|Drug|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
294567|NCT02618317|Drug|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
294867|NCT02613897|Drug|Dapagliflozin|Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
294868|NCT02613897|Drug|Placebo|Placebo
294869|NCT02613910|Drug|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
294870|NCT00192855|Drug|Entacapone|Entacapone 600mg BID
294871|NCT02613910|Drug|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
293971|NCT02629094|Drug|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Eplerenone can be taken with or without food. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
294250|NCT02622659|Drug|Fuganlin Oral Liquid|less than 1 years old: 5mL each time and three times a day
1~3 years old: 10mL each time and three times a day
4~6 years old: 10mL each time and four times a day
7~12 years old: 10mL each time and five times a day
294251|NCT02622659|Drug|Xiaoer Jiebiao Oral Liquid|1~2 years old: 5mL each time and twice a day
3~5 years old: 5mL each time and three times a day
6~14 years old: 10mL each time and twice a day
294252|NCT02622672|Dietary Supplement|water-soluble ubiquinol|100 mg/d
294253|NCT02622672|Dietary Supplement|Placebo|glycerin.soy-lecithin, and water
294254|NCT02622685|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
294255|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
294256|NCT02624973|Drug|Neoadjuvant olaparib|
294257|NCT02624973|Drug|Neoadjuvant olaparib + carboplatin (if lack of response to olaparib alone)|
294258|NCT02624973|Procedure|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
294259|NCT02624973|Radiation|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
294260|NCT02624973|Drug|Adjuvant trastuzumab|
294261|NCT02624973|Drug|Adjuvant letrozole (postmenopausal women)|
294262|NCT00002524|Drug|Cisplatin|
294263|NCT00193778|Procedure|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
294264|NCT02624973|Drug|Adjuvant tamoxifen + goserelin (premenopausal women)|
294265|NCT02624973|Drug|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
294266|NCT02624973|Drug|Adjuvant Epirubicin+ Cyclophosphamide|
294267|NCT02624986|Drug|Idasanutlin|Participants will receive idasanutlin film-coated tablets at a starting dose of 100 milligrams (mg) daily on Days 1 to 5 of each 28-day cycle. Escalation will occur in at least 50-mg increments, and daily dosages >/=400 mg will be split into twice-daily dosing.
299190|NCT00387933|Drug|imatinib mesylate|
299191|NCT00387933|Drug|vatalanib|
299192|NCT00387946|Drug|SSR591813L (dianicline)|
299193|NCT00387959|Biological|filgrastim|
299194|NCT00387959|Biological|rituximab|
299195|NCT00003187|Drug|methotrexate|
299196|NCT00387959|Drug|cyclophosphamide|
299197|NCT00390481|Procedure|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
293972|NCT02629120|Drug|Campath|a humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complementmediated lysis and antibodydependent cellular toxicity. for this study, being used as part of the conditioning regimen. Given IV (dose escalation) over 5 days per package insert and and standard of practice
293973|NCT02629120|Drug|Busulfan|an alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of the conditioning regimen for its myelosuppressive properties. Given IV over 2 or 3 days depending on donor cells (sibling vs. unrelated donors) per package insert and standard of practice
293974|NCT02629120|Other|allogeneic peripheral blood allograft infusion|Prepared per the standard of operating procedure established in Department of Transfusion Medicaine and infuse
293975|NCT02629120|Drug|cyclophosphamide|Cyclophosphamide is an antineoplastic and for this study being used for its immunosuppresive mechanism of action. Patient will be given Cyclophosphamide 50 mg/kg/d IV per package insert and standand of care on Day +3 and 4 after receiving the cells
293976|NCT02629133|Behavioral|SHE Program|The SHE program will be specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It will also be tailored to participants' alcohol or substance use status, and be designed to reach participants across levels of motivation for change. The content of SHE will be theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
293977|NCT02629146|Drug|Midazolam|
293978|NCT02629146|Drug|Fentanyl|
293979|NCT00194376|Procedure|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
293980|NCT02629146|Drug|Isotonic saline|
293981|NCT00194688|Drug|H. pylori treatment|
298828|NCT00395967|Drug|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
298829|NCT00395980|Device|surgical table pressure mat|
298830|NCT00395993|Drug|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
298831|NCT00395993|Drug|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
298832|NCT00003216|Radiation|radiation therapy|
298833|NCT00396006|Biological|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
298834|NCT00396019|Drug|PEG-Intron|
298835|NCT00396032|Drug|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
298836|NCT00398866|Drug|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
298837|NCT00398879|Drug|Perifosine in combination with capecitabine|Perifosine or Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks
298838|NCT00398892|Drug|Lipoic acid|Lipoic acid capsules
298839|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
298840|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
298841|NCT00003235|Drug|carboplatin|
298842|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
293710|NCT02635581|Device|Delta TT acetabular cup|
293711|NCT02635594|Dietary Supplement|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
293712|NCT02635594|Other|Placebo|1000mg cellulose + 475mg L-tartaric acid
293713|NCT02635607|Drug|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
298082|NCT00366028|Behavioral|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
298083|NCT00003087|Drug|cisplatin|
298084|NCT00366041|Drug|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
298085|NCT00366041|Device|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
298086|NCT00366067|Drug|Phenytoin|
298087|NCT00366080|Drug|GSK189254|
298088|NCT00366093|Drug|Eszopiclone|eszopiclone 3 mg
298089|NCT00366093|Drug|Placebo|placebo tablet
298090|NCT00366106|Drug|bortezomib|Patients will be treated with bortezomib at 1.3mg/m^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
298091|NCT00366106|Drug|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
298092|NCT00366106|Drug|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m^2 on Day 4 every 28 days (cycle).
298093|NCT00366119|Drug|Ramipril|
298094|NCT00003087|Drug|paclitaxel|
298095|NCT00366132|Device|Extracorporeal Shockwaves|
298096|NCT00366145|Biological|Mesenchymal Stem Cells|2 million cells/kg twice a week for 4 weeks
298097|NCT00366145|Biological|placebo|2 infusions a week for 4 weeks
298098|NCT00366158|Device|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
298099|NCT00366158|Device|Ventricular Intrinsic Preference|Programming of pacemaker
298100|NCT00366171|Drug|Bifeprunox|
298101|NCT00366210|Behavioral|Constraint-Induced Movement (CI) Therapy|
298102|NCT00369382|Drug|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
298466|NCT00404755|Drug|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
296973|NCT00392470|Procedure|neoadjuvant therapy|
296974|NCT00392470|Radiation|3-dimensional conformal radiation therapy|
296975|NCT00392470|Radiation|intensity-modulated radiation therapy|
297338|NCT00383825|Procedure|Anterior segment indocyanine green angiography|
297339|NCT00383838|Behavioral|brief, voluntary substance use intervention|
297340|NCT00383851|Drug|ATN-224|
297341|NCT00383851|Drug|Temozolomide|
297342|NCT00383864|Drug|Pegylated interferon and ribavirin|
297343|NCT00383877|Drug|insulin detemir|
297344|NCT00383877|Drug|insulin NPH|
297345|NCT00003163|Procedure|peripheral blood stem cell transplantation|
297346|NCT00383890|Drug|Dexmedetomidine HCL Injection|
297347|NCT00383890|Drug|Placebo|
297348|NCT00383903|Biological|HRV vaccine|Two or three oral doses
297349|NCT00383916|Drug|pantoprazole|
297350|NCT00383929|Drug|Candesartan cilexetil|32mg oral
297351|NCT00383929|Drug|Hydrochlorothiazide|12.5 mg oral
297352|NCT00383929|Drug|Hydrochlorothiazide|25 mg oral
297353|NCT00383942|Drug|Misoprostol|Misoprostol,25 mcg every 4 hours.
297354|NCT00383942|Procedure|Extra amniotic saline infusion|EASI catheter used for amniotic saline infusion.
297355|NCT00383994|Drug|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
297356|NCT00003163|Radiation|radiation therapy|
297357|NCT00383994|Drug|Rituximab|375 mg/m^2 by vein followed by 1000 mg/m^2 weekly for 3 weeks for a total of 4 doses.
297358|NCT00383994|Biological|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
296242|NCT02643680|Device|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
296243|NCT02643680|Device|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
296244|NCT02643693|Other|P3L|Ad libitum use for a maximum of three hours.
P3L delivers on average 80 µg of nicotine per puff under Health Canada Intense smoking regime.
296245|NCT02643693|Other|VUSE|Ad libitum use for a maximum of three hours.
VUSE delivers on average 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime.
296246|NCT02643693|Other|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
296247|NCT00196092|Device|Surgical|Surgery
296248|NCT02643719|Behavioral|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
296591|NCT00398138|Biological|sargramostim|
296592|NCT00398138|Genetic|polymerase chain reaction|
296593|NCT00398138|Other|flow cytometry|
296594|NCT00398138|Other|immunoenzyme technique|
296595|NCT00401011|Drug|Dexamethasone|All patients will received perifosine qhs daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine qhs and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
296596|NCT00401024|Drug|imatinib mesylate|
296597|NCT00003243|Drug|cyclophosphamide|
296598|NCT00401024|Other|pharmacological study|
296599|NCT00401024|Procedure|conventional surgery|
296600|NCT00401050|Procedure|chiropractic manipulative therapy|
296601|NCT00401050|Procedure|knee exercises|
296602|NCT00401050|Procedure|Graston Instrument Soft Tissue Mobilization (GISTM)|
295928|NCT02612051|Drug|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
295929|NCT02612051|Radiation|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of [18F]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
295930|NCT02612064|Device|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
295931|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
295932|NCT02612077|Other|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
295933|NCT02612077|Drug|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
295934|NCT00192660|Drug|Zidovudine|
295935|NCT02612090|Dietary Supplement|Active Treatment Beverage|Strawberry
295936|NCT02612090|Dietary Supplement|Placebo Treatment Beverage|Placebo
295937|NCT02612116|Drug|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
295938|NCT02612116|Drug|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
295939|NCT02612116|Drug|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
295940|NCT02612129|Drug|arimoclomol|
295941|NCT02612129|Drug|Placebo|
295942|NCT02612142|Behavioral|physical exercise|endurance-training or stretching (sham exercise)
295943|NCT02614339|Drug|control|The patients of this group are treated according to NCCN guideline for stage III colorectal cancer.
296249|NCT02645695|Device|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
296250|NCT02645695|Device|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
296251|NCT00196326|Drug|DR-1011|1 tablet daily
296252|NCT02645708|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
295346|NCT02623062|Drug|Matched placebo|Contents of 2 sachets taken four times daily for 7 days
295347|NCT00193583|Drug|Topotecan|
295348|NCT02623075|Biological|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
295644|NCT02618772|Drug|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
295645|NCT02618772|Drug|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
295646|NCT02618785|Drug|Hyoscine-N-butylbromide(Buscopan®)|
295647|NCT02618785|Drug|Placebo(for Hyoscine)|
295648|NCT02618824|Drug|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
295649|NCT02618824|Other|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
295650|NCT02618837|Procedure|Downstream strategy|At diagnosis:
Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel
Pre-procedure:
Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)
Peri- and post-procedure:
For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.
In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor
At the time of PCI, the loading doses required (according to randomization):
Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months
Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel* daily for at least 12 months
If subject is >75 years old or <60 kg, daily dose of prasugrel should be 5mg
295651|NCT02618837|Procedure|Upstream strategy|At the time of diagnosis:
Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.
Pre-procedure:
All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.
Peri- and post-procedure:
For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.
All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF).
295652|NCT02618850|Procedure|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
295653|NCT00193284|Drug|Docetaxel|
295654|NCT02618850|Drug|first-line chemotherapy|as prescribed by oncologist
295655|NCT02618863|Device|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
295039|NCT02629627|Drug|Metformin + Pacebo of ACL/Leucine|ACL/Leucine in a dosis of 2,475mg per 24hrs (1,650mg or 2 capsules with the first meal and 825 mg or 1 capsule with the second meal) plus homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
295040|NCT02629627|Drug|Placebo of ACL/Leucine plus Placebo of Metformin|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) plus homologate placebo of metformin (calcinated magnesia capsules) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks.
295041|NCT02629627|Drug|ACL/Leucine + Placebo of Metformin|ACL/Leucine in a dosis of 2,475mg per 24hrs (1,650mg or 2 capsules with the first meal and 825 mg or 1 capsule with the second meal) plus homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
295042|NCT02629640|Other|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
295043|NCT02629640|Other|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
295044|NCT02629640|Other|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
295045|NCT02629640|Other|Blood sample|Codon-129 genotyping; storage for future research.
295046|NCT00194441|Other|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
295047|NCT02629640|Other|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
295349|NCT02623088|Other|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
295350|NCT02623101|Device|Reflectance confocal microscopy|Non-invasive imaging of the lesion
295351|NCT02623101|Procedure|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
295352|NCT02625181|Drug|Meperidine|Analgesic drug / Opioid
295353|NCT02625181|Drug|Hydromorphone|Analgesic drug / Opioid
295354|NCT02625181|Drug|Methadone|Analgesic drug / Opioid
295355|NCT02625181|Drug|Oxycodone|Analgesic drug / Opioid
295356|NCT02625181|Drug|Oxymorphone|Analgesic drug / Opioid
295357|NCT00193843|Procedure|Post-operative chemoradiotherapy / accelerated radiotherapy|
295358|NCT02625181|Drug|Hydrocodone|Analgesic drug / Opioid
294731|NCT02633930|Drug|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
294732|NCT02635945|Drug|PBF-680|
294733|NCT02635945|Drug|Placebo|
294734|NCT02635971|Procedure|Transcatheter arterial infusion|
294735|NCT02635971|Procedure|Intravenous chemotherapy|
294736|NCT02635971|Drug|Gemcitabine|
294737|NCT02635971|Drug|Oxaliplatin|
294738|NCT00195104|Drug|Arsenic Trioxide (Tricenox)|
294739|NCT02635984|Drug|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
294740|NCT02635984|Drug|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
294741|NCT02635997|Drug|antiresorptive therapy|
294742|NCT02636010|Drug|Pembrolizumab|
294743|NCT02636023|Device|SPhENo-Cardiograph|SPhENo-Cardiograph
294744|NCT02636036|Biological|enadenotucirev|
294745|NCT02636036|Biological|pembrolizumab|
294746|NCT02636049|Drug|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
294747|NCT02636088|Drug|Cetuximab|
294748|NCT02636101|Drug|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
294749|NCT00195104|Drug|Cytarabine|
294750|NCT02636114|Procedure|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
294751|NCT02636127|Other|blood samples|one blood sample will be done for dosage and role of Fractalkine in the serum.
- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release.
294143|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
294144|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
294145|NCT00000375|Procedure|Bilateral electroconvulsive therapy (ECT)|
294146|NCT00002521|Procedure|autologous bone marrow transplantation|
294147|NCT00192608|Drug|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
294148|NCT02611388|Device|fake stimulation|Patients were only attached electrodes without electric current
294435|NCT02640716|Behavioral|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
294436|NCT02640716|Behavioral|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
294437|NCT02640729|Drug|Nelotanserin|once daily, oral, 20-mg tablets
294438|NCT02640729|Drug|Placebo|once daily, oral, matching tablets
294439|NCT02640755|Drug|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
294440|NCT02640755|Drug|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
294441|NCT02640755|Drug|Fulvestrant|Hormonal Agent
294442|NCT02640755|Drug|Paclitaxel|Taxane
294443|NCT02640768|Other|educational training|implementation of a structured educational program for physicians and nurses
294444|NCT00195663|Biological|Adalimumab|
294445|NCT02642952|Other|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
294446|NCT02642965|Drug|Cytarabine|Given IT or IV
294447|NCT02642965|Biological|Filgrastim|Given SC or IV
294448|NCT02642965|Drug|Fludarabine Phosphate|Given IV
293861|NCT02615743|Device|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
293862|NCT02615756|Behavioral|Exercise|
293863|NCT02615769|Behavioral|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
293864|NCT02615769|Behavioral|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
293865|NCT02615782|Drug|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
293866|NCT02615795|Device|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
293867|NCT02615808|Other|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
293868|NCT00193089|Drug|Trastuzumab|Trastuzumab
293869|NCT02615821|Behavioral|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
293870|NCT02615834|Procedure|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
293871|NCT02617940|Other|fissure sealant|Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.
Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil).
293872|NCT02617940|Other|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
298669|NCT00379119|Other|physiologic testing|
298670|NCT00381784|Behavioral|Printed materials|Role model stories comprise the "heart" of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors.
298671|NCT00381784|Behavioral|Peer advocates|Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the "peer advocates" who design and carry out all program activities.
Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.
Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.
Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.
Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers.
298672|NCT00381797|Biological|Bevacizumab|Given IV
298673|NCT00381797|Radiation|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
298674|NCT00381797|Drug|Irinotecan Hydrochloride|Given IV
299037|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
299038|NCT00372879|Dietary Supplement|Vitamin E|Vitamin E 800IU bid
299039|NCT00003116|Drug|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
299040|NCT00372892|Drug|Rituximab|375mg/m2 per week for 4 consecutive weeks
299041|NCT00372892|Drug|Placebo|Saline IV placebo once per week for 4 consecutive weeks
299042|NCT00372905|Drug|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
299043|NCT00372905|Drug|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
299044|NCT00372905|Drug|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
299045|NCT00372918|Procedure|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
298302|NCT00390195|Drug|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
298303|NCT00390208|Drug|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
298304|NCT00390208|Drug|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
298305|NCT00390221|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
298306|NCT00390221|Drug|Placebo|Placebo SC injection
298307|NCT00390234|Drug|ziv-aflibercept|Given IV
298308|NCT00390247|Drug|thalidomide|
298309|NCT00003197|Dietary Supplement|green tea extract|
298310|NCT00390260|Drug|MK0966 / Duration of Treatment: 1 Days|
298311|NCT00390260|Drug|Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|
298312|NCT00390260|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 1 Days|
298313|NCT00390273|Drug|Metformin|
298314|NCT00390299|Biological|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or intratumorally
298315|NCT00390299|Other|Laboratory Biomarker Analysis|Correlative studies
298316|NCT00390299|Procedure|Therapeutic Conventional Surgery|Undergo en bloc resection
298317|NCT00390312|Drug|Intranasal Placebo|Intranasal placebo
298318|NCT00390312|Drug|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
298319|NCT00390312|Drug|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
298320|NCT00003198|Drug|ifosfamide|
298321|NCT00390312|Drug|Intravenous morphine|Intravenous morphine 7.5 mg
298322|NCT00390312|Drug|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
298675|NCT00381810|Drug|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
298676|NCT00003152|Procedure|peripheral blood stem cell transplantation|
297565|NCT00407381|Drug|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.
297566|NCT00407381|Procedure|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
297567|NCT00407394|Drug|Amoxycillin|
297568|NCT00407407|Drug|ABI-007|80mg/m^2 to 150mg/m^2 IV every 3 weeks
297569|NCT00407407|Drug|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
297570|NCT00407420|Behavioral|mandometer|
297571|NCT00407433|Drug|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
297572|NCT00003273|Radiation|radiation therapy|
297573|NCT00407446|Drug|sildenafil|
297929|NCT00398554|Drug|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
297930|NCT00398554|Drug|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
297931|NCT00398554|Drug|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
297932|NCT00398554|Drug|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
297933|NCT00398554|Drug|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
297934|NCT00398554|Drug|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
297935|NCT00398554|Radiation|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
297936|NCT00398567|Drug|HKI-272|neratinib 160 mg daily by mouth
297937|NCT00003232|Drug|mitoxantrone hydrochloride|
297938|NCT00398567|Drug|Herceptin|Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter
297939|NCT00398567|Drug|HKI-272|neratinib 160 mg daily by mouth
297940|NCT00398567|Drug|Herceptin|Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter
297941|NCT00398567|Drug|HKI-272|neratinib 240 mg daily by mouth
294872|NCT02613910|Drug|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
294873|NCT02613910|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
294874|NCT02613923|Behavioral|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
294875|NCT02613923|Behavioral|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
294876|NCT02613923|Procedure|Blood Draw|blood sample measured for stress and sleep markers
294877|NCT02613923|Other|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
294878|NCT02613923|Other|Insomnia Severity Index (ISI)|
294879|NCT02613923|Other|SF-12 quality of life survey|
294880|NCT02613936|Device|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
294881|NCT00192868|Procedure|Distal protection and drug eluting stent|
294882|NCT02613936|Behavioral|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
294883|NCT02613949|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
294884|NCT02613962|Procedure|biopsy or surgical resection of tumor and blood sampling|
294885|NCT02613975|Device|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
294886|NCT02613988|Radiation|Radiation|
295187|NCT02645253|Drug|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
295188|NCT02645253|Drug|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
295189|NCT02645253|Drug|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
295190|NCT02645253|Drug|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
294268|NCT02624986|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 28 days. For eligible participants with FL, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months, until disease progression or unacceptable toxicity.
294269|NCT02624999|Biological|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
294270|NCT02624999|Drug|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
294568|NCT02618330|Device|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
294569|NCT02618343|Drug|IPA|IPA Aromatherapy for the experimental arm
294570|NCT02618343|Drug|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
294571|NCT02618356|Drug|Raltitrexed and S-1|Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.
BSA (body surface area) S-1 dosage <1.25 m2 80 mg/d
1.25m2 — <1.5 m2 100 mg/d
1.5 m2 120 mg/d
294572|NCT02618369|Device|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
294573|NCT02620579|Behavioral|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
294574|NCT02620592|Drug|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
294575|NCT02620592|Drug|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
294576|NCT02620605|Drug|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
294577|NCT02620605|Drug|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
294578|NCT02620618|Drug|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
294579|NCT00193414|Drug|Gemcitabine|1500mg/m2, 30min IV
294580|NCT02620631|Drug|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
293982|NCT02631291|Behavioral|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
293983|NCT02631291|Behavioral|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
293984|NCT02631304|Procedure|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
293985|NCT02631317|Behavioral|Advance hospital notification by EMS|Advance hospital notification by EMS
293986|NCT02631317|Behavioral|stroke team notification|stroke team notification
293987|NCT02631317|Behavioral|key performance indicators feedback form|a "key performance indicators real-time feedback form" as continuing quality improvement
293988|NCT02631317|Behavioral|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
294271|NCT02625025|Procedure|Low pression pneumoperitoneum|Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.
Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars.
294272|NCT02625025|Procedure|Standard Pression Pneumoperitoneum|Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.
Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars.
294273|NCT02625025|Procedure|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
294274|NCT00193778|Other|No Loco-regional treatment|This group will not receive any loco-regional treatment
294275|NCT02625038|Device|EUDAMED CIV-14-03-011940|
294276|NCT02625051|Procedure|Ureteroscopy|Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
294277|NCT02626988|Behavioral|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
293714|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
293715|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels＞600 pg/ml; and (iii) serum LH levels＞10 IU/l.
293716|NCT02635607|Drug|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
293717|NCT02635607|Drug|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
293718|NCT02635633|Device|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7*(DEF-DM1) [DEF = distance over EF; DM1 = distance over M1]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
293719|NCT02635646|Other|Family and interdisciplinary approach|Family and interdisciplinary approach that includes:
nutritional counseling,
physical activity counseling,
psychological counseling,
metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling.
293720|NCT00195065|Behavioral|Semi-structured, open-ended interviews|
293721|NCT02635646|Other|Individual approach|Individual approach that includes:
nutritional and physical activity counseling in individual appointments,
metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually.
293722|NCT02635659|Other|Encapsulated nutrients|
293723|NCT02635659|Other|Placebo|
293724|NCT02637973|Drug|Empagliflozin|25 mg once daily
293725|NCT02637973|Drug|Placebo|
293726|NCT02637986|Dietary Supplement|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|
293727|NCT02637986|Other|Placebo - capsule with no active ingredient|
293728|NCT00195312|Biological|Sodium chloride injection USP (0.9%)|
293989|NCT02631317|Behavioral|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
293990|NCT02631330|Other|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
298467|NCT00404768|Drug|GSK221149A|6mg/h and 12 mg/h
298468|NCT00404768|Drug|Placebo|Matched Placebo to Drug
298469|NCT00404781|Drug|cilostazol in addition to aspirin and clopidogrel|
298470|NCT00404794|Drug|prednisolone and mycophenolate mofetil|
298471|NCT00407823|Procedure|Central venous oxygen saturation continuous monitoring|
298472|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
298473|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
298474|NCT00407849|Drug|triamcinolone acetonide|Intravitreal injection
298475|NCT00003274|Biological|tyrosinase peptide|
298476|NCT00407862|Drug|Telmisartan 80 mg|
298477|NCT00407862|Drug|Losartan 50 mg|
298478|NCT00407875|Procedure|Intensity Modulated External Beam Radiation Therapy|
298479|NCT00407888|Drug|doxorubicin hydrochloride|Given IV
298480|NCT00407888|Drug|cyclophosphamide|Given orally
298481|NCT00407888|Biological|filgrastim|Given SC
298482|NCT00407888|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
298483|NCT00407888|Biological|trastuzumab|Given IV
298484|NCT00407888|Other|laboratory biomarker analysis|Correlative studies
298485|NCT00407888|Procedure|quality-of-life assessment|Ancillary studies
298486|NCT00003276|Drug|irinotecan hydrochloride|
298487|NCT00407914|Device|Aquamid|Subcutaneous injection
298488|NCT00407914|Device|Restylane|Injection in dermis
298489|NCT00407927|Drug|Epinastine Nasal Spray|
298490|NCT00407940|Device|Lower extremity Atherectomy and Cryoplasty|
297359|NCT00384007|Procedure|Hydrodiscectomy with Spinejet|
297360|NCT00384020|Drug|Paroxetine (Seroxat)|
297361|NCT00384020|Drug|Escitalopram (Lexapro)|
297362|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
297363|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
297712|NCT00375830|Procedure|Tc-99m MDP bone scan|Imaging modality to evaluate the skeleton
297713|NCT00003128|Drug|paclitaxel|
297714|NCT00375843|Drug|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
297715|NCT00375843|Drug|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
297716|NCT00375856|Device|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
297717|NCT00375869|Drug|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
297718|NCT00375869|Drug|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
297719|NCT00378560|Biological|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
297720|NCT00003141|Drug|vincristine sulfate|Given IV
297721|NCT00378573|Drug|docetaxel|
297722|NCT00378573|Drug|gemcitabine|
297723|NCT00378573|Drug|bevacizumab|
297724|NCT00378586|Procedure|Rectal biopsy|Rectal biopsy.
297725|NCT00378586|Procedure|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
297726|NCT00378586|Procedure|Measurement of rectal lactic acid|Equilibrium dialysis.
296603|NCT00401063|Device|Acupuncture|Acupuncture treatment twice a day for eight weeks
296604|NCT00401076|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
296605|NCT00401089|Drug|Panax Ginseng|The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
296606|NCT00401102|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
296607|NCT00401115|Drug|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
296608|NCT00000501|Behavioral|diet, reducing|
296609|NCT00003243|Drug|etoposide|
296610|NCT00401115|Drug|MS-R001 (rapamycin)|Intraocular injection in various dosages
296611|NCT00401128|Drug|gemcitabine hydrochloride|
296612|NCT00401128|Drug|irinotecan hydrochloride|
296976|NCT00392496|Drug|sunitinib malate|Given orally
296977|NCT00392509|Procedure|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
296978|NCT00392522|Drug|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
296979|NCT00392535|Drug|cyproterone acetate|
296980|NCT00392535|Drug|releasing hormone agonist therapy|
296981|NCT00392535|Radiation|hypofractionated radiation therapy|
296982|NCT00003209|Biological|bleomycin sulfate|
296983|NCT00392535|Radiation|intensity-modulated radiation therapy|
296984|NCT00392561|Dietary Supplement|Selenium|200 ug Selenium daily
296985|NCT00392561|Dietary Supplement|vitamin E|100 mg Vitamin E daily
296253|NCT02645708|Procedure|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
296254|NCT02645721|Behavioral|Extended self-help program with guidance|See arm description for Experimental
296255|NCT02645721|Behavioral|Briefer Self-help program, no guidance|See arm description for Active Comparator
296256|NCT02645721|Behavioral|Waiting list: Extended self-help program with choice of guidance intensity|See arm description for Waiting list.
296257|NCT02645734|Drug|bevacizumab|1.25 mg of bevacizumab is injected
296258|NCT02645734|Drug|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
296259|NCT02645734|Drug|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
296260|NCT02645747|Drug|aflibercept (Eylea, Bay 86-5321)|Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO). RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
296261|NCT02645760|Other|Core stabilization exercise|7-weeks of core stabilization exercise
296262|NCT00196339|Drug|DR-2031a|1 tablet daily
296263|NCT02645760|Other|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
296264|NCT02645773|Device|non-ablative laser|non-abaltive laser pre, immediate and post wounding
296265|NCT02645799|Drug|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
296266|NCT02645799|Drug|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
296267|NCT02645838|Behavioral|Motivational interviewing|1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
296268|NCT02645851|Drug|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
296613|NCT00401141|Procedure|Blood samples|
296614|NCT00401154|Other|Stationary Cycling|Use of a stationary bicycle for exercise
296615|NCT00401167|Drug|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
295656|NCT02618876|Drug|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
295657|NCT02618876|Drug|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
295944|NCT02614352|Drug|Atorvastatin + Candesartan|
295945|NCT02614352|Drug|AG1502|
295946|NCT00192972|Procedure|Catheter ablation (pulmonary vein isolation)|
295947|NCT02614365|Behavioral|Aerobic exercise|Cardiovascular fitness
295948|NCT02614365|Behavioral|Stretch exercise|Muscle stretch
295949|NCT02614378|Procedure|air insufflation|modulated air insufflation of the ear canal
295950|NCT02614378|Procedure|placebo|no air will be introduced in the ear canal
295951|NCT02614391|Other|Active distraction using a tablet|Playing a videogame using a computer tablet
295952|NCT02614391|Other|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
295953|NCT02614404|Drug|Imatinib|Experimental drug
295954|NCT02614404|Drug|Dihydroartemisinin-piperaquine|Standard of care
295955|NCT02614417|Other|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
295956|NCT02614430|Other|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
295957|NCT00192985|Device|Nitrofuranzone coated bladder catheter|
295958|NCT02614443|Other|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
295959|NCT02614443|Other|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
295359|NCT02625181|Drug|Ketamine|Analgetic / Analgesic drug
295360|NCT02625181|Drug|Ondansetron|Prophylactic antiemetic & rescue antiemetic
295361|NCT02625181|Drug|Granisetron|Prophylactic antiemetic & rescue antiemetic
295362|NCT02625181|Drug|Dolasetron mesylate|Prophylactic antiemetic & rescue antiemetic
295363|NCT02625181|Drug|Palonosetron|Prophylactic antiemetic & rescue antiemetic
295364|NCT02625181|Drug|Tropisetron|Prophylactic antiemetic & rescue antiemetic
295365|NCT02625181|Drug|Ramosetron|Prophylactic antiemetic & rescue antiemetic
295366|NCT02625194|Drug|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
295367|NCT02625207|Drug|Maraviroc (Part 1)|300 mg twice daily x 5 days
295368|NCT00193856|Drug|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
295369|NCT02625207|Drug|Maraviroc (Part 2)|150 mg once daily x 10 days
295370|NCT02625207|Drug|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
295371|NCT02625246|Biological|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
295372|NCT02625259|Drug|MLN1117|MLN1117 capsules
295373|NCT02625259|Drug|MLN1117|MLN1117 tablets
295658|NCT02618889|Behavioral|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
295659|NCT02621008|Other|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
295660|NCT00193440|Drug|CHOP|
295661|NCT02621021|Drug|Cyclophosphamide|Days -7 and -6, Cyclophosphamide 60 mg/kg/day IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hr X 2 days.
295662|NCT02621021|Drug|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
295048|NCT02629653|Device|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
295049|NCT02629666|Behavioral|ERS and/or Self-management Strategies|
295050|NCT02629679|Behavioral|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
295051|NCT02629679|Behavioral|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
295052|NCT02629692|Drug|SPARC1503|Oral administration
295053|NCT02629692|Drug|Placebo|Oral administration
295054|NCT02631655|Other|impact of 18F-FDOPA PET imaging on treatment decisions|Imagery device : impact of 18F-FDOPA PET imaging on treatment decisions taken during multidisciplinary case conferences (MCC) for patients with high-grade gliomas with an uncertain diagnosis.
295055|NCT02631668|Drug|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
295056|NCT00002524|Drug|Pentamidine|
295057|NCT00194740|Drug|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
295058|NCT02631668|Drug|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
295059|NCT02631668|Drug|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
295060|NCT02631681|Behavioral|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
295061|NCT02631694|Drug|Propranolol|Intake of propranolol pill (40 milligram)
295062|NCT02631694|Drug|Placebo|Intake of placebo pill (40 milligram)
295063|NCT02631694|Other|Carbon dioxide|Inhalation of 35% carbon dioxide
295064|NCT02631694|Other|Compressed air|Inhalation of air
295065|NCT02631707|Other|High protein diet|The intervention diet is higher in protein than the control diet.
295066|NCT02631720|Procedure|Blood Draw|
295067|NCT02631720|Procedure|Bronchoscopy|
295068|NCT00194753|Drug|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
294449|NCT02642965|Other|Laboratory Biomarker Analysis|Correlative studies
294450|NCT02642965|Drug|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
294451|NCT02642965|Other|Pharmacological Study|Correlative studies
294452|NCT00195923|Drug|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
294453|NCT02642978|Procedure|RSRCLM|The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
294454|NCT02642978|Procedure|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
294455|NCT02643004|Device|Senofilcon A|Study participants are randomized to wear Senofilcon A or Stenfilcon A pair of study lenses then crossover to the alternate pair.
294752|NCT02636140|Other|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
294753|NCT02636153|Other|normal diet|Diet containing 1500mg of phosphorus
294754|NCT02636153|Other|restricted phosphate diet|Diet containing 500mg of phosphorus
294755|NCT02636166|Other|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
294756|NCT02636166|Other|Professional pregnancy test|Alere Professional use pregnancy test
294757|NCT02636166|Other|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
294758|NCT02636179|Other|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
294759|NCT02638428|Drug|Crizotinib|
294760|NCT02638428|Drug|Dasatinib|
294761|NCT00195377|Drug|Etanercept|
294762|NCT02638428|Drug|Erlotinib|
294763|NCT02638428|Drug|Everolimus|
294764|NCT02638428|Drug|Imatinib|
294765|NCT02638428|Drug|Ruxolitinib|
294149|NCT02611401|Behavioral|Mindfulness|The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.
The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life.
294150|NCT02611401|Behavioral|Psychoeducation|The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.
This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session.
294151|NCT02611414|Device|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
294152|NCT02611414|Device|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
294153|NCT02611427|Behavioral|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
294154|NCT02611427|Behavioral|Education|The education group will receive information about safe physical activity.
294155|NCT02611440|Behavioral|Pharmaceutical care|Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.
Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.
HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load.
294156|NCT02611453|Other|"Air" contrast cholangiography using carbon dioxide gas|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
294157|NCT02613585|Other|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
294158|NCT02613598|Drug|Bortezomib|
294159|NCT02613598|Drug|Ruxolitinib|
294160|NCT02613637|Other|Registry|
299046|NCT00372931|Drug|AL-37807|
299047|NCT00372944|Drug|AZD6244|oral capsule
299048|NCT00372944|Drug|capecitabine|oral tablet
299049|NCT00372957|Drug|GW823093|
299050|NCT00003116|Drug|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
299051|NCT00372970|Drug|Botulinum toxin A|200 U given by injection into the pylorus.
299052|NCT00372970|Drug|Placebo|saline injection into pylorus.
299053|NCT00372983|Drug|NOV-205|
299054|NCT00372996|Drug|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
299055|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day.
299056|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
299057|NCT00372996|Drug|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
299058|NCT00373009|Behavioral|Traditional Army training|As usual training for Soldiers
293873|NCT02617953|Device|Active rTMS(A)|repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.
auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.
293874|NCT00193232|Drug|Docetaxel|
293875|NCT02617953|Device|Active rTMS(B)|repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.
auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.
293876|NCT02617953|Device|Sham condition(C)|The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.
auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.
293877|NCT02617979|Other|SAFECARE at Home customized lessons|
293878|NCT02618005|Dietary Supplement|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
298677|NCT00381810|Drug|Methylprednisolone|
298678|NCT00381810|Drug|Acetaminophen|
298679|NCT00381810|Drug|Diphenhydramine|
298680|NCT00381823|Behavioral|Cognitive Behavioral Therapy|
298681|NCT00381836|Drug|Darbepoetin Alfa|
298682|NCT00381849|Drug|Cystone|Participants will take 2 pills, 2 times a day.
Each tablet of Cystone contains:
Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.
298683|NCT00381849|Drug|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
298684|NCT00381862|Drug|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
298685|NCT00381862|Drug|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
298686|NCT00381862|Drug|fluorouracil|as per institutional standard of care
298687|NCT00003152|Radiation|radiation therapy|
298688|NCT00381862|Drug|irinotecan hydrochloride|as per institutional standard of care
298689|NCT00381862|Drug|leucovorin calcium|as per institutional standard of care
298690|NCT00381862|Drug|oxaliplatin|as per institutional standard of care
298691|NCT00381862|Drug|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
298692|NCT00381862|Procedure|quality-of-life assessment|baseline
298693|NCT00384410|Drug|Nabilone|
298694|NCT00003170|Dietary Supplement|glutamine|
298695|NCT00384423|Drug|PRX-03140|
298696|NCT00384436|Drug|escitalopram|
298697|NCT00384449|Drug|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
298698|NCT00384475|Drug|Ciclesonide Nasal Spray|
297942|NCT00398567|Drug|Herceptin|Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter
297943|NCT00398580|Drug|Nanomilled testosterone|
297944|NCT00398580|Drug|Nanomilled dutasteride|
297945|NCT00398580|Drug|commercially available dutasteride|
297946|NCT00398593|Behavioral|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
297947|NCT00398606|Drug|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
297948|NCT00003232|Drug|prednisone|
297949|NCT00398606|Drug|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
297950|NCT00398619|Drug|INCB13739|
297951|NCT00398632|Drug|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
297952|NCT00398645|Drug|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
297953|NCT00401609|Drug|vinorelbine|
298323|NCT00390312|Drug|Oral placebo|Oral placebo
298324|NCT00390312|Drug|Intravenous placebo|Intravenous placebo
298325|NCT00390325|Other|Laboratory Biomarker Analysis|Correlative studies
298326|NCT00390325|Other|Pharmacological Study|Correlative studies
298327|NCT00390325|Drug|Sorafenib Tosylate|Given orally
298328|NCT00390338|Biological|polarized dendritic cells|
298329|NCT00390338|Biological|non-polarized dendritic cells|
298330|NCT00390351|Device|optical coherence tomography|
298331|NCT00003198|Drug|topotecan hydrochloride|
298332|NCT00392860|Device|Natural-Fit|Ergonomic handrim for wheelchairs
298333|NCT00392860|Device|PalmRim|Ergonomic handrim for wheelchair
295191|NCT02645253|Drug|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
295192|NCT02645266|Drug|aflibercept|
295193|NCT02645279|Other|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
295194|NCT02645279|Drug|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
295195|NCT02645292|Device|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
295196|NCT02645292|Device|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
295197|NCT00196209|Procedure|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
295198|NCT02645305|Biological|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
295199|NCT02645331|Behavioral|Remind-to-move|
295200|NCT02645331|Behavioral|Modified constraint induced movement therapy|
295201|NCT02645331|Behavioral|Conventional rehabilitation|
295202|NCT02645344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
295203|NCT02645344|Behavioral|Sensory Cueing (SC)|
295204|NCT02645344|Behavioral|Conventional Rehabilitation|
295205|NCT02645357|Other|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
295206|NCT02645357|Other|Control group|control group
295207|NCT02645370|Drug|Danzhen|
295512|NCT02638818|Procedure|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
294581|NCT02620631|Drug|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
294582|NCT02620644|Device|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
294583|NCT02620657|Other|No intervention methods|No intervention methods required for this study
294584|NCT02620670|Behavioral|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
294585|NCT02620683|Drug|Lidocaine|See above
294586|NCT02620696|Drug|netazepide|
294887|NCT02613988|Device|3 Tesla magnetic resonance imaging|
294888|NCT02613988|Device|Chemical exchange saturation transfer MRI|
294889|NCT02613988|Device|Diffusion weighted MRI|
294890|NCT02613988|Device|Dynamic contrast enhancement MRI|
294891|NCT00193115|Drug|Doxorubicin|
294892|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
294893|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
294894|NCT02616107|Other|Managing Cancer Care: A Caregiver's Guide|MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:
Becoming a Cancer Caregiver [role, changes, challenges, adjusting, self-care]
Basics of Cancer Caregiving [physical, functional, emotional, social, & spiritual support; treatment timeline worksheet]
Caregiver's Role in Managing Patient Care [who/what is involved; health care professionals worksheet]
Managing Cancer Symptoms and Side Effects [common symptoms/side effects; maintaining health; nutrition & exercise; medication management worksheet]
Care Options: [information on curative, palliative and hospice care]
Talking About Goals of Care [information on goals of care conversations]
Managing Transitions [defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet]
294895|NCT02616107|Other|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
294278|NCT02627001|Device|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
294279|NCT02627001|Device|Bag Valve Mask|Conventional bag valve mask
294280|NCT02627014|Other|Manual therapy|6 treatments: 2 treatments for week
1 treatment = 30 minutes
294281|NCT02627014|Other|Home physical therapy|once a day: 15 minutes
294282|NCT02627014|Other|Manual therapy in cervical region|6 treatments: 2 treatments for week
1 treatment = 30 minutes
294283|NCT02627014|Other|Home physical therapy in cervical region|once a day: 15 minutes
294284|NCT02627027|Drug|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
294285|NCT00194038|Drug|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
294286|NCT02627027|Drug|CKD-395 0.25/750mg|oral administration
294287|NCT02627040|Device|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
294587|NCT02620709|Behavioral|Hula intervention|Hula and heart health education
294588|NCT02620722|Device|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
294589|NCT02620722|Device|Standard Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the existing distal sensor-based technique with the standard tourniquet instrument.
294590|NCT00193427|Drug|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
294591|NCT02620722|Device|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
294592|NCT02620735|Device|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
294593|NCT02620735|Behavioral|Exercise Only|12 week exercise program
294594|NCT02622685|Drug|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
294595|NCT02622685|Drug|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
294596|NCT02622685|Drug|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
293991|NCT02631343|Behavioral|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
293992|NCT00194701|Behavioral|Walking exercise|
293993|NCT02631343|Other|Essential newborn care|
293994|NCT02631356|Drug|Ringer's lactate solution|
293995|NCT02631356|Drug|Succinylated gelatin|
293996|NCT02631369|Device|Heidelberg Spectralis OCT device|
293997|NCT02631382|Procedure|wet cupping|In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).
In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected.
293998|NCT02631395|Other|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
293999|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
294000|NCT02631408|Drug|Vancomycin|Locally, intrawound applied vancomycin powder
294001|NCT02631421|Procedure|Blood Sampling|
294002|NCT02631421|Other|Cardiac MRI|
294003|NCT00194714|Biological|HER2 CTL vaccine (plus trastuzumab)|HER2 CTL peptide-based vaccine; administered intradermally every month for 6 total doses
294004|NCT02633449|Behavioral|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 60 minutes, two sessions per week for a total of six weeks
294005|NCT02633449|Device|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
294006|NCT02633449|Device|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
294007|NCT02633462|Procedure|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
294008|NCT02633462|Drug|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
294288|NCT02627040|Device|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
298843|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
298844|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
298845|NCT00398905|Drug|Enoxaparin|40 mg once daily (40 mg total daily dose)
298846|NCT00398918|Drug|zonisamide|zonisamide (100 mg)one time
298847|NCT00398918|Drug|Placebo|Placebo Comparator
298848|NCT00398931|Drug|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
298849|NCT00398931|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
298850|NCT00398944|Device|Evaluation of the impact of a guideline based computerized decision support system.|
298851|NCT00398957|Drug|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
298852|NCT00003235|Drug|paclitaxel|
298853|NCT00398970|Device|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
298854|NCT00398983|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days
298855|NCT00398996|Drug|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
298856|NCT00399009|Device|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
298857|NCT00399022|Drug|Duloxetine|
298858|NCT00399035|Drug|Cediranib|oral tablet
298859|NCT00399035|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
298860|NCT00399035|Drug|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m^2(day 1) followed by oral capecitabine 1,000 mg/ m^2twice daily (day 1 to day 15)
298861|NCT00399035|Drug|Cediranib Placebo|oral tablet
298862|NCT00399048|Drug|OROS hydromorphone HCL ; OxyContin|
298863|NCT00003235|Radiation|radiation therapy|
298864|NCT00401986|Device|Bronchial thermopladsty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY
297727|NCT00378599|Drug|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks
297728|NCT00378612|Device|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
297729|NCT00378625|Drug|Artesunate|
297730|NCT00378638|Drug|bevacizumab combined with dose dense chemotherapy|
297731|NCT00003141|Procedure|conventional surgery|
297732|NCT00378651|Procedure|Neck Auscultation|
297733|NCT00378664|Procedure|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
298103|NCT00369382|Drug|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
298104|NCT00369395|Drug|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
298105|NCT00369408|Drug|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
298106|NCT00369408|Drug|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
298107|NCT00003101|Drug|thiotepa|
298108|NCT00369434|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|
298109|NCT00369447|Procedure|External radiotherapy|Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
298110|NCT00369447|Biological|nimotuzumab|weekly dose until disease progression
298111|NCT00369460|Other|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
298112|NCT00369473|Drug|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
298113|NCT00369473|Drug|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
298114|NCT00369486|Procedure|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
298115|NCT00369486|Drug|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
296986|NCT00392574|Drug|Prulifloxacin|Tablet
296987|NCT00392574|Drug|Placebo|Tablet
296988|NCT00392587|Drug|GW856553|
296989|NCT00392613|Procedure|Strict versus lenient rate control|
296990|NCT00392639|Procedure|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
296991|NCT00392652|Drug|oral microencapsulated diindolylmethane|Given PO
296992|NCT00392665|Drug|Bevacizumab|Given intravenously on day one of each 3 week cycle
296993|NCT00003209|Drug|cisplatin|
296994|NCT00394966|Drug|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
296995|NCT00394966|Drug|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
296996|NCT00394966|Drug|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
296997|NCT00394966|Drug|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
296998|NCT00394966|Drug|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
297364|NCT00387075|Procedure|[123I]B-CIT injection and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
297365|NCT00387075|Drug|none established|PECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
297366|NCT00387088|Device|Respimat|
297367|NCT00387088|Drug|Tiotropium|
297368|NCT00387101|Device|Dermal - Living Skin Replacement (Dermal - LSR)|
297369|NCT00003185|Biological|autologous tumor cell vaccine|
296616|NCT00401180|Drug|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
296617|NCT00401180|Drug|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
296618|NCT00401193|Drug|Tranexamic acid tablets|3900 mg/Day
296619|NCT00401193|Drug|Tranexamic acid tablets|1950 mg/Day
296620|NCT00403806|Drug|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
296621|NCT00403806|Drug|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
296622|NCT00403806|Drug|Saline|Intravenous saline
296623|NCT00403819|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
296624|NCT00003262|Drug|etoposide|
296625|NCT00403832|Device|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
296626|NCT00403845|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
296627|NCT00403845|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
296628|NCT00403845|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
296629|NCT00403858|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
296630|NCT00403858|Drug|Lactulose|
296631|NCT00403884|Procedure|Selective RPE laser treatment|interventional SRT laser treatment
296632|NCT00403897|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
296633|NCT00403910|Drug|Canrenone|
296634|NCT00403923|Dietary Supplement|Lactose in water|
296635|NCT00003262|Drug|mechlorethamine hydrochloride|
296636|NCT00403936|Procedure|OA decompression manipulation|
296999|NCT00394992|Drug|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
295960|NCT02614443|Other|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
295961|NCT02614456|Drug|interferon-gamma and nivolumab|
295962|NCT02614469|Drug|Inosine|Inosine, 1000 mg
295963|NCT02614482|Drug|Fesoterodine|Administer medication to patients with overactive bladder
296269|NCT02645851|Device|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
296270|NCT02612155|Biological|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
296271|NCT02612155|Biological|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
296272|NCT00192660|Drug|Tenofovir|
296273|NCT02612168|Device|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm), and that result compared to the diagnosis made from the biopsy.
296274|NCT02612181|Drug|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
296275|NCT02612194|Drug|Crizotinib|
296276|NCT02612207|Device|Bilirubin Binding Capacity by hematofluorometry|
296277|NCT02612220|Procedure|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
296278|NCT02612220|Other|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
296279|NCT02612233|Drug|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
296280|NCT02612246|Drug|GLPG1972 single ascending doses|single dose, oral solution
296281|NCT02612246|Drug|Placebo single dose|single dose, oral solution, matching placebo
295663|NCT02621021|Drug|Aldeslaukin|Day 0 (within 24 hours of cell infusion), Aldesleukin 720,000 IU/kg (based on total body weight) IV over a 15 minute infusion and continuing for up to 4 days (maximum 12 doses).
295664|NCT02621021|Drug|Pembrolizumab|Day -2, day 21, day 42, and day 63, Pembrolizumab 2mg/kg IV over approximately 30 minutes.
295665|NCT02621021|Biological|young TIL|Day 0 (two to four days after last dose of fludarabine), cells will be administered intravenously over 20 to 30 minutes.
295666|NCT02621034|Procedure|k file|hand instrumentation
295667|NCT02621034|Procedure|Reciproc|reciprocating rotary instrument
295668|NCT02621034|Procedure|One shape|full rotation protocol
295669|NCT02621047|Drug|Alectinib|Participants will receive alectinib at a single oral dose of no more than 600 mg on Day 1.
295670|NCT02621060|Drug|Placebo|Placebo: 1200 mg per day for three months
295671|NCT00193440|Drug|CVP|
295672|NCT02621060|Drug|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
295673|NCT02621073|Drug|VeraFlo Negative Pressure Wound Therapy with Prontosan|VeraFlo device with Prontosan instillation (n=10).
295674|NCT02621073|Device|V.A.C Ulta Negative Pressure Wound Therapy System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
295675|NCT02621086|Dietary Supplement|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
295676|NCT02621099|Device|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
295677|NCT02621112|Biological|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
295964|NCT02614495|Drug|Sulfatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
295965|NCT02614508|Drug|Buparlisib|Given PO
295966|NCT02614508|Drug|Ibrutinib|Given PO
295967|NCT02616458|Other|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
295069|NCT02631733|Drug|Ferumoxytol|Correlative studies
295070|NCT02631733|Other|Laboratory Biomarker Analysis|Correlative studies
295374|NCT02625259|Drug|Lansoprazole|Lansoprazole capsules
295375|NCT02625272|Procedure|HALS-CME with no touch isolation|the novel hand-assisted laparoscopic surgery (HALS) with complete mesocolic excision (CME) and no touch isolation for right colon cancer
295376|NCT02625298|Device|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
295377|NCT02625298|Device|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
295378|NCT02625311|Procedure|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
295379|NCT00193856|Drug|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
295380|NCT02625324|Device|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
295381|NCT02627456|Biological|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites (PfSPZ) produced and manufactured by Sanaria Inc, located in Rockville, Maryland, USA. It is manufactured in compliance with GMP regulations (21 CFR 211), and USP& lt; 71& gt; sterility testing.
The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). PBS was manufactured in compliance with GMP by Sanaria, Inc. HSA is a licensed product approved for parenteral, IV administration to humans.
295382|NCT02627456|Biological|PfSPZ Challenge Material|PfSPZ Challenge are live and infectious aseptic, purified, cryopreserved NF54 P.falciparum sporozoites. PfSPZ Challenge is manufactured identical to PfSPZ Vaccine without irradiation.
295383|NCT00194103|Behavioral|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
295384|NCT02627456|Drug|PBS and HSA Diluent|Sterile 0.9% normal saline is commercially procured in the US and shipped to Mali. Normal saline is a clear liquid, making it indistinguishable from the study product.
295385|NCT02627469|Behavioral|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
295386|NCT02627469|Device|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
295387|NCT02627469|Device|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
294766|NCT02638428|Drug|Vandetanib|
294767|NCT02638428|Drug|Vemurafenib|
294768|NCT02638428|Drug|Trastuzumab|
294769|NCT02638441|Other|hospital anxiety and depression scale|Detection of infertility effect on emotional status
294770|NCT02638454|Procedure|Acute Resistance Exercise|1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
294771|NCT02638467|Drug|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
294772|NCT00195390|Biological|Prevenar|Prevenar 0.5ml/ Vial and PFS
294773|NCT02638467|Procedure|Bone Marrow Transplant|Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.
The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.
The goal is to transplant > 3 x 106 CD34+ cells/kg BW recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow
294774|NCT02638467|Drug|Bone Marrow cells|
295071|NCT02631733|Drug|Liposomal Irinotecan|Given IV
295072|NCT02631733|Procedure|Magnetic Resonance Imaging|Correlative studies
295073|NCT02631733|Drug|Veliparib|Given PO
295074|NCT02631746|Other|Laboratory Biomarker Analysis|Correlative studies
295075|NCT02631746|Biological|Nivolumab|Given IV
295076|NCT02631746|Other|Pharmacogenomic Study|Correlative studies
295077|NCT02631759|Drug|Lévétiracetam|Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .
The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.
The decay phase takes place in two phases:
A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)
Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening).
295078|NCT02631759|Drug|Placebo|Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .
The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.
The decay phase takes place in two phases:
A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)
Then a phase of 7 days of placebo 250 mg every 24 hours (evening).
294161|NCT02613650|Drug|MEK162 and FOLFIRI|MEK162 in combination with FOLFIRI in a 14 day cycle
MEK162 will be given single agent 6 day lead in and then will be given in combination with FOLFIRI
FOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 Leucovorin 400mg/m2 iv over 2 hours on day 1 5-fluoruracil 400mg/m2 slow iv push over 5 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)
Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle
Level -1: FOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: FOLFIRI + MEK162 30 mg twice daily Level 2: FOLFIRI + MEK162 45 mg twice daily
294456|NCT02643004|Device|Stenfilcon A|Study participants are randomized to wear Senofilcon A or Stenfilcon A pair of study lenses then crossover to the alternate pair.
294457|NCT02643017|Drug|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
294458|NCT02643017|Drug|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
294459|NCT02643030|Behavioral|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
294460|NCT02643030|Behavioral|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
294461|NCT02643043|Other|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
294462|NCT02643056|Drug|Panitumumab|IV administration every 2 weeks
294463|NCT00195936|Drug|Cinacalcet|
294464|NCT02643069|Other|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
294465|NCT02643082|Drug|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
294466|NCT02643082|Drug|Placebo MDI|Glycopyrronium and Formoterol Fumarate
294467|NCT02643095|Device|scleral contact lens|Scleral contact lens
294468|NCT02645006|Behavioral|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
294469|NCT02645006|Behavioral|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
294470|NCT02645019|Device|Cuffed ETT or LMA|
293879|NCT02618018|Procedure|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
293880|NCT02618031|Procedure|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA directly at the site of the clot.
293881|NCT02618057|Drug|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
293882|NCT02618057|Drug|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
293883|NCT02618070|Other|Yogurt|
293884|NCT02618083|Device|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
293885|NCT00193232|Drug|Bortezomib|
293886|NCT02618096|Drug|Oxytocin|
293887|NCT02618096|Drug|Dinoprostone|
293888|NCT02618096|Procedure|Membrane sweeping|
293889|NCT02618109|Biological|Collection of blood samples|Collection of blood samples
294162|NCT02613663|Procedure|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
294163|NCT02613663|Procedure|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
294164|NCT02613676|Device|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
294165|NCT00192816|Behavioral|reaction to pain|
294166|NCT02613676|Other|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
294167|NCT02613689|Behavioral|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
294168|NCT02613689|Behavioral|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
294169|NCT02613702|Procedure|Modified Free Gingival Graft|Free gingival graft technique at the inferior incisors area. In this technique, the graft is covered by a flap
298699|NCT00384488|Behavioral|Interactive Voice Response System (IVR)|
299059|NCT00376272|Drug|Valsartan|
299060|NCT00376272|Drug|Placebo|
299061|NCT00376285|Drug|CP-742,033|
299062|NCT00376285|Drug|Fenofibrate|
299063|NCT00376311|Drug|oral salmon calcitonin|
299064|NCT00376324|Drug|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
299065|NCT00003132|Drug|cisplatin|
299066|NCT00376337|Drug|Micafungin|IV
299067|NCT00376337|Drug|Systemic antifungal therapy|IV
299068|NCT00376350|Procedure|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
299069|NCT00376350|Procedure|Light Massage|light pressure massage of the low back.
299070|NCT00376350|Procedure|Pulsed Ultrasound|5 minutes pulsed ultrasound
299071|NCT00376363|Device|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
299072|NCT00376363|Device|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
299073|NCT00376376|Drug|levofloxacin at 250, 500, 750, and 1000 mg doses|
299074|NCT00376402|Biological|H5N1 Pandemic Influenza Vaccine|
299075|NCT00376415|Drug|Sutherlandia Phytotherapy|
299076|NCT00003133|Biological|filgrastim|
299077|NCT00376428|Drug|Gentamicin|
299078|NCT00376441|Procedure|Vaginal Surgery|patients undergoing vaginal surgery
299079|NCT00376454|Drug|GW493838|
299080|NCT00376467|Drug|Imatinib|
299081|NCT00376480|Biological|anti-thymocyte globulin|
298334|NCT00392860|Device|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
298335|NCT00392873|Behavioral|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
298336|NCT00392886|Drug|carboplatin|Given IV
298337|NCT00392886|Drug|cisplatin|Given IV
298338|NCT00392886|Drug|cyclophosphamide|Given IV
298339|NCT00003209|Drug|vinblastine sulfate|
298340|NCT00392886|Drug|etoposide|Given IV and orally
298341|NCT00392886|Drug|methotrexate|Given IV
298342|NCT00392886|Drug|temozolomide|Given orally
298343|NCT00392886|Drug|thiotepa|Given IV
298344|NCT00392886|Drug|vincristine sulfate|Given IV
298345|NCT00392886|Procedure|autologous bone marrow transplantation|Given on day 0
298346|NCT00392886|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
298347|NCT00392886|Procedure|peripheral blood stem cell transplantation|Given on day 0
298348|NCT00392886|Radiation|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
298700|NCT00384501|Device|Intacs|
298701|NCT00384514|Device|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
298702|NCT00384527|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
298703|NCT00384527|Drug|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
298704|NCT00384540|Procedure|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
298705|NCT00003170|Other|placebo|
295513|NCT02641106|Other|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
295514|NCT02641106|Other|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
295515|NCT02641132|Drug|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
295516|NCT02641132|Procedure|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
295517|NCT02641145|Radiation|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan, Gadolinium enhanced MRI scan
295518|NCT02641145|Device|MRI|
295519|NCT02641158|Other|Control Group|After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the "next step" visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward.
295520|NCT02641158|Behavioral|Care Facilitation Group|The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the "next step" visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services.
295521|NCT02641171|Other|Lack of intervention|This is an observational/validation study and there is no intervention involved.
295522|NCT02641197|Device|AngioDefender|Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.
Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators.
295523|NCT00002528|Drug|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
295524|NCT00195689|Biological|Human anti-TNF monoclonal antibody/adalimumab|
295525|NCT02641210|Procedure|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
295526|NCT02641210|Drug|Albendazole|All participants took Albendazole 400 mg before the intervention.
295527|NCT02641223|Device|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
294896|NCT02616120|Drug|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
294897|NCT02616120|Drug|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
294898|NCT02616133|Other|chart abstraction|abstraction of breast cancer patients with de-identified data
294899|NCT02616146|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
294900|NCT02616146|Drug|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
294901|NCT02616159|Other|Oatmeal|
294902|NCT00193115|Drug|Cyclophosphamide|
295208|NCT00002529|Drug|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
295209|NCT00196222|Procedure|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
295210|NCT02645370|Drug|Topiramate|
295211|NCT02611687|Drug|Placebo|Tablet
295212|NCT02611700|Drug|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
295213|NCT02611700|Drug|Paclitaxel|175mg/m^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
295214|NCT02611700|Drug|Cisplatin|60mg/m^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
295215|NCT02611700|Drug|Placebo|400mg,day1,weekly,until disease progression or toxicity
295216|NCT02611726|Other|Acupuncture|Acupuncture
295217|NCT02611739|Device|Medi-Port|Treatment
295218|NCT02611739|Device|Medi-Port|Control
295219|NCT02611752|Drug|CAM2038|CAM2038 subcutaneous injection
295220|NCT00192647|Drug|Peginterferon alfa-2a|For induction, participants will receive 360 mcg SC once weekly for 12 weeks. The standard regimen will include 180 mcg SC once weekly for 36 or 48 weeks, depending upon treatment assignment.
295221|NCT02611765|Drug|Enhanced therapy|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
294597|NCT02622698|Dietary Supplement|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
294598|NCT00193544|Drug|Arsenic Trioxide|
294599|NCT02622698|Other|Placebo|Placebo- Patients did not take any protein supplementation after surgery
294600|NCT02622711|Behavioral|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
294601|NCT02622711|Behavioral|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
294602|NCT02622711|Behavioral|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
294603|NCT02622711|Behavioral|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
294604|NCT02622724|Drug|Interferon beta-1a|Investigational drug
294605|NCT02622724|Drug|Placebo|Placebo for investigational drug
294606|NCT02622737|Other|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
294903|NCT02616172|Genetic|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
294904|NCT02616185|Biological|PF-06755992|PF-06755992 will be administered on Day 1 of each cycle. Two dose levels will be evaluated.
294905|NCT02616185|Biological|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
294906|NCT02616185|Device|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
294907|NCT02616185|Biological|Tremelimumab|PF-06753388 will be administered every 28 days. Two dose levels will be evaluated.
294908|NCT02616185|Drug|Sunitinib|Sunitinib will be taken daily. Up to three dose levels may be evaluated to determine the MTD when given in combination with the PrCa VBIR.
294909|NCT00193258|Drug|Erlotinib|150 mg po daily
294910|NCT02618382|Drug|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
294911|NCT02618395|Drug|SPARCHBA1|
294289|NCT02627053|Drug|rivaroxaban|
294290|NCT02627066|Behavioral|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
294291|NCT02627066|Behavioral|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
294292|NCT02627079|Other|Daily SMS text messaging|
294293|NCT02627092|Other|Copper linen exposure|Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
294294|NCT02627105|Behavioral|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
294295|NCT02627105|Behavioral|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
294296|NCT00194051|Procedure|gastric bypass surgery|
294297|NCT02627118|Device|FRESENIUS OPTIFLUX 160NR|BLOOD SAMPLING BEFORE AND AFTER 2 MONTHS OF DIALYSIS WITH THE FRESENIUS OPTIFLUX F160NR DIALYZER
294298|NCT02627118|Device|NIPRO ELISIO-15H|BLOOD SAMPLING BEFORE AND AFTER 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
294299|NCT02627131|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
294300|NCT02629159|Drug|ABT-494|ABT-494 Oral Tablet
294301|NCT02629159|Drug|Placebo for ABT-494|Placebo Oral Tablet
294302|NCT02629159|Drug|Adalimumab|Adalimumab subcutaneous injection
294303|NCT02629159|Drug|Placebo for Adalimumab|Placebo subcutaneous Injection
294304|NCT02629211|Device|NaviAid™ AB|NaviAid™ AB Procedure
294305|NCT02629224|Drug|ASP8825|Oral
294306|NCT02629237|Other|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
294307|NCT02629250|Procedure|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR <100 bpm, Hb >8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV >10% or blood loss >250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
298865|NCT00402012|Drug|Pioglitazone|During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
293729|NCT02637999|Drug|Myrcludex B|
293730|NCT02637999|Drug|pegINF|
293731|NCT02638012|Drug|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
293732|NCT02638012|Other|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
293733|NCT02638025|Device|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
293734|NCT02638038|Drug|INT131|
293735|NCT02638051|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
293736|NCT02638051|Dietary Supplement|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
293737|NCT02638051|Drug|IPCI (CDDP+5FU)|Inpraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
293738|NCT02638064|Procedure|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
293739|NCT00195325|Drug|TTI-237|
293740|NCT02638090|Drug|Vorinostat|Administered per treatment arm guidelines.
293741|NCT02638090|Drug|Pembrolizumab|Administered per treatment arm guidelines.
293742|NCT02638103|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
293743|NCT02638103|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
293744|NCT02638103|Drug|Placebo|Matching Placebo
293745|NCT02638116|Drug|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
298116|NCT00369486|Drug|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
298117|NCT00369486|Drug|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
298118|NCT00003101|Drug|vincristine sulfate|
298119|NCT00369486|Drug|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
298120|NCT00369499|Device|PFO Closure|
298121|NCT00369512|Drug|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
298122|NCT00369538|Drug|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
298123|NCT00369538|Drug|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
298491|NCT00407953|Device|Prolieve® Thermodilatation System|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH.
298492|NCT00407966|Drug|alvocidib|Given IV
298493|NCT00407966|Drug|cytarabine|Given IV
298494|NCT00407966|Drug|mitoxantrone hydrochloride|Given IV
298495|NCT00407992|Device|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
298496|NCT00407992|Device|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
298497|NCT00003278|Drug|dexamethasone|
298498|NCT00408005|Drug|Asparaginase|Given IM or IV
298499|NCT00408005|Drug|Cyclophosphamide|Given IV
298500|NCT00408005|Drug|Cytarabine|Given IT, IV, or SC
298501|NCT00408005|Drug|Daunorubicin Hydrochloride|Given IV
298502|NCT00408005|Drug|Dexamethasone|Given IV or PO
298503|NCT00410631|Radiation|radiation therapy|
297370|NCT00387114|Drug|Vitamin C|
297371|NCT00387127|Drug|Lapatinib oral tablets|Lapatinib is administered orally once daily.
297372|NCT00387127|Drug|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
297373|NCT00387127|Drug|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
297374|NCT00387140|Drug|MK2295|
297375|NCT00387153|Drug|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
297376|NCT00387179|Drug|Melatonin|5mg, pill, once
297377|NCT00387179|Drug|Methylxanthine|2.9 mg/kg, pill, once
297378|NCT00387179|Procedure|Light Therapy|Bright light exposure
297379|NCT00387192|Drug|Optivate|Plasma-derived Factor VIII
297380|NCT00003185|Biological|sargramostim|
297381|NCT00387205|Drug|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
297382|NCT00387218|Behavioral|Exercise, Physical therapy|
297383|NCT00387231|Procedure|Percutaneous coronary angioplasty/intervention (PCI)|
297384|NCT00387231|Drug|Anti-ischemic drug therapy|
297385|NCT00387244|Device|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
297734|NCT00378677|Drug|Cyclosporine A dry powder inhalation (Drug)|
297735|NCT00378690|Drug|leuprorelin acetate|LHRH antagonist
297736|NCT00378703|Drug|Sorafenib|Given PO
297737|NCT00378703|Drug|temsirolimus|Given IV
297738|NCT00378703|Biological|bevacizumab|Given IV
297739|NCT00378716|Drug|5-fluorouracil|
297000|NCT00394992|Drug|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
297001|NCT00395018|Drug|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
297002|NCT00395031|Drug|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
297003|NCT00395044|Drug|gabapentin|
297004|NCT00003215|Drug|methotrexate|
297005|NCT00395044|Behavioral|Standardized behavioral therapy|
297006|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
297007|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
297008|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
297009|NCT00395057|Drug|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
297010|NCT00395070|Biological|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
297011|NCT00395070|Drug|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
297012|NCT00395070|Drug|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
297013|NCT00395083|Behavioral|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
297014|NCT00395109|Device|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
297015|NCT00003215|Drug|methylprednisolone|
297016|NCT00395122|Device|Retinal nerve fiber layer and macular thickness measurements|
297017|NCT00395135|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
297018|NCT00398151|Drug|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
297019|NCT00398190|Behavioral|Control|Standard anti-tobacco programming
297020|NCT00398190|Behavioral|Media Literacy|Anti-smoking media literacy curriculum intervention
296282|NCT02612246|Drug|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
296283|NCT00192660|Drug|Abacavir|
296284|NCT02612246|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
296285|NCT02612259|Dietary Supplement|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
296286|NCT02612259|Other|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
296287|NCT02612272|Drug|Ketorolac|intra-articular ketorolac
296288|NCT02612272|Drug|Betamethasone|intra-articular betamethasone
296637|NCT00403949|Drug|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
296638|NCT00403949|Drug|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
296639|NCT00403962|Drug|vestipitant/paroxetine|
296640|NCT00403975|Drug|diquafosol tetrasodium ophthalmic solution, 2%|
296641|NCT00403988|Drug|Oxaliplatin|
296642|NCT00403988|Drug|vinorelbine|
296643|NCT00404001|Drug|MD-0727|
296644|NCT00404014|Drug|AL-208|1 dose of 300 mg
296645|NCT00404014|Drug|Placebo|1 dose of placebo
296646|NCT00000503|Drug|streptokinase|
296647|NCT00003262|Drug|prednisone|
296648|NCT00404040|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
296649|NCT00404040|Drug|Lactulose|
296650|NCT00404053|Drug|Clopidogrel|
296651|NCT00404066|Drug|Lapatinib|1250 mg, tablets, oral every day during treatment with docetaxel(every 3 weeks x 4 )
296652|NCT00406887|Drug|Difluprednate Ophthalmic Emulsion|
296653|NCT00406900|Procedure|Treatment of metastatic disease|
295968|NCT02616458|Other|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
295969|NCT02616471|Dietary Supplement|High-fat cheese|
295970|NCT02616471|Dietary Supplement|Low-fat cheese|
295971|NCT02616471|Dietary Supplement|No-cheese/carbohydrate|
295972|NCT02616484|Drug|Dichloroacetate (DCA)|Participants will receive the dosage of DCA (in liquid form) based on the genotyped GSTZ1 haplotype status. ECT carriers will receive 12.5 mg/kg/12hr DCA, which is the standard dose. EGT non-carriers will receive half that dose.
295973|NCT02616484|Other|Placebo|Participants will receive the exact dose of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
295974|NCT02616484|Genetic|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status for EGT carriers and EGT non-carriers will receive half that dose.
295975|NCT02616497|Drug|Aspirin|COX-1 inhibitor
295976|NCT00193141|Drug|Paclitaxel|
295977|NCT02616497|Drug|Triflusal|COX-1 inhibitor
295978|NCT02616510|Procedure|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
295979|NCT02616523|Drug|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
295980|NCT02616523|Drug|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
295981|NCT02616523|Other|placebo|The participants will be given infusion of normal saline intravenously.
295982|NCT02616523|Drug|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
295983|NCT02616536|Other|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
295984|NCT02616549|Behavioral|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
296289|NCT02612285|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
296290|NCT02612298|Drug|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
296291|NCT02612298|Drug|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
295388|NCT02627482|Device|Fetal heart rate monitor (Monica AN24)|The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.
The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements.
295389|NCT02627495|Device|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
295678|NCT02621112|Biological|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
295679|NCT02621112|Biological|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
295680|NCT02621125|Dietary Supplement|Fertilix|daily supplementation
295681|NCT02621125|Other|Placebo|Placebo
295682|NCT00193440|Drug|Ibritumomab Tiuxetan|
295683|NCT02621151|Biological|Pembrolizumab|
295684|NCT02621151|Procedure|Transurethral Resection of Bladder Tumor|
295685|NCT02621151|Drug|Gemcitabine|
295686|NCT02621151|Radiation|External Beam Radiation Therapy|
295687|NCT02623101|Procedure|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
295688|NCT02623114|Drug|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
295689|NCT02623114|Drug|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
295690|NCT02623127|Drug|Sunitinib|
295691|NCT02623140|Device|Biofreedom|PCI with Biofreedom stent
295692|NCT02623140|Device|Orsiro|PCI with Orsiro stent
295693|NCT00193583|Drug|Carboplatin|
295694|NCT02623153|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
295079|NCT02633930|Drug|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
295080|NCT02633930|Drug|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
295081|NCT02633930|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
295082|NCT02633943|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
295083|NCT02633956|Drug|Obeticholic Acid|Once a day (QD) by mouth (PO)
295084|NCT02633956|Drug|Atorvastatin|Initiate treatment with Atorvastatin at 4 Week Visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 Visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at 12 week visit as clinically indicated.
295085|NCT00194844|Behavioral|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
295086|NCT02633956|Drug|Placebo|Once a day (QD) by mouth (PO)
295390|NCT02627508|Drug|Pregnenolone|orally administered Pregnenolone capsules
295391|NCT02627508|Drug|Placebo|orally administered placebo capsules
295392|NCT02627521|Procedure|PRU guided CABG|Coronary Artery Bypass Surgery
295393|NCT02627521|Procedure|CABG per standard of care|Coronary Artery Bypass Surgery
295394|NCT00194103|Behavioral|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
295395|NCT02627521|Device|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
295396|NCT02627521|Drug|Ticagrelor|Ticagrelor administration prior to randomization
295397|NCT02627534|Procedure|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
294471|NCT02645032|Biological|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
294472|NCT00196170|Procedure|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
294473|NCT02645032|Biological|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
294775|NCT02638480|Device|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
294776|NCT02638506|Drug|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
294777|NCT02638506|Other|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
294778|NCT02638519|Other|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
294779|NCT02638519|Other|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
294780|NCT02638519|Drug|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
294781|NCT02640781|Device|self-expandable metal stent insertion|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
294782|NCT02640794|Drug|Aspirin/acetylsalicylic acid +clopidogrel|Aspirin/acetylsalicylic acid (80-325 mg/d) + clopidogrel (75 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
294783|NCT02640794|Drug|Aspirin/acetylsalicylic acid|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
294784|NCT02640807|Drug|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR>2.5 or platelet count < 35,000
294170|NCT02613702|Procedure|Original Free Gingival Graft technique|Original technique of free gingival graft at the inferior incisors area
294171|NCT02613715|Dietary Supplement|Blackberry juice with 12% ethanol|
294172|NCT02613715|Dietary Supplement|Blackberry juice|
294173|NCT02613728|Behavioral|Questionnaires|Questionnaires completed about levels of anxiety and depression, location and amount of pain, and quality of life at baseline, at hospital discharge, and 14 and 30 days after surgery.
294174|NCT02613728|Behavioral|Fluid Diary|Participants fill out a diary of how much they urinate each day. On Day 2 after surgery, surgical team will tell participant if they need to continue using it.
294175|NCT02613728|Device|TeleRecovery Device|On Day 2 after surgery, participant uses RecoverMI device to have a video conference call with surgical team in the morning. If the surgical team thinks it is needed, participant will have a follow-up video conference call with them that afternoon or evening.
294176|NCT00192829|Procedure|Blood sample withdrawal|
294177|NCT02615847|Drug|Memantinhydrochlorid|Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.
The study drug will be taken once a day per os, during 12 month.
294178|NCT02615860|Other|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
294474|NCT02645032|Biological|VAXIGRIP®|Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)
294475|NCT02645058|Procedure|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
294476|NCT02645058|Procedure|ESWL|Treatment by extracorporeal shock waves lithotripsy
294477|NCT02645058|Device|Rigid and flexible ureteroscope|
294478|NCT02645058|Device|Lithotripter|
294479|NCT02645058|Device|Holmium laser|
294480|NCT02645058|Device|Basket for fragment removal|
294481|NCT02645058|Procedure|General or spinal anesthesia|
294482|NCT02645058|Drug|Intravenous pain medication|If required by the patient
294483|NCT00196183|Procedure|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
299082|NCT00376480|Biological|peripheral blood lymphocyte therapy|
299083|NCT00376480|Drug|fludarabine phosphate|
299084|NCT00376480|Drug|methylprednisolone|
299085|NCT00376480|Drug|thiotepa|
293890|NCT02620371|Procedure|modified pectoral block|Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the " Pecs II block" by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.
We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line.
293891|NCT02620384|Drug|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
293892|NCT02620384|Drug|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
293893|NCT02620410|Device|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
293894|NCT02620423|Biological|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
293895|NCT02620423|Drug|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
293896|NCT00193388|Drug|Topotecan|
293897|NCT02620423|Drug|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
293898|NCT02620423|Drug|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
293899|NCT02620423|Drug|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
298706|NCT00384553|Drug|Rituximab|
298707|NCT00384553|Drug|DHAP|
298708|NCT00384553|Drug|TEC|
298709|NCT00384553|Drug|autologous stem cell transplantation|
298710|NCT00384566|Drug|Carvedilol|anit hypertensive medication
298711|NCT00384566|Drug|Metoprolol|Anti hypertensive medication
298712|NCT00384579|Drug|Botulinum toxin B|Botulinum Toxin B
298713|NCT00384579|Drug|Placebo|Placebo
298714|NCT00384592|Drug|Esomeprazole|
298715|NCT00384592|Procedure|Physical exam|
298716|NCT00003171|Drug|bryostatin 1|
298717|NCT00384592|Procedure|Pregnancy test if applicable|
298718|NCT00384605|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
298719|NCT00384605|Drug|placebo|Placebo capsule once daily. Treatment for 52 weeks.
298720|NCT00384618|Drug|pravastatin|
298721|NCT00384618|Drug|vitamin E|
298722|NCT00384631|Other|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
298723|NCT00384631|Drug|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
298724|NCT00387660|Drug|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
299086|NCT00376480|Procedure|allogeneic hematopoietic stem cell transplantation|
299087|NCT00003133|Drug|cisplatin|
299088|NCT00376480|Procedure|in vitro-treated peripheral blood stem cell transplantation|
299089|NCT00376480|Radiation|total-body irradiation|
299090|NCT00376493|Drug|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
295823|NCT02634307|Drug|ALKS 8700|Capsules taken twice daily
295824|NCT02634320|Drug|Aripiprazole Lauroxil|Monthly IM injection
295825|NCT02634333|Procedure|Prompt Sham|A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
295826|NCT02634333|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
295827|NCT02636491|Device|MD-Logic-Automated Insulin Delivery System|Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller "OFF", this will automatically save the log file. The patient will return to his regular insulin treatment.
295828|NCT00195156|Drug|Depakote|
295829|NCT02636491|Device|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
295830|NCT02636504|Device|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
295831|NCT02636517|Biological|Fecal Microbiota Transplant|Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
295832|NCT02636530|Behavioral|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
295833|NCT02636530|Behavioral|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
295834|NCT02636543|Other|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
295835|NCT02636543|Other|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
295836|NCT02636556|Radiation|concurrent radiochemotherapy|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w*4.
295837|NCT02636569|Drug|topical DFMO+diclofenac twice daily|Topical DFMO Diclofenac Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from two locations at the baseline visit. The biopsy will be taken from one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.
After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun.
295222|NCT02611765|Drug|Standard therapy|A single dose of intramuscular 2.4 million units of benzathine penicillin G
295223|NCT02611778|Biological|ranibizumab|
295224|NCT02611791|Device|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
295225|NCT02611791|Device|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
295226|NCT02611804|Drug|Diclofenac sodium|
295227|NCT02611804|Drug|Diclofenac sodium|
295228|NCT02611804|Drug|Placebo|
295528|NCT02641236|Drug|Vancomycin-polymyxin B|
295529|NCT02641249|Device|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
295530|NCT02641275|Other|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
295531|NCT02643381|Procedure|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
295532|NCT02643381|Device|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
295533|NCT02643394|Drug|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
295534|NCT02643394|Drug|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
295535|NCT02643407|Drug|Docetaxel|60mg/m2
295536|NCT02643407|Drug|Nedaplatin|80mg/m2
295537|NCT02643407|Drug|Cisplatin|75mg/m2
294912|NCT02618395|Drug|SPARCHBA2|
294913|NCT02618395|Drug|ReferenceHBA|
294914|NCT02618408|Drug|SPN-810|
294915|NCT02618408|Drug|Placebo|
294916|NCT02618434|Drug|SPN-810|
294917|NCT02618434|Drug|Placebo|
294918|NCT02618447|Device|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
294919|NCT02618447|Procedure|Portal vein embolization|
294920|NCT00193258|Drug|Imatinib|400-600mg daily
294921|NCT02618460|Device|Non contrast-enhanced magnetic resonance imaging|
294922|NCT02618473|Other|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
294923|NCT02618486|Procedure|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
294924|NCT02618499|Drug|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
294925|NCT02618512|Drug|SBC-103|1mg/kg or 3mg/kg every other week
295229|NCT02611817|Drug|Vedolizumab SC 108|
295230|NCT02611817|Drug|Placebo SC|
295231|NCT00192647|Drug|Ribavirin|Participants will receive 1000 or 1200 mg PO daily in divided doses, with the dose determined using body weight, for 48 weeks.
295232|NCT02611817|Drug|Vedolizumab IV 300 mg|
295233|NCT02611830|Drug|Vedolizumab IV 300 mg|
295234|NCT02611830|Drug|Placebo IV|
295235|NCT02611830|Drug|Vedolizumab SC 108 mg|
295236|NCT02611830|Drug|Placebo SC|
295237|NCT02613988|Device|Dynamic susceptibility contrast MRI|
294607|NCT02622737|Device|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
294608|NCT02622737|Device|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
294609|NCT00193544|Drug|Thalidomide|
294610|NCT02622750|Procedure|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
294611|NCT02622750|Procedure|four-branched Dacron graft|The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the "open" aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft.
294612|NCT02622763|Biological|Tolerogenic Dendritic Cells|Intralesional administration
294613|NCT02622776|Other|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
294614|NCT02622789|Other|Pilates Exercises|Pilates method based stability exercise intervention
294615|NCT02625051|Procedure|Percutaneous nephrolithotomy|Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
294616|NCT02625051|Device|Ureteral stent (double-J stent)|After ureteroscopy (URS) is done and stone clearance is achieved, a 4.6 french ureteral stent is routinely placed at the end of the procedure to drain the kidney for 1-3 weeks.
294617|NCT02625051|Device|Percutaneous nephrostomy tube|At the end of the percutaneous nephrolithotomy (PNL) procedure, a 10 french Cope loop percutaneous nephrostomy tube is placed in all patients to drain the kidney for 1-2 days.
294618|NCT02625064|Other|Blood samples collection before treatment|
294619|NCT02625064|Other|Blood samples collection after treatment|
294620|NCT02625064|Other|laboratory biomarker proteomic analysis|
294621|NCT02625077|Procedure|Laparoscopic gastroesophageal valvuloplasty|
294622|NCT02625077|Procedure|Laparoscopic Toupet fundoplication|
293746|NCT02638116|Drug|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
293747|NCT02638129|Drug|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
293748|NCT02638129|Drug|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
293749|NCT02640287|Biological|Blood or bone marrow samples|
294009|NCT02633475|Genetic|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
294010|NCT02633488|Drug|Metformin|
294011|NCT02633501|Drug|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
294012|NCT00194792|Radiation|radiation therapy|Undergo radiation therapy
294013|NCT02633501|Drug|Gadobenate dimeglumine|Single intravenous (IV) bolus injection at a rate of 2 mL/second
294014|NCT02633501|Device|MRI|
294015|NCT02633514|Drug|Cisplatin|25mg/m2,iv gtt,d1-3
294016|NCT02633514|Drug|Etoposide|75mg/m2,iv gtt,d1-3
294017|NCT02633514|Radiation|radiotherapy|60Gy/30Fx
294018|NCT02633527|Drug|Placebo|
294019|NCT02633527|Drug|SPN-812 ER, Low Dose|
294020|NCT02633527|Drug|SPN-812 ER, Low-Medium Dose|
294021|NCT02633527|Drug|SPN-812 ER, High-Medium Dose|
294022|NCT02633527|Drug|SPN-812 ER, High Dose|
294023|NCT00194792|Other|laboratory biomarker analysis|Correlative studies
294024|NCT02633540|Radiation|IMRT Radiation|Raditation to Larynx
294025|NCT02633553|Radiation|adjuvant radiotherapy|50Gy/25Fx
294026|NCT02633566|Device|Plantar orthoses|
294027|NCT02633579|Drug|erythromycin lactobionate|intravenous administration of erythromycin
294028|NCT02633579|Drug|Atropine|intravenous administration of atropine
298504|NCT00410644|Drug|OROS Hydromorphone HCI|
298505|NCT00410657|Biological|alemtuzumab|
298506|NCT00003294|Drug|amifostine trihydrate|
298507|NCT00410657|Drug|methylprednisolone|
298508|NCT00410657|Drug|prednisone|
298509|NCT00410657|Other|flow cytometry|
298510|NCT00410657|Other|immunologic technique|
298511|NCT00410657|Other|pharmacological study|
298512|NCT00410683|Other|clinical observation|
298513|NCT00410683|Procedure|adjuvant therapy|
298514|NCT00410683|Radiation|3-dimensional conformal radiation therapy|
298515|NCT00410696|Drug|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
298516|NCT00410696|Drug|Pegfilgrastim|6 mg/day sc at day +1
298517|NCT00003294|Drug|carboplatin|
298866|NCT00402025|Genetic|OncoVEX GM-CSF modified herpes-simplex 1 virus|multiple dose levels, every 3 weeks for up to 6 injections
298867|NCT00402038|Drug|SC Methylnaltrexone|Dose 1
298868|NCT00402038|Drug|SC Placebo|
298869|NCT00402051|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
298870|NCT00402051|Drug|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
298871|NCT00402051|Drug|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
298872|NCT00402077|Drug|pramlintide acetate|subcutaneous injection, three times a day, 120mcg
298873|NCT00402077|Drug|sibutramine|oral tablet, once a day, 10mg
298874|NCT00003251|Radiation|radiation therapy|
298875|NCT00402077|Drug|phentermine|oral tablet, once a day, 37.5mg
297740|NCT00378716|Drug|leucovorin calcium|
297741|NCT00378716|Drug|tegafur|
297742|NCT00003141|Procedure|peripheral blood stem cell transplantation|
297743|NCT00378716|Drug|uracil|
297744|NCT00378729|Drug|Metformin and FSHr|treatment for infertility
297745|NCT00378729|Procedure|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
297746|NCT00378755|Drug|velcade|
297747|NCT00378768|Biological|anti-thymocyte globulin|
297748|NCT00378781|Drug|Heparin|Heparin flush solution into CVC once daily.
297749|NCT00378781|Drug|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
297750|NCT00378820|Behavioral|Whey without milk minerals|
297751|NCT00381550|Drug|triapine|Given IV
297752|NCT00381550|Procedure|laboratory biomarker analysis|Correlative study
297753|NCT00381563|Device|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
297754|NCT00381563|Device|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
297755|NCT00381576|Behavioral|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
297756|NCT00003152|Drug|cyclophosphamide|
297757|NCT00381589|Drug|ipratropium bromide 0.03% spray|
297758|NCT00381602|Drug|GHRP-1/AG 70 mg depot in ESRD|
297759|NCT00381602|Other|Placebo|
298124|NCT00369551|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
298125|NCT00369551|Drug|paclitaxel|Given IV
298126|NCT00372593|Drug|etoposide|Given IV over 1-4 hours
298127|NCT00372593|Drug|gemtuzumab ozogamicin|Given IV over 2 hours
297021|NCT00398203|Device|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
297386|NCT00387257|Drug|Rilapladib (SB-659032)|
297387|NCT00387270|Drug|Dimebon|Dimebon 10 or 20 mg TID x 7 days
297388|NCT00387283|Drug|AVI-4020 Injection|
297389|NCT00387296|Device|functional microarray|functional microarray application
297390|NCT00387309|Drug|Methylnaltrexone (MOA-728)|
297391|NCT00389922|Drug|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
297392|NCT00389922|Drug|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
297393|NCT00389922|Genetic|comparative genomic hybridization|Molecular correlative study
297394|NCT00389922|Genetic|cytogenetic analysis|Molecular correlative study
297395|NCT00389922|Genetic|gene expression analysis|Molecular correlative study
297396|NCT00389922|Genetic|mutation analysis|Molecular correlative study
297397|NCT00389922|Genetic|polymerase chain reaction|Molecular correlative study
297398|NCT00389922|Genetic|polymorphism analysis|Molecular correlative study
297399|NCT00389922|Genetic|proteomic profiling|Molecular correlative study
297400|NCT00003196|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
297401|NCT00389922|Genetic|reverse transcriptase-polymerase chain reaction|Molecular correlative study
297402|NCT00389922|Other|immunohistochemistry staining method|Molecular correlative study
297403|NCT00389922|Other|laboratory biomarker analysis|Molecular correlative study
297404|NCT00389922|Drug|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
297405|NCT00389922|Drug|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
297406|NCT00389935|Drug|Thalidomide|Thalidomide 50 - 200 mg once at nightime
296654|NCT00406913|Drug|mupirocin ointment|
296655|NCT00406913|Other|SOC sterilization|
296656|NCT00406926|Drug|Somatropin|
296657|NCT00406939|Genetic|IL-12 gene|
296658|NCT00406952|Procedure|electronic diary|
296659|NCT00406952|Drug|Sertraline|
296660|NCT00003273|Drug|methotrexate|
296661|NCT00406952|Drug|Placebo|
296662|NCT00406952|Procedure|voice acoustics|
296663|NCT00406965|Drug|HAE1 (PRO98498)|
296664|NCT00406978|Drug|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
297022|NCT00398216|Drug|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
297023|NCT00398229|Drug|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
297024|NCT00003230|Drug|paclitaxel|
297025|NCT00398242|Device|above or below elbow cast for the last 3 weeks of treatment|
297026|NCT00398255|Behavioral|self-management program|
297027|NCT00398268|Procedure|Kirschner-wire fixation|
297028|NCT00398281|Drug|dutasteride|Given orally
297029|NCT00398281|Other|placebo|Given orally
297030|NCT00398294|Drug|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
297031|NCT00398307|Drug|S-1/Cisplatin|S-1 administration will be determined by degree of renal impairment as follows:
Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD
Pharmacokinetic Phase (Part 1):
On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.
Treatment will be followed by 1 week of recovery (Days 15 through 21).
Extension Phase (Part 2):
S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.
297032|NCT00398320|Drug|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
296292|NCT02612311|Biological|Obinutuzumab|Obinutuzumab: IV infusion
296293|NCT02612311|Biological|Ublituximab|Ublituximab: IV infusion
296294|NCT00192660|Drug|Efavirenz (EFV)|
296295|NCT02614508|Biological|Ofatumumab|Given IV
296296|NCT00193011|Drug|Docetaxel|Docetaxel
296297|NCT02614521|Other|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
296298|NCT02614534|Drug|MITOMYCIN-C 40 mg|
296299|NCT02614547|Drug|SAGE-547|
296300|NCT02614547|Drug|Placebo|
296301|NCT02614560|Drug|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
296302|NCT02614560|Drug|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
296303|NCT02614560|Drug|Methotrexate|5-10 mg/m2 on Day 1 and Day 5 mg/m2 intravenously (IV) on Days 3, 6, and 11 after the stem cell transplant
296304|NCT02614560|Drug|Tacrolimus|0.03 mg/kg/day intravenously (IV), initial dose given 1 day before the transplant; subsequent oral or IV doses will target blood levels 5-15 ng/ML
296305|NCT02614560|Drug|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
296306|NCT02614560|Drug|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
296307|NCT00193011|Drug|Cyclophosphamide|Cyclophosphamide
296308|NCT02614573|Device|CoagucheckXSR Capillary INR measures|We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.
If capillary INR is <2 or >3, then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If discordant results (for which clinical measures should be taken), then re-form venous INR measure within 24h and adaptation of treatment according to venous results.
If capillary INR is > 4, then verification by venous measure and refer to general practitioner.
296309|NCT02614586|Drug|TAK-058|TAK-058 oral solution.
296310|NCT02614586|Drug|Ondansetron|Ondansetron capsule.
296311|NCT02614586|Drug|TAK-058 Placebo|TAK-058 placebo-matching, solution.
296665|NCT00406978|Drug|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
295695|NCT02623153|Drug|capecitabine|capecitabine of 1000 mg/m2
295696|NCT02623153|Drug|S1|S1 of 40 mg/m2
295697|NCT02623153|Drug|Docetaxel|docetaxel 40 mg/m2
295698|NCT02623179|Other|culture versus Molecular diagnostics|Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
295699|NCT02623192|Other|Patients who have performed the ARDS pulmonary function test|
295700|NCT02623205|Drug|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission.
295701|NCT02623205|Drug|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders.
295985|NCT02616562|Drug|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once-weekly.
295986|NCT02616562|Drug|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
295987|NCT00193141|Drug|Carboplatin|
295988|NCT02616588|Behavioral|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
295989|NCT02616601|Drug|Carac Cream|Active drug product (brand) applied to face or scalp once daily for 2 weeks
295990|NCT02618902|Biological|tolerogenic dendritic cells (tolDC)|dose-escalation
295991|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
295992|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
295993|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
295994|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
295995|NCT00193284|Drug|Carboplatin|
295996|NCT02618941|Biological|AFFITOPE® PD01A|s.c. injection
295997|NCT02618954|Other|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
295398|NCT02629705|Dietary Supplement|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
295399|NCT02629705|Dietary Supplement|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
295400|NCT02629718|Drug|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
295401|NCT00194454|Behavioral|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
295402|NCT02629718|Procedure|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
295403|NCT02629731|Device|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
295404|NCT02629744|Drug|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
295405|NCT02629744|Device|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
295406|NCT02629757|Drug|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
295407|NCT02629770|Drug|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
295408|NCT02629783|Other|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
295409|NCT02629783|Other|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
295702|NCT02623218|Device|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
295703|NCT02623218|Device|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
295704|NCT00193596|Drug|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
295705|NCT02623231|Drug|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
294785|NCT02640807|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
294786|NCT02640820|Drug|Sensitizing DPCP Ointment|Sensitization
294787|NCT02640820|Drug|Treatment DPCP Ointment|Treatment
294788|NCT02640833|Drug|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
294789|NCT02640833|Drug|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
295087|NCT02633969|Drug|Indomethacin Capsules low dose|
295088|NCT02633969|Drug|Indomethacin Capsules high dose|
295089|NCT02633995|Procedure|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
295090|NCT02634008|Drug|Paritaprevir/ritonavir/ombitasvir|
295091|NCT02634008|Drug|Dasabuvir|
295092|NCT02634008|Drug|Ribavirin|
295093|NCT02634021|Drug|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
295094|NCT02634021|Drug|midazolam group|intravenous loading of midazolam for 0.05 mg/kg
295095|NCT02634034|Drug|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
295096|NCT00194857|Drug|erythropoietin, GCSF|
295097|NCT02634034|Drug|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
295098|NCT02634034|Drug|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
295099|NCT02634047|Device|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
295100|NCT02634047|Device|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
295101|NCT02636192|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study.
294484|NCT02645058|Device|X-ray|To focus the stone
294485|NCT02645058|Device|Ultrasound|To focus the stone
294486|NCT02645071|Behavioral|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
294487|NCT02645084|Other|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
294488|NCT02645097|Procedure|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
294489|NCT02645110|Device|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
294490|NCT02645110|Device|Tap water|Washing hand with water alone in comparison to hand washing with soap
294491|NCT02611466|Drug|ASP7962|oral
294492|NCT00192608|Drug|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
294493|NCT02611466|Drug|Naproxen|oral
294494|NCT02611466|Drug|Placebo|oral
294495|NCT02611492|Drug|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
294790|NCT02640846|Drug|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
294791|NCT00195663|Drug|Methotrexate|
294792|NCT02640846|Drug|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
294793|NCT02640885|Device|Foley's cather ballon|
294794|NCT02640898|Radiation|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
293900|NCT02620423|Drug|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
293901|NCT02620423|Drug|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
293902|NCT02620436|Other|Core Mother Shelter Model|
293903|NCT02620449|Other|Diet|Participants will be fed a low-additive diet as the primary intervention
293904|NCT02620462|Device|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
294179|NCT02615860|Procedure|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
294180|NCT02615873|Drug|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
294181|NCT02615886|Other|Observational Control|Participants will be observed and not provided any dietary supplementation.
294182|NCT02615886|Dietary Supplement|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
294183|NCT02615899|Other|Matched: Targeted (specific) balance exercise interventions|
294184|NCT02615899|Other|Mismatched: Untargeted (non-specific) balance exercise interventions|
294185|NCT00193102|Drug|Thalidomide|Thalidomide
294186|NCT02615912|Other|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
294187|NCT02615912|Other|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
294188|NCT02615912|Other|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
294189|NCT02615912|Other|Silwet* DA-63 (Momentive) 1.5%|
294190|NCT02615912|Other|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
294191|NCT02615912|Other|Water (control)|
294192|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation
294193|NCT02615938|Drug|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
299091|NCT00379119|Procedure|computed tomography|
299092|NCT00379132|Drug|131-I-TM-601 (chlorotoxin)|Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.
Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)
299093|NCT00379145|Drug|trabectedin|
299094|NCT00379158|Drug|Micronutrient supplements|
299095|NCT00379171|Behavioral|Cow's milk with fish oil|
299096|NCT00379171|Behavioral|Cow's milk without fish oil|
299097|NCT00003145|Radiation|Total-Body Irradiation|Undergo TBI
299098|NCT00379171|Behavioral|Formula with fish oil|
299099|NCT00379171|Behavioral|Formula without fish oil|
299100|NCT00379197|Drug|naltrexone hydrochloride|Naltrexone should be taken with water or food, and it can be taken at any time day. Naltrexone 50 mg will be taken once a day every day of a 28 day treatment course.
299101|NCT00379197|Procedure|Positron-emission tomography (PET) / computed tomography (CT)|Given with injection of 2-Deoxy-2-[18F]fluoro-D-Glucose (FDG). Follow-up scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
299102|NCT00379210|Behavioral|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
299103|NCT00379210|Behavioral|Nutrition Education course|8-week course in nutrition
299104|NCT00379223|Procedure|vitrectomy with radial optic neurotomy|
299105|NCT00379236|Device|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
299106|NCT00379236|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
299107|NCT00379249|Drug|Rosuvastatin|
293905|NCT02620475|Device|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
293906|NCT02620488|Behavioral|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
296148|NCT02632136|Drug|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
296149|NCT02632136|Drug|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
296150|NCT02632149|Device|PINS Vagus Nerve Stimulator|
296151|NCT00194779|Drug|paclitaxel|Given IV
296152|NCT02632162|Other|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
296153|NCT02634333|Procedure|Deferred laser|Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met
296154|NCT02634333|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
296155|NCT02634346|Drug|ALK3831|Daily dosing
296156|NCT02634346|Drug|Olanzapine|Daily dosing
296157|NCT02634346|Drug|Placebo|Daily dosing
296158|NCT02634359|Device|Pasive monitoring|Pasive contact-free monitoring at home, Aultrasound and Blood test at the clinic
296159|NCT00002524|Drug|Zidovudine (AZT)|
296160|NCT00194909|Drug|sildenafil (Viagra)|
296161|NCT02634372|Behavioral|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
296162|NCT02634372|Behavioral|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
296163|NCT02634385|Procedure|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
296164|NCT02634385|Procedure|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
295538|NCT02643420|Drug|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle, ~ 24 hours (±2 hours) after TC chemotherapy.
295539|NCT00196053|Device|Archimedes Constant Flow Implantable Pump|
295540|NCT02643420|Drug|Pegfilgrastim|Single-dose subcutaneous injection per manufacturer's Prescribing Information.
295541|NCT02643433|Biological|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
295542|NCT02643433|Biological|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
295543|NCT02643446|Biological|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4.
295544|NCT02643446|Biological|OPV|OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4.
OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7.
295545|NCT02643459|Behavioral|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
295838|NCT02636569|Drug|placebo|placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from two locations at the baseline visit. The biopsy will be taken from one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.
After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun.
295839|NCT00195182|Behavioral|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
295840|NCT02636582|Other|Laboratory Biomarker Analysis|Correlative studies
295841|NCT02636582|Drug|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
295842|NCT02638818|Procedure|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
295843|NCT02638831|Drug|Ketorolac Tromethamine|Ketorol Gel Ketorol®, (ketorolac) 2% for external application, manufactured by Dr Reddy's Laboratories Ltd. (India). Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
295238|NCT00192881|Device|Bx Sonic & Cypher stent from Cordis|
295239|NCT02614001|Device|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
295240|NCT02614001|Other|post-stroke rehabilitation program|
295241|NCT02614014|Behavioral|Cognitive-behavior interventional program|
295242|NCT02614027|Other|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
295243|NCT02614027|Other|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
295244|NCT02614040|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
295245|NCT02614040|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
295246|NCT02614053|Device|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI & spHB
295247|NCT02614066|Biological|KTE-C19|
295248|NCT02614079|Device|DSSEP|Collision testing after the placement of SCS leads
295249|NCT00192920|Behavioral|Transfusion practice|
295250|NCT02614092|Behavioral|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
295251|NCT02614105|Procedure|Pelvic floor muscle training|16 weeks of group-based exercise
295546|NCT02643472|Behavioral|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
295547|NCT02643472|Behavioral|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
295548|NCT02643485|Procedure|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
295549|NCT02643498|Radiation|Stereotactic Body Radiotherapy (SBRT)|
294623|NCT00193791|Other|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
294624|NCT02625090|Drug|UCB0942|Active Substance: UCB0942
Pharmaceutical form: Film-coated tablet
Concentration: 100 mg or 200 mg
Route of Administration: oral
294926|NCT02618525|Other|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
294927|NCT02618525|Other|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
294928|NCT02618551|Procedure|Bronchial thermoplasty for treatment of severe asthma|Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.
Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)
A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized.
294929|NCT02618564|Drug|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
294930|NCT02618577|Drug|Edoxaban|Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:
Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.
294931|NCT00193271|Drug|Docetaxel|
294932|NCT02618577|Drug|ASA|ASA 100 mg tablets or Placebo
294933|NCT02618603|Drug|Botulinum toxin A|
294934|NCT02620735|Behavioral|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
294935|NCT02620735|Behavioral|Health Coaching|10 over the phone health coaching sessions.
294936|NCT02620748|Drug|Tranexamic Acid|
294937|NCT02620748|Other|Saline Solution|
294938|NCT02620761|Drug|Fenoldopam|
294939|NCT02620761|Drug|0.9%NS|
294940|NCT02620774|Drug|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
294941|NCT00193427|Drug|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
294029|NCT02633579|Drug|Erythromycin with atropine|intravenous administration of erythromycin with saline
294030|NCT02633579|Drug|Saline|intravenous administration of saline
294031|NCT02633592|Other|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
294032|NCT02633592|Other|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
294033|NCT02635672|Drug|BAY 1251152|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
294308|NCT02629250|Procedure|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
294309|NCT00194402|Drug|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
294310|NCT02629263|Dietary Supplement|Soluble Fiber|Meta- analysis of Randomized Controlled Trials
294311|NCT02629276|Other|neurodynamic testing|
294312|NCT02629289|Drug|HSP-130|
294313|NCT02629289|Drug|US-approved Neulasta|
294314|NCT02629289|Drug|EU-approved Neulasta|
294315|NCT02629302|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
294316|NCT02629302|Other|standard therapy|standard physiotherapy, speech therapy and occupational therapy
294317|NCT02629315|Other|Carnoy's solution|
294318|NCT02629315|Other|10% neutral buffered formaldehyde|
294319|NCT02629328|Device|CardioCel|Treatment with CardioCel implant
294320|NCT00194415|Behavioral|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
294321|NCT02629341|Dietary Supplement|Functional yogurt powder|Once daily during 24 weeks, 150g of yogurt powder enriched with:
Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10
298876|NCT00402077|Drug|placebo|subcutaneous injection, three times a day
298877|NCT00402103|Drug|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
298878|NCT00402103|Drug|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
298879|NCT00402103|Drug|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
298880|NCT00402116|Drug|enzastaurin|Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles
298881|NCT00402116|Drug|temozolomide|75 mg/m2, oral, daily, 6 weeks 200 mg/m2, oral, daily, twelve 28 day cycles
298882|NCT00402116|Radiation|radiation|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
298883|NCT00402129|Procedure|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
298884|NCT00402142|Biological|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
298885|NCT00003252|Drug|amifostine trihydrate|
298886|NCT00402142|Biological|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
298887|NCT00402142|Biological|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
298888|NCT00402142|Biological|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
298889|NCT00402142|Biological|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
293750|NCT02640300|Drug|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
293751|NCT00195598|Drug|VENLAFAXINE|
293752|NCT02640313|Drug|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
293753|NCT02640326|Other|No Foley Urinary Catheter|
293754|NCT02640326|Other|Standard of care Foley urinary catheter insertion|
293755|NCT02640352|Dietary Supplement|Probi Defendum|
293756|NCT02640352|Dietary Supplement|Placebo|
298128|NCT00372593|Drug|mitoxantrone hydrochloride|Given IV over 1 hour
298129|NCT00372606|Behavioral|Online MiDieta Diet and Weight Management Program for Hispanics|
298130|NCT00372619|Drug|clofarabine|Given IV for 5 days
298131|NCT00372619|Drug|cytarabine|Given IV
298132|NCT00372619|Drug|methotrexate|Given intrathecally or IT age based dosage
298133|NCT00372619|Other|laboratory biomarker analysis|
298134|NCT00372632|Drug|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
298135|NCT00372632|Drug|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
298136|NCT00000484|Drug|Rauwolfia alkaloids|
298137|NCT00003114|Radiation|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
298138|NCT00372645|Dietary Supplement|Folic acid (supplement)|200 µg folate per day from supplemental folic acid
298139|NCT00372645|Dietary Supplement|Metafolin (supplement)|200 µg folate per day from supplemental Metafolin®
298140|NCT00372645|Drug|Placebo|Placebo
298141|NCT00372645|Other|Folate rich foods|200 µg folate per day from folate-rich foods
298142|NCT00372658|Drug|1% Lidocaine intracervical injection|
298143|NCT00372671|Behavioral|Survey|
298144|NCT00372671|Behavioral|Survey and videotape|
298145|NCT00372684|Genetic|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
298146|NCT00372684|Genetic|with uncomplicated malaria|with uncomplicated malaria
298147|NCT00372697|Drug|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
298148|NCT00003115|Drug|hydromorphone hydrochloride|
298518|NCT00410709|Drug|NatrOVA Creme Rinse (1%)|
297407|NCT00389948|Drug|Lanzoprazole|
297408|NCT00389974|Drug|sunitinib malate|Given PO
297409|NCT00389987|Drug|MK0826, /Duration of Treatment : 8 Weeks|
297760|NCT00381615|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
297761|NCT00381615|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
297762|NCT00381615|Biological|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
297763|NCT00381615|Biological|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
297764|NCT00381615|Biological|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
297765|NCT00381615|Biological|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
297766|NCT00381615|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
297767|NCT00003152|Drug|prednisone|
297768|NCT00381628|Procedure|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
297769|NCT00381641|Other|Laboratory Biomarker Analysis|Optional correlative studies
297770|NCT00381641|Other|Pharmacogenomic Study|Optional correlative studies
297771|NCT00381641|Drug|Sunitinib Malate|Given PO
297772|NCT00381654|Drug|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
297773|NCT00381667|Drug|GW642444M|M salt
297774|NCT00381667|Drug|GW642444H|H salt
297775|NCT00381667|Other|placebo|placebo
297033|NCT00398320|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
297034|NCT00398320|Drug|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
297035|NCT00003231|Drug|cisplatin|
297036|NCT00398333|Dietary Supplement|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
297037|NCT00398359|Behavioral|Motivational Interviewing (physicians)|Identifying and referring children with BMI >93%.
297038|NCT00398359|Behavioral|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
297039|NCT00398372|Drug|Rituximab|
297040|NCT00398372|Drug|Epratuzumab|
297041|NCT00398385|Drug|cisplatin|
297042|NCT00398385|Drug|gemcitabine hydrochloride|
297043|NCT00398385|Procedure|adjuvant therapy|
297044|NCT00398385|Procedure|conventional surgery|
297045|NCT00398385|Procedure|neoadjuvant therapy|
297410|NCT00389987|Drug|Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks|
297411|NCT00003196|Drug|cyclosporine|Given IV or PO
297412|NCT00390000|Drug|vatalanib|Given orally
297413|NCT00390000|Drug|pemetrexed disodium|Given IV
297414|NCT00390000|Other|pharmacological study|Correlative study
297415|NCT00390000|Procedure|ultrasound imaging|Correlative study
297416|NCT00390013|Drug|Gabapentin|300 mg. capsules
Dosage schedule for weeks 1 and 2 and weeks 12 and 13:
day 1 you will take 1 capsule for the day
day 2 you will take 1 capsule 2 times for that day
days 3-6 you will take 1 capsule 3 times for those days
days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day
days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day
days 13-14 you will take 2 capsules 3 times each day
continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.
at completion of study treatment you will titrate off study drug over a weeks time.
297417|NCT00390026|Drug|Bevacizumab (Avastin)|
296666|NCT00406978|Drug|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
296667|NCT00406978|Drug|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
296668|NCT00406991|Drug|aspirin|
296669|NCT00406991|Drug|clopidogrel|
296670|NCT00407004|Device|MARS (Molecular Adsorbents Recirculating System)|
296671|NCT00003273|Drug|temozolomide|
296672|NCT00407004|Device|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
296673|NCT00407017|Drug|Gatifloxacin|
296674|NCT00407017|Drug|Ketorolac LS|
296675|NCT00407017|Drug|Pred Forte|
296676|NCT00407017|Drug|Moxifloxacin|
296677|NCT00407017|Drug|Nepafenac|
296678|NCT00407017|Drug|EconoPred Plus|
296679|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (240 Units)|incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (240 Units)
296680|NCT00003288|Drug|tirapazamine|
296681|NCT00409968|Procedure|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
296682|NCT00409981|Device|paclitaxel coated balloon catheter (device with drug)|
296683|NCT00409994|Drug|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
296684|NCT00410007|Behavioral|High Sodium Diet|250-350 mmol
296685|NCT00410007|Behavioral|Low Sodium Diet|25-35 mmol
295998|NCT02618967|Biological|AMG 570|5 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
295999|NCT02618967|Biological|AMG 570 Matching Placebo|5 dose levels of Placebo administered as single dose subcutaneous in healthy volunteers.
296000|NCT02618980|Other|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
296001|NCT02618993|Procedure|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
296002|NCT02619006|Other|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
296003|NCT02619019|Drug|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
296004|NCT02619019|Drug|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
296005|NCT02619019|Drug|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
296312|NCT02614586|Drug|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
296313|NCT02614599|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
296314|NCT02614599|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
296315|NCT02614612|Drug|INCB039110 (200 mg)|
296316|NCT02614612|Drug|INCB039110 (300 mg)|
296317|NCT02614612|Drug|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
296318|NCT00193011|Drug|Methotrexate|Methotrexate
296319|NCT02616601|Drug|Generic Fluorouracil Cream|Active drug product (generic) applied to face or scalp once daily for 2 weeks
296320|NCT02616601|Drug|Placebo|Apply product to face or scalp once daily for 2 weeks
296321|NCT02616614|Drug|Onexton|Topical gel for treating acne
295706|NCT02623231|Drug|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
295707|NCT02623244|Procedure|Laparoscopic oophorocystectomy or oophorectomy|
295708|NCT02623257|Other|mutation detection|
295709|NCT02623257|Other|ARMS|
295710|NCT02623257|Genetic|ctDNA analysis|
295711|NCT02623270|Device|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
295712|NCT02625337|Drug|Pembrolizumab|
295713|NCT02625337|Drug|Dabrafenib|
295714|NCT02625337|Drug|Trametinib|
295715|NCT02625337|Procedure|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
295716|NCT02625337|Procedure|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
295717|NCT02625350|Other|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
295718|NCT02625350|Other|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
295719|NCT02625350|Other|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
295720|NCT02625363|Other|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
295721|NCT00193856|Radiation|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
296006|NCT00193284|Drug|Fluorouracil|
296007|NCT02619032|Drug|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
296008|NCT02619032|Drug|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
295102|NCT00195117|Behavioral|Positive affect and self-affirmation induction|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
295103|NCT02636205|Device|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
295104|NCT02636218|Drug|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
295105|NCT02636218|Drug|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
295106|NCT02636231|Drug|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
295107|NCT02636231|Radiation|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
295108|NCT02636244|Drug|SHAPE Gel|
295410|NCT02629783|Drug|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
295411|NCT02629796|Other|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
295412|NCT00002524|Drug|Leucovorin calcium|
295413|NCT00194454|Other|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
295414|NCT02629809|Drug|Obinutuzumab|100 mg on Day 1, 900 mg on Day 2, 1000 mg on Day 8, and 15 of Cycle 1, and 1000 mg on Day 1 of Cycles 2-3. Obinutuzumab given by vein.
295415|NCT02629809|Drug|Fludarabine|25 mg by vein on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2-3.
295416|NCT02629809|Drug|Cyclophosphamide|250 mg by vein Days 2-4 of Cycle 1, and Days 1-3 of Cycles 2-3.
295417|NCT02629809|Drug|Ibrutinib|420 mg by mouth every day during Cycles 1-3.
295418|NCT02629809|Drug|Allopurinol|300 mg by mouth daily on Days 1-7 of Cycle 1.
295419|NCT02629809|Drug|Valacyclovir|500 mg by mouth every day while on Ibrutinib and 3 months after last dose.
295420|NCT02629822|Drug|MK-1439A|A single FDC tablet of MK-1439 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg will be administered orally, once daily for up to 96 weeks
295421|NCT00194753|Drug|Doxorubicin|24 mg/m2 IV weekly x 12
294795|NCT02640898|Radiation|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
294796|NCT02640924|Radiation|Proton radiotherapy|
294797|NCT02640924|Procedure|Radiofrequency Ablation|
294798|NCT02640950|Device|NeuroStar TMS|Transcranial Magnetic Stimulation
294799|NCT02640963|Other|Exercise|to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
294800|NCT02643108|Procedure|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 2.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 45-60 degrees from the midline.
294801|NCT02643121|Other|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
294802|NCT02643134|Procedure|extracorporeal shockwave lithotripsy|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
294803|NCT02643134|Device|External Physical Vibration Lithecbole|Multi-dimensional physical harmonic vibration inertial guidance technology
294804|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
294805|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
294806|NCT00195949|Procedure|Laparoscopic pyloromyotomy|
294807|NCT02643147|Drug|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
294808|NCT02643160|Other|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
295109|NCT02636257|Procedure|Silicone Nasolacrimal Intubation|Surgery was performed preferably under local anesthesia. Regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to anteriorethmoidalartery and inferior orbital nerves. Nasal cavity was packed with gauge soaked in 2%lidocaine with 1:100000 adrenaline 15 minutes before procedure.A routine silicone tube of spherical cephalon intubation was performed. Tears dilator dilatates lacrimal point to the end slowly and smoothly ,then flush the lacrimal duct physiological saline in 5 mL, flowing into the throat. Insert the probe with silicon tube feom lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the probe is inserted into the nasolacrimal duct, then catch silicon tube with suction and fix.
294194|NCT02615938|Other|Placebo|Apply Placebo not to modify lysosomal pH
294195|NCT02615951|Other|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
294196|NCT00193102|Drug|Capecitabine|Capecitabine
294197|NCT02615964|Radiation|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
294198|NCT02618135|Other|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
294496|NCT02611492|Drug|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
294497|NCT02611492|Drug|Aracytine (Ara C)|Age<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
294498|NCT02611492|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils > 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
294499|NCT02611492|Drug|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
294500|NCT02611492|Drug|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
294501|NCT02611492|Drug|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
294502|NCT02611492|Drug|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
294503|NCT00192621|Drug|Combivir (zidovudine [AZT] / lamivudine [3TC])|
294504|NCT02611492|Drug|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
294505|NCT02611505|Drug|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
294506|NCT02611518|Drug|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
294507|NCT02611518|Drug|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
294508|NCT02611518|Drug|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
293907|NCT02622386|Dietary Supplement|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
293908|NCT02622386|Other|Placebo|Matching placebo capsule taken daily for 12 weeks.
293909|NCT02622399|Behavioral|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
293910|NCT02622412|Other|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
293911|NCT02622412|Other|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
293912|NCT02622425|Dietary Supplement|Placebo|maltodextrin
293913|NCT02622425|Dietary Supplement|PD01|Carotenoid-producing Bacillus strain PD01
293914|NCT00193531|Drug|Paclitaxel|
293915|NCT02622438|Other|Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.|
293916|NCT02622451|Behavioral|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
293917|NCT02622451|Behavioral|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
293918|NCT02622464|Other|micro injection of SVF in vocal cords|
293919|NCT02622477|Drug|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
293920|NCT02622490|Other|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
296165|NCT02634411|Drug|8 days of effective antibiotic treatment|Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).
Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days.
296461|NCT00386724|Device|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
296462|NCT00386750|Drug|Artemether-lumefantrine|
296463|NCT00386763|Drug|Artemether-lumefantrine|
296464|NCT00386776|Other|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
296465|NCT00386802|Drug|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
296466|NCT00003184|Biological|BCG vaccine|
296467|NCT00386815|Drug|pemetrexed|
296468|NCT00386815|Drug|cisplatin|
296469|NCT00389688|Procedure|neoadjuvant therapy|
296470|NCT00389701|Drug|bortezomib|
296471|NCT00389701|Drug|dexamethasone|
296472|NCT00003195|Drug|busulfan|
296473|NCT00389714|Device|dental restoration|
296474|NCT00389727|Procedure|Radiotherapy|
296475|NCT00389740|Drug|MK0217, /Duration of Treatment : 12 Months|
296476|NCT00389740|Drug|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
296477|NCT00389753|Drug|Application of Aruba Aloë formula F-BC-096 or control|
296478|NCT00389766|Drug|iodine I 131 metaiodobenzylguanidine|
296479|NCT00389766|Drug|topotecan hydrochloride|
296480|NCT00389766|Procedure|chemotherapy|
296481|NCT00389766|Procedure|peripheral blood stem cell transplantation|
295844|NCT02638831|Drug|Ketoprofen|Fastum Fastum® (ketoprofen) - gel 2.5% for external application manufactured by A. Menarini Manufacturing Logistics and Services S.r.L, (Italy). Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
295845|NCT02638857|Procedure|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
295846|NCT02638857|Biological|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
295847|NCT02638857|Drug|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
295848|NCT00002526|Drug|doxorubicin hydrochloride|
295849|NCT00195429|Drug|prednisone|
295850|NCT02638857|Drug|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
295851|NCT02638857|Drug|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
295852|NCT02638857|Biological|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
296166|NCT02634411|Drug|15 days of effective antibiotic treatment|Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).
Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days.
296167|NCT02634424|Device|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
296168|NCT02634437|Drug|Ulipristal acetate|
296169|NCT02634450|Device|Alere q|
296170|NCT02634463|Drug|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
296171|NCT00194922|Dietary Supplement|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
296172|NCT02636582|Biological|Sargramostim|Given ID
296173|NCT02636595|Drug|ABT-493/ABT-530|ABT-493/ABT-530 tablets
296174|NCT02636621|Device|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
295550|NCT02645383|Device|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
295551|NCT02645383|Device|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
295552|NCT02645409|Drug|OTL38|OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
295553|NCT02645409|Device|Intraoperative fluorescence imaging system|
295554|NCT02645435|Procedure|hip replacement|Total hip replacement
295555|NCT02645448|Other|Resistance Exercise|Control Session
Resistance exercise at different intensities (40%1RM or 80%1RM)
Duration of effect
295556|NCT02645461|Drug|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
295557|NCT02645461|Drug|Riluzole|Riluzole 50 mg twice daily
295558|NCT02645474|Procedure|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.75%, total volume 20 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
295559|NCT00196222|Procedure|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
295560|NCT02645474|Procedure|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.75%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
295561|NCT02645474|Drug|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
295853|NCT02638870|Drug|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
295854|NCT02638896|Drug|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
295855|NCT02638896|Drug|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
285920|NCT02655263|Drug|Somatropin|Somatropin infusion (Genotropin®)
285921|NCT02655263|Other|Ketone bodies|ketone bodies infusion
285922|NCT02655276|Other|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
285923|NCT02655276|Other|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
285924|NCT02655289|Device|Modulated TENS|Frequency: 100 Hz
Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity
Mode: intensity modulation (40% decrease every 0.5 seconds)
TENS device: ARTROSTIM® SELECT
Channels: 2
Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)
285925|NCT02655289|Device|Placebo TENS|Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)
Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.
Mode: continuous
TENS device: ARTROSTIM® SELECT
Channels: 2
Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)
285926|NCT00197444|Drug|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
286199|NCT02648477|Drug|Letrozole|Given PO
286200|NCT02648477|Biological|Pembrolizumab|Given IV
286201|NCT00196599|Drug|didanosine, ddI (drug)|
286202|NCT02648490|Drug|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
286203|NCT02648490|Drug|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
286204|NCT02648490|Drug|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
286205|NCT02648490|Drug|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
286206|NCT02648490|Drug|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
286207|NCT02648503|Drug|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
286208|NCT02648503|Drug|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
286209|NCT02648516|Other|Conventional plus AAC treatment|Participants received conventional treatment and taken i.v., at a dose of 2-3*10E8 allogenic adoptive cells/kg body at baseline, week 1 and 3.
285647|NCT02661685|Other|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
285648|NCT02661698|Dietary Supplement|Pronovum Omega-3: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
285649|NCT02661698|Dietary Supplement|Placebo|3 x 1 g capsules Placebo: olive oil
285650|NCT02663934|Behavioral|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
285651|NCT02663934|Behavioral|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
285652|NCT00198640|Procedure|Antibiotic use|
285653|NCT02663947|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
285654|NCT02663960|Other|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
285927|NCT02655302|Other|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
285928|NCT02655302|Other|Lung function measure|Measure lung function and follow it during 4 years
285929|NCT02655315|Drug|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
285930|NCT02655315|Drug|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
285931|NCT02655328|Other|blood sample|blood sample
285932|NCT02655328|Other|urine sample|urine sample
285933|NCT02655341|Device|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
285097|NCT02608034|Drug|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 980 mg BID for at least 40 conseutive days.
285373|NCT02670928|Behavioral|Lifestyle intervention|This study is aimed to achieve of long-term weight loss in T2DM patients by use of comprehensive lifestyle changes study, providing patients with structured diet, exercise plan, group behavioral support and group education. Additionally the study is designed to establish that reduction of the body weight leads to the improvement of glycemic and lipid metabolism, and can also reduce blood pressure level. The study is also directed to show that lifestyle changes study in T2DM patients can lead to decreasing of hospitalization rate and healthcare consumption. In order to demonstrate a change from standard of care, data will be collected from a parallel cohort from the same centers.
285374|NCT02670941|Drug|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
285375|NCT02670941|Drug|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
285376|NCT02670941|Drug|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
285377|NCT00199017|Drug|G-CSF|
285378|NCT02670941|Drug|Jojoba|The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a "fixative" for other essential oils.
285379|NCT02670954|Drug|Dexmedetomidine, tramadol and flurbiprofen|
285380|NCT02670954|Drug|tramadol and flurbiprofen|
285381|NCT02670967|Dietary Supplement|Soluble Fibre|
285382|NCT02670980|Device|Intelligent Retinal Implant System|
285383|NCT02670993|Behavioral|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
285384|NCT02670993|Behavioral|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
285385|NCT02671006|Other|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
285386|NCT02671019|Behavioral|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
285387|NCT02671032|Device|Nucleus CI532 cochlear implant|
284801|NCT02576444|Drug|AZD2014|The recommended dose will be available no earlier than November 2015.
284802|NCT02576457|Biological|BMS-936559|
284803|NCT02576457|Other|Placebo|
284804|NCT02576470|Behavioral|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
284805|NCT02578511|Drug|Vincristine|
284806|NCT02578511|Drug|Dexamethasone/Prednisone|
285098|NCT02608060|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
285099|NCT02608073|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
285100|NCT02608073|Drug|Cisplatin|Participants will receive cisplatin, 100 mg/m^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
285101|NCT02608086|Behavioral|Psychoeducation|Participants in Control Group will be delivered a flyer named "What can I do facing a crisis?", containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma.
285102|NCT02608086|Behavioral|Psychological First Aid|Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named "What can I do facing a crisis?".
285103|NCT02608099|Drug|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
285104|NCT02608099|Drug|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
285105|NCT02608112|Drug|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
285106|NCT02608112|Drug|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
284487|NCT02582944|Device|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
284488|NCT02582944|Device|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
284489|NCT02582944|Procedure|Biopsy|
284490|NCT02582957|Other|Sigh breaths|Sigh breaths delivered over 5 seconds once every 6 minutes, as part of usual invasive mechanical ventilation.
284491|NCT02582970|Drug|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered for approximately 10 months. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
284492|NCT00000373|Drug|placebo + fluoxetine|
284493|NCT00002514|Drug|thioguanine|
284494|NCT00189488|Drug|Methotrexate|
284495|NCT02582970|Drug|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks for approximately 10 months.
284496|NCT02582983|Drug|Enfuvirtide|All participants will receive enfuvirtide 90 mg SC BID until 4 weeks after commercial availability is established in Thailand.
284497|NCT02582996|Drug|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
284498|NCT02582996|Drug|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
284499|NCT02583009|Drug|PAC-14028 cream 0.1%|Topical application
284807|NCT02578511|Drug|Methotrexate (MTX)|
284808|NCT02578511|Drug|6-Mercaptopurine|
284809|NCT02578524|Other|Survey|
284810|NCT02578537|Drug|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
284811|NCT00002514|Drug|etoposide|
284812|NCT00188877|Procedure|intensity modulated radiation therapy|
284813|NCT02578537|Drug|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
284814|NCT02578550|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
284183|NCT02589756|Other|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
284184|NCT02589756|Other|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (~1400 kcal ~100 grams walnuts, ~50 grams hazelnuts and ~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
284185|NCT02589756|Other|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
284186|NCT02589769|Other|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
284187|NCT02589769|Other|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
284188|NCT02589782|Drug|Bedaquiline|
284189|NCT02589782|Drug|Pretomanid|
284190|NCT02589782|Drug|Moxifloxacin|
284191|NCT00190476|Drug|Weekly docetaxel + cisplatin combination|
284192|NCT02589782|Drug|Linezolid|
284193|NCT02589782|Drug|Clofazimine|
284194|NCT02589782|Drug|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
284195|NCT02589795|Biological|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
284196|NCT02589795|Biological|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
284197|NCT02589795|Device|Trigrid Delivery System - Intramuscular|Electroporation
284198|NCT02589795|Device|Trigrid Delivery System - Intradermal|Electroporation
284199|NCT02589808|Device|Echocardiography|Pocket ultrasound device.
284500|NCT02585089|Other|Spanish cured-pork ham|Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).
Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day.
284501|NCT00189696|Drug|YM060|
288742|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
288743|NCT02660554|Other|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
288744|NCT02660567|Procedure|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
288745|NCT02660580|Drug|MSB11022|MSB11022 will be administered at a dose of 80 milligram (mg) subcutaneously at Week 1, followed by 40 mg every other week starting 1 week after the initial dose up to and including Week 14. At week 16, subjects with a (PASI) 50 response will remain on study for up to 52 weeks.
288746|NCT00198198|Drug|Aripiprazole|
288747|NCT02660580|Drug|Humira®|Humira® will be administered at a dose of 80 mg subcutaneously at Week 1, followed by 40 mg every other week starting 1 week after the initial dose up to and including Week 14. At week 16, subjects with a (PASI) 50 response will remain on study for up to 52 weeks; subjects initially randomized to Humira® will be re-randomized (1:1) to MSB11022 or Humira® treatment for weeks 16-52.
288748|NCT02660593|Dietary Supplement|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
288749|NCT02660606|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
288750|NCT02660619|Other|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
288751|NCT02660632|Other|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
284200|NCT02589821|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
284201|NCT02589821|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
284202|NCT00190489|Drug|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
284203|NCT02589834|Other|Quran group|
284204|NCT02589847|Biological|RBX2660|suspension of intestinal microbes
284205|NCT02591914|Drug|Eylea®|Anti-VEGF
289071|NCT02658721|Drug|Atropine|The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.
In case of bradycardia (HR <50/min), 0.5 mg intravenous atropine was administered.
289376|NCT02652442|Behavioral|Gaze stability exercises|Gaze stability exercises include adaptation and substitution exercises. Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Substitution exercises specifically attempt to facilitate use of alternative strategies, rather than teaching the specific strategies. For example, during active eye-head exercise, a large eye movement to a target is made prior to the head moving to the target, potentially facilitating preprogrammed eye movements.
289377|NCT02654223|Biological|Sublingual placebo|Comparison between placebo and active group
289378|NCT02654236|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
289379|NCT02654236|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
289380|NCT02654249|Device|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
289381|NCT02654249|Procedure|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
289382|NCT02654249|Device|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
289383|NCT02654249|Device|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
289384|NCT00197275|Biological|Hib-MenAC mixed with Tritanrix™-HepB|
289385|NCT02654275|Other|Proprioceptive Intervention|
289386|NCT02654288|Other|gemcitabine-based chemotherapy|
289387|NCT02654301|Dietary Supplement|Test 1|sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
289388|NCT02654301|Dietary Supplement|Test 2|sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
289389|NCT02654301|Dietary Supplement|Test 3|sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
289390|NCT02654301|Dietary Supplement|Control|sucrose 50 g + deionized water 100 g
289391|NCT02654314|Dietary Supplement|Melatonin|
289392|NCT02654314|Other|Placebo|lactulose powder
293666|NCT02631174|Drug|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
293667|NCT02631187|Device|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
293668|NCT02631200|Behavioral|Advance care plan|Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
293669|NCT02631239|Drug|Methotrexate|1g/m2/d IV *1d
293670|NCT02631239|Drug|Etoposide|200mg/d PO *3d
293671|NCT00194675|Drug|Placebo dutasteride|placebo dutasteride orally daily
293672|NCT02631239|Drug|Dexamethasone|40mg/d PO *3d
289072|NCT02658721|Drug|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
289073|NCT02658721|Drug|Diclofenac sodium|The patients with a VAS score of >4 were administered with 75 mg diclofenac sodium via intramuscular route.
289074|NCT02658721|Drug|Ephedrine|In the event of hypotension (systolic arterial pressure <90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
289075|NCT02658721|Drug|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
289076|NCT02658734|Drug|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
289077|NCT00197873|Dietary Supplement|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
289078|NCT02658747|Other|No intervention|No intervention administered in this study
289079|NCT02658760|Drug|Dexmedetomidine|dexmedetomidine plus placebo
289080|NCT02658760|Drug|Bupivacaine|dexmedetomidine and Bupivacaine
289081|NCT02658773|Drug|lidocaine-Prilocaine cream|
289082|NCT02658773|Drug|placebo cream|
289083|NCT02660697|Procedure|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
293378|NCT02635503|Procedure|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
293379|NCT02635503|Procedure|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
293380|NCT02635516|Device|Near-Infrared Phototherapy|The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the "A" setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized.
293381|NCT02635529|Procedure|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
293382|NCT02635529|Procedure|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
293383|NCT02637830|Other|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
293673|NCT02631239|Drug|Pegaspargase|2500IU/m2/d IM *1d
293674|NCT02631239|Radiation|Radiotherapy|50-56Gy
293675|NCT02631252|Drug|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
293676|NCT02631252|Drug|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
293677|NCT02631252|Drug|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
293678|NCT02631265|Other|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
293679|NCT02631265|Other|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
287910|NCT02646891|Biological|Placebo|
287911|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 90 mcg|
287912|NCT02646904|Drug|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
287913|NCT02646904|Drug|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
287914|NCT02646917|Device|SkinPen|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
287915|NCT02646930|Procedure|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
288216|NCT02677168|Device|cNEP|continuous negative external pressure
288217|NCT02679456|Drug|Fluconazole|
288218|NCT02679469|Drug|nalmefene hydrochloride 10 mg|
288219|NCT02679495|Behavioral|Active measures of lifestyle modification|
288220|NCT02679508|Drug|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
288221|NCT00199420|Drug|Istradefylline (KW-6002)|
288222|NCT02679508|Drug|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
288223|NCT02679521|Device|ESWT|Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).
The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.
Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz).
288224|NCT02679521|Device|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
288225|NCT02679534|Other|hand massage|
288226|NCT02679534|Other|hand holding|
288227|NCT02679534|Other|application of unscented hypoallergenic cream|
288228|NCT02679534|Other|environmental adjustments|
288229|NCT02679547|Other|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
287608|NCT00197184|Biological|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
287609|NCT02653664|Behavioral|PsychoEducation|Condition #1
287610|NCT02653664|Behavioral|Self-Hypnosis Training|Condition #2
287611|NCT02653664|Behavioral|Mindfulness Meditation|Condition #3
287612|NCT02653677|Other|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
287613|NCT02653703|Other|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
287614|NCT02653703|Other|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
287615|NCT02653716|Behavioral|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
287916|NCT02649127|Behavioral|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity [i. e., >60% of oxygen uptake reserve (VO2R)], and a time of 20-25 minutes each bout of training
287917|NCT02649127|Behavioral|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
287918|NCT02649140|Dietary Supplement|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
287919|NCT02649153|Drug|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
287920|NCT02649153|Drug|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
287921|NCT02649166|Device|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
287922|NCT00196638|Drug|Pegylated Interferon alpha (drug)|
287923|NCT02649166|Device|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
287302|NCT02660047|Drug|Liraglutide - Placebo|Drug: Liraglutide - Placebo
Preparation and labelling of Investigational Medicinal Product:
Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
287303|NCT02660060|Drug|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
287304|NCT02660060|Drug|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH & Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
287305|NCT02660073|Device|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
287306|NCT02660073|Device|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
287307|NCT02660086|Behavioral|Personalized nutrition feedback|Automated personalized feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
287308|NCT02660099|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
287309|NCT02660112|Drug|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
287310|NCT02660125|Procedure|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
287616|NCT02653716|Behavioral|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
287617|NCT02653729|Behavioral|cognitive behaviour therapy|
287618|NCT02655913|Drug|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
287619|NCT02655913|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
287018|NCT02664662|Other|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
287019|NCT02664675|Procedure|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
287020|NCT02664675|Procedure|Open Flap Debridement|After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.
Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap.
287021|NCT00198744|Behavioral|standard recommendations for dietary intake in children|
287022|NCT02666781|Other|ApneaLink Plus, BIA Device and a 3-D accelerometer device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
287023|NCT02666794|Drug|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
287024|NCT02666794|Drug|Epidural sufentanil|10 mcg
287025|NCT02666794|Procedure|Placement of the epidural catheter|
287026|NCT02666794|Drug|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
287027|NCT02666794|Drug|Intrathecal morphine|60 mcg
287028|NCT02666794|Procedure|Placement of an epidural catheter to the catheter through technical needle|
287029|NCT02666794|Drug|Intrathecal sufentanil|5 mcg
287030|NCT02666807|Dietary Supplement|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
287031|NCT00198978|Drug|Dexamethasone / Prednisolone|
287311|NCT02660138|Drug|AbobotulinumtoxinA|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
287312|NCT00198107|Other|fMRI|Subjects will undergo an fMRI and a facial affect processing task.
287313|NCT02660138|Drug|AbobotulinumtoxinA|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
287314|NCT02660138|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
286757|NCT00002533|Radiation|radiation therapy|
286758|NCT00199017|Drug|HDARAC|
286759|NCT02671552|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
286760|NCT02671565|Drug|Hyaluronic Acid injections|
286761|NCT02671578|Drug|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
286762|NCT02671591|Behavioral|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
286763|NCT02671591|Behavioral|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
286764|NCT02671617|Other|High intensity interval training (HIIT)|Preoperative HIIT protocol.
286765|NCT02674126|Behavioral|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
286766|NCT02674139|Device|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
286767|NCT02674152|Drug|BI 836880|
286768|NCT02674165|Behavioral|HART|Skills based sexual education intervention plus PTSD awareness
286769|NCT02674178|Procedure|Invitro fertilization|All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days
Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm [18]
Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval
286770|NCT02674191|Device|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
286771|NCT02674191|Procedure|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
287032|NCT02666807|Dietary Supplement|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
286193|NCT02610543|Drug|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
286194|NCT02610543|Drug|Placebo|Active Substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
286195|NCT02610556|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
286196|NCT02610556|Drug|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
286197|NCT02648477|Drug|Exemestane|Given PO
286198|NCT02648477|Other|Laboratory Biomarker Analysis|Correlative studies
286479|NCT02678650|Drug|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
286480|NCT02678663|Procedure|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
286481|NCT02678663|Procedure|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
286482|NCT00199290|Drug|Trafermin (genetical recombination)|
286483|NCT02678676|Other|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
286484|NCT02678676|Other|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
286485|NCT02678689|Drug|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
286486|NCT02678702|Behavioral|CBT-I|CBT-I
286487|NCT02678702|Behavioral|Treatment as usual|Treatment as usual
286488|NCT02678715|Device|Solubrux®|prefabricated device adaptable by temperature
286489|NCT02678715|Device|Customized Appliance|customized device fabricated in the dental laboratory
286490|NCT02678715|Device|Somatics®|standard device
286491|NCT02678728|Drug|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia for 24hrs
286492|NCT02678728|Drug|normal saline|IV loading and infusion of same volume of normal saline after induction of anesthesia for 24hrs
286493|NCT00199303|Drug|pre-operatively followed by 30 mg three times per day after surgery|
286494|NCT02678741|Drug|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
286210|NCT02648516|Other|Conventional plus placebo treatment|Participants received conventional treatment and taken i.v., at 50 ml saline at baseline, week 1 and 3.
286211|NCT02648529|Procedure|MRI|Patients are investigated with the following sequences:
High-resolution 3D T1-weighted anatomical MRI.
DTI with 48 directions (to examine white matter)
286212|NCT00196599|Drug|efavirenz (drug)|
286213|NCT02648529|Procedure|functional MRI (fMRI)|fMRI investigations will be focused on :
language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.
Social cognition: investigations on social cognition skills
Memory :
Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence
Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups.
286214|NCT02648529|Behavioral|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
286215|NCT02648542|Other|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
286216|NCT02648542|Device|transcranial direct current stimulation|Low-current electrical brain stimulation
286217|NCT02648542|Other|Combined CAS and tDCS|Combined auditory and electrical stimulation
286218|NCT02648542|Other|Sham stimulation|Sham stimulation
286219|NCT02648555|Behavioral|Daily walking|Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
286501|NCT02680951|Drug|Intrathecal (IT) cytarabine|Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.
Cytarabine dose defined by age:
30 mg for patients age 1 - 1.99
50 mg for patients age 2 - 2.99
70 mg for patients ≥3 years of age
The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment.
286502|NCT02680977|Other|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
286503|NCT02680977|Other|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
286504|NCT02680977|Other|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
286505|NCT02680977|Drug|LD+DDCI|Levodopa plus Benserazide
286506|NCT02680977|Drug|LD-DDCI|Levodopa without any DDCI
286507|NCT02680977|Other|Placebo|Groundnuts powder
285934|NCT02655341|Procedure|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
285935|NCT02655341|Procedure|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
285936|NCT02657434|Drug|Atezolizumab|Participants will receive IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period in Arm A.
285937|NCT02657434|Drug|Carboplatin|Participants will receive IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles in induction dosing period in both arms (Arm A and Arm B) with doses calculated using Calvart formula.
285938|NCT02657434|Drug|Cisplatin|Participants will receive IV infusion of 75 mg/m^2 cisplatin on Day 1 q3w for 4 or 6 cycles in induction dosing period in both arms (Arm A and Arm B).
285939|NCT02657434|Drug|Pemetrexed|Participants will receive IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w for 4 or 6 cycles in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period in both arms (Arm A and Arm B).
285940|NCT02657447|Drug|Betalutin with HH1 pre-dosing|15 MBq/kg b.w. Betalutin (177Lu-DOTA-HH1) single injection, with HH1 pre-dosing
285941|NCT02657447|Drug|Betalutin with Rituximab pre-dosing|15 MBq/kg b.w. Betalutin (177Lu-DOTA-HH1) single injection, with Rituximab pre-dosing
285942|NCT02657460|Biological|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
285943|NCT02657460|Drug|cisplatin|cisplatin is a traditional drug for lung cancer
285944|NCT02657473|Drug|tobramycin inhalation solution|
285945|NCT00197743|Dietary Supplement|Multivitamins|one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
286220|NCT02650869|Dietary Supplement|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
286221|NCT02650869|Dietary Supplement|Breast milk|Normal breast milk will be given as part of standard care
286222|NCT02650882|Procedure|Device POWERbreathe|
286223|NCT00196859|Drug|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
285388|NCT02673424|Device|Drug-eluting stent|The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in each comparison arm.
FFR-guided strategy arm Pressure-Sensor Wire System (Boston Scientific) Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI.
IVUS-guided strategy arm iLabTM ultrasound imaging system (Boston Scientific) Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden >70%)
285389|NCT02673437|Other|This is a non-interventional study|This is a non-interventional study
285390|NCT02673463|Drug|Spironolactone|25 mg once daily
285655|NCT02663960|Other|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
285656|NCT02663986|Behavioral|Organizational Skills Training (OST) Intervention|
285657|NCT02663999|Drug|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
285658|NCT02664012|Other|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
285659|NCT02664012|Other|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
285660|NCT02664012|Other|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
285661|NCT02664012|Other|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
285662|NCT02664012|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
285663|NCT00002532|Drug|daunorubicin hydrochloride|
285664|NCT00198653|Behavioral|Newborn Thermal Care Practice|
285665|NCT02664025|Procedure|vaginal examination simulator|
285666|NCT02664038|Behavioral|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
285667|NCT02664051|Drug|Nalcrom|Drug: disodium cromoglycate 100mg 4x2 daily
Other Names:
• Nalcrom
285668|NCT02664051|Drug|placebo|100mg 4x2 daily mannitol
285669|NCT02664064|Behavioral|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
285107|NCT00192296|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
285108|NCT02608125|Drug|PRN1371|Oral PRN1371
285109|NCT02608138|Other|Iodine status among portuguese school children|
285110|NCT02608151|Other|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
285111|NCT02608151|Other|massage without oil|
285112|NCT02608164|Dietary Supplement|3000IU(75μg) vitamin D3|
285113|NCT02608177|Drug|Linagliptin|Receives 4 weeks of study drug linagliptin
285114|NCT02608177|Drug|Glipizide|Receives 4 weeks of study drug glipizide
285115|NCT02608190|Behavioral|Working memory training|See protocol
285391|NCT02673463|Drug|Placebo|Visually identical to spironolactone, once daily
285392|NCT02673476|Drug|ALS-008176|ALS-008176 tablets
285393|NCT02673476|Drug|Placebo|Identical placebo tablets
285394|NCT02673489|Drug|DCV|
285395|NCT02673489|Drug|SOF|
285396|NCT02673489|Drug|RBV|
285397|NCT00199056|Drug|Ifosfamide|
285398|NCT02673502|Dietary Supplement|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
285399|NCT02673502|Dietary Supplement|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
285400|NCT02673515|Behavioral|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
285401|NCT02673528|Procedure|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
284815|NCT02578550|Drug|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
284816|NCT02578550|Drug|Darunavir|A single tablet containing darunavir 800 mg will be administered.
284817|NCT02578550|Drug|Cobicistat|A single table containing cobistat 150 mg will be administered.
284818|NCT02578589|Procedure|Plica resection vs conservative treatment|Plica resection vs conservative treatment
284819|NCT02578602|Drug|Gadoxetate Disodium|Given IV
284820|NCT02578602|Device|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
284821|NCT02578615|Other|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
284822|NCT02578628|Other|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
284823|NCT00188877|Drug|cisplatinium and fluorouracil - standard treatment|
284824|NCT02578641|Biological|autologous EBV specific Cytotoxic T Lymphocytes|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
284825|NCT02578641|Drug|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
284826|NCT02578654|Other|Strategies to improve HIV care engagement|Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on "routine care" during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period.
285116|NCT02608203|Drug|[68Ga]-DOTANOC PET/CT|
285117|NCT02608216|Drug|[18F]FLT|[18F]FLT PET/CT scan, imaging tracer
285118|NCT02610075|Drug|AZD1775|All patients will receive intervention with AZD1775 orally at approximate 12-hour intervals for 5 days (a total of 10 doses) followed by 9 days of rest (no drug treatment). A cycle is defined as 14 days. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
285119|NCT02610088|Drug|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food
285120|NCT02610088|Drug|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food
285121|NCT02610101|Dietary Supplement|Specific Carbohydrate Diet, Modified SCD and Whole Foods Diet|The goal of the next study is to help determine what aspects of the diet are most important. Therefore three modified SCD diets will be studied.
284502|NCT02585089|Other|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
284503|NCT02585102|Other|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
284504|NCT02585102|Other|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
284505|NCT02585128|Other|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
284506|NCT02585128|Other|MMSE (Mini Mental State Examination)|
284507|NCT02585128|Other|Barthel index|
284508|NCT02585128|Other|HADS (Hospital Anxiety and Depression Scale)|
284509|NCT02585128|Other|MNA-SF (Mini Nutritional Assessment - Short Form)|
284510|NCT02585128|Device|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
284511|NCT02585128|Other|CIRS (Cumulative Illness Rating Scale)|
284512|NCT00189709|Drug|Micafungin|IV
284513|NCT02585141|Device|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
284514|NCT02585141|Procedure|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
284515|NCT02585141|Drug|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
284516|NCT02585154|Procedure|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
284517|NCT02585154|Procedure|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
284518|NCT02585154|Procedure|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
284519|NCT02585154|Device|STN-LFP and EEG recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
284827|NCT02578667|Device|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
284206|NCT02591927|Drug|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
284207|NCT02591927|Drug|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
284208|NCT02591940|Procedure|Surgery or Treatment by Heart Catheter|
284209|NCT02591953|Procedure|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
284210|NCT02591953|Procedure|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
284211|NCT02591953|Drug|Methylprednisolone|Corticosteroid used in injection (40 mg)
284212|NCT02591953|Drug|Lidocaine 1%|Anesthesic used in injection
284213|NCT02591992|Other|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
284214|NCT02591992|Other|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
284215|NCT00190671|Drug|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
284216|NCT02592005|Other|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
284217|NCT02592018|Drug|Secukinumab|Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
284218|NCT02592031|Drug|XM17|300 IU corresponds to an injection volume of 0.5 mL.
284219|NCT02592031|Drug|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
284220|NCT02592031|Drug|Zoladex®|3.6 mg
284221|NCT02592044|Procedure|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
284222|NCT02592044|Procedure|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
284520|NCT02585167|Procedure|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
284521|NCT02585167|Device|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
289393|NCT02654327|Device|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
289394|NCT02654353|Procedure|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
289395|NCT00197288|Biological|Influenza|
289682|NCT02649829|Biological|dendritic cell vaccination plus chemotherapy|A. Chemoimmunotherapy:
three 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.
four 2-weekly intradermal vaccination with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; first DC vaccination after second chemotherapy cycle.
B. Surgery: pleurectomy/decortication
289683|NCT02649842|Device|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
289684|NCT02649855|Biological|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
289685|NCT02649855|Biological|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
289686|NCT02649855|Drug|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
289687|NCT02649868|Radiation|TAE|Transarterial embolization
289688|NCT02649868|Radiation|RFA|Thermal ablation
289689|NCT00196716|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
289690|NCT02649868|Device|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
289691|NCT02649881|Procedure|The heart subject will undergo OCT|
289692|NCT02649907|Dietary Supplement|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
289693|NCT02649907|Other|Nutritional counseling|nutritional counseling for healthy eating behaviour
289694|NCT02649907|Dietary Supplement|formula diet|formula diet to help weight loss
289695|NCT02649920|Device|Cervical ripening balloon|
289696|NCT02649920|Drug|Dinoprostone|
289697|NCT02649933|Device|Watch PAT 200|screening of OSA with Watch PAT 200
289084|NCT02660710|Drug|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
289085|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
289086|NCT02660736|Drug|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
289087|NCT02660736|Drug|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
289088|NCT00198237|Drug|docetaxel & capecitabine|
289089|NCT02660736|Drug|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
289090|NCT02660736|Drug|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
289091|NCT02660762|Drug|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
289396|NCT02654366|Behavioral|Risk Reduction Group|The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.
The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support.
289397|NCT02654379|Biological|Rituximab|Rituximab use in non-oncology indications
289398|NCT02654392|Dietary Supplement|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
289399|NCT02656693|Behavioral|Population management support|Patients will receive weight-related population management support from their primary care practice; their online weight management program data will be monitored by the population manager, who will conduct outreach with patients according to the protocol.
289400|NCT02656706|Drug|Ipilumumab|
289401|NCT02656706|Drug|Nivolumab|
289402|NCT02656719|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
289403|NCT02656719|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
293680|NCT02631265|Other|Exercice 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
293681|NCT02631278|Device|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
293682|NCT02633319|Behavioral|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
293683|NCT02633319|Other|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
293684|NCT02633332|Drug|Vitamin D3|every 12 hours, orally form
293685|NCT02633332|Drug|Lipitor®|every 12 hours, orally form
293686|NCT02633332|Drug|Acycloguanosine|every 12 hours, orally form
293687|NCT02633332|Drug|Tetracycline|every 12 hours, orally form
293688|NCT02633332|Drug|methotrexate|every week, subcutaneous injection
289092|NCT02660762|Drug|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
289093|NCT02660762|Drug|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
289094|NCT02660762|Drug|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
289095|NCT02660762|Drug|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
289096|NCT02660762|Drug|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
289097|NCT02660762|Drug|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
289098|NCT02660762|Drug|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
288230|NCT02679560|Drug|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
288231|NCT02679560|Drug|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
288232|NCT00199433|Drug|Istradefylline (KW-6002)|
288233|NCT02679573|Drug|Delafloxacin|Antibacterial agent
288234|NCT02679573|Drug|Moxifloxacin|Antibacterial Agent
288235|NCT02679573|Drug|Linezolid|Antibacterial Agent
288236|NCT02679586|Device|Diffusion weighted MRI|
288237|NCT02679599|Other|B-MOBILE-CARDIAC smartphone application|
288524|NCT02674932|Behavioral|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
288525|NCT02674932|Behavioral|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
288526|NCT02674932|Behavioral|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
288527|NCT00199069|Procedure|Stem Cell Transplantation|
288528|NCT02674945|Device|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
288529|NCT02674958|Drug|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
288530|NCT02674971|Behavioral|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
288531|NCT02674984|Drug|BB-12 with LGG|Multistrain probiotic
288532|NCT02674984|Drug|Placebo|
287924|NCT02649179|Drug|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
287925|NCT02649179|Drug|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
287926|NCT02649192|Biological|FluMist®|Children will have the first FluMist® dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later. A total of 0.2 mL of FluMist® will be administered (0.1 mL into each nostril with the use of an intranasal-spray).
287927|NCT02649192|Dietary Supplement|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participants research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving FluMist® vaccination.
287928|NCT02649192|Other|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participants research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving FluMist® vaccination.
287929|NCT02649205|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
288238|NCT02679599|Behavioral|Cardiac rehabilitation as usual|
288239|NCT02679625|Device|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
288240|NCT02679638|Other|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
288241|NCT02679638|Other|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
288242|NCT02681614|Device|Uronav guided biopsy|All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia. Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum.
288243|NCT02681614|Device|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
288244|NCT02681627|Other|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
288245|NCT02681627|Other|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
287620|NCT02655913|Behavioral|lifestyle counseling|To educate and give advices to cancer patients to adjust their lifestyle twice a month
287621|NCT02655926|Procedure|Deep Brain Stimulation|Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
287622|NCT02655939|Dietary Supplement|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
287623|NCT02655939|Dietary Supplement|Placebo|Fructose,Orange flavor and sucralose
287624|NCT02655952|Drug|Foxy-5|
287625|NCT02655965|Drug|Ropivacaine|Ropivacaine 3.5 mg/ml
287626|NCT02655965|Drug|Clonidine|Clonidine 5µg/ml
287627|NCT02655965|Drug|Sodium Chloride|Sodium Chloride 0.9 %
287628|NCT00197561|Dietary Supplement|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
287629|NCT02655978|Other|Magnetic Resonance Imaging|
287630|NCT02655991|Behavioral|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
287631|NCT02655991|Behavioral|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
287632|NCT02656004|Other|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
287930|NCT02649218|Biological|QGE031|QGE031
287931|NCT02649231|Drug|Ketamine|0.8 mg/kg ketamine
287932|NCT02649231|Drug|Placebo|0.9% saline
287933|NCT02651740|Drug|Rifaximin|200mg tid* 3d
287934|NCT02651740|Procedure|infusing saline through enteral nutrition tube|250ml per time for at least once
287935|NCT02651740|Procedure|FMT with donor stool through enteral nutrition tube|250ml per time for at least once
287315|NCT02660138|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
287316|NCT02660151|Device|Hyper-CL™ lens|
287317|NCT02662257|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery.
287318|NCT02662283|Drug|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
287319|NCT02662283|Drug|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
287320|NCT00198445|Drug|Bromfenac|One drop in study eye every 12 hours for 14 days
287321|NCT02662296|Drug|Ibrutinib|Given PO
287322|NCT02662296|Drug|Idelalisib|Given PO
287323|NCT02662309|Drug|MPDL3280A|Intravenous infusion
287324|NCT02662322|Other|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
287325|NCT02662322|Other|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
287326|NCT02662322|Other|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
287327|NCT02662322|Other|peripheral intravenous catheterization|peripheral intravenous catheterization
287328|NCT02662335|Other|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
287329|NCT02662335|Other|Questionnaire Administration|Ancillary studies
287330|NCT02662335|Procedure|Standard Follow-Up Care|Undergo standard follow-up care
287331|NCT00198445|Drug|Placebo|One drop in study eye every 12 hours for 14 days
287332|NCT02662348|Drug|Recombinant Human Interleukin-2|Given SC
287633|NCT02656004|Other|Control Session|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
287634|NCT02656017|Drug|Metformin|Monitoring of tolerability and symptoms.
287033|NCT02666820|Procedure|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
287034|NCT02666820|Procedure|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
287035|NCT02666833|Device|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
287036|NCT02666846|Drug|Ibuprofen|Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).
287037|NCT02666846|Drug|Diclofenac|Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
287038|NCT02666846|Drug|Methyl-salicylate / Menthol|Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
287039|NCT02666846|Drug|Placebo|The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
287040|NCT02666859|Device|Virtual Reality|During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
287041|NCT02666872|Behavioral|Motivational interviewing|
287042|NCT02668952|Drug|0.9% Normal Saline (0.9% Sodium Chloride) injection|
287043|NCT02668952|Drug|Isolyte S injection|
287044|NCT02668965|Procedure|Intrauterine hCG (pregnyl)|
287045|NCT02668978|Device|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
287046|NCT02668978|Procedure|Standard surgical technique|Lung resuturing or restapling
287047|NCT02669004|Drug|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
287333|NCT02662348|Drug|HER2Bi-Armed T Cells|Given IV
286495|NCT02678754|Other|No intervention required, purely observational|
286496|NCT02678767|Drug|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
286497|NCT02678780|Drug|Lenvatinib|
286498|NCT02678793|Drug|CNTX-4975|
286499|NCT02678806|Radiation|Postoperative radiotherapy|
286500|NCT02678819|Device|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
286772|NCT02674191|Procedure|Administration of , Mepivacaine-l|local anesthesia
286773|NCT00199069|Drug|Ifosfamide|
286774|NCT02674191|Procedure|BETADINE povidone-iodine 10%|a local disinfectant
286775|NCT02674191|Drug|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
286776|NCT02674191|Drug|(Cataflam 25mg), are prescribed post-operatively|an analgesic
286777|NCT02674204|Drug|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
286778|NCT02674204|Drug|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
286779|NCT02674217|Procedure|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
286780|NCT02674243|Drug|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
286781|NCT02674243|Drug|Talc|In this group, Talc will be used as pleurodesis substance
286782|NCT02674256|Drug|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
286783|NCT02674256|Other|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
286784|NCT00199069|Drug|Cytarabine|
286785|NCT02674269|Drug|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
286786|NCT02674269|Drug|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
286508|NCT02680990|Behavioral|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
286509|NCT00199719|Drug|Ribavirine|
286510|NCT02680990|Other|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
286511|NCT02681003|Drug|FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide) Docetaxel|Arm A FEC: 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks
Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks
286512|NCT02681016|Device|DES "Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
286513|NCT02681016|Device|DES "Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
286514|NCT02681016|Procedure|Coronary angioplasty|
286795|NCT02676596|Drug|K-312 25 mg QD|
286796|NCT02676596|Drug|K-312 50 mg QD|
286797|NCT02676596|Drug|K-312 100 mg QD|
286798|NCT02676596|Drug|K-312 200 mg QD|
286799|NCT00199108|Drug|Dexamethasone|
286800|NCT02676596|Drug|K-312 400 mg QD|
286801|NCT02676596|Other|Placebo|
286802|NCT02676609|Device|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
286803|NCT02676622|Drug|mobilization of stem cells to prepare for Leukapheresis|Cyclophosphomide 2 g/m2 x 2 consecutive days.
Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis.
286224|NCT02650895|Biological|CD24Fc|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
286225|NCT02650895|Drug|Saline|0.9% sodium chloride
286226|NCT02650921|Device|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
286227|NCT02650934|Procedure|Percutanous coronary intervention|
286228|NCT02650947|Dietary Supplement|Sucralose|Sucralose 200 mg/day for 4 weeks
286229|NCT02650947|Dietary Supplement|Placebo|
286230|NCT02650973|Drug|CHS-1701|
286231|NCT02650973|Drug|Pegfilgrastim|
286232|NCT02650986|Drug|Cyclophosphamide|Given IV
286233|NCT02650986|Other|Laboratory Biomarker Analysis|Correlative studies
286234|NCT00196859|Drug|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
286235|NCT02650986|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
286236|NCT02650986|Biological|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
286237|NCT02650999|Drug|Pembrolizumab|200mg intravenously (IV)
286238|NCT02651012|Drug|sarecycline|1.5 mg/kg/day sarecycline or placebo tablets for duration of 12 week study
286239|NCT02651012|Drug|Placebo|1 tablet taken daily for duration of 12 week study
286240|NCT02651025|Other|Resistance Exercise Program|During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between "4" and "6".
286241|NCT02651038|Drug|Micafungin|Measurement of PK
286242|NCT02651051|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
286515|NCT02681029|Procedure|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
286516|NCT02681029|Procedure|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
285670|NCT02666222|Device|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
285671|NCT02666235|Procedure|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
285672|NCT02666235|Procedure|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
285946|NCT02657473|Drug|Saline 0.9% inhalation solution|
285947|NCT02657486|Drug|BGJ398|
285948|NCT02657499|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
285949|NCT02657512|Drug|rivaroxaban|rivaroxaban 40 mg/day (1 day)
285950|NCT02657512|Drug|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
285951|NCT02657538|Other|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
285952|NCT02657538|Other|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
285953|NCT02657538|Device|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
285954|NCT02657538|Other|Visual examination and bitewing (BW) radiography|established diagnostic methods
285955|NCT02657551|Drug|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
285956|NCT00197743|Other|Placebo|Placebo pill
285957|NCT02657564|Drug|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
285958|NCT02657577|Other|There is no intervention|There is no intervention
285959|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (LAX)
285960|NCT02659501|Drug|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
285402|NCT02673541|Device|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
285403|NCT02673541|Device|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
285404|NCT02673554|Drug|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
285405|NCT02673554|Drug|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
285406|NCT02673554|Procedure|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
285407|NCT02673554|Procedure|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l)
285408|NCT00199056|Procedure|CNS irradiation|
285409|NCT02673567|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
285410|NCT02673567|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
285411|NCT02673567|Drug|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
285412|NCT02673567|Drug|Placebo|Matching Placebo
285673|NCT02666287|Drug|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
285674|NCT02666287|Drug|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
285675|NCT02666287|Drug|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
285676|NCT02666287|Drug|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
285677|NCT02666287|Drug|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
285678|NCT02666300|Other|TaperGuard ETT|tracheal intubation with TaperGuard ETT
285122|NCT02610114|Other|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
285123|NCT00192491|Biological|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
285124|NCT02610114|Other|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
285125|NCT02610127|Biological|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
285126|NCT02610140|Drug|Anetumab ravtansine (BAY 94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
285127|NCT02610140|Drug|Vinorelbine|Starting dose: 30mg/m² administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
285128|NCT02610153|Drug|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
285129|NCT02610166|Behavioral|Game|In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to "lose" the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom.
285130|NCT02610166|Other|Usual Care|Children in usual care group receive standard medical care.
285413|NCT02675881|Device|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
285414|NCT02675894|Device|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
285415|NCT02675894|Device|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
285416|NCT02675907|Drug|N1539|
285417|NCT02675907|Drug|Intravenous Placebo|
284828|NCT02578680|Biological|Pembrolizumab 200 mg|IV infusion
284829|NCT02580825|Behavioral|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
284830|NCT02580825|Behavioral|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
284831|NCT00002514|Drug|mercaptopurine|
284832|NCT00189176|Drug|Tetrathiomolybdate|
284833|NCT02580838|Drug|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
284834|NCT02580851|Other|diagnostic test - cardiac magnetic resonance imaging|
284835|NCT02580851|Other|diagnostic test - coronary angiography|
284836|NCT02580877|Drug|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
284837|NCT02580877|Drug|500mg oral insulin crystals every other week|human insulin crystals in capsules
284838|NCT02580890|Device|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
284839|NCT02580890|Device|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
284840|NCT02580903|Radiation|Radiology|Only a small subsample will require CT and right heart catherisation
284841|NCT02580916|Other|SCQOLIT questionnaire|Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires [Appendices C & D) at:
baseline (after histological diagnosis of a NMSC is confirmed - both Groups)
3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up
at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)
284842|NCT02580929|Radiation|radiotherapy|radiotherapy before surgery
284843|NCT00189189|Behavioral|parent management training|
285131|NCT02610179|Dietary Supplement|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
284522|NCT02587364|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
284523|NCT02587364|Drug|Placebo|Placebo once daily (QD)
284524|NCT02587377|Other|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
284525|NCT02587390|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
284526|NCT02587390|Drug|Simvastatin 80 mg|2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
284527|NCT02587403|Device|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
284528|NCT02587403|Device|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
284529|NCT02587416|Drug|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
284530|NCT02587416|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
284531|NCT00190099|Device|Dexamethasone-Eluting Stent|
284532|NCT02587416|Drug|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
284533|NCT02587429|Behavioral|Patient education|
284534|NCT02587442|Drug|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
284535|NCT02587455|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
284536|NCT02587455|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
284537|NCT02587468|Dietary Supplement|Juice Plus+(R)|before-after comparison of plasma phenolics
284538|NCT02587494|Procedure|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
284539|NCT02587507|Other|Orange juice|Individuals will consume the HFHC meal with 500mL of orange juice.
284540|NCT02587507|Other|Water|Individuals will consume the HFHC meal with 500mL of water.
289698|NCT02649946|Device|Covera Vascular Covered Stent|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
289699|NCT02649946|Device|Percutaneous Transluminal Angioplasty (PTA)|Treatment of stenoses with PTA only
289700|NCT00196729|Drug|Thyrogen + Radioiodine (131I)|
289701|NCT02649959|Drug|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
289702|NCT02649972|Drug|Cobimetinib|Patients in this study will receive single-agent Cobimetinib 60mg oral daily for days 1-21 of each 28 day cycle. The rationale for single agent therapy, is the evidence for robust and sustained response to BRAF inhibitor monotherapy in histiocytic disorders harboring the BRAFV600E mutation.
290002|NCT02682381|Drug|Teduglutide|0.05 mg/kg
290003|NCT02682381|Drug|Standard of Care|Standard of Care The Standard of Care group does not receive an investigational drug. The subjects in this arm will receive standard medical therapy for short bowel syndrome, including personalized parenteral nutrition/IV fluids and enteral nutrition.
290004|NCT02682407|Biological|OMS721|Biological: OMS721
290005|NCT02682420|Device|everlinQ endoAVF System|
290006|NCT02682433|Device|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
290007|NCT02682433|Device|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
290008|NCT02682446|Drug|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen [lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week]
290009|NCT02682459|Drug|Lisinopril|
289404|NCT02656732|Biological|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
289405|NCT02656732|Procedure|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
289406|NCT02656745|Device|Clickotine®|The intervention regimen around Clickotine® is almost entirely user-directed. The users will download Clickotine® on their smartphones, and will engage with Clickotine® throughout their quit journey. They will be asked to complete "missions", daily activities which help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily "Check-Ins" are scheduled by the user to be performed each day, gathering within-Clickotine® information about their smoking habits. Ideally, the user will open and use Clickotine® several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using Clickotine®.
289407|NCT02656758|Behavioral|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
289408|NCT02656771|Device|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
289409|NCT00197613|Procedure|Adherence Strategy Standard of Care (SOC)|
289410|NCT02656784|Behavioral|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
289703|NCT02649985|Drug|[F-18]PBR06|PET radiopharmaceutical
289704|NCT02649998|Drug|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
289705|NCT02652442|Behavioral|Centrifugation|Participants will be rotated in a darkened rotary chair booth with 1 ear positioned 7-8 cm off-axis and the other ear positioned on-axis. Following a 5-minute rest period, the procedure will be repeated with the opposite ear positioned off-axis. Participants will receive 10 sessions in a 4-week period.
289706|NCT02652442|Behavioral|Balance rehabilitation|All participants will perform balance and gait exercises and will be provided a written home exercise program consisting of exercises designed to improve postural stability and mobility with progressively more challenging tasks.
289707|NCT02652455|Drug|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
289708|NCT02652455|Procedure|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
289709|NCT02652455|Drug|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
289099|NCT00198250|Drug|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
289100|NCT02660762|Drug|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
289101|NCT02660762|Drug|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
289102|NCT02660762|Drug|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
289103|NCT02660762|Drug|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
289104|NCT02662933|Other|Bedside assessment|The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.
Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization.
289105|NCT00198510|Drug|Vitrase|75 IU of Vitrase
289106|NCT02662946|Procedure|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
289107|NCT02662946|Procedure|No angiography|Extension of resection based on subjective measures
289108|NCT02662959|Drug|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
289109|NCT02662972|Drug|Botulinum Toxin Type A|
289110|NCT02662985|Drug|AIN457 (secukinumab)|Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.
Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose will be administered as 2 × PFS injections.
289411|NCT02656784|Behavioral|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
289412|NCT02656797|Drug|Topical Amphotericin-B 0.4% liposomal gel|
289413|NCT02656797|Drug|Placebo|
289414|NCT02656810|Drug|Teriparatide|Single subcutaneous injection
289415|NCT02656823|Device|ANKYLOS C/X 6.6 mm|
289416|NCT02656836|Other|Home tonometry, diagnostic study|Evaluating intraocular pressure
289417|NCT02656849|Drug|BAY 1000394|
288533|NCT02674997|Biological|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
288534|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
288535|NCT02675023|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
288536|NCT02675036|Procedure|Tooth extraction|
288537|NCT02675049|Drug|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
288538|NCT00199082|Drug|Adriamycin|
288539|NCT02675049|Drug|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
288540|NCT02675049|Drug|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
288541|NCT02675049|Drug|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
283971|NCT02605187|Other|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
283972|NCT02605187|Drug|Ibuprofen|Ibuprofen 600mg po q6h
283973|NCT02605187|Drug|Acetaminophen|Acetaminophen 650mg po q6h
283974|NCT02605187|Drug|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
283975|NCT02605187|Drug|Morphine (low)|Intrathecal morphine dose 50mcg
283976|NCT02605187|Drug|Morphine (med)|Intrathecal morphine dose 150mcg
283977|NCT02605187|Drug|Morphine (high)|Intrathecal morphine 300mcg
283978|NCT00191971|Drug|Gemcitabine|
283979|NCT02605200|Behavioral|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
283980|NCT02605200|Behavioral|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
288246|NCT02681640|Other|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
288247|NCT02681640|Device|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
288248|NCT00199836|Biological|NY-ESO-1b peptide plus CpG 7909 and Montanide ISA-51|
288249|NCT02681653|Drug|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
288250|NCT02681653|Drug|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
288251|NCT02681666|Dietary Supplement|Dietary intervention|Sessions will be spent with patients discussing the fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet and how to use this diet to treat their Irritable Bowel Syndrome.
288252|NCT02681666|Behavioral|Irritable Bowel Syndrome eating awareness training|A type of meditation about their eating habits.
288253|NCT02681679|Drug|0.1% bromfenac ophthalmic solution|
288254|NCT02681679|Procedure|femtosecond laser cataract surgery|
288255|NCT02681692|Device|Magnetic endoscopic imaging system|Trainees are randomly assigned to be trained with the help of magnetic scope navigation system in the first stage.They would independently perform colonoscopes with or without the assistance of magnetic scope navigation system alternately for the purpose of self-control in the second stage.
288542|NCT02675088|Radiation|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
288543|NCT02677181|Drug|ATG|rabbit ATG（Sanofi）
288544|NCT02677181|Drug|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
288545|NCT00199147|Procedure|Stem cell transplantation|
288546|NCT02677181|Drug|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
288547|NCT02677181|Drug|Methotrexate|short-term methotrexate
288548|NCT02677194|Device|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
288549|NCT02677194|Other|Control device|Device without any LED exposition
288550|NCT02677207|Drug|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
287936|NCT02651753|Drug|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
287937|NCT02651753|Drug|CKD-337|Test Drug: CKD-337
287938|NCT00196950|Biological|Meningococcal (vaccine)|
287939|NCT02651766|Procedure|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
287940|NCT02651779|Procedure|Open reduction and internal plate fixation|
287941|NCT02651779|Other|Closed reduction and plasterimmobilisation|
287942|NCT02651792|Drug|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
287943|NCT02651792|Drug|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
287944|NCT02651805|Device|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E) settings: 6 assisted cough cycles with pressures of 40 to -40cmH2O;inspiratory time-3s; expiratory time-4s and pause between cycles-4s. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy during the morning and afternoon. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in the MI-E group, or if they have already finished the period of follow-up (24 hours) they will be able to request this therapy, which will be provided by a member of the staff trained in the use of the MI-E. The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
287945|NCT02651805|Other|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
287946|NCT02651818|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
287947|NCT02651831|Other|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICI therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
287948|NCT02651831|Other|Questionnaire|Health related quality of life questionnaire (FACT-ICI) to be completed by patients
287949|NCT00196963|Biological|Meningococcal (vaccine)|
288256|NCT02681705|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
288257|NCT02681705|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
287635|NCT02656017|Other|Placebo|Monitoring of tolerability and symptoms.
287636|NCT02656030|Other|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
287637|NCT02656030|Other|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
287638|NCT02658110|Other|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
287639|NCT02658123|Other|Pre-operative education (standard of care)|
287640|NCT02658123|Other|Home health care visits (standard of care)|
287641|NCT02658123|Other|Follow-up post-operative visits|
287642|NCT02658123|Other|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
287643|NCT02658123|Other|Healthcare Utilization Form|Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized
Form allows patient to record reason for visit and date of visit
287644|NCT02658123|Other|The City of Hope QOL Survey for Ostomy Patients|Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.
Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem.
287645|NCT02658123|Other|Phone call with CWOCN or PA|
287646|NCT02658136|Other|Cardiac Computed tomography|
287647|NCT02658149|Drug|Ropivacaine with NaCl|50 mL (40 mL of 0.2% ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
287648|NCT00197808|Biological|menjugate|men C conjugate vaccine
287649|NCT02658149|Drug|Epinephrine|0.15 mg epinephrine are injected as part of the drug "cocktail"
287650|NCT02658149|Drug|Morphine|4 mg morphine are injected as part of the drug "cocktail"
287651|NCT02658149|Drug|Ketorolac Tromethamine|30 mg morphine are injected as part of the drug "cocktail"
287652|NCT02658149|Drug|Ropivacaine|30 mL 0.5% ropivicaine are injected as part of the drug "cocktail"
287653|NCT02658162|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
287654|NCT02658162|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
287334|NCT02662374|Drug|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
287335|NCT02662374|Drug|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
287336|NCT02662374|Drug|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
287337|NCT02662374|Device|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
287338|NCT02662374|Drug|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
287339|NCT02662387|Device|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
287340|NCT02662387|Other|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
287341|NCT02664688|Other|Lumbar stabilization exercises|The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position ("bird-dog")
287342|NCT02664688|Other|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
287343|NCT02664701|Other|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
287344|NCT02664701|Other|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
287345|NCT02664701|Other|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
287346|NCT02664701|Other|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
287347|NCT02664714|Other|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
287348|NCT02664727|Behavioral|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
286787|NCT02674269|Device|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
286788|NCT00199108|Drug|Depocyt|
286789|NCT02676518|Other|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
286790|NCT02676531|Other|Exercise|Walking meditation exercise program
286791|NCT02676544|Device|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
286792|NCT02676557|Device|Exposed to the high pressure during the surgery|
286793|NCT02676583|Procedure|Tonsillectomy|Closure or not closure of tonsil fossa
286794|NCT02676596|Drug|K-312 10 mg QD|
287048|NCT02669004|Drug|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
287049|NCT00198991|Drug|Cladribine|
287050|NCT02669017|Drug|ADCT-402|intravenous infusion
287051|NCT02669030|Drug|suvorexant|an FDA-approved sleep aid
287052|NCT02669030|Drug|Placebo|
287053|NCT02669043|Drug|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
287054|NCT02669056|Other|5-HT measurement|
287055|NCT02669056|Other|cerebral MRI|
287056|NCT02669056|Other|Video recording|
287057|NCT02669056|Other|EEG|
287058|NCT02669056|Other|growth curves|
287059|NCT02669056|Other|ASQ questionnaire|
287060|NCT00199004|Drug|Cyclophosphamide|
287061|NCT02669082|Drug|Ramelteon|Ramelteon tablets
287062|NCT02669108|Device|PET/ MRI of the Testis|
286804|NCT02676622|Other|Leukapheresis- Collection of stem cells|Placement of an Apheresis Catheter on the day of collection of stem cells.
Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight.
286805|NCT02676622|Drug|Preparative regimen 4-6 weeks after Leukapheresis|Prior to starting medicines, a central venous line will be placed (arm or chest)
Cyclophosphamide iv: 50 mg/kg iv over 2 hours
Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours
r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1
286806|NCT02676622|Other|Stem Cell Transplant|Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.
Day +5: start Filgrastim (G-csf) subcutaneous injections
Hospitalization in isolation room for 4-5 weeks
286807|NCT02676622|Drug|Low-dose IL-2 administration|IL-2 Subcutaneous injections will start once ANC is > 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.
Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits.
286808|NCT02676635|Behavioral|Ergonomics training and/or Safety Voice training|Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a "safety voice" about safety in general, and ergonomics specifically.
286809|NCT02678845|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
286810|NCT02678858|Behavioral|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
287071|NCT02671630|Other|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
287072|NCT02671656|Device|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
287073|NCT02671669|Behavioral|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
286517|NCT02646306|Other|shoulder proprioceptive rehabilitation tool|Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the "reaching" of an object.
286518|NCT02646319|Other|Laboratory Biomarker Analysis|Correlative studies
286519|NCT02646319|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
286520|NCT02646319|Other|Quality-of-Life Assessment|Ancillary studies
286521|NCT02646332|Drug|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
286522|NCT02646332|Drug|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
286523|NCT00196378|Drug|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
286524|NCT02646345|Procedure|Surgical checklist|Use of the World Health Organization Surgical checklist
286525|NCT02646358|Drug|Vepoloxamer|
286526|NCT02646371|Biological|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
286527|NCT02646371|Biological|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
286528|NCT02646384|Procedure|Ovarian tissue cryopreservation|Ovarian tissue will be removed
286529|NCT02646397|Drug|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
286530|NCT02646397|Drug|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
286531|NCT02646397|Drug|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
286532|NCT02646410|Other|FPD+NDOT|
286533|NCT02646410|Other|FPD+DOT|
286534|NCT00196378|Other|Placebo|1 tablet daily
286535|NCT02646410|Other|DDD+NDOT|Door to door delivery + non directly observed treatment
286536|NCT02646410|Other|DDD+DOT|Door to door delivery + directly observed treatment
285961|NCT02659501|Drug|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
285962|NCT02659501|Drug|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
285963|NCT02659501|Drug|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
285964|NCT00198042|Procedure|Surgical reconstruction of the ACL|
285965|NCT02659501|Drug|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
286243|NCT02651051|Other|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
286244|NCT02651064|Other|HIP|
286245|NCT00196872|Drug|Epirubicine|Epirbubicne is given
286246|NCT02651090|Drug|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
286247|NCT02653170|Other|SCM|One intervention (SCM) is provided. Stroke Care Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:
Biopsychosocial assessment of patient and caregiver needs.
Set up appointments.
Assist scheduling appointments with primary care physician and other medical providers.
Promote medication adherence through medication tool kits, pill organizers and other aids.
Facilitate patient and caregiver engagement and activation.
Facilitate access to social and community services.
286248|NCT02653170|Other|SCM and VSSP|SCM: Stroke Care Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:
Biopsychosocial assessment of patient and caregiver needs.
Set up appointments.
Assist scheduling appointments with primary care physician and other medical providers.
Promote medication adherence through medication tool kits, pill organizers and other aids.
Facilitate patient and caregiver engagement and activation.
Facilitate access to social and community services.
VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:
Contact list of care team members.
Access to hospital patient portal.
Stroke education materials, resources, and guidelines.
Access to Michigan 2-1-1 services.
Medication information and adherence tools.
Patient and Caregiver support networks.
286249|NCT02653183|Device|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing
286250|NCT02653183|Device|Experimental: Mepilex Border Post-Op|Aquacel Surgical is a sterile, one piece post-operative dressing
286251|NCT02653196|Procedure|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
285679|NCT00002532|Drug|idarubicin|
285680|NCT00198939|Other|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
285681|NCT02666313|Behavioral|Exercise|The physiotherapist will select exercises from the website exercise catalogue which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist and, depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.
Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days per week for 30 minutes each day. Participants will then receive weekly phone calls from the physiotherapist for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions.
285682|NCT02666326|Procedure|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is <9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is <14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
285683|NCT02666339|Other|Usual care|Usual care : drug therapy, nurse and physician consultations.
285684|NCT02666339|Behavioral|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
285685|NCT02668406|Other|Venous blood sampling (1 timepoint)|8.5ml at Day 1
285686|NCT00000131|Procedure|Photocoagulation Therapy|
285687|NCT00000379|Drug|Fluoxetine|
285688|NCT00002532|Drug|methotrexate|
285966|NCT02659514|Drug|Poziotinib|Supplied as oral tablets, administered for 14 consecutive days of each cycle
285967|NCT02659527|Drug|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
285968|NCT02659527|Device|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
285969|NCT02659540|Drug|Ipilimumab|
285970|NCT02659540|Drug|Nivolumab|
285971|NCT02659540|Radiation|Radiotherapy|
285972|NCT02659553|Procedure|steatosis|Liver Transplantation with graft steatosis
285418|NCT02675920|Drug|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
285419|NCT02675933|Behavioral|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
285420|NCT00199095|Drug|Cytarabine|
285421|NCT02675946|Drug|CGX1321|
285422|NCT02675959|Drug|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
285423|NCT02675985|Other|Physical Therapy|Early Intensive Physical therapy in the ICU
285424|NCT02675998|Drug|Tenapanor|
285425|NCT02675998|Drug|Placebo|
285426|NCT02676011|Drug|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
285427|NCT02676011|Drug|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
285428|NCT02676011|Drug|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
285429|NCT02676011|Drug|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
285430|NCT02676011|Drug|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
285431|NCT00199095|Drug|Dexamethasone|
285432|NCT02676011|Drug|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
285433|NCT02676024|Device|Knowledge-based cognitive aid|Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid "reader").
285689|NCT00198991|Drug|Adriamycin|
285690|NCT02668419|Device|Neuromuscular Electrical Stimulator|Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode "on-time" 10s and "off-time" 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min.
285132|NCT02610179|Dietary Supplement|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
285133|NCT02610192|Biological|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
285134|NCT02576470|Device|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
285135|NCT02576470|Behavioral|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
285136|NCT02576470|Behavioral|volitional Laryngeal Vestibule Closure (vLVC)|The volitional Laryngeal Vestibule Closure (vLVC), is a swallowing maneuver that emphasizes airway protection. Participants will be advised that they should not be able to breathe while performing the vLVC as the laryngeal vestibule should be closed. The biofeedback effects on vLVC training will be tested during 3 time periods: (1) Pre-training (establishing vLVC baseline performance), (2) Training (improving and generalizing vLVC skills); and (3) Post-training (generalizing and retaining skills when swallowing with no therapeutic technique, or natural swallowing).
285137|NCT02576470|Radiation|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing LVC kinematics during the pharyngeal swallow.
285138|NCT02576470|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
285139|NCT00188474|Behavioral|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
285140|NCT02576470|Device|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
285141|NCT02576483|Behavioral|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
285142|NCT02576496|Drug|EDO-S101|
285143|NCT02576509|Drug|Nivolumab|
285144|NCT02576509|Drug|Sorafenib|
285145|NCT02576522|Radiation|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
285146|NCT02576535|Procedure|Fractionated stereotactic radiosurgery|
284844|NCT02580942|Device|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
284845|NCT02580942|Device|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
284846|NCT02580942|Drug|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
284847|NCT02580955|Device|LEGFLOW DCB|
284848|NCT02580968|Device|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
284849|NCT02583009|Drug|PAC-14028 cream 0.3%|Topical application
284850|NCT02583009|Drug|PAC-14028 cream 1.0%|Topical application
284851|NCT02583009|Drug|PAC-14028 cream vehicle|Topical application
284852|NCT02583022|Drug|PAC-14028 cream 1.0%|Topical application
284853|NCT02583022|Drug|PAC-14028 cream vehicle|Topical application
284854|NCT00189501|Drug|Sensipar®|
284855|NCT02583022|Drug|Elidel cream 1%|Topical application
284856|NCT02583035|Other|Nurse telephone contact|Nurse will contact patient 3 days before consultation
284857|NCT02583048|Drug|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 22 weeks, for all study arms involving the use of this drug.
284858|NCT02583048|Drug|Delamanid|Delamanid will be administered with food as two 50 mg tablets (100 mg) by mouth twice a day for 24 weeks, for all study arms involving the use of this drug.
284859|NCT02583048|Drug|Dolutegravir|For HIV-positive participants only: dolutegravir will be administered at a dose of one 50 mg tablet once daily, to be used in combination with two NRTIs until study completion. (NRTIs will not be provided by the study.)
284860|NCT02583061|Other|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
284861|NCT02583074|Procedure|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
284862|NCT02583074|Procedure|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
290010|NCT02682472|Other|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
290011|NCT02682485|Drug|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
290012|NCT00199940|Drug|Ziprasidone|
290013|NCT02682485|Procedure|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
290014|NCT02682485|Drug|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
290015|NCT02682498|Drug|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
290294|NCT02677961|Other|Observation|
290295|NCT02677974|Device|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
290296|NCT02677987|Device|Intervention systematic light exposure|
290297|NCT02677987|Device|Comparison systematic light exposure|
290298|NCT02678000|Drug|LHW090|LHW090 is orally administered
290299|NCT02678000|Drug|Placebo|Matching placebo of LHW090
290300|NCT02678013|Procedure|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
290301|NCT02678013|Procedure|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
290302|NCT02678026|Device|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
290303|NCT00199212|Drug|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
290304|NCT02678039|Device|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
289710|NCT00197015|Biological|Havrix®|2 doses administered intramuscularly
289711|NCT02652455|Drug|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
289712|NCT02652455|Drug|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
289713|NCT02652455|Biological|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
289714|NCT02652455|Drug|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
289715|NCT02652468|Drug|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
289716|NCT02652468|Drug|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
289717|NCT02652468|Drug|Cyclophosphamide|Given IV for 2 days
289718|NCT02652468|Radiation|Total nodal irradiation|Undergo total lymphoid irradiation
289719|NCT02652468|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
289720|NCT02652468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
289721|NCT00197015|Biological|M-M-R®II|1 dose administered subcutaneously
290016|NCT02647762|Drug|CF101 2 mg|CF101 tablets, 2 mg BID for 16 weeks
290017|NCT02647762|Drug|Placebo|Placebo tablets, 1mg BID for 16 weeks
290018|NCT00196521|Device|Tension-free vaginal tape obturator system|
290019|NCT02647775|Procedure|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
290020|NCT02647775|Procedure|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
290021|NCT02647788|Drug|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
290022|NCT02647788|Drug|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
289418|NCT02656862|Other|No intervention|
289419|NCT02656875|Drug|TRV130|
289420|NCT00197613|Procedure|Adherence Strategy Community-Based DOT|
289421|NCT02656888|Drug|Guaifenesin and ibuprofen and Loratadine|
289422|NCT02658799|Drug|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
289423|NCT02658799|Drug|placebo|Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.
Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
289424|NCT02658812|Drug|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec given via intra-tumoral injection at visible locally recurrent breast cancer site and skin metastases at an initial dose of 10^6 PFU/mL .
Second talimogene laherparepvec dose administered 10^8 PFU/mL on Day 22, and talimogene laherparepvec administered every 2 weeks after the second course with same dose with the maximum dose of 4.0 mL for each course.
289425|NCT02658812|Other|Photographs|Photographs taken of lesions on chest at baseline, at Cycle 2, Cycles 4, 8, and 10 if the doctor thinks it is needed, Day 1 of Cycle 5, Day 1 of Cycle 7, and then every odd numbered cycle after that.
289426|NCT02658812|Behavioral|Follow-Up Visit/Phone Call|About 30 days after end-of-treatment visit and then every 3 months after that for up to 1 year, participant has follow-up visit or phone call from study staff.
289427|NCT00197873|Other|Placebo administration.|Placebo is administered during chemotherapy.
289428|NCT02658825|Drug|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
289429|NCT02658825|Drug|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
289430|NCT02658825|Drug|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
289722|NCT02652468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
289723|NCT02652468|Drug|Mycophenolate Mofetil|Given PO
289724|NCT02652468|Drug|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10^5 cells/kg ideal BW of the patient
289725|NCT02652468|Biological|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the patient
283981|NCT02605213|Drug|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
283982|NCT02605213|Drug|Placebo|Placebo for control Group of primary sclerosing vhlangitis
283983|NCT02605226|Procedure|Cryoablation therapy|Cryoablation therapy
283984|NCT02605226|Radiation|External beam radiation therapy|External beam radiation therapy
283985|NCT02605226|Drug|bicalutamide|bicalutamide
283986|NCT02605226|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
283987|NCT02605239|Drug|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
283988|NCT02607553|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
283989|NCT02607566|Behavioral|Yoga|
283990|NCT02607566|Behavioral|Walking Program|twice weekly walking program, 60 minutes for 12 weeks
283991|NCT02607579|Drug|Exparel|
283992|NCT02607579|Drug|Ropivacaine|
284303|NCT02600884|Behavioral|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
284304|NCT02600884|Behavioral|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
284305|NCT02600897|Drug|Lenalidomide|Participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle. For eligible participants, post-induction treatment may be given at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months, until disease progression or unacceptable toxicity.
284306|NCT00191503|Drug|Gemcitabine|
284307|NCT02600897|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 28 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months, until disease progression or unacceptable toxicity.
284308|NCT02600897|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
288551|NCT02677207|Drug|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
288552|NCT02677246|Drug|Denosumab|Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils > 0,5x10(9)/L and chimerism ≥ 10% of donor origin.
Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.
Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.
Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab
288553|NCT02677259|Drug|17-beta estradiol|
288554|NCT02677259|Drug|Micronized progesterone|
288555|NCT02677272|Other|Appropriateness of NH resident's transfer to ED|
288556|NCT00199160|Drug|BAY 43-9006|
288557|NCT02677285|Other|Different type of wound|
288558|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
288559|NCT02677298|Drug|Placebo|Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
288560|NCT02677311|Procedure|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
288561|NCT02677311|Procedure|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
283993|NCT02607592|Drug|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
283994|NCT02607592|Drug|nadaplatin+pemetrexed|nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
283995|NCT02607618|Drug|Iclaprim|Experimental treatment
283996|NCT00192218|Biological|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
283997|NCT02607618|Drug|Vancomycin|Active comparator
283998|NCT02607631|Drug|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
283999|NCT02607644|Device|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
284000|NCT02607644|Device|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
284001|NCT02607657|Drug|Eplerenone 25 mg|
288258|NCT02681718|Behavioral|Community health worker education|Diabetes self-management education by community health workers
288259|NCT00199849|Biological|NY-ESO-1 plasmid DNA Cancer Vaccine|
288260|NCT02681718|Behavioral|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
288261|NCT02681744|Behavioral|Resistance Training|24-weeks of progressive strength training
288262|NCT02681757|Device|triple antibiotic ointment dressing|used for control group under soft cast
288263|NCT00196404|Other|Placebo|Administered vaginally to match experimental arms
288264|NCT02646956|Other|sweeteners|Participants tasted a variety of nutritive and nonnutritive sweeteners
288265|NCT02646969|Dietary Supplement|Formula regimen 1|
288266|NCT02646969|Dietary Supplement|Formula regimen 2|
288267|NCT02646982|Drug|Placebo|A matched placebo will be given once daily for 12 months.
288268|NCT02646982|Drug|Candesartan|Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP>110 mm Hg, DBP>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
288269|NCT02646995|Dietary Supplement|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
288270|NCT02646995|Dietary Supplement|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
288271|NCT02647008|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
288272|NCT02647021|Behavioral|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
288273|NCT02647021|Behavioral|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
288274|NCT00196417|Drug|Standard heparin (UFH) versus certoparin (LMWH)|
288275|NCT02647034|Other|no intervention|no intervention
288562|NCT02677324|Drug|ABT199|Oral BCL-2 antagonist
288563|NCT02677337|Other|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
287950|NCT02651844|Drug|Mifepristone|At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).
Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file.
287951|NCT02651857|Device|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
287952|NCT02651857|Device|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
287953|NCT02651870|Drug|Candesartan 16mg|
287954|NCT02651870|Drug|Amlodipine 5mg|
287955|NCT02653729|Drug|Espidone|
287956|NCT00197184|Biological|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
287957|NCT02653729|Drug|Olepra|
287958|NCT02653729|Drug|Donu|
287959|NCT02653742|Drug|Ketorolac|
287960|NCT02653742|Drug|Fentanyl|
287961|NCT02653755|Device|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
287962|NCT02653768|Behavioral|Stepped Exercise Program|STEP 1: Participants have access to an internet-based exercise program for knee OA.
STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.
STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit
287963|NCT02653768|Behavioral|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
287964|NCT02653781|Behavioral|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
287965|NCT02653781|Behavioral|control group|The control group will have contents exposed solely from the dialogue-exhibition.
287966|NCT02653781|Behavioral|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
287967|NCT00197197|Drug|GW873140|
287968|NCT02653781|Behavioral|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
287349|NCT02664727|Behavioral|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
287655|NCT02658175|Drug|Volanesorsen|
287656|NCT02658188|Drug|ASP8825|Oral
287657|NCT02658201|Device|MRI|Ultrafast MRI to assess constipation
287658|NCT02658214|Drug|paclitaxel + carboplatin|IV infusion
287659|NCT00197808|Biological|Men C conjugate vaccine|men C conjugate vaccine
287660|NCT02658214|Drug|carboplatin + etoposide|IV infusion
287661|NCT02658214|Drug|gemcitabine + carboplatin|IV infusion
287662|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
287663|NCT02658214|Drug|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
287664|NCT02658214|Biological|durvalumab|IV infusion
287665|NCT02658214|Biological|tremelimumab|IV infusion
287666|NCT02660151|Device|Regular soft contact lens|
287667|NCT02660151|Drug|Salt solution|
287668|NCT02660164|Device|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
287669|NCT02660177|Drug|Metamizole|metamizole IV administration
287670|NCT02660190|Drug|hexaminoavolunate|
287671|NCT02660190|Procedure|WL cystoscopy|
287672|NCT00198120|Drug|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg Placebo: same dosing schedule and capsule strength
287063|NCT02669121|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV: 15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum as Al(OH)3, administered as 0.5 mL intramuscularly (IM)
287064|NCT02669121|Biological|NoV vaccine placebo|NoV vaccine placebo-matching solution [saline (0.9% sodium chloride)] administered as 0.5 mL intramuscularly (IM)
287065|NCT02669134|Other|Device programming|SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed "AV+VV"
287066|NCT02669160|Device|PC Innowalk|
287067|NCT02669160|Device|Conventional passive stander|
287068|NCT02669173|Drug|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
287069|NCT02669173|Drug|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
287070|NCT02669186|Drug|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
287350|NCT02664740|Drug|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
287351|NCT00198744|Behavioral|both diet plans with and without a parent dieting|
287352|NCT02664740|Drug|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
287353|NCT02664753|Drug|56 days of weight-adjusted L-Carnitine treatment|Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.
Day 1: a first bolus of 6g of L-Carnitine is administered in a 50 ml isotonic saline mini-perfusion bag.
Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each mini-perfusion For the next 46 days, patients will take oral doses of L-Carnitine at 50mg/kg/day (rounded up to the next gram)
287354|NCT02664753|Drug|10 days of intravenous placebo (isotonic saline)|Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).
Day 1: 1 50ml isotonic saline mini-perfusion bag + an additional 30 ml of saline solution.
Day 2 to Day 10 : Two mini-perfusions are prepared each day, one during the morning and one during the evening. Saline solution is added to each mini-perfusion.
287355|NCT00198978|Drug|Cytarabine|
287356|NCT02666885|Radiation|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
287357|NCT02666898|Drug|GA101|Part 1 :6 cycles
Obinutuzumab/GA101:
First cycle:
D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v
Cycle 2 to 6 (every 28 days) :
D1 of every cycle: 1000 mg i.v PART 2 4 cycles
-patients have BM MRD >10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1
287074|NCT02671669|Behavioral|Movn application (MVN)|Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:
Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.
Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions.
287075|NCT00199017|Procedure|CNS irradiation|
287076|NCT02671682|Procedure|Immunoadsorption|
287077|NCT02671682|Procedure|Plasmapheresis|
287078|NCT02671695|Drug|Spirulina|
287079|NCT02671695|Drug|Amlodipine|
287080|NCT02671708|Drug|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -11 and -9.
287081|NCT02671708|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
287082|NCT02671708|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
287083|NCT02671721|Other|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
287084|NCT02671721|Device|AVEA smartCath Nasogastric Pressure Monitoring Tube|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
287085|NCT02671734|Behavioral|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
287086|NCT00199017|Procedure|Mediastinal irradiation|
287087|NCT02671747|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
287363|NCT02666924|Dietary Supplement|Culturally specific chinese-canadian dietary cooking classes for persons with diabetes|Each cooking class will run for approximately 4 hours. Prior to the start of each cooking class, the chef, dietitian and nurse will have purchased the food and ingredients necessary for that class and set up the kitchen in preparation for class. In addition to working together to prepare various culturally appropriate meals, participants will have an opportunity to engage in learning, group discussions, group support, hands-on meal preparation, and to practice diabetes self-care activities, such as monitoring blood glucose levels and physical activity. Each of the 4 cooking classes in the series will have its own learning objectives, goals and recipes. Topics for discussion and practice include: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
287364|NCT02666950|Drug|Cytarabine|Given SC
286811|NCT02678858|Behavioral|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
286812|NCT00199316|Drug|spinal morphine|
286813|NCT02678871|Device|Lotus Heart valve system|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS heart valve system
286814|NCT02678871|Device|WATCHMAN|LAA closure with the WATCHMAN device
286815|NCT02678884|Drug|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
286816|NCT02678897|Drug|Oxynorm|We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)
If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.
Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5.
286817|NCT02678910|Procedure|Ovarian Cryopreservation|Ovarian tissue will be cryopreserved under the National Physicians Cooperative of the Oncofertility Consortium. The ovarian tissue will be removed at a UK or Norton Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
286818|NCT02678923|Drug|MDCO-216|
286819|NCT02678923|Drug|Placebo|
286820|NCT02678936|Biological|PRP|Application of platelet-rich plasma during surgery
286821|NCT02678949|Drug|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
286822|NCT02678949|Drug|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
286823|NCT02681042|Procedure|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
286252|NCT02653196|Drug|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
286253|NCT02653196|Drug|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
286254|NCT02653196|Drug|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
286255|NCT02653196|Drug|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
286256|NCT02653196|Drug|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
286257|NCT00197106|Drug|fluticasone propionate 2 x 100 mcg|comparator
286258|NCT02653196|Drug|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
286259|NCT02653196|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
286537|NCT02646423|Behavioral|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
286538|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
286539|NCT02646436|Other|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
286540|NCT02648555|Behavioral|Dietary recommendations|Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.
Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron.
286541|NCT02648568|Behavioral|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
286542|NCT02648568|Behavioral|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
286543|NCT00196612|Drug|emtricitabine, FTC (drug)|
285973|NCT02659579|Behavioral|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
285974|NCT02659579|Behavioral|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
285975|NCT00198055|Drug|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
285976|NCT02659592|Procedure|transplantation of ovarian tissue|operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
285977|NCT02659605|Procedure|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
285978|NCT02659605|Procedure|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
285979|NCT02659631|Drug|PF-06671008|Dose Escalation Phase - Part 1
285980|NCT02659631|Drug|PF-06671008|Dose Expansion Phase - Part 2
285981|NCT02661698|Dietary Supplement|Pronovum Omega-3: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
285982|NCT02661711|Drug|Aflibercept|2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.
Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye.
285983|NCT00002532|Biological|filgrastim|
285984|NCT00198380|Drug|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
286260|NCT02653196|Drug|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age > 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
286261|NCT02653196|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
286262|NCT02653209|Drug|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
286263|NCT02653209|Drug|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
286264|NCT02653209|Drug|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
285691|NCT02668419|Other|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure >15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as >200 mmHg; 6) a rise in diastolic blood pressure during exercise >110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
285692|NCT02668432|Drug|Amiodarone|
285693|NCT02668445|Other|Standard meal containing low or high carbohydrate content|
285694|NCT02668458|Procedure|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
285695|NCT02668458|Procedure|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
285696|NCT02668471|Procedure|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
285697|NCT02668471|Procedure|traditional method|Radial artery catheters will be placed by the palpation technique only.
285698|NCT02668484|Device|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
285699|NCT02668484|Device|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
285700|NCT00198991|Drug|Thioguanine|
285701|NCT02668497|Drug|Botulinum Toxin Type A|
285702|NCT02668510|Biological|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
285703|NCT02668510|Drug|Normal saline|placebo injection of normal saline immediately following shockwave therapy
285704|NCT02668536|Drug|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
285705|NCT02668536|Device|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
285706|NCT02668549|Other|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
285707|NCT02668562|Procedure|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
285434|NCT02676024|Device|Cognitive aids with roles defined (CARD)|Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid "reader").
285435|NCT02676024|Device|Integrated cognitive aids|Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid "reader".
285436|NCT02678234|Drug|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each subject randomized to the Theraflu Aktiv powder for oral solution
285437|NCT02678247|Device|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
285438|NCT02678247|Device|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
285439|NCT02678260|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
285440|NCT02678273|Other|Intervention group|The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents
285441|NCT02678286|Drug|N1539|
285442|NCT00199225|Procedure|Pharmacokinetic profile|
285443|NCT02678286|Drug|Intravenous Placebo|
285444|NCT02678299|Drug|PREBEN|
285445|NCT02678312|Drug|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), 50 mg, 100 mg, 200 mg dosage strengths
285446|NCT02678312|Drug|Enalapril|Enalapril will be open label in Part 1 and double blind in Part 2
285447|NCT02678312|Drug|Placebo of LCZ696|
285448|NCT02678312|Drug|Placebo of Enalapril|
284863|NCT02583087|Procedure|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
285147|NCT02576535|Device|Leskell gamma unit|FDA approved device
285148|NCT02576548|Biological|MEDI4276|MEDI4276 is an investigational product
285149|NCT02576561|Biological|TVGV-1|Antigen + Adjuvant
285150|NCT00002514|Drug|cytarabine|
285151|NCT00188487|Device|magnetic resonance imaging (MRI) of the thorax|
285152|NCT02576561|Biological|GPI-0100|Adjuvant Alone
285153|NCT02576561|Biological|Placebo|Placebo
285154|NCT02578680|Drug|Cisplatin|IV infusion
285155|NCT02578680|Drug|Carboplatin|IV infusion
285156|NCT02578680|Drug|Pemetrexed|IV infusion
285157|NCT02578680|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
285158|NCT02578680|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
285159|NCT00188903|Procedure|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
285160|NCT02578680|Drug|Dexamethsone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
285161|NCT02578680|Drug|Saline solution|IV infusion
285162|NCT02578706|Drug|Clopidogrel|Clopidogrel 75mg
285163|NCT02578706|Drug|Aspirin|81 mg
285164|NCT02578706|Drug|Placebo|
285165|NCT02578719|Drug|bupivacaine|marcaine %0.5 20 ml flacon
285166|NCT02578719|Drug|saline|%0.9 sodium chloride
285167|NCT02578732|Drug|FOLFOXA|FOLFOXA is a combination treatment including: Abraxane, Oxaliplatin, Leucovorin and 5-FU
290305|NCT02678039|Procedure|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
290306|NCT02678052|Drug|Vedolizumab|Vedolizumab exposure
290307|NCT02678052|Biological|Other Biological Agent|Other Biological Agent exposure
290308|NCT02680366|Device|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
290309|NCT02680379|Drug|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
290310|NCT00199576|Drug|Methylprednisolone|
290601|NCT02673320|Procedure|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
290602|NCT00199056|Drug|Idarubicin|
290603|NCT02673333|Drug|Pembrolizumab|
290604|NCT02673359|Drug|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
290605|NCT02673359|Procedure|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
290606|NCT02673372|Drug|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
290607|NCT02673372|Drug|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
290608|NCT02673385|Other|Brazelton scale|
290609|NCT02673398|Other|Comprehensive Geriatric Assessment|Ancillary studies
290023|NCT02647801|Behavioral|Mindfulness intervention|Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A "click" sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation).
290024|NCT02647814|Behavioral|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
290025|NCT02647827|Other|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
290026|NCT02647827|Device|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
290027|NCT02647827|Drug|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
290028|NCT02647840|Behavioral|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
290029|NCT00196534|Drug|Human Thrombin|
290311|NCT02680379|Drug|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
290312|NCT02680392|Procedure|Pulsed and Continuous Radiofrequency|Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.
The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.
The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as "Study Solution".
284617|NCT02594072|Radiation|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
284618|NCT02594072|Drug|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
284619|NCT02594085|Other|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
284620|NCT02594085|Other|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
284621|NCT00191139|Drug|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
284622|NCT02596594|Device|fetal nutrition port system, (PakuMed Company, Essen, Germany)|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
284920|NCT02590029|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
284921|NCT02590042|Biological|ADSC-SVF-002|ADSC-SVF with the following identity:
Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10^6 cells/g of liposuctioned (hydrated fat)
284922|NCT02590055|Drug|gemcitabine/docetaxel combination|
284923|NCT00000374|Drug|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
284924|NCT00002515|Procedure|autologous bone marrow transplantation|
284925|NCT00190502|Drug|Polyclonal anti-T-cell antibodies|
284926|NCT02590068|Drug|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
284927|NCT02590081|Drug|Dextrose 5%|
284928|NCT02590081|Drug|normal saline|
284929|NCT02590094|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab is given preoperatively at various time intervals and doses
284930|NCT02590107|Dietary Supplement|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
284309|NCT02600923|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
284310|NCT02600923|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
284311|NCT02600936|Device|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
284312|NCT02600949|Biological|Peptide Vaccine|Vaccine given consisting of a 1:1 mixture of peptide cocktail and IFA and injected subcutaneously into three separate sites of participant's thighs for a total of 2.0ml per vaccination day per cocktail. If participant is prescribed two cocktails then up to 6 sites on participant's thigh used. Amount of peptide delivered varies (range 200µg to 2.0mg) depending on how many peptides are identified and prescribed (range 1-5 per peptide cocktail, 2 total cocktails possible). Vaccinations given on day 1, week 0 and then every 3 weeks (day 1 week 3, day 1 week 6, day 1 week 9) for 4 total doses.
284313|NCT02600949|Behavioral|Phone Call|Participant called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit. Each call should take about 10 minutes.
284314|NCT02600975|Biological|R21 with ASO1B|
284315|NCT02600988|Drug|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
284316|NCT02600988|Drug|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
284317|NCT02603120|Drug|GS-9883/F/TAF Placebo|Placebo to match GS-9883/F/TAF FDC tablets administered orally once daily without regard to food
284318|NCT02603120|Drug|ABC/DTG/3TC Placebo|Placebo to match ABC/DTG/3TC FDC tablets administered orally once daily without regard to food
284623|NCT02596620|Drug|Nexium|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
284624|NCT02596620|Drug|Amolin|Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
284625|NCT02596620|Drug|Cravit|Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
284626|NCT02596620|Drug|Flagyl|Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
284627|NCT02596633|Behavioral|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
284628|NCT02596646|Procedure|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
284629|NCT02596646|Procedure|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
284002|NCT02607657|Drug|Eplerenone 50 mg|
284003|NCT02607657|Drug|Eplerenone 100 mg|
284004|NCT02607657|Drug|Eplerenone 50 mg twice a day|
284005|NCT02607657|Drug|Eplerenone 25 mg twice a day|
284006|NCT02607670|Drug|TAT4 Gel|
284007|NCT00192231|Biological|CAIV-T|
284008|NCT02607670|Drug|Matching placebo|
284009|NCT02607683|Drug|XAF5 (concentration A)|
284010|NCT02607683|Drug|XAF5 (concentration B)|
284011|NCT02607683|Drug|Matching placebo|
284012|NCT02607696|Drug|Zolpidem Hemitartarate|
284013|NCT02607709|Procedure|Lymphadenectomy in conjugation with nephroureterectomy|Lymphadenectomy (intervention group only):
Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively.
284014|NCT02607709|Procedure|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
284015|NCT02607722|Drug|Nintedanib|
284016|NCT02607735|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857 tablet administered orally once daily
284017|NCT02607735|Drug|Placebo|SOF/VEL/GS-9857 placebo tablet administered orally once daily
284018|NCT00192244|Biological|CAIV-T, Liquid|
284319|NCT02603120|Drug|GS-9883/F/TAF|GS-9883/F/TAF (50/200/25 mg) FDC tablets administered orally once daily without regard to food
284320|NCT02603133|Behavioral|WISER 1|Introduces prevalence of burnout, evidence of enhancing resilience and overview of the next 5 modules. In addition, this module provides a structured opportunity to learn about and express gratitude toward others through a guided gratitude letter writing exercise and sending several grateful text messages over two weeks. Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways, and we see improvements in resilience, sleep quality and depression.
284321|NCT02603133|Behavioral|WISER 2|This module introduces a structured opportunity to cultivate positive experiences by reflecting on them for a couple of minutes within two hours of sleep onset (daily email/SMS sent to each participant for 2 weeks). By savoring good moments from earlier that day just before sleep onset, we see improvements in resilience, sleep quality, relationships, work-life balance, and depression. Participants also benefit from electronically sharing the nightly Three Good Things with their colleagues.
288564|NCT02677337|Other|Educational Program|
288565|NCT02677350|Drug|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
288566|NCT02677363|Other|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
288567|NCT02679651|Other|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
288568|NCT00199446|Drug|Istradefylline (KW-6002)|
288569|NCT02679651|Other|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
288570|NCT02679651|Other|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
288571|NCT02679664|Drug|Rosuvastatin|20 mg tablet of rosuvastatin
288572|NCT02679677|Device|Whole Body Vibration|The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
288573|NCT02679690|Behavioral|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
288574|NCT02679690|Behavioral|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
288575|NCT02679703|Device|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
288576|NCT02679703|Device|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
288577|NCT02679703|Other|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
288578|NCT02679716|Other|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
288579|NCT00199472|Procedure|Dynamic Contrast Enhanced CT & Diuretic Renogram|
288580|NCT02679729|Drug|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
288581|NCT02679729|Drug|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
288582|NCT02679729|Other|Placebo|inactive substance
287969|NCT02653807|Other|mobilization with movement|manual therapy intervention
287970|NCT02653807|Other|osteopathic mobilization|manual therapy intervention
288276|NCT02647047|Procedure|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
288277|NCT02647047|Procedure|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
288278|NCT02647047|Procedure|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
288279|NCT02647047|Procedure|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
288280|NCT02647047|Drug|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
288281|NCT02647047|Drug|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
288282|NCT02647047|Drug|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
288283|NCT02647047|Drug|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
288284|NCT02647047|Drug|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
288285|NCT00196430|Device|silver-contained textiles|
288286|NCT02647047|Drug|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
288287|NCT00196651|Drug|IL-2|
288288|NCT02649231|Behavioral|Psychological Therapy|Manualised relapse prevention based CBT
288289|NCT02649231|Behavioral|Alcohol Education|Simple education about alcohol effects
288290|NCT02649244|Behavioral|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
288291|NCT02649257|Procedure|cataract surgery|
288292|NCT02649257|Device|intraocular lens (MC 6125 AS)|
288293|NCT02649257|Device|capsular tension ring (CTR 13/11)|
287673|NCT02660203|Procedure|Forced expiration|Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.
The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed
287674|NCT02660229|Drug|Oxycodone Hydrochloride|
287675|NCT02660229|Drug|Morphine Sulphate|
287676|NCT02660242|Drug|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 15 minutes before the start of exercise (SQ-abdomen).
287971|NCT02653820|Other|Reflexology|
287972|NCT02653833|Drug|Ranolazine|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the medication Ranolazine.
287973|NCT02653846|Procedure|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
287974|NCT02653846|Procedure|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
287975|NCT02653872|Drug|AZD7986|Oral solution, single dose, dilution from concentrate
287976|NCT02653872|Drug|Verapamil|Extended release tablet for oral use
287977|NCT02653872|Drug|Itraconazole|Oral solution
287978|NCT00197210|Biological|Rotavirus|
287979|NCT02653872|Drug|Diltiazem|Extended release capsule
287980|NCT02653885|Other|Red red cell distribution width|Results from hemogram
287981|NCT02656030|Other|usual care|usual care, 2 time per week, 6 weeks duration
287982|NCT00197561|Dietary Supplement|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
287983|NCT02656043|Drug|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
287984|NCT02656043|Drug|Placebo|
287985|NCT02656056|Other|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
287986|NCT02656069|Drug|G-Pen™ (glucagon injection)|
287358|NCT02666898|Drug|Ibrutinib|Part 1 :6 cycles
Cycle 2 to 6 (every 28 days) :Ibrutinib:
D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles
patients in CR with BM MRD < 10-4 : Ibrutinib alone 420mg daily
patients with BM MRD >10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine
287359|NCT02666898|Drug|Cyclophosphamide|PART 2 :
patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine
287360|NCT02666898|Drug|Fludarabine|PART 2 :
patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide
287361|NCT02666911|Procedure|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
287362|NCT02666911|Procedure|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
287677|NCT02660242|Other|Glucose Tabs|Dextrose tabs orally (20 grams) 15 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
287678|NCT02660242|Other|Basal Insulin Reduction|Basal insulin reduction to 50% one hour before the start of exercise.
287679|NCT02660255|Drug|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
287680|NCT02660268|Other|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
287681|NCT02660281|Radiation|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
287682|NCT02660281|Drug|Fludarabine|Fludarabine
287683|NCT00198133|Drug|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
287684|NCT02660281|Drug|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
287685|NCT02660281|Drug|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
287686|NCT02660281|Drug|Busulfan|Busulfan
287687|NCT02660281|Drug|Melphalan|Melphalan
287688|NCT02660281|Procedure|Stem Cell Infusion|Stem cell infusion
287365|NCT02666950|Other|Laboratory Biomarker Analysis|Correlative studies
287366|NCT00198978|Drug|Idarubicin|
287367|NCT02666950|Other|Pharmacological Study|Correlative studies
287368|NCT02666950|Other|Quality-of-Life Assessment|Ancillary studies
287369|NCT02666950|Other|Questionnaire Administration|Ancillary studies
287370|NCT02666950|Drug|WEE1 Inhibitor AZD1775|Given PO
287371|NCT02666963|Drug|RTA 901 Capsules, 10 or 40 mg|
287372|NCT02666963|Drug|Placebo|
287373|NCT00002532|Drug|prednisolone|
287374|NCT00199004|Drug|Dexamethasone / Prednisolone|
287375|NCT02669186|Drug|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
287376|NCT02669199|Biological|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
287377|NCT02669225|Radiation|[18F]florbetaben|PET radiotracer to image Amyloid beta
287378|NCT02669238|Device|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
287379|NCT02669238|Drug|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
287380|NCT02669251|Drug|AZD9668|Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID
Phase 2 Cycle=28 days: MTD PO BID
287381|NCT02669264|Drug|ADCT-402|intravenous infusion
287382|NCT02669277|Drug|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
287383|NCT02669277|Drug|standard IVIG product|to compare efficacy and safety with the minipool IVIG
287699|NCT02662452|Drug|GLPG2222 single dose|single ascending doses, oral suspension
287700|NCT02662452|Drug|Placebo single dose|single doses, oral suspension, matching placebo
286824|NCT02681042|Device|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
287088|NCT02671760|Drug|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
287089|NCT02671760|Drug|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
287090|NCT02671760|Drug|Placebo|Placebo
287091|NCT02674282|Procedure|ACL reconstruction|ACL reconstruction with hamstrings autograft.
287092|NCT02674295|Drug|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
287093|NCT02674295|Drug|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
287094|NCT02674308|Drug|Vedolizumab|
287095|NCT02674308|Other|Other Biologic Agents|Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
287096|NCT02674321|Drug|SD-809|
287097|NCT02674334|Device|NIRS|NIRS monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining MAP at least 60mmHG or at least 80% of baseline
287098|NCT00199069|Drug|Mitoxantrone|
287099|NCT02674347|Drug|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
287100|NCT02674347|Drug|Placebo|IV matching the Investigational drug
287101|NCT02674360|Behavioral|SDM Training|
287102|NCT02674386|Drug|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
287103|NCT02674399|Drug|JointStem|
287104|NCT02674399|Drug|Synvisc-One|
287105|NCT02674412|Drug|Buspirone|
287106|NCT02674412|Dietary Supplement|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
287107|NCT02674425|Device|Dark Adaptometer|
286544|NCT02648581|Drug|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
286545|NCT02648594|Device|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
286546|NCT02648607|Device|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
286547|NCT02648620|Device|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
286548|NCT02648620|Procedure|Angioplasty|
286549|NCT02648633|Radiation|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to a single lesion.
286550|NCT02648633|Drug|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
286551|NCT02648633|Drug|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
286825|NCT02681055|Drug|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
286826|NCT00199745|Drug|atorvastatin|
286827|NCT02681068|Other|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
286828|NCT02681081|Other|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
286829|NCT02681081|Other|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
286830|NCT02681081|Other|Control|Normal food intake
286831|NCT02681094|Drug|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
286832|NCT02681094|Drug|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
286833|NCT02681094|Drug|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
286834|NCT02681094|Drug|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
286265|NCT02653222|Procedure|Renal sympathicolysis|
286266|NCT02655341|Procedure|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
286267|NCT00197444|Radiation|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
286268|NCT02655354|Behavioral|Motivational Interviewing|
286269|NCT02655354|Behavioral|Cognitive Behavioral Therapy Elements|
286270|NCT02655354|Behavioral|Care Management|
286271|NCT02655354|Drug|Fluoxetine|Anti-depressant
286272|NCT02655354|Drug|Fluvoxamine|Anti-depressant
286273|NCT02655354|Drug|Paroxetine|Anti-depressant
286274|NCT02655354|Drug|Setraline|Anti-depressant
286275|NCT02655354|Drug|Citalopram|Anti-depressant
286276|NCT02655354|Drug|Venlafaxine|Anti-depressant
286277|NCT02655354|Drug|Duloxetine|Anti-depressant
286278|NCT00197457|Procedure|serum pepsinogen|
286279|NCT02655354|Drug|Mirtazapine|Anti-depressant
286280|NCT02655354|Drug|Diphenhydramine|Sleep medication
286281|NCT02655354|Drug|Trazodone|Sleep medication
286282|NCT02655354|Drug|Prazosin|Sleep medication
286552|NCT02648646|Other|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
286553|NCT02648659|Drug|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
286554|NCT00196612|Drug|didanosine, ddI (drug)|
286555|NCT02648659|Drug|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
285985|NCT02661724|Behavioral|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
285986|NCT02661737|Device|YVOIRE volumes|
285987|NCT02661750|Drug|Bowel Preparation|Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.
Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.
Step 1: 51 g MiraLAX* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
285988|NCT02661789|Drug|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
285989|NCT02661789|Drug|Placebo|Injection of saline
285990|NCT02661802|Other|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
285991|NCT02661815|Drug|Paclitaxel|
285992|NCT02661815|Drug|Ricolinostat|
285993|NCT02661815|Drug|Bevacizumab|
285994|NCT02661828|Other|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
285995|NCT00198393|Drug|Gefitinib|250 mg/day, until progression
285996|NCT02661828|Other|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
285997|NCT02661841|Other|LI-Guided Therapy|Preemptive treatment according to LI monitoring
285998|NCT02661841|Other|Heart Failure Guidelines|Treatment according to clinical signs
285999|NCT02661854|Biological|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
286000|NCT02661854|Biological|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
286001|NCT02664077|Drug|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
285449|NCT02678325|Other|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
285708|NCT00199017|Drug|Mercaptopurine|
285709|NCT02671045|Genetic|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
285710|NCT02671045|Genetic|Genomic profile by other methods|Genomic profiling by other testing methods.
285711|NCT02671058|Drug|Cortenema|Hydrocortisone Administered as a Liquid Enema
285712|NCT02671058|Drug|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
285713|NCT02671071|Behavioral|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
285714|NCT02671084|Drug|sevoflurane|
285715|NCT02671097|Drug|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
285716|NCT02671097|Drug|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
285717|NCT02671110|Behavioral|Transforming Your Life|See Transforming Your Life Arm
285718|NCT02671110|Behavioral|Diabetes Prevention Program|See Diabetes Prevention Program Arm
285719|NCT00199017|Drug|Cytarabine|
285720|NCT02671123|Procedure|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
285721|NCT02671123|Procedure|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
285722|NCT02671136|Device|Hyperbaric Oxygen therapy|
285723|NCT02671136|Other|Conventional Wound Therapies|
285724|NCT02671149|Dietary Supplement|Water|Participants will receive two cups of 150ml plain water
285725|NCT02671162|Drug|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
285726|NCT02671162|Drug|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
285168|NCT02578745|Device|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
285169|NCT02578745|Other|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
291191|NCT02625805|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
291192|NCT02625805|Drug|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
291193|NCT02625831|Other|Biological analysis|Biological analysis :
ficolin-3
anti-ficolin 3 antibodies
anti-C1q antibodies
291194|NCT00193908|Drug|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
291195|NCT02625844|Other|No intervention|No intervention administered in this study.
291196|NCT02625857|Biological|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU]) and at a higher dose in Cohort 1B (1x10^9 CFU).
291197|NCT02625857|Biological|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
291198|NCT02625870|Drug|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
291199|NCT02625870|Drug|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
291200|NCT02625883|Other|Interview|Interview by validated Quality-of-life-questionnaire
291201|NCT02627846|Drug|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
291202|NCT02627846|Drug|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
291203|NCT02627859|Device|Durolane SJ|1ml single intra-articular injection in ankle
291204|NCT02627885|Behavioral|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
290610|NCT02673398|Other|Laboratory Biomarker Analysis|Correlative studies
290611|NCT02673398|Drug|Neratinib|Given PO
290612|NCT02673398|Other|Pharmacological Study|Correlative studies
290613|NCT00199056|Drug|Fludarabine|
290614|NCT02673411|Device|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
290615|NCT02675777|Other|Quality Improvement Intervention|Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:
Identification of a clinical champion and Local Implementation Team.
Participatory Design.
Training primary care providers and Medical Assistants.
EHR clinical decision support tools
Weekly facilitated Local Implementation Team meetings.
Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.
Learning sessions for primary care providers during implementation.
Social worker use of an EHR registry with weekly supervision.
Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)
290616|NCT02675790|Drug|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
290617|NCT02675790|Drug|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
290618|NCT02675803|Biological|VAY736|VAY736 treatment
290619|NCT00199095|Drug|Adriamycin|
290902|NCT02630199|Drug|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
290903|NCT02630199|Drug|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
290904|NCT02630225|Behavioral|Critical Time Intervention|The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:
Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.
Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.
Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers.
290905|NCT02630225|Other|Treatment as Usual|Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:
All necessary medical care and scheduled follow-ups with subspecialty services
Evaluation by social work with referral to appropriate community services
Screening for alcohol use
Discharge planning services
Financial counseling
290906|NCT02630225|Behavioral|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
290313|NCT02680392|Drug|Continuous Adductor Canal Block|The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.
To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as "Study Solution". It will be always possible to crack the code and find out to which group the patient belongs
290314|NCT02680405|Procedure|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
290315|NCT02680405|Procedure|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
290316|NCT02680405|Procedure|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
290317|NCT02680418|Drug|FDL169|
290318|NCT02680431|Other|Blood sample|10 mL venous blood sample for analysis of plasma
290319|NCT02680444|Behavioral|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
290320|NCT02680444|Behavioral|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
290321|NCT00199589|Drug|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
290322|NCT02680444|Behavioral|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
290323|NCT02680457|Drug|Insulin Degludec|10 IU SC every 24 hours for 6 days
290324|NCT02680457|Drug|Insulin Glargine|10 IU SC every 24 hours for 6 days
290325|NCT02682511|Drug|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
290326|NCT02682511|Drug|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
290327|NCT02682524|Drug|Pelubiprofen CR 45mg tab.|
290620|NCT02675803|Biological|VAY736 placebo|VAY736 placebo
290621|NCT02675816|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
284931|NCT02590107|Dietary Supplement|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
284932|NCT02590107|Dietary Supplement|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
284933|NCT02590107|Other|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
284934|NCT02590120|Dietary Supplement|Enteral nutrition|
284935|NCT02590133|Drug|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
284936|NCT00190515|Drug|5FU+l-leucovorin|5FU+l-leucovorin
284937|NCT02590133|Drug|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
284938|NCT02590133|Drug|Nedaplatin|80mg/m2/d, ivdrip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
284939|NCT00190710|Drug|Carboplatin|
284940|NCT02592317|Drug|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administerd on Study Day 1 and 43.
285220|NCT00189735|Drug|FK778|
285221|NCT02585362|Dietary Supplement|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
285222|NCT02585375|Drug|Preservative-free latanoprost 50µg/ml|
285223|NCT02585375|Drug|Preserved latanoprost 0.005%|
285224|NCT02585388|Drug|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
285225|NCT02585388|Drug|Letrozole|Lestrozole at 2,5 mg every day , per oral
285226|NCT02585388|Drug|Anastrozole|Anastrozole at 1 mg every day, per oral
285227|NCT02585401|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
285228|NCT02585427|Dietary Supplement|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
284630|NCT02596659|Procedure|Radial extracorporeal shock wave therapy (rESWT)|Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.
284631|NCT02596659|Procedure|sham shockwave therapy|Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.
284632|NCT00191139|Radiation|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
284633|NCT02596659|Procedure|Physical therapy|The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
284634|NCT02596672|Behavioral|The friendly walking group|A 12 week peer led walking group for adults and older adults (> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
284635|NCT02596685|Procedure|Bronchoscopy|Undergo bronchoscopy
284636|NCT02596685|Other|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
284637|NCT02596685|Other|Laboratory Biomarker Analysis|Correlative studies
284638|NCT02596685|Other|Questionnaire Administration|Ancillary studies
284639|NCT02596711|Drug|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
284941|NCT02592317|Drug|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
284942|NCT02592317|Drug|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
284943|NCT02592330|Biological|CALEC|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
284944|NCT02592330|Procedure|CLAU|Donor tissue is obtained from the fellow eye (limbal autograft) with the goal of transplantation of a new source of epithelium for a diseased ocular surface after the removal of the recipient's scarred and diseased epithelium.
284945|NCT02592343|Biological|Lyophilized Fecal Microbiota Transplantation|
284322|NCT02603133|Behavioral|WISER 3|This module provides a structured opportunity to learn about and experience the benefits of awe and wonder through a series of visually and conceptually stunning images, followed by an exercise to recount in detail one of their own experiences of awe and a daily "moment of awe" log. When we experience awe, our sense of time expands, we are kinder to others, and we prefer experiences over material things. By cultivating awe we see improvements in life satisfaction, kindness, and sense that we have more time to do the important things in life.
284323|NCT02603133|Behavioral|WISER 4|This module uses a strengths-finder tool to examine what you do well, and sends daily email prompts to elicit how participants will be deliberate about using their strengths in new and more frequent ways to address their challenges. When you use your strengths personally and professionally, you feel engaged and invigorated, and you feel like what you are doing has more meaning to you personally. By deliberately choosing to do what we already do well, we see improvements in engagement, happiness, resilience and depression.
284324|NCT02603133|Behavioral|WISER 5|This module encourages participants to commit a random act of kindness. This intervention reliably produces improvements in happiness, resilience and depression.
284325|NCT02603133|Behavioral|WISER 6|This module pulls together the previous modules as strategies for enhancing resilience and builds to demonstrate the latest research on dealing with difficult colleagues, how long a nap should be if you are tired vs. well rested, and how to take advantage of sleep hygiene research findings.
284326|NCT00191724|Drug|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
284327|NCT02603146|Drug|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
284328|NCT02603146|Drug|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
284329|NCT02603159|Drug|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
284330|NCT02603159|Radiation|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
284331|NCT02603172|Drug|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
284332|NCT02603185|Drug|Hemay007|
284333|NCT02603185|Drug|placebo|
284334|NCT02603198|Drug|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
284640|NCT02598739|Other|Resistance exercise|Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.
It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).
The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension.
284641|NCT02598739|Other|Waiting list for the exercises|
284642|NCT02598752|Other|Symptom-limited cardiopulmonary exercise test (CPET)|
284019|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
284020|NCT02609698|Device|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
284021|NCT02609698|Drug|3 months DAPT|
284022|NCT02609698|Drug|6 months DAPT|
284023|NCT02609711|Drug|Candesartan cilexetil|
284024|NCT02609724|Other|Information|During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
284025|NCT02609724|Other|Skin care|The skin is hydrated during the session. If wounds are present, the wound is cared.
284026|NCT02609724|Other|Compression therapy|During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
284027|NCT02609724|Other|Fluoroscopy-guided MLD|Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
284028|NCT02609724|Other|Traditional MLD|Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
284029|NCT02609724|Other|Placebo MLD|During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
284030|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
284031|NCT02609737|Device|PET/CT Imaging|
284032|NCT02609737|Radiation|68Ga-DOTA-JR11|
284033|NCT02609737|Radiation|177Lu-DOTA-JR11|
284034|NCT02609750|Other|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
284035|NCT02609750|Other|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
288294|NCT02649270|Biological|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
288295|NCT02649283|Device|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
288583|NCT02679742|Dietary Supplement|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
288584|NCT02679742|Dietary Supplement|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
288585|NCT02679755|Drug|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
288586|NCT02679755|Drug|Letrozole|2.5 mg/d tablets orally on a continuous regimen
288587|NCT02679768|Behavioral|Circadian Reinforcement Therapy|Electronical monitoring plus psychoeducation on zeitgeber and sleep to learn how to create a stabile sleep-wake cycle
288588|NCT02679781|Drug|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
288589|NCT02679781|Drug|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
288590|NCT02681757|Device|Mepitel Ag|used for variable/experimental group under soft cast
288591|NCT02681783|Drug|aflibercept|
288592|NCT02681796|Drug|Bupivacaine|
288593|NCT02681809|Drug|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
288594|NCT02681809|Drug|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
288595|NCT02681809|Drug|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
288596|NCT02681835|Device|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
288597|NCT00199862|Drug|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
288598|NCT02681835|Device|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
288599|NCT02681848|Drug|Varenicline|Smoking cessation medication
287987|NCT02656069|Drug|Lilly Glucagon (glucagon injection [rDNA origin])|
287988|NCT02656082|Drug|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
287989|NCT02656095|Drug|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
287990|NCT02656108|Procedure|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
287991|NCT02656121|Drug|Vitamin D|One-Alpha Capsules 0.25 microgram One-Alpha Capsules 0.5 microgram One-Alpha Capsules 1 microgram
287992|NCT02656121|Drug|placebo|placebo instead of vitamin D
288296|NCT02649283|Procedure|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
288297|NCT02649296|Other|Skanlab bodywave|The intervention will be done twice a week
288298|NCT00196651|Biological|LIPO-6T|
288299|NCT02649309|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
288300|NCT02649309|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
288301|NCT02649309|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
288302|NCT02649309|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
288303|NCT02649322|Device|J-Tip|After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic "pop" and "hissing" sounds inherent to the J-tip injector.
288304|NCT02649322|Device|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
288305|NCT02649335|Drug|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
288306|NCT02649335|Procedure|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
287689|NCT02660281|Drug|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
287690|NCT02660281|Drug|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
287691|NCT02662400|Biological|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
287692|NCT00198458|Drug|Vitrase|
287693|NCT02662413|Other|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
287694|NCT02662426|Drug|Lingdancao granules|4 packs per time (3g/pack), three times per day
287695|NCT02662426|Drug|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
287696|NCT02662426|Drug|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
287697|NCT02662426|Drug|analogous Lingdancao granules|4 packs per time, three times per day
287698|NCT02662439|Device|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
287993|NCT00197587|Drug|Nevirapine|All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
287994|NCT02656134|Procedure|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
287995|NCT02656134|Genetic|Molecular analysis.|DNA analysis
287996|NCT02656147|Biological|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
287997|NCT02656160|Drug|Placebo|Placebo 3 hrs before sleep
287998|NCT02656160|Drug|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
287999|NCT02656173|Drug|Mirabegron|Oral
288000|NCT02656173|Drug|Placebo|Oral
288001|NCT02656186|Dietary Supplement|Pre-intervention|First 2-weeks : keeping routine dietary habit
287701|NCT02662452|Drug|GLPG2222 multiple doses|multiple ascending doses, daily for 14 days, oral suspension
287702|NCT02662452|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral suspension, matching placebo
287703|NCT00002532|Drug|asparaginase|
287704|NCT00198471|Drug|Vitrase|
287705|NCT02662465|Procedure|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
287706|NCT02662478|Procedure|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
287707|NCT02662491|Dietary Supplement|Vitamin D and calcium|
287708|NCT02662491|Dietary Supplement|Vitamin D|
287709|NCT02662491|Dietary Supplement|Calcium|
287710|NCT02662491|Dietary Supplement|Placebo|
287711|NCT02662504|Device|photodynamic therapy (PDT)|Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.
After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the "pleural" cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period.
287712|NCT02664766|Behavioral|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
287713|NCT02664779|Other|Arrhythmia diagnosis with the 10 steps method|
287714|NCT02664779|Other|Arrhythmia diagnosis with the 6 steps method|
287715|NCT02664779|Other|Arrhythmia diagnosis with the 4 steps method|
287716|NCT02664792|Other|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
287717|NCT02664805|Drug|LEO 124249 ointment|Ointment
287108|NCT02674438|Other|EHMRG/EHMRG30-ST + RAPID-HF transitional care clinic|Intervention consists of 2 components:
Determination of risk using the EHMRG 7-day and 30-day risk scores, where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores
Follow-up care in the RAPID-HF transitional care clinic begins at 48 days after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge.
287109|NCT00199069|Drug|Methotrexate|
287110|NCT02674451|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
287384|NCT02669290|Other|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
287385|NCT00199004|Drug|Vincristine|
287386|NCT02669290|Other|Non-guided|LV lead placement will be conventional posterolateral placement
287387|NCT02669303|Drug|platelet-rich plasma group|Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the "Recover(TM) Platelet Separation Kit" (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder.
287388|NCT02669303|Drug|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
287389|NCT02669329|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
287390|NCT02669342|Device|Radiance™ Clear Sharklet® Silicone Foley Catheter|
287391|NCT02669342|Device|Silicone Foley Catheter|
287392|NCT02669368|Drug|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
287393|NCT02669368|Drug|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
287394|NCT02669368|Drug|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
287395|NCT02669368|Drug|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
287396|NCT00199004|Drug|Daunorubicin|
287397|NCT02671773|Drug|Inhaled corticosteroid dose/type|
287398|NCT02671786|Other|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories & 15-17 gms of proteins.
286835|NCT02681107|Radiation|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
286836|NCT02681120|Procedure|Biopsy|
286837|NCT00199758|Drug|cisplatin|
286838|NCT02681120|Procedure|Blood draw|
286839|NCT02681120|Procedure|Mammogram|
286840|NCT02681120|Procedure|MRI|
286841|NCT02681133|Other|Epidemiological study Survey|
286842|NCT02681146|Other|Multimodal intervention|Educational advice + physiotherapist treatment
286843|NCT02681172|Drug|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
286844|NCT02681172|Procedure|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
287111|NCT02674464|Behavioral|Provider Audit-Feedback|
287112|NCT02674464|Behavioral|Provider Audit-Feedback, Stratified by race, ethnicity, payor status|
287113|NCT02674464|Behavioral|Blood Pressure Measurement Standardization|
287114|NCT02674464|Behavioral|System Level Leadership Intervention|
287115|NCT02674464|Behavioral|Collaborative Care Team Intervention|
287116|NCT02674464|Behavioral|Community Health Worker|As a "stepped up" component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants
287117|NCT02676648|Behavioral|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
287118|NCT00199121|Drug|Zidovudine (drug)|
287119|NCT02676648|Behavioral|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
287120|NCT02676648|Behavioral|Text messages|We will send participants text messages, to support intervention adherence.
286556|NCT02648659|Drug|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
286557|NCT02648659|Drug|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
286558|NCT02648672|Drug|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
286559|NCT02648672|Drug|Placebo|
286560|NCT02651103|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
286561|NCT02651116|Drug|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
286562|NCT02651116|Drug|Placebo|10 mL Placebo
286563|NCT02651116|Device|Cough counting device|FDA approved device validated for use in adults and children
286564|NCT02651129|Other|Noise measurement|We will be measuring noise levels in the operating room
286565|NCT02651142|Procedure|Patients receive SLNB|Patients receive sentinel lymph node biopsy
286566|NCT02651155|Drug|Lubiprostone|Lubiprostone capsules
286567|NCT02651155|Drug|Placebo|Lubiprostone placebo-matching capsules
286568|NCT02651168|Biological|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
286569|NCT00196872|Drug|Cyclophosphamide|Cyclophosphamide is given
286570|NCT02651181|Device|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
286571|NCT02651194|Drug|ABT-493/ABT-530|tablet
286572|NCT02651207|Other|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
286573|NCT02651220|Drug|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
286845|NCT02681185|Other|Virtual Care|Virtual Care consists of the following services and resources:
Have a virtual consult through online methods or telephone with one of the study endocrinologists
Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods
Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic
Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support.
286002|NCT02664077|Drug|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
286283|NCT02655367|Other|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
286284|NCT02655367|Other|Milled oats|Test meal consisting of 264g porridge made with milled oats
286285|NCT02655380|Drug|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
286286|NCT02655380|Drug|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
286287|NCT02655380|Drug|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
286288|NCT02655393|Dietary Supplement|AMAZ-02|
286289|NCT00197457|Procedure|urea breath test|
286290|NCT02655406|Other|Class 2 compression stockings|
286291|NCT02655419|Drug|ATM-AVI|targeted total dose on Day 1 will be 6500 mg ATM and 1777 mg AVI. For the following (full) days, this will be 6000 mg ATM / 1640 mg AVI
286292|NCT02655419|Drug|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
286293|NCT02655432|Device|Spot photoscreener|Screening of vision problem through an automated device
286294|NCT02655432|Procedure|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
286295|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (SAX)
286296|NCT02657603|Procedure|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
286297|NCT02657603|Procedure|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
286298|NCT02657616|Drug|vitamin-k-antagonists|
286299|NCT02657616|Drug|Novel oral anticoagulants|
286300|NCT02657629|Other|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
286301|NCT02657629|Other|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
285727|NCT02671175|Drug|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
286003|NCT02664103|Drug|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
286004|NCT02664116|Drug|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
286005|NCT02664116|Drug|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
286006|NCT00198666|Drug|Zinc|Elemental Zinc
286007|NCT02664129|Other|Video self-observation|Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
286008|NCT02664129|Other|Non Self video observation|Patients will not watch the video of them in acute decompensation phase.
286009|NCT02664142|Procedure|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
286010|NCT02664142|Procedure|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
286011|NCT02664155|Drug|Apixaban|Direct Oral Anticoagulant
286012|NCT02664155|Drug|Rivaroxaban|Direct Oral Anticoagulant
286013|NCT02664155|Drug|Heparin|Standard Of Care
286014|NCT02664155|Drug|VKA|Standard Of Care
286015|NCT02664168|Device|Aquacel Ag Surgical Dressing|
286016|NCT02664168|Device|Single-Use Negative Pressure Wound Therapy (PICO)|
286017|NCT00198679|Drug|Chlorhexidine|
286018|NCT02664181|Drug|Nivolumab|Nivolumab will be given at 3mg/kg by IV every two weeks until progression
286019|NCT02664181|Drug|Oral THU|Administered orally at 10mg/kg twice weekly on consecutive days
286020|NCT02664181|Drug|Decitabine|Oral Decitabine 0.2mg/kg administered 60 minutes after THU, twice weekly on consecutive days
291205|NCT02627885|Other|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
291206|NCT02627898|Drug|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
291207|NCT02627898|Drug|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
291208|NCT02627911|Device|Diabeloop System|Insulin delivery
291209|NCT02627911|Device|Continuous Glucose Monitoring|
291210|NCT00194194|Behavioral|moderate|moderate behavioral management with RD
291498|NCT02621645|Procedure|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge trocar, with a 1 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
291499|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
291500|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
291501|NCT00193479|Drug|Mitoxantrone|Mitoxantrone
291502|NCT02621645|Device|Laser coagulation of the cord or anastomising vessels through a 17 Gauge trocar, with a 1 mm fetoscope and a 400 µm laser fiber|
291503|NCT02621658|Other|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
291504|NCT02621658|Other|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
291505|NCT00193622|Drug|Bevacizumab|
291506|NCT02623790|Other|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
291507|NCT02623790|Other|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
291508|NCT02623803|Drug|Lidocaine|
291509|NCT02623803|Drug|Placebo D5W|
291510|NCT02623816|Drug|Optimal Dosing of Omeprazole|Omeprazole 20 mg
290907|NCT02630225|Other|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
290908|NCT02630238|Dietary Supplement|Branched-Chain Amino Acid Supplementation|All participants will partake in the same diet & exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
290909|NCT02630238|Other|Placebo|All participants will partake in the same diet & exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
290910|NCT00194519|Drug|Placebo|twice-daily oral
290911|NCT02630238|Other|Exercise|Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
290912|NCT02630238|Other|Diet|Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
290913|NCT02630251|Drug|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
290914|NCT02632175|Biological|Adalimumab|every other week or weekly subcutaneous injection
290915|NCT02632188|Procedure|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
290916|NCT02632188|Biological|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
291211|NCT02627911|Device|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
291212|NCT02627911|Dietary Supplement|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
291213|NCT02627950|Drug|Morphinhydrochloricum|5 mg morphine intravenously
291214|NCT02627950|Drug|Metoclopramide|10 mg MCP intravenously
291215|NCT02627950|Drug|Ticagrelor|180 mg ticagrelor orally
291216|NCT02627950|Drug|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
291217|NCT02627963|Drug|tivozanib hydrochloride|tivozanib hydrochloride
291218|NCT02627963|Drug|Sorafenib|tivozanib hydrochloride
290622|NCT02675829|Drug|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
290623|NCT02675842|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
290624|NCT02675842|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
290625|NCT02675855|Other|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
290626|NCT02675855|Procedure|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
290627|NCT02675855|Device|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
290628|NCT02675868|Drug|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
290629|NCT02675868|Drug|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
290630|NCT00199095|Drug|Cyclophosphamide|
290631|NCT02675868|Drug|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
290632|NCT02675868|Drug|Placebo|NaCl 0.9% infusion
290633|NCT02675881|Device|DSM|Monopolar RFA using dual switching mode (DSM)
290634|NCT02678065|Device|InPact Admiral DEB|
290635|NCT02678078|Procedure|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
290636|NCT02678091|Device|Ultrasound exam with Doppler|Ultrasound exam of the orbit
290637|NCT02678104|Procedure|Tooth extraction|Tooth removal
290638|NCT02678104|Drug|Chlorhexidine mouth wash|Chlorhexidine mouth wash
290917|NCT02632201|Biological|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
285229|NCT02585440|Drug|CMX157|Oral tablet
285230|NCT02585440|Drug|placebo|Oral tablet
285231|NCT00189748|Drug|Tacrolimus|
285232|NCT02585453|Device|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
285233|NCT02585453|Device|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
285234|NCT02585453|Device|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
285235|NCT02585479|Drug|Pirarubicin|Pirarubicin 30mg/m2 intravenously
Pirarubicin17mg/m2 are infused through the right and left hepatic arteries
285236|NCT02585479|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 intravenously
Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries
285237|NCT02585479|Drug|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
285238|NCT02585479|Device|Gelfoam|Hepatic artery embolization with Gelfoam.
285239|NCT02587663|Procedure|Therapeutic Conventional Surgery|Undergo breast conserving surgery
285240|NCT02587663|Procedure|Ultrasonography|Undergo bilateral whole-breast ultrasound
285241|NCT02587663|Procedure|Ultrasonography|Undergo targeted breast ultrasound
285242|NCT00190164|Procedure|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
285506|NCT02648282|Radiation|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX).
285507|NCT02648295|Procedure|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
285508|NCT02648308|Behavioral|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
285509|NCT02648321|Behavioral|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
285510|NCT02648321|Behavioral|Health Education|General education about healthy lifestyle and diet.
285511|NCT02648334|Device|IN.PACT drug coated balloon|
285512|NCT02648334|Device|Lutonix drug coated balloon|
284946|NCT02592356|Other|Strength and Balance Tests|Participants have basic tests of their physical strength and balance. Participant's hand grip strength measured. Participant asked to rise from a chair without using their arms to push off, and they will complete a 6-minute walk test.
Tests performed at baseline, and at months 3, 6, and 12.
284947|NCT02592356|Procedure|Dual-Energy X-Ray Absorptiometry (DXA) Scan|DXA full body scan performed at baseline, and at months 3, 6, and 12.
284948|NCT02592356|Behavioral|Questionnaires|Questionnaires completed about any pain or other symptoms participant may have had; about any gastrointestinal (GI) side effects they may be having before starting chemotherapy; about the amount of physical exercise and activity they get; and about their food intake over the last 24 hours.
Questionnaires completed at baseline, once a week during months 1, 2, and at months 3, 4, 5, 6, and 12.
284949|NCT02592356|Drug|Cabozantinib|After the baseline visit, participant starts receiving either Cabozantinib or Lenvatinib according to the treatment plan from their doctor.
284950|NCT00190723|Drug|Enzastaurin|
284951|NCT02592356|Other|Body Measurements and Weight|Participant's weight, height, hip and waist circumference measurements done at baseline and repeated at every study visit
284952|NCT02592356|Drug|Lenvatinib|After the baseline visit, participant starts receiving either Cabozantinib or Lenvatinib according to the treatment plan from their doctor.
284953|NCT02592369|Device|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
284954|NCT02592382|Dietary Supplement|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for two months
284955|NCT02592382|Other|Isotonic saline spray|saline nasal spray will be administered to this arm three times daily for two months
284956|NCT02592395|Drug|FOLFIRINOX|The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:
Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous
285243|NCT02587663|Other|Gadolinium|Contrast agent used in MRI
285244|NCT02587676|Other|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
285245|NCT02587689|Biological|anti-MUC1 CAR T Cells|
285246|NCT02587702|Other|β-Palmitate Content|
284643|NCT02598752|Other|minute walk test (6MWT) distance|
284644|NCT02598752|Behavioral|Patient-reported outcomes questionnaire|
284645|NCT02598765|Procedure|Standard Trabeculectomy|Fornix-based trabeculectomy with a 4x4 mm scleral flap.
284646|NCT02598765|Procedure|Microtrabeculectomy|Fornix-based trabeculectomy with a 2x2 mm scleral flap.
284647|NCT02598778|Drug|Chlorhexidine gluconate (.12%)|30 second oral rinse of 10mL of solution
284648|NCT00002516|Radiation|low-LET photon therapy|
284649|NCT00191308|Drug|cisplatin|75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
284650|NCT02598778|Drug|Sodium Fluoride (.05%)|30 second oral rinse of 10mL of solution
284651|NCT02598778|Other|Coconut Oil|30 second oral rinse of 10mL of solution
284652|NCT02598778|Other|Deionized water|30 second oral rinse of 10mL of solution
284653|NCT02598791|Other|GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min)
284654|NCT02598791|Other|GLP-1|glucagon-like peptide-1 (1 pmol/kg/min)
284655|NCT02598791|Other|NaCl (placebo)|i.v. NaCl
284656|NCT02598804|Other|5 educational workshop|
284657|NCT02598804|Other|written information booklet|
284658|NCT02598817|Other|Standard Infant Formula|Standard Infant Formula containing High Sn-2
284659|NCT02598830|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
284660|NCT00191308|Procedure|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
284661|NCT02598830|Dietary Supplement|Placebo|Olive oil, encapsuled
284957|NCT02594085|Other|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
284958|NCT02594085|Other|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
284335|NCT02603198|Drug|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
284336|NCT02605252|Drug|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
284337|NCT00191984|Drug|pemetrexed|400 mg/m^2, intravenous (IV), every 14 days x 12 cycles
284338|NCT02605265|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
284339|NCT02605265|Drug|Capecitabine|
284340|NCT02605265|Drug|Irinotecan|
284341|NCT02605265|Drug|Oxaliplatin|
284342|NCT02605278|Other|Clinical program for pain and depression|Already described
284343|NCT02605278|Other|Control|Care as usual
284344|NCT02605291|Other|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
284345|NCT02605291|Other|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
284346|NCT02605291|Other|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
284347|NCT02605291|Other|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
284348|NCT00191984|Drug|irinotecan|180 mg/m^2, intravenous (IV), every 14 days x 12 cycles
284349|NCT02605291|Other|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
284350|NCT02605304|Drug|Ledipasvir/sofosbuvir|Participants will receive one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
284351|NCT02605304|Drug|Ribavirin|Based on weight at entry- For weight <75 kg, participants will receive one 1000 mg tablet orally per day. For weight >75 kg: participants will receive one 1200mg tablet orally per day.
284352|NCT02605317|Other|WhatsApp|Consultations used WhatsApp Messenger
284353|NCT02605330|Procedure|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
284354|NCT02605343|Other|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
288600|NCT02681848|Drug|Nicotine replacement therapy|
288601|NCT02681861|Drug|ASP6294 Intravenous|Intravenous (IV)
288602|NCT02681861|Drug|ASP6294 Subcutaneous|Subcutaneous (SC)
288603|NCT02681861|Drug|Placebo Intravenous|Intravenous (IV)
288604|NCT02681861|Drug|Placebo Subcutaneous|Subcutaneous (SC)
284036|NCT02609776|Drug|JNJ-61186372|The first cohort of participants will receive intravenous infusions of JNJ-61186372 at a dose of 140 milligram (mg). Each subsequent cohort will receive intravenous infusions of JNJ-61186372 at an increased dose level. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered. Participants will receive intravenous infusion of JNJ-61186372 once weekly during cycle 1 and once every 2 weeks during subsequent cycles. The duration of each treatment cycle is 28 days.
284037|NCT02609776|Drug|JNJ-61186372|Participants will receive intravenous infusions of JNJ-61186372 at the recommended Phase 2 dose (RP2D) regimen. The duration of each treatment cycle is 28 days.
284038|NCT02609789|Drug|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
284039|NCT02576015|Device|insulated needle (Contiplex B Braun, Melsungen, Germany)|
284040|NCT02576015|Drug|ropivacaine|
284041|NCT02576015|Drug|saline|
284042|NCT02576028|Other|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
284043|NCT02576028|Other|standard active exercises|two sessions of 45 minutes of active exercises
284044|NCT02576041|Drug|Bilastine|
284045|NCT02576054|Biological|V501|V501 (GARDASIL™, Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
284046|NCT02576067|Drug|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
284047|NCT02576067|Drug|Placebo|
284048|NCT02576080|Drug|Imatinib|
284049|NCT00188396|Drug|Citalopram|
284050|NCT02576080|Other|Surveillance|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
288307|NCT02649348|Other|prehabilitation|Gastric Cancer Patients With Metabolic Syndrome will do preoperative exercise and to bind abdominal binder over 5 days before operation.
288308|NCT02649361|Drug|Anlotinib|Anlotinib p.o. qd
288309|NCT02651870|Drug|Amlodipine 10mg|
288310|NCT02651883|Other|Screening invitation (with brief education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
288311|NCT02651883|Other|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
288312|NCT02651896|Radiation|HypoIGRT|Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.
For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).
Image guidance with cone beam CT will be mandatory before every treatment fraction.
288313|NCT02651909|Other|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
288605|NCT02681874|Behavioral|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
288606|NCT02681874|Behavioral|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
288607|NCT02681887|Drug|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
288608|NCT00199875|Drug|Yttrium-90 conjugated chimeric G250 (90Y-cG250)|
288609|NCT02681887|Drug|Placebo|placebo tablet identical to circadian
288610|NCT02681900|Behavioral|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
288611|NCT02681900|Behavioral|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
288612|NCT02681913|Drug|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
288613|NCT02681926|Procedure|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
288614|NCT02681939|Drug|Tulsi(Ocimum sanctum Linn.) capsules|
288002|NCT02656186|Dietary Supplement|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
288003|NCT02656199|Procedure|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
288004|NCT00197587|Drug|No intervention|All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
288005|NCT02658227|Drug|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days.
288006|NCT02658240|Drug|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
288007|NCT02658240|Drug|Epinephrine|0.5 mg epinephrine
288008|NCT02658253|Biological|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
288009|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
288010|NCT02658253|Biological|GLA-SE|2.56 µg of GLA content
288011|NCT02658253|Biological|Alhydrogel|0.85 mg og Aluminium content
288012|NCT02658253|Biological|Placebo|0.9% Na cl
288314|NCT00196976|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
288315|NCT02651935|Device|Hamilton G5 Mechanical ventilator|Invasive mechanical ventilation and weaning strategy
288316|NCT02651948|Procedure|Transperineal, MRI-guided, prostate biopsy|
288317|NCT02651948|Procedure|Transrectal prostate biopsy (TRB):|
288318|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
288319|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
288320|NCT02651974|Behavioral|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
288321|NCT02651974|Behavioral|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
288013|NCT02658266|Behavioral|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
288014|NCT02658279|Drug|Pembrolizumab|
288015|NCT02658292|Drug|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
288016|NCT02658292|Drug|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
288017|NCT02658344|Biological|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml), 1 time injection
288018|NCT02658344|Drug|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
288019|NCT02658357|Drug|Risperidone Implant|
288020|NCT00197808|Biological|Men C Conjugate|men C conjugate vaccine
288021|NCT02658370|Device|animated home-based exercises (Wii-fit)|
288022|NCT02658370|Procedure|conventional home-based exercise program|
288023|NCT02658383|Other|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
288024|NCT02658383|Other|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
288025|NCT02658396|Drug|GO-203-2C|
288026|NCT02658396|Drug|Bortezomib|
288027|NCT02658409|Biological|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
288028|NCT02658409|Biological|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
288029|NCT02658422|Drug|Test Montelukast|Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
288030|NCT02660294|Biological|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
288031|NCT02660307|Other|PROGRESS group|
287399|NCT02671799|Device|VenTouch System Implant|
287400|NCT02671825|Drug|PUR0200|PUR0200 dry powder inhalation
287401|NCT02671825|Drug|Reference Product|Dry Powder Inhalation Reference Product
287402|NCT02671838|Behavioral|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
287403|NCT00199017|Drug|Cladribine|
287404|NCT02671851|Drug|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
287718|NCT02664805|Drug|LEO 124249 ointment vehicle|Ointment vehicle
287719|NCT00002532|Drug|dexamethasone|
287720|NCT00198757|Behavioral|Medifast Plus for Diabetics Meal Replacement Supplements|
287721|NCT02664844|Behavioral|Physical activity|
287722|NCT02664857|Drug|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
287723|NCT02664857|Drug|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
287724|NCT02664870|Procedure|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
287725|NCT02664870|Procedure|Arthroplasty|Total hip, shoulder, or knee arthroplasty
287726|NCT02664883|Procedure|Computed Tomography|Correlative studies
287727|NCT02664883|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
287728|NCT02664883|Other|Laboratory Biomarker Analysis|Correlative studies
287729|NCT02664883|Procedure|Magnetic Resonance Imaging|Correlative studies
287730|NCT02664896|Other|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
287731|NCT00198757|Behavioral|Standard ADA recommended diet for type 2 diabetics|
287732|NCT02664896|Other|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
287121|NCT02676648|Behavioral|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
287122|NCT02676674|Drug|Vitamin D3|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
287123|NCT02676687|Procedure|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
287124|NCT02676687|Procedure|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
287125|NCT02676700|Behavioral|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
287126|NCT02676700|Behavioral|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
287127|NCT02676713|Drug|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
287128|NCT02676713|Drug|post-ovulation Decoction|BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.
All are made into granules.
287129|NCT00199134|Drug|Letrozole|Size of the tumor is followed
287405|NCT02671851|Drug|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
287406|NCT02671864|Other|1: incretin-based therapy|
287407|NCT02671864|Other|2: other antidiabetic|
287408|NCT02671877|Procedure|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
287409|NCT02671890|Drug|Disulfiram|Given PO
287410|NCT02671890|Drug|Gemcitabine Hydrochloride|Given IV
287411|NCT02671890|Other|Laboratory Biomarker Analysis|Correlative studies
287412|NCT02671890|Other|Placebo|Given PO
287413|NCT02671903|Device|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
286846|NCT02646449|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
286847|NCT02646449|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
286848|NCT02646475|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
286849|NCT02646475|Drug|Saline|Normal saline will be used as a placebo comparator.
286850|NCT02646488|Behavioral|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
286851|NCT00196391|Drug|DR-2021a|1 capsule daily for 10 days
286852|NCT02646488|Behavioral|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
286853|NCT02646488|Behavioral|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
286854|NCT02646488|Behavioral|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
286855|NCT02646488|Behavioral|Standard Care Regimen 9 Months|
286856|NCT02646488|Behavioral|Standard Care Regimen 12 Months|
286857|NCT02646488|Behavioral|Standard Care Regimen 15 Months|
286858|NCT02646488|Behavioral|Standard Care Regimen 18 Months|
286859|NCT02646488|Behavioral|Standard Care Regimen 21 Months|
286860|NCT02646488|Behavioral|Standard Care Regimen 24 Months|
286861|NCT02646488|Behavioral|Standard Care Regimen 27 Months|
286862|NCT00196391|Drug|DR-2021b|1 capsule daily for 10 days
286863|NCT02646488|Behavioral|Follow Up Post Intervention 21 Months|
286864|NCT02646488|Behavioral|Follow Up Post Intervention 24 Months|
287130|NCT02676713|Drug|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
286302|NCT00197756|Dietary Supplement|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
286303|NCT02657655|Device|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
286574|NCT02651220|Drug|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
286575|NCT02651220|Drug|placebo gel|vehicle used as placebo
286576|NCT02651233|Other|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
286577|NCT02651246|Other|data collection|
286578|NCT02651259|Drug|Rifapentine (RPT)|900 mg of RPT
286579|NCT02651259|Drug|Isoniazid (INH)|900 mg of INH
286580|NCT00196872|Drug|Taxol|Taxol is given
286581|NCT02651259|Dietary Supplement|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
286582|NCT02651272|Drug|macitentan|10mg macitentan tablets
286583|NCT02651285|Other|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
286584|NCT02651285|Other|Control|incubation of IVF embryos with a medium without G-CSF
286585|NCT02651298|Device|Fractional Co2-laser|laser treatment
286586|NCT02651311|Other|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
286587|NCT02653222|Procedure|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
286588|NCT02653222|Radiation|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
286589|NCT00197119|Biological|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
286590|NCT02653222|Biological|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
286591|NCT02653235|Biological|Salmonella typhi vaccination|
286021|NCT02664194|Device|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
286022|NCT02664194|Procedure|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
286023|NCT02664207|Procedure|Open Fetal Repair of Myelomeningocele|Maternal Fetal Surgery for Open Neural Tube Defect in women with a BMI of 35 to 40kg/m2
286304|NCT02657668|Behavioral|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
286305|NCT02657681|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
286306|NCT02657681|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
286307|NCT02657694|Drug|Sofosbuvir+Ledipasvir|DAA medication treatment
286308|NCT02657694|Drug|Sofosbuvir+Daclatasvir|DAA medication treatment
286309|NCT02657707|Device|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
286310|NCT02657707|Device|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
286311|NCT02657720|Device|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
286312|NCT02657720|Device|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
286313|NCT00002531|Drug|thioguanine|
286314|NCT02659644|Drug|Oral L-citrulline|There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
286315|NCT02659657|Drug|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
291511|NCT02623829|Drug|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
291512|NCT02623829|Drug|Saline|1ml of normal saline will be administered
291513|NCT02623842|Device|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
291514|NCT02623855|Behavioral|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
291515|NCT02623855|Behavioral|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
291805|NCT02617199|Drug|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
291806|NCT02617199|Drug|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
291807|NCT02617212|Procedure|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
291808|NCT02617212|Device|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
291809|NCT02617212|Device|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
291810|NCT02619500|Other|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
291811|NCT02619500|Other|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
291812|NCT02619513|Drug|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
291813|NCT02619513|Drug|Ropivacaine|Group GE\GT\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
291219|NCT02627976|Device|Compression vest, Thuasne|Wearing a compression 4 days/weel with a minumum of 6 hours per day
291220|NCT02627989|Drug|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
291221|NCT00194194|Device|Resting Metablic Rate measurements|intensive behavior management
291222|NCT02627989|Drug|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
291223|NCT02628002|Device|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
291224|NCT02630264|Drug|Endostatins|Specification: 1mL/division, 1×1012 VP/1.0mL
E10A preparation:
Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.
Swirl gently. Do NOT shake.
Method of administration
E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.
After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.
Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding.
291225|NCT02630264|Drug|Paclitaxel injection|Specification:
30mg/5mL,
Usage:
160mg/m2 on day 3, according to instruction.
291226|NCT02630264|Drug|Cisplatin injection|Specification:
20mg
Usage:
Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction.
291227|NCT02630277|Drug|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
291228|NCT02630290|Drug|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
291229|NCT02630290|Drug|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
291516|NCT00193622|Drug|Erlotinib|
291517|NCT02623855|Device|Pedometry|Participants will record their daily pedometry.
291518|NCT02623855|Behavioral|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
291519|NCT02623868|Drug|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
291520|NCT02623868|Drug|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
291521|NCT02623868|Drug|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
290918|NCT02632201|Biological|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
290919|NCT02632214|Other|fMRI measure|
290920|NCT02632227|Procedure|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
290921|NCT02632240|Other|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
290922|NCT02632253|Procedure|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
290923|NCT00194779|Biological|filgrastim|Given SC
290924|NCT02632253|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
290925|NCT02632266|Dietary Supplement|Powder HMF|powder human milk fortifier
290926|NCT02632266|Dietary Supplement|Liquid HMF|Liquid human milk fortifier
290927|NCT02632279|Dietary Supplement|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
290928|NCT02632279|Dietary Supplement|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
290929|NCT02632279|Device|Stimulator ON|Participants will be tested while their stimulator is turned ON
290930|NCT02632279|Device|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
290931|NCT02632292|Device|Absorb GT1|Bioresorbable vascular scaffold
290932|NCT02634463|Other|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
285513|NCT00002531|Drug|cyclophosphamide|
285514|NCT00196586|Drug|pegylated interferon alpha 2a|
285515|NCT02648347|Drug|vadadustat|oral tablet
285516|NCT02648347|Drug|darbepoetin alfa|Subcutaneous
285517|NCT02648360|Behavioral|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
285518|NCT02648373|Behavioral|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
285519|NCT02650557|Procedure|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
285520|NCT02650583|Other|Educational Intervention|Receive Enhancing Connections Program
285521|NCT02650583|Other|Questionnaire Administration|Ancillary studies
285522|NCT02650596|Drug|GLP-1|Liraglutide were taken daily for 3 months
285523|NCT02650596|Drug|Placebo|Placebo were taken daily for 3 months
285524|NCT02650609|Drug|Methylprednisolone|
285525|NCT00196794|Drug|Tolevamer potassium-sodium (GT267-004)|
285526|NCT02650609|Drug|Placebo|
285785|NCT02678416|Other|Placebo tablet|tablet
285786|NCT02678416|Drug|Acetaminophen tablets|oral formulation
285787|NCT02678416|Other|IV Placebo|IV formulation
285788|NCT02678429|Device|Change DBS programming|Patient will change thier settings to move from one group to the other to trial the other DBS settings
285789|NCT02678442|Device|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
285790|NCT02678442|Device|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
285247|NCT02587702|Other|Placebo|
285248|NCT02587702|Other|β-Palmitate Content Naturely in Human Milk|
285249|NCT02587715|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
285250|NCT02587715|Other|Liberation therapy|
285251|NCT02587728|Procedure|Blood Draw|Samples to be obtained from all subjects will include 70cc samples of heparinized whole blood. Blood specimens will be obtained specifically for the purposes of this study, and will be collected at intervals required for clinical purposes to minimize the need for additional blood draws of study participants.
285252|NCT02587741|Drug|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
285253|NCT00190164|Procedure|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
285254|NCT02587741|Drug|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
285255|NCT02587741|Drug|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
285256|NCT02587754|Device|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
285257|NCT02587767|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
285258|NCT02587767|Device|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
285259|NCT02587793|Other|not interventional study|
285260|NCT02590146|Behavioral|Non-pharmacologic pain control adjuncts|
285527|NCT02650622|Procedure|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
285528|NCT02650635|Drug|Cyclophosphamide|Given IV
285529|NCT02650635|Other|Laboratory Biomarker Analysis|Correlative studies
284959|NCT02594085|Other|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
284960|NCT02594085|Other|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
284961|NCT02594098|Drug|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter through and including Week 12 in phase 1 of the study.
284962|NCT00190931|Drug|placebo|
284963|NCT02594098|Drug|Placebo|At Weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter through and including Week 12 in phase 1 of the study.
284964|NCT02594111|Drug|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
284965|NCT02594124|Drug|IONIS-SMN Rx|Administered by intrathecal injection
284966|NCT02594137|Procedure|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
284967|NCT02594150|Other|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
284968|NCT02594163|Drug|Brentuximab Vedotin|
284969|NCT02594163|Drug|Rituximab|
284970|NCT02594163|Drug|Bendamustine|
284971|NCT02594176|Device|FLEXISEQ®|applicable gel
284972|NCT02594176|Device|Placebo|applicable gel
284973|NCT00190944|Drug|Teriparatide|
284974|NCT02594189|Other|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
284975|NCT02594215|Drug|ARQ 092|
284976|NCT02594228|Behavioral|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
285261|NCT02590159|Device|BONGO NASAL EPAP|The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
284355|NCT02605356|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
284356|NCT02605356|Drug|Placebo|
284357|NCT02605356|Drug|Bortezomib|
284662|NCT02598843|Other|Standard treatment protocol|Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB) 2 weeks FWB out of cast, with 1cm heel raise
Followed by course of physiotherapy
284663|NCT00191516|Drug|Atomoxetine|
284664|NCT02601001|Drug|AMG 423|Omecamtiv mecarbil at 25 mg and 37.5 mg
284665|NCT02601001|Drug|AMG 423|Omecamtiv mercabil at 25 mg and 50 mg
284666|NCT02601001|Drug|Placebo|Placebo Comparator
284667|NCT02601014|Biological|Ipilimumab|Given IV
284668|NCT02601014|Other|Laboratory Biomarker Analysis|Correlative studies
284669|NCT02601014|Biological|Nivolumab|Given IV
284670|NCT02601027|Procedure|TAP block|
284671|NCT02601027|Other|saline infusion|
284672|NCT02601027|Drug|bupivacaine infusion|
284673|NCT02601027|Drug|acetominophen|
284674|NCT00191529|Drug|somatropin|
284675|NCT02601027|Drug|Hydromorphone|
284676|NCT02601027|Drug|Oxycodone|
284677|NCT02601027|Drug|Ondansetron|
284678|NCT02601040|Biological|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-16 years \6.50 lgCCID50/ml in adults aged 17 up to 65 years old
284679|NCT02601040|Biological|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \320EU/Vial in children aged 3-16 years \640EU/Vial in adults aged 17 up to 65 years old\boost at month 6\two-dose
284680|NCT02601040|Biological|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
284681|NCT02601053|Other|Dull movie|A dull movie (duration approximately 90 minutes)
284051|NCT02576093|Drug|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
284052|NCT02576093|Drug|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
284053|NCT02576093|Drug|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
284054|NCT02576093|Drug|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
284358|NCT02605356|Drug|Dexamethasone|
284359|NCT00191997|Drug|Olanzapine|
284360|NCT02605369|Behavioral|Intervention arm: An integrated package|See description in previous column
284361|NCT02605382|Drug|Chlorhexidine gluconate|
284362|NCT02605382|Drug|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
284363|NCT02607748|Other|18F-NaF PET and coronary CTA imaging|
284364|NCT02607761|Other|Video|Video-Audio Media
284365|NCT02607774|Drug|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
284366|NCT02607774|Drug|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
284367|NCT02607787|Behavioral|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
284368|NCT02607787|Other|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
284369|NCT02607800|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857 tablet administered orally once daily
284370|NCT02607800|Drug|SOF/VEL|SOF/VEL tablet administered orally once daily
284371|NCT02607813|Drug|LXH254|pan-RAF inhibitor
284372|NCT02607826|Procedure|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
288615|NCT02647073|Device|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
288616|NCT02647086|Drug|Dupilumab|
288617|NCT02647086|Drug|Cytochrome P450 Substrates|Midazolam
Omeprazole
Warfarin
Caffeine
Metoprolol
288618|NCT02647099|Drug|Acetylsalicylic acid|
288619|NCT02647099|Drug|Placebo|
288620|NCT02647112|Other|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
288621|NCT02647125|Drug|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
288622|NCT02647125|Radiation|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
288623|NCT02647138|Device|Marpac White Noise|The investigators will place a Marpac white noise machine in the patients room.
288624|NCT00196430|Drug|corticosteroid|
284055|NCT02576106|Device|Cryoablation|
284056|NCT02576119|Drug|BMS-955176, Placebo (Part 1)|The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
284057|NCT02576119|Drug|BMS-955176, Moxifloxacin, Placebo (Part 2)|Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
284058|NCT02576145|Biological|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show >=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
284059|NCT02576145|Drug|Daclizumab|The fifth dose (1 milligram per kilogram [mg/kg]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
284060|NCT00188409|Procedure|CT scan|
284061|NCT02578251|Drug|Paracetamol|
284062|NCT02578251|Drug|Pethidine|
284063|NCT02578277|Drug|Cocktail of CYP (cytochrome P450) and transporter probe substrates|
284064|NCT02578277|Drug|BMS-955176|
288322|NCT02651974|Behavioral|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
288323|NCT02651987|Drug|Lanreotide autogel 120 mg|
288324|NCT02652000|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
288325|NCT00196976|Biological|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
288326|NCT02652013|Other|cognitive evaluation|
288327|NCT02652026|Procedure|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
288328|NCT02652026|Procedure|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
288329|NCT02652039|Other|Questionnaires|Questionnaires
288330|NCT02652052|Drug|Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
288331|NCT02652052|Other|Standard of Care - Observation Only|Control Arm - Observation only
288332|NCT02653898|Drug|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
288333|NCT02653898|Drug|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
288625|NCT02647151|Drug|METHYLAMINOLEVULINATE HYDROCHLORIDE|This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.
skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
288626|NCT02647151|Drug|AMINOLEVULINIC ACID HYDROCHLORIDE|This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.
skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
288627|NCT02647177|Other|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
288032|NCT02660320|Device|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
288334|NCT02653898|Drug|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
288335|NCT02653898|Drug|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
288336|NCT02653911|Other|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China
288337|NCT02653911|Other|Sham-acupuncture group|Suzhou medical supplies factory Co., Ltd.
288338|NCT02653924|Other|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
288339|NCT02653924|Other|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
288340|NCT00197223|Biological|Influenza vaccine|
288341|NCT02653924|Other|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
288342|NCT02653924|Other|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
288343|NCT02653937|Drug|Tsumura's shigyakusan|Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:
Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne
288344|NCT02653950|Procedure|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
288345|NCT02653950|Procedure|Traditional septoplasty|septoplasty under direct vision
288346|NCT02653963|Drug|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
288347|NCT02653976|Drug|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
288348|NCT02653989|Biological|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
288349|NCT02654002|Drug|GS-9674|GS-9674 tablets administered orally
288350|NCT02654002|Drug|GS-9674 placebo|GS-9674 placebo tablets administered orally
287733|NCT02664909|Drug|Tranexamic Acid|
287734|NCT02664909|Drug|Placebo (saline)|
287735|NCT02664922|Drug|Propofol|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
1 of 2 sedation groups for VT ablation and afib procedures.
287736|NCT02664922|Drug|Ketamine|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
1 of 2 sedation groups for VT ablation and afib procedures.
287737|NCT02664922|Drug|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
287738|NCT02666976|Drug|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
287739|NCT02666989|Drug|placebo|2 placebo pills twice a day
288033|NCT00198146|Drug|Zenapax|
288034|NCT02660320|Device|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
288035|NCT02660333|Dietary Supplement|Placebo|Maltodextrin - 12g/day
288036|NCT02660333|Dietary Supplement|Prebiotic|Fructooligosaccharide - 12g/day
288037|NCT02660333|Dietary Supplement|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 12g/day
288038|NCT02660346|Drug|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
288039|NCT02660346|Drug|Vancomycin|Control Arm Treatment
288040|NCT02660346|Drug|Ceftaroline|Study Arm Treatment
288041|NCT02660359|Drug|AbobotulinumtoxinA|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
288042|NCT02660359|Drug|AbobotulinumtoxinA|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
288043|NCT02660359|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
288044|NCT00002531|Procedure|peripheral blood stem cell transplantation|
288045|NCT00198159|Drug|ZD1839 Iressa|
287414|NCT00199030|Drug|Alemtuzumab (MabCampath)|
287415|NCT02671916|Behavioral|questionnaire|Investigation on all study patients, no Intervention, no groups
287416|NCT02671929|Behavioral|self-help program|Access to the internet-based self-help program
287417|NCT02671929|Behavioral|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
287418|NCT02671942|Drug|Roflumilast|
287419|NCT02671942|Drug|Placebo|
287420|NCT02671955|Drug|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
287421|NCT02671968|Device|Continuous Glucose Monitoring System|
287422|NCT02671981|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
287423|NCT02671981|Biological|Bevacizumab|Given IV
287424|NCT02671981|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
287425|NCT02674464|Behavioral|Specialist Care|As a "stepped up" component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care
287426|NCT02674477|Device|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
287740|NCT02667002|Procedure|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
287741|NCT02667002|Procedure|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
287742|NCT00002532|Drug|ifosfamide|
287743|NCT00198978|Drug|Granulocyte-Colony-Stimulating Factor|
287744|NCT02667002|Other|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
287745|NCT02667015|Behavioral|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
287746|NCT02667028|Procedure|PCI|percutaneous coronary intervention
287747|NCT02667041|Device|NeuroQore rTMS Device|
287131|NCT02676713|Drug|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
287132|NCT02676726|Procedure|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
287133|NCT02676726|Procedure|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
287134|NCT02676739|Drug|Adderall XR|
287135|NCT02676752|Procedure|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
287136|NCT02676752|Other|Questionnaire Administration|Completion of questionnaires
287137|NCT02676752|Procedure|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
287138|NCT00199329|Drug|ondansetron adding in PCA|
287139|NCT02678949|Drug|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
287140|NCT02678962|Device|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
287141|NCT02678962|Device|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
287142|NCT02678962|Device|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
287143|NCT02678962|Device|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
287144|NCT02678962|Device|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
287145|NCT02678962|Device|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
287146|NCT02678975|Drug|Disulfiram|Disulfiram 400 mg daily
287147|NCT02678975|Dietary Supplement|Copper|nutritional supplement with copper, 2 mg daily
287148|NCT02678975|Drug|Alkylating Agents|Alkylating antineoplastic agent
287149|NCT00199342|Drug|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
287150|NCT02678988|Device|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter [mg/mL]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
286592|NCT02653235|Biological|Placebo|
286593|NCT02653248|Radiation|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
286594|NCT02653261|Drug|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
286595|NCT02653261|Drug|Placebo|An equal volume of saline
286596|NCT02653274|Other|Breakfast porridge|220 kcal breakfast porridge served with 240 mL glass of water
286865|NCT02646488|Behavioral|Follow Up Post Intervention 27 Months|
286866|NCT02646488|Behavioral|Follow Up Post Intervention 30 Months|
286867|NCT02646488|Behavioral|Follow Up Post Intervention 33 Months|
286868|NCT02646501|Drug|Antiarrhythmic drug|
286869|NCT02646501|Procedure|percutaneous stellate ganglion block (PSGB)|
286870|NCT02646514|Device|Radiofrequency ablation with stenting|Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.
After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage.
286871|NCT02648698|Drug|antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the experimental group
286872|NCT02648698|Drug|placebo|Vitamin c is used as a placebo
286873|NCT02648711|Drug|CRLX101|infusion CRLX101 weekly
286874|NCT02648711|Drug|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
286875|NCT02648724|Drug|Sym015|Sym015 is a mixture of two monoclonal antibodies Hu9006 and Hu9338. Both antibodies are humanized IgG1, which specifically binds to non-overlapping epitopes in the extracellular domain of MET.
286876|NCT00196612|Drug|efavirenz (drug)|
286877|NCT02648737|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch & Craske, 2009; Craske, 2010).
286316|NCT02659670|Other|internet survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
286317|NCT02659670|Drug|brimonidine topical gel 0.33%|All subjects will receive standard-of-care brimonidine topical gel 0.33%
286318|NCT02659683|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
286597|NCT02653287|Behavioral|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary. Participants receive 6 consecutive monthly group sessions, beginning shortly after randomization focusing on the following topics: introduction to physical activity; fruits/vegetables; motivation; lifestyle physical activity; healthy diet; and enhancing your environment. The 1 hour sessions are interactive so participants can share information and support each other.
286598|NCT02653287|Other|Control|The control group will receive 6 group educational sessions focusing on SLE disease management. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Sessions will be didactic followed by a brief question and answer period and last about 1 hour. A nurse practitioner will be responsible for conducting the group sessions. Control arm participants receive 4 individual phone calls checking in with participants regarding questions about the study or from the group sessions, each lasting about 10-15 minutes. They occur shortly before first group session, then at 1.5, 3, and 6 months.
286599|NCT02653300|Biological|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
286600|NCT00197119|Biological|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
286601|NCT02653313|Drug|Parvovirus H-1 (H-1PV)|Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.
The total dose levels are: 1E09, 5E09 and 1E10 pfu.
286602|NCT02653326|Device|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
286603|NCT02653326|Procedure|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
286604|NCT02655432|Procedure|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
286605|NCT02655445|Procedure|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
286606|NCT02655445|Procedure|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
291814|NCT02619513|Device|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
291815|NCT02619526|Drug|Nebivolol|Nebivolol 10mg, once a day
291816|NCT02619526|Drug|Carvedilol|Carvedilol 25mg, twice a day
291817|NCT02619539|Procedure|plasma fibrinogen measurement|plasma fibrinogen measurement
291818|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
291819|NCT00193336|Drug|ZD1839|
291820|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
292094|NCT02612870|Device|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
292095|NCT00192660|Drug|enfuvirtide (T20)|
292096|NCT02612870|Device|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
292097|NCT02612870|Device|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
292098|NCT02612870|Device|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
292099|NCT02612870|Device|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
292100|NCT02612896|Drug|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
292101|NCT02612896|Behavioral|Health education|in all study arms, using village meetings, posters, pamphlets.
292102|NCT02612909|Biological|A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine will be produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
292103|NCT02612909|Biological|Placebo Comparator|Placebo (PBS) will be manufactured by IVAC. PBS, pH 7.2, will also be in 0.5 mL single-dose vials. Every vial contain : Nacl 4.500mg;Na2HPO4.2H2O: 0.685 mg; NaH2PO4.2H2O:0.186 mg and Water For Injection (qs):0.5 mL
292104|NCT02612922|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
292105|NCT02612922|Drug|Placebo|Placebo administered orally twice daily for five days
291522|NCT02623881|Device|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 33 6/7 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
291523|NCT02623881|Drug|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 33 6/7 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
291524|NCT02623920|Drug|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
291525|NCT02623920|Drug|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
291526|NCT02623920|Drug|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
291527|NCT02625896|Behavioral|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
291528|NCT02625909|Drug|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
291529|NCT02625909|Drug|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
291530|NCT02625922|Drug|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
291531|NCT00193908|Radiation|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
291532|NCT02625922|Drug|Placebo|Matching placebo i.v infusion
291533|NCT02625948|Drug|Tranexamic Acid|
291821|NCT02619552|Drug|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
291822|NCT02619565|Other|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
291230|NCT02630303|Device|LED-RL Phototherapy|The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.
All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.
291231|NCT00194532|Drug|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
291232|NCT02630303|Device|Mock Therapy|Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.
All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.
291233|NCT02630316|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
291234|NCT02630316|Drug|Placebo|Placebo administered four times daily
291235|NCT02630329|Procedure|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
291236|NCT02630329|Procedure|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
291237|NCT02630342|Behavioral|Mock MRI scanner|Using a mock scanner for preparation for MRI
291238|NCT02630342|Behavioral|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
291239|NCT02630342|Behavioral|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
291240|NCT02630342|Behavioral|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
291241|NCT02630355|Other|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
291242|NCT00194532|Drug|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
291243|NCT02630368|Drug|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
291244|NCT02632292|Device|Promus|Everolimus-eluting stent
291245|NCT02632305|Drug|Combination of nab-paclitaxel, gemcitabine and cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
291246|NCT00000376|Behavioral|Cognitive therapy|
285791|NCT02678455|Biological|TV005 vaccine|Delivered by subcutaneous injection; contains 10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31, and 10^3 PFU of rDEN4Δ30.
285792|NCT00199264|Drug|Albaconazole oral solution|
285793|NCT02678455|Biological|Placebo|Delivered by subcutaneous injection
285794|NCT02678481|Device|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
285795|NCT02678481|Device|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
285796|NCT02678494|Other|Neurofeedback training|
285797|NCT02678507|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
285798|NCT02680704|Other|PEEP titrated mechanical ventilation|Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, cerebral blood velocity, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set > 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
285799|NCT00199654|Procedure|PET|
285800|NCT02680717|Drug|Clobetasol|ointment, twice daily (alternating weeks)
285801|NCT02680717|Drug|Calcipotriene|ointment, twice daily
285802|NCT02680717|Drug|Tacrolimus|ointment, 0.1%, twice daily
285803|NCT02680730|Behavioral|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
286087|NCT02671253|Procedure|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
286088|NCT02671266|Drug|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
286089|NCT02671266|Drug|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
286090|NCT02671279|Dietary Supplement|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
285530|NCT02650635|Biological|Pegfilgrastim|Given SC
285531|NCT02650635|Drug|TLR8 Agonist VTX-2337|Given SC
285532|NCT02650648|Drug|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight<70kg) or 1500mg/m^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
285533|NCT02650648|Biological|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
285534|NCT02650648|Biological|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.45 mg/kg/day and infused over ~0.5 hr
285535|NCT02650648|Drug|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10^6 U/m^2/day.
285536|NCT00002531|Drug|dexamethasone|
285537|NCT00196807|Behavioral|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
285538|NCT02650661|Behavioral|Online health management program|Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.
The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and "10 Rules for Highly Effective Health Behavior".
285539|NCT02650661|Behavioral|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
285540|NCT02650661|Behavioral|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
285541|NCT02652871|Drug|LY2510924|Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.
Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.
285542|NCT00197054|Biological|RTS,S/AS02A and RTS,S/AS01B|
285543|NCT02652871|Drug|Idarubicin|Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.
Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.
285804|NCT02680743|Other|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
285805|NCT02680756|Drug|Ferric Maltol|
285806|NCT02680756|Drug|Ferric Carboxy Maltose|
285262|NCT02590185|Drug|cocktail probe drugs|For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:
A capsule of omeprazole ABBOTT® 10mg
10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)
1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)
A tablet of fexofenadine Zentiva® 120mg
285263|NCT02590198|Other|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
285264|NCT02590198|Other|PCT algorithm|care based on PCT algorithm
285265|NCT02590211|Behavioral|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, description and role of the avatar, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
285266|NCT02590224|Drug|Ferrous bis-glycinate|
285267|NCT02590224|Drug|Ferrous glycine sulphate|
285268|NCT00190515|Drug|UFT+Leucovorin|UFT+Leucovorin
285269|NCT02590237|Device|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
285270|NCT02590237|Device|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
285271|NCT02590250|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
285272|NCT02590263|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
285273|NCT02590276|Behavioral|characterization|
285274|NCT02590289|Drug|BBI-5000|BBI-5000 low dose, middle dose, or high doses
285275|NCT02590302|Other|Implementation Phase|Core Components of the implementation intervention include:
Hospital and CMHA project commitment
Site champion teams (from hospital and CMHA)
Memorandum of Agreement between Hospital and CMHA
Pre-intervention site visits
Education sessions
Posters/reminders
Instructional videos (HEADS ED video)
Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site.
284682|NCT02601053|Other|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
284683|NCT02601053|Other|Heart rate measurement|Heart rate measurement using a actiheart device
284684|NCT02601066|Device|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
284685|NCT00191542|Drug|Atomoxetine|
284977|NCT02594228|Behavioral|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
284978|NCT02594241|Drug|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
284979|NCT02594241|Drug|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
284980|NCT02594254|Drug|C16G2 Gel|Antimicrobial peptide
284981|NCT02596711|Behavioral|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
284982|NCT02596711|Other|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
284983|NCT02596711|Behavioral|Health Education and Handouts|Participants receive general health education and handouts.
284984|NCT00191152|Drug|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
284985|NCT02596711|Behavioral|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
284986|NCT02596711|Behavioral|Counseling Sessions|Participants attend 3 counseling sessions during the study.
284987|NCT02596724|Other|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
284988|NCT02596737|Behavioral|wittyFit concept|
284989|NCT02596750|Device|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
284990|NCT02596750|Device|Sham microneedle Roller|Flat roller without microneedles
284991|NCT02596750|Drug|Topical 4% lidocaine|
284992|NCT02596763|Drug|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
284373|NCT00002520|Drug|nicotine|
284374|NCT00192257|Biological|CAIV-T and TIV|
284375|NCT02607839|Biological|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
284376|NCT02607852|Device|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
284377|NCT02607865|Drug|semaglutide|Oral administration once-daily
284378|NCT02607865|Drug|sitagliptin|Oral administration once-daily
284379|NCT02607865|Drug|placebo|Oral administration once-daily
284380|NCT02607891|Drug|GWP42003-P|Clear, pale yellow, oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
284686|NCT02601079|Device|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
284687|NCT02601079|Device|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
284688|NCT02601092|Procedure|Mini Gastric Bypass|The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.
No drugs or devices will be used.
284689|NCT02603211|Device|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
284690|NCT00191724|Drug|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
284691|NCT02603224|Drug|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
284692|NCT02603224|Drug|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
284693|NCT02603224|Drug|MRG-201|Intralesional injection of multiple ascending doses of MRG-201 in one cutaneous scleroderma lesion with starting dose selected based on MRG-201 tolerability in healthy volunteers.
284694|NCT02603224|Drug|Placebo|Intralesional injection of placebo in a second cutaneous scleroderma lesion. Each patient will serve as their own control.
284065|NCT02578277|Drug|BMS-955176 plus the cocktail of CYP and transporter probe substrates|
284066|NCT02578290|Other|Clinical Decision Support (CDS)|A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.
This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.
Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default.
284067|NCT02578303|Other|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
284068|NCT02578316|Drug|Lenvatinib|Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.
Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase.
284069|NCT00188838|Behavioral|Psychoeduction|
284070|NCT02578329|Behavioral|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
284071|NCT02578329|Behavioral|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
284072|NCT02578342|Device|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
284073|NCT02578368|Drug|5-Fluorouracil|2600 mg/m², d1 i.v., every 2 weeks
284381|NCT02607891|Drug|Placebo|Clear, pale yellow, oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
284382|NCT02607904|Drug|GWP42003-P|Clear, pale yellow, oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
284383|NCT02607917|Other|Mass Media plus clinic intervention.|
284384|NCT02607917|Other|Media|
284385|NCT00192270|Biological|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of ~3 x 10^7 TCID50 per dose.
284386|NCT02607930|Drug|ABC/DTG/3TC|ABC/DTG/3TC (600/50/300 mg) tablets administered orally, once daily, without regard to food
284387|NCT02607930|Drug|GS-9883/F/TAF Placebo|Placebo to match GS-9883/F/TAF tablets administered orally, once daily, without regard to food
284388|NCT02609789|Drug|Placebo|0.9 percent (%) normal saline.
288628|NCT02647190|Drug|Erwinia Chrysanthemi asparaginase|
288629|NCT02647203|Drug|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
288630|NCT02647216|Behavioral|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
288631|NCT02647216|Behavioral|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
288632|NCT02647229|Other|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
288633|NCT00196651|Biological|ALVAC VIH 1433|
288634|NCT02649361|Drug|Placebo|Placebo p.o. qd
288635|NCT02649374|Behavioral|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
288636|NCT02649387|Drug|Ibrutinib|Given PO
288637|NCT02649387|Other|Laboratory Biomarker Analysis|Correlative studies
288638|NCT02649413|Drug|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
288639|NCT02649426|Device|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
284074|NCT02578368|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
284075|NCT02578368|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
284076|NCT02578368|Drug|Docetaxel|50mg/m², d1, i.v., every 2 weeks
284077|NCT02578368|Drug|Trastuzumab|4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
284078|NCT02578368|Drug|sodium folinate|can be used to replace leucovorin (calcium folinate)
284079|NCT02578368|Procedure|Surgery|Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
288351|NCT00197236|Biological|Havrix™|2 intramuscular injections, 6 months apart
288352|NCT02654015|Device|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
288353|NCT02654015|Other|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
288640|NCT02649426|Device|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
288641|NCT02649439|Biological|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopopoxvirus
288642|NCT02649439|Biological|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
288643|NCT02649439|Other|Surveillance|
288644|NCT00196664|Drug|Paroxetine|
288645|NCT02649452|Other|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
288646|NCT02649465|Drug|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
288647|NCT02649465|Drug|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
288648|NCT02649478|Drug|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
288649|NCT02649478|Drug|Placebo|
288650|NCT02649478|Drug|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
288651|NCT02649491|Other|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
288652|NCT02649504|Drug|Rituximab|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
288653|NCT02649504|Drug|Dexamethasone|Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
288654|NCT02649504|Drug|Mycophenolate mofetil|Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
288046|NCT02660359|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
288047|NCT02660372|Drug|Imonogas|Simethicone 120 mg in gel capsules
288048|NCT02660372|Drug|Espumisan|Simethicone 40 mg in gel capsules
288049|NCT02660385|Behavioral|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
288050|NCT02660385|Behavioral|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
288051|NCT02660398|Procedure|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
288052|NCT02662504|Procedure|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
288354|NCT02656212|Drug|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
288355|NCT02656212|Drug|Placebo|Placebo pill, taken orally, one pill/day in the morning
288356|NCT02656225|Drug|Bazhen Capsule|Three capsules,twice daily, orally after breakfast Duration:4 weeks
288357|NCT02656225|Drug|Placebo tablet|one tablet,once daily, orally after breakfast Duration:4 weeks
288358|NCT02656225|Drug|Polysaccharide Iron Complex|150mg per tablet , one tablet ,once daily, orally after breakfast Duration:4 weeks
288359|NCT02656225|Drug|Placebo capsule|Three capsules,twice daily, orally after breakfast Duration:4 weeks
288360|NCT02656251|Drug|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
288361|NCT02656251|Drug|placebo|Use of placebo every 12 hours for 04 days
288362|NCT02656251|Drug|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
288363|NCT02656277|Other|Decision Tool|
288364|NCT00002531|Drug|prednisolone|
288365|NCT00197613|Drug|(A) zidovudine, lamivudine and nevirapine|
288366|NCT02656277|Other|Information on Shoulder Dislocation|
287748|NCT02667054|Drug|RX0041 4%|Anesthetic
287749|NCT02667054|Drug|Placebo|Placebo Comparator
287750|NCT02667054|Drug|RX0041 8%|Anesthetic
287751|NCT02667067|Device|Simplify Disc|The spinal system is a 3-piece design consisting of 2 polyetheretherketone (PEEK) end-plates with a plasma-sprayed titanium endplate coating and a fully articulating ceramic alumina matrix composite (AMC) core. The system is available in 3 foot print sizes (Size 1 - 12mm x 15mm, Size 2 - 14 mm x 16 mm and Size 3 - 16 mm x 18 mm) and 2 heights (5mm and 6mm). There are 4 additional lordotic configurations (5 deg., size 2, height 5mm and 6mm).In addition to serrated surfaces, the inferior endplate has inline keels and the superior endplate has two to three teeth to facilitate endplate fixation. Each superior endplate features a retention ring intended to mat with the retention feature of the core. The core is 5mm tall, is bi-convex with a radius of R 9.6 mm.
287752|NCT02667067|Procedure|Anterior Cervical Discectomy & Fusion|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®/C Disc trial.
287753|NCT02667080|Other|2-7 days of Sexual abstinence|2-7 days of Sexual abstinence
287754|NCT00198978|Drug|Mercaptopurine|
287755|NCT02667080|Other|2 hours of sexual abstinence|2 hours of sexual abstinence
287756|NCT02667106|Drug|RX0041-2|Pharmacokinetic study
287757|NCT02667119|Behavioral|Prolonged Exposure with Contingency Management|Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.
Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided.
287758|NCT02667119|Behavioral|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
287759|NCT02669381|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
288053|NCT02662504|Drug|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
288054|NCT02662530|Drug|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
288055|NCT00198484|Drug|Vitrase|
288056|NCT02662556|Drug|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
287427|NCT02674477|Other|Treatment as Usual (TAU)|Participants will received standard treatment during and after hospitalization.
287428|NCT00199069|Drug|6-Mercaptopurine|
287429|NCT02674490|Device|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
287430|NCT02674490|Behavioral|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
287431|NCT02674490|Device|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
287432|NCT02674503|Behavioral|Walking|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
287433|NCT02674503|Behavioral|Friendly visit|UC patients will receive three times a day "friendly visits", seven days a week by members of the research team to control for the daily attention that MP patients receive.
287434|NCT02674516|Device|Transcranial direct current stimulation|
287435|NCT02674516|Device|Sham transcranial direct current stimulation|
287436|NCT02674529|Drug|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
287437|NCT02674529|Drug|Placebo|Placebo
287438|NCT02674542|Other|In-depth interviews|Future family planning intentions and beliefs
Family planning experiences and beliefs:
Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise
287439|NCT00199069|Drug|6-Thioguanine|
287440|NCT02674542|Other|Focus Group|Future family planning intentions and beliefs
Family planning experiences and beliefs:
Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise
287441|NCT02674555|Drug|radio-labeled ASP8273|Oral administration
287442|NCT02674555|Drug|ASP8273|Oral administration
286878|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
286879|NCT02648750|Behavioral|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
286880|NCT02648776|Drug|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
286881|NCT02648802|Procedure|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
287151|NCT02678988|Device|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
287152|NCT02678988|Drug|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
287153|NCT02679001|Drug|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
287154|NCT02679014|Drug|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
287155|NCT02679014|Drug|RG7625|With the exception of the mornings of Days 7 and 21, RG7625 capsules will be taken with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RG7625 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
287156|NCT02679027|Other|Protrude tongue maximally and upward (PTMU)|The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
287157|NCT02679027|Other|Protrude tongue maximally and downward (PTMD)|The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
287158|NCT02679040|Procedure|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
287159|NCT02679040|Drug|Chemotherapy|Chemotherapy treatment
287160|NCT00002535|Biological|aldesleukin|
287161|NCT02681198|Drug|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
286607|NCT02655445|Procedure|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
286608|NCT02655458|Drug|Elotuzumab|The following must also be administered before any elotuzumab:
Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po).
286609|NCT00197470|Procedure|IL-1, TNF-alpha, Il-10|
286610|NCT02655458|Drug|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
286882|NCT02648802|Procedure|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
286883|NCT02648815|Procedure|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
286884|NCT02648815|Procedure|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
286885|NCT02648828|Other|Clinical deterioration|Patients at risk of clinical deterioration
286886|NCT02651311|Drug|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
286887|NCT02651311|Drug|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
286888|NCT02651324|Drug|Ketamine|
286889|NCT02651324|Other|Placebo|
286890|NCT00196872|Drug|Xeloda|Xeloda is given
286891|NCT02651337|Device|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
286892|NCT02651350|Drug|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
292106|NCT00192673|Drug|PEG-asparaginase|
292107|NCT02615041|Drug|Meropenem|1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.
Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and
1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.
292108|NCT02615041|Drug|Meropenem|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.
Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.
292109|NCT02615054|Device|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
292110|NCT02615054|Device|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
292111|NCT02615067|Drug|99mTc-MIP-1404 Injection|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
292112|NCT02615080|Drug|CRD007|
292113|NCT02615080|Drug|Placebo|
292417|NCT02644304|Other|Placebo|placebo(half tablet) every 3 days (4 doses).
292418|NCT00196105|Device|10 mm Nitinol Zilver Stent|
292419|NCT02644317|Device|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
292420|NCT02644330|Procedure|transthoracic device closure|minimally invasive transthoracic device closure
292421|NCT02644330|Procedure|surgical repair|surgical repair with cardiopulmonary bypass
292422|NCT02644356|Behavioral|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
292423|NCT02644369|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
292424|NCT02644382|Other|qualitative data collection|qualitative data collection
292425|NCT02644395|Drug|Chlorthalidone|Drug
292426|NCT02644395|Drug|Amlodipine|Drug
292427|NCT02644408|Drug|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
291823|NCT02619578|Other|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
291824|NCT02619578|Other|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
291825|NCT02619578|Drug|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
291826|NCT02619578|Other|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
291827|NCT02619591|Device|Ultrasound Imaging Technique - Single View|A single view of a hemithorax was obtained using the Zonare Ultrasound machine.
291828|NCT02619591|Device|Ultrasound Imaging Technique - Multiple Views|Multiple views of a hemithorax was obtained using the Zonare Ultrasound machine.
291829|NCT02621671|Behavioral|Cognitive interview|
291830|NCT02621671|Other|Survey|
291831|NCT02621684|Other|Community Health Activities Model Program for Seniors (CHAMPS)|Physical activity questionnaire for older adults
Asks about activities in the past 4 weeks
41 questions and asks to notate how long the activity took
291832|NCT02621684|Other|Lifetime Total Physical Activity Questionnaire|Questions about leisure time (27) and household activities (5)
Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years
291833|NCT02621684|Other|Expanded Prostate Cancer Index Composite (EPIC)|Measures urinary and sexual function before and after prostate cancer treatment
7 questions about urinary function
9 questions about sexual function
291834|NCT02621684|Other|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
291835|NCT02621684|Other|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
291836|NCT00193479|Drug|Vincristine|Vincristine
291837|NCT02621684|Other|Questionnaire regarding behavior/lifestyle changes since diagnosis|
291838|NCT02621684|Other|12 week Walking Program|
292114|NCT02615093|Drug|IDP-118 Lotion|The study drug will be applied topically to the affected areas (as determined by the investigator at baseline) once daily for 8 weeks.
291247|NCT00002524|Drug|Prednisone|
291248|NCT00194779|Drug|capecitabine|Given PO
291249|NCT02632318|Device|Light|30 minutes of dawn simulation
291534|NCT02625961|Biological|pembrolizumab|
291535|NCT02625974|Drug|Nifurtimox (BAYA2502)|For pediatric subjects with body weight ≤ 40 kg: maximum dosage15 mg/kg/day in three divided doses For pediatric subjects with body weight > 40 kg: 8 - 10 mg/kg/day in three divided doses.
60 days of nifurtimox treatment
291536|NCT02625974|Drug|Nifurtimox (BAYA2502) followed by Placebo|For pediatric subjects with body weight ≤ 40 kg: maximum dosage15 mg/kg/day in three divided doses For pediatric subjects with body weight > 40 kg: 8 - 10 mg/kg/day in three divided doses.
30 days of nifurtimox treatment followed by 30 days of placebo
291537|NCT02625987|Procedure|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
291538|NCT02625987|Procedure|Separated stitches|Appendectomy wound closure with a separated stitches.
291539|NCT02626000|Drug|Talimogene laherparepvec in combination with pembrolizumab|Talimogene laherparepvec will be administered in combination with pembrolizumab starting on day 1. Talimogene laherparepvec: 10^6 PFU/mL followed 3 weeks (+ 3 days) later by 10^8 PFU/mL every 3 weeks (± 3 days). Pembrolizumab: 200 mg will be administered intravenously every 3 weeks (± 3 days). The second dose of pembrolizumab will be administered 3 weeks (+ 3 days) after the initial dose. Subjects will be followed up for serious adverse events until 90 (+ 7) days after the cessation of all study treatment or 30 (+7) days following cessation of treatment if the subject initiates new anticancer therapy (whichever is earlier)
291540|NCT02626026|Drug|GS-4059|GS-4059 capsules administered orally
291541|NCT02626026|Drug|Placebo|GS-4059 placebo administered orally
291542|NCT00193921|Drug|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
291543|NCT02626052|Behavioral|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
291544|NCT02626052|Behavioral|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
291545|NCT02626052|Behavioral|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
291546|NCT02628002|Device|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
291547|NCT02628028|Drug|LY3337641|Administered orally
291548|NCT02628028|Drug|Placebo|Administered orally
286091|NCT00199017|Drug|Vindesine|
286092|NCT02671292|Behavioral|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
286093|NCT02673723|Drug|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
286094|NCT02673736|Drug|PLX73086|
286095|NCT02673749|Drug|RP-G28|Study drug taken orally
286096|NCT02673749|Other|Placebo|Placebo taken orally
286097|NCT02673775|Other|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
286098|NCT02673775|Other|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
286099|NCT02673788|Other|observation without intervention in this follow up study|observation without intervention in this follow up study
286100|NCT00199069|Drug|Asparaginase|
286101|NCT02673801|Other|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
286102|NCT02673814|Biological|durvalumab|
286103|NCT02673814|Biological|bavituximab|
286104|NCT02673827|Other|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
286105|NCT02673840|Drug|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
286390|NCT02666573|Other|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
286391|NCT02666586|Other|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
286392|NCT02666586|Other|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
285807|NCT02680769|Dietary Supplement|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
285808|NCT02680769|Other|Placebo|This group will take a placebo
285809|NCT02680782|Drug|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
285810|NCT00199667|Drug|Mycophenolate Mofetil|
285811|NCT02680795|Drug|Belinostat IV|Cohort A:
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.
285812|NCT02680795|Drug|Belinostat IV|Cohort B:
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.
285813|NCT02680795|Drug|Belinostat|Cohort C:
Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.
285814|NCT02680808|Drug|Midazolam with F901318|Pharmacokinetics of midazolam with F901318
285815|NCT02680821|Procedure|ALL reconstruction (Anterolateral ligament)|
285816|NCT02680821|Procedure|ACL revision (Anterior cruciate ligament )|
285817|NCT02680834|Device|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
285818|NCT02680834|Device|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
285819|NCT02680847|Drug|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
285820|NCT02683018|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
285821|NCT02683031|Other|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
285822|NCT02683044|Procedure|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
285823|NCT00200031|Device|Interstim therapy|
286106|NCT02673840|Drug|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
286107|NCT02673866|Drug|DS-1971a|
286108|NCT02673866|Drug|placebo|
285544|NCT02652871|Drug|Cytarabine|Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.
Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days.
285545|NCT02652884|Drug|phosphate and betamethasone acetate, 2 mL.|single dose of intramuscular depot corticosteroid
285546|NCT02652884|Drug|saline 0.9% NaCl|single dose of intramuscular placebo
285547|NCT02652897|Procedure|Exposure to glioma resection surgery|Blood samples will be drawn for hemostasis evaluation (conventional clotting tests, rotational thromboelastometry (ROTEM) and PFA-200 for platelet function), before (within a period 24-h before) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
285548|NCT02652897|Procedure|Exposure to colon resection surgery|Blood samples will be drawn for hemostasis evaluation (conventional clotting tests, rotational thromboelastometry (ROTEM) and PFA-200 for platelet function), before (within a period 24-h before) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
285549|NCT02652910|Drug|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
285550|NCT02652923|Drug|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
285551|NCT02652936|Drug|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
285552|NCT02652936|Drug|Placebo comparator|AF-130 matching placebo capsule
285553|NCT00197067|Biological|RTS,S/AS02D and RTS,S/AS02A|
285554|NCT02652949|Device|Valiant Evo Thoracic Stent Graft|
285555|NCT02652962|Device|Gelesis200|3 capsules each containing 0.70 g
285556|NCT02652962|Other|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
285557|NCT02652975|Procedure|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
285558|NCT02652975|Procedure|SphygmoCor|Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.
Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously.
285559|NCT02652975|Procedure|24hour blood pressure|24 hour blood pressure measurement
284993|NCT02596776|Procedure|Fat biopsy|up to 16 biopsy samples will be taken from each subject
284994|NCT02596776|Drug|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
284995|NCT00191152|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
284996|NCT02596776|Other|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
284997|NCT02596789|Device|TMS "Magpro®, Magventure Inc" device|
284998|NCT02596802|Device|FETO therapy|Fetoscopic surgery at 27 to 29 weeks and 6 days gestation.
285276|NCT02590315|Other|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
285277|NCT02661438|Drug|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
285278|NCT02661451|Device|SAPIEN 3 THV|
285279|NCT02661451|Biological|Optimal Heart Failure Therapy|
285280|NCT02661464|Biological|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
285281|NCT02661464|Biological|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
285282|NCT00198341|Procedure|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
285283|NCT02661477|Drug|pegylated interferon alfa 2|
285284|NCT02661477|Other|Placebo|0,9% natrium chlorine solution
285285|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
285286|NCT02661490|Drug|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
285287|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
285288|NCT02661503|Drug|Bleomycin|
285289|NCT02661503|Drug|Etoposide|
284695|NCT02603237|Other|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
284696|NCT02603237|Other|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
284697|NCT02603263|Other|Social Norms Poster|A poster containing a social norms message: "Most people here choose to eat vegetables with their lunch"
284698|NCT02603276|Dietary Supplement|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
284699|NCT02603276|Dietary Supplement|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
284700|NCT02603276|Dietary Supplement|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
284701|NCT00191724|Drug|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
284702|NCT02603289|Device|Invisalign|
284999|NCT02596815|Procedure|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
285000|NCT02596815|Device|Goniometer|
285001|NCT02596828|Drug|Temozolomide|Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).
Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
285002|NCT02596828|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
285003|NCT02598843|Other|Accelerated Rehabilitation|4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance.
2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance.
2 weeks in Rebound walking boot with foot in neutral with immediate but gradual weaning out off boot. At 8 weeks, remove boot completely and allow FWB out of boot.
Physiotherapy, commenced 4 weeks after initiation of treatment, involves: NWB early active plantar/dorsiflexion to neutral and active inversion/eversion below neutral. At 8 weeks after initiation of treatment, physiotherapy is expanded to include slow dorsiflexion stretching, graduated resistance exercises (open and closed kinetic chain) and proprioception and gait retraining.
285004|NCT02598856|Drug|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
284389|NCT02609802|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
284390|NCT00002521|Drug|cyclophosphamide|
284391|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
284392|NCT02609802|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
284393|NCT02609815|Drug|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
284394|NCT02609815|Drug|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
284395|NCT02609828|Drug|Tanezumab|Subcutaneous study treatment (tanezumab 10 mg or tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
284396|NCT02609854|Device|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
284397|NCT02609854|Device|Sham Device|Inactive ultrasound device
284398|NCT02609867|Device|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
284399|NCT02609880|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
284400|NCT02609880|Behavioral|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
284401|NCT02609893|Other|modified directly observed therapy (mDOT)|
284402|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
284703|NCT02603302|Radiation|Dose Escalation Radiotherapy|RT (jaws-only IMRT) 50,4 Gy to the whole pelvis + boost 10,8 Gy to the GTV Chemotherapy with 5-FU
284704|NCT02603302|Procedure|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
284705|NCT02603315|Other|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
284706|NCT02603328|Drug|Atorvastatin|20-80 mg OD
284707|NCT02603328|Other|Placebo|
284708|NCT02603341|Radiation|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
284080|NCT00188838|Behavioral|Cognitive-Behavioral Therapy|
284081|NCT02578381|Device|Boston Scientific Pressure Wire|St Jude Medical Pressure Wire
284082|NCT02578381|Device|Validation of Boston Scientific pressure wire|
284083|NCT02578394|Drug|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
284084|NCT02578394|Drug|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
284085|NCT00189137|Drug|ifosfamide and doxorubicin vs gemcitabine and docetaxel|Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.
Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.
All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection.
284086|NCT02580500|Procedure|spinal catheter|spinal anesthesia application for spinal catheter will be used
284087|NCT02580513|Behavioral|Circadian Misalignment|
284088|NCT02580526|Procedure|V-E mask ventilation for one minute|V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.
When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed "C-E" facemask ventilation technique or with "V-E" technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique.
284089|NCT02580526|Procedure|C-E mask ventilation for one minute|Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.
When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed "C-E" facemask ventilation technique or with "V-E" technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique.
284090|NCT02580539|Biological|Group A|Peptide-stimulated T cells 2 x 10^7/m^2
284091|NCT02580539|Biological|Group B|Peptide-stimulated T cells per dose-escalation protocol
284403|NCT02609893|Other|unobserved dosing|
284404|NCT02609893|Other|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
288655|NCT00196677|Drug|Vitamins, minerals and medical herbs|
288656|NCT02652052|Drug|Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
288657|NCT02652065|Other|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
288658|NCT02652065|Other|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
284092|NCT02580552|Drug|MRG-106|Decreasing intratumoral doses
284093|NCT02580552|Drug|MRG-106|Escalating subcutaneous doses with starting dose selected based on MRG-106 tolerability determined in Part A
284094|NCT02580565|Other|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
284095|NCT02580578|Other|No Intervention|No intervention is administered in this study.
284096|NCT00189150|Drug|Mycophenolate mofetil|
284097|NCT02580591|Drug|Empagliflozin|
284098|NCT02580591|Drug|Placebo|
284099|NCT02580591|Drug|Placebo|For blinding purposes
284100|NCT02580604|Drug|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
284101|NCT02580604|Drug|Placebo|Saline Infusion
284102|NCT02580617|Biological|ALLO-ASC|Infusion for Crohn's disease
284103|NCT02580630|Behavioral|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
284104|NCT02580630|Other|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week and stretching exercises every day. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month. The patient will register all training on a diary.
284105|NCT02582736|Drug|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
284106|NCT02582749|Drug|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
288367|NCT02656290|Device|Model 11000A in pulmonary position|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position
288368|NCT02656303|Biological|ublituximab|ublituximab IV infusion
288369|NCT02656303|Drug|TGR-1202|TGR-1202 oral daily dose
288370|NCT02656316|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
288371|NCT02656316|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
288372|NCT02656329|Drug|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All patients will be scheduled for an Iobenguane I-123 Injection, AdreView scan.
288373|NCT02656329|Device|Implantable Cardioverter Defibrillator|In the Iobenguane I-123 Injection group, patient with H/M ratio less or equal to 1.6 will undergo ICD device implantation, while those with H/M ratio greater than or equal to 1.6 will not. All patients allocated to the SoC (control) group will undergo ICD implantation.
288374|NCT02656329|Drug|Thyroid blocking|Patients will receive a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
288375|NCT02656342|Drug|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
288376|NCT00197613|Drug|(B) zidovudine, lamivudine and efavirenz|
288659|NCT02652065|Other|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
288660|NCT00196976|Biological|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
288661|NCT02652065|Other|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
288662|NCT02652078|Device|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
288663|NCT02652091|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
288664|NCT02652091|Device|BETACONNECT device|Used to apply Betaseron.
288665|NCT02652143|Device|AneVivo (Medical device for in vivo culture of embryos)|
288666|NCT02652143|Other|comparator for embryo culture in vitro|
288057|NCT02662569|Biological|Evolocumab (AMG 145)|Subjects will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously
288058|NCT02662569|Drug|Atorvastatin|All subjects will receive atorvastatin 20 mg po daily
288059|NCT02662569|Other|Placebo|Subjects will receive placebo subcutaneously every 2 weeks or every month
288060|NCT02662582|Drug|CK-2127107|Oral
288061|NCT02662582|Drug|Placebo|Oral
288062|NCT02662595|Other|SMS reminder message|
288063|NCT02662595|Other|Voice call + SMS message|
288064|NCT02662608|Drug|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
288065|NCT02662621|Other|blood samples|
288066|NCT00198497|Drug|Placebo|
288067|NCT02662621|Other|Urine samples|
288068|NCT02662634|Biological|AGS-003-LNG|autologous dendritic cell immunotherapy
288069|NCT02662634|Drug|Carboplatin|Carboplatin is an anticancer drug ("antineoplastic" or "cytotoxic") chemotherapy drug. Carboplatin is classified as an "alkylating agent."
288070|NCT02662634|Drug|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
288071|NCT02662634|Drug|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
288072|NCT02662634|Drug|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
288073|NCT02662634|Drug|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
288074|NCT02662634|Radiation|Radiation Therapy|Causes DNA strand breaks.
288377|NCT02656342|Drug|Placebo|Predicted to have no enhancing effect
288378|NCT02656355|Other|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
288379|NCT02656355|Other|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
287443|NCT02676765|Drug|Allergen|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
287760|NCT02669394|Behavioral|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
287761|NCT02669394|Behavioral|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
287762|NCT02669407|Procedure|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
287763|NCT02669407|Drug|regional nerve block with a local anesthetic (Lidocaine)|
287764|NCT02669420|Procedure|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
287765|NCT02669433|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
287766|NCT02669433|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
287767|NCT02669433|Drug|Placebo|once daily, oral, matching tablets
287768|NCT02669446|Device|Medical devices|
287769|NCT00199004|Drug|Asparaginase|
287770|NCT02669446|Device|traditional household remedy|
287771|NCT02669459|Drug|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
287772|NCT02669459|Procedure|LLETZ|surgical treatment for CIN, current gold standard
287773|NCT02669472|Other|Environmental Intervention|Intervention sites received regularly-scheduled, discount, fresh F&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
287774|NCT02669472|Behavioral|Educational Intervention|Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
287162|NCT02681198|Drug|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
287163|NCT00199758|Drug|Gemcitabine|
287164|NCT02681211|Other|Auricular Acupuncture|ASP gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
287165|NCT02681211|Drug|Ketorolac 0.5mg/kg, max 30mg|If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL
287166|NCT02681211|Drug|Metoclopramide 0.1 mg/kg, max 10mg|If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL
287167|NCT02681211|Drug|Diphenhydramine 1mg/kg, max 50mg|If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL
287444|NCT02676765|Drug|Placebo|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
287445|NCT00199147|Drug|Cytarabine|
287446|NCT02676778|Drug|E7777|
287447|NCT02676791|Drug|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
287448|NCT02676804|Other|High-intensity, aerobic exercise.|Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.
Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own.
287449|NCT02676830|Drug|K-312 100 mg|Single oral dose
287450|NCT02676830|Drug|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) [14C] given as a 5-ml IV push over 2 minutes
287451|NCT02676843|Drug|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
287452|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3*10^8/kg/once.
286893|NCT02651350|Drug|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
286894|NCT02651376|Other|Conventional plus AAC treatment|Participants received conventional treatment and taken i.v., at a dose of 2-3*10E8 allogenic adoptive cells/kg body at baseline, week 1 and 3.
286895|NCT02651376|Other|Conventional plus placebo treatment|Participants received conventional treatment and taken i.v., at 50 ml saline at baseline, week 1 and 3.
287168|NCT02681211|Drug|Normal saline fluid bolus 20mL/kg, max 1000mL|If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL
287169|NCT02681224|Other|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
287170|NCT02681224|Other|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
287171|NCT02681224|Other|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
287172|NCT02681224|Other|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
287173|NCT02681237|Drug|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
287174|NCT00199758|Drug|Taxol|
287175|NCT02681237|Drug|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
287176|NCT02681250|Procedure|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
287177|NCT02681250|Procedure|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
287178|NCT02681263|Drug|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
287179|NCT02681276|Procedure|Irrigation with 3% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
287180|NCT02681276|Procedure|Irrigation with 0.5% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
287181|NCT02646514|Device|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
292428|NCT02644408|Radiation|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
292429|NCT00196105|Device|10 mm Stainless Steel Wallstent|
292430|NCT02644408|Other|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
292431|NCT02644421|Drug|VVZ-149|
292432|NCT02644421|Drug|Lidocaine|
292433|NCT02644421|Drug|Placebo|
292434|NCT02610764|Procedure|Blood Test for CTC evaluation|
292435|NCT02610777|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
292436|NCT02610777|Drug|Pevonedistat|Pevonedistat intravenous infusion.
292437|NCT02610816|Other|elimination diet therapy|1FED: milk elimination 4FED: milk, egg, wheat, and soy elimination
Other Names:
1FED
4FED
292438|NCT02610816|Drug|Flovent (fluticasone propionate)|Drug: Flovent
Flovent (fluticasone propionate): swallowed glucocorticoid
Other Names:
•fluticasone propionate
292439|NCT02610829|Dietary Supplement|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
292736|NCT02639793|Procedure|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
292737|NCT02639806|Drug|Sevoflurane|
292738|NCT02639806|Drug|Lidocaine|
292739|NCT00195546|Drug|DVS-233|
292740|NCT02639819|Drug|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
292741|NCT02639832|Device|LiquidBiopsy®, NK VueTM|The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.
292742|NCT02639858|Drug|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
292743|NCT02639897|Other|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
292115|NCT00193050|Drug|Gemcitabine|Gemcitabine
292116|NCT02615093|Drug|Vehicle Lotion|Vehicle lotion will be applied topically to the affected areas (as determined by the investigator at baseline) once daily for 8 weeks.
292117|NCT02615106|Drug|Endostar|7.5 mg/m2/day, day 1-14
292118|NCT02615106|Radiation|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
292119|NCT02615119|Drug|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
292120|NCT02615119|Drug|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
292121|NCT02615132|Behavioral|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
292122|NCT02615158|Behavioral|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
292123|NCT02615158|Behavioral|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
292124|NCT02615158|Behavioral|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
292125|NCT02615171|Behavioral|RELAX-AS; Device: smartphone; Other: physical activity|
292126|NCT00193050|Drug|Epirubicin|Epirubicin
292127|NCT02615171|Behavioral|DIET-AS; Device: smartphone; Other: physical activity|
292128|NCT02617225|Behavioral|DHaAL Intervention|This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.
DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors.
292129|NCT02617225|Behavioral|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
291549|NCT02628041|Radiation|Permanent Iodine-125 seed implant|Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.
A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.
The catheters are removed at the end of the procedure.
291839|NCT02621684|Other|12 week Resistance Training Program|
291840|NCT02621697|Other|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
291841|NCT02621697|Other|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
291842|NCT02621710|Other|Questionnaire 3 months post-operatively|
291843|NCT02621736|Other|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
291844|NCT02621749|Device|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
291845|NCT02621762|Device|Magnesium|Magnesium in dialysate increased
291846|NCT02621762|Device|Bicarbonate|Bicarbonate in dialysate increased
291847|NCT00193479|Drug|Prednisone|Prednisone
291848|NCT02621775|Behavioral|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
291849|NCT02621775|Behavioral|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
291850|NCT02621775|Other|Waiting list|The patients are followed by their General Practitioners without change in treatment .
291851|NCT00193635|Drug|mycophenolate mofetil|oral drug administration
291852|NCT02623933|Radiation|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
291853|NCT02623959|Behavioral|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
286393|NCT02666586|Other|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
286394|NCT00198965|Behavioral|dietary education and provided full fat snack foods|
286395|NCT02666586|Other|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
286396|NCT02668744|Behavioral|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
286397|NCT02668757|Behavioral|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
286398|NCT00198991|Procedure|Mediastinal Irradiation|
286399|NCT02668770|Drug|MGN1703|Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
286400|NCT02668770|Drug|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
286401|NCT02668783|Drug|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 or 6 cycles of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
286402|NCT02668783|Drug|Placebo vaginal ring|Up to 4 or 6 cycles of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
286403|NCT02668783|Drug|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping.
286404|NCT02668796|Drug|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
286405|NCT02668796|Drug|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
286406|NCT02668796|Drug|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
286407|NCT02668809|Other|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
286672|NCT02662075|Device|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
286673|NCT02662088|Procedure|laparoscopic-lavage|
286109|NCT02673866|Drug|pregabalin|pregabalin
286110|NCT02673879|Other|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
286111|NCT00199069|Drug|Vincristine|
286112|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
286113|NCT02673892|Other|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
286114|NCT02673905|Other|Tissue Engineered Product|Implantation of tissue engineered products
286115|NCT02676206|Other|Classical music|Classical music will be played over the headphones
286116|NCT02676219|Other|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
286117|NCT02676219|Other|Water|
286118|NCT02676232|Behavioral|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
286119|NCT02676245|Behavioral|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
286120|NCT00199095|Drug|Methotrexate|
286121|NCT02676245|Behavioral|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
286122|NCT02676271|Procedure|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
286123|NCT02676284|Device|Durolane SJ|single dose injection
286124|NCT02676297|Drug|tiotropium|four inhalations
286125|NCT02676310|Drug|Bimatoprost|
286126|NCT02676323|Drug|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
285560|NCT02652975|Procedure|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
285561|NCT00197392|Device|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
285824|NCT02683057|Other|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
285825|NCT02683070|Procedure|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
285826|NCT02683070|Drug|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
285827|NCT02683083|Biological|[131I]-SGMIB Anti-HER2 VHH1|
285828|NCT02683096|Other|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
285829|NCT02683109|Drug|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
285830|NCT02683109|Drug|Placebo|
285831|NCT02683109|Drug|Tiotropium|
285832|NCT02683109|Drug|Olodaterol|
285833|NCT02683135|Behavioral|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
285834|NCT00200044|Device|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score >15.
285835|NCT02683135|Behavioral|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
285836|NCT02683135|Behavioral|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning ~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
285837|NCT02683148|Drug|DHEA|
285290|NCT02661503|Drug|Doxorubicin|
285291|NCT02661503|Drug|Cyclophosphamide|
285292|NCT02661503|Drug|Vincristine|
285293|NCT00198354|Drug|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
285294|NCT02661503|Drug|Procarbazine|
285295|NCT02661503|Drug|Prednisone|
285296|NCT02661503|Drug|Brentuximab Vedotin|
285297|NCT02661503|Drug|Dacarbazine|
285298|NCT02661503|Drug|Dexamethasone|
285562|NCT02655055|Procedure|high frequency voluntary apheresis blood donation|
285563|NCT02655068|Other|PET/CT|Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.
During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings.
285564|NCT02655068|Other|Computed Tomography (CT)|Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.
During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings
285565|NCT02655081|Dietary Supplement|high arginine nutritional supplement (Nestle's Impact AR)|Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
285566|NCT02655120|Procedure|Drilling|
285567|NCT02655120|Biological|Bone Marrow +BMP7|
285568|NCT02655133|Drug|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
285569|NCT02655133|Drug|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
285570|NCT02655146|Drug|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
285571|NCT02655146|Drug|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
285572|NCT00197418|Drug|rabeprazole, amoxicillin, clarithromycin, metronidazole|
285005|NCT02598856|Drug|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
285006|NCT02598856|Drug|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
285007|NCT02598856|Drug|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
285008|NCT02598869|Drug|Triamcinolone Acetonide|injection of triamcinolone acetonide
285009|NCT02598882|Device|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
285010|NCT02598882|Device|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
285011|NCT00191321|Drug|Teriparatide|
285012|NCT02598895|Drug|Carboplatin|Given IV
285013|NCT02598895|Drug|Docetaxel|Given IV
285014|NCT02598895|Other|Laboratory Biomarker Analysis|Correlative studies
285299|NCT02661529|Procedure|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
285300|NCT02661529|Procedure|Transthoracic Echocardiogram (TTE)|An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.
Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall.
285301|NCT02663752|Procedure|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment will get a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
285302|NCT02663752|Drug|Deferasirox|Patients are already on commercial deferasirox before entering the study.
285303|NCT00198614|Drug|Carvedilol versus Metoprolol|
285304|NCT02663778|Behavioral|Strength training|weight lifting to increase muscle strength
285305|NCT02663778|Behavioral|Endurance training|treadmill walking to increase endurance
284709|NCT02603341|Radiation|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
284710|NCT02603354|Drug|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
284711|NCT02603367|Other|Communication Intervention|Undergo communication coaching
284712|NCT00191737|Drug|Atomoxetine|
284713|NCT02603367|Other|Educational Intervention|Receive COMFORT communication curriculum
284714|NCT02605395|Drug|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
284715|NCT02605395|Drug|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
284716|NCT02605408|Device|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
284717|NCT02605408|Procedure|Phacoemulsification|Removal of the cataractous lens
284718|NCT02605421|Drug|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
284719|NCT02605421|Drug|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
284720|NCT02605421|Drug|Melphalan|Melphalan by IV once daily for 3 doses on Days -7, -6, and -5. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
284721|NCT00192023|Drug|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
284722|NCT02605421|Drug|Etoposide|Etoposide by IV once daily for 4 doses on Days -7, -6, -5 and -4. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
284723|NCT02605421|Drug|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -7, -6, -5 and -4. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
284724|NCT02605421|Biological|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
285015|NCT02598908|Other|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
285016|NCT02598921|Radiation|three dimensional ultrasound|
285017|NCT02598921|Device|Office hysteroscopy|
285018|NCT02598934|Drug|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
284405|NCT02609906|Device|PhilosTM with augmentation (Depuy-Synthes)|All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.
Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes).
284406|NCT02609906|Device|MultiLoc®-Nail (Depuy-Synthes)|All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.
Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
284407|NCT02609919|Drug|Gadoteric Acid|MRI Contrast Agent
284408|NCT02576145|Biological|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
284409|NCT02576158|Procedure|TCT，HPV，colposcopic inspection|
284410|NCT02576171|Behavioral|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
284411|NCT02576184|Device|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
284412|NCT02576184|Device|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
284413|NCT02576197|Dietary Supplement|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
284414|NCT02576197|Dietary Supplement|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
284415|NCT02576223|Drug|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
284416|NCT02576223|Drug|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
284417|NCT02576236|Other|sequential empirical treatment|Sequential therapy combining 5 days with PPI-amoxicillin + 5 days with PPI-clarithromycin-imidazole
284418|NCT00188422|Procedure|low dose CT|
284107|NCT02582749|Drug|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
284108|NCT02582749|Radiation|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
284109|NCT02582762|Drug|Nail gel|apply nail gel on affected nails twice daily for 2 months
284110|NCT02582775|Drug|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
284111|NCT02582775|Drug|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
284112|NCT02582775|Drug|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
284419|NCT02576236|Other|sequential therapy guided by the results of a PCR test|Sequential therapy guided by the results of a PCR test : based on the resistance of H. pylori to antibiotics
284420|NCT02576236|Other|quadruple bismuth therapy: Pylera®|Quadruple bismuth therapy (PPI + metronidazole + tetracyclin + bismuth),10 days
284421|NCT02576249|Drug|0.2% ropivacaine|
284422|NCT02576249|Drug|0.9% normal saline|
284423|NCT02576262|Procedure|TCT，HPV，colposcopic inspection|
284424|NCT02576275|Drug|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
284425|NCT02576275|Drug|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
284426|NCT02576275|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
284427|NCT02576275|Drug|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
284428|NCT02576288|Drug|Sitagliptin|anti-inflammatory properties
284429|NCT00188435|Procedure|Minimum Dose CT|
284430|NCT02576288|Drug|Placebo|No anti-inflammatory properties
284431|NCT02576301|Drug|OXi4503|Determination of MTD of OXi4503
284432|NCT02578407|Other|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
284433|NCT02578420|Other|open-label placebo|Placebo Cream, openly described as "Placebo"
288667|NCT02652156|Drug|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
288668|NCT02652156|Drug|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
288669|NCT02652156|Drug|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
288670|NCT02652169|Drug|Platelet rich fibrin with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
288671|NCT00196976|Biological|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
288672|NCT02652169|Drug|Platelet rich fibrin with PHMB plus Macrogolol (Lavasorb(R))|PRF, mixed with Lavasorb is applied to the chronic ulcer
288673|NCT02652169|Drug|Platelet rich fibrin plus sodium chloride 0.9%|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
288674|NCT02654028|Procedure|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
284113|NCT00189488|Drug|Placebo|Administered as an intravenous (IV) bolus.
284114|NCT02582775|Radiation|Total Body Irradiation|300 cGy as single dose day -1
284115|NCT02582775|Procedure|Bone marrow infusion|Bone marrow infusion
284116|NCT02582775|Drug|Tacrolimus|Day +5 through day 100
284117|NCT02582775|Drug|Mycophenolic Acid Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
284118|NCT02582775|Biological|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
284119|NCT02582788|Other|Bathing Additive|
288380|NCT02658422|Drug|Reference Montelukast|Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
288381|NCT00002531|Drug|vincristine sulfate|
288382|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
288383|NCT02658435|Drug|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
288384|NCT02658435|Drug|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
288385|NCT02658448|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
288386|NCT02658461|Drug|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed >1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
288387|NCT02658474|Behavioral|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
288388|NCT02658487|Drug|Cytarabine|Given IV
288389|NCT02658487|Drug|Vosaroxin|Given IV
288390|NCT02658500|Dietary Supplement|Infant Formula|
288391|NCT02658500|Dietary Supplement|breast milk|
288392|NCT02658513|Other|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
288393|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
288394|NCT02658513|Other|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
288395|NCT02658526|Behavioral|anesthesia - surgery|
288396|NCT02658552|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
288675|NCT02654028|Other|Control group|These group of patients will not receive autotransfusion before or after liver resection.
287775|NCT02669472|Behavioral|Control|We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
288075|NCT02662647|Drug|Decitabine 20 mg/m²/day for 5 days|
288076|NCT02662660|Drug|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
288077|NCT02664922|Drug|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
288078|NCT02664935|Drug|AZD4547|FGFR Inhibitor
288079|NCT02664935|Drug|AZD2014|MTORC1/2 Inhibitor
288080|NCT02664935|Drug|Palbociclib|CDK4/6 Inhibitor
288081|NCT00198770|Dietary Supplement|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
288082|NCT02664935|Drug|Crizotinib|ALK/MET/ROS1 Inhibitor
288083|NCT02664935|Drug|Selumetinib|MEK Inhibitor
288084|NCT02664935|Drug|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
288085|NCT02664935|Drug|AZD5363|AKT Inhibitor
288086|NCT02664935|Drug|AZD9291|EGFRm+ T790M+ Inhibitor
288087|NCT02664935|Drug|MEDI4736|Anti-PDL1
288088|NCT02664948|Procedure|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
288089|NCT02664961|Drug|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
288090|NCT02664961|Drug|Bevacizumab|Bevacizumab will be dosed every two weeks.
288091|NCT02664974|Dietary Supplement|Enteral nutrition|Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.
Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.
Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate.
288092|NCT00198796|Procedure|Dose-Finding Study of H10407 Enterotoxigenic E. Coli (ETEC) Challenge Strains|
287453|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3*10^8/kg/once.
287454|NCT02676856|Drug|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
287455|NCT02676856|Drug|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
287456|NCT00199147|Drug|Etoposide|
287457|NCT02676869|Drug|IMP321|Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks
287458|NCT02676869|Drug|Pembrolizumab|Administered according to the approved label.
287459|NCT02676882|Dietary Supplement|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
287460|NCT02676895|Biological|S. sonnei vaccine 25 μg|Two injections of the study vaccine will be administered 28 days apart.
287461|NCT02676895|Biological|S. sonnei vaccine 100 μg|Two injections of the study vaccine will be administered 28 days apart
287776|NCT02669485|Drug|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
287777|NCT00199030|Drug|Cladribine|
287778|NCT02671981|Radiation|Proton Beam Radiation Therapy|Undergo proton beam RT
287779|NCT02671994|Other|G8 screening|
287780|NCT02671994|Other|Geriatric assessment|
287781|NCT02672007|Device|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
287782|NCT02672020|Biological|omics identity card|
287783|NCT02672033|Radiation|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
287784|NCT02672033|Radiation|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
287785|NCT02672033|Other|Laboratory Biomarker Analysis|Correlative studies
287786|NCT02672033|Procedure|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
287182|NCT02646527|Behavioral|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
287183|NCT00196391|Drug|DR-2021c|1 capsule daily for 10 days
287184|NCT02646540|Drug|Tolvaptan 30 mg + IV Diuretics|Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
287185|NCT02646540|Drug|Metolazone 5 mg + IV Diuretics|Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
287462|NCT02676895|Biological|Menveo|One injection of Menveo will be administered in subjects in Group C
287463|NCT02676895|Biological|Boostrix|One injection of Boostrix will be administered in subjects in Group C
287464|NCT00199355|Drug|Istradefylline (KW-6002)|
287465|NCT02679040|Radiation|Radiation therapy|Radiation therapy
287466|NCT02679053|Behavioral|Aerobic exercise|
287467|NCT02679053|Behavioral|Placebo control|
287468|NCT02679066|Device|Sugar-tong splint|Plaster immobilization including the elbow
287469|NCT02679066|Device|Short forearm cast|Fiberglass immobilization with elbow free
287470|NCT02679079|Drug|NBI-98854|
287471|NCT02679079|Drug|Placebo|
287472|NCT02679092|Drug|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
287473|NCT02679092|Drug|Mifepristone|200 mg PO on the day prior to D&E
287474|NCT02679092|Device|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
287475|NCT00199368|Drug|Istradefylline ( KW-6002)|
287476|NCT02679105|Drug|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
287477|NCT02679105|Drug|ALK diluent|0,3% human albumin
292744|NCT02639910|Biological|MOR00208|For the first 3 months of the study, each 28-day cycle will consist of a MOR00208 intravenous infusion of the dose of 12 mg/kg administered weekly, thereafter, on a bi-weekly basis.
292745|NCT02639910|Drug|idelalisib|Idelalisib dose: Patients will self-administer the dose of 150 mg twice daily orally continuously during the study duration.
292746|NCT02639923|Procedure|Drawing of 7ml peripheral blood|puncture peripheral vein
292747|NCT02639949|Behavioral|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
292748|NCT02639949|Behavioral|Standard Care|
292749|NCT02639962|Radiation|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
292750|NCT00195559|Drug|Levonorgestrel/Ethinyl Estradiol|
292751|NCT02639975|Drug|PBF-677|once daily oral administration
292752|NCT02639975|Drug|Placebo|once daily oral administration
292753|NCT02640014|Dietary Supplement|Milk|Milk Oral immunotherapy
292754|NCT02642224|Behavioral|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
292755|NCT00195793|Drug|atorvastatin|
292756|NCT02642237|Biological|Fluenz|intranasal inoculation with Fluenz
293042|NCT02635295|Behavioral|Mobile cooperation during the clinical practicum|The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.
Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT.
293043|NCT02635308|Behavioral|Unilaterally Biased Resistance Training / "MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
293044|NCT02635334|Drug|Montelukast 10 mg orally|
293045|NCT02635334|Other|Placebo|
293046|NCT02635347|Procedure|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
292440|NCT02610842|Other|Handbook|The handbook named "Hands on" - a hand care guide in Systemic Sclerosis" contains instructions about the Systemic Sclerosis and hand exercises.
292441|NCT00192543|Behavioral|diet only|Fish and fruit
292442|NCT02610855|Procedure|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
292443|NCT02610855|Other|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
292444|NCT02610855|Device|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
292445|NCT02610855|Other|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
292446|NCT02610868|Drug|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
292447|NCT02610881|Dietary Supplement|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
292448|NCT02610881|Dietary Supplement|Micronutrient Powders (MNP)|One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:
Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base
292449|NCT02610881|Behavioral|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
292450|NCT02610894|Other|As usual with the Postoperative Care at Home mHealth application (PoCAH)|MHealth app, Postop Care at Home, is a theory based, patient-centered, and tailored self-management program delivered via mHealth technology (application on iPad mini) to orthopaedic ambulatory surgery patients.
292451|NCT02610894|Other|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
292452|NCT00192543|Behavioral|regular diet|no change in regular diet
292453|NCT02610894|Device|iPad mini|
292454|NCT02612935|Device|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
291854|NCT02623959|Drug|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
291855|NCT02623959|Drug|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
291856|NCT02623959|Other|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
292130|NCT02617238|Other|Cardiovascular risk management based on PWV|Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).
In the "PWV group", PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.
In the "conventional group", PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician
292131|NCT02617251|Other|No intervention|
292132|NCT02617264|Procedure|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
292133|NCT00193193|Drug|Carboplatin|
292134|NCT02617277|Drug|AZD1775|AZD1775 is available in capsules for oral administration.
292135|NCT02617277|Drug|MEDI4736|MEDI4736 will be administered by IV infusion.
292136|NCT02617290|Drug|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
292137|NCT02617290|Drug|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
292138|NCT02617303|Procedure|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 3 months and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
292139|NCT02617303|Procedure|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
292140|NCT02617316|Other|Barefoot|barefoot running test was 20 minutes.
292141|NCT02617316|Other|In shoes|In shoes test was 20 minutes.
292142|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
292143|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
286674|NCT02662101|Device|Exsalt SD7, Exsalt T7 Wound Dressing|
286675|NCT00198419|Drug|Vitrase|
286676|NCT02664376|Other|Sarcopenia detection|The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:
Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).
Walking speed measurement
Hand grip test
A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.
Data regarding the geriatric characteristics of this sarcopenic population will be collected.
286677|NCT02664389|Genetic|Genetic analysis|Sequencing of 200 selected genes in the different study populations
286678|NCT02664415|Biological|VRC01|40 mg/kg; administered IV
286679|NCT02664415|Biological|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
286680|NCT02664428|Dietary Supplement|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
286681|NCT00198718|Drug|Vitamin A (retinyl palmitate)|
286682|NCT02664428|Dietary Supplement|Control|A daily dose of about 90 gram will be given for 8 weeks
286683|NCT02664441|Drug|Exenatide|Weekly injections of active drug.
286684|NCT02664441|Drug|placebo|Weekly placebo injections
286685|NCT02664454|Other|health care organization|Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice
Interactive educational seminar Primary care
286686|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
286687|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
286688|NCT02664480|Other|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
286689|NCT02664493|Drug|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
286690|NCT02664506|Behavioral|Language Intervention|
286691|NCT02664519|Behavioral|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
286692|NCT00198731|Behavioral|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
286408|NCT02668809|Other|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
286409|NCT00198991|Procedure|Stem cell transplantation|
286410|NCT02668809|Other|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
286411|NCT02668809|Other|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
286412|NCT02668809|Other|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
286413|NCT02668809|Other|Varnish application|1% chlorhexidine varnish application group" will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish.
286414|NCT02671292|Other|Health Education|The HE group is based upon the "HEY-Durham" health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex.
286415|NCT02671305|Procedure|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
286416|NCT02671305|Procedure|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
286417|NCT02671318|Drug|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
286418|NCT02671318|Drug|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
286419|NCT02671331|Procedure|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
286420|NCT02671344|Other|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
285838|NCT02683148|Other|FACT-67 validated survey|Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2
7 questions with answers ranging from 0=Not At All to 4 = Very Much.
285839|NCT02648373|Other|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
285840|NCT02648386|Procedure|Laparoscopic surgery|Completely resected rectal tumor.
286127|NCT02676323|Drug|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m^2/dose over 30 minutes, daily for 5 days (days 8-12).
286128|NCT02676323|Drug|Cytarabine|Cytarabine will be given IV, 2 gram/m^2/dose over 4 hours, daily for 5 days (days 8-12).
286129|NCT02676323|Drug|Intrathecal Triples|Given intrathecally (IT).
286130|NCT02676323|Drug|Leucovorin|Leucovorin (5 mg/m^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
286131|NCT00000379|Behavioral|EMDR|
286132|NCT00002534|Procedure|allogeneic bone marrow transplantation|
286133|NCT00199095|Drug|Mercaptopurine|
286134|NCT02676336|Dietary Supplement|Violet™ Molecular Iodine (I2)|
286135|NCT02676336|Other|Placebo|
286136|NCT02676349|Drug|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
286137|NCT02676349|Radiation|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
286138|NCT02676349|Procedure|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
286139|NCT02676349|Drug|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
286140|NCT02676362|Other|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
286141|NCT02676375|Drug|Combination Bupropion + NRTs|
286142|NCT02676375|Other|Extended Treatment|
286143|NCT02678520|Radiation|3-D Conformal Radiation Therapy|Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.
The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily .
285573|NCT02655146|Drug|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
285574|NCT02655146|Drug|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
285575|NCT02655172|Other|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
285576|NCT02655172|Other|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
285577|NCT02655198|Drug|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
285578|NCT02655211|Procedure|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
285579|NCT02655211|Procedure|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
285841|NCT02648386|Device|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
285842|NCT02648386|Biological|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
285843|NCT02648386|Biological|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
285844|NCT02648399|Procedure|surgery：BCND（bilateral central lymph node dissection）|
285845|NCT00196586|Drug|ribavirin|
285846|NCT02648399|Procedure|surgery：UCND（unilateral central lymph node dissection）|
285847|NCT02648412|Drug|ketamine|bolus 1 mg/kg
285848|NCT02648412|Procedure|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
285849|NCT02648425|Drug|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
285850|NCT02648425|Drug|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
285851|NCT02648425|Drug|cisplatin + 5-fluorouracil (or+ Leucovorin)|Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;
Or
Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks.
285306|NCT02663778|Behavioral|Flexibility training|stretches to improve flexibility
285307|NCT02663778|Behavioral|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
285308|NCT02663778|Behavioral|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
285309|NCT02663817|Device|CT Scan|
285310|NCT02663830|Drug|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 8 hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
285311|NCT02663830|Drug|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
285312|NCT02663843|Device|i-gel airway|Fibreoptic intubation via i-gel airway device
285313|NCT02663843|Device|air-Q airway|Fibreoptic intubation via air-Q airway device
285314|NCT00198627|Drug|Co-Trimoxazole; TMP-SMZ|
285315|NCT02663856|Other|observational|Self assessment of ageing transition using a frailty index through MySAwH app
285316|NCT02663882|Behavioral|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
285580|NCT02655211|Other|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
285581|NCT02655224|Drug|TAK-385 40 mg|TAK-385 placebo tablets + TAK-385 40 mg tablets
285582|NCT02655224|Drug|TAK-385 placebo|TAK-385 placebo tablets + TAK-385 placebo tablets
285583|NCT02657291|Drug|Ropivacaine|Local anesthetic
285584|NCT02657291|Device|Ultrasound|Ultrasound guided block
285585|NCT02657304|Behavioral|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
285586|NCT02657304|Other|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
285587|NCT02657317|Behavioral|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
285019|NCT02598947|Other|Manual therapy|Exercise and manual therapy
285020|NCT02598960|Drug|BMS-986156|
285021|NCT02598960|Drug|Nivolumab|
285022|NCT00191334|Drug|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
285023|NCT02598973|Behavioral|Exercise|Aerobic walking
285024|NCT02598986|Dietary Supplement|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
285025|NCT02598999|Drug|ALX-009|Solution for inhalation administered through nebulization
285026|NCT02598999|Drug|OSCN-|Solution for inhalation administered through nebulization
285027|NCT02601092|Procedure|Roux-en-Y Gastric Bypass|This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a "Roux limb". In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.
No drugs or devices will be used.
285028|NCT02601105|Drug|Centella Asiatica|1% Centella Asiatica in lipoderm
285029|NCT02601105|Drug|Placebo Vehicle Cream|Lipoderm cream
285030|NCT02601118|Other|Micro Expression Training Tool|The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
285031|NCT02601131|Biological|Platelet transfusion|
285032|NCT02601144|Procedure|Deep Brain Stimulation|Deep Brain Stimulation
285033|NCT02601157|Device|CX-ISAR|Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
285034|NCT00191542|Drug|Placebo|
285035|NCT02601157|Device|Orsiro|Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, abluminal coatings with biodegradable polymer.
285036|NCT02601157|Drug|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
285317|NCT02663882|Behavioral|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
284725|NCT02605421|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC > 2000/μL for 3 consecutive days.
284726|NCT02605434|Drug|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
284727|NCT02605434|Drug|Sinemet®|Sinemet® tables containing carbidopa and levodopa 10/100 or 25/100 mg will be administered orally at least 4 times a day according to patients need
284728|NCT02605434|Drug|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
284729|NCT02605434|Drug|Placebo- Sinemet|Placebo for Sinemet tables
284730|NCT02605447|Drug|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
284731|NCT02605447|Device|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
284732|NCT00192023|Drug|placebo|
284733|NCT02605460|Drug|Busulfan|12mg/kg, ORAL, divided in 4 days, 3mg/kg/day ORAL, during days -7, -6, -5 y -4.
284734|NCT02605460|Drug|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
284735|NCT02605460|Drug|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
284736|NCT02605460|Procedure|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
284737|NCT02605473|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
284738|NCT02607930|Drug|ABC/DTG/3TC Placebo|Placebo to match ABC/DTG/3TC tablets administered orally, once daily, without regard to food
284739|NCT02607930|Drug|GS-9883/F/TAF|GS-9883/F/TAF (50/200/25 mg) tablets administered orally, once daily, without regard to food
284740|NCT02607943|Drug|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
284741|NCT02607943|Drug|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
284742|NCT02607956|Drug|DTG|DTG 50 mg tablets administered orally, once daily, without regard to food
284743|NCT02607956|Drug|F/TAF|F/TAF (200/25 mg) tablets administered orally, once daily, without regard to food
284744|NCT02607956|Drug|GS-9883/F/TAF Placebo|Placebo to match GS-9883/F/TAF administered orally, once daily, without regard to food
284434|NCT02578420|Other|deceptive placebo|Placebo Cream, described as "Voltaren, containing Diclofenac"
284435|NCT02578433|Behavioral|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
284436|NCT02578433|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
284437|NCT02578446|Device|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
284438|NCT00188851|Drug|therapeutic management strategy|
284439|NCT02578446|Device|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
284747|NCT02607956|Drug|F/TAF Placebo|Placebo to match F/TAF administered orally, once daily, without regard to food
284748|NCT02607956|Drug|GS-9883/F/TAF|GS-9883/F/TAF (50/200/25 mg) FDC tablets administered orally, once daily, without regard to food
284749|NCT02607969|Other|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
284750|NCT02607982|Drug|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
284751|NCT02607982|Drug|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
284752|NCT02607982|Radiation|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
284753|NCT02607995|Behavioral|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
284754|NCT02608008|Device|Data analysis|data parameters Analysis
284755|NCT02608034|Drug|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
284120|NCT02582801|Drug|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
284121|NCT02582814|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
284122|NCT02582814|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
284123|NCT02582827|Drug|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
284124|NCT00189488|Other|Conditioning Regimen|Each participant received 1 of the following conditioning regimens:
Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)
TBI/VP-16
Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)
Busulfan (Bu)/Cy
Bu/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])
Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])
284125|NCT02582840|Drug|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
284126|NCT02582840|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
284127|NCT02582840|Drug|Placebo tablet|Placebo tablet. Oral dose
284128|NCT02582853|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
284129|NCT02582853|Procedure|Blood Sample|Blood sample
284130|NCT02584894|Behavioral|psychoneurological assessment|psychoneurological assessment
284131|NCT02584894|Device|conductivity meter|electrodermal conductance measure
284132|NCT02584894|Device|electrocardiogram|heart rate measure
284133|NCT00189683|Procedure|Monitoring|
284134|NCT02584907|Other|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
284135|NCT02584920|Drug|HLX01|
284440|NCT02578459|Device|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
284441|NCT02578459|Other|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
284442|NCT02578472|Drug|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
288676|NCT02654041|Drug|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
288677|NCT02654054|Other|Placebo|Placebo for 6-month Treatment
288678|NCT02654054|Drug|Elagolix|Elagolix for 6-month Treatment
288679|NCT02654054|Drug|Elagolix + Estradiol/Norethindrone Acetate|Elagolix + Estradiol/Norethindrone Acetate for 6-month Treatment
288680|NCT02654067|Procedure|photograph|photograph of airway
288681|NCT02654080|Biological|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
288682|NCT00197236|Biological|Infanrix™|1 intramuscular injection
288683|NCT02654080|Biological|rVSV HIV envC vaccine|1 × 10^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
288684|NCT02654080|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%;
At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.
At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated).
288685|NCT02654093|Drug|Cholecalciferol|
288686|NCT02654093|Drug|Raloxifene|
288687|NCT02654093|Drug|Cholecalciferol and Raloxifene co-administration|
288688|NCT02654106|Radiation|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions＜2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
288689|NCT02654106|Drug|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2*5d, q28d, 6cycles
288690|NCT02654119|Drug|Cyclophosphamide|Given IV
288691|NCT02654119|Other|Laboratory Biomarker Analysis|Correlative studies
288692|NCT02654119|Drug|Paclitaxel|Given IV
288693|NCT00000378|Drug|Sertraline|12 week trial dose up to 200mgs
288694|NCT00002531|Drug|mercaptopurine|
288695|NCT00197236|Biological|ActHIB™|1 intramuscular injection
288696|NCT02654119|Biological|Trastuzumab|Given IV
288093|NCT02664974|Other|Dietary counseling|Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.
Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported.
288094|NCT02664987|Other|Patients receiving cancer pain treatment|
288095|NCT02665000|Procedure|Structured training programme|Participants will undergo 5-days training sessions
288397|NCT02658565|Procedure|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
288398|NCT02658578|Procedure|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
288399|NCT02658591|Dietary Supplement|Crackers with added faba bean protein concentrate|Protein concentrate treatment
288400|NCT02658591|Dietary Supplement|Crackers with added faba bean protein isolate|Protein isolate treatment
288401|NCT02658591|Dietary Supplement|Crackers with added faba bean starch|Starch treatment
288402|NCT02658591|Dietary Supplement|Crackers with added faba bean flour|Flour treatment
288403|NCT02660411|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
288404|NCT02660411|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
288405|NCT02660424|Drug|VX-150|
288406|NCT02660424|Drug|Placebo|
288407|NCT00198172|Drug|Cisplatin plus Epirubicin|
288408|NCT02660437|Other|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; ~30min).
288409|NCT02660450|Other|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
288410|NCT02660450|Other|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
287787|NCT02672046|Other|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
287788|NCT00199043|Drug|Allopurinol|
287789|NCT02672059|Other|Observation|No intervention
287790|NCT02672072|Other|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
287791|NCT02672072|Other|questionnaire to define the presence of job strain at 6 months|
287792|NCT02672072|Other|questionnaire to define the presence of job strain at 12 months|
287793|NCT02672085|Procedure|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
287794|NCT02672085|Procedure|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
287795|NCT02672098|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
287796|NCT02672098|Drug|Carboplatin|Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.
a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C).
287797|NCT02672111|Drug|CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)|
288096|NCT02665013|Behavioral|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
288097|NCT02665013|Behavioral|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
288098|NCT02665026|Procedure|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
288099|NCT02667145|Other|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
287478|NCT02679118|Device|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
287479|NCT02679131|Drug|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
287480|NCT02679144|Drug|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study.
287481|NCT02679170|Drug|Crizotinib|Treatment with crizotinib following routine clinical practice
287482|NCT02679183|Dietary Supplement|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
287483|NCT02679183|Other|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
287484|NCT02679196|Drug|KA2237|PI3 Kinase p110β/δ inhibitor
287485|NCT02679209|Biological|Bone allograft|it is a type of bone graft from human cadavers.
287798|NCT02672111|Drug|CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)|
287799|NCT00199043|Drug|Rasburicase|
287800|NCT02672137|Behavioral|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
287801|NCT02672150|Behavioral|Core|
287802|NCT02672150|Behavioral|Enhanced|
287803|NCT02672163|Procedure|CABG surgery|Elective CABG surgery
287804|NCT02674568|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
287805|NCT02674581|Drug|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529|
287806|NCT02674607|Dietary Supplement|Spirulina|
287807|NCT02674620|Other|Aerobic Exercise|Patients are treated with progressive exercise
287808|NCT02674633|Device|EVO|videogame-like digital therapy
287809|NCT02674646|Radiation|Radiotherapy|Radiation as indicated by the cancer diagnosis
287810|NCT02674646|Device|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
293047|NCT00195013|Drug|glutamine|10 grams three times a day (orally) for four days and then stop
293048|NCT02635347|Device|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
293049|NCT02635360|Drug|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
293050|NCT02635360|Radiation|Brachytherapy|Radiation is done for standard clinical care purposes.
293051|NCT02635360|Drug|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
293052|NCT02635386|Drug|Exenatide once weekly (EQW )|2 mg SC injection every 7 days
293053|NCT02635386|Drug|Dapagliflozin (DAPA)|One pill (10 mg) by mouth daily (QD) in am
293054|NCT02635386|Drug|EQW plus DAPA|2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
293055|NCT02635386|Drug|Dapagliflozin plus Glucophage (MET ER)|DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
293056|NCT02635386|Drug|Phentermine /Topiramate (PHEN/ TRP) ER|PHEN 3.75/TRP ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TRP ER 46mg- 1 pill by mouth once daily in am
293057|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
293058|NCT00195013|Drug|Placebo|10 grams three times a day (orally) for four days and then stop
293059|NCT02637713|Procedure|Radiofrequency energy to the LES|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter it is approved for the management of GRED.
293060|NCT02637726|Drug|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
293328|NCT02631044|Biological|JCAR017 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017. Participants who respond to treatment but who have not achieved a complete response (CR) may receive additional cycles of study treatment on the dose and schedule to which they were initially assigned.
293329|NCT02631057|Drug|Dabigatran|Dabigatran 110 mg coupsle twice a day or 75 mg x 2 capsles twice a day
293330|NCT02631057|Drug|Wafrarin|Warfarin tablet (adjustment by each patients)
293331|NCT02631070|Drug|Luspatercept|
293332|NCT02631070|Other|Placebo|
292455|NCT02612948|Drug|Quetiapine|escalating dose to prevent delerium.
292456|NCT02612961|Other|3mL of normal saline from the pink sodium chloride bullet|
292757|NCT02642237|Other|placebo|
292758|NCT02642237|Other|LPS|
292759|NCT02642250|Drug|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
292760|NCT02642250|Drug|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
292761|NCT02642263|Drug|Carbetocin|Postpartum uterotonic drug
292762|NCT02642276|Other|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
292763|NCT02642289|Dietary Supplement|Lactobacillus acidophilus|Probiotic 5000, a commercial probiotic product provided by the company "Complementos Fitonutricionales, S.L."
292764|NCT02642289|Dietary Supplement|Lactobacillus Rhamnosus GG ®|Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab "Laboratorios Nutergia"
292765|NCT02642289|Other|Placebo|Innocuous substance
292766|NCT00195806|Drug|divalproex sodium|
292767|NCT02642302|Behavioral|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
292768|NCT02642302|Behavioral|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
292769|NCT02642302|Behavioral|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
292770|NCT02642315|Drug|Horizant|Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 30, 60 and 90) during Phase I.
Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360).
292771|NCT02642328|Other|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
292144|NCT00193206|Drug|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
292145|NCT02617342|Behavioral|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
292146|NCT02617355|Device|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
292147|NCT02619604|Other|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
292457|NCT02612961|Other|Sham Comparator of 3mL normal saline|
292458|NCT02612974|Biological|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
292459|NCT02612987|Behavioral|Internet-based Cognitive Behaviour Therapy (iCBT)|
292460|NCT02613000|Other|No intervention|
292461|NCT02613013|Device|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
292462|NCT02613013|Device|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
292463|NCT02613013|Drug|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
292464|NCT00192686|Procedure|culture a.m. Kamme-Lindberg|
292465|NCT02613013|Procedure|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
292466|NCT02613013|Drug|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
292467|NCT02613013|Procedure|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
292468|NCT02613026|Drug|Pirarubicin|
286963|NCT02657993|Behavioral|Attention Control|The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.
Participants will be asked to complete questionnaires over a period of 12 months.
286964|NCT02658006|Procedure|Cardiac surgery|All cardiac surgery procedures
286965|NCT02658019|Drug|Pembrolizumab|
286966|NCT02659852|Procedure|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
286967|NCT02659865|Drug|Placebo|Administered orally
286968|NCT02659865|Drug|LY3039478|Administered orally
286969|NCT00198107|Drug|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 mg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
286970|NCT02659878|Procedure|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
286971|NCT02659891|Biological|IVIg|
286972|NCT02659891|Other|Placebo|
286973|NCT02659904|Other|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
286974|NCT02659904|Other|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
286975|NCT02659917|Other|Glass ionomer|Application of preventive agent
286976|NCT02659917|Other|Glass ionomer cement|Application of preventive agent
286977|NCT02659917|Other|-Glass ionomer-|Atraumatic Restorative Treatment
286978|NCT02659917|Other|-Glass ionomer cement-|Atraumatic Restorative Treatment
286979|NCT02659930|Drug|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
286421|NCT02671357|Procedure|Roux-en-Y gastro-enterostomy|Minimally invasive pancreaticoduodenectomy with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
286693|NCT02664532|Other|Miller group|Miller blade was used for laryngoscopy
286694|NCT02664532|Other|Macintosh group|Macintosh blade was used for laryngoscopy
286695|NCT02664558|Drug|ubenimex|
286696|NCT02664558|Other|placebo|
286697|NCT02664571|Device|Pet scan with FBB|Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.
Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself.
286698|NCT02664571|Device|MRI scan|Subjects will have an MRI scan at inclusion.
286699|NCT02664571|Biological|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
286700|NCT02666586|Other|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
286701|NCT02666599|Radiation|18F-FDG PET/CT|A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.
Resected pieces will be analysed histologically.
286702|NCT02666612|Procedure|Blood samples|
286703|NCT02666625|Procedure|saliva samples|
286704|NCT02666625|Procedure|blood samples|
286705|NCT02666638|Other|Control Volunteers|MRI on up to a 7T scanner without contrast.
286706|NCT02666638|Other|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
286707|NCT02666651|Drug|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
286708|NCT02666651|Other|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
286709|NCT00198965|Behavioral|dietary education and provided fat free snack foods|
286710|NCT02666664|Drug|ETC-1002|ETC-1002 180 mg tablets taken orally, once per day, in the morning. Patients remain on ongoing statin therapy (not study provided)
286144|NCT02678520|Radiation|Intensity Modulated Radiation Therapy|Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.
The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily .
286145|NCT02678520|Drug|Casodex, Zoladex , Lupron|Hormonal Therapy (6 Months): Required for "High Risk" Groups, and as per Standard of Care for "Low Risk" Groups.
Hormonal therapy protocol regimen for the high risk "adjuvant" and "salvage" groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.
Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months.
286146|NCT02678533|Drug|G-CSF and Plerixafor|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization) and an injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
286422|NCT02671357|Procedure|Iso-peristaltic gastro-enterostomy|Minimally invasive pancreaticoduodenectomy with stented pancreatic-gastrostomy & in-line iso-peristaltic gastro-enterostomy (Iso-GES)
286423|NCT00199017|Drug|Adriamycin|
286424|NCT02671370|Other|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
286425|NCT02671383|Drug|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
286426|NCT02671383|Drug|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
286427|NCT02671396|Behavioral|Virtual reality based intervention|Virtual reality based balance training
286428|NCT02671396|Behavioral|Conventional intervention|Conventional balance training
286429|NCT02671409|Other|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
286430|NCT02671435|Drug|Intervention|Biological: Durvalumab Biological: IPH2201
286431|NCT02673918|Other|Home-based upper-body rehabilitation with online support|Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.
On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes.
285852|NCT02648438|Drug|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
285853|NCT02648438|Drug|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
285854|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
285855|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
285856|NCT00196599|Drug|emtricitabine, FTC (drug)|
285857|NCT02648438|Drug|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
285858|NCT02648451|Dietary Supplement|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
285859|NCT02648464|Drug|Hydroxychloroquine|
285860|NCT02648464|Drug|Placebo|
286147|NCT02678546|Other|Other|case review of diagnosed disease
286148|NCT00199277|Drug|i.v. iron sucrose|
286149|NCT02678559|Other|tee measurement|
286150|NCT02678559|Other|flotrac measurement|
286151|NCT02678559|Other|clearsight measurement|
286152|NCT02678572|Procedure|Melphalan|Melphalan (3 mg/kg IBW) with PHP
286153|NCT02678572|Procedure|TACE|Transarterial chemoembolization is a procedure in which the blood supply to a tumor is blocked (embolized) and chemotherapy is administered directly into the tumor.
286154|NCT02678572|Drug|Dacarbazine|Dacarbazine is to be administered at 250 mg/m2 of body surface area/day given IV for 5 days, with treatment repeated every 3 weeks.
286155|NCT02678572|Drug|Ipilimumab|Ipilimumab is to administered at 3 mg/kg IV over 90 minutes every 3 weeks for a total of 4 treatments.
286156|NCT02678572|Drug|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg as an IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
286157|NCT02678585|Drug|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
285588|NCT02657317|Other|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
285589|NCT02657330|Drug|SBP-101|Subcutaneous drug, escalating dose cohorts
285590|NCT02657343|Drug|Ribociclib|
285591|NCT00197730|Drug|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
285592|NCT02657343|Drug|T-DM1|
285593|NCT02657343|Drug|Trastuzumab|
285594|NCT02657356|Drug|Placebo capsules|
285595|NCT02657356|Drug|Bardoxolone methyl capsules|
285596|NCT02657369|Drug|Lenvatinib 24 mg|
285597|NCT02657382|Behavioral|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
285861|NCT02648477|Drug|Anastrozole|Given PO
285862|NCT02648477|Drug|Doxorubicin Hydrochloride|Given IV
285863|NCT02650661|Behavioral|Standard health educational booklet|Standard health educational booklets about "10 Rules for Highly Effective Health Behavior" that are organized according to the Trans-theoretical Model (TTM).
Booklets are provided at 0-, 2-, and 4-month after the enrollment.
285864|NCT02650674|Other|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
285865|NCT02650674|Other|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
285866|NCT02650674|Other|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
285867|NCT02650674|Other|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
285868|NCT02650674|Other|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
285869|NCT02650674|Other|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
285318|NCT02663895|Drug|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
285319|NCT02663908|Drug|Degarelix|
285320|NCT02663908|Drug|Leuprolide|
285321|NCT02663921|Other|Part A: Baseline-Week 2|The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:
Immediately after the light exposure;
30 minutes after light exposure; and
1 hour after light exposure.
285322|NCT02663921|Other|Part B: Week 4-Week 12|The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography
Visual Clinical Assessment
Spectroscopy
Colorimetry
285323|NCT02666118|Procedure|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
285324|NCT02666118|Procedure|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
285325|NCT02666131|Drug|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
285326|NCT02666131|Drug|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
285327|NCT02666144|Device|Spectralis OCT|Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
285328|NCT02666157|Drug|Dabigatran etexilate|this drug is administered twice per day for the entire study period
285329|NCT02666157|Drug|Rivaroxaban|this drug is administered once per day for the entire study period
285330|NCT00198926|Behavioral|varying meal nutrition manipulation|
285331|NCT02666157|Drug|Apixaban|this drug is administered twice per day for the entire study period
285332|NCT02666170|Drug|Alpha-lipoic acid|
284745|NCT02607956|Drug|DTG Placebo|Placebo to match DTG administered orally, once daily, without regard to food
284746|NCT00192283|Biological|CAIV-T|The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
285037|NCT02601157|Drug|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
285038|NCT02601170|Biological|Platelet-Rich Plasma Intra-Articular Injection|
285039|NCT02601170|Drug|Hyaluronic Acid Viscosupplementation|
285040|NCT02601196|Drug|Ulipristal acetate|Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.
Another IVF cycle.
285041|NCT02601209|Other|Laboratory Biomarker Analysis|Correlative studies
285042|NCT02601209|Drug|Pazopanib Hydrochloride|Given PO
285043|NCT02601209|Drug|Sapanisertib|Given PO
285044|NCT02601222|Drug|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
285045|NCT00191555|Drug|olanzapine|
285046|NCT02601222|Drug|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
285047|NCT02601222|Drug|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
285048|NCT02601235|Drug|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
285049|NCT02601235|Drug|oxymetazoline hydrochloride|2 pumps in each nostril every 12 hours.
285050|NCT02603367|Other|Psychosocial Support for Caregiver|Undergo communication coaching
285051|NCT02603367|Other|Questionnaire Administration|Complete questionnaires
285052|NCT02603380|Other|No intervention|This is an observational study. No intervention will be given.
285053|NCT02603393|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
285054|NCT02603393|Drug|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
284756|NCT02608034|Drug|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
284757|NCT00192283|Other|Placebo|A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
284758|NCT02609932|Drug|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
284759|NCT02609945|Drug|zolmitriptan|Oral Tablet and Nasal Spray
284760|NCT02609945|Drug|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
284761|NCT02609958|Drug|ASLAN001|ASLAN001 tablets at 500mg BID
284762|NCT02609971|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
285059|NCT00191750|Drug|Pemetrexed|
285060|NCT02603419|Biological|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
285061|NCT02603419|Biological|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
285062|NCT02603419|Biological|Avelumab|Anti-PD-L1 antibody at X4 mg/kg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
285063|NCT02603432|Biological|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
285064|NCT02603432|Other|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
285065|NCT02603445|Drug|BCL201|
285066|NCT02603445|Drug|Idelalisib|
285067|NCT02603458|Drug|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
285068|NCT02603458|Drug|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
285069|NCT02603471|Other|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
284443|NCT02578472|Drug|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
284444|NCT02578472|Drug|Placebo|Matching Placebo will be administered orally.
284445|NCT02578485|Device|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
284446|NCT02578485|Device|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
284447|NCT02578485|Device|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
284448|NCT02578485|Device|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
284449|NCT00188864|Drug|dexamethasone|
284450|NCT02578485|Device|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
284451|NCT02578498|Dietary Supplement|High carbohydrate intake|Carbohydrate intake < 50 gram
284452|NCT02578498|Dietary Supplement|Low carbohydrate intake|Carbohydrate intake > 250 gram
284453|NCT02578511|Drug|Ixazomib|
284454|NCT02580630|Drug|Ultrasound guided injection|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon is below 7 mm in thickness determined by ultrasound scanning (max 3 injections).
Half of the patients will have an injection of 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. The other half wil have an injection of 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding).
284455|NCT02580643|Biological|APS|intra-articular injection
284456|NCT00189150|Drug|Valganciclovir|
284457|NCT02580656|Behavioral|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
284763|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
284764|NCT02609984|Biological|CMB305|CMB305 is a sequential combination of two investigational study agents, LV305 and G305, with each agent given at different times over several weeks or months.
288697|NCT02654132|Drug|Elotuzumab|
284136|NCT02584920|Drug|Rituximab|
284137|NCT02584933|Drug|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
284138|NCT02584946|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
284139|NCT02584959|Drug|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor [Human] Liquid administered Subcutaneously as specified on specified days
284140|NCT02584972|Other|no intervention required|no intervention required
284141|NCT02584985|Procedure|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
284142|NCT02584985|Procedure|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
284143|NCT02584998|Other|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is ≥100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
284144|NCT00002514|Procedure|autologous bone marrow transplantation|
284145|NCT00189683|Procedure|Xeloda|
284146|NCT02584998|Other|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
284147|NCT02585011|Drug|Ropivacaine|
284148|NCT02585011|Drug|Epinephrine|
284149|NCT02585011|Drug|Saline|
284150|NCT02585024|Drug|Cytisine|
284151|NCT02585037|Other|Kinesio Taping® bandage|The Kinesio Taping® bandage will be applied in an "I" format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups.
284152|NCT02585037|Other|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
284153|NCT02585037|Other|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
284154|NCT02585076|Other|Standard of care|As prescribed by treated physician
288411|NCT02660450|Other|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
288412|NCT02660463|Other|Registration of the diagnosis "CTEPH"|Registration of risk factors for thromboembolic events
288413|NCT02660489|Drug|OC459|
288414|NCT02660489|Drug|Placebo|
288415|NCT02660489|Other|Rhinovirus|Inoculation with rhinovirus serotype 16
288416|NCT02660502|Drug|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
288698|NCT02654132|Drug|Pomalidomide|
288699|NCT02654132|Drug|Dexamethasone|
288700|NCT02654145|Drug|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
288701|NCT02656368|Device|SEBORRHEAMEDIS Face Cream|SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
288702|NCT02656394|Drug|GL101|Topical Gel
288703|NCT02656394|Drug|Placebo|Placebo topical gel
288704|NCT02656407|Device|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
288705|NCT02656420|Drug|Broccoli Sprout Powder|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebo.
288706|NCT02656433|Device|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
288707|NCT02656433|Other|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
288708|NCT00197613|Drug|(C) zidovudine, didanosine, and nevirapine|
288709|NCT02656446|Device|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
288710|NCT02656446|Device|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
288711|NCT02656459|Other|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
288100|NCT02667158|Other|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
288101|NCT02667171|Behavioral|Supervised COPD Rehabilitation (control group)|The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).
Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises.
288102|NCT02667171|Behavioral|Online COPD rehabilitation (experimental)|Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.
Educations consists same information as for the control group.
288103|NCT02667184|Dietary Supplement|Low FODMAP Oral Nutrition Supplement|
288104|NCT02667197|Other|Algorithm to determine overdose from opioid abuse|
288105|NCT00198978|Drug|Methotrexate|
288106|NCT02667210|Other|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
288107|NCT02667223|Biological|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
288108|NCT02667223|Biological|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
288417|NCT02660502|Drug|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
288418|NCT00198185|Procedure|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
288419|NCT02660502|Drug|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
288420|NCT02660502|Drug|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
288421|NCT02660515|Procedure|Additional wrist arthroscopy|
288422|NCT02660515|Procedure|ORIF|
288423|NCT02660528|Drug|Tocilizumab|Subcutaneous tocilizumab
288424|NCT02660541|Device|Betafoam|Comparison between 2 medical devices
288425|NCT02660541|Device|Allevyn Silver Dressing|Comparison between 2 medical devices
287811|NCT00199069|Drug|VM26|
287812|NCT02674659|Behavioral|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session will be held for around 15 minutes.
287813|NCT02674659|Behavioral|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
287814|NCT02674672|Device|VenaTech® (VenaTech Retrievable Filter)|
287815|NCT02674698|Other|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
287816|NCT02674698|Other|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
287817|NCT02674698|Other|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
287818|NCT02674698|Other|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
287819|NCT02674711|Behavioral|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
288109|NCT02667223|Biological|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
288110|NCT02667223|Biological|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to hypercholesterolemic subjects receiving a statin
288111|NCT02667223|Biological|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
288112|NCT02667236|Drug|A-101 Solution|Active Drug
288113|NCT02667236|Other|Vehicle Solution|Placebo
288114|NCT02667249|Other|clinical pathway|implementation of a standardized clinical pathway
288115|NCT02667262|Other|Algorithm to identify patients experiencing opioid abuse/addiction|
288116|NCT00198978|Drug|Rituximab|
288117|NCT02667275|Drug|A-101 Solution|
288118|NCT02667275|Other|Vehicle Solution|Placebo
288119|NCT02669485|Device|Fluorescence imaging|
293333|NCT02631083|Other|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
293334|NCT00002524|Drug|Methylprednisolone|
293335|NCT00194675|Drug|Dutasteride|Dutasteride 0.5 mg orally daily
293336|NCT02631096|Drug|ARB-001467|An IV infusion of ARB-001467 once a month for three months.
293337|NCT02631096|Other|Placebo|An IV infusion of placebo once a month for three months.
293338|NCT02631109|Drug|Pegaspargase|2000U/m2 day5
293339|NCT02631109|Drug|doxorubicin|25mg/m2 day1
293340|NCT02631109|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
293341|NCT02631109|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
293342|NCT02631122|Procedure|Supraclavicular vs Retroclavicular Nerve Block|An ultrasound guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% mepivicaine will be performed on patients scheduled for lower arm surgery
293343|NCT02631135|Drug|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
293344|NCT02631135|Drug|Propofol|BIS values were arranged 40-60 until the end of operation
293345|NCT02631135|Drug|Dexmedetomidine|0.5 microgram/kg infusion, no changes
293346|NCT00194675|Drug|Testosterone gel|Testosterone gel 7.5 g daily topical
293347|NCT02633176|Drug|Cetuximab|400 mg/m^2 intravenously on day 1,then 250 mg/m^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m^2 intravenously every week concurrent with radiotherapy.
293348|NCT02633176|Drug|Cisplatin|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m^2 intravenously every week concurrent with radiotherapy.
293349|NCT02633176|Drug|Docetaxel|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
293632|NCT02626767|Other|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
293633|NCT02626780|Device|GID SVF-2|Comparison of the number and thickness of hair before and after treatment of autologous adipose-derived SVF.
293634|NCT02626819|Behavioral|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
292772|NCT02642328|Other|Control|Continuous aerobic exercise at 65% of VO2Max
292773|NCT02642367|Device|McGrath videolaryngoscope|without use of stylet
293061|NCT00195299|Drug|Temsirolimus|
293062|NCT02637726|Drug|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
293063|NCT02637726|Drug|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
293064|NCT02637726|Device|EEG Monitoring|Maintaining a bispectral index between 45 and 55
293065|NCT02637726|Drug|Remifentanil|Remifentanil at discretion of the anesthesiologist
293066|NCT02637739|Device|hysteroscope|Women of PUL with β-hCG > 1000 IU/L or abnormal β-hCG trend (increase < 66% or decrease < 15%) were offered HSC.
293067|NCT02637752|Behavioral|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
293068|NCT02637765|Behavioral|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
293069|NCT02637778|Dietary Supplement|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
293070|NCT02637778|Dietary Supplement|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
293071|NCT02637791|Device|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
293072|NCT00195312|Biological|HIV-1 gag DNA (formulated with bupivacaine)|
292469|NCT02613026|Drug|Docetaxel|
292470|NCT02613026|Drug|Cyclophosphamide|
292471|NCT02613039|Drug|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
292472|NCT02613052|Drug|normal saline|10 mL of normal saline agitated prior to IV administration
292473|NCT02613052|Drug|human albumin|10 mL of 5% albumin agitated prior to IV administration
292474|NCT02613052|Drug|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
292475|NCT00192699|Device|Bimetric femoral stem|Cemented Bi-Metric femoral stem
292774|NCT02644434|Procedure|Conventional Strategy|Jailed wire technique: Coronary guidewires are passed to the main vessel and the side branch. The main and side vessels are pretreated at the operator's discretion. The main vessel is stented with wire protection of the side branch. The side branch is not treated further unless there is Thrombolysis In Myocardial Infarction (TIMI) flow grade decrease in the side branch, severe ostial pinching of the side branch (>90%), threatened side-branch vessel closure, or side-branch vessel dissection greater than type A.
Provisional two-stent strategy: Both vessels are wired, with lesion preparation and Main Vessel (MV) stenting as for the jailed wire technique. T stenting of the side branch could be undertaken if the results of side branch is not satisfied.
292775|NCT02644434|Procedure|Intentional strategy|Jailed balloon technique: The technique has been detailed in previous studies. A monorail balloon that is angiographically sized to approximate the Side Branch (SB) vessel diameter is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard kissing balloon technique no matter there is SB compromise or not.
Primary two-stent strategy: Patients in this subgroup would undergo crush procedure or any other primary two-stent strategy which stenting SB before MV stenting.
292776|NCT02644447|Biological|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
292777|NCT02644447|Biological|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
292778|NCT02644460|Drug|Abemaciclib|
292779|NCT02644473|Drug|Tranexamic Acid|
292780|NCT00196118|Device|Günther Tulip Vena Cava Filter|
292781|NCT02644473|Drug|Normal saline|Control
292782|NCT02644486|Drug|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
292783|NCT02644486|Drug|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
286980|NCT00198107|Drug|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
287257|NCT02655770|Drug|Liraglutide|
287258|NCT00197522|Biological|CD34+ derived DCs|
287259|NCT02655770|Drug|Placebo|
287260|NCT02655783|Other|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
287261|NCT02655783|Other|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
287262|NCT02655796|Device|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
287263|NCT02655809|Radiation|Fluoroscopic examination|
287264|NCT02655822|Drug|CPI-444|100 mg orally twice daily for the first 14 days of each 28-day cycle.
287265|NCT02655822|Drug|CPI-444|100 mg orally twice daily for 28 days of each 28-day cycle.
287266|NCT02655822|Drug|CPI-444|200 mg orally once daily for the first 14 days of each 28-day cycle.
287267|NCT02655822|Drug|CPI-444 + atezolizumab|CPI-444 orally in combination with atezolizumab intravenously.
287268|NCT02655835|Behavioral|Internet Mindfulness Meditation|
287269|NCT00197548|Dietary Supplement|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
287270|NCT02655835|Behavioral|Access|
287271|NCT02655848|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
287272|NCT02655848|Procedure|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
287273|NCT02655848|Procedure|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
287274|NCT02655861|Other|Observation|
287275|NCT02655874|Biological|Influenza vaccine|Administered at day 1
287276|NCT02655874|Biological|Influenza vaccine|Administered at day 180
286711|NCT02666664|Drug|Placebo|Matching placebo tablets taken orally, once per day, in the morning. Patients remain on ongoing statin therapy (not study provided)
286712|NCT02666690|Device|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
286713|NCT02666703|Device|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
286981|NCT02659930|Drug|pomalidomide|pomalidomide once a day, days 1- 21 of a 28-day cycle, at the dose levels described in dose escalation plan
286982|NCT02659943|Biological|Anti-CD19-CAR T cells|Dose-escalation trial starting dose: 0.66x106 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
286983|NCT02659943|Drug|Cyclophosphamide|300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3
286984|NCT02659943|Drug|Fludarabine|30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
286985|NCT02659995|Other|No intervention|No interventions will be performed on these patients.
286986|NCT02660008|Drug|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
286987|NCT02660008|Drug|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
286988|NCT02660034|Biological|BGB-A317|
286989|NCT02662114|Other|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
286990|NCT02662127|Device|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
286991|NCT02662140|Behavioral|Mobile Health Applictaion|Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the "Design" and "Do" process of HW.
Component 2: Focuses on targeting factors putative related to poor HW implementation within the "Do" process
286992|NCT02662153|Other|Database review to evaluate opioid overdose and death|Database review to evaluate opioid overdose and death
286993|NCT02662166|Device|MR imaging|3 T MRI of the urinary bladder
286994|NCT02662179|Other|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
286432|NCT02673931|Drug|Byetta (Lilly, Exenatide)|See description of arms
286433|NCT02673931|Drug|Conoxia (AGA, oxygen)|See description arms
286434|NCT02673931|Drug|20% Human Albumin|
286435|NCT02673944|Device|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
286436|NCT02673957|Other|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
286437|NCT02673983|Procedure|Endoscopic full-thickness biopsy|
286438|NCT00199069|Drug|Daunorubicin, Adriamycin|
286439|NCT02673996|Drug|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
286714|NCT02666703|Drug|Methylprednisolone|
286715|NCT02666716|Drug|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
286716|NCT02666729|Procedure|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
286717|NCT02666729|Procedure|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
286718|NCT02666742|Drug|Apixaban|Apixaban is a blood thinning drug, also called an anticoagulant. Apixaban is approved by the U.S. Food and Drug Administration (FDA) for the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
286719|NCT02666742|Drug|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
286720|NCT00198978|Drug|Cyclophosphamide|
286721|NCT02666768|Drug|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
286722|NCT02668809|Other|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
286723|NCT02668809|Other|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
286158|NCT02678585|Drug|Lidocaine|53 patients received intravenous regional lidocaine
286159|NCT00199277|Drug|Oral iron|
286160|NCT02678598|Drug|Micafungin|Intravenous
286161|NCT02678611|Dietary Supplement|Basis 250|
286162|NCT02678611|Dietary Supplement|Basis 500|
286163|NCT02678611|Dietary Supplement|Placebo|
286164|NCT02680873|Other|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
286165|NCT00199680|Procedure|PET|
286166|NCT02680886|Device|Novosyn® Quick|Skin closure
286167|NCT02680899|Behavioral|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
286440|NCT02673996|Drug|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
286441|NCT02674009|Drug|Vismodegib|Dosing of Vismodegib in accordance with local clinical practice and local labeling
286442|NCT02674022|Dietary Supplement|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
286443|NCT02674035|Procedure|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
286444|NCT02674048|Other|Metvix|
286445|NCT02674061|Biological|pembrolizumab|IV infusion
286446|NCT02674074|Device|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
286447|NCT02674100|Other|Registry|
286448|NCT02674113|Drug|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
285870|NCT00196820|Drug|Capecitabine|
285871|NCT02650687|Procedure|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
285872|NCT02650700|Radiation|spleen radiation|In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
285873|NCT02650713|Drug|Atezolizumab|Atezolizumab will be administered 1200 mg fixed dose IV on Day 1 of each cycle.
285874|NCT02650713|Drug|RO6958688|RO6958688 will be administered by IV infusion at least one hour after the end of infusion of atezolizumab, on Day 1, Day 8 and Day 15 of each cycle.
285875|NCT02650726|Dietary Supplement|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
285876|NCT02650726|Other|Placebo|placebo 320mg daily for 24 weeks
285877|NCT02650739|Procedure|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
285878|NCT02650752|Drug|Lapatinib in Tandem With Capecitabine|
285879|NCT02650765|Other|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
285880|NCT02650778|Procedure|Breast ultrasound|automated whole breast ultrasound
285881|NCT00196846|Drug|Goserelin|
285882|NCT02650791|Drug|Tranexamic Acid|
286168|NCT02680912|Device|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
286169|NCT02680912|Device|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
286170|NCT02680925|Procedure|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
286171|NCT02680925|Procedure|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
285598|NCT02657382|Other|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
285599|NCT02657395|Device|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
285600|NCT02657408|Drug|BI 1026706|
285601|NCT02657408|Drug|Placebo|
285602|NCT00197743|Dietary Supplement|Vitamin A + Beta Carotene|one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
285603|NCT02657421|Procedure|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
285604|NCT02659410|Other|Heat stress (21) + TOL|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
285605|NCT02659410|Other|Heat stress (21) + ACE|4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
285606|NCT02659410|Other|Heat stress (25) + ACE|4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
285607|NCT02659410|Other|Heat stress (30) + ACE|4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
285608|NCT02659410|Other|Heat stress (21) + DCM|4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
285609|NCT00198016|Device|Coil|
285610|NCT02659410|Other|Heat stress (25) + DCM|4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
285611|NCT02659410|Other|Heat stress (30) + DCM|4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
285612|NCT02659410|Other|Heat stress (21) + TOL (dermal)|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
285613|NCT02659410|Other|Heat stress (25) + TOL (dermal)|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
285614|NCT02659410|Other|Heat stress (30) + TOL (dermal)|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
285615|NCT02659423|Behavioral|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
285055|NCT02603393|Drug|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
285056|NCT02603406|Drug|erythropoietin|
285057|NCT02603419|Biological|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
285058|NCT02603419|Biological|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
285333|NCT02666183|Behavioral|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
285334|NCT02666183|Behavioral|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
285335|NCT02666183|Behavioral|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
285336|NCT02666196|Drug|DAA-I|
285337|NCT02666196|Drug|Placebo|
285338|NCT02666209|Drug|Ulocuplumab|
285339|NCT02666209|Drug|Lenalidomide|
285340|NCT02666209|Drug|Bortezomib|
285341|NCT00198939|Behavioral|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
285342|NCT02666209|Drug|Dexamethasone|
285343|NCT02668276|Other|Standard NCCN counseling and Oncotype DX results|
285344|NCT02668289|Other|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
285345|NCT02668289|Other|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
285346|NCT02668289|Other|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
285347|NCT00198991|Drug|VP16|
285348|NCT02668289|Other|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
285070|NCT00191763|Drug|Gemcitabine|
285071|NCT02603471|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
285072|NCT02603497|Drug|ASP015K|oral
285073|NCT02603510|Drug|SAR342434|Pharmaceutical form:solution
Route of administration: subcutaneous
285074|NCT02605473|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
285075|NCT02605486|Drug|Palbociclib|
285076|NCT02605486|Drug|Bicalutamide|
285077|NCT02605499|Other|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
285078|NCT02605512|Other|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
285353|NCT02668289|Other|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
285354|NCT02668302|Device|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370μg of mometasone furoate designed for gradual release over 30 days
285355|NCT02668302|Other|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
285356|NCT02668315|Biological|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
285357|NCT02668328|Behavioral|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
285358|NCT00198991|Drug|Prednisolone|
285359|NCT02668341|Other|non-interventional|non-interventional survey study
285360|NCT02668367|Drug|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
285361|NCT02668367|Drug|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
285362|NCT02668393|Drug|Docetaxel|
284765|NCT02609984|Biological|atezolizumab|Atezolizumab is known as a checkpoint inhibitor (CPI) or immune checkpoint controller. It is a programmed cell death ligand 1 (PD-L1) inhibitor also known as MPDL3280A.
284766|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
284767|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
284768|NCT02609997|Drug|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
284769|NCT02609997|Device|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
284770|NCT02609997|Drug|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
284771|NCT02610010|Drug|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
284772|NCT02610010|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
284773|NCT02610023|Other|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
284774|NCT00192478|Biological|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
284775|NCT02610023|Other|Laboratory Biomarker Analysis|Correlative studies
284776|NCT02610023|Device|Spectroscopy|Undergo resonance Raman spectroscopy
284777|NCT02610049|Behavioral|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr.s Resick, Monson & Chard (11/2010)
284778|NCT02610049|Behavioral|Art + CPT|8 sessions of individual art therapy using several techniques with 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson & Chard (11/2010)
284779|NCT02610062|Drug|AGS67E|Intravenous (IV) infusion
284780|NCT02576301|Drug|OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
284781|NCT02576301|Drug|OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
284782|NCT02576301|Drug|OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
284783|NCT02576314|Drug|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
284155|NCT00190047|Drug|DP-b99|
284156|NCT02587208|Procedure|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
284458|NCT02580669|Other|Neuropsychological assessment|A neuropsychological assessment is done
284459|NCT02580669|Other|Neurologic consultation|A neurologic consultation is done
284460|NCT02580669|Other|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
284461|NCT02580682|Drug|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
284462|NCT02580682|Drug|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
284463|NCT02580682|Drug|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
284464|NCT02580695|Biological|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
284465|NCT02580695|Drug|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
284466|NCT02580708|Drug|Rociletinib|
284467|NCT00189163|Drug|Pioglitazone|
284468|NCT02580708|Drug|Trametinib|
284469|NCT02580721|Device|Dentsply Astra Tech Implant System EV|Dentsply Astra Tech Implant System EV will be placed
284470|NCT02580734|Dietary Supplement|melatonin|Cross-over randomized clinical trials
284471|NCT02580747|Biological|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
284472|NCT02580773|Drug|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
284473|NCT02580773|Drug|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
284474|NCT02580786|Behavioral|Breastfeeding peer support|
284475|NCT02580812|Other|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
288712|NCT02656472|Drug|Tranexamic acid|TXA Loading dose: 31 mg/kg diluted to 2 ml/kg NS (in syringe)
31 x _______kg = _______ mg TXA (max: 930mg)
2 x _______ kg = _______ ml NS (max: 60 ml)
TXA infusion: 14 mg/kg hour = 1 ml/kg/hour (6 hour bag) (Max rate of infusion = 30ml/hr)
14 x ______ kg = _____mg x 6 = ______ mg TXA (max: 2,520mg)
1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)
TXA second bolus in 1 ml/kg NS
< 16 kg: TXA 45 mg in 1 ml/kg NS = _______ml NS
16-30 kg: TXA 90 mg in 1 ml/kg NS = _______ml NS
> 30 kg: TXA 120 mg 1 ml/kg NS = _______ml NS (max 30ml)
288713|NCT02656472|Drug|Epsilon Aminocaproic Acid|Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
75 x _______kg = _______ mg EACA (max: 2,250mg)
2x _______ kg = _______ ml NS (max 60ml)
Aminocaproic acid infusion: 75 mg/kg hour = 1 ml/kg/hour (6 hour bag)
75 x ______ kg = _____mg x 6 = ______ mg EACA (max: 13,500 mg)
1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)
Aminocaproic acid second bolus: 75 mg/kg in 1ml/kg NS
75 x _______kg = _______ mg EACA (max: 2,250mg)
1 x _______ kg = _______ ml NS (max 30 ml)
288714|NCT02656485|Drug|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
288715|NCT02656485|Drug|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
288716|NCT02656498|Drug|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
288717|NCT02656511|Drug|Dolutegravir|Dolutegravir 50 mg PO daily
284157|NCT02587221|Biological|MF59-adjuvanted Quadrivalent Influenza Vaccine|1 dose approximately 0.5 mL of aQIV
284158|NCT02587221|Biological|Non-Influenza Comparator vaccine|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine
284159|NCT02587234|Device|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
284160|NCT02587247|Drug|TF2 antibody/68Ga-IMP-288|
284161|NCT02587260|Drug|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
284162|NCT02587260|Drug|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
284163|NCT02587260|Drug|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
284164|NCT02587273|Drug|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
284165|NCT02587286|Other|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
288426|NCT00198497|Drug|Vitrase|Hyaluronidase 55 IU in saline solution
288427|NCT02662660|Drug|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
288428|NCT02662660|Drug|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
288429|NCT02662673|Device|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
288430|NCT02662686|Other|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
288431|NCT02662686|Other|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
288432|NCT02662712|Drug|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
288433|NCT02662712|Drug|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
288434|NCT02662725|Drug|IPILIMUMAB|
288435|NCT02662725|Radiation|Stereotactic radiosurgery|
288436|NCT02662738|Dietary Supplement|Natural fruit extract|
288437|NCT00198497|Drug|Vitrase|Hyaluronidase 75 IU in saline solution
288718|NCT02656511|Drug|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg PO daily
288719|NCT00197613|Drug|(D) zidovudine, didanosine, and efavirenz|
288720|NCT02656524|Drug|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
288721|NCT02656537|Device|EnSite™ HD Grid Catheter mapping system|
288722|NCT02656550|Procedure|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
288723|NCT02656563|Radiation|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
288724|NCT02658591|Dietary Supplement|Crackers with no faba bean fraction|Control treatment
288120|NCT02669498|Procedure|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
288121|NCT02669511|Drug|PQR309|Oral PQR309, 80mg, daily
288122|NCT00199004|Drug|Methotrexate|
288123|NCT02669524|Drug|LY2409021|
288124|NCT02669524|Drug|LY2409021 placebo|
288125|NCT02669524|Procedure|OGTT|
288126|NCT02669524|Procedure|IIGI|
288127|NCT02669524|Procedure|Standardised liquid meal|
288128|NCT02669537|Device|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
288129|NCT02669550|Device|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
288130|NCT02669550|Device|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
288131|NCT02669563|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
288132|NCT02669563|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
288438|NCT02662738|Other|Placebo|
288439|NCT02662738|Other|Glucose solution|
288440|NCT02662751|Other|Routine Imaging Assessment|Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.
"Routine Imaging Assessment" refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers.
288441|NCT02662751|Device|LDWBA first (CT scan)|Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.
LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient.
288442|NCT02662764|Drug|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for up to 72 hours
293635|NCT02626819|Behavioral|Enhanced Usual Care|Patients will be given information on "healthy living messages" that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling.
293636|NCT02626832|Other|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
293637|NCT02626845|Drug|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
293638|NCT02626845|Other|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
293639|NCT02628938|Other|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
293640|NCT02628938|Other|Miswak stick|Miswak stick twice a day for 7 days
293641|NCT00194337|Radiation|fludeoxyglucose F 18|
293642|NCT02628938|Other|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
293643|NCT02628951|Drug|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
293644|NCT02628951|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
293645|NCT02628964|Device|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
293646|NCT02628977|Behavioral|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
293647|NCT02628977|Behavioral|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
293648|NCT02628990|Other|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
293649|NCT02628990|Other|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
293650|NCT02628990|Other|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
293073|NCT02637804|Device|stenfilcon A pair of lenses|stenfilcon A contact lens
293074|NCT02637804|Device|narafilcon A pair of lenses|narafilcon A contact lens
293075|NCT02637804|Device|delefilcon A pair of lenses|delefilcon A contact lens
293076|NCT02637830|Other|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
293350|NCT02633176|Drug|Capecitabine|1000mg/m^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
293351|NCT02633176|Radiation|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
293352|NCT02633189|Drug|Erlotinib|given orally 150 mg daily
293353|NCT00194792|Drug|methotrexate|Given IV
293354|NCT02633189|Drug|Bevacizumab|15 mg/kg intravenously every 21 days.
293355|NCT02633202|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
293356|NCT02633202|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
293357|NCT02633215|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
293358|NCT02633228|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
293359|NCT02633241|Drug|Dexmedetomidine-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
293360|NCT02633254|Device|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
293361|NCT02633267|Behavioral|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
293362|NCT02633267|Behavioral|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
292784|NCT02644486|Drug|Irbesartan|Irbesartan 300mg/d
292785|NCT02644499|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
292786|NCT02644499|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
292787|NCT02644499|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
292788|NCT02644499|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
292789|NCT02644499|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
292790|NCT02644512|Drug|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
292791|NCT00196131|Drug|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
293077|NCT02640027|Procedure|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
293078|NCT02640040|Device|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
293079|NCT02640040|Device|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
293080|NCT02640040|Procedure|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
293081|NCT02640053|Procedure|Cryotherapy|Applied topically
293082|NCT02640053|Drug|Paclitaxel|Given IV
293083|NCT02640053|Other|Quality-of-Life Assessment|Ancillary studies
293084|NCT00195572|Drug|Isovorin|
293085|NCT02640053|Other|Questionnaire Administration|Ancillary studies
293086|NCT02640066|Other|acupuncture|
293087|NCT02640079|Behavioral|Cognitive behavioral therapy|
293088|NCT02640092|Drug|[18F]MNI-798|All enrolled subjects will undergo [18F]MNI-798 PET imaging visits. [18F]florbetapir PET imaging and 3T brain MRI will be obtained at screening for eligibility evaluation.
287277|NCT02655874|Biological|Tetanus-diphtheria vaccine|Administered at day 180
287278|NCT02655887|Device|VENOVO™Venous Stent|VENOVO™ Venous stent Placement.
287279|NCT02655900|Other|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
287570|NCT02651610|Biological|Bavituximab|Biological: bavituximab
287571|NCT02651610|Drug|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
287572|NCT02651623|Drug|Sertraline|Multiple doses of sertraline for 14 days
287573|NCT02651623|Drug|Moxifloxacin|A single dose of 400 mg Moxifloxacin
287574|NCT00196924|Biological|HPV-16/18 L1/AS04|
287575|NCT02651623|Drug|Drug - Placebo|Placebo administered for 14 days
287576|NCT02651636|Drug|myo-inositol,alpha-lipoic acid and folic acid|
287577|NCT02651649|Device|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
287578|NCT02651662|Drug|REGN2810|
287579|NCT02651675|Genetic|AAV directed hLDLR gene therapy|A novel adeno-associated viral (AAV) vector with human low-density lipoprotein receptor (hLDLR) gene
287580|NCT02651688|Drug|Placebo|
287581|NCT02651688|Drug|12.5 mg Enclomiphene Citrate|
287582|NCT02651688|Drug|25 mg Enclomiphene Citrate|
287583|NCT02651701|Procedure|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
287584|NCT02651714|Drug|Tradipitant|
287585|NCT00196937|Biological|Cervarix™|Three doses of vaccine administered intramuscularly according to a 0, 1, 6 months
287586|NCT02651714|Drug|Placebo|
287587|NCT02651727|Drug|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
287588|NCT02651727|Drug|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
286995|NCT02662179|Other|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
286996|NCT02662179|Other|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
286997|NCT02662179|Other|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
287280|NCT00197548|Dietary Supplement|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
287281|NCT02658019|Procedure|Peripheral Blood Sample (optional)|Peripheral blood sample, if available, for biomarkers collected at during screening, every 12 weeks while on treatment, and at the end of treatment visit.
287282|NCT02658019|Genetic|Tumor Tissue Collection (optional)|Tissue sample (archival or newly obtained), if available, collected during screening.
287283|NCT02658032|Behavioral|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
287284|NCT02658032|Behavioral|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
287285|NCT02658032|Other|standard care|
287286|NCT02658045|Device|Standard Oximeter|Oxygen saturation will be measured by standard oximeter
287287|NCT00197782|Biological|Hib conjugate vaccine|
287288|NCT02658045|Device|Oxitone oximeter|Oxygen saturation will be measured by Oxitone oximeter
287289|NCT02658058|Other|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
287290|NCT02658058|Other|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
286724|NCT02668822|Drug|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
286725|NCT02668822|Drug|Placebo vaginal ring|Up to 4 cycles of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
286726|NCT02668822|Drug|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping.
286727|NCT02668835|Device|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
286728|NCT00198991|Drug|Idarubicin|
286729|NCT02668835|Genetic|Non intervention-Genetic testing|
286730|NCT02668848|Dietary Supplement|water|If USG>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
286731|NCT02668861|Drug|Vitamin D|Vitamin D 4000IU/day for 8 weeks
286998|NCT02662192|Other|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
286999|NCT00198432|Drug|Paclitaxel, vinorelbine, cisplatin|
287000|NCT02662192|Other|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
287001|NCT02662205|Other|Psychotherapy Group|Traditional process group
287002|NCT02662205|Other|Yoga class|Yin yoga class
287003|NCT02662205|Other|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
287004|NCT02662231|Procedure|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
287005|NCT02662244|Device|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
287006|NCT02662257|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
286449|NCT00002534|Drug|cytarabine|
286450|NCT00199069|Drug|Cyclophosphamide|
286451|NCT02674113|Drug|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
286452|NCT02674126|Behavioral|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
286453|NCT02676375|Other|Home Visits & Calls|
286454|NCT00199095|Drug|VM26|
286455|NCT02676375|Drug|Monotherapy|
286456|NCT02676388|Procedure|Freeze-dried, Capsulized FMT|
286457|NCT02676388|Procedure|Fresh FMT|
286458|NCT02676401|Drug|MT-3995 Low|
286459|NCT02676401|Drug|MT-3995 Middle|
286460|NCT02676401|Drug|MT-3995 High|
286461|NCT02676414|Behavioral|Interactive hypertension education program of the DHL©|
286462|NCT02676427|Procedure|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
286732|NCT02668861|Drug|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
286733|NCT02668861|Other|placebo|placebo for 8 weeks
286734|NCT02668874|Other|Isolite® technique|The Isolite technique utilizes a flexible plastic dental adapter to separate the cheek and tongue prior to sealant application.
286735|NCT02668874|Other|Cotton Roll technique|A cotton roll is placed between the cheek and tongue prior to sealant application
286736|NCT02668887|Behavioral|Quality of Life, status of employment|
286737|NCT02668900|Behavioral|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
286738|NCT02668913|Other|Diagnostic analysis|Molecular profiling
286172|NCT02680938|Drug|oxytocin|For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.
- The two groups will be compared in the following terms:
The duration of the third stage of labor by stopwatch.
Hemoglobin (Hb) difference before and 12 h after delivery.
The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery.
286173|NCT02680938|Drug|saline|For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.
- The two groups will be compared in the following terms:
The duration of the third stage of labor by stopwatch.
Hemoglobin (Hb) difference before and 12 h after delivery.
The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery.
286174|NCT02680951|Drug|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
286175|NCT02680951|Drug|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses
Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30
286176|NCT00199706|Drug|7.2% NaCl in 6% hydroxyethyl starch solution|
286177|NCT02680951|Drug|Cytarabine|2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses
Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30
286178|NCT02680951|Drug|Idarubicin|8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses
Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30
286179|NCT02610439|Other|Laboratory Biomarker Analysis|Correlative studies
286180|NCT02610452|Other|Clown therapy|The clowns intervene by twos: a game takes place.
The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.
The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.
The original game proposal is adjusted according to mutual empathy with those present.
The game is developed on the model of theatrical improvisation: an original creation that has "scenic" quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.
The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled.
286463|NCT02676440|Other|Treatment|F13/T38
286464|NCT02676440|Other|Comparitor|M26
286465|NCT00199095|Drug|Vincristine|
286466|NCT02676453|Other|Intervention|Dental hygienist support
286467|NCT02676466|Dietary Supplement|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
285616|NCT02659423|Behavioral|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
285883|NCT02650804|Drug|BPM31510 Nanosuspension Injection|
285884|NCT02650804|Drug|Gemcitabine|
285885|NCT02650817|Drug|RAD1901|RAD1901, a novel selective ER degrader (SERD)
285886|NCT02650843|Other|DAT SPECT imaging|
285887|NCT02650856|Drug|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
285888|NCT02650856|Biological|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
285889|NCT02652975|Biological|Laboratory blood samples|Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).
Further more urine samples to determine possible systemic impact of cardiovascular disease.
We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.
Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen.
285890|NCT02652988|Other|Active-tDCS|Active home-based tDCS applied at home.
285891|NCT02652988|Other|Sham-tDCS|Sham home-based tDCS applied at home.
285892|NCT00197080|Drug|Ropinirole Extended Release (XR)|
285893|NCT02653001|Other|Stool sample collection|Collection of complete stool sample
285894|NCT02653014|Drug|KBP-5074|Drug Intervention
285895|NCT02653027|Drug|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
285896|NCT02653027|Other|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
285897|NCT02653040|Other|Dynamic lighting|Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:
07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity
285898|NCT02653066|Other|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
285899|NCT02653066|Other|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
285349|NCT02668289|Other|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
285350|NCT02668289|Other|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT. This CBCT will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
285351|NCT02668289|Other|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
285352|NCT02668289|Procedure|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
285617|NCT02659423|Behavioral|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
285618|NCT02659436|Other|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
285619|NCT02659436|Other|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
285620|NCT00198029|Device|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
285621|NCT02659449|Device|made to measure compression gloves|Patients achieve tests with compression glove
285622|NCT02659449|Device|Compression bandaging|Patients achieve tests with compression bandaging
285623|NCT02659449|Other|Free Hands|Patients achieve tests without device
285624|NCT02659462|Other|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
285625|NCT02659475|Drug|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
285626|NCT02659488|Drug|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
285627|NCT02661529|Other|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
285628|NCT02661529|Other|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
285629|NCT02661542|Drug|FF-10502-01|
285630|NCT00198354|Drug|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
285631|NCT02661555|Other|Aerobic exercise|
285363|NCT02668393|Drug|Nintedanib|Low Dose
285364|NCT02668393|Drug|Nintedanib|Medium dose
285365|NCT02668393|Drug|Nintedanib|High dose
285366|NCT02668393|Drug|Nintedanib|Continuous high dose
285367|NCT02668406|Other|Venous blood sampling (2 timepoints)|8.5ml at Day 1 + 8.5ml at Day 5
285368|NCT02670902|Behavioral|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
285369|NCT02670902|Behavioral|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program, as well as three telephone recovery check-up calls post-discharge.
285370|NCT02670915|Drug|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
285371|NCT02670915|Drug|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
285372|NCT02670915|Drug|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
285638|NCT02661607|Device|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
285639|NCT02661607|Procedure|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
285640|NCT02661620|Device|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7 year post op telephone call to assess stem status and adverse events.
285641|NCT00198367|Drug|Chemotherapy (Gemcitabine, Paclitaxel, Vinorelbine)|
285642|NCT02661633|Device|BrainScope Battery|The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement.
285643|NCT02661633|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
285644|NCT02661646|Device|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
285645|NCT02661659|Biological|Multipeptide vaccine S-588210|
285646|NCT02661672|Device|Apollo MIES|surgery with use of the Apollo System.
285079|NCT00002519|Drug|chemotherapy|
285080|NCT00192023|Drug|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
285081|NCT02605525|Biological|SM101|Human soluble recombinant Fcγ Receptor IIB
285082|NCT02605525|Other|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
285083|NCT02605538|Biological|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
285084|NCT02605551|Procedure|Osteopathic Manipulative Therapy|All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:
OM Occipitomastoid release technique
Sub-Occipital Release Technique
Rib Raising Technique
Rotatory stimulation of posterior Chapman's Reflexes
Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)
285085|NCT02605551|Behavioral|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
285086|NCT02605564|Other|Gluten Free Diet|Gluten Free Diet
285087|NCT02605564|Other|Placebo|Placebo No intervention, standard T1DM diet
285088|NCT02605577|Procedure|new systemic nutrition management protocol|a new established systemic nutrition management protocol
285089|NCT02605590|Drug|AIR DNase|
285090|NCT02605590|Drug|Placebo|
285091|NCT00192023|Drug|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
285092|NCT02605616|Drug|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
285093|NCT02605616|Other|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
285094|NCT02605629|Other|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
285095|NCT02605629|Other|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
285096|NCT02605642|Drug|Infliximab (Inflectra™)|
284476|NCT02582866|Drug|Lacosamide|Pharmaceutical Form: Oral tablets
Concentration: 50 mg
Route of Administration: Oral administration
284477|NCT02582892|Drug|Vit D|20 mg/day
284478|NCT02582905|Drug|Placebo|Inactive ingredient matching the active comparators in appearance.
284479|NCT02582905|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
284784|NCT02576314|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.
once daily;
284785|NCT02576327|Drug|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
284786|NCT02576327|Drug|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
284787|NCT02576327|Drug|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
284788|NCT00188448|Device|MRI|
284789|NCT02576340|Drug|otilonium bromide|otilonium bromide was administered before the procedure
284790|NCT02576353|Drug|Fentanyl|Fentanyl Sublingual Spray (FSS)
284791|NCT02576353|Drug|Fentanyl Citrate|Fentanyl Citrate IV (FCIV)
284792|NCT02576366|Drug|Voriconazole|
284793|NCT02576366|Drug|Rifampin|
284794|NCT02576392|Behavioral|Intervention|
284795|NCT02576418|Other|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
284796|NCT02576431|Drug|LOXO-101|Oral capsule of LOXO-101 - 100mg BID
284797|NCT02576444|Drug|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
284798|NCT02576444|Drug|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
284799|NCT00188461|Device|CT Thorax|
284800|NCT02576444|Drug|AZD1775|The recommended dose will be available no earlier than March 2016.
284166|NCT00190060|Drug|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
284167|NCT02587312|Other|Very low nicotine content cigarettes|
284168|NCT02587312|Other|Standard nicotine content cigarettes|
284169|NCT02587325|Drug|ABI-009, nab-rapamycin, albumin-bound rapamycin|
284170|NCT02587338|Device|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anadal, right cathodal
284171|NCT02587338|Device|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
284172|NCT02587351|Drug|Metoprolol succinate|Extended release Metoprolol succinate
284173|NCT02587351|Other|Placebo|Matching placebo
284174|NCT02587364|Drug|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
284175|NCT02587364|Drug|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
284176|NCT02587364|Drug|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
284177|NCT00190060|Drug|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
284480|NCT02582905|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
284481|NCT00189488|Procedure|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
284482|NCT02582918|Behavioral|Outreach with patient education and patient navigation services|Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.
Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.
If results are normal, the patient is invited to repeat screening in 6 months.
If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.
If CT/MRI is unremarkable, the patient is referred back for routine screening.
If HCC is confirmed, the patient and their primary care provider will be contacted with the results.
All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic.
284483|NCT02582931|Device|MRI-guided SBRT|
284484|NCT02582931|Behavioral|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
284485|NCT02582931|Behavioral|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
284486|NCT02582944|Device|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
288725|NCT00197821|Biological|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
288726|NCT02658604|Other|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
288727|NCT02658630|Device|Robot + TTT exercise|The intervention will be completed 3x/week for 12 weeks. The training progression will be sequential with 4 weeks completed on the wrist robot, followed by 4 weeks on the shoulder-elbow robot and completing with 4 weeks alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
288728|NCT02658643|Procedure|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
288729|NCT02658643|Procedure|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
288730|NCT02658656|Device|ReWalk 6.0|Exoskeletal Assisted Walking Device
288731|NCT02658669|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
288732|NCT02658669|Behavioral|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
288733|NCT02658682|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
288734|NCT02658682|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
288735|NCT02658708|Other|Bright blue-green light using light visor cap|
288736|NCT00197834|Drug|Depakote|
284178|NCT02587364|Drug|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
284179|NCT02589730|Device|Welltang App|This App is a large platform of individualized diabetic management
284180|NCT00190476|Drug|Weekly docetaxel alone|
284181|NCT02589743|Device|Sealant|Application of preventive agent
284182|NCT02589743|Device|Adhesive and Sealant|Application of preventive agent and technique for control moisture
288443|NCT02662777|Device|Eso-SPONGE® vacuum treatment|
288444|NCT02662790|Other|Doppler|
288445|NCT02665039|Drug|Vinflunine|Vinflunine will be given intravenously once every 21 days, starting at a dose of:
280 mg/m2 in patients with GFR 40-60 ml/min
250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min
288446|NCT02665039|Drug|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
288447|NCT02665039|Drug|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
288448|NCT02665052|Device|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
288449|NCT00198809|Drug|Biolean + Diet education|
288450|NCT02665052|Device|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
288451|NCT02665052|Behavioral|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
288452|NCT02665065|Drug|Iomab-B|
288453|NCT02665065|Drug|Conventional Care|
288737|NCT02658708|Other|Dim red light using light visor cap|
288738|NCT02658708|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
288739|NCT02658708|Other|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
288740|NCT02658708|Other|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
288741|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
289058|NCT02656680|Behavioral|FB + Friends|Participants will receive a weight loss intervention. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. Participants will be able to invite their friends who are also interested in losing weight.
289059|NCT02656680|Behavioral|FB Only|Participants will receive a weight loss intervention. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
289060|NCT02656693|Behavioral|Online weight management program|Patients who are enrolled in online weight management program will create a personalized weight management plan (which includes setting goals for weight loss, calorie intake, and physical activity), complete structured learning modules, participate in self-monitoring activities, and interact with other features of the program.
289061|NCT00197613|Drug|(F) stavudine, lamivudine and efavirenz|
289062|NCT02658708|Device|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
289063|NCT02658708|Device|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
289064|NCT02658708|Other|Horne-Ostberg Morningness-Eveningness Questionnaire|
289065|NCT02658708|Other|Daily Fatigue and Sleep Log|Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness
Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)
289066|NCT00197860|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
289067|NCT02658721|Drug|Lidocaine|
289068|NCT02658721|Drug|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
289069|NCT02658721|Drug|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
289070|NCT02658721|Drug|Fentanyl|If the patient had a VAS score of >4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
293363|NCT02633293|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
293364|NCT00194792|Drug|vinorelbine tartrate|Given IV
293365|NCT02633306|Device|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
293366|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
293367|NCT02635412|Other|Scheduled timing of delivery|
293651|NCT02628990|Other|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
293652|NCT00002524|Drug|Ifosfamide|
293653|NCT00194350|Procedure|Test for Factor V Leiden gene mutation|
293654|NCT02628990|Other|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
293655|NCT02629003|Drug|[11C]Cimbi-36|
293656|NCT02629003|Drug|[11C]Cimbi-36-5|
293657|NCT02629016|Other|Mindfulness|
293658|NCT02629016|Other|Wellness|
293659|NCT02629029|Procedure|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
293660|NCT02629029|Device|Computed tomography angiography (CTA)|
293661|NCT02631135|Drug|Rocuronium|0.5 mg/kg iv for intubation, no change
293662|NCT02631148|Drug|Melatonin|2mg controlled release melatonin tablet
293663|NCT02631148|Drug|Placebo|placebo tablet identical to circadin
293664|NCT02631161|Other|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
293665|NCT02631161|Other|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
293089|NCT02640105|Other|Neurological clinical examination|Diagnostic and description of cluster headache
293090|NCT02640105|Other|Psychological clinical examination|Scale and questionnaires
293091|NCT02640105|Other|Questionnaires|Psychopathological and cognitive questionnaires
293092|NCT02640105|Other|Blood sample|Blood sample for DNA collection
293093|NCT02640105|Other|Endothelial function measurement|Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
293094|NCT02640118|Drug|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
293095|NCT00195572|Drug|TS-1|
293096|NCT02640118|Drug|Lixisenatide-Placebo|
293097|NCT02640118|Other|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
293098|NCT02640131|Behavioral|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
293368|NCT02635425|Procedure|7 eggs collection|vaginal US
293369|NCT02635425|Procedure|Full eggs collection|vaginal US
293370|NCT02635438|Drug|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
293371|NCT02635438|Drug|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
293372|NCT02635464|Biological|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
293373|NCT02635464|Biological|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
293374|NCT02635464|Procedure|CABG|Patients underwent CABG alone.
293375|NCT02635477|Behavioral|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
293376|NCT00195026|Device|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
293377|NCT02635477|Behavioral|Control|Behavioral: actigraphy device, step count measurement only
287589|NCT02651727|Drug|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
287590|NCT02651740|Drug|placebo|200mg tid* 3d
287591|NCT02653547|Other|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
287894|NCT00196404|Drug|DR-3001a|4mg daily vaginally
287895|NCT02646800|Drug|Micafungin|Injection
287896|NCT02646813|Procedure|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
287897|NCT02646813|Procedure|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
287898|NCT02646826|Other|Placebo|Subjects are treated with Placebo tablets
287899|NCT02646826|Drug|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
287900|NCT02646826|Drug|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
287901|NCT02646826|Drug|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
287902|NCT02646839|Device|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
287903|NCT02646852|Drug|DFP-13318|
287904|NCT02646865|Behavioral|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
287905|NCT00196404|Drug|DR-3001b|6 mg vaginally daily
287906|NCT02646865|Behavioral|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol
287907|NCT02646878|Device|Harmony 1 Sensors|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
287908|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 15 mcg|
287909|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 30 mcg|
287291|NCT02658058|Other|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
287292|NCT02658084|Drug|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
287293|NCT02658084|Drug|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
287294|NCT02658097|Drug|Pembrolizumab|
287295|NCT02658097|Radiation|Single Fraction Radiation Therapy|
287592|NCT02653560|Drug|Potassium chloride powder|
287593|NCT02653560|Drug|Potassium magnesium Citrate (KMgCit)|
287594|NCT02653560|Drug|Potassium citrate powder|
287595|NCT02653560|Drug|Placebo|
287596|NCT02653573|Behavioral|Coaching|Self-management education
287597|NCT00197171|Biological|Combined Hepatitis A and B vaccine|
287598|NCT02653586|Other|program "In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
287599|NCT02653599|Drug|TTP273|
287600|NCT02653599|Drug|Placebo|
287601|NCT02653612|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
287602|NCT02653625|Drug|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning
287603|NCT02653638|Other|Control|Transcranial Doppler
Blood Pressure
Heart Rate
Oxygen Saturation
287604|NCT02653638|Drug|Indomethacin|Transcranial Doppler
Blood Pressure
Heart Rate
Oxygen Saturation
287605|NCT02653651|Drug|Ketamine|Ketamine infused at 0.1 mg/kg/hour
287606|NCT02653651|Drug|Lidocaine|Lidocaine infused at 1 mg/kg/hour
287607|NCT02653651|Drug|Placebo|An equal volume of saline
287007|NCT02664597|Procedure|ADNEXMR Scoring System|Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
287008|NCT02664597|Other|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
287009|NCT02664610|Behavioral|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
287010|NCT00198744|Behavioral|Medifast FIT! for Kids|
287011|NCT02664623|Procedure|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
287012|NCT02664623|Procedure|Dietary advice sheet|At the beginning neurological consult, patients will be delivered a dietary advice sheet called "Grio".
287013|NCT02664636|Procedure|Physiotherapy|Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.
This is part of routine care.
287296|NCT02658110|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
287297|NCT02658110|Other|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
287298|NCT00197795|Biological|Meningococcal outer membrane vesicle vaccine "MenBVac"|
287299|NCT02660034|Drug|BGB-290|
287300|NCT02660047|Drug|Liraglutide|Drug: Liraglutide
Preparation and labelling of Investigational Medicinal Product:
Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
287301|NCT00198107|Drug|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
286739|NCT00198991|Drug|Fludarabine|
286740|NCT02668926|Drug|Lisdexamfetamine|100mg p.o, single dose
286741|NCT02668926|Drug|d-amphetamine sulfate|40.3mg p.o, single dose
286742|NCT02668926|Drug|Placebo|Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
286743|NCT02671448|Behavioral|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
286744|NCT02671448|Behavioral|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument, PG-SGA
286745|NCT02671448|Behavioral|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
286746|NCT00199017|Drug|Thioguanine|
286747|NCT02671461|Drug|BMS-986141|
286748|NCT02671461|Drug|Aspirin|
286749|NCT02671461|Other|Placebo|
286750|NCT02671474|Other|4-dimensional volume-rendered computed tomography|
286751|NCT02671487|Behavioral|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
286752|NCT02671500|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
287014|NCT02664636|Procedure|Occupational therapy|Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.
This is part of routine care.
287015|NCT02664636|Procedure|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
287016|NCT02664649|Drug|Apixaban|Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].
- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily
287017|NCT02664649|Drug|Standard of care|VKA or Antiplatelet therapy
286468|NCT02676466|Drug|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
286469|NCT02676466|Other|Placebo|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
286470|NCT02676466|Other|Placebo|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
286471|NCT02676479|Device|Uterine Lavage Group|The PI places the Lavage Catheter per instructions for use
Use of a tenaculum or cervical stitch is required
Use of saline to wash the cervix is required
Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix.
286472|NCT02676492|Other|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
286473|NCT02676492|Other|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
286474|NCT02676505|Behavioral|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
286475|NCT02676505|Behavioral|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
286476|NCT02678624|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
286477|NCT02678637|Other|MRI and muscle dynamometer|
286478|NCT02678650|Drug|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
286753|NCT02671513|Drug|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
286754|NCT02671526|Other|Computerized plasticity-based adaptive cognitive training|
286755|NCT02671539|Genetic|rAAV2.REP1|single subretinal injection
286756|NCT02671552|Drug|Perflutren Protein-Type A Microspheres|Given IV
285900|NCT02653079|Other|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
285901|NCT02653092|Drug|Insulin|
285902|NCT02653092|Drug|Intralipid|
285903|NCT00197093|Drug|SB773812|
286181|NCT00192517|Drug|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
286182|NCT02610478|Biological|High-Titer Plasma|2 units of human plasma (FFP or FP24, 250-350 mL per unit, or pediatric equivalent) with influenza A/H1N1 and A/H3N2 HAI titers of at least 1:80.
286183|NCT02610478|Biological|Low-Titer Plasma|2 units of human plasma (FFP or FP24, 250-350 mL per unit, or pediatric equivalent) with influenza A/H1N1 and A/H3N2 HAI titers of 1:10 or less.
286184|NCT02610491|Dietary Supplement|Hesperidin|Citrus peel extract
286185|NCT02610491|Dietary Supplement|Placebo|Cellulose
286186|NCT02610504|Device|Durolane|single injection of 3ml
286187|NCT02610517|Behavioral|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
286188|NCT02610517|Behavioral|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
286189|NCT02610530|Procedure|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
286190|NCT02610530|Procedure|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
286191|NCT02610530|Other|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
286192|NCT00192517|Other|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
285632|NCT02661581|Behavioral|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
285633|NCT02661594|Drug|Amisulpride 5 mg|Therapeutic dose of amisulpride
285634|NCT02661594|Drug|Amisulpride 40 mg|Supra-therapeutic dose of amisulpride
285635|NCT02661594|Drug|Moxifloxacin|Positive control for assay sensitivity
285636|NCT02661594|Drug|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
285637|NCT02661607|Procedure|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
285904|NCT02653092|Drug|Dextrose|
285905|NCT02653092|Drug|Heparin|
285906|NCT02653092|Drug|GnRH|
285907|NCT02653092|Procedure|Hyperinsulinemic Euglycemic Clamp|
285908|NCT02653105|Biological|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
285909|NCT02653118|Biological|V503|
285910|NCT02653118|Biological|GARDASIL|
285911|NCT02653131|Drug|Dipeptidyl peptidase-4 inhibitor|
285912|NCT02653144|Drug|Ropivacaine,Dexmedetomidine,Dexamethasone|pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
285913|NCT02653157|Other|MDR-GNB|
285914|NCT00197106|Drug|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
285915|NCT00197431|Drug|S-1|
285916|NCT02655237|Drug|TAK-385 40 mg|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
285917|NCT02655237|Drug|Leuprorelin 1.88 mg|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg injection
285918|NCT02655237|Drug|Leuprorelin 3.75 mg|TAK-385 placebo tablets + Leuprorelin acetate 3.75 mg injection
285919|NCT02655250|Other|Microbiome|
290768|NCT02652780|Other|Sham Intravitreal Injection|Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
Sham-treated Eyes: One eye of each subject will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
290769|NCT00002531|Drug|ifosfamide|
290770|NCT00197041|Biological|RTS,S/AS02A|
290771|NCT02652793|Drug|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
290772|NCT02652793|Drug|Lamivudine|Lamivudine 300 mg once dailly
290773|NCT02652806|Drug|FG-4592|
290774|NCT02652806|Drug|Epoetin Alfa|
290775|NCT02652819|Drug|FG-4592|
290776|NCT02652819|Drug|Placebo|
290777|NCT02652832|Device|non invasive brain stimulation|non invasive brain stimulation
290778|NCT02652845|Behavioral|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
290779|NCT02652858|Procedure|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
290780|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
290781|NCT02654899|Other|Placebo|Placebo
291044|NCT02645903|Drug|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
291045|NCT02645916|Drug|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
291046|NCT02645916|Drug|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
291047|NCT02645929|Behavioral|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
291048|NCT02645942|Dietary Supplement|L-carnitine|L-carnitine 900 mg daily for 8 weeks
291049|NCT00196339|Drug|DR-2031c|1 tablet daily
290170|NCT02663583|Behavioral|Symptom Questionnaires|Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.
TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.
290460|NCT02659176|Procedure|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
290461|NCT00197951|Drug|Treatment of psychiatric symptoms associated to alcoholism|
290462|NCT02659176|Procedure|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
290463|NCT02659202|Device|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
290464|NCT02659215|Device|Hyalofast|Arthroscopic implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate.
290465|NCT02659215|Procedure|Microfracture|Microfracture is performed arthroscopically and is a well-established surgical technique for cartilage repair.
290466|NCT02659228|Device|EEG recording|EEG recording with anesthetic (DIPRIVAN)
290467|NCT02659228|Drug|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
290468|NCT02659241|Drug|AZD1775|Starting the day of laparoscopic surgery, AZD1775 200 mg tablets taken by mouth 2 times each day on Days 1 - 3 of a 28-day study cycle. Depending on when tumor reduction surgery is scheduled, participant may be able to continue taking the study drug on Days 8 - 10, 15 - 17, and 22 -24.
290469|NCT02659254|Device|Bioresorbable rapamycin-eluting coronary stent|Implantation of the bioresorbable rapamycin-eluting coronary stent
290470|NCT02659267|Behavioral|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
290471|NCT02659280|Other|Adjunct Therapy|"Store and Forward" Tele-heath
290472|NCT00197964|Behavioral|Enhance asthma knowledge, self-efficacy, social support|
290473|NCT02659280|Other|Standard of Care|Standard of Care Outpatient Physical Therapy
290474|NCT02659293|Drug|Lenalidomide|
290475|NCT02659293|Drug|Carfilzomib|
289901|NCT02670421|Behavioral|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
289902|NCT02670434|Drug|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
289903|NCT02670434|Drug|Placebo|Placebo daily for 12 weeks
289904|NCT02670434|Drug|Livalo|Livalo® IR daily from week 12 to week 52
289905|NCT02670447|Procedure|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
289906|NCT00199004|Procedure|Stem cell transplantation|
289907|NCT02670460|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
289908|NCT02670486|Other|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
290171|NCT02665871|Biological|one dose of Influenza Vaccine|
290172|NCT02665871|Biological|one dose of Influenza Vaccine|
290173|NCT02665871|Biological|placebo|
290174|NCT00198900|Behavioral|survey of information|
290175|NCT02665871|Biological|placebo|
290176|NCT02665884|Other|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
290177|NCT02665910|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
290178|NCT02665910|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
290179|NCT02665923|Other|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
290180|NCT02665936|Drug|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
290181|NCT02665936|Drug|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
290182|NCT02665936|Drug|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
290183|NCT02665962|Other|Perioperative Caloric Restriction Program|
289587|NCT02675387|Drug|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
289588|NCT02677584|Drug|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
289589|NCT02677597|Drug|Cisplatin Combined With S-1|
289590|NCT02677597|Drug|Cisplatin Combined With Paclitaxel|
289591|NCT02677610|Drug|MSRD-100|MSRD-100 is a topical gel.
289592|NCT02677610|Drug|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
289593|NCT02677623|Drug|Pyridium|
289594|NCT02677623|Drug|Sodium Fluorescein|
289595|NCT02677623|Drug|Mannitol|
289596|NCT00002534|Radiation|low-LET electron therapy|
289597|NCT00199186|Drug|dexamethasone|
289598|NCT02677623|Other|Normal Saline|
289599|NCT02677636|Drug|MSRD-100|MSRD-100 is a topical gel.
289600|NCT02677636|Drug|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
289601|NCT02677649|Other|cranberry|the effect of cranberry on the gut microbiota
289602|NCT02677649|Other|placebo|the effect of placebo on the gut microbiota
289909|NCT02670499|Device|CPM|Used to aid in recovery from TKR
289910|NCT02670512|Device|Telehome Monitoring|
289911|NCT02670525|Genetic|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
289912|NCT02670538|Drug|cariprazine|
289913|NCT02670538|Drug|placebo|
289914|NCT02670551|Drug|cariprazine|
289915|NCT02670551|Drug|placebo|
289297|NCT02682134|Drug|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
289298|NCT02682147|Drug|Tadalafil|The inspiration/expiration CT pair and multi-detector computed tomography (DE-MDCT) will be performed before smoking cessation and 3 months post smoking cessation in subjects on once a day Tadalafil (Cialis) for the full cessation period (3 months)
289299|NCT02682147|Drug|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging
289300|NCT02682160|Other|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
289301|NCT02682173|Other|MR Abdomen|
289302|NCT02682186|Drug|Ropivacaine after dilution with sodium chloride 0.9%|After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.
Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.
In the other group, sterilization, sheating and US are performed but the needle is not inserted.
289303|NCT02682212|Other|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
289304|NCT02682225|Drug|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
289305|NCT02682225|Drug|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
289306|NCT02647385|Drug|Block with lidocaine for SAM and PEC I block|Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.
Interventions: include pain assessment, inflammatory response and opioid consumption.
289307|NCT00196456|Procedure|photosensitisation|
289308|NCT02647398|Behavioral|Vigorous aerobic training|Supervised vigorous aerobic training
289309|NCT02647424|Drug|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
289310|NCT02647424|Drug|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
289311|NCT02647437|Drug|Levetiracetam|
289312|NCT02647437|Drug|Placebo|
289603|NCT02677662|Other|Diesel Exhaust|Dilute diesel exhaust
293593|NCT02622334|Drug|Placebo|Matching placebo formulation will be administered in Part A.
288999|NCT02652169|Device|Acticoat 7 (R)|Acticoat 7 silver wound dressing is applied to the chronic ulcer
289000|NCT02652195|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
289001|NCT02652195|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
289002|NCT02652208|Behavioral|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
289003|NCT02652208|Behavioral|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
289004|NCT02652221|Device|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
289005|NCT02652234|Drug|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
289006|NCT02652234|Drug|Chemotherapy|
289007|NCT00002531|Drug|etoposide|
289008|NCT00196976|Biological|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
289009|NCT02652247|Procedure|molecular analysis of exhaled breath condensate|
289010|NCT02652247|Procedure|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
289011|NCT02652247|Procedure|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
289012|NCT02652260|Drug|MK-1439A - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded Period
289013|NCT02652260|Drug|MK-1439A - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period
289014|NCT02652260|Drug|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded Period
289015|NCT02652260|Drug|Placebo to ATRIPLA^TM|A single placebo to ATRIPLA^TM tablet administered orally, once daily for 12 weeks during the Blinded Period
289016|NCT02652260|Drug|Placebo to MK-1439A|A single placebo to MK-1439A tablet administered orally, once daily for 12 weeks during the Blinded Period
289017|NCT02652273|Drug|Abatacept|Abatacept 125mg/ml
293305|NCT02628821|Other|Preterm Infants treated with non-invasive ventilation.|
293306|NCT02628834|Other|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
293307|NCT02628834|Other|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
293308|NCT02628847|Drug|sildenafil citrate|
293594|NCT02622334|Drug|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
293595|NCT02622373|Device|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
293596|NCT02624687|Behavioral|Decreasing Sedentary Behavior|
293597|NCT02624687|Other|No intervention|
293598|NCT02624700|Drug|Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
293599|NCT02624700|Drug|Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg. Instruct patient to take sorafenib on an empty stomach (ie, at least 1 hour before or 2 hours after eating) starting the morning of each pemetrexed dose. If a sorafenib dose is missed, the patient will be instructed to omit the dose and to not take more than 2 doses of sorafenib on the same day to make up for doses that were missed on the previous day.
293600|NCT02624713|Behavioral|obesity treatment|Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.
Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.
Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. .
293601|NCT02624726|Drug|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in <5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
293602|NCT02624726|Drug|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
293603|NCT02624726|Drug|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
293604|NCT02624726|Drug|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
293038|NCT02635269|Other|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
293039|NCT02635282|Drug|intranasal ketamine|
293040|NCT02635282|Drug|intranasal fentanyl|
293041|NCT02635282|Drug|intranasal midazolam|
293309|NCT02628847|Drug|Placebo|
293310|NCT02628860|Drug|Ferinject (Ferric Carboxymaltose)|Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .
Study drug may be administered as IV drip infusion or IV undiluted bolus injection.
293311|NCT02628873|Procedure|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
293312|NCT02628886|Biological|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
293313|NCT02628886|Biological|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
293314|NCT00194337|Procedure|ultrasound imaging|
293315|NCT02628886|Other|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
293316|NCT02628899|Device|Transfemoral TAVR|
293317|NCT02628899|Device|SAVR|
293318|NCT02628912|Other|blood draw|
293319|NCT02628912|Behavioral|study questionnaire|
293320|NCT02628912|Other|cardiopulmonary exercise testing (CPET)|
293321|NCT02628912|Other|DXA (dual-energy x-ray absorptiometry) scan|
293322|NCT02628925|Device|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
293323|NCT00194649|Drug|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
293324|NCT02631018|Behavioral|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
297584|NCT00410410|Drug|abatacept|~10 mg/kg, once monthly
Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued
297585|NCT00410423|Drug|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
297586|NCT00410436|Behavioral|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
297587|NCT00410449|Drug|Alpha tocopherol|
297588|NCT00410462|Drug|brostallicin|
297589|NCT00410462|Drug|doxorubicin hydrochloride|
297590|NCT00410488|Drug|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
297591|NCT00003291|Other|laboratory biomarker analysis|
297592|NCT00410488|Drug|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
297593|NCT00410488|Drug|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
297954|NCT00401609|Drug|cisplatin|
297955|NCT00401609|Drug|etoposide|
297956|NCT00401609|Drug|carboplatin|
297957|NCT00401622|Behavioral|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
297958|NCT00003249|Drug|ketoconazole|
297959|NCT00401622|Behavioral|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
297960|NCT00401635|Drug|liposomal doxorubicin|
297961|NCT00401635|Drug|carboplatin|
297962|NCT00401648|Drug|Brivaracetam|
297963|NCT00401661|Drug|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
297964|NCT00401674|Drug|carboplatin|
297965|NCT00401674|Drug|paclitaxel|
297228|NCT00003114|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
297229|NCT00372255|Biological|Influsplit SSW® 2005/2006|
297230|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
297231|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
297232|NCT00372281|Drug|Cliavist|Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
297233|NCT00372294|Drug|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
297234|NCT00372294|Drug|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
297235|NCT00372307|Drug|Application of pimecrolimus|
297236|NCT00372320|Genetic|Gene Transfer|
297237|NCT00372320|Drug|AdhAQP1|
297238|NCT00372333|Drug|IDEA-033|
297239|NCT00003114|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
297240|NCT00372346|Procedure|Transplantation of autologous endothelial progenitor cells|
297241|NCT00372372|Drug|risedronate|
297242|NCT00372385|Drug|Ribavirin|tablet
297243|NCT00372385|Drug|Pegylated Interferon Alfa 2a|Solution for injection
297244|NCT00372385|Drug|Placebo|tablet
297245|NCT00372385|Drug|Telaprevir|tablet
297594|NCT00410488|Drug|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
297595|NCT00410488|Drug|Zinecard|750 mg/m2 as an IV bolus.
297596|NCT00410488|Drug|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
293101|NCT02642367|Drug|rocuronium|tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
293102|NCT02642380|Drug|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
293103|NCT00195819|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
293104|NCT02642380|Drug|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
293105|NCT02642393|Drug|Inosine|capsules containing 500 mg of inosine
293106|NCT02642393|Drug|Placebo|capsules containing 500 mg of lactose and appearing indistinguishable from inosine capsules
293107|NCT02642406|Procedure|Blood sampling|A blood sample will be taken during a routine blood draw before the application of any nab-Paclitaxel.
293108|NCT02642419|Drug|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)
Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)
Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg
Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.
Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk.
293109|NCT02642419|Drug|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
293110|NCT02642432|Drug|ABT-493/ABT-530|Tablet
293111|NCT02642445|Device|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
293112|NCT02642471|Procedure|no systematic pelvic lymphadnectomy|systematic pelvic lymphadnectomy is omitted in surgical treatment
293113|NCT02642484|Drug|Gabapentin|Gapapentin twice daily
293114|NCT00195819|Biological|placebo|Placebo every other week (eow)
293115|NCT02642484|Drug|Calcium Carbonate|calcium carbonate twice daily
293116|NCT02642497|Drug|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 20 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
293117|NCT02642497|Drug|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 20 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
293384|NCT02637830|Other|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
292506|NCT00193206|Drug|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
292507|NCT02617407|Other|PreviDent® 5000 plus|Dental Plaque, Gingivitis and Oral Microbiome Control
292508|NCT02617420|Device|Propeller Health Monitoring Device|
292509|NCT02617433|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
292510|NCT02617446|Drug|placebo|
292511|NCT02617446|Drug|Istaroxime|
292512|NCT02617459|Drug|Levobetaxolol eye drops|one drop per time; twice daily
292513|NCT02617459|Drug|Betaxolol eye drops|one drop per time; twice daily
292514|NCT02617472|Device|Pelvic floor exerciser|Daily exercise using the study device
292515|NCT02617485|Drug|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
292516|NCT02617485|Drug|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
292813|NCT02611037|Drug|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m^2).
292814|NCT00192569|Drug|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
292815|NCT02611037|Drug|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
292816|NCT02611037|Other|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
292817|NCT02613065|Dietary Supplement|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
292818|NCT02613065|Dietary Supplement|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
292819|NCT02613078|Behavioral|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
292199|NCT02624063|Drug|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
292200|NCT02624076|Other|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
292201|NCT02624076|Other|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
292202|NCT02624089|Drug|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
292203|NCT02624089|Drug|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
292204|NCT02624102|Behavioral|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
292205|NCT02624102|Behavioral|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
292206|NCT02624102|Drug|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
292207|NCT00193661|Drug|Testosterone Gel (1%)|
292208|NCT02624128|Drug|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
292209|NCT02624128|Drug|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
292210|NCT02624128|Drug|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
292211|NCT02624141|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
292517|NCT00193206|Drug|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
292518|NCT02617485|Drug|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
292519|NCT02617485|Drug|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
292520|NCT02617485|Drug|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
291911|NCT02628275|Behavioral|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
291912|NCT02630472|Drug|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
291913|NCT02630485|Behavioral|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
291914|NCT02630485|Dietary Supplement|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
291915|NCT02630485|Drug|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
291916|NCT00194558|Behavioral|Internet co-management module|
291917|NCT02630498|Procedure|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
291918|NCT02630511|Drug|Mannitol|
291919|NCT02630511|Drug|Methacholine|
291920|NCT02630511|Drug|Placebo|
291921|NCT02630511|Other|Rest|
291922|NCT02630511|Other|Exercise|
291923|NCT02630524|Behavioral|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
291924|NCT02630550|Device|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
291925|NCT02630550|Device|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
291926|NCT02630563|Drug|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
291345|NCT02641743|Dietary Supplement|Inslow|carbohydrate adjusted liquid food using palatinose as the major carbohydrate (>50%)
291346|NCT02641743|Dietary Supplement|standard balanced formula|
291619|NCT02634749|Other|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
291620|NCT02634749|Other|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
291621|NCT02634749|Other|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
291622|NCT02634775|Other|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
291623|NCT02634788|Drug|Buprenorphine|Buprenorphine delivered via sublingual spray
291624|NCT02634788|Drug|Placebo|Matching placebo delivered via sublingual spray
291625|NCT02637115|Dietary Supplement|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
291626|NCT02637115|Dietary Supplement|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
291627|NCT02637115|Dietary Supplement|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
291628|NCT02637128|Drug|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
291629|NCT02637128|Drug|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
291630|NCT02637141|Biological|AMG 714|A fully human anti-IL-15 monoclonal antibody
291631|NCT02637141|Biological|Placebo|Placebo comparator
291632|NCT02637154|Behavioral|Motivational Interviewing|Motivational Interviewing method
291633|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
291634|NCT02637154|Behavioral|Standard Education|Standard Education material will be used
291635|NCT02637167|Drug|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
291040|NCT02645877|Procedure|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
291041|NCT02645890|Drug|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
291042|NCT02645890|Drug|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
291043|NCT02645903|Drug|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
291347|NCT02641756|Other|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
291348|NCT02641769|Biological|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
291349|NCT02641782|Drug|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
291350|NCT00195728|Drug|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
291351|NCT02641782|Drug|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
291352|NCT02641782|Drug|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
291353|NCT02641782|Drug|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
291354|NCT02643862|Drug|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
291355|NCT02643875|Device|Orthokeratology|It is a kind of rigid permeable lens.
291356|NCT02643901|Biological|GW003|single SC injection
291357|NCT00196092|Device|High Risk|High Risk Endovascular repair.
291358|NCT02643914|Drug|Nicotine|
291359|NCT02643914|Device|MR Compatible Nicotine Delivery Device|
291050|NCT02645942|Dietary Supplement|Placebo|Placebo daily for 8 weeks
291051|NCT02645981|Drug|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
291052|NCT02645981|Drug|Sorafenib|Control
291053|NCT02645994|Device|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
291054|NCT02645994|Device|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
291055|NCT02646007|Biological|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
291056|NCT02612311|Drug|TGR-1202|TGR-1202: Oral daily dose
291057|NCT02612311|Drug|Chlorambucil|Chlorambucil: Oral dose
291058|NCT02612324|Behavioral|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
291059|NCT02612324|Behavioral|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
291060|NCT02612337|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
291061|NCT02612337|Drug|Placebo|Single intratympanic injection of placebo
291062|NCT02612350|Genetic|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
291063|NCT02612363|Drug|Dexmedetomidine for sedation|Dexmedetomidine or control drug for sedation
Analgesia
Propofol at lowest dosage.
Dose range: 0.1- 0.7 u/kg/hour
Target RASS score of -2 to +1
Supplemental propofol at lowest effective dose
291064|NCT02612376|Other|No Intervention(s)|No Intervention
291365|NCT02643979|Drug|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
291366|NCT02643979|Drug|Propofol|100mg of Propofol
291367|NCT02643979|Drug|Saline|1mL of saline
291368|NCT00196092|Device|Compassionate Use|Endovascular repair for compassionate use patients.
291369|NCT02643992|Other|DOAC concentration measurement|
290476|NCT02659293|Drug|Dexamethasone|
290477|NCT02661087|Procedure|Hysteroscopic resection with monopolar energy|
290478|NCT00198315|Procedure|Tumor surgical excision|Patients have their tumor surgically removed.
290479|NCT02661100|Drug|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
290782|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
290783|NCT02654912|Drug|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
290784|NCT02654925|Procedure|Adipose Tissue Biopsy|
290785|NCT02654938|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
290786|NCT02654938|Drug|Placebo|5% infusion solution of dextrose
290787|NCT02654951|Other|Visual Feedback|The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a "normal" error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.
The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible.
290788|NCT02654951|Other|Force Feedback|A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.
The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a "normal" error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.
The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible.
290789|NCT00197392|Device|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
290790|NCT02654964|Drug|Combination Drug Therapy|Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:
Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent
290791|NCT02654977|Drug|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
290792|NCT02654990|Drug|panobinostat capsules|20mg, 10mg or 15mg (for dose reductions only)
290184|NCT02665975|Behavioral|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
290185|NCT00198913|Behavioral|lower fat food supplied and education|
290186|NCT02665975|Behavioral|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
290187|NCT02665988|Device|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
290188|NCT02665988|Device|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
290189|NCT02666001|Drug|BMS-663068|
290190|NCT02666001|Drug|Methadone|
290191|NCT02666001|Drug|Suboxone|
290192|NCT02666014|Drug|Neuromuscular reversal by Sugammadex|Reversal of neuromuscular blockade
290480|NCT02661100|Biological|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
290481|NCT02661100|Biological|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
290482|NCT02661113|Drug|Dasatinib|Phase I dose of 100 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
290483|NCT02661113|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
290484|NCT02661113|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
290485|NCT02661126|Drug|MK-3682B|FDC oral tablet containing 225 mg MK-3682 + 50 mg MK-5172 + 30 mg MK-8408.
290486|NCT02661152|Drug|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
290487|NCT02661178|Drug|emodepside (BAY 44-4400)|
290488|NCT02661178|Drug|placebo|
289916|NCT02670564|Genetic|Pharmacogenomics|Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).
For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples.
289917|NCT00199017|Drug|Dexamethasone/Prednisolone|
289918|NCT02672943|Behavioral|Rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.
289919|NCT02672943|Other|non-rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
289920|NCT02672956|Procedure|Ten mm trocar|
289921|NCT02672969|Device|RapidVac Smoke Evacuator|The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).
Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas).
289922|NCT02672982|Other|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
289923|NCT00199056|Drug|VP16|
289924|NCT02672982|Other|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
289925|NCT02672995|Radiation|Fractionated stereotactic radiosurgery|Fractionated stereotactic radiosurgery:
Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.
289926|NCT02672995|Drug|bevacizumab|Concurrent bevacizumab:
Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab.
290193|NCT02666014|Drug|Neuromuscular reversal by Neostigmine|Reversal of neuromuscular blockade
290194|NCT02666014|Drug|Atropine sulfate-diphenoxylate hydrochloride combination|As an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered.
290195|NCT02667990|Other|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
290196|NCT00198991|Drug|Methotrexate|
290197|NCT02667990|Other|standard stiletto|standard stiletto without insole
289604|NCT02677662|Other|Filtered air|Filtered air
289605|NCT02677675|Behavioral|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
289606|NCT02677688|Biological|Autologous EBV specific CTL infusion|
289607|NCT02677701|Drug|azithromycin|500mg tablet over-encapsulated to match placebo
289608|NCT00199186|Drug|idarubicin|
289609|NCT02677701|Drug|placebo (for azithromycin)|
289610|NCT02677701|Drug|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
289611|NCT02677714|Radiation|99mTc-rhAnnexin V-128|
289612|NCT02677727|Other|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
289613|NCT02677740|Device|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention. One week before the MRI/MRS acquisitions, neurophysiological parameters are also measured before and between 20 and 40 minutes after the inhibitory rTMS intervention.
289614|NCT02680093|Other|Cervical length in pregnant women.|Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.
additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes.
289615|NCT02680106|Device|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous dressing is thus created.
289616|NCT02680106|Device|JELONET|The patient's DSW will be dressed by JELONET
289617|NCT02680119|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
289618|NCT00199550|Procedure|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
289619|NCT02680119|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
289620|NCT02680132|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
289621|NCT02680132|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
289018|NCT02652286|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
289019|NCT00196989|Drug|Pioglitazone|
289020|NCT02652299|Biological|Synovial biopsy|Synovial tissue for analysis and biobank.
289313|NCT02647450|Other|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
289314|NCT02647463|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|
289315|NCT02647476|Dietary Supplement|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
289316|NCT02647476|Dietary Supplement|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
289317|NCT02647489|Biological|PAMVAC|
289318|NCT00196469|Drug|heparin|
289319|NCT02647489|Biological|Alhydrogel|
289320|NCT02647489|Biological|GLA-SE|
289321|NCT02647489|Biological|GLA-LSQ|
289322|NCT02647489|Other|Placebo|
289323|NCT02647502|Other|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
289324|NCT02647515|Drug|ranibizumab|
289325|NCT02647528|Device|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
289326|NCT02647528|Device|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
289327|NCT02647541|Dietary Supplement|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
289328|NCT02647554|Drug|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
289329|NCT00002531|Drug|asparaginase|
289330|NCT00196482|Drug|changing of fortifier|
289331|NCT02647554|Drug|Placebo|matching placebo every 8 hours for 10 days
293605|NCT02624752|Dietary Supplement|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
293606|NCT00193739|Drug|Inj.Cisplatin|Concurrent chemo radiotherapy
293607|NCT02624765|Drug|Digoxin (monotherapy)|Digoxin: oral or intravenous loading dose 0.5 mg q 12 h (total 4 doses over 48 hours) Oral maintenance dose: 0.25 mg-1mg/day
293608|NCT02624765|Drug|Sotalol (monotherapy)|Sotalol: 80 mg TID (TID mg/day)
293609|NCT02624765|Drug|Flecainide (monotherapy)|Flecainide: 100 mg TID (300 mg/day)
293610|NCT02624765|Drug|Digoxin (dual therapy)|Digoxin: oral or intravenous loading dose 0.5 mg q 8 h (total 4 doses over 32 hours) Oral maintenance dose: 0.25 mg-1mg/day
293611|NCT02624765|Drug|Sotalol (dual therapy)|Sotalol: 160 mg BID (320 mg/day)
289021|NCT02652312|Drug|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
289022|NCT02652312|Drug|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
289023|NCT02652312|Procedure|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
289024|NCT02654145|Drug|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
289025|NCT02654145|Drug|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
289026|NCT02654158|Drug|Low-dose of Fuganlin Oral Liquid|less than 1 years old: 5mL each time and three times a day
1~3 years old: 10mL each time and three times a day
4~6 years old: 10mL each time and four times a day
7~12 years old: 10mL each time and five times a day
289027|NCT02654158|Drug|High-dose of Fuganlin Oral Liquid|less than 1 years old: 10mL each time and three times a day
1~3 years old: 20mL each time and three times a day
4~6 years old: 20mL each time and four times a day
7~12 years old: 20mL each time and five times a day
289028|NCT02654171|Drug|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
289029|NCT00197249|Biological|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
289030|NCT02654171|Drug|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
289031|NCT02654184|Procedure|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
293325|NCT02631018|Behavioral|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
293326|NCT02631031|Drug|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
293327|NCT02631044|Biological|JCAR017 single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by one IV dose of JCAR017. Participants who respond to treatment but who have not achieved a complete response (CR) may receive additional cycles of study treatment on the dose and schedule to which they were initially assigned.
293612|NCT02624765|Drug|Flecainide (dual therapy)|Flecainide: 100 mg TID (300 mg/day)
293613|NCT02624778|Biological|LY3002813|Administered IV
293614|NCT02624778|Drug|Placebo|Administered IV
293615|NCT02624791|Device|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
293616|NCT02624791|Device|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
293617|NCT00193739|Radiation|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
293618|NCT02626637|Other|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
293619|NCT00193999|Device|Placement of nasogastric tube|
293620|NCT02626650|Other|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
293621|NCT02626676|Other|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
293622|NCT02626689|Other|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
293623|NCT02626689|Other|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
293624|NCT02626702|Other|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
293625|NCT02626715|Drug|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
297966|NCT00401687|Drug|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
297967|NCT00401713|Procedure|Transplantation of autologous RPE|RPE cell suspension
297968|NCT00401713|Procedure|Translocation of autologous RPE and Choroid|RPE patch
297969|NCT00003250|Drug|fenretinide|
297970|NCT00401726|Drug|Venlafaxine ER|
297971|NCT00401726|Behavioral|Dialogues Time to Talk Program|
297972|NCT00401739|Drug|CSL360|Weekly IV Infusion. Dose escalation study.
297973|NCT00401752|Drug|Esomeprazole|
297974|NCT00401752|Drug|Ranitidine|
297975|NCT00401765|Drug|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
297976|NCT00401765|Drug|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
297977|NCT00401778|Drug|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
298349|NCT00392899|Drug|tegafur-uracil|
298350|NCT00003209|Drug|vindesine|
298351|NCT00392899|Other|clinical observation|
298352|NCT00392899|Procedure|adjuvant therapy|
298353|NCT00392912|Drug|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
298354|NCT00392925|Drug|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
298355|NCT00392925|Drug|metreleptin|subcutaneous injection, twice a day, 5mg
298356|NCT00392925|Drug|placebo-pramlintide 600 uL|twice a day
298357|NCT00392925|Drug|placebo-metreleptin 1 mL|twice a day
298358|NCT00392925|Drug|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
297597|NCT00410488|Drug|Vincristine|2 mg IV by rapid administration on day 0 (for patients with small cell histology).
For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only.
297598|NCT00410488|Drug|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
297599|NCT00410501|Drug|Indacaterol (QAB149)|
297600|NCT00410514|Drug|Mirabegron|oral
297601|NCT00410514|Drug|Placebo|oral
297602|NCT00003292|Drug|ifosfamide|
297603|NCT00410527|Drug|Merrem|
297604|NCT00410540|Drug|OROS hydromorphone HCL ; Morphine sulfate|
297605|NCT00410553|Drug|Eribulin Mesylate|Given IV
297606|NCT00410553|Drug|Gemcitabine Hydrochloride|Given IV
297607|NCT00410566|Drug|rhASM|Single dose of 0.03mg/kg body weight IV
297608|NCT00410566|Drug|rhASM|Single dose of 0.1mg/kg body weight IV
297609|NCT00312091|Drug|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
297610|NCT00312091|Drug|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
297611|NCT00312104|Drug|insulin detemir|
297612|NCT00312104|Drug|insulin glargine|
297613|NCT00312104|Drug|insulin aspart|
297614|NCT00312117|Drug|Sodium bicarbonate|
297615|NCT00312130|Drug|Vildagliptin|
297616|NCT00312143|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
297617|NCT00312156|Drug|insulin detemir|
297618|NCT00312156|Drug|insulin NPH|
297619|NCT00000458|Drug|sertraline (Zoloft)|
293385|NCT02637843|Device|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
293386|NCT02637856|Drug|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300 milligram (mg) infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
293387|NCT02637869|Other|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
293388|NCT02637882|Other|Ear plug|The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
293389|NCT00195312|Biological|IL-15 DNA (formulated with bupivacaine)|
293390|NCT02637882|Other|Eye mask|The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
293391|NCT02637882|Other|Mixed intervention (ear plug and eye mask)|The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
293392|NCT02637895|Drug|Placebo|
293393|NCT02637895|Drug|Vortioxetine|
293394|NCT02637908|Behavioral|Mindfulness training|6-weeks of group-based mindfulness training for parents
293395|NCT02637921|Other|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
293396|NCT02637921|Other|Ambulatory|Participants hava a standardized activity level throughout the intervention
293397|NCT02637921|Other|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
293398|NCT02637921|Other|Bed Rest|Participants remain on supine bed rest throughout the intervention
293399|NCT02637921|Other|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
293400|NCT00195312|Biological|IL-12 DNA (formulated with bupivacaine)|
293401|NCT02637934|Drug|[18F]FluorThanatrace|
293402|NCT02637934|Radiation|PET/CT imaging sessions|
293403|NCT02637947|Device|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
292820|NCT02613078|Dietary Supplement|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
292821|NCT02613078|Behavioral|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
292822|NCT02613091|Drug|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
292823|NCT02613104|Other|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
292824|NCT02613104|Other|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
292825|NCT02613104|Other|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
293118|NCT02642510|Other|Structured Education DVD + Verbal Teaching|The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.
Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
293119|NCT02642510|Other|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
293120|NCT02644538|Drug|PegIFN alfa-2a|chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA <1000copies/ml, and HBsAg<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
293121|NCT02644551|Drug|CELEXT07|
293122|NCT02644551|Drug|Penlac|
293123|NCT02644551|Other|vehicle solution|
293124|NCT02644564|Other|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
293125|NCT02644577|Drug|Metformin|
292521|NCT02617498|Device|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
292522|NCT02619799|Drug|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
292523|NCT02619799|Drug|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
292524|NCT02619812|Other|SBI|SBI 10 grams (You will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
292525|NCT02619812|Drug|Colesevelam|Welchol 1.875 g (You will take a total of 12 capsules of Wechol 1.875g per day; taken as 6 capsules twice a day by mouth).
292526|NCT02619812|Other|Double Placebo|Double placebo twice per day (You will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
292527|NCT02619825|Device|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
292528|NCT02619825|Device|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
292529|NCT02619838|Device|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
292530|NCT00193362|Drug|Paclitaxel|
292531|NCT02619851|Biological|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
292532|NCT02619851|Device|Conventional Therapy|Typical therapy conducted for burn injury patients
292533|NCT02619864|Drug|AZD2014|
292534|NCT02619877|Biological|ALLO-ASC-DFU|Dressing for diabetic foot ulcer wound
292535|NCT02619877|Procedure|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
292536|NCT02619890|Other|Brain Glioma Registry|
292537|NCT02619903|Procedure|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
292826|NCT02613104|Other|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
291927|NCT00194571|Behavioral|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
292212|NCT02624154|Procedure|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
292213|NCT02624167|Drug|NW-3509A|Patients will be given oral doses of 15-25 mg BID of NW-3509A
292214|NCT02624167|Drug|Placebo|Patients will be given oral dose of matching Placebo
292215|NCT02624180|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
292216|NCT02624180|Drug|Placebo|A substance containing no medication
292217|NCT02624193|Behavioral|MBSR Program|Mindfulness-based stress reduction, as described previously.
292218|NCT00193674|Drug|Dydrogesterone|20 mg/day, oral
292219|NCT02624193|Behavioral|HT Program|Health education curriculum, as described previously
292220|NCT02624206|Dietary Supplement|Juice A|Subjects to be given juice daily for 3 weeks.
292221|NCT02624206|Dietary Supplement|Juice B|Subjects to be given juice daily for 3 weeks.
292222|NCT02624219|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
292223|NCT02626130|Behavioral|Long-Term Follow-Up|Participant contacted by study staff about every 6 months. Participant contacted by phone call or e-mail. Phone call should last about 5 minutes.
292224|NCT02626143|Other|Investigational nutrient-rich whey protein formula|
292225|NCT02626143|Other|Cow's milk based formula|
292226|NCT02626156|Device|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
292227|NCT00193921|Drug|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
292228|NCT02626156|Device|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
292229|NCT02626169|Drug|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
291636|NCT02637167|Drug|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
291637|NCT02637180|Drug|anti-osteoporotic medication|check previous information
291638|NCT02637193|Drug|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
291928|NCT02630563|Drug|Cyclosporine|Cyclosporine will be administered as per center practice.
291929|NCT02630563|Drug|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
291930|NCT02630576|Device|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
291931|NCT02630589|Device|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
291932|NCT02632591|Drug|copaxone|every 24 hours
291933|NCT02632604|Behavioral|Computerized cognitive training|40 hours of a computerized cognitive training, given 1 hour daily
291934|NCT02632604|Behavioral|Computer games|
291935|NCT02632617|Other|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
291936|NCT02632630|Drug|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
291937|NCT02632630|Dietary Supplement|Ensure product|Patients will receive one package of Ensure three times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
291938|NCT02632630|Drug|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
291939|NCT02632630|Dietary Supplement|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
291940|NCT02632643|Behavioral|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
291360|NCT02643927|Behavioral|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
291361|NCT02643927|Behavioral|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
291362|NCT02643953|Behavioral|Incentives|1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
291363|NCT02643953|Behavioral|Community|1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
291364|NCT02643966|Device|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
291639|NCT02637193|Drug|Moxifloxacin|400 mg single dose moxifloxacin
291640|NCT02637193|Drug|Drug - placebo|Placebo administered for 16 days
291641|NCT02637206|Drug|GSK2894512 Cream|GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
291642|NCT02637206|Drug|Vehicle Cream|Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
291643|NCT02637206|Drug|Empty Patch|Empty patches without any ingredients will be used as negative control.
291644|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
291645|NCT02637232|Other|Mirvaso® / Onreltea TM|
291646|NCT02637245|Other|No intervention|No intervention
291647|NCT02637258|Other|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
291648|NCT02639403|Radiation|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
291370|NCT02644005|Device|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG & Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
291371|NCT02644018|Drug|Imidazolyl ethanamide pentandioic acid|
291372|NCT02644018|Drug|placebo|
291373|NCT02644031|Procedure|mtwo rotary system|post-treatment pain after using mtwo rotary system
291374|NCT02644031|Procedure|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
291375|NCT02646020|Drug|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
291376|NCT02646020|Drug|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
291377|NCT02646046|Behavioral|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
291378|NCT02646046|Behavioral|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
291379|NCT00196339|Drug|Placebo|1 tablet daily
291380|NCT02646059|Other|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
291381|NCT02646059|Other|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
291382|NCT02646072|Drug|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
291383|NCT02646085|Drug|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
291659|NCT02639481|Device|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
290793|NCT02654990|Drug|bortezomib injection|1.3mg/m2 sub-cutaneous administration; Cycle 1-4: 2 weeks on/1 week off twice a week for patients <=75 years at time of screening; once a week for patient > 75 years Cycle 5+: once a week for all patients
290794|NCT02654990|Drug|dexamethasone tablets|pre and 24h after BTZ administration; patients <= 75 years at time of screening: 20mg/dose patients > 75 years: 10mg/dose
290795|NCT02655003|Other|TIME|
290796|NCT02655003|Other|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
290797|NCT02655016|Drug|Niraparib|Niraparib vs Placebo 2:1 ratio
290798|NCT02655016|Drug|Placebo|
291065|NCT02612389|Other|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
291066|NCT00192660|Drug|Nevirapine|
291067|NCT02612402|Device|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
291068|NCT02612402|Device|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
291069|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
291070|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
291071|NCT02612428|Biological|ELAD System|An extracorporeal human hepatic cell-based liver treatment
291072|NCT02612428|Other|Standard of Care (Control)|Standard medical treatment as defined by the protocol
291073|NCT02612441|Device|real Acupuncture Needles|Acupuncture needles
291074|NCT02612441|Device|sham Acupuncture Needles|sham Acupuncture Needles
291075|NCT02612454|Drug|Dupilumab|
290489|NCT00198328|Device|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
290490|NCT02661191|Drug|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
290491|NCT02661204|Device|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
290492|NCT02661217|Drug|LCZ696|The target dose of LCZ696 is 200 mg twice daily. Starting dose of LCZ696 is either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.
290493|NCT02661230|Device|COGNIPLUS|Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
290494|NCT02661243|Device|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
290495|NCT02661256|Device|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
290496|NCT02661256|Dietary Supplement|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
290497|NCT02661269|Device|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
290799|NCT02655029|Drug|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
290800|NCT02657148|Drug|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
290801|NCT02657148|Drug|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
290802|NCT02657161|Biological|RABIPUR®|Biological rabies vaccine
290803|NCT02657161|Biological|PIKA rabies vaccine|Biological rabies vaccine
290804|NCT02657161|Biological|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
290198|NCT02667990|Other|comfy trainer|comfy trainer
290199|NCT02668003|Behavioral|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
290200|NCT02668016|Drug|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
290201|NCT02668016|Other|Placebo|Placebo tablets taken orally once daily for one month
290202|NCT02668029|Drug|oxygen|information already included in arm/group descriptions.
290203|NCT02668029|Drug|medical air|Placebo
290204|NCT02668042|Biological|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
290205|NCT02668055|Biological|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
290206|NCT02668068|Procedure|large volume whole-lung lavage (WLL)|Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
290207|NCT00198991|Drug|Cytarabine|
290208|NCT02668068|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
290209|NCT02668081|Procedure|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
290210|NCT02668081|Procedure|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
290211|NCT02668094|Drug|Lidocaine|
290212|NCT02668094|Drug|Pregabalin|
290213|NCT02668094|Drug|propofol|
290498|NCT02663583|Behavioral|Dysphagia Inventory Questionnaire|Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.
TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.
290499|NCT02663583|Behavioral|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
289927|NCT02673008|Biological|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
289928|NCT02673008|Drug|Cyclosporine A|CsA was withdrawn by 10%/week in patients without aGVHD by day +30.
289929|NCT02673021|Procedure|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
289930|NCT02673047|Biological|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
289931|NCT02673060|Drug|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
289932|NCT02673073|Other|Patient's diary|Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.
Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade.
289933|NCT02673073|Other|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
289934|NCT00199056|Drug|Adriamycin|
289935|NCT02675400|Drug|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse. If Vyvanse is not well tolerated, methylphenidate can be prescribed.
289936|NCT02675400|Behavioral|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
289937|NCT02675400|Drug|Methylphenidate|
289938|NCT02675413|Drug|Dimethyl Fumarate|Open-label
289939|NCT02675426|Drug|ABT-494|ABT-494 oral tablet
289940|NCT02675426|Drug|Placebo|Oral tablet
289941|NCT02675439|Drug|ADU-S100|
289942|NCT00199082|Drug|G-CSF|
289943|NCT02675452|Drug|AMG 176|Study Drug
289944|NCT02675465|Drug|ATB200|
289945|NCT02675465|Drug|AT2221|
289946|NCT02675478|Drug|AC220|
289332|NCT02647567|Other|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
289333|NCT02649634|Behavioral|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
289622|NCT02680145|Device|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
289623|NCT02680158|Device|Oculeve Intranasal Lacrimal Neurostimulator|Active Neurostimulation device
289624|NCT02680171|Behavioral|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
289625|NCT02680171|Other|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
289626|NCT02680184|Drug|CMP-001|The study is designed to be conducted in two phases:1) a dose escalation phase 2) an expansion phase. The key objective of 1: to identify dose levels to be further characterized in the expansion phase. The key objectives of 2: to further characterize the safety, pharmacodynamics, and preliminary evidence of antitumor activity of the CMP-001 + pembrolizumab combination at one or more dose levels.
Subjects in the study will continue treatment with pembrolizumab as per the labeled dose and schedule of administration that had been used prior to study entry. Each treatment cycle is 3 weeks in duration. CMP-001 will be administered by intratumoral injection every week for seven doses.
289627|NCT02680184|Drug|pembrolizumab|The study is designed to be conducted in two phases:1) a dose escalation phase 2) an expansion phase. The key objective of 1: to identify dose levels to be further characterized in the expansion phase. The key objectives of 2: to further characterize the safety, pharmacodynamics, and preliminary evidence of antitumor activity of the CMP-001 + pembrolizumab combination at one or more dose levels.
Subjects in the study will continue treatment with pembrolizumab as per the labeled dose and schedule of administration that had been used prior to study entry.
289628|NCT02680197|Drug|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
289629|NCT00199550|Procedure|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
289630|NCT02680210|Other|Questionnaires and cognitive measures|
289631|NCT02680223|Device|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
289632|NCT02680223|Device|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
289032|NCT02654184|Procedure|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
289033|NCT02654210|Other|No Intervention|No Intervention
289034|NCT02654223|Biological|MG56 Mannosylated 5.000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5.000 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
289035|NCT02654223|Biological|MG56 Mannosylated 10.000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 10.000 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
289036|NCT02654223|Biological|MG56 Mannosylated 30.000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 30.000 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
289037|NCT02654223|Biological|MG56 Mannosylated 50.000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 50.000 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
289038|NCT02654223|Biological|MG56 Mannosylated 5.000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5.000 MTU(Mannosylated Therapeutic Units)/ml sublingual
289334|NCT02649647|Procedure|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus.
289335|NCT02649647|Procedure|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus.
289336|NCT02649673|Drug|LCL161|
289337|NCT02649673|Drug|Topotecan|
289338|NCT00196703|Drug|memantine|
289339|NCT02649686|Drug|Durvalumab|
289340|NCT02649686|Drug|Trastuzumab|
289341|NCT02649699|Other|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
289342|NCT02649712|Device|biliary stent|Self-expandable biliary nitinol alloys stent
289343|NCT02649725|Behavioral|patient's satisfaction|Questionnaire based measurement.
289344|NCT02649738|Procedure|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
289345|NCT02649751|Drug|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
293626|NCT02626715|Drug|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
293627|NCT02626728|Procedure|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
293628|NCT02626741|Dietary Supplement|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
293629|NCT02626741|Behavioral|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
293630|NCT00194012|Other|Placebo|Addressed in arm description
293631|NCT02626754|Drug|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
289039|NCT02654223|Biological|MG56 Mannosylated 10.000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 10.000 MTU(Mannosylated Therapeutic Units)/ml sublingual
289040|NCT00197262|Drug|GW685698X Aqueous Nasal Spray|
289041|NCT02654223|Biological|MG56 Mannosylated 30.000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 30.000 MTU(Mannosylated Therapeutic Units)/ml sublingual
289042|NCT02654223|Biological|MG56 Mannosylated 50.000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 50.000 MTU(Mannosylated Therapeutic Units)/ml sublingual
289043|NCT02654223|Biological|Subcutaneous placebo|Comparison between placebo and active group
289044|NCT02656576|Procedure|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
289045|NCT02656576|Procedure|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
289046|NCT02656589|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
289047|NCT02656589|Drug|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
289048|NCT02656602|Other|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
289049|NCT02656615|Drug|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
298359|NCT00392938|Drug|antiandrogen therapy|
298360|NCT00392938|Drug|docetaxel|
298361|NCT00003209|Radiation|radiation therapy|
298362|NCT00392938|Procedure|positron emission tomography|
298363|NCT00395603|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
298364|NCT00395616|Drug|Botox (drug)|
298365|NCT00395629|Drug|Deferasirox (ICL670)|
298366|NCT00395642|Device|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
298367|NCT00395655|Drug|Hydralazine and magnesium valproate administration|
298368|NCT00003215|Procedure|peripheral blood stem cell transplantation|
298369|NCT00395655|Procedure|Core-needle biopsy of the breast|
298370|NCT00395668|Device|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
298371|NCT00395681|Drug|Diprivan|Propofol 200 mg versus 350 mg
298372|NCT00395694|Drug|lamictal|anti-epileptic drug
298373|NCT00395707|Drug|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
298374|NCT00395707|Drug|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
298725|NCT00387660|Drug|irinotecan hydrochloride|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
298726|NCT00387673|Behavioral|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
298727|NCT00387686|Drug|rhBMP-2/CPM|
298728|NCT00387686|Drug|rhBMP-2/CPM|
298729|NCT00387686|Drug|rhBMP-2/CPM|
297978|NCT00401791|Behavioral|Exercise|Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period
Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer.
297979|NCT00401804|Drug|Dexamethasone, Bortezomib, Doxorubicin|
297980|NCT00003251|Drug|amifostine trihydrate|
297981|NCT00404417|Drug|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
297982|NCT00404417|Drug|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
297983|NCT00404417|Drug|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
297984|NCT00003263|Radiation|radiation therapy|
297985|NCT00404417|Drug|Placebo / Placebo|Placebo at first injection / Placebo at second injection
297986|NCT00404443|Device|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
297987|NCT00404456|Drug|Melatonin|Melatonin 3 mg once-daily
297988|NCT00404469|Procedure|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
297989|NCT00404469|Procedure|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
297990|NCT00404469|Procedure|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
297991|NCT00404482|Drug|Cyclosporine A|
297992|NCT00404495|Drug|Irinotecan|Irinotecan 10 mg/m^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
297993|NCT00404495|Drug|Temozolomide|Temozolomide 100-125 mg/m^2 daily on days 1-5 in repeated 3 week cycles
297994|NCT00404508|Drug|Hydralazine and magnesium valproate|
297995|NCT00003264|Drug|cisplatin|
297996|NCT00404521|Drug|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
293404|NCT02637947|Device|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
293689|NCT02633332|Drug|etanercept|every week, subcutaneous injection
293690|NCT02633345|Dietary Supplement|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
293691|NCT00194792|Drug|paclitaxel|Given IV
293692|NCT02633345|Dietary Supplement|Placebo|Placebo tablets
293693|NCT02633358|Device|Therapeutic hypothermia|Therapeutic hypothermia
293694|NCT02633371|Drug|Oxybutynin 3% gel|
293695|NCT02633384|Other|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
293696|NCT02633384|Other|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
293697|NCT02633397|Drug|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
293698|NCT02633397|Drug|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
293699|NCT02633410|Procedure|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
293700|NCT02633423|Procedure|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
293701|NCT02633423|Procedure|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB, with an airway pressure of 5 cmH2O.
293702|NCT00194792|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
293703|NCT02633423|Procedure|Ventilation with low tidal volume during CPB|Ventilation will be provided with 5 acts per minute, with a tidal volume of 2-3 ml/kg of IBW and a PEEP of 5 cmH2O.
293704|NCT02633436|Other|SLC1A5 expression|To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
293705|NCT02635542|Drug|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
293706|NCT02635542|Drug|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
293126|NCT02644577|Other|Starch|
293127|NCT02644590|Drug|Melatonin|Detailed in arm description
293128|NCT00196144|Device|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
293129|NCT02644603|Procedure|Enhanced Recovery After Surgery|Before operation:
Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.
In operation:
Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.
After operation:
Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization.
293130|NCT02644616|Drug|tolvaptan+torasemide|tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
293131|NCT02644616|Drug|placebo+torasemide|placebo 15mg/d po(10 days) +torasemide 20mg/d iv
293132|NCT02644629|Drug|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
293133|NCT02644629|Drug|Ketamine|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
293134|NCT02644642|Other|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
293135|NCT02644655|Biological|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
293136|NCT02644668|Drug|CK-2127107 150 mg|
293405|NCT02637960|Drug|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
293406|NCT02637960|Drug|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
293407|NCT02640131|Behavioral|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
293408|NCT02640144|Drug|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
293409|NCT02640144|Drug|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
293410|NCT02640157|Drug|ABT-493/ABT-530|
293411|NCT02640157|Drug|sofosbuvir|sofosbuvir 400 mg tablets
292827|NCT00192712|Drug|irinotecan, gemcitabine|
292828|NCT02613117|Device|Potassium Oxalate Gel|Self applied
292829|NCT02613117|Device|Potassium Oxalate Liquid|Professionally Applied
292830|NCT02613117|Drug|Stannous fluoride paste|SnF2 Paste
292831|NCT02613130|Drug|Stannous fluoride toothpaste|
292832|NCT02613130|Drug|Potassium nitrate toothpaste|
292833|NCT02615301|Dietary Supplement|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
292834|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
292835|NCT02615301|Dietary Supplement|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
292836|NCT02615314|Procedure|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
292837|NCT02615327|Dietary Supplement|Polydextrose|8g of Polydextrose
292838|NCT02615327|Dietary Supplement|Polydextrose|12 g of Polydextrose
292839|NCT02615327|Dietary Supplement|Polydextrose|16 g of Polydextrose
292840|NCT02615327|Dietary Supplement|Placebo|0 g of Polydextrose
292841|NCT02615340|Drug|Melatonin|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
292842|NCT00193063|Drug|Gemcitabine|Gemcitabine
293137|NCT02644668|Drug|Placebo|
293138|NCT02644668|Drug|CK-2127107 450 mg|
292230|NCT02626169|Drug|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
292231|NCT02626182|Drug|sildenafil|active sildenafil
292232|NCT02626182|Drug|placebo|sugar pill that looks like sildenafil tablets
292538|NCT02619916|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
292539|NCT02619916|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
292540|NCT02619929|Drug|Vinorelbine oral|
292541|NCT00193362|Drug|Carboplatin|
292542|NCT02619942|Procedure|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
292543|NCT02619942|Procedure|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
292544|NCT02619955|Other|samples with DNA|
292545|NCT02621944|Behavioral|Generalized Motor Assessment|All participants will receive the GMA assessment.
292546|NCT02621957|Drug|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
292547|NCT02621957|Drug|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
292548|NCT00193492|Drug|Rituximab|
292549|NCT02621970|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
292550|NCT02621970|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1
292551|NCT02621970|Drug|Docetaxel|Docetaxel 60mg/m2, D1
292552|NCT02621970|Drug|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
292553|NCT02621970|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
292554|NCT02621983|Behavioral|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
291941|NCT02632656|Other|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
291942|NCT00194779|Other|immunohistochemistry staining method|Correlative studies
291943|NCT02632669|Radiation|Hemi gland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre - treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine 125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks,3,6,9,12,18,24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
292233|NCT02626195|Dietary Supplement|nutritional support program|Nutritional support program is briefly described below.
Interval: 5-10 days Contents: admission is required
Calories: 30-35Kg, via enteral or parenteral
Protein: 1.2-1.5g/Kg
Lipid : 1-1.5g/Kg
Mineral and vitamins supply
Blood glucose control
Daily monitoring by dietician and specialized nurse
292234|NCT02626208|Device|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
292235|NCT02626221|Other|Non Interventional Study|Non Interventional Study
292236|NCT02626234|Drug|INC280|
292237|NCT02626234|Drug|digoxin|
292238|NCT00193921|Drug|Cisplatin|20mg/m2, IV, weekly
292239|NCT02626234|Drug|rosuvastatin|
292240|NCT02626247|Dietary Supplement|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
292241|NCT02626247|Other|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
292242|NCT02626260|Other|adhesive strip|Adhesive strip with a standard adhesive base
292243|NCT02626273|Radiation|weight loss|
292244|NCT02626286|Other|HIV quarterly global care|
292245|NCT02626299|Drug|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
292246|NCT02626299|Drug|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
292247|NCT02628275|Behavioral|Light physical activity|40-55% maximum heart rate for 150min/week
291649|NCT00195494|Drug|Methotrexate|Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2
Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Group 2b: Oral Methotrexate weekly for both Periods 1 and 2
291650|NCT02639416|Dietary Supplement|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
291651|NCT02639416|Dietary Supplement|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
291652|NCT02639416|Other|Standard management|Standard management with F-100 and/or RUTF
291653|NCT02639429|Drug|Vaginal Misoprostol|
291654|NCT02639429|Device|Foley Balloon + Vaginal Misoprostol|
291655|NCT02639442|Device|ClearRing™|
291656|NCT02639455|Behavioral|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
291657|NCT02639468|Device|Stroke Volume estimation using electrical impedance tomography|
291658|NCT02639481|Behavioral|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
291944|NCT02632695|Device|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
291945|NCT02632708|Drug|AG-120|
291946|NCT02632708|Drug|AG-221|
291947|NCT02632708|Drug|cytarabine|
291948|NCT02632708|Drug|daunorubicin|
291949|NCT02632708|Drug|idarubicin|
291950|NCT02632708|Drug|mitoxantrone|
291951|NCT02632708|Drug|etoposide|
291952|NCT02632721|Drug|Decitabine|
291953|NCT00194779|Biological|trastuzumab|Given IV
291660|NCT00195494|Drug|Placebo|Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
291661|NCT02639481|Device|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
291662|NCT02639507|Procedure|Vitrectomy|
291663|NCT02639520|Drug|Canephron® N|2 tablets 3 times a day for 7 days
291664|NCT02639520|Drug|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
291665|NCT02639520|Drug|Canephron® N-placebo|2 tablets 3 times a day for 7 days
291666|NCT02639520|Drug|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
291667|NCT02639533|Drug|Pregabalin|Pregabalin 150 mg PO, single dose.
291668|NCT02639533|Other|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
291669|NCT02641782|Drug|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
291670|NCT02641795|Device|Minimally invasive robotic cochlear implantation|
291671|NCT02641808|Other|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
291672|NCT02641808|Other|no follicular flushing|
291673|NCT02641821|Drug|Nifedipine GITS|
291674|NCT02641834|Other|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
291675|NCT02641834|Other|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
291676|NCT00195741|Drug|divalproex sodium|
291677|NCT02641847|Drug|docetaxel|
291678|NCT02641847|Drug|doxorubicin or epirubicin|
291679|NCT02641847|Drug|cyclophosphamide|
291076|NCT02612467|Other|Stratified care|Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.
Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability.
291077|NCT02614638|Other|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
291078|NCT02614638|Other|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
291079|NCT02614651|Procedure|Find visual comfort threshold related to light intensity|In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.
The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the "space" bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally.
291384|NCT02646098|Procedure|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
291385|NCT02646111|Drug|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
291386|NCT02646111|Drug|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
291387|NCT02646111|Drug|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
291388|NCT02646124|Drug|Naproxen|Naproxen 500mg po BID #20
291389|NCT02646124|Drug|Placebo|28 placebo capsules
291390|NCT00196352|Drug|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
291391|NCT02646124|Drug|Diazepam|Diazepam 5mg capsules, 1-2 tabs po BID, #28
291392|NCT02646137|Procedure|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
291393|NCT02646137|Procedure|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
290805|NCT02657174|Device|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
290806|NCT00197704|Other|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
290807|NCT02657174|Device|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
290808|NCT02657187|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
290809|NCT02657187|Drug|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
290810|NCT02657200|Other|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
290811|NCT02657213|Device|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
290812|NCT02657213|Device|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
290813|NCT02657239|Behavioral|MOVE UP|Weight management behavioral program
290814|NCT02657252|Drug|Glucose|Sclerotherapy of telangiectasis in one lower limb.
290815|NCT02657252|Drug|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
290816|NCT02657265|Device|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
291080|NCT02614651|Procedure|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
291081|NCT02614651|Procedure|Effectiveness of brightness control|During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.
The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object.
291082|NCT02614651|Procedure|Performance of color correction|During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).
The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions.
290500|NCT02663596|Drug|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
290501|NCT02663609|Other|No intervention|No treatment (intervention) was administered.
290502|NCT02663622|Drug|CD24Fc|
290503|NCT02663622|Drug|Methotrexate|
290504|NCT02663622|Drug|Tacrolimus|
290505|NCT00198588|Drug|argatroban|beginning dose: 0.7microgram/kg/H
290506|NCT02663635|Device|Safe'N'Sound|
290507|NCT02663661|Procedure|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
290508|NCT02663661|Other|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
290509|NCT02663674|Drug|Fluconazole|Fluconazole is a synthetic triazole antifungal agent.
290510|NCT02663674|Other|Placebo|standard of care
290511|NCT02663687|Drug|Recombinant human C1 esterase inhibitor|subjects will receive escalating doses I-IV either in IV of SC form
290512|NCT02663687|Drug|Placebo|Subjects will receive matching placebo
290513|NCT02663700|Other|Placebo|Placebo
290514|NCT02663700|Biological|PfSPZ|4.5 x 10E5 PfSPZ organisms
290515|NCT02663700|Biological|PfSPZ|2.7 x 10E6 PfSPZ organisms
290516|NCT00198601|Drug|Gentamicin in Uniject Pre-filled syringe|
290517|NCT02663700|Biological|PfSPZ|1.8 x 10E6 PfSPZ organisms
290518|NCT02663700|Drug|Artesunate|10mg oral tablet
290519|NCT02663700|Biological|PfSPZ|9.0 x 10E5 PfSPZ organisms
290520|NCT02663713|Drug|Ticagrelor|Ticagrelor 60mg twice daily
290521|NCT02663713|Drug|Clopidogrel|Clopidogrel 75 mg once daily
289947|NCT02675491|Drug|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
289948|NCT02675504|Other|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
290214|NCT02668107|Other|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
290215|NCT02668133|Dietary Supplement|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
290216|NCT02668133|Dietary Supplement|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS) added during manufacturing
290217|NCT02668133|Dietary Supplement|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
290218|NCT00198991|Drug|Mercaptopurine|
290219|NCT02670564|Other|Busulfan plasma level measurements|Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).
Blood sampling:
->For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion
->For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.
For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:
-> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below
290220|NCT02670590|Behavioral|diet|diet
290221|NCT02670603|Drug|EVONAIL® solution|
290222|NCT02670616|Drug|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
290223|NCT02670616|Drug|Rituximab|
290224|NCT02670616|Drug|Cyclophosphamide|
290225|NCT02670616|Drug|Doxorubicin|
290226|NCT02670616|Drug|vincristine|
290227|NCT02670616|Drug|Prednisolone|
290228|NCT02670629|Procedure|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
290229|NCT00199017|Drug|Cyclophosphamide|
290230|NCT02670629|Procedure|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
289633|NCT02682225|Drug|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
289634|NCT00199914|Device|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
289635|NCT02682225|Drug|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
289636|NCT02682225|Drug|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
289637|NCT02682238|Drug|BBI-4000, 15%|
289638|NCT02682238|Other|Vehicle gel|
289949|NCT02675517|Drug|Spiolto Respimat|Tiotropium bromide + Olodaterol
289950|NCT02675530|Drug|ketamine|For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.
No drug administration for patients with schizophrenia
289951|NCT02675543|Device|Vitreous Tamponade with Silicone Oil|
289952|NCT02675556|Drug|Allo-hMSCs|
289953|NCT00002534|Drug|thiotepa|
289954|NCT00199082|Drug|Rituximab|
289955|NCT02675556|Drug|Placebo|
289956|NCT02675569|Procedure|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
289957|NCT02675569|Procedure|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
289958|NCT02675582|Other|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
289959|NCT02675608|Biological|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
289960|NCT02675621|Other|Phenolic Beverage|
289961|NCT02675634|Device|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
289962|NCT02675634|Device|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
289346|NCT02649751|Drug|Placebo|The placebo treatment is lactose capsule.
289347|NCT02649764|Drug|Fludarabine|Induction and Consolidation Phase Dose of Fludarabine: 30 mg/m2 by vein over 2 hours for 4 days.
289348|NCT02649764|Drug|Cytarabine|Induction and Consolidation Phase Dose of Cytarabine: 1.5 gram/m2 continuous infusion daily for 4 days.
289349|NCT00002531|Drug|daunorubicin hydrochloride|
289350|NCT00196703|Procedure|constraint-induced language therapy|
289351|NCT02649764|Drug|LY2606368|Induction Phase Starting Dose of LY2606368: 30 mg/m2 by vein daily for 3 days (days 1, 3, 4).
Consolidation Phase Starting Dose of LY2606368: Maximum tolerated dose (MTD) from Induction Phase.
289352|NCT02649790|Drug|KPT-8602|
289353|NCT02649803|Behavioral|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
289354|NCT02652312|Procedure|fentanyl|1.5 μg/kg intraoperative
289639|NCT02682251|Other|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
289640|NCT02682264|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
289641|NCT02682277|Device|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
289642|NCT02682277|Other|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
289643|NCT02682290|Other|Expectoration and measurement of sputum rheological properties|
289644|NCT02682303|Device|Optiplast C® (elastic adhesive bandaging)|Optiplast C® (6cm*2.5m) was used.
The individual is in supine position keeping the foot and ankle in a neutral position.
The first strip is applied in the inside of the leg just above the ankle, and then the rest of the strip is applied on the inside of the ankle and under the heel.
The second strip is applied in the outside of the leg above the ankle; the strip passes on the front of the ankle and the internal malleolus to the heel.
The third strip is applied in the opposite direction, from the inside of the leg to the outside of the leg, passing on the front of the ankle and under the heel.
This is the only intervention carried out in this group.
289645|NCT00199927|Drug|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
289646|NCT02682303|Device|Pretape cramer® (non standarized tape)|Pretape cramer® was used.
The individual is in supine position keeping the foot and ankle in a neutral position.
The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
This is the only intervention carried out in this group.
289050|NCT00197613|Drug|(E) stavudine, lamivudine, and nevirapine|
289051|NCT02656628|Device|Dynamic Locking Screw 3.7mm and 5.0mm|Treatment with DLS and locked plate constructs (small or large fragments)
289052|NCT02656641|Behavioral|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
289053|NCT02656641|Behavioral|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
289054|NCT02656654|Other|Whole-body compression|
289055|NCT02656667|Device|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
289056|NCT02656667|Device|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
289057|NCT02656667|Other|Conventional pulmonary rehabilitation|excercise training on treadmill
289355|NCT02652312|Procedure|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
289356|NCT02652312|Procedure|Atracurium|0.5 mg/kg IV for endotracheal intubation
289357|NCT02652312|Procedure|diclofenac sodium|1 mg/kg for postoperative analgesia
289358|NCT02652312|Procedure|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
289359|NCT02652325|Drug|Saline|
289360|NCT00196989|Drug|GW677954|
289361|NCT02652325|Drug|Povidone-Iodine|
289362|NCT02652325|Drug|5% Povidone-Iodine USP swabs|
289363|NCT02652338|Dietary Supplement|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
289364|NCT02652338|Dietary Supplement|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
289365|NCT02652351|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
289366|NCT02652377|Drug|EDP-494|10, 100 and 200 mg capsules
289367|NCT02652390|Drug|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
298730|NCT00387686|Drug|rhBMP-2/CPM|
298731|NCT00387699|Biological|bevacizumab|
298732|NCT00387699|Drug|cisplatin|
298733|NCT00387699|Drug|etoposide|
298734|NCT00003187|Biological|filgrastim|
298735|NCT00387699|Radiation|radiation therapy|
298736|NCT00387712|Other|Chronic stroke treadmill exercise to improve function|6 month of treadmill exercise with a safety harness to prevent falls. Exercise is gradually progressed in walking speed and time on treadmill based on individual participant's tolerance, abilities and safety. Stroke participants are randomized to a) walking longer duration or b) walking at faster speeds on a treadmill for 6 months.
298737|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
298738|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
298739|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
298740|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
298741|NCT00387738|Biological|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
298742|NCT00387738|Biological|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
298743|NCT00387751|Biological|Bevacizumab|Given IV
298744|NCT00387751|Other|Laboratory Biomarker Analysis|Correlative studies
298745|NCT00003187|Drug|cyclophosphamide|
298746|NCT00387751|Other|Pharmacological Study|Correlative studies
298747|NCT00387751|Drug|Sorafenib Tosylate|Given orally
299108|NCT00003145|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
299109|NCT00379262|Drug|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
299110|NCT00379262|Drug|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
299111|NCT00379262|Drug|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
297997|NCT00404534|Drug|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
297998|NCT00404547|Drug|Ciclesonide|Asthma Care with Alvesco
298375|NCT00395707|Drug|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
298376|NCT00395707|Drug|Ranibizumab (Lucentis)|0.5mg/0.05 ml
298377|NCT00395720|Biological|MVA85A (TB vaccine)|Intradermal vaccine
298378|NCT00395720|Biological|MVA 85A|Intradermal vaccine
298379|NCT00003215|Radiation|radiation therapy|
298380|NCT00395733|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
298381|NCT00395733|Drug|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
298382|NCT00395746|Drug|sulfonylurea|SU agent
298383|NCT00395746|Drug|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
298384|NCT00395746|Drug|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
298385|NCT00395759|Drug|Optiva artificial tear by Allergan|
298386|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
298387|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
298388|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
298389|NCT00395772|Drug|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
298390|NCT00003216|Drug|fluorouracil|
298391|NCT00398658|Drug|gentamycin and clindamycin|
298392|NCT00398671|Device|Application of cool cap after primary successful CPR|
293707|NCT02635555|Drug|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
293708|NCT02635568|Other|Cannabis Use|Observational Study
293709|NCT00195039|Drug|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated ("naked") J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min.
289111|NCT02662985|Drug|Placebo|Secukinumab placebo provided in a 1 mL PFS for s.c. injection.
289112|NCT02663011|Other|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool "Preschool Language Scale Corrected edition(PLS-C), Lin" was adopted for evaluation.
289113|NCT02663024|Biological|idursulfase beta|IV, weekly infusion for 24 weeks
289114|NCT02663024|Biological|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
289115|NCT02663050|Other|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
289116|NCT00198523|Drug|Prednisolone and Tobramycin|
289117|NCT02663050|Drug|NSAID's|twice a daily
289118|NCT02663063|Device|SSP treatment|SSP treatment 5 times a week
289119|NCT02663089|Drug|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of [14C]-GSK961081 (approximately 6.2 kilobecquerel [kBq]) intravenously as a single dose over 1 hour.
289120|NCT02663089|Drug|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of [14C]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
289121|NCT02663089|Drug|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
289122|NCT02663102|Other|Data collection|Safety monitoring and evaluation: ‒ Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. ‒ Recording of SAEs throughout the study period for each subject.
289123|NCT02663115|Other|Biopsy of the diaphragmatic muscle|
289124|NCT02663115|Other|Skeletal muscle biopsy|
289125|NCT02663128|Drug|AZD3293|Administered orally
289126|NCT02663141|Drug|Losartan|
293412|NCT02640157|Drug|daclatasvir|daclatasvir 30 mg tablets
293413|NCT00195585|Drug|Isovorin|
293414|NCT02640157|Drug|daclatasvir|daclatasvir 60 mg tablets
293415|NCT02640170|Other|Registry|
293416|NCT02640183|Drug|EMLA|
293417|NCT02640183|Other|Placebo|
293418|NCT02640196|Device|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
293419|NCT02640196|Device|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
293420|NCT02640196|Device|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
293421|NCT02640196|Device|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
293422|NCT02640209|Biological|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
293423|NCT02640222|Drug|VKA|
293424|NCT00195585|Drug|UFT|
293425|NCT02640222|Drug|Apixaban|
293426|NCT02640222|Drug|dabigatran|
293427|NCT02640222|Drug|rivaroxaban|
288832|NCT02669836|Procedure|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
288833|NCT02669849|Drug|VX-210|
288834|NCT02669849|Drug|Placebo|
288835|NCT02669862|Drug|A-101 Solution 40|
288836|NCT02669862|Drug|A-101 Solution 45|
288837|NCT02669862|Drug|Vehicle Solution|
288838|NCT02669875|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
293139|NCT00196144|Device|Nominal PVAB|nominal pacemaker settings
293140|NCT02644681|Procedure|Aortic Aneurysm, Thoracic surgery|
293141|NCT02644694|Drug|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
293142|NCT02644707|Dietary Supplement|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
293143|NCT02644707|Other|Placebo|The group will be randomized to receive placebo (control group) for 6 months
293144|NCT02611050|Behavioral|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
293145|NCT02611050|Behavioral|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
293146|NCT02611063|Drug|fostamatinib|100mg qd, 150mg qd, or 100mg bid
293147|NCT02611076|Behavioral|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
293148|NCT02611076|Behavioral|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
293149|NCT02611089|Procedure|Tissue biopsy|Sampling of tissue as described.
293150|NCT02611102|Dietary Supplement|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
293151|NCT02611128|Other|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
293152|NCT00192569|Drug|Ribavirin (HIV conifected patients only)|genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg)
Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
293153|NCT02611141|Procedure|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack & Lehane .
This score will be assessed at least 2 minutes after muscle relaxation:
Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):
If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.
Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used.
292555|NCT02621983|Behavioral|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
292556|NCT02621996|Device|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
292843|NCT02615340|Drug|Placebo|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
292844|NCT02615353|Behavioral|Intensive Lifestyle Intervention|6-months of lifestyle education
292845|NCT02615353|Other|Usual Care Control|Medical visit and dietary counseling
292846|NCT02615366|Drug|Tranexamic Acid|
292847|NCT02615366|Drug|Placebo|
292848|NCT02615379|Device|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
292849|NCT02615392|Behavioral|Park Prescription|Please refer to the information included in the arm description.
292850|NCT02615405|Dietary Supplement|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 & 2.
292851|NCT02615405|Dietary Supplement|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 & 2.
292852|NCT02615405|Dietary Supplement|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
292853|NCT02617498|Device|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
292854|NCT02617511|Dietary Supplement|Omega-3 Supplementation|
292855|NCT02617511|Dietary Supplement|Placebo|
292856|NCT02617524|Device|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
292857|NCT02617537|Drug|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
292248|NCT02628288|Device|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
292249|NCT00002524|Drug|Fluorouracil|
292250|NCT00194324|Drug|Miconazole nitrate|
292251|NCT02628301|Dietary Supplement|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
292252|NCT02628301|Other|Normocaloric diet|Normocaloric diet
292253|NCT02628340|Other|Ex-vivo analysis|
292254|NCT02628353|Dietary Supplement|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
292557|NCT02621996|Device|containment nest|In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests "U", made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation.
292558|NCT02622009|Procedure|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
292559|NCT00193505|Drug|Ifosfamide|
292560|NCT02622022|Drug|Morphine hydrochloride|
292561|NCT02622048|Behavioral|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
292562|NCT02622074|Biological|Pembrolizumab|
292563|NCT02622074|Drug|Nab-paclitaxel|
292564|NCT02622074|Drug|Anthracycline|
292565|NCT02622074|Drug|Cyclophosphamide|
292566|NCT02622074|Drug|Carboplatin|
292567|NCT02624219|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
292568|NCT02624219|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
291954|NCT00194974|Drug|methyldopa|
291955|NCT02634801|Drug|Ixekizumab|Administered SC
291956|NCT02634801|Drug|Fumaric Acid Esters|Administered orally
291957|NCT02634801|Drug|Methotrexate|Administered orally
291958|NCT02634814|Device|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
291959|NCT02634814|Other|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
291960|NCT02634814|Device|Sham Transcutaneous Electrical Nerve Stimulation|Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become "sub-sensory" in nature. The participants will wear the Sham TENS for 8 hours per day.
291961|NCT02634827|Drug|Decitabine|Given IV
291962|NCT02634827|Other|Laboratory Biomarker Analysis|Correlative studies
291963|NCT02634827|Drug|Midostaurin|Given PO
291964|NCT02634840|Procedure|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
291965|NCT00194974|Drug|labetalol|
292255|NCT02628353|Dietary Supplement|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
292256|NCT02628366|Other|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the temperature should be lowered by a minimum of 0.5°C and a maximum of 0.9°C.
292257|NCT02628392|Drug|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
292258|NCT02628392|Drug|Sitagliptin|capsules
292259|NCT02628392|Drug|placebo|matching DS-8500a tablets and sitagliptin capsules
292260|NCT02628405|Drug|Carboplatin|Given IV
291680|NCT02641847|Drug|gemcitabine|
291966|NCT02634853|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
291967|NCT02634853|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
291968|NCT02634879|Behavioral|Incentive Change|
291969|NCT02634892|Device|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
291970|NCT02634905|Other|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
291971|NCT02634905|Other|Phone Call|
291972|NCT02634918|Other|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
291973|NCT02634931|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
291974|NCT02634944|Other|Vestibular Ocular Motor Screening Tool (VOMS)|
291975|NCT02634957|Behavioral|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or wispering)
291976|NCT00194974|Drug|nifedipine|
291977|NCT02634970|Drug|Ranibizumab|0.5 mg, intravitreal injection
291978|NCT02634983|Drug|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
291979|NCT02637271|Other|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
291980|NCT02637271|Other|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
291981|NCT02637284|Drug|Bepecin|Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.
Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics.
291982|NCT02637284|Drug|Placebo|Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.
Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group.
291394|NCT02646137|Procedure|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
291395|NCT02646150|Procedure|Magnetic Resonance Perfusion Imaging|
291396|NCT00192660|Drug|Indinavir|
291397|NCT02612467|Other|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
291398|NCT02612480|Drug|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
291399|NCT02612480|Drug|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
291400|NCT02612480|Drug|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
291401|NCT02612480|Drug|Placebo|7 day treatment with placebo
291402|NCT02612493|Other|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
291403|NCT02612506|Drug|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 1.05mg, 2.1mg, 3.15mg, 4.2mg and 6.3mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will receive one abdominal subcutaneous injection of Hepalatide one time and monitored for 8 days.
291681|NCT02641847|Drug|cisplatin|
291682|NCT02641860|Biological|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
291683|NCT02641873|Drug|BBI608|240 mg twice daily (480 mg total daily dose)
291684|NCT02641873|Drug|FOLFIRI + Bevacizumab|Irinotecan 180 mg/m2 together with levofolinate 200 mg/m2 will be administered intravenously. 5-FU 400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion. This regimen will be repeated every 14 days thereafter.
291685|NCT02641886|Drug|Jian Pi Yi Shen Hua Tan Granules|Jian Pi Yi Shen Hua Tan Granules+ water 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
291686|NCT02641886|Other|the prescription of simulation|95%pure dextrin with the 5% of Jian Pi Yi Shen Hua Tan Granules+ water 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
291687|NCT00002528|Procedure|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
291688|NCT00195754|Drug|divalproex sodium|
291083|NCT02614651|Device|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
291084|NCT02614664|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
291085|NCT02614690|Procedure|No Split Cast of forearm fractures|Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to "No Split Cast" will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months.
291086|NCT02614690|Procedure|Univalve Split Cast of forearm fractures|Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to "Univalve Cast" will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months.
291087|NCT00193011|Drug|5-Fluorouracil|5-Fluorouracil
291088|NCT02614690|Procedure|Bivalve Split Cast of forearm fractures|Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to "Bivalve Cast" will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months.
291089|NCT02614703|Dietary Supplement|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
291090|NCT02616770|Drug|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
291091|NCT02616770|Drug|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
291092|NCT02616770|Drug|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
291093|NCT02616783|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
291094|NCT02616783|Drug|TDF|TDF 300 mg tablet administered orally once daily
291404|NCT02612506|Drug|Placebo|There are six cohorts as follows, 0.525mg, 1.05mg, 2.1mg, 3.15mg, 4.2mg and 6.3mg. At each dose level, healthy volunteers will receive one abdominal subcutaneous injection of placebo one time and monitored for 8 days.
291405|NCT02612519|Device|Alfapump|Implantation of Alfapump
291406|NCT02612519|Device|TIPS|Implantation of TIPS
291407|NCT00192660|Drug|Saquinavir|
290817|NCT00197730|Drug|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
290818|NCT02657265|Device|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
290819|NCT02657278|Procedure|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
290820|NCT02659306|Drug|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
290821|NCT02659319|Behavioral|Family Lifestyle (FL)|12-week Family Food & Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
290822|NCT02659319|Behavioral|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
290823|NCT02659319|Behavioral|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
290824|NCT02659332|Device|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
290825|NCT02659345|Behavioral|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
290826|NCT00197977|Behavioral|Educational program to address patients' expectations|
290827|NCT02659345|Behavioral|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
290828|NCT02659358|Device|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
290829|NCT02659371|Dietary Supplement|Low energy diet|
290830|NCT02659384|Drug|Bevacizumab|
290831|NCT02659384|Drug|atezolizumab|
290832|NCT02659384|Drug|acetyl salicylic acid|
290231|NCT02670642|Drug|Esomeprazole|Proton pump inhibitor
290232|NCT02670655|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
290233|NCT02670655|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
290522|NCT02663726|Other|Yoga|10 weekly 75-min sessions of specialised yoga
290523|NCT02663726|Behavioral|Written advice|Written advice about physical activity
290524|NCT02663739|Device|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
290525|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
290526|NCT00198913|Behavioral|gift cards for grocery foods and written education|
290527|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
290528|NCT02666040|Device|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
290529|NCT02666040|Device|"Prolene®" meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
290530|NCT02666040|Procedure|Detecting the mode of admission to hospital|Ordinary admission or day surgery
290531|NCT02666040|Procedure|Duration of surgery|Time operating room
290532|NCT02666040|Procedure|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
290533|NCT02666053|Drug|BMS-663068|
290534|NCT02666079|Device|LightPath™ Imaging System.|Intra-operative use of the LightPath™ Imaging System.
289963|NCT02675634|Device|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
289964|NCT02677740|Device|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention. One week before the MRI/MRS acquisitions, neurophysiological parameters are also measured before and between 20 and 40 minutes after the excitatory rTMS intervention.
289965|NCT02677753|Radiation|Fluoroscopy|
289966|NCT02677766|Other|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
289967|NCT02677766|Other|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
290234|NCT02670655|Drug|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
290235|NCT02670655|Device|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
290236|NCT02670655|Device|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
290237|NCT02670668|Other|Mutation analysis|
290238|NCT02670681|Behavioral|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
290239|NCT02670707|Drug|Cytarabine|Cytarabine 100 mg/m^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
290240|NCT00199017|Drug|Vincristine|
290241|NCT02673086|Other|infraclavicular block|Infraclavicular approach ultrasound guided brachial plexus block
290242|NCT02673086|Other|retroclavicular block|retroclavicular approach ultrasound guided brachial plexus block
290243|NCT02673099|Procedure|HDF online|Hemodialysis by the HDF online method
289647|NCT02682316|Other|dry gauze|
289648|NCT02682316|Device|The Prevena Incision Management System|
289649|NCT02682329|Other|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
289650|NCT02682329|Other|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
289651|NCT02682342|Other|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
289652|NCT02682368|Device|Bedside performed Ultrasound Scan by the surgeon|Bedside performed Ultrasound Scan performed by the surgeon and then compared to radiologist reports and/or surgery
289653|NCT02682368|Other|Radiology report|Radiologist report compared to the surgeon's report
289654|NCT02647567|Other|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
289655|NCT02647606|Procedure|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
289656|NCT02647606|Device|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
289968|NCT02677779|Procedure|CO2 laser|Single session of CO2 laser debridement
289969|NCT00199186|Drug|methotrexate (intrathecal)|
289970|NCT02677779|Procedure|traditional surgery|Single session of traditional debridement
289971|NCT02677792|Behavioral|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
289972|NCT02677805|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
289973|NCT02677805|Drug|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
289974|NCT02677844|Drug|Abemaciclib|Administered orally
289975|NCT02677844|Drug|Placebo|Administered orally
289976|NCT02677844|Drug|Loperamide|Administered orally
289368|NCT02652390|Drug|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
289369|NCT02652390|Other|Saline|2 mL saline + 1 mL lidocaine
289370|NCT02652403|Device|Complete conventional dentures|The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:
Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments.
289371|NCT00197002|Biological|Hepatitis A|Two doses
289372|NCT02652403|Device|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
289373|NCT02652416|Drug|BI 1026706|oral administration
289374|NCT02652416|Drug|Placebo|placebo
289375|NCT02652429|Drug|Inhaled Nitric Oxide|
289657|NCT02647606|Device|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
289658|NCT02647606|Device|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
289659|NCT02647619|Drug|Xiapex|Injection of collagenase of primary dupytren cord
289660|NCT02647619|Procedure|Needle aponeurotomy|26 G needle multiple perforation tecqnique with local anesthetic
289661|NCT02647632|Drug|Grazoprevir/Elbasvir|
289662|NCT00196495|Device|Polypropylene Mesh|
289663|NCT02647632|Drug|Sofosbuvir|
289664|NCT02647632|Drug|Ribavirin|
289665|NCT02647645|Device|Transcranial direct current stimulation|Direct current stimulation
289666|NCT02647658|Behavioral|GBC+PIPT|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
289667|NCT02647658|Behavioral|GBC|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
289668|NCT02647671|Drug|Aquamin®|90 days of Aquamin
299112|NCT00379288|Drug|mometasone furoate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
299113|NCT00379288|Drug|mometasone furoate combination MDI 400/10 mcg BID|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
299114|NCT00379288|Drug|Fluticasone/Salmeterol 250/50 mcg BID|F/SC 250/50 twice daily for 1 year
299115|NCT00381875|Biological|E1M184V peptide vaccine|
299116|NCT00381875|Biological|incomplete Freund's adjuvant|
299117|NCT00381875|Biological|sargramostim|
299118|NCT00381875|Other|immunoenzyme technique|
299119|NCT00381888|Drug|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
299120|NCT00003153|Biological|therapeutic allogeneic lymphocytes|
299121|NCT00381901|Biological|trastuzumab|
299122|NCT00381901|Genetic|polymorphism analysis|
299123|NCT00381901|Procedure|adjuvant therapy|
299124|NCT00381914|Drug|Vitamin D|400 IU vitamin D / day
299125|NCT00381914|Drug|Vitamin D|800 IU vitamin D / day
299126|NCT00381914|Drug|Vitamin D|1200 IU vitamin D / day
299127|NCT00381927|Behavioral|Physician Counseling|
299128|NCT00381940|Drug|ifosfamide|Given IV
299129|NCT00381940|Drug|bortezomib|Given IV
299130|NCT00381940|Drug|vinorelbine tartrate|Given IV
299131|NCT00000490|Behavioral|diet, fat-restricted|
293921|NCT02622503|Drug|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
289726|NCT02654392|Dietary Supplement|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils) every day for 5 weeks
289727|NCT02654405|Dietary Supplement|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
289728|NCT02654405|Other|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
289729|NCT02654418|Procedure|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
289730|NCT02654431|Procedure|Breast Cancer patient|Samples
289731|NCT02654431|Procedure|Cancer patients|Samples
289732|NCT02654457|Procedure|Women with Breast Cancer|IVD Study
289733|NCT00197301|Biological|Vaccination|
289734|NCT02654470|Device|Watchman FLX|
289735|NCT02654483|Drug|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
289736|NCT02654483|Drug|Placebo|Matching tablets to VPD-737 tablets without active drug
289737|NCT02654496|Other|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
289738|NCT02654509|Biological|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
289739|NCT02654522|Drug|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
289740|NCT02654535|Other|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
289741|NCT02654548|Other|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
289742|NCT02654561|Drug|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
289743|NCT02654561|Drug|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
290030|NCT02647853|Drug|TAT4 Gel concentration A|
290031|NCT02647853|Drug|TAT4 Gel concentration B|
290032|NCT02647853|Drug|Placebo|
289127|NCT02665286|Drug|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
289128|NCT02665286|Drug|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
289129|NCT02665286|Drug|Naproxen|Naproxen 500mg PO BID x 7 days
289130|NCT02665286|Drug|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
289131|NCT02665325|Drug|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
289132|NCT02665338|Device|Transcranial Magnetic Stimulation|
289431|NCT02658825|Drug|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
289432|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
289433|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
289434|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
289435|NCT02658825|Drug|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
289436|NCT02658838|Drug|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
289437|NCT02658838|Drug|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
289438|NCT00197886|Drug|Changing dose of norepinephrine and blood pressure|
289439|NCT02658838|Drug|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
289440|NCT02658838|Drug|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
289441|NCT02660762|Drug|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
288839|NCT02669875|Drug|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
288840|NCT02669888|Drug|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
288841|NCT00199004|Drug|VP16|
288842|NCT02669888|Drug|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
288843|NCT02669901|Behavioral|Naloxone Auto-Injector|Naloxone auto-injector is the only product FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
288844|NCT02669914|Drug|MEDI4736|
288845|NCT02669927|Other|Observational|
288846|NCT02669940|Drug|ABBVIE REGIMEN ± RBV|tablet
288847|NCT02669953|Drug|Aflibercept|
288848|NCT02669966|Procedure|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
288849|NCT02669979|Other|Intervention|Professional oral care
288850|NCT02669992|Procedure|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
288851|NCT02669992|Procedure|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
288852|NCT00002532|Drug|vindesine|
288853|NCT00199004|Drug|Adriamycin|
288854|NCT02670018|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets, for 1 day
289133|NCT00198835|Behavioral|Maternal nutrition and infant feeding advice|
289134|NCT02665351|Drug|Peramivir|The two regimens of Peramivir were compared
289135|NCT02665364|Biological|IFN-Kinoid|
289136|NCT02665364|Other|Placebo|
289137|NCT02665364|Other|ISA 51|
289138|NCT02665377|Drug|ANP|
293428|NCT02640235|Device|CELSTAT|
293429|NCT02640235|Device|Surgicel Original|
293430|NCT02640248|Device|Cuff ETT|
293431|NCT02640274|Behavioral|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
293432|NCT02640274|Other|Usual care|
293433|NCT02642523|Drug|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
293434|NCT02642523|Drug|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
293435|NCT02642523|Other|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
293436|NCT02642536|Behavioral|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
293437|NCT02642536|Behavioral|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
293438|NCT00195845|Drug|Galantamine|
293439|NCT02642549|Behavioral|Girls for Health|The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI "weeding exams." The FST will focus on English, math and science training, and safe spaces for social support development.
293440|NCT02642562|Drug|Iron (III) isomaltoside 1000|
293441|NCT02642588|Dietary Supplement|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
293442|NCT02642601|Drug|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
292858|NCT02617537|Drug|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
292859|NCT00193219|Drug|Bevacizumab|5 mg/kg IV
292860|NCT02617550|Drug|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
292861|NCT02617550|Drug|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets [o.d.].
292862|NCT02617550|Drug|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat [trough] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat [peak] or placebo) on day 13, day 27 and day 41
293154|NCT02611154|Drug|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
293155|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
293156|NCT02611180|Procedure|Skin punch biopsy|
293157|NCT02611180|Procedure|Peripheral blood draw|
293158|NCT02611193|Procedure|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
293159|NCT02611193|Procedure|Simulated manipulative treatment|Simulated Manipulative Treatment
293160|NCT02611206|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.
293161|NCT02613156|Procedure|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson & Johnson, USA), a laparoscopic linear cutter stapler (Johnson & Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
293162|NCT02613169|Drug|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
293163|NCT02613182|Drug|NEOD001|NEOD001
293164|NCT02613195|Drug|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
292569|NCT02624245|Other|Conventional Physical Therapy|
292570|NCT02624258|Biological|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
292571|NCT02624271|Other|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
292572|NCT02624284|Device|transcranial direct current stimulation (tDCS)|Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
292573|NCT00193674|Drug|Placebo|Placebo
292574|NCT02624297|Other|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
292863|NCT02617563|Device|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. The use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
292864|NCT02617589|Drug|Nivolumab|
292865|NCT02617589|Drug|Temozolomide|
292866|NCT02617589|Radiation|Radiotherapy|
292867|NCT02617602|Procedure|Goal directed therapy|Based on transpulmonary thermodilution data, the following interventions will be implemented:
Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;
cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:
decreased heart rate (HR): dobutamine, dopamine;
normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine.
292868|NCT02617602|Other|Control|
292869|NCT02617615|Drug|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
292870|NCT00193219|Drug|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
292871|NCT02617615|Drug|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
292261|NCT00194324|Procedure|Magnetic resonance imaging|
292262|NCT02628405|Drug|Etoposide|Given IV
292263|NCT02628405|Drug|Ifosfamide|Given IV
292264|NCT02628405|Other|Laboratory Biomarker Analysis|Correlative studies
292265|NCT02628405|Drug|Lenalidomide|Given PO
292266|NCT02628405|Biological|Rituximab|Given IV
292267|NCT02628418|Other|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
292268|NCT02628418|Device|Specific hand rehabilitation by Gloreha device|Each training session consisted of six parts:
A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);
7 min of a number sequence (counting from one to five);
A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)
A sequence of wave-like finger movements (7 min)
A sequence of fist opening/closing (7 min)
A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min).
292269|NCT02628418|Other|Specific hand rehabilitation performed by physiotherapist|The activities were:
Flexion-extension of the fingers (10 min);
Thumb opposition with the other fingers keeping the forearm in supine position (10 min);
Adduction and abduction of the fingers (10 min);
Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min).
292270|NCT02630602|Dietary Supplement|Functional goat cheese|60 g per day during 12 weeks
292271|NCT02630602|Dietary Supplement|Control cheese|60 g per day during 12 weeks
292272|NCT02630615|Other|Blood draw|
292273|NCT02630628|Drug|Tacrolimus|Dosage: start at 2mg twice a day, then taper as per protocol
292274|NCT02630628|Drug|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
292575|NCT02624310|Drug|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
292576|NCT02624310|Drug|Placebo|
292577|NCT02624323|Procedure|Real-time ultrasound-guided central vein catheterization.|
291983|NCT02637297|Procedure|Hypnotherapy|Undergo hypnotherapy
291984|NCT02637297|Other|Questionnaire Administration|Ancillary studies
291985|NCT02637310|Drug|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
292275|NCT02630641|Drug|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
292276|NCT00194584|Behavioral|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
292277|NCT02630654|Other|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
292278|NCT02630667|Other|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
292279|NCT02630667|Other|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
292280|NCT02630667|Other|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
292281|NCT02630680|Drug|Eziclen®/Izinova®|
292282|NCT02630693|Drug|Palbociclib 100mg|100mg PO daily
292283|NCT02630693|Drug|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
292284|NCT02630693|Drug|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
292285|NCT02630706|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
292286|NCT02630706|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tables) oral taken once daily
292287|NCT00194597|Drug|Viagra (sildenafil citrate)|
292288|NCT02630706|Drug|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
292289|NCT02630706|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
292290|NCT02630706|Drug|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
291689|NCT02641899|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
291690|NCT02641899|Drug|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
291691|NCT02641899|Drug|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
291692|NCT02641899|Drug|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
291693|NCT02641899|Drug|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
291694|NCT02641899|Drug|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
291695|NCT02644031|Procedure|hand files|post-treatment pain after using hand files
291696|NCT02644044|Drug|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
291697|NCT02644057|Drug|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
291698|NCT02644057|Drug|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
291699|NCT00196092|Device|Treatment for females|Endovascular repair in female patients
291700|NCT02644070|Device|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
291986|NCT00195273|Drug|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
291987|NCT02637310|Drug|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
291988|NCT02637323|Drug|FX006|Sustained Release Steroid
291989|NCT02637336|Device|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
291990|NCT02637336|Device|Aerobic exercise|aerobic exercise of moderate intensity
291991|NCT02637336|Device|Aromatherapy|inhalation of eucalyptus essential oil
291992|NCT02637349|Behavioral|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
291408|NCT02612532|Device|Exhaled Volatile Organic Compound collection|Breath sampling of tidal breathing in patients.
291409|NCT02612545|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
291410|NCT02612545|Drug|Mefloquine (MQ)|ACT partner drug
291411|NCT02612558|Drug|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid
291412|NCT02612558|Drug|Fostamatinib 100 mg bid|Fostamatinib 100 mg bid
291413|NCT02612571|Device|Intra-ocular Pressure meas|Coompare rates of glaucomatous optic neuropathy in professional wind-instrument players versus non-wind instrument players
291414|NCT02612584|Device|Pinhole Soft Contact Lens apply for presbyopia|
291415|NCT02612597|Other|Bedrest|
291416|NCT02612597|Other|Exercise Training|
291417|NCT02612610|Drug|AF-219|
291418|NCT00192660|Drug|Amprenavir|
291419|NCT02612610|Drug|Placebo (for AF-219)|
291420|NCT02612623|Drug|AF-219|
291421|NCT02612623|Drug|Placebo (for AF-219)|
291422|NCT02612636|Other|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
291423|NCT02612636|Other|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
291424|NCT02612649|Drug|Ramosetron|Oral
291425|NCT02614703|Other|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
291426|NCT02614716|Drug|LY3090106|Administered SC
291427|NCT02614716|Drug|Placebo|Administered SC
291428|NCT02614729|Other|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
291701|NCT02644070|Device|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
291702|NCT02644070|Device|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
290833|NCT02659384|Drug|placebo|
290834|NCT02659397|Drug|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
291095|NCT02616783|Drug|FTC|FTC 200 mg capsule administered orally once daily
291096|NCT02616783|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
291097|NCT00193154|Drug|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
291098|NCT02616783|Drug|3TC|3TC tablet administered orally
291099|NCT02616783|Drug|Third agent|Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)
Drug classes:
Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, and DRV
Pharmacokinetic enhancer: COBI
Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, and NVP, and ETR
Integrase inhibitors: RAL and DTG
291100|NCT02616796|Behavioral|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
291101|NCT02616809|Other|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
291102|NCT02616809|Other|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
291103|NCT02616809|Other|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
291104|NCT02616809|Other|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
291105|NCT02616822|Dietary Supplement|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
291106|NCT02616822|Other|Placebo|Used for placebo substance single dose
291107|NCT02616835|Device|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
291108|NCT00193167|Drug|Topotecan|
291109|NCT02616835|Device|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
291110|NCT02616848|Drug|Everolimus|
291111|NCT02616848|Drug|Eribulin|
290535|NCT02666092|Other|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
290536|NCT02666092|Biological|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
290537|NCT00198926|Behavioral|covert v overt nutrition labeling|
290538|NCT02666105|Drug|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
290835|NCT02659397|Drug|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
290836|NCT02659397|Drug|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
290837|NCT00198003|Behavioral|Educational program to address patients' expectations|
290838|NCT02659410|Other|Heat stress (21)|4h exposure to heat (WBGT of 21°C), no solvent
290839|NCT02659410|Other|Heat stress (25)|4h exposure to heat (WBGT of 25°C), no solvent
290840|NCT02659410|Other|Heat stress (30)|4h exposure to heat (WBGT of 30°C), no solvent
290841|NCT02659410|Other|Heat Stress (21) +TOL|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
290842|NCT02659410|Other|Heat stress (25) + TOL|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
290843|NCT02661269|Device|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
290844|NCT02661282|Drug|Temozolomide|100 mg/m2/day by mouth 1 time a day on Days 1 - 21 of Cycles 1 - 4.
Group 1, continues taking Temozolomide on Days 1 - 21 of Cycles 5 and beyond.
Group 2, takes Temozolomide on Days 1 - 5 of Cycles 5 and beyond.
290845|NCT00198328|Procedure|Surgical Excision|Patients have their tumor surgically removed.
290846|NCT02661282|Biological|T Cell Infusion|CMV-specific T cell infusion by vein on Day 22 for 4 cycles. Escalating doses of CMV-specific T cells are: 5 x10^6 in cycle 1, 1 x10^7 in cycle 2, 5 x10^7 in cycle 3 and 1 x10^8 in cycle 4.
290847|NCT02661282|Procedure|Surgery|Recurrent Glioblastoma + Surgery Group: Participants undergo surgery to remove the tumor on Day 30 of Cycle 1.
290848|NCT02661282|Behavioral|Phone Calls|Study staff calls participant on the following schedule: about 30 days after last study drug/cell dose, every 8 weeks, if participant stops study drug/cells because of intolerable side effects, every 3 months if participant stops study drug/cells because disease gets worse.
290849|NCT02661295|Drug|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and < 50% and ferritin ≥ 200 and < 500 ng/ml after a 2 week wash out period.
290244|NCT02673112|Behavioral|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
290245|NCT02673112|Behavioral|Light stretching (LS)|Brief daily stretching routine.
290246|NCT02673125|Genetic|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
290247|NCT02673138|Drug|canagliflozin|basal interruption with canagliflozin
290248|NCT02673138|Other|basal interruption without canagliflozin|basal interruption
290249|NCT02673151|Procedure|Computed Tomography|Undergo 68Ga-PSMA PET/CT
290250|NCT02673151|Radiation|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC|Given IV
290251|NCT00199056|Drug|Thioguanine|
290252|NCT02673151|Other|Laboratory Biomarker Analysis|Correlative studies
290253|NCT02673151|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA PET/CT
290254|NCT02673164|Biological|CSCC_ASC|The stem cells will be injected directly into the myocardium
290539|NCT02666118|Procedure|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
290540|NCT02666118|Procedure|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
290541|NCT02668133|Dietary Supplement|1 mg isotopically enriched 68Zn|administered intravenously
290542|NCT02668146|Drug|Perampanel|Study drug will be administered to study subjects
290543|NCT02668146|Drug|Placebo|Placebo will be administered to study subjects
290544|NCT02668159|Dietary Supplement|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
290545|NCT02668159|Dietary Supplement|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
289977|NCT02677857|Behavioral|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
289978|NCT02677870|Drug|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
289979|NCT02677870|Other|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
289980|NCT00199186|Drug|AraC (intrathecal)|
289981|NCT02677883|Other|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
289982|NCT02677883|Other|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
289983|NCT02680236|Other|Art Therapy Group|Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use
At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post.
289984|NCT02680249|Drug|CTP-656|
290255|NCT02673177|Procedure|robot-assisted total mesorectal excision|The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
290256|NCT02673177|Procedure|laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
290257|NCT02673203|Device|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
290258|NCT02673203|Behavioral|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
290259|NCT02673216|Other|No intervention|
289669|NCT02647671|Drug|Calcium Carbonate|90 days of Calcium Carbonate
289670|NCT02647671|Drug|Placebo|90 days of placebo
289671|NCT02647684|Behavioral|Self-Directed Triple P|10 Week Triple P Self directed workbook
289672|NCT02647697|Drug|Radiprodil oral|Active Substance: Radiprodil
Pharmaceutical Form: dry granules for oral suspension
Concentration: 30 mg
Route of Administration: oral use
289673|NCT00196508|Device|High Viscosity DERMABOND|
289674|NCT02647710|Behavioral|PHAT Life Intervention|HIV Prevention behavioral health intervention
289675|NCT02647710|Behavioral|Health Promotion Control|Behavioral health intervention control
289676|NCT02647723|Dietary Supplement|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
289677|NCT02647723|Dietary Supplement|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
289678|NCT02647736|Other|Hypertonic saline infusion|
289679|NCT02647749|Device|Cardioinsight® mapping system|
289680|NCT02647749|Other|Conventional method without non-invasive mapping|
289681|NCT02647762|Drug|CF101 1 mg|CF101 tablets, 1mg BID for 16 weeks
289985|NCT02680262|Behavioral|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
289986|NCT02680262|Behavioral|HPV self-sampling kit on demand|Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.
The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure).
289987|NCT02680262|Behavioral|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
289988|NCT02680275|Drug|Dead Sea Peloid Gel|intravaginally
289989|NCT02680288|Drug|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
289990|NCT00199563|Drug|Viagra|Sildenafil 100mg daily for 12 weeks
293922|NCT02622516|Other|Intervention Group (IG)|Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).
The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members.
293923|NCT02624804|Genetic|Stem Cell Educator Therapy|Patients will receive apheresis and then have their own blood returned to them with the "educated" stem cells
293924|NCT02624817|Drug|Sulfonylurea|See Arm description.
293925|NCT02624830|Drug|Sulfonylurea|See Arm description.
293926|NCT02624843|Drug|Benzyl Alcohol Lotion 5%|White topical lotion
293927|NCT02624843|Drug|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
293928|NCT02624843|Drug|Placebo|White topical lotion
293929|NCT02624856|Drug|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
293930|NCT02624856|Drug|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
293931|NCT02624869|Biological|evolocumab (AMG 145)|Administered by subcutaneous injection
293932|NCT02624882|Procedure|Positive rapid GAS test|If TDR positive, the child will be treated with antibiotics alone:
Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins
Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months.
293933|NCT00193752|Other|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
293934|NCT02624882|Procedure|Negative rapid GAS test|Usual care
293935|NCT02624908|Drug|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
293936|NCT02624908|Drug|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
293937|NCT02624921|Other|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
293938|NCT02624947|Biological|RSV F vaccine with adjuvant|
290033|NCT02649998|Drug|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
290034|NCT02650011|Other|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
290035|NCT02650024|Drug|ledipasvir and sofosbuvir|ledipasvir (90 mg) and sofosbuvir (400 mg) in a single tablet
290036|NCT02650024|Drug|Placebo (for ledipasvir and sofosbuvir)|Sugar pill manufactured to mimic ledipasvir and sofosbuvir (90 mg/400 mg)
290037|NCT02650037|Procedure|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
290038|NCT02650050|Radiation|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
290039|NCT00196755|Drug|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
290040|NCT02650063|Drug|DE-117|
290041|NCT02650076|Drug|SK-1405|
290042|NCT02650089|Other|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
290043|NCT02650089|Other|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
290044|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
290045|NCT02650102|Drug|Risperidone|a kind of antipsychotics
290046|NCT02650102|Drug|Olanzapine|a kind of antipsychotics
290047|NCT02650102|Drug|Quetiapine|a kind of antipsychotics
290048|NCT02650102|Drug|Aripiprazole|a kind of antipsychotics
290049|NCT02650102|Drug|Ziprasidone|a kind of antipsychotics
290328|NCT02682524|Drug|Aceclofenac 100mg tab.|
289442|NCT02660775|Behavioral|schizophrenia|The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:
for emotion perception : Facial emotions recognition task (TREF)
for theory of mind : Movie for the assessment of social cognition ( MASC-VF)
for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)
for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )
for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia
for self assessment : Self - assessment of social cognition (ACSo)
289443|NCT02660775|Behavioral|Autism|The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:
for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels
for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type
for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score
for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )
for empathy : Empathy quotient (EQ)
for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes
289444|NCT02660775|Behavioral|Healthy controls|only social cognitive measures
289445|NCT02660788|Other|Standard Reminder Postcard|
289446|NCT02660788|Other|Family Physician Reminder Letter|
289447|NCT00198263|Device|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
289744|NCT00197314|Behavioral|circular muscle exercises versus pelvic floor exercises|
289745|NCT02654574|Other|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
289746|NCT02654587|Drug|OSE2101|
289747|NCT02654587|Drug|Docetaxel|
289748|NCT02654587|Drug|Pemetrexed|
289749|NCT02656888|Drug|Transpulmin|
289750|NCT02656888|Drug|Alivium|
289751|NCT02656888|Drug|Claritin|
289752|NCT02656901|Device|closed-loop device|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
289753|NCT02656901|Device|total endovenous infusion pumps (Agilia, Fresenius Kabi, Bad Homburg, Germany)|total endovenous general anesthesia guided by BIS conducted manually by anesthesiologist
289139|NCT02665390|Procedure|Percutaneous cryoablation|Percutaneous cryoablation
289140|NCT02665403|Other|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
289141|NCT02665403|Other|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
289142|NCT02665416|Drug|RO7009789|RO7009789 will be provided as concentrate for solution to be administered via SC injection.
289143|NCT02665416|Drug|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
289144|NCT00198848|Drug|Iron-folic acid supplement|
289145|NCT02665429|Behavioral|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
289146|NCT02665442|Device|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
289147|NCT02665455|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.
During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed.
289148|NCT02665468|Behavioral|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
289149|NCT02667587|Drug|Nivolumab|
289150|NCT02667587|Drug|Temozolomide|
289151|NCT00198978|Drug|Asparaginase|
289152|NCT02667587|Radiation|Radiotherapy|
289153|NCT02667587|Other|Nivolumab Placebo|
289448|NCT02660801|Procedure|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
289449|NCT02660801|Procedure|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
293443|NCT02642614|Drug|BI 1026706|
293444|NCT02642614|Drug|Placebo|
288855|NCT02670018|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets, for 1day
288856|NCT02670031|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
288857|NCT02670031|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
288858|NCT02670031|Other|Electrocardiogram|To examine specific function of the heart.
288859|NCT00199056|Drug|Vincristine / Vindesine|
288860|NCT02672475|Drug|Galunisertib|Given PO
288861|NCT02672475|Other|Laboratory Biomarker Analysis|Correlative studies
288862|NCT02672475|Drug|Paclitaxel|Given IV
288863|NCT02672488|Drug|Sorafenib|Standard treatment for advanced HCC
288864|NCT02672488|Drug|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
288865|NCT02672501|Drug|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences
288866|NCT02672514|Device|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
288867|NCT02672514|Device|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
288868|NCT02672527|Drug|Trabectedin|
288869|NCT02672527|Drug|Dexamethasone|
288870|NCT00199056|Drug|Daunorubicin|
288871|NCT02672540|Drug|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
288872|NCT02672540|Drug|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
288873|NCT02672553|Device|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac perfor-mance characteristics and ad-verse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
293165|NCT02613208|Drug|Bevacizumab|Patients receiving bevacizumab as per local label will be observed for 24 months.
293166|NCT00192725|Other|rapid tryptophan depletion|Amino-acid mixture without tryptophan
293167|NCT02613208|Drug|Paclitaxel|Patients receiving paclitaxel as per local label will be observed for 24 months.
293168|NCT02613221|Drug|panitumumab, TAS-102|panitumumab: 6 mg/kg, every 2 weeks TAS-102: 35 mg/m², given orally twice a day in a 28-day) in 2-week cycle of 5 days of treatment followed by a 2-day rest period, and then a 14-day rest period.
293169|NCT02613234|Device|cathode tDCS|At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.
At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).
293445|NCT02642614|Drug|Placebo|For blinding purposes
293446|NCT02642627|Device|Bellafill|
293447|NCT02642640|Dietary Supplement|melatonin|5 mg of melatonin per os.
293448|NCT02642640|Drug|placebo|
293449|NCT00002528|Radiation|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
293450|NCT00195858|Behavioral|aerobic and resistance exercise|aerobic and resistance exercise
293451|NCT02642653|Drug|Lovastatin|Once per day dosing
293452|NCT02642653|Drug|Placebo|Once per day dosing
293453|NCT02644720|Procedure|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
293454|NCT02644720|Procedure|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
293455|NCT02644720|Drug|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
293456|NCT02644720|Device|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
293457|NCT02644720|Device|monofocal intraocular lens (IOL) (Tecnis ZCB)|
292872|NCT02617628|Drug|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
292873|NCT02619968|Other|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
292874|NCT02619981|Procedure|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
292875|NCT02619981|Drug|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
292876|NCT02619994|Drug|Linezolid|
292877|NCT02619994|Drug|Delamanid|
292878|NCT02619994|Drug|Levofloxacin|
292879|NCT02619994|Drug|Pyrazinamide|
292880|NCT00193362|Drug|Gemcitabine|
292881|NCT02619994|Drug|Locally-used WHO-approved MDR-TB regimen in Korea|
293170|NCT02613234|Device|Sham cathode tDCS|At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.
At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).
293171|NCT02613247|Device|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
293172|NCT02613260|Behavioral|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
293173|NCT02613273|Behavioral|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
293174|NCT02613273|Behavioral|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
293175|NCT02613286|Procedure|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
292578|NCT02624336|Other|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
292579|NCT02624336|Other|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
292580|NCT02624336|Other|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
292581|NCT02624349|Drug|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
292582|NCT02624362|Behavioral|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
292583|NCT02624362|Behavioral|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
292584|NCT00002524|Biological|Filgrastim|
292585|NCT00193687|Drug|bifeprunox|
292586|NCT02624362|Other|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
292587|NCT02626299|Other|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
292588|NCT02626312|Radiation|Radiation Therapy|Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.
292589|NCT00193921|Radiation|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
292590|NCT02626312|Drug|Chemotherapy|Participant may receive chemotherapy while on study based on decision of physician.
292591|NCT02626312|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up.
292592|NCT02626325|Other|High-carbohydrate or High-monounsaturated fat diets|
292593|NCT02626338|Drug|Crenolanib|
292594|NCT02626338|Drug|Mitoxantrone|
292595|NCT02626338|Drug|Cytarabine|
292882|NCT02620007|Drug|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
292883|NCT02620007|Drug|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
292884|NCT02620007|Drug|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
292291|NCT02630719|Drug|Timolol eye drops|eye drops
292292|NCT02630719|Drug|Artificial tears|Placebo drop
292293|NCT02630732|Behavioral|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
292294|NCT02632721|Drug|BI 836858|BI 836858 weekly i.v. infusion
292295|NCT02632734|Device|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
292596|NCT02626351|Other|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: [1] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; [2] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; [3] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; [4] Follow up.
292597|NCT02626351|Other|Baseline data collection (active comparator)|Endpoint data collection only
292598|NCT02626364|Drug|crenolanib|single-agent crenolanib at 100 mg PO TID
292599|NCT02626377|Behavioral|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
292600|NCT00193960|Procedure|1) Intraocular pressure 2) visual acuity|
292601|NCT02626377|Other|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
292602|NCT02626390|Other|Frequent instructions/feedback and an Internal Focus of Attention|
292603|NCT02626390|Other|Minimal instructions/feedback and an External Focus of Attention|
292604|NCT02626403|Device|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
292605|NCT02626403|Device|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
291993|NCT02637349|Behavioral|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
291994|NCT02637362|Procedure|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
291995|NCT02637362|Procedure|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
291996|NCT02637362|Procedure|Metatarsal block|A metatarsal block will be performed using a standardised technique
291997|NCT00195273|Drug|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
291998|NCT02639546|Drug|Cobimetinib|0.6 mg/kg cobimetinib tablets by mouth once daily on Days 1 to 21 of each 28-day treatment cycle. The dose will be increased by up to approximately 33% of the preceding dose level for each successive cohort until MTD or MAD is determined. During expansion stage participants will be enrolled in disease specific cohorts and treated at or below the MTD or MAD.
291999|NCT02639559|Drug|BL-8040|
292000|NCT00195507|Drug|Etanercept|
292001|NCT02639559|Procedure|Leukapheresis|
292002|NCT02639559|Procedure|Hematopoietic cell transplant|
292296|NCT02632734|Device|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
292297|NCT02632747|Drug|Empagliflozin|Empagliflozin will be taken once daily
292298|NCT02632747|Drug|Placebo (matching empagliflozin)|Placebo will be taken once daily
292299|NCT02632747|Drug|ramipril|Ramipril will be taken once or twice daily
292300|NCT02632760|Drug|Ferric carboxymaltose|treatment for Iron deficient anaemia
292301|NCT02632760|Drug|Placebo|placebo - no active drug
292302|NCT02632773|Behavioral|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
291703|NCT02644083|Drug|Dimethyl fumarate|
291704|NCT02644096|Other|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
291705|NCT02644109|Dietary Supplement|Phytosterol|Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.
Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.
Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged.
291706|NCT02644109|Dietary Supplement|Placebo|Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.
Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.
Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged.
291707|NCT02644122|Drug|SF1126|
291708|NCT02644135|Drug|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
291709|NCT02644135|Drug|Halo Placebo|Three sprays per use, total = 9 sprays per day
291710|NCT00002529|Drug|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
291711|NCT00196092|Device|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
291712|NCT02644148|Procedure|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
291713|NCT02644148|Procedure|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
291714|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
291715|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
291716|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
291717|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
291112|NCT02616861|Drug|IW-1973|IW-1973 Tablet
291113|NCT02616861|Drug|Matching Placebo Tablet|Matching placebo tablet
291114|NCT02616874|Drug|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
291115|NCT02619266|Drug|Megestrol Acetate|Megestrol Acetate 160mg tablet
291429|NCT02614729|Other|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
291430|NCT02614729|Other|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
291431|NCT02614729|Other|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
291432|NCT02614742|Drug|SFX-01|An intervention releasing sulforaphane.
291433|NCT00193024|Drug|Docetaxel|
291434|NCT02614742|Drug|Placebo|Placebo otherwise identical to Active product
291435|NCT02614768|Device|Glucose Sensor|The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received CE certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled "for investigative use only".
291436|NCT02614794|Drug|ONT-380|Treatment will be administered in cycles of 21 days each. ONT-380 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days, except in specific circumstances where it may be given weekly to compensate for modifications in treatment schedule.
291437|NCT02614794|Drug|Capecitabine|Treatment will be administered in cycles of 21 days each. ONT-380 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days, except in specific circumstances where it may be given weekly to compensate for modifications in treatment schedule.
291438|NCT02614794|Drug|Trastuzumab|Treatment will be administered in cycles of 21 days each. ONT-380 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days, except in specific circumstances where it may be given weekly to compensate for modifications in treatment schedule.
291439|NCT02614794|Drug|Placebo|Treatment will be administered in cycles of 21 days each. ONT-380 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days, except in specific circumstances where it may be given weekly to compensate for modifications in treatment schedule.
290850|NCT02661308|Device|Litebook|
290851|NCT02661321|Other|No intervention was used in this study, this was an observational study|
290852|NCT02661334|Dietary Supplement|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
290853|NCT02661334|Dietary Supplement|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
290854|NCT02661347|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
291116|NCT02619266|Drug|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
291117|NCT02619279|Other|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
291118|NCT02619292|Behavioral|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
291119|NCT02619305|Other|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
291120|NCT02619318|Behavioral|Balancing Everyday Life (BEL)|
291121|NCT02619318|Behavioral|Care as usual (generally standard occupational therapy)|
291122|NCT02619331|Procedure|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
291123|NCT00193310|Drug|Paclitaxel|
291124|NCT02619357|Device|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
291125|NCT02619357|Device|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
291126|NCT02619357|Device|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
291127|NCT02619357|Device|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
291128|NCT02619357|Device|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
290546|NCT02668159|Dietary Supplement|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
290547|NCT02668159|Dietary Supplement|Placebo|7 tablets of placebos administered prior to one the OGTT
290548|NCT02668172|Drug|Pasireotide LAR 60 mg|
290549|NCT02668172|Drug|Pasireotide LAR 60 mg combined with Pegvisomant|
290550|NCT02668185|Drug|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
290551|NCT00198991|Drug|G-CSF|
290552|NCT02668185|Drug|Placebo|Placebo
290553|NCT02668198|Device|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
290554|NCT02668198|Device|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
290555|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
290556|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine for any residual polyp at the prior site of resection.
290557|NCT02668211|Device|PROFEMUR Preserve Classic Femoral Components|
290558|NCT02668224|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
290855|NCT02661347|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
290856|NCT00198341|Procedure|Radiological Arm|Clinical Visit + X-Ray Chest
290857|NCT02661360|Behavioral|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
290858|NCT02661360|Behavioral|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
290859|NCT02661373|Drug|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single oral dose.
290260|NCT02673229|Drug|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, USP.
290261|NCT02673229|Drug|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
290262|NCT00002534|Drug|cyclophosphamide|
290263|NCT00199056|Drug|VM26|
290264|NCT02673242|Device|Threshold IMT Philips Respironics|Inspiratory muscle training
290265|NCT02675647|Drug|Heparin, IV route, based on patients body weights (UI/kg)|
290266|NCT00199082|Drug|Vincristine/Vindesine|
290267|NCT02675647|Procedure|Cardiopulmonary bypass|
290268|NCT02675647|Drug|Protamin administration|
290269|NCT02675660|Dietary Supplement|L-Homoarginine|125 mg L-homoarginine once daily
290270|NCT02675660|Drug|Placebo|placebo capsules once daily
290271|NCT02675673|Procedure|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
290272|NCT02675673|Procedure|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
290273|NCT02675686|Procedure|amniocentesis|amniotic fluid sample by amniocentesis
290559|NCT02668224|Other|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
290560|NCT02668237|Other|OptiPAC|Molecular and urinary tests.
290561|NCT02668237|Other|Usual care|Antibiotics for prevention.
290562|NCT00198991|Drug|Vindesine|
290563|NCT02668250|Procedure|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
290564|NCT02668250|Procedure|Usual Care|Patients receive the usual care.
290565|NCT02668263|Procedure|Surgery alone|Surgery
290566|NCT02668263|Procedure|Surgery and Drain(s)|Drains inserted as per standard practice
290567|NCT02668263|Procedure|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
289991|NCT02680288|Drug|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
289992|NCT02680288|Other|Oral Placebo|Oral inert treatment
289993|NCT02680301|Drug|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
289994|NCT02680301|Drug|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
289995|NCT02680314|Drug|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
289996|NCT02680340|Procedure|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
289997|NCT02680353|Procedure|Bilateral superficial cervical plexus block|A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
289998|NCT02680366|Device|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
289999|NCT02682368|Procedure|Intra-operative findings|Intra-operative findings compared to the bedside USS
290000|NCT02682381|Drug|Teduglutide|0.025 mg/kg
290001|NCT00199927|Drug|standard therapy|standard therapy
290274|NCT02675699|Behavioral|Optimisation + HENRY|HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.
OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend.
290275|NCT02675699|Behavioral|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
290276|NCT02675712|Other|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
290277|NCT00199082|Procedure|Irradiation (in specific conditions)|
294218|NCT02618239|Dietary Supplement|Bimuno Galacto-oligo-saccharide|
294219|NCT00193401|Drug|Topotecan|
294220|NCT02620501|Drug|Lidocaine|topical lidocaine
294221|NCT02620501|Drug|Placebo|0.45% Normal Saline
294222|NCT02620514|Behavioral|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
294223|NCT02620514|Behavioral|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
294224|NCT02620514|Behavioral|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
294225|NCT02620514|Behavioral|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
294226|NCT02620540|Device|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
294227|NCT02620553|Drug|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
294228|NCT02620553|Other|Oral Placebo|Oral Placebo is given orally daily
294229|NCT02620566|Procedure|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
294230|NCT00193414|Drug|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
294231|NCT02620566|Procedure|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
294232|NCT02620579|Drug|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
290329|NCT02682550|Procedure|blood drawing|blood drawing
290330|NCT02682563|Drug|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
290331|NCT02682563|Drug|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
290332|NCT00199953|Drug|Rabeprazole 20 mg twice a day for 90-day period treatment|
290333|NCT02682576|Procedure|Brachial artery ultrasound imaging|
290334|NCT02682589|Procedure|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
290335|NCT02682589|Procedure|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
290336|NCT02682602|Device|DePuy Synthes total hip arthroplasty|
290337|NCT02682602|Radiation|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
290338|NCT02682602|Radiation|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
290339|NCT02682615|Other|no intervention|no intervention
290340|NCT02682628|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
290341|NCT02682641|Drug|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
290342|NCT02682641|Drug|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
290343|NCT00199966|Drug|Divalproex sodium extended release|
290344|NCT02682654|Device|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
290345|NCT02682654|Device|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
290346|NCT02682680|Drug|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
290347|NCT02682680|Drug|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
289754|NCT02656901|Device|Baxter Vapour 2000 Sevoflurane Vapouriser|general anesthesia guided by BIS conducted manually by anesthesiologist. General anesthesia will be maintained with sevoflurane 1.5-2% by Baxter Vapour 2000 Sevoflurane Vapouriser in combination with oxygen/air mixture
289755|NCT02656901|Drug|Propofol|general anesthesia guided by BIS conducted manually by anesthesiologist. General anesthesia will be maintained with propofol 4-8 mg/kg/h by Injectomat TIVA Agilia, Fresenius Kabi, Bad Homburg, Germany or closed loop system
289756|NCT02656901|Drug|Sevorane|General anesthesia guided by BIS will be maintained with sevoflurane 1.5-2% by Baxter Vapour 2000 Sevoflurane Vapouriser
289757|NCT02656901|Drug|Desflurane|general anesthesia guided by BIS conducted manually by anesthesiologist. General anesthesia will be maintained with desflurane 5-6% by Baxter D-Vapor Desflurane Vaporiser in combination with oxygen/air mixture
289758|NCT00197639|Drug|Ritonavir-boosted indinavir|
289759|NCT02656901|Device|Baxter D-Vapor Desflurane Vaporiser|General anesthesia guided by BIS will be maintained with desflurane 5-6% by Baxter D-Vapor Desflurane Vaporiser
289760|NCT02656914|Drug|Guaifenesin and Ibuprofen and Loratadine|
289761|NCT02656914|Drug|Transpulmin|
289762|NCT02656914|Drug|Alivium|
289763|NCT02656914|Drug|Claritin|
289764|NCT02656927|Behavioral|Yoga Condition|
290050|NCT00196755|Drug|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
290051|NCT02650128|Device|Shockwave Medical Coronary Rx Lithoplasty System|
290052|NCT02650141|Drug|ziyinxiehuo Granules|Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing "Yin", removing "Fire" Usage: administered after dissolved, 3 times per day after breakfast and supper
290053|NCT02650141|Drug|zishenqinggan Granules|Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing "Kidney", Clearing "Liver" Usage: administered after dissolved, 3 times per day after breakfast and supper
290054|NCT02650167|Biological|Colostrum feeding|
290055|NCT02652481|Device|ImageReady MR Conditional Defibrillation System|ImageReady MR Conditional Defibrillation System Components:
Pulse Generators:
ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT-D INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT-D DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D*
Right Atrial Leads and Accessories:
FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug
Right Ventricular Leads and Accessories:
RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads* ENDOTAK RELIANCE™ (DF4)
Left Ventricular Leads and Accessories; Acuity™ X4 (IS4) Suture Sleeve for ACUITY X4 leads
289450|NCT02660814|Other|Non-surgical periodontal treatment|SRP under local anaesthesia, in a total of 2-3 clinical visits.
Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
289451|NCT02660814|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
289452|NCT02660827|Device|Insulin Pump|Closed Loop Algorithm
289453|NCT02660827|Other|i-STAT blood testing|Intravenous blood testing for 24 hours during hotel/hose stay. Testing is used for reference validation.
289454|NCT02660827|Other|Blood Glucose Meter Testing|Frequent finger stick blood glucose testing using a Blood Glucose meter is required
289455|NCT02660827|Other|YSI Blood Testing|Intravenous blood testing during Low Management Suspend before Low testing at end of run-in period. Testing is used for reference validation.
289456|NCT02660840|Drug|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
289457|NCT02660840|Drug|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
289458|NCT00198276|Device|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
289459|NCT02660840|Drug|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
289460|NCT02660840|Drug|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
289461|NCT00198523|Drug|Prednisolone|
289462|NCT02663141|Drug|Intravitreal bevacizumab|
289463|NCT02663141|Drug|Placebo|
289464|NCT02663154|Drug|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
289465|NCT02663154|Drug|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
289466|NCT02663167|Behavioral|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
289467|NCT02663180|Behavioral|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
288874|NCT02672553|Device|Stented Aortic Bioprostheses|In comparison to control valves available on the market under-going FS-AVR
288875|NCT02672566|Drug|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
288876|NCT02672566|Other|Usual care|Patients will all benefit from the classic cares, delivered to all pregnant patients.
288877|NCT02672592|Drug|Anakinra|Anakinra 100mg s.c. bid
289154|NCT02667613|Other|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
289155|NCT02667613|Other|Control|Usual customary care
289156|NCT02667626|Other|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
289157|NCT02667626|Other|Control|Web-based resource lists and text-based study adherence reminders
289158|NCT02667639|Biological|RPH-104|
289159|NCT02667639|Other|Sodium chloride Sterile Injection 0.9% w/v|
289160|NCT02667652|Procedure|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
289161|NCT02667652|Procedure|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
289162|NCT00198991|Drug|Cyclophosphamide|
289163|NCT02667678|Other|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
289164|NCT02667691|Dietary Supplement|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
289165|NCT02667691|Dietary Supplement|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
289166|NCT02667691|Other|caloric restriction|Caloric recommendation reduced by 20%
289167|NCT02667704|Drug|Bosentan|
289168|NCT02667704|Drug|Nintedanib|
293458|NCT02644733|Procedure|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
293459|NCT00196157|Procedure|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
293460|NCT02644733|Procedure|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
293461|NCT02644746|Device|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
293462|NCT02644746|Device|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
288878|NCT02672592|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
288879|NCT02672605|Other|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
288880|NCT02672631|Other|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
288881|NCT00199056|Drug|Asparaginase|
288882|NCT02672631|Other|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
288883|NCT02672631|Other|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
288884|NCT02675088|Radiation|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
288885|NCT02675101|Other|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
293176|NCT02613286|Procedure|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
293177|NCT00192751|Behavioral|Psychoeducational group sessions|
293178|NCT02613325|Device|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
293179|NCT00193076|Drug|Gemcitabine|Gemcitabine
293180|NCT02615418|Device|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
293181|NCT02615431|Other|MitraClip Intervention|
293182|NCT02615444|Dietary Supplement|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
293183|NCT02615444|Dietary Supplement|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
293184|NCT02615457|Drug|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
293185|NCT02615470|Behavioral|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
293186|NCT02615470|Other|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
293463|NCT02644759|Biological|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
293464|NCT02644785|Drug|protamine|Protamine infusion exposures
293465|NCT02644798|Other|Gene polymorphism|Samples of gene polymorphism in ARDS patients and patients with ARDS risk factors
293466|NCT02644811|Drug|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
293467|NCT02644811|Drug|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
293468|NCT02644811|Procedure|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
293469|NCT02644811|Drug|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
293470|NCT00002529|Drug|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
292885|NCT02620007|Drug|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
292886|NCT02620020|Drug|Fasinumab|
292887|NCT02620020|Drug|placebo|
292888|NCT02620033|Behavioral|Yoga therapy|
292889|NCT02620046|Drug|Vedolizumab SC|Vedolizumab SC 108 mg injection QW
292890|NCT02620059|Behavioral|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
292891|NCT00193362|Drug|Vinorelbine|
292892|NCT02620072|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period.
292893|NCT02620072|Other|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose).
292894|NCT02620085|Procedure|blood sampling|blood sampling
292895|NCT02620098|Other|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
292896|NCT02620111|Dietary Supplement|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
292897|NCT02622087|Behavioral|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
292898|NCT02622100|Device|Bioresorbable Vascular Scaffold|
292899|NCT02622113|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
292900|NCT00002523|Procedure|conventional surgery|
292606|NCT02626416|Device|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
292607|NCT02628431|Device|Elfi tech monitor|
292608|NCT02628444|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
292609|NCT00194324|Behavioral|Moderate levels of exercise|
292610|NCT02628444|Biological|NaCl + CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0 (placebo), 6 and 12 months (CYD), respectively
292611|NCT02628444|Biological|NaCl + CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0 and Month 6 (placebo), 12 months (CYD), respectively
292612|NCT02628457|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
292901|NCT00193505|Drug|Carboplatin|
292902|NCT02622126|Drug|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
292903|NCT02622126|Drug|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
292904|NCT02622126|Drug|Morphine|Sub arachnoid 200 meg morphine
292905|NCT02622126|Drug|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
292906|NCT02622126|Drug|Ephedrine|If severe hypotension (fall of > 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
292907|NCT02622126|Drug|Atropine|Bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
292908|NCT02622139|Device|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
292909|NCT02622152|Procedure|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
292910|NCT02622152|Procedure|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
292911|NCT02622152|Procedure|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
292912|NCT00193505|Drug|Etoposide|
292303|NCT02632773|Behavioral|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
292304|NCT00194779|Drug|tamoxifen citrate|Given PO
292305|NCT02632786|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
292306|NCT02632786|Drug|Placebo|Saline Bag
292307|NCT02632799|Device|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
292308|NCT02632799|Device|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
292309|NCT02632799|Device|CPAP|Nsal CPAP 5cm H2o by face mask
292310|NCT02632812|Drug|Rebamipide effervescent granules|
292311|NCT02632812|Drug|Placebo effervescent granules|
292312|NCT02632812|Drug|Naproxen tablet|
292313|NCT02632825|Device|Nasal High Flow|Nasal High Flow Therapy
292314|NCT02632838|Device|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
292315|NCT00194779|Drug|letrozole|Given PO
292613|NCT02628470|Procedure|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
292614|NCT02628470|Procedure|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
292615|NCT02628470|Procedure|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
292616|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
292617|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
292618|NCT02628496|Drug|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
292003|NCT02639572|Biological|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
292004|NCT02639572|Biological|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
292005|NCT02639585|Drug|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
292006|NCT02639598|Drug|Flunarizine|as in "arm descriptions"
292007|NCT02639598|Drug|Topiramate|as in "arm descriptions"
292008|NCT02639611|Other|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
292009|NCT02639611|Other|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
292010|NCT02639624|Drug|low bicarbonate dialysate + normal bicarbonate dialysate|
292011|NCT00000376|Drug|Desipramine|
292012|NCT00002526|Drug|ifosfamide|
292013|NCT00195520|Drug|Totelle®|
292014|NCT02639624|Drug|normal bicarbonate dialysate|
292015|NCT02639637|Drug|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
292016|NCT02639637|Drug|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
292017|NCT02639637|Drug|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
291440|NCT02614807|Dietary Supplement|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
291441|NCT02614820|Procedure|Remote Ischemic Preconditioning Training Apparatus|
291442|NCT02614833|Biological|IMP321|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
291443|NCT02616874|Drug|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
291718|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
291719|NCT00188110|Procedure|Water-Enema Computed Tomography|
291720|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
291721|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
291722|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
291723|NCT02574559|Behavioral|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
291724|NCT02574572|Biological|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
291725|NCT02574585|Biological|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
291726|NCT02574598|Drug|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
291727|NCT02574598|Drug|Docetaxel|Use on both arms as standard of care.
291728|NCT02574611|Drug|Neostigmine|
291729|NCT02574611|Drug|Glycopyrrolate|
291730|NCT00188136|Drug|Melphalan, ATG, Fludarabine|allo Tx during aplasia
291129|NCT02619357|Other|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
291130|NCT02619357|Other|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
291131|NCT02619357|Other|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
291132|NCT02619370|Behavioral|Conversation card game|
291133|NCT02619370|Behavioral|Active Control|
291134|NCT00193310|Drug|Carboplatin|
291444|NCT02616887|Radiation|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
291445|NCT02616900|Device|eSight Eyewear|primary intervention
291446|NCT02616913|Other|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
291447|NCT00193180|Drug|Imatinib|Imatinib
291448|NCT02616913|Other|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
291449|NCT02616913|Other|Placebo|Each subject consumes placebo in one of 3 treatment periods
291450|NCT02616926|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
291451|NCT02616926|Procedure|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
291452|NCT02616926|Procedure|RFA|RFA will be performed 1 week after TACE.
291453|NCT02616939|Other|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
291454|NCT02616952|Dietary Supplement|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
290860|NCT02661386|Device|Motility Procedure|The use of esophageal manometry device during general anesthesia
290861|NCT02661425|Other|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
290862|NCT00193895|Drug|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
290863|NCT02625636|Drug|placebo|Pharmaceutical form: solution
Route of administration: subcutaneous
290864|NCT02625636|Drug|r-glucagon|Pharmaceutical form: solution
Route of administration: subcutaneous
290865|NCT02625675|Other|Ultrasound scan|
290866|NCT02625688|Other|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
290867|NCT02625688|Other|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
290868|NCT02625688|Other|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
290869|NCT02625701|Procedure|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
291135|NCT02619383|Device|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
291136|NCT02619396|Procedure|Combination 1 of RF power and LSI on LA posterior wall|20 W RF power, target Force Time Integral (FTI) ≥400 gs and target LSI = 4 on LA posterior wall
291137|NCT00193466|Drug|Fludarabine|
291138|NCT02621463|Device|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
291139|NCT02621476|Behavioral|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
290568|NCT02668276|Other|Standard NCCN counseling|
290569|NCT02670707|Drug|Vinblastine/prednisone|Vinblastine 6 mg/m^2/dose IV push weekly
Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day
290570|NCT02670720|Drug|avoralstat|
290571|NCT02670733|Procedure|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
290572|NCT02670759|Drug|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
290573|NCT02670759|Drug|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
290574|NCT02670772|Drug|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
290575|NCT02670772|Drug|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
290576|NCT02670785|Drug|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
290577|NCT02670785|Drug|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
290578|NCT02670798|Procedure|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
290579|NCT00002533|Drug|fluconazole|
290580|NCT00199017|Drug|Daunorubicin|
290581|NCT02670811|Dietary Supplement|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
290870|NCT02625701|Procedure|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
290871|NCT02625714|Drug|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
290872|NCT02625714|Drug|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
290873|NCT00193895|Radiation|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
290874|NCT02625727|Other|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
290278|NCT02675725|Device|Measurement of sublingual microcirculation with Cytocam-IDF camera|The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.
When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes.
290279|NCT02675738|Other|good clinical practice|
290280|NCT02675751|Device|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
290281|NCT02675764|Other|Vibration|peripheral vibration at the wrist skin at an imperceptible level
290282|NCT02675764|Other|Placebo (for vibration)|No peripheral vibration at the wrist skin
290283|NCT02675764|Behavioral|therapy|standardized hand therapy program
290284|NCT02677896|Drug|Enzalutamide|Oral
290285|NCT02677896|Drug|Placebo|Oral
290286|NCT02677909|Device|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
290287|NCT02677922|Drug|AG-120|
290288|NCT02677922|Drug|Azacitidine|
290289|NCT02677922|Drug|AG-221|
290290|NCT02677935|Other|Community education programs|
290291|NCT02677948|Drug|Pacritinib|
290292|NCT00199186|Drug|dexamethasone (intrathecal)|
290293|NCT02677948|Drug|Ibrutinib|
290582|NCT02670811|Dietary Supplement|Acidified milk|150 mL daily of artificially acidified milk
290583|NCT02670824|Drug|CN-105|Single and multiple intravenous (IV) doses of CN-105
290584|NCT02670824|Drug|Placebo|Normal Saline
290585|NCT02670837|Device|Cellutome Epidermal Harvesting System|
290586|NCT02670850|Other|family careviver intervention program|The intervention program developed for this study included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
294233|NCT02620579|Drug|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
294535|NCT02615977|Behavioral|Zooming Joystick Task|Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).
Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates.
294536|NCT02615977|Behavioral|Zooming Joystick Task (Placebo)|Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).
Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates.
294537|NCT02615990|Device|Erigo Pro|Verticalization table with two integrated robotic devices for leg movement and cyclic loading
294538|NCT02615990|Other|Standard Physical Therapy|Patients receive standard physical therapy.
294539|NCT02616003|Drug|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
294540|NCT02616003|Other|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
294541|NCT02616003|Dietary Supplement|Caloric diet with 800 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
294542|NCT02616016|Device|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
294543|NCT02616029|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily
294544|NCT00193115|Drug|Docetaxel|
294545|NCT02616042|Other|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
294546|NCT02616042|Other|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
294547|NCT02616055|Drug|tesevatinib|
290348|NCT02682693|Drug|Denosumab|Denosumab 120 mg every 4 weeks for 6 cycles
290639|NCT02678104|Drug|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
290640|NCT00199225|Drug|Rupatadine|
290641|NCT02678117|Drug|Pregabalin & Placebo|
290642|NCT02678117|Drug|Magnesium sulphate & Placebo|
290643|NCT02678117|Drug|Pregabalin & Magnesium sulphate|
290644|NCT02678117|Drug|Placebo|
290645|NCT02678130|Device|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
290646|NCT02678130|Device|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
290647|NCT02678143|Drug|Alemtuzumab|
290648|NCT02678143|Drug|Cyclophosphamide|
290649|NCT02678143|Drug|Mycophenolate mofetil|
290650|NCT02678143|Drug|Sirolimus|
290651|NCT00199225|Drug|moxifloxacin|
290652|NCT02678143|Drug|Fludarabine|
290653|NCT02678143|Radiation|Total body irradiation|
290654|NCT02678143|Procedure|Hematopoietic stem cell transplant|
290655|NCT02678156|Device|Lyoplant Onlay|
290656|NCT02678169|Device|Penumbra Aspiration System|Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
290657|NCT02678182|Drug|Capecitabine|1250 mg/m2/day, 21 day cycle
290658|NCT02678182|Drug|MEDI4736|IV treatment on days 1&15 of 28 day cycle
290659|NCT02678182|Drug|Trastuzumab|6mg/kg on day 1 cycle every 21 days
290660|NCT02678195|Drug|Amoxicillin|
290661|NCT02678195|Drug|Placebo|
290056|NCT02652507|Drug|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
290057|NCT02652507|Drug|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
290058|NCT02652520|Procedure|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
290059|NCT02652533|Device|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
290060|NCT02652546|Drug|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
290061|NCT00197015|Biological|VARIVAX®|1 dose administered subcutaneously
290062|NCT02652546|Drug|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
290063|NCT02652546|Drug|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
290064|NCT02652546|Drug|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
290065|NCT02652559|Device|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
290349|NCT02682693|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
290350|NCT02647866|Drug|KHK4083|IV Infusion
290351|NCT02647866|Drug|Placebo|IV Infusion
290352|NCT02647892|Drug|lidocaine|local anesthesia
290353|NCT02647892|Drug|sodium bicarbonate|additional drug added to lidocaine
290354|NCT02647905|Device|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
290355|NCT02647918|Drug|Sotagliflozin|Single dose
290356|NCT02647918|Drug|Sotagliflozin|2 single doses
289765|NCT02656940|Dietary Supplement|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
289766|NCT02656940|Dietary Supplement|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
289767|NCT02656940|Dietary Supplement|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
289768|NCT02656953|Device|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
289769|NCT00197678|Dietary Supplement|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
289770|NCT02656953|Device|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
289771|NCT02656966|Device|Auricular acupuncture|Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed "New Pyonex" needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA.
289772|NCT02658851|Device|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
289773|NCT02658864|Drug|lafutidine|comparison of different doses, sex and medication conditions
289774|NCT02658877|Drug|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
289775|NCT02658877|Drug|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
289776|NCT02658890|Drug|BMS-986205|
289777|NCT02658890|Drug|Nivolumab|
289778|NCT02658903|Device|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
289779|NCT02658903|Device|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
289780|NCT00197899|Drug|E. Coli endotoxin|
289169|NCT02667717|Behavioral|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
289170|NCT02667717|Behavioral|Usual care|Patients will have the usual care as an intervention.
289171|NCT02667730|Drug|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
289172|NCT02667730|Drug|Naproxen|naproxen 500mg twice daily for 7 days
289173|NCT00198991|Drug|Dexamethasone|
289174|NCT02667730|Drug|Celecoxib|celecoxib 100mg twice daily
289175|NCT02667730|Other|physiotherapy only|physiotherapy only (no drug)
289468|NCT02663180|Behavioral|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
289469|NCT02663193|Other|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
289470|NCT02663206|Procedure|peroral endoscopic myotomy|peroral endoscopic myotomy
289471|NCT02663206|Procedure|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
289472|NCT00002532|Drug|cytarabine|
289473|NCT00198536|Drug|Ecabet 2.83%|
289474|NCT02663219|Behavioral|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
289475|NCT02663245|Other|Intervention 1|Diabetes specific consultation
Basic training in clinical guidelines
Platform of communication for professionals
Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.
7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.
Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes.
289476|NCT02663245|Other|Intervention 2|7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.
Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.
Basic training in clinical guidelines.
Platform of communication for professionals.
Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes.
289477|NCT02663258|Drug|Pembrolizumab|
289478|NCT02663271|Drug|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
288886|NCT02675101|Other|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
288887|NCT02675101|Other|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
288888|NCT02675114|Procedure|Surgical aortic valve replacement (SAVR)|SAVR with a commercially available bioprosthetic valve.
288889|NCT02675114|Device|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
288890|NCT00199082|Drug|Cyclophosphamide|
288891|NCT02675127|Drug|Daktavira|1 tablet contains 60 mg Daclatasvir
288892|NCT02675127|Drug|Daklinza|1 tablet contains 60 mg Daclatasvir
288893|NCT02675140|Drug|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
289176|NCT02670031|Device|Ambulatory Blood Pressure Monitoring|A 24-hour test.
289177|NCT02670044|Drug|Cobimetinib|Cobimetinib will be administered orally daily on Days 1-21 of each 28-day treatment cycle.
289178|NCT02670044|Drug|Idasanutlin|Idasanutlin will be administered orally daily or twice daily on Days 1-5 of each 28 day treatment cycle.
289179|NCT02670044|Drug|Venetoclax|Venetoclax will be administered orally daily on Days 1-28 of each 28 day treatment cycle.
289180|NCT02670057|Procedure|Transnasal SPG block|
289181|NCT00199004|Drug|Thioguanine|
289182|NCT02670070|Drug|gemigliptin and rosuvastatin|gemigliptin/rosuvastatin 20mg
289183|NCT02670083|Drug|Crenezumab|Crenezumab will be administered by IV infusion q4w for 100 weeks.
289184|NCT02670083|Drug|Placebo|Placebo will be administered as IV infusion q4w for 100 weeks.
289185|NCT02670096|Drug|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
293471|NCT00196157|Procedure|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
293472|NCT02611206|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Participants experience sham and active rTMS as identicle
293473|NCT02611219|Other|Child Health Ratings Inventories-General Health Module (5-12 years)|21 question health questionnaire
Displays question and response options using a main cartoon character to pictorially describe each health status concept in either a colored paper and pencil version or via audio-visual computer animation. In the computer-animated version, each of the questions is narrated via audio and sound effects and children receive interviewer assistance as needed. For all questions, the voice of the child is standard and responses to all health status questions are arrayed along a five-point Likert scale. It takes approximately 5-7 minutes to complete.
293474|NCT00192582|Behavioral|Motivational Interview with care plan and education|
293475|NCT02611219|Other|General Health Module-Baseline Adolescent-Self Report (13-18 years)|38 question questionnaire
Answers range from 1=all of the time to 5=none of the time
293476|NCT02611219|Other|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|38 question questionnaire about child
Answers range from 1=all of the time to 5=none of the time
293477|NCT02611219|Other|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|38 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time
293478|NCT02611219|Other|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|38 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time
293479|NCT02611219|Other|General Health Module-Baseline Parent Report-School Age (5-12 years)|34 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time
288894|NCT02675140|Drug|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
288895|NCT02675153|Drug|Sirolimus|Sirolimus 2mg daily will be given to subjects by oral for six months.
288896|NCT02675153|Drug|5-ASA, Prednisone, Azathioprine or Remicade|5-ASA, Prednisone, Azathioprine and Remicade are traditional treatments according to associated guidelines
288897|NCT02675166|Other|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
288898|NCT02675179|Device|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
288899|NCT02675179|Device|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
288900|NCT02675192|Other|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
293187|NCT02615483|Other|Web-based platform|The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.
The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café.
293188|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
293189|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet "Your guide to EYLEA," patient information leaflet, and audio CD.
293190|NCT00193076|Drug|Carboplatin|Carboplatin
293191|NCT02615522|Device|BPK-S Integration|
293192|NCT02615535|Device|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
293193|NCT02615535|Device|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
293194|NCT02615548|Other|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
293195|NCT02615548|Other|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
293196|NCT02615561|Device|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
293197|NCT02615561|Other|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
293198|NCT02615561|Other|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
293199|NCT02617641|Behavioral|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
292913|NCT02622152|Procedure|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
292914|NCT02622152|Procedure|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
292915|NCT02622165|Behavioral|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
292916|NCT02622178|Device|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
292917|NCT02624375|Drug|Zoster Vaccine Live|
292918|NCT02624388|Drug|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
292919|NCT02624388|Drug|Placebo|Pill that contains no medicine
292920|NCT02624401|Drug|Dexmedetomidine|Intravenous infusion
293202|NCT02617654|Drug|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
293203|NCT02617667|Drug|Cyclosporine A|topical ocular, eye drops
293204|NCT02617667|Drug|Placebo|topical ocular, eye drops
293205|NCT02617680|Drug|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
293206|NCT02617680|Drug|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
293207|NCT00193219|Drug|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
293208|NCT02617693|Dietary Supplement|No treatment given|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform
293209|NCT02617706|Device|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
292619|NCT02628496|Device|Confocal laser microlaryngoscopy|
292620|NCT00194337|Procedure|breast imaging study|
292621|NCT02628496|Procedure|Biopsy (standard of care)|
292622|NCT02628496|Procedure|KTP laser photoablation (standard of care)|
292623|NCT02628509|Device|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
292624|NCT02628522|Other|ADRCs therapy|Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
292625|NCT02628522|Device|Celution|Adipose derived regenerative cell isolation
292626|NCT02628522|Device|Tulip cannulas|Lipoaspiration
292627|NCT02628522|Other|20mL Lidocaine 2% and Epinephrine 1:100 000|Infiltration prior to liposuction
292628|NCT02628535|Biological|MGD009|B7-H3 x CD3 DART protein
292629|NCT02628548|Behavioral|Cognitive training program|8 week cognitive training program
292630|NCT02628561|Device|Transcranial direct current stimulation|
292631|NCT00194337|Procedure|comparison of screening methods|
292632|NCT02628561|Behavioral|Constraint-Induced Movement Therapy|
292633|NCT02628574|Drug|TRX518|comparison of different (ascending) doses of TRX518 given via IV fusion
292634|NCT02628587|Drug|Generic clopidogrel|Comparison of different brands of clopidogrel:
*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3.
292635|NCT02630732|Behavioral|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
292921|NCT02624401|Drug|Propofol|Intravenous infusion
292922|NCT02624401|Drug|S-ketamine|Intravenous infusion
292923|NCT02624401|Drug|Sevoflurane|Inhalation
292924|NCT02624414|Device|PillCam® COLON 2 Capsule Endoscopy|
292925|NCT02624427|Device|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
292018|NCT02641912|Other|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
292316|NCT02632864|Radiation|Proton arm|Proton beam therapy
292317|NCT02634983|Drug|Placebo|Matching placebo
292318|NCT02635009|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo PCI using 3DCRT
292319|NCT02635009|Other|Cognitive Assessment|Ancillary studies
292320|NCT02635009|Radiation|Intensity-Modulated Radiation Therapy|Undergo PCI with HA using IMRT
292321|NCT02635009|Other|Laboratory Biomarker Analysis|Correlative studies
292322|NCT02635009|Other|Quality-of-Life Assessment|Ancillary studies
292323|NCT02635035|Drug|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
292324|NCT02635035|Drug|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
292325|NCT00194974|Drug|clonidine|
292326|NCT02635048|Procedure|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
292327|NCT02635048|Procedure|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
292328|NCT02635061|Drug|ACY-241|
292329|NCT02635061|Drug|nivolumab|
292330|NCT02635061|Drug|ipilimumab|
292331|NCT02635074|Drug|Cytarabine|Given IV
292332|NCT02635074|Drug|Ibrutinib|Given PO
292333|NCT02635074|Drug|Idarubicin|Given IV
292334|NCT02635087|Device|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
291731|NCT02574611|Other|Saline (Placebo)|
291732|NCT02574611|Device|High Resolution Colonic Manometry|
291733|NCT02574624|Procedure|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
291734|NCT02574637|Drug|MEDI2070 High dose|MEDI2070 intravenous (IV)infusion wks 0 & 4 plus placebo SC injection wks 0 & 4, and then subcutaneous (SC) dose of MEDI2070 every 4 wks through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
291735|NCT02612662|Drug|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
291736|NCT02612662|Drug|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
292019|NCT02641912|Other|Mineral Water|During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.
At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use.
292020|NCT02641925|Procedure|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
292021|NCT02641925|Procedure|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
292022|NCT00195767|Drug|divalproex sodium|
292023|NCT02641938|Drug|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
292024|NCT02641938|Drug|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
292025|NCT02641951|Other|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
292026|NCT02641951|Other|Pecs II block|Ultrasound guided Pecs II block
292027|NCT02641990|Drug|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
292028|NCT02641990|Drug|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
292029|NCT02642003|Drug|Granulocyte Colony Stimulating Factor|
292030|NCT02642016|Biological|KTN0158|Single agent KTN0158 until unacceptable toxicity or progressive disease
291455|NCT02616952|Behavioral|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
291456|NCT02616965|Drug|Romidepsin|
291457|NCT02616965|Drug|Brentuximab vedotin|
291458|NCT00002522|Procedure|autologous bone marrow transplantation|
291459|NCT00193180|Drug|Docetaxel|Docetaxel
291460|NCT02616991|Procedure|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
291461|NCT02617017|Drug|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
291737|NCT02612675|Other|ONS|
291738|NCT02612688|Behavioral|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) Basic Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for the Healthy Patient. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
291739|NCT00192660|Drug|Ritonavir|
291740|NCT02612701|Other|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
291741|NCT02612701|Other|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
291742|NCT02612701|Other|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
291743|NCT02612701|Other|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
291744|NCT02612714|Drug|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
291745|NCT02612727|Procedure|Window tinting film for filtered sunlight phototherapy|Six hours of filtered sunlight phototherapy for 1 to 10 days.
291746|NCT02612727|Device|conventional phototherapy|Conventional phototherapy unit will be used for infants randomized to this arm for1-10 days
291140|NCT02621476|Behavioral|Personalized intervention|personalized intervention that includes components of the standardized intervention as well as additional information tailored to patient-specific characteristics
291141|NCT02621476|Behavioral|Usual care|Usual care
291142|NCT02621489|Drug|Bydureon|2 mg Once Weekly
291143|NCT02621489|Drug|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
291144|NCT02621489|Drug|Metformin|Metformin 1g BID
291145|NCT02621502|Dietary Supplement|Quinoa variety 1|On the intervention day, the volunteers will consume the Quinoa Variety 1.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
291146|NCT02621502|Dietary Supplement|Quinoa variety 2|On the intervention day, the volunteers will consume the Quinoa Variety 2.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
291147|NCT02621502|Dietary Supplement|Quinoa variety 3|On the intervention day, the volunteers will consume the Quinoa Variety 3.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
291148|NCT00193466|Drug|CAMPTH-1H|
291149|NCT02621502|Dietary Supplement|Quinoa variety 4|On the intervention day, the volunteers will consume the Quinoa Variety 4.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
291150|NCT02621502|Dietary Supplement|Anhydrous Glucose|On the intervention day, the volunteers will consume the control product.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
291462|NCT02617017|Drug|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
291463|NCT02617043|Radiation|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
291464|NCT02617069|Biological|botulinum toxin injection|
291465|NCT02619396|Procedure|Combination 2 of RF power and LSI on LA posterior wall|40 W RF power, target FTI ≥400 gs and target LSI = 4 on LA posterior wall
291466|NCT02619396|Procedure|Combination 3 of RF power and LSI on LA posterior wall|20 W RF power, target FTI ≥400 gs and target LSI = 5 on LA posterior wall
290875|NCT02625727|Other|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
290876|NCT02625740|Device|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
290877|NCT02625740|Device|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
290878|NCT02625740|Device|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
290879|NCT02625740|Drug|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
290880|NCT02627794|Device|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
290881|NCT02627807|Radiation|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
290882|NCT00194129|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
290883|NCT02627807|Radiation|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
290884|NCT02627807|Drug|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
290885|NCT02627807|Drug|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
291151|NCT02621515|Drug|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
291152|NCT02621528|Device|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
291153|NCT02621541|Device|PET/CT|
291154|NCT02621554|Dietary Supplement|resveratrol supplementation|6 months of resveratrol supplementation
291155|NCT02621554|Dietary Supplement|Placebo|6 months of placebo intake
290587|NCT02670863|Other|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
290588|NCT02670863|Other|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
290589|NCT02670876|Behavioral|Anti-bullying intervention|The title of each session were as follows :
Introduction of intervention and setting rules, building rapport
Understanding school bullying (The definition of school bullying and proper coping strategies)
Empathy of others ( Practice of understanding victims of school bullying)
Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)
Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)
Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)
Communication skills enhancement
Increasing self esteem
290590|NCT02670889|Drug|Acetohydroxamic Acid|
290591|NCT00199017|Drug|Asparaginase|
290592|NCT02670889|Drug|Isotopic Intravenous [13C]-Urea|Used to trace 13CO2 and 13C-urea in the blood.
290593|NCT02673255|Biological|Tetanus and Diphtheria (Td) Vaccine|
290594|NCT02673268|Procedure|Mastectomy|
290595|NCT02673268|Device|Da Vinci Robot Xi|
290596|NCT02673281|Other|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
290597|NCT02673281|Other|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
290598|NCT02673294|Other|balance virtual rehabilitation|
290599|NCT02673307|Behavioral|1 chewing gum over 45 minutes|
290600|NCT02673320|Procedure|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
290886|NCT02627807|Drug|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
290887|NCT02627807|Drug|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
290888|NCT02627820|Drug|Isis 420915/GSK 299872|Open label study in comparison to historic control.
294548|NCT02616068|Drug|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
294549|NCT02616068|Drug|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
294550|NCT02616068|Drug|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
294551|NCT02616068|Drug|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
294852|NCT02611622|Other|Survey|Demographic and Patient Satisfaction Survey
294853|NCT02611635|Drug|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
294854|NCT00192634|Drug|Emtricitabine 200mg - Tenofovir 300mg|1 tablet once daily for 96 weeks
294855|NCT02611635|Drug|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
294856|NCT02611635|Drug|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
294857|NCT02611635|Drug|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
294858|NCT02611635|Drug|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
294859|NCT02611635|Drug|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
294860|NCT02611648|Other|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
294861|NCT02611648|Other|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
290662|NCT00199225|Procedure|Continous electrocardiographic register|
290663|NCT02678208|Drug|Tranexamic Acid|
290664|NCT02678208|Drug|5% glucose|
290665|NCT02678221|Drug|Sildenafil citrate|
290666|NCT02678221|Drug|Aspirin|
290933|NCT02634463|Drug|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent [eq.] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
290934|NCT02634463|Drug|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
290935|NCT02634476|Behavioral|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
290936|NCT02634476|Behavioral|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
290937|NCT02634489|Drug|Tamsulosin HCl|Oral
290938|NCT02634489|Drug|Solifenacin Succinate|Oral
290939|NCT02634489|Drug|EC905|Oral
290940|NCT02634502|Procedure|radiofrequency ablation|
290941|NCT02634502|Drug|S-1|
290942|NCT00194935|Drug|Topotecan|
290943|NCT02634515|Drug|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
290944|NCT02634515|Drug|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
290945|NCT02634528|Drug|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
290357|NCT00196534|Drug|Bovine Thrombin|
290358|NCT02647931|Behavioral|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
290359|NCT02647944|Drug|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
290360|NCT02647944|Drug|Placebo|
290361|NCT02647957|Procedure|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
290362|NCT02647970|Behavioral|PUFA‒Cys/Met diet|Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
290363|NCT02647970|Behavioral|SFA+Cys/Met diet|Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
290364|NCT02647983|Drug|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
290365|NCT02647996|Procedure|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
290366|NCT02648009|Drug|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
290367|NCT02648022|Behavioral|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
290368|NCT00196547|Drug|Montelukast (drug)|
290369|NCT02648035|Biological|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
290667|NCT02680470|Device|Virtual observed therapy|Virtual Observation of participants taking their medication
290668|NCT02680496|Device|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
290669|NCT02680496|Other|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
290670|NCT02680496|Other|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
289781|NCT02658916|Drug|BMS-986168|Same dose as corresponding CN002003 study panel.
289782|NCT02658929|Biological|bb2121|
290066|NCT02652559|Device|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
290067|NCT02652559|Device|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
290068|NCT02652559|Other|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
290069|NCT02652559|Other|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
290070|NCT02652572|Drug|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
290071|NCT02652585|Drug|Naltrexone|
290072|NCT00197028|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
290073|NCT02652585|Drug|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
290074|NCT02654613|Other|Quality Improvement Model of Care|QI addresses the "how" of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context.
290075|NCT02654626|Drug|KBP-7072|Drug Intervention
290076|NCT02654626|Other|Placebo|
290077|NCT02654639|Drug|TAS-102 and Bevacizumab|TAS-102 Twice a day by mouth day 1-5 and 8-12 and Bevacizumab by intravenous infusion once every 14 days
290078|NCT02654652|Dietary Supplement|LactoFos|Patients will receive the product twice a day during seven days after surgical treatment
290079|NCT02654652|Dietary Supplement|Maltodextrin|Patients will receive maltodextrin twice a day during seven days after surgical treatment
290080|NCT00197327|Drug|Epidural bupivacaine (0.25% versus 0.0625%)|
290081|NCT02654665|Behavioral|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
290082|NCT02654665|Drug|Liraglutide|GLP-1 agonist
289479|NCT02663271|Device|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
289480|NCT02663271|Other|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
289481|NCT02665468|Behavioral|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
289482|NCT02665481|Behavioral|MBSR|
289483|NCT02665481|Behavioral|Exercise|
289484|NCT02665481|Behavioral|Health Education|
289485|NCT02665507|Device|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
289486|NCT02665507|Device|Sham|Hand held laser that emits no LLLI
289783|NCT02658942|Procedure|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
289784|NCT02658942|Procedure|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
289785|NCT02658955|Procedure|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
289786|NCT02658968|Drug|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (177Lu-DOTA-HH1 ), single injection with HH1 pre-dosing.
289787|NCT02658981|Biological|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
289788|NCT02658981|Biological|Anti-PD-1|Given IV
289789|NCT02658981|Other|Pharmacological Study|Correlative Studies
289790|NCT02658981|Other|Laboratory Biomarker Analysis|Correlative Studies
289791|NCT00197912|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
289792|NCT02658981|Biological|Anti-CD137|Given IV
289793|NCT02658994|Behavioral|Thinking Healthy Program Peer Delivered Plus|
289186|NCT02670109|Drug|Carmustine|300mg/m2, IV, in 3 hours, during day -4
289187|NCT02670109|Drug|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
289188|NCT02670109|Drug|Carboplatin|1400/m2, IV, in 1 hour, during day -3
289189|NCT02670109|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
289190|NCT02670122|Device|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
289191|NCT02670135|Drug|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
289192|NCT00199004|Drug|VM26|
289193|NCT02670135|Drug|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
289194|NCT02670148|Procedure|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
289487|NCT00002532|Drug|etoposide|
289488|NCT00198861|Other|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
289489|NCT02665520|Procedure|liposuction for retrieval of own stem cells from fat cells|
289490|NCT02665533|Drug|Dexamethasone|Dexamethasone 8 mg
289491|NCT02665533|Drug|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
289492|NCT02665572|Behavioral|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
289493|NCT02665585|Procedure|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
289494|NCT02665611|Behavioral|intervention for improvement of adherence|intervention for improvement of adherence
288901|NCT00199082|Drug|Cytarabine|
288902|NCT02675205|Drug|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
288903|NCT00199173|Device|SIR Spheres intra-arterial hepatic|
288904|NCT02677376|Other|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a secon NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
288905|NCT02677389|Other|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
288906|NCT02677389|Other|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
288907|NCT02677389|Device|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
288908|NCT02677389|Other|Quality-of-Life Assessment|Ancillary studies
288909|NCT02677389|Other|Questionnaire Administration|Ancillary studies
288910|NCT02677402|Other|immersion|
288911|NCT02677415|Other|Intravenous anesthetics|
288912|NCT02677415|Other|local anesthesia|
288913|NCT02677415|Other|Controlled ventilation|
288914|NCT00199186|Drug|imatinib|
288915|NCT02677415|Other|Spontaneous breathing|
289195|NCT02670161|Drug|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
289196|NCT02670174|Other|Traditional training|A home exercise program consisting of rotator cuff and scapular muscle training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
289197|NCT02672644|Device|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
293200|NCT02617641|Behavioral|Publicly available websites|Le Programme de marche (Institut de Cardiologie de Montréal)
L'activité physique (Institut de Cardiologie de Montréal)
L'activité physique (Fondation des maladies du cœur et de l'AVC)
Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)
Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)
293201|NCT02617654|Drug|Liraglutide|Treatment with liraglutide for 52 weeks
293480|NCT02611219|Other|General Health Module-Follow Up Parent Report-School Age (5-12 years)|34 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time
293481|NCT02611219|Other|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
293482|NCT02611219|Other|SCT Daily Activity Log|Uses Fitbit Flex
Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occured while out of bed
293483|NCT02611219|Other|The Functional Independence Measure for Children|18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards
Categorized into 2 main functional streams: "Dependent" (ie, requires helper: scores 1-5) and "Independent" (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the "Complete Dependence" category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the "Modified Dependence" category. Scores 6 (modified independence) and 7 (complete independence) belongs to the "Independent" category.
293484|NCT02611219|Other|Manual Muscle Testing|-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a "break" test, the test giver overpowers the muscle being tested to determine the muscle grade.
293485|NCT00192595|Drug|Tenofovir|
293486|NCT02611219|Other|3-Minute Step Test|Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after
Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance
293487|NCT02611232|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
293488|NCT02611232|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
293489|NCT02613325|Procedure|Standard of care surgical excision|
293490|NCT02613338|Device|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
293491|NCT02613351|Device|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
293492|NCT02613364|Behavioral|Behavioral Intervention|Undergo CBT-I intervention
293210|NCT02617732|Drug|Tianqi capsule|The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.
The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day
293211|NCT02617732|Drug|placebo|The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.
The placebo group patients are treated with placebo by oral, 5 pills three times a day
293212|NCT02617745|Other|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
293213|NCT02617758|Drug|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
293214|NCT02617758|Drug|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
293215|NCT02617771|Drug|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
293216|NCT02620111|Dietary Supplement|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
293217|NCT02620124|Drug|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
293218|NCT02620124|Drug|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
293499|NCT02613364|Other|Quality-of-Life Assessment|Ancillary studies
293500|NCT02613364|Other|Questionnaire Administration|Ancillary studies
293501|NCT02613364|Procedure|Yoga|Undergo yoga intervention
293502|NCT02613377|Other|Blood transfusion|
293503|NCT02613390|Procedure|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
293504|NCT02613390|Behavioral|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
293505|NCT02613403|Drug|MK- 3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (formerly IDX21437), and 30 mg MK-8408 taken once daily by mouth.
293506|NCT02613403|Drug|Ribavirin|Two to three Ribavirin 200 mg (800 or 1000 or 1200 or 1400 mg total daily dose) capsules taken twice daily by mouth as part of a weight-based dosing regimen.
293507|NCT02613416|Drug|Denosumab|monthly subcutaneous injections
292926|NCT00193700|Drug|Testosterone Gel (1%)|
292927|NCT02624440|Drug|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
292928|NCT02624440|Drug|Clarithromycin|P.o. clarithromycin 250 mg twice daily
292929|NCT02624440|Drug|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
292930|NCT02624440|Drug|Observation|Observation without prophylactic antibiotic
292931|NCT02624453|Drug|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
292932|NCT02624453|Drug|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
292933|NCT02624466|Other|CKD progress|CKD progress
292934|NCT02624479|Drug|Sodium thiosulfate|oral administration of thiosulfate
292935|NCT02624492|Drug|BI 836826|
292936|NCT02624492|Drug|GemOx|
292937|NCT00193713|Drug|bifeprunox|
292938|NCT02624492|Drug|Rituximab|
292939|NCT02624492|Drug|GemOx|
292940|NCT02624505|Drug|90 mcg Reference Product|Drug: 90 mcg Reference Product
292941|NCT02624505|Drug|180 mcg Reference Product|Drug: 180 mcg of Reference Product
292942|NCT02624505|Drug|90 mcg Test Product|Drug: 90 mcg of Test Product
292943|NCT02624505|Drug|Placebo|Placebo Product
292944|NCT02624518|Radiation|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Imaging with PET/MRI
292945|NCT02624518|Procedure|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
293219|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
293220|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
292335|NCT02635100|Device|CPAP machine with MNT algorithm|The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:
Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.
Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.
Five days with standard auto titration.
MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days.
292636|NCT02630745|Procedure|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment in concurrent endodontic periodontal lesions with communication .
292637|NCT02630745|Procedure|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
292638|NCT02630758|Behavioral|Mindfulness-based Yoga|See study arm description.
292639|NCT00194610|Drug|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
292640|NCT02630758|Behavioral|Walking Control Condition|See study arm description.
292641|NCT02630771|Procedure|PDAP only|Persistent pain in a tooth or in an intraoral site formally occupied by a tooth without pain over the TMJ, jaws or temples.
292642|NCT02630771|Procedure|PDAP + TMD|Persistent pain in a tooth or in an intraoral site formally occupied by a tooth with comorbid pain over the TMJ, jaws or temples.
292643|NCT02630771|Procedure|Painfree controls|Absence of any intraoral pain or pain over the TMJ, jaws or temples.
292644|NCT02630784|Procedure|Non-Invasive Ventilation with Homecare ventilator|
292645|NCT02630784|Procedure|Non-Invasive Ventilation with ICU ventilator|
292646|NCT02630797|Dietary Supplement|Blueberry Baseline|No blueberry products provided in addition to usual dietary intake
292647|NCT02630797|Dietary Supplement|Blueberry low|Products provided containing equivalent to 0.75 cups blueberries per day for 50 days
292648|NCT02630797|Dietary Supplement|Blueberry Medium|Products provided containing equivalent to 1.5 cups blueberries per day for 50 days
292649|NCT02630797|Dietary Supplement|Blueberry High|Products provided containing equivalent to 3 cups blueberries per day for 50 days
292650|NCT00194610|Other|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
292651|NCT02630810|Other|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
292031|NCT02642029|Device|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
292032|NCT02642029|Device|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
292033|NCT00195780|Drug|Divalproex Sodium (Depakote ER)|
292034|NCT02642029|Device|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
292035|NCT02642042|Drug|Docetaxel|Given IV
292036|NCT02642042|Other|Laboratory Biomarker Analysis|Correlative studies
292037|NCT02642042|Drug|Trametinib|Given PO
292038|NCT02642055|Behavioral|Neuro+ Attention Training|Attention training program with Neuro+ software
292039|NCT02642055|Other|Treatment as Usual|Continuation of current ADHD treatment
292336|NCT00002524|Radiation|Radiation Therapy|
292337|NCT00194987|Drug|IVIG (Intravenous Immunoglobulin)|one to two mg per kg once-twice weekly
292338|NCT02635113|Device|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
292339|NCT02637362|Procedure|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
292340|NCT02637375|Drug|Ganetespib|
292341|NCT02637375|Drug|Paclitaxel|
292342|NCT02637375|Drug|Doxorubicin|
292343|NCT02637375|Drug|Cyclophosphamide|
292344|NCT02637388|Dietary Supplement|Oatwell28 Oatwell Original Powder|
292345|NCT02637388|Dietary Supplement|Control Breakfast|Isocaloric breakfast without added beta-glucans
292346|NCT02637401|Behavioral|Dialectical Behaviour Therapy|
291747|NCT02612740|Procedure|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
291748|NCT02612740|Device|granules of deproteinized bovine bone (Bio-Oss)|
291749|NCT02612753|Procedure|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
291750|NCT00002521|Procedure|peripheral blood stem cell transplantation|
291751|NCT00192660|Drug|Nelfinavir|
291752|NCT02612753|Device|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
291753|NCT02612753|Device|tDCs|
291754|NCT02612766|Dietary Supplement|Pure, uncontaminated oats|
291755|NCT02612779|Drug|Elotuzumab|
291756|NCT02612779|Drug|Pomalidomide|
291757|NCT02612779|Drug|Dexamethasone|
291758|NCT02612792|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
292040|NCT02642094|Drug|Rapamycin|Low dose of rapamycin at 2 mg/day for 7 day treatment
292041|NCT02642107|Radiation|Elective neck irradiation|Whole neck irradiation is given in the positive neck. Elective neck irradiation of Level II,III,Va lymph node area is given in negative neck, and Level IV,Vb and Supraclavicular fossa lymph node area were not irradiated in negative neck.
292042|NCT02644161|Procedure|Dense cranial electroacupuncture stimulation|DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.
Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs).
292043|NCT02644161|Procedure|Body acupuncture|Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered.
292044|NCT02644161|Drug|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
292045|NCT02644161|Other|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
291467|NCT02619396|Procedure|Combination 4 of RF power and LSI on LA posterior wall|40 W RF power, target FTI ≥400 gs and target LSI = 5 on LA posterior wall
291468|NCT02619409|Drug|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
291469|NCT02619409|Drug|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
291470|NCT02619409|Drug|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
291471|NCT02619409|Drug|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
291472|NCT02619409|Drug|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
291473|NCT00002522|Procedure|syngeneic bone marrow transplantation|
291474|NCT00193323|Drug|Docetaxel|
291475|NCT02619422|Other|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
291476|NCT02619435|Drug|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
291477|NCT02619448|Drug|Carboplatin|chemotherapy
291478|NCT02619448|Drug|Paclitaxel|chemotherapy
291479|NCT02619448|Radiation|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
291480|NCT02619461|Other|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
291481|NCT02619474|Other|Whiteboard|On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.
The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.
Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning.
291759|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
291760|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
291761|NCT02614833|Drug|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
291762|NCT00002522|Drug|cisplatin|
291156|NCT00002524|Biological|Bleomycin Sulfate|
291157|NCT00193609|Drug|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
291158|NCT02623660|Device|ODIN1|Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.
All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges.
291159|NCT02623660|Other|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
291160|NCT02623660|Device|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
291161|NCT02623673|Drug|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
291162|NCT02623686|Other|Aroma Therapy Massage and Inhalation Patch|
291163|NCT02623699|Drug|BIIB067 (Isis-SOD1Rx)|Part A and B
291164|NCT02623699|Other|Placebo|Part A and B
291165|NCT02623712|Other|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
291166|NCT02623712|Other|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
291167|NCT02623725|Biological|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
291168|NCT00193609|Drug|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
291169|NCT02623725|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
291170|NCT02623738|Drug|Placebo ophthalmic solution|
291482|NCT02619487|Other|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
291483|NCT02619487|Other|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
291484|NCT02619500|Other|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
290889|NCT02627833|Other|observation|Record lung function, Lung clearance index, inflammatory status
290890|NCT02627846|Device|Endovenous Laser Ablation|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
290891|NCT02627846|Device|Mechanochemical Ablation|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
290892|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
290893|NCT00194181|Drug|TPA Infusion|
290894|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
290895|NCT02630160|Drug|Bupivacaine hydrochloride|Intraarticular infusion with bupivacaine
290896|NCT02630160|Other|Physiological Saline|Intraarticular infusion physiological serum
290897|NCT02630173|Procedure|Scaling and root planing|Scaling and root planing was done in both the groups
290898|NCT02630173|Other|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
290899|NCT00194519|Drug|Generic acyclovir|400 mg twice-daily oral
290900|NCT02630186|Drug|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
290901|NCT02630186|Drug|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
291171|NCT02623738|Drug|DE-117 ophthalmic solution low|
291172|NCT02623738|Drug|DE-117 ophthalmic solution high|
291173|NCT02623738|Drug|Latanoprost ophthalmic solution 0.005%|
294862|NCT02611661|Device|PET/MRI|
294863|NCT02611661|Radiation|Percutaneous microwave ablation|
294864|NCT02611661|Radiation|Stereotactic body radiotherapy|
294865|NCT00192634|Drug|Abacavir 600mg - Lamivudine 300mg|1 tablet once daily for 96 weeks
294866|NCT02611687|Drug|pitolisant|Tablet
295165|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
295166|NCT02643290|Device|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients and tracked for six months.
295167|NCT02643303|Drug|Durvalumab|
295168|NCT02643303|Drug|Tremelimumab|
295169|NCT02643303|Drug|Poly ICLC|
295170|NCT02643316|Drug|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
295171|NCT00196027|Device|PFX Closure System|
295172|NCT02643316|Drug|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
295173|NCT02643329|Drug|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
295174|NCT02643329|Drug|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
295175|NCT02643342|Device|Orthokeratology|
295176|NCT02643355|Drug|Olanzapine|
295177|NCT02643355|Drug|Clonidine|
295178|NCT02643368|Biological|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
295179|NCT02643368|Biological|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
295180|NCT02643368|Biological|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
290946|NCT02634528|Drug|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
290947|NCT02634541|Drug|Adalimumab|Biologic drug
290948|NCT02634541|Other|PET/CT imaging|PET/CT imaging
290949|NCT02634567|Behavioral|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
291250|NCT02632331|Drug|ASP8825|Oral
291251|NCT02632344|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
291252|NCT02632357|Other|Spinal Manipulation|
291253|NCT02632370|Drug|Gliolan|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
291254|NCT02632370|Procedure|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
291255|NCT02632383|Device|Young with Diabetes - app|The mHealth app "Young with Diabetes" containes 8 main functions:
Contact your health care provider (ask questions, set the agenda for the next clinical visit)
My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)
Chatroom
Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)
Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)
Tips packages (Receive a tip about alcohol, drivers license etc.)
To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)
Reminder
291256|NCT02632396|Drug|Ixazomib Citrate|Given PO
291257|NCT02632409|Biological|Nivolumab|
291258|NCT02632409|Other|Placebo|
291259|NCT00194779|Drug|methotrexate|Given IV
291260|NCT02632422|Other|Daily acute intermittent hypoxia (dAIH)|Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute hypoxia (FIO2=0.09±0.02, i.e. 9% O2). Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
291261|NCT02632422|Other|dSHAM|Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02) . Participants will receive 5 consecutive days of daily room air (dSHAM).
290671|NCT02680509|Procedure|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
290672|NCT02680522|Other|Exercise|exercise training with virtual reality in videogame
290673|NCT02680535|Device|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
290674|NCT00199602|Drug|warfarine - low molecular heparin|
290675|NCT02680548|Drug|0.9% saline|
290676|NCT02680548|Drug|0.25% bupivacaine hydrochloride injectable suspension USP|
290677|NCT02680548|Drug|4mg/cc methylprednisolone acetate injectable suspension USP|
290678|NCT02680561|Drug|Fluticasone Propionate MDPI|
290679|NCT02680561|Drug|Fluticasone Propionate/Salmeterol MDPI|
290680|NCT02680561|Drug|Fluticasone propionate/salmeterol|
290681|NCT02680574|Drug|vadadustat|oral tablet
290682|NCT02680574|Drug|darbepoetin alfa|Subcutaneous
290683|NCT02680587|Radiation|SBRT|SBRT (1-5 fractions) will be administered.
290684|NCT02680587|Drug|DCFPyL-PET/MRI or -PT/CT|Estimate the proportion of DCFPyL-PET/MRI or -PET/CT positive sites that are positive for new or progressive metastatic disease by bone scan at 6-months from SBRT and vice versa
290685|NCT00199615|Procedure|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
290686|NCT02680587|Other|Observational (no SBRT)|These patient will not receive SBRT. They will be observed.
290687|NCT02680600|Drug|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
290950|NCT02634580|Biological|Evolocumab|Subjects will receive Evolocumab (AMG 145) subcutaneous monthly and Ezetimibe matching placebo pill daily by mouth.
290951|NCT02636764|Device|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
290952|NCT02636764|Device|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
290083|NCT02654678|Drug|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
290084|NCT02654704|Biological|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
290085|NCT02654717|Drug|DFD-07 Cream|
290086|NCT02654717|Drug|Placebo Cream|
290370|NCT02648048|Drug|Pirfenidone|Participants will receive up to 2403 mg pirfenidone daily via oral administration for 24 weeks.
290371|NCT02648048|Drug|Vismodegib|Participants will receive 150 mg vismodegib once daily via oral administration for 24 weeks.
290372|NCT02648074|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
290373|NCT02650167|Biological|formula for preterm infants|
290374|NCT02650180|Device|Soberlink Cellular Device|Alcohol Breath Analyzer
290375|NCT02650193|Drug|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg-6 subjects Cycle 0 Regimen B - 6 mg-6 subjects Cycles 1-4 Regimen B - 6 mg-12 subjects Cycles 1-4 Regimen A- 3 mg-12 subjects Cycles 1-4 Regimen C- 12 mg-12 subjects
290376|NCT02650206|Drug|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
290377|NCT02650206|Other|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
290378|NCT02650219|Genetic|genetic analyses|
290379|NCT00196768|Drug|Arsenic trioxide|
290380|NCT02650232|Device|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
290381|NCT02650232|Procedure|Orthostatic test|For each arm we will proceed to an orthostatic test day one and day two with :
10 minutes in supine position
10 minutes in sitting position
5 minutes in standing position
5 minutes in supine position
290382|NCT02650232|Device|Finapres Nova device (FMS system)|
290383|NCT02650245|Dietary Supplement|EAS Myoplex Protein Drink + 10gm lactulose|
290384|NCT02650271|Drug|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
289794|NCT02658994|Other|Enhanced Usual Care|
289795|NCT02659007|Other|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
289796|NCT02659020|Drug|Olaratumab|Administered IV
289797|NCT02660840|Drug|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
289798|NCT02660840|Drug|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
289799|NCT02660866|Drug|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
289800|NCT02660866|Drug|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
289801|NCT02660879|Other|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
289802|NCT02660879|Other|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
289803|NCT02660892|Dietary Supplement|Protein intake|Oral consumption of eight hourly experimental meals
4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil
4 isotopically labeled experimental meals.
290087|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient individuals|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
290088|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient individuals|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
290089|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient individuals|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
290090|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal individuals|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
290091|NCT00197340|Drug|Epidural ropivacaine|
290092|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal individuals|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
289495|NCT02665611|Behavioral|treatment as usual|The control group will be treated according to the usual stadard of care.
289496|NCT02665624|Drug|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
289497|NCT02665624|Drug|Senna alone|comparison of bowel cleansing and patient comfort.
289498|NCT02665637|Drug|Trastuzumab|Each patient may receive single dose by intravenous infusion
289499|NCT00198874|Behavioral|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
289500|NCT02665650|Biological|AFM13|
289501|NCT02665650|Biological|Pembrolizumab|
289502|NCT02665663|Device|medical device|
289503|NCT02665689|Drug|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
289504|NCT02665702|Drug|NVB|25mg/m2 ，D1，8
289505|NCT02667743|Drug|Paclitaxel Micelles for Injection|
289506|NCT02667743|Drug|Paclitaxel Injection|
289507|NCT02667743|Drug|Cisplatin|
289508|NCT02667756|Other|Non-interventional|
289804|NCT02660905|Drug|E/C/F/TAF;|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
289805|NCT00198289|Drug|Aurexis® (tefibazumab)|
289806|NCT02660905|Drug|Ledipasvir-Sofosbuvir|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
289807|NCT02660918|Drug|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
289808|NCT02660918|Other|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
289809|NCT02660931|Other|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
289810|NCT02660944|Drug|RSLV-132|RNase-Fc fusion protein
289198|NCT02672644|Device|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
289199|NCT02672670|Behavioral|Experimental: Intervention group---coping-oriented supportive programme|
289200|NCT02672670|Behavioral|Active Comparator: Comparison group---a didactic talk (usual care)|
289201|NCT02672696|Device|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
289202|NCT02672709|Drug|apixaban|
289203|NCT02672722|Drug|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
289204|NCT02672722|Other|Exercise|
289205|NCT00199056|Drug|G-CSF|
289206|NCT02672722|Other|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
289207|NCT02672735|Other|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
289208|NCT02672748|Other|Garden|Two years of financial and technical home gardening support for new gardeners
289209|NCT02672761|Behavioral|MBSR meditation|Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as "a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness". The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head.
289509|NCT02667769|Other|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose <55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
293493|NCT02613364|Other|Cognitive Intervention|Undergo CBT-I intervention
293494|NCT02613364|Other|Educational Intervention|Receive health education
293495|NCT02613364|Other|Educational Intervention|Receive health education booklet
293496|NCT02613364|Other|Laboratory Biomarker Analysis|Correlative studies
293497|NCT02613364|Device|Monitoring Device|Correlative studies
293498|NCT00192764|Drug|high-dose cyclophosphamide|
288916|NCT02677428|Behavioral|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
288917|NCT02677428|Behavioral|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
288918|NCT02677441|Procedure|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
288919|NCT02677441|Procedure|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
288920|NCT02677454|Device|Flash Glucose Monitor|
288921|NCT02677467|Biological|Blood-pressure variability|Day to Night Blood pressure variability
288922|NCT02677480|Dietary Supplement|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
288923|NCT00199485|Drug|Angelica Sinensis|Angelica Sinensis / placebo
288924|NCT02679794|Behavioral|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
288925|NCT02679807|Biological|Bifidobacterium animalis subsp. lactis Bl-04|
288926|NCT02679807|Other|sucrose|
293508|NCT02613429|Behavioral|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
293509|NCT00002521|Procedure|syngeneic bone marrow transplantation|
293510|NCT00192777|Drug|Xeloda|
293511|NCT02613429|Behavioral|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
293512|NCT02613455|Procedure|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
293513|NCT02615574|Biological|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
293514|NCT02615574|Drug|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
293515|NCT00002522|Drug|cyclophosphamide|
293516|NCT00193076|Drug|Trastuzumab|Trastuzumab
293517|NCT02615587|Drug|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
293518|NCT02615600|Device|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
293519|NCT02615613|Other|Low Acceptability Meal|
288932|NCT02679898|Other|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
288933|NCT02679898|Other|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
288934|NCT00002535|Biological|lymphokine-activated killer cells|
288935|NCT00199498|Device|Permanent RV lead placement|RV lead placed at the randomized site
293221|NCT00002522|Radiation|radiation therapy|
293222|NCT00193375|Drug|Irinotecan|50mg/m2 days 1 & 8 each 21-day cycle 1 & 2, 28-day cycle 3 & 4
293223|NCT02620150|Drug|Escitalopram|10 week trial
293224|NCT02620150|Other|Placebo|10 week trial
293225|NCT02620163|Drug|telmisartan/amlodipine 40/5mg|
293226|NCT02620163|Drug|YH22162 40/5/12.5 mg|
293227|NCT02620163|Drug|telmisartan/amlodipine 80/5mg|
293228|NCT02620163|Drug|YH22162 80/5/25 mg|
293229|NCT02620163|Drug|telmisartan/amlodipine 40/5mg placebo|
293230|NCT02620163|Drug|YH22162 40/5/12.5 mg placebo|
293231|NCT02620163|Drug|telmisartan/amlodipine 80/5mg placebo|
293232|NCT02620163|Drug|YH22162 80/5/25 mg placebo|
293233|NCT00193375|Drug|Carboplatin|AUC 5
293234|NCT02620176|Device|Transcutaneous vagal nerve stimulation|Trans-auricular vagal nerve stimulation
293235|NCT02620189|Drug|Anti-TNF Biologics Therapy|
293236|NCT02620215|Device|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
293237|NCT02620215|Drug|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
293238|NCT02620228|Device|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
293239|NCT02620241|Other|sitting position|
293240|NCT02620267|Device|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
293520|NCT02615613|Other|High acceptability meal|
292652|NCT02630810|Other|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
292653|NCT02630823|Drug|MK-3475|
292654|NCT02630823|Procedure|Surgical resection (standard of care)|
292655|NCT02630823|Drug|Paclitaxel (standard of care)|
292656|NCT02630823|Drug|Carboplatin (standard of care)|
292657|NCT02630823|Radiation|Radiation (standard of care)|
292946|NCT02624518|Procedure|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
292947|NCT02626429|Dietary Supplement|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
292948|NCT02626442|Other|Exercise|6 month group exercise class
292949|NCT02626455|Drug|Copanlisib (BAY 80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days.
292950|NCT02626455|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
292951|NCT00193973|Drug|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
292952|NCT02626455|Drug|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
292953|NCT02626455|Drug|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
292954|NCT02626455|Drug|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
292955|NCT02626455|Drug|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
292956|NCT02626455|Drug|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
292957|NCT02626455|Drug|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
292347|NCT02637414|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
292348|NCT02637427|Biological|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
292349|NCT00002525|Procedure|surgical procedure|
292350|NCT00195273|Drug|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
292351|NCT02637440|Procedure|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
292352|NCT02637440|Procedure|Angio guided PCI|Patients receive PCI without FFR measurement
292353|NCT02637453|Procedure|CPVI|patients with circumferential pulmonary vein isolation （CPVI）
292354|NCT02637453|Procedure|CPVI+ALA|patients with circumferential pulmonary vein isolation（CPVI）and additional linear ablation perpendicular to the PV ostium （ALA）
292355|NCT02637466|Drug|Vortioxetine|
292356|NCT02637479|Device|GammaKnife®|
292658|NCT02630823|Procedure|Endometrial biopsy|
292659|NCT02630823|Procedure|Peripheral blood draw|
292660|NCT02630836|Drug|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
292661|NCT02632877|Drug|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
292662|NCT02632877|Drug|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
292663|NCT02632903|Drug|Zoledronic acid|
292664|NCT02632916|Drug|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg at baseline and 6 months
292665|NCT02632916|Drug|Denosumab|Subcutaneous denosumab 1.0mg/kg at baseline and 6 months
292666|NCT02632942|Procedure|HAQ criteria|Obliteration of accessory vein which satisfy the HAQ criteria as below:
60% or greater diameter of the main AVF
50% diameter of AVF with at least one more av>40% in diameter.
50% in diameter and divides into branches of same size.
av likely to interfere with cannulation on physical examination.
>30% in diameter and associated with stenosis at site of origin.
292046|NCT02644161|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
292047|NCT02644174|Procedure|Bariatric Surgery|
292048|NCT02644187|Device|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
292049|NCT02644187|Device|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
292050|NCT00196092|Device|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
292051|NCT02644187|Drug|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
292052|NCT02644200|Device|Gelatin tannate|
292053|NCT02644213|Other|protocol of using CAREN and MOTEK systems|The subjects will perform randomly 3 experimental days (at least weak between one to another):
simulated road march using a virtual reality environment without additional load
simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.
without physical or cognitive load (without march, waiting between performance evaluations) as control.
292054|NCT02644226|Other|Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged less than 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
292357|NCT02637479|Device|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
292358|NCT02637479|Device|MRI|
292359|NCT02637492|Other|Collection of clinical signs and symptoms|Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
292360|NCT02637505|Procedure|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
292361|NCT00195273|Drug|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
292362|NCT02637505|Procedure|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
292363|NCT02637518|Other|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
291763|NCT00193024|Drug|Epirubicin|
291764|NCT02614833|Drug|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
291765|NCT02614846|Drug|Hetrombopag Olamine|
291766|NCT02614859|Drug|Bicalutamide|Bicalutamide 50 mg daily beginning at cycle 3 to cycle 8
291767|NCT02614859|Drug|Metformin and Bicalutamide|Metformin 1000mg twice a day Bicalutamide 50 mg daily beginning at cycle 3
291768|NCT02614872|Drug|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) [GLASSIA®] add-on pharmacotherapy and Institution standard of care (SOC)
291769|NCT02614872|Drug|Institution standard of care (SOC) only|Institutions SOC for first lung transplant subjects
291770|NCT02614885|Device|Radiofrequency Ablation|
291771|NCT02614898|Other|Clinical assessments and laboratory tests.|Clinical assessments and laboratory tests required at a minimum monthly. Frequency is increased at enrollment and any time there is a change in Soliris® regimen. Treatment for aHUS is observational and remains at the discretion of the treating physician.
291772|NCT02614911|Other|Biological sampling|Biological sampling including blood, feces, biopsies...
291773|NCT02614924|Device|Flexible fibreoptic scope|Patient intubated using fibreoptic scope
291774|NCT00193037|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin
291775|NCT02614937|Drug|ranibizumab|0.5 mg IVT ranibizumab
291776|NCT02614937|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
291777|NCT02614950|Other|Treatment interruption|
291778|NCT02614963|Drug|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
291779|NCT02614963|Drug|placebo|Irritable bowel syndrome patients treated with placebo
291780|NCT02614976|Device|Padding|Padding webrill (Covidian) TM 6"
291781|NCT02614989|Procedure|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
292055|NCT02644226|Other|Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged less than 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
292056|NCT02644239|Dietary Supplement|ketogenic diet|Ketogenic diet with high fat (90%)
291485|NCT00193323|Drug|Gemcitabine|
291486|NCT02619500|Other|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
291487|NCT02621567|Device|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
291488|NCT02621567|Device|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
291489|NCT02621580|Device|Pan-Retinal Photocoagulation|Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.
During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment.
291490|NCT00193479|Drug|Cyclophosphamide|Cyclophosphamide
291491|NCT02621593|Device|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
291492|NCT02621606|Drug|[11C]MK-6884|IV bolus dose of ~370 MBq [11C]MK-6884
291493|NCT02621619|Drug|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
291494|NCT02621619|Drug|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
291495|NCT02621619|Drug|0.5 mg IV hydromorphone|Both groups (intervention and placebo) will receive 0.5 mg IV hydromorphone
291496|NCT02621632|Device|(Socknleg)To done of a novel compression system|To done a novel compression system.
291497|NCT02621645|Procedure|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
291782|NCT02615002|Drug|Piromelatine|
291783|NCT02615002|Drug|Placebo|
291784|NCT02615015|Other|Blood draw|
291785|NCT00193037|Drug|Docetaxel|Docetaxel
291174|NCT02623751|Drug|KHK2375|KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.
Exemestane will be orally adminitered once daily.
291175|NCT02623751|Drug|Exemestane|KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.
Exemestane will be orally adminitered once daily.
291176|NCT02623777|Dietary Supplement|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
291177|NCT02623777|Dietary Supplement|Short chain fatty acids|Short chain fatty acids administered
291178|NCT02623790|Other|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
291179|NCT02625740|Procedure|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
291180|NCT02625753|Drug|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
291181|NCT02625753|Drug|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
291182|NCT02625753|Drug|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
291183|NCT00193908|Drug|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
291184|NCT02625766|Procedure|LC fracture surgical fixation|
291185|NCT02625766|Procedure|LC fracture non-operative management|
291186|NCT02625779|Drug|Valproate and Placebo|
291187|NCT02625779|Drug|Valproate and Cytidine-containing Drug|
291188|NCT02625779|Drug|Valproate and Creatine-containing Drug|
291189|NCT02625792|Drug|Endo-Clot(TM)|The patients randomized assigned before ESD. After patients treated with ESD than Hemostatic power applying by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
291190|NCT02625805|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
296107|NCT02630004|Drug|Melatonin oral gel 3%|
296108|NCT02630004|Drug|Placebo oral gel|
295181|NCT02643368|Biological|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
295182|NCT00002528|Procedure|Axillary clearance|Axillary node dissection.
295183|NCT00196040|Device|PFX Closure System|
295184|NCT02643381|Drug|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
295185|NCT02643381|Drug|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
295186|NCT00196209|Procedure|catheter ablation|catheter ablation to treat persistent atrial fibrillation
295493|NCT02638675|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
295494|NCT02638675|Behavioral|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
295495|NCT02638688|Other|ultrasound|
295496|NCT02638701|Drug|Infliximab|
295497|NCT00195429|Drug|Tacrolimus|
295498|NCT02638714|Biological|Stem Cells|Intervention: Transplantation of autologous purified stem cells
295499|NCT02638727|Drug|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
295500|NCT02638727|Drug|placebo|This group treat with placebo dayley
295501|NCT02638740|Procedure|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
295502|NCT02638740|Procedure|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
295503|NCT02638753|Other|education|Patients will be educated about pain neurophysiology.
295504|NCT02638753|Other|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
295505|NCT02638766|Drug|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
295506|NCT02638779|Biological|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
291262|NCT02632422|Other|Walking|Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes.
Walking practice will incorporate 5 walking-related tasks:
walking balance (e.g., walking on different surfaces)
skilled walking tasks (e.g., negotiating obstacles)
walking with secondary task (e.g., walking and carrying object)
endurance
speed
291263|NCT02632435|Device|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
291264|NCT02632435|Device|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
291265|NCT02632448|Drug|LY2880070|Capsules
291266|NCT02632448|Drug|Gemcitabine|800 milligrams per square meter of body surface area (mg/m2)
291267|NCT02634580|Drug|Ezetimibe|Subjects will receive Ezetimibe pill daily by mouth and Evolocumab matching placebo subcutaneous monthly.
291268|NCT02634580|Biological|Evolocumab|Subjects will receive Evolocumab (AMG 145) subcutaneous every two weeks and Ezetimibe matching placebo pill daily by mouth.
291550|NCT02628041|Radiation|High-Dose-rate Prostate Brachytherapy|High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.
A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed.
291551|NCT02628054|Biological|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
291552|NCT02628054|Biological|Placebo|Saline injection given 7 days apart
291553|NCT02628067|Biological|pembrolizumab|
291554|NCT00194272|Drug|Methotrexate|Two dose methotrexate
291555|NCT02628080|Drug|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
291556|NCT02628093|Device|THUNDERBEAT|Tissue dissection and vessels ligation
291557|NCT02628093|Device|LIGASURE|Tissue dissection and vessels ligation
291558|NCT02628106|Drug|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
291559|NCT02628119|Procedure|Intra-procedural access flow|Intra-procedure access flow technique:
Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min.
290953|NCT02636764|Device|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
290954|NCT02636764|Device|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
290955|NCT02636777|Other|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
290956|NCT02636790|Procedure|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
290957|NCT02636803|Drug|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
290958|NCT02636803|Drug|albendazole|group receives one 400 mg dose of albendazole
290959|NCT00195234|Biological|HIV CTL MEP 1000 micrograms, 19 months per subject|
290960|NCT02636816|Drug|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
290961|NCT02636829|Other|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
290962|NCT02636829|Other|Determination of calcium intake by a dietician interview|All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL *.
* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital.
290963|NCT02636842|Drug|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
290964|NCT02636868|Drug|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
290965|NCT02636868|Drug|nCPAP|Nasal CPAP
290966|NCT02636881|Procedure|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
290967|NCT02636881|Procedure|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
290968|NCT02636894|Device|Restylane Silk|
291269|NCT00194948|Drug|escitalopram|
291270|NCT02634580|Drug|Ezetimibe|Subjects will receive Evolocumab (AMG 145) every two weeks and Ezetimibe matching placebo pill daily by mouth.
290385|NCT02650271|Drug|Lamivudine|Patients will be received lamivudine (100 mg/d) after 3 days of liver resection.
290386|NCT02650284|Device|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
290387|NCT02650284|Device|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
290388|NCT02650297|Other|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
290688|NCT02680600|Other|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
290689|NCT02680600|Other|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
290690|NCT02682693|Drug|Epirubicin|Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
290691|NCT02682693|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
290692|NCT02682693|Drug|Carboplatin|Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
290693|NCT02682693|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
290694|NCT00199979|Drug|Nevirapine|
290695|NCT02682693|Drug|Pertuzumab|Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
290696|NCT02682719|Drug|LCZ696|
290697|NCT02682719|Drug|Valsartan|
290698|NCT02682719|Other|Placebo to LCZ696|
290699|NCT02682719|Other|Placebo to Valsartan|
290700|NCT02682732|Procedure|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
290701|NCT02682745|Drug|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
290702|NCT02682745|Drug|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
290703|NCT02682758|Drug|Xenon|Wash-in of xenon for maintenance of anaesthesia
290093|NCT02654743|Dietary Supplement|Sulforaphane|Children with ASD will receive Sulforaphane in this study
290094|NCT02654769|Drug|Ingenol Mebutate (Picato®)|Brand product
290095|NCT02656979|Drug|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
290096|NCT02656992|Device|Inspiratory muscle training group|
290097|NCT02657005|Drug|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
290098|NCT02657018|Device|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
290099|NCT02657018|Other|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
290100|NCT02657031|Drug|Prochlorperazine|prochlorperazine 10 mg IV
290101|NCT02657031|Drug|Ketamine|Ketamine 0.3 mg/kg IV
290102|NCT02657031|Drug|Diphenhydromine|Diphenhydromine 25 mg IV
290103|NCT00002531|Drug|teniposide|
290104|NCT00197678|Dietary Supplement|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
290389|NCT02650297|Device|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
290390|NCT00196768|Drug|Trisenox|
290391|NCT02650310|Device|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
290392|NCT02650336|Drug|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
290393|NCT02650349|Device|spinal cord stimulation|After placement of definitive spinal cord stimulation (RestoreSensor® SureScan® MRI neurostimulator), patients will receive one month conventional spinal cord stimulation (60 Hz). After the conventional spinal cord stimulation, patients will receive one month paresthesia free high density stimulation.
290394|NCT02652598|Drug|Tolcapone|
290395|NCT02652611|Procedure|SI Screw Removal Surgery|
289811|NCT02660944|Drug|Placebo|Saline placebo
289812|NCT02660957|Behavioral|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
289813|NCT02660957|Other|placebo comparator|suggest a healthy life style as a placebo comparator
289814|NCT02660970|Other|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
289815|NCT02660970|Other|Placebo-band|Children will have to wear a 'placebo-wristband'
289816|NCT00000378|Drug|Nortriptyline|12 week trial dose adjusted to therapeutic level
289817|NCT00002531|Radiation|radiation therapy|
289818|NCT00198302|Drug|Aurexis®|
289819|NCT02660970|Drug|Iberogast|Children will have to take Iberogast drops
289820|NCT02660970|Other|Placebo-drops|Children will have to take placebo-drops
289821|NCT02660983|Drug|Donepezil hydrochloride|
289822|NCT02660983|Drug|Donepezil matching placebo|
289823|NCT02663271|Other|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
289824|NCT02663284|Drug|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
289825|NCT02663297|Drug|ATLCAR.CD30 cells|Three dose levels will be evaluated:
Group One, 2x10^7 cells/m^2
Group Two, 1x10^8 cells/m^2
Group Three, 2x10^8 cells/m^2;
Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc.
289826|NCT00198536|Drug|Ecabet 3.70%|
290105|NCT02657031|Drug|Ondansetron|Ondansetron 4 mg IV
290106|NCT02657031|Drug|Normal Saline|Normal Saline 500 cc IV Bolus
290107|NCT02657044|Procedure|EMR|
290108|NCT02657044|Procedure|ESD|
290109|NCT02657057|Device|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
289510|NCT02667782|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
289511|NCT02667782|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
289512|NCT02667795|Other|Monitored walking based exercise|
289513|NCT00002532|Drug|leucovorin calcium|
289514|NCT00198991|Drug|Vincristine|
289515|NCT02667808|Other|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
289516|NCT02667808|Other|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
289517|NCT02667821|Other|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue. Venous blood samples will be obtained by a professional certified in venipuncture on the day of and two days following the experimental maneuvers.
289518|NCT02667834|Behavioral|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
289519|NCT02667834|Behavioral|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
289520|NCT02667860|Procedure|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopath and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
289521|NCT02670174|Other|Kinetic chain training|A home exercise program consisting of traditional training exercises as well as exercises focusing on core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
289827|NCT02663310|Procedure|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
288927|NCT02679820|Device|Copper T intrauterine device|
288928|NCT02679833|Dietary Supplement|Placebo|Toothpaste not containing the vitamin.
288929|NCT02679833|Dietary Supplement|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
288930|NCT02679846|Other|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
288931|NCT02679859|Other|BNP guided medical therapy optimisation|
289210|NCT02672761|Behavioral|MBT training|A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories "working/semantic" and "episodic/optical" memory and "logic/calculation" adjusted to the individual's selection from all categories but various themes (like sports, cars etc.).
289211|NCT02672761|Behavioral|Wellness|The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair "3D-Float-plus" system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session.
289212|NCT02672761|Behavioral|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
289213|NCT02675205|Drug|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
289214|NCT02675205|Drug|aspirin|
289215|NCT02675218|Other|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
289216|NCT02675231|Drug|Abemaciclib|Administered Orally
289217|NCT02675231|Drug|Trastuzumab|Administered IV
289218|NCT02675231|Drug|Fulvestrant|Administered IM
289219|NCT02675231|Drug|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
289220|NCT02675244|Procedure|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
289221|NCT02675244|Procedure|MVS Alone|MVS will be performed using standard surgical techniques
289222|NCT00199082|Drug|Dexamethasone/Prednisolone|
289223|NCT02675257|Behavioral|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
288936|NCT02679911|Drug|Loceryl Nail Lacquer|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
288937|NCT02679911|Drug|Ciclopirox Nail Lacquer|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
288938|NCT02679924|Device|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
288939|NCT02679924|Other|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
288940|NCT02679937|Behavioral|Fit4Duty|Small (<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
288941|NCT02681952|Drug|Renamezin capsule|
288942|NCT02681952|Drug|Kremezin granule|
288943|NCT02681965|Behavioral|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
288944|NCT02681978|Drug|Ivabradine|Ivabradine 5 mg twice daily
288945|NCT00199888|Drug|124-Iodine-cG250 (124I-cG250)|
288946|NCT02681978|Drug|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
288947|NCT02681991|Drug|Renamezin capsule|
289229|NCT02675257|Behavioral|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
289230|NCT02675257|Behavioral|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
289231|NCT02675257|Behavioral|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
289232|NCT02675257|Behavioral|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
289233|NCT00199082|Drug|VP16|
289234|NCT02675257|Behavioral|Sports, activities and exercise|Education on sports, activities and exercise
293521|NCT02615626|Procedure|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
293522|NCT02615639|Biological|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells & Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
293523|NCT02615639|Drug|Entecavir|0.5mg tablet every night by mouth
293524|NCT02615639|Drug|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells & IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
293525|NCT02615639|Drug|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
293526|NCT02615639|Drug|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells & Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
293527|NCT00193089|Drug|Docetaxel|Docetaxel
293528|NCT02615639|Drug|Telbivudine|Telbivudine 600mg tablet every day by mouth
293529|NCT02615652|Other|no intervention|no intervention, observational study
293530|NCT02615665|Procedure|Hepatic resection|Removal of a part of the liver during surgery
293531|NCT02615678|Device|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
293532|NCT02615691|Biological|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
293533|NCT02615704|Device|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
293534|NCT02615704|Device|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
293535|NCT02615704|Device|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
293536|NCT02615704|Device|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
293537|NCT02617784|Drug|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
293538|NCT02617797|Device|Radiofrequecy|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
292958|NCT02626481|Drug|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
292959|NCT02626481|Drug|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
292960|NCT02626494|Drug|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
293241|NCT02622178|Device|Diopsys Visual evoked potential (VEP)|The viewing distance shall be set to 1 m, yielding a total display viewing angle of 15.5 degrees. The square black/white checkerboard pattern reversal stimulus has a height and width of 27 cm with a red circular ring used as a fixation target. The diameter of this target is approximately 1.5 cm with a ring thickness of 1.5 mm. The target ring shall be centered on the stimulus. Two pattern contrasts shall be used in the study, based on earlier studies that suggested that differential contrast stimulation could affect the NOVA-DN VEP protocol wave forms. The first pattern shall have a Michelson contrast of 15%. The second pattern shall have a Michelson contrast of 85%. These two patterns are referred to as Lc (Low contrast) and Hc (High contrast) respectively.
293242|NCT02622191|Device|Spectral domain Optical Coherence Tomography|Participants of the study, both Glaucoma patients and controls with normal eyes will be tested with spectral domain Optical Coherence Tomography.
293243|NCT02622204|Procedure|high tibial osteotomy|open wedge high tibial osteotomy
293244|NCT02622217|Behavioral|Sleep deprivation|
293245|NCT02622230|Drug|Mianhuahua Flavonoids Tablets|Tolerability Study:
Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)
Pharmacokinetic Study:
Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)
293246|NCT02622230|Drug|Placebo|Placebo to match with experimental groups
293247|NCT00193505|Drug|Rituximab|
293248|NCT02622243|Drug|Tiotropium|long acting muscarinic antagonist
293249|NCT02622243|Drug|glycopyrronium|long acting muscarinic antagonist
293250|NCT02622243|Device|Respimat|inhaler device used to deliver active tiotropium or placebo
293251|NCT02622243|Device|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
292667|NCT02632942|Procedure|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
292668|NCT02632955|Procedure|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
292669|NCT02632955|Procedure|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
292670|NCT00194779|Other|laboratory biomarker analysis|Correlative studies
292671|NCT02632968|Procedure|Pinhole surgery with and without buttons|
292672|NCT02632981|Other|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
292673|NCT02632981|Other|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
292674|NCT02632994|Drug|LY2503029|Administered orally.
292675|NCT02633007|Drug|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
292961|NCT02626494|Drug|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
292962|NCT00193973|Radiation|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
292963|NCT02626507|Drug|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
292964|NCT02628587|Drug|Patent clopidogrel|Comparison of different brands of clopidogrel:
*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3.
292965|NCT02628600|Drug|Liposomal Amikacin for Inhalation|
292966|NCT02628613|Drug|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of Vinorelbine plus Epirubicin for neoadjuvant chemotherapy in locally advanced HER-2(-) breast cancer with TEKT4 variation
292364|NCT02639637|Drug|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
292365|NCT02639650|Drug|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
292366|NCT02639650|Drug|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
292367|NCT02639650|Drug|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
292368|NCT02639650|Drug|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
292369|NCT02639650|Drug|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
292370|NCT00195533|Drug|piperacillin-tazobactam|
292371|NCT02639650|Drug|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
292372|NCT02639650|Drug|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
292373|NCT02639650|Drug|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
292374|NCT02639663|Device|dental device|Leboride
Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
Control group: participants will not receive any device for breastfeeding pain control
Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
292676|NCT02633007|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
292677|NCT02633007|Other|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
292678|NCT02633020|Biological|AMG 714|A fully human anti-IL-15 monoclonal antibody
292679|NCT02633020|Biological|Placebo|
292680|NCT02633033|Drug|H.P. Acthar® Gel (repository corticotropin injection)|
292681|NCT00002524|Drug|Trimethoprim-Sulfamethoxazole|
292682|NCT00194792|Drug|exemestane|Given PO
292683|NCT02635139|Behavioral|Breakfast skipping|18h fasting period in the morning
292057|NCT02644252|Drug|Day 1: Cisplatin 75 mg/m2|
292058|NCT02644252|Drug|Day 1: Vinorelbine 25 mg/m2|
292059|NCT02644252|Drug|Day 8: Capsule vinorelbine 50 mg/m2|
292060|NCT02644252|Drug|Day 1: Carboplatin AUC=5|
292061|NCT02610556|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
292062|NCT02610556|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
292063|NCT02610569|Device|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
292064|NCT02610569|Device|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
292065|NCT02610582|Drug|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
292066|NCT02610595|Drug|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
292067|NCT00002521|Drug|etoposide|
292068|NCT00192543|Behavioral|diet of fish and fruit|fish and fruit in specified quantities
292069|NCT02610608|Other|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
292070|NCT02610621|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
292071|NCT02610647|Drug|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
292072|NCT02610647|Other|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
292073|NCT02610647|Other|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
292074|NCT02610647|Other|Tapping test|Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.
After the last auditory signal, participants will continue the tapping task by themselves as directed: "after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test." The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail.
292375|NCT02639676|Other|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
291786|NCT02615028|Other|Closed eyes double-leg stance|Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
291787|NCT02615041|Drug|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
291788|NCT02617069|Biological|0.9% normal saline injection|
291789|NCT02617069|Device|Implantable loop recorder|
291790|NCT02617082|Radiation|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
291791|NCT02617095|Device|T2762|One drop in each eye 3 to 6 times daily
291792|NCT02617095|Device|Optive|One drop in each eye 3 to 6 times daily
291793|NCT00193193|Drug|Paclitaxel|
291794|NCT02617108|Device|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
291795|NCT02617121|Drug|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
291796|NCT02617121|Drug|Ramosetron|ramosetron 0.3 mg iv at end of surgery
291797|NCT02617121|Drug|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
291798|NCT02617134|Biological|anti-MUC1 CAR-T cells|
291799|NCT02617160|Device|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
291800|NCT02617160|Other|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
291801|NCT02617173|Device|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
291802|NCT02617186|Procedure|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
291803|NCT02617186|Procedure|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
291804|NCT00193193|Drug|Estramustine|
292075|NCT02610673|Device|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
296109|NCT02630017|Drug|methylphenidate|
296110|NCT02630017|Drug|Placebo|
296111|NCT02630030|Drug|Ixazomib Citrate|Given PO
296112|NCT02630043|Drug|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
296113|NCT00194493|Behavioral|ESRA-C|Graphical summary of patient symptoms and quality of life
296114|NCT02630043|Drug|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
296115|NCT02630069|Drug|CDP-choline|CDP-choline 500mg once a day for 12 weeks
296116|NCT02630069|Drug|Placebo|Placebo 500mg once a day for 12 weeks
296117|NCT02630069|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy 1 session/week for 12 weeks
296118|NCT02630082|Procedure|Circumcision|
296119|NCT02630082|Procedure|Flexible sigmoidoscopy|
296120|NCT02630095|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
296121|NCT02630095|Device|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
296122|NCT02630108|Procedure|Thermal Ablation|Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.
296123|NCT02630108|Drug|EADM|EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
296124|NCT00194506|Behavioral|Internet co-management module|
296125|NCT02630108|Drug|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
296126|NCT02630108|Other|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
296127|NCT02630121|Drug|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
296128|NCT02630121|Drug|Placebo|Proportion of the subjects with 50% reduction in AHI.
296129|NCT02630134|Device|These patients receive the Baeta device and take it home|
295507|NCT02638792|Behavioral|Internet-based exposure therapy (I-ET)|The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book "Sluta älta och grubbla med kognitiv beteendeterapi" (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images.
295508|NCT00195429|Drug|Sirolimus|
295509|NCT02638792|Behavioral|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
295510|NCT02638805|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
295511|NCT02638805|Drug|ITCA 650 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
295805|NCT02632006|Biological|DC-PMAT|DC cell suspension (1×10*7 DC+ physiological saline
+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
295806|NCT02634203|Drug|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
295807|NCT02634216|Dietary Supplement|Capros|250 mg BID
295808|NCT02634229|Genetic|blood sample|
295809|NCT02634242|Other|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
295810|NCT02634242|Other|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
295811|NCT00194896|Drug|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
295812|NCT02634255|Drug|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
295813|NCT02634255|Drug|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
295814|NCT02634255|Drug|Propofol|
295815|NCT02634255|Drug|Fentanyl|
295816|NCT02634255|Other|Ringer Lactate|
291560|NCT02628119|Procedure|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
291561|NCT02628132|Drug|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
291562|NCT02628132|Drug|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
291563|NCT02628145|Behavioral|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
291564|NCT02630368|Drug|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
291565|NCT02630368|Drug|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
291857|NCT02623959|Drug|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
291858|NCT02623959|Behavioral|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
291859|NCT02623972|Drug|Eribulin|administered IV for 4 cycles
291860|NCT02623972|Drug|Adriamycin|administered IV with cyclophosphamide for 4 cycles
291861|NCT02623972|Drug|Cyclophosphamide|administered IV with adriamycin for 4 cycles
291862|NCT00193648|Drug|Rosiglitazone (Avandia)|oral drug administration
291863|NCT02623985|Device|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
291864|NCT02623985|Device|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
291865|NCT02623985|Device|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
291866|NCT02623998|Drug|insulin glargine|
291867|NCT02623998|Drug|metformin|
291868|NCT02623998|Drug|sitagliptin|
291869|NCT02623998|Behavioral|lifestyle therapy|diet and exercise
291271|NCT02634593|Behavioral|Intervention|Replace night-time food and drinks.
291272|NCT02634606|Drug|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
291273|NCT02634606|Drug|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
291274|NCT02634606|Drug|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
291275|NCT02634619|Procedure|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
291276|NCT02634619|Procedure|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
291277|NCT02634632|Behavioral|Choosing to write advance directives|
291278|NCT02634645|Procedure|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
291279|NCT02634645|Procedure|Esophagectomy|The esophagus is surgically removed
291280|NCT00194948|Behavioral|interpersonal psychotherapy|
291281|NCT02634645|Drug|Chemotherapy|Chemical substances are used to treat cancer
291282|NCT02634645|Radiation|Radiation|Cancer cells are destroyed by radiation therapy.
291283|NCT02634658|Other|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
290704|NCT02682771|Device|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
290705|NCT00199992|Procedure|application of autologous platelet gel|
290706|NCT02682771|Device|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
290707|NCT02682771|Procedure|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
290969|NCT02636907|Drug|BI 695501 Autoinjector|
290970|NCT00195247|Drug|TTI-237|
290971|NCT02636907|Drug|BI 695501 Prefilled syringe|
290972|NCT02639052|Drug|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
290973|NCT02639052|Drug|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
290974|NCT02639065|Drug|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
290975|NCT02639078|Drug|TD-0714|One time dosing in capsule formulation
290976|NCT00195455|Drug|17b Estradiol|
290977|NCT02639078|Drug|Placebo Comparator|One time dosing in capsule formulation
290978|NCT02639091|Drug|BAY 94-9343|In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).
In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)
290979|NCT02639091|Drug|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
290980|NCT02639091|Drug|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
290981|NCT02639104|Radiation|Radiography|Obtaining patients lateral spot cervical spine radiography and will measure;
The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography
If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis
The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates
290396|NCT02652611|Procedure|Non-screw removal treatment (non-operative management)|
290397|NCT02652624|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
290398|NCT02652624|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC administered orally once daily with food
290399|NCT02652624|Drug|ATV|ATV 300 mg capsules administered orally once daily
290400|NCT02652624|Drug|RTV|RTV 100 mg tablets administered orally once daily
290401|NCT02652624|Drug|FTC/TDF|FTC/TDF (200/300 mg) tablet administered orally once daily
290402|NCT02652624|Drug|GS-9883/F/TAF|GS-9883/F/TAF (50/200/25 mg) FDC tablet administered orally once daily without regard to food
290403|NCT00197028|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
290404|NCT02652637|Drug|neomycin, metronidazole, polyethylene glycol (PEG)|
290405|NCT02652650|Drug|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
290406|NCT02652650|Drug|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
290407|NCT02652650|Drug|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
290708|NCT02682784|Drug|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
290709|NCT02682784|Drug|Placebo|
290710|NCT02682810|Device|DNA PCR HIV diagnostic test|standard of care
290711|NCT02682810|Device|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
290712|NCT02682823|Device|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
290713|NCT02682823|Drug|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3. The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
290714|NCT02682836|Behavioral|Walk with Ease|
290715|NCT02648074|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
290110|NCT02657057|Device|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
290111|NCT02657070|Behavioral|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
290112|NCT02657070|Behavioral|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
290113|NCT02657083|Device|DreaMed Substance Administration Device|2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).
New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.
The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.
The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision.
290114|NCT02659020|Drug|Gemcitabine|Administered IV
290115|NCT02659020|Drug|Docetaxel|Administered IV
290116|NCT02659020|Drug|Placebo|Administered IV
290117|NCT02659033|Drug|ceftriaxone|ceftriaxone (1 gram per day)
290118|NCT02659033|Drug|Cefotaxime|cefotaxime (1 gram every 8 hours)
290119|NCT00002531|Drug|vindesine|
290120|NCT00197925|Biological|Onco-peptide loaded autologous dendritic cells|
290121|NCT02659059|Biological|Nivolumab (Opdivo)+Ipilimumab (Yervoy)|
290122|NCT02659085|Drug|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
290123|NCT02659085|Procedure|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
290408|NCT02652676|Procedure|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
289828|NCT02663310|Procedure|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
289829|NCT02663323|Device|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|
289830|NCT02663336|Other|Comparison ABPM with OBPM|No interventions
289831|NCT02663349|Behavioral|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
289832|NCT02663349|Behavioral|Computer Skills|Computer Application course
289833|NCT02663362|Other|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|
289834|NCT02663375|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
289835|NCT02663388|Procedure|gastric bypass, sleeve, gastric banding|
289836|NCT02663401|Behavioral|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
289837|NCT00198536|Drug|Vehicle|
289838|NCT02663414|Device|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
289839|NCT02663427|Device|serological examination and gastroscope|
289840|NCT02663440|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
289841|NCT02663440|Biological|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
289842|NCT02663440|Drug|Temozolomide|Temozolomide
289843|NCT02663453|Drug|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
289844|NCT02665702|Drug|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
289845|NCT02665702|Drug|Endostar|15mg/d，d1-d7 civ
289224|NCT02675257|Behavioral|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
289225|NCT02675257|Behavioral|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
289226|NCT02675257|Behavioral|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
289227|NCT02675257|Behavioral|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
289228|NCT02675257|Behavioral|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
289522|NCT02670187|Biological|GLS-5300|
289523|NCT02670200|Behavioral|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
289524|NCT02670213|Drug|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
289525|NCT02670226|Other|Samples|Blood samples, muscle biopsy
289526|NCT02670239|Procedure|normothermic ex vivo lung perfusion|
289527|NCT00199004|Drug|Rituximab|
289528|NCT02670252|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
289529|NCT02670252|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
289530|NCT02670252|Radiation|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
289531|NCT02670265|Dietary Supplement|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
289532|NCT02670265|Dietary Supplement|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
289533|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
289534|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
289535|NCT02670304|Drug|letrozole|letrozole from the day of oocyte retrieval for 5 days
289536|NCT02670304|Drug|Aspirin|aspirin from the day of oocyte retrieval for 5 days
289235|NCT02675257|Behavioral|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
289236|NCT02675257|Behavioral|Diabetes complications|Education on diabetes complications
289237|NCT02675257|Behavioral|Social aspects of living with diabetes|Education on social aspects of living with diabetes
289238|NCT02677480|Dietary Supplement|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
289239|NCT02677493|Biological|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
289240|NCT00199186|Drug|vincristine|
289241|NCT02677493|Biological|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
289242|NCT02677493|Biological|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
289243|NCT02677506|Procedure|Brachial plexus block|Brachial plexus block with supraclavicular approach
289244|NCT02677519|Drug|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
289245|NCT02677532|Drug|Paracetamol|1 g every 8 hours
289246|NCT02677532|Drug|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
289247|NCT02677532|Drug|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
289248|NCT02677532|Drug|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
289249|NCT02677532|Drug|Morphine|Intravenous slow bolus of 10 mg morphine
289250|NCT02677532|Device|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
289251|NCT00199186|Drug|cyclophosphamide|
289545|NCT02670369|Behavioral|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
289546|NCT02670382|Dietary Supplement|EPA|10 week supplementation
289547|NCT02672774|Procedure|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
293539|NCT00002522|Procedure|bone marrow ablation with stem cell support|
288948|NCT02682004|Other|leptin, serotonin and adiponectin level|
288949|NCT02682004|Other|leptin,serotonin, adiponectin level|
288950|NCT02682017|Other|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
288951|NCT02682017|Other|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
288952|NCT02682030|Device|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
288953|NCT02682030|Device|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
288954|NCT02682043|Device|Toy car|The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.
Parents will keep a log of what days they use the toy car, where and for how long.
288955|NCT02682056|Device|Microneedle patch|The hydrogel microneedle patch will collect interstitial fluid to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
288956|NCT00199901|Biological|NY-ESO-1 ISCOMATRIX®|100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).
288957|NCT02682056|Device|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
288958|NCT02682056|Device|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
288959|NCT02682069|Device|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
288960|NCT02647229|Other|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
293252|NCT02622256|Behavioral|Twitter: HTN Intervention|Consented participants will be randomized into a control or intervention group and asked to complete 2 short surveys (months 1 [study beginning] and month 6 [study end]). Intervention participants will be asked to follow the study team. Once participants are following the study team, participants would receive daily private messages via Twitter about heart health. As a function of following the study team, they would also see public retweeted messages from the study team. For example, this would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about.
293253|NCT02622256|Behavioral|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete 2 short surveys (months 1 and 6). The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team & receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about.
293540|NCT00193219|Drug|Leucovorin|350 mg IV
293541|NCT02617797|Device|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
293542|NCT02617810|Drug|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
293543|NCT02617810|Drug|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
293544|NCT02617810|Drug|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
293545|NCT02617823|Procedure|lateral position|patients placed on their left side after epidural catheter insertion
293546|NCT02617849|Drug|Pembrolizumab|200 mg IV every 3 weeks
293547|NCT02617849|Drug|Carboplatin|AUC=6, every 3 weeks x 4
293548|NCT02617849|Drug|Paclitaxel|175 mg/m2, every 3 weeks x 4
293549|NCT02617862|Procedure|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
293550|NCT02617862|Device|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
293551|NCT00193219|Drug|Oxaliplatin|85 mg/m2 IV
293552|NCT02617862|Device|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
293553|NCT02617875|Other|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
292967|NCT02628613|Drug|Paclitaxel plus Carboplatin|standard neoadjuvant chemotherapy
292968|NCT02628626|Drug|Colesevelam|Patients who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
292969|NCT02628626|Drug|Clonidine|Patients who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
292970|NCT02628626|Other|Placebo|Placebo will be identical in appearance to the active drug.
292971|NCT00194337|Procedure|magnetic resonance imaging|
292972|NCT02628639|Device|high-density electroencephalography|
292973|NCT02628652|Dietary Supplement|GOS|
292974|NCT02628652|Dietary Supplement|GLOS|
292975|NCT02628652|Dietary Supplement|FOS|
292976|NCT02628665|Drug|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
292977|NCT02628665|Device|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
292978|NCT02628678|Dietary Supplement|FOS|
292979|NCT02628691|Other|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
292980|NCT02628704|Drug|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
293254|NCT02622256|Behavioral|Twitter: DM Intervention|Consented participants will be randomized into a control or intervention group and asked to complete 2 short surveys (months 1 [study beginning] and month 6 [study end]). Intervention participants will be asked to follow the study team. Once participants are following the study team, participants would receive daily private messages via Twitter about heart health. As a function of following the study team, they would also see public retweeted messages from the study team. For example, this would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about.
293255|NCT02624531|Drug|Taxane|NACT and Fertility-sparing Treatment Strategy
293256|NCT00193726|Drug|Ethinyl estradiol|
293257|NCT02624531|Procedure|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
293258|NCT02624544|Drug|esomeprazole|esomex 40 mg twice daily
292684|NCT02635139|Behavioral|Dinner skipping|18h fasting period in the evening
292685|NCT02635152|Behavioral|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
292686|NCT02635152|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
292687|NCT02635165|Device|Thoracic osteosyntheses with Stracos|
292688|NCT02635178|Other|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to the psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
292689|NCT02635178|Other|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
292690|NCT02635191|Drug|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
292691|NCT02635191|Drug|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
292692|NCT00195000|Drug|Mylotarg|6 mg/m2 on day 1
292693|NCT02635204|Drug|DFD06 Cream|Twice daily topical application for 14 days.
292981|NCT02628704|Drug|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
292982|NCT00194337|Procedure|positron emission tomography|
292983|NCT02628704|Drug|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
292984|NCT02628704|Drug|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
292985|NCT02628730|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
292376|NCT02639689|Device|WALKAIDE|A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.
Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device.
292377|NCT02639702|Drug|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
292378|NCT02639728|Other|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
292379|NCT02639728|Other|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
292380|NCT02639728|Other|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
292381|NCT00195533|Drug|glycopeptide|
292382|NCT02639741|Drug|Melatonin, Vitamin C and Placebo tablet|Preoperative melatonin, vit c or placebo tablet will be given and postoperative pain scores will be evaluated
292383|NCT02639754|Behavioral|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
292384|NCT02642107|Radiation|Whole neck irradiation|Whole neck irradiation is given regardless of negative neck or positive neck
292385|NCT02642120|Device|Dental device "Laboraide"|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire.
292386|NCT00195793|Drug|fenofibrate|
292387|NCT02642133|Procedure|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
292388|NCT02642146|Drug|Calcium Channel Blockers|
292389|NCT02642146|Drug|Phosphodiesterase Inhibitors|
292390|NCT02642146|Drug|Endothelin receptor blocker|
292391|NCT02642146|Drug|Prostanoids|
292076|NCT02610686|Drug|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
292077|NCT02610699|Other|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
292078|NCT02610699|Other|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
292079|NCT00192543|Behavioral|fruit and fish|no drugs
292080|NCT02610712|Drug|Ketamine|
292081|NCT02610725|Other|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
292082|NCT02610738|Behavioral|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
292083|NCT02612805|Other|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
292084|NCT00192660|Drug|Tipranavir|
292085|NCT02612805|Other|Combined training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.
Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed.
292086|NCT02612805|Other|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
292087|NCT02612818|Device|Coelioscopy|
292088|NCT02612831|Procedure|Early bariatric surgery|
292089|NCT02612831|Procedure|Delayed bariatric surgery|
292090|NCT02612844|Drug|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
292091|NCT02612844|Drug|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
292092|NCT02612857|Drug|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
296421|NCT02623634|Behavioral|Position, waveform|different positions and waveform
296422|NCT02623647|Radiation|SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
296423|NCT02625597|Device|Cotton Pellet|
296424|NCT02625597|Device|Polytetrafluoroethylene Tape|
296425|NCT02625597|Device|Synthetic Foam|
296426|NCT02625597|Device|Polyvinylsiloxane|
296427|NCT02625610|Drug|Avelumab|Avelumab will be administered as intravenous (IV) infusion at a dose of 10 milligram per kilogram (mg/kg) over 1 hour once every 2 weeks as part of maintenance phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation
296428|NCT00193882|Drug|5-Fluorouracil|800mg/m2/day IV days 1 - 4
296429|NCT02625610|Drug|Oxaliplatin|Induction Phase:Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with 5-Fluorouracil plus leucovorin every 2 weeks up to 12 weeks or 6 cycles. (or) Induction Phase: Oxaliplatin will be administered at a dose of 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks or 4 cycles. Maintenance Phase: Oxaliplatin will be administered at a dose of 85 mg/m^2 IV on Day 1 along with 5-Fluorouracil plus leucovorin every 2 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. (or) Maintenance Phase: Oxaliplatin will be administered at a dose of 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by 1-week rest period given every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
296430|NCT02625610|Drug|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks or 6 cycles.
Maintenance Phase: 5-FU will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 along with oxaliplatin and leucovorin every 2 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
296431|NCT02625610|Drug|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks or 6 cycles Maintenance Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
296432|NCT02625610|Drug|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 along with oxaliplatin twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
Maintenance Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 along with oxaliplatin twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
296433|NCT02625610|Other|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care will be administered per institutional guidelines and subjects will visit the clinic every 3 weeks.
295817|NCT02634255|Device|Acceleromyography device|
295818|NCT02634268|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
295819|NCT02634281|Drug|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
295820|NCT02634281|Drug|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
295821|NCT02634294|Drug|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
295822|NCT00194896|Drug|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
296130|NCT02630147|Other|Vanilla scent|A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
In addition, a 3-hour polysomnography will be done in a sub-sample on the morning following the night recording with vanilla solution.
296131|NCT02632019|Drug|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
296132|NCT02632019|Biological|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
296133|NCT02632032|Drug|Insulin|Monitoring insulin therapy of campers based on their usual regimen (one of the following):
premixed insulin in the morning and evening,
premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,
regular insulin in the morning and afternoon, and premixed insulin in the evening.
Education of campers on different aspects of diabetes care:
monitoring of blood glucose
injection of insulin
adaptation of insulin doses according to blood glucose and during exercise
correction of hypoglycemia
dietary advice
296134|NCT02632045|Drug|LEE-011|600 mg capsule (3x 200 mg capsules)
296135|NCT02632045|Drug|Fulvestrant|500 mg injection
296136|NCT02632045|Drug|Placebo|600 mg capsule (3x 200 mg capsules)
296137|NCT02632058|Other|Cognitive Behavioral Therapy|
291870|NCT02624011|Behavioral|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
291871|NCT02624037|Other|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
291872|NCT02624050|Drug|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
291873|NCT00193648|Drug|Adalimumab (Humira)|Injection of drug biweekly
291874|NCT02624050|Drug|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
291875|NCT02624063|Drug|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
291876|NCT02626052|Procedure|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
291877|NCT02626052|Procedure|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
292148|NCT00193349|Drug|Imatinib|
292149|NCT02619617|Drug|SOM230|There will be 2 parts to the study:
Part A will evaluate SOM230 vs Placebo Part B will evaluate SOM230 vs Sumatriptan
292150|NCT02619617|Drug|Placebo|There will be 2 parts to the study:
Part A will evaluate SOM230 vs Placebo
292151|NCT02619617|Drug|Sumatriptan|There will be 2 parts to the study:
Part B will evaluate SOM230 vs Sumatriptan
292152|NCT02619630|Drug|nelarabine|Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil >1 Giga/Liter
for a maximum of 5 blocks
292153|NCT02619643|Device|Transcranial Magnetic Stimulation (Magstim)|
292154|NCT02619656|Procedure|CO2 insufflation|Patients were randomized to insufflation with CO2.
292155|NCT02619656|Procedure|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
292156|NCT02619669|Drug|TAK-228 (MLN0128)|
292157|NCT02619669|Drug|Letrozole|
292158|NCT02619682|Drug|Ixazomib Citrate|Given PO
291566|NCT02630381|Device|Unfocused extracoporeal shock wave therapy|Shock waves are acoustical pulses that are characterized by high amplitude (~500 bar) and short rise time (~20 ns), which are followed by a longer low-magnitude negative wave (~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.
Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed.
291567|NCT02630394|Drug|Azithromycin|
291568|NCT02630407|Device|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
291569|NCT02630407|Other|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
291570|NCT02630420|Drug|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
291571|NCT02630433|Procedure|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
291572|NCT02630433|Procedure|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
291573|NCT00002524|Drug|Methotrexate|
291574|NCT00194545|Behavioral|Medication diaries|Caregivers expected to complete medication diaries daily
291575|NCT02630446|Other|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
291576|NCT02630459|Drug|AMG 334 Dose Level 1|Investigational Product
291577|NCT02630459|Drug|Placebo|Placebo Comparator
291578|NCT02630459|Drug|AMG 334 Dose Level 2|Investigational Product
291579|NCT02630459|Drug|AMG 334 Dose Level 3|Investigational Product
290982|NCT02639104|Other|Electromyography|Serratus anterior needle electromyography:
The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms.
290983|NCT02639117|Drug|Vismodegib|Vismodegib 150 mgs po qd for 3 months
290984|NCT02639130|Drug|Exendin [9-39]|Exendin [9-39] at 350 and 500 pmol/kg/min for infusion as challenge agent
290985|NCT02639130|Drug|Placebo|Placebo infusion as challenge agent
290986|NCT02639143|Drug|ticagrelor|
290987|NCT00195468|Drug|CYCLOSPORINE|
290988|NCT02639143|Drug|Clopidogrel|
290989|NCT02639156|Dietary Supplement|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
291284|NCT02636920|Other|Therapeutic Education to the Patient (TEP)|Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.
Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.
Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.
Assessing of the knowledges acquired by patients.
291285|NCT02636933|Other|Lung Function Assessment|Lung Function Assessment
291286|NCT02636946|Drug|Bimatoprost SR|Bimatoprost sustained-release (SR) Dose A administered on Day 4, Weeks 16 and 32.
291287|NCT02636946|Drug|Sham Bimatoprost SR|Sham Bimatoprost SR administered on Day 4, Weeks 16 and 32.
291288|NCT02636946|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
291289|NCT02636946|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
291290|NCT02636959|Other|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
291291|NCT02636972|Drug|OCPs|Participants in the contraceptive pill groups can use any one of the following contraceptive pills:
Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra
291292|NCT02637024|Radiation|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
290716|NCT02648087|Device|With and without SDB|Screening of sleep-disordered breathing (SDB)
290717|NCT02648100|Other|biomarker study|
290718|NCT02648113|Procedure|Restrictive transfusion|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
290719|NCT02648113|Procedure|Liberal transfusion|transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL
290720|NCT02648113|Biological|red blood transfusion|
290721|NCT00196560|Device|Immobilization in External Rotation|
290722|NCT02648126|Procedure|Pure Red Cell Aplasia diagnostic confirmation|Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.
The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa
290723|NCT02648139|Drug|Dentifrice|3x/day for 7 days.
290724|NCT02648152|Device|Osteoarthritis|Total Hip Arthroplasty
290725|NCT02648165|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
290726|NCT02648165|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
290727|NCT02648165|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
290728|NCT02648178|Device|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
290990|NCT02639169|Other|Music Therapy|apply live music through the techniques of music therapy
290991|NCT02639182|Drug|AGS-16C3F|Intravenous (IV) infusion
290992|NCT02639182|Drug|Axitinib|Oral
290993|NCT02639195|Other|Manual therapy|Retrospective chart review of patients treated with manual therapy.
290994|NCT02639208|Other|PatientsLikeMe (PLM)|
290995|NCT02639221|Drug|PXT002331|
290996|NCT02641509|Device|no NBI during polypectomy|no NBI to perform the polypectomy
290997|NCT02641522|Drug|Siltuximab|Single infusion of siltuximab (11 mg/kg)
290409|NCT02652676|Device|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
290410|NCT02652689|Radiation|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
290411|NCT02652702|Procedure|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
290412|NCT02652702|Procedure|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
290413|NCT02652715|Other|Laboratory Biomarker Analysis|Correlative studies
290414|NCT00197028|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
290415|NCT02652715|Other|Quality-of-Life Assessment|Ancillary studies
290416|NCT02652715|Other|Questionnaire Administration|Ancillary studies
290417|NCT02654769|Drug|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
290418|NCT02654769|Drug|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
290419|NCT02654782|Drug|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
290420|NCT02654782|Drug|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
290421|NCT02654795|Radiation|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
290422|NCT02654808|Device|AirSeal trocar|The AirSeal® trocar is a valveless trocar that has been designed to replace the "trap door" and silicone valve of standard trocars with a curtain of forced CO2 gas (Fig. 1)1. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes.
290423|NCT02654808|Device|Standard trocar|A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a "trap door" or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas.
290424|NCT00197353|Drug|Epidural bupivacaine (dose/concentration/volume ranging)|
290729|NCT02648191|Device|NeuroCoach II Stim|A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.
For this intervention, the stimulations are active.
290124|NCT02659098|Drug|CNTO 2476 3.0x10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL) given by subretinal access kit (SRAK-02).
290125|NCT02659098|Drug|CNTO 2476 6.0x10^4 cells|Participants will receive a single subretinal administration of CNTO 2476 6.0 x 10^4 cells in 50 microliter (mcL) given by subretinal access kit (SRAK-02).
290126|NCT02659098|Procedure|Sham-Surgery Procedure|Participants will receive a modified sham surgical procedure.
290127|NCT02659098|Device|Subretinal Access Kit (SRAK02)|Participants will receive CNTO 2476 by using the SRAK-02 custom delivery device.
290128|NCT02659111|Other|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
290129|NCT02659111|Other|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
290130|NCT02659124|Device|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
290131|NCT00197938|Procedure|Measurement of rectal lactic acid.|
290132|NCT02659124|Procedure|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
290133|NCT02659137|Other|HV measurement|Electrophysiology (EP) study during the TAVI procedure
290134|NCT02659150|Drug|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
290135|NCT02659163|Behavioral|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
290136|NCT02661022|Drug|SL-401/ Pomalidomide/ Dexamethasone|
290137|NCT02661035|Drug|Allopurinol|300 mg/day (for peds -150 mg/m^2/day), day -6 and continue through day 0 or longer if clinically indicated
290138|NCT02661035|Drug|Fludarabine|30 mg/m^2 IV over 1 hour, day -6, -5, -4, -3 and -2
290139|NCT02661035|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
289537|NCT02670317|Drug|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
289538|NCT00199004|Procedure|CNS irradiation|
289539|NCT02670317|Drug|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
289540|NCT02670317|Drug|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
289541|NCT02670330|Drug|Zorblisa (SD-101-6.0) cream|applied topically once a day to the entire body for 630 days
289542|NCT02670343|Drug|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
289543|NCT02670356|Dietary Supplement|Fish oil|two 750 mg/capsules/day
289544|NCT02670356|Dietary Supplement|Krill oil|one 300 mg capsule/day
289846|NCT02665715|Other|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
289847|NCT02665715|Other|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
289848|NCT02665728|Drug|BLI400 Laxative|
289849|NCT00198874|Other|Education|Drug education curriculum was delivered to participants assigned to this condition.
289850|NCT02665741|Device|Distal colonscope attachments (Olympus transparent cap, Medivators Endocuff)|
289851|NCT02665754|Biological|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
289852|NCT02665754|Biological|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
289853|NCT02665754|Drug|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
289854|NCT02665767|Device|Smartphone-based Telesonography|The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
289548|NCT02672774|Device|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
289549|NCT02672787|Behavioral|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
289550|NCT00199056|Drug|Cytarabine|
289551|NCT02672787|Behavioral|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
289552|NCT02672800|Behavioral|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
289553|NCT02672813|Procedure|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
289554|NCT02672826|Procedure|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
289555|NCT02672839|Drug|LGD-6972 Solution|15 mg of LGD-6972
289556|NCT02672839|Drug|LGD-6972 Capsules|15 mg LGD-6972
289557|NCT02672852|Drug|BI 655066|
289558|NCT02672852|Drug|Placebo|
289559|NCT02672865|Procedure|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
289560|NCT02672878|Device|Bioresorbable vascular scaffold|
289561|NCT00199056|Drug|6-Mercaptopurine|
289866|NCT02665845|Drug|Corticosteroids|Corticosteroids will be given to all patients.
289867|NCT02665858|Other|OCT Imaging|
289868|NCT02667860|Procedure|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Reloadable Stapler.
289869|NCT02667860|Device|Echelon Endopath|Use of an Echelon Endopath Powered Device to perform an ileocolonic side-to-side anastomosis.
288961|NCT02647242|Behavioral|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
288962|NCT00196443|Device|urea contained compressing stockings|
289252|NCT02677532|Device|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
289253|NCT02677532|Drug|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
289254|NCT02677532|Drug|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
289255|NCT02677545|Drug|Ticagrelor|
289256|NCT02677545|Drug|Clopidogrel|
289257|NCT02677545|Drug|Aspirin|
289258|NCT02677558|Other|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
289259|NCT02677571|Procedure|Paravertebral Thoracic block|
289260|NCT02677571|Procedure|Pectorals nerve block|
289261|NCT02677571|Drug|Levobupivacaine 0.25%|
289262|NCT00199186|Drug|cytosine arabinoside|
289263|NCT02677571|Drug|Morphine|
289264|NCT02677584|Drug|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
289265|NCT02679937|Other|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
289266|NCT02679950|Genetic|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
289267|NCT02679963|Drug|Olaparib|
289268|NCT02679963|Drug|Placebo|
293554|NCT02617875|Other|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
293555|NCT02617888|Radiation|CCTA|Breast shield placement (randomized) among women.
293556|NCT02617901|Radiation|Left hand DXA|All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.
Radiographs and DXA will be read in random and varied order.
293557|NCT02617914|Procedure|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
293558|NCT02617927|Other|N-A|N-A
293559|NCT02620280|Drug|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
293560|NCT02620280|Drug|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
288963|NCT02647255|Procedure|Plasma Exchange (PE)|PE treatment>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
288964|NCT02647255|Drug|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
288965|NCT02647268|Drug|Oxytocin|Oxytocin, 10-5M solution
288966|NCT02647268|Drug|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
288967|NCT02647281|Drug|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
288968|NCT02647281|Drug|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
288969|NCT02647294|Dietary Supplement|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
288970|NCT02647294|Other|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
288971|NCT02647307|Drug|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
288972|NCT02647320|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg
288973|NCT00196443|Device|compressing stockings|
288974|NCT02647320|Drug|DS-8500a 25mg|DS-8500a 25mg
288975|NCT02647320|Drug|placebo|placebo to match both sitagliptin and DS-8500a
293259|NCT02624544|Drug|desonide|topical corticosteroid desonid 0,1% b.i.d
293260|NCT02624557|Drug|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
293261|NCT02624570|Drug|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
293262|NCT02624596|Drug|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
293263|NCT02624596|Drug|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
293264|NCT02624609|Other|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water to which the response of the test meal with pomegranate juice will be compared to.
293265|NCT02624609|Other|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
293266|NCT02624622|Procedure|Chlorhexidine application to cord by mother|
293267|NCT00193739|Drug|NACT|3 cycles of neoadjuvant chemotherapy
293268|NCT02624622|Procedure|Chlorhexidine application by CHW|
293269|NCT02624635|Other|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
293270|NCT02624635|Other|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ [1.0278 - (0.0278 x number of repetitions)] as was used by (Shirazi et al., 2007).
293271|NCT02624648|Behavioral|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
293561|NCT02620280|Drug|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
293562|NCT00193375|Drug|Bevacizumab|10mg/kg IV every 2 weeks for 10 doses starting week 16
293563|NCT02620280|Procedure|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
293564|NCT02620280|Drug|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
293565|NCT02620293|Device|Eczema Repair Emollient|An Emollient
292986|NCT02628730|Device|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
292987|NCT02628743|Drug|Olesoxime|Participants will receive homogeneous suspension of olesoxime 10 mg/kg once a day, either orally or via gastric tube.
292988|NCT00194623|Drug|Botulinum Toxin A (Botox)|
292989|NCT02630836|Procedure|Surgical treatment|Isolated endomedullary nailing
292990|NCT02630849|Procedure|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
292991|NCT02630849|Procedure|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
292992|NCT02630862|Drug|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
292993|NCT02630862|Drug|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
292994|NCT02630875|Drug|A4250|A4250
292995|NCT02630888|Drug|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
292996|NCT02630888|Drug|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
292997|NCT02630901|Drug|PRX003|
292998|NCT02630901|Other|Placebo|
292999|NCT00194636|Procedure|nerve block|
293000|NCT02630914|Device|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
293001|NCT02630927|Drug|AG-519|AG519 will be tested.
293272|NCT02624648|Behavioral|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
293273|NCT02624648|Behavioral|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
293274|NCT02624648|Drug|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
292392|NCT02642146|Drug|Other vasodilator|
292694|NCT02635204|Drug|Vehicle Cream|Twice daily topical application for 14 days.
292695|NCT02635217|Device|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
292696|NCT02635217|Device|room air insufflation|using standard care room air will be infused on demand
292697|NCT02635217|Procedure|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
292698|NCT02635217|Procedure|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
292699|NCT02635230|Drug|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
292700|NCT02635243|Drug|SAR438544|Pharmaceutical form:solution
Route of administration: subcutaneous
292701|NCT02635243|Drug|r-glucagon|Pharmaceutical form:solution
Route of administration: subcutaneous
292702|NCT02635243|Drug|insulin|Pharmaceutical form:solution
Route of administration: intravenous
292703|NCT02637531|Drug|IPI-549|IPI-549 daily dose administered orally in 28-day cycles (Part A/B/D) and 21-day cycles (Part C/E).
292704|NCT02637531|Drug|Pembrolizumab|Pembrolizumab (2 mg/kg, Q3wk) administered intravenously (IV) in 21-day cycles (Part C/D-Annex/E).
292705|NCT02637544|Other|acupuncture|classical acupuncture therapy
292706|NCT02637557|Drug|IW-3718|
292707|NCT02637557|Drug|Matching Placebo|
292708|NCT02637570|Dietary Supplement|Hibiscus tea|
292709|NCT02637570|Dietary Supplement|green tea|
292710|NCT02637570|Dietary Supplement|placebo (dextrose)|
292711|NCT00195273|Drug|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
292712|NCT02637583|Drug|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
292713|NCT02637583|Drug|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
292714|NCT02637596|Procedure|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
292093|NCT02612857|Drug|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
292393|NCT02642159|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
292394|NCT02642159|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
292395|NCT02642159|Drug|statins|Pharmaceutical form:tablet Route of administration: oral
292396|NCT02642159|Drug|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
292397|NCT00195793|Drug|ezetimibe|
292398|NCT02642159|Drug|fenofibrate|Pharmaceutical form:tablet Route of administration: oral
292399|NCT02642159|Drug|nicotinic acid|Pharmaceutical form:tablet Route of administration: oral
292400|NCT02642159|Drug|omega-3 fatty acids|Pharmaceutical form:tablet Route of administration: oral
292401|NCT02642172|Dietary Supplement|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
292402|NCT02642172|Dietary Supplement|Placebo|Participants will consume 16 g/day maltodextrin
292403|NCT02642185|Procedure|Microwave ablation|CT-guided percutaneous ablation of 1-5, <31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
292404|NCT02642185|Procedure|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
292405|NCT02642198|Device|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
292406|NCT02642211|Procedure|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
292407|NCT00196105|Device|6 mm Nitinol Zilver Stent|
292408|NCT02644252|Drug|Day 1: Vinorelbine 30 mg/m2|
292409|NCT02644252|Drug|Day 8: Capsule vinorelbine 60 mg/m2|
292410|NCT02644252|Dietary Supplement|Tocotrienol 300 mg x 3 daily until progression|
292411|NCT02644252|Drug|Placebo 1 capsule x 3 daily until progression|
292412|NCT02644278|Drug|VX-984|oral administration
292413|NCT02644278|Drug|IV pegylated liposomal doxorubicin (PLD)|
296434|NCT02625623|Drug|Avelumab|Avelumab will be administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
296435|NCT02625623|Drug|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m ^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
296804|NCT00375271|Procedure|perioperative hemodynamic optimization protocol|
296805|NCT00375284|Drug|Pramipexole|
296806|NCT00375297|Drug|sildenafil|
296807|NCT00375310|Drug|Gemcitabine, Sorafenib|Gemcitabine is given IV
Sorafenib is given orally of varying doses:
Sorafenib 200 mg po qd ( during combination therapy)
Sorafenib 400 mg po qd ( during combination therapy)
Sorafenib 400 mg po bid ( during combination therapy)
296808|NCT00375310|Procedure|Radiotherapy|1.8 Gy CTV daily for 5 weeks
296809|NCT00375323|Drug|NovoSeven|
296810|NCT00375349|Procedure|Ultrasound to demonstrate existence of fatty liver|
296811|NCT00375362|Drug|Nitroderm patch|
296812|NCT00375375|Drug|Lactulose|
296813|NCT00003127|Drug|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
296814|NCT00375388|Drug|Metformin on top of intensive insulin therapy|
296815|NCT00375401|Drug|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
296816|NCT00375401|Drug|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
296817|NCT00375401|Drug|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
296818|NCT00375414|Procedure|PEG-Gastropexy|
296819|NCT00378118|Other|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
296820|NCT00378131|Drug|RC-1291|
296821|NCT00378131|Drug|placebo|
296822|NCT00378144|Drug|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]
296138|NCT02632071|Drug|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
296139|NCT02632071|Drug|Nab-paclitaxel|Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.
100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle
296140|NCT00194779|Drug|cyclophosphamide|Given PO
296141|NCT02632097|Procedure|Lichtenstein Hernioplasty with Histoacryl|Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:
0.5 ml of cyanoacrylate glue is used for mesh fixation
296142|NCT02632097|Procedure|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
296143|NCT02632110|Drug|ALA|20% ALA applied to face prior to light treatment
296144|NCT02632110|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
296145|NCT02632110|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
296146|NCT02632110|Procedure|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
296147|NCT02632110|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
296436|NCT02625623|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
296437|NCT02625623|Other|Best Supportive Care (BSC)|Best supportive care is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
296438|NCT02625636|Drug|SAR438544|Pharmaceutical form: solution
Route of administration: subcutaneous
296439|NCT00386581|Drug|placebo|
296440|NCT00386594|Drug|852A|
296441|NCT00386607|Drug|Aliskiren|Aliskiren 300 mg
296442|NCT00386607|Drug|Valsartan|Valsartan 320 mg
296443|NCT00386607|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
296444|NCT00003183|Biological|filgrastim|
296445|NCT00386620|Behavioral|Questionnaire|45 minute survey about health, pain and relationships
292159|NCT00193349|Drug|Irinotecan|
292160|NCT02619682|Other|Laboratory Biomarker Analysis|Correlative studies
292161|NCT02619682|Drug|Lenalidomide|Given PO
292162|NCT02619695|Drug|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
292163|NCT02619708|Behavioral|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
292164|NCT02619721|Device|PINS SNS|
292165|NCT02619734|Biological|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
292166|NCT02619747|Drug|Compound Sodium Alginate Oral Suspension sachet|
292167|NCT02619747|Drug|Matched placebo|
292168|NCT02619760|Drug|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
292169|NCT02619760|Drug|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
292170|NCT00193349|Drug|Carboplatin|
292476|NCT02615171|Behavioral|DIET; Other: physical activity|
292477|NCT02615184|Drug|Dexlansoprazole|
292478|NCT02615184|Drug|Placebo|Dexlansoprazole placebo-matching capsules
292479|NCT02615197|Behavioral|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
292480|NCT02615197|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
292481|NCT02615210|Device|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
291580|NCT02630472|Drug|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
291581|NCT02632461|Behavioral|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
291878|NCT02626052|Procedure|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
291879|NCT02626065|Biological|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
291880|NCT02626065|Drug|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
291881|NCT02626078|Other|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
291882|NCT02626091|Procedure|Left-sided colonic resection|During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.
In any case, the resection will be performed according to the surgeon's appreciation.
291883|NCT00002524|Drug|Cytarabine|
291884|NCT00193921|Radiation|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
291885|NCT02626104|Dietary Supplement|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
291886|NCT02626104|Dietary Supplement|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
291887|NCT02626117|Device|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
291293|NCT00195260|Drug|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
291294|NCT02637024|Radiation|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
291295|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
291296|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
291297|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
291298|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
291299|NCT02637050|Other|Standard of care|At the discretion of the attending physician.
291300|NCT02637063|Behavioral|BlipHub only|
291301|NCT02637063|Behavioral|BlipHub + coaching|
291302|NCT02637063|Other|Usual care|
291303|NCT02637076|Drug|Xyrem|single 3.0 gram dose
291582|NCT02632461|Behavioral|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
291583|NCT02632461|Behavioral|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
291584|NCT00194779|Drug|vinorelbine tartrate|Given IV
291585|NCT02632474|Drug|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
291586|NCT02632487|Behavioral|Exercise|Center-based walking + balance, stretching, and light resistance
291587|NCT02632487|Behavioral|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
291588|NCT02632500|Other|Quality of chest compressions|
291589|NCT02632513|Device|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
290998|NCT02641535|Other|exercise under hot and humid conditions protocol|acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously
experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously.
290999|NCT02641535|Device|BC membrane protective garment|
291000|NCT02641535|Device|NBC mask|
291001|NCT02641548|Device|Sock of silicone|
291002|NCT02641548|Other|Heel cream|
291003|NCT02641561|Drug|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
291004|NCT02641561|Drug|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
291005|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
291006|NCT02641561|Drug|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
291007|NCT02641561|Drug|Placebo|Placebo would be a suppository 50 mg x 2
291008|NCT02641574|Other|compare complication|
291009|NCT02641587|Other|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
291010|NCT02641587|Other|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
291304|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
291305|NCT02637102|Other|Not applicable - observational study|
291306|NCT02637115|Dietary Supplement|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
291307|NCT02639234|Biological|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
290730|NCT02648191|Device|NeuroCoach II Stim|A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.
For this intervention, the stimulations are inactive.
290731|NCT02648204|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
290732|NCT00196573|Procedure|Shoulder bursectomy alone|
290733|NCT02648204|Drug|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
290734|NCT02648217|Drug|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
290735|NCT02648217|Drug|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
290736|NCT02648230|Device|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
290737|NCT02648230|Device|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
290738|NCT02650362|Device|spinal cord stimulation|long term paresthesia-free high frequency spinal cord stimulation with RestoreSensor® SureScan® MRI neurostimulator
290739|NCT02650375|Drug|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
290740|NCT02650388|Behavioral|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
290741|NCT02650401|Drug|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
290742|NCT02650414|Biological|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB|
290743|NCT02650427|Drug|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
290744|NCT02650440|Procedure|Novel Protocol|
290745|NCT00196781|Behavioral|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
290746|NCT02650440|Procedure|Conventional Protocol|
290747|NCT02650453|Procedure|Deep venous reconstruction|PTA & stenting with/without endophlebectomy and/or arteriovenous fistula creation
291011|NCT02641600|Device|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
291012|NCT02641600|Device|Placebo stockings|Placebo stocking with pressure applied to the legs
290140|NCT02661035|Drug|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
290425|NCT02654821|Biological|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
290426|NCT02654821|Procedure|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
290427|NCT02654821|Procedure|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
290428|NCT02654834|Other|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
290429|NCT02654847|Drug|Norepinephrine|
290430|NCT02654847|Drug|Normal Saline|0.9% sodium chloride solution, used as a diluent.
290431|NCT02654860|Drug|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
290432|NCT02654860|Drug|Saline solution 0.9%|
290433|NCT02654860|Drug|Hyperbaric Bupivacaine HCl 0.5%|As spinal anaesthetic before the surgical procedure
290434|NCT02654860|Drug|Morphine|Postoperatively all patients will have access to morphine via a patient controlled analgesia (PCA) pump with a standard programme (1-mg bolus, 5-min lock-out interval, no 4-h dose limit)
290435|NCT00002531|Drug|methotrexate|
290436|NCT00197379|Drug|roxithromycin|
290437|NCT02654886|Other|Resistance Exercise Training|Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months
Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months
290438|NCT02657083|Device|Sensor Augmented Pump (SAP)|2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).
New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.
The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.
During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise
290439|NCT00197691|Procedure|blood draws, etc.|
290440|NCT02657096|Procedure|Hybenx treatment|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
289855|NCT02665780|Procedure|Periodontal debridement|
289856|NCT02665780|Other|Cetylpyridium chloride|
289857|NCT02665793|Other|DBPCFC to peanut cookie|
289858|NCT02665793|Other|Single-dose DBPCFC|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
289859|NCT02665806|Drug|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
289860|NCT00198887|Procedure|Operations research|
289861|NCT02665806|Drug|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
289862|NCT02665819|Other|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
289863|NCT02665832|Drug|DWJ1351|
289864|NCT02665832|Drug|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
289865|NCT02665845|Drug|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
290141|NCT02661035|Radiation|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
290142|NCT00198315|Device|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
290143|NCT02661035|Drug|Tacrolimus|All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.
An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.
Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.
The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:
Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.
Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT.
290144|NCT02661035|Drug|MMF|3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.
MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, MMF will continue as long as clinically indicated.
289870|NCT02667860|Device|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.
289871|NCT02667860|Device|Proximate Reloadable Stapler|Use of a Proximate Linear Cutter device to perform the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
289872|NCT00198991|Drug|daunorubicin|
289873|NCT02667873|Drug|SL-801|
289874|NCT02667886|Drug|X4P-001|Continuous, oral, twice-daily dosing
289875|NCT02667886|Drug|axitinib|Continuous, oral, twice-daily dosing
289876|NCT02667899|Device|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
289877|NCT02667899|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
289878|NCT02667899|Other|Routine treatment|Means without above additional treatment.
289879|NCT02667912|Procedure|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode is used for stepwise radiofrequency energy delivery to inner surface of segmental branches renal artery in a number of points equally distributed along the length and circumference of the vessels in order to ablate renal plexus accompanying the artery in its course from aorta to the kidney
289880|NCT02667912|Procedure|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode is used for stepwise radiofrequency energy delivery to inner surface of the main trunk of renal artery in a number of points equally distributed along its length and circumference in order to ablate renal plexus accompanying the artery in its course from aorta to the kidney
289881|NCT02667925|Drug|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
289882|NCT02667938|Drug|HCP1303 capsule 5/0.2mg|
289883|NCT00198991|Drug|Asparaginase|
289884|NCT02667938|Drug|HCP1303 capsule 5/0.4mg|
289885|NCT02667938|Drug|HGP1201|
289886|NCT02667938|Drug|HCP1303 capsule 5/0.2mg placebo|
289887|NCT02667938|Drug|HCP1303 capsule 5/0.4mg placebo|
289269|NCT02679976|Device|etafilcon A|Marketed Multifocal Contact Lens
289270|NCT00199511|Drug|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
289271|NCT02679989|Behavioral|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
289272|NCT02679989|Behavioral|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
289273|NCT02680002|Biological|7.5 mcg H5N1 (stored as monobulk)|
289562|NCT02672891|Device|condom balloon catheter|The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.
(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed.
289563|NCT02672904|Device|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
289564|NCT02672904|Device|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
289565|NCT02672917|Biological|MVT-5873|MVT-5873 is administered every 2 weeks by IV infusion. Dose will be increased during the study in order to define the MTD
289566|NCT02672930|Device|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
289567|NCT02675270|Behavioral|Phonological|This treatment involves picture viewing and word repetition.
289568|NCT02675270|Behavioral|Orthographic|This treatment involves picture viewing, reading, and writing.
289569|NCT02675270|Behavioral|Untrained|These words are not trained during the treatment phase.
289570|NCT02675283|Device|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
289571|NCT02675309|Drug|MT-8554|
289572|NCT02675309|Drug|rosuvastatin|
289573|NCT00199082|Drug|Ifosfamide|
289574|NCT02675309|Drug|simvastatin|
289575|NCT02675322|Drug|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
288976|NCT02647333|Dietary Supplement|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 acids for 6 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG Fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
288977|NCT02647333|Dietary Supplement|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 oil for 6 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
288978|NCT02647346|Device|Daily use of podimetrics smart-foot mat|
288979|NCT02647359|Drug|Ataluren|
288980|NCT02647359|Drug|Placebo|
288981|NCT02647372|Procedure|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
288982|NCT02647372|Procedure|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
288983|NCT02649504|Drug|Placebo|Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
289274|NCT02680002|Biological|15 mcg H5N1 (stored as monobulk)|
289275|NCT02680002|Biological|90 mcg H5N1 (stored as monobulk)|
289276|NCT02680002|Biological|90 mcg H5N1 (stored in vials)|
289277|NCT02680002|Other|MF59|
289278|NCT02680002|Other|MF59 (stored as monobulk)|
289279|NCT02680015|Behavioral|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
289280|NCT02680028|Device|targon pft nail|
289281|NCT00199524|Device|Navigator Ureteral Access Sheath|ureteral access sheath
289282|NCT02680041|Drug|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
289283|NCT02680054|Drug|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
289284|NCT02680067|Drug|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
293566|NCT02620306|Drug|Fimsartan 60mg~120mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
293567|NCT02620306|Drug|Fimsartan 60mg~120mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
293568|NCT02620306|Drug|Losartan 50mg~100mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
293569|NCT02620306|Drug|Losartan 50mg~100mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
293570|NCT02620319|Device|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
293571|NCT02620332|Drug|MultiPepT1De injection|A mix of peptides
293572|NCT02620332|Other|Placebo|Water for injection
293573|NCT00193375|Radiation|Radiation|
293574|NCT02620345|Drug|Dydrogesterone M ( case 1 )|Dydrogesterone Multivitamin nature
Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.
1tablet/24 hours/day (to 4 weeks after postpartum)
293575|NCT02620345|Drug|Dydrogesterone M ( case 2 )|Dydrogesterone Multivitamin nature
Fibroids/ Women of Reproductive age ( discovered fibroids )
1tablet/24 hours/day ( from discovered fibroids through 6 months)
293576|NCT02620358|Other|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
293577|NCT02620358|Other|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
288984|NCT02649517|Procedure|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
288985|NCT02649530|Drug|WNT974|
288986|NCT02649543|Procedure|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
293275|NCT02624648|Drug|Placebo|They will receive a capsule of Placebo twice a day for 120 days
293276|NCT02624661|Drug|Glycerol|
293277|NCT02624674|Device|Multi-spectral Imaging Device (MSID)|
293278|NCT00193739|Procedure|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
293279|NCT02626507|Drug|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
293280|NCT02626507|Drug|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
293281|NCT02626507|Drug|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
293282|NCT02626520|Drug|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
293283|NCT02626520|Drug|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
293284|NCT02626520|Radiation|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
293285|NCT02626520|Procedure|Definitive resection|Definitive surgical resection of primary tumor
293286|NCT02626533|Procedure|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
293287|NCT02626546|Procedure|Major surgical procedure|observation of postoperative outcomes
293288|NCT00193986|Device|Arbitrary Waveform Defibrillator|
293289|NCT02626559|Drug|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
293290|NCT02626572|Drug|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
293291|NCT02626572|Drug|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
292715|NCT02637609|Other|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
292716|NCT02637609|Other|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
293002|NCT02630927|Drug|Placebo|Placebo will be tested.
293003|NCT02630953|Behavioral|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
293004|NCT02630953|Behavioral|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
293005|NCT02630966|Drug|Vedolizumab|Vedolizumab 300 mg IV
293006|NCT02630966|Drug|Placebo|0.9% sodium chloride used as vedolizumab placebo-matching IV
293007|NCT02630979|Behavioral|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
293008|NCT02630992|Drug|Amoxicillin-Clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/21.5 mg/5 mL; 28:1) administered at 90/3.2 mg/kg in two divided doses for 10 days.
293009|NCT02631005|Other|"Walk With Ease"|Six-week walking program
293010|NCT02633046|Drug|Acthar 80 U 2x/week|Acthar 80 U 2x/week
293011|NCT02633046|Other|Placebo 80 U 2x/week|Placebo 80 U 2x/week
293012|NCT02633046|Drug|Acthar 80 U 3x/week|Acthar 80 U 3x/week
293013|NCT02633059|Drug|Dexamethasone|Given PO
293014|NCT02633059|Drug|Idasanutlin|Given PO
293015|NCT02633059|Drug|Ixazomib Citrate|Given PO
293016|NCT02633059|Other|Laboratory Biomarker Analysis|Correlative studies
293017|NCT02633059|Other|Pharmacological Study|Correlative studies
292414|NCT02644291|Drug|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
292415|NCT02644304|Drug|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
292416|NCT02644304|Drug|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
292717|NCT02637622|Other|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
292718|NCT02637622|Other|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
292719|NCT02637635|Procedure|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
292720|NCT02637635|Procedure|Expander prosthesis|breast reconstruction with expander prosthesis.
292721|NCT02637635|Drug|Prophylactic Antibiotics|During the reconstruction with prosthesis all patients are treated with prophylactic antibiotics. One dose Cloxacillin 2 g or if allergic one dose Clindamycin 600 mg.
292722|NCT00195286|Drug|piperacillin/tazobactam|
292723|NCT02637648|Drug|Sodium Oxybate|parallel Group administration
292724|NCT02637648|Drug|Placebo|parallel Group administration
292725|NCT02637661|Other|earlobe crease positive|
292726|NCT02637661|Other|earlobe crease negative|
292727|NCT02637674|Procedure|Uterus Transplant|
292728|NCT02637687|Drug|LOXO-101|Capsules / Liquid Administration
292729|NCT02637700|Drug|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
292730|NCT02637700|Drug|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
292731|NCT02639754|Behavioral|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
292732|NCT02639767|Drug|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m^2 for pemetrexed in combination with 75 mg/m^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
296823|NCT00003141|Drug|carboplatin|Given IV
296824|NCT00378157|Behavioral|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
296825|NCT00378170|Device|intubation of patients undergoing elective surgery|
296826|NCT00378183|Drug|risperidone|
296827|NCT00378196|Drug|Ranibizumab|0.3 mg/0.05 ml dose
296828|NCT00378196|Drug|Ranibizumab|0.5 mg/0.05 ml dose
297196|NCT00369018|Drug|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
297197|NCT00369031|Biological|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
297198|NCT00369031|Biological|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
297199|NCT00369031|Biological|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
297200|NCT00369044|Drug|prednisone|
297201|NCT00369070|Biological|Bevacizumab|15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
297202|NCT00369070|Drug|AMG 706|Starting on day 1 cycle 1 of the paclitaxel and carboplatin infusion, subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle:
Arm A: 125 mg once daily (QD)
Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
297203|NCT00369083|Procedure|Hospital at home treatment|
297204|NCT00369096|Drug|bemiparin 3500 IU/day|
297205|NCT00003100|Dietary Supplement|soy isoflavones|
297206|NCT00369109|Other|biologic sample preservation procedure|
297207|NCT00369109|Other|immunohistochemistry staining method|
297208|NCT00369109|Other|laboratory biomarker analysis|
297209|NCT00369109|Procedure|biopsy|
297210|NCT00369122|Radiation|external beam radiation therapy|Undergo EBRT
297211|NCT00369122|Radiation|brachytherapy|Undergo brachytherapy
296446|NCT00386620|Behavioral|Interview|Feedback on use of handheld computer electronic diaries (ED).
296447|NCT00386633|Biological|MVA-mBN32|3 immunizations; first study group: 10E7_TCID50
296448|NCT00386633|Biological|MVA-mBN32|3 immunizations; second study group: 10E8_TCID50
296449|NCT00386646|Drug|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
296450|NCT00386659|Drug|tenofovir + abacavir + lopinavir/ritonavir|
296451|NCT00386659|Drug|tenofovir + abacavir + efavirenz|
296452|NCT00386672|Drug|Calcium and Vitamin D|
296453|NCT00386672|Behavioral|Nutrition Counseling|
296454|NCT00386685|Drug|larotaxel (XRP9881)|intravenous administration
296455|NCT00003183|Drug|mitoxantrone hydrochloride|
296456|NCT00386685|Drug|trastuzumab|intravenous administration
296457|NCT00386698|Biological|Fluarix|
296458|NCT00386698|Biological|adjuvanted influenza vaccine|
296459|NCT00386711|Behavioral|training on identification of suicide risk and depression|
296460|NCT00386724|Device|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
296829|NCT00378209|Drug|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
296830|NCT00378209|Drug|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
296831|NCT00378209|Drug|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
296832|NCT00378222|Procedure|Autologous Stem Cell Transplantation|
296833|NCT00378235|Drug|IL13-PE38QQR|
296834|NCT00000487|Drug|diuretics|
296835|NCT00003141|Drug|cisplatin|Given IV
296836|NCT00378248|Behavioral|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
292482|NCT02615223|Procedure|cryoablation|Cryoablation therapy
292483|NCT02615223|Drug|Bicalutamide|bicalutamide
292484|NCT02615223|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
292485|NCT00193050|Drug|Docetaxel|Docetaxel
292486|NCT02615236|Device|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
292487|NCT02615236|Procedure|Clinical diagnosis|diagnosis of OASIS clinically
292488|NCT02615249|Biological|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
292489|NCT02615262|Drug|Dexamethasone|
292490|NCT02615262|Drug|Placebo|0.9% Sodium Chloride
292491|NCT02615275|Device|SECA mBCA|Body composition assessed at baseline, weekly throughout RT during clinic visits, and after completion of treatment at the 10-12 week follow up.
292492|NCT02615275|Procedure|X-Ray Imaging|Computed tomography (CT) or positron emission tomography (PET) scan performed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.
292493|NCT02615275|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.
292494|NCT02615275|Radiation|Radiation Therapy|Radiation treatment administered per treating physician for 6-7 weeks. Total prescribed dose is 60-70 Gy in 30-35 fx at 2.0-2.2 Gy/fx prescribed to the PTV. Radiation planned and delivered using intensity modulated radiation therapy (IMRT), volumetric arc therapy (VMAT), and/or three-dimensional conformal radiation therapy (3DCRT).
292495|NCT02615288|Dietary Supplement|Vitamin D3|
292792|NCT02644525|Drug|Imatinib Mesylate|Imatinib is a small molecule inhibitor which was US Food and Drug Administration (FDA) -approved for chronic myelogenous leukemia (CML) in 2001 which acts on the protein product of the Philadelphia chromosome, Bcr-Abl.
292793|NCT02644525|Drug|Placebo|Placebo pills
292794|NCT02610907|Other|Buffer|The sleeve contains phosphate buffered saline buffer
292795|NCT02610907|Other|Own output|The sleeve contains the subject own ileal effluent
292796|NCT02610907|Other|simulated output|The sleeve contains simulated output
291888|NCT02626117|Device|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
291889|NCT02626130|Drug|Tremelimumab|Participants receive a course of 2 preoperative doses of Tremelimumab. Tremelimumab administered intravenously at a dose of 10 mg/kg. Participants receive first dose at Week 1, second dose at Week 5. After surgery participants receive one dose of Tremelimumab every 4 weeks for 3 doses and every 12 weeks after that until progression .
291890|NCT02626130|Procedure|Cryoablation|Participants have cryoablation procedure about 2-6 days before first dose of Tremelimumab. Study doctor inserts cryoprobe needle and an ultrasound device used to help guide cryoprobe until it reaches the cancerous area. When in place, cryoprobe used to freeze the cancerous area.
291891|NCT02628145|Behavioral|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
292171|NCT02619773|Procedure|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
292172|NCT02619786|Drug|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
292173|NCT02621788|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
292174|NCT02621801|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
292175|NCT02621814|Dietary Supplement|Friso|Formula feeding on demand for 3 months
292176|NCT02621814|Dietary Supplement|Wyeth|Formula feeding on demand for 3 months
292177|NCT02621827|Other|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
292178|NCT02621840|Behavioral|Mandatory On-Site Pre-Admission Testing|
292179|NCT02621853|Device|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
292180|NCT00193479|Drug|Rituximab|Rituximab
292181|NCT02621866|Device|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
292182|NCT02621866|Device|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of <500nm, but permits visible light to pass.
291590|NCT02632526|Drug|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
291591|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
291592|NCT02632526|Drug|AZD5718 placebo oral suspension|Single and multiple doses
291593|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
291594|NCT02632539|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
291595|NCT00194779|Procedure|needle biopsy|Correlative studies
291596|NCT02632539|Procedure|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
291597|NCT02632552|Behavioral|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
291598|NCT02632552|Behavioral|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions
291599|NCT02632565|Drug|Lidocaine|
291600|NCT02632565|Drug|Saline|
291601|NCT02632578|Biological|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
291602|NCT02632591|Drug|Tetracycline|every 12 hours orally form
291892|NCT00194285|Procedure|FDG-PET Imaging|
291893|NCT02628158|Procedure|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
291894|NCT02628171|Other|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
291895|NCT02628171|Other|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
291896|NCT02628184|Other|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
291308|NCT02639234|Drug|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
291309|NCT00195481|Drug|Rapamune|
291310|NCT02639247|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857 (400/100/100 mg) FDC tablet administered orally once daily with food
291311|NCT02639247|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily without regard to food
291312|NCT02639260|Drug|N-acetyl|dose escalation
291313|NCT02639273|Drug|Nalmefene|
291314|NCT02639273|Other|Placebo|
291315|NCT02639286|Drug|ISIS 304801|300 mg or placebo administered as SC
291316|NCT02639286|Drug|Placebo|Placebo administered via SC
291317|NCT02639338|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857 (400/100/100 mg) FDC tablet administered orally once daily with food
291318|NCT02639338|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily without regard to food
291319|NCT02639351|Biological|MenC-CRM conjugate vaccine with 12.5 ug LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
291320|NCT00195494|Drug|Etanercept|Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2
Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
291321|NCT02639351|Biological|MenC-CRM conjugate vaccine with 25 ug LHD153R|IM vaccination of 1 dose of 0.5 mL
291322|NCT02639351|Biological|MenC-CRM conjugate vaccine with 50 ug LHD153R|IM vaccination of 1 dose of 0.5 mL
291323|NCT02639351|Biological|MenC-CRM conjugate vaccine with 100 ug LHD153R|IM vaccination of 1 dose of 0.5 mL
291324|NCT02639351|Biological|MenC-CRM conjugate vaccine|IM vaccination of 1 dose of 0.5 mL
291325|NCT02639364|Device|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
291603|NCT02632591|Drug|statin|every 12 hours
291604|NCT02632591|Drug|antimycotic|every 12 hours
291605|NCT02632591|Drug|Fingolimod|every 24 hours
291013|NCT02641613|Procedure|retroclavicular block|retroclavicular block for forearm or hand surgery
291014|NCT02641613|Procedure|supraclavicular block|supraclavicular block for forearm or hand surgery
291015|NCT02641626|Procedure|Urgent Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
291016|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
291017|NCT02641626|Procedure|Deferred Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
291018|NCT02643719|Drug|Topiramate|Preventive medication prescriptions given to the patient along with written instructions and information about side effects:
Topiramate 25mg tabs (with a plan to increase to 100mg)
291019|NCT02643719|Drug|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
291020|NCT02643719|Drug|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
291021|NCT02643732|Drug|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
291022|NCT02643732|Drug|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
291023|NCT02643745|Procedure|Nephrology Intervention|pre-operative study:
Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.
Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.
optimise the patient' s overall condition with a pre-operative strategy:
Obesity control
Control protein, caloric, salt intake
Stop smoking
Good glycemic control
Start ACEI/ARA II (enalapril, ramipril, valsartan, losartan) if there is proteinuria
Start additional antihypertensive drug if required (amlodipine, manidipine, doxazosine, enalapril, ramipril, valsartan, losartan, hidralazine, bisoprolol)
Start hypolipemic treatment if required (atorvastatine, simvastatine, ezetimibe)
Start hyperuricemia treatment if required (alopurinol, febuxostate)
Start AAS, clopidogrel if it is necessary (prophylaxis)
Phosphate control
Anemia control
Metabolic acidosis correction
291024|NCT02643758|Device|Bifocal soft contact lenses|
291025|NCT02643771|Procedure|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
291026|NCT02643784|Drug|Rosuvastatin|Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.
Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
291027|NCT00196092|Device|Standard Risk|Standard Endovascular repair
290441|NCT02657096|Procedure|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
290442|NCT02657109|Other|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
290748|NCT02650466|Device|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
290749|NCT02650479|Drug|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
290750|NCT02650479|Drug|Placebo|6 hour IV infusion.
290751|NCT02650479|Drug|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
290752|NCT02650479|Drug|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
290753|NCT02650492|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
290754|NCT02650505|Drug|LEO 43204|
290755|NCT02650505|Drug|LEO 43204 Vehicle|
290756|NCT00196781|Behavioral|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
290757|NCT02650518|Other|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
290758|NCT02650518|Device|Catheter Change|Urinary catheter change once randomization is complete.
290759|NCT02650544|Drug|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
290760|NCT02650544|Drug|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
290761|NCT02652715|Dietary Supplement|Salvia hispanica Seed|Given PO
290762|NCT02652728|Drug|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
290145|NCT02661035|Biological|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
290146|NCT02661035|Biological|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
290147|NCT02661048|Device|CyberHeart System|The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
290148|NCT02661061|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
290149|NCT02661061|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
290150|NCT02661074|Other|Questionnaire|A questionnaire will be completed in order to collect data on:
Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),
Occupational and/or domestic exposure to fish.
290151|NCT02661087|Procedure|Hysteroscopic resection with bipolar energy|
290152|NCT02663453|Drug|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
290443|NCT02657122|Drug|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
290444|NCT02657122|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
290445|NCT02657122|Drug|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
290446|NCT02657122|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
290447|NCT02657135|Behavioral|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
290448|NCT02657135|Other|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
290449|NCT02657135|Other|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
290153|NCT02663466|Procedure|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
290154|NCT02663479|Dietary Supplement|Cardiopressin|
290155|NCT02663479|Dietary Supplement|Placebo|
290156|NCT00198549|Drug|Vitrase (ovine hyaluronidase) Lyophilized|
290157|NCT02663492|Device|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
290158|NCT02663492|Drug|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
290159|NCT02663505|Procedure|Patients receiving the surgery planned for them|No intervention will be performed apart from the surgery planned for each patient. Different aspects of data i.e. patient-centered and surgery-centered will be collected.
290160|NCT02663518|Drug|TTI-621|TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory "do not eat" (antiphagocytic) signal to macrophages.
290161|NCT02663531|Device|DVA|
290162|NCT02663531|Device|FDOCT|
290163|NCT02663531|Device|Pattern ERG|
290164|NCT02663531|Device|Optical Coherence Tomography|
290165|NCT02663544|Other|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
290166|NCT02663544|Other|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
290167|NCT00198562|Drug|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
290168|NCT02663544|Other|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
290169|NCT02663570|Drug|Melatonin|
289576|NCT02675322|Other|Placebo|Placebo with no chemical effects.
289577|NCT02675335|Drug|Sitagliptin|
289578|NCT02675335|Drug|Placebo|
289579|NCT02675348|Dietary Supplement|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
289580|NCT02675348|Dietary Supplement|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
289888|NCT02667938|Drug|HGP1201 placebo|
289889|NCT02667951|Other|A home-based caregiver-training program|This training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
289890|NCT02667964|Other|spiroergometry|Spiroergometry on a bicycle ergometer
289891|NCT02667977|Other|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
289892|NCT02667977|Other|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
289893|NCT02670382|Dietary Supplement|DHA|10 week supplementation
289894|NCT02670382|Dietary Supplement|sunflower oil|10 week supplementation
289895|NCT00199004|Procedure|Mediastinal irradiation (if residual TU)|
289896|NCT02670395|Drug|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
289897|NCT02670395|Drug|Placebo|Placebo solution will be administered orally.
289898|NCT02670408|Procedure|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care
289899|NCT02670421|Behavioral|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder), followed by email communication every three weeks.
289900|NCT02670421|Behavioral|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
289285|NCT02680067|Device|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
289286|NCT02680080|Drug|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
289287|NCT02680080|Dietary Supplement|Grapefruit group|one liter of fresh pink-grapefruit juice
289288|NCT02682082|Procedure|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
289289|NCT02682082|Drug|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
289290|NCT02682108|Device|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
289291|NCT02682121|Drug|Metformin|Metformin 850 mg twice daily
289292|NCT02682121|Drug|Placebo|Placebo twice daily
289293|NCT02682134|Drug|xylocaine|First group were given xylocaine
289294|NCT02682134|Drug|Dexamethasone|Second group were given Dexamethasone
289581|NCT02675348|Dietary Supplement|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
289582|NCT02675361|Behavioral|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on CHD, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about GUCH program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
289583|NCT02675374|Drug|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
289584|NCT00199082|Drug|Methotrexate|
289585|NCT02675374|Drug|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
289586|NCT02675387|Device|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
288987|NCT02649543|Procedure|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
288988|NCT02649543|Procedure|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
288989|NCT02649556|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
288990|NCT02649556|Other|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks.
The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product.
288991|NCT02649569|Device|Monitoring Device|Wear activity monitor
288992|NCT02649569|Other|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
288993|NCT00196690|Drug|Donepezil|
288994|NCT02649582|Biological|Dendritic cell vaccine plus temozolomide chemotherapy|When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):
Leukocyte apheresis ± 1 week before chemoradiation (for DC vaccine production)
Chemoradiation (standard treatment): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)
Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly for 3 weeks, starting 1 week after radiotherapy
Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days (max. 12 months) starting 1 week after induction immunotherapy + DC on day 21 of every 28-day cycle
288995|NCT02649595|Other|Red Cross Respite care|See detailed description.
288996|NCT02649608|Drug|Lu AE04621|Low dose of Lu AE04621 on Day 1 followed by a medium dose of Lu AE04621 on Day 2, and a a high dose of Lu AE04621 on Day 3. If deemed appropriate the dosing period may be extended to 4 days. Oral solution, single dose
288997|NCT02649621|Biological|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
288998|NCT02649634|Behavioral|Motivational Interviewing|The semi-structured MI protocol was a 45-minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
289295|NCT00002535|Drug|indomethacin|
289296|NCT00199901|Biological|ISCOMATRIX® adjuvant|120 μg of ISCOMATRIX® alone.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).
293578|NCT02622256|Behavioral|Health System: DM Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete 2 short surveys (months 1 and 6). The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team & receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about.
293579|NCT02622269|Device|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
293580|NCT02622269|Device|Standard compression device|Compression of the abdomen with the standard compression device
293581|NCT00193505|Drug|90Y Zevalin|
293582|NCT02622282|Other|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
293583|NCT02622282|Other|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
293584|NCT02622282|Other|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
293585|NCT02622295|Behavioral|Single-session high-frequency active-resisted stance|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit high muscle forces.
293586|NCT02622295|Behavioral|Single-session low-frequency active-resisted stance|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit low muscle forces.
293587|NCT02622295|Behavioral|High-frequency active-resisted stance training|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit high muscle forces. Subjects will train for 16 weeks.
293588|NCT02622295|Behavioral|Low-frequency active-resisted stance training|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit low muscle forces. Subjects will train for 16 weeks.
293589|NCT02622308|Device|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the Boot to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump).FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes. The Boot acts as a pressure chamber, by sealing around the patient's leg below the knee.
293590|NCT02622321|Drug|Emicizumab|Emicizumab will be administered subcutaneously at a dose of 3 mg/kg/week for 4 weeks followed by 1.5 mg/kg/week up to the end of the study.
293591|NCT02622334|Drug|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
293592|NCT00193518|Drug|Arsenic Trioxide|
293018|NCT02633072|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
293019|NCT02633085|Device|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
293020|NCT00194792|Drug|triptorelin pamoate|Given IM
293021|NCT02633098|Drug|Artesunate 200mg|
293292|NCT02626572|Drug|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
293293|NCT02626572|Drug|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
293294|NCT02626585|Procedure|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
293295|NCT02626598|Device|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
293296|NCT02626611|Drug|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
293297|NCT02626611|Drug|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
293298|NCT02628756|Procedure|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
293299|NCT02628769|Drug|Solithromycin|
293300|NCT02628769|Drug|Placebo|
293301|NCT02628782|Device|InSeal's Vascular Closure Device|
293302|NCT02628795|Behavioral|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
293303|NCT00194337|Procedure|radiomammography|
293304|NCT02628795|Other|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
292733|NCT02639767|Radiation|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
292734|NCT02639767|Device|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
292735|NCT02639780|Other|protein expression pattern of packed red blood cells|the proteome of packed red blood cells will be assessed at predefined time points
293022|NCT02633098|Drug|Placebo|
293023|NCT02633111|Other|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
293024|NCT02633111|Other|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
293025|NCT02633111|Device|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
293026|NCT02633124|Device|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
293027|NCT02633124|Device|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
293028|NCT02633137|Drug|Lenalidomide|
293029|NCT02633137|Drug|R-CHOP|Rituximab 375 mg/m2 IVPB with premedications Day 1
Cyclophosphamide 750 mg/m2 IVPB Day 1
Doxorubicin 50 mg/m2 IVP Day 1
Vincristine 1.4 mg/m2 IVP (capped at 2 mg) Day 1
Prednisone 100 mg PO Daily on Days 1-5 or 2-6
293030|NCT02633137|Drug|high-dose cytarabine (HIDAC)|
293031|NCT00194792|Drug|capecitabine|Given PO
293032|NCT02633150|Other|Supplementation with red grapes polyphenol|
293033|NCT02633163|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
293034|NCT02633163|Drug|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution.
293035|NCT02633163|Drug|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
293036|NCT00195000|Drug|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
293037|NCT02635256|Radiation|Hypofractionated Radiosurgery|Image-guided stereotactic Linac based RT preferable with "dedicated radiosurgery system" such as CyberKnife
297212|NCT00369122|Biological|bevacizumab|Given IV
297213|NCT00369122|Drug|cisplatin|Given IV
297214|NCT00369135|Procedure|combined intervention|
297215|NCT00369148|Drug|nateglinide(drug) mitiglinide(drug)|
297216|NCT00003101|Biological|filgrastim|
297217|NCT00369161|Drug|Everolimus (RAD001)|
297218|NCT00369161|Drug|Tacrolimus|
297219|NCT00369161|Drug|Basiliximab|
297220|NCT00369161|Drug|Corticosteroids|
297221|NCT00369174|Drug|rosiglitazone maleate|Given orally
297574|NCT00407459|Drug|Bevacizumab, Pemetrexed, Carboplatin|Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks
Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks
Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks
297575|NCT00407472|Device|ATS-1 needle free device|
297576|NCT00407485|Biological|ziv-aflibercept|Given IV
297577|NCT00407485|Other|pharmacological study|Correlative studies
297578|NCT00407498|Drug|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
297579|NCT00407511|Drug|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
297580|NCT00407524|Drug|AKL 1|
297581|NCT00407537|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
297582|NCT00410410|Drug|abatacept (ABA)|Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57 (ABA 30/~10 mg/kg Group).
Induction Period 3 months
Maintenance Period 12 months
297583|NCT00410410|Drug|placebo|Normal saline, IV, 0 mg/kg, every 28 days.
Induction Period 3 months
Maintenance Period 12 months
296837|NCT00378248|Behavioral|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
296838|NCT00378261|Procedure|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
296839|NCT00378274|Behavioral|Observation|
296840|NCT00378287|Drug|rabeprazole sodium|
296841|NCT00378300|Drug|Oral Probiotics|
296842|NCT00378313|Drug|gemcitabine, epirubicin, paclitaxel|
296843|NCT00378326|Drug|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
296844|NCT00378339|Device|gold berlocks|
296845|NCT00378352|Drug|Epoietin Alfa|
296846|NCT00003141|Drug|cyclophosphamide|Given IV
296847|NCT00378352|Drug|Placebo|
296848|NCT00378365|Procedure|Arsenic trioxide|Arsenic trioxide
296849|NCT00381095|Drug|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
296850|NCT00381095|Drug|Placebo|Placebo
296851|NCT00381108|Drug|Placebo Tablet|Two tablets, twice daily.
296852|NCT00381108|Drug|Pomegranate Tablet|Two tablets, twice daily.
296853|NCT00381134|Drug|losartan 100 mg orally once daily|
296854|NCT00003151|Drug|metronidazole hydrochloride|
297222|NCT00369174|Other|laboratory biomarker analysis|Correlative studies
297223|NCT00369187|Drug|large protein molecule|
297224|NCT00369200|Drug|AFP464|Given IV
297225|NCT00372229|Drug|Pre-emptive therapy|As prescribed
297226|NCT00372229|Drug|valganciclovir [Valcyte]|900mg po for 100 days
297227|NCT00372242|Behavioral|Prospective Longitudinal Interventional Stury|
292797|NCT02610920|Procedure|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
292798|NCT02610920|Drug|Injection of iron-tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
292799|NCT02610933|Drug|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
292800|NCT02610933|Dietary Supplement|Vitamin K2|Vitamin K2 supplementation
292801|NCT02610946|Behavioral|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
292802|NCT02610946|Behavioral|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
292803|NCT00192556|Behavioral|food|
292804|NCT02610959|Other|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
292805|NCT02610959|Other|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
292806|NCT02610972|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
292807|NCT02610985|Device|3-D laparoscopy|3-D laparoscopy
292808|NCT02610985|Device|2-D laparoscopy|2-D laparoscopy
292809|NCT02611011|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
292810|NCT02611024|Drug|lurbinectedin ( PM01183)|lurbinectedin ( PM01183) 4mg vials
292811|NCT02611024|Drug|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
292812|NCT02611037|Drug|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
293099|NCT02640131|Behavioral|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
293100|NCT02642367|Device|McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)|use of stylet
292183|NCT02621879|Procedure|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
292184|NCT02621892|Drug|Tenapanor|
292185|NCT02621892|Drug|Placebo|
292186|NCT02621905|Drug|Sporanox|100 mg
292187|NCT02621905|Drug|Lozanoc|50 mg
292188|NCT02621918|Other|Progressive resistance training|
292189|NCT02621918|Other|Aerobic training|
292190|NCT02621918|Other|Placebo training|
292191|NCT00193492|Drug|Bevacizumab|
292192|NCT02621931|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
292496|NCT00193063|Drug|Trastuzumab|Trastuzumab
292497|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
292498|NCT02617355|Device|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
292499|NCT02617355|Device|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
292500|NCT02617355|Device|DeRoyal Magnetic Pad size 20" x 16"|Magnetic Instrument Pad #25-002, size 20" x 16", DeRoyal Industries Inc applied to the patient's thorax
292501|NCT02617355|Device|DeRoyal Magnetic Pad size 10" x 16"|Magnetic Instrument Pad #25-001, size 10" x 16", DeRoyal Industries Inc applied to the patient's thorax
292502|NCT02617381|Other|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
292503|NCT02617394|Other|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
292504|NCT02617394|Other|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
292505|NCT02617407|Other|Livionex®|Dental Plaque, Gingivitis and Oral Microbiome Control
291897|NCT02628197|Dietary Supplement|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
291898|NCT02628197|Procedure|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
291899|NCT02628210|Device|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
291900|NCT02628223|Procedure|Selective Laser Trabeculoplasty|
291901|NCT02628223|Device|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
291902|NCT02628236|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
291903|NCT00194298|Procedure|FDG-PET Imaging|
291904|NCT02628236|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
291905|NCT02628249|Dietary Supplement|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
291906|NCT02628249|Dietary Supplement|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
291907|NCT02628249|Dietary Supplement|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
291908|NCT02628249|Dietary Supplement|Essential amino acids|Essential amino acids modeled after egg protein.
291909|NCT02628249|Dietary Supplement|Non essential amino acids|Non essential amino acids modeled after egg protein.
292193|NCT02621931|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
292194|NCT02621931|Drug|Placebo|Matching Placebo
292195|NCT02621944|Drug|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
292196|NCT02621944|Other|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
292197|NCT02621944|Other|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
292198|NCT02621944|Behavioral|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
291606|NCT00194779|Procedure|therapeutic conventional surgery|Undergo definitive breast surgery
291607|NCT02634658|Other|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
291608|NCT02634658|Other|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
291609|NCT02634671|Other|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
291610|NCT02634671|Other|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
291611|NCT02634671|Other|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
291612|NCT02634684|Drug|d-amphetamine|
291613|NCT02634684|Drug|Placebo|
291614|NCT00194961|Drug|Recombinant Human Growth Hormone|
291615|NCT02634697|Behavioral|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
291616|NCT02634710|Radiation|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
291617|NCT02634723|Biological|Octocog alfa (recombinant human coagulation factor VIII)|
291618|NCT02634736|Device|Exergame plus usual treatment|An individualised [i.e. frequency and duration will be set according to each participant's baseline levels] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
291910|NCT02628262|Procedure|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
291326|NCT02639377|Drug|Chlorhexidine gluconate|
291327|NCT02639377|Drug|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
291328|NCT02639390|Device|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
291329|NCT02639390|Other|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
291330|NCT02641639|Drug|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
291331|NCT02641639|Drug|Placebo|Saline for infusion
291332|NCT02641652|Drug|Sertraline|25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
291333|NCT02641652|Drug|Placebo|1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
291334|NCT02641665|Procedure|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
291335|NCT02641678|Device|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
291336|NCT02641691|Radiation|Radiation|
291337|NCT02641691|Drug|Oxaliplatin|
291338|NCT02641691|Drug|Leucovorin|
291339|NCT00195715|Biological|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
291340|NCT02641691|Drug|Fluorouracil|
291341|NCT02641704|Behavioral|Multidisciplinary program|Coordinated multidisciplinary program
291342|NCT02641717|Other|vaginal swab|
291343|NCT02641730|Drug|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
291344|NCT02641730|Drug|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
290763|NCT02652741|Drug|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
290764|NCT02652754|Drug|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
291028|NCT02643784|Other|Control|Randomized Treatment Period (Day 1 through Day 14):
No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
291029|NCT02643797|Behavioral|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
291030|NCT02643810|Other|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
291031|NCT02643823|Biological|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
291032|NCT02643823|Drug|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
291033|NCT02643836|Device|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
291034|NCT02643849|Device|The Spanner Temporary Prostatic Stent|
291035|NCT02645851|Device|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
291036|NCT02645851|Other|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
291037|NCT02645864|Drug|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
291038|NCT00196339|Drug|DR-2031b|1 tablet daily
291039|NCT02645864|Drug|Irinotecan|150mg/m^2 i.v. q2w
290450|NCT00197704|Dietary Supplement|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
290451|NCT02657135|Other|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
290452|NCT02657135|Other|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
290453|NCT02657135|Other|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
290454|NCT02657135|Other|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
290455|NCT02659163|Behavioral|mHealth scale|A wireless scale used by participants to measure and record daily weight.
290456|NCT02659163|Behavioral|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
290457|NCT02659163|Behavioral|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
290458|NCT02659163|Behavioral|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
290459|NCT02659163|Behavioral|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
290765|NCT02652767|Genetic|GS010|Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
290766|NCT02652767|Other|Sham Intravitreal Injection|Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
Sham-treated Eyes: One eye of each subject will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
290767|NCT02652780|Genetic|GS010|Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
262316|NCT00174629|Drug|docetaxel/gemcitabine|
262317|NCT02467738|Procedure|Conventional surgery|Undergo surgical resection
262318|NCT02467764|Other|Retrospective study|
262319|NCT02467777|Device|Bair Hugger|
262320|NCT02467777|Device|VitaHeat|
262321|NCT02467790|Drug|PEX168|PEX 168: 200µg,Subcutaneous,one time.
262322|NCT02467803|Other|Scapula mobilization|
262323|NCT02467803|Other|Shoulder ROM exercises|
262324|NCT02467816|Behavioral|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
262325|NCT02469805|Device|Shepherd catheter|Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
262326|NCT00174837|Drug|Tirapazamine (SR259075)|in combination with cisplatin and concomitant radiation
262327|NCT02469831|Drug|Cisatracurium|
262328|NCT02469857|Drug|AB103 0.5 mg/kg|
262603|NCT02499133|Other|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
262604|NCT02499146|Drug|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
262605|NCT02499146|Drug|Letrozole|2.5 mg , orally once daily (continuously)
262606|NCT02499159|Drug|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
262607|NCT02499159|Drug|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
262608|NCT02499172|Biological|Shanchol|Oral cholera vaccine
262609|NCT02499172|Other|Non-intervention|Non recipients of the vaccine
262610|NCT02499185|Device|Nephro Check Test|Urine sample
262027|NCT02474199|Drug|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
262028|NCT02474199|Drug|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
262029|NCT02474199|Drug|Immunosuppression (IS) Withdrawal|Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI‐based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-"pre darTregs"), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS.
262030|NCT00002474|Drug|carboplatin|
262031|NCT00175344|Procedure|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
262032|NCT02474199|Procedure|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
262033|NCT02474212|Drug|Enoxaparin|
262034|NCT02474225|Drug|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
262035|NCT02474238|Device|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
262036|NCT02474238|Device|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
262329|NCT02469857|Other|NaCl 0.9%|
262330|NCT02469870|Behavioral|Autism Parent Trainer (APT)|Experimental condition
262331|NCT02469870|Behavioral|self-paced ABC training online|Content comparison group.
262332|NCT02469883|Drug|Sinotecean|
262333|NCT02469896|Drug|Tocilizumab|IV Infusion
262334|NCT02469896|Other|Placebo|IV Infusion
262335|NCT02469909|Other|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
261707|NCT02478268|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
261708|NCT02478268|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
261709|NCT02478281|Drug|Methylene Blue|
261710|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
261711|NCT02478294|Procedure|Thoracoscopic Left Atrial Appendage Excision|
261712|NCT02478294|Drug|Warfarin|
261713|NCT02478307|Other|Cognitive Therapy|
261714|NCT02478307|Other|Mindfulness Meditation|
261715|NCT02478307|Other|Mindfulness-Based Cognitive Therapy|
261716|NCT02478320|Drug|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
261717|NCT02478333|Drug|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
261718|NCT02478333|Drug|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
261719|NCT02478333|Drug|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
261720|NCT02478333|Other|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
261721|NCT00175955|Drug|Levetiracetam|
261722|NCT02478346|Drug|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
261723|NCT02478359|Behavioral|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention includes a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
261724|NCT02478372|Drug|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
261131|NCT02489435|Drug|VM-1500|VM-1500
261409|NCT02483013|Other|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
261410|NCT02483026|Dietary Supplement|Multi vitamin|Multi vitamin
261411|NCT00176501|Biological|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
261412|NCT02483026|Dietary Supplement|vitamin D|Vitamin D
261413|NCT02483026|Dietary Supplement|Placebo|Placebo
261414|NCT02485093|Device|Septal ventricular pacing|Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
261415|NCT02485093|Device|VIP|Ventricular pacing must be less than 10%.
261416|NCT02485106|Drug|Rifaximin|400mg three times per day for 28 days
261417|NCT02485106|Drug|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
261418|NCT02485119|Drug|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
261419|NCT00176774|Drug|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
261420|NCT02485132|Other|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with gliclazide or gliclazide MR, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
261421|NCT02485145|Drug|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
261422|NCT02485145|Drug|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
261423|NCT02485145|Drug|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
261424|NCT02485158|Drug|Oral THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
261425|NCT02485158|Drug|d-Amphetamine|This is a within-subjects, double-blind, placebo controlled design. We administered oral d-amphetamine to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
260861|NCT02496455|Procedure|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
260862|NCT02496455|Drug|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
260863|NCT00178139|Behavioral|Music Therapy|Music Therapy
260864|NCT02496481|Behavioral|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
261132|NCT02489435|Drug|Placebo|Placebo
261133|NCT02489448|Drug|MEDI4736|The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.
Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments.
261134|NCT02489461|Drug|VM-1500|VM-1500 up to 48 weeks
261135|NCT02491788|Drug|Placebo|
261136|NCT02491801|Other|Dietary intervention|All arms are given to all participants, in a randomized order
261137|NCT02491814|Other|1% M.F. Milk|
261138|NCT02491814|Other|Yogurt Beverage|
261139|NCT02491814|Other|Soy Beverage|
261140|NCT02491814|Other|Almond Beverage|
261141|NCT02491814|Other|Water|
261142|NCT02491814|Other|Breakfast cereal|
261143|NCT02491827|Other|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
261144|NCT02491840|Procedure|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
261145|NCT00177476|Behavioral|behavioral weight loss|
261146|NCT02491853|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
260581|NCT02467010|Drug|Dexamethasone|Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.
Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
260582|NCT02467023|Device|Bilateral quadriceps strength training by Shuttle mini press|The device will be placed in the bed and positioned so that when the patient's feet are placed on the training plate the knees are at a 90° angle, and the device will be secured to the bed frame with straps. A force plate with an interface to a laptop computer with analysis software will be positioned between the patient's feet and the device. Resistance is provided to knee extension by a series of surgical tubes that increase the force needed to extend the device by 5 to 10 pounds per tube to a maximum of about 120 pounds. The actual force generated in training will be logged by the force plate and interfaced software. Training will be conducted 5 days a week, starting at ~ ICU day 14 and continuing for 28 days or until discharge. Four sets of 6-10 repetitions will be completed each day.
260583|NCT02467023|Device|Measurement of maximal isometric strength by Shuttle mini press and Vernier force transducer|The mini slide device will be placed and secured in the patient's bed with straps so the knee is at a 90° angle. The force dynamometer will be placed between the patient's feet and the mini slide device. The mini slide foot plate will be prevented from moving with a clamp/strap system. The patient will be asked to generate as much force as they possibly can for 3-5 seconds. The maximal isometric strength measure will be repeated 2 more times with a minimum 2 minute rest between each effort. The maximal force will be recorded by the dynamometer interfaced to a laptop computer. Measurement of maximal isometric strength will be repeated on the first day of investigation, approximately every 7 days thereafter and the last day of study participation.
260865|NCT02496481|Behavioral|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
260866|NCT02496494|Drug|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
260867|NCT02498327|Other|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
260868|NCT02498327|Other|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
260869|NCT02498340|Dietary Supplement|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
260870|NCT02498353|Radiation|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
260871|NCT02498353|Radiation|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
260872|NCT02498353|Procedure|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
284549|NCT02589860|Genetic|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
284550|NCT02589873|Behavioral|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
284551|NCT02589873|Behavioral|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
284552|NCT02589886|Other|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
284553|NCT02589899|Other|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
284554|NCT02589912|Device|Nucleus Profile ABI541 Auditory Brainstem Implant|
284555|NCT00190489|Drug|Docetaxel 60mg/m2 every 21 days for 6 cycles|
284556|NCT02589925|Device|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
284557|NCT02589925|Procedure|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
284558|NCT02589925|Procedure|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
284559|NCT02589925|Procedure|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
284560|NCT02589938|Other|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
284864|NCT02583100|Behavioral|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
284865|NCT00189514|Drug|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
284866|NCT02583100|Behavioral|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
284867|NCT02583113|Device|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
284868|NCT02583126|Behavioral|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
284244|NCT02593851|Drug|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
284245|NCT02593851|Drug|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
284246|NCT02593864|Device|Variable-Stiffness Shoe|A load-modifying variable-stiffness shoe previously shown to reduce joint loading
284247|NCT02593877|Device|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
284248|NCT02593890|Device|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
284249|NCT00190905|Drug|duloxetine HCl|
284250|NCT02593903|Drug|Septra|
284251|NCT02593929|Drug|ruxolitinib|
284252|NCT02593942|Drug|Remifentanil|0.1-0.5 mcg/kg/min infusion
284253|NCT02593942|Drug|Propofol|75-200 mcg/kg/min infusion
284254|NCT00191139|Drug|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
284255|NCT02596425|Procedure|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
284256|NCT02596438|Other|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
284257|NCT02596451|Drug|Diclofenac Sodium gel, 1%|
284258|NCT02596451|Drug|Voltaren® Gel|
284259|NCT02596451|Drug|Placebo|
284260|NCT02596477|Drug|Vepoloxamer|
284261|NCT02596477|Other|5% dextrose in water|
284262|NCT02596490|Behavioral|Questionnaires|Couples complete 13 questionnaires before first session, after last session, and again 3 months later.
Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
284263|NCT02596490|Behavioral|Couple-Based Meditation Program|Couple-based meditation (CBM) group receives 1 weekly practice session for 4 weeks (4 total sessions, approximately 60 min. each). All meditation sessions videotaped.
288794|NCT00198809|Drug|Placebo + Diet education|
288795|NCT02665195|Behavioral|questionnaire|
288796|NCT02665208|Other|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
288797|NCT02665208|Drug|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
288798|NCT02665208|Behavioral|Text Message Intervention (TMI)|
288799|NCT02665221|Other|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
288800|NCT02665221|Drug|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
288801|NCT02665234|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
288802|NCT02665234|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
288803|NCT02665247|Behavioral|C-SIP|
288804|NCT02665247|Other|Dream discussion|
288805|NCT00198822|Dietary Supplement|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
288806|NCT02665260|Drug|Cantharidin|cantharidin 0.7% topical liquid
288807|NCT02665260|Drug|Placebo|Placebo topical liquid
288808|NCT02665273|Procedure|Greater occipital nerve block|Bilateral greater occipital nerve block
288809|NCT02665273|Procedure|Sham|0.5 cc of 0.5% bupivacaine injected intradermally
288810|NCT02667392|Procedure|Gait Training with Biofeedback|Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.
Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they "push off with their (paretic) leg to swing it forward" when the participant-specific pre-programmed threshold is exceeded.
284264|NCT02596490|Behavioral|Couple-Based Discussion Program|Attention control (AC) group takes part in a discussion program. Participants have 1 discussion session each week for 4 weeks with a trained interventionist. These will be one-on-one sessions. All discussion sessions videotaped.
288213|NCT02677155|Biological|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
288214|NCT02677155|Biological|GM-CSF|Subcutaneous injection of 50 ug
288215|NCT02677155|Biological|Pembrolizumab|Intravenous infusion of 200 mg
288505|NCT02672332|Drug|Placebo (vehicle)|Placebo comparator
288506|NCT02672345|Drug|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
288507|NCT02672358|Drug|Dabrafenib|Oral Dabrafenib 150 mg BID
288508|NCT02672358|Drug|Trametinib|Oral Trametinib 2 mg QD
288509|NCT00002534|Biological|anti-thymocyte globulin|
288510|NCT00199056|Drug|Methotrexate|
288511|NCT02672371|Device|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using 3 frequency intervals: 1-4 Hz, 8-12Hz and 60-90 Hz, 2) The intensity will vary between low (2 mA) to high (4-6 mA) frequency 3) The duration of the pulse be 200 µs 4) The interstimulation interval (ISI) will vary between 10 to 60 seconds of ON & OFF cycles. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
288512|NCT02672371|Device|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
288513|NCT02672384|Procedure|Dental examination and a point of care P. gingivalis test (GC-Corporation Japan)|Dental examination Study exams (oral and blood sample collection)
288514|NCT02672397|Behavioral|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
288515|NCT02672423|Drug|Abemaciclib Capsules (Reference Formulation)|Administered orally
288516|NCT02672423|Drug|Abemaciclib Tablet(s) (Test Formulation)|Administered orally
288517|NCT02672436|Drug|ENERGI-F703|
288518|NCT02672436|Drug|ENERGI-F703 matched vehicle|
259488|NCT00178074|Behavioral|total sleep deprivation|
259489|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
259490|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
259491|NCT02495844|Drug|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
259492|NCT02495857|Device|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
259776|NCT02491164|Other|BAC TWO|BAC TWO administration
259777|NCT02491164|Device|FE and Cellvizio viewer software|
259778|NCT02491177|Behavioral|cMM|Home visits from community mentor mothers
259779|NCT00177359|Behavioral|gait intervention|
259780|NCT02491177|Behavioral|Text Messaging|Text messages received on mobile phone
259781|NCT02491190|Behavioral|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
259782|NCT02491203|Other|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
259783|NCT02491216|Other|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
259784|NCT02491229|Other|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
259785|NCT02491229|Other|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
259786|NCT02491242|Other|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
259787|NCT02491255|Device|Lotus Valve System|Device: Lotus Valve System
259788|NCT02491268|Drug|Cilostazol|
259789|NCT02491268|Drug|Placebo|
259790|NCT00177372|Drug|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
264045|NCT00158418|Procedure|Cemented Humeral Stem|
264046|NCT02354664|Other|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
264047|NCT02354677|Other|In vitro experiments on bronchial epithelial cells|
264048|NCT02354690|Drug|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
264049|NCT02354690|Drug|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
264050|NCT02354690|Drug|TIL infusion|7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.
On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells).
264051|NCT02354690|Drug|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
264052|NCT02354703|Drug|Ondansetron|Ondansetron (4 mg) bid+ BBCET counseling
264053|NCT02354703|Drug|Placebo|Placebo (4mg) bid + BBCET counseling
259493|NCT02495857|Device|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
259494|NCT02495857|Device|Placebo|0.9% sodium chloride, sterile
259495|NCT02495870|Other|Pork|
259496|NCT02495883|Other|Ethanol|50ml of 40% Ethanol
259497|NCT02495883|Drug|Propranolol|Beta blocker
259498|NCT02495896|Drug|Cisplatin|Given IV
259499|NCT00002481|Drug|etoposide|
259500|NCT00178074|Procedure|PET imaging|
259501|NCT02497898|Biological|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
259502|NCT02497911|Procedure|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
259503|NCT02497911|Procedure|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
263746|NCT02362126|Device|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
263747|NCT02362139|Drug|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
263748|NCT02362152|Drug|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
263749|NCT02362152|Drug|5-fluorouracil|Topical field treatment as prescribed by dermatologist
263750|NCT02362152|Drug|Imiquimod|Topical field treatment as prescribed by dermatologist
263751|NCT02362152|Drug|Diclofenac|Topical field treatment as prescribed by dermatologist
263752|NCT02362165|Drug|Cyclophosphamide|500mg/d,once-weekly,per oral.
263753|NCT02362165|Drug|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
263754|NCT00159211|Drug|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
263755|NCT02362165|Drug|Dexamethasone|40mg/d,once-weekly,per oral
263756|NCT02362165|Drug|Doxorubicin|9mg/㎡,d1-4
263757|NCT02362178|Procedure|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time>40 mm and/or platelets (PLTs 10 units/Kg) for MA<30 mm
263758|NCT02362178|Procedure|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR>1.8 and/or PLTS (10 units/Kg) If PLTs count < 50000/μl
264054|NCT02354716|Device|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions & function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- & post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, & what characteristics determine & predict refractory & recurrent strictures.
264055|NCT02357147|Drug|Placebo|Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.
Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression.
264056|NCT02357147|Drug|Amatuximab|Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.
Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression.
264057|NCT02357147|Drug|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
263166|NCT02373904|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
263460|NCT00159692|Drug|Amlodipine|
263461|NCT02366910|Device|omafilcon A|Two contact lenses will be randomized to right and left eyes (contra lateral wear) according to the randomization table
263462|NCT02366910|Device|delefilcon A|Two contact lenses will be randomized to right and left eyes (contra lateral wear) according to the randomization table
263463|NCT02366923|Device|stenfilcon A|Two contact lenses will be randomized to right and left eyes (contra lateral wear) according to the randomization table
263464|NCT02366923|Device|delefilcon A|Two contact lenses will be randomized to right and left eyes (contra lateral wear) according to the randomization table
263465|NCT02366936|Device|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
263466|NCT02369107|Other|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
263467|NCT02369120|Other|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
263468|NCT02369120|Other|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
263469|NCT02369133|Drug|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
263470|NCT02369133|Drug|Placebo|
263471|NCT02369146|Drug|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
263472|NCT02369159|Drug|Peramivir|
263473|NCT00159913|Drug|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
263474|NCT02369159|Drug|Oseltamivir|
262882|NCT02380664|Behavioral|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
262883|NCT02380677|Drug|CRLX301|
262884|NCT02380690|Behavioral|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
262885|NCT00161356|Drug|Ambisome|5mg/kg IV - one time dose during liver transplant
263167|NCT02373930|Drug|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
263168|NCT02373930|Drug|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
263169|NCT00160407|Drug|Orlistat (Xenical)|
263170|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
263171|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
263172|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
263173|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
263174|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
263175|NCT02373943|Other|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
263176|NCT02375828|Drug|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
263177|NCT02375841|Behavioral|psychometric tests, questionnaires and neurocognitive assessments|
263178|NCT00160667|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening of Brivaracetam 400 mg/day in a double-blinded way for the 4-week treatment period
263179|NCT02375854|Other|Observation|
263180|NCT02375867|Drug|prednisolone|Oral administration of 1-2 mg/Kg/day
262598|NCT02499107|Dietary Supplement|Fried french fries treatment|
262599|NCT02499120|Drug|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
262600|NCT02499120|Drug|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
262601|NCT00178555|Device|DCI Video Intubation System-Macintosh Laryngoscope|
262602|NCT02499120|Drug|Placebo|Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.
Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
262886|NCT02380703|Behavioral|Aggression Prevention Training (APT)|
262887|NCT02380703|Other|Enhanced Usual Primary Care (EU-PC)|
262888|NCT02380729|Genetic|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
262889|NCT02380729|Genetic|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
262890|NCT02380742|Drug|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
262891|NCT02380742|Drug|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
262892|NCT02380755|Drug|Clomiphene Citrate|50 mg orally daily during 12 weeks
262893|NCT02380755|Drug|Placebo|1 pill orally daily during 12 weeks
262894|NCT02383017|Dietary Supplement|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
262895|NCT02383017|Dietary Supplement|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
262896|NCT02383030|Drug|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemothereapy
262611|NCT02499185|Other|serum creatinine measurement|Blood sample
262612|NCT00178555|Device|Macintosh Laryngoscope|
262613|NCT02499198|Drug|[D4]Nornicotine - Highest|Level equal to highest level of [D4]Nornicotine found in commercial tobacco based snuff
262614|NCT02499198|Other|[D4]Nornicotine - Mean|Level equal to mean level of [D4]Nornicotine found in commercial tobacco based snuff
262615|NCT02499198|Other|[D4]Nornicotine - Lowest|Level equal to lowest level of [D4]Nornicotine found in commercial tobacco based snuff
262616|NCT02499198|Other|[D4]Nornicotine - 50% Lowest|Level equal to 50% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
262617|NCT02501369|Behavioral|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
262618|NCT02501395|Other|No intervention, observational|
262619|NCT00178919|Drug|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
262620|NCT02501408|Device|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
262621|NCT02501421|Biological|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
262622|NCT02501421|Biological|Placebo|Buffer
262907|NCT02383121|Drug|Midodrine hydrochloride|
262908|NCT00002427|Drug|Stavudine|
262909|NCT00161603|Behavioral|Semi-structured, open-ended interviews|
262910|NCT02383147|Device|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
262911|NCT02383147|Device|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
262912|NCT02383160|Device|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
262913|NCT02383160|Device|Sham device|Placebo device with no active therapy
262336|NCT02469909|Other|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
262337|NCT00002472|Drug|cisplatin|
262338|NCT00174837|Drug|cisplatin|with concomitant radiation
262339|NCT02469909|Other|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
262340|NCT02469909|Procedure|immediate decannulation|the tracheostomy tube is removed at once
262341|NCT02469909|Procedure|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
262342|NCT02469922|Device|Positron emission tomography|
262343|NCT02469922|Radiation|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
262344|NCT02469935|Procedure|ultrasound|surgeon-performed ultrasound
262345|NCT02469948|Drug|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
262346|NCT02469961|Drug|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
262347|NCT02469961|Drug|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
262348|NCT02469961|Other|Interscalene block|Interscalene block is used for the main anesthetic for the case
262349|NCT00174850|Drug|Gaitril|
262350|NCT02469974|Drug|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
262623|NCT02501434|Drug|Continuous Low-Dose Intravenous Unfractionated Heparin Infusion (14 days)|Continuous intravenous infusion of a low-dose unfractionated heparin drip (Approximately 12 units/kg/hr over 14 days)
262624|NCT02501447|Behavioral|Guided audio-visual relaxation|
262625|NCT02501460|Other|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
262037|NCT02474251|Device|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
262038|NCT02474264|Other|Endothelial function assessment|reactive hyperemia index
262039|NCT02474264|Other|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
262040|NCT02474277|Other|30 sec chair stand test|diagnostic test for functional impairment
262041|NCT02476214|Behavioral|group prenatal care|Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.
There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse.
262042|NCT02476227|Procedure|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
262043|NCT02476240|Behavioral|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
262044|NCT00175656|Procedure|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
262045|NCT02476253|Drug|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
262046|NCT02476266|Other|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
262047|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
262048|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
262049|NCT02476292|Other|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
261426|NCT02485158|Drug|Alcohol|This is a within-subjects, double-blind, placebo controlled design. We administered oral alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
261725|NCT02478372|Drug|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
261726|NCT02478385|Other|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
261727|NCT02478398|Biological|MK-3641|
261728|NCT02478398|Biological|Placebo|
261729|NCT02480309|Device|Outpatient use of the MMPPC/DiAs system|An outpatient evaluation of the use of the MMPPC/DiAs system in day and night closed-loop control in adolescents and adults with type 1 diabetes over 2-3 days.
261730|NCT02480322|Procedure|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
261731|NCT02480335|Drug|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
261732|NCT02480348|Device|Polymer-free DES (Drug Eluting Stent)|
261733|NCT02480361|Device|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
261734|NCT02480374|Biological|GEN-1|
261735|NCT02480387|Drug|Ledipasvir/Sofosbuvir FDC|
261736|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
261737|NCT00176267|Drug|Carboplatin|AUC of 6 on Days 1 & 22
261738|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
261739|NCT02480413|Other|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
261740|NCT02480426|Device|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
261741|NCT02480426|Drug|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
261742|NCT02480439|Drug|TAK-648 Tablet|Tak-648 tablet.
261743|NCT02480439|Drug|TAK-648 Oral Solution|TAK-648 oral solution.
261147|NCT02491866|Other|to develop and validate a Computerized Adaptative Testing|Elaboration of a pool of items, based on literature review and interview with patients.
Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.
Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.
Metrological validation of the CAT.
Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients.
261148|NCT02491879|Drug|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
261149|NCT02491879|Other|Placebo|Placebo gel with a 2 g local use
261150|NCT02491892|Drug|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
261151|NCT02491905|Drug|HL tablet|
261152|NCT02491905|Drug|Placebo|
261153|NCT02491918|Procedure|cataract surgery|cataract surgery in children
261427|NCT02485158|Other|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
261428|NCT02485158|Other|Placebo drink|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol (added as a taste mask) to healthy volunteers as a control for when they received either amphetamine or THC.
261429|NCT02485171|Device|SAFEWALKER|Medical device walking aids.
261430|NCT00176774|Drug|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
261431|NCT02485184|Procedure|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
261432|NCT02485184|Drug|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
261433|NCT02485184|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
261434|NCT02487446|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
261435|NCT02487459|Biological|BPX-501|T cells transduced with CaspaCIDe suicide gene
261436|NCT02487459|Drug|AP1903|dimerizer drug administered to treat GVHD
261437|NCT02487472|Other|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
260873|NCT02498366|Other|physical tests|each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.
day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3.
260874|NCT02498379|Drug|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu[64]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
260875|NCT00178438|Device|Capsule Endoscopy|
260876|NCT02498392|Drug|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
260877|NCT02498392|Other|Placebo|Matching Placebo will be administered orally.
260878|NCT02498418|Drug|Rifaximin 200mg Tablet|Generic rifaximin tablets
260879|NCT02498418|Drug|Xifaxan 200mg Tablet|Brand reference standard for comparison
260880|NCT02498418|Drug|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin
260881|NCT02498431|Procedure|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
260882|NCT02498431|Procedure|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
261154|NCT02491918|Procedure|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
261155|NCT02491931|Dietary Supplement|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
261156|NCT00177489|Behavioral|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
261157|NCT02491944|Drug|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
261158|NCT02491944|Drug|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of [14C] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
261159|NCT02494193|Other|Definitive restoration|Definite restoration will be performed using composite.
261160|NCT02494206|Drug|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
284869|NCT02583139|Behavioral|Designed Music Narratives|Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.
The narrative and music reflect and support each other.
284870|NCT02583165|Biological|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
284871|NCT02583178|Device|Aegis Sentinel Ligation System|
284872|NCT02583191|Drug|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
284873|NCT02585180|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
284874|NCT00189709|Drug|fluconazole|IV
284875|NCT02585180|Device|Endotracheal tubes allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
284876|NCT02585193|Behavioral|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
284877|NCT02585206|Behavioral|Personalization|Phase I Factor
Personalized text messages using the participant's username and gender ("Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!"). Both data points will be pulled from BecomeAnEX registration data.
284878|NCT02585206|Behavioral|Integration|Phase I Factor
Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:
Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community
Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online.
284879|NCT02585206|Behavioral|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
285170|NCT00188929|Procedure|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
285171|NCT02578758|Behavioral|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
284561|NCT02589938|Other|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
284562|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
284563|NCT02589951|Other|admission to non-psychiatric service|
284564|NCT02589964|Dietary Supplement|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
284565|NCT02589964|Other|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
284566|NCT00190489|Drug|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
284567|NCT02589977|Drug|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
284568|NCT02589990|Behavioral|Strength training|see arm description
284569|NCT02590003|Drug|Carboplatin|
284570|NCT02592096|Drug|Pazufloxacin mesilate injection|
284571|NCT02592109|Behavioral|Enhanced Counseling using CFR based on Linear Programming|
284572|NCT02592122|Drug|Salbutamol Aerosol|
284573|NCT02592122|Drug|No drugs|
284574|NCT02592135|Other|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
284575|NCT00190697|Drug|arzoxifene|
284576|NCT02592161|Drug|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)
Three times a day, oral administration for 24weeks
284577|NCT02592174|Other|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
284578|NCT02592174|Other|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
284579|NCT02592174|Radiation|cerebral images sub-study|Standard magnetic resonance imaging
284580|NCT02592187|Behavioral|ReMemory-MCI|
284265|NCT00191139|Drug|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
284266|NCT02596503|Drug|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
284267|NCT02596503|Drug|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
284268|NCT02596503|Other|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
284269|NCT02596529|Device|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
284270|NCT02596529|Other|NO Fixation|NO Fixation of the posterior malleolus.
284271|NCT02596542|Other|Water immersion|Different temperatures of cold water immersion will be assessed
284272|NCT02596555|Drug|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
284273|NCT02596568|Device|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
284274|NCT02596568|Other|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
284275|NCT02596581|Other|non-surgical periodontal treatment|scaling and root planing were performed
284276|NCT00002516|Drug|vincristine sulfate|
284277|NCT02598648|Other|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
284278|NCT02598648|Other|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
284279|NCT02598661|Drug|Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) of study drug given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
284280|NCT02598661|Drug|Placebo|Matching Placebo to Imetelstat will be administered.
284281|NCT02598674|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
288519|NCT02672449|Radiation|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
288520|NCT02672462|Device|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
288521|NCT02674906|Drug|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
288522|NCT02674919|Other|Nordic Hamstring|
288523|NCT02674919|Other|Control|
288811|NCT02667392|Procedure|Gait Training with Verbal Feedback|Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.
Verbal Feedback Group: Therapist-provided internal-focus feedback ("directed towards components of body movement") will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation.
288812|NCT00198978|Drug|Vincristine|
288813|NCT02667405|Procedure|Hot Pack|Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
288814|NCT02667405|Procedure|Whirlpool|Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
288815|NCT02667418|Drug|Fidaxomicin|200 mg PO twice daily for 10 days
288816|NCT02667418|Drug|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
288817|NCT02667418|Drug|Vancomycin|125 mg PO for times daily for 10 days
288818|NCT02667444|Drug|SB204 4%|Once daily
288819|NCT02667444|Drug|Placebo|Placebo comparator
288820|NCT02667457|Radiation|99mTc-rhAnnexin V-128|
288821|NCT02667470|Drug|Solifenacin|Oral
288822|NCT02667483|Drug|DS-5141b|DS-5141b, Subcutaneous injection
288823|NCT00198978|Drug|Depocyte|
259791|NCT02491281|Drug|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
259792|NCT02491281|Drug|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
259793|NCT02491294|Behavioral|School|students receive Cooking With Kids (CWK) - Colorado cooking & tasting lessons, SPARK active recess, and Cafeteria Connections
259794|NCT02491294|Behavioral|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
259795|NCT02491294|Behavioral|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
259796|NCT02491307|Other|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
260089|NCT02484612|Behavioral|acute exercise|
260090|NCT02484625|Other|Dietary treatment|Commercially available food products
260091|NCT02484638|Drug|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
260092|NCT02484638|Drug|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
260093|NCT02486978|Dietary Supplement|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
260094|NCT00176852|Radiation|Total Body Irradiation|300 cGY Day -1
260095|NCT02486991|Procedure|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
260096|NCT02486991|Procedure|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
260097|NCT02487004|Device|hemodialysis|
260098|NCT02487017|Procedure|Transcatheter Arterial Chemoembolization (TACE)|Transcatheter Arterial Chemoembolization (TACE):
5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min
260099|NCT02487017|Biological|DC-CIK|Transcatheter Arterial Chemoembolization (TACE):
5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min
DC-CIK:
8×10^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32
260100|NCT02487030|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
260101|NCT02487030|Drug|RBV|RBV tablets administered orally in a divided daily dose based on weight (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
259504|NCT02497911|Drug|Ropivicaine|
259505|NCT02497911|Drug|Bupivicaine|
259506|NCT00178373|Drug|Modafinil|
259507|NCT02497924|Drug|GBT440|GBT440 capsules followed by single dose of [C14] GBT440 oral suspension
259508|NCT02497937|Drug|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
259509|NCT02497937|Drug|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
259510|NCT02497950|Device|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
259511|NCT02497963|Procedure|Foreskin Graft-Tubularized Incised Plate|TIP Urethroplasty with foreskin graft in primary hypospadias
259512|NCT02497963|Procedure|Tubularized Incised Plate|TIP Urethroplasty without foreskin graft in primary hypospadias
259513|NCT02497976|Biological|Certolizumab pegol|400 mg
259514|NCT02497976|Drug|Placebo|Normal saline
259797|NCT02491320|Other|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
259798|NCT02491320|Drug|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
259799|NCT02493634|Procedure|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
259800|NCT02493634|Device|MRWire|
259801|NCT02493647|Behavioral|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
259802|NCT02493660|Device|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
259803|NCT02493660|Procedure|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
259804|NCT00177645|Procedure|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
264058|NCT02357147|Drug|Cisplatin|Combination Phase - Cisplatin 75 mg/m2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
264059|NCT02357160|Behavioral|Artwork|Prints by local artists that are hung on the walls of patient rooms.
264060|NCT02357173|Other|electronic cigarette|
264061|NCT00158639|Behavioral|Home BP;secure messaging;pharmaceutical care;|
264062|NCT02357173|Other|cigarette group|
264063|NCT02357199|Other|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
264064|NCT02357212|Procedure|coronary angiography|invasive procedure performed to determine coronary anatomy
264065|NCT02357212|Procedure|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
264066|NCT02357225|Drug|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
264067|NCT02357251|Other|Enhanced recovery protocol|
264068|NCT02357264|Device|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
264069|NCT02357277|Drug|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
264070|NCT02357277|Other|Placebo Inhaler|inhaled placebo
264071|NCT02357290|Drug|Open-label Treatment with N-Acetylcysteine|
264072|NCT00158652|Procedure|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
264073|NCT02357303|Drug|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
259515|NCT02497989|Other|Inter-personal Communication (IPC)|RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
263475|NCT02369172|Drug|Bupropion|
263476|NCT02369172|Drug|ASP2151|
263759|NCT02362191|Device|Alternating current stimulator|The stimulator used in this study was developed by the Frohlich lab and has been reviewed by the biomedical engineering department. The stimulator has multiple safety features and is considered to be non-significant risk.
263760|NCT02362204|Behavioral|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
263761|NCT02362217|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
263762|NCT02362217|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
263763|NCT02362217|Biological|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
263764|NCT02362217|Biological|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
263765|NCT00159224|Drug|Lopinavir/ritonavir simplification strategy|Simplification
263766|NCT02362230|Drug|Icotinib|Icotinib 125 mg BID
263767|NCT02364713|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
263768|NCT02364713|Drug|Paclitaxel|Given IV
263769|NCT02364713|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
263770|NCT02364713|Other|Quality-of-Life Assessment|Ancillary studies
263771|NCT02364713|Drug|Topotecan Hydrochloride|Given IV
263772|NCT02364726|Procedure|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
263773|NCT02364726|Behavioral|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session on the same day as the last chemotherapy.
263774|NCT02364726|Behavioral|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session on the same day as the last chemotherapy.
263181|NCT02375867|Drug|methylprednisolone|Intravenous injection of 10 mg/kg/day
263182|NCT02375867|Drug|growth hormone|Subcutaneous injection of 0.1-0.2 i.u./kg/day
263183|NCT02375867|Drug|growth hormone plus prednisolone|Subcutaneous injection of growth hormone 0.1-0.2 i.u./kg/day Plus Oral administration of prednisolone 1-2 mg/Kg/day
263184|NCT02375867|Drug|growth hormone plus methylprednisolone|Subcutaneous injection of growth hormone 0.1-0.2 i.u./kg/day Plus Intravenous injection of methylprednisolone 10 mg/kg/day
263185|NCT02375880|Drug|DKN-01|Administration by intravenous (IV) infusion.
263186|NCT02375880|Drug|gemcitabine|Administered by IV infusion.
263477|NCT02369198|Drug|TargomiRs|TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.
TargomiRs are IV injected.
263478|NCT02369211|Drug|Acetaminophen (Ofirmev)|
263479|NCT02369211|Drug|Placebo|
263480|NCT02369250|Drug|Rosuvastatin|Rosuvastatin, is a statin group of drug.
263481|NCT02369250|Biological|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
263482|NCT02369276|Other|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
263483|NCT02369289|Other|bone mineral density test|
263484|NCT00002419|Drug|Adefovir dipivoxil|
263485|NCT00159913|Drug|Placebo|oral; 3 times a day(TID)
263486|NCT02369302|Drug|DWC20141|Tablet
263487|NCT02369302|Drug|DWC20142|Tablet
263488|NCT02369302|Drug|DWC20141, DWC20142|Tablet
263489|NCT02371798|Drug|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
263490|NCT02371811|Device|uterine manipulator (v care)|
263491|NCT00160225|Drug|Daglutril|
262897|NCT00161590|Drug|CHOP and alemtuzumab|
262898|NCT02383043|Drug|Cocaine|
262899|NCT02383043|Drug|Sustained Release d-Amphetamine|
262900|NCT02383056|Device|Omnilux|633nm
262901|NCT02383069|Other|Intervention Group|Aerobic training
262902|NCT02383069|Other|Control Group|Chest physiotherapy: Flutter and muscle stretching
262903|NCT02383095|Behavioral|Art therapy|
262904|NCT02383095|Behavioral|metacognitive therapy|
262905|NCT02383108|Drug|EVG +DRV/r|
262906|NCT02383108|Drug|SOC|
263187|NCT02375880|Drug|cisplatin|Administered by IV infusion
263188|NCT02375893|Other|No intervention|Collecting blood and feces samples
263189|NCT00160680|Drug|Levocetirizine|
263190|NCT02375893|Other|Healthy subject|Collecting blood and feces samples
263191|NCT02375919|Other|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
263192|NCT02375932|Behavioral|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
263193|NCT02375932|Behavioral|Usual Care Control|Patients continue to receive usual care from their primary care provider
263194|NCT02375945|Device|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
263195|NCT02375945|Device|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
263196|NCT02375958|Drug|PCA062|
263197|NCT02375971|Drug|Ranibizumab|0.2 mg Intravitreal administration Administration in both eyes on day 1 Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
263198|NCT02375971|Drug|Ranibizumab|0.1 mg Intravitreal administration Administration in both eyes on day 1 Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
262914|NCT02383173|Other|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
262915|NCT02383173|Other|Enhanced Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-"champion" workshops to prepare PCCT members to be leaders and trainers at their home sites
262916|NCT02383186|Procedure|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
262917|NCT02383186|Procedure|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
262918|NCT02383212|Drug|REGN2810|
262919|NCT02383212|Radiation|Hypofractionated radiotherapy|
262920|NCT02385474|Drug|12% SDF|12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
262921|NCT02385474|Drug|38% SDF|38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
262922|NCT02385500|Drug|Fesoterodine|For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.
For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.
The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
262923|NCT02385500|Drug|Placebo|For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.
For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.
The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
262924|NCT02385513|Biological|10-valent pneumococcal conjugate vaccine|
262925|NCT02385526|Device|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
263209|NCT02378389|Drug|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
263210|NCT02378402|Other|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
263211|NCT02378415|Drug|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
263212|NCT02378415|Drug|Placebo|Normal Saline Infusion
262626|NCT02501460|Other|Resistance training|Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).
Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed.
262627|NCT02501460|Dietary Supplement|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
262628|NCT02501460|Other|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
262629|NCT02501473|Drug|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
262630|NCT00178919|Drug|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
262631|NCT02501473|Drug|Pembrolizumab|PD-1 Inhibitor
262632|NCT02501486|Other|ACTH stimulation test|An ACTH stimulation test will be done
262633|NCT02501499|Other|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
262634|NCT02501525|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
262635|NCT02501525|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
262636|NCT02501538|Device|TransCu O2 device|A portable device that delivers continuous diffusion of oxygen.
262637|NCT02467816|Behavioral|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
262638|NCT02467816|Behavioral|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
262639|NCT00000367|Behavioral|Suicide prevention intervention|
262640|NCT00002471|Drug|therapeutic hydrocortisone|
262050|NCT02476305|Device|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
262051|NCT02476318|Device|ArterX Vascular Sealant|
262351|NCT02472262|Dietary Supplement|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
262352|NCT02472262|Dietary Supplement|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
262353|NCT02472275|Drug|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
262354|NCT02472275|Other|Laboratory Biomarker Analysis|Correlative studies
262355|NCT02472275|Drug|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
262356|NCT02472275|Radiation|Radiation Therapy|Undergo radiation therapy
262357|NCT02472288|Device|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
262358|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
262359|NCT02472288|Device|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
262360|NCT02472301|Dietary Supplement|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
262361|NCT02472301|Dietary Supplement|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
262362|NCT02472301|Dietary Supplement|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
262363|NCT02472314|Drug|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
262364|NCT02472314|Drug|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
261744|NCT02480465|Drug|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
261745|NCT02480465|Drug|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
261746|NCT02480491|Other|measuring cell freeDNA|measuring cell free DNA using PCR
262052|NCT02476331|Behavioral|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
262053|NCT02476344|Other|experiment protocol|each subject will perform the following 3 days experiment protocol, consisting of army training exercises:
sack carrying exercise.
crawling exercise.
combined exercise: sack carrying, crawling and sprints.
heart rate, core temperature, lactic acid and CPK levels will be monitored continuously.
262054|NCT02476357|Device|Harmonic scalpel|
262055|NCT00002474|Procedure|autologous bone marrow transplantation|
262056|NCT00175669|Drug|Botox injections|Data not known.
262057|NCT02478398|Drug|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for rescue medication
262058|NCT02478398|Drug|Albuterol/Salbutamol|Inhalation albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed for rescue medication
262059|NCT02478398|Drug|Loratadine|Oral syrup at doses of 5 mg (1 mg/mL syrup) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rescue medication
262060|NCT00002475|Biological|autologous tumor cell vaccine|
262061|NCT00175968|Procedure|bed rest, hypocaloric nutrition|
262062|NCT02478398|Drug|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rescue medication
262063|NCT02478398|Drug|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rescue medication
262064|NCT02478411|Procedure|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
262065|NCT02478411|Procedure|Conventional physiotherapy|30 minutes of conventional physiotherapy
261438|NCT02487485|Drug|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions—once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
261439|NCT02487485|Drug|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
261440|NCT02487485|Drug|Placebo|Placebo oral dose
261441|NCT02487498|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
261442|NCT02487498|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
261443|NCT00176891|Procedure|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
261444|NCT02487498|Drug|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
261445|NCT02487498|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
261446|NCT02487511|Other|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
261747|NCT02480504|Other|dietary intervention intermittent energy restriction|Randomized clinical trial
261748|NCT00176280|Drug|Leukine|
261749|NCT02480504|Other|continuous energy restriction|
261750|NCT02480517|Device|Ultrasound|
261751|NCT02480517|Device|Sham Ultrasound|
261752|NCT02480530|Behavioral|Individual Feedback|Patient gets feedback reports on adherence weekly.
261753|NCT02480530|Behavioral|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
261754|NCT02480543|Drug|Misoprostol (cytotec)|
261755|NCT02483039|Behavioral|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
261756|NCT02483052|Device|RejuvenAir|RejuvenAir
261161|NCT02494219|Procedure|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
261162|NCT02494245|Other|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
261163|NCT02494258|Drug|CC-486|The subject will continue at the same dose, frequency and schedule used for the last dose of CC-486 given in the preceding CC-486 study. Subjects are allowed to rollover after the last cycle is finished and before the new cycle begins in the parent protocol. There is a 7 day window from End of Study on the parent protocol and when the participant will start Day 1 of the rollover study.
261164|NCT02494284|Drug|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
261165|NCT02494284|Drug|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
261166|NCT02494310|Device|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
261167|NCT02494323|Device|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
261168|NCT02494336|Procedure|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
261169|NCT00177749|Drug|Posaconazole|
261447|NCT02487524|Other|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
261448|NCT02487524|Other|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
261449|NCT02487524|Other|QST|Quantitative sensory testing.
261450|NCT02487537|Dietary Supplement|custom-made soft drink|
261451|NCT02487550|Biological|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
261452|NCT02487550|Biological|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
261453|NCT02487563|Drug|decitabine|decitabine, 15mg/m2 daily intravenously for 3 consecutive days
285172|NCT02578758|Behavioral|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
285173|NCT02580968|Drug|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
285174|NCT02580981|Other|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
285175|NCT02580994|Drug|Pembrolizumab|IV infusion at the dose of 200 mg on day 1
285176|NCT02580994|Drug|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
285177|NCT02581007|Drug|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
285178|NCT00189202|Drug|Sirolimus|
285179|NCT02581007|Drug|Melphalan|
285180|NCT02581007|Drug|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
285181|NCT02581007|Procedure|peripheral blood stem cell transplant|
285182|NCT02581033|Drug|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
285183|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
285450|NCT02678325|Other|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
285451|NCT02678338|Biological|Hu5F9-G4|
285452|NCT02678351|Drug|gallium Ga 68-PSMA|Undergo gallium Ga 68-PSMA PET/MRI
285453|NCT00002534|Radiation|low-LET photon therapy|
284581|NCT02592187|Behavioral|Active control training|
284582|NCT02592200|Dietary Supplement|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
284880|NCT02585206|Behavioral|Message Intensity|Phase I Factor
Varying levels of text message intensity over a 12-week period.
284881|NCT02585206|Behavioral|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
284882|NCT02585232|Behavioral|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
284883|NCT02585232|Behavioral|Care Consultation (CC)|Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the "initial assessment," which then immediately shapes development of concrete action plans.
284884|NCT02585258|Drug|Prednisolone|capsules 5 mg / day
284885|NCT00189722|Drug|Tacrolimus|
284886|NCT02585258|Other|Placebo|capsules 1 / day
284887|NCT02585271|Device|Transanal decompression tube|22 Fr transanal decompression tube
284888|NCT02585271|Device|Stent|self-expandable colorectal nitinol alloys stent
284889|NCT02585297|Other|no intervention|
284890|NCT02585310|Other|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
284891|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
284892|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
284893|NCT02587533|Other|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
284894|NCT02587533|Other|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
284895|NCT02587533|Other|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
284896|NCT02587533|Other|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
284282|NCT02598674|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
284583|NCT02592200|Dietary Supplement|Placebo|Two doses per day for 28 days
284584|NCT02592213|Procedure|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
284585|NCT02592226|Procedure|Anesthesia: alveolar recruitment maneuver|
284586|NCT00190710|Drug|Gemcitabine|
284587|NCT02592226|Procedure|Anesthesia: standardized|
284588|NCT02592239|Device|Functional brain MRI|Functional brain MRI before and after test meal ingestion
284589|NCT02592239|Dietary Supplement|A warm ham and cheese sandwich and a 200 ml fruit juice|
284590|NCT02592252|Behavioral|Participatory gender training|10 sessions of participatory gender training
284591|NCT02592252|Other|Microfinance|Microfinance loan
284592|NCT02592278|Drug|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
284593|NCT02592278|Drug|Control Group|Twice a day brush with fluoride toothpaste.
284594|NCT02592291|Device|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
284595|NCT02592304|Device|Dual energy computed tomography|one extra scanning with a dual energy ct.
284596|NCT02592317|Drug|JNJ 56021927|JNJ 56021927 will be adminitered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
284597|NCT00002516|Biological|dactinomycin|
284598|NCT02593955|Behavioral|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
284599|NCT02593955|Behavioral|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
284600|NCT02593968|Drug|Recombinant Human Interferon a-2b Gel|
284601|NCT02593968|Drug|Placebo|
288824|NCT02667496|Drug|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
288825|NCT02667496|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
288826|NCT02667496|Drug|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
288827|NCT02667522|Behavioral|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
288828|NCT02667535|Drug|Isosorbide Mononitrate|
288829|NCT02667548|Procedure|PCI|percutaneous coronary intervention
288830|NCT02667561|Drug|Testosterone|
288831|NCT02667574|Drug|ERIVEDGE|
284283|NCT02598674|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
284284|NCT02598674|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
284285|NCT00191295|Drug|Placebo|
284286|NCT02598674|Drug|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
284287|NCT02598687|Drug|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
284288|NCT02598687|Other|HX4 scan|HX 4 scan day 1 and day 8
284289|NCT02598687|Drug|Carboplatin|2mg/ml/min
284290|NCT02598687|Drug|Paclitaxel|50 mg/m2
284291|NCT02598687|Radiation|Radiotherapy|23 x 1.8 Gy
284292|NCT02598687|Procedure|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
284293|NCT02598713|Drug|Aspiration Marker|Instillation of Quinine, FD&C Blue N. 1 and FD&C Red N. 3 suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients every 12 hours for two consecutive days.
284294|NCT02598726|Biological|Curcumin|Given PO
260102|NCT02487043|Behavioral|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
260103|NCT02487069|Procedure|HSCT from SMD|HSCT from SMD is the first choice for the patients who have HLA-matched sibling donors.
260104|NCT02487069|Procedure|HSCT from MUR|HSCT from MUR is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
260105|NCT00176852|Procedure|Stem cell infusion|Given Day 0
260106|NCT02487069|Procedure|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
260107|NCT02487069|Drug|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
260108|NCT02487069|Drug|Methotrexate|CsA is used in all the patients for GVHD prophylaxis.
260399|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
260400|NCT00176241|Radiation|radiation|50-80 cGy on days 1,2,15,16
260401|NCT02482493|Device|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
260402|NCT02482506|Behavioral|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
260403|NCT02482506|Behavioral|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
260404|NCT02482519|Other|High calorie diet|High calorie diet for 10 days
260405|NCT02482519|Other|Fasting|10 day fast
260406|NCT02482532|Biological|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
259805|NCT02493673|Device|Continuous positive airway pressure device|(ResMed Spirit S8)
259806|NCT02493686|Other|n.a.|
259807|NCT02493699|Other|physical exercise- based intervention (Karate techniques training)|
259808|NCT02493712|Drug|High dose|6 capsules of IBD98-M, twice a day
259809|NCT02493712|Drug|Low dose|4 capsules of IBD98-M
259810|NCT02493712|Drug|Placebo|Placebo
259811|NCT02493725|Drug|Eculizumab|
259812|NCT02493725|Drug|Placebo|
259813|NCT02493738|Drug|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
259814|NCT02493738|Drug|Sporanox 100mg|Sporanox 100mg single dose under fed condition
259815|NCT00002481|Drug|cyclophosphamide|
259816|NCT00177671|Drug|Escitalopram|Escitalopram, 10mg to 20mg daily.
259817|NCT02493751|Drug|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
259818|NCT02493751|Drug|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
260109|NCT02487069|Drug|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MURD and HRD for GVHD prophylaxis.In MURD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
260110|NCT02487069|Drug|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from HRD for GVHD prophylaxis.
260111|NCT02487082|Drug|Melatonin and Donepezil|The duration depends on group assignment.
260112|NCT02487082|Other|Placebo|The duration depends on group assignment.
260113|NCT02487095|Drug|Topotecan|Topotecan (in combination with VX-970) administered by IV Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
260114|NCT02487095|Drug|VX-970|VX-970 (in combination with Topotecan) administered by IV Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
260115|NCT02487108|Drug|Hydrocodone bitartrate|5.0 mg, 7.5 mg, 10 mg
259516|NCT02497989|Other|Dedicated Service Outlets (DSO)|RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
259517|NCT00178373|Drug|sugar pill|
259518|NCT02498002|Device|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
259519|NCT02498002|Other|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
259520|NCT02498002|Other|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
259521|NCT02498002|Procedure|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
259522|NCT02500069|Other|Casein (in ileum)|infusion of protein in ileum
259523|NCT02500082|Drug|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
259524|NCT02500095|Other|Fasting|72 hours of fasting
259525|NCT02500095|Drug|Saline|Concomitant saline during fasting
259526|NCT02500095|Drug|Pegvisomant|Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
259527|NCT02500108|Drug|Domperidone|Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.
Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).
Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date).
259528|NCT00002482|Drug|cyclophosphamide|
259529|NCT00178698|Drug|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
259819|NCT02493764|Drug|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
259820|NCT02493764|Drug|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
263775|NCT00159419|Drug|Alendronate|10 mg po q day
263776|NCT02364739|Other|Written information|Brochure
263777|NCT02364739|Other|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
263778|NCT02364752|Procedure|Blood Draw|
264074|NCT02357303|Drug|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
264075|NCT02357303|Other|Placebo|100mL of water
264076|NCT02357342|Drug|Sirolimus|intravitreal injection
264077|NCT02357342|Drug|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
264078|NCT02357355|Device|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
264079|NCT02357368|Drug|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
264080|NCT00158873|Drug|midazolam|
264081|NCT02359539|Procedure|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
264082|NCT02359552|Drug|Rasagiline|
264083|NCT02359552|Drug|Placebo|
264084|NCT02359565|Procedure|Diffusion Tensor Imaging|Correlative studies
264085|NCT02359565|Procedure|Diffusion Weighted Imaging|Correlative studies
264086|NCT02359565|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
264087|NCT02359565|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
264088|NCT02359565|Other|Laboratory Biomarker Analysis|Correlative studies
264089|NCT02359565|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative studies
264090|NCT02359565|Biological|Pembrolizumab|Given IV
264091|NCT00158873|Drug|lorazepam|
263492|NCT02371824|Other|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
263493|NCT02371837|Other|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
263494|NCT02371850|Drug|Nicoderm CQ patch|This is a single-dose, Open-label, Non-Randomized, 2-way Crossover Pivotal Bioequivalence Study compaing nicotine release after heating in adult smokers
263495|NCT02371850|Drug|Aveva nicotine patch|This is a single-dose, Open-label, Non-Randomized, 2-way Crossover Pivotal Bioequivalence Study compaing nicotine release after heating in adult smokers
263496|NCT02371889|Drug|Topiramate|Max therapeutic dose of 200mg/day
263779|NCT02364752|Procedure|Loop Diuretic Withdrawal/Salt Load|
263780|NCT02364765|Drug|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
263781|NCT02364791|Device|standard techniques used to achieve air leak control|
263782|NCT02364791|Device|Hemopatch|
263783|NCT02364804|Drug|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
263784|NCT02364817|Behavioral|cognitive and psychiatric assessment|Administered at baseline:
Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)
hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)
psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)
cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)
impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)
alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.
administered at week 12: ASRS
263785|NCT02364830|Drug|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
263786|NCT00159419|Drug|Pamidronate|1mg/kg/day x 3days
263787|NCT02364830|Other|Placebo|One Placebo Capsule/Day for 4 Weeks
263788|NCT02364830|Drug|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
263789|NCT02366949|Drug|BAY 1217389|BAY 1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY 1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).
After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY 1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
In a higher dose level Cohort 4 > (or equal to) a relative bioavailability assessment of BAY 1217389 liquid capsule formulation compared to BAY 1217389 oral solution will be performed.
263199|NCT02375971|Procedure|Laser therapy|Treatment in both eyes on day 1 Supplementary laser treatments are allowed until 11 days after first treatment
263200|NCT00002423|Drug|Nelfinavir mesylate|
263201|NCT02378337|Other|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
263202|NCT02378350|Device|Hemodialysis treatment (no specific device is defined)|
263203|NCT02378350|Drug|Peritoneal Dialysis treatment (no specific drug is defined)|
263204|NCT02378363|Other|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
263205|NCT02378376|Dietary Supplement|Arabinoxylan oligosaccharides|
263206|NCT00002424|Drug|Indinavir sulfate|
263207|NCT00160992|Biological|Melan-A analog peptide|
263208|NCT02378376|Dietary Supplement|Dietary fiber enriched bran|
263497|NCT02371889|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
263498|NCT02371889|Drug|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
263499|NCT02371902|Device|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
263500|NCT02371902|Device|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
263501|NCT02371915|Other|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
263502|NCT00160238|Drug|Betahistine 24 mg bid (Betaserc)|
263213|NCT02378428|Drug|MIBG|
263214|NCT02378441|Drug|Atorvastatin|Group 1 receives Atorvastatin 20mg and Metformin SR 750mg first, then CJ-30056 second, with at 7-day wash-out period in between.
Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin SR 750mg second, with 7-day wash-out period in between.
263215|NCT02378441|Drug|Metformin|SR 750mg
263216|NCT02378441|Drug|CJ-30056|
263217|NCT02378454|Device|Comparison of two MBWN2 devices : "EasyOne Pro Lab" versus "Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
263218|NCT00161005|Procedure|PCI|Immediate transport to invasive center after thrombolysis
263219|NCT02378467|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
263220|NCT02378467|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
263221|NCT02378480|Drug|Omadacycline|Injection for IV dosing; Tablets for oral dosing
263222|NCT02378480|Drug|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
263223|NCT02378493|Biological|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
263224|NCT02378506|Biological|etanercept|50mg subcutaneous, once weekly, 24 weeks
263225|NCT02380768|Device|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
263226|NCT02380768|Device|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
263227|NCT00000128|Device|Bifocal Spectacle Lenses|
263512|NCT02373995|Biological|LAB4|Additional treatment with the specific LAB4 probiotic preparation
263513|NCT02374008|Drug|Ropivacaine|
263514|NCT02374021|Drug|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route and/or titrated up to 25mg/week.
263515|NCT02374021|Drug|Sulfasalazine|1 gm bid
262926|NCT02385539|Drug|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
262927|NCT02385552|Behavioral|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
262928|NCT02385565|Other|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
262929|NCT00161967|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
262930|NCT02385565|Other|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
262931|NCT02385578|Other|an educational intervention|the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation "hand in hand" teach by Professor Yano Takeshiin,and the case discussion,and so on
262932|NCT02385591|Behavioral|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
262933|NCT02385591|Behavioral|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
262934|NCT02385617|Drug|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
262935|NCT02385617|Drug|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
262936|NCT02385630|Other|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
262937|NCT02385643|Behavioral|SmartPhone Support System|
262938|NCT02385656|Drug|Modafinil|200mg of modafinil daily for 4 weeks
262939|NCT02385669|Drug|Ipilimumab|Checkpoint blockade inhibitor
262940|NCT00161980|Drug|Fibrin Sealant VH S/D|
262941|NCT02388009|Biological|Flexyn2a|Intramuscular doses of 0.5 mL
262942|NCT02388009|Biological|Placebo|Intramuscular doses of 0.5 mL
262943|NCT02388009|Biological|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
262944|NCT02388022|Device|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
262365|NCT02472327|Behavioral|Pre-operative support|
262366|NCT02472340|Procedure|Muscle Biopsy|Muscle Biopsy
262367|NCT02472353|Drug|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
262368|NCT02472353|Drug|Doxorubicin|Standard of care treatment with doxorubicin
262641|NCT00174642|Drug|Insulin Glargine|One daily injection in the evening. 100 U/ml
262642|NCT02467829|Device|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
262643|NCT02467842|Biological|NBP607-QIV(Quadrivalent)|0.5ml, intramuscular, a single dosing at Day 0
262644|NCT02467842|Biological|NBP607-Y(Trivalent)|0.5ml, intramuscular, a single dosing at Day 0
262645|NCT02467842|Biological|NBP607-V(Trivalent)|0.5ml, intramuscular, a single dosing at Day 0
262646|NCT02467855|Other|No Intervention|No intervention was administered in this study.
262647|NCT02467868|Biological|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
262648|NCT02467868|Biological|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
262649|NCT02467881|Behavioral|Physical Activity Increase (GLB-MOD)|The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.
The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.
The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression.
262650|NCT02467881|Behavioral|Sedentary Time Decrease (GLB-SED)|As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.
The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression.
262651|NCT02467881|Other|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
262652|NCT00174642|Drug|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
262066|NCT02478424|Drug|Cannabidiol|Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.
Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100.
262067|NCT02478424|Drug|cyclosporine|
262068|NCT02478424|Drug|Methotrexate|
262069|NCT02478437|Procedure|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
262369|NCT00175058|Device|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
262370|NCT02472366|Drug|ILUVIEN|
262371|NCT02472379|Behavioral|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
262372|NCT02474290|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
262373|NCT00175357|Drug|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
262374|NCT02474303|Drug|Truvada|Demonstration Study
262375|NCT02474316|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
262376|NCT02474316|Drug|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
262377|NCT02474329|Other|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.ors) for every included patient. This assessment will last for 60 minutes, and it will be done once.
262378|NCT02474329|Device|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
262379|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|Study drugs: Autologous adipose tissue derived MSCs
Injection dosage and volume of the study drugs:
Low dose: 1x10e7 cells/3mL
Number of injections : only once during the study period
Device: Ultrasound
Injection technique: Injection into the lesion by investigator
262380|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|Study drugs: Autologous adipose tissue derived MSCs
Injection dosage and volume of the study drugs:
Mid dose: 5x10e7 cells/3mL
Number of injections : only once during the study period
Device: Ultrasound
Injection technique: Injection into the lesion by investigator
261757|NCT02483065|Other|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
261758|NCT02483078|Drug|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
261759|NCT02483078|Drug|Placebo|
261760|NCT02483078|Drug|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
261761|NCT02483091|Behavioral|Multifaceted KT intervention|The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.
After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.
The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months.
261762|NCT02483104|Drug|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
261763|NCT00176514|Drug|Administration of the antineoplastic|
261764|NCT02483104|Drug|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
262070|NCT02478437|Procedure|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
262071|NCT02478450|Biological|Q-Cells|
262072|NCT00175981|Drug|sildenafil, fluvoxamine|
262073|NCT02478463|Drug|Cabotegravir tablet 30 mg once daily for 28 days.|Cabotegravir will be supplied as 30 mg tablet. Each tablet appears as white to almost white coated oval tablet and contains GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876.
262074|NCT02478463|Drug|Cabotegravir injection 400 mg/2mL (2 x 400 mg split injection) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 400 mg/2mL vial. Each vial appears as sterile white to slightly colored suspension containing 400 mg/2 mL of CAB for administration by intramuscular (intragluteal) injection.
262075|NCT02478489|Drug|Oral naltrexone|oral naltrexone
262076|NCT02478489|Drug|extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
261454|NCT00176891|Drug|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
261455|NCT02487563|Drug|rhTPO|rhTPO, 300U/Kg, subcutaneous injection，qd x 18d
261456|NCT02487576|Other|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
261457|NCT02487576|Other|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
261458|NCT02489461|Drug|Efavirenz|Efavirenz up to 48 weeks
261459|NCT02489461|Drug|Antiretroviral therapy (ART)|ART up to 48 weeks
261460|NCT02489487|Drug|VM-1500|VM-1500 40 mg
261461|NCT02489487|Drug|Darunavir|Darunavir 600 mg
261462|NCT02489487|Drug|Ritonavir|Ritonavir 100 mg
261463|NCT00177164|Drug|Injectable Risperidone (Consta) or oral antipsychotic|Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks
Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder
261464|NCT02489487|Drug|Raltegravir|400 mg Raltegravir
261465|NCT02489500|Drug|Bortezomib|Conditioning Regimen:
Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1
261466|NCT02489500|Drug|Melphalan|Conditioning Regimen:
Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0
261467|NCT02489500|Drug|Neupogen|GCSF mobilization 16mcg/kg x 4 days
261468|NCT02489500|Procedure|Stem Cell Collection|collect at least 2.5 million CD34+ stem cells
261469|NCT02489500|Procedure|Stem cell infusion|infusion of previously collected autologous stem cells
261470|NCT02489513|Drug|[14C]-AG-120|Labeled investigational drug
261765|NCT02483104|Drug|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
261766|NCT02483117|Other|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
285454|NCT00199238|Drug|RUPATADINE (ANTI-HISTAMINE)|
285455|NCT02678351|Procedure|Magnetic Resonance Imaging|Undergo gallium Ga 68-PSMA PET/MRI
285456|NCT02678351|Procedure|Positron Emission Tomography|Undergo gallium Ga 68-PSMA PET/MRI
285457|NCT02678364|Dietary Supplement|Control eggs|Control eggs containing no additional vitamin D beyond norm
285458|NCT02678364|Dietary Supplement|Vitamin D3 eggs|Vitamin D3-biofortified eggs
285459|NCT02680600|Other|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
285460|NCT02680600|Other|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
285461|NCT02680600|Other|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
285462|NCT02680600|Other|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
285463|NCT02680613|Behavioral|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
285464|NCT02680613|Behavioral|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
285465|NCT00002535|Biological|therapeutic tumor infiltrating lymphocytes|
285466|NCT00199641|Device|enteral nutrition|
285467|NCT02680626|Drug|Magnesium Sulfate|Given via transversus abdominis plane block
285728|NCT02671188|Drug|GSK3050002|The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
284897|NCT00190138|Device|Bi-ventricular pacing|
284898|NCT02587546|Procedure|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
284899|NCT02587546|Procedure|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
284900|NCT02587546|Procedure|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
285184|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
285185|NCT02581046|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
285186|NCT02581059|Drug|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
285187|NCT02581059|Dietary Supplement|Ginseng|Subjects randomized to ginseng will receive 2,000 mg orally once every day of each 28-day cycle for 2 cycles.
285188|NCT02581072|Drug|SB204|therapeutic dose of SB204
285189|NCT00189215|Device|cardiac stabilizer instead of cardiopulmonary bypass|
285190|NCT02581072|Drug|SB204 8% or 12%|Supratherapeutic dose
285191|NCT02581072|Drug|Moxifloxacin|
285192|NCT02581072|Drug|Placebo|
285193|NCT02581085|Dietary Supplement|Tocotrienol|Vitamin E is a dietary supplement. Vitamin E is a fat-soluble vitamin that exists in eight different forms. Each form has its own biological activity, which is the measure of potency or functional use in the body. Vitamin E is a dietary antioxidant that assists in maintaining cell integrity. It is obtained from sunflower, safflower, canola, and olive oils; also from many grains, nuts, fruits as well as fatty parts of meats. The tocotrienol form of natural vitamin E is found in rice and cereals but more abundantly in palm oil. Palm oil is an integral part of daily diet in southeastern Asia
285194|NCT02581085|Other|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
285195|NCT02583191|Drug|low-molecular heparine|LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.
Enoxaparin 1 mg/kg BW twice daily
Tinzaparin 175 I.E./kg BW once daily
Dalteparin 200 I.E./kg BW once daily
285196|NCT02583204|Device|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
284602|NCT02593981|Dietary Supplement|Group 1: Fruit/Honey product|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
284603|NCT02593981|Dietary Supplement|Group 2: Placebo product|2 canisters of powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
284604|NCT00190918|Drug|Pemetrexed|
284605|NCT02593994|Device|Onyx Drug Eluting Stent group|
284901|NCT02587559|Procedure|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
284902|NCT02587572|Biological|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
284903|NCT02587585|Behavioral|Feedback of daily activity|Participants will wear a smart watch every weekday during in-patient rehabilitation to monitor activity levels while receiving their usual care. Augmented feedback will be provided by the smart watch
284904|NCT02587598|Drug|INCB053914|Initial cohort dose of INCB053914 at the protocol-specified starting dose in three treatment groups in dose escalation, with subsequent cohort escalations in the four treatment groups based on protocol-specific criteria.
INCB053914 tablets to be administered by mouth.
284905|NCT02587611|Other|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
284906|NCT02587611|Other|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
284907|NCT02587624|Procedure|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
284908|NCT00190151|Drug|ciprofloxacin|
284909|NCT02587637|Device|Dorsal Root Ganglion Stimulation|
284910|NCT02587650|Drug|INC280|
284911|NCT02587650|Drug|Ceritinib|
284912|NCT02587650|Drug|Regorafenib|
284913|NCT02587650|Drug|Entrectinib|
284914|NCT02587663|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
284915|NCT02587663|Procedure|Mammography|Undergo bilateral mammography
284295|NCT02598726|Other|Laboratory Biomarker Analysis|Correlative studies
284296|NCT00191308|Drug|pemetrexed|500 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
284297|NCT02598726|Biological|Piperine Extract (Standardized)|Given PO
284298|NCT02598726|Other|Quality-of-Life Assessment|Ancillary studies
284299|NCT02600845|Device|ACCU-CHEK AVIVA CONNECT|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK aviva connect blood gucose monitoring system, ACCU-CHEK connect diabetes management app, ACCU-CHEK connect online diabetes management system.
284300|NCT02600858|Behavioral|Upper limb feeding training|Participants will spoon two raw kidney beans at a time from a center proximal "start" cup to three distal "target" cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days.
284301|NCT02600871|Drug|Provodine|
284302|NCT02600871|Procedure|Incision and Drainage|
284606|NCT02594007|Device|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
284607|NCT02594007|Device|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
284608|NCT02594007|Device|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
284609|NCT02594020|Procedure|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
284610|NCT02594020|Procedure|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
284611|NCT02594020|Procedure|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
284612|NCT02594033|Drug|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
284613|NCT02594046|Other|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
284614|NCT02594059|Other|endothelial function|measure of reactive hyperemia-peripheral artery tone index
284615|NCT00190931|Drug|Atomoxetine Hydrochloride|
284616|NCT02594072|Radiation|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
260407|NCT02482545|Dietary Supplement|Meal replacement|
260408|NCT02482558|Other|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
260409|NCT02482571|Device|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from ~21% (room air) to ~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic MRI (fMRI) and spectroscopy (fMRS) while they are presented with visual stimuli.
260410|NCT02482584|Device|CPAP|CPAP intervention
260411|NCT00176462|Drug|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
260412|NCT02482584|Other|Control|Control
260676|NCT02477865|Drug|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
260677|NCT02477865|Drug|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
260678|NCT02477865|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
260679|NCT02477878|Biological|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
260680|NCT00175903|Drug|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
260681|NCT02477878|Drug|AP1903|AP1903 administered to treat GVHD
260682|NCT02477891|Drug|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
260683|NCT02477904|Other|Ketogenic Diet|Dietary
260684|NCT02477917|Biological|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
260685|NCT02477930|Other|No interventions are done|No intervention is done. This is a registry study.
260686|NCT02477943|Device|BrainScope Battery|The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement.
260116|NCT00176865|Procedure|Stem Cell Transplant|Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
260117|NCT02488980|Drug|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
260118|NCT02488980|Drug|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
260119|NCT02488980|Drug|Placebo|Placebo
260120|NCT02488993|Other|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
260121|NCT02488993|Other|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
260122|NCT02488993|Other|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
260123|NCT02489006|Drug|Olaparib|
260124|NCT02489006|Drug|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
260125|NCT02489019|Drug|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
260126|NCT02489019|Drug|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
260127|NCT00177086|Other|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
260128|NCT02489032|Behavioral|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
260129|NCT02489032|Other|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
260413|NCT02482597|Device|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
260414|NCT02482610|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
260415|NCT02482610|Other|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
260416|NCT02482610|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
260417|NCT02482623|Behavioral|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
259821|NCT02493764|Drug|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
259822|NCT02493764|Drug|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
259823|NCT02493764|Drug|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
259824|NCT02493764|Drug|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
259825|NCT02495896|Drug|Docetaxel|Given IV
259826|NCT02495896|Drug|Gemcitabine Hydrochloride|Given IV
259827|NCT02495896|Other|Laboratory Biomarker Analysis|Correlative studies
259828|NCT02495896|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
259829|NCT02495896|Other|Pharmacological Study|Correlative studies
259830|NCT02495896|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
259831|NCT02495922|Drug|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
259832|NCT02495922|Drug|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
259833|NCT02495922|Drug|Bortezomib|all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
259834|NCT02495922|Drug|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).
8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).
20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).
12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2).
259835|NCT00178100|Behavioral|Interpersonal Psychotherapy|
259836|NCT02495948|Device|Lotrafilcon B contact lenses|
259837|NCT02495948|Device|Samfilcon A contact lenses|
259838|NCT02495974|Drug|enzalutamide|oral
264092|NCT02359565|Procedure|Perfusion Magnetic Resonance Imaging|Correlative studies
264093|NCT02359578|Drug|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
264094|NCT02359591|Other|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
264095|NCT02359604|Drug|PPI therapy|PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.
The medication used (esomeprazole) in this trial is approved by the FDA
264096|NCT02359604|Procedure|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
264097|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
259530|NCT02500121|Other|Placebo|Normal saline
259531|NCT02500121|Drug|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
259532|NCT02500134|Other|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
259533|NCT02500147|Drug|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
259534|NCT02500147|Drug|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
259535|NCT02500160|Device|Patient specific instrumentation (MRI)|
259536|NCT02500160|Device|Patient specific instrumentation (CT)|
259537|NCT02500173|Radiation|Radiation|Radiation therapy
259538|NCT02500186|Drug|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
259539|NCT02500186|Other|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
259540|NCT00178698|Other|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
259541|NCT02500199|Drug|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg and 480mg. Tablets will be orally administered with water, once daily, 30 min after meal.
263790|NCT02366949|Drug|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY 1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY 1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
263791|NCT02366962|Biological|ASP7374|subcutaneous
263792|NCT02366975|Drug|Testosterone gel 2%|testosterone gel 2% (50mg/die).
263793|NCT02366975|Other|Placebo|placebo gel
263794|NCT00159705|Drug|pregabalin|
263795|NCT02366988|Device|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
264098|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
264099|NCT02359617|Drug|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
264100|NCT02359617|Device|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
264101|NCT02359630|Device|EasyTube|Insertion for ventilation
264102|NCT00158873|Drug|fentanyl|
264103|NCT02359630|Device|Endotracheal tube|Insertion for ventilation
264104|NCT02359643|Drug|Aspirin|This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:
Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).
Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year).
264105|NCT02362243|Other|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
263503|NCT02371928|Other|Neuromuscular exercise program|Exercises can be individually progressed from basic to elite level.
Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.
Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.
Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.
Supervision will be given two times a week for the first two weeks and then once a week for the remaining period.
263504|NCT02371928|Other|Standard home exercise program|Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.
All exercises are performed three times a week with 2 sets of 10 repetitions.
263505|NCT02371941|Drug|oral cromolyn sodium|Oral cromolyn sodium
263506|NCT02371941|Drug|Placebo|Saline
263507|NCT02373943|Other|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
263508|NCT02373943|Other|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
263509|NCT02373956|Device|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
263510|NCT02373956|Procedure|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
263511|NCT00160407|Behavioral|1400 kcal diet (30% fat)|
263796|NCT02366988|Procedure|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
263797|NCT02367001|Other|Normal invitation|No modification and signed by the coordinating doctor as usual
263798|NCT02367001|Other|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
263799|NCT02367001|Other|Revised invitation signed by the attending physician|signature typed or typed + handwritten
263800|NCT02367014|Drug|MTP-131|MTP-131 (low dose) administered as single day intravenous infusion over 2 hours for 5 days
263801|NCT02367014|Drug|MTP-131|MTP-131 (intermediate dose) administered as single day intravenous infusion over 2 hours for 5 days
263802|NCT02367014|Drug|MTP-131|MTP-131 (high dose) administered as single day intravenous infusion over 2 hours for 5 days
263803|NCT02367014|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
263516|NCT02374021|Drug|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
263517|NCT02374021|Drug|Etanercept|50 mg SC weekly
263518|NCT02374021|Drug|Adalimumab|40 mg SQ every other week
263519|NCT02374034|Other|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
263520|NCT02374047|Drug|CAT-2054|
263521|NCT02374047|Drug|Placebo|
263522|NCT00160420|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 months
263523|NCT02374047|Drug|CAT-2054-C|
263524|NCT02374047|Drug|Atorvastatin|
263525|NCT02374060|Drug|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
263526|NCT02374060|Drug|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
263527|NCT02374060|Drug|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
263528|NCT02374073|Other|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
263529|NCT02374073|Other|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
263530|NCT02374086|Behavioral|Exercise training|
263531|NCT00160693|Biological|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
263532|NCT02375984|Biological|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
263815|NCT02369354|Other|Financial Assistance Intervention|The financial assistance intervention offers potential donors the ability to draw from a "bank" of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating.
262945|NCT02388035|Drug|Cefotaxime|
262946|NCT02388048|Drug|Ibrutinib + ofatumumab|
263228|NCT00000359|Behavioral|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
263229|NCT00002425|Drug|Saquinavir|
263230|NCT00161356|Procedure|Liver Biopsy|post drug delivery (60 min. after completion of Ambisome infusion)
263231|NCT02380781|Behavioral|Information in the form of a video|see intervention description
263232|NCT02380794|Drug|Danshen Gegen Capsule|Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.
Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption.
263233|NCT02380794|Drug|Placebo|
263234|NCT02380807|Device|Dry Needling|Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by "dense contraction knots".
263235|NCT02380807|Other|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
263236|NCT02380820|Device|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
263237|NCT02380820|Device|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
263238|NCT02380833|Behavioral|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
263239|NCT02380833|Behavioral|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
263240|NCT02380833|Behavioral|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
263241|NCT00161382|Behavioral|HIV, STD, and pregnancy prevention curriculum|This HIV, STD, and pregnancy intervention program entitled, "It's Your Game...Keep it Real", consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits.
262653|NCT02467894|Other|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
262654|NCT02467907|Drug|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
262655|NCT02467907|Drug|Carboplatin|Administration of carboplatin at area under the curve (AUC) 5 on day 1 every 3 weeks for at least 6 cycles
262656|NCT02469974|Drug|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
262657|NCT02469974|Drug|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
262947|NCT02388061|Drug|Tenecteplase|
262948|NCT02388061|Drug|Tissue Plasminogen Activator|
262949|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
262950|NCT02388074|Device|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
262951|NCT02388087|Device|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
262952|NCT02388087|Procedure|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
262953|NCT02388100|Procedure|Capillary HbA1c collection|
262954|NCT02388113|Behavioral|accumulated exercise|
262955|NCT02388113|Behavioral|traditional exercise|
262956|NCT02388126|Device|3T multiparametric MRI|Magnetom Verio 3T, Erlangen, Germany
262957|NCT02388126|Device|Transrectal ultrasound|Bk Medical Pro Focus Ultraview 2202 system
262958|NCT02388139|Procedure|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
262959|NCT02388139|Procedure|coronarography|
262960|NCT00162266|Drug|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
262381|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|Study drugs: Autologous adipose tissue derived MSCs
Injection dosage and volume of the study drugs:
High dose: 1x10e8 cells/3mL
Number of injections : only once during the study period
Device: Ultrasound
Injection technique: Injection into the lesion by investigator
262382|NCT02474355|Procedure|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
262383|NCT02474355|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
262384|NCT00175357|Drug|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
262385|NCT02474355|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
262386|NCT02474355|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
262658|NCT02469987|Drug|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
262659|NCT02469987|Drug|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
262660|NCT02469987|Drug|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
262661|NCT02470000|Device|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
262662|NCT02470000|Device|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
262663|NCT02470000|Other|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
262664|NCT02470013|Dietary Supplement|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
262665|NCT00174863|Drug|SR31747A|
262666|NCT02470026|Drug|yohimbine|single low dose treatment
262667|NCT02470026|Drug|placebo|single control treatment
262668|NCT02470039|Drug|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
262669|NCT02470039|Drug|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
262670|NCT02470039|Drug|placebo|Administered once daily
262077|NCT02478502|Drug|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
262078|NCT02478515|Drug|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
262079|NCT02480556|Procedure|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction & cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
262080|NCT02480556|Procedure|Conservative separation of placenta|Conservative separation of placenta:
in group B but following fetal extraction and cord clamping, the placenta will be left insitu & uterus is massaged awaiting spontaneous placental separation
262081|NCT02480569|Other|FFR Measurement|
262082|NCT02480582|Other|Almonds|
262083|NCT00002475|Biological|sargramostim|
262084|NCT00176280|Drug|Dexamethasone|
262085|NCT02480582|Other|Cheese Savouries|
262086|NCT02480595|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
262087|NCT02480608|Drug|Imatinib|
262088|NCT02480608|Drug|Hydroxyurea|
262089|NCT02480621|Drug|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
262090|NCT02480634|Drug|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
262091|NCT02480634|Radiation|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/10f
262387|NCT02474355|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
262388|NCT02474368|Radiation|Intensity Modulated Radiation Therapy (IMRT)|
262389|NCT02474368|Drug|Cisplatin|
262390|NCT02474368|Radiation|Stereotactic Body Radiotherapy (SBRT)|
262391|NCT02474381|Biological|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
262392|NCT02474381|Device|Single PTA|Angioplasty of arteries below tibial plateau level only
261767|NCT02483130|Dietary Supplement|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
261768|NCT02483130|Other|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
261769|NCT02483143|Drug|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
261770|NCT02483143|Drug|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
261771|NCT02485184|Drug|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
261772|NCT02485197|Other|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
261773|NCT02485210|Procedure|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
261774|NCT02485236|Device|Low flow oxygen supplementation via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
261775|NCT02485236|Device|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
261776|NCT02485249|Drug|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
261777|NCT02485262|Drug|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
261778|NCT00176774|Drug|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
261779|NCT02485301|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
261780|NCT02485301|Drug|Placebo|A single dose administrated intramuscular
286319|NCT00002531|Procedure|allogeneic bone marrow transplantation|
286320|NCT00198081|Drug|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
286321|NCT02659683|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
285729|NCT02671188|Drug|Placebo|Normal saline (0.9% sodium chloride) will be used as placebo.
285730|NCT00199017|Drug|Methotrexate|
285731|NCT02673580|Other|Open Access follow-up|In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website "Sundhed.dk".
285732|NCT02673580|Other|Standard follow-up|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
285733|NCT02673593|Drug|DS102|
285734|NCT02673593|Drug|Placebo|
285735|NCT02673606|Drug|Estradiol|
285736|NCT02673606|Drug|Placebo|
285737|NCT00199056|Procedure|Mediastinal irradiation (if residual tumor)|
285738|NCT02673619|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
285739|NCT02673619|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2
285740|NCT02673632|Drug|Merional ®|Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 < 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
285741|NCT02673645|Other|SAGA Innovations|An intensive math tutoring program.
285742|NCT02673658|Behavioral|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
285743|NCT02673658|Behavioral|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
285744|NCT02673671|Device|GTech Gutcheck Myoelectric recording device|A patch is placed on the abdomen of the patient to record myoelectric activity.
285745|NCT02673684|Device|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
285197|NCT02583204|Other|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
285198|NCT00189514|Drug|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
285199|NCT02583217|Drug|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
285468|NCT02680626|Drug|Ropivacaine|Given via transversus abdominis plane block
285469|NCT02680639|Device|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
285470|NCT02680678|Other|Colloid Preload|preload infusion
285471|NCT02680678|Other|colloid coload|coload infusion
285472|NCT02680678|Other|Crystalloid preload|preload infusion
285473|NCT02680678|Other|Crystalloid Coload|coload infusion
285474|NCT02680691|Other|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
285475|NCT02680691|Other|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
285476|NCT02682862|Drug|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
285477|NCT00200005|Device|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
285478|NCT02682862|Drug|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
285479|NCT02682888|Behavioral|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
285480|NCT02682888|Drug|Oxytocin|intranasal administration of oxytocin
285481|NCT02682888|Drug|Placebo|intranasal administration of placebo
285482|NCT02682901|Drug|Cycloset|Cycloset 1.6 -3.2 mg/day
284916|NCT02590003|Drug|Nab-paclitaxel|
284917|NCT02590016|Drug|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
284918|NCT02590029|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
284919|NCT02590029|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
285200|NCT02583217|Drug|remifentanyl|
285201|NCT02583217|Drug|propofol|
285202|NCT02583217|Device|laryngeal mask|
285203|NCT02583230|Behavioral|MedLink System|Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.
The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status.
285204|NCT02583243|Behavioral|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
285205|NCT02583243|Drug|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
285206|NCT02583256|Biological|aQIV-aQIV|aQIV in V118_05 and aQIV in V118_05E3
285207|NCT02583256|Biological|aQIV-QIV|aQIV in V118_05 and QIV in V118_05E3
285208|NCT02583256|Biological|QIV-aQIV|QIV in V118_05 and aQIV in V118_05E3
285209|NCT00189527|Procedure|respiratory settings|
285210|NCT02583256|Biological|QIV-QIV|QIV in V118_05 and QIV in V118_05E3
285211|NCT02583269|Other|Laboratory Biomarker Analysis|Correlative studies
285212|NCT02583269|Dietary Supplement|Muscadine Grape Skin Extract|Given PO
285213|NCT02583269|Procedure|Quality-of-Life Assessment|Ancillary studies
260963|NCT02471872|Behavioral|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
260964|NCT02471872|Other|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
260965|NCT02471885|Procedure|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) to 200mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
260966|NCT02471885|Other|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
260967|NCT02471898|Drug|HTX-011|
260968|NCT02473627|Drug|Tolbutamide|500mg tablet
260969|NCT02473640|Drug|SYN-004|
260970|NCT02473640|Drug|Esomeprazole|
261246|NCT02467153|Other|RET|RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.
The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.
Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months.
261247|NCT02467153|Dietary Supplement|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
261248|NCT02467153|Dietary Supplement|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
261249|NCT02467166|Device|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
261250|NCT02467179|Device|Amigo™ Robotic Catheter Manipulation|Ablation is a standard procedure that patients may undergo for the atrial flutter.
In this study, this group will be assigned to robotic catheter manipulation.
261251|NCT00174538|Drug|Codeine (30 mg)|
261252|NCT02467179|Device|Manual Catheter Manipulation|Ablation is a standard procedure that patients may undergo for the atrial flutter.
In this study, this group will be assigned to manual catheter manipulation.
261253|NCT02467192|Device|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
261254|NCT02467205|Other|pedometer supported walking and education|A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.
The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support).
260687|NCT02477943|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
260688|NCT02477956|Dietary Supplement|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
260689|NCT02477956|Dietary Supplement|vitamin D|
260690|NCT02477969|Drug|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
260691|NCT00175903|Drug|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
260692|NCT02477969|Drug|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
260693|NCT02477969|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
260694|NCT02477969|Drug|Metformin|0.5mg,oral,tid.
260695|NCT02477995|Biological|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
260971|NCT02473640|Drug|Ceftriaxone|
260972|NCT02473653|Biological|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
260973|NCT02473692|Other|Online Migraine Treatment Optimization|The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:
Introduction to the series
Getting to know migraine
Making the most of your medical care
Partnering with your doctor
Best use of migraine medication
Keeping tabs on your migraine
Take home message (summary)
260974|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
260975|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate Placebo|1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
260976|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate|Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
260977|NCT00175266|Procedure|islet transplant|
260978|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate Placebo|Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
260979|NCT02473718|Other|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
260418|NCT02484651|Drug|Sugammadex|Reversal of deep neuromuscular block
260419|NCT02484651|Drug|Rocuronium|Maintenance of deep neuromuscular block
260420|NCT02484664|Drug|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
260421|NCT02484677|Drug|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
260422|NCT02484677|Drug|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
260423|NCT00176683|Procedure|Capnography|device which measures carbon dioxide at intubation
260424|NCT02484677|Drug|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
260425|NCT02484690|Drug|RG7716|Participants will receive RG7716, 1.5 or 6 mg, administered IVT and according to treatment assignment.
260426|NCT02484690|Drug|Ranibizumab|Participants will receive ranibizumab, 0.5 mg administered IVT every 4 weeks.
260427|NCT02484703|Drug|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
260428|NCT02484703|Drug|RG1662|Participants will receive 1 of 3 dosages of RG1662 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
260429|NCT02484716|Drug|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
260430|NCT02484716|Drug|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
260431|NCT02484729|Drug|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
260696|NCT02477995|Biological|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
260697|NCT02479971|Drug|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
260698|NCT02479971|Drug|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
260130|NCT02489045|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
260131|NCT02489071|Behavioral|Brain Training Program|
260132|NCT02489071|Behavioral|Brain Health Program|
260133|NCT02489084|Other|Blood sampling|
260134|NCT02489097|Drug|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
260135|NCT02489097|Other|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
260136|NCT02489110|Behavioral|Webnovela|
260137|NCT02489123|Drug|Enzalutamide|Given PO
260138|NCT00000368|Drug|Paroxetine or other medication - algorithm used|
260139|NCT00002477|Drug|cyclophosphamide|
260140|NCT00177099|Drug|FK506, GP11046, GP11511|
260141|NCT02489123|Other|Laboratory Biomarker Analysis|Correlative studies
260142|NCT02489136|Other|laying of hands (Spiritist "passe")|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
260143|NCT02491333|Other|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
260144|NCT02491333|Other|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
260145|NCT00177385|Behavioral|Modest sleep deprivation with sleep hygiene education|
260146|NCT02491333|Drug|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
260147|NCT02491333|Drug|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
260148|NCT02491346|Procedure|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
260149|NCT02491346|Procedure|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
259542|NCT02466607|Device|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
259543|NCT02466607|Device|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
259544|NCT02466607|Other|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
259545|NCT02466633|Other|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
259546|NCT02466646|Drug|Klorhex® Gel, rinse and sprey|nitial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Sprey 0,2% and Klorhex® rinse 0,2% for 3 weeks).
259547|NCT02466646|Procedure|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
259548|NCT00174473|Drug|Voriconazole|
259839|NCT02496000|Drug|ORMD-0801|Oral Insulin
259840|NCT02496000|Drug|Placebo Comparator|Placebo
259841|NCT02496013|Drug|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
259842|NCT02496026|Device|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
259843|NCT02496026|Device|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
259844|NCT02496039|Drug|NUEDEXTA®|NUEDEXTA® only
259845|NCT02496052|Procedure|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
259846|NCT00178100|Drug|paroxetine|
259847|NCT02496052|Device|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
259848|NCT02496052|Drug|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
259849|NCT02498002|Procedure|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
259850|NCT02498002|Drug|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
259851|NCT02498002|Other|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
264106|NCT02362243|Other|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
264107|NCT02362256|Drug|Naltrexone|
264108|NCT02362256|Drug|Clonidine|
264109|NCT02362256|Drug|Lorazepam|
264110|NCT02362269|Dietary Supplement|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
259549|NCT02466646|Procedure|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
259550|NCT02466659|Device|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
259551|NCT02466672|Other|none - observational only|
259552|NCT02466685|Drug|JNJ-18038683|JNJ-18038683 10-20 mg/day for 8 weeks
259553|NCT02466698|Procedure|London Protocol|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 1000cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 500cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 4 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
259554|NCT02466698|Drug|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
259555|NCT02466698|Drug|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
259556|NCT02466698|Drug|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
263804|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
263805|NCT00159718|Drug|amlodipine|
263806|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
263807|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
263808|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
263809|NCT02367040|Drug|Copanlisib (BAY 80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
263810|NCT02369315|Behavioral|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
263811|NCT02369315|Behavioral|Control (Invited entry 2013)|Entry to music program offered in September 2013
263812|NCT02369328|Device|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
263813|NCT02369341|Biological|Fluarix Tetra|1 dose administered intramuscularly in the deltoid of the non-dominant arm.
263814|NCT02369354|Behavioral|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
264111|NCT02362282|Behavioral|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in our prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
264112|NCT02362282|Behavioral|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
264113|NCT02362282|Behavioral|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
264114|NCT00159237|Procedure|blood test|
263816|NCT02369367|Drug|Irinotecan|200 mg/m^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
263817|NCT00159913|Drug|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
263818|NCT02369367|Drug|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
263819|NCT02369380|Device|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
263820|NCT02369393|Behavioral|Behavioral Activation|
263821|NCT02369393|Behavioral|Physical Activity|
263822|NCT02369393|Other|Treatment as Usual|
263823|NCT02369406|Drug|Nevirapine|
263824|NCT02369406|Drug|Kaletra|
263825|NCT02369406|Drug|Lamivudine|
263826|NCT02369406|Drug|Zidovudine|
263827|NCT02369419|Other|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as <14/17 points using the ONCODAGE score
263828|NCT00159926|Procedure|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
263829|NCT02369432|Drug|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
263830|NCT02369445|Behavioral|Moisture Pager Intervention for Toilet Training|
263831|NCT02369445|Behavioral|Standard of Care|
263832|NCT02369458|Drug|Mitomycin-C|
263833|NCT02369458|Drug|Pegfilgrastim|
263834|NCT02369471|Drug|GWP42006|
263835|NCT02369471|Drug|Placebo|
263836|NCT02371954|Behavioral|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
263837|NCT02371954|Other|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
263838|NCT02371967|Drug|Erivedge®|
263242|NCT02380833|Behavioral|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
263243|NCT00161616|Drug|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
263244|NCT02383212|Drug|Cyclophosphamide|
263533|NCT02375997|Other|Palliative care|Early nutrition intervention and psychological intervention
263534|NCT02376010|Drug|rivaroxaban|
263535|NCT02376010|Drug|Warfarin|
263536|NCT02376023|Other|Text Message|Text messages sent to study participants reminding them to schedule a PAP smear.
263537|NCT02376036|Drug|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
263538|NCT02376036|Drug|Placebo|Placebo comparator.
263539|NCT02376049|Drug|Pimecrolimus cream|
263540|NCT02376049|Drug|Betamethasone dipropionate cream|
263541|NCT02376049|Drug|Clobetasol propionate cream|
263542|NCT00160706|Biological|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.
Up to 84 months of therapy in this study.
263543|NCT02376049|Drug|Glaxal Base cream vehicle|
263544|NCT02376062|Behavioral|Online mental health modules|The authors have designed online educational modules to improve clinical capacity and competency about mental health for Nepali Primary Care Providers.
263545|NCT02376075|Drug|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
263546|NCT02376075|Drug|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
263547|NCT02376088|Drug|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
263548|NCT02376101|Procedure|Surgery less than 60 minutes|
262961|NCT02388139|Procedure|coronary angioplasty|
262962|NCT02388139|Procedure|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
262963|NCT02388139|Procedure|body composition monitoring|using Fresenius device
262964|NCT02388152|Biological|Lu AF20513, low dose|
262965|NCT02388152|Biological|Lu AF20513, medium dose|
262966|NCT02388152|Biological|Lu AF20513, high dose|
263245|NCT02383212|Drug|Docetaxel|
263246|NCT02383212|Drug|Carboplatin|
263247|NCT02383212|Drug|GM-CSF|
263248|NCT02383225|Behavioral|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
263249|NCT02383225|Behavioral|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
263250|NCT02383225|Behavioral|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
263251|NCT02383238|Drug|Dapagliflozin|10 mg, oral for 6 weeks
263252|NCT02383238|Drug|Placebo|oral for 6 weeks
263253|NCT02383251|Drug|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
263254|NCT00161629|Drug|rhBMP-2/CPM|
263255|NCT02383251|Drug|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
263256|NCT02383277|Other|Stretching|Stretching of the rib cage muscles
263257|NCT02383277|Other|Control|Rest without stretching (sham)
263258|NCT02383277|Other|Exercise|Constant load exercise on a bike
262671|NCT02470052|Device|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
262672|NCT02470065|Drug|Afatinib|once daily afatinib at a dose of 40 mg for 8 weeks
262673|NCT02470065|Procedure|Immediate surgery|anatomical resection and systematic lymph node dissection
262674|NCT02470078|Device|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
262675|NCT02470078|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
262676|NCT00174876|Drug|Drug Abilify|
262677|NCT02470091|Biological|Denosumab|Given SC
262967|NCT02390323|Device|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
262968|NCT02390336|Other|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
262969|NCT02390336|Other|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
262970|NCT02390349|Other|Placebo|
262971|NCT02390349|Dietary Supplement|Curamin|
262972|NCT02390349|Dietary Supplement|CuraMed|
262973|NCT02390362|Drug|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
262974|NCT02390362|Drug|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
262975|NCT02390375|Drug|DW-0929|5/10mg
262393|NCT02474394|Device|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
262394|NCT02476370|Behavioral|relaxation program|relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises
1 week programm, one introductory session and daily home practice
262395|NCT02476370|Behavioral|surgery education|intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery
1 single unit in the week before the surgery
262396|NCT02476383|Procedure|spinal manipulative therapy|refer to arm descriptions
262397|NCT02476396|Procedure|Carotid Endarterectomy|Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).
This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.
In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).
Source: Mayo Clinic
262398|NCT02476409|Drug|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
262399|NCT02476409|Other|Placebo|Placebo for tolvaptan
262400|NCT02476422|Drug|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule would be given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth
262401|NCT02476422|Drug|Ibuprofen|Single dose of ibuprofen 400 mg tablet would be given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth.
262402|NCT02476422|Drug|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet would be given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth.
262403|NCT02476422|Drug|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule would be given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth
262404|NCT00175682|Drug|Prazosin HCL|See Detailed Description
262405|NCT02476435|Device|Active rTMS|Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
262678|NCT02470091|Other|Laboratory Biomarker Analysis|Correlative studies
262679|NCT02472379|Other|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
262680|NCT02472392|Drug|Rabbit anti-thymocyte globulin|Active treatment
262681|NCT02472392|Drug|Busulfan|comparitor
286322|NCT02659709|Device|Smartphone Application|Smartphone Application designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
286323|NCT02659722|Device|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
286324|NCT02659735|Drug|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
286325|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
286326|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
286327|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
286328|NCT02659748|Dietary Supplement|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
286329|NCT02659748|Dietary Supplement|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
286330|NCT02659761|Drug|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
286331|NCT00198081|Drug|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
286332|NCT02659774|Behavioral|Motivational intervention|Use motivational interview strategies to provide smoking cessation intervention
286333|NCT02659787|Drug|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
286334|NCT02659787|Drug|Placebo|Placebo
286335|NCT02659787|Drug|0.4mg Buprenorphine|Sublingual buprenorphine tablets (0.4mg)
286336|NCT02661854|Biological|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
286337|NCT02661854|Biological|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
286338|NCT02661854|Biological|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
286611|NCT02655471|Drug|"Raltegravir" and "Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
286024|NCT02664220|Drug|Povidone-iodine irrigation|Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.
1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister.
286025|NCT02666352|Drug|MK-3682|MK-3682 150 mg oral tablets
286026|NCT02666352|Drug|MK-8408|MK-8408 10 mg oral capsules
286027|NCT02666365|Procedure|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the whipple procedure
286028|NCT02666365|Procedure|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the whipple procedure
286029|NCT02666378|Other|Cardiac Magnetic Resonance Imaging (CMR)|
286030|NCT02666378|Other|Echocardiogram (ECHO)|
286031|NCT00198952|Drug|DietPro|
286032|NCT02666391|Biological|umbilical cord mesenchymal stem cells|
286033|NCT02666404|Other|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
286034|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
286035|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
286036|NCT02666430|Drug|Mylan's insulin glargine|
286037|NCT02666430|Drug|Lantus®|
286038|NCT02666443|Drug|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
286039|NCT02666443|Drug|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
286040|NCT02666443|Drug|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
286041|NCT02666456|Other|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
285483|NCT02682901|Drug|Placebo|Non-active placebo for cycloset
285484|NCT02682927|Drug|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
285485|NCT02682927|Drug|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
285486|NCT02682940|Device|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
285487|NCT02682953|Drug|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
285488|NCT00002536|Drug|cisplatin|
285746|NCT02673684|Device|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
285747|NCT02673697|Device|Perceval valve|Sutureless Aortic Biological Valve
285748|NCT00199056|Procedure|stem cell transplantation|
285749|NCT02673697|Device|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
285750|NCT02673710|Other|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
285751|NCT02673723|Drug|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
285752|NCT02676037|Device|foot pressure plate form|
285753|NCT02676050|Other|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
285754|NCT02676050|Device|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
285755|NCT02676050|Device|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
285756|NCT02676076|Drug|CHF 5993 100/6/12.5 µg|
285757|NCT02676076|Drug|CHF 1535 100/6 µg|
285758|NCT00199095|Drug|Idarubicin|
285214|NCT02583282|Other|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
285215|NCT02585323|Behavioral|Education session, Fitbit/MaC app, and remote counselling by a PT|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a MaC app, and remote counseling by a PT. Intervention will be received immediately.
285216|NCT02585323|Behavioral|Same intervention with a 3 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
285217|NCT02585336|Behavioral|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
285218|NCT02585362|Behavioral|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
285219|NCT02585362|Behavioral|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
285489|NCT00200018|Device|Enterra Therapy System (H9900014)|
285490|NCT02682953|Procedure|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
285491|NCT02682953|Drug|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
285492|NCT02682966|Radiation|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
285493|NCT02682979|Other|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
285494|NCT02682992|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
285495|NCT02683005|Drug|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
285496|NCT02683018|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
261255|NCT02467218|Other|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
261256|NCT02467244|Drug|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
261257|NCT02467257|Dietary Supplement|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
261258|NCT02467270|Drug|ponatinib 45 mg|45 mg tablet, taken orally once daily
261259|NCT02467270|Drug|ponatinib 30 mg|30 mg tablet, taken orally once daily
261260|NCT02467270|Drug|ponatinib 15 mg|15 mg tablet, taken orally once daily
261261|NCT02467283|Genetic|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
261262|NCT00174551|Drug|prazosin|
261263|NCT02467296|Other|Diet with Sodium|
261545|NCT02498639|Procedure|percutaneous balloon aortic valvuloplasty|Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.
The procedure terminates in case of:
Reduction of the mean aortic gradient ≥50%.
Aortic pressure drop during the inflations, indicative of valve orifice sealing.
Intraprocedural complication.
Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded.
261546|NCT02498652|Drug|RDEA3170 2.5 mg|Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).
Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets).
261547|NCT02498652|Drug|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
261548|NCT02498665|Drug|DSP-7888 Dosing Emulsion|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.
261549|NCT02498678|Procedure|Tetanus|tetanic electric stimulation
261550|NCT00178490|Drug|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
261551|NCT02498691|Biological|Biological collection|Blood and saliva samples, placenta and cord blood collection
260980|NCT02473718|Device|Ultrasound|
260981|NCT02473731|Biological|KTN3379|
260982|NCT02473744|Other|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
260983|NCT02473783|Drug|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
260984|NCT02473783|Other|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
260985|NCT02473796|Other|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight <2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term & weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
260986|NCT02473809|Drug|Liraglutide|Once daily
260987|NCT02473809|Drug|Placebo|Once daily
260988|NCT00175266|Drug|infliximab|
260989|NCT02473835|Other|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
261264|NCT02467322|Drug|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
261265|NCT02467322|Drug|ascitic fluid|
261266|NCT02467335|Drug|BMS-663068|
261267|NCT02467348|Drug|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
261268|NCT02469389|Behavioral|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE)
includes evidence-based psychosocial treatment
strategies to target the affective-motivational deficits,
negative expectancies, and behavioral skills deficits
that are central to the maintenance of negative
symptoms. Behavioral strategies include motivational
enhancement, psychoeducation, cognitive therapy, and
social skills tr
261269|NCT02469389|Behavioral|Health & Wellness (H&W)|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related
concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.
Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing
Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions),
8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1sessi
261270|NCT02469402|Dietary Supplement|Standard infant formula|
260699|NCT02479984|Procedure|Staging Laparoscopy|Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.
Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port.
260700|NCT02479984|Device|Laparoscopic ultrasound|
260701|NCT02479997|Drug|Indocyanine green|ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.
In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty.
260702|NCT02479997|Drug|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
260703|NCT02480010|Drug|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
260704|NCT02480023|Radiation|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
260705|NCT02480036|Radiation|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
260706|NCT02480036|Device|Intrabeam®|
260707|NCT00176254|Radiation|Radiotherapy|80 centigray (cGy) on Day 1 & 2 and 22 & 23 of chemotherapy
260708|NCT02480049|Drug|Asmakast|1 tablet contains 10 mg of montelukast
260709|NCT02480049|Drug|Singulair|1 tablet contains 10 mg of montelukast
260710|NCT02480062|Other|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
260711|NCT02480062|Other|Usual Care|Usual care at the community health centers
260712|NCT02480075|Other|Observational|Observational Study only
260990|NCT02475876|Drug|Clindamycin|Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:
Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;
Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose =12 mg/kg;
Cohort 3; No. Subjects = 5; Age >1-2 years; Dose =12 mg/kg.
Cohort 4; No. Subjects = 4; Age >2-6 years; Dose =12 mg/kg.
Cohort 5; No. Subjects = 4; Age >6-12 years; Dose =10 mg/kg.
Cohort 6; No. Subjects = 4; Age >12-16 years; Dose =10 mg/kg.
260150|NCT02491359|Drug|Carfilzomib|Given IV
260151|NCT02491359|Other|Laboratory Biomarker Analysis|Correlative studies
260432|NCT02484729|Drug|Placebo, oral suspension|Matching placebo
260433|NCT02484729|Drug|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
260434|NCT00176696|Device|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
260435|NCT02484742|Behavioral|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
260436|NCT02484755|Drug|Gefitinib|See Arm Description
260437|NCT02484768|Drug|Iron isomaltoside 1000|Intravenous treatment
260438|NCT02484768|Drug|Sodium Chloride 0.9%|Intravenous treatment
260439|NCT02484781|Other|Gait analysis on a trendmill|Gait analysis on a trendmill "GRAIL" to analyse spatio-temporal kinetics and kinematics when flat walking and inclining
260440|NCT02487108|Drug|Acetaminophen|325 mg
260441|NCT02487108|Drug|Placebo|Matching Placebo
260442|NCT02487121|Behavioral|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
260443|NCT02487121|Behavioral|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
260444|NCT02487134|Device|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
260445|NCT02487134|Device|Control|Closure of the abdomen with conventional technique
260446|NCT02487147|Device|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
260447|NCT02487147|Device|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
260448|NCT02487160|Device|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
260449|NCT02487160|Device|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
260450|NCT00002476|Radiation|radiation therapy|
259852|NCT02498002|Radiation|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
259853|NCT02498002|Other|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
259854|NCT02498002|Other|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
259855|NCT00002482|Biological|antibody therapy|
259856|NCT00178399|Procedure|Stereotactic Body Radiation Therapy|
259857|NCT02498002|Other|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
259858|NCT02498002|Other|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
259859|NCT02498015|Drug|"3D" regimen|The "3D" regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis.
259860|NCT02498015|Drug|"3D" regimen with ribavirin|The "3D" regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis.
260152|NCT02491359|Other|Quality-of-Life Assessment|Ancillary studies
260153|NCT02491359|Other|Questionnaire Administration|Ancillary studies
260154|NCT02491372|Behavioral|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
260155|NCT02491385|Procedure|thoracic epidural analgesia|In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
260156|NCT00002479|Drug|tretinoin|
260157|NCT00177398|Drug|Glargine insulin vs regular insulin|
260158|NCT02491385|Drug|iv-PCA|iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
260159|NCT02491398|Drug|Bendamustine + Rituximab|
260160|NCT02491411|Drug|Dexamethasone|Given PO
260161|NCT02491411|Drug|Enzalutamide|Given PO
260162|NCT02491411|Other|Laboratory Biomarker Analysis|Correlative studies
259557|NCT02466711|Drug|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
259558|NCT02466711|Drug|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
259559|NCT00174486|Drug|UK0369,003|
259560|NCT02468739|Drug|EC-T or TC plus GM1|EC-T: Patients will receive dose-dense EC (epirubicin and cyclophosphamide) every 2 weeks followed by taxotere (every 3 weeks) or paclitaxel (every 2 weeks or weekly).
TC: Patients will receive taxotere and cyclophosphamide every 3 weeks.
GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day 0) to the completion of chemotherapy (Day 2), and the dosages of GM1 are 80mg per day.
259561|NCT02468739|Drug|EC-T or TC plus placebo|EC-T: Patients will receive dose-dense EC (epirubicin and cyclophosphamide) every 2 weeks followed by taxotere (every 3 weeks) or paclitaxel (every 2 weeks or weekly).
TC: Patients will receive taxotere and cyclophosphamide every 3 weeks.
Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day 0) to the completion of chemotherapy (Day 2), and the dosages of placebo are 80mg per day.
259562|NCT02468752|Drug|Oxygen|
259563|NCT02468752|Other|Air|
259861|NCT02498028|Procedure|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
259862|NCT02498028|Procedure|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
259863|NCT02498041|Procedure|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
259864|NCT02498041|Device|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
259865|NCT02498041|Device|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
259866|NCT02498041|Procedure|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
259867|NCT00178412|Behavioral|Care Project for Hospitalized Elders & Family Caregivers|Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)
Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home
259868|NCT02498054|Behavioral|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
264115|NCT02362295|Other|qualitative interview|some patient are interviewed.
264116|NCT02362308|Other|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
264117|NCT02362308|Drug|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
264118|NCT02362321|Drug|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
264119|NCT02362321|Other|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
264120|NCT02362347|Device|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
264121|NCT02362347|Other|exercise|exercise
264122|NCT02364843|Dietary Supplement|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
264123|NCT02364856|Device|Analgesia Nociception Index|The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.
ANI is calculated from heart rate recording.
264124|NCT02364869|Dietary Supplement|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
264125|NCT02364869|Dietary Supplement|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
264126|NCT02364882|Drug|Sildenafil|
264127|NCT02364895|Other|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
259564|NCT02468765|Other|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
259565|NCT02468778|Device|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.
259566|NCT02468778|Device|Abiomed Impella® Recover® LP 2.5|
259567|NCT02468791|Drug|Rituximab|
264128|NCT02364895|Other|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
264129|NCT02364895|Other|Males Group 2: New letter with neutral gender content|Unisex letter
264130|NCT00002418|Drug|Nevirapine|
264131|NCT00159432|Drug|Oxaliplatin|
264132|NCT02364895|Other|Males Group 3: New letter with male-specific content|New letter tailored for men
264133|NCT02364895|Other|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
264134|NCT02364895|Other|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
264135|NCT02364895|Other|Females Group 2: New letter with neutral gender content|Unisex letter
264136|NCT02364908|Other|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
264137|NCT02364921|Device|Two multilayer compression bandage|Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.
Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days
264138|NCT02364921|Device|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
264139|NCT02364934|Drug|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
264140|NCT02364934|Drug|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
264141|NCT02364947|Drug|Nalmefene hydrochloride|As-needed; tablets, orally
264142|NCT00159432|Drug|Bevacizumab|
264143|NCT02364947|Drug|Placebo|As-needed; tablets, orally
264144|NCT02367040|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
263549|NCT02376114|Drug|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
263550|NCT02376114|Drug|Placebo to Ginkgo biloba|
263551|NCT02376127|Procedure|Dynamic contrast enhancement MRI|
263552|NCT02376153|Device|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
263553|NCT00160719|Procedure|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
263839|NCT02371980|Drug|Vortioxetine|Vortioxetine capsules
263840|NCT02371980|Drug|Placebo|Vortioxetine placebo-matching capsules
263841|NCT02371993|Dietary Supplement|Choline|
263842|NCT00160251|Drug|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
263843|NCT02371993|Other|Placebo|
263844|NCT02372006|Drug|afatinib|
263845|NCT02372019|Behavioral|CBM With Active Fear Reactivation|Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 20 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the "memory reconsolidation window" that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting.
263846|NCT02372019|Behavioral|CBM With Inert Fear Reactivation|Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the "memory reconsolidation window" that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control.
263847|NCT02372019|Behavioral|Inert CBM With Inert Fear Reactivation|Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the "memory reconsolidation window" that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions.
263848|NCT02372032|Procedure|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
263849|NCT02372032|Procedure|ozone therapy|percutaneous intradiscal ozone injection
263259|NCT02383290|Other|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
263260|NCT02383303|Behavioral|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
263261|NCT02383316|Other|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
263262|NCT02383329|Dietary Supplement|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
263263|NCT02383355|Drug|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
263264|NCT02383355|Drug|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
263554|NCT02378519|Behavioral|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
263555|NCT02378519|Behavioral|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
263556|NCT02378532|Drug|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level.
263557|NCT02378532|Radiation|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
263558|NCT00161018|Drug|Quetiapine, Risperidone, Fluphenazine|
263559|NCT02378532|Drug|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
263560|NCT02378545|Drug|Oxygen|On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.
On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask.
262976|NCT00162565|Drug|beta-blocker treatment|beta-blocker treatment
262977|NCT02390375|Drug|DW-0929|10/10mg
262978|NCT02390375|Drug|DW-0929|20/10mg
262979|NCT02390375|Drug|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
262980|NCT02390375|Drug|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
262981|NCT02390375|Drug|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
262982|NCT02390388|Procedure|pudendal nerve block|nerve stimulator-guided Pudendal block
262983|NCT02390388|Procedure|caudal block|caudal block
262984|NCT02390401|Device|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
262985|NCT02390401|Device|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
262986|NCT02390427|Drug|Taselisib|
262987|NCT00162591|Drug|remifentanyl|
263265|NCT00161642|Drug|CMD-193|
263266|NCT02383368|Drug|ASP4132|oral
263267|NCT02385669|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
263268|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
263269|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
263270|NCT02385695|Procedure|Posterior Dynamic Stabilization|
263271|NCT02385695|Procedure|Internal Fixation and Fusion|
263272|NCT02385708|Drug|2% Chlorohexidine Gluconate|Use of 2% Chlorhexidine cloths chin to toes daily
263273|NCT02385734|Other|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
263274|NCT02385734|Procedure|Coronally Advanced Flap|Periodontal plastic surgery technique
262682|NCT02472392|Drug|Melphalan|comparitor
262683|NCT02472392|Drug|Fludarabine|comparitor
262684|NCT02472392|Drug|Cyclophosphamide|comparitor
262685|NCT02472405|Device|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
262686|NCT02472405|Device|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
262687|NCT00175071|Behavioral|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
262688|NCT02472418|Drug|DFN15A|
262689|NCT02472418|Drug|DFN15B|
262690|NCT02472418|Other|Placebo|
262691|NCT02472431|Other|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
262692|NCT02472431|Procedure|Liposuction|
262693|NCT02472431|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
262694|NCT02472457|Other|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
262695|NCT02472457|Other|Free Diet|This diet contains no restrictions.
262696|NCT02472470|Device|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
262697|NCT02472483|Behavioral|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
262988|NCT02390427|Drug|Trastuzumab emtansine|
262989|NCT02390427|Drug|Pertuzumab|
262990|NCT02390427|Drug|Trastuzumab|
262991|NCT02390427|Drug|Paclitaxel|
262992|NCT02390440|Drug|EXPAREL|
286612|NCT02655484|Device|BiPAP® Vision® ventilator（"Ventilator", "Philips Respironics™ BiPAP® Vision®" ）|See details from arm descriptions.
286613|NCT02655497|Behavioral|Cognitive training|
286614|NCT02655497|Behavioral|Psychosocial education|
286615|NCT02655510|Drug|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
286616|NCT02655523|Drug|Triamcinolone|1 mL of 40mg of Triamcinolone
286617|NCT02655523|Drug|Dexamethasone|1 mL of 4mg of Dexamethasone
286618|NCT02655523|Drug|Normal Saline|1 mL of preservative free normal saline
286619|NCT02655536|Drug|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
286620|NCT00002531|Drug|mitoxantrone hydrochloride|
286621|NCT00197483|Drug|Pergolide (drug)|
286622|NCT02655536|Drug|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
286623|NCT02655549|Biological|Px563L, RPA563, or placebo|Two intramuscular injections
286624|NCT02655562|Drug|Montelukast|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO＜25ppb were given placebo (p.o., 10mg, qd).
Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO＜25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
286625|NCT02655575|Behavioral|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
286626|NCT00197756|Dietary Supplement|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
286627|NCT02657720|Device|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
286628|NCT02657733|Device|Radical-7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.
Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa).
286042|NCT00198952|Drug|Placebo|
286339|NCT02661854|Biological|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
286340|NCT02661854|Biological|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
286341|NCT00198393|Drug|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
286342|NCT02661854|Biological|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
286343|NCT02661854|Biological|Subcutaneous placebo|Comparison between placebo and active group
286344|NCT02661854|Biological|Sublingual placebo|Comparison between placebo and active group
286345|NCT02661867|Behavioral|delivery|delivery either vaginal or by cesarean section
286346|NCT02661880|Behavioral|preferred music|listening to preferred music choices
286347|NCT02661893|Drug|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
286348|NCT02661893|Drug|Rifampin|Oral dose of rifampin 600 mg (2*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5 to 12.
286349|NCT02661906|Other|SKY yoga|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
286350|NCT02661919|Device|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
286351|NCT02661932|Drug|Letrozole|Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or "random start"). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.
"Random start" protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.
Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis.
286352|NCT00198393|Drug|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
286353|NCT02661945|Device|Near focus with narrow band imaging|
286354|NCT02661958|Drug|S6G5T-3|once a day topical cream
285759|NCT02676089|Drug|CHF 5993 200/6/12.5 µg|
285760|NCT02676089|Drug|CHF 1535 200/6 µg|
285761|NCT02676089|Drug|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
285762|NCT02676102|Behavioral|Control Group|Generic Video about organ donation
285763|NCT02676102|Behavioral|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
285764|NCT02676102|Behavioral|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
285765|NCT02676115|Other|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
286043|NCT02666469|Other|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
286044|NCT02666469|Other|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
286045|NCT02666469|Device|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
286046|NCT02666482|Behavioral|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
286047|NCT02668562|Procedure|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
286048|NCT02668575|Behavioral|Supportive Care Intervention|Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
286049|NCT02668588|Drug|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
286050|NCT00198991|Drug|VM26|
286051|NCT02668588|Drug|extended release of placebo|1 intramuscular injection of extended release of placebo
286052|NCT02668614|Device|WR-22 model microwave sensor|
286053|NCT02668627|Procedure|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
286054|NCT02668653|Drug|Cytarabine|
285497|NCT02648243|Behavioral|Structured intervention at discharge and tailored follow up post discharge|At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.
The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge.
285498|NCT02648256|Other|Polymerase Chain Reaction on Oropharyngeal rinse|
285499|NCT02648269|Drug|SEL-110|
285500|NCT02648269|Biological|SEL-212|
285501|NCT02648269|Biological|SEL-037|
285502|NCT00196586|Drug|Interleukin 2|
285503|NCT02648282|Drug|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX for a total of 8 doses.
285504|NCT02648282|Drug|GVAX|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of eight doses.
285505|NCT02648282|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine for a total of 8 doses.
285766|NCT02676115|Other|Medipore Tape|One layer of Medipore tape will be placed across the incision.
Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.
When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken.
285767|NCT02676128|Behavioral|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
285768|NCT02676128|Behavioral|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
285769|NCT00199095|Drug|Ifosfamide|
285770|NCT02676141|Other|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
285771|NCT02676154|Drug|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
285772|NCT02676167|Behavioral|PrEP Intervention|
285773|NCT02676180|Other|Group|
261552|NCT02498704|Procedure|Dry Needling|Trigger point dry needling to hamstring muscle group.
261553|NCT02498704|Other|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
261554|NCT02498717|Device|GameReady|Cryotherapy and compression
261555|NCT02498717|Other|RICE|SOC ice and elevation
261556|NCT02498730|Behavioral|Interval Training|High Intensity Interval Training at 100% VO2Max
261557|NCT02498730|Behavioral|Continuous Training|Continuous Stimulous at 60% VO2Max
261558|NCT02498730|Behavioral|Control|Only Dependent Variables Measures
261559|NCT02498743|Procedure|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
261560|NCT02498743|Behavioral|Watching Animated cartoons|
261561|NCT00002482|Biological|biological therapy|
261562|NCT00178503|Drug|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
261879|NCT02494687|Drug|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
261880|NCT02494700|Radiation|Radiation Therapy|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy.
261881|NCT02494713|Drug|Degarelix|Subcutaneous injection, once/month for 4 months
261882|NCT02494713|Drug|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
261883|NCT02496741|Drug|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
261884|NCT02496754|Drug|GnRH-a|In experimental group, patients use long term GnRH-a;
261885|NCT02496754|Drug|GnRH-a|In control group, patients use short term GnRH-a.
261886|NCT02496767|Drug|tirasemtiv|
261887|NCT02496767|Drug|Placebo tablets|
261888|NCT02496780|Drug|novolog insulin|3x daily rapid-acting insulin
261271|NCT00174785|Drug|placebo|oral administration (tablets)
261272|NCT02469402|Dietary Supplement|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
261273|NCT02469415|Drug|Pacritinib|Part 1: Pacritinib 200 mg taken by mouth twice daily.
Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy.
261274|NCT02469415|Drug|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
261275|NCT02469415|Drug|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
261276|NCT02469428|Other|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
261277|NCT02469428|Other|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
261278|NCT02469454|Drug|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
261279|NCT02469454|Drug|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
261280|NCT02469467|Dietary Supplement|VS-505|VS-505 is orally administered with meal for 8 weeks
261281|NCT02469480|Drug|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
261563|NCT02498756|Biological|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
261564|NCT02498756|Drug|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
261565|NCT02498769|Drug|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
261566|NCT02500914|Drug|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
261567|NCT00178776|Behavioral|Education & Advice|
261568|NCT02500927|Drug|ASP8273 Capsules|oral
261569|NCT02500927|Drug|ASP8273 Capsules A|oral
261570|NCT02500940|Drug|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
260991|NCT02475876|Drug|trimethoprim-sulfamethoxazole|Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:
Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.
Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose = 6 mg/kg.
Cohort 3; No. Subjects = 5; Age >1-2 years; Dose = 6 mg/kg.
Cohort 4; No. Subjects = 4; Age >2-6 years; Dose = 6 mg/kg.
Cohort 5; No. Subjects = 4; Age >6-12 years; Dose = 6 mg/kg.
Cohort 6; No. Subjects = 4; Age >12-16 years; Dose = 4 mg/kg.
260992|NCT02475889|Procedure|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
260993|NCT02475889|Procedure|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
260994|NCT02475902|Behavioral|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
260995|NCT00175604|Drug|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
260996|NCT02475902|Behavioral|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
260997|NCT02475915|Drug|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
260998|NCT02475915|Drug|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
260999|NCT02475915|Drug|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
261000|NCT02475915|Drug|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
261001|NCT02475915|Drug|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
261002|NCT02475915|Drug|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
261003|NCT02475915|Drug|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
261004|NCT02475928|Dietary Supplement|zinc gluconate|Zinc supplementation plus nutritional education
261005|NCT02475928|Dietary Supplement|Placebo|
261006|NCT00175617|Drug|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
261007|NCT02475928|Behavioral|Nutritional education|
261282|NCT00174798|Drug|SSR240600C|once daily
260451|NCT00176865|Drug|Fludarabine, melphalan, ATG or Campath|all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day
260452|NCT02487173|Device|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
260713|NCT02480088|Drug|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
260714|NCT02480088|Drug|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
260715|NCT02480101|Biological|H7N9 live influenza vaccine|H7N9 live influenza vaccine
260716|NCT02480101|Biological|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
260717|NCT02482636|Biological|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
260718|NCT02482636|Biological|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
260719|NCT02482636|Biological|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
260720|NCT02482636|Biological|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
260721|NCT00176462|Drug|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
260722|NCT02482636|Biological|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
260723|NCT02482636|Biological|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
260724|NCT02482649|Behavioral|EAA/T|bi-weekly for 12weeks
260725|NCT02482649|Drug|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
260726|NCT02482649|Drug|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
260727|NCT02482662|Procedure|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
260728|NCT02482675|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
260729|NCT02482675|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
260730|NCT02482675|Other|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
260163|NCT02491411|Other|Quality-of-Life Assessment|Ancillary studies
260164|NCT02491424|Device|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
260165|NCT02491437|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
260166|NCT02491437|Drug|intravaginal progesterone gel 90 mg|
260167|NCT02493777|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
260168|NCT02493790|Other|Cognitive and motor performances|
260169|NCT00177671|Drug|Donepezil|Donepezil, 5mg to 10mg daily.
260170|NCT02493803|Behavioral|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
260171|NCT02493816|Drug|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
260172|NCT02493829|Biological|AML Cell Vaccine|
260453|NCT02487173|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
260454|NCT02487173|Device|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
260455|NCT02487186|Drug|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
260456|NCT02487186|Procedure|Full-mouth debridment|The patients will be treated by a single-session of periodontal debridement
during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de
Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed.
260457|NCT02487199|Drug|Ombitasvir/Paritaprevir/Ritonavir|
260458|NCT02487199|Drug|Dasabuvir|
260459|NCT02487212|Drug|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
259869|NCT02500212|Drug|ENVARSUS®|
259870|NCT02500212|Drug|ADVAGRAF®|
259871|NCT02500225|Drug|Etomidate|0.2 mg/kg etomidate
259872|NCT02500225|Drug|Sevoflurane|8% Sevoflurane
259873|NCT02500238|Other|Saliva sample|All participants will provide a saliva sample.
259874|NCT02500238|Other|Urine Sample|All participants will provide a urine sample.
259875|NCT02500238|Other|Toe nail clippings|All participants will provide toe nail clippings.
259876|NCT02500238|Other|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
259877|NCT02500251|Drug|belimumab|Belimumab will be administered per study protocol.
259878|NCT00178711|Device|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
259879|NCT02500251|Drug|Bortezomib|Bortezomib will be administered per study protocol.
259880|NCT02500251|Drug|Rituximab|Rituximab will be administered per study protocol.
260173|NCT02493842|Device|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
260174|NCT02493855|Drug|ombitasvir/ABT-450/ritonavir|ombitasvir/ABT-450/ritonavir tablets
260175|NCT02493855|Drug|dasabuvir|dasabuvir tablets
260176|NCT02493855|Drug|ribavirin|ribavirin tablets
260177|NCT02493868|Drug|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. From Day 4 to 15, dose may be adjusted per protocol at investigator's discretion based on efficacy and/or tolerability. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
260178|NCT02493868|Drug|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
259568|NCT02468804|Device|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
259569|NCT00174707|Drug|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
259570|NCT02468804|Device|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
259571|NCT02468817|Procedure|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
259572|NCT02468817|Procedure|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
259573|NCT02468830|Drug|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
259574|NCT02468843|Device|Biphasic DBS stimulation|The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.
Current best/optimized DBS setting (considered "baseline")
DBS off for 30 minutes
Biphasic pulse stimulation mode (immediate assessment)
Biphasic pulse stimulation mode (assessment at 1h)
Biphasic pulse stimulation mode (assessment at 2h)
259575|NCT02468843|Other|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
259576|NCT02468843|Other|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
259577|NCT02471105|Drug|Tafluprost Unit Dose Preservative Free 15microgram/ml|Eye drops solution Topical use Once in the evening 3 months
259578|NCT02471118|Drug|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
259579|NCT02471118|Drug|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
259580|NCT02471131|Device|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
259881|NCT02500251|Drug|Plasmapheresis|Plasmapheresis will be administered per study protocol.
259882|NCT02500264|Device|TENS|
259883|NCT02500277|Device|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
264145|NCT02367040|Drug|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
264146|NCT02367053|Drug|ZP4207|
259581|NCT02471144|Biological|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
259582|NCT02471144|Biological|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
259583|NCT02471144|Biological|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(<25 kg, 25- <50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
259584|NCT02471144|Biological|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
259585|NCT02471157|Other|Observation|
259586|NCT00174967|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
259587|NCT02471183|Drug|Selexipag|Tablet for oral administration twice a day. The individual dose will be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
259588|NCT02471196|Drug|ORM-12741|ORM-12741 low dose twice a day
259589|NCT02471196|Drug|ORM-12741|ORM-12741 high dose twice a day
259590|NCT02471196|Drug|Placebo|Placebo twice a day
259591|NCT02471209|Drug|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
259592|NCT02471222|Drug|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
259593|NCT02471222|Other|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
263850|NCT02372058|Device|BiliCare|Three non invasive measurements of TcB:
Two measurements with the BiliCare device and one measurement with a competitive FDA approved device
263851|NCT02372071|Device|BiliCare|Two measurements with the BiliCare device
263852|NCT02372084|Drug|osilodrostat|
263853|NCT00160251|Biological|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
263854|NCT02372097|Drug|SYR-472|SYR-472 25mg, 50mg
263855|NCT02372110|Drug|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
263856|NCT02372110|Drug|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
264147|NCT02367053|Drug|Glucagon|
264148|NCT02367066|Drug|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
264149|NCT02367066|Other|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
264150|NCT00159718|Drug|atorvastatin|
264151|NCT02367079|Device|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
264152|NCT02367092|Behavioral|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
264153|NCT02367105|Drug|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
264154|NCT02367105|Other|Lifestyle Therapy|Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week
264155|NCT02367105|Drug|Placebo|Placebo gel for testosterone
264156|NCT02367118|Drug|Prednisone|
264157|NCT02367118|Drug|Placebo|
264158|NCT02367131|Drug|Jardiance|Empagliflozin
264159|NCT02367157|Procedure|Kenzo Kase Method|
264160|NCT02367157|Device|Kinesio Taping|
264161|NCT00159731|Drug|Pregabalin|
263561|NCT02378558|Device|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
263562|NCT02378571|Behavioral|Medication adherence telemonitoring|The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
263563|NCT02378584|Other|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
263564|NCT02378597|Behavioral|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
263565|NCT02378610|Other|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
263566|NCT02378623|Drug|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
263857|NCT02374099|Drug|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
263858|NCT02374099|Drug|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
263859|NCT00160433|Drug|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
263860|NCT02374112|Dietary Supplement|Creatine|Creatine supplementation
263861|NCT02374112|Other|Placebo|Placebo supplementation
263862|NCT02374125|Device|Diacutaneous Fibrolysis|Applied only around teres major muscle.
263863|NCT02374125|Other|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
263864|NCT02374125|Other|Protocolized physiotherapy|Exercises, TENS and cryotherapy
263865|NCT02374138|Behavioral|Parental stress management|The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by "community wellness coaches."
263866|NCT02374138|Other|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
263867|NCT02374151|Device|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
263275|NCT02385747|Procedure|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
263276|NCT02385760|Drug|CTX-4430|
263277|NCT00161980|Procedure|Surgical intervention alone without Fibrin Sealant VH S/D application|
263278|NCT02385760|Drug|Placebo|
263279|NCT02385773|Dietary Supplement|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
263280|NCT02385773|Dietary Supplement|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
263281|NCT02385786|Behavioral|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
263282|NCT02385799|Drug|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
263283|NCT02385799|Drug|Sertraline|Active medication
263284|NCT02385812|Procedure|Low-dose computed tomography Annual scan x3|Annual scan x3
263285|NCT02385812|Procedure|Low-dose computed tomography Baseline scan only|Baseline scan only
263286|NCT02385825|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
263567|NCT02378623|Drug|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
263568|NCT02378636|Device|600S|Monofocal Aspheric Intraocular Lens (IOL)
263569|NCT02380846|Other|White rice|Control - white rice
263570|NCT02380846|Other|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
263571|NCT02380846|Other|Rice with fish|Treatment 2 - steamed white rice with steamed fish
263572|NCT02380846|Other|Rice with egg white|Treatment 3 - steamed white rice with egg white
263573|NCT02380846|Other|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
262993|NCT02392728|Behavioral|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
262994|NCT02392728|Behavioral|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
262995|NCT02392741|Other|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
262996|NCT02392754|Device|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
262997|NCT02392767|Dietary Supplement|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
262998|NCT02392780|Drug|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
262999|NCT02392780|Drug|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
263000|NCT02392780|Drug|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
263001|NCT02392793|Drug|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
263002|NCT00162890|Behavioral|Therapeutic exercise|
263003|NCT02392793|Drug|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
263004|NCT02392793|Drug|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
263005|NCT02392806|Device|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus verses B&B Bubbler at time of extubation
263006|NCT02392806|Device|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to BabiPlus verses B&B Bubbler at time of extubation
263007|NCT02392819|Dietary Supplement|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
263287|NCT02385838|Behavioral|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
263288|NCT00161993|Drug|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
286896|NCT02651402|Behavioral|FRIENDS for Life|Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
286897|NCT02651402|Behavioral|Adapted FRIENDS|Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
286898|NCT02651402|Behavioral|Train-the-Trainer|Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
286899|NCT02651402|Behavioral|Train-the-Trainer Plus|Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
286900|NCT02651415|Drug|Regorafenib|Stivarga® will be used as per the marketed indication ("on label"), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.
Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is <30% fat, ~300-550 calories.
286901|NCT00196872|Drug|Ibandronat|Ibandronat is given
286902|NCT02651415|Drug|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
286903|NCT02653326|Behavioral|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
286904|NCT02653326|Other|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
286905|NCT02653326|Drug|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
286906|NCT02653339|Drug|Qufeng Shengshi Fang and Ebastine|The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The experimental group patients are treated with Qufeng by oral, 200ml two times a day and ebastine by oral,10mg QD
286907|NCT02653339|Drug|Ebastine|The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The control group patients are treated with ebastine by oral, 10mg QD
286355|NCT02661958|Drug|S6G5T-1|once a day topical cream
286356|NCT02661958|Drug|S6G5T-5|once a day topical cream
286357|NCT02664220|Procedure|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
286629|NCT02657733|Device|Nellcor™ Bedside Respiratory Patient Monitoring System|Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.
Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi).
286630|NCT02657733|Device|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
286631|NCT02657746|Other|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
286632|NCT02657759|Dietary Supplement|CARDICHOL|
286633|NCT02657759|Dietary Supplement|PLACEBO|
286634|NCT02657785|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
286635|NCT02657811|Device|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
286636|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
286637|NCT00197756|Dietary Supplement|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
286638|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
286639|NCT02657824|Other|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
286640|NCT02657850|Other|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
286055|NCT02668653|Drug|Daunorubicin|
286056|NCT02668653|Drug|Idarubicin|
286057|NCT02668653|Drug|Quizartinib|
286058|NCT02668653|Drug|Placebo|
286059|NCT02668666|Drug|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
286060|NCT02668666|Drug|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
286061|NCT00198991|Procedure|CNS irradiation|
286062|NCT02668679|Procedure|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
286063|NCT02668679|Device|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
286358|NCT02664233|Behavioral|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
286359|NCT02664246|Device|percutaneous coronary intervention|
286360|NCT00198692|Behavioral|self-management|
286361|NCT02664259|Procedure|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
286362|NCT02664259|Procedure|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
286363|NCT02664259|Procedure|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
286364|NCT02664272|Procedure|Total Hip Arthroplasty|
286365|NCT02664285|Other|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
286366|NCT02664285|Other|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
286367|NCT02664311|Device|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
285774|NCT02676193|Behavioral|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
285775|NCT02678364|Dietary Supplement|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
285776|NCT02678377|Drug|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
285777|NCT02678377|Drug|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
285778|NCT02678390|Dietary Supplement|MCT supplement|30 g of MCT per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.
285779|NCT02678390|Dietary Supplement|MCT supplement + physical exercise|30 g of MCT per day in combination with 30 minutes of aerobic exercise (70% to 80% HRMax) per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.
285780|NCT02678403|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
285781|NCT00199251|Drug|RUPATADINE|
285782|NCT02678403|Device|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
285783|NCT02678416|Drug|IV Acetaminophen|IV formulation
285784|NCT02678416|Drug|IV Morphine|IV formulation
286064|NCT02668679|Biological|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
286065|NCT02668679|Other|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
286066|NCT02668692|Drug|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
286067|NCT02668692|Drug|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
286068|NCT02668705|Other|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
286069|NCT02668718|Radiation|Adjuvant radiotherapy|The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
261889|NCT02496780|Drug|levemir insulin|basal insulin once a day
261890|NCT02496780|Drug|placebo|once or 3x daily
261891|NCT02496793|Behavioral|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
261892|NCT02496806|Dietary Supplement|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
261893|NCT00178178|Drug|Placebo|Drug: Placebo
261894|NCT02496819|Other|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
261895|NCT02496819|Other|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
261896|NCT02496819|Other|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
261897|NCT02496832|Drug|18F-Fluoroazomycin arabinoside|
261898|NCT02496845|Drug|VL#FIA3-30|Vasoactive dual treatment (MH30-01 & IS045-01)
261899|NCT02496871|Behavioral|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
262195|NCT02489955|Drug|Tobramycin|
262196|NCT02489955|Drug|Colomycin|
262197|NCT02489968|Drug|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
262198|NCT02489968|Drug|empagliflozin 10 mg|empagliflozin low dose once daily
262199|NCT00177229|Behavioral|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
262200|NCT02492256|Device|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
261571|NCT02500940|Drug|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
261572|NCT02500940|Radiation|Radiation therapy|Intensity-Modulated Radiation Therapy
261573|NCT02500940|Drug|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
261574|NCT02500953|Drug|ASP3325|
261575|NCT02500953|Drug|Placebo|
261576|NCT02500966|Device|DUDA device|Insertion DUDA device
261577|NCT02500966|Procedure|LEEP|Loop Electrosurgical Excision Procedure
261578|NCT00178802|Other|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days
Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour
Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily
Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol
261579|NCT02500979|Drug|Pramlintide acetate|Pramlintide acetate administered by a separate pump
261580|NCT02500979|Drug|Placebo|Placebo administered by separate pump
261581|NCT02500979|Drug|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
261582|NCT02500979|Drug|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
261583|NCT02500992|Procedure|Transrectal sigmoidectomy|
261584|NCT02501005|Procedure|VT ablation|Catheter ablation of ventricular tachycardia
261585|NCT02501018|Biological|CLBS12|Intramuscular transfusion of CLBS12.
261586|NCT02501018|Drug|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
261900|NCT02496871|Behavioral|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
261901|NCT02496884|Drug|DS-5565|7.5 mg tablet DS-5565
261902|NCT02496884|Drug|placebo|placebo tablet to match 7.5mg tablet DS-5565
261903|NCT02496897|Biological|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
261904|NCT00178191|Other|Bladder diary|3-day bladder diary
261905|NCT02496897|Other|Placebo|Placebo
261283|NCT02469480|Drug|Ferro sanol|200 mg ferro sanol per day over 12 weeks
261284|NCT02469493|Device|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
261285|NCT02469506|Device|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
261286|NCT02469519|Drug|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
261287|NCT00175019|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
261288|NCT02471898|Drug|Placebo|Saline
261289|NCT02471911|Drug|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
261290|NCT02471911|Drug|Rituximab|IV Rituximab 375 mg/m2 on D1
261291|NCT02471911|Drug|Etoposide|IV Etoposide 100 mg/m2 on D1-3
261292|NCT02471911|Drug|Carboplatin|IV Carboplatin AUC 5 on D2
261293|NCT02471911|Drug|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
261294|NCT02471911|Drug|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
261295|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
261296|NCT02471937|Biological|Bacteriological analyses on clinical samples performed with Eswabs|Clinical samples analysed :
mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR
261297|NCT02471950|Procedure|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
261298|NCT00175019|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
261299|NCT02471963|Drug|Empagliflozin|
261300|NCT02471963|Drug|Placebo|
260731|NCT02482675|Other|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
260732|NCT00176462|Drug|Leucovorin|
260733|NCT02482688|Behavioral|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
261008|NCT02475941|Other|Non Weight bearing|The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).
The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient.
261009|NCT02478008|Device|CardiAQ TMVI System (Transapical DS)|
261010|NCT02478021|Other|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
261011|NCT02478034|Other|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
261012|NCT02478047|Drug|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
261013|NCT02478047|Other|Matching points ST36+CV12 plus antiemetic drug|Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a "de Qi" sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.
261014|NCT00175916|Drug|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
261015|NCT02478047|Other|Matching points PC6+CV12 plus antiemetic drug|Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a "de Qi" sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.
260460|NCT02487212|Drug|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
260461|NCT02489149|Other|Multi-sector interventions|Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.
For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.
For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.
Helping families to have more knowledge about your citizen rights.
260462|NCT02489149|Other|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
260463|NCT02489162|Device|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
260464|NCT02489162|Device|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
260465|NCT02489175|Device|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
260466|NCT02489188|Procedure|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
260467|NCT02489188|Other|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
260734|NCT02482701|Device|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
260735|NCT02482714|Behavioral|Physical activity.|Have subject do moderate physical activity.
260736|NCT02482727|Device|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
260737|NCT02482740|Drug|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
260738|NCT02482740|Drug|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
260739|NCT02482753|Drug|Chidamide|30 mg, administered orally twice per week (BIW)
260179|NCT02493868|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
260180|NCT00177671|Drug|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
260181|NCT02493868|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
260182|NCT02493868|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
260183|NCT02493868|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
260184|NCT02493881|Device|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
260185|NCT02493894|Drug|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
260186|NCT02496065|Drug|BLZ-100|
260187|NCT02496078|Drug|Daclatasvir|Daclatasvir tablet 60mg
260188|NCT02496078|Drug|Asunaprevir|Asunaprevir soft capsule 100 mg
260468|NCT02489188|Procedure|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
260469|NCT00177112|Procedure|clean patient preparation for cystoscopy|
260470|NCT02489201|Drug|donafenib tosilate tablets|200mg,bid
260471|NCT02489214|Drug|donafenib tosilate tablets|200mg bid
260472|NCT02489227|Drug|CHS-1420|
260473|NCT02489227|Drug|Adalimumab|
260474|NCT02489240|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
260475|NCT02489240|Drug|placebo|2000 IU placebo tablets were taken daily for 6 days
259884|NCT02500277|Device|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
259885|NCT02500316|Drug|MOD-4023|Once weekly subcutaneous injection
259886|NCT02500329|Drug|Gemigliptin|Gemigliptin for 4 weeks
259887|NCT02500329|Drug|Acarbose|Acarbose for 4 weeks
259888|NCT02500342|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
259889|NCT00178724|Other|No treatment|Intervention is not given.
259890|NCT02500342|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
259891|NCT02500355|Procedure|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
259892|NCT02500355|Procedure|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
259893|NCT02466724|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
259894|NCT02466737|Procedure|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
259895|NCT02466737|Procedure|SLNB versus completion ALND|in cases with 1-2 macrometastases in sentinel lymph nodes
259896|NCT02466750|Biological|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
259897|NCT02466763|Procedure|Cochlear implant surgery|Surgical placement of a cochlear implant device.
259898|NCT02466776|Device|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean section.
260189|NCT02496091|Device|ATLANTIS Abutment|
260190|NCT02496104|Behavioral|Package n°1 of the APIB|
260191|NCT02496117|Procedure|Electrical mapping, nerve stimulation checked renal denervation procedure|
259594|NCT02471235|Behavioral|Physiotherapy|Pulmonary rehabilitation
259595|NCT02473211|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
259596|NCT02473211|Drug|Daclatasvir|Daclatasvir 60mg tablet administered once daily
259597|NCT00175201|Procedure|Proactive care and rehabilitation|
259899|NCT02466776|Device|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean section.
259900|NCT02466802|Drug|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
259901|NCT02466802|Drug|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
259902|NCT02466815|Drug|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
259903|NCT00174486|Drug|Cialis (Tadalafil)|
259904|NCT02466815|Drug|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
259905|NCT02466815|Drug|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
259906|NCT02466828|Drug|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
259907|NCT02466841|Procedure|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
259908|NCT02466867|Drug|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
259909|NCT02466867|Drug|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
259910|NCT02466880|Device|Telemedicine|A diabetes self-management and education program delivered via telemedicine
259911|NCT02466880|Other|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
264162|NCT02367170|Procedure|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
264163|NCT02367170|Drug|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
264164|NCT02369484|Drug|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
264165|NCT02369497|Device|HRA|Humeral head resurfacing with the HRA device
264166|NCT02369510|Drug|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
264167|NCT00159926|Procedure|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
259598|NCT02473224|Biological|Snow Mountain stool filtrate|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10^2 GEC or 1.2 x10^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, or 1.2 x 10^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: either 1.2 x 10^6 GEC or 1.2 x 10^4 GEC.
259599|NCT02473224|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
259600|NCT02473237|Drug|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
259601|NCT02473237|Drug|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
259602|NCT02473250|Drug|Fluoxetine|Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
259603|NCT02473263|Drug|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
259604|NCT02473263|Drug|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
259605|NCT02473263|Drug|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
259606|NCT02473263|Drug|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
259607|NCT02473276|Drug|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
259608|NCT00175214|Behavioral|Multifaceted intervention (patient education, physician guidelines, reminders)|
263868|NCT02374164|Drug|Febuxostat XR 40 mg|Febuxostat XR 40 mg tablets orally administered as a single dose.
263869|NCT02374164|Drug|Febuxostat XR 80 mg|Febuxostat XR 80 mg tablets orally administered as a single dose.
263870|NCT00160433|Drug|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
263871|NCT02374190|Other|Standard Hospital Care|Retrospective, observational analysis will be used to examine the relationship between primary care, pre‐hospital patient status, acute clinical management and patient outcomes. Standard hospital care is here defined as interventional (e.g., primary angioplasty) and pharmaceutical (e.g., warfarin, beta-blockers) care provided to patients during index hospitalization for MI.
263872|NCT02374203|Dietary Supplement|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
263873|NCT02374216|Procedure|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
263874|NCT02374229|Procedure|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
263875|NCT02374229|Procedure|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
264168|NCT02369510|Drug|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
264169|NCT02369510|Drug|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
264170|NCT02369523|Drug|Exparel|Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
264171|NCT02369523|Drug|Ropivacaine cocktail (PIC)|400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
264172|NCT02369523|Drug|Bupivacaine|Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.
Sciatic nerve block - 0.125% bupivacaine
264173|NCT02369536|Dietary Supplement|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
264174|NCT02369536|Dietary Supplement|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
264175|NCT02369549|Other|Micro-particle Curcumin|as described in Arm
264176|NCT02369549|Other|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
263574|NCT02380859|Device|Goggles with fitted lenses that distort vision|These distortions include but are not limited to restricting the visual field to only a narrow window and fogging the vision
263575|NCT02380872|Procedure|Connective tissue graft|gingival recession treated with connective tissue graft
263576|NCT02380872|Procedure|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
263577|NCT02380885|Behavioral|SCIT|psychosocial group intervention
263578|NCT00161382|Behavioral|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
263579|NCT02380885|Behavioral|TAFT|psychosocial group intervention
263580|NCT02380898|Drug|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
263581|NCT02380898|Drug|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
263582|NCT02380911|Other|Educational Intervention|Multifaceted educational intervention targeting physicians improves detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina
263583|NCT02380924|Drug|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
263584|NCT02380924|Drug|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
263585|NCT02380937|Procedure|ablation for typical atrial flutter|ablation for typical atrial flutter
263586|NCT02380937|Device|Vision Ablation Catheter|
263876|NCT02374242|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD‐1 (programmed death‐1 or programmed cell death‐1/PCD‐1) with immunopotentiation activity.
263877|NCT02374242|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4). CTLA‐4 is a negative regulator of T‐cell activation. Ipilimumab binds to CTLA‐4 and blocks the interaction of CTLA‐4 with its ligands, CD80/CD86. Blockade of CTLA‐4 has been shown to augment T‐cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T‐cell mediated anti‐tumour immune responses.
263878|NCT02376153|Device|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
263879|NCT02376166|Drug|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade > 1 toxicities)
263880|NCT02376179|Device|Cuff ETT|
263289|NCT02385838|Behavioral|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
263290|NCT02385838|Behavioral|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
263291|NCT02385838|Behavioral|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
263292|NCT02388165|Biological|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
263293|NCT02388165|Other|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
263294|NCT02388178|Drug|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
263295|NCT02388178|Drug|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
263296|NCT00162279|Drug|Abatacept|
263297|NCT02388178|Drug|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
263298|NCT02388191|Drug|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
263299|NCT02388191|Other|Placebo tablet|
263300|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
263301|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
263302|NCT02388230|Device|Ultrasound imaging|
263303|NCT02388243|Behavioral|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
263587|NCT02380950|Behavioral|250 ml alcohol consumption|Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser "Dräger Alcotest 7510".
287186|NCT02646540|Drug|2.5 times the Diuretics Dose|Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
287187|NCT02646553|Other|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
287188|NCT02646566|Drug|APD421|
287189|NCT02646566|Drug|Placebo|
287190|NCT02646579|Device|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
287191|NCT02646579|Device|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
287192|NCT02646592|Drug|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
287193|NCT02646592|Drug|sevoflurane or propofol|
287194|NCT00196391|Drug|DR-2021d|1 capsule daily for 10 days
287195|NCT02646605|Other|depression screening|Patient Health Questionnaire
287196|NCT02646618|Behavioral|Get Social|Online-delivered weight loss intervention
287197|NCT02646618|Behavioral|Traditional|Group-delivered weight loss intervention
287198|NCT02646618|Device|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
287199|NCT02646631|Other|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
287200|NCT02648841|Radiation|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
287201|NCT00196625|Drug|Amprenavir (drug)|
287202|NCT02648841|Drug|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
287203|NCT02648841|Drug|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
286641|NCT02657850|Other|head neck self reporting|head and neck patient self reports dysphagia symptoms
286642|NCT02657850|Other|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
286643|NCT02657863|Procedure|urine and blood draw|
286644|NCT02659800|Other|Laboratory Biomarker Analysis|Correlative studies
286645|NCT02659800|Biological|Glycosylated Recombinant Human Interleukin-7|Given IV
286908|NCT02653352|Behavioral|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
286909|NCT02653365|Device|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
286910|NCT00197132|Drug|Avandia|
286911|NCT02653378|Behavioral|DIET|25% Energy Depletion by Diet only for 3 Days
286912|NCT02653378|Behavioral|EX|25% Energy Depletion by Exercise only for 3 Days
286913|NCT02653391|Drug|MTP-131 1.0% Ophthalmic Solution|Each subject will receive one drop of MTP-131 1.0% ophthalmic solution in the randomly selected study eye BID and one drop of vehicle ophthalmic solution BID in the fellow control eye.
286914|NCT02653391|Drug|Vehicle Control|Each subject will receive one drop of MTP-131 1.0% ophthalmic solution in the randomly selected study eye BID and one drop of vehicle ophthalmic solution BID in the fellow control eye.
286915|NCT02653404|Other|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
286916|NCT02653417|Drug|RAD1901|RAD1901
286917|NCT02653417|Other|Placebo|Placebo
286918|NCT02653430|Procedure|Sleeve gastrectomy|After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate the"Sleeve gastrectomy laparoscopically" by a group of experienced surgeons.
286919|NCT02653443|Biological|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
286368|NCT02664311|Device|Conventional ventilation|Conventional ventilator - control arm
286369|NCT02664337|Other|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
286370|NCT02664337|Other|Standard treatment information|Participants will receive information pertaining to one of the 11 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
286371|NCT00198705|Behavioral|Improved management of severe neonatal infections|
286372|NCT02664350|Genetic|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
286373|NCT02664350|Behavioral|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 1, 2, and 4.
286374|NCT02664350|Behavioral|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 1, 2, and 4.
286375|NCT02664350|Genetic|OPRM1|Genetic testing of the OPRM1 will be performed at week 4.
286646|NCT02659800|Other|Placebo|Given IV
286647|NCT02659813|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
286648|NCT02659826|Device|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
286649|NCT02659826|Device|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
286650|NCT00198094|Drug|Sertraline and Alprazolam XR|
286651|NCT02659826|Device|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
286652|NCT02659826|Device|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
286070|NCT02671201|Other|Education|Different methods in education of emergency ultrasound
286071|NCT02671214|Other|Control|100 g high fibre flour
286072|NCT02671214|Other|Active 2|98 g high fibre flour + 2 g guar gum
286073|NCT02671214|Other|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
286074|NCT02671214|Other|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
286075|NCT02671214|Other|Active 5|96 g high fibre flour + 4 g guar gum
286076|NCT02671214|Other|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
286077|NCT02671214|Other|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
286078|NCT02671214|Other|Active 8|94 g high fibre flour + 6 g guar gum
286079|NCT02671214|Other|Active 9|98 g high fibre flour + 2 g konjac mannan
286080|NCT00199017|Drug|VP16|
286081|NCT02671214|Other|Active 10|96 g high fibre flour + 4 g konjac mannan
286082|NCT02671214|Other|Active 11|100 g low fibre flour
286083|NCT02671214|Other|Active 1|85 g high fibre flour + 15 g legume flour
286084|NCT02671227|Drug|intrathecal morphine .|intrathecal morphine 0.1 mg.
286085|NCT02671227|Drug|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
286086|NCT02671227|Drug|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
286376|NCT02664363|Biological|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
286377|NCT02666495|Other|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement & stabilisation; phase 2 - developing trust & understanding; phase 3 - developing awareness & acceptance; phase 4 - testing change & strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
262201|NCT02492256|Device|GP ablation guided by SUMO technology|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)
• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
262202|NCT02492256|Device|ILR implantation|Implantation the ECG loop recorder according to standard procedure
262203|NCT02492269|Drug|Dexmedetomidine|
262204|NCT02492269|Drug|Placebo|
262205|NCT02492282|Device|Closed-Loop propofol and remifentanil system by Bispectral Index|
262206|NCT02492282|Device|Open-Loop propofol and remifentanil by Target Controlled Infusion|
262207|NCT00177541|Behavioral|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
262208|NCT02492282|Drug|propofol|
262209|NCT02492295|Drug|Propofol|Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 ("light sedation - awakens to voice <10 seconds") to RASS target of -3 ("moderate sedation - movement or eye opening without eye contact") for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge.
262210|NCT02492308|Procedure|SVF-MSC induction|Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.
Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD
262211|NCT02492308|Drug|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
262212|NCT02492321|Drug|EBI-005|
262213|NCT02492321|Drug|Placebo Comparator|
262503|NCT00176917|Drug|Busulfan, Cyclophosphamide, ATG|Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow "take" and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
262504|NCT02487914|Device|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
262505|NCT02487914|Drug|Lidocaine 10% was sprayed at the identified region|
262506|NCT02487914|Device|interferential current|
261906|NCT02496897|Other|IC31® Adjuvant|IC31® Adjuvant
261907|NCT02496910|Drug|YH22162|
261908|NCT02496910|Drug|Telmisartan/Amlodipine 80/5 mg (FDC)|
261909|NCT02496910|Drug|Chlorthalidone 25mg|
261910|NCT02498769|Drug|Placebo|
261911|NCT02498782|Drug|Fexinidazole|
261912|NCT02498782|Drug|Placebo|
261913|NCT02498795|Other|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
261914|NCT02498795|Other|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
261915|NCT02498795|Other|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
261916|NCT02498821|Device|X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to makes sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
261917|NCT00178503|Drug|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
261918|NCT02498821|Device|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
261919|NCT02498821|Procedure|Peripherally Inserted Central Catheter (PICC)|
261920|NCT02498834|Behavioral|Educational Video and Question Prompt List|Educational Video and Question Prompt List
262214|NCT02492334|Drug|Doxazosin|Doxazosin is a quinazoline compound that is a selective inhibitor of the alpha-1 subtype of alpha-adrenergic receptors. The chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate. The molecular formula for doxazosin is C23H25N5O5 • CH4O3S and the molecular weight is 547.6. Doxazosin is used clinically to treat hypertension and improve urination in men with benign prostatic hyperplasia.
262215|NCT02492334|Drug|Placebo|Placebo, or inactive pill.
261587|NCT02501031|Dietary Supplement|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for ~ 2 months
261588|NCT02501057|Behavioral|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
261589|NCT00178828|Drug|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
261590|NCT02501057|Behavioral|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
261591|NCT02501057|Behavioral|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
261592|NCT02467348|Drug|Ascitic fluid|
261593|NCT02467361|Drug|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
261594|NCT02467361|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
261595|NCT02467361|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
261596|NCT02467361|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
261597|NCT00174564|Drug|oxaliplatin|
261598|NCT02467374|Behavioral|Behavior Therapy|BT for OCD focuses primarily on "exposure with response prevention (ERP)." "ERP" involves gradual exposure to anxiety-provoking situations (things or situations that frighten or disturb some people), and will help to prevent compulsions (repetitive behaviors).
261599|NCT02467387|Drug|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
261600|NCT02467387|Drug|Lactated Ringer's Solution|One time infusion 1.5mL/kg
261601|NCT02467400|Drug|Atenolol|beta blocker
261602|NCT02467400|Drug|Nebivolol|beta blocker
261603|NCT02467400|Drug|Propranolol|beta blocker
261604|NCT02467400|Drug|placebo|placebo
261605|NCT02467413|Drug|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
261016|NCT02478047|Other|Matching points CV13+CV12 plus antiemetic drug|Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a "de Qi" sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.
261017|NCT02478060|Biological|Birch-SPIRE|
261018|NCT02478060|Biological|Placebo|
261301|NCT02471976|Other|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
261302|NCT02471989|Dietary Supplement|Low-FODMAP diet|
261303|NCT02471989|Dietary Supplement|GERD diet|
261304|NCT02472002|Biological|Mesenchymal cell therapy|Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow
Registry Type: autologous
Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).
Route of administration: endomyocardial injection
Dose administered: 120-140 x106 MSC (mesenchymal stem cells)
261305|NCT02472015|Procedure|telemedicine|psycho-behavioural care by telemedicine
261306|NCT02472028|Other|blood pressure lowering algorithm|The treatments used in the "enhanced strategy" arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study.
261307|NCT02472028|Other|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
261308|NCT02473835|Other|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
261309|NCT02473835|Other|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
260740|NCT02484794|Behavioral|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
260741|NCT02484794|Behavioral|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
260742|NCT02484807|Other|no intervention, only observation of different groups|
260743|NCT02484820|Device|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
260744|NCT02484833|Drug|Cetuximab|
260745|NCT00176722|Other|table tilt|One group randomized to table tilt. One group will be flat.
260746|NCT02484833|Drug|FOLFIRI|
260747|NCT02484846|Behavioral|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
260748|NCT02484859|Drug|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the infusion will be lowered to 0.05 µg/kg/min, and continued until the patient is extubated.
260749|NCT02484859|Drug|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via pump. The infusion will be started just before the induction.
260750|NCT02484859|Drug|Metoprolol|5 mg of metoprolol will be administered intravenously in 2 minutes after the administration of neuromuscular blocking agent (rocuronium).
261019|NCT02478086|Dietary Supplement|use amine acids parenteral 3.5g|Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet.
261020|NCT02478086|Dietary Supplement|use amine acids parenteral 4g|Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet.
261021|NCT02478099|Drug|MPDL3280A|Anti-PD-L1 antibody
260476|NCT02489253|Other|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
260477|NCT02489266|Biological|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
260478|NCT02489266|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
260479|NCT02489266|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
260480|NCT00177112|Procedure|sterile patient preparation for cystoscopy|
260481|NCT02489266|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
260482|NCT02489279|Behavioral|Attentional Intelligence Method|Participants use the mobile software, Attentional Intelligence Method, on their mobile device to develop sustained attention control and executive control skills that provides self-awareness of attention control. Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
260483|NCT02491450|Drug|Heterosofir|1 tablet contains 400 mg sofosbuvir
260484|NCT00177411|Drug|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
260485|NCT02491450|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
260486|NCT02491463|Biological|GSK vaccine GSK3389245A low dose|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
260487|NCT02491463|Biological|GSK vaccine GSK3389245A high dose|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
260488|NCT02491463|Biological|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
260489|NCT02491463|Drug|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
260751|NCT02484885|Other|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
260752|NCT02484898|Device|SEEQ™ MCT/ECM System.|
260753|NCT02484911|Drug|Olanzapine|5mg,twice a day orally on day 1 to day 4
260754|NCT02484911|Drug|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
260192|NCT02496117|Procedure|Electrial mapping, nerve stimulation guided renal denervation procedure|
260193|NCT02496143|Drug|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
260194|NCT00178113|Drug|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
260195|NCT02496143|Drug|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
260196|NCT02496156|Behavioral|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
260197|NCT02496156|Behavioral|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
260198|NCT02496169|Device|eucaLimus|Percutaneous Coronary Intervention (PCI)
260199|NCT02496182|Drug|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
260200|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
260201|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
260202|NCT02496208|Drug|Cabozantinib S-malate|Given PO
260203|NCT02496208|Biological|Ipilimumab|Given IV
260204|NCT02496208|Other|Laboratory Biomarker Analysis|Correlative studies
260205|NCT00178113|Drug|- Certagen (multivitamins with minerals)|
260206|NCT02496208|Biological|Nivolumab|Given IV
260207|NCT02496221|Drug|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
260208|NCT02496221|Drug|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
260209|NCT02496221|Drug|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
259912|NCT02468856|Drug|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Psychomotor Vigilance Task (PVT), Go/no-go association task (GNAT), Flanker inhibitory control and attention task (FLANKER), Iowa Gambling Task (IGT)
259913|NCT02468856|Drug|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Psychomotor Vigilance Task (PVT), Go/no-go association task (GNAT), Flanker inhibitory control and attention task (FLANKER) , Iowa Gambling Task (IGT)
259914|NCT02468869|Other|Communication skills training "emotional skills"|
259915|NCT00174707|Drug|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
260210|NCT02496247|Other|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
260211|NCT02498067|Behavioral|rPlan dual protection waiting room app intervention|
260212|NCT02498080|Procedure|DEB PTA|paclitaxel drug eluting balloon PTA
260213|NCT02498080|Procedure|Standard PTA|Standard PTA
260214|NCT02498093|Behavioral|Maximal strength training|
260215|NCT02498093|Behavioral|conventional rehabilitation|
260216|NCT02498106|Dietary Supplement|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins [B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene] and minerals [Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid [EPA] and docosahexaenic acid [DHA])
260217|NCT02498132|Other|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, & Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
260218|NCT02498132|Other|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
260219|NCT02498132|Other|Treatment as Usual|Individuals will be provided with one on one therapy sessions
260220|NCT00178412|Behavioral|Comparison Group|Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.
Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center.
260221|NCT02498145|Other|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
259609|NCT02473276|Drug|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
259610|NCT02473289|Drug|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
259611|NCT02473289|Drug|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
259612|NCT02473302|Other|ham|160g per day during 4 days
259613|NCT02473302|Other|ham + pomegranate extract|160g per day during 4 days
259614|NCT02473302|Other|ham + tocopherol|160g per day during 4 days
259615|NCT02473302|Other|rare sirloin steak|110g per day during 4 days
259616|NCT02473302|Other|marinated rare sirloin steak|110g per day during 4 days
259617|NCT02473302|Other|marinated cooked sirloin steak|110g per day during 4 days
259618|NCT02473315|Other|cryotherapy|The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).
The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks).
259916|NCT02468869|Other|Communication skills training "information structuring"|
259917|NCT02468882|Dietary Supplement|Watercress|100g of watercress daily during radiation therapy
259918|NCT02468908|Drug|Molgramostim|
259919|NCT02468908|Drug|Placebo|
259920|NCT02468921|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
259921|NCT02468934|Device|Smartpatch Peripheral Nerve Stimulation (PNS) System|The Smartpatch System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The Smartpatch System includes a small wire (called a "Lead") that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).
259922|NCT02468960|Device|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
259923|NCT02468960|Device|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
259924|NCT02468960|Device|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
259925|NCT02468960|Procedure|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
264177|NCT02369562|Procedure|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
264178|NCT00159939|Procedure|prone positioning|prone positioning
264179|NCT02369575|Other|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
264180|NCT02369588|Other|Food portion size|
264181|NCT02369601|Other|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
264182|NCT02369614|Other|Active Comparator: 1 Hz rTMS|1 Hz rTMS
264183|NCT02369614|Other|Active Comparator: 10 Hz rTMS|10 Hz rTMS
264184|NCT02369614|Other|Sham Comparator:|Sham rTMS
264185|NCT02369627|Device|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
264186|NCT02372123|Other|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
264187|NCT02372123|Other|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
259619|NCT00175227|Drug|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
259620|NCT02475317|Drug|Placebo|Subjects will receive matching placebo
259621|NCT02475317|Drug|LUM001|
259622|NCT02475317|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
259623|NCT00175487|Procedure|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
259624|NCT02475330|Dietary Supplement|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
259625|NCT02475343|Device|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
259626|NCT02475343|Device|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
263881|NCT02376192|Device|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
263882|NCT02376192|Drug|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
263883|NCT02376192|Device|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
263884|NCT02376192|Drug|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
263885|NCT02376192|Drug|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
263886|NCT02376205|Drug|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
263887|NCT02376205|Drug|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
263888|NCT00160732|Drug|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
263889|NCT02376218|Drug|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
263890|NCT02376231|Device|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
263891|NCT02376244|Other|High intensity interval training (HIIT)|The exercise training during cardiac rehabilitation delivered as intervals of short intense sessions
263892|NCT02376244|Other|Standard care|The current standard care of longer but less intense exercise sessions
263893|NCT02376257|Drug|250 mg DCS|Drug
264188|NCT02372136|Dietary Supplement|Individualized Nutrition|Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.
In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik KY. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.
In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent ESPGHAN guidelines (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91).
264189|NCT02372136|Dietary Supplement|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
264190|NCT02372149|Drug|10% intravenous immunoglobulin (IVIg)|
263588|NCT02380963|Dietary Supplement|Colorado Diet with soy protein foods.|Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.
Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.
Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.
Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)
263589|NCT00161395|Behavioral|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
263590|NCT02383381|Procedure|lateral rectus recession|typical surgery for correcting intermittent exotropia
263591|NCT02383394|Other|follow up antenatal care|ultrasound follow up of pregnancy
263592|NCT02383407|Device|Medtronic Deep Brain Stimulation|
263593|NCT02383433|Drug|Regorafenib|Given PO
263594|NCT02383433|Drug|Gemcitabine Hydrochloride|Given IV
263595|NCT02383446|Device|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
263596|NCT02383472|Device|MedX Health Console model 1100|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
263597|NCT02383485|Behavioral|Exercise|Heart rate monitors worn by each child at each session
263598|NCT02383485|Behavioral|After-school program|Supervised recreational program with token economy
263599|NCT00161655|Drug|Etanercept|
263600|NCT02383498|Other|GI-6301 Placebo|GI-6301 Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of GI-6301 placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
263601|NCT02383498|Biological|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
263602|NCT02383498|Radiation|Radiotherapy|Standard of care
287204|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
287205|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
287486|NCT00199381|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
287487|NCT02679209|Biological|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
287488|NCT02679209|Biological|Combined membrane and bone allograft|it is a type of bone graft from human cadavers combined with A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
287489|NCT02679209|Procedure|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
287490|NCT02679222|Dietary Supplement|Supplementation|coconut oil and MCT oils (60-40, tricaprylin and triheptanoate)
287491|NCT02681289|Other|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
287492|NCT02681302|Drug|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
287493|NCT02681302|Drug|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
287494|NCT02681315|Device|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
287495|NCT00002535|Drug|cyclophosphamide|
287496|NCT00199771|Drug|7.5% NaCl in 6% dextran 70 solution|
287497|NCT02681315|Device|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
287498|NCT02681328|Other|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
287499|NCT02681328|Other|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
287500|NCT02681354|Other|Biorescue training|
287501|NCT02681367|Other|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
286920|NCT02653443|Biological|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
286921|NCT02655575|Behavioral|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
286922|NCT02655588|Behavioral|Interactive Media-Based Problems Solving Treatment|
286923|NCT02655601|Drug|BMX-001|
286924|NCT02655601|Radiation|Radiation Therapy|
286925|NCT02655601|Drug|Temozolomide|
287206|NCT02648867|Device|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
287207|NCT02648880|Behavioral|Exercise program|Individual exercise sessions in this program implement a "whole body" approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation.
287208|NCT02648880|Other|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
287209|NCT02648893|Other|Multiple biofortified food crops basket (MBFC-Exp)|Four biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
287210|NCT02648893|Other|Commercially available four food crops (MBFC-C)|The Commercially available food crops arm will consume four commercially available food crops three times per day, six days per week, for 9 months.
287211|NCT02648906|Drug|Choline alfoscerate|
287212|NCT00196625|Drug|ABT-378/r (drug)|
287213|NCT02648906|Drug|Placebo|
287214|NCT02648919|Drug|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
287215|NCT02648932|Biological|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
286653|NCT02659826|Device|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
286654|NCT02659826|Device|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
286655|NCT02659826|Device|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
286656|NCT02659839|Other|Standard ICU management|There will be no change in the standard ICU treatment.
286926|NCT02655614|Drug|GDC-0134|GDC-0134 at various doses, depending on the cohort and treatment period.
286927|NCT00197496|Procedure|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
286928|NCT02655614|Drug|Placebo|Placebo at various doses, depending on the cohort and treatment period.
286929|NCT02655627|Other|Internet based exercise training|
286930|NCT02655627|Other|group exercise training|
286931|NCT02655627|Other|Physical activity counselling via a brochure|
286932|NCT02655640|Other|Questionnaires|Questionnaires will be provided to patients
286933|NCT02655653|Drug|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
286934|NCT02655653|Drug|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
286378|NCT02666508|Other|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
286379|NCT02666508|Other|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
286380|NCT02666534|Drug|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
286381|NCT02666534|Device|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
286382|NCT02666534|Drug|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
286383|NCT00198965|Behavioral|dietary education|
286384|NCT02666534|Device|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
286385|NCT02666547|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
286386|NCT02666547|Radiation|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
286387|NCT02666547|Radiation|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
286388|NCT02666560|Device|Auditory Cueing|Auditory cueing set at different frequency rates
286389|NCT02666573|Device|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
286657|NCT02659852|Procedure|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
286658|NCT02661958|Drug|S6G5T-6|once a day topical cream
286659|NCT02661958|Drug|S6G5T-7|once a day topical cream
286660|NCT02661958|Drug|S6G5T-8|once a day topical cream
262507|NCT02487927|Behavioral|weaning|T piece
262508|NCT02487940|Drug|Intralipid 20%|Intralipid administration intravenously on egg collection days in patients with recurrent implantation failure
262509|NCT02487940|Drug|Normal saline|Normal saline given as placebo to women with recurrent implantation failure
262510|NCT02487953|Drug|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
262511|NCT02487953|Other|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
262512|NCT02487953|Other|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
262513|NCT02487953|Other|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
262514|NCT00176930|Procedure|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
262515|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
262516|NCT02487966|Behavioral|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
262517|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
262790|NCT02371551|Other|Conventional routine CT examination|Standard diagnostic examination
262791|NCT02371551|Other|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
262792|NCT00002420|Drug|Delavirdine mesylate|
262793|NCT00160186|Drug|Placebo|Placebo
262794|NCT02371551|Other|Functional MRI|Study-specific diagnostic examination
262216|NCT02492347|Procedure|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
262217|NCT02492360|Procedure|Blood sample collection|Six tubes of blood will be collected during one blood draw.
262218|NCT00177554|Drug|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
262219|NCT02494713|Drug|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
262220|NCT02494713|Drug|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
262221|NCT00177853|Drug|irinotecan|Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
262222|NCT02494713|Drug|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
262223|NCT02494726|Other|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
262224|NCT02494739|Other|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
262225|NCT02494739|Other|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
262226|NCT02494752|Procedure|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
262227|NCT02494752|Procedure|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
262228|NCT02494765|Device|I-gel TM|Airway management with I-gel
262229|NCT02494765|Device|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
262230|NCT02494778|Drug|Pridopidine|45 mg BID
262231|NCT02494791|Behavioral|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
261606|NCT02467413|Other|BAC Matched Vehicle|BAC Matched Vehicle
261607|NCT02467426|Drug|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
261608|NCT00174577|Drug|Risperidone|
261921|NCT02498847|Behavioral|ENGAGE|Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:
What is Osteoarthritis?
Information about treatments
Exercise
Sleep hygiene
Relaxation
Pleasant Activity Scheduling
Goal setting
Problem Solving
Pacing
Communication
261922|NCT02498860|Drug|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
261923|NCT02498860|Drug|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
261924|NCT02498873|Behavioral|Linear Periodization|Linear Intensity Periodization Running
261925|NCT02498873|Behavioral|Non Linear Periodization|Non Linear Periodization Running
261926|NCT02498886|Dietary Supplement|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
261927|NCT02498886|Dietary Supplement|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
261928|NCT00178503|Other|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
261929|NCT02498899|Behavioral|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
261930|NCT02498899|Behavioral|Video|Participants watch a video lasting about 4 minutes.
261931|NCT02501083|Other|no intervention|The study will not include any intervention.
261932|NCT02501096|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
261933|NCT02501096|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
261934|NCT02501109|Drug|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
261935|NCT02501122|Other|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
261936|NCT02501135|Procedure|Femoral nerve block with ropivacaine or bupivacaine|
261310|NCT02473848|Drug|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
261311|NCT02473861|Other|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
261312|NCT02473874|Device|Skin Spect dermoscope|Skin imaging
261313|NCT02473874|Device|Spatially modulated quantitative|Skin imaging
261314|NCT02473887|Drug|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
261609|NCT02467439|Other|Notification cards|detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
261610|NCT02467452|Drug|BDP/FF/GB|
261611|NCT02467452|Drug|FlF/VI + Tiotropium|
261612|NCT02467465|Other|Physical therapy|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
261613|NCT02467465|Device|Dry needling|
261614|NCT02467478|Drug|Linagliptin|5 mg tablet once daily for 12 weeks
261615|NCT02467478|Drug|Placebo|1 tablet daily for 12 weeks
261616|NCT02467491|Device|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
261617|NCT02467504|Drug|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
261618|NCT02467504|Drug|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
261619|NCT02469519|Other|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
261620|NCT02469532|Device|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
261621|NCT02469532|Device|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
261022|NCT02480114|Other|Educational Intervention|Undergo oral care and pain management education session
261023|NCT00176254|Drug|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
261024|NCT02480114|Drug|Gabapentin|Given PO
261025|NCT02480114|Other|Pain Therapy|Receive usual oral health care
261026|NCT02480114|Other|Quality-of-Life Assessment|Ancillary studies
261027|NCT02480114|Other|Questionnaire Administration|Ancillary studies
261028|NCT02480114|Drug|Oxycodone/Acetaminophen|Analgesia
261029|NCT02480114|Drug|Hydrocodone/Acetaminophen|Analgesia
261030|NCT02480114|Drug|Fentanyl|Transdermal Analgesia
261031|NCT02480114|Drug|Ibuprofen|NSAID Analgesia
261032|NCT02480114|Drug|Magic Mouthwash|Oral Solution to treat mucositis
261033|NCT02480127|Procedure|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
261034|NCT00176254|Drug|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
261035|NCT02480140|Other|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
261315|NCT02473900|Drug|HIP1403|oseltamivir 75mg
261316|NCT02473900|Drug|HGP0919|oseltamivir phosphate 75mg
261317|NCT00175279|Behavioral|Opinion leader generated and endorsed evidence summaries|
261318|NCT02473913|Drug|Milk Thistle|
261319|NCT02473913|Drug|Placebo|
261320|NCT02473926|Behavioral|Physical Activity|Physical Activity Program Intervention
261321|NCT02473926|Behavioral|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
260755|NCT02484911|Drug|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
260756|NCT00002476|Drug|vincristine sulfate|
260757|NCT00176735|Drug|Capecitabine|
260758|NCT02484911|Drug|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
260759|NCT02484924|Drug|Ticagrelor|No intervention- purely observational
260760|NCT02484937|Other|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
260761|NCT02487212|Device|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
260762|NCT00176878|Procedure|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.
260763|NCT02487225|Drug|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
260764|NCT02487225|Drug|Placebo|a harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
260765|NCT02487238|Biological|Fecal Microbial Enema|Active intervention.
260766|NCT02487238|Biological|Normal Saline Enema|Placebo comparator.
260767|NCT02487251|Behavioral|Meal Delivery|Participants receive a healthy, prepared family meal for consumption at home. Meals are received one per week for 8 weeks. Recipes for the meals are provided.
260768|NCT02487251|Behavioral|Ingredient Delivery|Participants receive ingredients to prepare a healthy, family meal for consumption at home. Meal ingredients are received one per week for 8 weeks. Recipes for the meals are provided.
260769|NCT02487251|Behavioral|Community Kitchen|Participants come to a Head Start site to prepare a family entree to take home, cook, and consume. Participants prepare their meals in small groups with an MSU Extension paraprofessional as a facilitator. The Community Kitchen is held once per week for 8 weeks.
261036|NCT02480140|Other|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
260490|NCT02491476|Device|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
260491|NCT02491489|Other|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (~50 degrees abduction, slight horizontal adduction, external rotation).
260492|NCT02491502|Device|Echopulse|HIFU Under ultrasound guidance
260493|NCT02491515|Drug|Denosumab|every 6 month injection
260494|NCT02491528|Biological|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
260495|NCT00177424|Drug|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
260496|NCT02491528|Biological|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
260497|NCT02491541|Biological|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
1.0 ml experimental vaccine on day 0,3,7,14,28
260498|NCT02491541|Biological|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
1.0 ml comparator vaccine on day 0,3,7,14,28
260499|NCT02491554|Device|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
260500|NCT02491554|Device|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
260501|NCT02491593|Device|fecal occult blood test|
260502|NCT02491606|Drug|Tafenoquine|Tafenoquine 200mg and 400 mg
260503|NCT02491606|Other|Placebo|Placebo
260504|NCT02493894|Drug|placebo|placebo each 8 hours for 24 hours
260505|NCT02493894|Drug|Cefazolin|cefazolin 1gram, every 6hours for 2 days
260506|NCT02493920|Other|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm).
260222|NCT02498145|Other|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
260223|NCT02498158|Device|MRI scans|20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:
anatomical scan according to standard protocol
functional scan according to the standard protocol of rest-state fMRI.
scans of 10 healthy subjects will be taken from existing scans at the imaging department.
260224|NCT02498171|Drug|Intrathecal morphine with fentanyl|Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.
The fetus was monitored with an ultrasonic aided fetal Doppler until delivery
260225|NCT02498171|Drug|Intrathecal morphine with bupivacaine|Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.
The fetus was monitored with an ultrasonic aided fetal Doppler until delivery
260509|NCT00177671|Drug|Placebo|
260510|NCT02493946|Drug|Clostridium Botulinum Toxin Type A|
260511|NCT02493946|Drug|Placebo|
260512|NCT02493959|Biological|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
260513|NCT02493959|Biological|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
260514|NCT02493959|Biological|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
260515|NCT02493959|Biological|placebo|Infusion of saline for 2 hrs.
260516|NCT02493972|Procedure|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
260517|NCT02493972|Procedure|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
260518|NCT02493985|Other|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
260519|NCT02493985|Other|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
260520|NCT00177671|Drug|Duloxetine|
260521|NCT02494011|Other|traditional exercise|mobilization stretching exercise
260522|NCT02494011|Other|Russian current stimulation|stimulation to wrist flexors for 15 minutes
259926|NCT00174720|Drug|Ciclesonide (XRP1526)|
259927|NCT02468960|Other|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
259928|NCT02468973|Behavioral|Life style counseling|Life style counseling for chronic patients by medical students
259929|NCT02468999|Drug|human insulin|
259930|NCT02469012|Drug|Combination #1|Sofosbuvir + Ribavirin
259931|NCT02469012|Drug|Combination #2|Sofosbuvir + Daclatasvir
259932|NCT02469012|Drug|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
259933|NCT02469012|Drug|Combination #4|Sofosbuvir + Ledipasvir
259934|NCT02469012|Drug|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
259935|NCT02469025|Other|Manual caudal traction mobilization in resting position|
259936|NCT02469025|Other|Manual caudal traction mobilization in end range position|
259937|NCT00174733|Drug|Ciclesonide (XRP1526)|
260226|NCT02498184|Other|acupuncture|
260227|NCT02498197|Behavioral|Participatory Intervention|
260228|NCT02498197|Behavioral|Control|
260229|NCT02500355|Procedure|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
260230|NCT02500355|Device|endoscope or an arthroscopic device|
260231|NCT02500381|Drug|SRP-4045|SRP-4045 30 mg/kg will be administered as an IV infusion once a week for 48 weeks.
260232|NCT02500381|Drug|SRP-4053|SRP-4053 30 mg/kg will be administered as an IV infusion once a week for 48 weeks.
260233|NCT02500381|Drug|Placebo|Placebo will be administered as an IV infusion once a week for 48 weeks
260234|NCT02500394|Procedure|Ionosteril|biomarker guided volume substitution with Ionosteril
260235|NCT02500407|Drug|BTCT4465A|Participants with B-cell NHL and CLL will receive BTCT4465A via IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles.
260236|NCT00178737|Behavioral|Electronic reminder message|
259627|NCT02475343|Device|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
259628|NCT02475343|Device|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
259629|NCT02475343|Device|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
259630|NCT02475343|Device|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
259631|NCT02475356|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|The treatment of Mirena should comply with the local product information
259632|NCT02475369|Drug|pancrelipase|
259633|NCT02475382|Drug|Nivolumab|
259634|NCT00175500|Device|Large Diameter Femoral Head|Unspecified
259635|NCT02475395|Device|TRAK device|Use of TRAK to attain sperm concentration measurement
259636|NCT02475408|Device|Amplatzer vascular plug|
259637|NCT02475421|Biological|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
259938|NCT02471248|Device|Ankle Robot with Power Assistance|Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.
They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded.
259939|NCT02471248|Device|Sham|Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.
They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion.
259940|NCT00174967|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
259941|NCT02471274|Drug|sotagliflozin|single 400 mg dose
264191|NCT02372149|Drug|0.9% sodium chloride|
264192|NCT02372162|Other|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
264193|NCT00160251|Drug|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight [weight-based dosing {WBD}])
264194|NCT02372162|Other|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
264195|NCT02372175|Biological|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
264196|NCT02372188|Other|water|Control
264197|NCT02372188|Dietary Supplement|caffeine|
264198|NCT02372188|Dietary Supplement|caffein + homoeriodictyol sodium salt|
264199|NCT02372188|Dietary Supplement|homoeriodictyol sodium salt|
264200|NCT02372201|Other|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
264201|NCT02372214|Procedure|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
264202|NCT02372227|Drug|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
264203|NCT02372240|Drug|VLX1570 and dexamethasone|
264204|NCT00160264|Drug|Lactulose, Vitamin D, Calcium|
264205|NCT02372253|Drug|Verapamil|
264206|NCT02372253|Drug|Placebo|
264207|NCT02372266|Other|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
259638|NCT02475434|Dietary Supplement|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
259639|NCT02475447|Drug|Asimadoline|kappa-opioid receptor agonist
259640|NCT02475447|Drug|Placebo|placebo-matched control
263894|NCT02376257|Drug|100 mg Modafinil|Drug
263895|NCT02376257|Drug|Placebo|Drug
263896|NCT02376270|Dietary Supplement|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
263897|NCT02376270|Dietary Supplement|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
263898|NCT02376283|Drug|Prasugrel|
263899|NCT00160732|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
263900|NCT02376283|Drug|Clopidogrel|
263901|NCT02376283|Drug|ticagrelor|
263902|NCT00161031|Drug|Atomoxetine|
263903|NCT02378649|Drug|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
263904|NCT02378649|Drug|Placebo|Placebo comparator concomitant with best practice usual care
263905|NCT02378662|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
263906|NCT02378675|Other|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
263907|NCT02378688|Drug|MT-1303|
263908|NCT02378688|Drug|Placebo|
263909|NCT02378701|Behavioral|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
263910|NCT02378701|Behavioral|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
263911|NCT02378714|Drug|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
263912|NCT02378714|Behavioral|BASC|The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
263913|NCT00161044|Drug|Galantamine|
287502|NCT02681380|Other|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
287503|NCT02681380|Other|Control group|No session will be planned for the participants.
287504|NCT02681393|Behavioral|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
287505|NCT02681393|Behavioral|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
287820|NCT02674724|Other|Gym Group|Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.
The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets.
287821|NCT02674724|Other|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
287822|NCT00199069|Drug|Dexamethasone / Prednisolone|
287823|NCT02674724|Other|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
287824|NCT02674737|Drug|dexmedetomidine, tramadol and flurbiprofen|
287825|NCT02674737|Drug|tramadol and flurbiprofen|
287826|NCT02676908|Other|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
287827|NCT02676934|Device|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
287828|NCT02676947|Drug|Tocilizumab|
287829|NCT00199147|Drug|Idarubicin|
287830|NCT02676960|Other|MRI without sedation|
287831|NCT02676973|Procedure|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
287216|NCT02648932|Procedure|Matched Unrelated Donor Transplant|
287217|NCT02651428|Drug|Neutrolin|Neutrolin® or heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
287218|NCT02651428|Drug|Heparin|Neutrolin® or heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
287219|NCT02651441|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
287220|NCT02651441|Drug|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
287221|NCT02651441|Biological|D-CIK|8×10^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
287222|NCT02651454|Drug|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
287506|NCT02681406|Behavioral|ACHESS|Smartphone based additions focused application, encouraging social support
287507|NCT00199784|Drug|Phenylephrine|
287508|NCT02681406|Behavioral|TMC|Brief telephone monitoring and counseling
287509|NCT02681419|Procedure|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
287510|NCT02681419|Procedure|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
287511|NCT02681432|Procedure|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
287512|NCT02681432|Procedure|No HIPEC|Cytoreductive surgery without HIPEC
287513|NCT02681432|Drug|Paclitaxel|
287514|NCT02681432|Drug|carboplatin|
287515|NCT02681445|Device|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
287516|NCT02646631|Behavioral|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
286935|NCT02655679|Drug|VTP-38543|VTP-38543 administered topically every 12 hours
286936|NCT02655679|Drug|Vehicle|Vehicle matching VTP-38543 administered topically every 12 hours
286937|NCT02655692|Drug|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
286938|NCT00197509|Behavioral|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
286939|NCT02655692|Drug|Placebo|This is a saline placebo/non-active solution.
286940|NCT02655705|Drug|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
286941|NCT02655705|Drug|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
286942|NCT02655718|Other|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
286943|NCT02655718|Device|MRI|
286944|NCT02655731|Device|PVI with HeartLight|Catheter ablation
286945|NCT02655744|Radiation|Standard treatment protocol with combined chemoradiation|
287223|NCT02651454|Drug|Jowiseungcheung-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
287224|NCT02651454|Drug|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
287225|NCT02651467|Other|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
287226|NCT00002531|Drug|doxorubicin hydrochloride|
287227|NCT00196885|Drug|N-acetylcysteine|
287228|NCT02651467|Other|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
287229|NCT02651467|Other|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
287230|NCT02651480|Dietary Supplement|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
287231|NCT02651480|Dietary Supplement|Control Group|Unrestricted diet with no instruction.
287232|NCT02651493|Device|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
286661|NCT02661971|Drug|FLOT alone|Pre-operative therapy:
Docetaxel 50 mg/m², d1
Oxaliplatin 85 mg/m², d1
Leucovorin 200 mg/m², d1
5-FU 2600 mg/m², d1 Start of next cycle on day 15. 4 pre-operative cycles (cycle 1-4). Surgery planned to occur 4 to 6 weeks after d1 of last FLOT.
Post-operative therapy (start 6 to 8 weeks (max. 12) weeks after surgery):
Docetaxel 50 mg/m², d1
Oxaliplatin 85 mg/m², d1
Leucovorin 200 mg/m², d1
5-FU 2600 mg/m², d1 Start of next cycle on day 15. 4 post-operative cycles (cycle 5-8).
286662|NCT02661971|Biological|FLOT + ramucirumab|Pre-operative therapy:
Ramucirumab 8mg/kg, d1
Docetaxel 50 mg/m², d1
Oxaliplatin 85 mg/m², d1
Leucovorin 200 mg/m², d1
5-FU 2600 mg/m², d1 Start of next cycle on day 15. 4 pre-operative cycles (cycle 1-4). Surgery is planned to occur 4 to 6 weeks after d1 of last FLOT/ramucirumab dose (but never earlier than 4 weeks after d1 of last FLOT/ramucirumab dose).
Post-operative therapy (start 6 to 8 weeks (max. 12) weeks after surgery):
Ramucirumab 8mg/kg, d1
Docetaxel 50 mg/m², d1
Oxaliplatin 85 mg/m², d1
Leucovorin 200 mg/m², d1
5-FU 2600 mg/m², d1 Start of next cycle on day 15. 4 post-operative cycles (cycle 5-8). Moreover, patients will receive 16 additional cycles (cycle 9-24) of ramucirumab without chemotherapy every 2nd week
286663|NCT02661997|Behavioral|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
286664|NCT00198406|Procedure|diagnostic and therapeutic management|
286665|NCT02661997|Behavioral|Wellness Intervention|The investigators will utilize a wellness education and stretching program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. Each session will begin with 40 minutes of didactic sessions on 1) GWVI education; 2) diet and nutrition; and 3) physical and mental health education (recognizing and dealing with stress, depression, etc.). The final 20 minutes of the hourly session will consist of stretching exercises involving the upper body, trunk and lower body, each stretch being held for 10 to 15 seconds. Participants will be instructed to practice at least 30 minutes of stretching exercises per day at home.
286666|NCT02662023|Drug|perineural ropivacaine administration|
286667|NCT02662036|Drug|Bupivicaine HCL|
286668|NCT02662036|Drug|Liposomal bupivacaine|
286669|NCT02662062|Drug|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
286670|NCT02662062|Drug|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
286671|NCT02662062|Radiation|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
286946|NCT02657876|Biological|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
286947|NCT02657889|Drug|niraparib|
286948|NCT02657889|Biological|pembrolizumab|
262795|NCT02371564|Device|High flow humidified oxygen|
262796|NCT02371564|Device|Standard flow humidified oxygen|
262797|NCT02371577|Drug|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
262798|NCT02371590|Drug|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.
The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject.
262799|NCT02371590|Drug|Obinutuzumab|Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
262800|NCT02371603|Drug|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
262801|NCT02371603|Drug|Pioglitazone 15 mg Tablet|White to off-white, round, convex, non scored tablet with "ACTOS" on one side, and "15" on the other, to be taken orally in the fasted state in the morning
262802|NCT02371603|Drug|Rosuvastatin 10 mg Tablet|Pink, round, biconvex, coated tablets. Debossed "CRESTOR" and "10" on one side, to be taken orally in the fasted state in the morning
262803|NCT02371603|Drug|Trimethoprim 100 mg Tablet|White, round, scored, convex tablet, debossed "93" above the score and debossed "2159" below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening
262804|NCT00160199|Drug|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
262805|NCT02371616|Device|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
262806|NCT02371616|Other|Sodium fluoride|1426 ppm fluoride as sodium fluoride
262807|NCT02371616|Other|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
262808|NCT02371629|Drug|NVA237 (glycopyrronioum bromide)|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
262809|NCT02371655|Procedure|Diet|A low-fibre diet for three days before the examination
263092|NCT02366728|Biological|111In-labeled DCs|111In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
263093|NCT02366728|Drug|Temozolomide|Temozolomide is a chemotherapy given as per standard of care for all enrolled patients.
263094|NCT02366728|Drug|Saline|Given in the opposite groin 12-24 hours before the fourth vaccine in all groups
262518|NCT02487966|Behavioral|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
262519|NCT02489968|Drug|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
262520|NCT02489968|Drug|empagliflozin 25 mg|empagliflozin high dose once daily
262521|NCT02489968|Drug|Placebo|
262522|NCT02489981|Drug|Spiriva|60 puffs
262523|NCT02489994|Device|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
262524|NCT02490020|Biological|mesenchymal stem cell|
262525|NCT02490033|Device|Ablation Catheter|
262526|NCT02490046|Dietary Supplement|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
262527|NCT02490059|Other|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
262528|NCT02490072|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
262529|NCT00177242|Drug|Gefitinib|
262530|NCT02490072|Drug|normal saline(Saline 0.9%)|
262531|NCT02490085|Other|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
261937|NCT02501148|Device|Paladin® Embolic Protection System|Revascularization of carotid artery stenosis
261938|NCT02501161|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
261939|NCT00178828|Drug|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
262232|NCT00177853|Procedure|concurrent radiotherapy|50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
262233|NCT02494804|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
262234|NCT02494804|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
262235|NCT02494817|Behavioral|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
262236|NCT02494830|Drug|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
262237|NCT02496923|Device|High flow nasal oxygen therapy (Optiflow™)|
262238|NCT02496923|Device|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
262239|NCT02496936|Other|SFA|High saturated fatty acid/SFA oil source
262240|NCT02496936|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
262241|NCT02496936|Other|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
262242|NCT00178191|Other|Questionnaires|Incontinence Quality of Life questionnaires
262243|NCT02496936|Other|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
262244|NCT02496936|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
262245|NCT02496949|Drug|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
261622|NCT02469545|Drug|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
261623|NCT02469545|Drug|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
261624|NCT02469545|Drug|Escitalopram|5-20mg daily
261625|NCT00174798|Drug|Placebo|oral
261626|NCT02469545|Drug|Sertraline|50-100mg daily
261627|NCT02469558|Dietary Supplement|Winclove 851 and 110|prebiotic and probiotic mixture
261628|NCT02469558|Dietary Supplement|Placebo|white powder without pro/probiotic
261629|NCT02469571|Dietary Supplement|Winclove 607|multispecies probiotic
261630|NCT02469571|Dietary Supplement|Placebo|Placebo
261940|NCT02501161|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
261941|NCT02501187|Procedure|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
261942|NCT02501187|Procedure|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
261943|NCT02501187|Procedure|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
261944|NCT02501200|Drug|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
261945|NCT02501200|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
261946|NCT02501213|Drug|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
261947|NCT02501226|Other|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
261322|NCT02473939|Drug|VR942 delivered via a Vectura Dry Powder Inhaler|
261323|NCT02473939|Drug|Placebo delivered via a Vectura Dry Powder Inhaler|
261324|NCT02473952|Drug|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
261325|NCT02473952|Drug|Placebo|
261326|NCT02473965|Drug|IGIV-C|Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C
Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks
261327|NCT02473965|Drug|Placebo|
261328|NCT00175292|Drug|Probiotic - VSL#3|
261329|NCT02473978|Device|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
261330|NCT02475941|Other|Early Weight Bearing|The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).
The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient.
261331|NCT02475954|Behavioral|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via V2H.
261332|NCT02475954|Other|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable ADMs, established psychotherapy, clinical monitoring).
261333|NCT02475967|Other|E-Learning|Intervention Description: Patients will receive the E-Learning packages 2 à 5/week. The medical content of the packages will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists).
261631|NCT02469584|Procedure|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
261632|NCT02469597|Drug|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
261633|NCT02469597|Drug|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
261634|NCT02469610|Other|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
261635|NCT02469662|Device|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
261037|NCT02480140|Other|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
261038|NCT02480153|Biological|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
261039|NCT02480153|Biological|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
261040|NCT02480166|Drug|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
261041|NCT02480166|Drug|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
261042|NCT02482753|Drug|exemestane|25 mg, PO daily
261043|NCT02482753|Drug|placebo|Administered orally twice per week (BIW)
261044|NCT02482766|Drug|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
261045|NCT00176475|Biological|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
261046|NCT02482766|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
261047|NCT02482766|Device|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
261048|NCT02482792|Other|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPPT) or COPE combined with active physiotherapy. In NPPT the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
261049|NCT02482792|Other|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by traditional physiotherapy.
261050|NCT02482805|Behavioral|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
261051|NCT02482818|Drug|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
261052|NCT02482818|Drug|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
260507|NCT02493920|Device|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
260508|NCT02493933|Drug|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
260770|NCT02487251|Behavioral|Healthy Eating Classes|Participants attend a small-group class on healthy eating, nutrition and meal planning ideas. Recipes are provided. Classes are held once per week for 8 weeks.
260771|NCT02487251|Behavioral|Cooking Demonstrations|Participants meet in small groups and observe as an MSU paraprofessional demonstrates the preparation of a healthy family entree. Participants taste the recipe but do not take food home with them. Recipes are provided. Demonstrations are held once per week for 8 weeks.
260772|NCT02487251|Behavioral|Provision of Cookware|Participants receive a set of basic cookware and dishes to use in preparing healthy family meals at home. Recipes are provided. The cookware set is provided at the beginning of the typical 8 week intervention cycle.
260773|NCT00176878|Drug|Fludarabine monophosphate|fludarabine 175 mg/m^2 (total) on Days -6 through -3.
260774|NCT02487251|Behavioral|Usual Head Start Exposure|Participants receive no supplemental information on family mealtimes beyond what is already addressed in Head Start programming.
260775|NCT02487277|Drug|PEGPH20|
260776|NCT02487277|Drug|Gemcitabine|
260777|NCT02487277|Drug|Nab-paclitaxel|
260778|NCT02487290|Device|Aneufix ACP-T5|
260779|NCT02487303|Drug|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
260780|NCT02487303|Drug|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
260781|NCT02487316|Drug|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
260782|NCT02487329|Other|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
260783|NCT02489279|Behavioral|Scrabble|Participants play Scrabble on their mobile device to develop concentration and executive control skills. They use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
260784|NCT02489292|Biological|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
260785|NCT02489318|Drug|JNJ-56021927|Participants will receive JNJ-56021927 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
260786|NCT02489318|Drug|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
260523|NCT02494011|Other|closed kinetic chain exercise|wall press exercise plyometric exercise
260524|NCT02494024|Drug|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
260525|NCT02494024|Drug|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
260526|NCT02494050|Behavioral|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
260527|NCT02494050|Behavioral|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
260790|NCT02489357|Drug|Degarelix|Given SC
260791|NCT00177125|Device|ErectAid|
260792|NCT02489357|Other|Laboratory Biomarker Analysis|Correlative studies
260793|NCT02489357|Biological|Pembrolizumab|Given IV
260794|NCT02489370|Device|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
260795|NCT02489383|Other|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
260796|NCT02489383|Other|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
260797|NCT02489383|Behavioral|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
260237|NCT02500420|Other|Diagnosis examens|Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).
Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice.
260238|NCT02500433|Other|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
260239|NCT02500433|Other|Conventional therapy|
260240|NCT02500446|Drug|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
260241|NCT02500446|Other|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
260242|NCT02500459|Drug|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
260243|NCT02500472|Dietary Supplement|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
260528|NCT02496260|Procedure|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
260529|NCT02496260|Procedure|Biomarkers|We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.
All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples.
260530|NCT02496273|Biological|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
259942|NCT02471313|Drug|[18F] FMISO|Each patient will receive up to 10 mCi of [18F] FMISO
259943|NCT02471326|Biological|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
259944|NCT02471339|Other|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
259945|NCT02471391|Drug|ABT-199|
259946|NCT02471391|Drug|Ibrutinib|
259947|NCT02471404|Drug|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
259948|NCT02471404|Drug|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
259949|NCT02471404|Drug|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
259950|NCT02471404|Drug|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
259951|NCT00174967|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
259952|NCT02471404|Drug|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
259953|NCT02471404|Drug|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
259954|NCT02471417|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
259955|NCT02471417|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
259956|NCT02471430|Drug|Panobinostat|Panobinostat will be administered orally.
260244|NCT02500485|Drug|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
260245|NCT02500498|Drug|Nulojix|
260246|NCT02500511|Biological|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
260247|NCT00178750|Device|18G Tuohy epidural needle|
260248|NCT02500524|Drug|Cocamide diethanolamine|Topical lotion
260249|NCT02500524|Drug|Permethrin|Topical creme rinse
259641|NCT02475460|Procedure|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
259642|NCT02475460|Device|HeartMate 3™|HM 3 LIS
259643|NCT02477397|Drug|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
259644|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from blood (HPB)|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
259645|NCT00175838|Drug|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
259646|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from muscle (HPM)|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
259647|NCT02477410|Dietary Supplement|Hydrolysed whey protein (HW)|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
259648|NCT02477423|Drug|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
259649|NCT02477423|Drug|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
259650|NCT02477423|Drug|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
259651|NCT02477436|Drug|Avanafil|One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.
Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.
Investigational products were administered prior to the sexual intercourse for total 8 weeks.
259652|NCT02477436|Drug|Placebo|One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.
Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.
Placebos were administered prior to the sexual intercourse for total 8 weeks.
259653|NCT02477449|Drug|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
259654|NCT02477449|Drug|9% Saline (NS)|infusion for 24 hours
259655|NCT02477462|Other|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
259656|NCT00175851|Drug|Seletracetam (ucb 44212)|
259657|NCT02477462|Other|Baseline visit|Blood draw and quality of life surveys
259957|NCT02471430|Drug|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
263914|NCT02378714|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
264208|NCT02374255|Behavioral|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
264209|NCT02374268|Behavioral|Exercise program alone|
264210|NCT02374268|Dietary Supplement|Combined exercise program and nutrition supplement|
264211|NCT00160433|Drug|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
264212|NCT02374268|Other|Waitlist control group|
264213|NCT02374281|Drug|Glucose sucking|
264214|NCT02374281|Drug|Water sucking|
264215|NCT02374281|Other|No sucking|
264216|NCT02374294|Device|Epiflo|EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60" long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound.
264217|NCT02374307|Other|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
264218|NCT02374320|Drug|liposomal bupivacaine|injected as an axillary block
264219|NCT02374333|Biological|huCART19|
264220|NCT02374359|Other|follow-up|
264221|NCT02374372|Device|conventional hemodialysis|
264222|NCT00002423|Drug|Indinavir sulfate|
264223|NCT00160433|Drug|Placebo|Tablet, oral Daily for 12 weeks
264224|NCT02374372|Device|hemodiafiltration On-line|
264225|NCT02374385|Biological|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
264226|NCT02374385|Other|Placebo|Normal saline
264227|NCT02374398|Drug|Tranexamic Acid|see arm/group descriptions
264228|NCT02374398|Device|Aquamantys System|see arm/group descriptions
287832|NCT02676973|Procedure|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
287833|NCT02676973|Procedure|Uphold™ LITE or Elevate™-AA|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
287834|NCT02676986|Drug|Enzalutamide|Anti-androgen
287835|NCT02676986|Drug|Exemestane|Hormonal therapy (Licenced)
287836|NCT02676999|Procedure|Implantation of a Scheker total distal radioulnar joint prosthesis|
288133|NCT00199004|Drug|Cytarabine|
288134|NCT02669563|Drug|[13N]ammonia|IV injection of [13N]ammonia
288135|NCT02669563|Drug|[11C]HED|IV injection of [11C]HED
288136|NCT02669576|Behavioral|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
288137|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
288138|NCT02669589|Drug|Heparin|
288139|NCT02669589|Drug|Citrate|
288140|NCT02669615|Drug|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
288141|NCT02669628|Procedure|Surgical technique|Laparoscopic surgery
288142|NCT02669628|Procedure|Alcohol sclerotherapy|US-guided sclerotherapy
288143|NCT02669641|Dietary Supplement|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
288144|NCT00199004|Drug|Mercaptopurine|
288145|NCT02669654|Other|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
288146|NCT02669667|Drug|MEDI9314|single dose of MEDI9314
288147|NCT02672163|Procedure|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
287517|NCT02646631|Behavioral|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
287518|NCT02646631|Other|Educational Materials|Printed educational materials on the management of epilepsy
287519|NCT02646644|Other|Metastasized intestinal NET|This is an observational study
287520|NCT02646657|Drug|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
287521|NCT00196391|Drug|DR-2021e|1 capsule daily for 10 days
287522|NCT02646670|Drug|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
287523|NCT02646670|Drug|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
287524|NCT02646670|Drug|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
287525|NCT02646670|Drug|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
287837|NCT02677012|Procedure|REVOLVE™ Tissue Process|Tissue is washed with a medical solution and spun at low speed to clean the fatty tissue and separate the fat tissue from other substances before it is transplanted.
287838|NCT02677012|Procedure|PureGraft™ Tissue Process|System of filters used to wash fatty tissue with a medical solution and separate out unwanted substances before it is transplanted.
287839|NCT02677012|Procedure|Coleman Technique Tissue Process Group|Fatty tissue is placed in a centrifuge. Tissue spun at high speed in order to separate the different substances in the tissue. Once the spinning is done, fat cells collected and transplanted.
287840|NCT00002534|Procedure|in vitro-treated bone marrow transplantation|
287841|NCT00199147|Drug|G-CSF|
287842|NCT02677025|Behavioral|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
287843|NCT02677025|Behavioral|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
287844|NCT02677038|Drug|Olaparib|300 mg by mouth twice daily in a 28 day cycle.
287233|NCT02651506|Procedure|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
287234|NCT02651506|Procedure|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
287235|NCT02651519|Drug|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
287236|NCT02651519|Drug|saline|stellate-ganglion block with saline
287237|NCT02651532|Device|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
287238|NCT00002531|Drug|leucovorin calcium|
287239|NCT00197145|Drug|GW873140|
287240|NCT02653456|Device|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
287241|NCT02653469|Other|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
287526|NCT02646683|Drug|vedolizumab|
287527|NCT02646696|Other|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
287528|NCT02646709|Drug|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
287529|NCT02646709|Drug|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
287530|NCT02646709|Drug|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
287531|NCT02646709|Drug|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
287532|NCT00196391|Other|Placebo|1 matching placebo capsule for 10 days
287533|NCT02646735|Drug|Fulvestrant 500 mg|Fulvestrant 500mg will be given on days 1, 15, 29 and every 28 days thereafter.
287534|NCT02646735|Drug|Exemestane 25 mg|Exemestane 25mg will be given orally, once daily.
286949|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail|
286950|NCT00197756|Other|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
286951|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
286952|NCT02657928|Other|Laboratory Biomarker Analysis|Correlative studies
286953|NCT02657928|Drug|Letrozole|Given PO
286954|NCT02657928|Drug|Ribociclib|Given PO
286955|NCT02657941|Behavioral|Motivational group|Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education
Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines
286956|NCT02657941|Behavioral|educational group|Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education
Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions
286957|NCT02657954|Behavioral|CCT|10-week Compensatory Cognitive Training
286958|NCT02657954|Behavioral|HCE|10-week Holistic Cognitive Education
286959|NCT02657980|Device|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
286960|NCT02657980|Device|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
286961|NCT00197769|Biological|9 valent pneumococcal con jugate vaccine|
286962|NCT02657993|Behavioral|Hypnosis|The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.
Participants will be asked to complete questionnaires over a period of 12 months.
287242|NCT02653469|Other|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
287243|NCT02653482|Drug|Dapagliflozin|
287244|NCT02653482|Drug|Dapagliflozin matching placebo|
287245|NCT02653495|Biological|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
263095|NCT02366728|Drug|Group III basiliximab and Td|Group III will receive basiliximab infusions 1 week before the first and 1 week before the second vaccine and Td pre-conditioning before the fourth vaccine
263096|NCT02366741|Radiation|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
263097|NCT02366754|Device|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
263098|NCT02366754|Device|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
263099|NCT02366767|Device|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
263100|NCT00159666|Drug|pregabalin|
263101|NCT02366767|Device|Control|Threshold suspend
263102|NCT02366780|Procedure|Pump|Breast milk expression using manually or using an electric pump
263103|NCT02366793|Other|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
263104|NCT02366793|Other|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
263105|NCT02366819|Drug|Oxaliplatin|Given IV
263106|NCT02366819|Drug|Leucovorin Calcium|Given IV
263107|NCT02366819|Drug|Irinotecan Hydrochloride|Given IV
263108|NCT02366819|Drug|Fluorouracil|Given IV
263109|NCT02366819|Procedure|Conventional Surgery|Undergo surgery
263396|NCT02361853|Other|Exposure: abundance of Immature neutrophils counts in blood samples|
263397|NCT02361866|Biological|GC1107|0.5 ml, Intramuscular, single dose(day0)
263398|NCT02361866|Biological|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
262532|NCT02490085|Other|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
262810|NCT02371655|Drug|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
262811|NCT02373670|Behavioral|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
262812|NCT02373670|Behavioral|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
262813|NCT02373683|Device|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
262814|NCT02373722|Procedure|Mohs Surgery|Undergo Mohs surgery
262815|NCT02373722|Other|Internet-Based Intervention|Watch website application based educational video
262816|NCT02373722|Behavioral|Telephone-Based Intervention|Receive text messages
262817|NCT02373722|Other|Educational Intervention|Watch website application based educational video
262818|NCT02373722|Behavioral|Exercise Intervention|Use Fitbit
262819|NCT00160381|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
262820|NCT02373722|Other|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
262821|NCT02373722|Other|Questionnaire Administration|Ancillary studies
262822|NCT02373722|Other|Survey Administration|Ancillary studies
262823|NCT02373735|Other|crystalloid|Group A (SVV <10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
262824|NCT02373735|Other|colloid|Group A (SVV <10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is > 20%
262825|NCT02373735|Other|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is < 10%
262826|NCT02373735|Other|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is < 10%
262246|NCT02496962|Drug|Atorvastatin|atorvastatin were taken daily for 5 days
262247|NCT02496962|Drug|placebo|placebo were taken daily for 5 days
262248|NCT02496975|Drug|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
262249|NCT02496975|Other|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
262250|NCT02496988|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
262533|NCT02490085|Drug|Insulin|Subject's usual insulin analog will be used.
262534|NCT02490085|Device|Insulin pump MiniMed® Paradigm® Veo™|During closed-loop intervention, the MiniMed® Paradigm® Veo™ (Medtronic) insulin pump will be used
262535|NCT02490085|Device|Continuous Glucose Monitoring System Enlite sensor®|In both visits, glucose levels will be measure with the Enlite sensor® from Medtronic
262536|NCT02492360|Behavioral|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
262537|NCT02492373|Drug|topical 0.05% Clobetasol propionate ointment|Apply only on the treated area twice a day as mentions
262538|NCT02492373|Device|Q switched Nd:YAG laser 532 nm|Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
262539|NCT02492386|Device|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
262540|NCT02492399|Procedure|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
262541|NCT02492399|Procedure|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
262542|NCT02492412|Drug|HE 10|
262543|NCT02492412|Drug|Restasis|
261948|NCT02501226|Behavioral|ENVIE psychoeducational program|The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.
261949|NCT02501239|Behavioral|Accept Yourself!|
261950|NCT00178841|Drug|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
261951|NCT02501239|Behavioral|Weight Watchers|
261952|NCT00174590|Drug|risperidone|
261953|NCT02467504|Drug|MTX|Methotrexate (oral administration)
261954|NCT02467504|Drug|Folic Acid|Folic Acid (oral administration)
261955|NCT02467504|Drug|Loxoprofen|Loxoprofen (oral administration)
261956|NCT02467517|Drug|Ketamine|
261957|NCT02467517|Drug|Magnesium Sulfate|
261958|NCT02467517|Drug|placebo : sodium chloride|
261959|NCT02467530|Other|AGE|
261960|NCT02467543|Other|20% Ethanol|Unmedicated 20% Ethanol
262251|NCT02496988|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
262252|NCT02497001|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])
262253|NCT00178191|Procedure|Urodynamics|Urodynamics
262254|NCT02497001|Drug|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
262255|NCT02497001|Drug|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
262256|NCT02497001|Drug|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
261636|NCT00174798|Drug|Tolterodine|once daily
261637|NCT02469675|Device|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
261638|NCT02469675|Device|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
261639|NCT02469675|Device|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
261640|NCT02469688|Drug|ASP4070|
261641|NCT02469688|Drug|Placebo|
261642|NCT02469701|Drug|nivolumab and ablation|
261643|NCT02469714|Behavioral|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
261644|NCT02469727|Behavioral|Fitbit|Participants will use the FitBit device to track their physical activity
261645|NCT02472041|Device|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
261646|NCT00175019|Drug|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
261647|NCT02472041|Device|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
261648|NCT02472054|Drug|Alemtuzumab|
261649|NCT02472054|Drug|Methyl Prednisolone (MP)|
261650|NCT02472054|Drug|Cyclosporin A (CSA)|
261961|NCT02467543|Other|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
261962|NCT02467556|Drug|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
261963|NCT00174603|Drug|quetiapine|
261334|NCT02475980|Behavioral|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
261335|NCT02475993|Device|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
261336|NCT02476006|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
261337|NCT02476006|Drug|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
261338|NCT00175617|Drug|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
261339|NCT02476019|Drug|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
261340|NCT02476019|Drug|Placebo|Placebo administered subcutaneously
261341|NCT02476032|Device|Professionally applied Crest Sensi-Stop strips (Procter & Gamble™)|Crest Sensi-Stop strips (Procter & Gamble™) with or without the active ingredient will be placed on the qualifying teeth by a dental professional.
261342|NCT02476032|Device|Self applied Crest Sensi-Stop strips (Procter & Gamble™)|Subjects will apply the strips (Procter & Gamble™), that may or may not contain the active ingredient, by themselves following the manufacturer's instructions.
261343|NCT02476045|Drug|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
261344|NCT02476045|Drug|panitumumab|Maintenance treatment (ARM B)
261345|NCT02476045|Drug|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
261346|NCT02476058|Drug|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
261347|NCT02476058|Drug|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
261348|NCT02478112|Device|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
261349|NCT02478125|Drug|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
260787|NCT02489318|Drug|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog [GnRHa] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
260788|NCT02489344|Drug|GZ/SAR402671|Pharmaceutical form:capsule
Route of administration: oral
260789|NCT02489357|Procedure|Cryosurgery|Undergo whole gland cryoablation
261053|NCT02482831|Procedure|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
261054|NCT02482844|Other|pacemaker implantation|
261055|NCT02482844|Other|holter implantation|
261056|NCT00002476|Drug|fluorouracil|
261057|NCT00176475|Biological|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
261058|NCT02482857|Drug|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
261059|NCT02482870|Device|Macintosh laryngoscope|Cormack-Lehane grade was determined using Macintosh laryngoscope.
261060|NCT02482870|Device|King Vision video laryngoscope|Cormack-Lehane grade was determined using King Vision video laryngoscope.
261061|NCT02482883|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized [active stimulation vs non-active (placebo) stimulation], for an initial period of 10 days.
261062|NCT02482909|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor
261063|NCT02482909|Procedure|Radiofrequency ablation|Percutaneous ablation using radiofrequency under the imaging guidance
261064|NCT02482922|Other|Exercise & Dietary Supplement|
261065|NCT02482935|Drug|Abemaciclib|Administered orally
261066|NCT02484937|Other|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
261067|NCT02484950|Biological|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
260798|NCT02489396|Behavioral|Nutrition facts automatically or not automatically displayed|For two months nutrition information on the Rosie site will be displayed in a "tab" that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen "healthiest," and fifteen "least healthy" items in six grocery categories; chips, cookies, cereal & breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items.
260799|NCT02491619|Procedure|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
260800|NCT02491632|Drug|Dexamethasone|High-Dose Group: 8 mg orally twice a day for 7 days.
Low-Dose Group: 4 mg orally twice a day for 7 days.
260801|NCT00177424|Drug|Placebo|matching placebo tablets
260802|NCT02491632|Other|Physical Activity|Participants perform resistance exercises 3 days a week, and walk at least 5 day a week.
260803|NCT02491632|Other|Physical Activity Tests|Participants perform physical activity tests at baseline, Days 8, 15, 29, and 57. Tests will include a 30-second chair-stand test and a 6-minute walk test.
260804|NCT02491632|Behavioral|Questionnaires|Quality of life questionnaires completed at baseline, Days 8, 15, 29, and 57.
261071|NCT02484976|Behavioral|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
261072|NCT02484989|Other|Surviellance card|
261073|NCT00176748|Drug|AG 6013736|5 mg po bid
261074|NCT02485002|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
261075|NCT02485002|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
261076|NCT02485015|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
261077|NCT02485015|Drug|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
261078|NCT02485028|Drug|Dapoxetine 30mg tablet|
261079|NCT02485028|Drug|Mirodenafil 50mg tablet|
261080|NCT02485041|Drug|Dapoxetine 30mg|Tablet, Orally administered
261081|NCT02485041|Drug|Mirodenafil 100mg|Table, Orally administered
260531|NCT02496286|Drug|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
260532|NCT02496299|Drug|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
260533|NCT00178126|Device|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
260534|NCT02496299|Drug|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
260535|NCT02496312|Behavioral|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
260536|NCT02496325|Procedure|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
260537|NCT02496338|Other|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
260538|NCT02496351|Device|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
260539|NCT02496364|Drug|Placebo (Topical)|Saline Solution 0,9% in situ, up to 100ml;
260540|NCT02496364|Drug|Placebo (Intravenous)|Saline Solution 0,9% in the vein, up to 500ml: 200ml as loading dose over 15 minutes followed by 1ml/Kg/hr throughout the surgery, in a maximum volume of 300ml
260805|NCT02491632|Other|Phone Calls|Study staff calls participants 1 time each week while on study.
260806|NCT02491645|Other|Sensory interventions|Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.
Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.
Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.
Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.
Auditory stimulation : Sound familiarisation and music time will be done.
260807|NCT02491658|Biological|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
260808|NCT02491671|Device|Hemopatch|
260809|NCT02491671|Procedure|standard preventive measures|
260810|NCT02491684|Drug|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
260250|NCT02466893|Other|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
260251|NCT02466906|Drug|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC>20.0X109/L.
260252|NCT00174499|Drug|2 mg nicotine gum|2 mg nicotine gum
260253|NCT02466906|Drug|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
260254|NCT02466919|Drug|Pantoprazole|H. pylori eradication therapy
260255|NCT02466919|Drug|Amoxicillin|H. pylori eradication therapy
260256|NCT02466919|Drug|Metronidazole|H. pylori eradication therapy
260257|NCT02466919|Drug|Levofloxacin|H. pylori eradication therapy
260258|NCT02466919|Drug|Clarithromycin|H. pylori eradication therapy
260259|NCT02466932|Device|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
260260|NCT02466945|Device|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
260261|NCT02466958|Drug|levomilnacipran|antidepressant
260262|NCT02466958|Drug|Placebo|inactive substance
260263|NCT00174499|Drug|4 mg nicotine gum|4 mg nicotine gum
260264|NCT02466971|Drug|Cisplatin|Given IV
260541|NCT02496364|Drug|Tranexamic Acid (Topical)|30mg/ml of tranexamic acid in situ during surgery, up to 100ml
260542|NCT02498210|Other|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
259958|NCT02471443|Procedure|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
259959|NCT02471456|Other|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
259960|NCT02473328|Drug|Atazanavir 200 mg/r|In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),
switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.
The administration will be done once a day orally for 48 weeks.
The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir.
259961|NCT02473341|Drug|Bovine Colostrum + Corticosteroids|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily.
Oral prednisolone 40mg/day for 4 weeks. Pasteurized Bovine colostrum (20 gm thrice a day) for 4 weeks.
259962|NCT02473341|Drug|Placebo + Corticosteroids|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily.
Oral prednisolone 40mg/day for 4 weeks plus placebo (Pasteurized Milk Powder) 20 gms thrice a day for 4 weeks.
259963|NCT02473354|Drug|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air [21% Oxygen]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
259964|NCT02473354|Drug|Oxygen|
259965|NCT02473354|Drug|Carbon dioxide|
259966|NCT02473367|Drug|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
259967|NCT02473367|Drug|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
259968|NCT02473367|Drug|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
259969|NCT02473380|Device|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
259970|NCT00175227|Drug|intravenous saline hydration|500 mls half-normal saline
259971|NCT02473393|Drug|OPS-2071 tablet|
259972|NCT02473406|Drug|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
259973|NCT02473406|Drug|physiological saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
264229|NCT02374398|Other|Control Group|Saline and Standard Elecdrocautery
264230|NCT02374424|Drug|GA101_DHAP|Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.
Scheme of treatment:
GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)
Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion
Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles
Dexamethasone 40 mg day 1-4 of every cycles
Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)
GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy
259658|NCT02477488|Drug|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
259659|NCT02477501|Drug|Norepinephrine|continuous infusion
259660|NCT02477501|Drug|Ephedrine|continuous infusion
259661|NCT02477514|Drug|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
259662|NCT02477514|Drug|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
259663|NCT02477514|Drug|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
259664|NCT02477527|Drug|elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
259665|NCT02479620|Drug|Placebo|Following atherectomy-based revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and "Investigational Drug".
"Investigational Drug" administered via Bullfrog Micro-Infusion Device.
259666|NCT02479633|Other|Coronally advanced flap with connective tissue graft|Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.
The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction.
259667|NCT02479646|Biological|MYL-1401H|
259668|NCT02479646|Biological|EU-Neulasta|
259669|NCT02479646|Biological|US-Neulasta|
259670|NCT02479659|Other|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
288148|NCT02672176|Behavioral|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
288149|NCT02672176|Behavioral|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
288150|NCT02672189|Behavioral|EVA-Online|Internet-based cognitive behavioral therapy
288151|NCT02672202|Drug|Duloxetine|60 mg/d - twice before surgery and once a day for post operative days 3-7
30 mg/d - once a day for post operative days 1-2
288152|NCT02672202|Drug|Pregabalin|75 mg/d - twice a day for post operative days 1-2
150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery
288153|NCT00199056|Drug|Dexamethasone / Prednisolone|
288454|NCT02665065|Procedure|HCT|
288455|NCT02665078|Other|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
288456|NCT02665091|Behavioral|Peer Education Program|
288457|NCT02665104|Device|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
288458|NCT02665117|Drug|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
288459|NCT02665117|Drug|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
288460|NCT00198809|Drug|Biolean Free + Diet education|
288461|NCT02665117|Drug|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
288462|NCT02665130|Other|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
288463|NCT02665130|Other|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
287845|NCT02677051|Drug|Sulforaphane|Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
287846|NCT02677051|Drug|Placebo|
287847|NCT02679235|Dietary Supplement|Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
287848|NCT02679248|Dietary Supplement|Neo40 Daily®|
287849|NCT02679248|Dietary Supplement|Placebo|
287850|NCT02679261|Drug|Atorvastatin|Oral administration atorvastatin 20 mg per day
287851|NCT02679261|Drug|Placebo|Oral administration placebo
287852|NCT02679274|Drug|Placebo|Intermittent intramuscular injections of saline (males and females).
287853|NCT00199394|Drug|Istradefylline (KW-6002)|
287854|NCT02679274|Drug|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
287855|NCT02679287|Device|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
287856|NCT02679300|Other|Virtual reality exercise group|
287857|NCT02679300|Other|Conventional exercise group (control group)|
288154|NCT02672202|Drug|Placebo|non-active - twice before surgery
non-active - twice a day for post operative days 1-7
288155|NCT02672215|Behavioral|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
288156|NCT02672215|Behavioral|generic advice|general, non-tailored web-based generic advice with tips
288157|NCT02672228|Device|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
288158|NCT02672241|Drug|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
288159|NCT02672241|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
287535|NCT02646748|Drug|Pembrolizumab|Pembrolizumab will be an intravenous (IV) infusion, day 1 of every 3 week cycle.
287536|NCT02646748|Drug|INCB039110|INCB039110 tablets will be administered orally once daily.
287537|NCT02646748|Drug|INCB050465|INCB050465 tablets will be administered orally once daily.
287538|NCT02646761|Device|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
287539|NCT02646761|Other|Standard of Care Physical Therapy|Physical therapy rehabilitation program
287540|NCT02648945|Other|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
287541|NCT02648958|Drug|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
287542|NCT02648958|Other|normal saline|
287543|NCT02648971|Procedure|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
287544|NCT02648971|Procedure|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
287545|NCT02648984|Other|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
287546|NCT00002531|Drug|cytarabine|
287858|NCT02679313|Device|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
287859|NCT02679326|Device|Therapeutic ultrasound|
287860|NCT02679339|Drug|CNTX-2022 (lidocaine gel, 40%)|
287861|NCT02679339|Drug|Placebo|
287862|NCT02679352|Device|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
287863|NCT02679365|Procedure|lower segment cesarean section and double lock closure of rectus sheath|
287246|NCT02653508|Behavioral|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
287247|NCT02653508|Behavioral|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
287248|NCT02653521|Radiation|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
287249|NCT02653534|Behavioral|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
287250|NCT00197158|Biological|Hepatitis B vaccine|
287251|NCT02653534|Other|Essential newborn care|
287252|NCT02653547|Other|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
287253|NCT02653547|Other|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
287254|NCT02653547|Other|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
287255|NCT02655757|Drug|Sitagliptin|5 mg, 1 tablet per day for 12 months
287256|NCT02655757|Drug|Placebo|Placebo,1 tablet per day for 12 months
287547|NCT00196625|Drug|Ritonavir (drug)|
287548|NCT02648997|Drug|Nivolumab|
287549|NCT02649010|Device|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
263399|NCT00159159|Drug|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
263400|NCT02361879|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
263401|NCT02361879|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
263402|NCT02361892|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
263403|NCT02361905|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
263404|NCT02361905|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
263405|NCT02361918|Procedure|Colon surgery|
263406|NCT02361931|Drug|A formula with erythropoietin|
263407|NCT02361931|Drug|Hydrogel|
263408|NCT02361944|Drug|Oxygen|
263409|NCT02361957|Dietary Supplement|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
263410|NCT00159172|Device|Motor cortex stimulation|
263411|NCT02361957|Dietary Supplement|Placebo|Placebo
263412|NCT02361983|Device|DLT versus bronchial blockers|Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
263413|NCT02362022|Drug|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
263414|NCT02362035|Drug|ACP-196|oral
263415|NCT02362035|Drug|Pembrolizumab|intravenous
263416|NCT02362048|Drug|ACP-196|
263417|NCT02362048|Drug|ACP-196 in combination with pembrolizumab|
263418|NCT02362061|Radiation|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
263703|NCT02357004|Drug|Carvedilol|CR 40 mg daily in addition to normal BP medications
262827|NCT02373748|Device|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
262828|NCT02373761|Device|Stryker Triathlon Tritanium primary knee|
262829|NCT02373774|Device|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
262830|NCT00160381|Drug|Placebo|Tablet, oral Daily for 12 months
262831|NCT02373787|Device|creos xenoprotect|Implant placement with simultaneous bone augmentation
262832|NCT02373787|Device|Bio-Gide|resorbable collagen membrane
263110|NCT02368925|Device|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
263111|NCT02368951|Drug|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
263112|NCT02368964|Drug|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
263113|NCT02368964|Drug|high dose hCG 500 mcg|Treatment for triggering
263114|NCT02368977|Device|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
263115|NCT00159900|Drug|Sildenafil Citrate|
263116|NCT02369003|Procedure|Autologous Peripheral Nerve Graft|Implantation of Autologous Peripheral Nerve Graft into the substantia nigra pars compacta (SNpc) or basal forebrain of participants with PD undergoing deep brain stimulation (DBS) surgery.
263117|NCT02369016|Drug|BAY No. 80 6946|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
263118|NCT02369016|Drug|Placebo|placebo solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
263119|NCT02369029|Drug|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
263120|NCT02369042|Device|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
263121|NCT02369068|Drug|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
262544|NCT02492438|Biological|PPV23 vaccination or PCV13 vaccination|
262545|NCT02492451|Other|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
262546|NCT00177567|Drug|lithium carbonate|
262547|NCT02492451|Drug|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
262548|NCT02492464|Dietary Supplement|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
262549|NCT02492464|Dietary Supplement|Placebo|
262833|NCT02373800|Device|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
262834|NCT02373813|Drug|etanercept pre-filled syringe sq injection|etanercept for injection in pre-filled syringes
262835|NCT02373813|Drug|Oral methotrexate|methotrexate capsules
262836|NCT02373813|Drug|Placebo for etanercept sq injection|etanercept placebo for injection in pre-filled syringes
262837|NCT02375672|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
262838|NCT02375672|Drug|mFOLFOX6|mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)
Oxaliplatin 85 mg/m2 IV over 2 hours (±15 min) concurrently with
Leucovorin 400 mg/m2 IV over 2 hours (±15 min), followed by
5FU 400 mg/m2 bolus and then 2400 mg/m2 via 46 hour continuous infusion
262839|NCT02375685|Biological|Gevokizumab|
262840|NCT02375698|Biological|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
262841|NCT02375698|Biological|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4. Each arm has 3:1 treated to placebo (N=18 AERAS-456; N=6 placebo) for a total of 18 placebo subjects in the study.
262842|NCT02375711|Biological|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
262843|NCT02375724|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day
262844|NCT02375724|Drug|Placebo|Inhaled dose-matched placebo, twice per day
262257|NCT02497014|Device|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
262258|NCT02498912|Procedure|Production of Genetically-modified T cells|
262259|NCT02498912|Drug|Cyclophosphamide|
262260|NCT02498912|Device|IP Catheter Insertion|
262261|NCT02498912|Genetic|Infusion of 4H11-28z/fIL-12/EFGRt+ Genetically-modified T cells|
262262|NCT02498925|Behavioral|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
262263|NCT02498938|Genetic|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
262264|NCT02498951|Biological|Obinutuzumab|Given IV
262265|NCT02498951|Other|Quality-of-Life Assessment|Ancillary studies
262266|NCT00178516|Other|behavior, procedure|
262267|NCT02498964|Other|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
262268|NCT02498977|Genetic|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
262269|NCT02498977|Drug|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
262550|NCT02492477|Procedure|evaluation of PORT-A-CATH®|after completion of adjuvant chemotherapy, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
262551|NCT02492477|Drug|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
262552|NCT02492477|Drug|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
261964|NCT02467556|Behavioral|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
261965|NCT02467556|Other|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
261966|NCT02467569|Drug|Hemay020|
261967|NCT02467582|Drug|Aspirin|Aspirin 100 mg daily
261968|NCT02467582|Drug|Placebo|Placebo
261969|NCT02467595|Drug|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
261970|NCT02467595|Drug|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
261971|NCT02467595|Drug|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
261972|NCT02467595|Drug|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
261973|NCT02467595|Drug|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
261974|NCT00174616|Drug|Oxaliplatin, capecitabine, radiotherapy|Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses
Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks
Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks
261975|NCT02467608|Drug|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
261976|NCT02467608|Drug|HRZE|the same as experimental group,without the excipient of HUEXC030 only
261977|NCT02467621|Drug|Pantoprazole|40 mg x 1 daily intravenously from ICU admission to ICU discharge
261978|NCT02467621|Other|Saline (0.9%)|10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
261979|NCT02469727|Behavioral|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
261980|NCT02469740|Drug|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
262270|NCT02498990|Behavioral|Low calorie diet followed by life style intervention|Low calorie diet of 800 kcal/day for 7 weeks.
Life style intervention for the remaining study period
261350|NCT02478125|Drug|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
261651|NCT02472067|Behavioral|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
261652|NCT02472080|Drug|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
261653|NCT02472093|Other|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
261654|NCT02472093|Other|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
261655|NCT02472093|Other|Control group|The control group did brief educational sessions.
261656|NCT02472106|Device|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
261657|NCT00175032|Drug|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
261658|NCT02472119|Dietary Supplement|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
261659|NCT02472119|Dietary Supplement|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
261660|NCT02472119|Dietary Supplement|Gluten-free diet|gluten-free diet
261661|NCT02472132|Device|POC US|Use of point of care ultrasound in insertion of CVC
261662|NCT02472145|Drug|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/[m^2]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
261663|NCT02472145|Drug|JNJ-56022473 9 mg/kg|JNJ-56022473 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
261664|NCT02472158|Device|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
261665|NCT02473991|Radiation|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
261068|NCT02484950|Procedure|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
261069|NCT02484963|Drug|Zolpidem|
261070|NCT02484963|Drug|placebo|
261351|NCT00175929|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
261352|NCT02478125|Drug|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
261353|NCT02478138|Procedure|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
261354|NCT02478138|Drug|Indocyanine Green (ICG)|
261355|NCT02478138|Device|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
261356|NCT02478151|Device|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
261357|NCT02478164|Drug|Ponatinib|
261358|NCT02478190|Other|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
261359|NCT02478190|Other|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
261360|NCT02478203|Device|Airtraq|videolaryngoscope for difficult airway
261361|NCT02478203|Device|Glidescope|videolaryngoscope for difficult airway
261362|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
261363|NCT02478203|Device|direct laryngoscopy|gold standart for intubation
261364|NCT02478216|Procedure|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
261365|NCT02478229|Drug|Sofosbuvir (SOF) and Ledipasvir (LDV)|
261366|NCT02478242|Drug|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
261082|NCT02485054|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
261083|NCT02485067|Drug|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
261084|NCT00176761|Drug|Interleukin-2 (IL-2)|
261085|NCT02485067|Drug|Placebo(For THVD-201)|
261086|NCT02485067|Drug|Detrusitol 2mg tablet|Tolterodine 2mg
261087|NCT02485067|Drug|Placebo(For Detrusitol 2mg tablet)|
261088|NCT02485080|Drug|Simeprevir|
261089|NCT02485080|Drug|Sofosbuvir|
261090|NCT02487329|Other|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
261091|NCT00176878|Procedure|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
261371|NCT02480192|Other|Cognitive Behavioural Therapy for Menopausal Symptoms|This 12-week CBT- based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
261372|NCT02480205|Device|NeuroBox to deliver the NeuroPAP|The patients will be studied during the following conditions:
On conventional NIPPV device with the clinically prescribed settings (30 min)
With NeuroPAP and no change of Pmin (=peep) (60 min)
With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)
During CPAP delivered with NeuroPAP device (15 min)
Again with original NIPPV device and settings for 30 minutes
261373|NCT00176267|Radiation|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 & 36 of chemotherapy
261374|NCT02480218|Other|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
261375|NCT02480231|Device|Retropubic Midurethral Sling|
261376|NCT02480244|Behavioral|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
260811|NCT02491684|Drug|Placebo|Placebo solution for once daily inhalation for 14 days
260812|NCT00177437|Behavioral|home testing kit|
260813|NCT02491697|Biological|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
260814|NCT02491697|Drug|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
260815|NCT02491710|Device|Training on low-cost box trainer|
260816|NCT02491710|Device|Training on standard box trainer|
260817|NCT02491723|Drug|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
260818|NCT02491736|Drug|Ketoprofen|2.5% ketoprofen gel
260819|NCT02491736|Other|Placebo|Placebo gel
260820|NCT02491749|Procedure|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
260821|NCT02491762|Procedure|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
260822|NCT02491788|Drug|Suvorexant|
260823|NCT00177463|Drug|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
260824|NCT02494050|Behavioral|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
260825|NCT02494063|Procedure|Systematic pelvic lymphadenectomy|Lymph nodes removal from 5 standardized pelvic regions.
261092|NCT02487329|Other|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
261093|NCT02487329|Other|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
261094|NCT02487342|Other|milk|small serving (217 mL) of british semi-skimmed milk
261095|NCT02487342|Other|orange fruit-juice|small serving (217 mL) of orange juice
260543|NCT02498223|Other|experiment protocol|the subjects will undergo the following experiment protocol:
recruitment and medical examination day.
physiological evaluation day- the subjects will perform twice* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.
biomechanical valuation day- the subjects will perform twice* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.
once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances.
260544|NCT00178425|Procedure|Serial blood sampling as described in protocol|
260545|NCT02498236|Drug|Intranasal Oxytocin|
260546|NCT02498249|Device|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
260547|NCT02498249|Device|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
260548|NCT02498262|Other|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
260549|NCT02498288|Drug|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
260550|NCT02498288|Drug|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
260551|NCT02498288|Drug|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
260552|NCT02498301|Drug|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
260553|NCT02498301|Drug|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
260554|NCT02498314|Other|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
260555|NCT00178425|Procedure|Estimation of Creatinine Clearance at regular intervals|
260826|NCT02494063|Procedure|Sentinel lymph node biopsy|Sentinel lymph node detection and removal from each pelvic side; all techniques for SLN detection acceptable (color tracer; radiocolloid; indocyanine green)
260827|NCT00177684|Drug|Amphotericin B|
260828|NCT02494076|Drug|EzPAP|
260829|NCT02494076|Other|Standard Care|
259974|NCT02473419|Drug|Vayarin|
260265|NCT02466971|Radiation|External Beam Radiation Therapy|Undergo EBRT
260266|NCT02466971|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
260267|NCT02466971|Radiation|Internal Radiation Therapy|Undergo brachytherapy
260268|NCT02466971|Other|Laboratory Biomarker Analysis|Correlative studies
260269|NCT02466971|Radiation|Radiation Therapy|Undergo conventional RT
260270|NCT02466971|Drug|Triapine|Given IV
260271|NCT02466984|Drug|metoclopramide intravenous|Administration route
260272|NCT02466997|Drug|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
260273|NCT02466997|Drug|Placebo|
260274|NCT00174512|Drug|GTN|
260275|NCT02469025|Other|Selftreatment|Each subject is advice to do some exercises at home
260276|NCT02469038|Device|AccuCath catheter|
260277|NCT02469051|Device|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
260278|NCT02469051|Device|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
260279|NCT02469051|Device|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
260280|NCT02469064|Other|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
260281|NCT02469064|Other|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
260282|NCT02469077|Behavioral|exercise|Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out.
259671|NCT02479659|Other|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
259672|NCT02479659|Other|Opt-out HIV testing for mothers and newborns|Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:
If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.
If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner.
259975|NCT02473419|Drug|Placebo|
259976|NCT02473432|Procedure|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
259977|NCT02473432|Procedure|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
259978|NCT02473432|Procedure|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
259979|NCT02473445|Drug|Cysteamine Bitartrate Delayed-release Capsules|Treatment with experimental drug as detailed in arm/group descriptions
259980|NCT02475473|Other|Exercise Training|Chronic High-Intensity Resistance Training
259981|NCT02475486|Device|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
259982|NCT00175513|Drug|Valacyclovir (Valtrex)|Unspecified
259983|NCT02475499|Drug|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
259984|NCT02475499|Drug|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
259985|NCT02475499|Drug|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
259986|NCT02475499|Drug|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
259987|NCT02475499|Drug|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
259988|NCT02475499|Drug|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
288464|NCT02667288|Drug|A-101 Solution|
288465|NCT02667301|Device|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
288466|NCT02667301|Device|Tuba manometry test|Tuba monometric test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tuba manometry computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
288467|NCT02667301|Device|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
288468|NCT02667314|Behavioral|Jigsaw puzzles|Solving jigsaw puzzles 6 times per week for at least 1 hour over a period of 5 weeks.
288752|NCT02660632|Other|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
288753|NCT02660645|Drug|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
288754|NCT02660645|Device|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
288755|NCT02660658|Drug|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
288756|NCT02660671|Behavioral|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
288757|NCT00198224|Procedure|phlebotomy|
288758|NCT02660671|Behavioral|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
288759|NCT02660671|Behavioral|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
288760|NCT02660684|Drug|Prograf|Injection or oral
288761|NCT02660684|Drug|Methotrexate|Injection
288762|NCT02660684|Drug|Cyclosporine|Injection or oral
288160|NCT02672254|Radiation|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
288161|NCT02672267|Biological|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
288162|NCT02672267|Other|Placebo|Lactated Ringer's Solution
288163|NCT02672280|Device|Medical Collagen Membrane with MSC|
288164|NCT00199056|Drug|Cyclophosphamide|
288165|NCT02672280|Device|Medical Collagen Membrane|
288166|NCT02672293|Drug|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
288167|NCT02672306|Biological|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
288168|NCT02674750|Drug|CUDC-907|
288169|NCT02674750|Drug|Rituximab|
288170|NCT02674763|Drug|IMGN779|
288171|NCT02674776|Drug|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
288172|NCT02674776|Drug|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
288173|NCT02674789|Behavioral|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
288174|NCT02674815|Other|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
288469|NCT02667314|Behavioral|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline and three telephone calls during a 5-week period for expert monitoring.
288470|NCT02667327|Drug|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
288471|NCT02667327|Other|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
288472|NCT00198978|Drug|HDARAC|
288473|NCT02667340|Dietary Supplement|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game & at halftime)
287864|NCT00199407|Drug|Istradefylline (KW-6002)|
287865|NCT02679365|Procedure|lower segment cesarean section and continuous non-locking closure of rectus sheath|
287866|NCT02679378|Device|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
287867|NCT02679417|Behavioral|exercise|12 weeks of aerobic or resistant exercise
287868|NCT02679430|Device|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
287869|NCT02679443|Dietary Supplement|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
287870|NCT02679456|Drug|SCY-078|
287871|NCT02681458|Other|Direct Examination|It was an observational study and subjects received their routine treatment.
287872|NCT02681471|Other|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
287873|NCT00199797|Drug|huA33 antibody plus chemotherapy|huA33 will be administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2. Every second week, Oxaliplatin, 5-FU and Leucovorin are administered additionally. Oxaliplatin and Leucovorin will be given as an infusion over 2 hours. Afterwards patients will receive an bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.
The doses of Oxaliplatin will be 85mg/m2, Leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus infusion and 600mg/m2 as an continuous infusion. A complete treatment cycle consists of 12 weekly treatment days.
287874|NCT02681471|Other|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
287875|NCT02681471|Device|monopolar resectoscope|
288175|NCT00199069|Procedure|CNS Irradiation|
288176|NCT02674828|Behavioral|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
287550|NCT02649049|Other|there is no intervention|
287551|NCT02649062|Biological|NGM282|
287552|NCT02649062|Other|Placebo|
287553|NCT02649075|Other|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
287554|NCT02649075|Other|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
287555|NCT02649088|Device|Microscan|It allows to look at sublingual microcirculation
287556|NCT02649088|Device|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
287557|NCT02649101|Drug|Thalidomide|Thalidomide tablet 100mg qn po.
287558|NCT00196638|Drug|Antiretroviral combination (drugs)|
287559|NCT02649101|Drug|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
287560|NCT02649114|Behavioral|Cognitive-Behavioural Therapy|
287561|NCT02649114|Behavioral|Compassion-Focused Therapy|
287562|NCT02649127|Behavioral|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
287563|NCT00196911|Procedure|Implantation of stimulation electrodes in the STN|
287564|NCT02651558|Device|CSEM BP system 2015-MD-0022|At the onset of general anesthesia:
continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)
continuous estimates of optical blood pressure values (optical blood pressure system, via Swissmedic approved measuring device 2015-MD-0022 developed by CSEM)
will be recorded.
287565|NCT02651584|Drug|CAM2038 subcutaneous injection|
287566|NCT02651584|Drug|SL BPN tablets|
287567|NCT02651584|Drug|placebo subcutaneous (SC) injections|
287568|NCT02651584|Drug|SL placebo tablets|
287569|NCT02651597|Other|Oatmeal|
287876|NCT02681471|Device|bipolar resectoscope TURis|
263704|NCT02357004|Drug|Chlorthalidone|12.5 mg daily in addition to normal BP medications
263705|NCT02357017|Dietary Supplement|NaCl tablets|
263706|NCT02357030|Drug|Methyl-P plus GWI Nutrient Formula|Week 1:
One tablet of Methyl-P (5mg) twice daily
Four tablets of GWI Nutrient Formula twice daily
Week 2 to Week 12 :
Two tablets of Methyl-P (10mg) twice daily
Four tablets of GWI Nutrient Formula twice daily
263707|NCT02357043|Device|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
263708|NCT02357043|Device|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
263709|NCT02357056|Other|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
263710|NCT02357056|Other|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
263711|NCT00158613|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
263712|NCT02357056|Other|Virtual Reality|daVinci Surgical Skills simulation
263713|NCT02357069|Drug|Enbrel|Etanercept
263714|NCT02357069|Drug|LBEC0101|Etanercept
263715|NCT02357082|Radiation|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
263716|NCT02357095|Procedure|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
263717|NCT02357108|Other|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
263718|NCT02357108|Behavioral|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
263719|NCT02357121|Device|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
263720|NCT02357134|Other|Stationary Bicycle Test|All groups: After screening, participants perform a cycle test using a stationary bicycle. Participants pedal with no resistance for 60 seconds. Participants perform the cycle test without receiving any air or oxygen for as long as they can. After a 2 hour rest, participant performs the cycle test again using low-flow air for as long as they can.
263721|NCT02357134|Behavioral|Questionnaires|Four symptom questionnaires completed at screening and after the second cycle test. This should take about 40 minutes to complete.
263722|NCT00158626|Behavioral|pelvic floor muscle training|
263122|NCT02369068|Drug|Kenalog|Intravaginal pelvic floor injection one series
263123|NCT02369081|Drug|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
263124|NCT02369081|Drug|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
263125|NCT02369081|Drug|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
263126|NCT00159913|Drug|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
263127|NCT02369081|Drug|Placebo|Placebo treatment for 12 weeks.
263419|NCT02362087|Other|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
263420|NCT02362100|Other|Non operative|non operative treatment
263421|NCT00159211|Drug|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
263422|NCT00159380|Procedure|Spirometry|
263423|NCT02364570|Other|Glucose (100g)|Ingestion of glucose (100g)
263424|NCT02364570|Other|Glucose (75g)|Ingestion of glucose (75g)
263425|NCT02364570|Other|Whole Eggs|Ingestion of 1.5 whole eggs
263426|NCT02364570|Other|Egg Whites|Ingestion of 7 egg whites
263427|NCT02364570|Other|Egg Yolks|Ingestion of 2 egg yolks
263428|NCT02364583|Drug|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
263429|NCT02364596|Biological|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
263430|NCT02364596|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
263431|NCT02364609|Drug|Afatinib Dimaleate|Given PO
263432|NCT02364609|Biological|Pembrolizumab|Given IV
263433|NCT00159393|Other|registry and database|data collection
262845|NCT02375737|Behavioral|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
262846|NCT02375750|Device|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
262847|NCT00160667|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening of Brivaracetam 200 mg/day in a double-blinded way for the 4-week treatment period
262848|NCT02375750|Other|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
262849|NCT02375763|Other|Software instruction|
262850|NCT02375776|Other|CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
263128|NCT02369094|Other|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
263129|NCT02369107|Other|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
263130|NCT02371655|Drug|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
263131|NCT02371655|Procedure|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
263132|NCT02371668|Biological|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
263133|NCT02371668|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
263134|NCT00160199|Drug|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
263135|NCT02371681|Drug|Moxifloxacin|TB drug
263136|NCT02371681|Drug|Pyrazindamide|TB drug
263137|NCT02371681|Drug|Rifampicin|TB drug
263138|NCT02371681|Drug|Isonizaid|TB drug
262553|NCT02492490|Other|SVFderived MSC transplantations|infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.
Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab.
262554|NCT02492490|Drug|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
262555|NCT02494843|Other|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
262556|NCT02494843|Other|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
262557|NCT02494856|Drug|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
262558|NCT02494856|Drug|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
262559|NCT02494869|Behavioral|Nonlinear Aerobic Training|
262560|NCT02494869|Other|Height, Weight, BMI measure|
262561|NCT00177866|Drug|Celebrex|Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week "washout period" then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week "washout period" then Celebrex 200 mg PO BID for the remaining 8 weeks.
262562|NCT02494869|Other|Blood draw|
262563|NCT02494869|Other|Cardiopulmonary exercise test|
262564|NCT02494882|Drug|Ruxolitinib|
262565|NCT02494882|Drug|Dasatinib|
262566|NCT02494882|Drug|Dexamethasone|
262567|NCT02494895|Drug|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
262568|NCT02494895|Drug|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
262569|NCT02494908|Behavioral|Playing a computer game simulating a car race|Playing a computer game simulating a car race
262851|NCT02375789|Device|Active RhinoChill|The device is intended for use for the reduction of temperature via the nasal cavity.
The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity.
262271|NCT02499003|Drug|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
262272|NCT02499016|Procedure|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
262273|NCT02499029|Drug|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
262274|NCT02499029|Drug|Placebo|Identical looking placebo pills were administered each week.
262275|NCT02499042|Drug|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
262276|NCT02499055|Behavioral|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
262277|NCT00178529|Behavioral|Psychoeducation, Counseling and Skill Training|
262278|NCT02499068|Device|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
262279|NCT02499081|Drug|Ixazomib|
262280|NCT02499094|Other|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
262281|NCT02501252|Procedure|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
262282|NCT02501265|Behavioral|High-Intensity Behavioral Intervention|High-Intensity Behavioral Intervention (HIBI) is a video-based intensive group-therapy intervention that integrates motivational interviewing, cognitive behavioral skills training, mindfulness training, and group therapy techniques. HIBI is comprised of seven weekly meetings (2 ½ hours each) with a 6½-hour meeting on the quit day (24 total hours), and is taught by TSCP Instructors (typically therapists). Intervention participants are provided with web-based access to the Instructional Video, Course Manual and a Guided Audio Recording to practice relapse prevention skills.
262283|NCT02501265|Behavioral|Low-Intensity Behavioral Intervention|Low-Intensity Behavioral Intervention (LIBI) consists of a 20-minute video accessed via Internet plus written smoking cessation materials. The video and written materials include guided instruction in skills such as identifying motivations to quit, identifying and avoiding triggers, garnering social support, quit day planning, and development of urge management strategies.
262284|NCT02501265|Drug|Varenicline|Day 1-3: 0.5 mg once per day (AM); Day 4-7: 0.5 mg twice per day; Day 8 to end of 14 weeks: 1 mg twice per day
262285|NCT02501265|Drug|Bupropion|Day 1-3: 150 mg once per day (AM); Day 4 to end of 13 weeks: 150 mg twice per day
261666|NCT02474004|Procedure|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis & knee scores 6 mo after the procedures
261667|NCT02474017|Drug|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
261668|NCT02474017|Device|CRC749 inhaler|
261981|NCT00174811|Drug|telithromycin (HMR3647)|
261982|NCT02469740|Drug|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
261983|NCT02469753|Drug|NSAIDs|continuous daily
261984|NCT02469753|Drug|NSAIDs|on demand
261985|NCT02469753|Drug|anti-TNF|
261986|NCT02469766|Procedure|SWL|Patients in this arm will undergo SWL
261987|NCT02469766|Procedure|Semirigid URS|Patients in this arm will undergo semirigid URS
261988|NCT02469766|Procedure|Flexible URS|Patients in this arm will undergo Flexible URS
261989|NCT02469779|Behavioral|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
261990|NCT02469779|Behavioral|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
261991|NCT02469779|Behavioral|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
261992|NCT00174824|Drug|Insulin glargine|
261993|NCT02469779|Behavioral|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
261994|NCT02469792|Procedure|Liposuction|
261995|NCT02469792|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
261996|NCT02469792|Procedure|Arthroscopic surgery|
261997|NCT02469792|Other|Intraarticular administration of autologous ADRC|
261367|NCT02478242|Drug|Normal saline|
261368|NCT02478255|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
261369|NCT02478255|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
261370|NCT02480179|Device|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
261669|NCT02474043|Behavioral|Hep-Net Intervention|The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
261670|NCT02474043|Behavioral|Usual Care|Clients receive health education and risk reduction counseling from a trained prevention specialist.
261671|NCT02474069|Drug|Secukinumab|
261672|NCT02474082|Biological|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
261673|NCT02474082|Drug|Fumaderm®|Fumaderm® INITIAL, gastro-resistant tablets 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarat calcium salt, 5 mg ethylhydrogenfumarat magnesium salt, 3 mg ethylhydrogenfumarat zinc salt Fumaderm®, gastro-resistant tablets 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarat calcium salt, 5 mg ethylhydrogenfumarat magnesium salt, 3 mg ethylhydrogenfumarat zinc salt
261674|NCT00175305|Drug|Sandostatin LAR|
261675|NCT02474095|Other|Quality-of-Life Assessment|Ancillary studies
261676|NCT02474095|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
261677|NCT02474108|Procedure|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
261678|NCT02474108|Device|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
261679|NCT02474121|Device|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
261680|NCT02474134|Drug|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
261681|NCT02474147|Other|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
261377|NCT02480244|Other|Control|Control arm receives no health-related behavioral intervention
261378|NCT02480257|Behavioral|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
261379|NCT02480283|Procedure|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
261380|NCT02480283|Radiation|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
261381|NCT02480283|Procedure|Venipuncture|To collect blood cells and serum for analyses.
261382|NCT02480283|Procedure|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
261383|NCT02480296|Drug|MYK-461|
261384|NCT00176267|Drug|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
261385|NCT02480296|Drug|Placebo|Placebo comparator
261688|NCT00175630|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
261689|NCT02476071|Other|Mass media|Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
261690|NCT02476071|Other|Stylish Man (SMEvent)|Stylish Man Events: community mobilization via music, contests, testimonials from satisfied VMC adopters. Messages on how VMC, in conjunction with other HIV prevention, can make men feel more in control of their lives, less stressed, and more "Stylish" are interwoven through the mobilization.
The Stylish Man Van (SMV) accompanies the SMEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages.
261691|NCT02476084|Other|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
261692|NCT02476084|Other|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
261693|NCT02476084|Other|Biological samples collection|Draw of research blood samples.
261694|NCT02476084|Other|Questionnaires|Administration of validated patients' questionnaires.
261695|NCT02476097|Drug|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
261096|NCT02487355|Drug|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
261097|NCT02487355|Drug|Magnesium Sulphate|Magnesium Sulphate 50 mg
261098|NCT02487355|Drug|Bupivacaine|1ml/kg of 0.25%of bupivacaine
261099|NCT02487368|Device|Needle stimulation pad|
261100|NCT02487381|Drug|delta-9-tetrahydrocannabinol|
261101|NCT02487381|Drug|Cannabidiol|
261102|NCT00176878|Drug|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
261103|NCT02487381|Drug|Placebo|
261104|NCT02487394|Other|Asthma, Smokers and Non-Smokers|Comparing protein expressions between the two groups.
261105|NCT02487394|Other|COPD, Smokers and Non-Smokers|We will validate the prdictive value of the proteomic signatures for therapeutic responses.
261106|NCT02487407|Drug|ODM-109|ODM-109 1 mg capsule for oral administration.
261107|NCT02487407|Drug|Placebo for ODM-109|Placebo capsule for oral administration.
261108|NCT02487420|Behavioral|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
261109|NCT02487433|Drug|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
261110|NCT02487433|Drug|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
261111|NCT02487446|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
261112|NCT02487446|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
261113|NCT00176878|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
261386|NCT02480309|Device|Inpatient use of the MMPPC/DiAs system|An inpatient evaluation of the use of the MMPPC/DiAs system in day and night closed-loop control in adolescents and adults with type 1 diabetes.
261387|NCT02482948|Device|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
261388|NCT02482948|Drug|Collagenase|Study agent to be applied daily to the wound.
261389|NCT00176488|Drug|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
260830|NCT02494089|Other|distress analysis|
260831|NCT02494102|Drug|Modafinil|Atypical Psychomotor stimulant
260832|NCT02494102|Drug|Placebo|
260833|NCT02494115|Procedure|subcutaneous drainage|
260834|NCT02494128|Other|Education|Education in group leadership
260835|NCT02494141|Drug|Curcumin|Dietary Supplement
260836|NCT02494141|Other|Placebo|
260837|NCT02494154|Device|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
260838|NCT00177697|Behavioral|behavioral weight loss program|
260839|NCT02494154|Device|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
260840|NCT02494167|Biological|MultiTAA-specific T cells|The 3 dose levels are:
Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2
The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.
If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions every 4-6 weeks.
260841|NCT02494180|Drug|fentanyl|arm A receiving iv fentanyl
260842|NCT02494180|Drug|pethidine|arm B receiving iv pethidine
260843|NCT02494180|Drug|Diazepam|arm B receiving iv diazepam
260844|NCT02494180|Drug|Midazolam|arm A receiving iv midazolam
260845|NCT02494193|Other|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
260846|NCT02494193|Other|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
260847|NCT02494193|Other|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
260848|NCT02494193|Other|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
261114|NCT02487446|Drug|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
260283|NCT02469077|Drug|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
260556|NCT02498314|Other|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
260557|NCT02498314|Other|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
260558|NCT02500537|Device|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
260559|NCT02500550|Biological|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
260560|NCT02500563|Other|Amino acid based infant formula|
260561|NCT02500563|Other|Extensively hydrolyzed casein infant formula|
260562|NCT02500563|Other|Mother's own breast milk|
260563|NCT02500576|Drug|Cyclophosphamide|60 mg/kg/day by vein on Days -7 and -6.
260564|NCT02500576|Drug|Mesna|60 mg/kg by vein on Days -7 and -6.
260565|NCT02500576|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to -1.
260566|NCT00178750|Device|CompuFlo® computerized syringe pump|
260567|NCT02500576|Procedure|TIL (T-cells)|On day 0, TIL infused as an inpatient by vein approximately 15-60 minutes depending on the volume of cells infused. Up to 150 billion cells infused.
260568|NCT02500576|Drug|IL-2|High dose IL-2 Group: 720,000 IU/kg by vein every 8-16 hours for up to 15 doses starting 12-16 hours after T cell infusion on Day 1.
Low Dose IL-2 Group: 2 million IU/kg subcutaneously for 14 days starting 12-16 hours after T cell infusion on Day 1.
260569|NCT02500576|Drug|MK-347|If participants develop stable or partially responding disease, up to 31 doses (2 years) of MK-3475, 200 mg by vein every 21 days.
260570|NCT02500576|Behavioral|Questionnaires|Questionnaires completed at baseline, Day 63, then every 12 weeks.
260571|NCT02500576|Behavioral|Phone Calls|After 2 years of pembrolizumab, phone calls made by study staff to participant every 3 months.
259989|NCT02475499|Drug|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
259990|NCT02475512|Other|Wash wipes (3M)|
259991|NCT02475512|Other|water and pH neutral soap|
259992|NCT02475525|Dietary Supplement|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
259993|NCT00175526|Behavioral|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
260284|NCT02469077|Drug|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
260285|NCT00174746|Drug|AVE2635A|
260286|NCT02469077|Drug|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
260287|NCT02469090|Drug|APL-130277|Use to treat up to 5 "OFF" episodes per day
260288|NCT02469090|Drug|Placebo|
260289|NCT02469103|Device|C2 videos|C2 and colonoscopy will be performed one after another on the same day
260290|NCT02469103|Procedure|colonoscopy|
260291|NCT02469116|Drug|Docetaxel|
260292|NCT02469116|Drug|Carboplatin|
260293|NCT02469116|Drug|Pegylated G-CSF|
260294|NCT02471456|Other|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
260295|NCT02471469|Drug|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
260296|NCT00002472|Procedure|conventional surgery|
260297|NCT00174967|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
288763|NCT02662803|Other|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
288764|NCT02662803|Other|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
288765|NCT02662816|Device|Proton magnetic resonance spectroscopy (1H MRS)|
288766|NCT00198510|Drug|Vitrase|7.5 IU of Vitrase
288767|NCT02662816|Other|a protein rich breakfast at home|
288768|NCT02662816|Other|a protein rich lunch at the Clinical Investigation Center|
288769|NCT02662829|Behavioral|Community-based intervention|
288770|NCT02662829|Other|Standard of care|
288771|NCT02662842|Device|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
288772|NCT02662842|Device|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
288773|NCT02662855|Other|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
284223|NCT02592044|Procedure|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
284224|NCT02592057|Drug|SOF|SOF tablets administered orally once daily based on approved prescribing information
284225|NCT02592070|Behavioral|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
284226|NCT00190684|Drug|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
284227|NCT02592083|Drug|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
284228|NCT02592083|Drug|Palbociclib|
284229|NCT02592096|Drug|0.1% Pazufloxacin Mesilate Ear Drops|
284230|NCT02592096|Drug|0.3% Pazufloxacin Mesilate Ear Drops|
284231|NCT02592096|Drug|0.5% Pazufloxacin Mesilate Ear Drops|
284232|NCT02593747|Drug|Loratadine 10 mL (BAY 76-2211) solution/syrup|10 mL, orally, syrup, fasted ,single dose
288474|NCT02667340|Other|Placebo|0.7 g glucose per kg body mass in two ingestions (before game & at halftime)
288475|NCT02667353|Procedure|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) < 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
288476|NCT02667353|Drug|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
288477|NCT02667353|Drug|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
288478|NCT02667366|Behavioral|Tel-PT|
288479|NCT02667366|Behavioral|TAU and text messages|
288480|NCT02667379|Other|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
288481|NCT02669667|Drug|placebo|single dose of placebo
288482|NCT02669680|Drug|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
288483|NCT02669680|Other|Standard therapy|
288484|NCT02669693|Dietary Supplement|bread without olives|
288485|NCT02669693|Dietary Supplement|bread with olives|
288486|NCT02669706|Drug|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
288487|NCT02669719|Biological|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
288488|NCT02669719|Drug|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
288774|NCT02662855|Drug|Favipiravir|oral administration of Favipiravir tablets
288775|NCT02662881|Device|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
288776|NCT02662881|Device|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
288777|NCT00198510|Drug|Vitrase|55 IU of Vitrase
288177|NCT02674828|Other|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
288178|NCT02674841|Other|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
288179|NCT02674841|Other|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
288180|NCT02674841|Other|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
288181|NCT02674854|Drug|PG324 Ophthalmic Solution|1 drop daily (evening) both eyes
288182|NCT02674854|Drug|Netarsudil (AR-13324) ophthalmic solution|1 drop daily (evening) both eyes
288183|NCT02674854|Drug|Latanoprost ophthalmic solution|1 drop daily (evening) both eyes
288184|NCT02674867|Other|Blood draw|
288185|NCT02674880|Drug|HMW-HA|Aerolized administration b.i.d.
288186|NCT00002534|Drug|methylprednisolone|
288187|NCT00199069|Procedure|Mediastinal Irradiation|
288188|NCT02674880|Other|Placebo|Standard therapy
288189|NCT02674893|Drug|Liraglutide|
288190|NCT02674893|Other|Observation alone|
288191|NCT02674906|Drug|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
288192|NCT02677064|Other|assessments|Thus, a prospective observational study in which all newly diagnosed or newly relapsed acute leukemia patients would be registered close to the beginning of induction or re-induction therapy would allow us to follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
288193|NCT02677077|Drug|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
288489|NCT00199004|Drug|G-CSF|
288490|NCT02669732|Drug|DS-8500a|tablets
288491|NCT02669732|Drug|placebo|tablets
287877|NCT02681484|Behavioral|Anthroposophic speech therapy|Anthroposophic speech therapy uses sound-combinations like "KLSFM" or "OM" and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking.
287878|NCT02681510|Drug|Varenicline plus combination NRT|Standard FDA approved 12 weeks of treatment with Varenicline, nicotine patch and nicotine lozenge.
287879|NCT02681523|Drug|Eribulin|
287880|NCT02681536|Drug|Triptorelin|
287881|NCT02681549|Drug|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4. Three weeks constitutes one cycle.
287882|NCT02681562|Drug|olaparib|
287883|NCT02681575|Behavioral|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
287884|NCT00199823|Genetic|Intracoronary aotologous stem cell transplantation|
287885|NCT02681588|Procedure|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
287886|NCT02681601|Dietary Supplement|Nutrawell Powder|The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.
OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.
Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA.
287887|NCT02681601|Other|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
287888|NCT02681601|Dietary Supplement|OmegaRich fish oil supplement|OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.
OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.
Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA.
287889|NCT02646774|Drug|Micafungin|Injection
287890|NCT02646787|Behavioral|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
287891|NCT02646787|Behavioral|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
287892|NCT00000377|Drug|Nortriptyline|
263723|NCT02357134|Other|Structured Exercise with High Flow Oxygen|About 3 days after baseline cycle test, second cycle test performed using high flow oxygen.
264013|NCT02390739|Drug|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
264014|NCT02390739|Drug|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
264015|NCT02390739|Biological|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
264016|NCT02390752|Drug|PLX3397|Take oral drug daily for a 28 day cycle
264017|NCT00162643|Drug|zidovudine + lamivudine + efavirenz|
264018|NCT02390778|Behavioral|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
264019|NCT02390778|Behavioral|leisure activity (film showing)|
264020|NCT02390791|Other|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
264021|NCT02390791|Other|treatment as usual standard portal|Standard version of myADHDportal.com web software
264022|NCT02390804|Device|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
264023|NCT02390804|Device|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
264024|NCT02390817|Drug|Sugammadex|Sugammadex intravenously
264025|NCT02390817|Drug|Neostigmine|Neostigmine intravenously
264026|NCT02390830|Other|Falls Prevention|
264027|NCT02390830|Other|Reduction of limitations at body function and activity levels|
264028|NCT00162656|Drug|half cyclophosphamide|
264029|NCT02390843|Drug|Simvastatin|The starting dose of simvastatin will be 140 mg/m^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m^2/dose BID, 225 mg/m^2/dose BID, and 290 mg/m^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
264030|NCT02390843|Drug|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
263434|NCT02364622|Device|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
263435|NCT02364622|Device|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
263436|NCT02364622|Device|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
263437|NCT02364635|Drug|icosabutate|Single dose at each dose levet
263438|NCT02364648|Dietary Supplement|MitoQ|Mitochondria targeted antioxidant
263439|NCT02364648|Dietary Supplement|Placebo|Placebo
263440|NCT02364661|Behavioral|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
263441|NCT02364674|Radiation|High Resolution Computed Tomography scan|a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.
An Upper Airway (UA) scan will be taken on visit 1.
263724|NCT02357134|Other|Structured Exercise with High Flow Air|About 3 days after baseline cycle test, second cycle test performed using high flow air.
263725|NCT02357134|Other|Structured Exercise with Low Flow Oxygen|About 3 days after baseline cycle test, second cycle test performed using low flow oxygen.
263726|NCT02357134|Other|Structured Exercise with Low Flow Air|About 3 days after baseline cycle test, second cycle test performed using low flow air.
263727|NCT02359396|Drug|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
263728|NCT02359409|Device|goggle balloon|Colonoscopy will be performed using the water immersion technique.
263729|NCT02359409|Other|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
263730|NCT02359422|Behavioral|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
263731|NCT02359435|Drug|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
263732|NCT02359435|Drug|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
263733|NCT00158860|Drug|valaciclovir (Valtrex)|
263139|NCT02371694|Other|Test drink|The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.
All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.
263140|NCT02371707|Drug|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
263141|NCT02371707|Drug|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
263142|NCT02371720|Behavioral|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
263143|NCT02371733|Other|Upper extremity aerobic exercise training|Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.
Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.
263144|NCT02371733|Other|Alternative upper extremity exercises|Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.
Control group will be followed-up by telephone once a week.
263145|NCT00160212|Drug|Daglutril|
263442|NCT02364687|Radiation|Computed tomography late enhancement imaging|
263443|NCT02364700|Device|Hand of Hope (HOH)|Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:
warm up-passive stretch of hand in flexion and extension (5 minutes);
setting the EMG threshold parameters for the device;
active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)
active practice of closing then hand (UFO Catcher game; 10 min)
open and closing the hand (Ball and Basket game; 10 min)
open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)
cool down-passive stretch of hand in flexion and extension (5 minutes)
263444|NCT00159406|Other|Registry and Database|Data Collection
263445|NCT02364713|Drug|Gemcitabine Hydrochloride|Given IV
263446|NCT02364713|Other|Laboratory Biomarker Analysis|Correlative studies
263447|NCT02366832|Procedure|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
263448|NCT00159679|Drug|Pregabalin|
263449|NCT02366832|Device|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
262852|NCT02375789|Device|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
262853|NCT02375802|Biological|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
262854|NCT02375802|Drug|Placbo|
262855|NCT02375815|Other|Statin Choice Implementation|
262856|NCT02378207|Biological|H56:IC31|
262857|NCT02378207|Biological|BCG|
262858|NCT00160966|Drug|Tacr + MMF with conversion to Tacr + ERL|according to Giessen protocol
262859|NCT02378207|Biological|Control Sodium Chloride 0.9%|
262860|NCT02378220|Genetic|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
262861|NCT02378233|Dietary Supplement|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
262862|NCT02378233|Dietary Supplement|Placebo|Patients are given a non-iodine containing multivitamin tablet
262863|NCT02378246|Dietary Supplement|Iodine|We use multivitamin tablets one with 150 microgram iodine for Active comparator and one without iodine as placebo
262864|NCT02378246|Dietary Supplement|Placebo|multivitamin tablets without iodine
262865|NCT02378259|Procedure|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
262866|NCT02378259|Procedure|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
262867|NCT02378272|Other|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
262868|NCT02378285|Device|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
262869|NCT00160979|Procedure|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
262286|NCT02501265|Drug|Nicotine patches|21 mg per day for 10 weeks; 14 mg per day for 2 weeks; 7 mg per day for 2 weeks
262570|NCT02494921|Drug|Docetaxel|
262571|NCT02494921|Drug|Ribociclib|
262572|NCT00177866|Drug|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
262573|NCT02494921|Drug|Prednisone|
262574|NCT02494921|Drug|Filgrastim|
262575|NCT02494934|Behavioral|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
262576|NCT02494934|Behavioral|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
262577|NCT02497014|Device|2 Stents|Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual "ostial" dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion.
262578|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
262579|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
262580|NCT02497040|Drug|Levobupivacaine|local injection
262581|NCT02497040|Drug|Bupivacaine|local injection
262582|NCT02497040|Drug|placebo|local injection
262583|NCT00178191|Other|Pad weight|Pad weight
262584|NCT02497053|Drug|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
261998|NCT02469805|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
261999|NCT02469805|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
262000|NCT02469805|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
262001|NCT02469805|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
262287|NCT02501278|Biological|INO-3112 vaccine|INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:
VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)
INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device
262288|NCT02501278|Radiation|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.
Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.
Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost.
262289|NCT02501278|Drug|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
262290|NCT00178854|Drug|Risperidone|
262291|NCT02501291|Drug|Thalidomide|
262292|NCT02501304|Device|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
262293|NCT02501317|Behavioral|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
262294|NCT02501317|Behavioral|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
262295|NCT02501330|Drug|Bosutinib|The usual adult dosage of once 500 mg per day postprandial oral administration as bosutinib. The dosage may be adjusted according to the patient's condition, but can be increased to once 600 mg 1 day.
262296|NCT02501343|Drug|Sodium Bicarbonate (oral)|As entered in arm descriptions
262297|NCT02501356|Dietary Supplement|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
262298|NCT02501356|Dietary Supplement|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
261682|NCT02474147|Other|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
261683|NCT02474160|Other|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
261684|NCT02474173|Drug|Hsp90 Inhibitor AT13387|Given IV
261685|NCT00175318|Behavioral|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
261686|NCT02474173|Other|Laboratory Biomarker Analysis|Correlative studies
261687|NCT02476058|Drug|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
262002|NCT02472158|Device|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
262003|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
262004|NCT02472171|Dietary Supplement|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
262005|NCT00175032|Drug|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
262006|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
262007|NCT02472184|Procedure|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
262008|NCT02472184|Procedure|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
262009|NCT02472197|Procedure|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
262010|NCT02472197|Procedure|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
261696|NCT02476097|Other|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
261697|NCT02476097|Drug|Placebo|
261698|NCT02476110|Dietary Supplement|Oral nutritive supplements|
261699|NCT00175643|Drug|imiquimod|
261700|NCT02476123|Biological|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
261701|NCT02476136|Drug|paroxetine, duloxetine, fluoxetine or venlafaxine|
261702|NCT02476149|Procedure|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
261703|NCT02476162|Device|iHealth Wireless Blood Pressure Monitor|Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.
Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening.
261704|NCT02476175|Drug|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
261705|NCT02476188|Procedure|Sample of Blood|
262019|NCT02472249|Drug|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds.
262020|NCT02472262|Dietary Supplement|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
262021|NCT02474173|Drug|Paclitaxel|Given IV
262022|NCT02474173|Other|Pharmacological Study|Correlative studies
262023|NCT02474186|Radiation|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
262024|NCT02474186|Drug|Xeloda|chemotherapy agent daily for two weeks
262025|NCT02474186|Drug|paclitaxel|chemotherapy agent weekly for two weeks
262026|NCT02474199|Biological|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
261390|NCT02482961|Drug|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
261391|NCT02482987|Device|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
261392|NCT02482987|Device|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
261393|NCT02482987|Procedure|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
261394|NCT02482987|Procedure|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
261395|NCT02483000|Biological|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
261396|NCT02483000|Radiation|indium In 111-DOTA-biotin|Given IV
261397|NCT02483000|Radiation|yttrium Y 90 DOTA-biotin|Given IV
261398|NCT02483000|Drug|Clearing Agent|Given IV
261399|NCT02483000|Drug|Carmustine|Given IV
261400|NCT00176488|Drug|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
261401|NCT02483000|Drug|Etoposide|Given IV
261402|NCT02483000|Drug|Cytarabine|Given IV
261403|NCT02483000|Drug|Melphalan|Given IV
261404|NCT02483000|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
261405|NCT02483000|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
261406|NCT02483000|Other|Pharmacological Study|Correlative studies
261407|NCT02483000|Other|Laboratory Biomarker Analysis|Correlative studies
261408|NCT02483013|Other|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
261706|NCT02476201|Device|MPP ON Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
261115|NCT02489396|Behavioral|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
261116|NCT02489396|Behavioral|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
261117|NCT02489396|Behavioral|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
261118|NCT00177138|Drug|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
261119|NCT02489409|Drug|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
261120|NCT02489409|Drug|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
261121|NCT02489409|Drug|Navelbine|40 mg/d, iv, d1, 8
261122|NCT02489409|Drug|Platinum|30 mg/m2, iv 3h, d1-3
261123|NCT02489409|Drug|Xeloda Tablets:|2 000 mg/m2, po, d1-14
261124|NCT02489422|Other|Laboratory Biomarker Analysis|Correlative studies
261125|NCT02489422|Other|Questionnaire Administration|Ancillary studies
261126|NCT02489422|Other|Daily Survey Administration|Ancillary studies
261127|NCT02489422|Behavioral|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
261128|NCT02489422|Behavioral|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
261129|NCT00177138|Drug|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV >monthly for 1 year (only if ALC>200 mm, up to a total of 10 doses in year)
261130|NCT02489422|Other|Actigraphy Assessment|Ancillary studies
260572|NCT02500589|Behavioral|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
260849|NCT00177710|Drug|Amphotericin B|
260850|NCT02496364|Drug|Tranexamic Acid (Intravenous)|5mg/ml of tranexamic acid in the vein, up to 500ml: 200ml (5mg/ml) as loading dose over 15 minutes followed by 1ml/Kg/hr (5mg/ml) throughout the surgery, in a maximum volume of 300ml.
260851|NCT02496377|Drug|ferrous glycine sulfate Tardyferon|
260852|NCT00178126|Device|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
260853|NCT02496377|Drug|Epoetin Alfa|
260854|NCT02496377|Drug|ferric carboxymaltose Ferinject|
260855|NCT02496390|Biological|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
260856|NCT02496390|Biological|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
260857|NCT02496403|Behavioral|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
260858|NCT02496416|Behavioral|Aquatic Exercise Program|The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
260859|NCT02496429|Device|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
260860|NCT02496442|Device|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
260298|NCT02471482|Other|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
260299|NCT02471495|Device|Synergo® RITE + MMC|Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.
MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection.
260300|NCT02471508|Device|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
260301|NCT02471521|Other|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 6 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
260573|NCT02500589|Other|Health education|In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's "Health Living Messages" on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information.
260574|NCT02500602|Drug|doxazosin xL|active medication
260575|NCT02500602|Drug|placebo|placebo pill
260576|NCT02500615|Other|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
260577|NCT00178763|Device|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
260578|NCT02500628|Drug|Metformin|500 mg po after baseline testing of heart rate
260579|NCT02467010|Drug|Bortezomib|Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.
Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
260580|NCT02467010|Drug|Cyclophosphamide|Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.
Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
284233|NCT02593760|Other|Placebo|Placebo will be administered PO QD for up to 48 weeks.
284234|NCT02593760|Drug|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
284235|NCT02593760|Drug|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD) for up to 48 weeks.
284236|NCT02593773|Drug|Interferon γ-1b|Approximately 90 subjects will receive subcutaneous (SC) doses of ACTIMMUNE® three times a week (TIW) for a total of 26 weeks. The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By week 13, all subjects are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related AEs.
284237|NCT02593786|Drug|Nivolumab|
284238|NCT00190892|Drug|carbamazepine|
284239|NCT02593799|Procedure|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
284240|NCT02593812|Behavioral|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 7 blocks of 5 trials per day for 3 consecutive days.
284241|NCT02593825|Behavioral|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill; the focus is not on a "normal" movement pattern. Parents and children learn to problem-solve motor challenges, and link small motor changes to cognitive skills.
284541|NCT02587507|Other|Water with glucose|Individuals will consume the HFHC meal with 500mL of water with glucose.
284542|NCT00190112|Procedure|ventral cardiac denervation|
284543|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 mL, Intramuscular
284544|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
284545|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
284546|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
284547|NCT02589860|Other|Melphalan kinetic study|Concentration of Melphalan in plasma samples
284548|NCT02589860|Genetic|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
288778|NCT02662894|Drug|Valsartan + Rosuvastatin FDC|
288779|NCT02662894|Drug|Diovan + Crestor|
288780|NCT02662907|Procedure|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
288781|NCT02662907|Behavioral|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
288782|NCT02662907|Device|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
288783|NCT02662907|Device|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
288784|NCT02662907|Behavioral|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
288785|NCT02662907|Drug|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
288786|NCT02662920|Other|No Intervention|
288787|NCT02665143|Drug|nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle or disease evaluation. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid). Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib bid or placebo will be added at day 8 and continued until end of cycle or disease evaluation.
288788|NCT02665143|Drug|AML induction only (with placebo)|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Nintedanib bid or placebo will be added at day 8 and continued until end of cycle or disease evaluation.
288789|NCT02665156|Procedure|Intracorporeal stapled neobladder using robotic staplers|Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to "Vescica Ileal Padovana".
288790|NCT02665169|Behavioral|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
288791|NCT02665169|Other|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
288792|NCT02665182|Behavioral|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
284242|NCT02593825|Behavioral|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
284243|NCT02593838|Other|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
288492|NCT02669758|Drug|ALKS 3831|Daily dosing
288493|NCT02669771|Drug|Xtandi|
288494|NCT02669784|Drug|Contrast (Omnipaque)|The patient will be administered a low dose of intravenous contrast (Omnipaque) based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100 mL of intravenous contrast.
288495|NCT02669797|Behavioral|Family Meals Coaching|The experimental arm includes three incremental phases over 18 months. Phase I includes 12 bi-weekly in-home visits that last 90 mins. facilitated by a behavioral health and dietitian team. Meal quality and quantity will be targeted. The primary caregiver will also receive daily EMI messages about increasing meal quantity and quality via a smartphone, based on the stress level reported earlier in the day. Phase II visits will occur every 3 weeks over 6 months. Daily EMI prompts will continue and video feedback will be introduced. In between visits, families will video-record via an iPad at least 3 family dinner meals. Family meal coaches will watch the videos in between home visits to identify specific footage to show family members at the next in-home visit that highlights both positive and negative family interactions and diet quality patterns. During Phase III, parents will receive monthly booster phone calls for six months. The EMI and the video feedback will discontinue.
288496|NCT02669797|Behavioral|Usual Care|The usual care condition will receive childhood obesity prevention messages (i.e., 5-2-1-0) from primary care providers and monthly newsletters focusing on general child health. All clinics in the study already use 5-2-1-0 messages for childhood obesity prevention. These are evidence-based messages (i.e., 5 fruits and vegetables/day; no more than 2 hours of screen time/day; at least 1 hour of physical activity/day; 0 sugar-sweetened beverages/day) that providers share with parents during well-child visits. The monthly newsletters will cover general child health issues, such as car seat safety, immunizations, etc.
288497|NCT02669810|Drug|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
288498|NCT02669810|Device|Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)|
288499|NCT02669823|Other|None, treatment as actual best practice|
288500|NCT00199004|Drug|Vindesine|
288501|NCT02669836|Procedure|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
288502|NCT02672306|Biological|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
288503|NCT02672319|Procedure|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
288504|NCT02672332|Drug|SB204 4%|Once daily
288793|NCT02665195|Other|saliva specimen|
287893|NCT00002529|Drug|toremifene|Toremifene 60 mg daily.
288194|NCT02677090|Drug|Placebo (including Maltodextrin)|
288195|NCT02677090|Drug|Dose 1 - Promitor®|
288196|NCT02677090|Drug|Dose 2 - Promitor®|
288197|NCT00199147|Drug|Fludarabine|
288198|NCT02677090|Drug|Dose 3 - Promitor®|
288199|NCT02677103|Device|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
288200|NCT02677103|Procedure|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
288201|NCT02677103|Procedure|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
288202|NCT02677116|Drug|Olaratumab|Olaratumab administered IV.
288203|NCT02677116|Drug|Doxorubicin|Doxorubicin administered IV.
288204|NCT02677116|Drug|Vincristine|Vincristine administered IV.
288205|NCT02677116|Drug|Irinotecan|Irinotecan administered IV.
288206|NCT02677116|Drug|Ifosfamide|Ifosfamide administered IV.
288207|NCT02677129|Other|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
288208|NCT00199147|Procedure|Stem cell apheresis|
288209|NCT02677142|Behavioral|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
288210|NCT02677142|Behavioral|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
288211|NCT02677155|Radiation|Radiotherapy|Radiotherapy 8 Gy single dose
288212|NCT02677155|Biological|Rituximab|Intranodal injection 5 mg
264031|NCT02390843|Drug|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
264032|NCT02390843|Drug|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm^3
259470|NCT02493582|Drug|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
259471|NCT02493608|Device|scalpel|used to cut the abdominal wall.
259472|NCT02493608|Device|Diathermy|Diathermy used to cut , coagulate the tissue
259473|NCT02495753|Procedure|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
259474|NCT02495753|Procedure|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
259475|NCT02495766|Drug|XCEL-MC-ALPHA|Single infusion
259476|NCT02495766|Drug|Placebo|Single infusion
259477|NCT00178061|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
259478|NCT02495779|Drug|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
259479|NCT02495779|Behavioral|CBT-based counseling|Brief CBT-based counseling to promote adherence
259480|NCT02495792|Device|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
259481|NCT02495805|Procedure|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
259482|NCT02495805|Procedure|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
259483|NCT02495818|Procedure|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
259484|NCT02495818|Procedure|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
259485|NCT02495818|Other|Homemade exercises|Codman and Hughston exercises.
259486|NCT02495831|Drug|Diclofenac sodium|Diclofenac sodium 50 mg single dose
259487|NCT02495831|Drug|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
263734|NCT02359448|Drug|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
263735|NCT02359461|Device|Combination pulsatile Stendo3|
263736|NCT02359474|Drug|Trabectedin|
263737|NCT02359474|Genetic|DNA double-strand breaks|The rationale for combining Trabectedin and regional hyperthermia is that clinical hyperthermia might also prevent repair of DNA double-strand breaks (DSBs) which are induced by Trabectedin. Preclinical investigations show an enhanced anti-tumor efficacy of Trabectedin in different human STS cell lines by heat exposure (41.8°C). Using BRCA2 deficient cells or BRCA2 knock-down the thermal enhancement of Trabectedin efficacy seems to be related to DSB repair.
263738|NCT02359487|Behavioral|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
264033|NCT02354651|Other|Resting breathing pattern|Record resting ventilatory flow and timing
264034|NCT00158405|Drug|Indinavir (IDV)|
264035|NCT02354651|Other|Respiratory muscle endurance test|Subjects will maintain breathing rate with loaded breaths
264036|NCT02354651|Other|Phrenic nerve stimulation|
264037|NCT02354651|Other|Maximal inspiratory pressure|Measure the maximal airflow on inhalation
264038|NCT02354651|Other|Forced expiratory testing|Measure the maximal airflow and volume of gas that can be exhaled with the subject breathing or coughing forcefully
264039|NCT02354651|Other|EMG|Evaluate electrical activity of diaphragm via pacer
264040|NCT02354664|Other|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
264041|NCT02354664|Other|Spirometry|Upright forced vital capacity (FVC)
264042|NCT02354664|Other|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
264043|NCT02354664|Other|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
264044|NCT02354664|Other|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
263450|NCT02366845|Biological|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
263451|NCT02366858|Procedure|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
263452|NCT02366858|Procedure|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
263453|NCT02366871|Drug|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
263454|NCT02366871|Drug|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
263455|NCT02366884|Drug|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
263456|NCT02366884|Drug|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
263457|NCT02366884|Drug|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
263458|NCT02366897|Device|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
263459|NCT00002419|Drug|Abacavir sulfate|
263739|NCT02359487|Behavioral|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
263740|NCT02359500|Device|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
263741|NCT02359513|Drug|Antidepressants|bulimic patients are treated during 3 months
263742|NCT02359513|Drug|Positron Emission Tomography (PET)|PET scan using [18F]MPPF is performed before and after (3 months)antidepressant treatment
263743|NCT02359526|Drug|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
263744|NCT02362100|Procedure|locking plate surgical fixation|
263745|NCT02362113|Other|GI/GL|GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
263146|NCT02371746|Drug|ENV515 Travoprost XR|
263147|NCT02371746|Drug|TRAVATAN Z|
263148|NCT02371759|Procedure|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
263149|NCT02371759|Procedure|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
263150|NCT02371759|Procedure|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
263151|NCT02371759|Procedure|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
263152|NCT02371772|Other|Training|Patients were trained to monitor INR and dose warfarin
263153|NCT02371785|Device|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
263154|NCT02373813|Drug|Placebo for methotrexate|methotrexate placebo capsules
263155|NCT02373839|Other|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
263156|NCT02373852|Device|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
263157|NCT02373865|Drug|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
263158|NCT00160394|Drug|Duac® Gel / Differin® Gel|
263159|NCT02373865|Drug|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
263160|NCT02373865|Drug|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
263161|NCT02373865|Drug|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
263162|NCT02373878|Behavioral|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
263163|NCT02373878|Behavioral|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
263164|NCT02373891|Drug|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
263165|NCT02373891|Drug|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
262585|NCT02497053|Drug|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
262586|NCT02497066|Other|Neuropathic pain cream|Subjects will apply the cream to the painful area.
262587|NCT02497066|Other|Nociceptive pain cream|Subjects will apply the cream to the painful area.
262870|NCT02378285|Other|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
262871|NCT02378298|Drug|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
262872|NCT02378298|Drug|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
262873|NCT02378298|Drug|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
262874|NCT02378324|Other|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
262875|NCT02380625|Drug|Azithromycin|Adults (>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to <18 yrs): 30mg/kg (oral suspension) daily for 5 days
262876|NCT02380625|Drug|Sunitinib and Erlotinib|Sunitinib - Adults (>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to <18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to <20kg): 3.5 mg/kg daily for 7 days; Children (>20kg to <30kg): 3.0 mg/kg daily for 7 days; Children (>30kg to < 18 yrs): 25 mg/kg daily for 7 days
262877|NCT02380625|Drug|Atorvastatin and Irbesartan|Atorvastatin - Adults (>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to <18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to <18 yrs): 1 x 75mg tablet daily until discharge.
262878|NCT02380625|Other|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
262879|NCT02380638|Device|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
262880|NCT02380651|Procedure|Limb salvage|Local or free flaps
262881|NCT02380664|Device|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
262299|NCT02467634|Biological|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
262300|NCT02467647|Drug|Thalidomide|
262301|NCT02467647|Drug|HLJDT|
262302|NCT02467660|Behavioral|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
262303|NCT02467660|Behavioral|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
262304|NCT02467673|Drug|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
262305|NCT00174629|Drug|Docetaxel/DDP|
262588|NCT02497066|Other|Mixed pain cream|Subjects will apply the cream to the painful area.
262589|NCT02497079|Device|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
262590|NCT02497079|Device|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
262591|NCT02497079|Device|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
262592|NCT02497092|Other|Technique of injection|
262593|NCT02497105|Other|Ketogenic Diet|Dietary
262594|NCT02499107|Dietary Supplement|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
262595|NCT02499107|Dietary Supplement|Pasta treatment|
262596|NCT02499107|Dietary Supplement|Boiled and mashed potato treatment|
262597|NCT02499107|Dietary Supplement|Baked french fries treatment|
262011|NCT02472210|Drug|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
262012|NCT02472223|Drug|Betadine 5%|One-time, in-office administration of Betadine 5%.
Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions.
262013|NCT02472223|Drug|Artificial Tears|Standard of care
262014|NCT02472236|Drug|PEX168|200µg,injected subcutaneously,once a week.
262015|NCT02472236|Drug|Digoxin|0.5mg,oral,two times.
262016|NCT00002472|Procedure|neoadjuvant therapy|
262017|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
262018|NCT02472249|Radiation|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
262306|NCT02467673|Drug|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
262307|NCT02467686|Behavioral|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
262308|NCT02467686|Behavioral|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
262309|NCT02467686|Behavioral|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
262310|NCT02467686|Drug|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
262311|NCT02467686|Drug|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
262312|NCT02467686|Drug|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
262313|NCT02467725|Other|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
262314|NCT02467738|Radiation|Brachytherapy|Undergo brachytherapy with Cesium-131
262315|NCT02467738|Radiation|Cesium-131|Undergo brachytherapy with Cesium-131
318082|NCT00293293|Other|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
318083|NCT00293293|Other|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
318084|NCT00293293|Drug|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
318085|NCT00293319|Biological|filgrastim|
318086|NCT00293319|Radiation|iobenguane I 131|
318087|NCT00002798|Drug|therapeutic hydrocortisone|
318088|NCT00293332|Biological|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
318089|NCT00293332|Drug|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
318090|NCT00293332|Drug|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
318091|NCT00293332|Procedure|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
318092|NCT00293345|Drug|gemcitabine hydrochloride|
318093|NCT00296283|Behavioral|integrative behavior couples therapy|
318094|NCT00296296|Drug|Cyclosporin|
318095|NCT00296296|Drug|Tacrolimus|
318445|NCT00283595|Drug|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
318446|NCT00283595|Drug|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
318447|NCT00283608|Genetic|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
318448|NCT00287027|Drug|Risperdal Long Acting Injectable Antipsychotic Medication|
318449|NCT00287040|Behavioral|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
318450|NCT00287053|Drug|divalproex sodium|Divalproex sodium vs. placebo
317366|NCT00314886|Drug|Diet|
317367|NCT00314912|Drug|Tramiprosate (3APS)|
317368|NCT00314925|Drug|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10^7 vp/kg), IV (in the vein) over 1 hour in a single administration
317714|NCT00302718|Behavioral|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
317715|NCT00302718|Behavioral|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
317716|NCT00302731|Drug|Prempro, premarin, provera conjugated estrogens, medroxyprogesterone acetate|Prempro, premarin .45mg, provera 1.5mg conjugated estrogens, medroxyprogesterone acetate
317717|NCT00302731|Drug|Estradiol , estriol , progesterone|Estradiol .5mg, estriol 210mg, progesterone 100mg
317718|NCT00302731|Drug|estradiol,progesterone|estradiol,progesterone
317719|NCT00002818|Drug|cytarabine|
317720|NCT00302731|Drug|estriol, progesterone|estriol 2.5mg, progesterone 100mg
317721|NCT00302744|Drug|Psilocybin (drug)|One placebo session (niacin) and one active drug session (.2 mg/kg). Treatment sessions are six hours.
317722|NCT00302757|Drug|Radioimmunotherapy|
317723|NCT00302757|Procedure|allogeneic hematopoietic cell transplantation|
317724|NCT00302770|Drug|quetiapine|
317725|NCT00305799|Procedure|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
317726|NCT00305812|Drug|dexamethasone|
317727|NCT00305812|Drug|lenalidomide|
317728|NCT00305812|Drug|melphalan|
317729|NCT00305825|Biological|bevacizumab|
317730|NCT00002828|Drug|raltitrexed|
323066|NCT00298740|Device|Aventis U-400 Insulin|
323067|NCT00298753|Procedure|fluid restriction for 14 days (15ml fluid per kg weight)|
323068|NCT00298766|Drug|VELCADE|Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2
Or
Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2
323069|NCT00301925|Procedure|adjuvant therapy|
323070|NCT00301938|Drug|7-hydroxystaurosporine|Given IV
323071|NCT00301938|Drug|perifosine|Given orally
323072|NCT00301938|Other|pharmacological study|Correlative studies
323073|NCT00301951|Biological|anti-thymocyte globulin|
323074|NCT00301951|Biological|sargramostim|
323075|NCT00002816|Drug|mesna|Given IV
323076|NCT00301951|Drug|busulfan|
323077|NCT00301951|Drug|fludarabine phosphate|
323078|NCT00301951|Drug|mycophenolate mofetil|
323079|NCT00301951|Drug|tacrolimus|
323080|NCT00301951|Procedure|umbilical cord blood transplantation|
323081|NCT00301964|Biological|bevacizumab|Given IV
323082|NCT00301964|Other|laboratory biomarker analysis|Correlative studies
323083|NCT00301990|Biological|aldesleukin|
317369|NCT00314938|Drug|PHA-794428|
317370|NCT00314951|Drug|fidaxomicin|200 mg capsules q12hr (2 times a day)
317371|NCT00314951|Drug|Vancomycin|125 mg capsules q6hr (4 times a day)
317372|NCT00002855|Drug|Therapeutic Hydrocortisone|
317373|NCT00314964|Drug|PD-0299685|
317374|NCT00314977|Drug|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
317375|NCT00314977|Drug|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
322332|NCT00268853|Drug|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
322333|NCT00268866|Behavioral|Education|
322334|NCT00002718|Drug|thiotepa|
322335|NCT00268879|Drug|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
322695|NCT00308113|Drug|Prednisone|Prednisone 0/75 mg/kg/day.
322696|NCT00308113|Dietary Supplement|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
322697|NCT00310817|Biological|MenACWY polysaccharide vaccine|
322698|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
322699|NCT00310830|Drug|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
322700|NCT00310843|Drug|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
322701|NCT00002839|Procedure|conventional surgery|
322702|NCT00310856|Biological|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
322703|NCT00310856|Biological|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
322704|NCT00310856|Biological|DTaP-Hib-IPV|
322705|NCT00310856|Biological|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
322706|NCT00310856|Biological|MMR|
322707|NCT00310856|Biological|Varicella|
322708|NCT00310869|Behavioral|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
322709|NCT00310895|Drug|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
322710|NCT00310908|Drug|Tramadol Hcl|Active Comparator
321971|NCT00278512|Biological|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
321972|NCT00278525|Drug|standard of care|standard of care medication will be given
321973|NCT00002757|Drug|prednisolone|
321974|NCT00278525|Procedure|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
321975|NCT00278538|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
321976|NCT00278551|Biological|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
321977|NCT00278564|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
321978|NCT00278577|Biological|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
321979|NCT00278590|Biological|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
321980|NCT00278603|Biological|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
321981|NCT00278616|Biological|Stem Cell Transplantation|Autologous Stem Cell Transplantation
321982|NCT00278629|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
321983|NCT00278642|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
321984|NCT00002757|Drug|prednisone|
321985|NCT00278655|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
321986|NCT00278681|Drug|Zinc and ORS|One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.
Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water.
321987|NCT00278694|Drug|Oxaliplatin and 5-FU based preoperative chemoradiation|
322336|NCT00268892|Drug|Degarelix|Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.
322337|NCT00268892|Drug|Degarelix|Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.
321246|NCT00297700|Behavioral|Active referral|
321247|NCT00297713|Drug|ALTU-238|
321248|NCT00297726|Behavioral|Self-Management Program|
321249|NCT00297739|Drug|Risperidone|
321250|NCT00297752|Drug|ceriumnitrate silversulfadiazine (flammacerium)|
321251|NCT00297752|Drug|silversulfadiazine (flammazine)|
321252|NCT00002805|Drug|therapeutic hydrocortisone|
321253|NCT00297765|Drug|Tacrolimus, Prograf®|
321612|NCT00288288|Procedure|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
321613|NCT00288301|Behavioral|Weight loss intervention|weight loss intervention
321614|NCT00002785|Drug|etoposide|
321615|NCT00288314|Procedure|Magnetic Resonance Imaging, Functional|Structural and functional MRI
321616|NCT00288327|Behavioral|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
321617|NCT00288327|Behavioral|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
321618|NCT00288340|Device|functional magnetic resonance imaging|
321619|NCT00288353|Drug|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
321620|NCT00288353|Drug|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
321621|NCT00288366|Drug|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
321622|NCT00288366|Drug|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
321623|NCT00288379|Drug|formoterol|
321624|NCT00288379|Drug|budesonide/formoterol|
321625|NCT00002785|Drug|leucovorin calcium|
320879|NCT00307216|Behavioral|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
320880|NCT00307216|Behavioral|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
320881|NCT00307229|Biological|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
320882|NCT00307242|Drug|Adefovir Dipivoxil|
320883|NCT00307255|Drug|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
320884|NCT00307255|Drug|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
320885|NCT00307281|Other|Phlebotomy, Pulmonary Function Tests|
320886|NCT00307294|Drug|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
320887|NCT00002832|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
320888|NCT00307294|Drug|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
320889|NCT00307307|Drug|Niacin/simvastatin compared to simvastatin alone at 2 doses|
320890|NCT00307320|Behavioral|Relaxation Training|Relaxation techniques training
320891|NCT00307333|Device|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
320892|NCT00307398|Drug|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
320893|NCT00307398|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
321254|NCT00297778|Drug|Pramipexole|Dopamine agonist
321255|NCT00297778|Other|Placebo|
321256|NCT00297791|Procedure|surgery|randomized to open or laparoscopic technique
320157|NCT00274781|Drug|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
320158|NCT00274781|Drug|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
320159|NCT00274794|Biological|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
320160|NCT00274794|Biological|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
320161|NCT00274807|Biological|filgrastim|
320162|NCT00274807|Drug|cytarabine|
320163|NCT00274807|Drug|etoposide|
320164|NCT00002744|Drug|prednisone|
320165|NCT00274807|Drug|mitoxantrone hydrochloride|
320166|NCT00274820|Dietary Supplement|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
320508|NCT00264732|Drug|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
320509|NCT00264732|Drug|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
320510|NCT00264732|Other|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
320511|NCT00264745|Behavioral|TASK intervention|The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
320512|NCT00264745|Behavioral|Attention Control|Minimal intervention beyond initial hospital visit.
320513|NCT00264758|Device|Conventional hemodialysis|Three times per week in-center hemodialysis
320514|NCT00264758|Device|Frequent hemodialysis|Six times per week in-center hemodialysis
320515|NCT00264797|Drug|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
319767|NCT00280969|Drug|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
319768|NCT00280969|Drug|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
319769|NCT00280982|Biological|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
319770|NCT00280995|Drug|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
319771|NCT00002766|Drug|carmustine|
319772|NCT00280995|Drug|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
319773|NCT00280995|Drug|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
319774|NCT00280995|Drug|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
319775|NCT00281008|Drug|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
319776|NCT00281008|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
319777|NCT00281008|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
319778|NCT00281008|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
319779|NCT00281021|Drug|Erlotinib plus Digoxin|Each subject will receive erlotinib and digoxin daily until progression.
319780|NCT00281047|Drug|FP-10|
319781|NCT00281060|Procedure|primary stenting|
319782|NCT00002766|Drug|cyclophosphamide|
319783|NCT00281073|Device|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
319784|NCT00281073|Device|Intracardiac Echo|Intracardiac Echo Viewmate
319785|NCT00281073|Device|ICE|ICE or TEE
320167|NCT00274820|Drug|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
319034|NCT00300378|Drug|desvenlafaxine 100 mg|
319035|NCT00300391|Drug|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
319036|NCT00300391|Other|Saline placebo|control arem
319037|NCT00300404|Drug|daraprim|
319038|NCT00300404|Drug|pyrimethamine|
319039|NCT00300404|Drug|folinic acid|
319040|NCT00300417|Drug|VRC-WNVDNA020-00-VP|
319391|NCT00290498|Drug|Vincristine|Arm A: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.
Arm B: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle.
319392|NCT00290498|Drug|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
319393|NCT00290498|Drug|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
319394|NCT00290498|Drug|Cytarabine|Arm B: Cytarabine 3 g/m^2 by vein over 2 hours every 12 hours X 4 doses on days 3 & 4, cycle 2 and alternating cycles.
319395|NCT00290498|Drug|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
319396|NCT00290511|Drug|Fludarabine|25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4.
319397|NCT00002789|Drug|methotrexate|
319398|NCT00290511|Drug|Mitoxantrone|10 mg/m^2 IV over 5-30 minutes on Day 2.
319399|NCT00290511|Drug|Rituximab|375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
319400|NCT00290511|Drug|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
319401|NCT00290511|Drug|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
319402|NCT00290524|Behavioral|Oral alimentation started 12 hours after colorectal surgery|
311250|NCT00315315|Procedure|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
311251|NCT00315315|Procedure|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
311252|NCT00002858|Drug|doxorubicin hydrochloride|
311253|NCT00315328|Drug|Atropine|Atropine 1% each weekend day in the sound eye
311254|NCT00315328|Device|Patching|Patching 2 hours per day
311255|NCT00315328|Procedure|Near activities|near visual activities for at least one hour per day
311256|NCT00318214|Drug|Vehicle gel|Gel administered once per day
311257|NCT00002870|Drug|cyclophosphamide|
311258|NCT00318227|Procedure|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
311259|NCT00318240|Device|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
311260|NCT00318253|Procedure|cranberry juice|
311261|NCT00318266|Device|Use of Nuclear Matrix Protein 22 Urine sample kit to determine Bladder Cancer|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
311262|NCT00318279|Device|Surgical simulator to practice vascular anastomosis|
311608|NCT00362804|Drug|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
311609|NCT00362817|Drug|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
311610|NCT00362817|Drug|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
311611|NCT00003078|Drug|fluorouracil|
311612|NCT00362830|Drug|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
311613|NCT00362856|Drug|AT1001|
311614|NCT00362869|Drug|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
316503|NCT00317486|Drug|bosentan|
316504|NCT00317499|Other|Placebo|Placebo
316505|NCT00317499|Drug|Etanercept|Etanercept
316847|NCT00362011|Behavioral|Salba diet|
316848|NCT00362024|Drug|MK0952|
316849|NCT00362024|Drug|Comparator: Placebo|
316850|NCT00362037|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
316851|NCT00362050|Drug|Treatment with 3 dose groups of RBx11160 over 7 days|
316852|NCT00362063|Drug|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
316853|NCT00003072|Drug|amifostine trihydrate|
316854|NCT00362089|Dietary Supplement|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
316855|NCT00362102|Drug|Cetuximab|
316856|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
316857|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
316858|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
316859|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
316860|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
316861|NCT00362115|Drug|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
316862|NCT00362115|Drug|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
316863|NCT00362141|Drug|levetiracetam (add-on)|
316864|NCT00003072|Drug|carboplatin|
316865|NCT00362180|Drug|mipomersen|200 mg subcutaneous injections
316866|NCT00362180|Drug|Placebo|subcutaneous injections
316139|NCT00323895|Device|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
316140|NCT00323921|Device|dermatological infrared laser|
316141|NCT00326976|Drug|FX06|400 mg as intravenous injection in two divided boluses
316142|NCT00326976|Procedure|Percutaneous coronary intervention|
316143|NCT00326989|Procedure|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
316144|NCT00327002|Drug|LY518674|
316145|NCT00002905|Drug|didanosine|
316146|NCT00327015|Drug|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
316147|NCT00327015|Drug|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
316148|NCT00327015|Drug|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
316149|NCT00327015|Drug|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
316150|NCT00327015|Drug|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
316151|NCT00327028|Drug|Diphenine|
316152|NCT00327054|Drug|Nigella sativa seed|
316153|NCT00327080|Procedure|MRI|
316154|NCT00327080|Drug|L-NMMA|
316155|NCT00327080|Drug|Acetylcholine|
316156|NCT00002905|Drug|doxorubicin hydrochloride|
316157|NCT00327093|Drug|cetuximab|indication : second intention treatment
316158|NCT00327093|Drug|bevacizumab|Indication: first intention treatment
316159|NCT00327106|Drug|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
316160|NCT00327106|Drug|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
316506|NCT00317512|Procedure|Percutaneous Coronary Revascularization|
316507|NCT00317512|Drug|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
315034|NCT00355199|Drug|Rituximab-CHOP|Rituximab-CHOP
315035|NCT00355212|Procedure|percutaneous ablation of hepatocellular carcinoma|
315036|NCT00355225|Procedure|ITN distribution channel|
315037|NCT00355238|Drug|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
315038|NCT00355251|Drug|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
315039|NCT00003037|Drug|gemcitabine hydrochloride|
315040|NCT00355264|Drug|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
315041|NCT00355277|Drug|Amitriptyline|
315042|NCT00355290|Behavioral|Changes on Oral Vitamin K Intake|
315386|NCT00002989|Drug|idarubicin|
315387|NCT00345917|Device|Retinal transplantation instrument|
315388|NCT00345917|Device|Fetal tissue.|
315389|NCT00345943|Other|MRI|Magnetic Resonance Imaging scans
315390|NCT00345943|Behavioral|Neuropsychological Testing|Neuropsychological tests
315391|NCT00345956|Biological|Human rotavirus liquid vaccine|
315392|NCT00345969|Drug|Testosterone replacement therapy|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
315393|NCT00345969|Behavioral|Exercise training|Six months of supervised exercise training on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and low resistance exercises, followed by 4 months of progressive resistance training.
315394|NCT00345982|Drug|Serdolect|16 mg, 12 weeks
315395|NCT00345982|Drug|placebo|placebo
315396|NCT00346008|Genetic|mutation analysis|
315397|NCT00349089|Drug|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
315398|NCT00349102|Radiation|Free breathing|Free breathing during conformal radiation
315399|NCT00003007|Biological|recombinant interferon alfa|
313940|NCT00002887|Drug|vindesine|
319952|NCT00300833|Drug|Tirofiban|pci
319953|NCT00300846|Drug|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
319954|NCT00002812|Drug|methotrexate|Given PO
319955|NCT00300846|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
319956|NCT00303667|Biological|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
319957|NCT00002822|Drug|doxorubicin hydrochloride|
319958|NCT00303667|Biological|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10^7 cells/kg.
319959|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
319960|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 40 mg/m^2 on Days -18 through -14
319961|NCT00303667|Procedure|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
319962|NCT00303667|Radiation|total body irradiation|Administered on Day -13, 200 cGy two times.
319963|NCT00303667|Biological|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
319964|NCT00303667|Drug|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
319965|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
319966|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 35 mg/m^2 on Days -18 through -14
319967|NCT00303706|Procedure|Endoscopic Radial Artery Harvest|
319968|NCT00002822|Drug|etoposide|
319969|NCT00303719|Biological|anti-thymocyte globulin|ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.
Those that should/will receive ATG in the preparative regimen:
Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should
Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will
Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should
Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG.
318819|NCT00274248|Drug|MLN518|
318820|NCT00276991|Drug|"Kallunk oxide (Immunotherapy) "|The study was assigned only one Arm >450 cu/mm^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of "Kallunk oxide(Immunotherapy) + Long Pepper", that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as "Kallunk oxide" and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg "Kallunk oxide" molecules with 199.900 mg, and 499.800 mg "Antidote"( This antidote was used as a carrier of "Kallunk oxide" molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is "Piper Longum".
318821|NCT00277017|Drug|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.
Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.
Treatment will be followed by 2 weeks of rest then repeated.
318822|NCT00277030|Drug|Surfactant|
318823|NCT00002756|Biological|filgrastim|
318824|NCT00277030|Device|Nasal CPAP|
319189|NCT00264225|Drug|Lamaline® , 3 different doses, Dafalgan codeine|
319190|NCT00264238|Drug|Memantine|
319191|NCT00264251|Behavioral|Weight loss through diet and exercise|
319192|NCT00267202|Drug|Immunotherapy|Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or "maintenance" solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.
319193|NCT00267215|Drug|Lumiracoxib|
319194|NCT00267241|Other|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
319195|NCT00267254|Drug|torcetrapib/atorvastatin|
319196|NCT00267254|Drug|simvastatin|
319197|NCT00267267|Drug|torcetrapib/atorvastatin|
319198|NCT00267267|Drug|ezetimibe/simvastatin|
319199|NCT00267280|Drug|torcetrapib/atorvastatin|
319200|NCT00267280|Drug|simvastatin|
318451|NCT00002784|Drug|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
318452|NCT00287066|Drug|Inhaled Human Insulin|
318453|NCT00287066|Drug|Regular Human Insulin|
318454|NCT00287079|Drug|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
318455|NCT00287079|Other|No Treatment|No treatment for 96 weeks
318456|NCT00287092|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
318457|NCT00287092|Biological|Infanrix® -IPV+Hib|0.5 mL, IM
318458|NCT00287105|Drug|Standard chemotherapy + Imatinib|Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
318459|NCT00287118|Drug|efalizumab=Raptiva|Each patient will receive an initial conditioning dose of 0.7 mg/kg/week followed by 1.0 mg/kg/week study drug during the treatment period, 23 weeks. If four or more consecutive doses have been missed, dosing should resume with the conditioning dose of 0.7 mg/kg and then continue receiving 1mg/kg/week thereafter. Study drug will be administered by SC injection.
318460|NCT00287131|Procedure|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
318461|NCT00287157|Drug|Sublingual Tizanidine HCl|
318462|NCT00002784|Drug|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
318463|NCT00287170|Drug|Delayed Release 6MP or Calcitriol vs. Purinethol|
318464|NCT00287183|Drug|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
318465|NCT00287183|Other|Placebo|Placebo
318825|NCT00277043|Drug|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
318826|NCT00277043|Drug|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
318827|NCT00277069|Drug|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
318828|NCT00277069|Device|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
317731|NCT00305825|Drug|letrozole|
317732|NCT00305838|Drug|tamoxifen citrate|
317733|NCT00305838|Other|diagnostic laboratory biomarker analysis|
317734|NCT00305851|Procedure|music therapy (books on tape)|
317735|NCT00305851|Procedure|psychosocial assessment and care|
317736|NCT00305851|Procedure|quality-of-life assessment|
318096|NCT00296296|Behavioral|Diabetes Education / Management|
318097|NCT00002803|Drug|vincristine sulfate|
318098|NCT00296309|Drug|Tacrolimus|Immunosuppression
318099|NCT00296322|Drug|cisplatin, mitomycin-C, doxifluridine|Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
318100|NCT00296335|Drug|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
318101|NCT00296335|Drug|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
318102|NCT00296348|Drug|tacrolimus|immunosuppression
318103|NCT00296348|Drug|mycophenolate mofetil|oral
318104|NCT00296348|Drug|daclizumab|oral
318105|NCT00296348|Drug|steroids|oral
318106|NCT00296361|Drug|Tacrolimus|immunosuppression
318107|NCT00296374|Drug|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
318108|NCT00002803|Procedure|conventional surgery|
318109|NCT00296374|Drug|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
318110|NCT00296374|Drug|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
318111|NCT00296387|Drug|Rosuvastatin|
317376|NCT00314977|Drug|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
317377|NCT00314990|Drug|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
317378|NCT00315003|Drug|Telithromycin|
317379|NCT00317798|Biological|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
317380|NCT00317798|Drug|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
317381|NCT00002868|Procedure|peripheral blood stem cell transplantation|
317382|NCT00317811|Dietary Supplement|ascorbic acid|
317383|NCT00317811|Drug|bortezomib|
317384|NCT00317811|Drug|melphalan|
317385|NCT00317837|Procedure|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
317386|NCT00317837|Procedure|bipolar hemiarthroplasty|bipolar hemiarthroplasty
317387|NCT00317850|Drug|Gabapentin (Neurontin)|
317388|NCT00317876|Drug|cyclophosphamide|
317389|NCT00317876|Drug|cyclosporine|
317390|NCT00317876|Drug|methotrexate|
317391|NCT00317876|Procedure|allogeneic bone marrow transplantation|
317392|NCT00002869|Biological|recombinant interferon alfa|
317393|NCT00317876|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
317737|NCT00305851|Behavioral|Music Video|Song writing, recording the song with a digital accompaniment track, completing a video layout worksheet (determining the contents of the video), taking photos or making drawings for the video, and viewing clip art and pictures on a computer.
317738|NCT00305864|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
317739|NCT00305864|Drug|temozolomide|Given orally
317740|NCT00305864|Drug|motexafin gadolinium|Given IV
322711|NCT00310921|Drug|Misoprostol|
322712|NCT00002839|Procedure|neoadjuvant therapy|
322713|NCT00310934|Drug|methadone|
322714|NCT00310934|Drug|buprenorphine / methadone sequence|
322715|NCT00310934|Behavioral|Relapse prevention|
322716|NCT00310934|Behavioral|Contingency management|
322717|NCT00310973|Behavioral|Social Network Intervention|
317013|NCT00327379|Drug|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
317014|NCT00327392|Drug|AQUAVAN® (fospropofol disodium) Injection|
317015|NCT00327418|Drug|Atorvastatin|
317016|NCT00327431|Genetic|Cheek swab samples for DNA|
317017|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
317018|NCT00002905|Drug|zidovudine|
317019|NCT00327444|Drug|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
317020|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
317021|NCT00327457|Behavioral|Help with physician office and patient management|
317022|NCT00327457|Behavioral|Tailored physician recommendation letter|
317023|NCT00327470|Drug|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
317024|NCT00327483|Behavioral|Internet based education software|
317025|NCT00327496|Biological|DC vaccine|
317026|NCT00327522|Biological|pneumococcal vaccine|
317027|NCT00327535|Drug|Darbepoetin alfa|6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week
317028|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|6.3 micrograms/kg every 3 weeks
322338|NCT00268892|Drug|Degarelix|Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.
322339|NCT00268905|Drug|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
322340|NCT00268905|Drug|E7389 + carboplatin AUC 6|After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).
If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5.
322341|NCT00268905|Drug|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
322342|NCT00268918|Drug|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
322343|NCT00268918|Drug|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
322344|NCT00268931|Behavioral|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
322345|NCT00272116|Drug|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
322346|NCT00272116|Drug|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
322347|NCT00272142|Drug|Zinc|
322348|NCT00272142|Drug|Placebo|
322349|NCT00272155|Behavioral|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
322718|NCT00310986|Behavioral|Breathing Meditation|
322719|NCT00310999|Device|Shikani Optical Stylet|
322720|NCT00311012|Drug|Aliskiren|
322721|NCT00311025|Procedure|intensive endurance, strength and balance exercises|
321626|NCT00288392|Drug|Soluble beta-1,3/1,6-glucan|
321627|NCT00288405|Device|Cordis Self Expanding Stent|
321628|NCT00288418|Device|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
321629|NCT00288431|Drug|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
321630|NCT00288431|Drug|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
321631|NCT00288444|Drug|Lonafarnib|
321632|NCT00288444|Drug|Docetaxel|
321988|NCT00278694|Drug|Chemoradiation|
321989|NCT00278707|Drug|GTA: Glyceryltriacetate|
321990|NCT00278733|Behavioral|Brief intervention (physician advice)|
321991|NCT00278746|Drug|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
321992|NCT00278746|Drug|ORS only|Promoted routine management of diarrhea in underfive with ORS
321993|NCT00278759|Procedure|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
321994|NCT00278772|Drug|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
321995|NCT00002757|Drug|therapeutic hydrocortisone|
321996|NCT00278772|Other|Placebo|oral dose, placebo
321997|NCT00278785|Behavioral|Brief Motivational Interview|10-20 minute brief motivational interview
321998|NCT00281853|Procedure|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
321999|NCT00281866|Drug|erlotinib hydrochloride|
322000|NCT00281879|Biological|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
321257|NCT00297804|Device|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
321258|NCT00297804|Device|Control stent|control stent
321259|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
321260|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
321261|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
321262|NCT00297830|Drug|zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
321263|NCT00002805|Procedure|allogeneic bone marrow transplantation|
321264|NCT00297830|Drug|alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
321265|NCT00297843|Procedure|allergen challenge (grass pollen), nasal lavage|
321266|NCT00297856|Biological|Boostrix®|Single dose
321267|NCT00297856|Biological|Td (Tetanus diphtheria) vaccine|Single dose
321268|NCT00297869|Procedure|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
321269|NCT00301210|Drug|Tramadol|oral doses four times per day
321270|NCT00301223|Drug|Pregabalin|
321271|NCT00301236|Drug|Dexmethylphenidate HCl extended-release capsules|
321272|NCT00301262|Drug|Viagra (Sildenafil citrate)|
321273|NCT00301288|Procedure|Autologous stem cell transplant|
321274|NCT00301301|Drug|Gemcitabine|
321275|NCT00301301|Drug|Cisplatinum|
321276|NCT00301301|Drug|Rituximab|
321277|NCT00301314|Procedure|Autologous stem cell transplant|
321278|NCT00002813|Drug|cisplatin|
320516|NCT00264797|Drug|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
320517|NCT00264810|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
320518|NCT00002704|Radiation|low-LET electron therapy|
320519|NCT00264810|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
320520|NCT00268164|Drug|lactobacilus acidophilus & bifidobacterium animalis/lactis|
320521|NCT00268177|Drug|Salmeterol/fluticasone propionate 50/500mcg Diskus|
320894|NCT00307411|Drug|Growth hormone|
320895|NCT00307424|Device|AutoCPAP|
320896|NCT00307424|Device|FixCPAP|
320897|NCT00307437|Drug|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
320898|NCT00310128|Procedure|antibody therapy|
320899|NCT00310128|Procedure|biological therapy|
320900|NCT00310128|Procedure|chemotherapy|
320901|NCT00310128|Procedure|monoclonal antibody therapy|
320902|NCT00310128|Procedure|radiation therapy|
320903|NCT00310128|Procedure|radioimmunotherapy|
320904|NCT00002837|Drug|Cyclophosphamide|
320905|NCT00310128|Procedure|radioisotope therapy|
320168|NCT00274820|Drug|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
320169|NCT00274820|Drug|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience < grade 1 thalidomide-attributed toxicity using CTC criteria.
320170|NCT00274833|Drug|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
320171|NCT00274833|Drug|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
320172|NCT00274833|Radiation|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
320173|NCT00274846|Biological|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
320174|NCT00274846|Biological|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10^9
320175|NCT00002744|Drug|therapeutic hydrocortisone|
320176|NCT00277758|Biological|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
320177|NCT00277758|Drug|Ribavirin|Ribavirin @ 800 mg daily (< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
320178|NCT00002756|Drug|mercaptopurine|
320179|NCT00277758|Biological|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
320180|NCT00277758|Biological|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
320181|NCT00277758|Drug|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight <65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight >85 kg.
320182|NCT00277771|Behavioral|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
320183|NCT00277771|Behavioral|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
319403|NCT00290537|Drug|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg PO Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
319404|NCT00290537|Drug|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
319405|NCT00293722|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
319406|NCT00293735|Drug|labetalol (seizure prevention)|20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.
20mg labetalol PO every 6 hours
319407|NCT00293735|Drug|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
319408|NCT00293761|Drug|Travoprost, Investigational|One drop in study eye once daily for 13 days
319409|NCT00293761|Drug|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
319410|NCT00293787|Drug|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
319411|NCT00293787|Other|Timolol Vehicle|Placebo
319786|NCT00281099|Device|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
319787|NCT00281125|Drug|PTK787 and Pemetrexed with or without Cisplatin|
319788|NCT00281177|Behavioral|Asthma Disparity Reduction Strategy|
319789|NCT00281190|Procedure|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
319790|NCT00283959|Drug|AT1001 (migalastat hydrochloride)|administered every other day
319791|NCT00283972|Device|LAP-BAND System|
319792|NCT00002773|Biological|allogeneic tumor cell vaccine|
319793|NCT00283985|Drug|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
319794|NCT00283985|Drug|Methotrexate|3 gr/m2 at J1
319795|NCT00283985|Drug|Dexamethasone|40 mg/ per os at J1, J2 and J4.
319796|NCT00283985|Drug|Erwinase|In case of allergy to Kidrolase
20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles
319797|NCT00283998|Procedure|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
311615|NCT00362869|Drug|Placebo|Sodium bicarbonate solution
311616|NCT00362869|Biological|Enteroaggregative E. coli (EAEC)|Dosages: 1X10^9, 5X10^9, 1X10^10, and 5X10^10 cfu; given in a sodium bicarbonate solution
311617|NCT00362882|Drug|docetaxel|Given IV
311618|NCT00362882|Drug|bortezomib|Given IV
311619|NCT00362882|Other|laboratory biomarker analysis|correlative study
311620|NCT00362882|Other|immunoenzyme technique|correlative study
311621|NCT00362882|Other|immunohistochemistry staining method|correlative study
311622|NCT00003078|Radiation|brachytherapy|
311623|NCT00362882|Other|pharmacological study|correlative study
311624|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
311625|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
311626|NCT00362908|Behavioral|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
311627|NCT00362908|Behavioral|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
311628|NCT00362921|Drug|Gliadel wafers in combination with O6-benzylguanine|
311629|NCT00362934|Drug|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
311630|NCT00362934|Drug|Atorvastatin|Atorvastatin 10 mg and 20mg
311973|NCT00354172|Drug|methylprednisolone|This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.
Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity.
311974|NCT00354172|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -1. Patients
≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.
Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9 /L).
311975|NCT00354172|Procedure|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
316867|NCT00362193|Behavioral|Telephonic diabetes care|
316868|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
316869|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
316870|NCT00362206|Drug|Pravastatin|Pravastatin 40 mg
316871|NCT00362219|Other|Placebo|Gel with no active ingredient.
311263|NCT00318292|Drug|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
311264|NCT00318292|Drug|Placebo|20 ml normal saline injection.
311265|NCT00318318|Drug|Premarin|
311266|NCT00318331|Drug|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
311267|NCT00318344|Drug|Atuna Racemosa|
311268|NCT00002870|Drug|epirubicin hydrochloride|
311269|NCT00318357|Device|Medtronic CRT InSync® family devices|Implantation of CRT device and medical treatment according normal hospital routine.
311270|NCT00318370|Drug|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
311271|NCT00318370|Drug|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
311272|NCT00318383|Biological|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
311273|NCT00318383|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
311274|NCT00318396|Procedure|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
311275|NCT00318396|Procedure|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
311276|NCT00318409|Drug|Bupropion|
311277|NCT00318409|Drug|Placebo|
311278|NCT00318422|Drug|liraglutide|
311279|NCT00000461|Drug|gemfibrozil|
316508|NCT00317512|Drug|Voluven|
316509|NCT00317525|Device|Spectacle Lenses|
316510|NCT00317538|Drug|infliximab, etanercept|
316511|NCT00002868|Drug|cytarabine|
316512|NCT00317551|Device|Aberration controlled contact lens|
316513|NCT00317551|Behavioral|Vision training|
316514|NCT00317577|Drug|brimonidine, timolol|
316515|NCT00317590|Device|Rapid Diagnostic Test for Malaria (Paracheck®)|
316516|NCT00317603|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
316517|NCT00317629|Drug|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
316518|NCT00317629|Drug|meglumine antimoniate|20mg/kg daily during 20 days
316519|NCT00317642|Drug|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m^2 / day up to 3 cycles
316520|NCT00317642|Drug|placebo|placebo (sodium Chloride) 1-hour IV infusion
316521|NCT00317642|Drug|cytarabine|cytarabine IV infusion 1g/m^2/day for up to 3 cycles
316522|NCT00000461|Drug|cholestyramine|
316523|NCT00002868|Drug|etoposide|
316524|NCT00320905|Behavioral|Observational|No intervention
316525|NCT00320931|Device|PET/CT|
316526|NCT00320957|Device|OculusGen Biodegradable Collagen Matrix Implant|
316527|NCT00320970|Drug|Candesartan|
316528|NCT00320983|Drug|Topotecan|Topotecan
316529|NCT00320983|Drug|Cisplatin|Cisplatin
316530|NCT00002881|Drug|leuprolide acetate|
316531|NCT00321009|Drug|Enoxaparin|
315400|NCT00349102|Radiation|Breath holding|Breath holding during conformal radiation
315401|NCT00349115|Drug|Thalidomide|
315402|NCT00349128|Drug|fenofibrate and metformin combination (drug)|
315403|NCT00349141|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
315404|NCT00349167|Drug|PR-104|
315405|NCT00349167|Other|laboratory biomarker analysis|
315406|NCT00349167|Other|pharmacological study|
315407|NCT00349180|Drug|Enoxaparin sodium|
315408|NCT00349193|Drug|laquinimod 0.3|laquinimod 0.3mg
315409|NCT00349193|Drug|laquinimod 0.6|laquinimod 0.6mg
315410|NCT00000473|Behavioral|dietary supplements|
315411|NCT00003007|Biological|sargramostim|
315763|NCT00336583|Drug|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
315764|NCT00336596|Procedure|transcranial ultrasound in patients treated with iv t-PA|
315765|NCT00336622|Device|Splint fabricated by an OT versus an off-the-shelf splint|Experimental:
Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
Control:
Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises
315766|NCT00336635|Biological|cell-culture derived smallpox vaccine|
315767|NCT00336648|Drug|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
315768|NCT00336648|Drug|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
315769|NCT00336648|Procedure|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
315770|NCT00336661|Device|PerioWave|
315771|NCT00336674|Biological|Intranasal insulin|440IU Insulin
315772|NCT00002960|Biological|recombinant adenovirus-p53 SCH-58500|
319970|NCT00303719|Drug|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
319971|NCT00303719|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of >200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
320320|NCT00294229|Procedure|manipulative therapy|
320321|NCT00294242|Procedure|membrane sweeping|
320322|NCT00294255|Drug|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
320323|NCT00294268|Behavioral|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
320324|NCT00294281|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
320325|NCT00294294|Biological|Prevenar|
320326|NCT00294294|Biological|Infanrix hexa|
320327|NCT00294307|Behavioral|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners [low intensity];
320328|NCT00294307|Behavioral|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home [medium intensity];.
320329|NCT00294307|Behavioral|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers [high intensity].
320330|NCT00000444|Drug|nicotine replacement patch|
320331|NCT00002800|Biological|filgrastim|
320332|NCT00294320|Drug|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
320333|NCT00294320|Other|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
320334|NCT00294346|Drug|AV608|
320335|NCT00297232|Drug|Natalizumab|
320336|NCT00297245|Drug|cognitive function|
319201|NCT00267293|Drug|Acetaminophen|Given for fever control 15mg/kg
319202|NCT00002715|Drug|etoposide|
319203|NCT00267293|Drug|Ibuprofen|Given for fever control 10 mg/kg
319204|NCT00267306|Drug|Visilizumab|
319205|NCT00267319|Drug|Glatiramer acetate|
319206|NCT00267332|Drug|Modafinil|
319207|NCT00267358|Drug|RC-1291 HCl|
319208|NCT00267358|Drug|Placebo|
319209|NCT00267371|Device|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
319210|NCT00267371|Drug|Medical management/current medications|Medical management with current medications.
319211|NCT00267384|Drug|Oral N-Acetylcysteine|
319561|NCT00309842|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW > 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
319562|NCT00309842|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of > 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
319563|NCT00309842|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
319564|NCT00309842|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day.
319565|NCT00309842|Procedure|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
319566|NCT00309842|Radiation|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
319567|NCT00309855|Drug|Placebo|im and orally
319568|NCT00002836|Drug|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
319569|NCT00309855|Drug|Testosterone|injections
318829|NCT00277069|Drug|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
318830|NCT00277082|Drug|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
318831|NCT00277095|Device|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
318832|NCT00277108|Drug|Escitalopram (Lexapro)|
318833|NCT00277147|Drug|BB IND 6989|
318834|NCT00002756|Drug|asparaginase|
318835|NCT00277160|Drug|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
318836|NCT00277173|Behavioral|Adoption of Crew Resource Management approach|
318837|NCT00277186|Other|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
318838|NCT00277199|Drug|Abatacept|
318839|NCT00277212|Drug|Lamotrigine + Aripiprazole|Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks
Lamotrigine 100-200 mg/day
Aripiprazole 10-30 mg/day
318840|NCT00277212|Drug|Lamotrigine + Placebo|Tablets, Oral, once daily, Phase 2 - up to 52 weeks
Lamotrigine 100-200 mg/day
placebo 0 mg/day
318841|NCT00277225|Drug|Abatacept|
318842|NCT00280566|Drug|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
318843|NCT00280592|Drug|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
318844|NCT00280592|Drug|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
318845|NCT00280605|Drug|Alfuzosin|
319212|NCT00267410|Behavioral|Healthy Relationships|"Healthy Relationships," grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts.
318112|NCT00296387|Drug|Atorvastatin|
318113|NCT00296400|Drug|Rosuvastatin|
318114|NCT00296400|Drug|Atorvastatin|
318115|NCT00296426|Procedure|New technology - PAML|
318116|NCT00296439|Behavioral|Behavior|
318117|NCT00296452|Behavioral|behavior|
318118|NCT00296465|Drug|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
318119|NCT00002804|Biological|filgrastim|
318466|NCT00287196|Radiation|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
318467|NCT00287209|Drug|Amiodarone|
318468|NCT00287222|Drug|Bevacizumab|15 mg/KG I.V. every 21 days
318469|NCT00287222|Drug|Erlotinib|150 mg orally every day
318470|NCT00287235|Device|MARS|
318471|NCT00287235|Drug|Standard Medical Therapy|
318472|NCT00287248|Drug|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of [123I]IMPY, followed by SPECT imaging
318473|NCT00000437|Drug|nicotine replacement patch|
318474|NCT00002784|Drug|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
318475|NCT00290082|Drug|Midazolam|Midazolam 1 mL / 10 Kg
318476|NCT00290108|Drug|Propofol|
318477|NCT00290121|Drug|Olanzapine|
318478|NCT00290134|Drug|Fispemifene once daily for 4 weeks|
318479|NCT00290147|Biological|D1ME (dengue-1 premembrane/envelope DNA vaccine)|
318480|NCT00290160|Behavioral|Protein supplementation|
318481|NCT00290173|Drug|efficacy of oral ritodrine in maintaining uterine quiescence|
317741|NCT00002829|Biological|Recombinant Interferon Alfa|Daily
317742|NCT00305877|Biological|cetuximab|Given IV
317743|NCT00305877|Drug|gemcitabine hydrochloride|Given IV
317744|NCT00305877|Drug|capecitabine|Given orally
317745|NCT00305877|Radiation|radiation therapy|Undergo radiation therapy
317746|NCT00305877|Biological|bevacizumab|Given IV
317747|NCT00305877|Other|laboratory biomarker analysis|Correlative studies
317748|NCT00305890|Behavioral|Lifestyle Behavioral Weight Management Program|The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
317749|NCT00305890|Behavioral|Pain-Coping Skills Training|The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
317750|NCT00305890|Other|Standard Care|Standard care will include routine medical care.
317751|NCT00305903|Drug|Rivastigmine, memantine|
317752|NCT00000452|Behavioral|Cognitive Behavior Therapy|
317753|NCT00002829|Drug|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
317754|NCT00308971|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
317755|NCT00308971|Drug|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
317756|NCT00308971|Drug|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
317757|NCT00308971|Drug|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
317758|NCT00308997|Device|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
318120|NCT00296465|Drug|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
318121|NCT00296465|Drug|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
317029|NCT00002907|Drug|bryostatin 1|
317030|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|9 micrograms/kg every 3 weeks
317031|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|12 micrograms/kg every 3 weeks
317032|NCT00327548|Behavioral|guided imagery|
317033|NCT00327561|Procedure|Intensive periodontal therapy|
317034|NCT00327561|Procedure|Community based periodontal therapy|
317035|NCT00327574|Behavioral|Home heath education +/_ GP training|
317036|NCT00327587|Drug|Valsartan + amlodipine|
317037|NCT00327587|Drug|Valsartan + HCTZ|
317394|NCT00317889|Procedure|Bone preparation technique: compaction|
317395|NCT00317889|Procedure|Bone preparation technique: broaching|
317396|NCT00317902|Drug|Epoetin alfa|
317397|NCT00317915|Drug|Irbesartan treatment|
317398|NCT00317928|Drug|Metformin|
317399|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject
317400|NCT00317941|Drug|Rebif|44ug administered with Rebiject II
317401|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject light
317402|NCT00317954|Drug|Spironolactone|
317403|NCT00002869|Drug|cytarabine|
317404|NCT00317967|Drug|Atorvastatin|80 mg pills daily
317405|NCT00317967|Drug|Placebo|80 mg pills daily
317406|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
317407|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
317408|NCT00317993|Drug|ezetimibe|
317409|NCT00317993|Drug|simvastatin|
322722|NCT00311038|Drug|ONO-1101|
322723|NCT00002839|Radiation|radiation therapy|
322724|NCT00311051|Drug|ramatroban|
322725|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
322726|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
322727|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
322728|NCT00002701|Drug|mercaptopurine|
322729|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
322730|NCT00262548|Drug|Rosuvastatin; improvement of lipid profile|
322731|NCT00262561|Drug|Aspirin|The effect of Aspirin on platelet function was assessed.
322732|NCT00262574|Drug|Nesiritide,|PCI
322733|NCT00262587|Drug|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
322734|NCT00262587|Drug|Placebo|Inhaled sugar powder in a placebo inhaler
322735|NCT00262600|Drug|warfarin|once a day
322736|NCT00262600|Drug|Dabigatran dose 1|twice daily
322737|NCT00262600|Drug|Dabigatran dose 2|twice a day
322738|NCT00262613|Drug|sodium pyruvate in 0.9% sodium chloride solution|
322739|NCT00002701|Drug|methotrexate|
322740|NCT00262626|Drug|Intraocular pressure reduction|
322741|NCT00262626|Procedure|Argon laser trabeculoplasty|
322742|NCT00262626|Procedure|Trabeculectomy|
317038|NCT00327587|Drug|Amlodipine + HCTZ|
322001|NCT00281879|Biological|filgrastim|Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.
Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.
322002|NCT00281879|Drug|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
322003|NCT00281879|Drug|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
322004|NCT00281879|Drug|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
322005|NCT00281879|Drug|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
322006|NCT00281879|Drug|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
322350|NCT00272155|Behavioral|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
322351|NCT00272168|Behavioral|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
322352|NCT00002735|Drug|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
322353|NCT00272168|Other|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
322354|NCT00272181|Drug|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
322355|NCT00272194|Device|Ambu Laryngeal Mask|
322356|NCT00272194|Device|Aintree Exchange Catheter|
322357|NCT00272194|Device|Laryngeal Mask Airway|
322358|NCT00272207|Drug|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
321633|NCT00291317|Device|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD). Children were scheduled to attend three cycling sessions per week on non-consecutive days for up to 30 minutes per session over a 9 month period. The intervention was provided at Children's Specialized Hospital in Mountainside, and families were required to provide their own transportation. During the study, the participants continued to participate in their standard, primary rehabilitation program.
321634|NCT00291330|Drug|dabigatran etexilate 150 mg|twice daily
321635|NCT00291330|Drug|warfarin (INR 2-3)|prn to maintain INR (2-3)
321636|NCT00291343|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
321637|NCT00291343|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
321638|NCT00291343|Biological|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
321639|NCT00291356|Drug|GSK189075 oral tablets|
321640|NCT00291356|Drug|GW869682 oral tablets|
321641|NCT00002791|Radiation|brachytherapy|
321642|NCT00291369|Drug|Interleukin-2|
321643|NCT00291369|Drug|Interferon alfa|
321644|NCT00291369|Drug|medroxyprogesterone acetate|
321645|NCT00291382|Drug|Salmeterol/fluticasone propionate combination|
321646|NCT00291395|Drug|PGI2|
321647|NCT00291408|Procedure|Skin Prick Test|
321648|NCT00291408|Procedure|Impulse Oscillometry|
321649|NCT00291408|Procedure|Exhaled Nitric Oxide|
321650|NCT00291408|Procedure|Spirometry|
321651|NCT00291408|Procedure|Reversibility|
321652|NCT00002791|Radiation|intraoperative radiation therapy|
321653|NCT00291408|Procedure|Exhaled Breath Condensate|
321654|NCT00291408|Procedure|Sputum Induction|
321655|NCT00291447|Drug|ch806|
320906|NCT00310141|Behavioral|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
320907|NCT00310141|Other|Counseling intervention|In-person counseling (5 sessions)
320908|NCT00310141|Drug|Nicotine patch|6-week supply of the nicotine patch
320909|NCT00310154|Drug|docetaxel|
320910|NCT00310154|Drug|gefitinib|
320911|NCT00310154|Other|laboratory biomarker analysis|
320912|NCT00310154|Radiation|radiation therapy|
320913|NCT00310167|Radiation|radiation therapy|
320914|NCT00310180|Drug|Anastrozole|Given PO
320915|NCT00002837|Drug|Doxorubicin Hydrochloride|
320916|NCT00310180|Drug|Exemestane|Given PO
320917|NCT00310180|Other|Laboratory Biomarker Analysis|Correlative studies
320918|NCT00310180|Drug|Letrozole|Given PO
320919|NCT00310180|Other|Quality-of-Life Assessment|Ancillary studies
320920|NCT00310180|Radiation|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
321279|NCT00301327|Drug|Summers 5% L.A.|
321280|NCT00301340|Drug|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
321281|NCT00301353|Drug|Isoflavones-enriched foods|
321282|NCT00301366|Drug|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
321283|NCT00301379|Other|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
321284|NCT00301392|Other|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
321285|NCT00301392|Drug|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
320522|NCT00268203|Biological|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
320523|NCT00268216|Drug|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
320524|NCT00268229|Drug|cytarabine|300 mg/m2/day
320525|NCT00268229|Drug|daunorubicin hydrochloride|45 mg/m2/day
320526|NCT00268229|Drug|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
320527|NCT00002716|Drug|fluorouracil|
320528|NCT00268242|Drug|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
320529|NCT00268242|Drug|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
320530|NCT00268255|Drug|gefitinib|
320531|NCT00268255|Procedure|adjuvant therapy|
320532|NCT00268255|Procedure|enzyme inhibitor therapy|
320533|NCT00268255|Procedure|neoadjuvant therapy|
320534|NCT00268255|Procedure|protein tyrosine kinase inhibitor therapy|
320535|NCT00268255|Procedure|radiation therapy|
320536|NCT00268255|Procedure|radiosensitization|
320537|NCT00268281|Device|Left Ventricular Capture Management Software|
320538|NCT00002716|Drug|leucovorin calcium|
320539|NCT00268294|Device|Cardiac Resynchronization Therapy|
320540|NCT00268307|Drug|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
320541|NCT00268320|Device|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
320542|NCT00268333|Drug|fluorouracil|
319798|NCT00284011|Dietary Supplement|SAMe|800 mg dose daily for 4 weeks.
319799|NCT00284011|Other|Placebo|2 placebo pills daily for 4 weeks.
319800|NCT00284024|Drug|domperidone|
319801|NCT00284037|Device|continuous positive airway pressure therapy|
319802|NCT00284050|Drug|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
319803|NCT00002773|Biological|recombinant interferon alfa|
319804|NCT00284050|Drug|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
319805|NCT00284050|Drug|Sham injection|Non-treatment control for sham intravitreal injection.
319806|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
319807|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
319808|NCT00284063|Procedure|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
319809|NCT00284076|Drug|L-arginine|
320184|NCT00277771|Behavioral|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
320185|NCT00277784|Procedure|Ultrasound examination|one ultrasound examination
320186|NCT00277797|Device|Biowave Targeted Non-Invasive Electronic Pain Control Device|This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms ("Feed Signals") between two electrodes.
320187|NCT00277797|Device|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
320188|NCT00277810|Drug|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extesnion to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
320189|NCT00002756|Drug|methotrexate|
320190|NCT00277823|Drug|DVS-SR 50 mg|
320191|NCT00277823|Drug|DVS-SR 100 mg|
311976|NCT00354172|Radiation|Total body irradiation (TBI)|TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days
-16 to -13).
311977|NCT00354185|Drug|tanespimycin|Given IV
311978|NCT00003031|Drug|amphotericin B deoxycholate|
311979|NCT00354185|Drug|belinostat|Given IV
311980|NCT00356915|Drug|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
311981|NCT00003045|Procedure|hyperthermia treatment|
311982|NCT00356915|Drug|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
311983|NCT00356928|Biological|donor lymphocytes|
311984|NCT00356928|Biological|therapeutic allogeneic lymphocytes|
311985|NCT00356928|Drug|cyclophosphamide|
311986|NCT00356941|Drug|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
311987|NCT00356941|Drug|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
311988|NCT00356941|Procedure|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
311989|NCT00356954|Drug|N-acetylcystein|
311990|NCT00356954|Drug|ascorbic acid|
311991|NCT00356967|Drug|dianicline|
311992|NCT00003045|Radiation|radiation therapy|
311993|NCT00356980|Biological|colloidal gold-bound tumor necrosis factor|
311994|NCT00356980|Other|pharmacological study|
312362|NCT00347815|Drug|Buprenorphine|
312363|NCT00347828|Drug|Moxifloxacin ophthalmic solution 0.5%|
312364|NCT00347828|Drug|Gatifloxacin ophthalmic solution 0.3%|
312365|NCT00347841|Drug|Bimatoprost 0.03%, Latanoprost|
311280|NCT00002870|Drug|fluorouracil|
311281|NCT00318422|Drug|rosiglitazone|
311282|NCT00318422|Drug|glimepiride|
311283|NCT00318435|Device|Stent or stent-graft deployment|
311284|NCT00318448|Drug|Zolpidem (SL800750)|
311285|NCT00321828|Biological|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
311286|NCT00321828|Drug|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
311631|NCT00362947|Drug|LMWH parnaparin subcutaneously|
311632|NCT00362960|Drug|Olmesartan medoxomil|
311633|NCT00003078|Radiation|radiation therapy|
311634|NCT00362960|Drug|Losartan|
311635|NCT00260559|Procedure|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
311636|NCT00260572|Behavioral|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
311637|NCT00260572|Behavioral|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
311638|NCT00002697|Radiation|radiation therapy|
311639|NCT00260572|Behavioral|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
311640|NCT00260572|Behavioral|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
311641|NCT00260585|Procedure|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
311642|NCT00260585|Procedure|Blood specimen for non-DNA and DNA parts|Blood specimen is collected intraoperatively.
311643|NCT00260585|Procedure|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
311644|NCT00260585|Procedure|Biopsies from routine clinical surveillance endoscopies|Tissue from the biopsies is collected intraoperatively.
316532|NCT00321022|Behavioral|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
316872|NCT00362219|Drug|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
316873|NCT00365352|Drug|XP13512 600MG|XP13512 600MG ONCE DAILY
316874|NCT00365352|Drug|XP13512 1200MG|XP13512 1200MG ONCE DAILY
316875|NCT00365352|Drug|PLACEBO|PLACEBO ONCE DAILY
316876|NCT00365365|Drug|Doxorubicin and cyclophosphamide (AC) + bevacizumab|For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
doxorubicin 60 mg/m^2 IV push or infusion followed by cyclophosphamide 600 mg/m^2 IV push or infusion
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
316877|NCT00365365|Drug|Docetaxel (T) + bevacizumab|For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
docetaxel 100 mg/m^2 IV
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Note: The starting dose of docetaxel was reduced to 75 mg/m^2 if toxicity occurred that met the criteria for doxorubicin dose reduction
316878|NCT00003086|Drug|cyclophosphamide|
316879|NCT00365365|Drug|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
doxorubicin 50 mg/m^2 IV push or infusion followed by cyclophosphamide 500 mg/m^2 IV push or infusion followed by docetaxel 75 mg/m^2
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
316880|NCT00365365|Drug|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
docetaxel in 75 mg/m^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by
trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
316881|NCT00365365|Drug|Bevacizumab and trastuzumab maintenance therapy|bevacizumab 15 mg/kg was infused IV followed by
trastuzumab 6 mg/kg IV
Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
316882|NCT00365365|Drug|Bevacizumab maintenance therapy|- bevacizumab 15 mg/kg was infused IV
Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
316883|NCT00365378|Biological|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
316884|NCT00365378|Biological|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
316885|NCT00365391|Biological|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
316886|NCT00365391|Drug|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
316887|NCT00365404|Behavioral|Diet and exercise promotion|
315773|NCT00336674|Other|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
315774|NCT00336700|Drug|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
315775|NCT00336700|Drug|Erlotinib|150 mg/d Daily, oral 12 months
315776|NCT00336713|Drug|Saredutant (SR48968C)|oral administration (capsules)
315777|NCT00336713|Drug|Placebo|oral administration (capsules)
315778|NCT00336739|Drug|cinacalcet|
315779|NCT00336752|Procedure|non operative treatment|non operative treatment -casting for 6 weeks
315780|NCT00336752|Procedure|operative versus non operative treatment of ankle fractures|operative versus non operative treatment of ankle fractures
315781|NCT00336765|Drug|XL647|Tablets supplied in 50-mg strength administered orally daily
315782|NCT00336778|Drug|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
315783|NCT00002961|Drug|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
315784|NCT00336791|Drug|5-Fluorouracil|FEC Chemotherapy: 500 mg/m^2 IV on day 1 of 21 day cycle.
FAC Chemotherapy: 500 mg/m^2 IV on day 1 and day 4 of 21 day cycle.
315785|NCT00341354|Behavioral|Prolonged Mechanical Ventilation|
316161|NCT00327119|Drug|ABX-EGF (panitumumab)|
316162|NCT00327132|Drug|Omeprazole, Amoxicillin, Clarithromycin|
316163|NCT00327145|Drug|valsartan|
316164|NCT00327145|Drug|hydrochlorothiazide|
316165|NCT00327145|Drug|amlodipine|
316166|NCT00327158|Procedure|Transesophageal transducer|One time use of reamer during surgery
316167|NCT00002905|Drug|etoposide|
316168|NCT00327158|Procedure|echocardiography|takes photos of right atrium during the reaming processes
320337|NCT00297258|Drug|pazopanib|oral tablet
320338|NCT00297271|Other|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
320339|NCT00297284|Drug|Modafinil|
320340|NCT00297297|Other|No intervention. Applying gene profiling on needle aspirates|
320341|NCT00297310|Drug|tacrolimus|
320699|NCT00284557|Behavioral|Group-based behavioral intervention|The group-based behavioral intervention targets eating behaviors, physical activity, and "screen time", and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter.
320700|NCT00284583|Drug|Injection of Steroid into Foot|
320701|NCT00287989|Drug|carboplatin|
320702|NCT00287989|Drug|erlotinib hydrochloride|
320703|NCT00287989|Drug|paclitaxel|
320704|NCT00002785|Drug|cyclophosphamide|
320705|NCT00288002|Biological|trastuzumab|
320706|NCT00288002|Drug|capecitabine|
320707|NCT00288002|Drug|cyclophosphamide|
320708|NCT00288002|Drug|docetaxel|
320709|NCT00288002|Drug|epirubicin hydrochloride|
320710|NCT00288002|Procedure|adjuvant therapy|
320711|NCT00288002|Procedure|conventional surgery|
320712|NCT00288002|Procedure|neoadjuvant therapy|
320713|NCT00288015|Biological|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
320714|NCT00288028|Drug|bortezomib|Dose of Bortezomib* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
320715|NCT00002785|Drug|cyclosporine|
320716|NCT00288041|Drug|carboplatin|Given IV
319570|NCT00309855|Drug|Anastrazole|orally x 21 days
319571|NCT00309855|Drug|Dutasteride|orally x 21 days
319572|NCT00309868|Drug|neseritide|
319573|NCT00309881|Biological|rituximab|
319574|NCT00309881|Drug|cyclophosphamide|
319575|NCT00309881|Drug|doxorubicin hydrochloride|
319576|NCT00309881|Drug|prednisone|
319577|NCT00000135|Other|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
319578|NCT00000415|Drug|Calcium supplement|
319579|NCT00002700|Drug|dexamethasone|
319580|NCT00261105|Drug|telithromycin|
319581|NCT00261118|Drug|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
319582|NCT00261131|Drug|Botulinum Toxin A|
319583|NCT00261144|Drug|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
319972|NCT00303719|Drug|fludarabine|Fludarabine 30 mg/m^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m^2 for 5 days.
319973|NCT00303719|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if < 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) > 0.5 x 109 /L).
319974|NCT00303719|Procedure|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
319975|NCT00303719|Radiation|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
319976|NCT00303719|Drug|filgrastim|Patients with white blood cell (WBC) counts < 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) > 2500 for 2 consecutive days.
319977|NCT00303732|Drug|RAD001 (everolimus)|
319978|NCT00306826|Drug|simvastatin|
319979|NCT00306826|Drug|pioglitazone + simvastatin|
319213|NCT00002715|Drug|mechlorethamine hydrochloride|
319214|NCT00267436|Behavioral|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
319215|NCT00270621|Behavioral|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
319216|NCT00270634|Drug|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
319217|NCT00002723|Drug|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
319218|NCT00270634|Drug|tacrolimus|tacrolimus 0.05 mg/kg po BID
319219|NCT00270647|Dietary Supplement|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
319220|NCT00270647|Dietary Supplement|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
319221|NCT00270647|Dietary Supplement|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
319222|NCT00270647|Dietary Supplement|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
319223|NCT00270660|Behavioral|biopsy, audiometry, ET function test, ear swab culture, DNE|
319224|NCT00270673|Procedure|Early lactate-directed therapy|
319225|NCT00270699|Biological|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
319226|NCT00270699|Biological|Placebo|Placebo for rDEN4delta30-200,201
319227|NCT00270738|Procedure|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
319228|NCT00002723|Drug|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
319229|NCT00270738|Procedure|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
319584|NCT00261144|Biological|Biological|Collagenase injection
319585|NCT00261157|Device|InTouch Telerounding Robot|
318482|NCT00290186|Device|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
318483|NCT00290186|Device|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
318484|NCT00290199|Device|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
318485|NCT00002788|Drug|etoposide|
318486|NCT00290212|Drug|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
318487|NCT00290212|Drug|Placebo capsules|
318488|NCT00290225|Behavioral|Breath Water Sound Course and Traumatic Incident Reduction|
318489|NCT00290238|Device|Vertis Percutaneous Neuromodulation Therapy (PNT)|Ten PNT sessions in eleven weeks
On average, one PNT session per week
Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage
Forty-five minutes of electrical stimulation for each session
Electrical stimulation parameters:
Continuous 50 Hz current
Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform
Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level
318846|NCT00280618|Drug|Oxaliplatin|
318847|NCT00002764|Drug|ifosfamide|
318848|NCT00280631|Drug|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
318849|NCT00280644|Drug|Leflunomide|
318850|NCT00280657|Drug|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
318851|NCT00280657|Drug|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
318852|NCT00280657|Drug|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
318853|NCT00280670|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
318854|NCT00280683|Drug|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
318855|NCT00280683|Drug|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
318856|NCT00280696|Drug|Levetiracetam 250 mg|Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 250 mg
Route of Administration: Oral Use
318857|NCT00280696|Drug|Levetiracetam 500 mg|Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 500 mg
Route of Administration: Oral Use
318122|NCT00299585|Procedure|using "PD" VitalOs Cement with dental implants|supporting dental implants with Vitalos bone cement
318123|NCT00299598|Device|alkylated polyethylenimine nanoparticles antibacterial evaluation|
318124|NCT00299611|Drug|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
318125|NCT00299611|Drug|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
318126|NCT00299611|Drug|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
318127|NCT00299650|Drug|cisatracurium|
318128|NCT00299650|Drug|Placebo|physiological serum infusion
318129|NCT00299650|Drug|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
318130|NCT00299676|Drug|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
318131|NCT00002810|Drug|melphalan|
318132|NCT00299689|Drug|Denileukin diftitox|12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
318133|NCT00299702|Drug|Abilify|10-30 mg once daily for 104 weeks
318134|NCT00299702|Drug|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
318135|NCT00299715|Drug|Paliperidone extended-release|
318136|NCT00299728|Biological|NY-ESO-1 protein with CpG 7909 and Montanide|
318137|NCT00299741|Drug|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
318138|NCT00299754|Drug|Misoprostol|
318139|NCT00299767|Procedure|sequential cord blood transplantation|Infused on Day 0
318140|NCT00299780|Drug|Stem cell mobilization|
318141|NCT00299806|Drug|Aliskiren|
318142|NCT00002810|Procedure|bone marrow ablation with stem cell support|
318143|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
318144|NCT00299819|Biological|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
317410|NCT00321464|Drug|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
317411|NCT00321477|Drug|GW679769 oral tablets|
317412|NCT00321490|Drug|Quetiapine fumarate|
317413|NCT00002882|Biological|Recombinant Interferon Alfa (IFN-A)|IFN-A Therapy Groups:
Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks
Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5
317414|NCT00321490|Drug|Duloxetine|
317415|NCT00321516|Drug|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
317416|NCT00321529|Device|motion analysis by durometer|
317417|NCT00321542|Other|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
317418|NCT00321555|Drug|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 g/Kg will be infused in 50 ml of 0.9% NaCl and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
317419|NCT00321581|Drug|Cediranib, AZD2171, RECENTIN|
317759|NCT00308997|Device|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
317760|NCT00309023|Drug|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
317761|NCT00002835|Drug|Idarubicin|
317762|NCT00309036|Biological|Recombinant grass pollen|
317763|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
317764|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
317765|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
317766|NCT00309062|Biological|Recombinant birch pollen|
317039|NCT00327587|Drug|Valsartan + amlodipine + HCTZ|
317040|NCT00002908|Drug|bryostatin 1|
317041|NCT00327600|Drug|imexon|
317042|NCT00330746|Drug|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
317043|NCT00002925|Drug|PSC-833|
317044|NCT00330746|Drug|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
317045|NCT00330746|Drug|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
317046|NCT00330759|Biological|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
317047|NCT00330759|Drug|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
317048|NCT00330772|Drug|Aspirin|
317049|NCT00330772|Drug|Clopidogrel|
317050|NCT00330785|Drug|Amlodipine/Atorvastatin|
317051|NCT00330798|Drug|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
317052|NCT00330798|Other|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
317053|NCT00330824|Drug|antibiotic/steroid combination|1gtt, 4x/d, 15 days
317054|NCT00002925|Biological|Aldesleukin|
317055|NCT00330824|Drug|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
317056|NCT00330850|Drug|PRO-513|
317057|NCT00330863|Drug|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
317058|NCT00330863|Drug|Risperidone|Target dose is 4 mg/day.
317059|NCT00330863|Drug|Olanzapine|Target dose is 15 mg/day.
317060|NCT00330863|Drug|Quetiapine|Target dose is 600 mg/day.
317061|NCT00330863|Drug|Ziprasidone|Target dose is 120 mg/day.
317062|NCT00330863|Drug|Aripiprazole|Target dose is 20 mg/day.
322359|NCT00272220|Behavioral|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
322360|NCT00272246|Procedure|deep brain stimulation of the internal globus pallidus|
322361|NCT00272259|Procedure|Participants will interact with up to two small robots and a visual display|
322362|NCT00272272|Behavioral|Music Therapy|Listening to Music while standing
322363|NCT00002735|Drug|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
322364|NCT00272285|Drug|Ramosetron|IV, concomitant administration with dexamethasone
322365|NCT00275379|Drug|ERB-041|
322366|NCT00275392|Behavioral|Vestibular rehabilitation|vestibular adaptation and substitution exercises
322743|NCT00262639|Drug|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
322744|NCT00262639|Drug|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
322745|NCT00262652|Drug|sodium pyruvate|
322746|NCT00262665|Drug|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
322747|NCT00262665|Drug|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
322748|NCT00262678|Drug|EN3267|
322749|NCT00262704|Behavioral|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
322750|NCT00000417|Procedure|Counseling intervention|
322751|NCT00002701|Drug|mitoxantrone hydrochloride|
322752|NCT00265551|Drug|placebo|
322753|NCT00265564|Behavioral|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
321656|NCT00291447|Drug|111-Indium-ch806|
321657|NCT00291460|Device|inspiratory muscle training|
322007|NCT00281879|Drug|etoposide|Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.
Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload.
322008|NCT00002767|Biological|Detox-B adjuvant|
322009|NCT00281879|Drug|fludarabine phosphate|Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.
Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2.
322010|NCT00281879|Drug|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
322011|NCT00281879|Drug|methotrexate|Administered on days +1, +3, and +7.
322012|NCT00281879|Drug|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
322013|NCT00281879|Drug|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
322014|NCT00281879|Drug|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
322015|NCT00281879|Procedure|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
322016|NCT00281879|Procedure|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
322017|NCT00281879|Radiation|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
322018|NCT00281892|Biological|darbepoetin alfa|
322019|NCT00284999|Drug|Refresh Tears|
322020|NCT00285012|Drug|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
322021|NCT00285012|Drug|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
322022|NCT00285025|Drug|SR57667B|
322023|NCT00002778|Biological|sargramostim|
322024|NCT00285051|Drug|inhaled delta-8-THC|
321286|NCT00301405|Drug|Thalidomide|Open label drug
321287|NCT00301418|Drug|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
321288|NCT00301431|Drug|DVS-233|
321289|NCT00002813|Drug|vinorelbine tartrate|
321290|NCT00301444|Device|mirror-box treatment|
321291|NCT00301444|Behavioral|Mental visualization|
321292|NCT00301457|Drug|Anastrozole|1 mg once daily oral dose
321293|NCT00301470|Device|MR urography|undergoing both renal scintigraphy and MR within a month
321294|NCT00301483|Drug|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
321295|NCT00303992|Drug|irinotecan hydrochloride|
321296|NCT00304005|Drug|laromustine|
321297|NCT00304018|Biological|anti-thymocyte globulin|
321298|NCT00304018|Biological|sargramostim|
321299|NCT00304018|Drug|busulfan|
321658|NCT00291473|Drug|CHP-HER2, CHP-NY-ESO-1|
321659|NCT00291486|Drug|Capecitabine|Capecitabine will be administered at doses between 1000 and 1250 mg/m2/day depending on assigned dose level for 14 days per 21 day cycle. Daily doses may be rounded to the nearest 150mg.
321660|NCT00291486|Drug|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients will receive a scout dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 will comprise a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I therapy dose will be determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
321661|NCT00291499|Drug|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
321662|NCT00294736|Drug|Tarceva|Dose Escalation: 150-350+ mg/day
321663|NCT00294749|Drug|Ciprofloxacine|
320543|NCT00268333|Drug|leucovorin calcium|
320544|NCT00268333|Drug|oxaliplatin|
320921|NCT00310180|Drug|Tamoxifen Citrate|Given PO
320922|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
320923|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
320924|NCT00310219|Procedure|computed tomography|
320925|NCT00310219|Procedure|positron emission tomography|
320926|NCT00002837|Drug|Paclitaxel|
320927|NCT00310232|Drug|Epoetin Alfa|
320928|NCT00310245|Procedure|STI (structured Treatment Interruption)|
320929|NCT00310258|Behavioral|Drug use prevention intervention|
320930|NCT00310271|Biological|pPJV7630 with pPJV2012 administered by PMED|
320931|NCT00261820|Drug|tacrolimus|
320932|NCT00002700|Drug|therapeutic hydrocortisone|
320933|NCT00261820|Drug|mycophenolate mofetil|
320934|NCT00261820|Drug|methylprednisolone|
320935|NCT00261820|Drug|prednisolone|
320936|NCT00261820|Drug|sirolimus|
320937|NCT00261833|Biological|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
320938|NCT00261833|Other|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
320939|NCT00261846|Drug|Bosutinib|Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.
Part 2, 500 mg oral, continuous, daily dosing.
320940|NCT00261859|Behavioral|BNI|behavioral- brief intervention
320941|NCT00261872|Drug|Methylphenidate|
320942|NCT00261898|Procedure|Increase sleep|
320192|NCT00277823|Drug|Placebo|
320193|NCT00277836|Drug|MST-997|
320194|NCT00277862|Drug|Pegylated IFN- alpha 2b|
320195|NCT00277862|Drug|Ribavirin|
320196|NCT00277875|Drug|ALT-711 (alagebrium chloride)|
320197|NCT00277888|Procedure|Femoral route for hemodialysis|
320198|NCT00277888|Procedure|Jugular route for hemodialysis|
320199|NCT00277914|Drug|Flibanserin|flibanserin flexible dosing
320200|NCT00002756|Drug|prednisone|
320201|NCT00278018|Procedure|Immunotherapy treatment for solid tumors|
320202|NCT00281190|Procedure|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
320203|NCT00281203|Procedure|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
320204|NCT00281203|Procedure|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
320205|NCT00002766|Drug|cytarabine|
320545|NCT00268333|Procedure|neoadjuvant therapy|
320546|NCT00268346|Drug|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
320547|NCT00268359|Biological|bevacizumab|
320548|NCT00271154|Device|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
320549|NCT00271167|Drug|INO-1001|
320550|NCT00271193|Behavioral|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
320551|NCT00271206|Drug|Progesterone|compared to placebo
312366|NCT00347854|Other|Systane Free lubricant eye drops|
312367|NCT00347854|Other|Visine Tears Lubricant Eye Drops|
312368|NCT00347854|Other|Refresh Liquigel Lubricant Eye Drops|
312369|NCT00347854|Other|Refresh Plus Lubricant Eye Drops|
312370|NCT00003000|Drug|morphine sulfate|
312371|NCT00347867|Drug|Viagra administration in IUGR/PET pregnancies|
312372|NCT00347893|Procedure|Selective laser trabeculoplasty|
312373|NCT00347906|Procedure|laser treatment|
312374|NCT00347919|Drug|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
312375|NCT00347919|Drug|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
312376|NCT00347919|Drug|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
312377|NCT00347919|Drug|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
312378|NCT00347932|Drug|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
312379|NCT00347932|Drug|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
312380|NCT00347945|Procedure|Pencil Push-ups|
312381|NCT00003001|Drug|fluorouracil|
312382|NCT00347945|Procedure|Office-based Vision Therapy|
312383|NCT00347945|Procedure|Placebo Office-based Vision Therapy|
312384|NCT00347958|Biological|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
312385|NCT00347971|Drug|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
312386|NCT00347984|Other|Systane Lubricant eye drops|
312387|NCT00347997|Device|217z Laser|LASIK correction of myopia and myopic astigmatism
312747|NCT00002949|Radiation|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
311645|NCT00260598|Procedure|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
311646|NCT00260611|Drug|Oxaliplatin|
311647|NCT00260611|Drug|Taxotere|
311648|NCT00260624|Drug|Escitalopram (Lexapro)|
311649|NCT00002700|Drug|asparaginase|
311650|NCT00260637|Procedure|Acupuncture|
311651|NCT00260650|Behavioral|Heart PACT Program|patient activation intervention
311652|NCT00260663|Procedure|Group hearing aid fittings|
311653|NCT00260663|Procedure|Group hearing aid follow-up|
311654|NCT00260676|Procedure|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
311995|NCT00356993|Drug|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
311996|NCT00356993|Behavioral|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
311997|NCT00357006|Drug|Estradiol|100 mcg adjunctive transdermal estradiol
311998|NCT00357006|Drug|Estradiol|200 mcg adjunctive transdermal estradiol
311999|NCT00357006|Other|placebo|adjunctive transdermal placebo
312000|NCT00357019|Drug|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
312001|NCT00357032|Drug|belinostat|Given IV
312002|NCT00357032|Other|laboratory biomarker analysis|Correlative studies
312003|NCT00000478|Drug|isosorbide dinitrate|
312004|NCT00003046|Biological|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
312005|NCT00357045|Drug|Paroxetine|
312006|NCT00357084|Drug|methotrexate|
312007|NCT00357084|Drug|methylprednisolone|
316888|NCT00365417|Drug|Bevacizumab|15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
316889|NCT00003086|Drug|doxorubicin hydrochloride|
316890|NCT00365417|Drug|Doxorubicin|60 mg/m^2 IV every 21 days x 4 cycles
311287|NCT00321828|Drug|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
311288|NCT00321828|Drug|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
311289|NCT00321854|Drug|pramipexole|
311290|NCT00321867|Procedure|Graft augmented posterior repair|Posterior repair with graft
311291|NCT00002883|Drug|cisplatin|
311292|NCT00321867|Procedure|Control|Native tissue repair
311293|NCT00321880|Procedure|therapeutic touch|administration of healing touch in 30 minute sessions
311294|NCT00321893|Drug|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
311295|NCT00321893|Other|Placebo|Inhaled placebo twice daily for one year.
311296|NCT00321906|Drug|azathioprine|azathioprine 2mg/kg
311297|NCT00321906|Drug|sirolimus|sirolimus 2-4mg daily
311298|NCT00321919|Drug|epoetin beta [NeoRecormon]|Patients in the early treatment group immediately started epoetin\nbeta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
311299|NCT00321919|Drug|epoetin beta [NeoRecormon]|Patients in the late treatment Group started epoetin beta treatment once a decline in Hb level to <10.5 g/dL had occurred.
311300|NCT00321932|Dietary Supplement|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
311301|NCT00321932|Dietary Supplement|cholecalciferol|Given orally
311302|NCT00002883|Drug|fluorouracil|
316169|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.
Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
316170|NCT00330304|Other|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
316171|NCT00330317|Drug|letrozole|2.5mg letrozole once-daily
316172|NCT00330330|Drug|ISIS 113715|
316173|NCT00002923|Drug|KRN5500|
316174|NCT00330343|Drug|naloxone|
316175|NCT00330356|Behavioral|Low Salt Diet versus High salt diet|
316176|NCT00330369|Drug|Darusentan|Darusentan administered orally once daily
316177|NCT00330369|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
316178|NCT00330382|Drug|Bowman-Birk inhibitor concentrate|Given orally
316179|NCT00330382|Other|placebo|Given orally
316180|NCT00330382|Other|laboratory biomarker analysis|Correlative studies
316181|NCT00330395|Drug|caspofungin acetate|Duration of Treatment 28 Days
316182|NCT00330408|Behavioral|GP training|
316183|NCT00330421|Drug|sorafenib tosylate|Given PO
316184|NCT00002924|Other|mutation analysis|
316185|NCT00330421|Procedure|therapeutic conventional surgery|Undergo surgery
316186|NCT00330421|Other|laboratory biomarker analysis|Correlative studies
316533|NCT00321035|Device|OculusGen Biodegradable Collagen Matrix Implant|
316534|NCT00321048|Device|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
316535|NCT00321061|Drug|VRC-HIVDNA016-00, VRC-HIVADV014-00|
316536|NCT00321074|Drug|TACROLIMUS|Immunosuppression
316537|NCT00321087|Drug|T2000|Dose escalation from 600 to 1000 mg
320717|NCT00288041|Drug|paclitaxel|Given IV
320718|NCT00288041|Drug|bortezomib|Given IV
320719|NCT00288054|Biological|cetuximab|Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.
250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles.
320720|NCT00288054|Drug|docetaxel|Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.
20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2.
320721|NCT00288054|Radiation|radiation therapy|Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.
RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications.
321099|NCT00278278|Drug|cisplatin|Given IV
321100|NCT00278278|Drug|etoposide|Given IV
321101|NCT00278278|Drug|ifosfamide|Given IV
321102|NCT00002757|Drug|cytarabine|
321103|NCT00278278|Drug|lomustine|Given IV
321104|NCT00278278|Drug|methotrexate|Given IV
321105|NCT00278278|Drug|prednisone|Given IV
321106|NCT00278278|Drug|vincristine sulfate|Given IV
321107|NCT00278304|Radiation|brachytherapy|
321108|NCT00278304|Radiation|radiation therapy|
321109|NCT00278330|Drug|alvocidib|Given by infusion
321110|NCT00278330|Drug|vorinostat|Given orally
321111|NCT00278343|Drug|cediranib maleate|Given PO
321112|NCT00278343|Other|laboratory biomarker analysis|Correlative studies
321113|NCT00002757|Drug|doxorubicin hydrochloride|
321114|NCT00278369|Biological|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
319980|NCT00306839|Procedure|standardized Lichtenstein technique|
319981|NCT00306852|Procedure|Baerveldt implant|Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
319982|NCT00306852|Procedure|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant
319983|NCT00000454|Drug|nicotine replacement patch|
319984|NCT00002831|Drug|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
319985|NCT00306878|Drug|Abatacept|
319986|NCT00306891|Drug|Cediranib|45 mg oral dose
319987|NCT00306891|Drug|Cediranib 30 - 90 mg|oral tablet dose escalation
319988|NCT00306904|Drug|bevasiranib|
319989|NCT00306917|Device|non-coated femoral hip stem|total hip replacement
319990|NCT00306917|Device|coated femoral hip stem|total hip replacement
319991|NCT00306930|Device|Acetabular cup|Acetabular cup replacement
319992|NCT00306943|Biological|Influsplit SSW®|
319993|NCT00306956|Behavioral|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
319994|NCT00306969|Drug|bexarotene|
320342|NCT00000447|Drug|nicotine replacement patch|
320343|NCT00002805|Drug|cladribine|
320344|NCT00297323|Drug|Topiramate|75 patients over the age of 2 years old with epilepsy.
320345|NCT00297336|Drug|Topiramate|80 patients with diagnosed with migraine
320346|NCT00297349|Drug|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
320347|NCT00297362|Drug|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
320348|NCT00297375|Drug|tramadol HCl/acetaminophen|
320349|NCT00297388|Drug|Risperidone, long-acting injectable|
319586|NCT00261170|Drug|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
319587|NCT00261170|Other|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
319588|NCT00261183|Drug|Melatonin|
319589|NCT00261196|Drug|Collagenase|
319590|NCT00002700|Drug|doxorubicin hydrochloride|
319591|NCT00261209|Drug|Collagenase|Collagenase injection into adhesion restricting tendon gliding
319592|NCT00261209|Drug|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
319593|NCT00261222|Drug|Amodiaquine|
319594|NCT00261235|Behavioral|Supported Employment|
319595|NCT00261235|Behavioral|Using Strengths in Employment System (USES)|
319596|NCT00261248|Biological|Immunization with inactivated bacteria|
319597|NCT00261261|Behavioral|ADVANCE|
319598|NCT00261261|Drug|Midazolam|
319599|NCT00261261|Procedure|Parental presence|
319600|NCT00261274|Procedure|Enzyme converted ECO red blood cells|
319601|NCT00002700|Drug|leucovorin calcium|
319602|NCT00261287|Drug|Ciclesonide|
319603|NCT00261300|Drug|Pantoprazole|Long term Pantoprozole trial
319604|NCT00261313|Drug|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
319605|NCT00261313|Drug|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
319606|NCT00261326|Drug|simvastatin|80 mg once daily
319607|NCT00261326|Drug|placebo|calcium tablets once daily
319608|NCT00261339|Drug|Pantoprazole|
319609|NCT00261352|Drug|Tesaglitazar|
318858|NCT00000432|Behavioral|Education about disease prevention|
318859|NCT00002764|Procedure|conventional surgery|
318860|NCT00280696|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Film-coated tablet
Concentration: 250 mg and 500 mg
Route of Administration: Oral Use
318861|NCT00280709|Device|"Nitinella" ; SX-ELLA Stent Biliary (biliary metal stent)|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
318862|NCT00280722|Behavioral|patient information leaflet|
318863|NCT00280735|Drug|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin AUC dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
318864|NCT00280735|Drug|docetaxel|75 mg/m² intravenously, once, every 3 weeks
318865|NCT00280735|Procedure|adjuvant therapy|Adjuvant therapy with carboplatin and docetaxel will begin within 8 weeks of surgical resection
318866|NCT00283608|Other|high performance liquid chromatography|analysis of plasma concentrations of drugs
318867|NCT00283608|Other|measurements by DXA|determine bone mineral density (BMD)
319230|NCT00270738|Procedure|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
319231|NCT00270751|Procedure|1 apical pleurectomy|
319232|NCT00270751|Procedure|2 pleural abrasion + minocycline pleurodesis|
319233|NCT00270777|Drug|adrenaline, promethazine, hydrocortisone|
319234|NCT00270790|Drug|Amifostine|
319235|NCT00270790|Drug|Carboplatin|
319236|NCT00270790|Drug|Taxol|
319237|NCT00270790|Device|Radiotherapy|
319238|NCT00270803|Drug|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
319239|NCT00002725|Drug|bryostatin 1|
319240|NCT00270816|Drug|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
319241|NCT00270816|Drug|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
318490|NCT00290238|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Ten TENS sessions in eleven weeks
On average, one TENS session per week
Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage
Forty-five minutes of electrical stimulation for each session
Electrical stimulation parameters:
Current at 2 Hz—low frequency
Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec
Intensity titrated according to subject's sensory threshold
To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device.
318491|NCT00290251|Drug|ulipristal acetate|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
318492|NCT00290251|Drug|ulipristal acetate|10 mg given daily for three menstrual cycles or 90 - 102 days
318493|NCT00290251|Drug|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
318494|NCT00290264|Drug|Budesonide/formoterol|
318495|NCT00290277|Biological|HPV-16/18 L1/AS04|
318496|NCT00002788|Procedure|peripheral blood stem cell transplantation|
318497|NCT00290290|Drug|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
318498|NCT00290290|Drug|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
318499|NCT00290303|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
318500|NCT00290316|Procedure|Endoscopy ultrasound|
318501|NCT00293345|Drug|triapine|
318502|NCT00293358|Drug|carboplatin|
318503|NCT00293358|Drug|cisplatin|
318504|NCT00293358|Drug|etoposide phosphate|
318505|NCT00293358|Drug|ifosfamide|
318506|NCT00002798|Procedure|allogeneic bone marrow transplantation|
318507|NCT00293358|Procedure|adjuvant therapy|
318508|NCT00293358|Procedure|conventional surgery|
318509|NCT00293358|Procedure|neoadjuvant therapy|
318510|NCT00293358|Radiation|radiation therapy|
318511|NCT00293371|Drug|docetaxel|
317767|NCT00309075|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
317768|NCT00309088|Drug|tacrolimus|oral
317769|NCT00309088|Drug|placebo|oral
317770|NCT00309101|Drug|tacrolimus|Oral
317771|NCT00309114|Procedure|bacterial interference|
317772|NCT00002835|Drug|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
317773|NCT00309127|Behavioral|Multidisciplinary team care|
317774|NCT00309140|Drug|enzastaurin|500 mg, oral, daily, six 42 day cycles
317775|NCT00309166|Biological|HPV vaccine|
317776|NCT00309179|Drug|E7820 plus cetuximab|Escalating doses from 40 mg/m^2 irinotecan plus E7820 in combination with cetuximab.
317777|NCT00309192|Drug|Triamcinolone Acetonide 4 mg intravitreal injection|
317778|NCT00309192|Procedure|ETDRS grid laser technique|
317779|NCT00311675|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
318145|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
318146|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
318147|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
318148|NCT00299832|Drug|Aliskiren|
318149|NCT00299845|Drug|Lansoprazole|
318150|NCT00299858|Drug|Theophylline|Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.
Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time.
318151|NCT00299871|Drug|LIXISENATIDE (AVE0010)|
318152|NCT00302783|Behavioral|Multi-Source Feedback: including self-assessment & coaching|
318153|NCT00302796|Drug|Bioclavid|500 + 125 mg times 3 or 6
317063|NCT00330863|Drug|Paliperidone|Target dose is 6 mg/day.
317064|NCT00330876|Drug|Pitavastatin|
317420|NCT00321594|Drug|belinostat|Given IV
317421|NCT00321620|Drug|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
317422|NCT00321620|Biological|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
317423|NCT00321633|Drug|carboplatin|
317424|NCT00002882|Drug|Cisplatin|IV Days 1-4
317425|NCT00321633|Drug|docetaxel|
317426|NCT00321646|Drug|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
317427|NCT00321646|Drug|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
317428|NCT00321659|Behavioral|exercise and behavior change education|
317429|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
317430|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
317431|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
317432|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
317433|NCT00321685|Biological|Bevacizumab|Given IV
317434|NCT00321685|Drug|Capecitabine|Given PO
317435|NCT00002882|Drug|Dacarbazine|IVPB on day 1
317436|NCT00321685|Drug|Fluorouracil|Given IV
317437|NCT00324415|Biological|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
317438|NCT00002894|Drug|paclitaxel|
322754|NCT00265564|Behavioral|Standard outpatient SUD care|Patients assigned to standard care meet twice weekly in "Recovery 1" groups, which focuses on building abstinence.
322755|NCT00265603|Procedure|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
322756|NCT00265616|Drug|propofol|liquid, mg/kg.h, titrated after EEG
322757|NCT00265616|Drug|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
322758|NCT00002708|Procedure|surgical procedure|
322759|NCT00265629|Device|RF catheter ablation|RF ablation using mesh device
322760|NCT00265642|Drug|Irbesartan|one tablet of 150 mg/d during 2 years
322761|NCT00265642|Drug|placebo|one tablet per day during 2 years
322762|NCT00265655|Drug|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
317065|NCT00002926|Drug|cytarabine|
317066|NCT00330902|Drug|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
317067|NCT00330902|Drug|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
317068|NCT00330915|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
317069|NCT00330928|Device|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
317070|NCT00330928|Device|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
317071|NCT00330941|Drug|lidocaine|
317072|NCT00334165|Procedure|Auricular acupuncture (procedure)|
317073|NCT00334178|Drug|Laxymig ER (drug)|
317074|NCT00334191|Drug|Sodium Bicarbonate|
322025|NCT00285064|Procedure|CT|
322026|NCT00285077|Drug|SR57667B|
322027|NCT00285090|Dietary Supplement|Calcium, Vitamin D|
322028|NCT00285090|Dietary Supplement|Calcium,Vitamin D|
322367|NCT00002748|Biological|gene-modified tumor cell vaccine therapy|
322368|NCT00275392|Behavioral|Placebo|placebo vestibular exercises
322369|NCT00275405|Drug|Garlic Oil Macerate|
322370|NCT00275418|Drug|beta carotene from Dunaliella algae|
322371|NCT00275431|Drug|AT-101|Oral
322372|NCT00275444|Drug|Tipranavir|
322373|NCT00275457|Drug|pramipexole|
322374|NCT00275483|Device|Vital-band (R)|
322375|NCT00275496|Procedure|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
322376|NCT00275496|Procedure|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
322377|NCT00275496|Procedure|Wide Excision|Subject has wide excision only for primary melanoma.
322378|NCT00002748|Biological|interleukin-2 gene|
322379|NCT00275509|Drug|Thymoglobulin|
322380|NCT00275522|Drug|Sirolimus|
322381|NCT00275535|Drug|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
322382|NCT00275535|Drug|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
322383|NCT00275535|Drug|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
322384|NCT00275535|Drug|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
322385|NCT00275535|Drug|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
321664|NCT00294762|Drug|Tarceva|oral tablet
321665|NCT00294762|Drug|carboplatin|IV
321666|NCT00294762|Drug|paclitaxel|IV
321667|NCT00294775|Drug|Candesartan|
321668|NCT00294788|Biological|Fluvax|
321669|NCT00294788|Drug|PCC® (Lactobacillus fermentum VRI 003)|
321670|NCT00294801|Drug|flex-a-new (food supplement)|
321671|NCT00294814|Device|Proximal anastomosis using Heartstring anastomotic device|
321672|NCT00002801|Drug|tegafur-uracil|
321673|NCT00294827|Procedure|Liver transplantation and colo-rectal cancer|Liver transplantation
321674|NCT00294840|Device|PET-CT|
321675|NCT00294853|Procedure|MDCT calcium score|
321676|NCT00294866|Drug|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
321677|NCT00294879|Procedure|pressure support ventilation at 0, 5, and 10% IRT|
321678|NCT00294892|Drug|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
321679|NCT00294892|Drug|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
321680|NCT00294905|Behavioral|Implementation of a combined smoking cessation strategy|
322029|NCT00285090|Dietary Supplement|Calcium, VitaminD|
322030|NCT00285090|Other|Sugar Pill|
322031|NCT00285103|Drug|SPC2996|
322032|NCT00285116|Procedure|Clinical examination and radiological evaluation|
322033|NCT00285129|Device|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
322034|NCT00002778|Biological|therapeutic allogeneic lymphocytes|
322035|NCT00285142|Drug|rosiglitazone|
320943|NCT00002700|Drug|vincristine sulfate|
320944|NCT00261911|Drug|sibutramine|
320945|NCT00261924|Device|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
320946|NCT00261937|Drug|Inhaled Furosemide vs Placebo (Normal Saline)|
321300|NCT00304018|Drug|etoposide|
321301|NCT00304018|Drug|fludarabine phosphate|
321302|NCT00304018|Drug|prednisone|
321303|NCT00304018|Drug|tacrolimus|
321304|NCT00002823|Drug|vindesine|
321305|NCT00304018|Procedure|allogeneic hematopoietic stem cell transplantation|
321306|NCT00304018|Procedure|umbilical cord blood transplantation|
321307|NCT00304031|Drug|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
321308|NCT00304031|Radiation|Concurrent radiation therapy|60 Gy in 2 Gy fractions
321309|NCT00304031|Drug|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
321310|NCT00304031|Drug|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
321311|NCT00304070|Drug|doxorubicin hydrochloride|Given IV
321312|NCT00304070|Procedure|conventional surgery|Patients undergo surgery
321313|NCT00304070|Drug|cisplatin|Given IV
321314|NCT00304070|Drug|mitotane|Given orally
321315|NCT00002823|Drug|vinorelbine tartrate|
321316|NCT00304070|Drug|etoposide|Given IV
321317|NCT00304070|Biological|filgrastim|Given subcutaneously
313112|NCT00329030|Drug|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); VP-16 100 mg/m2 BID (Days -5 to -2); Cytarabine 100 mg/m2 BID (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
313113|NCT00329043|Drug|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
313114|NCT00002916|Biological|synthetic human papillomavirus 16 E6 peptide|
313115|NCT00329043|Drug|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
313116|NCT00329043|Procedure|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
313117|NCT00329056|Drug|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
313118|NCT00329069|Drug|atorvastatin (drug)|
313119|NCT00329082|Drug|LY2062430|100mg QW IV for 12 weeks
100mg Q4W IV for 12 weeks
400mg QW IV for 12 weeks
400mg Q4W IV for 12 weeks
313120|NCT00329082|Drug|Placebo|5: Placebo QW IV for 12 weeks
313121|NCT00329095|Drug|travoprost, latanoprost, or bimatoprost|
313122|NCT00329095|Drug|Additional ocular hypotensive medication|
313458|NCT00319436|Behavioral|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
313459|NCT00319449|Drug|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
313460|NCT00319449|Drug|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
313461|NCT00319449|Drug|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
313462|NCT00319462|Device|hemoclip|
313463|NCT00319475|Procedure|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
313464|NCT00319488|Drug|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
312748|NCT00335543|Procedure|conventional surgery|
312749|NCT00335543|Procedure|neoadjuvant therapy|
312750|NCT00335543|Radiation|radiation therapy|
312751|NCT00335556|Drug|Doxorubicin Hydrochloride|Given IV
312752|NCT00335556|Drug|Irinotecan Hydrochloride|Given IV
312753|NCT00338338|Drug|Lacidipine 4 or 6 mg (oral)|
312754|NCT00338338|Drug|Amlodipine 5 or 10 mg(oral)|
312755|NCT00338351|Biological|Pneumococcal (vaccine)|
312756|NCT00338364|Behavioral|PAT|Coping and Distraction Intervention
312757|NCT00338377|Biological|Dendritic Cell Immunization|1x10^7 to 2.5x10^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
312758|NCT00338377|Drug|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
312759|NCT00338377|Drug|Fludarabine|25 mg/m^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
312760|NCT00338377|Biological|T-Cells|On Days 0, up to 1.5 x 10^11 T-cells by vein infusion over 30-60 minutes.
312761|NCT00338377|Biological|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
312762|NCT00338377|Drug|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
312763|NCT00002969|Drug|paclitaxel|
312764|NCT00338377|Biological|Intrathecal T-Cells|5.0x109 T-cells administered on Day 1, and 10x109 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
312765|NCT00338377|Biological|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
312766|NCT00338390|Drug|Abacavir|Change tenofovir to abacavir
312767|NCT00338390|Drug|Didanosine|Increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
312768|NCT00338390|Drug|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
312008|NCT00357084|Drug|prednisone|
312009|NCT00357097|Drug|Ropinirole|
312010|NCT00357110|Drug|Fulvestrant|intramuscular injection
312011|NCT00359970|Drug|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
312012|NCT00359970|Drug|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
312013|NCT00359970|Drug|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
312014|NCT00359970|Other|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
312015|NCT00359983|Biological|MenHibrix (Hib-MenCY-TT)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
312016|NCT00359983|Biological|Hib conjugate vaccine (ActHIB)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
312017|NCT00003061|Radiation|radiation therapy|
312018|NCT00359996|Procedure|health disparities collaborative|
312019|NCT00360009|Procedure|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
312388|NCT00003013|Drug|doxorubicin hydrochloride|
312389|NCT00350935|Procedure|fMRI|One 30 minute session
312390|NCT00350948|Drug|Telcyta|Day 1 of 28 day Cycle.
312391|NCT00350948|Drug|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
312392|NCT00350961|Drug|Gemcitabine|
312393|NCT00350961|Drug|Oxaliplatin|
312394|NCT00350961|Drug|Capecitabine|
312395|NCT00350987|Behavioral|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
312396|NCT00351000|Drug|Ziprasidone|
312397|NCT00351013|Other|Malaria Tropica Nosode D200|5 pellets every four months
312398|NCT00351026|Drug|Methadone|short-term methadone maintenance
311303|NCT00321932|Drug|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
311304|NCT00321945|Procedure|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
311305|NCT00321958|Device|CSA System (CryoSpray AblationTM System)|10 second spray times
311306|NCT00321958|Device|CryoSpray Ablation|10 second spray times
311307|NCT00321971|Behavioral|Problem-solving therapy|The self-management intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. All participants attend weekly individual training sessions, either in their home, another convenient location, or by telephone for a total of 9 weeks.
311655|NCT00260689|Biological|Anti-thymocyte globulin (rabbit)|
311656|NCT00260689|Biological|Anti-thymocyte globulin (horse)|
311657|NCT00260689|Drug|Cyclosporine|
311658|NCT00260702|Drug|Omalizumab (Xolair)|
311659|NCT00260715|Behavioral|Community-Popular Opinion Leader Model|
311660|NCT00002700|Drug|cyclophosphamide|
311661|NCT00260715|Behavioral|Diffusion of Innovations|
311662|NCT00260728|Device|vascular access graft implantation|vascular access graft implantation
311663|NCT00260741|Drug|Smoked Cannabis|
311664|NCT00315341|Drug|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
311665|NCT00315341|Drug|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
311666|NCT00315354|Other|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
311667|NCT00315354|Other|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
316538|NCT00321087|Drug|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
316539|NCT00321087|Drug|T2000|Placebo followed by dose escalation from 600 to 1000
316540|NCT00321100|Drug|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
316541|NCT00002881|Drug|suramin|
316542|NCT00321100|Drug|Cetuximab|Cetuximab 250mg/m2 IV weekly each 21 day cycle
316543|NCT00321100|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
316544|NCT00321100|Drug|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
316545|NCT00321113|Drug|tacrolimus|immunosuppression
316546|NCT00321113|Drug|mycophenolate mofetil|oral
316547|NCT00321113|Drug|steroids|oral
316548|NCT00321126|Drug|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
316549|NCT00321152|Other|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
316550|NCT00321165|Drug|taurolidine|
316551|NCT00321178|Drug|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
316552|NCT00000462|Procedure|coronary artery bypass|
316553|NCT00323934|Drug|MGCD0103|Oral dosage 2 times weekly.
316554|NCT00323947|Drug|Extended Release Methylphenidate (OROS-Methylphenidate)|Participants will first take either immediate release MPH or placebo "A" for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo "B." This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH.
316891|NCT00365417|Drug|Cyclophosphamide|600 mg/m^2 IV every 21 days x 4 cycles
316892|NCT00365417|Drug|Capecitabine|Following clinical response assessment, 650 mg/m^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
321115|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
321116|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
321117|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
321118|NCT00002766|Drug|methotrexate|
321119|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
321120|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
321121|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
321122|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
321123|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
321124|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
321465|NCT00271713|Drug|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
321466|NCT00002734|Drug|paclitaxel|
321467|NCT00271713|Drug|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
321468|NCT00271726|Procedure|Osteosynthesis with palmar locking plate|
321469|NCT00271726|Procedure|Osteosynthesis with external fixator|
321470|NCT00271726|Procedure|Osteosynthesis with Kirschner wires|
321471|NCT00271739|Device|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
321472|NCT00271739|Other|usual care|usual diabetes care, as provided by primary care providers
321473|NCT00271752|Procedure|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
321474|NCT00271765|Drug|INO-1001|
321475|NCT00271778|Procedure|mastoidotympanoplasty and tympanoplasty|
320350|NCT00297401|Drug|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
320351|NCT00297401|Drug|placebo|QD, PO, up to 8 weeks
320352|NCT00297414|Other|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
320353|NCT00297427|Procedure|Acupuncture|Acupuncture twice weekly for 6 weeks.
320354|NCT00002805|Drug|cytarabine|
320355|NCT00297427|Other|Sham acupuncture|Twice a week for 6 weeks
320356|NCT00297440|Behavioral|Cognitive-behavioral treatment|
320357|NCT00297440|Behavioral|Exercise|
320358|NCT00297453|Behavioral|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
320359|NCT00297453|Behavioral|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
320360|NCT00297453|Behavioral|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
320361|NCT00297466|Drug|transdermal nicotine patches|
320362|NCT00297466|Behavioral|Motivational interview|
320363|NCT00297479|Behavioral|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
320364|NCT00297479|Drug|Nicotine|6 weeks of nicotine patch therapy
320365|NCT00300859|Behavioral|brief motivational intervention|
320722|NCT00288067|Drug|fenretinide|Given PO
320723|NCT00288067|Drug|rituximab|Given IV
320724|NCT00288080|Drug|bicalutamide|Given orally
320725|NCT00288080|Drug|buserelin|Patients receive luteinizing hormone-releasing hormone as a component of androgen suppression therapy
320726|NCT00002785|Drug|cytarabine|
320727|NCT00288080|Drug|docetaxel|Given IV
319610|NCT00264251|Drug|Rosiglitazone insulin sensitizing agent|
319995|NCT00002831|Drug|Methylprednisolone|Given according to clinical grade of GVHD procedures.
319996|NCT00306969|Device|photopheresis|
319997|NCT00306982|Biological|Fluarix|
319998|NCT00306995|Biological|3 adjuvanted pandemic influenza candidate vaccines + 4 non-adjuvanted pandemic influenza candidate vaccines|
319999|NCT00307008|Biological|Pneumovax 23™|Single dose intramuscular injection
320000|NCT00307021|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
320001|NCT00307034|Biological|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
320002|NCT00307034|Biological|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
320003|NCT00307034|Biological|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
320004|NCT00307047|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
320005|NCT00307047|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
320006|NCT00002831|Drug|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
320007|NCT00309881|Drug|vincristine sulfate|
320008|NCT00309894|Biological|sargramostim|
320009|NCT00002836|Drug|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
320010|NCT00309894|Drug|ketoconazole|
320011|NCT00309894|Drug|therapeutic hydrocortisone|
320012|NCT00309907|Biological|etanercept|Given IV and subcutaneously
320013|NCT00309907|Drug|methylprednisolone|Given IV and orally
320014|NCT00309920|Biological|darbepoetin alfa|
320015|NCT00309920|Drug|cyclophosphamide|
319242|NCT00274261|Drug|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
319243|NCT00274261|Drug|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
319244|NCT00274274|Drug|insulin detemir|
319245|NCT00274274|Drug|insulin aspart|
319246|NCT00274287|Drug|GM-CSF (Leukine)|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
319247|NCT00274300|Biological|pPJV7630 administered by PMED|
319248|NCT00274313|Drug|552-02|
319249|NCT00274326|Drug|SR121463B|
319250|NCT00274339|Drug|Prevacid 30mg BID|
319251|NCT00002744|Drug|daunorubicin hydrochloride|
319252|NCT00274339|Behavioral|Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.|
319253|NCT00274352|Drug|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
319254|NCT00274365|Procedure|videoconference|
319611|NCT00264264|Procedure|Closure Device|
319612|NCT00264264|Procedure|Direct Compression|
319613|NCT00264277|Drug|Vitamin K antagonist (Coumarin anticoagulants)|
319614|NCT00002704|Drug|mercaptopurine|
319615|NCT00264290|Drug|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
319616|NCT00264290|Drug|Placebo|Placebo designed to resemble Valganciclovir
319617|NCT00264303|Drug|Levocetirizine|5mg oral capsules, once daily, 4 week duration
319618|NCT00264303|Drug|Desloratadine|5mg oral capsules, once daily, 4 week duration
319619|NCT00264316|Procedure|bone marrow-derived stem cell transfer|
318512|NCT00293371|Drug|prednisone|
318513|NCT00293371|Drug|vatalanib|
318514|NCT00293384|Drug|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
318868|NCT00002772|Drug|tamoxifen citrate|
318869|NCT00283608|Other|questionnaire administration|determine attitude changes
318870|NCT00283621|Drug|Aranesp (darbepoetin alfa)|
318871|NCT00283621|Drug|Neulasta (pegfilgrastim)|
318872|NCT00283621|Drug|Adriamycin|
318873|NCT00283621|Drug|Ifosfamide|
318874|NCT00283634|Drug|erlotinib and bortezomib|
318875|NCT00283660|Dietary Supplement|10 mg zinc oxide|10 mg zinc oxide
318876|NCT00283660|Other|Placebo|Placebo pill taken five days a week for six months.
318877|NCT00283673|Behavioral|Exercise|
318878|NCT00283686|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
318879|NCT00002772|Drug|thiotepa|
318880|NCT00283686|Drug|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
318881|NCT00283686|Drug|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
318882|NCT00283686|Other|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
318883|NCT00283686|Other|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
318884|NCT00283699|Drug|albendazole|Active drug or placebo dosed bid p o for 8days
318885|NCT00283699|Other|placebo|an inactive substance
318886|NCT00283712|Drug|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg at Study entry and Weeks 2, 6, and 14
318154|NCT00302796|Drug|Placebo|
318155|NCT00302809|Dietary Supplement|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
318156|NCT00302822|Drug|enfuvirtide|from week 0 to 24
318157|NCT00002818|Drug|deoxycytidine|
318158|NCT00302822|Drug|emtricitabine/tenofovir|1 pill/day
318159|NCT00302822|Drug|lopinavir or efavirenz|investigator choice
318160|NCT00302835|Drug|non-phenacetin containing analgesics|
318161|NCT00302848|Drug|Drospirenone|
318162|NCT00302848|Drug|Levonorgestrel|
318163|NCT00302848|Drug|Other progestin containing oral contraceptive|
318164|NCT00302861|Biological|MyVax|
318165|NCT00302874|Behavioral|Implementation of a protocol for treatment of hyperglycemia|
318166|NCT00302887|Device|combined ultrasound therapy|
318167|NCT00302887|Procedure|connective tissue manipulation|
318168|NCT00002819|Drug|carboplatin|
318169|NCT00302900|Behavioral|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
318170|NCT00302900|Behavioral|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
318515|NCT00293384|Drug|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
318516|NCT00293384|Drug|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
318517|NCT00002798|Radiation|3-dimensional conformal radiation therapy|
318518|NCT00293384|Drug|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
318519|NCT00293397|Device|doxorubicin hydrochloride|Doxorubicin eluting beads
318520|NCT00293410|Drug|clofarabine|
318521|NCT00293410|Drug|cyclophosphamide|
317439|NCT00324415|Drug|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
317440|NCT00324415|Drug|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
317441|NCT00324415|Radiation|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy [5 weeks if given on schedule and without interruption], maximum 54.0 Gy [6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
317780|NCT00002842|Procedure|adjuvant therapy|Chemotherapy given after hepatic resection
317781|NCT00311688|Drug|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
317782|NCT00311714|Drug|CS-8958 formulated as dry powder|
317783|NCT00311714|Other|Placebo|
317784|NCT00311727|Biological|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
317785|NCT00311740|Drug|Valsartan|
317786|NCT00311740|Drug|Hydrochlorothiazide|
317787|NCT00311753|Drug|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
317788|NCT00311753|Drug|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
317789|NCT00311766|Drug|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
317790|NCT00311766|Drug|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
317791|NCT00002842|Procedure|conventional surgery|Hepatic resection
317792|NCT00311779|Drug|Spinosad Creme Rinse|
317793|NCT00311792|Behavioral|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
317794|NCT00311792|Behavioral|Traditional clinical education|
317795|NCT00311805|Biological|Autologous Stem Cells (CD34+)|Intramuscular Injections
317796|NCT00311818|Drug|Insulin glargine|
317797|NCT00311831|Behavioral|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
317075|NCT00334191|Drug|Placebo|
317076|NCT00334204|Device|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
317077|NCT00334217|Behavioral|Cognitive Remediation|PSS Cogrehab
317078|NCT00334243|Drug|Microflare protocol for IVF|
317079|NCT00334243|Drug|Antagonist protocol for IVF|
317080|NCT00334243|Drug|Demi-halt protocol for IVF|
317081|NCT00002944|Drug|lomustine|Given IV
317082|NCT00334256|Drug|Tenofovir (TDF)|
317083|NCT00334256|Drug|Emtricitabine (FTC)|
317084|NCT00334269|Behavioral|Health messaging at weekly home visits by health counsellor|
317085|NCT00334269|Behavioral|Weekly home delivery of bottled spring water|
317086|NCT00334269|Behavioral|Weekly afterschool physical activity program for 5-18y.o.|
317087|NCT00334269|Behavioral|Cooking classes and grocery store tours with dietician|
317088|NCT00334269|Behavioral|Pedometers to track/increase weekly physical activity|
317089|NCT00334282|Drug|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
317442|NCT00324428|Procedure|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
317443|NCT00324441|Device|Iratherm® 1000|
317444|NCT00324454|Biological|Levetiracetam|Levetiracetam 1500 mg BID
317445|NCT00324467|Drug|Cyclophosphamide|Dose: 750 mg/m^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
317446|NCT00324467|Drug|Doxorubicin|Dose: 50 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
317447|NCT00324467|Drug|Vincristine|Dose: 1.4 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
322386|NCT00275548|Drug|Pegasys|135-180 micrograms administered sc once weekly
322387|NCT00275548|Drug|Copegus|400-1200 mg/day for 48 weeks
322388|NCT00275561|Drug|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
322389|NCT00002749|Drug|carboplatin|
322390|NCT00275561|Drug|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
322391|NCT00275574|Procedure|acupuncture|acupuncture
322392|NCT00275600|Drug|Vitamin E, Evening Oil of Primrose, and Placebo|
322763|NCT00265681|Behavioral|Phone counseling and written materials|
322764|NCT00265694|Drug|vinorelbine, gemcitabine and carboplatin|
322765|NCT00265707|Device|Blood pressure measurement|
322766|NCT00265720|Other|Control|Written materials only
322767|NCT00265720|Other|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
322768|NCT00265720|Behavioral|one on one education|one on one education with a health educator
322769|NCT00002708|Radiation|radiation therapy|
322770|NCT00265720|Behavioral|Group education|Education in a small group
322771|NCT00265733|Drug|capecitabine|
322772|NCT00265733|Drug|paclitaxel poliglumex|
322773|NCT00265746|Drug|Metformin|
322774|NCT00265746|Behavioral|Lifestyle intervention - diet, physical activity|
322775|NCT00265759|Drug|anastrozole|Given PO
322776|NCT00265759|Drug|exemestane|Given PO
322777|NCT00265759|Drug|letrozole|Given PO
322778|NCT00265759|Procedure|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
322779|NCT00002718|Procedure|in vitro-treated bone marrow transplantation|
322036|NCT00285155|Drug|Bupropion|
322037|NCT00285168|Behavioral|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
322038|NCT00285181|Drug|Simvastatin|
322039|NCT00285194|Drug|Allogeneic Islets of Langerhans|
322040|NCT00285194|Drug|hOKT3γ1 (Ala-Ala)|
322041|NCT00285207|Drug|placebo|5 days of 28 day cycle for 2 cycles
322042|NCT00285207|Drug|A007|5 days of 28 day cycle
322043|NCT00285220|Procedure|Laparoscopic Truncal Vagotomy|
322044|NCT00285233|Biological|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
322045|NCT00000137|Procedure|Histocompatibility Matching|
322046|NCT00000436|Procedure|High-intensity strength training|
322047|NCT00002778|Procedure|allogeneic bone marrow transplantation|
322048|NCT00285259|Biological|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
322049|NCT00285259|Other|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
322050|NCT00285285|Device|Point of Care Device; i-Stat Analyzer|
322051|NCT00288457|Device|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
322052|NCT00288470|Device|Hylaform, Hylaform Plus (hylan B gel)|
322053|NCT00288483|Drug|Policosanol|
322054|NCT00002785|Drug|mercaptopurine|
322393|NCT00275613|Drug|Rituximab|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
322394|NCT00275639|Drug|Cozaar|
322395|NCT00275652|Drug|LdT (Telbivudine) and lamivudine|
322396|NCT00278811|Procedure|mobile crisis team|
321318|NCT00304083|Biological|filgrastim|Given subcutaneously
321319|NCT00304083|Drug|doxorubicin hydrochloride|Given IV
321320|NCT00304083|Drug|etoposide|Given IV
321321|NCT00304083|Drug|ifosfamide|Given IV
321322|NCT00304083|Procedure|conventional surgery|Patients undergo surgery
321323|NCT00304083|Radiation|radiation therapy|Patients undergo radiotherapy
321324|NCT00304096|Biological|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
321681|NCT00294918|Drug|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
321682|NCT00294931|Drug|irinotecan|
321683|NCT00002801|Radiation|radiation therapy|
321684|NCT00294931|Drug|carboplatin|
321685|NCT00294931|Drug|bevacizumab|
321686|NCT00294944|Drug|Idazoxan|
321687|NCT00294996|Drug|Myocet|
321688|NCT00295009|Device|ProDisc|Total disc replacement with ProDisc
321689|NCT00295009|Procedure|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
321690|NCT00295022|Drug|Levocetirizine|
321691|NCT00295035|Drug|CELECOXIB|
321692|NCT00297882|Drug|Artemether-Lumefantrine , Amodiaquine-Artesunate|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
Amodiaquine-ArtemetherD0(0H),D1(24H),D2(48H)- Artesunate 4mg/kg and Amodiaquine at 10mg/kg
321693|NCT00297895|Procedure|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
321694|NCT00297895|Procedure|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
313465|NCT00319488|Drug|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
313466|NCT00002875|Drug|cyclophosphamide|
313467|NCT00319488|Drug|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
313468|NCT00319501|Drug|Placebo|Intramuscular autoinjector; vehicle; onset of an episode
313469|NCT00319501|Drug|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on subject's age and weight); onset of an episode
313470|NCT00319514|Drug|Docetaxel|
313471|NCT00319540|Behavioral|Control with depression course (CWD)|
313472|NCT00319553|Biological|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
313473|NCT00319553|Biological|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
313474|NCT00319566|Drug|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
313475|NCT00319592|Biological|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
313476|NCT00319592|Biological|JE-VAX® vaccine|1.0 mL, subcutaneously
313477|NCT00002875|Drug|lomustine|
313826|NCT00003081|Drug|thiotepa|
313827|NCT00363870|Biological|Fluarix vaccine|
313828|NCT00363883|Drug|vorinostat|Given orally
313829|NCT00363883|Other|laboratory biomarker analysis|Correlative studies
313830|NCT00363896|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
313831|NCT00363896|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
313832|NCT00363909|Drug|citalopram hydrobromide|
313833|NCT00363909|Other|placebo|
313834|NCT00363922|Behavioral|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
312769|NCT00338403|Procedure|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
313123|NCT00329108|Drug|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
313124|NCT00329108|Drug|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
313125|NCT00002916|Procedure|adjuvant therapy|
313126|NCT00329121|Drug|PEP005|
313127|NCT00329134|Drug|Administration of quinine sulphate taste-masked pellets|
313128|NCT00329147|Drug|desvenlafaxine SR|
313129|NCT00329147|Drug|desipramine|
313130|NCT00329147|Drug|paroxetine|
313131|NCT00329160|Drug|Rosuvastatin|2.5-20 mg
313132|NCT00329160|Drug|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
313133|NCT00329173|Drug|Rosuvastatin|
313134|NCT00329173|Drug|Atorvastatin|
313135|NCT00329186|Drug|desvenlafaxine SR|
313136|NCT00002916|Procedure|surgical procedure|
313137|NCT00329186|Drug|venlafaxine ER|
313138|NCT00332267|Procedure|Endotoxin infusion, Normobaric hypoxia|
313139|NCT00332280|Drug|AMT2003|
313140|NCT00332293|Drug|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
313141|NCT00332293|Drug|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
313142|NCT00332306|Drug|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients <60kg, 400mg patients > 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
313143|NCT00332306|Drug|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients < 60kg, 400 mg OD patients > 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
312399|NCT00003013|Drug|fluorouracil|
312400|NCT00351039|Drug|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
312401|NCT00351039|Drug|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
312402|NCT00351039|Drug|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
312403|NCT00351052|Drug|Pimecrolimus|Pimecroliums cream 1 % bid.
312404|NCT00351052|Drug|Placebo|Vehicle control (placebo) bid.
312405|NCT00351065|Drug|SK3530|
312406|NCT00351078|Drug|PTC124|
312407|NCT00351091|Drug|RISEDRONATE|
312408|NCT00351104|Drug|Ketoprofen Topical Patch 20%|
312409|NCT00351117|Drug|St. John's Wort|SJW in capsule form 300 mg PO TID
312410|NCT00003013|Drug|methotrexate|
312411|NCT00351117|Drug|Lactose|lactose in gelatin capsule that same as St. John's wort
312412|NCT00351130|Drug|valsartan|
312413|NCT00351130|Drug|amlodipine|
312414|NCT00351143|Behavioral|motivation asthma education (compliance enhancement)|
312770|NCT00338416|Drug|Epoetin alfa|
312771|NCT00338429|Behavioral|FHP Sleep Program|Cognitive-Behavioral Intervention
312772|NCT00338442|Drug|VariZIG™|Biological / Vaccine
312773|NCT00338455|Drug|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
312774|NCT00002970|Drug|nelarabine|Given IV
312775|NCT00338455|Drug|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
312776|NCT00338468|Drug|epoetin alfa|
311668|NCT00315354|Other|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
311669|NCT00315367|Drug|Donepezil HCI (drug)|
311670|NCT00315432|Drug|Pegylated Interferon and Ribavirin|
311671|NCT00000460|Behavioral|High intensity exercise|
311672|NCT00002858|Drug|etoposide|
311673|NCT00315445|Drug|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
311674|NCT00315445|Drug|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
311675|NCT00315445|Drug|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
311676|NCT00315445|Drug|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
311677|NCT00315458|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
312020|NCT00360009|Procedure|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
312021|NCT00360022|Other|Transition program|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
312022|NCT00360035|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
312023|NCT00360048|Drug|oxytocin|
312024|NCT00360061|Behavioral|Cognitive Behaviour Therapy|
312025|NCT00360074|Drug|Thyroxin, Triiodothyronine|
312026|NCT00360087|Drug|Bosentan|
312027|NCT00360100|Drug|Zmax|
312028|NCT00003062|Drug|temozolomide|
312029|NCT00360126|Drug|lamotrigine|
312030|NCT00360139|Device|Sculptra Injection|
312031|NCT00360152|Procedure|Fine needle aspiration biopsy (FNAB)|
312032|NCT00360152|Procedure|Sentinel Lymph Node Biopsy|
316893|NCT00365417|Drug|Docetaxel|Following clinical response assessment, 75 mg/m^2 IV every 21 days x 4 cycles
316894|NCT00365430|Behavioral|safety program|Education, patient involvement, tailored implementation and a computerized registration system
316895|NCT00002855|Drug|Doxorubicin hydrochloride|
316896|NCT00314405|Procedure|Surgical procedure|
316897|NCT00314405|Procedure|Anatomo-pathologic procedure|
316898|NCT00314418|Procedure|Colonoscopy in the prone position|
316899|NCT00314431|Procedure|Care coordination by telephone contacts with a nurse|
316900|NCT00314457|Drug|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
316901|NCT00314483|Drug|Mesenchymal Stem Cell Infusion|
316902|NCT00314509|Drug|Ciclesonide/Formoterol Combination|
316903|NCT00314548|Drug|PGE1 (prostacyclin)|alprostadil nebulization
316904|NCT00314548|Drug|normal saline|nebulize for 30 mins
316905|NCT00314561|Drug|Pioglitazone, Rosiglitazone|
316906|NCT00000460|Behavioral|Low intensity exercise|
316907|NCT00002855|Drug|Estramustine Phosphate Sodium|
316908|NCT00314574|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
316909|NCT00314574|Drug|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
316910|NCT00314574|Drug|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
316911|NCT00314574|Drug|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
316912|NCT00314587|Procedure|1 or 2 elastic stable intramedullary nails|
316913|NCT00314600|Device|above and below elbow cast|
316914|NCT00314613|Drug|Antipsychotic/Risperidone Consta|
321476|NCT00271791|Drug|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
321477|NCT00000425|Drug|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
321478|NCT00002734|Drug|topotecan hydrochloride|
321479|NCT00271791|Drug|Prednisone|PO, Placebo, 17 days
321480|NCT00271804|Drug|bortezomib|
321481|NCT00271817|Drug|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
321482|NCT00271817|Drug|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be ~24 weeks.
321483|NCT00271817|Drug|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
321484|NCT00271817|Drug|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~24 weeks.
321485|NCT00271817|Drug|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~24 weeks.
321486|NCT00271817|Drug|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be ~40 additional weeks for a total of 64 weeks
321847|NCT00262340|Other|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
321848|NCT00262353|Device|Dialysis with different artificial devices|
321849|NCT00002701|Drug|cyclophosphamide|
321850|NCT00262366|Device|Comparison of automatic CPAP versus fixed CPAP|
321851|NCT00262379|Drug|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
321852|NCT00262392|Drug|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
321853|NCT00262405|Drug|zileuton|
321854|NCT00262405|Drug|azathioprine/prednisone|
321855|NCT00262418|Drug|Administration of ivermectin or permethrin|
320728|NCT00288080|Drug|flutamide|Given orally
320729|NCT00288080|Drug|goserelin acetate|Patients receive luteinizing hormone-releasing hormone as a component of androgen suppression therapy
320730|NCT00290745|Procedure|neoadjuvant therapy|
320731|NCT00290758|Dietary Supplement|genistein|Given orally
320732|NCT00290758|Other|placebo|Given orally
320733|NCT00290771|Drug|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
320734|NCT00290771|Drug|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
320735|NCT00290810|Biological|bevacizumab|Given IV
320736|NCT00290823|Drug|Albendazole|400 mg tablet taken orally twice daily
320737|NCT00002791|Drug|dacarbazine|
320738|NCT00290823|Drug|Dexamethasone|6mg or 8mg taken daily
320739|NCT00290823|Drug|Omeprazole|20 mg tablet taken orally daily
320740|NCT00290836|Drug|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
320741|NCT00290849|Drug|Bivalirudin|
320742|NCT00290862|Device|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
320743|NCT00290875|Behavioral|Use of Xrays for diagnosis|
320744|NCT00290888|Procedure|Acromioplasty|
320745|NCT00290901|Drug|Tramadol Hydrochloride 50mg|
320746|NCT00290901|Drug|Celebrex 200mg|
320747|NCT00290914|Drug|Vilazodone|
320748|NCT00002791|Drug|doxorubicin hydrochloride|
321125|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
321126|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
320016|NCT00309920|Drug|docetaxel|
320017|NCT00309920|Drug|doxorubicin hydrochloride|
320018|NCT00309920|Drug|epirubicin hydrochloride|
320019|NCT00309920|Drug|fluorouracil|
320366|NCT00300872|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
320367|NCT00300872|Device|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
320368|NCT00300885|Drug|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
320369|NCT00300885|Drug|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
320370|NCT00300898|Procedure|Nucleoplasty|
320371|NCT00300898|Procedure|Percutaneous decompression|
320372|NCT00300898|Procedure|Intervertebral electrothermal disc decompression (IDET)|
320373|NCT00300898|Behavioral|Conservative treatment with oral medications, physical therapy, epidural steroid injections.|
320374|NCT00000449|Behavioral|cognitive behavioral therapy|
320375|NCT00002812|Drug|pegaspargase|Given IV
320376|NCT00300911|Drug|Rosiglitazone(drug), cardiac adverse effects|
320377|NCT00300924|Drug|Rizatriptan co-administered with Acetaminophen|
320378|NCT00300937|Dietary Supplement|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
320379|NCT00300950|Biological|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
320380|NCT00300950|Drug|Gemcitabine|Chemotherapy
320381|NCT00300963|Drug|Talnetant|
319620|NCT00264329|Other|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
319621|NCT00264355|Drug|cyclosporine A|
319622|NCT00264368|Drug|intravenous (IV) ganciclovir|
319623|NCT00264381|Drug|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
319624|NCT00264394|Behavioral|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
319625|NCT00002704|Drug|mesna|
319626|NCT00264394|Behavioral|Guidelines|provision of guidelines for CHD risk factor management only
319627|NCT00264407|Drug|Hormone Replacement Therapy - HRT|
319628|NCT00264420|Drug|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
319629|NCT00264433|Drug|ADH -1 (Exherin™)|
319630|NCT00264446|Drug|ADH300004|
319631|NCT00264459|Biological|Grass pollen formulation|Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.
The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
320020|NCT00002836|Drug|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
320021|NCT00309933|Procedure|cognitive assessment|
320022|NCT00309933|Procedure|psychosocial assessment and care|
320023|NCT00309933|Procedure|quality-of-life assessment|
320024|NCT00309946|Drug|cediranib maleate|Given orally
320025|NCT00309959|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
320026|NCT00309959|Other|Laboratory Biomarker Analysis|Correlative studies
318887|NCT00283712|Drug|Prednisone|Systemic corticosteroid at therapeutic levels. Dosage may be tapered by approximately 15% every 2 weeks if no new lesions are observed as determined by clinical assessment of the investigator.
318888|NCT00283712|Other|Placebo|Placebo given in place of infliximab for control group
318889|NCT00283725|Other|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor [AChEI] nor memantine).
318890|NCT00002772|Procedure|autologous bone marrow transplantation|
319255|NCT00274378|Device|ALLOMATRIX injectable putty in distal radius fractures|
319256|NCT00274391|Drug|7% NaCl|
319257|NCT00274391|Drug|Amiloride HCl|
319258|NCT00274404|Drug|valacyclovir|
319259|NCT00274417|Drug|dutasteride|
319260|NCT00274430|Drug|dexamethasone 8 mg bid|
319261|NCT00274430|Drug|tadalafil 10mg bid|
319262|NCT00002744|Drug|dexamethasone|
319263|NCT00274443|Drug|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
319264|NCT00274456|Drug|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
319265|NCT00274456|Drug|Docetaxel|Docetaxel dosed q3w at 100 mg/m^2
319266|NCT00274469|Drug|fulvestrant|500 mg intramuscular injection
319267|NCT00274469|Drug|anastrozole|1 mg oral tablet
319268|NCT00274495|Drug|Rosiglitazone and Pegasys/Ribavirin|
319269|NCT00274508|Drug|tiotropium bromide|
319270|NCT00274521|Drug|Tiotropium|
319271|NCT00274534|Drug|Tiotropium|
319272|NCT00274534|Drug|Salmeterol|
319273|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
318522|NCT00293423|Biological|HSPPC-96|25 mcg ID
318523|NCT00293423|Procedure|conventional surgery|craniotomy
318524|NCT00293436|Drug|celecoxib|
318525|NCT00293436|Drug|erlotinib hydrochloride|
318526|NCT00293436|Procedure|adjuvant therapy|
318527|NCT00293462|Biological|sargramostim|
318528|NCT00000138|Drug|Prednisolone Phosphate|
318529|NCT00000443|Drug|ondansetron (Zofran)|
318530|NCT00002798|Biological|filgrastim|Given SC
318531|NCT00293462|Other|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
318532|NCT00293475|Drug|Carboplatin|Given IA
318533|NCT00293475|Drug|Mannitol|Given IA
318534|NCT00293475|Drug|Methotrexate|Given IA
318535|NCT00296465|Drug|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
318536|NCT00296478|Drug|Endometrin|Endometrin 100mg BID x 10weeks
318537|NCT00296478|Drug|Endometrin|Endometrin 100mg TID x 10weeks
318538|NCT00296478|Drug|Crinone|Crinone QD x 10weeks
318539|NCT00296491|Drug|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
318540|NCT00296491|Drug|montelukast (MON)|montelukast capsule
318541|NCT00296491|Drug|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
318891|NCT00283738|Device|BioSTAR Septal Repair Implant System|PFO Closure
318892|NCT00283738|Procedure|Sham Procedure|Catheterization
318893|NCT00283751|Drug|insulin detemir|
318894|NCT00287261|Drug|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
317798|NCT00311831|Behavioral|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
317799|NCT00311844|Drug|desloratadine|
317800|NCT00311857|Drug|Cetuximab|
317801|NCT00311857|Drug|Temozolomide|
317802|NCT00002844|Drug|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
317803|NCT00311857|Procedure|Radiation therapy|
317804|NCT00311870|Drug|nisoldipine|
318171|NCT00302900|Behavioral|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
318172|NCT00302913|Drug|Adjustment of clopidogrel dose|
318173|NCT00302926|Procedure|energy restriction and maintenance|
318174|NCT00302952|Drug|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
318175|NCT00302952|Drug|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
318176|NCT00302965|Drug|Frozen Plasma|
318177|NCT00302978|Behavioral|Behavior therapy|
318178|NCT00303004|Drug|Bosentan and Sildenafil|
318179|NCT00000451|Drug|sertraline|16 week outpatient study
318180|NCT00002819|Drug|cyclophosphamide|
318181|NCT00303017|Dietary Supplement|flavocoxid|flavonoid mixture
318182|NCT00303017|Drug|Naproxen|non-steroidal anti-inflammatory drug
318183|NCT00303030|Procedure|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
318184|NCT00305916|Procedure|Multislice spiral computed tomography coronary angiography|
318185|NCT00305916|Procedure|conventional coronary angiography|
318186|NCT00305929|Drug|Treatment with Tookad VTP|
317448|NCT00324467|Drug|Prednisone|Dose: 45 mg/m^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
317449|NCT00000464|Drug|amiodarone|
317450|NCT00002895|Drug|chemotherapy|
317451|NCT00324467|Drug|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
317452|NCT00324467|Drug|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
317453|NCT00324467|Drug|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
317454|NCT00324467|Drug|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
317455|NCT00324467|Drug|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
317456|NCT00324467|Drug|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
317457|NCT00324467|Drug|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
317458|NCT00327600|Drug|DTIC|
317459|NCT00327626|Drug|ISIS 113715|
317460|NCT00327652|Drug|CRS-100|Live-attenuated Listeria monocytogenes
317461|NCT00327665|Biological|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
317462|NCT00327665|Biological|Pneumo 23™|Single-dose intramuscular injection.
317805|NCT00311870|Drug|lisinopril|
317806|NCT00311883|Drug|hydroxychloroquine|
317807|NCT00311896|Drug|Bemiparin|
317808|NCT00311896|Drug|Placebo|
317809|NCT00263328|Drug|CP-690,550|CP-690,550 5 mg BID
317810|NCT00263328|Drug|CP-690,550|CP-690,550 10 mg BID
322780|NCT00268931|Behavioral|Social Training|This group underwent special social interactions with their parents two times each day.
322781|NCT00268944|Biological|Myozyme|20 mg/kg qow
322782|NCT00268957|Drug|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
322783|NCT00268957|Drug|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
322784|NCT00268970|Drug|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
322785|NCT00268983|Biological|Tositumomab and Iodine I 131 Tositumomab|Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes
Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes.
322786|NCT00268983|Biological|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
317090|NCT00334282|Drug|placebo|matching placebo (800 mg tablet) once daily
317091|NCT00334295|Drug|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
317092|NCT00002944|Drug|procarbazine hydrochloride|Given PO
317093|NCT00334308|Procedure|Barley protein bread or control (casein) bread|
317094|NCT00334321|Radiation|IMRT|
317095|NCT00334321|Radiation|Intracavitary vaginal brachytherapy|
317096|NCT00334321|Drug|Paclitaxel|
317097|NCT00334321|Drug|Carboplatin|
317098|NCT00334334|Biological|Pneumococcal (vaccine)|
317099|NCT00334347|Drug|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
317100|NCT00334347|Drug|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
317101|NCT00334360|Drug|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
317102|NCT00334360|Drug|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
322397|NCT00278824|Drug|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
322398|NCT00278824|Drug|Placebo Patch|Placebo patch applied every 3 days for 15 days
322399|NCT00278837|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
322400|NCT00278850|Behavioral|Educational|three 1 hour long educational seminars
322401|NCT00278863|Drug|S-1|
322402|NCT00278863|Drug|Capecitabine|
322403|NCT00278876|Drug|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
322404|NCT00002757|Drug|vincristine sulfate|
322405|NCT00278889|Drug|AZD2171|oral tablet
322406|NCT00278889|Drug|5-fluorouracil|intravenous infusion
322407|NCT00278889|Drug|Leucovorin|intravenous infusion
322408|NCT00278889|Drug|Oxaliplatin|intravenous infusion
322409|NCT00278889|Drug|Bevacizumab|intravenous infusion
322410|NCT00278902|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
322411|NCT00278915|Drug|Fulvestrant|intramuscular injection
322412|NCT00278928|Drug|Liposyn III 20% (lipid infusion)|
322413|NCT00278928|Drug|Intralipid 20% (lipid infusion)|
322414|NCT00278941|Drug|Quetiapine Fumarate Sustained Release|
322415|NCT00000430|Drug|Estrogen/progestin therapy|
322416|NCT00002759|Drug|cyclosporine|
322417|NCT00278954|Biological|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
322418|NCT00278967|Drug|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
322787|NCT00268996|Drug|SB-480848|
321695|NCT00297921|Drug|tandutinib|
321696|NCT00297934|Device|Pro-adjuster mechanical spinal manipulative device|
321697|NCT00002805|Procedure|autologous bone marrow transplantation|
321698|NCT00297947|Drug|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
321699|NCT00297947|Drug|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
321700|NCT00297960|Drug|ziprasidone or olanzapine|
321701|NCT00297960|Procedure|hyperinsulinaemic euglycaemic clamp|
321702|NCT00297960|Procedure|microdialysis (skeletal muscle)|
321703|NCT00297973|Procedure|Blood pressure measurements|
322055|NCT00288496|Drug|polyethylene glycol bowel lavage solution|
322056|NCT00288509|Drug|abobotulinumtoxinA (Dysport) 250-1000 units|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety & efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
322057|NCT00288522|Drug|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
322058|NCT00288535|Procedure|PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique|
322059|NCT00288548|Drug|Metoprolol|
322060|NCT00288561|Drug|ranibizumab|
322061|NCT00288574|Drug|Fluoxetine|
322062|NCT00288587|Drug|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
322063|NCT00288587|Device|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
322064|NCT00288600|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin
322065|NCT00002785|Drug|mesna|
322066|NCT00288600|Drug|Normal saline solution|Normal saline solution 10 ml/Kg
313835|NCT00363922|Behavioral|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
313836|NCT00313079|Drug|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
313837|NCT00313079|Drug|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
313838|NCT00313092|Device|nCPAP treatment|treatment with positive air pressure during night
313839|NCT00313105|Drug|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
313840|NCT00313105|Behavioral|smoking cessation counseling|individual visits
313841|NCT00002850|Drug|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet [TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole] every 12 hours for two months..
313842|NCT00313131|Drug|tinidazole+fluconazole vs metronidazole+clotrimazole|
313843|NCT00313144|Drug|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
313844|NCT00313157|Drug|Metoprolol|
313845|NCT00313157|Drug|Diltiazem|
313846|NCT00313157|Drug|Verapamil|
313847|NCT00313157|Drug|Carvedilol|
313848|NCT00313170|Drug|Fulvestrant|intramuscular injection 250 mg & 500 mg
313849|NCT00313183|Drug|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
313850|NCT00313196|Drug|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
314220|NCT00360971|Other|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
314221|NCT00360971|Procedure|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
314222|NCT00000479|Behavioral|Placebo|Participants will receive placebo.
314223|NCT00003065|Biological|filgrastim|
313144|NCT00332319|Drug|GW679769|
313145|NCT00332332|Biological|etanercept|etanercept subcutaneous injection
313146|NCT00332345|Drug|brimonidine/timolol fixed combination|
313478|NCT00322491|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
313479|NCT00322504|Procedure|Accupuncture|
313480|NCT00322517|Drug|SU014813|100 mg capsule/day for 6 cycle of 21 days
313481|NCT00322530|Procedure|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
313482|NCT00322543|Device|Corio™ Pimecrolimus-eluting stent|
313483|NCT00322556|Drug|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
313484|NCT00322569|Device|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
313485|NCT00002887|Drug|etoposide|
313486|NCT00322569|Device|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
313487|NCT00322569|Device|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
313488|NCT00322595|Drug|Quetiapine fumarate|
313489|NCT00322595|Drug|Paroxetine|
313490|NCT00322608|Drug|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
313491|NCT00322621|Drug|Duloxetine|
313492|NCT00322660|Drug|Adrenaline|
313493|NCT00322673|Drug|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
313494|NCT00322686|Drug|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
312777|NCT00338481|Drug|Morphine p.o.|Morphine p.o. in "red morphine drops" calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c.
312778|NCT00338481|Drug|Morphine s.c.|False "red morphine drops" without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg
312779|NCT00344526|Drug|Melphalan|
312780|NCT00344526|Drug|Dexamethasone|
312781|NCT00344526|Procedure|Autologous stem cell transplantation|
312782|NCT00344539|Biological|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
312783|NCT00344539|Biological|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
312784|NCT00344552|Drug|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
312785|NCT00344565|Drug|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
312786|NCT00344565|Behavioral|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
312787|NCT00344578|Device|Restor IOL|
312788|NCT00344591|Behavioral|Structured Ecosystems Therapy (SET)|
312789|NCT00002985|Drug|daunorubicin hydrochloride|
312790|NCT00344591|Behavioral|Individually tailored intervention|
312791|NCT00344604|Behavioral|Role of psychosocial and quality of life parameters prior to and following LASIK.|
313147|NCT00002933|Drug|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
312033|NCT00360178|Drug|Valsartan plus Hydrochlorothiazide|
312034|NCT00360178|Drug|Candesartan plus Hydrochlorothiazide|
312035|NCT00360178|Drug|Amlodipine|
312036|NCT00360191|Drug|Buspirone|
312037|NCT00360191|Procedure|Motivational enhancement therapy|
312038|NCT00360204|Behavioral|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
312039|NCT00003063|Biological|recombinant interferon alfa|
312040|NCT00360217|Drug|docosahexanoic acid (DHA)|
312041|NCT00362973|Other|laboratory biomarker analysis|
312042|NCT00362973|Procedure|needle biopsy|
312043|NCT00362973|Procedure|positron emission tomography|
312044|NCT00362973|Procedure|radionuclide imaging|
312045|NCT00362973|Radiation|F-18 16 alpha-fluoroestradiol|
312046|NCT00362973|Radiation|fludeoxyglucose F 18|
312415|NCT00351156|Procedure|Blood sample|
312416|NCT00351169|Drug|Quetiapine SR|
312417|NCT00351169|Drug|Escitalopram|
312418|NCT00351182|Drug|Telithromycin|
312419|NCT00351182|Drug|Doxycycline|
312420|NCT00351195|Drug|Etoposide|
312421|NCT00354185|Other|laboratory biomarker analysis|Correlative studies
312422|NCT00354185|Other|pharmacological study|Correlative studies
312423|NCT00354198|Drug|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
311308|NCT00324623|Biological|therapeutic autologous lymphocytes|
311309|NCT00324623|Drug|cyclophosphamide|
311310|NCT00324623|Drug|fludarabine phosphate|
311311|NCT00324649|Drug|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
311312|NCT00324649|Drug|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
311313|NCT00324662|Device|Implantable cardioverter-defibrillator|
311314|NCT00324675|Drug|Rosiglitazone|4 mg tablets, bid, 12 months
311315|NCT00002896|Procedure|conventional surgery|
311316|NCT00324675|Drug|Placebo|2 tablets per day
311317|NCT00324688|Drug|Viread|
311318|NCT00324701|Behavioral|Telepsychology|therapy done at patients house
311319|NCT00324701|Behavioral|Face-to-face therapy|therapy delivered at the VAMC
311320|NCT00324714|Drug|risedronate sodium|
311321|NCT00324714|Other|diagnostic laboratory biomarker analysis|
311322|NCT00324727|Drug|melphalan|Given throug isolated hepatic artery infusion
311323|NCT00324727|Drug|regional chemotherapy|Patients receive the best alternative therapy
311324|NCT00324727|Drug|systemic chemotherapy|Patients receive the best alternative therapy
311325|NCT00324727|Procedure|hepatic artery embolization|Patients receive the best alternative therapy
311326|NCT00002896|Radiation|low-LET cobalt-60 gamma ray therapy|
311327|NCT00324740|Drug|vorinostat|Given orally
311328|NCT00324740|Drug|isotretinoin|Given orally
311329|NCT00324753|Behavioral|Communication|Communication sheet
311330|NCT00324753|Behavioral|Standard of care|Standard of care brochures
311331|NCT00324766|Drug|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
321856|NCT00262431|Procedure|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
321857|NCT00262444|Procedure|Different turning frequencies|
321858|NCT00262457|Device|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
321859|NCT00265122|Drug|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
321860|NCT00265122|Drug|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
321861|NCT00265122|Drug|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
321862|NCT00265135|Drug|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
321863|NCT00265148|Drug|Rosiglitazone|Extended Release Tablets
321864|NCT00265148|Other|Placebo|Placebo dummy to match
321865|NCT00265200|Drug|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
321866|NCT00265226|Biological|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
322225|NCT00307723|Procedure|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
322226|NCT00002833|Drug|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
322227|NCT00307736|Drug|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
322228|NCT00307736|Drug|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
322229|NCT00307736|Drug|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
322230|NCT00307736|Procedure|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
322231|NCT00307749|Drug|Placebo|once daily for 24 weeks
322232|NCT00307749|Drug|MCC-257|20mg, once daily for 24 weeks
321127|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
321128|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
321129|NCT00002766|Drug|mitoxantrone hydrochloride|
321130|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
321131|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
321132|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
321133|NCT00281593|Drug|Telmisartan|
321134|NCT00281593|Drug|Ramipril|
321135|NCT00281606|Drug|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
321136|NCT00281619|Drug|CellCept (mycophenolate mofetil)|
321137|NCT00281619|Behavioral|Dietary Monitoring|
321138|NCT00281619|Behavioral|Drug Diary|
321139|NCT00281619|Procedure|Blood Sampling|
321140|NCT00002766|Drug|pegaspargase|
321141|NCT00281632|Drug|GW786034|800 mg GW786034 administered orally on a daily basis.
321142|NCT00281645|Drug|Bicifadine|
321143|NCT00281645|Drug|Standard of Care (pharmacological analgesic treatment)|
321144|NCT00281658|Drug|lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
321145|NCT00281658|Drug|paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
321146|NCT00284583|Drug|Injection of Alcohol into Foot|
321147|NCT00284583|Drug|Injection of Lidocaine into Foot|
321487|NCT00271817|Drug|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
321488|NCT00002746|Biological|aldesleukin|
321489|NCT00275041|Biological|cetuximab|
320382|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.
Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c < 6.2%, BP < 120/75 mmHg, HDL-C 40 mg/dL , LDL-C < 80 mg/dL, TG < 120 mg/dL.
320383|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.
320384|NCT00300989|Device|Inion OTPS Biodegradable Fixation System|
320385|NCT00301002|Drug|Alefacept|
320386|NCT00002812|Drug|prednisone|Given PO
320749|NCT00290927|Drug|insulin glulisine|
320750|NCT00290940|Drug|CS-917|
320751|NCT00290940|Drug|metformin hydrochloride|
320752|NCT00290940|Drug|pioglitazone|
320753|NCT00290953|Drug|SR48692|
320754|NCT00290966|Drug|XRP6976|
320755|NCT00290979|Drug|insulin glulisine|
320756|NCT00290992|Drug|rasburicase (SR29142)|
320757|NCT00291005|Drug|ARD6562, Docetaxel|
320758|NCT00291018|Device|Total Disc Replacement|
320759|NCT00002791|Drug|ifosfamide|
320760|NCT00291018|Device|ACDF|
320761|NCT00294359|Drug|Mitomycin C; Capecitabine; Bevacizumab|
320762|NCT00294372|Drug|BILR 355 BS|
320763|NCT00294372|Drug|Placebo|
320764|NCT00294385|Drug|Docetaxel|
320765|NCT00294385|Drug|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
320027|NCT00309972|Drug|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
320028|NCT00309972|Drug|Experimental arm (CON):|concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
320029|NCT00309985|Drug|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
320030|NCT00309985|Drug|docetaxel|Given IV
320031|NCT00000456|Behavioral|motivational enhancement therapy|
320032|NCT00002836|Drug|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
320033|NCT00309998|Biological|bevacizumab|
320034|NCT00309998|Drug|vinorelbine tartrate|
320035|NCT00310011|Drug|cisplatin|
320036|NCT00310011|Drug|gemcitabine hydrochloride|
320037|NCT00261352|Drug|Metformin|
320038|NCT00261352|Drug|Fenofibrate|
320039|NCT00002700|Drug|mercaptopurine|
320040|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
320041|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
320042|NCT00261378|Device|Transarterialchemoembolisation (TACE)|
320043|NCT00261378|Device|DC Bead with Doxorubicin|
320387|NCT00301015|Device|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
320388|NCT00301028|Biological|Cetuximab|Beginning weekly dose 400 mg/m^2 IV over 1-2 hours, and 250 mg/m^2 weeks 2-6.
320389|NCT00303732|Drug|PTK787 (vatalanib)|
320390|NCT00000451|Drug|naltrexone|16 week outpatient study
320391|NCT00002822|Drug|ifosfamide|
319274|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
319275|NCT00277238|Drug|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
319276|NCT00000136|Drug|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
319277|NCT00000429|Drug|Calcium carbonate|
319278|NCT00002756|Drug|cyclophosphamide|
319279|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
319632|NCT00264459|Other|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
319633|NCT00264472|Drug|ADH300004|5 mg
319634|NCT00264485|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
319635|NCT00264498|Drug|Gefitinib|oral tablet
319636|NCT00267449|Device|SoftScan Optical Breast Imaging System|
319637|NCT00267488|Drug|topotecan|
319638|NCT00267514|Drug|sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)|sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
319639|NCT00267514|Drug|sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)|sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
319640|NCT00267527|Drug|CJC 1295|
319641|NCT00267540|Behavioral|cholecalciferol (D3) (vitamin)|
319642|NCT00267553|Drug|Atamestane|
319643|NCT00267553|Drug|toremifene|
319644|NCT00267553|Drug|letrozole|
319645|NCT00002715|Drug|prednisone|
319646|NCT00267566|Behavioral|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
318895|NCT00287274|Device|computerized physician order entry|
318896|NCT00287287|Drug|Lenalidomide|Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
318897|NCT00287300|Drug|Sulfadoxine-Pyrimethamine|
318898|NCT00287300|Drug|Azithromycin|
318899|NCT00287300|Drug|Artesunate|
318900|NCT00287313|Drug|Vitamin K|
318901|NCT00287326|Drug|Bupivacaine, Clonidine, Morphine|
318902|NCT00287339|Drug|Esomeprazole|40mg capsule BID for 12 weeks
318903|NCT00287339|Drug|Placebo|placebo capsule BID for 12 weeks
318904|NCT00002784|Drug|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
318905|NCT00287352|Drug|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
318906|NCT00287352|Drug|Olanzapine and placebo|Olanzapine continuing as clinically indicated
318907|NCT00287365|Drug|ozone|2 hour exposure to 0.4 ppm ozone
318908|NCT00287378|Drug|omalizumab|omalizumab as per weight and IgE
318909|NCT00287391|Drug|Rabeprazole|
318910|NCT00287417|Device|echography|
318911|NCT00287417|Other|blood sample|
318912|NCT00287430|Drug|Growth Hormone|
318913|NCT00287430|Procedure|Whole body Protein Turnover Study|
318914|NCT00287430|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
318915|NCT00002784|Drug|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
318916|NCT00287443|Procedure|Oral Glucose tolerance test|
318917|NCT00287443|Procedure|Whole body protein turnover|
319280|NCT00277251|Drug|Alendronate|
318187|NCT00305929|Drug|Treatment with Tookad VTP|Tookad 2 mg/kg
318188|NCT00305929|Drug|Treatment with Tookad VTP|2 mg/kg
318189|NCT00305942|Drug|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
318190|NCT00305942|Drug|carboplatin|Carboplatin AUC=5 IV day 1 only .
318191|NCT00305955|Device|Spectacles|optimal spectacle correction
318192|NCT00305968|Behavioral|patient education|Patient education group
318193|NCT00306020|Drug|topical morphine|
318194|NCT00002829|Drug|Etoposide|Administered intravenously on Day -8
318195|NCT00306033|Drug|Intravenous ImmuneGlobulin|
318196|NCT00306046|Drug|Bisphosphonate treatment|
318542|NCT00296491|Drug|placebo nasal|vehicle placebo nasal spray
318543|NCT00000447|Drug|naltrexone (Revia)|
318544|NCT00002804|Drug|doxorubicin hydrochloride|
318545|NCT00296491|Drug|ADVAIR DISKUS|ADVAIR DISKUS
318546|NCT00296491|Drug|placebo capsule|placebo capsule
318547|NCT00296491|Drug|placebo DISKUS|placebo DISKUS
318548|NCT00296504|Drug|fosamprenavir (GW433908)|
318549|NCT00296504|Drug|ritonavir|
318550|NCT00296517|Drug|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
318551|NCT00296517|Drug|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
318552|NCT00296530|Drug|fluticasone propionate/salmeterol|
318553|NCT00296530|Drug|fluticasone propionate|
318554|NCT00296530|Drug|montelukast|
317811|NCT00002703|Radiation|high-LET heavy ion therapy|
317812|NCT00263341|Drug|NES/EE CVR|This is a Phase 3, multicenter, open-label study of a 21/7-day regimen of the 150/15 NES/EE CVR, in healthy women followed on an outpatient basis up to one year (13 cycles) of treatment over one year. Because of the stop treatment date of December 31, 2008 for all participants, women enrolling or re-enrolling in 2008 may not complete a full 13 cycles of treatment. Subjects may also participate in a 6 month follow-up period after the 300B study. The ring is designed to last for 12 months.
317813|NCT00263354|Drug|Oxaliplatin|
317814|NCT00263367|Other|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
317815|NCT00263393|Drug|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
317816|NCT00263393|Behavioral|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
317817|NCT00263406|Drug|Administration of an ACE-inhibitor or not|
317818|NCT00263419|Behavioral|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
317819|NCT00263432|Procedure|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
317820|NCT00263458|Other|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
317821|NCT00263471|Drug|7-methylxanthine|
317822|NCT00002703|Radiation|low-LET photon therapy|
317823|NCT00263484|Drug|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
317824|NCT00263484|Drug|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
317825|NCT00263484|Drug|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
318197|NCT00306059|Procedure|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
318198|NCT00306072|Drug|nutritional herbal extract from Salacia oblonga|
317103|NCT00337194|Other|placebo|Given IV
317104|NCT00337194|Drug|vinorelbine tartrate|Given IV
317105|NCT00337194|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
317106|NCT00337194|Drug|gemcitabine hydrochloride|Given IV
317107|NCT00337194|Other|laboratory biomarker analysis|Correlative studies
317108|NCT00002961|Radiation|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) [200 cGy twice a day (BID)].
317109|NCT00337194|Other|pharmacological study|Correlative studies
317110|NCT00337207|Biological|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
317111|NCT00337233|Procedure|yoga therapy|10 week yoga class
317112|NCT00337246|Biological|rituximab|
317113|NCT00337246|Drug|cyclophosphamide|
317114|NCT00337246|Drug|fludarabine phosphate|
317463|NCT00327665|Biological|Placebo|1 intramuscular injection.
317464|NCT00327665|Biological|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
317465|NCT00327678|Drug|Rituximab|
317466|NCT00327678|Drug|Imatinib Mesylate|
317467|NCT00000464|Drug|propafenone|
317468|NCT00002908|Drug|vincristine sulfate|
317469|NCT00327691|Drug|Atorvastatin|
317470|NCT00327704|Drug|albumin|albumin 20% 100 ml/8 hours for 3 days
317471|NCT00327704|Drug|saline|saline 100 ml/8hours for 3 days
317472|NCT00327717|Drug|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
322788|NCT00269009|Behavioral|CHERL|
322789|NCT00269022|Drug|SB-705498|
322790|NCT00002718|Procedure|in vitro-treated peripheral blood stem cell transplantation|
322791|NCT00269035|Drug|SB773812 (risperidone)|
322792|NCT00269048|Drug|SB-480848|
322793|NCT00269061|Drug|pioglitazone|
322794|NCT00269074|Drug|IDEA-070|
322795|NCT00269087|Drug|fluticasone propionate/salmeterol combination DISKUS|
322796|NCT00269113|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
322797|NCT00269113|Drug|Standard chemotherapy|As prescribed
322798|NCT00269126|Drug|fluticasone propionate/salmeterol combination DISKUS|
322799|NCT00269126|Drug|salmeterol xinafoate|
322800|NCT00269139|Behavioral|Crisis resolution|
322801|NCT00002718|Radiation|radiation therapy|
322802|NCT00269152|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 4 cycles
322803|NCT00269152|Drug|cisplatin|75 mg/m^2, intravenous (IV), every 21 days x 4 cycles
322804|NCT00269152|Drug|carboplatin|area under the curve (AUC) 5 milligrams per milliliter*minute (mg/ml*min), intravenous (IV), every 21 days x 4 cycles
322805|NCT00269165|Procedure|Balloon Aortic Valvuloplasty|
322806|NCT00269165|Procedure|External Beam Radiation|
322807|NCT00269178|Behavioral|Peer Health Education Programme|
322808|NCT00272285|Drug|Granisetron|IV, concomitant administration with dexamethasone
322809|NCT00272311|Drug|Aspirin|Dosage
322810|NCT00272324|Drug|Aspirin|
322811|NCT00272324|Drug|Folate|
322812|NCT00272337|Drug|Aspirin|Dosage
322067|NCT00288626|Drug|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
322068|NCT00288626|Drug|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
322069|NCT00288626|Procedure|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
322070|NCT00288639|Drug|Pregabalin|Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).
Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID).
322071|NCT00288652|Drug|[S,S]-Reboxetine|
322072|NCT00288665|Device|Export catheter (Medtronic)|
322073|NCT00288678|Procedure|Health Education|
322074|NCT00288691|Drug|Asoprisnil (BAY86-5294)|5mg/day
322075|NCT00288691|Drug|Asoprisnil (BAY86-5294)|10mg/day
322076|NCT00291499|Other|Placebo|800 mg placebo/day for 6 months
322419|NCT00278967|Drug|HalfLytely - Reformulation|
322420|NCT00278980|Drug|C-peptide|
322421|NCT00278993|Drug|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
322422|NCT00279006|Procedure|Percutaneous coronary intervention|
322423|NCT00279019|Drug|GSK233705|
322424|NCT00279032|Drug|GW406381|
322425|NCT00279045|Drug|Rosiglitazone|
322426|NCT00279045|Drug|glyburide|
322427|NCT00002759|Drug|irinotecan hydrochloride|
322428|NCT00002767|Biological|recombinant interferon alfa|
322429|NCT00281892|Drug|fludarabine phosphate|
322430|NCT00281905|Drug|carboplatin|
322431|NCT00281905|Drug|cisplatin|
314224|NCT00360971|Radiation|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
314225|NCT00360984|Drug|insulin glargine|
314226|NCT00360984|Device|continuous subcutaneous insulin infusion|
314227|NCT00360997|Behavioral|Conventional UK physical therapy (Con UK PT)|
314228|NCT00360997|Behavioral|Con UK PT + 30 minutes/day Mobilisation & Tactile Stimulation (MTS)|
314229|NCT00360997|Behavioral|Con UK PT + 60 minutes a day MTS|
314230|NCT00360997|Behavioral|Con UK PT + 120 minutes a day MTS|
314231|NCT00361010|Drug|Levetiracetam|
314232|NCT00361023|Drug|losartan|
314233|NCT00361036|Device|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
314234|NCT00003065|Drug|paclitaxel|
314235|NCT00361036|Device|Uterine fibroid embolization Embosphere®|Embosphere - control arm
314236|NCT00361049|Biological|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
314237|NCT00361049|Genetic|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
314238|NCT00361049|Other|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
314239|NCT00361049|Other|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
314588|NCT00003018|Drug|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
314589|NCT00352196|Other|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
314590|NCT00352222|Device|stent implantation|
314591|NCT00352235|Drug|KRN7000|
314592|NCT00352248|Procedure|Tongue Acupuncture (Procedure)|
313495|NCT00322686|Drug|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
313496|NCT00000463|Drug|cholestyramine|
313497|NCT00002887|Drug|hydroxyurea|
313498|NCT00322699|Procedure|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
313499|NCT00322699|Drug|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
313851|NCT00313209|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
313852|NCT00002851|Procedure|adjuvant therapy|
313853|NCT00313209|Drug|Placebo|once daily
313854|NCT00313222|Drug|bosentan|
313855|NCT00313235|Biological|DC Vaccine and Cyclophosphamide|Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).
Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.
CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure.
313856|NCT00313248|Drug|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
313857|NCT00313248|Drug|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
313858|NCT00313261|Drug|Clevudine|
313859|NCT00313274|Drug|Clevudine|
313860|NCT00313287|Drug|clevudine|
313861|NCT00313300|Drug|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
313862|NCT00313300|Drug|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
313863|NCT00316342|Device|Back supports|
313864|NCT00316355|Behavioral|Cognitive-Behavioral Therapy with EX/RP|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
313865|NCT00002865|Drug|cytarabine|
313148|NCT00332371|Device|CPFA (Coupled Plasma Filtration Adsorption)|CPFA is a specific method for the treatment of sepsis.
It consists of:
a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)
a hemofilter (polyethersulfone 1,4 m2)
a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)
The kit is lodged in the Bellco "Lynda" machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter.
313149|NCT00332384|Drug|brimonidine/timolol fixed combination|
313150|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
313151|NCT00332397|Device|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
313152|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
313153|NCT00332436|Drug|brimonidine/timolol fixed combination|
313154|NCT00332462|Drug|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
313155|NCT00332462|Drug|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
313156|NCT00332488|Drug|Technosphere Insulin|Inhalation, 15U/30U, prandial
313157|NCT00332488|Drug|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
313158|NCT00002934|Procedure|long-term screening|
313159|NCT00332488|Drug|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
313160|NCT00332514|Behavioral|telephone call by a pharmacist|
313161|NCT00332540|Drug|bimatoprost/timolol fixed combination|
313162|NCT00335556|Procedure|Conventional Surgery|Patients undergo resection
313163|NCT00335556|Drug|Cyclophosphamide|Given IV
313164|NCT00335556|Drug|Etoposide|Given IV
313165|NCT00335556|Drug|Carboplatin|Given IV
313166|NCT00335556|Biological|Dactinomycin|Given IV
313167|NCT00000467|Behavioral|exercise|
312424|NCT00354198|Drug|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
312425|NCT00354211|Device|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
312426|NCT00354224|Drug|capecitabine|
312427|NCT00354224|Drug|oxaliplatin|
312428|NCT00354237|Other|Conventional antidiabetic treatment|No intensive treatment
312429|NCT00354237|Other|Intensive insulin treatment|Intensive insulin treatment
312430|NCT00003031|Drug|voriconazole|
312431|NCT00354250|Drug|ispinesib|Given IV
312432|NCT00354263|Biological|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
312433|NCT00354263|Biological|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
312434|NCT00354276|Drug|cytarabine|
312435|NCT00354276|Drug|laromustine|
312436|NCT00354302|Dietary Supplement|calcium carbonate|
312437|NCT00354302|Dietary Supplement|calcium citrate|
312438|NCT00354302|Dietary Supplement|cholecalciferol|
312792|NCT00344617|Drug|Bevacizumab (tradename: Avastin)|
312793|NCT00344630|Device|TAXUS Stent and Cypher Stent|
312794|NCT00344643|Device|Silicone Hydrogel Soft Contact Lenses|
312795|NCT00344669|Drug|Albendazole 400 mg, given 6 monthly|
312796|NCT00344682|Drug|memantine|memantine 5mg - 20mg PO daily
312797|NCT00344682|Drug|Placebo|5mg - 20mg PO daily over 8 weeks
312798|NCT00344695|Drug|bupropion SR|
312799|NCT00344708|Procedure|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
311332|NCT00324766|Drug|placebo,|24 h, infusion
311333|NCT00324779|Biological|rituximab|
311334|NCT00324792|Drug|intensive insulin therapy|
311678|NCT00315458|Drug|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
311679|NCT00315484|Drug|Epoetin alfa and Darbepoetin alfa|
311680|NCT00315510|Drug|Rosuvastatin|
311681|NCT00315523|Drug|Levocetirizine|
311682|NCT00315536|Drug|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
311683|NCT00002858|Radiation|radiation therapy|
311684|NCT00315549|Drug|Telithromycin|
311685|NCT00315549|Drug|Penicillin|
311686|NCT00315562|Procedure|carotid endarterectomy|
311687|NCT00315575|Procedure|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
311688|NCT00315588|Drug|Islet Transplantation|Islet transplantation
311689|NCT00315601|Drug|Telithromycin|800 mg once a day for 5 days
311690|NCT00315601|Drug|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
311691|NCT00318461|Drug|liraglutide|0.6 mg for s.c. (under the skin) injection.
311692|NCT00318461|Drug|metformin|1.5-2.0 g tablets
311693|NCT00318461|Drug|glimepiride|4 mg tablets
311694|NCT00318461|Drug|placebo|Glimepiride placebo 1 mg and 2 mg tablets
311695|NCT00318461|Drug|placebo|Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
311696|NCT00318461|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
311697|NCT00002870|Drug|thiotepa|
311698|NCT00318461|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
322233|NCT00307749|Drug|MCC-257|40mg, once daily for 24 weeks
322234|NCT00307749|Drug|MCC-257|80mg, once daily for 24 weeks
322235|NCT00307762|Behavioral|intensified gait trainer|Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
322236|NCT00307775|Drug|oestradiol|
322237|NCT00002833|Drug|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
322238|NCT00307788|Procedure|acupuncture|acupuncture
322239|NCT00307801|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
322240|NCT00307801|Drug|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
322241|NCT00307814|Drug|Epoetin Alfa|
322242|NCT00307827|Drug|Visilizumab|Visilizumab administered intravenously once per day for two days
322243|NCT00307840|Drug|paricalcitol|
322244|NCT00307853|Drug|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
322245|NCT00307853|Other|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
322593|NCT00298337|Drug|Mixture of probiotic bacteria and prebiotic oligosaccharide|
322594|NCT00298350|Drug|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
322595|NCT00298363|Drug|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
322596|NCT00298363|Drug|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
322597|NCT00298363|Drug|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
322598|NCT00298363|Drug|TDF placebo|Placebo to match TDF QD
321490|NCT00275041|Drug|irinotecan hydrochloride|
321491|NCT00275054|Biological|rituximab|
321492|NCT00275054|Drug|cyclophosphamide|
321493|NCT00275054|Drug|fludarabine phosphate|
321494|NCT00275067|Drug|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
321495|NCT00275067|Drug|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
321496|NCT00275067|Radiation|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
321497|NCT00275080|Drug|vorinostat|Given orally
321498|NCT00275080|Drug|decitabine|Given IV
321499|NCT00002747|Drug|cisplatin|
321500|NCT00275093|Drug|temsirolimus|Given IV
321501|NCT00275093|Other|laboratory biomarker analysis|Correlative studies
321502|NCT00275093|Other|pharmacological study|Correlative studies
321503|NCT00275106|Drug|asparaginase|
321504|NCT00275106|Drug|cyclophosphamide|
321505|NCT00275106|Drug|cytarabine|
321506|NCT00275106|Drug|daunorubicin hydrochloride|
321507|NCT00275106|Drug|dexamethasone|
321508|NCT00275106|Drug|doxorubicin hydrochloride|
321509|NCT00275106|Drug|leucovorin calcium|
321510|NCT00002747|Drug|fluorouracil|
321511|NCT00275106|Drug|mercaptopurine|
321512|NCT00275106|Drug|methotrexate|
321513|NCT00275106|Drug|prednisolone|
320766|NCT00294385|Drug|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
320767|NCT00294398|Other|ICS Prescription + Standard Asthma ED Discharge Therapy|Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:
1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily
320768|NCT00002800|Biological|lintuzumab|
320769|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
320770|NCT00294411|Procedure|elective cesarean section|
320771|NCT00294424|Procedure|Short waiting time|
320772|NCT00294424|Procedure|Non-fixed waiting time|
321148|NCT00002774|Radiation|Radiotherapy (RT)|During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.
After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).
Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery.
321149|NCT00284596|Procedure|High tibial osteotomy|HTO
321150|NCT00284609|Behavioral|Group based non-pharmacological rehabilitation|6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.
24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.
3 x 3 hours cooking sessions in group classes supervised by a dietitian.
Intervention period: 6 month
321151|NCT00284609|Behavioral|Individual non-pharmacological rehabilitation|Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.
4 x 1 hour with a diabetes nurse,
3 x 0.5 hour with a dietitian and
1 hour with a chiropodist.
Intervention period: 6 month
321152|NCT00284622|Procedure|Arthroscopy|HTO with pre-scope
321153|NCT00284635|Procedure|Fast track vs conventional|
321154|NCT00284648|Procedure|Surgical repair Achilles tendon rupture|
321155|NCT00284648|Procedure|Non-surgical repair Achilles tendon rupture|
321156|NCT00284661|Procedure|FAST FIX|Fast fix repair of a meniscal tear
320392|NCT00303745|Drug|capecitabine|
320393|NCT00303745|Drug|irinotecan hydrochloride|
320394|NCT00303758|Drug|cisplatin|
320395|NCT00303758|Drug|fluorouracil|
320396|NCT00303758|Drug|gemcitabine hydrochloride|
320397|NCT00303758|Drug|leucovorin calcium|
320398|NCT00303771|Drug|fluorouracil|
320399|NCT00303771|Drug|irinotecan hydrochloride|
320400|NCT00303771|Drug|leucovorin calcium|
320401|NCT00303784|Drug|releasing hormone agonist therapy|
320402|NCT00002822|Drug|mesna|
320403|NCT00303784|Drug|transdermal estrogen|
320404|NCT00303797|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
320405|NCT00303797|Drug|sorafenib tosylate|
320406|NCT00303810|Drug|carboplatin|
320407|NCT00303810|Drug|cisplatin|
320408|NCT00303810|Drug|cyclophosphamide|
320409|NCT00303810|Drug|etoposide phosphate|
320410|NCT00303810|Drug|high-dose chemotherapy|
320411|NCT00303810|Drug|lomustine|
320412|NCT00303810|Drug|methotrexate|
320413|NCT00002822|Drug|vincristine sulfate|
320414|NCT00303810|Drug|thiotepa|
320415|NCT00303810|Drug|vincristine sulfate|
320773|NCT00294437|Drug|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
320774|NCT00294450|Device|Fistula Pouching System|3 different sizes of fistula pounching system
319647|NCT00267579|Behavioral|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
319648|NCT00267592|Drug|Talampanel|Radiation Therapy (RT) 5 days a week + temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks. One month later, adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months. Talampanel was administered orally TID beginning the first day of RT + TMZ and continued until there was talampanel-related toxicity or tumor progression.
319649|NCT00267605|Behavioral|FHPADHD|Evidence-based psychological and behavioural distance intervention
319650|NCT00267605|Behavioral|ADHD Standard Care|
319651|NCT00267618|Behavioral|FHP Pain|Evidence-based psychological and behavioural Intervention
319652|NCT00267657|Drug|Reserpine|
319653|NCT00267670|Drug|Pentoxifylline|400mg PO TID
319654|NCT00267670|Drug|Placebo|1 pill PO TID
319655|NCT00267683|Drug|insulin aspart|
320044|NCT00261391|Drug|Marimastat|
320045|NCT00261404|Drug|TNFerade™|
320046|NCT00261417|Drug|Tesaglitazar|
320047|NCT00261430|Behavioral|GAIN Acceptance Approach|
320048|NCT00261443|Drug|Lithium or Valproate with placebo (PBO)|Tablets, Oral, once daily
lithium 250-2100 mg/day
valproate 250-2500mg/day
Placebo once daily
320049|NCT00261443|Drug|Lithium or Valproate with Aripiprazole|Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)
lithium 250-2100 mg/day
valproate 250-2500mg/day
aripiprazole 15-30 mg/day
320050|NCT00002700|Drug|methotrexate|
320051|NCT00261456|Behavioral|PSA test|Patients tested for their level of Prostate Specific Antigen.
320052|NCT00261456|Procedure|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
320053|NCT00261469|Drug|topiramate|
320054|NCT00261482|Drug|norelgestromin + ethinyl estradiol|
320055|NCT00261495|Drug|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
320056|NCT00261495|Drug|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
319281|NCT00277264|Drug|Tiotropium (Spiriva®)|
319282|NCT00277277|Behavioral|Healthium|
319283|NCT00277290|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
319284|NCT00277303|Drug|XL999|XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.
319285|NCT00277316|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
319286|NCT00277329|Drug|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
319287|NCT00277342|Procedure|measurement of lipid-induced hepatic insulin resistance|
319288|NCT00277355|Drug|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (~ 8 hours apart)
319289|NCT00002756|Drug|cytarabine|
319290|NCT00277355|Drug|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
319291|NCT00277368|Other|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
319292|NCT00277381|Behavioral|Automated feedback regarding drug adherence|
319293|NCT00277394|Drug|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
319294|NCT00277394|Drug|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
319295|NCT00277407|Procedure|NAET with acupressure and/or chiropractic procedures|
319296|NCT00277420|Behavioral|Comprehensive weight management|
319297|NCT00277433|Other|Buccal Swab|collection of buccal swab
319298|NCT00280748|Drug|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
319299|NCT00280748|Radiation|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
318555|NCT00002804|Drug|ifosfamide|
318556|NCT00296556|Drug|Rivenprost (drug)|
318557|NCT00296569|Drug|MK0686|
318558|NCT00296582|Behavioral|Gastric Motor Function Measurement|
318559|NCT00296595|Behavioral|Nutrition|
318560|NCT00296608|Drug|fluorouracil|
318561|NCT00296608|Drug|leucovorin calcium|
318562|NCT00296608|Procedure|adjuvant therapy|
318563|NCT00296608|Procedure|conventional surgery|
318564|NCT00296608|Procedure|neoadjuvant therapy|
318565|NCT00296608|Radiation|radiation therapy|
318566|NCT00002804|Drug|mesna|
318567|NCT00299884|Drug|Lipitor 20 mg|A/A for 6 weeks
318568|NCT00002810|Procedure|peripheral blood stem cell transplantation|
318918|NCT00287443|Procedure|IV glucose tolerance test|
318919|NCT00287443|Procedure|Indirect Calorimetry|
318920|NCT00287443|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
318921|NCT00287443|Procedure|Growth Hormone Stimulation Test|
318922|NCT00287456|Device|Insulin Pump|
318923|NCT00287456|Drug|Insulin|
318924|NCT00287456|Procedure|Oral Glucose Tolerance Test|
318925|NCT00287456|Procedure|Whole body Protein Turnover|
318926|NCT00002784|Drug|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
318927|NCT00290329|Biological|Mencevax ACWY|1 subcutaneous injection.
318928|NCT00290342|Biological|DTPa-IPV|3 intramuscular injections
318199|NCT00306085|Genetic|Autologous bone marrow cells|
318200|NCT00306098|Drug|islets|Islet transplantation
318201|NCT00306111|Drug|pegfilgrastim|Single dose (6mg) one day after chemotherapy
318202|NCT00306124|Drug|Levodopa|
318203|NCT00306137|Drug|Trasylol (Aprotinin, BAYA0128)|Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.
Subjects will be stratified into one of the 4 following strata:
Stratum 1: complete primary pneumonectomy
Stratum II: decortication or completion pneumonectomy
Stratum III: esophagectomy by transhiatal approach
Stratum IV: esophagectomy by transthoracic approach
318204|NCT00306137|Drug|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
318205|NCT00002829|Drug|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
318206|NCT00306150|Drug|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
318207|NCT00306150|Drug|Placebo|Placebo is used according to the description of Arm 1
318208|NCT00306163|Drug|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
318209|NCT00306163|Drug|Fluticasone|inhaled Fluticasone 100 µg, twice daily
318210|NCT00306176|Drug|Rosiglitazone|
318211|NCT00309205|Drug|dapivirine (TMC120) vaginal gel|
318212|NCT00309218|Drug|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
318213|NCT00309231|Procedure|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
318214|NCT00309244|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
318215|NCT00002835|Drug|Leucovorin Calcium|
318216|NCT00309244|Drug|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
318217|NCT00309257|Drug|ACE I, ATA II and Statins|
317473|NCT00327717|Drug|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
317474|NCT00327730|Drug|Eperisone|
317475|NCT00327743|Drug|larotaxel (XRP9881)|IV infusion
317476|NCT00327743|Drug|capecitabine|oral route
317477|NCT00327756|Drug|Coenzyme Q10|
317478|NCT00327769|Drug|Fulvestrant|250 mg intramuscular injection
317479|NCT00002909|Drug|chemotherapy|
317480|NCT00327769|Drug|Anastrozole|1 mg tablet
317481|NCT00327808|Drug|TPI-1020|600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
317482|NCT00327808|Drug|budesonide|400 mcg BID x 14 days then 800 mcg/day x 7 more days
317483|NCT00327821|Behavioral|calorie controlled diet|
317484|NCT00327834|Drug|atomoxetine|
317485|NCT00327847|Drug|Oral Vitamin D Supplementation|
317486|NCT00327873|Other|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
317487|NCT00327873|Other|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
317488|NCT00327912|Procedure|Laparoscopic Biliopancreatic diversion with Duodenal switch|
317826|NCT00263497|Device|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
317827|NCT00263523|Drug|[11C] (-)-RWAY|
317828|NCT00263536|Procedure|Interpersonal Psychotherapy|
317829|NCT00263549|Biological|House dust mite Novo Helisen Depot|
317830|NCT00263562|Drug|Methylprednisolone plus prednisone taper|
317831|NCT00263575|Drug|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
317832|NCT00266448|Drug|Chlorhexidine solution 4%|
322813|NCT00272350|Drug|Steroids|
322814|NCT00272350|Drug|ZD6474|
317115|NCT00337246|Drug|mitoxantrone hydrochloride|
317116|NCT00337259|Drug|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
317117|NCT00337272|Drug|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
317118|NCT00337272|Drug|Ramelteon|8 mgs daily for days 1-28 of treatment period
317119|NCT00002961|Drug|Busulfan|Conditioning Regimen Arm B:
Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.
Patients </= 20kg to receive busulfan 1.0 mg/kg/dose IV**Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients >20kg and 1.25 mg/kg/dose by mouth (po) for patients </= 20 kg.
317120|NCT00337285|Drug|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
317121|NCT00337298|Drug|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
317122|NCT00337298|Drug|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
317123|NCT00337324|Device|Frequency-modulated electromagnetic neural stimulation|
317124|NCT00337337|Behavioral|Multiple grain|
317125|NCT00337337|Behavioral|Ordinary Asian- rice|
317126|NCT00337350|Drug|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
317127|NCT00337350|Drug|placebo|matched placebo for rosiglitazone 4mg/day
317128|NCT00337376|Drug|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
317129|NCT00337376|Drug|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
317130|NCT00343369|Drug|cytarabine|
317131|NCT00343369|Drug|daunorubicin hydrochloride|
317132|NCT00343369|Drug|dexamethasone|
317133|NCT00343369|Drug|doxorubicin hydrochloride|
317134|NCT00343369|Drug|mercaptopurine|
322432|NCT00281905|Drug|cyclophosphamide|
322433|NCT00281905|Drug|methotrexate|
322434|NCT00281905|Drug|vincristine sulfate|
322435|NCT00281905|Radiation|radiation therapy|
322436|NCT00281918|Drug|Rituximab|Intravenous repeating dose
322437|NCT00281918|Drug|Cyclophosphamide|Intravenous repeating dose
322438|NCT00281918|Drug|Fludarabine Phosphate|Intravenous repeating dose
322439|NCT00002768|Biological|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
322440|NCT00281931|Biological|rituximab|
322441|NCT00281931|Drug|cyclophosphamide|
322442|NCT00281931|Drug|fludarabine phosphate|
322443|NCT00281944|Drug|oxaliplatin|Given IV
322444|NCT00281944|Drug|fluorouracil|Given IV
322445|NCT00281944|Drug|leucovorin calcium|Given IV
322446|NCT00281944|Other|pharmacological study|Correlative studies
322815|NCT00272402|Behavioral|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
322816|NCT00272402|Behavioral|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
322817|NCT00002735|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
322818|NCT00272415|Drug|INO-1001|Intravenous repeating dose
322819|NCT00272415|Drug|temozolomide|Oral repeating dose
322820|NCT00272428|Behavioral|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
322821|NCT00272441|Drug|inhaled corticosteroids|
322822|NCT00272454|Drug|Cilostazol|
322823|NCT00272454|Drug|Aspirin|
314593|NCT00352261|Drug|Esomeprazole|
314594|NCT00352261|Drug|Lansoprazole|
314595|NCT00352287|Drug|Recombinant human growth hormone; pioglitazone|
314596|NCT00354913|Drug|hydroxyurea|Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
314597|NCT00354913|Drug|imatinib mesylate|Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.
Dose for Imatinib:
Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.
If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately.
314598|NCT00354926|Biological|AME-133v (LY2469298)|IV 4X weekly X 4
314599|NCT00354939|Drug|Insulin glargine|
314600|NCT00354952|Drug|Macrolides (azithromycin or clarithromycin)|
314601|NCT00354965|Drug|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
314602|NCT00354978|Drug|5-Fluorouracil|400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.
2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection.
314603|NCT00354978|Drug|Bevacizumab|5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.
5 mg/kg by vein on Day 1 of 14 day cycle.
314604|NCT00354978|Drug|Leucovorin|400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
314605|NCT00354978|Drug|Irinotecan|180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.
314606|NCT00003035|Radiation|radiation therapy|
314955|NCT00345748|Drug|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
314956|NCT00345761|Drug|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
314957|NCT00345761|Drug|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
314958|NCT00345761|Drug|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
313866|NCT00316355|Behavioral|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
313867|NCT00316368|Device|Ethicon TPW32 60 cm (pacing wires x 2)|
313868|NCT00316381|Procedure|Autologous bone marrow-derived stem cells|
313869|NCT00316394|Device|Preventive Care Checklist Form|
313870|NCT00316407|Drug|lapatinib (GW572016)|1000 mg po qd
313871|NCT00316407|Drug|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
313872|NCT00316407|Drug|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
314240|NCT00361049|Other|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
314241|NCT00363922|Behavioral|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
314242|NCT00003081|Procedure|peripheral blood stem cell transplantation|
314243|NCT00363935|Drug|Dexmedetomidine|
314244|NCT00363948|Drug|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
314245|NCT00363948|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
314246|NCT00363961|Behavioral|Resistance exercise|resistance exercise vs sham comparison
314247|NCT00363974|Drug|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
314248|NCT00363987|Drug|Ketosteril®|1 tablet Ketosteril/5kgBW/d
314249|NCT00363987|Other|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
314250|NCT00364000|Drug|Calcium acetate|Calcium acetate in 240 chronic HD patients
314251|NCT00364000|Drug|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
313168|NCT00002950|Biological|sargramostim|
313500|NCT00322751|Drug|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
313501|NCT00322764|Drug|Uridine|
313502|NCT00325546|Drug|Placebo|
313503|NCT00325559|Procedure|Normoinsulinemic eu- or hyperglycemic clamp|
313504|NCT00325572|Biological|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
313505|NCT00325585|Behavioral|Couples HIV counseling and testing|
313506|NCT00325585|Behavioral|Women's relationship-focused HIV counseling and testing|
313507|NCT00325598|Radiation|Partial Breast Irradiation (PBI)|
313508|NCT00002898|Procedure|adjuvant therapy|
313509|NCT00325611|Behavioral|Multidisciplinary palliative care team met with patient|
313510|NCT00325624|Device|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
313511|NCT00325637|Drug|cilnidipine|Cilnidipine 10~20mg, qd, po for 4 weeks.
313512|NCT00325650|Drug|rimonabant (SR141716)|oral administration once daily
313513|NCT00325650|Drug|placebo|oral administration once daily
313514|NCT00325663|Procedure|Acupuncture|
313515|NCT00325676|Drug|Pantoprazole|
313516|NCT00325689|Drug|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
313517|NCT00325689|Drug|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
313518|NCT00325702|Behavioral|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
312800|NCT00002985|Drug|pegylated liposomal doxorubicin hydrochloride|
312801|NCT00344721|Drug|Essential fatty acid supplement|
312802|NCT00344734|Drug|Ng-monomethyl-L-arginine (drug)|
312803|NCT00344747|Behavioral|dietary, behavioral, physical activity|
312804|NCT00344760|Drug|Enfuvirtide|subcutaneously twice a day
312805|NCT00344760|Drug|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
312806|NCT00348010|Drug|Tramadol HCl ER|
312807|NCT00348023|Drug|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
312808|NCT00348036|Behavioral|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
312809|NCT00348036|Other|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
312810|NCT00003001|Drug|gemcitabine hydrochloride|
312811|NCT00348049|Procedure|Laser in Situ Keratomileusis (LASIK)|
312812|NCT00348049|Procedure|Photorefractive Keratectomy (PRK)|
312813|NCT00348062|Drug|Bimatoprost|
312814|NCT00348075|Device|Neurovision|
312815|NCT00348101|Drug|Combined therapy with enoximone and esmolol|
313169|NCT00335556|Drug|Vincristine Sulfate|Given IV
313170|NCT00335556|Radiation|Radiation Therapy|Undergo radiotherapy
313171|NCT00335556|Other|Laboratory Biomarker Analysis|Correlative studies
313172|NCT00335569|Drug|hCG-IBSA|
313173|NCT00335582|Drug|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
311699|NCT00318474|Drug|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
311700|NCT00318474|Drug|MMF Placebo|Placebo only, oral administration
311701|NCT00318474|Drug|ACEi|Administer same as pre-treatment regimen.
311702|NCT00318474|Drug|FOS|Administer same as pre-treatment regimen
311703|NCT00318487|Procedure|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
312047|NCT00362986|Drug|sunscreen|
312048|NCT00362986|Other|placebo|
312049|NCT00363012|Biological|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
312050|NCT00003079|Drug|bryostatin 1|
312051|NCT00363012|Other|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
312052|NCT00363012|Other|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
312053|NCT00363012|Procedure|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
312054|NCT00363012|Other|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
312055|NCT00363025|Procedure|Two post-remission strategies|
312056|NCT00363025|Drug|Idarubicin versus daunorubicin|
312057|NCT00363038|Drug|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
312058|NCT00363038|Drug|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
312059|NCT00363038|Drug|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
312060|NCT00363038|Drug|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
312061|NCT00003079|Drug|cytarabine|
322599|NCT00298363|Drug|FTC/TDF placebo|Placebo to match FTC/TDF QD
322600|NCT00298363|Drug|ETV placebo|Placebo to match ETV QD
322601|NCT00002806|Drug|procarbazine hydrochloride|
322602|NCT00298415|Drug|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
322603|NCT00298415|Drug|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
322604|NCT00298428|Procedure|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
322605|NCT00301834|Procedure|peripheral blood stem cell transplantation|
322606|NCT00301834|Procedure|umbilical cord blood transplantation|
322607|NCT00301847|Drug|sorafenib tosylate|
322608|NCT00301860|Biological|anti-thymocyte globulin|
322609|NCT00301860|Biological|filgrastim|
322610|NCT00301860|Biological|therapeutic allogeneic lymphocytes|
322611|NCT00301860|Drug|cyclosporine|
322612|NCT00301860|Drug|fludarabine phosphate|
322613|NCT00002816|Drug|idarubicin|Given IV
322614|NCT00301860|Drug|melphalan|
322615|NCT00301860|Drug|methotrexate|
322616|NCT00301860|Procedure|allogeneic hematopoietic stem cell transplantation|
322617|NCT00301860|Procedure|peripheral blood stem cell transplantation|
322618|NCT00301873|Drug|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
322979|NCT00291954|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
322980|NCT00291967|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
322981|NCT00291980|Biological|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
321867|NCT00265239|Drug|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
321868|NCT00265252|Drug|Alendronate|
321869|NCT00002707|Drug|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
321870|NCT00265265|Drug|Atomoxetine|
321871|NCT00265278|Drug|Modafinil|
321872|NCT00265291|Drug|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
321873|NCT00265304|Drug|Ketoprofen|
321874|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
321875|NCT00265317|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
321876|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
321877|NCT00265317|Drug|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
321878|NCT00265330|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
321879|NCT00265343|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
321880|NCT00002707|Drug|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
321881|NCT00265343|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
321882|NCT00265356|Procedure|PET diagnostic imaging|PET diagnostic imaging
321883|NCT00265369|Drug|Spores of Bacillus Clausii Probiotic Strain|
321884|NCT00268593|Drug|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
321885|NCT00268593|Drug|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
321886|NCT00268593|Drug|prednisone|5 mg twice a day orally
321887|NCT00002718|Drug|cyclophosphamide|
321157|NCT00284661|Procedure|Meniscal suturing|standard suturing of meniscal tear
321158|NCT00284674|Device|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
321159|NCT00002775|Drug|docetaxel|
321160|NCT00284687|Drug|Artesunate|PO Artesunate
321161|NCT00284700|Drug|Iron|
321162|NCT00284713|Procedure|intracoronary infusion of BMC|catheter delivery of stem cells
321163|NCT00284726|Device|Celsior Cold Storage Solution|
321164|NCT00284739|Drug|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
321165|NCT00284739|Other|saline|saline injection twice daily for three days
321166|NCT00284752|Drug|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
321167|NCT00284765|Procedure|flector|
321514|NCT00275106|Drug|thioguanine|
321515|NCT00275106|Drug|vincristine sulfate|
321516|NCT00275106|Procedure|radiation therapy|
321517|NCT00275119|Drug|fluorouracil|
321518|NCT00275119|Drug|gemcitabine hydrochloride|
321519|NCT00275119|Drug|oxaliplatin|
321520|NCT00275119|Radiation|radiation therapy|
321521|NCT00002747|Procedure|conventional surgery|
321522|NCT00278369|Biological|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
321523|NCT00278382|Drug|sorafenib tosylate|Given orally
321524|NCT00278382|Other|laboratory biomarker analysis|Correlative studies
321525|NCT00278395|Drug|Vorinostat|Given orally
320775|NCT00294463|Drug|Tibolone|
320776|NCT00294463|Drug|Estradiol|
320777|NCT00294463|Drug|Estradiol + Medroxy Progesterone Acetate|
320778|NCT00294476|Drug|IVIG|
320779|NCT00002800|Drug|cytarabine|
320780|NCT00294476|Procedure|Biological Therapy|
320781|NCT00294502|Drug|Gentamycin/citrate, Minocycline/EDTA|
320782|NCT00294515|Drug|Valganciclovir|900 mg orally daily for up to 100 days
320783|NCT00294515|Drug|Valganciclovir|900 mg orally daily for up to 200 days
320784|NCT00294528|Device|Nexgen LPS-flex and AGC|
320785|NCT00294541|Drug|ICA-17043|
320786|NCT00294554|Drug|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day)through week 24 unless unable to tolerate. The dose will be decreased as needed.
320787|NCT00294567|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
320788|NCT00294580|Drug|Maloprim|
320789|NCT00002805|Drug|etoposide|
320790|NCT00297479|Behavioral|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
320791|NCT00297479|Behavioral|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
320792|NCT00297492|Behavioral|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
320793|NCT00297492|Behavioral|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
320794|NCT00297492|Behavioral|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
320057|NCT00261508|Drug|risperidone|
320058|NCT00261521|Drug|epoetin alfa|
320059|NCT00261547|Drug|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
320060|NCT00261560|Drug|acetaminophen|
320061|NCT00002700|Drug|mitoxantrone hydrochloride|
320062|NCT00261573|Drug|galantamine hydrobromide|
320063|NCT00261586|Drug|aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib|
320064|NCT00261599|Drug|AQUAVAN® (fospropofol disodium) Injection|
320065|NCT00261599|Drug|Midazolam HCI|
320066|NCT00261612|Drug|bortezomib|
320067|NCT00261612|Drug|rituximab|
320068|NCT00261612|Drug|dexamethasone|
320069|NCT00002704|Drug|methotrexate|
320070|NCT00264498|Drug|Gemcitabine|intravenous injection
320416|NCT00303810|Radiation|radiation therapy|
320417|NCT00303823|Drug|placebo|Given orally
320418|NCT00303823|Dietary Supplement|defined green tea catechin extract|Given orally
320419|NCT00303823|Other|laboratory biomarker analysis|Correlative studies
320420|NCT00303836|Drug|cyclophosphamide|Given IV
320421|NCT00303836|Drug|fludarabine phosphate|Given IV
320422|NCT00303836|Biological|therapeutic autologous lymphocytes|Given IV
320423|NCT00303836|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
320424|NCT00307060|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
320425|NCT00307060|Drug|losartan / Duration of Treatment: 6 weeks|
319300|NCT00280761|Drug|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
319656|NCT00000421|Drug|Placebo|
319657|NCT00002715|Drug|vinblastine|
319658|NCT00267683|Drug|glibenclamide|
319659|NCT00267696|Drug|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
319660|NCT00267696|Drug|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
319661|NCT00267696|Drug|Carboplatin|
319662|NCT00267709|Drug|Visilizumab|
319663|NCT00267722|Drug|Visilizumab|
319664|NCT00267735|Behavioral|Use of Computerized Decision Aid on Childbirth|
319665|NCT00267748|Drug|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
319666|NCT00270829|Drug|nesiritide|Drug given intrarenally or placebo
319667|NCT00270842|Behavioral|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
319668|NCT00270842|Behavioral|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
319669|NCT00270842|Behavioral|Education Control group|This control group participated in 10 weeks of general health education classes.
319670|NCT00270855|Procedure|Arm Crank Ergometry|Use of an upper body cycle to perform exercise.
319671|NCT00270855|Procedure|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise
319672|NCT00270868|Procedure|Double guide wire technique|
319673|NCT00270868|Procedure|Standard bile duct cannulation|
319674|NCT00002725|Drug|chemotherapy|
319675|NCT00270881|Procedure|Cord blood transplantation|unrelated cord blood transplantation
319676|NCT00270881|Radiation|TBI|Total body irradiation (TBI) 12Gy
318929|NCT00290342|Biological|DTPa|3 intramuscular injections
318930|NCT00290342|Biological|IMOVAX Polio®|3 intramuscular injections
318931|NCT00290355|Biological|GSK 249553 vaccine|Intramuscular injection, 13 doses
318932|NCT00290355|Biological|Placebo|Intramuscular administration, 13 doses
318933|NCT00000440|Drug|sertraline (Zoloft)|
318934|NCT00002788|Radiation|radiation therapy|
318935|NCT00290368|Procedure|Skin Prick Test|
318936|NCT00290368|Procedure|Nasal allergen challenge|
318937|NCT00290368|Procedure|Nasal filter paper placement|
318938|NCT00290368|Procedure|Nasal lavage|
318939|NCT00290368|Procedure|Nasal scrape|
318940|NCT00290368|Procedure|Nasal symptoms score|
318941|NCT00290381|Drug|Study drug administration|
318942|NCT00290381|Procedure|Skin prick test|
318943|NCT00290381|Procedure|12-lead ECG|
318944|NCT00290381|Procedure|Laboratory safety samples|
318945|NCT00002789|Drug|busulfan|
319301|NCT00280761|Drug|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
319302|NCT00002765|Biological|LMB-2 immunotoxin|
319303|NCT00280761|Procedure|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
319304|NCT00280761|Radiation|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
319305|NCT00280774|Drug|Memantine|
319306|NCT00280787|Drug|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
318569|NCT00299884|Drug|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
318570|NCT00299897|Drug|SP01A|
318571|NCT00299910|Drug|Montelukast|
318572|NCT00299923|Drug|Peginterferon alfa-2a, Ribavirin, Amantadine|
318573|NCT00299936|Drug|Ribavirin, PEG-Intron|
318574|NCT00299962|Biological|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
318575|NCT00299962|Biological|SCH 721015|Comparison of different doses and frequency of investigational agent
318576|NCT00299975|Drug|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
318577|NCT00299975|Drug|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
318578|NCT00299975|Drug|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
318579|NCT00000449|Drug|naltrexone (Revia)|
318580|NCT00002811|Drug|liposomal T4N5 lotion|
318581|NCT00299988|Drug|Intravenous Immunoglobulin|
318582|NCT00300014|Procedure|Intravitreal triamcinolone injection|
318583|NCT00300014|Procedure|Air-fluid exchange|
318584|NCT00300027|Drug|BMS-582664|
318585|NCT00300040|Drug|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
318586|NCT00300040|Drug|6% Hydroxyethylstarch|250ml for intravenous infusion
318587|NCT00300053|Device|stem cell injection|
318588|NCT00300079|Drug|brinzolamide 1.0%|
318589|NCT00300092|Drug|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
318590|NCT00300105|Drug|Tesaglitazar|
318591|NCT00002812|Drug|asparaginase|Given IV
317833|NCT00266461|Drug|Daikenchuto Extract Granules (TU-100)|
317834|NCT00266474|Other|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
317835|NCT00266487|Drug|Folic acid|
317836|NCT00266487|Drug|Vitamin B12|
317837|NCT00002714|Drug|mechlorethamine hydrochloride|
317838|NCT00266487|Drug|Vitamin B6|
317839|NCT00266526|Biological|Recombinant birch pollen|
317840|NCT00266539|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
317841|NCT00266552|Drug|risperidone|
317842|NCT00266565|Drug|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
317843|NCT00266578|Drug|Fluticasone Propionate|Flovent vs. placebo daily for 3 months
317844|NCT00266591|Drug|topiramate|
317845|NCT00266604|Drug|Topiramate|
317846|NCT00266617|Drug|epoetin alfa|
317847|NCT00266630|Drug|olanzapine|oral, daily
317848|NCT00000421|Drug|Prednisone|
317849|NCT00002714|Drug|prednisone|
317850|NCT00266630|Drug|lithium|Dose adjusted according to local package insert
317851|NCT00266630|Drug|valproate|Dose adjusted according to local package insert
317852|NCT00266630|Drug|carbamazepine|Dose adjusted according to local package insert
318218|NCT00309257|Drug|Benazepril, Valsartan and Fluvastatin|Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.
Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate.
318219|NCT00309270|Drug|Campath-1H|
318220|NCT00309283|Drug|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
317135|NCT00343369|Drug|methotrexate|
317136|NCT00002981|Radiation|methionine C 11|
317137|NCT00343369|Drug|pegaspargase|
317138|NCT00343369|Drug|prednisolone|
317139|NCT00343369|Drug|teniposide|
317489|NCT00330967|Drug|20% Intralipid|lipid infusion
317490|NCT00330980|Drug|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
317491|NCT00330980|Drug|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
317492|NCT00330980|Drug|Placebo|Participants will receive placebo for 6 months.
317493|NCT00002926|Drug|etoposide|
317494|NCT00330993|Drug|mifepristone, misoprostol|
317495|NCT00331006|Drug|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
317496|NCT00331032|Drug|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
317497|NCT00331032|Drug|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
317498|NCT00331045|Drug|alvimopan|0.25 mg/day
317499|NCT00331045|Drug|Placebo|
317500|NCT00331045|Drug|Alvimopan 0.5 mg/day|
317501|NCT00331045|Drug|Alvimopan 1 mg/day|
317502|NCT00331058|Procedure|Bronchoscopsy|Healthy and Asthmatic Volunteers
317503|NCT00331058|Procedure|Prednisolone|Asthmatic Volunteers
317504|NCT00000465|Procedure|coronary artery bypass|
317505|NCT00002926|Drug|idarubicin|
317506|NCT00331071|Drug|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
322824|NCT00272467|Drug|Rebamipide|Brand name: Mucosta® Tab.
Generic name: Rebamipide.
Chemical name:
(±)-2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid.
Formulation: Tablet (White, film-coated tablet).
Strength: One tablet contains rebamipide 100mg.
Storage condition: 15℃~25℃.
Manufacturer: Korea Otsuka Pharmaceuticals
322825|NCT00272467|Drug|Omeprazole|Brand name: Losec® Cap.
Generic name: Omeprazole.
Chemical name:
5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃~25℃. 7) Manufacturer: AstraZenaca Korea.
322826|NCT00272480|Drug|Zidovudine/lamivudine|
322827|NCT00272493|Biological|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
322828|NCT00002737|Biological|recombinant interferon alfa|
322829|NCT00272493|Biological|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
322830|NCT00272506|Drug|inhaled corticosteroid|
322831|NCT00272506|Drug|long-acting beta2-agonist|
322832|NCT00272519|Behavioral|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
322833|NCT00272532|Drug|Thiocolchicoside|
322834|NCT00272545|Behavioral|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
322835|NCT00272545|Behavioral|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
322836|NCT00275665|Drug|Valganciclovir|
317140|NCT00343369|Drug|thioguanine|
317141|NCT00343369|Drug|vincristine sulfate|
317142|NCT00343369|Radiation|radiation therapy|
317143|NCT00343382|Drug|pilocarpine hydrochloride|Given orally
317144|NCT00343382|Other|placebo|Given orally
317145|NCT00343395|Drug|AVANDAMET|2/500 mg
317146|NCT00343408|Drug|cediranib maleate|
317147|NCT00000470|Procedure|cardiopulmonary bypass|
314959|NCT00345774|Drug|PRX-08066|
314960|NCT00345787|Drug|Placebo|Corresponding placebo is applied for 12weeks
314961|NCT00002989|Drug|busulfan|
314962|NCT00345787|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
314963|NCT00345800|Drug|Sodium Oxybate (Xyrem)|Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral
314964|NCT00345813|Dietary Supplement|soy isoflavones|Given orally
314965|NCT00345813|Dietary Supplement|soy protein isolate|Given orally
314966|NCT00345813|Other|placebo|Given orally
314967|NCT00345826|Drug|dasatinib|
314968|NCT00345839|Drug|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
314969|NCT00345839|Drug|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
314970|NCT00348959|Behavioral|'Open Window' Project|Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.
Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference.
314971|NCT00348972|Drug|Lantus® (insulin glargine)|
314972|NCT00348985|Drug|belinostat|
314973|NCT00003006|Genetic|reverse transcriptase-polymerase chain reaction|
314974|NCT00348985|Drug|bortezomib|
315320|NCT00336336|Drug|Placebo|10 mg c. per os
315321|NCT00336349|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
314252|NCT00364013|Drug|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
314253|NCT00003081|Radiation|radiation therapy|
314254|NCT00364013|Drug|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m^2 IV bolus followed by 600 mg/m^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
314255|NCT00364026|Drug|darusentan|
314256|NCT00364039|Drug|AV650|
314257|NCT00364052|Drug|oral Valganciclovir vs oral Ganciclovir|
314258|NCT00364065|Device|Ferris PainWrap|
314259|NCT00364091|Drug|R89674 0.025% ophthalmic solution|
314260|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
314607|NCT00354991|Drug|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
314608|NCT00355004|Other|counseling intervention|
314609|NCT00355004|Procedure|fecal occult blood test|
314610|NCT00355004|Procedure|screening colonoscopy|
314611|NCT00355017|Procedure|BNP-guided care in addition to multidisciplinary management|
314612|NCT00355030|Drug|somatropin|0.05 mg/kg/day
314613|NCT00355030|Drug|leuprorelin|11.25 mg/3 months
314614|NCT00355043|Drug|Zinc sulphate 20 mg|
314615|NCT00355056|Other|Sham Procedure|Sham Procedure
314616|NCT00355056|Device|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
314617|NCT00003037|Drug|cisplatin|
314618|NCT00355069|Behavioral|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
313519|NCT00002898|Procedure|conventional surgery|
313520|NCT00325715|Drug|AGN 201904|
313521|NCT00325715|Drug|esomeprazole|
313522|NCT00325728|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
313873|NCT00316420|Drug|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
313874|NCT00316420|Drug|Gemcitabine|750 mg/m2 IV Days 1 & 8 q 21 days
313875|NCT00316433|Drug|Irinotecan (CPT-11)|
313876|NCT00002865|Drug|dexamethasone|
313877|NCT00316433|Drug|Oxaliplatin (Eloxatin)|
313878|NCT00316459|Drug|ERB-041|
313879|NCT00316472|Drug|Niacinamide|
313880|NCT00316498|Drug|OGT918|
313881|NCT00316511|Drug|Aroplatin|
313882|NCT00316524|Biological|MVA-BN® (IMVAMUNE)|2 immunizations: 1 x 10E8_TCID
313883|NCT00316524|Biological|IMVAMUNE|1x 10E8_TCID50, 1x Placebo
313884|NCT00316524|Biological|IMVAMUNE|2 x Placebo
313885|NCT00316524|Biological|IMVAMUNE|1x 10E8_TCID50
313886|NCT00316537|Drug|ATG002 (study drug)|
313887|NCT00002865|Drug|doxorubicin hydrochloride|
313888|NCT00316550|Drug|AV608|
313889|NCT00316563|Drug|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
313890|NCT00316563|Other|Placebo|
313891|NCT00316576|Procedure|Blood sampling for PCR|
313892|NCT00316589|Biological|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
313893|NCT00316602|Biological|MVA-BN® (IMVAMUNE)|x
313174|NCT00335595|Drug|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
313175|NCT00335595|Drug|XELOXA-A|XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.
One cycle every 3 weeks
313176|NCT00335621|Drug|Inhaled Tiotropium|
313177|NCT00335647|Drug|fluphenazine hydrochloride|
313178|NCT00335660|Drug|AV608|
313179|NCT00002950|Drug|topotecan hydrochloride|
313180|NCT00335673|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
313181|NCT00335686|Drug|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
313182|NCT00335686|Drug|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
313183|NCT00335699|Drug|Rosuvastatin|
313184|NCT00335712|Drug|ONO-5129|
313185|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
313186|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
313187|NCT00335738|Drug|liposomal vincristine sulfate|Given IV
313188|NCT00335738|Drug|carboplatin|Given IV
313189|NCT00335738|Drug|etoposide|Given IV
313190|NCT00002951|Drug|fluorouracil|
313191|NCT00338494|Drug|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
313192|NCT00338507|Drug|Erdosteine|
313523|NCT00325728|Drug|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
313524|NCT00325741|Procedure|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
312062|NCT00363051|Drug|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
312063|NCT00363051|Drug|Octreotide Depot|
312064|NCT00363077|Biological|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
312065|NCT00363077|Biological|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
312066|NCT00363090|Biological|alemtuzumab|
312067|NCT00363090|Drug|cyclophosphamide|
312068|NCT00363090|Drug|doxorubicin hydrochloride|
312069|NCT00363090|Drug|prednisone|
312439|NCT00354302|Drug|alendronate sodium|
312440|NCT00354302|Drug|calcium gluconate|
312441|NCT00003032|Biological|filgrastim|
312442|NCT00354302|Drug|risedronate sodium|
312443|NCT00354302|Other|laboratory biomarker analysis|
312444|NCT00354302|Procedure|dual x-ray absorptometry|
312445|NCT00354315|Behavioral|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
312446|NCT00354341|Drug|epoetin beta [NeoRecormon]|
312447|NCT00354354|Drug|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
312448|NCT00357110|Drug|Anastrozole|1 mg oral tablet
312449|NCT00357123|Drug|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
312450|NCT00357136|Behavioral|password usage|
312451|NCT00357149|Drug|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
312452|NCT00003048|Drug|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
322982|NCT00291980|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
322983|NCT00292006|Device|Computerized tomography|
322984|NCT00292019|Procedure|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
322985|NCT00292045|Biological|NY-ESO-1 protein/CpG|
322986|NCT00292058|Device|Videoconference equipment (telepsychiatry)|
322987|NCT00002792|Procedure|allogeneic bone marrow transplantation|
322988|NCT00292071|Drug|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
322989|NCT00292084|Drug|Celgosivir|
322990|NCT00292097|Procedure|Early tracheostomy|early conversion - less than or equal to 72 hours
322991|NCT00292097|Procedure|Late tracheostomy|Late conversion (10-14 days)
322992|NCT00292110|Drug|Methadone|100 mg/day orally
322993|NCT00292110|Behavioral|Contingency Management|Incentives given for cocaine abstinence
322994|NCT00292110|Drug|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
322995|NCT00292110|Behavioral|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
322996|NCT00292123|Drug|Methadone|
322997|NCT00292123|Behavioral|Contingency Management|
322998|NCT00002792|Procedure|peripheral blood stem cell transplantation|
322999|NCT00292162|Procedure|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
323000|NCT00292162|Drug|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
323001|NCT00292162|Drug|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
323002|NCT00292162|Drug|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
321888|NCT00268606|Behavioral|cognitive-behavioral therapy|
321889|NCT00268619|Drug|Ramipril|
321890|NCT00268632|Drug|risedronate|
322246|NCT00307853|Other|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
322247|NCT00307866|Procedure|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
322248|NCT00310661|Other|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
322249|NCT00310674|Biological|Meningococcal C Conjugate Vaccine|
322250|NCT00310687|Procedure|BLOOD DRAW|
322251|NCT00310700|Biological|Meningococcal C conjugate vaccine|
322252|NCT00310713|Biological|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
322253|NCT00310726|Other|abrupt weaning at 4 months|abrupt weaning at 4 months
322254|NCT00310726|Other|Continued exclusive breastfeeding|Continued exclusive breastfeeding
322255|NCT00310752|Device|DermaStream(tm) application and Streaming of Saline|
322256|NCT00002839|Drug|cisplatin|
322257|NCT00310765|Drug|Pregabalin|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days
322258|NCT00310765|Drug|Pregabalin|75 mg po BID
322259|NCT00310778|Drug|high sodium diet|high sodium diet
322260|NCT00310778|Drug|low sodium diet|low sodium diet
322261|NCT00310778|Drug|ramipril 10 mg|ramipril 10 mg
322262|NCT00310778|Drug|valsartan 160 mg|valsartan 160 mg
321526|NCT00278408|Biological|filgrastim|
321527|NCT00278408|Biological|rituximab|
321528|NCT00278408|Drug|cyclophosphamide|
321529|NCT00278408|Drug|doxorubicin hydrochloride|
321530|NCT00278408|Drug|prednisone|
321531|NCT00002757|Drug|etoposide|
321532|NCT00278408|Drug|vincristine sulfate|
321533|NCT00278408|Radiation|radiation therapy|
321534|NCT00278421|Biological|rituximab|
321535|NCT00278421|Drug|cyclophosphamide|
321536|NCT00278421|Drug|doxorubicin hydrochloride|
321537|NCT00278421|Drug|prednisone|
321538|NCT00278421|Drug|vincristine sulfate|
321539|NCT00278434|Drug|zoledronic acid|
321540|NCT00278447|Behavioral|Chronic Disease Management for substance abuse|Referral to primary medical care & longitudinal, multidisciplinary care for persons with substance dependence.
321541|NCT00278447|Behavioral|Standard care|Referral to primary medical care for persons with substance dependence.
321891|NCT00268645|Drug|Insulin Glargine|
321892|NCT00268658|Device|SmartStep(tm) biofeedback device|
321893|NCT00268671|Drug|Docetaxel|
321894|NCT00268684|Drug|Erlotinib, Temozolomide|
321895|NCT00268697|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
321896|NCT00268697|Drug|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
321897|NCT00268697|Drug|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
321898|NCT00002718|Drug|cytarabine|
321168|NCT00284778|Drug|Alimta®|
321169|NCT00284778|Drug|Taxotere®|
321170|NCT00288080|Drug|leuprolide acetate|Patients receive luteinizing hormone-releasing hormone as a component of androgen suppression therapy
321171|NCT00288080|Drug|prednisone|Given orally
321172|NCT00288080|Drug|triptorelin|Patients receive luteinizing hormone-releasing hormone as a component of androgen suppression therapy
321173|NCT00288080|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for approximately 8 weeks.
321174|NCT00288093|Radiation|3-Dimensional Conformal Radiation Therapy|
321175|NCT00288093|Drug|Triapine|
321176|NCT00288106|Other|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
321177|NCT00002785|Drug|daunorubicin hydrochloride|
321178|NCT00288132|Behavioral|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted. The intervention goal was to achieve an A1c <7%, with secondary goals of 10% weight loss and increasing exercise to at least 30 minutes a day, 5 days a week. Participants attend 13 sessions, 2 in the first month (1 group, 1 individual), monthly thereafter (9 group, 2 individual). Three group sessions were conducted in-person, all others were conducted via telemedicine. The self-management education team consisted of an RN/CDE and an RD. Sessions were conducted remotely, with a trained facilitator (LPN) at the clinic site. Participants were given a notebook and new material was added at each session. Completion of self-monitoring logs, including blood sugar, diet and physical activity, was assigned daily followed by less frequently based on progress towards intervention goals.
321179|NCT00288132|Behavioral|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
321180|NCT00288145|Behavioral|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
321181|NCT00288158|Drug|Allopurinol vs. Probenecid vs. Placebo|
321182|NCT00288171|Drug|placebo|placebo capsule twice daily for one month
321183|NCT00288171|Drug|Allopurinol and placebo|Allopurinol 200mg twice daily for one month
321184|NCT00288184|Drug|Allopurinol|Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
321185|NCT00288197|Drug|voriconazole|
320426|NCT00307073|Device|Implantable Pulse Generator|
320427|NCT00307086|Drug|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
320428|NCT00307086|Drug|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
320429|NCT00307086|Procedure|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
320430|NCT00307099|Drug|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
320431|NCT00307099|Drug|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
320432|NCT00307125|Drug|Rituximab plus immunosuppression|Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma
Standard immunosuppression is site-specific.
320433|NCT00307125|Drug|Placebo plus immunosuppression|Placebo dosing: Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).
Standard immunosuppression is site-specific.
320434|NCT00002831|Procedure|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
320435|NCT00307138|Drug|hetastarch|
320436|NCT00307151|Drug|Lamivudine|4 mg/kg twice daily
320437|NCT00307151|Drug|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
320795|NCT00297492|Drug|Pre-Quit Nicotine Lozenges|2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.
4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.
Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke.
320796|NCT00297492|Drug|Post-Quit Nicotine Lozenges|2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.
4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.
Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke.
320797|NCT00297505|Drug|citalopram|
320798|NCT00297518|Device|PerioWave|
320799|NCT00297518|Procedure|Scaling and Root Planing|
320800|NCT00002805|Drug|methotrexate|
319677|NCT00270881|Drug|cyclophosphamide|cyclophosphamide 120mg/kg
319678|NCT00270881|Drug|cytarabine|cytarabine 3g/m2x4
319679|NCT00270894|Drug|epirubicin|epirubicin (100 mg/m^2) every 2 weeks for 4 cycles
319680|NCT00270894|Drug|cyclophosphamide|cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles
320071|NCT00264498|Drug|Carboplatin|intravenous injection
320072|NCT00264511|Procedure|Hyperbaric Oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
320073|NCT00264524|Procedure|venipuncture to withdraw patient's blood|
320074|NCT00264537|Drug|Placebo injections|SC injections
320075|NCT00264537|Drug|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
320076|NCT00264537|Drug|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
320077|NCT00264537|Biological|Golimumab 50 mg injections|SC injections
320078|NCT00264537|Biological|Golimumab 100 mg injections|SC injections
320079|NCT00264550|Drug|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
320080|NCT00002704|Drug|therapeutic hydrocortisone|
320081|NCT00264550|Drug|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
320082|NCT00264550|Drug|Methotrexate|Participants will receive methotrexate capsules weekly.
320083|NCT00264550|Drug|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
320084|NCT00264550|Drug|Placebo capsules|Participants will receive placebo capsules weekly
320085|NCT00264563|Behavioral|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
320086|NCT00264563|Behavioral|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
320087|NCT00264576|Biological|Influenza Virus Vaccine|
319307|NCT00280787|Drug|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
319308|NCT00280787|Drug|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
319309|NCT00280787|Drug|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
319310|NCT00280787|Radiation|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
319311|NCT00280800|Device|constant CPAP devices|different CPAP mode
319312|NCT00280800|Device|automatic CPAP devices|different CPAP mode
319313|NCT00002766|Biological|dactinomycin|
319314|NCT00280813|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|
319315|NCT00280826|Drug|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
319316|NCT00280839|Drug|Topiramate|
319317|NCT00280839|Drug|Placebo|
319318|NCT00280865|Drug|Tesaglitazar|
319319|NCT00280865|Drug|Pioglitazone|
319320|NCT00280865|Behavioral|Dietary and Lifestyle Modification Counseling|
319321|NCT00280878|Drug|gemcitabine|
319322|NCT00280878|Drug|vinorelbine|
319323|NCT00280878|Drug|ifosfamide|
319324|NCT00002766|Biological|sargramostim|
319681|NCT00270894|Drug|docetaxel|docetaxel (75 mg/m^2) every 2 weeks for 4 cycles
319682|NCT00270894|Drug|trastuzumab|trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments
319683|NCT00270907|Drug|CT-2103|135 mg/m^2 IV on Day 1.
319684|NCT00270907|Drug|Gemcitabine|1000 mg/m^2 IV on Day 1 and 8.
319685|NCT00000424|Procedure|Tidal lavage vs. sham lavage of the knee|
318592|NCT00300118|Drug|budesonide|9 mg
318593|NCT00300118|Drug|mesalazine|4.5 g
318594|NCT00300131|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
318946|NCT00290381|Procedure|Alcohol breath test|
318947|NCT00290381|Procedure|Smokerlyzer test|
318948|NCT00290381|Procedure|Urine drug test|
318949|NCT00290381|Procedure|Blood test for drug concentrations|
318950|NCT00290381|Procedure|Nasal allergen challenge|
318951|NCT00290381|Procedure|Nasal filter paper placement|
318952|NCT00290381|Procedure|Total nasal symptoms scores|
318953|NCT00290394|Drug|rosiglitazone(drug), blood pressure lowering effect|
318954|NCT00290407|Drug|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
318955|NCT00290407|Dietary Supplement|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
318956|NCT00002789|Drug|cyclophosphamide|
318957|NCT00290420|Drug|Chloroquine profilaxis|Prevention:
Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes
318958|NCT00290433|Drug|Cyclophosphamide|Cycle 1: 300 mg/m^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
318959|NCT00290433|Drug|Mesna|Cycle 1: 600 mg/m^2 by vein Continuous Infusion Over Days 1, 2, and 3.
318960|NCT00293475|Other|Quality-of-Life Assessment|Ancillary studies
318961|NCT00293475|Biological|Rituximab|Given IV
318962|NCT00293475|Drug|Sodium Thiosulfate|Given IV
318963|NCT00293488|Drug|polyamine analogue PG11047|
318964|NCT00293501|Drug|tinzaparin sodium|
318965|NCT00293514|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|
318966|NCT00002798|Drug|cytarabine|Given IV or IT
318221|NCT00309283|Other|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
318222|NCT00309296|Behavioral|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
318223|NCT00309309|Drug|Rosiglitazone|
318224|NCT00309322|Drug|Phentolamine Mesylate (NV-101)|
318225|NCT00309335|Drug|Phentolamine Mesylate (NV-101)|
318226|NCT00002835|Drug|Melphalan|
318227|NCT00309348|Procedure|possible angioplasty|possible angioplasty
318228|NCT00309361|Drug|Phentolamine Mesylate (NV-101)|
318229|NCT00309374|Drug|LPS 2ng/kg intravenous bolus|
318230|NCT00309374|Drug|Simvastatin 80mg; administered daily p.o. over 5 days|
318231|NCT00309374|Drug|Rosuvastatin 40mg; administered daily p.o. over 5 days|
318232|NCT00309387|Dietary Supplement|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
318233|NCT00309387|Other|Placebo|placebo tablets manufactured to mimic Centrum tablets.
318234|NCT00309413|Drug|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
318235|NCT00309413|Drug|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
318236|NCT00311909|Device|Thalamic deep brain stimulation|
318237|NCT00311922|Behavioral|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
318238|NCT00311922|Behavioral|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
318239|NCT00311935|Procedure|method of hernia repair|
318595|NCT00300157|Device|Percutaneous coronary intervention with Taxus stent|
318596|NCT00300196|Biological|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
317507|NCT00331071|Drug|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
317508|NCT00331084|Drug|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
317509|NCT00331084|Drug|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
317510|NCT00331097|Drug|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
317511|NCT00331097|Drug|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
317512|NCT00331097|Drug|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
317513|NCT00331097|Drug|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
317853|NCT00266643|Drug|duloxetine hydrochloride|
317854|NCT00266656|Drug|Somatropin|According to investigator's clinical practice and guided by the approved package insert
317855|NCT00266669|Drug|Topical organogel with nitroglycerin|
317856|NCT00266682|Device|Pacing Lead|
317857|NCT00266695|Drug|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
317858|NCT00266708|Drug|risedronate 35 mg weekly vs placebo|
317859|NCT00266721|Drug|Pancrelipase (Creon) 2 tablets with each meal|
317860|NCT00002714|Drug|vinblastine sulfate|
317861|NCT00266734|Device|RPS Adeno Detector|
317862|NCT00266747|Drug|SR58611A|
317863|NCT00266773|Behavioral|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
317864|NCT00269867|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
317865|NCT00269880|Drug|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
317866|NCT00269880|Drug|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
317148|NCT00002982|Biological|filgrastim|
317149|NCT00343408|Drug|cisplatin|
317150|NCT00343408|Drug|fluorouracil|
317151|NCT00343408|Drug|gemcitabine hydrochloride|
317152|NCT00343408|Drug|leucovorin calcium|
317153|NCT00343408|Drug|oxaliplatin|
317154|NCT00343421|Biological|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
317155|NCT00343421|Biological|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
317156|NCT00343434|Behavioral|behavioral dietary intervention|
317157|NCT00343434|Behavioral|exercise intervention|
317158|NCT00343434|Dietary Supplement|soy isoflavones|
317159|NCT00002982|Drug|carboplatin|
317160|NCT00343434|Dietary Supplement|soy protein isolate|
317161|NCT00343434|Other|counseling intervention|
317162|NCT00343434|Other|educational intervention|
317163|NCT00343434|Procedure|psychosocial assessment and care|
317164|NCT00343434|Procedure|quality-of-life assessment|
317165|NCT00346671|Other|Sham|30 min session with Sham practitioner
317166|NCT00002995|Biological|dactinomycin|
317167|NCT00346671|Other|Reiki|30 min session with Reiki practitioner
317168|NCT00346684|Drug|Rituximab|
317514|NCT00331110|Device|Laterally-Wedged Insole with Ankle Strapping|
317515|NCT00331110|Device|Laterally-Weged Insole|
317516|NCT00002926|Procedure|allogeneic bone marrow transplantation|
317517|NCT00331123|Drug|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
315322|NCT00336362|Drug|Hydroxyurea|Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).
G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis.
315323|NCT00336375|Drug|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
315324|NCT00336388|Device|Paracheck Device|
315325|NCT00002955|Drug|leucovorin calcium|
315326|NCT00336401|Drug|Sevoflurane or Propofol|
315327|NCT00336414|Drug|cyclophosphamide-prednisone-azathioprine|
315328|NCT00336453|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
315329|NCT00336453|Biological|Influenza Vaccination|0.25mL dose for intramuscular injection
315330|NCT00336466|Drug|Human recombinant erythropoietin|
315331|NCT00336479|Drug|Telaprevir|tablet
315332|NCT00336479|Drug|Ribavirin|tablet
315333|NCT00336479|Drug|Pegylated Interferon Alfa 2a|Solution for injection
315334|NCT00336479|Other|Placebo|matching placebo tablet
315335|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
315336|NCT00002955|Drug|trimetrexate glucuronate|
315337|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
315338|NCT00336492|Biological|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
315339|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
315340|NCT00336505|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
314619|NCT00357903|Biological|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
314620|NCT00357916|Drug|PEP005 Topical Gel (0.01% concentration)|
314621|NCT00357929|Procedure|Permissive hypercarbia|
314622|NCT00357942|Drug|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
314623|NCT00357942|Drug|Placebo|Placebo mouthwash
314624|NCT00357942|Drug|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
314625|NCT00357942|Drug|Placebo|Placebo solution for injection every 3 hour for 24 hours
314626|NCT00357955|Behavioral|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
314627|NCT00357955|Behavioral|Interactive Education|interactive lectures with hands-on learning
314628|NCT00003052|Drug|ifosfamide|
314975|NCT00348985|Other|pharmacological study|
314976|NCT00348998|Biological|bevacizumab|
314977|NCT00348998|Drug|bicalutamide|
314978|NCT00348998|Drug|goserelin acetate|
314979|NCT00348998|Radiation|radiation therapy|
314980|NCT00349011|Procedure|Personalized risk assessment|
314981|NCT00349011|Procedure|genetic counseling intervention|
314982|NCT00349024|Drug|polyvinylpyrrolidone-sodium hyaluronate gel|
314983|NCT00349037|Biological|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
314984|NCT00003006|Other|immunohistochemistry staining method|
313894|NCT00319605|Drug|Levetiracetam|
313895|NCT00319618|Drug|Gefitinib|
313896|NCT00319618|Drug|Docetaxel|
313897|NCT00319644|Device|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
313898|NCT00319657|Device|Immune tolerance|Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for at least 6 months. Immunosuppressive drugs are stopped at 6 to 12 months if stable mixed chimerism achieved and there is no rejection of the transplant kidney.
The IDE used in this study is the column used for hematopoietic cell sorting.
314261|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
314262|NCT00364104|Drug|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
314263|NCT00364104|Drug|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
314264|NCT00000481|Behavioral|diet, fat-restricted|
314265|NCT00003082|Biological|monoclonal antibody A27.15|
314266|NCT00364117|Behavioral|Timely Discharge (Remote Presence Technology)|
314267|NCT00002851|Radiation|low-LET electron therapy|
314268|NCT00313300|Drug|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
314269|NCT00313300|Drug|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
314270|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term [ST], 12 months long-term [LT])
314271|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
314272|NCT00313313|Drug|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
314273|NCT00313313|Drug|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
314274|NCT00313313|Drug|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
314275|NCT00313313|Drug|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
313525|NCT00325754|Device|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder|
313526|NCT00325754|Device|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart|
313527|NCT00325767|Drug|nebulized albuterol (2.5 mg/3ml/dose)|
313528|NCT00325767|Drug|nebulized levalbuterol (1.25 mg/3ml/dose)|
313529|NCT00329199|Behavioral|Attachment-Based Family Therapy|
313530|NCT00329212|Drug|San Huang Xie Jin Tang|
313531|NCT00329225|Drug|rosiglitazone|
313532|NCT00329238|Drug|Dabigatran|Dabigatran 150 mg BID (twice daily)
313533|NCT00329238|Drug|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
313534|NCT00329251|Biological|Hepatitis A|
313535|NCT00329251|Biological|Hepatitis B|
313536|NCT00329251|Biological|Influenza|
313537|NCT00329251|Biological|Pneumococcal|
313538|NCT00002916|Radiation|radiation therapy|
313539|NCT00329251|Biological|Tetanus-diphteria|
313540|NCT00329251|Biological|Varicella|
313541|NCT00329251|Biological|Measles-Mumps-Rubella|
313542|NCT00329264|Drug|Quetiapine fumarate|
313543|NCT00329277|Procedure|perimetry|
313544|NCT00329303|Drug|Certolizumab pegol (cimzia®)|
313545|NCT00329316|Drug|Crinone Gel 8%|
313546|NCT00329329|Drug|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
313547|NCT00329342|Behavioral|Occupational ergonomic training|Adequate postural habits in activities of daily living
313899|NCT00319670|Drug|MiraLax|
313900|NCT00319683|Drug|ADH300004|
312453|NCT00357149|Drug|Concomitant cisplatin, 5-FU and radiotherapy|
312454|NCT00357162|Drug|belinostat|Given IV
312455|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
312456|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
312457|NCT00357201|Drug|Food supplement (T1675)|
312458|NCT00357214|Dietary Supplement|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
312459|NCT00357214|Dietary Supplement|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
312460|NCT00357214|Dietary Supplement|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
312461|NCT00357214|Dietary Supplement|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
312462|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
312463|NCT00003049|Drug|fluorouracil|
312816|NCT00348114|Procedure|Transplantation of cultivated limbal epithelium|
312817|NCT00348127|Device|Neurovision|
312818|NCT00348140|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
312819|NCT00348140|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
312820|NCT00348140|Other|Placebo|Placebo
312821|NCT00003001|Drug|leucovorin calcium|
312822|NCT00348140|Other|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months and with no intent to change for the duration of the study).
312823|NCT00348140|Other|Galantamine|Galantamine (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months and with no intent to change for the duration of the study).
312824|NCT00348140|Other|Rivastigmine|Rivastigmine (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months and with no intent to change for the duration of the study).
312825|NCT00348153|Drug|Adalimumab|
317304|NCT00362232|Drug|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
317305|NCT00362232|Drug|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
317306|NCT00362245|Drug|Systemic and Intra-Thecal Amikacin Therapy|
317307|NCT00362258|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
317308|NCT00362271|Drug|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
317309|NCT00362284|Behavioral|Enhanced Counseling and Support|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
317310|NCT00362284|Behavioral|Usual care|Usual care; information and referral support if needed
317311|NCT00362297|Drug|acyclovir|800 mg orally three times daily for 7 weeks
317312|NCT00003073|Drug|liposomal cytarabine|
317313|NCT00362297|Drug|valacyclovir|500 mg orally once daily for 7 weeks
317314|NCT00362310|Drug|indinavir|
317315|NCT00362323|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
317316|NCT00362323|Drug|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
317317|NCT00362336|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
317318|NCT00362336|Biological|CombAct-HIB®|0.5 mL, IM
317319|NCT00362336|Biological|Engerix B® Pediatric|0.5 mL, IM
317320|NCT00362349|Drug|IgNextGen 10%|Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:
Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.
Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days
317321|NCT00365443|Biological|V502|
322263|NCT00310778|Drug|candesartan 8 mg|candesartan 8 mg
322264|NCT00310778|Drug|atenolol 50 mg|atenolol 50 mg
322265|NCT00310791|Drug|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
322266|NCT00310791|Other|Placebo (Sugar Pill)|Placebo (sugar pill)
322267|NCT00002839|Drug|fluorouracil|
322619|NCT00301886|Drug|ibandronate|
322620|NCT00301886|Drug|zoledronate|
322621|NCT00301886|Procedure|quality-of-life assessment|
322622|NCT00301899|Biological|pertuzumab|
322623|NCT00301899|Biological|trastuzumab|
322624|NCT00002816|Drug|ifosfamide|Given IV
322625|NCT00301912|Biological|filgrastim|
322626|NCT00301912|Drug|busulfan|
322627|NCT00301912|Drug|fludarabine phosphate|
322628|NCT00301912|Drug|methotrexate|
322629|NCT00301912|Drug|tacrolimus|
322630|NCT00301912|Procedure|allogeneic bone marrow transplantation|
322631|NCT00301912|Procedure|allogeneic hematopoietic stem cell transplantation|
322632|NCT00301912|Procedure|peripheral blood stem cell transplantation|
322633|NCT00301925|Biological|pegfilgrastim|
322634|NCT00301925|Drug|capecitabine|
322635|NCT00002816|Drug|leucovorin calcium|
322636|NCT00301925|Drug|cyclophosphamide|
322637|NCT00301925|Drug|epirubicin hydrochloride|
322638|NCT00301925|Drug|fluorouracil|
321899|NCT00268710|Drug|docetaxel|
321900|NCT00268723|Drug|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
321901|NCT00268723|Drug|Placebo|Placebo MDI QID
321902|NCT00268749|Drug|glycine|0.8 g/kg/day
321903|NCT00268762|Drug|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
321904|NCT00268775|Behavioral|training and follow-up of pharmacists|
321905|NCT00268775|Behavioral|patient-directed discontinuation letter|
321906|NCT00268788|Drug|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
321907|NCT00268788|Drug|Intravenous immunoglobulin|Individual dose and frequency
321908|NCT00268814|Drug|Diacetylmorphine|Diacetylmorphine (i.v.), daily
321909|NCT00002718|Drug|methylprednisolone|
321910|NCT00268814|Behavioral|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
321911|NCT00268814|Drug|Methadone|Methadone (p.o.), daily
321912|NCT00268814|Behavioral|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
321913|NCT00268827|Drug|Kaletra soft-gel capsules switched to Kaletra tablets|
321914|NCT00271817|Drug|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
321915|NCT00002734|Radiation|lutetium Lu 177 monoclonal antibody CC49|
321916|NCT00271856|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
322268|NCT00310791|Drug|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
322269|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
322270|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
322271|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
321186|NCT00288210|Procedure|Primary angioplasty in acute myocardial infarction|
321187|NCT00288223|Drug|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
321542|NCT00002757|Drug|methotrexate|
321543|NCT00278460|Drug|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
321544|NCT00278460|Drug|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
321545|NCT00278473|Behavioral|Cognitive Behavioral Group Treatment|Cognitive behavioral therapy focuses on changing patterns of thinking and behavior. Each group consists of 6 to 8 members and sessions are led by a psychologist.
321546|NCT00278473|Behavioral|Social Support Problem-Solving Group Treatment|Social support problem-solving focuses on general support, problem solving, and information sharing. Each group consists of 6 to 8 members and sessions are led by a psychologist.
321547|NCT00278486|Biological|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
321548|NCT00278499|Behavioral|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
321549|NCT00278499|Behavioral|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
321550|NCT00278512|Biological|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
321551|NCT00281671|Drug|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
321552|NCT00281684|Drug|SB-705498|
321553|NCT00281697|Drug|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
321554|NCT00281697|Drug|Placebo|
321555|NCT00281697|Drug|Standard chemotherapy|Patients received one of the following four standard chemotherapies for metastatic breast cancer.
Taxane - Paclitaxel (Taxol) 90 mg/m^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m^2 IV every 3 weeks.
Gemcitabine (Gemzar) 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle.
Vinorelbine (Navelbine) 30 mg/m^2 IV every week of each 3-week cycle.
Capecitabine (Xeloda) 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week cycle.
321556|NCT00002766|Drug|prednisone|
321557|NCT00281710|Drug|Methylprednisolone|
321558|NCT00281723|Drug|Pro-Pe adhesive tablet|
320801|NCT00297531|Device|PerioWave|
320802|NCT00297531|Procedure|Scaling and Root Planing|
320803|NCT00297544|Drug|Viagra|
320804|NCT00297570|Drug|Pegylated Interferon and Imatinib|
320805|NCT00297583|Drug|Insulin Glulisine|
320806|NCT00297596|Drug|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
320807|NCT00297596|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.
For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab
320808|NCT00297635|Device|GlucoDYNAMIX™ intervention system|
320809|NCT00297635|Device|GlucoMON™ telemetry device|
320810|NCT00301028|Drug|Carboplatin|AUC 2 weekly for 6 courses.
320811|NCT00301028|Drug|Paclitaxel|135 mg/m^2 weekly for 6 courses.
320812|NCT00301028|Procedure|Conventional Surgery|Following induction in second part of study.
320813|NCT00301028|Radiation|Radiation Therapy|Following induction in second part of study.
320814|NCT00301041|Other|laboratory biomarker analysis|
320815|NCT00301041|Procedure|adjuvant therapy|
320816|NCT00301041|Radiation|radiation therapy|
320817|NCT00301054|Drug|Ferrous sulphate|
320818|NCT00002812|Drug|thioguanine|Given IV
321188|NCT00002785|Drug|dexamethasone|
321189|NCT00288236|Drug|Rimonabant (SR141716)|
321190|NCT00288236|Drug|Placebo|
321191|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
321192|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
320088|NCT00264589|Behavioral|8 weeks individualized training program|no drugs added
320089|NCT00264602|Procedure|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
320090|NCT00264615|Drug|lamotrigine extended-release|
320091|NCT00002704|Drug|thiotepa|
320092|NCT00264628|Drug|GW679769|
320093|NCT00264641|Drug|insulin|
320094|NCT00264654|Drug|BRL29060A|
320438|NCT00307151|Drug|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m^2/dose to max 200 mg twice daily
320439|NCT00307151|Drug|Zidovudine|180 mg/m^2 twice daily
320440|NCT00307164|Drug|NucleomaxX|36 g sachet taken orally three times daily
320441|NCT00307164|Drug|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
320442|NCT00307177|Biological|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
320443|NCT00307177|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
320444|NCT00307203|Drug|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
320445|NCT00002831|Procedure|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
320446|NCT00310011|Drug|paclitaxel|
320447|NCT00310011|Procedure|conventional surgery|
320448|NCT00310024|Drug|bortezomib|Given IV
320449|NCT00310024|Drug|vorinostat|Given orally
320450|NCT00310024|Other|laboratory biomarker analysis|Correlative studies
320451|NCT00310024|Other|pharmacological study|Correlative studies
320452|NCT00002836|Drug|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
319686|NCT00002727|Radiation|radiation therapy|
319687|NCT00270920|Behavioral|Lactation counseling|
319688|NCT00270933|Device|Registry|
319689|NCT00270946|Device|Bilayered Cellular Matrix (OrCel)|
319690|NCT00270959|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
319691|NCT00270959|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
319692|NCT00270959|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
319693|NCT00000427|Drug|Parathyroid hormone|
319694|NCT00002744|Drug|doxorubicin hydrochloride|
319695|NCT00274547|Drug|Tiotropium|
319696|NCT00274560|Drug|Tiotropium|
319697|NCT00274560|Drug|Salmeterol|
319698|NCT00274573|Drug|Tiotropium bromide|
319699|NCT00274586|Drug|Aggrenox® modified release capsules|
319700|NCT00274586|Drug|Aggrenox® modified release capsules matching placebo|
319701|NCT00274599|Drug|Telmisartan|
319702|NCT00274599|Drug|Ramipril|
319703|NCT00274612|Drug|Telmisartan|
319704|NCT00274612|Drug|Ramipril|
319705|NCT00002744|Drug|mercaptopurine|
320095|NCT00264654|Drug|paroxetine hydrochloride hydrate|
320096|NCT00264667|Drug|GW677954|
320097|NCT00264680|Drug|lamotrigine|
318967|NCT00293527|Drug|Interferon Alpha-2b|
318968|NCT00293540|Procedure|oophorectomy|Excision of an ovary
318969|NCT00293540|Drug|Tamoxifen|20 mg orally every day
318970|NCT00293553|Procedure|Electronic Barostat|
318971|NCT00293579|Drug|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
318972|NCT00293592|Drug|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
319325|NCT00283751|Drug|insulin glargine|
319326|NCT00283764|Drug|Xalatan|
319327|NCT00283777|Drug|Chromium Picolinate|
319328|NCT00283790|Drug|zolpidem tartrate|
319329|NCT00283803|Drug|Flutamide|250 mg tid
319330|NCT00283803|Drug|Leuprolide Acetate|7.5 mg q month
319331|NCT00283803|Drug|Exisulind|Exisulind 125 mg
319332|NCT00002772|Procedure|peripheral blood stem cell transplantation|
319333|NCT00283816|Drug|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
319334|NCT00283816|Drug|Oral Contraceptive Pill|Yasmin, drospirenone and ethinyl estradiol 28 tablets
1 tab daily for duration of study
319335|NCT00283816|Behavioral|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise & behavior modification skills on a regular weekly basis over the 24 week study
319336|NCT00283816|Behavioral|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
319337|NCT00283816|Procedure|Oral Glucose Tolerance Test|Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.
Performed twice during study, at baseline and conclusion
319338|NCT00283816|Procedure|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
319339|NCT00283816|Procedure|Abdominal Ultra Sound|transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.
Performed twice during study, at baseline and conclusion
318597|NCT00300196|Drug|Placebo|0.6 mL/kg/hr
318598|NCT00303030|Procedure|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
318599|NCT00303043|Procedure|Mixed venous saturation monitoring|Mixed venous saturation monitoring
318600|NCT00303056|Drug|HOE140 Icatibant|
318601|NCT00303069|Biological|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
318602|NCT00303069|Biological|Comparator: Placebo|Single dose of saline placebo intramuscularly
318603|NCT00303082|Drug|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
318604|NCT00303108|Drug|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
318605|NCT00002819|Drug|mitoxantrone hydrochloride|
318606|NCT00303108|Drug|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
318607|NCT00303108|Drug|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
318608|NCT00303134|Procedure|Islet Cell Transplantation|
318609|NCT00303147|Behavioral|Expressive Writing|
318610|NCT00303160|Drug|vitamin C & E supplements|
318611|NCT00303173|Behavioral|Guided Imagery|
318612|NCT00303199|Drug|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
318613|NCT00303212|Other|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
318614|NCT00303225|Drug|Vaccine: SIGA-246|
318615|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + resveravine|
318616|NCT00002819|Drug|paclitaxel|
318617|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
318618|NCT00303238|Drug|Rose hips extract + resveravine + Aframomum melegueta extract|
317867|NCT00269880|Drug|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
317868|NCT00002720|Procedure|conventional surgery|
317869|NCT00269893|Drug|Abciximab|0.25 mg/kg of body weight of abciximab either bolus or infusion.
317870|NCT00269893|Drug|Placebo|Matching Placebo soulution either bolus or infusion.
317871|NCT00269906|Drug|Abciximab|
317872|NCT00269906|Drug|Placebo|
317873|NCT00269919|Drug|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
317874|NCT00269932|Drug|levofloxacin|
317875|NCT00269945|Drug|epoetin alfa|
317876|NCT00269958|Drug|epoetin alfa|
317877|NCT00269971|Drug|epoetin alfa|
318240|NCT00002844|Procedure|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
318241|NCT00311948|Behavioral|Telephone counseling + interactive website = more abstinence|
318242|NCT00311948|Behavioral|Behavioral: interactive website|
318243|NCT00311961|Drug|Intravenous prednisolone|
318244|NCT00311961|Drug|Oral prednisolone|
318245|NCT00311974|Drug|Dihydralazine|
318246|NCT00311987|Drug|3,5-Diiodothyropropionic acid (DITPA) therapy|
318247|NCT00312000|Drug|capecitabine-irinotecan|st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14
nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1
318248|NCT00312000|Drug|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
318249|NCT00312013|Drug|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
318250|NCT00312026|Drug|efalizumab|
317518|NCT00331123|Drug|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
317519|NCT00000466|Drug|estrogen replacement therapy|
317520|NCT00002944|Drug|thioguanine|Given PO
317521|NCT00334360|Drug|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
317522|NCT00334360|Drug|Control|No drugs given during controlled hypothermia
317523|NCT00334373|Procedure|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
317524|NCT00334386|Drug|Torasemide Prolonged Release (loop diuretic)|
317525|NCT00334386|Drug|Torasemide Immediate Release (loop diuretic)|
317526|NCT00334399|Drug|Miglitol|
317527|NCT00334412|Drug|Ambisome|
317528|NCT00334412|Drug|caspofungin|
317529|NCT00334425|Drug|MENOPUR; GONAL-F|
317530|NCT00334438|Biological|rituximab|250mg/m2, IV, Days 1 and 8
317531|NCT00002944|Drug|vincristine sulfate|Given PO and IV
317532|NCT00334438|Drug|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
317533|NCT00334438|Radiation|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
317534|NCT00334438|Radiation|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
317535|NCT00334464|Drug|Standard of care or genotyping dosing of warfarin dosing|
317536|NCT00334477|Drug|tadalafil|
317537|NCT00334490|Drug|Sildenafil|12.5 mg Sildenafil once with optional second dose
317538|NCT00334490|Drug|Sildenafil|12.5 mg orally once with optional second dose
317539|NCT00334490|Drug|Placebo|Oral Placebo in 5 mls distilled water
317878|NCT00269984|Drug|Epoetin alfa|
315341|NCT00336505|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
315691|NCT00326911|Biological|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
315692|NCT00326911|Biological|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
315693|NCT00326911|Drug|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
315694|NCT00002905|Drug|cyclophosphamide|
315695|NCT00326911|Biological|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
315696|NCT00326924|Biological|Transfusion|PRBC blood transfusions.
315697|NCT00326950|Drug|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
315698|NCT00326963|Drug|Background ARVs|As prescribed
315699|NCT00326963|Drug|PI|As prescribed
315700|NCT00326963|Drug|enfuvirtide [Fuzeon]|90mg sc bid
315701|NCT00330109|Procedure|PET Scanning|Using an Allegro scanner, the patient will be scanned for approximately 20-30 minutes. All emission scan data is processed by a multi-step procedure.
315702|NCT00330109|Procedure|Diffusion Tensor Imaging|Subjects will be scanned with a 3T Philips Intera MRI scanner for approximately 26 minutes for anatomical and DTI imaging. Total DTI acquisition time will be 6:06 minutes with 40 contiguous axial slices for full brain coverage.
315703|NCT00330122|Procedure|fore locked plate|
315704|NCT00330122|Procedure|external radiocarpal fixer|
315705|NCT00330135|Drug|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
315706|NCT00330135|Drug|placebo injection|placebo injection - 1 injection
315707|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d|
315708|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d|
315709|NCT00330148|Drug|nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d|
315710|NCT00002921|Drug|therapeutic hydrocortisone|
315711|NCT00330161|Drug|vorinostat|Given orally
314985|NCT00349050|Device|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
314986|NCT00349050|Procedure|transcranial magnetic stimulation|There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and "sham" TMS (which does not involve real stimulation) for the second treatment. Group B will receive "sham" TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and "sham" TMS.
314987|NCT00349063|Device|soft contact lens|
314988|NCT00349063|Drug|Soft contact lens multipurpose disinfection regimen|
314989|NCT00349076|Drug|5-FU and oxaliplatin|Preoperative radiochemotherapy:
Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35
Adjuvant Chemotherapy:
Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles
314990|NCT00349076|Drug|5-FU|Preoperative radiochemotherapy:
5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d
Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles
314991|NCT00349089|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
314992|NCT00349089|Drug|Cisplatin|PPemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
Comparator:
Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29
314993|NCT00352300|Procedure|Adjuvant Therapy|
314994|NCT00352300|Drug|Carboplatin|Given IV
314995|NCT00352300|Drug|Paclitaxel|Given IV
314996|NCT00003018|Drug|fluorouracil|200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle
315342|NCT00336518|Drug|peginterferon alfa-2a|
315343|NCT00336518|Drug|ribavirin|
315344|NCT00340106|Behavioral|Counseling|
315345|NCT00340184|Drug|paclitaxel, carboplatin|
315346|NCT00340314|Procedure|Circumferential Pulmonary Vein Ablation|
315347|NCT00340314|Drug|Antiarrhythmic Drug Therapy|
315348|NCT00340327|Drug|IMA-638|
315349|NCT00340379|Drug|Ziprasidone|Target dosage 120-160mg/day based on tolerance
314276|NCT00313326|Procedure|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
314277|NCT00313339|Drug|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
314278|NCT00002851|Radiation|low-LET photon therapy|
314279|NCT00313365|Procedure|Surgical Lavage (Arthrotomy)|
314280|NCT00313365|Procedure|Arthrocentesis (Serial needle aspiration)|
314281|NCT00313378|Drug|Hypothetica|
314282|NCT00313391|Drug|Risperdal Consta|
314283|NCT00313404|Biological|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
314284|NCT00313417|Dietary Supplement|Creatine monohydrate|Up to 10 grams
314629|NCT00357955|Behavioral|Role modeling|learning from peers with similar disease and problems
314630|NCT00357955|Procedure|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
314631|NCT00357968|Drug|Prasugrel|Administered orally
314632|NCT00357968|Drug|Clopidogrel|Administered orally
314633|NCT00357968|Drug|Placebo for Prasugrel|Administered orally
314634|NCT00357968|Drug|Placebo for Clopidogrel|Administered orally
314635|NCT00357981|Drug|ORTHO EVRA, the contraceptive patch|
314636|NCT00357994|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
314637|NCT00357994|Drug|Placebo gel|
314638|NCT00357994|Drug|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
314639|NCT00003052|Procedure|conventional surgery|
314640|NCT00357994|Drug|Placebo (PBO) oral capsules|
314641|NCT00357994|Device|CADD-Legacy® 1400 ambulatory infusion pump|
313901|NCT00319696|Drug|bosentan|Initial dose: bosentan 62.5 mg tablets b.i.d. for 4 weeks Maintenance dose: bosentan 125 mg tablets b.i.d.
313902|NCT00319709|Drug|SR58611A|
313903|NCT00319735|Procedure|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
313904|NCT00002875|Drug|mesna|
313905|NCT00319735|Procedure|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
313906|NCT00319735|Procedure|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
313907|NCT00319748|Drug|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
313908|NCT00319761|Drug|Calcitriol|
313909|NCT00319774|Device|Hemocontrol Biofeedback System|
313910|NCT00319787|Drug|Iressa|
313911|NCT00319800|Drug|Gefitinib|
313912|NCT00319800|Drug|Irinotecan|
313913|NCT00319813|Behavioral|Education|
313914|NCT00319826|Other|No intervention|This is an observational study with no intervention
313915|NCT00002875|Drug|vincristine sulfate|
313916|NCT00319839|Drug|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
313917|NCT00319839|Drug|Centuximab|Centuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly:250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
313918|NCT00319852|Biological|DTaP-IPV combined vaccine|0.5 mL, IM
313919|NCT00319852|Biological|DTaP vaccine|0.5 mL, IM
313920|NCT00319865|Drug|Velcade|
313921|NCT00319865|Drug|Thalidomide|
313922|NCT00319865|Drug|Adriamycin|
312826|NCT00348166|Drug|cyclopentolate|
312827|NCT00348179|Procedure|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
312828|NCT00348192|Drug|SB-742457|
312829|NCT00348192|Drug|donepezil|
312830|NCT00348205|Device|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
312831|NCT00348218|Device|NeuroVision|
312832|NCT00003002|Biological|HER-2/neu peptide vaccine|
312833|NCT00003013|Drug|paclitaxel|
312834|NCT00351195|Drug|Oxaliplatin|
312835|NCT00351195|Drug|Capecitabine|
312836|NCT00351208|Device|Medtronic Manufactured Spinal Cord Stimulators|
312837|NCT00351221|Drug|rhIGF-1/rhIGFBP-3|
312838|NCT00351234|Drug|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
312839|NCT00351247|Procedure|Postconditioning|
312840|NCT00351260|Procedure|Coronary Angioplasty|
313193|NCT00338533|Device|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
313194|NCT00338546|Drug|Cocaine hydrochloride|
313195|NCT00338546|Drug|Dexmedetomidine|
313196|NCT00338546|Procedure|Microneurography|
313197|NCT00002970|Drug|methotrexate|Given IT
313198|NCT00338546|Procedure|Laser doppler velocimetry|
313199|NCT00338572|Behavioral|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
317322|NCT00365456|Drug|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
317323|NCT00365456|Drug|Risedronate|Orally once weekly as one 35 mg tablet.
317668|NCT00296244|Drug|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
317669|NCT00296257|Drug|SMP-114|
317670|NCT00296270|Behavioral|Memory for truth|
317671|NCT00299390|Drug|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
317672|NCT00299403|Procedure|Right prefrontal lowfrequency ( 1 hz) rTMS.|Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes
Arms: 2
317673|NCT00299403|Procedure|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
317674|NCT00002809|Procedure|allogeneic bone marrow transplantation|
317675|NCT00299416|Drug|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
317676|NCT00299416|Procedure|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
317677|NCT00299429|Procedure|Stenting and minimally invasive bypass surgery|
317678|NCT00299442|Behavioral|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
317679|NCT00299455|Drug|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
317680|NCT00299455|Drug|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
317681|NCT00299468|Behavioral|Patient Activation Measure Intervention Package|
317682|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
317683|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
317684|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
322639|NCT00301925|Drug|methotrexate|
322640|NCT00304746|Drug|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
322641|NCT00304746|Drug|Placebo|Placebo
322642|NCT00304759|Procedure|7800 cGy/39 fractions in 8 weeks|see above
322643|NCT00304759|Procedure|6000 cGy/20 fractions in 4 weeks|see above
322644|NCT00304772|Drug|Fluconazole|400mg/day
322645|NCT00304772|Drug|Micafungin|150mg/day
322646|NCT00002825|Drug|docetaxel|
322647|NCT00304785|Drug|latanoprost 0.005%|
323003|NCT00292175|Procedure|Narrow Band Imaging|
323004|NCT00292175|Procedure|colonoscopy|
323005|NCT00292188|Drug|pregabalin|pregabalin
323006|NCT00295542|Procedure|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
323007|NCT00295542|Drug|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
323008|NCT00295542|Drug|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
323009|NCT00295542|Drug|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
323010|NCT00295542|Drug|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
323011|NCT00295542|Procedure|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
323012|NCT00295555|Drug|Effects of doxazosin on morning surge in diabetic patients|
323013|NCT00295581|Drug|PpPfs25/ISA51 & ScPvs25/ISA51|
323014|NCT00295594|Drug|tacrolimus|Immunosuppression
323015|NCT00002802|Drug|ifosfamide|
323016|NCT00295607|Drug|Tacrolimus|immunosuppression
323017|NCT00295607|Drug|steroids, monoclonal anti-IL2R antibody|immunosuppression
322272|NCT00310804|Biological|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
322273|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
322274|NCT00262470|Drug|Acetazolamide|250 mg PO x 1
322275|NCT00002701|Drug|cytarabine|
322276|NCT00262470|Drug|Atomoxetine|10-40 mg PO x 1 dose
322277|NCT00262470|Other|NO Drug|No intervention - just monitoring
322278|NCT00262470|Drug|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
322279|NCT00262470|Drug|Entacapone|Entacapone 200-400 mg PO x 1 dose
322280|NCT00262470|Drug|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
322281|NCT00262470|Drug|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
322282|NCT00262470|Drug|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
322283|NCT00262470|Drug|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
322284|NCT00262470|Drug|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
322285|NCT00262470|Dietary Supplement|Melatonin|melatonin 3 mg PO x 1 dose
322286|NCT00002701|Drug|etoposide|
322287|NCT00262470|Drug|Midodrine|midodrine 2.5-10 mg PO x 1 dose
322288|NCT00262470|Drug|Modafinil|modafinil 100-200 mg PO x 1 dose
322289|NCT00262470|Drug|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
322290|NCT00262470|Radiation|Placebo|lactose tablet x 1 pill
322291|NCT00262470|Drug|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
322648|NCT00304785|Drug|Fotil|
322649|NCT00304785|Drug|placebo|
322650|NCT00304798|Behavioral|Hospital admission|
322651|NCT00304811|Drug|Vancomycin|
321559|NCT00281736|Drug|HPPH|Given IV
321560|NCT00281749|Procedure|TELEPHONE CALL|
321561|NCT00281762|Drug|NSAID|
321562|NCT00281788|Drug|capecitabine|
321563|NCT00281788|Drug|carboplatin|
321917|NCT00271856|Behavioral|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
321918|NCT00271869|Procedure|Extracorporeal photoimmunotherapy|
321919|NCT00271908|Behavioral|Community Mobilization|ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or "population of focus."
321920|NCT00271921|Behavioral|Calorie controlled diet|
321921|NCT00271934|Biological|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
321922|NCT00271947|Biological|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
321923|NCT00271960|Behavioral|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
321924|NCT00271960|Behavioral|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
321925|NCT00271960|Behavioral|Usual care|Participants will receive usual prenatal care.
321926|NCT00002734|Radiation|yttrium Y 90 monoclonal antibody CC49|
321927|NCT00271973|Drug|Oxycodone|
321928|NCT00271999|Behavioral|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
321929|NCT00272012|Drug|Insulin glulisine|
321930|NCT00272025|Drug|Escitalopram|10mg to 20mg tablet daily for 6 weeks
321931|NCT00272025|Drug|placebo|
321932|NCT00272038|Drug|Tarceva|150mg QD
321193|NCT00291031|Behavioral|Imagery Rehearsal Therapy (IRT)|Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.
IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments.
321194|NCT00291044|Other|testing for HSV 1 and 2 IgG type specific antibosy|
321195|NCT00291057|Drug|MALG|30 minute application
321196|NCT00291070|Drug|L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.
321197|NCT00291109|Drug|letrozole 2.5 mg|
321198|NCT00291122|Drug|celecoxib 400 mg BID|
321199|NCT00291135|Drug|letrozole|Letrozole 2.5 mg daily
321200|NCT00291148|Drug|paroxetine|
321201|NCT00291148|Drug|pregabalin|
321202|NCT00002791|Drug|mesna|
321203|NCT00291161|Behavioral|Care Coordination in Primary Care|Care coordination within the primary care setting is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:
Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient.
321204|NCT00291161|Behavioral|Care Coordination in Alz. Association|Care coordination with the Alzheimer's Association is facilitated by the Alzheimer's Association Care Coordinator (AA CC) that is located within the local chapter but is a part of the study. The role of the AA CC includes conducting follow up assessments with the subject and caregiver that leads to: Facilitating referral and linkage of the veteran/family caregiver to all relevant chapter services and supports; Linking veterans/families to further assessment or attention from community care providers; for example: help with respite services, legal referrals, etc.; Ensuring education is provided about emotional needs, behavior problems, etc. issues; and Following up with patient/caregiver on self-care activities he/she committed to do.
321205|NCT00291187|Drug|20 mg VEC-162|20 mg VEC-162
321206|NCT00291187|Drug|50 mg VEC-162|50 mg VEC-162
321564|NCT00281788|Drug|paclitaxel|
321565|NCT00281788|Radiation|radiation therapy|
321566|NCT00281801|Procedure|psychosocial assessment and care|psychosocial assessment and care
320453|NCT00310037|Drug|bortezomib|Given IV
320454|NCT00310050|Drug|pemetrexed disodium|500 milligrams per meter squared day 1,15,29 for 14 days for three cycles
320455|NCT00310063|Procedure|acupressure therapy|Acupressure wristband
320456|NCT00310063|Procedure|sham intervention|Sham wristband
320457|NCT00310076|Drug|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
320458|NCT00310076|Procedure|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
320459|NCT00310089|Biological|filgrastim|
320460|NCT00310089|Biological|pegfilgrastim|
320461|NCT00310089|Drug|cediranib maleate|
320819|NCT00301054|Drug|Sulphadoxine-Pyrimethamine|
320820|NCT00301067|Dietary Supplement|calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
320821|NCT00301067|Drug|temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
320822|NCT00301080|Drug|D-cycloserine|
320823|NCT00301080|Other|Placebo|
320824|NCT00301093|Biological|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
320825|NCT00301093|Drug|imatinib mesylate|Participants will continue on current dose
320826|NCT00301106|Biological|adenovirus-mediated human interleukin-12|
320827|NCT00301145|Behavioral|smoking cessation intervention|
320828|NCT00301145|Drug|varenicline|
320829|NCT00002812|Drug|vincristine sulfate|Given IV
320830|NCT00301145|Other|counseling intervention|
320831|NCT00301145|Other|internet-based intervention|
320832|NCT00301158|Behavioral|exercise intervention|
320098|NCT00267748|Drug|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
320099|NCT00267774|Device|Fractional flow reserve|
320100|NCT00002715|Drug|vincristine sulfate|
320101|NCT00267774|Procedure|Angio-guided PCI|
320102|NCT00267787|Other|genetic analysis|standard of care
320103|NCT00267813|Drug|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
320104|NCT00267826|Drug|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
320105|NCT00267839|Behavioral|physical exercise, wellness|
320106|NCT00267852|Other|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
320107|NCT00267865|Drug|Methotrexate|6000 mg/m2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patient s urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
320108|NCT00267865|Drug|Rituximab|375 mg/m2 IV day 1 of each cycle prior to administration of high-dose methotrexate
320109|NCT00267865|Drug|Leucovorin|Leucovorin calcium doses will be administered orally or by short IV infusion over 15 minutes
320110|NCT00267917|Device|Berodual Respimat|
320111|NCT00002716|Drug|dexamethasone|
320112|NCT00267917|Device|Berodual HFA-MDI|
320113|NCT00267930|Drug|Vernakalant (oral)|
320114|NCT00267930|Drug|Placebo comparator|
320115|NCT00267943|Drug|telmisartan 80 mg + hydrochlorothiazide 25 mg|
320116|NCT00267956|Drug|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
320117|NCT00267956|Drug|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
320118|NCT00267969|Drug|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
319340|NCT00283816|Procedure|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
319341|NCT00283816|Drug|placebo|placebo capsules, two capsules BID
319342|NCT00283829|Drug|docetaxel|chemotherapy
319343|NCT00002772|Radiation|radiation therapy|
319344|NCT00283829|Drug|IL2|immunotherapy
319345|NCT00283842|Drug|DVS SR|
319346|NCT00283842|Drug|Placebo|
319706|NCT00274625|Device|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
319707|NCT00274625|Procedure|Control|Incision is closed without the placement of a graft material (standard of care control)
319708|NCT00274638|Drug|Telmisartan & Hydrochlorothiazide|
319709|NCT00274638|Drug|Losartan & Hydrochlorothiazide|
319710|NCT00274638|Procedure|ABPM|
319711|NCT00274651|Drug|belinostat|
319712|NCT00274664|Device|6 hours occlusion by patching|
319713|NCT00274664|Device|12 hours occlusion by patching|
319714|NCT00274677|Drug|Placebo|Experimental treatment arm
319715|NCT00274677|Drug|lamotrigine|Experimental treatment
319716|NCT00002744|Drug|methotrexate|
319717|NCT00274690|Drug|GW679769|
319718|NCT00274703|Drug|mepolizumab|
319719|NCT00274716|Drug|MK0736|
319720|NCT00274716|Drug|MK0916|
319721|NCT00274716|Drug|Placebo|
319722|NCT00274729|Behavioral|Mono Unsaturated Fatty Acids in Obesity|
318973|NCT00293605|Procedure|Total Hip Replacement|Implantation of one of 3 stem designs
318974|NCT00293618|Device|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
318975|NCT00293618|Other|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
318976|NCT00293618|Other|Feedback|Feedback about the physician's personal performance on prevention of PONV
318977|NCT00002798|Drug|idarubicin|Given IV
318978|NCT00293631|Drug|Lornoxicam 8 mg|
318979|NCT00293631|Drug|Lornoxicam 16 mg|
318980|NCT00293631|Drug|Ketorolac 30 mg|
318981|NCT00293631|Drug|Placebo|
318982|NCT00293644|Drug|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
318983|NCT00293657|Drug|Lornoxicam 8 mg|
318984|NCT00293657|Drug|Lornoxicam 16 mg|
318985|NCT00293657|Drug|Placebo|
318986|NCT00293670|Drug|Goserelin (Zoladex)|
318987|NCT00293683|Device|Insorb absorbable skin staple|
318988|NCT00002798|Drug|dexamethasone|Given PO
318989|NCT00293696|Drug|bicalutamide (Casodex), goserelin (Zoladex)|
318990|NCT00293709|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
318991|NCT00296621|Drug|L-Glutamine|L-Glutamine
318992|NCT00296621|Drug|placebo|placebo
318993|NCT00296634|Drug|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
318251|NCT00002844|Procedure|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
318252|NCT00312039|Drug|elvucitabine|Elvucitabine 10 mg QD for 14days
318253|NCT00312039|Drug|Lamivudine|Lamivudine 300 mg QD for 14 days
318254|NCT00312052|Drug|E5555|50 mg (one 50 mg active and two 100 mg placebo) tablets taken once daily for 24 weeks.
318255|NCT00312052|Drug|E5555|100 mg (one 50 mg placebo, one 100 mg active and one 100 mg placebo) tablets taken once daily for 24 weeks.
318256|NCT00312052|Drug|E5555|200 mg (one 50 mg placebo and two 100 mg active) tablets taken once daily for 24 weeks.
318257|NCT00312052|Drug|Placebo|Placebo (one 50 mg placebo and two 100 mg placebo) tablets taken once daily for 24 weeks.
318258|NCT00312065|Device|Application of reflective heat shield to thermistor probe|
318259|NCT00312078|Dietary Supplement|Yogurt Supplementation|
318260|NCT00312091|Drug|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
318261|NCT00312091|Drug|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
318619|NCT00303251|Drug|TKI258|
318620|NCT00303264|Drug|dexloxiglumide|
318621|NCT00303264|Drug|Nexium (esomeprazole)|
318622|NCT00303277|Drug|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
318623|NCT00303277|Drug|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
318624|NCT00303290|Drug|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
318625|NCT00303290|Drug|Ara-C (cytosine arabinoside)|10 mg under the skin daily
318626|NCT00306189|Drug|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
318627|NCT00306189|Drug|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
318628|NCT00306189|Drug|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
318629|NCT00306189|Drug|Placebo|Placebo SC every 6 months
317879|NCT00002721|Drug|doxorubicin hydrochloride|
317880|NCT00269997|Drug|epoetin alfa|
317881|NCT00270010|Drug|epoetin alfa|
317882|NCT00270023|Drug|epoetin alfa|
317883|NCT00270036|Drug|epoetin alfa|
317884|NCT00270049|Drug|epoetin alfa|
317885|NCT00270062|Drug|epoetin alfa|
317886|NCT00270075|Drug|epoetin alfa|
317887|NCT00270088|Drug|epoetin alfa|
317888|NCT00270101|Drug|epoetin alfa|
317889|NCT00270114|Drug|epoetin alfa|
317890|NCT00000423|Behavioral|Social support and education group|
317891|NCT00002721|Drug|estramustine phosphate sodium|
317892|NCT00270127|Drug|Epoetin alfa|
317893|NCT00270140|Drug|epoetin alfa|
317894|NCT00270153|Drug|enalapril|5mg enalapril vs placebo pill po daily for 6 months
317895|NCT00270166|Drug|epoetin alfa|
317896|NCT00270179|Drug|epoetin alfa|
317897|NCT00002740|Procedure|conventional surgery|
317898|NCT00273520|Drug|Telithromycin|
317899|NCT00273533|Drug|Ramipril|
317900|NCT00273546|Drug|XRP6976 (Docetaxel/Taxotere)|
317901|NCT00273559|Drug|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
317902|NCT00273572|Other|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
315712|NCT00330161|Other|laboratory biomarker analysis|Correlative studies
315713|NCT00330174|Drug|Acamprosate|2 333mg tablets three times daily
315714|NCT00330187|Drug|Bupropion SR|
315715|NCT00330187|Behavioral|Contingency Management|
316089|NCT00320723|Drug|bupropion, transdermal nicotine patch|
316090|NCT00320736|Drug|galantamine|
316091|NCT00320749|Drug|Capecitabine|Will be give on days 8-21
316092|NCT00320749|Drug|Docetaxel|Will be given on days 1 and 8,
316093|NCT00320749|Drug|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
316094|NCT00320762|Device|OculusGen Biodegradable Collagen Matrix Implant|
316095|NCT00002881|Drug|flutamide|
316096|NCT00320775|Drug|VEGF Trap|Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.
Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.
Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.
After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap.
316097|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
316098|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
316099|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
316100|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
316101|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
316102|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
316103|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
315350|NCT00340379|Drug|Sertraline|Target dosage 150-200mg/day based on tolerance.
315351|NCT00340379|Drug|Haloperidol|Target dosage 6-8mg/day based on tolerance.
315352|NCT00340431|Drug|MSP1(42)-FVO & MSP1(42)-3D7|
315353|NCT00002974|Procedure|hyperthermia treatment|
315354|NCT00340470|Behavioral|Driver Education|
315355|NCT00340483|Behavioral|Smoking cessation|
315356|NCT00340574|Drug|AMA1-C1/Alhydrogel + CpG 7909|
315357|NCT00340613|Drug|glargine insulin|
315358|NCT00340678|Drug|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
315359|NCT00340678|Drug|Placebo|Treatment with placebo corresponding to each dose of losartan.
315360|NCT00340691|Drug|Doxycycline|
315361|NCT00340704|Drug|tamsulosin hydrochloride|oral
315362|NCT00340834|Drug|Fingolimod 1.25 mg|Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.
Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
315363|NCT00340834|Drug|Fingolimod 0.5 mg|Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.
Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
315364|NCT00000470|Procedure|cardiac surgical procedures|
315365|NCT00002975|Drug|aminolevulinic acid|
315716|NCT00330200|Drug|ISIS 113715|
315717|NCT00330213|Behavioral|red wine and cognac consumption|
315718|NCT00330239|Drug|Paroxetine CR|
315719|NCT00330252|Drug|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
315720|NCT00330252|Drug|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
314642|NCT00357994|Device|PEG tube|percutaneous endoscopic gastrostomy tube
314643|NCT00357994|Device|J-tube|jejunal tube
314644|NCT00358007|Device|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
314645|NCT00358020|Drug|THALIDOMIDE|
314646|NCT00358020|Drug|BORTEZOMIB|
314647|NCT00361049|Procedure|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
314648|NCT00361049|Procedure|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
314649|NCT00361062|Behavioral|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
314650|NCT00361075|Drug|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
314651|NCT00003065|Drug|topotecan hydrochloride|
314652|NCT00361088|Drug|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
314997|NCT00352300|Biological|Pegfilgrastim|Given IV
314998|NCT00352313|Drug|ATN-161|Given IV
314999|NCT00352313|Drug|carboplatin|Given IV
315000|NCT00352326|Device|reprogramming assisted communication device interface|
315001|NCT00352339|Drug|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
315002|NCT00352339|Drug|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
315003|NCT00352339|Drug|Abilify|Start with abilify and keep it through the end of study
315004|NCT00352352|Procedure|Tongue Acupuncture (Procedure)|
315005|NCT00352365|Drug|lenalidomide|Given orally
315006|NCT00352378|Drug|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:
Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
314285|NCT00313417|Other|Placebo|Placebo will be given in the same way and appearance as the active treatment
314286|NCT00313443|Procedure|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
314287|NCT00313456|Drug|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
314288|NCT00313482|Drug|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
314289|NCT00002852|Drug|paclitaxel|Given IV
314290|NCT00313482|Drug|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
314291|NCT00313482|Drug|Prednisone|5 mg orally BID on Day 1 continuously
314292|NCT00313508|Biological|Autologous Dendritic Cells (DC)|Given intranodally
314293|NCT00313508|Drug|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
314294|NCT00313508|Biological|Autologous Lymphocyte Infusion (ALI)|Infusion
314295|NCT00316602|Biological|IMVAMUNE|x
314296|NCT00316615|Biological|influenza vaccine|
314297|NCT00316628|Biological|influenza vaccine|
314298|NCT00316641|Drug|Lipid-lowing Tea|
314299|NCT00002865|Drug|etoposide|
314300|NCT00316654|Biological|Meningococcal C conjugate vaccine|
314301|NCT00316680|Biological|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
314302|NCT00316693|Biological|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
314303|NCT00316693|Biological|Aimmugen™|Intramuscular injection, 3 doses
314304|NCT00316706|Biological|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
314305|NCT00316706|Biological|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
314306|NCT00316719|Drug|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
313200|NCT00338572|Behavioral|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
313201|NCT00338585|Drug|alfimeprase|
313202|NCT00338598|Drug|Glycine|Glycine, 0.8 gr per kg given in two daily doses
313203|NCT00338611|Behavioral|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
313204|NCT00338611|Behavioral|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
313205|NCT00338611|Behavioral|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
313206|NCT00338611|Behavioral|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
313207|NCT00338624|Drug|oxybutynin chloride extended release|
313208|NCT00000469|Drug|lovastatin|
313209|NCT00002970|Drug|cytarabine|Given IT
313210|NCT00338637|Device|APOS shoe kit|
313211|NCT00338650|Drug|adalimumab|
313212|NCT00338663|Device|knee immobilization splint|
313213|NCT00338689|Dietary Supplement|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
313548|NCT00329355|Drug|sumatriptan succinate/naproxen sodium|
313549|NCT00002917|Drug|paclitaxel|
313550|NCT00329368|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
313551|NCT00329368|Biological|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
317685|NCT00002809|Radiation|radiation therapy|
317686|NCT00299494|Drug|Rituximab|rituximab 375 mg/m^2 via IV infusion on Day 1
317687|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
317688|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
318050|NCT00289978|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
318051|NCT00289978|Drug|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
318052|NCT00289991|Drug|Itraconazole|Prophylaxis
318053|NCT00289991|Drug|Vfend - voriconazole|Prophylaxis
318054|NCT00290004|Drug|motexafin gadolinium|
318055|NCT00290017|Drug|talabostat|
318056|NCT00002788|Drug|cyclophosphamide|
318057|NCT00290017|Drug|pemetrexed|
318058|NCT00290030|Drug|Alfuzosin|
318059|NCT00290043|Drug|Insulin glulisine|
318060|NCT00290056|Drug|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
318061|NCT00290069|Drug|Tacrolimus|
318062|NCT00290069|Drug|Rapamycin|
318063|NCT00290082|Drug|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
318064|NCT00290082|Biological|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
318065|NCT00290082|Other|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
318066|NCT00290082|Drug|Loxapine|Loxapine 1 mL / 10 kg
318067|NCT00002788|Drug|dexamethasone|
323018|NCT00295620|Drug|Anastrozole|1mg tablet daily
323019|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
323020|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
323021|NCT00295633|Drug|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
323022|NCT00295633|Drug|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
323023|NCT00295633|Drug|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
323024|NCT00295633|Drug|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
323025|NCT00295646|Drug|tamoxifen|20 mg/d
323026|NCT00002802|Drug|melphalan|
323027|NCT00295646|Drug|anastrozole|1 mg/d
323028|NCT00295646|Drug|zoledronic acid|4 mg q6m
317324|NCT00365469|Dietary Supplement|Probiotic|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
317325|NCT00365469|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
317326|NCT00003086|Drug|fluorouracil|
317327|NCT00365495|Procedure|Physical training (aerobic training)|
317328|NCT00365508|Drug|nicotine lozenge|nicotine lozenge
317329|NCT00365508|Drug|nicotine patch|transdermal nicotine patch
317330|NCT00365521|Procedure|Photodynamic Therapy|
317331|NCT00365534|Procedure|MEI|
317332|NCT00365547|Biological|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
317333|NCT00365547|Drug|topotecan hydrochloride|Topotecan 4 mg/m^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
317334|NCT00365560|Drug|tiotropium|
317335|NCT00365560|Drug|placebo|
322652|NCT00304811|Drug|Vancomycin plus Gentamicin|
322653|NCT00304811|Drug|Vancomycin plus Rifampin|
322654|NCT00304811|Drug|Vancomycin plus Gentamicin plus Rifampin|
322655|NCT00304837|Genetic|pVGI.1 (VEGF-2)|
322656|NCT00304850|Behavioral|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
322657|NCT00002826|Drug|paclitaxel|
322658|NCT00304850|Drug|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
322659|NCT00304863|Drug|Lactobacillus GG|
322660|NCT00304915|Behavioral|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
322661|NCT00304954|Drug|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
322662|NCT00304954|Drug|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
322663|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
322664|NCT00304954|Drug|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
322665|NCT00304980|Drug|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
322666|NCT00304993|Drug|fenofibrate|
322667|NCT00304993|Drug|niacin|
322668|NCT00002833|Drug|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
322669|NCT00307879|Drug|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
323029|NCT00295672|Drug|Vinorelbine|
323030|NCT00295685|Drug|Antacids|
321933|NCT00272051|Drug|SR57746A|
321934|NCT00272064|Drug|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal < 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
321935|NCT00272064|Drug|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) <= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
321936|NCT00272064|Drug|Metformin|1000 mg b.i.d, since the qualification phase, oral
321937|NCT00002735|Drug|Induction chemotherapy|Cisplatin and 5-Fluorouracil
321938|NCT00272077|Drug|Insuline glargine|
321939|NCT00272090|Drug|Insulin glargine|
322292|NCT00262470|Drug|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
322293|NCT00262470|Drug|Sertraline|sertraline 25-50 mg PO x 1 dose
322294|NCT00262470|Procedure|IV Saline|1 liter IV over 2 hours
322295|NCT00262470|Other|Drinking Water|16 fluid ounces
322296|NCT00262470|Device|Breathing Device|Breathing through a dead space tube
322297|NCT00002701|Drug|idarubicin|
322298|NCT00262470|Drug|memantine|memantine 5-20 mg PO x 1 dose
322299|NCT00262470|Device|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
322300|NCT00262483|Drug|VX-950|
322301|NCT00262483|Drug|ribavirin|
322302|NCT00262483|Drug|peginterferon alfa-2a|
322303|NCT00262496|Drug|Botox|
322304|NCT00262509|Device|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
322305|NCT00265382|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
321567|NCT00002766|Drug|vincristine sulfate|
321568|NCT00281801|Procedure|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
321569|NCT00281814|Procedure|psychosocial assessment and care|psychosocial assessment and care
321570|NCT00281827|Drug|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
321571|NCT00281827|Drug|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
321572|NCT00281827|Drug|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
321573|NCT00281827|Procedure|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
321574|NCT00281840|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
321575|NCT00281840|Drug|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
321576|NCT00281840|Procedure|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
321577|NCT00281840|Radiation|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
321578|NCT00002766|Radiation|radiation therapy|
321579|NCT00002775|Drug|estramustine phosphate sodium|
321580|NCT00284791|Drug|Lamotrigine (drug)|
321581|NCT00284791|Drug|Fluoxetine (drug)|
321582|NCT00284791|Drug|sertraline (drug)|
321583|NCT00284804|Drug|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
321584|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
321585|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
321586|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
321587|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
320833|NCT00301158|Other|counseling intervention|
320834|NCT00301158|Other|educational intervention|
320835|NCT00301158|Procedure|complementary or alternative medicine procedure|
320836|NCT00301171|Drug|Inhaled Fluticasone|
320837|NCT00301184|Biological|pGA2/JS7 DNA|DNA Vaccine
320838|NCT00301184|Biological|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
320839|NCT00301197|Behavioral|Behavioral Skills Maintenance|
320840|NCT00002812|Radiation|radiation therapy|
320841|NCT00301197|Behavioral|Social Facilitation Maintenance|
320842|NCT00002822|Radiation|radiation therapy|
320843|NCT00303836|Biological|gp100 antigen|Given SC
320844|NCT00303836|Biological|MART-1 antigen|Given SC
320845|NCT00303836|Biological|incomplete Freund's adjuvant|Given SC
321207|NCT00291187|Drug|100 mg VEC-162|100 mg VEC-162
321208|NCT00291187|Drug|Placebo|Placebo
321209|NCT00291213|Drug|levetiracetam|
321210|NCT00291213|Drug|placebo|
321211|NCT00291226|Drug|Glycine|Glycine 0.4 g/kg bid
321212|NCT00291226|Drug|Placebo|Placebo
321213|NCT00002791|Procedure|conventional surgery|
321214|NCT00291239|Behavioral|partial sleep deprivation|
321215|NCT00291304|Procedure|MRI|pre-surgery
321216|NCT00294593|Drug|folinic acid|
321217|NCT00002800|Drug|etoposide|
321218|NCT00294606|Drug|Comparison of Effects of Phenylephrine and Norepinephrine|
320462|NCT00310089|Drug|cyclophosphamide|
320463|NCT00002836|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
320464|NCT00310089|Drug|docetaxel|
320465|NCT00310089|Drug|doxorubicin hydrochloride|
320466|NCT00310089|Other|laboratory biomarker analysis|
320467|NCT00310089|Procedure|conventional surgery|
320468|NCT00310089|Procedure|neoadjuvant therapy|
320469|NCT00310115|Behavioral|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
320470|NCT00310115|Behavioral|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
320471|NCT00310115|Behavioral|Counseling Intervention|2 in-person counseling sessions
320472|NCT00310128|Drug|cisplatin|
320473|NCT00310128|Drug|cytarabine|
320474|NCT00002837|Biological|Filgrastim (G-CSF)|
320475|NCT00310128|Drug|etoposide|
320476|NCT00310128|Drug|methylprednisolone|
320477|NCT00310128|Drug|rituximab|
320478|NCT00310128|Drug|yttrium Y 90 ibritumomab tiuxetan|
320479|NCT00261612|Procedure|treatment protocol|
320480|NCT00261625|Drug|alendronate|
320481|NCT00261664|Device|telehomecare|
320482|NCT00002700|Drug|prednisolone|
320483|NCT00261677|Drug|epoetin alfa|
320484|NCT00261690|Behavioral|Virtual Reality Distraction|Using virtual reality distraction during a procedure
320485|NCT00261703|Drug|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
319723|NCT00274742|Biological|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m^2/24hours by continuous intravenous infusion
319724|NCT00274755|Drug|chemotherapy|
319725|NCT00274755|Procedure|conventional surgery|
319726|NCT00274755|Procedure|magnetic resonance imaging|
319727|NCT00002744|Drug|pegaspargase|
319728|NCT00277446|Drug|Soy isoflavones|
319729|NCT00277472|Drug|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
319730|NCT00002756|Drug|daunorubicin hydrochloride|
319731|NCT00277472|Drug|HCTZ|25 mg taken once daily orally
319732|NCT00277498|Drug|Xalacom|
319733|NCT00277498|Drug|Xalatan|
320119|NCT00267969|Drug|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
320120|NCT00268125|Device|Acupression's bracelet|
320121|NCT00268125|Behavioral|Hygiene and dietetic advices|
320122|NCT00002716|Drug|floxuridine|
320123|NCT00268138|Drug|elmex gel|elmex gel once a week
320124|NCT00268151|Drug|Oxaliplatin|
320125|NCT00268151|Drug|Capecitabine|
320126|NCT00270959|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
320127|NCT00270972|Device|Bilayered Cellular Matrix (OrCel)|
320128|NCT00270985|Behavioral|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
320129|NCT00270985|Behavioral|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
320130|NCT00002730|Drug|buthionine sulfoximine|
320131|NCT00270998|Behavioral|Pelvic muscle training and exercises|Pelvic muscle training and exercises
318994|NCT00296634|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
318995|NCT00296647|Drug|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
318996|NCT00296647|Drug|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
319347|NCT00283855|Behavioral|Online self-management program|Customized web application offers secure, encrypted communication allowing private and community-wide exchange of information. Components include discussion board, chat room, messaging, online delivery of Stress-Management sessions (online reading material and "homework assignments"). Completion of SM sessions followed by telephone call from study staff to address participant questions, reinforce cognitive-behavioral principles, provide ongoing encouragement and direction to engage in the community and complete homework assignments.
319348|NCT00283920|Drug|[(11)C] PBR28|
319349|NCT00283933|Drug|AT1001 (migalastat hydrochloride)|
319350|NCT00283946|Drug|Zolpidem MR|Oral
319351|NCT00283946|Drug|Zolpidem|Oral
319352|NCT00287469|Biological|Hepatitis E vaccine, recombinant (Sar 56 kDa)|
319353|NCT00287482|Drug|Essiac|
319354|NCT00287495|Drug|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
319355|NCT00287508|Device|Carotid artery stenting with filter (interventional)|
319356|NCT00287521|Drug|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
319357|NCT00287521|Drug|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
319358|NCT00287521|Other|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
319359|NCT00287521|Drug|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
319360|NCT00287534|Drug|Anastrozole|oral
319361|NCT00287534|Drug|Tamoxifen|oral
319362|NCT00002784|Drug|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
319363|NCT00287547|Drug|CTLA4Ig / Abatacept|
318630|NCT00306202|Drug|Dasatinib|Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. Once daily (QD), as long as clinical benefit was maintained.
Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT).
318631|NCT00002829|Procedure|Bone Marrow Transplantation|Infusion on Day 0.
318632|NCT00306202|Drug|Dasatinib|Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. QD, as long as clinical benefit was maintained.
Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.
318633|NCT00306202|Drug|Dasatinib|Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose level 2 of 80 mg/m^2, Escalated/Dose level 3 of 100 mg/m^2, and Escalated/Dose level 4 of 120 mg/m^2. QD, as long as clinical benefit was maintained.
Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.
318634|NCT00306215|Drug|CCX282-B|CCX282-B or placebo capsules
318997|NCT00296647|Drug|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
318998|NCT00296647|Drug|bupropion|dosage according to prescription directions: 12 weeks
318999|NCT00296647|Drug|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
319000|NCT00296647|Drug|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
319001|NCT00002804|Drug|vincristine sulfate|
319002|NCT00296673|Device|Rehabilitation device|
319003|NCT00296686|Drug|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
319004|NCT00296686|Drug|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
317903|NCT00273572|Other|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
317904|NCT00273585|Device|Personally-tailored educational software program|
318262|NCT00002844|Radiation|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
318263|NCT00263588|Drug|lapatinib|tyrosine kinase inhibitor
318264|NCT00002704|Biological|filgrastim|
318265|NCT00263601|Biological|Allergovit 6-grasses|Subcutaneous injections
318266|NCT00263601|Other|Placebo|Subcutaneous injections
318267|NCT00263627|Biological|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
318268|NCT00263627|Other|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
318269|NCT00263640|Biological|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
318270|NCT00263640|Drug|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
318271|NCT00263653|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
318272|NCT00263666|Biological|Rotarix|Oral vaccination
318273|NCT00263666|Biological|Placebo|Oral administration
318274|NCT00263666|Biological|TritanrixTM-HB+Hib|Concomitant routine vaccination, IM administration
318275|NCT00002704|Drug|asparaginase|
318276|NCT00263666|Biological|SabinPolioTM vaccine|Oral administration, concomitant routine vaccination
318277|NCT00263679|Biological|Prophylaxis: Diphtheria, tetanus and pertussis|
318278|NCT00263692|Biological|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
318279|NCT00263705|Drug|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
316104|NCT00320814|Drug|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
316105|NCT00320827|Drug|CS-1008 (humanized anti-DR5 antibody)|
316106|NCT00002881|Drug|goserelin acetate|
316107|NCT00320853|Drug|Vitamin D|
316108|NCT00320866|Device|syringe driver|
316109|NCT00320879|Drug|irbesartan|
316458|NCT00365326|Procedure|catheter-based intracoronary injection|
316459|NCT00003086|Drug|cisplatin|
316460|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
316461|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
316462|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
316463|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
316464|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
316465|NCT00314249|Drug|Placebo|Placebo, oral administration, twice daily for 12 weeks
316466|NCT00314249|Drug|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID [twice a day])
316467|NCT00314262|Drug|Erlotinib & Celecoxib|Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.
Celecoxib given 400 mg orally BID continuously for 6 months.
316468|NCT00314275|Device|Coronary Artery Stenting|Drug eluting stent
316469|NCT00002854|Procedure|peripheral blood stem cell transplantation|
316470|NCT00314275|Device|Endeavor|Drug eluting stent
316471|NCT00314288|Drug|Sarizotan HCl|
316472|NCT00314301|Device|loaded sit-to-stand training|
316473|NCT00314314|Drug|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
316474|NCT00314314|Drug|Diluent|Intranasal spray; 8 weeks
315721|NCT00000465|Procedure|angioplasty, transluminal, percutaneous coronary|
315722|NCT00002922|Drug|paclitaxel|
315723|NCT00330265|Device|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
315724|NCT00330265|Other|Conventional Wound Therapy|Normal Saline Dressings
315725|NCT00330278|Drug|Cefazolin|
315726|NCT00330291|Drug|Xyrem|
315727|NCT00330304|Drug|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
315728|NCT00330304|Drug|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
315729|NCT00330304|Drug|isoniazid|Isoniazid, 10mg/kg daily for study period
315730|NCT00333502|Drug|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
315731|NCT00333515|Drug|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
315732|NCT00000140|Drug|Sulfur Hexafluoride|
315733|NCT00000466|Drug|progesterone|
315734|NCT00002941|Procedure|peripheral blood stem cell transplantation|
315735|NCT00333515|Drug|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
315736|NCT00333528|Drug|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
315737|NCT00333528|Drug|Placebo: Normal saline|Intramuscular administration
315738|NCT00333541|Behavioral|Using internet/E-mail for follow-up|follow-up via email link to survey
316110|NCT00320892|Drug|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
316111|NCT00323713|Behavioral|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
316112|NCT00323713|Behavioral|Low protein diet|0.6 g of protein per kilo of body weight per day
315007|NCT00003018|Drug|leucovorin calcium|30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle
315008|NCT00352391|Other|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
315009|NCT00352404|Device|Endomicroscope|
315010|NCT00352417|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
315011|NCT00352417|Drug|Placebo|oral dosing, 1 time daily for 12 weeks
315012|NCT00352430|Drug|Nitric Oxide/INP Pulse Delivery|
315013|NCT00352430|Drug|Nitric Oxide/INO Pulse Delivery|
315014|NCT00352443|Drug|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
315015|NCT00352443|Drug|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
315016|NCT00352469|Drug|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
315017|NCT00352482|Drug|Sildenafil (50 mg)|
315018|NCT00000142|Drug|Cidofovir|Three groups:
the deferral group, treatment deferred until retinitis progressed
Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.
High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
315366|NCT00340834|Drug|Interferon β-1a 30 µg|Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.
Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
315367|NCT00340938|Procedure|Blood testing|
315368|NCT00341055|Drug|Epoetin alfa|
315369|NCT00341224|Behavioral|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
315370|NCT00341250|Drug|AMA1-C1/Alhydrogel Malaria Vaccine|
315371|NCT00341328|Biological|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
315372|NCT00345852|Procedure|Fetoscopic Selective Laser Photocoagulation|
314307|NCT00316719|Drug|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
314308|NCT00316732|Procedure|IPSS Questionnaire|
314309|NCT00316732|Procedure|EQ-5D Questionnaire|
314653|NCT00361088|Drug|R11577|Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.
Phase II: Maximum Tolerated Dose (MTD)
314654|NCT00361101|Drug|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
314655|NCT00361114|Drug|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
314656|NCT00361114|Drug|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
314657|NCT00361114|Drug|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
314658|NCT00361127|Drug|isotonic saline infusion|
314659|NCT00361140|Drug|Busulfan|Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.
Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.
Subsequent daily doses will be adjusted to achieve target AUCs.
314660|NCT00361140|Drug|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
314661|NCT00361153|Drug|Colesevelam hydrochloride|Welchol tablet 625mg
314662|NCT00003066|Drug|docetaxel|
314663|NCT00361153|Drug|placebo|placebo
314664|NCT00361166|Drug|ACP-103|
314665|NCT00361192|Procedure|biopsy of temporal artery|
314666|NCT00361205|Device|Electronic Monitoring cap|
314667|NCT00361218|Drug|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
313552|NCT00329368|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
313553|NCT00329368|Drug|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
313554|NCT00329368|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
313555|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
313556|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
313557|NCT00329394|Drug|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
313558|NCT00332553|Drug|Raloxifene|
313559|NCT00332553|Drug|medroxyprogesterone acetate|
313560|NCT00332553|Drug|estrogen|
313561|NCT00332553|Drug|17 beta estradiol|
313562|NCT00332566|Biological|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
313563|NCT00332566|Biological|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
313564|NCT00332579|Drug|Naltrexone|daily
313565|NCT00002935|Drug|porfimer sodium|
313566|NCT00332579|Drug|Placebo|daily
313567|NCT00332605|Drug|Naltrexone plus N-Acetyl Cysteine|daily
313568|NCT00332605|Drug|Placebo|daily
313569|NCT00332618|Device|OXYGENATED GLYCEROL TRIESTERS|
313570|NCT00332631|Drug|N-acetylcysteine|
313571|NCT00332631|Drug|Placebo|
318068|NCT00293202|Drug|Etanercept|Hemodialysis patients having a serum albumin of less than or equal to 3.8 g/dl and a CRP greater than or equal to 0.8 mg/dL will receive either etanercept at a dose of 25 mg by subcutaneous injection twice a week or a placebo for a period of 48 weeks. The outcome is an increase in serum albumin and pre-albumin in the treated group.
318069|NCT00293202|Drug|Saline|Saline will be injected subcutaneously twice a week
318070|NCT00293215|Drug|111-Indium-CMD-193|
318071|NCT00293215|Drug|CMD-193|
318072|NCT00293228|Drug|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
318073|NCT00293228|Drug|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
318421|NCT00283387|Drug|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
318422|NCT00283400|Drug|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
318423|NCT00283413|Device|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
318424|NCT00283413|Device|Bare metal stent|Any commercially available bare metal stent for coronary indication
318425|NCT00283426|Drug|Soluble beta-1,3/1,6-glucan|
318426|NCT00283439|Biological|AMG 531|Planned Cohorts:
100 mcg,
300 mcg,
700 mcg,
1000 mcg;
Optional Cohorts:
cohort expansion,
schedule change,
new dose
318427|NCT00002772|Drug|doxorubicin hydrochloride|
318428|NCT00283452|Behavioral|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
318429|NCT00283465|Drug|Epoetin alfa|
318430|NCT00283478|Drug|Iscar Quercus|
318431|NCT00283478|Drug|Gemcitabine|
318432|NCT00283491|Behavioral|Active Lactobacillus plantarum 299v|10^11 cfu/meal in 2 meals on 2 consecutive days
318433|NCT00283491|Dietary Supplement|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
318434|NCT00283504|Drug|ANTI-IGE THERAPY (XOLAIR)|
318435|NCT00283517|Drug|antipsychotics|as prescribed
318436|NCT00283530|Procedure|Tumor biopsy|
317336|NCT00365586|Drug|Ketoprofen Topical Patch , 20%|
317337|NCT00003086|Drug|ifosfamide|
317338|NCT00365599|Drug|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
317339|NCT00365599|Drug|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
317340|NCT00365612|Drug|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
317341|NCT00365638|Drug|simvastatin|
317342|NCT00365651|Procedure|Youth Soccer|
317343|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
317344|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
317689|NCT00299507|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
317690|NCT00299520|Drug|intravenous iclaprim or intravenous linezolid|
317691|NCT00299533|Drug|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
317692|NCT00299546|Drug|Placebo|SC injections
317693|NCT00299546|Biological|Golimumab 50 mg|SC injections
317694|NCT00299546|Biological|Golimumab 100 mg|SC injections
317695|NCT00299559|Drug|smart textiles containing menthol, camphor, cineol|application to skin
317696|NCT00002810|Biological|filgrastim|
317697|NCT00299572|Drug|alendronate (Fosamax)|
317698|NCT00302575|Procedure|Integrated parole and outpatient addiction treatment|
317699|NCT00302601|Procedure|Scintigraphic interpretation|
317700|NCT00302627|Drug|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
317701|NCT00302627|Drug|vitamin D|baseline, 6,12 months
323031|NCT00295698|Drug|Diethylcarbamazine|
323032|NCT00295711|Drug|Bicifadine|
323033|NCT00295724|Drug|Bicifadine|
323034|NCT00295737|Procedure|bronchoscopy, allergen/endotoxin instillation|
323035|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
323036|NCT00298441|Drug|chondroitin sulfate-iron colloid|
323037|NCT00298454|Drug|Furosemide|
323038|NCT00298467|Drug|MDX-060|
323039|NCT00298493|Procedure|Sedation management strategy|
323040|NCT00298506|Drug|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
323041|NCT00298532|Procedure|Advanced Life Support|
323042|NCT00298545|Drug|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
323043|NCT00002806|Drug|vincristine sulfate|
323044|NCT00298545|Drug|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
323045|NCT00298558|Behavioral|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
323046|NCT00298571|Drug|.5% bupivacaine with epinephrine|
323047|NCT00298584|Procedure|Percutaneous Suprapubic Aspiration|
323048|NCT00298584|Procedure|Urethral Catheterization|
323049|NCT00298597|Drug|granulocyte - colony stimulating factor (G-CSF)|
323050|NCT00298597|Drug|erythropoetin (EPO)|
323051|NCT00298610|Drug|Artesunate|
323052|NCT00298623|Drug|XP13512 (GSK1838262)|
323053|NCT00298623|Other|placebo|
323054|NCT00002806|Radiation|low-LET photon therapy|
322306|NCT00265395|Drug|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks
322307|NCT00265395|Drug|Combination of pegylated interferon alfa-2b and ribavirin|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks
322308|NCT00265408|Drug|aspirin|
322309|NCT00265408|Drug|warfarin|
322310|NCT00265421|Procedure|Suture technique for perineal repair after delivery|
322311|NCT00265434|Drug|Pulmozyme|
322312|NCT00002707|Drug|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
322313|NCT00265447|Behavioral|self-directed exercise|
322314|NCT00265447|Behavioral|3 months of aerobic conditioning|self-directed exercise
322315|NCT00265460|Drug|Oliwer Twist smokeless tobacco (tobacco)|
322670|NCT00307879|Procedure|collection of mobilized peripheral blood stem cells|
322671|NCT00307879|Procedure|Intracoronary infusion of mobilized cells|
322672|NCT00307892|Drug|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
322673|NCT00307892|Drug|Placebo|placebo remedy
322674|NCT00307905|Drug|Traumeel S|homeopathic remedy
322675|NCT00307905|Drug|Placebo remedy|identical size, shape and taste of treatment medication
322676|NCT00307918|Device|acupuncture|
322677|NCT00307931|Biological|Certolizumab pegol|certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.
Treatment duration: 12 weeks.
322678|NCT00307944|Drug|Pantoprazole|
322679|NCT00002833|Drug|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
322680|NCT00307957|Device|Pillar Palatal Implants|
322681|NCT00307970|Drug|HFA FP MDI|
321940|NCT00272103|Drug|Itopride (drug)|
321941|NCT00275132|Drug|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
321942|NCT00275132|Drug|Matched placebo|Matched placebo PO daily
321943|NCT00275145|Behavioral|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
321944|NCT00275145|Behavioral|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
321945|NCT00275145|Behavioral|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
321946|NCT00275145|Behavioral|Continued Sedentary lifestyle|No changes
321947|NCT00275158|Drug|L-Arginine Supplementation|
321948|NCT00275171|Drug|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
321949|NCT00275171|Drug|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
321950|NCT00275171|Other|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
321951|NCT00002747|Radiation|low-LET cobalt-60 gamma ray therapy|
321952|NCT00275184|Drug|Senna|
321953|NCT00275184|Drug|Citramag powder|
321954|NCT00275184|Drug|Metoclopramide|
321955|NCT00275197|Drug|Sertraline and Elzasonan Combination|
321956|NCT00275197|Drug|Sertraline|
321957|NCT00275197|Drug|Placebo|
321958|NCT00275210|Drug|Oxaliplatin (SR96669)|
321959|NCT00275236|Drug|Rotigotine|
321960|NCT00275249|Drug|levorphanol|
321961|NCT00275262|Drug|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
321962|NCT00002747|Radiation|low-LET photon therapy|
321219|NCT00294619|Drug|growth hormone|subcutaneous injection, once-weekly
321220|NCT00294632|Drug|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
321221|NCT00294632|Drug|Rituximab|375 mg/m^2 By Vein Weekly for 4 Weeks
321222|NCT00294645|Other|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
321223|NCT00294645|Other|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
321224|NCT00294658|Procedure|thymectomy|The thymectomy will be performed as soon as possible after randomization.
321225|NCT00294658|Drug|prednisone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
321226|NCT00294671|Drug|diflunisal|given twice daily for 24 months
321227|NCT00294671|Other|placebo|an inactive substance given twice daily for 24 months
321228|NCT00002800|Drug|idarubicin|
321229|NCT00294684|Drug|Corticosteroids|Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.
Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop
321588|NCT00284817|Drug|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
321589|NCT00284830|Device|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
321590|NCT00002777|Drug|exemestane|
321591|NCT00284856|Drug|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
321592|NCT00284856|Drug|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
321593|NCT00284856|Drug|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
321594|NCT00284856|Drug|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
320486|NCT00261703|Drug|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
320846|NCT00303836|Biological|filgrastim|Given SC
320847|NCT00303836|Biological|aldesleukin|Given IV
320848|NCT00303849|Drug|Carboplatin|Given IA
320849|NCT00303849|Drug|Etoposide Phosphate|Given IV
320850|NCT00303849|Other|Laboratory Biomarker Analysis|Correlative studies
320851|NCT00303849|Drug|Mannitol|Given IA
320852|NCT00303849|Drug|Melphalan|Given IA
320853|NCT00002823|Drug|cisplatin|
320854|NCT00303849|Other|Quality-of-Life Assessment|Ancillary studies
320855|NCT00303849|Drug|Sodium Thiosulfate|Given IV
320856|NCT00303862|Drug|cediranib maleate|Given orally
320857|NCT00303862|Other|laboratory biomarker analysis|Correlative studies
320858|NCT00303875|Behavioral|behavioral dietary and exercise intervention|
320859|NCT00303888|Drug|docetaxel|Given IV
320860|NCT00303888|Drug|idronoxil|Given orally
320861|NCT00303888|Other|placebo|Given orally
320862|NCT00303901|Procedure|cryosurgery|
320863|NCT00303901|Procedure|positron emission tomography|
320864|NCT00002823|Drug|etoposide|
320865|NCT00303914|Procedure|assessment of therapy complications|
320866|NCT00303914|Procedure|cognitive assessment|
320867|NCT00303914|Procedure|psychosocial assessment and care|
320868|NCT00303927|Drug|capecitabine|
320869|NCT00303940|Drug|carboplatin|
320132|NCT00270998|Device|Intravaginal incontinence pessary|Intravaginal incontinence pessary
320133|NCT00270998|Device|Both pessary and pelvic muscle exercises|Intravaginal incontinence pessary and pelvic muscle training and exercises
320134|NCT00271011|Drug|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
320135|NCT00271011|Drug|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
320136|NCT00271011|Drug|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2.
320137|NCT00271024|Drug|Naltrexone (drug)|50 mg q.d. for 13 weeks
320138|NCT00271024|Drug|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
320139|NCT00271037|Procedure|Colpocleisis prolapse repair surgery|
320140|NCT00271037|Procedure|sling or other to treat or prevent stress incontinence|
320141|NCT00002730|Drug|melphalan|
320142|NCT00271050|Other|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
320487|NCT00261703|Other|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
320488|NCT00261716|Behavioral|Supported employment with motivational interviewing.|supported employment with 4 sessions of motivational interviewing prior to each job search
320489|NCT00261716|Behavioral|Supported employment with illness education.|supportive employment with 4 sessions of illness education
320490|NCT00261729|Drug|Paroxetine|paroxetine 20 mg
320491|NCT00261729|Drug|Prazosin|Prazosin
320492|NCT00261729|Drug|placebo|placebo capsules
320493|NCT00002700|Drug|prednisone|
320494|NCT00261742|Drug|Penicillin versus cefuroxim per os|
319364|NCT00287560|Drug|propofol (drug)|
319365|NCT00287573|Device|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
319366|NCT00287573|Procedure|Brachytherapy (beta source)|Brachytherapy (beta source)
319367|NCT00287586|Drug|Testosterone Gel (Androgel)|The subjects will receive either 7.5 g testosterone gel to achieve a nominal delivery of 75 mg testosterone daily or placebo gel. Dose adjustments will be made by an unblinded observer.
This will be implemented as follows: Serum testosterone level measured on treatment day 15 will measured in a sample sent separately to the laboratory such that the result will be reported directly to unblinded physician, who will then communicate the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.
319368|NCT00287612|Procedure|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
319734|NCT00277498|Drug|Timolol|
319735|NCT00277511|Drug|Levofloxacin|
319736|NCT00277537|Drug|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
319737|NCT00277537|Drug|placebo|BD for 12 weeks
319738|NCT00277550|Drug|Tegaserod and Placebo|
319739|NCT00277563|Device|reduction of pain scores by magnetic energy|
319740|NCT00277576|Biological|ppdpSC18 administered by PMED|
319741|NCT00002756|Drug|etoposide|
319742|NCT00277589|Drug|Levothyroxin-Na|1 tablet 30 minutes before breakfast
319743|NCT00277589|Drug|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
319744|NCT00277589|Drug|Iodide|1 tablet 30 minutes before breakfast
319745|NCT00277589|Drug|Placebo|1 tablet 30 minutes before breakfast
319746|NCT00277602|Drug|Riluzole|
319747|NCT00277641|Drug|Lamotrigine|25 mg or 100 mg
319748|NCT00277641|Drug|placebo|identical tablets to study drug
319749|NCT00277654|Drug|Risperidone|risperidone 0.5mg up to 4mg daily vs. placebo
319750|NCT00277667|Drug|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
319005|NCT00296686|Drug|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
319006|NCT00296699|Drug|Duloxetine|Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.
* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating.
319007|NCT00296712|Drug|escitalopram + bupropion|same dosing as for monotherapy arms
319008|NCT00296725|Drug|Fluoxetine|wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day *All increases only if tolerated.
319009|NCT00296725|Drug|Imipramine|wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. *All increases only if tolerated.
319010|NCT00296738|Device|SPECT/CT|GE INFINIA HAWKEYE
319011|NCT00296751|Procedure|ECG recording|
319012|NCT00002804|Procedure|conventional surgery|
319013|NCT00296751|Procedure|Epidural catheter insertion|
319014|NCT00296751|Drug|Intravenous meperidine injection|
319015|NCT00296751|Drug|Epidural Bupivacaine and fentanyl injection|
319016|NCT00296777|Drug|Escitalopram|8 weeks: up to 40 mg/day
319017|NCT00300222|Drug|NGX-4010|
319369|NCT00287612|Procedure|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
319370|NCT00287625|Procedure|Pulmonary rehabilitation|Pulmonary rehabilitation
319371|NCT00287638|Device|CPAP|Continuous positive pressure device with a time clock
319372|NCT00287638|Device|placebo|no CPAP
319373|NCT00002784|Drug|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
319374|NCT00287651|Procedure|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
319375|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
318280|NCT00263705|Drug|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
318281|NCT00263718|Drug|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
318282|NCT00263731|Other|13-C-glucose|10 grams of 13-C-glucose intravenously, as a 30-minute "piggyback" infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer.
318283|NCT00263744|Biological|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
318635|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
318636|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
318637|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
318638|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
318639|NCT00306241|Biological|HPV-16/18 L1 VLP AS04|
318640|NCT00306254|Drug|PD 0348292|
318641|NCT00306254|Drug|Enoxaparin|
318642|NCT00002829|Radiation|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
318643|NCT00306267|Drug|epoetin alfa|
318644|NCT00306280|Device|Phototherapy|
318645|NCT00309439|Procedure|ALA-rich diet|
318646|NCT00000139|Behavioral|Stress|
318647|NCT00000456|Behavioral|cognitive behavior therapy|
318648|NCT00002835|Drug|Methotrexate|
318649|NCT00309452|Behavioral|Cognitive Behavioral Group Therapy|once per week
318650|NCT00309452|Behavioral|Cognitive remediation|as needed
318651|NCT00309452|Drug|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
318652|NCT00309452|Behavioral|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
316475|NCT00314327|Drug|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
316476|NCT00314340|Behavioral|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
316477|NCT00314340|Drug|ER Morphine|
316478|NCT00314340|Drug|hydrocodone plus acetaminophen|
316479|NCT00314340|Drug|placebo|
316480|NCT00002855|Drug|Bicalutamide|
316829|NCT00358956|Drug|ZD6474 (vandetanib)|100 mg once daily oral tablet
316830|NCT00358969|Drug|guanfacine (Tenex)|
316831|NCT00358982|Drug|MGCD0103|MGCD0103 administered orally three times per wek
316832|NCT00358995|Behavioral|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
316833|NCT00358995|Behavioral|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
316834|NCT00359021|Drug|TMC125|200 mg twice daily until commercially available
316835|NCT00359047|Behavioral|Control Group|No specific intervention other than the interest raised by the questionnaires.
316836|NCT00359047|Behavioral|Written documentation on osteoporosis group|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
316113|NCT00323739|Drug|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
316114|NCT00323739|Drug|RAD001|RAD001 10 mg by mouth daily
316115|NCT00002890|Biological|lintuzumab|
316116|NCT00323752|Procedure|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
316117|NCT00323778|Drug|Hyalgan|
316118|NCT00323791|Drug|gemcitabine hydrochloride|
316119|NCT00323791|Drug|imatinib mesylate|
316120|NCT00323791|Genetic|gene expression analysis|
316121|NCT00323791|Genetic|protein expression analysis|
316122|NCT00323791|Other|immunohistochemistry staining method|
316123|NCT00323791|Other|laboratory biomarker analysis|
316124|NCT00323804|Biological|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
316125|NCT00323804|Drug|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
316126|NCT00002892|Biological|recombinant interferon alfa|
316127|NCT00323804|Drug|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
316128|NCT00323817|Drug|Z-338|
316129|NCT00323830|Drug|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
316130|NCT00323843|Drug|Isoproterenol|
316131|NCT00323856|Drug|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
316132|NCT00323869|Drug|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
316133|NCT00323869|Drug|Gemcitabine|Nucleoside analog
316134|NCT00323869|Drug|Carboplatin|Alkylating agent
315373|NCT00345865|Drug|carmustine|Day -6, 300 mg/m^2 over 2 hour
315374|NCT00002989|Drug|cyclophosphamide|
315375|NCT00345865|Drug|cyclophosphamide|NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.
HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m^2 over 2 hours daily x 4 days.
Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing.
315376|NCT00345865|Drug|etoposide|NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.
HL without radiation: 150 mg/m^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4.
315377|NCT00345865|Procedure|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
315378|NCT00345865|Radiation|irradiation therapy|Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.
> 1000 cGy to whole lung, kidney, or abdominal bath.
> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.
> 3600 cGy to whole brain.
315379|NCT00345865|Biological|G-CSF|Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.
Continue G-CSF until absolute neutrophil count (ANC) > 1500/μl x 3 consecutive days.
If ANC falls <1000/μL, restart G-CSF.
315380|NCT00345865|Drug|Cytarabine|100 mg/m^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
315381|NCT00345878|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
315382|NCT00345878|Biological|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
315383|NCT00345891|Behavioral|Coping-focused counseling telephone calls|
315384|NCT00345904|Biological|Fluarix|
315385|NCT00000471|Behavioral|exercise|
315739|NCT00333554|Drug|1. DHA Treatment Group: Experimental|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
315740|NCT00333554|Drug|2. Control Group|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
315741|NCT00333567|Drug|Lumiracoxib|
315742|NCT00333593|Device|Large pore dialyser|
315743|NCT00333593|Device|Standard dialyser|
315744|NCT00333606|Procedure|Acupuncture|
314668|NCT00361231|Drug|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
314669|NCT00364130|Device|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
314670|NCT00364130|Device|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
314671|NCT00364143|Drug|IHL-305 (irinotecan liposome injection)|
314672|NCT00364156|Drug|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
315019|NCT00355082|Drug|lamotrigine, 300 mg/day|300 mg/day
315020|NCT00355082|Drug|lamotrigine, 250 mg/day|250 mg/day
315021|NCT00355095|Drug|Erythropoietin|intravenous daily 3.3 *10^4 Units, duration 3 days
315022|NCT00355108|Drug|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
315023|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
315024|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
315025|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
315026|NCT00355134|Drug|Fingolimod|Fingolimod capsules for oral administration
315027|NCT00355134|Drug|Placebo|Matching placebo capsules for oral administration.
315028|NCT00003037|Drug|docetaxel|
315029|NCT00355147|Behavioral|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
315030|NCT00355147|Behavioral|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
315031|NCT00355173|Device|Lubo cervical collar|
315032|NCT00355186|Procedure|intracoronary bone marrow cells infusion|intracoronary bone marrow cell infusion via a OTW balloon; "Stop-flow-technique" as previously described
315033|NCT00355199|Drug|Rituximab-HDS|Rituximab-HDS
313923|NCT00322777|Behavioral|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
313924|NCT00322803|Drug|ELB139|
313925|NCT00322842|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
313926|NCT00322868|Drug|pioglitazone|
313927|NCT00322881|Drug|Paclitaxel|
313928|NCT00322881|Drug|Carboplatin|
313929|NCT00002887|Drug|vinblastine sulfate|
313930|NCT00322907|Drug|Cotrifazid vs mefloquine or quinine+SP|
313931|NCT00322920|Drug|Topotecan|
313932|NCT00322920|Drug|Cisplatin|
313933|NCT00322933|Procedure|renal replacement therapy (intermittent or continuous)|
313934|NCT00322946|Biological|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
313935|NCT00322946|Biological|Placebo|Placebo for rDEN4delta30-4995
313936|NCT00322972|Drug|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
313937|NCT00322985|Drug|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
313938|NCT00323011|Drug|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
313939|NCT00323024|Drug|NX1011|
318437|NCT00283543|Drug|Gliadel Wafer|
318438|NCT00000435|Drug|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
318439|NCT00002772|Drug|paclitaxel|
318440|NCT00283543|Drug|Temozolomide|
318441|NCT00283543|Procedure|Limited field radiation|
318442|NCT00283556|Drug|Irinotecan (Camptosar, CPT-11)|Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.
Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.
318443|NCT00283569|Other|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
318444|NCT00283582|Drug|rhTPO|
318804|NCT00274118|Drug|telmisartan|
318805|NCT00274118|Drug|enalapril|
318806|NCT00274131|Drug|Pramipexole 0.125 mg tablets|
318807|NCT00002744|Drug|cyclophosphamide|
318808|NCT00274131|Drug|Pramipexole 0.5 mg tablets|
318809|NCT00274144|Drug|telmisartan 40 mg|
318810|NCT00274144|Drug|placebo 40 mg|
318811|NCT00274157|Behavioral|Behavior|
318812|NCT00274157|Behavioral|diet control, smoking cessation, exercize|
318813|NCT00274170|Drug|Octreotide|
318814|NCT00274196|Procedure|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
318815|NCT00274196|Procedure|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
318816|NCT00274209|Procedure|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
318817|NCT00274235|Drug|sulfadoxine-pyrimethamine / mefloquine|
318818|NCT00002744|Drug|cytarabine|
317702|NCT00302627|Drug|calcium supplement|baseline, 6,12 months
317703|NCT00302640|Drug|Alinia (nitazoxanide)|
317704|NCT00302653|Drug|Rasburicase|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
317705|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
317706|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
317707|NCT00302692|Drug|Esmolol|
317708|NCT00002817|Biological|vaccinia-GM-CSF vaccine|
317709|NCT00302692|Drug|Metoprolol|
317710|NCT00302705|Drug|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
317711|NCT00302705|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
317712|NCT00302705|Procedure|Missing one dose|Patients skip the dose the second day of monitoring
317713|NCT00302718|Behavioral|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
318074|NCT00293241|Device|Managed Ventricular Pacing programmed ON/OFF|Device programming
318075|NCT00293254|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
318076|NCT00002798|Drug|fludarabine phosphate|
318077|NCT00293254|Drug|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
318078|NCT00293267|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
318079|NCT00293267|Drug|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
318080|NCT00293280|Drug|lomustine|
318081|NCT00293293|Other|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
323055|NCT00298636|Drug|adenosine|
317345|NCT00365690|Behavioral|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
317346|NCT00314704|Drug|dopamine versus norepinephrine|
317347|NCT00314717|Behavioral|Control diet|
317348|NCT00314717|Behavioral|Low GI diet|
317349|NCT00314730|Device|handheld Personal Digital Assistant (PDA)|
317350|NCT00002855|Drug|Ketoconazole|
317351|NCT00314743|Drug|Ondansetron|
317352|NCT00314743|Drug|Dexamethasone|
317353|NCT00314743|Drug|Aprepitant|
317354|NCT00314756|Drug|imiquimod|
317355|NCT00314782|Drug|ZD4054 (Zibotentan)|oral tablet
317356|NCT00314782|Drug|Docetaxel|intravenous infusion
317357|NCT00314782|Drug|Placebo|
317358|NCT00314795|Drug|peginesatide|
317359|NCT00314808|Drug|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
317360|NCT00314821|Drug|ropinirole|
317361|NCT00002855|Drug|Nilutamide|
317362|NCT00314834|Drug|Intradialytic parenteral nutrition|
317363|NCT00314847|Device|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
317364|NCT00314860|Drug|ropinirole Extended Release (XR)|
317365|NCT00314873|Drug|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
322682|NCT00307970|Device|conventional chamber/mask; anti-static chamber/mask|
322683|NCT00307996|Drug|Coenzyme Q10 (drug)|
322684|NCT00308009|Procedure|Vaginal Repair for prolapse, TVT procedure|TVT at the time of Vaginal Repair
TVT 3 months after Vaginal Repair
322685|NCT00308009|Procedure|TVT and Prolapse surgery|TVT at the time of Prolapse surgery
TVT 3 months after Prolapse Surgery
322686|NCT00308022|Device|High Frequency Percussive Ventilation|
322687|NCT00308048|Drug|Pegylated Interferon alfa 2b and ribavirin|
322688|NCT00308061|Biological|FMP1/AS02A|
322689|NCT00308074|Drug|Aripiprazole|open-label, flexible-dosing
322690|NCT00002833|Drug|Idarubicin|IV Days -6, -5 and -4.
322691|NCT00308087|Drug|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
322692|NCT00308087|Drug|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
322693|NCT00308100|Drug|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
322694|NCT00308100|Drug|5% Albumin|5% albumin, administered intra- and perioperatively
323056|NCT00298649|Behavioral|Lay Health Advisor|
323057|NCT00298662|Drug|Interferon beta-1b and Tacrolimus|
323058|NCT00298675|Drug|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
323059|NCT00298675|Drug|irinotecan|Irinotecan administered weekly, IV.
323060|NCT00298688|Drug|Gefitinib|
323061|NCT00298701|Biological|ALK Grass tablet|
323062|NCT00298714|Drug|Losartan|
323063|NCT00298727|Behavioral|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
323064|NCT00298727|Behavioral|ePBL|Online Problem-Based Course
323065|NCT00002807|Radiation|radiation therapy|45 Gy in 25 fractions over 5 weeks
321963|NCT00275262|Drug|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
321964|NCT00275275|Drug|Requip PR|Requip 24-Hour once a day for one month
322316|NCT00265473|Biological|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
322317|NCT00265486|Drug|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
322318|NCT00265499|Procedure|Skeletonization of the internal thoracic artery|
322319|NCT00265512|Behavioral|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
322320|NCT00265512|Behavioral|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
322321|NCT00265525|Behavioral|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
322322|NCT00265538|Behavioral|Patient education to engage provider in hypertension treatment discussion|Patients will receive a customized/tailored letter including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s)
322323|NCT00002707|Drug|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
322324|NCT00265538|Behavioral|Financial incentive and health educator phone call|Patients may receive 20$ for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the 20$ discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt.
322325|NCT00265551|Drug|SCA-136 (200 mg)|
322326|NCT00265551|Drug|SCA-136 (400 mg)|
322327|NCT00265551|Drug|olanzapine (15 mg)|
322328|NCT00268827|Device|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
322329|NCT00268840|Drug|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
322330|NCT00268840|Drug|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
322331|NCT00268853|Drug|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
321595|NCT00284869|Drug|LPS|
321596|NCT00284908|Drug|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
321597|NCT00284921|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
321598|NCT00284934|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
321599|NCT00284934|Drug|Tacrolimus|
321600|NCT00284934|Drug|Corticosteroids|At a dose of at least 5 mg/day.
321601|NCT00002777|Drug|tamoxifen citrate|
321602|NCT00284947|Drug|basiliximab|40 mg once every 28 days intravenously for 24 weeks
321603|NCT00284947|Drug|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
321604|NCT00284947|Drug|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
321605|NCT00284973|Biological|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
321606|NCT00284986|Drug|Prochymal (TM)|
321607|NCT00284999|Drug|Soothe|
321608|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
321609|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
321610|NCT00288262|Drug|melatonin 0.5 mg|
321611|NCT00288288|Procedure|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
321965|NCT00275275|Drug|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
321966|NCT00275301|Drug|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
321967|NCT00275314|Drug|Valganciclovir|
321968|NCT00275340|Other|Peer Support|
321969|NCT00275353|Behavioral|Individualized Symptom Education|
321970|NCT00275366|Device|Robotic Therapy|
320870|NCT00303940|Drug|talabostat mesylate|
320871|NCT00303940|Drug|temozolomide|
320872|NCT00303940|Other|pharmacological study|
320873|NCT00303953|Drug|belinostat|Given IV
320874|NCT00303966|Drug|sorafenib tosylate|Given orally
321230|NCT00294684|Drug|Placebo|Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:
Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop
321231|NCT00294710|Drug|Aliskiren|
321232|NCT00294723|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
321233|NCT00294723|Drug|glimepiride|8 mg capsule
321234|NCT00294723|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
321235|NCT00294723|Drug|glimepiride|8 mg capsule
321236|NCT00294723|Drug|placebo|Glimepiride placebo, 8mg capsule
321237|NCT00294723|Drug|placebo|Liraglutide placebo, 200 mcl
321238|NCT00294723|Drug|placebo|Liraglutide placebo, 300 mcl
321239|NCT00002801|Drug|leucovorin calcium|
321240|NCT00297648|Biological|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
321241|NCT00002805|Drug|mitoxantrone hydrochloride|
321242|NCT00297661|Device|Sirolimus-eluting stent|
321243|NCT00297661|Device|Paclitaxel-eluting stent|
321244|NCT00297674|Drug|Intravenous Clarithromycin|
321245|NCT00297687|Biological|MnB rLP2086|
320495|NCT00261755|Procedure|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
320496|NCT00261755|Other|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
320497|NCT00261755|Other|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
320498|NCT00261768|Behavioral|Digital noise reduction|
320499|NCT00261781|Behavioral|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
320500|NCT00261794|Behavioral|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
320501|NCT00261794|Behavioral|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
320502|NCT00261807|Drug|Daptomycin 6mg/kg/day|
320503|NCT00264680|Drug|valproic acid|
320504|NCT00264706|Drug|Nona-L-arginine|
320505|NCT00264719|Drug|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
320506|NCT00264719|Drug|placebo|placebo 10 mg
320507|NCT00002704|Drug|vincristine sulfate|
320875|NCT00002823|Drug|vinblastine sulfate|
320876|NCT00303992|Biological|trastuzumab|
320877|NCT00307203|Behavioral|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
320878|NCT00307203|Drug|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
319751|NCT00277680|Procedure|Laparoscopic bilateral occlusion of uterine artery|
319752|NCT00002756|Drug|leucovorin calcium|
319753|NCT00277680|Procedure|Radiological embolization (UFE)|
319754|NCT00277693|Drug|Spironolactone (drug)|
319755|NCT00277706|Procedure|Periodontal surgery|
319756|NCT00277706|Drug|FORTEO|parathyroid hormone; self-administration for 6 weeks
319757|NCT00277706|Drug|Placebo|placebo; self administration for 6 weeks
319758|NCT00277706|Dietary Supplement|Vitamin D and Calcium|PO, QD, for six weeks
319759|NCT00277732|Procedure|Pharmaceutical care at baseline and follow-up visits over 6 months|
319760|NCT00277745|Device|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
320143|NCT00271063|Drug|Liposomal Annamycin|3-day IV infusion
320144|NCT00271076|Procedure|IVUS|
320145|NCT00271076|Device|CAS|
320146|NCT00271076|Procedure|CEA|
320147|NCT00271089|Procedure|PBSC Collection|
320148|NCT00271089|Procedure|Bone Marrow Harvest|
320149|NCT00271089|Device|CliniMacs Cell Selection System|
320150|NCT00271102|Procedure|anterior vaginal repair (colporrhaphy)|vaginal repair
320151|NCT00271102|Procedure|abdominal paravaginal defect repair|abdominal repair
320152|NCT00002733|Biological|aldesleukin|
320153|NCT00271115|Behavioral|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
320154|NCT00274755|Procedure|magnetic resonance spectroscopic imaging|
320155|NCT00274755|Radiation|radiation therapy|
320156|NCT00274768|Drug|capecitabine|
319376|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
319377|NCT00287664|Drug|terlipressin|
319378|NCT00287677|Biological|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
319379|NCT00290433|Drug|Vincristine|Cycle 1: 1.4 mg/m^2 by vein On Day 4 and 11.
319380|NCT00290433|Drug|Methotrexate|Cycle 1 and 2: 200 mg/m^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m^2 IV Over 22 Hours on Day 1.
319381|NCT00290433|Drug|Ara-C|Cycle 1 and 2: 3 Gm/m^2 Over 2 Hours Twice Daily On Days 2 and 3.
319382|NCT00290433|Drug|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
319383|NCT00290433|Drug|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
319384|NCT00290433|Drug|Doxil|Cycle 1: 25 mg/m^2 by vein Over 1 Hour on Day 2.
319385|NCT00290472|Drug|temsirolimus|
319386|NCT00002789|Drug|cyclosporine|
319387|NCT00290485|Drug|Imatinib mesylate|
319388|NCT00290498|Drug|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
319389|NCT00290498|Drug|Cyclophosphamide|Arm A: Cyclophosphamide 300 mg/m^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.
Arm B: Cyclophosphamide 750 mg/m² by vein day 1
319390|NCT00290498|Drug|Doxorubicin|Arm A: Doxorubicin 50 mg/m^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
319761|NCT00280878|Drug|rituximab|
319762|NCT00280904|Device|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
319763|NCT00280917|Drug|CF101|
319764|NCT00280930|Drug|Letrozole|
319765|NCT00280943|Behavioral|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
319766|NCT00280956|Drug|Natalizumab|
318653|NCT00309452|Behavioral|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
318654|NCT00309452|Other|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
318655|NCT00309465|Drug|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
318656|NCT00309465|Other|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
319018|NCT00300261|Behavioral|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
319019|NCT00300274|Drug|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
319020|NCT00300274|Drug|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
319021|NCT00002812|Drug|cyclophosphamide|Given IV
319022|NCT00300274|Drug|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
319023|NCT00300274|Drug|corticosteroids|Corticosteroids standard dose.
319024|NCT00300287|Drug|Vildagliptin|
319025|NCT00300300|Procedure|Computer-assisted surgery|no description
319026|NCT00300313|Drug|Escitalopram|10 to 20 mg / day
319027|NCT00300313|Drug|Placebo|1-2 capsules
319028|NCT00300326|Device|LPS Flex knee system|flex knee system
319029|NCT00300339|Drug|SL650472, Clopidogrel|
319030|NCT00300352|Drug|Folic Acid|
319031|NCT00300365|Drug|Pioglitazone +/- placebo in combination with niacin ER|
319032|NCT00002812|Drug|cytarabine|Given IV
319033|NCT00300378|Drug|desvenlafaxine 50 mg|
316837|NCT00359047|Behavioral|Written documentation on osteoporosis and video group|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
316838|NCT00359060|Behavioral|Physical activity|
316839|NCT00003057|Drug|octreotide acetate|
316840|NCT00359073|Drug|montelukast|10 mg QD
316841|NCT00359073|Drug|placebo|like placebo
316842|NCT00359086|Drug|MGCD0103|MGCD0103 given orally three times per week
316843|NCT00361972|Drug|placebo|placebo comparator to lansoprazole, 30 mg, twice a day
316844|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally.
316845|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally
316846|NCT00361998|Drug|NITROFURANTOIN MACROCRYSTALS|
311242|NCT00315250|Drug|[123I]β-CIT|Single Photon Emission Computed Tomography
SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
311243|NCT00315276|Drug|Modafinil|
311244|NCT00315289|Procedure|Nasolacrimal balloon catheter duct dilation|
311245|NCT00315289|Procedure|Nasolacrimal intubation|
311246|NCT00315289|Procedure|Simple Nasolacrimal duct probing|
311247|NCT00315302|Drug|Atropine|Atropine 1% once each weekend day
311248|NCT00315302|Device|Plano Lens|Plano lens for the sound eye
311249|NCT00315315|Procedure|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
316481|NCT00314353|Drug|Bevacizumab|7.5 mg/kg IV Day 1 every 21 days for eight cycles*
*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression.
316482|NCT00314353|Drug|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
316483|NCT00314353|Drug|Capecitabine|850 mg/m2 po BID Days 1-14 every 21 days for eight cycles*#
*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.
#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID
316484|NCT00314353|Drug|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
316485|NCT00314366|Biological|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
316486|NCT00314366|Other|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
316487|NCT00314379|Drug|Vitamin E 400IU/day|
316488|NCT00314392|Behavioral|Information (behavior)|
316489|NCT00314405|Drug|Methylene blue (1%)|
316490|NCT00314405|Drug|Rhenium sulfure|
316491|NCT00317408|Drug|vindesine|
316492|NCT00317408|Procedure|allogeneic hematopoietic stem cell transplantation|
316493|NCT00317408|Procedure|autologous hematopoietic stem cell transplantation|
316494|NCT00317408|Procedure|peripheral blood stem cell transplantation|
316495|NCT00317408|Radiation|total-body irradiation|
316496|NCT00317421|Drug|Sildenafil citrate|
316497|NCT00317434|Drug|lapatinib|
316498|NCT00317447|Drug|Oral Prednisone|
316499|NCT00317460|Other|Physician Management|Standard physician care
316500|NCT00002868|Drug|busulfan|
316501|NCT00317460|Behavioral|Counseling|Physician Management and Counseling
316502|NCT00317473|Biological|MSP-1 (FMP-1) with AS02A vs Imovax rabies vaccine|
315745|NCT00002942|Procedure|autologous bone marrow transplantation|
315746|NCT00333619|Behavioral|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
315747|NCT00333619|Behavioral|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
315748|NCT00333632|Drug|Dexmedetomidine|
315749|NCT00333632|Drug|Propofol|
315750|NCT00333632|Drug|Midazolam|
315751|NCT00333632|Drug|Fentanyl|
315752|NCT00333632|Drug|Isoflurane|
315753|NCT00333645|Drug|Caspofungin|
315754|NCT00333658|Behavioral|Goal setting and work feedback group|Goal setting and feedback using WBI
315755|NCT00333671|Drug|Glycerol|
315756|NCT00002942|Procedure|peripheral blood stem cell transplantation|
315757|NCT00333684|Device|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
315758|NCT00336531|Drug|itraconazole|2.5 mg/kg twice daily for the first two days --> once daily
315759|NCT00336544|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
315760|NCT00336544|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
315761|NCT00002956|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
315762|NCT00336557|Procedure|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
316135|NCT00323882|Drug|MDX-010|selected dose administered IV every 3 weeks
316136|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
316137|NCT00002893|Drug|fluorouracil|
316138|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
306244|NCT00254423|Drug|Dasatinib (BMS-354825)|Arm A: Starting dose 100 mg orally daily
Arm B: Starting dose of 50 mg orally twice daily
306245|NCT00254436|Drug|Procrit (epoetin alfa)|Weekly dose
306246|NCT00254449|Drug|NGX-4010|
306247|NCT00254462|Drug|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
306248|NCT00002679|Drug|cyclophosphamide|
306610|NCT00002649|Drug|cyclophosphamide|Given IV
306611|NCT00244946|Drug|carmustine|
306612|NCT00244946|Drug|cytarabine|
306613|NCT00244946|Drug|etoposide|
306614|NCT00244946|Drug|melphalan|
306615|NCT00244946|Procedure|peripheral blood stem cell transplantation (PBSCT)|
306616|NCT00244959|Drug|anastrozole|1 mg orally daily for 12 months
306617|NCT00244959|Procedure|adjuvant therapy|treatment received after breast cancer surgery
306618|NCT00244972|Other|Laboratory Biomarker Analysis|Correlative studies
306619|NCT00244972|Drug|Sorafenib Tosylate|Given PO
306620|NCT00244972|Drug|Tipifarnib|Given PO
306621|NCT00000407|Behavioral|Reading materials for control participants|
306622|NCT00002649|Drug|etoposide|Given IV
306623|NCT00244985|Biological|rituximab|IV
306624|NCT00244985|Drug|pegylated liposomal doxorubicin hydrochloride|IV
306625|NCT00244998|Drug|fulvestrant|IM
306626|NCT00245011|Biological|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC count is achieved.
306627|NCT00245011|Drug|ifosfamide|Ifosfamide administered IV.
306628|NCT00245011|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
305881|NCT00207194|Behavioral|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.).
305882|NCT00207207|Procedure|Alternate site blood glucose testing|
305883|NCT00207220|Procedure|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
305884|NCT00207220|Procedure|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
305885|NCT00207233|Behavioral|MCT oil hypocaloric liquid diet|The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.
The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study.
305886|NCT00207233|Behavioral|LCT hypocaloric liquid diet|The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.
The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study.
305887|NCT00207233|Procedure|Subcutaneous abdominal adipose tissue biopsy|Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.
This will be performed at baseline, 6 weeks, and 12 weeks.
305888|NCT00210665|Drug|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
305889|NCT00210678|Behavioral|No intervention|No treatment is given to the patients as this is an observational study.
305890|NCT00210691|Drug|Risperidone|
305891|NCT00210704|Drug|Dapoxetine|
306249|NCT00254462|Drug|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
306250|NCT00254462|Behavioral|Parent Training|All children will receive parent training for the duration of the study.
306251|NCT00254475|Drug|simvastatin|
306252|NCT00254475|Drug|valsartan|
305174|NCT00229515|Other|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
305175|NCT00229528|Drug|Paxil-CR|
305176|NCT00229541|Procedure|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
305177|NCT00229567|Drug|Lidocaine infusion plus ketamine injection|
305178|NCT00229580|Behavioral|3 session brief intervention with health behavior feedback|
305179|NCT00229580|Other|treatment as usual|
305180|NCT00229593|Drug|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
305524|NCT00218114|Drug|divalproex sodium|divalproex sodium in 250 mgs doses titrated to 10 mgs /lb to reach a blood level between 50-110 micrograms/ml
305525|NCT00218127|Drug|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
305526|NCT00218127|Drug|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
305527|NCT00218127|Drug|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
305528|NCT00002576|Drug|prednisolone|
305529|NCT00218140|Drug|nicotine transdermal system|
305530|NCT00218153|Drug|Naltrexone|
305531|NCT00218166|Drug|GABA Agonists|GABA drugs administered acutely by mouth
305532|NCT00218179|Other|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
305533|NCT00218192|Behavioral|Behavior Therapy|
305534|NCT00218205|Drug|Epirubicin|
305535|NCT00218205|Drug|Estramustine Phosphate|
305536|NCT00218205|Drug|Celecoxib|
305537|NCT00218218|Drug|Transdermal Nicotine Patch|42 mg transdermal nicotine
305538|NCT00218218|Drug|21 mg transdermal nicotine|
305539|NCT00002576|Drug|vincristine sulfate|
310751|NCT00362518|Dietary Supplement|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
310752|NCT00362518|Dietary Supplement|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
310753|NCT00362518|Dietary Supplement|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
310754|NCT00362518|Dietary Supplement|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
310755|NCT00362531|Drug|tacrolimus combined with prednisone|
310756|NCT00362544|Drug|Ambisome|
310757|NCT00362557|Device|MRI|Magnetic resonance imaging
310758|NCT00365690|Behavioral|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
310759|NCT00365690|Behavioral|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
310760|NCT00003086|Drug|melphalan|
310761|NCT00365703|Procedure|Feeding tube insertion|Orogastric feeding tube
Nasogastric feeding tube
310762|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
310763|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
310764|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
310765|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
305181|NCT00229593|Drug|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
310026|NCT00224484|Biological|HavrixTM (investigational formulation)|3 IM doses
310027|NCT00224484|Biological|Placebo|3 IM doses
310028|NCT00224497|Drug|SB-742457|
310029|NCT00227773|Procedure|anti-cytokine therapy|
310030|NCT00227773|Procedure|antiangiogenesis therapy|
310031|NCT00227773|Procedure|biological therapy|
310032|NCT00227773|Procedure|endocrine therapy|
310033|NCT00227773|Procedure|enzyme inhibitor therapy|
310034|NCT00227773|Procedure|growth factor antagonist therapy|
310035|NCT00227773|Procedure|hormone therapy|
310036|NCT00227773|Procedure|protein tyrosine kinase inhibitor therapy|
310399|NCT00002565|Drug|mitoxantrone hydrochloride|
310400|NCT00213577|Drug|type A botulinum toxin|
310401|NCT00213590|Drug|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
310402|NCT00213616|Procedure|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
310403|NCT00002571|Drug|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
310404|NCT00217217|Device|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
310405|NCT00217230|Biological|CAIV-T|
310406|NCT00217243|Other|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
310407|NCT00217256|Device|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
310408|NCT00217256|Device|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
309302|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.
Positive on the Berlin Questionnaire
Clinic visit, exam with a physician, given a home diagnostic device (HDD)
High risk on HDD, seen by physician, given a CPAP machine
Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed
Contacted by a sleep health clinic at 3, 6, 12 months
After 12 months subject will be referred to their primary care physician
309660|NCT00235807|Procedure|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
309661|NCT00235807|Procedure|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
309662|NCT00235807|Procedure|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
309663|NCT00235820|Drug|adalimumab|40 mg every other week following an 80 mg dose
309664|NCT00235820|Drug|MTX|MTX 7.5 to 25 mg once weekly
309665|NCT00235820|Drug|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
309666|NCT00235833|Biological|adalimumab|40 mg every other week (eow), subcutaneous (sc)
309667|NCT00235846|Procedure|vein harvest|Conventional open vein harvest or endoscopic vein harvest
309668|NCT00239226|Procedure|Pacing RAA control group|site of implant and permanent pacing
309669|NCT00239239|Drug|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
309670|NCT00239252|Drug|Interferon alfacon-1|
309671|NCT00239265|Drug|Tamuslosin|
309672|NCT00239278|Drug|budesonide/formoterol, 2x 200/6 microgram. 4 times daily|
309673|NCT00002633|Drug|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
309674|NCT00239278|Drug|prednisolone, 30 mg once daily and placebo|
308926|NCT00255684|Procedure|umbilical cord blood transplantation|
308927|NCT00255684|Radiation|radiation therapy|
308928|NCT00255697|Procedure|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
308929|NCT00255697|Procedure|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
308930|NCT00255710|Biological|filgrastim|
308931|NCT00255710|Drug|cyclophosphamide|
308932|NCT00255710|Drug|fludarabine phosphate|
308933|NCT00002682|Drug|Amoxicillin|
308934|NCT00255710|Drug|mycophenolate mofetil|
308935|NCT00255710|Drug|tacrolimus|
308936|NCT00259038|Drug|Carperitide (human recombinant atrial natriuretic peptide)|
308937|NCT00259051|Drug|Omeprazole|
308938|NCT00259064|Drug|Gefitinib|
308939|NCT00259064|Other|Placebo|
308940|NCT00259077|Drug|Omeprazole|
308941|NCT00259090|Drug|Fulvestrant|500 mg intramuscular injection
309303|NCT00249756|Behavioral|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments — increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
308175|NCT00219518|Procedure|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
308176|NCT00219531|Behavioral|perception of rectal balloon distention|fMRI study with measurement of brain MRI response to rectal balloon distention.
308177|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
308178|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
308179|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
308180|NCT00219544|Drug|Placebo|Placebo
308181|NCT00002580|Drug|goserelin acetate|
308182|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
308183|NCT00219557|Drug|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
308546|NCT00208546|Drug|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
308547|NCT00208546|Drug|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
308548|NCT00208559|Drug|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
308549|NCT00208572|Drug|Citalopram|
308550|NCT00208585|Drug|sertraline|
308551|NCT00208611|Dietary Supplement|Vitamin B12 Supplementation|1000 micrograms daily
308552|NCT00208637|Behavioral|moderate carbohydrate, high protein diet (MCHP)|
308553|NCT00208637|Behavioral|high carbohydrate-high fibre (HCHF) diet|
308554|NCT00002554|Drug|methotrexate|
308555|NCT00208702|Drug|Triiodothyronine|
308556|NCT00208702|Other|Placebo|
308557|NCT00208702|Drug|Sertraline|
308558|NCT00208715|Drug|Provigil|
307812|NCT00231140|Drug|Thalidomide (drug)|
307813|NCT00231153|Drug|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
307814|NCT00002609|Drug|idarubicin|
307815|NCT00231153|Drug|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
307816|NCT00231166|Drug|HCD122|
307817|NCT00231179|Behavioral|Home visiting professional support model|Home visits and telephone calls keyed to well child visits.
307818|NCT00231179|Other|Control|The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
307819|NCT00231192|Drug|Repaglinide and Insulin|
307820|NCT00231205|Procedure|Revascularization|
307821|NCT00231218|Drug|dietary supplement--echinacea, propolis, and vitamin c|
307822|NCT00231231|Device|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
307823|NCT00231231|Device|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
307824|NCT00231244|Device|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
307825|NCT00002610|Biological|dactinomycin|
307826|NCT00231257|Device|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
307827|NCT00231257|Procedure|Brachytherapy|Brachytherapy
307828|NCT00231270|Device|Cordis Nitinol Stent|
307829|NCT00231270|Device|PRECISE tapered stent|
307830|NCT00231270|Device|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
307831|NCT00234819|Drug|Bazedoxifene/Conjugated Estrogen|
307832|NCT00002619|Drug|thiotepa|
307140|NCT00002693|Biological|filgrastim|
307141|NCT00258362|Drug|docetaxel|75 mg/m^2 on Day 1 of each course
307142|NCT00258362|Radiation|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
307143|NCT00258375|Drug|custirsen sodium|
307144|NCT00258375|Drug|docetaxel|
307145|NCT00258388|Drug|custirsen sodium|640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)
Subsequent cycles:
weekly on days 1, 8, 15 (3 week cycles)
307146|NCT00258388|Drug|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
307147|NCT00258388|Drug|prednisone|5mg PO BID
307481|NCT00245089|Drug|vincristine sulfate|
307482|NCT00245102|Drug|sorafenib tosylate|Given orally
307483|NCT00245115|Biological|filgrastim|
307484|NCT00245115|Drug|busulfan|
307485|NCT00245115|Drug|cyclophosphamide|
307486|NCT00245115|Procedure|in vitro-treated bone marrow transplantation|
307487|NCT00245115|Procedure|in vitro-treated peripheral blood stem cell transplantation|
307488|NCT00245128|Drug|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
307489|NCT00245141|Biological|dactinomycin|
307490|NCT00245141|Drug|cyclophosphamide|
307491|NCT00002650|Dietary Supplement|folic acid|
307492|NCT00245141|Drug|vincristine sulfate|
307493|NCT00245141|Radiation|radiation therapy|
307494|NCT00245154|Drug|carboplatin|Given IV
307495|NCT00245154|Drug|cediranib maleate|Given orally
307496|NCT00245154|Drug|paclitaxel|Given IV
307497|NCT00245154|Other|placebo|Given orally
282951|NCT02609386|Drug|Cyclophosphamide|Method of Administration: Cyclophosphamide is administered once by IV
282952|NCT02609386|Drug|Indomethacin|Method of Administration: Indomethacin is administered orally for 21 days.
282953|NCT02609386|Dietary Supplement|Zinc-containing multivitamin|Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
282954|NCT02609386|Drug|Omeprazole|Method of Administration: Omeprazole is administered orally for 21 days
282955|NCT02609399|Drug|Oseltamivir|Oral
282956|NCT02609399|Drug|Peramivir|IV
Note: Should a patient remain in the hospital after 5 days of treatment, and the patient is symptomatically better, treatment will stop. If the patient remains hospitalized after 5 days of treatment and has not improved, the treating physician will continue to have an option to continue use of peramivir daily for another 5 day course.
282957|NCT02609412|Other|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
282958|NCT02609412|Other|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
282959|NCT02609412|Device|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
282960|NCT02609425|Device|Stratafix PGA Suture|Subject leak Stricture rates post procedure
282961|NCT00192413|Biological|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
282962|NCT00188318|Procedure|hyperfractionated accelerated radiotherapy|
282963|NCT02575625|Device|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
283258|NCT02604810|Biological|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
283259|NCT02604823|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
283260|NCT02604836|Drug|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
283261|NCT02604849|Drug|Neomycin|
283262|NCT00191919|Drug|Duloxetine Hydrochloride|
283263|NCT02604849|Drug|Streptomycin|
283264|NCT02604849|Drug|Gentamicins|
309068|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
309069|NCT00216463|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
309070|NCT00216463|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
309071|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
309072|NCT00216476|Drug|Aripiprazole|10-30 mg oral once daily for 104 weeks
309073|NCT00002571|Drug|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
309074|NCT00216476|Drug|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
309075|NCT00216476|Drug|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
309076|NCT00216489|Drug|rabeprazole sodium|
309077|NCT00216502|Drug|galantamine hydrobromide|
309078|NCT00216515|Drug|galantamine hydrobromide|
309079|NCT00216528|Drug|risperidone|
309080|NCT00216541|Drug|epoetin alfa|
309081|NCT00216554|Drug|risperidone|
309082|NCT00216567|Drug|topamax|
309083|NCT00216580|Drug|Risperidone, long-acting injectable|
309084|NCT00219843|Drug|PV-10 (rose bengal disodium, 10%)|
309085|NCT00219856|Drug|Propofol|Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml
Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml
309086|NCT00219856|Drug|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
309087|NCT00219856|Drug|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
309088|NCT00219869|Drug|Galantamine|
309089|NCT00002580|Procedure|conventional surgery|
308325|NCT00238615|Procedure|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
308326|NCT00238615|Procedure|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
308327|NCT00238628|Drug|Bexarotene|
308328|NCT00000401|Drug|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
308329|NCT00002631|Radiation|low-LET photon therapy|
308695|NCT00227357|Drug|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
308696|NCT00227357|Drug|Off-site - methadone or no agonist|
308697|NCT00227370|Drug|valganciclovir|valgan 900mg QD x 9 months post lung transplant
308698|NCT00227370|Other|Placebo|
308699|NCT00227383|Device|Electroacupuncture (device)|
308700|NCT00227409|Drug|calcium disodium EDTA (edetate calcium disodium)|
308701|NCT00227422|Biological|Mencevax ACWY|
308702|NCT00227435|Drug|val-mCyd|
308703|NCT00002598|Drug|etoposide|
308704|NCT00227448|Drug|intravenous saline|
308705|NCT00227448|Drug|intravenous phenylephrine|
308706|NCT00227448|Drug|intravenous levophed|
308707|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
308708|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
308709|NCT00231569|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
308710|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
308711|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
307963|NCT00249197|Drug|levofloxacin|
307964|NCT00249210|Drug|levofloxacin|
307965|NCT00249223|Drug|Risperidone Long acting injectable|
307966|NCT00249236|Drug|Risperidone, oral tablets|
307967|NCT00002658|Procedure|peripheral blood stem cell transplantation|
307968|NCT00249249|Drug|Pitavastatin|
307969|NCT00249249|Drug|Atorvastatin|
307970|NCT00249262|Drug|Taxoprexin|
307971|NCT00249275|Device|spectacles|
307972|NCT00249288|Drug|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
307973|NCT00249288|Drug|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
307974|NCT00249301|Drug|MLN8054|MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
307975|NCT00249327|Behavioral|education|
307976|NCT00249340|Behavioral|Weight Watchers|
307977|NCT00252044|Drug|Pergolide|
307978|NCT00252057|Behavioral|Re-Engineered Discharge|The "Re-engineered Hospital Discharge" (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist.
307979|NCT00252070|Behavioral|Functional Exercise for People with Arthritis (FEPA)|
307980|NCT00252083|Behavioral|Popular Opinion Leader|
307981|NCT00252096|Device|Nucleic acid amplification test|
308330|NCT00238628|Drug|Iressa|
308331|NCT00238641|Drug|Botulinum Toxin type B|
308332|NCT00238667|Drug|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
308333|NCT00238667|Drug|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
307251|NCT00215852|Drug|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
307252|NCT00215865|Drug|PEGIntron plus ribavirin|
307253|NCT00215878|Drug|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine ~2g /day), in the second arm adjuvant treatment with placebo (~2g /day)
307254|NCT00215891|Drug|PEG-Interferon a-2b + Ribavirin|
307255|NCT00215904|Drug|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (~2g/day). Second arm : adjuvant treatment with placebo (~2g/day).
307256|NCT00215917|Drug|D-serine 2100 mg daily|
307596|NCT00258479|Drug|Modafinil|See Modafinil Intervention Description above.
307597|NCT00258492|Behavioral|Aerobic exercise|
307598|NCT00258505|Procedure|Procedure: intracranial monitoring up to 9 days after injury|
307599|NCT00258518|Procedure|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
307600|NCT00258531|Device|Olympus ScopeGuide®, 3-dimentional magnetic imager|
307601|NCT00258557|Drug|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
307602|NCT00258557|Drug|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
307603|NCT00258596|Device|sirolimus-eluting stent|
307604|NCT00258609|Drug|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
307605|NCT00002695|Genetic|microsatellite instability analysis|
307606|NCT00204529|Drug|interferon-alpha-2a|
307607|NCT02719977|Drug|CX5461|
307608|NCT02719990|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
307609|NCT02720003|Device|LTX DCB|Treatment with a drug-coated balloon
307610|NCT02720016|Behavioral|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 15 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
306944|NCT00230646|Behavioral|Exercise counseling|
306945|NCT00002608|Drug|tamoxifen citrate|
306946|NCT00230659|Other|Blood sample to be taken.|Blood sample to be taken.
306947|NCT00230698|Drug|topiramate|
306948|NCT00230711|Behavioral|Physical activity counseling|
306949|NCT00230724|Behavioral|Exercise Counseling|
306950|NCT00230737|Drug|Melatonin 0.4 mg|
306951|NCT00230737|Drug|Melatonin 4.0 mg|
306952|NCT00230737|Drug|Placebo|
306953|NCT00230750|Biological|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
306954|NCT00230750|Drug|Placebo|Saline placebo.
306955|NCT00230763|Procedure|GSS questionnaire|D0, D30 and D84
306956|NCT00000396|Behavioral|Patient self-care education|
306957|NCT00002608|Procedure|conventional surgery|
306958|NCT00230763|Procedure|IOP|D0, D30 and D84
306959|NCT00230763|Drug|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
306960|NCT00230763|Procedure|Visual acuity|D0 and D84
306961|NCT00230776|Drug|pregabalin|
307257|NCT00215930|Drug|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
307258|NCT00215930|Drug|Docetaxel|RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.
RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.
RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
307259|NCT00218803|Behavioral|Control Group|Asthma Education
306629|NCT00245011|Radiation|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
306630|NCT00248430|Biological|aldesleukin|
306631|NCT00248430|Biological|therapeutic allogeneic lymphocytes|
306632|NCT00002658|Drug|daunorubicin hydrochloride|
306633|NCT00248430|Drug|melphalan|
306634|NCT00248430|Procedure|bone marrow ablation with stem cell support|
306635|NCT00248430|Procedure|peripheral blood stem cell transplantation|
306636|NCT00248443|Procedure|Fiberoptic bronchoscopy and bronchoalveolar lavage|
306962|NCT00230776|Drug|placebo|
306963|NCT00234169|Drug|VTP195183|VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
306964|NCT00234182|Drug|Interferon alpha-2b|
306965|NCT00234195|Drug|bupropion extended release (Wellbutrin XL)|
306966|NCT00234208|Procedure|Medical thoracoscopy|
306967|NCT00234208|Procedure|Simple chest tube drainage|
306968|NCT00234221|Behavioral|Strengths Based Case Management|
306969|NCT00234221|Behavioral|Motivational Enhancement Therapy|
306970|NCT00000398|Behavioral|Coping skills training plus physical exercise training|
306971|NCT00002618|Radiation|low-LET cobalt-60 gamma ray therapy|
306972|NCT00234221|Behavioral|Brief Informational Feedback|
306973|NCT00234234|Drug|Adalimumab|
306974|NCT00234247|Drug|Inhaled Nitric Oxide|
306975|NCT00234273|Procedure|Rehabilitation programme in Adapted Physical Activity (APA)|
306253|NCT00254488|Drug|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
306254|NCT00254488|Drug|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
306255|NCT00254501|Behavioral|Regularly-scheduled consulting session with pharmacists|Regularly scheduled consulting session with pharmacist
306256|NCT00254514|Drug|somatropin|
306257|NCT00257894|Drug|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
306258|NCT00257920|Drug|Zemplar® injection|6 mcg QOD
306259|NCT00257920|Drug|Hectorol® injection|3.6 mcg QOD
306260|NCT00257933|Drug|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
306261|NCT00257933|Drug|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
306262|NCT00257946|Procedure|Repair of CDH w/SIS Gold|
306263|NCT00257946|Procedure|Repair of CDH w/Alloderm|
306264|NCT00257959|Drug|amiodarone beta blocker sotalol|
306265|NCT00002691|Drug|mesna|
306266|NCT00257972|Drug|aripiprazole|
306267|NCT00257985|Drug|GTN|
306268|NCT00257998|Procedure|Mobilization|manualtherapy techniques
306269|NCT00258011|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
306270|NCT00258024|Drug|IPT-sulphadoxinepyrimethamine|
306271|NCT00258037|Behavioral|Pelvic Floor Muscle training|
306272|NCT00258050|Drug|GW572016 oral tablets|
306273|NCT00258063|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
306637|NCT00248456|Drug|Calcipotriol plus betamethasone dipropionate ointment|
306638|NCT00248469|Behavioral|In-school Sexual Health Education|
305540|NCT00218218|Drug|placebo patch|
305541|NCT00218231|Drug|300 mg/day bupropion-sr|300 mg/day for 1 week
305542|NCT00218231|Drug|0 mg/day bupropion-sr|0 mg/day bupropion-sr
305543|NCT00218244|Other|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
305544|NCT00222105|Drug|Doxil|Doxil 40 mg/m2 IV day 1
305545|NCT00222105|Drug|Thalidomide|50-100 mg day 1-28
305546|NCT00222105|Drug|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
305547|NCT00222118|Behavioral|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
305548|NCT00002583|Drug|vinorelbine ditartrate|25 mg/m2 IV
305549|NCT00222118|Other|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
305892|NCT00210717|Drug|paliperidone palmitate|
305893|NCT00210730|Drug|epoetin alfa|
305894|NCT00210743|Drug|epoetin alfa|
305895|NCT00210756|Drug|epoetin alfa|
305896|NCT00002559|Drug|cisplatin|
305897|NCT00210769|Drug|paliperidone ER Oros|
305898|NCT00210782|Drug|topiramate, phenytoin|
305899|NCT00210795|Drug|epoetin alfa|
305900|NCT00210808|Drug|topiramate|
305901|NCT00210821|Drug|topiramate|
305902|NCT00210834|Drug|epoetin alfa|
305903|NCT00210847|Drug|tramadol, acetaminophen|
305904|NCT00210860|Drug|topiramate|
305905|NCT00210873|Drug|topiramate|
305906|NCT00210886|Drug|levofloxacin|
305182|NCT00229619|Drug|Rituximab|Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
305183|NCT00229632|Drug|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
305184|NCT00002601|Drug|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
305185|NCT00229645|Drug|Quetiapine Fumarate (Seroquel®)|
305186|NCT00229658|Drug|pramlintide acetate|Subcutaneous injection prior to each major meal
305187|NCT00229671|Device|Computerized Physician Order Entry|
305188|NCT00229684|Drug|Tesaglitazar|2 mg once daily in oral form
305189|NCT00233324|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
305190|NCT00233324|Drug|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
305191|NCT00233324|Drug|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
305192|NCT00002616|Drug|cyclophosphamide|
305193|NCT00233337|Drug|Co-artemether|
305194|NCT00233350|Device|use of navigated 3D ultrasound during surgery|
305195|NCT00233363|Drug|Rebamipide|
305196|NCT00233376|Procedure|Access to an antibiotic decision support system|
305197|NCT00233376|Behavioral|Distribution of local antibiotic guidelines|
305198|NCT00233389|Drug|Rebamipide|
305199|NCT00233402|Drug|Hexvix|Single Instillation, Transurethral Resection of the Bladder
305200|NCT00233402|Procedure|Standard white light cystoscopy|
305201|NCT00233415|Device|Stereotactic Radiosurgery (Cyberknife)|
305202|NCT00233428|Procedure|Blood Draw|
310409|NCT00217269|Device|Coronary Artery Stenting|Endeavor Drug eluting stent
310410|NCT00217269|Device|Coronary Artery Stenting|Taxus Drug Eluting Stent
310411|NCT00217282|Drug|oxaliplatin, gemcitabine, bevacizumab|Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.
Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:
Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression
310412|NCT00217295|Drug|Avonex and Topamax|
310413|NCT00217308|Drug|Lactobacilli GR-1 and RC-14|
310414|NCT00000132|Procedure|Argon Laser Trabeculoplasty|
310415|NCT00000387|Behavioral|Self-management therapy|Behavioral
310416|NCT00002571|Radiation|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
310417|NCT00217334|Behavioral|Volunteer-led pharmacy sessions with feedback to physicians|
310418|NCT00217347|Device|Esophageal Capsule Endoscopy|
310766|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
310767|NCT00365729|Behavioral|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
310768|NCT00365742|Drug|simvastatin|
310769|NCT00365742|Drug|red yeast rice|
310770|NCT00365742|Drug|pharmaceutical grade fish oil|
310771|NCT00003086|Drug|paclitaxel|
310772|NCT00365742|Behavioral|therapeutic lifestyle changes|
310773|NCT00365755|Drug|carboplatin|
310774|NCT00365755|Drug|cisplatin|
310775|NCT00365755|Drug|cyclophosphamide|
310776|NCT00365755|Drug|etoposide|
310777|NCT00365755|Drug|melphalan|
309675|NCT00239291|Drug|Gefitinib, radiotherapy|
309676|NCT00239304|Drug|Gefitinib|
309677|NCT00239304|Drug|Cisplatin|
309678|NCT00239304|Procedure|Radiotherapy|
309679|NCT00239317|Drug|Tamusulosin|
309680|NCT00239330|Drug|Rosuvastatin|
309681|NCT00239330|Drug|Atorvastatin|
310037|NCT00227773|Procedure|somatostatin analogue therapy|
310038|NCT00227786|Behavioral|smoking cessation intervention|
310039|NCT00002599|Biological|sargramostim|
310040|NCT00227786|Other|counseling intervention|
310041|NCT00227812|Drug|Bupropion|
310042|NCT00227825|Behavioral|Motivational interviewing|
310043|NCT00227838|Behavioral|Behavior Therapy|
310044|NCT00227864|Behavioral|Behavior Therapy|
310045|NCT00227864|Other|Treatment as Usual|
310046|NCT00227877|Behavioral|Computerized CRAFFT screen and brief physician advice|Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested "talking point" which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use.
310047|NCT00227890|Behavioral|Behavior Therapy|
310048|NCT00227903|Behavioral|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
310049|NCT00227903|Behavioral|Brief Advice|Advice and education
310050|NCT00002599|Drug|carmustine|
310051|NCT00227916|Behavioral|Behavior Therapy|
310052|NCT00227929|Procedure|Care Management|
310053|NCT00227942|Drug|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
309304|NCT00249756|Behavioral|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
309305|NCT00249769|Biological|Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine|
309306|NCT00002664|Biological|edrecolomab|
309307|NCT00249782|Drug|Vehicle control, 2x/day|
309308|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 2x/day|
309309|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day|
309310|NCT00249782|Drug|MetroGel® (metronidazole gel), 1.0% 1x/day|
309311|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
309312|NCT00249795|Drug|Irbesartan|oral administration (tablets) once daily
309313|NCT00249795|Drug|placebo|oral administration (tablets) once daily
309314|NCT00249808|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive 12 doses of 1 mg/kg/week during a period of 12 weeks. Depending on the response at 12 weeks patients might receive additional 8 to 12 weekly injections at 1.0 mg/kg/week.
309315|NCT00249821|Drug|Saizen®|Saizen® [somatropin (recombinant deoxyribonucleic acid [rDNA] origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
309316|NCT00249821|Drug|Saizen®|Saizen® [somatropin (rDNA origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
309317|NCT00002664|Biological|sargramostim|
309318|NCT00249834|Other|CONSORT calculator|The subject's Age, Body Mass Index (kg/m2), Number of follicles < 11 mm on a baseline ultrasound scan, Serum FSH level in the early follicular phase of a menstrual cycle were entered in an algorithm (CONSORT calculator), which then calculated the optimal fixed starting dose of r-hFSH for each subject according to her individual characteristics.
309319|NCT00249847|Drug|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
309320|NCT00249847|Drug|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
309682|NCT00239343|Drug|gefitinib|
309683|NCT00239356|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
308559|NCT00208728|Device|PC/SMART cardiopulmonary bypass circuit|
308560|NCT00208728|Device|PMEA modified cardiopulmonary bypass circuit|
308561|NCT00208728|Device|Standard of care uncoated cardiopulmonary bypass circuit|
308562|NCT00212277|Drug|Norethindrone,Ethinyl Estradiol|
308563|NCT00212290|Drug|pioglitazone|
308564|NCT00002565|Biological|bleomycin sulfate|
308565|NCT00212290|Drug|nateglinide|
308566|NCT00212290|Drug|placebo|
308567|NCT00212303|Behavioral|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
308568|NCT00212316|Drug|sodium phenylbutyrate|
308569|NCT00212329|Procedure|T Cell Proliferation and Autoreactivity Assays|
308570|NCT00212329|Procedure|Cellular Immunoblot Assays|
308571|NCT00212329|Procedure|Tetramer Studies|
308572|NCT00212329|Procedure|Cytokine ELISPOT|
308942|NCT00259090|Drug|Anastrazole|oral tablet
308943|NCT00259103|Drug|Serelaxin|
308944|NCT00259103|Drug|Placebo|
308945|NCT00259116|Drug|Relaxin|
308946|NCT00000414|Behavioral|SMART Program|
308947|NCT00002696|Drug|doxorubicin hydrochloride|
308948|NCT00259129|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
308949|NCT00259142|Drug|Chloroquine, sulphadoxine-pyrimethamine|
308950|NCT00259155|Drug|Rifaximin|
308951|NCT00259168|Drug|Nateglinide|
308952|NCT00259181|Procedure|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
307833|NCT00234832|Drug|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
308184|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
308185|NCT00219570|Drug|clindamycin|
308186|NCT00219570|Drug|nadifloxacin|
308187|NCT00219583|Drug|UK-390,957|
308188|NCT00219596|Drug|Xalacom|
308189|NCT00219596|Drug|unfixed Latanoprost and Timolol|
308190|NCT00219609|Drug|UK-390,957|
308191|NCT00223691|Drug|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
308192|NCT00223691|Drug|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
308193|NCT00223691|Device|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
308194|NCT00000391|Drug|Peptide T|
308195|NCT00002590|Drug|doxorubicin hydrochloride|
308196|NCT00223691|Device|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
308197|NCT00223704|Drug|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
308198|NCT00223704|Drug|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
308199|NCT00223704|Drug|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
308200|NCT00223717|Drug|Clonidine|0.1-0.2mg po. Single dose.
308201|NCT00223717|Drug|Nitroglycerin transdermal|0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
308202|NCT00223717|Drug|Dipyridamole/ Aspirin (Aggrenox)|dipyridamole 200 mg and aspirin 25 mg po. Single dose.
307498|NCT00245167|Procedure|Tracheal Aspirate Fluid|
307499|NCT00245180|Behavioral|Diet|
307500|NCT00245180|Behavioral|Exercise|
307501|NCT00248729|Drug|Etomidate (20mg) or Midazolam (7mg)|
307502|NCT00248742|Behavioral|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
307503|NCT00248755|Procedure|mucociliary clearance scan|
307504|NCT00248768|Device|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
307505|NCT00248781|Device|Telecommunications system|
307506|NCT00248781|Device|attention control|health education
307507|NCT00248794|Behavioral|Cognitive rehabilitation (CRT and ICBR)|Methods to improve cognitive abilities
307834|NCT00234832|Drug|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
307835|NCT00234832|Drug|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
307836|NCT00234845|Drug|adalimumab|
307837|NCT00234845|Drug|methotrexate|
307838|NCT00234858|Drug|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
307839|NCT00234858|Drug|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
307840|NCT00234871|Drug|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
307841|NCT00234871|Drug|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
307842|NCT00234884|Biological|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
307843|NCT00002619|Procedure|autologous bone marrow transplantation|
307844|NCT00234897|Drug|adalimumab|
307845|NCT00234910|Drug|Tenofovir DF|TDF 300mg QD for 72 wks
283265|NCT02604862|Other|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
283266|NCT02604875|Other|observation|blood sampling during 24 hours
283267|NCT02604888|Other|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
283268|NCT02604901|Behavioral|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR*S (BI). BI was considered an active intervention method.
283269|NCT02604901|Behavioral|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
283270|NCT02604914|Drug|ND0612|Subcutaneous solution
283271|NCT02604914|Drug|LCIG|Intrajejunal Gel
283272|NCT02604927|Dietary Supplement|Beta-alanine|
283273|NCT00002517|Radiation|radiation therapy|
283274|NCT00191919|Drug|Placebo|
283275|NCT02607345|Dietary Supplement|Glucomedics®|25gr
283276|NCT02607358|Other|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
283277|NCT02607371|Other|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
283548|NCT02600728|Behavioral|Control Training|The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.
Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.
Phase 2: Patients received a general verbal attentional instruction of "pay attention to your steps and try to walk as better as you can", before starting the walk.
Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction "Walk in your ordinary speed, paying attention to your steps" in the identical trajectories of ET. Additional instructions or cues were not provided.
283549|NCT02600741|Other|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
283550|NCT00191490|Drug|Gemcitabine|
283551|NCT02600741|Other|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
309090|NCT00219882|Drug|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
309451|NCT00208975|Drug|Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF|Initial patients (n=9) received fludarabine (25 mg/m^2 intravenously) and mitoxantrone (10 mg/m^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m^2) on day 8.
After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m^2 intravenously) and cyclophosphamide (250 mg/m^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management.
309452|NCT00208988|Procedure|Educational handout about prostate cancer screening|
309453|NCT00208988|Procedure|Simple cue for patient to talk to doctor|
309454|NCT00209001|Procedure|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
309455|NCT00209001|Procedure|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
309456|NCT00209014|Drug|Thalidomide|
309457|NCT00209027|Other|fMRI|fMRI scanning during behavioral reward task
309458|NCT00209027|Drug|Aripiprazole|30 mg by mouth once daily
309459|NCT00002555|Radiation|low-LET cobalt-60 gamma ray therapy|
309460|NCT00209040|Procedure|acoustic startle testing|See protocol description for methodological details
309461|NCT00209053|Procedure|Coronary Artery Bypass|
309462|NCT00209079|Drug|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
309463|NCT00209092|Drug|Docetaxel|Sequential Therapy: Docetaxel will be given at 100 mg/m^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.
Concurrent Therapy: Docetaxel will be given at 50 mg/m^2 IV Day 1.
309464|NCT00209092|Drug|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
309465|NCT00209105|Drug|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
309466|NCT00209105|Behavioral|Psychosocial stress induction|Laboratory stress induction, no drug administration
309467|NCT00209105|Procedure|Brain imaging of sad mood , self-reference, reward|Brain imaging
308712|NCT00231582|Drug|epirubicin|epirubicin
308713|NCT00231582|Procedure|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
308714|NCT00231582|Drug|paclitaxel|paclitaxel
308715|NCT00002610|Drug|doxorubicin hydrochloride|
308716|NCT00231582|Drug|etoposide|etoposide
308717|NCT00231582|Drug|ifosfamide|ifosfamide
308718|NCT00231582|Drug|carboplatin|carboplatin
308719|NCT00231595|Drug|topiramate|
308720|NCT00231608|Drug|topiramate|
308721|NCT00231621|Drug|topiramate|
309091|NCT00219895|Drug|Ibuprofen|
309092|NCT00219908|Drug|Mitoxantrone|
309093|NCT00219921|Drug|Intrathecal morphine at surgery, 0.1mg and placebo|
309094|NCT00219921|Drug|Patient Controlled Analgesia with iv morphine and placebo|
309095|NCT00219921|Drug|intrathecal morphine AND patient controlled analgesia with iv morphine|
309096|NCT00219934|Drug|Antiretroviral therapy|HAART therapy
309097|NCT00219947|Other|blood draw|T cell subset enumeration
Serologic reactivity with HIV antigens
Viral load assays by bDNA, PCR, or RT-PCR
Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
HIV-1 Resistance Testing
309098|NCT00219960|Drug|North American Ginseng (Panax Quinquefolius)|
309099|NCT00219973|Drug|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
309100|NCT00002580|Procedure|laparoscopic surgery|
309101|NCT00219986|Drug|Potent HAART during acute or early HIV-1 infection|
309102|NCT00220012|Procedure|Folate depletion and supplementation|
309103|NCT00220025|Device|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
308334|NCT00242515|Procedure|CD8+ T-cell depleted donor lymphocyte infusion|
308335|NCT00242528|Drug|Zoledronic acid|
308336|NCT00242541|Drug|Octreotide acetate|
308337|NCT00242554|Drug|Zoledronic acid|
308338|NCT00242567|Drug|Zoledronic Acid|Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.
After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.
The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes.
308339|NCT00242567|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
308340|NCT00242580|Drug|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
308341|NCT00000405|Procedure|Exercise intervention|
308342|NCT00002641|Drug|doxorubicin hydrochloride|
308343|NCT00242580|Drug|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
308344|NCT00242580|Drug|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
308345|NCT00242593|Drug|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
308346|NCT00242606|Drug|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
308347|NCT00242606|Drug|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
308722|NCT00231634|Drug|topiramate|
308723|NCT00231647|Drug|topiramate|
308724|NCT00231660|Drug|topiramate|
308725|NCT00231673|Drug|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
307611|NCT02720016|Behavioral|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 15 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
307612|NCT02720029|Device|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
307613|NCT02720042|Device|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutrate (P4HB)
307614|NCT02720055|Other|Psychological workbook|
307615|NCT02720055|Other|Basic information workbook|Basic rehabilitation information that represents current practice.
307616|NCT02720068|Drug|MK-4280|IV infusion
307617|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
307618|NCT02720068|Biological|Pembrolizumab|IV infusion
307982|NCT00252109|Behavioral|Popular Opinion Leader|Popular opinion leaders of social networks are identified and attend 4 sessions to prepare them to have casual conversations with persons in the social networks that are meant to shift social norms to embrace safer behaviors (e.g., increased condom use, fewer sexual partners)
307983|NCT00252122|Drug|Ketamine|Ketamine. 0.2 mg/kg, intravenously
307984|NCT00252148|Biological|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
307985|NCT00252161|Procedure|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
307986|NCT00002670|Radiation|low-LET cobalt-60 gamma ray therapy|
307987|NCT00252161|Drug|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
307988|NCT00252174|Drug|3,4-methylenedioxymethamphetamine (MDMA)|Dosage form: capsule
Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):
Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg.
307989|NCT00252174|Drug|3,4-methylenedioxymethamphetamine (MDMA)|Drug:
Dosage form: capsule
Dosage frequency and duration for the control arm (4 subjects):
Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg.
307990|NCT00252187|Drug|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
307991|NCT00252187|Other|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
307260|NCT00218816|Behavioral|Nebulizer Education Intervention|Asthma Education
307261|NCT00218816|Behavioral|Standard Asthma Education Groups|Asthma Education
307262|NCT00218842|Behavioral|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
307263|NCT00218855|Drug|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
307264|NCT00002579|Drug|fluorouracil|
307265|NCT00218855|Drug|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
307266|NCT00218868|Procedure|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
307267|NCT00218881|Procedure|HIV educational video|
307268|NCT00218894|Procedure|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
307269|NCT00218907|Procedure|Educational video|
307270|NCT00218920|Behavioral|Exercise training|
307271|NCT00218933|Behavioral|Exercise training|
307272|NCT00218946|Drug|Sucrose|30 % sucrose
307273|NCT00218946|Device|Pacifier|
307274|NCT00218946|Other|sterile water|
307275|NCT00002579|Drug|methotrexate|
307276|NCT00218959|Behavioral|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos & Monelli).
307277|NCT00218959|Behavioral|treatment as usual|
307278|NCT00218972|Behavioral|Aerobic interval training|
307619|NCT02720081|Drug|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
307620|NCT02720081|Drug|Placebo for MK-1029|Placebo tablet administered orally, QD, at bedtime
307621|NCT02720081|Drug|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
306976|NCT00234273|Behavioral|Therapeutic education primarily focused on dietary|
306977|NCT00234286|Behavioral|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
306978|NCT00234299|Drug|Aspirin|325mg, one tablet orally, six months
306979|NCT00234299|Drug|Placebo|325mg, one tablet orally every day, 6 months
306980|NCT00234312|Drug|escitalopram and sertraline|
306981|NCT00234377|Drug|Seroquel SR|
306982|NCT00002618|Radiation|low-LET electron therapy|
306983|NCT00234390|Drug|Pulmicort (budesonide) pMDI|
306984|NCT00234403|Drug|gefitinib and fulvestrant|
306985|NCT00234416|Drug|Gefitinib|
306986|NCT00234416|Drug|Gemcitabine|
307279|NCT00218972|Behavioral|moderate intensity training|
307280|NCT00218972|Behavioral|Recommendation of regular exercise|
307281|NCT00218985|Behavioral|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
307282|NCT00218998|Behavioral|exercise training|
307283|NCT00219011|Drug|aliskiren|
307284|NCT00219024|Drug|aliskiren|
307285|NCT00219037|Drug|aliskiren|
307286|NCT00002579|Drug|tamoxifen citrate|
307287|NCT00219050|Drug|aliskiren|
307288|NCT00219063|Drug|aliskiren|
307289|NCT00219076|Drug|aliskiren|
307290|NCT00223249|Drug|Quetiapine|
307291|NCT00223262|Drug|Lamotrigine (Drug)|
307292|NCT00223275|Drug|Naltrexone|
306639|NCT00248469|Behavioral|Youth-friendly health services|
306640|NCT00248469|Behavioral|Youth condom promotion & distribution|
306641|NCT00248469|Behavioral|Community activities related to adolescent sexual health|
306642|NCT00248482|Drug|Cisplatin|Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
306643|NCT00002658|Drug|etoposide|
306644|NCT00248482|Drug|Gleevec™|Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
306645|NCT00248482|Drug|irinotecan|Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
306646|NCT00248495|Drug|cisplatin|Given IV
306647|NCT00248495|Drug|pemetrexed disodium|Given IV
306648|NCT00248495|Procedure|adjuvant therapy|Metastasis prevention/control
306649|NCT00248495|Procedure|conventional surgery|Undergoing tissue removal
306650|NCT00248495|Procedure|neoadjuvant therapy|Tumor Reduction
306651|NCT00248521|Drug|alvespimycin hydrochloride|
306652|NCT00248534|Biological|rituximab|
306653|NCT00248534|Drug|methylprednisolone|
306654|NCT00002658|Drug|idarubicin|
306655|NCT00248534|Drug|temozolomide|
306656|NCT00248547|Drug|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
306657|NCT00248547|Drug|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
306658|NCT00248547|Drug|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
306659|NCT00251485|Drug|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
305907|NCT00002559|Drug|ifosfamide|
305908|NCT00210899|Drug|ceftobiprole medocaril|
305909|NCT00210899|Drug|Vancomycin plus Ceftazidime|
305910|NCT00210912|Drug|topiramate|
305911|NCT00210925|Drug|topiramate|
305912|NCT00210938|Drug|Doripenem|
305913|NCT00210951|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
305914|NCT00210964|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
305915|NCT00210964|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
305916|NCT00210977|Drug|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
305917|NCT00210990|Drug|doripenem|
306274|NCT00258076|Drug|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
306275|NCT00258089|Drug|Levofloxacin|
306276|NCT00002691|Drug|methotrexate|
306277|NCT00258102|Drug|Levofloxacin|
306278|NCT00258115|Drug|salsalate|
306279|NCT00258128|Drug|salicylate|
306280|NCT00258141|Drug|Rupatadine|
306281|NCT00258141|Drug|Placebo|
306282|NCT00258154|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
306283|NCT00258154|Biological|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
305203|NCT00000398|Behavioral|Physical exercise training|
305204|NCT00002616|Drug|thiotepa|
305550|NCT00222118|Other|usual care|no intervention
305551|NCT00222131|Drug|Esomeprazole|Esomeprazole 40 mg QD
305552|NCT00222131|Other|Placebo|Placebo
305553|NCT00222144|Drug|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
305554|NCT00222170|Drug|Rabeprazole|
305555|NCT00222183|Drug|Elidel (pimecrolimus)|
305556|NCT00222196|Procedure|lifestyle, PTA|
305557|NCT00222209|Behavioral|Experimental heat pain model|
305558|NCT00222222|Procedure|vein puncture|comparison of different inflammatory markers in the blood of septic patients
305559|NCT00002585|Drug|pyrazoloacridine|
305560|NCT00222235|Drug|d-cycloserine|
305561|NCT00222235|Drug|glycine|
305562|NCT00222235|Drug|placebo|
305563|NCT00222248|Behavioral|Pelvic floor muscle training and bladder training|
305564|NCT00222261|Drug|aspirin|Aspirin 160 mg once daily for two years
305565|NCT00222261|Drug|clopidogrel|clopidogrel 75 mg once daily for two years
305566|NCT00222274|Behavioral|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
305567|NCT00222274|Behavioral|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
310778|NCT00365755|Drug|vincristine sulfate|
310779|NCT00365755|Procedure|autologous bone marrow transplantation|
310780|NCT00365755|Procedure|conventional surgery|
310781|NCT00365768|Drug|Glutamine|Administered orally twice daily for 21 days
310782|NCT00000482|Drug|clofibrate clofibrate|
310783|NCT00315003|Drug|Azithromycin|
310784|NCT00315016|Drug|eplerenone|active comparator
310785|NCT00315016|Drug|fosinopril|doubling of fosinopril dose
310786|NCT00315016|Drug|placebo|placebo (double dummy)
310787|NCT00002855|Drug|Vinblastine|
310788|NCT00315029|Behavioral|evidence based decision aid|evidence based decision aid
310789|NCT00315029|Behavioral|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
310790|NCT00315042|Drug|Telithromycin (HMR3647)|
310791|NCT00315042|Drug|Penicillin|
310792|NCT00315055|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
310793|NCT00315055|Biological|DTaP-IPV//PRP~T combined|0.5 mL, IM
305205|NCT00233441|Drug|CELIVARONE (SSR149744C)|
305206|NCT00233454|Drug|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
305207|NCT00233480|Drug|atorvastatin|atorvastatin 10mg PO QD
305208|NCT00233480|Drug|placebo|matched placebo Qd x 3 months
305209|NCT00233506|Drug|CpG 7909|
305210|NCT00233519|Drug|SomatoKine/IPLEX|Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.
Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection.
305211|NCT00233532|Drug|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
310054|NCT00227942|Drug|Zolpidem|10 mg/day, po qhs
310055|NCT00227942|Drug|placebo|placebo
310056|NCT00227955|Drug|Imipramine|
310057|NCT00227955|Behavioral|Interpersonal Psychotherapy|
310058|NCT00227968|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
310059|NCT00227968|Behavioral|Clinical Status and Symptom Response Therapy (CSSRT)|
310060|NCT00227981|Behavioral|Interpersonal Psychotherapy|
310061|NCT00232154|Procedure|Endoscopic Sinus Surgery|
310062|NCT00232154|Procedure|Blood sampling for hematology|
310419|NCT00217360|Behavioral|a customised multifactorial falls prevention program|
310420|NCT00217373|Biological|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
310421|NCT00217373|Biological|Recombinant Interferon Alfa-2b|Given SC
310422|NCT00217373|Biological|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
310423|NCT00217373|Biological|Sargramostim|Given SC
310424|NCT00217386|Biological|anti-thymocyte globulin|
310425|NCT00217386|Biological|etanercept|
310426|NCT00217399|Drug|sorafenib tosylate|Given orally
310427|NCT00002571|Drug|Intrathecal cytarabine|If initial bone marrow positive:
Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.
If initial CSF cytology positive:
Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.
If initial bone marrow and CSF negative:
Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy.
310428|NCT00220740|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
309684|NCT00002633|Drug|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
309685|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
309686|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
309687|NCT00239382|Drug|Meloxicam ampoule|
309688|NCT00239382|Drug|Meloxicam tablet|
309689|NCT00239395|Drug|Meloxicam ampoule|
309690|NCT00239395|Drug|Meloxicam tablet|
309691|NCT00239408|Device|Pulmonary function Testing|
309692|NCT00239408|Drug|tiotropium bromide|
309693|NCT00239421|Drug|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
309694|NCT00239421|Drug|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
309695|NCT00002633|Procedure|orchiectomy|Optional orchiectomy
309696|NCT00239434|Drug|tiotropium inhalation powder capsule|
309697|NCT00243035|Drug|tipifarnib|Given orally
309698|NCT00243035|Other|laboratory biomarker analysis|Correlative studies
309699|NCT00243048|Dietary Supplement|soy protein isolate|
309700|NCT00243048|Radiation|radiation therapy|
309701|NCT00002642|Drug|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
309702|NCT00243061|Drug|cediranib maleate|Given orally
309703|NCT00243074|Drug|cediranib maleate|Given orally
309704|NCT00243074|Other|laboratory biomarker analysis|Correlative studies
309705|NCT00243087|Drug|BI 2536|
309706|NCT00243100|Drug|vorinostat|Given orally
308953|NCT00259194|Behavioral|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
308954|NCT00259194|Behavioral|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
308955|NCT00259207|Procedure|Pulmonary valve insertion|Pulmonary valve insertion
308956|NCT00259207|Procedure|medical surgery hybride|medical surgery hybride
308957|NCT00259220|Drug|erythomycin|erythomycin
308958|NCT00002696|Drug|fluorouracil|
308959|NCT00259220|Procedure|gastric lavage alone|gastric lavage alone
308960|NCT00259220|Procedure|erythromycine and gastric lavage|erythromycine and gastric lavage
308961|NCT00259233|Drug|peripheral Peptide YY administration|
308962|NCT00259246|Drug|Peptide YY infusion|
308963|NCT00259259|Behavioral|SALATRIM|
308964|NCT00259272|Drug|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
308965|NCT00259285|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
308966|NCT00259285|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 3 cycles
308967|NCT00259298|Drug|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
308968|NCT00259311|Drug|LY2422347|
309321|NCT00249860|Drug|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
309322|NCT00249860|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
309323|NCT00252746|Drug|ZD6474 (vandetanib) 200mg|once daily oral dose
309324|NCT00252746|Drug|ZD6474 (vandetanib) 300mg|once daily oral dose
309325|NCT00252772|Drug|Tesaglitazar|
309326|NCT00252772|Behavioral|Dietary and Lifestyle counseling|
309327|NCT00002674|Drug|etoposide|
308203|NCT00223717|Drug|Desmopressin (DDAVP)|0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
308204|NCT00223717|Drug|Sildenafil|25- 100 mg po. Single dose.
308205|NCT00223717|Drug|Nifedipine|10-30 mg po. Single dose.
308206|NCT00002590|Drug|etoposide|
308573|NCT00212342|Drug|Norethisterone,Ethinylestradiol|
308574|NCT00212342|Drug|Sugar pill|
308575|NCT00002565|Drug|CHOP regimen|
308576|NCT00212355|Drug|NPC-02|zinc acetate
308577|NCT00212368|Drug|Zinc acetate|
308578|NCT00212381|Drug|diindolylmethane (DIM)|
308579|NCT00212407|Biological|Umbilical Cord Blood Transplantation|
308580|NCT00212420|Procedure|parenteral nutrition; enteral nutrition|
308581|NCT00212433|Drug|Tagitol V, Lo So, Readi-Cat 2|
308582|NCT00212446|Device|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
308583|NCT00212459|Behavioral|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
308584|NCT00212459|Behavioral|Control|No more contacts are made with control patients after the initial counseling session.
308585|NCT00212472|Drug|Factor VIII concentrates|To be determined at the discretion of the investigator.
308586|NCT00002565|Drug|cisplatin|
308587|NCT00212472|Other|Low-dose treatment|50 FVIII u/kg three times a week.
308588|NCT00212472|Other|High-dose treatment|200 FVIII u/kg per day.
308589|NCT00212485|Procedure|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
308590|NCT00212485|Procedure|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
307846|NCT00234910|Drug|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
307847|NCT00234923|Drug|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
307848|NCT00234923|Drug|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
307849|NCT00234936|Drug|Adalimumab|
307850|NCT00234936|Drug|Methotrexate|
307851|NCT00234949|Drug|cefdinir|
307852|NCT00234949|Drug|cephalexin|
307853|NCT00234962|Drug|Lopinavir/Ritonavir|
307854|NCT00002619|Procedure|peripheral blood stem cell transplantation|
307855|NCT00234975|Drug|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
307856|NCT00234988|Drug|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
307857|NCT00235001|Drug|trandolapril/verapamil|180/2 mg QD
307858|NCT00235014|Drug|trandolapril|2 mg QD
308207|NCT00223717|Drug|Hydralazine|10-50 mg po. Single dose
308208|NCT00223717|Drug|Hydrochlorothiazide|12.5-100 mg po. Single dose.
308209|NCT00223717|Drug|Placebo|Po or patch. Single dose.
308210|NCT00223717|Drug|Bosentan|62.5 -125 mg po. Single dose.
308211|NCT00223717|Drug|Diltiazem|30-60 mg po. Single dose.
308212|NCT00223717|Drug|Eplerenone|50-100 mg po. Single dose.
308213|NCT00223717|Drug|guanfacine|1-3 mg po. Single dose.
308214|NCT00223717|Dietary Supplement|L-arginine|6-17 g po. Single dose
308215|NCT00223717|Drug|captopril|25-50 mg PO. Single dose.
308216|NCT00223717|Drug|carbidopa|25-200 mg PO. Single dose.
308217|NCT00002590|Drug|leucovorin calcium|
283552|NCT02600741|Drug|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
283553|NCT02600741|Drug|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283554|NCT02600741|Drug|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283555|NCT02600741|Drug|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283556|NCT02600741|Drug|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283557|NCT02600741|Drug|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283558|NCT02600741|Drug|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283559|NCT02600741|Drug|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283560|NCT02600741|Drug|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283561|NCT00191490|Drug|docetaxel|
283562|NCT02600741|Drug|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283563|NCT02600741|Drug|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283564|NCT02600741|Drug|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283565|NCT02602860|Radiation|[11C]UCB-J|Pharmaceutical form: Sterile solution for intravenous infusion
Concentration: 20 mCi
Route of Administration: iv
283866|NCT02596269|Drug|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
283867|NCT02596269|Drug|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
309468|NCT00209105|Behavioral|Acoustic startle|No drugs involved
309469|NCT00209118|Drug|paroxetine|
309470|NCT00002555|Radiation|low-LET electron therapy|
309471|NCT00209131|Drug|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
309821|NCT00255983|Drug|placebo|placebo tablets BID for 5 days
309822|NCT00255996|Drug|linezolid|
309823|NCT00256009|Drug|Cytotec|
309824|NCT00256022|Drug|Lactobacillus Probiotic|
309825|NCT00256022|Other|Lactose Powder|
309826|NCT00002682|Drug|Tetracycline Hydrochloride|
309827|NCT00256035|Procedure|Measuring IL-4 levels|
309828|NCT00256048|Procedure|Nasojejunal feeding|
309829|NCT00256074|Procedure|Enteral feeding formula|
309830|NCT00256087|Drug|Probiotic Lactobacillus|
309831|NCT00256087|Other|Lactose Powder|
309832|NCT00256100|Drug|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
309833|NCT00256113|Drug|Saredutant succinate (SR48968C)|
309834|NCT00256126|Drug|Saizen|blood sampling (10 ml) at baseline and one month (10 ml)
309835|NCT00256139|Drug|Raptiva|
309836|NCT00256152|Device|AF Suppression Pacing Algorithm|
309837|NCT00259623|Device|Radiofrequency ablation|
309838|NCT00002696|Procedure|neoadjuvant therapy|
309839|NCT00259636|Drug|zonisamide|zonisamide 100 mg -300 mg daily vs placebo
309840|NCT00259649|Drug|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
309104|NCT00220038|Behavioral|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
309105|NCT00220051|Drug|Oxaliplatin, Capecitabine|
309106|NCT00220051|Procedure|Pre operative radiotherapy|
309107|NCT00220051|Procedure|Surgical Resection|
309108|NCT00220064|Drug|Irinotecan, 5-Fluorouracil, Leucovorin|
309109|NCT00220077|Procedure|Endoscopy|
309110|NCT00220090|Drug|dexloxiglumide|
309111|NCT00002580|Procedure|oophorectomy|
309112|NCT00220103|Drug|epirubicin, capecitabine, cisplatin|
309113|NCT00223899|Genetic|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
309114|NCT00223912|Device|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
309472|NCT00209131|Drug|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
309473|NCT00209144|Drug|Intensive insulin therapy|
309474|NCT00209170|Behavioral|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
309475|NCT00212784|Drug|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
309476|NCT00212797|Drug|Org 34517|low dose Org 34517
309477|NCT00212797|Drug|Org 34517|high dose Org 34517
309478|NCT00002565|Drug|doxorubicin hydrochloride|
309479|NCT00212797|Drug|Placebo|placebo
309480|NCT00212810|Drug|Topiramate|
309481|NCT00212823|Drug|almotriptan malate|
309482|NCT00212836|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
309483|NCT00212836|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
308726|NCT00000397|Behavioral|Behavioral insomnia therapy|
308727|NCT00002610|Drug|etoposide|
308728|NCT00231686|Behavioral|Supervised aerobic training|
308729|NCT00231686|Behavioral|Supervised strength training|
308730|NCT00231686|Behavioral|Unsupervised training|
308731|NCT00231699|Procedure|Plastic wrap (study group) and cotton (control group) wrap.|
308732|NCT00231725|Drug|insulin lispro injection [rDNA origin] Low Mix|
308733|NCT00231738|Drug|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
308734|NCT00231764|Drug|daclizumab|
308735|NCT00231777|Drug|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
308736|NCT00231777|Drug|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
308737|NCT00231790|Drug|MK-0634 50 mg|one capsule orally, once daily in morning
308738|NCT00002610|Drug|vincristine sulfate|IV
308739|NCT00235235|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
308740|NCT00235235|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
308741|NCT00235235|Drug|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
308742|NCT00235235|Drug|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
308743|NCT00235248|Drug|Warfarin|Warfarin
308744|NCT00235248|Drug|Clopidogrel-aspirin|Clopidogrel-aspirin
308745|NCT00235261|Drug|Pregabalin|
308746|NCT00235261|Drug|Dexamethasone|
308747|NCT00235274|Drug|Subcutaneous Secretin|
308748|NCT00002620|Radiation|low-LET cobalt-60 gamma ray therapy|
309115|NCT00223925|Drug|Maribavir|
307992|NCT00252200|Drug|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
307993|NCT00252213|Drug|Human BNP|
307994|NCT00252226|Drug|Quetiapine|
307995|NCT00252239|Drug|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
307996|NCT00252239|Drug|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
307997|NCT00000410|Procedure|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
307998|NCT00002670|Radiation|low-LET electron therapy|
307999|NCT00252252|Device|VPAP non-invasive ventilator|
308000|NCT00252252|Device|AutoVPAP non-invasive ventilator|
308001|NCT00252278|Drug|atomoxetine|
308002|NCT00252291|Drug|Aridol|
308003|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
308348|NCT00242619|Drug|rosiglitazone|Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as [AKA] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinking. We, the researchers at Stanford University, are recruiting men and women who have been diagnosed with depression, and are willing to participate in this 3 month study. Participation involves neuropsychological testing, 2 blood draws called an oral glucose tolerance test (oGTT), which tests for glucose and insulin levels, and the medication, rosiglitazone. Participants are allowed to continue on their current psychiatric medication.
308349|NCT00242632|Drug|Namenda|Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
308350|NCT00242645|Behavioral|Health Information|
308351|NCT00242645|Behavioral|Preventive Services|
308352|NCT00242645|Behavioral|Computer tailored information|
308353|NCT00002641|Drug|ifosfamide|
308354|NCT00245401|Device|CYPHERTM Sirolimus-Eluting Coronary Stent|
308355|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 48 weeks
307622|NCT02720081|Drug|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
307623|NCT02720094|Drug|Cabotegravir tablets|30 mg tablets
307624|NCT02720094|Drug|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
307625|NCT02720094|Drug|TDF/FTC placebo tablets|
307626|NCT02720094|Drug|CAB placebo tablets|
307627|NCT02720094|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
307628|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
307629|NCT02720094|Drug|Placebo for CAB LA|Administered as one 3 mL (600 mg) injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
307630|NCT02720107|Other|Sampling of blood and urine|Sampling of blood and urine - primarily for biomarker analyses
307631|NCT02720120|Drug|Ocrelizumab|Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
307632|NCT00208091|Drug|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
307633|NCT00208104|Behavioral|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
307634|NCT00208117|Drug|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
307635|NCT00208117|Drug|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
307636|NCT00208130|Drug|Topiramate|
307637|NCT00208143|Drug|Quetiapine|
307638|NCT00208143|Drug|Risperidone|
307639|NCT00208156|Drug|Mifepristone|
308004|NCT00255073|Drug|baclofen|
307293|NCT00223288|Drug|Lexapro|
307294|NCT00223301|Drug|Mycophenolate Mofetil (cellcept)|
307295|NCT00223314|Behavioral|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
307296|NCT00223340|Behavioral|Patient Activation and Diabetes Registry|
307297|NCT00002589|Procedure|adjuvant therapy|
307298|NCT00223353|Other|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
307299|NCT00223379|Procedure|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
307300|NCT00223405|Device|crown placement|
307301|NCT00223418|Drug|aripiprazole|
307302|NCT00223431|Device|all-ceramic fixed partial denture|
307303|NCT00223457|Behavioral|Factors that influence compliance|
307640|NCT00208169|Drug|Aripiprazole|
307641|NCT00208182|Drug|Risperidone|
307642|NCT00002552|Radiation|radiation therapy|
307643|NCT00208195|Drug|Divalproex ER|
307644|NCT00208208|Drug|Ziprasidone|
307645|NCT00208221|Drug|ramipril|
307646|NCT00208221|Drug|ramipril-telmisartan|
307647|NCT00208234|Drug|Omalizumab|0.016 mg/kg IgE
307648|NCT00208234|Drug|Placebo for Omalizumab|Placebo
307649|NCT00208234|Drug|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
307650|NCT00208247|Behavioral|Cognitive behavioral psychotherapy|
306987|NCT00234429|Drug|Gefitinib, raltitrexed|
306988|NCT00234442|Drug|Iressa (Gefitinib)|
306989|NCT00234455|Device|drug eluting-stent|PCI
306990|NCT00234455|Device|drug-eluting stent|PCI
306991|NCT00234468|Drug|Iressa (Gefitinib)|
306992|NCT00234481|Drug|XL844|
306993|NCT00002618|Radiation|low-LET photon therapy|
306994|NCT00238082|Drug|HFA-134A Beclomethasone DIpropionate (QVAR)|
306995|NCT00238108|Drug|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
306996|NCT00238108|Drug|Placebo|Placebo
306997|NCT00238121|Drug|sorafenib tosylate|Given orally
306998|NCT00000400|Drug|alendronate|70 mg/week by oral route
306999|NCT00002630|Biological|filgrastim|
307000|NCT00238147|Drug|capecitabine|
307001|NCT00238147|Drug|carboplatin|
307002|NCT00238147|Drug|docetaxel|
307003|NCT00238147|Procedure|conventional surgery|
307004|NCT00238147|Procedure|neoadjuvant therapy|
307005|NCT00238147|Radiation|radiation therapy|
307006|NCT00238160|Drug|cisplatin|
307007|NCT00238160|Drug|fluorouracil|
307008|NCT00238160|Procedure|adjuvant therapy|
307009|NCT00238160|Procedure|chemotherapy|
307010|NCT00002630|Drug|cyclophosphamide|
307011|NCT00238160|Procedure|conventional surgery|
307012|NCT00238160|Procedure|hepatic arterial infusion|
306284|NCT00258154|Biological|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
306285|NCT00258167|Behavioral|filling the "Experience of Caregiving Inventory"|8 weeks of group therapy for family members
306286|NCT00258180|Biological|filgrastim|
306287|NCT00002691|Drug|vincristine sulfate|
306288|NCT00258180|Drug|cyclophosphamide|
306289|NCT02719522|Device|Pipeline™ Flex Embolization Device with Shield Technology™|Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.
The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot.
306290|NCT02719535|Other|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
306291|NCT02719548|Device|Soft edge oval - Hard oval - Modified PF breast shield|Treatment order:
soft-edge oval breast shield
Hard oval breast shield
modified PersonalFit breast shield
306292|NCT02719548|Device|Modified PF breast shield - Soft edge oval - Hard oval|modified PersonalFit breast shield
soft-edge oval breast shield
Hard oval breast shield
306293|NCT02719548|Device|Hard oval - Soft edge oval - Modified PF breast shield|Hard oval breast shield
soft-edge oval breast shield
modified PersonalFit breast shield
306294|NCT00002549|Biological|filgrastim|
306295|NCT00204490|Dietary Supplement|carbohydrate|carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
306660|NCT00251498|Drug|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
306661|NCT00002668|Behavioral|Observation|
306662|NCT00251511|Drug|Arsenic Trioxide|
306663|NCT00251524|Drug|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
306664|NCT00251537|Drug|LTB4|
306665|NCT00251550|Drug|Pemetrexed|
306666|NCT00251550|Drug|Cisplatin|
305568|NCT00222287|Behavioral|Feldenkrais Movement class|
305569|NCT00222300|Behavioral|Strength training program|
305570|NCT00002586|Drug|13-cis retinoic acid|
305571|NCT00225615|Drug|sapropterin dihydrochloride|
305572|NCT00225628|Behavioral|Computerized Reminders Medications Monitoring|
305918|NCT00002559|Drug|paclitaxel|
305919|NCT00214916|Drug|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
305920|NCT00214929|Behavioral|treatment at home|
305921|NCT00214942|Drug|ORAVESCENT Fentanyl Citrate|
305922|NCT00214955|Drug|ORAVESCENT Fentanyl Citrate|
305923|NCT00214968|Drug|Modafinil|maximum dosage 400 mg/day (4 tablets)
305924|NCT00214981|Drug|Modafinil|
305925|NCT00214994|Drug|Gabitril|
305926|NCT00002567|Biological|filgrastim|
305927|NCT00215007|Drug|Levofloxacin|
305928|NCT00215046|Drug|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
305929|NCT00215046|Drug|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
305930|NCT00215111|Behavioral|Low carbohydrate, reduced glycemic load, and a control diet|
305931|NCT00215124|Drug|Filgrastim|
305932|NCT00215137|Drug|escitalopram|Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
305933|NCT00215137|Drug|Placebo ( sugar pill)|Placebo Comparator in double.blind phase.
305934|NCT00215150|Drug|Ziprasidone|Sertraline augmentation with ziprasidone
305935|NCT00215150|Drug|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
305212|NCT00233545|Drug|miltefosine|
305213|NCT00233545|Drug|antimony|
305214|NCT00233558|Drug|adalimumab (up to 9 months exposure)|
305215|NCT00002616|Procedure|peripheral blood stem cell transplantation|
305216|NCT00233558|Drug|methotrexate|
305217|NCT00233571|Biological|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
305218|NCT00233584|Procedure|Pulmicort (budesonide) pMDI|
305219|NCT00237185|Drug|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
305220|NCT00000400|Drug|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
305221|NCT00002627|Drug|cyclophosphamide|
305222|NCT00237198|Drug|Letrozole|
305223|NCT00237211|Drug|Letrozole|
305224|NCT00237224|Drug|Letrozole|
305225|NCT00237237|Drug|vildagliptin|
305226|NCT00237250|Drug|vildagliptin|
305227|NCT00237263|Drug|Entacapone|
305228|NCT00237276|Procedure|colonoscopy|
305229|NCT00237289|Drug|topiramate|
305573|NCT00225628|Behavioral|Computerized Test Results Management Application|
305574|NCT00225628|Behavioral|Computerized Reminders Hypertension Management|
305575|NCT00225628|Behavioral|Computerized Reminders Osteoporosis Screening and Mgt|
305576|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
305577|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
310429|NCT00220753|Device|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
310430|NCT00220766|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
310431|NCT00220766|Drug|Dextrose, 5% in Water|
310432|NCT00002581|Procedure|conventional surgery|
310433|NCT00220779|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
310434|NCT00220779|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|
310435|NCT00220792|Behavioral|Brief supportive-expressive group therapy|
310436|NCT00220805|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
310437|NCT00220805|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
310794|NCT00315055|Biological|Hepatitis B vaccine|0.5 mL, IM
310795|NCT00315081|Drug|Bromocriptin|
310796|NCT00315094|Behavioral|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
310797|NCT00315107|Drug|Alesse|
310798|NCT00002855|Procedure|Conventional Surgery|Surgical castration
310799|NCT00315120|Procedure|Active osteopathic manipulation and active ultrasound physical therapy|Active osteopathic manipulation and active ultrasound physical therapy
310800|NCT00315120|Procedure|Sham osteopathic manipulation and active ultrasound physical therapy|Sham osteopathic manipulation and active ultrasound physical therapy
310801|NCT00315120|Procedure|Active osteopathic manipulation and sham ultrasound physical therapy|Active osteopathic manipulation and sham ultrasound physical therapy
310802|NCT00315120|Procedure|Sham osteopathic manipulation and sham ultrasound physical therapy|Sham osteopathic manipulation and sham ultrasound physical therapy
310063|NCT00232154|Procedure|Blood sampling for plasma chemistry profile|
310064|NCT00232154|Procedure|Serum pregnancy test (for women of child-bearing potential)|
310065|NCT00002611|Drug|cyclophosphamide|
310066|NCT00232167|Drug|Indiplon|
310067|NCT00232167|Drug|Sertraline|
310068|NCT00232180|Drug|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
310069|NCT00232206|Drug|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
310070|NCT00232219|Drug|Fish oil|
310071|NCT00232232|Drug|Fish oil|
310072|NCT00232245|Drug|Fish oil|
310073|NCT00232258|Drug|Nolpitantium besylate|
310074|NCT00232271|Drug|Clexane|
310075|NCT00232284|Drug|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
310076|NCT00002611|Drug|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; <5% in the urine. The drug has a very short initial t½ of <20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
310077|NCT00232284|Behavioral|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
310078|NCT00232297|Drug|SSR149744C|
310079|NCT00232310|Drug|CELIVARONE (SSR149744C)|
310080|NCT00232323|Behavioral|simulation training|
310081|NCT00232336|Drug|quetiapine|
310082|NCT00232349|Drug|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
310083|NCT00232362|Drug|Pioglitazone (Actos)|
310084|NCT00232362|Drug|Anti-diabetic agent other than pioglitazone or rosiglitazone|
309328|NCT00252785|Drug|Budesonide/Formoterol|
309329|NCT00252785|Drug|Budesonide|
309330|NCT00252785|Drug|Theophylline|
309331|NCT00252798|Drug|Gefitinib|
309332|NCT00252798|Drug|Carboplatin|
309333|NCT00252798|Drug|Paclitaxel|
309334|NCT00252798|Procedure|Radiation|
309335|NCT00252811|Drug|Gefitinib|
309336|NCT00252824|Drug|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
309337|NCT00252837|Drug|Tesaglitazar|
309338|NCT00002674|Drug|hydroxyurea|
309339|NCT00252837|Behavioral|Dietary and Lifestyle counseling|
309340|NCT00252850|Genetic|CERE-120: AAV2-NTN|
309341|NCT00252863|Drug|Symbicort, used twice daily (b.i.d) and as needed (prn)|
309342|NCT00252863|Drug|Budesonide Turbuhaler 200 µg|
309343|NCT00252863|Drug|Fluticasone Discus 250 µg|
309344|NCT00252863|Drug|Formoterol Turbuhaler 4.5 µg|
309345|NCT00252863|Drug|Terbutaline Turbuhaler 0.5 mg|
309346|NCT00252863|Drug|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
309347|NCT00252863|Drug|Salmeterol Discus 50 µg|
309707|NCT00243100|Drug|gemcitabine hydrochloride|Given IV
309708|NCT00243113|Drug|docetaxel|
309709|NCT00243113|Radiation|radiation therapy|
308591|NCT00216138|Drug|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
308592|NCT00216138|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
308593|NCT00216138|Drug|Premedication|Dexamethasone and antiemetic premedication
308594|NCT00216151|Drug|Zoledronic Acid|Zoledronic Acid 4mg, every three months
308595|NCT00216164|Drug|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
308596|NCT00002571|Biological|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
308969|NCT00204633|Drug|Darbepoetin alfa|
308970|NCT00204646|Drug|Adriamycin|
308971|NCT00204646|Drug|Ifosfamide|
308972|NCT00002549|Drug|cyclophosphamide|
308973|NCT00204646|Drug|Etoposide|
308974|NCT00204646|Drug|Carboplatin|
308975|NCT00204659|Drug|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
308976|NCT00204672|Drug|Achipex|
308977|NCT00204685|Drug|dornase alfa|
308978|NCT00204698|Drug|Aciphex|20 mg of aciphex taken twice daily
308979|NCT00204737|Drug|prednisone|20mg x 2 weeks
308980|NCT00204737|Drug|placebo|placebo
308981|NCT00204750|Procedure|Bougie Dilation|Bougie dilation will be performed as standard
308982|NCT00204750|Procedure|Needle-knife incision|Needle-knife incision will be performed
308983|NCT00002549|Drug|cytarabine|
308984|NCT00204763|Device|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
308985|NCT00204763|Device|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
308986|NCT00204776|Drug|Capecitabine and Oxaliplatin|
308218|NCT00227019|Drug|dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
308219|NCT00227032|Drug|erlotinib hydrochloride|300 mg, per day for subjects taking EIAEDs
150 mg, per day for those NOT taking EIAEDs
308220|NCT00227058|Drug|Orotic acid and Glutathione-(Nutritional Supplements)|
308221|NCT00227071|Behavioral|exercise|
308222|NCT00227084|Drug|Arista AH hemostasis powder|
308223|NCT00002598|Biological|recombinant interferon alfa|
308224|NCT00227097|Behavioral|Education Notebook for anticoagulant treatment|
308225|NCT00227110|Drug|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
308226|NCT00227110|Drug|Placebo|Placebo is given to match pioglitazone.
308227|NCT00227123|Drug|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
308228|NCT00227136|Drug|5-Hydroxy-Tryptamine|
308229|NCT00227162|Behavioral|Self-affirmation and positive affect induction|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention, positive affect intervention, both positive affect and self-affirmation intervention or no intervention.
308230|NCT00227175|Behavioral|Semi-structured, open ended interview|
308231|NCT00227188|Drug|Pneumococcal 7-valent conjugate vaccine Prevnar|
308597|NCT00216164|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
308598|NCT00216177|Drug|Infliximab|Remicade
308599|NCT00216177|Drug|Adalimumab|Humira
308600|NCT00216190|Drug|Dexmedetomidine HCL Injection|
308601|NCT00216190|Drug|Midazolam Injection|
308602|NCT00216203|Drug|Pemetrexed|Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
308603|NCT00216203|Drug|Cetuximab|Cetuximab 400 mg/m2, week 1, day 1
Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle
308604|NCT00216216|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
283868|NCT02596282|Procedure|Neonatal circumcision under topical anesthesia|The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine <1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.
Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care.
283869|NCT02596308|Biological|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
283870|NCT02596321|Drug|Mitizax|Allergen extract
283871|NCT02596321|Drug|Placebo|Placebo tablet
283872|NCT02596334|Drug|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
283873|NCT02596334|Drug|dolutegravir|
283874|NCT02596347|Procedure|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
283875|NCT02596347|Procedure|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
283876|NCT00191139|Drug|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
283877|NCT02596360|Drug|Pulmodexane® 30mg|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
283878|NCT02596360|Drug|lactose|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
283879|NCT02596373|Drug|Mitoxantrone Hydrochloride Liposome Injection|
283880|NCT02596386|Procedure|sialometry|potassium evaluation
283881|NCT02596386|Procedure|blood test|potassium evaluation
283882|NCT02596399|Drug|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
283883|NCT02596399|Drug|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
279303|NCT02689674|Behavioral|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
279304|NCT02689674|Behavioral|Telephone counseling|one telephone counseling session per week for 10 weeks.
309841|NCT00259662|Drug|atorvastatin|
309842|NCT00259675|Drug|carboplatin/gemcitabine, carboplatin/taxol|
309843|NCT00259688|Device|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
309844|NCT00259701|Device|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
309845|NCT00259714|Drug|dialysate sodium individualization|Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium ("individualized"). In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L.
310209|NCT00250029|Drug|Oxaliplatin|Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion & the administration of any other drug.
Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 & the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days.
310210|NCT00250042|Drug|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, & were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) & then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
310211|NCT00250055|Procedure|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
310212|NCT00250068|Drug|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
310213|NCT00002665|Drug|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
310214|NCT00250081|Procedure|Upper Extremity Tendon transfer|
310215|NCT00250081|Procedure|Botulinum Toxin injections in Upper Extremity|
310216|NCT00250081|Procedure|Regularly ongoing therapy|
310217|NCT00250094|Drug|Topotecan and VP16|Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.
Course 1B: On day 28, if ANC is >1,500 and platelets > 100,000, VP-16 will be administered orally at 50 mg/day for 14 days.
309484|NCT00212862|Other|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
309485|NCT00212875|Drug|epoetin alfa|
309486|NCT00212888|Biological|Remune and ALVAC|Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);
Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or
Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.
309487|NCT00212901|Drug|High dose ACE-I vs ARB|
309488|NCT00212914|Behavioral|Reminder letter|
309489|NCT00002565|Drug|etoposide|
309490|NCT00212940|Behavioral|Supportive Therapy for Adherence to ART (behavior)|
309491|NCT00212953|Procedure|Advanced Life Support|
309492|NCT00212992|Procedure|fixed versus escalating biphasic defibrillation|
309493|NCT00213005|Drug|Carraguard (PC-515)|
309494|NCT00213018|Drug|Carraguard (PC-515)|
309495|NCT00213031|Drug|Carraguard (PC-515)|
309496|NCT00213044|Drug|Carraguard (PC-515)|
309846|NCT00259740|Drug|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
309847|NCT00259753|Drug|Bevasiranib|
309848|NCT00259766|Drug|Budesonide|
309849|NCT00002696|Radiation|radiation therapy|
309850|NCT00259766|Drug|Formoterol|
309851|NCT00259766|Drug|Terbutaline|
309852|NCT00259779|Drug|budesonide/formoterol|
309853|NCT00259779|Drug|Prednisolone|
309854|NCT00259792|Drug|Budesonide/formoterol Turbuhaler|
309855|NCT00259805|Drug|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
309116|NCT00223925|Drug|Placebo|
309117|NCT00223938|Drug|Oral Iron|Oral Iron
309118|NCT00002590|Drug|prednisone|
309119|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 1
309120|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 2
309121|NCT00223951|Drug|R89674 (generic name not yet established)|
309122|NCT00223964|Drug|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
309123|NCT00223977|Drug|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
309124|NCT00223977|Drug|Sodium Ferric Gluconate Complex|250 mg weekly x 4
309125|NCT00223977|Drug|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
309126|NCT00223990|Biological|FMP1/AS02A|
309127|NCT00224003|Drug|Sodium Ferric Gluconate Complex in Sucrose.|
309128|NCT00224016|Drug|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
309129|NCT00002590|Drug|thioguanine|
309130|NCT00224016|Drug|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
309131|NCT00224029|Drug|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
309132|NCT00224042|Drug|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
309133|NCT00224042|Drug|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
309134|NCT00224055|Drug|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
309135|NCT00224055|Drug|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
309136|NCT00224068|Drug|Sodium ferric gluconate, ferrous sulfate, standard of care|
309137|NCT00224081|Drug|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
309138|NCT00224094|Drug|Premarin® (oral) vs. Alora® (transdermal)|
308356|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 24 weeks
308357|NCT00245427|Drug|all macrolide antibiotics|Varies based on antibiotic
308358|NCT00245427|Drug|all beta-lactam antibiotics|Varies based on antibiotic
308359|NCT00245440|Drug|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
308360|NCT00245440|Drug|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
308361|NCT00245453|Drug|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
308362|NCT00002652|Drug|suramin|
308363|NCT00245453|Drug|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
308364|NCT00245453|Drug|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
308365|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
308366|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
308367|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
308368|NCT00245479|Drug|Primary nocturnal enuresis|Desmopressin
308369|NCT00245492|Procedure|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
308749|NCT00235287|Drug|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
308750|NCT00235287|Drug|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
308751|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
308752|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
308753|NCT00235300|Biological|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
308754|NCT00235300|Drug|Simulect (basliximab)|20 mg per day on 2 days
308005|NCT00255086|Drug|Memantine|
308006|NCT00255099|Drug|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
308007|NCT00255099|Drug|Placebo|2 tablets b.i.d. / 96 weeks
308008|NCT00255112|Behavioral|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
308009|NCT00255125|Drug|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
308010|NCT00255125|Drug|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
308011|NCT00255138|Drug|Atomoxetine|
308012|NCT00002680|Drug|tamoxifen citrate|
308013|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
308014|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
308015|NCT00255151|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
308016|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
308017|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
308018|NCT00255164|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
308019|NCT00255177|Drug|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
308020|NCT00255177|Drug|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
308021|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
308022|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
308023|NCT00002680|Drug|thiotepa|
308024|NCT00255216|Drug|Policosanol supplement (oral capsule) vs. placebo|
308025|NCT00255229|Drug|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
307651|NCT00208260|Drug|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
307652|NCT00208260|Drug|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
307653|NCT00002553|Drug|cyclophosphamide|
307654|NCT00208260|Drug|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
307655|NCT00208260|Drug|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
307656|NCT00208260|Drug|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
307657|NCT00208273|Drug|Letrozole - Concomitant|
307658|NCT00208273|Drug|Letrozole - Sequential|
307659|NCT00211887|Drug|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
307660|NCT00002562|Drug|paclitaxel|
307661|NCT00211887|Drug|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
307662|NCT00211887|Other|placebo|an inactive substance
307663|NCT00211900|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
307664|NCT00211913|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
308027|NCT00255242|Drug|Simvastatin treatment for 28 days|40 mg / day
308028|NCT00255255|Drug|Budesonide/Formoterol|
308029|NCT00255268|Drug|Goserelin|
308030|NCT00255268|Drug|Bicalutamide|
308031|NCT00258622|Drug|NS1209|
308032|NCT00258622|Drug|Lidocaine|
308033|NCT00258635|Biological|RagweedMATAMPL|
307013|NCT00238160|Procedure|surgery|
307014|NCT00238173|Biological|filgrastim|
307015|NCT00238173|Drug|acetylcysteine|administered i.v. over 30 to 60 minutes
307304|NCT00223483|Genetic|Isolation of genomic DNA|One time blood draw
307305|NCT00223496|Drug|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
307306|NCT00223509|Drug|Lamotrigine|
307307|NCT00223522|Device|MEMS caps|
307308|NCT00002590|Biological|filgrastim|
307309|NCT00223535|Behavioral|Cognitive Remediation|
307310|NCT00223535|Behavioral|Social Skills Training|
307311|NCT00223548|Drug|sodium 2-mercaptoethane sulfonate|
307312|NCT00223561|Drug|methylphenidate|
307313|NCT00223574|Drug|Control - high carbohydrate, high glycemic index foods|
307314|NCT00223574|Drug|high carbohydrate, low glycemic index foods|
307315|NCT00223574|Drug|low carbohydrate, high monounsaturate fat foods|
307316|NCT00223587|Other|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
307317|NCT00223600|Behavioral|Nutritional and life style counseling|
307318|NCT00223613|Drug|daily intranasal administration of insulin|
307319|NCT00002590|Drug|cyclophosphamide|
307320|NCT00226590|Drug|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
307321|NCT00226590|Procedure|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
307322|NCT00226603|Behavioral|Specific training programme (behavior)|
307323|NCT00226616|Drug|Zinc|
307324|NCT00226629|Procedure|Endovascular vs Open Repair|
306667|NCT00251576|Drug|A-Phase: tirofiban; Z-Phase simvastatin|
306668|NCT00251576|Drug|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
306669|NCT00251576|Drug|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
306670|NCT00251576|Drug|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
306671|NCT00251576|Drug|Duration of Treatment: Z-Phase, 2 years.|
306672|NCT00002668|Behavioral|Educational Intervention and Behavioral Skills Training|
306673|NCT00251589|Drug|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
306674|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
306675|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
306676|NCT00251589|Drug|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
306677|NCT00251589|Drug|erlotinib|erlotinib 150 mg once a day.
306678|NCT00251602|Drug|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
306679|NCT00251602|Drug|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
306680|NCT00251602|Drug|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
306681|NCT00251628|Other|Standard Care|standard care
306682|NCT00251628|Other|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
306683|NCT00002669|Biological|aldesleukin|
307016|NCT00238173|Drug|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
307017|NCT00238173|Drug|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
307018|NCT00238173|Drug|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
305936|NCT00215163|Drug|Cognitive-behavioral therapy and paroxetine-CR|
305937|NCT00002567|Drug|etoposide|
305938|NCT00215176|Drug|modafinil|
305939|NCT00215189|Behavioral|In SHAPE (Pilot Health Promotion Intervention)|
305940|NCT00215202|Drug|Iressa (ZD1839)|
305941|NCT00215215|Device|Vagus Nerve Stimulation Therapy|
305942|NCT00215228|Drug|duloxetine vs. escitalopram|
305943|NCT00215241|Drug|sertraline and risperidone|
306296|NCT02719561|Behavioral|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
306297|NCT02719574|Drug|FT-2102|FT-2102 will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
306298|NCT02719574|Drug|Azacitidine|azacitidine will be administered per site's standard of care
306299|NCT02719587|Procedure|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
306300|NCT02719587|Procedure|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
306301|NCT02719587|Procedure|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
306302|NCT02719600|Behavioral|Virtual reality|Evaluation of observational motor learning using virtual reality
306303|NCT02719613|Drug|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
306304|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
306305|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
306306|NCT00204503|Drug|Depakote ER|
306307|NCT02719613|Drug|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
305578|NCT00002595|Procedure|conventional surgery|
305579|NCT00225654|Device|coronary stent|
305580|NCT00225667|Drug|Irbesartan|
305581|NCT00225680|Device|drug eluting coronary stent|
305582|NCT00225693|Device|drug eluting coronary stent|
305583|NCT00225706|Drug|Caldolor|
305584|NCT00225719|Drug|rHDL|
305585|NCT00225732|Other|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
305586|NCT00225732|Drug|Intravenous ibuprofen|800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.
Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
305587|NCT00225745|Procedure|Blood draw|One blood draw prior to first treatment
305588|NCT00225758|Drug|Lapatinib|1500 mg po daily for 26 weeks or longer
305589|NCT00002596|Biological|bleomycin sulfate|
305590|NCT00225784|Drug|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
305591|NCT00225784|Procedure|Radiotherapy|Daily radiotherapy for 28 days
305592|NCT00225797|Drug|Oxymorphone Extended Release|
305593|NCT00225810|Drug|Crohn's Disease|
305594|NCT00225823|Drug|GW685698X|
305595|NCT00225836|Device|OVA (TENS apparatus)|
305596|NCT00225849|Drug|Aspirin|
305597|NCT00225862|Drug|ropinirole|
305598|NCT00225875|Drug|Mabthéra|
305944|NCT00215254|Drug|quetiapine|
305945|NCT00215267|Drug|praziquantel|
310803|NCT00315133|Procedure|Immunosuppression and autologous stem cell transplantation|Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and G-CSF (10 ug/kg/d), followed by collection and freezing of HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit ATG (4,5 mg/kg).
310804|NCT00315133|Procedure|Autologous hematopoietic stem cell transplantation|Mobilization of hematopoietic stem cells (HSC) to peripheral blood with G-CSF (10 ug/kg/d) and cyclophosphamide (2 g/m2) followed by collection and freezing of HSC and high dose chemotherapy with cyclophosphamide again (200 mg/kg) plus rabbit antithymocyte globulin (4,5 mg/kg).
310805|NCT00315146|Drug|Pioglitazone|
310806|NCT00315146|Behavioral|Resistance exercise training to maximize muscle power|
310807|NCT00315146|Behavioral|Hypocaloric diet|
310808|NCT00315146|Drug|Placebo|
310809|NCT00002858|Drug|cisplatin|
310810|NCT00317993|Drug|ezetimibe plus simvastatin|
310811|NCT00318006|Procedure|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
310812|NCT00318006|Procedure|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
305230|NCT00237302|Drug|topiramate|
305231|NCT00237328|Drug|Heparin|Heparin will be used as the intra-operative anticoagulant
305232|NCT00002627|Drug|mesna|
305233|NCT00237341|Drug|fentanyl|
305234|NCT00237354|Drug|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
305235|NCT00237367|Drug|rabeprazole and pantoprazole|
305236|NCT00237380|Drug|PTC124|
305237|NCT00237393|Drug|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
305238|NCT00237393|Drug|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
305239|NCT00237406|Procedure|interactive voice response|
310085|NCT00232375|Drug|Insulin|
310086|NCT00232388|Procedure|Blood draw|
310087|NCT00002611|Drug|etoposide|
310438|NCT00220818|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
310439|NCT00220818|Drug|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
310440|NCT00220831|Drug|Natural source Vitamin E 400IU/day|
310441|NCT00220844|Drug|Desipramine|
310442|NCT00220844|Drug|Amitriptyline|
310443|NCT00002581|Radiation|radiation therapy|
310444|NCT00220857|Drug|Rabeprazole|
310445|NCT00220870|Behavioral|Decision aid|
310446|NCT00220896|Drug|Donepezil|
310447|NCT00220909|Drug|Lansoprazole|
310448|NCT00220922|Procedure|Alcohol Wipes vs. No Alcohol Wipes|
310449|NCT00220935|Device|Orthotrac Pneumatic Vest|
310450|NCT00220948|Procedure|CERSR Myoelectric monitoring during standardized tasks|
310451|NCT00220961|Drug|Pioglitazone|
310452|NCT00220974|Behavioral|Internet-based tailored advice on cardiovascular risk|
310453|NCT00220987|Other|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
310454|NCT00002582|Drug|CMF regimen|
310455|NCT00224510|Drug|lamotrigine|
310456|NCT00224523|Drug|GW685698X|
310457|NCT00224523|Drug|mometasone furoate|
310458|NCT00224536|Procedure|Intracoronary bone marrow cell transfer|
310459|NCT00224549|Drug|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
309710|NCT00243126|Behavioral|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
309711|NCT00243139|Device|Mandibular advancement device (activator)|
309712|NCT00002642|Procedure|conventional surgery|surgery some time between weeks 9 and 12
309713|NCT00243152|Drug|Lamotrigine|: 25mg and 50mg tablets
309714|NCT00243165|Behavioral|Lifemel honey intake every day|
309715|NCT00243178|Drug|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
309716|NCT00243191|Drug|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
309717|NCT00243204|Drug|talabostat mesylate|
309718|NCT00243204|Drug|docetaxel|
309719|NCT00243217|Drug|SPM 936|
309720|NCT00243230|Drug|Vicriviroc maleate 20 mg|Two tablets of vicriviroc maleate 10 mg and one tablet of placebo once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc.
309721|NCT00243230|Drug|Vicriviroc maleate 30 mg|Three tablets of vicriviroc maleate 10 mg once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc.
309722|NCT00243230|Drug|Placebo|Three tablets of placebo once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc
309723|NCT00002642|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
309724|NCT00246051|Other|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
309725|NCT00246064|Drug|infliximab|
309726|NCT00246090|Drug|E7389|E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
310088|NCT00232414|Drug|Quetiapine|
308987|NCT00204789|Drug|Difluoromethylornithine|
308988|NCT00204802|Behavioral|Patient-Centered Advance Care Planning|
308989|NCT00204854|Behavioral|telephone counseling|
308990|NCT00204867|Other|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
308991|NCT00204893|Drug|calcium formate|
308992|NCT00204906|Dietary Supplement|vitamin D supplementation|
308993|NCT00204919|Drug|Vitamin D|once-monthly vitamin D oral capsules (50,000 units)
308994|NCT00002549|Drug|daunorubicin hydrochloride|
308995|NCT00204919|Drug|placebo|once-monthly placebo capsules
309348|NCT00252863|Drug|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
309349|NCT00002674|Drug|mitoxantrone hydrochloride|
309350|NCT00252863|Drug|Fluticasone/Salmeterol Discus 250/50 µg|
309351|NCT00252863|Drug|Fluticasone/Salmeterol Discus 500/50 µg|
309352|NCT00252863|Drug|Theophylline 200 mg|
309353|NCT00252863|Drug|Theophylline 300 mg|
309354|NCT00252863|Drug|Singulair 10 mg|
309355|NCT00252876|Drug|tesaglitazar|
309356|NCT00252889|Drug|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
309357|NCT00255710|Procedure|allogeneic bone marrow transplantation|
309358|NCT00255710|Procedure|peripheral blood stem cell transplantation|
309359|NCT00255710|Radiation|radiation therapy|
309360|NCT00255723|Drug|carboplatin|Given IV
309361|NCT00255723|Drug|etoposide|Given IV
309362|NCT00255723|Drug|ifosfamide|Given IV
309363|NCT00255749|Biological|epoetin alfa|
279603|NCT02684916|Procedure|Chiropractic treatment|The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.
The parents and the child are unaware of group allocation.
279604|NCT02684916|Procedure|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
279605|NCT02684929|Dietary Supplement|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
279606|NCT00200278|Behavioral|PROJECT STRIDE|
279607|NCT02684942|Drug|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
279608|NCT02684942|Drug|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
279609|NCT02684955|Device|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
279610|NCT02684955|Device|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
279611|NCT02684968|Procedure|Colorectal surgery|
279612|NCT02684994|Behavioral|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
279613|NCT02685007|Other|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
279614|NCT02685020|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
279913|NCT02578784|Device|Angioplasty with drug-coated balloon|Angioplasty with drug-coated balloon "Elutax" (Aachen Resonance, Germany)
279914|NCT02578784|Device|Angioplasty with plain old balloon|Angioplasty with plain old balloon "Sterling" (BostonScientific, Switzerland)
279305|NCT02689674|Behavioral|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
279306|NCT02689687|Behavioral|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
279307|NCT02689687|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
279308|NCT00201149|Behavioral|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
279309|NCT02692040|Drug|G3215|Gut hormone analogue
279310|NCT02692040|Drug|Placebo|0.9% saline
279311|NCT02692053|Biological|blood sampling|additional blood sampling (volume: 18 mL)
279312|NCT02692066|Biological|varicella vaccine|
279313|NCT02692079|Procedure|T-PRF|Flap Surgery
279314|NCT02692079|Procedure|Allograft|Flap Surgery
279315|NCT02692105|Radiation|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
279316|NCT02692105|Radiation|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
279317|NCT02692144|Other|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
279318|NCT02692157|Drug|Placebo|Placebo for Neurokinin 1,3 antagonist
279319|NCT00201162|Behavioral|diet, soy proteins|
279320|NCT02692157|Drug|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
279321|NCT02692157|Drug|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
279322|NCT02692157|Drug|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
279615|NCT02685020|Biological|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
310218|NCT00250120|Drug|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
310219|NCT00250133|Procedure|Blood draws|
310220|NCT00250146|Behavioral|Gluten (behaviour)|
310221|NCT00250172|Drug|[C-11](R)-rolipram|
310222|NCT00250185|Drug|Sodium Nitrate|
310223|NCT00250185|Drug|Acetylcholine|
310224|NCT00002665|Drug|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
310225|NCT00250198|Drug|STA-5326|
310226|NCT00250211|Procedure|Functional MRI imaging and tomotherapy|
310587|NCT00343564|Drug|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
310588|NCT00343564|Drug|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
310589|NCT00343590|Device|Whole Body Vibration machine|
310590|NCT00343616|Procedure|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
310591|NCT00343616|Procedure|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
310592|NCT00343616|Procedure|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
310593|NCT00343616|Procedure|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
310594|NCT00343629|Drug|sulindac|
310595|NCT00002982|Drug|etoposide|
310596|NCT00343629|Other|pharmacological study|
310597|NCT00343642|Dietary Supplement|Time and attention + fructo-oligosaccharide placebo|2 teaspoons of placebo powder daily
310598|NCT00346879|Drug|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
310599|NCT00346892|Biological|Rotavirus (vaccine)|
309856|NCT00259818|Drug|EM-1421|
309857|NCT00259831|Drug|CVT-E002 (Cold-FX); a natural health product|
309858|NCT00259844|Biological|TroVax|
309859|NCT00259857|Drug|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
309860|NCT00002697|Biological|filgrastim|
309861|NCT00259870|Drug|SB-773812|
309862|NCT00259870|Drug|Olanzapine|
309863|NCT00259883|Drug|paroxetine|1 or 2 tablets once a day
309864|NCT00259896|Drug|exenatide|
309865|NCT00259922|Drug|Placebo|Placebo
309866|NCT00205374|Drug|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
309867|NCT00205387|Procedure|cardiac elastography and echocardiography|standard echocardiogram
309868|NCT00205400|Procedure|medical care delivery model|
310227|NCT00250224|Device|Radiotherapy stent|
310228|NCT00250237|Drug|Haloperidol|Haloperidol 1mg twice daily during 72hours
310229|NCT00250237|Drug|placebo|Placebo 1mg twice daily during 72hours
310230|NCT00250250|Drug|ZOMACTON|
310231|NCT00253188|Drug|galantamine hydrobromide|
310232|NCT00253201|Drug|galantamine hydrobromide|
310233|NCT00253214|Drug|galantamine hydrobromide|
310234|NCT00253227|Drug|galantamine hydrobromide|
310235|NCT00253240|Procedure|Screening|
309139|NCT00224107|Drug|Silodosin|8 mg daily for 12 weeks
309140|NCT00002590|Drug|vincristine sulfate|
309497|NCT00213057|Drug|Carraguard (PC-515)|
309498|NCT00213070|Drug|Miglitol|
309499|NCT00213083|Drug|Carraguard (PC-515)|
309500|NCT00002565|Drug|idarubicin|
309501|NCT00213096|Drug|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
309502|NCT00213109|Drug|Miglitol|
309503|NCT00213122|Drug|miglitol|
309504|NCT00213135|Drug|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
309505|NCT00002571|Drug|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
309506|NCT00216593|Drug|galantamine hydrobromide|
309507|NCT00216606|Drug|topiramate|
309508|NCT00216619|Drug|Topiramate|topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
309509|NCT00216619|Drug|Topiramate - Placebo|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
309510|NCT00216632|Drug|risperidone|
309511|NCT00216645|Drug|doxorubicin hydrochloride|
309512|NCT00216658|Drug|fentanyl|
309513|NCT00216671|Drug|early initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
309514|NCT00216671|Drug|routine initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
308755|NCT00235313|Procedure|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
308756|NCT00235313|Drug|nicotine patch|normal following with a nicotine patch
308757|NCT00235339|Behavioral|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
308758|NCT00235339|Behavioral|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
308759|NCT00002620|Radiation|low-LET photon therapy|
308760|NCT00235352|Drug|CX516 (Ampakine)|
308761|NCT00235365|Behavioral|meta-cognitive therapy|Meta-cognitive therapy
308762|NCT00235365|Other|waiting list|waiting list control
308763|NCT00235391|Drug|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
308764|NCT00235404|Other|Multicomponent treatment|Specialized care in preparing recharge to home
308765|NCT00235404|Other|usual care|Usual recharge directly from hospital to home
308766|NCT00238680|Behavioral|Bladder rehabilitation|
308767|NCT00238680|Behavioral|Bladder rehabilitation with programmable timer|
308768|NCT00238706|Device|Radiofrequency ablation|
308769|NCT00238719|Drug|Venlafaxine ER|
308770|NCT00238732|Drug|Bazedoxifene/Conjugated Estrogen|
308771|NCT00238745|Drug|Bazedoxifene|
309141|NCT00224107|Other|Placebo|1 capsule daily for 12 weeks
309142|NCT00224120|Drug|Silodosin|8 mg daily for 12 weeks
309143|NCT00227448|Drug|oral midodrine|
309144|NCT00227461|Drug|Levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
309145|NCT00227461|Drug|Levetiracetam|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
308026|NCT00255229|Other|Placebo|Glutamine placebo
308370|NCT00245505|Drug|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
308371|NCT00245518|Drug|Revival soy|1 packet of placebo/daily from visit 2 to visit 3, 1 packet of placebo/supplement daily from visit 3 to visit 5.
308372|NCT00245544|Drug|MK0759|
308373|NCT00002653|Drug|carmustine|
308374|NCT00245557|Drug|Sertraline|Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.
Duration of treatment was 12 weeks.
308375|NCT00245570|Drug|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
308376|NCT00245570|Drug|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
308377|NCT00245570|Drug|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
308378|NCT00245570|Drug|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
308379|NCT00245583|Drug|topiramate (Topomax)|
308380|NCT00245596|Drug|sildenafil|
308381|NCT00245609|Drug|Pregabalin|
308382|NCT00245609|Drug|Alprazolam|
308383|NCT00245609|Drug|Placebo|
308384|NCT00249340|Behavioral|brief behavioral weight loss treatment|
308385|NCT00002658|Radiation|radiation therapy|
308386|NCT00249340|Behavioral|brief behavioral + Weight Watchers combined treatment|
308387|NCT00249353|Drug|methylphenidate hydrochloride|
308388|NCT00249366|Drug|Lorazepam (drug)|
308389|NCT00249379|Drug|Acamprosate|Alcohol-dependent criminal justice supervisees will receive acamprosate
308390|NCT00249405|Drug|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
308034|NCT00258661|Procedure|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
308035|NCT00258661|Procedure|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
308036|NCT00258661|Procedure|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
308037|NCT00258674|Other|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
308038|NCT00258674|Other|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
308039|NCT00258674|Other|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
308040|NCT00258687|Biological|GVAX|4 vaccines every two weeks
308041|NCT00002695|Genetic|mutation analysis|
308042|NCT00258700|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
308043|NCT00258713|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
308044|NCT00258726|Biological|MMR-II|
308045|NCT00258726|Biological|Pro-Quad|
308046|NCT00258726|Biological|Varivax|
308047|NCT00258739|Drug|Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine|Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
308394|NCT00249431|Behavioral|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
308395|NCT00249444|Drug|Mirtazapine|Mirtazapine
308396|NCT00002659|Drug|cisplatin-e therapeutic implant|
308397|NCT00249444|Drug|Placebo|placebo
308398|NCT00249457|Behavioral|Contingency management|
307325|NCT00226642|Drug|Sertralin|
307326|NCT00226642|Behavioral|Cognitive-behavioral therapy|
307327|NCT00226642|Drug|Placebo|
307328|NCT00226642|Behavioral|Non-specific supporting group therapy|
307329|NCT00002596|Radiation|radiation therapy|
307330|NCT00226655|Drug|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
307665|NCT00211913|Biological|placebo|single IM dose
307666|NCT00211926|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
307667|NCT00211926|Biological|placebo|single dose of placebo
307668|NCT00211939|Drug|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
307669|NCT00211939|Drug|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
307670|NCT00211939|Drug|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
307671|NCT00002563|Procedure|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
307672|NCT00211952|Drug|celecoxib|
307673|NCT00211965|Biological|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
307674|NCT00211965|Biological|placebo|single dose IM
307675|NCT00211978|Drug|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
307676|NCT00211978|Drug|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
307677|NCT00211991|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
307678|NCT00212004|Drug|pioglitazone|
307679|NCT00212004|Drug|sulfonylurea agents|
307680|NCT00212017|Drug|voglibose|
307681|NCT00212030|Drug|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
307019|NCT00238173|Drug|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
307020|NCT00238173|Drug|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
307021|NCT00002630|Drug|melphalan|
307022|NCT00238199|Dietary Supplement|calcitriol|
307023|NCT00238199|Drug|docetaxel|
307024|NCT00238212|Drug|sorafenib tosylate|Given orally
307025|NCT00241839|Drug|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
307026|NCT00241839|Drug|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
307027|NCT00241852|Behavioral|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
307028|NCT00241852|Behavioral|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
307029|NCT00241878|Behavioral|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
307331|NCT00226668|Drug|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
307332|NCT00226668|Drug|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
307333|NCT00226681|Behavioral|Nursing Telephone Support Protocol|
307334|NCT00226681|Behavioral|Usual Care|
306308|NCT02719613|Drug|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
306309|NCT02719665|Dietary Supplement|Specialized Pro-resolving Lipid Mediator (SPM) Emulsion,|
306310|NCT00207259|Behavioral|Reiki & Relaxation Response Therapy with Cognitive Restructuring|Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.
Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant.
306311|NCT00207272|Behavioral|1170-1870 kcal/day liquid diet|
306312|NCT00207272|Procedure|Gastric bypass surgery|
306313|NCT00002552|Drug|methotrexate|
306314|NCT00207272|Procedure|Biopsy.visceral adipose tissue|
306315|NCT00207272|Procedure|Biopsy.omental adipose tissue|
306316|NCT00207272|Procedure|Biopsy. subcutaneous abdominal adipose tissue|
306684|NCT00251628|Other|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
306685|NCT00254540|Drug|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
306686|NCT00254553|Drug|Testim 1% (testosterone gel)|Testim_ 100 mg: two tubes of 50 mg of Testim_per day
306687|NCT00002679|Drug|doxorubicin hydrochloride|
306688|NCT00254553|Drug|Placebo|two tubes of placebo per day
306689|NCT00254566|Other|Moxifloxacin Placebo|1 capsule once daily for 5 days
306690|NCT00254566|Drug|Moxifloxacin|1 X 400mg capsule once daily for 5 days
306691|NCT00254566|Other|Azithromycin SR Placebo|single dose, oral.
306692|NCT00254566|Drug|Azithromycin SR|single dose 2.0 g oral
306693|NCT00254579|Drug|CP-675,206|15 mg/kg Q12W dosing regimen
306694|NCT00254592|Drug|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
305946|NCT00215280|Drug|ivermectin and albendazole|
305947|NCT00215293|Device|Cervical I/F Cage|
305948|NCT00002567|Procedure|peripheral blood stem cell transplantation|
305949|NCT00215293|Device|Autograft or allograft with a plate, or autograft alone.|
305950|NCT00215306|Device|CHARITÉ Artificial Disc|
305951|NCT00218244|Other|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
305952|NCT00218257|Drug|Progesterone|200mg progesterone BID
305953|NCT00218257|Other|placebo|
305954|NCT00218270|Drug|Tobacco free snuff|Tobacco free snuff
305955|NCT00218283|Drug|Nicotine Lozenge|Oral Nicotine replacement product
305956|NCT00218283|Behavioral|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
305957|NCT00002577|Radiation|radiation therapy|
305958|NCT00218296|Drug|Usual Care Group|Nicotine replacement therapy
305959|NCT00218296|Other|Reduction Group|Subject selects preferred method for reduction.
305960|NCT00218309|Drug|Hydromorphone|
305961|NCT00218322|Drug|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
305962|NCT00218322|Drug|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
305963|NCT00218335|Behavioral|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
305964|NCT00218335|Behavioral|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
305965|NCT00218348|Drug|Dextro-Amphetamine Sulfate|
305966|NCT00218361|Drug|Hydromorphone|
305240|NCT00237419|Drug|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
305241|NCT00237445|Drug|telithromycin|
305242|NCT00237445|Drug|azithromycin|
305243|NCT00002627|Drug|paclitaxel|
305244|NCT00237458|Drug|Lacosamide|Dosage: Lacosamide up to 400 mg/day;
Dosage form: Film-coated tablets;
Dosage Frequency and Duration: Two times per day; 9.5 years
305245|NCT00237471|Drug|Insulin (tight blood glucose control)|
305246|NCT00237484|Drug|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:
powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks
305247|NCT00240682|Drug|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
305248|NCT00240695|Drug|galantamine hydrobromide|
305249|NCT00240708|Drug|risperidone|
305250|NCT00240721|Drug|topiramate|
305251|NCT00240734|Drug|Epoetin alfa|
305252|NCT00240747|Drug|Synercid|
305253|NCT00002634|Radiation|low-LET photon therapy|
305254|NCT00240760|Drug|Memantine Hydrochloride|
305599|NCT00225888|Behavioral|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
305600|NCT00002596|Biological|filgrastim|
305601|NCT00225901|Drug|Recombinant human hepatocyte growth factor|
305602|NCT00229684|Drug|pioglitazone|45 mg once daily in oral form
305603|NCT00229697|Drug|Gefitinib|
305604|NCT00229697|Drug|Tamoxifen|
305605|NCT00229710|Drug|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
310460|NCT00002592|Drug|cyclophosphamide|
310461|NCT00224562|Drug|TNF-alpha antagonists|
310462|NCT00224575|Other|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
310463|NCT00224575|Other|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
310464|NCT00224588|Drug|Ketamine (or placebo : isotonic saline solution)|
310813|NCT00318019|Dietary Supplement|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
310814|NCT00002869|Drug|hydroxyurea|
310815|NCT00318019|Other|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
310816|NCT00318032|Drug|multi-factorial intervention|
310817|NCT00318045|Device|Eyeglass lenses|
310818|NCT00318058|Biological|influenza vaccine Fluarix, Adjuvanted Fluarix|
310819|NCT00318071|Device|Merci Retriever|For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.
Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.
Recanalization was defined as TIMI II or TIMI III per angiography.
310820|NCT00318084|Drug|Esomeprazole|
310821|NCT00318084|Procedure|Ambulatory 24-hour esophageal pH-monitoring|
310822|NCT00318110|Procedure|NST using MUD for metastatic renal cell carcinoma|Preparative regimen:
Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11
310823|NCT00318123|Drug|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
310824|NCT00318136|Drug|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
310825|NCT00002870|Biological|filgrastim|
310826|NCT00318136|Drug|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
310827|NCT00318136|Drug|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
310089|NCT00232427|Procedure|Hemodynamic monitoring system PiCCO|
310090|NCT00232440|Device|BodyFIX|
310091|NCT00232453|Procedure|Combined Radiation and Chemotherapy|
310092|NCT00235859|Drug|adalimumab|
310093|NCT00002623|Drug|cisplatin|
310094|NCT00235859|Drug|methotrexate|
310095|NCT00235872|Biological|adalimumab|40 mg eow, sc
310096|NCT00235885|Drug|adalimumab|
310097|NCT00235898|Drug|CoFactor|
310098|NCT00235898|Drug|5-FU|
310099|NCT00235898|Drug|Leucovorin|
310100|NCT00235911|Drug|budesonide/formoterol Turbuhaler|
310101|NCT00235924|Drug|soy isoflavone|
310102|NCT00235937|Drug|Anastrozole and goserelin|
310103|NCT00235950|Drug|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
310104|NCT00002623|Procedure|conventional surgery|
310105|NCT00235963|Drug|Simvastatin|
310106|NCT00235976|Drug|Gantacurium Chloride for Injection (AV430A)|
310107|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
310108|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
310109|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
310110|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
310111|NCT00236002|Drug|Alendronate|Alendronate 70mgm once a week for one year
310112|NCT00236015|Drug|Gabitril|
309364|NCT00255762|Drug|carboplatin|Given IV
309365|NCT00002682|Drug|Bismuth Subsalicylate|
309366|NCT00255762|Drug|paclitaxel|Given IV
309367|NCT00255762|Biological|bevacizumab|Given IV
309368|NCT00255762|Other|laboratory biomarker analysis|Correlative studies
309369|NCT00255775|Dietary Supplement|broccoli sprout extract|
309370|NCT00255775|Procedure|complementary or alternative medicine procedure|
309371|NCT00255788|Drug|everolimus|
309372|NCT00255801|Drug|Targretin® (bexarotene)|
309373|NCT00255801|Drug|pegylated liposomal doxorubicin hydrochloride|
309374|NCT00255814|Radiation|radiation therapy|
309375|NCT00255827|Biological|HyperAcute-Pancreatic Cancer Vaccine|
309727|NCT00246103|Drug|valproic acid|
309728|NCT00246103|Drug|epirubicin|
309729|NCT00246103|Drug|5-fluorouracil|
309730|NCT00246103|Drug|Cyclophosphamide.|
309731|NCT00246116|Procedure|Functional Imaging of Treatment Effects|PET & VQ Scans
309732|NCT00002654|Drug|chemotherapy|
309733|NCT00246129|Drug|Alemtuzumab|Monoclonal antibody induction therapy
309734|NCT00246129|Drug|Daclizumab|Monoclonal antibody induction therapy
309735|NCT00246142|Drug|Botulinum type A toxin (Dysport)|
309736|NCT00246155|Drug|Botulinum toxin type A (Dysport)|
309737|NCT00246168|Drug|tramadol hydrochloride + acetaminophen|
309738|NCT00246181|Procedure|radiation therapy|Patients will receive 3 fractions
309739|NCT00246194|Drug|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
279915|NCT02578797|Drug|JNJ-56021927|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
279916|NCT00188942|Drug|Fluoxetine+Olanzapine|
279917|NCT02578823|Device|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
279918|NCT02578823|Device|Arcticgel™|
279919|NCT02578823|Procedure|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
279920|NCT02578836|Procedure|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
279921|NCT02578849|Drug|L-DOPA|Patients and healthy controls are recruited to participate in [11C]yohimbine scans before and after L-DOPA challenge.
279922|NCT02578862|Drug|Propofol|
279923|NCT02578862|Drug|Sevoflurane|
279924|NCT02578888|Other|Palliative Therapy|Palliative Therapy
279925|NCT02578888|Other|Palliative Therapy + idiographic|Ancillary studies
279926|NCT02578901|Drug|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
279927|NCT00188942|Drug|Olanzapine|
279928|NCT02578901|Drug|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
279929|NCT02578914|Drug|NS2 Ophthalmic Drops (0.5%)|
279930|NCT02578914|Drug|NS2 Ophthalmic Drops Vehicle (0.0%)|
279931|NCT02578927|Dietary Supplement|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
279932|NCT02581098|Other|Tissue Biopsy|4-6 tissue biopsies will be obtained. Each biopsies will be sent for Laser Capture Molecular (LCM) - wound-edge endothelial cell capture, immunohistochemistry studies, to determine if the wound is infected using quantitative bacterial cultures and scanning electron microsopy for biofilm structure detection.
279616|NCT02685020|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
279617|NCT00200291|Behavioral|hypocaloric, low-fat diet|hypocaloric, low-fat diet
279618|NCT02685033|Drug|Dalbavancin|
279619|NCT02685033|Drug|Comparator|
279620|NCT02687399|Other|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
279621|NCT00200577|Drug|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
279622|NCT02687399|Biological|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
279623|NCT02687412|Procedure|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
279624|NCT02687412|Procedure|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
279625|NCT02687412|Procedure|only oral intestinal cleaner 12 h pre-operation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
279626|NCT02687412|Procedure|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
279627|NCT02687412|Procedure|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
279628|NCT02687412|Procedure|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
279629|NCT02687412|Procedure|Postoperative glycaemic control|Postoperative glycaemic control;
279630|NCT02687412|Procedure|postoperative nausea and vomiting (PONV) control;|
279631|NCT02687412|Procedure|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
279632|NCT00200590|Drug|acetaminophen and nalbuphine|
279633|NCT02687412|Procedure|pre-operative fasting at least 8h|
279634|NCT02687412|Procedure|Oral bowel preparations|Oral bowel preparations or mechanical bowl until liquid stool
310600|NCT00346905|Drug|Enteryx|
310601|NCT00346918|Drug|Sirolimus|Standard plus Sirolimus
310602|NCT00002995|Drug|cyclophosphamide|
310603|NCT00346918|Other|Standard|Standard
310604|NCT00346931|Procedure|Phacoemulsification, implantation of intraocular lens|
310605|NCT00346931|Procedure|Phacoemulsification, Implantation of IOL, trabeculotomy|
310606|NCT00346944|Procedure|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
310607|NCT00346957|Drug|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
310608|NCT00346957|Drug|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
310609|NCT00346957|Drug|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
310956|NCT00334776|Biological|gp100:209-217(210M) peptide vaccine|
310957|NCT00334776|Biological|therapeutic autologous dendritic cells|
310958|NCT00334776|Biological|tyrosinase peptide|
310959|NCT00002945|Drug|idarubicin|IV
310960|NCT00334789|Drug|Belinostat|Given IV
310961|NCT00334789|Drug|Isotretinoin|Given orally
310962|NCT00334789|Other|Pharmacological Study|Correlative studies
310963|NCT00334802|Drug|gemcitabine|Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)
Phase 2: dose determined by phase 1
310964|NCT00334802|Drug|paclitaxel|Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles
Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles
310965|NCT00334815|Drug|cisplatin|Given IV
310966|NCT00334815|Drug|etoposide|Given IV
310967|NCT00334815|Radiation|radiation therapy|Undergo thoracic radiotherapy
310968|NCT00334815|Biological|bevacizumab|Given IV
310236|NCT00253240|Procedure|Management|
310237|NCT00253266|Drug|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
310238|NCT00253266|Drug|Quetiapine|Quetiapine up to 200 mg/d for four weeks
310239|NCT00002675|Drug|cisplatin|
310240|NCT00253279|Procedure|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
310241|NCT00253305|Drug|Organogel of naftifine, 2%|
310242|NCT00253305|Drug|Organogel of terbinafine, 2%|
310243|NCT00253305|Drug|Organogel of naftifine, 6%|
310244|NCT00253305|Drug|Organogel of terbinafine, 6%|
310245|NCT00253318|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
310246|NCT00253318|Drug|RAD001|30 mg orally on Days 1 and 8.
310247|NCT00253318|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
310248|NCT00253331|Drug|topical organogel with nitroglycerin|
310249|NCT00253344|Drug|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
310250|NCT00002675|Drug|cyclophosphamide|
310251|NCT00253344|Drug|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
310252|NCT00253370|Drug|BAY 43-9006|Given orally
310253|NCT00253370|Drug|docetaxel|Given IV
310610|NCT00346957|Other|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
310611|NCT00346970|Drug|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
310612|NCT00346970|Drug|Placebo|Placebo tablets
310613|NCT00002995|Drug|vincristine sulfate|
310614|NCT00346983|Drug|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
309515|NCT00216684|Drug|fentanyl|
309516|NCT00002571|Drug|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
309517|NCT00216697|Drug|bortezomib|
309518|NCT00216710|Behavioral|Home Visiting|
309869|NCT00205426|Drug|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
309870|NCT00205465|Drug|VX-765|
309871|NCT00205478|Drug|VX-702|
309872|NCT00205491|Drug|Venlafaxine|
309873|NCT00002549|Drug|mitoxantrone hydrochloride|
309874|NCT00205504|Drug|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
309875|NCT00205517|Procedure|Daily interruption of sedation versus sedation algorithm|
309876|NCT00205530|Behavioral|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
309877|NCT00205543|Procedure|uvulopalatopharyngoplasty with or without sutures|standard UPPP
309878|NCT00205556|Procedure|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
309879|NCT00205556|Procedure|low flux hemodialysis|standard treatment
309880|NCT00205569|Behavioral|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
309881|NCT00205582|Device|Positron Emission Tomography|
309882|NCT00205595|Device|Positron Emission Tomography|
309883|NCT00205608|Device|Positron Emission Tomography|camera is new
309884|NCT00002549|Procedure|allogeneic bone marrow transplantation|
309885|NCT00205621|Device|Positron Emission Tomography|
309146|NCT00227474|Drug|recombinant modified vaccinia Ankara-5T4 vaccine|
309147|NCT00227474|Procedure|adjuvant therapy|
309148|NCT00227474|Procedure|recombinant viral vaccine therapy|
309149|NCT00227500|Drug|Pravastatin|
309150|NCT00002598|Drug|methotrexate|
309151|NCT00227513|Drug|bortezomib|Given IV
309152|NCT00227513|Drug|vorinostat|Given orally
309153|NCT00227526|Behavioral|Prehabilitation|
309154|NCT00227539|Drug|cisplatin|
309155|NCT00227539|Drug|pemetrexed disodium|
309156|NCT00227539|Procedure|adjuvant therapy|
309157|NCT00227539|Procedure|therapeutic conventional surgery|
309158|NCT00227539|Radiation|fludeoxyglucose F 18|
309159|NCT00227565|Drug|carboplatin|
309160|NCT00227565|Drug|pemetrexed disodium|
309161|NCT00002598|Drug|mitoxantrone hydrochloride|
309162|NCT00227565|Radiation|radiation|
309163|NCT00227591|Drug|lenalidomide|Given orally (PO)
309164|NCT00227591|Drug|prednisone|Given PO
309165|NCT00227591|Other|laboratory biomarker analysis|Correlative studies
309166|NCT00227617|Biological|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
309519|NCT00216723|Drug|Aripiprazole|The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.
(Administer 10 to 30 mg/day according to the patient's condition)
309520|NCT00216736|Drug|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
309521|NCT00216736|Drug|placebo|Single dose oral placebo at ED discharge
308391|NCT00249405|Behavioral|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
308392|NCT00249418|Behavioral|Contingency management|Rewards (prizes) for abstinence
308393|NCT00249431|Drug|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
308772|NCT00002632|Drug|paclitaxel|
308773|NCT00238745|Drug|Placebo|
308774|NCT00238758|Drug|Omega-3 Polyunsaturated Fatty Acids|
308775|NCT00238784|Drug|Budesonide/formoterol Turbuhaler|
308776|NCT00238797|Drug|Gefitinib|
308777|NCT00238836|Behavioral|Self-management of chronic illness|
308778|NCT00238849|Drug|Oxaliplatin|
308779|NCT00238862|Procedure|Amniotic membrane transplantation|
308780|NCT00238862|Drug|Autologous serum/BSS 20%|
308781|NCT00238875|Procedure|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
308782|NCT00238888|Procedure|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit|
308783|NCT00002633|Drug|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
308784|NCT00238901|Drug|Basiliximab|
308785|NCT00238914|Drug|Naltrexone|50mg of oral naltrexone daily
308786|NCT00238914|Behavioral|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
308787|NCT00238914|Behavioral|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
308788|NCT00238927|Drug|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
308789|NCT00238940|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
308399|NCT00249470|Behavioral|Contingency management|
308400|NCT00249483|Drug|Venlafaxine|Venlafaxiine 300mg/day
308401|NCT00249483|Drug|Placebo|Placebo
308402|NCT00249496|Behavioral|Contingency management|
308403|NCT00249509|Drug|Nefazodone|
308404|NCT00249509|Drug|Bupropion|
308405|NCT00249522|Behavioral|Contingency management|
308406|NCT00249535|Behavioral|Contingency management|Rewards (prizes) for abstinence
308407|NCT00002662|Drug|docetaxel|
308408|NCT00249548|Behavioral|Contingency management|
308409|NCT00249561|Behavioral|Recovery by Choice|The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program "trauma informed" and "trauma sensitive."
308410|NCT00252291|Drug|Methacholine|
308411|NCT00252291|Procedure|Exercise challenge|
308412|NCT00252304|Drug|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
308413|NCT00252304|Drug|Placebo|Placebo
308414|NCT00252317|Drug|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
308415|NCT00252317|Drug|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
308416|NCT00002670|Radiation|low-LET photon therapy|
308417|NCT00252330|Drug|SR58611A|
308796|NCT00242697|Procedure|spinal analgesia and anesthesia for coronary artery surgery|
308797|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
307682|NCT00002563|Procedure|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
307683|NCT00212030|Drug|placebo|Control
307684|NCT00212043|Drug|carboplatin and gemcitabine|
307685|NCT00212056|Drug|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
307686|NCT00212056|Drug|Control|placebo
307687|NCT00215930|Drug|Gemcitabine|Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.
RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.
308048|NCT00258739|Other|Docetaxel + gemcitabine + carboplatin + radiotherapy|Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
308049|NCT00258752|Behavioral|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
308050|NCT00258752|Other|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
308051|NCT00258752|Other|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
308052|NCT00002695|Other|laboratory biomarker analysis|
308053|NCT00258765|Drug|Zoledronic Acid|
308054|NCT00258765|Drug|Docetaxel|
308055|NCT02720120|Drug|Placebo|Participants will receive single IV infusion of placebo.
308056|NCT02720133|Biological|biochemical parameters|patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.
All these tests should be practice before, during and after Ramadan fasting for comparison.
308057|NCT02720159|Device|Percutaneous Osseintegrated Prosthesis|
308058|NCT02720172|Behavioral|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
308059|NCT02720172|Other|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
308060|NCT02720185|Drug|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery
307335|NCT00226694|Drug|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
307336|NCT00226694|Other|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
307337|NCT00226707|Drug|Pimecrolimus Cream 1%|
307338|NCT00226720|Procedure|Outpatient detoxification program|Outpatient detoxification program
307339|NCT00226733|Behavioral|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
307340|NCT00002597|Drug|flutamide|
307341|NCT00226733|Behavioral|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
307342|NCT00226746|Drug|Paclitaxel and gemcitabine|
307343|NCT00226746|Procedure|Hyperfractionated external beam irradiation|
307344|NCT00226759|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
307345|NCT00226759|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
307346|NCT00226772|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
307347|NCT00226772|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
307348|NCT00226785|Drug|Dexmedetomidine|
307349|NCT00226798|Drug|Capecitabine (Xeloda)|
307350|NCT00230789|Drug|Tolterodine ER 4 mg QD|
307351|NCT00230789|Behavioral|OAB Patient Behavioral Training Material|
307352|NCT00230802|Drug|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
307353|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
307354|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
306695|NCT00254592|Drug|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
306696|NCT00254592|Drug|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
306697|NCT00254592|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
306698|NCT00002679|Drug|paclitaxel|
306699|NCT00254592|Drug|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
306700|NCT00254592|Drug|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
306701|NCT00254592|Drug|Bevacizumab|10mg/kg q 2 wks
306702|NCT00254618|Drug|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
306703|NCT00254618|Drug|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
306704|NCT00254618|Drug|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
306705|NCT00254631|Drug|Oxycodone hydrochloride|
306706|NCT00254644|Procedure|Morphological and functional MRI|one time
307030|NCT00241878|Behavioral|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
307031|NCT00241891|Behavioral|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
307032|NCT00241891|Behavioral|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
307033|NCT00241891|Behavioral|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
307034|NCT00002638|Drug|cytarabine|
307035|NCT00241904|Behavioral|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
307036|NCT00241904|Drug|Antiplatelet Agents|Aspirin 81 mg q day
305967|NCT00218374|Drug|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
306317|NCT00207272|Procedure|Blood sample|
306318|NCT00207285|Behavioral|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
306319|NCT00207285|Procedure|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
306320|NCT00207298|Procedure|Positron Emission Tomography|
306321|NCT00207311|Drug|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
306322|NCT00207311|Behavioral|Xenicare Program|Xenicare program for 36 weeks.
306323|NCT00207324|Device|Silver Leaf Dressing|
306324|NCT00002552|Drug|perfosfamide|
306325|NCT00207337|Device|Exhale Drug-Eluting Stent|
306326|NCT00207350|Device|Interstitial Laser Therapy|Device
306327|NCT00207363|Drug|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
306328|NCT00207363|Drug|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
306329|NCT00207376|Device|Solysafe Septal Occluder|
306330|NCT00207389|Procedure|Oral glucose tolerance test|
306331|NCT00207389|Procedure|G tube glucose tolerance test|
306332|NCT00207402|Drug|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
306333|NCT00207415|Behavioral|ASHC and CDSMP|
306334|NCT00207428|Drug|Carbamazepine|
305606|NCT00229723|Drug|gefitinib (Iressa)|250 mg oral tablet
305607|NCT00229723|Drug|cisplatin|intravenous infusion
305608|NCT00000395|Dietary Supplement|Folic acid|
305609|NCT00002601|Drug|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
305610|NCT00229723|Radiation|radiotherapy|radiation therapy
305611|NCT00229723|Drug|Gefitinib (Iressa)|500 mg oral tablet
305612|NCT00229736|Genetic|AAV-hAADC-2|9 x 10^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
305613|NCT00229736|Genetic|AAV-hAADC-2|3 x 10^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
305614|NCT00229749|Drug|AVI-4065 Injection|
305615|NCT00229762|Behavioral|phone call from nurses - informational only|
305616|NCT00229775|Drug|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
305617|NCT00229801|Radiation|MRI|
305618|NCT00229840|Procedure|Functional MRI, Diffusion Tensor Imaging|
305619|NCT00229918|Drug|triamcinolone acetonide|
305620|NCT00002601|Drug|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
305621|NCT00229931|Drug|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
305622|NCT00229931|Procedure|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
305623|NCT00229944|Drug|Azithromycin|
305624|NCT00229957|Behavioral|Occupational therapy|
305968|NCT00002578|Drug|cytarabine|
305969|NCT00218387|Drug|Modafinil|200mg Modafinil
305970|NCT00218387|Drug|Modafinil|400mg Modafinil
305971|NCT00218387|Drug|Matching Placebo|Matching Placebo
310828|NCT00318149|Biological|Fluarix, 4 adjuvanted candidate influenza vaccines|
310829|NCT00318162|Drug|low dose naltrexone|
310830|NCT00318175|Drug|Bosentan (Tracleer)|
310831|NCT00318188|Procedure|standardized reeducation and readaptation program|
310832|NCT00318201|Drug|Erythromycin|
310833|NCT00318201|Drug|Diltiazem|
310834|NCT00318214|Drug|MRE0094|Gel, 500 mcg/g once each day
310835|NCT00321685|Drug|Leucovorin Calcium|Given IV
310836|NCT00321685|Drug|Oxaliplatin|Given IV
305255|NCT00240773|Drug|acetaminophen|4 grams daily for six months
305256|NCT00240773|Drug|naproxen|750 mg daily for 12 months
305257|NCT00240773|Drug|acetaminophen|4 grams daily for 12 months
305258|NCT00240773|Drug|naproxen|750 mg daily for six months
305259|NCT00240786|Drug|acetaminophen extended release|
305260|NCT00240799|Drug|acetaminophen extended release|
305261|NCT00240799|Drug|placebo|
305262|NCT00240812|Drug|ibuprofen; pseudoephedrine HCl|
305263|NCT00240825|Drug|Ibuprofen|
305264|NCT00002634|Radiation|radioisotope therapy|
305265|NCT00240825|Drug|Placebo|
305266|NCT00240825|Drug|Acetaminophen|
305267|NCT00240838|Drug|acetaminophen extended release caplets|
305268|NCT00240851|Drug|acetaminophen extended release|
305269|NCT00240864|Drug|placebo|
305270|NCT00240864|Drug|acetaminophen|
310113|NCT00236028|Drug|Infliximab|
310114|NCT00236041|Drug|ACTIQ®|
310115|NCT00002623|Radiation|radiation therapy|
310465|NCT00224601|Procedure|Colonoscopy with chromoscopy|
310466|NCT00224614|Procedure|Allogenic transplantation|
310467|NCT00224627|Procedure|Capsule GIVEN IMAGING LTD|
310468|NCT00224640|Drug|Iron chelating intervention|Iron chelating intervention
310469|NCT00224653|Procedure|Mechanical Ventilation|
310470|NCT00224666|Device|Cortex stimulation|
310471|NCT00002592|Procedure|autologous bone marrow transplantation|
310472|NCT00224679|Drug|Aspirin|
310473|NCT00224692|Drug|Low dose ketamine|
310474|NCT00224705|Device|Molecular Adsorbent Recirculating System (MARS®)|
310475|NCT00224718|Procedure|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
310476|NCT00224718|Procedure|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
310477|NCT00224744|Device|ultracision|Surgery by Ultracision
310478|NCT00224744|Device|classical lymphadenectomy|classical lymphadenectomy
310479|NCT00224757|Procedure|Transoesophageal echocardiography|TEE
310480|NCT00224770|Drug|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
310481|NCT00002599|Drug|cyclophosphamide|
310482|NCT00227981|Drug|Fluoxetine|
309740|NCT00246207|Drug|CONCERTA (OROS methylphenidate hydrochloride)|
309741|NCT00246220|Drug|methylphenidate hydrochloride|
309742|NCT00246233|Drug|methylphenidate|
309743|NCT00002654|Drug|cisplatin|
309744|NCT00246246|Drug|risperidone|
309745|NCT00246259|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
309746|NCT00246259|Drug|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
309747|NCT00246272|Drug|risperidone|
309748|NCT00246285|Drug|risperidone|
309749|NCT00246298|Drug|epoetin alfa|
309750|NCT00246324|Drug|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
309751|NCT00246337|Drug|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
309752|NCT00246337|Drug|MK0974|MK0974 25 mg; one orally-administered dose
310116|NCT00236054|Drug|Gabitril|
310117|NCT00236067|Drug|Gabitril|
310118|NCT00236080|Drug|PROVIGIL 200 mg|PROVIGIL 200 mg/day
310119|NCT00236080|Drug|Armodafinil 250 mg|Armodafinil 250 mg/day
310120|NCT00236080|Drug|Armodafinil 200 mg|Armodafinil 200 mg/day
310121|NCT00236080|Drug|Armodafinil 150 mg|Armodafinil 150 mg/day
310122|NCT00236080|Drug|Placebo|Matching placebo tablets
310123|NCT00236093|Drug|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
310124|NCT00236106|Drug|tacrolimus ointment 0.1%|
310125|NCT00236106|Drug|mometasone furoate 0.1%|
280223|NCT02610361|Drug|BGB-283|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
280224|NCT02610374|Other|Agrarian Diet|A diet higher in carbohydrates and lower in fats and sugars
280225|NCT00192504|Biological|MEDI-524|
280226|NCT02610374|Other|Western-type Diet|A diet higher in fats and lower in carbohydrates
280227|NCT02610387|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
280228|NCT02610387|Device|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
280229|NCT02610400|Other|RACD|Active malaria surveillance using rapid diagnostic test (RDT) in households around a passively-detected index case. RDT-positive subjects are treated by national policy, under which the combination medication artemether-lumefantrine (A-L) is first-line, using A-L dosing (mg artemether / mg lumefantrine):
(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) > 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop
280230|NCT02610400|Other|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a WHO-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
280231|NCT02610400|Other|TPE|Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. We will administer A-L with dosing as follows (mg artemether / mg lumefantrine):
(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) > 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop
280232|NCT02610413|Other|Laboratory Biomarker Analysis|Correlative studies
280233|NCT02610426|Other|Laboratory Biomarker Analysis|Correlative studies
280234|NCT02576665|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
280235|NCT02576665|Drug|Toca FC|Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with "TOCA FC" embossed on one side and "500" embossed on the other side
280236|NCT02576678|Drug|Apremilast|
279635|NCT02687412|Procedure|intra-operative lowtemperature at 34.7 ±0.6 degree centigrade|keeping the intra-operative lowtemperature at 34.7 ±0.6 degree centigrade
279933|NCT02581111|Drug|Naloxone|Naloxone 8-mg IV bolus
279934|NCT02581111|Drug|Normal saline|
279935|NCT02581124|Drug|JTZ-951|
279936|NCT02581124|Drug|Lapatinib|
279937|NCT00189228|Drug|Xolair|Patients are administered Xolair
279938|NCT02581137|Other|Laboratory Biomarker Analysis|Correlative studies
279939|NCT02581137|Drug|Metformin Hydrochloride|Given PO
279940|NCT02581150|Procedure|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
279941|NCT02581176|Drug|Apixaban|
279942|NCT02581202|Drug|lopinavir/ritonavir|tablet
279943|NCT02581202|Drug|Lamivudine|tablet
279944|NCT02581215|Drug|mFOLFIRINOX|mFOLFIRINOX:
Oxaliplatin 85 mg/m2 over 2-4 hours
Irinotecan 165 mg/m2 over 90 minutes
5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
279945|NCT02581215|Drug|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
279946|NCT02581215|Other|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
279947|NCT02581228|Device|ML-PrediCare|
279948|NCT00189241|Drug|imiquimod|
279949|NCT02581241|Device|tilt table|Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.
Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital
279950|NCT02581254|Device|Thin Wire Snare|
279951|NCT02581254|Device|Thick Wire Snare|
279952|NCT02581280|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
310969|NCT00334815|Drug|docetaxel|Given IV
310970|NCT00002945|Drug|melphalan|IV
310971|NCT00334815|Biological|filgrastim|Given SC
310972|NCT00334815|Biological|pegfilgrastim|Given SC
310973|NCT00334828|Drug|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
310974|NCT00334828|Drug|Placebo|Matching placebo; intravenous infusion.
310975|NCT00334854|Drug|doxorubicin hydrochloride|
310976|NCT00334854|Drug|ifosfamide|
310977|NCT00334854|Procedure|adjuvant therapy|
310978|NCT00337493|Drug|mycophenolate mofetil [CellCept]|1g po bid
310979|NCT00002963|Drug|aminolevulinic acid hydrochloride|
310980|NCT00337493|Drug|Cyclosporine or tacrolimus|Reduced
310981|NCT00337493|Drug|Cyclosporine or tacrolimus|Standard, as prescribed
310982|NCT00337506|Drug|Dexamethasone|
305387|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|2.5 million cells
305388|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0.5 million cells
305389|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0 cells
305390|NCT00257478|Drug|YM155|
305391|NCT00257491|Drug|Telmisartan|
305392|NCT00257491|Drug|Telmisartan/HCTZ|
305393|NCT00257530|Drug|Imiquimod|
305394|NCT00257543|Procedure|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
305395|NCT00002691|Drug|cytarabine|
305396|NCT00257556|Drug|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
310615|NCT00346983|Drug|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
310616|NCT00346996|Drug|insulin levemir / aspart|for subcutaneous injection
310617|NCT00346996|Drug|human insulin /insulin isophane|for subcutaneous injection
310618|NCT00347009|Drug|adefovir dipivoxil|10mg once daily
310619|NCT00347022|Drug|Xenetix|300 mg of iodine/ml
310620|NCT00347022|Drug|Visipaque|270 mg of iodine/ml
310621|NCT00347035|Drug|brimonidine|
310622|NCT00347048|Drug|tacrolimus|oral
310623|NCT00347048|Drug|Placebo|oral
310624|NCT00002995|Radiation|radiation therapy|
310625|NCT00347061|Drug|afuzosin|
310626|NCT00347087|Drug|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
310627|NCT00347100|Drug|Insulin Glargine|Throughout study period
310628|NCT00350194|Dietary Supplement|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
310629|NCT00350207|Drug|Tiotropium bromide|
310630|NCT00003011|Drug|marimastat|10 mg PO BID
310631|NCT00350207|Drug|Placebo|
310632|NCT00350207|Drug|Salmeterol xinafoate|
310633|NCT00350220|Other|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb >13.0 g/dl
310634|NCT00350220|Other|Low Hb transfusion group|RBCs will not be transfused unless the Hb < 9.0 g/dl
310635|NCT00350233|Device|ExAblate 2000|
310636|NCT00350246|Procedure|Laser Refractive Surgery|
310983|NCT00337506|Drug|velcade|
310984|NCT00337519|Procedure|allogeneic stem cell transplantation|see detailed description
309886|NCT00205634|Drug|Biaxin ( clarithromycin)|
309887|NCT00205647|Drug|Oral N-acetycystein (NAC)|
309888|NCT00205660|Drug|ziprasidone|Subjects are randomized to continue current ziprasidone or to switch to aripiprazole
309889|NCT00205660|Drug|risperidone|Subjects are randomized to continue current risperidone or to switch to aripiprazole
309890|NCT00205660|Drug|olanzapine|Subject's are randomized to continue current olanzapine or switch to aripiprazole
309891|NCT00205660|Drug|quetiapine|Subject's are randomized to continue current use of quetiapine or switch to aripiprazole
310254|NCT00253370|Drug|cisplatin|Given IV
310255|NCT00253383|Other|counseling intervention|
310256|NCT00253383|Other|educational intervention|
310257|NCT00253383|Procedure|psychosocial assessment and care|
310258|NCT00253383|Procedure|quality-of-life assessment|
310259|NCT00253396|Drug|Unfractionated heparin|
310260|NCT00253396|Drug|Enoxaparin|
310261|NCT00002675|Drug|etoposide|
310262|NCT00253409|Drug|chemotherapy|
310263|NCT00253409|Procedure|adjuvant therapy|
310264|NCT00002684|Drug|cisplatin|
310265|NCT00256165|Device|Tissue valve|Aortic valve replacement
310266|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
310267|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
310268|NCT00256178|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
310269|NCT00256191|Drug|TPI 287 Injection|
310270|NCT00256204|Drug|Rasagiline Mesylate|tablet, 1mg once daily
309522|NCT00216762|Drug|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
309523|NCT00216775|Drug|interferon-alfa-2b and ribavirin|
309524|NCT00216788|Drug|Esomeprazole (Nexium) 40 mg/day|
309525|NCT00216827|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
309526|NCT00216840|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
309527|NCT00002571|Drug|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
309528|NCT00216866|Drug|Dalteparin|
309529|NCT00216866|Drug|Warfarin|
309530|NCT00216879|Drug|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
309531|NCT00216892|Drug|Calcipotriol, (calcipotriol + betamethasone)|
309532|NCT00220103|Procedure|Surgical resection|
309533|NCT00220116|Drug|Capecitabine, Oxaliplatin|
309534|NCT00220129|Drug|Epirubicin, Cisplatin, Capecitabine|
309535|NCT00220129|Procedure|Surgical Resection|
309536|NCT00220155|Drug|Gemcitabine|
309537|NCT00220168|Drug|Irinotecan, Capecitabine|
309538|NCT00220194|Drug|leuprolide acetate|
309539|NCT00220207|Behavioral|Internet co-management module|
309540|NCT00220220|Drug|olmesartan medoxomil|
309541|NCT00002580|Radiation|radiation therapy|
309542|NCT00220220|Drug|amlodipine|
309543|NCT00220233|Drug|olmesartan medoxomil|
309544|NCT00220233|Drug|amlodipine|
309545|NCT00220233|Drug|hydrochlorothiazide|
309892|NCT00209170|Drug|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
308790|NCT00238953|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
308791|NCT00238966|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
308792|NCT00238979|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
308793|NCT00238992|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
308794|NCT00242658|Behavioral|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
308795|NCT00242671|Procedure|Isocapnic Hyperponea|
309167|NCT00227617|Drug|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
309168|NCT00227617|Drug|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
309169|NCT00227617|Drug|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
309170|NCT00227630|Drug|cisplatin|
309171|NCT00227630|Drug|pemetrexed disodium|
309172|NCT00002598|Procedure|bone marrow ablation with stem cell support|
309173|NCT00227630|Procedure|adjuvant therapy|
309174|NCT00231790|Drug|MK-0634 125 mg|one or three capsules orally, once daily in morning
309175|NCT00231790|Drug|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
309176|NCT00231803|Procedure|Combined CKD and CVD Prevention|
309177|NCT00231803|Procedure|Cardiovascular Disease prevention|
309178|NCT00231803|Procedure|Treatment of Chronic Kidney Disease complications|
309179|NCT00231816|Biological|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
309180|NCT00231816|Biological|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
309181|NCT00231816|Biological|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
309182|NCT00231829|Drug|Celecoxib|
308798|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
308799|NCT00242710|Drug|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
308800|NCT00242710|Other|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
308801|NCT00242736|Drug|Esomeprazole|
308802|NCT00242749|Drug|Gefitinib, Cisplatin and Radiotherapy|
308803|NCT00242762|Drug|ZD1839 (IRESSA™)|
308804|NCT00002641|Drug|isolated perfusion|
308805|NCT00242762|Drug|Docetaxel|
308806|NCT00242762|Drug|Cisplatin|
308807|NCT00242775|Drug|Budesonide/formoterol Turbuhaler|
308808|NCT00242775|Drug|Salmeterol/fluticasone Diskus|
308809|NCT00242788|Drug|Gefitinib and capecitabine|
308810|NCT00242801|Drug|Gefitinib|
308811|NCT00242814|Drug|Micardis|
308812|NCT00242814|Drug|Amlodipine|
308813|NCT00242814|Procedure|Abdominal biopsy|
308814|NCT00242827|Drug|Oral CEP-701|
308815|NCT00002641|Procedure|adjuvant therapy|
308816|NCT00242840|Drug|No intervention; Observational study|
308817|NCT00242853|Procedure|Power doppler ultrasonography|
308818|NCT00242853|Procedure|High frequency ultrasonography|
308819|NCT00242853|Procedure|Exhaled nitric oxide assessment|
308820|NCT00242866|Drug|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
308821|NCT00242866|Other|Placebo|Placebo to Match GW274150
308061|NCT02720185|Procedure|Conventional Surgery|Undergo surgery
308062|NCT00204555|Drug|Imiquimod|
308063|NCT02720185|Other|Laboratory Biomarker Analysis|Correlative studies
308064|NCT02720198|Drug|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
308065|NCT02720198|Drug|Quetiapine|Quetiapine XR will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
308066|NCT02720211|Device|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
308067|NCT02720211|Device|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
308068|NCT02720224|Drug|Estetrol|15 mg [14C]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
308418|NCT00252343|Drug|SR58611A|
308419|NCT00252356|Drug|SR58611A|
308420|NCT00252369|Drug|Infliximab|
308421|NCT00252369|Procedure|Instillation of fibrin glue|
308422|NCT00252382|Drug|SNS-595 Injection|
308423|NCT00252395|Device|PDA-based Electronic Prescribing Software|
308424|NCT00252408|Drug|Hormone replacement therapy|
308425|NCT00252421|Drug|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
308426|NCT00252421|Drug|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
308427|NCT00002671|Drug|aminocamptothecin|
308428|NCT00252434|Behavioral|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
308429|NCT00252447|Procedure|Pre-Operative Conformal Radiotherapy|
308430|NCT00252460|Device|Computed Tomography Scan and Magnetic Resonance Imaging|
308431|NCT00252473|Device|MedTec S-frame Immobilization Masks|
307688|NCT00215930|Drug|Carboplatin|Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.
RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.
307689|NCT00002569|Drug|procarbazine hydrochloride|
307690|NCT00215943|Drug|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
307691|NCT00215943|Drug|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
307692|NCT00215943|Drug|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
307693|NCT00215943|Drug|vincristine|As outlined in VAD Treatment Arm
307694|NCT00215943|Drug|adriamycin|As outlined in VAD Treatment arm
307695|NCT00215956|Drug|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
307696|NCT00215956|Procedure|radiation|Preoperative radiation
307697|NCT00215956|Procedure|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
307698|NCT00215982|Drug|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
307699|NCT00215982|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
307700|NCT00002569|Drug|vincristine sulfate|
307701|NCT00215982|Drug|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
307702|NCT00215995|Drug|Cisplatin|As outlined in Detailed Description
307703|NCT00215995|Drug|Irinotecan|As outlined in Detailed Description
307704|NCT00215995|Drug|ZD 1839|As outlined in Detailed Description
307705|NCT00216008|Drug|docetaxel|
307706|NCT00216008|Drug|cisplatin|
307707|NCT00216008|Procedure|radiation|
307037|NCT00241904|Drug|Beta Blocker|Oral medication
307038|NCT00241904|Drug|ACE Inhibitors|Oral medications, recieved 1-2 times per day
307039|NCT00241917|Behavioral|Hepatitis C educational video|
307040|NCT00241917|Other|Video|Prevention education video about hepatitis C
307041|NCT00241930|Behavioral|Integrating drug treatment into HIV services|
307042|NCT00241943|Procedure|Hepatitis C educational video|
307043|NCT00245011|Radiation|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
307044|NCT00245024|Drug|sulindac|
307045|NCT00245024|Other|laboratory biomarker analysis|
307046|NCT00002649|Radiation|radiation therapy|Undergo radiation therapy
307047|NCT00245037|Biological|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
307048|NCT00245037|Drug|busulfan|Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV busulfan is available and diluted and administered per package insert guidelines.
307355|NCT00002608|Radiation|radiation therapy|
307356|NCT00230815|Device|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
307357|NCT00230815|Device|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
307358|NCT00230828|Drug|bifeprunox|
307359|NCT00230841|Device|nebulized humidity|
307360|NCT00230854|Drug|EMZ702|
307361|NCT00230867|Device|iontophoretic acyclovir|
307362|NCT00230880|Behavioral|follow-up phone counseling|9 calls over 12 months
306335|NCT00211003|Drug|doripenem|
306336|NCT00211016|Drug|doripenem|
306337|NCT00211042|Other|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
306707|NCT00254657|Drug|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
306708|NCT00254657|Drug|Placebo|
306709|NCT00002679|Drug|tamoxifen citrate|
306710|NCT00254670|Drug|Naltrexone|
306711|NCT00254683|Device|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
306712|NCT00254696|Drug|Extended-Spectrum-Lactamases (ESBLs)|
306713|NCT00254709|Drug|Sirolimus|
306714|NCT00258193|Drug|MD-1100 Acetate|
306715|NCT00258206|Biological|rituximab|
306716|NCT00258206|Drug|cyclophosphamide|
306717|NCT00258232|Drug|capecitabine|
306718|NCT00258232|Drug|celecoxib|
306719|NCT00258232|Drug|irinotecan hydrochloride|
306720|NCT00258245|Dietary Supplement|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11
306721|NCT00258245|Drug|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
306722|NCT00258245|Drug|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
306723|NCT00002692|Drug|fluorouracil|
306724|NCT00258245|Drug|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
306725|NCT00258245|Drug|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
306726|NCT00258245|Drug|Aspirin|Aspirin - 325 mg by mouth (PO) every day
305972|NCT00218413|Biological|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
305973|NCT00218413|Biological|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
305974|NCT00218413|Biological|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
305975|NCT00218413|Biological|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
305976|NCT00218413|Biological|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
305977|NCT00218426|Drug|naltrexone implant|The implant is 1000 mg naltrexone
305978|NCT00218426|Drug|Oral naltrexone|oral naltrexone 50 mg/day
305979|NCT00002578|Drug|gallium nitrate|
305980|NCT00222326|Behavioral|Pelvic floor muscle training and lifestyle modification|
305981|NCT00222339|Behavioral|task-specific training|
305982|NCT00222365|Drug|Arnica montana, 5 CH|
305983|NCT00222365|Drug|Bryonia alba, 5 CH|
305984|NCT00222365|Drug|Hypericum perforatum, 5 CH|
305985|NCT00222365|Drug|Ruta graveolens, 3 DH|
305986|NCT00222417|Procedure|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
305987|NCT00222417|Procedure|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
305988|NCT00222430|Procedure|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
305989|NCT00222430|Procedure|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
305990|NCT00002586|Dietary Supplement|Tocopherol|
305991|NCT00222443|Drug|Irinotecan|
305992|NCT00222456|Behavioral|Sensitizing parents|
305993|NCT00222469|Drug|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
306338|NCT00211068|Drug|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
305271|NCT00240864|Drug|ibuprofen|
305272|NCT00240877|Biological|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
305273|NCT00240877|Other|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
305274|NCT00240903|Biological|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
305275|NCT00002635|Biological|filgrastim|
305276|NCT00240916|Biological|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
305277|NCT00240916|Biological|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
305278|NCT00240929|Drug|MEDI-493|Active Comparator
305279|NCT00240942|Drug|Letrozole|
305280|NCT00244348|Drug|Oxaliplatin (via HAI)|
305281|NCT00244348|Drug|5 Fluorouracil (systemic)|
305282|NCT00244361|Drug|rituximab|
305625|NCT00229957|Behavioral|Physiotherapy|
305626|NCT00229957|Behavioral|Self-management|
305627|NCT00229970|Drug|montelukast sodium|7 mg or 14 mg single injection
305628|NCT00229970|Drug|Comparator: Placebo|Placebo single injection
305629|NCT00229983|Behavioral|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
305630|NCT00229996|Drug|Oral Contraceptive|
305631|NCT00002601|Procedure|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
305632|NCT00233597|Drug|ferumoxytol or oral iron|
305633|NCT00233610|Drug|Bicalutamide|
305634|NCT00233610|Drug|Tamoxifen|
305635|NCT00233623|Drug|Iressa (Gefitinib)|
310483|NCT00227994|Drug|Galantamine|
310484|NCT00227994|Drug|Donepezil|
310485|NCT00228007|Drug|Antidepressant Medication|
310486|NCT00228020|Drug|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
310487|NCT00228020|Drug|MMF, cyclosporine, steroids|
310837|NCT00321685|Radiation|Radiation Therapy|Undergo radiotherapy
310838|NCT00321685|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
310839|NCT00321698|Drug|docetaxel|4 groups of men in phase I study.
Group 1=radiation only; Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation
Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation
310840|NCT00321698|Radiation|radiation therapy|All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
310841|NCT00321711|Drug|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
310842|NCT00321711|Biological|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
310843|NCT00321711|Drug|Azacitidine|hypomethylating agent
310844|NCT00002882|Drug|Vinblastine|IVPB on days 1-4
310845|NCT00321711|Drug|Decitabine|hypomethylating agent
310846|NCT00321724|Drug|cediranib maleate|Given orally
310847|NCT00321724|Other|laboratory biomarker analysis|Correlative studies
310848|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
310849|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
310850|NCT00321737|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
310851|NCT00321750|Drug|1% pimecrolimus cream|
310852|NCT00321763|Biological|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
310126|NCT00239434|Drug|ipratropium bromide Metered Dose Inhaler|
310127|NCT00239447|Drug|Tiotropium|
310128|NCT00239447|Device|HandiHaler|
310129|NCT00239447|Device|Respimat SMI|
310130|NCT00239460|Drug|Tiotropium|
310131|NCT00239473|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
310132|NCT00239473|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
310133|NCT00239486|Drug|Pramipexole|
310134|NCT00239499|Drug|Tiotropium|
310135|NCT00002633|Radiation|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
310136|NCT00239499|Drug|Salmeterol plus Fluticasone|
310137|NCT00239512|Drug|Indomethacin and Ibuprofen|
310138|NCT00239525|Device|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
310488|NCT00228033|Drug|Elemental calcium (as carbonate)|
310489|NCT00228046|Drug|Divalproex Sodium|
310490|NCT00228046|Drug|Methylphenidate|
310491|NCT00228046|Drug|Dextroamphetamine|
310492|NCT00002599|Drug|doxorubicin hydrochloride|
310493|NCT00228046|Drug|Mixed Amphetamine Salts|
310494|NCT00228046|Behavioral|Family Counseling|
310495|NCT00228046|Behavioral|Behavior Management Training with Parents|
310496|NCT00228059|Drug|Licarbazepine|
310497|NCT00228072|Procedure|Suction-curettage|
310498|NCT00228098|Behavioral|Smoking cessation|
280237|NCT02576691|Device|percutaneous coronary intervention|
280536|NCT02605993|Biological|Study Drug- ALXN1210|Cohort 1: ascending dose escalation to therapeutic dose level
280537|NCT02605993|Biological|Study Drug- ALXN1210|Cohort 2: ascending dose escalation to therapeutic dose level
280538|NCT02605993|Biological|Study Drug- ALXN1210|Cohort 3: ascending dose escalation to therapeutic dose level
280539|NCT02606006|Behavioral|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
280540|NCT02606006|Behavioral|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
280541|NCT00192062|Drug|gemcitabine|
280542|NCT02606032|Drug|Metronidazole|active comparator
280543|NCT02606032|Drug|Doxycycline|active comparator
280544|NCT02606032|Drug|Terbinafine|active comparator
280545|NCT02606032|Drug|Placebo|identical placebos to all antibiotics
280546|NCT02606045|Drug|recombinant von Willebrand factor|Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
280547|NCT02606045|Drug|tranexamic acid|Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
280548|NCT02606058|Procedure|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
280549|NCT02606071|Device|CRT-D|HF patients treated in clinical practice with a CRT-D device
280550|NCT02606084|Drug|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
280551|NCT02606097|Drug|regorafenib|
280552|NCT00192062|Drug|vinorelbine|
279953|NCT02581293|Procedure|Group 1: Only visceral peritoneum will be closed|
279954|NCT02581293|Procedure|Group 2 : Only parietal peritoneum will be closed|
279955|NCT02581293|Procedure|Group 3 : Both of them will be closed|
279956|NCT02581293|Procedure|Group 4: None of them will be closed|
280238|NCT02576704|Device|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
280239|NCT02576717|Drug|RPC1063|
280240|NCT00188513|Procedure|conformal intensity modulated radiotherapy (IMRT)|
280241|NCT02576730|Procedure|ORIF|surgery for foot and ankle fractures
280242|NCT02576743|Device|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
280243|NCT02576769|Other|No intervention|
280244|NCT02576782|Drug|Perineural Dexamethasone and bupivacaine|
280245|NCT02576782|Drug|Systemic Dexamethasone plus perineural bupivacaine|
280246|NCT02576782|Drug|intravenous saline plus perineural bupivacaine|
280247|NCT02576795|Genetic|BMN 270|
280248|NCT02576808|Drug|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
280249|NCT02576808|Drug|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
280250|NCT02576821|Other|Neurological examinations|
280251|NCT00188526|Device|lung biopsy|
280252|NCT02576821|Other|Neuropsychological examinations|
280253|NCT02576821|Other|Clinical examinations|
280254|NCT02576821|Radiation|MRI 3T|
280255|NCT02576821|Radiation|MRI 7T|
280256|NCT02576834|Behavioral|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
305397|NCT00257556|Drug|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
305398|NCT00257569|Drug|Cetirizine Dry Syrup|
305399|NCT00257582|Drug|Cetirizine Dry Syrup|
305400|NCT00257595|Drug|Cetirizine Dry Syrup|
305401|NCT00257608|Drug|bevacizumab|Intravenous repeating dose
305402|NCT00257608|Drug|placebo|Oral repeating dose
305403|NCT00257608|Drug|erlotinib HCl|Oral repeating dose
305404|NCT00257621|Drug|GW640385|
305405|NCT00257621|Drug|Ritonavir|
305406|NCT00000413|Behavioral|Psychoeducational program|
305407|NCT00002691|Drug|daunorubicin hydrochloride|
305408|NCT00257634|Drug|dexamethasone to injury site|
305409|NCT00257647|Other|SV40 vectors carrying siRNA|in vitro only use of gene therapy
305410|NCT00257660|Drug|Botulinum type A toxin (Dysport®)|500 units
305411|NCT02719171|Drug|Placebo|
305412|NCT02719171|Drug|BI 655066 high dose|
305413|NCT02719171|Drug|BI 655066 medium high dose|
305767|NCT00248092|Drug|NRP104|
305768|NCT00002658|Drug|amsacrine|
305769|NCT00248105|Behavioral|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
305770|NCT00248118|Drug|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
305771|NCT00251173|Behavioral|Strengths-Based Case Management|
305772|NCT00251173|Behavioral|Motivational Enhancement Therapy|
305773|NCT00251173|Behavioral|Brief Informational Feedback|
310985|NCT00337519|Drug|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
310986|NCT00337532|Drug|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
310987|NCT00337532|Drug|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
310988|NCT00337545|Drug|RAD001|
310989|NCT00337558|Drug|Solifenacin succinate|tablet
310990|NCT00002963|Procedure|conventional surgery|
310991|NCT00337558|Behavioral|Simplified bladder training|Instructions
310992|NCT00337571|Drug|Aripiprazole|Tablets, Oral, once daily, 8 weeks
310993|NCT00337571|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
310994|NCT00337584|Procedure|Pre-surgical screening|
310995|NCT00337597|Other|Glucose 5%|
310996|NCT00337597|Other|NaCl 0.9%|
310997|NCT00337610|Drug|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
310998|NCT00337610|Drug|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
310999|NCT00337623|Drug|Prednisolone|
311000|NCT00337636|Procedure|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
311001|NCT00002964|Drug|porfimer sodium|
311002|NCT00337636|Drug|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
311003|NCT00337649|Drug|Epothilone D|<100mg/m2 iv on days 1, 8 and 15 every 4 weeks
311004|NCT00337649|Drug|Herceptin|4mg/kg iv loading dose followed by 2mg/kg iv weekly
311005|NCT00337662|Drug|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
310271|NCT00256204|Drug|Rasagiline Mesylate|tablet, 2mg once daily
310272|NCT00256204|Other|Placebo|Placebo
310273|NCT00256217|Drug|Anastrozole|1 mg. oral every day for 2 - 4 weeks
310274|NCT00256230|Drug|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
310275|NCT00002684|Drug|ifosfamide|
310276|NCT00256243|Drug|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
310277|NCT00256243|Drug|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
310278|NCT00256243|Drug|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
310637|NCT00350272|Drug|elvucitabine|elvucitabine 10 mg orally daily
310638|NCT00350272|Drug|Lamivudine|lamivudine 300 mg orally daily
310639|NCT00350272|Drug|Tenofovir|tenofovir open-label 300 mg orally daily
310640|NCT00350272|Drug|Efavirenz|efavirenze open-label 600 mg orally daily
310641|NCT00003011|Drug|Placebo|10 mg PO BID
310642|NCT00350285|Behavioral|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
310643|NCT00350285|Behavioral|Marijuana education|Information about health and behavioral effects of marijuana use.
310644|NCT00350298|Biological|GS-CDA1|one dose IV
310645|NCT00350298|Biological|MDX-1388|one dose IV
310646|NCT00350298|Biological|normal saline|200ml IV once
310647|NCT00350311|Drug|nicotine transdermal patch/lozenge|
310648|NCT00350337|Biological|Live attenuated tetravalent dengue vaccine|
310649|NCT00350350|Device|oxygenated oil|oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
310650|NCT00350350|Device|medical device. Spray containing essentially oxygenated oil|protective oral spray containing :
94.4% of oxygenated oil
Silicium dioxide
aspartame artificial flavoring
309893|NCT00209170|Drug|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
309894|NCT00209209|Drug|Rituximab|antibody
309895|NCT00209209|Drug|Cyclophosphamide|chemotherapy
309896|NCT00209209|Drug|Doxorubicin|chemotherapy
309897|NCT00209209|Drug|Vincristine|chemotherapy
309898|NCT00002555|Radiation|low-LET photon therapy|
309899|NCT00209209|Drug|Prednisone|coricosteroide
309900|NCT00209209|Drug|Fludarabine|chemotherapy
309901|NCT00209209|Drug|Interferon-alpha|cytokine
309902|NCT00209209|Drug|pegylated formula Interferon-alpha 2b|cytokine
309903|NCT00209209|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
309904|NCT00209209|Procedure|chemotherapy: R-FC|immuno-chemotherapy
309905|NCT00209209|Procedure|Interferon maintenance|cytokine
309906|NCT00209209|Procedure|Rituximab maintenance|antibody
309907|NCT00209222|Drug|Rituximab|antibody
309908|NCT00209222|Drug|Cyclophosphamide|chemotherapy
309909|NCT00002556|Drug|vincristine sulfate|Given IV
309910|NCT00209222|Drug|Doxorubicin|chemotherapy
309911|NCT00209222|Drug|Vincristine|chemotherapy
309912|NCT00209222|Drug|Prednisone|corticosteroide
309913|NCT00209222|Drug|Cisplatinum|chemotherapy
309914|NCT00209222|Drug|Ara-C|chemotherapy
309915|NCT00209222|Drug|Dexamethasone|corticosteroide
309916|NCT00209222|Drug|BCNU|chemotherapy
309917|NCT00209222|Drug|Melphalan|chemotherapy
309183|NCT00231842|Drug|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.
309184|NCT00002610|Procedure|conventional surgery|
309185|NCT00231842|Procedure|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.
309186|NCT00231855|Drug|Topotecan and Taxotere|
309187|NCT00231868|Drug|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
309188|NCT00231868|Procedure|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
309546|NCT00220259|Drug|Fluticasone or placebo|
309547|NCT00220272|Drug|SR57667B|
309548|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
309549|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
309550|NCT00220298|Drug|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
309551|NCT00220311|Drug|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
309552|NCT00002581|Drug|cyclophosphamide|
309553|NCT00220324|Drug|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
309554|NCT00220337|Drug|lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
309555|NCT00220350|Drug|leuprolide acetate|
309556|NCT00220363|Drug|SPM 907|
309557|NCT00220376|Drug|SPM 907|
309558|NCT00220389|Drug|SPM 907|
309559|NCT00220402|Drug|SPM 907|
309189|NCT00231868|Drug|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
309190|NCT00231894|Drug|Pioglitazone|pioglitazone 15-45 mg/day
309191|NCT00231894|Behavioral|Life style diet group|life style diet education group 1x/week
309192|NCT00231894|Other|placebo|placebo comparator
309193|NCT00231907|Biological|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
309194|NCT00231907|Biological|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
309195|NCT00002610|Radiation|radiation therapy|
309196|NCT00231920|Biological|Fluzone|
309197|NCT00235417|Procedure|Bone marrow transplantation|
309198|NCT00235443|Drug|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
309199|NCT00235456|Procedure|Perioperative supplemental oxygen|
309200|NCT00235469|Drug|SPM 927|
309201|NCT00002621|Biological|recombinant interferon alfa|
309202|NCT00235482|Drug|Coxsackievirus A21|
309203|NCT00235495|Biological|human serum albumin infusion|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
309204|NCT00235495|Drug|placebo|equivalent volume of saline control
309205|NCT00235508|Drug|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
309206|NCT00235521|Drug|aerosolized iloprost|
309207|NCT00235534|Behavioral|Immediate initiation of OCPs|
309208|NCT00235534|Behavioral|Delayed initiation of OCPs|
308432|NCT00252486|Drug|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
308433|NCT00252499|Drug|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
308434|NCT00252499|Drug|fenofibrate|PPAR-alpha agonist, reduces triglycerides
308435|NCT00252499|Drug|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
308436|NCT00252499|Drug|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
308437|NCT00252512|Behavioral|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value ($1, $20, or $80 canteen voucher).
308438|NCT00255281|Drug|AZD7009, no generic name available|
308439|NCT00255294|Drug|Cellulose sulfate vaginal gel|
308440|NCT00255307|Drug|CVT-E002 ginseng extract|
308441|NCT00002680|Procedure|conventional surgery|
308822|NCT00242879|Drug|Physician determined comparator PI + ritonavir|
308823|NCT00242879|Drug|GW640385 + ritonavir|
308824|NCT00242892|Procedure|Intra coronary measures of pressure|Intra coronary measures of pressure
308825|NCT00000407|Behavioral|Standard of care|No education or behavioral intervention
308826|NCT00002653|Drug|cyclophosphamide|
308827|NCT00245622|Biological|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
308828|NCT00245622|Biological|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
308829|NCT00245635|Drug|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
308830|NCT00245635|Drug|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
308831|NCT00245648|Drug|fibrinolytic therapy or combination reduced fibrinolytic therapy|
307708|NCT00216008|Procedure|surgery|
307709|NCT00216021|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
308069|NCT02720237|Behavioral|Brief Intervention|Two in-person individual sessions (occurring one month apart) and two booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
308070|NCT02720237|Behavioral|MET+CBT Intervention|Six in-person individual sessions (one session per week) and three optional group sessions, delivered by a trained counselor.
308071|NCT02720250|Dietary Supplement|Chicken eggs with OMEGA-3|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
308072|NCT02720250|Dietary Supplement|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
308073|NCT00204568|Drug|Adriamycin|60 mg/m2, d1, W d22
308074|NCT02720263|Drug|ASP4345|Oral
308075|NCT02720263|Drug|Matching Placebo|Oral
308076|NCT02720276|Other|Training after acute stroke|Outdoor walking (10-30 minutes) together with strength training (chair-rising, 5-25 repetitions) six days/week during 12 weeks.
308077|NCT02720289|Other|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
308078|NCT02720289|Other|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
308079|NCT00208286|Device|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
308080|NCT00208286|Device|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
308081|NCT00208299|Drug|Regadenoson|0.4 mg, bolus intravenous injection
308082|NCT00208299|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
308083|NCT00208312|Drug|Regadenoson|0.4 mg, bolus intravenous injection
308084|NCT00002553|Procedure|allogeneic bone marrow transplantation|
308085|NCT00208312|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
308086|NCT00208325|Device|P.F.C Sigma Fixed Bearing total knee system|Orthopaedic implant for total knee replacement
308087|NCT00208325|Device|P.F.C Sigma RP Mobile Bearing knee system|Orthopaedic implant for total knee replacement
307363|NCT00230906|Procedure|Haemodialysis with either low or high flux membranes|
307364|NCT00230919|Behavioral|Diet counseling|
307365|NCT00230945|Behavioral|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
307366|NCT00002609|Biological|lintuzumab|
307367|NCT00230958|Drug|Viramidine|
307368|NCT00230958|Drug|Ribavirin|
307369|NCT00230958|Drug|pegylated interferon alfa-2b|
307370|NCT00230971|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
307371|NCT00230971|Drug|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
307372|NCT00230984|Behavioral|education|
307373|NCT00230984|Drug|Oral dietary supplements (563 kcal/d), RESPIFOR|
307374|NCT00230984|Behavioral|exercises on an ergometric bicycle 3 to 5 times a week|
307375|NCT00234494|Drug|Cisplatin|Cisplatin 70 mg/m2, day 1
307376|NCT00234494|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
307710|NCT00216021|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
307711|NCT00002569|Radiation|radiation therapy|
307712|NCT00219089|Drug|aliskiren|
307713|NCT00219102|Drug|aliskiren|
307714|NCT00219115|Drug|aliskiren|
307715|NCT00219128|Drug|aliskiren|
307716|NCT00219141|Drug|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
307717|NCT00219141|Drug|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
306727|NCT00258258|Drug|paricalcitol|
306728|NCT00258258|Drug|zoledronic acid|
306729|NCT00258271|Biological|filgrastim|
306730|NCT00258271|Drug|cladribine|
306731|NCT00258271|Drug|cytarabine|
306732|NCT00258271|Drug|imatinib mesylate|
307049|NCT00245037|Drug|cyclosporine|Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).
- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d.
307050|NCT00245037|Drug|fludarabine phosphate|Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.
Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.
Monitoring: Fludarabine level is not monitored.
Dose Adjustments: There are no provisions for fludarabine dose adjustments.
307051|NCT00245037|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.
Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).
Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).
307052|NCT00245037|Procedure|peripheral blood stem cell transplantation|Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:
In autologous transplants, patients receive their own stem cells.
In syngeneic transplants, patients receive stem cells from their identical twin.
In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used.
307053|NCT00245037|Radiation|Total Body Irradiation (TBI)|TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.
Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.
Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min.
307054|NCT00245037|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).
It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.
Toxicities: At the dosage used, the most common side effect will be medullary bone pain.
Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all).
307055|NCT00245037|Drug|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
306339|NCT00211081|Drug|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
306340|NCT00211094|Drug|Dapoxetine|
306341|NCT00211107|Drug|Dapoxetine|
306342|NCT00211120|Drug|Epoetin Alfa|
306343|NCT00211133|Drug|epoetin alfa|
306344|NCT00211146|Drug|epoetin alfa|
306345|NCT00000385|Drug|Placebo|Matching placebo
306346|NCT00002560|Biological|monoclonal antibody 3F8|
306347|NCT00211159|Drug|EPAX 1050TG|
306348|NCT00211172|Behavioral|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
306349|NCT00211185|Drug|ONTAK (denileukin diftitox, DAB389 IL-2)|Ontak + CHOP every 3 weeks.
306350|NCT00211198|Drug|ONTAK (denileukin difitox, DAB389IL-2)|
306351|NCT00211211|Device|Balloon Kyphoplasty|
306352|NCT00211224|Drug|Riluzole|
306353|NCT00211237|Device|Balloon Kyphoplasty|Vertebral Augmentation
306354|NCT00211237|Other|Non Surgical Management|Non-surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with VCF(s).
306355|NCT00211250|Drug|Valproic Acid and Depakote ER|
306356|NCT00211263|Behavioral|Enhanced Clinical Intervention|
306357|NCT00002560|Biological|sargramostim|
306358|NCT00211263|Drug|mood stabilizer|
306359|NCT00211276|Drug|ONTAK (denileukin diftitox)|
306360|NCT00211289|Behavioral|Education by community pharmacist|
305636|NCT00233623|Drug|Irinotecan|
305637|NCT00233623|Drug|5Fluorouracil|
305638|NCT00233623|Drug|Leucovorin|
305639|NCT00002618|Biological|filgrastim|
305640|NCT00233636|Drug|Iressa (Gefitinib)|
305641|NCT00233636|Procedure|Radiotherapy|
305642|NCT00233662|Drug|Alefacept|
305643|NCT00233675|Drug|GABITRIL (tiagabine hydrochloride; CEP-6671)|
305644|NCT00233688|Device|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
305645|NCT00233688|Procedure|Open surgical repair|Open surgical repair
305646|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
305647|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
305648|NCT00233727|Procedure|HPV DNA Testing + Cryosurgery|Patients will undergo a "Screen and Treat" program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women.
305649|NCT00233727|Procedure|VIA + Cryosurgery|Patients will undergo a "Screen and Treat" program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women.
305650|NCT00002618|Drug|cytarabine|
305994|NCT00222469|Drug|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
305995|NCT00222469|Drug|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
305996|NCT00222482|Drug|Depakote ER|
305997|NCT00222495|Drug|quetiapine|
305998|NCT00222495|Drug|olanzapine|
305999|NCT00222495|Drug|risperidone|
306000|NCT00222521|Drug|Glargine insulin|
306001|NCT00002587|Drug|paclitaxel|
306002|NCT00222534|Drug|Acetazolamide|
310853|NCT00321763|Biological|Fluarix TM|Single dose, Intramuscular injection
310854|NCT00321789|Behavioral|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
310855|NCT00002882|Procedure|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
310856|NCT00321802|Drug|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
310857|NCT00321802|Drug|Placebo|Placebo
305283|NCT00002643|Radiation|low-LET photon therapy|
305284|NCT00244374|Biological|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects>18 years of age will receive the Twinrix vaccine and subjects<18 years of age will receive the Engerix-B vaccine. Cohort subjects>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
305285|NCT00244374|Behavioral|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
305286|NCT00244374|Behavioral|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
305287|NCT00244374|Behavioral|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
305288|NCT00244387|Drug|SPM 962|
305289|NCT00244426|Drug|indobufen|Indobufen capsules 100 and 200mg
305290|NCT00244426|Drug|aspirin|Acetylsalicylic acid capsules 300mg
305291|NCT00244439|Drug|MALG|30 minute application
305292|NCT00244439|Drug|Ovide (malathion) lotion 0.05%|8-12 hour application
305293|NCT00244439|Drug|Permethrin 1%|10 minute application
310499|NCT00228150|Drug|SR57667B|
310500|NCT00228163|Drug|teriflunomide (HMR1726)|tablet, oral administration once daily.
310501|NCT00228176|Drug|rimonabant (SR141716)|oral administration
310502|NCT00228176|Drug|placebo|oral administration
310503|NCT00002599|Drug|melphalan|
310504|NCT00228189|Biological|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
310505|NCT00228215|Behavioral|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
310506|NCT00228228|Biological|T cell vaccination|
310507|NCT00228241|Device|AAI vs. DDD vs. BIV pacing in different patients groups|
310508|NCT00228254|Drug|Zinc (12.5 mg/day)|
310509|NCT00228254|Drug|vitamin A 10,000 IU per week|
310510|NCT00228267|Drug|Propofol|
310511|NCT00228280|Procedure|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
310512|NCT00228293|Device|investigational monitor/defibrillator with CPR feedback|
310513|NCT00228306|Behavioral|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
310514|NCT00334581|Drug|Irbesartan|Administration throughout the study period
310858|NCT00321815|Drug|PF-3512676 + Erlotinib|PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.
Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
310859|NCT00321815|Drug|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
310860|NCT00324467|Drug|Carboplatin|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.
Estimate Creatinine Clearance (CrCl)
310861|NCT00324467|Drug|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
310862|NCT00324467|Drug|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
280553|NCT02608463|Device|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
280841|NCT02601755|Behavioral|Attention control group|The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the "iCanCope with Pain" smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies.
280842|NCT02601768|Device|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
280843|NCT02601781|Procedure|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
280844|NCT02601781|Device|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
280845|NCT02601794|Behavioral|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
280846|NCT02601807|Device|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
280847|NCT02601807|Device|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
280848|NCT00191607|Drug|Gemcitabine|
280849|NCT02601833|Device|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
280850|NCT02601833|Procedure|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
280851|NCT02601846|Other|No intervention|This is an observational study, without any specific intervention.
280852|NCT02601859|Drug|Lithium Carbonate|
280853|NCT02601872|Drug|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
280854|NCT02601872|Drug|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses,Subcutaneously 3 doses per week until at corrected age of 34 weeks.
280257|NCT02576834|Other|Services as Usual|Services as usually provided in the community
280258|NCT02576847|Drug|Omiganan|Topical gel
280259|NCT02576860|Drug|Omiganan|Topical gel
280260|NCT02576860|Drug|Vehicle|Vehicle gel
280261|NCT02576873|Other|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
280262|NCT00188539|Procedure|Pre-treatment tumour oxygen measurements (under anesthesia)|
280554|NCT02608476|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
280555|NCT02608476|Drug|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
280556|NCT00192309|Biological|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
280557|NCT02608489|Drug|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
280558|NCT02608489|Drug|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
280559|NCT02608502|Biological|RSV-F Vaccine|
280560|NCT02608502|Biological|Phosphate Buffer Placebo|
280561|NCT02608528|Radiation|[18F]fluoroglucose(FDG)|
280562|NCT02608541|Other|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
280563|NCT02608554|Behavioral|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
280564|NCT02608554|Behavioral|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
280565|NCT02608580|Other|Survey|
280566|NCT02608593|Procedure|Strattice|Implant based reconstruction with strattice cover of part or all of implant
280567|NCT00002520|Behavioral|Usual Care|
305774|NCT00251186|Drug|Capecitabine and Cetuximab|
305775|NCT00251199|Drug|VX-950|
305776|NCT00251199|Drug|peginterferon|
305777|NCT00251212|Behavioral|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
305778|NCT00251225|Drug|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m2 administered IV
305779|NCT00251225|Drug|Docetaxel|60 mg/m2 administered IV on day 0
305780|NCT00251238|Drug|Ginkgo biloba extract EGb 761®|
305781|NCT00002667|Other|cytology specimen collection procedure|
305782|NCT00251251|Device|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
305783|NCT00251251|Device|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
305784|NCT00251264|Procedure|Open stabilization|Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a "T" shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy.
305785|NCT00251264|Procedure|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
306135|NCT00241319|Drug|R89674 (generic name not yet established)|
306136|NCT00241332|Drug|fentanyl|
306137|NCT00002637|Biological|recombinant interferon gamma|
306138|NCT00241345|Drug|Valganciclovir|
306139|NCT00241345|Drug|Ganciclovir|
306140|NCT00241358|Drug|AMD3100|
306141|NCT00241358|Procedure|Stem Cell Transplant|
306142|NCT00241371|Drug|Clofarabine|
305414|NCT02719171|Drug|BI 655066 medium dose|
305415|NCT00204464|Procedure|Exercise|
305416|NCT02719171|Drug|BI 655066 low dose|
305417|NCT02719197|Drug|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
305418|NCT02719197|Drug|Placebo|Placebo capsules matching AC-083 capsules
305419|NCT02719210|Biological|High Volume Plasma Exchange|
305420|NCT02719210|Drug|Hypertonic 3% saline|
305421|NCT02719210|Drug|Mannitol|
305422|NCT02719210|Device|Elective positive pressure ventilation|
305423|NCT02719223|Device|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
305424|NCT02719236|Procedure|direct anterior approach|The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.
Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.
Once the final implants are in situ, the hip is reduced and assessed.
305425|NCT02719236|Procedure|direct lateral approach|The procedure begins by positioning the patient in the supine decubitus position.
A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.
The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.
When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed.
305426|NCT00204477|Dietary Supplement|soy protein|soy protein
305427|NCT02719249|Other|Dried blood spot test|
305428|NCT02719262|Device|installing ventilation in the workplace|Environmental improvement by installing ventilation
305429|NCT02719275|Behavioral|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
305430|NCT02719288|Biological|CLARIX® CORD 1K graft|
310651|NCT00350363|Drug|Zymar|zymar qid
310652|NCT00003012|Drug|CMF regimen|
310653|NCT00350389|Behavioral|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
310654|NCT00350402|Behavioral|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
310655|NCT00350415|Drug|Mesalamine|Asacol 400g/day (400 mg tablet), oral, for 6 weeks
OR
Asacol 4,8 g/day (800 mg table), oral, for 6 weeks
310656|NCT00350428|Procedure|Laser Preipheral Iridotomy and phacoemulsification|
310657|NCT00353470|Behavioral|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
310658|NCT00353483|Procedure|Blood draw|
310659|NCT00353496|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
310660|NCT00353496|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
311006|NCT00343642|Dietary Supplement|dietary therapy + fructo-oligosaccharide placebo|Medical nutrition therapy and 2 teaspoons of placebo powder
311007|NCT00343642|Drug|Time and attention + active fructooligosaccharide supplementation|2 teaspoons of fructooligosaccharides daily
311008|NCT00343655|Drug|Atorvastatin|
311009|NCT00343668|Drug|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
311010|NCT00343681|Biological|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
311011|NCT00343707|Drug|vestipitant|
311012|NCT00343707|Drug|paroxetine|
311013|NCT00343720|Drug|VELCADE|
311014|NCT00002982|Drug|ifosfamide|
311015|NCT00343720|Drug|Alimta|
311016|NCT00343733|Drug|OraVescent Fentanyl|
311017|NCT00343759|Drug|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
309918|NCT00209222|Drug|Etoposide|chemotherapy
309919|NCT00209222|Drug|G-CSF|growth factor
310279|NCT00256243|Drug|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
310280|NCT00256243|Drug|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
310281|NCT00256243|Drug|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
310282|NCT00256256|Drug|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
310283|NCT00256269|Drug|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
310284|NCT00256269|Drug|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
310285|NCT00256282|Drug|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
310286|NCT00002684|Drug|paclitaxel|
310287|NCT00256282|Drug|Docetaxel|40mg/m2 IV over 1 hour every 14 days
310288|NCT00256282|Drug|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
310289|NCT00256295|Drug|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
310290|NCT00256295|Drug|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
310291|NCT00256308|Drug|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
310292|NCT00259922|Drug|Alvimopan|0.5 mg QD
310293|NCT00259922|Drug|Alviompan|0.5 mg BID
310294|NCT00259935|Drug|topotecan|
310295|NCT00259948|Procedure|Aerobic exercise training|
310296|NCT00259961|Procedure|open fundoplication|
310297|NCT00002697|Biological|sargramostim|
310298|NCT00259961|Procedure|laparoscopic fundopliaction|
310299|NCT00259974|Drug|Rituximab|Rituximab
310300|NCT00259987|Drug|Lapatinib (GW572016) oral tablets|
309560|NCT00220415|Drug|SPM 927|
309561|NCT00220428|Biological|T-Cell Vaccination|
309562|NCT00220441|Behavioral|Aerobic exercise|
309563|NCT00002581|Drug|fluorouracil|
309564|NCT00220454|Drug|Climara|
309565|NCT00220454|Drug|Hydrocortone|
309566|NCT00224120|Other|Placebo|One capsule daily for 12 weeks
309567|NCT00224133|Drug|Silodosin|8 mg daily
309568|NCT00224146|Drug|oxybutynin transdermal delivery system (Oxytrol(r))|
309569|NCT00224159|Behavioral|Drug and Dietary behavior|
309570|NCT00224185|Procedure|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
309920|NCT00002556|Drug|carmustine|Given IV
309921|NCT00209222|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
309922|NCT00209222|Procedure|chemotherapy: R-DHAP|immuno-chemotherapy
309923|NCT00209222|Procedure|chemotherapy: Dexa-BEAM|chemotherapy
309924|NCT00209222|Procedure|stem cell harvest|procedure
309925|NCT00209222|Procedure|total body irradiation|radiation
309926|NCT00213135|Drug|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
309927|NCT00213135|Other|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
309928|NCT00213148|Drug|Anastrozole 1mg|Anastrozole 1mg, once per day for 5 days.
309929|NCT00213148|Drug|Anastrozole 5mg dose|Anastrozole 5mg, once per day for 5 days.
309930|NCT00213148|Drug|Anastrozole 10mg dose|Anastrozole 10mg, once per day for 5 days.
309209|NCT00235547|Behavioral|timing of initiation of transdermal patch after an abortion|the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
309210|NCT00235560|Drug|rapamycin|sirolimus
309571|NCT00224185|Procedure|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
309572|NCT00224185|Procedure|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
309573|NCT00224198|Procedure|Bronchopulmonary Lung Lavage|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.
309574|NCT00002590|Radiation|radiation therapy|
309575|NCT00224198|Procedure|Bronchial Brushing|During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway.
309576|NCT00224198|Procedure|Bronchial Wall Biopsy|In selected individuals, bronchial wall biopsy may be carried out. This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.44
309577|NCT00224211|Behavioral|Music|
309578|NCT00224250|Procedure|One- versus two-layer hysterotomy closure|
309579|NCT00224263|Drug|Lingzhi (Ganoderma)|
309580|NCT00224289|Drug|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
309581|NCT00224302|Drug|Duloxetine|
309582|NCT00224315|Drug|ziprasidone|
309583|NCT00224315|Drug|risperidone|
309584|NCT00224328|Device|ODISsey Tissue Oximeter|
309585|NCT00002592|Biological|c-myb antisense oligonucleotide G4460|
308832|NCT00245661|Drug|Temazepam|
308833|NCT00245674|Drug|amisulpride|
308834|NCT00245687|Device|Tiger Tube|
308835|NCT00245713|Drug|levetiracetam|
308836|NCT00245726|Device|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
308837|NCT00002653|Drug|doxorubicin hydrochloride|
308838|NCT00245726|Device|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
308839|NCT00245726|Device|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
308840|NCT00245739|Drug|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
308841|NCT00245752|Device|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
308842|NCT00245765|Drug|CDP870 (Certolizumab pegol)|
308843|NCT00245791|Drug|Levofloxacin|
308844|NCT00245817|Behavioral|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
308845|NCT00245830|Procedure|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
309211|NCT00235573|Dietary Supplement|Vitamin B12|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
309212|NCT00002622|Drug|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
309213|NCT00235586|Procedure|10 vit. D deficient subjects take vit. D for 3 months.|
309214|NCT00235599|Procedure|IGFBP-3 Stimulation Test|
309215|NCT00235625|Drug|Curcuminoids C3 Complex®|
309216|NCT00235651|Drug|Amphotericin B|
309217|NCT00235664|Procedure|Collection of stool and endotracheal aspirate samples|collection of samples
309218|NCT00235677|Procedure|Endoscopic gastroplication|
308088|NCT00208338|Device|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
308089|NCT00208338|Procedure|Rotator cuff repair|Standard surgical repair of torn rotator cuff
308090|NCT00208351|Device|Ultima LX Collared Stem - Blasted Finished|A collared blasted finished cementless femoral component for use in total hip replacement.
308442|NCT00255320|Drug|VIP|
308443|NCT00255333|Drug|INNO-105|
308444|NCT00255346|Drug|Dasatinib (BMS-354825)|70 mg orally twice daily
308445|NCT00255359|Drug|XTL-2125|
308446|NCT00255372|Drug|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
308447|NCT00255372|Drug|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
308448|NCT00255385|Drug|Micronutrient (Zinc and Iron) fortification|
308449|NCT00255385|Drug|Pre and Probiotic fortification|
308450|NCT00255424|Drug|ferumoxytol or oral iron|
308451|NCT00255437|Drug|ferumoxytol or oral iron|
308452|NCT00002680|Procedure|peripheral blood stem cell transplantation|
308453|NCT00255450|Drug|ferumoxytol or placebo|
308454|NCT00255463|Drug|Anastrazole|
308455|NCT00255463|Drug|Gefitinib|
308456|NCT00255476|Drug|gefitinib|
308457|NCT00255476|Drug|cisplatin|
308458|NCT00255476|Drug|5-flourouracil|
308459|NCT00255489|Drug|Gefitinib|
308460|NCT00255489|Procedure|palliative thoracic radiotherapy|
308461|NCT00255502|Drug|metoprolol succinate|
308462|NCT00255515|Drug|Quetiapine fumarate|oral
307718|NCT00219141|Drug|Aliskiren placebo|Aliskiren 150 mg placebo tablet
307719|NCT00002579|Procedure|conventional surgery|
307720|NCT00219141|Drug|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
307721|NCT00219154|Drug|aliskiren|
307722|NCT00219167|Drug|aliskiren|
307723|NCT00219180|Drug|aliskiren|
307724|NCT00219193|Drug|aliskiren|
307725|NCT00219219|Drug|Zoledronic acid|
307726|NCT00219232|Drug|Rivastigmine Transdermal Patch|
307727|NCT00219245|Drug|Rivastigmine|
307728|NCT00219258|Drug|Zoledronic acid|
307729|NCT00219271|Drug|Zoledronic acid|
307730|NCT00002579|Radiation|radiation therapy|
307731|NCT00219284|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
307732|NCT00219297|Drug|Patupilone|
307733|NCT00219310|Drug|Famciclovir|
307734|NCT00219323|Drug|Omalizumab|
307735|NCT00219336|Behavioral|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention will be compared to an intervention directed at preventing fetal alcohol syndrome (FAS). The proposed study will evaluate the effectiveness of a media-based self-guided motivational intervention to reduce alcohol-exposed pregnancies (AEP). Participants will be women 18 to 44 years of age who are at risk of an AEP.
308091|NCT00208351|Device|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
308092|NCT00208351|Device|Ultima LX Collarless Stem - Blasted Finished|A collarless blasted finished cementless femoral component for use in total hip replacement.
308093|NCT00208351|Device|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
308094|NCT00208364|Device|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
307056|NCT00245037|Drug|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
307057|NCT00248547|Drug|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
307058|NCT00248560|Drug|docetaxel|Gemcitabine hydrochloride given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine hydrochloride.
307059|NCT00248560|Drug|gemcitabine hydrochloride|Gemcitabine hydrochloride given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine hydrochloride.
307060|NCT00248586|Behavioral|Cognitive Behavior Therapy|
307377|NCT00234494|Drug|Bevacizumab|Bevacizumab 15mg/kg, day 1
307378|NCT00234507|Drug|Botulinum toxin type A (Dysport®)|
307379|NCT00234533|Drug|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
307380|NCT00234546|Drug|Botulinum toxin type A (Dysport®)|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
307381|NCT00234546|Other|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
307382|NCT00234559|Device|VAC® Therapy System|
307383|NCT00234572|Drug|Lanreotide (Autogel formulation)|
307384|NCT00234585|Device|Renal Artery Stent with Protective Device/Drug|
307385|NCT00002619|Biological|filgrastim|
307386|NCT00234598|Procedure|Toothbrushing only|Toothbrushing three times per 24 hours without chlorhexidine
307387|NCT00234598|Procedure|Chlorhexidine only|Chlorhexidine oral rinse twice per 24 hours without toothbrushing
307388|NCT00234598|Procedure|Toothbrushing and Chlorhexidine|Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
307389|NCT00234611|Procedure|Echocardiogram guided left ventricular lead placement|
307390|NCT00234637|Drug|Rivastigmine, memantine|
307391|NCT00234650|Procedure|Colonoscopy|
307392|NCT00234663|Drug|PTC124|
306361|NCT00211302|Drug|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
306362|NCT00211315|Drug|anecortave acetate|
306733|NCT00258284|Drug|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
306734|NCT00002692|Drug|isolated perfusion|
306735|NCT00258284|Drug|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
306736|NCT00258297|Drug|gefitinib|
306737|NCT00258297|Procedure|conventional surgery|
306738|NCT00258297|Procedure|enzyme inhibitor therapy|
306739|NCT00258297|Procedure|neoadjuvant therapy|
306740|NCT00258297|Procedure|protein tyrosine kinase inhibitor therapy|
306741|NCT00258297|Procedure|surgery|
306742|NCT00258310|Drug|capecitabine|Capecitabine 1000mg/day for one year
306743|NCT00258310|Procedure|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
306744|NCT00258323|Drug|cisplatin|20mg/m2d/IV continuous infusion x days
306745|NCT02719678|Other|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
306746|NCT02719691|Drug|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
306747|NCT02719691|Drug|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
306748|NCT02719704|Behavioral|"MEXA-SE"|MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction ("Espelho, espelho meu": School based Intervention) conducted by Physical Education researcher.
306003|NCT00222534|Drug|Placebo|
306004|NCT00222547|Drug|Vitamin A|
306005|NCT00222547|Drug|Albendazole|
306006|NCT00222560|Behavioral|Intensive physical activity counselling by an integrated physical activity counsellor|
306007|NCT00222573|Drug|clopidogrel and metoprolol|
306008|NCT00222612|Other|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
306009|NCT00222612|Drug|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
306010|NCT00222612|Drug|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
306011|NCT00222625|Drug|rFVIIa + (vit K in AO patients)|
306012|NCT00225914|Drug|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
306013|NCT00225914|Drug|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
306014|NCT00225927|Procedure|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
306015|NCT00225966|Device|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
306016|NCT00225979|Drug|Octreotide LAR|
306017|NCT00225992|Drug|Arsenic Trioxide|
306018|NCT00226005|Drug|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
306363|NCT00211328|Drug|anecortave acetate|
306364|NCT00215306|Device|Anterior Interbody Fusion with BAK Cage|
306365|NCT00215319|Device|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
306366|NCT00215332|Device|CHARITE|Lumbar Total Disc Replacement
306367|NCT00215345|Drug|Taxotere|
306368|NCT00215345|Drug|Celecoxib|
305294|NCT00002644|Drug|tamoxifen citrate|
305295|NCT00244452|Drug|Cetrorelix|
305296|NCT00244478|Dietary Supplement|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
305297|NCT00244478|Dietary Supplement|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
305298|NCT00244491|Behavioral|Care Transitions Intervention|
305299|NCT00244504|Drug|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
305651|NCT00233740|Device|OPTEASE Vena Cava Filter|
305652|NCT00233753|Device|Cordis Neurovascular Self-Expanding Stent|
305653|NCT00233766|Device|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
305654|NCT00233779|Device|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
305655|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - fast release|
305656|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - slow release|
305657|NCT00233805|Device|Sirolimus coated Bx Velocity™|drug-eluting stent
305658|NCT00233805|Device|Bare metal Bx Velocity™|bare-metal stent
305659|NCT00233818|Device|Sirolimus-coated Bx VELOCITY Stent|
305660|NCT00233831|Device|Generator of electromagnetic millimeter waves|
305661|NCT00002618|Drug|doxorubicin hydrochloride|
305662|NCT00233844|Procedure|Venipuncture with "cough-trick"|
305663|NCT00233857|Procedure|Auricular acupuncture|
305664|NCT00237484|Drug|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks
305665|NCT00237497|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
310863|NCT00002896|Drug|chemotherapy|
310864|NCT00324467|Drug|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
310865|NCT00324467|Drug|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
310866|NCT00324467|Drug|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
310867|NCT00324467|Drug|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
310868|NCT00324467|Other|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
310869|NCT00324480|Drug|alvocidib|Given IV
310870|NCT00324480|Drug|vorinostat|Given orally
310871|NCT00324480|Other|pharmacological study|Correlative studies
310872|NCT00324506|Drug|Mycophenolate Mofetil (CellCept)|
310873|NCT00324519|Device|Foley bulb|
310874|NCT00002896|Drug|fluorouracil|
310875|NCT00324519|Drug|misoprostol|
310876|NCT00324532|Drug|ProBactrix|
310877|NCT00324545|Behavioral|Medium-intensity Minimally-directive Counseling|
310878|NCT00324558|Drug|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
310879|NCT00324571|Drug|Sevelamer hydrochloride|
310880|NCT00324571|Drug|Calcium-based phosphate binder|
305300|NCT00244517|Drug|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
305301|NCT00247468|Procedure|Strict Glucose Control|
305302|NCT00247481|Drug|Gefitinib|
305303|NCT00247481|Drug|Docetaxel|
305304|NCT00247494|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
280855|NCT02601885|Drug|ABT-555|Intravenous Infusion
280856|NCT02601885|Other|Placebo|Intravenous Infusion
280857|NCT02601898|Device|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
280858|NCT02604030|Other|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
281132|NCT02597478|Behavioral|Phone Call|Thirty days study visit participant called by study staff. This call should last about 10 minutes.
281133|NCT00191230|Drug|gemcitabine|
281134|NCT02597491|Behavioral|TLC monthly|Tobacco longitudinal care monthly
281135|NCT02597491|Behavioral|TLC quarterly|Tobacco longitudinal care quarterly
281136|NCT02597491|Behavioral|MTM|Medication management therapy
281137|NCT02597491|Behavioral|4 week assessment|4 week assessment
281138|NCT02597491|Behavioral|8 week assessment|8 week assessment
281139|NCT02597504|Other|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
281140|NCT02597504|Device|Quick Test|Quick Test, computerized test will be administered to all subjects.
281141|NCT02597517|Device|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
281142|NCT02597530|Device|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
281143|NCT02597543|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
281144|NCT00191230|Drug|carboplatin|
281145|NCT02597543|Drug|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
281146|NCT02597543|Procedure|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
280568|NCT00192309|Biological|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
280569|NCT02608593|Device|Acellular Dermal Matrix|
280570|NCT02608593|Radiation|Radiotherapy|
280571|NCT02608606|Drug|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
280572|NCT02608619|Radiation|F-choline PET Scan|
280573|NCT02608619|Device|FDG-PET|
280574|NCT02608619|Procedure|biopsy|
280575|NCT02608632|Device|Renal denervation guided by HFS|
280859|NCT02604043|Device|supraglottic impendence/pH probe|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
280860|NCT02604043|Device|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
280861|NCT02604056|Behavioral|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
280862|NCT02604056|Behavioral|Audit + Feedback + Educational Outreach|The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: "an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia." The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home.
280863|NCT02604069|Device|Continuous Glucose Monitor|
280864|NCT02604082|Other|Vibrocompression (VB)|Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
280865|NCT02604082|Other|Hyperinflation (HMV)|Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
280866|NCT00191815|Drug|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
280867|NCT02604082|Other|HMV+VB|Association between Vibrocompression and Hyperinflation with mechanical ventilator
280868|NCT02604095|Dietary Supplement|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
306143|NCT00241384|Procedure|External beam radiation|
306144|NCT00241384|Procedure|Pd-103|
306145|NCT00241410|Biological|OralvacB2MPL|Comparison of different dosages of drug
306146|NCT00241423|Drug|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
306147|NCT00241423|Drug|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
306148|NCT00002638|Biological|filgrastim|
306149|NCT00241436|Drug|Anastrozole (ARIMIDEX™)|
306150|NCT00241449|Drug|Fulvestrant|intramuscular injection 250 mg
306151|NCT00241449|Drug|Tamoxifen|20 mg oral tablet
306152|NCT00241475|Drug|Gefitinib|
306153|NCT00241488|Drug|Rosuvastatin|
306154|NCT00244764|Drug|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
306155|NCT00244764|Drug|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
306156|NCT00244777|Drug|Hypo-osmolar ORS|
306157|NCT00244790|Behavioral|Diet|crossover low vs high protein diet before and after weight loss
306158|NCT00244816|Drug|Taxoprexin|
306159|NCT00244829|Drug|imatinib mesylate|
306160|NCT00002647|Procedure|conventional surgery|
306511|NCT00234052|Biological|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
306512|NCT00234052|Drug|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
306513|NCT00234052|Drug|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
306514|NCT00234065|Drug|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
305431|NCT02719314|Drug|Glucocorticoid treatment|Glucocorticoid treatment
305432|NCT02719327|Drug|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
305786|NCT00251277|Drug|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
305787|NCT00251290|Procedure|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
305788|NCT00251303|Drug|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
305789|NCT00251303|Drug|Placebo|Capsules matched active drug in appearance.
305790|NCT00251316|Drug|Lithium Carbonate|30 mCi of 131I
305791|NCT00251316|Drug|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
305792|NCT00254176|Dietary Supplement|Parenteral cysteine-HCl supplementation|cysteine-HCl supplementation 121 mg per kg per day
305793|NCT00254176|Dietary Supplement|Placebo - added premasol|Premasol 121 mg per kg per day
305794|NCT00254189|Drug|Levonorgestrel|
305795|NCT00254189|Drug|Ethinyl Estradiol|
305796|NCT00254202|Drug|iloperidone|
305797|NCT00254202|Drug|active comparator|
305798|NCT00254202|Drug|placebo|
305799|NCT00254215|Behavioral|high protein & low glycemic index diets|
305800|NCT00254228|Device|Electrotactile sensory substitution|
305801|NCT00002678|Drug|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
305802|NCT00254241|Drug|Seroquel and Risperidone|
305803|NCT00254254|Drug|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
311018|NCT00343785|Drug|cyclophosphamide|Given IV
311019|NCT00343785|Biological|anti-thymocyte globulin|Given IV
311020|NCT00343785|Drug|cyclosporine|Given IV or PO
311021|NCT00343785|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
311022|NCT00343785|Drug|methotrexate|Given IV
311023|NCT00343785|Genetic|DNA analysis|Correlative studies
311024|NCT00343785|Other|flow cytometry|Correlative studies
311025|NCT00002982|Drug|melphalan|
311026|NCT00343785|Genetic|polymorphism analysis|Correlative studies
311027|NCT00343785|Other|laboratory biomarker analysis|Correlative studies
311028|NCT00343798|Drug|cyclophosphamide|Given IV
311029|NCT00343798|Drug|fludarabine phosphate|Given IV
311030|NCT00343798|Drug|cyclosporine|Given IV
311031|NCT00343798|Drug|mycophenolate mofetil|Given IV or PO
311032|NCT00343798|Other|ex-vivo umbilical cord blood expansion|Undergo double-unit umbilical cord blood transplantation
305433|NCT02719327|Other|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
305434|NCT00206869|Behavioral|heat|
305435|NCT00206869|Procedure|red light illumination|
305436|NCT00206882|Drug|corticosteroids|
305437|NCT00206895|Procedure|Photodynamic therapy|
305438|NCT00206921|Device|Pulsed dye laser|
305439|NCT00206921|Device|Intense pulsed light|
305440|NCT00002552|Drug|cyclophosphamide|
305441|NCT00206934|Drug|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
310301|NCT00260000|Drug|5,6,7,8-tetrahydrobiopterin|
310302|NCT00260013|Procedure|program of care delivery|
310303|NCT00260026|Drug|Docetaxel|
310304|NCT00260026|Drug|Jin Fu Kang|
310661|NCT00353509|Device|Device Closure of a Septal Defect|
310662|NCT00353522|Drug|Placebo|po daily for 24 weeks
310663|NCT00353522|Drug|dalcetrapib|900mg po daily for 24 weeks
310664|NCT00353535|Procedure|Total Lymphoid irradiation|
310665|NCT00003027|Biological|aldesleukin|
310666|NCT00353561|Drug|Boric|Gelatin capsules filled with 600 mg of boric acid
310667|NCT00353561|Drug|Fluconazole|150 mg oral fluconazole gives once in 14 days
310668|NCT00353574|Drug|Darusentan|Darusentan capsules administered orally once daily
310669|NCT00353587|Drug|MBX-102|MBX-102 200 mg once daily for 16 weeks
310670|NCT00353587|Drug|MBX-102|MBX-102 400 mg once daily for 16 weeks
310671|NCT00353587|Drug|MBX-102|MBX-102 600 mg once daily for 16 weeks
310672|NCT00353587|Drug|Placebo|MBX-102 Placebo once daily for 16 weeks
310673|NCT00353587|Drug|Actos|Actos 30 mg once daily for 16 weeks
310674|NCT00353613|Behavioral|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
310675|NCT00353652|Drug|Chlorthalidone|12.5-25 mg taken orally, once daily
310676|NCT00003027|Biological|filgrastim|
310677|NCT00353652|Drug|Spironolactone|50-75 mg taken orally, once daily
310678|NCT00353652|Drug|Eplerenone|50-100 mg taken orally, once daily
310679|NCT00353652|Drug|Quinapril|20 mg taken orally, once daily
310680|NCT00353652|Drug|Irbesartan|150 mg taken orally, once daily
309931|NCT00213148|Drug|Clomiphene Citrate 50mg|Clomiphene Citrate 50mg, once per day for 5 days.
309932|NCT00000386|Behavioral|Family Treatment Program|
309933|NCT00002565|Drug|ifosfamide|
309934|NCT00213161|Drug|iron supplement, iron drops|
309935|NCT00213174|Behavioral|school playgrounds|
309936|NCT00213187|Behavioral|Aerobic and Qi gong Exercise|
309937|NCT00213200|Drug|morphine, amethocaine|
309938|NCT00213213|Drug|Sucrose|
309939|NCT00213226|Drug|dexamethasone|
309940|NCT00213239|Drug|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
309941|NCT00213239|Drug|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
309942|NCT00213252|Drug|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
309943|NCT00213252|Drug|Prednisolone|Six daily doses of oral prednisolone
310305|NCT00260039|Biological|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
310306|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
310307|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
310308|NCT00002697|Drug|carboplatin|
310309|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
310310|NCT00260052|Drug|Erythropoietin administration|
310311|NCT00260065|Drug|Decitabine|20mg/m^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
310312|NCT00260078|Drug|Atazanavir|200 mg to 400 mg orally daily
310313|NCT00260078|Drug|Darunavir|300 mg or 600 mg orally twice daily
309586|NCT00224341|Device|Pacemaker Vitatron Selection 9000|
309587|NCT00224341|Device|Pacemaker Vitatron T70|
309588|NCT00227630|Procedure|conventional surgery|
309589|NCT00227630|Procedure|neoadjuvant therapy|
309590|NCT00227630|Radiation|radiation therapy|
309944|NCT00002565|Drug|mesna|
309945|NCT00213265|Biological|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
309946|NCT00213265|Biological|Pneumococcal 7-valent Conjugate Vaccine|Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)
Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:
7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)
12-23 months of age: 2 doses (at least 2 months apart)
≥24 months through 9 years of age: 1 dose
309947|NCT00213278|Drug|vinblastine sulphate injection|Vinblastine dose: 6 mg/m^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
309948|NCT00216918|Drug|Atomoxetine Hydrochloride|
309949|NCT00216931|Drug|iloprost|
309950|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
309951|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
309952|NCT00216957|Procedure|Coronary bypass surgery without cardiopulmonary bypass|
309953|NCT00216970|Dietary Supplement|Alteration in nutritional support|The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
309954|NCT00002571|Drug|prednisone|60 mg/m2 po QD x 14days for 6 cycles
309955|NCT00216996|Drug|glutamine enriched TPN vs. standard TPN .|Subjects are randomized into one of two groups. Each group receives different diets adn different stable isotopes. Blood and air samples will be obtained at different points in the study.
309956|NCT00217009|Procedure|Narrowband Ultraviolet B (TL-01UVB) Therapy|
309219|NCT00235690|Procedure|Blood draws|PK samples obtained around a clinical dosing of colistin
309220|NCT00235690|Other|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
309221|NCT00235703|Device|Antimicrobial Prescribing Decision Support|
309222|NCT00235716|Drug|dl-alpha-tocopherol|Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate ("synthetic") vitamin E.
309223|NCT00002622|Drug|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
309224|NCT00002633|Drug|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
309225|NCT00239005|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
309226|NCT00239005|Drug|Mycophenolate Mofetil (MMF)|
309227|NCT00239018|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
309228|NCT00239031|Drug|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
309229|NCT00239044|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
309230|NCT00239057|Drug|Enteric-Coated Mycophenolate Sodium|
309231|NCT00239070|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
309232|NCT00239083|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
309233|NCT00239096|Drug|losartan (drug)|
309234|NCT00239109|Drug|Ziprasidone|
309591|NCT00227656|Biological|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
309592|NCT00227656|Drug|Capecitabine|1000 mg/m^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
309593|NCT00227669|Drug|docetaxel|
309594|NCT00227669|Drug|gemcitabine hydrochloride|
309595|NCT00227682|Dietary Supplement|ascorbic acid|
308463|NCT00002680|Radiation|radiation therapy|
308464|NCT00255515|Drug|conventional treatment for schizophrenia|various standard therapies
308465|NCT00255528|Drug|metoprolol succinate|
308466|NCT00255541|Drug|Tesaglitazar|
308467|NCT00255541|Drug|Glibenclamide|
308468|NCT00255554|Behavioral|Dialectical Behavioral Therapy|
308469|NCT00255554|Drug|Escitalopram|
308846|NCT00245843|Behavioral|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
308847|NCT00245856|Drug|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
308848|NCT00002653|Drug|melphalan|
308849|NCT00245856|Drug|Warfarin|Titrated to INR 2-3 through study month 3
308850|NCT00245869|Procedure|Contrast-enhanced Ultrasound|
308851|NCT00245882|Behavioral|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
308852|NCT00249561|Behavioral|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg & Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
308853|NCT00249574|Drug|Buprenorphine/naloxone|
308854|NCT00249587|Drug|Methadone|dosed to effect, every six hours
308855|NCT00249600|Behavioral|Contingency management|
308856|NCT00249613|Behavioral|Women-Only|Gender-responsive treatment for women only
308857|NCT00249626|Behavioral|Contingency management|Rewards (prizes) for abstinence
308858|NCT00249639|Behavioral|Contingency management|Rewards valued $1-$100
308859|NCT00249652|Behavioral|TAP|12-session motivational interviewing-based telephone intervention.
308095|NCT00002553|Radiation|low-LET cobalt-60 gamma ray therapy|
308096|NCT00208377|Device|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
308097|NCT00208390|Device|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
308098|NCT00208403|Device|Smartset HV Bone Cement|A high viscosity bone cement for use in total hip replacement
308099|NCT00208403|Device|Palacos R|A high viscosity bone cement for use in total hip replacement
308100|NCT00208416|Procedure|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
308101|NCT00208416|Procedure|Conventional surgical technique|A conventional surgical technique used in total hip replacement
308102|NCT00208429|Device|Pinnacle Acetabular System|
308103|NCT00208442|Device|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
308104|NCT00208442|Device|Enduron|Standard polyethylene liner in a modular acetabular component
308105|NCT00208455|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
308106|NCT00212069|Drug|gemcitabine, carboplatin|
308107|NCT00212082|Drug|doxorubicin, docetaxel|
308108|NCT00212095|Drug|docetaxel and ketoconazole|Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.
Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration.
308109|NCT00212108|Drug|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
308110|NCT00212121|Radiation|high dose boost|high dose boost
308470|NCT00255567|Drug|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
308471|NCT00255567|Drug|Paromomycin sulphate|Paromomycin sulphate
308472|NCT00258778|Drug|Human Glucocerebrosidase (prGCD)|
307393|NCT00234676|Drug|Premarin ®|Premarin ® 0.625 mg per day orally
307394|NCT00234689|Drug|Naltrexone|
307395|NCT00234702|Drug|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
307396|NCT00002619|Drug|carboplatin|
307397|NCT00234702|Drug|Placebo|Placebo
307398|NCT00234728|Device|Occlusive dressing|
307399|NCT00234741|Drug|STA-5326 mesylate|
307400|NCT00234754|Procedure|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
307401|NCT00234767|Device|Pulmonary Artery Catheter|
307402|NCT00234767|Behavioral|Protocolized Fluid Management|
307736|NCT00219336|Behavioral|Promoting Healthy Choices|Using a randomized two-group design, a self-guided motivational intervention will be compared to an intervention directed at preventing fetal alcohol syndrome (FAS). The proposed study will evaluate the effectiveness of a media-based self-guided motivational intervention to reduce alcohol-exposed pregnancies (AEP). Participants will be women 18 to 44 years of age who are at risk of an AEP
307737|NCT00219349|Behavioral|Cognitive Behavioral-Therapy|14 weekly sessions of individualized CBT
307738|NCT00219349|Drug|escitalopram|10-20 mg per day for 12 weeks
307739|NCT00219362|Biological|one injection of vCP1452 at W0, W4, W8 and W20|
307740|NCT00219362|Biological|one injection of vCP1452 at W4, W8 and W20|
307741|NCT00002580|Drug|cyclophosphamide|
307742|NCT00223626|Drug|Topiramate|the maximum topiramate test dose is 200 mg/d.
307743|NCT00223639|Drug|Topiramate|200mg twice a day
307744|NCT00223652|Behavioral|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
307745|NCT00223665|Drug|Flutamide|250 mg tid
307746|NCT00223665|Drug|Leuprolide Acetate|7.5 mg q month
306749|NCT02719704|Behavioral|"Espelho, espelho meu"|Behavioral: "Espelho, espelho meu": School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters.
306750|NCT02719717|Device|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
307061|NCT00248612|Drug|Venlafaxine (Effexor XR)|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
307062|NCT00248612|Behavioral|Cognitive Behavioral Therapy|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
307063|NCT00000409|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
307064|NCT00002658|Drug|mitoxantrone hydrochloride|
307065|NCT00248612|Other|Placebo medication and relaxation training|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
307066|NCT00248625|Drug|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
307067|NCT00248638|Drug|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
307068|NCT00248638|Drug|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
307069|NCT00248651|Drug|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
307070|NCT00248651|Drug|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
307071|NCT00248651|Drug|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
307072|NCT00248677|Behavioral|Behavioral Family-Based Intervention|Behavioral family intervention
307073|NCT00248677|Behavioral|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
306369|NCT00215358|Drug|Formoterol Fumarate|
306370|NCT00215371|Drug|Formoterol Fumarate|
306371|NCT00215384|Drug|Formoterol Fumarate|
306372|NCT00002567|Radiation|low-LET electron therapy|
306373|NCT00215397|Drug|Formoterol Fumarate|
306374|NCT00215410|Drug|Formoterol Fumarate|
306375|NCT00215423|Drug|Formoterol Fumarate|
306376|NCT00215436|Drug|Formoterol Fumarate|
306377|NCT00215449|Drug|Formoterol Fumarate|
306378|NCT00215462|Drug|Vinorelbine|
306379|NCT00215501|Drug|Capecitabine|Orally twice a day for 14 days (dosage will vary)
306380|NCT00215501|Drug|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
306381|NCT00215501|Drug|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
306382|NCT00215501|Drug|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
306383|NCT00002567|Radiation|low-LET photon therapy|
306384|NCT00215514|Drug|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
306385|NCT00215514|Drug|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
306386|NCT00215514|Drug|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
306751|NCT02719730|Behavioral|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
306752|NCT00204516|Biological|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
305666|NCT00237497|Drug|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
305667|NCT00237497|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
305668|NCT00237510|Drug|terazosin|
305669|NCT00237523|Drug|IoGen (molecular iodine)|
305670|NCT00237536|Drug|Lonidamine|
305671|NCT00002627|Procedure|peripheral blood stem cell transplantation|
305672|NCT00237549|Procedure|optimised treatment|The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.
The training included meetings, practice visiting, written feed back reports and reminders on controls.
305673|NCT00237562|Procedure|Large loop electrosurgical excision|
305674|NCT00237575|Drug|gemcitabine|
306019|NCT00226018|Device|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
306020|NCT00226018|Device|Placebo|placebo
306021|NCT00002596|Drug|carboplatin|
306022|NCT00226031|Procedure|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
306023|NCT00226044|Drug|Omeprazole suppository|
306024|NCT00226057|Drug|Raptiva|
306025|NCT00226070|Procedure|interview and advising|
306026|NCT00226070|Behavioral|3 follow up interviews and personal advising|
306027|NCT00226070|Procedure|interview SF-36 self rated health|
306028|NCT00226096|Drug|Labetalol Hydrochloride|
306029|NCT00226096|Drug|Metoprolol tartrate|
306030|NCT00226096|Drug|Hydralazine Hydrochloride|
306031|NCT00226096|Drug|Glycerol Trinitrate|
305305|NCT00247507|Drug|acetylcysteine|
305306|NCT00247520|Drug|topical nasal rEV131|
305307|NCT00247533|Procedure|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
305308|NCT00247546|Behavioral|Multifactorial prevention|
305309|NCT00000409|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
305310|NCT00002657|Drug|vincristine sulfate|1.4 mg/m^2
305311|NCT00247559|Drug|Botulinum type A toxin (BoNT-A)|
305312|NCT00247572|Drug|NRP104|
305313|NCT00247585|Drug|Ethanol (Bourbon or Vodka)|
305314|NCT00247611|Behavioral|LifeWindows Intervention Sessions|At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
305315|NCT00247611|Other|Control|At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
305316|NCT00247624|Drug|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
305317|NCT00247624|Drug|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
305318|NCT00247624|Drug|Placebo|Placebo every night for 8 weeks
305319|NCT00247650|Drug|Zoledronic Acid; Letrozole|
305320|NCT00247663|Drug|Letrozole|
305321|NCT00002657|Procedure|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
305322|NCT00247676|Drug|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
305675|NCT00237575|Drug|cisplatin|
305676|NCT00237575|Drug|sargramostim|
305677|NCT00237575|Drug|filgrastim|
305678|NCT00237588|Drug|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
281147|NCT02597556|Drug|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
281148|NCT02597556|Drug|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
281149|NCT02597569|Behavioral|CO-OP KT Exposure|Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.
The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support.
281150|NCT02599597|Behavioral|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
281443|NCT02592824|Drug|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
281444|NCT02592824|Drug|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
281445|NCT02592837|Device|Flexible 19G EBUS-TBNA needle|
281446|NCT02592837|Device|21G EBUS-TBNA needle|
281447|NCT02592850|Other|osteopathic manipulative treatment|This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.
Duration: 45 minutes. Administered once a week for four weeks.
281448|NCT02592850|Other|sham|In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.
Duration: 45 minutes. Administered once a week for four weeks.
281449|NCT02592863|Drug|Pentoxifylline|
281450|NCT00002516|Drug|cyclophosphamide|
281451|NCT00190788|Drug|placebo|
281452|NCT02592863|Drug|Placebo|
281453|NCT02592876|Drug|denintuzumab mafodotin|Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
281454|NCT02592876|Drug|rituximab|375 mg/m2 by IV infusion, every 3 weeks for up to 3 cycles
281455|NCT02592876|Drug|ifosfamide|5000 mg/m2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
280869|NCT02604108|Behavioral|Physical Exercise|The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.
The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors
280870|NCT02604108|Behavioral|Healthy Diet|The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.
The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors
280871|NCT02604121|Device|Orcellex® Rovers brush|transepithelial brushing
280872|NCT02604134|Procedure|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
280873|NCT02604134|Drug|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
281151|NCT02599610|Other|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
281152|NCT02599610|Device|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
281153|NCT02599623|Procedure|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
281154|NCT02599623|Procedure|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
281155|NCT02599636|Other|None intervention|Investigators will study the usual medical assistance
281156|NCT02599649|Drug|Lirilumab|3 mg/kg by vein every 4 weeks.
281157|NCT00191412|Drug|Pemetrexed|
281158|NCT02599649|Drug|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
281159|NCT02599649|Drug|Azacitidine|75 mg/m^2 by vein for 7 days of a 28 day cycle.
281160|NCT02599662|Radiation|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
306515|NCT00234065|Drug|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
306516|NCT00234078|Drug|0.5% OPC-12759|
306517|NCT00234078|Drug|1% OPC-12759|
306518|NCT00234078|Drug|2% OPC-12759|
306519|NCT00234078|Drug|placebo|
306520|NCT00002618|Drug|prednisone|
306521|NCT00234091|Drug|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
306522|NCT00234091|Drug|Efavirenz|200 to 600 mg taken orally once daily
306523|NCT00234091|Drug|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
306524|NCT00234091|Drug|Lopinavir/Ritonavir|230 mg/57.5 mg/m^2 body surface area taken orally twice daily with food
306525|NCT00234091|Drug|Nelfinavir|45-55 mg/kg taken orally twice daily with food
306526|NCT00234091|Drug|Nevirapine|120 mg/m^2 once daily for first 14 days, tehn 200 mg/m^2 (up to 400 mg/day) twice daily
306527|NCT00234091|Drug|Zidovudine|180-240 mg/m^2 every 12 hours (up to 300 mg/dose)
306528|NCT00234104|Drug|OPC-41061(Tolvaptan)|
306529|NCT00234117|Drug|Rabeprazole|
306530|NCT00234130|Procedure|nocturnal vs conventional dialysis|
306531|NCT00002618|Drug|vincristine sulfate|
306532|NCT00234143|Behavioral|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
306533|NCT00234143|Drug|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
306862|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
306863|NCT00218751|Behavioral|Home Visiting|
306864|NCT00218764|Drug|Fluoxetine (Prozac)|Fluoxetine 10 to 40 mg/day for 8 months
305804|NCT00254254|Drug|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
305805|NCT00254254|Drug|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
305806|NCT00254267|Drug|AMG 706|AMG 706 125mg, oral, once a day
305807|NCT00254280|Procedure|Intense Pulsed Light + paring versus paring alone|
306161|NCT00244829|Procedure|adjuvant therapy|
306162|NCT00244842|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
306163|NCT00244842|Drug|Placebo|Placebo
306164|NCT00244855|Other|pharmacological study|Correlative studies
306165|NCT00244855|Biological|rituximab|Given IV
306166|NCT00244855|Drug|dexamethasone|Given IV
306167|NCT00244855|Other|laboratory biomarker analysis|Correlative studies
306168|NCT00244868|Other|counseling intervention|
306169|NCT00244868|Other|educational intervention|
306170|NCT00244881|Drug|cediranib maleate|Given orally
306171|NCT00002649|Biological|aldesleukin|Given IV
306172|NCT00244881|Other|laboratory biomarker analysis|Correlative studies
306173|NCT00244894|Procedure|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
306174|NCT00244894|Procedure|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
306175|NCT00244894|Procedure|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
306176|NCT00244894|Procedure|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
305442|NCT00206934|Drug|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
305443|NCT00206947|Drug|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
305444|NCT00206947|Drug|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
305445|NCT00206960|Drug|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
305446|NCT00206960|Drug|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
305447|NCT00206973|Procedure|mannitol test|
305448|NCT00206986|Drug|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
305449|NCT00206986|Drug|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
305450|NCT00206999|Drug|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
305451|NCT00002552|Drug|cytarabine|
305452|NCT00207012|Drug|BMS-599626|
305453|NCT00207025|Drug|BMS-275183|
305454|NCT00207051|Drug|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
305455|NCT00207064|Drug|quetiapine|flexible doses according to the clinical condition
305456|NCT00207077|Drug|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
305808|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
305809|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
305810|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
310681|NCT00353665|Drug|Memantine (Ebixa)|10 mg bid
310682|NCT00353665|Drug|riluzole|riluzole 50 mg bid
310683|NCT00353665|Drug|Placebo|
310684|NCT00353678|Drug|YM150|
310685|NCT00353691|Drug|glimepiride|
310686|NCT00353691|Drug|metformin|
310687|NCT00003027|Biological|recombinant interferon alfa|
311033|NCT00343798|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit umbilical cord blood transplantation
311034|NCT00343798|Procedure|biopsy|Optional correlative studies
311035|NCT00343798|Other|immunologic technique|Correlative studies
311036|NCT00002982|Procedure|autologous bone marrow transplantation|
311037|NCT00343798|Other|diagnostic laboratory biomarker analysis|Correlative studies
311038|NCT00347100|Drug|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
311039|NCT00347100|Drug|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
311040|NCT00347100|Drug|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
311041|NCT00347100|Drug|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
311042|NCT00347100|Drug|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
311043|NCT00347113|Drug|Albendazole and praziquantel|
311044|NCT00347139|Drug|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
311045|NCT00002996|Drug|flecainide acetate|
311046|NCT00347139|Drug|Salmeterol 50mcg|Salmeterol 50mcg
311047|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
311048|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
311049|NCT00347165|Drug|bevacizumab intravitreal injection|
310314|NCT00260078|Drug|Efavirenz|Dosage dependent on participant
310315|NCT00260078|Drug|Nevirapine|Dosage dependent on participant
310316|NCT00260078|Drug|Ritonavir|50 mg or 100 mg orally twice daily
310317|NCT00260078|Drug|Tenofovir disoproxil fumarate|300 mg orally daily
310318|NCT00260078|Procedure|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
310319|NCT00000415|Procedure|Physical activity|
310320|NCT00002697|Drug|etoposide|
310321|NCT00260091|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
310322|NCT00205660|Drug|aripiprazole|participants randomized to stay on current treatment (ziprasidone) or switch to aripiprazole
310323|NCT00205660|Drug|aripiprazole|Participants randomized to stay on current treatment (risperidone) or switch to aripiprazole
310324|NCT00205660|Drug|aripiprazole|Participants randomized to stay on current treatment (olanzapine) or switch to aripiprazole.
310325|NCT00002549|Procedure|autologous bone marrow transplantation|
310326|NCT00205660|Drug|aripiprazole|Participants are randomized to either stay on their current treatment (quetiapine) or switch to aripiprazole
310327|NCT00205686|Drug|DHEA|
310328|NCT00205686|Behavioral|exercise|
310688|NCT00353704|Drug|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
310689|NCT00356317|Behavioral|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
310690|NCT00356317|Behavioral|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
310691|NCT00356343|Device|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
309957|NCT00217009|Procedure|Topical Psoralen plus ultraviolet A (PUVA)|
309958|NCT00217022|Other|Placebo|Placebo, 3 tablets daily
309959|NCT00217022|Drug|Budesonide|9 mg daily (three tablets)
309960|NCT00217035|Dietary Supplement|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
309961|NCT00217048|Drug|Yohimbine, oral|
309962|NCT00217061|Device|Decision Aid Statin Choice|
309963|NCT00217074|Other|acupuncture|
310329|NCT00205699|Drug|risperidone|randomized to begin 12 week trial of ziprasidone
310330|NCT00205699|Drug|olanzapine|randomized to begin 12 week trial of olanzapine
310331|NCT00205699|Drug|aripiprazole|randomized to 12 week trial of aripiprazole
310332|NCT00205712|Drug|Ketamine|Ketamine without dexmedetomidine
310333|NCT00205712|Drug|Dexmedetomidine|Ketamine plus dexmedetomidine
310334|NCT00205725|Drug|Ziprasidone, Olanzapine|
310335|NCT00205738|Drug|Risperidone, Olanzapine|
310336|NCT00000383|Behavioral|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
310337|NCT00002549|Procedure|peripheral blood stem cell transplantation|
310338|NCT00205751|Drug|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
310339|NCT00205764|Drug|Melphalan|
310340|NCT00205777|Drug|Bazedoxifene Acetate|BZA 20mg, daily, oral
310341|NCT00205777|Other|Placebo|Placebo, daily, oral
310342|NCT00205790|Device|Vascular graft|
310343|NCT00205803|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
310344|NCT00205803|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
310345|NCT00205816|Drug|Tigecycline|
309596|NCT00227682|Drug|arsenic trioxide|
309597|NCT00002598|Radiation|radiation therapy|
309598|NCT00227682|Drug|dexamethasone|
309599|NCT00227682|Drug|thalidomide|
309600|NCT00227695|Biological|rituximab|comparing two maintenance schedules of Rituximab
309601|NCT00227708|Drug|docetaxel|
309602|NCT00227708|Procedure|quality-of-life assessment|
309603|NCT00227721|Drug|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
309604|NCT00227721|Drug|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
309605|NCT00227734|Drug|capecitabine and oxaliplatin + cetuximab|cetuximab
309606|NCT00227734|Drug|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
309607|NCT00227747|Drug|capecitabine|
309608|NCT00000395|Drug|Methotrexate|
309609|NCT00002599|Biological|filgrastim|
309610|NCT00227747|Drug|oxaliplatin|
309611|NCT00227747|Procedure|conventional surgery|
309612|NCT00227747|Procedure|neoadjuvant therapy|
309613|NCT00227747|Radiation|radiation therapy|
309614|NCT00227760|Drug|Cediranib Maleate|Given PO
309615|NCT00227760|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
309616|NCT00227760|Other|Laboratory Biomarker Analysis|Correlative studies
309617|NCT00227760|Other|Pharmacological Study|Correlative studies
309964|NCT00217087|Procedure|Endoscopic Mucosal Resection|Endoscopic mucosal resection at time of endoscopy if indicated.
309965|NCT00002571|Drug|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
308860|NCT00002662|Drug|paclitaxel|
308861|NCT00249652|Other|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
308862|NCT00249665|Drug|Perindopril|0mg to 16mg
308863|NCT00249665|Drug|Placebo|Capsule
308864|NCT00249665|Drug|perindopril|2mg
308865|NCT00249665|Drug|perindopril|4mg
308866|NCT00249665|Drug|perindopril|8mg
308867|NCT00249665|Drug|perindopril|16mg
308868|NCT00249678|Behavioral|Behavior Therapy|
308869|NCT00249691|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
309235|NCT00002633|Drug|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
309236|NCT00239109|Drug|Olanzapine|
309237|NCT00239109|Procedure|Scales|
309238|NCT00239109|Procedure|measures of the body (Weight...)|
309239|NCT00239109|Procedure|Serum analysis|
309240|NCT00239122|Behavioral|Recovery Therapy (Cognitive Behaviour Therapy for psychosis)|
309241|NCT00239135|Drug|PEP005|
309242|NCT00239148|Drug|E1 and G1|
309243|NCT00239161|Drug|Levofloxacin|
309244|NCT00239174|Drug|SR147778|
309245|NCT00239187|Drug|E1 and G1|
309246|NCT00002633|Drug|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
308473|NCT00258791|Drug|Ibuprofen|
308474|NCT00258804|Drug|Insulin glargine|
308475|NCT00258817|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
308476|NCT00258817|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
308477|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
308478|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
308479|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
308480|NCT00002696|Drug|CAF regimen|
308481|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, IM
308482|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
308483|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
308484|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
308485|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
308486|NCT00258882|Biological|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
308487|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
308488|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
308489|NCT00258908|Biological|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
308490|NCT00258934|Biological|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
308491|NCT00002696|Drug|CMF regimen|
308492|NCT00258934|Biological|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
308493|NCT00258947|Biological|Smallpox vaccine, LISTER strain, from chick embryo cells|
308494|NCT00258960|Drug|Liposomal Doxorubicin|
308495|NCT00258960|Drug|Cyclophosphamide|
307747|NCT00223678|Drug|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prgraf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
307748|NCT00223691|Drug|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
307749|NCT00223691|Drug|Acarbose|25-100 mg, PO. Single dose.
307750|NCT00223691|Drug|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
307751|NCT00223691|Drug|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
307752|NCT00002590|Drug|cytarabine|
307753|NCT00223691|Drug|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
307754|NCT00223691|Drug|placebo|PO.Single dose.
307755|NCT00223691|Drug|Modafinil|50-400 mg PO. Single dose
307756|NCT00223691|Drug|Octreotide|5-50 µg, S.C. Single dose.
307757|NCT00223691|Other|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
307758|NCT00223691|Drug|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
308111|NCT00212121|Procedure|boost|low dose versus high dose
308112|NCT00000386|Behavioral|Exposure and Response Prevention|
308113|NCT00002564|Other|educational intervention|
308114|NCT00212134|Device|hyperopic correction of infant surgical aphakia with Contact Lens|optical correction of infant surgical aphakia with Contact lens
308115|NCT00212134|Device|primary implantation of aphakic intraocular lens|optical correction of surgical aphakia with intraocular lens
308116|NCT00212147|Drug|general anesthesia|anesthesia regimen with nitrous oxide or without nitrous oxide
308117|NCT00212160|Procedure|omentectomy|RYGB with omentectomy
308118|NCT00212173|Drug|Sibutramine|
308119|NCT00212173|Dietary Supplement|Slim Fast|
308120|NCT00212186|Drug|Selenium Supplements (essential nutrient)|
307074|NCT00248690|Device|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
307075|NCT00002658|Drug|thioguanine|
307076|NCT00248703|Drug|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
307077|NCT00248716|Drug|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
307078|NCT00251628|Other|As needed dosing|"As needed" analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain.
307403|NCT00234780|Procedure|pediatric nursing used in home to avoid hospitalization|
307404|NCT00234793|Behavioral|Problem-Solving Skills Training|
307405|NCT00234806|Other|Health-e-Access|telemedicine intervention
307406|NCT00238212|Other|laboratory biomarker analysis|Correlative studies
307407|NCT00238225|Dietary Supplement|calcitriol|
307408|NCT00238225|Drug|dexamethasone|
307409|NCT00238225|Drug|ketoconazole|
307410|NCT00238238|Biological|rituximab|Given IV
307411|NCT00238238|Drug|lenalidomide|Given orally
307412|NCT00238251|Drug|gefitinib|Once daily during days 1-28
307413|NCT00002630|Procedure|peripheral blood stem cell transplantation|
307414|NCT00238251|Drug|temozolomide|Once daily on days 1-21
307415|NCT00238251|Radiation|radiation therapy|Whole brain radiotherapy
307416|NCT00238264|Radiation|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
307417|NCT00238277|Drug|temozolomide|
307418|NCT00238277|Procedure|adjuvant therapy|
307419|NCT00238277|Procedure|chemotherapy|
307420|NCT00238277|Procedure|radiation therapy|
306753|NCT02719743|Biological|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
306754|NCT02719756|Drug|Metformin|Metformin tablets 1000 mg
306755|NCT02719756|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets
306756|NCT02719756|Drug|Metformin up-titration|
306757|NCT02719782|Other|Biological: HBV antigen specific TCR redirected T cell|Patients will receive escalating doses of HBV specific TCR redirected T cell infusion
306758|NCT02719795|Drug|Ropivacaine|Local injection of local anesthetic into the fascial spaces
306759|NCT02719795|Drug|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
306760|NCT02719808|Drug|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
306761|NCT02719808|Drug|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
306762|NCT02719808|Drug|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
306763|NCT00204516|Drug|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
306764|NCT02719808|Drug|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
306765|NCT00002552|Drug|therapeutic hydrocortisone|
306766|NCT00207441|Behavioral|Arthritis Self management program|
306767|NCT00207441|Behavioral|Chronic Disease Self Management Program|
306768|NCT00207454|Behavioral|Social Cognitive Counseling|
306769|NCT00207467|Behavioral|Patient-delivered partner treatment|
306770|NCT00207467|Behavioral|Booklet-enhanced partner referral|
306771|NCT00207480|Behavioral|Brief, motivational interviewing intervention|
306772|NCT00207493|Behavioral|Kit enhancement to referral|
306773|NCT00207493|Procedure|patient referral versus contract referral|
306032|NCT00002596|Drug|cisplatin|
306033|NCT00226096|Drug|Phentolamine mesylate|
306034|NCT00226096|Drug|Nicardipine|
306035|NCT00226096|Drug|Urapidil|
306036|NCT00226096|Drug|Esmolol|
306037|NCT00226096|Drug|Clonidine|
306038|NCT00226096|Drug|Enalaprilat|
306039|NCT00226096|Drug|Nitroprusside|
306040|NCT00226109|Drug|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
306041|NCT00226122|Drug|Indomethacin|Indomethacin capsules 50 mg
306042|NCT00229996|Drug|Depot-Leuprolide/Norethindrone|
306043|NCT00230009|Behavioral|Brief motivational intervention|
306044|NCT00230022|Behavioral|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
306387|NCT00215514|Procedure|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
306388|NCT00215527|Drug|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
306389|NCT00215540|Drug|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
306390|NCT00218426|Drug|placebo oral and placebo implant|placebos resemble active medications
306391|NCT00218439|Drug|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
306392|NCT00218439|Drug|Placebo|
306393|NCT00218452|Behavioral|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
306394|NCT00218465|Drug|GW468816|Pharmacotherapies for Relapse Prevention
306395|NCT00218465|Drug|Placebo Comparator: Placebo|
305679|NCT00237601|Other|obstetric care|
305680|NCT00237614|Drug|intravenous and oral N-acetylcysteine|
305681|NCT00237627|Drug|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
305682|NCT00002628|Biological|filgrastim|
305683|NCT00237627|Drug|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
305684|NCT00237627|Drug|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
305685|NCT00237640|Drug|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
305686|NCT00237653|Drug|Valganciclovir|
305687|NCT00237666|Drug|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
305688|NCT00237679|Behavioral|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
305689|NCT00237679|Behavioral|Unstimulated|No current is generated.
305690|NCT00240955|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
305691|NCT00240968|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
305692|NCT00240981|Drug|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
305693|NCT00240981|Drug|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
305694|NCT00240994|Drug|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
306045|NCT00230035|Procedure|Leukapheresis|
306046|NCT00230035|Procedure|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
281456|NCT02592876|Drug|carboplatin|AUC 5 by IV infusion, every 3 weeks for up to 3 cycles
281457|NCT02592876|Drug|etoposide|100 mg/m2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
281458|NCT02592889|Device|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
281459|NCT02592902|Procedure|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
281460|NCT02592902|Procedure|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
281461|NCT02592915|Drug|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
281462|NCT00190801|Drug|pemetrexed|
281763|NCT02588768|Device|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
281764|NCT02591069|Device|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
281765|NCT02591082|Device|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter is an endovascular multi-lumen, two handled catheter designed to isolate variable segments of arteries supplying the target organ using two slideable, compliant balloons.
281766|NCT02591095|Drug|ABT-263|
281767|NCT02591108|Device|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
281768|NCT02591108|Device|Standard of Care: Microstim Plus and Direct Visualization|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
281161|NCT02599662|Radiation|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
281162|NCT02599662|Radiation|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
281163|NCT02599675|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
281164|NCT02599675|Dietary Supplement|Placebo|Olive oil, encapsuled
281165|NCT02599688|Other|None in this study|No intervention in this study.
281166|NCT02599701|Drug|Gabapentin|A single dose Gabapentin 300mg at bedtime.
281167|NCT02599701|Drug|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
281168|NCT00191425|Drug|Teriparatide|
281169|NCT02599714|Drug|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
281170|NCT02599714|Drug|Placebo to match AZD2014|The doublet combination will be comprised of Matching AZD2014 placebo + palbociclib + fulvestrant.
281463|NCT02595190|Procedure|sacral canal cyst microscopic tamponade|sacral canal cyst microscopic tamponade treatment
281464|NCT02595190|Drug|gabapentin + tramadol|dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
281465|NCT02595190|Device|resting state functional magnetic resonance imaging (rfMRI)|First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
281466|NCT02595203|Drug|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
281467|NCT02595203|Drug|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
281468|NCT02595216|Device|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
281469|NCT02595229|Procedure|Pronator quadratus repair|Suturing of the pronator quadratus muscle
281470|NCT02595242|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
281471|NCT00191022|Drug|placebo|
306865|NCT00002579|Drug|cyclophosphamide|
306866|NCT00218764|Behavioral|Cognitive therapy (CT)|Participants will attend CT sessions every-other week for 8 weeks, then monthly for 6 months.
306867|NCT00218764|Drug|Placebo|Placebo daily for 8 months
306868|NCT00218777|Behavioral|Comprehensive Behavioral Intervention for Tics|
306869|NCT00218790|Procedure|Cool Dialysate|Decreased temperature of the dialysis bath
306870|NCT00218803|Behavioral|Nurse asthma education intervention|Asthma Education
306871|NCT00222989|Drug|PPI|
306872|NCT00223002|Drug|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
306873|NCT00223015|Drug|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
306874|NCT00223028|Drug|sirolimus, mycophenolat mofetil, fluvastatin|
306875|NCT00002589|Biological|aldesleukin|
306876|NCT00223041|Drug|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
306877|NCT00223054|Drug|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
306878|NCT00223054|Drug|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
306879|NCT00223054|Drug|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
306880|NCT00223054|Drug|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
306881|NCT00223067|Drug|TAIZ|
306882|NCT00223080|Biological|ALVAC-HIV vCP1521 + AIDSVAX|1cc injected into left deltoid muscle at day 0,weeks 4, 12, 24
Prime/Boost Vaccination
306883|NCT00223080|Biological|ALVAC Placebo + AIDSVAX Placebo|1cc ALVAC Placebo in left deltoid at day 0 and week 4
1 cc ALVAC Placebo + AIDSVAX Placebo in left deltoid on weeks 12 and 24
306884|NCT00223093|Drug|TAIZ|
307187|NCT00207740|Drug|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
307188|NCT00207740|Drug|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
306177|NCT00244894|Procedure|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
306178|NCT00244907|Dietary Supplement|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
306179|NCT00244920|Drug|bicalutamide|
306180|NCT00244920|Drug|leuprolide acetate|
306181|NCT00248131|Drug|Octreotide acetate in microspheres|
306182|NCT00248144|Drug|Famciclovir|
306183|NCT00248157|Drug|Octreotide acetate in microspheres|
306184|NCT00248170|Drug|Letrozole|2.5 mg tablets
306534|NCT00234156|Procedure|oral fructose and high fat diet|High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.
Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours.
306535|NCT00237796|Behavioral|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
306536|NCT00237809|Drug|D-serine|D-serine (30 mg/kg)
306537|NCT00237809|Behavioral|Cognitive retraining|Cog rehab
306538|NCT00237822|Behavioral|Adherence Feedback (AF)|
306539|NCT00002628|Drug|mesna|
306540|NCT00237822|Behavioral|AF + Contingency Management (AF + CM)|
306541|NCT00237822|Behavioral|AF + Motivational Enhancement Therapy (AF + MET)|
306542|NCT00237848|Drug|D-serine|
306543|NCT00237848|Behavioral|Cognitive retraining|
306544|NCT00237861|Drug|risperidone|
306545|NCT00237861|Drug|olanzapine|
306546|NCT00237861|Drug|quetiapine|
306547|NCT00237874|Drug|Aripiprazole|
306548|NCT00237887|Drug|adalimumab|
305811|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
305812|NCT00000412|Drug|Alendronate|
305813|NCT00002678|Drug|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
305814|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
305815|NCT00254293|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
305816|NCT00254319|Drug|Avastin, Alimta|
305817|NCT00257660|Drug|Placebo|500 units
305818|NCT00257673|Drug|MEM 1003|30 mg twice a day
305819|NCT00257673|Drug|MEM 1003|90 mg MEM 1003 twice a day
305820|NCT00257673|Drug|Placebo for MEM 1003|Placebo twice a day
305821|NCT00257686|Drug|Pitavastatin|
305822|NCT00257686|Drug|Pravastatin|
305823|NCT00257699|Drug|Metronidazole placebo|
305824|NCT00002691|Drug|dexamethasone|
305825|NCT00257699|Drug|ciprofloxacin placebo|
305826|NCT00257699|Drug|ciprofloxacin|500 mg bid po
305827|NCT00257699|Drug|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
305828|NCT00257712|Drug|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
305829|NCT00257725|Drug|Ritalin LA™|
305830|NCT00257738|Biological|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
306185|NCT00248170|Drug|Anastrozole|1 mg tablets
306186|NCT00248183|Drug|PRX-00023|
306187|NCT00248196|Device|Reprieve Endovascular Temperature Therapy System|
311050|NCT00347178|Procedure|Laser Peripheral Iridotomy|
311051|NCT00347204|Drug|ketorolac (Acular LS)|
311052|NCT00347204|Drug|Nepafenac (Nevanac)|
311053|NCT00347230|Device|Intacs intracorneal ring insertion for the treatment of keratoconus|
311054|NCT00347243|Procedure|phacoemulsification (cataract surgery)|
311055|NCT00347256|Drug|cisplatin|
311056|NCT00002997|Procedure|cryosurgery|
311057|NCT00347256|Procedure|targeted radiation therapy|
311058|NCT00347256|Procedure|tumor resection|
305457|NCT00207090|Drug|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
305458|NCT00207090|Drug|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
305459|NCT00207103|Drug|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
305460|NCT00207103|Drug|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
305461|NCT00207103|Drug|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
305462|NCT00210418|Dietary Supplement|Fortified food rations|The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ <-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
305463|NCT00210418|Behavioral|Education and communication to improve feeding practices|The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
305464|NCT00002558|Drug|paclitaxel|
305465|NCT00210444|Drug|Botulinum toxin type A (Dysport)|
305466|NCT00210457|Drug|Lanreotide (Autogel formulation)|
305467|NCT00210470|Biological|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day), 1 initial injection of cyclophosphamide, and 3 weeks of indomethacin (tablets or injection) and zinc supplementation (multivitamin tablet)
305468|NCT00210470|Drug|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
310692|NCT00356343|Other|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
310693|NCT00003042|Drug|paclitaxel|
310694|NCT00356356|Drug|Etanercept|Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
310695|NCT00356369|Biological|meningococcal ACWY (vaccine)|One intramuscular dose.
310696|NCT00356369|Biological|Mencevax™ ACWY|One subcutaneous dose.
310697|NCT00356382|Drug|Lactobacillus (L.) casei|
310698|NCT00356395|Drug|ramipril, candesartan|
310699|NCT00356408|Biological|Certolizumab pegol|Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).
Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2.
310700|NCT00356421|Drug|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
310701|NCT00356421|Drug|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
310702|NCT00356434|Device|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
310703|NCT00356434|Device|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
310704|NCT00003042|Drug|tamoxifen citrate|
310705|NCT00356447|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
310706|NCT00356447|Drug|Placebo|Same administration.
305111|NCT00221845|Drug|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
305112|NCT00221858|Procedure|Ultrasound guided blocks|
305113|NCT00221871|Drug|Different dosages of Ketamine|
305114|NCT00221884|Procedure|Ultrasound|
310346|NCT00205829|Device|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
310347|NCT00205842|Drug|alvimopan|
310348|NCT00002549|Radiation|radiation therapy|
310349|NCT00205855|Device|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
310350|NCT00205868|Device|Precision Spinal Cord Stimulation System|Stimulation on throughout study
310351|NCT00205881|Device|HiRes 90K Bionic Ear System|Cochlear implant system
310352|NCT00209222|Procedure|high-dose chemotherapy: Cyclophosphamide|chemotherapy
310353|NCT00209222|Procedure|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
310707|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
310708|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
310709|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
310710|NCT00359255|Behavioral|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
310711|NCT00359255|Behavioral|An inpatient homework based exercise program for the upper limb post stroke|The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.
The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing.
310712|NCT00359281|Drug|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
310713|NCT00359281|Drug|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
310714|NCT00359281|Drug|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
310715|NCT00000479|Drug|Aspirin|Participants will receive 100 mg of aspirin every other day.
310716|NCT00003060|Drug|busulfan|
309966|NCT00217087|Procedure|Photodynamic Therapy|Porfimer sodium 2mg/kg
309967|NCT00217100|Dietary Supplement|Multivitamin|1 tablet a day
309968|NCT00217100|Dietary Supplement|Placebo|1 tablet a day
309969|NCT00217113|Behavioral|Geriatric home visit and Action Plan|
309970|NCT00217139|Drug|Celgosivir|
309971|NCT00217152|Drug|CellCept|
309972|NCT00217165|Drug|taurine|taurine 2mg BID po
309973|NCT00217178|Drug|Vitamins: Folic acid, B6, B12|
309974|NCT00217191|Drug|Ibuprofen|
309975|NCT00217204|Drug|Pancrelipase microtablets|
309976|NCT00220467|Behavioral|Aerobic exercise|
309977|NCT00220480|Drug|escitalopram|10 to 30 mg / day
309978|NCT00220493|Drug|Ritalin|
309979|NCT00220506|Drug|Provigil|
309980|NCT00220519|Drug|Lactobacillus GG|
309981|NCT00220532|Drug|Folic acid with riboflavin|
309982|NCT00220545|Procedure|Laparoscopic ovarian diathermy|
309983|NCT00220558|Device|Coronary placement of bare metal stent vs. drug eluting stent|
309984|NCT00002581|Drug|methotrexate|
309985|NCT00220571|Device|Coronary Angioplasty (PTCA)|
309986|NCT00220584|Drug|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
309987|NCT00220597|Behavioral|Trauma-focused group therapy|
309988|NCT00220610|Device|Transcranial magnetic stimulation|
309989|NCT00220623|Drug|antidepressant medications, flexible drug choice|
309990|NCT00220623|Behavioral|CBT, Psychodynamic or Supportive Psychotherapy|
309247|NCT00239200|Drug|Lapatinib|
309248|NCT00239213|Drug|catechin extracts (health food)|
309249|NCT00239226|Procedure|IAS pacing - study group|site of implant and permanent pacing
309250|NCT00239226|Procedure|IAS pacing control group|site of implant and permanent pacing
309251|NCT00239226|Procedure|Pacing RAA study group|site of implant and permanent pacing
309252|NCT00242905|Behavioral|Study of memory using MRI|Study of memory using MRI
309253|NCT00002641|Procedure|conventional surgery|
309254|NCT00242918|Drug|docetaxel|
309255|NCT00242918|Drug|ZD1839|
309256|NCT00242931|Other|Nonmyeloablative stem cell conditioning regimen|Conditioning:
Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0
Hematopoeitic Stem Cell Transplantation:
Infusion of peripheral blood stem cells, day 0
Immunosuppression:
For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop
For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181.
309618|NCT00227773|Drug|octreotide acetate|
309619|NCT00227773|Drug|vatalanib|
309620|NCT00002599|Biological|recombinant interferon alfa|
309621|NCT00231933|Behavioral|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
309622|NCT00231933|Behavioral|Community integration (CI)|CI includes recovery group sessions and community integration activities.
309623|NCT00231933|Behavioral|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
309624|NCT00231946|Drug|VP4896|
309625|NCT00231959|Drug|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
309626|NCT00231959|Drug|Placebo|sugar pill
308870|NCT00249691|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
308871|NCT00000409|Procedure|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
308872|NCT00002663|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
308873|NCT00249704|Drug|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
308874|NCT00249704|Procedure|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
308875|NCT00249704|Procedure|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
308876|NCT00249704|Drug|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
308877|NCT00249717|Behavioral|Contingency management|Receive rewards (prizes) abstinence and attendance
308878|NCT00249730|Drug|Sildenafil|
308879|NCT00249743|Device|FallSaver (formerly called NOCwatch)|
308880|NCT00002673|Procedure|infection prophylaxis and management|
308881|NCT00252512|Other|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
308882|NCT00252551|Procedure|Osteosynthesis|
308883|NCT00252551|Procedure|Simple surgery|Surgery without device
308884|NCT00252564|Drug|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
308885|NCT00252564|Drug|Oxaliplatin|85 mg/m2 on Days 1 and 15
308886|NCT00252564|Drug|Leucovorin|400 mg/m2 on Days 1 and 15
308887|NCT00252564|Drug|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
308888|NCT00252564|Drug|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
308889|NCT00252577|Drug|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
308121|NCT00212199|Drug|orlistat|
308122|NCT00212199|Behavioral|Brief cognitive behavioral counseling|
308123|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenate
308124|NCT00002564|Procedure|therapeutic dietary intervention|
308125|NCT00212212|Dietary Supplement|selenium|400 µg selenium as selenate
308126|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenomethionine
308127|NCT00212212|Dietary Supplement|placebo|placebo tablet
308128|NCT00212238|Behavioral|internet behavioral weight loss program|
308129|NCT00212251|Behavioral|moderate exercise and healthy, low-fat diet|
308130|NCT00212264|Behavioral|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
308131|NCT00212264|Device|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
308132|NCT00212264|Behavioral|Biofeedback|Pelvic Floor Muscle training via biofeedback
308133|NCT00216034|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
308134|NCT00216034|Drug|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
308135|NCT00216047|Drug|PTK787|PTK787 daily
308496|NCT00258960|Drug|Trastuzumab|
308497|NCT00258973|Procedure|Carotid Ultrasound performed in office practice|
308498|NCT00258986|Procedure|Living donornephrectomy|
308499|NCT00258999|Device|Skin Cholesterol Testing|
308500|NCT00259012|Drug|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
308501|NCT00259025|Drug|lipid emulsion with a high content of n-3 fatty acids|
308502|NCT00002696|Drug|cyclophosphamide|
307421|NCT00238290|Drug|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
307422|NCT00238303|Drug|vorinostat|Given orally
307423|NCT00238303|Procedure|conventional surgery|Patients undergo surgery to remove tumor
307424|NCT00002630|Radiation|low-LET cobalt-60 gamma ray therapy|
307425|NCT00238316|Drug|letrozole|2.5 mg PO daily for 1 year
307426|NCT00238316|Other|Placebo|2.5 mg PO daily for one 1 year
307427|NCT00238329|Biological|PEG-interferon alfa-2b|
307428|NCT00238329|Drug|thalidomide|
307759|NCT00223691|Drug|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
307760|NCT00223691|Drug|Tranylcypromine|5 - 40 mg PO. Single dose
307761|NCT00223691|Drug|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
307762|NCT00223691|Drug|Celecoxib|50-200 mg PO. Single dose
307763|NCT00002590|Drug|daunorubicin hydrochloride|
307764|NCT00223691|Drug|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
307765|NCT00223691|Drug|Methylphenidate|5 or 10 mg PO. Single dose.
307766|NCT00223691|Drug|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
307767|NCT00223691|Drug|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
307768|NCT00223691|Drug|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
307769|NCT00223691|Dietary Supplement|Bovril|6-10 g, PO. Single dose.
307770|NCT00223691|Drug|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
307771|NCT00226811|Drug|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
307772|NCT00002597|Drug|goserelin acetate|
307079|NCT00251641|Drug|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
307080|NCT00251641|Drug|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a <25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
307081|NCT00251654|Procedure|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
307082|NCT00251680|Drug|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
307083|NCT00251680|Drug|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
307084|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
307085|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
307086|NCT00251693|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
307087|NCT00002669|Biological|recombinant interferon alfa|
307088|NCT00251706|Drug|amiodarone|
307089|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
307090|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
307091|NCT00251719|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
307092|NCT00251732|Drug|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
307093|NCT00251732|Drug|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
307094|NCT00251732|Drug|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
307095|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
307096|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
307097|NCT00251745|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
306396|NCT00218478|Behavioral|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
306397|NCT00218491|Drug|N-Acetylcysteine|1200mg N-Acetylcysteine
306398|NCT00218491|Drug|N-Acetylcysteine|2400mg N-Acetylcysteine
306399|NCT00218491|Drug|Matching Placebo|Matching Placebo
306400|NCT00002578|Drug|leucovorin calcium|
306401|NCT00218504|Drug|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
306402|NCT00218517|Drug|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
306403|NCT00218517|Drug|Placebo|Matching placebo capsules using blue 00 capsules
306404|NCT00218530|Drug|Lofexidine|
306405|NCT00218543|Drug|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
306406|NCT00218556|Behavioral|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
306407|NCT00218569|Drug|Naltrexone|Naltrexone
306774|NCT00207506|Behavioral|HoMBReS: A lay health advisor approach to STD prevention|
306775|NCT00207519|Behavioral|weekly behavioral modification group|
306776|NCT00000132|Drug|Betaxolol|
306777|NCT00000384|Behavioral|Cognitive Behavior Therapy|
306778|NCT00002552|Procedure|allogeneic bone marrow transplantation|
306779|NCT00207519|Behavioral|liquid meal replacements|
306780|NCT00207532|Drug|folic acid|
306781|NCT00207558|Drug|folic acid|
306782|NCT00207571|Behavioral|Computer|
306783|NCT00207584|Drug|Doxycycline treatment|
306047|NCT00230035|Procedure|Autologous CD34+HPC transplantation (HSCT)|
306048|NCT00230035|Procedure|Plasmapheresis|
306049|NCT00230035|Drug|Rabbit anti-thymocyte globulin|
306050|NCT00230035|Drug|Methylprednisolone|
306051|NCT00230035|Drug|Growth colony stimulating factor (G-CSF)|
306052|NCT00002602|Radiation|3D-CRT|3 dimensional conformal radiation therapy
306053|NCT00230035|Drug|Corticosteroids|
306054|NCT00230035|Drug|Mycophenolate mofetil|
306055|NCT00230035|Drug|Azathioprine|
306056|NCT00230035|Drug|Intravenous immunoglobulin|
306057|NCT00230035|Drug|Methotrexate|
306058|NCT00230035|Drug|Rituximab|
306059|NCT00230035|Drug|Leflunomide|
306060|NCT00230048|Behavioral|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
306061|NCT00230061|Biological|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
306062|NCT00230074|Drug|TCH346|
306063|NCT00002604|Drug|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
306064|NCT00230087|Procedure|blood donation|phlebotomy until iron depleted
306065|NCT00230100|Behavioral|group treatment for substance use disorders|Subjects receiving the Women's Recovery Group therapy attended 12 sessions, 90 minutes each, focused on themes that are relevant to women with Substance Use Disorders. Subjects receiving the standard Group Drug Counseling in a mixed-gender group attended 12 sessions, 90 minutes each, focused on recovery principles for alcohol and drug recovery.
306066|NCT00230113|Dietary Supplement|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
306067|NCT00230113|Dietary Supplement|safflower oil|4 gm per day safflower oil
306068|NCT00230126|Drug|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
281769|NCT02591134|Other|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
281770|NCT02591134|Other|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
281771|NCT02591147|Drug|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
281772|NCT02591147|Drug|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
281773|NCT02591160|Procedure|NO hydrochlorothiazide (HCTZ)|Patients will stop taking their HCTZ for 3 months
281774|NCT00190593|Drug|placebo|
281775|NCT02591173|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
281776|NCT02591173|Drug|Saline|Normal saline will be used as the placebo comparator.
282060|NCT02584257|Drug|180 mcg of Reference product|
282061|NCT02584257|Drug|90 mcg of Test product|
282062|NCT02584257|Drug|180 mcg of Test product|
282063|NCT02586415|Device|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
282064|NCT02586415|Device|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
282065|NCT02586415|Device|Penumbra thrombectomy system|Penumbra thrombectomy system including is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:
Penumbra Aspiration Pump 115V
Penumbra System Separator Flex [026, 032, 041 and 054]
Penumbra System MAX
Penumbra Pump MAX
282066|NCT02586428|Other|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
282067|NCT02586441|Device|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
282068|NCT00189930|Biological|IMVAMUNE|3 immunizations: 1E8_TCID50 IMVAMUNE
281472|NCT02595242|Drug|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
281473|NCT02595242|Drug|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
281474|NCT02595255|Other|No intervention|No intervention
281475|NCT02595268|Drug|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
281476|NCT02595268|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
281477|NCT02595281|Other|Experimental arm|Serum samples are collected:
at each neoadjuvant chemotherapy cycle
before surgery
at each adjuvant chemotherapy cycle
at each injection of bevacizumab as maintenance therapy
stop at the progression or after 24 months post chemotherapy
281478|NCT02595294|Procedure|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
281479|NCT02595307|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
281480|NCT02595320|Drug|Capecitabine|Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).
Capecitabine will be given to participants in group B at 1250 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7).
281481|NCT02595333|Drug|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
307909|NCT00242437|Device|Hemostatic matrix|
307910|NCT00242437|Device|bovine thrombin|
307911|NCT00242450|Drug|Metoclopramide|
307912|NCT00242463|Drug|Nandrolone (anabolic steroid)|
307913|NCT00242463|Drug|Placebo|
307914|NCT00242476|Drug|MK0822A|
307915|NCT00242489|Drug|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
307916|NCT00002641|Biological|filgrastim|
307917|NCT00242489|Drug|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
307918|NCT00242502|Drug|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
307189|NCT00207753|Drug|albendazole vs. combined albendazole/ivermectin treatment|
307190|NCT00207766|Drug|infliximab or placebo|
307191|NCT00207779|Device|heparin impregnated central venous catheters|
307192|NCT00207792|Drug|filgrastim|
307193|NCT00207805|Procedure|autologous PBSC transplant|optimal timining of a second autologous transplant
307194|NCT00207818|Device|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
307195|NCT00002552|Procedure|peripheral blood stem cell transplantation|
307196|NCT00207831|Drug|Tegafur and Uracil|
307197|NCT00207844|Drug|Selenium as sodium selenite|
307198|NCT00207935|Behavioral|Swallow instruction|
307199|NCT00207948|Drug|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
307200|NCT00207974|Drug|Marine active|
307201|NCT00208000|Drug|Marine active|
307202|NCT00208026|Drug|Pimecrolimus 1% Cream|Open label single arm
307203|NCT00208039|Drug|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
307204|NCT00208065|Drug|almotriptan or pseudoephedrine|
307205|NCT00208078|Device|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
307206|NCT00002552|Procedure|syngeneic bone marrow transplantation|
307207|NCT00211614|Drug|Lansoprazole|
307208|NCT00211627|Device|KEEPASLEEP enhanced breathing device|
307209|NCT00211653|Drug|N-Acetylcysteine|
307210|NCT00211666|Behavioral|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
307211|NCT00211679|Drug|Botulinum Toxin Type A|
307550|NCT00002670|Drug|cisplatin|
306549|NCT00237900|Drug|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
306550|NCT00002628|Drug|paclitaxel|
306551|NCT00237913|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
306552|NCT00237913|Drug|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
306553|NCT00237926|Behavioral|Exercise|aerobic or resistance training
306554|NCT00237939|Drug|Aripiprazole|
306555|NCT00237952|Drug|EDTA chelating agents|
306556|NCT00237965|Behavioral|Mole Mapping Diagram|
306557|NCT00237978|Drug|Adapalen|
306558|NCT00237978|Radiation|VIS and wIRA|
306885|NCT00223106|Device|Vaginal Sling|
306886|NCT00002589|Biological|muromonab-CD3|
306887|NCT00223119|Device|Absorbable Sutures|
306888|NCT00223132|Device|Absorbable sutures|
306889|NCT00223145|Radiation|Radiotherapy 70 Gy|Radiotherapy to the prostate
306890|NCT00223145|Radiation|Radiotherapy 76 Gy|Radiotherapy to the prostate
306891|NCT00223145|Drug|Androgen blockade|Duration : 6 months
306892|NCT00223158|Drug|Liothyronine|
306893|NCT00223171|Drug|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
306894|NCT00223197|Drug|Pregnenolone|
306895|NCT00223210|Drug|Quetiapine|Active Quetiapine
306896|NCT00223210|Drug|PLacebo|Placebo
306897|NCT00002589|Biological|therapeutic autologous lymphocytes|
306898|NCT00223223|Drug|Levetiracetam, Keppra|
306188|NCT00248209|Drug|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
306189|NCT00002658|Drug|cyclophosphamide|
306190|NCT00248222|Behavioral|Supervised aerobic training|
306191|NCT00248235|Behavioral|Exercise|
306192|NCT00248248|Drug|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
306193|NCT00248261|Drug|ziprasidone, sertraline|
306194|NCT00248287|Drug|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
306195|NCT00248287|Drug|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
306196|NCT00248300|Other|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
306197|NCT00248313|Drug|Rapamune®|
306198|NCT00248339|Drug|Peginterferon-alpha-2b (PEG-Intron)|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
306199|NCT00248339|Drug|Ribavirin|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
306200|NCT00002658|Drug|cytarabine|
306201|NCT00248339|Drug|Epoetin-alpha (Procrit)|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
306202|NCT00248352|Behavioral|Consultation with Endocrinologist|
306203|NCT00248352|Behavioral|Counseling from Dietician|
306204|NCT00248352|Behavioral|Counseling from Diabetes Educator|
306205|NCT00248365|Biological|Theralux extracorporeal photochemotherapy|
306206|NCT00248378|Drug|Smoked Cannabis|
306207|NCT00248391|Behavioral|upright feeding|
305469|NCT00210470|Drug|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
305470|NCT00210470|Drug|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
305471|NCT00210470|Drug|Omeprazole|21 days of 20 mg. orally
305472|NCT00210483|Drug|almotriptan malate|
305473|NCT00210496|Drug|topiramate; almotriptan malate|
305474|NCT00210509|Drug|almotriptan malate|
305475|NCT00002558|Procedure|peripheral blood stem cell transplantation|
305476|NCT00210522|Drug|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
305477|NCT00210535|Drug|Topiramate; Placebo|
305478|NCT00210548|Drug|paliperidone palmitate|
305831|NCT00257738|Biological|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
305832|NCT00257751|Procedure|Aprotinine|
305833|NCT00257764|Behavioral|behavioral swallowing exercises/ strategies|
305834|NCT00257777|Procedure|Myocardial protection techniques|
305835|NCT00002691|Drug|etoposide|
305836|NCT00257790|Drug|Tobramycin once a day|
305837|NCT00257803|Drug|Oxytocin|See detailed description
305838|NCT00257803|Drug|Saline solution|See detailed description
305839|NCT00257816|Drug|Topotecan|2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
305840|NCT00257816|Drug|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
305841|NCT00257829|Drug|Methazolamide|
305842|NCT00257829|Drug|Cisplatin|
305843|NCT00257842|Procedure|Standard treatment, sham feedback and biofeedback therapy|
305844|NCT00257855|Drug|Lamotrigine|
305115|NCT00221910|Procedure|Ultrasound|
305116|NCT00002582|Radiation|radiation therapy|
305117|NCT00221936|Behavioral|Self-administration or nurse administered medication|
305118|NCT00221949|Device|Ultrasound|
305119|NCT00221962|Drug|Aripiprazole|Open label
305120|NCT00221975|Drug|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
305121|NCT00221975|Drug|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
305122|NCT00221975|Drug|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (<2 months versus ≥2 months).
305123|NCT00221988|Drug|Levetiracetam (Keppra)|
305124|NCT00222014|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
305125|NCT00222014|Procedure|Paracenthese|Paracenthese
305126|NCT00222027|Procedure|Collection of treatment-stratefying prognostic factors|
305127|NCT00002583|Drug|cisplatin|50 mg/m2 IV
305128|NCT00222040|Radiation|Ultrasound|2-MHz, low intensity transcranial ultrasound
305129|NCT00222040|Drug|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
305130|NCT00222053|Drug|Thalidomide|Per os thalidomide
305131|NCT00222053|Drug|Biphosphonates|Biphosphonates
305132|NCT00222066|Procedure|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
305133|NCT00222079|Drug|Esomeprazole (Nexium)|
305134|NCT00225381|Procedure|adding PEEP during anesthesia|same
305479|NCT00210561|Drug|tramadol hydrochloride , acetaminophen|
305480|NCT00210574|Drug|topiramate|
310717|NCT00359281|Drug|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
310718|NCT00359281|Drug|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
310719|NCT00359281|Drug|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
310720|NCT00359294|Drug|Zalypsis (PM00104)|Intravenously over 1 hour daily for 5 days, every 3 weeks.
310721|NCT00359320|Procedure|pancreaticojejunostomy|
310722|NCT00359333|Drug|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
310723|NCT00359359|Drug|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
310724|NCT00359359|Drug|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
310725|NCT00359385|Drug|Alendronate 70mg weekly|70mg weekly
310726|NCT00359398|Procedure|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
310727|NCT00003060|Drug|cyclophosphamide|
305135|NCT00225381|Procedure|placement of esophageal Doppler for cardiac output measurements|same
305136|NCT00225381|Device|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
305137|NCT00002594|Procedure|bone marrow ablation with stem cell support|
305138|NCT00225381|Device|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
305139|NCT00225381|Device|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
305140|NCT00225381|Device|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
305141|NCT00225407|Drug|Smoking of cannabis cigarettes (different strength)|
305142|NCT00225420|Drug|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
305143|NCT00225420|Drug|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
310354|NCT00209235|Drug|Growth hormone|Growth hormone
310355|NCT00209235|Drug|Growth Hormone|Pseudohypoparathyroidism type 1a (growth hormone deficient): subcutaneous form, 0.15 mg - 0.30 mg per kg per week divided into daily doses, titrated by response and IGF-1 levels. The duration is participant dependent.
For phase for growth hormone sufficient participants with PHP1a, dosage may be up to 0.37 mg per kg per week divided into daily doses subcutaneously, titrated by response and IGF-1 levels. The duration is participant dependent and also dependent on length of study and period of active recruitment.
For all GH-sufficient participants, the GH use is initiated in patients who are over 3 years of age and who are pre-pubertal provided that there are no contraindications to its use. [Enrollment for study drug has been completed.]
310356|NCT00209261|Drug|MINIRIN Oral Lyophilisate|
310357|NCT00000384|Drug|Sertraline|
310358|NCT00002556|Drug|melphalan|Given PO
310359|NCT00209261|Drug|Minirin tablet|
310360|NCT00209274|Device|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
310361|NCT00209274|Procedure|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
310362|NCT00209287|Behavioral|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
310363|NCT00209300|Drug|Pentasa|
310364|NCT00209313|Drug|Acyclovir|Acyclovir 800 mg twice daily or placebo
310365|NCT00209326|Drug|FE200440|
310366|NCT00209339|Device|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardovascular Valve Repair System.
310367|NCT00209352|Drug|Acyclovir|
310368|NCT00209365|Procedure|exposure to grass pollen/starch granules|
310369|NCT00002556|Drug|cyclophosphamide|Given IV
310370|NCT00209378|Other|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
310371|NCT00209378|Other|HfCitPre|regional anticoagulation with citrate containing replacement solution
310372|NCT00209391|Drug|Gadodiamide Injection|
310373|NCT00209404|Drug|Iodixanol 320 mg I/Ml|
310374|NCT00209417|Drug|Iodixanol 320-Arm 1|
309627|NCT00231972|Behavioral|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
309628|NCT00231972|Behavioral|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
309629|NCT00231985|Behavioral|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
309630|NCT00002611|Biological|dactinomycin|
309631|NCT00231985|Behavioral|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
309632|NCT00231998|Drug|Pimecrolimus|Pimecrolimus cream 1 %
309633|NCT00232011|Drug|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
309634|NCT00232024|Drug|Tegaserod|
309635|NCT00232037|Drug|Tegaserod|
309636|NCT00232050|Drug|Omalizumab|
309637|NCT00232063|Drug|ciclosporin|
309638|NCT00232076|Drug|ciclosporin|
309639|NCT00232089|Drug|Tegaserod|
309640|NCT00232102|Drug|Tegaserod|
309991|NCT00220636|Drug|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
309992|NCT00220649|Drug|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
309993|NCT00220662|Behavioral|Readiness and Motivation Therapy|
309994|NCT00220675|Drug|Erythropoietin infusion|
309995|NCT00000388|Behavioral|Assessment-and-Referral|
309996|NCT00002581|Drug|tamoxifen citrate|
309997|NCT00220688|Device|Acupressure Wristbands|
308890|NCT00252590|Behavioral|Health Motivational Feedback|Personalized feedback on health status
308891|NCT00002674|Biological|filgrastim|
308892|NCT00252590|Behavioral|Health Education|Generalized health education related to alcohol use
309257|NCT00242944|Drug|Pitavastatin|Pitavastatin 4mg per day
309258|NCT00242944|Drug|Atorvastatin|Atorvastatin 20mg per day
309259|NCT00242957|Behavioral|Intervention with Microfinance for AIDS and Gender Equity|
309260|NCT00242970|Device|3-Dimensional Color Scanning|Color imaging of the face and neck.
309261|NCT00242983|Procedure|quality-of-life assessment|
309262|NCT00242996|Biological|filgrastim|
309263|NCT00242996|Biological|rituximab|
309264|NCT00002641|Radiation|radiation therapy|
309265|NCT00242996|Biological|sargramostim|
309266|NCT00242996|Drug|carmustine|
309267|NCT00242996|Drug|cyclophosphamide|
309268|NCT00242996|Drug|etoposide|
309269|NCT00242996|Procedure|adjuvant therapy|
309270|NCT00242996|Procedure|bone marrow ablation with stem cell support|
309271|NCT00242996|Procedure|peripheral blood stem cell transplantation|
309272|NCT00243009|Drug|cyclosporine|
309273|NCT00243009|Drug|fludarabine phosphate|
309274|NCT00243009|Drug|mycophenolate mofetil|
309275|NCT00002642|Drug|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
309276|NCT00243009|Procedure|allogeneic bone marrow transplantation|
309277|NCT00243009|Procedure|peripheral blood stem cell transplantation|
309278|NCT00243009|Radiation|radiation therapy|
308503|NCT02720302|Behavioral|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
308504|NCT02720302|Behavioral|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
308505|NCT02720315|Procedure|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
308506|NCT02720328|Biological|Blood samples for DOAC measurement|
308507|NCT02720341|Device|ARMin|single sessions of about one hour each
308508|NCT00000382|Behavioral|Parent Education|
308509|NCT00002549|Drug|busulfan|
308510|NCT00204568|Drug|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
308511|NCT02720354|Drug|[11C]‑DMDPA|
308512|NCT02720367|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)|GemRIS is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7 day period.
308513|NCT02720380|Other|Buteyko|Intervention will be held twice a week during 3 weeks.
308514|NCT02720380|Other|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
308515|NCT02720393|Other|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
308516|NCT02720393|Other|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
308517|NCT02720406|Drug|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
308518|NCT02720406|Drug|Nebulized Ketamine 0.5mg/kg|Nebulized Ketamine 0.5mg/kg given by neutralizer before anesthesia.
308519|NCT02720406|Drug|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by neutralizer before anesthesia.
308893|NCT00252590|Behavioral|Control - treatment as usual|Control group with no additional intervention
308894|NCT00252603|Drug|Galantamine|
308895|NCT00252616|Behavioral|trophic enteral feeds|10cc/hr
307773|NCT00226824|Drug|galantamine|
307774|NCT00226837|Drug|Nitrous oxide|nitrous oxide by inhalation during induction
307775|NCT00226850|Behavioral|hypnosis|
307776|NCT00226863|Behavioral|meditation plus education|
307777|NCT00226863|Behavioral|group psychotherapy with hypnosis plus education|
307778|NCT00226863|Behavioral|education|
307779|NCT00226889|Drug|bosentan|
307780|NCT00226902|Procedure|Changing hemoglobin concentration|
307781|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
307782|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
307783|NCT00002597|Drug|leuprolide acetate|
307784|NCT00226928|Behavioral|Supportive-Expressive Group Therapy plus education|
308136|NCT00216047|Drug|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle*
308137|NCT00216060|Drug|Risedronate|Daily oral risedronate combined with androgen deprivation
308138|NCT00216060|Drug|Placebo|Daily oral placebo combined with androgen deprivation
308139|NCT00216073|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
308140|NCT00216073|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
308141|NCT00216073|Drug|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
308142|NCT00216086|Drug|Capecitabine|Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles
*For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid
308143|NCT00002570|Drug|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
308144|NCT00216086|Drug|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
308145|NCT00216086|Procedure|EUS|biopsy per EUS
307098|NCT00002669|Drug|cisplatin|
307099|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
307429|NCT00238342|Genetic|proteomic profiling|
307430|NCT00238342|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
307431|NCT00238342|Procedure|biopsy|
307432|NCT00238355|Drug|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
307433|NCT00238355|Drug|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
307434|NCT00238368|Biological|filgrastim|
307435|NCT00002630|Radiation|low-LET photon therapy|
307436|NCT00238368|Biological|rituximab|
307437|NCT00241969|Behavioral|Behavioral plus Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills.
307438|NCT00241969|Behavioral|Attention Control Treatment|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.
307439|NCT00002638|Drug|etoposide|
307440|NCT00241982|Drug|long-circulating liposomal prednisolone|
307441|NCT00241995|Drug|Anticonvulsants|
307442|NCT00242008|Drug|Rotigotine|
307443|NCT00242021|Behavioral|Fatty acid composition of a margarine (spread)|
307444|NCT00242034|Procedure|CT and MRI with contrast|
307445|NCT00242047|Biological|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
307446|NCT00242060|Procedure|MRI|
307447|NCT00242073|Procedure|MRI Prostate|
307448|NCT00242086|Procedure|CT, PET and MRI|
307449|NCT00242099|Procedure|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
306784|NCT00207610|Behavioral|Daily iron supplements of 65 mg a day for 3 months|
306785|NCT00207610|Behavioral|Universal anemia screening and treatment|
306786|NCT00207610|Behavioral|Selective anemia screening and treatment|
306787|NCT00207623|Behavioral|Arthritis Basics for Change Education program|
306788|NCT00207636|Behavioral|Computer-based prostate cancer screening decision aid|
306789|NCT00002552|Procedure|autologous bone marrow transplantation|
306790|NCT00207649|Behavioral|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
306791|NCT00207662|Drug|infliximab or placebo|
306792|NCT00207675|Drug|infliximab|
306793|NCT00207688|Drug|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
306794|NCT00211341|Dietary Supplement|Vitamin A|Weekly single oral dose 7000 micrograms
306795|NCT00211354|Drug|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
306796|NCT00211367|Drug|Anecortave Acetate|
307100|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
307101|NCT00251758|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
307102|NCT00254722|Procedure|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10^6 mononuclear cells/kg body weight, administered within 36 hours of injury
307103|NCT00254735|Drug|quetiapine fumarate|
307104|NCT00254735|Drug|SSRI/Clomipramine|
307105|NCT00254748|Drug|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
306069|NCT00230139|Device|SPECT/CT|
306408|NCT00218569|Drug|Placebo|Placebo
306409|NCT00218582|Behavioral|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
306410|NCT00218582|Behavioral|Standard psychiatric day treatment|Individual counseling, groups, medication
306411|NCT00002578|Drug|methotrexate|
306412|NCT00218595|Behavioral|DBT|Dialectical behavior therapy plus opiate replacement medication.
306413|NCT00218595|Behavioral|I/GDC|Individual and group drug counseling plus opiate replacement medication.
306414|NCT00218608|Drug|Disulfiram|Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
306415|NCT00218621|Procedure|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
306416|NCT00002587|Drug|topotecan hydrochloride|
306417|NCT00222625|Drug|FFP or aPCC+ vit K in AO treated patients|
306418|NCT00222638|Drug|Influenza vaccination|
306419|NCT00222651|Drug|tenecteplase|
306420|NCT00222664|Biological|Hep-V Vax|
306421|NCT00222677|Drug|aspirin|100 mg daily
306422|NCT00222703|Behavioral|Smoking relapse prevention|
306423|NCT00222716|Behavioral|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
306424|NCT00222729|Drug|Pemetrexed|500 mg/m2 day 1 q 21 days
306425|NCT00222729|Drug|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
306426|NCT00222742|Procedure|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
306427|NCT00000390|Drug|Imipramine hydrochloride|
306428|NCT00002588|Drug|etoposide|
306429|NCT00222755|Behavioral|Disease Management|Self-management, care management, guidelines
282069|NCT02586441|Drug|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
282070|NCT02586441|Drug|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
282071|NCT02586454|Procedure|Transmuscular quadratus lumborum block|
282072|NCT02586454|Drug|morphine|
282073|NCT02586454|Drug|ropivacaine|
282074|NCT02586467|Behavioral|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
282075|NCT02586467|Behavioral|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
282076|NCT02586467|Behavioral|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
282369|NCT02579876|Drug|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
282370|NCT02579876|Drug|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
282371|NCT02579889|Device|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
282372|NCT02579889|Device|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
282373|NCT00189059|Drug|amitriptyline|
282374|NCT02579902|Dietary Supplement|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
282375|NCT02582073|Biological|Grass MATA (0.5ml) 5100SU|
282376|NCT02582086|Other|BOR15001L7|Active cream
282377|NCT00189397|Drug|azathioprine and corticosteroids for Parthenium dermatitis|
282378|NCT02582086|Other|Placebo|Placebo Cream
282379|NCT02582099|Drug|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
307919|NCT00242502|Drug|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
307920|NCT00245193|Behavioral|Motivationally-Enhanced Interpersonal Psychotherapy|
307921|NCT00002651|Drug|bicalutamide|Given orally
307922|NCT00245206|Drug|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
307923|NCT00245206|Drug|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
307924|NCT00245206|Drug|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
307925|NCT00245219|Behavioral|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
307926|NCT00245219|Behavioral|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
307927|NCT00245232|Behavioral|Cognitive Therapy|
307928|NCT00245232|Behavioral|Cognitive Processing Therapy|
307929|NCT00245232|Behavioral|Written Exposure|
307930|NCT00245245|Drug|recombinant porcine coagulation factor VIII (OBI-1)|
308280|NCT00235079|Drug|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
308281|NCT00235079|Drug|Placebo|Placebo comparator
308282|NCT00235092|Device|Cypher Sirolimus-Eluting Stent|
308283|NCT00235092|Device|Taxus Paclitaxel-Eluting Stent|
308284|NCT00235105|Drug|Adalimumab 40 mg sc every other week|
308285|NCT00235118|Device|Cordis AAA Bilateral Device|
308286|NCT00235131|Device|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
307551|NCT00252031|Behavioral|Dialectical Behavioral Therapy|
307552|NCT00254904|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
307553|NCT00254904|Drug|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
307554|NCT00002680|Drug|cyclophosphamide|
307555|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
307556|NCT00254904|Drug|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
307557|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
307558|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
307559|NCT00254930|Drug|risperidone|
307560|NCT00254956|Drug|ciclesonide (XRP1526)|
307561|NCT00254969|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
307562|NCT00254982|Biological|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
307563|NCT00254995|Biological|None administered in this study|N/A in this study
307564|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
307565|NCT00002680|Drug|megestrol acetate|
307566|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
307567|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
307568|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
307569|NCT00255021|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
307570|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
307571|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
306899|NCT00223236|Drug|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
306900|NCT00223236|Drug|Placebo|Placebo matching active medication in all other aspects.
306901|NCT00226395|Drug|Oxymorphone immediate release|
306902|NCT00226408|Drug|Interferon-alpha-2b|
306903|NCT00226421|Drug|Oxymorphone Extended Release|
306904|NCT00226434|Procedure|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
306905|NCT00226434|Procedure|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
306906|NCT00226447|Drug|Pegylated Interferon|
306907|NCT00002596|Procedure|bone marrow ablation with stem cell support|
306908|NCT00226447|Drug|Lamivudine|
306909|NCT00226460|Drug|Fetal porcine cells, Neurocell-PD|
306910|NCT00226473|Drug|Cisplatin, Vindesine, Dacarbazine (drugs)|
307212|NCT00211692|Drug|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
307213|NCT00002561|Drug|vinblastine|6mg/m2
307214|NCT00211692|Drug|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
307215|NCT00211705|Behavioral|Diet|
307216|NCT00211705|Drug|Diet+pravastatin|
307217|NCT00211718|Drug|intra-articular botulinum toxin type a|
307218|NCT00211731|Behavioral|Chronic Disease Self Management Course|
307219|NCT00211744|Drug|topiramate|
307220|NCT00211757|Drug|Divalproex sodium|Study drug.
307221|NCT00211757|Drug|Placebo|Placebo comparator.
306559|NCT00237991|Biological|Hepatitis A|
306560|NCT00238004|Drug|Nicotinic acid|
306561|NCT00002628|Procedure|peripheral blood stem cell transplantation|
306562|NCT00238017|Drug|amodiaquine-artesunate versus amodiaquine|
306563|NCT00238030|Drug|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
306564|NCT00238030|Drug|iv thryoxine|thyroxine 2 mcg/kg iv
306565|NCT00238043|Drug|Biogeneric Epoetin|
306566|NCT00238056|Drug|domperidone Drug|
306567|NCT00238069|Device|CPAP machine as a result of sleep study|
306568|NCT00241501|Drug|Esomeprazole (Nexium)|
306569|NCT00241514|Drug|Esomeprazole|
306570|NCT00241527|Drug|Esomeprazole|
306571|NCT00241540|Drug|Esomeprazole|
306572|NCT00241553|Drug|Esomeprazole|
306573|NCT00000404|Behavioral|Patient education in self-care of knee OA|
306574|NCT00002638|Biological|sargramostim|
306575|NCT00241566|Device|implantation of stimulator|
306576|NCT00241579|Drug|Smoked Cannabis|
306577|NCT00241592|Drug|Cannabis|
306578|NCT00241605|Drug|rosiglitazone/metformin|
306579|NCT00241618|Drug|Pegylated interferon alpha 2|
306580|NCT00241618|Drug|Ribavirin|
306581|NCT00241631|Drug|fluticasone|500 mg b.d.
306582|NCT00241631|Drug|placebo|
306583|NCT00241644|Biological|Rotarix™|Two or Three doses, oral administration
305845|NCT00257868|Drug|Rivastigmine prevention of delirium|
305846|NCT00002691|Drug|leucovorin calcium|
305847|NCT00257881|Drug|CMD-193|
305848|NCT00257894|Drug|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
305849|NCT02719340|Procedure|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
305850|NCT02719379|Biological|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
305851|NCT02719392|Dietary Supplement|N-acetylcysteine|
305852|NCT00204477|Dietary Supplement|cow's milk protein|cow's milk protein
305853|NCT02719392|Drug|Minocycline|
305854|NCT02719392|Other|Placebo|
305855|NCT02719405|Dietary Supplement|Lactobacillus GG|Lactobacillus GG
306208|NCT00248404|Drug|NB1011|
306209|NCT00002667|Other|immunoenzyme technique|
306210|NCT00251329|Drug|neoadjuvant chemotherapy|
306211|NCT00251342|Procedure|Edinburgh Postnatal Depression Scale|
306212|NCT00251355|Drug|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
306213|NCT00251355|Drug|5-Fluorouracil|5-FU via continuous IV infusion.
306214|NCT00251355|Procedure|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
306215|NCT00251368|Drug|9-Aminocamptothecin (9-AC)|
306216|NCT00251381|Drug|Cetuximab|
306217|NCT00251394|Drug|Rituxan|Given intravenously once weekly for four weeks.
306218|NCT00251394|Drug|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
305481|NCT00210587|Drug|epoetin alfa|
305482|NCT00210600|Drug|PROCRIT (Epoetin alfa)|
305483|NCT00210613|Drug|Dapoxetine|
305484|NCT00210626|Drug|PROCRIT|40,000 IU/mL/week for max of 12 weeks
305485|NCT00210626|Drug|Placebo|40,000 IU/mL/week for max of 12 weeks
305486|NCT00002559|Biological|filgrastim|
305487|NCT00210639|Drug|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
305488|NCT00210652|Drug|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
305489|NCT00214682|Drug|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
305490|NCT00214682|Behavioral|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
305491|NCT00214682|Behavioral|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
305492|NCT00214695|Drug|Experimental Peritoneal Dialysis Solution|
305493|NCT00214708|Procedure|Screening for Tuberculosis|
305494|NCT00214721|Drug|Experimental Peritoneal Dialysis Solution|
305495|NCT00214734|Drug|rAHF-PFM|
305496|NCT00214747|Drug|Vehicle gel formulations|
305497|NCT00002566|Procedure|conventional surgery|
305144|NCT00225420|Radiation|radiation therapy|The total dose will be 7800 cGy in 200 cGy per fraction for a total of 39 treatments.
305145|NCT00225433|Drug|follitropin beta|Follitropin beta
305146|NCT00225433|Drug|ganirelix acetate|Ganirelix acetate
305147|NCT00225446|Device|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
305148|NCT00002594|Procedure|peripheral blood stem cell transplantation|
305149|NCT00225472|Device|Modified Viaspan|
305150|NCT00225485|Drug|Effexor XR|
305151|NCT00225498|Drug|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
305152|NCT00225511|Drug|Effexor XR|
305153|NCT00225511|Drug|Milnacipran|
305154|NCT00225524|Drug|Effexor XR|
305155|NCT00225537|Drug|4-Methylumbelliferone (Heparvit®)|
305156|NCT00225550|Drug|ADH -1 (Exherin™)|
305157|NCT00225563|Device|Electronic Medical Record|
305498|NCT00214760|Device|PGET|resolbable liner
305499|NCT00214760|Device|PMMA|cement liner
305500|NCT00214786|Biological|Islet cell transplantation|Allogenic islet transplantation
305501|NCT00214812|Drug|HEC placebo gel|
305502|NCT00214825|Drug|eplerenone|50 mg daily for 6 weeks with placebo
305503|NCT00214825|Drug|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
305504|NCT00214838|Drug|Atiprimod|
305505|NCT00214851|Drug|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
305506|NCT00214864|Drug|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8
310375|NCT00209417|Drug|Iopamidol 300-Arm 2|
310376|NCT00209430|Drug|Iodixanol 320 mgI/mL|
310377|NCT00209443|Drug|Gadodiamide Injection|
310728|NCT00359424|Drug|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
310729|NCT00359424|Other|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
310730|NCT00359437|Drug|satavaptan (SR121463B)|oral administration once daily
310731|NCT00359437|Drug|placebo|oral administration once daily
310732|NCT00359450|Drug|BMS-275183 (oral taxane)|
310733|NCT00359463|Drug|eltrombopag|
310734|NCT00362375|Behavioral|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
310735|NCT00362375|Behavioral|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
310736|NCT00003075|Drug|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
310737|NCT00362388|Procedure|Intramyocardial injection of autologous bone marrow cells|
310738|NCT00362414|Drug|Beta-hCG + Erythropoietin|10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation
30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation
310739|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
310740|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
310741|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
310742|NCT00362440|Drug|Leptin|
309998|NCT00220701|Drug|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
309999|NCT00220714|Drug|atypical antipsychotics:oral vs. long-acting route|
310000|NCT00220714|Behavioral|Family Psychoeducation|
310001|NCT00220727|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
310002|NCT00220740|Drug|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
310003|NCT00224354|Biological|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
310004|NCT00224354|Biological|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
310005|NCT00224354|Biological|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
310006|NCT00224354|Drug|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
310007|NCT00224354|Biological|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
310008|NCT00224367|Behavioral|time to first ambulation|
310009|NCT00224380|Behavioral|Using Medications Effectively|
310010|NCT00224393|Drug|Enbrel|
310011|NCT00000392|Drug|Peptide T|
310012|NCT00002592|Biological|filgrastim|
310378|NCT00209456|Drug|DatSCAN|
310379|NCT00209469|Drug|alendronate sodium|
310380|NCT00002556|Drug|prednisone|Given PO
310381|NCT00213291|Drug|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
309279|NCT00243022|Drug|Boswellia serrata extract|given orally
309280|NCT00243022|Dietary Supplement|cyanocobalamin|given orally
309281|NCT00243035|Drug|bortezomib|Given IV
309282|NCT00245882|Behavioral|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
309283|NCT00245895|Drug|Aranesp|Aranesp
309284|NCT00245908|Drug|azithromycin|
309641|NCT00002611|Biological|filgrastim|
309642|NCT00232115|Drug|Pimecrolimus|Pimecrolimus cream 1 %
309643|NCT00232115|Drug|Placebo|Vehicle cream (placebo)
309644|NCT00232128|Procedure|Radiofrequency Ablation of pulmonary neoplasms|
309645|NCT00232141|Drug|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
309646|NCT00232141|Drug|Placebo|Placebo
309647|NCT00232154|Drug|Zithromax&#153; (azithromycin) 500mg tablets|
309648|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
309649|NCT00235716|Drug|dl-alpha-tocopherol|Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate ("synthetic") vitamin E.
309650|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
309651|NCT00235716|Drug|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
309652|NCT00235729|Drug|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
309653|NCT00235729|Drug|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
308896|NCT00252629|Other|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
308897|NCT00252642|Drug|Peginterferon Alpha-2a|
308898|NCT00252655|Drug|Rapamune and Prograf|
308899|NCT00252668|Drug|Etanercept|
308900|NCT00252668|Drug|Methotrexate|
308901|NCT00252681|Procedure|laparotomy|
308902|NCT00002674|Drug|cytarabine|
308903|NCT00252681|Procedure|primary peritoneal drainage|
308904|NCT00252694|Drug|candesartan|32 mg oral tablet
308905|NCT00252707|Drug|Gefitinib or Docetaxel|
308906|NCT00252720|Drug|candesartan|32 mg oral tablet
308907|NCT00252733|Drug|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
308908|NCT00252746|Drug|ZD6474 (vandetanib) 100mg|once daily oral dose
308909|NCT00255567|Drug|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
308910|NCT00255580|Drug|Smoked cannabis|
308911|NCT00002681|Biological|aldesleukin|
308912|NCT00255593|Drug|rituximab|
308913|NCT00255606|Drug|docetaxel|Given in 3- or 4- week courses
308914|NCT00255606|Drug|prednisone|Given in 3- or 4- week courses
308915|NCT00255619|Device|Baxter’s UltraBag® and FMC Andy·Disc®|
308916|NCT00255658|Drug|sorafenib tosylate|Given orally
308917|NCT00255658|Drug|temsirolimus|Given IV
308918|NCT00255658|Other|laboratory biomarker analysis|Correlative studies
309285|NCT00245921|Drug|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
308146|NCT00216086|Drug|Neoadjuvant Chemotherapy|Irinotecan 200 mg/m2 IV, day 1 Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles
308147|NCT00216086|Procedure|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
308148|NCT00216086|Procedure|Surgery|Surgery within 8 weeks following chemoradiotherapy
308149|NCT00216086|Procedure|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
308150|NCT00216099|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
308151|NCT00216099|Dietary Supplement|Folic Acid|Folic Acid (350-1000 mcg) po qd; 5 doses during 7-day period preceding first dose of pemetrexed and dosing should continue during full course of therapy, and 21 days after last dose.
308152|NCT00216099|Dietary Supplement|Vitamin B12|Vitamin B12 (1000ug) IM during week preceding first dose of pemetrexed and every 3 cycles thereafter.
308153|NCT00216112|Drug|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
308154|NCT00002570|Drug|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
308155|NCT00216112|Drug|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
308156|NCT00216125|Drug|Cisplatin|Cisplatin 50 mg/m2 day 1, 8, 29, 36
308157|NCT00216125|Drug|Etoposide|Etoposide 50 mg/m2, days 1-5, 29-33
308158|NCT00216125|Radiation|Radiation|Radiation 5940 cGy (180 cGy/day)
308520|NCT02720432|Other|CIMT|Constraint-induced movement therapy
308521|NCT00204581|Drug|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
308522|NCT02720432|Other|HABIT|hand-arm bimanual intensive training
308523|NCT02720432|Other|baby-massage|instructions for baby-massage
308524|NCT02720445|Drug|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
308525|NCT02720445|Drug|Placebo Patch|Matching placebo patches worn during waking hours.
308526|NCT00204594|Drug|rM28|
308527|NCT00204594|Drug|autologous PBMCs|
308528|NCT00204607|Biological|mRNA|
307450|NCT00002638|Procedure|peripheral blood stem cell transplantation|
307451|NCT00242112|Procedure|MRI Prostate|
307452|NCT00242138|Behavioral|Erectile Dysfunction|
307453|NCT00242164|Drug|Dialysate Magnesium (Concentration)|
307454|NCT00242177|Drug|ACTOS (Pioglitazone)|
307785|NCT00226928|Behavioral|Education|
307786|NCT00226941|Drug|Oxaliplatin|Oxaliplatin is supplied as freeze-dried powder for IV infusion in vials containing 50 mg and 100 mg of the drug.
307787|NCT00226941|Drug|Capecitabine|The calculated dose by cohort designation and body surface area (BSA) will be rounded down to allow equivalent morning and evening doses using a combination of 150 mg and 500 mg tablets.
307788|NCT00226941|Drug|Cetuximab|Cetuximab may be administered via a gravity drip, infusion pump or syringe pump with in-line filtration. Cetuximab requires in-line filtration during administration. Calculate and draw the appropriate volume of cetuximab into a sterile syringe based on either the 400 mg/m2 initial dose or 250 mg/m2 weekly dose
307789|NCT00226954|Drug|zoledronic acid|
307790|NCT00226967|Drug|Sandostatin|Calculated per patient
307791|NCT00226980|Drug|Thalidomide|
307792|NCT00226980|Drug|Capecitabine|
307793|NCT00226993|Drug|CPG 7909|
307794|NCT00000394|Procedure|Acupuncture therapy|
307795|NCT00002597|Radiation|radiation therapy|
307796|NCT00227006|Behavioral|Behavioral lifestyle/weight-loss intervention|
307797|NCT00227019|Drug|Bevacizumab|15 mg/kg
307798|NCT00227019|Drug|Pemetrexed|500mg/m2; IV over 10 minutes every 3 weeks
307799|NCT00227019|Drug|Vitamin B12|1000 micrograms
307800|NCT00227019|Drug|folate|350-1000 micrograms
307801|NCT00230984|Drug|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
307802|NCT00230997|Drug|Galantamine|
307106|NCT00254748|Drug|Placebo|placebo
307107|NCT00254761|Drug|Cannabis|
307108|NCT00002679|Radiation|radiation therapy|
307109|NCT00254774|Drug|quetiapine fumarate or valproate|
307110|NCT00254787|Drug|IR (Immediate-Release) quetiapine fumarate (drug)|
307111|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
307112|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
307113|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
307114|NCT00254813|Drug|Quetiapine|
307115|NCT00254826|Biological|YF-VAX® plus saline|YF-VAX® plus saine
307116|NCT00254826|Biological|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
307117|NCT00254852|Procedure|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
307118|NCT00254852|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
307119|NCT00002680|Biological|filgrastim|
307120|NCT00254852|Procedure|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
307121|NCT00254852|Procedure|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
307122|NCT00254852|Procedure|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
307455|NCT00242190|Drug|oxaliplatin|
307456|NCT00242190|Drug|gemcitabine|
307457|NCT00242190|Procedure|radiation therapy|
307458|NCT00242203|Drug|Zometa|
307459|NCT00242203|Drug|Epirubicin|
306430|NCT00222794|Drug|Atomoxetine (Strattera)|
306431|NCT00222820|Drug|escitalopram|
306432|NCT00222820|Behavioral|Interpersonal Psychotherapy|
306433|NCT00222833|Drug|Aripiprazole|
306797|NCT00211380|Drug|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
306798|NCT00002561|Biological|bleomycin sulfate|10 units/m2
306799|NCT00211393|Drug|ketoconazole|600mg. /day for 6 weeks
306800|NCT00211406|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
306801|NCT00211419|Drug|Anecortave Acetate 15 mg|
306802|NCT00211419|Drug|Triamcinolone Acetate 4 mg|
306803|NCT00211419|Procedure|Photodynamic Therapy with Verteporfin|
306804|NCT00211419|Procedure|Thermal Laser|
306805|NCT00211432|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
306806|NCT00211445|Procedure|Photodynamic Therapy with Verteporfin|
306807|NCT00211445|Drug|verteporfin|
306808|NCT00211458|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
306809|NCT00002561|Drug|dacarbazine|375mg/m2
306810|NCT00211471|Drug|anecortave acetate|
306811|NCT00211484|Drug|Anecortave Acetate|
306812|NCT00211497|Drug|MBI 226 Acne Solutions|
306813|NCT00211510|Device|Paradigm 722 Sensor-augmented pump|Subjects transferred from current insulin pump to use the Paradigm 722 sensor augmented pump
306814|NCT00211510|Device|Paradigm 715 insulin pump|Subjects transferred from their current insulin pump to use the paradigm 715 insulin pump
306815|NCT00211523|Drug|MBI 226 Acne Solutions|
306816|NCT00211536|Drug|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
282380|NCT02582099|Drug|Normal saline nasal irrigation|Nasal wash with normal saline solution
282381|NCT02582112|Other|Active Comparator: Warming group|Placebo Comparator: Control group
282382|NCT02582125|Drug|ONO-4538|
282383|NCT02582138|Other|Multicomponent intervention (MCI)|The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .
The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:
a daily total energy intake of 25-30 kcal/kg body weight;
an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.
The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme.
282384|NCT02582138|Other|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
282385|NCT02582151|Device|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
282386|NCT02582164|Device|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
282661|NCT02577653|Other|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
282662|NCT02577666|Behavioral|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
282663|NCT00188669|Drug|alpha-Tocopherol|
282664|NCT02577666|Behavioral|Housing Only|receives 3 months of project supported rental assistance
282665|NCT02577666|Behavioral|Treatment as Usual|receives services as normally offered within the community
282666|NCT02577692|Other|Oxygen|breathing oxygen
282667|NCT02577692|Other|Ambient|breathing ambient air
308287|NCT00235131|Device|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
308288|NCT00235144|Device|sirolimus-coated Bx Velocity stent|drug-eluting stent
308289|NCT00002620|Drug|chemotherapy|
308290|NCT00235144|Device|uncoated Bx Velocity stent|bare-metal stent
308291|NCT00235157|Device|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
308292|NCT00235170|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
308293|NCT00235183|Other|plasma|transfusion of more than 15 mL/Kg of plasma
308294|NCT00235196|Device|Collagen ORC Antimicrobial Matrix (CAM)|
308295|NCT00235209|Device|Collagen ORC Antimicrobial Matrix (CAM)|
308296|NCT00235222|Drug|stavudine|
308297|NCT00235235|Procedure|Biopsy|core biopsy
308298|NCT00235235|Procedure|Serum Collection|serum collection
308299|NCT00235235|Procedure|Urine Collection|urine collection
308300|NCT00000105|Biological|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
308301|NCT00000134|Drug|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
308302|NCT00000399|Drug|Hormone replacement therapy|
308303|NCT00002620|Drug|mitolactol|
308304|NCT00235235|Drug|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
308305|NCT00238433|Procedure|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
308673|NCT00223821|Behavioral|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
308674|NCT00002590|Drug|pegaspargase|
308675|NCT00223834|Behavioral|single session of Motivational Interviewing|
308676|NCT00223847|Behavioral|Constraint Induced Language Therapy|
307572|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
307931|NCT00245258|Drug|Sildenafil Citrate|
307932|NCT00002651|Drug|goserelin acetate|Given subcutaneously
307933|NCT00245271|Drug|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
307934|NCT00245271|Drug|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
307935|NCT00245297|Drug|Kogenate FS, reconstituted in a suspension of liposomes|
307936|NCT00245310|Procedure|Indocyangreen (ICG) clearance|
307937|NCT00245323|Behavioral|Smoking status as a routine vital sign|
307938|NCT00245336|Biological|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
307939|NCT00245336|Drug|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
307940|NCT00245349|Procedure|F-18 Fluorothymidine|
307941|NCT00245362|Biological|CG 8020 and CG 2505|
307942|NCT00245375|Drug|Tylenol #3|
307943|NCT00002651|Other|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
307944|NCT00245375|Drug|Combination Tylenol and Ibuprofen|
307945|NCT00245388|Drug|Muraglitazar|
307946|NCT00248950|Behavioral|Positive affect induction and /or self affirmation induction|
307947|NCT00248963|Drug|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
307948|NCT00248976|Behavioral|Net-present value of individual health behaviors in years|
307949|NCT00248989|Drug|Dehydroepiandrosterone|
307950|NCT00249002|Drug|ABI-007|
307951|NCT00249015|Behavioral|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
307952|NCT00249041|Drug|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
307222|NCT00211770|Behavioral|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
307223|NCT00211783|Procedure|fMRI|there is no intervention
307224|NCT00002561|Radiation|radiation therapy|35Gy in 20 fractions (daily)
307225|NCT00211796|Drug|Divalproex Sodium ER|
307226|NCT00211809|Behavioral|Cognitive Behavioral Therapy|
307227|NCT00211822|Procedure|fMRI|fMRI
307228|NCT00211835|Behavioral|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
307229|NCT00211835|Behavioral|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
307230|NCT00211848|Drug|Polyenylphosphatidylcholine (PPC)|
307231|NCT00211848|Drug|Pegylated Interferon|
307232|NCT00211848|Drug|Ribavirin|
307233|NCT00211874|Behavioral|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
307573|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
307574|NCT00255047|Biological|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
307575|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
307576|NCT00000412|Drug|Calcitriol|
307577|NCT00002680|Drug|melphalan|
307578|NCT00255047|Biological|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
307579|NCT00258427|Biological|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
306584|NCT00241644|Biological|Placebo|One or three doses, oral administration.
306585|NCT00002638|Drug|carmustine|
306586|NCT00241657|Biological|BCG|
306911|NCT00226486|Other|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
306912|NCT00226486|Other|Usual care|No intervention, but ususal care after an accidental fall.
306913|NCT00226499|Biological|Priorix-tetra™|2 IM doses
306914|NCT00226499|Biological|Priorix™|2 IM doses in Group C, 1 IM dose in Group B
306915|NCT00226499|Biological|Varilrix™|1 IM dose in Group B
306916|NCT00226512|Drug|Campath-1H /ATG|
306917|NCT00226525|Procedure|skin sensitivity test|
306918|NCT00002596|Procedure|conventional surgery|
306919|NCT00226538|Drug|Phenytoin|
306920|NCT00226538|Drug|Rifampicin|
306921|NCT00226538|Drug|Diclophenac|
306922|NCT00226538|Drug|Fluconazole|
306923|NCT00226551|Drug|Isoproterenol|
306924|NCT00226564|Drug|Alfentanil|
306925|NCT00226577|Drug|Gemcitabine|Gemcitabine (GemzarR) 1500 mg/m2
306926|NCT00226577|Drug|Pemetrexed|Pemetrexed (AlimtaR) 500 mg/m2
306927|NCT00226577|Procedure|Surgery|When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
306928|NCT00226590|Drug|Gemcitabine|Induction Chemotherapy.
306929|NCT00002596|Procedure|peripheral blood stem cell transplantation|
306930|NCT00226590|Drug|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
306219|NCT00251407|Drug|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
306220|NCT00000410|Procedure|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
306221|NCT00002667|Procedure|study of high risk factors|
306222|NCT00251407|Drug|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
306223|NCT00251407|Drug|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
306224|NCT00251420|Procedure|writing about disease|writing about physical or emotional consequences of pulmonary disease
306225|NCT00251433|Drug|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
306587|NCT00241670|Drug|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
306588|NCT00241722|Drug|Alvimopan|
306589|NCT00241722|Drug|Placebo|
306590|NCT00241813|Behavioral|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
306591|NCT00241813|Behavioral|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
306592|NCT00241813|Behavioral|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
306593|NCT00241826|Procedure|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
306594|NCT00241826|Procedure|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
306595|NCT00241839|Drug|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
305856|NCT02719405|Dietary Supplement|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
305857|NCT02719405|Dietary Supplement|Amino Acid Formula|Amino Acid Formula
305858|NCT02719418|Drug|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
305859|NCT02719431|Drug|Warfarin|
305860|NCT02719431|Drug|K-877|
305861|NCT02719457|Other|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
305862|NCT02719457|Other|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
305863|NCT00204490|Dietary Supplement|isoflavones|soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
305864|NCT02719470|Behavioral|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
305865|NCT02719483|Device|Swiss DolorClast|"Radial" (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied.
305866|NCT02719483|Procedure|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
305867|NCT02719496|Drug|IBEROGAST|
305868|NCT02719509|Procedure|Cardiac Ultrasound|
305869|NCT00002552|Drug|etoposide|
305870|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
305871|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
305872|NCT00207103|Drug|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
305507|NCT00214877|Drug|Methylene Blue|
305508|NCT00002566|Procedure|peripheral blood stem cell transplantation|
305509|NCT00214890|Drug|Tenofovir|300 mg once daily
305510|NCT00214890|Drug|Abacavir|600 mg once daily
305511|NCT00214916|Drug|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
305512|NCT00218062|Drug|Dextro amphetamine sulfate and Modafinil|d-amphetamine 30mg / modafinil 200mg
305513|NCT00218062|Drug|modafinil|10 day medication run-up of modafinil from 0-200mg
305514|NCT00218062|Drug|Modafinil 400 mg|10 day run up to 400mg of modafinil
305515|NCT00218062|Drug|Placebo|Placebo
305516|NCT00218075|Drug|Levodopa|
305517|NCT00002576|Drug|mitoxantrone hydrochloride|
305518|NCT00218075|Drug|Carbidopa|
305519|NCT00218075|Behavioral|Clinical Management|
305520|NCT00218075|Behavioral|Relapse Prevention Therapy|
305521|NCT00218075|Behavioral|Contingency Management|
305522|NCT00218101|Drug|Buprenorphine|
305523|NCT00218114|Drug|Divalproex Sodium (Depakote)|Subjects are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml
305875|NCT00207129|Drug|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
305876|NCT00207142|Drug|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
305877|NCT00207142|Drug|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
305878|NCT00207155|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
305879|NCT00207168|Behavioral|Compliance|
305880|NCT00002552|Drug|leucovorin calcium|
310743|NCT00362440|Drug|Pioglitazone or metformin|
310744|NCT00362453|Behavioral|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
310745|NCT00362466|Drug|Dasatinib|Tablets, Oral, Once daily, 5-7 years
310746|NCT00362466|Drug|Imatinib|Tablets, Oral, Once daily, 5-7 years
310747|NCT00003075|Other|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
305158|NCT00225576|Other|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
305159|NCT00002595|Drug|toremifene|
305160|NCT00225589|Drug|Rosuvastatin calcium|
305161|NCT00225602|Behavioral|Assertive Community Treatment|
305162|NCT00225602|Behavioral|Treatment in Community Mental Health Center|
305163|NCT00229424|Other|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
305164|NCT00229437|Drug|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
305165|NCT00229437|Drug|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
305166|NCT00229437|Drug|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
305167|NCT00229437|Drug|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
305168|NCT00229450|Drug|estrogen|
305169|NCT00229476|Drug|sertraline (Zoloft)|
305170|NCT00229515|Other|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
305171|NCT00229515|Other|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
305172|NCT00229515|Other|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
305173|NCT00002601|Drug|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
310382|NCT00213304|Biological|varicella vaccine (VARIVAX)|
310383|NCT00213317|Procedure|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
310384|NCT00213330|Procedure|rectal distension|
310385|NCT00213395|Device|Interface for noninvasive ventilation|
310386|NCT00213408|Procedure|Radiofrequency catheter ablation of typical atrial flutter|
310387|NCT00213421|Drug|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight < 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight > 45kg or for multibullous form with weight < 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth > 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
310388|NCT00002565|Drug|methylprednisolone|
310389|NCT00213434|Device|Herbst oral appliance|
310390|NCT00213486|Drug|irinotecan|
310391|NCT00213499|Procedure|non invasive ventilation|
310392|NCT00213512|Drug|Mabthera|
310393|NCT00213525|Other|Questionnary for environmental factors research|Questionnary for environmental factors research
310394|NCT00213538|Drug|Response to anakinra associated with methotrexate|
310395|NCT00213551|Drug|Glutamine|
310396|NCT00213551|Drug|Glucose|
310397|NCT00213551|Drug|glutamine-antioxidants containing solution|
310398|NCT00213564|Drug|response to infliximab associated with methotrexate|
310748|NCT00362479|Drug|DR-1021|1 tablet daily
310749|NCT00362492|Procedure|Bilateral ultrasound examination 7+/- 2 after surgery|
310750|NCT00362505|Drug|Clevudine|
309654|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
309655|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
309656|NCT00235755|Drug|Placebo|Oral tablet.
309657|NCT00235781|Drug|Thymoglobulin|
309658|NCT00002623|Drug|carboplatin|
309659|NCT00235794|Drug|temsirolimus|
310013|NCT00224406|Drug|repertaxin|
310014|NCT00224419|Behavioral|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
310015|NCT00224419|Behavioral|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
310016|NCT00224419|Drug|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
310017|NCT00224432|Drug|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
310018|NCT00224445|Drug|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
310019|NCT00224445|Drug|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
310020|NCT00224445|Drug|Ritonavir|Ritonavir 100 mg capsule administered orally QD
310021|NCT00224458|Drug|Truvada|
310022|NCT00224458|Drug|efavirenz|
310023|NCT00002592|Drug|busulfan|
310024|NCT00224471|Biological|GSK208141 vaccine|3 IM doses
310025|NCT00224484|Biological|GSK208141|3 IM doses
309286|NCT00245934|Drug|Enbrel|
309287|NCT00245947|Drug|ERB-041|
309288|NCT00245960|Drug|etanercept|Group A: Period 1: 50mg BIW. Period 2: 50 mg QW. Group B: Period 1 and 2: 50mg QW.
309289|NCT00002653|Drug|prednisone|
309290|NCT00245973|Drug|Bifeprunox|
309291|NCT00245986|Procedure|Blood draw|
309292|NCT00246012|Drug|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
309293|NCT00246012|Drug|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
309294|NCT00246012|Drug|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
309295|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
309296|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
309297|NCT00246025|Drug|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
309298|NCT00246025|Drug|placebo|matching placebo capsule, once a day, oral administration
309299|NCT00246038|Device|Boston Scientific ENOVUS AAA Endograft|
309300|NCT00002653|Radiation|radiation therapy|
309301|NCT00246051|Behavioral|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
308529|NCT00204607|Drug|GM-CSF s.c.|
308530|NCT00204620|Drug|Bendamustin|
308531|NCT00002554|Drug|busulfan|
308532|NCT00208468|Device|Future Hip|A cementless femoral component for use in total hip replacement
308533|NCT00208468|Device|Omniflex|A cementless femoral component for use in total hip replacement
308534|NCT00208468|Device|Zueymüller|A cementless femoral component for use in total hip replacement
308535|NCT00208468|Device|CLS Spotorno|A cementless femoral component for use in total hip replacement
308536|NCT00208494|Device|Total Hip Replacement|Total hip replacement
308537|NCT00208494|Device|Total hip replacement|Total hip replacement
308538|NCT00208507|Device|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
308539|NCT00208507|Device|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
308540|NCT00208520|Drug|Carbamazepine|
308541|NCT00208520|Drug|Lamotrigine|
308542|NCT00000384|Behavioral|Educational Support|
308543|NCT00002554|Drug|cyclophosphamide|
308544|NCT00208520|Drug|Levetiracetam|
308545|NCT00208533|Drug|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
308919|NCT00255671|Other|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
308920|NCT00255684|Biological|graft-versus-tumor induction therapy|
308921|NCT00255684|Drug|cyclophosphamide|
308922|NCT00002681|Biological|daclizumab|
308923|NCT00255684|Drug|cyclosporine|
308924|NCT00255684|Drug|fludarabine phosphate|
308925|NCT00255684|Drug|mycophenolate mofetil|
307803|NCT00002609|Drug|cytarabine|
307804|NCT00231023|Drug|Peribulbar Triamcinolone Acetonide|
307805|NCT00231049|Drug|AG-707|
307806|NCT00231062|Device|Sinuplasty|
307807|NCT00231075|Drug|Paraplatin|
307808|NCT00231075|Drug|Paclitaxel|
307809|NCT00231101|Drug|Quetiapine|
307810|NCT00231114|Device|Alair System|Treatment of airways with the Alair System
308159|NCT00216125|Drug|Docetaxel|docetaxel 75mg/m2 q3wk x 3 cycles
308160|NCT00219362|Biological|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
308161|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
308162|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
308163|NCT00219388|Drug|Levosimendan|
308164|NCT00219401|Biological|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
308165|NCT00219414|Device|Adacolumn Apheresis System|
308166|NCT00219440|Other|Actos plus standard diet|Actos plus standard diet
308167|NCT00219440|Other|Actos plus structured diet|Actos plus structured diet
308168|NCT00219440|Other|Metformin plus standard diet|Metformin plus standard diet
308169|NCT00219453|Device|Jet Injector with Protector Cap (HSI-500)|
308170|NCT00002580|Drug|fluorouracil|
308171|NCT00219466|Other|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
308172|NCT00219466|Other|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
308173|NCT00219479|Drug|Phenytoin (Dilantin) levels during change in enteral feeding|
308174|NCT00219505|Procedure|acupuncture|
307460|NCT00242203|Drug|Docetaxel|
307461|NCT00002638|Radiation|radiation therapy|
307462|NCT00242203|Drug|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
307463|NCT00242203|Radiation|External beam radiation|
307464|NCT00242203|Procedure|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
307465|NCT00242216|Drug|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
307466|NCT00242216|Drug|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
307467|NCT00242229|Drug|DVS-233 SR|
307468|NCT00242268|Drug|Simvastatin|
307469|NCT00002649|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
307470|NCT00245050|Dietary Supplement|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
307471|NCT00245050|Drug|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
307472|NCT00245050|Drug|doxorubicin HCL liposome|IV, 40mg/m2
307473|NCT00245063|Drug|cediranib maleate|Given PO
307474|NCT00245063|Other|laboratory biomarker analysis|Correlative studies
307475|NCT00245063|Other|pharmacogenomic studies|Optional correlative studies
307476|NCT00245076|Behavioral|smoking cessation intervention|
307477|NCT00245076|Other|internet-based intervention|
307478|NCT00245089|Biological|dactinomycin|
307479|NCT00245089|Drug|cyclophosphamide|
307480|NCT00002649|Procedure|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
307811|NCT00231114|Device|Alair System|Sham treatment of airways with the Alair System
306817|NCT00211536|Device|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
306818|NCT00211536|Drug|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
306819|NCT00211549|Drug|IDEA-033|
306820|NCT00002561|Drug|doxorubicin hydrochloride|25mg/m2
306821|NCT00211562|Drug|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
307123|NCT00254865|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
307124|NCT00254878|Drug|Methylphenidate hydrochloride|
307125|NCT00254891|Drug|PF-3512676 + Paclitaxel + Carboplatin|PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.
Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.
Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles.
307126|NCT00254891|Drug|Paclitaxel + Carboplatin|Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.
Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles.
307127|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
307128|NCT00002692|Drug|leucovorin calcium|
307129|NCT00258323|Drug|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
307130|NCT00258323|Drug|Iressa|250mg po qd days 1-28 then x 2 years
307131|NCT00258323|Procedure|conventional surgery|conventional surgery
307132|NCT00258323|Radiation|radiation therapy|150 cGy bid
307133|NCT00258336|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
307134|NCT00258336|Biological|rituximab|
307135|NCT00258336|Biological|sargramostim|
307136|NCT00258349|Drug|vorinostat|Given orally
307137|NCT00258349|Drug|trastuzumab|Given IV
307138|NCT00258362|Drug|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
307139|NCT00000414|Behavioral|Arthritis Self-Management Program|
282668|NCT02577705|Behavioral|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
282669|NCT02577705|Behavioral|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
282670|NCT02577705|Behavioral|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
282671|NCT02577718|Drug|Nitroglycerin - citrate - ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
282672|NCT02577731|Other|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
282673|NCT02577731|Other|Muscle tissue collection|Muscle tissue will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
282674|NCT00188695|Procedure|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
282675|NCT02577731|Other|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
282946|NCT02609360|Other|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
282947|NCT02609360|Other|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
282948|NCT02609373|Behavioral|Sleep intervention|Session 1: Intervener & participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.
Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.
Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss "Sleep Restriction with Relaxation Exercises." Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.
Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.
Booster sessions: At 8 & 10 months: reinforcement, question answering, encouragement and monitoring.
282949|NCT02609386|Biological|IRX-2|Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.
282950|NCT00192413|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
308677|NCT00223860|Drug|Human chorionic gonadotropin (hCG)|
308678|NCT00223860|Drug|Luteinizing hormone releasing hormone (LHRH)|
308679|NCT00223873|Procedure|Penile Vibratory Stimulation|
308680|NCT00227253|Procedure|Orthopedic evaluation|Physical exam by orthopedic surgeon and a dysplasia series of radiographs including AP and lateral radiographics of the feet, APs of the knees, pelvis, thoracic lumbar spine and chest, laterals of thoracic lumbar and cervical spine, lateral of the skull, AP and lateral of the forearm, bone age evaluation with radiograph of left hand
308681|NCT00002598|Drug|cyclophosphamide|
308682|NCT00227253|Procedure|Ophthalmologic evaluation|exam will determine visual acuity using one of the following: Snellen chart, Allen acuity, target acuity, optokinetic nystagmus (OKN), or Teller acuity depending on study participants ability level. Motility/alignment will also be determined using cover/uncover test. Pupils examined using slit lamp. Dilated fundus exam and cycloplegic refraction which will require dilating drops in both eyes. Cyclogen 1% and NeuSynephrine 2.5% are using. In children less than 6 months old, less potent mydriatrics and cycloplegics are used Cyclogel 0.5% or Tropicamide 1%. Intraocular pressure will be measured in adults and cooperative teens using applanation tonometry. A topical anesthetic will be used to perform this measurement.
308683|NCT00227253|Procedure|Gastrointestinal evaluation|physical exam and medical history by board certified gastroenterologist.
308684|NCT00227266|Drug|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
308685|NCT00227266|Drug|Placebo|
308686|NCT00227279|Biological|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
308687|NCT00227292|Drug|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
308688|NCT00227292|Drug|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
308689|NCT00227305|Drug|quetiapine fumarate|Oral dosing, flexible dosing
308690|NCT00227318|Drug|ATACAND|
308691|NCT00227331|Drug|Oral amoxicillin|
308692|NCT00002598|Drug|cytarabine|
308693|NCT00227344|Device|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
308694|NCT00227344|Drug|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
309067|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
307953|NCT00249041|Drug|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
307954|NCT00249054|Device|ASR (THA)|
307955|NCT00249093|Drug|oxygen|
307956|NCT00002658|Procedure|autologous bone marrow transplantation|
308306|NCT00002631|Drug|fluorouracil|
308307|NCT00238433|Procedure|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
308308|NCT00238446|Drug|EC-MPS|
308309|NCT00238459|Drug|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
308310|NCT00238459|Drug|multiple licensed drugs not randomized|
308311|NCT00238459|Drug|multiple licensed antiretroviral drugs; not randomized|
308312|NCT00238459|Other|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
308313|NCT00238472|Drug|nateglinide|
308314|NCT00238485|Drug|Licarbazepine|
308315|NCT00238498|Drug|vildagliptin|
308316|NCT00238511|Drug|SPM 927|
308317|NCT00002631|Radiation|low-LET electron therapy|
308318|NCT00238524|Drug|SPM 927|
308319|NCT00238537|Drug|Alteplase t-PA|
308320|NCT00238550|Drug|Cannabis based medicine extract (CBME)|
308321|NCT00238563|Drug|Triamcinolone injection, sub-tenon|
308322|NCT00238602|Procedure|Stereotactic radiosurgery|unknown
308323|NCT00238615|Drug|Docetaxel|20 mg/m2, 75 mg/m2 infusion
308324|NCT00238615|Drug|Carboplatin|AUC of 2 and 6 infusion
307580|NCT00258440|Drug|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
307581|NCT00258440|Drug|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
307582|NCT00258453|Other|metabolic assessment|
307583|NCT00002693|Drug|topotecan hydrochloride|
307584|NCT00258453|Other|physiologic testing|
307585|NCT00258453|Procedure|biopsy|
307586|NCT00258453|Procedure|computed tomography|
307587|NCT00258453|Procedure|conventional surgery|
307588|NCT00258453|Procedure|magnetic resonance imaging|
307589|NCT00258453|Procedure|management of therapy complications|
307590|NCT00258453|Procedure|psychosocial assessment and care|
307591|NCT00258453|Procedure|quality-of-life assessment|
307592|NCT00258453|Radiation|radiation therapy|
307593|NCT00258466|Radiation|radiation therapy|
307594|NCT00002695|Genetic|DNA stability analysis|
307595|NCT00258479|Drug|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
307957|NCT00249106|Biological|ADVAX|
307958|NCT00249119|Drug|risperidone|
307959|NCT00249132|Drug|risperidone|
307960|NCT00249145|Drug|risperidone|
307961|NCT00249158|Drug|Risperidone|
307962|NCT00249171|Drug|risperidone|
306931|NCT00230503|Drug|adefovir dipivoxyl|
306932|NCT00230516|Drug|Nexium|
306933|NCT00230516|Drug|Prevacid|
306934|NCT00002608|Drug|doxorubicin hydrochloride|
306935|NCT00230529|Drug|infliximab|
307234|NCT00215657|Drug|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
307235|NCT00215657|Drug|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
307236|NCT00215670|Drug|pegaptanib sodium (Macugen)|
307237|NCT00215683|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
307238|NCT00215696|Genetic|BioBypass®|
307239|NCT00002568|Procedure|conventional surgery|
307240|NCT00215709|Drug|docetaxel|
307241|NCT00215722|Drug|Cetuximab|
307242|NCT00215735|Device|debridement, dressing, and APC|ebridement, dressing, and APC
307243|NCT00215748|Drug|Dexamethasone|
307244|NCT00215774|Drug|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
307245|NCT00215787|Drug|lansoprazole|Lansoprazole 30 mg BID for 1 year
307246|NCT00215800|Drug|Ampligen|
307247|NCT00215813|Drug|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
307248|NCT00215826|Drug|Alferon LDO|
307249|NCT00215839|Drug|Peginterferon a-2a plus Ribavirin|
307250|NCT00002569|Drug|lomustine|
306596|NCT00002638|Drug|cyclophosphamide|
306597|NCT00241839|Drug|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
306598|NCT00244920|Drug|squalamine lactate|
306599|NCT00002649|Biological|filgrastim|Given SC or IV
306600|NCT00244920|Procedure|adjuvant therapy|
306601|NCT00244920|Procedure|antiandrogen therapy|
306602|NCT00244920|Procedure|antiangiogenesis therapy|
306603|NCT00244920|Procedure|conventional surgery|
306604|NCT00244920|Procedure|neoadjuvant therapy|
306605|NCT00244920|Procedure|releasing hormone agonist therapy|
306606|NCT00244933|Dietary Supplement|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
306607|NCT00244933|Drug|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days
306608|NCT00244933|Procedure|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
306609|NCT00244946|Biological|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
306936|NCT00230542|Drug|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
306937|NCT00230542|Drug|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
306938|NCT00230555|Behavioral|professional support model|
306939|NCT00230568|Drug|Aricept|
306940|NCT00230581|Drug|DDP225|
306941|NCT00230594|Drug|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
306942|NCT00230594|Drug|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
306943|NCT00230607|Biological|agalsidase beta|Mothers receive Fabrazyme (agalsidase beta) treatment at their prescribed dose and regimen as determined by their treating physician.
305873|NCT00207116|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
305874|NCT00207129|Drug|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
306226|NCT00251433|Drug|Docetaxel, trastuzumab|For Phase II, subjects will be pre-stratified for Eastern Cooperative Oncology Group (ECOG) performance (0 vs. 1; see Appendix 4 ) and site of disease (visceral vs. non-visceral). Subjects will then be randomised in a 2:1 ratio to receive either the triplet regimen or the docetaxel and trastuzumab combination.
306227|NCT00251446|Drug|Vinflunine|320 mg/m2 as a 20-minute IV infusion
306228|NCT00251459|Drug|rhuFab V2 (ranibizumab)|
306229|NCT00251472|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
306230|NCT00254345|Procedure|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
306231|NCT00254371|Procedure|Androgen Replacement|
306232|NCT00254384|Drug|Erlotinib|150 mg by mouth daily for 1 year.
306233|NCT00254384|Drug|Cisplatin|80 mg/m^2 IV over a 30 minutes - 1 hour infusion every 3 weeks (21 day cycle) for 3 cycles before surgery.
306234|NCT00254384|Drug|Docetaxel|75 mg/m^2 IV over a 1 hour infusion every 3 weeks (21 day cycle) for 3 cycles before surgery.
306235|NCT00254397|Drug|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
306236|NCT00254397|Biological|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
306237|NCT00002679|Biological|filgrastim|
306238|NCT00254397|Biological|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
306239|NCT00254410|Drug|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
306240|NCT00254410|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
306241|NCT00254410|Drug|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
306242|NCT00254410|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
306243|NCT00254410|Drug|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
316624|NCT00330746|Drug|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
316625|NCT00333866|Drug|pregabalin|600mg/day
316626|NCT00333866|Drug|pregabalin|450mg/day
316627|NCT00333866|Drug|pregabalin|300mg/day
316628|NCT00333866|Drug|placebo|placebo
316629|NCT00333879|Device|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
316630|NCT00333892|Procedure|leukapheresis|pack of cells as per protocol
316631|NCT00002943|Drug|etoposide|
316632|NCT00333905|Procedure|Ischemic exercise training|
316633|NCT00333918|Drug|bromfenac ophthalmic solution|
316634|NCT00333918|Drug|placebo comparator|
316635|NCT00333931|Drug|Phenytoin|
316636|NCT00333931|Behavioral|Cognitive Behavioral Therapy|
316637|NCT00333944|Drug|Pralidoxime(drug)|
316638|NCT00333970|Behavioral|cognitive remediation|individual cognitive training
316639|NCT00333983|Device|Robotic Upper Extremity Neurorehabilitation|Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
316990|NCT00002894|Drug|carboplatin|
316991|NCT00324194|Drug|MGCD0103|MGCD0103 oral dose given 2 times per week.
316992|NCT00324220|Drug|MGCD0103|MGCD0103 Oral administration 3 times per week.
316993|NCT00324233|Device|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
316994|NCT00324233|Device|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
316995|NCT00324259|Drug|Estradiol|
315904|NCT00355576|Drug|Minocycline|Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
315905|NCT00355589|Drug|Ramipril and hydrochlorothiazide|
315906|NCT00355602|Drug|Cefuroxime|
315907|NCT00355602|Drug|Ciprofloxacin|
315908|NCT00355602|Drug|Clarithromycin|
316274|NCT00343161|Drug|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
316275|NCT00343174|Drug|Ancrod|
316276|NCT00346151|Drug|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
316277|NCT00346164|Drug|doxorubicin hydrochloride|Given IV
316278|NCT00346164|Other|clinical observation|Patients undergo observation
316279|NCT00346164|Procedure|therapeutic conventional surgery|Patients undergo surgery
316280|NCT00346164|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
316281|NCT00346164|Drug|ifosfamide|Given IV
316282|NCT00002993|Drug|cisplatin|
316283|NCT00346177|Biological|Autologous Stem Cells|Intramyocardial injections
316284|NCT00346190|Drug|Alendronate|
316285|NCT00346216|Drug|celecoxib|100 to 200 mg twice daily, taken by mouth
316286|NCT00346216|Drug|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
316287|NCT00346216|Drug|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
316288|NCT00346229|Biological|filgrastim|
316289|NCT00346229|Biological|pegfilgrastim|
316290|NCT00346229|Drug|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
316291|NCT00346229|Procedure|hyperthermia treatment|
316292|NCT00346242|Drug|Zoledronic Acid|
315533|NCT00361517|Other|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
315534|NCT00361517|Drug|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
315535|NCT00361517|Other|blood test|Blood will be tested twice a week for the presence of Galactomannan.
315536|NCT00361517|Other|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
315537|NCT00003068|Drug|cyclophosphamide|
315538|NCT00361530|Drug|Statin|
315539|NCT00364676|Drug|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
315540|NCT00364676|Drug|VLI|Patients are dosed on Day 1 of a 21-day cycle.
315541|NCT00364689|Drug|Rifaximin alone, Rifaximin combined with Lactulose|
315542|NCT00364702|Drug|methylphenidate|
315543|NCT00003084|Drug|Paclitaxel|IV over 1 hour on day 2.
315544|NCT00364741|Drug|Oxygen|During and 2 hours after surgery
315545|NCT00364754|Drug|Tesmilifene (YMB 1002)|
315546|NCT00364767|Dietary Supplement|A|Alcohol consumption (32 g/day) for 4 weeks
315547|NCT00364767|Dietary Supplement|B|Water
315548|NCT00364780|Drug|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 & 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
315549|NCT00364793|Drug|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|Oral Solution, Capsules or Tablets, Oral, once daily
Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)
Didanosine (ddI) 240 mg/m2 (max 400 mg)
Emtricitabine (FTC) 6 mg/kg (max 200 mg)
Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);
Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)
315550|NCT00364806|Drug|Prochlorperazine|
315551|NCT00364806|Drug|Metoclopramide|
315909|NCT00355602|Drug|Cotrimoxazole|
314827|NCT00326443|Biological|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
314828|NCT00326456|Drug|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
314829|NCT00326456|Drug|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
314830|NCT00326456|Drug|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
314831|NCT00326469|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
314832|NCT00329706|Procedure|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
314833|NCT00002919|Drug|vinblastine sulfate|
314834|NCT00329719|Drug|sorafenib tosylate|Given PO
314835|NCT00329719|Drug|temsirolimus|Given IV
315180|NCT00320268|Drug|Quetiapine fumarate|
315181|NCT00320281|Drug|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
315182|NCT00320281|Other|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
315183|NCT00002878|Drug|doxorubicin hydrochloride|
315184|NCT00320294|Drug|irinotecan|
315185|NCT00320294|Drug|cisplatin|
315186|NCT00320307|Drug|abacavir|
315187|NCT00320320|Drug|Irinotecan|
315188|NCT00320333|Procedure|pulmonary rehabilitation programme|
315189|NCT00320346|Biological|Pandemic Influenza Vaccine|
315190|NCT00320359|Drug|Intravenous topotecan/cisplatin|Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.
Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan.
314481|NCT00336063|Drug|Vorinostat|Given PO
314482|NCT00336089|Behavioral|exercise intervention|
314483|NCT00336089|Other|educational intervention|
314484|NCT00336089|Procedure|complementary or alternative medicine procedure|
314485|NCT00336089|Procedure|fatigue assessment and management|
314486|NCT00002953|Drug|cyclophosphamide|
314487|NCT00336089|Procedure|management of therapy complications|
314488|NCT00336089|Procedure|pain therapy|
314489|NCT00336089|Procedure|quality-of-life assessment|
314490|NCT00336102|Other|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
314491|NCT00336102|Procedure|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
314492|NCT00336102|Procedure|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
314493|NCT00336115|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
314494|NCT00339040|Biological|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
314495|NCT00339040|Other|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
314496|NCT00339053|Drug|Immunonutrition ( Impact)|
314497|NCT00339066|Drug|Sertraline|
314498|NCT00339079|Drug|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
313751|NCT00003035|Drug|doxorubicin hydrochloride|
313752|NCT00354744|Drug|cyclophosphamide|Age based dosage: ≥ 3 years 1200 mg/m2, <3 years 40 mg/kg.
Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.
Given IV
313753|NCT00354744|Drug|doxorubicin hydrochloride|Age based dosage: ≥ 1 year: 37.5mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².
Days 1 and 2 of weeks 7, 11, 15, 28 and 32.
Given IV
313754|NCT00354744|Drug|etoposide|Age based dosage: ≥ 1 year: 100 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.
Days 1-5 of weeks 9, 13, 17, 26 and 30.
Given IV
313755|NCT00354744|Drug|ifosfamide|Age based dosage: ≥ 1 year: 1800 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.
Days 1-5 of weeks 9, 13, 17, 26 and 30.
Given IV
313756|NCT00354744|Drug|irinotecan hydrochloride|Dosage 50 mg/m2-max dose 100 mg/day.
Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.
Given IV
313757|NCT00354744|Drug|vincristine sulfate|Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and < 3 years 0.05 mg/kg (max dose 2 mg), < 1 year 0.025 mg/kg.
Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.
Given IV
313758|NCT00357565|Drug|melphalan|Administered 60 mg/m^2 intravenous (IV) over 30 minutes on Days -4 through -2.
313759|NCT00357565|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients <45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
314126|NCT00348816|Drug|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
314127|NCT00348816|Drug|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
314128|NCT00348816|Procedure|adjuvant therapy|radical prostatectomy as part of standard care
314129|NCT00003004|Drug|paclitaxel|
314130|NCT00348816|Radiation|radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
314131|NCT00348816|Drug|Docetaxel|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
314132|NCT00348829|Procedure|mitral valve repair|surgical mitral valve repair
314133|NCT00351910|Drug|Venlafaxine|
314134|NCT00351923|Biological|MeMuRu-OKA (study vaccine)|
313401|NCT00363649|Biological|sargramostim|Given by injection
313402|NCT00363675|Behavioral|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
313403|NCT00363688|Drug|Penicillin test and challenge|
313404|NCT00363701|Drug|esomeprazole|
313405|NCT00363714|Drug|AGN211745|100microgram single intravitreal injection
313406|NCT00003081|Drug|busulfan|
313407|NCT00363714|Drug|AGN211745|200microgram single intravitreal injection
313408|NCT00363714|Drug|AGN211745|400microgram single intravitreal injection
313409|NCT00363714|Drug|AGN211745|800microgram single intravitreal injection
313410|NCT00312897|Drug|corn oil|placebo comparator
313411|NCT00312910|Drug|Probiotics-Bio-plus|
313412|NCT00312923|Drug|Policosanol|20 mg of policosanol in capsular form daily
313413|NCT00312923|Dietary Supplement|Placebo|Two capsules of 10 mg of microcrystalline cellulose daily
313414|NCT00312936|Behavioral|Mindfulness-based Stress Reduction (MBSR)|8 week program
313415|NCT00312949|Behavioral|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
313416|NCT00312949|Behavioral|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
313417|NCT00312962|Behavioral|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
313418|NCT00000458|Behavioral|cognitive behavior therapy|
313419|NCT00002850|Drug|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
313420|NCT00312962|Behavioral|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
312691|NCT00328926|Drug|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
312692|NCT00002916|Biological|human papillomavirus 16 E7 peptide|
312693|NCT00328939|Drug|ARIXTRA infusion|
312694|NCT00328939|Drug|Enoxaparine infusion|
312695|NCT00328965|Drug|Lacidipine|Lacidipine 2, 4, 6mg
312696|NCT00328978|Drug|Quetiapine|
312697|NCT00328991|Device|duct tape occlusion therapy|
312698|NCT00332098|Behavioral|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
312699|NCT00002931|Procedure|bone marrow ablation with stem cell support|Two cycles of high dose chemotherapy followed by stem cell reinfusion
312700|NCT00332124|Drug|Choline|900 mg every day until birth of infant
313058|NCT00319410|Procedure|vaginoscopic hysteroscopy|
313059|NCT00002875|Drug|cisplatin|
313060|NCT00319423|Procedure|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
313061|NCT00322374|Drug|Epirubicin|Infusion, intravenous (IV): 75 mg/m^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
313062|NCT00322387|Drug|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
313063|NCT00322400|Drug|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
313064|NCT00322400|Drug|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
313065|NCT00322400|Drug|AMG 706|Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.
Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days.
312318|NCT00338221|Drug|glycine|
312319|NCT00338247|Drug|lapatinib + capecitabine|Experimental
312320|NCT00002968|Biological|edrecolomab|Given IV
312321|NCT00338260|Drug|MK0954, /Duration of Treatment : 5 Years|
312322|NCT00338260|Drug|Comparator : atenolol /Duration of Treatment : 5 Years|
312323|NCT00338273|Drug|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
312324|NCT00338273|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
312325|NCT00338286|Other|Standard supportive care (packed RBC transfusion)|Per doctor prescription
312326|NCT00338286|Drug|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
312327|NCT00338299|Drug|Epoetin alfa|
312328|NCT00338312|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
312329|NCT00338312|Drug|Placebo patch|placebo patch changed twice a week for one year
312330|NCT00338325|Behavioral|Reading program|Reading of children's story/picture books preoperatively
312331|NCT00002968|Other|laboratory biomarker analysis|Correlative studies
312332|NCT00344253|Drug|Interferon beta|
312333|NCT00002984|Drug|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
312334|NCT00344253|Drug|Methotrexate|
312335|NCT00344305|Biological|Trivalent influenza virus vaccine live, intranasal|A single intranasal dose of trivalent influenza virus vaccine live, intranasal was administered on Day 0.
312336|NCT00344318|Biological|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
312337|NCT00344318|Biological|Prevenar|3 Intramuscular injections
312338|NCT00344318|Biological|Tritanrix-HepB|3 Intramuscular injections
312339|NCT00344318|Biological|Hiberix|Reconstituted with Tritanrix before injection
312340|NCT00344318|Biological|Polio Sabin.|3 oral doses.
311604|NCT00359944|Other|Sugar Pill|Sugar Pill twice daily
311605|NCT00359957|Behavioral|Pediatric Obesity Intervention (STANDARD)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
311606|NCT00359957|Behavioral|Pediatric Obesity Intervention + High Activity (ADDED)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
311607|NCT00362791|Behavioral|"HIV Prevention Education": 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies|
311958|NCT00350909|Behavioral|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
311959|NCT00350922|Behavioral|Psychoeducation|
311960|NCT00354107|Other|laboratory biomarker analysis|Correlative studies
311961|NCT00354120|Drug|Alentuzumab|Alentuzumab
311962|NCT00354120|Drug|Globulina antilinfocitaria|Globulina antilinfocitaria
311963|NCT00354133|Device|Kinetra and Soletra (neurostimulator, Medtronic)|Arm I: Implantation of stimulation electrodes in the STN and best medical treatment Arm II: Best medical treatment only
311964|NCT00354146|Drug|tipifarnib (R115777)|
311965|NCT00354159|Device|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
311966|NCT00354172|Biological|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If < 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
311967|NCT00003029|Drug|fluorouracil|
311968|NCT00354172|Biological|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
306826|NCT00215540|Drug|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
306827|NCT00215553|Drug|Lucinactant|Suspension for instillation
306828|NCT00215553|Other|Standard of Care|Standard ARDS management and ICU care
306829|NCT00000386|Behavioral|Behavior therapy|
306830|NCT00002568|Drug|cisplatin|
306831|NCT00215566|Drug|DDP733|
306832|NCT00215579|Drug|Depot Risperidone Microsphere (Consta)|
306833|NCT00215592|Drug|Zonegran|
306834|NCT00215605|Drug|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
306835|NCT00215618|Device|Uterine Balloon Therapy|UBT with post procedure curettage
306836|NCT00215618|Device|Uterine Balloon Therapy|UBT without post procedure curettage
306837|NCT00215631|Drug|tadalafil|
306838|NCT00215644|Drug|ECX|ECX given until progression of disease or unacceptable toxicity, for a maximum of 8 cycles- E= 50 mg per metre squared of Epirubicin given i.v. once every 3 weeks, C= 60 mg per metre squared of cisplatin given i.v. once every 3 weeks, X= 1250mg per metre squared divided into two oral doses of capecitabine given every day.
306839|NCT00215644|Drug|Matuzumab + ECX|800mg matuzumab given i.v. (into the vein) once per week until progression or unacceptable toxicity, along with intervention in Arm 1 (ECX)
306840|NCT00215657|Drug|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
306841|NCT00002568|Drug|paclitaxel|
306842|NCT00215657|Drug|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
307148|NCT00258401|Dietary Supplement|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
307149|NCT00258401|Procedure|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
306112|NCT00237744|Device|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
306113|NCT00237744|Device|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
306114|NCT00237744|Other|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
306115|NCT00002628|Drug|cyclophosphamide|
306459|NCT00226239|Drug|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour, day 1
306460|NCT00002596|Drug|etoposide|
306461|NCT00226239|Drug|Cisplatin|Cisplatin 75 mg/m2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
306462|NCT00226239|Drug|Cetuximab|Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
306463|NCT00226239|Procedure|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies>6 MV may be utilized when appropriate to boost target localized centrally.
306464|NCT00226252|Procedure|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
306465|NCT00226252|Procedure|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
306466|NCT00226278|Drug|ORG 34517|
306467|NCT00226291|Other|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
306468|NCT00226317|Drug|Aripiprazole|
306469|NCT00226330|Drug|Tesaglitazar|(0.5 or 1 mg)
306470|NCT00226330|Drug|Pioglitazone|(15, 30 or 45 mg)
306471|NCT00002596|Procedure|autologous bone marrow transplantation|
306472|NCT00226343|Drug|Depakote-ER|
306473|NCT00226356|Drug|Supplements of L-methionine, betaine and folate|
306474|NCT00226369|Drug|CY-1503|
306475|NCT00226382|Drug|Pegylated Interferon-alfa-2a|Pegasys once weekly
305755|NCT00247962|Drug|etanercept|50 mg
305756|NCT00247962|Drug|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
305757|NCT00002658|Biological|filgrastim|
305758|NCT00247975|Drug|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
305759|NCT00247988|Drug|Weekly Taxotere with weekly carboplatin|
305760|NCT00248014|Device|Mandibular Advancement Via A Functional Appliance|Functional appliance
305761|NCT00248040|Drug|Reparixin continuous infusion|Reparixin continuous infusion
305762|NCT00248040|Drug|reparixin intermittent infusion|reparixin intermittent infusion
305763|NCT00248040|Other|placebo infusion|placebo infusion
305764|NCT00248053|Drug|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
305765|NCT00248066|Drug|RESTEN-MP|
305766|NCT00248079|Device|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
306116|NCT00237757|Behavioral|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
306117|NCT00237757|Behavioral|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
306118|NCT00237770|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
306119|NCT00237770|Procedure|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
312093|NCT00312377|Drug|Docetaxel|infusion
312094|NCT00312377|Drug|Vandetanib|oral
312095|NCT00312390|Procedure|Flicker|
312464|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
312465|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
312466|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
312467|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
312468|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
312469|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
312470|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
312471|NCT00357253|Drug|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
312472|NCT00357253|Radiation|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
312473|NCT00360230|Biological|Rabipur|3-dose intramuscular injection.
312474|NCT00360230|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
312475|NCT00360243|Drug|flibanserin|Experimental: flibanserin 25 mg b.i.d
312476|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg qhs
312477|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg b.i.d.
312478|NCT00360243|Drug|placebo|placebo
312479|NCT00360269|Drug|Atomoxetine|25 to 100 mg daily
312480|NCT00360269|Procedure|Motivational enhancement therapy|Three sessions
312481|NCT00360269|Drug|Placebo|25 to 100 mg daily
311736|NCT00322062|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
311737|NCT00322062|Drug|Sodium Phosphate Solution|1 x 45ml solution, BID
311738|NCT00322075|Drug|insulin glargine|
311739|NCT00322101|Radiation|total-body irradiation|Radiation
311740|NCT00002883|Procedure|conventional surgery|
311741|NCT00322101|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
311742|NCT00322101|Drug|cyclophosphamide|Given IV
311743|NCT00322101|Drug|mycophenolate mofetil|Given orally
311744|NCT00324805|Drug|Pemetrexed Disodium|Given IV
311745|NCT00324805|Other|Questionnaire Administration|Ancillary studies
311746|NCT00324805|Drug|Vinorelbine Tartrate|Given IV
311747|NCT00324818|Drug|metronidazole and azithromycin|
311748|NCT00324831|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
312096|NCT00312390|Procedure|Retinal Vessel Diameter|
312097|NCT00312390|Procedure|Retinal Blood Flow|
312098|NCT00002847|Biological|recombinant interferon alfa|
312099|NCT00312403|Procedure|Blood Sample|A single venous blood sample will be taken (10 ml).
312100|NCT00312416|Drug|Clonidin|
312101|NCT00312416|Drug|Brimonidine|
312102|NCT00315601|Procedure|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
312103|NCT00315601|Drug|Telithromycin|Telithromycin 800 mg once a day
312104|NCT00315614|Drug|Islet Transplantation|Islet transplantation
312105|NCT00002860|Procedure|Surgery|Complete surgical resection of metastatic melanoma
312106|NCT00315627|Drug|Islet transplantation|Islet transplantation
316988|NCT00324168|Drug|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
316989|NCT00324168|Drug|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
311379|NCT00331526|Procedure|adjuvant therapy|
311380|NCT00331526|Procedure|conventional surgery|
311381|NCT00331539|Device|Cochlear Implant|
311382|NCT00331552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
311383|NCT00331552|Drug|cyclophosphamide|Given orally
311384|NCT00331552|Biological|trastuzumab|Given IV
311385|NCT00331565|Procedure|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
311386|NCT00331578|Device|Excel drug-eluting coronary artery stent|
311387|NCT00002931|Biological|filgrastim|5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.
311388|NCT00331604|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
311389|NCT00331604|Drug|insulin detemir|Injection s.c., 50% of daily dose.
311390|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
311391|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
311392|NCT00331630|Drug|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
311393|NCT00334854|Procedure|conventional surgery|
311394|NCT00334854|Procedure|neoadjuvant therapy|
311395|NCT00334854|Radiation|radiation therapy|
311396|NCT00002945|Procedure|peripheral blood stem cell transplantation|IV
311397|NCT00334867|Drug|cyclophosphamide|Given IV
311398|NCT00334867|Drug|dexrazoxane hydrochloride|Given IV
311399|NCT00334867|Drug|doxorubicin hydrochloride|Given IV
316996|NCT00324272|Drug|Fibrin Sealant (Tisseel) used in the Experimental Arm.|For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.
For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects).
316997|NCT00324285|Drug|Amylase resistant starch added ORS|
316998|NCT00324298|Biological|bleomycin sulfate|
316999|NCT00324298|Drug|cisplatin|
317000|NCT00324298|Drug|etoposide|
317001|NCT00002894|Drug|cisplatin|
317002|NCT00324298|Procedure|management of therapy complications|
317003|NCT00324311|Drug|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
317004|NCT00324324|Drug|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
317005|NCT00324324|Drug|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
317006|NCT00324350|Drug|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
317007|NCT00324363|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
317008|NCT00324363|Drug|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
317009|NCT00324376|Drug|Sevelamer hydrochloride|
317010|NCT00324389|Drug|Interferon alpha|
317011|NCT00327366|Procedure|Light therapy|
317012|NCT00327379|Drug|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
311405|NCT00334867|Procedure|radiation therapy|Patients undergo radiation therapy in week 19
311406|NCT00334880|Drug|NRP104|
311407|NCT00000467|Behavioral|diet|
311408|NCT00002945|Radiation|radiation therapy|delivered to the cancer cells
311409|NCT00334893|Drug|eribulin mesylate|Given IV
316293|NCT00002993|Drug|doxorubicin hydrochloride|
316294|NCT00346255|Drug|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
316295|NCT00346268|Drug|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
316296|NCT00346268|Drug|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
316297|NCT00346281|Device|32P BioSilicon|
316640|NCT00333983|Other|Traditional Upper Extremity Exercise Group|Upper extremity stretching, skateboard reaching activities, and arm ergometer
316641|NCT00333996|Drug|Dexamethasone|
316642|NCT00002943|Procedure|autologous bone marrow transplantation|
316643|NCT00334022|Drug|enfuvirtide|1ml BID
316644|NCT00334035|Drug|Quetiapine|
316645|NCT00334048|Drug|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
316646|NCT00334061|Device|Penumbra System|
316647|NCT00334074|Drug|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
316648|NCT00334087|Behavioral|feeding habits|
316649|NCT00334100|Behavioral|Exercise|Treadmill exercise
316650|NCT00334113|Behavioral|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
316651|NCT00334126|Drug|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
316652|NCT00334139|Drug|Zoledronic Acid|every 4 weeks for 4 months
316653|NCT00002944|Drug|carboplatin|Given IV
316654|NCT00334152|Drug|casopitant|
315910|NCT00355602|Drug|Coamoxiclav|
315911|NCT00003040|Procedure|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
315912|NCT00355602|Drug|metronidazole|
315913|NCT00355602|Drug|neomycin|
315914|NCT00355602|Drug|rifaximin|
315915|NCT00355602|Drug|Vancomycin|
315916|NCT00355602|Drug|Doxycycline|
315917|NCT00355615|Drug|Rosuvastatin|oral
315918|NCT00355615|Drug|Placebo|oral
315919|NCT00355628|Drug|KW-2246 (fentanyl citrate)|KW-2246
315920|NCT00355641|Drug|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
315921|NCT00355654|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
315922|NCT00003040|Radiation|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
315923|NCT00355654|Biological|DT3aP-HBs-IPV|0.5 mL, IM
315924|NCT00355667|Drug|furosemide|Patients with chronic heart failure receive furosemide and other standard treatment/
315925|NCT00355667|Drug|azosemide|Patients with chronic heart failure receive azosemide and other standard treatment.
315926|NCT00355680|Device|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
315927|NCT00355680|Device|Green Laser (Iridex)|Already available green laser
315928|NCT00355693|Device|Pump for propofol delivery|
315929|NCT00355706|Procedure|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
315930|NCT00355719|Drug|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
315931|NCT00358462|Drug|Doxycycline|one 100mg capsule administered twice daily for seven days
315932|NCT00358475|Drug|GW685698|
315933|NCT00358488|Drug|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
315191|NCT00320359|Drug|Intravenous etoposide/cisplatin|Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.
Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3.
315192|NCT00320385|Drug|Lapatinib|oral lapatinib once daily
315193|NCT00320385|Biological|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
315194|NCT00002878|Drug|valspodar|
315195|NCT00320398|Drug|Fondaparinux|
315196|NCT00320411|Drug|lapatinib|Lapatinib 1500mg QD
315197|NCT00320424|Drug|Fondaparinux|
315198|NCT00320450|Drug|SB-681323|
315199|NCT00320463|Biological|DTPa-HBV-IPV/Hib vaccine|
315200|NCT00320476|Drug|Velcade|
315201|NCT00320489|Drug|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
315552|NCT00364819|Drug|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
315553|NCT00364832|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
315554|NCT00003084|Drug|Vinblastine|IV on days 8, 22, and 36.
315555|NCT00364845|Drug|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
315556|NCT00364845|Drug|Placebo|Prefilled syringe placebo, to match active arm
315557|NCT00364858|Drug|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
315558|NCT00364871|Drug|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
315559|NCT00364884|Drug|ketoaminoacid|
315560|NCT00364910|Behavioral|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
315561|NCT00364910|Behavioral|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
314499|NCT00339079|Behavioral|Cognitive Behavioral Therapy|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
314836|NCT00329719|Procedure|conventional surgery|Undergo surgery
314837|NCT00329732|Drug|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
314838|NCT00329732|Drug|Saline placebo|matching volume of saline (placebo)
314839|NCT00329745|Biological|Rotarix™|Oral administration, 2 doses
314840|NCT00329745|Biological|Placebo|Oral administration, 2 doses
314841|NCT00329758|Drug|rosuvastatin|20 mg oral, during 10 days
314842|NCT00329758|Drug|Placebo|
314843|NCT00329771|Other|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
314844|NCT00002919|Procedure|conventional surgery|
314845|NCT00329784|Biological|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
314846|NCT00329797|Dietary Supplement|calcium carbonate|Given orally
314847|NCT00329797|Dietary Supplement|calcium citrate|Given orally
314848|NCT00329797|Dietary Supplement|calcium glucarate|Given orally
314849|NCT00329797|Dietary Supplement|cholecalciferol|Given orally
314850|NCT00329797|Drug|buserelin|Given concurrently
314851|NCT00329797|Drug|calcium gluconate|Given orally
314852|NCT00329797|Drug|goserelin acetate|Given concurrently
314853|NCT00329797|Drug|leuprolide acetate|Given concurrently
314854|NCT00329797|Drug|triptorelin|Given concurrently
314855|NCT00002920|Drug|medroxyprogesterone|
314135|NCT00351936|Drug|Aripiprazole|
314136|NCT00351936|Drug|placebo|
314137|NCT00351949|Biological|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
314138|NCT00351962|Procedure|Fractionated Stereotactic Radiotherapy|
314139|NCT00003015|Radiation|radiation therapy|
314140|NCT00351975|Drug|Belinostat|Given IV
314141|NCT00351975|Drug|Azacitidine|Given SC
314142|NCT00351975|Other|Laboratory Biomarker Analysis|Correlative studies
314143|NCT00351988|Behavioral|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
314144|NCT00351988|Behavioral|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
314145|NCT00352001|Drug|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
314146|NCT00352001|Drug|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
314500|NCT00339079|Other|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
314501|NCT00339079|Drug|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
314502|NCT00002973|Procedure|hyperthermia treatment|
314503|NCT00339092|Behavioral|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
313421|NCT00312975|Drug|CP-675,206|Given intravenously every 3 months
313760|NCT00357565|Procedure|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
313761|NCT00357591|Device|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
313762|NCT00357604|Drug|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
313763|NCT00357604|Drug|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
313764|NCT00357617|Drug|celecoxib|
313765|NCT00357617|Genetic|microarray analysis|
313766|NCT00003050|Drug|tamoxifen citrate|
313767|NCT00357617|Genetic|protein expression analysis|
313768|NCT00357617|Other|immunoenzyme technique|
313769|NCT00357617|Other|immunohistochemistry staining method|
313770|NCT00357617|Other|laboratory biomarker analysis|
313771|NCT00357617|Procedure|biopsy|
313772|NCT00357617|Procedure|conventional surgery|
313773|NCT00357617|Procedure|neoadjuvant therapy|
313774|NCT00357630|Drug|gemcitabine hydrochloride|
313775|NCT00357630|Procedure|quality-of-life assessment|
313776|NCT00357643|Drug|Calcium 500 mg/day and vitamin D 700 IU/day|
313777|NCT00000478|Procedure|coronary artery bypass coronary artery bypass|
313778|NCT00003050|Procedure|surgical procedure|
313779|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|An initial loading dose will be administered intravenously over a period <= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.
CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.
All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always >= 0.4 mL/h.
313066|NCT00002884|Radiation|radiation therapy|
313067|NCT00322413|Drug|Epoetin|
313068|NCT00322426|Device|Sensory Cueing Device|
313069|NCT00322439|Drug|Etanercept|Observational study - no drug administered
313070|NCT00322452|Drug|Gefitinib|oral tablet
313071|NCT00322452|Drug|Carboplatin|IV
313072|NCT00322452|Drug|Paclitaxel|IV
313073|NCT00322465|Drug|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
313074|NCT00322465|Other|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
313075|NCT00322465|Drug|Doxycycline|100 mg orally, twice daily for 7 days.
313076|NCT00322465|Drug|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
313077|NCT00002887|Drug|cisplatin|
313078|NCT00322478|Behavioral|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
313422|NCT00312975|Drug|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
313423|NCT00312988|Drug|Hycamtin|
313424|NCT00312988|Drug|Gemcitabine|
313425|NCT00313001|Drug|biphasic insulin aspart|
313426|NCT00313001|Drug|exenatide|
313427|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
313428|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
313429|NCT00313014|Drug|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
313430|NCT00002850|Drug|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
312701|NCT00332124|Dietary Supplement|Placebo|Corn oil every day in place of choline
312702|NCT00332137|Drug|Tolterodine|
312703|NCT00332163|Biological|Panitumumab|Administered by intravenous infusion
312704|NCT00332163|Drug|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
312705|NCT00332163|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
312706|NCT00332163|Drug|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
312707|NCT00332163|Drug|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
312708|NCT00332176|Drug|Celgosivir|400mg qd + standard of care for 12 weeks
312709|NCT00332176|Drug|Celgosivir|600mg qd + standard of care for 12 weeks
312710|NCT00002932|Drug|cisplatin|
312711|NCT00332176|Drug|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
312712|NCT00332189|Drug|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
312713|NCT00332202|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
312714|NCT00332202|Drug|placebo|oral, daily
312715|NCT00332215|Drug|Inhaled Sodium Pyruvate|
312716|NCT00332228|Drug|depot naltrexone|long-acting depot parenteral formulation of naltrexone
312717|NCT00332228|Behavioral|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
312718|NCT00332228|Drug|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
312719|NCT00332241|Drug|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
311969|NCT00354172|Biological|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
311970|NCT00354172|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
311971|NCT00354172|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
311972|NCT00354172|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
312341|NCT00344318|Biological|Poliorix.|3 intramuscular injections
312342|NCT00344370|Drug|Pitavastatin|Pitavastatin 4 mg QD
312343|NCT00344370|Drug|Atorvastatin|Atorvastatin 40 mg
312344|NCT00002984|Procedure|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
312345|NCT00344383|Drug|Norgestimate/Ethinyl Estradiol tablet|
312346|NCT00344409|Drug|darbepoetin alfa|
312347|NCT00344422|Drug|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
312348|NCT00344448|Drug|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
312349|NCT00344461|Drug|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
312350|NCT00344474|Behavioral|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
312351|NCT00344487|Drug|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
312352|NCT00344500|Behavioral|Behavioral Weight Loss Program|Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient
Be given a 7% weight loss goal
Be assisted in obtaining a 500 calorie reduction per day
Exercise for at least 30 min/day, at least 5 days a week
Maintain weekly food and exercise diaries
Be quizzed on their knowledge of healthy eating habits and nutrition
307150|NCT00258401|Procedure|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
307151|NCT00002693|Drug|carboplatin|
307152|NCT00258427|Biological|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
307153|NCT00258427|Biological|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10^9/L)
307154|NCT00258427|Drug|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if <4 years old)
307155|NCT00258427|Drug|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
307156|NCT00258427|Drug|fludarabine phosphate|35 mg/m^2 intravenously (IV) on Days -5 through -2.
307157|NCT00258427|Drug|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
307158|NCT02719821|Behavioral|Behavioral techniques|Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.
Device: Actiwatch-2 (Philips Respironics)
307159|NCT02719834|Drug|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
307160|NCT02719834|Other|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
307161|NCT02719847|Procedure|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
307162|NCT02719860|Dietary Supplement|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
307163|NCT02719860|Dietary Supplement|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
307164|NCT02719860|Dietary Supplement|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
307165|NCT02719873|Other|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
307166|NCT02719886|Device|Ultrasound|Estimation of fetal weight by ultrasound
307167|NCT00204529|Drug|pegylated interferon-alpha-2a|
307508|NCT00248807|Drug|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
306476|NCT00230178|Drug|Rasburicase (SR29142)|30-min IV infusion
306477|NCT00230178|Drug|Allopurinol|Oral administration
306478|NCT00230191|Drug|RK-0202|
306479|NCT00002604|Drug|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
306480|NCT00230204|Procedure|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
306481|NCT00230217|Drug|Rasburicase (SR29142)|
306482|NCT00230230|Drug|SCH 486757|
306843|NCT00215657|Drug|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
306844|NCT00215657|Drug|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
306845|NCT00215657|Drug|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
306846|NCT00215657|Drug|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
306847|NCT00218634|Behavioral|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
306848|NCT00218634|Behavioral|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
306849|NCT00218660|Drug|Naltrexone|150mg/day Naltrexone
306850|NCT00218660|Behavioral|BRENDA|Psychosocial Treatment
306851|NCT00218660|Behavioral|CBT|Cognitive Behavioral Therapy
306852|NCT00218660|Drug|Placebo|
306853|NCT00000388|Behavioral|Psychosocial treatment|
306854|NCT00002579|Drug|CMF regimen|
306855|NCT00218673|Behavioral|Peer mentor intervention|groups sessions, 8
306120|NCT00237783|Drug|dialysate sodium concentration|
306121|NCT00237796|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
306122|NCT00241189|Drug|rapamycin|
306123|NCT00241189|Drug|methotrexate|
306124|NCT00241202|Behavioral|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
306125|NCT00241215|Drug|Botulinum toxin serotype A|
306126|NCT00002637|Biological|gene-modified tumor cell vaccine therapy|
306127|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
306128|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
306129|NCT00241241|Drug|pegylated interferon-alfa 2a|
306130|NCT00241254|Drug|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
306131|NCT00241254|Drug|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
306132|NCT00241267|Device|Dedicated ultrasonographic probe during bronchoscopy|
306133|NCT00241280|Device|etafilcon A|
306134|NCT00241280|Device|galyfilcon A|
306483|NCT00230269|Procedure|PET-CT|
306484|NCT00230282|Drug|Alemtuzumab|3 to 30 mg, IV
306485|NCT00230282|Drug|Fludarabine|[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid
306486|NCT00230282|Drug|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
306487|NCT00230295|Procedure|IMR LAG|
306488|NCT00230321|Drug|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
306489|NCT00230334|Drug|Gleevec|
312482|NCT00000143|Device|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
312483|NCT00000479|Drug|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
312484|NCT00003063|Drug|fluorouracil|
312485|NCT00360282|Drug|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
312486|NCT00360282|Other|Placebo|In an unlabeled pill given once on one of two visits.
312841|NCT00351273|Drug|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
312842|NCT00351273|Drug|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
312843|NCT00351273|Drug|Placebo|Methylcellulose
312844|NCT00003013|Drug|tamoxifen citrate|
312845|NCT00351286|Drug|L-citrulline tablets, 1000 mg|
312846|NCT00351286|Drug|Placebo tablets matching L-citrulline tablets|
312847|NCT00351286|Drug|Background simvastatin at a stable dose of 40 mg qHS|
312848|NCT00351299|Drug|Dexmedetomidine|
312849|NCT00351312|Device|special socks|
312850|NCT00351325|Drug|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
312851|NCT00351351|Device|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
312852|NCT00351351|Device|single probe ultrasonic|FDA-approved - single probe ultrasonic
312853|NCT00351364|Drug|Montelukast Sodium|100 mg P.O. One time only
312854|NCT00351377|Drug|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
312855|NCT00003013|Procedure|conventional surgery|
312856|NCT00351390|Other|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
312857|NCT00351390|Other|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP <1000 pg/mL
312107|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
312108|NCT00315640|Drug|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
312109|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
312110|NCT00315640|Other|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
312111|NCT00315666|Drug|memantine|
312112|NCT00315679|Drug|Pentoxifylline (also known as oxpentifylline)|
312113|NCT00315692|Device|Biomarker Assay (CA125 and HE4)|
312114|NCT00315705|Drug|clofarabine|Clofarabine 20‑40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
312115|NCT00315705|Drug|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
312116|NCT00002862|Drug|perillyl alcohol|
312117|NCT00315705|Drug|Cyclophosphamide|Cyclophosphamide 340‑440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
312118|NCT00315718|Drug|Extract from Hintonia latiflora bark|
312119|NCT00315731|Biological|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
312487|NCT00360295|Drug|Azithromycin SR|
312488|NCT00360308|Drug|Placebo|
312489|NCT00360308|Drug|E2007|
312490|NCT00360308|Drug|E2007|
312491|NCT00360334|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
312492|NCT00360334|Drug|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
312493|NCT00360347|Drug|C.E.R.A.|
312494|NCT00360360|Drug|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
311400|NCT00334867|Drug|etoposide|Given IV
311401|NCT00334867|Drug|ifosfamide|Given IV
311402|NCT00334867|Drug|topotecan hydrochloride|Given IV
311403|NCT00334867|Drug|vincristine sulfate|Given IV
311404|NCT00334867|Procedure|conventional surgery|Patients undergo surgery in week 18
311749|NCT00324831|Drug|cyclophosphamide|
311750|NCT00324831|Drug|doxorubicin hydrochloride|
311751|NCT00002897|Drug|cisplatin|
311752|NCT00324831|Drug|prednisone|
311753|NCT00324831|Drug|rituximab|
311754|NCT00324831|Drug|sargramostim|
311755|NCT00324831|Drug|vincristine|
311756|NCT00324831|Procedure|Intervention/procedure|
311757|NCT00324831|Procedure|antibody therapy|
311758|NCT00324831|Procedure|biological therapy|
311759|NCT00324831|Procedure|chemotherapy|
311760|NCT00324831|Procedure|colony-stimulating factor therapy|
311761|NCT00324831|Procedure|cytokine therapy|
311762|NCT00002897|Drug|fluorouracil|
311763|NCT00324831|Procedure|monoclonal antibody therapy|
311764|NCT00324831|Procedure|non-specific immune-modulator therapy|
311765|NCT00324831|Procedure|therapeutic procedure|
311766|NCT00324831|Procedure|tumor cell derivative vaccine|
311767|NCT00324831|Procedure|vaccine therapy|
311410|NCT00334906|Drug|memantine HCl|
311411|NCT00334919|Behavioral|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
311412|NCT00334932|Drug|bortezomib|
311413|NCT00334932|Drug|melphalan|
311414|NCT00334932|Drug|pegylated liposomal doxorubicin hydrochloride|
311415|NCT00334958|Drug|Placebo|BID for 12-day Titration Phase and 12-week Maintenance Phase.
311416|NCT00334958|Drug|Rufinamide|400 mg twice daily (BID) orally uptitrated every 3 days in 400 mg BID increments up to 1600 mg BID (total daily dose of 3200 mg/day) over 12-day Titration Phase; followed by 1600 mg BID over 12-week Maintenance Phase.
311417|NCT00334971|Procedure|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
311418|NCT00334984|Drug|glutamine|
311419|NCT00002946|Drug|penclomedine|
311420|NCT00334984|Procedure|chemoprotection|
311421|NCT00334984|Procedure|management of therapy complications|
311422|NCT00334984|Procedure|therapeutic nutritional supplementation|
311423|NCT00334997|Procedure|endoscopic surgery|
311424|NCT00334997|Procedure|laser surgery|
311425|NCT00334997|Radiation|radiation therapy|
311426|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, for 10 weeks.
311427|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, 10 weeks
311428|NCT00337675|Drug|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
311429|NCT00337675|Drug|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
311775|NCT00328432|Drug|celecoxib 400 mg bid|
311776|NCT00328445|Behavioral|Positive Action|See publications
311777|NCT00328458|Drug|EPO906 (epothilone B)|
316655|NCT00336947|Drug|tegafur-uracil|
316656|NCT00336947|Procedure|adjuvant therapy|
316657|NCT00336960|Drug|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
316658|NCT00336960|Drug|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
316659|NCT00336960|Procedure|conventional surgery|4-10 weeks after completion of chemoradiotherapy
316660|NCT00336960|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
316661|NCT00336960|Procedure|tumor biopsy|at baseline and then at the time of surgical resection
316662|NCT00336960|Other|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
311059|NCT00347269|Behavioral|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
311060|NCT00347269|Drug|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
311061|NCT00347269|Behavioral|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
311062|NCT00347295|Drug|Brotizolam|
311063|NCT00347295|Drug|Estazolam|
311064|NCT00347308|Behavioral|Eyebrow Position|Photography of brow positions
311065|NCT00347321|Procedure|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
311066|NCT00347334|Behavioral|infant home positioning|
311067|NCT00002998|Drug|cisplatin|
311068|NCT00347360|Drug|lisinopril|
311069|NCT00350441|Drug|Sildenafil Citrate|
311070|NCT00350454|Device|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
311071|NCT00350454|Device|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
315934|NCT00358488|Drug|salbutamol|salbutamol
315935|NCT00003054|Drug|paclitaxel|
316298|NCT00346294|Other|Etanercept|Intervention type was to study the drug delivery method.
316299|NCT00346320|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
316300|NCT00346333|Drug|Lutein|12mg/d
316301|NCT00346333|Dietary Supplement|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
316302|NCT00346359|Biological|anti-thymocyte globulin|
316303|NCT00346359|Drug|busulfan|
316304|NCT00002993|Drug|mitomycin C|
316305|NCT00349518|Drug|Dasatinib|
316306|NCT00349531|Drug|Pramipexole|
316307|NCT00349557|Drug|bevacizumab, bicalutamide and goserelin|
316308|NCT00349557|Procedure|intensity modulated radiation therapy (IMRT)|
316309|NCT00349570|Device|Xtract Aspiration Catheter|
316310|NCT00349583|Drug|Topical Cyclosporine, Tears|
316311|NCT00003008|Drug|indinavir sulfate|
316312|NCT00349596|Drug|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
316313|NCT00349622|Drug|ceftriaxone|Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years.
316314|NCT00349622|Other|placebo|an inactive substance
316315|NCT00349635|Drug|Metformin and Metformin + Fenofibrate|
316316|NCT00349648|Procedure|acromioplasty|
316317|NCT00349661|Drug|impact on VASP test|
316318|NCT00349674|Drug|Azathioprine: 2 mg/kg/day|
315562|NCT00364923|Drug|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
315563|NCT00313872|Drug|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre & Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre & post hydration (if Mg <WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
315564|NCT00313872|Drug|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
315565|NCT00313885|Drug|eplivanserin (SR46349)|oral administration
315566|NCT00313885|Drug|placebo|oral administration
315567|NCT00313898|Drug|sildenafil (viagra)|
315568|NCT00313911|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
315569|NCT00002854|Drug|cyclophosphamide|
315570|NCT00313911|Biological|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
315571|NCT00313924|Drug|DETRUSITOL|
315572|NCT00313937|Drug|Insulin glargine|
315573|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
315936|NCT00358488|Drug|salmeterol 50mcg|salmeterol 50mcg
315937|NCT00358488|Drug|placebo|placebo
315938|NCT00358501|Drug|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
315939|NCT00358514|Device|Continuous Compartment Pressure Monitoring|See Detailed Description.
315940|NCT00358527|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
315941|NCT00358527|Other|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
315942|NCT00358540|Drug|eltrombopag|Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
315943|NCT00358553|Drug|Insulin|
314856|NCT00329797|Drug|zoledronic acid|Given IV
314857|NCT00329797|Radiation|brachytherapy|Given concurrently
314858|NCT00329797|Radiation|radiation therapy|Given concurrently
314859|NCT00329810|Drug|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
314860|NCT00329823|Drug|Etanercept sc 50mg per week for 12 weeks|
315202|NCT00320489|Drug|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
315203|NCT00320502|Drug|BXT-51072|
315204|NCT00320515|Drug|pemetrexed|Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression
Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression
315205|NCT00323362|Drug|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
315206|NCT00323362|Drug|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
315207|NCT00323375|Drug|AQ-13 and Chloroquine|
315208|NCT00323401|Other|Antenatal classes|3 sessions of 3 hours each
315209|NCT00323401|Other|Antenatal classes|antenatal programme
315210|NCT00323401|Other|Educational programme|3 times, 3 hours intervention programme
315211|NCT00002888|Drug|paclitaxel|
315212|NCT00323401|Other|Educational programme|no programme are offered
315213|NCT00323414|Drug|PUFA (Opti-EPA)|EPA:DHA (360 mg EPA and 240 DHA in each capsule) 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
315214|NCT00323414|Drug|Placebo|Placebo gelcaps containing cornoil 6 capsules-3 capsules by mouth 2x per day x 48 weeks
315215|NCT00323427|Behavioral|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
315216|NCT00323427|Device|hearing aid services|Standard VA audiological hearing aid dispensing services
315217|NCT00323453|Device|Alexis Wound Retractor use in open appendectomy|
314504|NCT00339092|Behavioral|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
314505|NCT00339118|Drug|doxorubicin, cytoxan|
314506|NCT00339131|Drug|Ultratrace iobenguane I 131|
314507|NCT00339144|Drug|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
314508|NCT00339144|Drug|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
314509|NCT00339144|Drug|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
314510|NCT00339157|Drug|Anakinra|
314511|NCT00339157|Biological|Pneumo23|
314512|NCT00339170|Behavioral|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
314513|NCT00002987|Drug|vincristine sulfate|
314514|NCT00345579|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
314515|NCT00345579|Biological|ActHIB|3-dose intramuscular injection
314516|NCT00345579|Biological|Pediarix/Infanrix Penta|3-dose intramuscular injection
314517|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
314861|NCT00333112|Drug|tamsulosin|oral
314862|NCT00333112|Drug|placebo|oral
314863|NCT00333125|Drug|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
314864|NCT00333125|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
314865|NCT00002940|Drug|hydroxyurea|
314866|NCT00333125|Other|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
313780|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period <= 5 minutes (maximum infusion rate, 10 mL/min).
313781|NCT00357669|Drug|Brivaracetam 25 mg|Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 25 mg
Route of Administration: Oral use
314147|NCT00352027|Drug|Adriamycin, Vinblastine, Vincristine, Bleomycin, Etoposide, Nitrogen Mustard (Cyclophosphamide), Prednisone|See Detailed Description section for details of treatment interventions.
314148|NCT00352027|Procedure|Radiotherapy|See Detailed Description section for details of treatment interventions.
314149|NCT00352027|Drug|Etoposide, Nitrogen Mustard (Cyclophosphamide) , Vincristine, Vinblastine, Adriamycin, Bleomycin, Prednisone|See Detailed Description section for details of treatment interventions.
314150|NCT00003016|Drug|tamoxifen citrate|
314151|NCT00352053|Drug|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
314152|NCT00352053|Drug|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
314153|NCT00352066|Drug|apricitabine|
314154|NCT00352079|Biological|BCG vaccine|Intravesical BCG:
Induction:
q weekly x 6 (cycle 1)
Maintenance:
q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)
314155|NCT00352079|Drug|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
314156|NCT00352079|Procedure|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
314157|NCT00352092|Drug|calcineurin inhibitor|
314158|NCT00352092|Drug|sirolimus|
314159|NCT00352092|Drug|mycophenolate mofetil|
314160|NCT00354744|Procedure|conventional surgery|Resection of the primary tumor with a surrounding "envelope" of normal tissue
314161|NCT00354744|Radiation|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
314162|NCT00354744|Biological|filgrastim|5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.
Given subcutaneously.
314163|NCT00354757|Drug|rabeprazole|
313431|NCT00313027|Radiation|PET scan|
313432|NCT00313040|Behavioral|Brief Consultation with Health Counselor, workbook|
313433|NCT00313040|Behavioral|Usual Care wait list|
313434|NCT00313053|Drug|Human mAb 216|
313435|NCT00313053|Drug|Vincristine|
313436|NCT00002865|Biological|filgrastim|
313437|NCT00316199|Drug|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
313438|NCT00316212|Drug|INS50589 Intravenous Infusion|
313439|NCT00316225|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2) IV every 21 days for 6 cycles
313440|NCT00316238|Drug|olanzapine-RAIM|
313441|NCT00316238|Drug|placebo|
313442|NCT00316251|Device|Vibration Plate Therapy|
313443|NCT00316264|Biological|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
313444|NCT00316264|Biological|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
313445|NCT00316264|Biological|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
313782|NCT00357669|Drug|Brivaracetam 50 mg|Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 50 mg
Route of Administration: Oral use
313783|NCT00360802|Behavioral|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
313784|NCT00360815|Behavioral|Insulin|
313785|NCT00360828|Drug|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride [CPT-11; CAMPTOSAR] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
313786|NCT00360828|Drug|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
312720|NCT00332241|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
312721|NCT00002932|Radiation|radiation therapy|
312722|NCT00332254|Drug|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
313079|NCT00322478|Behavioral|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
313080|NCT00322478|Behavioral|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
313081|NCT00325299|Drug|Magnesium|
313082|NCT00002898|Drug|etoposide|
313083|NCT00325312|Drug|carbon dioxide, subcutaneous application|
313084|NCT00325325|Drug|everolimus and tacrolimus|
313085|NCT00325338|Biological|Ragweed MATAMPL|
313086|NCT00325351|Drug|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
313087|NCT00325364|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
313088|NCT00325364|Drug|Injectable insulin|patient specific dose, injectable, before meals, 24 months
313089|NCT00325377|Procedure|MME Procedure|
313090|NCT00325390|Drug|clopidogrel (SR25990C)|
313091|NCT00325403|Drug|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
313092|NCT00325403|Other|Placebo|Placebo oral tablet twice daily
313093|NCT00002898|Drug|ifosfamide|
313094|NCT00325416|Drug|melphalan|(Days -4,-3,-2) 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2)
313095|NCT00325416|Drug|topotecan (TPT)|Phase I Dose Escalation: Level 1 - 20 mg/m^2; Level 2 - 30 mg/m^2; Level 4 - 54 mg/m^2; Level 5 - 72 mg/m^2; Level 6 - 96 mg/m^2; Level 7 - 127.8 mg/m^2; Level 8 - 170.1 mg/m^2
Phase II: Treatment at maximum tolerated dose (MTD)
313096|NCT00325416|Procedure|Autologous Stem Cell Rescue|Day 0
312353|NCT00344513|Drug|Beta-blockers including Carvedilol|
312354|NCT00344513|Drug|ACE inhibitors|
312355|NCT00002984|Radiation|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
312356|NCT00347763|Procedure|10% permethrin in water applied as low volume spray|
312357|NCT00347776|Drug|azithromycin|oral antibiotic
312358|NCT00347776|Drug|topical tetracycline|
312359|NCT00003000|Drug|fentanyl citrate|
312360|NCT00347789|Procedure|Glaucoma surgery- Bleb revision|
312361|NCT00347802|Drug|Bimatoprost 0.03%, Travoprost 0.004%|
312723|NCT00335374|Drug|Pardoprunox|12 -42 mg
312724|NCT00335400|Drug|Anesthetic Dilating Gel|
312725|NCT00002949|Drug|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
312726|NCT00335413|Drug|Spironolactone|
312727|NCT00335426|Procedure|Spinal manipulative therapy|
312728|NCT00335439|Drug|ketorolac tromethamine 0.5% (Acular®)|
312729|NCT00335452|Drug|Clopidogrel|oral administration
312730|NCT00335452|Drug|acetylsalicyclic acid (ASA)|oral administration
312731|NCT00335465|Drug|Insulin glargine|once a daily, sc injection, 100IU/ml
312732|NCT00335478|Drug|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.
312733|NCT00335491|Behavioral|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
312734|NCT00335491|Procedure|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
312735|NCT00335491|Procedure|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
312736|NCT00002949|Drug|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
307509|NCT00002658|Drug|tretinoin|
307510|NCT00248807|Other|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
307511|NCT00248820|Procedure|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
307512|NCT00248833|Biological|Meningococcal 44/76 MOS NOMV 5D|
307513|NCT00248846|Behavioral|Positive affect and self-affirmation induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
307514|NCT00248872|Behavioral|Positive affect and self-affirmation induction|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
307515|NCT00248885|Procedure|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
307516|NCT00248898|Behavioral|Semi-structured and structured interview|A retrospective analysis was performed on these patients highlighting their clinical history, coronary risk factors, peri-operative course, and survival at specified post-operative endpoints.
307517|NCT00248911|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
307518|NCT00248924|Behavioral|Social Services|
307519|NCT00248937|Behavioral|Positive affect and self-affect induction|
307520|NCT00002658|Procedure|allogeneic bone marrow transplantation|
307521|NCT00251771|Procedure|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
307522|NCT00251784|Drug|Sildenafil|
307523|NCT00251797|Drug|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
306856|NCT00218686|Behavioral|psychoeducational|psychoeducational
306857|NCT00218686|Behavioral|control|VTC
306858|NCT00218699|Behavioral|Cognitive-Behavioral Intervention|
306859|NCT00218712|Behavioral|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
306860|NCT00218712|Behavioral|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
306861|NCT00218725|Behavioral|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
307168|NCT02719912|Device|mitral valve replacement|transcatheter mitral valve replacement
307169|NCT02719925|Other|Mg(+)|1,5 L per day during 30 days
No livestyle counseling
307170|NCT02719925|Other|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
307171|NCT02719938|Behavioral|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
307172|NCT02719951|Drug|[18F]FPEB PET imaging|PET exam
307173|NCT02719951|Other|Biological samples|blood sample and urine sample
307174|NCT02719951|Other|MRI|MRI exam
307175|NCT02719964|Other|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
307176|NCT02719964|Other|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
306490|NCT00002604|Drug|chemosensitization/potentiation therapy|
306491|NCT00230347|Procedure|Stereotactic radiosurgery|
306492|NCT00230373|Drug|imiquimod 5% cream (Aldara)|
306493|NCT00230386|Device|MRI|
306494|NCT00230399|Drug|Celecoxib|
306495|NCT00230399|Drug|Capecitabine|
306496|NCT00230399|Drug|Irinotecan|
306497|NCT00230438|Procedure|External Beam Radiotherapy|
306498|NCT00230451|Procedure|Radiation|
306499|NCT00230451|Drug|Paclitaxel|
306500|NCT00230451|Drug|Cisplatin|
306501|NCT00002608|Drug|cisplatin|
306502|NCT00230451|Drug|5-Fluorouracil|
306503|NCT00230464|Drug|LAF 237|
306504|NCT00230477|Drug|Hepsera|
306505|NCT00230477|Drug|Hepsera and lamivudine|
306506|NCT00230490|Drug|pradefovir mesylate|
306507|NCT00230490|Drug|adefovir dipivoxyl|
306508|NCT00230503|Drug|pradefovir mesylate|
306509|NCT00002618|Drug|methotrexate|
306510|NCT00234039|Drug|gemcitabine hydrochloride|
313941|NCT00323037|Drug|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
313942|NCT00323037|Drug|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
313943|NCT00323050|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
313944|NCT00323063|Drug|gemcitabine hydrochloride|Given IV
312858|NCT00351403|Drug|Ribavirin|Rebetol 200 mg: applied as hard capsule
312859|NCT00351403|Drug|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
312860|NCT00351416|Drug|Letrozole|Letrozole 20mg orally one time
312861|NCT00351416|Drug|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
312862|NCT00351416|Drug|GnRH|For GnRH-deficient subjects only: 75 ng/kg GnRH IV
312863|NCT00354367|Drug|Certolizumab pegol|
312864|NCT00354380|Drug|Methylene blue|
312865|NCT00354380|Drug|Artesunate|
313214|NCT00338702|Procedure|Autologous Platelet Gel|
313215|NCT00338715|Device|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
313216|NCT00344773|Drug|Gefitinib|250mg tablet oral tablet once daily
313217|NCT00344786|Drug|CNF2024 (BIIB021)|Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.
Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment.
313218|NCT00344812|Drug|LAAM. buprenorphine and methadone|
313219|NCT00344825|Drug|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.
QoL at baseline, Change in QoL over time evaluated using an analysis of Variance.
313220|NCT00344838|Device|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
313221|NCT00002986|Drug|carmustine|
313222|NCT00344851|Drug|metformin, exenatide or combined (metformin & exenatide )|
313223|NCT00344864|Device|LADARWave|
313224|NCT00344890|Procedure|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
313225|NCT00344916|Drug|Ng-monomethyl-L-arginine (drug)|
312495|NCT00003063|Drug|leucovorin calcium|
312496|NCT00360360|Drug|carboplatin|Carboplatin AUC 6.0 IV Day 1
312497|NCT00360360|Drug|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
312498|NCT00360360|Drug|erlotinib|Erlotinib 150 mg by mouth daily
312499|NCT00360386|Drug|Clopidogrel|
312500|NCT00360399|Drug|Escitalopram|Escitalopram 10 to 20 mg per day for 12 weeks
312501|NCT00360399|Drug|Duloxetine|Duloxetine 30 to 60 mg per day for 12 weeks
312502|NCT00360399|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 16 one-hour sessions provided over 12 weeks.
312503|NCT00360412|Drug|E2007|
312504|NCT00360425|Drug|ferumoxytol|
312505|NCT00363090|Drug|vincristine sulfate|
312506|NCT00363090|Other|flow cytometry|
312507|NCT00003080|Drug|endocrine-modulating drug therapy|
312508|NCT00363090|Other|pharmacological study|
312509|NCT00363116|Drug|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
312510|NCT00363129|Dietary Supplement|vitamin E|Given orally
312511|NCT00363129|Other|placebo|Given orally
312512|NCT00363142|Drug|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
312513|NCT00363142|Drug|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
312514|NCT00363155|Drug|KRN7000|
312866|NCT00354380|Drug|Amodiaquine|
312867|NCT00003032|Drug|cisplatin|
312868|NCT00354393|Drug|cisplatin|
312869|NCT00354393|Drug|methotrexate|
312870|NCT00354393|Drug|vinorelbine ditartrate|
311768|NCT00324857|Behavioral|Decision Aid Video|The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled "Treatment Choices for Knee Osteoarthritis." The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.
311769|NCT00324857|Behavioral|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
311770|NCT00324857|Behavioral|MI plus Decision aid|Patient viewed the video and then underwent MI.
311771|NCT00324857|Other|Attention control|patients received a booklet.
311772|NCT00324870|Drug|vorinostat|Given orally
311773|NCT00002897|Procedure|conventional surgery|
311774|NCT00324870|Drug|bevacizumab|Given IV
312120|NCT00315744|Drug|SERETIDE|
312121|NCT00315744|Drug|Salmeterol|
312122|NCT00315744|Drug|Fluticasone propionate|
312123|NCT00315757|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
312124|NCT00315757|Biological|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
312125|NCT00315757|Drug|Bortezomib|1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
312126|NCT00315770|Procedure|weight loss diets for young adults|
312127|NCT00002863|Drug|chemotherapy|
312128|NCT00315796|Device|Biophilic Nature Scene and Sound|
312129|NCT00318708|Drug|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
312130|NCT00318708|Drug|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
312131|NCT00318708|Drug|placebo clarithromycin|placebo clarithromycin twice daily
312132|NCT00318721|Device|Long Lasting Impregnated Nets (LLIN)|Distribution of LLIN in selected clusters
311778|NCT00328471|Behavioral|care management|
311779|NCT00328484|Behavioral|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
311780|NCT00328484|Behavioral|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
311781|NCT00002913|Drug|paclitaxel|Given IV
311782|NCT00328497|Drug|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
311783|NCT00328510|Device|GTC frame|
311784|NCT00328510|Device|Thermoplastic facemask|
311785|NCT00328510|Radiation|Stereotactic radiation therapy|
311786|NCT00328523|Drug|MK-0653, ezetimibe|
311787|NCT00328523|Drug|Duration of Treatment: 3 months|
311788|NCT00328536|Drug|Omacor|
311789|NCT00328549|Drug|Pegylated Interferon and Ribavirin|
311790|NCT00328562|Drug|ZD1839 (Iressa)|
311791|NCT00328562|Radiation|Thoracic Radiotherapy|
311792|NCT00002913|Drug|cisplatin|Given IV
311793|NCT00328575|Radiation|Intensity-Modulated Radiotherapy (IMRT)|The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.
For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the "inverse method" of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing.
311794|NCT00328588|Drug|YM155|IV
311795|NCT00328601|Drug|Thioctic Acid|
311796|NCT00328614|Drug|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
311072|NCT00350454|Device|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
311073|NCT00350467|Drug|ER OROS paliperidone and Olanzapine|
311074|NCT00350480|Drug|Provera|
311075|NCT00003012|Drug|cyclophosphamide|
311076|NCT00350480|Drug|Combination Birth Control pills|
311077|NCT00350506|Device|64 Channel VCT|
311078|NCT00350519|Drug|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
311079|NCT00350519|Drug|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
311080|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
311081|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
311082|NCT00350545|Drug|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
311430|NCT00337675|Drug|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
311431|NCT00337688|Device|isometric joystick|isometric joystick
311432|NCT00002964|Other|fluorophotometry|
311433|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
311434|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
311435|NCT00337714|Procedure|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
311436|NCT00337714|Procedure|CVC cannulation|placement of conventional trilumen CVCs
311437|NCT00337727|Drug|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
311438|NCT00337727|Drug|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
311439|NCT00337727|Drug|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
316319|NCT00349674|Drug|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
316320|NCT00349687|Behavioral|self-control practice|
316321|NCT00349700|Procedure|Compression: 2 weeks four layer bandages, then stockings|
316322|NCT00003008|Drug|nelfinavir mesylate|
316663|NCT00336973|Drug|efalizumab|Subcutaneous repeating dose
316664|NCT00000468|Drug|tissue plasminogen activator|
316665|NCT00002961|Drug|methotrexate|methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.
Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is >2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted.
316666|NCT00336986|Drug|recombinant interleukin-21|
316667|NCT00337038|Drug|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
316668|NCT00337051|Drug|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
316669|NCT00337051|Drug|Propofol|General anesthesia with propofol TCI
316670|NCT00337064|Procedure|Radiation Therapy|
316671|NCT00337077|Drug|eribulin mesylate|Given IV
316672|NCT00337090|Drug|YM178|
316673|NCT00337103|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
316674|NCT00337103|Drug|Capecitabine|Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
316675|NCT00337116|Drug|iso sorbide dinitrate iv bolus or s/l|
316676|NCT00002961|Procedure|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
316677|NCT00337129|Drug|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
316678|NCT00337155|Drug|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
316679|NCT00337168|Drug|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
315944|NCT00358566|Biological|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
315945|NCT00358566|Drug|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
315946|NCT00003055|Drug|cisplatin|
315947|NCT00358579|Drug|Adrenaline|1 mg
315948|NCT00358579|Drug|Vasopressin|40 IU
315949|NCT00358592|Device|Mobius™ retractor|
315950|NCT00358592|Device|traditional metal retraction instruments|
315951|NCT00358605|Device|The Klearway™ oral appliance|See Detailed Description.
315952|NCT00358618|Drug|Propofol|See Detailed Description.
315953|NCT00358631|Drug|SSR149415|
315954|NCT00358644|Drug|Decitabine|20 mg/m^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
315955|NCT00358657|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
315956|NCT00358657|Drug|Cyclophosphamide|Given IV
315957|NCT00003055|Drug|irinotecan hydrochloride|
315958|NCT00358657|Drug|Fludarabine Phosphate|Given IV
315959|NCT00358657|Other|Laboratory Biomarker Analysis|Correlative studies
315960|NCT00358657|Drug|Mycophenolate Mofetil|Given PO
316323|NCT00349700|Procedure|debridement|
316324|NCT00349700|Procedure|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
316325|NCT00349713|Biological|FMP2.1/AS02A|
316326|NCT00349713|Biological|Rabies vaccine|
316327|NCT00349726|Drug|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
316328|NCT00349726|Drug|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
315218|NCT00323466|Procedure|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
315219|NCT00323479|Drug|Anastrozole|1mg/Day oral
315220|NCT00323492|Drug|Truvada|Truvada + NNRTI or PI.
315221|NCT00323492|Drug|Current HAART regimen|Maintain baseline regimen
315222|NCT00002889|Drug|flutamide|
315223|NCT00323505|Drug|Pegylated Interferon|
315224|NCT00323505|Drug|Interferon-alpha2a|
315225|NCT00323518|Drug|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
315574|NCT00313950|Biological|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
315575|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
315576|NCT00313963|Drug|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
315577|NCT00313963|Drug|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
315578|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
315579|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
315580|NCT00002854|Drug|etoposide|
315581|NCT00313989|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants
315582|NCT00314002|Device|Mechanical Thrombectomy|
315583|NCT00314015|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
315584|NCT00314015|Procedure|Questionnaires|Questionnaires will be used
315585|NCT00314028|Behavioral|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
315586|NCT00314028|Other|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
315587|NCT00314041|Biological|Meningococcal C|
314867|NCT00333138|Drug|FTY720|FTY720 capsule was taken orally once a day
314868|NCT00333138|Drug|Placebo|Placebo 1.25 mg capsule was given once daily
314869|NCT00333151|Drug|liraglutide|
314870|NCT00333151|Drug|rosiglitazone|
314871|NCT00333151|Drug|metformin|
314872|NCT00333164|Drug|Asprin, Cilostazol|
314873|NCT00333177|Behavioral|Cognitive remediation|Cognitive remediation training includes computerized cognitive training plus learning skills group.
314874|NCT00333177|Behavioral|Health behavior training|Health behavior training includes group skills training in nutrition, exercise, and relaxation.
314875|NCT00333177|Drug|Risperidone, administered orally|Oral risperidone at dosage judged optimal by treating psychiatrist
314876|NCT00002941|Drug|carmustine|
314877|NCT00333177|Drug|Risperidone, administered via injection|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
314878|NCT00333177|Behavioral|Individual Placement and Support|Supported education/employment
314879|NCT00333190|Device|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
314880|NCT00333203|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
314881|NCT00333203|Other|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
314882|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
314883|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
314884|NCT00333216|Other|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
315226|NCT00323518|Drug|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
315227|NCT00323531|Procedure|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
315228|NCT00323531|Procedure|VATS decortication|thoracoscopic decortication
315229|NCT00323544|Drug|zidovudine and lamivudine (Combivir®)|
314164|NCT00003035|Drug|paclitaxel|
314165|NCT00354770|Drug|Placebo|daily
314166|NCT00354770|Drug|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
314167|NCT00354809|Drug|GW679769|
314168|NCT00354822|Drug|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
314169|NCT00354835|Drug|Irinotecan Hydrochloride|Given IV
314518|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
314519|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
314520|NCT00345605|Drug|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
314521|NCT00345605|Drug|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
314522|NCT00345618|Drug|Idrabiotaparinux sodium|0.5 mL pre-filled syringe for 3.0 mg
Subcutaneous injection
314523|NCT00345618|Drug|Warfarin|Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)
Oral administration
314524|NCT00002987|Radiation|radiation therapy|
314525|NCT00345618|Drug|Placebo (for idrabiotaparinux sodium)|0.5 mL pre-filled syringe
Subcutaneous injection
314526|NCT00345618|Drug|Avidin|100 mg in 10 mg/mL solution
Intravenous infusion for 30 minutes
314527|NCT00345618|Drug|Placebo (for warfarin)|Warfarin matching capsules
Oral administration
314528|NCT00345618|Drug|Enoxaparin|Prefilled syringes as locally registered
Subcutaneous injection
314529|NCT00345631|Other|Manual Compression|Manual compression
314530|NCT00345631|Device|Vascular Closure Device|Investigational vascular closure device
314531|NCT00345644|Drug|risedronate|risedronate sodium 35 mg tablets (once a week dose)
313787|NCT00360841|Procedure|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
313788|NCT00360841|Procedure|Sham auricular acupuncture|
313789|NCT00360854|Drug|erlotinib hydrochloride|
313790|NCT00360854|Genetic|mutation analysis|
313791|NCT00003064|Drug|topotecan hydrochloride|
313792|NCT00360854|Genetic|polymorphism analysis|
313793|NCT00360854|Other|laboratory biomarker analysis|
313794|NCT00360854|Other|pharmacological study|
313795|NCT00360854|Radiation|radiation therapy|
313796|NCT00360867|Drug|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
313797|NCT00360906|Drug|Triomar™ (omega-3 fatty acids)|
313798|NCT00360919|Behavioral|cheese ingestion|On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.
Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.
At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal.
313799|NCT00360932|Device|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
313800|NCT00360945|Drug|cisplatin|
313801|NCT00360945|Drug|temozolomide|
314170|NCT00354835|Biological|Dactinomycin|Given IV
314171|NCT00354835|Drug|Cyclophosphamide|Given IV
314172|NCT00354835|Drug|Vincristine Sulfate|Given IV
314173|NCT00354835|Radiation|Radiation Therapy|Undergo radiotherapy
314174|NCT00354835|Other|Laboratory Biomarker Analysis|Correlative studies
314175|NCT00003035|Drug|tamoxifen citrate|
313097|NCT00325429|Drug|Vildagliptin|
313098|NCT00325442|Drug|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
313099|NCT00325442|Drug|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
313100|NCT00325455|Drug|MK0859|
313101|NCT00325468|Drug|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
313446|NCT00316277|Behavioral|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
313447|NCT00000461|Drug|pravastatin|
313448|NCT00002865|Drug|cyclophosphamide|
313449|NCT00316277|Behavioral|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
313450|NCT00316290|Behavioral|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
313451|NCT00316290|Behavioral|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
313452|NCT00316303|Drug|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
313453|NCT00316303|Behavioral|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
313454|NCT00316316|Behavioral|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
313455|NCT00316316|Behavioral|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
313456|NCT00316329|Drug|Artesunate + Amodiaquine|
312737|NCT00335491|Procedure|physical therapy|12 weeks of 3x/week training on the eccentron
312738|NCT00335504|Drug|oligofructose-enriched inulin|Given orally
312739|NCT00335504|Drug|sulindac|Given orally
312740|NCT00335504|Drug|placebo|Given orally
312741|NCT00335504|Drug|atorvastatin calcium|Given orally
312742|NCT00335504|Other|laboratory biomarker analysis|Correlative studies
312743|NCT00335517|Drug|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
312744|NCT00335543|Drug|cisplatin|
312745|NCT00335543|Drug|gemcitabine hydrochloride|
312746|NCT00335543|Procedure|adjuvant therapy|
313102|NCT00325481|Drug|FluMist|
313103|NCT00325494|Drug|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m^2 up to 400 mg/m^2.
313104|NCT00002898|Drug|vincristine sulfate|
313105|NCT00325507|Biological|TroVax®|
313106|NCT00325533|Behavioral|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
313107|NCT00325533|Other|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
313108|NCT00325546|Drug|Rimonabant (SR141716)|
313109|NCT00329004|Drug|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
313110|NCT00329017|Procedure|Fine needle aspiration|Fine needle aspiration
313111|NCT00329030|Drug|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); VP-16 100 mg/m2 BID (Days -5 to -2); Cytarabine 100 mg/m2 BID (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
307859|NCT00235014|Drug|trandolapril/verapamil|180/2 mg QD
307860|NCT00235014|Drug|placebo|1 tablet QD
307861|NCT00238368|Drug|busulfan|
307862|NCT00238368|Drug|cisplatin|
307863|NCT00238368|Drug|cyclophosphamide|
307864|NCT00238368|Drug|cytarabine|
307865|NCT00238368|Drug|doxorubicin hydrochloride|
307866|NCT00238368|Drug|etoposide|
307867|NCT00238368|Drug|methylprednisolone|
307868|NCT00238368|Drug|prednisone|
307869|NCT00238368|Drug|vincristine sulfate|
307870|NCT00002631|Drug|chemotherapy|
307871|NCT00238368|Procedure|autologous bone marrow transplantation|
307872|NCT00238368|Procedure|peripheral blood stem cell transplantation|
307873|NCT00238368|Procedure|positron emission tomography|
307874|NCT00238368|Radiation|fludeoxyglucose F 18|
307875|NCT00238368|Radiation|radiation therapy|
307876|NCT00238381|Procedure|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
307877|NCT00238381|Procedure|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
307878|NCT00238381|Procedure|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
307879|NCT00238394|Drug|cediranib maleate|Given orally
307880|NCT00238394|Other|laboratory biomarker analysis|Correlative studies
307881|NCT00002631|Drug|cisplatin|
307882|NCT00238407|Drug|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
307177|NCT02719964|Other|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
307178|NCT00207688|Drug|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
307179|NCT00207688|Drug|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
307180|NCT00207701|Drug|infliximab|
307181|NCT00207714|Drug|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
307182|NCT00207714|Drug|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
307183|NCT00207714|Drug|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
307184|NCT00002552|Procedure|in vitro-treated bone marrow transplantation|
307185|NCT00207714|Drug|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
307186|NCT00207727|Drug|CNTO 1275|
307524|NCT00251797|Drug|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
307525|NCT00251810|Device|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
307526|NCT00251823|Drug|Eptifibatide facilitated PCI|
307527|NCT00251836|Procedure|Laparoscopic hand-assisted donor nephrectomy|
307528|NCT00002669|Drug|dacarbazine|
307529|NCT00251849|Drug|Rifalazil|
307530|NCT00251862|Behavioral|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
307531|NCT00251862|Behavioral|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
307532|NCT00251862|Behavioral|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
307533|NCT00251875|Device|online health information journal|
307534|NCT00251888|Drug|campto (irinotecan)|
313945|NCT00325767|Drug|nebulized placebo (3ml/dose)|
313946|NCT00002898|Procedure|neoadjuvant therapy|
313947|NCT00325780|Drug|Pitavastatin|Pitavastatin 4 mg once daily
313948|NCT00325793|Drug|Nicardipine|
313949|NCT00325806|Drug|Ramipril|
313950|NCT00325819|Drug|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
313951|NCT00325819|Other|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
313952|NCT00325832|Device|BpTRU|
313953|NCT00325832|Device|Conventional mercury sphygmomanometry|
313954|NCT00325845|Procedure|Synvisc viscosupplementation|
313955|NCT00325858|Drug|Tramadol HCl ER|
313956|NCT00325871|Procedure|concurrent chemoradiation|
313957|NCT00000464|Drug|mexiletine|
313958|NCT00002898|Radiation|brachytherapy|
313959|NCT00325897|Drug|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
313960|NCT00325897|Drug|Placebo|Placebo taken on a daily basis
313961|NCT00325910|Drug|Metformin|
313962|NCT00325923|Behavioral|Decision aid|
313963|NCT00325936|Drug|Cilnidipine|10~20mg, qd, po for 3 months or 12 months.
313964|NCT00325949|Drug|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
313965|NCT00325949|Drug|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
313966|NCT00325949|Drug|placebo|2 tablets BID
314310|NCT00002865|Drug|ifosfamide|
314311|NCT00316745|Drug|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
313226|NCT00344942|Drug|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
313227|NCT00344942|Drug|placebo|a double spray into each nostril once daily
313228|NCT00344955|Drug|HMG-CoA reductase inhibition (atorvastatin)|
313229|NCT00344968|Drug|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
313230|NCT00344968|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
313231|NCT00344968|Procedure|Standard of care laser photocoagulation|Laser photocoagulation
313232|NCT00002986|Drug|topotecan hydrochloride|
313233|NCT00344981|Drug|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
313572|NCT00332644|Drug|nicotine patch|used according to FDA package label
313573|NCT00332644|Drug|nicotine lozenge|used according to FDA-approved package directions
313574|NCT00332644|Drug|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
313575|NCT00332644|Drug|bupropion|dosage according to FDA-approved instructions
313576|NCT00002936|Drug|altretamine|
313577|NCT00332644|Drug|bupropion + lozenge|dosage according to FDA approved standard instructions
313578|NCT00332644|Drug|placebo|dosage same as active drug conditions
313579|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
313580|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
313581|NCT00332657|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
313582|NCT00332670|Procedure|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
313583|NCT00332670|Procedure|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
313584|NCT00332683|Procedure|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
312871|NCT00354393|Procedure|adjuvant therapy|
312872|NCT00354393|Procedure|conventional surgery|
312873|NCT00354393|Procedure|neoadjuvant therapy|
312874|NCT00354393|Radiation|3-dimensional conformal radiation therapy|
312875|NCT00354393|Radiation|intensity-modulated radiation therapy|
312876|NCT00354406|Drug|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
312877|NCT00354419|Radiation|total-body irradiation|Undergo radiotherapy
312878|NCT00003032|Drug|cyclophosphamide|
312879|NCT00354419|Drug|cyclophosphamide|Given IV
312880|NCT00354419|Biological|anti-thymocyte globulin|Given IV
312881|NCT00354419|Drug|cyclosporine|Given IV
312882|NCT00354419|Procedure|umbilical cord blood transplantation|Undergo transplantation
312883|NCT00354419|Drug|mycophenolate mofetil|Given IV or orally
312884|NCT00354419|Procedure|bone marrow aspiration|Correlative study
312885|NCT00354419|Genetic|DNA analysis|Correlative study
312886|NCT00354419|Biological|filgrastim|Given IV or SC
312887|NCT00354432|Dietary Supplement|soy isoflavones|Given orally
312888|NCT00354432|Dietary Supplement|soy protein isolate|Given orally
312889|NCT00003032|Drug|mitoxantrone hydrochloride|
312890|NCT00354432|Drug|venlafaxine|Given orally
312891|NCT00354432|Drug|placebo|Given orally
312892|NCT00354445|Drug|pegaptanib sodium (Macugen)|
312893|NCT00354458|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
312133|NCT00318747|Drug|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
312134|NCT00318760|Drug|Clonidine|0.1 or 0.2 mg oral, one dose
312135|NCT00318760|Drug|Placebo|oral capsule 1 dose
312136|NCT00002872|Drug|doxycycline|
312137|NCT00318773|Drug|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
312138|NCT00318786|Drug|biphasic insulin aspart|
312139|NCT00318799|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
312140|NCT00318799|Drug|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
312141|NCT00318812|Drug|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
312142|NCT00318812|Drug|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
312143|NCT00318825|Drug|Nitrous oxide|
312515|NCT00363168|Drug|Ranibizumab|0.3 mg/0.05 ml dose
312516|NCT00363168|Drug|Ranibizumab|0.5 mg/0.05 ml dose
312517|NCT00363194|Drug|Pazopanib (GW786034)|
312518|NCT00003080|Drug|melphalan|
312519|NCT00363233|Drug|flax lignans|
312520|NCT00363259|Drug|Peginterferon alfa-2b|
312521|NCT00363259|Drug|Ribavirin|
312522|NCT00363272|Drug|ispinesib|Given IV
312523|NCT00363272|Other|laboratory biomarker analysis|Correlative studies
312524|NCT00363272|Other|pharmacological study|Correlative studies
312525|NCT00363285|Biological|gonadotrophin releasing hormone|
312526|NCT00363285|Drug|cyproterone acetate|
312527|NCT00363285|Procedure|quality-of-life assessment|
312144|NCT00318838|Drug|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
312145|NCT00318838|Drug|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
312146|NCT00318851|Device|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
312147|NCT00002872|Other|talc|
312148|NCT00318864|Behavioral|Cognitive behavioral therapy|
312149|NCT00318877|Behavioral|After school team sports program|
312150|NCT00318877|Behavioral|After school health education program|
312151|NCT00318890|Drug|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
312152|NCT00318890|Drug|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
312153|NCT00318890|Procedure|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
312154|NCT00318890|Drug|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
312155|NCT00318903|Drug|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
312156|NCT00322101|Drug|busulfan|Given IV or orally
312157|NCT00322101|Drug|cyclosporine|Given IV or orally
312158|NCT00322101|Drug|fludarabine phosphate|Given IV
312159|NCT00322101|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
312160|NCT00322101|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
312161|NCT00322101|Other|laboratory biomarker analysis|Correlative studies
312162|NCT00322101|Genetic|cytogenetic analysis|Correlative studies
312163|NCT00002883|Procedure|neoadjuvant therapy|
312164|NCT00322101|Other|flow cytometry|Correlative studies
311440|NCT00337727|Drug|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
311441|NCT00337727|Drug|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
311442|NCT00337727|Drug|Comparator; Placebo (unspecified)|Aprepitant 80 mg & 125 mg Pbo capsules.
311443|NCT00000469|Drug|aspirin|
311444|NCT00002965|Biological|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
311445|NCT00337740|Procedure|endoscopic variceal banding|
311446|NCT00337740|Drug|propranolol|
311447|NCT00337753|Behavioral|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
311448|NCT00337753|Behavioral|Wait-list|subjects assigned to wait-list condition for six-weeks
311449|NCT00337766|Drug|Desmopressin (DDAVP)|
311450|NCT00337766|Drug|Placebo|
311451|NCT00337779|Drug|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
311452|NCT00337779|Drug|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
311453|NCT00337792|Drug|oxycodone + lorazepam versus fentanyl + midazolam|
311454|NCT00343811|Drug|Modafinil|
311797|NCT00328614|Drug|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
311798|NCT00328614|Drug|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
311799|NCT00331630|Drug|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
311800|NCT00331643|Drug|ixabepilone|Given IV
311801|NCT00331656|Device|Non-invasive positive pressure mask ventilators|
311802|NCT00331656|Device|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
316680|NCT00337168|Drug|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
316681|NCT00337194|Biological|monoclonal antibody SGN-30|Given IV
316682|NCT00343187|Drug|ACZONE (dapsone) Gel, 5%|
316683|NCT00343187|Drug|Vehicle Control|
316684|NCT00343200|Drug|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
311083|NCT00350545|Drug|Prednisone|1 mg/kg; po per day with taper
311084|NCT00350545|Drug|cyclosporine A|trough 200-300 or lower; po
311085|NCT00350545|Drug|tacrolimus|trough 5-10 or lower; po
311086|NCT00003012|Drug|epirubicin hydrochloride|
311087|NCT00350571|Behavioral|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
311088|NCT00350571|Behavioral|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
311089|NCT00350571|Behavioral|standard care follow up|routine counselor phone calls and letters
311090|NCT00350584|Behavioral|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
311091|NCT00350584|Behavioral|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
311092|NCT00350597|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
311093|NCT00350610|Other|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
311094|NCT00350610|Behavioral|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
311095|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
311096|NCT00353704|Drug|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
311097|NCT00353704|Drug|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
316329|NCT00349726|Drug|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
316330|NCT00349726|Drug|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
316331|NCT00349739|Drug|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
316332|NCT00349752|Biological|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
316333|NCT00003008|Drug|paclitaxel|
316334|NCT00352885|Drug|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
316335|NCT00352898|Biological|MeMuRu-OKA (study vac)|
316336|NCT00352898|Biological|MMR, Varicella vacc (control)|
316337|NCT00352911|Drug|VGX-410 (Mifepristone)|
316338|NCT00352911|Drug|Placebo for VGX-410 (Mifepristone)|
316339|NCT00352950|Drug|AMG 954/Panitumumab|
316340|NCT00352963|Biological|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
316341|NCT00003023|Biological|BCG vaccine|
316342|NCT00352976|Drug|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
316343|NCT00352976|Drug|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m^2 intravenous (IV)
316344|NCT00352976|Procedure|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
316685|NCT00343200|Drug|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
316686|NCT00002980|Drug|decitabine|
316687|NCT00343213|Procedure|colposcopy|
316688|NCT00343226|Drug|Basiliximab|
315588|NCT00314041|Biological|DTP/Hib|
315589|NCT00314054|Drug|HCV-796|HCV-796 1000mg single dose
315590|NCT00317070|Drug|dimethyl sulfoxide|intravesical installation 50 ml
315591|NCT00317070|Drug|IC Cocktail|Heparin 10,000 units
Gentamicin 80 mg
Hydrocortisone sodium succinate (Solucortef) 100 mg
Lidocaine hydrochloride 1% 10 ml
Sodium Bicarbonate 8.4% 5 ml
315592|NCT00317083|Procedure|Cough reflex test|
315593|NCT00317096|Procedure|FCM|Active comparator: Chemotherapy
315594|NCT00317096|Procedure|R-FCM|experimental: Chemotherapy with additional rituximab
315595|NCT00317096|Drug|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
315596|NCT00002865|Radiation|low-LET photon therapy|
315597|NCT00317096|Other|observation only|no Intervention after completion of FCM or R-FCM
315961|NCT00361543|Drug|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
315962|NCT00361543|Other|Lactose Capsules|1 tablet daily for 12 weeks
315963|NCT00361556|Behavioral|The Back Book|A book on how to prevent back pain
315964|NCT00361556|Behavioral|The Back Guide|A guide for the prevention of back pain.
315965|NCT00361556|Behavioral|General health book|A book on general health
315966|NCT00361569|Drug|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
315967|NCT00361569|Drug|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
315968|NCT00361569|Other|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
315969|NCT00361569|Other|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
315970|NCT00003068|Drug|mitoxantrone hydrochloride|
315971|NCT00361582|Drug|CG5503 IR; tapentadol|
315972|NCT00361595|Drug|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
315973|NCT00361608|Device|EarlySense ES 16|
315230|NCT00323544|Drug|emtricitabine and tenofovir DF|
315231|NCT00323557|Drug|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
315232|NCT00323557|Biological|Pneumococcal Vaccine|Subcutaneously on Day 0
315233|NCT00002889|Drug|goserelin|
315234|NCT00326495|Drug|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
315235|NCT00326495|Drug|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
315236|NCT00326508|Drug|Daclizumab|
315237|NCT00326560|Procedure|Pterygium excision and conjunctival autograft|
315238|NCT00002902|Drug|irinotecan hydrochloride|
315239|NCT00326573|Behavioral|Motivational Interviewing|
315240|NCT00326586|Drug|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
315241|NCT00326599|Drug|carboplatin|Given IV
315242|NCT00326599|Drug|cediranib maleate|Given orally
315243|NCT00326599|Drug|gemcitabine hydrochloride|Given IV
315244|NCT00326612|Drug|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
315245|NCT00326612|Drug|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
315246|NCT00326625|Drug|40 mg glatiramer acetate|parenteral drug
315247|NCT00326625|Drug|Placebo|
315598|NCT00317109|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
315599|NCT00317109|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
314532|NCT00345644|Drug|risedronate placebo|placebo for risedronate tablets (once a week dose)
314533|NCT00345657|Drug|Niacin Extended Release/Lovastatin|
314534|NCT00345670|Biological|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
314535|NCT00002988|Drug|carmustine|
314536|NCT00345670|Biological|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
314537|NCT00345670|Biological|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
314538|NCT00345683|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
314539|NCT00348842|Procedure|Newcastle Virus|
314885|NCT00333229|Drug|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
314886|NCT00333229|Drug|Placebo|Matching Placebo
314887|NCT00002941|Drug|cyclophosphamide|
314888|NCT00333242|Drug|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
314889|NCT00333255|Drug|Nepafenac Ophthalmic Suspension, 0.1%|
314890|NCT00336128|Behavioral|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
314891|NCT00336128|Behavioral|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
314892|NCT00336141|Drug|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
314893|NCT00000467|Behavioral|smoking cessation|
314894|NCT00002953|Drug|epirubicin hydrochloride|
314895|NCT00336154|Drug|tetracyclin|
314896|NCT00336167|Drug|bezafibrate (drug)|
314897|NCT00336180|Behavioral|HealthWise South Africa curriculum|18 classroom lessons
314898|NCT00336193|Behavioral|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
314899|NCT00336206|Drug|Alemtuzumab|
314176|NCT00354835|Other|Questionnaire Administration|Ancillary studies
314177|NCT00354861|Biological|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
314178|NCT00354861|Biological|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
314179|NCT00354861|Biological|Engerix B|20 µg hepatitis B antigen absorbed on alum
314180|NCT00354874|Drug|GW642444|drug
314181|NCT00354874|Drug|Placebo|placebo
314182|NCT00354874|Drug|salmeterol 50mcg|salmeterol
314183|NCT00354887|Drug|Capecitabine|Oral capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m^2) on Days 1-14 in 21 Day Cycle.
314184|NCT00354887|Drug|Oxaliplatin|130 mg/m^2 by vein Day 1 over 2 hours in 21 Day Cycle
314185|NCT00354900|Drug|Aprotinin|
314186|NCT00003035|Procedure|surgical procedure|
314187|NCT00357669|Other|Placebo|Active Substance: Placebo Pharmaceutical Form: Tablet
Concentration: 25 mg and 50 mg
Route of Administration: Oral use
314188|NCT00357682|Drug|Esomeprazole|20mg per day
314189|NCT00357682|Drug|Esomeprazole|80mg per day
314190|NCT00357682|Drug|Aspirin|300mg per day
314191|NCT00357708|Drug|decitabine|Given IV
314192|NCT00357708|Drug|vorinostat|Given orally
314193|NCT00003050|Radiation|radiation therapy|
314194|NCT00357708|Other|laboratory biomarker analysis|Correlative studies
314195|NCT00357708|Other|pharmacological study|Correlative studies
314196|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
314540|NCT00348855|Other|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
314541|NCT00348855|Behavioral|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
313457|NCT00319436|Behavioral|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
313802|NCT00003064|Procedure|peripheral blood stem cell transplantation|
313803|NCT00360945|Genetic|fluorescence in situ hybridization|
313804|NCT00360945|Genetic|loss of heterozygosity analysis|
313805|NCT00360945|Other|immunohistochemistry staining method|
313806|NCT00360945|Other|laboratory biomarker analysis|
313807|NCT00360945|Radiation|radiation therapy|
313808|NCT00363714|Drug|AGN211745|1200microgram single intravitreal injection
313809|NCT00363714|Drug|AGN211745|1600microgram single intravitreal injection
313810|NCT00363727|Drug|ropinirole controlled-release (REQUIP CR) for RLS|
313811|NCT00363740|Drug|GW685698X Aqueous Nasal Spray|
313812|NCT00363753|Drug|aspirin versus clopidogrel|
313813|NCT00363766|Drug|LY573636|A loading dose to target 380 micrograms/ml Cmax followed by a lower chronic dose to maintain Cmax within this target range, IV, every 21 days until disease progression.
313814|NCT00363779|Drug|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
313815|NCT00003081|Drug|melphalan|
313816|NCT00363779|Genetic|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
313817|NCT00363779|Genetic|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
313818|NCT00363779|Other|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
308605|NCT00216229|Biological|Combined vaccine against hepatitis A and B (Twinrix)|
308606|NCT00216242|Biological|Influenza virus vaccine (Fluviral)|
308607|NCT00000386|Behavioral|Family Counseling|
308608|NCT00002571|Biological|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
308609|NCT00216242|Biological|Saline placebo|
308610|NCT00216255|Drug|Pagoclone|
308611|NCT00216255|Drug|Placebo|
308612|NCT00216268|Drug|Ribavirin|
308613|NCT00216281|Drug|Clozapine augmented with atomoxetine up to 40 mg or placebo|
308614|NCT00216294|Drug|RG1068 (Synthetic Human Secretin)|
308615|NCT00216320|Device|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
308616|NCT00216320|Device|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
308617|NCT00216320|Device|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
308618|NCT00216333|Drug|combined fixed dose combination|
308619|NCT00002571|Drug|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
308620|NCT00216346|Drug|Paromomycin sulfate|
308621|NCT00216346|Drug|Amphotericin B|
308622|NCT00216359|Drug|Fuzeon (Enfuvirtide)|
308623|NCT00219622|Drug|tofimilast|
308996|NCT00204932|Drug|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
308997|NCT00204945|Drug|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
308998|NCT00204958|Drug|nutritional supplement|
308999|NCT00204958|Drug|glutamine popsicle|
309000|NCT00204971|Dietary Supplement|Enteral glutamine powder|nutritional supplement
307883|NCT00238407|Radiation|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
307884|NCT00238420|Drug|Paclitaxel|Given IV
307885|NCT00238420|Biological|Trastuzumab|Given IV
308232|NCT00227201|Behavioral|Self-affirmation intervention|
308233|NCT00227253|Procedure|Determination of growth hormone status|Growth hormone stimulating testing using Arginine and Clonidine, Corticotrophin releasing hormone stimulation test
308234|NCT00002598|Biological|sargramostim|
308235|NCT00227253|Procedure|Measurement of growth, thyroid and sex hormone levels|Gonadotrophin releasing hormone stimulation test Thyroid testing - T4, TSH, T3 uptake, and anti-thyroidal antibodies baseline sample - no medication administered
308236|NCT00227253|Procedure|Behavior and neuropsychometric evaluations|evaluation by neuropsychologist, standardized testing geared to study participant's age, abilities and past medical history
308237|NCT00227253|Procedure|Audiological and ear, nose and throat examination|neurotological exam, behavioral audiometry, immittance audiometry, assessment of the function of the inner ear using otoacoustic emissions, Auditory brain responses
308238|NCT00227253|Procedure|Magnetic resonance imaging of the brain|MRI of the brain - standard clinical procedure
308239|NCT00227253|Procedure|Dysmorphology evaluation|Genetic evaluation with picture and measurements, physical exam
308240|NCT00227253|Procedure|Neurology examination|physical examination including observation of balance, coordination and reflexes.
308241|NCT00227253|Procedure|Dental evaluation|Visual detal inspection with panorex X-ray of the entire mouth
308242|NCT00227253|Procedure|Speech pathology evaluation|Standardized speech & language tests and naturalistic assessment procedures.
308243|NCT00227253|Procedure|Psychiatric evaluation|Psychiatric interview about history of psychiatric and medical illnesses, family psychiatric and medical history, demographic info also obtained
308244|NCT00231283|Device|CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
308245|NCT00231296|Device|Cardiac cryoablation system|Treatment with CryoCor cardiac cryoablation system
308246|NCT00231296|Drug|Medical management|Treatment with standard medical therapy
308247|NCT00231309|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
308248|NCT00231322|Drug|praziquantel|
307535|NCT00251888|Drug|cisplatin (cisplatyl)|
307536|NCT00251901|Drug|Esomeprazole|
307537|NCT00251914|Drug|Esomeprazole|
307538|NCT00251927|Drug|esomeprazole|40 mg oral tablet administered daily
307539|NCT00002670|Drug|chemotherapy|
307540|NCT00251927|Procedure|Laparoscopic fundoplication (surgery)|Surgery
307541|NCT00251940|Drug|Tesaglitazar 0.5 or 1 mg|
307542|NCT00251940|Drug|Glibenclamide 2.5, 5, 10 or 15 mg|
307543|NCT00251953|Drug|Tesaglitazar|
307544|NCT00251953|Drug|Metformin|
307545|NCT00251966|Drug|Esomeprazole|
307546|NCT00251979|Drug|Esomeprazole|
307547|NCT00251992|Drug|Esomeprazole|
307548|NCT00252005|Drug|Apixaban|
307549|NCT00252018|Behavioral|Daily intake of broccoli sprouts|
307886|NCT00238420|Radiation|Radiation Therapy|Undergo radiation therapy
307887|NCT00238433|Biological|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC> 1500 for 2 consecutive days.
307888|NCT00238433|Drug|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
307889|NCT00238433|Drug|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
307890|NCT00238433|Drug|thiotepa|250 mg/m2/day/iv on days -3 and -2
307891|NCT00242281|Drug|APC-111 MP Tablet, 775 mg|
307892|NCT00242294|Drug|Roflumilast|
307893|NCT00242307|Drug|Roflumilast|
307894|NCT00002639|Drug|chemotherapy|
314312|NCT00316745|Drug|TS-1|S-1 Day1~14, everyday P.O.(Day 15~28 rest)
314313|NCT00316745|Drug|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
314314|NCT00316745|Drug|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
314315|NCT00316745|Drug|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1~3 (48 hours) of each 28 day cycle.
314316|NCT00316758|Drug|GK Activator (2)|Escalating doses bid
314317|NCT00316758|Drug|Metformin|As prescribed, in patients who were in study BM18249
314318|NCT00316771|Drug|P38 Inhibitor (4)|50mg po qd
314319|NCT00316771|Drug|P38 Inhibitor (4)|150mg po qd
314320|NCT00316771|Drug|P38 Inhibitor (4)|300mg po qd
314321|NCT00002865|Drug|leucovorin calcium|
314322|NCT00316771|Drug|P38 Inhibitor (4)|25mg po bid
314323|NCT00316771|Drug|P38 Inhibitor (4)|75mg po bid
314324|NCT00316771|Drug|Placebo|po bid
314325|NCT00316784|Drug|IDEA-033 (and rescue medication)|
314326|NCT00319865|Drug|Dexamethasone|
314327|NCT00319878|Drug|Sirolimus|Oral loading dose followed by a once daily dose:
Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg
Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg
Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg
Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg
314328|NCT00319878|Drug|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
314329|NCT00002875|Radiation|low-LET electron therapy|
314330|NCT00319891|Procedure|Computer-based Cognitive Training|
314331|NCT00319917|Drug|tacrolimus|oral
314332|NCT00319917|Drug|placebo|oral
314333|NCT00319930|Drug|CNF1010 (17-AAG)|
314334|NCT00319943|Procedure|Computer-based training for Mild Cognitive Impairment (MCI)|
313585|NCT00332683|Procedure|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
313586|NCT00332696|Drug|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
313587|NCT00002936|Drug|etoposide|
313588|NCT00335751|Procedure|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
313589|NCT00335764|Drug|sorafenib tosylate|
313590|NCT00335764|Drug|erlotinib hydrochloride|
313591|NCT00335764|Drug|tipifarnib|
313592|NCT00335764|Drug|temsirolimus|
313593|NCT00335777|Drug|Migranal nasal spray|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
313967|NCT00325962|Drug|6R-BH4 (sapropterin dihydrochloride)|
313968|NCT00326001|Device|Gold tip catheter|Radiofrquency ablation using gold tip catheter
313969|NCT00002898|Radiation|radiation therapy|
313970|NCT00326001|Device|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
313971|NCT00326014|Device|iStent|Glaucoma Surgery
313972|NCT00326027|Drug|Pantoprazole|Efficacy of Pantoprazole
313973|NCT00326040|Device|Glaucoma Surgery|
313974|NCT00326053|Drug|Budesonide/formoterol|
313975|NCT00326066|Device|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
313976|NCT00326066|Procedure|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
313977|NCT00329407|Drug|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
313234|NCT00344981|Drug|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches >400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
313235|NCT00344994|Drug|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
313236|NCT00345007|Procedure|Scleral buckling|
313237|NCT00345020|Procedure|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
313238|NCT00345033|Drug|Aripiprazole|15-mg dose once a day for 8 weeks
313239|NCT00345033|Drug|Placebo|1 tablet placebo dose once a day for 8 weeks
313240|NCT00348231|Drug|dual-action insulin analog|
313241|NCT00348244|Drug|Ketorolac, Prednisolone Acetate|
313242|NCT00348257|Device|Hair removal by laser/IPL device|
313243|NCT00348270|Device|Tecnis Z9000 intraocular lens|
313244|NCT00348270|Device|MA60 intraocular lens|
313245|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
313246|NCT00348283|Biological|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
313247|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
313248|NCT00348296|Drug|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
313249|NCT00348309|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
313250|NCT00003002|Biological|sargramostim|
312528|NCT00363298|Drug|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
Caffeine dosage form: 200 mg capsules in Bottle A, 100 mg capsules in Bottle B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
312529|NCT00000480|Device|defibrillators, implantable|
312530|NCT00003080|Drug|mitoxantrone hydrochloride|
312531|NCT00363311|Drug|Dutasteride|Dutasteride 0.5mg
312532|NCT00363311|Drug|Matching placebo|Matching placebo
312533|NCT00363324|Procedure|intracoronary injection of bone marrow cells|
312534|NCT00363337|Drug|aripiprazole|open label treatment with aripiprazole
312535|NCT00363350|Drug|rituximab (anti-CD20)|2 infusions of 1000 mg
312536|NCT00312429|Procedure|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
312537|NCT00312442|Drug|Treatment with WST09 Vascular Photodynamic therapy|
312538|NCT00312455|Drug|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
312539|NCT00312455|Drug|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
312540|NCT00312455|Drug|Placebo|5 capsules/day
312894|NCT00354458|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
312895|NCT00354471|Procedure|Uterine Artery Embolization|
312896|NCT00357279|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
312897|NCT00003049|Drug|leucovorin calcium|
312898|NCT00357279|Drug|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
312899|NCT00357292|Drug|Azithromycin (T1225)|
312900|NCT00357305|Drug|vorinostat|Given orally
312901|NCT00357305|Drug|cytarabine|Given IV
312902|NCT00357305|Drug|etoposide|Given IV
312165|NCT00322101|Genetic|fluorescence in situ hybridization|Correlative studies
312166|NCT00322101|Other|pharmacological study|Correlative studies
312167|NCT00322101|Genetic|polymorphism analysis|Correlative studies
312541|NCT00312481|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
312542|NCT00312481|Drug|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
312543|NCT00002847|Procedure|conventional surgery|
312544|NCT00312494|Drug|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
312545|NCT00312494|Drug|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
312546|NCT00312494|Drug|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
312547|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by lavage)|
312548|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by bolus)|
312549|NCT00312520|Drug|prednisolone|
312550|NCT00312520|Drug|methylprednisolone|
312551|NCT00312533|Drug|Hylan F- 20|
312552|NCT00312546|Drug|Enfuvirtide|90 mg subcutaneously twice daily
312553|NCT00312546|Drug|Valproic acid|500 to 750 mg, taken orally twice daily
312554|NCT00002848|Procedure|psychosocial assessment and care|
312555|NCT00312559|Behavioral|Yoga Training|
312556|NCT00312572|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
312557|NCT00312585|Procedure|Acupuncture|
312558|NCT00312585|Procedure|Sham comparator|
312559|NCT00312585|Procedure|Usual care only|
312560|NCT00312598|Drug|Aripiprazole|
311803|NCT00331669|Procedure|deep brain stimulation|high frequency stimulation
311804|NCT00002931|Drug|carboplatin|AUC=7, daily X 3
311805|NCT00331682|Drug|alvocidib|Given IV
311806|NCT00331682|Drug|docetaxel|Given IV
311807|NCT00331695|Drug|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
311808|NCT00331708|Drug|Artesunate plus sulfadoxine-pyrimethamine|
311809|NCT00331721|Drug|Enecadin|Dose escalating
311810|NCT00331721|Drug|Placebo|Placebo comparator
311811|NCT00331747|Drug|Glatiramer acetate|
311812|NCT00331760|Drug|cisplatin|
311813|NCT00331760|Radiation|intensity-modulated radiation therapy|
311814|NCT00331773|Radiation|3-dimensional conformal radiation therapy (3D-CRT)|41 or 28 treatments
311815|NCT00002931|Drug|etoposide|20 mg/kg by 2 hours infusion daily X 3
311816|NCT00331773|Radiation|hypofractionated radiation therapy|Once daily 5 days a week for 5.6 weeks
311817|NCT00331773|Radiation|Intensity-modulated radiation therapy (IMRT)|41 or 28 treatments
311818|NCT00331786|Drug|nitric oxide-releasing acetylsalicylic acid derivative|
311819|NCT00331786|Other|laboratory biomarker analysis|
311820|NCT00331786|Procedure|biopsy|
311821|NCT00331799|Drug|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
312168|NCT00322101|Drug|tacrolimus|Given IV or orally
312169|NCT00322101|Drug|methotrexate|Given IV
312170|NCT00322114|Dietary Supplement|lycopene|Given orally
312171|NCT00322114|Other|placebo|Given orally
312172|NCT00322127|Drug|AMD3100|
311098|NCT00353717|Drug|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
311099|NCT00353743|Drug|placebo|placebo
311100|NCT00353743|Drug|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
311101|NCT00353756|Drug|C326, IL-6 Inhibitory Avimer protein|
311102|NCT00353769|Procedure|Hair Apposition Technique|
311103|NCT00353795|Procedure|MR Imaging of the Coronary Arteries|
311104|NCT00353808|Drug|[S,S]-Reboxetine|
311105|NCT00003027|Drug|cisplatin|
311455|NCT00343824|Procedure|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
311456|NCT00343850|Drug|Asacol (mesalamine)|
311457|NCT00343863|Drug|palonosetron hydrochloride|Given IV
311458|NCT00343863|Drug|cyclophosphamide|Given orally
311459|NCT00343863|Drug|dexamethasone|Given orally or IV
311460|NCT00343863|Drug|doxorubicin hydrochloride|Given IV
311461|NCT00343863|Procedure|quality-of-life assessment|Ancillary studies
311462|NCT00343863|Procedure|nausea and vomiting therapy|Given IV
311463|NCT00002982|Procedure|peripheral blood stem cell transplantation|
311464|NCT00343863|Procedure|management of therapy complications|Given IV
311465|NCT00343863|Drug|ondansetron hydrochloride|Given IV
311466|NCT00343863|Other|survey administration|Ancillary studies
311467|NCT00343876|Drug|aspirin|
311468|NCT00343876|Drug|clopidogrel|
311469|NCT00343889|Biological|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
311470|NCT00343889|Biological|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
316689|NCT00343239|Drug|Docetaxel|Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2
316690|NCT00343239|Drug|Cisplatin|Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2
316691|NCT00343239|Drug|Fluorouracil|Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 750 mg/m2/day for 5 days
316692|NCT00343252|Drug|teriparatide|20 ug/day, subcutaneous, 18 months
316693|NCT00343252|Drug|risedronate|35 mg/once weekly, oral, 18 months
316694|NCT00343252|Drug|placebo|once weekly, oral, 18 months
316695|NCT00343252|Drug|placebo|daily, subcutaneous, 18 months
316696|NCT00343265|Drug|Vaginal progesterone gel|Vaginal gel once daily
316697|NCT00002981|Procedure|positron emission tomography|
316698|NCT00343265|Drug|Placebo gel|once daily
316699|NCT00343278|Drug|Valaciclovir Hydrochloride|
316700|NCT00343291|Biological|Cetuximab|Administered intravenously
316701|NCT00343291|Biological|Bevacizumab|Administered intravenously
316702|NCT00343291|Drug|Paclitaxel|Administered intravenously
316703|NCT00343291|Drug|Carboplatin|Administered intravenously
316704|NCT00343304|Device|Robot|
316705|NCT00343304|Device|Ergometer|
316706|NCT00343317|Drug|Intrapartum Cefoxitin (2g) vs. placebo|
316707|NCT00343343|Device|NovoFine® needle 6 mm|
316708|NCT00002981|Radiation|fludeoxyglucose F 18|
316709|NCT00343343|Device|NovoFine® needle 4 mm|
316710|NCT00343356|Drug|Trement|
311106|NCT00353834|Drug|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
315974|NCT00361621|Drug|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
315975|NCT00361621|Drug|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
315976|NCT00361621|Drug|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
315977|NCT00361621|Drug|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
315978|NCT00361621|Drug|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
315979|NCT00361621|Drug|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
315980|NCT00361621|Radiation|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
315981|NCT00000480|Procedure|electrophysiology|
315982|NCT00003068|Drug|thiotepa|
315983|NCT00361634|Drug|Etanercept|
315984|NCT00361647|Procedure|Diagnostic screening for occult malignancy|
316345|NCT00352976|Procedure|Bone Marrow Transplantation|A target of 5 * 10^6/kg and a minimum of 4 * 10^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
316346|NCT00352976|Drug|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 * 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
316347|NCT00352976|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
316348|NCT00352989|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
316349|NCT00353002|Drug|Ametop (4% Amethocaine cream )|
316350|NCT00353002|Drug|Maxilene (4% Liposomal Lidocaine)|
316351|NCT00353015|Drug|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
316352|NCT00003023|Biological|monoclonal antibody A1G4 anti-idiotype vaccine|
316353|NCT00353015|Drug|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
315600|NCT00317109|Biological|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
315601|NCT00317122|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
315602|NCT00317135|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
315603|NCT00317148|Drug|Dehydroepiandrosterone|
315604|NCT00317161|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
315605|NCT00317174|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
315606|NCT00317187|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
315607|NCT00002866|Biological|filgrastim|
315608|NCT00317200|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
315609|NCT00317200|Drug|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
315610|NCT00317213|Drug|LIBERTAL- a phospholipid mixture|
315611|NCT00317226|Drug|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
315612|NCT00317239|Drug|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
315613|NCT00317239|Drug|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
315614|NCT00317252|Drug|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
315615|NCT00317265|Procedure|Coronary bypass surgery|
315616|NCT00317278|Other|massage therapy|massage therapy to stable preterm infants
315617|NCT00317278|Other|Sham|Sham (placebo) provided to the control group
315618|NCT00002866|Drug|docetaxel|
315619|NCT00002878|Drug|vincristine sulfate|
315620|NCT00320515|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
315621|NCT00320528|Drug|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
314900|NCT00336219|Drug|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
314901|NCT00336232|Drug|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
314902|NCT00336245|Device|Copper T Intrauterine Contraceptive Device|
314903|NCT00336245|Drug|Hormonal Contraception|
314904|NCT00336284|Other|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
314905|NCT00002953|Drug|paclitaxel|
314906|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
314907|NCT00336297|Procedure|Woman Abuse Screening Tool|
314908|NCT00336297|Procedure|Partner Violence Screen|
314909|NCT00336297|Procedure|Computerized screening|
315248|NCT00326638|Radiation|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks
Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23
Boost IMRT to Prostate 3,200 cGy/16
315249|NCT00002902|Drug|raltitrexed|
315250|NCT00326638|Other|Arm A: 3D-Conformal Radiation|3DCRT 7800 cGY/39 Fractions/ STD Technique* once daily Monday to Friday for 8 weeks
Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23
Boost 6 F 3DCRT to Prostate 3,200 cGy/16
315251|NCT00326664|Drug|Cediranib Maleate|Given orally
315252|NCT00326677|Behavioral|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
315253|NCT00326677|Behavioral|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
315254|NCT00326690|Device|Blue Egg Device|
315255|NCT00326703|Procedure|Hypobaric hypoxia|
315256|NCT00326716|Drug|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
315257|NCT00326742|Behavioral|Trier Social Stress Test|
315258|NCT00326768|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
314542|NCT00348855|Behavioral|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
314543|NCT00348855|Behavioral|Stop Smoking|Minimal intervention
314544|NCT00348855|Behavioral|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
314545|NCT00348855|Other|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
314546|NCT00003005|Drug|Cordycepin|Dose escalation study using the following doses:
6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2
314547|NCT00348868|Behavioral|enhanced behavioral motivation counseling|
314548|NCT00348868|Behavioral|Motivational counseling|
314549|NCT00348868|Behavioral|Standard counseling|
314550|NCT00348881|Biological|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
314551|NCT00348881|Biological|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
314552|NCT00348881|Biological|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
314553|NCT00348894|Drug|[S,S]-Reboxetine|[S,S]-reboxetine
314554|NCT00348894|Drug|Any|Any standard of care treatment for DPN
314555|NCT00348907|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
314556|NCT00348907|Drug|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
314557|NCT00003005|Drug|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
314558|NCT00348920|Procedure|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
314559|NCT00348933|Drug|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
314560|NCT00348933|Drug|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
314561|NCT00348933|Drug|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
314562|NCT00348933|Drug|Vitamin B12|1 mg by mouth per day for all weights and ages
313819|NCT00363792|Drug|Glyceryl trinitrate, azetazolamide|
313820|NCT00363805|Dietary Supplement|green tea|Given orally
313821|NCT00363805|Drug|Polyphenon E|Given orally
313822|NCT00363805|Other|placebo|Given orally
313823|NCT00363831|Drug|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
313824|NCT00363844|Drug|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
313825|NCT00363857|Drug|Ropinirole|
314197|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
314198|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
314199|NCT00357734|Drug|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
314200|NCT00357747|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
314201|NCT00357747|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
314202|NCT00357760|Other|Laboratory Biomarker Analysis|Correlative studies
314203|NCT00357760|Other|Pharmacological Study|Correlative studies
314204|NCT00003052|Drug|doxorubicin hydrochloride|
314205|NCT00357760|Biological|Ziv-Aflibercept|Given IV
314206|NCT00357773|Drug|Azithromycin (T1225)|
314207|NCT00357786|Drug|Replagal agalsidase alfa|
314208|NCT00357786|Drug|Replagal|
314209|NCT00357799|Device|VeinViewer|Using the VeinViewer, IV attempts will be made
314210|NCT00357825|Drug|[S,S]-Reboxetine|
314211|NCT00357851|Drug|Aprotinin|
314212|NCT00357864|Drug|carbachol|
309001|NCT00204971|Other|placebo|placebo control
309002|NCT00208741|Drug|Gabitril|
309003|NCT00208767|Drug|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
309004|NCT00208767|Drug|Placebo|A matched placebo pill will be given orally daily.
309005|NCT00002554|Procedure|allogeneic bone marrow transplantation|
309006|NCT00208780|Drug|Tetrahydrobiopterin|
309007|NCT00208780|Drug|Tetrahydrobiopterin|
309008|NCT00208793|Dietary Supplement|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
309009|NCT00208793|Drug|Placebo|Placebo
309010|NCT00208793|Dietary Supplement|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
309011|NCT00208793|Dietary Supplement|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
309012|NCT00208806|Other|congestive heart failure patients|observational echo data on congestive heart failure patients
309013|NCT00208819|Drug|risperidone|
309014|NCT00208819|Drug|quetiapine|
309015|NCT00208819|Drug|olanzapine|
309016|NCT00002554|Radiation|radioimmunotherapy|
309017|NCT00208819|Drug|divalproex|
309018|NCT00208832|Procedure|Graphic medication schedule (Pill card)|
309019|NCT00208832|Procedure|Refill reminder postcard|
309020|NCT00208858|Drug|Topiramate|
309021|NCT00208871|Procedure|Stereoscopic Digital Mammography|screening digital 3D mammogram
309376|NCT00000412|Drug|Placebo Alendronate|
309377|NCT00002682|Drug|Clarithromycin|
309378|NCT00255840|Behavioral|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
308249|NCT00002610|Biological|filgrastim|
308250|NCT00231335|Drug|escitalopram|
308251|NCT00231348|Drug|Nefazodone|
308252|NCT00231374|Procedure|Myelogram|
308253|NCT00231387|Drug|rosiglitazone|
308254|NCT00231413|Biological|Novel HPV vaccine|
308624|NCT00000388|Drug|Anti-ADHD medication|
308625|NCT00002580|Drug|leuprolide acetate|
308626|NCT00219635|Drug|UK-390,957|
308627|NCT00219648|Drug|PEP03|
308628|NCT00219661|Procedure|drainage of subglottic secretions (HiLo Evac tube)|
308629|NCT00219674|Behavioral|Group I: Video training|Participants will receive the AED with a video that provides "instructional" training.
308630|NCT00219674|Behavioral|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
308631|NCT00219674|Behavioral|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
308632|NCT00219674|Behavioral|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
308633|NCT00219687|Other|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
308634|NCT00219687|Other|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
308635|NCT00219700|Drug|Ibuprofen-PC|
308636|NCT00002580|Drug|methotrexate|
308637|NCT00219713|Drug|nitrous oxide and oxygen|
308638|NCT00219726|Drug|Imatinib mesylate|
308639|NCT00219739|Drug|Imatinib mesylate 400 mg|
307895|NCT00242320|Drug|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
307896|NCT00242320|Drug|Placebo|
307897|NCT00242333|Drug|AD 237|
307898|NCT00242346|Drug|candesartan cilexetil|
307899|NCT00242359|Drug|omalizumab|
307900|NCT00242372|Drug|Tesaglitazar 0.5|
307901|NCT00242372|Drug|Insulin at least 30 units/day|
307902|NCT00242385|Biological|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
307903|NCT00242385|Biological|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
307904|NCT00242398|Device|AN69 ST|
307905|NCT00002639|Drug|suramin|
307906|NCT00242411|Drug|Budesonide/Formoterol Turbuhaler|
307907|NCT00242411|Drug|Conventional Best Asthma Therapy|
307908|NCT00242424|Biological|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
308255|NCT00231426|Device|ICD|
308256|NCT00231439|Drug|IvIg|
308257|NCT00231452|Drug|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
308258|NCT00231465|Drug|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
308259|NCT00231465|Drug|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
308260|NCT00002610|Drug|carboplatin|
314335|NCT00319956|Drug|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
314673|NCT00364156|Drug|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
314674|NCT00364169|Procedure|Degree of constipation|
314675|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
314676|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
314677|NCT00364195|Drug|Tesmilifene (YMB1002)|
314678|NCT00003082|Biological|monoclonal antibody E2.3|
314679|NCT00364221|Drug|Rosiglitazone|
314680|NCT00364234|Device|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
314681|NCT00364247|Drug|CG5503 IR;tapentadol|
314682|NCT00364260|Drug|epoetin alfa|
314683|NCT00364273|Drug|GSK159802|
314684|NCT00364286|Drug|Dasatinib (BMS-354825)|50mg Orally twice daily
314685|NCT00364299|Device|Automatic control of tracheal tube cuff pressure|
314686|NCT00364312|Behavioral|diet and physical activity|
314687|NCT00364325|Other|Acute Decompensated Heart Failure|Standard of Care
314688|NCT00364338|Behavioral|gourment cooking workshop|
314689|NCT00003084|Drug|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
314690|NCT00364351|Drug|Vandetanib|once daily oral tablet
314691|NCT00364351|Drug|Erlotinib|oral dose
314692|NCT00364364|Drug|Radiolabeled humanized PAM4 IgG|
314693|NCT00364377|Drug|Sitagliptin|100 mg once daily
314694|NCT00364377|Other|Placebo|once daily for duration of the study
314695|NCT00364390|Drug|Anginera, a human tissue replacement therapy|
313978|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
313979|NCT00002919|Biological|filgrastim|
313980|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
313981|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
313982|NCT00329433|Drug|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
313983|NCT00329433|Drug|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
313984|NCT00329446|Drug|Quetiapine Fumarate|
313985|NCT00329446|Drug|Escitalopram oxylate|
313986|NCT00329459|Drug|sumatriptan succinate/naproxen sodium|
313987|NCT00329459|Drug|placebo|placebo to match
314336|NCT00319956|Drug|D5W|Dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
314337|NCT00319969|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
314338|NCT00319969|Drug|Topotecan|Topotecan 1.5mg/m<2> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
314339|NCT00319982|Drug|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
314340|NCT00002875|Radiation|low-LET photon therapy|
314341|NCT00319982|Drug|Placebo|Placebo comparator (double-blind allocation of study medication)
314342|NCT00319995|Drug|loratadine; montelukast|
314343|NCT00320008|Behavioral|Diet|
314344|NCT00320008|Behavioral|Exercise|
314345|NCT00320008|Behavioral|Stop smoking|
313251|NCT00348309|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
313252|NCT00348309|Other|Placebo|Placebo
313594|NCT00335777|Drug|Migranal nasal spray|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
313595|NCT00335790|Procedure|Hyperbaric Therapy|
313596|NCT00335816|Drug|fluorouracil|Given IV
313597|NCT00335816|Drug|leucovorin calcium|Given IV
313598|NCT00002951|Drug|hydroxyurea|
313599|NCT00335816|Drug|oxaliplatin|Given IV
313600|NCT00335816|Procedure|conventional surgery|Patients undergo surgery
313601|NCT00335816|Radiation|radiation therapy|Patients undergo radiotherapy
313602|NCT00335816|Other|laboratory biomarker analysis|Correlative studies
313603|NCT00335816|Genetic|DNA analysis|Correlative studies
313604|NCT00335816|Genetic|polymerase chain reaction|Correlative studies
313605|NCT00335816|Other|immunohistochemistry staining method|Correlative studies
313606|NCT00335829|Biological|bevacizumab|
313607|NCT00335829|Drug|chemotherapy|
313608|NCT00335829|Drug|embolization therapy|
313609|NCT00002951|Procedure|surgical procedure|
313610|NCT00335829|Procedure|hepatic artery infusion|
313611|NCT00335855|Device|Auto-injector for IM/SC vaccine administration|
313612|NCT00335868|Drug|danusertib|
313613|NCT00335868|Other|laboratory biomarker analysis|
313614|NCT00335868|Other|pharmacological study|
313615|NCT00335881|Biological|hepatitis B vaccine|
312903|NCT00357305|Other|pharmacological study|Correlative studies
312904|NCT00357305|Other|laboratory biomarker analysis|Correlative studies
312905|NCT00357318|Drug|sunitinib malate|Given PO
312906|NCT00357318|Biological|bevacizumab|Given IV
312907|NCT00357318|Other|pharmacological study|Correlative studies
312908|NCT00003049|Procedure|conventional surgery|
312909|NCT00357318|Other|laboratory biomarker analysis|Correlative studies
312910|NCT00357331|Drug|potassium citrate|20 meq by mouth in capsule form twice daily
312911|NCT00357357|Drug|HF0220|comparison of different dosages of drug
312912|NCT00357370|Drug|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
312913|NCT00357370|Drug|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
312914|NCT00357383|Drug|Azithromycin (T1225)|
312915|NCT00357396|Biological|graft versus host disease prophylaxis/therapy|
312916|NCT00357396|Drug|busulfan|
312917|NCT00357396|Drug|melphalan|
312918|NCT00357396|Drug|thiotepa|
312919|NCT00003049|Radiation|radiation therapy|
313253|NCT00348309|Other|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
313254|NCT00348322|Drug|Systane Free Lubricant Eye Drops|
313255|NCT00348335|Drug|Cyclosporine 0.05%|
313256|NCT00348335|Drug|Ocular lubricant|
313257|NCT00348348|Drug|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
313258|NCT00348348|Drug|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
313259|NCT00348361|Drug|Fluticasone Propionate|
312561|NCT00312611|Device|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
312562|NCT00312624|Procedure|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
312563|NCT00312637|Procedure|Magnetic Resonance Spectroscopy|
312564|NCT00312650|Drug|liposomal doxorubicin and gemcitabine|
312565|NCT00002848|Procedure|quality-of-life assessment|
312566|NCT00312663|Biological|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
312920|NCT00357396|Procedure|allogeneic bone marrow transplantation|
312921|NCT00357396|Procedure|allogeneic hematopoietic stem cell transplantation|
312922|NCT00357396|Procedure|peripheral blood stem cell transplantation|
312923|NCT00357422|Procedure|Operation|No drug needed
312924|NCT00357422|Procedure|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
312925|NCT00357448|Biological|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
312926|NCT00360425|Drug|moxifloxacin|
312927|NCT00003063|Drug|levamisole hydrochloride|
312928|NCT00360425|Drug|placebo|
312929|NCT00360438|Drug|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
312930|NCT00360451|Behavioral|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
312931|NCT00360451|Behavioral|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
312932|NCT00360464|Drug|Azithromycin SR|
312933|NCT00360477|Procedure|Floseal|Bioglue that seals the kidney
312934|NCT00360477|Procedure|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
312935|NCT00360477|Procedure|Fascial Stitch|Stitch that closes the kidney
312173|NCT00322140|Drug|CDDO|
312174|NCT00002884|Drug|chemotherapy|
312175|NCT00322153|Drug|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
312176|NCT00322153|Drug|Placebo|Matching placebo oral administration once daily.
312177|NCT00322166|Other|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
312178|NCT00322166|Other|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
312179|NCT00322166|Other|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
312180|NCT00322192|Behavioral|Conventional UK Physical therapy|
312181|NCT00322192|Behavioral|Increased intensity of UK conventional physical therapy|
312182|NCT00322192|Behavioral|UK conventional physical therapy plus functional strength training|
312183|NCT00322205|Drug|zyban|
312184|NCT00322218|Drug|Zevalin Therapeutic Regimen|Zevalin Therapeutic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
312185|NCT00324896|Drug|eszopiclone|eszopiclone
312186|NCT00324896|Other|placebo|matching placebo administered at night
312187|NCT00324909|Drug|Hyperbaric Oxygen Therapy|
312188|NCT00324922|Drug|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
312189|NCT00324922|Drug|vancomycin|1g iv bid
312190|NCT00324948|Drug|Topical alprostadil (PGE-1)|
312191|NCT00324961|Drug|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
312567|NCT00315822|Other|oxygen|Supplemental oxygen will be administered during surgery
312568|NCT00315835|Drug|Buprenorphine transdermal delivery system|
311471|NCT00343889|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine
311472|NCT00343902|Drug|Crataegus Special Extract WS 1442|
311473|NCT00343915|Biological|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, & 6)
311474|NCT00002982|Radiation|radiation therapy|
311475|NCT00343915|Biological|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 & 6)
311476|NCT00343915|Biological|placebo|In the primary study: 1 deep intramuscular injection (month 1)
311477|NCT00343928|Other|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
311478|NCT00343941|Drug|Tucaresol tablets 25 mg|
311479|NCT00343954|Drug|L-citrulline tablets, 1000 mg|
311480|NCT00343980|Drug|rosiglitazone|Tablets, 4 mg once or twice a day.
311822|NCT00331812|Procedure|Mitochondrial functions and oxidative stress|
311823|NCT00331825|Drug|Risperidone and Olanzapine|
311824|NCT00331838|Drug|Semuloparin sodium|0.8 mL solution in Type I amber glass vials
Subcutaneous injection
311825|NCT00331838|Drug|Placebo (for Enoxaparin sodium)|0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component
Subcutaneous injection
311826|NCT00002931|Drug|ifosfamide|3 gm/m2 IV over 30 minutes X 3 days
311827|NCT00331838|Drug|Enoxaparin sodium|0.4 mL solution in ready-to-use pre-filled syringe
Subcutaneous injection
311828|NCT00331838|Drug|Placebo (for Semuloparin sodium)|0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component
Subcutaneous injection
311829|NCT00335010|Drug|Nitroglycerin|
311830|NCT00335023|Other|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
311831|NCT00335036|Device|ICD lead implant|Randomization of ICD lead type at implant
311832|NCT00335049|Device|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
311107|NCT00353834|Drug|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
311108|NCT00353847|Device|Acupuncture|
311109|NCT00353860|Device|SOLEX 300i Stem Cell Selection|
311110|NCT00353873|Drug|Fluticasone propionate|200μg twice daily
311111|NCT00353873|Drug|Fluticasone propionate/salmeterol|50/100μg twice daily
311112|NCT00353886|Procedure|TONI-3|
311113|NCT00353886|Procedure|WRAT-3|
311114|NCT00353886|Procedure|Connor's Rating Scales PRS & TRS|
311115|NCT00353886|Procedure|Peabody Picture Vocabulary Test|
311116|NCT00003027|Drug|dacarbazine|
311117|NCT00353886|Procedure|Children's Memory Scale|
311118|NCT00353886|Procedure|WISC-3|
311119|NCT00353886|Procedure|Behavioral Assessment System for Children PRS & TRS|
311120|NCT00353912|Drug|valsartan + amlodipine|
311121|NCT00353938|Drug|3,4-methylenedioxymethamphetamine 125 mg|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2-2.5 hours later they receive 62.5 mg MDMA orally.
311122|NCT00353938|Drug|3,4 methyelendioxymethamphetamine 25 mg|Participants will receive a 25 mg MDMA and if investigator and participant agree, 2 to 2.5 hours later a dose of 12.5 mg MDMA.
311123|NCT00353938|Behavioral|Psychotherapy|Psychotherapy performed by a team of two co-therapists
311124|NCT00353964|Drug|rEV131|
311125|NCT00353964|Drug|Prenisolone sodium phosphate 1.0%|
311126|NCT00353964|Drug|rEV131 vehicle|
311127|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
311128|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
316354|NCT00353028|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
316355|NCT00353028|Drug|Placebo|Placebo
316356|NCT00353041|Drug|lidocaine topical|
316357|NCT00353054|Drug|Caltrate® 600 + D|
316358|NCT00355719|Drug|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
316359|NCT00355719|Drug|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h*)
316360|NCT00003041|Drug|pyrazoloacridine|
316361|NCT00355732|Procedure|Weaning from mechanical ventilation|
316362|NCT00355745|Device|Ultrasound breast scanning|breast scanning
316363|NCT00355771|Drug|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
316364|NCT00355771|Drug|Placebo|1 tablet OD in the morning for 8 weeks
316365|NCT00355784|Other|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
316711|NCT00343369|Drug|asparaginase|
316712|NCT00343369|Drug|cyclophosphamide|
316713|NCT00346359|Drug|fludarabine phosphate|
316714|NCT00346359|Drug|methotrexate|
316715|NCT00346359|Drug|tacrolimus|
316716|NCT00346359|Procedure|allogeneic hematopoietic stem cell transplantation|
316717|NCT00346359|Procedure|peripheral blood stem cell transplantation|
316718|NCT00346385|Drug|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
316719|NCT00346398|Biological|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
316720|NCT00346398|Biological|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
316721|NCT00346424|Drug|Alfimeprase|
315985|NCT00361660|Behavioral|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
315986|NCT00361660|Behavioral|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
315987|NCT00361686|Drug|tramadol|
315988|NCT00361686|Drug|remifentanyl|
315989|NCT00364936|Procedure|Palliative care service|
315990|NCT00364975|Behavioral|gourmet cooking workshop|
315991|NCT00003085|Procedure|laparoscopy|
315992|NCT00364988|Drug|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
315993|NCT00364988|Drug|losartan|losartan (100 mg daily)
315994|NCT00365001|Drug|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
315995|NCT00365001|Drug|Methotrexate|10-25mg po/week
315996|NCT00365001|Drug|Simvastatin|40mg po on days 1, 15 and 43
315997|NCT00365027|Procedure|Delayed embryo transfer|
315998|NCT00365040|Procedure|Prk with mitomycin vs Lasik|
315999|NCT00365053|Drug|belinostat|Given IV
316000|NCT00365053|Other|laboratory biomarker analysis|Correlative studies
316001|NCT00365092|Procedure|Insertion of tympanostomy tubes|
316002|NCT00003085|Procedure|ultrasound imaging|
316003|NCT00365105|Dietary Supplement|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
316004|NCT00365105|Dietary Supplement|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
316005|NCT00365105|Drug|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
315259|NCT00326768|Drug|Telmisartan 40 mg|
315260|NCT00329836|Other|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
315261|NCT00329849|Biological|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
315262|NCT00329849|Biological|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
315263|NCT00329862|Procedure|Laparoscopic Truncal Vagotomy|
315264|NCT00329888|Procedure|Endoscopic papillary balloon dilatation|
315265|NCT00002920|Drug|tamoxifen citrate|
315266|NCT00329888|Procedure|Endoscopic sphincterotomy|
315267|NCT00329901|Biological|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
315268|NCT00329901|Biological|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
315269|NCT00329901|Biological|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
315622|NCT00320541|Drug|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
315623|NCT00320541|Drug|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
315624|NCT00320541|Drug|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
315625|NCT00320554|Behavioral|Durometer analysis|
315626|NCT00320567|Drug|norgestimate/ethinyl estradiol|
315627|NCT00320580|Drug|norelgestromin/ethinyl estradiol|
315628|NCT00320593|Device|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
315629|NCT00320593|Device|Single Vision Lenses (SVLs)|Single vision lenses
315630|NCT00002879|Drug|cladribine|
315631|NCT00320606|Procedure|Gradual withdrawal of immunosuppressive medication|With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
314910|NCT00336297|Procedure|Face to face screening|
314911|NCT00336297|Procedure|Written screening on forms|
314912|NCT00336310|Drug|Repaglinide|
314913|NCT00336323|Procedure|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
314914|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
314915|NCT00336323|Drug|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
314916|NCT00002955|Drug|fluorouracil|
314917|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
314918|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
314919|NCT00002974|Drug|carboplatin|
314920|NCT00339170|Behavioral|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
314921|NCT00339183|Drug|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
314922|NCT00339183|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m^2, leucovorin 400 mg/m^2 racemate (or 200 mg/m^2 I-leucovorin), 5-FU bolus 400 mg/m^2, 5-FU infusion 2400 mg/m^2.
314923|NCT00339196|Drug|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
314924|NCT00339365|Behavioral|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
314925|NCT00339365|Behavioral|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
314926|NCT00339417|Drug|Albendazole|
314927|NCT00339417|Drug|Ivermectin|
314928|NCT00339456|Drug|HAART|
314213|NCT00357877|Drug|10% w/v chlorhexidine acetate coating FDA IND #45466|dental coating topical applied by dental professional supragingivally to the full dentition
314214|NCT00357890|Device|Pump therapy (CSII)|CSII initiated within 1 month of dx
314215|NCT00003052|Drug|etoposide|
314216|NCT00357890|Drug|Multiple daily injections (MDI) using insulin glargine + rapid acting analog|MDI as control
314217|NCT00360958|Procedure|ultrafiltration|
314218|NCT00360971|Biological|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
314219|NCT00360971|Drug|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
314563|NCT00348946|Drug|androgen oxandrolone|Oxandrolone or placebo capsule, .06 >mg/kg/day, orally, for 2 years
314564|NCT00348946|Other|placebo|an inactive substance
314565|NCT00352105|Drug|cisplatin|20mg/m2/d IV continuous infusion x4 days
314566|NCT00003016|Procedure|adjuvant therapy|
314567|NCT00352105|Drug|fluorouracil|1000mg.m2/d IV continuous x 4 days
314568|NCT00352105|Drug|Iressa|250mg/PO qd x 2 years
314569|NCT00352105|Radiation|hyperfractionated radiation therapy|120cGy bid
314570|NCT00352118|Biological|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
314571|NCT00352118|Biological|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
314572|NCT00352118|Drug|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
314573|NCT00352118|Drug|docetaxel|Intravenous over 1 hour on day 1.
314574|NCT00352118|Drug|fluorouracil|Intravenous continuously on days 1-4.
314575|NCT00352118|Procedure|conventional surgery|As appropriate, neck dissection.
314576|NCT00352118|Radiation|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
314577|NCT00003017|Biological|recombinant interleukin-12|
309379|NCT00255840|Behavioral|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
309380|NCT00255840|Drug|Efavirenz|600 mg tablet taken orally daily
309381|NCT00255840|Drug|Lamivudine|150 mg tablet taken orally daily
309382|NCT00255840|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
309383|NCT00255840|Drug|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
309384|NCT00255840|Drug|Stavudine|Tablet taken orally daily. Dosage depends on weight.
309385|NCT00255866|Behavioral|Skills training for the care of dementia patients|
309386|NCT00255879|Drug|Quetiapine|
309387|NCT00255879|Drug|Risperidone|
309388|NCT00002682|Drug|Metronidazole Hydrochloride|
309389|NCT00255879|Drug|Olanzapine|
309390|NCT00002696|Drug|methotrexate|
309391|NCT00259311|Drug|placebo|
309392|NCT00259324|Behavioral|Diet and Activity|Diet and Activity
309393|NCT00259337|Biological|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
309394|NCT00259350|Drug|Skin disinfection|
309395|NCT00259363|Drug|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
309396|NCT00259376|Drug|Dronedarone (SR33589)|oral administration
309397|NCT00259376|Drug|placebo|oral administration
309398|NCT00259389|Behavioral|Directly observed therapy (DOT)|
309399|NCT00259402|Drug|Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)|OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
309400|NCT00259415|Behavioral|Caregiver support via telephone|
309401|NCT00002696|Procedure|adjuvant therapy|
308640|NCT00219739|Drug|Imatinib mesylate 600 mg|
308641|NCT00219739|Drug|Imatinib 400 mg + Peg-Interferon|
308642|NCT00219739|Drug|Imatinib mesylate 400 mg + Cytarabine|
308643|NCT00219752|Drug|Imatinib mesylate 400 mg|
308644|NCT00219765|Drug|Imatinib mesylate 600 mg|
308645|NCT00219765|Drug|Cytarabine|
308646|NCT00219765|Drug|Daunorubicine|
308647|NCT00002580|Drug|tamoxifen citrate|
308648|NCT00219778|Drug|mifepristone|
309022|NCT00208897|Drug|Fluoxetine|
309023|NCT00208910|Behavioral|Odorant Cue|
309024|NCT00208923|Drug|Busulfan, Cyclophosphamide and Fludarabine|Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.
Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.
Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days.
309025|NCT00208936|Drug|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
309026|NCT00208949|Drug|G-CSF|G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
309027|NCT00002555|Drug|cisplatin|
309028|NCT00208949|Drug|GM-CSF|GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
309029|NCT00208962|Procedure|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
309030|NCT00212498|Procedure|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
309031|NCT00212550|Procedure|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
309032|NCT00212576|Behavioral|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
308261|NCT00231478|Drug|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
308262|NCT00231478|Drug|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
308263|NCT00231491|Drug|Botulinum Toxin A (Botox )|
308264|NCT00231504|Procedure|Blood samples|Blood samples
308265|NCT00231517|Drug|topical opiod|
308266|NCT00231517|Drug|morphine sulphate in intrasite gel|
308267|NCT00231530|Drug|topiramate|
308268|NCT00231543|Procedure|Laparoscopic fundoplication|
308269|NCT00231543|Procedure|open Nissen fundoplication|
308270|NCT00231556|Drug|topiramate|
308271|NCT00002610|Drug|cyclophosphamide|
308272|NCT00231569|Drug|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
308273|NCT00231569|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
308274|NCT00235014|Drug|verapamil|SR 240 mg QD
308275|NCT00235027|Other|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
308276|NCT00235040|Behavioral|Smart Form|Computer Decision Support System
308277|NCT00235053|Drug|fluticasone/salmeterol DISKUS 250/50|
308278|NCT00002620|Drug|carmustine|
308279|NCT00235066|Device|PCI|PCI with Cypher Sirolimus-Eluting Stent
308649|NCT00219791|Drug|glucarpidase (50 Units/kg)|
308650|NCT00219804|Drug|tetrabenazine or placebo|
308651|NCT00219817|Drug|RC-1291 HCl|
308652|NCT00219830|Behavioral|cardiac rehabilitation program|Attended a formal cardiac rehabilitation program/did not attend
308653|NCT00223717|Drug|losartan|25-200 mg PO. Single dose.
314696|NCT00364403|Behavioral|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
314697|NCT00364403|Behavioral|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
314698|NCT00364416|Other|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
315043|NCT00355303|Drug|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
315044|NCT00355303|Drug|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
315045|NCT00355316|Other|Blood draw|
315046|NCT00355329|Procedure|Tongue Acupuncture (Procedure)|
315047|NCT00358033|Behavioral|Counseling|
315048|NCT00358033|Behavioral|Interactive Education|
315049|NCT00358033|Behavioral|Group Support|
315050|NCT00003052|Procedure|hyperthermia treatment|
315051|NCT00358033|Procedure|Pharmacologic case management|Provided by clinical pharmacists
315052|NCT00358046|Drug|ILY101|
315053|NCT00358059|Behavioral|Behavioral Family Systems Therapy for Diabetes|
315054|NCT00358072|Behavioral|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
315055|NCT00358085|Procedure|Endovascular Repair of Abdominal Aortic Aneurysm|
315056|NCT00358085|Procedure|Conventional open repair of Abdominal Aortic Aneurysm|
315057|NCT00358111|Device|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
315058|NCT00358124|Drug|insulin glargine|
315059|NCT00358124|Drug|rosiglitazone|
315060|NCT00358124|Drug|metformin|
315061|NCT00003052|Radiation|radiation therapy|
314346|NCT00320008|Drug|Glucose lowering therapy|
314347|NCT00320008|Drug|Blood pressure lowering therapy|
314348|NCT00320008|Drug|Lipid lowering therapy|
314349|NCT00320021|Drug|Pyridorin (pyridoxamine dihydrochloride)|
314350|NCT00320034|Drug|R-albuterol, S-albuterol|
314351|NCT00002876|Drug|cisplatin|
314352|NCT00320047|Drug|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
314353|NCT00320060|Drug|Pyridorin (pyridoxamine dihydrochloride)|
314354|NCT00320073|Drug|erlotinib hydrochloride|75 mg to 150mg
314355|NCT00323063|Drug|imatinib mesylate|Given orally
314356|NCT00323076|Drug|18F-FAZA PET Imaging|Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.
Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient.
314357|NCT00323089|Procedure|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
314358|NCT00323102|Drug|Multihance|
314699|NCT00364429|Drug|[123]I-CNS 1261|Study Drug
314700|NCT00313521|Drug|thiotepa|
314701|NCT00313521|Procedure|adjuvant therapy|
314702|NCT00313521|Radiation|radiation therapy|
314703|NCT00313534|Drug|masoprocol|
314704|NCT00313547|Drug|Quinapril 40 mg|
314705|NCT00002852|Drug|carboplatin|Given IV
314706|NCT00313547|Drug|Quinapril 10 mg and amlodipine 5 mg|
314707|NCT00313560|Drug|erlotinib hydrochloride|Given orally
313616|NCT00335894|Drug|hMG-IBSA|
313617|NCT00335907|Procedure|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
313618|NCT00335920|Drug|Dexamethasone-dihydrogenphosphate (4mg/ml)|
313619|NCT00338728|Drug|Imatinib Mesylate|400 mg orally twice daily
313620|NCT00338728|Drug|Letrozole|2.5 mg orally once daily
313988|NCT00329472|Drug|gemcitabine, cisplatin|
313989|NCT00329485|Drug|CORvalen (D-Ribose)|
313990|NCT00000464|Drug|sotalol|
313991|NCT00002919|Drug|cisplatin|
313992|NCT00329498|Drug|L-Ascorbic Acid|
313993|NCT00329511|Drug|methyldopa vs. clonidine|Comparison of compliance
313994|NCT00329511|Drug|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
313995|NCT00329524|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
313996|NCT00329537|Drug|Sargramostim (Leukine)|Self-subcutaneous injection
313997|NCT00329537|Drug|Placebo|Self-subcutaneous injection
313998|NCT00332696|Drug|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
313999|NCT00332696|Drug|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
314000|NCT00332696|Drug|Placebo|Physiologic saline solution
314001|NCT00332709|Drug|Letrozole|2.5 mg/day for 3 years
314002|NCT00332709|Drug|Zoledronic acid|4 mg every 6 months
314003|NCT00332722|Procedure|Cervical facet joint nerve blocks|
313260|NCT00348374|Drug|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
313261|NCT00003003|Biological|sargramostim|
313262|NCT00348374|Drug|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
313263|NCT00351429|Device|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
313264|NCT00351455|Behavioral|smoking cessation|
313265|NCT00351455|Behavioral|tighter diabetic control|
313266|NCT00003013|Radiation|radiation therapy|
313267|NCT00351455|Behavioral|diet and exercise program|
313268|NCT00351468|Drug|eltrombopag olamine (SB-497115-GR)|Eltrombopag at a dose up to 75mg daily
313269|NCT00351494|Procedure|contrast enhanced ultrasonography|Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.
Abdominal route 2.4 ml sonovue per injection / bolus
313270|NCT00351494|Procedure|embolization|Intervention is described in the case report form for each patient
313271|NCT00351507|Drug|Vildagliptin|
313272|NCT00351520|Drug|Miltefose|
313273|NCT00351533|Drug|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
313274|NCT00351546|Drug|Vildagliptin|
313275|NCT00351559|Device|AlloMap molecular expression testing|
313276|NCT00351559|Procedure|Right ventricular endomyocardial biopsy|
313277|NCT00003014|Drug|carboplatin|
313621|NCT00338754|Drug|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
313622|NCT00338767|Behavioral|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
313623|NCT00002970|Drug|therapeutic hydrocortisone|Given IT
312936|NCT00360490|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
312937|NCT00360490|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
312938|NCT00003064|Biological|filgrastim|
312939|NCT00360516|Behavioral|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
312940|NCT00360529|Drug|flibanserin|
312941|NCT00360555|Drug|flibanserin|placebo
312942|NCT00360555|Drug|flibanserin|25 mg
312943|NCT00360555|Drug|flibaserin|50 mg qhs/bid
313278|NCT00351572|Procedure|Cell Search Assay|
313279|NCT00351585|Drug|Vildagliptin|
313280|NCT00351598|Radiation|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
313281|NCT00351611|Drug|Lyrica (pregabalin)|150 mg twice a day, oral administration
313282|NCT00351611|Drug|placebo|Twice a day, oral administration
313283|NCT00351624|Behavioral|DHA|
313284|NCT00351624|Behavioral|placebo|
313285|NCT00351637|Drug|Sublingual Methadone|
313286|NCT00351663|Drug|Enoxaparine|Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:
Intravenously according to their weight (0.5mg/kg x 1/day)
Subcutaneously according to their weight (0.5mg/kg x 1/day)
Subcutaneously 40mg x1/day
313287|NCT00351676|Behavioral|Integration of a team based clinical pharmacist|
313288|NCT00003014|Radiation|radiation therapy|
313289|NCT00351676|Drug|Optimizing therapeutic treatments|
313290|NCT00351676|Behavioral|Optimizing processes of care|
313291|NCT00351689|Behavioral|dietary supplement|
312569|NCT00315848|Drug|Buprenorphine transdermal delivery system|
312570|NCT00315861|Drug|pemetrexed|
312571|NCT00315861|Drug|topotecan|
312572|NCT00315874|Drug|Buprenorphine transdermal delivery system|
312573|NCT00315887|Drug|Buprenorphine transdermal delivery system|
312574|NCT00315900|Drug|Depakote ER|depakote ER
312575|NCT00315900|Drug|Seroquel|seroquel
312576|NCT00002863|Procedure|conventional surgery|
312577|NCT00315913|Drug|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
312578|NCT00315913|Other|IV Placebo|IV Saline Solution
312579|NCT00315926|Drug|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
312580|NCT00315926|Drug|Placebo|a mixture of ethanol and physiological saline
312581|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring & Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
312582|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring & Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
312583|NCT00315952|Drug|Exubera|
312584|NCT00315965|Drug|Nitric oxide, Carbon monoxide, Helium|
312585|NCT00315978|Device|Heart-to-Heart Decision Aid|
312586|NCT00315991|Behavioral|Blood Glucose Awareness Training for Parents|
312587|NCT00002863|Procedure|cryosurgery|
311833|NCT00002947|Radiation|indium In 111 pentetreotide|
311834|NCT00335049|Device|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
311835|NCT00335075|Drug|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
311836|NCT00335075|Drug|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
311837|NCT00335088|Drug|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
311838|NCT00335101|Drug|Iodixanol, Ioversol, Iopromide|
311839|NCT00335114|Drug|cyclosporine ophthalmic emulsion|
311840|NCT00335140|Biological|rituximab|
311841|NCT00335140|Drug|cytarabine|
311842|NCT00335140|Drug|dexamethasone|
311843|NCT00335140|Drug|leucovorin calcium|
311844|NCT00002948|Biological|filgrastim|
311845|NCT00335140|Drug|methotrexate|
311846|NCT00335140|Drug|procarbazine hydrochloride|
312192|NCT00324974|Drug|Lansoprazole microgranules suspension|Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;
Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks.
312193|NCT00324974|Drug|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
312194|NCT00000140|Drug|Perfluoropropane|
312195|NCT00000464|Drug|imipramine|
312196|NCT00002898|Biological|dactinomycin|
312197|NCT00324987|Biological|Bevacizumab|Given IV
312198|NCT00324987|Drug|Imatinib Mesylate|Given PO
312199|NCT00324987|Other|Laboratory Biomarker Analysis|Correlative studies
312200|NCT00324987|Other|Pharmacological Study|Correlative studies
311129|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
311481|NCT00343980|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
311482|NCT00343980|Drug|glimepiride|Tablets, 4 mg/day.
311483|NCT00343993|Device|noninvasive positive pressure ventilation|
311484|NCT00344006|Drug|chlorproguanil-dapsone-artesunate|
311485|NCT00347360|Drug|carvedilol controlled release formulation|
311486|NCT00347373|Drug|Tonalin Conjugated linoleic acid (dietary supplement)|
311487|NCT00347386|Drug|Drug: Zinc (zinc sulphate)|Dissolvable tablet 10 mg. Once daily during the illness
311488|NCT00347386|Drug|Placebo|Placebo tablet, once daily
311489|NCT00347399|Drug|bevacizumab intravitreal injection|
311490|NCT00347399|Procedure|verteporfin photodynamic therapy|
311491|NCT00347412|Drug|Paclitaxel and Carboplatin|Paclitaxel and carboplatin: (All randomized patients)
All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.
The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel,as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.
311492|NCT00347412|Drug|NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin|NOV-002: (Group A only)
Two 60mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one
For each nominal 21-day paclitaxel and carboplatin cycle:
60mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin
followed by 60mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins.
Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first.
311493|NCT00347425|Drug|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
311494|NCT00002998|Drug|gemcitabine hydrochloride|
311495|NCT00347425|Drug|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
311496|NCT00347425|Drug|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
316722|NCT00346437|Genetic|Ad5FGF-4 vs. Placebo|Intracoronary infusion
316723|NCT00002994|Biological|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
316724|NCT00346450|Procedure|Cultivated conjunctival transplantation|
316725|NCT00346463|Drug|Allopurinol|
316726|NCT00346489|Drug|5-fluorouracil|
316727|NCT00346489|Drug|Mitomycin C|
316728|NCT00346502|Drug|20% betulinic acid ointment|
316729|NCT00346502|Drug|BA|20% Betulinic Acid Ointment
316730|NCT00346515|Device|FiberNet Emboli Protection System|
316731|NCT00346528|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
316732|NCT00346528|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
316733|NCT00346567|Drug|Zidovudine and Lamivudine (Combivir)|
316734|NCT00002994|Biological|rhuMAb|90 min IV infusion day 7 of each cycle
316735|NCT00346567|Drug|Emtricitabine and Tenofovir (Truvada)|
316736|NCT00346580|Drug|Nelfinavir|
311130|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
311131|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
311132|NCT00003042|Procedure|bone marrow ablation with stem cell support|
311133|NCT00356473|Drug|Atorvastatin|
311134|NCT00356486|Drug|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
311135|NCT00356486|Drug|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
316006|NCT00365105|Drug|Sm-153|Single dose intravenously 1 mCi/kg body weight.
316007|NCT00365105|Radiation|Sr-89|Single dose intravenously 4 mCi.
316008|NCT00365118|Device|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
316366|NCT00355784|Drug|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
316367|NCT00355797|Device|Closed Loop Stimulation (CLS)|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
316368|NCT00355797|Device|Standard Rate Adaptive (R) Technology|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
316369|NCT00355797|Device|Non-rate adaptive (DDD) pacing|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
316370|NCT00355810|Dietary Supplement|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
316371|NCT00003042|Biological|filgrastim|
316372|NCT00355810|Dietary Supplement|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
316373|NCT00355836|Behavioral|Mental Imagery|
316374|NCT00355849|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
316375|NCT00355849|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
316376|NCT00355862|Drug|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
316377|NCT00355862|Drug|Sirolimus|Sirolimus based immunosuppression
316378|NCT00355875|Procedure|titration of oxygen during resuscitation|
316379|NCT00355888|Drug|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
316380|NCT00355901|Drug|Visilizumab (Nuvion®; HuM291)|
316381|NCT00355914|Procedure|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
315632|NCT00320619|Drug|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
315633|NCT00320619|Drug|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
315634|NCT00320632|Drug|Desipramine|
315635|NCT00320658|Biological|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
315636|NCT00320658|Biological|CPG 7909|Adjuvant
315637|NCT00320671|Drug|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
315638|NCT00320671|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
315639|NCT00320671|Drug|Clozapine|The dosage for clozapine will be 12.5 mg per day on day 1; 25 mg per day on days 2 and 3; 50 mg per day on days 4 and 5; 75 mg per day on days 6 and 7; 100 mg per day on days 8 and 9, and increments of 50 mg per day every 2 days until treatment response, dose-related side effects, or a maximum dose of 600 mg/day. Safety monitoring for clozapine-treated subjects will follow the established procedures for multi-episode patients (e.g. weekly CBC monitoring). Subjects who participate in the clozapine trial will be seen for research assessments weekly for 4 weeks, then every two weeks until study end
315640|NCT00320697|Drug|bupropion|
315641|NCT00002880|Drug|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
316009|NCT00365131|Drug|Cerezyme (imiglucerase for injection)|
316010|NCT00365144|Biological|bevacizumab|
316011|NCT00365144|Drug|erlotinib hydrochloride|
316012|NCT00365144|Other|laboratory biomarker analysis|
316013|NCT00000482|Drug|estrogen|
316014|NCT00003086|Biological|filgrastim|
316015|NCT00365157|Drug|Eribulin Mesylate|Given IV
316016|NCT00365157|Other|Laboratory Biomarker Analysis|Correlative studies
316017|NCT00365157|Other|Pharmacological Study|Correlative studies
316018|NCT00365170|Drug|human insulin|
314929|NCT00339469|Dietary Supplement|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
315270|NCT00329914|Drug|Progesterone|Vaginal pessaries, 200 mg/day
315271|NCT00329914|Drug|Placebo|Placebo pessaries containing peanut oil
315272|NCT00329927|Biological|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
315273|NCT00329940|Drug|Letrozole|
315274|NCT00329966|Biological|Surface Antigen, Inactivated, Influenza (form.2006-07)|
315275|NCT00329979|Behavioral|vascular access site|Randomized vascular access site
315276|NCT00002920|Procedure|adjuvant therapy|
315277|NCT00329992|Behavioral|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
315278|NCT00330005|Behavioral|Group Psychotherapy|
315279|NCT00330018|Drug|Valganciclovir|Valganciclovir
315280|NCT00330018|Drug|Acyclovir|Acyclovir
315281|NCT00330044|Drug|Premetrexed (Alimta)|
315282|NCT00330070|Drug|IPL512,602 20 mg once daily|
315283|NCT00330070|Drug|IPL512,602 Matching Placebo once daily|
315284|NCT00330083|Biological|ALK Ragweed Tablet|
315285|NCT00330096|Drug|Hesperidin|
315286|NCT00330096|Other|Placebo|
315287|NCT00002921|Drug|suramin|
315288|NCT00330109|Procedure|MRS Imaging|Performed on a 3.0 Tesla Philips Intera MRI Unit (Best, Netherlands). Scout views and T2 transverse images are obtained to locate the tumor in conjunction with any previous diagnostic images.
315289|NCT00333268|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
314578|NCT00352131|Drug|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
314579|NCT00352144|Drug|Eszopiclone|Eszopiclone 3 mg
314580|NCT00352144|Drug|Placebo|Placebo tablet
314581|NCT00352157|Behavioral|Revival Soy Dietary Supplement|
314582|NCT00352170|Dietary Supplement|calcium supplementation|calcium carbonate 1500 mg/day
314583|NCT00352170|Dietary Supplement|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
314584|NCT00352170|Dietary Supplement|Placebo|calcium and vitamin D3 placebo
314585|NCT00352183|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
314586|NCT00352183|Drug|Simvastatin|Simvastatin 40mg
314587|NCT00352196|Drug|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
314930|NCT00002974|Drug|etoposide|
314931|NCT00339586|Drug|Erlotinib|
314932|NCT00339625|Other|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
314933|NCT00339690|Other|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
314934|NCT00339768|Drug|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
314935|NCT00339833|Drug|Salsalate|The intervention was salsalate (3g/day) for 7 days.
314936|NCT00339833|Drug|Placebo|Identical placebo for 7 days.
314937|NCT00339872|Drug|IMA-638|
314938|NCT00340054|Other|questionnaire administration|
314939|NCT00340054|Procedure|study of high risk factors|
314940|NCT00340080|Drug|Abacavir|
314941|NCT00002974|Drug|ifosfamide|
309753|NCT00249860|Drug|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
309754|NCT00249873|Drug|clopidogrel (SR25990C)|oral administration (tablets)
309755|NCT00249873|Drug|placebo|oral administration (tablets)
309756|NCT00249886|Drug|Citalopram|
309757|NCT00249899|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
309758|NCT00002665|Drug|asparaginase|10,000 units/d IV or IM 15 - 24
309759|NCT00249899|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
309760|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
309761|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
309762|NCT00249912|Drug|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
309763|NCT00249925|Behavioral|Home-Based Intervention|
309764|NCT00249925|Behavioral|Multi-component home-based intervention|
309765|NCT00249938|Drug|Minute Maid Heart Wise orange juice|
309766|NCT00249938|Drug|Welchol|
309767|NCT00249951|Drug|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
309768|NCT00249964|Drug|Combination Treatment - Cohort 1|Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 75 mg/m2 per day from day 2 to day 6.
309769|NCT00002665|Drug|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
309770|NCT00249964|Drug|Combination Treatment - Cohort 2|Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 100 mg/m2 per day from day 2 to day 6.
309771|NCT00249964|Drug|Combination Treatment - Cohort 3|Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 125 mg/m2 per day from day 2 to day 6.
309033|NCT00212576|Behavioral|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
309034|NCT00212589|Drug|Capecitabine|
309035|NCT00212589|Drug|Fluorouracil + folinic acid|
309036|NCT00002565|Drug|cyclophosphamide|
309037|NCT00212602|Drug|ONO-7436|
309038|NCT00212615|Drug|Oxaliplatin (Eloxatin)|
309039|NCT00212615|Drug|Capecitabine (Xeloda)|
309040|NCT00212628|Drug|Minodronic acid hydrate|
309041|NCT00212641|Drug|ONO-5129|
309042|NCT00212654|Drug|ONO-1101|
309402|NCT00259428|Drug|Dronedarone (SR33589)|oral administration
309403|NCT00259428|Drug|placebo|oral administration
309404|NCT00259441|Drug|Simvastatin|
309405|NCT00259454|Behavioral|In-home intervention|occupational therapy techniques to reduce caregiver stress
309406|NCT00259467|Behavioral|Home-Based Behavorial Intervention|
309407|NCT00259480|Behavioral|Home Based Intervention|occupational therapy
309408|NCT00259493|Procedure|Off-Pump Coronary Artery Bypass Graft Surgery|
309409|NCT00259506|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|
309410|NCT00259519|Procedure|Induction of delivery|Induction of delivery
309411|NCT00259532|Procedure|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
309412|NCT00002696|Procedure|conventional surgery|
309413|NCT00259545|Drug|Retarded Release Phosphatidylcholine (rPC)|
308654|NCT00223717|Drug|metoprolol tartrate|25-100 mg PO. Single dose.
308655|NCT00223717|Drug|nebivolol hydrochloride|2.5-40 mg PO. Single dose.
308656|NCT00223717|Drug|prazosin hydrochloride|0.5-1 mg PO. Single dose.
308657|NCT00223717|Drug|tamsulosin hydrochloride|0.4-0.8 mg PO. Single dose.
308658|NCT00223717|Other|Head-up tilt.|Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
308659|NCT00223717|Drug|aliskiren|aliskiren (Tekturna) 150-300mg po single dose
308660|NCT00223717|Other|Local heat stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
308661|NCT00223730|Drug|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
308662|NCT00223743|Drug|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
308663|NCT00002590|Drug|methotrexate|
308664|NCT00223756|Other|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
308665|NCT00223769|Drug|Oxandrolone|
308666|NCT00223782|Behavioral|Gait Training with Feedback|
308667|NCT00223782|Behavioral|Gait Training with no feedback|
308668|NCT00223795|Device|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
308669|NCT00223808|Other|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
308670|NCT00223808|Other|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
308671|NCT00223808|Other|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
308672|NCT00223821|Drug|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
309043|NCT00212667|Drug|ONO-5920|
309044|NCT00212680|Drug|ONO-1101|
315062|NCT00358137|Behavioral|Aerobic Conditioning Program|
315063|NCT00358137|Behavioral|Strength Training Program|
315064|NCT00358150|Drug|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 milligram (mg) dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, and then either eliglustat 50 mg BID (if Genz-99067 [active moiety of eliglustat in plasma] trough plasma concentration was greater than or equal to [>=] 5 nanogram per milliliter [ng/mL] on Day 10) or eliglustat 100 mg BID (if Genz-99067 trough plasma concentration was less than [<] 5 ng/mL), from day 20 to Month 48. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing the same treatment up to Month 48. Participant receiving 100 mg BID could be considered for a further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme), and if all other causes for lack of treatment effect had been evaluated and ruled out).
315412|NCT00349193|Other|Placebo|Blinded Placebo
315413|NCT00349206|Drug|sorafenib tosylate|Given orally
315414|NCT00349206|Drug|temsirolimus|Given IV
315415|NCT00349219|Drug|erlotinib|erlotinib 150 mg taken orally daily until disease progression
315416|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
315417|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
315418|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
315419|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
315420|NCT00349219|Drug|erlotinib|erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
315421|NCT00349232|Behavioral|lifestyle intervention (diet and physical activity)|
315422|NCT00003007|Drug|cyclophosphamide|
315423|NCT00349245|Drug|Remifentanil|
315424|NCT00349245|Drug|Dexmedetomidine|
315425|NCT00349258|Drug|Leuprolide acetate|
315426|NCT00349271|Procedure|Stem cell|Stem cell
315427|NCT00349271|Drug|Filgrastime (G-CSF)|Filgrastime (G-CSF)
315428|NCT00349271|Drug|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
314708|NCT00313560|Other|placebo|Given orally
314709|NCT00313573|Procedure|management of therapy complications|
314710|NCT00313573|Procedure|pain therapy|
314711|NCT00313573|Procedure|psychosocial assessment and care|
314712|NCT00313573|Procedure|quality-of-life assessment|
314713|NCT00313586|Drug|Azacitidine|Given SC
314714|NCT00313586|Drug|Entinostat|Given PO
314715|NCT00313586|Other|Laboratory Biomarker Analysis|Correlative studies
314716|NCT00002852|Procedure|therapeutic conventional surgery|Undergo surgery
314717|NCT00313599|Drug|lapatinib|
314718|NCT00313599|Drug|paclitaxel|
314719|NCT00313612|Drug|oxaliplatin|Given IV
314720|NCT00313612|Drug|topotecan|Given IV
314721|NCT00313625|Drug|busulfan|
314722|NCT00313625|Drug|melphalan|
314723|NCT00313625|Drug|methotrexate|
314724|NCT00313625|Drug|tacrolimus|
314725|NCT00313625|Procedure|allogeneic hematopoietic stem cell transplantation|
314726|NCT00313625|Procedure|peripheral blood stem cell transplantation|
314727|NCT00002854|Biological|filgrastim|
315065|NCT00358163|Drug|PTK787/ZK 222584|Taken in tablet form daily
315066|NCT00358163|Drug|paclitaxel|Given as a 3-hour infusion once every 21 days
315067|NCT00358176|Drug|Risedronate (HMR4003)|
315068|NCT00358189|Device|Deep Brain Stimulation|
315069|NCT00358202|Drug|cefepime|cefepime hydrochloride 1gm IM q24h
314004|NCT00332735|Drug|spinal administration of articaine|
314005|NCT00332735|Drug|spinal administration of bupivacaine|
314006|NCT00332748|Drug|Oral Taxane|
314007|NCT00332761|Drug|Caduet|
314008|NCT00000466|Drug|medroxyprogesterone|
314009|NCT00002937|Drug|paclitaxel|
314010|NCT00332774|Drug|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
314011|NCT00332774|Drug|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
314359|NCT00323115|Biological|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
314360|NCT00323115|Drug|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
314361|NCT00002887|Drug|vinorelbine tartrate|
314362|NCT00323115|Procedure|Radiotherapy|RT is standard of care (SOC) post surgery
314363|NCT00323115|Biological|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
314364|NCT00323128|Procedure|Calculation of inuline clearance|Calculation of inuline clearance.
314365|NCT00323128|Procedure|Measuring serum creatinine|Measuring serum creatinine.
314366|NCT00323141|Device|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
314367|NCT00323154|Drug|Nalbuphine|
314368|NCT00323193|Behavioral|MOVE!|group based psychoeducation, motivation and support
314369|NCT00323206|Genetic|IL-12pDNA|
314370|NCT00323206|Procedure|electroporation|
314371|NCT00323219|Drug|Cefazolin and Moxifloxacin|See Detailed Description.
314372|NCT00002887|Procedure|drug resistance inhibition treatment|
314373|NCT00323232|Device|2 Versus 4 Hole DHS|See Detailed Description.
313624|NCT00338767|Drug|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
313625|NCT00338780|Drug|Lamivudine/ Placebo 100mg daily|
313626|NCT00338793|Drug|prednisolone|
313627|NCT00338806|Behavioral|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
313628|NCT00338806|Behavioral|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
313629|NCT00338832|Behavioral|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
313630|NCT00338832|Behavioral|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
313631|NCT00338845|Behavioral|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
313632|NCT00338845|Behavioral|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
313633|NCT00338858|Other|walking and balance performance evaluation|
313634|NCT00002971|Drug|O6-benzylguanine|
314012|NCT00332774|Other|Nepafenac ophthalmic suspension vehicle|
314013|NCT00332787|Drug|Fluoxetine|
314014|NCT00332800|Drug|Nutritional Supplementation|
314015|NCT00332813|Behavioral|HIV Risk Behavior Intervention|
313292|NCT00351702|Drug|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
313293|NCT00354484|Drug|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
313294|NCT00354484|Drug|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
313295|NCT00354497|Other|physiologic testing|
313296|NCT00354497|Other|study of socioeconomic and demographic variables|
313297|NCT00003032|Drug|tamoxifen citrate|
313298|NCT00354497|Procedure|evaluation of cancer risk factors|
313299|NCT00354497|Procedure|mutation carrier screening|
313300|NCT00354497|Procedure|study of high risk factors|
313301|NCT00354510|Drug|GW842470X cream|
313302|NCT00354523|Drug|Capecitabine (Xeloda)|Starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle.
313635|NCT00338858|Procedure|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
313636|NCT00345046|Drug|Pred Forte|Four drops daily decreasing to once daily over four weeks.
313637|NCT00345046|Drug|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
313638|NCT00345046|Drug|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
313639|NCT00002987|Biological|bleomycin sulfate|
313640|NCT00345059|Drug|docetaxel|
313641|NCT00345059|Drug|vinorelbine|
313642|NCT00345059|Drug|gemcitabine|
313643|NCT00345059|Drug|capecitabine|
313644|NCT00345072|Device|Web-based decision aid system|
313645|NCT00345085|Device|Wavefront and Contrast Sensitivity|
313646|NCT00345098|Drug|SR58611A|
312588|NCT00316004|Drug|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
312944|NCT00360555|Drug|flibanserin|50 mg bid/100qhs
312945|NCT00360568|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
312946|NCT00360568|Device|CADD-Legacy® 1400 ambulatory infusion pump|
312947|NCT00360568|Device|PEG tube|percutaneous endoscopic gastrostomy tube
312948|NCT00360568|Device|J-tube|jejunal tube
312949|NCT00003064|Drug|carboplatin|
312950|NCT00360581|Behavioral|Yoga|
312951|NCT00360581|Behavioral|Yoga and Cognitive Behavioral Therapy|
312952|NCT00360594|Drug|Acamprosate|3 pills (666 mg) for 1998mg/day
312953|NCT00360594|Drug|Placebo|3 pills (666mg) for 1998mg/day
312954|NCT00360607|Drug|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
312955|NCT00363363|Behavioral|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
312956|NCT00363363|Behavioral|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
312957|NCT00363376|Drug|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
312958|NCT00363376|Drug|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
312959|NCT00363376|Drug|Zonisamide|zonisamide ranging from 100mg to 600mg daily
312201|NCT00325000|Behavioral|Interpersonal Psychotherapy|
312202|NCT00325000|Drug|sertraline or amitriptyline|
312203|NCT00325013|Drug|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
312204|NCT00325026|Drug|Misoprostol|
312205|NCT00325026|Device|Foley bulb|
312206|NCT00325039|Procedure|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
312207|NCT00002898|Drug|carboplatin|
312208|NCT00325039|Procedure|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
312209|NCT00325078|Drug|Infliximab|
312210|NCT00325104|Procedure|Parathyroid hormone testing|
312211|NCT00325104|Procedure|Serum calcium testing|
312212|NCT00325117|Drug|Vildagliptin|
312213|NCT00328614|Device|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
312214|NCT00328627|Drug|Alogliptin|Alogliptin tablets.
312589|NCT00316004|Drug|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
312590|NCT00316004|Drug|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
312591|NCT00318903|Drug|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
312592|NCT00318903|Procedure|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
312593|NCT00002873|Radiation|brachytherapy|
311497|NCT00347425|Drug|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
311498|NCT00347425|Drug|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
311499|NCT00347425|Drug|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
311847|NCT00335140|Drug|vincristine sulfate|
311848|NCT00335153|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
311849|NCT00335153|Device|CADD-Legacy® 1400 ambulatory infusion pump|
311850|NCT00335153|Device|PEG tube|percutaneous endoscopic gastrostomy tube
311851|NCT00335153|Device|J-tube|jejunal tube
311852|NCT00335166|Drug|Pardaprunox|12-42 mg
311853|NCT00335166|Drug|pramipexole|1.5-4.5 mg
311854|NCT00335166|Drug|Placebo Comparator|Placebo
311855|NCT00002948|Drug|topotecan hydrochloride|
311856|NCT00335179|Drug|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
311857|NCT00335179|Drug|Vehicle cream|Vehicle cream in 250 mg
311858|NCT00335192|Drug|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
311859|NCT00337805|Other|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
311860|NCT00002967|Drug|cyclophosphamide|
311861|NCT00337818|Biological|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
311862|NCT00337831|Procedure|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
311863|NCT00337870|Behavioral|PAT|Cognitive-Behavioral/Relaxation Intervention
311864|NCT00337883|Drug|Erlotinib HCl (OSI-774)|
311136|NCT00356525|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
311137|NCT00356525|Drug|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
311138|NCT00356525|Drug|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
311139|NCT00356525|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
311140|NCT00356551|Behavioral|Family Spirit curriculum|
311141|NCT00356564|Biological|hepatitis B vaccine|
311142|NCT00356590|Biological|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
311143|NCT00003042|Procedure|conventional surgery|
311144|NCT00356603|Drug|Sumatriptan Succinate|
311145|NCT00356616|Drug|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
311146|NCT00356616|Drug|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
311147|NCT00356642|Drug|GW842470X|
311148|NCT00356655|Behavioral|Psychoeducation|
311149|NCT00356668|Device|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
311150|NCT00356681|Drug|AMG 706 placebo|Blinded placebo
311151|NCT00356681|Drug|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
311152|NCT00359476|Drug|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
311500|NCT00347425|Drug|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
311501|NCT00347425|Drug|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
311502|NCT00347425|Drug|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
311503|NCT00347425|Drug|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
316382|NCT00003042|Drug|cisplatin|
316383|NCT00358657|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
316384|NCT00358657|Drug|Sirolimus|Given PO
316385|NCT00358657|Drug|Tacrolimus|Given IV or PO
316386|NCT00358657|Radiation|Total-Body Irradiation|Undergo total-body irradiation
316737|NCT00346593|Device|Silicone hydrogel contact lens|
316738|NCT00346606|Drug|Denosin® and Xyzal®|
316739|NCT00346619|Drug|Nelfinavir|
316740|NCT00346632|Drug|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
316741|NCT00346645|Drug|Bortezomid (VELCADE®)|
316742|NCT00346658|Drug|magnesium|
316743|NCT00346671|Other|Rest|30 min supine rest
316744|NCT00349752|Other|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
316745|NCT00349765|Behavioral|higher fat, high polyunsaturated fat diet|
316746|NCT00349765|Behavioral|higher fat, high saturated and trans fat diet|
316747|NCT00349765|Behavioral|lower fat diet|
316748|NCT00349778|Drug|cyclophosphamide|
316749|NCT00349778|Drug|etoposide|
316750|NCT00349778|Drug|BCNU Melphalan|
316751|NCT00349791|Drug|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
316752|NCT00349791|Drug|Placebo patch|placebo patch replaced twice a week for two years
316753|NCT00349804|Other|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
316754|NCT00003008|Drug|ritonavir|
316019|NCT00365170|Drug|insulin aspart|
316020|NCT00365183|Drug|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
316021|NCT00314067|Procedure|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
316022|NCT00002854|Drug|ifosfamide|
316023|NCT00314067|Procedure|Physician training|
316024|NCT00314067|Procedure|Practice team training|
316025|NCT00314080|Drug|Botulinum AntiToxin|
316026|NCT00314080|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
316027|NCT00314080|Procedure|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
316028|NCT00314093|Drug|RFT5pdgA|
316029|NCT00314106|Biological|Melanoma Reactive TIL|
316030|NCT00314106|Drug|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
316031|NCT00314106|Biological|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
316032|NCT00314106|Drug|Fludarabine|25 mg/m^2/day intravenous x 5 days
316033|NCT00002854|Drug|mesna|
316034|NCT00314106|Radiation|1200 total body irradiation (TBI)|1200 cGY total body radiation
316035|NCT00314132|Biological|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
316387|NCT00358670|Biological|infliximab|Infliximab maintenance therapy
intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2).
316388|NCT00358670|Biological|infliximab|Infliximab intermittent therapy:
Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 [NCT00251641] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a >=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse.
316389|NCT00358683|Drug|Certolizumab pegol|
315290|NCT00333268|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
315291|NCT00333281|Drug|tadalafil|
315292|NCT00333294|Drug|Gefitinib|
315293|NCT00333294|Procedure|Radiation therapy|
315294|NCT00333294|Drug|Cisplatin|
315295|NCT00333294|Drug|Vinorelbine|
315296|NCT00333307|Drug|recombinant human relaxin|
315642|NCT00323570|Drug|activated recombinant human factor VII|
315643|NCT00323583|Drug|paclitaxel|
315644|NCT00323583|Drug|oxaliplatin|
315645|NCT00323583|Drug|leucovorin|
315646|NCT00323583|Drug|5-fluorouracil|
315647|NCT00323583|Drug|glutathione|
315648|NCT00323583|Drug|calcium and magnesium|
315649|NCT00323583|Procedure|Chemotherapy|
315650|NCT00323583|Procedure|Chemoprotection|
315651|NCT00323583|Procedure|Complementary and alternative therapy|
315652|NCT00000463|Drug|warfarin|
315653|NCT00002889|Drug|leuprolide acetate|
315654|NCT00323596|Behavioral|physical activity program of strength and balance retraining|Unspecified
315655|NCT00323609|Procedure|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
315656|NCT00323609|Procedure|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
315657|NCT00323622|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
315658|NCT00323622|Biological|Engerix™-B|IM injection in the deltoid muscle
314942|NCT00340093|Behavioral|Managing Diabetes|
314943|NCT00345683|Biological|PedvaxHIB|Booster dose by intramuscular injection
314944|NCT00345683|Biological|Prevnar|Booster dose by intramuscular injection
314945|NCT00345683|Biological|M-M-R II|Single dose by subcutaneous injection
314946|NCT00345683|Biological|Varivax|Single dose by subcutaneous injection
314947|NCT00345696|Drug|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
314948|NCT00345696|Drug|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
314949|NCT00345696|Drug|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
314950|NCT00002988|Drug|irinotecan hydrochloride|
314951|NCT00345709|Behavioral|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
314952|NCT00345722|Procedure|strawberry dietary intervention|
314953|NCT00345735|Drug|Fentanyl|
314954|NCT00345748|Drug|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
315297|NCT00002941|Drug|etoposide|
315298|NCT00333320|Procedure|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
315299|NCT00333320|Procedure|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
315300|NCT00333333|Procedure|Cord blood|Cord blood will be obtained at the time of delivery.
315301|NCT00333346|Drug|Administration of tramadol intravenously|
315302|NCT00333359|Drug|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
315303|NCT00333372|Drug|Z-338|
315304|NCT00333385|Drug|ceftazidime|
315305|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
309772|NCT00249964|Drug|Combination Treatment - Cohort 4|Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 150 mg/m2 per day from day 2 to day 6.
309773|NCT00249977|Drug|Capecitabine in Combination with Cisplatin and Irinotecan|Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).
Capecitabine will be administered from day 1 to day 10 PO starting on course 2.
310139|NCT00239525|Drug|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
310140|NCT00239538|Drug|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
310141|NCT00239538|Drug|valsartan combined with hydrochlorothiazide (160/12.5mg)|
310142|NCT00239551|Drug|Prevacid|Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 & EGD with biopsy at 8 weeks
310143|NCT00239564|Drug|CD-LD ER|flexible dose
310144|NCT00239564|Drug|CD-LD IR|flexible dose
310145|NCT00239577|Biological|Live attenuated tetravalent dengue vaccine|
310146|NCT00000402|Drug|Calcium|
310147|NCT00002634|Biological|filgrastim|
310148|NCT00239590|Drug|Testosterone undecanoate|
310149|NCT00239603|Device|OV-Watch|
310150|NCT00239616|Drug|iron sucrose injection USP|
310151|NCT00239629|Drug|Teriparatide|
310152|NCT00239629|Drug|Strontium ranelate|
310153|NCT00239629|Procedure|Transiliac bone biopsy|
310154|NCT00243243|Drug|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
310155|NCT00243256|Drug|Cholecalciferol|
309414|NCT00259558|Drug|retarded release phosphatidylcholine|
309415|NCT00259571|Drug|retarded release phosphatidylcholine|2g daily, given orally QTD
309416|NCT00259584|Behavioral|Management and Outcome of SVCO|
309417|NCT00259597|Procedure|breast ductal lavage|breast ductal lavage and nipple aspiration done once
309418|NCT00259610|Drug|methotrexate|varies
309419|NCT00259610|Drug|sulfasalazine|varies
309420|NCT00259610|Drug|hydroxychloroquine|varies
309421|NCT00259610|Drug|etanercept|varies
309422|NCT00204984|Drug|oral hydralazine and intravenous nesiritide|vasodilators
309423|NCT00204997|Procedure|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
309424|NCT00205010|Procedure|Lymphoscintigraphy|
309425|NCT00002549|Drug|etoposide|
309426|NCT00205023|Procedure|Sonohysterography|SHG during surgery for endometrial cancer.
309427|NCT00205049|Drug|pentoxifylline|daily dosing
309428|NCT00205062|Procedure|PET-CT|
309774|NCT00249990|Drug|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
309775|NCT00250003|Behavioral|Preventive home visits|
309776|NCT00252902|Behavioral|Behavior change counseling|
309777|NCT00252915|Biological|GM-CSF (verum)|sagramostim
309778|NCT00252928|Other|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
309779|NCT00002674|Procedure|peripheral blood stem cell transplantation|
309780|NCT00252928|Other|Placebo|Placebo
309781|NCT00252941|Device|Memokath 028SW Urethral Stent|
309045|NCT00212693|Drug|ONO-2506PO|
309046|NCT00212706|Drug|ONO-8025 (KRP-197)|
309047|NCT00002565|Drug|cytarabine|
309048|NCT00212719|Drug|ONO-5920|
309049|NCT00212732|Drug|ONO-8025 (KRP-197)|
309050|NCT00212745|Behavioral|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
309051|NCT00212758|Drug|Nutropin AQ|Nutropin AQ
309052|NCT00212771|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
309053|NCT00212771|Drug|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
309054|NCT00212784|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
309055|NCT00216359|Procedure|Laboratory diagnostic (CD4-cells)|
309056|NCT00216359|Procedure|Laboratory diagnostics (HIV-1 viral load)|
309057|NCT00216359|Drug|antiretroviral co-medication beside Fuzeon|
309058|NCT00216372|Drug|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
309059|NCT00216372|Other|Placebo|A single intra-muscular injection on day 0.
309060|NCT00216385|Drug|Gatifloxacin combined regimen|
309061|NCT00216398|Drug|Lanreotide (Autogel formulation)|
309062|NCT00002571|Drug|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
309063|NCT00216411|Drug|Botulinum type A toxin (Dysport)|
309064|NCT00216424|Drug|Capecitabine (Xeloda)|
309065|NCT00216437|Drug|Capecitabine (Xeloda)|
309066|NCT00216450|Drug|rabeprazole sodium|
315429|NCT00000475|Behavioral|health education|
315430|NCT00003018|Drug|mitomycin C|10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
315431|NCT00352495|Drug|carboplatin|
315432|NCT00352495|Drug|vinblastine sulfate|
315433|NCT00352508|Behavioral|Dietary advice|
315434|NCT00352521|Drug|bevacizumab|
315435|NCT00352521|Drug|irinotecan|
315436|NCT00352521|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
315437|NCT00352534|Procedure|therapeutic conventional surgery|Undergo surgery
315438|NCT00352534|Drug|vincristine sulfate|Given IV
315786|NCT00341432|Behavioral|Nicotine Replacement Therapy|
315787|NCT00341445|Behavioral|Effect of Cockroach Allergen|
315788|NCT00341471|Procedure|Risk Behavior Prevention Intervention Program|
315789|NCT00002976|Drug|conjugated estrogens|
315790|NCT00341614|Behavioral|3-month Exercise Training and Diet Education|
315791|NCT00341640|Procedure|Blood testing|
315792|NCT00342108|Behavioral|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
315793|NCT00342134|Procedure|Stem Cell Transplanataion|
315794|NCT00342316|Procedure|Reduced Intensity Conditioning Stem Cell Transplantation|One of the following conditioning regimens:
Busulphan (orally or IV), fludarabine
Fludarabine, carmustine, melfalan
Cyclophosphamide, fludarabine
315795|NCT00342355|Drug|Zidovudine|600 mg once daily
315796|NCT00342355|Drug|Stavudine|40 mg once daily
315797|NCT00342355|Drug|Didanosine|<60 kg/125 mg twice daily or >60kg/200 mg twice daily
315798|NCT00342355|Drug|Lamivudine|300 mg once daily
315799|NCT00342355|Drug|Efavirenz|600 mg once daily
315070|NCT00358202|Drug|ceftriaxone|ceftriaxone 1 gm IM q24h
315071|NCT00358215|Drug|Darbepoetin alfa|Administered by subcutaneous injection
315072|NCT00003053|Drug|cisplatin|
315073|NCT00358215|Drug|Placebo|Placebo subcutaneous injection
315074|NCT00361231|Drug|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
315075|NCT00361231|Drug|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
315076|NCT00361244|Drug|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
315077|NCT00361244|Drug|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
315078|NCT00003066|Drug|estramustine phosphate sodium|
315079|NCT00361244|Drug|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
315080|NCT00361257|Drug|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
315081|NCT00361257|Drug|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
315082|NCT00361270|Behavioral|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
315083|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
315084|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
315085|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
315086|NCT00361283|Drug|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
315439|NCT00352534|Biological|dactinomycin|Given IV
315440|NCT00352534|Drug|doxorubicin hydrochloride|Given IV
315441|NCT00003019|Drug|methotrexate|
314374|NCT00323245|Behavioral|Physiotherapy for urinary incontinence|See Detailed Description.
314375|NCT00323258|Behavioral|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
314376|NCT00323258|Device|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
314377|NCT00323258|Device|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
314378|NCT00323258|Behavioral|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
314379|NCT00326079|Device|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
314380|NCT00326092|Drug|Brinzolamide/Timolol|
314381|NCT00326105|Drug|Quetiapine fumarate|
314728|NCT00313690|Drug|Bortezomib, Docetaxel and Cisplatin|
314729|NCT00313716|Drug|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
314730|NCT00313716|Other|placebo|an inactive substance
314731|NCT00313729|Drug|temozolomide|Chemotherapy
314732|NCT00313742|Drug|insulin detemir|
314733|NCT00316797|Drug|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
314734|NCT00316810|Drug|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
314735|NCT00316810|Drug|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
314736|NCT00316823|Genetic|gene expression analysis|
314016|NCT00332826|Drug|Technosphere Insulin|
314017|NCT00332839|Drug|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
314018|NCT00332839|Drug|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
314019|NCT00332839|Drug|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
314020|NCT00002937|Drug|valspodar|
314021|NCT00332839|Drug|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
314022|NCT00332839|Drug|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
314023|NCT00332852|Drug|Letrozole|2.5 mg/day - oraly
314024|NCT00332865|Behavioral|Swallowing Exercises|Daily exercises
314025|NCT00332878|Behavioral|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
314026|NCT00332878|Behavioral|stepping Stones short|3 hour intervention on HIV and safer sex
314027|NCT00332891|Drug|SR58611A|
314028|NCT00335933|Drug|Gabapentin extended-release tablets|
314029|NCT00002951|Radiation|radiation therapy|
314030|NCT00335946|Device|HANS non-needle acupuncture|
314031|NCT00335946|Procedure|Stimulation of two acupuncture points bi-lateral|
314032|NCT00335959|Drug|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
314033|NCT00335959|Drug|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
314034|NCT00335959|Procedure|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
314035|NCT00335959|Radiation|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
314382|NCT00002899|Procedure|adjuvant therapy|
313647|NCT00345111|Procedure|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
313648|NCT00345124|Behavioral|high sodium diet|250-350 mmol
313649|NCT00345124|Behavioral|Low Sodium Diet|25-35 mmol
313650|NCT00000471|Behavioral|diet, fat-restricted|
313651|NCT00002987|Drug|cyclophosphamide|
313652|NCT00345137|Drug|Ng-monomethyl-L-arginine (drug)|
313653|NCT00345150|Drug|Ng-monomethyl-L-arginine (drug)|
313654|NCT00345163|Drug|bevacizumab|Intravenous repeating dose
313655|NCT00345163|Drug|irinotecan|Intravenous repeating dose
313656|NCT00345176|Dietary Supplement|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
313657|NCT00345176|Dietary Supplement|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
313658|NCT00345176|Drug|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
314036|NCT00335972|Drug|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
314037|NCT00335972|Drug|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
314038|NCT00335972|Drug|Remifentanil and Desflurane|Remifentanil will be infused throughout the surgery at a rate of 01-0.2 µg/kg/min. Desflurane will be titrated to maintain BIS as close to 45 as clinically practical
314039|NCT00335972|Drug|Desflurane|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Desflurane will be titrated to maintain BIS as close to 45 as clinically practical.
314040|NCT00002952|Biological|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
314041|NCT00335972|Drug|Dexmedetomidine and Desflurane|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Desflurane will be titrated to maintain BIS as close to 45 as clinically practical.
312960|NCT00003080|Drug|tamoxifen citrate|
312961|NCT00363376|Drug|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
312962|NCT00363389|Drug|misoprostol and cervical ripening|
312963|NCT00363402|Procedure|PET-CT|
313303|NCT00354523|Drug|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle.
313304|NCT00354523|Drug|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
313305|NCT00354536|Drug|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
313306|NCT00354536|Biological|placebo injection|placebo injection
313307|NCT00354549|Drug|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
313308|NCT00003034|Drug|doxorubicin hydrochloride|Given IV
313309|NCT00354549|Drug|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
313310|NCT00354562|Drug|ABT-751|200mg ABT-751 daily for 14 days every 21 days
313311|NCT00354562|Drug|Placebo|Placebo daily for 14 days every 21 days
313312|NCT00354562|Drug|Docetaxel|Standard Docetaxel every 21 days
313313|NCT00354575|Drug|Chinese Herb: CCH1|1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
313314|NCT00354601|Drug|capecitabine|oral capecitabine twice daily on days 1-21
313315|NCT00354601|Drug|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
313316|NCT00354614|Device|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
313317|NCT00354627|Drug|TMC125|200 mg b.i.d. till commercially available.
313318|NCT00354640|Drug|anastrozole|1 milligram tablet PO QD for 14 days
313319|NCT00000478|Drug|atenolol|
312594|NCT00318903|Procedure|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
312595|NCT00318929|Drug|Divalproex Sodium Extended-Release Tablets|Once a day dosing
312596|NCT00318942|Drug|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
312597|NCT00318942|Drug|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
312598|NCT00318942|Drug|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
312599|NCT00318942|Drug|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
312600|NCT00318955|Drug|Dexmedetomidine|
312601|NCT00318955|Drug|Propofol|
312602|NCT00318968|Drug|Esomeprazole|
312603|NCT00318981|Drug|Concerta|
312604|NCT00002874|Drug|bicalutamide|
312605|NCT00318994|Drug|Meropenem|
312606|NCT00319007|Drug|Sulindac (drug)|
312607|NCT00319007|Drug|VSL#3 (probiotic)|
312608|NCT00319007|Drug|Inulin (probiotic)|
312609|NCT00319020|Drug|bosentan|32 mg breakable tablets 4 mg maintenance dose
312610|NCT00319033|Drug|bosentan|
312611|NCT00319046|Drug|miglustat|miglustat oral capsules 100mg three times daily (TID)
312964|NCT00363415|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
312965|NCT00363415|Drug|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
312966|NCT00363415|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
312967|NCT00363428|Behavioral|exercise intervention|life style
312968|NCT00363428|Behavioral|smoking cessation intervention|Life style
311865|NCT00337909|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
311866|NCT00337909|Other|Educational DVDs|
311867|NCT00337922|Drug|Lamivudine / Abacavir Sulfate|
311868|NCT00337935|Drug|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
311869|NCT00337935|Other|Standard of care|
311870|NCT00337948|Drug|Epoetin alfa|
311871|NCT00002967|Drug|doxorubicin hydrochloride|
312215|NCT00328627|Drug|Alogliptin placebo|Alogliptin placebo-matching tablets.
312216|NCT00328627|Drug|Pioglitazone|Pioglitazone tablets.
312217|NCT00002913|Drug|topotecan hydrochloride|Given IV
312218|NCT00328627|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
312219|NCT00328640|Drug|Optimal treatment|
312220|NCT00328653|Drug|cyclosporine|
312221|NCT00328666|Behavioral|Iyengar yoga|
312222|NCT00328666|Behavioral|Enhanced nutritional care classes|
312223|NCT00328679|Device|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
312224|NCT00328692|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
312225|NCT00328692|Drug|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
312226|NCT00328705|Device|Implantable Cardioverter Defibrillator|
312227|NCT00328718|Drug|montelukast (5mg QD)|
312228|NCT00000464|Drug|quinidine|
312229|NCT00002913|Biological|filgrastim|Given SC
312230|NCT00328718|Drug|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
312231|NCT00328731|Procedure|Procedure|
311504|NCT00347438|Drug|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
311505|NCT00002999|Drug|cisplatin|
311506|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
311507|NCT00003012|Drug|fluorouracil|
311508|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
311509|NCT00350636|Drug|Oxybutynin topical gel|1 application daily to skin for 12 weeks
311510|NCT00350636|Other|Placebo topical gel|1 application daily to skin for 12 weeks
311511|NCT00350649|Behavioral|Standard CBT|Manualized delivery of CBT by trained clinicians
311512|NCT00350649|Behavioral|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
311513|NCT00350649|Behavioral|CM/abstinence|Contingency Management
311514|NCT00350649|Behavioral|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
311515|NCT00350662|Drug|Deferiprone (L1)|75 mg/kg body weight daily
311516|NCT00350662|Drug|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
311517|NCT00350688|Radiation|Helical tomotherapy IMRT|Helical tomotherapy IMRT
311518|NCT00003012|Drug|methotrexate|
311519|NCT00350701|Drug|androgel|androgel 5g
311520|NCT00350701|Drug|androgel 10g|androgel 10g
311521|NCT00350701|Drug|placebo|placebo
311522|NCT00350714|Other|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
311872|NCT00337961|Procedure|Optic Nerve Sheath Fenestration|
311873|NCT00337974|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
311874|NCT00337974|Other|Educational DVDs|
316755|NCT00349817|Behavioral|web-based learning, didactic lecture and role-play|
316756|NCT00349830|Procedure|blood draw|
316757|NCT00349843|Device|Soft contact lens|
316758|NCT00349843|Drug|Marketed soft lens multipurpose disinfection regimen|
316759|NCT00349856|Device|Biofinity|Soft contact lens
316760|NCT00349869|Behavioral|yoga|8-week yoga program.
316761|NCT00349882|Device|soft contact lens|
316762|NCT00349882|Drug|Marketed multipurpose disinfection regimen|
316763|NCT00349895|Device|Coronary stent implantation|Percutaneous Coronary Intervention
311153|NCT00359489|Device|cardiac echosonography|
311154|NCT00359554|Biological|VAXIGRIPPE|
311155|NCT00359567|Drug|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
311156|NCT00003060|Drug|cyclosporine|
311157|NCT00359567|Drug|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
311158|NCT00359593|Behavioral|Knowledge translation intervention package|
311159|NCT00359606|Drug|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
311160|NCT00359606|Other|Laboratory Biomarker Analysis|Correlative Studies
311161|NCT00359606|Other|Pharmacological Study|Correlative Studies
311162|NCT00359606|Drug|Tetrahydrouridine (THU)|Given PO and IV
311163|NCT00359619|Biological|CervarixTM|Subjects were administered three doses of HPV vaccine
311164|NCT00359619|Biological|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
311165|NCT00359632|Drug|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
316390|NCT00003056|Drug|cyclosporine|
316391|NCT00358696|Drug|tenofovir|See Detailed Description.
316392|NCT00358709|Behavioral|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
316393|NCT00358722|Drug|Fermagate|Film coated tablet 500mg
316394|NCT00358735|Device|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
316395|NCT00358735|Drug|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
316396|NCT00358748|Drug|Hydrocortisone|See detailed description above.
316397|NCT00358774|Procedure|homeopathic nasal spray|
316398|NCT00358787|Procedure|Crossed K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
316399|NCT00358787|Procedure|Lateral K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
316400|NCT00358800|Device|REMStar Auto with C-Flex|
316401|NCT00003056|Drug|cyclosporine and methotrexate|
316402|NCT00358813|Drug|GW679769|
316403|NCT00358826|Drug|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
316404|NCT00358826|Drug|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
316405|NCT00358839|Drug|CGRP|
316406|NCT00361686|Device|patient contolled analgesia|
316764|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
316765|NCT00003008|Drug|saquinavir mesylate|
316766|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
315659|NCT00323622|Biological|Hiberix®|IM injection in the deltoid muscle
315660|NCT00323622|Biological|Prevnar™|IM injection in the deltoid muscle
315661|NCT00323622|Drug|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
315662|NCT00323622|Drug|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
315663|NCT00323635|Drug|tolterodine|tablet, 4 mg, daily, 1 month
315664|NCT00002889|Radiation|low-LET photon therapy|
315665|NCT00323648|Drug|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
315666|NCT00323661|Device|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
316036|NCT00314132|Biological|0.9% Saline|0.5 mL, Subcutaneous
316037|NCT00314145|Biological|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
316038|NCT00314145|Biological|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
316039|NCT00314158|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
316040|NCT00314158|Drug|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
316041|NCT00314158|Drug|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
316042|NCT00314171|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
316043|NCT00314171|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
316044|NCT00002854|Drug|paclitaxel|
316045|NCT00314184|Drug|quetiapine fumarate|
316046|NCT00314197|Behavioral|Telephone Linked Care - Behavior Change Counseling System|
316047|NCT00314197|Behavioral|Telephone-linked behavioral counseling|
316048|NCT00314210|Drug|Quetiapine SR|
316049|NCT00314236|Device|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
315306|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
315307|NCT00333398|Biological|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
315308|NCT00002941|Drug|mesna|
315309|NCT00333411|Drug|BIRT 2584 XX|
315310|NCT00333411|Drug|Placebo|
315311|NCT00333424|Biological|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
315312|NCT00333437|Drug|Mycophenolate mofetil|
315313|NCT00333450|Biological|Pneumococcal vaccine|
315314|NCT00333463|Behavioral|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
315315|NCT00333476|Drug|MSI-1256F (Squalamine Lactate)|
315316|NCT00333489|Drug|valsartan|
315317|NCT00336336|Drug|n-3 PUFA|1 g die per os
315318|NCT00336336|Drug|Rosuvastatin|10 mg die per os
315319|NCT00336336|Drug|Placebo|1 gram c. per os
315667|NCT00323661|Device|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
315668|NCT00323674|Device|Polysoft Mesh|Polysoft Mesh is used.
315669|NCT00323674|Device|Light Weight Mesh|Light Weight Mesh is used.
315670|NCT00323687|Drug|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
315671|NCT00002903|Drug|docetaxel|
315672|NCT00326768|Drug|Telmisartan 80 mg/HCTZ 12.5 mg|
315673|NCT00326781|Drug|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
310156|NCT00243269|Behavioral|Acupressure expectancy enhancement|This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.
This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea.
310157|NCT00243282|Behavioral|Relaxation Response (instruction, pocket practice card prov)|
310158|NCT00243282|Behavioral|Mindfulness training using model developed from UMass|
310159|NCT00243295|Drug|rhBMP-2/CPM|
310160|NCT00243308|Drug|Serine proteinase-1 (Serp-1)|
310515|NCT00334594|Drug|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
310516|NCT00334594|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
310517|NCT00002945|Biological|filgrastim|IV
310518|NCT00334594|Procedure|Therapeutic conventional surgery|Extrapleural pneumonectomy
310519|NCT00334594|Radiation|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
310520|NCT00334607|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
310521|NCT00334620|Procedure|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
310522|NCT00334633|Drug|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
310523|NCT00334646|Drug|Oral GW679769|150mg oral, once daily on days 1-3
310524|NCT00334646|Drug|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
310525|NCT00334659|Drug|apricitabine|
310526|NCT00334672|Biological|anti-thymocyte globulin|
310527|NCT00334672|Drug|busulfan|
310528|NCT00002945|Drug|cyclophosphamide|IV
310529|NCT00334672|Drug|cyclophosphamide|
310530|NCT00334672|Drug|cyclosporine|
310531|NCT00334672|Drug|dexamethasone|
309782|NCT00252954|Drug|Levetiracetam|Tablets 2000-3000 mg per day
309783|NCT00252967|Drug|Atorvastatin|80 mg of Atorvastatin
309784|NCT00252967|Drug|Placebo|
309785|NCT00252980|Behavioral|Psychotherapy|
309786|NCT00252993|Drug|DDP225|
309787|NCT00253006|Procedure|Tissue examination for protein- and mRNA-expression of NO|
309788|NCT00253032|Device|PRIMA|
309789|NCT00253045|Behavioral|Motivational groups|Motivational interviewing in group format
309790|NCT00000135|Drug|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
309791|NCT00000411|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
309792|NCT00002675|Biological|filgrastim|
309793|NCT00253058|Drug|Cetirizine Dry Syrup|
309794|NCT00253071|Behavioral|Prophylactic combined medical and psychological treatment|Medical treatment is naturalistic and evidence based according to international recommendations.
Psychological treatment is either group psychoeducation or group cognitive behavioural therapy.
309795|NCT00253084|Drug|CD-LD ER|b.i.d.
309796|NCT00253084|Drug|Carbidopa-Levodopa|q.i.d.
310161|NCT00243321|Procedure|high dose-rate brachytherapy|High dose-rate brachytherapy
310162|NCT00243321|Procedure|intensity-modulated radiation therapy|intensity-modulated radiation therapy
310163|NCT00243334|Other|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
310164|NCT00000406|Procedure|Progressive resistance exercise|
310165|NCT00002643|Biological|filgrastim|
310166|NCT00243347|Drug|AZD2171|oral tablet
310167|NCT00243360|Behavioral|diagnostic and treatment clinical algorithms|
309429|NCT00205114|Behavioral|Individualized multifactorial intervention for community-living high-risk older adults|
309430|NCT00205114|Behavioral|Health professional education program about fall prevention|
309431|NCT00205127|Procedure|Cardiac PET imaging- rest and pharmacological stress|
309432|NCT00205153|Behavioral|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
309433|NCT00205166|Procedure|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
309434|NCT00205166|Drug|Caffeine|Caffeine 400 mg po
309435|NCT00205166|Drug|Caffeine|Caffeine 200 mg po
309436|NCT00002549|Drug|idarubicin|
309437|NCT00205179|Drug|Novasoy|100mg/day soy isoflavones
309438|NCT00205179|Drug|Placebo|100mg/day matching placebo
309439|NCT00205192|Procedure|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
309440|NCT00205205|Behavioral|peer mentoring|
309441|NCT00205231|Drug|etanercept|
309442|NCT00205244|Behavioral|Healing images, relaxation and distraction materials|
309443|NCT00205270|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
309444|NCT00205283|Drug|Nelfinavir|
309445|NCT00205296|Behavioral|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
309446|NCT00205322|Drug|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
309447|NCT00002549|Drug|mesna|
309448|NCT00205335|Device|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
309449|NCT00205335|Device|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
309450|NCT00205374|Drug|Cidofovir|Subjects will be randomly assigned to either a cidofovir injection or a placebo group, based upon a pre-determined random schedule
315800|NCT00002977|Biological|filgrastim|
315801|NCT00342355|Drug|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
315802|NCT00342368|Procedure|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
315803|NCT00342381|Drug|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
315804|NCT00342381|Drug|Placebo|Single dose placebo treatment
315805|NCT00342563|Drug|mecamylamine|mecamylamine 10mg/day
315806|NCT00342563|Drug|Placebo|Placebo
315807|NCT00342628|Biological|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
315808|NCT00342628|Biological|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
315809|NCT00342628|Biological|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
315810|NCT00342706|Procedure|Community based intervention|
316187|NCT00330421|Other|pharmacological study|Correlative studies
316188|NCT00330421|Procedure|computed tomography|Correlative studies
316189|NCT00330421|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
316190|NCT00330434|Drug|Bupropion|
316191|NCT00330434|Drug|Chlorzoxazone|
316192|NCT00330434|Drug|Ethanol|
316193|NCT00330460|Drug|Alendronate|ALN; 70 mg; oral; once weekly
316194|NCT00330460|Drug|Denosumab|60 mg; SC; every 6 months
316195|NCT00002925|Drug|ara-C|
316196|NCT00330473|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
316197|NCT00330473|Drug|Insulin|patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
315442|NCT00352534|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
315443|NCT00352560|Drug|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
315444|NCT00352560|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
315445|NCT00352599|Drug|Lovastatin|
315446|NCT00352599|Drug|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
315447|NCT00352599|Drug|placebo pill|
315448|NCT00352612|Drug|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
315449|NCT00352612|Drug|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
315450|NCT00352625|Drug|Ketoprofen Topical Patch 20%|
315451|NCT00352638|Other|counseling intervention|
315452|NCT00003019|Drug|vinblastine sulfate|
315453|NCT00352638|Other|educational intervention|
315454|NCT00352638|Other|study of socioeconomic and demographic variables|
315455|NCT00352651|Drug|Pregabalin|
315456|NCT00352664|Drug|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
315457|NCT00352664|Drug|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
315458|NCT00352677|Drug|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
315459|NCT00352690|Drug|Paclitaxel poliglumex|
315460|NCT00352690|Drug|Carboplatin|
315461|NCT00355342|Drug|fluticasone propionate/salmeterol powder|
315462|NCT00355342|Drug|salmeterol powder|
315463|NCT00355355|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
315464|NCT00000478|Drug|nifedipine|
314737|NCT00316823|Genetic|polymerase chain reaction|
314738|NCT00316823|Genetic|reverse transcriptase-polymerase chain reaction|
314739|NCT00002865|Drug|mesna|
314740|NCT00316823|Other|diagnostic laboratory biomarker analysis|
314741|NCT00316823|Other|immunohistochemistry staining method|
314742|NCT00316823|Procedure|needle biopsy|
314743|NCT00316836|Procedure|mammography|
314744|NCT00316849|Other|pharmacological study|
314745|NCT00316849|Procedure|adjuvant therapy|
314746|NCT00316849|Radiation|3-dimensional conformal radiation therapy|
314747|NCT00316849|Radiation|intensity-modulated radiation therapy|
314748|NCT00316849|Drug|temsirolimus|Given IV
314749|NCT00316849|Drug|temozolomide|Given orally
314750|NCT00002865|Drug|methotrexate|
315087|NCT00361296|Biological|GM-K562 cell vaccine|
315088|NCT00361309|Drug|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
315089|NCT00003067|Biological|aldesleukin|
315090|NCT00361322|Drug|clindamycin phosphate|
315091|NCT00361322|Drug|salicylic acid|
315092|NCT00361335|Drug|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
315093|NCT00361335|Drug|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
315094|NCT00361335|Drug|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
315095|NCT00361348|Drug|Palifermin|
315096|NCT00361348|Drug|Heparin|
314383|NCT00326118|Biological|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
314384|NCT00326118|Biological|Priorix™|One subcutaneous dose at 12-18 months of age
314385|NCT00326118|Biological|Hiberix™|One intramuscular dose at 12-18 months of age.
314386|NCT00326118|Biological|Meningitec™|One intramuscular dose at 12-18 months of age
314387|NCT00326131|Drug|Oral Taxane|
314388|NCT00326144|Drug|Quetiapine fumarate|
314389|NCT00326157|Drug|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
314390|NCT00326170|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
314391|NCT00326170|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
314392|NCT00326170|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
314393|NCT00002899|Radiation|radiation therapy|
314394|NCT00326183|Biological|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
314395|NCT00326183|Biological|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
314396|NCT00326196|Device|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
314397|NCT00326196|Procedure|Coronary artery bypass graft (CABG)|coronary bypass
314398|NCT00326209|Drug|Mesalamine pellets|subjects receive 4 capsules each morning of 375mg MG each (total of 1.5g QD)
314399|NCT00326222|Behavioral|Lifestyle counseling|Self-management group education
314400|NCT00326235|Drug|Buspirone|
314401|NCT00326248|Drug|GW679769 (casopitant)|
314402|NCT00326261|Procedure|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
314403|NCT00326261|Procedure|Ultrasound|
314404|NCT00002899|Radiation|stereotactic radiosurgery|
314042|NCT00335985|Drug|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
314043|NCT00335985|Drug|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
314044|NCT00335998|Drug|triapine|Given IV
314045|NCT00335998|Other|laboratory biomarker analysis|Correlative studies
314046|NCT00335998|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
314047|NCT00335998|Radiation|brachytherapy|Undergo intracavitary or interstitial brachytherapy
314048|NCT00335998|Drug|cisplatin|Given IV
314049|NCT00335998|Other|pharmacological study|Correlative studies
314050|NCT00336011|Device|Magnetic resonance imaging|
314051|NCT00002952|Biological|recombinant MAGE-3.1 antigen|
314052|NCT00336024|Drug|etoposide|Given IV
314053|NCT00338871|Procedure|home exercise|
314054|NCT00338884|Drug|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
314055|NCT00338897|Drug|SR123781A|
314056|NCT00338910|Drug|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
314407|NCT00326287|Drug|Ceftriaxone with or without Linezolid|
314408|NCT00326300|Drug|methylphenidate hydrochloride extended-release tablets|
314409|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
314410|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
314411|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
313320|NCT00003034|Drug|ranpirnase|Given IV
313321|NCT00357448|Procedure|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
313322|NCT00357448|Other|laboratory biomarker analysis|Correlative studies
313323|NCT00357448|Other|enzyme-linked immunosorbent assay|Correlative studies
313324|NCT00357448|Other|flow cytometry|Correlative studies
313325|NCT00003050|Drug|cyclophosphamide|
313659|NCT00345189|Drug|CNF2024|CNF2024 capsules administered orally following 2 schedules:
starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or
starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.
313660|NCT00345202|Drug|HMG-CoA reductase inhibition (atorvastatin)|
313661|NCT00345215|Behavioral|High Sodium Diet|250-350 mmol
313662|NCT00002987|Drug|doxorubicin hydrochloride|
313663|NCT00345215|Behavioral|Low Sodium Diet|25-35 mmol
313664|NCT00345241|Drug|Systane Ocular Drops (OTC)|
313665|NCT00345241|Drug|Placebo - Saline Drops|
313666|NCT00348387|Biological|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
313667|NCT00348387|Biological|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
313668|NCT00348400|Drug|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
313669|NCT00348413|Drug|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
313670|NCT00348426|Drug|Botulinum AntiToxin|
313671|NCT00348426|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
313672|NCT00348426|Procedure|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
313673|NCT00348439|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
312969|NCT00363428|Other|counseling intervention|life style
312970|NCT00363428|Other|educational intervention|life style
312971|NCT00003080|Drug|thiotepa|
312972|NCT00363428|Procedure|conventional surgery|life style
312973|NCT00363428|Procedure|pulmonary complications management/prevention|life style
312974|NCT00363441|Procedure|Intensity Modulated Radiotherapy|
312975|NCT00363454|Drug|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m^2; Level 2: 25 mg/m^2; 35 mg/m^2; 45 mg/m^2.
312976|NCT00363467|Drug|G-CSF|Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.
Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously.
312977|NCT00363467|Drug|Leukapheresis|leukapheresis
312978|NCT00312676|Procedure|Rapid versus slow conversion|
312979|NCT00312702|Biological|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
312980|NCT00312728|Drug|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
312981|NCT00312728|Drug|First-Line Chemotherapy Agents|Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.
All agents were dosed and administered per institutional standards using the respective package insert as a guideline.
312982|NCT00312728|Drug|Second-Line Chemotherapy Agents|Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.
All agents were dosed and administered per institutional standards using the respective package insert as a guideline.
312983|NCT00312741|Procedure|empirical versus microbiological guided treatment|
313326|NCT00357461|Biological|gp100:209-217(210M) peptide vaccine|
313327|NCT00357461|Biological|gp100:280-288(288V) peptide vaccine|
313328|NCT00357461|Biological|incomplete Freund's adjuvant|
312232|NCT00328744|Behavioral|Standard|18-month standard behavioral weight loss intervention
312233|NCT00328744|Behavioral|Limited Variety|Two chosen snack foods
312234|NCT00328757|Behavioral|Regular diet as the first postoperative meal|
312235|NCT00328770|Drug|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
312236|NCT00328783|Device|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
312237|NCT00328783|Radiation|Radiation Therapy|
312238|NCT00328796|Procedure|acupuncture in 6 specific points|
312239|NCT00328796|Drug|lidocaine 10mg/ml|
312240|NCT00002914|Drug|piritrexim|
312612|NCT00319059|Drug|systemic administration of 99mTc-HYNIC-Annexin A5|
312613|NCT00319059|Behavioral|10 minutes of ischemic handgripping|
312614|NCT00319072|Behavioral|TalkToYourDoc(sm) hormone therapy module|
312615|NCT00002874|Radiation|low-LET cobalt-60 gamma ray therapy|
312616|NCT00319085|Procedure|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
312617|NCT00319098|Biological|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
312618|NCT00319098|Biological|Fluarix|One intramuscular injection
312619|NCT00319098|Biological|Placebo|One intramuscular injection
312620|NCT00002884|Drug|cisplatin|
312621|NCT00322218|Other|Observation|Observation
312622|NCT00322231|Biological|zoster vaccine live (ZOSTAVAX™)|1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
312623|NCT00322231|Biological|Comparator: Placebo|1 dose 0.65 mL/dose subcutaneous injection of placebo.
312624|NCT00322244|Procedure|Massage Therapy|
312625|NCT00322257|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
311875|NCT00337987|Drug|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
311876|NCT00337987|Drug|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
311877|NCT00338000|Drug|Epoetin alfa|
311878|NCT00338026|Drug|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
311879|NCT00338039|Drug|Cetuximab|500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
311880|NCT00338039|Drug|Gemcitabine|Induction Therapy: 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.
Chemotherapy Maintenance: 1 gm/m^2/week over 100 minutes weekly for 3 weeks then 1 week off.
311881|NCT00338039|Drug|Oxaliplatin|Induction Chemotherapy: 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
311882|NCT00002967|Drug|octreotide pamoate|
311883|NCT00338039|Drug|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
311884|NCT00338039|Radiation|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
311885|NCT00000140|Drug|Silicone Oil|
311886|NCT00000471|Behavioral|diet, vegetarianism|
311887|NCT00002984|Drug|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
311888|NCT00344006|Drug|artemether-lumefantrine|
311889|NCT00344019|Drug|atorvastatin|
311890|NCT00344032|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
311891|NCT00344032|Biological|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
311892|NCT00344045|Drug|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
311893|NCT00344045|Drug|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
311166|NCT00359632|Drug|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
311167|NCT00003060|Drug|methotrexate|
311168|NCT00359645|Procedure|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
311169|NCT00359658|Drug|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
311170|NCT00359658|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
311171|NCT00359658|Drug|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
311172|NCT00359671|Drug|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
311173|NCT00359671|Drug|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
311174|NCT00359684|Drug|Cysteamine|Cystine-depleting agent
311523|NCT00350727|Drug|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
311524|NCT00350727|Drug|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
311525|NCT00350753|Drug|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
311526|NCT00350766|Procedure|Catheter based Stem cells delivery|About 100 ml of Bone Marrow aspirate will be harvested from iliac crest between the fifth and seventh day after myocardial reperfusion therapy. ABMMC will be isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions. A total of 100 million cells will be resuspended in a 10 ml solution of saline with autologous serum and filtered through 100 um nylon mesh to remove cell aggregates for injection.
311527|NCT00350766|Other|Autologous Bone Marrow Mononuclear Cells Transplantation|About 100 ml of Bone Marrow aspirate will be harvested from iliac crest between the fifth and seventh day after myocardial reperfusion therapy. ABMMC will be isolated by density gradient centrifugation on Ficoll- PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions. A total of 100 million cells will be resuspended in a 10 ml solution of saline with autologous serum and filtered through 100 um nylon mesh to remove cell aggregates for injection.
311528|NCT00350779|Drug|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
311529|NCT00003013|Drug|CMF regimen|
311530|NCT00003027|Drug|vinblastine|
316767|NCT00349921|Drug|clonidine|Clonidine—a drug commonly used to treat high blood pressure—has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
316768|NCT00349921|Drug|adenosine|Adenosine—a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms—has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
316769|NCT00349921|Drug|placebo|inactive substance
316770|NCT00349921|Drug|placebo|inactive substance
316771|NCT00353054|Behavioral|Weight loss intervention|
316772|NCT00353067|Drug|veliflapon (DG-031)|
316773|NCT00353080|Drug|risedronate (HMR4003)|
316774|NCT00353093|Procedure|Ultrasonography of the deep vein system of the legs|
316775|NCT00353106|Behavioral|Interview|30-minute interviews of participating patients and their caregiver(s).
316776|NCT00003025|Biological|vitespen|
316777|NCT00353106|Behavioral|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
316778|NCT00353119|Drug|Placebo comparator|Patients received placebo subcutaneously twice weekly
316779|NCT00353119|Drug|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
316780|NCT00353145|Drug|Gemcitabine (Gemox)|1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 repeated every 14 days (one cycle).
316781|NCT00353145|Drug|Oxaliplatin|100 mg/m^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
316782|NCT00353145|Behavioral|Questionnaire|Quality of Life Surveys
316783|NCT00353158|Drug|Doxycycline|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
316784|NCT00353158|Drug|Voriconazole|After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
316785|NCT00353184|Drug|Montelukast 5-mg orally added to standard therapy|
311175|NCT00359697|Drug|Hypertonic Saline, Mannitol|
311176|NCT00359723|Drug|methylphenidate|
316050|NCT00314236|Procedure|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
316051|NCT00317291|Procedure|Acupuncture/Moxibustion|
316052|NCT00317304|Behavioral|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
316053|NCT00317317|Procedure|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
316054|NCT00317330|Drug|Isoniazid|
316055|NCT00317330|Drug|Pyrazinamide|
316056|NCT00317330|Drug|Rifampin|
316057|NCT00317343|Drug|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
316058|NCT00317356|Drug|OPC-6535(Tetomilast)|
316059|NCT00317369|Drug|OPC-6535(Tetomilast)|
316407|NCT00361699|Drug|Statin|
316408|NCT00361712|Procedure|Epidural analgesia|
316409|NCT00361738|Drug|AVE2268|
316410|NCT00003068|Procedure|peripheral blood stem cell transplantation|
316411|NCT00361751|Drug|fenofibrate|
316412|NCT00361790|Drug|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
316413|NCT00361803|Drug|topotecan|
316414|NCT00361842|Drug|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
316415|NCT00361855|Drug|NX-CP105|
316416|NCT00361868|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
316417|NCT00361868|Drug|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
316418|NCT00361881|Drug|ME-609|Cream, dose 5 times daily during 5 days.
315674|NCT00326781|Drug|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
315675|NCT00326794|Procedure|mobilisation (rehabilitation)|
315676|NCT00326807|Drug|Naltrexone|
315677|NCT00326820|Drug|ibandronate sodium|
315678|NCT00326820|Drug|zoledronic acid|
315679|NCT00326820|Drug|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
315680|NCT00326833|Drug|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
315681|NCT00326859|Drug|remifentanil|
315682|NCT00000464|Drug|procainamide|
315683|NCT00002904|Drug|trabectedin|
315684|NCT00326872|Drug|Cediranib Maleate|
315685|NCT00326885|Drug|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
315686|NCT00326898|Other|Laboratory Biomarker Analysis|Correlative studies
315687|NCT00326898|Other|Placebo|Given PO
315688|NCT00326898|Other|Quality-of-Life Assessment|Ancillary studies
315689|NCT00326898|Drug|Sorafenib Tosylate|Given PO
315690|NCT00326898|Drug|Sunitinib Malate|Given PO
316060|NCT00317382|Device|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
316061|NCT00002866|Drug|epirubicin hydrochloride|
316062|NCT00317395|Drug|Otamixaban (XRP0673)|intravenous administration
316063|NCT00317395|Drug|unfractionated heparin|intravenous administration
316064|NCT00317395|Drug|eptifibatide|intravenous administration
316065|NCT00317408|Biological|anti-thymocyte globulin|
310532|NCT00334672|Drug|etoposide|
310533|NCT00334672|Drug|methotrexate|
310534|NCT00334672|Drug|mycophenolate mofetil|
310535|NCT00334672|Drug|therapeutic hydrocortisone|
310536|NCT00334672|Other|laboratory biomarker analysis|
310537|NCT00334672|Procedure|allogeneic hematopoietic stem cell transplantation|
310538|NCT00334672|Procedure|biopsy|
310539|NCT00002945|Drug|cytarabine|IV
310540|NCT00334685|Drug|[S,S]-Reboxetine|
310541|NCT00334698|Drug|Cetirizine|
310881|NCT00324584|Device|Telemonitoring of glucose values using GlucoNet device|
310882|NCT00324597|Drug|gemcitabine hydrochloride|
310883|NCT00324597|Drug|motesanib diphosphate|
310884|NCT00324597|Other|pharmacological study|
310885|NCT00002896|Drug|leucovorin calcium|
310886|NCT00324610|Drug|capecitabine|
310887|NCT00324623|Biological|Melan-A VLP vaccine, IMP321 adjuvant|
310888|NCT00324623|Biological|adoptive immunotherapy|
310889|NCT00327912|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
310890|NCT00002909|Drug|oral sodium phenylbutyrate|
310891|NCT00327925|Procedure|Find Cancer Associated Antibodies|
310892|NCT00327938|Device|Measuring of skin conductance|
310893|NCT00327938|Procedure|Tetanic stimuli|
310894|NCT00327990|Drug|Ibandronate|
310895|NCT00327990|Drug|Alendronate|
310168|NCT00243373|Device|Barcode technology/eMAR|
310169|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
310170|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
310171|NCT00243399|Drug|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
310172|NCT00243412|Drug|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
310173|NCT00243412|Drug|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
310174|NCT00243412|Drug|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
310175|NCT00243412|Drug|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
310176|NCT00002643|Drug|amifostine trihydrate|
310177|NCT00243412|Drug|Rituximab|500 mg or 1000 mg IV*2.
310178|NCT00243425|Procedure|Standard Quality Improvement|
310179|NCT00246337|Drug|MK0974|MK0974 50 mg; one orally-administered dose
310180|NCT00002654|Radiation|low-LET cobalt-60 gamma ray therapy|
310181|NCT00246337|Drug|MK0974|MK0974 100 mg; one orally-administered dose
310182|NCT00246337|Drug|MK0974|MK0974 200 mg; one orally-administered dose
310183|NCT00246337|Drug|MK0974|MK0974 300 mg; one orally-administered dose
310542|NCT00334698|Drug|Pseudoephedrine|
310543|NCT00334698|Drug|Cetirizine with Pseudoephedrine|
310544|NCT00334711|Drug|Sulfonylurea|
310545|NCT00334724|Procedure|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
310546|NCT00334724|Procedure|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
309797|NCT00253097|Behavioral|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
309798|NCT00253110|Drug|risperidone|
309799|NCT00253110|Drug|haloperidol|
309800|NCT00253123|Drug|risperidone|
309801|NCT00253136|Drug|risperidone|
309802|NCT00253149|Drug|risperidone|
309803|NCT00002675|Drug|carboplatin|
309804|NCT00253162|Drug|risperidone|
309805|NCT00253175|Drug|topiramate|
309806|NCT00255905|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|
309807|NCT00255905|Behavioral|Clinician monitoring|
309808|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
309809|NCT00255918|Drug|Placebo|Placebo dosed to match active medication
309810|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
309811|NCT00255931|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
309812|NCT00255931|Behavioral|Attention Placebo|Untrained relaxation
309813|NCT00255944|Behavioral|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
309814|NCT00255944|Behavioral|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
309815|NCT00002682|Drug|Omeprazole|
309816|NCT00255957|Drug|HES administration|
309817|NCT00255957|Drug|Hydroxy Ethyl Starch administration to stroke patients|
309818|NCT00255970|Other|DFDBA|Demineralized Freeze Dried Allograft bone
316198|NCT00330486|Drug|Acamprosate|
316199|NCT00330499|Drug|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
316200|NCT00330499|Radiation|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
316201|NCT00330525|Drug|sibutramine|
316202|NCT00333697|Other|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
316203|NCT00333710|Behavioral|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
316204|NCT00333710|Behavioral|Telehealth Intervention|Individual telephone contact with educational and goal setting components
316205|NCT00333723|Drug|Rosiglitazone|
316206|NCT00333736|Device|Biojector|All patients received biojector to use with BID enfuvirtide doses
316207|NCT00333749|Biological|Drinking or rinsing the mouth 2-3 times for 1 day|
316208|NCT00333749|Biological|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
316209|NCT00333762|Device|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
316210|NCT00333762|Device|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
316555|NCT00323960|Drug|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
316556|NCT00323960|Drug|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
316557|NCT00323960|Drug|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
316558|NCT00323973|Drug|Bisoprolol|10 mg qd
316559|NCT00323986|Drug|azithromycin (drug)|
316560|NCT00002893|Drug|leucovorin calcium|
316561|NCT00323999|Procedure|Hysteroscopic resection of fibroids, polyps and endometrium.|
315811|NCT00002977|Drug|melphalan|
315812|NCT00342836|Procedure|Akt levels|
315813|NCT00002989|Drug|melphalan|
315814|NCT00346008|Other|high performance liquid chromatography|
315815|NCT00346008|Other|laboratory biomarker analysis|
315816|NCT00346008|Other|questionnaire administration|
315817|NCT00346021|Behavioral|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
315818|NCT00346034|Drug|Pregabalin|150 to 600mg/day
315819|NCT00346047|Drug|Placebo|Corresponding placebo is applied for 12weeks
315820|NCT00346047|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
315821|NCT00346060|Device|Retinal transplantation instrument|
315822|NCT00346060|Device|Fetal tissue.|
315823|NCT00346073|Biological|Tetanus, reduced diph toxoids, acellular pertussis vaccine|
315824|NCT00002989|Radiation|radiation therapy|
315825|NCT00346086|Drug|AIC (Amb a 1 Immunostimulatory Conjugate)|
315826|NCT00346099|Drug|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
315827|NCT00346099|Drug|Panitumumab with capecitabine and radiation|
315828|NCT00346112|Procedure|psycho-educational|
315829|NCT00346125|Biological|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
315830|NCT00346125|Drug|doxorubicin hydrochloride|65 mg/m^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
315831|NCT00346125|Drug|ifosfamide|9 g/m^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m^2 by continuous IV infusion over 7 days beginning on day 1
315832|NCT00346125|Drug|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
315097|NCT00361361|Device|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
315098|NCT00361374|Dietary Supplement|eicosapentaenoic acid|1 gram/day
315099|NCT00003084|Drug|Estramustine phosphate sodium|Arm I: Oral estramustine three times a day for 21 day cycle.
Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle.
315100|NCT00364429|Drug|Lorazepam|Study Drug
315101|NCT00364429|Drug|Risperidone|Study Drug
315102|NCT00364442|Drug|fluticasone propionate/salmeterol|
315103|NCT00364455|Drug|Epoetin alfa|
315104|NCT00364468|Drug|pegfilgrastim|
315105|NCT00364481|Drug|omeprazole|
315106|NCT00364481|Behavioral|Tongue exercises|
315107|NCT00364494|Procedure|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht>25% bleed or not
315108|NCT00364520|Other|Shanghai workers|
315109|NCT00364533|Drug|Tapentadol IR (CG5503)|Fixed Dose 50, 75, & 100 mg BID for 3 days
315110|NCT00003084|Drug|Etoposide|Oral etoposide twice daily on days 1-14.
315111|NCT00364533|Drug|Placebo|Fixed Dose Matching placebo for 3 days
315465|NCT00003038|Drug|doxorubicin hydrochloride|
315466|NCT00355355|Device|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
315467|NCT00355355|Procedure|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
315468|NCT00355355|Procedure|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
315469|NCT00355368|Drug|Succinylcholine|1mg/kg iv
315470|NCT00355368|Drug|Rocuronium|0.6mg/kg iv
314405|NCT00326274|Drug|Helioblock® SX Cream|
314406|NCT00326287|Drug|Ceftobiprole medocaril|
314751|NCT00316862|Drug|cisplatin|Given IV
314752|NCT00316862|Drug|irinotecan hydrochloride|Given IV
314753|NCT00316862|Procedure|therapeutic conventional surgery|Undergo Surgery
314754|NCT00316862|Radiation|radiation therapy|Undergo radiation
314755|NCT00316875|Drug|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
314756|NCT00316875|Drug|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
314757|NCT00316888|Biological|cetuximab|Given IV
314758|NCT00316888|Drug|cisplatin|Given IV
314759|NCT00316888|Drug|fluorouracil|Given IV
314760|NCT00316888|Radiation|radiation therapy|Given once daily 5 days a week for 5 weeks
314761|NCT00002865|Drug|therapeutic hydrocortisone|
314762|NCT00320073|Drug|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
314763|NCT00320073|Drug|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
314764|NCT00320099|Drug|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
314765|NCT00320099|Drug|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
314766|NCT00320099|Drug|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
314767|NCT00320099|Drug|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
314768|NCT00320112|Behavioral|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
314769|NCT00002876|Drug|etoposide|
314770|NCT00320112|Behavioral|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
314412|NCT00329563|Procedure|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
314413|NCT00002919|Drug|doxorubicin hydrochloride|
314414|NCT00329563|Procedure|Induction of mild hypothermia|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline.
314415|NCT00329576|Biological|Hepatitis B vaccine|
314416|NCT00329589|Drug|Velcade (bortezomib)|
314417|NCT00329602|Drug|Placebo|Matching Placebo
314418|NCT00329602|Drug|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
314419|NCT00329615|Drug|Insulatard, flexpen|
314420|NCT00329628|Drug|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
314421|NCT00329628|Drug|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
314422|NCT00329641|Drug|carboplatin|Given IV
314423|NCT00329641|Drug|paclitaxel|Given IV
314424|NCT00002919|Drug|methotrexate|
314425|NCT00329641|Drug|sorafenib tosylate|Given orally
314426|NCT00329654|Procedure|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
314427|NCT00329667|Device|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
314774|NCT00320138|Procedure|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
314775|NCT00320190|Drug|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
314776|NCT00320190|Drug|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
314777|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Single injection, anterior juxtascleral depot (AJD)
314778|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single injection, anterior juxtascleral depot (AJD)
313674|NCT00348439|Drug|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
313675|NCT00000472|Drug|heparin|
313676|NCT00003003|Drug|mitomycin C|
313677|NCT00348452|Drug|tramadol HCl ER; celecoxib|
313678|NCT00348465|Procedure|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
313679|NCT00348478|Behavioral|water and health education program to improve hygiene|
313680|NCT00348491|Drug|Lumiracoxib|
313681|NCT00348504|Drug|levosimendan|
313682|NCT00348504|Drug|dobutamine|
314057|NCT00338923|Drug|HO/03/03|
314058|NCT00338936|Drug|Valsartan + Hydrochlorothiazide|
314059|NCT00338949|Drug|Ziprasidone|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
314060|NCT00338949|Drug|Standard atypical antipsychotic drug|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
314061|NCT00338962|Drug|paroxetine|paroxetine (40mg/day)
314062|NCT00002972|Drug|paclitaxel|
314063|NCT00338962|Drug|desipramine|200 mg per day
314064|NCT00338962|Drug|Naltrexone|50 mg per day
314065|NCT00338962|Drug|Placebo|placebo
314066|NCT00338975|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
313329|NCT00357461|Biological|ipilimumab|
313330|NCT00357474|Procedure|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
313331|NCT00357474|Procedure|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
313332|NCT00357487|Device|peroperative scintillating probe|
313333|NCT00357487|Device|operative gamma camera|
313334|NCT00357500|Drug|celecoxib|
313335|NCT00357500|Drug|cyclophosphamide|
313336|NCT00003050|Drug|doxorubicin hydrochloride|
313337|NCT00357500|Drug|etoposide|
313338|NCT00357500|Drug|fenofibrate|
313339|NCT00357500|Drug|thalidomide|
313340|NCT00357526|Drug|OCPs|
313341|NCT00357526|Device|vaginal ring|
313342|NCT00357539|Drug|Azithromycin (T1225)|
313343|NCT00357552|Drug|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
313344|NCT00357552|Drug|Lopinavir/Ritonavir|Twice daily
313345|NCT00357565|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
313346|NCT00357565|Drug|busulfan|Administered 1.1 mg/kg if <12 kg intravenous (IV) every 6 hours (0.8 mg/kg if >12 kg IV every 6 hours on Days -8 through -5.
313347|NCT00003050|Drug|paclitaxel|
313348|NCT00357565|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of >200 ng/mL. For children < 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
313349|NCT00357565|Drug|fludarabine phosphate|Administered 25 mg/m^2 intravenous (IV) over 60 minutes on Days -4 through -2.
313350|NCT00360607|Drug|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
312626|NCT00322257|Drug|insulin detemir|Injection s.c., 50% of daily dose
312627|NCT00322257|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
312628|NCT00322270|Drug|Alfimeprase|single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
312629|NCT00322283|Drug|Oglemilast|Oglemilast, 15mg once per day, oral administration
312630|NCT00322283|Drug|Placebo|Dose-marched placebo, once per day, oral administration
312631|NCT00002884|Drug|fluorouracil|
312632|NCT00322296|Drug|Bexarotene 1% gel|
312633|NCT00322309|Drug|Mirtazapine (Remeron)|Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
312634|NCT00322322|Drug|L-Carnitine|L-Carnitine
312635|NCT00322335|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
312636|NCT00322335|Biological|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
312984|NCT00312754|Drug|Atazanavir|
312985|NCT00312767|Drug|Fabrazyme (agalsidase beta)|
312986|NCT00312780|Drug|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
312987|NCT00002849|Biological|recombinant interferon alfa|first 2 years
312988|NCT00312793|Device|stimulation of the quadriceps muscle with Myospare|
312989|NCT00312806|Drug|Pantoprazole|Pantoprazole 40 mg o.d.
312990|NCT00312819|Drug|chemotherapy +/- disulfiram|
312991|NCT00312832|Drug|switching; dose reduction|
312992|NCT00312845|Drug|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
312993|NCT00312845|Drug|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
312241|NCT00328809|Drug|spironolactone|spironolactone administered to ESRD patients at low dose
312242|NCT00328822|Drug|Quetiapine|
312243|NCT00328822|Drug|placebo|
312244|NCT00331851|Drug|liraglutide|
312245|NCT00331851|Drug|insulin glargine|
312246|NCT00331851|Drug|metformin|
312247|NCT00331851|Drug|glimepiride|
312248|NCT00331864|Drug|Ranibizumab|
312249|NCT00331877|Procedure|family conference with bereavement information leaflet|
312250|NCT00331890|Drug|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
312251|NCT00331890|Drug|Placebo|As active drug
312252|NCT00000466|Drug|estrogens, conjugated|
312253|NCT00002931|Drug|paclitaxel|425 mg/m2 as 24 hour continuous infusion
312254|NCT00331916|Drug|quinolone|
312255|NCT00331929|Device|Minato A 500 AS spirometer|Spirometry at rest
312256|NCT00331955|Drug|doxorubicin hydrochloride|Given IV
312257|NCT00331955|Drug|vorinostat|Given orally
312258|NCT00331955|Other|pharmacological study|Correlative studies
312259|NCT00331955|Other|laboratory biomarker analysis|Correlative studies
312260|NCT00331981|Drug|Amisulpride|
312261|NCT00331994|Drug|Bacillus clausii|3 bacillus clausii vials/day for one month
312262|NCT00331994|Drug|Metronidazole|3 Metronidazole tablets/day for one week
312263|NCT00332007|Drug|Tonabersat|two tablets once daily
312264|NCT00002931|Procedure|autologous bone marrow transplantation|Given in two divided infusions on day -2 and day 0
312265|NCT00332007|Drug|Placebo|two tablets once daily
311531|NCT00353977|Biological|ALVAC-CMV (vCP260)|ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.
Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.
Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)
311532|NCT00353990|Drug|Insulin Aspart|
311533|NCT00354003|Behavioral|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
311534|NCT00354016|Biological|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
311535|NCT00354029|Drug|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
311536|NCT00354029|Drug|Placebo|isotonic saline
311537|NCT00354042|Drug|GW597901X|
311538|NCT00354068|Drug|imatinib mesylate|
311539|NCT00354068|Drug|temozolomide|
311540|NCT00354068|Other|pharmacological study|
311894|NCT00344058|Drug|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
311895|NCT00344097|Procedure|Soy protein|
311896|NCT00344110|Drug|Aliskiren|
311897|NCT00344123|Drug|Tipranavir/Ritonavir|On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).
On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.
311898|NCT00002984|Drug|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
311899|NCT00344123|Drug|Rosuvastatin|On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).
On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r..
311900|NCT00344149|Drug|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
311901|NCT00344175|Drug|pitavastatin|
311177|NCT00359736|Drug|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
311178|NCT00000480|Drug|anti-arrhythmia agents|
311179|NCT00003076|Drug|eflornithine|
311180|NCT00362570|Drug|Temozolomide|p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off] using a standardized dosing range.
Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake).
311181|NCT00362583|Drug|Fentanyl|
311182|NCT00362596|Drug|acyclovir|
311183|NCT00362609|Drug|pantoprazole|
311184|NCT00362635|Drug|Clevudine|
311185|NCT00362648|Biological|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
311186|NCT00362648|Biological|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
311187|NCT00362661|Drug|Cortisol|Cortisol 10 mg/d for 3 months
311188|NCT00362687|Drug|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
311189|NCT00362687|Drug|FTC alone|emtricitabine 200 mg
311190|NCT00003077|Dietary Supplement|omega-3 fatty acid|
311191|NCT00362687|Procedure|No HAART|No HAART
311192|NCT00362700|Drug|Clevudine|
311193|NCT00362713|Drug|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
311194|NCT00362726|Drug|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
311195|NCT00362726|Drug|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
311196|NCT00362726|Drug|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
311197|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
311198|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
316419|NCT00361881|Drug|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
316420|NCT00361881|Drug|Vehicle|Dose 5 times daily for 5 days
316421|NCT00003070|Drug|enalapril maleate|
316422|NCT00361894|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
316423|NCT00361894|Drug|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
316424|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
316425|NCT00361907|Procedure|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
316426|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
316427|NCT00361920|Drug|prednisone|
316428|NCT00361933|Drug|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
316429|NCT00361959|Drug|Tiotropium bromide 18mcg|
316786|NCT00353223|Behavioral|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
316787|NCT00003026|Drug|bicalutamide|
316788|NCT00353223|Behavioral|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
316789|NCT00353249|Behavioral|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
316790|NCT00353262|Drug|Avastin|7.5mg/kg iv (cycle 3 only)
316791|NCT00353262|Drug|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
316792|NCT00353262|Drug|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
316066|NCT00317408|Drug|busulfan|
316067|NCT00317408|Drug|carboplatin|
316068|NCT00317408|Drug|carmustine|
316069|NCT00317408|Drug|cyclosporine|
316070|NCT00317408|Drug|cytarabine|
316071|NCT00317408|Drug|dexamethasone|
316072|NCT00002868|Biological|filgrastim|
316073|NCT00317408|Drug|etoposide phosphate|
316074|NCT00317408|Drug|idarubicin|
316075|NCT00317408|Drug|ifosfamide|
316076|NCT00317408|Drug|leucovorin calcium|
316077|NCT00317408|Drug|lomustine|
316078|NCT00317408|Drug|melphalan|
316079|NCT00317408|Drug|methotrexate|
316080|NCT00317408|Drug|mitoxantrone hydrochloride|
316081|NCT00317408|Drug|prednisolone|
316082|NCT00317408|Drug|thiotepa|
316083|NCT00002868|Biological|recombinant interferon alfa|
316084|NCT00317408|Drug|vinblastine sulfate|
316085|NCT00320697|Drug|transdermal nicotine patch|
316086|NCT00320697|Drug|short-acting nicotine replacement therapy|
316087|NCT00320710|Drug|Zoledronic acid|4mg IV
316088|NCT00320710|Drug|Placebo|Placebo to zoledronic acid
316430|NCT00361959|Drug|Fluticasone propionate/ salmeterol combination 50/500mcg|
316431|NCT00361972|Drug|lansoprazole|30 mg of placebo or lansoprazole twice daily for 2-4 months
316432|NCT00003070|Procedure|quality-of-life assessment|
310896|NCT00328016|Behavioral|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
310897|NCT00328016|Device|Resperate|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
310898|NCT00328029|Drug|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
310899|NCT00328029|Procedure|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
310900|NCT00328029|Procedure|pharmacokinetics, done during the treatment|12 blood collections :
after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.
3 hours after 2nd taken of Busulfan
3 hours after 3rd taken of Busulfan
3 hours after 4th taken of Busulfan
3 hours after 5th taken of Busulfan
3 hours after 6th taken of Busulfan.
310901|NCT00002911|Drug|marimastat|
310902|NCT00328042|Behavioral|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
310903|NCT00328042|Behavioral|Information Only|This is an individual self-paced at home study program.
310904|NCT00328055|Behavioral|AD-Easy (Advance Directive-Easy)|
310905|NCT00328055|Behavioral|AD-Standard (Advance Directive-Standard)|
305323|NCT00247702|Drug|warfarin|
305324|NCT00247715|Drug|algeldrate/magnesium oxide|
305325|NCT00247715|Drug|ranitidine|
305326|NCT00247715|Drug|pantoprazole|
305327|NCT00247728|Drug|PI-88|
305328|NCT00247741|Drug|spinal administration of articaine|
305329|NCT00247741|Drug|spinal administration of lidocaine|
305330|NCT00247754|Behavioral|Cognitive Behaviour Treatment|
305331|NCT00251069|Drug|Glucosamine sulphate|
305332|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
305333|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
305334|NCT00251082|Drug|Placebo|Placebo
310547|NCT00002961|Drug|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
310548|NCT00337389|Drug|5- Fluorouracil (5-FU)|
310549|NCT00337389|Drug|bevacizumab (Avastin)|
310550|NCT00337389|Drug|Leucovorin|
310551|NCT00337389|Drug|CoFactor (ANX-510)|
310552|NCT00337415|Drug|MK0354|
310553|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
310554|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
310555|NCT00337428|Biological|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
310556|NCT00337428|Biological|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
310557|NCT00337441|Drug|Epoetin Alfa (drug)|
310558|NCT00002961|Radiation|Radiation|Central Nervous System (CNS) therapy:
a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) >/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses >3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.
Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-
310559|NCT00337454|Drug|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
310906|NCT00328094|Drug|continuous intravenous insulin infusion|Tight glucose control versus standard of care
310907|NCT00328107|Biological|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
310908|NCT00328120|Drug|Fulvestrant|500 mg intramuscular injection
309819|NCT00255970|Device|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
309820|NCT00255983|Drug|Faropenem medoxomil|600 mg BID for 5 days
310184|NCT00246337|Drug|MK0974|MK0974 400 mg; one orally-administered dose
310185|NCT00246337|Drug|MK0974|MK0974 600 mg; one orally-administered dose
310186|NCT00246337|Drug|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
310187|NCT00246350|Procedure|massage|8 light massage treatments and hot pack
310188|NCT00246350|Procedure|massage|16 light massage treatments and hot packs
310189|NCT00246350|Procedure|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
310190|NCT00246350|Procedure|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
310191|NCT00002654|Radiation|low-LET electron therapy|
310192|NCT00246363|Drug|Silymarin|Silymarin (milk thistle)
310193|NCT00246363|Drug|Placebo|Placebo
310194|NCT00246376|Behavioral|Diet|ATP-III diet
310195|NCT00246376|Behavioral|Exercise|Supervised exercise in study gym
310196|NCT00246376|Drug|Niacin|Niaspan, titrated up to 2 grams per day
310197|NCT00246376|Drug|Fenofibrate|Tricor, 120 mg per day
310198|NCT00246376|Other|Placebos|Placebos for Niaspan and Tricor
310199|NCT00246389|Drug|cyclobenzaprine hydrochloride|
310200|NCT00246402|Drug|Acipimox|
310201|NCT00246415|Drug|Memantine|
310202|NCT00002654|Radiation|low-LET photon therapy|
310203|NCT00246428|Behavioral|Motivational Interviewing|Experimental manipulations will be evaluated 6, 9, and 12 months
310204|NCT00246441|Drug|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
316562|NCT00324012|Drug|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
316563|NCT00324025|Drug|Mycograb|
316564|NCT00324025|Drug|placebo|
316565|NCT00324038|Drug|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
316566|NCT00324038|Drug|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
316567|NCT00324051|Drug|olanzapine therapy|
316568|NCT00324064|Procedure|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
316569|NCT00324077|Drug|Dasatinib in combination with imatinib|
316570|NCT00324090|Behavioral|High and low glycemic index|
316571|NCT00002893|Drug|raltitrexed|
316572|NCT00324103|Drug|Structured Treatment Interruptions|
316573|NCT00324116|Drug|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
316574|NCT00324129|Drug|MGCD0103|MGCD0103 given orally three times per week.
316575|NCT00324142|Drug|Oral tinidazole|
316576|NCT00324155|Drug|Ipilimumab|Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent
In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression
316915|NCT00314626|Drug|efavirenz|Efavirenz
316916|NCT00314626|Drug|Abacavir+lamivudine|Abacavir+lamivudine
316917|NCT00314639|Drug|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
316918|NCT00002855|Drug|Flutamide|
316919|NCT00314652|Drug|Buprenorphine transdermal delivery system|
316920|NCT00314665|Drug|Thalidomide|
316921|NCT00314678|Drug|Topotecan|
315833|NCT00346125|Procedure|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
315834|NCT00346125|Radiation|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
316211|NCT00002943|Drug|carboplatin|
316212|NCT00333775|Drug|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
316213|NCT00333775|Drug|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
316214|NCT00333775|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
316215|NCT00333788|Biological|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
316216|NCT00333801|Behavioral|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
316217|NCT00333801|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
316218|NCT00333814|Drug|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
316219|NCT00333814|Drug|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
316220|NCT00333814|Drug|Sham injection|Sham injection at Day 0
316221|NCT00333827|Procedure|Stem cell|
316222|NCT00002943|Drug|cyclophosphamide|
316223|NCT00333840|Drug|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
316224|NCT00333840|Drug|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day.
316225|NCT00333840|Drug|cytarabine (ARA-C)|cytarabine 20 mg/m^2/day (max 40 mg) SC for 10 days every month.
316226|NCT00333853|Device|OneTouch(r) UltraSmart(r)|
316227|NCT00336791|Drug|Cyclophosphamide|FAC and FEC Chemotherapy:
500 mg/m^2 IV on day 1 of 21 day cycle.
315471|NCT00355381|Behavioral|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
315472|NCT00355394|Drug|Metoclopramide|Intravenous bolus administration.
315473|NCT00355394|Other|Placebo|Standard care including intravenous fluid, but no metoclopramide.
315474|NCT00355407|Drug|Darbepoetin alfa|
315475|NCT00355433|Procedure|Urodymanics|
315476|NCT00003038|Drug|suramin|
315477|NCT00355446|Drug|Bimatoprost 0.03%|
315478|NCT00355459|Drug|Tetracycline: Doxycycline analog|
315479|NCT00355472|Drug|KW-0761|IV administration at 4 escalating dose levels.
315480|NCT00355485|Device|microdermabrasion|Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.
Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart.
315481|NCT00355511|Behavioral|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
315482|NCT00355524|Drug|TMC114|TMC114 will be administered as oral tablets (75 milligram [mg] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
315483|NCT00355524|Drug|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
315484|NCT00355537|Drug|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
315485|NCT00355537|Drug|0.9% saline|Saline injection intramuscular every 2 weeks
315835|NCT00002990|Biological|BCG vaccine|
315836|NCT00346138|Procedure|Corneal transplantation|
315837|NCT00346151|Drug|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
315838|NCT00346151|Drug|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
314771|NCT00320112|Behavioral|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
314772|NCT00320125|Dietary Supplement|Orange juice plus calcium|> 1,200mg Ca (four glasses of orange juice plus calcium)per day
314773|NCT00320125|Dietary Supplement|Dairy products|> 1,200mg Ca (by consuming milk, yogurt, and cheese)
315112|NCT00364533|Drug|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
315113|NCT00364533|Drug|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
315114|NCT00364546|Drug|CG 5503;tapentadol|
315115|NCT00364559|Drug|Rosuvastatin|20 mg 10 days daily
315116|NCT00364572|Drug|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
315117|NCT00364572|Drug|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
315118|NCT00364585|Device|GreenLight Model 120 Laser System|
315119|NCT00364598|Drug|Anginera, a human tissue replacement therapy|
315120|NCT00364611|Drug|Bevacizumab|Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on
On Day 1 of the 1st cycle over 120 minutes
On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose
On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses
On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses
315121|NCT00003084|Drug|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
315122|NCT00364611|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
315123|NCT00364611|Drug|Trastuzumab|A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.
For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion
315124|NCT00364637|Drug|Sevoflurane (Volatile Anesthetic)|
315125|NCT00364637|Drug|Total intravenous anesthesia|
315126|NCT00364650|Drug|Probiotic Supplement|2 capsules twice daily
315127|NCT00364650|Other|Placebo|placebo
315128|NCT00313742|Drug|insulin glargine|
315129|NCT00313742|Drug|insulin NPH|
314779|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single injection, anterior juxtascleral depot (AJD)
314780|NCT00000462|Procedure|angioplasty, transluminal, percutaneous coronary|
314781|NCT00002878|Drug|dexamethasone|
314782|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
314783|NCT00320216|Drug|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
314784|NCT00320216|Drug|Placebo|Patients in the placebo group will receive placebo medication.
314785|NCT00320229|Drug|abciximab|
314786|NCT00320242|Device|Laser Cane and U-Step Walker with Laser Accessory|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
314787|NCT00320255|Drug|Apixaban|Tablets, Oral, 5 mg QD, once daily for 12 weeks
314788|NCT00323258|Behavioral|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
314789|NCT00323258|Behavioral|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
314790|NCT00323258|Behavioral|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
314791|NCT00323258|Other|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
314792|NCT00002888|Drug|cisplatin|
314793|NCT00323271|Behavioral|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
315136|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
315137|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
315138|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
314067|NCT00338975|Behavioral|Goal-focused supportive contact (GFSC)|There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize "non-specific" therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills.
314068|NCT00338975|Behavioral|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
314069|NCT00338975|Behavioral|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
314070|NCT00338988|Drug|Capecitabine|1500 mg/m^2 PO twice daily x 14 days.
314071|NCT00338988|Drug|Oxaliplatin|130 mg/m^2 IV over 2 hours on day 1 of cycle.
314072|NCT00339001|Drug|erythropoietin and early iron supplements|
314073|NCT00002973|Drug|melphalan|
314074|NCT00339014|Drug|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
314075|NCT00339014|Other|Placebo|Identical placebo
314076|NCT00345254|Procedure|severing umbilical cord|
314428|NCT00329680|Dietary Supplement|Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins|An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
314429|NCT00329680|Dietary Supplement|Standard ICU enteral diet, isocaloric to the study diet|Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
314430|NCT00329693|Drug|Norprolac|Placebo
314431|NCT00329693|Drug|Norprolac|Quinagolide
314432|NCT00329693|Drug|Norprolac|Quinagolide
314433|NCT00329693|Drug|Norprolac|Quinagolide
314434|NCT00332904|Drug|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
314435|NCT00332904|Drug|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
313683|NCT00348517|Other|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
313684|NCT00348517|Other|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
313685|NCT00348530|Drug|Verapamil|
313686|NCT00348543|Procedure|laser treatment|
313687|NCT00003003|Drug|mitoxantrone hydrochloride|
313688|NCT00348556|Drug|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
313689|NCT00348569|Device|64 Channel VCT|
313690|NCT00348582|Drug|Ketorolac, Nepafenac|
313691|NCT00348595|Drug|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
313692|NCT00348608|Drug|iodixanol|
313693|NCT00348621|Procedure|visual impairment interventions|
313694|NCT00348634|Drug|Tegaserod|
313695|NCT00348647|Behavioral|physical training program to prevent injuries|
313696|NCT00351715|Drug|Sublingual Methadone|
313697|NCT00351741|Device|Ventilation - High Frequency Percussive Ventilation|Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator
313698|NCT00351741|Device|Ventilation - ARDSnet|Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
313699|NCT00351754|Drug|Isovue|
313700|NCT00351767|Drug|placebo|Topically applied
313701|NCT00351767|Drug|telbermin|Topically applied
313702|NCT00000474|Behavioral|behavior therapy|
313703|NCT00003015|Drug|carboplatin|
313704|NCT00351780|Device|FFR measurement, side branch angioplasty|
313705|NCT00351793|Device|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
312994|NCT00312858|Biological|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
312995|NCT00312858|Biological|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
312996|NCT00312858|Biological|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
312997|NCT00312871|Drug|Epoetin alfa|
312998|NCT00002849|Drug|dexamethasone|40 mg*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles*
312999|NCT00312884|Device|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
313000|NCT00312897|Drug|Omega-3 Fatty Acids|10 wk treatment period
313001|NCT00316017|Drug|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
313002|NCT00316017|Drug|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
313003|NCT00316017|Drug|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
313004|NCT00316030|Drug|Bexarotene|
313005|NCT00316043|Behavioral|Written information for parents|
313006|NCT00316043|Behavioral|Distance learning package for General Practitioners|
313007|NCT00316043|Behavioral|Distance learning package for practice assistants|
313351|NCT00360607|Drug|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
313352|NCT00360607|Drug|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
313353|NCT00360659|Device|Continuous Positive Airway Pressure|
313354|NCT00360672|Drug|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
313355|NCT00003064|Drug|etoposide phosphate|
313356|NCT00360685|Drug|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
313357|NCT00360685|Drug|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
312266|NCT00332020|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
312267|NCT00332020|Drug|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
312637|NCT00322335|Biological|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
312638|NCT00322335|Biological|Engerix-B|Intramuscular injection into the thigh as a birth dose
312639|NCT00322335|Biological|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
312640|NCT00322335|Biological|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
312641|NCT00322335|Biological|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
312642|NCT00002884|Radiation|brachytherapy|
312643|NCT00322348|Drug|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
312644|NCT00322348|Drug|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
312645|NCT00322361|Biological|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
312646|NCT00322361|Biological|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
312647|NCT00322374|Drug|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
312648|NCT00325130|Biological|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a
0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
312649|NCT00325130|Biological|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
312650|NCT00325130|Biological|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
312651|NCT00325130|Biological|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
312652|NCT00325130|Biological|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
312653|NCT00002898|Drug|cyclophosphamide|
311902|NCT00344175|Drug|simvastatin|
311903|NCT00344201|Device|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
311904|NCT00344214|Behavioral|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
311905|NCT00344214|Behavioral|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
311906|NCT00344227|Drug|Lucentis (Ranibizumab)|
311907|NCT00344240|Behavioral|Functional circuit training with lifestyle behavior|
311908|NCT00347477|Drug|HyperHAES vs. RA-solution/NaCl|
311909|NCT00347490|Drug|Enoxaparine|
311910|NCT00347503|Drug|ketorolac 0.4%, bromfenac 0.09%|
311911|NCT00347516|Procedure|IOL calculation formula|
311912|NCT00347529|Biological|pPML7789 with and without pPJV2012 administered by PMED|
311913|NCT00347542|Drug|Vitamin D|
312268|NCT00332033|Drug|Pirfenidone|
312269|NCT00332046|Drug|GW679769|
312270|NCT00332059|Drug|bimatoprost/timolol fixed combination|
312271|NCT00332072|Drug|bimatoprost/timolol fixed combination|
312272|NCT00332085|Drug|Chromium Picolinate|
312273|NCT00332098|Behavioral|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
312274|NCT00335192|Drug|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
311199|NCT00362752|Drug|Norfloxacin|400 mg po bid
311541|NCT00003028|Drug|sabarubicin|
311542|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
311543|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
311544|NCT00354081|Drug|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
311545|NCT00354081|Drug|placebo|placebo, in a capsule, taken orally once a day
311546|NCT00354094|Drug|[S,S]-Reboxetine|
311547|NCT00354107|Biological|monoclonal antibody SGN-30|Given IV
311548|NCT00354107|Drug|therapeutic hydrocortisone|Given IT
311549|NCT00354107|Drug|ifosfamide|Given IV
311550|NCT00354107|Drug|carboplatin|Given IV
311551|NCT00354107|Drug|etoposide|Given IV
311552|NCT00000477|Drug|lovastatin|
311553|NCT00003029|Drug|cisplatin|
311554|NCT00354107|Drug|methotrexate|Given IT
311555|NCT00354107|Drug|cytarabine|Given IT
311556|NCT00354107|Other|pharmacological study|Correlative studies
311557|NCT00356681|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
311558|NCT00356681|Drug|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
311559|NCT00003042|Procedure|peripheral blood stem cell transplantation|
311560|NCT00356720|Drug|Azithromycin|
311561|NCT00356733|Drug|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
316793|NCT00353275|Drug|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
316794|NCT00353275|Drug|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
316795|NCT00353288|Biological|MeMuRu-OKA (study vacc)|
316796|NCT00355927|Procedure|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
316797|NCT00355940|Device|Technological Methods|Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.
In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images
316798|NCT00355940|Device|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
316799|NCT00355953|Drug|Genistein|
316800|NCT00355966|Drug|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
316801|NCT00355966|Drug|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
316802|NCT00355979|Device|intragastric balloon|
316803|NCT00356005|Drug|azithromycin plus artesunate|
316804|NCT00356005|Drug|Artesunate|
311200|NCT00362752|Drug|Placebo|Placebo 400 mg po bid
311201|NCT00003078|Drug|cisplatin|
311202|NCT00362765|Drug|Fenofibrate|160 mg
311203|NCT00362765|Drug|Metformin|2000 mg
311204|NCT00362765|Drug|Placebo|Placebo
311205|NCT00362778|Drug|Insulin|intravenous continuous insulin infusion for 48 hours
311206|NCT00362791|Behavioral|"Enhanced HIV/STD Counseling:" 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model|
311207|NCT00362791|Behavioral|"Brief Counseling" (aka "client-centered counseling"): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior|
316433|NCT00365196|Behavioral|CBT Hostility Reduction Program|
316434|NCT00365209|Other|laboratory biomarker analysis|Correlative studies
316435|NCT00365209|Other|pharmacological study|Correlative studies
316436|NCT00365209|Drug|curcumin|Given orally
316437|NCT00003086|Drug|CAF regimen|
316438|NCT00365222|Drug|Temozolomide|temozolomide 75 mg/m2 /d
316439|NCT00365248|Drug|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
316440|NCT00365261|Drug|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
316441|NCT00365261|Drug|Placebo|placebo 2 to 3 mg po at bedtime
316442|NCT00365274|Drug|Cyclophosphamide|Given IV 750 mg/m^2 day 1
316443|NCT00365274|Drug|Doxorubicin hydrochloride|Given 50 mg/m^2 IV day 1
316444|NCT00365274|Drug|vincristine sulfate|Given 1.4 mg/m^2 IV
316445|NCT00365274|Drug|prednisone|100 mg orally daily days 1 - 5
316446|NCT00365274|Drug|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
316447|NCT00365287|Drug|anti-thymocyte globulin|
316448|NCT00003086|Drug|carboplatin|
316449|NCT00365287|Drug|cyclophosphamide|
316450|NCT00365287|Drug|cyclosporine|
316451|NCT00365287|Drug|fludarabine phosphate|
316452|NCT00365287|Drug|mycophenolate mofetil|
316453|NCT00365287|Procedure|radiation therapy|
316454|NCT00365287|Procedure|umbilical cord blood transplantation|
316455|NCT00365300|Drug|pantoprazole|
316456|NCT00365300|Drug|Placebo|
316457|NCT00365313|Drug|celecoxib, esomeprazole|
305335|NCT00251095|Drug|Taxol|
305336|NCT00002665|Procedure|allogeneic bone marrow transplantation|day 0
305337|NCT00251095|Drug|TOCOSOL Paclitaxel|100 mg/m2/week
305338|NCT00251108|Procedure|Cardiorespiratory fitness training|
305339|NCT00251121|Other|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
305340|NCT00251121|Other|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
305341|NCT00251134|Drug|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
305342|NCT00251134|Drug|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
305343|NCT00251147|Procedure|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
305695|NCT00240994|Drug|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacromlimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
305696|NCT00002635|Drug|aminocamptothecin|
305697|NCT00240994|Drug|Mycophenolate mofetil|Per recommendation
305698|NCT00240994|Drug|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
305699|NCT00241007|Drug|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
305700|NCT00241020|Drug|Octreotide|
305701|NCT00241046|Drug|Letrozole|
305702|NCT00241059|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
305703|NCT00241072|Drug|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
305704|NCT00241085|Drug|valsartan|
305705|NCT00241098|Drug|valsartan|
310909|NCT00328159|Drug|Oil special 107 and MYGLIOL 810|
310910|NCT00328172|Drug|Placebo|Placebo matching BI 1356
310911|NCT00328172|Drug|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
310912|NCT00002912|Drug|etoposide|
310913|NCT00328172|Drug|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
310914|NCT00328172|Drug|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
310915|NCT00328172|Drug|Metformin|Metformin
310916|NCT00331136|Drug|Pyronaridine-Artesunate|once a day for 3 days
310917|NCT00331149|Drug|Ropinirole prolonged release|
310918|NCT00331149|Drug|ropinirole immediate release|
310919|NCT00331162|Drug|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
310920|NCT00331162|Drug|Anti-Thymocyte Globulin|1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr < 3-4 mg/dL.
Give first dose over 6 hours, subsequent doses over 4 hours.
Premedication to be given with the first 3 doses:
Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.
Hold infusion if temperature > 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours
310921|NCT00331175|Drug|Peptide YY3-36|
310922|NCT00331188|Drug|Sanvar® (vapreotide)|
310923|NCT00331201|Drug|SAFEstart|
310924|NCT00002926|Procedure|peripheral blood stem cell transplantation|
310925|NCT00331214|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
310926|NCT00331214|Drug|placebo patch|placebo patch replaced every 3-4 days for 6 months
310927|NCT00331227|Drug|Isotonix OPC-3 (flavonoid supplement)|
310928|NCT00331240|Drug|travoprost/timolol fixed combination|
310929|NCT00331240|Drug|placebo (artificial tears)|
310205|NCT00246441|Drug|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
310206|NCT00246467|Biological|Alhydrogel|
310207|NCT00246467|Biological|rF1 and rV protein antigens|
310208|NCT00246506|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
310560|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
310561|NCT00337454|Drug|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
310562|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
310563|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
310564|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
310565|NCT00337467|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
310566|NCT00337480|Behavioral|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
310567|NCT00337493|Drug|mycophenolate mofetil [CellCept]|Concentration-controlled
310568|NCT00343447|Biological|autologous tumor cell vaccine|
310569|NCT00343447|Biological|rituximab|
310570|NCT00343447|Drug|cyclophosphamide|
310571|NCT00343460|Drug|APF530|Given subcutanously
310572|NCT00343460|Drug|dexamethasone|Given IV and orally
310573|NCT00002982|Drug|carmustine|
310574|NCT00343460|Drug|palonosetron hydrochloride|Given IV
310575|NCT00343460|Other|placebo|Given subcutanously or IV
310576|NCT00343486|Drug|Solabegron|
310577|NCT00343499|Drug|valsartan|
310578|NCT00343512|Drug|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
316922|NCT00314678|Drug|Cisplatin|
316923|NCT00314678|Drug|Paclitaxel|
316924|NCT00314691|Genetic|Blood samples|
316925|NCT00317655|Drug|Glucosamine sulphate|
316926|NCT00317655|Drug|Ginger|
316927|NCT00317655|Drug|Ginger-Avocado-Soya|
316928|NCT00317655|Drug|Ginger-ibuprofen|
316929|NCT00317681|Drug|Tacrolimus ointment|
316930|NCT00317694|Drug|Fermagate|Film coated tablet 500mg
316931|NCT00317694|Drug|Placebo|Oral administration, film coated tablet, 0mg
316932|NCT00317707|Drug|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
316933|NCT00317707|Drug|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
316934|NCT00317720|Drug|Trastuzumab|Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.
If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose.
316935|NCT00002868|Drug|hydroxyurea|
316936|NCT00317720|Drug|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
316937|NCT00317733|Drug|Ketoprofen in Transfersome|
316938|NCT00317746|Drug|Citalopram|
316939|NCT00317759|Biological|therapeutic autologous lymphocytes|
311335|NCT00324805|Biological|Bevacizumab|Given IV
311336|NCT00324805|Drug|Cisplatin|Given IV
311337|NCT00002896|Radiation|low-LET photon therapy|
311338|NCT00324805|Drug|Docetaxel|Given IV
311339|NCT00324805|Drug|Gemcitabine Hydrochloride|Given IV
316228|NCT00336791|Drug|Doxorubicin|FAC Chemotherapy: 50 mg/m^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
316229|NCT00336791|Drug|Paclitaxel|80 mg/m^2 by vein (IVPB) over 1 hour every week for 12 weeks
316230|NCT00336791|Drug|Epirubicin|FEC: 100 mg/m^2 IV on day 1 of 21 day cycle.
316231|NCT00336817|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
316232|NCT00336817|Drug|CellCept|CellCept 500mg or 1000mg BID for 90 days
316577|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.
Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
316578|NCT00327184|Biological|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
316579|NCT00327184|Biological|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
316580|NCT00327184|Biological|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
316581|NCT00327184|Biological|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
316582|NCT00327197|Drug|Prednisolone|Oral prednisolone
316583|NCT00327210|Behavioral|Blood Glucose Awareness Training|
316584|NCT00327223|Drug|imexon|
316585|NCT00002905|Drug|mitoxantrone hydrochloride|
316586|NCT00327249|Drug|imexon|
316587|NCT00327262|Drug|Imatinib|
316588|NCT00327275|Behavioral|strength training|
316589|NCT00327288|Drug|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
316590|NCT00327288|Drug|docetaxel|IV once every 21 days for duration of study
316591|NCT00327314|Procedure|Transplantation|
316592|NCT00327314|Procedure|Hematopoietic cell transplantation|
316593|NCT00327327|Drug|imexon|30-60 minutes IV, days 1,8,15 every 28 days
315839|NCT00346151|Drug|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
315840|NCT00349284|Drug|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
315841|NCT00349310|Drug|Pramipexole|
315842|NCT00349323|Behavioral|Community directed treatment|
315843|NCT00349336|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
315844|NCT00003007|Drug|dexamethasone|
315845|NCT00349336|Drug|XELOX|As prescribed
315846|NCT00349336|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
315847|NCT00349336|Drug|FOLFOX-4|As prescribed
315848|NCT00349349|Drug|ofatumumab|Intravenous infusion
315849|NCT00349362|Drug|Testosterone|Sustanon- 200mg intramuscular testosterone
315850|NCT00349362|Drug|0.9% saline|Saline intramuscular injection every two weeks
315851|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
315852|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
315853|NCT00349375|Drug|Simvastatin|Simvastatin 40 mg
315854|NCT00349388|Drug|Asacol|Asacol is given once a day versus twice or three times a day
315855|NCT00003007|Drug|melphalan|
315856|NCT00349401|Drug|ketorolac|
315857|NCT00349401|Drug|morphine|
315858|NCT00349414|Procedure|Micropulse Transscleral Cyclophotocoagulation|
315859|NCT00349414|Procedure|Conventional Transscleral Cyclophotocoagulation|
315860|NCT00349427|Drug|Rosiglitazone 4 mg|
316233|NCT00336830|Behavioral|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
315130|NCT00313755|Procedure|Narrow Band Imaging|
315131|NCT00313768|Drug|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
315132|NCT00313768|Drug|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
315133|NCT00000459|Behavioral|diet, fat-restricted|
315134|NCT00002854|Drug|carboplatin|
315135|NCT00313781|Drug|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
315486|NCT00358228|Drug|Rimonabant|
315487|NCT00358241|Procedure|Nerve block|
315488|NCT00358267|Procedure|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
315489|NCT00358267|Procedure|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
315490|NCT00358280|Drug|Ropivacaine|
315491|NCT00358280|Drug|Bupivacaine|
315492|NCT00358293|Drug|Tizanidine (sublingual or oral)|
315493|NCT00358319|Drug|Karenitecin|
315494|NCT00358319|Drug|Valproic Acid|
315495|NCT00003053|Drug|etoposide|
315496|NCT00358332|Biological|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
315497|NCT00358332|Biological|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
315498|NCT00358358|Drug|Fluticasone Propionate/Salmeterol 500/50mcg combination|
315499|NCT00358358|Drug|Fluticasone Propionate 500mcg|
315500|NCT00358358|Drug|Salmeterol 50mcg|
315501|NCT00358371|Drug|flucloxacillin|
315139|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
315140|NCT00313794|Drug|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
315141|NCT00313807|Drug|Amino Acid|7% amino acid infusion
315142|NCT00313807|Drug|Placebo|0.9% Saline Infusion
315143|NCT00313820|Drug|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
315144|NCT00313820|Drug|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
315145|NCT00002854|Drug|cisplatin|
315146|NCT00313833|Drug|Buprenorphine transdermal delivery system|
315147|NCT00313846|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
315148|NCT00313846|Drug|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
315149|NCT00313859|Drug|simvastatin|
315150|NCT00316901|Procedure|computed tomography|
315151|NCT00316901|Procedure|positron emission tomography|
315152|NCT00316901|Radiation|fludeoxyglucose F 18|
315153|NCT00316914|Drug|calcium gluconate|Given IV
315154|NCT00316914|Drug|magnesium sulfate|Given IV
315155|NCT00316914|Other|placebo|Given IV
315510|NCT00358436|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
314436|NCT00332917|Drug|Pardoprunox|12-42 mg
314437|NCT00002938|Procedure|conventional surgery|Salvage prostatectomy
314438|NCT00332930|Biological|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
314439|NCT00332930|Biological|HIV gag-pol antigens and interferon-gamma (IFN-y)|
314440|NCT00332943|Procedure|MR colonography with fecal tagging|
314441|NCT00332956|Biological|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
314442|NCT00332956|Biological|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
314443|NCT00332956|Biological|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
314444|NCT00332956|Biological|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
314445|NCT00332969|Drug|Octreotide|
314446|NCT00332982|Behavioral|Focused knowledge translation strategies|
314447|NCT00332995|Drug|dapivirine (TMC120) vaginal ring|
314448|NCT00002939|Drug|irinotecan hydrochloride|
314449|NCT00333008|Drug|Doxil|
314450|NCT00333008|Drug|Cyclophosphamide|
314451|NCT00333008|Drug|Vincristine|
314794|NCT00323271|Other|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
314795|NCT00323284|Device|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
314796|NCT00323284|Procedure|Cataract surgery only|Cataract surgery only
314797|NCT00323297|Drug|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
314798|NCT00323297|Other|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
313706|NCT00351806|Drug|Erigeron breviscapus injection|
313707|NCT00351806|Drug|hua tuo zai zao wan (a herbal medicine pill)|
313708|NCT00351806|Drug|Compound stroke herbal medicine (8 herbal)|
314077|NCT00345267|Device|Integrated Care Pathway|
314078|NCT00345280|Procedure|impression cytology, obtain the tear fluid|Vitamin A
314079|NCT00345293|Biological|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukapheresate, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
314080|NCT00345306|Drug|Comparison between two different progesterone administration|
314081|NCT00345319|Biological|rabies vaccine|Administration of PCECV according to ESSEN regimen
314082|NCT00345332|Drug|Botox|Injected
314083|NCT00002987|Drug|etoposide|
314084|NCT00345332|Drug|Placebo|Injected
314085|NCT00345345|Drug|Alemtuzumab (Campath)|
314086|NCT00345358|Biological|Pneumococcal conjugate vaccine GSK1024850A.|1, 2, 3 or 4 Intramuscular injections, depending on age group
314087|NCT00345358|Biological|Infanrix IPV/Hib|4 intramuscular injections
314088|NCT00345371|Drug|Topiramate|100 mg
314089|NCT00345384|Drug|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
314090|NCT00345384|Other|Placebo (Normal Saline)|
314091|NCT00345397|Device|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
314092|NCT00345410|Drug|AVE1625 B|
314093|NCT00345449|Behavioral|Decision Aid|
314094|NCT00002987|Drug|prednisolone|
314095|NCT00345462|Biological|Trivalent virosomal influenza vaccine|
314096|NCT00345501|Drug|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
313358|NCT00360698|Drug|Insulin Glargine|One daily injection at bedtime
313359|NCT00360698|Drug|Glimepiride|At same dosage as during the run-in period
313360|NCT00360698|Drug|Insulin Glulisine|One bolus given before the main meal
313361|NCT00360698|Drug|Metformin|At same dosage as during the run-in period
313362|NCT00360724|Drug|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
313363|NCT00360737|Biological|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 Experimental with 8 Cohorts of 5 Subjects each evaluating 2 Dosage levels of 1 or 2 vials of NP-018 administered intravenously.
313364|NCT00360750|Drug|carboplatin|
313365|NCT00360750|Drug|cytarabine|
313366|NCT00003064|Drug|paclitaxel|
313367|NCT00360750|Drug|etoposide|
313368|NCT00360750|Drug|vincristine sulfate|
313369|NCT00360750|Other|clinical observation|
313370|NCT00360750|Procedure|adjuvant therapy|
313371|NCT00360750|Radiation|radiation therapy|
313372|NCT00360763|Drug|candesartan cilexetil|
313373|NCT00360776|Drug|tipifarnib|Given orally
313374|NCT00360776|Other|laboratory biomarker analysis|Correlative studies
313375|NCT00360789|Behavioral|Conventional UK physical therapy|
313709|NCT00351819|Drug|Androgel (testosterone gel)|5g gel, applied once daily to the upper arms, upper back or shoulders.
313710|NCT00351819|Other|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
313711|NCT00351832|Drug|Vildagliptin|
313712|NCT00351845|Behavioral|Low carbohydrate diet (behavior)|
313713|NCT00351858|Drug|ertumaxomab|
313714|NCT00003015|Drug|vincristine sulfate|
312654|NCT00325143|Biological|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
312655|NCT00325143|Biological|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
312656|NCT00325156|Biological|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
312657|NCT00325169|Drug|Tiotropium + SERETIDE 50/500|
312658|NCT00325182|Drug|Keppra (Levetiracetam)|
313008|NCT00002864|Drug|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
313009|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
313010|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
313011|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
313012|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
313013|NCT00316082|Drug|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
313014|NCT00316082|Drug|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
313015|NCT00316095|Drug|telmisartan|
313016|NCT00316095|Drug|simvastatin|
313017|NCT00316108|Device|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
313018|NCT00316121|Device|HEALOS and Leopard Cage|Placement in interbody space
313019|NCT00002864|Drug|tamoxifen citrate|20 mg PO for 5 years
313020|NCT00316121|Device|Leopard Cage and Autograft|Placement in the interbody space
313021|NCT00316134|Procedure|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
313022|NCT00316147|Biological|DTPa-HBV-IPV/Hib vaccine|
313023|NCT00316160|Drug|Bupropion Hydrochloride Extended-release|
313024|NCT00316160|Drug|Extended-release Venlafaxine|
313025|NCT00316173|Drug|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
312275|NCT00335192|Drug|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
312276|NCT00335205|Drug|ropinirole|
312277|NCT00335218|Drug|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
312278|NCT00335218|Drug|Placebo|1 tablet daily
312279|NCT00335231|Drug|gatifloxacin ophthalmic (ZYMAR)|
312280|NCT00335244|Drug|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
312281|NCT00002948|Procedure|bone marrow ablation with stem cell support|
312282|NCT00335244|Drug|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
312283|NCT00335270|Drug|fos-amprenavir calcium, ritonavir|
312284|NCT00335270|Drug|abacavir/lamivudine as Epzicom|
312285|NCT00335283|Drug|Lansoprazole Tablet|40 mg bid x 16 weeks
312286|NCT00335283|Procedure|PH and impedence testing|24 hour ph monitoring
312287|NCT00335283|Procedure|manometry|done prior to pH probe to measure length of esophagus
312288|NCT00335283|Drug|lansoprazole|40mg bid
312289|NCT00335283|Drug|placebo|one tablet bid
312290|NCT00335296|Device|PFx catheter|
312291|NCT00335309|Procedure|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
312659|NCT00325195|Other|placebo|placebo by intravenous infusion every 2 weeks
312660|NCT00325195|Biological|pegloticase|8 mg pegloticase by intravenous infusion
312661|NCT00325208|Device|partial-vacuum milk bottle|
312662|NCT00325208|Device|anti-vacuum milk bottle|
312663|NCT00325221|Device|HM on|Home Monitoring activated after implantation
312664|NCT00002898|Drug|epirubicin hydrochloride|
311562|NCT00356759|Drug|Prolongation of the interval between monitoring of warfarin|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
311563|NCT00356772|Drug|Azithromycin|
311564|NCT00356785|Behavioral|health education|
311565|NCT00356785|Behavioral|food supplementation|
311914|NCT00347555|Biological|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
311915|NCT00347555|Drug|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
311916|NCT00347555|Biological|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
311917|NCT00347568|Device|TX-plore|PI has terminated at institution and there is no one available to report.
311918|NCT00000472|Drug|tissue plasminogen activator|
311919|NCT00002999|Drug|fluorouracil|
311920|NCT00347581|Procedure|Base-in prism glasses for reading|
311921|NCT00347581|Procedure|Placebo reading glasses|
311922|NCT00347594|Device|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
311923|NCT00347594|Device|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
311924|NCT00347607|Behavioral|community surveillance and re-treatment|
311925|NCT00347620|Device|spectacles|
311926|NCT00347620|Procedure|Cataract Surgery|
311927|NCT00347646|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
311928|NCT00347659|Drug|BLVR System|Treatment is administered in a single treatment session.
311929|NCT00347672|Biological|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
311930|NCT00002999|Radiation|radiation therapy|
311208|NCT00003086|Drug|thiotepa|
311209|NCT00365768|Other|Placebo|Administered orally twice daily for 21 days
311210|NCT00365781|Drug|ISIS 113715|
311211|NCT00365794|Drug|Topical testosterone (Androgel) 10 g/day|Testosterone therapy for 20 weeks
311212|NCT00365807|Behavioral|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
311213|NCT00365807|Other|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
311214|NCT00365820|Drug|Tegaserod|
311215|NCT00365846|Drug|Campath-1H|
311216|NCT00365859|Drug|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
311217|NCT00365872|Biological|Dendritic Cell (DC) Injections|DCs (10^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.
One additional DC injection was given before surgery to assess DC migration
Patients were assigned to one of three cohorts:
Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery
311218|NCT00365872|Procedure|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
311219|NCT00003086|Procedure|peripheral blood stem cell transplantation|
311220|NCT00365872|Procedure|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
311221|NCT00365885|Other|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
311222|NCT00365898|Drug|Hydromorphone Hydrochloride Extended-Release|
311566|NCT00356785|Behavioral|food supplementation combined with physical activity program|
311567|NCT00356798|Biological|an inactivated whole virion H5N1 vaccine, adjuvanted|
311568|NCT00356811|Drug|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
316805|NCT00356018|Behavioral|Compliance|
316806|NCT00003042|Drug|cyclophosphamide|
316807|NCT00356031|Drug|Bevacizumab|Given intravenously every 2 weeks for a total of 2 doses
316808|NCT00356031|Procedure|Radiation Therapy|Given two weeks after the first bevacizumab infusion and delivered 5 days a week over 6 weeks/
316809|NCT00356044|Procedure|Coronary angioplasty|
316810|NCT00356057|Device|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
316811|NCT00356070|Drug|Strattera|
316812|NCT00356083|Drug|Methadone|
316813|NCT00356096|Drug|pramipexole|
316814|NCT00356109|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
316815|NCT00356109|Drug|Injectable insulin|patient specific dose, injected, before meals, 6 months
316816|NCT00356109|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
316817|NCT00003042|Drug|doxorubicin hydrochloride|
316818|NCT00356122|Drug|Docetaxel|70 mg/m^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
316819|NCT00356122|Drug|Oxaliplatin|100 mg/m^2 administered IV on Day 1 for Cycles 1-6
316820|NCT00356122|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
316821|NCT00356135|Drug|prasugrel 10 mg|10 mg tablet taken orally
316822|NCT00358852|Other|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
316823|NCT00358878|Drug|satavaptan (SR121463B)|oral administration once daily
316824|NCT00358878|Drug|placebo|oral administration once daily
316825|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
305706|NCT00241111|Drug|zoledronic acid|
305707|NCT00002637|Biological|aldesleukin|
305708|NCT00241124|Drug|valsartan|
305709|NCT00241124|Drug|lisinopril|
305710|NCT00241137|Drug|valsartan|
305711|NCT00241150|Drug|VALSARTAN|
305712|NCT00241163|Procedure|Fibrinogen (human) + thrombin (human) (TachoSil)|
305713|NCT00241176|Drug|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS & CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
305714|NCT00244517|Drug|Sevoflurane, Isoflurane, Desflurane|1 MAC
305715|NCT00244530|Drug|Nifedipine|
305716|NCT00244543|Drug|R89674 (generic name not yet established)|
305717|NCT00244556|Drug|Methotrexate plus ENBREL or ENBREL alone|
306070|NCT00230152|Device|Imaging|
306071|NCT00233870|Drug|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
306072|NCT00233883|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
306073|NCT00233883|Drug|enfuvirtide [Fuzeon]|90mg sc bid by 27G1/2" needle/syringe for 4 weeks
306074|NCT00233896|Drug|Oral beclomethasone dipropionate (drug)|
306075|NCT00233909|Drug|Zosuquidar|
306076|NCT00233909|Drug|gemtuzumab ozogamicin|
306077|NCT00233922|Device|Osteosheet(r)|
306078|NCT00233935|Other|placebo|Given PO
306079|NCT00002618|Drug|leucovorin calcium|
305344|NCT00251147|Procedure|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
305345|NCT00251160|Procedure|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
305346|NCT00251160|Procedure|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
305347|NCT00002665|Radiation|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
305348|NCT00253929|Procedure|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
305349|NCT00253942|Procedure|Injecting bee venom as a treatment for OA|
305350|NCT00253955|Drug|Levofloxacin|
305351|NCT00253955|Drug|Piperacillin/Tazobactam|
305352|NCT00253968|Drug|Eplivanserin|oral administration
305353|NCT00253968|Drug|placebo|oral administration
305354|NCT00253981|Device|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
305355|NCT00002677|Drug|chemotherapy|
305356|NCT00253994|Procedure|Acupuncture|
305357|NCT00254007|Drug|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
305358|NCT00254020|Drug|Citalopram|Patients who are found to have major depression will be referred to a psychologist
310579|NCT00343512|Genetic|protein expression analysis|protein expression analysis
310580|NCT00343512|Other|laboratory biomarker analysis|laboratory biomarker analysis
310581|NCT00343512|Procedure|biopsy|biopsy
310582|NCT00343512|Procedure|conventional surgery|conventional surgery
310583|NCT00343512|Procedure|neoadjuvant therapy|neoadjuvant therapy
310584|NCT00002982|Drug|cytarabine|
310585|NCT00343525|Drug|bavituximab|
310586|NCT00343551|Drug|Aliskiren|
310930|NCT00331253|Procedure|Indocyanine Green-Mediated Photothrombosis|
310931|NCT00331279|Drug|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
310932|NCT00331279|Drug|Placebo|Placebo pills in likeness of the cinnamon extract
310933|NCT00331305|Behavioral|Supervised Exercise|
310934|NCT00331305|Behavioral|Home-Based Exercise|
310935|NCT00002928|Drug|paclitaxel|
310936|NCT00331305|Drug|Sertraline (Zoloft)|
310937|NCT00331305|Drug|Placebo Pill|
310938|NCT00331344|Drug|mitoxantrone hydrochloride|Given IV
310939|NCT00331344|Drug|ixabepilone|Given IV
310940|NCT00331344|Drug|prednisone|Given orally
310941|NCT00331370|Behavioral|GP training and Health Education|
310942|NCT00331409|Drug|Everolimus|2.5 mg by mouth daily
310943|NCT00331409|Drug|imatinib mesylate|600 mg by mouth daily
310944|NCT00331422|Drug|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
310945|NCT00334737|Drug|darbepoetin alfa|darbepoetin 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
311340|NCT00324805|Other|Laboratory Biomarker Analysis|Correlative studies
311341|NCT00328198|Biological|Alemtuzumab|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.
Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study.
311342|NCT00328198|Biological|Alemtuzumab|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.
Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration.
311343|NCT00328211|Dietary Supplement|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
311344|NCT00328211|Dietary Supplement|Sphingomyelin|1000mg/day for 19 days
311345|NCT00328211|Drug|Pluronic F-68|Pluronic F-68 is a "detergent" and potent inhibitor of cholesterol absorption. Dose = 0.5%-1.0% by weight of the diet.
311346|NCT00328211|Other|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
311347|NCT00328237|Procedure|Cord Blood Transplant|
311348|NCT00002912|Drug|mitoxantrone hydrochloride|
311349|NCT00328250|Behavioral|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
311350|NCT00328263|Dietary Supplement|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
311351|NCT00328263|Dietary Supplement|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
311352|NCT00328276|Drug|Sarcosine|
311353|NCT00328289|Device|transcutaneous muscle stimulation, treadmill|
311704|NCT00318500|Drug|ERB-041|
311705|NCT00318513|Drug|Bevacizumab|
311706|NCT00318539|Drug|Quetiapine|
316594|NCT00327327|Drug|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
316595|NCT00327340|Drug|custirsen (OGX-011)/mitoxantrone|All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.
Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.
Patients could receive a maximum of 9 cycles of treatment.
316596|NCT00002905|Drug|prednimustine|
316940|NCT00317759|Drug|fludarabine phosphate|
316941|NCT00317772|Drug|Topotecan|Phase I Starting Dose: 2 mg/m^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.
Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15.
316942|NCT00317772|Drug|Gefitinib|Phase I: 250 mg by mouth daily for 28 Days.
Phase II: 250 mg by mouth daily for 28 Days.
316943|NCT00317785|Drug|cyclophosphamide|
316944|NCT00317785|Drug|cyclosporine|
316945|NCT00317785|Drug|methotrexate|
316946|NCT00002868|Drug|idarubicin|
316947|NCT00317785|Drug|mycophenolate mofetil|
316948|NCT00317785|Drug|sirolimus|
316949|NCT00317785|Drug|tacrolimus|
316950|NCT00317785|Other|pharmacological study|
316951|NCT00317785|Procedure|allogeneic bone marrow transplantation|
316952|NCT00317785|Procedure|allogeneic hematopoietic stem cell transplantation|
316953|NCT00317785|Procedure|peripheral blood stem cell transplantation|
316954|NCT00317785|Radiation|total-body irradiation|
316955|NCT00002881|Drug|therapeutic hydrocortisone|
316956|NCT00321191|Drug|No nitrous oxide|
316957|NCT00321191|Drug|Administration of N2O|
316958|NCT00321204|Procedure|TZD reducing the incidence of atrial arrhythmias|
316234|NCT00336830|Behavioral|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
316235|NCT00336843|Drug|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days −21 and −14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day −14) Busulfan (IV, 0.8 mg/kg every 6 h from day −7 to day −5) Cyclophosphamide (IV, 50 mg/kg on days −3 and −2) Etoposide (IV, 200 mg/m2 every 12 h on days −5 and −4) Autologous stem cells infusion on day 0
316236|NCT00002961|Drug|cyclosporine|graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.
When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy.
316237|NCT00336856|Drug|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
316238|NCT00336856|Drug|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
316239|NCT00336882|Drug|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
316240|NCT00336882|Drug|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
316241|NCT00336895|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
316242|NCT00336908|Drug|a combination of MCT, LCT , and Fish Oil|
316243|NCT00336921|Drug|Alfuzosin|Once daily
316244|NCT00336921|Drug|Placebo|Once daily
316245|NCT00336934|Dietary Supplement|pomegranate juice|Given orally daily.
316246|NCT00336934|Other|placebo|Given orally daily.
316247|NCT00002961|Drug|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
316248|NCT00336947|Drug|tegafur-gimeracil-oteracil potassium|
316249|NCT00342849|Drug|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
315502|NCT00358384|Drug|pazopanib (GW786034)|
315503|NCT00358397|Drug|Clostridium novyi-NT spores|TBD
315504|NCT00358410|Drug|GW679769 oral tablets|2x GW679769 60mg tablets
315505|NCT00358410|Drug|Placebo|Placebo oral tablets to match experimental intervention
315506|NCT00000478|Procedure|angioplasty, transluminal, percutaneous coronary|
315507|NCT00003053|Procedure|adjuvant therapy|
315508|NCT00358423|Drug|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
315509|NCT00358423|Drug|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
315861|NCT00349440|Drug|Cyclosporine, Refresh Plus|Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.
Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.
315862|NCT00349453|Drug|Deferiprone (L1)|50-100 mg/kg body weight daily
315863|NCT00349453|Drug|Deferiprone (L1)|75 mg/kg body weight daily
315864|NCT00349453|Drug|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
315865|NCT00349466|Drug|CF101|Orally CF101 1mg
315866|NCT00003007|Procedure|peripheral blood stem cell transplantation|
315867|NCT00349466|Drug|Placebo|Orally matching Placebo
315868|NCT00349479|Behavioral|Barrier assessment / interactive educational intervention|Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual "stroke champions" meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education.
315869|NCT00349492|Drug|IP|irinotecan+cisplatin
315870|NCT00349505|Procedure|hyper thermic chemo + surgery|
315871|NCT00352690|Radiation|External beam radiation therapy|
315872|NCT00352703|Drug|Kepivance (Palifermin)|
315873|NCT00003020|Biological|LMB-7 immunotoxin|
315874|NCT00352716|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
315511|NCT00358436|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
315512|NCT00358449|Drug|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
315513|NCT00358462|Drug|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
315514|NCT00361374|Dietary Supplement|docosahexaenoic acid|1 gram/day
315515|NCT00003067|Biological|lymphokine-activated killer cells|
315516|NCT00361374|Drug|Placebo|980 milligram/day
315517|NCT00361387|Drug|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
315518|NCT00361413|Drug|Alefacept (AMEVIVE®)|Alefacept
315519|NCT00361413|Drug|control group|these patients will receive the same treatment as group A, without alefacept
315520|NCT00361426|Device|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
315521|NCT00361439|Drug|Mometasone|2 puffs in each nostril once daily of nasal spray
315522|NCT00361439|Drug|Placebo|2 puffs in each nostril once daily of nasal spray
315523|NCT00361452|Drug|nebulized epinephrine and nebulized albuterol|
315524|NCT00361465|Other|EMG and Kinematics recording|The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:
discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.
try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.
For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment ("off") and under treatment ("one").
315525|NCT00361478|Behavioral|Exercise and education|Weekly exercise and education program for 8 weeks
315526|NCT00003068|Drug|amifostine trihydrate|
315527|NCT00361478|Behavioral|Education|Written educational material
315528|NCT00361491|Drug|SSR149415|
315529|NCT00361504|Drug|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
314799|NCT00323297|Drug|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
314800|NCT00323297|Drug|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
314801|NCT00323310|Drug|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
314802|NCT00323323|Drug|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
314803|NCT00002888|Drug|fluorouracil|
314804|NCT00323323|Drug|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
314805|NCT00323323|Procedure|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
314806|NCT00323349|Procedure|Oral Glucose Tolerance Testing|
314807|NCT00323349|Behavioral|Education tailored to learning style preferences|
314808|NCT00326326|Drug|CP-778,875|
314809|NCT00326339|Drug|R788|R788 50 mg, 100 mg, or 150 mg PO bid
314810|NCT00326339|Drug|Placebo|Placebo PO bid
314811|NCT00326352|Drug|Sedation with propofol and remifentanil|
314812|NCT00326365|Drug|Kali bichromicum 10-60 (C30)|
314813|NCT00326378|Drug|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
314814|NCT00002900|Procedure|management of therapy complications|
315156|NCT00316927|Drug|acetylsalicylic acid|
315157|NCT00316927|Drug|dexamethasone|
315158|NCT00316927|Drug|diethylstilbestrol|
315159|NCT00316940|Drug|bortezomib|
315160|NCT00000105|Drug|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
314097|NCT00345501|Drug|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
314098|NCT00345514|Behavioral|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
314099|NCT00345514|Behavioral|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
314100|NCT00345527|Behavioral|Emotion and Behaviour Regulation Treatment (EBRT)|
314452|NCT00333008|Drug|Prednisone|
314453|NCT00333008|Drug|Rituximab|
314454|NCT00333008|Drug|Pegfilgrastim|
314455|NCT00333021|Drug|Fondaparinux sodium|
314456|NCT00333021|Drug|GSK576428|
314457|NCT00333034|Drug|Etanercept|
314458|NCT00333047|Drug|Letrozole|
314459|NCT00002939|Drug|paclitaxel|
314460|NCT00333060|Drug|OT-551 ophthalmic solution|
314461|NCT00333073|Device|Bulkamid|initial injection with option for second (if required)
314462|NCT00333086|Drug|Letrozole|
314463|NCT00333099|Dietary Supplement|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
314464|NCT00333099|Other|impact|1500 calories every day :
-5 days before the begining of the chemoradiotherapy and until the last day of the treatment
314465|NCT00333112|Drug|solifenacin succinate|Oral
314466|NCT00336024|Drug|cyclophosphamide|Given IV
314467|NCT00336024|Drug|cisplatin|Given IV
314468|NCT00336024|Biological|filgrastim|Given IV or SC
314469|NCT00336024|Drug|carboplatin|Given IV
314470|NCT00336024|Drug|thiotepa|Given IV
314471|NCT00336024|Drug|methotrexate|Given IV
313715|NCT00351871|Drug|PEG-Intron Plus REBETOL|
313716|NCT00351884|Drug|Vildagliptin AM|
313717|NCT00351884|Drug|vildagliptin pm|
313718|NCT00351884|Drug|placebo|
313719|NCT00351897|Device|pulsed dye (585nm) laser therapy|
313720|NCT00351910|Drug|Quetiapine|
313721|NCT00351910|Drug|Amitriptyline|
313722|NCT00351910|Drug|Bupropion|
313723|NCT00351910|Drug|Citalopram|
313724|NCT00351910|Drug|Duloxetine|
313725|NCT00003015|Procedure|conventional surgery|
313726|NCT00351910|Drug|Escitalopram|
313727|NCT00351910|Drug|Fluoxetine|
313728|NCT00351910|Drug|Paroxetine|
313729|NCT00351910|Drug|Sertraline|
313730|NCT00354640|Drug|simvastatin|40 milligram tablet PO QD for 14 days
313731|NCT00354640|Other|pharmacological study|laboratory analysis
313732|NCT00354640|Procedure|adjuvant therapy|laboratory analysis
313733|NCT00354653|Drug|LAMIVUDINE|
313734|NCT00354666|Drug|GSK159797|
313735|NCT00354679|Biological|bevacizumab|
313736|NCT00354679|Drug|cisplatin|
313737|NCT00354679|Drug|irinotecan hydrochloride|
314101|NCT00345527|Behavioral|Cognitive Behavioural Therapy|
314102|NCT00345540|Drug|NOV-002|60 mg / mL / day / 20-23 Days
314103|NCT00345540|Drug|Carboplatin|AUC 5 following IV bolus administration of NOV-002
313026|NCT00316173|Drug|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
313027|NCT00316186|Drug|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
313028|NCT00316186|Drug|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
313029|NCT00316199|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
313030|NCT00319111|Drug|bosentan|Oral bosentan
Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients
Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight < 40 kg)
313031|NCT00319137|Drug|GW274150|
313376|NCT00360789|Behavioral|Increased intensity of UK conventional physical therapy (PT)|
313377|NCT00003064|Drug|thiotepa|
313378|NCT00360789|Behavioral|UK conventional PT plus functional strength training|
313379|NCT00360802|Behavioral|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
313380|NCT00363467|Drug|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
313381|NCT00363467|Procedure|Stem cell reinfusion|autologous stem cell transplant
313382|NCT00363480|Drug|Fluticasone propionate/salmeterol(50/250µg)|
313383|NCT00363506|Behavioral|Serotona Plus and dietary behavior management|
313384|NCT00003080|Procedure|peripheral blood stem cell transplantation|
313385|NCT00363519|Drug|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
313386|NCT00363519|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
313387|NCT00363532|Drug|infusion of calcitonin gene related peptide (CGRP)|
313388|NCT00363545|Biological|Lyophilized & Liquid formulation of HRV vaccine|
313389|NCT00363571|Drug|GTN, Diamox|
313390|NCT00363584|Drug|capecitabine|
312665|NCT00325221|Device|HM Off|Home Monitoring activated 9 months after implantation
312666|NCT00325234|Drug|Pemetrexed|600 mg/m^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
312667|NCT00325234|Drug|Carboplatin|AUC 5 mg*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
312668|NCT00325234|Drug|Gemcitabine|1200 mg/m^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
312669|NCT00325234|Drug|Vinorelbine|30 mg/m^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
312670|NCT00325247|Drug|ZINC|
312671|NCT00325260|Biological|Influvac; subunit influenza vaccine|
312672|NCT00325273|Dietary Supplement|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
312673|NCT00325286|Drug|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
312674|NCT00328835|Procedure|Brief Elevation of IOP|
312675|NCT00328848|Behavioral|Behavioral|Group Treatment(patient education, self management support, caregiver support)
312676|NCT00328848|Behavioral|behavioral|patient education, self management support, caregiver support
312677|NCT00328861|Drug|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
312678|NCT00328861|Biological|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
312679|NCT00328861|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
312680|NCT00328861|Drug|Fludarabine|Fludarabine 25 mg/m^2 day intravenous on days -6 through -2.
312681|NCT00002915|Drug|penclomedine|
313032|NCT00319150|Drug|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
313033|NCT00319163|Drug|levonorgestrel/ethinyl estradiol|
313034|NCT00319189|Drug|Nateglinide|
313035|NCT00319202|Drug|Candesartan|32 mg/d for 6 months
311931|NCT00347685|Drug|tramadol ER|
311932|NCT00347698|Drug|intravitreal injection of bevacizumab|
311933|NCT00347698|Procedure|panretinal photocoagulation|
311934|NCT00347711|Drug|Intravitreal injection|
311935|NCT00347724|Drug|Tramadol HCl ER|
311936|NCT00347737|Drug|teriparatide|Teriparatide
311937|NCT00347750|Drug|Lopinavir pharmacokinetic/pharmacodynamic analysis|
312292|NCT00002948|Procedure|peripheral blood stem cell transplantation|
312293|NCT00335309|Drug|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
312294|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
312295|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
312296|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
312297|NCT00335335|Drug|iodixanol|
312298|NCT00335348|Drug|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
312299|NCT00335348|Drug|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
312300|NCT00335361|Device|Intra Vas Device (IVD)|
312301|NCT00338052|Drug|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
312302|NCT00338065|Behavioral|1. Postural change and 2. Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes.
Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
312303|NCT00338078|Device|nocturnal oxygen treatment from oxygen concentrators|
312304|NCT00338091|Drug|Benazepril|
312305|NCT00338091|Drug|Losartan|
311569|NCT00356811|Drug|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
311570|NCT00003044|Drug|cisplatin-e therapeutic implant|
311571|NCT00356824|Drug|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
311572|NCT00356824|Drug|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
311573|NCT00356837|Procedure|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
311574|NCT00356850|Drug|Azithromycin|
311575|NCT00356863|Behavioral|Increasing awareness to cardiac rehabilitation programs|Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
311576|NCT00356889|Drug|erlotinib hydrochloride|Given orally, 150 mg, once daily.
311577|NCT00356889|Biological|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
311578|NCT00356902|Procedure|titration of oxygen during resuscitation|
311579|NCT00356915|Drug|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
311580|NCT00003060|Procedure|allogeneic bone marrow transplantation|
311581|NCT00359762|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
311582|NCT00359762|Drug|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
311583|NCT00359775|Behavioral|Coping Skills Training|6 session behavioral program
311584|NCT00359788|Drug|tiotropium|
311585|NCT00359788|Drug|Combivent (Ipratropium/Albuterol)|
311938|NCT00350779|Drug|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
311939|NCT00350779|Drug|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
316826|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
316827|NCT00358930|Drug|ARQ 501|
316828|NCT00003057|Drug|loperamide hydrochloride|
311223|NCT00365911|Procedure|Taking blood sample|A blood sample will be taken.
311224|NCT00365924|Drug|Forteo|Open label single arm study with Forteo as an intervention
311225|NCT00365937|Biological|Immunological peptides and immunological adjuvants|
311226|NCT00365937|Biological|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
311227|NCT00365937|Biological|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
311228|NCT00365937|Biological|IMP321|Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.
The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials.
311229|NCT00365950|Drug|Duration of anticoagulation|
311230|NCT00003086|Radiation|samarium Sm 153 lexidronam pentasodium|
311231|NCT00315159|Procedure|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
311232|NCT00315172|Procedure|Non-Exercise Activity Thermogenesis (NEAT)|
311233|NCT00315185|Drug|Cetuximab|
311234|NCT00315198|Device|Eye Patch|2 hours daily patching
311235|NCT00315198|Procedure|Near activities|near visual activities while patching
311236|NCT00315198|Procedure|Distance activities|distance visual activities while patching
311237|NCT00315211|Drug|Intravenous Topotecan|Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
311238|NCT00315211|Drug|Intravenous Docetaxel|Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 & 8 of a 21 day cycle
306080|NCT00233935|Drug|defined green tea catechin extract|Given PO
306081|NCT00233948|Drug|nelfinavir mesylate|Given orally
306082|NCT00233948|Procedure|biopsy|Correlative studies
306083|NCT00233948|Other|laboratory biomarker analysis|Correlative studies
306084|NCT00233948|Other|pharmacological study|Correlative studies
306085|NCT00233948|Genetic|gene expression analysis|Correlative studies
306086|NCT00233948|Genetic|western blotting|Correlative studies
306087|NCT00233948|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
306088|NCT00233948|Other|immunoenzyme technique|Correlative studies
306089|NCT00233961|Biological|filgrastim|
306090|NCT00002618|Drug|mercaptopurine|
306091|NCT00233974|Procedure|PET (positron emission tomography)|Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
306092|NCT00233987|Drug|carmustine|150 mg/m^2 IV over 2 hours 4, 5, and 6 days before transplant.
306093|NCT00233987|Drug|cyclophosphamide|100 mg/kg IV 2 days before transplant.
306094|NCT00233987|Drug|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
306095|NCT00233987|Drug|melphalan|150 mg/m^2 IV 1 day before transplant.
306434|NCT00222846|Behavioral|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
306435|NCT00222846|Behavioral|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
306436|NCT00222872|Drug|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
306437|NCT00222872|Drug|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
306438|NCT00222898|Procedure|DNA analysis of pancreatic cyst fluid / buccal swab|
306439|NCT00002588|Drug|topotecan hydrochloride|
305359|NCT00254033|Drug|Dextroamphetamine|
305360|NCT00254033|Drug|Methylphenidate|
305718|NCT00002646|Drug|fenretinide|
305719|NCT00244569|Drug|13C-Methacetin|
305720|NCT00244569|Device|Breath ID Machine|
305721|NCT00244595|Drug|candsartan cilexetil|
305722|NCT00244608|Drug|Budesonide/Formoterol Turbuhaler|
305723|NCT00244608|Drug|Budesonide Turbuhaler (Pulmicort)|
305724|NCT00244608|Drug|Terbutaline Turbuhaler|
305725|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
305726|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
305727|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
305728|NCT00244634|Drug|candsartan cilexetil|
305729|NCT00002646|Drug|tamoxifen citrate|
305730|NCT00244647|Drug|RESTEN-MP|
305731|NCT00244660|Procedure|Frequent blood pressure measurements|
305732|NCT00244660|Behavioral|Education|
305733|NCT00244673|Biological|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
305734|NCT00244686|Drug|mepolizumab|open label investigational product
305735|NCT00244699|Behavioral|MI Alone or Plus Mindfulness-Based Skills Training|
305736|NCT00244712|Drug|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
305737|NCT00244712|Drug|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
305738|NCT00244725|Drug|Odiparcil|
305739|NCT00244725|Drug|Warfarin|
310946|NCT00334737|Drug|erythropoietin|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
310947|NCT00334737|Drug|sham injection|sham injection
310948|NCT00002945|Drug|etoposide|IV
310949|NCT00334750|Other|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
310950|NCT00334763|Biological|bevacizumab|
310951|NCT00334763|Drug|carboplatin|
310952|NCT00334763|Drug|chemoprotection|
310953|NCT00334763|Drug|paclitaxel|
310954|NCT00334763|Radiation|radiation therapy|
310955|NCT00334776|Biological|MART-1 antigen|
305361|NCT00254046|Drug|TMC125|2 X100 mg tablets b.i.d.96 weeks
305362|NCT00254046|Drug|Placebo|2 tablets b.i.d.96 weeks
305363|NCT00254059|Procedure|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
305364|NCT00254072|Procedure|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
305365|NCT00254085|Drug|Insulin Aspart|
305366|NCT00002677|Drug|tributyrin|
305367|NCT00254111|Device|Ultra Probe Laser System|
305368|NCT00254124|Device|The Diet Plate (R) TM portion control plate and bowl|
305369|NCT00254137|Drug|capecitabine|
305370|NCT00254137|Drug|irinotecan|
305371|NCT00254137|Drug|oxaliplatin|
305372|NCT00254137|Drug|cetuximab|
305373|NCT00254150|Procedure|Increase oxygen extraction rate|
305374|NCT00254163|Drug|Fludarabine|
311707|NCT00318552|Drug|Meropenem|
311708|NCT00002870|Procedure|peripheral blood stem cell transplantation|
311709|NCT00318565|Device|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
311710|NCT00318591|Device|SpeediCath|hydrophilic coated urinary intermittent catheter
311711|NCT00318591|Device|Conveen Uncoated|Uncoated urinary intermittent catheter
311712|NCT00318617|Drug|GW510516X|
311713|NCT00318630|Drug|Avandia|
311714|NCT00318643|Drug|Chemophase|
311715|NCT00318643|Drug|Mitomycin C|
311716|NCT00318656|Drug|rosiglitazone-metformin fixed dose combination|
311717|NCT00318656|Drug|metformin + glimepiride|
311718|NCT00318669|Drug|Paroxetine hydrochloride hydrate|
311719|NCT00002872|Biological|bleomycin sulfate|
311720|NCT00318682|Device|FIBROSCAN|diagnostic examination of the hepato fibrosis
311721|NCT00318695|Dietary Supplement|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
311722|NCT00318695|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
311723|NCT00321971|Behavioral|Nutritional education program|The nutritional education program will be based on the new USDA dietary recommendations. All participants attend weekly individual training sessions, either in their home or another convenient location for a total of 6 weeks.
311724|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
311725|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
311726|NCT00321984|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
311727|NCT00321997|Drug|Pegaptanib sodium|
311728|NCT00000463|Drug|lovastatin|
311729|NCT00002883|Procedure|adjuvant therapy|
316959|NCT00321230|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
316960|NCT00321243|Behavioral|Visual clues|
316961|NCT00321256|Procedure|human pancreatic islet transplantation|
316962|NCT00321269|Behavioral|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
316963|NCT00321269|Behavioral|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
316964|NCT00321282|Procedure|Atrial Fibrillation|
316965|NCT00321295|Device|Atrial synchronous bi-ventricular pacing|
316966|NCT00002881|Procedure|orchiectomy|
311354|NCT00328302|Drug|Candesartan|
311355|NCT00328302|Drug|Placebo|
311356|NCT00328367|Drug|aripiprazole|aripiprazole augmentation of clozapine
311357|NCT00328367|Drug|placebo|placebo
311358|NCT00328380|Drug|Rifaximin|
311359|NCT00002912|Drug|valspodar|
311360|NCT00328393|Drug|Pioglitazone|45 mg 8 weeks
311361|NCT00328393|Drug|Placebo|Placebo
311362|NCT00328419|Device|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
311363|NCT00328419|Device|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
311364|NCT00331422|Drug|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
311365|NCT00002930|Procedure|positron emission tomography|
311366|NCT00331422|Procedure|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
311367|NCT00331435|Procedure|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
311368|NCT00331474|Biological|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
316597|NCT00327340|Drug|custirsen (OGX-011)/docetaxel|All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.
Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.
Patients could receive a maximum of 9 cycles of treatment.
316598|NCT00327353|Drug|formoterol (TURBOHALER)|
316599|NCT00327353|Drug|Salmeterol (DISKUS)|
316600|NCT00330551|Behavioral|Group Skills Training and Psychoeducation|Group skills training sessions will be weekly throughout the study. The sessions will include group therapy meetings focused on everyday living skills, family education about schizophrenia, assessments of medication response, and individual meetings with a case manager for counseling and evaluations of schizophrenia symptoms.
316601|NCT00330551|Behavioral|Individual Case Management|An individual therapist will provide therapy focused on everyday life skills and aid in interfacing with community agencies, work, and/or school settings.
316602|NCT00330551|Drug|Oral Risperidone|Daily oral risperidone dosage will determined by treating psychiatrist.
316603|NCT00330551|Drug|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone once every 2 weeks. Dosage will be adjusted if needed.
316604|NCT00002925|Drug|Daunorubicin|
316605|NCT00330564|Drug|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
316606|NCT00330577|Drug|timolol maleate 0.5%|
316607|NCT00330577|Drug|latanoprost/timolol fixed combination|
316608|NCT00330577|Drug|placebo (artificial tears)|
316609|NCT00330603|Procedure|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
316610|NCT00330616|Drug|323U66 SR|
316611|NCT00330629|Behavioral|Standard Behavioral Treatment|
316612|NCT00330629|Behavioral|Standard Behavior Treatment plus Lacto-ovo-vegetarian diet|
316613|NCT00330655|Drug|memantine|
316614|NCT00330668|Drug|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
315875|NCT00352729|Device|ACell dressing|dressing
315876|NCT00352742|Drug|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
315877|NCT00352755|Procedure|Surgical debulking with peritonectomy|
315878|NCT00352755|Drug|Intraperitoneal 5FU|
315879|NCT00352755|Drug|FOLFOX|
315880|NCT00352768|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
315881|NCT00352768|Drug|Placebo|Placebo
315882|NCT00352781|Drug|nicotine replacement therapy|nicotine transdermal patches as per product monograph
315883|NCT00352781|Behavioral|behavioural intervention|Smoking cessation counselling and relapse prevention
315884|NCT00003021|Drug|bizelesin|
316250|NCT00342849|Drug|Placebo|
316251|NCT00342862|Drug|Amevive exposure|Observational
316252|NCT00342940|Biological|influenza surface antigen inactivated vaccine|
316253|NCT00343005|Biological|AMA1-C1|
316254|NCT00343005|Drug|AMA1-C1/alhydrogel Malaria Vaccine|
316255|NCT00343044|Drug|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
316256|NCT00343044|Drug|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
316257|NCT00343057|Other|Patients' questionnaire|
316258|NCT00002977|Drug|thiotepa|
316259|NCT00343070|Drug|Oral administration of escitalopram during 8 weeks|
316260|NCT00343083|Drug|Erbitux, Paclitaxel & Carboplatin|Paclitaxel, 40 mg/m2/week,
1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.
Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.
Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)
315530|NCT00361504|Drug|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
315885|NCT00352794|Drug|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
315886|NCT00352794|Drug|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
315887|NCT00352807|Drug|Brimonidine Purite|
315888|NCT00352820|Behavioral|Interview|Recorded face-to-face session.
315889|NCT00352820|Behavioral|Questionnaire|Written survey lasting approximately 30 minutes.
315890|NCT00352833|Drug|catumaxomab|
315891|NCT00352846|Drug|Zoledronic Acid|4 mg/m^2 by vein over 30 Minutes at baseline and 6 months.
315892|NCT00352846|Drug|Vitamin D|400 mg by mouth daily
315893|NCT00352846|Drug|Calcium Carbonate|1200 mg by mouth daily
315894|NCT00352859|Drug|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
315895|NCT00003022|Radiation|iodine I 131 monoclonal antibody 3F8|
315896|NCT00352859|Drug|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
315897|NCT00352885|Drug|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
315898|NCT00352885|Drug|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
315899|NCT00355550|Drug|Ketasyn|
315900|NCT00003039|Drug|alvocidib|
315901|NCT00355563|Device|PAS-Port Automated Proximal Anastomosis System|
315902|NCT00355576|Drug|Celecoxib|Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
315903|NCT00355576|Drug|Creatine|10 g BID for either study arm
315161|NCT00000139|Drug|Acyclovir|
315162|NCT00000461|Drug|niacin|
315163|NCT00002865|Drug|vincristine sulfate|
315164|NCT00316940|Radiation|samarium Sm 153 lexidronam pentasodium|
315165|NCT00316953|Drug|dasatinib|Given orally
315166|NCT00316953|Other|pharmacological study|Correlative studies
315167|NCT00316953|Other|laboratory biomarker analysis|Correlative studies
315168|NCT00316966|Behavioral|Multidisciplinary dietary intervention|
315169|NCT00316979|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
315170|NCT00316992|Drug|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
315171|NCT00317005|Drug|folate treatment|
315172|NCT00317018|Behavioral|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
315173|NCT00317031|Drug|Acamprosate or Naltrexone|mg&d 90 days
315174|NCT00002865|Radiation|low-LET cobalt-60 gamma ray therapy|
315175|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg twice daily
315176|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg once daily
315177|NCT00317044|Drug|Placebo|Placebo twice daily
315178|NCT00317057|Procedure|Patient education and disease management|
315179|NCT00320255|Drug|Placebo|Tablets, Oral, 0 mg, once daily for 12 weeks
315531|NCT00361517|Behavioral|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
315532|NCT00361517|Other|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
314472|NCT00336024|Drug|leucovorin calcium|Given IV or orally
314473|NCT00336024|Drug|vincristine sulfate|Given IV
314474|NCT00336024|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSC transplantation
314475|NCT00002952|Biological|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
314476|NCT00336024|Other|laboratory biomarker analysis|Correlative studies
314477|NCT00336024|Procedure|quality-of-life assessment|Ancillary studies
314478|NCT00336063|Drug|Azacitidine|Given SC
314479|NCT00336063|Other|Laboratory Biomarker Analysis|Correlative studies
314815|NCT00326378|Drug|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
314816|NCT00326391|Drug|methylphenidate hydrochloride extended-release tablets|
314817|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
314818|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
314819|NCT00326417|Drug|Fludarabine|Doses of 30 mg/m2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
314820|NCT00326417|Drug|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
314821|NCT00326417|Drug|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
314822|NCT00326417|Drug|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
314823|NCT00326430|Behavioral|Cognitive Therapy, Interpersonal Therapy|
314824|NCT00326443|Biological|CVD 909|5 X 10^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
314825|NCT00002901|Drug|docetaxel|
314826|NCT00326443|Drug|Placebo|Buffer placebo administered on Day 0.
314104|NCT00345566|Procedure|Nutrition composition|
314105|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
314106|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
314107|NCT00003004|Drug|alvocidib|
314108|NCT00348686|Drug|Candesartan|16 mg once daily in oral tablet form
314109|NCT00348686|Drug|Candesartan|32 mg once daily in oral tablet form
314110|NCT00348686|Drug|Felodipine|5 mg once daily in oral tablet form
314111|NCT00348686|Drug|Felodipine|10 mg once daily in oral tablet form
314112|NCT00348699|Drug|AFP464|Given IV
314113|NCT00348699|Other|pharmacological study|Correlative studies
314114|NCT00348699|Other|laboratory biomarker analysis|Correlative studies
314115|NCT00348712|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
314116|NCT00348712|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
314117|NCT00348712|Drug|metformin|Tablets, 2000 mg/day.
314118|NCT00003004|Drug|cisplatin|
314119|NCT00348725|Drug|fenofibrate and metformin fixed combination (drug)|
314120|NCT00348738|Drug|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of >14g/dl, <15g/dl is reached or until the end of the radiation therapy.
314121|NCT00348751|Device|CholGate|
314122|NCT00348764|Drug|lauromacrogol|
314123|NCT00348777|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
314124|NCT00348777|Drug|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
314125|NCT00348790|Drug|vatalanib|
314480|NCT00336063|Other|Pharmacological Study|Correlative studies
313391|NCT00363584|Other|clinical observation|
313392|NCT00363584|Procedure|adjuvant therapy|
313393|NCT00363597|Device|in vitro and in vivo permeability testing|single oral dose, 2 mL/kg (maximum 100 mL) of Sugar Absorption Solution containing 5 gm lactulose, 2 gm mannitol and 40 gm sucrose dissolved in demineralized water.
313394|NCT00363610|Drug|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
313395|NCT00003081|Biological|filgrastim|
313396|NCT00363623|Device|Silicone hydrogel contact lens|
313397|NCT00363636|Drug|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
313398|NCT00363636|Drug|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
313399|NCT00363649|Biological|GM-K562 cell vaccine|Given by injection
313738|NCT00354679|Genetic|proteomic profiling|
313739|NCT00354679|Other|diagnostic laboratory biomarker analysis|
313740|NCT00003035|Biological|filgrastim|
313741|NCT00354679|Other|mass spectrometry|
313742|NCT00354679|Procedure|adjuvant therapy|
313743|NCT00354679|Procedure|neoadjuvant therapy|
313744|NCT00354679|Procedure|therapeutic conventional surgery|
313745|NCT00354679|Radiation|radiation therapy|
313746|NCT00354692|Drug|Sodium Ferric Gluconate and Iron sucrose|
313747|NCT00354705|Behavioral|Questionnaire|Two questionnaires taking 30 minutes to complete.
313748|NCT00354731|Drug|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
313749|NCT00354731|Drug|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
313750|NCT00354744|Biological|dactinomycin|Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), < 1 year 0.025 mg/kg.
Day 1 of Weeks 35, 38, 41 and 44.
Given IV
313036|NCT00002874|Radiation|low-LET photon therapy|
313037|NCT00319202|Drug|Placebo|Placebo administration for 6 months
313038|NCT00319215|Drug|Ramelteon 8 mg|
313039|NCT00319215|Drug|Zopiclone 7.5 mg|
313040|NCT00319228|Drug|Plasma-derived AT-III concentrate|Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.
Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.
313041|NCT00319241|Behavioral|Parenting Intervention|
313042|NCT00319254|Drug|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
313043|NCT00319267|Drug|bosentan|
313044|NCT00319280|Procedure|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
313045|NCT00319293|Drug|Metformin|
313046|NCT00319306|Drug|Budesonide/formoterol|
313047|NCT00000461|Drug|fatty acids, omega-3|
313048|NCT00002875|Biological|filgrastim|
313049|NCT00319306|Device|Symbicort® Turbohaler®|
313050|NCT00319319|Drug|Mecamylamine hydrochloride (Inversine)|
313051|NCT00319332|Drug|Ibritumomab Tiuxetan|
313052|NCT00319332|Drug|Iodine I 131 Tositumomab|
313053|NCT00319345|Drug|Mannitol, Sodium-Lactate|
313054|NCT00319358|Dietary Supplement|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
313055|NCT00319358|Dietary Supplement|Placebo|placebo
313056|NCT00319384|Device|Ultrafiltration therapy|
313057|NCT00319397|Behavioral|Exercise-Training Program|
313400|NCT00363649|Biological|recombinant interferon alfa|Given by injection
312306|NCT00338104|Drug|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
312307|NCT00338104|Drug|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
312308|NCT00338104|Drug|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
312309|NCT00002967|Drug|tamoxifen citrate|
312310|NCT00338117|Drug|Galantamine hydrobromide|
312311|NCT00338130|Drug|AZD6244|Oral liquid or Capsule
312312|NCT00338130|Drug|Temozolomide|oral
312313|NCT00338143|Drug|efalizumab|
312314|NCT00338182|Drug|AZD1152|48-hour continuous intravenous infusion
312682|NCT00328874|Drug|Coenzyme Q10|
312683|NCT00328887|Genetic|CD40 Ligand Gene (AdcuCD40L)|gene transfer, intratumoral administration
312684|NCT00328900|Drug|Administration of 0,7 mg of atropine|
312685|NCT00328900|Device|Measurement of skin conductance with Pain detector|
312686|NCT00328913|Drug|5-hydroxytryptophan (food supplement)|
312687|NCT00328926|Drug|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol [E2] levels). Total duration will be of 3 treatment cycles.
312688|NCT00328926|Drug|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
312689|NCT00328926|Drug|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
312690|NCT00328926|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
311940|NCT00350779|Drug|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
311941|NCT00350779|Drug|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
311942|NCT00350792|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles
311943|NCT00350792|Drug|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
311944|NCT00350805|Procedure|EEG|One 20 minutes session
311945|NCT00350818|Drug|Azacitidine|8 mg/m^2 Subcutaneously Once Daily for 5 Days
311946|NCT00350831|Drug|XL820|
311947|NCT00350844|Drug|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
311948|NCT00000473|Behavioral|diet, fat-restricted|
311949|NCT00003013|Drug|cyclophosphamide|
311950|NCT00350857|Drug|Extended-Release Carbamazepine|
311951|NCT00350870|Drug|disulfiram|250mg per day of Disulfiram plus CBT
311952|NCT00350870|Drug|Placebo|Placebo plus CBT
311953|NCT00350870|Behavioral|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
311954|NCT00350870|Drug|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
311955|NCT00350883|Behavioral|Cognitive Therapy|Goal-oriented talk therapy
311956|NCT00350883|Other|Treatment as Usual|Keep getting usual care
311957|NCT00350896|Device|Thumb orthoses|
312315|NCT00338195|Behavioral|Individualized caffeine cessation instructions|Intervention is described in the protocol
312316|NCT00338208|Behavioral|Training in the Use of Low Vision Devices|
312317|NCT00338221|Drug|alanyl-glutamine|
311239|NCT00315224|Behavioral|heart-rate controlled 12 week exercise program|
311240|NCT00315237|Drug|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
311241|NCT00002858|Drug|cyclophosphamide|
311586|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
311587|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
311588|NCT00359814|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
311589|NCT00359814|Drug|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
311590|NCT00359840|Drug|darbepoetin alfa|
311591|NCT00003061|Drug|cytarabine|
311592|NCT00359853|Drug|Oral norfloxacin|
311593|NCT00359866|Radiation|IMRT with tomotherapy|
311594|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
311595|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
311596|NCT00359892|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
311597|NCT00359905|Drug|Silodosin|8 mg daily for 12 weeks
311598|NCT00359905|Drug|Tamsulosin|0.4 mg daily for 12 weeks
311599|NCT00359905|Drug|Placebo|once daily for 12 weeks
311600|NCT00359918|Drug|fibrinolysis|
311601|NCT00359944|Drug|AC-3933|5mg twice daily
311602|NCT00003061|Drug|methotrexate|
311603|NCT00359944|Drug|AC-3933|AC-3933, 20 mg twice daily
306440|NCT00222911|Device|dorsiflexion night splint|
306441|NCT00222911|Device|medial arch support|
306442|NCT00222924|Behavioral|weight loss/ exercise|
306443|NCT00222937|Behavioral|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
306444|NCT00222937|Behavioral|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
306445|NCT00222976|Drug|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
306446|NCT00226135|Drug|lithium or lamotrigine|
306447|NCT00000133|Procedure|Trans-scleral Cryotherapy|
306448|NCT00000393|Drug|Peptide T|
306449|NCT00002596|Drug|cyclophosphamide|
306450|NCT00226148|Procedure|Use of a membrane to cover bonedefects around implant|
306451|NCT00226148|Device|Use of bonechips to fill up defects around implant|
306452|NCT00226148|Procedure|Use of membrane and bonechips to manage defects|
306453|NCT00226161|Procedure|Inguinal herniorrhaphy|
306454|NCT00226174|Drug|Curcuminoids|
306455|NCT00226187|Procedure|Supplement of fatty acid (DHA and AA)|
306456|NCT00226200|Drug|Omalizumab|
306457|NCT00226213|Procedure|Peripherally Inserted Central Catheter Placement|
306458|NCT00226226|Procedure|Peripherally Inserted Central Catheter Placement|
306822|NCT00211575|Behavioral|Disease Management Assessment|
306823|NCT00211588|Drug|galantamine|
306824|NCT00211601|Behavioral|Disease Management Assessment|
306825|NCT00215540|Drug|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
305740|NCT00002647|Drug|verteporfin|
305741|NCT00244725|Drug|Coumadin|
305742|NCT00244738|Dietary Supplement|Castor oil|Patients who received castor oil for labor induction
305743|NCT00244738|Dietary Supplement|Sunflower oil|Patients who received sunflower oil as a placebo
305744|NCT00244751|Drug|GI262570|
306096|NCT00233987|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
306097|NCT00233987|Radiation|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
306098|NCT00234000|Drug|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
306099|NCT00234000|Drug|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
306100|NCT00234026|Drug|gemcitabine hydrochloride|
306101|NCT00237692|Behavioral|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
306102|NCT00237692|Behavioral|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
306103|NCT00237692|Behavioral|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral & medication management
306104|NCT00002628|Drug|carboplatin|
306105|NCT00237705|Drug|metoclopramide|
306106|NCT00237718|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
306107|NCT00237718|Drug|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
306108|NCT00237718|Drug|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
306109|NCT00237718|Drug|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
306110|NCT00237731|Drug|morphine|morphine 0.05
306111|NCT00237731|Drug|morphine|morphine 0.10
305375|NCT00254163|Drug|Cyclophosphamide|
305376|NCT00254163|Drug|Rituximab|
305377|NCT00002678|Drug|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
305378|NCT00254163|Drug|Pentostatin|
305379|NCT00257413|Procedure|Transplantation of autologous endothelial progenitor cells|
305380|NCT00257426|Drug|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
305381|NCT00257452|Drug|tiotropium 18 mcg or 54 mcg qd|
305382|NCT00257452|Drug|placebo matching tiotropium qd|
305383|NCT00257452|Drug|moxifloxacin 200 mg|
305384|NCT00002691|Drug|cyclophosphamide|
305385|NCT00257465|Biological|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
305386|NCT00257465|Biological|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
305745|NCT00247780|Procedure|Pulmonary vein isolation and cavotricuspid ishtmusblock|
305746|NCT00002657|Radiation|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
305747|NCT00247793|Drug|Oral Impact (preoperative enteral nutritional supplement)|
305748|NCT00247819|Procedure|Blood draw|
305749|NCT00247832|Behavioral|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
305750|NCT00247832|Behavioral|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
305751|NCT00247897|Drug|Skin antisepsis|See Detailed Description
305752|NCT00247910|Drug|Hydrochlorothiazide|Not recorded in detailed description.
305753|NCT00247923|Procedure|Hysteroscopic resection of endometrial polyps. (TCRP)|
305754|NCT00247936|Procedure|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
312070|NCT00312286|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
312071|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
312072|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
312073|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
312074|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
312075|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
312076|NCT00002846|Procedure|conventional surgery|
312077|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
312078|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
312079|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
312080|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
312081|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
312082|NCT00312299|Device|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
312083|NCT00312299|Device|Round edge PMMA IOL|Round edge PMMA IOL
312084|NCT00312299|Device|Acrysof IOL|Acrysof IOL
312085|NCT00312299|Device|square Edge PMMA IOL|Square edge PMMA intra ocular lens
312086|NCT00312299|Device|Square Edge PMMA IOL|Square Edge PMMA IOL lens
312087|NCT00002847|Biological|aldesleukin|
312088|NCT00312312|Biological|Specific immunotherapy|
312089|NCT00312325|Drug|Prednisolone|
312090|NCT00312338|Drug|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
312091|NCT00312351|Drug|Pegaptanib sodium|
312092|NCT00312364|Drug|MRE0094|
311369|NCT00331487|Drug|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
311370|NCT00331487|Drug|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
311371|NCT00331500|Drug|olopatadine 0.2%|
311372|NCT00331513|Drug|vorinostat|Given orally
311373|NCT00331513|Drug|idarubicin|Given IV
311374|NCT00331513|Other|laboratory biomarker analysis|Correlative studies
311375|NCT00331513|Other|pharmacological study|Correlative studies
311376|NCT00002930|Radiation|fludeoxyglucose F 18|
311377|NCT00331526|Biological|aldesleukin|
311378|NCT00331526|Biological|therapeutic autologous lymphocytes|
311730|NCT00322010|Procedure|early PT OT|Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).
Sessions began with active assisted and active range of motion exercises in the supine position.
If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.
Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.
The session progresses to transfer training, and finally pre-gait exercises and ambulation.
Progression of activities is dependent on patient tolerance and stability.
Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged.
311731|NCT00322023|Drug|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
311732|NCT00322036|Drug|MPC-7869|Oral 800 mg BID
311733|NCT00322036|Drug|MPC-7869|Oral BID dosing
311734|NCT00322049|Biological|Tetravalent live attenuated dengue vaccine|DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.
Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.
A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit).
311735|NCT00322049|Biological|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
316615|NCT00002925|Drug|Etoposide|
316967|NCT00321308|Drug|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
316968|NCT00321308|Drug|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
316969|NCT00321321|Drug|Sulfonylurea|
316970|NCT00321334|Procedure|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
316971|NCT00321347|Drug|Lidocaine|
316972|NCT00321360|Drug|Propofol|
316973|NCT00321360|Device|Patient maintained sedation|
316974|NCT00321373|Biological|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
316975|NCT00321373|Biological|FluarixTM|Single dose, Intramuscular injection
316976|NCT00321412|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
316977|NCT00002882|Biological|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
316978|NCT00321425|Procedure|brachial plexus block|
316979|NCT00321425|Procedure|ultrasound guidance|
316980|NCT00321425|Procedure|electrical nerve stimulation|
316981|NCT00321451|Behavioral|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
316982|NCT00321451|Behavioral|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
316983|NCT00321451|Other|Usual care|3 outpatient visits with study physician
316984|NCT00321464|Biological|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
316985|NCT00324155|Drug|Placebo|Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
316986|NCT00324155|Drug|Dacarbazine|Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
316987|NCT00324168|Drug|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
316261|NCT00343083|Radiation|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
316262|NCT00343096|Drug|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
316263|NCT00343109|Biological|HER-2/neu intracellular domain protein|Given ID
316264|NCT00343109|Procedure|leukapheresis|Optional correlative studies
316265|NCT00343109|Other|laboratory biomarker analysis|Correlative studies
316266|NCT00343109|Biological|sargramostim|Given ID
316267|NCT00343109|Other|immunologic technique|Correlative studies
316268|NCT00343109|Biological|synthetic tumor-associated peptide vaccine therapy|Given ID
316269|NCT00002977|Procedure|peripheral blood stem cell transplantation|
316270|NCT00343122|Procedure|echocardiography for intrapulmonary vasodilatation|
316271|NCT00343135|Drug|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
316272|NCT00343148|Drug|AVI-4126 Injection (RESTEN-NG®)|
316273|NCT00343161|Drug|esomeprazole|
316616|NCT00330681|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
316617|NCT00330681|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
316618|NCT00330694|Other|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
316619|NCT00330694|Other|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
316620|NCT00330707|Drug|Bacillus Calmette Guerin and interferon alpha|
316621|NCT00330720|Device|Emergency Response System (Device)|
316622|NCT00330733|Drug|Salsalate|Salsalate therapy
316623|NCT00330733|Drug|Placebo|Matching placebo
281892|NCT02604355|Drug|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
281893|NCT02604368|Drug|SC411|Soft gelatin capsule
281894|NCT02604368|Drug|Placebo|Soft gelatin capsule
281895|NCT02604381|Dietary Supplement|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
281896|NCT02604381|Other|Placebo|
281897|NCT02604394|Procedure|Rheolytic Thrombectomy|RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).
The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:
The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.
The disposable pump connects to a bag of heparinized saline.
The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,
281898|NCT02604394|Procedure|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
281899|NCT02604407|Drug|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
281900|NCT00191854|Drug|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
281901|NCT02604407|Other|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
281902|NCT02604407|Drug|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
281903|NCT02604420|Drug|eculizumab|
281904|NCT02604433|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
281905|NCT02604433|Other|Placebo|Placebo, Subcutaneous, every 21 days.
281906|NCT02604446|Drug|Tapentadol|
281907|NCT02604446|Drug|Oxycodone|
281908|NCT02604446|Drug|Placebo|
281909|NCT02604446|Drug|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
281593|NCT02575001|Procedure|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
281594|NCT00188214|Procedure|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
281595|NCT02575001|Procedure|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
281596|NCT02575014|Drug|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
281597|NCT02575027|Radiation|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
281598|NCT02575027|Other|Questionnaire Administration|Ancillary studies
281599|NCT02575027|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
281600|NCT02575040|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
281601|NCT02575053|Procedure|assessment of a new latex protocol|All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.
Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.
Removal of all materials containing latex from the resuscitation carts.
Further requirements in case of latex allergic patients:
Identification of patients with (suspected) latex allergy.
All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.
All latex containing materials should be removed from the room and latex free alternatives should be available.
All staff present in the room should use latex free synthetic gloves.
Operating tables and supports should be made of latex free material or should be covered with blankets.
The entire OR staff is thoroughly educated concerning the latex safe protocol.
281602|NCT02575066|Radiation|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy
281603|NCT02575066|Drug|pazopanib|pazopanib QD 800 mg
281604|NCT02575079|Device|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
281605|NCT00188227|Drug|Midazolam (sedative)|
281606|NCT02575092|Drug|Enalapril Maleate Tablets(as the program-based antihypertension)|
281607|NCT02575092|Drug|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
281608|NCT02575092|Drug|Placebo|
281609|NCT02575118|Device|Restoration of dental caries with dental composite|
281015|NCT02583750|Behavioral|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
281016|NCT02583750|Behavioral|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
281017|NCT02583763|Other|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
281018|NCT02583763|Procedure|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
281019|NCT02583776|Device|Unblinded - CGM|Data from device will be readable and alarms on
281300|NCT02579343|Device|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
281301|NCT02579343|Drug|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
281302|NCT02579356|Drug|Telmisartan|
281303|NCT02579356|Drug|Atorvastatin|
281304|NCT02579369|Other|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
281305|NCT02579382|Drug|TDF|TDF 300 mg tablets administered orally once daily
281306|NCT02579382|Drug|GS-9620|GS-9620 tablets administered orally once a week (every 7 days) for 12 doses
281307|NCT02579382|Drug|GS-9620 Placebo|Placebo to match GS-9620 administered orally once a week (every 7 days) for 12 doses
281308|NCT02579395|Behavioral|Collaborative implementation Intentions|With spouse/romantic partner
281309|NCT00189007|Drug|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
281310|NCT02579395|Behavioral|Individual implementation Intentions|Without spouse/romantic partner
281311|NCT02579395|Behavioral|Control|
281312|NCT02579421|Drug|Progesterone|generic progesterone
280745|NCT00190567|Drug|duloxetine|
280746|NCT02590783|Procedure|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
280747|NCT02590783|Procedure|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
280748|NCT02590796|Other|No intervention given to participants|This is an observational study. Participants will receive no intervention.
280749|NCT02590809|Drug|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
280750|NCT02590809|Drug|Placebo|Placebo will be given for 30 days
280751|NCT02590809|Other|Walk distance test|Walk distance test during 6 minutes
280752|NCT02590809|Other|Exercise echocardiography|
281020|NCT00189566|Drug|Carboplatin|
281021|NCT02585999|Drug|Xulane Contraceptive Patch (generic version of Ortho Evra®*)|Extended use (12 Weeks) of Contraceptive Patch
281022|NCT02586012|Drug|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: [(weight in kg x desired FVIII increase of 100 IU/dL)/(2)].
281023|NCT02586025|Drug|FEC chemotherapy|Fluorouracil (5-FU) 500-600 mg/m2, epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by IV infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
281024|NCT00189852|Device|Chronic heart failure monitoring system|
281025|NCT02586025|Procedure|Surgery|All patients who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
281026|NCT02586025|Drug|docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
280428|NCT02597088|Other|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
280429|NCT02597101|Drug|Metformin|background drug
280430|NCT02597101|Drug|saxagliptin|background drug
280431|NCT02597101|Drug|AZD9668|study drug
280432|NCT02597101|Drug|placebo|placebo for AZD9668 to be added to background drugs
280433|NCT00191178|Drug|insulin glargine|
280434|NCT02597114|Drug|AGT-181|intravenous infusion over 3-4 hours
280435|NCT02597127|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering RNA that inhibits PCSK9 synthesis and is given as subcutaneous injections
280436|NCT02597140|Drug|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
280437|NCT02597140|Drug|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
280438|NCT02597140|Drug|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
280439|NCT02597153|Drug|Mitoxantrone HCL Liposome Injection|
280440|NCT02597166|Drug|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
280441|NCT02597192|Other|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
280442|NCT02597192|Other|oral hygiene products without Bacillus|products without Bacillus
280443|NCT02597205|Behavioral|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
280444|NCT00191191|Drug|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
280445|NCT02597231|Dietary Supplement|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
280446|NCT02597231|Other|Placebo|Patients in this group will receive a matching placebo pill.
279854|NCT02608242|Drug|Twynsta 80/10mg|
279855|NCT02608242|Drug|Crestor 20mg|
279856|NCT02608255|Other|blood samples|
279857|NCT00192296|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
279858|NCT02608268|Drug|MBG453|anti human TIM-3 monoclonal antibody
279859|NCT02608268|Drug|PDR001|anti-human PD-1 monoclonal antibody
279860|NCT02608281|Device|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
280141|NCT02601586|Drug|Levodopa|Levodopa+ Placebo of Oxycodone
280142|NCT02601586|Drug|Placebo|Placebo of PR Oxycodone+ Placebo of Levodopa
280143|NCT02601599|Behavioral|Motivational interviewing|The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).
Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support.
280144|NCT02601612|Biological|D46cpΔM2-2 vaccine|Delivered as nose drops
280145|NCT02601612|Biological|Placebo|Delivered as nose drops
280146|NCT02603679|Drug|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
280147|NCT02603692|Other|PROMIS-QOL|PROMIS questionnaires completed every 3 months for up to 2 years.
280148|NCT02603705|Drug|Oxycodone extended-release|
280149|NCT02603718|Other|Rehabilitation treatment|
280150|NCT02603744|Biological|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
280151|NCT02603757|Dietary Supplement|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
280152|NCT00191789|Drug|doxorubicin|60 mg/m^2, IV, every 21 days x 4 cycles (1-4)
280153|NCT02603770|Drug|XueZhiKang|
279551|NCT02713802|Drug|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
279552|NCT02713802|Drug|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
279553|NCT02713815|Radiation|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 24 weeks by Theta-burst stimulation (TBS), once a day for the first 8 weeks and twice a week for the last 16 weeks
279554|NCT00203788|Behavioral|Workplace Fundamentals Module|Group skills training on job/school topics
279555|NCT02713815|Radiation|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 24 weeks by sham Theta-burst stimulation (TBS), once a day for the first 8 weeks and twice a week for the last 16 weeks, with the coil set at 90° against the skull
279556|NCT02713815|Behavioral|motivational-cognitive psychotherapy|self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training
279557|NCT00203996|Drug|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
279558|NCT02715856|Behavioral|Surveys|After each visit, participant completes a survey about their physical and emotional health as well as their pain. At the end of the study, participant completes a survey regarding the study.
279559|NCT02715856|Behavioral|Electronic Questionnaires|At the end of each follow-up visit, participant completes an electronic questionnaire about their quality of life. At the end of the study, participant completes a survey regarding the study and use of the mobile device.
279861|NCT02608294|Device|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
279862|NCT02608294|Device|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
279863|NCT02608320|Drug|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
279249|NCT02684760|Drug|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
279250|NCT02684773|Procedure|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
279251|NCT02684773|Procedure|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
279252|NCT02684786|Drug|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
279253|NCT02684786|Procedure|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
279254|NCT02684786|Drug|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
279255|NCT02684799|Drug|Cenicriviroc|
279256|NCT02684799|Drug|Omeprazole|
279257|NCT02684799|Drug|Famotidine|
279258|NCT00200265|Behavioral|diet|diet
279259|NCT02684812|Drug|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
279260|NCT02684825|Device|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
279261|NCT02684851|Drug|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
279262|NCT02684851|Drug|Placebo|Placebo
279263|NCT02684864|Other|Non-interventional|
279264|NCT02684877|Other|Questionnaire|
279560|NCT02715856|Behavioral|Mobile Device Training|At a clinic visit before surgery, participant taught how to take photos of their surgical wounds and make videos using a mobile device.
279561|NCT02715869|Drug|A pharmacologic cardiac preconditioning (Sevoflurane)|A (10 patient). Patients are anaesthetized by Sevoflurane more than 1 mac.
283526|NCT02598349|Radiation|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
283527|NCT02598349|Drug|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
283528|NCT02598349|Procedure|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
283529|NCT02598349|Behavioral|FACT-Hep questionnaire|The FACT-Hep questionnaire is specific to those with gastrointestinal cancers focusing on hepatobiliary and pancreatic cancer.
283824|NCT02591810|Procedure|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
283825|NCT02591810|Procedure|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
283826|NCT02591810|Procedure|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
283827|NCT02591836|Drug|Gemcabene|Gemcabene
283828|NCT02591836|Drug|Atorvastatin|Atorvastatin
283829|NCT02591836|Drug|Placebo|
283830|NCT00190671|Drug|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
283831|NCT02591849|Other|Glucagon-like peptide-1 (GLP-1)|
283832|NCT02591849|Other|Isotonic saline|
283833|NCT02591862|Drug|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
283834|NCT02591888|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
283835|NCT02591888|Drug|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
283836|NCT02591901|Drug|Uro vaxom|Prevention of recurrent lower urinary tract infections
283837|NCT02591901|Other|Placebo comparator|Placebo comparator
283250|NCT02602847|Biological|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
283251|NCT00191906|Drug|placebo|Placebo, every day (QD), by mouth (PO)
283252|NCT02604784|Drug|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC)|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. Ascites is removed if present and the amount documented. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer (MIP, Regr Medizintechnik, Rottweil, Germany) is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
283253|NCT02604797|Drug|Nalbuphine|patient-controlled intravenous analgesia
283254|NCT02604797|Drug|Sufentanil|patient-controlled intravenous analgesia
283255|NCT02604797|Drug|flurbiprofen axetil|patient-controlled intravenous analgesia
283256|NCT02604797|Drug|ramosetron|patient-controlled intravenous analgesia
283257|NCT02604810|Biological|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
283530|NCT02598362|Drug|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
283531|NCT02598375|Other|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
283532|NCT02598388|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles).
283533|NCT02598388|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units).
283534|NCT02598388|Biological|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
283535|NCT00191282|Drug|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
283536|NCT02598401|Other|observation|
283537|NCT02598414|Procedure|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
283538|NCT02598414|Procedure|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
283580|NCT02602977|Other|Single-dose Remote Ischemic Preconditioning|A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.
1 "RIPC-dose" consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.
Single-dose RIPC consists of 1 dose of RIPC as described above
283884|NCT02596412|Other|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
283885|NCT02596425|Procedure|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
283886|NCT02596425|Procedure|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
283887|NCT00191282|Drug|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
283888|NCT02598479|Other|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
283889|NCT02598492|Other|arterial blood gas|Just record clinical lab data
283890|NCT02598505|Drug|Indacaterol|
283891|NCT02598505|Drug|Placebo|
283892|NCT02598518|Behavioral|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
283893|NCT02598518|Behavioral|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
283894|NCT02598544|Other|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
283895|NCT02598557|Drug|Exemestane|Given PO
283896|NCT02598557|Other|Laboratory Biomarker Analysis|Correlative studies
283897|NCT02598557|Other|Pharmacological Study|Correlative studies
283898|NCT00191282|Drug|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values >8.0%.
283899|NCT02598557|Other|Placebo|Given PO
283900|NCT02598557|Other|Quality-of-Life Assessment|Ancillary studies
283304|NCT02609490|Drug|olmesartan medoxomil placebo tablets|placebo tablet
283305|NCT02609503|Drug|Pembrolizumab|Pembrolizamab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
283306|NCT02609503|Radiation|Intensity Modulated Radiation Theapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
283307|NCT02609516|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
283308|NCT02609529|Other|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
283309|NCT02609529|Other|Placebo|
283581|NCT02602977|Biological|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group [n=10], single-dose RIPC group [n=10] and control group [n=10]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
283582|NCT02602990|Device|SQUID™|
283583|NCT02604927|Dietary Supplement|Dextrose|
283584|NCT02604940|Drug|Dexmedetomidine|1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure
283585|NCT02604940|Drug|Normal Saline|60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
283586|NCT02604953|Device|Short Duration Transient Visual Evoked Potential (SDtVEP)|Visual evoked potentials (VEPs) are able to detect the disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, the VEP may have an advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status
283587|NCT02604953|Device|Pattern electroretinogram (PERG)|The pattern electroretinogram (PERG) is another important test, which is aimed for evaluating early damage to retinal ganglion cells (RGC). In PERG the retinal response is tested by pattern stimuli in the visual field
283588|NCT02604966|Drug|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
283589|NCT02604966|Drug|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
283590|NCT02604992|Drug|Treatment A|Dronabinol oral solution, under fed conditions
283591|NCT02604992|Drug|Treatment B|Dronabinol oral capsule, under fed conditions
283592|NCT02604992|Drug|Treatment C|Dronabinol oral capsule, under fasted conditions
283022|NCT02580058|Drug|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
283023|NCT02580071|Dietary Supplement|Sheng-Yu-Tang|Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)
patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)
283024|NCT02580084|Procedure|Hybrid Intervention|The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.
Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.
arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).
Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims.
283025|NCT02580084|Procedure|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
283310|NCT02609542|Other|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
283311|NCT02609555|Procedure|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
283312|NCT02575820|Procedure|New red blood cells transfusion|Red blood cells (shelf life =< 14 days) transfusion during the operation (total hip replacement arthroplasty)
283313|NCT02575833|Drug|AMG 334|Single dose of IV AMG 334
283314|NCT02575833|Drug|Placebo|Single dose of IV Placebo
283315|NCT02575846|Dietary Supplement|Enteral Intake - Human Milk|Comparing formula and human milk
283316|NCT02575846|Dietary Supplement|Enteral Intake - Formula|Comparing formula and human milk
283317|NCT02575859|Drug|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
283318|NCT02575859|Procedure|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
282740|NCT02584478|Drug|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
282741|NCT00189644|Procedure|6 FEC 100|
282742|NCT02586636|Drug|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
282743|NCT02586636|Drug|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
282744|NCT02586649|Drug|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
282745|NCT00189969|Biological|Elstree-BN|
282746|NCT02586649|Drug|Placebo|Placebo is a non-active inhalation capsule .
282747|NCT02586675|Drug|Tamoxifen|Tamoxifen will be given orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
282748|NCT02586675|Drug|Ribociclib|Ribociclib will be given orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a "rest" period from dosing with LEE011. In the continuous cohort, 400 mg ribociclib will be given daily (QD).
283026|NCT02580097|Other|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
283027|NCT02580110|Other|Sucrose|
283028|NCT00189098|Drug|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
283029|NCT02580110|Other|Stevia glycosides|
283030|NCT02580110|Other|saccharin|
283031|NCT02580123|Behavioral|Intervention taught by trained educators|
283032|NCT02580149|Drug|Ticagrelor|Subjects will receive an oral loading dose of 180 mg ticagrelor on study day
1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15).
283033|NCT02580149|Drug|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
282456|NCT02591394|Behavioral|Usual Care|Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.
After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.
Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers.
282457|NCT02591407|Procedure|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
282458|NCT02591407|Procedure|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
282459|NCT02591420|Biological|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 60 minutes using a volumetric pump
282460|NCT02591420|Biological|Placebo for VRC01|Administered as an intravenous infusion over 60 minutes using a volumetric pump
282461|NCT02591420|Drug|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended first line once-daily oral combination therapy: either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
282462|NCT02591433|Other|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
282463|NCT02591433|Other|Support Group Therapy|Undergo JeffQuit group therapy
282464|NCT00190606|Drug|placebo|
282465|NCT02591433|Other|Quality-of-Life Assessment|Ancillary studies
282466|NCT02593162|Drug|Ribavirin|
282467|NCT02593175|Drug|Panitumumab|One week before Cycle 1 participants receive a single dose of Panitumumab 1000 mg by vein. On Day 1, 8, and 15 of each 21 day cycle, participants receive Panitumumab 1000 mg by vein.
282749|NCT02586675|Drug|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
282750|NCT02586688|Device|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
282751|NCT02586688|Device|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
282752|NCT02586688|Device|Open Label Active NeuroStar® TMS|Open label NeuroStar® coil.
282753|NCT02586701|Other|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
282754|NCT02586714|Other|No intervention|Observation only
282174|NCT02597842|Device|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
282175|NCT02597855|Drug|Aflibercept|At initial visit, indocyanine green angiography was performed. After diagnosis of PCV, monthly intravitreal Aflibercept injection was done. (3 times) After 1monts of 3rd Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
282176|NCT02597855|Drug|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After diagnosis of PCV, monthly intravitreal Aflibercept injection was done. (3 times) After 1monts of 3rd Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
282177|NCT02597868|Drug|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
282178|NCT02597868|Procedure|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
282179|NCT02597894|Procedure|Biopsy of Prostate|Undergo biopsy
282180|NCT02597894|Other|Laboratory Biomarker Analysis|Correlative studies
282181|NCT02597907|Drug|aprepitant|aprepitant 80 mg is given to all patients before surgery
282182|NCT02597907|Drug|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
282183|NCT00191256|Drug|Carboplatin|
282184|NCT02597907|Drug|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
282185|NCT02597933|Drug|Nintedanib|
282186|NCT02597933|Drug|Placebo|
282468|NCT02593175|Drug|Paclitaxel|On Day 1, 8, and 15 of each 21 day cycle, participants receive Paclitaxel 80mg/m2 by vein.
282469|NCT02593175|Procedure|Biopsy|About 1 week after the first Panitumumab dose, participants have an image-guided core biopsy and/or a fine needle aspiration (FNA) to remove breast tissue.
282470|NCT02593175|Drug|Carboplatin|On Day 1 of each 21 day cycle Carboplatin AUC 5 received by vein.
282471|NCT00190827|Drug|duloxetine|
282472|NCT02593188|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
282473|NCT02593201|Drug|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
282187|NCT02600039|Other|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
282188|NCT02600039|Device|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
282189|NCT02600052|Other|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
282190|NCT02600052|Device|treadmill|AEROBIC TRAINING
282191|NCT00191451|Drug|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
282192|NCT02600065|Other|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
282193|NCT02600078|Device|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
282194|NCT02600078|Other|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
282195|NCT02600078|Other|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
282196|NCT02600078|Other|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
282197|NCT02600091|Behavioral|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
282198|NCT02600104|Device|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
282199|NCT02600117|Drug|Tenofovir disoproxil fumarate|300 mg, oral, once a day
282200|NCT02600130|Biological|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
281610|NCT02575131|Other|whole wheat bread yeast basis|
281611|NCT02575131|Other|Oatmeal|
281612|NCT02575131|Other|Cheerios|
281910|NCT02606578|Other|Questionnaires|The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.
At your clinical follow-up visits (~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.
You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back.
281911|NCT00192088|Drug|oxaliplatin|
281912|NCT02606591|Procedure|Electroencephalograph|EEG performed at beginning and end of school year.
281913|NCT02606591|Behavioral|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
281914|NCT02606591|Other|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
281915|NCT02606604|Device|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
281916|NCT02606617|Drug|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
281917|NCT02606617|Drug|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
281918|NCT02606630|Drug|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
281919|NCT02606643|Procedure|Slight traction|Slight traction will be applied to the balloon catheter
281920|NCT02606643|Procedure|Foley Catheter to no traction|No traction will be applied to the catheter
281921|NCT02606643|Device|Foley Catheter|
281922|NCT00192101|Drug|gemcitabine|
281923|NCT02606669|Dietary Supplement|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
281924|NCT02606682|Drug|NPT200-11|Single doses of NPT200-11capsules, orally administered
281925|NCT02606682|Drug|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
281313|NCT02579421|Drug|placebo|placebo
281314|NCT02579434|Drug|Midazolam I.V.|Midazolam I.V. 1mg/ml
281315|NCT02579460|Other|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications.
281316|NCT02579473|Drug|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
281317|NCT02579499|Drug|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
281613|NCT02575131|Other|whole wheat sourdough bread|
281614|NCT02575131|Other|standard breakfast|
281615|NCT02575144|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
281616|NCT00002514|Drug|asparaginase|
281617|NCT02577237|Behavioral|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
281618|NCT00188617|Drug|GEFITINIB|250 mg once a day for 28 days before surgery
281619|NCT02577237|Behavioral|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
281620|NCT02577237|Other|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
281621|NCT02577237|Other|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
281622|NCT02577250|Drug|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
281623|NCT02577263|Other|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
281624|NCT02577276|Device|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
281027|NCT02586025|Drug|pertuzumab|Pertuzumab intravenous (IV) infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 mg loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
281028|NCT02586025|Drug|placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
281029|NCT02586025|Drug|trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
281030|NCT02586038|Drug|MLN9708|
281031|NCT02586038|Drug|Dexamethasone|
281032|NCT02586038|Drug|Cyclophosphamide|
281033|NCT02586038|Drug|Bendamustine|
281034|NCT02586038|Drug|Thalidomide|
281035|NCT00189852|Device|Lifestyle monitoring system|
281036|NCT02586051|Drug|Obinutuzumab|Participants will receive obinutuzumab IV infusion on Day 1 in Cohort 1 and on Days 1 and 15 and 169 (at investigator's discretion) in Cohort 2.
281037|NCT02586064|Behavioral|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
281318|NCT02579499|Drug|targeted LDL-C goal statin|Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)
Patients already received statin therapy
Baseline LDL-C <70mg: same intensity of statin therapy
Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C < 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C < 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)
281319|NCT02581774|Other|normal delivery tracking|normal delivery tracking
281320|NCT02581787|Biological|Fresolimumab|Given IV
281321|NCT02581787|Other|Pharmacological Study|Correlative studies
281322|NCT02581787|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
281323|NCT02581800|Other|App group|
281324|NCT00189332|Drug|852A|
280753|NCT02590822|Dietary Supplement|Cambridge Weight Plan|Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.
The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.
Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study.
280754|NCT02590822|Other|Supervised Exercise Sessions|The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.
Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study.
280755|NCT02592642|Device|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine [NeuroTrac TENS from Verity Medical Ltd (U.K.)] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
280756|NCT02592642|Device|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
280757|NCT00190762|Drug|Pemetrexed|
280758|NCT02592642|Device|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
280759|NCT02592655|Device|Automatic Tourniquet System (ATS)|Automated pneumatic tourniquet.
280760|NCT02592655|Device|Single Windlass Tourniquet SOFTT-W|The Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) is a 3.81 cm (1.5 inch) wide windlass tourniquet.
280761|NCT02592655|Device|Double Windlass Tourniquet SOFTT-W|The Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) is a 3.81 cm (1.5 inch) wide windlass tourniquet.
280762|NCT02592655|Device|Battle Wrap TQ Tape 5 cm|Battle Wrap Tourniquet Tape is 5.08 cm (2 inch) in width. BW TQ Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
280763|NCT02592655|Device|Battle Wrap TQ Tape 10 cm|Battle Wrap Tourniquet Tape is 10.16 cm (4 inch) in width. BW TQ Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
280154|NCT02603770|Drug|Lovastatin|
280155|NCT02603783|Other|Capsaicin|capsaicin 1,5 mg
280156|NCT02603783|Other|Placebo|0,9% saline 75 ml
280157|NCT02603796|Other|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
280158|NCT02603809|Drug|ERA|ERA Dose 1, Dose 2, Dose 3, and Dose 4 administered as capsules orally once a day (o.d.) for 8 weeks
280159|NCT02603809|Drug|Lisinopril|20 mg capsules orally o.d. for 8 weeks
280160|NCT02603809|Other|Placebo|Placebo matching ERA and placebo matching lisinopril capsules will be administered concomitantly orally o.d. for 8 weeks
280161|NCT02603822|Dietary Supplement|12C mannitol|12C mannitol 100 mg
280162|NCT02603822|Drug|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
280447|NCT02597244|Device|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
280448|NCT02597257|Drug|Lidocaine HCl|lidocaine continuous infusion
280449|NCT02597257|Drug|Normal saline|Normal saline continuous infusion
280450|NCT02597283|Device|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
280451|NCT02597283|Device|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
280452|NCT02597309|Drug|Canagliflozin|
280453|NCT02599272|Other|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
280454|NCT02599272|Other|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
280455|NCT02599285|Device|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
280456|NCT02599285|Device|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
280457|NCT02599298|Device|Continuous Positive Airway Therapy|
279864|NCT02608320|Drug|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
279865|NCT02608320|Drug|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
279866|NCT02608320|Drug|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
279867|NCT02608320|Drug|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
279868|NCT00192491|Biological|FluMist|Nasal sprayer of FluMist
279869|NCT02610205|Other|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
279870|NCT02610218|Other|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
279871|NCT02610231|Drug|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
279872|NCT02610244|Other|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
280163|NCT00191789|Drug|cisplatin|70 mg/m^2, IV, every 21 days x 4 cycles (5-8)
280164|NCT02603822|Dietary Supplement|13C mannitol|13C mannitol 100 mg
280165|NCT02603822|Dietary Supplement|Lactulose|lactulose 1 g
280166|NCT02603835|Device|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
280167|NCT02603848|Drug|Ibuprofen|
280168|NCT02603848|Drug|Morphine|
280169|NCT02603861|Drug|LY3154207|LY3154207 administered orally.
279562|NCT02715869|Procedure|B ischeamic preconditioning|B (10 patients ) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
279563|NCT02715882|Drug|CBLB502|
279564|NCT02715882|Drug|Placebo|
279565|NCT02715895|Dietary Supplement|Friso|Formula feeding on demand for 3 months
279566|NCT02715895|Dietary Supplement|Non-friso|Formula feeding on demand for 3 months
279567|NCT02715895|Dietary Supplement|Breast milk|Breast milk feeding on demand
279568|NCT00203996|Procedure|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
279569|NCT02715908|Drug|LBEC0101|Etanercept
279570|NCT02715921|Other|Tele-exercise|
279571|NCT02715934|Other|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
279572|NCT02715934|Other|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
279573|NCT02715947|Drug|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
279574|NCT02715960|Drug|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
279575|NCT02715973|Dietary Supplement|Nutritional Supplement|
279576|NCT02715973|Dietary Supplement|Standard Nutritional Treatment|
279577|NCT02715986|Device|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
279578|NCT02718092|Device|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
279579|NCT02718105|Genetic|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
283838|NCT02591914|Drug|Fovista™|Anti-PDGF-B pegylated aptamer
283839|NCT02591914|Drug|Lucentis®|Anti-VEGF
283840|NCT02591914|Drug|Avastin®|Anti-VEGF
283841|NCT00190671|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
283842|NCT02593643|Other|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
283843|NCT02593656|Behavioral|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
279265|NCT02687230|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
279266|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
279267|NCT02687243|Device|Interactive Virtual Application|Online application via tablet
279268|NCT02687256|Device|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
279269|NCT02687256|Device|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
279270|NCT02687269|Drug|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
279271|NCT02687269|Drug|Placebo|Patients receive Placebo twice daily in the three days before surgery
279272|NCT02687282|Other|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
279273|NCT02687295|Dietary Supplement|Thylakoids|
279274|NCT02687295|Other|Control|
279275|NCT02687308|Procedure|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
279276|NCT02687308|Procedure|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
279277|NCT00200564|Drug|ketamine|
283539|NCT02598414|Device|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
283540|NCT02598427|Drug|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
283541|NCT02598427|Drug|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
283542|NCT02598440|Drug|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
283543|NCT02598440|Drug|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
283544|NCT02598453|Drug|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
283545|NCT02598466|Drug|Abatacept|
283546|NCT02600715|Drug|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
283547|NCT02600728|Behavioral|Experimental Training|The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.
Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.
Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction "Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement.
283844|NCT02593656|Behavioral|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
283845|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
283846|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
283847|NCT02593669|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
283848|NCT02593669|Drug|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
283849|NCT02593682|Drug|suvorexant|
283850|NCT00190879|Drug|placebo|
283851|NCT02593682|Drug|placebo|
283852|NCT02593695|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
283901|NCT02598557|Procedure|Therapeutic Conventional Surgery|Undergo surgery
283902|NCT02598570|Drug|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
283903|NCT02598583|Biological|Study Drug - ALXN1210|Cohort 1: Intrapatient dose escalation to therapeutic dose level
283904|NCT02598583|Biological|Study Drug - ALXN1210|Cohort 2: Intrapatient dose escalation to therapeutic dose level
283905|NCT02598596|Biological|Pegloticase|A total of 20 patients will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
279323|NCT02692170|Biological|CVI-HBV-001|Investigational product: CVI-HBV-001
Dose: 5, 10, 20 or 40ug
Frequency: 3 times
Vaccination schedule: at 0, 1, 6 months
Administration route: Intramuscular injection
279324|NCT02692170|Biological|Conventional Hepatitis B vaccine (20 μg)|Active comparator: Conventional Hepatitis B vaccine (20 μg)
Dose: 20ug
Frequency: 3 times
Vaccination schedule: at 0, 1, 6 months
Administration route: Intramuscular injection
279325|NCT02692196|Device|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
279326|NCT02692209|Device|FFDM Plus DBT|FFDM + DBT Images
FujiFilm Aspire Cristalle System
279327|NCT02692209|Device|FFDM Alone|FFDM Alone Images
279328|NCT02692222|Other|Calculation of PPV and CO with two methods|
279329|NCT02692235|Dietary Supplement|carnitine|1000 mg/d l-carnitine-l-tartrate
279330|NCT00002540|Procedure|Medical Examination|Undergo DRE
279331|NCT00201162|Behavioral|dietary supplements|
279332|NCT02692235|Dietary Supplement|leucine|1000 mg/d l-leucine
279333|NCT02694471|Behavioral|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
279334|NCT02694484|Other|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
279335|NCT02694497|Other|Chlamydia care as usual|
279336|NCT02694510|Other|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
279337|NCT02694523|Drug|BI 655066|
283593|NCT00191932|Drug|Duloxetine|
283594|NCT02605018|Drug|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
283595|NCT02605018|Device|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
283596|NCT02605044|Drug|Masitinib (AB1010)|
283597|NCT02605044|Drug|FOLFIRI|
283598|NCT02605057|Drug|LEO 80185 gel|
283599|NCT02605057|Drug|Dovobet(r) Ointment|
283600|NCT02605070|Drug|Bravelle|
283601|NCT02605083|Drug|eFT508|Will be given orally once daily. Each treatment cycle = 21 days.
283602|NCT02605096|Procedure|MRI|Magnetic Resonance Imaging Scan
283906|NCT02598609|Behavioral|Education program for NICU caregivers|educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it
implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a prevention of unplanned extubation checklist in the units
multicenter sharing of prooved strategies to prevent adverse events in the NICU
283907|NCT02598622|Drug|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
283908|NCT02598622|Drug|Placebo|Placebo is taken 2 times a day for days 1 through 21.
283909|NCT00191295|Drug|Atomoxetine|
283910|NCT02598635|Drug|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels <20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
283911|NCT02598635|Drug|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
283912|NCT02600741|Drug|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283913|NCT02600741|Drug|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283914|NCT02600741|Drug|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283915|NCT02600741|Drug|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283319|NCT00188344|Procedure|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
283320|NCT02575872|Behavioral|Exercise Intervention|Participate in physical activity behavioral intervention
283321|NCT02575885|Other|Electronic Cigarette|Receive different type of ENDS product at each visit
283322|NCT02575885|Other|Electronic Cigarette|Receive BLU e-cigarette ENDS product
283323|NCT02575885|Other|Laboratory Biomarker Analysis|Correlative studies
283324|NCT02575885|Other|Pharmacological Study|Correlative studies
283325|NCT02575885|Other|Questionnaire Administration|Ancillary studies
283326|NCT02575898|Other|First Session|Creative Practice and Positive Re-enforcement
283327|NCT02575898|Other|Second Session|Disease Related
283328|NCT02575898|Behavioral|Third through Sixth Sessions|Life Review and Legacy
283329|NCT02575911|Device|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
283603|NCT02605096|Procedure|X-ray|X-ray exam (conventional radiography)
283604|NCT00191945|Drug|Atomoxetine Hydrochloride|
283605|NCT02605109|Other|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
283606|NCT02605122|Drug|Solithromycin|
283607|NCT02605122|Drug|Standard of Care|Age- and weight-based dosing as appropriate.
283608|NCT02605135|Device|Continued Pessary Use|Pessary Fitting
283609|NCT02605148|Dietary Supplement|Gluten free diet|Gluten free diet during 18 months.
283610|NCT02607423|Radiation|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
283611|NCT02607423|Drug|Gemcitabine Hydrochloride|Given IV
283612|NCT02607423|Drug|Pemetrexed Disodium|Given IV
283613|NCT02607423|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
283034|NCT02582411|Device|Doppler Optical Coherence Tomography|A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.
calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time.
283035|NCT02582424|Other|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
283036|NCT02582424|Other|placebo|placebo
283037|NCT02582437|Other|History for opioid use|
283038|NCT00189436|Drug|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
283039|NCT02582450|Other|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
283040|NCT02582476|Drug|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
283041|NCT02582476|Drug|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
283042|NCT02582489|Biological|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
283043|NCT02582489|Procedure|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
283330|NCT00000373|Drug|olanzapine + fluoxetine|
283331|NCT00002514|Drug|cyclophosphamide|
283332|NCT00188357|Behavioral|Education|
283333|NCT02575911|Procedure|LASIK surgery|
283334|NCT02575924|Drug|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
283335|NCT02575924|Drug|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
283336|NCT02575937|Behavioral|low glycemic diet|nutrition education-based low glycemic diet intervention
282755|NCT02586727|Drug|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
282756|NCT00189982|Drug|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.
The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.
282757|NCT02586740|Procedure|Pulmonary artery rehabilitation|
282758|NCT02586753|Other|Paclitaxel plus Cisplatin with radiotherapy|we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.
Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
282759|NCT02589145|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
282760|NCT02589145|Drug|Busulfan|Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The "test dose" of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
282761|NCT02589145|Drug|Melphalan|60 mg/m2 by vein on days -3 and -2.
282762|NCT02589145|Drug|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
282763|NCT02589145|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
282764|NCT02589145|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
282765|NCT00190372|Behavioral|Self-hypnotic relaxation|Self-hypnotic relaxation
282766|NCT02589145|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
283044|NCT02582502|Other|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
283045|NCT02582502|Other|Sham Hyperbaric Oxygen|The only intervention given will be a sham hyperbaric oxygen treatment.
283046|NCT02582515|Drug|D-cycloserine|
283047|NCT02582515|Drug|Placebo|
283048|NCT02582515|Behavioral|Habit Reversal Training|
282474|NCT02593201|Drug|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
282475|NCT02593214|Device|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
282476|NCT02593227|Biological|Low dose FRα vaccine|165ug per peptide ID injection
282477|NCT02593227|Drug|Cyclophosphamide|IV infusion over 1 hour
282478|NCT02593227|Biological|High dose FRα vaccine|500ug per peptide ID injection
282479|NCT02593240|Behavioral|Weight Watchers® with Food|Intensive Weight Watchers (WW) group behavioral weight loss program delivered live in the worksite and with support of a web platform; this program will be delivered by WW trainers and will initially consist of weekly 1-hour support and education meetings of 20 participants/group with access to online tools for individual support. Over time support will be provided online rather than in live meetings. Ten participants per worksite per WW intervention arm will be randomized to receive commercial dried food products from Yevo Intl., (partial supply) which are designed to help with weight control and health.
282480|NCT02593240|Behavioral|Weight Watchers® with Voucher|Intensive Weight Watchers (WW) group behavioral weight loss program delivered live in the worksite and with support of a web platform; this program will be delivered by WW trainers and will initially consist of weekly 1-hour support and education meetings of 20 participants/group with access to online tools for individual support. Over time support will be provided online rather than in live meetings. Ten participants per worksite per WW intervention arm will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
282481|NCT02593240|Behavioral|The iDiet® with Food|Intensive iDiet group behavioral weight loss program delivered in-person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Ten participants per worksite per iDiet intervention arm will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
282482|NCT00190827|Drug|placebo|
282483|NCT02595671|Other|Digital Super Coach|Receive Digital Super Coach during 12 weeks
282484|NCT02595671|Other|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
282767|NCT02589145|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
282768|NCT02589145|Drug|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
282769|NCT02589145|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
282770|NCT02589145|Drug|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
282201|NCT02600130|Biological|Placebo|via peripheral intravenous infusion
282202|NCT00002517|Drug|daunorubicin hydrochloride|
282485|NCT02595671|Other|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
282486|NCT02595671|Other|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
282487|NCT02595684|Drug|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
282488|NCT02595684|Drug|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
282489|NCT02595697|Behavioral|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
282490|NCT02595710|Other|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
282491|NCT02595710|Other|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
282492|NCT02595710|Other|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
282493|NCT00191100|Drug|Cisplatin|
282494|NCT02595723|Drug|Phenytoin|Phenytoin is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
282495|NCT02595723|Drug|Megestrol Acetate|Megestrol Acetate is a frequently prescribed medication that is used to stimulate appetite in HIV patients. It is also used for cancer patients and in the elderly, particularly nursing home patients who may be at risk for cognitive impairment or delirium.
282496|NCT02595723|Drug|Placebo|Inactive ingredient matching the active medication in appearance
282497|NCT02595736|Drug|Placebo (SC)|Administered SC
282498|NCT02595736|Drug|LY3200327 (SC)|Administered SC
282499|NCT02595736|Drug|LY3200327 (IV)|Administered IV
282500|NCT02595736|Drug|Placebo (IV)|Administered IV
282501|NCT02595749|Drug|Oxytocin|
282502|NCT02595749|Drug|Placebo|
281926|NCT02606708|Radiation|Accelerated intensity modulated radiation therapy (AIMRT)|
281927|NCT02606734|Device|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
281928|NCT02606760|Drug|P-3073|
281929|NCT02606760|Drug|Vehicle of P-3073|
282203|NCT00191451|Drug|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
282204|NCT02600156|Procedure|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
282205|NCT00002517|Drug|idarubicin|
282206|NCT00191646|Drug|Paclitaxel|175 mg/m^2, IV, Day 1, q 21 days x 6 cycles
If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m^2, IV, 3 hours q 28 days x 12 cycles (1 year)
If no complete response, then Gemcitabine arm patients may receive 175 mg/m^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity
282207|NCT02602288|Device|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
282208|NCT02602288|Drug|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
282209|NCT02602301|Drug|Oxytocin|different oxytocin diluents and effect on fetal bilirubin&sodium levels.
282210|NCT02602314|Drug|Imatinib|
282211|NCT02602314|Drug|Nilotinib|
282212|NCT02602327|Drug|Tas-102|Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
282213|NCT02602327|Device|SIR-Sphere|20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
282214|NCT02602340|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
282215|NCT02602353|Drug|New Pain Patch|One Active Pain Patch applied once daily for 3 days
282216|NCT02602353|Drug|Placebo|One Placebo Patch applied daily for 3 days
282217|NCT00191646|Drug|Carboplatin|Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles
Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles
282218|NCT02602353|Drug|No Treatment|No Treatment for 3 days
282219|NCT02602366|Other|HEC Placebo Gel|
281625|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
281626|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
281627|NCT02577302|Device|CTNS - StimGuard Protect CTNS System|CTNS subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the StimGuard CTNS System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 12 weeks. Subjects who are considered a responder at the 13-week follow-up, will continue therapy and followed for a total of 12 months.
281628|NCT02577302|Device|PTNS - Uroplasty PTNS System|PTNS subjects will receive in-office PTNS therapy using the Uroplasty device. Unilateral percutaneous stimulation will be performed in the standard fashion for a total of 12 weeks. Primary objectives will be measured at the 13-week follow-up. At this point study participants who received the in-office PTNS therapy may choose to receive a CTNS device at least 8 weeks after their last PTNS session.
281629|NCT00188630|Drug|N-acetylcysteine|
281630|NCT02577315|Drug|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
281930|NCT02606773|Drug|Ascorbic Acid|Ascorbic acid in different ways and doses
281931|NCT02606786|Other|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
281932|NCT02606799|Device|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
281933|NCT02608983|Dietary Supplement|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
281934|NCT02608996|Drug|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
281935|NCT02608996|Drug|Placebo|For comparison to elucidate the true effect of nesiritide
281936|NCT02609009|Other|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
281937|NCT02609009|Other|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
281938|NCT02609022|Biological|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
Two dose levels: low and high dose.
281325|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
281326|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
281327|NCT02581826|Drug|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
281328|NCT02581826|Drug|Placebo|No column specified.
281329|NCT02581839|Drug|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
281330|NCT02581839|Device|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
281331|NCT02581839|Drug|Pre-Medication: Zofran|Zofran at 8mg orally
281332|NCT02581839|Drug|Pre-Medication: Decadron|decadron at 8mg orally
281333|NCT02581852|Other|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
281334|NCT02581865|Drug|NBI-98854|
281335|NCT00189345|Biological|anti-EpCAM x anti-CD3 (removab)|
281336|NCT02581865|Drug|Placebo|
281631|NCT02577315|Drug|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
281632|NCT02577315|Drug|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
281633|NCT02577315|Drug|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
281634|NCT02577341|Drug|Nimotuzumab|Patients received five cycles of weekly nimotuzumab (200mg, IV) in combined with chemoradiotherapy.
281635|NCT02577341|Drug|docetaxel and cisplatin|Patients received five cycles of weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
281636|NCT02577341|Radiation|daily RT (65Gy in 25 fractions) to the chest|Patients received daily RT (65Gy in 25 fractions) to the chest
280764|NCT02592668|Device|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
281038|NCT02586064|Behavioral|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
281039|NCT02586077|Drug|Exparel|
281040|NCT02586090|Behavioral|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
281041|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
281042|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
281043|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 3|Mometasone furoate drug formulation (MFF) 3 will be administered by suspension-based nasal spray.
281044|NCT02588339|Drug|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
281045|NCT00190242|Drug|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
281046|NCT02588339|Drug|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
281047|NCT02588339|Drug|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
281048|NCT02588352|Dietary Supplement|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
281049|NCT02588365|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
281050|NCT02588365|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
281051|NCT02588365|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
281052|NCT02588378|Procedure|multi-modal cSLO imaging|
280458|NCT02599298|Behavioral|Sleep-Study Guided Multidisciplinary Therapy|
280459|NCT02599311|Device|transvaginal synthetic mesh|transvaginal synthetic mesh
280460|NCT02599311|Drug|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
280461|NCT02599324|Drug|ibrutinib|
280462|NCT02599324|Drug|everolimus|
280463|NCT00191373|Drug|Trastuzumab|
280464|NCT02599324|Drug|docetaxel|
280465|NCT02599324|Drug|paclitaxel|
280466|NCT02599324|Drug|cetuximab|
280467|NCT02599337|Drug|Nexavar|Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.
Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose.
280468|NCT02599337|Drug|Sorafenib|Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.
Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose.
280469|NCT02599363|Drug|Ribociclib (LEE011)|
280765|NCT02592681|Procedure|verum acupuncture|Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as "de-qi" in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of "de-qi". Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
280766|NCT02592681|Procedure|acupressure|The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of "de-qi". Duration of each session will be 15 min.
280767|NCT02592681|Procedure|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
280768|NCT02594774|Other|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
280769|NCT02594787|Dietary Supplement|Phosphorus|
280170|NCT02603861|Drug|Placebo|Placebo administered orally.
280171|NCT02603861|Drug|Modafinil|Modafinil administered orally.
280172|NCT02603874|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
280173|NCT02603887|Drug|Pembrolizumab|200 mg by vein every 3 weeks (one cycle=21 days) for up to 24 cycles.
280174|NCT02605811|Radiation|prophylaxis cranial radiotherapy|2
280175|NCT02605824|Drug|n-acetylcystine|NAC is a mucolytic drug.
280176|NCT00192036|Radiation|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
280177|NCT02605824|Drug|0.9% saline|Normal saline is a placebo agent.
280178|NCT02605837|Drug|OBS|Oral Budesonide Suspension 10 mL of 0.2 mg/mL every morning and at bedtime
280179|NCT02605837|Drug|Placebo|Identical presentation of the experimental drug administered subcutaneously as specified
280180|NCT02605850|Other|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
280181|NCT02605850|Dietary Supplement|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
280182|NCT02605850|Dietary Supplement|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
280183|NCT02605863|Drug|Enzalutamide|160 mg by mouth daily for 12 months
280184|NCT02605876|Device|Whole body vibration|
280185|NCT02605876|Device|Local muscle vibration|
280186|NCT02605889|Other|Laser acupuncture|Laser acupuncture
280187|NCT00192049|Drug|Gemcitabine|
280470|NCT02599363|Drug|Paclitaxel|
280471|NCT02599376|Device|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
280472|NCT02599389|Device|Drug-coated balloons|
280473|NCT02599389|Device|Drug-coated balloons and laser|
280474|NCT00002517|Drug|cytarabine|
279873|NCT02610257|Device|Mechanical stimulus (vibration) applied on the forearm|Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.
Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports.
279874|NCT02610270|Dietary Supplement|2 Gums|760 mg DHA
279875|NCT02610270|Dietary Supplement|3 Gums|1140 mg DHA
279876|NCT02610283|Drug|QPI-1002|IV injection
279877|NCT02610283|Drug|Placebo|isotonic saline
279878|NCT02610296|Drug|QPI-1002|IV injection
279879|NCT00192491|Other|Placebo|Nasal Sprayer of Placebo
279880|NCT02610296|Other|Placebo|isotonic saline
279881|NCT02610309|Behavioral|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
279882|NCT02610322|Behavioral|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
279883|NCT02610322|Behavioral|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and <30% of energy as total fat.
279884|NCT02576574|Drug|Avelumab|Subjects will be administered with avelumab at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
279885|NCT02576574|Drug|Pemetrexed|Pemetrexed 500 mg per square meter (mg/m^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
279886|NCT02576574|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
279887|NCT02576574|Drug|Gemcitabine|Gemcitabine 1250 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
279278|NCT02687321|Other|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
279279|NCT02687334|Drug|50% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 50% oxygen
279280|NCT02687347|Drug|oral methadone|Oral methadone is the study drug
279281|NCT02687347|Drug|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
279282|NCT02687360|Device|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
279283|NCT02687360|Device|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
279284|NCT02687373|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
279580|NCT00204308|Drug|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
279581|NCT02718118|Device|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects will be treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
279582|NCT02718118|Device|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects will be treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
279583|NCT02718131|Device|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
279584|NCT02718131|Procedure|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
279585|NCT02718144|Drug|Phase I: estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer to assess dose-limiting toxicity (DLT) of estetrol.
279586|NCT02718144|Drug|Phase II: estetrol|Estetrol formulated in tablets will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer to assess the Clinical Benefit Rate (CBR).
279587|NCT02718170|Procedure|Buried Intramedullary K-wire Fixation|
279588|NCT02718170|Procedure|Plate and Screw Fixation|
279589|NCT02718183|Other|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
279590|NCT02718183|Other|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
283853|NCT02593695|Other|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
283854|NCT02593708|Drug|Neratinib|
283855|NCT02593708|Drug|Paclitaxel|
283856|NCT02593708|Drug|Pertuzumab|
283857|NCT02593708|Drug|Trastuzumab|
283858|NCT02593721|Procedure|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
283859|NCT02593721|Drug|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
283860|NCT02593734|Drug|olanzapine|oral antipsychotic drug therapy
283861|NCT00190892|Drug|olanzapine|
283862|NCT02593734|Drug|risperidone|oral antipsychotic drug therapy
283863|NCT02593734|Drug|amitryptaline|oral antidepressant drug therapy
283864|NCT02593734|Drug|fluoxetine|oral drug therapy for depression
283865|NCT02593747|Drug|Loratadine solution/syrup (BAY 76-2211)|10 mL, orally, syrup, fasted ,single dose
279285|NCT02687373|Other|Normal Saline|0.9% Sodium chloride
279286|NCT02687386|Drug|Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)|EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
279287|NCT02689557|Other|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
279288|NCT00200876|Drug|Isotonic saline|
279289|NCT02689570|Other|observational|no interventions; observational study
279338|NCT00201513|Behavioral|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
279339|NCT02694523|Drug|Placebo|Matching placebo for blinding purposes
279340|NCT02694523|Drug|Adalimumab|
279341|NCT02694523|Drug|Placebo|Matching placebo for blinding purposes
279342|NCT02694536|Drug|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
279343|NCT02694536|Drug|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
279344|NCT02694549|Device|CaveoVasc|
279636|NCT02687412|Procedure|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
279637|NCT02687425|Drug|Pioglitazone|15mg/day,po
279638|NCT02687425|Drug|imatinib mesylate|400mg/day,po
279639|NCT02687438|Device|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
279640|NCT02687438|Other|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
279641|NCT02687451|Drug|Oxymorphone HCl|Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
279642|NCT02687451|Drug|Placebo|Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
279643|NCT00200590|Drug|acetaminophen and morphine|
279644|NCT02689687|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
279645|NCT02689687|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
279646|NCT00200889|Procedure|Electro-acupuncture|Acupuncture needle will be inserted and electrodes attached to this needle. Electrical current will be passed to stimulate the body via the needle. Current strength will be below pain thresholds.
279647|NCT02689700|Other|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
283916|NCT02600741|Drug|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283917|NCT02600741|Drug|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283918|NCT02600741|Drug|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283919|NCT00191490|Drug|cisplatin|
283920|NCT02600741|Drug|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283921|NCT02600741|Drug|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
283922|NCT02600754|Behavioral|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
283923|NCT02600754|Behavioral|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
283924|NCT02600767|Drug|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
283925|NCT02600780|Drug|Febuxostat|Comparison of two anti-hyperuricemic molecules
279345|NCT02694562|Device|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
279346|NCT02694588|Drug|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
279347|NCT02694588|Drug|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
279348|NCT02694601|Dietary Supplement|Caffeine|For each 4-hour visit, a dose of 0 mg/kg, 2.5 mg/kg or 5 mg/kg of Caffeine is given during a standardize breakfast follow by repeated blood sampling.
279349|NCT00201513|Behavioral|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
279350|NCT02694614|Behavioral|smartphone-assisted dietary coaching|
279351|NCT02694627|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
283614|NCT02607436|Drug|Sarpogrelate|Sarpogrelate
283615|NCT02607436|Drug|Aspirin|Aspirin
283616|NCT02607449|Drug|FS-1|FS-1 is a liquid solution for internal intake and bears antimicrobial and antibacterial activities.
283617|NCT02607449|Drug|Placebo|Placebo without any active pharmaceutical ingredients
283618|NCT02607462|Biological|PRP|
283619|NCT02607462|Other|Placebo|
283620|NCT00192192|Biological|CAIV-T|
283621|NCT02607475|Device|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
283622|NCT02607475|Device|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
283623|NCT02607488|Drug|Placebo|Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]
283624|NCT02607488|Drug|Lidocaine 1%|Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]
283926|NCT02600780|Drug|Allopurinol|Comparison of two anti-hyperuricemic molecules
283927|NCT02600793|Drug|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
283928|NCT02600806|Drug|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are < 0.5 ng/ml
283929|NCT02600806|Drug|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are >= 0.5 ng/ml.
283930|NCT00002517|Drug|dexamethasone|
283931|NCT00191503|Drug|Pemetrexed|
283932|NCT02600819|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily
283933|NCT02600832|Behavioral|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
283337|NCT02575950|Drug|LEO43204|
283338|NCT02577861|Procedure|ECG|A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.
283339|NCT02577861|Behavioral|Questionnaires|Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)
283340|NCT02577861|Procedure|Physical examination and vital signs|A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
283341|NCT02577887|Device|Patients implanted with a St. Jude Medical pacemakers|
283342|NCT00188773|Drug|N-acetylcysteine, intralipid, heparin|One visit subject will receive N-acetylcysteine plus intralipid and heparin, another visit n-acetylcyksteine plus saline, another visit intralipid and heparin and another visit saline alone
283343|NCT02577900|Device|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
283344|NCT02577900|Device|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
283345|NCT02577900|Device|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
283346|NCT02577926|Drug|Ruxolitinib|Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
283347|NCT02577926|Drug|BAT|BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
283348|NCT02577939|Behavioral|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
283349|NCT02577965|Procedure|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
283625|NCT02607488|Drug|Lidocaine 1.5%|Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]
283626|NCT02607488|Drug|Lidocaine 2%|Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]
283627|NCT02607501|Device|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
283628|NCT02607514|Behavioral|hyperthermic yoga|heated yoga, 90-minutes
283049|NCT00189436|Drug|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
283050|NCT02582528|Behavioral|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
283051|NCT02582528|Behavioral|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
283052|NCT02582541|Procedure|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
283053|NCT02584478|Drug|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
283054|NCT02584478|Drug|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
283055|NCT02584491|Behavioral|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
283056|NCT02584504|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
283057|NCT02584504|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
283058|NCT02584504|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
283059|NCT02584504|Drug|fenofibrate|Pharmaceutical form:tablet Route of administration: oral
283060|NCT02584504|Drug|bezafibrate|Pharmaceutical form:tablet Route of administration: oral
283061|NCT02584504|Drug|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
283062|NCT02584530|Procedure|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
283063|NCT00189644|Procedure|4 FEC 100 followed by 4 Taxol|
283064|NCT02584543|Biological|HEV vaccine|
283065|NCT02584543|Biological|HBV vaccine|
283350|NCT02577965|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
283351|NCT02577978|Device|Medacta GMK posterior stabilized prosthesis|
282771|NCT02589158|Drug|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
282772|NCT02589158|Drug|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
282773|NCT02589171|Device|Neo Close Abdominal Closure|Neo Close Abdominal Closure
282774|NCT02589171|Device|Carter Thomason Device|Carter Thomason Device
282775|NCT02589184|Other|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
282776|NCT00190385|Procedure|Ultrasonographic screening|Ultrasonographic screening
282777|NCT02589184|Other|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
282778|NCT02589184|Other|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
282779|NCT02589197|Device|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
282780|NCT02589197|Device|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
282781|NCT02589210|Other|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
282782|NCT02589223|Other|Multisensory Stimulation|
282783|NCT02589223|Other|Control|
282784|NCT02589236|Drug|N91115|GSNOR inhibitor
282785|NCT02589236|Drug|Placebo|Control sample with only capsule excipients and fillers
282786|NCT02591459|Other|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
282787|NCT02591472|Procedure|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
283066|NCT02584556|Drug|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
283067|NCT02584556|Drug|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
282503|NCT02595775|Other|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
282504|NCT00191100|Radiation|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
282505|NCT02595775|Other|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
282506|NCT02595775|Other|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
282788|NCT02591472|Procedure|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
282789|NCT02591472|Other|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282790|NCT02591472|Other|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282791|NCT02591472|Other|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282792|NCT02591472|Other|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282793|NCT02591472|Other|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282794|NCT02591472|Other|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282795|NCT00190619|Drug|Duloxetine|
282796|NCT02591472|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282797|NCT02591472|Other|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
282220|NCT02602366|Other|Placebo Vaginal Insert|
282221|NCT02602366|Other|Placebo Vaginal Film|
282222|NCT02602366|Other|Placebo Intravaginal ring (IVR)|
282223|NCT02602379|Other|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
282224|NCT02602392|Behavioral|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
282507|NCT02595775|Other|A/F report alone|
282508|NCT02595788|Other|Change from supine to prone position|Change from supine to prone position
282509|NCT02597946|Drug|afatinib|
282510|NCT02597946|Drug|paclitaxel|
282511|NCT02597972|Device|Fracture repair|
282512|NCT02597972|Device|Fracture repair with joint replacement|
282513|NCT02597985|Other|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
282514|NCT02597985|Other|Usual Care|
282515|NCT02597998|Drug|14C-BI 409306|
282516|NCT00191256|Drug|Paclitaxel|
282517|NCT02598011|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
282518|NCT02598011|Drug|Toca FC|Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with "TOCA FC" embossed on one side and "500" embossed on the other side
282519|NCT02598024|Behavioral|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
281939|NCT02609022|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
281940|NCT00192335|Biological|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
281941|NCT02609035|Behavioral|Telephonic prompt|
281942|NCT02609048|Drug|Placebo Comparator|Placebo Capsule (2 taken once daily)
281943|NCT02609048|Drug|Experimental: MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
281944|NCT02609048|Drug|Experimental: MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
281945|NCT02609061|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
281946|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
281947|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
281948|NCT02609074|Procedure|Minimally invasive internal fixation surgeries|
281949|NCT02609074|Device|CPC/rhBMP-2 micro-scaffolds|
282225|NCT02602392|Behavioral|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
282226|NCT02602418|Device|CogMedTM Training|The subjects will have one of the following interventions:
Adaptive working memory CogMedTM training: They will be trained using 12 different computerized visual and spatial Working Memory tasks. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an "adaptive" manner, which is hypothesized as optimal for learning and training effect.
Non-adaptive working memory CogMedTM training: The subjects will be performing tasks at a fixed ("non-adaptive") and low difficulty level.
282227|NCT02602431|Device|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
282228|NCT00191659|Drug|Atomoxetine Hydrochloride|
282229|NCT02604459|Device|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
282230|NCT00191854|Drug|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
282231|NCT02604459|Device|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
281637|NCT02579512|Other|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
281638|NCT00189020|Biological|PCV7|PCV7 at age 2 and 4 months
281639|NCT02579525|Other|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
281640|NCT02579525|Other|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
281641|NCT02579551|Procedure|Therapeutic Conventional Surgery|Undergo surgical excision
281642|NCT02579564|Drug|Gemcitabine|
281643|NCT02579564|Drug|Vinorelbine|
281644|NCT02579564|Drug|Paclitaxel|
281645|NCT02579564|Drug|Pemetrexed|
281646|NCT02579564|Drug|Oncorine|
281647|NCT02579564|Drug|Endostar|
281648|NCT02579564|Drug|Cisplatin|
281649|NCT00189020|Biological|PCV7|PCV7 at age 2, 4 and 11 months
281650|NCT02579577|Other|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
281651|NCT02579577|Other|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
281652|NCT02579577|Other|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
281950|NCT02609074|Device|CPC paste|
281951|NCT00192348|Biological|CAIV-T|
281952|NCT02609087|Drug|Sevoflurane|
281953|NCT02609087|Drug|Propofol|
281053|NCT02588391|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
281054|NCT02588391|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
281337|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.4 MBq and increase in steps of 1.4 MBq, with a protein dose of 2 or 10 mg.
281338|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. The dose for this expansion part of the study will be selected on the basis of all available information from the dose-escalation part and will not necessarily be the MTD.
281339|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
281340|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
281341|NCT02583776|Device|Blinded - CGM|Data from device will be blinded and alarms off
281342|NCT02583789|Drug|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
281343|NCT02583789|Drug|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
281344|NCT02583802|Drug|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
281345|NCT02583802|Drug|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
281346|NCT02583828|Drug|Cyclophosphamide 50mg|
281347|NCT02583828|Drug|Letrozole 2.5 mg|
281348|NCT02583841|Procedure|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
281349|NCT02583854|Device|RY-STOP hemostasis device|
281350|NCT02583854|Device|TR-Band, Terumo|
281351|NCT00189579|Drug|Herceptin|
281352|NCT02583867|Behavioral|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
280770|NCT00190996|Drug|placebo|
280771|NCT02594787|Dietary Supplement|Placebo|
280772|NCT02594800|Drug|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
280773|NCT02594813|Procedure|Biopsy or polypectomy|
280774|NCT02594826|Behavioral|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
280775|NCT02594826|Behavioral|General health education control|General health and cancer education
280776|NCT02594839|Drug|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
280777|NCT02594839|Drug|Placebo|intravenous infusion of 400 mL saline
280778|NCT02594852|Device|+ laser|Use of laser in the treatment
280779|NCT02594865|Dietary Supplement|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
280780|NCT02594865|Dietary Supplement|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
280781|NCT00191009|Drug|atomoxetine hydrochloride|
280782|NCT02594878|Drug|Pamidronatdinatrium|
281055|NCT02588391|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
281056|NCT00190242|Drug|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
281057|NCT02588404|Drug|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
281058|NCT02588417|Drug|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
281059|NCT02588417|Drug|Levobupivacaine|levobupivacaine 2.5 mg
281060|NCT02588443|Drug|RO70097890|
281061|NCT02588443|Drug|nab-paclitaxel|
281062|NCT02588443|Drug|gemcitabine|
281063|NCT02588456|Biological|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
280475|NCT00191386|Drug|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
280476|NCT02599402|Drug|Nivolumab|
280477|NCT02599402|Drug|Ipilimumab|
280478|NCT02599415|Device|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
280479|NCT02599454|Drug|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
280480|NCT02601625|Drug|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
280481|NCT02601625|Drug|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
280482|NCT02601625|Drug|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
280483|NCT02601625|Drug|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
280484|NCT02601625|Drug|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
280485|NCT00191581|Drug|Humalog Mix 50|
280486|NCT02601625|Drug|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
280487|NCT02601638|Other|Demographics and Health History Questionnaire|
280488|NCT02601638|Other|Pre-Class Laryngectomy Survey|
280489|NCT02601638|Behavioral|Counseling session with speech pathologist|
280490|NCT02601638|Behavioral|Total Laryngectomy Preoperative Education Class|
280491|NCT02601638|Other|Day of Hospital Discharge Laryngectomy Survey|
280492|NCT02601638|Other|Day of Discharge Practicum|
280493|NCT02601638|Other|Laryngectomy Education Study Exit Survey|
280783|NCT02594878|Other|Natrium chloride 9mg/ml|
280784|NCT02594891|Device|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
279888|NCT02576574|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
279889|NCT02576574|Drug|Carboplatin|Carboplatin AUC 5 mg/mL*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
280188|NCT02605902|Behavioral|(i)Comprehensive Behavioral Intervention for Tics|
280189|NCT02605902|Behavioral|internet-delivered psychoeducation and relaxation training|
280190|NCT02605915|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
280191|NCT02605915|Drug|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter*min (mg/mL*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
280192|NCT02605915|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) administered via IV infusion on Day 1 every 21-days for 6 cycles.
280193|NCT02605915|Drug|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
280194|NCT02605915|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
280195|NCT02605915|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
280196|NCT02605928|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
280197|NCT02605954|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily
280198|NCT00192049|Drug|mitomycin C|
280199|NCT02605954|Drug|ABC/3TC|ABC/3TC (600/300 mg) tablets administered orally once daily
280200|NCT00192296|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
280201|NCT02608320|Drug|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
280202|NCT02608333|Behavioral|ESDM-12|ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).
Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery.
280203|NCT02608333|Behavioral|control group|heteregenous "as usual "community intervention
279591|NCT00204321|Drug|sirolimus (drug), mmf (drug)|
279592|NCT02718196|Behavioral|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
279593|NCT02718209|Device|Mid-Infrared Spectroscopy with ATR|
279594|NCT02718222|Device|Post-partum IUD|The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
279595|NCT02718235|Other|Overall survival|Observation of overall and disease free survival
279596|NCT02718248|Device|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
279597|NCT02718248|Behavioral|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
279598|NCT02718261|Drug|Pantoprazole|
279599|NCT02718261|Drug|Saline 0.9% (matching placebo)|
279600|NCT02718274|Device|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|
279890|NCT02576574|Drug|Cisplatin|Cisplatin 75 mg/m^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
279891|NCT02576574|Drug|Carboplatin|Carboplatin AUC 6 mg/mL*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
279892|NCT00188500|Behavioral|atkins diet|
279893|NCT02576587|Other|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI >=15) will be place on CPAP therapy.
279894|NCT02576600|Device|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
279895|NCT02576600|Other|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
279896|NCT02576600|Drug|Propofol|TCI
279897|NCT02576600|Drug|Remifentanil|TCI
279898|NCT02576613|Other|MPP-S|> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
279899|NCT02576613|Other|TAU|standard medical treatment without structured psychotherapeutic intervention
279290|NCT02689583|Biological|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin > Clarithromycin > Levofloxacin >Tetracycline > Furazolidone > Metronidazole.
279291|NCT02689583|Genetic|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
279292|NCT02689583|Dietary Supplement|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
279293|NCT02689596|Drug|Oxytocin|
279294|NCT02689596|Other|Placebo|
279295|NCT02689609|Radiation|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
279296|NCT02689622|Other|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
279297|NCT02689622|Other|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
279298|NCT02689622|Other|physical performance|Activities of Daily Living and physical performance
279299|NCT00200889|Device|Manual acupuncture|Acupuncture needle will be inserted and stimulated by manual twisting by an acupuncturist.
279300|NCT02689635|Other|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
279301|NCT02689635|Other|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
279302|NCT02689674|Drug|Naltrexone|pills, 50mgs per day, taken for 10 weeks.
279601|NCT02718287|Behavioral|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
279602|NCT02684903|Behavioral|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
279648|NCT02689713|Drug|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
279649|NCT02689713|Drug|Topical Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
279650|NCT02689726|Drug|GTL001+|
279651|NCT02689726|Drug|Aldara|5% imiquimod cream
279652|NCT02689739|Procedure|venous duplex ultrasound|Venous duplex ultrasound
279653|NCT02689752|Drug|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
279654|NCT02689765|Dietary Supplement|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
279655|NCT02689765|Dietary Supplement|Placebo|Placebo capsules is identically packaged.
279957|NCT02581306|Other|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
279958|NCT02583282|Other|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
279959|NCT02583295|Behavioral|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
279960|NCT02583295|Behavioral|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
279961|NCT02583308|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
279962|NCT02583308|Device|Endotracheal tubes allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
279963|NCT00189540|Genetic|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
279964|NCT02583321|Device|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
279352|NCT02694640|Behavioral|Reach Plus|In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or "coaches" will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff.
279353|NCT02696694|Other|Progesterone <25, >75|Impact of serum progesterone concentrations (<25, >75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
279354|NCT02696707|Procedure|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
279355|NCT02696707|Procedure|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
279356|NCT02696720|Drug|Lidocaine|
279357|NCT02696720|Other|Sham|
279358|NCT02696733|Device|Ultrasound|Ultrasound-guided obturator nerve localization
279359|NCT02696733|Drug|lidocaine 2%|local anesthetic used to block the obturator nerve
279360|NCT02696733|Drug|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
279361|NCT02696746|Other|Observation|No intervention
279656|NCT02689778|Drug|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
279657|NCT00002539|Drug|doxorubicin hydrochloride|
279658|NCT00200889|Procedure|Sensory stimulation|A sham stimulation will be produced over the body location. no insertion will be made.
279659|NCT02689778|Drug|Placebo|Identical tablets without active substance
279660|NCT02689791|Dietary Supplement|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
279661|NCT02689804|Drug|Levonorgestrel 1.5mg|The investigators plan to enroll women with normal BMI and obese women of reproductive age in order to compare LNG-EC and UPA-EC PK parameters between the two groups of women. A research coordinator will randomly assign the order in which women receive the two drugs at the enrollment visit. Women will be admitted to CUMC for two 24-hour periods separated by at least 5 half-lives (~ 8 days). During this admission, the women will receive a single dose of an FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg and have serial 13 blood specimens collected. The woman will be discharged from CUMC after her 24-hour blood collection and will return to CUMC the following day for a 48-hour blood collection. This blood collection will conclude participation in this arm of the study.
279662|NCT02590315|Device|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
279663|NCT02590315|Device|Conventional digital mammography.|Conventional digital mammography.
283934|NCT02600832|Behavioral|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
283935|NCT02603003|Drug|JinFuKang|po.tid.30ml
283936|NCT02603003|Drug|Cisplatin|According to the individual patient's condition
283937|NCT00002517|Drug|mitoxantrone hydrochloride|
283938|NCT00191724|Drug|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
283939|NCT02603003|Drug|Pemetrexed|According to the individual patient's condition
283940|NCT02603016|Drug|GLSE compound|
283941|NCT02603016|Drug|Maitake mushroom extract compound|
283942|NCT02603016|Drug|Ginseng compound|
283943|NCT02603029|Other|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
283944|NCT02603029|Other|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
283945|NCT02603055|Biological|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
283946|NCT02603055|Biological|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
283947|NCT02603068|Drug|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
279362|NCT02696759|Other|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
279363|NCT00201734|Drug|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
279364|NCT02696772|Other|Energy intake|
279365|NCT02696785|Drug|Ixekizumab|Administered SC
279366|NCT02696785|Drug|Placebo|Administered SC
279367|NCT02696785|Drug|Adalimumab|Administered SC
283629|NCT02607527|Device|Mitral Valve IRIS Ring|implantation of mitral implant surgically or mini thoracotomy
283630|NCT02607540|Other|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
283631|NCT00192205|Biological|CAIV-T or TIV|
283632|NCT02607540|Other|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
283633|NCT02607540|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
283634|NCT02609581|Drug|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
283635|NCT00192439|Behavioral|High Risk Respiratory Disease|
283636|NCT02609594|Other|Weekly application of Amnioband|Weekly application of Amnioband.
283637|NCT02609594|Other|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
283638|NCT02609594|Other|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
283639|NCT02609607|Drug|Bisacodyl|Rectal suppository
283640|NCT02609607|Other|Placebo|Rectal suppository
283641|NCT02609620|Device|Peristaltic Feeding Tube|
283642|NCT02609620|Device|ConvaTec Levin Duodenal Tube|
283643|NCT02609633|Device|Accu-Chek(R) Connect DMS|SMBG will be performed during the 6-month study using the Accu-Chek(R) Aviva Connect monitoring device, and corresponding Smartphone app and online tracking tool.
283644|NCT02609633|Device|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek(R) Connect DMS).
283948|NCT02603081|Drug|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
283949|NCT00191724|Drug|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
283950|NCT02603094|Procedure|clear fluid ingestion|drinking of clear fluid in preoperative period
283951|NCT02603107|Drug|RTV|RTV 100 mg capsule coadministered orally with ATV or DRV once daily with food
283352|NCT02577978|Device|Medacta GMK Sphere prosthesis|
283353|NCT00188786|Procedure|daily Cone Beam CT for imaging guidance for radiotherapy|
283354|NCT02577991|Drug|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
283355|NCT02577991|Drug|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
283356|NCT02578004|Other|biochemical and molecular analysis|
283357|NCT02578017|Behavioral|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
283358|NCT02578030|Drug|SHP465 12.5mg|
283359|NCT02578030|Drug|SHP465 25mg|
283360|NCT02578043|Drug|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
283361|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
283362|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
283363|NCT02580162|Behavioral|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
283364|NCT02580175|Procedure|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
283365|NCT02580175|Procedure|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
283366|NCT00189098|Drug|Placebo|
283367|NCT02580188|Drug|Neostigmine|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium is continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block).
283368|NCT02580188|Drug|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium is continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
283645|NCT02609646|Drug|Amikacin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
283068|NCT02584569|Drug|TAK-915|TAK-915 oral suspension
283069|NCT02584582|Drug|Liraglutide|
283070|NCT02584582|Drug|Exenatide|
283071|NCT02584582|Procedure|Liquid meal test|
283072|NCT02584582|Other|No drug (Baseline day)|
283073|NCT02584595|Device|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
283074|NCT00189657|Procedure|5FU/LV Mayo Clinic or LV5FU2|
283075|NCT02584608|Drug|ACTIMMUNE|
283076|NCT02584621|Behavioral|Check Yourself App with Feedback|
283077|NCT02584634|Drug|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
283078|NCT02586753|Other|S1 plus Cisplatin with radiotherapy|we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).
Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.
Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
283079|NCT02586766|Behavioral|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
283080|NCT02586779|Other|whatsApp|whatsApp application will be used for consultations.
283081|NCT02586779|Other|without whatsApp|whatsApp application will be not used for consultations.
283082|NCT02586792|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
283083|NCT02586805|Drug|DX-2930|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
283084|NCT02586805|Drug|DX-2930|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
282798|NCT02591485|Behavioral|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
283085|NCT02586805|Drug|DX-2930|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
283086|NCT00189995|Drug|clozapine|
283087|NCT02586805|Drug|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
283088|NCT02586818|Procedure|SOC fingerstick|sample collection
283089|NCT02586818|Procedure|Venous blood draw|sample collection
283090|NCT02586831|Drug|Anti-Thymocyte Globulin (ATG)|Concomitant Drug Administration
283091|NCT02586831|Drug|Placebo|Drug Administration
283092|NCT02586831|Drug|Pegylated GCSF|Concomitant Drug Administration
283093|NCT02586831|Drug|Interleukin 2|Concomitant Drug Administration
283094|NCT02586831|Drug|Etanercept|Concomitant Drug Administration
283095|NCT02586831|Drug|Exenatide|Concomitant Drug Administration
283096|NCT02586857|Drug|ACP-196|
283097|NCT00189995|Drug|haloperidol|
283098|NCT02586870|Device|Intravascular Ultrasound|
283099|NCT02586883|Other|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
283100|NCT02589249|Dietary Supplement|AyuFlex|Active product
283101|NCT00190398|Device|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
283102|NCT02589249|Dietary Supplement|Placebo|Placebo
283103|NCT02589262|Drug|AUT00206|
283104|NCT02589275|Drug|TNX-102 SL Tablet 2.8 mg|TNX-102 SL 2.8 mg tablet taken daily at bedtime
282520|NCT02598024|Behavioral|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
282521|NCT02598037|Dietary Supplement|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
282522|NCT02598050|Other|Mini Cog|Cognitive screen
282523|NCT02598063|Drug|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
282799|NCT02593240|Behavioral|The iDiet® with Voucher|Intensive iDiet group behavioral weight loss program delivered in-person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Ten participants per worksite per iDiet intervention arm will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
282800|NCT02593240|Behavioral|Human Performance Institute©|Human Performance Institute© (HPI) training workshop: Is comprised of a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
282801|NCT02593253|Other|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
282802|NCT02593253|Other|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
282803|NCT02593266|Behavioral|Preventive Intervention Program (PIP) for depression|Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)
Module 1: Depression and family
Module 2: Psychoeducation about depression
Module 3:The child's perspective on their parent's depression
Module 4: Skills development
Module 5: Preparation for the family session
Module 6: Family session
Module 7: Revision and future planning
Follow-up
282804|NCT02593279|Genetic|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
282805|NCT02593279|Genetic|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
282232|NCT02604459|Procedure|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
282233|NCT02604459|Procedure|General anesthesia|General anesthesia will be used in both groups
282234|NCT02604459|Drug|propofol|
282235|NCT02604459|Drug|fentanyl|
282236|NCT02604459|Drug|maintenance of anesthesia with inhaled sevoflurane|
282237|NCT02604472|Other|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
282238|NCT02604472|Other|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
282239|NCT02604485|Drug|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
282240|NCT02604485|Drug|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
282241|NCT00191854|Drug|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
282242|NCT02604498|Drug|Nemonoxacin|Single dose 500mg oral
282243|NCT02604511|Drug|Ibrutinib|
282244|NCT02604524|Device|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
282245|NCT02604524|Other|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
282524|NCT02598063|Drug|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
282525|NCT02598063|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
282526|NCT02598076|Behavioral|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
282527|NCT02600169|Drug|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
282528|NCT02600182|Device|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
281954|NCT02609100|Procedure|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
281955|NCT02609100|Procedure|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
281956|NCT02609100|Device|1.0 X 2.5 cm 'pill' containing a camera|
281957|NCT02609113|Device|Strong Magnetic Wristband|
281958|NCT00188227|Drug|Piritramid (analgetic)|
281959|NCT02575144|Drug|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min
281960|NCT02575144|Drug|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
281961|NCT02575157|Other|No intervention|No intervention
281962|NCT02575170|Drug|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
281963|NCT02575170|Drug|Ringer's lactate solution|200 ml of Ringer's lactate solution
281964|NCT02575183|Drug|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
281965|NCT02575183|Drug|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
281966|NCT02575183|Behavioral|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
281967|NCT02575196|Device|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
281968|NCT02575209|Other|GENDER|
281969|NCT00188227|Behavioral|Cognitive exercises|
282246|NCT02604537|Drug|Celestone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml celestone OR
281353|NCT02583893|Drug|Sirolimus|Given PO
281354|NCT02583893|Drug|Mitoxantrone|Given IV
281355|NCT02583893|Drug|Etoposide|Given IV
281356|NCT02583893|Drug|Cytarabine|Given IV
281357|NCT02583906|Device|CPAP|Treatment with CPAP for six months in the CPAP arm.
281653|NCT02579590|Drug|Depot Medroxyprogesterone Acetate 150 mg|
281654|NCT02579590|Drug|Implanon( 68 mg etonogestrel implant)|
281655|NCT02579590|Drug|Cerazette pills (75 micrograms desogestrel)|
281656|NCT02579603|Drug|Nintedanib|Nintedanib 150mg bid
281657|NCT02579603|Drug|Pirfenidone|
281658|NCT02579616|Drug|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
281659|NCT02579629|Drug|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
281660|NCT00189033|Drug|psyllium fibre (dietary supplement)|
281661|NCT02581904|Device|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
281662|NCT02581904|Device|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
281663|NCT02581917|Other|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
281664|NCT02581917|Other|Laboratory Biomarker Analysis|Undergo metabolic analysis
281665|NCT02581930|Drug|Ibrutinib|Given PO
281666|NCT00189358|Drug|ZD1839|
281667|NCT02581930|Other|Laboratory Biomarker Analysis|Correlative studies
281668|NCT02581930|Other|Pharmacogenomic Study|Correlative studies
281064|NCT02590835|Procedure|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
281065|NCT00002515|Procedure|bone marrow ablation with stem cell support|
281066|NCT00190567|Drug|Placebo|
281067|NCT02590835|Procedure|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
281068|NCT02590848|Dietary Supplement|Walnut intake|Nutritional intervention: 30g walnut kernels per day
281069|NCT02590861|Procedure|Dental implant|All participants will receive the same intervention, this is a single group study.
281070|NCT02590874|Drug|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
281071|NCT02590874|Drug|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
281358|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
281359|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
281360|NCT02583919|Drug|Placebo|once weekly dosing for 26 weeks
281361|NCT02583932|Behavioral|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
281362|NCT00189592|Device|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
281363|NCT02583932|Behavioral|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
281364|NCT02583945|Procedure|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
280785|NCT02594891|Device|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
280786|NCT02594904|Drug|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
280787|NCT02594930|Procedure|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
280788|NCT02594943|Device|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
280789|NCT02594943|Device|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
280790|NCT02594956|Device|no nasogastric tube|
280791|NCT02594956|Device|nasogastric tube|
280792|NCT00191009|Drug|placebo|
280793|NCT02597322|Drug|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
280794|NCT02597335|Radiation|Spectro-MRI|Spectro-MRI for D-2HG detection
280795|NCT00000130|Procedure|Initial Pars Plana Vitrectomy|
280796|NCT00000374|Drug|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
280797|NCT00002516|Procedure|conventional surgery|
280798|NCT00191191|Drug|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
280799|NCT02597335|Other|Dosage of free circulating plasmatic DNA|
280800|NCT02597335|Other|Dosage of D-2HG in the urine|
280801|NCT02597348|Procedure|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
280802|NCT02597361|Drug|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
280803|NCT02597361|Drug|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
280204|NCT02608346|Procedure|Blood sampling|Patients will have a blood draw at each visit to the hospital,
with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam
with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation
280205|NCT02608359|Drug|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
280494|NCT02601651|Drug|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
280495|NCT02601651|Drug|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
280496|NCT00191581|Drug|Human Insulin Mix 50:50|
280497|NCT02601664|Procedure|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
280498|NCT02601664|Procedure|Conventional PCI|Conventional PCI
280499|NCT02601677|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
280500|NCT02601677|Drug|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
280501|NCT02601690|Other|Blood Sampling|
280502|NCT02601703|Drug|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
280503|NCT02601703|Drug|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
280504|NCT02601703|Drug|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
280505|NCT02601716|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
280506|NCT02601716|Other|CHMI|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
280507|NCT00191789|Procedure|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
280508|NCT02603900|Drug|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
280509|NCT02603900|Drug|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
279900|NCT02576626|Drug|indacaterol/glycopyrronium 110/50 Breezhaler®|
279901|NCT02576626|Device|Placebo by Breezhaler®|
279902|NCT02576626|Drug|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
279903|NCT00188500|Behavioral|ability to follow low carbohydrate diet|
279904|NCT02576626|Device|Placebo by nebulisation|
279905|NCT02576639|Drug|CNP520|CNP520 will be taken oral, once-daily for 13 weeks
279906|NCT02576639|Drug|Placebo|The study is placebo controlled
279907|NCT02576652|Other|Tetracycline/Demeclocycline|Standard bone labeling procedures with tetracycline, demeclocycline, or other tetracycline derivative will be performed prior to the prescheduled THR.
279908|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
279909|NCT02578771|Drug|ZuraPrep with 70% IPA|Apply topically
279910|NCT02578771|Drug|ZuraPrep without 70% IPA|Apply topically. 0% IPA
279911|NCT02578771|Drug|ChloraPrep CHG/IPA Teal Tint|Apply topically
279912|NCT02578771|Other|Normal Saline|Apply topically
280206|NCT02608372|Other|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
280207|NCT02608372|Other|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
280208|NCT02608372|Other|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
280209|NCT02608385|Drug|Stereotactic body radiotherapy|
280210|NCT02608385|Drug|Pembrolizumab|
280211|NCT00192309|Biological|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
280212|NCT02608398|Other|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
295160|NCT02641093|Procedure|Surgery|gross total surgical resection
295161|NCT02641093|Radiation|Radiation Therapy|60-66 Gy over 6 weeks
295162|NCT02641093|Drug|Cisplatin|Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
295163|NCT00195676|Drug|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
295164|NCT02643277|Behavioral|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
295472|NCT02636322|Drug|Cyclophosphamide|At completion of Smart Start: Cyclophosphamide 750 mg/m2 by vein on Day 5 of each 21 day cycle for 6 cycles.
295473|NCT02636322|Drug|Doxorubicin|At completion of Smart Start: Doxorubicin 10 mg/m2 by vein on Days 1 - 4 of each 21 day cycle for 6 cycles.
295474|NCT02636335|Device|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
295475|NCT02636348|Dietary Supplement|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
295476|NCT02636348|Dietary Supplement|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
295477|NCT02636361|Drug|LY900014|Administered subcutaneously (SC)
295478|NCT02636361|Drug|Insulin lispro|Administered SC
295479|NCT02636374|Behavioral|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
295480|NCT02636387|Drug|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and if <50 % improvement then increase to three 0.2 mg tablets at bedtime for 14 days
295481|NCT02636387|Drug|Placebo|Sugar pill manufactured to mimic 0.2 pill of desmopressin. Take two pills at bedtime, if no improvement in 14 days then will take 3 pills at bedtime for an additional 14 days
295482|NCT00195156|Drug|ATRA-IV|
295483|NCT02636400|Other|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
295484|NCT02636413|Drug|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
295485|NCT02636413|Dietary Supplement|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
279965|NCT02583321|Device|Endotracheal tubes allowing SSD|In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
279966|NCT02583334|Device|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
279967|NCT02583334|Device|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
279968|NCT02583347|Device|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
279969|NCT02583360|Other|Slower Flow Rate|Use of nipple that has a slower flow rate than used prior to testing. No change in formula prescription
279970|NCT02583360|Other|Thickened Formula|Use of a predetermined amount of rice cereal to thicken formula. Use of nipple preferred by patient
279971|NCT02583373|Drug|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
279972|NCT02583373|Drug|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
280263|NCT02578927|Dietary Supplement|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
280264|NCT02578927|Dietary Supplement|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
280265|NCT02578940|Radiation|Fluciclovine 18 F|Radioligand for PET CT scanning
280266|NCT02578953|Drug|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
280267|NCT02578953|Drug|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
280268|NCT02578966|Behavioral|Motivational Interview|
280269|NCT00188942|Procedure|Functional Magnetic Resonance Imaging|
280270|NCT02578966|Other|Traditional health education|
280271|NCT02578979|Device|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
279664|NCT00190528|Drug|neoadjuvant chemotherapy + radical hysterectomy|
279665|NCT02590354|Other|ART interruption|
279666|NCT02590367|Drug|FOLFOX regimen|FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.
XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks.
279667|NCT02590367|Drug|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
279668|NCT02590367|Drug|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
279669|NCT02590380|Device|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
279670|NCT02590380|Device|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
279671|NCT02590393|Other|E-cigarettes|
279672|NCT02590406|Procedure|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
279673|NCT02590406|Procedure|Reverse Trendelenburg and NIPPV|Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.
NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface
279973|NCT02583373|Drug|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
279974|NCT00189540|Genetic|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
279975|NCT02583386|Behavioral|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
279976|NCT02583386|Device|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
279977|NCT02585492|Other|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
279978|NCT02585492|Other|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
279979|NCT02585505|Procedure|stem cells|stem cell will be injected
279980|NCT00189761|Drug|Tacrolimus|
279368|NCT02696798|Drug|Ixekizumab|Administered SC
279369|NCT02696798|Drug|Placebo|Administered SC
279370|NCT02696811|Dietary Supplement|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
279371|NCT02696811|Dietary Supplement|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
279372|NCT02696824|Behavioral|Cognitive Behavioral Therapy for Adherence and Depression|This treatment involves integrating CBT for depression with CBT for adherence following our "Life-Steps" approach.
279373|NCT02696837|Device|ETT|
279374|NCT00201747|Drug|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
279375|NCT02696837|Device|Proseal LMA|
279376|NCT02696837|Drug|Rocuronium|
279377|NCT02696837|Other|No Muscle Relaxant|
279378|NCT02696837|Drug|Rocuronium|
279379|NCT02698761|Other|Comprehensive Care Plan|Care Plan
Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.
Other Medications. All medications will be given during daytime hours, if possible.
Pain Psychology.
Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.
Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.
Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).
Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily.
279380|NCT02698774|Other|No Intervention / Not Applicable|Not Applicable. No interventions will be tested in this study. Blood specimens will be collected for laboratory evaluation. No information will be shared with clinical providers or no clinical decisions will be based on information generated from collected specimens.
279674|NCT02590419|Device|BrightMatter™ products|BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.
BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.
BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively.
279675|NCT00190528|Procedure|radical hysterectomy|
279676|NCT02590432|Drug|Linaclotide 290 micrograms|IBS-C patients only
283952|NCT02603107|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily with food
283953|NCT02603107|Drug|DRV|Darunavir (DRV) 800 mg tablet administered orally once daily with food
283954|NCT02603107|Drug|COBI|COBI 150 mg tablet coadministered orally with ATV or DRV once daily with food
283955|NCT02603107|Drug|ATV/co|ATV/co (300/150 mg) FDC tablet administered orally once daily with food
283956|NCT02603107|Drug|DRV/co|DRV/co (800/150 mg) FDC tablet administered orally once daily with food
283957|NCT02603107|Drug|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily without regard to food
283958|NCT02603107|Drug|ABC/3TC|ABC/3TC (600/300 mg) tablet administered orally once daily with or without regard to food
283959|NCT02603107|Drug|GS-9883/F/TAF|GS-9883/F/TAF (50/200/25 mg) FDC tablet administered orally once daily without regard to food
283960|NCT00191724|Drug|Placebo|intravenous (IV), one infusion, over 12 hours
283961|NCT02603120|Drug|ABC/DTG/3TC|ABC/DTG/3TC (600/50/300 mg) FDC tablets administered orally once daily without regard to food
283962|NCT02605148|Dietary Supplement|Omega 3 fatty acid|Omega 3 fatty acid
283963|NCT02605148|Dietary Supplement|Vitamin D|Vitamin D 800 U/day
283964|NCT02605148|Dietary Supplement|Probiotics|Probiotics
283965|NCT02605174|Drug|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
283966|NCT02605174|Drug|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
283967|NCT00191945|Drug|placebo|
283968|NCT02605174|Drug|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
283969|NCT02605174|Drug|Placebo|Two placebo tablets to match lasmiditan doses.
283970|NCT02605187|Other|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
279381|NCT02698800|Device|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
279382|NCT02698800|Device|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
283646|NCT00192452|Drug|MEDI-507|
283647|NCT02609646|Drug|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
283648|NCT02609646|Drug|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
283649|NCT02609646|Drug|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
283650|NCT02609646|Drug|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
283651|NCT02609659|Drug|Ombitasvir/paritaprevir/ritonavir|Tablet; Ombitasvir co-formulated with Paritaprevir and Ritonavir
283652|NCT02609659|Drug|Dasabuvir|Tablet
283653|NCT02609659|Drug|Ribavirin|Tablet
283654|NCT02609672|Other|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; strength; cardiovascular fitness; and resilience.
283655|NCT02609672|Other|No Exercise|A no exercise (control) group will maintain their existing activity level for 12 weeks. Outcomes will include mobility performance; pain; strength; cardiovascular fitness; and resilience.
283656|NCT02609685|Other|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
283657|NCT02575950|Drug|Placebo|
283658|NCT02575963|Drug|Cytarabine|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
283659|NCT02575963|Biological|Lintuzumab-Ac225|Starting dose level 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles.
283660|NCT02575963|Drug|Furosemide|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
283661|NCT02575963|Drug|Spironolactone|25 mg by mouth daily, administered 11 days after second dose of 225Ac-HuM195 (the day after completion of furosemide) and continued for 12 months.
283662|NCT00188370|Procedure|high frequency ultrasound imaging|
283369|NCT02580201|Biological|Oral Polio Vaccine|Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.
The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container.
283370|NCT02580214|Dietary Supplement|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
283371|NCT02580227|Drug|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
283372|NCT02580227|Other|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
283373|NCT02580240|Drug|Hydrocortisone|Hydrocortisone (300 mg/d as a continuous infusion for 6d, then tapered off.) Once all vasopressors were discontinued, the hydrocortisone taper protocol was initiated (HC 50 mg every 8 h for two days, then HC 50 mg every 12 h for two days, then HC 50 mg daily for one day, then stopped)
283374|NCT02580240|Drug|saline|Normal saline (300 mg/d as a continuous infusion for 6d, then tapered off.) Once all vasopressors were discontinued, the normal saline taper protocol was initiated (NS 50 mg every 8 h for two days, then NS 50 mg every 12 h for two days, then NS 50 mg daily for one day, then stopped)
283375|NCT02580253|Drug|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
283376|NCT02580253|Drug|mFOLFOX6|Oxaliplatin,Fluorouracil
283377|NCT00189111|Procedure|Cardiac Imaging + Treatment|
283378|NCT02580279|Drug|EGCG|
283379|NCT02580279|Drug|placebo|
283380|NCT02580305|Drug|SUVN-502|
283381|NCT02582541|Procedure|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
283382|NCT02582554|Behavioral|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
283663|NCT02575976|Behavioral|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
283105|NCT02589288|Procedure|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
283106|NCT02589288|Procedure|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
283107|NCT02589301|Biological|Pegfilgrastim|
283108|NCT02589314|Device|Mechanical periodontal therapy|
283109|NCT02589314|Procedure|nonsurgical periodontal therapy|
283383|NCT02582567|Other|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
283384|NCT02582580|Other|Perineal massage|Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter "U". All movements should be repeated four times.
283385|NCT02582580|Device|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
283386|NCT02582580|Other|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
282806|NCT02593292|Behavioral|PROSPERO|The intervention is carried out in 3 steps:
At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.
During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system
The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives.
282807|NCT02593292|Other|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
282808|NCT02593305|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
282809|NCT00190840|Drug|pemetrexed|
282810|NCT02593305|Dietary Supplement|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
283110|NCT02589327|Other|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
283111|NCT02589340|Drug|Buspirone|
283112|NCT00190411|Drug|celiprolol|celiprolol
283113|NCT02589340|Drug|Placebo|Sugar Pill
283114|NCT02589353|Drug|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
283115|NCT02589366|Drug|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
283116|NCT02589379|Procedure|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
283117|NCT02589392|Other|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
283118|NCT02589392|Other|Cetaphil® Restoraderm® body wash|
283119|NCT02589405|Drug|Benzoyl Peroxide|
283120|NCT02589405|Other|Dermotivin® Soft Liquid cleanser|
283121|NCT02589405|Other|Cetaphil® Dermacontrol Moisturizer SPF30|
282529|NCT02600195|Behavioral|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
282530|NCT02600208|Biological|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
282531|NCT02600247|Drug|Duloxetine|Experimental: Duloxetine group
Phase I (preemptive): 1day before operation (30mg for 1 day)
Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon
Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
282532|NCT02600247|Drug|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
282533|NCT02600260|Drug|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
282534|NCT02600260|Other|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
282535|NCT02600273|Other|Usual brand cigarettes|Usual brand cigarettes
282536|NCT00191451|Drug|Herceptin|Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).
Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion).
282537|NCT02600273|Other|Lower nicotine content cigarettes|SPECTRUM research cigarettes
282538|NCT02600273|Other|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
282811|NCT02593318|Drug|Oxaloacetate (OAA)|Pills to be taken orally in 500mg or 1000mg doses two times per day depending on the part of the study
282812|NCT02593331|Drug|BFKB8488A|Participants will receive a single, escalated dose of BFKB8488A administered subcutaneously.
282813|NCT02595801|Other|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
282814|NCT02595827|Other|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
282815|NCT02595840|Other|Collection of tumor and blood specimen|
282247|NCT02604537|Drug|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
282248|NCT02604550|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
282249|NCT02604550|Drug|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
282250|NCT02604550|Drug|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
282251|NCT02604563|Procedure|Cognitive Assessment|
282252|NCT00191867|Drug|Teriparatide|
282253|NCT02604563|Procedure|Timed Up and Go|-A timed test where the participant will stand up from a chair and walk to a spot 10 feet away.
282254|NCT02604563|Procedure|Activities of Daily Living Questionnaire|-10 items about daily functional status
282255|NCT02604563|Procedure|Instrumental Activities of Daily Living, subscale of the OARS|-7 items about daily functional status
282256|NCT02604563|Procedure|Karnofsky Self-reported Performance Rating Scale|-1 item about daily functional status
282257|NCT00192101|Drug|cisplatin|
282258|NCT02606812|Dietary Supplement|Traditional-food|Intake of ethnic local food
282259|NCT02606825|Other|Registry of AML patients > 60 years|
282260|NCT02606864|Drug|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
282261|NCT02606877|Drug|nintedanib|
282262|NCT02606877|Drug|pirfenidone|
282263|NCT02606890|Other|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
282264|NCT02606903|Drug|BI 695501 prefilled syringe|
282265|NCT02606903|Drug|BI 695501 autoinjector|
282266|NCT02606916|Radiation|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
282267|NCT02606916|Drug|DDP|DDP(25 mg/m2.qw) for six weeks.
282268|NCT00192114|Drug|Enzastaurin HCl|1200 mg loading dose then 500 mg, oral, daily, up to six 28 day cycles
281669|NCT02581943|Drug|Carboplatin|Given IV
281670|NCT02581943|Other|Laboratory Biomarker Analysis|Correlative studies
281671|NCT02581943|Drug|Paclitaxel|Given IV
281672|NCT02581943|Biological|Pembrolizumab|Given IV
281673|NCT02581943|Other|Quality-of-Life Assessment|Ancillary studies
281674|NCT02581956|Behavioral|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
281675|NCT02581956|Behavioral|No walking exercise|no exercise
281970|NCT02575222|Drug|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
281971|NCT02575235|Drug|CPC|Two study groups take cetylpyridinium chloride of 1.5mg and 4.5mg daily for four weeks.
281972|NCT02575235|Drug|placebo|Control group takes the placebo for the same period.
281973|NCT02575248|Drug|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
281974|NCT02575248|Drug|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
281975|NCT02575261|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
281976|NCT02575274|Procedure|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
281977|NCT02575287|Device|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
281978|NCT02575287|Device|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
281979|NCT02577341|Drug|placebo|
281980|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Subject Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a Subject-appropriate level and subjects instructed to deliver stimulation in two 30-minute sessions per day.
281981|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and subjects instructed to deliver stimulation in two 30-minute sessions per day.
281365|NCT02583958|Device|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
281366|NCT02583958|Device|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
281367|NCT02586090|Behavioral|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
281368|NCT02586103|Device|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
281369|NCT02586116|Device|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
281370|NCT02586116|Device|C-Plus|C-Plus PEEK IBF Device with autograft
281371|NCT02586129|Drug|YH14755|20/1500mg, QD
281372|NCT00189878|Drug|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
281373|NCT02586129|Drug|Metformin|1500mg, QD
281374|NCT02586129|Drug|Rosuvastatin|20mg, QD
281375|NCT02586142|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
281376|NCT02586142|Other|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
281377|NCT02586155|Drug|RVX000222|100 mg capsule
281378|NCT02586155|Drug|Placebo (for RVX000222)|Capsule manufactured to mimic RVX000222 100 mg capsule
281676|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
281677|NCT00189358|Drug|tamoxifen|
281678|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
281679|NCT02581982|Other|Laboratory Biomarker Analysis|Correlative studies
281680|NCT02581982|Drug|Paclitaxel|Given IV
281681|NCT02581982|Biological|Pembrolizumab|Given IV
281072|NCT02590887|Other|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (15, 28 and 42 days) drinking the beverage.
281073|NCT02590900|Drug|intravenous paracetamol (acetaminophen)|paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
281074|NCT02590913|Dietary Supplement|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
281075|NCT02590913|Dietary Supplement|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
281076|NCT02590926|Procedure|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
281077|NCT00190580|Drug|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
281078|NCT02590939|Device|CEFALY Active|Active external trigeminal nerve stimulation
281079|NCT02590939|Device|CEFALY Placebo|Placebo external trigeminal nerve stimulation
281080|NCT02590952|Drug|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
281081|NCT00190775|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
281082|NCT02592694|Drug|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
281083|NCT02592694|Device|thrombus aspiration|manual thrombus aspiration
281084|NCT02592707|Drug|177Lu-OPS201|177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks
281085|NCT02592720|Drug|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
281086|NCT02592720|Device|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
281087|NCT02592720|Device|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
281088|NCT02592733|Device|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
281089|NCT02592746|Drug|Palbociclib|Palbociclib 125mg, orally once daily
280510|NCT02603900|Device|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
280511|NCT02603900|Device|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
280512|NCT02603926|Drug|Allopregnanolone|
280513|NCT02603939|Procedure|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
280514|NCT02603952|Drug|Oseltamivir|Commercially supplied capsule.
280804|NCT02597374|Device|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
280805|NCT02597387|Drug|Mitoxantrone HCL Liposome Injection|
280806|NCT02597400|Drug|Metformin|Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;
Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals
280807|NCT02597400|Drug|HMS5552|Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;
HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals.
280808|NCT02597413|Procedure|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
280809|NCT00191204|Drug|Duloxetine|
280810|NCT02597439|Drug|Omega-3 fatty acids|
280811|NCT02597439|Other|Placebo|
280812|NCT02597452|Device|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
280813|NCT02597465|Drug|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
280814|NCT02597465|Drug|Reference1507|Investigators choice including chemotherapy or supportive therapy
280815|NCT02597478|Drug|Fentanyl Sublingual Spray|Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
280816|NCT02599454|Radiation|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
280213|NCT02608411|Drug|ARQ197|
280214|NCT02608424|Device|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
280215|NCT02608437|Drug|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
280216|NCT02608437|Drug|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
280217|NCT02608450|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
280218|NCT02608450|Drug|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
280219|NCT02610335|Other|Control group (C)|kyphosis reeducation on Huber platform during 2 weeks,
patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),
flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),
exercises on cycle ergometer or walking on treadmill : to continue at home.
280220|NCT02610335|Other|Test group|spinal mobility reeducation on Huber platform during 2 weeks,
patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),
flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),
exercises on cycle ergometer or walking on treadmill : to continue at home.
280221|NCT02610348|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
280222|NCT02610348|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
280515|NCT02603952|Drug|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
280516|NCT02603952|Drug|Placebo|Salt-water solution containing no active ingredients.
280517|NCT02603965|Radiation|Copper Cu 64 TP3805|Given IV
280518|NCT00191802|Drug|teriparatide|
280519|NCT02603965|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
280520|NCT02603965|Procedure|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
280521|NCT02603965|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
280522|NCT02603965|Other|Laboratory Biomarker Analysis|Correlative studies
295486|NCT02636426|Drug|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
295487|NCT02636439|Behavioral|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
295488|NCT02636439|Behavioral|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
295489|NCT02636452|Other|cardiopulmonary exercise test|
295490|NCT02636465|Other|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
295491|NCT02636478|Other|questionnaire for travel habits|questionnaire has been used to collect information about travelling
295492|NCT02638675|Behavioral|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
295785|NCT02631889|Device|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
295786|NCT02631902|Behavioral|Exercise|Community-based exercise program with 3 weekly exercise sessions
295787|NCT02631902|Behavioral|Dietary intervention|Community-based dietary intervention program
295788|NCT02631928|Drug|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
295789|NCT02631928|Drug|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
295790|NCT02631941|Drug|Z7200|
295791|NCT02631941|Drug|Symbicort Turbohaler|
295792|NCT02631941|Drug|Z7200 with charcoal|
295793|NCT00194766|Drug|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
295794|NCT02631941|Drug|Symbicort Turbohaler with charcoal|
295795|NCT02631941|Drug|Symbicort Turbohaler replicate|
295796|NCT02631954|Drug|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
295797|NCT02631954|Drug|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
280272|NCT02578979|Device|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
280273|NCT02578992|Procedure|Head-elevating position|A 7 cm high pillow was set beneath the patients' head with head extension position for intubation.
280274|NCT02578992|Device|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
280275|NCT02579005|Other|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through leukapheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
280276|NCT02579005|Other|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 2 x 10exp7 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
280277|NCT02579018|Behavioral|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
280278|NCT02579031|Device|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
280279|NCT02579031|Device|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
280280|NCT00188955|Drug|sirolimus|
280576|NCT02574637|Drug|MEDI2070 High-Med dose|MEDI2070 intravenous (IV) infusion wk 0 plus placebo SC injection wk 0, and then subcutaneous (SC) dose of MEDI2070 wk 4 plus placebo IV infusion wk 4, and then subcutaneous (SC) dose of MEDI2070 every 4 wks from wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
280577|NCT02574637|Drug|MEDI2070 Low-Med dose|Subcutaneous (SC) low-med dose of MEDI2070 wk 0 & wk 4 plus placebo intravenous (IV) infusion wk 0 & wk 4, then subcutaneous (SC) low-med dose of MEDI2070 every 4 wks wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
280578|NCT02574637|Drug|MEDI2070 Low dose|Subcutaneous (SC) low dose of MEDI2070 Wk 0 & Wk 4 plus intravenous (IV) Placebo dose Wk 0 & Wk 4, then subcutaneous (SC) low dose of MEDI2070 every 4 wks wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
280579|NCT02574637|Drug|Placebo|Placebo SC and IV infusion wks 0 & 4 and then SC dose of placebo every 4 weeks wk 8 through wk 24. then SC dose of MEDI2070 once every 4 weeks during Open Label period.
280580|NCT02574650|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is intended for the treatment of symptomatic chronic functional tricuspid regurgitation in patients with a minimum of moderate tricuspid regurgitation and whom left-sided valve surgery is not planned.
280581|NCT02574663|Drug|TGR-1202|TGR-1202 oral daily dose
279981|NCT02585531|Drug|Hypertonic Saline 3%|The treatment will be administered in the following order :
First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours .
279982|NCT02585531|Drug|Epinephrine and Dexamethasone|The treatment will be administered in the following order :
First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours.
279983|NCT02585544|Procedure|day-care surgery|day-care surgery
279984|NCT02585557|Other|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
279985|NCT02585570|Drug|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
279986|NCT02585583|Radiation|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
279987|NCT02585596|Drug|YH23537 1000mg/day|YH23537 500mg 2 tab
279988|NCT02585596|Drug|YH23537 2000mg/day|YH23537 500mg 4 tab
279989|NCT02585596|Drug|YH23537 3000mg/day|YH23537 500mg 6 tab
279990|NCT02585596|Drug|placebo|YH23537 500mg tab placebo
279991|NCT00189774|Drug|nateglinide|
279992|NCT02585622|Biological|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6MSC, fixed dose) over 10-20 minutes. Volume total of fluid infused: 50 ml
279993|NCT02585622|Other|Placebo|Volume total of fluid infused: 50 ml
280281|NCT02579044|Drug|Everolimus and lonafarnib|
280282|NCT02579057|Drug|Furosemide Injection Solution (SCP-101)|
280283|NCT02579057|Drug|Furosemide Injection Solution, USP|
280284|NCT02581319|Procedure|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
280285|NCT00189267|Drug|Imiquimod 5 % Cream|
280286|NCT02581332|Behavioral|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
279677|NCT02590432|Drug|Linaclotide 145 micrograms|IBS-C and CIC patients
279678|NCT02590432|Drug|Linaclotide 72 micrograms|Patients who meet criteria for dose adjustment during the Open-label Treatment Period may be offered a treatment paradigm including possible doses of 290 µg or 145 µg or 72 µg for IBS-C patients, or 145 µg or 72 µg for CIC patients.
279679|NCT02590445|Device|deep brain stimulation system|
279680|NCT02590458|Procedure|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
279681|NCT02592395|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
279682|NCT02592408|Drug|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
279683|NCT02592408|Drug|SDPQ|single dose primaquine on day 2
279684|NCT02592408|Drug|14DPQ|14 day primaquine starting on day 2
279685|NCT00190736|Drug|Atomoxetine Hydrochloride|
279686|NCT02592408|Drug|14DPQ on Day 42|14 day primaquine starting on day 42
279687|NCT02592421|Drug|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
279688|NCT02592421|Drug|Placebo|Placebo Comparator
279689|NCT02592434|Drug|CP-690,550 (tofacitinib)|During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.
During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.
Body Weight (Dosage in tablet [BID] or solution [BID]):
5<7kg (2mg or 2mL); 7<10kg(2.5mg or 2. mL); 10 <15kg (3mg or 3mL); 15<20kg (3.5mg or 3.5mL); 20<25kg (4mg or 4mL); 25<40kg (5mg or 5mL); 40kg (5 mg or 5 ml in AM, 10mg or 10ml in PM).
Oral solution (1 mg/mL) is used for subjects <25 kg. Oral tablets (5 mg) is used for subjects >=25 kg.
279690|NCT02592434|Other|placebo|matching placebo tablet or solution for tofacitinib
279994|NCT02585648|Device|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
279995|NCT02585648|Device|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
279996|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
279997|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
279998|NCT02585674|Drug|Insulin glargine (U300)|Pharmaceutical form: solution for injection
Route of administration: subcutaneous
279383|NCT00201929|Procedure|Computer Decision Board|
279384|NCT02698813|Biological|umbilical cord mesenchymal stem cells and hyaluronic acid|
279385|NCT02698813|Drug|hyaluronic acid|
279386|NCT02698826|Other|Protocol for rapid FiO2 optimization|We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas [ABG] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value <100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential "overshoot" in FiO2 reduction.
279387|NCT02698839|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
279388|NCT02698839|Device|BuMA™|Stent platform: stainless steel
279389|NCT02698852|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
279390|NCT02698878|Dietary Supplement|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
279391|NCT02698878|Other|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
279392|NCT02698878|Device|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
279393|NCT02698891|Drug|Paclitaxel|
279394|NCT00201929|Procedure|Paper Decision Board|
279395|NCT02698891|Drug|Neulasta|
279396|NCT02698891|Drug|Cyclophosphamide|
279397|NCT02698891|Drug|Doxorubicin|
279398|NCT02698904|Behavioral|Guided Relaxation Technique|
279399|NCT02698904|Other|Documentary Movie|
279400|NCT02701140|Procedure|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
279401|NCT02701140|Procedure|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
279097|NCT02705417|Procedure|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
279098|NCT02705417|Procedure|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
279099|NCT02705417|Procedure|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
279100|NCT02705417|Procedure|arteriovenous graft placement|surgical placement of arteriovenous graft
279101|NCT02705430|Dietary Supplement|EPA and DHA capsules of 2 g/day|
279102|NCT02705430|Behavioral|Stress management phone application (Eco Fusion Mentally)|
279103|NCT02705430|Behavioral|life style program using a mobile phone (Eco Mentally and NewMe)|
279104|NCT02705430|Device|mobile phone|
279105|NCT00002546|Radiation|radiation therapy|
279106|NCT00202852|Other|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
279107|NCT02705443|Other|No Intervention|Standard of Care Only
279108|NCT02705456|Procedure|Tooth Brushing HA|2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks).
279109|NCT02705456|Procedure|Tooth Brushing FL|2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks).
279110|NCT02705469|Drug|ZEN003694|
279111|NCT02705482|Biological|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
279112|NCT02705482|Biological|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
279113|NCT02705482|Biological|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
279114|NCT02705495|Other|acupuncture|Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The "deqi sensation" (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture.
283664|NCT02575976|Other|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
283665|NCT02575976|Other|wait list control|No cardiac rehabilitation.
283666|NCT02575989|Other|1: control group|Classic - current management of trauma patients by French medical teams
283667|NCT02575989|Other|2: interventional group|Intervention Name : monitoring, treatment, control and prevention of hypothermia
Continuous monitoring of body temperature
Ambulance warming (target : 30°C)
Patient warming with dedicated blanket
Infusion fluid warming (and temperature control)
283668|NCT02576002|Drug|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
283669|NCT02576015|Procedure|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
283670|NCT02576015|Procedure|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
283671|NCT02576015|Drug|lidocaine|
283672|NCT02576015|Device|ultrasound|
283673|NCT00188383|Drug|Amantadine|
283674|NCT02578043|Drug|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
283675|NCT02578043|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
283676|NCT02578056|Device|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
283677|NCT00188799|Procedure|daily Xray volume imaging for planning radiotherapy|
283678|NCT02578056|Procedure|Genital prolapse surgery|Surgical correction of genital prolapse
283387|NCT02582593|Device|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
283388|NCT00189462|Drug|Montelukast|
283389|NCT02582593|Device|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
283390|NCT02584634|Drug|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
283391|NCT02584634|Drug|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
283392|NCT02584647|Drug|PLX3397|PLX3397 is a selective inhibitor of FMS, as well as the ligand interleukin 34, KIT, and oncogenic Flt3 activity intended for oral administration.
283679|NCT02578069|Device|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
283680|NCT02578069|Device|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
283681|NCT02578082|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
283682|NCT02578095|Drug|VK5211|Capsule
283683|NCT02578095|Drug|Placebo for VK5211|Capsule
283684|NCT02578108|Procedure|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
283685|NCT02578108|Procedure|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
283686|NCT02578121|Drug|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
283687|NCT02578121|Drug|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
283688|NCT00188812|Drug|donepezil hcl|
283689|NCT02578121|Drug|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
283690|NCT02578134|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
283691|NCT02578134|Other|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
283122|NCT02589418|Procedure|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
283123|NCT00002515|Drug|topotecan hydrochloride|
283124|NCT00190411|Drug|Control|Untreated controls excluding betablockers
283125|NCT02589418|Procedure|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
283126|NCT02591485|Behavioral|Psych-educational intervention|The computerized psycho-educational control intervention is consists of six learning sessions delivered over the internet in the same way and frequency as the ACT intervention. Lessons describe symptoms and prognosis of PTSD, along with case studies and examples.
283127|NCT02591498|Behavioral|Computerized cognitive training|
283128|NCT02591511|Device|smart phone and pad|The mobile include the smart phone and pad, that can download the APP from internet.
283129|NCT02591511|Other|stroke education handbook|
283130|NCT02591524|Other|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
283393|NCT02584647|Drug|Sirolimus|Sirolimus is a macrocyclic lactone that binds to FK-506 binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.
Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day.
283394|NCT02584660|Drug|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
283395|NCT02584660|Drug|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
283396|NCT02584673|Device|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
283397|NCT00189657|Procedure|LV5FU2 + irinotecan|
283398|NCT02584686|Drug|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
283399|NCT02584686|Drug|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
283400|NCT02584699|Radiation|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
282816|NCT02595853|Other|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
282817|NCT02595866|Other|Laboratory Biomarker Analysis|Correlative studies
282818|NCT02595866|Biological|Pembrolizumab|Given IV
282819|NCT00002516|Drug|mesna|
282820|NCT00191100|Radiation|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
282821|NCT02595879|Drug|Cisplatin|Given IV
282822|NCT02595879|Radiation|External Beam Radiation Therapy|Undergo pelvic EBRT
282823|NCT02595879|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
282824|NCT02595879|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
282825|NCT02595879|Radiation|Internal Radiation Therapy|Undergo LDR brachytherapy
282826|NCT02595879|Other|Laboratory Biomarker Analysis|Correlative studies
282827|NCT02595879|Other|Pharmacological Study|Correlative studies
282828|NCT02595879|Drug|Triapine|Given IV and PO
282829|NCT02595892|Drug|ATR Kinase Inhibitor VX-970|Given IV
282830|NCT02595892|Drug|Gemcitabine Hydrochloride|Given IV
282831|NCT00191113|Drug|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
282832|NCT02595892|Other|Laboratory Biomarker Analysis|Correlative studies
282833|NCT02595905|Drug|Cisplatin|Given IV
282834|NCT02595905|Other|Laboratory Biomarker Analysis|Correlative studies
283131|NCT02591537|Device|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
283132|NCT02591563|Other|procedures|Throat swab, nasopharyngeal swab, tympanocentesis (if acute otitis media occurs)
283133|NCT00002515|Procedure|in vitro-treated bone marrow transplantation|
282269|NCT02606916|Drug|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
282270|NCT02606929|Drug|Tetracycline - Statin - Antimycotic|every 12 hours, orally form
282539|NCT02600273|Other|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
282540|NCT02600286|Drug|EllaOne|5 mg/per os of EllaOne every day through 12 months.
10 mg/per os of EllaOne every day through 12 months.
EllaOne placebo/per os every day through 12 months.
282541|NCT02600286|Drug|EllaOne placebo|5 mg/per os of EllaOne every day through 12 months.
10 mg/per os of EllaOne every day through 12 months.
EllaOne placebo/per os every day through 12 months.
282542|NCT02600299|Behavioral|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
282543|NCT02600299|Behavioral|Usual Care|Usual Care
282544|NCT02600312|Device|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
282545|NCT02600325|Drug|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
282546|NCT02602431|Device|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
282547|NCT02602431|Device|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
282548|NCT02602431|Device|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
282549|NCT02602444|Drug|ticagrelor|180 mg loading dose
282550|NCT02602457|Behavioral|moderate-intensity continuous exercise training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
282551|NCT02602457|Behavioral|high-intensity interval training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
282552|NCT02602470|Drug|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser & Moisturizing
282553|NCT02602470|Drug|Azelaic Acid Cream|Azelaic Acid Cream 20%
282554|NCT02602470|Drug|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
281982|NCT00188630|Other|5% dextrose solution|
281983|NCT02577367|Drug|Levothyroxine|Administer Levothyroxine
281984|NCT02577380|Behavioral|IPV/GBV HTC|Participants will be interviewed after receiving their services.
281985|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
281986|NCT02577393|Drug|placebo|The placebo is 0.9% saline solution. Patients are also given three times daily and swallow 10ml solution which are same as the EGCG group.
281987|NCT02577406|Drug|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
282271|NCT02606942|Other|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
282272|NCT02606955|Device|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
282273|NCT02606981|Device|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
282274|NCT02606981|Device|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
282275|NCT02606994|Drug|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
282276|NCT02606994|Drug|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
282277|NCT02606994|Drug|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
282278|NCT02607007|Other|2% M.F. Milk|
282279|NCT00192127|Biological|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
282280|NCT02607007|Other|White Bread|
282281|NCT02607007|Other|Strawberry Jam|
282282|NCT02607007|Other|31% M.F. Cheddar Cheese|
281682|NCT02581995|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
281683|NCT02582008|Drug|Bupropion Hydrochloride|Given PO
281684|NCT02582008|Other|Laboratory Biomarker Analysis|Correlative studies
281685|NCT02582008|Drug|Nicotine Replacement|Given NRT
281686|NCT02582008|Other|Quality-of-Life Assessment|Ancillary studies
281687|NCT02582008|Other|Questionnaire Administration|Ancillary studies
281688|NCT00189371|Drug|paclitaxel, carboplatin, epoetin alpha|
281689|NCT02582008|Drug|Varenicline|Given PO
281690|NCT02583984|Procedure|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
281691|NCT02583984|Procedure|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
281692|NCT02583997|Procedure|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
281693|NCT02583997|Procedure|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
281694|NCT02584010|Other|Silicon-based aerosol|Apply twice a day over the postoperative scar
281695|NCT02584010|Other|Silicon-based gel|Apply twice a day over the postoperative scar
281696|NCT00189592|Procedure|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
281697|NCT02584023|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
281698|NCT02584036|Biological|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
281699|NCT02584036|Behavioral|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
281988|NCT02577406|Other|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
281989|NCT02577406|Drug|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
281990|NCT02577406|Drug|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
281090|NCT02592746|Drug|Exemestane|Exemestane 25mg, orally once daily
281091|NCT02592746|Drug|Goserelin|Goserelin 3.6mg SC q 4weeks
281379|NCT02586155|Drug|atorvastatin|High-Intensity Statin
281380|NCT02586155|Drug|rosuvastatin|High-Intensity Statin
281381|NCT02586168|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
281382|NCT02586168|Drug|Placebo|Placebo
281383|NCT00189878|Drug|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
281384|NCT02586181|Dietary Supplement|Vitamin D and Calcium|a combination of dietary supplement including "all" 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate
1200 IE Vitamin D3 plus 800 mg Calcium Carbonate
Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12
1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12
281385|NCT02586181|Dietary Supplement|Vitamin D, Calcium, Vitamins B9, B6, B12|a combination of dietary supplement including "all" 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12
281386|NCT02586194|Drug|ASP015K|Oral
281387|NCT02586207|Drug|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
281388|NCT02586207|Drug|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
281389|NCT02586207|Radiation|Radiation|70 Gy fractionated over 35 days
281390|NCT02586233|Drug|DS-1040b|IV infusion of DS-1040b
281391|NCT02586233|Drug|placebo|placebo IV infusion
281392|NCT02586246|Drug|CDP870|Self-injection
281393|NCT02586259|Drug|budesonide MMX®|
281394|NCT02588469|Other|Interventional group|Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.
To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA.
281395|NCT02588469|Other|Control group|Standard obesity care with physical activity program
281396|NCT02588482|Device|high-density electroencephalography|Auditory stimulations during electroencephalography recording
281397|NCT00190255|Procedure|CY2PC9 genotyping|CY2PC9 genotyping
280817|NCT02599467|Other|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
280818|NCT02599480|Drug|mirabegron|50 mg daily during 12 months
280819|NCT02599480|Procedure|Echocardiography|Echocardiography
280820|NCT02599480|Procedure|Cardiac MRI|Cardiac MRI
280821|NCT02599480|Procedure|Maximal exercise capacity|Maximal exercise capacity
280822|NCT00191399|Drug|Olanzapine|
281092|NCT00190775|Drug|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
281093|NCT02592746|Drug|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
281094|NCT02592759|Device|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
281095|NCT02592772|Other|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
281096|NCT02592772|Other|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
281097|NCT02592772|Other|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
281098|NCT02592785|Drug|BAY1163877|Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.
Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.
281099|NCT02592798|Drug|Abatacept|
281100|NCT02592798|Other|Normal Saline|
281101|NCT02592798|Other|D5W|
281102|NCT02592811|Procedure|ERCP|Common bile duct cannulation with a cannulation catheter
281103|NCT00190788|Drug|Drotrecogin Alfa (Activated)|
280523|NCT02603978|Behavioral|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
280524|NCT02603978|Behavioral|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
280525|NCT02603978|Behavioral|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
280526|NCT02603991|Procedure|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
280527|NCT02603991|Drug|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
280528|NCT02604004|Drug|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
280529|NCT00191815|Drug|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
280530|NCT02604004|Drug|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
280531|NCT02604017|Drug|ABT-493/ABT-530|Tablets
280532|NCT02605954|Drug|Third Antiretroviral Agent|Third antiretroviral agents could include one of the following:
lopinavir/ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC, darunavir (DRV; Prezista®) + RTV, DRV+COBI or DRV/COBI FDC, efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP; Viramune®), etravirine (ETR; Intelence®), raltegravir (RAL; Isentress®), or dolutegravir (DTG; Tivicay®)
Drug classes:
Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, and DRV Pharmacokinetic enhancer: COBI Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR Integrase inhibitors: RAL and DTG
280533|NCT02605967|Drug|PDR001|PDR001 is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
280534|NCT02605967|Drug|Investigator choice of chemotherapy|commonly used chemotherapy as per investigator's choice
280535|NCT02605980|Behavioral|Sedentary time|
280823|NCT02599480|Procedure|Blood sampling|Blood sampling for study assessments and future exploratory studies.
280824|NCT02599480|Procedure|Endothelial function measurement|EndoPAT assessment
280825|NCT02599480|Radiation|18FDG-PET|PET scanning for beige/brown fat activation
280826|NCT02599493|Drug|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
280827|NCT02599532|Drug|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
295798|NCT02631967|Procedure|Kono anastomosis|Kono anastomosis
295799|NCT02631967|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
295800|NCT02631980|Drug|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
295801|NCT02631980|Drug|IV placebo|Intravenous 0.9% saline (250 ml)
295802|NCT02631993|Radiation|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320−400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2−1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3−5 times each week.
295803|NCT02632006|Biological|PIK-PD-1 cells|DC cell suspension (1×10*7 DC+ physiological saline
+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
295804|NCT00194779|Drug|doxorubicin hydrochloride|Given IV
296090|NCT02627677|Drug|ponatinib 30 mg QD|ponatinib 30 mg, taken orally once daily
296091|NCT02627677|Drug|ponatinib 15 mg QD|ponatinib 15 mg, taken orally once daily
296092|NCT02627677|Drug|nilotinib 400 mg BID|nilotinib 400 mg, taken orally twice daily
296093|NCT02627690|Other|islet transplanted|
296094|NCT02627690|Other|non islet transplanted|
296095|NCT02627703|Other|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
296096|NCT00194129|Drug|Lithium|Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
296097|NCT02627716|Procedure|SOS Plan|It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.
The booklet outlines four avenues to consider:
Contact details / contact person
Treatment and current follow-ups
Medical care in the event of a crisis
Practical aid in the event of a crisis
Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks.
296098|NCT02627729|Device|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
280582|NCT00188149|Drug|Combined chemotherapy (ABVD, BACOPP-D)|
280583|NCT02574663|Drug|nab-paclitaxel + gemcitabine|IV infusion
280584|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
280585|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
280586|NCT02574676|Other|non-interventional|
280587|NCT02574689|Behavioral|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
280588|NCT02574689|Behavioral|Wellness contact control|Cancer prevention information on topics other than physical activity (e.g., "Add Fruits and Veggies to Your Diet") from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials.
280589|NCT02574702|Procedure|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
280590|NCT02574715|Drug|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
280591|NCT02574728|Drug|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
280874|NCT02606123|Drug|EPI-506|Patients will receive EPI-506 as an oral soft gel capsule.
Part 1:
Six planned cohort doses will be studied beginning at 80mg/day. During the Single Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive daily dosing until they meet discontinuation criteria.
Part 2:
The dose in Part 2 will be determined in Part 1 of the study. Patients in will receive the Part 2 dose daily until they meet discontinuation criteria.
280875|NCT02606136|Drug|FG-3019|FG-3019, 10 mg/mL, single dose vials
280876|NCT02606149|Behavioral|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
280877|NCT02606149|Behavioral|Standard of information|
280878|NCT02606175|Other|Taking questionnaires and tests|At predefined timepoints:
2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)
1 questionnaire for medication adherence: BAASIS
1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)
1 questionnaire about medication knowledge
280879|NCT02606188|Device|Modified High-flow nasal cannula|Modified High-flow nasal cannula
280287|NCT02581332|Other|Wait-list Control/Usual Care Group|If assigned to the wait-list control group, participants may complete sessions 1 and 8 of the study. No behavioral intervention will be performed, and subjects will continue their usual treatment.
280288|NCT02581345|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
280289|NCT02581345|Biological|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
280290|NCT02581358|Other|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
280291|NCT02581371|Drug|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
280292|NCT02581371|Other|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
280293|NCT02581384|Radiation|Stereotactic Body Radiotherapy (SBRT)|
280294|NCT02581397|Drug|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
280295|NCT02581397|Drug|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
280296|NCT00189280|Drug|Imiquimod|cream 5%, 5 days out of seven, for 6 weeks
280297|NCT02581397|Drug|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
280298|NCT02581410|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
280299|NCT02581423|Drug|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
280592|NCT02574728|Drug|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
280593|NCT00188149|Procedure|Radiation therapy|
280594|NCT02574728|Drug|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
280595|NCT02576886|Device|Gamma Camera|All images acquired with the General Electric Discovery 530c
280596|NCT02576886|Procedure|Prone Imaging|
279999|NCT02585674|Device|MyStar DoseCoach|Glucose meter
280000|NCT02585687|Device|liver Perfusion MRI|
280001|NCT02585700|Biological|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen`s eggs, and inactivated with beta-propiolactone.
280002|NCT02587806|Biological|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
280003|NCT02587806|Other|Liberation therapy|
280004|NCT02587819|Drug|Treatment with BSCT|The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.
Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing.
280005|NCT02587832|Device|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
280006|NCT00002515|Drug|carboplatin|
280007|NCT00190190|Procedure|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
280008|NCT02587832|Device|NCPAP|Bubble CPAP System.
280009|NCT02587845|Drug|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
280010|NCT02587845|Drug|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
280011|NCT02587871|Drug|Cytarabine|Given IV
280012|NCT02587871|Other|Laboratory Biomarker Analysis|Correlative studies
280013|NCT02587871|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
280014|NCT02587871|Biological|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
280300|NCT02581436|Other|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one month after treatment as well as kSORT assay. Should the kSORT result be negative, the maintenance immunosuppressor dosages will remain as established in our institutional follow-up guidelines. In case the kSORT is still consistent with acute rejection, and in the absence of graft dysfunction, the increased immune suppressant dosages will remain as such and no new graft biopsy will be obtained. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
279691|NCT02592447|Other|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
279692|NCT02592447|Other|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
279693|NCT02592460|Other|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
279694|NCT02592460|Other|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
279695|NCT02592473|Device|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
279696|NCT00190736|Drug|placebo|
279697|NCT02592486|Biological|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
279698|NCT02592486|Biological|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
279699|NCT02592499|Device|HM II|
279700|NCT02594254|Other|Placebo|Placebo
279701|NCT02594267|Drug|Pralatrexate Injection|Drug: Folotyn (Pralatrexate Injection)
CHOP : Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone
279702|NCT02594293|Drug|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
279703|NCT00002516|Drug|etoposide|
279704|NCT00190944|Drug|placebo|
279705|NCT02594306|Device|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
279706|NCT02594306|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
279707|NCT02594306|Procedure|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
279708|NCT02594306|Procedure|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
279115|NCT02705495|Drug|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
279402|NCT02701140|Procedure|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
279403|NCT00202254|Behavioral|Occupational therapy|
279404|NCT02701140|Procedure|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
279405|NCT02701153|Procedure|Conventional Surgery|Undergo surgery
279406|NCT02701153|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
279407|NCT02701153|Other|Laboratory Biomarker Analysis|Correlative studies
279408|NCT02701166|Drug|Bezafibrate|bezafibrate 400mg per day
279409|NCT02701166|Drug|Placebo|placebo 400mg per day
279410|NCT02701179|Drug|Lignocaine 1% concentration solution|
279411|NCT02701179|Drug|Lignocaine 2% concentration solution|
279412|NCT02701192|Other|Coccygectomy|Patient receiving coccygectomy surgery.
279413|NCT02701205|Biological|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
279414|NCT00202254|Behavioral|Speech pathology|
279415|NCT02701205|Biological|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
279416|NCT02701205|Drug|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
279417|NCT02701218|Procedure|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
279418|NCT02701231|Device|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
279116|NCT02707536|Procedure|Socket grafting with PRF|Extraction with socket grafting using PRF.
279117|NCT02707536|Procedure|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
279118|NCT02707549|Drug|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
279119|NCT02707549|Drug|0.9% sodium chloride|
279120|NCT02707562|Drug|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
279121|NCT02707562|Drug|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
279122|NCT02707562|Drug|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
279123|NCT02707575|Drug|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
279124|NCT02707588|Drug|Pembrolizumab|200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.
Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
279125|NCT02707588|Drug|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
279126|NCT00203034|Drug|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
279127|NCT02707588|Radiation|Conventional Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
279128|NCT02707601|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) fixed dose combination (FDC) tablet administered orally once daily
279129|NCT02707601|Drug|F/R/TAF|F/R/TAF (200/25/25 mg) FDC tablet administered orally once daily
279130|NCT02707601|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
279131|NCT02707614|Procedure|Robotic vs open prostastectomy|robotic minimal invasive surgery
279132|NCT02707627|Device|Ablative fractional carbon dioxide laser therapy (AFCL)|AFCL is a new form of treatment for hypertrophic burn scars.
279133|NCT02707627|Procedure|Standard Scar Management (SSM)|SSM may include any of the following: range of motion exercises, massage, custom fit pressure garments, and silicone sheeting.
279134|NCT02707640|Drug|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
283692|NCT02578147|Behavioral|Mighty Girls|
283693|NCT02578147|Behavioral|Game Girls|
283694|NCT02578160|Procedure|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
283695|NCT02578173|Device|AVERT PLUS|
283696|NCT02578186|Drug|Diphenhydramine Hydrochloride|30 mL at bedtime
283697|NCT02578186|Drug|Placebo|30 mL at bedtime
283698|NCT02578199|Behavioral|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
283699|NCT00188825|Drug|basiliximab|
283700|NCT02578212|Other|Placebo|
283701|NCT02578225|Other|Non interventional study|
283702|NCT02580305|Drug|Placebo|
279137|NCT00203034|Other|Placebo|oral placebo once daily
279138|NCT02707653|Drug|Misoprostol|400 mcg sublingual misoprostol
279139|NCT02707666|Drug|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
279140|NCT02707666|Drug|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
279141|NCT02709603|Drug|placebo|oral placebo; one tablet 30 minutes before the procedure
279142|NCT02709616|Biological|Personalized cellular vaccine|Biological: DC-based and allogeneic PBMC based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive a total of 12 cellular vaccines with 8 DC-based and 4 allogeneic PBMC vaccines.
279143|NCT02709629|Behavioral|Individualized and adaptive computerized cognitive training|
279144|NCT02709629|Behavioral|Active control|
279145|NCT00002547|Procedure|allogeneic bone marrow transplantation|
279146|NCT00203281|Drug|tacrolimus|
279147|NCT02709642|Behavioral|Deposit Contract|A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of "earning" it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer.
283401|NCT02584712|Other|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
283402|NCT02584725|Drug|Tranexamic Acid|Comparison of 3 different doses of the drug
283403|NCT02584738|Drug|Nebulized Magnesium Sulfate|Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.
will be continued with nebulized standard treatment every hour for 4 hours.
283404|NCT02584738|Drug|Nebulized isotonic saline|Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.
will be continued with nebulized standard treatment every hour for 4 hours.
283405|NCT02584738|Drug|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
283406|NCT02584738|Drug|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
283407|NCT02584738|Drug|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
283408|NCT00189670|Procedure|6 TEC q 3 weeks|
283409|NCT02584751|Drug|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
283410|NCT02584751|Device|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
283703|NCT02580318|Device|breathalyzer|
283704|NCT02580331|Drug|SRP and placebo|Placement of placebo gel into classII furcation defects after scaling and root planing
283705|NCT02580331|Drug|SRP and 1% metformin|Placement of 1% metformin gel into classII furcation defects after scaling and root planing
283706|NCT02580344|Drug|Ibuprofen|The women will receive 600mg ibuprofen 3 times per day from the first day of the cycle for 5 days
283707|NCT02580357|Procedure|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
283708|NCT02580357|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
283709|NCT00189124|Drug|Dehydroepiandrosterone (DHEA)|
283710|NCT02580370|Biological|Botulinum toxin type A|Topical botulinum toxin type A
283711|NCT02580370|Biological|Placebo comparator|Topical placebo comparator
283134|NCT00190619|Drug|Placebo|
283135|NCT02591589|Other|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 between 70-100mmHg
283136|NCT02591589|Other|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
283137|NCT02591602|Other|Teleradiology Service|Teleradiology Service at home or in nursing homes
283138|NCT02591615|Drug|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
283139|NCT02591615|Drug|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
283140|NCT02591615|Drug|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
283141|NCT02591615|Drug|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
283142|NCT02591628|Behavioral|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
283143|NCT02591641|Device|Anti-shear mattress overlay|
283144|NCT02591641|Other|No Intervention Standard of Care|
283145|NCT00190632|Drug|Duloxetine|
283146|NCT02591654|Drug|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
283147|NCT02591654|Drug|FLT PET|
283148|NCT02591667|Procedure|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
283149|NCT02591667|Drug|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab
Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;
283150|NCT02593331|Other|Placebo|Participants will receive a single dose of placebo administered subcutaneously.
283151|NCT02593344|Device|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
283152|NCT02593357|Device|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
282555|NCT02602470|Drug|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
282556|NCT00191672|Drug|Gemcitabine|
282557|NCT02602470|Drug|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
282558|NCT02602470|Drug|Metronidazole Lotion|Study phase 2 / Cohort 6
282835|NCT02595905|Other|Placebo|Given PO
282836|NCT02595905|Drug|Veliparib|Given PO
282837|NCT02595918|Procedure|Conventional Surgery|Undergo nephrectomy
282838|NCT02595918|Other|Laboratory Biomarker Analysis|Correlative studies
282839|NCT02595918|Biological|Nivolumab|Given IV
282840|NCT02595931|Drug|ATR Kinase Inhibitor VX-970|Given IV
282841|NCT02595931|Drug|Irinotecan Hydrochloride|Given IV
282842|NCT00002516|Radiation|low-LET cobalt-60 gamma ray therapy|
282843|NCT00191269|Drug|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
282844|NCT02598076|Behavioral|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
282845|NCT02598089|Biological|Trivalent Seasonal Influenza Vaccine|The seasonal trivalent influenza vaccine produced by IVAC uses embryonated chicken eggs. This is a split virion, inactivated vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge (Alfa Wassermann, West Caldwell, NJ) and inactivated with formaldehyde.
282846|NCT02598089|Biological|Placebo Comparator|Placebo (PBS) will be manufactured by IVAC. PBS, pH 7.2, will also be in 0.5 mL single-dose vials. Every vial contain : Nacl 4.500mg;Na2HPO4.2H2O: 0.685 mg; NaH2PO4.2H2O:0.186 mg and Water For Injection (qs):0.5 mL
282847|NCT02598102|Drug|Diclofenac sodium|Diclofenac for pain relief
282848|NCT02598102|Drug|Placebo|Placebo for comparison
282849|NCT02598115|Other|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
282850|NCT02598128|Device|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
282283|NCT02607007|Other|2% M.F. Plain Greek yogurt|
282284|NCT02607007|Other|Soy Beverage|
282285|NCT02609113|Device|Weaker Magnetic Wristband|
282286|NCT02609126|Drug|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
282287|NCT02609126|Drug|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
282288|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
282289|NCT00192361|Biological|CAIV-T|
282290|NCT02609139|Drug|PF-06650833|100mg modified release tablet administered under fasted conditions
282291|NCT02609139|Drug|PF-06650833|20mg modified release tablet administered under fasted conditions
282292|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
282293|NCT02609139|Drug|PF-06650833|100mg modified released tablet administered with high fat meal food intake
282559|NCT02602470|Drug|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
282560|NCT02602483|Drug|Ibuprofen|
282561|NCT02602483|Drug|Magnesium|
282562|NCT02602483|Drug|Ascorbic Acid|
282563|NCT02602483|Drug|Placebo|
282564|NCT02602496|Other|Fruits and Vegetables|5 servings of fruits or vegetables
282565|NCT02602496|Other|Whole Grain|3 servings of whole grain
282566|NCT02602496|Other|Control|3 servings of refined grain
282567|NCT00191672|Drug|Paclitaxel|
282568|NCT02602509|Drug|Celecoxib|
282569|NCT02602509|Drug|Rifampicin|
282570|NCT02602509|Drug|Pyrazinamide|
281991|NCT02577406|Drug|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
281992|NCT02577419|Other|Target Fortification|
281993|NCT00188643|Drug|Venlafaxine and Lamotrigine|
281994|NCT02577419|Other|Higher Initial Concentration|
281995|NCT02577419|Other|Portagen Formula|
281996|NCT02577432|Drug|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
281997|NCT02577432|Drug|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
281998|NCT02577432|Drug|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
281999|NCT02577432|Drug|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
282000|NCT02577458|Drug|CM082|CM082 tablets taken orally once a day on 28-day cycles
282001|NCT02577458|Drug|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
282002|NCT02579629|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
282003|NCT02579629|Drug|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
282004|NCT02579629|Device|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
282005|NCT02579642|Drug|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
282294|NCT02609139|Drug|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
281398|NCT02588482|Device|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
281399|NCT02588495|Other|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
281400|NCT02588508|Procedure|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
281401|NCT02588508|Procedure|Perineal massage|The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like "count coins".
281700|NCT02584036|Behavioral|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
281701|NCT02584049|Other|Osteopathy|3 sessions of osteopathy during 60 minutes each
281702|NCT02584049|Other|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
281703|NCT02584062|Procedure|no-touch fluid-air exchange|
281704|NCT02584062|Procedure|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
281705|NCT02584075|Drug|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
281706|NCT02584075|Drug|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
281707|NCT00189605|Device|Perc-DLR/Perc-DLG|Device technique will be used per IFU
281708|NCT02584088|Other|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
281709|NCT02584101|Behavioral|ACT|ACT therapy administered in 3 sessions over a 4 week period
281710|NCT02584101|Behavioral|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
281711|NCT02584114|Behavioral|Peak app for memory training|
281712|NCT02584114|Behavioral|Non-memory training group|
281713|NCT02584127|Behavioral|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
281714|NCT02584127|Behavioral|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
281715|NCT02584140|Behavioral|Text Messaging/Counseling|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
281104|NCT02594969|Other|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
281105|NCT02594982|Other|intervention bundle (sedation, pain, mobilization and sleep)|Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.
Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night
281106|NCT02594995|Drug|NBP|
281107|NCT02595008|Drug|DSXS|Active treatment
281108|NCT02595021|Procedure|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
281109|NCT02595021|Procedure|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
281110|NCT02595034|Drug|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
281402|NCT02588521|Drug|AL-794|
281403|NCT02588521|Other|Placebo/Vehicle|Suspension vehicle without active drug
281404|NCT02588534|Device|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
281405|NCT02588534|Other|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
281406|NCT02588547|Drug|Granisetron|IV granisetron 1 mg before spinal anethesia
281407|NCT02588547|Drug|Granisetron|IV granisetron 0.7 mg before spinal anethesia
281408|NCT00190268|Drug|3,4-diaminopyridine|3,4-diaminopyridine
281409|NCT02588547|Drug|pethidine|IV Pethidine 25 mg before spinal anethesia
281410|NCT02588547|Drug|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
281411|NCT02588573|Device|1-Day Acuvue® Moist contact lens|
281412|NCT02588573|Device|Clariti 1-day contact lens|
281413|NCT02588586|Drug|3BNC117|3BNC117 infusions
280828|NCT02599558|Device|Cytosponge|Patients undergoing the six food elimination diet will be monitored through the diet with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
280829|NCT02599558|Other|Diet|Investigators will reintroduce 1 of the six food for two weeks, then another for two weeks. Participant will return for the cytosponge procedure which will help the Investigator to direct which foods will be add or removed for the next two to four weeks. This will be repeated until all six foods have been reintroduced back into the participants diet.
280830|NCT02599558|Other|Phone call|The study coordinator will call the participant two weeks after the participate has added in one of the six foods as directed by the Investigator, completing a short questionnaire (esophageal eosinophilic Activity Index Pro) EEsAI Pro.
280831|NCT02599558|Other|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline, two weeks after a food has been added to the diet and at the final visit.
280832|NCT02599571|Other|Very low nicotine content cigarettes|
280833|NCT00191399|Drug|Fluoxetine|
280834|NCT02599571|Other|Conventional nicotine content cigarettes|
280835|NCT02599584|Behavioral|precritical staff|free pre critical scenario team staff
280836|NCT02599597|Behavioral|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
280837|NCT00191594|Drug|Duloxetine Hydrochloride|
280838|NCT02601742|Other|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
280839|NCT02601742|Other|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
280840|NCT02601755|Behavioral|iCanCope app and website|In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the "iCanCope with Pain" smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources.
281111|NCT02595034|Drug|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
281112|NCT02595034|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
281113|NCT02595047|Procedure|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
281114|NCT00191022|Drug|LY686017|
281115|NCT02595060|Drug|inhaled molgramostim (rhGM-CSF)|
296099|NCT02627729|Device|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
296100|NCT02627742|Device|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
296101|NCT02627755|Device|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
296102|NCT02627755|Device|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
296103|NCT02627768|Drug|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
296104|NCT02627794|Device|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
296105|NCT02629991|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
296106|NCT02629991|Drug|Matched Placebo|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
281482|NCT00191035|Drug|Atomoxetine|
281483|NCT02595333|Drug|Group S1|sufentanil was administered for analgesia in primary cesarean section
281484|NCT02595333|Drug|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
281485|NCT02595333|Drug|Group S2|sufentanil was administered for analgesia in repeated cesarean section
281486|NCT02597582|Device|Ligasure small jaw (Covidien, Colorado, USA)|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
281487|NCT02597582|Device|Conventional neck dissection|The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.
281488|NCT02597595|Other|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
281489|NCT02597608|Behavioral|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
280880|NCT02606188|Device|nasal cannula|Conventional oxygen therap
280881|NCT02606201|Other|Peri sphincter injection Autologous myofibers|The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.
All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.
During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control.
280882|NCT02606214|Drug|TBA-354|
280883|NCT02606214|Drug|TBA-354 Placebo|
280884|NCT00192075|Drug|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
280885|NCT02606227|Behavioral|Financial incentive|Vouchers
280886|NCT02606227|Other|No financial incentive|No financial intervention
280887|NCT02606240|Device|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
280888|NCT02606253|Drug|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
280889|NCT02606253|Drug|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
280890|NCT02606253|Drug|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
280891|NCT02606266|Drug|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
281171|NCT02599714|Drug|palbociclib|cyclin dependent kinase inhibitor
281172|NCT02599714|Drug|fulvestrant|fulvestrant hormonal therapy as background
281173|NCT02601898|Drug|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
281174|NCT00191607|Drug|liposomal doxorubicin|
281175|NCT02601911|Drug|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
281176|NCT02601911|Drug|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
281177|NCT02601911|Other|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
280597|NCT02576899|Behavioral|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
280598|NCT02576899|Behavioral|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
280599|NCT02576912|Drug|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
280600|NCT02576912|Drug|Active Pregnenolone|A dose given sublingually.
280601|NCT02576912|Drug|Placebo|A placebo dose given sublingually.
280602|NCT02576912|Drug|Placebo|Placebo dose given intravenously.
280603|NCT02576925|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
280604|NCT02576938|Drug|Baricitinib|Administered orally
280605|NCT00188552|Drug|pentoxifylline|
280606|NCT02576938|Drug|Placebo|Administered orally
280607|NCT02576938|Drug|Triamcinolone (Optional)|Administered topically
280608|NCT02576951|Drug|LY2951742|Administered SC
280609|NCT02576951|Drug|Placebo|Administered SC
280610|NCT02576964|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
280611|NCT02576964|Drug|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
280892|NCT02606279|Drug|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
280893|NCT02606279|Other|Placebo|
280894|NCT02606292|Procedure|Photoacoustic endoscopy|
280895|NCT00002519|Drug|paclitaxel|
280301|NCT02583399|Drug|Ibuprofen|Ibuprofen, 10 mg/kg
280302|NCT02583412|Biological|Bexsero®|Multicomponent meningococcal B vaccine
280303|NCT02583412|Biological|Havrix®|Hepatitis A vaccine
280304|NCT02583425|Drug|DFN-11 Injection|
280305|NCT02583438|Drug|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
280306|NCT02583451|Drug|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
280307|NCT02583451|Drug|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
280308|NCT02583451|Drug|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
280309|NCT00189553|Drug|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
280310|NCT02583451|Drug|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
280311|NCT02583451|Drug|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
280312|NCT02583451|Drug|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
280313|NCT02583464|Drug|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
280314|NCT02583477|Drug|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
280315|NCT02583477|Drug|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
280316|NCT02583490|Device|spectrum 5000Q ECT device (RUL ECT)|
280317|NCT02583490|Device|spectrum 5000Q ECT device (RUL LAP ECT)|
280318|NCT02583503|Radiation|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
280319|NCT02583516|Drug|vemurafenib and cobimetinib|Comparison between different treatment regimens
280320|NCT00189553|Drug|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
280612|NCT02576977|Biological|Pembrolizumab|pembrolizumab 200 mg IV infusion
280613|NCT02576977|Drug|Pomalidomide|pomalidomide 4 mg capsules
279709|NCT02594319|Behavioral|Monetary incentives|
279710|NCT02594319|Behavioral|Self monitoring|
280015|NCT02587884|Procedure|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
280016|NCT02587897|Other|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
280017|NCT02587897|Other|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
280018|NCT00190190|Procedure|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
280019|NCT02587910|Dietary Supplement|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
280020|NCT02587910|Dietary Supplement|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
280021|NCT02587936|Other|Collaborative Model of Primary care and Subspecialty care|Pieces will access EHR for all patients receiving care at the participating sites to detect patients with a triad of CKD, diabetes and hypertension, detect eligible participants, facilitate management and monitor outcomes. In order to maximize the successful implementation of care, there will be a Practice Facilitator at each site, whose role training will be standardized using a curriculum based on the AHRQ Practice Facilitation Handbook adapted for the study. Specific interventions include maintaining BP less than 140/90mmHg, use of ACEI or ARB, treatment with statins, aiming for hemoglobin A1C at the recommended target for coexisting comorbidities, and avoiding nephrotoxic medications. Others include CKD education for Primary Care Providers (PCP) and patients using NKDEP materials.
280022|NCT02587962|Drug|Birinapant|Birinapant IV on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2
280023|NCT02590458|Behavioral|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
280024|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.
Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months.
280025|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months.
279419|NCT02701231|Drug|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
279711|NCT02594332|Drug|Mepolizumab|100 mg SC every 4 weeks for 13 injections
279712|NCT02594332|Drug|Placebo|
279713|NCT02594345|Other|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
279714|NCT02594358|Drug|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
279715|NCT00190957|Drug|Atomoxetine|
279716|NCT02594371|Drug|Oraxol|
279717|NCT02594371|Drug|IV paclitaxel|
279718|NCT02594384|Drug|LAM-002A|25 mg capsules
279719|NCT02594397|Other|acupoints combination 1|
279720|NCT02594397|Other|acupoints combination 2|
279721|NCT02594397|Other|sham acupoints combination|
279722|NCT02594410|Device|stent|patients receiving renal artery stenting for renal artery atherosclerosis
279723|NCT02594410|Drug|Aspirine|100mg Qd
279724|NCT02594410|Drug|Clopidogrel|75mg Qd
279725|NCT02594410|Drug|Lercanidipine|10-20mg Qd
279726|NCT00190957|Drug|placebo|
279727|NCT02594423|Device|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
279728|NCT02594423|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
279729|NCT02594436|Drug|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
279135|NCT02707640|Drug|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
279136|NCT02707640|Drug|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, beginning 8 weeks prior to administration of study medication.
279420|NCT02703233|Drug|Nitrous Oxide|
279421|NCT02703233|Other|Oxygen|
279422|NCT00002546|Drug|cisplatin|
279423|NCT00202553|Drug|Perindopril|
279424|NCT02703246|Procedure|abdominal morcellation|patients will be randomized to receive abdominal morcellation
279425|NCT02703246|Procedure|vaginal morcellation|patients will be randomized to receive vaginal morcellation
279426|NCT02703259|Drug|Gabapentin|
279427|NCT02703259|Drug|Acetaminophen|
279428|NCT02703259|Drug|Celecoxib|
279429|NCT02703272|Drug|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m^2 /329 mg/m^2) during part 1 and part 2.
279430|NCT02703272|Drug|Rituximab|Participants will receive rituximab 750 mg/m^2 in part 1 and part 2 as a part of RICE/RVICI regimen.
279431|NCT02703272|Drug|Ifosfamide|Participants will receive Ifosfamide 9 g/m^2 as a part of RICE regimen in part 1 and part 2. Participants will receive Ifosfamide10 g/m^2 as a part of RVICI regimen in part 1 and part 2.
279432|NCT02703272|Drug|Carboplatin|Participants will receive carboplatin 635 mg/m^2 as a part of RICE regimen in part 1 and part 2. Participants will receive carboplatin 800 mg/m^2 as a part of RVICI regimen in part 1 and part 2.
279433|NCT02703272|Drug|Etoposide|Participants will receive etoposide 300 mg/m^2 in part 1 and part 2 as a part of RICE regimen.
279434|NCT00202566|Drug|Ivabradine|
279435|NCT02703272|Drug|Vincristine|Participants will receive vincristine 1.6 mg/m^2 in part 1 and part 2 as a part of RVICI regimen.
279436|NCT02703272|Drug|Idarubicin|Participants will receive idarubicin 20 mg/m^2 in part 1 and part 2 as a part of RVICI regimen.
279437|NCT02703272|Drug|Dexamethasone|Participants will receive dexamethasone 100 mg/m^2 in part 1 and part 2 as a part of RICE/RVICI regimen.
279438|NCT02703285|Other|Sound|task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
279148|NCT02709655|Drug|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
279149|NCT02709655|Drug|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
279150|NCT02709655|Drug|Fluoxetine 20mg/day|20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
279151|NCT02709655|Other|Placebo|Encapsulated tablet, orally
279152|NCT02709668|Dietary Supplement|Enlyte|gel cap of reduced B vitamins
279153|NCT02709668|Other|placebo|identical to Enlyte
279154|NCT02709681|Other|Physician standard-of-care in SCD patients|
279155|NCT02709694|Other|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
279156|NCT02709707|Device|Blood glucose monitor|
279157|NCT00203281|Drug|mycophenolate mofetil|
279444|NCT02703337|Drug|Insulin Lispro|Administered SC
279445|NCT00202579|Drug|Ivabradine|
279446|NCT02703350|Drug|LY900014|Administered subcutaneously (SC)
279447|NCT02703350|Drug|Insulin Lispro|Administered SC
279448|NCT02703363|Drug|Minocycline|
279449|NCT02705508|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
279450|NCT00202852|Drug|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
279451|NCT02705508|Drug|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
279452|NCT02705508|Drug|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
279453|NCT02705508|Radiation|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
283712|NCT02580383|Procedure|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
283713|NCT02580396|Device|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
283714|NCT02580409|Behavioral|Exercise Intervention|Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.
283715|NCT02580448|Drug|VT-464; given orally once daily in 28 day cycles|
283716|NCT02580461|Behavioral|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
283717|NCT02580474|Drug|Daclatasvir plus Asunaprevir|
283718|NCT02580487|Procedure|appendicectomy|Appendix was removed either laparoscopically or open surgery
283719|NCT02580500|Procedure|epidural catheter|epidural anaesthesia application for spinal catheter will be used
279158|NCT02709720|Drug|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
279159|NCT02709720|Drug|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
279160|NCT02709720|Drug|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
279161|NCT02709720|Drug|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
279162|NCT02709720|Radiation|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
279163|NCT02709733|Behavioral|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
279164|NCT02709746|Drug|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
283411|NCT02586896|Behavioral|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
283412|NCT02586896|Behavioral|Screening, Assessment, and Referral (SAR)|The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than "treatment as usual." Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment.
283413|NCT02586909|Drug|RVT-101 35 mg tablets|once daily, oral tablets
283414|NCT02586922|Device|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
283415|NCT02586935|Drug|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
283416|NCT02586935|Other|Placebo|Administered orally after dispersion in approximately 100 ml of water
283417|NCT02586948|Device|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
283418|NCT02586961|Drug|0.9% saline solution|Placebo:
Nebulized 0.9% saline solution
283419|NCT00190008|Drug|piracetam|
283420|NCT02586961|Drug|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
283421|NCT02586961|Drug|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
283422|NCT02586961|Drug|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
283423|NCT02586974|Device|Humigard|warmed and humidified CO2 insufflation
283424|NCT02586987|Drug|Selumetinib and Medi4736|Selumetinib orally, Medi4736 IV
283425|NCT02587000|Drug|Ulipristal acetate|
283426|NCT02587000|Drug|Placebo|
282851|NCT02598141|Biological|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
282852|NCT02598141|Biological|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
282853|NCT02598180|Device|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
282854|NCT00191269|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
282855|NCT02598193|Drug|Nintedanib|Participants with IPF will receive nintedanib at the 300 mg/day dose up to 24 months.
283153|NCT02593370|Drug|Lidocaine-epinephrine added gadoterate meglumine|
283154|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
283155|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
283156|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
283157|NCT00190853|Drug|Duloxetine|
283158|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
283159|NCT02593383|Drug|Placebo|
283160|NCT02593396|Drug|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
283161|NCT02593396|Drug|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
283162|NCT02593409|Drug|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
283163|NCT02593422|Behavioral|Writing about ovarian cancer|Participants will be asked to write about their experiences with ovarian cancer
282571|NCT02602522|Drug|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
282572|NCT02604563|Procedure|Number of Falls|-1 item about daily functional status
282573|NCT02604563|Procedure|Physical Health Section, subscale of the OARS|-13 items about comorbidity
282574|NCT02604563|Procedure|MOS Social Activity Survey|-4 items about social activity
282575|NCT02604563|Procedure|Body Mass Index & Unintentional Weight Loss|-2 items about nutrition
282576|NCT02604563|Genetic|Peripheral Blood Draw|
282577|NCT02604563|Genetic|Buccal Swab|-Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)
282578|NCT00191880|Drug|atomoxetine|
282579|NCT02604576|Drug|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
282580|NCT02604576|Drug|FDC Bromopride 10 mg and Simethicone 150 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 150 mg
282581|NCT02604576|Drug|Bromopride 10 mg|Bromopride 10 mg
282582|NCT02604589|Drug|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
282583|NCT02604589|Procedure|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
282856|NCT02598193|Drug|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 months.
282857|NCT02598206|Drug|PF-04136309|Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.
Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets.
282858|NCT02598219|Drug|Pre-operative SN mapping with Nanocis|Preparation : four 1ml syringe are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.
Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.
Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available.
282859|NCT02600338|Other|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
282860|NCT00191464|Drug|premeal insulin lispro mixtures|
282295|NCT02609152|Drug|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
282296|NCT02609152|Drug|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
282297|NCT02609165|Drug|rhNGF 180 µg/ml eye drops solution|eye drops
282298|NCT02609165|Drug|vehicle eye drops|placebo
282299|NCT02609178|Procedure|1.modeling|In axial contour design study, modeling technique would be used if the abutment tooth lacks proper contour of the original axial surface. Back cut the buccal and lingual surface of the interim and apply recording resin onto the surface. Seat the interim and ask the subject to perform swallowing, sucking, licking and air-blowing several times to model both the buccal and lingual surface. Trim off excessive resin until no excess can be observed.
282300|NCT00002521|Drug|cisplatin|
282301|NCT00192374|Biological|CAIV-T, Liquid|
282302|NCT02609178|Procedure|1.copy|In axial contour design study, copy technique would be used if the axial contour of the abutment tooth is remained. Use the CAD/CAM scanner to scan the study cast made before tooth preparation and make adjustments only on the occlusal surface.
282303|NCT02609178|Procedure|2.FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and a piece of 50μm articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences.
282304|NCT02609178|Procedure|2.average|This technique would use average setting of the virtual articulator to fabricate the occlusal surface of the crown.
282305|NCT02609191|Device|Whole body exam using the "Discovery A"|Whole body exam using the "Discovery A" machine made by Hologic.
282306|NCT02575287|Device|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
282307|NCT00188240|Drug|Pegasys; Copegus.|
282308|NCT02575300|Drug|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
282309|NCT02575313|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
281716|NCT00189904|Biological|IMVAMUNE (MVA-BN)|
281717|NCT02586272|Device|Daifert|
281718|NCT02586272|Procedure|Control Group|
281719|NCT02586285|Drug|S-Adenosyl Methionine|500mg-1000mg,iv,qd
281720|NCT02586298|Other|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
281721|NCT02586298|Other|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
281722|NCT02586311|Drug|CKD-330|Once a day, 8 weeks
281723|NCT02586311|Drug|Amlodipine 5mg Placebo|Once a day, 8 weeks
282006|NCT02579642|Drug|Placebo|Normal saline administered with usual induction drugs for ECT
282007|NCT02579655|Behavioral|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
282008|NCT02579655|Behavioral|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
282009|NCT02579668|Other|Language Therapy|
282010|NCT02579681|Drug|dimethyl fumarate|dimethyl fumarate administered as per the arm description
282011|NCT02579694|Device|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
282012|NCT00189033|Drug|wheat bran (dietary supplement)|
282013|NCT02579707|Drug|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
282014|NCT02579733|Drug|Azathioprine|
282015|NCT02579733|Drug|Placebo|
282016|NCT02579746|Behavioral|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
282017|NCT02579746|Behavioral|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
282018|NCT02579759|Drug|PXT3003 dose 1|
282019|NCT02579759|Drug|PXT3003 dose 2|
281414|NCT02588586|Other|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
281415|NCT02588599|Device|Erchonia LUNULA|Active low level laser light therapy
281416|NCT02588612|Genetic|Autologous Genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|
281417|NCT02588625|Drug|BMS-986020|
281418|NCT02588625|Other|Placebo|
281419|NCT00002515|Drug|thiotepa|
281420|NCT00190294|Drug|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
281421|NCT02590965|Drug|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
281422|NCT02590965|Drug|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
281423|NCT02590978|Procedure|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
281424|NCT02590978|Procedure|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
281724|NCT02586311|Drug|CKD-330 Placebo|Once a day, 8 weeks
281725|NCT02586311|Drug|Amlodipine 5mg|Once a day, 8 weeks
281726|NCT02586324|Biological|global medium|
281727|NCT00189917|Biological|IMVAMUNE (MVA-BN)|
281728|NCT02586324|Biological|SSM|
281729|NCT02586337|Drug|Anlotinib|Anlotinib p.o. qd
281730|NCT02586337|Drug|Placebo|Placebo p.o. qd
281731|NCT02586350|Drug|Anlotinib|
281732|NCT02586350|Drug|Placebo|Placebo p.o. qd
281733|NCT02586363|Drug|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
281734|NCT02586363|Drug|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
281116|NCT02595060|Drug|inhaled placebo|formulated as the active substance without molgramostim
281117|NCT02595073|Drug|DSXS|Active treatment
281118|NCT02595073|Drug|Placebo|Placebo treatment
281119|NCT02595086|Procedure|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
281120|NCT02595086|Procedure|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
281121|NCT02595099|Other|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
281122|NCT02595112|Other|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
281123|NCT02595125|Device|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
281124|NCT02595138|Drug|Zoledronic acid|
281125|NCT00002516|Drug|ifosfamide|
281126|NCT00191022|Drug|paroxetine|
281127|NCT02595151|Device|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
281128|NCT02595177|Procedure|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
281129|NCT02597478|Procedure|Shuttle Walk Test|Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
281130|NCT02597478|Behavioral|Questionnaires|Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
281131|NCT02597478|Behavioral|Mental Ability Tests|After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
281425|NCT02590991|Other|Prebiotics|To study the long term effect of supplementation in early life
281426|NCT02590991|Other|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
281427|NCT02591004|Drug|Magesium sulphate|*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
281490|NCT02597608|Dietary Supplement|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
281491|NCT00191230|Drug|cisplatin|
281492|NCT02597608|Behavioral|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
281493|NCT02597608|Dietary Supplement|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
281494|NCT02597608|Behavioral|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
281495|NCT02597608|Dietary Supplement|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
281777|NCT02591186|Procedure|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
281778|NCT02591199|Drug|URG101|
281779|NCT02591199|Drug|Placebo|
281780|NCT02591199|Drug|Lidocaine|
281781|NCT02591199|Drug|Heparin|
281782|NCT02592915|Other|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
281783|NCT02592928|Other|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
281784|NCT02592941|Drug|Deflazacort|
281178|NCT02601924|Drug|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
281179|NCT02601924|Other|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
281180|NCT02601937|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
281181|NCT02601950|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
281182|NCT02601963|Drug|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
281183|NCT02601963|Drug|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
281184|NCT02601963|Drug|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
281185|NCT00191620|Drug|Gemcitabine|
281186|NCT02601976|Drug|Peginterferon alfa-2a|PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
281187|NCT02601976|Drug|Ribavirin|Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
281188|NCT02601989|Drug|Tadalafil|
281189|NCT02601989|Drug|Placebo|Per oral intake of placebo for six weeks
281190|NCT02602002|Drug|Remifentanil|IV
281191|NCT02602002|Drug|Placebo|Placebo
281496|NCT02597608|Other|UPPR: Control|No interventions provided.
281497|NCT02597621|Other|no intervention|no intervention
281498|NCT02597634|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
281499|NCT02597634|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
280896|NCT02608632|Device|Renal denervation as standard procedure|
280897|NCT02608658|Other|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|Visit 1, screening (Day 0): At this visit, the investigators of the study will:
Obtain demographic information, as will past medical history and medications.
Perform a physical examination.
Collect samples for labs
Administer the Chronic Liver Disease Questionnaire (CLDQ)
Perform a lactulose breath test
From Day 0 to 8 weeks: subjects will take the medical food twice daily
Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:
Perform a physical examination
Collect and record returned investigational product
Dispense investigational product and instruct again regarding use
Record any adverse events
Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:
Perform a physical examination.
Collect samples for labs
Administer the Chronic Liver Disease Questionnaire (CLDQ)
Perform a lactulose breath test
280898|NCT02608671|Procedure|Skin adhesive tape|
280899|NCT00192322|Biological|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
280900|NCT02608684|Drug|Pembrolizumab|Pembrolizumab IV solution
280901|NCT02608684|Drug|Gemcitabine|Gemcitabine IV solution
280902|NCT02608684|Drug|Cisplatin|Cisplatin IV solution
280903|NCT02608697|Drug|CAT-2054|
280904|NCT02608697|Drug|Placebo|
280905|NCT02608697|Drug|Atorvastatin|
280906|NCT02608710|Drug|RDEA3170 4.5 mg|
280907|NCT02608710|Drug|RDEA3170 6 mg|
280908|NCT02608710|Drug|RDEA3170 12 mg|
280909|NCT02608723|Device|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
280910|NCT00192322|Biological|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T <10^5
280911|NCT02608723|Device|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
280912|NCT02608723|Device|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
281192|NCT02602015|Drug|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
281193|NCT02602015|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
280614|NCT02576977|Drug|Dexamethasone|dexamethasone 40 mg tablets
280615|NCT02576990|Biological|pembrolizumab|
280616|NCT00188552|Drug|α-Tocopherol|
280617|NCT02577003|Drug|Ipragliflozin|
280618|NCT02577003|Drug|Placebo|Placebo to ipragliflozin
280619|NCT02577003|Drug|Sitagliptin|Background medication
280620|NCT02577016|Drug|Sitagliptin|
280621|NCT02579070|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
280622|NCT02579083|Drug|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
280623|NCT02579083|Drug|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
280624|NCT02579096|Drug|Allopurinol|Patients will be titrated up to the dose that will lower to target uric acid levels.
280625|NCT02579096|Drug|Febuxostat|Febuxostat will be titrated up to the dose that will lower to target uric acid levels.
280626|NCT02579109|Other|memory test|
280627|NCT02579135|Behavioral|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
280628|NCT00188968|Procedure|Nasal Continuous Positive Airway Pressure|
280629|NCT02579135|Behavioral|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
280630|NCT02579148|Biological|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.`
280631|NCT02579148|Biological|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.`
280632|NCT02579161|Other|Course of Antibiotics|Looking at the same drugs and doses the variable is the timeframe of the medication
280633|NCT02579174|Device|Medacta GMK Sphere|
280634|NCT02579187|Procedure|tooth extraction|The study tooth will be removed
280635|NCT02579187|Radiation|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
280026|NCT02590484|Procedure|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
280027|NCT02590497|Procedure|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
280321|NCT02583529|Device|Back Tibial Nerve Electrostimulation|The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
280322|NCT02583529|Device|Placebo Electrostimulation|The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
280323|NCT02583542|Drug|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
280324|NCT02583542|Drug|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
280325|NCT00189787|Drug|tacrolimus|
280326|NCT02585700|Biological|Phosphate buffered saline|0.5 mL of phosphate buffered saline
280327|NCT02585713|Drug|Apixaban|Given PO
280328|NCT02585713|Drug|Dalteparin|Given SC
280329|NCT02585713|Other|Questionnaire Administration|Ancillary studies
280330|NCT02585726|Device|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins.
280331|NCT02585739|Genetic|blood sample|
280332|NCT02585765|Drug|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
280333|NCT02585765|Drug|Placebo|8 weeks of daily placebo capsules.
280334|NCT02585778|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
280335|NCT02585778|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
280336|NCT00002514|Procedure|peripheral blood stem cell transplantation|
279730|NCT02596828|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
279731|NCT02596828|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
279732|NCT02596867|Drug|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
279733|NCT00191152|Drug|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
280028|NCT00190541|Procedure|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
280029|NCT02590497|Drug|Gadolinium|Undergo gadolinium-enhanced MRI
280030|NCT02590497|Other|Laboratory Biomarker Analysis|Tissue genetic analysis
280031|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
280032|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
280033|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo FLAIR sequence
280034|NCT02590497|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
280035|NCT02590510|Drug|methotrexate|The quantity of methotrexate is different in the two groups.
280036|NCT02590523|Drug|Vancomycin|Intracameral vancomycin injection during cataract surgery
280037|NCT02590523|Drug|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
280038|NCT02590523|Drug|Placebo|Intracameral placebo injection with BSS during cataract surgery
280039|NCT00190541|Procedure|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
280040|NCT02590536|Drug|Sildenafil citrate|In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.
This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet.
280041|NCT02590536|Drug|placebo|
279439|NCT02703298|Drug|TRX-818 capsules|
279440|NCT02703311|Device|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
279441|NCT02703324|Drug|LY900014|Administered subcutaneously (SC)
279442|NCT02703324|Drug|Insulin Lispro|Administered SC
279443|NCT02703337|Drug|LY900014|Administered subcutaneously (SC)
279734|NCT02596880|Drug|Sofosbuvir|400 mg, included in a combination pill (SoDac) with 60 mg daclatasvir
279735|NCT02596880|Drug|Daclatasvir|60 mg, included in a combination pill (SoDac) with 400 mg sofosbuvir
279736|NCT02596880|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
279737|NCT02596893|Drug|GED-0301|
279738|NCT02596893|Drug|Placebo|
279739|NCT02596906|Device|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. Participant can bring a book to read or something to work on during the 20 minute session.
279740|NCT02596906|Behavioral|Brain Training Program|The Brain training program includes 8 1-hour sessions conducted over 4 weeks. The goal of these treatment sessions is to provide strategies to improve brain function. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
279741|NCT02596906|Device|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
279742|NCT02596919|Other|photography|photography of meibomian glands
279743|NCT02596932|Other|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL
279744|NCT00191165|Drug|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
279745|NCT02596932|Other|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL
279746|NCT02596945|Drug|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
279454|NCT02705521|Device|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
279455|NCT02705534|Drug|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
279456|NCT02705534|Drug|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
279457|NCT02705534|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
279458|NCT02705547|Drug|Rosuvastatin|Daily administration of oral tablets of Rosuvastatin, 10 mg.
279459|NCT02705560|Other|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
279460|NCT02705560|Other|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
279461|NCT00202852|Biological|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
279462|NCT02705560|Other|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
279463|NCT02705573|Drug|Mannitol|
279464|NCT02705586|Behavioral|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
279465|NCT02705612|Drug|Cisplatin|
279466|NCT02705612|Radiation|External Beam Radiation Therapy|
279753|NCT02599038|Dietary Supplement|Serine supplementation|Serine supplementation (200 mg/kg/day)
279754|NCT00191334|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
279755|NCT02599051|Device|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
279756|NCT02599051|Device|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
279757|NCT02599064|Drug|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
279758|NCT02599077|Drug|Dienogest|patients assigned to this treatment receive 2 milligrams per day
279759|NCT02599077|Drug|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
279165|NCT02711553|Drug|Gemcitabine|Administered IV
279166|NCT02711553|Drug|Placebo Oral|Administered orally
279167|NCT02711553|Drug|Placebo IV|Administered IV
279168|NCT00002548|Drug|carmustine|20 mg/m2 I.V. day 1 q 35 days
279169|NCT00203502|Drug|Docetaxel|60 mg per meter squared, IV every 21 days
279170|NCT02711566|Device|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
279171|NCT02711566|Device|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
279172|NCT02711579|Drug|Celecoxib|
279173|NCT02711579|Drug|Placebo|
279174|NCT02711592|Genetic|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
279175|NCT02711605|Device|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
279176|NCT02711618|Device|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
279177|NCT02711631|Behavioral|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
279467|NCT02705612|Radiation|Internal Radiation Therapy|
279468|NCT02705612|Drug|nimotuzumab|
279469|NCT02705625|Drug|MIV-711|MIV-711 administered orally once daily
279470|NCT02705625|Drug|Placebo|Placebo manufactured to mimic MIV-711 capsule.
279471|NCT02705638|Drug|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
283427|NCT02587013|Procedure|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
283428|NCT02587013|Procedure|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
283720|NCT02582606|Other|Regular meal pattern|a 14-day period of eating 6 meal per day
283721|NCT02582606|Other|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
283722|NCT02582619|Other|Focus groups, semistructured interviews and Delphi rounds|
283723|NCT02582632|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet
283724|NCT02582632|Drug|dasabuvir|Tablet
283725|NCT02582645|Procedure|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
283726|NCT02582645|Procedure|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
283727|NCT02582684|Drug|Dolutegravir|Participants will receive 50 mg of DTG orally daily
283728|NCT02582684|Drug|Lamivudine|Participants will receive 300 mg of 3TC orally daily.
283729|NCT00189475|Drug|Montelukast|
283730|NCT02582697|Drug|Bleomycin (active name: Bleomycin Sulfate)|Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.
Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses.
283731|NCT02582697|Drug|Etoposide|Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.
Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.
283732|NCT02582697|Drug|Cisplatin|Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.
Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.
283733|NCT02582697|Drug|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
283734|NCT02582710|Dietary Supplement|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
283735|NCT02582710|Dietary Supplement|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
283736|NCT02582723|Other|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
283164|NCT02593435|Genetic|NGS test|To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.
To know mutation characteristic spectrum of BRCA1/2.
283165|NCT02593448|Procedure|NIRS during VOT|Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:
30 minutes after anaesthesia induction,
directly after the sternotomy,
during CPB - 20 minutes after aortic cross-clamping ,
40 minutes after aortic cross-clamping,
20 minutes after the release of the aortic cross-clamp,
45 minutes after weaning of CPB.
283166|NCT02593448|Procedure|General anaesthesia with propofol use|Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.
Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.
Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.
Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.
Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.
283167|NCT00191113|Drug|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
283168|NCT02595931|Other|Laboratory Biomarker Analysis|Correlative studies
283429|NCT02587026|Other|Blood sample collection|
283430|NCT00190021|Drug|donepezil|
283431|NCT02587026|Other|Tumor tissue sample collection|
283432|NCT02589418|Procedure|No Acupuncture|Control intervention: No needle insertion and manipulation
283433|NCT02589444|Dietary Supplement|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
283434|NCT02589444|Other|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
283435|NCT02589444|Other|Sputum Sample|Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.
This will be done upon enrollment (baseline) and at 3 month follow-up.
283436|NCT02589444|Other|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
283437|NCT02589444|Procedure|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
283438|NCT02589457|Drug|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
283439|NCT02589457|Drug|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
282861|NCT02600351|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
282862|NCT02600351|Drug|RBV|RBV tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
282863|NCT02600377|Other|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
282864|NCT02600390|Biological|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
282865|NCT02600403|Device|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a machine that scans the eyes and has the capability of measuring the thickness of the various layers of the retina and NFL.
282866|NCT02600403|Device|Diopsys Visual Evoked Potential (VEP)|Diopsys Visual Evoked Potential (VEP) is an imaging system that measures the electrical signal from the eye to the brain by using electrodes placed on the forehead and back of the head.
282867|NCT02600403|Device|Visual Field|Visual field testing is done to evaluate the extent of side vision loss a patient has with various diseases of the eye, including glaucoma.
282868|NCT02600416|Other|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
282869|NCT02600429|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
282870|NCT02600429|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
282871|NCT00191464|Drug|insulin glargine|
282872|NCT02600442|Other|non interventional study|
282873|NCT02600455|Drug|Orencia|
282874|NCT02600468|Drug|Orencia|
283169|NCT02595931|Other|Pharmacological Study|Correlative studies
283170|NCT02595944|Other|Laboratory Biomarker Analysis|Correlative studies
283171|NCT02595944|Biological|Nivolumab|Given IV
283172|NCT02595970|Drug|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52
283173|NCT02595983|Drug|Revusiran (ALN-TTRSC)|500mg Revusiran by subcutaneous (sc) injection
283174|NCT02595996|Drug|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
282310|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
282584|NCT02604589|Drug|bupivicaine 0.25%|Low Dose analgesia
282585|NCT02604589|Drug|bupivicaine 0.5%|High dose analgesia
282586|NCT02604602|Other|blood exam|laboratory test
282587|NCT02604615|Drug|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
282588|NCT02604615|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
282589|NCT00191893|Drug|teriparatide|
282590|NCT02604615|Radiation|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
282591|NCT02604628|Behavioral|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
282592|NCT02604641|Dietary Supplement|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
282593|NCT02604641|Dietary Supplement|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
282594|NCT02604641|Dietary Supplement|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
282595|NCT02604654|Drug|Yiqitongluo granule|administered after dissolved
282596|NCT02607007|Other|Water|
282597|NCT02607020|Other|Physical exercises in an self-management setting|Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:
1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session.
282598|NCT02607020|Other|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
282599|NCT02607033|Other|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
282020|NCT02579759|Drug|placebo|
282021|NCT02579772|Drug|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
282022|NCT02579772|Drug|Placebo|Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
282023|NCT00189033|Drug|rice wheat (placebo)|
282024|NCT02582021|Procedure|Coronary Angiography|A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).
The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography.
282025|NCT02582021|Procedure|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
282311|NCT02575326|Behavioral|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
282312|NCT02575339|Drug|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
282313|NCT02575339|Drug|MLN0128 (RP2D)|Phase II Arm A:
MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly.
282314|NCT02575339|Drug|Sorafenib|Phase II Arm B:
Sorafenib administered at 400mg PO BID daily
282315|NCT02575365|Drug|0,5 mg Fingolimod|Treatment will be 0.5 mg p.o fingolimod daily
282316|NCT02575378|Drug|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
282317|NCT02575378|Drug|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
282318|NCT00188266|Drug|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
282319|NCT02575391|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
282320|NCT02575404|Drug|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
282321|NCT02575404|Drug|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
282322|NCT02575417|Behavioral|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
281735|NCT02586363|Drug|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
281736|NCT02586376|Device|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
281737|NCT02586376|Device|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
281738|NCT00002514|Radiation|radiation therapy|
281739|NCT00189930|Biological|MVA-nef|3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm
281740|NCT02586376|Device|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
281741|NCT02586376|Device|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
281742|NCT02586402|Drug|pegol-Sihematide|
281743|NCT02586402|Drug|Epoetin Alfa|
281744|NCT02586415|Procedure|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
281745|NCT02588651|Drug|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
282026|NCT02582021|Procedure|Cardiac Magnetic Resonance Imaging|Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.
Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI.
282027|NCT02582021|Procedure|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
282028|NCT02582021|Procedure|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
282029|NCT02582021|Procedure|Rest-Stress Millar Testing|Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.
Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging.
282030|NCT02582021|Procedure|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
281428|NCT00190580|Drug|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
281429|NCT02591004|Drug|Nifedipine|*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
281430|NCT02591004|Radiation|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
281431|NCT02591017|Drug|Morphine|
281432|NCT02591017|Drug|Ketamine|
281433|NCT02591017|Drug|Placebo|
281434|NCT02591017|Drug|Chitosan|
281435|NCT02591030|Drug|GEMCIS|At D1 and D8 of each cycle, i.e. every 21 days for 6 months:
Cisplatin 25 mg/m² over 1 hour at D1 and D8
Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8.
281436|NCT02591030|Drug|mFolfirinox|At D1 of each cycle, i.e. every 15 days for 6 months:
Oxiplatin: 85 mg/m² (IP/120 minutes)
Irinotecan: 180 mg/m² (IV/90 minutes)
Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan
5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1
281437|NCT02591043|Procedure|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
281438|NCT02591056|Device|Erchonia Verju Laser + Green PRESS 8|There are 12 procedure administrations with the Erchonia® Verju™ Laser + Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration phase, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes front and 15 minutes back) followed by 30 minutes of procedure administration with the Green PRESS 8, for a total of 60 minutes of procedure administration time.
281439|NCT00190593|Drug|raloxifene|
281440|NCT02592811|Procedure|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
281441|NCT02592811|Device|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
281442|NCT02592811|Procedure|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
281785|NCT02592954|Drug|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
281786|NCT02592954|Drug|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
281787|NCT02592967|Biological|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU] ) and at a higher dose in Cohort 1B (1x10^9 CFU)
281788|NCT02592967|Biological|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
281789|NCT02592980|Genetic|Pharmacogenetic anticoagulation|
281790|NCT02592993|Device|PicoWayTM device|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
281791|NCT02593019|Drug|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date).
281792|NCT00190801|Drug|cisplatin|
281793|NCT02593032|Device|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
281794|NCT02593045|Biological|IPH4102|
281795|NCT02593058|Behavioral|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
282077|NCT02586467|Behavioral|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
282078|NCT02586467|Behavioral|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
282079|NCT00189943|Biological|MVA-BN|
281500|NCT02597647|Biological|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
281501|NCT02599714|Drug|Placebo to match palbociclib|In the case of a chosen palbociclib dose less than 125mg the triplet combination will include both palbociclib and matching palbociclib placebo to disguise the dose
281502|NCT02599727|Other|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
281503|NCT02599727|Other|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
281504|NCT02599740|Other|Natural fruit extract|Natural fruit extract consumed with rice
281505|NCT02599740|Other|Assumed active|Assumed key active consumed with rice
281506|NCT02599740|Other|Placebo|Rice only
281507|NCT00191425|Drug|Raloxifene|
281508|NCT02599753|Drug|18-FDTBZ|During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.
The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
281509|NCT02599766|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
281510|NCT02599766|Other|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
281511|NCT02599779|Drug|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
281512|NCT02599779|Radiation|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
281513|NCT02599792|Drug|CTP-656|
281514|NCT02599792|Drug|Placebo for CTP-656|
281515|NCT02599792|Drug|Kalydeco|
281796|NCT02593058|Behavioral|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
281797|NCT02593071|Biological|RSV-F Vaccine|
281194|NCT02602028|Drug|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
281195|NCT02602041|Other|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
281196|NCT02604134|Drug|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
281197|NCT02604147|Device|Simulated Inspiratory Muscle Training|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
281198|NCT02604147|Device|Inspiratory Muscle Training|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
281199|NCT00191828|Drug|olanzapine|
281200|NCT02604160|Drug|LY3113593|Administered by slow intravenous (IV) infusion.
281201|NCT02604160|Drug|Placebo|Administered by slow intravenous (IV) infusion.
281202|NCT02604173|Drug|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
281203|NCT02604173|Drug|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
281204|NCT02604173|Drug|Placebo|Placebo pill and sham inhaler
281205|NCT02604186|Other|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
281206|NCT02604186|Other|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
281207|NCT02604199|Drug|ARC-520 Injection|
281208|NCT02604199|Other|Placebo|
281209|NCT02604212|Drug|ARC-520|
281210|NCT00191841|Drug|gemcitabine|
280913|NCT02608736|Drug|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
280914|NCT02608736|Drug|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
280915|NCT02608749|Behavioral|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
280916|NCT02574728|Drug|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
280917|NCT02574741|Behavioral|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
280918|NCT02574741|Drug|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
280919|NCT02574741|Drug|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
280920|NCT02574754|Drug|warfarin|warfarin 7.5mg PO x 1
280921|NCT02574767|Behavioral|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet & Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
280922|NCT02574767|Dietary Supplement|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
280923|NCT02574767|Behavioral|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet & PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
280924|NCT02574767|Dietary Supplement|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
280925|NCT00188162|Device|CT|
280337|NCT00189800|Drug|Solifenacin succinate|
280338|NCT02585778|Drug|insulin|Pharmaceutical form:solution for injection Route of administration: subcutaneous
280339|NCT02585778|Drug|insulin|Pharmaceutical form:powder Route of administration: inhalation
280340|NCT02585778|Drug|statin|Pharmaceutical form:tablet Route of administration: oral
280636|NCT02579187|Drug|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
280637|NCT02579187|Other|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
280638|NCT02579187|Drug|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
280639|NCT00188968|Procedure|Synchronized Nasal Positive Pressure Ventilation|
280640|NCT02579187|Drug|miR-200C plasmids in a biodegradable sponge|subjects in the experimental group will receive a miR-200C plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
280641|NCT02579187|Procedure|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
280642|NCT02579200|Device|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual ~50% Pimax values.
280643|NCT02579200|Device|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
280644|NCT02581436|Other|Standard follow-up|Surveillance will be the usual, which includes creatinine determinations and clinical evaluation as often as established in the institutional protocol and according to the time period since the transplant. A kidney graft biopsy will be obtained in case of dysfunction (clinical suspicion of rejections: increase in serum creatinine >25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with the kidney biopsy results. In all cases of rejection in this group of patients, a kidney biopsy will be obtained one month after initiating treatment (as established in our institutional protocol to determine response to treatment). In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
280645|NCT02581449|Dietary Supplement|omega-3|dietary supplement
280646|NCT02581449|Other|empty soft gelatin capsules|empty softgels of matched size, shape and color
280042|NCT02592499|Other|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
280043|NCT02592512|Other|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
280044|NCT02592512|Other|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
280045|NCT02592525|Behavioral|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
280341|NCT02585778|Drug|lipid modifying therapy|Pharmaceutical form:tablet Route of administration: oral
280342|NCT02585791|Biological|PG|inhaled PG by vaporing
280343|NCT02585791|Biological|Vegetable oil-VG|inhaled VG by vaporing
280344|NCT02585791|Biological|PG+VG|inhaled PG+VG by vaporing
280345|NCT02585804|Drug|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
280346|NCT02585817|Device|Remote CIED Management|Information Technology
280347|NCT02585843|Drug|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
280348|NCT00189813|Drug|YM060|
280349|NCT02585843|Drug|Spironolactone 25mg|25mg/day of spironolactone
280350|NCT02585856|Device|PDT|Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.
PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length).
280351|NCT02587962|Drug|Pembrolizumab|200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
280352|NCT02587975|Drug|Evogliptin|10 mg
280353|NCT02587988|Drug|HCP1302|
279747|NCT02596958|Drug|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
279748|NCT02598999|Drug|bLF|Solution for inhalation administered through nebulization
279749|NCT02598999|Drug|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
279750|NCT02599012|Drug|Ferinject®|intravenous Ferinject 1000mg injection
279751|NCT02599025|Device|Innowalk cycling system|Innowalk is a unique, motorized medical device
279752|NCT02599025|Device|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
280046|NCT02592538|Device|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
280047|NCT02592538|Drug|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if <1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
280048|NCT02592538|Device|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
280049|NCT00190749|Drug|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
280050|NCT02592551|Drug|MEDI4736|
280051|NCT02592551|Drug|Tremelimumab|
280052|NCT02592564|Behavioral|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
280053|NCT02592577|Genetic|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
280054|NCT02592590|Behavioral|Group A|This condition receives three study components:
The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.
The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.
The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of "program points" is awarded. These are weighted by task difficulty, and accumulate to earn "levels". Levels accumulate to earn "badges" depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn "titles" (e.g., "expert exerciser").
279760|NCT02599090|Drug|Temozolomide|Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.
Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle.
279761|NCT02599090|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
279762|NCT02599090|Drug|Sorafenib|Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.
Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
279763|NCT02599103|Other|Fat-free milkshake|participants drinks a fat-free milk shakes
279764|NCT02599103|Other|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
279765|NCT00191347|Drug|pemetrexed|
279766|NCT02599103|Other|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
279767|NCT02599103|Other|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
279768|NCT02599103|Other|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
279769|NCT02599103|Other|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
279770|NCT02599103|Other|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
279771|NCT02599103|Other|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
279772|NCT02599103|Other|Tallow|participants drinks the milk shakes prepared from 60g of tallow
279773|NCT02601248|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
280058|NCT02594488|Device|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
280059|NCT02594501|Device|COBRA PzF|
280060|NCT02594501|Device|DES|
280061|NCT02594527|Other|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
280062|NCT00190970|Drug|Ruboxistaurin|
279472|NCT00202852|Drug|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
279473|NCT02705638|Drug|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
279474|NCT02705651|Drug|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
279475|NCT02707679|Other|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
279476|NCT02707679|Other|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
279477|NCT02707679|Other|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
279478|NCT02707679|Other|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
279479|NCT02707692|Biological|Fluarix|Intramuscular injection with Fluarix® .
279480|NCT02707692|Biological|Pneumovax|Intramuscular injection with Pneumovax.
279481|NCT02707692|Other|Placebo|Intramuscular injection with sterile saline (placebo).
279482|NCT00203047|Drug|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
279774|NCT02601261|Other|At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires|Some of these questionnaires will have to be completed every day and others every other day:
The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.
The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.
The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.
The short questionnaire on critical events occurring during the day,
The short questionnaire with obstetric anamnesis.
279775|NCT02601274|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
283737|NCT02582723|Other|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
283738|NCT02582723|Other|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
283739|NCT02582736|Drug|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
279178|NCT02711644|Behavioral|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
279179|NCT02711644|Behavioral|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
279180|NCT00203515|Device|Standard Latex Foley Catheter|
279181|NCT02711657|Other|Fibrocyte measurement and lung function test.|
279182|NCT02711670|Drug|chlorthalidone|
279183|NCT02711670|Drug|Hydrochlorothiazide|
279184|NCT02711683|Drug|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
279185|NCT02713568|Other|Magnetic resonance examination|MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.
Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031*Fetal Body Volume = MR imaging weight (g) developed by Baker.
General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.
For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99.
279186|NCT02713581|Biological|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
279187|NCT02713594|Behavioral|Counseling from WTQL|WTQL coaching and encouragement to see their health care provider to obtain Medicaid-approved medications to help them quit
279188|NCT02713594|Other|Financial incentive to participate|Financial incentive provided for participation in WTQL coaching and for achieving biochemically-confirmed abstinence at the 6 month time point
279189|NCT02713607|Drug|Doxycycline|Given doxycycline to acne subjects
279190|NCT02713620|Biological|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
283440|NCT02589470|Other|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
283441|NCT00190424|Drug|CpG-ODN|
283442|NCT02589483|Procedure|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
283443|NCT02589483|Device|Hemopatch|The rectal anastomosis reinforced with Hemopatch
283444|NCT02589496|Drug|pembrolizumab|200 mg every 3 weeks
283445|NCT02589509|Behavioral|Direct-attention training using web-based BrainHQ|BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: "Divided attention," "Target tracker," "Double Decision," "Mixed Signals," and "Freeze Frame."
283446|NCT02589509|Behavioral|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
283447|NCT02589522|Drug|ATR Kinase Inhibitor VX-970|Given IV
283448|NCT02589522|Other|Laboratory Biomarker Analysis|Correlative studies
283449|NCT02589522|Other|Pharmacological Study|Correlative studies
283740|NCT00189488|Drug|Palifermin|Administered as an intravenous (IV) bolus.
283741|NCT02582736|Drug|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
283742|NCT02582736|Drug|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
283743|NCT02584751|Procedure|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometer, and max inspiration/expiration pressures.
283744|NCT02584751|Procedure|Exhaled Nitric Oxide|
283745|NCT02584751|Procedure|Exhaled Breath Moisture|
283746|NCT02584751|Procedure|Bernstein's Acid Clearance Test|
283747|NCT02584764|Behavioral|Cognitive behavior therapy|
283748|NCT02584764|Behavioral|Internet support|
283749|NCT02584777|Biological|Pacritinib|QD (Once a day)
283175|NCT02596009|Device|Breezhaler®|No active drug or placebo will be administered to patients during this study. Each patient will be required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient is required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
283176|NCT02596009|Device|Ellipta®|No active drug or placebo will be administered to patients during this study. Each patient will be required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient is required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
283177|NCT02596009|Device|Handihaler®|No active drug or placebo will be administered to patients during this study. Each patient will be required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient is required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
283178|NCT00191113|Drug|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
283179|NCT02596022|Drug|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
283180|NCT02596022|Drug|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
283181|NCT02596035|Drug|Nivolumab|
283182|NCT02596048|Other|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
283183|NCT02596061|Behavioral|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
283184|NCT02596061|Other|Incentives|Patients receive incentives for completing smoking cessation activities.
283185|NCT02596074|Drug|Omiganan (CLS001) topical gel|
283186|NCT02596074|Drug|Vehicle topical gel|
283450|NCT02589522|Other|Quality-of-Life Assessment|Ancillary studies
283451|NCT02589522|Procedure|Therapeutic Conventional Surgery|Undergo surgery
283452|NCT00190437|Drug|Amoxicillin-clavulanic|Amoxicillin-clavulanic
283453|NCT02589522|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
283454|NCT02589561|Procedure|Remote fitting|remote fitting of hearing aids
283455|NCT02589561|Procedure|Face to face fitting|face to face fitting of hearing aids
282600|NCT02607033|Other|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
282601|NCT00192127|Other|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
282602|NCT02607046|Other|Exercise training|The exercise program includes supervised treadmill walking and home-based walking exercise.
282875|NCT02600481|Procedure|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
282876|NCT02600481|Procedure|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
282877|NCT02600494|Drug|ITI-007|
282878|NCT02600494|Drug|Placebo|
282879|NCT02600507|Drug|ITI-007|
282880|NCT02600507|Drug|Placebo|
282881|NCT02600520|Drug|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
282882|NCT00191464|Drug|metformin|
282883|NCT02600520|Drug|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
282884|NCT02600520|Drug|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
282885|NCT02602522|Drug|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
282886|NCT02602535|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
282887|NCT02602535|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
282888|NCT02602548|Other|Culture|Specimens will be obtained and sent to the lab for cultures.
282889|NCT02602561|Dietary Supplement|HMB|
282890|NCT02602561|Dietary Supplement|Placebo|
282891|NCT00191672|Drug|Docetaxel|
282323|NCT02575430|Other|No treatment: retrospective chart review|
282324|NCT02575443|Drug|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
282325|NCT02575443|Drug|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
282326|NCT02575456|Biological|Ebola Vaccine|
282327|NCT02575456|Biological|Placebo|control
282328|NCT02575482|Drug|SUVN-D4010|
282329|NCT00188279|Procedure|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
282330|NCT02575482|Drug|Placebo|
282603|NCT02607046|Other|NMES|This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
282604|NCT02607059|Other|Registry|
282605|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
282606|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
282607|NCT02607072|Drug|Placebo|
282608|NCT02607111|Drug|Dalteparin|
282609|NCT02607124|Drug|Ribociclib|
282610|NCT02607137|Behavioral|Health Education|Information on healthy living style in relation to physical activity
282611|NCT02607150|Other|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
282612|NCT00002519|Radiation|radiation therapy|
282613|NCT00192140|Biological|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
282614|NCT02607163|Drug|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
282615|NCT02607163|Drug|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
282616|NCT02607176|Drug|Heweizhixie capsule|3 #, Tid, Oral for 3 days
282031|NCT02582034|Radiation|Optimized Internal Radiation Therapy|Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).
Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:
An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy
A dose at the treated healthy liver < 120 Gy in case of lobar treatment
Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve > 30%
A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments.
282032|NCT02582034|Radiation|Standard Internal Radiation Therapy|Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:
An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)
A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments.
282033|NCT00189384|Drug|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
282034|NCT02582047|Biological|Influenza vaccination with PPV23|GCflu and Pneumovax-23
282035|NCT02582047|Biological|Influenza vaccination with PCV13|GCflu and Prevenar-13
282036|NCT02582060|Other|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
282037|NCT02582073|Biological|Placebo (0.5ml)|
282038|NCT02582073|Biological|Placebo (1.0ml)|
282039|NCT02582073|Biological|Grass MATA MPL (0.5ml) 5100SU|
282040|NCT02582073|Biological|Grass MATA MPL (1.0ml) 10200SU|
282041|NCT02582073|Biological|Grass MATA MPL (1.0ml) 18200SU|
282331|NCT02577484|Device|RXi System|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.
The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics.
282332|NCT02577484|Device|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
282333|NCT00188656|Procedure|CT thorax|
282334|NCT02577497|Drug|beclomethasone|
282335|NCT02577497|Drug|fluticasone|
281746|NCT02588664|Other|COMPASS Intervention|A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.
Patient will receive a follow-up telephone call two days after having been discharged.
7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.
Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services.
281747|NCT02588677|Drug|Masitinib (AB1010)|4.5 mg/kg/day, 3 mg/kg/day
281748|NCT02588677|Drug|Riluzole|50 mg
281749|NCT02588677|Drug|Placebo|
281750|NCT02588690|Procedure|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
281751|NCT02588690|Other|Atherosclerosis Cardiovascular Disease Risk assessment|This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol <190 mg/dL.
The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status.
281752|NCT02588690|Procedure|Blood pressure measurement|Blood pressure measurement
281753|NCT02588703|Behavioral|Cognitive Behavioral Therapy|Coping Skills Treatment
281754|NCT02588703|Behavioral|Usual Care|Existing DUI program group counseling
281755|NCT00190307|Drug|aspirin 75 mg/day|aspirin 75 mg/day
281756|NCT02588716|Drug|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 50ml of NaCl over 30 mins, then 2mg in 50ml of NaCl infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.
281757|NCT02588716|Drug|normal saline|50ml of normal saline over 30 mins, then 50ml of normal saline infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.
281758|NCT02588729|Other|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
281759|NCT02588742|Dietary Supplement|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
281760|NCT02588742|Dietary Supplement|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
281761|NCT02588755|Procedure|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
282080|NCT02588781|Drug|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
282081|NCT02588794|Device|CytoSorb 300 ml device (3804606CE01)|additional cytokine adsorber
282082|NCT00190320|Procedure|Induction of labor vs waiting|
282083|NCT02588807|Drug|Spirit1|
282084|NCT02588820|Drug|Antiretroviral Therapy (Experimental)|Initial ART until HLA-B5701 results became available (48 hours):
Tenofovir 245 mg once a day
Emtricitabine 200 mg once a day
Dolutegravir 50 mg once a day
Darunavir 800 mg once a day
Ritonavir 100 mg once a day
Maraviroc 150 mg twice a day
Three months continuation treatment (after HLA-B5701 confirmed as negative):
Dolutegravir 50 mg once a day.
Abacavir 600 mg once a day
Lamivudine 300 mg once a day
Darunavir 800 mg once a day
Ritonavir 100 mg once a day
Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.
Nine months continuation treatment (till complete 12 months treatment):
Abacavir, 600mg once a day
Lamivudine, 300 mg once a day
Dolutegravir, 50 mg once a day
282085|NCT02588833|Drug|APL-2|
282086|NCT02588846|Device|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
282087|NCT02588872|Biological|Platelet-rich Plasma (PRP)|
282088|NCT02588872|Biological|Hyaluronic Acid|
282089|NCT02588885|Behavioral|Trauma-sensitive Care|Psychological intervention
education
empowerment
desensitization
relaxation tools
Physical therapy intervention
techniques to address muscular tension
empowerment
comfort
encouragement of trauma-related coping skills
282090|NCT02588898|Device|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
282091|NCT02588911|Procedure|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
282092|NCT02588911|Procedure|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
282387|NCT02582177|Drug|Ketoconazole + betamethasone dipropionate|Apply on the affected area and around it twice a day
282388|NCT00189410|Drug|Pegylated Liposomal Doxorubicin and Carboplatin|
282389|NCT02582177|Drug|Clotrimazole + Dexamethasone acetate|Apply on the affected area and around it twice a day
282390|NCT02582190|Drug|Colchicine group|antiarrhythmic therapy plus colchicine & antiarrhythmic therapy alone.
281798|NCT02593071|Biological|Phosphate Buffer Placebo|
281799|NCT02593084|Behavioral|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
281800|NCT02595346|Drug|Hydroxychloroquine|endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.
glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.
oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
281801|NCT02595346|Drug|placebo|endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.
glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.
oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
281802|NCT02595359|Drug|Moxifloxacin|Moxifloxacin intracameral
281803|NCT02595372|Drug|Omeprazole|
281804|NCT02595385|Device|Cell Salvage|Reinfusion of shed blood during the operation
281805|NCT02595385|Procedure|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
281806|NCT02595398|Drug|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 4 mg in 100 microliters, will be administered as a single injection at 2 timepoints
281807|NCT00191048|Drug|Atomoxetine|
281808|NCT02595398|Drug|Sham Procedure|Sham procedure will be administered at 2 timepoints
281809|NCT02595424|Drug|Capecitabine|Given IV
281810|NCT02595424|Drug|Cisplatin|Given PO
281811|NCT02595424|Drug|Etoposide|Given PO
281812|NCT02595424|Other|Laboratory Biomarker Analysis|Correlative studies
281813|NCT02595424|Drug|Temozolomide|Given IV
281814|NCT02595437|Drug|Triferic|
281815|NCT02595450|Drug|Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
282093|NCT00190333|Drug|escitalopram|escitalopram
281516|NCT02599805|Device|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
281517|NCT02599818|Behavioral|Patient Navigation|Proactive motivational intervention and barrier resolution services
281518|NCT00191438|Drug|gemcitabine|
281519|NCT02599831|Device|G6805-2 Multi-Purpose Health Device|Electrical pudendal nerve stimulation. Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
281520|NCT02599831|Device|AM1000B (Shenzhen Creative Industry Co.Ltd, China)|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
281521|NCT02599831|Device|PHENIX USB 4 (Transanal ES)|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
281522|NCT00191620|Drug|cisplatin|
281523|NCT02602054|Procedure|Surgical treatment|Standard left thoracotomy
281524|NCT02602054|Drug|Control group|- Indomethacin:
Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:
Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:
Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:
First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg
- Acetaminophen
Administer 1 full cycle, in the first fourteen days of life in preterm infants:
Acetaminophen 15 mg/kg every 6 hours for 3 days
281525|NCT02602067|Radiation|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
281526|NCT02602093|Procedure|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
281527|NCT02602093|Procedure|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
280926|NCT02574780|Other|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
281211|NCT02604212|Other|Placebo|
281212|NCT02604225|Drug|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
281213|NCT02604225|Drug|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
281214|NCT02604238|Drug|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc [LMWH], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing <50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
281215|NCT02604251|Device|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
281216|NCT02604251|Device|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
281217|NCT00192075|Drug|avastin|5 milligrams per kilogram (mg/kg)
281218|NCT02606292|Procedure|Endoscopic ultrasound (standard of care)|
281219|NCT02606292|Procedure|Endoscopic surgery (standard of care)|
281220|NCT02606305|Drug|IMGN853|
281221|NCT02606305|Drug|Bevacizumab|
281222|NCT02606305|Drug|Carboplatin|
281223|NCT02606305|Drug|Doxorubicin|
281224|NCT02606318|Other|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
281225|NCT02606318|Other|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
281226|NCT02606331|Procedure|Piezosurgery|Corticotomy cuts will be performed by this technique.
280647|NCT02581462|Drug|FLOT alone|Pre-operative therapy:
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43
Surgery is recommended to be scheduled 4 weeks after d43.
Post-operative therapy (start 6 to 8 weeks after surgery):
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43
280648|NCT02581462|Biological|FLOT + Herceptin/Pertuzumab|Pre-operative therapy:
Herceptin 8/6 mg/kg, d1, d22, d43
Pertuzumab 840 mg, d1, d22, d43
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43
Surgery is recommended to be scheduled 4 weeks after d43.
Post-operative therapy (start 6 to 8 weeks after surgery):
Herceptin 8/6 mg/kg, d1, d22, d43
Pertuzumab 840 mg, d1, d22, d43
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43.
280649|NCT02581475|Procedure|Routine examination|
280927|NCT02574780|Other|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
280928|NCT02574793|Device|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
280929|NCT02574806|Procedure|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
280930|NCT02574819|Drug|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
280931|NCT02574819|Drug|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
280932|NCT02574832|Drug|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
280933|NCT02574845|Drug|Rosuvastatin|
280934|NCT02574845|Drug|Metformin HCl|
280935|NCT02574845|Drug|Furosemide|
280936|NCT02577016|Drug|Placebo|Placebo to sitagliptin
280937|NCT02577016|Drug|Ipragliflozin|Background medication
280938|NCT02577029|Drug|ARC-520|
280939|NCT02577029|Drug|Entecavir|
280940|NCT02577029|Biological|Pegylated Interferon alpha 2a|
280354|NCT02587988|Drug|HGP0904|
280355|NCT02587988|Drug|Placebo (for HCP1302)|
280356|NCT02587988|Drug|Placebo (for HGP0904)|
280357|NCT00190203|Procedure|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
280358|NCT02588001|Drug|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
280359|NCT02588014|Other|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
280650|NCT00189293|Drug|Imiquimod|Imiquimod 5% cream three times per week for 4 weeks (1 sachet)
1 or 2 sachet(s)
280651|NCT02581475|Procedure|Extending withdrawal time in the proximal colon|
280652|NCT02581475|Procedure|Segmental examination twice of the proximal colon|
280653|NCT02581488|Biological|Santyl|
280654|NCT02581488|Other|Product containing silver|Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
280655|NCT02581501|Drug|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
280656|NCT02581514|Other|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
280657|NCT02581527|Drug|Rifampicin 1200mg|4FDC + additional rifampicin tablets to = 1200mg
280658|NCT02581527|Drug|Rifampicin 1800mg|4FDC + additional rifampicin tablets to = 1800mg
280659|NCT02581527|Drug|4FDC|Standard Fixed dose combination
280660|NCT02581553|Drug|lesinurad/allopurinol 200/300 FDC tablets|
280661|NCT00189293|Other|vehicle cream|vehicle cream three times per week for 4 weeks (1 sachet)
1 or 2 sachet(s)
280662|NCT02581553|Drug|lesinurad 200 mg|
280055|NCT02594449|Drug|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
280056|NCT02594462|Drug|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
280057|NCT02594475|Procedure|Endoscopic retrograde cholangiopancreatography|Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.
Selective bile duct cannulation is performed using wire-guided cannulation.
In case of difficult cannulation, precut is performed using a needle-knife.
After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed.
280360|NCT02588027|Drug|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
280361|NCT02588027|Drug|Placebo|Pharmacy formulated placebo
280362|NCT02588040|Biological|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
280363|NCT02588066|Procedure|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
280364|NCT02588079|Behavioral|Internet-based cognitive behavioral therapy|
280365|NCT02588092|Drug|ADCT-301|intravenous infusion
280366|NCT02588105|Drug|AZD0156|All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
280367|NCT02588105|Drug|Olaparib|Module 1 combination with orlaparib
280368|NCT00190203|Procedure|hemicraniectomy|hemicraniectomy
280369|NCT02588118|Drug|propofol|Propofol 3 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 2 min (t2). Patients will be monitored using bispectral index monitoring for propofol and TOF-Watch neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
280063|NCT02594540|Device|Mechanical Peripheral Stimulation (GONDOLA)|
280064|NCT02594553|Behavioral|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
280065|NCT02594566|Drug|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
280066|NCT02594579|Drug|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
280067|NCT02594579|Drug|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
280068|NCT02594592|Other|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
280069|NCT02594605|Device|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
280070|NCT02594605|Device|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
280071|NCT02594631|Procedure|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
280072|NCT02594631|Procedure|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
280073|NCT00190983|Drug|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
280074|NCT02596971|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|MPDL-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. MPDL-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6/8, during induction treatment, followed by 1200 mg IV on Days 1 and 2 of each month, starting with Month 1 (in safety run-in) and 1200 mg IV on Day 1 of Cycles 9-25 (in expansion), during consolidation treatment.
280075|NCT02596971|Drug|Bendamustine|MPDL-G-Benda: Bendamustine 90 milligrams per square meter (mg/m^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
280376|NCT02590601|Drug|Bromocriptine|
280377|NCT02590601|Other|Guideline-driven medical therapy (GDMT)|
280378|NCT02590614|Dietary Supplement|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
280379|NCT00190554|Drug|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
279776|NCT02601287|Biological|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
279777|NCT02601300|Drug|GED-0301|
279778|NCT02601313|Biological|KTE-C19|
279779|NCT00191555|Drug|haloperidol|
279780|NCT02601326|Procedure|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
279781|NCT02601326|Procedure|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
279782|NCT02601339|Procedure|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
279783|NCT02601339|Procedure|VP shunt|ventriculoperitoneal (VP) shunting is a surgical procedure to treat infant hydrocephalus
279784|NCT02601365|Drug|inhaled GM-CSF (sargramostim)|GM-CSF will be administered over 4h via a nebulizer
279785|NCT02601378|Drug|LXS196|
279786|NCT02601391|Behavioral|Adapting STEPPS within forensic inpatient services.|
279787|NCT02601404|Device|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
279788|NCT02601417|Other|Ignoring result of bile culture|Patients in the trial arm will do bile cultures which will not be considered when choosing antibiotics.
279789|NCT02601430|Other|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
279790|NCT00191568|Drug|Gemcitabine|
279791|NCT02601443|Device|Cervical Pessary|
279792|NCT02601469|Drug|DSXS|twice daily for 28 days
279793|NCT02601482|Behavioral|CON|
279794|NCT02601482|Behavioral|IW-60|
280076|NCT02596971|Drug|Cyclophosphamide|MPDL-G-CHOP: Cyclophosphamide 750 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
280077|NCT02596971|Drug|Doxorubicin|MPDL-G-CHOP: Doxorubicin 50 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
279191|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
279192|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
279483|NCT02707705|Device|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|Intervention Description :
The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.
Data collected :
T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency
T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects
T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects
T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects
279484|NCT02707705|Device|Apply a device having no real effect|The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.
Data collected :
T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency
T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects
T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects
T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects
279485|NCT02707705|Procedure|Disinfection|The ear is disinfected by applying Chlorhexidine®.
279486|NCT02707718|Biological|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
279487|NCT02707731|Procedure|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
279488|NCT02707744|Other|no intervention|
279489|NCT02709746|Drug|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
279490|NCT02709746|Drug|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
279491|NCT02709746|Other|Placebo|Encapsulated tablet
279492|NCT00203281|Drug|daclizumab|
279493|NCT02709759|Behavioral|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
283750|NCT02584790|Device|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
283751|NCT00189670|Procedure|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
283752|NCT02584803|Radiation|Ultrasound|Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.
Patient Acceptability of procedure
Patient Comfort:
Ease of exam for the examiner
283753|NCT02584816|Biological|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
283754|NCT02584816|Biological|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
283755|NCT02584816|Biological|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
283756|NCT02584816|Biological|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
283757|NCT02584829|Drug|Avelumab|Given IV
283758|NCT02584829|Other|Laboratory Biomarker Analysis|Correlative studies
283759|NCT02584829|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
283760|NCT02584829|Radiation|Radiation Therapy|Undergo radiation therapy
283761|NCT02584829|Biological|Recombinant Interferon Beta|Given via intra-tumor injection
279193|NCT02713659|Behavioral|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
279194|NCT02713659|Behavioral|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
279195|NCT00203775|Drug|risperidone|
279196|NCT02713672|Other|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
279197|NCT02713685|Procedure|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
279198|NCT02713685|Procedure|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
283456|NCT02591667|Procedure|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
283457|NCT02591680|Other|Neuromuscular training|
283458|NCT02591680|Other|Muscle strengthening|
283459|NCT02591680|Device|Sensorimotor|
283460|NCT02591693|Behavioral|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
283461|NCT02591706|Device|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
283462|NCT00190645|Drug|Duloxetine|
283463|NCT02591719|Device|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
283464|NCT02591719|Device|MagPro magnetic stimulator (sham)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
283465|NCT02591719|Device|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS findings: Contralesional homologs of Broca's area.
Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
283466|NCT02591745|Procedure|Fetal intervention|Type of fetal conditions requiring intervention and medications administered to fetuses undergoing varying types of fetal intervention will be documeted in this database.
283762|NCT00189670|Procedure|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
283763|NCT02584855|Drug|Ixekizumab|Administered SC
283764|NCT02584855|Drug|Placebo|Administered SC
283765|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
282892|NCT02602574|Other|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
282893|NCT02602587|Biological|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
282894|NCT02602587|Biological|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
282895|NCT02602600|Drug|Liraglutide|Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.
Weight maintenance diet for 2 weeks
282896|NCT02602613|Device|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
283187|NCT02596087|Other|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
283188|NCT02596100|Drug|Betrixaban|
283189|NCT02598219|Drug|Intra-operative SN mapping with patent V blue dye|Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.
Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.
SN are detected by direct visualization of blue colored lymphatics and node
283190|NCT02598219|Drug|Intra-operative SN mapping with indocyanin green|1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.
2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible
3- SN detection by near-infrared fluorescence imaging
283191|NCT02598219|Procedure|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)
Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)
Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)
283192|NCT02598219|Procedure|Current initial staging protocols|Current French initial staging protocols
283193|NCT02598232|Device|1,414nm Nd:YAG Laser System|The intervention is an ACCUPLASTI which is an 1,414 nm Nd:YAG interstitial fiber laser.
283194|NCT02598245|Device|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
283195|NCT00191282|Drug|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
282617|NCT02607202|Drug|nab-paclitaxel|
282618|NCT02607202|Drug|Carboplatin|
282619|NCT02609191|Device|First whole body exam using the "Stratos DR"|First whole body exam using the "Stratos DR" machine made by the DMS group.
282620|NCT02609191|Device|Second whole body exam using the "Stratos DR"|Second whole body exam using the "Stratos DR" machine made by the DMS group. This second exam is required for reproducibility purposes.
282621|NCT02609204|Device|Diopsys NOVA|Every participant will have both eyes tested by the Diopsys NOVA machine using the Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
282622|NCT02609217|Other|Questionnaires and interviews|
282623|NCT02609230|Drug|ONC-201|
282624|NCT02609243|Behavioral|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
282625|NCT00192387|Biological|CAIV-T, Liquid|
282897|NCT02602639|Device|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
282898|NCT02602652|Biological|a live attenuated chimeric JE vaccine|The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.
At the second visit (D28), blood samples were collected for evaluate the immunogenicity.
282899|NCT02602665|Procedure|central line placement with high and low catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina, for deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
282900|NCT02602678|Procedure|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
282901|NCT02602678|Procedure|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
282902|NCT00191685|Drug|duloxetine|
282903|NCT02602691|Other|AlloMap®|
282904|NCT02602691|Procedure|Endomyocardial biopsies|
282336|NCT02577510|Drug|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament [7]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic [7]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
282337|NCT02577510|Drug|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle [6]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
282338|NCT02577523|Drug|ND0612 (Levodopa/Carbidopa solution)|
282339|NCT02577536|Other|No Interventions|No Interventions will be conducted under this study.
282340|NCT02577549|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
282341|NCT02577549|Behavioral|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
282342|NCT02577562|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
282343|NCT02577575|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
282344|NCT00188669|Drug|pentoxifylline|
282345|NCT02577575|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
282346|NCT02577588|Biological|re-activated T cells|autologous reactivated T cells against p53
282347|NCT02577601|Drug|Ulipristal Acetate|
282626|NCT02609256|Procedure|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
282627|NCT02609256|Other|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
281762|NCT02588755|Procedure|TACE|TACE alone
282042|NCT02584140|Behavioral|Text Messaging/Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of <1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of <1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
282043|NCT02584153|Drug|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
282044|NCT00189605|Drug|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
282045|NCT02584153|Drug|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
282046|NCT02584166|Behavioral|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
282047|NCT02584179|Device|Biparametric MRI before biopsy|ALL subjects will have a Biparametric MRI before biopsy
282048|NCT02584192|Behavioral|entailing an early home-based CR program|enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
282049|NCT02584192|Other|enter the usual care program|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
282050|NCT02584205|Device|Powerbreathe|In this intervention we will use an equipment called "powerbreathe classic light". It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea.
282051|NCT02584218|Procedure|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
282052|NCT02584218|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
282053|NCT02584231|Drug|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: >6 months and < 2years: 60µg; ≥2 years and <4 years: 120µg PO and ≥4 years and <8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
282054|NCT02584244|Drug|LUM015|
282055|NCT00189618|Drug|Aspirin|100mg p.o. OD
282056|NCT02584244|Device|LUM 2.6 Imaging Device|
282391|NCT02582203|Drug|Ceftaroline|
282392|NCT02582203|Drug|Vancomycin|
282393|NCT02582216|Device|3D augmented reality|
282394|NCT02582229|Device|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
282395|NCT02582242|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
282396|NCT02584270|Device|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis improves speech and swallowing function through reshaping the palatal contours in order to obtain contact of the tongue to the hard palate during function. It is intended to be fabricated after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.
282397|NCT02584270|Other|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
282398|NCT02584283|Procedure|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
282399|NCT00189618|Drug|Clopidogrel|75mg p.o. OD
282400|NCT02584283|Device|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
282401|NCT02584283|Procedure|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
282402|NCT02584283|Drug|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
282403|NCT02584296|Behavioral|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, ~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
282404|NCT02584309|Drug|Dexrazoxane|
282676|NCT02577731|Other|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
282094|NCT02588924|Other|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
282095|NCT02588924|Other|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
282096|NCT02588937|Drug|EntecaBell ODT. 0.5mg|
282097|NCT02588937|Drug|Baraclude Tab. 0.5mg|
282098|NCT02588950|Drug|U-500R|Administered SC
282099|NCT02588963|Other|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
282100|NCT02591212|Behavioral|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
282101|NCT02591212|Behavioral|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
282102|NCT02591212|Behavioral|Green Dot Enhanced|Green Dot Intensive Bystander Training AND Substance Abuse Prevention cross-programming. In-depth information related to interpersonal violence and substance use/abuse, activities to help participants explore their connection to these issues; information and activities related to the culture of violence, drinking and drug use and how everyone has a role in impacting that culture; information about bystanding and barriers to taking action when they encounter problem situations; participant self-evaluation of their own attitudes, beliefs and biases around these issues; in-depth skill building activities to prepare participants to safely intervene in problem situations.
282103|NCT00190606|Drug|Duloxetine|
282104|NCT02591225|Drug|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
282105|NCT02591225|Drug|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
282106|NCT02591238|Other|non-smoker oral placebo|Participants oral placebo last 2 weeks.
282107|NCT02591238|Drug|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
281816|NCT02595463|Drug|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
281817|NCT02595463|Drug|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
281818|NCT00191061|Drug|duloxetine hydrochloride|
281819|NCT02595476|Drug|Remifentanil|
281820|NCT02595476|Drug|propofol|
281821|NCT02595476|Device|TCI|
281822|NCT02595476|Procedure|Tetanic stimulation|
281823|NCT02595476|Device|Algiscan|Pupillometry
281824|NCT02595489|Dietary Supplement|vitamin D3|Daily oral supplement provided by study investigators
281825|NCT02595502|Device|Vistakon Marketed Contact Lens (Test)|
281826|NCT02595502|Device|Competitor Marketed Contact Lens (Control)|
281827|NCT02595515|Other|Chiropractic treatment|Procedure: chiropractic treatment.
281828|NCT02597647|Other|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
281829|NCT00191243|Drug|Gemcitabine|A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression
B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure
281830|NCT02597660|Drug|Somatropin|Active drug
281831|NCT02597660|Drug|Bacteriostatic saline|Placebo, the diluent used to reconstitute somatropin
281832|NCT02597660|Other|Progressive exercise program|Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Patients will perform three weekly sessions at the University of Michigan Health System MedSport clinic. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
281833|NCT02597660|Procedure|Patellar tendon biopsy|Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
281227|NCT02606331|Radiation|ER:YAG laser|Corticotomy cuts will be performed by this technique.
281228|NCT00192075|Drug|5FU/folinic acid|Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).
Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).
5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).
281229|NCT02606344|Other|Mico-finance based intervention|
281528|NCT02602106|Behavioral|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
281529|NCT02602119|Drug|OTL38|Infusion of OTL38 prior to surgery
281530|NCT02602132|Procedure|Clamping|To clamp before the removal of short-term indwelling urethral catheters
281531|NCT02602145|Other|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a standard post-operative contrast-enhanced CTA of the lower extremities at 6 months after stenting.
281532|NCT02602158|Other|13C Octanoic acid (Cambridge isotope laboratories)|13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm
Optional study pending interim analysis:
Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm
281533|NCT00191633|Drug|Atomoxetine|
281534|NCT02602158|Other|13C Trioctanoin (Cambridge isotope laboratories)|13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability
Lipid emulsion 1: acid stable, particle size 0.6 µm
Optional study pending interim analysis:
Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm
281535|NCT02602171|Other|Oldenburger sentence test, localization test|
281536|NCT02602184|Drug|AR/101|
281537|NCT02602184|Drug|Placebo|
281538|NCT02604264|Device|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
281539|NCT02604277|Behavioral|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
280941|NCT02577042|Drug|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
280942|NCT00188565|Drug|Celecoxib|
280943|NCT02577042|Drug|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
280944|NCT02577042|Drug|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
280945|NCT02577055|Procedure|Poly-myomectomy|Surgical ablation of all fibroids
280946|NCT02577055|Procedure|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of >500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
280947|NCT02577068|Drug|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
281230|NCT02606357|Drug|INSULIN GLARGINE|Pharmaceutical form:Solution
Route of administration: Subcutaneous
281231|NCT02606370|Other|Unstable shoe|Wearing Unstable shoes during 1 month
281232|NCT02606383|Drug|Dapaconazole|
281233|NCT02606383|Drug|Ketoconazole|
281234|NCT02606396|Procedure|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
281235|NCT02606396|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
281236|NCT02606396|Procedure|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
281237|NCT02606409|Drug|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
281238|NCT02606409|Drug|Propofol|Propofol sedation at a starting dose of 10-50 µg/kg/hour.
281239|NCT00192075|Drug|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
281240|NCT02608749|Behavioral|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
280663|NCT02583555|Behavioral|Interview followed by frequent telephone support|Interview followed by telephone support
280664|NCT02583568|Drug|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
280665|NCT02583581|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
280666|NCT02583581|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
280667|NCT02583594|Drug|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
280668|NCT02583594|Drug|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
280669|NCT00189553|Drug|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
280670|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
280948|NCT02577068|Drug|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
280949|NCT02577081|Other|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
280950|NCT02577094|Drug|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
280951|NCT02577094|Drug|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
280952|NCT02577094|Biological|allogeneic stem cell transplantation.|At Day 0
280953|NCT00188578|Procedure|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
280954|NCT02577094|Drug|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
280955|NCT02577094|Biological|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
280956|NCT02577107|Drug|ranibizumab|This prospective, randomized, open label study will enroll patients with neovascular AMD who are naïve to anti-VEGF therapy or have not received intravitreal anti-VEGF therapy for the previous 3 months.
Monthly injections of 0.5mg Ranibizumab during 3 month Blood sample (plasma/serum) will be collected at baseline (pre-dose), 3h post-injections and days 1, 3, 7 and 28, following doses 1 and 3 for PK and systemic VEGF analysis. The lab staff will be blinded for treatment allocation.
Plasma VEGF concentration will be measured by a blinded laboratory using Quantikine® ELISA kits. Serum ranibizumab concentration will be determined using validated ELISA assay.
280370|NCT02588118|Drug|Cisatracurium|Propofol 3 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 2 min (t2). Patients will be monitored using bispectral index monitoring for propofol and TOF-Watch neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
280371|NCT02590549|Procedure|Corneal Collagen Crosslinking|Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.
Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.
After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,
280372|NCT02590549|Device|Ufalink|UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
280373|NCT02590562|Other|Routine clinical practice|
280374|NCT02590575|Device|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows
Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value
280375|NCT02590588|Drug|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
280671|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
280672|NCT02583594|Drug|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
280673|NCT02583594|Drug|Loratadine|Pharmaceutical form:tablet Route of administration: oral
280674|NCT02583594|Drug|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
280675|NCT02583594|Drug|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
280676|NCT02583607|Device|Brava|The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.
woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it.
280677|NCT02583620|Genetic|blood sample|A blood test is realized on the subject
280678|NCT02583633|Drug|Transdermal nitroglycerin|
280679|NCT02583633|Drug|nifedipine|
280680|NCT00002514|Drug|vincristine sulfate|
280681|NCT00189566|Drug|Paclitaxel|
280682|NCT02583672|Drug|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
280380|NCT02590614|Dietary Supplement|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
280381|NCT02590627|Drug|Artemether-lumefantrine|Artemether-lumefantrine
280382|NCT02590627|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
280383|NCT02590640|Device|Repetitive transcranial magnetic stimulation, MagStim Rapid2|
280384|NCT02590640|Device|Sham repetitive transcranial magnetic stimulation|
280385|NCT02590653|Drug|Atorvastatin|Lipid-lowering therapy
280386|NCT02590666|Procedure|Bipolar Polypectomy|Polyps resection with bipolar electrode
280387|NCT02590666|Procedure|Mechanical Polypectomy|Polyps resection with microscissors or graspers
280388|NCT02590666|Device|Bipolar electrode|Bipolar electrode used to performs polypectomy
280389|NCT02590666|Device|Microscissors or graspers|Mechanical instruments used to performs polypectomy
280390|NCT00190554|Drug|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
280391|NCT02590679|Device|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
280392|NCT02590692|Biological|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
280393|NCT02590705|Drug|Lidocaine|surface anesthesia with lidocaine
280394|NCT02590718|Procedure|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
280395|NCT02592590|Behavioral|Group B|This condition receives two study components:
The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.
The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.
280691|NCT02585869|Drug|Placebo|Blinded capsule and tablets, once daily, 84 days
280692|NCT02585882|Other|Fluoride table salt|
280693|NCT02585895|Biological|evolocumab (AMG 145)|Administered by subcutaneous injection
280694|NCT00189826|Drug|tacrolimus|immunosuppression
280078|NCT02596971|Drug|Obinutuzumab|MPDL-G-Benda: 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. MPDL-G-CHOP: 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6/8 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 (in safety run-in only), during maintenance treatment.
280079|NCT02596971|Drug|Prednisone|MPDL-G-CHOP: Prednisone 40 mg/m^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment.
280080|NCT02596971|Drug|Vincristine|MPDL-G-CHOP: Vincristine 1.4 mg/m^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
280081|NCT00191165|Drug|Somatropin|In-label dosage
280082|NCT02596984|Drug|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
280083|NCT02596997|Drug|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
280084|NCT02597010|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
280085|NCT02597010|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
280086|NCT02597023|Drug|MitoQ|Mitoquinone pill, 20 mg/day
280087|NCT02597023|Drug|Placebo|Placebo pill with inert excipient, 1 time/day
280088|NCT02597036|Drug|LY3127804|Administered IV
280089|NCT02597036|Drug|Ramucirumab|Administered IV
280090|NCT02597049|Drug|Dulaglutide|Administered SC
280091|NCT02597049|Drug|Placebo|Administered SC
280092|NCT00191178|Drug|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
280093|NCT02597062|Drug|Carfilzomib|
280094|NCT02597062|Drug|Cyclophosphamide|
280095|NCT02597062|Drug|Dexamethasone|
280096|NCT02597075|Other|standard therapy + physical activity program|
280097|NCT02597075|Other|standard therapy|
280098|NCT02599103|Other|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
279494|NCT02709759|Behavioral|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
279495|NCT02709759|Behavioral|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
279496|NCT02709772|Behavioral|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
279497|NCT02709785|Drug|SmartMouth ACF rinse|
279498|NCT02709785|Drug|0.12% chlorhexidine rinse|
279499|NCT02709785|Drug|Placebo rinse|
279795|NCT02601482|Behavioral|IW-45|
279796|NCT02601495|Behavioral|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
279797|NCT02603510|Drug|insulin lispro|Pharmaceutical form:solution
Route of administration: subcutaneous
279798|NCT02603523|Behavioral|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
279799|NCT02603536|Other|WelTel|An evidence-based, text messaging solution for improving patient adherence.
279800|NCT02603549|Other|Pituitary panel will be drawn pre-op and post-op for all patients.|
279801|NCT02603562|Biological|ATYR1940|ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg using intrapatient dose escalation. The dose level in this study will not exceed 3.0 mg/kg
279802|NCT02603562|Biological|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
279803|NCT02603575|Drug|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
279804|NCT00191763|Drug|cisplatin|
279805|NCT02603575|Drug|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
279806|NCT02603575|Drug|Sulfanilamides|1.92g q8h
279807|NCT02603588|Procedure|active sphenopalatine ganglion acupuncture|The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt "de-qi" sensations.
279199|NCT02713698|Drug|Propofol|Induction of general anaesthesia: propofol at 200 mL/h until loss of consciousness (LOC).
Maintenance of general anaesthesia: propofol will be altered by 5 mg/mL changes targeting the BIS values between 40 and 60.
Arterial blood samples will be obtained immediately after LOC, immediately before surgery and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL.
279200|NCT02713711|Radiation|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
279201|NCT02715765|Device|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
279202|NCT02715791|Behavioral|TAP-HC-DM|Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.
Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.
Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.
Clinicians will see and triage the reports, and may follow up on various aspects identified.
279203|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
279204|NCT02715804|Other|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilograms (μg/kg) as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond.
279500|NCT02709798|Drug|Shenfu Injection|
279501|NCT02709798|Drug|5% Glucose Injection|
279502|NCT02709811|Drug|Electrochemotherapy|
279503|NCT00203281|Drug|intravenous immune globulin|
279504|NCT02709824|Drug|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
279505|NCT02709824|Drug|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
279506|NCT02709837|Other|Nutritional|
279507|NCT02709850|Drug|IONIS ANGPTL3-LRx|
279508|NCT02709850|Drug|Placebo (0.9%NaCl, water, riboflavin)|
279509|NCT02709863|Drug|Sevoflurane|1-1.5 MAC, inhalation route, during operation
283766|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
283767|NCT02584881|Other|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
283768|NCT02584894|Device|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
283769|NCT02584894|Device|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
283770|NCT02587039|Procedure|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
283771|NCT02587039|Behavioral|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
283772|NCT02587052|Drug|Generic tacrolimus|Generic tacrolimus
283773|NCT02587052|Drug|Prograf|Prograf, the original tacrolimus
283774|NCT02587065|Drug|peginterferon beta-1a|
283775|NCT02587078|Drug|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
283776|NCT02587078|Drug|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
283777|NCT02587091|Behavioral|Portable obstetric ultrasound|This intervention was advertised at the cluster level
283778|NCT02587104|Other|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
283779|NCT00002515|Biological|filgrastim|
283780|NCT00190034|Drug|N-Acetylcysteine 600mg/tab|
283781|NCT02587117|Drug|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
283196|NCT02598245|Device|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
283197|NCT02598258|Other|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
283198|NCT02598284|Other|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
283467|NCT02591758|Device|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
283468|NCT02591758|Behavioral|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
283469|NCT02591758|Other|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
283470|NCT02591758|Other|Angina assessment with the angina diary, the SAQ and the SF-36|
283471|NCT02591758|Other|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
283472|NCT02591758|Other|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
283473|NCT02593448|Procedure|General anaesthesia with sevoflurane use|Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.
Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.
Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.
Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.
283474|NCT00190866|Drug|Duloxetine|
283475|NCT02593461|Device|Daifert|
283476|NCT02593461|Other|Control Group|
283477|NCT02593474|Drug|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
283478|NCT02593487|Drug|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
283479|NCT02593487|Drug|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
282905|NCT02602704|Drug|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
282906|NCT02604667|Other|Blood tests|Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.
Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.
Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes.
282907|NCT02604667|Other|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
282908|NCT02604680|Drug|BLI1100-1|BLI1100-1 Topical gel
282909|NCT02604680|Drug|BLI1100-2|BLI1100-2 Topical gel
282910|NCT00191906|Drug|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
282911|NCT02604680|Drug|BLI1100-3|BLI1100-3 Topical gel
282912|NCT02604680|Drug|Control group|Control group - Topical gel
282913|NCT02604680|Drug|Placebo|Placebo - Topical gel
283199|NCT02598284|Other|Population Management|Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).
Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program.
283200|NCT02598297|Drug|Ruxolitinib|Tablet for oral use
283201|NCT02598297|Drug|Ruxolitinib Placebo|Matching placebo tablet for oral use
283202|NCT02598310|Drug|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
283203|NCT02598310|Drug|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
283204|NCT02598323|Device|ultrasound|
283205|NCT02600533|Procedure|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
283206|NCT02600559|Drug|OTO-201 (ciprofloxacin)|
282628|NCT02609269|Other|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
282629|NCT02609269|Other|Decipher Genomics Resource Information Database (GRID)|The GRID currently consists of thousands of cancer patients with clinical follow-up and treatment & outcomes data. Clinical-genomic data can be compared to the GRID database to infer a more detailed classification of current patients in comparison to historical patients with known treatment and outcomes data.
282630|NCT02609282|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|
282631|NCT02609295|Dietary Supplement|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
282632|NCT02609295|Dietary Supplement|ALA group|1.2 g (two capsules) of perilla oil
282633|NCT02609308|Other|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
282634|NCT02609308|Procedure|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
282635|NCT02609321|Procedure|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
282636|NCT00192400|Biological|CAIV-T|
282637|NCT02609321|Procedure|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
282638|NCT02609334|Drug|CRD007|One single dose given 3 hours prior to Mannitol challenge
282639|NCT02609334|Other|Placebo|One single dose given 3 hours prior to Mannitol challenge
282640|NCT02575495|Drug|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
282641|NCT02575495|Drug|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
282642|NCT02575508|Drug|Fluorouracil|Given IV
282643|NCT02575508|Drug|Irinotecan Hydrochloride|Given IV
282644|NCT02575508|Other|Laboratory Biomarker Analysis|Correlative studies
282914|NCT02604693|Other|Nothing|No interventions will be administered.
282057|NCT02584257|Other|methacholine chloride|
282058|NCT02584257|Drug|Placebo dose|
282059|NCT02584257|Drug|90 mcg Reference Product|
282348|NCT02577601|Drug|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
282349|NCT02577614|Drug|FEIBA|Administration of FEIBA after cardiopulmonary bypass
282350|NCT02577614|Drug|Normal Saline|Administration of placebo after cardiopulmonary bypass
282351|NCT02577627|Device|PrediCare|
282352|NCT02579785|Behavioral|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
282353|NCT02579798|Device|PEEP (positive end-expiratory pressure)|
282354|NCT02579811|Drug|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
282355|NCT02579824|Drug|DS-3032b|Dose Escalation Phase: DS-3032b administered once daily by mouth on Days 1 - 21 of a 28 day cycle. Starting dose level 90 mg/day.
Dose Expansion Phase: Starting dose level maximum tolerated dose from Dose Escalation Phase.
282356|NCT02579837|Device|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
282357|NCT02579837|Device|Zeiss Cirrus|optical coherence tomographer (OCT)
282358|NCT02579850|Drug|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
282359|NCT02579850|Drug|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
282360|NCT02579850|Procedure|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
282361|NCT02579850|Other|COPD assessment test|COPD assessment test (CAT) at visit 1
282362|NCT00189046|Behavioral|driving and laboratory tests|
282363|NCT02579850|Procedure|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
282677|NCT02579902|Dietary Supplement|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
282678|NCT02579915|Behavioral|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
282679|NCT02579915|Behavioral|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
282680|NCT02579928|Drug|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
282681|NCT02579928|Drug|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
282682|NCT02579941|Procedure|Blood sampling (pregnant)|5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.
This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 511 UtPA/ml). Tranexamic acid will be added at increasing concentrations (5 microg/ml up to 100 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM.
282683|NCT02579941|Procedure|Blood sampling (non pregnant)|5.4 ml of venous blood will be taken.
This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 511 UtPA/ml). Tranexamic acid will be added at increasing concentrations (5 microg/ml up to 100 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM.
282684|NCT02579954|Behavioral|Rehabilitation|
282685|NCT02579967|Drug|Immunosuppression Only Conditioning|Pentostatin 4 mg/m(2)/day IV on days -9 and -5, low-dose cyclophosphamide orally daily on days -9 through -2
282686|NCT00002514|Drug|leucovorin calcium|
282687|NCT00189072|Drug|gabapentin|
282688|NCT02579967|Drug|Reduced Intensity Conditioning|pentostatin 4 mg/m(2)/day IV on days -11 and -7, low-dose cyclophosphamide orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days - 3 and -2.
282689|NCT02579967|Drug|Myeloablative Conditioning|Pentostatin 4 mg/m(2)/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2.
282690|NCT02579967|Drug|GVHD Prophylaxis|High-dose, posttransplantation cyclophosphamide (PTCy) on days +3 and +4, sirolimus on days +5 through +180, and mycophenolate mofetil (MMF) on days +5 through +35 (exception of patients with DNA repair defects or telomere maintenance defects)
282691|NCT02579967|Procedure|Allo BMT|Allogeneic blood or marrow transplantation
282964|NCT02575625|Biological|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
282108|NCT02591238|Other|smoker oral placebo|Participants oral placebo last 2 weeks.
282405|NCT02584309|Drug|Doxorubicin|
282406|NCT02584322|Other|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
282407|NCT02584335|Drug|Lidocaine solution ("A")|Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.
The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is "A", the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).
Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception.
282408|NCT02584335|Drug|Saline solution ("B")|Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.
The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is "B", the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).
Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception.
282409|NCT02584348|Device|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
282410|NCT02586480|Device|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
282411|NCT02586493|Drug|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
282412|NCT02586493|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
282413|NCT02586506|Drug|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
282414|NCT02586506|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
281834|NCT02597673|Behavioral|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
282109|NCT02591238|Drug|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
282110|NCT02591251|Drug|Povidone-iodine solution|
282111|NCT02591251|Drug|Normal saline solution|
282112|NCT02591264|Other|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
282113|NCT02591277|Drug|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
282114|NCT00190606|Procedure|Pelvic Floor Muscle Training (PFMT)|
282115|NCT02591290|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses at 8 weeks interval)
282116|NCT02591303|Other|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
282117|NCT02591316|Other|no intervention|
282118|NCT02591329|Behavioral|Experimental|
282119|NCT02591329|Behavioral|Standard Care|
282120|NCT02593084|Behavioral|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
282121|NCT02593097|Drug|Metformin|Metformin 500mg twice daily
282122|NCT02593097|Drug|Matching Placebo|Matching Placebo twice daily
282123|NCT00190814|Drug|duloxetine|
282124|NCT02593110|Behavioral|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
282125|NCT02593110|Drug|Telmisartan|Participants randomized to the telmisartan arm of the study will take 40 mg of telmisartan daily. Participants will have their dose increased to up to 80 mg as tolerated.
282126|NCT02593110|Other|"No exercise" control group|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
281540|NCT02604277|Behavioral|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
281541|NCT02604277|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MSBR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
281542|NCT00191841|Drug|Cisplatin|
281835|NCT02597673|Device|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
281836|NCT02597673|Device|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
281837|NCT02597686|Behavioral|SD-PB training|
281838|NCT02597699|Drug|Ultiva ® associated with a lethal reference agent, Xylocaine ® in Procedure of foeticide|Arm 2: Ultiva ® associated with a lethal reference agent, Xylocaine ® in Procedure of foeticide Arm 1 :Sufentanil ® associated with Xylocaine ® in Procedure of foeticide
281839|NCT02597712|Drug|YF476 or placebo|gastrin receptor antagonist
281840|NCT00191243|Drug|docetaxel|A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine
B: 80 mg/m2, IV, q 21 days until treatment failure
281841|NCT02597738|Other|Fresh tissue biopsy and blood collection|Fresh tissue biopsy and research blood work samples will be collected for one year.
281842|NCT02597738|Other|Blood Sample Collection|A one time blood sample will be collected.
281843|NCT02599831|Procedure|PFM Training|
281844|NCT02599844|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
281845|NCT02599844|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
281241|NCT02608749|Behavioral|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
281242|NCT02608762|Radiation|standard adjuvant local radiation therapy or cranial radiation therapy|
281243|NCT02608775|Device|Metrodoloris Medical System|Application of a skin electrode
281244|NCT02608788|Drug|S.L.®|"1.5mg/ml Benzydamine hydrochloride"," S.L.®" spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
281245|NCT00192322|Biological|Placebo|a single intranasal 0.2 mL dose of placebo
281246|NCT02608788|Drug|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride" , " Difflam Forte ®" spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
281247|NCT02608788|Drug|Acular®|"5％ Ketorolac Tromethamine" , " Acular® " spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
281248|NCT02608788|Drug|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
281543|NCT02604277|Behavioral|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education & Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education & Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
281544|NCT02604277|Behavioral|Social Skills Training|Social Skills Training will be given once a week over a six week period for 55-60 minutes. Social Skills Training is a structured program designed to help participants learn how to maintain positive and meaningful social relationships as well as emphasize independent living skills. The intervention employs behavioral learning techniques, such as coaching, modeling, and positive reinforcement, and aims in ameliorating cognitive deficits that interfere with rehabilitation.
281545|NCT02604290|Device|Kinesio Taping method|The tape is applied depending on the physical examination:
Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.
Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.
Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers.
281546|NCT02604290|Device|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
281547|NCT02604303|Other|No Intervention|No intervention; prospective observational study
281548|NCT02604316|Other|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
280957|NCT02579213|Other|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
280958|NCT02579226|Drug|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B1, B2, and B3). All patients in both parts of the study with receive AZD2811. In Part B2 and B3 AZD2811 will be combined with Irinotecan.
280959|NCT02579226|Drug|Irinotecan|Irinotecan will be administered in combination with AZD2811 to a select group of patients in the dose expansion segment of this study, Parts B2 and B3.
280960|NCT02579239|Biological|ATYR1940|Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
280961|NCT02579239|Biological|Placebo|Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
280962|NCT02579252|Biological|AADvac1|
280963|NCT00002514|Drug|imatinib mesylate|
280964|NCT00188994|Drug|Insulin Cardioplegia|
280965|NCT02579252|Drug|Placebo|
281249|NCT02608814|Procedure|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
281250|NCT02608814|Other|Ultrasound|
281251|NCT02608827|Device|Resperate®-InterCure Ltda|The device-guided breathing a type that uses sound to guide and therefore reduce the respiration rate in individuals.
281252|NCT02608827|Other|Music group (GC)|The patients in this arm will hear slow music.
281253|NCT02608827|Device|Portable radio|
281254|NCT02608840|Other|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
281255|NCT02608840|Other|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
281256|NCT00192322|Biological|TIV|commercially available TIV injected intramuscularly
281257|NCT02608853|Other|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
281258|NCT02608866|Radiation|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
280683|NCT02583685|Drug|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
280684|NCT02583685|Drug|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
280685|NCT02583685|Drug|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
280686|NCT02585856|Device|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
280687|NCT02585869|Drug|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
280688|NCT02585869|Drug|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
280689|NCT02585869|Drug|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
280690|NCT02585869|Drug|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
280966|NCT02579265|Drug|Smoflipid 20% (investigational lipid for parenteral nutrition)|Dose: The targeted maximal lipid dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the lipid dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.
Investigational or control drug will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.
The lipid emulsions will be infused into a central or peripheral vein.
280967|NCT02579265|Drug|Intralipid® 20%|Dose: The targeted maximal lipid dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the lipid dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.
Investigational or control drug will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.
The lipid emulsions will be infused into a central or peripheral vein.
280968|NCT02579278|Other|Blood sample|Three blood samples are taken from each patient. Two from the arm (one pre-surgery and one during surgery) and one from the resected tumour specimen vein.
280969|NCT02579291|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
280970|NCT02579291|Other|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
280971|NCT02579304|Procedure|transbronchial lung cryobiopsy|bronchoscopic sampling
280695|NCT02585895|Other|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Subjects will continue apheresis at the same schedule, every week or every two weeks, as prior to study entry
280696|NCT02585908|Biological|CIK|CIK cells will be used against tumor cells.
280697|NCT02585908|Biological|γδ T|γδ T cells will be used against tumor cells.
280698|NCT02585908|Biological|CIK and γδ T|CIK and γδ T cells will be used against tumor cells.
280699|NCT02585921|Behavioral|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
280700|NCT02585921|Behavioral|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
280701|NCT02585934|Drug|RVT-101|once daily, oral, 35 mg tablets
280702|NCT02585934|Drug|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
280703|NCT02585947|Drug|Tenofovir disoproxil|
280704|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
280705|NCT00189839|Drug|tacrolimus|Immunosuppression
280706|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Standard treatment
280707|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Intensified treatment
280708|NCT02585973|Drug|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
280709|NCT02585973|Drug|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
280710|NCT02585973|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
280711|NCT02585986|Dietary Supplement|Probiotic|daily intake of 1 capsule probiotic
280712|NCT02585986|Dietary Supplement|Placebo|daily intake of 1 capsule containing placebo
280713|NCT02588131|Drug|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
280983|NCT02581631|Drug|Nivolumab|
280984|NCT02581631|Drug|Brentuximab Vedotin|
280396|NCT02592590|Behavioral|Group C|This condition receives two study components:
The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.
The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of "program points" is awarded. These are weighted by task difficulty, and accumulate to earn "levels". Levels accumulate to earn "badges" depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn "titles" (e.g., "expert exerciser"). As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
280397|NCT02592590|Behavioral|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
280398|NCT02592603|Device|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
280399|NCT02592616|Behavioral|CON|No exercise intervention.
280400|NCT00190749|Drug|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
280401|NCT02592616|Behavioral|CW|One hour of continuous walking on a treadmill.
280402|NCT02592616|Behavioral|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
280403|NCT02592629|Drug|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
280404|NCT02592629|Drug|ethyl chloride|topical spray
280405|NCT02592629|Drug|Kenalog|used with lidocaine in shoulder injection
280406|NCT02592642|Behavioral|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
280407|NCT02592642|Behavioral|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
279808|NCT02603588|Procedure|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
279809|NCT02603601|Behavioral|Mind-body lifestyle intervention|
279810|NCT02603601|Behavioral|Standard lifestyle intervention|
279811|NCT02603614|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
279812|NCT02603614|Drug|Placebo|Placebo control
279813|NCT02603640|Device|MRI scanning|
279814|NCT02603653|Device|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
280099|NCT02599116|Other|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
280100|NCT02599116|Other|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
280101|NCT00191347|Drug|gemcitabine|
280102|NCT02599129|Drug|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
280103|NCT02599129|Drug|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
280104|NCT02599142|Device|Group A: Closed-face shell|As for arm description
280105|NCT02599142|Device|Group B: Open-face shell|As for arm description
280106|NCT02599155|Drug|Crystalloid|normal saline administration for volume expansion in hypovolemic status
280107|NCT02599155|Drug|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
280108|NCT02599168|Drug|Propofol|
280109|NCT02599168|Drug|Dexmedetomidine|
280110|NCT02599168|Drug|Placebo (normal saline)|
280111|NCT02599181|Other|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland.
280112|NCT00191360|Drug|Somatropin|
279510|NCT02709863|Drug|Desflurane|1-1.5 MAC, inhalation route, during operation
279511|NCT02709863|Drug|Propofol|6-10 mg/kg/h, iv infusion, during operation
279512|NCT02709876|Biological|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
279513|NCT02709889|Drug|Rovalpituzumab tesirine|
279514|NCT00203281|Procedure|plasmapheresis|
279515|NCT02709902|Drug|Adapalene/BP gel, 0.3%/2.5%|Gel
279516|NCT02709902|Drug|EPIDUO® FORTE|Gel
279517|NCT02709902|Drug|Placebo|Gel
279518|NCT02711683|Drug|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
279519|NCT02711696|Behavioral|GCED, Gluten Contamination Elimination Diet|a diet based exclusively on naturally gluten-free products, and on elimination from the diet of commercially available processed food and products labeled "gluten free " (Gluten Contamination Elimination Diet, GCED).
279520|NCT02711709|Other|Frailty Measurements|A frailty index will be determined as a combination of factors.
An older adult is considered physically vulnerable when they experience:
muscle weakness
fatigue
low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.
This will be collected at baseline, 3, 6 and 12 months.
279521|NCT02711709|Other|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
279522|NCT02711709|Other|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
279815|NCT00002517|Drug|thioguanine|
279816|NCT00191789|Drug|gemcitabine|1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
279817|NCT02603666|Device|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
279818|NCT02603679|Drug|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
279819|NCT02603679|Drug|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
279820|NCT02603679|Drug|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
279821|NCT02605655|Drug|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
279205|NCT00203996|Drug|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
279206|NCT02715804|Drug|Placebo|Matching placebo for PEGPH20
279207|NCT02715804|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as an IV infusion at 125 milligrams per square meter (mg/m2), once weekly for Weeks 1 to 3 of all treatment cycles.
279208|NCT02715804|Drug|Gemcitabine|Gemcitabine will be administered as an IV infusion at 1000 mg/m2, once weekly for Weeks 1 to 3 of all treatment cycles.
279209|NCT02715817|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
279210|NCT02715817|Other|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
279211|NCT02715817|Other|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
279212|NCT02715830|Procedure|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
279213|NCT02715843|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
279214|NCT02715856|Other|Physical Tasks|About 2, 6, 12, and 24 weeks after surgery, participant has standard follow-up visits. At these visits, participant asked to perform different physical tasks. Physical therapist will observe one of the walking tests.
279215|NCT02715856|Other|Follow Up with Mobile Device|At weeks 3, 7, 13, and 25 participant uses a mobile device to send the study staff photos of their surgical wound and videos of their walking tests.
279216|NCT02717975|Procedure|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
279217|NCT02717975|Procedure|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
279218|NCT02717988|Drug|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
279219|NCT02717988|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
279220|NCT02718001|Device|Transcatheter Mitral Valve Replacement (TMVR)|Replacement of the mitral valve through a transcatheter approach
283480|NCT02593500|Drug|Budesonida Pulmictan® 200 µg|
283481|NCT02593500|Drug|Budesonide 200 µg|
283482|NCT02593513|Device|Daifert|
283483|NCT02593513|Procedure|Control Group|Control - Morphological Assessment
283484|NCT02593526|Drug|Bumetanide|Diuretic
283485|NCT00002516|Drug|doxorubicin hydrochloride|
283486|NCT00190866|Drug|placebo|
283487|NCT02593526|Other|Cool Dialysate|Cool dialysate (35°C)
283782|NCT02587117|Drug|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
283783|NCT02587130|Drug|Ketamine|ketamine administered in bolus by subcutaneous injection
283784|NCT02587143|Drug|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
283785|NCT02587143|Drug|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
283786|NCT02587156|Dietary Supplement|Dietary protein|
283787|NCT02587169|Drug|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
283788|NCT02587182|Device|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
283789|NCT02587195|Drug|Teriflunomide|
283790|NCT02587208|Device|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
283791|NCT02589574|Other|electronic text message|Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.
it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority.
283207|NCT02600572|Other|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
283208|NCT02600572|Other|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
283209|NCT02600585|Biological|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
283210|NCT02600585|Biological|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
283211|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
283212|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
283213|NCT00191477|Drug|Gemcitabine|2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
283214|NCT02600611|Drug|iclaprim|Experimental treatment
283215|NCT02600611|Drug|vancomycin|Active comparator
283216|NCT02600637|Behavioral|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
283217|NCT02600637|Behavioral|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
283218|NCT02600650|Dietary Supplement|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
283219|NCT02600650|Dietary Supplement|Placebo Comparator|Daily administration of Placebo Comparator
283488|NCT02593539|Drug|GSK2269557 DPI 500 mcg|Subjects will receive 2 inhalations of GSK2269557 500 mcg in DPI (total dose: 1000 mcg) to be taken every day before breakfast (with the exception of days when the subjects have a planned visit to the study clinic. On those days, they will be dosed at the clinic). The subject should hold their breath for 10 seconds before exhaling. Inhalations should be taken approximately 30 seconds apart.
283489|NCT02593552|Device|DriveCam|Video event monitoring device
283490|NCT02593565|Other|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
283491|NCT02593617|Other|Addiction Profile Index|
283492|NCT02593617|Other|Alcohol Use Disorders Identification Test|
283493|NCT02593617|Other|Barratt Impulsiveness Scale|
283494|NCT02593617|Other|Zuckerman Sensation Seeking Scale|
283495|NCT02593617|Other|Energy Drink Consumption Questionnaire|
282915|NCT02604706|Device|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
282916|NCT02604706|Device|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
282917|NCT02604706|Behavioral|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
282918|NCT02604719|Drug|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
282919|NCT02604732|Procedure|Laparoscopic inguinal hernia repair|
282920|NCT02604758|Behavioral|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
282921|NCT02607202|Drug|Gemcitabine|
282922|NCT02607215|Drug|Vinorelbine|25 mg/m2, D1, D8
282923|NCT02607215|Drug|DDP|75 mg/m2, D1
282924|NCT02607228|Drug|GS-5829|GS-5829 tablet administered orally once daily
282925|NCT02607228|Drug|Enzalutamide|Enzalutamide capsules administered orally once daily
282926|NCT00192153|Biological|CAIV-T or TIV|
282927|NCT02607241|Device|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
282364|NCT02579850|Other|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
282365|NCT02579850|Other|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
282366|NCT02579863|Drug|lenalidomide|
282367|NCT02579863|Drug|dexamethasone|
282368|NCT02579863|Biological|pembrolizumab|
282645|NCT02575508|Drug|Oxaliplatin|Given IV
282646|NCT02575508|Drug|pan FGFR Kinase Inhibitor BGJ398|Given IV
282647|NCT02575508|Other|Pharmacological Study|Correlative studies
282648|NCT02575521|Drug|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
282649|NCT00188305|Behavioral|General health counselling and risk information|General health counselling and risk information
282650|NCT02575521|Drug|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
282651|NCT02575534|Drug|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
282652|NCT02575547|Drug|cisplatin and docetaxel|NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.
CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\three cycles during radiation therapy(RT).
Dietary supplement: enteral nutrition and parenteral nutrition
282653|NCT02575560|Other|history data|history data of PFS after 1st line or second line theray
282654|NCT02575573|Other|Factors influencing resuscitation decisions of patients|
282655|NCT02575573|Other|Factors leading to not asking patients about resuscitation preference|
282656|NCT02575586|Device|Intervention-Dry Needling|Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.
1 session in soleus muscle moving the needle up and down ten times.
282657|NCT02575586|Device|Control-Dry Needling|Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.
1 session in soleus muscle moving the needle up and down ten times.
282965|NCT02575625|Device|MRI|Liver MRI
282966|NCT02575638|Drug|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
282967|NCT02575651|Drug|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
282968|NCT02575664|Drug|Buprenorphine|Buprenorphine 5 microg/h/7 days
282969|NCT02575664|Drug|Placebo|Placebo patch
282970|NCT02575677|Drug|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
282971|NCT02575690|Dietary Supplement|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
282972|NCT02575690|Other|Placebo|Individuals receive a placebo daily, for 3 months.
282973|NCT00188331|Behavioral|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
282974|NCT02575703|Drug|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi [¹⁴C]-LY3023414
282975|NCT02575716|Device|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
282976|NCT02575729|Drug|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
282977|NCT02575742|Device|3D-Transit system|
282978|NCT02575755|Drug|Azithromycin plus piperaquine phosphate|
282979|NCT02575755|Drug|Sulfadoxine-pyrimethamine|
282980|NCT02575768|Other|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
282981|NCT02575781|Drug|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
282982|NCT02575794|Drug|Terameprocol|Given PO
282983|NCT02575794|Other|Pharmacological Study|Correlative studies
282984|NCT00188344|Procedure|pneumatic dilatation|The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.
The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours.
282415|NCT02586519|Device|SurroSense Rx System|The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when "safe" pressure and time thresholds have been exceeds so that on-demand offloading can occur.
282416|NCT02586545|Other|Shared care|
282692|NCT02579980|Procedure|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
282693|NCT02579980|Procedure|Surgery|Standard of care procedure for sarcoma patients
282694|NCT02579980|Device|MRI|Standard of care procedure for sarcoma patients
282695|NCT02579993|Procedure|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
282696|NCT02582255|Biological|Sabin mOPV2|Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.
One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine.
282697|NCT02582268|Device|intrauterine device TCu 380A|
282698|NCT02582268|Radiation|Trans-abdominal sonography|
282699|NCT00002514|Drug|prednisone|
282700|NCT00189423|Device|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.
The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR.
282701|NCT02582281|Device|intrauterine device TCu 380A|
282702|NCT02582294|Other|Questionnaire|
282703|NCT02582307|Drug|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
282704|NCT02582307|Drug|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
282705|NCT02582320|Drug|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
282706|NCT02582333|Other|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
282127|NCT02593110|Drug|Placebo|
282128|NCT02593123|Drug|MMF-30|MMF beginning Day 0 and continuing for 30 days.
282129|NCT02593123|Drug|MMF-15|MMF beginning Day 0 and continuing for 15 days.
282130|NCT02593123|Drug|Tacrolimus|Tacrolimus beginning day -2. Tacrolimus will be initiated orally at 0.04 mg/kg/day in divided doses beginning on day -2 and continuing until day 90 maintaining levels of approximately 10-14 ng/μL in the first month after transplant and 8-12 ng/μL in the next 2 months after transplant.
282417|NCT02586558|Other|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
282418|NCT02586558|Other|Reference group|Ready-to-feed infant formula to be fed ad libitum
282419|NCT02586571|Behavioral|Breastfeeding|Breastfeeding at 5.5 months of age (exclusive or partial)
282420|NCT00189956|Biological|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
282421|NCT02586597|Device|Transcranial magnetic stimulation & median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.
PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.
PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.
PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min.
282422|NCT02586610|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Days 1, 22 and 43
282423|NCT02586610|Drug|Capecitabine|Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
282424|NCT02586610|Radiation|Radiation Therapy|Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
282425|NCT02586623|Drug|Droxidopa capsules|100, 200 or 300 mg
282426|NCT02586623|Drug|Placebo capsules|
282427|NCT02586636|Drug|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
282428|NCT02588963|Other|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
282429|NCT02588963|Other|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
281846|NCT02599844|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
281847|NCT02599844|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
281848|NCT02599844|Drug|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
281849|NCT02599857|Device|CONCOR smartphone application|
281850|NCT00191438|Drug|capecitabine|
281851|NCT02599870|Genetic|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
282131|NCT02593123|Biological|granulocyte macrophage colony stimulating factor|GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.
Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF.
282132|NCT02593123|Biological|granulocyte colony stimulating factor|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
282133|NCT02593123|Drug|Antithymocyte Globulin (Rabbit)|All patients will receive rabbit ATG (Thymoglobulin, Sanofi-Aventis) at a dose of 1.7 mg/kg/day for 3 days (5.1 mg/kg total). ATG will be administered intravenously over 10-12 hours, starting on day -9 and continuing daily through day -7.
282134|NCT00190814|Drug|placebo|
282135|NCT02593136|Dietary Supplement|Home Fortification Product (HFP)|The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:
Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)
282136|NCT02593136|Other|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
282137|NCT02593149|Device|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
282138|NCT02593162|Drug|Faldaprevir|
282139|NCT02593162|Drug|TD-6450|
281549|NCT02604316|Other|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
281550|NCT02604329|Device|"Oncolase Digi" therapy laser diode|The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).
Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).
Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm.
281551|NCT02606422|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
281552|NCT02606422|Device|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
281553|NCT02606435|Procedure|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
281554|NCT02606435|Device|thrombus aspiration|thrombus aspiration with export catheter
281555|NCT02606448|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
281852|NCT02599883|Radiation|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
281853|NCT02599896|Biological|VRC-HIVMAB080-00-AB|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
281854|NCT02599922|Biological|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
281855|NCT02599935|Dietary Supplement|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
281856|NCT02599935|Other|standard treatment|No other than standard treatment
281857|NCT02599935|Other|educational structured counseling|Nutritional counseling leaded to patient and caregivers
281858|NCT02599948|Other|no intervention|
281859|NCT02599961|Drug|UX007|UX007 is a liquid intended for oral (PO) administration.
281860|NCT02599987|Device|POWERbreathe® Classic Light|Inspiratory Muscle Training
281861|NCT00191438|Drug|docetaxel|
281259|NCT02608866|Radiation|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
281260|NCT00188175|Radiation|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
281261|NCT02574858|Drug|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
281262|NCT02574871|Other|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
281263|NCT02574884|Procedure|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
281264|NCT02574897|Other|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
281265|NCT02574897|Other|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
281266|NCT02574910|Drug|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
281267|NCT02574923|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
281556|NCT02606448|Procedure|Femoral nerve block|Pre-operative femoral nerve block
281557|NCT02606448|Drug|Ropivicaine|Ropivicaine was used in all femoral nerve blocks
281558|NCT02606461|Drug|Selinexor|Selinexor 60mg
281559|NCT02606461|Drug|Placebo|Placebo
281560|NCT02606500|Drug|Elonva|20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). GnRH antagonist will be used to prevent premature LH surge. Additional daily doses of 200 IU of rFSH will be used if necessary. hCG will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. CC samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.
The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age > 38 years.
281561|NCT00192088|Drug|pemetrexed|
281562|NCT02606513|Other|MR Urography; CT Urography|
281563|NCT02606526|Biological|Delayed BCG|See previous description
281564|NCT02606526|Biological|Control arm: BCG at birth|See previous description
280972|NCT02579317|Behavioral|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
280973|NCT02579317|Behavioral|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
280974|NCT02579330|Device|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
280975|NCT00189007|Drug|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
280976|NCT02581553|Drug|allopurinol 300 mg|
280977|NCT02581566|Drug|Dexmedetomidine|
280978|NCT02581579|Dietary Supplement|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
280979|NCT02581579|Other|Placebo|Placebo, 1 capsule per day during 14
280980|NCT02581592|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
280981|NCT02581605|Device|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
280982|NCT02581618|Other|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
281268|NCT02574936|Procedure|A new surgical technique|Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.
A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used
281269|NCT02574949|Radiation|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
281270|NCT02574949|Radiation|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
281271|NCT00188188|Drug|quinipril|
281272|NCT02574949|Radiation|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
281273|NCT02574962|Drug|H.P. Acthar® Gel|
281274|NCT02574975|Drug|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
280985|NCT00002514|Drug|methotrexate|
280986|NCT00189306|Drug|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
280987|NCT02581657|Drug|PE0139 Injection|PE0139 Injection
280988|NCT02581657|Drug|Placebo Injection|Placebo Injection
280989|NCT02581670|Radiation|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
280990|NCT02581683|Drug|Magnesium Sulfate|Given via adductor canal block
280991|NCT02581683|Drug|Ropivacaine|Given via adductor canal block
280992|NCT02581683|Other|Sham|Sham adductor canal block
280993|NCT02581696|Drug|Lafutidine|Lafutidine 10mg, 1 tablet, bid
280994|NCT02581696|Drug|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
280995|NCT02581709|Behavioral|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
280996|NCT02581722|Device|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
280997|NCT00189319|Drug|Flecainide controlled release|
280998|NCT02581735|Other|Patients with haemophilia|Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.
At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale .
280999|NCT02581748|Drug|HLX02|
281000|NCT02581748|Drug|Herceptin|
281001|NCT02581761|Drug|CYTOTEC|synthetic prostaglandin E1
281002|NCT02581761|Other|Placebo|no active material
281003|NCT02583685|Drug|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
280408|NCT02592642|Device|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
280714|NCT02588144|Procedure|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
280715|NCT02588144|Procedure|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
280716|NCT02588157|Device|Macintosh|Direct laryngoscopy
280717|NCT02588157|Device|Glidescope|Glidescope videolaryngoscope
280718|NCT02588157|Device|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
280719|NCT02588170|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
280720|NCT02588170|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
280721|NCT00190216|Device|Magnetic stimulator|
280722|NCT02588183|Device|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
280723|NCT02588196|Drug|Dexamethasone acetate|
280724|NCT02588209|Behavioral|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
280725|NCT02588209|Behavioral|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
280726|NCT02588235|Drug|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
280727|NCT02588235|Drug|Atorvastatin|atorvastatin (20 mg/day）
280728|NCT02588248|Drug|Peppermint Oil|
280729|NCT02588248|Other|Placebo|
280730|NCT02588261|Drug|ASP8273|oral
280731|NCT02588261|Drug|Erlotinib|oral
280732|NCT00190229|Drug|Cyclophosphamide|Cyclophosphamide
280113|NCT02599194|Procedure|Computed Tomography|
280114|NCT02599194|Radiation|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
280115|NCT02599194|Procedure|Positron Emission Tomography|
280116|NCT02599194|Procedure|Magnetic Resonance Imaging|
280117|NCT02599207|Biological|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
280118|NCT02599233|Other|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
280119|NCT02599233|Other|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 & 7.
280120|NCT02599233|Other|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
280409|NCT02594644|Device|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 200 micrometers in length.
280410|NCT02594644|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
280411|NCT02594644|Radiation|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
280412|NCT02594657|Procedure|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
280413|NCT02594657|Procedure|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
280414|NCT02594670|Other|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
280415|NCT02594670|Other|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
280416|NCT02594670|Other|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
279822|NCT02605655|Other|Placebo|Instant noodles without drug
279823|NCT02605668|Behavioral|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
279824|NCT02605668|Behavioral|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
279825|NCT02605681|Other|Therapy for sepsis|Conventional therapy to treat sepsis
279826|NCT00192036|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
279827|NCT02605694|Drug|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
279828|NCT02605694|Drug|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
279829|NCT02605694|Drug|R-CHOP|IV infusion on Day 1 of Cycles 1-6 (21-day cycles)
Cyclophosphamide (750 mg/m2)
Doxorubicin hydrochloride (50 mg/m2)
Vincristine sulfate (1.4 mg/m2) (2 mg maximum)
Rituximab (375 mg/m2)
279830|NCT02605694|Drug|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
279831|NCT02605707|Drug|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
279832|NCT02605720|Drug|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
279833|NCT02605733|Device|EEG|amplitude integrated electroencephalography
279834|NCT02605733|Device|NIRS|regional tissue oximetry
279835|NCT02605746|Drug|ceritinib 750mg|
280121|NCT02599259|Device|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
280122|NCT02599272|Other|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
280123|NCT00191373|Drug|Gemcitabine|
280124|NCT02601508|Drug|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
280125|NCT02601508|Drug|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine & Glycopyrrolate
279221|NCT00204282|Behavioral|Educational presentation, group discussion, questionnaires|
279222|NCT02718014|Other|scaling and root planing (srp)|
279523|NCT02711709|Other|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
279524|NCT00203515|Device|Silver Coated Latex Foley Catheter|
279525|NCT02711722|Device|Neurally adjusted ventilatory assist|Ventilation supported by NAVA
Blood gas analysis
Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured.
279526|NCT02711722|Device|PScli1|Pressure support set by clinicians prior to inclusion
279527|NCT02711722|Device|PScli2|Pressure support at the same level as prior to the study
279528|NCT02711735|Biological|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
279529|NCT02711735|Biological|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
279530|NCT02711748|Device|electrostimulation|Electrostimulation using manual defibrillator
279531|NCT02711748|Device|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
279532|NCT02711761|Device|central venous catheterization|15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.
17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.
20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm.
279533|NCT02711774|Device|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
279534|NCT02711787|Device|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
279535|NCT00203528|Drug|divalproex sodium ER|
279536|NCT02711787|Device|Control group|Physiotherapy and occupational therapy.
279537|NCT02711787|Device|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
279538|NCT02713711|Procedure|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
279539|NCT02713711|Procedure|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
283792|NCT02589587|Procedure|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
283793|NCT02589587|Other|no intervention|lean control group
283794|NCT02589600|Drug|Zoledronic acid|Annual intravenous 5.0 mg
283795|NCT02589600|Dietary Supplement|vitamin D|800 IU daily
283796|NCT02589600|Dietary Supplement|calcium|1200 mg (dietary and supplement)
283797|NCT02589600|Other|Saline|Annual intravenous saline placebo
283798|NCT00190450|Procedure|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
283799|NCT02589613|Dietary Supplement|tap water|300ml tap water via nasogastric tube
283800|NCT02589613|Dietary Supplement|Glucose|300ml tap water with 75g Glucose via nasogastric tube
283801|NCT02589613|Dietary Supplement|Fructose|300ml tap water with 25g Fructose via nasogastric tube
279223|NCT02718040|Device|Emervel Classic and/or Deep Treatment Group|Severity of Wrinkle Severity to be treated by product type:
Emervel Classic:
Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3
Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4
Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)
279224|NCT02718053|Other|L-stiff|spasticity measurement with Lokomat
279225|NCT02718053|Other|Ashworth|spasticity measurement with Ashworth scale
279226|NCT02718066|Drug|HBI-8000 in combination with nivolumab|Phase 1b: HBI-8000, orally, twice a week, dose escalation 20 mg, 30 mg, 40 mg; in combination with nivolumab 3 mg/kg by 60 minutes intravenous infusion once every 2 weeks; for Phase 2: HBI-8000 MTD or 40 mg; in combination with nivolumab 3 mg/kg by 60 minutes intravenous infusion once every 2 weeks.
279227|NCT02718079|Biological|High Volume Plasma Exchange|
279228|NCT02718079|Drug|Prometheus|
279229|NCT02718079|Other|Management of cerebral edema/intracranial hypertension:|
279230|NCT02718079|Other|Transfer to Intensive Care Unit|
279231|NCT02718079|Drug|Prophylactic Antibiotics|
279232|NCT00204295|Drug|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
283496|NCT02593630|Device|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
283497|NCT00190879|Drug|Atomoxetine hydrochloride|
283498|NCT02593643|Drug|Ketamine|
283499|NCT02593643|Drug|Midazolam|
283500|NCT00191126|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
283501|NCT02596126|Drug|Cardiovascular Polypill|Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.
Participants will receive one of the following cardiovascular polypill:
(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).
or
(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).
283502|NCT02596126|Drug|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
283503|NCT02596139|Other|No Interventions|
283504|NCT02596152|Other|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
283505|NCT02596152|Other|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
283506|NCT02596165|Device|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
283507|NCT02596178|Device|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
283508|NCT02596191|Other|Clinical evaluation|
283802|NCT02589626|Drug|empagliflozin 10mg|
283803|NCT02589626|Drug|empagliflozin 25 mg|
283804|NCT02589626|Drug|Placebo|For blinding purposes
283805|NCT02589639|Drug|Empagliflozin|
283806|NCT02589639|Drug|Placebo|
283807|NCT02589639|Drug|Placebo|For blinding purposes
283808|NCT02589652|Drug|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
283220|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
283221|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
283222|NCT02600689|Behavioral|Physical exercise training|
283223|NCT02600689|Behavioral|Cognitive exercise training|
283224|NCT00191477|Drug|Placebo|intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
283225|NCT02600702|Other|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
283226|NCT02600702|Other|Physical modalities|
283227|NCT02600715|Drug|Onabotulinumtoxin A (BoNT)|
283228|NCT02600715|Drug|belladonna|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
283229|NCT02600715|Drug|Morphine|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
283230|NCT02600715|Drug|Placebo|matching placebo to B&O suppository
283231|NCT02602704|Drug|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day) for 48 weeks
283232|NCT02602717|Other|lymph nodes cyto-punction|
283233|NCT02602730|Behavioral|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
283234|NCT02602730|Behavioral|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
283235|NCT02602743|Drug|Remifentanyl|
283236|NCT02602743|Drug|Propofol|
283237|NCT02602743|Drug|Ketamine|
283238|NCT00191698|Drug|atomoxetine hydrochloride|
283239|NCT02602756|Radiation|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
282658|NCT02575599|Behavioral|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
282659|NCT02575612|Procedure|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (> 50 ultrasound guided minimal invasive biopsies per year, > 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
282660|NCT02577640|Dietary Supplement|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
282928|NCT02607241|Device|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR > 0.8, residual diameter stenosis < 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis > 40% or FFR < 0.8).
282929|NCT02607254|Drug|Pregabalin|This enriched enrollment randomized withdrawal study comprises 4 phases: a screening and selection phase, a washout period from previous pain medication for enriched enrollment, an 8 week single blind pregabalin treatment phase; and a 4 week randomized withdrawal phase.
282930|NCT02607254|Drug|Placebo|After finishing the first phase of treatment with Pregabalin for 8 weeks, patients who report significant improvement in their pain will be randomized to either receive placebo or Pregabalin.
282931|NCT02607267|Other|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
282932|NCT02607280|Drug|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7,5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
282933|NCT02607293|Drug|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
282934|NCT02607293|Drug|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
282935|NCT02607293|Drug|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
282936|NCT02607306|Drug|insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
282985|NCT02575807|Biological|CRS-207|via IV infusion
282986|NCT02575807|Drug|epacadostat (INCB024360)|PO BID
283278|NCT02607371|Other|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
283279|NCT02607371|Other|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
283280|NCT00192179|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
283281|NCT02607371|Other|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
283282|NCT02607371|Other|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
283283|NCT02607384|Behavioral|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
283284|NCT02607384|Behavioral|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
283285|NCT02607384|Other|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
283286|NCT02607410|Drug|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
283287|NCT02607410|Drug|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
283288|NCT02607423|Drug|Cisplatin|Given IV
283289|NCT02607423|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
283290|NCT02607423|Drug|Docetaxel|Given IV
282707|NCT02582346|Procedure|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
282708|NCT02582359|Drug|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
282709|NCT02582359|Drug|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
282710|NCT02582359|Drug|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
282987|NCT02575820|Procedure|Old red blood cells transfusion|Red blood cells (shelf life > 14 days) transfusion during the operation (total hip replacement arthroplasty)
282988|NCT02577744|Other|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
282989|NCT02577744|Other|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
282990|NCT02577757|Device|MRI|MRI
282991|NCT02577770|Device|acupuncture|therapeutic acupuncture treatment with actual needles
282992|NCT02577770|Dietary Supplement|200mg caffeine|8g coffee, po
282993|NCT02577770|Dietary Supplement|400mg caffeine|16g coffee, po
282994|NCT02577770|Dietary Supplement|Decaffeinated|decaffeinated coffee, po
282995|NCT02577783|Drug|Chemotherapy with PDD regimen|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
282996|NCT00188708|Procedure|hypoxia measurement|transrectal oxygen measurement
282997|NCT02577783|Drug|Chemotherapy with PAD regimen|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
282998|NCT02577809|Drug|Morphine100|100mcg added to the spinal anaesthetic
282999|NCT02577809|Drug|Morphine50|50mcg added to the spinal anaesthetic
283000|NCT02577809|Drug|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
283001|NCT02577809|Drug|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
283002|NCT02577809|Drug|Indomethacin|100mg Indomethacin suppository
283003|NCT02577822|Device|Taperloc standard length stem|
282430|NCT02588976|Device|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
282431|NCT02589002|Other|Sucralose|
282432|NCT00190346|Device|Humidification devices: HH vs HME|
282433|NCT02589028|Dietary Supplement|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
282434|NCT02589028|Other|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
282711|NCT00189423|Procedure|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
282712|NCT02582372|Drug|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
282713|NCT02582372|Drug|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
282714|NCT02582385|Other|in-situ cytokine expression|
282715|NCT02582398|Other|Light Therapy|
282716|NCT02582398|Other|Placebo Light|
282717|NCT02582411|Device|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
282718|NCT00002514|Procedure|allogeneic bone marrow transplantation|
282719|NCT00189631|Procedure|UFT/LV|
282720|NCT02584361|Procedure|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
282721|NCT02584361|Procedure|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
282722|NCT02584374|Other|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
282140|NCT02595515|Other|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
282141|NCT00191074|Drug|somatropin, rDNA origin, for injection|
282142|NCT02595528|Drug|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
282143|NCT02595528|Drug|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
282144|NCT02595528|Drug|AGN-190584 vehicle|Vehicle to AGN-190584
282145|NCT02595528|Drug|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
282146|NCT02595528|Drug|AGN-199201 vehicle|Vehicle to AGN-199201
282147|NCT02595541|Drug|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
282435|NCT02589041|Procedure|intraneural sciatic nerve injection|A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.
A baseline and postoperative electrophysiological study will assess the presence of any neurological complication.
282436|NCT02589041|Drug|Ropivacaine 1%|
282437|NCT02589054|Other|Monitoring|
282438|NCT02589067|Drug|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
282439|NCT02589067|Drug|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
282440|NCT02589080|Behavioral|Non-invasive sensory feedback|A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a "tactile display" on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of "real touch". Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a "map" of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback.
282441|NCT02589093|Device|Stimulation|
282442|NCT02589106|Device|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
281862|NCT02600000|Radiation|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
281863|NCT02600000|Device|Cardiopulmonary test|Assessment of maximal functional capacity
281864|NCT02600000|Device|AVD-Glittre Test|Assessment of submaximal functional capacity
281865|NCT02600000|Device|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
281866|NCT02600026|Device|DriveCam|Video event monitoring device
281867|NCT02600026|Behavioral|Feedback|Video feedback intervention
281868|NCT02602197|Drug|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
281869|NCT02602197|Drug|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
281870|NCT02602210|Drug|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
281871|NCT02602210|Drug|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
282148|NCT02595541|Drug|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
282149|NCT02595554|Radiation|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
282150|NCT02595554|Drug|Paclitaxel|Paclitaxel 150mg/m2 over 3 hours
282151|NCT02595554|Procedure|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
282152|NCT00191087|Drug|Duloxetine|
282153|NCT02595554|Drug|Cisplatin|Cisplatin 70mg/m2
282154|NCT02595567|Device|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
282155|NCT02595580|Device|Glucopred|
281565|NCT02606539|Procedure|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
281566|NCT02606539|Drug|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
281567|NCT02606552|Drug|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
281568|NCT02606552|Drug|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
281569|NCT02606552|Device|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
281570|NCT02606565|Biological|Intervention arm: 4% chlorhexidine|See previous description
281571|NCT02608879|Procedure|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
281572|NCT02608879|Procedure|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
281872|NCT02602223|Device|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
281873|NCT02602223|Device|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
281874|NCT00191646|Drug|Gemcitabine|1000 mg/m^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles
If anything other than complete response in Paclitaxel arm patients, 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity
281875|NCT02602236|Device|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
281275|NCT02574975|Drug|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
281276|NCT02574975|Drug|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
281277|NCT02574975|Device|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
281278|NCT02574975|Drug|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
281279|NCT02575001|Behavioral|Psychological background determinations|For the psychological background determinations a structured interview and questionnaires will be administered:
Child Attachment Interview (CAI)
General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy
"Parenting Stress Index" with the "19-item Life Stress Scale" (PSI)
Achenbach System of Empirically Based Assessment (CBCL, YSR)
Holmes and Rahe "Social readjustment rating scale"
Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)
Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)
281280|NCT02575001|Genetic|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
281281|NCT02577107|Drug|Conbercept|This prospective, randomized, open label study will enroll patients with neovascular AMD who are naïve to anti-VEGF therapy or have not received intravitreal anti-VEGF therapy for the previous 3 months.
Monthly injections of 0.5mg Conbercept during 3 month Blood sample (plasma/serum) will be collected at baseline (pre-dose), 3h post-injections and days 1, 3, 7 and 28, following doses 1 and 3 for PK and systemic VEGF analysis. The lab staff will be blinded for treatment allocation.
Plasma VEGF concentration will be measured by a blinded laboratory using Quantikine® ELISA kits. Serum Conbercept concentration will be determined using validated ELISA assay.
281282|NCT02577120|Device|Epiceram Skin Barrier Function|Epiceram is a non-sterile, viscous, lipid-rich emulsion
281283|NCT02577120|Biological|Vaseline Petroleum Jelly|A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
281573|NCT02608879|Device|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
281574|NCT02608879|Drug|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
281575|NCT02608892|Behavioral|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
281576|NCT02608905|Drug|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
281284|NCT02577120|Biological|Ceramiseal|Topical serum designed to fortify delicate skin with essential lipids. The proprietary blend of naturally occurring lipids contained in Ceramiseal are designed to improve the barrier function of your skin's outer layer; thereby restoring critical moisture balance and improving physical appearance and function.
281285|NCT02577133|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
281286|NCT02577133|Dietary Supplement|Placebo|The placebo consisted of an identical bottle with distilled water
281287|NCT02577146|Device|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
281288|NCT00002514|Drug|daunorubicin hydrochloride|
281289|NCT00188604|Drug|sodium selenite|
281290|NCT02577159|Drug|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
281291|NCT02577172|Behavioral|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of maximal heart rate) to moderate/high (between aerobic intervals 60-70% of maximal heart rate and during aerobic intervals 80-85 %).
281292|NCT02577172|Behavioral|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
281293|NCT02577185|Drug|Botulinum Toxin Type A|
281294|NCT02577185|Drug|Sodium chloride 9 mg/ml|
281295|NCT02577198|Other|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
281296|NCT02577211|Dietary Supplement|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
281297|NCT02577211|Dietary Supplement|Normocaloric enteral nutrition|25 kcal/kg of body weight
281298|NCT02577224|Other|Patient-initiated treatment|Please see Intervention Arm
281299|NCT02579330|Other|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
280733|NCT02588261|Drug|Gefitinib|oral
280734|NCT02588274|Device|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
280735|NCT02588274|Device|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
280736|NCT02588287|Other|Blood draws for tenofovir PK, renal function|
281004|NCT02583685|Drug|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
281005|NCT02583685|Drug|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
281006|NCT02583685|Drug|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
281007|NCT02583685|Drug|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
281008|NCT02583698|Drug|Carvedilol|
281009|NCT00189566|Drug|Topotecan|
281010|NCT02583698|Drug|Placebo|
281011|NCT02583711|Device|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
281012|NCT02583724|Device|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv).|EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).
EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises.
281013|NCT02583737|Procedure|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
281014|NCT02583737|Procedure|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
280417|NCT02594696|Other|Proactive Psychiatry Consultation (PPC)|The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.
The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.
The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks
The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).
Recommendations are documented in the medical record and communicated directly to the oncology team
280418|NCT02594709|Radiation|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
280419|NCT00190996|Drug|Duloxetine Hydrochloride|
280420|NCT02594722|Device|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
280421|NCT02594722|Device|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
280422|NCT02594735|Drug|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight < 50 KG).
280423|NCT02594748|Behavioral|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
280424|NCT02594748|Behavioral|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
280737|NCT02588300|Procedure|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
280738|NCT02588313|Dietary Supplement|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
280739|NCT02590744|Behavioral|eye patch|cover the sick eye with eye patch preoperatively for 3 hours
280740|NCT02590744|Behavioral|non-eye patch|do not cover the sick eye with eye patch preoperatively
280741|NCT02590757|Device|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
280742|NCT02590757|Device|N-CPAP|Nasal-continuous positive airway pressure
280743|NCT02590770|Behavioral|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
280744|NCT02590770|Other|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
280126|NCT02601521|Behavioral|Internal tobacco coach|The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:
Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.
The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.
Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program.
280127|NCT02601521|Behavioral|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
280128|NCT00191568|Drug|Oxaliplatin|
280129|NCT02601534|Behavioral|3 zero exercise|Two interactive sessions and monthly mobile messages related to 3 zero exercise
280130|NCT02601534|Behavioral|Healthy diet|Two interactive sessions and monthly mobile messages related to healthy diet
280131|NCT02601547|Device|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
280132|NCT02601560|Biological|MEDI6012|MEDI6012
280133|NCT02601560|Biological|Placebo|
280134|NCT02601573|Drug|Grazoprevir|GZR 100 mg provided in a FDC tablet also containing EBR 50 mg (MK-5172A) taken q.d. by mouth in the morning.
280135|NCT02601573|Drug|Elbasvir|EBR 50 mg provided in a FDC tablet also containing GZR 100 mg (MK-5172A) taken q.d. by mouth in the morning.
280136|NCT02601573|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose of 800 mg to 1400 mg based on participant body weight.
280137|NCT02601573|Drug|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
280138|NCT02601586|Drug|PR Oxycodone|PR Oxycodone+ Placebo of Levodopa
280139|NCT00002517|Drug|etoposide|
280140|NCT00191568|Procedure|Radiotherapy|
280425|NCT02594761|Biological|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
280426|NCT02594761|Biological|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
280427|NCT02594761|Biological|Herceptin US|Intravenous Infusion, 440 mg/vial
279540|NCT02713724|Behavioral|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will recieve a membership at a gym but limited instructions
279541|NCT02713724|Behavioral|limited physical exercise|The standard group will recieve a membership at a gym but limited instructions and no access to a personal trainer
279542|NCT02713737|Device|heated humidified high-flow nasal cannula|HFNC device (Optiflow™, Fisher＆Paykel, Auckland, New Zealand) with a heated chamber ( Fisher＆Paykel, MR850 humidifier) and a circuit (Fisher＆Paykel,RT310). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) > 92%.
279836|NCT02605759|Device|CryoBalloon Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface to a temperature of approximately -80°C. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
279837|NCT00192036|Drug|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
279838|NCT02605772|Drug|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
279839|NCT02605772|Drug|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
279840|NCT02605772|Drug|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
279841|NCT02605785|Drug|F-18 AV 1451|Tau PET scan
279842|NCT02605798|Drug|Elbanovir|1 tablet contains 400 mg sofosbuvir
279843|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
279844|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
279845|NCT02605811|Drug|temozolomide|
279846|NCT00192296|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
279847|NCT02608216|Device|PET/CT|[18F]FLT PET/CT scan
279848|NCT02608216|Drug|ribociclib|therapeutic
279849|NCT02608216|Drug|paclitaxel|therapeutic
279850|NCT02608229|Drug|BVD-523|
279851|NCT02608229|Drug|Nab-paclitaxel|
279852|NCT02608229|Drug|Gemcitabine|
279853|NCT02608242|Drug|YH22189|
279233|NCT02718079|Other|Intubation of trachea|
279234|NCT02718079|Other|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
279235|NCT02718079|Other|Volume Replacement|
279236|NCT02718079|Other|Pressor Support|
279237|NCT02718079|Drug|N-acetyl-L-cysteine|
279238|NCT02718079|Other|Correction of metabolic parameters|
279239|NCT02718079|Dietary Supplement|Correction of nutrition|
279240|NCT02718092|Device|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
279241|NCT02684695|Other|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
279242|NCT02684695|Other|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
279243|NCT02684708|Drug|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
279244|NCT02684708|Drug|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
279543|NCT00203788|Behavioral|Individual Placement and Support|Supported education/employment
279544|NCT02713737|Device|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 > 92%.
279545|NCT02713750|Other|reversible contraceptive methods|Consistent male condom use only
Consistent female condom use only
Hormonal contraception, combined oral contraceptive pills and male/female condom
Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom
Hormonal contraception , progestin only hormonal implant and male/female condom
Intrauterine device and male/female condom
279546|NCT02713763|Drug|Sunitinib|Sunitinib 37.5 mg/day
279547|NCT02713776|Drug|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
279548|NCT02713776|Drug|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
279549|NCT02713789|Drug|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
279550|NCT02713789|Drug|Placebo (PBS-20% sucrose)|
283809|NCT00190463|Drug|Amphotericin B|
283810|NCT02589652|Drug|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
283811|NCT02589652|Drug|Entecavir|ETV 0.5mg oral daily for 48 weeks
283812|NCT02589665|Drug|LY3074828|
283813|NCT02589665|Drug|Placebo|
283814|NCT02589678|Biological|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
283815|NCT02589678|Biological|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
283816|NCT02589691|Drug|Rocuronium|
283817|NCT02589691|Other|NaCl 0.9%|
283818|NCT02589717|Drug|Atezolizumab|1200 mg, administered by intravenous (IV) infusion every 3 weeks
283819|NCT00190658|Drug|Somatropin (rDNA origin) for injection|
283820|NCT02591771|Drug|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
283821|NCT02591784|Drug|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
283822|NCT02591784|Radiation|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
283823|NCT02591797|Procedure|inferior alveolar and lingual nerve block procedure|In this technique the needle is inserted laterally to the pterigomandibular pit at its deepest point without noticing any resistance. It is similarly performed in adults and children. The only difference is that the hole in the mandibular dentition is located in slightly below the occlusal plane. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution, thereby anesthetizing the lingual nerve.
279245|NCT02684721|Other|8-week home-based exercise programme|8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
279246|NCT02684747|Other|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
279247|NCT00200252|Drug|oxytocin|
279248|NCT02684747|Other|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
283240|NCT02602769|Procedure|Body composition|The investigators will measure body composition by Dual energy X-ray absorptiometry, a non-invasive procedure with minimal radiation and provides body composition including fat - and fat-free body mass.
283241|NCT02602769|Behavioral|Energy intake|The investigators will obtain dietary intake over 3-days by using food-intake questionnaire and diet recall.
283509|NCT02596191|Other|electrophysiological record|
283510|NCT02596191|Other|Muscle MRI|
283511|NCT00191126|Drug|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
283512|NCT02596191|Other|blood samples analysis|
283513|NCT02596204|Other|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
283514|NCT02596204|Device|FitBit|All subjects will wear a FitBit activity monitor.
283515|NCT02596217|Drug|BI 655066|i.v. infusion
283516|NCT02596217|Drug|Placebo|Placebo (stage1)
283517|NCT02596217|Drug|Placebo|Placebo (stage2)
283518|NCT02596243|Biological|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
283519|NCT02596243|Biological|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
283520|NCT02596256|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
283521|NCT02596256|Drug|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
283522|NCT00191126|Procedure|surgery|surgery
283523|NCT02598336|Device|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
283524|NCT00191282|Drug|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values >8.0%
283525|NCT02598336|Device|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
282937|NCT00192166|Biological|CAIV-T|
282938|NCT02607306|Drug|insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
282939|NCT02607306|Drug|liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
282940|NCT02607319|Drug|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
282941|NCT02607332|Drug|Paclitaxel|
282942|NCT02607345|Dietary Supplement|Zusto|25gr
282943|NCT02609347|Other|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
282944|NCT02609347|Other|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
282945|NCT02609360|Other|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
283242|NCT02602769|Procedure|Resting energy expenditure|This will be measured by Indirect calorimetry. Indirect calorimetry is a non-invasive, 30-minute test during which a clear plastic hood will be placed over the subject's head to measure oxygen consumption and carbon dioxide production.
283243|NCT02602769|Procedure|Total energy expenditure|This will be measured by standard technique of doubly labeled water. The subjects receive a one-time dose of doubly labeled water (DLW) based on their weight for measurement of total energy expenditure. We will also collect baseline and 4-hour post-dose urine sample. Subjects will receive instructions in collecting daily urine samples for measurement of energy expenditure in labeled containers for the next 7 -days at home.
283244|NCT02602769|Other|Mixed meal tolerance test|Subjects will consume 6 cc/kg (maximum 360 cc) of a liquid mixed meal (t=0), (Boost High Protein; Mead Johnson Nutritionals; 45% carbohydrate, 15% protein, and 40% fat) within a 10-min window. Blood samples will be obtained at t= -15, 0, 15, 30, 60, 90, 120, and 180 min. Leptin will be measured at t=-15 and 0 min. Postprandial samples will be assayed for active ghrelin.
283245|NCT02602795|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
283246|NCT02602795|Behavioral|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
283247|NCT02602834|Other|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
283248|NCT02602834|Other|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
283249|NCT00191698|Drug|placebo|
283291|NCT00192179|Biological|Placebo|The placebo consisted of physiologic normal saline.
283566|NCT02602860|Drug|Brivaracetam|Pharmaceutical form: Sterile solution for intravenous infusion
Concentration: 10 mg/ml
Route of Administration: iv
283567|NCT02602860|Drug|Levetiracetam|Pharmaceutical form: Sterile solution for intravenous infusion
Concentration: 100 mg/ml
Route of Administration: iv
283568|NCT02602873|Other|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
283569|NCT02602886|Behavioral|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
283570|NCT02602899|Procedure|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
283571|NCT02602912|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
283572|NCT02602925|Other|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
283573|NCT02602925|Other|Usual care|Usual care
283574|NCT00191711|Drug|Gemcitabine|
283575|NCT02602938|Drug|Aspirin|Take aspirin (100mg) orally once a day for 2 months
283576|NCT02602951|Other|Pilot MRI program|Pilot MRI program
283577|NCT02602951|Other|MRI with 4D Flow sequence|MRI with 4D Flow sequence
283578|NCT02602964|Other|Deep neuromsucular block|Deep or standard neuromuscular block
283579|NCT02602977|Other|Multiple-dose Remote Ischemic Preconditioning|A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.
1 "RIPC-dose" consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.
Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days.
283004|NCT02577822|Device|Taperloc short length stem|
283005|NCT02577835|Device|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
283006|NCT02577848|Drug|GLP-1|GLP-1 were taken daily for 7 days
283007|NCT00002514|Drug|dexamethasone|
283008|NCT00188747|Procedure|Thromboelastograph, Point of Care|
283009|NCT02577848|Drug|Placebo|Placebo were taken daily for 7 days
283010|NCT02577861|Procedure|Biopsy from donor eye|Corneal biopsy from undamaged limbus
283292|NCT02609438|Behavioral|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
283293|NCT02609438|Behavioral|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
283294|NCT02609451|Procedure|Ileostomy closure|Ileostomy closure at a different time point
283295|NCT02609464|Device|Interrupted Knotted Sutures|
283296|NCT02609464|Device|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
283297|NCT02609477|Drug|Istradefylline|Istradefylline 40, 80, 160 mg
283298|NCT02609477|Drug|Phentermine 45 mg|Phentermine 45 or 90 mg
283299|NCT02609477|Other|Placebo|Placebo
283300|NCT02609490|Drug|Azilsartan tablets|20mg/tablet
283301|NCT02609490|Drug|Azilsartan placebo tablets|placebo tablet
283302|NCT00192426|Biological|CAIV-T|
283303|NCT02609490|Drug|Olmesartan medoxomil tablets|20mg/tablet
282723|NCT02584387|Behavioral|360° Video Virtual Reality Exposure Therapy|360-Degree Video VR is a radical filmmaking technology that can turn live action footage into a 360-degree environment that users can interact with. 360-Degree Video VR is made by filming with an array of multiple HD cameras carefully arranged to capture all angles in a 360-degree area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users HDM. Leading to the effect that when a user turns his head, their view of the live action video footage turns with them in real time (e.g. if the user looks down, the camera pans down and the user sees the floor) allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event.
282724|NCT02584400|Drug|Injection with the hypoxia tracer [18F]HX4,|The [18F]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) [18F]HX4 via a bolus IV injection.
282725|NCT02584413|Device|Magnetic resonance imaging|
282726|NCT02584413|Drug|Gadolinium contrast|
282727|NCT02584426|Device|Ultrasonic Distribution of Cefazolin|
282728|NCT02584439|Drug|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
283011|NCT02577861|Procedure|Implant of Holoclar|Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus
283012|NCT02577861|Procedure|Ophtalmologic examination|The following assessments are performed:
Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia.
283013|NCT02577861|Procedure|Blood sample collection|Standard haematology, biochemistry and Infectious profile (Virology) are assessed
283014|NCT02577861|Procedure|Digital pictures|At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera
283015|NCT02579993|Procedure|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
283016|NCT02580006|Drug|EPORON|single dose administration subcutaneously
283017|NCT00189085|Drug|simvastatin and ezetimibe|
283018|NCT02580006|Drug|EPREX|single dose administration subcutaneously
283019|NCT02580019|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
283020|NCT02580032|Other|No treatment given|No treatment given.
283021|NCT02580058|Biological|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
282443|NCT00190372|Behavioral|Controlled diet|Controlled diet
282444|NCT02589119|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
282445|NCT02589132|Other|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
282446|NCT02589145|Drug|Lenalidomide|Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I.
282447|NCT02589145|Drug|Vorinostat|1000 mg by mouth on Days -9 to -2.
282448|NCT02591355|Device|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
282449|NCT02591355|Device|Saline solution injection|Placebo is a saline solution
282450|NCT02591368|Procedure|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
282729|NCT02584439|Drug|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
282730|NCT00189631|Procedure|Observation|
282731|NCT02584452|Procedure|Femoral Nerve Block|single bolus femoral nerve block
282732|NCT02584452|Drug|ropivacaine|with 20cc of 0.5% ropivacaine <20 minutes prior to in room time
282733|NCT02584452|Drug|Mepivacaine|20cc of 2% mepivacaine <20 minutes prior to in room time.
282734|NCT02584452|Procedure|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
282735|NCT02584452|Drug|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
282736|NCT02584452|Procedure|adductor canal nerve block|ultrasound guided adductor canal nerve block
282737|NCT02584452|Drug|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
282738|NCT02584465|Drug|Tamoxifen|Tamoxifen: 40 mg/day
282739|NCT02584465|Drug|Regorafenib|Stivarga; 160mg/day
282156|NCT02595593|Device|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
282157|NCT02595606|Drug|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
282158|NCT02595619|Device|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
282159|NCT02595632|Other|No intervention|
282160|NCT02595645|Genetic|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
282161|NCT02595658|Dietary Supplement|Meal composition|
282162|NCT02595658|Drug|Rapid-Acting Insulin Dose|
282163|NCT00191100|Drug|Gemcitabine|
282164|NCT02597751|Behavioral|Cognitive Orientation to Occupational Performance (CO-OP)|CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the "breakdown" is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention.
282165|NCT02597764|Behavioral|Diaphragmatic Breathing|
282166|NCT02597764|Behavioral|Standard Urotherapy|
282451|NCT02591368|Procedure|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
282452|NCT02591368|Procedure|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
282453|NCT00190606|Procedure|Imitation PFMT|
282454|NCT02591381|Procedure|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
282455|NCT02591394|Behavioral|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
281876|NCT02602249|Biological|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
281877|NCT02602249|Biological|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
281878|NCT02602262|Other|HIV-infected deceased donor organ|HIV-infected deceased donor organ transplant
281879|NCT02602275|Drug|Neurexan®|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the experimantal arm participants will receive verum on DAY1/PERIOD 1 and will receive placebo on DAY2/PERIOD 2.
281880|NCT02602275|Other|Placebo|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the comparator arm participants will receive placebo on DAY1/PERIOD 1 and will receive verum on DAY2/PERIOD 2.
281881|NCT02602288|Behavioral|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
281882|NCT02602288|Behavioral|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
281883|NCT02602288|Behavioral|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
281884|NCT02602288|Device|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
281885|NCT02604342|Drug|Alectinib|Participants will receive oral alectinib at a dosage of 600 mg BID, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
281886|NCT02604342|Drug|Docetaxel|Participants will receive docetaxel 75 mg per square meter every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
281887|NCT00000375|Drug|Nortriptyline-lithium (NOR-Li)|
282167|NCT02597777|Other|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
282168|NCT02597777|Other|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
282169|NCT02597803|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
282170|NCT02597803|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
282171|NCT02597816|Radiation|Three dimensional ultrasound|
282172|NCT00191256|Drug|Gemcitabine|
282173|NCT02597829|Drug|Certolizumab Pegol|Subcutaneous Injection
281577|NCT02608905|Drug|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
281578|NCT00192335|Biological|CAIV-T|
281579|NCT02608918|Drug|BMS-955176|
281580|NCT02608931|Drug|Dronabinol|
281581|NCT02608931|Other|Placebo|placebo
281582|NCT02608944|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
281583|NCT02608944|Drug|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
281584|NCT02608944|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
281585|NCT02608944|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
281586|NCT02608944|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
281587|NCT02608957|Device|Latella Knee Implant System|
281588|NCT02608970|Drug|BMS-986177|
281589|NCT00192335|Biological|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
281590|NCT02608970|Other|Placebo|
281591|NCT02608983|Dietary Supplement|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
281592|NCT02608983|Dietary Supplement|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
281888|NCT00002517|Procedure|allogeneic bone marrow transplantation|
281889|NCT00191854|Drug|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
281890|NCT02604342|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg per square meter of body-surface area every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
281891|NCT02604355|Other|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
335730|NCT00424190|Drug|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
335731|NCT00424203|Drug|AC regimen|
335732|NCT00424203|Drug|cyclophosphamide|
335733|NCT00003375|Radiation|radiation therapy|
335734|NCT00424203|Drug|doxorubicin hydrochloride|
335735|NCT00424203|Procedure|adjuvant therapy|
335736|NCT00424203|Procedure|cognitive assessment|
335737|NCT00424203|Procedure|management of therapy complications|
335738|NCT00424203|Procedure|psychosocial assessment and care|
335739|NCT00424203|Procedure|quality-of-life assessment|
335740|NCT00424216|Procedure|DC Polarization|
335741|NCT00424229|Drug|LENALIDOMIDE|
335742|NCT00424242|Drug|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
335743|NCT00424255|Drug|Lapatinib|Dual ErbB1/2 inhibitor
335744|NCT00003376|Drug|carboplatin|
335745|NCT00424255|Radiation|Chemoradiation|Radiation plus platinum based chemotherapy
335746|NCT00424255|Other|Placebo|Placebo
336103|NCT00415857|Biological|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
336104|NCT00000509|Behavioral|diet, sodium-restricted|
336105|NCT00003323|Drug|finasteride|5 mg/d PO
336106|NCT00415857|Drug|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
336107|NCT00415857|Drug|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
336108|NCT00415857|Drug|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
336109|NCT00415870|Behavioral|Printed Material|Printed Material
335028|NCT00441168|Drug|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
335378|NCT00433056|Drug|stable HAART|continuous therapy
335379|NCT00433069|Drug|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
335380|NCT00433069|Drug|Interferon Alfa-2a|Standard of care for chronic hepatitis C
335381|NCT00433069|Drug|Ribavirin|Standard of care for chronic hepatitis C
335382|NCT00433082|Behavioral|Ramadan Fasting|
335383|NCT00433095|Drug|Navelbine|
335384|NCT00433095|Drug|Herceptin|
335385|NCT00433095|Drug|Navelbine (oraly)|
335386|NCT00003401|Drug|cyclophosphamide|
335387|NCT00433108|Drug|Mitoquinone mesylate (MitoQ)|
335388|NCT00433121|Drug|Risperidone|
335389|NCT00433121|Drug|Olanzapine|
335390|NCT00433121|Drug|Haloperidole|
335391|NCT00433121|Drug|Quetiapin|
335392|NCT00433121|Drug|Escitalopram|
335393|NCT00433121|Drug|Citalopram|
335394|NCT00433121|Drug|Sertralin|
335395|NCT00433134|Behavioral|Adherence|
335396|NCT00433147|Drug|AT2101|AT2101 25 mg orally once a day (25 mg capsule), AT2101 150mg (six 25 mg capsules)once a day, AT2101 150mg once every fourth day, or AT2101 150 mg once per week for 28 days.
335397|NCT00003401|Drug|dexamethasone|
335398|NCT00433160|Drug|Teriparatide|daily, subcutaneous
335399|NCT00433160|Drug|Placebo|daily, subcutaneous
334664|NCT00447200|Procedure|Esophagus Doppler monitoring|
334665|NCT00447200|Procedure|Fluid optimization|
334666|NCT00003477|Drug|antineoplaston A10|
334667|NCT00450034|Procedure|drug - oriented multifaceted intervention|oriented multifaceted intervention
334668|NCT00450047|Device|Speed-feedback therapy system with a bicycle ergometer|
334669|NCT00450047|Device|Ergometer at conventional settings|
334670|NCT00450060|Device|lumbar puncture with Quincke-design needles|
334671|NCT00450060|Device|lumbar puncture with Sprotte-design needles|
334672|NCT00450073|Drug|ergocalciferol (vitamin D2)|50,000 IU weekly
334673|NCT00450073|Device|Sperti Del Sol Lamp|5 times a week for 12 weeks
334674|NCT00450073|Drug|Vitamin D3|50,000 IU weekly
334675|NCT00450086|Drug|Budesonide|9 mg per day
334676|NCT00450086|Drug|Mesalazine|3 g per day
334677|NCT00003477|Drug|antineoplaston AS2-1|
334678|NCT00450086|Drug|Placebo|0 g per day
334679|NCT00450099|Drug|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
334680|NCT00450112|Device|Gel-200|Single Intra-articular Injection
335029|NCT00441168|Drug|vincristine|vincristine: 0.4mg IV push on days 1 to 4
335030|NCT00441181|Drug|Travoprost|
335031|NCT00441194|Device|Visual Field (Octopus 311 and the HFA 700 series)|
335032|NCT00441207|Drug|Ascorbic Acid|Delivered via IV Infusion.
335033|NCT00441233|Device|Silicone hydrogel contact lens|
335034|NCT00441246|Drug|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
334317|NCT00455572|Biological|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
334318|NCT00455572|Drug|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
334319|NCT00455572|Drug|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
334320|NCT00455572|Procedure|Radiotherapy|Regimen will be based upon the site's own standard procedures
334321|NCT00455585|Drug|nevirapine, stavudine, lamivudine|
334322|NCT00455598|Drug|ISIS 113715|doses of 100 and 200 mg per week
334323|NCT00458978|Other|Laboratory Biomarker Analysis|Correlative studies
334324|NCT00458991|Drug|Dextromethorphan and Caffeine|All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic "probes" (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH.
334325|NCT00459004|Drug|rimonabant (SR141716)|
334326|NCT00459017|Device|Portable blood pressure wrist manometer|
334327|NCT00459030|Other|educational intervention via internet|additional cancer screening information via password protected internet site
334328|NCT00459030|Other|educational intervention mailed|
334329|NCT00000151|Drug|Aspirin|
334330|NCT00000527|Drug|dipyridamole|
334331|NCT00003523|Drug|aminocamptothecin colloidal dispersion|
334332|NCT00459030|Other|No additional educational intervention|
334333|NCT00459043|Drug|ZD6474|Taken orally once every morning
334334|NCT00459043|Drug|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
334335|NCT00459056|Drug|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
334336|NCT00459056|Drug|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
339443|NCT00546052|Drug|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
339444|NCT00546065|Drug|esomeprazole treatment|concomitant esomeprazole treatment
339445|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
339446|NCT00546078|Biological|Cervarix™|Intramuscular injection, one or three doses
339447|NCT00546104|Drug|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
339448|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
339449|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
339450|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
339451|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
339452|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
339793|NCT00540904|Drug|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
339794|NCT00540917|Procedure|cooling spray during laser treatment|skin temperature measurement
339795|NCT00540930|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
339796|NCT00540943|Drug|pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
339797|NCT00540956|Drug|cytarabine|
339798|NCT00540956|Other|laboratory biomarker analysis|
339799|NCT00540969|Procedure|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
339800|NCT00540969|Radiation|radiation therapy|Patients undergo radiotherapy for 1 week
339801|NCT00540982|Drug|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
339802|NCT00003927|Drug|doxorubicin hydrochloride|
339803|NCT00540982|Drug|lidocaine|1 mg/kg will be administered to determine metabolic capacity
344027|NCT00518206|Drug|Cyclophosphamide|Cyclophosphamide (300mg/sq.m dose) intravenous injection 1 day prior to each of 3x fourth weekly intramuscular injections with NY-ESO-1 ISCOMATRIX® vaccine (100 microgram of NY-ESO-1 protein formulated with 120 microgram of ISCOMATRIX® adjuvant). Treatment may continue for further cycles unless other systemic melanoma treatment is required.
344028|NCT00518219|Drug|TW|TW,120mg/d
344029|NCT00518232|Drug|OROS-methylphenidate|
344382|NCT00507416|Drug|Thalidomide|Thalidomide for oral administration
344383|NCT00507429|Drug|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
344384|NCT00507429|Drug|paclitaxel|200mg/m squared on Day 1
344385|NCT00507429|Drug|carboplatin|6 AUC on Day 1 following paclitaxel
344386|NCT00507442|Drug|VELCADE (bortezomib)|bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
344387|NCT00507442|Drug|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
344388|NCT00507442|Drug|cyclophosphamide|cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
344389|NCT00507442|Drug|Revlimid (lenalidomide)|lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)
lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)
344390|NCT00507455|Drug|solifenacin succinate|Solifenacin succinate tablets
344391|NCT00507455|Drug|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
344392|NCT00003747|Drug|carboplatin|
344393|NCT00507455|Drug|Placebo to solifenacin|
344394|NCT00507455|Drug|Placebo to tamsulosin|
344395|NCT00507468|Procedure|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
344396|NCT00507494|Drug|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
344397|NCT00507507|Drug|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
344398|NCT00463515|Drug|carboplatin/gemcitabine|
343689|NCT00526318|Drug|ifosfamide|
343690|NCT00526318|Drug|isotretinoin|
343691|NCT00526318|Drug|melphalan|
343692|NCT00526318|Drug|topotecan hydrochloride|
343693|NCT00526318|Drug|vincristine sulfate|
343694|NCT00526318|Drug|vindesine|
343695|NCT00526318|Procedure|autologous hematopoietic stem cell transplantation|
343696|NCT00526318|Radiation|iobenguane I 131|
343697|NCT00003852|Drug|cyclophosphamide|
343698|NCT00526318|Radiation|radiation therapy|
343699|NCT00526331|Device|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
343700|NCT00526331|Device|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
344030|NCT00518245|Drug|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
344031|NCT00003805|Drug|piperacillin sodium|
344032|NCT00518271|Drug|Rapamune® (Sirolimus)|
344033|NCT00518271|Drug|Tacrolimus|
344034|NCT00518271|Drug|Corticosteroids|Perioperative
344035|NCT00518284|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m^2.
344036|NCT00518297|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
344037|NCT00518297|Drug|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
344038|NCT00518297|Drug|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
344039|NCT00518310|Drug|Placebo|
343043|NCT00539526|Drug|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
343365|NCT00531882|Drug|Pioglitazone|30 mg once a day
343366|NCT00531882|Drug|Simvastatin|40 mg once a day
343367|NCT00531882|Drug|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
343368|NCT00531895|Drug|duloxetine|duloxetine 60 mg/d
343369|NCT00531908|Drug|furosemide|furosemide
343370|NCT00003874|Procedure|in vitro-treated peripheral blood stem cell transplantation|
343371|NCT00531934|Drug|Doxycline|100mg po daily
343372|NCT00531934|Drug|erlotinib [Tarceva]|150mg po daily
343373|NCT00531947|Drug|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
343374|NCT00531947|Drug|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
343375|NCT00531960|Drug|Erlotinib|150 mg, PO, daily
343376|NCT00534482|Behavioral|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
343377|NCT00534482|Behavioral|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
343378|NCT00534495|Biological|Rilonacept|2.2 mg/kg subcutaneously
343379|NCT00534508|Drug|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
343380|NCT00534521|Device|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
343381|NCT00003891|Drug|lurtotecan liposome|
342711|NCT00547235|Radiation|total-body irradiation|
342712|NCT00547248|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
342713|NCT00547248|Biological|Tritanrix-HepB|Intramuscular injection, 1 dose
342714|NCT00547248|Biological|Hiberix Hib vaccine|Reconstituted with Tritanrix-Hep B before injection
342715|NCT00547248|Biological|Polio Sabin|Oral, 1 dose
342716|NCT00547248|Biological|Poliorix|Intramuscular injection, 1 dose
342717|NCT00003957|Biological|recombinant human stem cell factor|
342718|NCT00547248|Biological|Prevenar (Wyeth)|Intramuscular injection, 1 dose
342719|NCT00547261|Drug|SSR97225|every 3 weeks
342720|NCT00547274|Drug|MK0767|
342721|NCT00547287|Drug|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
342722|NCT00547287|Drug|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
343044|NCT00539526|Drug|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
343045|NCT00539539|Other|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
343046|NCT00539565|Drug|prednisolone|2 mg/kg /day from post-op day 7 - day 21
1 mg/kg /day from post-op day 22 - day 30
343047|NCT00003920|Drug|cyclosporine|
343048|NCT00539565|Drug|placebo|
343049|NCT00539578|Drug|MK0777|Duration of Treatment: 4 weeks
343050|NCT00539578|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
343051|NCT00539591|Drug|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
343052|NCT00539591|Drug|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
342032|NCT00514657|Drug|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
342033|NCT00003788|Procedure|neoadjuvant therapy|
342350|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
342351|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
342352|NCT00550147|Drug|Oros Methylphenidate|Oros methylphenidate will be titrated over 3 visits according to the following schedule:
Visit 2 dose of 18 mg QAM
Visit 3 dose of 36mg QAM
Visit 4 dose of 54mg QAM.
342353|NCT00509106|Drug|Ceftriaxone|1 g dose parenteral infused over 30 minutes over 30 minutes, every 24 hours for 5 to 7 days
342354|NCT00509106|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
342355|NCT00509132|Drug|trodusquemine|
342356|NCT00509145|Drug|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
342357|NCT00509145|Other|Placebo|oral, once daily, capsule
342358|NCT00509158|Biological|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
342359|NCT00509158|Biological|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
342360|NCT00509171|Device|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
342361|NCT00003758|Procedure|peripheral blood stem cell transplantation|
342362|NCT00509184|Drug|Rituximab|375 mg/m^2, weekly (4 weeks), repeated after 4 weeks gap
342363|NCT00509197|Drug|Placebo|Fluticasone 250 mcg bid
342364|NCT00509197|Drug|Fluticasone|Fluticasone 250mcg bid for one month
342365|NCT00509210|Drug|telaprevir (VX-950)|
342366|NCT00509223|Device|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
334499|NCT00429715|Biological|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
334500|NCT00429715|Biological|Alum-ALM + BCG|Alum-ALM + BCG
334501|NCT00003394|Drug|paclitaxel|
334502|NCT00429728|Drug|GW876008|
334503|NCT00429754|Drug|Aprepitant|
334504|NCT00429780|Biological|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
334505|NCT00429793|Drug|temsirolimus|Given IV
334506|NCT00429806|Drug|DHEA|DHEA
334507|NCT00429806|Drug|Placebo|Placebo
334508|NCT00429832|Drug|Ondansetron|
334509|NCT00429832|Drug|promethazine|
334510|NCT00429845|Behavioral|Nutritional|
334511|NCT00432666|Drug|Placebo|Placebo
334512|NCT00432679|Drug|Rosiglitazone (BRL49653C)|
334513|NCT00432692|Procedure|Falls Prevention Program|
334514|NCT00432705|Procedure|Checking stability of ankle|Flexing and walking
334515|NCT00003400|Drug|melphalan|
334516|NCT00432718|Procedure|Saline Instillation before Tracheal Suctioning|
334517|NCT00432731|Biological|VARIVAX®|
334518|NCT00432731|Biological|M-M-RTM II|
334519|NCT00432744|Drug|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
334520|NCT00432744|Drug|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
334521|NCT00432757|Drug|Ketotifen with a Contact Lens (generic name not yet established)|
334522|NCT00432770|Drug|ARC1779|
339634|NCT00521820|Drug|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
339635|NCT00000556|Device|pacemaker, artificial|
339636|NCT00524550|Dietary Supplement|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
339637|NCT00524576|Biological|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
339638|NCT00524589|Dietary Supplement|calcitriol|IV
339639|NCT00524589|Drug|dexamethasone|Oral
339640|NCT00003842|Biological|interleukin-4 PE38KDEL cytotoxin|
334151|NCT00438399|Drug|Corticosteroid 3 - C. propionate|Twice daily application
334152|NCT00438425|Dietary Supplement|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
334153|NCT00440739|Drug|flavoxate|flavoxate 200 mg 3 times
334154|NCT00003428|Drug|arzoxifene hydrochloride|
334155|NCT00440739|Drug|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
334156|NCT00440739|Drug|placebo|placebo once and placebo 3 times
334157|NCT00440765|Drug|bortezomib|dose as determined (observational study) by treating physician
334158|NCT00440778|Drug|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
334159|NCT00440791|Device|PillCam Colon capsule endoscopy|
334160|NCT00440804|Drug|ibuprofen l-lysine iv solution (NeoProfen (R) )|
334161|NCT00440817|Other|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
334162|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
334163|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
339274|NCT00530049|Procedure|quality-of-life assessment|
339275|NCT00530062|Drug|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
339276|NCT00530062|Drug|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
339277|NCT00530075|Drug|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
339278|NCT00530088|Drug|porfimer sodium|IV
339279|NCT00530088|Drug|Photdynamic Therapy (PDT)|
339280|NCT00003867|Drug|irinotecan hydrochloride|
339281|NCT00530101|Drug|Doxorubicin|This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:
Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2
339282|NCT00530114|Drug|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
339283|NCT00530114|Drug|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
339284|NCT00530127|Drug|placebo|Same dose and frequency as treatment
339285|NCT00530127|Drug|deferiprone|100 mg/mL
339286|NCT00530127|Drug|deferiprone|100 mg/mL
339287|NCT00530127|Drug|placebo|Same dosage and frequency as study drug
339288|NCT00530127|Drug|deferiprone|100 mg/mL
339289|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
339290|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
339291|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
339292|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
339293|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
338281|NCT00550784|Drug|paclitaxel|
338282|NCT00550784|Drug|topotecan hydrochloride|
338283|NCT00550784|Genetic|TdT-mediated dUTP nick end labeling assay|
338284|NCT00550784|Genetic|gene expression analysis|
338285|NCT00550784|Other|immunohistochemistry staining method|
338286|NCT00550784|Other|pharmacological study|
338287|NCT00550784|Procedure|peripheral blood stem cell transplantation|
338288|NCT00003976|Drug|indisulam|
338614|NCT00543153|Behavioral|Interview|Interview lasting approximately 30-45 minutes.
338615|NCT00543166|Drug|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
338616|NCT00543179|Drug|Somatuline (Lanreotide Autogel®)|
338617|NCT00003937|Drug|ifosfamide|
338618|NCT00543205|Drug|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
338619|NCT00543218|Drug|teriparatide 20 micrograms/day subcutaneous|
338620|NCT00543218|Drug|calcitonin 100 IU/day subcutaneous|
338621|NCT00543231|Drug|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
338622|NCT00543244|Drug|Pegylated interferon alfa and ribavirin|Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: < 75 kg 1000 mg/day, >=75 kg 1200 mg/day; genotype 2: 800 mg/day)
HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)
338623|NCT00545558|Drug|Efavirenz|600 mg tablet taken orally daily
338624|NCT00545558|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
338625|NCT00545571|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120 or 200 micrograms iv monthly, starting dose
338626|NCT00545584|Drug|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
338627|NCT00545584|Behavioral|Comparator: Diet|Diet
337589|NCT00431041|Drug|oxybutynin immediate release|Oral
337590|NCT00431054|Drug|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
337591|NCT00431054|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour every 4 weeks
337592|NCT00431067|Drug|BIBW 2992|
337593|NCT00431080|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
337594|NCT00431080|Drug|Paclitaxel|Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
337595|NCT00431080|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
337596|NCT00431080|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
337597|NCT00003397|Procedure|bone marrow ablation with stem cell support|
337598|NCT00431080|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
337599|NCT00431080|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
337600|NCT00433771|Device|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
337601|NCT00433784|Drug|Clopidogrel|
337602|NCT00433784|Procedure|Blood sampling - platelet aggregation|
337603|NCT00003402|Drug|melphalan|
337604|NCT00433784|Procedure|Blood sampling - genotyping|
337605|NCT00433797|Dietary Supplement|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
337606|NCT00433823|Drug|Atorvastatin, Ezetimibe|
337929|NCT00515437|Biological|Botulinum Toxin Type B (Myobloc)|
337930|NCT00515437|Biological|Matched placebo to Myobloc|
337931|NCT00515450|Biological|GB-0998 (Intravenous immunoglobulin)|
337932|NCT00515450|Procedure|Plasmapheresis|
336481|NCT00453817|Drug|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
336482|NCT00003501|Drug|antineoplaston A10|
336483|NCT00453817|Procedure|Islet transplantation|intraportal percutaneous islet transplantation
336484|NCT00453817|Procedure|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
336485|NCT00453830|Procedure|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
336486|NCT00453843|Device|rehabilitation robotics|sequence of intervention
336828|NCT00445289|Device|SmartCare/PS|
336829|NCT00445302|Drug|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
336830|NCT00445315|Drug|PF-00868554|300 mg BID
336831|NCT00003447|Drug|gemcitabine hydrochloride|
336832|NCT00445315|Drug|PF-00868554|450 mg BID
336833|NCT00445315|Drug|PF-00868554|100 mg BID
336834|NCT00445315|Drug|PF-00868554|300 mg TID
336835|NCT00445315|Drug|Placebo|Placebo
336836|NCT00445328|Drug|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
336837|NCT00445328|Drug|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
336838|NCT00445341|Drug|Flavopiridol|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
336839|NCT00445354|Drug|cinnamon|
336840|NCT00445406|Drug|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
336841|NCT00445406|Drug|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
336842|NCT00000522|Behavioral|alcohol restriction|
336110|NCT00415870|Behavioral|Weekly Weighing|Weekly Weighing
336111|NCT00415870|Behavioral|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
336112|NCT00415870|Device|Text Message|Text Message
336113|NCT00415870|Behavioral|Diet Goals via Cell Phone|Diet Goals via Cell Phone
336114|NCT00415870|Behavioral|Food Monitoring|Food Monitoring
336115|NCT00415883|Drug|Valsartan|
336116|NCT00003323|Drug|flutamide|250 mg PO tid
336117|NCT00415896|Device|positive pressure ventilation|
336118|NCT00415909|Drug|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
336119|NCT00415909|Drug|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
336120|NCT00415922|Drug|ELC200 (carbidopa+levodopa+entacapone)|
336121|NCT00415935|Drug|methotrexate|
336122|NCT00415948|Device|Biomarkers|
336123|NCT00415961|Device|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
336124|NCT00418561|Drug|rhASA|intravenous infusion 25 U/kg,50 U/kg, 100U/kg or 200 U/kg every other week for 26 weeks
336125|NCT00418574|Biological|Abagovomab|2 mg/ml SC (subcutaneously)
336126|NCT00418574|Biological|Placebo|2 mg/ml SC (subcutaneously)
336127|NCT00418587|Drug|Cholecalciferol|800 IU oral daily
336487|NCT00453843|Procedure|Movement therapy|sequence of intervention
336488|NCT00453856|Drug|Sulfadoxine Pyrimethamine|
336489|NCT00453869|Other|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
336490|NCT00453882|Device|flostat (TM) System|
336491|NCT00453895|Drug|Sunitinib|
335400|NCT00433173|Procedure|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
335401|NCT00433173|Drug|testosterone|transdermal 7.5 g/per day for 3 months
335402|NCT00433173|Drug|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
335403|NCT00433173|Drug|goserelin acetate implant|single depot injection 10.8 mg 3 months
335747|NCT00424268|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
335748|NCT00424268|Drug|Placebo|once daily
335749|NCT00424281|Drug|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
335750|NCT00424294|Drug|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
335751|NCT00424294|Drug|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
335752|NCT00424294|Drug|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
335753|NCT00424307|Device|HiResolution Bionic Ear System|
335754|NCT00424320|Drug|Sodium bicarbonate|
335755|NCT00003376|Drug|cisplatin|
335756|NCT00424333|Drug|Inhaled human insulin|
335757|NCT00424346|Drug|Canakinumab|
335758|NCT00424346|Drug|Placebo|
335759|NCT00424372|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
335760|NCT00427154|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
335761|NCT00003387|Drug|paclitaxel|
335762|NCT00427154|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
335763|NCT00427154|Drug|metformin|Tablets, 2000 mg/day.
335035|NCT00441259|Biological|ChimeriVax™-JE|One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged > 3 years and 0.5 ml to children and infants aged < 3 years administered subcutaneously
335036|NCT00003431|Biological|recombinant flt3 ligand|
335037|NCT00441259|Biological|Japanese Encephalitis Inactivated Mouse Brain Vaccine|Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged > 3 years and 0.5 ml is given to children and infants aged < 3 years administered subcutaneously
335038|NCT00441272|Drug|Pioglitazone|
335039|NCT00441285|Drug|Praziquantel|- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
335040|NCT00441285|Drug|Albendazole|Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.
Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.
335041|NCT00441285|Drug|ABZ Placebo|- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
335042|NCT00441285|Drug|PZQ Placebo|- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
335043|NCT00441298|Drug|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
335044|NCT00441298|Drug|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
335045|NCT00441311|Behavioral|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
335046|NCT00444509|Drug|GW685698X|
335047|NCT00003440|Procedure|quality-of-life assessment|Ancillary studies
335048|NCT00444522|Drug|Alprazolam thermal aerosol|
335049|NCT00444535|Drug|lapatinib|1500 mg oral lapatinib (once daily)
335404|NCT00433173|Procedure|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
335405|NCT00433173|Procedure|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
334337|NCT00459069|Biological|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
334338|NCT00459082|Drug|Dexmedetomine|
334681|NCT00450125|Other|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
334682|NCT00450125|Other|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
334683|NCT00450138|Drug|ZD6474 (vandetanib)|once daily oral dose
334684|NCT00450138|Drug|Cisplatin|intravenous infusion
334685|NCT00450138|Radiation|Radiation|radiation of head and neck
334686|NCT00450164|Procedure|esofagic varices ligation|
334687|NCT00450164|Drug|Nadolol|
334688|NCT00003478|Procedure|conventional surgery|
334689|NCT00450164|Drug|Isosorbide mononitrate|
334690|NCT00450164|Drug|Prazosin|
334691|NCT00450177|Drug|Ferrous Sulfate 325 mg PO TID, or placebo|
334692|NCT00450190|Device|Electronic device; Electronic Auto-Injector of Saizen®|
334693|NCT00450203|Biological|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
334694|NCT00450203|Drug|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
334695|NCT00450203|Drug|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
334696|NCT00452829|Drug|Folic Acid and inositol|Folic Acid and inositol
334697|NCT00452829|Drug|Folic acid and placebo|Folic acid and placebo
334698|NCT00003495|Drug|antineoplaston A10|
334699|NCT00452855|Procedure|Sevoflurane-remifentanil anaesthesia|
334700|NCT00452868|Drug|Donepezil|Donepezil 5 milligrams a day for 6 weeks
334701|NCT00452881|Drug|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
339804|NCT00540982|Drug|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
339805|NCT00540982|Other|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
339806|NCT00540982|Other|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
339807|NCT00540982|Other|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
339808|NCT00540982|Other|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
339809|NCT00540982|Other|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
339810|NCT00540995|Drug|busulfan|Given IV
339811|NCT00540995|Drug|etoposide|Given IV
339812|NCT00543569|Drug|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
339813|NCT00543582|Drug|MGCD0103 and Azacitidine|In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.
In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops.
334339|NCT00459108|Drug|dasatinib|Given orally
334340|NCT00459121|Drug|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
334341|NCT00459121|Drug|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
334342|NCT00003524|Drug|antineoplaston A10|
334343|NCT00459121|Drug|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
334344|NCT00459121|Procedure|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
334345|NCT00459134|Dietary Supplement|ArginMax|Given orally
334346|NCT00459134|Dietary Supplement|Placebo|Given orally
334347|NCT00459160|Procedure|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
344399|NCT00463515|Procedure|cisplatin/radiation therapy|
344400|NCT00463541|Drug|solifenacin succinate|oral
344401|NCT00463554|Device|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
344402|NCT00463567|Drug|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
344403|NCT00463567|Drug|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
344404|NCT00003548|Drug|aminocamptothecin colloidal dispersion|
344738|NCT00502099|Drug|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
344739|NCT00502112|Drug|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
344740|NCT00502112|Drug|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
344741|NCT00502125|Procedure|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
344742|NCT00502138|Drug|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
344743|NCT00502164|Drug|AZD2171|
344744|NCT00502177|Behavioral|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
344745|NCT00502190|Device|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
344746|NCT00003719|Drug|irinotecan hydrochloride|
344747|NCT00502203|Drug|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
344748|NCT00502203|Drug|Paclitaxel|175 mg/m^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
344749|NCT00502216|Drug|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
344750|NCT00502216|Drug|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
344751|NCT00502229|Drug|Clomiphene citrate, metformin, highly purified urinary FSH|
344040|NCT00518310|Drug|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
344041|NCT00518323|Drug|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
344042|NCT00003805|Drug|piperacillin-tazobactam|
344043|NCT00518323|Drug|Placebo|Once daily for 6 weeks
344044|NCT00518323|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
344045|NCT00518323|Drug|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
344046|NCT00518336|Procedure|Blood sampling|Blood sampling at Visit 3, 5 and 7.
344047|NCT00518336|Procedure|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
344048|NCT00520884|Drug|ghrelin or saline|At time 0, an infusion (ghrelin or saline) will be started in one of the IV sites at a dose of 2.5 pmol/kg/min (an equivalent amount of saline will be infused in a stepwise fashion if it is the placebo dose). After 60 minutes, the infusion rate will be increased to 5 pmol/kg/min. After 120 minutes, the ghrelin infusion will be increased again to a dose of 10 pmol/kg/min, and will be continued until 180 minutes, when the infusion will be stopped. will be administered in an identical fashion.
344049|NCT00520897|Drug|Raltegravir (MK0518)|400mg BID; 48 weeks
344050|NCT00520897|Drug|Placebo|400mg QD
344051|NCT00520897|Procedure|Leukopheresis|pack of cells as per protocol
344052|NCT00520897|Procedure|Sigmoid Biopsy|gut samples as per protocol
344405|NCT00463567|Drug|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
344406|NCT00463567|Drug|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
344407|NCT00463567|Drug|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
344408|NCT00463580|Drug|infliximab (remicade)|Three infusions across a 12 week period. (Baseline, week 2 and week 6)
344409|NCT00463580|Drug|Placebo|Placebo 3 infusions across a 12 week period (Baseline, Week#2 and Week#6)
344410|NCT00463606|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
344411|NCT00463606|Drug|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
343382|NCT00534521|Device|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
343701|NCT00526357|Drug|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
343702|NCT00526383|Drug|Tricyclic antidepressants|antidepressant version medical dispositive
343703|NCT00526396|Drug|cisplatin|80 mg/m2 on day 1 for 6 cycles
343704|NCT00526396|Drug|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
343705|NCT00526396|Drug|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
343706|NCT00526396|Drug|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
343707|NCT00526409|Drug|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
343708|NCT00003852|Drug|epirubicin hydrochloride|
343709|NCT00526409|Drug|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
343710|NCT00526409|Drug|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
343711|NCT00526409|Drug|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
343712|NCT00526409|Drug|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
343713|NCT00529139|Device|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. <90 mg/dL (<15 mmol/L)
343714|NCT00529152|Drug|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
343715|NCT00529165|Procedure|injection-meal-interval|The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:
Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes
Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval
Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks.
343716|NCT00529178|Drug|Pravastatin|
343053|NCT00539591|Drug|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
343054|NCT00539604|Procedure|MDCT and Coronary Angiography|
343055|NCT00542152|Drug|CYCLOSPORINE VS INFLIXIMAB|Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.
Infliximab 5mg/kg at weeks 0, 2 and 6
343056|NCT00542165|Drug|Alfuzosin|
343057|NCT00542178|Drug|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
343058|NCT00542178|Drug|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
343059|NCT00542178|Drug|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
343060|NCT00542178|Drug|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
343061|NCT00542178|Drug|Fenofibrate|Blinded fenofibrate
343062|NCT00003934|Drug|cytarabine|Given IV
343063|NCT00542178|Drug|Simvastatin|Simvastatin 20-40 mg/d
343064|NCT00542178|Drug|Placebo|Placebo
343065|NCT00542191|Drug|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
343066|NCT00542191|Procedure|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
343383|NCT00534534|Behavioral|Repeated behavioural intervention without any drugs|All these patients will be advised, i.e. undergo "behavioural intervention", against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
343384|NCT00534547|Procedure|Duodenal Exclusion|duodenal-jejunal bypass
343385|NCT00534560|Drug|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
343386|NCT00534560|Drug|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
343387|NCT00534560|Drug|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
343388|NCT00534573|Drug|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
342367|NCT00509223|Behavioral|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
342368|NCT00509236|Drug|Sitagliptin|25 mg (one 25-mg tablet) once daily
342369|NCT00509236|Drug|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
342370|NCT00509249|Biological|ziv-aflibercept|Given IV
342723|NCT00547300|Drug|Nebivolol, Metoprolol ER, Hydrochlorothiazide|Nebivolol QD, Oral Admin Metoprolol ER QD, Oral Admin Hydrochlorothiazide, QD, Oral Admin
342724|NCT00547326|Procedure|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
342725|NCT00547326|Procedure|Treatment with placebo|Treatment with placebo
342726|NCT00547339|Radiation|stereotactic body radiation therapy|
342727|NCT00547352|Drug|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
342728|NCT00003957|Drug|cyclophosphamide|
342729|NCT00547352|Drug|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
342730|NCT00547365|Biological|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
342731|NCT00547378|Device|InterStim|
342732|NCT00547378|Drug|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
342733|NCT00547391|Procedure|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
342734|NCT00547391|Other|no intervention|No intervention (controls). Follow up started from the day of randomization.
342735|NCT00547404|Drug|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
342736|NCT00550147|Drug|quetiapine|Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).
Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)
Visit 5 dose of 25mg BID
Visit 6 dose of 50mg BID
Visit 7 dose of 100mg BID
Visit 8 dose of 200mg BID
Visit 9 dose of 300mg BID
Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule.
334523|NCT00432796|Drug|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
334864|NCT00423878|Drug|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
334865|NCT00423891|Drug|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
334866|NCT00423904|Behavioral|Brief intervention|
334867|NCT00423917|Biological|bevacizumab|
334868|NCT00423917|Drug|fulvestrant|
334869|NCT00423930|Biological|bevacizumab|
334870|NCT00423930|Drug|cisplatin|
334871|NCT00003372|Drug|topotecan hydrochloride|
334872|NCT00423930|Procedure|conventional surgery|
334873|NCT00423930|Radiation|intensity-modulated radiation therapy|
334874|NCT00423943|Drug|modafinil|200 milligrams daily dose
334875|NCT00423956|Procedure|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
334876|NCT00423969|Drug|Galantamine|
334877|NCT00423969|Drug|Escitalopram|
334878|NCT00423982|Drug|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
334879|NCT00423982|Drug|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
334880|NCT00423995|Drug|Loratadine/montelukast combination|
334881|NCT00424008|Drug|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
334882|NCT00003375|Drug|lomustine|
334883|NCT00426725|Device|EasyLabour|According to the trial protocol
334884|NCT00000513|Drug|chlorthalidone|
334885|NCT00003386|Drug|paclitaxel|
334164|NCT00440830|Drug|placebo|placebo patch applied to smokers
334165|NCT00003429|Procedure|biopsy|
334166|NCT00440830|Drug|placebo|placebo patch applied to nonsmokers
334167|NCT00440843|Drug|Olanzapine (Zyprexa)|OLZ
334168|NCT00440843|Drug|Typicals|Stay on typicals regimen
334169|NCT00440856|Behavioral|Presentation of excised intervertebral disc fragments|
334170|NCT00440869|Dietary Supplement|N-acetylcysteine|600 mg po bid
334171|NCT00440869|Dietary Supplement|placebo|bid oral dosing
334172|NCT00440895|Drug|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
334173|NCT00440921|Drug|Single donor Allogenous Fibrin Sealant|
334524|NCT00432796|Other|Placebo|patients will be randomized post-operative to receive either active treatment or placebo.
the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.
ie. 5,000 iu or 200 iu/kg
334525|NCT00432809|Procedure|Gastric bypass|Roux-en-Y gastric bypass
334526|NCT00003400|Drug|vinorelbine tartrate|
334527|NCT00432809|Procedure|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
334528|NCT00432822|Drug|tetrahydrobiopterin (BH4)|
334529|NCT00432835|Device|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
334530|NCT00432861|Drug|PANCRECARB® (pancrelipase)|Capsules
334531|NCT00432861|Drug|Placebo|Capsules
334532|NCT00432874|Procedure|wound hydration method|Anterior vs lateral wound hydration
334533|NCT00432887|Drug|caffeine administration|
334534|NCT00432900|Radiation|[(11)C]PBR28|PET Ligand
334535|NCT00432913|Drug|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
339641|NCT00524589|Genetic|protein expression analysis|Correlative Study
339642|NCT00524589|Other|laboratory biomarker analysis|Correlative Study
339643|NCT00524602|Procedure|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
339644|NCT00524615|Drug|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
339645|NCT00524654|Procedure|HVLA chiropractic manipulation|
339646|NCT00524667|Drug|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
339647|NCT00524680|Dietary Supplement|cholecalciferol|Given orally
339648|NCT00524693|Drug|Montelukast|4mg sachets
339649|NCT00524693|Drug|Placebo granules|
339650|NCT00524706|Drug|S-1, oral Leucovorin, Oxaliplatin|
339651|NCT00003842|Drug|isolated perfusion|
339652|NCT00524719|Procedure|Open Reduction and Internal Fixation|Fixation with volar locked plate
339653|NCT00524719|Procedure|Non-Spanning External Fixation|Radio-radial external fixation
339654|NCT00524719|Procedure|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
339655|NCT00524732|Biological|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
339656|NCT00524745|Biological|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
339657|NCT00524758|Device|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
339658|NCT00524758|Drug|MMC in Trabeculectomy|MMC in Trabeculectomy
339659|NCT00524784|Biological|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
339660|NCT00524797|Dietary Supplement|Profonycia|
338628|NCT00545584|Behavioral|Comparator: Physical Activity|Physical Activity
338629|NCT00545597|Drug|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
338630|NCT00545623|Procedure|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
338631|NCT00545623|Behavioral|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
338632|NCT00003953|Procedure|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
338633|NCT00545623|Other|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
338634|NCT00545636|Other|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
338635|NCT00545649|Behavioral|Exercise and education|
338951|NCT00537888|Drug|fluconazole|Intravenous or oral 400 md/d
338952|NCT00537901|Radiation|First-Line Bevacizumab and Chemotherapy|Chemotherapy
338953|NCT00537901|Drug|Bevacizumab|Chemotherapy
338954|NCT00537914|Drug|Somatropin|Infant, Small for Gestational Age, Omnitrope®/Somatropin, rhGH,
338955|NCT00537927|Procedure|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
338956|NCT00537940|Drug|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
338957|NCT00537940|Drug|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
338958|NCT00537953|Drug|Miltefosine , meglumine antimoniate|
338959|NCT00003910|Drug|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
338960|NCT00537966|Drug|lopinavir|In this arm patients with primary HIV-1 infection are treated with standard antiretroviral combination therapy (only drugs that have been approved by Swiss Medic)
338961|NCT00537966|Drug|atazanavir|standard dosage
338962|NCT00537966|Drug|efavirenz|standard dosage
338963|NCT00537966|Drug|fosamprenavir|standard dosage
337933|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
337934|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
337935|NCT00515476|Behavioral|physical exercise|8 weeks of regular exercise training
337936|NCT00515489|Drug|Risperidone|as prescribed
337937|NCT00515502|Drug|GSK573719|
337938|NCT00003792|Biological|flu matrix peptide p58-66|
337939|NCT00515528|Drug|4-peptide melanoma vaccine|draft
337940|NCT00515528|Drug|4-peptide melanoma vaccine plus Ontak|draft
337941|NCT00515528|Drug|ontak|draft
337942|NCT00515541|Drug|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
337943|NCT00515554|Drug|Rituximab|addition of Rituximab to BEACOPP escalated
337944|NCT00515554|Drug|BEACOPP escalated|chemotherapy with BEACOPP escalated
337945|NCT00515580|Procedure|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
337946|NCT00515593|Drug|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
337947|NCT00515606|Drug|helium:oxygen|
337948|NCT00515619|Drug|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
337949|NCT00000556|Drug|moricizine|
337950|NCT00003792|Biological|gp100 antigen|
337951|NCT00515632|Drug|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
337952|NCT00515645|Other|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
337953|NCT00515658|Device|theta-burst rTMS|
338289|NCT00550797|Biological|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
336843|NCT00003447|Drug|vinorelbine tartrate|
336844|NCT00445419|Biological|PEV2A PEV2B|
336845|NCT00448019|Drug|Fludarabine|25 mg/m^2 IV over 30 minutes daily for 3 days
336846|NCT00448019|Drug|Cyclophosphamide|250 mg/m^2 IV over 30 minutes daily for 3 days
336847|NCT00448019|Drug|Rituximab|375 mg/m^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m^2 IV 30-minute infusion.
336848|NCT00448019|Drug|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
336849|NCT00448032|Drug|PPM-204|
337216|NCT00439543|Drug|Iloprost inhalation|
337217|NCT00439556|Drug|Carmustine|300 mg/m^2 IV on Day -6
337218|NCT00003423|Drug|cyclophosphamide|
337219|NCT00439556|Drug|Cytarabine|100 mg/m^2 IV twice a day x 4 Days (Days -5 through -2)
337220|NCT00439556|Drug|Etoposide|100 mg/m^2 IV twice a day x 4 Days (Days -5 through -2)
337221|NCT00439556|Drug|Melphalan|100 mg/m^2 IV on Day -1
337222|NCT00439556|Drug|Rituximab|375 mg/m^2 IV on Day -13; 1000 mg/m^2 on Days -6, 1, & 8.
337223|NCT00439556|Drug|Bortezomib|1.3 mg/m^2 IV on Days -13, -6, -1 and +2.
337224|NCT00439556|Other|Allogeneic Stem Cell Infusion|Allogeneic Stem Cell Infusion administered on Day 0.
337225|NCT00442208|Drug|PN 200|
337226|NCT00442221|Drug|Sumatriptan and Naproxen sodium|
337227|NCT00003435|Radiation|radiation therapy|
337228|NCT00442234|Drug|Monteplase|
337229|NCT00442247|Device|Pelvicol|
337230|NCT00442260|Drug|DOXIL|
337231|NCT00442260|Drug|Abraxane|
337232|NCT00442273|Drug|Umbilical cord serum eyedrops|
336492|NCT00456625|Biological|Engerix™-B|Intramuscular injection, 1 dose
336493|NCT00456638|Drug|Depodur|Depodur vs. traditional management
336494|NCT00456651|Device|CPAP (Continuous Positive Airway Pressure)|
336495|NCT00003515|Drug|antineoplaston AS2-1|
336496|NCT00456664|Genetic|IE gene|
336497|NCT00456677|Drug|minocycline|
336498|NCT00456690|Other|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
336499|NCT00456703|Other|intraoperative fluid management|fluid restriction
336500|NCT00456703|Other|fluid restriction|restriction of fluids
336501|NCT00456716|Drug|sorafenib|400mg po bid
336502|NCT00456729|Drug|Metronidazole|
336503|NCT00456729|Procedure|Blood tests|
336504|NCT00456755|Drug|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
336505|NCT00456755|Other|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
336506|NCT00003516|Drug|antineoplaston A10|
336507|NCT00456781|Device|Augmentation|Rotator Cuff Repair plus Graft Jacket
336508|NCT00456781|Procedure|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
336509|NCT00456794|Drug|Istradefylline (KW-6002)|
336510|NCT00456807|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
336511|NCT00456807|Biological|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
336512|NCT00456820|Drug|Wellbutrin XL|
335764|NCT00427154|Drug|glimepiride|Tablets, 8 mg/day.
335765|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
335766|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
335767|NCT00427167|Drug|AMA1-C1/Alhydrogel + CPG 7909|
335768|NCT00427180|Device|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
335769|NCT00427193|Behavioral|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
335770|NCT00427193|Behavioral|Control|Participants continue their current diet for 24 months
335771|NCT00427206|Drug|acetaminophen (4g/day)|
336128|NCT00418587|Drug|Cholecalciferol|2000 IU oral daily
336129|NCT00418587|Drug|Cholecalciferol|4000 IU oral daily
336130|NCT00418600|Drug|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
336131|NCT00418600|Drug|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
336132|NCT00003339|Biological|incomplete Freund's adjuvant|
336133|NCT00418600|Drug|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
336134|NCT00418613|Drug|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
336135|NCT00418613|Drug|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
336136|NCT00418626|Drug|Nilotinib|
336137|NCT00418639|Drug|Nitazoxanide|
336138|NCT00418652|Device|No TMS intervention|In the "no TMS" condition, no simulation was given and no coil placed near participants' heads.
336139|NCT00418652|Device|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
336140|NCT00418652|Device|TMS over the vertex|10Hz TMS for over vertex.
336141|NCT00418665|Biological|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
335406|NCT00436007|Biological|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
335407|NCT00003409|Radiation|radiation therapy|
335408|NCT00436007|Biological|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
335409|NCT00436007|Biological|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
335410|NCT00436007|Biological|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
335411|NCT00436020|Device|TMS|Transcranial Magnetic Stimulation
335412|NCT00436020|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
335413|NCT00436033|Drug|milnacipran|
335414|NCT00436033|Drug|Placebo|
335415|NCT00436046|Biological|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
335416|NCT00436046|Biological|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
335417|NCT00436059|Drug|bortezomib|
335418|NCT00003410|Drug|motexafin gadolinium|
335419|NCT00436072|Drug|ZD6474|Orally on a daily basis
335420|NCT00436072|Drug|Cetuximab|Infusion once weekly
335421|NCT00436072|Drug|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
335422|NCT00436085|Behavioral|Cognitive behavioral stress management training|
335423|NCT00436098|Behavioral|Motorpedagogic exercise|physical training
335424|NCT00436124|Drug|oseltamivir [Tamiflu]|
335425|NCT00436137|Behavioral|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
335426|NCT00436150|Behavioral|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
334702|NCT00452881|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
334703|NCT00452881|Drug|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
334704|NCT00452894|Drug|varenicline tartrate|
334705|NCT00452907|Drug|Artesunate|oad, per os, 3 days of treatment
335050|NCT00444535|Drug|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
335051|NCT00444548|Drug|[S,S]-Reboxetine|
335052|NCT00444561|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC administration
335053|NCT00444574|Drug|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
335054|NCT00444574|Drug|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
335055|NCT00444574|Drug|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
335056|NCT00444587|Drug|Second line chemotherapy|As prescribed
335057|NCT00444587|Drug|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
335058|NCT00000522|Behavioral|exercise|
335059|NCT00003440|Other|laboratory biomarker analysis|Correlative studies
335060|NCT00444600|Drug|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
335061|NCT00444600|Drug|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
335062|NCT00444600|Drug|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
335063|NCT00444600|Drug|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
335064|NCT00444613|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
334348|NCT00459173|Drug|rimonabant (SR141716)|
334349|NCT00459186|Drug|RAD001|Daily for two weeks
334350|NCT00415051|Biological|RVF MP-12|Administer 1 ml SQ
334351|NCT00415064|Drug|Perifosine|Perifosine given in either 50 mg or 100 mg / day
334352|NCT00415064|Drug|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
334353|NCT00415064|Drug|Dexamethasone|Dexamethasone given in 20 mg / day
334354|NCT00415077|Procedure|PRK|PRK
334355|NCT00415077|Procedure|MMC PRK|mitomycin C PRK
334356|NCT00415077|Procedure|LASEK|LASEK
334357|NCT00415090|Drug|Nevirapine|Switch one of ARV drugs to Nevirapine
334358|NCT00415103|Drug|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
334359|NCT00415103|Drug|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
334360|NCT00000508|Behavioral|diet, fat-restricted|
334361|NCT00003317|Radiation|radiation therapy|
334362|NCT00415103|Drug|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
334363|NCT00415116|Drug|carboplatin|
334364|NCT00415116|Drug|docetaxel|
334706|NCT00452907|Drug|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
334707|NCT00452907|Drug|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
334708|NCT00452920|Drug|docetaxel|
334709|NCT00003495|Drug|antineoplaston AS2-1|
334710|NCT00452920|Radiation|cesium Cs 137|
334711|NCT00452920|Radiation|radiation therapy|
334712|NCT00452972|Drug|Spinal Anesthesia|
344752|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
344753|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
344754|NCT00502255|Device|Health Buddy system|Patients are followed on distance by the Health Buddy system.
344755|NCT00502255|Device|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
344756|NCT00502268|Drug|Doxercalciferol administration|Doxercalciferol administration
344757|NCT00003720|Drug|semaxanib|
344758|NCT00502268|Drug|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
344759|NCT00502281|Drug|highly purified urinary FSH|
344760|NCT00502281|Behavioral|timed intercourses, intrauterine insemination|
345082|NCT00003673|Drug|chemotherapy|
345083|NCT00494299|Drug|Placebo|Placebo: matching placebo
345084|NCT00494312|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
345085|NCT00494312|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
345086|NCT00494338|Drug|Docetaxel|
345087|NCT00494351|Procedure|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
345088|NCT00494377|Drug|duloxetine|
345089|NCT00496951|Device|Vagal tone assessment|An EKG will be obtained using a Physio-control EKG monitor (R wave Electronics of Florida) in standard application, with three chest leads. The EKG data is inputted into a vagal tone monitor (Delta Biometrix, Bethesda MD) which computes vagal tone from the EKG signal. This data is then transferred to a disk which is analyzed off-line.
345090|NCT00496964|Drug|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
345091|NCT00496964|Drug|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
345092|NCT00496977|Procedure|annual CT screening|
345093|NCT00496990|Behavioral|Enhanced care|this group received counseling, contingency management and methadone or detoxification
344412|NCT00463606|Drug|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
344413|NCT00463619|Drug|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
344414|NCT00463645|Procedure|microdialysis|
344415|NCT00003549|Drug|CMF regimen|
344416|NCT00463645|Procedure|microperfusion|
344417|NCT00463658|Other|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
344418|NCT00463671|Drug|N-acetylcysteine|
344419|NCT00463684|Biological|Japanese encephalitis live attenuated SA 14-14-2 vaccine|
344420|NCT00463697|Drug|GW642444H (100mcg)|H salt
344421|NCT00463697|Drug|placebo|placebo
344422|NCT00463697|Drug|GW642444M (25, 100 & 400 mcg)|M salt
344423|NCT00463710|Drug|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
344424|NCT00463723|Drug|FK506 0.06% (eye drops)|
344425|NCT00463736|Drug|Magnesium sulfate|
344426|NCT00466882|Device|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two.
344761|NCT00502294|Drug|Visilizumab (HuM291; Nuvion®)|
344762|NCT00502307|Drug|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
344763|NCT00504946|Drug|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children > 14 years old received 10mg oral tablet once daily at bedtime
344764|NCT00504946|Drug|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
344765|NCT00504959|Drug|ranibizumab|
343717|NCT00529191|Drug|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
343718|NCT00003862|Drug|paclitaxel|
343719|NCT00529191|Other|Placebo|One out of three subjects will receive a placebo.
344053|NCT00003816|Drug|cyclophosphamide|Given IV
344054|NCT00520910|Drug|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
344055|NCT00520910|Other|No Treatment|Patient is not given any treatment.
344056|NCT00520923|Drug|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
344057|NCT00520923|Drug|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
344058|NCT00520923|Drug|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
344059|NCT00520923|Drug|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
344060|NCT00520923|Drug|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
344061|NCT00520923|Drug|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
344062|NCT00520923|Drug|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
344063|NCT00520936|Drug|pemetrexed|1910 milligrams per meter squared (mg/m^2) (or 60 milligrams per kilogram [mg/kg] if patient <12 months old), intravenous (IV), for 21 days x 17 cycles
344064|NCT00003816|Drug|etoposide|Given IV
344065|NCT00520949|Drug|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
344066|NCT00520949|Drug|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
344067|NCT00520949|Drug|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
344068|NCT00520949|Drug|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
344069|NCT00520975|Biological|Bevacizumab|Given IV
344070|NCT00520975|Drug|Carboplatin|Given IV
344071|NCT00520975|Other|Laboratory Biomarker Analysis|Correlative studies
343389|NCT00534586|Drug|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
343390|NCT00534586|Drug|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
343391|NCT00534586|Drug|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
343392|NCT00003892|Drug|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
343393|NCT00534586|Drug|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
343394|NCT00534599|Drug|Placebo|oral
343395|NCT00534599|Drug|quetiapine fumarate XR|oral
343396|NCT00534612|Procedure|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
343397|NCT00537043|Drug|SK&F-105517 (COREG CR FDC)|
343398|NCT00537056|Procedure|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
343399|NCT00537056|Procedure|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
343400|NCT00537056|Drug|F-18 Fluoro-deoxi-glucose|15 mCi iv
343401|NCT00537056|Drug|Gadolinium-DTPA|0.1 mmol/kg iv
343402|NCT00537056|Drug|Sunitinib|50 mg/day po
343403|NCT00537082|Drug|FTY720|Administered orally once daily for 6 months
343404|NCT00003906|Drug|Raloxifene|60 mg/day plus placebo for 5 years
343405|NCT00537082|Drug|Placebo|Administered orally once daily for 6 months
343406|NCT00537095|Drug|Vandetanib|300 mg oral once daily oral dose
343720|NCT00529204|Drug|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
343721|NCT00529217|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
343722|NCT00529230|Behavioral|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
343723|NCT00529230|Other|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
342737|NCT00550160|Drug|Amodiaquine plus Artesunate co-administration|Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.
Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.
342738|NCT00003972|Drug|carboplatin|
342739|NCT00550173|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
342740|NCT00550173|Drug|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
343067|NCT00542191|Radiation|Radiotherapy|Standard of care RADIATION THERAPY as indicated
343068|NCT00542204|Behavioral|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
343069|NCT00542217|Biological|Imprime PGG|
343070|NCT00542243|Drug|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
343071|NCT00542243|Drug|Placebo|Placebo will be given once a day for 6 months.
343072|NCT00542256|Device|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
343073|NCT00003934|Drug|mercaptopurine|Given IV
343074|NCT00542256|Device|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
343075|NCT00542269|Drug|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
343076|NCT00542269|Drug|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
343077|NCT00542269|Drug|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
343078|NCT00542295|Drug|alverine citrate and simeticone|
334886|NCT00426738|Drug|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
334887|NCT00426738|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
335231|NCT00415597|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
335232|NCT00418171|Drug|Ziprasidone|
335233|NCT00418171|Drug|Olanzapine|
335234|NCT00418184|Dietary Supplement|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
335235|NCT00418184|Other|Colored cellulose tainted with fishy odor|as arm 1
335236|NCT00003337|Procedure|immunoscintigraphy|
335237|NCT00418197|Device|Total Facet Arthroplasty System® (TFAS®)|
335238|NCT00418210|Radiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
335239|NCT00418249|Drug|AS101|
335240|NCT00418262|Drug|atomoxetine hydrochloride|0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
335241|NCT00418275|Genetic|Recombinant Human Plasminogen Activator (HTUPA)|
335242|NCT00418288|Drug|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
335243|NCT00418288|Drug|placebo|intravenous infusion of 1.2pmol/kg/min
335244|NCT00418301|Other|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
335245|NCT00418314|Device|Control|Empiric programming or one-time optimization using a non-IEGM method.
335246|NCT00418314|Device|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
335247|NCT00003337|Radiation|technetium Tc 99m epratuzumab|
335248|NCT00418327|Drug|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
335249|NCT00418340|Drug|probiotic (bacterial/dietary supplement)|
334536|NCT00432913|Procedure|Endoscopy|At baseline, month 3 and month 6.
334537|NCT00000518|Procedure|electrophysiology|
334538|NCT00003400|Procedure|peripheral blood stem cell transplantation|
334539|NCT00435474|Other|relaxation therapy|relaxation therapy
334540|NCT00435487|Drug|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
334541|NCT00435487|Drug|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg [units per kilogram] and initial infusion of 12 U/kg/h [units per kilogram per hour]).
334542|NCT00003407|Drug|mitoxantrone hydrochloride|
334543|NCT00435500|Drug|Fluoride varnish|
334544|NCT00435526|Biological|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
334545|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
334546|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
334888|NCT00426738|Radiation|Radiation Therapy|Radiation Therapy will be given daily, five times weekly (excluding holidays), starting on the first day of the first cycle of chemotherapy. Treatment will generally begin on a Monday. A Tuesday start will be allowed as long as the patient can be treated on Saturday of that week. On the days of chemotherapy, radiation therapy will be delivered after chemotherapy infusion. The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
334889|NCT00426751|Drug|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
334890|NCT00426751|Drug|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
334891|NCT00426764|Drug|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
334892|NCT00426777|Drug|risedronate|risedronate 35mg tablet, weekly for 12 months
334893|NCT00426777|Drug|risedronate|35mg weekly
334894|NCT00426777|Drug|Control|risedronate-matched placebo weekly
334895|NCT00426790|Procedure|Positive end-expiratory pressure|
334896|NCT00003386|Other|dinitrophenyl|
339661|NCT00524810|Drug|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
339662|NCT00003842|Procedure|surgical procedure|
334174|NCT00440934|Device|Amplitude-modulated electromagnetic fields|
334175|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
334176|NCT00003429|Procedure|computed tomography|
334177|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
334178|NCT00440960|Drug|propofol|
334179|NCT00440960|Drug|midazolam|
334180|NCT00440960|Drug|alfentanil|
334181|NCT00440960|Drug|lidocaine|
334182|NCT00440973|Drug|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
334183|NCT00444041|Drug|Bevacizumab|neoadjuvant therapy prior to elective surgery
334184|NCT00444054|Behavioral|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
334185|NCT00444067|Device|Spinal Sealant|Spinal Sealant System
334186|NCT00444067|Other|Standard of Care|Standard of Care
334187|NCT00444080|Procedure|Trabeculectomy|Standard trabeculectomy procedure
Creation of a fornix or limbal based conjunctival flap in upper quadrants
Creation of a limbal-based scleral flap extending into clear cornea
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)
Creation of fistula 1mm x 2mm in size
Iridectomy
Suturing the scleral flap
Repositioning of conjunctiva with sutures After procedure, antibiotics & steroids are administered topically; eye is covered with a pad - patient is discharged.
334188|NCT00444080|Device|Ex-PRESS mini shunt|Ex-PRESS implantation procedure:
Creation of a fornix or limbal based conjunctival flap in upper quadrants
Creation of limbal-based scleral flap extending into clear cornea
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus
Prior to implantation, a thorough mobility check should be performed
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision
Withdrawal of introducer
Tucking plate under the scleral flap, and verification of its position
Suturing scleral flap After implantation procedure, antibiotics & steroids administered topically; eye is covered with a pad - patient is discharged.
334189|NCT00003437|Radiation|radiation therapy|
338964|NCT00537966|Drug|darunavir|standard dosage
338965|NCT00537966|Drug|tipranavir|standard dosage
338966|NCT00003926|Drug|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
338967|NCT00540540|Device|Diffuse Optical Spectroscopy|Breast properties scanning
338968|NCT00540553|Drug|placebo|
338969|NCT00540553|Drug|GSK971086|
338970|NCT00540566|Device|Optical Biopsy imaging|Optical Biopsy imaging
338971|NCT00540579|Drug|Pomalidomide|Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
338972|NCT00540579|Drug|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
338973|NCT00540592|Biological|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
338974|NCT00540592|Biological|Fluarix|Single dose, Intramuscular injection
339294|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
339295|NCT00532792|Biological|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
339296|NCT00003877|Drug|thiotepa|
339297|NCT00532818|Drug|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
339298|NCT00532818|Drug|Placebo|Cisplatin + Topotecan plus placebo
339299|NCT00532844|Drug|6R-BH4 (sapropterin dihydrochloride)|5 mg/kg BID of 6R-BH4 tablets to be administered orally for 13.5 days
339300|NCT00532844|Drug|6R-BH4 (sapropterin dihydrochloride)|5 mg/kg BID of 6R-BH4 tablets, plus 500 mg BID of Vitamin C caplets to be administered orally for 13.5 days
339301|NCT00532857|Drug|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
339302|NCT00532870|Other|laparoscopic|
339303|NCT00532883|Drug|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
338290|NCT00550797|Biological|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
338291|NCT00550810|Drug|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
338292|NCT00550823|Device|Cardiac CT 0BRILLIANT 64|Cardiac CT
338293|NCT00550836|Biological|panitumumab|Given IV
338294|NCT00550836|Drug|erlotinib hydrochloride|Given orally
338295|NCT00550836|Drug|gemcitabine hydrochloride|Given IV
338296|NCT00003765|Drug|carmustine|
338297|NCT00510094|Behavioral|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
338298|NCT00510107|Drug|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
338299|NCT00510107|Drug|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
338300|NCT00510120|Behavioral|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
338301|NCT00510120|Behavioral|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
338302|NCT00510120|Behavioral|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
338303|NCT00510133|Biological|GRNVAC1|Autologous dendritic cell vaccine
338304|NCT00510146|Drug|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
338305|NCT00510146|Drug|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
338306|NCT00510159|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
338307|NCT00003766|Drug|O6-benzylguanine|
338308|NCT00510159|Drug|Praziquantel|
337233|NCT00442273|Drug|Autologous serum eyedrops|
337234|NCT00442286|Device|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
337235|NCT00442299|Device|Fractionated Plasma Separation and Adsorption (FPSA)|
337236|NCT00442312|Drug|Combigan Ophthalmic Solutiom|
337237|NCT00442325|Drug|Atorvastatin (Lipitor)|
337238|NCT00003436|Drug|amsacrine|
337239|NCT00442338|Drug|montelukast|Montelukast single injection of either 7 mg or 14 mg Intravenous Administration
337240|NCT00442338|Drug|Comparator: Aminophylline|Single injection Aminophylline 250 mg Intravenous Drip Infusion
337241|NCT00442351|Drug|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
337242|NCT00442351|Other|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
337607|NCT00433836|Drug|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
337608|NCT00433836|Drug|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
337609|NCT00433849|Drug|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
337610|NCT00433849|Drug|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
337611|NCT00433875|Drug|AMG 714|
337612|NCT00433888|Drug|R744|100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
337613|NCT00433888|Drug|R744|150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
337614|NCT00003402|Drug|paclitaxel|
337615|NCT00433901|Behavioral|Targeted parental instruction for positive lifestyle change with follow-up calls.|
337616|NCT00433914|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
337617|NCT00433914|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
337618|NCT00433927|Drug|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
336850|NCT00448045|Behavioral|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
336851|NCT00448045|Behavioral|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
336852|NCT00448058|Drug|GSK372475|daily administration during the 10-week treatment phase
336853|NCT00003463|Procedure|surgical procedure|
336854|NCT00448058|Drug|venlafaxine|daily administration during the 10-week treatment phase
336855|NCT00448058|Drug|placebo|daily administration during the 10-week treatment phase
336856|NCT00448071|Drug|MTR107|
336857|NCT00448097|Drug|cetuximab|No verifiable data available, PI relocated
336858|NCT00448097|Drug|docetaxel|No verifiable data available, PI relocated
336859|NCT00448110|Drug|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
336860|NCT00448110|Drug|Intravenous Ketorolac|Intravenous Ketorolac
336861|NCT00448110|Drug|placebo|placebo
336862|NCT00448123|Drug|Tamsulosin (Flomax)|
336863|NCT00448136|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
336864|NCT00003464|Drug|temozolomide|
336865|NCT00448136|Drug|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
336866|NCT00448136|Drug|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
336867|NCT00448136|Drug|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
336868|NCT00448149|Drug|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
336869|NCT00448149|Drug|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
336142|NCT00418665|Drug|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
336143|NCT00003339|Biological|recombinant interleukin-12|
336144|NCT00418678|Drug|Cesamet|2 mg BID on Days 2-5.
336145|NCT00418691|Drug|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
336146|NCT00418691|Drug|Modafinil|200 mg PO Once Daily x 4 Weeks
336147|NCT00418691|Drug|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
336148|NCT00418704|Drug|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
336149|NCT00418704|Drug|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
336150|NCT00418717|Drug|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
336151|NCT00418730|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
336513|NCT00456833|Drug|RAD001|
336514|NCT00456833|Drug|erlotinib|
336515|NCT00456846|Drug|ABI-007|100 mg/m2 ABI-007 will be administered by intravenous infusion over 30 minutes weekly for 3 weeks followed by 1 week rest
336516|NCT00456846|Drug|Nab-paclitaxel|100 mg/m^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
336517|NCT00003516|Drug|antineoplaston AS2-1|
336518|NCT00456859|Drug|Kremezin|
336519|NCT00456872|Drug|lidocaine|
336520|NCT00456885|Drug|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
336521|NCT00456898|Drug|desvenlafaxine sustained release (DVS SR)|
336522|NCT00456898|Drug|Paroxetine|
336523|NCT00459940|Drug|Pioglitazone|
335772|NCT00003387|Radiation|radiation therapy|
335773|NCT00427206|Drug|placebo|
335774|NCT00427219|Drug|Ozarelix/Placebo|Ozarelix 15 mg or placebo will be administered IM on Day 0 and Day 14
335775|NCT00427219|Drug|Placebo|Eligible patients entered a placebo run-in phase in which placebo was administered twice over a 2 week period (Day -28 and Day -14) and patients were assessed to establish baseline values approximately 14 days following the second placebo injection
335776|NCT00427232|Drug|BQ-123 and BQ-788|
335777|NCT00427245|Drug|cyclophosphamide|
335778|NCT00427245|Drug|goserelin acetate|
335779|NCT00427245|Procedure|adjuvant therapy|
335780|NCT00427245|Procedure|fertility assessment and management|
335781|NCT00427245|Procedure|neoadjuvant therapy|
335782|NCT00427258|Drug|MOA-728|
335783|NCT00003388|Biological|filgrastim|
335784|NCT00427271|Drug|aspirin|
335785|NCT00427297|Drug|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
335786|NCT00427297|Drug|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
335787|NCT00427297|Drug|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
335788|NCT00427297|Drug|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of<8g/dl), AZT will be substituted for d4T.
335789|NCT00427297|Drug|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
335790|NCT00430118|Drug|mercaptopurine|
335791|NCT00430118|Drug|methotrexate|
335792|NCT00003396|Radiation|radiation therapy|
335793|NCT00430118|Drug|prednisone|
335794|NCT00430118|Drug|thioguanine|
335795|NCT00430118|Drug|vincristine sulfate|
335065|NCT00444613|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
335066|NCT00444613|Drug|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
335067|NCT00444626|Device|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
335068|NCT00444626|Device|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
335427|NCT00436150|Behavioral|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
335428|NCT00436163|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
335429|NCT00003410|Procedure|magnetic resonance imaging|
335430|NCT00436176|Behavioral|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
335431|NCT00436189|Procedure|Blood Draw|
335432|NCT00436202|Behavioral|Iron supplement|
335433|NCT00438789|Drug|eculizumab|600mg IV every week and 900mg IV every 2 weeks
335434|NCT00438802|Drug|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
335435|NCT00438815|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
335436|NCT00438828|Drug|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
335437|NCT00438841|Drug|bortezomib|
335438|NCT00438841|Drug|cyclophosphamide|
335439|NCT00003421|Drug|procarbazine hydrochloride|
335440|NCT00438841|Drug|dexamethasone|
335441|NCT00438841|Drug|thalidomide|
335442|NCT00438854|Drug|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
334713|NCT00452985|Drug|Docetaxel|60-75 mg/m²
334714|NCT00452985|Drug|Carboplatin|AUC 5
334715|NCT00452998|Procedure|Q-switched fd Nd:yag in Laser Iridotomy|
334716|NCT00453011|Device|posterior chamber intraocular lens|
334717|NCT00453011|Device|anterior chamber intraocular lens|
334718|NCT00453024|Procedure|Pericardial graft & tissue glue|
334719|NCT00453024|Procedure|scleral flap & sutures|
334720|NCT00003496|Drug|antineoplaston A10|
334721|NCT00453037|Behavioral|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
334722|NCT00453037|Behavioral|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
334723|NCT00453050|Drug|imiquimod|
334724|NCT00453050|Drug|indocyanine green solution|
334725|NCT00453050|Other|flow cytometry|
334726|NCT00453050|Other|immunologic technique|
334727|NCT00453050|Other|laboratory biomarker analysis|
334728|NCT00455611|Device|CPAP (Continuous Positive Airway Pressure)|
334729|NCT00455624|Drug|Androgen deprivation therapy|According to standard medical care
334730|NCT00455637|Drug|Botulinum type A toxin (Dysport®)|
334731|NCT00003513|Drug|antineoplaston AS2-1|
335069|NCT00447213|Drug|Insulin glargine|Patient specific, injected, daily, 24 weeks
335070|NCT00447213|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
335071|NCT00447213|Drug|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
345094|NCT00496990|Behavioral|control|this group receives the opportunity to participate in a support group
345095|NCT00497003|Drug|Treatment with either metoprolol or carvedilol|
345096|NCT00497016|Drug|atorvastatin 80 mg|
345097|NCT00003685|Radiation|radiation therapy|
345098|NCT00497029|Drug|fluoride varnish|
345099|NCT00497029|Behavioral|patient education|
345100|NCT00497042|Device|Self Adjusting File|
345101|NCT00497055|Drug|Aripiprazole|
345102|NCT00497055|Drug|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
345103|NCT00497068|Behavioral|tobacco abstinent contingent|Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
345104|NCT00497068|Behavioral|non-contingent|Participants receive vouchers regardless of tobacco use status
345451|NCT00488735|Behavioral|Traditional primary care|
345452|NCT00488748|Device|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
345453|NCT00488748|Device|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
345454|NCT00488761|Drug|Tigecycline|
345455|NCT00488774|Other|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
345456|NCT00003652|Radiation|radiation therapy|
345457|NCT00488774|Drug|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
345458|NCT00488774|Drug|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
345459|NCT00488774|Drug|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
345460|NCT00488787|Drug|intranasal ketamine|low dose
345461|NCT00488787|Drug|intranasal ketamine|medium dose
345462|NCT00488787|Drug|intranasal ketamine|high dose
344766|NCT00504972|Drug|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
344767|NCT00504985|Behavioral|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
344768|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
344769|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
344770|NCT00003729|Drug|cytarabine|
344771|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
344772|NCT00504998|Genetic|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
344773|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
344774|NCT00505024|Behavioral|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
344775|NCT00505024|Other|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
344776|NCT00505037|Drug|ASP1585|Oral
344777|NCT00505037|Drug|Placebo|Oral
344778|NCT00505037|Drug|Sevelamer hydrochloride|Oral
344779|NCT00505050|Other|Disease Program Management|This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.
After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms.
345105|NCT00497068|Behavioral|control|this group receives no vouchers
345106|NCT00497081|Drug|mirtazapine|mirtazapine 30 mg daily for 3 months
345107|NCT00497081|Drug|placebo|placebo 30 mg daily for 3 months
345108|NCT00003686|Drug|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
344072|NCT00520975|Drug|Paclitaxel|Given IV
344073|NCT00520975|Other|Placebo|Given IV
344074|NCT00520975|Other|Quality-of-Life Assessment|Ancillary studies
344075|NCT00003816|Drug|fludarabine phosphate|Given IV
344076|NCT00520975|Biological|Trastuzumab|Given IV
344077|NCT00523562|Other|diet intervention|controled hypercalori high fructose, high fat, or high fat/high protein diet
344427|NCT00466895|Drug|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
344428|NCT00466908|Device|Pentacam and IOL Master|Pentacam and IOL Master
344429|NCT00466921|Drug|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
344430|NCT00466947|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
344431|NCT00466947|Biological|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
344432|NCT00466947|Biological|Engerix-B|Intramuscular injection, 3 doses
344433|NCT00466947|Biological|Infanrix hexa|Intramuscular injection,3 doses
344434|NCT00466947|Biological|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
344435|NCT00466960|Biological|sargramostim|Given SC
344436|NCT00003565|Drug|docetaxel|
344437|NCT00466960|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
344438|NCT00466960|Other|laboratory biomarker analysis|Correlative studies
344439|NCT00466960|Other|immunologic technique|Correlative studies
344440|NCT00466973|Device|AtriCure dry bipolar radiofrequency (RF) clamp|
344441|NCT00466973|Device|Boston Scientific FLEX 10 unipolar microwave antenna|
344442|NCT00466973|Device|Cryocath SurgiFrost unipolar cryothermic probe|
343724|NCT00529243|Drug|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
343725|NCT00529256|Behavioral|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
343726|NCT00529269|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
343727|NCT00529282|Drug|Ceftobiprole Medocaril|500 mg every 8 hours
343728|NCT00529282|Drug|Cefepime with or without vancomycin|120-minute infusion [250 mL]
343729|NCT00003862|Procedure|conventional surgery|
343730|NCT00529295|Drug|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
343731|NCT00529308|Device|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
343732|NCT00529308|Device|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
343733|NCT00529321|Biological|MVA-HCV (Immunotherapy)|MVA-HCV
343734|NCT00531960|Drug|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
343735|NCT00531960|Drug|Standard platinum-based chemotherapy|At the discretion of the investigator
343736|NCT00531973|Drug|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
343737|NCT00531973|Drug|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
343738|NCT00531986|Drug|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
343739|NCT00000566|Procedure|ventilation-perfusion ratio|
344078|NCT00523575|Dietary Supplement|Cubitan|400 ml/d
343079|NCT00544804|Other|diagnostic laboratory biomarker analysis|
343080|NCT00544817|Radiation|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
343081|NCT00544817|Drug|Temozolomide|In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily
In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles
343082|NCT00544817|Drug|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
343083|NCT00003944|Procedure|peripheral blood stem cell transplantation|
343084|NCT00544830|Drug|bicalutamide|50 mg orally every day for a total of 36 weeks (+/- 2 weeks)
343085|NCT00544830|Drug|goserelin|3.6 mg subcutaneously every 4 weeks or 10.8 mg subcutaneously every 12 weeks for a total of 36 weeks (+/- 2 weeks)
343086|NCT00544830|Drug|leuprolide acetate|22.5 mg intramuscularly every 12 weeks for a total of 36 weeks (+/- 2 weeks)
343407|NCT00537095|Other|Placebo|
343408|NCT00537108|Behavioral|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support & skills-building for school continuation, higher education, and job readiness.
343409|NCT00537121|Drug|fluorouracil|Given IV
343410|NCT00537121|Drug|irinotecan hydrochloride|Given IV
343411|NCT00537121|Drug|leucovorin calcium|Given IV
343412|NCT00537121|Drug|vorinostat|Taken Orally
343413|NCT00537121|Other|pharmacological study|Correlative Study
343414|NCT00537134|Device|Embolization, coiling|Endovascular embolization with platinum coils
343415|NCT00003906|Drug|Tamoxifen|20 mg/day plus placebo for 5 years
343416|NCT00537147|Biological|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
343417|NCT00537147|Biological|Placebo|Placebo for WN/DEN4delta30 vaccine
343418|NCT00537160|Behavioral|Behavior modification, Nutrition Education, Exercise|
335250|NCT00418353|Drug|Betamethasone(Celestone soluspan) and Dexamethasone|
335251|NCT00418366|Drug|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
335252|NCT00418379|Drug|Sublingual Immunotherapy tablets of grass pollen allergen extract|300 IR sublingual tablets starting 4 months before the pollen season
300 IR sublingual tablets starting 2 months before the pollen season
Placebo.
335253|NCT00418392|Procedure|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
335608|NCT00456235|Drug|Ciclosporine A|
335609|NCT00456235|Drug|Tacrolimus|
335610|NCT00456248|Drug|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
335611|NCT00003514|Procedure|cancer prevention intervention|
335612|NCT00456261|Drug|Pemetrexed|pemetrexed 500 mg/m2
335613|NCT00456261|Drug|Gemcitabine|gemcitabine 1500 mg/m2
335614|NCT00456261|Drug|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
335615|NCT00456261|Drug|Carboplatin|carboplatin AUC=5
335616|NCT00456274|Procedure|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
335617|NCT00456287|Device|CPAP (Continuous Positive Airway Pressure)|
335618|NCT00456300|Drug|Exenatide|3 doses of exenatide will be tested in same group of patients
335619|NCT00456313|Drug|FLIXOTIDE and SERETIDE|comparator
335620|NCT00456339|Drug|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
335621|NCT00456352|Procedure|duodenal exclusion|
335622|NCT00003514|Procedure|complementary and alternative therapy|
335623|NCT00003526|Drug|antineoplaston AS2-1|
335624|NCT00459550|Drug|GSK933776|Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.
Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg
335625|NCT00459550|Drug|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
334897|NCT00426803|Drug|activated recombinant human factor VII|
334898|NCT00426816|Drug|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
334899|NCT00426816|Drug|Placebo|Placebo to match SB-649868
334900|NCT00426829|Drug|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
334901|NCT00426829|Radiation|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
334902|NCT00426842|Drug|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
334903|NCT00426855|Drug|Bendamustine|starting with 60 mg/m^ 2, IV, dose escalation, weekly d1,8,15 q5w
334904|NCT00426855|Drug|Bortezomib|weekly 1.5mg/m^2, IV, d1,8,15,22 q5w
334905|NCT00426868|Other|Direct injection of ADRCs into the Left Ventricle|Dose escalation
334906|NCT00426868|Other|Direct injection of placebo into the Left Ventricle|
334907|NCT00003386|Procedure|surgical procedure|
334908|NCT00426881|Behavioral|Exercise Training|Twice weekly resistance training for 52 weeks.
334909|NCT00426881|Behavioral|Exercise training|Once weekly resistance training for 52 weeks.
334910|NCT00429858|Drug|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
335254|NCT00418392|Procedure|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
335255|NCT00418418|Procedure|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
335256|NCT00418418|Procedure|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
335257|NCT00418418|Biological|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
335258|NCT00421434|Drug|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
335259|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
334190|NCT00444093|Drug|Tinctura opii|
334191|NCT00444106|Drug|Artesunate-mefloquine|
334192|NCT00444106|Drug|Atovaquone-proguanil|
334193|NCT00444106|Drug|Artemether-lumefantrine|
334194|NCT00444132|Drug|clopidogrel|
334547|NCT00435539|Drug|Sham Comparator|Intravitreal sham injection
334548|NCT00435552|Procedure|Ease-It Spray|
334549|NCT00435578|Drug|Glufosfamide|
334550|NCT00435591|Drug|Conivaptan|ampoule or premix bag
334551|NCT00435591|Drug|placebo|ampoule or premix bag
334552|NCT00435604|Drug|Hylenex|
334553|NCT00000518|Drug|procainamide|
334554|NCT00003408|Biological|aldesleukin|
334555|NCT00435617|Device|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
334556|NCT00435630|Other|LapSim training|complete curriculum training on LapSim surgical simulator
334557|NCT00435643|Procedure|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
334558|NCT00435669|Drug|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
334559|NCT00435669|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
334560|NCT00435682|Drug|Botox (Allergan Inc., US)|
334561|NCT00435695|Drug|GSK163090|
334562|NCT00435708|Behavioral|5 portions fruit and vegetables/day|Participants consume > = 5 portions fruit and veg per day
334563|NCT00435721|Behavioral|Psychoeducation|
334564|NCT00435734|Behavioral|obesity intervention|
334565|NCT00003408|Biological|recombinant interferon alfa|
339304|NCT00532883|Drug|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
339305|NCT00532883|Other|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
339306|NCT00532909|Drug|Vandetanib|100mg or 300mg By mouth every day continuous
339307|NCT00003877|Procedure|in vitro-treated bone marrow transplantation|
339308|NCT00532909|Drug|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
339309|NCT00532909|Drug|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
339310|NCT00532909|Drug|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
339311|NCT00532935|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an ~32 wk treatment period
339312|NCT00532935|Drug|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an ~32-wk treatment period.
339313|NCT00532948|Drug|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
339314|NCT00532961|Drug|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
339315|NCT00535509|Radiation|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
339663|NCT00527488|Drug|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
339664|NCT00003855|Procedure|axillary lymph node dissection|
339665|NCT00527488|Drug|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
339666|NCT00527488|Drug|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
339667|NCT00527488|Drug|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
339668|NCT00527501|Drug|Travoprost/brinzolamide|
339669|NCT00527514|Drug|Amlodipine|Tablets
339670|NCT00527514|Drug|Olmesartan medoxomil plus amlodipine|Tablets
339671|NCT00527527|Procedure|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
338636|NCT00545649|Behavioral|Education|
338637|NCT00545662|Drug|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
338638|NCT00545662|Drug|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
338639|NCT00545675|Drug|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
338640|NCT00545675|Drug|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
338641|NCT00545688|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
338642|NCT00545688|Drug|docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
338643|NCT00003953|Procedure|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
338644|NCT00545688|Drug|pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
338645|NCT00545701|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
338646|NCT00545714|Drug|Cyclophosphamide|250mg/m2 iv on days 1-3
338647|NCT00545714|Drug|Fludarabine|25mg/m2 on days 1-3
338648|NCT00545714|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of cycle 1; 500mg/m2 iv on day 1 of cycles 2-6
338649|NCT00545727|Behavioral|Diet|Whole-foods, low glycemic index diet
338650|NCT00548327|Procedure|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
338651|NCT00548327|Procedure|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
338652|NCT00548327|Drug|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
338653|NCT00003958|Biological|filgrastim|Given SC
338654|NCT00548340|Drug|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
338655|NCT00548340|Drug|Placebo|Placebo capsules, PO daily for five weeks
338656|NCT00548340|Drug|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
337619|NCT00433927|Drug|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
337620|NCT00433927|Drug|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
337621|NCT00433927|Drug|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
337622|NCT00433927|Drug|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
337623|NCT00433940|Drug|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
337624|NCT00433953|Drug|Mycophenolate Mofetil (CellCept)|
337625|NCT00003402|Procedure|bone marrow ablation with stem cell support|
337626|NCT00433953|Behavioral|Dietary Monitoring|
337627|NCT00526565|Behavioral|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
337954|NCT00518336|Biological|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
337955|NCT00518349|Device|Passive bending function|Colonoscope with a passive bending function
337956|NCT00518349|Device|No passive bending function|Examination using standard colonoscope without passive bending function
337957|NCT00518362|Drug|TW|TW,120 mg/d
337958|NCT00518375|Drug|Rapamune® (Sirolimus)|
337959|NCT00003805|Drug|tazobactam sodium|
337960|NCT00518375|Drug|Neoral® (Cyclosporine)|
337961|NCT00518375|Drug|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
337962|NCT00518388|Behavioral|Focus Group|Focus groups each lasting about 2 hours.
337963|NCT00518388|Behavioral|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
337964|NCT00518401|Biological|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
336870|NCT00450723|Procedure|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
336871|NCT00450723|Procedure|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
337243|NCT00442364|Drug|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
337244|NCT00442364|Procedure|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
337245|NCT00442377|Procedure|exposure to malaria sporozoites|
337246|NCT00442390|Drug|hydrocortisone substitution therapy versus withdrawal|
337247|NCT00442403|Drug|chloroquine|
337248|NCT00442403|Drug|dehydroepiandrosterone sulphate|
337249|NCT00003436|Drug|asparaginase|
337250|NCT00442416|Drug|Epoetin alfa|As prescribed, sc
337251|NCT00442416|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms sc monthly, starting dose
337252|NCT00442442|Device|mosquito coils|mosquito coil / night mosquito coil & LLIN / night
337253|NCT00442442|Device|LLIN|Sleep under LLIN every night
337254|NCT00442455|Drug|Erlotinib chlorhydrate|150 mg/day for 7 weeks
337255|NCT00442455|Drug|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
337256|NCT00445432|Biological|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
337257|NCT00445432|Other|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
337258|NCT00445445|Other|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
337259|NCT00445445|Other|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
337260|NCT00445445|Procedure|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
336524|NCT00459953|Drug|cognitive and behavioral skills training, nicoderm CQ|all participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. Half of the participants receive an additional 9 sessions of cognitive behavior therapy and half receive brief support
336525|NCT00459966|Procedure|Preoperative rehabilitation|
336526|NCT00459979|Drug|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
336527|NCT00459979|Procedure|conventional surgery|nephrectomy
336528|NCT00459992|Drug|Betahistine Hydrochloride|
336529|NCT00460018|Behavioral|Diet, Exercise, and Breastfeeding Intervention|Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant
Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant
Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant
Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)
336530|NCT00460031|Drug|ketoconazole|400 tid
336531|NCT00460031|Drug|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
336532|NCT00460031|Drug|therapeutic hydrocortisone|20mg qam 10mg qhs
336533|NCT00003532|Drug|antineoplaston AS2-1|
336534|NCT00460057|Drug|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
336872|NCT00450723|Radiation|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
336873|NCT00450736|Drug|celecoxib|
336874|NCT00450736|Procedure|adjuvant therapy|
336875|NCT00450736|Radiation|radiation therapy|
336876|NCT00450749|Other|placebo|Given PO
336877|NCT00450749|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
336878|NCT00003485|Drug|antineoplaston A10|
336879|NCT00450749|Other|laboratory biomarker analysis|Correlative studies
336880|NCT00450749|Drug|lycopene|Given PO
335796|NCT00430118|Drug|vindesine|
335797|NCT00430118|Radiation|radiation therapy|
335798|NCT00430131|Procedure|Cognitive Orientation to Occupational Performance|
336152|NCT00418756|Drug|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
336153|NCT00421863|Drug|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
336154|NCT00421863|Drug|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
336155|NCT00421863|Drug|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
336156|NCT00421863|Drug|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
336157|NCT00421863|Drug|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
336158|NCT00421863|Drug|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
336159|NCT00000148|Procedure|Trabeculectomy|
336160|NCT00000512|Drug|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
336161|NCT00003356|Biological|aldesleukin|
336162|NCT00421863|Drug|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
336163|NCT00421876|Behavioral|multifactorial continued educational - behavioural programme|
336164|NCT00421889|Drug|belinostat|
336165|NCT00421889|Drug|Paclitaxel|
336166|NCT00421889|Drug|Carboplatin|
336167|NCT00421902|Procedure|Acupuncture|
336168|NCT00421915|Drug|Enbrel (etanercept)|
336169|NCT00421928|Drug|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
335443|NCT00438867|Genetic|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
335444|NCT00438867|Genetic|Placebo|Control group
335445|NCT00438880|Drug|Agatolimod Sodium|Given IV
335446|NCT00438880|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
335447|NCT00438880|Other|Laboratory Biomarker Analysis|Correlative study
335448|NCT00438880|Procedure|Radionuclide Imaging|Undergo imaging scans
335449|NCT00438880|Biological|Rituximab|Given IV
335450|NCT00003421|Drug|vinblastine sulfate|
335451|NCT00438880|Procedure|Single Photon Emission Computed Tomography|Undergo imaging scans
335799|NCT00430131|Procedure|Contemporary Treatment Approach|
335800|NCT00430144|Drug|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
335801|NCT00430157|Drug|GSK256066|
335802|NCT00430170|Drug|Dipyridamole|Dipyridamole 2x200mg 7day per os
335803|NCT00003397|Biological|filgrastim|
335804|NCT00430170|Drug|caffeine|caffeine 4mg/kg iv
335805|NCT00430183|Drug|docetaxel|75 mg/m^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
335806|NCT00430183|Drug|LHRH agonist|Given intramuscularly
335807|NCT00430183|Procedure|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
335808|NCT00430196|Drug|BOTOX®|
335809|NCT00430196|Drug|Zanaflex®|
335810|NCT00430235|Drug|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
335811|NCT00430248|Drug|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
335812|NCT00430248|Drug|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
335072|NCT00447226|Drug|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
335073|NCT00447239|Procedure|glucontrol (insulin therapy)|
335074|NCT00447265|Drug|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
335075|NCT00447265|Drug|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
335076|NCT00003459|Drug|antineoplaston A10|
335077|NCT00447265|Drug|Placebo|
335078|NCT00447278|Drug|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
335079|NCT00447278|Drug|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
335080|NCT00447291|Drug|Supplement: Omega-3 Fish Oil|
335081|NCT00447291|Behavioral|Multi-Disciplinary Nutrition & Exercise program|
335082|NCT00447304|Drug|moxifloxacin|
335083|NCT00447304|Procedure|cholecystectomy|
335084|NCT00447317|Behavioral|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
335085|NCT00447317|Behavioral|Attention control|Standard peritoneal dialysis dietary education
335086|NCT00447330|Drug|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.
Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.
Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin.
335087|NCT00003459|Drug|antineoplaston AS2-1|
335088|NCT00447343|Procedure|Decompressive cervical spine surgery|Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery
Healthy volunteers will ONLY undergo two scans 6 months apart.
335452|NCT00438880|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
345463|NCT00488787|Drug|placebo|placebo
345464|NCT00488800|Biological|pneumococcal conjugate vaccine|
345465|NCT00488813|Drug|Third generation cephalosporins|
345466|NCT00488826|Biological|7-valent pneumococcal conjugate vaccine|
345467|NCT00491725|Drug|metformin|
345468|NCT00491738|Drug|bevacizumab|Intravenous repeating dose
345469|NCT00491738|Drug|sunitinib|Oral repeating dose
345470|NCT00491738|Drug|placebo|Intravenous repeating dose
345471|NCT00491751|Drug|atorvastatin|atorvastatin 40 or 80 mg/day
345472|NCT00491751|Drug|ascorbic acid|ascorbic acid 500 mg/day
345473|NCT00491751|Drug|Placebo|matching placebo
345474|NCT00003662|Drug|busulfan|
345475|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
345476|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
340175|NCT00535925|Drug|fibrate|Therapy for hypertriglyceridemia
- for reducing triglycerides < 150 mg/dl and/or increasing HDL cholesterol > 40-50 mg/dl: a fibrate
340176|NCT00535925|Drug|erythropoietin|Treatment of anaemia:
- erythropoietin
340177|NCT00535925|Drug|aspirin|Antiplatelet therapy (in all patients without contraindications):
- aspirin up to 160 mg/die
340178|NCT00535938|Other|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
340179|NCT00538265|Drug|tacrolimus, ATG|immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.
In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.
In this study arm, tacrolimus will be administered as in arm (A)
345109|NCT00497094|Device|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
345110|NCT00497107|Drug|UFT, Calcium Folinate, PSK|
345111|NCT00497107|Drug|UFT, Calcium Folinate|
345112|NCT00497120|Drug|acetazolamide|
345113|NCT00497120|Drug|placebo|
345114|NCT00497120|Procedure|uvulopalatopharygoplasty|
345115|NCT00499382|Procedure|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
345116|NCT00499395|Procedure|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
345117|NCT00499395|Procedure|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
345118|NCT00499408|Dietary Supplement|cholecalciferol|
345119|NCT00499408|Dietary Supplement|genistein|
345120|NCT00499408|Dietary Supplement|soy isoflavones|
345121|NCT00000550|Behavioral|health education|
345122|NCT00003700|Drug|methotrexate|15mg intrathecal Day 1 Courses II & V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, & 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III & VI.
345123|NCT00499408|Genetic|polymerase chain reaction|
345477|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
345478|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
344443|NCT00466973|Device|ESTECH Cobra Adhere irrigated unipolar RF antenna|
344444|NCT00466973|Device|Medtronic Cardioblate BP irrigated bipolar RF clamp|
344445|NCT00466973|Device|St. Jude Epicor hi-intensity focused ultrasound wand|
344446|NCT00466986|Drug|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
344447|NCT00003566|Procedure|videothoracoscopy|
344448|NCT00466999|Drug|misoprostol|single dose of 400 mcg misoprostol administered sublingually
344449|NCT00466999|Procedure|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
344450|NCT00467012|Drug|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
344780|NCT00505063|Biological|Immunization Schedule patients <7 years.|Time 0 months: Prevnar 13 #1, Hib #1
Time 1 months: Pediarix #1
Time 2 months: Prevnar 13 #2, Hib #2
Time 3-4 months: Pediarix #2
Time 4-6 months: Draw post vaccine titers
Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.
344781|NCT00003729|Drug|fludarabine phosphate|
344782|NCT00505063|Biological|Immunization Schedule patients > or = to 7 years and <11 years of age|Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1
Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2
Time 2-3 months: Prevnar 13 #2, Hib #2
Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.
344783|NCT00507507|Drug|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
344784|NCT00507507|Drug|Placebo|Placebo to match FTC taken once daily
344785|NCT00507520|Procedure|Full dose almonds|
344786|NCT00507520|Procedure|Half dose almonds+half dose muffin|
344787|NCT00507520|Procedure|Full dose whole wheat muffin|
344788|NCT00000555|Drug|estrogens, conjugated|
344789|NCT00003747|Drug|temozolomide|
344790|NCT00507533|Procedure|Continuous positive airway pressure|
344791|NCT00507546|Drug|Ramelteon|8 mg nightly
344792|NCT00507546|Drug|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
344079|NCT00523588|Procedure|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
344080|NCT00523640|Drug|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
344081|NCT00523653|Other|blood test|looking at DNA
344082|NCT00523666|Drug|Galantamine (Reminyl®)|8mg - 24mg
344083|NCT00523666|Drug|Placebo/Galantamine (Reminyl®)|Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.
Dose scheme: 8mg-24mg
344084|NCT00523692|Drug|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
344085|NCT00523692|Drug|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
344086|NCT00523705|Drug|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
344087|NCT00003833|Genetic|DNA stability analysis|
344088|NCT00523705|Other|placebo|Placebo tablets matched to drug
344089|NCT00523718|Drug|riluzole|50 mg PO bid, 12 weeks
344090|NCT00523718|Drug|placebo|placebo, 1 capsule PO bid, 12 weeks
344091|NCT00523731|Procedure|Angiogenic Cell Precursors (ACPs) or Vescell TM|
344092|NCT00523744|Drug|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
344093|NCT00523744|Drug|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
344094|NCT00523744|Drug|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
344095|NCT00523744|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
344096|NCT00523757|Drug|Spironolactone|
336346|NCT00439283|Drug|infliximab|
336347|NCT00439283|Drug|methotrexate|
336348|NCT00003435|Drug|melphalan|
336349|NCT00441792|Drug|midazolam|Midazolam at induction dose based on weight
336350|NCT00441805|Device|Radio Frequency|
336351|NCT00441818|Drug|TNX-650|
336352|NCT00441844|Drug|Simvastatin|
336353|NCT00441857|Behavioral|plant stanol consumption|
336354|NCT00441870|Drug|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
336355|NCT00441870|Drug|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
336356|NCT00441883|Drug|PF-03187207 and Latanoprost Vehicle|
336357|NCT00441883|Drug|Latanoprost 0.005% and PF-03187207 Vehicle|
336358|NCT00441896|Drug|Ganaxolone|
336359|NCT00003435|Procedure|antiviral therapy|
336360|NCT00441909|Drug|UC-781|0.1% UC-781 Vaginal Gel
336361|NCT00441909|Drug|UC-781 placebo|Vaginal Gel Placebo
336362|NCT00441922|Drug|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
336363|NCT00441922|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
336364|NCT00441935|Device|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
336365|NCT00441948|Device|Peterio|
336366|NCT00441961|Drug|methotrexate|methotrexate
336710|NCT00433485|Procedure|biopsy|
336711|NCT00433498|Drug|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
335626|NCT00459563|Drug|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
335627|NCT00459563|Drug|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
335628|NCT00459563|Drug|Placebo|Placebo once a week for 3 weeks
335629|NCT00459589|Behavioral|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
335630|NCT00459589|Behavioral|usual nutritional care|usual nutritional care
335631|NCT00459615|Drug|Artesunate for Injection|
335982|NCT00450424|Other|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
335983|NCT00450424|Other|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
335984|NCT00003483|Drug|antineoplaston AS2-1|
335985|NCT00450437|Biological|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
335986|NCT00450437|Biological|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
335987|NCT00450450|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
335988|NCT00450450|Other|laboratory biomarker analysis|Correlative studies
335989|NCT00450450|Biological|filgrastim|Given IV
335990|NCT00450463|Drug|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant DNA technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
335991|NCT00450463|Drug|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
335260|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
335261|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
335262|NCT00003353|Drug|melphalan|
335263|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
335264|NCT00421447|Drug|Anastrozole|Group of women with breast cancer
335265|NCT00421460|Drug|Testosterone Undecanoate,1000mg|duration for 4 injections
335266|NCT00421473|Drug|Atovaquone / Proguanil|
335267|NCT00421486|Procedure|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
335268|NCT00421499|Drug|dark chocolate|
335269|NCT00421512|Drug|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
335270|NCT00421525|Biological|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
335271|NCT00421538|Drug|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
335272|NCT00421538|Drug|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
335273|NCT00003353|Procedure|bone marrow ablation with stem cell support|
335274|NCT00421551|Drug|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
335632|NCT00459628|Radiation|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
335633|NCT00459628|Radiation|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
335634|NCT00003528|Drug|raltitrexed|Given IV
335635|NCT00459641|Drug|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
335636|NCT00459641|Other|Standard of Care|Bone marrow aspirate or steroids
334566|NCT00435747|Drug|PARECOXIB SODIUM|
334567|NCT00435760|Drug|Aclidinium bromide|200 micro grams, once daily, 1 day treatment
334568|NCT00438425|Dietary Supplement|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
334911|NCT00000514|Drug|reserpine|
334912|NCT00003395|Drug|arsenic trioxide|
334913|NCT00429858|Drug|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
334914|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
334915|NCT00429871|Drug|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
334916|NCT00429871|Drug|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
334917|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
334918|NCT00429897|Drug|Bendroflumethiazide 2.5mg - 5mg|
334919|NCT00429897|Drug|Amiloride 20-40mg|
334920|NCT00429897|Drug|Spironolactone 50-100mg|
334921|NCT00429897|Drug|Frusemide 20-40mg|
334922|NCT00429897|Drug|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
334923|NCT00003396|Biological|anti-thymocyte globulin|
334924|NCT00429910|Procedure|quality-of-life assessment|
334925|NCT00429923|Drug|Difluprednate|
334926|NCT00429923|Drug|Difluprednate|
334927|NCT00429923|Drug|Placebo|
334928|NCT00429936|Drug|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
339672|NCT00527527|Other|placebo control|Placebo for comparison with flexion distraction treatment
339673|NCT00527540|Drug|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
339674|NCT00527553|Dietary Supplement|not enriched egg|daily egg, not enriched
339675|NCT00003855|Radiation|whole breast irradiation|
339676|NCT00527553|Dietary Supplement|lutein|daily enriched egg
339677|NCT00527553|Dietary Supplement|zeaxanthin|daily zeaxanthin enriched egg
339678|NCT00527553|Dietary Supplement|egg product from enriched eggs|daily egg product from enriched eggs
339679|NCT00527553|Dietary Supplement|normal diet|control, normal diet, no additional eggs
339680|NCT00527566|Biological|Mepolizumab|IV mepolizumab, 750 mg
339681|NCT00527579|Drug|[F-18]FBR|
339682|NCT00527592|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
339683|NCT00527592|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
339684|NCT00527605|Drug|Dutasteride 0.5mg capsule|Dutasteride 0.5mg once daily orally
339685|NCT00527605|Drug|Dutasteride matched placebo|Dutasteride matched placebo once daily orally
339686|NCT00003856|Drug|temoporfin|
334195|NCT00444145|Drug|Lansoprazole Tablet|30 mg bid for 3 months
334196|NCT00444145|Procedure|Esophageal and Laryngeal Biopsies|repeat egd with biopsy
334197|NCT00444158|Drug|MOA-728|
334198|NCT00444171|Procedure|insulin infusion rate controled by computer algorithm|
334199|NCT00444171|Procedure|insulin infusion rate guided by in-house glucose management protocol|
334200|NCT00003439|Biological|recombinant interleukin-12|
334201|NCT00444184|Drug|Travoprost/timolol fixed combination, travoprost|
338657|NCT00548353|Drug|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
338658|NCT00548353|Drug|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
338975|NCT00540605|Drug|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
338976|NCT00540618|Drug|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
338977|NCT00003926|Drug|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
338978|NCT00540618|Other|Placebo|
338979|NCT00540618|Drug|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
338980|NCT00540618|Drug|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
338981|NCT00540631|Biological|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection
to be det. A 0.1 100 TU
7 (+7) days later A 0.2 200 TU
7 (+7) days later A 0.4 400 TU
7 (+7) days later A 0.6 600 TU
7 (+7) days later B 0.1 1000 TU
7 (+7) days later B 0.2 2000 TU
7 (+7) days later B 0.4 4000 TU
7 (+7) days later B 0.6 6000 TU
Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection
to be det. A 0.1 100 TU
7 (+7) days later A 0.2 200 TU
7 (+7) days later A 0.4 400 TU
7 (+7) days later A 0.6 600 TU
7 (+7) days later B 0.1 1000 TU
7 (+7) days later B 0.2 2000 TU
7 (+7) days later B 0.4 4000 TU
7 (+7) days later B 0.6 6000 TU
Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued
338982|NCT00540644|Drug|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
338983|NCT00540644|Drug|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
338984|NCT00540644|Drug|Prednisone|50 mg p.o. Q.O.D.
338985|NCT00540657|Drug|CCX282-B|250mg capsule, twice daily, 13 weeks
338986|NCT00540657|Drug|Placebo|Placebo capsule, twice daily, 13 weeks
338987|NCT00540670|Drug|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
338988|NCT00000575|Drug|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
338989|NCT00003926|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
338990|NCT00540670|Drug|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
338991|NCT00543257|Other|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
337965|NCT00518414|Other|Marketed infant formula with DHA and ARA|
337966|NCT00518414|Other|Milk-based infant formula with DHA and ARA|
337967|NCT00518414|Other|Milk-based formula with DHA, ARA, prebiotics|
337968|NCT00518427|Drug|Insulin Glargine|Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml.
Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment.
337969|NCT00518453|Biological|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
337970|NCT00003805|Drug|vancomycin|
337971|NCT00518466|Drug|topiramate|25 mg modified-release capsules
337972|NCT00518466|Drug|phentermine|7.5 mg immediate-release capsules
337973|NCT00518466|Drug|topiramate|100 and 25 mg immediate-release tablets
337974|NCT00518466|Drug|phentermine|37.5 and 7.5 mg immediate-release tablets
337975|NCT00518479|Drug|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
337976|NCT00518479|Drug|Valsartan 160mg OD; Moxonidine 400mcg OD|
337977|NCT00518492|Procedure|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
338309|NCT00510172|Drug|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
338310|NCT00510172|Drug|Placebo|NaCL 0,9%
338311|NCT00510185|Other|systematic coronary intervention|Coronary angiography within 72 hrs
338312|NCT00510185|Other|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
338313|NCT00510198|Device|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
338314|NCT00510211|Drug|olanzapine|
338315|NCT00510224|Drug|Sandostatin|Sandostatin 30mg intramuscular every 28 days
338316|NCT00510237|Behavioral|"Adolescents Coping, Connecting, Empowering, and Protecting Together" (Project ACCEPT)|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
337261|NCT00445445|Procedure|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
337628|NCT00526578|Behavioral|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
337629|NCT00526591|Drug|everolimus|Low-dose Cohort: Patients will receive 5.0mg P.O. daily continuously for 8 weeks; High-dose Cohort: Patients will receive 10mg P.O. daily continuously for 8 weeks
337630|NCT00526591|Procedure|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
337631|NCT00526604|Behavioral|work related rehabilitation|The workplace intervention includes two steps:
Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.
Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.
337632|NCT00526617|Drug|ABT-888|Oral capsules
337633|NCT00526617|Drug|Temozolomide|Oral capsules
337634|NCT00526630|Drug|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
337635|NCT00003852|Drug|paclitaxel|
337636|NCT00526630|Drug|Placebo|Participants will be given placebo instead of active MPD.
337637|NCT00526643|Drug|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
337638|NCT00526643|Drug|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
337639|NCT00526656|Drug|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
337640|NCT00526669|Drug|Lapatinib and Capecitabine|oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
337641|NCT00526682|Dietary Supplement|Irvingia/cissus combo|
337642|NCT00526695|Drug|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
337643|NCT00526734|Biological|filgrastim|
337644|NCT00526734|Biological|pegfilgrastim|
337645|NCT00526734|Drug|melphalan|
336881|NCT00450762|Drug|gemcitabine|
336882|NCT00450762|Drug|carboplatin|
336883|NCT00450775|Drug|Dermatix Q|Dermatix Q applied twice daily
336884|NCT00450801|Drug|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
336885|NCT00450801|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
336886|NCT00450801|Drug|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
336887|NCT00450801|Drug|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
336888|NCT00450801|Drug|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
336889|NCT00003485|Drug|antineoplaston AS2-1|
336890|NCT00450801|Drug|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
336891|NCT00450801|Drug|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
336892|NCT00450801|Drug|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
336893|NCT00450801|Drug|Thalidomide|Maintenance therapy.
336894|NCT00450801|Drug|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
336895|NCT00450801|Drug|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
337262|NCT00445445|Procedure|study of high risk factors|Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
337263|NCT00445458|Drug|HKI-272|neratinib 160 mg daily by mouth
337264|NCT00445458|Drug|HKI-272|neratinib 240 mg daily by mouth
337265|NCT00003449|Drug|dexamethasone|
336170|NCT00421928|Drug|placebo|matching placebo twice a day (BID) during 15 weeks
336171|NCT00421928|Drug|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
336172|NCT00003356|Biological|rituximab|
336173|NCT00421941|Procedure|Tube feeding|
336174|NCT00421954|Drug|Ziprasidone|subjects will use ziprasidone
336535|NCT00460083|Drug|Elidel(R) (pimecrolimus 1%)|
336536|NCT00460083|Device|EpiCeram(R) -ceramide based barrier repair cream|
336537|NCT00460096|Drug|Kamada-API|
336538|NCT00460109|Biological|denileukin diftitox|
336539|NCT00460109|Biological|rituximab|
336540|NCT00460135|Behavioral|resistance training|2 times a week resistance training
336541|NCT00460148|Drug|Ropinirole|
336542|NCT00460161|Procedure|acupuncture|2 treatments/week for 4 weeks
336543|NCT00460161|Other|placebo/sham acupuncture|2 treatments/week for 4 weeks
336544|NCT00003533|Drug|antineoplaston A10|
336545|NCT00460174|Biological|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
336546|NCT00460174|Drug|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
336547|NCT00460174|Procedure|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
336548|NCT00460174|Radiation|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
336549|NCT00415974|Behavioral|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
335813|NCT00430248|Drug|Allopurinol|Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.
Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.
335814|NCT00003397|Biological|rituximab|
335815|NCT00430261|Drug|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
335816|NCT00430300|Drug|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
335817|NCT00430300|Drug|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
335818|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
335819|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at a inactive site on the bottom of the foot (a "placebo" site).
335820|NCT00433173|Procedure|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
335821|NCT00433173|Procedure|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
336175|NCT00421967|Drug|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
336176|NCT00421967|Drug|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
336177|NCT00421980|Drug|Etanercept|
336178|NCT00421993|Drug|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
336179|NCT00421993|Drug|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
336180|NCT00424385|Drug|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
336181|NCT00424398|Drug|Bepreve|sterile ophthalmic solution
336182|NCT00424398|Drug|Placebo|sterile ophthalmic solution
336183|NCT00424398|Drug|Bepotastine Besilate|sterile ophthalmic solution
336184|NCT00424411|Drug|Inhaled human insulin (EXUBERA™)|
336185|NCT00424424|Drug|MK0719|
335453|NCT00438893|Dietary Supplement|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
335454|NCT00438906|Procedure|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
335455|NCT00438906|Drug|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
335456|NCT00438919|Device|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
335457|NCT00438932|Drug|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
335458|NCT00438932|Dietary Supplement|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
335459|NCT00438932|Dietary Supplement|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
335460|NCT00438932|Drug|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
335461|NCT00441324|Procedure|recombinant human LH|
335462|NCT00003432|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
335463|NCT00441337|Biological|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
335464|NCT00441350|Drug|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
335465|NCT00441350|Drug|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
335466|NCT00441363|Drug|bromocriptine mesylate|
335467|NCT00441376|Drug|ThermoDox|15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
335468|NCT00441415|Drug|Adapalene BPO|
335469|NCT00441428|Drug|solifenacin|
335470|NCT00441441|Drug|fluticasone propionate|fluticasone propionate 100mcg HFA
340180|NCT00538265|Drug|ATG+mycophénolate mofétil+tacrolimus|immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.
In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months.
340181|NCT00538278|Other|Database|database
340182|NCT00538291|Biological|cetuximab|
340183|NCT00538291|Drug|capecitabine|
340184|NCT00538291|Genetic|gene expression analysis|
340185|NCT00538291|Genetic|microarray analysis|
340186|NCT00538291|Genetic|polymorphism analysis|
340187|NCT00538291|Genetic|reverse transcriptase-polymerase chain reaction|
340188|NCT00000572|Procedure|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
340189|NCT00003913|Biological|anti-thymocyte globulin|
340190|NCT00538291|Other|immunohistochemistry staining method|
340191|NCT00538304|Drug|bimatoprost eye drops|1 drop in each eye daily for 1 month
340192|NCT00538304|Drug|placebo|1 drop in each eye daily for 1 month
340193|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
340517|NCT00530634|Genetic|gene expression analysis|
340518|NCT00530634|Genetic|reverse transcriptase-polymerase chain reaction|
340519|NCT00530634|Other|immunohistochemistry staining method|
340520|NCT00530634|Procedure|adjuvant therapy|
340521|NCT00530634|Procedure|conventional surgery|
340522|NCT00003869|Drug|carboxyamidotriazole|Given PO
340523|NCT00530634|Radiation|radiation therapy|
345479|NCT00491764|Drug|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
345480|NCT00491764|Drug|Placebo|Placebo for 24 weeks.
345481|NCT00491777|Device|Noninvasive Hemodynamic Patient Monitor|
345482|NCT00491790|Drug|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
345483|NCT00491790|Other|Sterile water|Sterile water
345484|NCT00491803|Drug|Sildenafil|sildenafil 20 mg orally
345485|NCT00003662|Drug|cyclophosphamide|
345486|NCT00491803|Drug|Sildenafil|sildenafil 40 mg orally
345487|NCT00491816|Drug|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
345488|NCT00491829|Drug|50 mg qhs|flibanserin 50 mg
345489|NCT00491829|Drug|100 mg|flibanserin 100mg
345490|NCT00491829|Drug|placebo|placebo
345491|NCT00491855|Drug|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
345492|NCT00491855|Drug|Oxaliplatin|Starting dose level 25 mg/m^2 given intraperitoneally on day 2.
345493|NCT00491855|Drug|Paclitaxel|Starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
345494|NCT00491868|Drug|R744|100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
345495|NCT00491868|Drug|R744|150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
345496|NCT00003662|Drug|cyclosporine|
345497|NCT00491868|Drug|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
345498|NCT00494416|Other|delivery approaches of malaria intermittent preventive treatment in pregnancy|Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs).
345499|NCT00494429|Drug|Morphine|Gestational Age< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
344793|NCT00507559|Device|Aptus Endovascular AAA Repair System|EVAR
344794|NCT00507572|Other|Data Collection|Information about the type of cancer, type of treatment, and details about pregnancy will be collected.
344795|NCT00507585|Drug|Fluorouracil|300 mg/m^2 IV over 10 Minutes, then 600 mg/m^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
344796|NCT00507585|Drug|Avastin|10 mg/m^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
344797|NCT00507585|Drug|Leucovorin|200 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
344798|NCT00507585|Drug|Oxaliplatin|60 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
344799|NCT00507598|Other|No intervention|Correlative study collecting serum and tissue samples
344800|NCT00003748|Drug|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
345124|NCT00499408|Genetic|protein expression analysis|
345125|NCT00499408|Other|immunologic technique|
345126|NCT00499408|Other|laboratory biomarker analysis|
345127|NCT00499421|Procedure|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
345128|NCT00499447|Procedure|radiofrequency ablation|
345129|NCT00499447|Radiation|radiation therapy|
345130|NCT00499460|Dietary Supplement|garlic|
345131|NCT00499460|Drug|digoxin|
345132|NCT00499460|Drug|midazolam hydrochloride|
345133|NCT00003700|Drug|prednisone|60mg/sq m/day PO Days 1-21 (pts<60y/o) OR Days 1-7 (pts >/= 60y/o) Courses I & IV and Days 1-5 of ea 4 cycle in Course VII
345134|NCT00499460|Drug|oxycodone hydrochloride|
345135|NCT00499460|Genetic|gene expression analysis|
345136|NCT00499460|Genetic|protein expression analysis|
345137|NCT00499460|Other|laboratory biomarker analysis|
345138|NCT00499460|Other|liquid chromatography|
344097|NCT00523757|Drug|Placebo|
344451|NCT00467012|Drug|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
344452|NCT00467025|Drug|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
344453|NCT00469846|Procedure|L-arginine supplementation in a medical food|
344454|NCT00469846|Procedure|Vitamin C and E supplementation in a medical food|
344455|NCT00469859|Drug|cytarabine|given IV
344456|NCT00469859|Drug|idarubicin|Given IV
344457|NCT00469859|Drug|lestaurtinib|Given orally
344458|NCT00469872|Procedure|Context-focused compared to child-focused interventions|
344459|NCT00469885|Drug|Nicotine replacement|For reduction
344460|NCT00469885|Behavioral|Motivational counseling|No drugs
344461|NCT00469898|Drug|Carboplatin|Carboplatin dosage calculation to be given on day 1, every 21 days:
Carboplatin (mg) = (AUC of 5) x (GFR + 25)
*up to 6 cycles at physician's discretion
344462|NCT00003576|Procedure|surgical procedure|
344463|NCT00469898|Drug|irinotecan hydrochloride|50 mg/m2 IV on days 1 and 8 every 21 days
Should be infused IV over 30- 90 minutes.
344464|NCT00469911|Procedure|Magnetic Resonance Spectroscopy|It is basically the same as an MRI. It is a noninvasive procedure that provides detailed body images on any plane.
344465|NCT00469911|Procedure|Endocardial Biopsy|This is a standard of care procedure that is already performed on heart transplant patients. This is a procedure that takes a biopsy (tissue sample) of the heart muscle.
344466|NCT00469924|Procedure|Real Time Clinical Alerting|
344467|NCT00469937|Drug|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
344468|NCT00469937|Procedure|cognitive assessment|cognitive assessment
344469|NCT00469937|Procedure|quality-of-life assessment|quality-of-life assessment
344470|NCT00469937|Radiation|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
336712|NCT00433498|Drug|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
336713|NCT00433498|Drug|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
336714|NCT00003402|Drug|carmustine|
336715|NCT00433498|Drug|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
336716|NCT00433511|Biological|Bevacizumab|Given IV
336717|NCT00433511|Drug|Cyclophosphamide|Given IV
336718|NCT00433511|Drug|Doxorubicin Hydrochloride|Given IV
336719|NCT00433511|Other|Laboratory Biomarker Analysis|Correlative studies
336720|NCT00433511|Drug|Paclitaxel|Given IV
336721|NCT00433511|Other|Placebo|Given IV
336722|NCT00433511|Other|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
336723|NCT00433524|Procedure|computed tomography|
336724|NCT00433537|Drug|bortezomib|Given IV
336725|NCT00003402|Drug|cisplatin|
336726|NCT00433537|Biological|rituximab|Given IV
336727|NCT00433537|Drug|cyclophosphamide|Given IV
336728|NCT00433537|Drug|doxorubicin hydrochloride|Given IV
336729|NCT00433537|Drug|vincristine|Given IV
336730|NCT00433537|Drug|dexamethasone|Given IV
336731|NCT00433537|Biological|filgrastim|Given SC
336732|NCT00433537|Biological|pegfilgrastim|Given SC
336733|NCT00433537|Procedure|Autologous stem cell transplantation (ASCT)|
336734|NCT00433550|Drug|capecitabine|given orally
336735|NCT00436514|Procedure|Standard colonoscopy|1l of PEG the morning just before colonoscopy
335992|NCT00450463|Biological|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
335993|NCT00450463|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
335994|NCT00450476|Device|Hi-Lo Evac Endotracheal Tube|
335995|NCT00003484|Drug|carmustine|
335996|NCT00450502|Drug|Batracylin|
335997|NCT00450515|Drug|capecitabine|
335998|NCT00450515|Drug|vinflunine|
335999|NCT00450541|Behavioral|Questionnaire|Four questionnaires taking 15-20 minutes total to complete.
336000|NCT00450541|Behavioral|Interview|Interview lasting about 30 minutes.
336367|NCT00441974|Drug|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
336368|NCT00441987|Drug|GSI-953|
336369|NCT00442000|Procedure|Prostatectomy|Patients undergoing prostatectomy.
336370|NCT00000521|Behavioral|diet, potassium-supplemented|
336371|NCT00003435|Procedure|bone marrow ablation with stem cell support|
336372|NCT00442013|Drug|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
336373|NCT00442013|Drug|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
336374|NCT00442026|Drug|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
336375|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
336376|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
336377|NCT00445003|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
336378|NCT00445003|Drug|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
335637|NCT00459654|Drug|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
335638|NCT00459654|Drug|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
335639|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
335640|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
335641|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.
Phase B: All patients will receive 500µg s.c.every other day (open-label).
335642|NCT00459680|Device|Laser acupoint treatment|Laser
335643|NCT00459680|Procedure|Acupuncture|Needle acupuncture on ST36 and LI11.
335644|NCT00459693|Drug|[11C]PBR28|
335645|NCT00003530|Drug|antineoplaston A10|
335646|NCT00459706|Device|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
335647|NCT00459706|Device|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
335648|NCT00415610|Drug|nicardipine|Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.
Started at 5mg/h
Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour *Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.
335649|NCT00415623|Drug|Amlodipine|Amlodipine 5mg/ day
335650|NCT00415623|Drug|Amlodipine|Amlodipine 10mg/ day
335651|NCT00415636|Drug|IC83/LY2603618|40 mg/m2 day 1 and day 9 cycle 1, day 2 of subsequent cycles, unlimited 21 day cycles. Dose finding study: dose is escalated after a minimum of 6 patients receive 40 mg/m2.
335652|NCT00003322|Drug|cisplatin|
336001|NCT00450567|Procedure|computed tomography|
336002|NCT00450567|Procedure|positron emission tomography|
336003|NCT00450567|Radiation|fludeoxyglucose F 18|
334929|NCT00429949|Drug|Dasatinib|
334930|NCT00429962|Drug|intravitreal ranibizumab|intraocular injection
334931|NCT00429962|Drug|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
334932|NCT00429975|Drug|levofloxacin|
334933|NCT00429975|Drug|ceftriaxone|
334934|NCT00003396|Biological|graft-versus-tumor induction therapy|
334935|NCT00429988|Genetic|fluorescence in situ hybridization|
334936|NCT00429988|Genetic|polymerase chain reaction|
335275|NCT00421551|Drug|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
335276|NCT00421564|Drug|DBT-Danggui Buxue Tang|
335277|NCT00421590|Drug|SMC021|
335278|NCT00421603|Drug|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
335279|NCT00421603|Drug|Placebo|Placebo
335280|NCT00421616|Behavioral|High protein diet study|
335281|NCT00421629|Behavioral|After-sales service and supportive supervision (AfterSS)|
335282|NCT00421629|Behavioral|Prospective reimbursement (PR)|
335283|NCT00421629|Behavioral|Both (AfterSS and PR)|
335284|NCT00003353|Procedure|peripheral blood stem cell transplantation|
335285|NCT00424008|Drug|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
335286|NCT00424021|Drug|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
335287|NCT00424034|Drug|GSK1325760A|
335288|NCT00424047|Drug|Lenalidomide|25 mg Lenalidomide administered by mouth daily on Days 1-21 of each 28-day treatment cycle until disease progression.
335289|NCT00424047|Drug|Dexamethasone|Oral pulse dexamethasone for oral administration
334202|NCT00444197|Behavioral|Mentoring and violence prevention curriculum with parental monitoring|
334203|NCT00444210|Device|DL6049 (injectable poly-L-lactic acid)|
334204|NCT00444223|Procedure|fluorine F 18 FEQA + positron emission tomography|
334205|NCT00444236|Drug|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
334206|NCT00444236|Drug|Placebo|matching placebo for active drug
334207|NCT00444249|Procedure|White Alcon IOL|Implantation of white Alcon IOL
334208|NCT00444249|Procedure|Yellow Alcon IOL|Implantation of yellow Alcon IOL
334209|NCT00446732|Device|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
334210|NCT00446758|Dietary Supplement|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.
334211|NCT00446771|Drug|Mannitol|
334212|NCT00446784|Drug|CE-224,535|
334213|NCT00446784|Drug|Methotrexate|
334214|NCT00446797|Drug|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
334215|NCT00446797|Drug|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
334216|NCT00446810|Drug|Benfotiamine|
334217|NCT00446810|Drug|Placebo|
334218|NCT00003456|Drug|antineoplaston AS2-1|
334219|NCT00446823|Device|XCell cellulose wound dressing|
334220|NCT00446823|Device|Impregnated gauze dressing|
334569|NCT00438425|Dietary Supplement|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
334570|NCT00000519|Behavioral|exercise|
334571|NCT00003421|Drug|chlorambucil|
338992|NCT00543257|Other|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
338993|NCT00543270|Device|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
338994|NCT00543270|Procedure|Open Surgery|Open surgical abdominal aortic aneurysm repair
338995|NCT00543296|Drug|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
339316|NCT00535509|Other|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
339317|NCT00535509|Drug|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
339318|NCT00535522|Drug|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
339319|NCT00535522|Drug|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
339320|NCT00003895|Biological|HPV 16 E7:12-20 peptide vaccine|Given SC
339321|NCT00535535|Dietary Supplement|Fructose|Fructose, 0.5 g/kg
339322|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
339323|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
339324|NCT00535548|Biological|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
339325|NCT00535561|Drug|Ferrous sulfate tablets 325 mg, po, TID|
339326|NCT00535561|Drug|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
339327|NCT00535574|Drug|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
339328|NCT00535574|Drug|bexarotene|75 mg/day 6 weeks
339329|NCT00535587|Behavioral|Exercise|
339330|NCT00535587|Drug|pyridostigmine|
339331|NCT00003895|Biological|gp100:209-217(210M) peptide vaccine|Given SC
339332|NCT00535587|Drug|Placibo|
338317|NCT00510250|Drug|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
338318|NCT00003768|Drug|fosbretabulin disodium|
338319|NCT00510250|Drug|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
338320|NCT00513162|Drug|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
338321|NCT00513162|Drug|Etoposide|25 - 50 mg/m^2 By Mouth Daily
338322|NCT00513188|Biological|denileukin diftitox|
338323|NCT00513188|Drug|cyclophosphamide|
338324|NCT00003783|Drug|cyclophosphamide|
338325|NCT00513188|Drug|cytarabine|
338326|NCT00513188|Drug|doxorubicin hydrochloride|
338327|NCT00513188|Drug|leucovorin calcium|
338328|NCT00513188|Drug|methotrexate|
338329|NCT00513188|Drug|prednisone|
338330|NCT00513188|Drug|vincristine sulfate|
338331|NCT00513188|Genetic|protein expression analysis|
338332|NCT00513188|Other|flow cytometry|
338333|NCT00513188|Other|laboratory biomarker analysis|
338659|NCT00548366|Other|Sodium restriction|4 gram sodium diet
338660|NCT00548366|Other|Sodium restriction|2 gram sodium diet
338661|NCT00548379|Drug|vitamin D|vitamin D 100,000 units once in 3 months
338662|NCT00548379|Drug|placebo|olive oil 1ml
338663|NCT00548405|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
338664|NCT00003958|Biological|sargramostim|Given SC
338665|NCT00548405|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
337646|NCT00003852|Drug|thiotepa|
337647|NCT00526734|Procedure|autologous hematopoietic stem cell transplantation|
337648|NCT00526760|Drug|Dexmedetomidine|
337649|NCT00526773|Other|telephone management plus a motivational intervention|heart failure intervention
337978|NCT00518505|Other|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
337979|NCT00518518|Drug|Staloral 300|Staloral 300
337980|NCT00518518|Drug|placebo|placebo
337981|NCT00003808|Drug|theophylline|
337982|NCT00520988|Behavioral|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
337983|NCT00521001|Drug|everolimus|
337984|NCT00521001|Drug|temozolomide|
337985|NCT00521014|Biological|filgrastim|
337986|NCT00521014|Biological|rituximab|
337987|NCT00521014|Biological|sargramostim|
337988|NCT00521014|Drug|carmustine|
337989|NCT00521014|Drug|cytarabine|
337990|NCT00521014|Drug|etoposide|
337991|NCT00000556|Procedure|catheter ablation|
337992|NCT00003816|Drug|melphalan|Given IV
337993|NCT00521014|Drug|melphalan|
337994|NCT00521014|Procedure|autologous hematopoietic stem cell transplantation|
337995|NCT00521027|Device|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
337996|NCT00521027|Procedure|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
337997|NCT00521040|Drug|Levocetirizine dihydrochloride|
337266|NCT00445458|Drug|Paclitaxel|paclitaxel 80 mg/m^2 weekly IV
337267|NCT00445471|Behavioral|Mifne Approach to PDD|
337268|NCT00445471|Behavioral|Treatment as usual|
337269|NCT00445484|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
337270|NCT00445484|Drug|lenalidomide|Given orally
337271|NCT00445497|Drug|amoxicillin-clavulanate potassium|
337272|NCT00445497|Drug|ciprofloxacin|
337273|NCT00445497|Procedure|psychosocial assessment and care|
337274|NCT00445497|Procedure|quality-of-life assessment|
337275|NCT00445510|Drug|GSK256066|
337276|NCT00003449|Drug|gemcitabine hydrochloride|
337277|NCT00445523|Biological|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
337278|NCT00445523|Drug|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
337279|NCT00445549|Drug|Vandetanib|300 mg daily dose, 28 day cycle
337280|NCT00448175|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
337281|NCT00448175|Drug|Tolterodine|
337282|NCT00448188|Procedure|central venous catheter application|
337283|NCT00448201|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
337650|NCT00529334|Radiation|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
337651|NCT00529347|Device|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
337652|NCT00529360|Drug|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
337653|NCT00529360|Drug|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
336550|NCT00415974|Behavioral|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
336896|NCT00450801|Drug|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
336897|NCT00450801|Drug|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
336898|NCT00450801|Drug|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
336899|NCT00453908|Drug|Alfuzosin|
336900|NCT00003501|Drug|antineoplaston AS2-1|
336901|NCT00453921|Drug|Methylphenidate|Dosage dependent on weight
336902|NCT00453921|Behavioral|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
336903|NCT00453921|Other|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
336904|NCT00453934|Device|h-Patch|
336905|NCT00453947|Device|CPAP and Non Invasive Ventilation|
336906|NCT00453960|Dietary Supplement|Genivis|54 mg/day daily for 6 months
336907|NCT00453960|Drug|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
336908|NCT00453960|Other|placebo|tablets daily for 6 months
336909|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
336910|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
336911|NCT00003502|Drug|antineoplaston A10|
336186|NCT00003376|Drug|doxorubicin hydrochloride|
336187|NCT00424437|Drug|Inhaled human insulin|
336188|NCT00424450|Procedure|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
336189|NCT00424450|Procedure|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
336190|NCT00424463|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
336191|NCT00424463|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
336192|NCT00424476|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
336193|NCT00424476|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
336194|NCT00424476|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
336195|NCT00424489|Biological|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
336196|NCT00424502|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
336197|NCT00000512|Other|Placebo for lovastatin|Placebo for lovastatin
336551|NCT00415974|Behavioral|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
336552|NCT00003323|Other|quality-of-life assessment|Assessment survey administered at baseline, and 3 & 6 months post initiation of treatment
336553|NCT00415974|Behavioral|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
335471|NCT00441441|Drug|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
335822|NCT00003401|Drug|etoposide|
335823|NCT00433173|Procedure|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
335824|NCT00433173|Procedure|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
335825|NCT00433186|Drug|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
335826|NCT00433199|Drug|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
335827|NCT00433199|Drug|Placebo|Placebo Control
335828|NCT00433212|Device|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
335829|NCT00433212|Device|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
335830|NCT00433225|Drug|Prednisolone Acetate|
335831|NCT00433225|Drug|Ketorolac 0.4%|
335832|NCT00433225|Drug|Gatifloxacin 0.3%|
335833|NCT00003401|Drug|gemcitabine hydrochloride|
335834|NCT00433238|Behavioral|Participants will be screened for depression and cognitive impairment, then receive screening results.|
335835|NCT00433264|Procedure|peritoneal dialysis|individualised
335836|NCT00433277|Drug|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
335837|NCT00433290|Drug|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
335838|NCT00433290|Drug|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
335839|NCT00433303|Behavioral|Correlation between early delivery and coital activity|
335840|NCT00433316|Drug|ropivacaine|1% ropivacaine
335841|NCT00433316|Device|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
340524|NCT00530660|Biological|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
340525|NCT00530686|Drug|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
340526|NCT00530699|Drug|AZD1152|intravenous
340527|NCT00530712|Device|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
340528|NCT00533299|Drug|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
340529|NCT00533299|Drug|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
340530|NCT00533312|Drug|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
340531|NCT00533312|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
340532|NCT00533312|Drug|Comparator : niacin / Duraton of Treatment: 4 Weeks|
340533|NCT00533338|Behavioral|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
340534|NCT00533338|Behavioral|Questionnaire|Packet of questionnaires will be completed.
340535|NCT00003880|Drug|carboplatin|
340536|NCT00533351|Drug|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
340537|NCT00533351|Drug|placebo|placebo 50 mg capsules three-times daily for 2 weeks
340893|NCT00003846|Drug|carboplatin|
340894|NCT00525330|Drug|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
340895|NCT00525330|Drug|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
340896|NCT00525356|Device|Medtronic Talent Stent-Graft-System|
340194|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
340195|NCT00538330|Drug|Tamoxifen|Tamoxifen
340196|NCT00538343|Drug|berubicin hydrochloride (RTA 744)|
340197|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
340198|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
340199|NCT00538369|Other|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
340200|NCT00003913|Biological|filgrastim|
340201|NCT00538369|Device|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
340202|NCT00538382|Drug|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
340203|NCT00540995|Radiation|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
340204|NCT00003927|Drug|paclitaxel|
340205|NCT00540995|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
340206|NCT00540995|Procedure|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
340207|NCT00540995|Procedure|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
340208|NCT00540995|Radiation|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
340209|NCT00541008|Drug|sunitinib malate|
340210|NCT00541021|Drug|gemcitabine hydrochloride|
340211|NCT00541021|Drug|sorafenib tosylate|
340212|NCT00541034|Biological|rituximab|
340213|NCT00541034|Drug|cyclophosphamide|
340214|NCT00541034|Drug|pentostatin|
340215|NCT00003927|Procedure|peripheral blood stem cell transplantation|
340216|NCT00541047|Drug|bicalutamide|
345139|NCT00499460|Other|mass spectrometry|
345140|NCT00499460|Other|pharmacological study|
345141|NCT00502307|Drug|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
345142|NCT00502320|Drug|Ramelteon|one 8 mg tablet at bed for up to 4 months
345143|NCT00502320|Drug|Placebo|one tablet at bedtime for up to 4 months
345144|NCT00502346|Drug|PM10|
345145|NCT00502359|Device|capillary blood glucose measurement|
345146|NCT00003721|Drug|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
345147|NCT00502372|Dietary Supplement|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
345148|NCT00502372|Dietary Supplement|Juven|comparison of Juven with arginine only product in wound healing
345500|NCT00494429|Drug|Morphine|Gestational Age>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
345501|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
345502|NCT00003673|Drug|gemtuzumab ozogamicin|
345503|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
345504|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
345505|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
345506|NCT00494468|Drug|Zolpidem|
345507|NCT00494481|Drug|Vandetanib (ZD6474)|once daily oral dose
345508|NCT00494481|Drug|Docetaxel|intravenous infusion
345509|NCT00494494|Drug|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
345510|NCT00494494|Drug|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
344471|NCT00469950|Behavioral|exercise training|Exercise training in groups
344472|NCT00469963|Procedure|quality-of-life assessment|quality-of-life assessment
344473|NCT00003576|Radiation|radiation therapy|
344801|NCT00507611|Procedure|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
344802|NCT00507637|Drug|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
344803|NCT00507650|Dietary Supplement|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
344804|NCT00507650|Dietary Supplement|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
344805|NCT00507663|Drug|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
344806|NCT00507689|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
344807|NCT00507689|Drug|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
344808|NCT00003549|Drug|cyclophosphamide|
344809|NCT00463749|Drug|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
344810|NCT00463749|Drug|Placebo|NaCl as placebo
344811|NCT00463762|Drug|CP-75385-02 Cefoperazone/sulbactam|
344812|NCT00463775|Drug|Topiramate|SSRI plus topiramate SSRI plus placebo
344813|NCT00463788|Drug|cetuximab, cisplatin|Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m^2) followed by weekly doses of 250 mg/m^2. All doses will be given by intravenous (IV) infusion.
Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.
Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent.
344814|NCT00463788|Drug|cisplatin|Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.
Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.
Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent.
337100|NCT00427843|Behavioral|home exercise program for the hip abductor muscles|All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.
The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns.
337101|NCT00427856|Drug|Obatoclax mesylate (GX15-070MS)|Obatoclax 40mg, Obatoclax 60mg
337102|NCT00427856|Drug|Rituximab|Rituximab
337103|NCT00427882|Drug|ALFUZOSIN|
337104|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
337105|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
337106|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
337107|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
337108|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
337109|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
337110|NCT00003389|Drug|Doxorubicin|given IV
337111|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
337112|NCT00427908|Biological|meningococcal vaccine 134612|One intramuscular dose.
337113|NCT00430690|Procedure|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
337114|NCT00430703|Behavioral|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
337115|NCT00430716|Drug|Sildenafil citrate|oral, 20 mg, tid
337116|NCT00430716|Drug|Sildenafil citrate|oral 1 mg, tid
337117|NCT00430716|Drug|Sildenafil citrate|oral 5 mg, tid
336379|NCT00445003|Behavioral|Sham injection|Sham injection at baseline and 4 weeks
336380|NCT00445003|Procedure|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
336381|NCT00445016|Procedure|peripheral regional anesthesia|evaluation and description of adverse effects
336382|NCT00445042|Drug|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
336383|NCT00445055|Drug|Droperidol|Intravenous injection
336384|NCT00003446|Drug|fluorouracil|
336385|NCT00445068|Drug|LBH589|
336386|NCT00445081|Drug|Prednisolone|
336387|NCT00445081|Drug|Ciclosporine A|
336388|NCT00445094|Drug|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
336389|NCT00445094|Drug|Comparator: amikacin / Duration of Treatment: 3 Days|
336736|NCT00436527|Drug|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
336737|NCT00436540|Drug|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
336738|NCT00436540|Drug|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
336739|NCT00436553|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 (Standard Fluence rate) or 25 J/cm^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
336740|NCT00436553|Drug|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
336741|NCT00003413|Drug|carmustine|
336742|NCT00436553|Drug|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
336743|NCT00436553|Drug|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
336744|NCT00436566|Biological|trastuzumab|
336745|NCT00436566|Drug|cyclophosphamide|
336004|NCT00453375|Drug|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
336005|NCT00453375|Drug|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
336006|NCT00453388|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
336007|NCT00453388|Drug|Cyclophosphamide|Given IV
336008|NCT00453388|Drug|Cyclosporine|Given IV or PO
336009|NCT00003499|Drug|antineoplaston A10|
336010|NCT00453388|Drug|Fludarabine Phosphate|Given IV
336011|NCT00453388|Other|Laboratory Biomarker Analysis|Correlative studies
336012|NCT00453388|Drug|Mycophenolate Mofetil|Given PO
336013|NCT00453388|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
336014|NCT00453388|Radiation|Total-Body Irradiation|Undergo TBI
336015|NCT00453401|Drug|NB-001|
336016|NCT00453414|Drug|Iloprost Inhalation Solution (Ventavis)|
336017|NCT00453427|Drug|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
336018|NCT00453440|Procedure|Cheek swab & blood test|
336019|NCT00453453|Drug|Nesiritide|Nesiritide given orally in the emergency department
336020|NCT00003499|Drug|antineoplaston AS2-1|
336021|NCT00453466|Behavioral|EBW group intervention to empower battered women|
336022|NCT00453479|Drug|GSK233705B|
336023|NCT00453492|Drug|risedronate sodium|
336024|NCT00453518|Device|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
336025|NCT00453531|Procedure|Limb Ischemia|
335290|NCT00424047|Drug|Placebo|
335291|NCT00424060|Drug|sagopilone|
335292|NCT00424060|Genetic|fluorescence in situ hybridization|
335293|NCT00424060|Genetic|gene expression analysis|
335294|NCT00424060|Other|immunohistochemistry staining method|
335295|NCT00003375|Drug|procarbazine hydrochloride|
335296|NCT00424060|Other|laboratory biomarker analysis|
335297|NCT00424060|Other|pharmacological study|
335298|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
335299|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
335300|NCT00424099|Drug|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
335653|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m2, IV, day 8 of cycle 1, day one of subsequent cycles, unlimited 21 day cycles
335654|NCT00415649|Biological|VRC-HIVDNA016-00-VP|
335655|NCT00415649|Biological|VRC-HIVADV014-00-VP|
335656|NCT00415649|Biological|Vaccine placebo|Placebo comparator
335657|NCT00415662|Device|Pulsed Signal Therapy (PST)|
335658|NCT00415675|Procedure|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
335659|NCT00415688|Behavioral|Low carbohydrate, ketogenic diet|
335660|NCT00415688|Behavioral|Low glycemic index, reduced calorie diet|
335661|NCT00415701|Drug|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
335662|NCT00415701|Drug|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
335663|NCT00003322|Drug|paclitaxel|
335664|NCT00415701|Drug|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
334572|NCT00438438|Behavioral|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
334573|NCT00438451|Drug|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
334574|NCT00438451|Drug|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
334575|NCT00438451|Drug|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
334576|NCT00438464|Drug|Finasteride|Given PO
334577|NCT00438464|Other|Placebo|Given PO
334578|NCT00438464|Procedure|Prostatectomy|Undergo prostatectomy
334579|NCT00438464|Other|Laboratory biomarker analysis|Correlative studies
334580|NCT00438477|Drug|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
334581|NCT00438477|Procedure|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
334582|NCT00003421|Drug|dacarbazine|
334583|NCT00438477|Radiation|Technetium Tc 99m sulfur colloid|At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.
At the time of surgery, patients receive isosulfan blue by subareolar injection.
334584|NCT00438490|Drug|Recombinant Human Prolactin|
334585|NCT00438503|Procedure|Procedure|
334586|NCT00438516|Behavioral|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
334587|NCT00438555|Behavioral|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
334588|NCT00438555|Behavioral|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
334589|NCT00438568|Drug|Regular Insulin|administered intra-nasally twice a day for 16 weeks
334937|NCT00429988|Genetic|proteomic profiling|
334938|NCT00429988|Other|cytology specimen collection procedure|
339333|NCT00535587|Behavioral|Attention Control|
339334|NCT00535613|Drug|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
339335|NCT00535626|Device|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
339336|NCT00535639|Drug|Betula Verrucosa allergen extract|
339337|NCT00535652|Drug|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
339338|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
339339|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
339687|NCT00527618|Drug|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
339688|NCT00527618|Drug|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
339689|NCT00527631|Radiation|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
339690|NCT00527644|Device|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
339691|NCT00530140|Biological|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
339692|NCT00530153|Behavioral|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
339693|NCT00003868|Drug|cyclophosphamide|
339694|NCT00530153|Dietary Supplement|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
339695|NCT00530166|Drug|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
339696|NCT00530166|Drug|sham comparator|3(100 mg) tablets once daily for 12 weeks
339697|NCT00530179|Procedure|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
339698|NCT00530179|Drug|R-CHOP (Rituximab, Cyclphosphamide, Etoposide, Cisplatin, Mesna, G-CSF|6 - 21 DAY Cycles of R-CHOP
339699|NCT00530192|Other|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
338666|NCT00548405|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
338667|NCT00548418|Drug|Topotecan|
338668|NCT00548418|Drug|Cisplatin|
338669|NCT00548418|Drug|Bevacizumab|
338670|NCT00548431|Drug|6-mercaptopurine|Standard dose 25 mg/m^2/day. Can be increased up to 75 mg/m^2/day if the myelosuppression is acceptable (ANC>0.5 T-count >50)
338671|NCT00548444|Biological|MVA85A|Vaccine. Dose: 1 x 10^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
338672|NCT00548444|Other|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
338673|NCT00548470|Drug|Varenicline|Varenicline 1-3 mg/day
338674|NCT00548483|Drug|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
338675|NCT00003958|Other|laboratory biomarker analysis|Correlative studies
338676|NCT00548496|Drug|SB-751689|SB-751689
338677|NCT00548496|Other|Placebo|Placebo to match
338678|NCT00460980|Behavioral|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
338679|NCT00460993|Drug|Lunesta|Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.
Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4.
338680|NCT00461006|Drug|Actos|45mg po daily
338996|NCT00003937|Drug|methotrexate|
338997|NCT00543309|Drug|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
338998|NCT00543309|Drug|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
338999|NCT00543309|Drug|placebo|Placebo bolus on CPB, then placebo infusion
339000|NCT00543335|Drug|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
337998|NCT00521053|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
337999|NCT00521066|Device|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
338000|NCT00521079|Device|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
338001|NCT00521092|Drug|sunitinib malate|Given orally
338002|NCT00521092|Procedure|laboratory biomarker analysis|Correlative study
338003|NCT00003816|Drug|thiotepa|Given IV
338004|NCT00521092|Procedure|pharmacological study|Correlative study
338334|NCT00513201|Drug|lyspro|
338335|NCT00003783|Drug|cytarabine|
338336|NCT00513201|Drug|regular insulin|
338337|NCT00513214|Drug|XOMA 052|Part 1, Single IV infusion at one of six dose levels (mg/kg).
Part 2, Single SC injection at one of three dose levels (mg/kg).
Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
338338|NCT00513214|Drug|Placebo|Part 1, Single IV infusion at one of six dose levels (mg/kg).
Part 2, Single SC injection at one of three dose levels (mg/kg).
Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
338339|NCT00513240|Drug|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
338340|NCT00513240|Drug|Normal saline|Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.
338341|NCT00513253|Drug|lapatinib|
338342|NCT00513266|Biological|bevacizumab|
338343|NCT00513266|Biological|cetuximab|
338344|NCT00513266|Drug|fluorouracil|
338345|NCT00513266|Drug|irinotecan hydrochloride|
338346|NCT00003783|Drug|daunorubicin hydrochloride|
338347|NCT00513266|Drug|leucovorin calcium|
338348|NCT00513266|Drug|oxaliplatin|
337654|NCT00529373|Drug|Odanacatib|50 mg tablet orally once weekly
337655|NCT00529373|Drug|Placebo for Odanacatib|50 mg tablet orally once weekly
337656|NCT00003862|Procedure|neoadjuvant therapy|
337657|NCT00529373|Dietary Supplement|Vitamin D3|5600 IU orally once weekly
337658|NCT00529386|Drug|Botox|300 units
337659|NCT00529386|Drug|Lidocaine|1%
337660|NCT00529399|Drug|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
337661|NCT00529399|Drug|GAD-Alum|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
337662|NCT00529399|Drug|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
337663|NCT00529412|Other|Seprafilm|two sheets per body
337664|NCT00529425|Drug|Ropivacaine|
337665|NCT00529438|Drug|Bardoxolone methyl|
337666|NCT00529451|Drug|Aliskiren|Aliskiren
337667|NCT00003862|Radiation|radiation therapy|
337668|NCT00529451|Drug|Ramipril|comparator
337669|NCT00529464|Procedure|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
337670|NCT00529464|Procedure|Colposcopy|A standard colposcopy will be performed.
337671|NCT00529464|Procedure|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
337672|NCT00529477|Other|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
338005|NCT00521105|Other|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
338006|NCT00521118|Other|laboratory biomarker analysis|
336912|NCT00453986|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
336913|NCT00453986|Biological|Mencevax™ACWY|One subcutaneous dose
336914|NCT00453986|Biological|Fluarix™|One intramuscular dose
336915|NCT00453999|Drug|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
336916|NCT00453999|Drug|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
336917|NCT00453999|Drug|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
337284|NCT00448201|Biological|sargramostim|GM-CSF 500 ug QD subcutaneously will be given to recipients who remain with an ANC < 1000/uL past day 20
337285|NCT00003464|Radiation|radiation therapy|
337286|NCT00448201|Biological|therapeutic allogeneic lymphocytes|A minimum total CD34+ cell dose of 3 x 10^6 cells/kg and a maximum 8 x 10^6 cells/kg will be infused on day 0
337287|NCT00448201|Drug|busulfan|6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
337288|NCT00448201|Drug|fludarabine phosphate|fludarabine 30 mg/m^2/day x 5 days IVPB over 30 minutes on Days -7 through -3
337289|NCT00448201|Drug|methotrexate|Methotrexate 5 mg/m^2 per day on days +1, +3 and +6
337290|NCT00448201|Drug|tacrolimus|Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
337291|NCT00448201|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
337292|NCT00448201|Procedure|peripheral blood stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
337293|NCT00448214|Drug|YM150|Oral
337294|NCT00448214|Drug|warfarin|Oral
337295|NCT00448227|Drug|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
337296|NCT00000522|Drug|amlodipine|
337297|NCT00003465|Drug|temozolomide|
337298|NCT00448240|Drug|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
336554|NCT00415987|Procedure|Hematopoietic Stem Cell Transplantation|
336555|NCT00416026|Behavioral|Educational/Counseling/Training|
336556|NCT00416039|Drug|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
336557|NCT00416039|Drug|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
336558|NCT00416065|Device|PET/CT imaging|
336559|NCT00416078|Behavioral|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
336560|NCT00416078|Behavioral|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
336561|NCT00416117|Procedure|Manual Physical Therapy and Exercise|
336562|NCT00416117|Procedure|Minimal Intervention|
336563|NCT00003324|Procedure|conventional surgery|
336564|NCT00416130|Drug|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
336565|NCT00418769|Drug|Nilotinib|
336566|NCT00003339|Biological|tyrosinase peptide|
336567|NCT00418782|Drug|naproxen|
336568|NCT00418782|Drug|CE-224535|
336569|NCT00418782|Drug|placebo|
336918|NCT00454012|Procedure|biophysical profile|
336919|NCT00454038|Device|HYPRO SORB F|resorbable, double layered, collagen membrane
336920|NCT00454051|Drug|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
336921|NCT00454051|Drug|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
336922|NCT00003502|Drug|antineoplaston AS2-1|
336923|NCT00454064|Behavioral|cognitive-behavioral treatment|
335842|NCT00433329|Drug|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
335843|NCT00433329|Drug|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
335844|NCT00003401|Drug|melphalan|
335845|NCT00433342|Drug|Flucloxacillin|500 mg QD oral
336198|NCT00003376|Drug|methotrexate|
336199|NCT00424502|Drug|Methotrexate|10-25mg po/week
336200|NCT00424515|Drug|Imatinib|Participants will take four 100mg tablets once daily for approximately one year (Dosage may be increased to twice daily if disease worsens)
336201|NCT00424528|Drug|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
336202|NCT00424528|Drug|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
336203|NCT00424528|Drug|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
336204|NCT00424528|Drug|Placebo|Placebo inhalation solution and placebo inhalation powder
336205|NCT00424541|Drug|SPP100 (aliskiren)|
336206|NCT00424554|Drug|temozolomide|Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion.
336207|NCT00427297|Drug|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
336208|NCT00427297|Drug|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
336209|NCT00427310|Drug|fluorouracil|
336210|NCT00427310|Other|Observation|
336211|NCT00003388|Drug|cyclophosphamide|
336212|NCT00427310|Drug|sodium heparin|
336213|NCT00427323|Procedure|light exposure|
336214|NCT00427336|Drug|Fludarabine|30 mg/m^2 by vein daily over 30 minutes
340897|NCT00525382|Drug|levocetirizine dihydrochloride|
340898|NCT00525395|Genetic|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
340899|NCT00525395|Procedure|Continuous phototherapy|Group B: 6 months non-stop treatment.
340900|NCT00525408|Biological|Mycobacterium w.|Immunomodulator
340901|NCT00525408|Drug|Docetaxel|Chemotherapeutic agent
340902|NCT00525421|Drug|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
340903|NCT00525421|Drug|Placebo|
340904|NCT00003846|Drug|cyclophosphamide|
340905|NCT00525434|Device|Seraffix LTB|wounds closure by using laser and albumin
340906|NCT00525447|Drug|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
340907|NCT00525447|Drug|lenalidomide|Up to 25 mg daily of a 21-day cycle.
340908|NCT00525447|Drug|dexamethasone|40 mg administered weekly.
340909|NCT00525460|Behavioral|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
340910|NCT00525473|Drug|Azathioprine|azathioprine usual dosage 100mg per day
340911|NCT00525486|Drug|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
340912|NCT00525499|Drug|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
340913|NCT00525499|Drug|placebo|vehicle control applied topically twice daily for 12 weeks
340914|NCT00525512|Drug|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
340915|NCT00003846|Drug|thiotepa|
340916|NCT00003859|Drug|carboplatin|
341240|NCT00519818|Drug|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
341241|NCT00519831|Biological|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
341242|NCT00003814|Drug|eflornithine|
340217|NCT00541047|Drug|goserelin acetate|
340218|NCT00541047|Drug|leuprolide acetate|
340219|NCT00541047|Procedure|adjuvant therapy|
340538|NCT00533364|Drug|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
340539|NCT00533377|Drug|CP-533, 536|Active study drug
340540|NCT00533377|Drug|Placebo|Placebo vehicle
340541|NCT00533377|Procedure|Standard of Care|Standard surgical procedure
340542|NCT00533377|Drug|CP-533,536|Active study drug
340543|NCT00533377|Drug|CP-533,536|Active study drug
340544|NCT00533377|Drug|CP-533,536|Active study drug
340545|NCT00533390|Drug|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
340546|NCT00003880|Drug|paclitaxel|
340547|NCT00533403|Drug|MK0686|
340548|NCT00533416|Drug|ON 01910 Na|
340549|NCT00533429|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until disease progression
340550|NCT00533429|Drug|pemetrexed|500 mg/m2, IV, day 8 of cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
340551|NCT00533429|Drug|carboplatin|AUC 6, IV day 8 cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
340552|NCT00533429|Drug|bevacizumab|15 mg/kg, IV, Day 8 of cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
340553|NCT00533429|Drug|Placebo|oral, daily
340554|NCT00533442|Drug|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
340555|NCT00003897|Biological|sargramostim|
340556|NCT00535951|Drug|LBH589|
340557|NCT00535977|Dietary Supplement|Broccoli|400g ITC-enriched broccoli per week for 12 months
345511|NCT00494507|Drug|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
345512|NCT00494507|Drug|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
345513|NCT00003674|Drug|dalteparin|
345514|NCT00494507|Drug|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
345515|NCT00494520|Procedure|Cueing systems to improve picture naming|
345516|NCT00494533|Drug|Remodulin (treprostinil sodium)|
345517|NCT00494546|Procedure|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
345518|NCT00494559|Drug|Pioglitazone|Actos 15mg once a day before breakfast
345519|NCT00494559|Drug|Placebo|Placebo drug with the same appearance as actos
345520|NCT00494572|Drug|Montelukast|10 mg rapid dissolving granule in sterile water orally once
345521|NCT00494572|Other|sterile water|sterile water
345522|NCT00494585|Drug|CEP-701|80 mg orally twice a day for 30 days
345523|NCT00494598|Drug|Sufentanil|200 mcg intra-arterial one time bolus
345524|NCT00003674|Drug|standard therapy|
345525|NCT00497146|Drug|paricalcitol|2 µg capsule
340220|NCT00541047|Procedure|quality-of-life assessment|
340221|NCT00541047|Radiation|radiation therapy|
340222|NCT00541060|Genetic|mutation|a mutation of a gene coding
340223|NCT00541073|Dietary Supplement|vitamin B12|
340224|NCT00541073|Drug|cisplatin|
340225|NCT00541073|Drug|pemetrexed disodium|
340226|NCT00003928|Drug|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
340227|NCT00541073|Genetic|gene expression analysis|
340228|NCT00541073|Other|laboratory biomarker analysis|
344815|NCT00463801|Drug|Daptomycin|
344816|NCT00463814|Drug|AZD6244|oral capsule
344817|NCT00463827|Drug|Atorvastatin|
344818|NCT00463827|Drug|atorvastatin|atorvastatin 40mg
344819|NCT00000530|Procedure|electromyography|
344820|NCT00003549|Drug|fluorouracil|
345149|NCT00502385|Drug|AZD2171|
345150|NCT00502398|Procedure|Blood test|
345151|NCT00502411|Drug|Doxorubicin|17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
345152|NCT00502411|Radiation|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
345153|NCT00502424|Device|Splint|
345154|NCT00502437|Drug|GRANISETRON|
345155|NCT00502463|Procedure|radio-immunotherapy|
345156|NCT00502476|Procedure|Bathing with Chlorhexidine Impregnated Washcloths|
345157|NCT00000552|Drug|thrombolytic therapy|
345158|NCT00003723|Drug|gemcitabine hydrochloride|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days)
345159|NCT00502489|Procedure|Closed-loop sytem for5 weaning from mechanical ventilation|
345160|NCT00502502|Behavioral|Questionnaire|Weekly questionnaires lasting about 30 minutes.
345161|NCT00502515|Drug|SSR180575|Oral, once daily dosing
345162|NCT00502515|Drug|Placebo|Oral, once daily dosing
345163|NCT00502528|Drug|Placebo|Peri-interventional
345164|NCT00502528|Drug|BQ-123|Peri-interventional
345165|NCT00502541|Drug|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
345166|NCT00502541|Procedure|Standard of Care|Repeat macular grid laser or observation
337118|NCT00430716|Drug|Sildenafil citrate|oral 20 mg, tid
337119|NCT00430729|Drug|Roflumilast|
337484|NCT00422292|Biological|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
337485|NCT00422318|Drug|Benzbromarone (drug)|
337486|NCT00422331|Drug|Lithium Carbonate Capsule|
337487|NCT00422344|Drug|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
337488|NCT00422357|Drug|Urtica Dioica (Tea bag)|
337489|NCT00422370|Device|lipid based additives based on vegetable oil & lecithin|
337490|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
337491|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
337492|NCT00003359|Drug|batabulin sodium|
337493|NCT00422383|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
337494|NCT00422396|Drug|Fenofibrate (drug)|
337495|NCT00422409|Procedure|Endoscopic stenting|
337496|NCT00422422|Drug|Brivaracetam|Oral solution
Evaluation period (3 weeks up-titration):
For subjects ≥8 years:
~0.4 mg/kg bid for Week 1
~0.8 mg/kg bid for Week 2
~1.6 mg/kg bid for Week 3
For subjects <8 years:
~0.5 mg/kg bid for Week 1
~1.0 mg/kg bid for Week 2
~2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
~0.8 mg/kg bid for Week 4
~0.4 mg/kg bid for Week 5
For subjects <8 years:
~1.0 mg/kg bid for Week 4
~0.5 mg/kg bid for Week 5
337497|NCT00422435|Device|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
337498|NCT00422448|Genetic|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
337499|NCT00422461|Drug|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
337500|NCT00422461|Drug|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
336746|NCT00436566|Drug|doxorubicin hydrochloride|
336747|NCT00436566|Drug|lapatinib ditosylate|
336748|NCT00436566|Drug|paclitaxel|
336749|NCT00436566|Genetic|gene expression analysis|
336750|NCT00436566|Genetic|reverse transcriptase-polymerase chain reaction|
336751|NCT00436566|Other|fluorophotometry|
336752|NCT00003413|Drug|cisplatin|
336753|NCT00436566|Other|laboratory biomarker analysis|
336754|NCT00436566|Other|mass spectrometry|
336755|NCT00436566|Procedure|adjuvant therapy|
336756|NCT00436566|Procedure|quality-of-life assessment|
336757|NCT00436579|Drug|sorafenib tosylate|Given orally
336758|NCT00436579|Other|pharmacological study|
336759|NCT00436579|Procedure|assessment of therapy complications|Ancillary studies
336760|NCT00436579|Other|laboratory biomarker analysis|Correlative studies
337120|NCT00430742|Drug|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
337121|NCT00430742|Drug|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
337122|NCT00003397|Drug|etoposide|
337123|NCT00430755|Device|Computer-assisted history|Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.
Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees.
337124|NCT00430755|Procedure|physician taken history|Convential history taking by physicians
337125|NCT00430755|Other|Computer-assisted history taking|
337126|NCT00430768|Biological|rAAV1-CB-hAAT|Three groups of 3 subjects in drug escalation. Group 1 receives rAAV1-CB-hAAT 6.9 x1012 vg (vector genomes), Group 2 receives rAAV1-CB-hAAT 2.1 x1013 vg, and Group 3 receives rAAV1-CB-hAAT 6.0 x1013 vg
336390|NCT00445094|Drug|Comparator: tazocin / Duration of Treatment: 3 Days|
336391|NCT00445094|Drug|Comparator: vancomycin / Duration of Treatment: 3 Days|
336392|NCT00445107|Drug|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
336393|NCT00445120|Drug|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
336394|NCT00445120|Drug|placebo (sugar)|Placebo will be administered to patients once daily for six months
336395|NCT00003446|Drug|leucovorin calcium|
336396|NCT00445133|Device|Magnetic Sleep Pad|
336397|NCT00445146|Drug|Elvitegravir|Elvitegravir 150 mg tablet administered orally once daily with food
336398|NCT00445146|Drug|Ritonavir|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
336399|NCT00445146|Drug|ARV regimen|The components of the antiretroviral (ARV) regimen will be selected by the investigator without input from the sponsor. The Antiretroviral Regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine or delavirdine, the protease inhibitors saquinavir, nelfinavir or indinavir, or investigational agents (without sponsor approval).
336400|NCT00445159|Drug|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
336401|NCT00445172|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin twice a week.
336402|NCT00445185|Biological|Henogen HB vaccine|Month 12, 24 and 36
336403|NCT00445185|Biological|Fendrix vaccine|Month 12, 24 and 36
336404|NCT00447824|Procedure|Introduction of better conditions during blood sampling|
336405|NCT00447837|Drug|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
336406|NCT00447850|Procedure|endometrial biopsy|
336407|NCT00447863|Drug|Levonorgestrel/Ethinyl Estradiol|
336408|NCT00447876|Drug|Botulinum type A toxin (Dysport®)|Placebo: 0,9% sodium chloride, 2 ml Drug: Botulinum type A toxin (Dysport®) 200 Units / 2 ml injected at the root of the plantar fascia
336409|NCT00447889|Drug|gadoteric acid|
336410|NCT00447902|Drug|tipranavir|
336411|NCT00003463|Drug|carmustine|
335665|NCT00415701|Drug|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
335666|NCT00415701|Other|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
335667|NCT00415714|Device|Portable Biofeedback|
335668|NCT00415727|Device|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
335669|NCT00415740|Drug|ELC200 (carbidopa+levodopa+entacapone)|
335670|NCT00415753|Behavioral|No antibiotics if se-procalcitonin is below stated limit|
335671|NCT00415766|Drug|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
335672|NCT00415766|Drug|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
335673|NCT00415766|Drug|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
335674|NCT00003322|Procedure|quality-of-life assessment|
335675|NCT00415779|Drug|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
335676|NCT00415779|Drug|zoledronic acid|2 mg IV every 2 weeks
335677|NCT00003338|Procedure|immunoscintigraphy|
336026|NCT00453531|Drug|Acetylcholine|
336027|NCT00453544|Procedure|Enhanced Consent Procedure|
336028|NCT00453557|Drug|rhGH|
336029|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
336030|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
336031|NCT00003500|Drug|antineoplaston A10|
336032|NCT00453570|Biological|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
336033|NCT00453609|Drug|long-lasting injectable naltrexone|
336034|NCT00456365|Drug|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
336035|NCT00456365|Drug|Placebo|Placebo daily
334939|NCT00429988|Other|immunohistochemistry staining method|
334940|NCT00429988|Procedure|breast duct lavage|
334941|NCT00430001|Drug|docetaxel|
334942|NCT00432913|Procedure|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
334943|NCT00432913|Procedure|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
334944|NCT00432913|Procedure|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
334945|NCT00432913|Procedure|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
334946|NCT00432913|Procedure|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
334947|NCT00432913|Procedure|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
334948|NCT00432913|Procedure|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
334949|NCT00432926|Behavioral|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
334950|NCT00432926|Behavioral|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
334951|NCT00432926|Behavioral|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
334952|NCT00003401|Drug|carmustine|
334953|NCT00432952|Behavioral|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
334954|NCT00432965|Device|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
334955|NCT00432978|Drug|Bosentan administration|
334956|NCT00432991|Drug|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
334957|NCT00432991|Drug|Saline Placebo|0.5 mL, IM (in the muscle), one time
339700|NCT00530205|Other|physiologic testing|
339701|NCT00530205|Other|questionnaire administration|
339702|NCT00530205|Procedure|management of therapy complications|
339703|NCT00530205|Radiation|radiation therapy|
339704|NCT00003868|Drug|methotrexate|
339705|NCT00530218|Drug|ganciclovir|
339706|NCT00530218|Other|pharmacological study|
339707|NCT00530218|Procedure|allogeneic hematopoietic stem cell transplantation|
339708|NCT00530244|Dietary Supplement|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
339709|NCT00530244|Dietary Supplement|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
339710|NCT00530257|Drug|Placebo|Placebo (sugar pill)
334221|NCT00446836|Drug|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
334222|NCT00446849|Drug|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
334223|NCT00446862|Drug|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
334224|NCT00446875|Procedure|Administration of oral sucrose|
334225|NCT00446888|Behavioral|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
334226|NCT00446888|Dietary Supplement|Forticare|400 ml of commercially-available nutritional supplement.
334227|NCT00446888|Dietary Supplement|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
334228|NCT00446901|Dietary Supplement|Selenium|Selenized yeast, 300 ug/day
334229|NCT00003457|Drug|antineoplaston A10|
334230|NCT00446914|Behavioral|Systems Change (High Blood Pressure Strategy)|
334231|NCT00446940|Drug|rosuvastatin|
334232|NCT00446940|Drug|atorvastatin|
339001|NCT00543335|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
339002|NCT00543348|Procedure|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
339003|NCT00543348|Procedure|HIGH PRESSURE BALLOON|
339004|NCT00543361|Drug|MK0767|Duration of Treatment: 52 Weeks
339005|NCT00543361|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
339006|NCT00543361|Drug|Comparator: metformin|Duration of Treatment: 52 Weeks
339007|NCT00003937|Procedure|conventional surgery|
339008|NCT00543374|Drug|Placebo|Placebo
339009|NCT00543374|Drug|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
339010|NCT00543387|Drug|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
339011|NCT00543387|Drug|docetaxel|intravenous (I.V.) dose of docetaxel (60 mg/m^2)
339012|NCT00543400|Drug|M118|75 IU/KG of M118, 100 IU/kg of M118 and 70 U/kg of unfractionated heparin given IV (in the vein) prior to Percutaneous Coronary Intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
339013|NCT00543400|Drug|Unfractionated Heparin|Please see other invention description
339014|NCT00543413|Drug|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
339015|NCT00543413|Drug|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
339016|NCT00543413|Drug|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
339017|NCT00543426|Drug|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
339018|NCT00003938|Drug|liposomal amphotericin B|
339019|NCT00545727|Other|Standard diet|Standard diet meeting American Diabetes Association guidelines
339340|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
339341|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
338349|NCT00513266|Other|laboratory biomarker analysis|
338350|NCT00513266|Procedure|adjuvant therapy|
338351|NCT00513266|Procedure|biopsy|
338352|NCT00515671|Behavioral|Illness Management and Recovery|a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
338353|NCT00515671|Behavioral|Problem Solving|Weekly problem-solving support group
338354|NCT00515684|Drug|bevacizumab (Avastin)|
338355|NCT00515697|Biological|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
338356|NCT00515723|Drug|risperidone|randomized switch from current antipsychotic treatment to risperidone
338357|NCT00515723|Drug|olanzapine|randomized switch from current antipsychotic treatment to olanzapine
338681|NCT00003536|Procedure|cancer prevention intervention|
338682|NCT00461006|Drug|aleglitazar|0.6mg po daily
338683|NCT00461019|Procedure|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
338684|NCT00461032|Drug|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
338685|NCT00461032|Drug|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
338686|NCT00461045|Drug|NPI-0052|I.V. injection on Days 1, 4, 8 and 11 in 21 day cycles
338687|NCT00461058|Drug|aleglitazar|1
338688|NCT00461071|Behavioral|Guided Self-help for Bulimia nervosa|bibliotherapy
338689|NCT00461084|Drug|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
338690|NCT00461084|Drug|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
338691|NCT00461097|Drug|Egg oral immunotherapy|Egg white solid powder
338007|NCT00521118|Procedure|conventional surgery|
338008|NCT00521131|Drug|Levocetirizine dihydrochloride|
338009|NCT00521144|Drug|obatoclax mesylate|Given IV
338010|NCT00521144|Drug|topotecan hydrochloride|Given IV
338011|NCT00521144|Other|laboratory biomarker analysis|Correlative studies
338012|NCT00521157|Drug|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
338013|NCT00523809|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
338014|NCT00523809|Drug|Fludarabine|25 mg/m^2 IV Daily Over 30 Minutes for 5 Days
338015|NCT00523809|Drug|Melphalan|70 mg/m^2 IV Daily Over 30 Minutes for 2 Days
338016|NCT00523809|Drug|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
338017|NCT00523822|Other|Spinal Manipulative Therapy|
338018|NCT00523848|Drug|bortezomib|IV
338019|NCT00523848|Drug|pegylated liposomal doxorubicin hydrochloride|IV
338020|NCT00523848|Drug|thalidomide|Oral
338021|NCT00003834|Drug|fluorouracil|
338022|NCT00523861|Dietary Supplement|Moderate alcohol consumption|
338023|NCT00523887|Drug|Fentanyl transdermal therapeutic system|
338024|NCT00523900|Dietary Supplement|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
338025|NCT00523913|Drug|rosiglitazone|
338026|NCT00523926|Drug|TMC207|
338027|NCT00523939|Drug|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
338028|NCT00523952|Drug|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
338029|NCT00523965|Drug|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
337299|NCT00448253|Biological|NP-015|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.
And a Fourth Cohort at 840 units TNA with 2 additional product lots.
337300|NCT00448266|Drug|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
337301|NCT00448266|Drug|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
337302|NCT00448279|Drug|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
337303|NCT00448279|Drug|Chemotherapy|Schedule and dose at the investigator's discretion
337304|NCT00448292|Drug|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
337305|NCT00448292|Drug|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
337306|NCT00450814|Drug|Cyclophosphamide|Given IV
337673|NCT00529477|Other|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
337674|NCT00529477|Other|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
337675|NCT00529490|Drug|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
337676|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
337677|NCT00532129|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of cycle 1; 500mg/m2 on day 1 of cycles 2-6
337678|NCT00532142|Drug|Intravitreal Triamcinolone|
337679|NCT00532142|Procedure|Radial Optic Neurotomy|
337680|NCT00532142|Other|Placebo - Sham Intravitreal Injection|
337681|NCT00003875|Biological|aldesleukin|Given SC
337682|NCT00532155|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
337683|NCT00532155|Drug|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
337684|NCT00532155|Drug|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
336924|NCT00456898|Drug|Codeine|
336925|NCT00456911|Behavioral|Fat and carbohydrate controlled diet|
336926|NCT00456924|Drug|VA2914|
336927|NCT00456937|Drug|Escitalopram|
336928|NCT00456963|Behavioral|Diet|total fat < 5%, saturated fat < 10%, vegetables, fruit
336929|NCT00003517|Drug|antineoplaston A10|
336930|NCT00456963|Behavioral|Moderate exercise|30 min at least 5 times/week
336931|NCT00456963|Drug|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
336932|NCT00456963|Drug|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
336933|NCT00456963|Drug|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
336934|NCT00456976|Drug|Selegiline|
336935|NCT00456989|Drug|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
336936|NCT00456989|Drug|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
336937|NCT00457002|Drug|Apixaban|Apixaban: Twice daily, 30 days
Placebo: Once daily, 6-14 days
336938|NCT00457002|Drug|Enoxaparin|Enoxaparin: Once daily, 6-14 days
Placebo: Twice daily, 30 days
336939|NCT00457015|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
336940|NCT00003517|Drug|antineoplaston AS2-1|
337307|NCT00003486|Drug|antineoplaston A10|
337308|NCT00450814|Other|Laboratory Biomarker Analysis|Correlative studies
337309|NCT00450814|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
337310|NCT00450814|Other|Pharmacological Study|Correlative studies
337311|NCT00450827|Biological|bevacizumab|
336215|NCT00427336|Drug|Cyclophosphamide|300 mg/m^2 by vein daily over 2 hours
336216|NCT00427336|Drug|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
336217|NCT00427349|Drug|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
336218|NCT00427349|Drug|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
336219|NCT00427362|Drug|Adalimumab|
336570|NCT00418795|Drug|recombinant human porphobilinogen deaminase (Porphozym)|
336571|NCT00418821|Biological|Aldurazyme (laronidase)|dose of 0.58mg/kg body weight intravenously (IV) every week
336572|NCT00418834|Drug|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
336573|NCT00418834|Drug|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
336574|NCT00418834|Drug|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
336575|NCT00418847|Drug|miglustat|Target dose of 320 mg/m^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA > 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
336576|NCT00418860|Drug|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
336577|NCT00003340|Drug|cyclophosphamide|
336578|NCT00418873|Drug|Zotepine|Oral
336579|NCT00418873|Drug|Risperidone|Oral
336580|NCT00418886|Drug|Vandetanib|oral once daily tablet
336581|NCT00418886|Drug|Pemetrexed|intravenous infusion
336582|NCT00418899|Behavioral|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
336583|NCT00418925|Drug|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
336584|NCT00418938|Drug|Panitumumab|6mg/kg IV
336585|NCT00418938|Drug|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
341243|NCT00519831|Drug|vinflunine|Vinflunine 320 mg/m² every 21 days
341244|NCT00519844|Drug|somatropin|
341245|NCT00519857|Drug|Tibolone|1.25 mg p.o, once daily for 3 years
341246|NCT00519857|Drug|Placebo|Tablet p.o, once daily for 3 years
341247|NCT00519870|Drug|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
341248|NCT00519870|Drug|losartan|II: losartan
341249|NCT00519870|Drug|Nifedipine, losartan|I: nifedipine II: losartan
341250|NCT00519883|Other|Exercise|
341251|NCT00519883|Other|Supportive Care|
341252|NCT00519896|Drug|sunitinib malate|Given PO
341253|NCT00003815|Biological|bleomycin sulfate|
341254|NCT00519896|Other|laboratory biomarker analysis|Correlative studies
341255|NCT00519909|Other|Dairy calcium|Diets with different content of calcium and fat
341256|NCT00519922|Other|Kinesthesia, Balance, and Agility (KBA) Exercise|Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion & agility, dynamic proprioception,functional strength & endurance.
Kinesthesia & Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability & confidence in ADL activities.
Soft pads will be used to progress some of the kinesthesia & balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads.
341257|NCT00519922|Other|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal & external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
341584|NCT00511719|Drug|Actrapid|24IU
341585|NCT00511732|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
341586|NCT00511732|Drug|Technosphere Placebo|Technosphere Inhalation Powder
341587|NCT00003777|Drug|fluorouracil|
340558|NCT00535977|Dietary Supplement|Peas|400g frozen garden peas per week for 12 months
340559|NCT00536003|Drug|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
340560|NCT00536003|Drug|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
340561|NCT00536016|Drug|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
340917|NCT00528021|Drug|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
340918|NCT00528034|Procedure|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
340919|NCT00528047|Drug|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
340920|NCT00528060|Drug|Atazanavir|2pills/day
340921|NCT00528060|Drug|Ritonavir|1 pill/day
340922|NCT00528060|Drug|Tenofovir/emtricitabine|1 pill/day
340923|NCT00528073|Drug|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
340924|NCT00528099|Drug|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
340925|NCT00528112|Drug|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
340926|NCT00528112|Drug|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
340927|NCT00000157|Drug|Aspirin|
340928|NCT00000561|Device|pacemaker, artificial|
340929|NCT00003859|Drug|cyclophosphamide|
340930|NCT00528125|Procedure|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
340931|NCT00528125|Procedure|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
340932|NCT00528138|Other|Laboratory Test|CRP, white blood cell count, hepatic function tests
340229|NCT00541073|Other|pharmacological study|
340230|NCT00541086|Drug|anastrozole|1 mg per day, orally
340231|NCT00541086|Drug|exemestane|25 mg per day, orally
340232|NCT00541086|Drug|letrozole|2.5 mg per day, orally
340233|NCT00541086|Drug|tamoxifen citrate|20 mg per day, orally
340234|NCT00541099|Biological|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
340235|NCT00003941|Drug|etoposide|
340236|NCT00543777|Procedure|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
340237|NCT00543790|Drug|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
340238|NCT00543816|Drug|MK0767|
340239|NCT00543829|Drug|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
340240|NCT00543829|Drug|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
340241|NCT00543842|Drug|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
340242|NCT00543842|Drug|Capecitabine|Starting Dose 650 mg/m^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
340243|NCT00543842|Drug|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
340244|NCT00543842|Radiation|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
340562|NCT00536042|Drug|minocycline|add-on therapy: 150 mg bid to 250 mg bid for up to one year
340563|NCT00536068|Drug|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days
Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days
Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days
Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days
340564|NCT00536081|Drug|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
340565|NCT00536094|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
340566|NCT00003898|Dietary Supplement|glutamine|Oral
345167|NCT00502554|Procedure|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
345168|NCT00502567|Drug|AZD2171|oral tablet once daily
345169|NCT00003724|Procedure|surgical procedure|
345170|NCT00505063|Biological|Immunization Schedule patients > or = to 11 years of age|Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1
Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2
Time 2-3 months: Hib #2, Prevnar 13#2, Menactra
Time 3-6 months: IPV, Draw post vaccine titers
Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)
345171|NCT00505076|Drug|MK-0777|MK-0777 GEM, 8 mg BID
345172|NCT00505076|Drug|MK-0777|MK-0777 GEM, 3 mg BID
345173|NCT00505076|Drug|placebo|2 tablets placebo BID
345174|NCT00505089|Drug|ACZ885|
345526|NCT00497146|Drug|placebo|placebo capsule
345527|NCT00497159|Other|Placebo|Placebo TID x 90 days
345528|NCT00497159|Drug|Dimebon|Dimebon 20 mg TID x 90 days
345529|NCT00003686|Drug|Placebo|Placebo 5 mg po qid x 4 weeks
345530|NCT00497172|Device|CYPHER Sirolimus-eluting stent|drug-eluting stent
345531|NCT00497172|Device|Bx SONIC bare metal stent|bare-metal stent
345532|NCT00497185|Behavioral|Mindfulness-Based Cognitive Therapy for Functional Disorders|Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.
The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system.
345533|NCT00497198|Drug|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
345534|NCT00497198|Drug|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
345535|NCT00497211|Procedure|Intracoronary mononuclear cell infusion|
345536|NCT00497224|Drug|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
345537|NCT00497237|Drug|Beclomethasone plus formoterol fixed combination|100+6 pMDI
337501|NCT00422461|Drug|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
337502|NCT00422461|Drug|placebo|placebo, oral, tablets, once daily, for 28 days
337503|NCT00003360|Radiation|iodine I 131 monoclonal antibody A33|
337504|NCT00422487|Drug|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
337505|NCT00422487|Drug|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
337844|NCT00548106|Dietary Supplement|Nan HA|Total infant diet by study formula.
337845|NCT00548119|Biological|NeoCart|autologous tissue implant
337846|NCT00003958|Procedure|therapeutic conventional surgery|Undergo surgery
337847|NCT00548119|Procedure|microfracture|microfracture
337848|NCT00548132|Device|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
337849|NCT00548145|Drug|Pitavastatin|2 mg by orally/day Duration: 12 months
337850|NCT00550615|Drug|Dasatinib|Dasatinib will be orally administered once daily for 28 day cycles.
There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:
Dose cohort # 1 will be 100 mg per day
The MTD will be determined in the Phase I portion of this trial. An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
337851|NCT00550615|Drug|Dasatinib|Dose cohort # 2 will be 150 mg per day
337852|NCT00003974|Biological|lung tumor associated antigen|
337853|NCT00550615|Drug|Dasatinib|Dose cohort # 3 will be 200 mg per day
337854|NCT00550628|Genetic|DNA methylation analysis|
337855|NCT00550628|Genetic|fluorescence in situ hybridization|
337856|NCT00550628|Genetic|gene expression analysis|
337857|NCT00550628|Genetic|polymerase chain reaction|
337858|NCT00550628|Genetic|protein expression analysis|
337859|NCT00550628|Genetic|reverse transcriptase-polymerase chain reaction|
337127|NCT00430781|Drug|pazopanib (GW786034)|
337128|NCT00430781|Drug|lapatinib (GW572016)|
337129|NCT00430794|Drug|Spironolactone|
337130|NCT00430807|Drug|hydroxychloroquine/placebo|
337131|NCT00430820|Procedure|per intervention|per intervention
337132|NCT00430833|Drug|candesartan|
337133|NCT00003397|Drug|gemcitabine hydrochloride|
337134|NCT00430846|Drug|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
337135|NCT00430859|Drug|Alkaline Phosphatase|Intravenous over a period of 24 hours
337136|NCT00430859|Drug|Placebo|Saline over a period of 24h
337137|NCT00430872|Behavioral|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
337138|NCT00430885|Drug|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
337139|NCT00433550|Drug|irinotecan hydrochloride|given IV
337140|NCT00003402|Drug|cyclophosphamide|
337141|NCT00433550|Drug|oxaliplatin|given IV
337142|NCT00433563|Radiation|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
337143|NCT00433563|Radiation|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
337506|NCT00422487|Drug|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
337507|NCT00422487|Drug|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
337508|NCT00422487|Drug|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
337509|NCT00424931|Drug|JNJ-17216498|50mg one time
337510|NCT00424931|Drug|JNJ-17216498|10mg one time
337511|NCT00424931|Drug|Modafinil|200 mg X 2
337512|NCT00424944|Biological|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
336412|NCT00447902|Drug|ritonavir|
336413|NCT00447915|Drug|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
336414|NCT00447915|Drug|RIS placebo|0 mg(p.o.)/day for 36 months
336761|NCT00436592|Device|NeuroFlo™ Catheter|45 minute Treatment
336762|NCT00436605|Drug|dasatinib|
336763|NCT00003413|Drug|melphalan|
336764|NCT00436618|Drug|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
336765|NCT00003422|Procedure|conventional surgery|
336766|NCT00439296|Drug|ABT-751|Oral capsule to be given daily for 21 days.
336767|NCT00439296|Drug|dexamethasone|IV or Oral daily for 14 days
336768|NCT00439296|Drug|PEG-asparaginase|Intramuscular injection
336769|NCT00439296|Drug|doxorubicin|IV infusion
336770|NCT00439296|Drug|cytarabine|Intrathecal dose on day 1
336771|NCT00439296|Drug|methotrexate|Intrathecal dose
336772|NCT00439296|Drug|cyclophosphamide|Intravenous dose
336773|NCT00439296|Drug|6-thioguanine|Oral dose, course #2
336774|NCT00439309|Device|Gelfoam/Thrombin|Gelfoam/Thrombin
336775|NCT00439309|Device|VascuSeal|VascuSeal
336776|NCT00003422|Procedure|neoadjuvant therapy|
336777|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
336778|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
336779|NCT00439335|Drug|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
336780|NCT00439335|Drug|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
336036|NCT00456378|Device|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
336037|NCT00456378|Procedure|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
336038|NCT00456391|Procedure|Medical history|
336039|NCT00456391|Procedure|Brain CT scan|
336040|NCT00456404|Drug|peppermint water|
336041|NCT00456417|Procedure|123-I MNI-187 Injection and Imaging Procedures|
336042|NCT00456430|Drug|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
336043|NCT00456443|Procedure|Historical records|
336044|NCT00000526|Drug|flecainide|
336045|NCT00003514|Procedure|differentiation therapy|
336046|NCT00456482|Drug|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
336047|NCT00456482|Drug|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
336048|NCT00456495|Drug|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
336049|NCT00456508|Drug|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
336050|NCT00456521|Drug|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
336051|NCT00456521|Drug|Placebo|
336415|NCT00447915|Drug|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
336416|NCT00447915|Drug|ibandronic acid placebo|0mg(i.v.)/month for 35 months
336417|NCT00447915|Drug|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
336418|NCT00447915|Dietary Supplement|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
336419|NCT00447928|Drug|OrthoDerm transdermal nitroglycerin patch|
336420|NCT00447941|Drug|SCA-136|
336421|NCT00447954|Drug|NT-501 implant|High Dose
335301|NCT00424099|Behavioral|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
335302|NCT00424099|Drug|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
335303|NCT00424125|Behavioral|Enhanced Pharmacy Care|Participants randomized to "Enhanced Pharmacy Care" will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.
Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to "enhanced care" will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers.
335304|NCT00424125|Behavioral|Control|Usual care.
335305|NCT00424138|Drug|chemotherapy|
335306|NCT00003375|Drug|vincristine sulfate|
335307|NCT00424138|Radiation|fludeoxyglucose F 18|
335308|NCT00424151|Drug|Rituximab|
335309|NCT00424164|Drug|lapatinib ditosylate|
335310|NCT00424164|Drug|tamoxifen citrate|
335311|NCT00424164|Other|pharmacological study|
335312|NCT00424177|Drug|eltrombopag|experimental
335313|NCT00426881|Behavioral|Exercise training|Twice weekly resistance training for 52 weeks.
335314|NCT00426894|Procedure|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
335315|NCT00426907|Procedure|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
335316|NCT00426920|Drug|Insulin|
335317|NCT00426933|Drug|Daptomycin|
335318|NCT00426933|Drug|Vancomycin|
335319|NCT00426946|Drug|Reboxetine|
335320|NCT00426959|Device|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
335321|NCT00003387|Drug|carboplatin|
335322|NCT00426972|Drug|estradiol (Zesteem)|
334233|NCT00446953|Drug|betamethasone|2x12 mg betamethazone c-section at 38 weeks
334234|NCT00446953|Other|placebo|c-section at 39 weeks
334235|NCT00446966|Drug|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams oraly daily after until primary endpoint or 14 days.
334236|NCT00446979|Drug|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
334237|NCT00446979|Drug|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
334238|NCT00449839|Drug|Insulin Aspart|A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.
C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted.
334239|NCT00449852|Behavioral|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
334240|NCT00449865|Drug|creatine|Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.
The study is comparing creatine 5 grams twice daily with placebo.
334241|NCT00449865|Other|placebo|an inactive substance
334242|NCT00449878|Drug|Liprotamase|Administered orally
334590|NCT00440973|Drug|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T & B lymphocyte proliferation
334591|NCT00440986|Procedure|Eritrocytoapheresis|
334592|NCT00440999|Drug|Pyronaridine artesunate|
334593|NCT00440999|Drug|Chloroquine|
334594|NCT00003429|Procedure|positron emission tomography|
334595|NCT00441012|Biological|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 & 12 months of age. Duration of treatment is 11 months.
334596|NCT00441012|Biological|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
334597|NCT00441025|Drug|Alemtuzumab|
334598|NCT00441038|Behavioral|The Back Guide|Education on postural hygiene and handout of The Back Guide
334599|NCT00441038|Behavioral|The Back Book|Education on active management and Handout of The Back Book
339342|NCT00003895|Other|laboratory biomarker analysis|Correlative studies
339343|NCT00537966|Drug|ritonavir|used only as booster for the protease inhibitors that are prescribed in this study according to standard boosting
339344|NCT00537966|Drug|nevirapine|standard dosage
339345|NCT00537966|Drug|zidovudine|standard dosage
339346|NCT00537966|Drug|lamivudine|standard dosage
339347|NCT00003911|Radiation|stereotactic radiosurgery|
339348|NCT00537966|Drug|tenofovir|standard dosage
339349|NCT00537966|Drug|emtricitabine|standard dosage
339350|NCT00537966|Drug|abacavir|standard dosage
339351|NCT00537979|Drug|Paricalcitol injection|Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
339352|NCT00537979|Drug|Paricalcitol capsules|Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
339353|NCT00537992|Procedure|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
339354|NCT00538005|Biological|bevacizumab|
339355|NCT00538005|Drug|oxaliplatin|
339356|NCT00538005|Drug|sorafenib tosylate|
339357|NCT00538018|Drug|Telithromycin|
339358|NCT00003912|Drug|carboplatin|
339359|NCT00538031|Drug|cyclophosphamide|Given orally
339360|NCT00538031|Drug|celecoxib|Given orally
339361|NCT00538044|Drug|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
339362|NCT00538057|Drug|GW685698X & GW642444M|
339363|NCT00538070|Dietary Supplement|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
338692|NCT00003536|Procedure|chemotherapy|
338693|NCT00461097|Drug|Control Group|Placebo for egg white solid
338694|NCT00461110|Drug|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
338695|NCT00461123|Drug|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
338696|NCT00461123|Drug|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
338697|NCT00461136|Drug|Aliskiren|
338698|NCT00461149|Drug|Octreotide-LAR|
338699|NCT00461162|Behavioral|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
338700|NCT00510250|Procedure|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
339020|NCT00545740|Drug|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
339021|NCT00545740|Drug|SPD476 (2.4 g)|2.4g SPD476 QD orally
339022|NCT00545740|Drug|SPD476 (4.8 g)|4.8g SPD476 QD orally
339023|NCT00003953|Radiation|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
339024|NCT00545740|Drug|Placebo|QD orally
339025|NCT00545753|Drug|Spinosad|10 minute topical application product, following by a complete rinse off.
339026|NCT00545753|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
339027|NCT00545753|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
339028|NCT00545766|Drug|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
339029|NCT00545779|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
338358|NCT00515723|Drug|quetiapine|randomized switch from current antipsychotic treatment to quetiapine
338359|NCT00003792|Biological|recombinant MAGE-3.1 antigen|
338360|NCT00515723|Drug|ziprasidone|randomized switch from current antipsychotic treatment to ziprasidone
338361|NCT00515736|Drug|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
338362|NCT00515736|Drug|Placebo|vehicle
338363|NCT00515762|Device|elasto-gel cap|scalp cooling cap
338364|NCT00515788|Drug|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
338365|NCT00515788|Drug|Temozolomide|100 mg/m^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
338366|NCT00515801|Drug|glibenclamide|glibenclamide 15 mg single dose
338367|NCT00515801|Drug|placebo|placebo capsules, single dose
338368|NCT00515814|Device|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation & mobility.
338369|NCT00515827|Drug|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
338370|NCT00003792|Biological|tyrosinase peptide|
338371|NCT00515827|Drug|Placebo|400 mg placebo tablet taken orally twice daily
338372|NCT00515840|Other|Physiotherapist|Physiotherapist administered breathing retraining programme
338373|NCT00515853|Behavioral|Biofeedback|Biofeedback sessions or biofeedback exercises
338374|NCT00515866|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
338375|NCT00515866|Drug|Gemcitabine|intravenous injection
338376|NCT00515879|Drug|D-cycloserine|50 mg
338377|NCT00515879|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
338378|NCT00515879|Drug|Placebo|Same dosage as active pill
338379|NCT00515892|Drug|Immunotoxin therapy|
337685|NCT00532155|Drug|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
337686|NCT00532168|Drug|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
337687|NCT00532168|Drug|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
337688|NCT00532168|Drug|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
337689|NCT00532181|Behavioral|Savings Behavior and Consumer's Approach to Risk|
337690|NCT00532194|Drug|cediranib|Once-daily oral tablet starting dose 20mg
337691|NCT00532207|Drug|teriparatide|subcutaneous 20 micrograms
337692|NCT00003875|Procedure|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
337693|NCT00532220|Drug|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
337694|NCT00532220|Drug|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
338030|NCT00523965|Drug|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or > 25 kg Miltefosine 50 mg once daily if patient weighs <25 mg
338031|NCT00523965|Drug|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
338032|NCT00003834|Drug|leucovorin calcium|
338033|NCT00523965|Drug|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
338034|NCT00523978|Device|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
338035|NCT00523978|Drug|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
338036|NCT00523991|Drug|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
338037|NCT00523991|Drug|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
338038|NCT00524004|Other|Anti Cs17 Bovine Milk Immunoglobulin|Three times a day for seven days
337312|NCT00450827|Biological|filgrastim|
337313|NCT00450827|Procedure|autologous hematopoietic stem cell transplantation|
337314|NCT00450827|Radiation|iodine I 131 monoclonal antibody 3F8|
337315|NCT00450840|Drug|Simvastatin|
337316|NCT00450853|Drug|granisetron|Granisetron SC followed by granisetron IV
337317|NCT00450866|Biological|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
337318|NCT00003486|Drug|antineoplaston AS2-1|
337319|NCT00450879|Drug|Pazopanib Hydrochloride|Given PO
337320|NCT00450879|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
337321|NCT00450879|Other|Pharmacological Study|Correlative studies
337322|NCT00450879|Other|Laboratory Biomarker Analysis|Correlative studies
337323|NCT00450892|Drug|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
337324|NCT00450892|Drug|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
337325|NCT00450892|Drug|docetaxel + trastuzumab + lapatinib|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule
+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100
337326|NCT00450905|Device|PRIMA Device|
337327|NCT00450931|Other|counseling intervention|
337328|NCT00450931|Other|educational intervention|
337329|NCT00000150|Procedure|Subfoveal Choroidal Neovascularization Removal|
337330|NCT00000524|Drug|prednisone|
337331|NCT00003486|Procedure|alternative product therapy|
337332|NCT00450944|Biological|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
337695|NCT00532233|Drug|QAX576|
337696|NCT00532246|Drug|raloxifene|
336586|NCT00418938|Drug|Leucovorin|400mg/m^2 IV (in the vein)
336587|NCT00418938|Drug|Irinotecan|180mg/m^2 IV (in the vein)
336588|NCT00003340|Drug|topotecan hydrochloride|
336589|NCT00418938|Drug|5-Fluorouracil|400mg/m^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m^2 thereafter if no significant side effects
336590|NCT00418951|Drug|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
336591|NCT00418951|Drug|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
336592|NCT00418951|Drug|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
336593|NCT00418964|Procedure|Single bundle hamstring|Single bundle hamstring
336941|NCT00457015|Drug|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
336942|NCT00457054|Drug|Lithium|starting dose 600 mg increase as tolerated
336943|NCT00457067|Drug|Ranibizumab|
336944|NCT00457080|Device|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
336945|NCT00457093|Drug|glargine|
336946|NCT00457093|Drug|detemir|
336947|NCT00457106|Drug|Paroxetine|
336948|NCT00457106|Drug|Risperidone|
336949|NCT00457119|Drug|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
336950|NCT00457132|Device|APOS biomechanical gait system|
336951|NCT00003517|Drug|bicalutamide|
336952|NCT00457145|Drug|Ranibizumab|
336953|NCT00457158|Device|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
336954|NCT00460187|Device|Percutaneous intervention of the carotid artery|
336955|NCT00460200|Genetic|polymorphism analysis|
341588|NCT00511745|Drug|Rabeprazol|As prescribed
341589|NCT00511758|Procedure|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
341590|NCT00511771|Drug|Tegaserod|Tegaserod maleate
341591|NCT00511797|Drug|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
341592|NCT00514241|Device|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
341593|NCT00514254|Other|questionnaire administration|
341594|NCT00514254|Other|study of socioeconomic and demographic variables|
341595|NCT00003787|Behavioral|therapeutic dietary intervention|
341596|NCT00514254|Procedure|evaluation of cancer risk factors|
341597|NCT00514267|Drug|YM 155|IV
341598|NCT00514267|Drug|Docetaxel|IV
341599|NCT00514267|Drug|Prednisone|Oral
341600|NCT00514293|Drug|bexarotene|
341601|NCT00514293|Drug|capecitabine|
341602|NCT00514293|Drug|carboplatin|
341603|NCT00514293|Drug|cisplatin|
341604|NCT00514293|Drug|docetaxel|
341605|NCT00514293|Drug|tretinoin|
341606|NCT00003788|Drug|carmustine|
341607|NCT00514306|Drug|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
341608|NCT00514332|Procedure|stent|stent placement for colorectal cancer obstruction
341609|NCT00514345|Genetic|gene expression analysis|
341946|NCT00549848|Drug|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
340933|NCT00528151|Drug|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
340934|NCT00528164|Behavioral|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
340935|NCT00528177|Drug|Morphine and oxycodone|At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.
The patients will use the PCA until the next morning.
340936|NCT00528190|Drug|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
341258|NCT00519935|Behavioral|Multisystemic Therapy (MST)|MST is a family and community-based treatment model that draws upon social-ecological and family systems theories of behavior. Extra-familial systems, such as the health care system, school, work, peers, and even community and cultural institutions are seen as interconnected with the individual and his or her family. Problem behavior such as severe adherence problems may be a function of difficulty within or between any of these systems (e.g., family-health provider relations, family-school relations, child-peer relations).
MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
341259|NCT00519948|Drug|new MPS, opti-free express no rub MPS|
341260|NCT00519961|Device|Elecsys®proBNP|
341261|NCT00519974|Other|counseling intervention|
341262|NCT00522392|Drug|dexamethasone|Given PO
341263|NCT00522405|Procedure|TACE|Under local anesthesia, the Femoral artery would be punctured
A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency
Superselective catheterization of the hepatic artery feeding the tumor would be done
By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.
Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.
The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.
Gelfoam particles would be injected following this for embolization
341264|NCT00003824|Drug|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
341265|NCT00522418|Device|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
341266|NCT00522418|Drug|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
341267|NCT00522431|Drug|Testosterone|2% gel
341268|NCT00522444|Drug|Nebulized Magnesium Sulfate|
340567|NCT00536094|Behavioral|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
340568|NCT00536107|Drug|Gefitinib|250 mg oral
340569|NCT00536107|Procedure|CT or MRI|performed at screening and every 6 weeks
340570|NCT00536107|Drug|Docetaxel|60mg/m2 intravenous infusion
340571|NCT00536120|Biological|BG00002 (natalizumab)|
340572|NCT00536120|Biological|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
340573|NCT00536120|Biological|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
340574|NCT00536133|Drug|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
340575|NCT00536133|Other|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
340576|NCT00536159|Other|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
340577|NCT00003899|Biological|filgrastim|
340578|NCT00538395|Drug|Adriamycin, Taxol and Cytoxan|Chemotherapy
340579|NCT00538408|Procedure|Whole body magnetic resonance angiography (dotarem)|
340580|NCT00538408|Device|Whole body magnetic resonance angiography (vasovist)|
340581|NCT00538421|Drug|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
340582|NCT00538421|Drug|Sevoflurane|0,7-1,5 MAC
340583|NCT00538434|Biological|Reslizumab|IV (in the vein) on Day 0 of each 28 days cycle (+/-7 days) Number of Cycles=4
340937|NCT00528216|Drug|Capsaicin Dermal Liquid|
340938|NCT00528229|Radiation|Computer Tomography|
340939|NCT00528242|Drug|SLx-2101|
340940|NCT00003859|Drug|etoposide|
345538|NCT00497237|Drug|Fluticasone plus salmeterol fixed combination|diskus 250/50
345539|NCT00497250|Drug|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
345540|NCT00003687|Drug|dextromethorphan hydrobromide|
345541|NCT00497250|Device|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
345542|NCT00497263|Device|Niti CAR|
345543|NCT00497276|Procedure|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
345544|NCT00497289|Drug|Lipofundin MCT/LCT 20 %|daily i.v. infusion for up to 5 days
345545|NCT00497289|Drug|Lipidem 20%|daily i.v. infusion for up to 5 days
345546|NCT00497302|Behavioral|RBT|Contingency management and behavioral counseling including motivational interviewing
345547|NCT00497302|Behavioral|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
340245|NCT00543842|Procedure|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
340246|NCT00003941|Drug|ifosfamide|
340247|NCT00543855|Drug|3 mg Donepezil hydrochloride|Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.
340248|NCT00543855|Drug|5 mg Donepezil hydrochloride|Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).
Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks).
340249|NCT00543855|Drug|10 mg Donepezil hydrochloride|Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).
Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).
Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks).
340250|NCT00543855|Drug|Placebo|Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.
340251|NCT00543868|Drug|MK0782|
337860|NCT00550628|Other|diagnostic laboratory biomarker analysis|
337861|NCT00550628|Other|immunoenzyme technique|
337862|NCT00550628|Other|immunohistochemistry staining method|
337863|NCT00003974|Drug|DetoxPC|
337864|NCT00550628|Procedure|biopsy|
337865|NCT00550628|Procedure|therapeutic conventional surgery|
337866|NCT00550628|Radiation|fludeoxyglucose F 18|
337867|NCT00550641|Other|physical therapy|physical therapy in warm pool performing stretching
338203|NCT00542893|Drug|Genasense® (G3139, oblimersen sodium)|
338204|NCT00542893|Drug|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
338205|NCT00542893|Drug|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
338206|NCT00542906|Other|localization|localization of the several types of somatosensory stimuli
338207|NCT00003937|Drug|dexrazoxane hydrochloride|
338208|NCT00542919|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
338209|NCT00542932|Other|Exercise|Watched Film A (promotional film)
Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home
338210|NCT00542945|Device|ICD|Implantation of an ICD
338211|NCT00542945|Other|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
338212|NCT00542958|Drug|NK012|Dose escalation starting at 9 mg/m2 in UGT1A1*28 (wt/wt and wt/*28) genotype patients, IV (in the vein) over 30 minutes on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity or disease progression develops: patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient, as long as toxicity remains acceptable.
338213|NCT00542971|Drug|Idarubicin|12 mg/m2 IV over 1 hour daily (days 1-3)
338214|NCT00542971|Drug|Sorafenib|Starting dose 400 mg by mouth for 7 days
338215|NCT00542971|Drug|Ara-C|1.5 g/m2 IV over 24 hours daily (days 1-4)
338216|NCT00542984|Drug|teriparatide 20 micrograms/day subcutaneous|
337513|NCT00003377|Radiation|radiation therapy|
337514|NCT00424944|Biological|GMZ2 malaria vaccine|100 micrograms of GMZ2
337515|NCT00424944|Biological|Verorab vaccine|Anti-rabies vaccine
337516|NCT00424970|Drug|acetazolamide|
337517|NCT00424983|Drug|Zoledronic acid|
337518|NCT00425009|Drug|Berberine|
337519|NCT00425009|Drug|Metformin|
337520|NCT00425022|Procedure|thoracoscopy|
337521|NCT00425035|Drug|Panitumumab (ABX-EGF)|
337522|NCT00425048|Procedure|wearing gloves|
337523|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
337524|NCT00003378|Drug|carboplatin|
337525|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
337526|NCT00425061|Other|placebo|placebo
337527|NCT00425074|Drug|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
337528|NCT00425074|Drug|ASA|normal release acetylsalicylic acid
337529|NCT00425074|Drug|SR-ASA|slow release acetylsalicylic acid 150 mg
337530|NCT00425100|Drug|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
337531|NCT00425113|Drug|Metronidazole|
337532|NCT00425113|Procedure|Blood Draw|
337868|NCT00550641|Other|physical therapy|physical therapy in warm pool performing Ai Chi
337869|NCT00550654|Other|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
337870|NCT00550654|Radiation|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
336781|NCT00439348|Behavioral|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
336782|NCT00439348|Behavioral|Prescription|Patients receive a prescription for a specific over-the-counter medication.
336783|NCT00439361|Drug|Bortezomib|1.0 mg/m^2 by Vein Over 5 Seconds on Days 1 and 4
336784|NCT00439361|Drug|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
336785|NCT00439361|Drug|Etoposide|100 mg/m^2 By Vein Over 2 Hours On Days 1-3
337144|NCT00433576|Drug|resveratrol|Given orally
337145|NCT00433576|Other|pharmacological study|Correlative studies
337146|NCT00433576|Other|laboratory biomarker analysis|Correlative studies
337147|NCT00433589|Drug|anthracycline-based|
337148|NCT00433589|Drug|docetaxel and capecitabine|
337149|NCT00433602|Other|clinical observation|
337150|NCT00433602|Procedure|management of therapy complications|
337151|NCT00003402|Drug|dexamethasone|
337152|NCT00433602|Procedure|ultrasound imaging|
337153|NCT00433615|Drug|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
337154|NCT00433615|Drug|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
337155|NCT00433641|Drug|sibutramine|placebo
337156|NCT00433641|Drug|sibutramine|oral 15 mg sibutramine once per day
337157|NCT00433641|Drug|sibutramine|oral sibutramine 10 mg once per day
337158|NCT00433654|Device|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
337159|NCT00433654|Other|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
337160|NCT00433667|Drug|RWJ-333369|
337161|NCT00433680|Behavioral|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
336422|NCT00003463|Drug|irinotecan hydrochloride|
336423|NCT00447954|Drug|NT-501 implant|Low Dose
336424|NCT00447954|Other|Sham Procedure|Sham Procedure
336425|NCT00447967|Drug|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
336426|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
336427|NCT00447967|Drug|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
336428|NCT00447967|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
336429|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
336430|NCT00447980|Drug|NT-501|High Dose
336431|NCT00447980|Drug|NT-501|Low Dose
336432|NCT00447993|Drug|NT-501|High Dose
336433|NCT00003463|Drug|polifeprosan 20 with carmustine implant|
336434|NCT00447993|Drug|NT-501|Low Dose
336435|NCT00448006|Device|Allium Biliary Stent|
336436|NCT00450580|Drug|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
336437|NCT00450593|Genetic|gene expression analysis|
336438|NCT00003484|Drug|irinotecan hydrochloride|
336439|NCT00450593|Genetic|microarray analysis|
336440|NCT00450593|Genetic|molecular genetic technique|
336786|NCT00439361|Drug|Ifosfamide|5 Gm/m^2 By Vein Continuous Infusion Over 24 Hours On Day 1
336787|NCT00003422|Radiation|radiation therapy|
336788|NCT00439361|Drug|Mesna|5 mg/m^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
335323|NCT00426985|Drug|Ketoprofen Topical Patch 20%|
335324|NCT00426998|Drug|Verteporfin|
335325|NCT00426998|Drug|Bevacizumab|
335678|NCT00418418|Biological|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
335679|NCT00418431|Drug|Intravitreal injection of Bevacizumab|
335680|NCT00418444|Behavioral|Group Therapy Intervention|
335681|NCT00418457|Drug|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
335682|NCT00418457|Drug|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
335683|NCT00418470|Procedure|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
335684|NCT00418470|Procedure|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
335685|NCT00418483|Biological|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
335686|NCT00418483|Biological|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
335687|NCT00418483|Biological|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
335688|NCT00003338|Radiation|technetium Tc 99m epratuzumab|
335689|NCT00418483|Biological|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
335690|NCT00418483|Biological|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
335691|NCT00418483|Biological|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
335692|NCT00418483|Biological|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
335693|NCT00418496|Drug|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
335694|NCT00418496|Drug|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
334600|NCT00441038|Behavioral|Cardiovascular and general health|Education on cardiovascular and general health
334601|NCT00441051|Drug|Diclofenac sodium 1mg/g|
334602|NCT00441064|Drug|Aliskiren|
334603|NCT00441077|Behavioral|Education|
334604|NCT00441090|Drug|Placebo|Placebo Tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
334605|NCT00000521|Behavioral|diet, sodium-restricted|
334606|NCT00003429|Radiation|fludeoxyglucose F 18|
334607|NCT00441090|Drug|AKR-501 Tablets|AKR-501 Tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
334608|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
334609|NCT00441103|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
334610|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
334611|NCT00441116|Drug|Dutasteride 0.5mg oral tablets|Dutasteride
334612|NCT00441129|Device|Minimed paradigm Real Time Sytem|
334613|NCT00441142|Drug|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
334958|NCT00433004|Drug|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
334959|NCT00433017|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of the infusion.
334960|NCT00433017|Drug|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
334961|NCT00433017|Drug|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
334962|NCT00433043|Drug|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
334963|NCT00003401|Drug|cisplatin|
339711|NCT00530257|Drug|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
339712|NCT00530270|Drug|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
339713|NCT00530270|Drug|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
339714|NCT00530283|Other|PET-CT|
339715|NCT00000564|Procedure|oxygen inhalation therapy|
339716|NCT00003868|Procedure|allogeneic bone marrow transplantation|
339717|NCT00532961|Drug|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
339718|NCT00532974|Biological|EP1090|Low dose
339719|NCT00532974|Biological|EP1090|High dose
339720|NCT00003877|Procedure|in vitro-treated peripheral blood stem cell transplantation|
339721|NCT00532987|Behavioral|Questionnaire|Questionnaire form to be completed by patient
339722|NCT00533000|Procedure|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
339723|NCT00533013|Other|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
339724|NCT00533013|Other|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
339725|NCT00533026|Drug|Duloxetine|
339726|NCT00533026|Drug|Warfarin|
339727|NCT00533039|Drug|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
339728|NCT00533039|Drug|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
339729|NCT00533052|Behavioral|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
339030|NCT00545792|Drug|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
339031|NCT00545805|Procedure|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
339032|NCT00545805|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
339033|NCT00545818|Device|OsseoSpeed™|OsseoSpeed™ implant, length: 6 mm
339034|NCT00003954|Drug|melphalan|Given IV
339035|NCT00545818|Device|OsseoSpeed™|OsseoSpeed™ implant, length: 11 mm
339036|NCT00545831|Device|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
339037|NCT00545831|Device|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
339038|NCT00545844|Drug|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
339039|NCT00545857|Drug|pioglitazone|Pioglitazone daily; dose varies with size
339040|NCT00545857|Drug|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
339041|NCT00545870|Drug|bevacizumab|intravitreal application
339042|NCT00545870|Drug|Ranibizumab|intravitreal application
339364|NCT00538083|Other|Chocolate|74 grams of single dose solid dark chocolate versus placebo
339365|NCT00538083|Other|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
339366|NCT00538083|Other|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, & placebo given for six weeks
339367|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
339368|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
339369|NCT00003912|Drug|cisplatin|
339370|NCT00540670|Drug|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
339371|NCT00540670|Drug|Placebo|Placebo (tablet) taken orally, once a day.
338380|NCT00515892|Drug|CAT-8015 Immunotoxin|
338381|NCT00518531|Drug|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
338701|NCT00510263|Drug|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
338702|NCT00510263|Drug|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
338703|NCT00510263|Drug|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
338704|NCT00510263|Drug|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
338705|NCT00510276|Drug|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
338706|NCT00510276|Drug|Placebo|twice a day, by mouth for 12 weeks
338707|NCT00510289|Drug|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
338708|NCT00510302|Behavioral|Questionnaire|Questionnaire regarding melanoma risk-reduction.
338709|NCT00003769|Drug|perillyl alcohol|
338710|NCT00510302|Behavioral|Interview|Interview via telephone about topics related to melanoma risk-reduction.
338711|NCT00510315|Other|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
338712|NCT00510328|Device|Whole Body Vibration|
338713|NCT00510341|Behavioral|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
338714|NCT00510354|Drug|Imatinib mesylate|
338715|NCT00510367|Drug|5-Fluorouracil|500 mg/m^2 By Vein Daily x 2 Days
338716|NCT00510367|Drug|Cyclophosphamide|500 mg/m^2 By Vein On Day 1
338717|NCT00510367|Drug|Doxorubicin|50 mg/m^2 By Vein Over 72 Hours
338039|NCT00524004|Other|Anti CsbD Bovine Milk Immunoglobulin|Three times a day for seven days
338040|NCT00524004|Other|Lacto-free milk supplement|three times a day for seven days
338041|NCT00526773|Other|telephone management with standard patient education|heart failure intervention
338042|NCT00526786|Device|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
338043|NCT00526799|Drug|Sorafenib|Phase I: Dose Escalation, Phase II: MTD
Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid
338044|NCT00526799|Drug|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
338045|NCT00526812|Drug|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
338046|NCT00526812|Drug|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
338047|NCT00526838|Drug|XL228|1-hour IV infusion
338048|NCT00003852|Procedure|bone marrow ablation with stem cell support|
338049|NCT00526851|Other|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
338382|NCT00518531|Drug|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
338383|NCT00518544|Drug|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
338384|NCT00518557|Procedure|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
338385|NCT00518570|Drug|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
338386|NCT00518583|Drug|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
338387|NCT00518596|Dietary Supplement|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
337697|NCT00532246|Drug|Placebo|
337698|NCT00532259|Drug|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
337699|NCT00532272|Drug|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
337700|NCT00532285|Drug|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
337701|NCT00534846|Drug|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
337702|NCT00534846|Drug|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
337703|NCT00534859|Device|High Risk PCI|High Risk Percutaneous Coronary Intervention
337704|NCT00534872|Drug|SB-649868|10 mg
337705|NCT00534885|Biological|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
337706|NCT00534885|Biological|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
337707|NCT00534885|Biological|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
337708|NCT00534885|Biological|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
337709|NCT00534898|Drug|Bexarotene|
337710|NCT00003893|Drug|epirubicin hydrochloride|
337711|NCT00534898|Drug|Fenretinide|
337712|NCT00534898|Drug|Placebo|
337713|NCT00534911|Behavioral|Cognitive Behavioral Therapy|Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
Other Name: Primary and secondary coping enhancement training (PASCET)
338050|NCT00526877|Drug|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
336956|NCT00460200|Other|laboratory biomarker analysis|
336957|NCT00460200|Other|physiologic testing|
336958|NCT00460200|Other|questionnaire administration|
336959|NCT00460200|Procedure|conventional surgery|
336960|NCT00003533|Drug|antineoplaston AS2-1|
336961|NCT00460200|Procedure|fatigue assessment and management|
336962|NCT00460200|Procedure|psychosocial assessment and care|
336963|NCT00460213|Drug|Valsartan 80mg daily|
336964|NCT00460213|Drug|Valsartan 160mg daily|
336965|NCT00460226|Drug|lamotrigine|lamotrigine treatment for 12weeks
336966|NCT00460239|Drug|Buprenorphine|IM, doses are blind; administered up to 1-2 times per week.
336967|NCT00460239|Drug|Morphine|IM; up to 1-2 times per week; doses double blind
342628|NCT00539227|Behavioral|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
342629|NCT00539240|Drug|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
342630|NCT00539240|Drug|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast & Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
342631|NCT00539240|Drug|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
342632|NCT00539253|Drug|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
342633|NCT00539266|Biological|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
342634|NCT00539266|Biological|placebo|40 IM injections (calf muscle) of placebo suspension
342635|NCT00539279|Behavioral|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
342636|NCT00539279|Behavioral|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
341947|NCT00549861|Procedure|Cardiac Magnetic Resonance study|Cardiac MRI study
341948|NCT00549874|Drug|Rosiglitazone|oral 8 mg/once daily for 6 months
341949|NCT00549874|Drug|Glyburide|20 mg/ once daily for 6 months
341950|NCT00549887|Drug|Analog or Human Insulin|prescribed in accordance with usual clinical practice
341951|NCT00549900|Biological|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
341952|NCT00549913|Genetic|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
341953|NCT00003972|Biological|filgrastim|
341954|NCT00549913|Procedure|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
341955|NCT00549926|Drug|Fluvastatin|
341956|NCT00509002|Drug|ZD1839 (Iressa)|250 mg by mouth once a day, every day, at about same time in morning.
341957|NCT00509015|Drug|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S&25mg P/20 kg, 1 day, single dose
341958|NCT00509015|Drug|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
341959|NCT00509015|Drug|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
341960|NCT00509015|Drug|placebo tablets|3 days of lactose tablets (160mg) albochin
341961|NCT00509028|Drug|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
341962|NCT00509028|Drug|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
341963|NCT00509041|Drug|dasatinib|50 mg PO bid
341964|NCT00003758|Procedure|allogeneic bone marrow transplantation|
341965|NCT00509054|Procedure|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
341966|NCT00509067|Drug|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
341269|NCT00522457|Drug|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
341270|NCT00522470|Drug|rosiglitazone|
341271|NCT00522509|Drug|Floxuridine FUDR|
341272|NCT00522535|Procedure|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
341273|NCT00522535|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
341274|NCT00522548|Drug|Myfortic (enteric coated mycophenolate sodium)|Patients in this group will receive Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, in combination with Myfortic (enteric-coated mycophenolate sodium, Prograf (tacrolimus) or its generic equivalent and corticosteroid immunosuppression.
341275|NCT00003825|Drug|pentosan polysulfate sodium|
341610|NCT00514345|Genetic|polymorphism analysis|
341611|NCT00514345|Procedure|management of therapy complications|
341612|NCT00514371|Drug|tanespimycin|High dose
341613|NCT00514371|Drug|Bortezomib|Mid dose, and low dose
341614|NCT00514397|Drug|motexafin gadolinium|
341615|NCT00514397|Drug|temozolomide|
341616|NCT00514397|Procedure|adjuvant therapy|
341617|NCT00003788|Drug|lomustine|
341618|NCT00514397|Procedure|quality-of-life assessment|
341619|NCT00514397|Radiation|radiation therapy|
341620|NCT00514410|Drug|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
341621|NCT00514410|Drug|Placebo|Matching placebo taken once a day for three months
341622|NCT00514423|Other|Psychoeducation by professonals|
341623|NCT00514423|Other|Psychoeducation by peer-moderators|
340941|NCT00530725|Procedure|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
340942|NCT00530725|Other|close clinical observation|careful clinical follow-up in an operating room or intensive care unit without active intervention
340943|NCT00530738|Drug|Lipoplus|i.v. fat emulsion for parenteral nutrition
340944|NCT00530738|Drug|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
340945|NCT00530751|Other|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool [GREAT]) are explored.
340946|NCT00003869|Other|placebo|Given PO
340947|NCT00530764|Drug|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
340948|NCT00530764|Drug|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
340949|NCT00530764|Drug|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
340950|NCT00530777|Drug|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
340951|NCT00530777|Drug|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
340952|NCT00530790|Drug|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
340953|NCT00530803|Drug|EMLA Cream|60 minutes x1
340954|NCT00530803|Drug|Synera Patch|20 minutes x1
340955|NCT00530816|Drug|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
340956|NCT00530829|Drug|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
340957|NCT00003869|Procedure|quality-of-life assessment|Ancillary studies
340958|NCT00530842|Drug|Tiotropium plus Salmeterol|
340959|NCT00530842|Drug|Fluticasone/Salmeterol|
340252|NCT00543881|Device|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
340253|NCT00543881|Device|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
340254|NCT00543920|Drug|MK0777|
340255|NCT00543933|Drug|inhaled nitric oxide|iNO at 40 ppm through a non-rebreather mask for 5 minutes
340256|NCT00546273|Biological|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
340257|NCT00546273|Biological|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
340258|NCT00546273|Biological|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
340259|NCT00546273|Biological|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
340260|NCT00546286|Drug|dorzolamide hydrochloride (+) timolol maleate|Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.
For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks.
340261|NCT00546286|Drug|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.
For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks.
340584|NCT00538434|Other|Saline|IV (in the vein) on Day 0 of each 28 days cycle (+/-7 days) Number of Cycles=4)
340585|NCT00538447|Other|Database|data base for CML
340586|NCT00003913|Drug|busulfan|
340587|NCT00538473|Biological|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
340588|NCT00538473|Biological|Fluarix™|Single dose, intramuscular injection
340589|NCT00538486|Drug|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
340590|NCT00538486|Drug|Telmisartan|Telmisartan 80mg 1/d
340591|NCT00538486|Drug|Candesartan|Candesartan 8mg daily
340592|NCT00538486|Drug|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
340593|NCT00538486|Drug|Amlodipine|Amlodipine 5mg 1/d
338217|NCT00542984|Drug|salmon calcitonin 100 IU/day subcutaneous|
338218|NCT00003937|Drug|doxorubicin hydrochloride|
338219|NCT00542997|Biological|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
338220|NCT00545415|Dietary Supplement|Order 3|Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
338221|NCT00545415|Dietary Supplement|Order 4|Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
338550|NCT00537667|Drug|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
338551|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients > 45 kg/99 lbs: idebenone 900 mg/day
338552|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
338553|NCT00000572|Procedure|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
338554|NCT00003909|Radiation|radiation therapy|Undergo radiation therapy
338555|NCT00537680|Drug|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
338556|NCT00537693|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
338557|NCT00537719|Drug|GSK716155|albiglutide subcutaneous injection
338558|NCT00537719|Drug|Placebo|placebo injection
338559|NCT00537732|Drug|omeprazole|20 mg daily
338560|NCT00537732|Drug|omeprazole|20 vs. 60 mg daily, genotype dependent
338561|NCT00537745|Drug|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
338562|NCT00537745|Other|Medication Management Therapy|Medication Management Therapy once a month.
338563|NCT00537758|Behavioral|Cognitive Behavior Therapy|
337871|NCT00550654|Radiation|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
337872|NCT00550654|Radiation|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
337873|NCT00550654|Radiation|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
337874|NCT00003974|Drug|chemotherapy|
337875|NCT00550680|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly, starting dose
337876|NCT00550693|Device|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
337877|NCT00509886|Drug|Drioff|1% aluminum acetate
337878|NCT00509899|Drug|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
337879|NCT00003764|Drug|fludarabine phosphate|
337880|NCT00509925|Drug|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
337881|NCT00509925|Drug|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
337882|NCT00509925|Drug|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
337883|NCT00509938|Drug|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
337884|NCT00509951|Behavioral|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
337885|NCT00509951|Behavioral|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
337886|NCT00509964|Drug|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
338222|NCT00545415|Dietary Supplement|Order 5|Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
337162|NCT00003402|Drug|etoposide|
337163|NCT00433693|Drug|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25~300μg(i.v.)/4 week
337164|NCT00433706|Procedure|Control position by 3DOBI before the fraction|
337165|NCT00433719|Drug|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
337166|NCT00433732|Drug|sumatriptan|
337167|NCT00433732|Drug|naproxen sodium|
337168|NCT00433745|Drug|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
337169|NCT00433758|Device|GlucoTrack|GT
337533|NCT00425113|Procedure|CT Scan|
337534|NCT00425113|Procedure|PET Scan|
337535|NCT00003378|Drug|gemcitabine hydrochloride|
337536|NCT00425126|Drug|Epoetin Alfa|
337537|NCT00425139|Behavioral|Re-Mission|
337538|NCT00425152|Drug|fluorouracil|
337539|NCT00425152|Drug|leucovorin calcium|
337540|NCT00425152|Drug|levamisole hydrochloride|
337541|NCT00425165|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
337542|NCT00427908|Biological|Mencevax™ ACWY|One subcutaneous dose.
337543|NCT00427908|Biological|Meningitec™|One intramuscular dose.
337544|NCT00427921|Biological|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
337545|NCT00427934|Drug|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
337546|NCT00427934|Drug|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
337547|NCT00427947|Drug|ropivacaine/placebo|Continuous sciatic nerve bloc
336789|NCT00439374|Drug|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
336790|NCT00439400|Drug|doxycycline|
336791|NCT00439400|Drug|placebo|
336792|NCT00439413|Drug|Selegiline|Transdermal
336793|NCT00442039|Drug|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing < 20 kg
336794|NCT00442039|Drug|Lithium Carbonate|The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient‟s response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient‟s response and tolerability
336795|NCT00442039|Drug|Lithium Carbonate|The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient‟s response and tolerability.
336796|NCT00442039|Drug|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
336797|NCT00442052|Drug|aspirin|
336798|NCT00003435|Procedure|peripheral blood stem cell transplantation|
336799|NCT00442052|Drug|omeprazole|
336800|NCT00442065|Device|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
336801|NCT00442078|Device|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
336802|NCT00442091|Drug|dandelion juice|10 ml bid for 20-30 days
336803|NCT00442104|Drug|Ganaxolone|
336804|NCT00442117|Drug|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
336805|NCT00442117|Drug|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
336806|NCT00442130|Biological|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
337170|NCT00436631|Behavioral|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
335695|NCT00418509|Drug|Mometasone furoate|
335696|NCT00418509|Drug|Formoterol fumarate|
335697|NCT00418522|Drug|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
335698|NCT00418522|Drug|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
336052|NCT00456521|Behavioral|Intensive group lifestyle modification counseling|
336053|NCT00456547|Procedure|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
336054|NCT00456560|Drug|AV650|
336055|NCT00456560|Drug|Fluvoxamine|
336056|NCT00003515|Drug|antineoplaston A10|
336057|NCT00456560|Drug|Paroxetine|
336058|NCT00456573|Procedure|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
336059|NCT00456586|Drug|KW-6002 (istradefylline)|
336060|NCT00456599|Drug|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
336061|NCT00456599|Drug|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
336062|NCT00456599|Procedure|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
336063|NCT00456612|Procedure|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
336064|NCT00459719|Drug|Tacrolimus modified-release|oral
336065|NCT00459719|Drug|Prograf|oral
336066|NCT00459732|Dietary Supplement|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
336067|NCT00459732|Dietary Supplement|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
336068|NCT00459745|Drug|Pravafen (combination of Pravastatin and Fenofibrate)|
336069|NCT00459758|Device|Hans unit|
334964|NCT00435760|Drug|Placebo Tiotropium|1 puff once daily, 1 day treatment
334965|NCT00435760|Drug|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
334966|NCT00435760|Drug|Placebo LAS34273|1 puff, 1 dat treatment
334967|NCT00435773|Procedure|Single Leeching|
334968|NCT00435773|Procedure|Repeated Leeching after 4 weeks|
334969|NCT00435773|Procedure|Placebo Leeching|
334970|NCT00435799|Procedure|corneal cross-linking (CCL)|
334971|NCT00435799|Drug|Riboflavin/dextran eyedrops|
334972|NCT00003408|Biological|sargramostim|
334973|NCT00435799|Device|UV-X system|
334974|NCT00435812|Biological|1018 ISS with HBsAg|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
334975|NCT00435812|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
334976|NCT00435825|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
334977|NCT00435838|Drug|No Intervention -- Observational study|
334978|NCT00435851|Drug|Thyrogen, thyroid hormone withdrawal, iode 131|
334979|NCT00435864|Procedure|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
335326|NCT00427011|Drug|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
335327|NCT00427037|Drug|Cholecalciferol|50,000 IU weekly by mouth
335328|NCT00427037|Drug|Placebo|identical placebo pill orally by mouth
335329|NCT00427050|Drug|PEP005|
339730|NCT00533065|Drug|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
339731|NCT00003878|Drug|polifeprosan 20 with carmustine implant|
334243|NCT00003476|Drug|antineoplaston A10|
334244|NCT00449878|Drug|Placebo|Administered orally
334245|NCT00449904|Drug|Liprotamase|Administered orally
334246|NCT00449917|Drug|lutein|
334247|NCT00449917|Drug|DHA|
334248|NCT00449917|Drug|vitamins|
334249|NCT00449930|Drug|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
334250|NCT00449930|Drug|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
334251|NCT00449943|Procedure|Computed Tomographic Angiography|CT scan
334252|NCT00449943|Procedure|Myocardial Perfusion Imaging Scan|SPECT
334253|NCT00449956|Drug|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
334254|NCT00003476|Drug|antineoplaston AS2-1|
334255|NCT00449956|Drug|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
334256|NCT00449956|Drug|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
334257|NCT00449969|Device|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
334258|NCT00449969|Device|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
334259|NCT00449982|Drug|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
334260|NCT00449995|Procedure|confocal laser microscopy|
334261|NCT00450008|Drug|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
334262|NCT00450008|Drug|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
339372|NCT00540683|Device|Diffuse Optical Spectroscopy|Muscle properties
339373|NCT00540696|Drug|darbepoetin alfa|Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.
Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses.
339374|NCT00540709|Drug|Insulin Glargine|
339375|NCT00540722|Drug|R-(-)-gossypol acetic acid|Given PO
339376|NCT00540722|Other|laboratory biomarker analysis|Correlative studies
339377|NCT00540735|Procedure|photodynamic therapy|
339378|NCT00540748|Drug|oxytocin|5 U i.v. during surgical abortion
339379|NCT00003927|Biological|filgrastim|
339380|NCT00540761|Device|OFDI system|Imaging of the culprit lesion using the OFDI system.
339381|NCT00540774|Device|detection of oral pathology|detection of oral pathology
339382|NCT00540787|Device|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
339383|NCT00540787|Drug|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
339384|NCT00540787|Device|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
339385|NCT00540800|Drug|docetaxel|given in combination with epirubicin or capecitabine
339732|NCT00533078|Dietary Supplement|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
339733|NCT00533091|Biological|MEDI-545|MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.
Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.
339734|NCT00533091|Other|Placebo|Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.
Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.
Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks.
338718|NCT00510393|Device|XIENCE V everolimus eluting coronary stent system|
338719|NCT00510393|Device|MULTILINK VISION coronary stent system|
338720|NCT00000555|Drug|ascorbic acid|
338721|NCT00003769|Procedure|surgical procedure|
338722|NCT00510406|Drug|tamsulosin hydrochloride|Alphablocker
338723|NCT00510406|Drug|solifenacin succinate|antimuscarinic
339043|NCT00545896|Procedure|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
339044|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
339045|NCT00003954|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
339046|NCT00548509|Drug|Menatetrenone (Vitamin K2)|
339047|NCT00548535|Procedure|Reliability of complication assessment|
339048|NCT00548548|Drug|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
339049|NCT00548548|Drug|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
339050|NCT00548548|Drug|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
339051|NCT00548548|Drug|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
339052|NCT00548548|Drug|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
339053|NCT00548561|Drug|Dexrazoxane|
339054|NCT00003959|Biological|ras peptide cancer vaccine|
339055|NCT00548574|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
339056|NCT00548574|Drug|Mesalazine|
339057|NCT00548587|Drug|E5555|
339058|NCT00548587|Drug|Placebo|
338388|NCT00518622|Drug|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
338389|NCT00518622|Drug|Comparator: Placebo|MK7009 Placebo
338390|NCT00518635|Drug|Nutropin|Nutropin 0.1 mg/day self-administered once a day
338391|NCT00003809|Biological|cetuximab|
338392|NCT00518648|Other|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
338393|NCT00518648|Other|Usual care|Usual care
338394|NCT00518674|Procedure|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
338395|NCT00518687|Biological|V710|0.5-mL single injection of V710 (60 µg)
338396|NCT00518687|Biological|Placebo|0.5-mL single injection of matching placebo
338397|NCT00518700|Other|new MPS|
338398|NCT00518700|Other|RepleniSH|
338399|NCT00518713|Drug|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
338400|NCT00518713|Drug|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
338401|NCT00518713|Drug|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
338402|NCT00003809|Drug|cisplatin|
338724|NCT00510406|Drug|Placebo|Placebo
338725|NCT00510419|Drug|"Investigational"Auto-injector (sumatriptan succinate)|
338726|NCT00513266|Procedure|conventional surgery|
338727|NCT00513266|Procedure|neoadjuvant therapy|
338728|NCT00513279|Drug|GSK618334|
338729|NCT00513292|Drug|Cyclophosphamide|Given IV
338730|NCT00513292|Drug|Epirubicin Hydrochloride|Given IV
338731|NCT00003783|Drug|dexamethasone|
338732|NCT00513292|Other|Laboratory Biomarker Analysis|Correlative studies
338051|NCT00526890|Dietary Supplement|selenomethionine|Oral Twice daily
338052|NCT00526890|Drug|carboplatin|Weekly IV
338053|NCT00526890|Drug|paclitaxel|Weekly IV
338054|NCT00526890|Other|laboratory biomarker analysis|Correlative Study
338055|NCT00526890|Radiation|radiation therapy|Undergoing radiation Therapy
338056|NCT00526903|Behavioral|Elimination Diet|Daily diet change for 8 days.
338057|NCT00526916|Drug|[C-11]PBR28|
338058|NCT00526929|Drug|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
338059|NCT00003852|Procedure|peripheral blood stem cell transplantation|
338060|NCT00526942|Behavioral|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
338061|NCT00526968|Drug|EVT 101|8 mg capsule, single oral dose
338062|NCT00526968|Drug|EVT 101|15 mg capsule, single oral dose
338063|NCT00526968|Drug|placebo|Placebo capsule, single oral dose
338064|NCT00526981|Other|Prone position|Prone position during spontaneous breathing.
338065|NCT00526994|Other|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
338066|NCT00526994|Behavioral|universal education|receives referral information
338067|NCT00529490|Drug|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
338068|NCT00529503|Drug|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
338069|NCT00003863|Genetic|comparative genomic hybridization|
338070|NCT00529503|Drug|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
338071|NCT00529503|Drug|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
342637|NCT00003916|Radiation|stereotactic radiosurgery|
342638|NCT00539292|Procedure|Primary placement of a spring-loaded silo|
342639|NCT00539292|Procedure|Primary Closure|primary closure of abdomen
342640|NCT00539305|Drug|testosterone gel|50-100mg applied topically daily for six months
342641|NCT00539305|Drug|placebo gel|applied topically daily for six months
342642|NCT00539318|Procedure|Blood drawing|Once when enroll in study
342643|NCT00539331|Drug|AZD2171|oral tablet
342644|NCT00539331|Drug|Paclitaxel|intravenous infusion
342645|NCT00539331|Drug|Carboplatin|intravenous injection
342646|NCT00539344|Drug|ANG1005|IV infusion once every 21 days
342647|NCT00539357|Device|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
342648|NCT00003917|Drug|topotecan hydrochloride|
342649|NCT00539383|Drug|ANG1005|IV infusion once every 21 days
342972|NCT00534417|Drug|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight < 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
342973|NCT00534417|Drug|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
342974|NCT00534430|Drug|busulfan|
342975|NCT00534430|Drug|cyclosporine|
342976|NCT00534430|Drug|etoposide|
342977|NCT00534430|Drug|mycophenolate mofetil|
342978|NCT00534430|Procedure|allogeneic bone marrow transplantation|
342979|NCT00534430|Procedure|allogeneic hematopoietic stem cell transplantation|
342980|NCT00534430|Procedure|peripheral blood stem cell transplantation|
342274|NCT00544583|Procedure|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
342275|NCT00544583|Procedure|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
342276|NCT00544596|Drug|R-(-)-gossypol acetic acid|Given orally
342277|NCT00544596|Drug|cisplatin|Given IV
342278|NCT00544596|Drug|etoposide|Given IV
342279|NCT00544609|Drug|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
342280|NCT00544609|Procedure|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
342281|NCT00544622|Procedure|structured therapeutic chain of stroke treatment|
342282|NCT00544635|Device|no intervention|no intervention
342283|NCT00544635|Device|light|scars will be treated with light
342284|NCT00003944|Drug|carboplatin|
342285|NCT00544648|Drug|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
342286|NCT00544648|Drug|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
342287|NCT00544648|Radiation|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
342288|NCT00544674|Drug|PR104|administered at a dose of 1100 mg/m^2 by intravenous infusion over 1 hour and repeated every three weeks
342289|NCT00544674|Other|F-18-fluoromisonidazole|administered intravenously prior to PET scan
342290|NCT00544687|Drug|CRx-191|topical (mometasone furoate + nortriptyline HCl)
342291|NCT00544687|Drug|mometasone furoate|topical mometasone furoate
342292|NCT00544687|Drug|nortriptyline HCl|topical nortriptyline HCl
342293|NCT00544687|Drug|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
342294|NCT00547131|Drug|temozolomide|
342295|NCT00547131|Other|laboratory biomarker analysis|
341624|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
341625|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
341626|NCT00517075|Device|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
341627|NCT00003799|Procedure|therapeutic conventional surgery|Undergo surgery
341628|NCT00517088|Drug|IPAQ|
341629|NCT00517114|Drug|Rabeprazole 20mg twice daily|
341630|NCT00517127|Drug|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
341967|NCT00509067|Drug|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
341968|NCT00509067|Drug|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
341969|NCT00509067|Drug|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
341970|NCT00509093|Drug|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
341971|NCT00509093|Genetic|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
341972|NCT00509093|Genetic|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
341276|NCT00522548|Drug|CellCept (Mycophenolate mofetil)|Patients in this group will receive Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, in combination with CellCept (mycophenolate mofetil) or its generic equivalent, Prograf (tacrolimus) or its generic equivalent and corticosteroid immunosuppression.
341277|NCT00522561|Other|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
341278|NCT00522574|Drug|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
341279|NCT00522587|Drug|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
341280|NCT00522587|Drug|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
341281|NCT00522587|Drug|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
341282|NCT00522587|Drug|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
341283|NCT00522587|Drug|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
341284|NCT00522587|Drug|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
341285|NCT00522587|Drug|Fixed remifentanil dose 1|Dose 1 of remifentanil
341286|NCT00003825|Procedure|quality-of-life assessment|
341287|NCT00525512|Drug|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
341288|NCT00525525|Drug|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
341289|NCT00525525|Drug|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
341290|NCT00525525|Drug|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
341291|NCT00525538|Radiation|conformal radiotherapy|
341292|NCT00525551|Drug|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
341293|NCT00525551|Drug|Placebo (NaCl)|300 mL 0.9% NaCl
341294|NCT00525564|Drug|Placebo|Placebo diskus inhalation powder
341295|NCT00525564|Drug|Salmeterol diskus inhalation powder|50 micrograms twice a day
340594|NCT00538486|Drug|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
340595|NCT00538499|Drug|Fentanyl citrate|
340596|NCT00538499|Drug|Bupivacaine hydrocloride|
340597|NCT00003913|Drug|cyclophosphamide|
340598|NCT00538499|Procedure|videothoracoscopy|
340599|NCT00538512|Biological|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
340600|NCT00538512|Biological|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
340601|NCT00538512|Other|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
340602|NCT00538525|Drug|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
340603|NCT00538538|Procedure|vitrectomy|A gas bubble will be placed in the eye after the gel has been removed.
340604|NCT00538538|Procedure|vitrectomy|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
340605|NCT00538551|Other|Database|Database
340606|NCT00538564|Drug|tadalafil|10mg oral tablets taken 3 times a week for 2 months
340607|NCT00538564|Drug|placebo|Placebo tablets taken orally 3 times a week for 2 months
340608|NCT00003913|Drug|methylprednisolone|
340609|NCT00541099|Drug|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
340960|NCT00530855|Drug|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
340961|NCT00530868|Other|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
340962|NCT00530868|Drug|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
340963|NCT00530881|Drug|PHX1149|
340964|NCT00530894|Device|Edwards SAPIEN Transcatheter Heart Valve|
340965|NCT00530894|Device|Surgical Valve Replacement|
340966|NCT00530894|Other|medical management and/or balloon aortic valvuloplasty|
338564|NCT00537758|Behavioral|CBT and BWL|
338565|NCT00003909|Other|pharmacological study|Correlatives studies
338566|NCT00537758|Behavioral|Behavioral Weight Loss Treatment|
338567|NCT00537771|Drug|Anastrozole|1 mg once daily oral dose
338568|NCT00537771|Drug|Tamoxifen|20 mg once daily oral dose
338569|NCT00537784|Biological|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
338570|NCT00537784|Biological|no injection|
338571|NCT00537797|Other|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
338572|NCT00537810|Drug|Sibutramine|15 mg daily
338573|NCT00537810|Drug|Placebo|Daily
338574|NCT00537810|Behavioral|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
338890|NCT00529971|Other|Control|Treatment as usual, which could include medications or psychotherapy
338891|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
338892|NCT00529984|Biological|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
338893|NCT00532701|Drug|Peg-IFN + WB RBV for 16 weeks|Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 5-16
338894|NCT00532701|Drug|Peg-IFN + LD RBV for 16 weeks|Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-6
Rapid virologic response (RVR) at week 4 of therapy: achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16
338895|NCT00532701|Drug|Peg-IFN + WB RBV for 24 weeks|Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: not achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24
338223|NCT00545415|Dietary Supplement|Order 6|Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
338224|NCT00545428|Procedure|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
338225|NCT00545441|Device|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
338226|NCT00545441|Device|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
338227|NCT00545454|Drug|SSR150106|
338228|NCT00545467|Drug|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
338229|NCT00003953|Drug|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
338230|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
338231|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
338232|NCT00545493|Drug|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
338233|NCT00545493|Drug|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
338234|NCT00545506|Device|conventional bandage|
338235|NCT00545506|Device|warming bandage|
338236|NCT00545519|Drug|thymoglobulin|
338237|NCT00545532|Drug|oseltamivir|60-150 mg (depending on patients age and weight) po bid for 10 days
338238|NCT00545532|Drug|oseltamivir|30-75 mg (depending on patients age and weight) po bid for 10 days
338239|NCT00545545|Biological|Safety and efficacy of escalating doses|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
338240|NCT00003953|Drug|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
338241|NCT00545545|Biological|Safety and efficacy of escalating doses.|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
337548|NCT00427960|Behavioral|Dietary advice|
337549|NCT00427960|Drug|rosuvastatin|rosuvastatin 5 mg
337550|NCT00003389|Drug|Bleomycin|given IV
337551|NCT00427960|Drug|atorvastatin|atorvastatin 10 mg
337552|NCT00427973|Drug|cediranib maleate|Given orally
337553|NCT00427973|Other|laboratory biomarker analysis|
337554|NCT00427973|Procedure|computed tomography|
337555|NCT00427973|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
337556|NCT00427973|Other|pharmacological study|
337557|NCT00427986|Drug|Galactose, intravenous|
337558|NCT00427999|Drug|imatinib mesylate|
337559|NCT00428012|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
337887|NCT00509964|Drug|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
337888|NCT00509977|Procedure|Light Treatment|Light treatment applied to half of the face at each study visit
337889|NCT00509977|Procedure|Laser Treatment|Laser treatment applied to half of the face at each study visit
337890|NCT00003765|Drug|O6-benzylguanine|
337891|NCT00509990|Drug|Pimecrolimus|Pimecrolimus cream 1 %
337892|NCT00510003|Drug|Pimecrolimus|Pimecrolimus cream 1 %
337893|NCT00510016|Drug|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
337894|NCT00510029|Drug|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
337895|NCT00510055|Procedure|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
337896|NCT00510055|Procedure|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
337897|NCT00510068|Drug|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
337171|NCT00436644|Drug|Lapatinib|1250 mg orally days 1 -28.
337172|NCT00436644|Drug|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 & 15.
337173|NCT00436657|Drug|CHPP of Cisplatin|Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
337174|NCT00436657|Procedure|Abdominal Surgery|Surgical removal of abdominal tumors.
337175|NCT00436670|Biological|AMG 317 75 mg|75 mg SC weekly injection
337176|NCT00436670|Biological|AMG 317 150 mg|150 mg SC once weekly injection
337177|NCT00436670|Biological|AMG 317 300 mg|300 mg weekly SC injection
337178|NCT00436670|Biological|Placebo|Placebo SC once weekly injection
337179|NCT00003413|Drug|paclitaxel|
337180|NCT00436683|Drug|Fermagate|Film coated tablet 500mg
337181|NCT00436683|Drug|Sevelamer HCl|tablet 800mg
337182|NCT00436696|Genetic|gene mapping|
337183|NCT00436696|Genetic|polymorphism analysis|
337184|NCT00436709|Biological|bevacizumab|
337185|NCT00436709|Biological|pegfilgrastim|
337186|NCT00436709|Drug|cyclophosphamide|
337187|NCT00436709|Drug|doxorubicin hydrochloride|
337188|NCT00436709|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
337189|NCT00436709|Other|flow cytometry|
337190|NCT00003413|Procedure|peripheral blood stem cell transplantation|
337191|NCT00436709|Other|immunoenzyme technique|
337192|NCT00436709|Other|immunologic technique|
337193|NCT00436709|Other|laboratory biomarker analysis|
337194|NCT00436709|Procedure|adjuvant therapy|
336070|NCT00459771|Drug|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
336071|NCT00459771|Drug|Placebo|Placebo, 32 mg, oral QD
336072|NCT00003531|Drug|antineoplaston A10|
336073|NCT00459784|Procedure|Dementia Training Program|
336074|NCT00459797|Device|Conventional (reusable) Glidescope|
336075|NCT00459797|Device|Single-use Glidescope videolaryngoscope|
336076|NCT00459810|Drug|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
336441|NCT00450593|Genetic|mutation analysis|
336442|NCT00450593|Other|laboratory biomarker analysis|
336443|NCT00450593|Procedure|mutation carrier screening|
336444|NCT00450593|Procedure|study of high risk factors|
336445|NCT00450606|Procedure|Balneotherapy and hydrotherapy|
336446|NCT00450619|Radiation|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
336447|NCT00450619|Biological|Sargramostim|100 mcg/injection x 4 days given subcutaneously
336448|NCT00450619|Biological|Recombinant vaccinia-TRICOM vaccine|2 x 10^8 PFU given subcutaneously on day 1.
336449|NCT00003484|Procedure|surgical procedure|
336450|NCT00450619|Biological|Recombinant fowlpox-TRICOM vaccine|1 x 10^9 PFU given subcutaneously on days 15 and 29
336451|NCT00450645|Drug|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
336452|NCT00450658|Drug|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
336453|NCT00450658|Drug|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
336454|NCT00450671|Procedure|Collagen Plug Placement|
336455|NCT00450671|Procedure|Seton placement|
335330|NCT00427076|Drug|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR<30.
335331|NCT00427076|Drug|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR <10 1gr Q 4-7 days.
335332|NCT00003387|Drug|chemotherapy|
335333|NCT00427089|Drug|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
335334|NCT00427089|Drug|Sodium Phosphate solution (NaP)|45 ml solution; BID
335335|NCT00427102|Drug|Oral MRX-1024|
335336|NCT00427102|Procedure|Standard Fractionation Radiation Therapy|
335337|NCT00427102|Drug|High-Dose Cisplatin Chemotherapy|
335338|NCT00427115|Behavioral|Multimodal exercise and psychosocial program|
335339|NCT00427128|Drug|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
335340|NCT00427128|Drug|placebo|Week 13-36.
335341|NCT00427141|Drug|GSK580416|
335342|NCT00430001|Drug|vinorelbine|
335343|NCT00430001|Drug|trastuzumab|
335344|NCT00430014|Drug|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
335345|NCT00003396|Drug|cyclophosphamide|
335346|NCT00430027|Drug|Capecitabine|Given 650 mg/m^2 BID on days of ration therapy, 825 mg/m^2 day 1-14, day 15-20 off x 4
335347|NCT00430027|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2, 130mg/m2 IV Q 21 days x 4
335348|NCT00430027|Drug|Cetuximab|Initial Cetuximab 400 mg/m^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
335699|NCT00000510|Procedure|angioplasty, transluminal, percutaneous coronary|
334263|NCT00450008|Drug|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
334264|NCT00450021|Drug|[(11)C] MePPEP|
334265|NCT00452634|Drug|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
334266|NCT00452634|Drug|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
334614|NCT00441142|Drug|temozolomide|During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.
During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles.
334615|NCT00444249|Procedure|White Hoya IOL|Implantation of white Hoya IOL
334616|NCT00444249|Procedure|Yellow Hoya IOL|Implantation of yellow Hoya IOL
334617|NCT00003440|Drug|paclitaxel|Given IV over 1 hour or 3 hours
334618|NCT00444262|Procedure|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
334619|NCT00444262|Drug|VOLUVEN and others solute|VOLUVEN and others solute
334620|NCT00444275|Drug|esomeprazole (Nexium®)|This randomized study was conducted on parallel groups and included two phases:
One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
334621|NCT00444275|Drug|Xolaam®|This randomized study was conducted on parallel groups and included two phases:
One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
334622|NCT00444314|Drug|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
334623|NCT00444314|Drug|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
334624|NCT00444340|Drug|Enbrel (Etanercept)|
334625|NCT00444353|Device|DL6049 (injectable poly-L-lactic acid)|
334626|NCT00444379|Drug|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
339735|NCT00533104|Procedure|BM-MNC preparation|For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.
Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection).
339736|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
339737|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
339738|NCT00535704|Behavioral|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
339739|NCT00535704|Behavioral|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
339740|NCT00535717|Procedure|uttarbasti (per urethral administration of medicated oil )|
339741|NCT00535730|Biological|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
339742|NCT00535730|Biological|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
339743|NCT00535730|Biological|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
339744|NCT00535743|Drug|sugammadex (Org 25969)|Sugammadex (2, 4, 8, 12 and 16 mg/kg) was given as a reversal agent at 3 and 15 minutes following administration of 1.0 and 1.2 mg/kg of Esmeron®, respectively
339745|NCT00535743|Drug|Placebo|5 mL NaCl 0.9%
339746|NCT00000158|Procedure|Argon Blue-Green Laser Photocoagulation|
339747|NCT00000569|Drug|triamcinolone|
339748|NCT00003896|Drug|cisplatin|
339749|NCT00535756|Drug|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
334267|NCT00452660|Drug|Exjade|
334268|NCT00452673|Drug|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
334269|NCT00452673|Drug|Capecitabine|Tablets, Oral, 660 - 1250 mg/m^2 twice a day (BID). Treatment may continue until disease progression.
334270|NCT00452686|Biological|Boostrix|
334271|NCT00452686|Biological|Chinese DT vaccine|
339059|NCT00548600|Procedure|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
339060|NCT00548600|Radiation|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
339061|NCT00548613|Biological|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
339062|NCT00548613|Biological|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
339063|NCT00548626|Procedure|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
339386|NCT00540800|Drug|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
339387|NCT00540800|Drug|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
339388|NCT00540813|Device|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
339389|NCT00540826|Drug|Atomoxetine|in-label use
339390|NCT00003927|Drug|amifostine trihydrate|
339391|NCT00540826|Drug|stimulants (any approved ADHD medication)|in-label use
339392|NCT00540839|Drug|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
339393|NCT00540839|Drug|Placebo to montelukast|Placebo OG or CT
339394|NCT00540839|Drug|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
339395|NCT00540839|Drug|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
339396|NCT00540852|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
339397|NCT00543426|Drug|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
339398|NCT00543439|Biological|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
339399|NCT00543439|Biological|Moroctocog alfa (AF-CC)|Routine prophylaxis crossover:
45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year.
338733|NCT00513292|Drug|Paclitaxel|Given IV
338734|NCT00513292|Procedure|Therapeutic Conventional Surgery|Undergo surgery
338735|NCT00513292|Biological|Trastuzumab|Given IV
338736|NCT00513305|Drug|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
338737|NCT00513305|Drug|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m^2 subcutaneously (sc) twice a day (bid).
338738|NCT00513331|Procedure|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
338739|NCT00513331|Procedure|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
338740|NCT00513331|Procedure|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
338741|NCT00513344|Dietary Supplement|Dark Chocolate|1 portion
338742|NCT00003783|Drug|etoposide|
338743|NCT00513344|Dietary Supplement|Milk Chocolate|1 portion
338744|NCT00513344|Dietary Supplement|Control (polyphenol-free) "Chocolate"|one portion
338745|NCT00513357|Drug|Melatonin|20 mg by mouth daily for 4 Weeks
338746|NCT00513357|Drug|Placebo|Capsule by mouth daily for 4 Weeks
338747|NCT00513370|Biological|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
339064|NCT00548626|Procedure|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
339065|NCT00003959|Biological|sargramostim|
339066|NCT00548639|Other|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
339067|NCT00548639|Other|Control Pamphlet|ADA Diabetes Sheet
339068|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
339069|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
338072|NCT00529503|Drug|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
338403|NCT00518713|Drug|Placebo|tablets; orally; daily for 15-18 weeks
338404|NCT00521170|Drug|Levocetirizine|
338405|NCT00003816|Radiation|total-body irradiation|Given twice daily for 3 days
338406|NCT00521183|Drug|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
338407|NCT00521183|Drug|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
338408|NCT00521183|Radiation|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
338409|NCT00521196|Device|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
338410|NCT00521209|Behavioral|Self-Care Stimulating Disease Prevention Program (SCSDPP)|The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or "self-prescription" of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or "self-prescription" of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling
338411|NCT00521209|Other|Stand procedures, no intervention|
338412|NCT00521222|Drug|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
338413|NCT00521222|Drug|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
338414|NCT00521248|Drug|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
342981|NCT00534430|Radiation|total-body irradiation|
342982|NCT00003888|Radiation|radiation therapy|
342983|NCT00534443|Procedure|Endoscopy of upper GI tract|Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.
Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines.
342984|NCT00534456|Drug|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
342985|NCT00534456|Drug|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
342986|NCT00534469|Biological|aldesleukin|
342987|NCT00534469|Biological|filgrastim|
342988|NCT00534469|Drug|busulfan|
342989|NCT00534469|Drug|cytarabine|
342990|NCT00534469|Drug|etoposide|
342991|NCT00534469|Drug|idarubicin|
342992|NCT00534469|Procedure|autologous hematopoietic stem cell transplantation|
342993|NCT00003890|Drug|MG 98|
342994|NCT00534469|Procedure|bone marrow transplantation|
342995|NCT00534469|Procedure|peripheral blood stem cell transplantation|
343323|NCT00526318|Drug|carboplatin|
343324|NCT00526318|Drug|cisplatin|
343325|NCT00526318|Drug|cyclophosphamide|
343326|NCT00526318|Drug|dacarbazine|
343327|NCT00529048|Other|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
342296|NCT00547131|Other|liquid chromatography|
342297|NCT00547131|Other|mass spectrometry|
342298|NCT00547131|Other|pharmacological study|
342650|NCT00539396|Drug|Technosphere Insulin|
342651|NCT00539409|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
342652|NCT00542009|Drug|CE-326,597 50 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
342653|NCT00542009|Drug|CE-326,597 25 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
342654|NCT00542009|Drug|Placebo|Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
342655|NCT00542009|Drug|CE-326,597 5mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
342656|NCT00542022|Drug|MK0812 / Duration of Treatment: 12 Weeks|
342657|NCT00542022|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
342658|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
342659|NCT00542035|Drug|Placebo; oral|dose 1, dose 2
342660|NCT00542035|Drug|Placebo; oral|dose 1
342661|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
342662|NCT00000575|Drug|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
342663|NCT00003934|Drug|tretinoin|Given orally
342664|NCT00542048|Drug|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
342665|NCT00542061|Device|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
342666|NCT00542074|Other|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
341973|NCT00509093|Genetic|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
341974|NCT00509093|Other|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
341975|NCT00003758|Procedure|autologous bone marrow transplantation|
341976|NCT00509093|Procedure|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
341977|NCT00509106|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
341978|NCT00511797|Drug|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
341979|NCT00511797|Drug|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
341980|NCT00511797|Drug|Placebo|Placebo
341981|NCT00511810|Drug|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
341982|NCT00511810|Drug|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
341983|NCT00511823|Drug|casopitant|
341984|NCT00003777|Procedure|surgical procedure|
341985|NCT00511836|Drug|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
342299|NCT00547131|Procedure|conventional surgery|
342300|NCT00003956|Drug|leucovorin calcium|
342301|NCT00547131|Radiation|stereotactic radiosurgery|
342302|NCT00547144|Drug|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
342303|NCT00547144|Procedure|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
342304|NCT00547157|Drug|Panitumumab|Arm 2 consists of panitmumab plus RT
342305|NCT00547157|Drug|Cisplatin|Cisplatin
342306|NCT00547170|Drug|Doxycycline pre-operatively|Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo "100 mg" twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
341296|NCT00525577|Drug|Placebo|Placebo tablet, once daily
341297|NCT00003846|Drug|vincristine sulfate|
341298|NCT00525577|Drug|AGI-1067|75 mg AGI-1067 tablet, once daily
341631|NCT00517127|Drug|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
341632|NCT00517140|Procedure|Repeat Caesaen section|
341633|NCT00517140|Procedure|vaginal delivery|
341634|NCT00517153|Drug|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
341635|NCT00517166|Device|CAT (Combat Arms Tourniquet)|device
341636|NCT00517179|Drug|Vardenafil 10mg|
341637|NCT00517192|Drug|Tipranavir|
341638|NCT00000556|Drug|procainamide|
341639|NCT00003800|Other|immunohistochemistry staining method|
341640|NCT00517192|Drug|Darunavir|
341641|NCT00517192|Drug|Ritonavir|
341642|NCT00517205|Procedure|Non-contrast helical computerized tomogram (NCHCT)|
341643|NCT00517218|Drug|Genasense® (, oblimersen sodium G3139)|
341644|NCT00517257|Drug|Atorvastatin|80 mg orally once daily for 24 weeks
341645|NCT00517257|Drug|Placebo|Placebo tablet orally once daily for 24 weeks
341646|NCT00517270|Drug|Rabeprazole 20mg twice daily|
341647|NCT00519974|Other|study of socioeconomic and demographic variables|
341648|NCT00519974|Procedure|management of therapy complications|
341649|NCT00003815|Drug|carmustine|
341650|NCT00519974|Procedure|psychosocial assessment and care|
341651|NCT00519987|Drug|intranasal ketamine|intranasal ketamine
340967|NCT00530907|Drug|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
340968|NCT00533442|Drug|Tacrolimus and mycophenolate mofetil|MMF 1 gm BID beginning 1st day postoperative day
340969|NCT00533442|Drug|Rapamune and Tacrolimus|Sirolimus 2 mg/day beginning 1st postoperative day (trough target levels:
10-15ng/ml)
340970|NCT00003881|Biological|trastuzumab|
340971|NCT00533442|Drug|Mycophenolate Mofetil|Patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
340972|NCT00533455|Drug|Gabapentin|
340973|NCT00533468|Drug|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
340974|NCT00533481|Drug|MK0557|
340975|NCT00533494|Behavioral|physician feedback (A)|Feedback information to physicians
340976|NCT00533507|Biological|Synflorix|Intramuscular injection, 3 doses.
340977|NCT00533507|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
340978|NCT00533507|Biological|Rotarix|Oral, 2 doses.
340979|NCT00533520|Drug|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
340980|NCT00533533|Drug|docetaxel, oxaliplatin|Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.
Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1
340981|NCT00000567|Procedure|high-frequency ventilation|
340982|NCT00003881|Drug|carboplatin|
341299|NCT00525577|Drug|AGI-1067|150 mg AGI-1067 Tablet, once daily
341300|NCT00525590|Drug|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
341301|NCT00525603|Drug|Cyclophosphamide|200 mg/m^2/day 3-5 IV 5-30 minutes
338896|NCT00532701|Drug|Peg-IFN + WB RBV for 48 weeks|Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: not achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48
338897|NCT00532701|Drug|Peg-IFN + LD RBV for 24 weeks|Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24
Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved
338898|NCT00003877|Drug|cyclophosphamide|
338899|NCT00532714|Drug|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.
Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period).
338900|NCT00532727|Drug|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
338901|NCT00532727|Drug|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
338902|NCT00532740|Radiation|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
338903|NCT00532753|Behavioral|Community Empowerment|
338904|NCT00532766|Drug|Jusline|
338905|NCT00532779|Drug|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
338906|NCT00532779|Drug|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
339232|NCT00524459|Procedure|conventional surgery|
339233|NCT00524459|Procedure|neoadjuvant therapy|
339234|NCT00524472|Other|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
339235|NCT00524472|Other|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
339236|NCT00524485|Drug|aminolevulinic acid|
339237|NCT00003840|Biological|DTGM fusion protein|
339238|NCT00524485|Procedure|laser therapy|
339239|NCT00524498|Drug|OPC-18|OPC-18: 500IU * 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
339240|NCT00524498|Drug|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
338575|NCT00537810|Behavioral|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
338576|NCT00540384|Drug|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
338577|NCT00540397|Drug|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
338578|NCT00540410|Drug|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
338579|NCT00540410|Drug|Coartem® (arthemether+ lumefantrine)|Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.
Duration of treatment: 3 days
338580|NCT00540423|Drug|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
338581|NCT00540423|Drug|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
338582|NCT00540423|Drug|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
338583|NCT00540423|Drug|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
338584|NCT00540436|Drug|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
338585|NCT00540449|Drug|TMC278|25 mg tablet once daily for 96 weeks
338586|NCT00003926|Drug|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
338587|NCT00540449|Drug|Efavirenz|600mg once daily for 96 weeks
338588|NCT00540462|Procedure|gastric bypass|
338589|NCT00540462|Procedure|sleeve gastrectomy|
338590|NCT00540488|Other|Adult enteral formula|
338591|NCT00540501|Drug|Oseltamivir and Intravenous Zanamivir|Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.
Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.
Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.
338592|NCT00540514|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
338593|NCT00540514|Drug|Paclitaxel|Administered by intravenous infusion.
338594|NCT00540514|Drug|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate [GFR] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
337898|NCT00510068|Drug|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
337899|NCT00510081|Device|Calcium Hydroxylapatite injection|filler injection
337900|NCT00510094|Behavioral|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
337901|NCT00512993|Drug|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
337902|NCT00513019|Drug|Lamictal (lamotrigine)|once daily from beginning to end of study. Dosage varies.
337903|NCT00513019|Drug|Placebo|daily
337904|NCT00513032|Drug|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
337905|NCT00513045|Behavioral|IRT|Cognitive behavior intervention
337906|NCT00000156|Device|Goggles|
337907|NCT00000556|Drug|sotalol|
337908|NCT00003783|Biological|filgrastim|
337909|NCT00513045|Behavioral|Exposure|Exposure intervention
338242|NCT00548145|Drug|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
338243|NCT00548171|Biological|Boostrix™|Intramuscular injection, 1 dose
338244|NCT00548184|Drug|Lapatinib|Monoclonal Antibody
338245|NCT00548184|Drug|Trastuzumab|Monoclonal Antibody
338246|NCT00548184|Drug|Endocrine|Hormonal Therapy
338247|NCT00548197|Drug|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
338248|NCT00548223|Drug|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid*1year
338249|NCT00003958|Radiation|radiation therapy|Undergo radiotherapy
338250|NCT00548223|Drug|placebo|Capsule, 0.18g, 2#, Bid*1year
337195|NCT00436709|Procedure|immunoscintigraphy|
337560|NCT00428012|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
337561|NCT00003389|Drug|Vinblastine|given IV
337562|NCT00428025|Drug|diclofenac|100 mg diclofenac rectal suppository
337563|NCT00428025|Drug|placebo|similar shape and size suppository
337564|NCT00428051|Other|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
337565|NCT00428064|Drug|Sirolimus|
337566|NCT00428064|Drug|cyclosporine|
337567|NCT00428077|Biological|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
337568|NCT00428077|Genetic|reverse transcriptase-polymerase chain reaction|A "baseline" reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a "baseline" circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction.
337569|NCT00428090|Drug|Rosiglitazone|XR (extended release) oral tablets
337570|NCT00430898|Drug|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
337571|NCT00430911|Drug|Radiotherapy|
337572|NCT00430924|Drug|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
337573|NCT00430937|Drug|Daptomycin|4 mg/kg intravenous once daily
337574|NCT00430937|Drug|Vancomycin|1 g intravenous twice daily
337575|NCT00003397|Drug|melphalan|
337576|NCT00430937|Drug|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
337577|NCT00430950|Drug|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
336456|NCT00450684|Device|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
336457|NCT00450684|Device|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
336458|NCT00450710|Procedure|ileal interposition with a sleeve gastrectomy|
336459|NCT00450723|Drug|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
336460|NCT00003484|Radiation|iodine I 131 monoclonal antibody 81C6|
336461|NCT00450723|Procedure|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
336462|NCT00450723|Procedure|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
336807|NCT00442130|Procedure|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
336808|NCT00442143|Procedure|Stem cell implantation|
336809|NCT00003435|Procedure|umbilical cord blood transplantation|
336810|NCT00442156|Procedure|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
336811|NCT00442169|Biological|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
336812|NCT00442169|Biological|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
336813|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
336814|NCT00442169|Biological|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
336815|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
336816|NCT00442169|Biological|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
336817|NCT00442182|Drug|ITF2357|
335700|NCT00003339|Biological|gp100 antigen|
335701|NCT00418535|Drug|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
335702|NCT00418548|Drug|Etanercept|
335703|NCT00421642|Drug|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
335704|NCT00421655|Drug|Grazax|Tablets 75,000 SQT and matching placebo. One tablet daily.
335705|NCT00421668|Drug|Zinc|zinc
335706|NCT00421668|Drug|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
335707|NCT00421668|Drug|Placebo|Placebo
335708|NCT00421681|Behavioral|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
335709|NCT00421694|Drug|Bicalutamide|
335710|NCT00421707|Drug|GW876008|
335711|NCT00421707|Other|Placebo|
335712|NCT00421720|Drug|Sufentanil|
335713|NCT00003354|Procedure|conventional surgery|
335714|NCT00421720|Drug|Remifentanil|
335715|NCT00421733|Drug|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
335716|NCT00421733|Drug|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
335717|NCT00421733|Drug|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
335718|NCT00421746|Drug|Piboserod|
335719|NCT00421759|Device|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
335720|NCT00421785|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
334627|NCT00444392|Behavioral|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
334628|NCT00003440|Biological|trastuzumab|Given IV
334629|NCT00444418|Drug|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
334630|NCT00444418|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
334631|NCT00444418|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
334632|NCT00444431|Procedure|Pyeloplasty|
334980|NCT00435890|Behavioral|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
334981|NCT00435903|Device|Palm Pilot|
334982|NCT00435916|Drug|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
334983|NCT00003409|Drug|motexafin gadolinium|
334984|NCT00435929|Drug|Ritonavir|100mg po bid
334985|NCT00435929|Drug|saquinavir [Invirase]|1000mg po bid
334986|NCT00435942|Device|Relay Thoracic Stent-Graft|implant
334987|NCT00435955|Procedure|High dose chemotherapy with autologous transplantation|
334988|NCT00435955|Drug|Rituximab|
334989|NCT00435968|Drug|CVT E002 (Cold-fX)|
334990|NCT00435981|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
334991|NCT00435994|Drug|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primetine mist will be given to the patient. Infant pulmonary functions will follow the breathing treatment.
334992|NCT00436007|Biological|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
334993|NCT00438568|Drug|Placebo|administered intra-nasally twice a day for 16 weeks
334994|NCT00438581|Drug|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
334272|NCT00452699|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
334273|NCT00003494|Drug|antineoplaston A10|
334274|NCT00452699|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
334275|NCT00452712|Procedure|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
334276|NCT00452725|Drug|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
334277|NCT00452738|Behavioral|Therapy dog|
334278|NCT00452738|Behavioral|Costumed character|
334279|NCT00452738|Behavioral|Parents-only|
334280|NCT00452751|Procedure|laparoscopy-assisted distal gastrectomy|
334281|NCT00452751|Procedure|open distal gastrectomy|
334282|NCT00452764|Behavioral|Withdrawal of medication|
334283|NCT00452777|Drug|BVT.115959|
334284|NCT00003494|Drug|antineoplaston AS2-1|
334285|NCT00452777|Drug|Placebo|
334286|NCT00452790|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
334287|NCT00452790|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
334288|NCT00452803|Drug|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
334289|NCT00452803|Drug|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
334290|NCT00452803|Radiation|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
334633|NCT00444457|Biological|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
334634|NCT00444457|Biological|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
334635|NCT00444470|Drug|Tranexamic acid|Eligible patients who have consented to be in the study and have been randomised to be in Arm "A" will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid.
339400|NCT00543452|Other|Oxygen|4 liters of oxygen a minute
339401|NCT00543452|Other|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
339402|NCT00543465|Drug|MK0782|
339403|NCT00543478|Drug|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
339404|NCT00543478|Drug|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
339405|NCT00543491|Drug|MK0767|
339406|NCT00543504|Drug|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
339407|NCT00003939|Drug|trabectedin|
339408|NCT00543504|Drug|Sorafenib|200 mg By Mouth Daily for 28 Days
339409|NCT00543504|Drug|Erlotinib|50 mg By Mouth Daily for 28 Days.
339750|NCT00535756|Drug|Placebo|Placebo
339751|NCT00535769|Device|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
339752|NCT00535769|Device|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
339753|NCT00535782|Drug|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
339754|NCT00535782|Drug|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
339755|NCT00535782|Drug|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
339756|NCT00535795|Radiation|Radiation Therapy|Radiation Therapy
339757|NCT00535808|Drug|nitroprusside|Administration of nitroprusside
339758|NCT00535808|Drug|nitroglycerine|Administration of nitroglycerine
339759|NCT00003896|Drug|liposomal doxorubicin|
339760|NCT00535808|Drug|sevoflurane|Administration of Sevoflurane
339761|NCT00535821|Device|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
339762|NCT00535821|Device|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
339070|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
339071|NCT00507858|Drug|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
339072|NCT00507884|Procedure|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
339073|NCT00507923|Behavioral|Tibetan Yoga|4 sessions of yoga over 12 weeks.
339074|NCT00507923|Behavioral|Stretching Program|4 sessions of simple stretching exercises for 12 weeks. Each session lasting 90 minutes.
339075|NCT00507923|Other|No Intervention|Option of participating in the Tibetan yoga program after completion of the study.
339076|NCT00507923|Behavioral|Questionnaire|Questionnaires to be completed before and after the end of the yoga or stretching sessions (or similar time for the usual care group).
339077|NCT00507923|Behavioral|Booster Program|3 "booster" sessions consisting of a review and practice of the entire program.
339078|NCT00507936|Drug|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
339079|NCT00507936|Drug|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
339080|NCT00003749|Radiation|radiation therapy|
339081|NCT00507936|Drug|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
339082|NCT00507936|Drug|placebo|placebo capsule BID throughout the treatment period
339083|NCT00507936|Drug|Duloxetine|Duloxetine 60 mg QD throughout treatment period
339084|NCT00507949|Drug|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
339085|NCT00507949|Drug|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
339086|NCT00507962|Drug|Cisplatin|100 mg/m^2 Intraarterial On Day 1 Every 4 Weeks
339410|NCT00543504|Drug|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
339411|NCT00543504|Drug|Lapatinib|250 mg By Mouth Daily for 21 Days.
339412|NCT00543504|Drug|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
339413|NCT00543504|Drug|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
339414|NCT00543517|Drug|MK0767|
338415|NCT00521248|Drug|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
338416|NCT00003817|Drug|dolasetron mesylate|
338748|NCT00513383|Drug|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
338749|NCT00513383|Drug|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
338750|NCT00513383|Drug|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
338751|NCT00513383|Radiation|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
338752|NCT00513383|Drug|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
338753|NCT00003792|Procedure|in vitro-treated peripheral blood stem cell transplantation|
338754|NCT00515892|Procedure|Biological therapy|
338755|NCT00515892|Procedure|Antibody Therapy|
338756|NCT00515892|Procedure|Monoclonal Antibody Therapy|
338757|NCT00515905|Drug|Sevoflurane/propofol|Sevoflurane/propofol
338758|NCT00515918|Dietary Supplement|iron|
338759|NCT00515931|Radiation|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
338760|NCT00515944|Drug|Botulinum neurotoxin type A, free of complexing proteins|
338761|NCT00515957|Genetic|genetically modified CTLs in combo with CD45 antibodies|LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).
--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.
Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level <100 ng/ml)
--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
2x 10^7 cells/m2
1x 10^8 cells/m2 3 x 10^8 cells/m2
1 x 10^9 cells/m2
343328|NCT00529074|Device|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
343329|NCT00529087|Drug|N-methylnaltrexone bromide (MOA-728)|Subcutaneous
343330|NCT00529087|Other|placebo|placebo
343331|NCT00529100|Drug|Pemetrexed Phase 1|300 mg/m^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m^2 IV; then 500 mg/m^2 IV, repeated every 21 days (q 21 days) x 2 cycles
343332|NCT00529100|Drug|Cisplatin Phase 1|Cohorts 1-3: 25 mg/m^2 IV, Days 1-3 and 22-24 then 75 mg/m^2 IV, q21 days x 2 cycles
Cohort 4 carried into Phase 2: 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.
343333|NCT00529100|Procedure|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
343334|NCT00003862|Drug|fluorouracil|
343335|NCT00529100|Drug|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22.
343336|NCT00529100|Drug|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.
343337|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
343338|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
343339|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
343340|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
343341|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
343342|NCT00529113|Drug|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
343343|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
343658|NCT00520845|Drug|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
343659|NCT00003816|Drug|carboplatin|Given IV
343660|NCT00520845|Other|laboratory biomarker analysis|Blood collection
342667|NCT00542074|Other|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
342668|NCT00542087|Drug|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
342669|NCT00542087|Drug|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
342670|NCT00542100|Device|PCMRI|
342671|NCT00542113|Behavioral|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
342996|NCT00534469|Radiation|total-body irradiation|
342997|NCT00534482|Behavioral|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
342998|NCT00534482|Behavioral|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
342999|NCT00536939|Drug|placebo|oral, daily, until disease progression
343000|NCT00536952|Drug|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
343001|NCT00536952|Drug|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
343002|NCT00003902|Drug|capecitabine|
343003|NCT00536952|Radiation|Radiation Therapy|5 days per week for 4 weeks
343004|NCT00536978|Drug|ARA-C|100 mg/m^2 IV Daily Over 1 Hour for 4 Days
343005|NCT00536978|Drug|BCNU|300 mg/m^2 IV Over 1 Hour for 1 Day
343006|NCT00536978|Drug|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
343007|NCT00536978|Drug|Cyclophosphamide|1000 mg/m^2 IV Daily Over 1 Hour for 3 Days
343008|NCT00536978|Drug|Etoposide|100 mg/m^2 IV Daily Over 3 Hours for 4 Days
343009|NCT00536978|Drug|Fludarabine|30 mg/m^2 IV Daily Over 1 Hour for 3 Days
343010|NCT00536978|Drug|Melphalan|100 mg/m^2 IV Over 30 Minutes for 1 Day.
343011|NCT00536978|Drug|Rituximab|375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks.
343012|NCT00536978|Other|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
342307|NCT00547170|Drug|Doxycycline post-operatively|Two capsules of placebo "100 mg" before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
342308|NCT00547183|Drug|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
342309|NCT00547183|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
342310|NCT00547183|Drug|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
342311|NCT00003956|Drug|lonafarnib|
342312|NCT00547196|Biological|filgrastim|
342313|NCT00547196|Drug|busulfan|
342314|NCT00547196|Drug|cyclophosphamide|
342315|NCT00547196|Drug|cyclosporine|
342316|NCT00547196|Drug|fludarabine phosphate|
342317|NCT00547196|Drug|melphalan|
342318|NCT00547196|Drug|mycophenolate mofetil|
342319|NCT00547196|Procedure|allogeneic hematopoietic stem cell transplantation|
342320|NCT00547196|Procedure|umbilical cord blood transplantation|
342321|NCT00547196|Radiation|total-body irradiation|
342322|NCT00003957|Biological|filgrastim|
342323|NCT00547209|Drug|air|60% air combined with 40% oxygen for ventilation
342324|NCT00547209|Drug|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
342672|NCT00542113|Behavioral|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
342673|NCT00542113|Behavioral|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
342674|NCT00003934|Drug|daunorubicin hydrochloride|Given IV
342675|NCT00542126|Drug|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
341652|NCT00520000|Drug|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
341653|NCT00520000|Drug|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
341654|NCT00520000|Drug|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
341655|NCT00520000|Drug|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
341656|NCT00520013|Drug|bevacizumab|
341986|NCT00511836|Drug|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
341987|NCT00511849|Drug|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
341988|NCT00511862|Device|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
341989|NCT00511875|Drug|doxycycline monohydrate|50mg once daily for 24 months
341990|NCT00511875|Drug|placebo|placebo taken once daily for 24 months
341991|NCT00511901|Drug|placebo|
341992|NCT00511901|Drug|epoetin alpha|
341993|NCT00511901|Drug|Niferex|
341994|NCT00511914|Biological|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
341995|NCT00003777|Radiation|radiation therapy|
341996|NCT00511940|Drug|acamprosate|999 mg/day - 2997 mg/day, oral
341997|NCT00511940|Other|placebo|oral, placebo
341998|NCT00511953|Drug|Gabapentin Extended Release tablets|1800mg
341999|NCT00511953|Drug|Gabapentin|1800mg
342000|NCT00511966|Other|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
342001|NCT00511966|Drug|Rabeprazole|As prescribed
342002|NCT00511979|Drug|Technosphere Insulin|
341302|NCT00525603|Drug|Fludarabine|20 mg/m^2/day 3-5 IV 5-30 minutes
341303|NCT00525603|Drug|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
341304|NCT00525603|Drug|Rituximab|375 mg/m^2/day 2 IV 4-6 hours
341305|NCT00525616|Drug|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
341306|NCT00525629|Dietary Supplement|Walnuts|48 Grams of Walnuts Daily
341307|NCT00525629|Dietary Supplement|Control|Control Diet with No Walnuts
341308|NCT00003846|Procedure|bone marrow ablation with stem cell support|
341309|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
341310|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
341311|NCT00525655|Behavioral|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
341312|NCT00528242|Drug|Placebo|
341313|NCT00528255|Drug|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
341314|NCT00528268|Drug|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
341315|NCT00528281|Drug|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
341316|NCT00528281|Drug|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
341317|NCT00528294|Radiation|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
341318|NCT00528307|Device|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
341657|NCT00520013|Drug|erlotinib|
341658|NCT00520013|Drug|paclitaxel|
341659|NCT00520013|Drug|carboplatin|
339241|NCT00524511|Device|Surgical skin staples|Standard method to close abdominal surgical wounds
339242|NCT00524511|Device|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
339243|NCT00524524|Drug|ARQ 501|Weekly IV Infusion; 450 mg/m2
339244|NCT00527332|Drug|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
339245|NCT00527332|Drug|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
339246|NCT00527332|Drug|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
339247|NCT00527332|Drug|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
339248|NCT00527332|Drug|Morphine|5 mg is given IV (intravenously) before end of surgery
339249|NCT00527358|Behavioral|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;
youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;
school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;
Youth drop-in center will provide youth with an adult supervised place to "hang out", do homework, or participate in sports and job training.
339250|NCT00527371|Device|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
339594|NCT00519116|Drug|Rapamune® (Sirolimus)|
339595|NCT00519116|Drug|Tacrolimus|
339596|NCT00519116|Drug|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
339597|NCT00519129|Device|3D-imager|3D-imager vs fluoroscopy during coloscopy
339598|NCT00003811|Drug|cisplatin|
339599|NCT00519142|Drug|placebo for mitiglinide|three times a day with meals
339600|NCT00519142|Drug|mitiglinide|three times a day with meals
339601|NCT00519142|Drug|mitiglinide|two times a day with meals
338907|NCT00532779|Drug|Placebo|
338908|NCT00532779|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
338909|NCT00000566|Procedure|angiography|
338910|NCT00003877|Drug|paclitaxel|
338911|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
338912|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
338913|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
338914|NCT00535353|Drug|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
338915|NCT00535366|Drug|Tiotropium|Oral inhalation by HandiHaler® device
338916|NCT00535366|Drug|Salmeterol|Oral inhalation from Diskus®
338917|NCT00535366|Drug|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
338918|NCT00535366|Drug|Ciclesonide low|Oral inhalation from MDI
338919|NCT00535366|Drug|Ciclesonide high|Oral inhalation from MDI
338920|NCT00003893|Radiation|radiation therapy|
338921|NCT00535366|Drug|Placebo|Oral inhalation from MDI
338922|NCT00535379|Drug|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
338923|NCT00535392|Drug|Levetiracetam|Intravenous 100 mg/mL, twice a day, maximum of 4 days
Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.
Dosage for subjects not on levetiracetam at study entry was based on weight: if <50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily).
338924|NCT00535405|Drug|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
338925|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
338251|NCT00548236|Behavioral|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
338252|NCT00548249|Device|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
338253|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
338254|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
338255|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
338256|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
338257|NCT00548262|Drug|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
338258|NCT00548262|Drug|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if <40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if <40 kg body weight).
338259|NCT00548275|Behavioral|Enhanced Sexual Risk Management|management of sexual risk
338260|NCT00000579|Procedure|Positive End-Expiratory Pressure|
338261|NCT00003958|Drug|topotecan hydrochloride|Given IV
338262|NCT00548275|Behavioral|Standard Sexual Risk Management|management of sexual risk
338263|NCT00548288|Drug|pamidronate|
338264|NCT00548301|Drug|cyclosporine|
338595|NCT00540527|Drug|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
338596|NCT00540527|Drug|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
338597|NCT00543010|Drug|MK0767|
337578|NCT00430950|Drug|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
337579|NCT00430963|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|
337580|NCT00430963|Drug|Placebo|
337581|NCT00430976|Behavioral|Minds in Motion|
337910|NCT00513058|Drug|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
337911|NCT00513058|Drug|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
337912|NCT00513071|Drug|saracatinib|Given orally
337913|NCT00513071|Other|laboratory biomarker analysis|Correlative studies
337914|NCT00513084|Behavioral|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
337915|NCT00513097|Behavioral|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
337916|NCT00513097|Behavioral|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
337917|NCT00513097|Behavioral|Survey|On-line evaluations and questionnaires
337918|NCT00513110|Genetic|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
337919|NCT00003783|Drug|asparaginase|
337920|NCT00513110|Drug|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
337921|NCT00513110|Drug|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
337922|NCT00513123|Procedure|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
337923|NCT00513136|Behavioral|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
337924|NCT00513136|Behavioral|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
336818|NCT00445198|Drug|ABT-263|Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.
- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.
Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.
- 40 patients with SCLC
336819|NCT00445211|Drug|Heparin|Heparin administered at 500units/hour while IABP in position.
336820|NCT00003446|Drug|trimetrexate glucuronate|
336821|NCT00445224|Other|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
336822|NCT00445224|Other|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
336823|NCT00445237|Device|H1 and H2 deep TMS coils|
336824|NCT00445250|Drug|Calcipotriol|
336825|NCT00445263|Drug|TIROFIBAN|intravenous infusion
336826|NCT00445263|Procedure|CORONAROGRAPHY|standard procedure of coronarography
336827|NCT00445276|Drug|Diacerein|
337196|NCT00436722|Drug|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
337197|NCT00436735|Drug|midazolam hydrochloride|
337198|NCT00436735|Drug|nelfinavir mesylate|
337199|NCT00436735|Genetic|gene expression analysis|
337200|NCT00436735|Genetic|polymerase chain reaction|
337201|NCT00003413|Procedure|surgical procedure|
337202|NCT00439426|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
337203|NCT00439426|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
337204|NCT00439439|Radiation|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
335721|NCT00421811|Drug|ADH-1|4 gm IV Days 1 and 8
336077|NCT00459810|Drug|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
336078|NCT00459823|Drug|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
336079|NCT00459836|Drug|PR-104|
336080|NCT00459836|Drug|docetaxel|
336081|NCT00459836|Drug|gemcitabine hydrochloride|
336082|NCT00459836|Other|laboratory biomarker analysis|
336083|NCT00000528|Behavioral|diet, sodium-restricted (Phase III) diet, sodium-restricted|
336084|NCT00003531|Drug|antineoplaston AS2-1|
336085|NCT00459836|Other|pharmacological study|
336086|NCT00459849|Procedure|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
336087|NCT00459862|Other|laboratory biomarker analysis|Correlative study
336088|NCT00459862|Drug|pazopanib hydrochloride|Given orally
336089|NCT00459875|Drug|sunitinib malate|
336090|NCT00459888|Device|PolarCath Peripheral Dilatation System (Boston Scientific)|
336091|NCT00459901|Drug|Erlotinib and capecitabine|
336092|NCT00459914|Device|cpap treatment during sleep|CPAP
336093|NCT00459927|Device|Floseal tonsillectomy|
336094|NCT00459927|Device|Coblation tonsillectomy|
336095|NCT00003532|Drug|antineoplaston A10|
336096|NCT00415792|Drug|Arvekap, Pregnyl|
336097|NCT00415805|Drug|Multihance|0.5 Molar, single injection at 0.2 mL/kg
336098|NCT00415805|Drug|vasovist|0.25 molar single injection 0.03 ml/kg
334995|NCT00438594|Behavioral|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
334996|NCT00003421|Drug|doxorubicin hydrochloride|
334997|NCT00438607|Drug|BIIB014|oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
334998|NCT00438607|Drug|Placebo|Matched placebo for MTD or MTD-1
334999|NCT00438620|Behavioral|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
335000|NCT00438659|Drug|mometasone furoate|Applied to treatment area
335001|NCT00438659|Other|placebo|Applied to treatment area
335002|NCT00438672|Drug|Placebo Injection|Injection without steroid
335003|NCT00438672|Drug|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
335004|NCT00438685|Behavioral|Outpatient MST/OPTION-A|
335349|NCT00430040|Drug|carvedilol|carvedilol
335350|NCT00430040|Drug|lisinopril|lisinopril
335351|NCT00430053|Genetic|gene rearrangement analysis|
335352|NCT00430053|Genetic|polymerase chain reaction|
335353|NCT00430053|Genetic|proteomic profiling|
335354|NCT00430053|Other|flow cytometry|
335355|NCT00430053|Other|immunohistochemistry staining method|
335356|NCT00003396|Drug|melphalan|
335357|NCT00430053|Procedure|biopsy|
335358|NCT00430066|Drug|Imatinib Mesylate|400 mg/die for 6 months
335359|NCT00430079|Drug|etanidazole|Given IV
335360|NCT00430079|Procedure|conventional surgery|Undergo surgery
335361|NCT00430079|Other|pharmacological study|Correlative studies
335362|NCT00430079|Other|laboratory biomarker analysis|Correlative studies
334636|NCT00444470|Drug|Placebo|Eligible patients who have consented to be in the study and have been randomised to be in Arm "B" will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo.
334637|NCT00444483|Behavioral|Structured diabetes teaching and treatment program|
334638|NCT00446992|Drug|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
334639|NCT00447005|Drug|Axitinib (AG-013736)|AG-013736 5mg twice daily [BID]
334640|NCT00003457|Drug|antineoplaston AS2-1|
334641|NCT00447018|Drug|20% mannitol|
334642|NCT00447018|Drug|7.45% hypertonic saline solution|
334643|NCT00447031|Drug|intravitreal bevacizumab and triamcinolone acetonide|
334644|NCT00447044|Behavioral|Resistance Exercise|Subjects will lift weights with their legs.
334645|NCT00447044|Dietary Supplement|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
334646|NCT00447044|Dietary Supplement|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
334647|NCT00447057|Drug|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
334648|NCT00447057|Drug|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
334649|NCT00447057|Drug|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
334650|NCT00447057|Drug|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
334651|NCT00003458|Drug|antineoplaston A10|
334652|NCT00447070|Drug|ATAZANAVIR|
334653|NCT00447083|Procedure|Ultraviolet Light|
334654|NCT00447096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
334655|NCT00447109|Device|Closed system suction|
335005|NCT00438685|Behavioral|Usual Services|
335006|NCT00438698|Other|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
339763|NCT00535834|Procedure|diagnostic procedure|
339764|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
339765|NCT00538109|Drug|Glivec®/Gleevec®|Chemotherapy
339766|NCT00538122|Device|24 Holter Monitor Recording|All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.
From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects.
339767|NCT00538135|Behavioral|Cognitive Behavioural Therapy|
339768|NCT00538135|Other|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
339769|NCT00538148|Drug|Telithromycin|
339770|NCT00538161|Other|Ventilation strategy|
339771|NCT00538174|Drug|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
334291|NCT00452816|Behavioral|Workplace Solutions Consulting approach|Consulting process includes:
baseline measure of best practices
gap analysis and recommendations reporting
delivery of "solution set" toolkits for each practice chosen for implementation
334292|NCT00452816|Behavioral|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
334293|NCT00455429|Drug|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
334294|NCT00455429|Drug|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
334295|NCT00455429|Drug|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
334296|NCT00455429|Drug|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
334297|NCT00455442|Drug|Mifepristone|
334298|NCT00455455|Drug|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
334299|NCT00455455|Drug|ReNu Multiplus Multipurpose Solution|lens care system
334300|NCT00455468|Procedure|Day-care treatment vs. hospital care|
334301|NCT00455494|Drug|AQ-13|
339415|NCT00543530|Drug|MK0831|
339416|NCT00543543|Biological|Comparator: GARDASIL|GARDASIL (quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
339417|NCT00543543|Biological|Experimental: V503|V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
339418|NCT00003941|Biological|bleomycin sulfate|
339419|NCT00543556|Drug|MK0767|
339420|NCT00543569|Drug|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
339421|NCT00543569|Drug|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
339422|NCT00543569|Drug|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
339423|NCT00543569|Drug|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
339424|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
339425|NCT00545922|Behavioral|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
339426|NCT00545922|Behavioral|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
339427|NCT00545935|Drug|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
339428|NCT00545935|Drug|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
339429|NCT00545935|Drug|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
339430|NCT00545948|Drug|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
339772|NCT00538174|Drug|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
339773|NCT00538187|Drug|obatoclax mesylate|Given IV
339774|NCT00003912|Drug|doxorubicin hydrochloride|
339775|NCT00538187|Drug|bortezomib|Given IV
338762|NCT00515970|Procedure|Curettage|Curettage without subcutaneous tissue using a 7 mm ring curette and the "fountain-pen technique" (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm.
338763|NCT00515970|Procedure|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
338764|NCT00003793|Genetic|clonality analysis|
339087|NCT00507962|Drug|Liposomal Doxorubicin|Starting dose 20 mg/m^2 IV On Day 1 Every 4 Weeks
339088|NCT00507975|Drug|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
339089|NCT00507988|Behavioral|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
339090|NCT00507988|Behavioral|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
339091|NCT00003750|Biological|hu14.18-IL2 fusion protein|
339092|NCT00508001|Drug|Vandetanib|ZD6474 300mg
339093|NCT00508001|Drug|Vandetanib|ZD6474 100 mg
339094|NCT00508001|Drug|Best Supportive Care|Placebo + Best Supportive Care
339095|NCT00508014|Other|Usual Care|Usual Care with primary care provider during time period
339096|NCT00508014|Behavioral|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
339097|NCT00510445|Drug|Imetelstat Sodium (GRN163L)|The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.
Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle.
339098|NCT00510458|Device|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
339099|NCT00510471|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
343661|NCT00520858|Other|Resistance Exercise (RE)|
343662|NCT00520858|Other|Aerobic Exercise (AE)|
343663|NCT00520858|Other|Resistance and Aerobic Exercise (RAE)|
343664|NCT00520871|Drug|Blueberry juice|
343665|NCT00523380|Drug|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
343666|NCT00523393|Drug|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
343667|NCT00523393|Drug|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
343668|NCT00523406|Procedure|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
343669|NCT00523419|Drug|Pemetrexed|500 mg/m^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
343670|NCT00523432|Drug|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
343671|NCT00523432|Drug|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
343672|NCT00523445|Drug|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
343673|NCT00000558|Drug|angiotensin-converting enzyme inhibitors|
343674|NCT00003832|Procedure|conventional surgery|Undergo surgery
343675|NCT00523445|Drug|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
343676|NCT00523458|Drug|efavirenz or nevirapine|Patients co-infected with HIV and TB will receive either "standard" doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or "high" doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin.
343677|NCT00523471|Procedure|Blood test|
343678|NCT00523497|Device|Non invasive mechanical ventilation|
343679|NCT00523510|Procedure|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
343013|NCT00003902|Drug|vinorelbine tartrate|
343014|NCT00536978|Radiation|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
343015|NCT00536978|Drug|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
343016|NCT00536978|Drug|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
343017|NCT00536978|Procedure|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
343018|NCT00536991|Dietary Supplement|Calcitriol|Given PO
343019|NCT00536991|Drug|Ketoconazole|Given PO
343344|NCT00529113|Drug|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
343345|NCT00003862|Drug|leucovorin calcium|
343346|NCT00529113|Drug|Placebo|Placebo capsules x 28 days
343347|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
343348|NCT00529126|Drug|SKY0402|SKY0402
343349|NCT00529126|Drug|Bupivacaine HCl|Bupivacaine HCl
343350|NCT00529139|Device|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
343351|NCT00531791|Drug|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
343352|NCT00531804|Drug|gantenerumab|Administered iv at escalating doses (7 cohorts)
343353|NCT00531817|Drug|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
343354|NCT00531817|Drug|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
343355|NCT00531817|Drug|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
342676|NCT00542139|Drug|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
342677|NCT00542139|Drug|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
342678|NCT00544687|Drug|Vehicle|topical (placebo)
342679|NCT00003944|Drug|cyclophosphamide|
342680|NCT00544700|Biological|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
342681|NCT00544700|Other|no maintenance|No treatment until progression
342682|NCT00544713|Drug|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
342683|NCT00544713|Drug|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
342684|NCT00544726|Behavioral|Physical training|
342685|NCT00544726|Behavioral|No training|
342686|NCT00544752|Other|16|indoor temperature of 16 degrees celcius
342687|NCT00544752|Other|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
342688|NCT00544752|Other|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
342689|NCT00544765|Drug|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
342690|NCT00003944|Drug|paclitaxel|
342691|NCT00544765|Drug|NX|Vinorelbine 25 mg/m² as a < 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
342692|NCT00544778|Biological|filgrastim|
342693|NCT00544778|Drug|dexrazoxane hydrochloride|
342694|NCT00544778|Drug|doxorubicin hydrochloride|
342695|NCT00544778|Drug|ifosfamide|
343020|NCT00536991|Other|Laboratory Biomarker Analysis|Correlative studies
343021|NCT00536991|Other|Pharmacological Study|Correlative studies
342003|NCT00511979|Drug|Technosphere insulin|
342004|NCT00511979|Drug|Technosphere insulin|
342005|NCT00511979|Drug|Regular human insulin|
342006|NCT00003778|Drug|dolastatin 10|
342007|NCT00514423|Other|Video-education|
342008|NCT00514423|Other|Noneducational video group (control group)|
342009|NCT00514436|Behavioral|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
342010|NCT00514449|Drug|Valacyclovir + Antipsychotic|1 g PO BID x 4 weeks after 4 weeks it goes up to 1.5 g PO BID x 12 weeks
342325|NCT00549926|Drug|Pravastatin|
342326|NCT00549926|Drug|Pitavastatin|
342327|NCT00549926|Drug|Atorvastatin|
342328|NCT00549939|Drug|Alfuzosin|Form: solution or tablet according to age
Route: oral
Dose: daily dose adjusted to body weight
342329|NCT00549939|Drug|Placebo|Form: matching solution or matching tablet according to age
Route: oral
Dose: daily dose adjusted to body weight
342330|NCT00549952|Other|no intervention study|
342331|NCT00549965|Drug|Risedronate Sodium|
342332|NCT00549978|Drug|Cilostazol|cilostazol, then cilostazol/probucol
342333|NCT00003972|Biological|sargramostim|
342334|NCT00549978|Drug|Probucol|Probucol probucol/ cilostazol
342335|NCT00550004|Drug|RP101|190 mg oral tablet
342336|NCT00550004|Drug|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
342337|NCT00550017|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
342338|NCT00550030|Radiation|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
342339|NCT00550030|Other|No treatment|no UV exposure
341660|NCT00003815|Drug|cyclophosphamide|
341661|NCT00520026|Drug|lithium|
341662|NCT00520026|Drug|placebo|
341663|NCT00520039|Procedure|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
341664|NCT00520052|Drug|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
341665|NCT00520065|Other|enteral nutritional formula|Meal glucose tolerance test
341666|NCT00520065|Other|Diabetes specific enteral product|Meal Glucose tolerance test
341667|NCT00520091|Drug|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
341668|NCT00520091|Drug|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
341669|NCT00520091|Drug|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
341670|NCT00520091|Radiation|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
341671|NCT00003815|Drug|cytarabine|
341672|NCT00520091|Procedure|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
341673|NCT00520104|Drug|intranasal ketamine|drug interaction
341674|NCT00520130|Biological|Rituximab|Rituximab: 375 mg/m2 IV, day 1 for patients with CD20-positive disease
341675|NCT00520130|Drug|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if GVHD does not develop.
341676|NCT00520130|Drug|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
341677|NCT00522587|Drug|Fixed remifentanil dose 2|Dose 2 of remifentanil
341678|NCT00522587|Drug|Fixed remifentanil dose 3|Dose 3 of remifentanil
341679|NCT00522587|Drug|Fixed remifentanil dose 4|Dose 4 of remifentanil
341680|NCT00522587|Drug|Fixed remifentanil dose 5|Dose 5 of remifentanil
341681|NCT00522587|Drug|Fixed remifentanil dose 6|Dose 6 of remifentanil
339602|NCT00519155|Drug|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
339603|NCT00519155|Procedure|Open flap debridement|Open flap debridement alone
339604|NCT00519168|Procedure|Urine sample|Standard of care
339605|NCT00519168|Device|Electrode sleep recorder|Standard of care
339606|NCT00519168|Procedure|phlebotomy|Standard of care
339607|NCT00519181|Drug|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
339608|NCT00519194|Device|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
339609|NCT00003811|Drug|etoposide|
339610|NCT00519194|Procedure|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
339611|NCT00521638|Biological|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
339612|NCT00521664|Biological|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
339613|NCT00003819|Biological|QS21|
339614|NCT00521664|Biological|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
339615|NCT00521677|Procedure|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
339616|NCT00521677|Procedure|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
339617|NCT00521690|Drug|insulin detemir|
339618|NCT00521703|Drug|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
334125|NCT00438230|Drug|Warfarin|
334126|NCT00438243|Drug|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
334127|NCT00438243|Drug|Refresh Plus|1 drop in the affected eye twice daily
334128|NCT00438256|Procedure|Proton Beam Radiation|Given over different schedules and duration
334129|NCT00438256|Drug|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
338926|NCT00535405|Drug|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
338927|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
339251|NCT00527371|Procedure|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
339252|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
339253|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
339254|NCT00003854|Radiation|whole breast irradiation|
339255|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
339256|NCT00527410|Drug|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
339257|NCT00527423|Drug|VEGF Trap Eye|Intravitreal injection
339258|NCT00527436|Dietary Supplement|fish oil|
339259|NCT00527449|Drug|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
339260|NCT00527462|Procedure|Bronchoscopy|bronchoscopy with segmental allergen challenge
339261|NCT00527462|Other|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
339262|NCT00527475|Drug|ranibizumab|0.5 mg. given as an intraocular injection
339263|NCT00527475|Drug|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
339264|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
339265|NCT00529984|Biological|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
339266|NCT00529984|Biological|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
338598|NCT00543023|Drug|teriparatide 20 micrograms/day subcutaneous|
338599|NCT00543023|Drug|salmon calcitonin 100 IU/day subcutaneous|
338600|NCT00543036|Device|H-Coil deep TMS|
338601|NCT00543049|Drug|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
338602|NCT00543049|Drug|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
338603|NCT00543062|Drug|Prochlorperazine|
338604|NCT00543075|Drug|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
338605|NCT00543101|Drug|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
338606|NCT00003937|Drug|etoposide|
338607|NCT00543101|Drug|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
338608|NCT00543114|Drug|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
338609|NCT00543114|Drug|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
338610|NCT00543114|Drug|Rituximab|Given intravenously on Day 1 of each 28 day cycle
338611|NCT00543127|Drug|fulvestrant + anastrozol|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral anastrozol per day during 5 years.
338612|NCT00543127|Drug|Anastrozol|1 mg oral Anastrozol per day during 5 years.
338613|NCT00543140|Device|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
338928|NCT00535405|Drug|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
338929|NCT00535418|Drug|Letrozole|
338930|NCT00535431|Drug|AER 001|60 mg (in nebuliser), twice daily for 28 days
338931|NCT00003894|Drug|thalidomide|
338932|NCT00535431|Drug|placebo|Sterile saline nebulised, twice daily for 28 days
337925|NCT00513149|Drug|Clopidogrel|Clopidogrel 600 mg loading
337926|NCT00515411|Drug|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17
* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg
Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter.
337927|NCT00003792|Biological|filgrastim|
337928|NCT00515424|Drug|RKI983|
338265|NCT00548314|Other|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
338266|NCT00548314|Procedure|Split skin graft|
338267|NCT00548314|Device|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
338268|NCT00548327|Drug|Atomoxetine|Comparison between Atomoxetine and Placebo
338269|NCT00550732|Drug|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
338270|NCT00550745|Biological|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
338271|NCT00550745|Biological|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
338272|NCT00550758|Drug|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
338273|NCT00550758|Device|spirometry|spirometry
338274|NCT00550771|Drug|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m^2 IV push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
338275|NCT00550771|Drug|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
338276|NCT00550784|Biological|filgrastim|
338277|NCT00003974|Drug|cyclophosphamide|
338278|NCT00550784|Drug|cisplatin|
338279|NCT00550784|Drug|cyclophosphamide|
338280|NCT00550784|Drug|melphalan|
337205|NCT00439452|Other|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
337206|NCT00439452|Other|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
337207|NCT00003423|Drug|asparaginase|
337208|NCT00439465|Biological|Autologous ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
337209|NCT00439478|Drug|Radioiodine|
337210|NCT00439491|Behavioral|Hypocaloric diet|
337211|NCT00439504|Drug|Lobeline|
337212|NCT00439517|Drug|UFOX + Cetuximab|Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)
Oxaliplatin infusion (85mg/m^2) on days 1 and 15 (every 2 weeks)
Oral UFT® (250mg/m^2 tegafur + 560 mg/m^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21
Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21
337213|NCT00439517|Drug|FOLFOX4 + Cetuximab|Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)
Oxaliplatin infusion (85 mg/m^2) on days 1 and 15 (every 2 weeks)
5-FU bolus + infusions (400 mg/m^2) on days 1, 2, 15 and 16
Folinic Acid infusions (200 mg/m^2) on days 1, 2, 15 and 16
337214|NCT00439530|Drug|oseltamivir|
337215|NCT00439530|Drug|probenecid|
337582|NCT00430989|Drug|Nitrous Oxide|70% N2O V's No N2O
337583|NCT00430989|Drug|Nitrous Oxide|N2O 70% v's No N2O
337584|NCT00431002|Behavioral|Resistance training|See Detailed Description.
337585|NCT00431015|Drug|IPI-504|IV Hsp90 inhibitor
337586|NCT00003397|Drug|paclitaxel|
337587|NCT00431028|Device|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
337588|NCT00431041|Drug|solifenacin|Oral
336099|NCT00415818|Biological|MVA-MUC1-IL2|MVA-MUC1-IL2:
Dose of 10exp8 plaque forming units (pfu).
Chemotherapy:
Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first.
336100|NCT00415818|Drug|1st line Chemotherapy|
336101|NCT00415831|Drug|ELC200 (carbidopa+levodopa+entacapone)|
336102|NCT00415844|Drug|ELC200 (carbidopa+levodopa+entacapone)|
336463|NCT00453622|Device|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
336464|NCT00453635|Drug|Docetaxel|Docetaxel at the dose of 75mg/m^2 IV on day 1 every 3 weeks for 6 consecutive cycles
336465|NCT00453635|Drug|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
336466|NCT00453635|Drug|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
336467|NCT00453635|Drug|Vinorelbine|Vinorelbine at the dose of 60mg/m^2 per os,weekly
336468|NCT00453648|Behavioral|Consumption of orange-fleshed sweet potatoes|Two servings of orange-fleshed sweet potatoes are delivered to women daily for 60 days
336469|NCT00453661|Behavioral|Questionnaire|Intervention Group:
Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.
Comparison Group:
Exit Questionnaire only.
336470|NCT00453661|Behavioral|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
336471|NCT00003500|Drug|antineoplaston AS2-1|
336472|NCT00453687|Drug|GSK233705|
336473|NCT00453700|Procedure|Trypanosoma cruzi serology|
336474|NCT00453726|Procedure|Non invasive mechanical ventilation|
336475|NCT00453765|Drug|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
336476|NCT00453765|Drug|placebo|placebo
336477|NCT00453778|Drug|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
336478|NCT00453791|Drug|GW805858|
336479|NCT00453804|Drug|injectable naltrexone|
336480|NCT00453804|Drug|oral naltrexone|
335363|NCT00430092|Drug|Difluprednate|
335364|NCT00430092|Drug|Difluprednate|
335365|NCT00430092|Drug|Placebo|
335366|NCT00430105|Drug|cyclophosphamide|
335367|NCT00003396|Procedure|peripheral blood stem cell transplantation|
335368|NCT00430118|Drug|asparaginase|
335369|NCT00430118|Drug|cyclophosphamide|
335370|NCT00430118|Drug|cytarabine|
335371|NCT00430118|Drug|daunorubicin hydrochloride|
335372|NCT00430118|Drug|dexamethasone|
335373|NCT00430118|Drug|doxorubicin hydrochloride|
335374|NCT00430118|Drug|etoposide|
335375|NCT00430118|Drug|ifosfamide|
335376|NCT00433043|Procedure|CRT (cardiac resynchronization therapy)|Both arms
335377|NCT00433056|Other|STI|CD4 guided treatment interruption
335722|NCT00421811|Drug|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
335723|NCT00421824|Drug|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
335724|NCT00003354|Procedure|laparoscopic surgery|
335725|NCT00421824|Drug|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
335726|NCT00421850|Behavioral|UNITED Planned Care|
335727|NCT00421863|Drug|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
335728|NCT00421863|Drug|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
335729|NCT00424190|Drug|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
335007|NCT00003421|Drug|etoposide|
335008|NCT00438698|Other|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
335009|NCT00438724|Behavioral|Information, counseling and support|
335010|NCT00438737|Biological|bevacizumab|
335011|NCT00438737|Biological|cetuximab|
335012|NCT00438737|Drug|fluorouracil|
335013|NCT00438737|Drug|leucovorin calcium|
335014|NCT00438737|Drug|oxaliplatin|
335015|NCT00438737|Procedure|adjuvant therapy|
335016|NCT00438737|Procedure|conventional surgery|
335017|NCT00438737|Procedure|neoadjuvant therapy|
335018|NCT00003421|Drug|prednisolone|
335019|NCT00438750|Other|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
335020|NCT00438750|Other|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
335021|NCT00438776|Drug|olanzapine|2.5mg to 15mg daily
335022|NCT00438776|Drug|sugar pill|matching placebo to olanzapine
335023|NCT00441142|Radiation|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
335024|NCT00441155|Drug|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
335025|NCT00003430|Drug|L-778,123|
335026|NCT00441168|Drug|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
335027|NCT00441168|Drug|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
334302|NCT00455507|Drug|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
334303|NCT00000526|Drug|encainide|
334304|NCT00003512|Drug|antineoplaston AS2-1|
334305|NCT00455507|Drug|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
334306|NCT00455507|Drug|Placebo|Two placebo tablets orally once daily for 12 weeks
334307|NCT00455520|Drug|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
334308|NCT00455520|Drug|placebo|matching placebo twice daily for 12 weeks
334309|NCT00455533|Drug|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
334310|NCT00455533|Drug|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
334311|NCT00455533|Drug|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
334312|NCT00455533|Drug|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
334313|NCT00455546|Drug|A-002|
334314|NCT00455559|Drug|Perifosine|All patients: Imatinib mesylate
334315|NCT00003513|Drug|antineoplaston A10|
334656|NCT00447122|Drug|gemcitabine and Lapatinib|
334657|NCT00447148|Procedure|3-dimensional coronary angiography|3-dimensional coronary angiography
334658|NCT00447161|Drug|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water
334659|NCT00447161|Drug|Placebo|Matched placebo
334660|NCT00447174|Behavioral|Dyadic treatment for parental bereavement|
334661|NCT00447187|Drug|LX201|LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.
LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
334662|NCT00003458|Drug|antineoplaston AS2-1|
334663|NCT00447187|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
339776|NCT00538187|Other|laboratory biomarker analysis|correlative study
339777|NCT00538187|Other|pharmacological study|correlative study
339778|NCT00538200|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
339779|NCT00538200|Other|Dietary Advice|Standard dietary advice
339780|NCT00538213|Biological|Fluarix™|Single dose, Intramuscular injection
339781|NCT00538213|Biological|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
339782|NCT00538226|Device|External Electric Muscle Stimulation|
339783|NCT00538239|Drug|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
339784|NCT00538239|Drug|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
339785|NCT00003912|Procedure|conventional surgery|
339786|NCT00538265|Drug|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
339787|NCT00540865|Behavioral|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
339788|NCT00540865|Behavioral|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
339789|NCT00540878|Drug|SB-751689 oral tablets (400 mg)|
339790|NCT00540891|Drug|ALFUZOSIN|
339791|NCT00003927|Drug|cyclophosphamide|
339792|NCT00540904|Drug|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
334316|NCT00455559|Drug|Imatinib Mesylate|All patients: Imatinib mesylate
339100|NCT00510484|Drug|Pancrelipase Delayed Release|24000 unit Capsule
339101|NCT00510484|Drug|Placebo Comparator|Placebo
339102|NCT00510497|Biological|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
339103|NCT00003771|Biological|therapeutic estradiol|
339104|NCT00510510|Drug|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
339105|NCT00510510|Drug|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
339106|NCT00510510|Drug|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
339107|NCT00510523|Device|Whole Body Vibration machine|
339431|NCT00545948|Drug|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
339432|NCT00545961|Drug|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
339433|NCT00545961|Drug|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
339434|NCT00003954|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
339435|NCT00545974|Drug|memantine|memantine 10mg BID
339436|NCT00545974|Drug|Placebo pill|Placebo pill BID
339437|NCT00545987|Device|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
339438|NCT00545987|Device|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
339439|NCT00546000|Drug|Fluticasone propionate 0.05% lotion|Daily applications
339440|NCT00546026|Other|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
339441|NCT00546039|Drug|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
339442|NCT00546039|Drug|Placebo|Capsule
344008|NCT00515333|Drug|TRx0014|Hard capsule; 30 milligrams; t.i.d.
344009|NCT00515333|Drug|Placebo|Hard capsule; 0 milligrams; t.i.d.
344010|NCT00515333|Drug|TRx0014|Hard capsule, 100 milligrams, t.i.d.
344011|NCT00515346|Device|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
344012|NCT00003792|Biological|MART-1 antigen|
344013|NCT00515359|Procedure|Intermittent Propofol Sedation|Intermittent versus continuous dosage
344014|NCT00515359|Procedure|Continuous Propofol Sedation|intermittent vs continuous dosage
344015|NCT00515372|Other|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
344016|NCT00515372|Other|Usual Care|Lists of professional resources and referral recommendations will be provided.
344017|NCT00515385|Drug|MGAWN1|Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.
Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
344018|NCT00515385|Drug|MGAWN1|Single IV dose
344019|NCT00515385|Other|Placebo|Single IV dose
344020|NCT00515398|Other|Observation|Ex vivo administration of AT2220
344021|NCT00515411|Drug|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
344022|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
344023|NCT00518180|Biological|Tdap Vaccine|One dose of vaccine administered intramuscularly
344024|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
344025|NCT00518193|Drug|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
344026|NCT00518206|Biological|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOMATRIX® vaccine intramuscular injection every 4 weeks for 3 doses (1 cycle). NY-ESO-1 ISCOMATRIX® vaccine (100 microgram of NY-ESO-1 protein formulated with 120 microgram of ISCOMATRIX® adjuvant). Treatment may continue for further cycles unless other systemic melanoma treatment is required. (This cohort was completed in 2005)
343356|NCT00531843|Drug|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
343357|NCT00531843|Device|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
343358|NCT00531856|Drug|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
343359|NCT00003874|Biological|monoclonal antibody CD20|
343360|NCT00531856|Drug|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
343361|NCT00531856|Drug|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
343362|NCT00531856|Drug|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
343363|NCT00531856|Drug|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
343364|NCT00531869|Behavioral|biases towards products|
343680|NCT00523523|Behavioral|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
343681|NCT00523523|Behavioral|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
343682|NCT00523536|Behavioral|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
343683|NCT00523549|Drug|valsartan|160 mg or 320 mg tablets once a day
343684|NCT00523549|Drug|amlodipine|5 mg or 10 mg tablets once a day
343685|NCT00003832|Other|laboratory biomarker analysis|Correlative studies
343686|NCT00003852|Drug|carboplatin|
343687|NCT00526318|Drug|doxorubicin hydrochloride|
343688|NCT00526318|Drug|etoposide phosphate|
343022|NCT00536991|Drug|Therapeutic Hydrocortisone|Given PO
343023|NCT00537017|Drug|SCH 420814|SCH 420814, 5 mg BID
343024|NCT00000571|Device|ventilators, negative pressure|
343025|NCT00003903|Procedure|management of therapy complications|
343026|NCT00537030|Other|laboratory biomarker analysis|Correlative studies
343027|NCT00537030|Other|pharmacological study|Correlative studies
343028|NCT00537030|Drug|asparaginase|Given IM
343029|NCT00539422|Genetic|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
343030|NCT00539435|Procedure|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
343031|NCT00539448|Drug|insulin glargine|in combination with insulin Glulisine as bolus regimen
343032|NCT00539448|Drug|insulin glulisine|in combination with insulin Glargine as bolus regimen
343033|NCT00539474|Procedure|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
343034|NCT00539500|Drug|Carboplatin|Carboplatin by vein over 24 hours x 4 days, dosing as determined at day 1.
343035|NCT00539500|Drug|Etoposide|300 mg/m^2 by vein over 24 Hours x 4 Days
343036|NCT00003920|Biological|filgrastim|
343037|NCT00539500|Drug|Melphalan|70 mg/m^2 Intravenous Bolus x 3 Days
343038|NCT00539500|Procedure|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10^8 TNC cells/kg CD133+ selected) on Day 0.
343039|NCT00539500|Device|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
343040|NCT00539513|Drug|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
343041|NCT00539513|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
343042|NCT00539526|Drug|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
342340|NCT00550043|Drug|INCB018424|
342341|NCT00550043|Drug|Placebo|
342342|NCT00550056|Behavioral|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
342343|NCT00550056|Behavioral|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
342344|NCT00003972|Drug|busulfan|
342345|NCT00550095|Drug|valsartan|
342346|NCT00550108|Other|Ethanol lavage|Ethanol lavage of pancreatic cysts.
342347|NCT00550121|Drug|vitamin C|
342348|NCT00550121|Drug|placebo|
342349|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
342696|NCT00544778|Drug|irinotecan hydrochloride|
342697|NCT00544778|Genetic|protein expression analysis|
342698|NCT00544778|Other|immunoenzyme technique|
342699|NCT00544778|Procedure|adjuvant therapy|
342700|NCT00544778|Procedure|conventional surgery|
342701|NCT00000577|Drug|Adrenal Cortex Hormones|
342702|NCT00003944|Drug|topotecan hydrochloride|
342703|NCT00544778|Procedure|neoadjuvant therapy|
342704|NCT00544778|Radiation|radiation therapy|
342705|NCT00544791|Drug|melatonin|5 mg, oral, daily dose for 6 months
342706|NCT00544791|Drug|placebo like melatonin tablets|
342707|NCT00544804|Drug|lapatinib ditosylate|
342708|NCT00544804|Genetic|gene expression analysis|
342709|NCT00547235|Biological|therapeutic allogeneic lymphocytes|
342710|NCT00547235|Procedure|allogeneic bone marrow transplantation|
342011|NCT00003788|Drug|porfimer sodium|
342012|NCT00514449|Drug|Placebo + Antipsychotic|2 pills twice a day x 4 weeks, after 4 weeks 3 pills twice a day x 12 weeks
342013|NCT00514462|Device|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
342014|NCT00514475|Drug|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
342015|NCT00514488|Drug|STI571 (400 mg/day; or 800 mg/day)|
342016|NCT00514501|Drug|Iodofiltic acid I 123|
342017|NCT00514514|Drug|Everolimus|experimental
342018|NCT00514514|Drug|Myfortic and Neoral|active comparator
342019|NCT00514527|Drug|oritavancin|Oritavancin as a single, infrequent or daily dose.
342020|NCT00514540|Drug|Docetaxel|75 mg/m^2 IV Over 60 Minutes On Day 1 Repeat Every 3 Weeks.
342021|NCT00514540|Drug|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 repeat every 3 weeks.
342022|NCT00003788|Drug|procarbazine hydrochloride|
342023|NCT00514566|Device|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
342024|NCT00514579|Procedure|Cord blood transplantation|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
342025|NCT00514592|Other|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
342026|NCT00514605|Other|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
342027|NCT00514605|Device|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
342028|NCT00514618|Drug|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
342029|NCT00514618|Dietary Supplement|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
342030|NCT00514644|Other|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
342031|NCT00514644|Other|Panorama examination|Examination with the odontological radiological method "Panorama", including a frontal verification image
334130|NCT00438269|Drug|Site-specific empiric regimens included: Meropenem|
334131|NCT00438269|Drug|Piperacillin/tazobactam|
334132|NCT00438269|Drug|Ciprofloxacin and cefazolin +/- metronidazole|
334133|NCT00003421|Biological|bleomycin sulfate|
334134|NCT00438282|Behavioral|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
334135|NCT00438295|Procedure|temperature control|
334136|NCT00438321|Drug|Zoladex|
334137|NCT00438321|Drug|AndroGel|
334138|NCT00438321|Drug|Arimidex|
334139|NCT00438334|Device|Programmable directional/omni-directional hearing aid|
334140|NCT00438347|Behavioral|Aerobic Exercise|One hour per day three times a week for one year
334141|NCT00438347|Behavioral|Stretching and toning|One hour per day three times a week for one year
334142|NCT00438360|Drug|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
334143|NCT00438360|Drug|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
334144|NCT00003421|Drug|ABVD regimen|
334145|NCT00438386|Drug|Aripiprazole|
334146|NCT00438399|Drug|C. propionate - Corticosteroid 1|Twice daily application
334147|NCT00438399|Drug|C. propionate- Corticosteroid 2|Twice daily application
334148|NCT00438399|Drug|C. propionate -Corticosteroid 3|Twice daily application
334149|NCT00438399|Drug|Corticosteroid 1- C. propionate|Twice daily application
334150|NCT00438399|Drug|Corticosteroid 2 - C. propionate|Twice daily application
334497|NCT00429702|Drug|ondansetron hydrochloride|Given IV
334498|NCT00429715|Biological|Alum-ALM + BCG|Alum precipitated autoclaved L. major
339267|NCT00529997|Device|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
339268|NCT00530010|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
339269|NCT00003867|Drug|capecitabine|
339270|NCT00530023|Device|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
339619|NCT00521703|Drug|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
339620|NCT00521716|Device|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
339621|NCT00521716|Device|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
339622|NCT00521729|Procedure|Exposure to Cold Temperature|
339623|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
339624|NCT00003819|Biological|TF(c)-KLH conjugate vaccine|
339625|NCT00521742|Drug|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
339626|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
339627|NCT00521742|Drug|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
339628|NCT00521755|Device|Seraffix LTB|laser soldering for soft tissue wounds
339629|NCT00521768|Behavioral|Prolonged exposure|
339630|NCT00521781|Drug|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
339631|NCT00521781|Drug|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
339632|NCT00521781|Drug|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
339633|NCT00521807|Procedure|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
338933|NCT00535444|Other|Parish nurse visit|One visit with the parish nurse in 2 weeks
338934|NCT00535457|Other|Preoperative Magic Tricks|Watching "magic"; Study patients will watch the anesthesiologist performing tricks ("magic") before anesthesia induction.
338935|NCT00535470|Drug|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
338936|NCT00535496|Drug|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
338937|NCT00003910|Drug|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
338938|NCT00537823|Drug|Cetuximab|
338939|NCT00537823|Drug|Bevacizumab|
338940|NCT00537823|Drug|Leucovorin|
338941|NCT00537823|Drug|Oxaliplatin|
338942|NCT00537823|Drug|Fluorouracil|
338943|NCT00537836|Drug|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
338944|NCT00537836|Drug|Placebo|Placebo, once daily p.o. over 8 weeks
338945|NCT00537836|Drug|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
338946|NCT00537849|Device|Sonablate 500(SB-500)|
338947|NCT00537862|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
338948|NCT00003910|Drug|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
338949|NCT00537875|Dietary Supplement|Ginger|Capsule, 1000 mg, BID, 3 days
338950|NCT00537875|Dietary Supplement|Placebo|Capsule, 1000 mg, BID, 3 days
339271|NCT00530049|Other|questionnaire administration|
339272|NCT00530049|Procedure|assessment of therapy complications|
339273|NCT00530049|Procedure|psychosocial assessment and care|
300572|NCT00393796|Other|Placebo|
300573|NCT00393809|Drug|DTA-H19|
300574|NCT00393822|Drug|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
300575|NCT00393822|Drug|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
300576|NCT00393835|Drug|Azithromycin SR|
300577|NCT00396552|Device|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
300578|NCT00396552|Device|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
300579|NCT00003217|Drug|vincristine sulfate|
300580|NCT00396565|Drug|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
300581|NCT00396565|Drug|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
300582|NCT00396565|Drug|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
300583|NCT00396578|Drug|aerosolized vancomycin or gentamicin|
300584|NCT00396591|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
300585|NCT00396604|Drug|indacaterol maleate|
300928|NCT00388557|Drug|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
300929|NCT00388570|Device|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
300930|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
300931|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
300932|NCT00388596|Drug|SB-751689|
299873|NCT00003298|Drug|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
299874|NCT00411424|Drug|Placebo|IV
299875|NCT00411437|Drug|Tolterodine ER|
299876|NCT00411437|Drug|Oxybutynin ER|
300218|NCT00402545|Drug|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
300219|NCT00402545|Drug|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
300220|NCT00402558|Drug|Thymoglobulin|1.5 mg/kg By Vein Daily x 3 Days
300221|NCT00402558|Drug|Busulfan|130 mg/m^2 By Vein Over 3 Hours x 4 Days
300222|NCT00402558|Drug|Fludarabine|40 mg/m^2 By Vein Over 30 Minutes x 4 Days
300223|NCT00402558|Procedure|Alloreactive NK Infusion|Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
300224|NCT00402558|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.
300225|NCT00405444|Drug|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
300226|NCT00405444|Drug|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
300227|NCT00405457|Drug|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
300228|NCT00405470|Device|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
300229|NCT00405483|Procedure|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
300230|NCT00405483|Procedure|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
300231|NCT00003269|Drug|cisplatin|
300232|NCT00405496|Drug|Difluprednate Ophthalmic Emulsion|
333990|NCT00003367|Dietary Supplement|soy protein isolate|
333991|NCT00423670|Drug|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
333992|NCT00423670|Drug|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
333993|NCT00423683|Drug|Arixtra|Arixtra
333994|NCT00423683|Device|Inferior Vena Cava Filter (with or without)|IVC filter - filter of choice by radiologist
333995|NCT00423683|Drug|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
333996|NCT00423683|Device|Arixtra + filter|Atrixa as daily injections similar to arm I and placement of IVC filter.
333997|NCT00423683|Device|Arixtra + filter|Arixtra subq injection + IVC filter
333998|NCT00423696|Biological|bevacizumab|
333999|NCT00423696|Drug|capecitabine|
334000|NCT00423696|Drug|fluorouracil|
334001|NCT00003367|Dietary Supplement|vitamin E|
334002|NCT00423696|Drug|irinotecan hydrochloride|
334003|NCT00423696|Drug|leucovorin calcium|
334004|NCT00423696|Procedure|quality-of-life assessment|
334005|NCT00423709|Procedure|Allogeneic Blood Stem Cell Transplantation|
334006|NCT00423709|Drug|Fludarabine|
334007|NCT00423709|Drug|Melphalan|
334008|NCT00423722|Drug|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
328802|NCT00559494|Procedure|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
328803|NCT00559494|Procedure|SCPP control|maintenance of Mean arterial pressure of >65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
328804|NCT00559507|Drug|saracatinib|
328805|NCT00559507|Other|laboratory biomarker analysis|Correlative studies
333291|NCT00437918|Drug|acarbose|
333292|NCT00437957|Drug|Temozolomide|75 Mg/m2/day for all Cohorts
333293|NCT00437957|Drug|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
333294|NCT00437957|Procedure|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
333295|NCT00440505|Drug|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
333296|NCT00440505|Drug|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
333637|NCT00003399|Drug|paclitaxel|
333638|NCT00432250|Procedure|Cervical length ultrasound|
333639|NCT00432263|Drug|Genotropin (PN-180,307) Somatropin|
333640|NCT00432276|Drug|Alogliptin|Alogliptin tablets.
333641|NCT00432276|Drug|Pioglitazone|Pioglitazone tablets.
333642|NCT00432276|Drug|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
333643|NCT00432276|Drug|Placebo|Matching placebo tablets.
333644|NCT00432289|Procedure|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
333645|NCT00432302|Drug|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg [14C]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
333646|NCT00432315|Drug|Docetaxel + CDDP|3 cycles chemotherapy : docetaxel + CDDP
Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)
3 cycles adjuvant chemotherapy docetaxel
333647|NCT00432315|Drug|docetaxel + CDDP|3 cycles chemotherapy: docetaxel + CDDP
Radiochemotherapy
3 cycles adjuvant chemotherapy docetaxel
333648|NCT00003399|Procedure|in vitro-treated peripheral blood stem cell transplantation|
333649|NCT00432328|Drug|Avotermin|
333650|NCT00432341|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
333651|NCT00432341|Biological|botulinum toxin type A|500 Units at Visit 1 (Day 1)
333652|NCT00432354|Drug|atorvastatin|
332934|NCT00446264|Drug|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
332935|NCT00003455|Procedure|biological therapy|
332936|NCT00446277|Procedure|cataract surgery|
332937|NCT00446290|Drug|Docetaxel, Capecitabine and Oxaliplatin|
332938|NCT00446303|Drug|Azacitidine|Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.
Extension of maintenance in responders after 24 courses until relapse or death.
332939|NCT00446316|Drug|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
332940|NCT00449150|Drug|Cetrorelix|Cetrorelix 78 mg combining Week 0 and Week 2 + 52 mg combining Week 26 and Week 28
332941|NCT00449150|Drug|Placebo|Placebo at Week 0/2 and Placebo at Week 26/28
332942|NCT00449163|Biological|bevacizumab|
332943|NCT00449163|Drug|floxuridine|
332944|NCT00449163|Drug|irinotecan hydrochloride|
332945|NCT00449163|Drug|leucovorin calcium|
332946|NCT00003472|Drug|antineoplaston A10|
332947|NCT00449163|Procedure|adjuvant therapy|
332948|NCT00449163|Procedure|neoadjuvant therapy|
332949|NCT00449176|Drug|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
333297|NCT00440518|Drug|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
333298|NCT00440518|Other|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
333299|NCT00440518|Drug|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
333300|NCT00440531|Biological|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
333301|NCT00003426|Drug|gemcitabine hydrochloride|
332250|NCT00416975|Other|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
332576|NCT00454909|Biological|Menactra®|Single dose intramuscular injection.
332577|NCT00454909|Biological|Meningococcal vaccine 134612|Single dose intramuscular injection.
332578|NCT00454922|Behavioral|standard of care|no intervention
332579|NCT00454922|Other|education|meet with trained glaucoma educator 6 times over life of study
332580|NCT00003505|Procedure|differentiation therapy|
332581|NCT00454948|Behavioral|Home-based nutrition sessions and play group exercise|
332582|NCT00454948|Behavioral|Group-based nutrition sessions and mail-out activities|
332583|NCT00454961|Drug|artemether-lumefantrine|
332584|NCT00454974|Device|Wearable artificial kidney|
332585|NCT00454987|Biological|Menitorix|Menitorix was only administered to subjects of the group NoBoost at 40 to 43 months of age.
332586|NCT00454987|Biological|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
332587|NCT00455000|Biological|PF-04360365|Monoclonal antibody
332588|NCT00458250|Drug|Cyclophosphamide|
332589|NCT00458250|Drug|CAMPATH-1H|
332590|NCT00458250|Drug|Cyclosporin A|
332591|NCT00458250|Drug|Methotrexate|
332592|NCT00458263|Drug|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
332593|NCT00458276|Drug|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
332594|NCT00458276|Drug|placebo|Placebo (i.e., normal saline) for i.v. use.
331906|NCT00425516|Drug|Taxotere|
331907|NCT00425516|Drug|5-Fluorouracil|
331908|NCT00425516|Drug|Epirubicin|
331909|NCT00003380|Drug|pegylated liposomal doxorubicin hydrochloride|
331910|NCT00425516|Drug|Cyclophosphamide|
331911|NCT00425529|Device|Module AOX (attached to Sondalis ISO)|
331912|NCT00425542|Other|Outpatient care (vs traditional inpatient care)|Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
331913|NCT00425555|Drug|Panobinostat|
331914|NCT00425568|Drug|AndroGel (Transdermal Testosterone Gel)|
331915|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 1|
331916|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 2|
331917|NCT00425594|Drug|NuLYTELY|
331918|NCT00428532|Drug|Licorice root extract or Pomegranate juice|
331919|NCT00428545|Drug|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
331920|NCT00003389|Drug|Cyclophosphamide|given IV
331921|NCT00428545|Drug|Bortezomib|Starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days
332251|NCT00416975|Other|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
332252|NCT00420030|Drug|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
332253|NCT00420043|Drug|imatinib|
332254|NCT00420056|Drug|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
332255|NCT00420069|Device|MRTX device|device for ventilation
331176|NCT00003436|Drug|mitoxantrone hydrochloride|
331177|NCT00442832|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
331178|NCT00442845|Drug|Atorvastatin (Lipitor)|
331179|NCT00442871|Drug|eltrombopag|eltrombopag 50 mg oral
331180|NCT00442884|Behavioral|Trier Social Stress Test (TSST)|
331551|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
331552|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
331553|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
331554|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
331555|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
331556|NCT00434343|Procedure|Physical Therapy|
331557|NCT00434356|Drug|bevacizumab|Intravenous repeating dose
331558|NCT00434356|Drug|sunitinib|Oral repeating dose
331559|NCT00003405|Drug|amifostine trihydrate|
331560|NCT00434356|Drug|paclitaxel|Intravenous repeating dose
331561|NCT00434369|Drug|CoFactor (ANX-510)|
331562|NCT00434382|Drug|Sevoflurane|
331563|NCT00436995|Drug|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
330817|NCT00451061|Drug|Alfuzosin|
330818|NCT00003486|Procedure|biologically based therapies|
330819|NCT00451061|Drug|Tamsulosin|
330820|NCT00451074|Drug|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
330821|NCT00451087|Procedure|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
330822|NCT00451087|Procedure|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
330823|NCT00451100|Drug|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
330824|NCT00451100|Drug|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
330825|NCT00451113|Drug|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
330826|NCT00451139|Drug|artemether/lumefantrine|
330827|NCT00451139|Drug|quinine|
330828|NCT00451139|Drug|atovaquone/proguanil|
330829|NCT00003486|Procedure|cancer prevention intervention|
330830|NCT00454246|Drug|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
330831|NCT00454259|Drug|Fentanyl/Placebo injection|Ultra low dose intravenous injection
330832|NCT00003502|Procedure|biologically based therapies|
330833|NCT00454272|Drug|Teicoplanin|
330834|NCT00454272|Drug|Vancomycin|
331181|NCT00442897|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
331182|NCT00442897|Drug|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
331183|NCT00442910|Drug|3% SPL7013 Gel (VivaGel)|3% vaginal gel
331184|NCT00442910|Drug|Placebo Gel|Placebo for SPL7013 gel
330210|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
330211|NCT00552565|Drug|Rezular 15mg|Oral Tablets
330212|NCT00552565|Drug|Placebo|placebo
330213|NCT00554970|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
330214|NCT00554970|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
330498|NCT00585260|Other|guideline based dose adjustment|standard dose adjustment
330499|NCT00585260|Drug|mannitol|indirect mannitol challenge
330500|NCT00585260|Drug|methacholine|methacholine challenge
330501|NCT00585286|Device|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
330502|NCT00585299|Other|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
330503|NCT00004164|Drug|docetaxel|
330504|NCT00585299|Other|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
330505|NCT00585312|Drug|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
330506|NCT00585312|Drug|Placebo|Masked, placebo comparator
330507|NCT00585325|Drug|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
330508|NCT00585325|Other|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
330509|NCT00585338|Device|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
330510|NCT00585351|Drug|Ranitidine|50 mg single dose injection of Ranitidine
330511|NCT00585351|Drug|Placebo|50 mg single dose injection of normal saline (placebo)
330512|NCT00585351|Other|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
330513|NCT00585351|Other|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
330514|NCT00004164|Drug|fluorouracil|
303353|NCT00228319|Drug|Carboplatin|Six cycles
303712|NCT00213928|Drug|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
303713|NCT00213941|Device|Echocardiography|
303714|NCT00002565|Drug|vincristine sulfate|
303715|NCT00213954|Procedure|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
303716|NCT00213967|Device|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
303717|NCT00213980|Drug|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
303718|NCT00213993|Drug|antiperspirant|antiperspirant topically once daily to one foot
303719|NCT00214019|Drug|salmeterol, fluticasone|
303720|NCT00214032|Drug|Pycnogenol|pycnogenol 300 mg daily
303721|NCT00214032|Drug|Placebo|placebo 3 capsules daily
303722|NCT00217399|Drug|anastrozole|Given orally
303723|NCT00217412|Drug|vorinostat|Given orally
303724|NCT00217412|Drug|isotretinoin|Given orally
303725|NCT00217425|Biological|bevacizumab|A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.
Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus.
303726|NCT00217425|Drug|cyclophosphamide|IV infusion per institutional guidelines.
303727|NCT00217425|Drug|doxorubicin|Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
303728|NCT00217425|Drug|prednisone|Prednisone is taken orally.
303729|NCT00217425|Drug|vincristine|IV push using extravasation precautions.
303730|NCT00217438|Drug|melphalan|Given IV
303731|NCT00217438|Drug|amifostine trihydrate|Given IV
303732|NCT00002572|Biological|aldesleukin|
303006|NCT00386321|Drug|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
303007|NCT00386334|Drug|Eszopiclone|2 mg tablet once per day in the evening
303008|NCT00003181|Drug|vinblastine sulfate|
303009|NCT00386334|Drug|Placebo|Tablet one per day in the evening.
303010|NCT00386347|Drug|GSK364735 oral solution and oral tablets|
303011|NCT00386360|Drug|Placebo comparator|oral weekly for one year
303012|NCT00386360|Drug|risedronate|35 mg risedronate, once a week for one year
303013|NCT00386373|Drug|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
303014|NCT00386386|Other|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
303015|NCT00386399|Drug|Mitomycin C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
303354|NCT00228319|Drug|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
303355|NCT00228319|Dietary Supplement|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
303356|NCT00228319|Dietary Supplement|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
303357|NCT00228332|Drug|Administration of zinkgluconaat or placebo|
303358|NCT00228345|Procedure|Optical coherence tomography,Fluorescein angiography|
303359|NCT00228358|Drug|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
303360|NCT00228358|Drug|cyclophosphamide|Given IV
303361|NCT00002599|Drug|prednisone|
303362|NCT00228358|Biological|denileukin diftitox|Given IV
303363|NCT00228358|Other|flow cytometry|Intracellular cytokine staining (correlative study)
303364|NCT00228358|Other|immunoenzyme technique|ELIspot assay (correlative study)
303365|NCT00228371|Device|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
302668|NCT00392067|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
302669|NCT00392080|Drug|CJ-023,423|75 mg BID
302670|NCT00392080|Drug|placebo|placebo
302671|NCT00392080|Drug|naproxen|naproxen
302672|NCT00394433|Drug|Bevacizumab|Given intravenously once a week for 2 weeks followed by a one week rest period (3 weeks equals one cycle). Participants will receive at least two cycles of treatment.
302673|NCT00394433|Drug|Docetaxel|Given intravenously once a week for 2 weeks followed by a one week rest period (3 weeks equals one cycle). Participants will receive at least two cycles of treatment.
302674|NCT00394433|Drug|Cisplatin|Given intravenously once a week for 2 weeks followed by a one week rest period (3 weeks equals one cycle). Participants will receive at least two cycles of treatment.
302675|NCT00394433|Drug|Irinotecan|Given intravenously once a week for 2 weeks followed by a one week rest period (3 weeks equals one cycle). Participants will receive at least two cycles of treatment.
302676|NCT00394446|Drug|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
302677|NCT00003215|Biological|filgrastim|
302678|NCT00394459|Device|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
302679|NCT00394459|Device|Perifix Standard|Perifix Standard
302680|NCT00394459|Device|Perifix New|Perifix New
302681|NCT00394472|Drug|AZD3355|
302682|NCT00394485|Drug|Procaterol|
302683|NCT00394485|Drug|Tiotropium|
302684|NCT00394498|Drug|Granulocyte Colony Stimulating Factor|
302685|NCT00394511|Procedure|low-LET photon therapy|
302686|NCT00394524|Device|Glucommander|Computer-guided IV insulin infusion (Glucommander)
302687|NCT00394524|Drug|Standard insulin infusion drip|Insulin infusion with glulisine per columnar algorithm
302688|NCT00003215|Drug|CHOP regimen|
302689|NCT00394524|Device|Glucommander|Glucommander computer assisted program to run glulisine insulin drip
301959|NCT00409331|Drug|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
301960|NCT00409331|Procedure|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
301961|NCT00409344|Drug|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
301962|NCT00409344|Other|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
301963|NCT00409357|Drug|SL77.0499-10 (alfuzosin hydrochloride)|
301964|NCT00409370|Device|SOMA safe enclosure|
301965|NCT00409383|Drug|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
302340|NCT00400673|Behavioral|Two-step remission induction and risk-oriented consolidation|
302341|NCT00403247|Other|placebo|placebo capsule
302342|NCT00403260|Drug|Pyronaridine artesunate|once a day for 3 days
302343|NCT00403260|Drug|Mefloquine plus artesunate|once a day for 3 days
302344|NCT00403273|Drug|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
302345|NCT00403273|Drug|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
302346|NCT00003261|Procedure|neoadjuvant therapy|
302347|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
302348|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
302349|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
302350|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
302351|NCT00403286|Drug|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
302352|NCT00403286|Drug|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
301600|NCT00370942|Drug|GW823093C A|A=45 mg
301601|NCT00000483|Drug|niacin|
301602|NCT00003109|Drug|raltitrexed|
301603|NCT00370942|Drug|GW823093C B|B=30 mg
301604|NCT00370942|Drug|GW823093C C|C=25 mg
301605|NCT00370955|Procedure|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
301606|NCT00370968|Drug|Zinc sulphate|
301607|NCT00370981|Drug|pagoclone|
301608|NCT00370994|Procedure|Caudal epidural injection|Caudal epidural injection with catheterization
301609|NCT00370994|Procedure|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
301610|NCT00371007|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
301611|NCT00371007|Drug|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
301612|NCT00371020|Drug|low molecular weight heparin, 5-FU|
301613|NCT00003110|Biological|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
301614|NCT00371033|Drug|Pregabalin|dosage
301615|NCT00371033|Drug|Placebo|dosage
301616|NCT00371046|Procedure|Transvaginal ultrasound cervical length|
301617|NCT00371046|Procedure|Cervicovaginal fetal fibronectin|
301618|NCT00371059|Drug|Memantine|Memantine 10mg BD
301966|NCT00409383|Drug|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
301967|NCT00409383|Drug|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
301968|NCT00003284|Radiation|radiation therapy|
300922|NCT00385710|Drug|valproic acid|Depakine
300923|NCT00385710|Drug|Placebo|Placebo
300924|NCT00388531|Drug|Depocyte®|Depocyte® is a cytostatic drug
300925|NCT00388544|Behavioral|Activity matched to interest|Recreational activities are tailored to subject's style of interest
300926|NCT00388544|Behavioral|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
300927|NCT00388544|Behavioral|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
301255|NCT00379925|Behavioral|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
301256|NCT00379938|Biological|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
301257|NCT00379938|Drug|Placebo|Saline control
301258|NCT00379938|Biological|MF-59|Adjuvant
301259|NCT00379951|Drug|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
301260|NCT00003147|Biological|Ad5CMV-p53 gene|
301261|NCT00379964|Drug|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC>500/mm3), and for up to 72 hours later.
301262|NCT00379977|Biological|diphtheria, tetanus, pertussis & Hib vaccine|
301263|NCT00379990|Drug|GW274150|60 mg /day
301264|NCT00379990|Drug|Prednisolone|7.5 mg/day
301265|NCT00379990|Other|Placebo|Placebo
301266|NCT00380003|Drug|EVT 201|
301267|NCT00380016|Procedure|Percutaneous Transluminal Angioplasty|
300933|NCT00388609|Drug|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
300934|NCT00003191|Drug|fenretinide|
300935|NCT00388609|Drug|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
300936|NCT00388622|Behavioral|Pharmacist intervention|
300937|NCT00388635|Drug|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
300938|NCT00388635|Drug|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
300939|NCT00388635|Drug|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
300940|NCT00388648|Drug|mixture of amino and keto acids|
300941|NCT00388661|Drug|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
300942|NCT00388661|Drug|Placebo comparator|Placebo comparator
300943|NCT00388674|Drug|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
300944|NCT00388674|Drug|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
300945|NCT00003192|Drug|aminocamptothecin|
300946|NCT00388687|Drug|18F Fluoroazomycin Arabinoside (FAZA)|
300947|NCT00388700|Drug|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
300948|NCT00388700|Drug|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
300949|NCT00003202|Radiation|radiation therapy|
301276|NCT00380081|Drug|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
301277|NCT00380081|Drug|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
300233|NCT00405522|Drug|Propofol + Remifentanil|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
300234|NCT00405522|Drug|Propofol + Remifentanil|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
300235|NCT00405535|Dietary Supplement|glycine|
300236|NCT00405535|Other|placebo powder|
300237|NCT00405548|Drug|BNP (nesiritide)|
300586|NCT00396617|Device|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
300587|NCT00396617|Procedure|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
300588|NCT00396630|Biological|Rotarix|Two-dose oral vaccination.
300589|NCT00396630|Biological|Placebo|Two-dose oral administration.
300590|NCT00003219|Drug|perillyl alcohol|
300591|NCT00396643|Drug|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
300592|NCT00396656|Drug|Atenolol|100 mg tablets orally once a day (od) in the morning.
300593|NCT00396656|Drug|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
300594|NCT00396656|Drug|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
300595|NCT00396669|Drug|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
300596|NCT00396669|Drug|Bupropion|Brain imaging after treatment with Bupropion
300597|NCT00396682|Drug|Cyclophosphamide|150 - 250 - 350 mg
328806|NCT00559520|Dietary Supplement|Impact|Patient receiving 3 drinks "Impact" a day during 5 days before surgery
328807|NCT00559520|Dietary Supplement|Oral Impact|Patient receiving 3 drinks "Oral Impact" a day during 5 days before surgery
328808|NCT00559533|Drug|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
328809|NCT00559546|Drug|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
328810|NCT00004036|Drug|cyclophosphamide|
328811|NCT00559559|Device|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
328812|NCT00561626|Dietary Supplement|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
328813|NCT00561652|Behavioral|Education & Exercise|Education & Exercise
328814|NCT00561652|Procedure|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education & Exercise)
328815|NCT00561678|Drug|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
328816|NCT00561678|Drug|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
328817|NCT00004054|Drug|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
328818|NCT00561691|Drug|nimotuzumab|monoclonal antibody
328819|NCT00561704|Drug|losartan|losartan, 100mg daily,
328820|NCT00561717|Drug|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
328821|NCT00561717|Drug|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
328822|NCT00561717|Drug|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
329108|NCT00554658|Drug|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
329109|NCT00004008|Drug|bryostatin 1|
333653|NCT00432367|Drug|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|Eligible women will be allocated randomly to one of three groups and treated as follows:
Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.
Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.
Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.
All enrolled women will be given one long lasting insecticide treated bed net each for use.
333654|NCT00432380|Biological|HRV liquid vaccine (GSK 357941A)|
333655|NCT00432393|Drug|levodopa-carbidopa|
333656|NCT00432406|Drug|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
333657|NCT00432406|Drug|Etanercept|Etanercept 25 mg twice weekly
333658|NCT00432419|Procedure|autologous peripheral blood cell transplantation|
334009|NCT00423722|Drug|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
334010|NCT00423735|Drug|Dasatinib|Given PO
334011|NCT00423735|Other|Pharmacological Study|Correlative studies
334012|NCT00003368|Drug|irinotecan hydrochloride|
334013|NCT00423748|Drug|ambrisentan|
334014|NCT00423761|Drug|midazolam|
334015|NCT00423761|Drug|GW876008|
334016|NCT00423774|Behavioral|Problem-Solving Education|
334017|NCT00423787|Biological|Ragweed MATA MPL|4 injections of increasing dose strength:
300 SU/0.5 ml
700 SU/0.5 ml
2000 SU/0.5 ml
6000 SU/0.5 ml
334018|NCT00426322|Device|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
334019|NCT00426348|Drug|Valsartan|Valsartan (80-160mg/day)
334020|NCT00426348|Drug|Probucol|Probucol (750mg/day)
334021|NCT00426348|Drug|Placebo|Placebo
334022|NCT00426361|Biological|Boostrix ® Polio|One dose of vaccine administered intramuscularly
333302|NCT00440531|Biological|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
333303|NCT00440531|Biological|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
333304|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
333305|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
333306|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
333307|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
333308|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
333309|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
333310|NCT00440557|Drug|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
333311|NCT00440557|Drug|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
333312|NCT00003426|Radiation|radiation therapy|
333313|NCT00440557|Drug|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
333314|NCT00440570|Device|Low levels of amplitude-modulated electromagnetic fields|
333315|NCT00440570|Device|Emitter of low levels of amplitude-modulated electromagnetic fields|
333316|NCT00440583|Drug|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
333317|NCT00440596|Behavioral|Mindfulness based stress reduction|8 weeks group MBSR
333659|NCT00003400|Biological|filgrastim|
333660|NCT00432432|Drug|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
333661|NCT00432445|Radiation|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
332595|NCT00458289|Drug|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
332596|NCT00000527|Drug|aspirin|
332597|NCT00003518|Drug|paclitaxel|
332598|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
332599|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
332600|NCT00458315|Drug|Cisplatin|
332601|NCT00458315|Drug|Paclitaxel|
332950|NCT00449176|Drug|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
332951|NCT00449176|Drug|placebo|matching placebo twice daily for 15 weeks
332952|NCT00449189|Drug|Mirtazapine|Mirtazapine vs. placebo
332953|NCT00449189|Drug|Placebo|Placebo vs. Mirtazapine
332954|NCT00449202|Drug|oleoyl-estrone (MP 101)|
332955|NCT00449228|Procedure|-preoperative education and total hip replacement|-preoperative education and total hip replacement
332956|NCT00449241|Device|Acupuncture|
332957|NCT00003472|Drug|antineoplaston AS2-1|
332958|NCT00449254|Drug|oleoyl-estrone (MP-101)|
332959|NCT00449267|Device|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
332960|NCT00449280|Drug|Sorafenib|400mg BID (200 mg twice daily)
332961|NCT00449280|Drug|Rapamycin|30mg once weekly
332962|NCT00449280|Drug|Rapamycin|3mg once daily
332963|NCT00449293|Behavioral|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
332964|NCT00449293|Behavioral|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
332965|NCT00449319|Procedure|Identification of appropriate therapies according to risks factors|
332256|NCT00003344|Radiation|radiation therapy|
332257|NCT00420082|Drug|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
332258|NCT00420082|Drug|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
332259|NCT00420082|Drug|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
332260|NCT00420082|Drug|Placebo|Encapsulated Placebo tablets Q.D.
332261|NCT00420095|Drug|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
332262|NCT00420095|Drug|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
332263|NCT00420121|Procedure|laboratory analysis|blood withdrawal for laboratory analysis
332264|NCT00420134|Procedure|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
332265|NCT00420147|Device|wedged inshoe orthosis|
332266|NCT00420160|Behavioral|Smoking cessation treatment plus moderate intensity exercise|
332267|NCT00003345|Drug|cisplatin|
332268|NCT00420160|Behavioral|Smoking cessation treatment plus health education|
332269|NCT00420173|Procedure|Laboratory analysis|blood withdrawal
332270|NCT00420186|Drug|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
332271|NCT00420199|Drug|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
332272|NCT00420199|Drug|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
332273|NCT00420212|Drug|BG00012|
332602|NCT00458315|Drug|Gemcitabine|
332603|NCT00458315|Drug|Avastin (Bevacizumab)|
332604|NCT00458328|Drug|Z-338|
332605|NCT00458341|Drug|PTC124|
332606|NCT00458354|Device|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
331564|NCT00437008|Drug|Benfotiamine 1050mg, 3 days|
331565|NCT00437008|Behavioral|high-AGE vs. low-AGE meal|
331566|NCT00437021|Drug|Placebo (subcutaneous)|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia [Sterile Saline Placebo (SSP)].
331567|NCT00437021|Drug|Placebo (scarification)|Physiologic normal saline for injection.
331568|NCT00437021|Biological|Dryvax®|Dryvax® Vaccinia Vaccine (~10^5 [plaque forming units (pfu)/dose] given via scarification, titer 10^8 pfu per mL after reconstitution).
331569|NCT00437021|Biological|IMVAMUNE®|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
331922|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
331923|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
331924|NCT00428571|Procedure|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
331925|NCT00428571|Procedure|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
331926|NCT00428571|Procedure|Intensive Medical Management|lifestyle, diet, medication optimization
331927|NCT00428584|Drug|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
331928|NCT00428584|Drug|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
331929|NCT00428597|Drug|sunitinib malate|sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).
Dose may be decreased to 25 mg daily in case of adverse events.
It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.
Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination.
331930|NCT00428597|Drug|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
331931|NCT00003389|Radiation|Radiotherapy|
331932|NCT00428610|Drug|LY573636|LY573636 dose is dependent on patient's height, weight, and gender and is adjusted to target a specific Cmax based on patient laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for patient discontinuation are met.
331933|NCT00428623|Procedure|wound dressing|
331934|NCT00428636|Procedure|ileostomy|
331935|NCT00428649|Dietary Supplement|20 µg selenium|20 µg selenium as selenomethionine
331185|NCT00442910|Drug|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
331186|NCT00442923|Drug|Coreg|
331187|NCT00003436|Drug|therapeutic hydrocortisone|
331188|NCT00442936|Drug|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
331189|NCT00445692|Drug|Clarithromycin|Given PO
331190|NCT00445692|Drug|Dexamethasone|Given PO
331191|NCT00445692|Drug|Lenalidomide|Given PO
331192|NCT00445705|Drug|placebo|Part A: Placebo every 12 hours for 4 weeks
331193|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
331194|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
331195|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
331196|NCT00445718|Procedure|computed tomography|
331197|NCT00445718|Procedure|3-Tesla magnetic resonance imaging|
331198|NCT00445718|Procedure|Abdominal Sonogram|Sonogram of the abdomen area
331199|NCT00003451|Biological|recombinant interleukin-12|
331200|NCT00445731|Behavioral|exercise intervention|
331201|NCT00445731|Procedure|management of therapy complications|
331202|NCT00445731|Procedure|observation|
331203|NCT00445744|Drug|cyclophosphamide|Given IV
331204|NCT00445744|Drug|busulfan|Given IV
331205|NCT00445744|Drug|tacrolimus|Given IV or PO
331206|NCT00445744|Drug|methotrexate|Given IV
331207|NCT00445744|Genetic|cytogenetic analysis|Correlative studies
331570|NCT00437034|Biological|aflibercept|Given IV
331571|NCT00437060|Procedure|cognitive assessment|Ancillary studies
330515|NCT00585377|Drug|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
330516|NCT00588094|Drug|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.
Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.
For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is > 100kg. Leukapheresis will continue.
330517|NCT00588107|Other|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
330835|NCT00454285|Drug|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
330836|NCT00454298|Drug|AGG-523 (Aggrecanase Inhibitor)|
330837|NCT00454311|Procedure|Biopsy of Day 3 Embryo|
330838|NCT00454311|Procedure|· day embryo biopsy|
330839|NCT00454324|Drug|Carboplatin|Carboplatin will be given at a dose of AUC=6, on Day 1 of a 21 Day Cycle
330840|NCT00454324|Drug|Abraxane|Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)
Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)
330841|NCT00454337|Drug|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
330842|NCT00454337|Drug|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
330843|NCT00003502|Procedure|cancer prevention intervention|
330844|NCT00454350|Drug|Hectorol (doxercalciferol injection)|
330845|NCT00454350|Drug|Zemplar (Paricalcitol injection)|
330846|NCT00454363|Other|Laboratory Biomarker Analysis|Correlative studies
330847|NCT00454363|Drug|Pazopanib Hydrochloride|Given PO
330848|NCT00454363|Other|Pharmacological Study|Correlative studies
330849|NCT00454376|Other|questionnaire administration|
303733|NCT00217438|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
303734|NCT00217438|Genetic|fluorescence in situ hybridization|Correlative study
303735|NCT00217438|Procedure|bone marrow ablation with stem cell support|Undergo transplant
304091|NCT00206193|Drug|sulprostone|
304092|NCT00206206|Procedure|Hyperglycemia Protocol Procedure|
304093|NCT00206219|Drug|Gefitinib|
304094|NCT00206219|Drug|methotrexate|
304095|NCT00206232|Drug|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
304096|NCT00206245|Drug|AZD0865|
304097|NCT00206258|Drug|Pramlintide and glucagon|
304098|NCT00206271|Behavioral|neck collar; advice to act-as-usual; active mobilisation|
304099|NCT00206284|Drug|AZD0865|
304100|NCT00206297|Drug|Pramlintide|
304101|NCT00002551|Drug|fluorouracil|See arm assignments.
304102|NCT00206310|Drug|CRESTOR|
304103|NCT00206323|Drug|Topiramate (drug)|
304104|NCT00206336|Drug|Topiramate (drug)|
304105|NCT00206375|Drug|Growth hormone|Growth hormone + Synthroid + Lupron
304106|NCT00206375|Drug|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
304107|NCT00206388|Drug|Zolendric acid|IV, 2mg/m2/dose on day 0
304108|NCT00206388|Drug|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
304109|NCT00206401|Drug|Lantus and short acting analogs Vs NPH and short acting analogs|
304110|NCT00206414|Drug|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
304111|NCT00206414|Drug|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
303366|NCT00228384|Device|GORE VIABAHN Endoprosthesis|Implantation
303367|NCT00228384|Device|Bare Nitinol Stent|Implantation
303368|NCT00228397|Drug|CCI-779|
303369|NCT00228410|Drug|Tigecycline|
303370|NCT00228410|Drug|vancomycin with aztreonam|
303371|NCT00228423|Drug|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel and 162 mg aspirin or Placebo and 162 mg aspirin during one year
303372|NCT00002599|Drug|vincristine sulfate|
303373|NCT00228436|Drug|peginesatide|
303374|NCT00228449|Drug|peginesatide|
303375|NCT00228462|Drug|Seroquel (quetiapine)|
303376|NCT00228475|Drug|Pulmicort (budesonide) Turbuhaler|
303377|NCT00228488|Drug|Gefitinib|
303378|NCT00228514|Drug|Rosuvastatin|
303379|NCT00228514|Procedure|Positron emission tomography|
303736|NCT00217451|Drug|Fosmidomycin-clindamycin|
303737|NCT00217464|Drug|fulvestrant|intramuscularly
303738|NCT00217477|Drug|gemcitabine hydrochloride|Given IV
303739|NCT00217477|Drug|paricalcitol|Given IV
303740|NCT00217490|Behavioral|behavioral dietary intervention|
303741|NCT00217490|Dietary Supplement|dietary intervention|
303742|NCT00217490|Other|counseling intervention|
303743|NCT00002572|Biological|muromonab-CD3|
303744|NCT00217490|Other|preventative dietary intervention|
303745|NCT00217503|Biological|bevacizumab|
303746|NCT00217503|Biological|filgrastim|
303016|NCT00386412|Drug|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
303017|NCT00386425|Drug|Drotrecogin alfa (activated)|intravenous
303018|NCT00386438|Procedure|Honan balloon application|
303019|NCT00000494|Procedure|surgery, cardiovascular|
303020|NCT00003182|Drug|cisplatin|
303021|NCT00386451|Device|Catheter locking systems|
303022|NCT00386464|Device|noninvasive positive pressure ventilation|
303023|NCT00386477|Procedure|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
303024|NCT00386490|Drug|AT-1001|
303025|NCT00386503|Drug|Artesunate + Amodiaquine|
303026|NCT00386516|Drug|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
303027|NCT00386516|Drug|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
303028|NCT00386529|Drug|Aspirin enteric coated pellests 100mg|
303029|NCT00386542|Biological|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
303030|NCT00386542|Device|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
303031|NCT00003182|Drug|gemcitabine hydrochloride|
303032|NCT00386555|Drug|docetaxel|
303033|NCT00386555|Drug|CP-868,596 + docetaxel|
303034|NCT00386555|Drug|AG-013736 + docetaxel|
303035|NCT00386555|Drug|CP-868,596 + AG-013736 + docetaxel|
303036|NCT00386581|Drug|atomoxetine|
303037|NCT00389493|Drug|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
303038|NCT00003194|Drug|topotecan hydrochloride|
303039|NCT00389506|Biological|LMB-2 immunotoxin|
302353|NCT00403286|Drug|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
302354|NCT00403286|Drug|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
302355|NCT00403299|Procedure|MDCT of the coronary arteries.|
302356|NCT00403312|Behavioral|Smoking Cessation Behavioral Program|
302357|NCT00003261|Radiation|radiation therapy|
302358|NCT00403312|Drug|Nicotine Patch|
302359|NCT00403312|Behavioral|Physical Activity|
302360|NCT00403325|Drug|rhuFab V2 [ranibizumab] ( Lucentis )|
302361|NCT00403338|Device|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
302362|NCT00403364|Drug|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
302363|NCT00403377|Behavioral|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
302690|NCT00394524|Drug|Glulisine drip using columnar algorithm|Apidra insulin per insulin infusion algorithm
302691|NCT00394537|Drug|Labetalol 10mg iv|
302692|NCT00394550|Procedure|supraglottoplasty with laser|Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are "new" or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children
302693|NCT00394550|Procedure|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
302694|NCT00394563|Drug|RN624 (PF-04383119)|10 mcg/kg
302695|NCT00394563|Drug|RN624 (PF-04383119)|25 mcg/kg
302696|NCT00394563|Drug|RN624 (PF-04383119)|50 mcg/kg
302697|NCT00394563|Drug|RN624 (PF-04383119)|100 mcg/kg
302698|NCT00394563|Drug|RN624 (PF-04383119)|200 mcg/kg
301969|NCT00409396|Procedure|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
301970|NCT00409396|Procedure|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
301971|NCT00409409|Drug|Sublingual immunotherapy tablets of grass pollen allergen extract|
301972|NCT00409422|Behavioral|weight management program|
301973|NCT00409435|Drug|pyridostigmine|one 180 mg capsule per day for 3 days
301974|NCT00409435|Drug|Placebo|one capsule per day for 3 days
301975|NCT00409448|Behavioral|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
301976|NCT00409448|Behavioral|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
301977|NCT00409461|Drug|ATG-Sirolimus-Tacrolimus|
301978|NCT00409487|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
301979|NCT00000505|Procedure|angioplasty, transluminal, percutaneous coronary|
301980|NCT00003302|Procedure|magnetic resonance imaging|
301981|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
301982|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
301983|NCT00412347|Drug|Insulin Drip Therapy|
301984|NCT00412360|Biological|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
301985|NCT00412360|Biological|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
301986|NCT00412360|Radiation|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
301987|NCT00412360|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
302364|NCT00403390|Drug|Levothyroxine versus Levothyroxine|Randomized crossover study using 8 weeks of one form of levothyroxine, then 8 weeks of the other form of levothyroxine. The dose of medication does not change throughout the duration of the study.
301268|NCT00380029|Drug|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
301269|NCT00380029|Procedure|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
301270|NCT00380042|Device|Cortical Stimulation|Cortical stimulation of prefrontal cortex
301271|NCT00003148|Biological|aldesleukin|
301272|NCT00380042|Device|Sham|Sham stimulation
301273|NCT00380055|Behavioral|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
301274|NCT00380055|Behavioral|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
301275|NCT00380068|Drug|Ambrisentan|Oral tablets taken once daily.
301619|NCT00371059|Drug|Placebo|Placebo 10 mgs BD
301620|NCT00371072|Procedure|trabeculectomy with mitomycin-C|
301621|NCT00371085|Behavioral|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
301622|NCT00371098|Biological|Influenza vaccination: Influvac (SolvayPharma)|
301623|NCT00371098|Biological|placebo influenza vaccine|
301624|NCT00003111|Drug|carboplatin|
301625|NCT00371111|Drug|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
301626|NCT00371111|Drug|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
301627|NCT00371124|Drug|Atropine Eye drops|
301628|NCT00371137|Drug|Xyrem®|two doses
301629|NCT00371137|Drug|Placebo|Oral Solution
301630|NCT00371150|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
301631|NCT00003119|Drug|etoposide|
301632|NCT00373997|Procedure|egd with biopsy|standard of care procedure with biopsy
301278|NCT00003159|Drug|gemcitabine hydrochloride|
301279|NCT00382889|Drug|beclomethasone|
301280|NCT00382889|Drug|salbutamol|
301281|NCT00382902|Device|OptiFree Multi-Purpose Disinfecting Solution|
301282|NCT00382915|Device|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
301283|NCT00382928|Device|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
301284|NCT00382941|Device|Red and near infrared LED phototherapy device|
301285|NCT00382954|Drug|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
301286|NCT00382954|Drug|Idarubicin|I.V., 8, or 10 or 12 mg/m^2 weekly (days 1, 8, 15, and 22) for 4 weeks
301287|NCT00382967|Procedure|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
301288|NCT00382980|Biological|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
301289|NCT00003159|Drug|ifosfamide|
301290|NCT00382980|Biological|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
301291|NCT00382980|Drug|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
301292|NCT00382993|Drug|Placebo|Matching placebo tablet
301293|NCT00382993|Drug|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
301643|NCT00003119|Procedure|adjuvant therapy|
300598|NCT00399607|Procedure|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
300599|NCT00399607|Procedure|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
300600|NCT00399620|Procedure|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
300601|NCT00399633|Drug|sumatriptan|
300602|NCT00399646|Device|Metricath Gemini System|
300603|NCT00399659|Drug|Tegaserod|
300950|NCT00391209|Drug|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
300951|NCT00391209|Drug|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
300952|NCT00391222|Drug|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
300953|NCT00391222|Drug|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
300954|NCT00391222|Drug|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
300955|NCT00391248|Drug|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
300956|NCT00391261|Drug|Metformin|open-label, flexible dosing
300957|NCT00391274|Drug|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
300958|NCT00391274|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
300959|NCT00391300|Procedure|bioelectric field imaging|
300960|NCT00003203|Biological|filgrastim|Given IV
300961|NCT00391300|Procedure|biopsy|
300962|NCT00391300|Procedure|histopathologic examination|
329110|NCT00554671|Other|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
329111|NCT00554671|Behavioral|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
329112|NCT00554671|Behavioral|Group support|Peer support are provided in the group setting
329113|NCT00554671|Behavioral|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
329114|NCT00556998|Drug|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
329115|NCT00557011|Drug|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
329116|NCT00557011|Drug|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
329117|NCT00004024|Biological|muromonab-CD3|
329118|NCT00557011|Drug|Placebo|Placebo capsule taken once daily in the morning
329119|NCT00557024|Procedure|RFA|radiofrequency ablation
329120|NCT00557024|Procedure|radiotherapy after RFA|radiotherapy after RFA
329121|NCT00557037|Drug|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
329122|NCT00557050|Other|Training|10-week eccentric hamstring muscle training
329123|NCT00557076|Behavioral|Familiar Voice Stimulation High Dose|The High Dose intervention is 1,680 minutes of Familiar Vocal Stimulation (FVs) provided in 40 minute daily segments at least 2 hours apart and for 6 weeks. Four CDs with 10 minutes of FVs preceded by the familiar voice calling out the subject's name, will be played (1 at a time) each day for 6 weeks providing 1,680 minutes of FVs.
329124|NCT00557076|Behavioral|Sham Auditory Stimulation|The sham intervention is zero minutes of Familiar Voice Stimulation. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
329125|NCT00557089|Drug|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
329126|NCT00557089|Other|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
329127|NCT00557102|Biological|cetuximab|
329128|NCT00004024|Biological|sargramostim|
334023|NCT00426361|Biological|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
334024|NCT00003386|Biological|autologous tumor cell vaccine|
334025|NCT00426374|Procedure|echocardiography and blood test|
334026|NCT00426400|Drug|The cessation of anti-aggregative treatment for 10 days|
334027|NCT00426413|Drug|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
334028|NCT00426426|Behavioral|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
334029|NCT00426426|Behavioral|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
334030|NCT00426426|Behavioral|Waiting list|
334031|NCT00426439|Drug|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
328823|NCT00561717|Drug|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
328824|NCT00561730|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
328825|NCT00561743|Drug|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
328826|NCT00561756|Biological|plasmid DNA vaccine therapy|
328827|NCT00561756|Other|flow cytometry|
328828|NCT00004054|Drug|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
328829|NCT00561756|Other|immunoenzyme technique|
328830|NCT00561769|Drug|Norditropin pen|12 IU per day
328831|NCT00561795|Drug|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
328832|NCT00561795|Drug|carboplatin|IV over one hour every 3 weeks of 6 cycles
328833|NCT00561795|Drug|paclitaxel|IV 175 mg/m^2 given over 3 hours on day one of a 21 day cycle for six cycles
333662|NCT00435058|Drug|brimonidine tartrate 0,2%|
333663|NCT00435058|Drug|travoprost 0,004%|
333664|NCT00435071|Procedure|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
333665|NCT00435071|Procedure|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
333666|NCT00435084|Drug|APO866|
333667|NCT00435110|Procedure|standard ventilatory settings|
333668|NCT00003406|Procedure|autologous bone marrow transplantation|
333669|NCT00435110|Procedure|PEEP and FiO2|
333670|NCT00435123|Dietary Supplement|Nutritional Supplement ProStat 64 twice a day|
333671|NCT00435123|Dietary Supplement|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
333672|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
333673|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
333674|NCT00435162|Drug|Valsartan 0.25 mg/kg|once daily
333675|NCT00435162|Drug|Valsartan 1.0 mg/kg|once daily
333676|NCT00435162|Drug|Valsartan 4.0 mg/kg|once daily
333677|NCT00435175|Drug|estradiol|
333678|NCT00435188|Behavioral|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
333679|NCT00003406|Procedure|bone marrow ablation with stem cell support|
333680|NCT00435227|Biological|MEDI-524|30 mg/kg of MEDI-524
333681|NCT00435227|Other|Placebo|30 mg/kg of Placebo
332966|NCT00449319|Drug|Daunorubicine|
332967|NCT00449319|Procedure|Transplant|
332968|NCT00003473|Drug|antineoplaston A10|
332969|NCT00449345|Procedure|Blood test for Quantiferon-GOLD assay|
332970|NCT00449358|Procedure|apply methyl-ALA cream|
332971|NCT00449384|Behavioral|Diagnostic Screening|
332972|NCT00452101|Drug|Aquamin F|
332973|NCT00452114|Device|In-Exsufflator Cough Assist Device|
332974|NCT00452127|Drug|PRO131921|Escalating doses by IV infusion
332975|NCT00452140|Biological|ertumaxomab|10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.
333318|NCT00440596|Behavioral|Progressive Muscle Relaxation|8 weeks PMR in group format
333319|NCT00443716|Drug|estrogen|
333320|NCT00000149|Procedure|Argon Laser Trabeculoplasty|
333321|NCT00000522|Behavioral|diet, reducing|
333322|NCT00003437|Drug|methotrexate|
333323|NCT00443729|Drug|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
333324|NCT00443729|Drug|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
333325|NCT00443729|Drug|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
333326|NCT00443729|Drug|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
333327|NCT00443742|Procedure|Validation|
333328|NCT00443755|Drug|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
333329|NCT00443755|Drug|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
332607|NCT00458354|Procedure|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
332608|NCT00003519|Drug|cyclophosphamide|
332609|NCT00458367|Drug|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
332610|NCT00458380|Procedure|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
332611|NCT00458393|Drug|Emtricitabine/tenofovir disoproxil fumarate|Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
332612|NCT00458393|Drug|Placebo|Placebo for emtricitabine/tenofovir disoproxil fumarate
332613|NCT00458406|Device|Bi-Flex|Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
Positive pressure used during sleep for 3 months
332614|NCT00458406|Device|CPAP|CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.
Positive pressure used during sleep for 3 months.
332615|NCT00458419|Drug|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
332616|NCT00458419|Drug|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
332617|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB (currently licensed product) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months.
332618|NCT00414050|Biological|Comparator: ENGERIX-B|ENGERIX-B given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months
332619|NCT00414076|Drug|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
332620|NCT00414089|Drug|90Y-ibritumomab tiuxetan (Zevalin)|
332621|NCT00003312|Radiation|iodine I 125|
332622|NCT00414102|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
332623|NCT00414102|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
332624|NCT00414128|Drug|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
332976|NCT00452153|Procedure|Characterization Legionnella|Characterisation Legionnella by polymerase chain reaction (PCR)
Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region
332977|NCT00452166|Drug|rosiglitazone|
331936|NCT00428649|Dietary Supplement|40 µg selenium|40 µg selenium as selenomethionine
331937|NCT00428649|Dietary Supplement|60 µg selenium|60 µg selenium as selenomethionine
331938|NCT00428649|Dietary Supplement|80 µg selenium|80 µg selenium as selenomethionine
331939|NCT00428649|Dietary Supplement|100 µg selenium|100 µg selenium as selenomethionine
331940|NCT00428649|Dietary Supplement|120 µg selenium|120 µg selenium as selenomethionine
331941|NCT00428649|Dietary Supplement|placebo|placebo
331942|NCT00003390|Drug|irofulven|
331943|NCT00428662|Device|drug eluting nonpolymeric nanoporous stent|
331944|NCT00428701|Drug|Esomeprazole Sodium|
332274|NCT00420212|Drug|Placebo|
332275|NCT00420225|Device|Low-weight prolypropylene mesh|
332276|NCT00420238|Drug|Etanercept (Enbrel)|50 mg injection once weekly
332277|NCT00420238|Other|Placebo|placebo
332278|NCT00000511|Dietary Supplement|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
332279|NCT00003345|Drug|irinotecan hydrochloride|
332280|NCT00420251|Drug|Genotropin|
332281|NCT00420264|Device|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
332282|NCT00420277|Drug|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
332283|NCT00423007|Drug|Placebo|
332284|NCT00423020|Drug|Erythropoietin|
332285|NCT00423046|Biological|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
332286|NCT00423046|Biological|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
332287|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
331572|NCT00003414|Procedure|peripheral blood stem cell transplantation|
331573|NCT00437060|Procedure|psychosocial assessment and care|Ancillary studies
331574|NCT00437060|Procedure|diffusion tensor imaging|Correlative studies
331575|NCT00437060|Other|laboratory biomarker analysis|Correlative studies
331576|NCT00437060|Other|pharmacological study|Correlative studies
331577|NCT00437073|Drug|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
331578|NCT00437073|Drug|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
331579|NCT00437073|Drug|lapatinib|lapatinib administered 1250mg once daily orally
331580|NCT00437086|Drug|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
331581|NCT00437099|Drug|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
331582|NCT00437099|Drug|Placebo|Placebo
331583|NCT00003414|Radiation|radiation therapy|
331584|NCT00437112|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
331585|NCT00437112|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
331586|NCT00437125|Drug|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
331587|NCT00437138|Behavioral|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
331588|NCT00437151|Other|More frequent than normal office visits|Mode of patient reminder
331589|NCT00437151|Other|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
331590|NCT00437151|Other|Parenteral involvement / intervention reminders|Mode of patient reminder
331591|NCT00437151|Other|No intervention or reminders|Mode of patient reminder
331592|NCT00439881|Drug|SB-681323|
331593|NCT00439894|Procedure|Blood draw|blood draw at baseline, week 12 and week 24
330850|NCT00454376|Procedure|quality-of-life assessment|
330851|NCT00454389|Device|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
330852|NCT00454389|Drug|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
330853|NCT00454402|Drug|Alfuzosin|
330854|NCT00003502|Procedure|complementary and alternative therapy|
330855|NCT00454428|Procedure|pulsatile intra-aortic balloon pump|
330856|NCT00454441|Drug|MF101|
330857|NCT00454467|Procedure|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
330858|NCT00454467|Procedure|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
331208|NCT00445744|Other|flow cytometry|Correlative studies
331209|NCT00445744|Other|pharmacological study|Correlative studies
331210|NCT00003452|Drug|antineoplaston A10|
331211|NCT00445744|Other|pharmacogenomic studies|Correlative studies
331212|NCT00445744|Procedure|peripheral blood stem cell transplantation|Undergo PBPC transplantation
331213|NCT00445744|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
331214|NCT00445757|Procedure|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
331215|NCT00445757|Radiation|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
331216|NCT00445770|Drug|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
331217|NCT00445770|Drug|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
331218|NCT00445770|Drug|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
331219|NCT00445783|Genetic|gene expression analysis|
331220|NCT00448461|Drug|bivalirudin|comparison between heparin and bivalirudin
304112|NCT00002551|Drug|leucovorin calcium|See arm assignments.
304113|NCT00206427|Drug|GW572016|Lapatinib, 500 mg
304114|NCT00206427|Drug|lapatinib|Lapatinib 500 mg PO
304115|NCT00206440|Drug|esomeprazole|nexium
304116|NCT00206440|Drug|Esomeprazole (aka Nexium)|Esomeprazole (20 mg daily ranitidine 300 mg daily) during Cycle 1 Days 1-5 and Cycle 2 Days 1-5
304117|NCT00002557|Drug|CHOP regimen|
304478|NCT00253669|Procedure|management of therapy complications|
304479|NCT00253695|Device|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
304480|NCT00253708|Procedure|management of therapy complications|
304481|NCT00253708|Procedure|massage therapy|
304482|NCT00253708|Procedure|pain therapy|
304483|NCT00253708|Procedure|psychosocial assessment and care|
304484|NCT00253708|Procedure|quality-of-life assessment|
304485|NCT00253721|Drug|Melphalan|All levels: Every 4 weeks for up to one year
Dose Escalation Plan:
Level 1: 4mg/m2/day x 2 days
Level 2: 6mg/m2/day x 2 days
Level 3: 8mg/m2/day x 2 days
Level 4: 10mg/m2/day x 2 days
Level 5: 12mg/m2/day x 2 days
304486|NCT00253734|Biological|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
304487|NCT00253734|Biological|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
304488|NCT00002676|Drug|vincristine sulfate|
304489|NCT00256815|Procedure|Radiation|
304490|NCT00002689|Drug|fluorouracil|
304491|NCT00256828|Drug|didanosine + lamivudine + efavirenz|
304492|NCT00256841|Drug|Chemotherapy|
304493|NCT00256841|Procedure|Radiation Therapy|
304494|NCT00256854|Drug|ropinirole controlled-release for RLS|
303747|NCT00217503|Biological|pegfilgrastim|
303748|NCT00217503|Drug|bortezomib|
303749|NCT00217503|Drug|cyclophosphamide|
303750|NCT00217503|Drug|doxorubicin hydrochloride|
303751|NCT00217503|Drug|etoposide|
303752|NCT00217503|Drug|ganciclovir|
303753|NCT00220987|Other|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
303754|NCT00221000|Drug|Methoxsalen|
303755|NCT00221000|Procedure|Extracorporeal Photopheresis|
303756|NCT00221013|Procedure|"augmented" CRRT regimen|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
303757|NCT00221026|Drug|Methoxsalen +ECP|ECP + Uvadex given at weeks 1-12 weeks.
303758|NCT00221026|Procedure|Extracorporeal Photopheresis|ECP given at weeks 1 through 12.
303759|NCT00221039|Drug|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
303760|NCT00221052|Drug|Diclofenac|
303761|NCT00221065|Device|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
304118|NCT00209716|Drug|Taxotere|30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
304119|NCT00209716|Drug|5-Fluorouracil|800 mg/m2, CIV (CIV.in the vein) on day 1~5 of each 28 day cycle.
304120|NCT00209716|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle.
304121|NCT00209729|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
304122|NCT00209729|Drug|TS-1|Day 1-14, P.O. everyday
304123|NCT00209742|Drug|UFT|P.O. everyday
304124|NCT00209742|Drug|USEL/Leucovorin|P.O. everyday
304125|NCT00209742|Drug|Krestin|P.O. everyday
303040|NCT00389506|Drug|cyclophosphamide|
303041|NCT00389506|Drug|fludarabine phosphate|
303042|NCT00389506|Other|pharmacological study|
303380|NCT00228527|Drug|Esomeprazole (Nexium)|
303381|NCT00228540|Drug|Modafinil|
303382|NCT00232466|Procedure|Vertebroplasty|Procedure:
The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay.
303383|NCT00232479|Drug|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
303384|NCT00232492|Drug|Placebo males|Intravenous saline bolus (Placebo-control) males
303385|NCT00232492|Drug|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
303386|NCT00232492|Drug|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
303387|NCT00232492|Drug|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
303388|NCT00002611|Drug|vincristine sulfate|
303389|NCT00232492|Drug|Placebo females|Intravenous saline bolus (Placebo-control) females
303390|NCT00232492|Drug|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
303391|NCT00232492|Drug|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
303392|NCT00232492|Drug|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
303393|NCT00232505|Biological|cetuximab|Given IV
303394|NCT00232505|Drug|carboplatin|Given IV
303395|NCT00232518|Procedure|Infection with hookworm larvae|
303396|NCT00232531|Drug|Niaspan|
303397|NCT00232544|Device|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
303398|NCT00232557|Device|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
302699|NCT00397696|Drug|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of [123I] 5-IA followed by SPECT imaging as described below. A second [123I] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial [123I] 5IA imaging session.
302700|NCT00397709|Drug|I ( isoniazid), II (isoniazid + rifampin )|
302701|NCT00397722|Drug|GW876008|
302702|NCT00397722|Drug|paroxetine|
302703|NCT00397735|Procedure|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
302704|NCT00397735|Drug|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
302705|NCT00397761|Drug|capecitabine|
302706|NCT00397761|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
302707|NCT00397761|Procedure|neoadjuvant therapy|
302708|NCT00397774|Behavioral|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
302709|NCT00003224|Biological|p946/tet-p|This peptide is a longer version of p946 (gp100 [280-288]) sythesized colinearly with the tetanus helper peptide (Tet-p)
302710|NCT00397774|Other|best supportive care|
303043|NCT00389519|Drug|ramipril|once a day oral ramipril capsules given for 4 weeks
303044|NCT00389519|Drug|placebo|once a day oral placebo capsule for 4 weeks
303045|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
303046|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
303047|NCT00389545|Procedure|Intracoronary infusion of autologous bone-marrow derived stem cells|
303048|NCT00389558|Procedure|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
303049|NCT00000495|Behavioral|exercise|
303050|NCT00003194|Procedure|peripheral blood stem cell transplantation|
302365|NCT00403403|Drug|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
302366|NCT00403403|Drug|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve [AUC]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
302367|NCT00003270|Radiation|radiation therapy|High energy X-rays
302368|NCT00406393|Drug|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
302369|NCT00406393|Drug|Sirolimus|Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.
Children: Children aged < 12.0 years OR weighing < 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.
The target serum level for sirolimus is 3-12 ng/mL.
302370|NCT00406406|Drug|SKI-606|
302371|NCT00406419|Drug|methotrexate|Oral repeating dose
302372|NCT00406419|Drug|ocrelizumab|Intravenous repeating dose (200mg)
302373|NCT00406419|Drug|ocrelizumab|Intravenous repeating dose (500mg)
302374|NCT00406419|Drug|placebo|Intravenous repeating dose
302375|NCT00406432|Drug|Paroxetine Controlled Release Tablet 25mg|
302376|NCT00406458|Drug|SB-509|60 mg dose
302377|NCT00406458|Other|Normal Saline|
302378|NCT00003273|Biological|filgrastim|
302379|NCT00406471|Drug|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
302380|NCT00406484|Behavioral|Standard drug counseling|Individual drug counseling
302381|NCT00406484|Behavioral|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
302382|NCT00406497|Drug|Difluprednate Ophthalmic Emulsion|
302383|NCT00406510|Drug|Optive, Systane|
302384|NCT00406523|Device|JANUS Stent|
302711|NCT00397787|Drug|sunitinib malate|Given PO
301633|NCT00374010|Behavioral|Patient-Centered Advance Care Planning|The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:
Representational assessment (10 - 15 minutes);
Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);
Creating conditions for conceptual change (5 minutes);
Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and
Summary (3 - 5 minutes)
301634|NCT00374023|Drug|Zinc, or Vitamin A or both|
301635|NCT00374036|Drug|ECC|capecitabine
301636|NCT00374036|Drug|FOLFIRI|Irinotecan
301637|NCT00374049|Drug|MUC_1|Pretreatment with Poly-ICLC alone week 1 &2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
301638|NCT00374062|Behavioral|relaxation therapy 1|relaxation therapy 1
301639|NCT00374062|Behavioral|relaxation therapy 2|relaxation therapy 2
301640|NCT00374062|Behavioral|relaxation therapy 3|relaxation therapy 3
301641|NCT00374075|Drug|Valproic Acid|
301642|NCT00000485|Drug|antihypertensive agents|
301988|NCT00412360|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
301989|NCT00412360|Drug|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
301990|NCT00412360|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if > 50 kg or 15 mg/kg IV q 8 hours if < 50 kg beginning the morning of Day -3.
301991|NCT00003302|Procedure|radiomammography|
301992|NCT00412373|Drug|Placebo|for 6 weeks
301993|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
301994|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
301995|NCT00412412|Drug|CNF2024|Oral doses of CNF2024 as specified in the protocol.
301996|NCT00412412|Drug|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
301997|NCT00412425|Drug|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
301644|NCT00374088|Drug|N-acetylcysteine|Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.
Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs.
301645|NCT00374088|Drug|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
301646|NCT00374101|Drug|omeprazole|
301647|NCT00374101|Drug|pantoprazole|
301648|NCT00374114|Procedure|cervical conization|
301649|NCT00374114|Procedure|ultrasonic surgical aspiration of the cervix|
301650|NCT00374127|Drug|Marijuana|
301651|NCT00374140|Drug|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
301652|NCT00374153|Behavioral|Feedback|Online personal feedback report
301653|NCT00374153|Behavioral|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
301654|NCT00003119|Procedure|conventional surgery|
301655|NCT00374153|Behavioral|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
301656|NCT00377403|Drug|Acetaminophen|Symptomatic treatment:
Dose: 500mg every 4 to 6 hours for pain or fever
301657|NCT00377403|Drug|Amoxicillin|Intervention drug:
Dose: 500mg tid for 10 days
301658|NCT00377403|Drug|Dextromethorphan hydrobromide with guaifenesin|Symptomatic treatment:
Dose: 10mls every 4 to 6 hours for cough
301659|NCT00377403|Drug|Guaifenesin|Symptomatic treatment:
Dose: 600mg every 12 hours to thin secretions
301660|NCT00377403|Drug|Pseudoephedrine Sustained Action|Symptomatic treatment:
Dose: 120mg every 12 hours for nasal congestion
301661|NCT00377403|Drug|Saline spray (0.65%)|Symptomatic treatment:
Dose: 2 squeezes per nostril as needed for nasal congestion
301662|NCT00377416|Genetic|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
300963|NCT00391313|Drug|Chloroquine|
300964|NCT00391339|Drug|Bryophyllum p.|
300965|NCT00391352|Drug|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
300966|NCT00391365|Procedure|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
300967|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
300968|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
300969|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
300970|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
300971|NCT00000146|Drug|Prednisone|
300972|NCT00000497|Behavioral|diet, sodium-restricted|
301294|NCT00383006|Behavioral|Skills for affect regulation (behavior)|
301295|NCT00383019|Drug|Xalacom (KP2035)|
301296|NCT00383019|Drug|Xalatan|
301297|NCT00383032|Drug|mifepristone|
301298|NCT00383045|Drug|Buprenorphine/Subutex|
301299|NCT00383045|Drug|Naltrexone|
301300|NCT00003159|Drug|mitomycin C|
301301|NCT00383045|Procedure|Drug counseling|
301302|NCT00383058|Drug|the extract of green tea|
301303|NCT00385723|Dietary Supplement|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
301304|NCT00385723|Dietary Supplement|Placebo|matching placebo capsule daily for 4 months
301305|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
329429|NCT00590317|Drug|Ondansetron|Patients receiving Ondansetron
329430|NCT00590343|Drug|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
329431|NCT00590356|Device|StarClose®|Closure device for femoral artery suture site occlusion
329432|NCT00590356|Device|AngioSeal®|Closure device for femoral artery suture site occlusion
329433|NCT00590369|Device|KCI -VAC|Negative pressure wound therapy device
329434|NCT00590369|Device|Versatile One (EZCare)|Negative pressure wound therapy device
329435|NCT00590382|Device|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
329436|NCT00590395|Drug|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
329437|NCT00590408|Dietary Supplement|coenzyme Q10|60mg capsule twice daily for 12 weeks
329438|NCT00590408|Dietary Supplement|matching placebo|matching placebo capsule twice daily for 12 weeks
329439|NCT00552006|Behavioral|Academic Counseling|Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.
AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.
329440|NCT00552032|Drug|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
329441|NCT00552032|Drug|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
329442|NCT00552058|Biological|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
329443|NCT00552058|Other|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
329444|NCT00552071|Drug|Sandostatin LAR|use of consistent monthly dose of medication for duration of 6 months.
329445|NCT00552071|Drug|Sandostatin LAR|All patients receive Sandostatin LAR throughout trial at a fixed dose established at entry into the study.
329446|NCT00000580|Drug|immunoglobulins, intravenous|
329447|NCT00003994|Drug|carboplatin|Given IV
328834|NCT00561808|Other|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
328835|NCT00561821|Drug|Esmirtazapine|one tablet daily
328836|NCT00561821|Drug|Placebo|one tablet daily
328837|NCT00564057|Drug|candesartan|tablet 8-16 mg once daily, one year
328838|NCT00564057|Drug|lercanidipine|tablets 10-20 mg once daily, one year
328839|NCT00564070|Behavioral|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
328840|NCT00564070|Behavioral|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
328841|NCT00564083|Procedure|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
328842|NCT00004062|Radiation|iodine I 131|
328843|NCT00564096|Device|DEEP TMS H1 coil|A new coil ("H"-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS.
329129|NCT00557102|Biological|filgrastim|
329130|NCT00557102|Drug|fluorouracil|
329131|NCT00557102|Drug|irinotecan hydrochloride|
329132|NCT00557102|Drug|leucovorin calcium|
329133|NCT00557115|Other|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
329134|NCT00557128|Drug|COREG CR and lisinopril (FDC)|
329135|NCT00557154|Device|ultrasound|ultrasound used to identify target vein
329136|NCT00557154|Device|standard technique for venipuncture|routine equipment
329137|NCT00557180|Drug|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
334032|NCT00426439|Drug|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, < 34 kg: 4 tablets.
334033|NCT00426452|Drug|Vatalinib|
334034|NCT00426478|Drug|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
334035|NCT00003386|Drug|carboplatin|
334036|NCT00426478|Drug|Amlodipine (5mg)|
334037|NCT00426491|Drug|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
334038|NCT00426504|Procedure|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
334039|NCT00426517|Drug|Fludarabine|For patients with inflammatory disorders or immunodeficiencies with a predominant inflammatory component, we may use Fludarabine instead of TBI to increase the immunosuppression induced by the regimen as well as to try to decrease the target cells responsible for the inflammatory symptoms
334040|NCT00426517|Drug|Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine|Conditioning regimen in various combination based on patient underlining immune deficiency disorder
334041|NCT00426517|Drug|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
334042|NCT00429416|Drug|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
334043|NCT00429416|Drug|Tacrolimus|Tacrolimus given before and after HSCT infusion
334044|NCT00429416|Drug|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
334045|NCT00429416|Biological|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
334046|NCT00429416|Procedure|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
334047|NCT00003394|Drug|endocrine-modulating drug therapy|
334048|NCT00429429|Procedure|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
334049|NCT00429442|Drug|Simvastatin|80 mg once daily
334050|NCT00429442|Drug|placebo|calcium tablets once daily
334051|NCT00429455|Behavioral|Survey|3-Part Questionnaire
333330|NCT00443755|Drug|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
333331|NCT00443781|Procedure|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
333332|NCT00443781|Procedure|provocative discography|Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as ("concordant") or different from ("not concordant" or "discordant") typical back pain.
333333|NCT00003437|Drug|pegaspargase|
333334|NCT00443794|Drug|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
333335|NCT00443794|Drug|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
333336|NCT00443794|Drug|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
333337|NCT00443794|Drug|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
333338|NCT00443794|Drug|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
333682|NCT00435240|Behavioral|Paleolithic diet|
333683|NCT00435253|Biological|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
333684|NCT00435266|Procedure|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
333685|NCT00435279|Drug|Eszopiclone|Eszopiclone 3 mg
333686|NCT00435279|Drug|Placebo|Placebo
333687|NCT00435279|Drug|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
333688|NCT00435292|Drug|Naproxen|nonsteroidal anti-inflammatory drug
333689|NCT00435292|Dietary Supplement|flavocoxid 250 mg|flavonoid mixture
333690|NCT00437970|Drug|Pioglitazone|15mg of Pioglitazone taken orally twice a day
333691|NCT00437970|Drug|Metformin|500 mg of Metformin taken orally twice a day
333692|NCT00437983|Dietary Supplement|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
332978|NCT00003491|Drug|antineoplaston A10|
332979|NCT00452179|Drug|APD125|
332980|NCT00452192|Drug|Telmisartan|telmisartan 80 mg daily over 2 weeks
332981|NCT00452218|Drug|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
332982|NCT00452231|Drug|D-cycloserine|
332983|NCT00452231|Behavioral|Cognitive-Behavioral Therapy|
332984|NCT00452244|Drug|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
332985|NCT00452244|Drug|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
332986|NCT00452257|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
332987|NCT00452270|Drug|Xylometazoline|
332988|NCT00452296|Drug|tight insulin treatment in patients hospitalized with COPD exacerbation|treatment with basal plus bolus insulin
332989|NCT00003491|Drug|antineoplaston AS2-1|
332990|NCT00452296|Procedure|tight glycemic control|treatment with basal and bolus insulin
332991|NCT00452322|Drug|Testosterone Substitution by Testosterone Undecanoate i.m.|
332992|NCT00452335|Drug|Lubiprostone|12 mcg capsule once daily (QD)
332993|NCT00452335|Drug|Lubiprostone|12 mcg capsule twice daily (BID)
332994|NCT00452335|Drug|Lubiprostone|24 mcg capsule twice daily (BID)
332995|NCT00452348|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
332996|NCT00452348|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
332997|NCT00452361|Drug|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
332998|NCT00452361|Drug|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|The maintenance dose of:
MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day
AZA will not exceed 75 mg/day
Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:
continued for the entire 104-week period of randomized therapy
subsequently discontinued
restarted after discontinuation
332288|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
332289|NCT00423059|Drug|bevacizumab|
332290|NCT00423085|Drug|Rivastigmine transdermal patch|Rivastigmine transdermal patch was provided in the following sizes and doses:
2.5 cm^2 (4.5 mg), 5 cm^2 (9 mg), 7.5 cm^2 (13.5 mg), and 10 cm^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
332291|NCT00423085|Drug|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm^2, 5 cm^2, 7.5 cm^2 and 10 cm^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
332292|NCT00003364|Drug|doxorubicin hydrochloride|
332293|NCT00423098|Drug|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
332294|NCT00423098|Drug|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
332295|NCT00423098|Drug|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
332296|NCT00423124|Genetic|HSV-TK|Infusion of genetically modified lymphocytes (1x10^6-1x10^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
332625|NCT00414128|Drug|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
332626|NCT00414141|Biological|Grass MATA MPL|4 subcutaneous injections
332627|NCT00414141|Biological|Placebo|4 subcutaneous injections
332628|NCT00414154|Behavioral|Group based multidisciplinary patient education programme|
332629|NCT00414167|Drug|bupropion|300 mg per day for 8 weeks
332630|NCT00414167|Other|Placebo|Placebo
332631|NCT00414180|Drug|Bupropion SR|
332632|NCT00000148|Procedure|Argon Laser Trabeculoplasty|
332633|NCT00000508|Behavioral|exercise|
332634|NCT00003313|Biological|filgrastim|
332635|NCT00414206|Drug|Mecamylamine|
332636|NCT00414206|Drug|Placebo|
331594|NCT00439907|Procedure|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
331945|NCT00431561|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
331946|NCT00431561|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
331947|NCT00431574|Procedure|dosing|
331948|NCT00431600|Other|100% Oxygen|100% Oxygen- breathing over 30 minutes
331949|NCT00003398|Procedure|allogeneic bone marrow transplantation|
331950|NCT00431613|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
331951|NCT00431613|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
331952|NCT00431613|Drug|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
331953|NCT00431613|Radiation|Chemoradiotherapy|After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.
During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32
331954|NCT00431613|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
331955|NCT00431626|Drug|Dutasteride (Avodart)|
331956|NCT00431626|Drug|Placebo|Placebo before and after treatment of TURP
331957|NCT00431639|Behavioral|Animal Assisted Therapy|
331958|NCT00431665|Drug|NG-monomethyl-L-Arginine (L-NMMA)|
331959|NCT00431665|Drug|triglycerides (Intralipid 20%)|
331960|NCT00003398|Procedure|bone marrow ablation with stem cell support|
331961|NCT00431665|Drug|heparin|
331962|NCT00431665|Drug|somatostatin|
331963|NCT00431665|Drug|insulin|
331964|NCT00431665|Drug|glucose|
331965|NCT00431665|Drug|inulin|
331221|NCT00448474|Behavioral|Mailed Arthritis Self-Management Education|
331222|NCT00448513|Dietary Supplement|catechin extracts|comparison with placebo
331223|NCT00448526|Behavioral|low protein diet|
331224|NCT00448539|Drug|Rufinamide|400 mg tablet administered in two equally divided daily doses.
331225|NCT00448539|Drug|Placebo|Subjects who had received placebo began receiving rufinamide at a dose of 800 mg/day at the start of the Transition Phase, with subsequent dose increases to 3200 mg/day over the 12-day Transition Phase.
331226|NCT00448552|Drug|capecitabine|
331227|NCT00448552|Drug|oxaliplatin|
331228|NCT00003467|Procedure|surgical procedure|
331229|NCT00448578|Drug|Quetiapine Fumarate|
331230|NCT00448578|Drug|Lithium|
331231|NCT00448591|Drug|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
331232|NCT00448591|Drug|Taxane-based chemotherapy|As prescribed
331595|NCT00439907|Procedure|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
331596|NCT00439920|Drug|High-dose anthracycline|
331597|NCT00439933|Behavioral|low fat and polysaccharide rich diet|
331598|NCT00003423|Drug|methotrexate|
331599|NCT00439933|Behavioral|specific physical training program for obese children|
331600|NCT00439946|Drug|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
331601|NCT00439946|Device|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
331602|NCT00439959|Drug|GSK625433/placebo|
331603|NCT00439972|Drug|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
304495|NCT00256867|Drug|GSK523338|
304496|NCT00256880|Drug|GW786034|
304497|NCT00256893|Drug|ropinirole|
304498|NCT00256919|Drug|GW856553|
304499|NCT00256932|Drug|alvimopan|0.5 mg
304500|NCT00256932|Drug|Placebo|
304501|NCT00002689|Radiation|brachytherapy|
304502|NCT00256945|Procedure|dental restorative material surface preparation|
304503|NCT00256958|Procedure|total knee replacement|
304504|NCT00256971|Procedure|meniscectomy|
304865|NCT00244296|Drug|placebo|
304866|NCT00244309|Drug|tamsulosin and/or dutasteride|
304867|NCT00244322|Drug|LY450139 dihydrate|
304868|NCT00244322|Drug|placebo|
304869|NCT00247221|Behavioral|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
304870|NCT00247221|Behavioral|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
304871|NCT00247234|Behavioral|Schema Therapy|group based schema therapy
304872|NCT00247234|Behavioral|standard care|standard psychiatric out-patient care
304873|NCT00247247|Drug|Comtess®|
304874|NCT00002657|Drug|etoposide|120 mg/m^2
304875|NCT00247260|Device|32P BioSilicon|
304876|NCT00247273|Drug|risedronate|tablet, 5 mg risedronate, once a day for 2 years
304877|NCT00247273|Drug|risedronate|oral, 150 mg risedronate, once a month for 2 years
304878|NCT00247286|Behavioral|weighted vaginal cones|
304126|NCT00209755|Procedure|therapeutic drug monitoring of ribavirin and dose adaptation|
304127|NCT00209768|Device|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
304128|NCT00002557|Drug|doxorubicin hydrochloride|
304129|NCT00209781|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
304130|NCT00209781|Device|ITNs|
304131|NCT00209794|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
304132|NCT00209807|Drug|escitalopram|escitalopram 10 mg/d for 6 weeks
304133|NCT00209807|Drug|Reboxetine|Reboxetine 8 mg/d for 6 weeks
304134|NCT00209807|Other|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
304135|NCT00209820|Behavioral|Supervised Nordic Walking|
304136|NCT00209820|Behavioral|Unsupervised Nordic Walking|
304137|NCT00209820|Behavioral|Advice to stay active|
304138|NCT00209833|Drug|Cytarabine|
304139|NCT00002557|Drug|etoposide|
304140|NCT00209833|Drug|Idarubicin|
304141|NCT00209833|Drug|Etoposide|
304142|NCT00209833|Drug|Fludarabine|
304143|NCT00209833|Drug|G-CSF|
304144|NCT00209833|Drug|Daunorubicine|
304145|NCT00209846|Drug|Gaboxadol|
304505|NCT00256984|Procedure|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
304506|NCT00256997|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
304507|NCT00256997|Drug|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
303399|NCT00000398|Behavioral|Coping skills training|
303400|NCT00002611|Procedure|conventional surgery|
303401|NCT00232557|Device|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
303402|NCT00232570|Drug|quetiapine|
303403|NCT00232583|Drug|Metformin|Metformin 1000mg/BID
303762|NCT00221078|Device|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
303763|NCT00002582|Drug|cyclophosphamide|
303764|NCT00221091|Procedure|ventriculo-peritoneal shunt|
303765|NCT00221104|Drug|Pravastatin|
303766|NCT00221117|Device|Neuroprosthesis|The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
303767|NCT00221130|Procedure|surgical operation of cell transplantation|
303768|NCT00221143|Genetic|Autologous peripheral blood CD34 positive cell therapy|
303769|NCT00221156|Drug|Acarbose|
303770|NCT00221169|Procedure|Surgical resection|pet ct prior to surgery
303771|NCT00221182|Genetic|Autologous peripheral blood CD34 positive cell therapy|
303772|NCT00221195|Drug|activated prothrombin complex concentrate (FEIBA)|
303773|NCT00221208|Behavioral|Resistance Training|
303774|NCT00002582|Drug|doxorubicin hydrochloride|
303775|NCT00221221|Device|Pedometer|
303776|NCT00221221|Device|Exercise guidebook|
303777|NCT00221234|Behavioral|Print materials, pedometers/logbooks|
303778|NCT00221234|Behavioral|Print materials, pedometers/logbooks, telephone counselling|
303051|NCT00389558|Procedure|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
303052|NCT00389584|Drug|irinotecan hydrochloride|
303053|NCT00389584|Procedure|cognitive assessment|
303054|NCT00389584|Procedure|management of therapy complications|
303055|NCT00389584|Radiation|radiation therapy|
303056|NCT00389597|Device|Cervical Artificial Disc|Cervical artificial disc mechanical device
303057|NCT00389610|Biological|allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine|Given subcutaneously
303058|NCT00389636|Device|TheraGauze|TheraGauze
303059|NCT00389636|Drug|Regranex|Regranex + TheraGauze
303060|NCT00389649|Device|heart rate setting|
303061|NCT00003195|Biological|recombinant interferon alfa|
303062|NCT00389662|Device|Wearing the "Nike Free" shoe|
303063|NCT00389675|Drug|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
303064|NCT00389675|Drug|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
303065|NCT00389688|Drug|cisplatin|
303066|NCT00389688|Drug|pemetrexed disodium|
303067|NCT00389688|Procedure|adjuvant therapy|
303068|NCT00389688|Procedure|conventional surgery|
303404|NCT00232583|Drug|Insulin|Insulin Novolg 70/30 per protocol titration
303405|NCT00232583|Drug|Metfomin|Metformin 1000mg/BID
303406|NCT00232583|Drug|Pioglitazone|Pioglitazone 45mg
303407|NCT00232583|Drug|glyburide|Glyburide per protocol titration
303408|NCT00232596|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
302712|NCT00397800|Biological|rituximab|
302713|NCT00397800|Drug|cyclophosphamide|
302714|NCT00397800|Drug|fludarabine phosphate|
302715|NCT00397800|Radiation|yttrium Y 90 ibritumomab tiuxetan|
302716|NCT00397813|Drug|Cyclosporine|Given PO
302717|NCT00397813|Drug|Fludarabine Phosphate|Given IV
302718|NCT00397813|Other|Laboratory Biomarker Analysis|Correlative studies
302719|NCT00397813|Drug|Mycophenolate Mofetil|Given PO
302720|NCT00003224|Biological|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
302721|NCT00397813|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
302722|NCT00397813|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
302723|NCT00397813|Radiation|Total-Body Irradiation|Undergo TBI
302724|NCT00397826|Drug|MK0733|Duration of Treatment: 12 Weeks
302725|NCT00397839|Drug|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
302726|NCT00400686|Biological|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
302727|NCT00003242|Drug|cisplatin|
302728|NCT00400699|Other|counseling intervention|
302729|NCT00400699|Other|study of socioeconomic and demographic variables|
302730|NCT00400699|Procedure|psychosocial assessment and care|
302731|NCT00400712|Behavioral|physical rehabilitation|two weeks intensive physical rehabilitation
302732|NCT00400725|Drug|Clobex Shampoo 0.05%|twice weekly
302733|NCT00400725|Drug|clobex shampoo placebo|twice weekly
302734|NCT00400738|Drug|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
301998|NCT00412451|Drug|ocriplasmin|Intravitreal injection, single administration
301999|NCT00412451|Other|Sham injection|Sham intravitreal injection
302000|NCT00412464|Drug|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
302001|NCT00412477|Biological|HIV LFn-p24|
302002|NCT00003304|Drug|temozolomide|
302003|NCT00412490|Behavioral|Questionnaire|Written survey at 1 Month & 6 Months post surgery.
302004|NCT00412490|Behavioral|Interview|One-on-One meeting lasting about one hour, at 1 Month & 6 Months post surgery.
302005|NCT00412503|Drug|Topotecan, Temozolomide|
302006|NCT00003093|Procedure|neoadjuvant therapy|
302007|NCT00368056|Drug|Eszopiclone|eszopiclone 3 mg
302008|NCT00368056|Drug|Placebo|Placebo tablet
302009|NCT00368069|Drug|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
302010|NCT00368069|Drug|Placebo|oral tablets, 2 tablets once daily
302385|NCT00406536|Dietary Supplement|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
302386|NCT00406536|Dietary Supplement|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is >99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
302387|NCT00406562|Biological|Boostrix|
302388|NCT00406575|Drug|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
302389|NCT00003273|Drug|carboplatin|
302390|NCT00406575|Drug|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
302391|NCT00406588|Drug|Levodopa (Pardoprunox)|12-42mg
302392|NCT00406588|Drug|Placebo Comparator|Placebo
301663|NCT00000487|Behavioral|diet, fat-restricted|
302011|NCT00368082|Genetic|TGFbeta resistant LMP-specific CTLs|Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Group One:
Day 0 2 x 10^7 cells/m2 Day 14 2 x 10^7 cells/m2
Group Two:
Day 0 6 x 10^7 cells/m2 Day 14 6 x 10^7 cells/m2
Group Three:
Day 0 1.5 x 10^8 cells/m2 Day 14 1.5 x 10^8 cells/m2
302012|NCT00368095|Behavioral|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
302013|NCT00368108|Drug|2 mg perampanel|2 mg perampanel
302014|NCT00368108|Drug|4 mg perampanel|4 mg perampanel
302015|NCT00368108|Drug|placebo comparator|placebo comparator
302016|NCT00368121|Drug|Cetuximab +/- Dexamethasone|Cetuximab dosing schedule:
• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion
Dexamethasone dosing schedule:
• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.
Mode of administration: orally
302017|NCT00003094|Other|preventative dietary intervention|
302018|NCT00368134|Drug|Vildagliptin|
302019|NCT00368160|Drug|Eszopiclone|eszopiclone 3 mg
302020|NCT00368160|Drug|Placebo|Placebo tablet
302021|NCT00368173|Drug|rhIGF-I/rhIGFBP-3|
302022|NCT00368186|Biological|Pneumo 23|
302023|NCT00368212|Behavioral|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
302024|NCT00368212|Behavioral|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
302025|NCT00368238|Drug|Recombinant human erythropoietin alfa (drug)|
302026|NCT00368238|Drug|Aspirin (drug)|
302027|NCT00368238|Drug|Clopidogrel (drug)|
302028|NCT00003096|Genetic|DNA ploidy analysis|
302029|NCT00368251|Other|Placebo|Pharmaceutical Form: Tablet, Route of Administration: Oral use,
301306|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
301307|NCT00385736|Biological|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
301308|NCT00385749|Device|RV apical vs RV septal defibrillation threshold testing|
301309|NCT00385762|Drug|paroxetine|paroxetine 10-40mg daily x 5 weeks
301310|NCT00385775|Drug|AEG35156|weekly IV solution infused over 2 hrs
301311|NCT00003176|Drug|carmustine|
301312|NCT00385788|Drug|Gemcitabine|800 mg/m^2 IV over 30 minutes on Day -7 (1 day)
301313|NCT00385788|Drug|Fludarabine|33 mg/m^2 IV over 30 minutes Day -5 to Day -2 (4 days)
301314|NCT00385788|Drug|Melphalan|70 mg/m^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
301315|NCT00385788|Drug|Antithymocyte Globulin|2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.
If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant.
301316|NCT00385788|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
301317|NCT00385788|Drug|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
301664|NCT00003137|Drug|irinotecan hydrochloride|
301665|NCT00377429|Drug|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
301666|NCT00377442|Drug|GK Activator (2)|100mg po
301667|NCT00377442|Drug|Simvastatin|80mg po
301668|NCT00377455|Drug|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
301669|NCT00377455|Drug|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
301670|NCT00377468|Drug|Delta9-Tetrahydrocannabinol|
301671|NCT00377481|Drug|darbepoetin alfa|30 micrograms sc weekly (2 doses)
301672|NCT00377481|Drug|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
329448|NCT00552084|Drug|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
329449|NCT00552084|Drug|Placebo|Placebo supplements will be taken daily for 24 weeks.
329773|NCT00584948|Drug|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
329774|NCT00584961|Other|non-interventional|non-interventional
329775|NCT00584974|Drug|SEP-225289|0.5 mg SEP-225289
329776|NCT00584974|Drug|SEP-225289|2.0 mg SEP-225289
329777|NCT00584974|Drug|Venlafaxine|150 mg Venlafaxine
329778|NCT00584974|Drug|placebo|Placebo
329779|NCT00584987|Drug|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
329780|NCT00004162|Drug|vincristine sulfate|
329781|NCT00584987|Drug|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
329782|NCT00584987|Drug|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
329783|NCT00584987|Drug|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
329784|NCT00585000|Drug|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
329785|NCT00587756|Procedure|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
329786|NCT00587769|Drug|Bupropion SR & Varenicline|Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.
Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
329787|NCT00587795|Device|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after iniital injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months. X-rays and an exam will be obtained at each visit. In addition, patients will be asked to complete the Disability of the Arm, Shoulder and Hand (DASH) and Patient Rated Wrist Evaluation (PRWE) questionniares regarding their general health, daily activities and pain.
329788|NCT00587795|Other|Placement of sugar tong splint or plaster cast|Patients will recevie a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
329138|NCT00559559|Procedure|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
329139|NCT00559572|Behavioral|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
329140|NCT00559572|Other|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
329141|NCT00559585|Drug|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
329142|NCT00559585|Drug|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
500mg (for body weight up to 60 kg)
750 mg (body weight between 61 and 100 kg)
1g (body weight above 100 kg)infusions
329143|NCT00559598|Genetic|proteomic profiling|
329144|NCT00559598|Other|medical chart review|
329145|NCT00559611|Procedure|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
329146|NCT00559611|Procedure|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
329147|NCT00004037|Drug|docetaxel|
329148|NCT00559624|Drug|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
329450|NCT00552097|Drug|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
329451|NCT00552097|Drug|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
329452|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
329453|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
329454|NCT00552110|Drug|mometasone furoate nasal spray (MFNS) once daily|MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
329455|NCT00552110|Drug|oxymetazoline nasal spray (OXY) twice daily|OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
334052|NCT00429468|Drug|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
334053|NCT00429481|Biological|Rotarix|
328844|NCT00564096|Device|Deep H1 coil TMS|A new coil ("H"-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS.
328845|NCT00564109|Procedure|retrospective Observation|retrospective Observation
328846|NCT00564122|Device|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
328847|NCT00564122|Other|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
328848|NCT00564135|Procedure|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
328849|NCT00564148|Drug|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
328850|NCT00564174|Drug|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
328851|NCT00564174|Drug|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
328852|NCT00564187|Drug|Irbesartan|Irbesartan: 150mg tablets
Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
• 150mg/day for normalized patients and patients responding non normalized randomized in the group A
328853|NCT00004063|Biological|recombinant interferon alfa|
328854|NCT00564187|Drug|Irbesartan|Irbesartan: 150mg tablets
Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
328855|NCT00564200|Drug|Bortezomib|PREACONDICIONAMIENTO:
2 cycles of 21 days : Velcade days: 1, 4, 8 and 11
1 cycle of 13 days : Velcade days 1, 4, 8 and 11
ACONDICIONAMIENTO:
- Day -2: Velcade
POSTRANSPLANTATION:
2 cycles of 21 days : Velcade days 1, 8 and 15
5 cycles of 56 days : Velcade days 1, 8 and 15
328856|NCT00566527|Biological|ProQuad® manufactured with recombinant Human Albumine|2-dose regimen of ProQuad® (0.5 mL per dose) given at a 3-month interval
328857|NCT00566540|Drug|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
333693|NCT00437983|Dietary Supplement|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
333694|NCT00437996|Drug|Clonidine|
333695|NCT00003418|Drug|tamoxifen citrate|
333696|NCT00437996|Drug|Levobupivacaine|
333697|NCT00437996|Drug|Sufentanil|
333698|NCT00438009|Drug|Coxsackievirus A21|Two doses of drug, separated by 48 hours
333699|NCT00438035|Procedure|ECG spectral|
333700|NCT00438048|Procedure|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
333701|NCT00438048|Drug|Artificial Saliva|5ml 3 times daily
333702|NCT00438061|Behavioral|Weight loss by dietary restriction|
333703|NCT00438087|Drug|methylprednisolone|methylprednisolone administrated intra and post operatively
333704|NCT00438100|Drug|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
333705|NCT00438100|Drug|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
333706|NCT00003419|Procedure|antiviral therapy|
334054|NCT00429494|Drug|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
334055|NCT00429494|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
334056|NCT00429494|Procedure|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
334057|NCT00429507|Drug|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
334058|NCT00003394|Drug|estramustine phosphate sodium|
334059|NCT00429507|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
334060|NCT00429507|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
334061|NCT00429520|Drug|Hyaluronic acid filler/IMD1 basic|
333339|NCT00443794|Drug|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
333340|NCT00443794|Drug|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
333341|NCT00443794|Drug|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
333342|NCT00443794|Drug|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
333343|NCT00446316|Drug|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
333344|NCT00446329|Drug|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
333345|NCT00446342|Drug|SNS-032 Injection|Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle
Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1
333346|NCT00446368|Drug|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
333347|NCT00446381|Drug|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
333348|NCT00446381|Drug|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
333349|NCT00003455|Procedure|biologically based therapies|
333350|NCT00446394|Behavioral|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
333351|NCT00446394|Behavioral|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
333352|NCT00446407|Other|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
333353|NCT00446407|Other|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
333354|NCT00446420|Drug|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
333355|NCT00446433|Drug|CC-5013|
333356|NCT00446446|Drug|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
333357|NCT00446459|Drug|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
332637|NCT00414219|Behavioral|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
332638|NCT00414245|Drug|metformin|
332639|NCT00414258|Procedure|breastfeeding|See detailed description.
332640|NCT00414271|Drug|Capecitabine, doxcetaxol|
332641|NCT00414284|Drug|Increased dose of Kaletra|
332642|NCT00414297|Device|ECP Therapy|application of ECP Therapy to CAD Patients
332643|NCT00414310|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days.
332644|NCT00414310|Drug|Valproic Acid|50 mg/kg orally daily for 7 days
332645|NCT00003313|Drug|amifostine trihydrate|
332646|NCT00414323|Drug|Duloxetine|
332647|NCT00414323|Drug|Escitalopram|
332648|NCT00414323|Drug|Placebo|
332649|NCT00416975|Procedure|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
332999|NCT00452374|Drug|Cytarabine|1 g/m^2 given IV for two days (Days 2 and 3).
333000|NCT00455000|Drug|Placebo|Placebo
333001|NCT00455013|Drug|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
333002|NCT00455013|Drug|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
333003|NCT00003508|Drug|antineoplaston A10|
333004|NCT00455013|Drug|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
331966|NCT00431665|Drug|paraamino hippurate (PAH)|
331967|NCT00431678|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
331968|NCT00431678|Drug|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
332297|NCT00423137|Drug|BIBW 2948 BS|
332298|NCT00423137|Drug|Placebo|
332299|NCT00423150|Drug|Temozolomide|Temozolomide capsules 150 mg/m^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
332300|NCT00423163|Drug|micafungin|
332301|NCT00423163|Drug|voriconazole|
332302|NCT00423176|Drug|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
332303|NCT00003364|Drug|etoposide|
332304|NCT00423176|Drug|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
332305|NCT00423189|Drug|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
332306|NCT00423189|Drug|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
332307|NCT00423202|Drug|ambrisentan|
332308|NCT00423215|Drug|Insulin glargine (LANTUS)|The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.
Treatment duration: 4 months.
332309|NCT00425607|Drug|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
332310|NCT00425620|Drug|SinuNase|Lavage
332311|NCT00003382|Biological|filgrastim|
332312|NCT00425633|Drug|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
332313|NCT00425646|Biological|bevacizumab|
332314|NCT00425646|Drug|imatinib mesylate|
299694|NCT00393354|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
299695|NCT00393367|Drug|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
299696|NCT00393367|Drug|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
299697|NCT00393367|Drug|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
299698|NCT00393367|Drug|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
299699|NCT00393380|Drug|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC>2000/microL: PTH 100 mcg
299700|NCT00003211|Drug|cyclophosphamide|
299701|NCT00393393|Drug|intra-articular injection of Hylan G-F 20|
299702|NCT00393419|Behavioral|Comprehensive pharmacy care program|
299703|NCT00393445|Drug|GLP-1 control|intravenous infusion of GLP-1
299704|NCT00393445|Drug|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
299705|NCT00393445|Drug|saline control|intravenous infusion of saline
299706|NCT00393445|Drug|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
299707|NCT00393445|Drug|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
299708|NCT00393445|Drug|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
300067|NCT00385177|Drug|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
300068|NCT00003173|Biological|filgrastim|
300069|NCT00385190|Drug|HCV-796|
304879|NCT00247286|Behavioral|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
304880|NCT00247299|Device|IPL Quantum Product manufactured by Luminis Ltd.|
304881|NCT00247312|Radiation|Pd-103|
304882|NCT00247325|Drug|Iodixanol(Drug)|
304883|NCT00247338|Drug|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
304884|NCT00247351|Procedure|Cryoablation|
304885|NCT00002657|Drug|methotrexate|120 mg/m^2
304886|NCT00247364|Drug|Levetiracetam (Keppra)|
304887|NCT00247377|Procedure|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
304888|NCT00247377|Procedure|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
304889|NCT00247390|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
299318|NCT00003253|Drug|paclitaxel|
299319|NCT00402194|Drug|Losartan|Tablet, 100mg, once per day for 3 months
299320|NCT00402207|Drug|extrafine HFA-beclomethasone|
299321|NCT00402207|Drug|HFA-fluticasone|
299322|NCT00402220|Drug|TMS|Active Transcranial Magnetic Stimulation
299323|NCT00402220|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
299324|NCT00402233|Drug|Pramipexole|
299325|NCT00402233|Drug|Placebo|
299326|NCT00402246|Other|Remote Management|The Remote Management method of treating patients consists of 3 components:
CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)
Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line
CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.
The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action.
299327|NCT00402246|Other|In-Office Care|Routine in-office care
304508|NCT00257010|Drug|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
304509|NCT00257023|Drug|paliperidone|
304510|NCT00257036|Drug|levofloxacin|
304511|NCT00257049|Drug|levofloxacin|
304512|NCT00002689|Radiation|phosphorus P32|
304513|NCT00257062|Drug|Levofloxacin|
304514|NCT00257075|Drug|Risperidone, oral tablets|
304515|NCT00257088|Behavioral|whole day first grade program|
304516|NCT00257101|Behavioral|self-medication monitoring|
304517|NCT00257114|Drug|bortezomib|
304518|NCT00257127|Biological|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
304519|NCT00257127|Biological|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
304520|NCT00257127|Biological|Hepatitis B vaccine|0.5 mL administered intramuscularly
304521|NCT02718807|Other|RP model explanation and questionnaire|Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
304522|NCT02718820|Drug|Docetaxel|Docetaxel 75mg/m2; q21
304523|NCT02718820|Drug|Pembrolizumab|Pembrolizumab 200mg, q21
304524|NCT02718833|Drug|Elotuzumab|
304525|NCT02718833|Drug|Pomalidomide|
304526|NCT02718833|Drug|Bortezomib|
304527|NCT02718833|Drug|Dexamethasone|
304528|NCT02718846|Drug|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
304890|NCT00247390|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
304891|NCT00247403|Drug|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
303779|NCT00221247|Procedure|Acupuncture; deep massage; physical therapy; occupational therapy; and hydrotherapy|
303780|NCT00221260|Procedure|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
303781|NCT00224770|Procedure|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
303782|NCT00002592|Procedure|in vitro-treated bone marrow transplantation|
303783|NCT00224783|Biological|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
303784|NCT00224783|Biological|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
304146|NCT00209859|Drug|Methotrexate|
304147|NCT00209859|Drug|Intraarticular betamethasone|
304148|NCT00209859|Drug|Cyclosporine/placebo-cyclosporine|
304149|NCT00209872|Drug|Gabapentin|
304150|NCT00002557|Drug|leucovorin calcium|
304151|NCT00214045|Device|Flexible versus Rigid Cystoscopes|
304152|NCT00214058|Drug|Carboplatin|
304153|NCT00214058|Drug|Docetaxel|
304154|NCT00002566|Drug|carboplatin|
304155|NCT00214071|Biological|Influenza vaccine|
304156|NCT00214084|Drug|Allopurinol|
304157|NCT00214097|Procedure|Radiotherapy|Daily radiation to prescribed dose
304158|NCT00214110|Drug|Tamoxifen|
304159|NCT00214123|Radiation|radiation therapy (radiotherapy)|Bin assignment based on tumor volume
304160|NCT00214136|Radiation|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
304161|NCT00214149|Radiation|brachytherapy|breast brachytherapy to 34 Gy
304162|NCT00214162|Behavioral|Comprehensive Health Enhancement Support System|Full CHESS
303409|NCT00232596|Drug|Placebo|Oral tablet.
303410|NCT00000399|Procedure|Strength training|
303411|NCT00002624|Procedure|adjuvant therapy|
303412|NCT00236119|Drug|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
303413|NCT00236119|Drug|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
303414|NCT00236119|Drug|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
303415|NCT00236119|Drug|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
303416|NCT00236145|Drug|ACTIQ (Oral transmucosal fentanyl citrate)|
303417|NCT00236158|Device|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
303418|NCT00236171|Drug|Protopic, Advantan|
303419|NCT00236171|Procedure|Blood and Urine Test|
303420|NCT00236171|Procedure|coherence tomography|
303421|NCT00236184|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
303422|NCT00002624|Procedure|diagnostic thoracoscopy|
303423|NCT00236184|Other|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
303785|NCT00224796|Device|V.A.C. ® System|
303786|NCT00224809|Drug|Angiotensin-Converting Enzyme Inhibitors|
303787|NCT00224809|Procedure|Coronary Artery Bypass Graft|
303788|NCT00224809|Drug|Angiotensin Receptor Blockers|
303789|NCT00224809|Drug|Spironolactone|
302735|NCT00400751|Behavioral|FAMCON (Family Consultation)|
302736|NCT00400764|Drug|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
303069|NCT00392093|Drug|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
303070|NCT00392106|Drug|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
303071|NCT00392106|Drug|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
303072|NCT00392106|Drug|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
303073|NCT00000497|Behavioral|diet, reducing|
303074|NCT00003204|Biological|rituximab|Given IV
303075|NCT00392106|Drug|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
303076|NCT00392106|Device|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
303077|NCT00392106|Drug|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
303078|NCT00392119|Device|MR-guided Laser Interstitial Thermal Therapy System|
303079|NCT00392145|Drug|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
303080|NCT00392145|Drug|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
303081|NCT00392158|Device|Closed-loop anesthesia system|
303082|NCT00392171|Drug|Temozolomide|Subjects will receive temozolomide 50 mg/m^2 for cycles of 28 days for 12 months or until progression
303083|NCT00392184|Procedure|Accelerated partial breast irradiation|
303084|NCT00392197|Drug|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
303085|NCT00003204|Other|laboratory biomarker analysis|Correlative studies
303086|NCT00392210|Genetic|Voiding Trial|Post-void residual and uroflow study will be done twice
303087|NCT00392223|Drug|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
302393|NCT00003287|Drug|FOLFOX regimen|
302394|NCT00409487|Drug|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
302395|NCT00409500|Drug|AQW051|
302396|NCT00409526|Drug|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
302397|NCT00409539|Drug|Placebo|Placebo, 2 week duration.
302398|NCT00409539|Drug|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
302399|NCT00409539|Drug|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
302400|NCT00409552|Behavioral|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
302401|NCT00409552|Behavioral|VR with flat projection display|VR with flat projection display
302402|NCT00409552|Behavioral|non-interactive video with head display|non-interactive video with head display
302403|NCT00409552|Behavioral|non-interactive video with with flat projection display|non-interactive video with with flat projection display
302404|NCT00003287|Drug|fluorouracil|
302405|NCT00409565|Drug|Cetuximab|Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY
Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
302406|NCT00409565|Drug|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
302737|NCT00400764|Drug|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
302738|NCT00003242|Drug|paclitaxel|
302739|NCT00400777|Drug|Valsartan, hydrochlorothiazide and amlodipine|
302740|NCT00400790|Drug|propofol|Propofol used as the primary anaesthetic agent
302741|NCT00400790|Drug|desflurane|Desflurane used as the primary anaesthetic
302742|NCT00400803|Drug|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
302030|NCT00368251|Drug|BRV 2.5 mg|Active Substance: Brivaracetam, Pharmaceutical Form: Tablet, Concentration: 2.5 mg, Route of Administration: Oral use
302031|NCT00368251|Drug|BRV 25 mg|Active Substance: Brivaracetam, Pharmaceutical Form: Tablet, Concentration: 25 mg, Route of Administration: Oral use
302032|NCT00368251|Drug|BRV 50 mg|Active Substance: Brivaracetam, Pharmaceutical Form: Tablet, Concentration: 50 mg, Route of Administration: Oral use,
302407|NCT00409578|Drug|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
302408|NCT00409578|Drug|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
302409|NCT00409578|Drug|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
302410|NCT00409578|Drug|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
302411|NCT00412516|Biological|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
302412|NCT00412529|Drug|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
302413|NCT00412529|Drug|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
302414|NCT00412542|Drug|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
302415|NCT00412542|Drug|CPT-11|125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
302416|NCT00412542|Procedure|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
301673|NCT00377494|Biological|MVA-CSO Vaccine|
301674|NCT00377494|Biological|PfCSP DNA (VCL-2510) Vaccine|
301675|NCT00003138|Biological|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
301676|NCT00377507|Dietary Supplement|catechin extracts|catechin extracts solution
301677|NCT00377520|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
301678|NCT00377533|Device|wheelchair rear anti-tip device|assistive device
301679|NCT00377546|Drug|Nepafenac|
301680|NCT00377546|Drug|Ketorolac LS, Bromfenac|
301681|NCT00377559|Drug|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
301682|NCT00377572|Biological|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
301683|NCT00380081|Drug|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
301684|NCT00380120|Drug|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
301685|NCT00380120|Drug|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
301686|NCT00380133|Drug|SB681323|5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
302033|NCT00371176|Behavioral|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
302034|NCT00371176|Drug|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
302035|NCT00371176|Other|Placebo pill|
302036|NCT00371189|Drug|Placebo|Normal saline.
302037|NCT00003111|Drug|cisplatin|
302038|NCT00371189|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
329789|NCT00587808|Procedure|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
329790|NCT00587821|Other|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
329791|NCT00587834|Device|Gintuit|Application of Gintuit at Day 0 to the gingival bed
329792|NCT00587834|Other|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
330090|NCT00577278|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
330091|NCT00577278|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
330092|NCT00577278|Other|laboratory biomarker analysis|Correlative Studies
330093|NCT00004125|Drug|tamoxifen citrate|
330094|NCT00577304|Drug|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
330095|NCT00577304|Drug|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
330096|NCT00579527|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV prior to thymus or thymus and parathyroid transplantation. Each dose is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to thymus or thymus and parathyroid transplantation. Medications (diphenenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
330097|NCT00579527|Drug|Cyclosporine|Csa may be given every 8 to 12 hours orally or IV before and after thymus transplantation or thymus and parathyroid transplantation. The Csa dose is dependant on T cell numbers and the targert Csa trough levels. Csa is weaned as per protocol.
330098|NCT00004135|Procedure|peripheral blood stem cell transplantation|
330099|NCT00579527|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 to 12 hours orally or IV before and after the thymus transplant or the thymus/parathyroid transplant. FK506 dose is dependent on the T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
330100|NCT00579527|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and after thymus or thymus/parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Steroids are weaned as per protocol.
329456|NCT00552110|Drug|Placebo|Matching placebo to MFNS given every morning and every evening x 2 weeks.
329457|NCT00552136|Procedure|Ankle Arthroplasty|
329458|NCT00003995|Biological|trastuzumab|
329459|NCT00552136|Procedure|Ankle Arthrodesis|
329460|NCT00552149|Drug|Gemox, Cetuximab|GEMOX (Arms 1 and 2), every two weeks:
Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h
Cetuximab (ErbituxÒ) (Arm B only) every two weeks:
(chemotherapy will be started one hour after the end of the cetuximab infusion).
Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes
329461|NCT00552162|Procedure|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
329462|NCT00554710|Drug|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
329463|NCT00554710|Drug|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
329464|NCT00554723|Drug|NeuroAid|4 capsules 3 times daily, for three months
329465|NCT00554723|Drug|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
329466|NCT00554736|Biological|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
329467|NCT00554749|Behavioral|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
329468|NCT00004009|Drug|tipifarnib|
329793|NCT00587847|Drug|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
329794|NCT00004174|Drug|paclitaxel|
329795|NCT00587860|Drug|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
329796|NCT00587860|Drug|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
329797|NCT00587873|Drug|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
328858|NCT00566540|Drug|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
328859|NCT00566540|Radiation|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
329149|NCT00559637|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|1.2 micrograms/kg sc monthly, starting dose
329150|NCT00559650|Drug|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
329151|NCT00559650|Drug|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
329152|NCT00559663|Dietary Supplement|Green tea|The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.
After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.
Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels
329153|NCT00559663|Dietary Supplement|70% dark chocolate|The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.
After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).
Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels.
329154|NCT00559676|Drug|capecitabine|
329155|NCT00559676|Drug|fluorouracil|
329156|NCT00559676|Drug|irinotecan hydrochloride|
329157|NCT00559676|Drug|leucovorin calcium|
329158|NCT00004038|Biological|Ad5CMV-p53 gene|
329159|NCT00559676|Drug|oxaliplatin|
329160|NCT00559676|Other|laboratory biomarker analysis|
329161|NCT00561834|Drug|ranibizumab|0.5mg ranibizumab given intravitreally as needed after initial treatment
329162|NCT00561860|Device|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
329163|NCT00004054|Drug|etoposide|50 mg/m^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
329164|NCT00561886|Drug|Formoterol|One inhalation of 24µg Formoterol
334062|NCT00429533|Drug|Dapsone|
334063|NCT00429546|Behavioral|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
334064|NCT00429546|Other|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
334065|NCT00429559|Drug|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
334066|NCT00429559|Drug|Gemcitabine|Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.
Number of cycles: until progression
334067|NCT00429572|Drug|Fludarabine|30 mg/m^2 intravenously Daily for 5 Days
334068|NCT00429572|Drug|Melphalan|70 mg/m^2 intravenously Daily for 2 Days
334069|NCT00432445|Procedure|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
334070|NCT00432458|Drug|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
334071|NCT00432458|Drug|zoledronic acid|4 mg^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
334072|NCT00432471|Procedure|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
334073|NCT00432484|Drug|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
334074|NCT00432510|Drug|C1 esterase inhibitor [human] (C1INH-nf)|
328860|NCT00566540|Procedure|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
328861|NCT00566553|Dietary Supplement|Grape Seed Extract|200 mg dose daily for 12 weeks.
328862|NCT00566553|Dietary Supplement|Grape Seed Extract|400 mg dose daily for 12 weeks.
328863|NCT00004077|Drug|paclitaxel|
328864|NCT00566553|Dietary Supplement|Grape Seed Extract|600 mg dose daily for 12 weeks.
333358|NCT00446472|Drug|Regranex®|Regranex gel will be used for a total of 16 weeks
333359|NCT00446472|Drug|Hydrogel|Placebo hydrogel will be applied for 16 weeks
333360|NCT00003455|Procedure|cancer prevention intervention|
333707|NCT00438113|Drug|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
333708|NCT00438126|Behavioral|A lifestyle educational program|
333709|NCT00438139|Drug|Dronabinol|
333710|NCT00438152|Drug|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
333711|NCT00438152|Drug|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
333712|NCT00438165|Behavioral|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
333713|NCT00438178|Drug|Obatoclax mesylate (GX15-070MS)|
333714|NCT00438204|Biological|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
333715|NCT00438204|Drug|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
333716|NCT00438204|Drug|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
333717|NCT00003420|Procedure|computed tomography|
333718|NCT00438217|Drug|Triptorelin (GnRH agonists)|
333719|NCT00438217|Drug|Leuprolide (GnRH agonists)|
333720|NCT00440609|Drug|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
333721|NCT00440622|Drug|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
333722|NCT00440622|Drug|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
333005|NCT00455013|Drug|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
333006|NCT00455013|Drug|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
333007|NCT00455026|Drug|remifentanil|target effect site concentration during induction
333008|NCT00455039|Drug|GW572016|Dose: 1500 mg daily
333009|NCT00455052|Drug|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
333010|NCT00455065|Behavioral|Whole Grain Foods|
333011|NCT00455078|Procedure|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
333012|NCT00455078|Other|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
333013|NCT00455078|Procedure|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
333014|NCT00003508|Drug|antineoplaston AS2-1|
333015|NCT00455078|Procedure|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
333016|NCT00455078|Procedure|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
333017|NCT00455091|Drug|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/> 105 copies/mL and ALT > 2.0 x UNL
333018|NCT00455104|Drug|agalsidase alfa|agalsidase alfa (Replagal®) 0.2 mg/kg IV Q2weeks
333361|NCT00446485|Drug|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
333362|NCT00446485|Drug|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
333363|NCT00446485|Drug|placebo|placebo during 6 months
333364|NCT00446498|Device|CPAP and Non Invasive Ventilation|
333365|NCT00446511|Drug|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
332315|NCT00425659|Device|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
332316|NCT00425659|Device|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
332317|NCT00425659|Device|CPAP|usual practice
332318|NCT00425672|Biological|ONTAK|Given IV
332319|NCT00425672|Other|flow cytometry|Correlative studies
332320|NCT00425672|Other|immunohistochemistry staining method|Correlative studies
332650|NCT00416988|Other|educational intervention|
332651|NCT00417001|Procedure|Aroma therapy|
332652|NCT00417014|Drug|chlorambucil|
332653|NCT00003335|Biological|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
332654|NCT00417014|Drug|prednisolone|
332655|NCT00417014|Drug|procarbazine hydrochloride|
332656|NCT00417014|Drug|vinblastine sulfate|
332657|NCT00417014|Radiation|radiation therapy|
332658|NCT00417027|Procedure|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
332659|NCT00417040|Other|internet-based intervention|Use the STAR database system
332660|NCT00417040|Procedure|assessment of therapy complications|Use the STAR database system
332661|NCT00417040|Other|Questionnaire Administration|Ancillary studies
332662|NCT00417053|Biological|filgrastim|
332663|NCT00417053|Drug|busulfan|
332664|NCT00003335|Drug|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
332665|NCT00417053|Drug|carboplatin|
332666|NCT00417053|Drug|cyclophosphamide|
300070|NCT00385203|Drug|AZD2171|45 mg oral tablet once daily dose
300071|NCT00385216|Drug|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
300072|NCT00385216|Other|Placebo|Placebo nasal spray 0mg x 1 before surgery
300073|NCT00385229|Drug|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
300074|NCT00385242|Procedure|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
300075|NCT00385242|Other|PET imaging|PET viability imaging
300076|NCT00385255|Biological|Tetanus toxoid,reduced diphtheria toxoid&acellular pertussis|
300077|NCT00385268|Drug|acamprosate|1998 mg/dau fpr 8 weeks
300078|NCT00388089|Other|immunoenzyme technique|No description
300079|NCT00003187|Procedure|in vitro-treated bone marrow transplantation|
300080|NCT00388089|Other|immunohistochemistry staining method|No description
300081|NCT00388089|Other|laboratory biomarker analysis|No description
300082|NCT00388115|Procedure|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
300083|NCT00388115|Procedure|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
300084|NCT00388115|Procedure|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
300085|NCT00388128|Drug|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
300086|NCT00388141|Behavioral|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
300087|NCT00388154|Drug|Gemcitabine|900 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
300088|NCT00388154|Drug|Cisplatin|30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
300089|NCT00388167|Drug|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
300090|NCT00003187|Radiation|radiation therapy|
299328|NCT00402259|Drug|Esomeprazole IV|
299329|NCT00003253|Other|antitumor drug screening assay|
299330|NCT00402259|Drug|Omeprazole IV|
299331|NCT00402272|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
299332|NCT00402285|Dietary Supplement|lycopene supplement|
299333|NCT00402285|Dietary Supplement|fish oil supplement|
299334|NCT00402285|Other|Placebo|placebos for lycopene and fish oil.
299335|NCT00402298|Drug|3,4-methylenedioxymethemphetmaine (MDMA_|Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long psychotherapy session.
299336|NCT00402298|Drug|3,4-methylenedioxymethamphetamine|Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long psychotherapy sessions.
299337|NCT00405080|Drug|Rifampin oral tablets|
299338|NCT00405119|Drug|AH23844 (lavoltidine)|
299339|NCT00405119|Drug|NEXIUM (esomeprazole)|
299340|NCT00405119|Drug|ZANTAC (ranitidine)|
299709|NCT00393458|Drug|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
299710|NCT00393458|Drug|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
299711|NCT00003211|Drug|vincristine sulfate|
299712|NCT00393458|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
299713|NCT00393458|Drug|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
299714|NCT00396227|Drug|vildagliptin|vildagliptin as add-on to metformin
299715|NCT00396227|Drug|thiazolidinedione (TZD)|TZD add-on to metformin
299716|NCT00396240|Drug|Rosuvastatin|
299717|NCT00396240|Procedure|Initiatives to improve compliance|
304892|NCT00247416|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
304893|NCT00247416|Drug|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
304894|NCT00247416|Drug|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
304895|NCT00247442|Behavioral|Decision aid|
304896|NCT00002657|Drug|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m^2.
304897|NCT00247455|Drug|Low fibre breakfast cereal (puffed rice/cornflakes)|
304898|NCT00247455|Drug|High fibre cereal (All Bran/Bran Flakes)|
304899|NCT00250913|Behavioral|Telephone-based physical activity counseling program|
304900|NCT00250926|Drug|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
304901|NCT00250926|Drug|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
304902|NCT00250926|Drug|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
304903|NCT00250939|Biological|Myozyme|20 mg/kg qow
304904|NCT00250952|Drug|Botox Cosmetic™|
304905|NCT00250965|Drug|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
304906|NCT00250978|Drug|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
304907|NCT00250991|Drug|activase|
304908|NCT00002665|Drug|thioguanine|main: 60 mg/m2/day PO 1 - 14
304909|NCT00250991|Drug|integrilin|
304910|NCT00251004|Drug|Everolimus|oral, bis in diem/twice a day (bid)
304911|NCT00251004|Drug|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
304912|NCT00251004|Drug|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
304163|NCT00214162|Behavioral|computer with internet|computer with internet use x 1 year
304164|NCT00214201|Drug|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
304165|NCT00002566|Drug|cisplatin|
304166|NCT00214214|Drug|Campath 1H® (Alemtuzumab)|
304167|NCT00214240|Drug|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
304168|NCT00214253|Drug|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
304169|NCT00214266|Drug|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
304170|NCT00214279|Drug|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
304171|NCT00214292|Procedure|fluorescence spectroscopy and diffuse spectroscopy|
304529|NCT02718846|Drug|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
304530|NCT00204425|Dietary Supplement|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
304531|NCT02718859|Biological|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
304532|NCT02718859|Procedure|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
304533|NCT02718872|Behavioral|Tobacco cessation online training|The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the "Brief Intervention for Smoking Cessation Training Program" is composed of 4 modules.
304534|NCT02718885|Dietary Supplement|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
304535|NCT02718885|Dietary Supplement|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
304536|NCT02718898|Drug|Ixekizumab|Administered SC
304537|NCT02718898|Drug|Placebo|Administered SC
303790|NCT00224809|Drug|Aspirin|
303791|NCT00224809|Drug|Clopidogrel|
303792|NCT00224809|Procedure|Surgical Ventricular Restoration|
303793|NCT00002593|Drug|fluorouracil|Given IV as described in Arm Description
303794|NCT00224822|Drug|Aripiprazole|
303795|NCT00224835|Behavioral|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
303796|NCT00224835|Behavioral|Cardiac Education Class|Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour "special experience" session, all of which will provide information about CAD in a didactic format.
303797|NCT00224848|Behavioral|Palm-Pilot Intervention|Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as "lunch and learn" sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed.
303798|NCT00224861|Behavioral|Self-Management|
303799|NCT00224861|Behavioral|Adherence|
303800|NCT00224874|Drug|Etanercept|Etanercept [25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks].
303801|NCT00224874|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) [20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks].
303802|NCT00224874|Drug|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) [9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19].
303803|NCT00224874|Drug|Pentostatin|Pentostatin [1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
303804|NCT00002593|Drug|leucovorin calcium|Given IV as described in Arm description.
303805|NCT00228553|Drug|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
304172|NCT00214305|Behavioral|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
303088|NCT00392223|Drug|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
303089|NCT00392223|Drug|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
303090|NCT00392223|Drug|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
303424|NCT00236197|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
303425|NCT00236197|Drug|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
303426|NCT00236210|Behavioral|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
303427|NCT00236210|Behavioral|VIP program|Risk assessment, lifestyle counselling, exercise program
303428|NCT00236223|Drug|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
303429|NCT00236223|Drug|Placebo|Matching placebo
303430|NCT00236236|Device|Cardiac Resynchronization Therapy|
303431|NCT00236249|Drug|Lidocaine|
303432|NCT00236262|Device|ventilatory strategies with pressure|
303433|NCT00002624|Procedure|therapeutic thoracoscopy|
303434|NCT00239642|Drug|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
303435|NCT00239642|Drug|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
303436|NCT00239642|Drug|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
303437|NCT00239655|Drug|MK0812|
303438|NCT00002634|Biological|monoclonal antibody 3F8|
303439|NCT00239681|Drug|Rosuvastatin|Oral
303440|NCT00239681|Other|Placebo|Oral
303441|NCT00239694|Biological|Pneumococcal Vaccine|One time preventative vaccine
302743|NCT00400816|Drug|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off]
302744|NCT00400829|Drug|eribulin mesylate|Given IV
302745|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
302746|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
302747|NCT00400842|Drug|Placebo|Placebo
302748|NCT00400855|Drug|Fluticasone propionate|
302749|NCT00003243|Biological|aldesleukin|
302750|NCT00400868|Behavioral|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
302751|NCT00400881|Other|automatic tube compensation mode of ventilation (Puritan Bennet 840 ventilator)|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
302752|NCT00400907|Other|clinical observation|
302753|NCT00403403|Drug|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
302754|NCT00003262|Biological|bleomycin sulfate|
302755|NCT00403416|Drug|AEB071|
302756|NCT00403416|Drug|Mycophenolic Acid|
302757|NCT00403429|Drug|capecitabine|
302758|NCT00403442|Device|Verteporfin Therapy/ Drug: Bevacizumab|
302759|NCT00403455|Drug|Paroxetine|SSRI
303091|NCT00392236|Device|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
303092|NCT00392236|Behavioral|Treatment as usual|Participants will receive treatment as usual.
303093|NCT00392249|Behavioral|Supervised Treatment of Schizophrenia by a family member|
303094|NCT00392262|Drug|valsartan + amlodipine|
302417|NCT00412542|Procedure|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
302418|NCT00000508|Behavioral|smoking cessation|
302419|NCT00003305|Drug|aminopterin|
302420|NCT00412555|Drug|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
302421|NCT00412568|Procedure|Photorefractive Keratectomy (PRK)|vision correction with PRK
302422|NCT00412581|Drug|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
302760|NCT00403481|Drug|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
302761|NCT00403481|Drug|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
302762|NCT00403494|Drug|Placebo for 6R-BH4 (sapropterin dihydrochloride)|Placebo to be administered in the same manner as that of the investigational product for 24 weeks
302763|NCT00403494|Drug|6R-BH4 (sapropterin dihydrochloride)|800 mg/day 6R-BH4 tablets, divided into two doses, administered orally for 24 weeks
302764|NCT00403494|Drug|6R-BH4 (sapropterin dihydrochloride)|800 mg/day of 6R-BH4 tablets, divided into two doses, administered orally, plus 1000mg/day Vitamin C caplets, divided into two doses, administered orally for 24 weeks
302765|NCT00003262|Biological|filgrastim|
302766|NCT00403494|Drug|Placebo for 6R-BH4 (sapropterin dihydrochloride)|Placebo to be administered in the same manner as that of the investigational product, plus 1000mg/day Vitamin C, divided into two doses, for 24 weeks
302767|NCT00403507|Behavioral|Participation in a monitored exercise program|No contact with control group during 20 weeks.
302768|NCT00403507|Behavioral|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
302769|NCT00403520|Drug|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
302770|NCT00403520|Drug|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
302771|NCT00403533|Drug|20 mg of atorvastatin daily|
302772|NCT00403546|Drug|Geodon|Geodon 160mg or placebo bid
302773|NCT00403559|Drug|Elidel|
302774|NCT00403585|Drug|adefovir dipivoxil 10mg|
302039|NCT00371202|Procedure|keratoplasty|
302040|NCT00371215|Biological|rThrombin|1000 U/mL applied topically
302041|NCT00371228|Procedure|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
302042|NCT00371254|Drug|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg <6 months)
302043|NCT00371254|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg <6 months)
302044|NCT00371267|Behavioral|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
302045|NCT00371267|Other|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
302046|NCT00371280|Procedure|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
302047|NCT00371293|Behavioral|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
302048|NCT00003111|Drug|irinotecan hydrochloride|
302049|NCT00371293|Device|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
302050|NCT00371306|Drug|Insulin versus glucovance (glyburide/metformin)|
302051|NCT00371319|Drug|tacrolimus|0.06-0.1 mg/kg/day
302052|NCT00371319|Drug|mycophenolate mofetil|2-3 gm/day
302053|NCT00371332|Drug|Minocycline HCL Microspheres|
302054|NCT00371345|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average <6 months)
302055|NCT00371345|Drug|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average <6 months)
331042|NCT00428207|Drug|insulin Aspart versus insulin Lispro|Subjects will be randomly assigned to one of the two insulins by the statistician working in the study via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
Period 1: four weeks using insulin aspart in the pump, followed by Period 2: four weeks using insulin lispro in the pump, or vice versa depending on randomization.
331043|NCT00428207|Device|insulin pump|
331044|NCT00428220|Drug|sunitinib|sunitinib
330101|NCT00579527|Drug|Daclizumab|A single dose of Daclizumab 1 mg/kg IV may be given. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before thymus transplantation. If Daclizumab is not given before thymus transplantation, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after thymus transplantation.
330102|NCT00579527|Drug|Mycophenolate mofetil|Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after thymus transplantation. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after thymus transplantation or continued for up to six months after thymus transplantation.
330103|NCT00579540|Dietary Supplement|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
330104|NCT00579540|Dietary Supplement|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
330105|NCT00579540|Dietary Supplement|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
330391|NCT00569985|Drug|carmustine|Given IV
330392|NCT00572221|Behavioral|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
330393|NCT00572234|Drug|bupropion SR|12 week course of bupropion SR 150 mg, BID
330394|NCT00572247|Behavioral|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
330395|NCT00572260|Drug|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
330396|NCT00004097|Drug|gemcitabine hydrochloride|
330397|NCT00572299|Drug|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
330398|NCT00572312|Drug|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
330399|NCT00572338|Other|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
329798|NCT00587873|Drug|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
329799|NCT00587873|Drug|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
329800|NCT00587886|Behavioral|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
329801|NCT00587886|Behavioral|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers.
329802|NCT00004184|Drug|alum adjuvant|
329803|NCT00590447|Drug|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
329804|NCT00590447|Drug|sequential R-CHOP|375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.
In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy.
329805|NCT00590460|Biological|CAMPATH-1H|Given intravenous on days -8, -7, and -6
329806|NCT00590460|Biological|Anti-CD45|Given intravenous on days -5, -4, -3 and -2
dose is 400 micrograms/kg
329807|NCT00590460|Drug|Fludarabine|Given intravenous on days -8, -7, -6, -5 and -4
Dose is 30 mg/m2
329808|NCT00590460|Procedure|Stem cell infusion|Stem cells are infused on day 0
329809|NCT00590473|Device|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
329810|NCT00590512|Dietary Supplement|High sodium|
330106|NCT00579553|Drug|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
330107|NCT00579553|Drug|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
330108|NCT00579566|Other|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
329165|NCT00561899|Drug|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
329166|NCT00561899|Drug|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
329167|NCT00561899|Drug|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
329168|NCT00561912|Drug|Decitabine|15 mg/m^2 IV Daily over one hour for 5 days
329469|NCT00554762|Drug|GW842166X|Administer
329470|NCT00554775|Drug|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
329471|NCT00554775|Drug|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
329472|NCT00554788|Procedure|autologous bone marrow transplantation|Undergo peripheral blood stem cell or bone marrow transplant
329473|NCT00554788|Procedure|autologous hematopoietic stem cell transplantation|Undergo peripheral blood stem cell or bone marrow transplant
329474|NCT00554788|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo peripheral blood stem cell or bone marrow transplant
329475|NCT00554788|Drug|cisplatin|Given IV
329476|NCT00554788|Drug|cyclophosphamide|Given IV
329477|NCT00554788|Drug|etoposide|Given IV
329478|NCT00554788|Biological|filgrastim|Given SC
329479|NCT00004010|Biological|bleomycin sulfate|
329480|NCT00554788|Drug|carboplatin|Given IV
329481|NCT00554788|Drug|vincristine sulfate|Given IV
329482|NCT00554788|Drug|thiotepa|Given IV
329483|NCT00554788|Radiation|radiation therapy|Undergo radiotherapy
329484|NCT00554801|Procedure|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
329485|NCT00554814|Drug|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
328865|NCT00566553|Dietary Supplement|Grape Seed Extract|800 mg dose daily for 12 weeks.
328866|NCT00566566|Other|sample without DNA|family history, anthropometric measurements and blood sampling
328867|NCT00566579|Procedure|Cryotherapy|Double freezing technique
328868|NCT00566592|Other|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
328869|NCT00566592|Other|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
328870|NCT00566592|Other|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
328871|NCT00566592|Other|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
328872|NCT00566605|Procedure|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty [IEK])
328873|NCT00566605|Procedure|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
328874|NCT00000597|Drug|nandrolone|
328875|NCT00004078|Drug|irinotecan hydrochloride|Given IV
328876|NCT00566618|Drug|Dasatinib|Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.
Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I.
328877|NCT00566618|Drug|Zoledronic Acid|Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.
Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I.
328878|NCT00566631|Drug|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
328879|NCT00566644|Device|levonorgestrel-releasing intrauterine system|
328880|NCT00569075|Other|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
329169|NCT00561912|Drug|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
329170|NCT00561925|Drug|nevirapine IR|200 mg BID
329171|NCT00561925|Drug|nevirapine XR|400 mg QD
333723|NCT00440622|Drug|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
333724|NCT00003427|Drug|irinotecan hydrochloride|
333725|NCT00440635|Drug|Bortezomib, tradename Velcade|
333726|NCT00440648|Drug|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
333727|NCT00440648|Drug|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
328553|NCT00574067|Drug|Buprenorphine|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
328554|NCT00574080|Drug|Dexamethasone|20 mg to start Day 21 after transplant, Days 1-4 every 3 weeks in the interim between transplants
328555|NCT00574080|Drug|DPACE/Melphalan|with or without VTD (Velcade, thalidomide, and dexamethasone) (a single dose of Melphalan on Day -2)
328556|NCT00574093|Drug|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
328557|NCT00574106|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
328558|NCT00574119|Drug|spironolactone|spironolactone 50 mg daily for 6 months
328559|NCT00574132|Drug|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
328560|NCT00574132|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
328561|NCT00574132|Drug|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
328562|NCT00004105|Drug|estramustine phosphate sodium|
328563|NCT00574145|Procedure|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
328564|NCT00574145|Procedure|fatigue assessment and management|duration
328565|NCT00574145|Procedure|psychosocial assessment and care|duration
328566|NCT00574145|Procedure|quality-of-life assessment|duration
328567|NCT00574145|Procedure|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
333366|NCT00446511|Drug|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
333367|NCT00446511|Drug|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
333368|NCT00449397|Drug|Quetiapine Fumarate|
333369|NCT00449410|Drug|Atorvastatin|
333370|NCT00449410|Drug|ezetimibe|
333371|NCT00449423|Drug|acipimox|
333372|NCT00449436|Drug|TRIZIVIR|
333373|NCT00449436|Drug|Non-nucleoside reverse transcriptase inhibitor|
333374|NCT00449436|Drug|Boosted Protease Inhibitor|
333375|NCT00003473|Drug|antineoplaston AS2-1|
333376|NCT00449449|Drug|Pertubation with Lidocain Solution|
333377|NCT00449462|Procedure|consumption of CLA enriched food|
333378|NCT00449488|Drug|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
333379|NCT00449501|Drug|Budesonide/formoterol pMDI|
333380|NCT00449501|Drug|Budesonide HFA pMDI|
333381|NCT00449514|Drug|tamoxifen|
333382|NCT00449514|Drug|clomiphene citrate|
333383|NCT00449527|Drug|Budesonide/formoterol pMDI|
333384|NCT00449527|Drug|Budesonide HFA pMDI|
333385|NCT00449540|Device|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
333386|NCT00003474|Drug|antineoplaston A10|
333728|NCT00440661|Drug|Diacerhein|
333729|NCT00440674|Device|CoStar Paclitaxel-eluting coronary stent system|
333730|NCT00440687|Drug|Fluticasone 500mcg BD via accuhaler or identical placebo|
332667|NCT00417053|Drug|doxorubicin hydrochloride|
332668|NCT00417053|Drug|etoposide phosphate|
332669|NCT00417053|Drug|melphalan|
332670|NCT00417053|Drug|vincristine sulfate|
332671|NCT00417053|Procedure|autologous bone marrow transplantation|
332672|NCT00417053|Procedure|bone marrow ablation with stem cell support|
332673|NCT00417053|Procedure|conventional surgery|
332674|NCT00417053|Procedure|peripheral blood stem cell transplantation|
332675|NCT00003335|Drug|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
333019|NCT00455104|Drug|Agalsidase beta|Agalsidase beta Fabrazyme® 1 mg/kg IV Q2 weeks
333020|NCT00455117|Drug|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
333021|NCT00455130|Drug|Inhaled mannitol|
333022|NCT00455143|Drug|Precedex (Dexmedetomidine)|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
333023|NCT00458445|Drug|SPD465|
333024|NCT00458458|Drug|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
333025|NCT00003519|Drug|docetaxel|
333026|NCT00458458|Drug|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
333027|NCT00458471|Device|Insertion of a urinary catheter coated with benign E. coli|
333028|NCT00458484|Radiation|stereotactic radiosurgery|Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy. The radiation treatment planning and evaluation details are appended.
Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each.
333029|NCT00458484|Procedure|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
300420|NCT00003146|Drug|melphalan|
300421|NCT00379639|Drug|Romidepsin|7, 10 or 12 mg/m^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
300422|NCT00379639|Drug|Gemcitabine|800 or 1000 mg/m^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
300423|NCT00379652|Behavioral|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
300424|NCT00379652|Behavioral|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
300425|NCT00379652|Other|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
300426|NCT00379665|Drug|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
300427|NCT00379691|Drug|phenylephrine|
300428|NCT00379717|Drug|Cisplatinum|
300429|NCT00379717|Drug|Docetaxel|
300430|NCT00379717|Device|Tomotherapy|
300431|NCT00003146|Drug|thiotepa|
300432|NCT00379730|Drug|Prednisolone|
300433|NCT00382434|Procedure|presence of an emergency pharmacist in the ED|
300434|NCT00382447|Device|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
300435|NCT00382447|Device|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
300436|NCT00382460|Drug|PRAVASTATIN SODIUM|
300437|NCT00382473|Behavioral|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
300438|NCT00382486|Procedure|Reduce the risk of allograft rejection|
300439|NCT00382499|Drug|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
300440|NCT00382512|Drug|Raptiva (efalizumab)|
300441|NCT00382525|Device|Cardiac Rhythm Management device|
299718|NCT00396253|Drug|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
299719|NCT00003217|Drug|cytarabine|
299720|NCT00396266|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
299721|NCT00396279|Biological|Denosumab|Administered by subcutaneous injection
299722|NCT00396279|Dietary Supplement|Calcium/Vitamin D|
299723|NCT00396292|Drug|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
299724|NCT00396292|Drug|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
299725|NCT00396305|Drug|Placebo|Sterile phosphate buffered saline solution.
299726|NCT00396305|Biological|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
299727|NCT00396318|Drug|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.
Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
300091|NCT00388180|Drug|GW501516|
300092|NCT00388180|Drug|GW590735|
300093|NCT00388193|Drug|RITUXIMAB|375 mg/m2/d day 1
300094|NCT00388219|Drug|Transtec (R) PRO (buprenorphine)|
300095|NCT00388245|Procedure|Percutaneous Coronary Intervention|
300096|NCT00388245|Procedure|Coronary Artery Bypass Grafting|
300097|NCT00388258|Drug|Alvimopan|
300098|NCT00388271|Drug|Alfuzosin (Xatral)|standard treatment plus alfuzosin
300099|NCT00388271|Drug|standard treatment|standard treatment
299341|NCT00003268|Drug|amifostine trihydrate|
299342|NCT00405158|Procedure|Acupuncture treatment|
299343|NCT00405158|Procedure|Administration of oxytocin nasal spray|
299344|NCT00405158|Procedure|Improved breast milk removal|
299345|NCT00405158|Procedure|Warmth applied to breasts|
299346|NCT00405158|Procedure|Breast massage|
299347|NCT00405158|Drug|Anti-pyretic medication, paracetamol|
299348|NCT00405158|Drug|cefadroxil|
299349|NCT00405158|Drug|penicillin|
299350|NCT00405158|Drug|flucloxacillin|
299351|NCT00405171|Drug|Nevirapine|
299352|NCT00003268|Drug|cytarabine|
299353|NCT00405184|Drug|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
299354|NCT00405184|Drug|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
299355|NCT00405197|Behavioral|Isocaloric diet high in MUFA or Mediterranean diet|
299356|NCT00405210|Drug|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
299357|NCT00405236|Drug|tiotropium|
299358|NCT00405249|Drug|elvucitabine|
299359|NCT00405262|Drug|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
299360|NCT00405262|Drug|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
304538|NCT02718911|Drug|LY3022855|Administered IV
304539|NCT02718911|Drug|Durvalumab|Administered IV
304540|NCT02718911|Drug|Tremelimumab|Administered IV
304541|NCT00204438|Drug|0.15mg desogestrel /0.03mg ethinyl estradiol|
304542|NCT02718937|Drug|BTA-C585 oral capsule|
304543|NCT02718937|Drug|Matching placebo capsules|
304544|NCT02718950|Drug|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
304545|NCT02718963|Device|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
304546|NCT02718976|Procedure|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
304547|NCT00206440|Other|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
304548|NCT00206453|Drug|Taxotere|Chemotherapy IV
304913|NCT00251004|Drug|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
304914|NCT00251004|Drug|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
304915|NCT00251017|Procedure|Vancomycin|Two hour creatinine clearance before and after vancomycin
304916|NCT00251017|Procedure|DNA are extracted from the whole blood of subjects|
304917|NCT00251030|Drug|Nelfinavir and Omeprazole|
304918|NCT00251043|Behavioral|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
304919|NCT00002665|Drug|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
304920|NCT00251043|Behavioral|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
304921|NCT00251056|Drug|mannitol|120mg BD
304922|NCT00251056|Drug|mannitol|40 mg BD
304173|NCT00214305|Behavioral|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
304174|NCT00214318|Drug|Terbutaline plus Metoprolol or carvedilol|
304175|NCT00214331|Drug|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
304176|NCT00002566|Drug|cyclophosphamide|
304177|NCT00214331|Drug|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
304178|NCT00214331|Drug|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
304179|NCT00217503|Drug|valganciclovir|
304180|NCT00002572|Biological|therapeutic tumor infiltrating lymphocytes|
304181|NCT00217503|Drug|zidovudine|
304182|NCT00217516|Drug|selenium|Given orally
304183|NCT00217516|Other|placebo|Given orally
304184|NCT00217529|Biological|pegfilgrastim|
304185|NCT00217529|Drug|carboplatin|
304186|NCT00217529|Drug|docetaxel|
304187|NCT00217529|Drug|erlotinib hydrochloride|
304188|NCT00217542|Biological|recombinant interferon alfa-2b|Given SC
304189|NCT00217542|Drug|amifostine/azacitidine|Given SC
304190|NCT00217555|Drug|gemcitabine hydrochloride|
304191|NCT00002572|Procedure|conventional surgery|
304192|NCT00217555|Drug|topotecan hydrochloride|
304193|NCT00217568|Biological|pegfilgrastim|
304194|NCT00217568|Drug|carboplatin|
304195|NCT00217568|Drug|docetaxel|
303442|NCT00239694|Biological|Meningococcal Vaccine|One time preventative vaccine
303443|NCT00239707|Drug|GIP|One-time 20 ng/kg/min infusion over 3 hours
303444|NCT00239707|Drug|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
303445|NCT00239707|Drug|Normal Saline|one-time infusion over 3 hours
303446|NCT00239720|Drug|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
303447|NCT00239720|Drug|Placebo|i.v. given over 5 days of each 28 day cycle
303806|NCT00000395|Dietary Supplement|Folinic acid|
303807|NCT00002599|Radiation|low-LET cobalt-60 gamma ray therapy|
303808|NCT00228566|Drug|Armodafinil|
303809|NCT00228592|Drug|HepeX-B|
303810|NCT00228592|Drug|Hepatitis B Immune Globulin (HBIg)|
303811|NCT00228605|Drug|OraVescent Fentanyl|
303812|NCT00228657|Drug|4% Albumin / 0.9% Sodium Chloride|
303813|NCT00228683|Procedure|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
303814|NCT00228696|Other|none, screening only|Screening protocol with no intervention
303815|NCT00228813|Drug|Granulocyte Colony Stimulating Factor|FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.
Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.
Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.
Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.
Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection
303816|NCT00228839|Drug|Infliximab|
303817|NCT00228852|Drug|Busulfan, Fludarabine and ATG|
303818|NCT00002599|Radiation|low-LET photon therapy|
303819|NCT00228865|Procedure|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
303095|NCT00392275|Drug|Ofloxacin 0.3%|
303096|NCT00003215|Drug|cyclophosphamide|
303097|NCT00394563|Drug|placebo|
303098|NCT00394576|Behavioral|Internet-based nutrition module|usual care plus Internet-based nutrition module
303099|NCT00394576|Behavioral|usual care|usual care
303100|NCT00394589|Drug|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
303101|NCT00394589|Drug|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
303102|NCT00394589|Drug|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
303103|NCT00394602|Behavioral|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
303104|NCT00394602|Other|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
303105|NCT00394615|Procedure|Metabolic Imaging|
303106|NCT00394628|Drug|AQ4N|
303107|NCT00003215|Drug|cytarabine|
303108|NCT00394628|Drug|Temozolomide|
303109|NCT00394628|Procedure|Radiotherapy|
303110|NCT00394641|Behavioral|listening to music / stories via stereophonic headphones|
303111|NCT00394654|Biological|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
303112|NCT00394654|Other|Placebo|Placebo administered as a single intravenous infusion
303113|NCT00394667|Drug|Tesofensine|
303114|NCT00394693|Genetic|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
303115|NCT00394706|Device|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
303448|NCT00239733|Drug|Anti-D|30-minute infusion administered in an outpatient setting
303449|NCT00002634|Drug|cisplatin|
302775|NCT00403611|Drug|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
302776|NCT00003262|Drug|Stanford V regimen|
302777|NCT00403611|Drug|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
302778|NCT00403624|Drug|OXALIPLATIN|
302779|NCT00403637|Drug|indacaterol maleate|
302780|NCT00403650|Drug|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
302781|NCT00406601|Drug|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
303116|NCT00394706|Device|Sham ITD|Sham ITD
303117|NCT00394706|Other|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
303118|NCT00000498|Drug|antihypertensive agents|
303119|NCT00003215|Drug|doxorubicin hydrochloride|
303120|NCT00394706|Other|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
303121|NCT00394732|Device|Total Disc Prosthesis|
303122|NCT00394732|Behavioral|Multidisciplinary rehabilitation program|
303123|NCT00394745|Drug|Valsartan|
303124|NCT00394758|Procedure|CO2 laser surgery|
303125|NCT00394758|Procedure|ultrasonic surgical aspiration|
303126|NCT00397839|Drug|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
303127|NCT00397852|Procedure|Kirschner-wires or not|
303128|NCT00397865|Behavioral|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
303129|NCT00397878|Drug|saracatinib|Given orally
303130|NCT00397878|Other|laboratory biomarker analysis|Correlative studies
303131|NCT00003225|Drug|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
331045|NCT00428233|Procedure|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
331046|NCT00428246|Drug|paricalcitol|1 mcg or 2 mcg for 4 weeks.
331047|NCT00428246|Drug|Placebo|Placebo
331048|NCT00428272|Drug|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
331049|NCT00000514|Drug|chlorthalidone|
331050|NCT00003389|Drug|Mechlorethamine|given IV
331051|NCT00428272|Drug|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
331052|NCT00428272|Drug|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
331053|NCT00431093|Drug|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
331054|NCT00431093|Drug|low-dose estradiol/noresterone|Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.
Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).
331055|NCT00431106|Drug|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
331056|NCT00431106|Drug|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
331057|NCT00431106|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
331058|NCT00431119|Drug|Azathioprine or Mycophenolate mofetil|
331059|NCT00431132|Drug|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
331060|NCT00431145|Drug|Niacin|
331061|NCT00003397|Procedure|peripheral blood stem cell transplantation|
331062|NCT00431145|Drug|Niacin+Statin|
331063|NCT00431158|Other|Different Mechanical Ventilation Protocols|OLA Group: Open lung approach protocol and recruitment maneuvers
ARDSnet Group: ARDSnet protocol
331433|NCT00422682|Drug|bsi-201 + topotecan|21 day cycle
331434|NCT00422682|Drug|bsi-201 + temozolomide|28 day cycle
330400|NCT00572351|Other|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
330401|NCT00572351|Other|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
330402|NCT00572364|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
330403|NCT00572377|Drug|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
330404|NCT00572377|Drug|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
330405|NCT00572390|Drug|oestrogen|Cyclic oestrogen substitution therapy
330406|NCT00572416|Behavioral|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
330407|NCT00004097|Drug|paclitaxel|
330408|NCT00572416|Behavioral|Healthy Eating Control|Equal time and attention and information about healthy eating
330686|NCT00439595|Device|Hemocue 210 meter|Diagnostic device
330687|NCT00003423|Drug|cytarabine|
330688|NCT00439595|Device|Copack HBCS|
330689|NCT00439608|Drug|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
330690|NCT00439621|Biological|RP 01|Active immunotherapy
330691|NCT00439634|Drug|AVE1625|oral administration
330692|NCT00439634|Drug|placebo|oral administration
330693|NCT00439647|Drug|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
330694|NCT00439647|Drug|Placebo|Placebo intravenous (i.v.) once a year
330695|NCT00439660|Biological|Oral Rotavirus Vaccine 116E Live Attenuated|
330696|NCT00439673|Drug|5-Azacytidine|
330697|NCT00439673|Drug|Valproic Acid|
330698|NCT00003423|Drug|daunorubicin hydrochloride|
330109|NCT00004136|Procedure|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
330110|NCT00579579|Behavioral|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
330111|NCT00579592|Drug|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
330112|NCT00582166|Drug|Zevalin (Ibritumomab Tiuxetan )+ Rituximab|Subjects will receive the Zevalin(Ibritumomab Tiuxetan) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
330113|NCT00582179|Procedure|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
330114|NCT00582179|Device|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
330115|NCT00582192|Other|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
330116|NCT00582205|Drug|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
330117|NCT00582231|Other|Questionnaires.|Questionnaires.
330118|NCT00582244|Behavioral|CBT and relaxation|Group A: CBT and relaxation.
330119|NCT00582244|Behavioral|Physical activity|Group B: Physical exercise program.
330120|NCT00582244|Behavioral|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
330121|NCT00582244|Other|Control group|Waiting list control group
330122|NCT00004149|Drug|arsenic trioxide|
330409|NCT00572429|Dietary Supplement|l-carnitine|3 gram daily dose
330410|NCT00572455|Drug|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
329486|NCT00554814|Drug|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
329487|NCT00557180|Drug|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
329488|NCT00000587|Procedure|erythropoietin, recombinant|
329489|NCT00004024|Biological|therapeutic autologous lymphocytes|
329490|NCT00557180|Drug|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
329491|NCT00557193|Drug|vincristine sulfate|Given IV
329811|NCT00590512|Dietary Supplement|Low sodium|
329812|NCT00590525|Procedure|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
329813|NCT00004186|Drug|carboplatin|
329814|NCT00590538|Drug|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
329815|NCT00590538|Drug|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
329816|NCT00590538|Drug|Placebo|The placebo is given to match the active comparator for four days.
329817|NCT00590551|Other|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
329818|NCT00590564|Drug|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
329819|NCT00590577|Drug|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
329820|NCT00590577|Drug|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
329821|NCT00590577|Drug|Placebo|Placebo i.m. Days 1, 8, 36, 64
329172|NCT00561938|Procedure|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
329173|NCT00561938|Procedure|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
329174|NCT00004054|Drug|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
329175|NCT00561951|Drug|fesoterodine fumarate|8mg tablets OD for 12 weeks
329176|NCT00561951|Drug|Placebo|Corresponding placebo tablets OD for 12 weeks
329177|NCT00561951|Drug|fesoterodine fumarate|4mg tablets OD for 12 weeks
329178|NCT00561964|Drug|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
329179|NCT00564200|Drug|dexamethasone|PREACONDICIONAMIENTO:
- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11
329180|NCT00564200|Drug|Fludarabine|ACONDICIONAMIENTO:
- Days -9 al -5: Fludarabine
329181|NCT00564200|Drug|Melphalan|ACONDICIONAMIENTO:
- Days -4 and -3: Melphalan.
329182|NCT00564213|Drug|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
329183|NCT00564226|Drug|SSR240600C|oral administration
329184|NCT00564226|Drug|tolterodine|oral administration
329185|NCT00564226|Drug|placebo|oral administration
329492|NCT00557193|Drug|daunorubicin hydrochloride|Given IV
329493|NCT00557193|Drug|cyclophosphamide|Given IV
328568|NCT00574171|Drug|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
328569|NCT00574171|Drug|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
328570|NCT00574197|Drug|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
328571|NCT00574210|Drug|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
328572|NCT00574210|Drug|Placebo|Placebo Tablets administered twice per day
328573|NCT00004105|Drug|paclitaxel|
328574|NCT00574223|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
328881|NCT00569088|Drug|Chinese herbs formula|The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).
Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days
328882|NCT00004088|Drug|melphalan|
328883|NCT00569088|Drug|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
328884|NCT00569101|Drug|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg ~0.02 mg/kg + prednisolone tapering
328885|NCT00569114|Drug|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
328886|NCT00569127|Biological|Recombinant Interferon Alfa-2b|Given SC
328887|NCT00569127|Drug|Octreotide Acetate|Given IM
328888|NCT00569127|Biological|Bevacizumab|Given IV
328889|NCT00569140|Drug|E10030|Intravitreal injection
328890|NCT00569153|Drug|TAK-700|Phase 1 portion of study:
TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.
Phase 2 portion of study:
Patients will receive one of 4 treatments:
TAK-700 at 300 mg twice/day
TAK-700 at 400 mg and 5 mg prednisone twice/day
TAK-700 at 600 mg and 5 mg prednisone twice/day
TAK-700 at 600 mg once/day in the morning
328891|NCT00569166|Behavioral|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
328892|NCT00569166|Behavioral|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
333731|NCT00440700|Behavioral|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
333732|NCT00440700|Behavioral|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
333733|NCT00440700|Behavioral|Control 2: Standard of Care|Usual ICU nursing care.
333734|NCT00440713|Drug|Aripiprazole|
333735|NCT00003427|Drug|oxaliplatin|
333736|NCT00440713|Behavioral|Interpersonal Therapy|
333737|NCT00440726|Drug|bortezomib (Velcade)|Intravenous at 1.3mg/m2 on days 1, 4, 8 and 11
333738|NCT00440726|Drug|dexamethasone|Intravenous or oral administration for 14 days.
333739|NCT00440726|Drug|PEG-asparaginase|Intramuscular injection
333740|NCT00440726|Drug|doxorubicin|Intravenous infusion
333741|NCT00440726|Drug|cytarabine|Intrathecal administration on day 1
333742|NCT00440726|Drug|methotrexate|Intrathecal administration
333743|NCT00440726|Drug|vincristine|Intravenous push on days 1, 8, 15, 22
333744|NCT00440739|Drug|etoricoxib|etoricoxib 120 mg
333745|NCT00443807|Device|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
333746|NCT00003437|Drug|prednisolone|
333747|NCT00443807|Device|EEGo vs BIS|comparison of two processed EEG monitors.
333748|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
333749|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 48 weeks
333750|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
333751|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 24 weeks
333752|NCT00443846|Biological|RotaTeq®|
333030|NCT00458484|Procedure|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
333031|NCT00458497|Device|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
333032|NCT00458497|Device|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
333033|NCT00458510|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
333034|NCT00458523|Biological|alemtuzumab|
333035|NCT00458523|Genetic|fluorescence in situ hybridization|
333036|NCT00003519|Drug|doxorubicin hydrochloride|
333037|NCT00458523|Genetic|mutation analysis|
333038|NCT00458523|Other|flow cytometry|
333039|NCT00458536|Biological|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
333387|NCT00449540|Device|Sham TMS Device|Simulated Sham treatment without TMS delivery
333388|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
333389|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
333390|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
333391|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
333392|NCT00449579|Device|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
333393|NCT00449592|Drug|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
333394|NCT00449592|Drug|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
333395|NCT00449605|Drug|rimonabant (SR141716)|on top of metformin
333396|NCT00449605|Drug|glimepiride|on top of metformin
333397|NCT00003474|Drug|antineoplaston AS2-1|
300442|NCT00382538|Drug|Addition of mifepristone 200 mg 24 hours before induction|
300443|NCT00003158|Radiation|radiation therapy|
300444|NCT00382551|Behavioral|Moderate daily consumption of Red wine|
300791|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied QD|
300792|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied BID|
300793|NCT00373529|Drug|clofarabine|Induction cycle 1: cycle 1 of clofarabine 30 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.
Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.
300794|NCT00373542|Drug|ropinirole CR-RLS|
300795|NCT00373555|Procedure|Bronchoscopy|
300796|NCT00373568|Drug|miltefosine: 2.5 mg/kg/day for 42 days|
300797|NCT00373581|Drug|Vigabatrin|
300798|NCT00373581|Drug|Cocaine|
300799|NCT00003119|Biological|sargramostim|
300800|NCT00373594|Drug|Rituximab|
300801|NCT00373594|Drug|Fludarabine|
300802|NCT00373607|Drug|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
300803|NCT00373607|Drug|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
300804|NCT00373620|Drug|paclitaxel|
300805|NCT00373633|Procedure|Thoracic Epidural|Gold standard for post thoracotomy pain
300806|NCT00373633|Procedure|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
300807|NCT00373646|Drug|Thalidomide, Pharmion|200 mg p.o. daily
300808|NCT00373659|Drug|Ranibizumab (Lucentis)|
300809|NCT00373672|Drug|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
300810|NCT00003119|Drug|carboplatin|
300100|NCT00388284|Device|Arterial Sealing|
300101|NCT00003190|Drug|cytarabine|Given IV
300102|NCT00388297|Drug|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
300103|NCT00388297|Drug|Placebo for Levothyroxine|
300104|NCT00388310|Procedure|Culture|Culture
300105|NCT00388323|Other|blood and biopsies|blood and biopsies
300106|NCT00390845|Drug|SB681323|
300107|NCT00390858|Drug|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
300108|NCT00390871|Drug|Precedex|
300109|NCT00390871|Drug|Propofol|
300110|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
300111|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
300112|NCT00390897|Drug|Glivec|
300113|NCT00390897|Drug|Interferon|
300114|NCT00390910|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
300115|NCT00003200|Drug|docetaxel|
300445|NCT00382551|Behavioral|Moderate daily consumption of beer|
300446|NCT00382551|Behavioral|Moderate consumption of fruit juice rich in polyphenolics|
300447|NCT00382577|Drug|Itopride|
300448|NCT00382590|Drug|5-Azacytidine|75 mg/m^2 daily for 7 days (days 1-7) via subcutaneous injection.
300449|NCT00382590|Drug|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
299361|NCT00405262|Drug|ketorolac + bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
299362|NCT00405275|Drug|Etanercept|etanercept, subcutaneous injection
299728|NCT00396331|Drug|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2*10^6 CD34+ cells/kg were collected.
299729|NCT00396344|Other|Çontrol|Intravenous saline
299730|NCT00003217|Drug|dexamethasone|
299731|NCT00396344|Drug|Hydrocortisone|Intravenous stress dose of hydrocortisone
299732|NCT00396344|Drug|Hydrocortisone|Intravenous pharmacologic hydrocortisone
299733|NCT00396357|Drug|Vildagliptin|
299734|NCT00396357|Drug|metformin|
299735|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
299736|NCT00003237|Drug|cisplatin|
299737|NCT00399308|Device|Control (compression bandaging)|Multi-layer compression bandaging
299738|NCT00399334|Drug|antipsychotic medications|as prescribed
299739|NCT00399360|Drug|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
299740|NCT00399360|Drug|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
299741|NCT00399360|Behavioral|Lifestyle Modification|Lifestyle Modification
299742|NCT00399386|Procedure|EP|
299743|NCT00399386|Procedure|ICD|
299744|NCT00399386|Procedure|Ablation|
299745|NCT00399399|Drug|azathioprine|
304923|NCT00251056|Drug|mannitol|240mg BD
304924|NCT00251056|Drug|mannitol|400mg BD
304925|NCT00253747|Drug|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
304926|NCT00253747|Drug|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
304927|NCT00253760|Drug|dietary amino acids; cysteine and methionine|
304928|NCT00253773|Drug|acetominophen, sulfer amino acids; cysteine and methionine|
304929|NCT00253786|Drug|ACE inhibitors,ARB, HMG-CoA reductase inhibitors, vitamins|
304930|NCT00253786|Behavioral|Compliance, antismoking, and nutrition instruction|
304931|NCT00253799|Device|Hylan GF-20|
304932|NCT00253812|Procedure|flexible sigmoidoscopy|
304933|NCT00253825|Device|mCIMT combined with or without eye patching|
299363|NCT00003268|Drug|idarubicin|
299364|NCT00408161|Behavioral|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
299365|NCT00408174|Drug|Balsalazide disodium|
299366|NCT00408187|Drug|voclosporin|voclosporin 0.4 mg/kg po BID
299367|NCT00408187|Drug|Ciclosporin|ciclosporin 1.5 mg/kg po BID
299368|NCT00408187|Drug|Placebo|Placebo
299369|NCT00408200|Drug|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
299370|NCT00408200|Device|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
299371|NCT00408213|Drug|mycophenolate mofetil [CellCept]|1g po bid
304549|NCT00206466|Drug|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
304550|NCT00206466|Drug|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
304551|NCT00206492|Drug|Iressa|Iressa
304552|NCT00206492|Drug|Tamoxifen|Tamoxifen
304553|NCT00002551|Drug|levamisole hydrochloride|See arm assignments.
304554|NCT00206505|Drug|Taxotere|
304555|NCT00206518|Drug|Taxotere|Taxotere
304556|NCT00206518|Drug|Adriamycin/Cytoxan|Adriamycin/Cytoxan
304557|NCT00206518|Drug|docetaxol|Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery.
304558|NCT00206518|Drug|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
304559|NCT00206544|Drug|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
304560|NCT00206544|Drug|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
304561|NCT00206544|Other|placebo|adjunctive placebo daily in oral capsule
304562|NCT00206557|Drug|Raloxifene|
304563|NCT00206557|Drug|Estradiol/dyhydroprogestrone|
304564|NCT00002551|Radiation|radiation therapy|See arm assignments.
304565|NCT00206570|Drug|Estradiol|
304566|NCT00206583|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
304567|NCT00206596|Drug|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
304568|NCT00206596|Drug|Placebo|Once daily via subcutaneous injection for up 22 weeks
303820|NCT00228865|Procedure|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
303821|NCT00228878|Procedure|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
303822|NCT00228891|Procedure|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
303823|NCT00228891|Procedure|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
303824|NCT00228904|Procedure|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
304196|NCT00217581|Biological|Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
304197|NCT00217581|Drug|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
304198|NCT00217581|Drug|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
304199|NCT00217594|Drug|Alemtuzumab (Campath)|
304200|NCT00217607|Drug|paclitaxel|
304201|NCT00217620|Drug|sorafenib|800 mg per day, daily until progression
304202|NCT00002574|Biological|recombinant interferon alfa|
304203|NCT00217633|Procedure|Conventional Surgery|
304204|NCT00217646|Drug|Sorafenib Tosylate|Given orally
304205|NCT00217659|Drug|anastrozole|
304206|NCT00217659|Drug|goserelin acetate|
304207|NCT00217672|Biological|bevacizumab|15 mg/kg IV every 3 weeks. Subjects continue on study until disease progression, unacceptable toxicity, or withdrawal of patient consent.
304208|NCT00217672|Drug|docetaxel|75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
303450|NCT00239746|Drug|Ibuprofen|200mg taken orally daily for 6-12 weeks
303451|NCT00239746|Drug|Placebo|200mg matched placebo taken orally daily for 6-12 weeks
303452|NCT00239772|Behavioral|Cognitive Processing Therapy|
303453|NCT00239772|Behavioral|Prolonged Exposure Therapy|
303454|NCT00239785|Drug|FTY720|
303455|NCT00239798|Drug|FTY720|
303456|NCT00239811|Drug|FTY720|
303457|NCT00239824|Behavioral|Strength training of the pelvic floor muscles|Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.
Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist.
303458|NCT00239824|Behavioral|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
303459|NCT00239837|Behavioral|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
303460|NCT00002634|Drug|cyclophosphamide|
303461|NCT00239850|Behavioral|lifestyle changes|
303462|NCT00243425|Procedure|Patient-centered Intervention|
303463|NCT00243438|Device|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
303464|NCT00243451|Other|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
303465|NCT00243464|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
303466|NCT00243477|Drug|Escitalopram|Escitalopram 10mg or placebo once a day
303467|NCT00243490|Procedure|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
303468|NCT00243503|Drug|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
303132|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
303133|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
303134|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
303135|NCT00397904|Biological|cetuximab|
303136|NCT00397904|Drug|cisplatin|
303137|NCT00397904|Drug|irinotecan hydrochloride|
303138|NCT00397904|Other|immunohistochemistry staining method|
303469|NCT00243516|Device|PREtest Consult|
303470|NCT00002643|Drug|cyclophosphamide|
303471|NCT00243529|Biological|autologous dendritic cell vaccine|
303472|NCT00243542|Drug|ACZONE Gel, 5%|
303473|NCT00243542|Drug|Vehicle|
303474|NCT00243555|Procedure|allergy skin testing|
303475|NCT00243555|Procedure|venepuncture|
303476|NCT00243568|Drug|Vicriviroc|
303477|NCT00243581|Behavioral|Dean Ornish Heart Disease Reversing Program|
303478|NCT00243594|Biological|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
303479|NCT00243607|Other|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
303480|NCT00243620|Device|Vacuum therapy (device)|
303481|NCT00002643|Drug|doxorubicin hydrochloride|
303482|NCT00243633|Procedure|Real-time contrast-enhanced ultrasound sonography|
303483|NCT00243646|Radiation|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
331435|NCT00422682|Drug|bsi-201 + gemcitabine|28 day cycle
331436|NCT00422682|Drug|bsi-201 + carboplatin/paclitaxel|21 day cycle
331437|NCT00422708|Procedure|Local anesthesia|
331438|NCT00422721|Procedure|realization of a family tree|
331439|NCT00422721|Procedure|refractometry|
331440|NCT00422721|Procedure|evaluation of the presence of a nystagmus|
331441|NCT00003362|Biological|incomplete Freund's adjuvant|
331442|NCT00422721|Procedure|ocular behavior|
331443|NCT00422721|Procedure|test of baby vision|
331444|NCT00422721|Procedure|test of keenness|
331445|NCT00422721|Procedure|reading test|
331446|NCT00422721|Procedure|visual field|
331447|NCT00422721|Procedure|color vision|
331448|NCT00422721|Procedure|electroretinographical activity|
331449|NCT00422721|Procedure|biomicroscopical test|
331450|NCT00422721|Procedure|retinal imaging|
331451|NCT00422721|Procedure|retinal autofluorescence|
331452|NCT00003362|Biological|sargramostim|
331453|NCT00422721|Procedure|genotyping|
331454|NCT00422734|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
331455|NCT00422734|Drug|Placebo|placebo tablet taken by mouth once a day for 12 weeks
331456|NCT00422747|Drug|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
331457|NCT00422773|Drug|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
331458|NCT00003379|Drug|paclitaxel|
330699|NCT00439673|Drug|ATRA|
330700|NCT00439686|Drug|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
330701|NCT00439699|Drug|Memantine|Mematine administration
330702|NCT00439712|Drug|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
330703|NCT00439712|Drug|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
330704|NCT00439725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
330705|NCT00439725|Drug|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
330706|NCT00439738|Drug|HCTZ + Amlodipine|12.5 mg HCTZ capsules
25 mg HCTZ capsules
5 mg amlodipine capsules
10 mg amlodipine capsules
330707|NCT00439738|Drug|Valsartan/HCTZ|160 mg film-coated valsartan tablets
320 mg film-coated valsartan tablets
12.5 mg HCTZ capsules
25 mg HCTZ capsules
330708|NCT00439751|Drug|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
330709|NCT00003423|Drug|dexamethasone|
330710|NCT00439764|Behavioral|General health talk|Routine clinical practice and talk on general health
331064|NCT00431171|Drug|Lithium carbonate|
331065|NCT00431184|Drug|Pentazocine|see arms description
331066|NCT00431184|Drug|Lorazepam|see arms description
331067|NCT00431197|Drug|Ketoconazole, Dexamethesone, Androgel,GnRH|
331068|NCT00431210|Biological|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
331069|NCT00431223|Behavioral|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
331070|NCT00431236|Drug|Oral Casopitant (GW679769)|
331071|NCT00431236|Drug|IV Casopitant (GW679769)|
331072|NCT00000516|Drug|enalapril|
331073|NCT00003398|Biological|anti-thymocyte globulin|
330411|NCT00572455|Drug|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
330412|NCT00572455|Drug|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
330413|NCT00574717|Procedure|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
330414|NCT00574730|Drug|CHOP/Rituximab|Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.
Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2
330415|NCT00574730|Drug|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
330416|NCT00574743|Drug|Enteric-coated Mycophenolate Sodium|
330417|NCT00574756|Drug|ranolazine|extended release 500 mg twice a day for two weeks
330418|NCT00574769|Drug|RAD001, Docetaxel, Bevacizumab|RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily
Bevacizumab infusion (IV), 15 mg/kg every 21 days
Docetaxel infusion (IV), 75 mg/m^2 every 21 days
330419|NCT00574795|Biological|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
330420|NCT00574808|Other|Outreach Facilitation implementing elements of the Chronic Care Model|An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the "intense" phase of program implementation.
330421|NCT00004109|Drug|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
330422|NCT00574834|Drug|Ramipril|Ramipril 20 mg once daily for 6 months
330423|NCT00574834|Drug|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
330424|NCT00574834|Drug|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
330425|NCT00574847|Drug|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
329822|NCT00590577|Drug|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
329823|NCT00590590|Drug|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
329824|NCT00552162|Procedure|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
329825|NCT00552175|Drug|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
329826|NCT00552175|Drug|placebo|placebo taken orally every day
329827|NCT00552175|Drug|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
329828|NCT00552188|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 24 weeks
329829|NCT00552188|Drug|Placebo|oral dosing, 1 time daily for 24 weeks
329830|NCT00552201|Drug|Tacrolimus|Administration Twice a day after adjustment to blood level
330123|NCT00582257|Behavioral|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) and the gastric cancer risk factor questionnaire. Registry participants (both Patient/Relative and Control cohorts) will also be invited to submit germline DNA and tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC. Relatives of High Genetic Risk cohort participants who undergo a clinical upper endoscopy will be asked to submit the results of that procedure to the database.
330124|NCT00582283|Drug|I124-NM404|I-124-NM404
330125|NCT00582296|Behavioral|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
330126|NCT00582296|Behavioral|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
330127|NCT00582309|Procedure|Glucommander-Guided Intravenous Insulin Infusion|Glucommander-Guided Intravenous Insulin Infusion.
Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.
During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels.
330128|NCT00585013|Drug|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
329494|NCT00557193|Drug|pegaspargase|Given IM
329495|NCT00557193|Drug|asparaginase|Given IV, IM, or PO
329496|NCT00557193|Drug|prednisone|Given PO
329497|NCT00557193|Drug|methylprednisolone|Given IV
329498|NCT00557193|Drug|dexamethasone|Given IV or PO
329499|NCT00557193|Drug|cytarabine|Given IV or IT
329500|NCT00004024|Procedure|surgical procedure|
329501|NCT00557193|Drug|methotrexate|Given IV, IT, or PO
329502|NCT00557193|Drug|therapeutic hydrocortisone|Given IT
329503|NCT00557193|Biological|filgrastim|Given IV or SC
329504|NCT00557193|Drug|leucovorin calcium|Given IV
329505|NCT00557193|Drug|etoposide|Given IV
329506|NCT00557193|Drug|mercaptopurine|Given PO
329507|NCT00557193|Drug|lestaurtinib|Given PO
329508|NCT00557193|Other|laboratory biomarker analysis|Correlative studies
329509|NCT00557193|Other|pharmacological study|Correlative studies
329510|NCT00557206|Drug|Oxaliplatin and Docetaxel|Chemotherapy
Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days.
329511|NCT00004024|Radiation|radiation therapy|
329512|NCT00557219|Drug|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
329513|NCT00557219|Drug|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
329514|NCT00557219|Drug|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
329515|NCT00557232|Drug|bevacizumab|1.25mg/month
329516|NCT00557245|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
329517|NCT00559676|Other|pharmacological study|
328893|NCT00004088|Drug|pamidronate disodium|
328894|NCT00569166|Behavioral|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
328895|NCT00569179|Device|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
328896|NCT00569192|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
328897|NCT00569192|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
328898|NCT00569192|Drug|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
328899|NCT00569231|Drug|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
328900|NCT00569244|Drug|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
329186|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
329187|NCT00004063|Drug|cisplatin|
329188|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions
329189|NCT00564252|Drug|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
329190|NCT00564265|Other|Observation|Not applied
329191|NCT00564278|Drug|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
329192|NCT00564278|Behavioral|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
329193|NCT00564291|Other|Examination with an OCT device|
329194|NCT00564317|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
329195|NCT00564317|Behavioral|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
329196|NCT00564330|Drug|Esomeprazole|20mg bid
328575|NCT00574223|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
328576|NCT00574236|Drug|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
328577|NCT00576654|Other|Pharmacological Study|Correlative studies
328578|NCT00576654|Drug|Veliparib|Given PO
328579|NCT00576667|Drug|rimonabant (SR141716)|20 mg daily
328580|NCT00576667|Drug|Placebo|daily administration
328581|NCT00576680|Drug|RAD001|Given orally once a day
328582|NCT00004123|Radiation|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
328583|NCT00576680|Drug|Temozolomide|Taken orally once a day for one week followed by a one-week break period
328584|NCT00576693|Device|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
328585|NCT00576693|Other|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
328586|NCT00576706|Drug|Rebamipide|Rebamipide 100㎎, 12 weeks
328587|NCT00576706|Drug|Misoprostol|Misoprostol 200㎍ 12 weeks
328588|NCT00576719|Behavioral|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
328589|NCT00576719|Behavioral|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
328590|NCT00576719|Other|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
328591|NCT00576732|Drug|Placebo|Oral solution qd or bid for 6 weeks
333398|NCT00449618|Drug|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
333399|NCT00003492|Drug|antineoplaston A10|
333400|NCT00452374|Drug|Fludarabine|30 mg/m^2 given IV for two days (Days 2 and 3).
333401|NCT00452374|Drug|Oxaliplatin|Starting dose of 17.5 mg/m^2 IV for 4 days (Days 1 through 4).
333402|NCT00452374|Drug|Rituximab|375 mg/m^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
333403|NCT00452387|Drug|Mitoxantrone|Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.
Dose Level -2, Mitoxantrone 9mg/m2
Dose Level -1 Mitoxantrone 12mg/m2
Dose Level 1 Mitoxantrone 12mg/m2
333404|NCT00452387|Drug|Prednisone|Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.
Dose Level -2, Prednisone 5mg bid
Dose Level -1 Prednisone 5mg bid
Dose Level 1 Prednisone 5mg bid
333405|NCT00452387|Drug|Sorafenib|Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.
Dose Level -2, Sorafenib 400 mg QD
Dose Level -1 Sorafenib 400 mg QD
Dose Level 1 Sorafenib 400 mg bid
333406|NCT00452400|Drug|BI 1744CL|
333753|NCT00443846|Biological|NeisVac-C®|
333754|NCT00443872|Drug|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
333755|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
333756|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 48 weeks
333757|NCT00003437|Drug|thioguanine|
333758|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
333759|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 24 weeks
333760|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
333761|NCT00443924|Drug|Placebo|One drop of placebo in each eye every 12 hours for three days
300811|NCT00373672|Drug|placebo|identical in appearance to active comparator
300812|NCT00373685|Drug|Celecoxib|open-label
300813|NCT00373685|Drug|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
300814|NCT00373698|Behavioral|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
300815|NCT00373711|Drug|Iodine-124|2 mCi, oral
301151|NCT00412074|Drug|Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating women and 0 IU vitamin D3/day (placebo) given as oral supplement to her breastfeeding infant
301152|NCT00412087|Drug|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
301153|NCT00412087|Drug|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
301154|NCT00412087|Drug|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
301155|NCT00367640|Biological|Sublingual immunotherapy tablets - grass pollen|
301156|NCT00000482|Drug|niacin|
301157|NCT00003093|Drug|carboplatin|
301158|NCT00367653|Drug|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
301159|NCT00367653|Drug|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg [three 250 mg capsules]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
301160|NCT00367666|Device|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
301161|NCT00367679|Drug|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
301162|NCT00367692|Drug|PSI-697|
301163|NCT00367705|Dietary Supplement|VSL#3®|1-2 sachets/day per os, 6 months
301164|NCT00367705|Dietary Supplement|Placebo|1-2 sachets/day per os, 6 months
301165|NCT00367718|Drug|Velcade|
301166|NCT00367731|Drug|Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
300450|NCT00382590|Drug|Valproic Acid (VPA)|50 mg/m^2 orally daily days 1-7.
300451|NCT00382603|Device|OptiFree Multi-Purpose Disinfecting Solution|
300452|NCT00382616|Drug|Phosphatidylserine-Omega3|
300453|NCT00382629|Drug|BHT-3009 0.5 mg|
300454|NCT00003159|Drug|carboplatin|
300455|NCT00382629|Drug|BHT-3009 1.5 mg|
300456|NCT00382629|Drug|Placebo|
300457|NCT00382642|Drug|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
300458|NCT00382642|Drug|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
300459|NCT00382655|Procedure|Education and referral|
300460|NCT00382668|Drug|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
300461|NCT00382668|Drug|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
300462|NCT00382668|Drug|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
300463|NCT00382681|Device|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
300464|NCT00385268|Drug|placebo|placebo pills
300465|NCT00003173|Drug|thiotepa|
300466|NCT00385268|Behavioral|Cognitive Behavioral Therapy|Weekly individual psychosocial treatment sessions.
300467|NCT00385281|Biological|FluMist|
300468|NCT00385307|Drug|amibegron (SR58611A)|
300469|NCT00385320|Biological|HRV vaccine|
300470|NCT00385333|Procedure|Feasibility Study - Imaging System|
300816|NCT00376961|Drug|bortezomib|1.3 mg/m^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
300817|NCT00376961|Drug|cyclophosphamide|750 mg/m^2 on day 1 of cycles 1-6.
300818|NCT00376961|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 1 of cycles 1-6.
299746|NCT00399399|Drug|cyclophosphamide|
299747|NCT00003237|Drug|paclitaxel|
299748|NCT00399412|Device|subcutaneous ICD|
299749|NCT00399425|Drug|bemiparin (low molecular weight heparin)|
299750|NCT00399438|Drug|Placebo|Tablets, Oral, once daily, 2 weeks
299751|NCT00399438|Drug|BMS-562086|Tablets, Oral, once daily, 2 weeks
299752|NCT00399451|Drug|Polidocanol Sclerotherapy|
300116|NCT00390910|Biological|Infanrix hexa|Intramuscular injection, 3 doses
300117|NCT00390923|Drug|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
300118|NCT00390923|Drug|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
300119|NCT00390936|Drug|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
300120|NCT00390949|Behavioral|Peer education among commercial sex workers and clients|
300121|NCT00390949|Behavioral|Condom distribution and promotion|
300122|NCT00390949|Procedure|Syndromic treatment of sexually transmitted infections|
300123|NCT00390949|Procedure|Systemic counselling for STI patients|
300124|NCT00390975|Drug|Tegaserod|
300125|NCT00390988|Procedure|blood sampling|
300126|NCT00003200|Radiation|radiation therapy|
300127|NCT00391001|Drug|Taurine|double-blind, placebo-controlled, adjunctive medication
300128|NCT00391014|Drug|liposomal Amphotericine B|AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.
If patient required ALO-TPH, the prophylaxis should be followed.
299372|NCT00003280|Biological|rituximab|
299373|NCT00408213|Drug|Placebo|po bid
299374|NCT00408226|Drug|MKC-1|capsules, twice daily for 14 days in 21 day cycle
299375|NCT00408226|Drug|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
299376|NCT00408239|Drug|YM150|Oral
299377|NCT00408239|Drug|enoxaparin|Sub cutaneous
299378|NCT00408252|Other|biopsies|No intervention, only biopsy for translational project
299379|NCT00408252|Drug|SU011248|no intervention
299380|NCT00408265|Behavioral|Contingency Management|
299381|NCT00408278|Drug|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
299382|NCT00408278|Drug|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
299383|NCT00003281|Drug|paclitaxel|
299384|NCT00408278|Drug|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
299385|NCT00408278|Drug|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
299386|NCT00408291|Procedure|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
299387|NCT00408304|Drug|omega-3 fatty acid|
299753|NCT00399464|Drug|alfuzosin|
299754|NCT00399477|Drug|rasagiline mesylate|Azilect®
299755|NCT00399477|Drug|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
299756|NCT00399477|Drug|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
299757|NCT00399477|Drug|Rasagiline mesylate with Requip|Azilect®, Requip
299758|NCT00003237|Procedure|surgical procedure|
299759|NCT00399490|Drug|RN624 (PF-04383119)|50 mcg/kg
299760|NCT00399503|Procedure|Spectral T Wave Alternans|
304569|NCT00206609|Procedure|Oxygen and air administration|
304570|NCT00206622|Drug|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
304934|NCT00253838|Procedure|BMD|bone mineral density
304935|NCT00002676|Radiation|low-LET cobalt-60 gamma ray therapy|
304936|NCT00253838|Procedure|BMD|bone mineral density
304937|NCT00253851|Drug|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
304938|NCT00253877|Device|Hip Resurfacing System|All patients received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology
304939|NCT00253890|Drug|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
304940|NCT00253890|Drug|Placebo|1-3 at bedtime
304941|NCT00253903|Drug|eplivanserin (SR46349)|oral administration
304942|NCT00253903|Drug|placebo|oral administration
304943|NCT00253916|Behavioral|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
304944|NCT00253916|Behavioral|Resistance Exercise Program|Resistance Exercise Program
304945|NCT00253929|Drug|Intra-arterial infusion of adenosine|
304946|NCT00002676|Radiation|low-LET photon therapy|
304947|NCT00253929|Drug|intra-arterial infusion of caffeine|
304948|NCT00253929|Drug|intra-arterial infusion of acetylcholine|
304949|NCT00253929|Drug|intra-arterial infusion of sodium nitroprusside|
304950|NCT00257127|Biological|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
304951|NCT00257140|Drug|levofloxacin|
304952|NCT00002689|Radiation|radiation therapy|
304209|NCT00217698|Drug|cisplatin|
304210|NCT00221273|Procedure|ACL surgery|Unspecified
304211|NCT00221286|Drug|pegylated interferon alfa-2a|
304212|NCT00221286|Drug|tenofovir DF / emtricitabine combination therapy|
304213|NCT00221286|Drug|pegIFN / TDF / FTC combination therapy|
304214|NCT00002582|Drug|fluorouracil|
304215|NCT00221299|Drug|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
304216|NCT00221299|Drug|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
304217|NCT00221312|Drug|Fosamax|
304571|NCT00206622|Drug|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
304572|NCT00206622|Drug|Placebo transdermal|Placebo
304573|NCT00209872|Drug|Lidocaine|
304574|NCT00209872|Drug|S-ketamine|
304575|NCT00209872|Procedure|Epidural analgesia|
304576|NCT00209885|Drug|Gabapentin|
304577|NCT00209885|Drug|S-ketamine|
304578|NCT00209885|Drug|Lidocaine|
304579|NCT00209885|Drug|Droperidol|
304580|NCT00209898|Procedure|Fast initiation procedure|
304581|NCT00209911|Procedure|cardioversion|
304582|NCT00209924|Drug|Gaboxadol|
304583|NCT00002557|Drug|methotrexate|
304584|NCT00209937|Drug|Gaboxadol|
304585|NCT00209950|Drug|Gaboxadol|
304586|NCT00209963|Drug|Gaboxadol|
303825|NCT00228904|Procedure|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
303826|NCT00232609|Device|GameCycle Exercise System|
303827|NCT00002611|Radiation|radiation therapy|
303828|NCT00232622|Drug|Streptokinase|Accelerated infusion of streptokinase
303829|NCT00232622|Drug|Streptokinase|Standard dose streptokinase
303830|NCT00232635|Drug|A-60444|
303831|NCT00232648|Drug|Pulmicort (budesonide) Respules|
303832|NCT00232661|Drug|ARIMIDEX (anastrazole)|
303833|NCT00232661|Drug|NOLVADEX (tamoxifen)|
303834|NCT00232674|Drug|Pulmicort (budesonide) Turbuhaler|
303835|NCT00232687|Drug|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
303836|NCT00232687|Drug|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
303837|NCT00232700|Drug|Escitalopram|
303838|NCT00002615|Drug|cisplatin|
303839|NCT00232726|Drug|CP-4055 (ELACYT)|
303840|NCT00232739|Device|CYPHER Sirolimus-eluting Coronary Stent|2.25 Cypher Sirolimus-eluting Coronary Stent
303841|NCT00232752|Device|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
303842|NCT00232765|Device|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
303843|NCT00232765|Device|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
303844|NCT00232778|Device|GAMMA-Iridium-192 catheter|
303845|NCT00232791|Device|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
303846|NCT00232791|Device|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
303847|NCT00232804|Device|Bx Cypher stent|
303484|NCT00243646|Drug|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
303485|NCT00243646|Drug|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
303486|NCT00243659|Biological|ReFacto AF|
303487|NCT00243672|Drug|Atorvastatin|
303488|NCT00243672|Drug|Gemfibrozil|
303489|NCT00243685|Other|Laboratory Assay|Chemotherapy
303490|NCT00246506|Procedure|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
303491|NCT00246519|Drug|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
303492|NCT00246519|Drug|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
303493|NCT00246532|Drug|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
303850|NCT00232830|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
303851|NCT00232830|Device|bare-metal stent|any bare-metal stent brand
303852|NCT00232843|Device|stent|Cordis SMART™ nitinol self-expanding stent.
303853|NCT00232843|Device|angioplasty|balloon angioplasty
303854|NCT00232856|Device|drug-eluting stent|PCI
303855|NCT00232869|Device|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
303856|NCT00232869|Device|bare-metal stent|SMART™ bare-metal stent
303857|NCT00236275|Drug|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
303858|NCT00236288|Drug|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
303859|NCT00236301|Drug|CLIMASTON (drug)|CLIMASTON(drug)
303860|NCT00236301|Drug|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
303861|NCT00236301|Drug|placebo|placebo
331459|NCT00425360|Drug|capecitabine|
331797|NCT00003311|Drug|doxorubicin hydrochloride|
331798|NCT00413868|Behavioral|Small target contrast sensitivity and disability glare|
331799|NCT00413881|Procedure|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
331800|NCT00416728|Drug|Valsartan|
331801|NCT00416741|Behavioral|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting [plasma flucose
331802|NCT00416754|Other|counseling intervention|subjects will receive genetic counseling
331803|NCT00416767|Drug|fluorouracil|
331804|NCT00416767|Drug|irinotecan hydrochloride|
331805|NCT00416767|Drug|leucovorin calcium|
331806|NCT00416780|Other|counseling intervention|
331807|NCT00416780|Other|educational intervention|
331808|NCT00416780|Procedure|psychosocial assessment and care|
331809|NCT00416793|Drug|bortezomib|Given IV
331810|NCT00003332|Drug|gemcitabine hydrochloride|
331811|NCT00416793|Drug|carboplatin|Given IV
331812|NCT00416793|Other|laboratory biomarker analysis|Correlative studies
331813|NCT00416819|Biological|filgrastim|
331814|NCT00416819|Biological|rituximab|
331815|NCT00416819|Drug|cytarabine|
331816|NCT00416819|Drug|etoposide phosphate|
331817|NCT00416819|Drug|leucovorin calcium|
331818|NCT00416819|Drug|methotrexate|
331819|NCT00416819|Drug|temozolomide|
331820|NCT00416832|Drug|cyclophosphamide|
331074|NCT00431236|Drug|IV ondansetron hydrochloride|
331075|NCT00431236|Drug|Oral dexamethasone|
331076|NCT00431249|Drug|Cilostazol|
331077|NCT00431262|Drug|antabuse (disulfiram)|
331078|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
331079|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
331080|NCT00431288|Behavioral|diet high in fruits, vegetables, and dairy|
331081|NCT00431288|Behavioral|Routine nutrition care|
331082|NCT00434122|Drug|Placebo|Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.
or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day.
331083|NCT00434135|Drug|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&8
331084|NCT00434148|Drug|Pasireotide|
331085|NCT00434161|Drug|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 & 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
331086|NCT00434161|Drug|Placebo|One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).
Minimum of 4 days between pre-chemotherapy and post-transplantation dosing.
331087|NCT00003404|Procedure|adjuvant therapy|
331460|NCT00425360|Drug|gemcitabine hydrochloride|
331461|NCT00425373|Drug|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
331462|NCT00425373|Drug|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
331463|NCT00425373|Drug|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
331464|NCT00425373|Drug|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
331465|NCT00425373|Drug|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
330711|NCT00439764|Behavioral|Handout of The Back Book|Talk on health of the back and handout of The Back Book
330712|NCT00442455|Procedure|Radiation therapy|63 Gy, five days a week, for 7 weeks
330713|NCT00442468|Other|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
330714|NCT00442481|Drug|Escitalopram|
330715|NCT00442481|Procedure|A baseline overnight polysomnography (oPSG)|
330716|NCT00003436|Drug|cytarabine|
330717|NCT00442494|Drug|intravenous hydrocortisone|
330718|NCT00442507|Drug|Erlotinib|
330719|NCT00442507|Drug|Avastin|
330720|NCT00442533|Drug|High Dose Indium-111 pentetreotide|3 cycles of 500 mCi treatments every 10-12 weeks
330721|NCT00442546|Drug|pregabalin|150 milligram (mg)/ day (double blind)
330722|NCT00442546|Drug|pregabalin|300 mg/day (double blind)
330723|NCT00442546|Drug|Placebo|Placebo
330724|NCT00442559|Drug|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks
330725|NCT00442559|Drug|Comparator: inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks
330726|NCT00442572|Drug|peginterferon alfa-2a [Pegasys]|4 cycles of 135 micrograms sc weekly for 12 weeks followed by no treatment for 12 weeks.
330727|NCT00003436|Drug|daunorubicin hydrochloride|
330728|NCT00442585|Drug|S(+)-ibuprofen|
330729|NCT00442598|Drug|Glufosfamide|
330730|NCT00442611|Drug|Abatacept|Active drug, abatacept, will be administered intravenously in a blinded fashion
330731|NCT00442611|Drug|Abatacept|Abatacept will be administered, dosed based upon weight, intravenously on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
330732|NCT00442637|Drug|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
330733|NCT00442637|Other|observation|observation after induction treatment
330129|NCT00585026|Device|D-28 bifocal lenses and frame|
330130|NCT00585026|Device|Progressive addition computer lenses and frame|
330131|NCT00585039|Drug|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
330132|NCT00585052|Drug|Lovastatin and Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly; lovastatin, 80 mg, po, daily will be self-administered by the subject.
330133|NCT00585065|Other|Cardiac Resynchronization Therapy|Cardiac Resynchronization Therapy
330134|NCT00004163|Biological|trastuzumab|
330135|NCT00585078|Drug|Capecitabine|Orally twice a day for 14 days, from the evening of Day 1 to the morning of Day 15 of each 3-week cycle.
330136|NCT00585078|Drug|Oxaliplatin|Given on Day 1 of each 3-week cycle
330137|NCT00585091|Drug|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
330138|NCT00585104|Drug|levosimendan|10-minute infusion
330139|NCT00585117|Procedure|PET-imaging with CuATSM|imaging with CuATSM
330426|NCT00574847|Drug|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
330427|NCT00574860|Drug|EN3285|Oral rinse
330428|NCT00574860|Drug|Placebo|Oral rinse
330429|NCT00574860|Other|Standard of care|This will be the therapy most commonly used the the institution treating the patient
330430|NCT00574873|Drug|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
330431|NCT00577317|Procedure|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
330432|NCT00577317|Procedure|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
330433|NCT00577317|Other|Quality-of-Life Assessment|Ancillary studies
330434|NCT00577330|Dietary Supplement|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
330435|NCT00577356|Drug|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
329518|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
329831|NCT00003995|Drug|irinotecan hydrochloride|
329832|NCT00552214|Device|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
329833|NCT00552227|Drug|ruboxistaurin|oral 32 mg daily
329834|NCT00552227|Other|placebo|placebo
329835|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
329836|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
329837|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
329838|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
329839|NCT00552240|Drug|Nevirapine 200 mg BID|200 mg BID
329840|NCT00552240|Drug|Atazanavir 300 mg|300 mg QD
329841|NCT00552240|Drug|Ritonavir 100 mg|100 mg QD
329842|NCT00003996|Drug|carmustine|
329843|NCT00552253|Drug|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1~0.3 mU/L. It will be discontinued for 3 months. Then
329844|NCT00552266|Drug|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
329845|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
329846|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
329847|NCT00552305|Drug|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
329848|NCT00552331|Device|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
329849|NCT00552331|Device|LISS|treatment of distal femur fractures with less invasive stabilization systems
329850|NCT00552344|Biological|Cimzia|Active substance: Certolizumab Pegol
Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe
Concentration: 200 mg/ml
Route of Administration: Subcutaneous use
329197|NCT00564330|Drug|Placebo|Placebo bid
329198|NCT00000596|Drug|cyclophosphamide|
329199|NCT00004063|Drug|gemcitabine hydrochloride|
329200|NCT00564343|Other|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
329201|NCT00564356|Procedure|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
329202|NCT00564369|Other|CDC HIV testing recommendations|Current vs. prior CDC recommendations
329203|NCT00564382|Procedure|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
329204|NCT00564395|Drug|Insulin detemir mixed with RAI injection|Insulin detemir injection and RAI injection
329205|NCT00564408|Drug|Carbachol|3 microgram per kg bodyweight infused intravenously
329206|NCT00566644|Other|questionnaire administration|
329207|NCT00566644|Procedure|observation|
329208|NCT00566657|Biological|riferminogene pecaplasmid|Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid
Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated
329519|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
329520|NCT00559702|Drug|natalizumab|natalizumab
329521|NCT00559702|Other|standard of care|standard of care as determined by the Investigator and Treating Neurologist
329522|NCT00559715|Drug|bevacizumab|1.25 mg intravitreally monthly/on demand
329523|NCT00559715|Drug|ranibizumab|0.5 mg intravitreally monthly/on demand
329524|NCT00559741|Biological|cetuximab|
329525|NCT00004038|Drug|chemotherapy|
329526|NCT00559741|Drug|fluorouracil|
329527|NCT00559741|Drug|irinotecan hydrochloride|
329528|NCT00559741|Drug|leucovorin calcium|
329529|NCT00559741|Other|pharmacological study|
328592|NCT00576732|Drug|Risperidone high dose|Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
328593|NCT00004123|Radiation|Radiation Therapy (RT)|5 days a week for 4 weeks
328901|NCT00569244|Drug|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
328902|NCT00569257|Drug|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
328903|NCT00571714|Drug|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
328904|NCT00004094|Drug|paclitaxel|
328905|NCT00571727|Drug|mecasermin|injections BID of rhIGF-1, mecasermin
328906|NCT00571740|Biological|bevacizumab|Given IV
328907|NCT00571740|Biological|cetuximab|Given IV
328908|NCT00571740|Drug|fluorouracil|Given IV
328909|NCT00571740|Drug|leucovorin calcium|Given IV
328910|NCT00571740|Drug|oxaliplatin|Given IV
328911|NCT00571753|Drug|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
328912|NCT00571753|Drug|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
328913|NCT00571766|Drug|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
328914|NCT00571766|Drug|Placebo|Placebo 2 g twice a day for 14 weeks
328915|NCT00000600|Drug|Vitamin C|
328916|NCT00004094|Procedure|conventional surgery|
328917|NCT00571779|Device|AtriCure Bipolar System|
328918|NCT00571805|Drug|varencline|2.0 mg/day varencline (1.0 mg BID)
328919|NCT00571805|Drug|placebo|matching placebo
328920|NCT00571818|Procedure|Oral glucose tolerance test|test done over 2 hours
333762|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
333763|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
333764|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
333765|NCT00443937|Drug|enteric-coated mycophenolate sodium|oral
333766|NCT00443937|Drug|everolimus|oral
333767|NCT00443950|Drug|Etanercept|
333768|NCT00003437|Drug|vincristine sulfate|
333769|NCT00443963|Drug|Esomeprazole Magnesium|
333770|NCT00443976|Drug|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
333771|NCT00444015|Drug|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
333772|NCT00444028|Drug|Loxapine thermal aerosol|
333773|NCT00446511|Drug|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
333774|NCT00446524|Drug|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
333775|NCT00446537|Procedure|Methylphenidate|
328594|NCT00576732|Drug|Risperidone low dose|Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
328595|NCT00576745|Procedure|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
328596|NCT00576745|Device|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
328597|NCT00576758|Drug|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
328598|NCT00576758|Drug|rituximab|375 mg/m^2 rituximab IV infusion once a week for 4 weeks.
328599|NCT00578942|Procedure|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 8 mcg/kg/d subcutaneously twice daily (dose will be rounded to the nearest whole vial size), Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
301167|NCT00367744|Drug|Rosiglitazone|Rosiglitazone 4mg BID
301168|NCT00003093|Drug|cyclophosphamide|
301169|NCT00367744|Drug|Placebo|Placebo for rosiglitazone
301170|NCT00367757|Procedure|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
301171|NCT00367757|Procedure|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
301172|NCT00367757|Procedure|Combined approach for AF ablation|Combined trigger and substrate based approach
301173|NCT00367770|Drug|Tracleer® (bosentan)|
301174|NCT00367783|Drug|CP-741,952|
301500|NCT00406029|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
301501|NCT00406029|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
301502|NCT00406042|Drug|prednisolone acetate 1%|
301503|NCT00406055|Device|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
301504|NCT00406068|Drug|Mycobacterial cell wall-DNA complex|8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
301505|NCT00406094|Drug|montelukast|10mg
301506|NCT00406094|Drug|placebo|placebo
301507|NCT00406107|Drug|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
301508|NCT00003270|Drug|methylprednisolone|IV
301509|NCT00406120|Procedure|Fine needle aspiration biopsy|
301510|NCT00406133|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
301511|NCT00406146|Drug|amodiaquine+artesunate/artemether-lumefantrine|
301512|NCT00406159|Device|Hyperbaric Oxygen Therapy|
300819|NCT00003136|Biological|filgrastim|
300820|NCT00376961|Drug|prednisone|100 mg on days 1-5 of cycles 1-6.
300821|NCT00376961|Drug|vincristine sulfate|1.4 mg/m^2 on day 1 of cycles 1-6.
300822|NCT00376974|Behavioral|American Academy of Ophthalmology Glaucoma Educational Tape|
300823|NCT00376987|Dietary Supplement|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
300824|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% gel pump|
300825|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% tube|
300826|NCT00377026|Behavioral|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
300827|NCT00377039|Drug|AD 337|
300828|NCT00377052|Drug|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
300829|NCT00377052|Drug|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
300830|NCT00003136|Drug|amifostine trihydrate|
300831|NCT00377065|Drug|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
300832|NCT00377078|Drug|recombinant human lactoferrin|
300833|NCT00377091|Drug|Fondaparinux|
300834|NCT00377104|Drug|alvocidib|Given IV
300835|NCT00377104|Other|pharmacological study|Correlative studies
300836|NCT00377104|Other|laboratory biomarker analysis|Correlative studies
300837|NCT00377117|Procedure|Management|
300838|NCT00377117|Procedure|Screening|
301175|NCT00367809|Behavioral|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
300129|NCT00391027|Drug|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
300130|NCT00393471|Drug|Etanercept|
300131|NCT00393484|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
300132|NCT00393484|Drug|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
300133|NCT00393484|Drug|Lamivudine|Capsules, Oral, 100 mg, once daily (0-96 weeks)
Tablets, Oral, 100 mg, once daily (96-240 weeks)
300134|NCT00393484|Drug|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
300135|NCT00393497|Drug|bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
300471|NCT00385346|Behavioral|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
300472|NCT00385359|Procedure|aerosol drug deposition strategies|
300473|NCT00385359|Drug|Albuterol|
300474|NCT00385372|Procedure|elimination diet|
300475|NCT00385372|Procedure|provocation diet|
300476|NCT00003173|Procedure|autologous bone marrow transplantation|
300477|NCT00385385|Drug|Rifalazil|
300478|NCT00385398|Drug|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
300479|NCT00385398|Drug|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
300480|NCT00385398|Radiation|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
300481|NCT00385411|Drug|valproate microgranules|20 to 30 mg/kg/day
300482|NCT00385437|Behavioral|Driving Simulator Testing|
300483|NCT00385437|Drug|Mirtazapine Treatment|
300484|NCT00385450|Drug|Nelfinavir/placebo|1250mg/twice each day/four days.
300485|NCT00385463|Drug|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
299761|NCT00399503|Procedure|Modified Moving Average T Wave Alternans|
299762|NCT00399503|Procedure|Baroreceptor Sensitivity|
299763|NCT00399503|Procedure|Heart Rate Variability|
299764|NCT00399503|Procedure|Heart Rate Turbulence|
299765|NCT00399503|Procedure|Deceleration Capacity|
299766|NCT00399503|Procedure|Signal Averaged ECG|
299767|NCT00399516|Device|Precision|
299768|NCT00402311|Procedure|DOC-PG: integrated multidisciplinary assessment|
299769|NCT00402311|Procedure|Usual care: assessment by GP or one of the regional services|
299770|NCT00402324|Drug|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
299771|NCT00003254|Drug|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
299772|NCT00402324|Drug|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
299773|NCT00402324|Drug|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
299774|NCT00402337|Drug|linaclotide acetate|oral, once daily.
299775|NCT00402337|Drug|Matching placebo|oral, once daily
299776|NCT00402350|Drug|Staccato Fentanyl|Single dose
299777|NCT00402350|Drug|Staccato Fentanyl|4 doses
299778|NCT00402350|Drug|Staccato Fentanyl|2 doses
299779|NCT00402350|Drug|Staccato Fentanyl|6 doses
300136|NCT00393510|Drug|TCM|The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.
The formula consisted of 12 herbs, viz:
Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae
300137|NCT00393510|Drug|Placebo|Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.
The placebo was made with starch and colouring materials.
304953|NCT00257153|Device|Coronary thrombus aspiration catheter|
304954|NCT00257166|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
304955|NCT00257166|Drug|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
299388|NCT00408317|Drug|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
299389|NCT00408317|Drug|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
299390|NCT00408330|Drug|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
299391|NCT00408330|Drug|Inactive 15% gel base|placebo, topically applied daily for six weeks
299392|NCT00410982|Drug|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
299393|NCT00410995|Drug|Naproxen|
299394|NCT00411021|Procedure|Pipelle (Endometrial Sampling)|
299395|NCT00411034|Drug|OROS Hydromorphone HCI|
299396|NCT00411047|Drug|gefitinib|oral drug taken daily around the same time
299397|NCT00411073|Drug|Darapladib|
299398|NCT00003297|Drug|thiotepa|
299399|NCT00411086|Biological|Rituximab|375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22.
299400|NCT00411086|Biological|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
299401|NCT00411099|Drug|agomelatine|
299402|NCT00411099|Drug|placebo|
299403|NCT00411112|Procedure|blue and isotopic detection of sentinel lymph nodes|
299404|NCT00411125|Drug|Oral salmon calcitonin|
299405|NCT00411138|Radiation|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
299406|NCT00411138|Drug|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
304587|NCT00209989|Drug|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
304588|NCT00209989|Procedure|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
304589|NCT00210002|Drug|Darbepoetin alfa (Aranesp®)|
304590|NCT00210002|Drug|Ferric saccharose(Venofer®)|
304591|NCT00210015|Drug|INS37217 Nasal Spray|
304592|NCT00210028|Drug|Tamoxifen|
304593|NCT00210028|Drug|Zarnestra|
304594|NCT00000385|Drug|Lithium|Lithium 600 mg to 2700 mg per day
304595|NCT00002558|Biological|filgrastim|
304596|NCT00210041|Drug|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
304597|NCT00210041|Drug|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
304598|NCT00210054|Drug|denufosol tetrasodium (INS37217)|
304956|NCT00257192|Drug|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
304957|NCT00257192|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
304958|NCT00257205|Drug|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
304959|NCT00257205|Drug|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
304960|NCT00257205|Drug|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
304961|NCT00257218|Behavioral|Life style modification|
304962|NCT00257257|Drug|Rimonabant (SR141716)|
304963|NCT00002691|Biological|filgrastim|
304964|NCT00257270|Drug|gabapentin|
303848|NCT00232817|Drug|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
303849|NCT00002615|Drug|epirubicin hydrochloride|
304218|NCT00221325|Drug|Intraventricular Rituximab Plus MTX|Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.
First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.
If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.
Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing.
304219|NCT00221338|Drug|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
304220|NCT00221351|Procedure|CRP point of care testing|
304221|NCT00221364|Drug|Mass treatment with oral azithromycin to an entire village|
304222|NCT00221377|Device|Intubation using tracheal tubes with or without cuff|
304223|NCT00221390|Drug|Ropinirole (+ physical therapy)|
304224|NCT00221390|Drug|(vs.) Placebo + physical therapy|
304225|NCT00002582|Drug|goserelin acetate|
304226|NCT00221403|Drug|Risperidone Valproate|liquid, BID dosing.
304227|NCT00221416|Drug|Aripiprazole|5-20 mg/day
304228|NCT00221429|Drug|lithium sodium divalproex|
304229|NCT00221442|Drug|Zonegran|zonegran (zonisamide)
304230|NCT00221442|Drug|sugar pill|fake pill
304231|NCT00221455|Behavioral|Patient diabetic self-management using the diabetic patient portal tools|
304232|NCT00221455|Behavioral|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
304233|NCT00221468|Drug|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
304234|NCT00221481|Drug|divalproex or olanzapine|
304235|NCT00221494|Drug|citalopram + tiodothyronine, or + pindolol, or + placebo|
304236|NCT00002582|Drug|leuprolide acetate|
303862|NCT00236327|Drug|fentanyl|
303863|NCT00236340|Device|syringe aspiration|
303864|NCT00236340|Device|Wall suction|
303865|NCT00236353|Drug|risperidone|
303866|NCT00236366|Drug|fentanyl|
303867|NCT00002624|Procedure|video-assisted surgery|
303868|NCT00236379|Drug|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
303869|NCT00236379|Drug|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
303870|NCT00236392|Drug|rabeprazole|
303871|NCT00236405|Drug|epoetin alfa|
303872|NCT00236418|Drug|topiramate|
303873|NCT00236431|Drug|Galantamine hydrobromide|
303874|NCT00236444|Drug|risperidone|
303875|NCT00236457|Drug|risperidone|
303876|NCT00236470|Drug|risperidone|
304241|NCT00224939|Drug|Potassium Chloride|
304242|NCT00224952|Other|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
304243|NCT00224965|Behavioral|Behavior Therapy|
304244|NCT00224978|Drug|Chloroquine|
304245|NCT00224991|Procedure|Intensive systematic information (osteoporosis school)|
304246|NCT00225004|Procedure|DEXA scan|orto
304247|NCT00002593|Drug|levamisole hydrochloride|Given as described in arm description
304248|NCT00225017|Drug|Atazanavir|atazanavir 400 mg once daily
304249|NCT00225017|Drug|current antiretroviral regimen|Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus > 2 NRTIs
304250|NCT00225030|Drug|antihypertensive drugs according to current guidelines|
331821|NCT00003332|Procedure|surgical procedure|
331822|NCT00416832|Drug|dacarbazine|
331823|NCT00416832|Drug|doxorubicin hydrochloride|
331824|NCT00416832|Drug|etoposide|
332162|NCT00454688|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
332163|NCT00003505|Procedure|biologically based therapies|
332164|NCT00454701|Drug|Alefacept exposure|Observational
332165|NCT00454714|Drug|single dose Sildenafil|Application of a single dose Sildenafil
332166|NCT00454714|Drug|Single dose placebo|Application of a single dose placebo
332167|NCT00454740|Drug|solifenacin succinate|Oral
332168|NCT00454753|Drug|Dasatinib|tablet, Oral, 140mg/day, BID, until;
the time of reimbursement in Korea
the application for marketing authorization is withdrawn
the application for marketing authorization is denied
332169|NCT00454766|Behavioral|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
332170|NCT00454779|Drug|Cisplatin|chemotherapy arm
332171|NCT00454779|Drug|Panitumumab|experimental arm
332172|NCT00454779|Drug|Docetaxel|chemotherapy arm
332173|NCT00454779|Drug|Cisplatin|experimental arm
332174|NCT00000525|Drug|chlorthalidone|
332175|NCT00003505|Procedure|cancer prevention intervention|
332176|NCT00454779|Drug|Docetaxel|experimental arm
332177|NCT00458081|Drug|Rimonabant|20 mg once per day + slightly reduced calorie diet
332178|NCT00458081|Drug|Placebo|placebo once per day + slightly reduced calorie diet
332179|NCT00458094|Behavioral|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
331466|NCT00425373|Drug|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
331467|NCT00425373|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
331468|NCT00425373|Drug|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
331469|NCT00003379|Radiation|brachytherapy|
331470|NCT00425373|Drug|Placebo|4 tablet and 2 capsule placebos taken once daily
331471|NCT00425386|Drug|erlotinib hydrochloride|Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;
100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;
150 mg/day, continuous daily
331472|NCT00425386|Drug|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
331473|NCT00425386|Procedure|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
331474|NCT00425399|Procedure|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
331475|NCT00425425|Biological|cetuximab|
331476|NCT00425425|Drug|fluorouracil|
331477|NCT00425425|Drug|oxaliplatin|
331478|NCT00425425|Procedure|conventional surgery|
331479|NCT00425425|Procedure|neoadjuvant therapy|
331480|NCT00003379|Radiation|radiation therapy|
331481|NCT00425425|Radiation|radiation therapy|
331482|NCT00425438|Drug|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
331825|NCT00416832|Drug|prednisone|
331826|NCT00416832|Drug|procarbazine hydrochloride|
331827|NCT00416832|Drug|vincristine sulfate|
331828|NCT00416832|Radiation|radiation therapy|
331829|NCT00416845|Drug|FTY720|
330734|NCT00442650|Drug|Efalizumab|
330735|NCT00442663|Device|Transcervical Foley Catheter|
330736|NCT00442663|Device|Transcervical Foley Catheter with an EASI|
331088|NCT00434161|Drug|Palifermin before and after|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).
Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
331089|NCT00434174|Drug|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.
Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed.
331090|NCT00434174|Drug|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
331091|NCT00434187|Drug|ERB-041|
331092|NCT00434200|Procedure|long-term intensive exercise|
331093|NCT00434213|Drug|Daytrana|Methylphenidate Transdermal System (MTS)
331094|NCT00434226|Drug|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
331095|NCT00434226|Drug|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
331096|NCT00434226|Drug|carboplatin|On the first day of each cycle for 4 cycles
331097|NCT00434226|Drug|paclitaxel|On the first day of each cycle for 4 cycles
331098|NCT00003404|Radiation|radiation therapy|
331099|NCT00434239|Drug|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
331100|NCT00434252|Drug|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
331101|NCT00434252|Drug|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
331102|NCT00434252|Drug|paclitaxel|175 mg/m^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
331103|NCT00434252|Drug|placebo|Administered by IV infusion on the first day of each 3-week cycle
331104|NCT00434265|Behavioral|Physical training|
330436|NCT00577356|Biological|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
330437|NCT00577369|Other|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
330438|NCT00577382|Drug|Sunitinib|Oral pill taken daily for 4 weeks
330439|NCT00004125|Radiation|radiation therapy|
330440|NCT00577395|Drug|placebo|oral tablet once a month for 12 months
330441|NCT00577395|Drug|risedronate|tablet, 150 mg once a month for 12 months
330442|NCT00577408|Drug|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
330443|NCT00577408|Drug|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
330444|NCT00577421|Drug|risedronate|5 mg tablet of risedronate once a day for 2 years
330445|NCT00577447|Dietary Supplement|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
330737|NCT00442676|Drug|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
330738|NCT00003436|Drug|etoposide|
330739|NCT00442676|Drug|Placebo|Gelatin capsules of lactose
330740|NCT00442689|Drug|flutamide|250 mg twice daily
330741|NCT00442689|Drug|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
330742|NCT00442689|Other|placebo|
330743|NCT00445562|Other|biologic sample preservation procedure|
330744|NCT00445562|Other|informational intervention|
330745|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
329851|NCT00552370|Drug|Lantus®|
329852|NCT00554814|Drug|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
329853|NCT00554827|Drug|Pralatrexate Injection|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest.
330140|NCT00585117|Procedure|PET Imaging|Imaging with CuATSM
330141|NCT00585117|Procedure|PET CuATSM|Imaging with CuATSM
330142|NCT00585117|Procedure|PET imaging|imaging with CuATSM
330143|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
330144|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
330145|NCT00004164|Biological|filgrastim|
330146|NCT00585143|Drug|ABT-335|45 mg once daily for 10 consecutive days
330147|NCT00585143|Drug|Rosuvastatin|10 mg once daily for 10 days
330148|NCT00585156|Drug|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
330149|NCT00585169|Drug|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
330150|NCT00585182|Drug|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
330151|NCT00585195|Drug|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
330152|NCT00585195|Drug|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
330153|NCT00587899|Procedure|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
330154|NCT00587925|Other|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
329530|NCT00559754|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
329531|NCT00559754|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
329532|NCT00559754|Drug|Standard chemotherapy|As prescribed
329533|NCT00559780|Behavioral|Resistance training|12 weeks of resistance training (3/week)
329534|NCT00559780|Behavioral|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
329535|NCT00559780|Behavioral|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
329536|NCT00004039|Biological|recombinant interferon alfa|
329537|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
329538|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
329539|NCT00559819|Drug|placebo|Placebo (orange juice), same volume as alcohol
329540|NCT00559819|Drug|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
329541|NCT00559832|Other|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
329542|NCT00559845|Drug|FEC|As prescribed
329543|NCT00559845|Drug|Paclitaxel|As prescribed
329854|NCT00554827|Dietary Supplement|Vitamin B12|1 mg intramuscular injection
Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.
Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
329855|NCT00004010|Biological|filgrastim|
329856|NCT00554827|Dietary Supplement|Folic Acid|1 mg orally
Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.
Administered daily throughout the study and for at least 30 days after last dose of pralatrexate.
329857|NCT00554840|Drug|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
328921|NCT00571818|Procedure|IV Glucose Tolerance Test|Done over 4 hours
328922|NCT00571831|Procedure|intraocular lens implantation|Intraocular lens implantation
328923|NCT00571844|Behavioral|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
329209|NCT00566657|Biological|Placebo (for riferminogene pecaplasmid)|Formulation: 5 ml glass vials containing 2,5 ml placebo
Route: IM injection of 2.5 mL in the ischemic leg to be treated
329210|NCT00566683|Drug|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
329211|NCT00566683|Drug|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
329212|NCT00004079|Drug|SarCNU|Given PO
329213|NCT00566696|Device|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
329214|NCT00566696|Procedure|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
329215|NCT00566696|Drug|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329216|NCT00566696|Drug|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329217|NCT00566696|Drug|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329218|NCT00566696|Drug|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329219|NCT00566696|Drug|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329220|NCT00566696|Drug|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
329221|NCT00566696|Drug|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329222|NCT00566696|Drug|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329223|NCT00004079|Other|pharmacological study|Correlative studies
328600|NCT00004132|Drug|ifosfamide|
328601|NCT00578955|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
328602|NCT00578955|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
328603|NCT00578955|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
328604|NCT00578968|Drug|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
328605|NCT00578968|Drug|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
328606|NCT00578981|Behavioral|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
328607|NCT00578994|Device|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
328608|NCT00579007|Behavioral|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
328609|NCT00579020|Drug|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
328610|NCT00579020|Drug|Moxifloxacin ophthalmic solution 0.5%|
328611|NCT00004132|Procedure|quality-of-life assessment|
328612|NCT00579020|Drug|Dexamethasone phosphate solution, 0.1%|
328613|NCT00579033|Other|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
328924|NCT00571844|Behavioral|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
328925|NCT00574249|Biological|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
301513|NCT00406172|Drug|Bevacizumab|
301514|NCT00406198|Procedure|venovenous hemofiltration|
301515|NCT00406211|Biological|MMRV|
301516|NCT00406211|Biological|MMR (Priorix®)|
301517|NCT00409097|Drug|Rosiglitazone|
301518|NCT00409136|Behavioral|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
301519|NCT00409149|Behavioral|CALM Approache|
301520|NCT00409149|Behavioral|DASH approach|standard dietary DASH approach in hypertensive patients
301521|NCT00409162|Device|Eraser TM device, with washing fluid|
301522|NCT00003284|Drug|ifosfamide|
301871|NCT00400231|Drug|Study Drug: fenofibrate|145mg/day of fenofibrate
301872|NCT00400231|Drug|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
301873|NCT00400244|Procedure|Wheelchair skills traing program|
301874|NCT00400257|Behavioral|Early detection of heart failure|Early detection of heart failure
301875|NCT00003240|Drug|vinorelbine tartrate|
301876|NCT00400270|Procedure|Breathing and relaxation exercises: the Papworth Method|
301877|NCT00400283|Drug|NNC 55-0414|
301878|NCT00400296|Drug|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
301879|NCT00400309|Biological|Tetanus, Diphtheria, Poliomyelitis and Pertussis|
301880|NCT00400322|Drug|Valganciclovir (Valcyte)|
301881|NCT00400335|Drug|Nanomilled testosterone|
301882|NCT00400335|Drug|commercially available dutasteride|
301883|NCT00400335|Drug|Nanomilled dutasteride|
301884|NCT00400348|Drug|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
301176|NCT00367809|Behavioral|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
301177|NCT00367809|Behavioral|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
301178|NCT00367822|Drug|Lisuride|
301179|NCT00003093|Drug|doxorubicin hydrochloride|
301180|NCT00370747|Drug|Ecabet|ophthalmic solution 2.83%
301181|NCT00370747|Drug|Ecabet|ophthalmic solution 3.70%
301182|NCT00370747|Drug|Placebo|
301183|NCT00370760|Drug|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
301184|NCT00003108|Drug|cisplatin|
301185|NCT00370760|Drug|placebo|
301186|NCT00370773|Device|Precision Spinal Cord Stimulation System|
301187|NCT00370786|Drug|bevacizumab|
301188|NCT00370799|Drug|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
301189|NCT00370799|Drug|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
301190|NCT00370799|Drug|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
301191|NCT00370799|Drug|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
301192|NCT00370812|Procedure|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
301193|NCT00370825|Drug|Combination therapy with AmBisome and miltefosine|
301523|NCT00409175|Drug|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
301524|NCT00409175|Drug|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
300486|NCT00385476|Behavioral|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
300487|NCT00003173|Procedure|peripheral blood stem cell transplantation|
300488|NCT00385489|Drug|LXR-623|
300489|NCT00385502|Drug|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
300490|NCT00385515|Drug|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
300491|NCT00385515|Drug|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
300492|NCT00385528|Behavioral|Multi-faceted psychiatric intervention|
300493|NCT00385541|Drug|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
300494|NCT00388336|Drug|Epoetin Alfa|
300839|NCT00377130|Other|Self Administered Stress Management|The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The "positive thinking" exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training.
300840|NCT00377143|Drug|Warfarin Dosing|
300841|NCT00003136|Drug|carboplatin|
300842|NCT00377156|Radiation|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
300843|NCT00377156|Radiation|stereotactic radiosurgery|
300844|NCT00379743|Behavioral|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
300845|NCT00379743|Behavioral|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
300846|NCT00379756|Drug|LEVITRA (vardenafil)|active comparator
300847|NCT00379756|Drug|placebo|placebo comparator
300138|NCT00003211|Procedure|peripheral blood stem cell transplantation|
300139|NCT00393523|Biological|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
300140|NCT00393523|Biological|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
300141|NCT00393536|Behavioral|Educational outreach visiting|
300142|NCT00393549|Device|NeuroPath|
300143|NCT00393562|Drug|modafinil|
300144|NCT00393562|Drug|methylphenidate|
300145|NCT00393575|Behavioral|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
300146|NCT00393614|Drug|levetiracetam|20 mg pr. kg a day
300147|NCT00393627|Behavioral|Sleep Education Program|The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
300148|NCT00393640|Procedure|Early and regular breast milk expression|Breast pump given to be used on regular intervals
300149|NCT00003211|Radiation|radiation therapy|
300150|NCT00393653|Procedure|N-of-1 prescription method|
300151|NCT00393679|Drug|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
300152|NCT00396370|Biological|Connaught strain BCG|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10^5 CFU vaccine for intradermal administration.
300153|NCT00396370|Drug|Placebo (PO)|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
300495|NCT00388349|Drug|Gemcitabine|
300496|NCT00388349|Drug|Vinorelbine|
300497|NCT00388349|Drug|Carmustine|
299407|NCT00411138|Drug|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
299408|NCT00411138|Drug|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
299409|NCT00003297|Drug|topotecan hydrochloride|
299410|NCT00411151|Drug|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
299411|NCT00411164|Drug|OROS hydromorphone HCI (slow release)|
299780|NCT00402350|Drug|Staccato Fentanyl|12 doses
299781|NCT00402350|Drug|Staccato placebo|single & multiple doses
299782|NCT00003254|Drug|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
299783|NCT00402363|Drug|omega-3-acid ethyl esters|
299784|NCT00402363|Drug|Placebo|
299785|NCT00402376|Drug|Pravastatin, Carvedilol, Perindopril|
299786|NCT00402376|Device|Biventricular assist device (Thoratec paracorporeal assist device)|
299787|NCT00402389|Drug|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
299788|NCT00402389|Behavioral|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
299789|NCT00402389|Drug|Placebo|Four capsules will be taken daily for 8 weeks.
299790|NCT00402402|Procedure|Tuberculin skin test|
299791|NCT00402402|Procedure|Quantiferon-TB Gold assay|
299792|NCT00402415|Drug|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
299793|NCT00003255|Drug|carboplatin|
299794|NCT00402415|Drug|Rapamycin|Dose escalation until MTD as follows:
C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly
299795|NCT00402428|Drug|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
299796|NCT00402428|Drug|peginterferon alfa-2a|180 mcg once a week for 48 weeks
304965|NCT00257283|Drug|Omega-3-acid ethyl esters 90|
304966|NCT00257296|Procedure|Screening Protocol for Intimate Partner Violence|
304967|NCT00257296|Procedure|Intervention Protocol for Intimate Partner Violence|
304968|NCT00257309|Drug|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
304969|NCT00257309|Procedure|Primary angioplasty|
304970|NCT00257322|Drug|GM-CSF|250ug/m2 SQ QD with a cap of 500mcg SQ QD
304971|NCT00257335|Procedure|IMRT|
304972|NCT00257348|Drug|Capecitabine|
304973|NCT00257348|Drug|Docetaxel|
304974|NCT00002691|Drug|asparaginase|
304975|NCT00257361|Drug|D-Cycloserine|
304976|NCT00257374|Drug|Gatorade, Pedialyte and New Solution|
304977|NCT00257387|Drug|Cyclosporine|
304978|NCT00257400|Behavioral|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
304979|NCT00257400|Behavioral|Individual Psychotherapy|Individual Psychotherapy
304980|NCT02718976|Procedure|Ultrasound guided lumbar plexus block (Shamrock)|
299412|NCT00411177|Procedure|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
299413|NCT00411177|Procedure|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
299414|NCT00411190|Drug|Relacatib|
299415|NCT00411203|Drug|Tamoxifen Citrate|
299416|NCT00411203|Drug|Placebo|
299417|NCT00411216|Other|Control exercises|saccadic eye movements against a plain background; no head movements
299418|NCT00411216|Other|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
299419|NCT00411229|Drug|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
304237|NCT00224887|Behavioral|In home nutrition counseling|
304238|NCT00224913|Procedure|Neuromuscular electrical stimulation|
304239|NCT00224913|Procedure|Voluntary exercise|
304240|NCT00224926|Procedure|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
304599|NCT00210067|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
304600|NCT00210080|Drug|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
304601|NCT00210093|Drug|denufosol tetrasodium (INS37217)|
304602|NCT00210106|Device|Ablathermy|
304603|NCT00210119|Drug|Imatinib mesylate and zoledronic acid|
304604|NCT00210132|Drug|Ropivacaine|
304605|NCT00210145|Behavioral|Aesthetic care|
304606|NCT00002558|Drug|carboplatin|
304607|NCT00214344|Behavioral|family preparation for withdrawing life support|
304608|NCT00214357|Behavioral|Mindfulness-based stress reduction|
304609|NCT00214370|Drug|Propofol-Fentanyl|
304610|NCT00214370|Drug|Propofol alone|
304611|NCT00214383|Behavioral|CHESS Internet telehealth|CHESS Internet telehealth
304612|NCT00214422|Radiation|External Beam Radiation|Radiation will be given in dose escalations from 5040 cGy to a maximum of 5900cGy to lymph nodes.
304613|NCT00214435|Drug|once daily minimum 3-drug regimen of anti-retroviral medications|
304614|NCT00214461|Biological|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
304615|NCT00002566|Drug|etoposide|
304616|NCT00214461|Biological|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
304617|NCT00214461|Biological|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
304251|NCT00225043|Drug|Epinephrine/phenylephrine|
304252|NCT00225056|Drug|docetaxel and capecitabine|
304253|NCT00225069|Procedure|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
304254|NCT00225082|Drug|Nucleoside analogue switch|stavudine switched to tenofovir
304255|NCT00225095|Drug|Mesenchymal Stem Cells|
304256|NCT00225095|Drug|Hyaluronan|
304257|NCT00225108|Drug|Tinzaparin|
304258|NCT00002594|Biological|Sargramostim|Given IV
304259|NCT00225121|Drug|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
304260|NCT00225147|Drug|Recombinant Human C1 Inhibitor|IV
304261|NCT00225147|Drug|placebo|saline solution
304262|NCT00225160|Drug|acetyl L-carnitine|
304263|NCT00225173|Drug|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
304264|NCT00225173|Drug|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
304265|NCT00225173|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
304266|NCT00225173|Drug|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
304623|NCT00214500|Drug|AT1001 (migalastat hydrochloride)|AT1001 was administered as follows during the 12-week treatment period; a 6-week dose escalation from 25, to 100, to 250 mg twice daily, then 6 weeks of 25 mg twice daily. Subjects opting to participate in two treatment extension periods from 12 - 48 weeks and then 48 - 96 weeks were administered 50 mg every day.
304624|NCT00214513|Behavioral|Home-based exercise training|
304625|NCT00214526|Procedure|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
304626|NCT00000386|Behavioral|Relaxation Training|
304627|NCT00002566|Drug|ifosfamide|
304628|NCT00214526|Drug|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
332180|NCT00458094|Behavioral|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
332181|NCT00458107|Drug|SCA-136|
332182|NCT00458120|Biological|rDEN1delta30|Live attenuated 10^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
332183|NCT00458120|Biological|rDEN2/4delta30(ME)|Live attenuated 10^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
332184|NCT00458120|Biological|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
332509|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
332510|NCT00449072|Drug|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
332511|NCT00449072|Drug|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
332512|NCT00003471|Drug|antineoplaston A10|
332513|NCT00449085|Procedure|Electrophysiology|
332514|NCT00449085|Device|CARTO™ XP EP Navigation System V9|
332515|NCT00449098|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
332516|NCT00449098|Drug|Trabeculectomy with MMC|Trabeculectomy with MMC
332517|NCT00449111|Drug|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
332518|NCT00449124|Drug|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
332519|NCT00449124|Biological|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10^6 PFU, TG4040 10^7 PFU and TG4040 10^8 PFU.
332520|NCT00449137|Drug|Arsenic trioxide|ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
331830|NCT00416858|Drug|cisplatin|
331831|NCT00416858|Drug|fluorouracil|
331832|NCT00003332|Radiation|radiation therapy|
331833|NCT00416858|Procedure|adjuvant therapy|
331834|NCT00416858|Procedure|conventional surgery|
331835|NCT00419783|Drug|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
331836|NCT00419783|Drug|Placebo|Placebo tablets
331837|NCT00419796|Drug|Lumiracoxib|
331838|NCT00419809|Drug|SB-681323 oral tablets|
331839|NCT00419822|Procedure|Acupuncture|6 Acupuncture visits
331840|NCT00419822|Procedure|Sham Acupuncture|6 Acupuncture visits with sham procedure
331841|NCT00419822|Other|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
331842|NCT00419835|Drug|enalapril|
331843|NCT00419835|Drug|losartan|
331844|NCT00419848|Drug|Doxycycline|Cap 100mg- 100mg/daily
331845|NCT00003343|Drug|prinomastat|
331846|NCT00419848|Drug|Azithromycin|Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
331847|NCT00419887|Drug|Vildagliptin (LAF237)|
331848|NCT00419900|Procedure|diagnosis of breast cancer by x-ray diffraction of hair|
331849|NCT00419913|Dietary Supplement|Dehydroepiandrosterone|DHEA 25 mg tid
331850|NCT00419926|Drug|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
331851|NCT00419926|Drug|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
332185|NCT00003517|Procedure|hormone therapy|
331105|NCT00436839|Drug|Docetaxel|75mg/m² intravenously (day 1) every 21 days
331106|NCT00436839|Drug|Mitoxantrone|12mg/m² intravenously every 21 days
331107|NCT00436839|Drug|Prednisone|10mg orally given daily
331108|NCT00000518|Drug|sotalol|
331109|NCT00003414|Drug|busulfan|
331483|NCT00425438|Drug|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
331484|NCT00425438|Drug|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
331485|NCT00428272|Drug|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
331486|NCT00428285|Procedure|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
331487|NCT00428298|Drug|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
331488|NCT00428298|Drug|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
331489|NCT00428311|Drug|Metformin|
331490|NCT00428311|Drug|Ethynyl-estradiol plus cyproterone acetate|
331491|NCT00428337|Biological|EP-1233|DNA-HIV-recombinant vaccine
331492|NCT00428337|Biological|MVA-mBN32|HIV-recombinant viral vaccine
331493|NCT00003389|Drug|Etoposide|given IV
331494|NCT00428350|Drug|Quetiapine Fumarate (Seroquel)|
331495|NCT00428363|Device|Cataract surgery with implantation of an intraocular lens|
331496|NCT00428376|Device|Building Blocks|
331497|NCT00428389|Drug|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
331498|NCT00428389|Drug|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
330746|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
330747|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
330748|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
330749|NCT00445588|Drug|erlotinib hydrochloride|Given orally
330750|NCT00003449|Drug|paclitaxel|
330751|NCT00445588|Drug|sorafenib tosylate|Given orally
330752|NCT00445588|Other|pharmacological study|Correlative studies
330753|NCT00445601|Drug|gemcitabine hydrochloride|Given intravesically
330754|NCT00445601|Other|placebo|Given intravesically
330755|NCT00445614|Behavioral|Effects of trout on CVD risk markers and plasma proteome|
330756|NCT00445666|Biological|graft-versus-tumor induction therapy|
330757|NCT00445666|Biological|therapeutic tumor infiltrating lymphocytes|
330758|NCT00445666|Genetic|cytogenetic analysis|
330759|NCT00445666|Genetic|fluorescence in situ hybridization|
330760|NCT00445666|Genetic|microarray analysis|
330761|NCT00003450|Biological|Ad5CMV-p53 gene|
331110|NCT00436852|Drug|ABT-751|Given orally
331111|NCT00436852|Procedure|quality-of-life assessment|Ancillary studies
331112|NCT00436865|Behavioral|Weight loss|
331113|NCT00436878|Behavioral|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
331114|NCT00436904|Drug|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
330155|NCT00587964|Radiation|Stereotactic Radiosurgery|All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.
A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY.
330156|NCT00004174|Drug|thiotepa|
330446|NCT00577447|Dietary Supplement|Placebo|Placebo capsule containing corn and soybean oil
330447|NCT00577460|Drug|Pramipexole|Pramipexole ER 0.375 -4.5 mg
330448|NCT00577460|Drug|Placebo|Placebo tablets identical to Pramipexole ER tablets
330449|NCT00577473|Drug|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
330450|NCT00004126|Drug|oxaliplatin|
330451|NCT00577473|Drug|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
330452|NCT00577512|Drug|DTPACE|Dexamethasone 200 mg IVPB Days 1-7
Thalidomide 200 mg PO Days 1-7
Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)
Adriamycin 15 mg/m2 Days 1-4
Cyclophosphamide 600 mg/m2 Days 1-4
Etoposide 60 mg/m2 Days 1-4
330453|NCT00577577|Drug|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
330454|NCT00577577|Drug|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
330455|NCT00579605|Behavioral|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
330456|NCT00579618|Other|Saliva or Blood samples|Extracting sample of saliva or blood only once.
330457|NCT00579631|Behavioral|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
330458|NCT00579644|Drug|Combination of Minocycline and MTX or MTX alone|Methotrexate Dosing:
1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.
3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.
4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg
329858|NCT00554840|Drug|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
329859|NCT00554853|Drug|pioglitazone|daily dose
329860|NCT00554866|Other|blood sample and buccal swab sample|one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.
Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab.
329861|NCT00554879|Procedure|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
329862|NCT00554879|Procedure|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
329863|NCT00554892|Procedure|bowel preparation|oral laxatives, retrograde enemas
329864|NCT00554892|Procedure|no preparation bowel|no preparation bowel
329865|NCT00554905|Procedure|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
329866|NCT00004010|Drug|ABVD regimen|
329867|NCT00554905|Procedure|TACE|TACE first, then RFA within 2 weeks
329868|NCT00554918|Drug|docetaxel|
329869|NCT00554918|Drug|prednisolone|
329870|NCT00554918|Drug|zoledronic acid|
329871|NCT00554918|Procedure|quality-of-life assessment|
329872|NCT00554918|Radiation|strontium chloride Sr 89|
330157|NCT00587990|Genetic|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 107 cells. The injections will be administered following completion of CABG surgery.
330158|NCT00587990|Genetic|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
330159|NCT00587990|Genetic|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 108 cells. The injections will be administered following completion of CABG surgery.
329224|NCT00566696|Drug|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
329225|NCT00566696|Drug|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
329226|NCT00566709|Procedure|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
329227|NCT00566722|Biological|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
329228|NCT00566735|Drug|Razadyne|The starting dose of study medication is 4 mg twice a day
329544|NCT00559845|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
329545|NCT00559858|Dietary Supplement|pyridoxine hydrochloride|
329546|NCT00559858|Other|placebo|
329547|NCT00561964|Drug|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
329548|NCT00561977|Behavioral|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
329549|NCT00561977|Behavioral|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
329550|NCT00561977|Behavioral|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
329551|NCT00561990|Drug|Nimotuzumab|
329552|NCT00562003|Procedure|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
329553|NCT00004054|Drug|paclitaxel|135 mg/m^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
329554|NCT00562003|Drug|Ad5-delta24RGD|Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.
The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'.
329555|NCT00562016|Device|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
329556|NCT00562016|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
328926|NCT00574249|Drug|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
328927|NCT00574249|Drug|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
328928|NCT00574275|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
328929|NCT00574275|Drug|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
328930|NCT00574275|Drug|Gemcitabine|1000 mg/m^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
328931|NCT00574288|Drug|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
328932|NCT00004105|Drug|vinorelbine ditartrate|
328933|NCT00574288|Drug|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
328934|NCT00574288|Other|Methylprednisolone|Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.
Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions.
328935|NCT00574288|Other|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
329229|NCT00569270|Drug|tiotropium|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
329230|NCT00004088|Drug|thalidomide|
329231|NCT00569270|Drug|placebo|18ug tiotropium placebo capsule daily for 1 month
329232|NCT00569270|Drug|tiotropium|daily tiotropium 18ug versus daily placebo for 30 days
329233|NCT00569283|Biological|therapeutic allogeneic lymphocytes|
301885|NCT00400361|Drug|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
301886|NCT00000501|Behavioral|diet, sodium-restricted|
301887|NCT00003240|Procedure|conventional surgery|
301888|NCT00400374|Drug|Erlotinib|Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
301889|NCT00400374|Drug|Celecoxib|Celecoxib, 400 mg, daily for 6 months.
301890|NCT00400387|Drug|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
301891|NCT00400387|Dietary Supplement|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
301892|NCT00400400|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
301893|NCT00400400|Drug|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
301894|NCT00400400|Drug|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
301895|NCT00400400|Drug|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
302267|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
302268|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
302269|NCT00394329|Drug|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
302270|NCT00394355|Drug|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
302271|NCT00394355|Drug|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
302272|NCT00394355|Drug|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
302273|NCT00394355|Drug|montelukast|10 mg given once daily in the evening by mouth for 1 year.
302274|NCT00394368|Drug|beclomethasone dipropionate plus formoterol fumarate combination|
302275|NCT00394368|Drug|fluticasone propionate plus salmeterol xinafoate combination|
301525|NCT00409188|Biological|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
301526|NCT00409188|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
301527|NCT00409188|Drug|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
301528|NCT00409201|Drug|reboxetine adjuvant therapy|
301529|NCT00409214|Drug|LS11 (talaporfin sodium)|
301530|NCT00409214|Device|Light source (interstitial light emitting diodes)|
301531|NCT00409214|Procedure|Intraoperative placement of device in glioma|
301532|NCT00409227|Drug|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
301533|NCT00003284|Drug|paclitaxel|
301534|NCT00409227|Drug|placebo|placebo once a day for 3 months or stone free
301535|NCT00409240|Other|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
301536|NCT00409253|Drug|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
301537|NCT00409253|Drug|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD >105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
301538|NCT00409266|Device|Computer assisted navigation|
301539|NCT00409279|Behavioral|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
301540|NCT00409292|Drug|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
301541|NCT00409305|Drug|Betahistine|
301542|NCT00412100|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
301543|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 5 mg
300848|NCT00379769|Drug|Rosiglitazone|Rosiglitazone maximum 8 mg per day
300849|NCT00379769|Drug|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
300850|NCT00379769|Drug|Metformin|Metformin maximum permitted daily dose .
300851|NCT00379782|Other|Navigation|Navigation and escourt
300852|NCT00379795|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
300853|NCT00003146|Procedure|bone marrow transplantation|
300854|NCT00379808|Drug|montelukast|10 mg tablet (masked by capsule) daily for 1 month
300855|NCT00379808|Drug|Placebo|1 lactose-containing capsule daily for 1 month
300856|NCT00379821|Drug|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
300857|NCT00379821|Drug|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
300858|NCT00379821|Drug|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
301194|NCT00370838|Drug|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
301195|NCT00003109|Drug|irinotecan hydrochloride|
301196|NCT00370838|Drug|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
301197|NCT00370851|Drug|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
301198|NCT00370864|Biological|H5N1 pandemic influenza vaccine|
301199|NCT00370877|Drug|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
301200|NCT00370877|Procedure|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
301201|NCT00370890|Drug|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
300498|NCT00388349|Drug|Etoposide|
300499|NCT00388349|Drug|Cyclophosphamide|
300500|NCT00003190|Drug|daunorubicin hydrochloride|Given IV
300501|NCT00388349|Procedure|Autologous hematopoietic stem cell transplantation.|
300502|NCT00388362|Drug|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml.
300503|NCT00388362|Drug|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun.
300504|NCT00388375|Procedure|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
300505|NCT00388388|Drug|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
300506|NCT00388401|Drug|Alvimopan|
300507|NCT00388414|Drug|duloxetine|30-60mg of duloxetine daily
300508|NCT00388414|Drug|Placebo|Placebo pill once daily
300509|NCT00388427|Drug|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
300510|NCT00388427|Drug|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m^2 on Day 1 of Cycle 1; IV 250 mg/m^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
300511|NCT00003190|Drug|etoposide|Given IV
300512|NCT00388440|Biological|MMR vaccine (Priorix)|
300513|NCT00388453|Device|Dx-pH Probe|24 hour ph monitoring
300514|NCT00388453|Procedure|Manometry|procedure to measure LES and UES
300515|NCT00388466|Device|GALILEO|
300516|NCT00388479|Drug|Alvimopan|
300517|NCT00388505|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
300518|NCT00388505|Drug|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
299797|NCT00402428|Drug|Ribavirin|1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects
=,> 75kg)
299798|NCT00405275|Drug|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
299799|NCT00405275|Drug|Sulfasalazine|sulfasalazine, oral
299800|NCT00405275|Drug|Hydroxychloroquine|hydroxychloroquine, oral
299801|NCT00405275|Drug|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
299802|NCT00405275|Drug|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
299803|NCT00405288|Drug|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
300154|NCT00396370|Biological|BCG (ID)|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
300155|NCT00396370|Biological|BCG (PO)|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
300156|NCT00396370|Drug|Placebo (ID)|0.1 mL of sterile Sauton medium for intradermal administration.
300157|NCT00396383|Drug|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4*10^6 CD34+ cells/kg body weight had been collected.
300158|NCT00000499|Drug|reserpine|
300159|NCT00003217|Drug|doxorubicin hydrochloride|
300160|NCT00396396|Drug|Acetylcysteine|
300161|NCT00396409|Drug|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
300162|NCT00396409|Drug|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
300163|NCT00396409|Drug|Placebo|Placebo given during the 2006 core study
300164|NCT00396422|Drug|RWJ-445380|
300165|NCT00396435|Drug|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
300166|NCT00396448|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
300167|NCT00396448|Drug|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
299420|NCT00003297|Procedure|peripheral blood stem cell transplantation|
299421|NCT00411229|Drug|Oxaliplatin|IV infusion, 130mg/m²
299422|NCT00411242|Drug|agomelatine|
299423|NCT00366691|Drug|Acular LS|
299424|NCT00000482|Drug|dextrothyroxine sodium|
299425|NCT00003089|Drug|amifostine trihydrate|
299426|NCT00366691|Drug|Lotemax|
299427|NCT00366704|Drug|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
299428|NCT00366704|Drug|risperidone|4mg, QD, 8 week treatment
299429|NCT00366730|Drug|Nitazoxanide|
299430|NCT00366743|Procedure|Conventional LASIK|
299431|NCT00366743|Procedure|Wavefront-guided LASIK|
299432|NCT00366769|Device|Wavefront-guided LASIK using CustomVue platform|
299433|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^6 TCID50
299434|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^5 TCID50
299435|NCT00366782|Biological|Placebo|Placebo for rB/HPIV3 vaccine
299436|NCT00003089|Drug|carboplatin|
299437|NCT00366795|Drug|satavaptan (SR121463B)|oral administration once daily
299438|NCT00366795|Drug|placebo|oral administration once daily
299804|NCT00405301|Drug|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
299805|NCT00405314|Device|Continuous positive airway pressure ventilation mask|
299806|NCT00405327|Biological|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
299807|NCT00405327|Other|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
304618|NCT00214461|Biological|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
304619|NCT00214474|Behavioral|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
304620|NCT00214474|Behavioral|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
304621|NCT00214487|Device|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
304622|NCT00214487|Device|Placebo Control|Single vision soft contact lenses
304981|NCT02718976|Drug|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
304982|NCT02718989|Device|Transcutaneous Electrical Stimulation|TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
304983|NCT02718989|Device|10Kilohertz (KHz)|10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
304984|NCT02718989|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
304985|NCT00204451|Drug|0.75 levonorgestrel|
304986|NCT02719002|Device|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
304987|NCT02719015|Drug|rAd.CD40L|Dose Escalation Phase Starting Dose: 5x10^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10^11 vp. Subsequently enrolled patients injected at the same dose of 1x10^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have >/=2 injectable lesions, at the same injection dose of 1x10^10 up to three separate sites/lesions if patients have > 3 injectable lesions.
Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase.
304988|NCT02719015|Drug|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
304989|NCT02719028|Drug|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
304990|NCT02719028|Drug|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
304991|NCT02719041|Other|Immunohistochemistry staining method|
304629|NCT00214539|Procedure|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
304630|NCT00214539|Drug|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
304631|NCT00214552|Drug|rabeprazole|
304632|NCT00214565|Drug|Galida|
304633|NCT00217698|Drug|gefitinib|
304634|NCT00217698|Drug|gemcitabine hydrochloride|
304635|NCT00217711|Drug|Capecitabine|capecitabine
304636|NCT00002574|Drug|omacetaxine mepesuccinate|
304637|NCT00217711|Drug|irinotecan hydrochloride|irinotecan hydrochloride
304638|NCT00217711|Drug|oxaliplatin|oxaliplatin
304639|NCT00217724|Dietary Supplement|glutamine|Given orally
304640|NCT00217724|Other|placebo|Given orally
304641|NCT00217737|Biological|Bevacizumab|Given IV
304642|NCT00217737|Drug|Fluorouracil|Given IV
304643|NCT00217737|Other|Laboratory Biomarker Analysis|Correlative studies
304644|NCT00217737|Drug|Leucovorin Calcium|Given IV
304645|NCT00217737|Drug|Oxaliplatin|Given IV
304646|NCT00217763|Drug|3APS|
304647|NCT00002575|Procedure|conventional surgery|
305000|NCT02719158|Drug|6 mg ciprofloxacin|Single administration of OTO-201
305001|NCT02719158|Drug|12 mg ciprofloxacin|Single administration of OTO-201
305002|NCT02719158|Other|Sham|
305003|NCT00206635|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
332521|NCT00449137|Drug|Fluorouracil|Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
332522|NCT00449137|Drug|Leucovorin calcium|On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
332523|NCT00003471|Drug|antineoplaston AS2-1|
332524|NCT00449137|Other|Plasma levels of elemental arsenic|Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
332525|NCT00449137|Genetic|Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
332526|NCT00449137|Procedure|Tumor Biopsy (Fine-Needle Aspiration)|Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
332885|NCT00440453|Other|Nutritional therapy|Nutritional therapy by dietician
332886|NCT00440466|Drug|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
332887|NCT00440466|Drug|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
332888|NCT00003425|Procedure|peripheral blood stem cell transplantation|
332889|NCT00440466|Drug|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
332890|NCT00440479|Drug|Bortezomib|dose as determined (observational study) by treating physician
332891|NCT00440492|Drug|PLA-695|
332892|NCT00440505|Drug|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
332893|NCT00443534|Drug|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
332894|NCT00443547|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
332895|NCT00443560|Other|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
332896|NCT00003437|Drug|doxorubicin hydrochloride|
332186|NCT00458133|Behavioral|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching & relaxing groups.
332187|NCT00458146|Drug|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
332188|NCT00458159|Drug|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, & 50mg, taken once daily, orally.
332189|NCT00458172|Behavioral|Assessment of beliefs and attitudes|
332190|NCT00458185|Drug|etanercept|
332191|NCT00458198|Behavioral|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
332192|NCT00458211|Drug|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
332193|NCT00458224|Behavioral|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
332194|NCT00458237|Drug|Everolimus|Everolimus is being administered orally 7 days per week.
332195|NCT00458237|Drug|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
332196|NCT00003518|Drug|gemcitabine hydrochloride|
332197|NCT00458250|Procedure|Haploidentical hematopoietic stem cell transplantation|
332198|NCT00458250|Drug|Busulfan|
332199|NCT00413881|Procedure|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
332200|NCT00413894|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
332201|NCT00413920|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
332202|NCT00413920|Drug|Prednisone|Oral tablets
332203|NCT00413933|Procedure|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
331499|NCT00428402|Behavioral|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
331500|NCT00428415|Drug|Tesofensine|
331501|NCT00428428|Drug|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
331502|NCT00428441|Drug|Warfarin|tablets, based on INR levels, according to D-dimer levels
331503|NCT00428454|Device|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
331504|NCT00003389|Drug|Prednisone|taken orally
331505|NCT00428467|Procedure|LV Apex Compression|
331852|NCT00419926|Drug|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
331853|NCT00419952|Drug|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
331854|NCT00419952|Drug|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
331855|NCT00419978|Procedure|Colectomy|
331856|NCT00003344|Drug|irinotecan hydrochloride|
331857|NCT00419991|Drug|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
331858|NCT00420004|Drug|LY2216684|3 mg - 12 mg once daily oral dose (tablets) with flexible titration for 8 weeks.
331859|NCT00420004|Drug|Placebo|tablet and capsule equivalents to LY2216684 and escitalopram taken once daily for 8 weeks
331860|NCT00420004|Drug|escitalopram|10 mg or 20 mg once daily oral dose (capsules) with flexible titration for 8 weeks
331861|NCT00420017|Drug|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
331862|NCT00420017|Other|Control|No amiodarone
331863|NCT00422786|Drug|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
331864|NCT00422799|Drug|Bortezomib|Once weekly for 3 weeks
331865|NCT00422799|Drug|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
331115|NCT00436904|Drug|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
331116|NCT00436917|Drug|zoledronic acid|zoledronic acid
331117|NCT00436917|Procedure|Letrozole as adjuvant therapy|standard care
331118|NCT00436930|Biological|autologous tumor cell vaccine|Given subcutaneously
331119|NCT00436930|Biological|sargramostim|Given subcutaneously
331120|NCT00003414|Drug|cyclophosphamide|
331121|NCT00436930|Biological|therapeutic autologous dendritic cells|Given subcutaneously
331122|NCT00436943|Drug|nicotine replacement therapy and bupropion|3-6 months
331123|NCT00436943|Behavioral|smoking cessation counseling and referrals|Organizational counseling and referrals
331124|NCT00436956|Procedure|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
331125|NCT00436956|Drug|AZD2171|20 mg oral daily for 28 days
331126|NCT00436956|Drug|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
331127|NCT00436969|Device|Orthovisc|Orthovisc injection
331128|NCT00436969|Drug|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
331129|NCT00436969|Drug|Control|Marcaine (bupivacaine) - 6 mL
331130|NCT00436982|Device|Cemented Triathlon total knee system|Orthopaedic implant
331131|NCT00003414|Drug|cyclosporine|
331132|NCT00436982|Device|Duracon total knee system|Orthopaedic implant
331133|NCT00439764|Behavioral|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
331506|NCT00428480|Behavioral|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
331507|NCT00428480|Behavioral|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
331508|NCT00428506|Drug|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
330459|NCT00579644|Drug|methotrexate|Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.
2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.
4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.
6, 8 and 10 month evaluations:
If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.
If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study.
330460|NCT00579657|Other|control diet, supported by dietary supplement twice daily|control diet, see above
330461|NCT00579657|Other|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
330462|NCT00579657|Other|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
330463|NCT00004137|Biological|filgrastim|
330762|NCT00445666|Genetic|polymerase chain reaction|
330763|NCT00445666|Other|flow cytometry|
330764|NCT00445666|Other|immunoenzyme technique|
330765|NCT00445666|Other|immunohistochemistry staining method|
330766|NCT00445666|Other|immunologic technique|
330767|NCT00445666|Other|laboratory biomarker analysis|
330768|NCT00445666|Procedure|biopsy|
330769|NCT00445666|Procedure|conventional surgery|
330770|NCT00445679|Drug|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
330771|NCT00445679|Drug|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
330772|NCT00003451|Biological|recombinant interferon alfa|
330773|NCT00448305|Drug|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
330774|NCT00448305|Drug|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
330775|NCT00003466|Drug|temozolomide|
330776|NCT00448305|Drug|Paclitaxel|Paclitaxel 90 mg/m² weekly
330777|NCT00448318|Procedure|Music Therapy|
330160|NCT00588003|Drug|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
330161|NCT00588003|Other|Placebo|No medication before surgery
330162|NCT00588016|Drug|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
330163|NCT00588042|Device|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
330164|NCT00588042|Device|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
330165|NCT00588068|Other|Tumor and Marrow Markers|Tumor and Marrow Markers
330166|NCT00588081|Behavioral|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
330167|NCT00004174|Procedure|peripheral blood stem cell transplantation|
330168|NCT00000611|Drug|estrogen replacement therapy|
330169|NCT00004186|Drug|etoposide|
330170|NCT00590590|Drug|lidocaine|semi solid, twice weekly for 4 months
330171|NCT00590590|Drug|placebo|semi solid, twice weekly for 4 months
330172|NCT00590603|Drug|Arsenic Trioxide, Ascorbic Acid and Bortezomib|Phase I/Cohort I
Loading:
Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)
Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days
Maintenance cycles (21 days)
ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.
Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.
Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.
Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I.
330173|NCT00590616|Procedure|transthoracic examination|observational transthoracic examination
330174|NCT00590629|Drug|Niaspan|1500 mg Niaspan for 16 weeks
330175|NCT00590655|Behavioral|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
330464|NCT00579657|Other|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
330465|NCT00579670|Drug|Ziprasidone|Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
329557|NCT00562029|Procedure|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
329558|NCT00562055|Drug|Atomoxetine|
329559|NCT00562055|Drug|PNU-165442G; [S,S]-reboxetine|
329560|NCT00562068|Biological|alemtuzumab|
329561|NCT00562068|Drug|cyclophosphamide|
329562|NCT00562068|Drug|doxorubicin hydrochloride|
329563|NCT00562068|Drug|prednisolone|
329564|NCT00004054|Drug|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
329565|NCT00562068|Drug|vincristine sulfate|
329566|NCT00562068|Genetic|polymerase chain reaction|
329873|NCT00554944|Procedure|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
329874|NCT00557245|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
329875|NCT00557245|Drug|Placebo|Placebo TDF & Placebo FTC/TDF, 1 tablet each daily.
329876|NCT00557284|Drug|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
329877|NCT00557284|Drug|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
329878|NCT00557310|Drug|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
329879|NCT00004025|Biological|aldesleukin|
329880|NCT00557323|Drug|Lanthanum carbonate|
329881|NCT00557336|Drug|somatropin|
329882|NCT00557349|Drug|Omeprazole/Sodium Bicarbonate (Zegerid)|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
329883|NCT00557349|Drug|Famotidine (Pepcid)|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
329234|NCT00569296|Biological|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
329235|NCT00569296|Biological|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
329236|NCT00569296|Biological|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
329237|NCT00569309|Biological|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
329238|NCT00569309|Other|laboratory biomarker analysis|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
329239|NCT00569309|Other|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
329240|NCT00569322|Procedure|BG Test|
329241|NCT00004088|Procedure|peripheral blood stem cell transplantation|
329242|NCT00569335|Drug|S-1, Irinotecan, Bevacizumab|S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1.
329243|NCT00569361|Procedure|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
329244|NCT00569374|Drug|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
329245|NCT00569387|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
329246|NCT00569400|Drug|human insulin|
329247|NCT00569426|Device|NovoFine® needle 6 mm|
329248|NCT00569426|Device|NovoFine® needle 8 mm|
329249|NCT00569439|Drug|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
329567|NCT00562068|Other|flow cytometry|
329568|NCT00562068|Other|laboratory biomarker analysis|
329569|NCT00562068|Other|pharmacological study|
302276|NCT00003214|Drug|paclitaxel|
302277|NCT00394381|Procedure|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
302278|NCT00394394|Drug|Amiloride 2,5/d or Enalapril/d 10 mg|
302279|NCT00394407|Drug|sliding scale regular insulin|SSRI acqhs
302280|NCT00394407|Drug|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
302281|NCT00394420|Behavioral|Telephone Quitline|
302282|NCT00397449|Biological|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
302283|NCT00397462|Device|plantar micromechanical stimulation|
302284|NCT00397475|Drug|Colecalciferol|
302285|NCT00397488|Drug|sunitinib malate|
302286|NCT00003224|Biological|QS21|vaccine adjuvant
302287|NCT00397501|Biological|trastuzumab|Trastuzamab, 6mg/kg, within 48 hrs before BBBD
Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles
302288|NCT00397501|Drug|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
302289|NCT00397501|Drug|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
302623|NCT00389324|Biological|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
302624|NCT00389350|Drug|Extract of Green and Black Tea|
302625|NCT00003194|Drug|etoposide|
302626|NCT00389363|Drug|ALK HDM tablet|
302627|NCT00389376|Drug|Placebo|Placebo
302628|NCT00389376|Drug|Silymarin|140 mg every 8 hours
301896|NCT00400413|Procedure|fMRI|
301897|NCT00400426|Procedure|Radiotherapy|20 Gy in 4 fx
301898|NCT00403026|Drug|Bevacizumab ( Avastin)|
301899|NCT00403039|Drug|Ranibizumab (Lucentis )|
301900|NCT00003260|Drug|oxaliplatin|
301901|NCT00403052|Drug|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
301902|NCT00403065|Drug|dexamethasone|
301903|NCT00403065|Procedure|quality-of-life assessment|
301904|NCT00403065|Radiation|radiation therapy|
301905|NCT00403091|Behavioral|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
301906|NCT00403091|Behavioral|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
301907|NCT00403104|Drug|ONO-2506PO|1200 mg QD / 18 months
301908|NCT00403104|Drug|ONO-2506PO|0 mg QD / 18 months
301909|NCT00403117|Drug|Naltrexone|
301910|NCT00403117|Drug|Marijuana|
301911|NCT00003261|Drug|methotrexate|
301912|NCT00403130|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
301913|NCT00403130|Drug|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
301914|NCT00403130|Drug|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
301915|NCT00403143|Procedure|cataract surgery|
301916|NCT00403156|Drug|Imatinib Mesylate /Ranibizumab|
301917|NCT00403169|Drug|lenalidomide|
301918|NCT00403182|Drug|chemotherapy|
301919|NCT00403182|Drug|letrozole|
301202|NCT00370916|Behavioral|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
301203|NCT00370916|Behavioral|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
301204|NCT00370929|Behavioral|Meditation|
301205|NCT00373711|Drug|Iodine-123|2 mCi, oral
301206|NCT00373711|Drug|F-18 FDG|10-15 mCi, iv
301207|NCT00373724|Procedure|radiofrequency denervation|
301208|NCT00373750|Procedure|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
301209|NCT00373763|Procedure|Fetoscopic tracheal balloon occlusion|
301210|NCT00003119|Drug|cyclophosphamide|
301211|NCT00373776|Drug|miltefosine 2.5 mg/kg/day for 28 days|
301212|NCT00373789|Drug|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
301544|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
301545|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 10 mg
301546|NCT00003301|Drug|irinotecan hydrochloride|
301547|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
301548|NCT00412126|Drug|Insulin|
301549|NCT00412152|Drug|Oxycodone nalaxone prolonged release tablets (OXN)|
301550|NCT00412165|Behavioral|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
301551|NCT00412165|Behavioral|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
301552|NCT00412165|Behavioral|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
300859|NCT00379821|Drug|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
300860|NCT00379834|Drug|Cosopt|Cosopt twice daily in both eyes
300861|NCT00379847|Drug|conivaptan|IV
300862|NCT00379860|Drug|LXR-623|
300863|NCT00379873|Device|ProAdjuster|
300864|NCT00003146|Procedure|peripheral blood stem cell transplantation|
300865|NCT00379886|Drug|Propofol Thiopental|
300866|NCT00379899|Drug|cinacalcet|Low dose vitamin D with cinacalcet
300867|NCT00379912|Drug|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
300868|NCT00379912|Drug|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
300869|NCT00379912|Drug|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
300870|NCT00382681|Device|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
300871|NCT00000491|Drug|aspirin|
300872|NCT00003159|Drug|cisplatin|
300873|NCT00382694|Drug|Fludarabine|
300874|NCT00382707|Device|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
300875|NCT00382720|Drug|Docetaxel + Oxaliplatin|Dose level 1 (non-optimal dose):
Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1
Dose level 2 (optimal dose):
Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1
300876|NCT00382720|Drug|Docetaxel + Oxaliplatin + 5-FU|Dose level 1 (non-optimal dose):
Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.
Dose level 2 (optimal dose):
Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1.
300877|NCT00382720|Drug|Docetaxel + Oxaliplatin + Capecitabine|Dose level 1 (optimal dose):
Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.
Dose level 2 (non-optimal dose):
Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously.
300168|NCT00396448|Drug|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
300169|NCT00396461|Drug|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
300170|NCT00003217|Drug|methotrexate|
300171|NCT00396461|Drug|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
300172|NCT00396474|Other|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
300173|NCT00396487|Drug|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
300174|NCT00396500|Drug|Albendazole (400 mg) and/or Vitamin a|
300175|NCT00396513|Drug|Simvastatin|
300176|NCT00396513|Drug|Simvastatin and Metformin|
300177|NCT00396513|Drug|Metformin|
300519|NCT00388518|Drug|Actos|45mg po daily
300520|NCT00388518|Drug|Placebo|po daily
300521|NCT00388518|Drug|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
300522|NCT00003190|Drug|valspodar|Given IV
300523|NCT00391027|Drug|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
300524|NCT00391040|Behavioral|SGS education|
300525|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
300526|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
300527|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
300528|NCT00391053|Biological|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
300529|NCT00391066|Drug|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
300530|NCT00003202|Drug|cisplatin|
300531|NCT00391066|Drug|FCR|Dose, schedule, and duration specified in protocol
299808|NCT00003269|Biological|sargramostim|
299809|NCT00405340|Drug|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
299810|NCT00405353|Drug|Androgel 100mg gel|
299811|NCT00405366|Drug|sorafenib tosylate|Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
299812|NCT00405379|Device|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
299813|NCT00405392|Drug|Ibandronate (SB743830HD)|
299814|NCT00405405|Drug|Cisplatin|Two cycles during neoadjuvant therapy
Response assessment at approximately day 36
Concurrent biochemoradiotherapy
299815|NCT00405405|Drug|Docetaxel|Two cycles during neoadjuvant therapy
Response assessment at approximately day 36
Concurrent biochemoradiotherapy
299816|NCT00405405|Drug|Bevacizumab|Two cycles during neoadjuvant therapy
Response assessment at approximately day 36
Concurrent biochemoradiotherapy
299817|NCT00405405|Drug|Erlotinib|Two cycles during neoadjuvant therapy (dose escalation)
Response assessment at approximately day 36
Concurrent biochemoradiotherapy
299818|NCT00405405|Radiation|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
299819|NCT00003269|Drug|amifostine trihydrate|
299820|NCT00405418|Drug|Insulin glargine|Subcutaneous injection, once a day in the evening
299821|NCT00405418|Drug|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
299822|NCT00405431|Drug|Restasis|1 drop in study eye twice a day X 6 months
299823|NCT00405431|Drug|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
299824|NCT00408356|Drug|Zinc|
299825|NCT00408369|Drug|DB289|
299826|NCT00003281|Drug|topotecan hydrochloride|
300178|NCT00396526|Drug|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
304992|NCT02719054|Behavioral|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|A:Cognitive Behavioral Therapy specifically focused on "changing thinking style toward positive" and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.
B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum.
304993|NCT02719093|Drug|recombinant FSH|Subcutaneous injection
304994|NCT02719106|Device|Ultimaster stent|
304995|NCT02719119|Procedure|monthly Endoscopic Variceal Ligation (EVL)|
304996|NCT00204451|Drug|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
304997|NCT02719119|Procedure|bi-weekly Endoscopic Variceal Ligation (EVL)|
304998|NCT02719132|Drug|Dapagliflozin|Dapagliflozin, 10 mg
304999|NCT02719132|Drug|Metformin|Metformin, up to 2500 mg
299439|NCT00366808|Procedure|LASIK surgery|
299440|NCT00366834|Drug|Casopitant (GW679769) oral tablets|
299441|NCT00366834|Drug|Casopitant (GW679769) intravenous|
299442|NCT00366834|Drug|Dexamethasone intravenous|
299443|NCT00366834|Drug|Ondansetron oral tablets|
299444|NCT00366834|Drug|placebo|casopitant placebo
299445|NCT00366860|Behavioral|Soy bread|
299446|NCT00366873|Procedure|Calcium absorption|formula with or without prebiotics
299447|NCT00003089|Drug|paclitaxel|
299448|NCT00366899|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
299449|NCT00366899|Biological|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
299450|NCT00366912|Device|non-invasive ventilation|
299451|NCT00366925|Device|Adacolumn®|
299452|NCT00366938|Drug|Lumiracoxib|
299453|NCT00366951|Procedure|Foley catheter only|
305004|NCT00206648|Drug|Betaferon/Betaseron|Betaseron 250 µg SC every other day
305005|NCT00000383|Behavioral|Child-Centered Therapy|Client-directed supportive interventions
305006|NCT00002552|Biological|filgrastim|
305007|NCT00206648|Drug|Betaferon/Betaseron|Avonex 30 µg IM once per week
305008|NCT00206661|Drug|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
305009|NCT00206661|Drug|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
305010|NCT00206674|Drug|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
305011|NCT00206674|Drug|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
305012|NCT00206687|Biological|Spheramine (BAY86-5280)|Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
305013|NCT00206687|Procedure|Placebo|Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
305014|NCT00206700|Drug|Sargramostim (Leukine)|Open Label, 8 week cycle
305015|NCT00206713|Drug|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
305016|NCT00206713|Drug|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
305017|NCT00002552|Biological|sargramostim|
305018|NCT00206726|Drug|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
305019|NCT00206739|Drug|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
305020|NCT00206752|Radiation|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
305021|NCT00206752|Radiation|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
305022|NCT00206765|Drug|Risperidone|
305023|NCT00206765|Drug|Paroxetine|
299463|NCT00003104|Radiation|radiation therapy|
299464|NCT00369915|Drug|Scopolamine|
332897|NCT00443573|Drug|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
332898|NCT00443586|Behavioral|Nurse home visitation|Nurse-visited young adult participants were visited at home by a nurse 9 times during their mother's pregnancy and 23 times during the first 2 years of their life.
332899|NCT00443586|Behavioral|Comparison services|Control group participants assigned to receive comparison services were provided with free transportation for prenatal and child care, as well as sensory and developmental screening for the child.
332900|NCT00443599|Drug|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
332901|NCT00443599|Other|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
332902|NCT00443612|Drug|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
332903|NCT00443612|Drug|Irbesartan|Administration of irbesartan 150 mg/day
332904|NCT00443625|Drug|SK3530|
332905|NCT00443638|Behavioral|nurse home visitation|Nurse home visitation
333249|NCT00434967|Drug|Candesartan/HCT 32/25 mg|
333250|NCT00434980|Behavioral|Family-Directed Cognitive Adaptation Program|
333251|NCT00434993|Drug|Albuterol Sulfate|Albuterol sulfate, USP, solution for inhalation will be diluted as follows:
The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.
The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.
A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.
333252|NCT00434993|Procedure|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
333253|NCT00434993|Drug|Placebo|Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.
A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).
The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.
333254|NCT00435019|Drug|insulin detemir|s.c. injection, once or twice daily.
333255|NCT00435019|Drug|insulin NPH|s.c. injection, once or twice daily.
333256|NCT00435019|Drug|insulin aspart|s.c. injection, at main meals.
332527|NCT00449150|Drug|Cetrorelix|Cetrorelix 78 mg combining Week 0 and Week 2 + 78 mg combining Week 26 and Week 28
332528|NCT00451867|Drug|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
332529|NCT00451867|Drug|Placebo|Placebo
332530|NCT00451880|Drug|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
332531|NCT00451880|Drug|famotidine|single dose, supplied as 20-mg or 40-mg tablets
332532|NCT00451893|Procedure|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
332533|NCT00003490|Drug|cyclophosphamide|
332534|NCT00451893|Procedure|Lichtenstein operation with a light-weight mesh|Johnson&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
332535|NCT00451906|Drug|Platinum-based chemotherapy|As prescribed
332536|NCT00451906|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
332537|NCT00451932|Drug|FK778|
332538|NCT00451945|Procedure|biopsy|
332539|NCT00451945|Device|3d-ultrasound and fusion of UL and PET/CT|
332540|NCT00451958|Drug|Degarelix 80 mg / Degarelix 80 mg|
332541|NCT00451958|Drug|Degarelix 160 mg / Degarelix 160 mg|
332542|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 80 mg|
332543|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 160 mg|
332544|NCT00003490|Drug|prednisone|
332545|NCT00451971|Drug|LEFLUNOMIDE|
332546|NCT00451984|Biological|Twinrix|
332547|NCT00451984|Biological|interleukin-2|
332548|NCT00451997|Drug|Gleevec|600 mg (capsules) by mouth once daily
332549|NCT00451997|Drug|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
332550|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
331866|NCT00422812|Drug|Prochlorperazine thermal aerosol|
331867|NCT00422825|Drug|imatinib|
331868|NCT00003362|Biological|tyrosinase peptide|
331869|NCT00422838|Procedure|fine-needle aspiration biopsy|aspiration of intrahepatic cells
331870|NCT00422864|Drug|oxaliplatin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
331871|NCT00422864|Drug|fluorouracil|Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
331872|NCT00422864|Drug|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
332204|NCT00413946|Drug|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
332205|NCT00413946|Drug|saline|three doses of 1.0 ml saline per body weight
332206|NCT00413959|Drug|VELCADE®|1.6 mg/m^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
332207|NCT00003311|Drug|methotrexate|
332208|NCT00413959|Drug|Rituximab|375 mg/m^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
332209|NCT00413959|Drug|Cyclophosphamide|400 mg/m^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
332210|NCT00413959|Drug|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
332211|NCT00413972|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
332212|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
332213|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
332214|NCT00413972|Drug|Placebo|Placebo once daily for a total of eight weeks
332215|NCT00413985|Drug|Nutrient-enriched human milk|
332216|NCT00413998|Procedure|CABG + Mitral valve annuloplasty|Patients will receive a mitral annuloplasty ring in addition to coronary artery bypass grafting.
331509|NCT00428506|Drug|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
331510|NCT00428519|Drug|Placebo|Placebo for 14 days
331511|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
331512|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
331513|NCT00431327|Behavioral|Peer coach phone call|
331514|NCT00431340|Drug|PXD101|
331515|NCT00003398|Biological|filgrastim|
331516|NCT00431353|Drug|Ganciclovir|5mg/kg iv bid for 21 days
331517|NCT00431353|Drug|valganciclovir [Valcyte]|900mg po bid for 21 days
331518|NCT00431379|Drug|Tenecteplase|
331519|NCT00431392|Drug|Phenylephrine|
331520|NCT00431392|Drug|NG-Monomethyl-L-Arginine|
331521|NCT00431392|Drug|Propanolol|
331522|NCT00431392|Drug|Atropine|
331523|NCT00431418|Drug|Sildenafil|Sildenafil oral solution
331524|NCT00431418|Drug|Placebo|Placebo solution
331525|NCT00431431|Drug|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
331526|NCT00003398|Drug|cyclophosphamide|
331527|NCT00431431|Drug|raloxifen|2 years treatment with raloxifene (60 mg)
331528|NCT00431444|Drug|Raloxifene|
331529|NCT00431444|Drug|Zoledronic acid|
331530|NCT00431444|Drug|Placebo oral pills|
331531|NCT00431444|Drug|Placebo intravenous (i.v.) infusion|
331873|NCT00422864|Procedure|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
330778|NCT00448344|Behavioral|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
330779|NCT00448344|Behavioral|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
330780|NCT00448357|Biological|rabbit anti-thymocyte globulin|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
330781|NCT00448357|Biological|therapeutic allogeneic lymphocytes|minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
330782|NCT00448357|Drug|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
330783|NCT00448357|Drug|fludarabine phosphate|30 mg/m^2/day x 5 days IVPB over 30 minutes on Days -7 through -3
330784|NCT00448357|Drug|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
330785|NCT00448357|Procedure|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10^6 cells/kg and maximum of 8 x 10^6 cells/kg will be infused on day 0
331134|NCT00439777|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
331135|NCT00439777|Drug|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
331136|NCT00439790|Procedure|Microneurography|Microneurography
331137|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
331138|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
331139|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
331140|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
331141|NCT00000520|Drug|immunoglobulins, intravenous|
331142|NCT00003423|Drug|etoposide|
331143|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
331144|NCT00439803|Biological|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
330466|NCT00579683|Other|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
330467|NCT00579709|Biological|Thymus Tissue for Transplantation|3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained <4000/cumm Csa weaned over 8 weeks. If T cell >4,000/cumm, Csa held at 180-300ng/ml.
Thymus tissue, donor, & mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.
Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx.
330468|NCT00579774|Other|Low AGE Diet|Diet
330469|NCT00579774|Other|Regular Diet|Diet
330470|NCT00579800|Procedure|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
330471|NCT00579813|Drug|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
330472|NCT00582309|Procedure|Standard Intravenous Insulin Infusion|Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.
Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving >80 units/day of insulin as an outpatient.
Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here.
330473|NCT00582309|Procedure|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
330474|NCT00582361|Procedure|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
330475|NCT00582361|Device|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
330476|NCT00582387|Genetic|specimen samples|blood, urine and tissue
330477|NCT00004150|Drug|fluorouracil|
330478|NCT00582387|Behavioral|questionnaires|
330786|NCT00003467|Drug|carmustine|
329884|NCT00557362|Drug|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
329885|NCT00557362|Drug|Voriconazole|Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.
One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
329886|NCT00557362|Procedure|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
329887|NCT00557388|Dietary Supplement|Protein/Amino Acids|Casein Whey Leucine
329888|NCT00557388|Other|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
329889|NCT00557401|Drug|XP19986 SR3, 20 mg QD|After the washout period, subjects will be randomized to receive placebo or XP19986 SR study treatments. XP19986 Sustained Release (SR) Tablet will be dosed orally, QD or BID, for approximately 32 days with titration and taper periods
329890|NCT00004025|Biological|dendritic cell-gp100-MART-1 antigen vaccine|
329891|NCT00557401|Drug|XP19986 SR3, 40 mg QD|After the washout period, subjects will be randomized to receive placebo or XP19986 SR study treatments. XP19986 Sustained Release (SR) Tablet will be dosed orally, QD or BID, for approximately 32 days with titration and taper periods
330176|NCT00590655|Behavioral|weight loss programme|
330177|NCT00590681|Drug|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
330178|NCT00590694|Drug|ranibizumab|0.5mg injection monthly according to protocol for one year
330179|NCT00590707|Device|Maintenance of level of awareness by use of a BIS monitor & the OASS.|The level of awareness in this arm, as measured by the BIS score, will be kept at 50-60.
330180|NCT00004186|Drug|ifosfamide|
330181|NCT00590707|Device|Maintenance of level of awareness by use of a BIS monitor and the OASS.|The level of awareness in this arm, as measured by the BIS score, will be kept at 70-80.
330182|NCT00590720|Biological|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
330183|NCT00590720|Other|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
329570|NCT00562081|Behavioral|Education|24/7 access to a Certified Asthma Educator
329571|NCT00562081|Behavioral|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
329572|NCT00562094|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
329573|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
329574|NCT00564421|Drug|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
329575|NCT00564421|Drug|placebo nasal spray|2 sprays in each nostril, dosed twice a day
329576|NCT00564421|Drug|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
329577|NCT00564421|Drug|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
329578|NCT00004063|Procedure|hyperthermia treatment|
329579|NCT00564421|Drug|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
329580|NCT00564447|Drug|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
329581|NCT00564447|Drug|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
329582|NCT00564460|Drug|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
329583|NCT00564460|Drug|Placebo|Placebo once daily for 8 weeks
329584|NCT00564473|Behavioral|questionnaire|questionnaire of demographic and medical data, use of and attituded toward herbal medicine.
Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation
329585|NCT00564486|Drug|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
329586|NCT00564486|Drug|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
329587|NCT00564486|Drug|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
329588|NCT00564486|Drug|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
329589|NCT00004064|Biological|oregovomab|
329590|NCT00564512|Biological|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
302629|NCT00389376|Drug|Silymarin|280 mg single dose
302630|NCT00389376|Drug|Silymarin|280 mg single dose + every 8 hours
302631|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
302632|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
302633|NCT00389376|Drug|Silymarin|280 mg every 8 hours
302634|NCT00389376|Drug|Silymarin|700 mg single dose + every 8 hours
302635|NCT00389389|Drug|AZD4877|intravenous infusion
302636|NCT00003194|Drug|thiotepa|
302637|NCT00389402|Drug|saquinavir/ritonavir|
302638|NCT00389402|Drug|atazanavir/ritonavir|
302639|NCT00389415|Drug|Vildagliptin|
302640|NCT00389428|Drug|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
302641|NCT00389441|Drug|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
302642|NCT00389467|Device|Merci Retriever and Penumbra System|The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).
The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2).
302643|NCT00389480|Drug|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
302970|NCT00381043|Drug|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
302971|NCT00003151|Drug|clarithromycin|
302972|NCT00381056|Behavioral|Labor and Delivery Team Coordination Course|
301920|NCT00403208|Procedure|Analgesia based sedation in ICU patients|
301921|NCT00403221|Genetic|RTVP-1 Gene|Cohort Level #1 1.0 x 1010vp Cohort Level #2 5.0x1010vp Cohort Level #3 1.0 x 1011vp Cohort Level #4 5.0x1011vp Cohort Level #5 1.0 x 1012vp Cohort Level #6 5.0x1012vp
One dose only followed by a radical prostatectomy 4 weeks later.
302290|NCT00397501|Drug|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
302291|NCT00397514|Procedure|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
302292|NCT00397527|Drug|lactoserum|
302293|NCT00397540|Procedure|PEIT|Percutaneous Ethanol Injection Therapy
302294|NCT00397540|Procedure|RFTA|Radiofrequency Thermal Ablation
302295|NCT00397553|Drug|Insulin glulisine|
302296|NCT00397566|Drug|HIV Integrase Inhibitor (BMS-707035)|
302297|NCT00003224|Biological|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
302298|NCT00397579|Drug|DT388IL3|Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
302299|NCT00397592|Drug|Growth Hormone|
302300|NCT00397605|Drug|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
302301|NCT00397631|Drug|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
302302|NCT00397631|Drug|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
302303|NCT00397644|Behavioral|Prompting (survey instrument/resources list) (behavior)|
302304|NCT00397657|Drug|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
302305|NCT00397657|Drug|ezetimibe|Ezetimibe 10mg once daily
302306|NCT00397670|Drug|Drug: BufferGel® with diaphragm|
302307|NCT00397683|Drug|MK0822|
301553|NCT00412178|Device|telecommunication based glucose monitoring system|
301554|NCT00412191|Drug|Lamotrigine|
301555|NCT00412204|Drug|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
301556|NCT00412204|Other|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
301557|NCT00003302|Procedure|biopsy|
301558|NCT00412217|Drug|Standard of care treatment|As prescribed
301559|NCT00412217|Drug|erlotinib [Tarceva]|150mg po daily
301560|NCT00412243|Drug|Clofarabine|40 mg/m^2 Daily for 3 Days
301561|NCT00412243|Drug|Cyclophosphamide|Beginning dose 200 mg/m^2 every 12 hours for 3 days
301562|NCT00412256|Drug|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
301563|NCT00412295|Device|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
301564|NCT00412308|Procedure|Tidal volume used in mechanical ventilation|
301565|NCT00412321|Drug|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
301922|NCT00000503|Drug|nitroglycerin|
301923|NCT00003261|Drug|zidovudine|
301924|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
301925|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
301926|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
301927|NCT00403234|Drug|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
301928|NCT00403247|Dietary Supplement|Capsule with folate, Vitamin B12 & pyridoxine|
300878|NCT00382733|Drug|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
300879|NCT00382746|Device|EarlySense monitoring device|
301213|NCT00373789|Drug|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
301214|NCT00373802|Drug|Phenylephrine|
301215|NCT00373815|Drug|Everolimus|
301216|NCT00373867|Behavioral|Standard physical therapy|Treatment-based classification physical therapy
301217|NCT00373867|Behavioral|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
301218|NCT00373867|Other|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
301219|NCT00373880|Drug|Aripiprazole|
301220|NCT00373880|Drug|Cocaine|
301221|NCT00003119|Drug|doxorubicin hydrochloride|
301222|NCT00373893|Drug|Lidoderm Patch|
301223|NCT00373906|Drug|Bortezomib (Velcade)|
301224|NCT00373919|Drug|intravenous (IV) administration of erythromycin|
301225|NCT00373932|Behavioral|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
301226|NCT00373932|Behavioral|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
301227|NCT00373945|Drug|Observational Study|
301228|NCT00373958|Biological|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
301229|NCT00373958|Biological|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
301230|NCT00373971|Behavioral|Involving the patients in their own nutritional care|
301231|NCT00373997|Procedure|Esophageal and Laryngeal biopsies|one day procedure
300532|NCT00391079|Drug|Sativex|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.
Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg.
300533|NCT00391079|Drug|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
300534|NCT00391092|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
300535|NCT00391092|Drug|Docetaxel|100mg/m2 iv every 3 weeks
300536|NCT00391092|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
300537|NCT00391105|Drug|Remifentanil|
300538|NCT00391118|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, six 21 day cycles or up to 3 years
300539|NCT00391118|Drug|carboplatin|AUC 5, IV, q 21 days, six 21 day cycles
300540|NCT00391118|Drug|paclitaxel|175 mg/m2, IV, q 21 days, six 21 day cycles
300541|NCT00003202|Drug|gemcitabine hydrochloride|
300542|NCT00391118|Drug|placebo|oral, daily
300543|NCT00391131|Drug|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
300880|NCT00382759|Procedure|stem cell transplant|
300881|NCT00382772|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
300882|NCT00382785|Behavioral|moderated support|one 12-week online support group led by a professional healthcare provider
300883|NCT00003159|Drug|docetaxel|
300884|NCT00382785|Behavioral|peer-led|12-week online support in a peer-led format
300885|NCT00382798|Drug|RO5024048|
300886|NCT00382811|Drug|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
300887|NCT00382811|Drug|carboplatin|AUC=2 weekly in 28 day cycles
300888|NCT00382824|Drug|CoenzymeQ10|active drug
300889|NCT00382837|Drug|Epratuzumab|
300890|NCT00382850|Procedure|Nissen fundoplication|
300179|NCT00399529|Biological|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
300180|NCT00000500|Drug|carotene|
300181|NCT00003238|Drug|perillyl alcohol|
300182|NCT00399529|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu (Carter et al., 1992) that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms (Emens, 2005). The antibody decreases heterodimer formation with other members of the EGFR family, thereby indirectly inhibiting signaling through the ras/Raf/MAPK and PI3K/Akt pathways (Arteaga, 2003). It also inhibits tumor neovascularization (Izumi et al., 2002), and augments apoptosis both in vitro and in vivo (Lee et al., 2002; Chang et al., 2003). Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
300183|NCT00399529|Drug|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
300184|NCT00399542|Drug|Lubiprostone|
300185|NCT00399542|Drug|Placebo|
300186|NCT00399568|Drug|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
300187|NCT00399568|Drug|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
300188|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
300189|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
300190|NCT00399594|Procedure|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
300191|NCT00399594|Procedure|B|LV lead placement in standard (lateral / posterolateral) position.
300192|NCT00003239|Biological|Recombinant Interferon Alfa|Daily by subcutaneous injection.
300193|NCT00399607|Procedure|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
299454|NCT00366951|Procedure|Extraamniotic saline infusion|
299455|NCT00369837|Drug|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
299456|NCT00369850|Other|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
299457|NCT00369850|Procedure|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
299458|NCT00369850|Procedure|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
299459|NCT00369863|Drug|Triamcinolone acetonide|
299460|NCT00369889|Drug|bevacizumab|iv every 21 days
299461|NCT00369889|Drug|Erlotinib|oral daily
299462|NCT00369902|Procedure|acupuncture|
299827|NCT00408382|Drug|atorvastatin, Lipitor|
299828|NCT00408395|Biological|Influenza vaccine|Seasonal Influenza Vaccine
299829|NCT00408408|Biological|bevacizumab|15 mg/kg IV
299830|NCT00408408|Drug|capecitabine|825 mg/m2 orally
299831|NCT00408408|Drug|cyclophosphamide|600 mg/m2 IV
299832|NCT00408408|Drug|docetaxel|100 mg/m2 IV
299833|NCT00408408|Drug|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
299834|NCT00408408|Drug|gemcitabine hydrochloride|1000 mg/m2 IV
299835|NCT00408421|Drug|Duloxetine|
299836|NCT00408421|Drug|placebo|
299837|NCT00003281|Radiation|radiation therapy|
299838|NCT00408434|Drug|CS-7017|CS-7017 0.05mg and 1.0mg tablets
299839|NCT00408447|Drug|Busulfan|Busulfan 4 mg/kg/d x 4d
299465|NCT00369928|Drug|PG-760564|100 mg BID, of oral PG-760564
299466|NCT00369928|Drug|Placebo dose|placebo, BID, oral for 12 weeks
299467|NCT00369928|Drug|PG-760564|25 mg BID, of oral PG-760564
299468|NCT00369941|Drug|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
299469|NCT00369941|Drug|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
299470|NCT00369941|Drug|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
299471|NCT00369941|Drug|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
299472|NCT00369941|Drug|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
299473|NCT00369954|Drug|carboplatin|
299474|NCT00000483|Drug|dextrothyroxine sodium|
299475|NCT00003105|Biological|filgrastim|
299476|NCT00369954|Drug|gemcitabine hydrochloride|
299477|NCT00369967|Drug|NuvaRing|Initiation of NuvaRing for contraception
299478|NCT00369993|Drug|fluticasone propionate/salmeterol|
299479|NCT00370006|Biological|Towne CMV vaccine|
299480|NCT00370019|Drug|Estradiol/Medroxyprogesterone acetate|
299481|NCT00370032|Drug|alosetron|
299482|NCT00370045|Drug|Bivalirudin with and without eptifibatide|
299483|NCT00370058|Procedure|ECT treatment|
299484|NCT00373009|Behavioral|Core stabilization exercise only|Core stabilization exercise
299485|NCT00373009|Behavioral|Psychosocial education class only|Psychosocial education class
299486|NCT00003116|Procedure|bone marrow ablation with stem cell support|
299487|NCT00373009|Behavioral|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
333257|NCT00435032|Procedure|early appendectomy|Appendectomy within 24 hours of admission
333258|NCT00003406|Drug|ifosfamide|
333259|NCT00435032|Procedure|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
333260|NCT00435045|Drug|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
333261|NCT00435045|Drug|atorvastatin|atorvastatin + placebo
333262|NCT00435058|Drug|timolol maleate 0,5%|
333263|NCT00437671|Drug|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
333264|NCT00437671|Biological|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
333265|NCT00437684|Drug|LPV/r|200/50 mg 2 cpr bid monotherapy
333266|NCT00437684|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
333267|NCT00003417|Drug|carmustine|
333268|NCT00437684|Drug|Ribavirin|Ribavirin 1-1.2 g/day
333269|NCT00437684|Drug|NUCS|Nucleoside Reverse Transcriptase Inhibitors
333270|NCT00437697|Drug|dalteparin|
333614|NCT00429260|Drug|Saredutant|
333615|NCT00429273|Drug|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
333616|NCT00429273|Drug|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
333617|NCT00429286|Behavioral|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
333618|NCT00429299|Drug|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
333619|NCT00429299|Biological|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
333620|NCT00003392|Procedure|peripheral blood stem cell transplantation|
333621|NCT00429299|Drug|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
332551|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
332552|NCT00452023|Drug|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
332906|NCT00443651|Drug|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
332907|NCT00003437|Drug|mercaptopurine|
332908|NCT00443651|Drug|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
332909|NCT00443664|Device|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
332910|NCT00443677|Drug|COPPEBVCAD vs BEACOPP vs ABVD|
332911|NCT00443690|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
332912|NCT00443690|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
332913|NCT00443703|Drug|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
332914|NCT00443703|Drug|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
332915|NCT00443703|Drug|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
332916|NCT00443703|Drug|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
332917|NCT00446173|Drug|GM-CSF|250 mcg/kg Subcutaneously Once Daily
332918|NCT00446186|Drug|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
332919|NCT00446186|Drug|Comparator: placebo / Duration of Treatment: 2 Weeks|
332920|NCT00446199|Drug|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
332921|NCT00446199|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
332922|NCT00446199|Drug|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
332923|NCT00446199|Drug|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
332217|NCT00413998|Procedure|CABG|Patients will undergo coronary artery bypass grafting alone.
332218|NCT00003311|Drug|vincristine sulfate|
332219|NCT00414011|Drug|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
332220|NCT00414011|Drug|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
332221|NCT00414024|Drug|Tegaserod|
332222|NCT00414037|Drug|Eszopiclone|
332223|NCT00414037|Drug|Placebo|Placebo-treatment
332224|NCT00414050|Biological|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months (Arm 1). Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Arm 3).
332225|NCT00416858|Procedure|neoadjuvant therapy|
332226|NCT00416858|Radiation|radiation therapy|
332227|NCT00416871|Biological|aldesleukin|
332553|NCT00452049|Procedure|parathyroidectomy|parathyroidectomy
332554|NCT00452062|Drug|Dexamethasone|
332555|NCT00003490|Drug|vincristine sulfate|
332556|NCT00452075|Drug|erlotinib|150mg daily
332557|NCT00452088|Biological|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
332558|NCT00452088|Biological|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
332559|NCT00452088|Biological|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
332560|NCT00454792|Other|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
332561|NCT00454792|Other|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
332562|NCT00454805|Drug|AZD2171|Oral tablet
332563|NCT00454805|Drug|Fulvestrant|intramuscular injection
331874|NCT00422877|Drug|Taxoprexin|
331875|NCT00422890|Drug|5-Azacytidin|in case of decreasing CD34 chimerism
331876|NCT00422903|Drug|lapatinib|1500 mg administered orally daily
331877|NCT00422903|Drug|letrozole|2.5 mg administered orally daily
331878|NCT00422903|Other|placebo|1500 mg administered orally daily
331879|NCT00003364|Drug|cisplatin|
331880|NCT00422916|Behavioral|behavioral intervention|
331881|NCT00422942|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
331882|NCT00422942|Drug|Methotrexate|10-25mg po weekly
331883|NCT00422955|Drug|AVANDIA (rosiglitazone)|
331884|NCT00422968|Device|Percutaneous coronary intervention|Using silorimus eluting stent
331885|NCT00422968|Procedure|coronary artery bypass graft|coronary artery bypass graft
331886|NCT00422981|Drug|AL-108|5 mg QD
331887|NCT00422981|Drug|AL-108|15 mg BID
331888|NCT00422981|Drug|Placebo|Placebo
331889|NCT00422994|Drug|ropinirole dosing for up to 28 days|
331890|NCT00003364|Drug|cyclophosphamide|
331891|NCT00423007|Drug|Bromfenac|
331892|NCT00425438|Drug|Cyclophosphamide|0.75 g/m^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m^2 to maintain a minimum WBC count of ≥ 2500 per mm^3 from Weeks 5 through 24
331893|NCT00425451|Drug|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
331894|NCT00425464|Device|Standard Monofocal Intraocular Lens|The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.
Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis.
331895|NCT00425464|Device|Synchrony® Dual Optic Intraocular Lens|The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.
Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis.
331145|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
331146|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
331147|NCT00439816|Behavioral|Group Visits|
331148|NCT00439829|Drug|Gonal F|450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).
Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).
Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS.
331149|NCT00439829|Drug|Luveris|0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:
leading follicle is > 13 mm in diameter
if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L
Dosing to continue until administration of hCG (see below).
331150|NCT00439829|Drug|Cetrotide|0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:
leading follicle is > 13 mm in diameter
if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L
Dosing to continue until administration of hCG (see below).
331151|NCT00439829|Drug|hCG|- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:
o > 3 follicles are > 17 mm in diameter
331152|NCT00439842|Behavioral|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
331153|NCT00003423|Drug|mercaptopurine|
331154|NCT00439855|Drug|Enoxaparin i.v.|
331532|NCT00431457|Device|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
331533|NCT00431457|Procedure|amygddohyppocampertomy|Resective surgery
331534|NCT00431470|Behavioral|Six classroom based character building education lessons|
331535|NCT00431483|Behavioral|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
331536|NCT00431496|Drug|Cinacalcet|Cinacalcet tablets
331537|NCT00003398|Drug|thiotepa|
331538|NCT00431509|Procedure|conventional vs. navigated total knee arthroplasty|
331539|NCT00431522|Drug|Valproic acid, sodium salt|
331540|NCT00431548|Drug|100% O2|
331541|NCT00431561|Drug|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
330787|NCT00448357|Procedure|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
330788|NCT00448357|Drug|methotrexate|5 mg/m^2 on days +1, +3 and +6
330789|NCT00448383|Biological|adalimumab|40mg every other week
330790|NCT00448396|Drug|Patupilone|
330791|NCT00448409|Biological|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
330792|NCT00448409|Drug|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
330793|NCT00448422|Drug|prulifloxacin|Tablet
330794|NCT00448435|Drug|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
330795|NCT00448435|Drug|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
330796|NCT00448448|Device|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
330797|NCT00003467|Drug|polifeprosan 20 with carmustine implant|
330798|NCT00448448|Other|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
330799|NCT00448461|Drug|heparin|comparison between heparin and bivalirudin
330800|NCT00450970|Drug|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
330801|NCT00450983|Biological|muromonab-CD3|
330802|NCT00450983|Biological|natural killer cell therapy|
330803|NCT00450983|Drug|fludarabine phosphate|
330804|NCT00450983|Drug|methotrexate|
330805|NCT00450983|Drug|thiotepa|
330806|NCT00450983|Genetic|gene expression analysis|
330807|NCT00003486|Procedure|biological therapy|
330184|NCT00590759|Device|GORE TAG® Thoracic Endoprosthesis|implant
330185|NCT00590772|Drug|montelukast|10 mg po each day (compared to placebo for 2 weeks)
330186|NCT00590772|Drug|placebo|placebo for 2 weeks
330187|NCT00590785|Drug|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
330188|NCT00590785|Drug|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
330189|NCT00590785|Drug|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
330190|NCT00552383|Procedure|NIDCAP based developmental care|Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff [this includes 3 of the investigators], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided "baby -friendly" care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU.
330191|NCT00003996|Drug|chemotherapy|
330192|NCT00552396|Drug|Anti-KIR (1-7F9)|human monoclonal antibody
330193|NCT00552409|Dietary Supplement|Cholecalciferol|2000 IU by mouth daily for one year
330194|NCT00552409|Dietary Supplement|Placebo|One softgel daily for one year
330479|NCT00582400|Drug|arsenic trioxide|Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.
The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution.
330480|NCT00582413|Behavioral|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
330481|NCT00582426|Drug|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
330482|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
329892|NCT00557401|Drug|XP19986 SR3, 60 mg QD|After the washout period, subjects will be randomized to receive placebo or XP19986 SR study treatments. XP19986 Sustained Release (SR) Tablet will be dosed orally, QD or BID, for approximately 32 days with titration and taper periods
329893|NCT00557401|Drug|XP19986 SR3, 30 mg BID|After the washout period, subjects will be randomized to receive placebo or XP19986 SR study treatments. XP19986 Sustained Release (SR) Tablet will be dosed orally, QD or BID, for approximately 32 days with titration and taper periods
329894|NCT00004039|Biological|rituximab|
329895|NCT00559858|Procedure|quality-of-life assessment|
329896|NCT00559871|Drug|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
329897|NCT00559884|Drug|GSK189075 (Modified and immediate release formulations)|
329898|NCT00559897|Other|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
329899|NCT00559897|Procedure|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
329900|NCT00559910|Drug|PH-797804|PH-797804 at four dose levels
329901|NCT00559910|Drug|Placebo|Placebo
329902|NCT00559936|Drug|Topical Avastin 1%|Avastin (bevacizumab) 1%
329903|NCT00559949|Other|Laboratory Biomarker Analysis|Correlative studies
329904|NCT00559949|Other|Pharmacological Study|
329905|NCT00004039|Drug|cyclophosphamide|
329906|NCT00559949|Drug|Selumetinib|Given orally
329907|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
329908|NCT00559962|Drug|placebo|3 capsules each evening for each 4-week period
329909|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
329910|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
329911|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
329912|NCT00559962|Drug|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
302973|NCT00381069|Behavioral|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
302974|NCT00381082|Drug|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
302975|NCT00381082|Drug|Banlice Mousse Aerosol (Pfizer, Australia)|
302976|NCT00381082|Drug|3) KP24 Medicated Foam (Nelson Laboratories)|
302977|NCT00383487|Drug|Naproxen-n-butyl nitrate|400 mg BID, oral
302978|NCT00383500|Device|Flexitouch|Standard of Care
302979|NCT00383513|Biological|Epratuzumab|360 mg/m^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
302980|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
302981|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
302982|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
302983|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
302984|NCT00003162|Radiation|radiation therapy|
302985|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
302986|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Control Vaccine
302987|NCT00383552|Drug|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
302988|NCT00383552|Drug|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
302989|NCT00383552|Drug|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
302990|NCT00383552|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
302991|NCT00383565|Drug|romidepsin|Given IV
303327|NCT00374985|Drug|Docetaxel, Oxaliplatin|weekly doses
302308|NCT00003224|Biological|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
302309|NCT00003240|Radiation|radiation therapy|
302310|NCT00400439|Drug|Placebo|po daily for 24 weeks
302311|NCT00400439|Drug|dalcetrapib|900mg po daily for 24 weeks
302312|NCT00400452|Behavioral|wheelchair skills training|
302313|NCT00400465|Procedure|Normal dressing|Normal dressing
302644|NCT00389493|Drug|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
302645|NCT00389493|Behavioral|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
302646|NCT00391898|Drug|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
302647|NCT00391898|Drug|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
302648|NCT00391911|Drug|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
302649|NCT00391911|Other|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
302650|NCT00391911|Other|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
302651|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
302652|NCT00391924|Drug|Dehydroepiandrosterone|
302653|NCT00391937|Device|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
302654|NCT00003204|Drug|vincristine sulfate|Given IV
302655|NCT00391950|Drug|Zoledronic acid|
302656|NCT00391963|Device|Bispectral index, Entropy|
301929|NCT00406211|Biological|Varicella (Varilrix®)|
301930|NCT00406224|Drug|breathing 100% oxygen|
301931|NCT00003270|Procedure|bone marrow ablation with stem cell support|IV
301932|NCT00406237|Drug|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
301933|NCT00406250|Drug|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
301934|NCT00406250|Drug|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
301935|NCT00406263|Procedure|Scheimpflug crystalline lens photographs|scheimpflug photographs
301936|NCT00406276|Drug|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
301937|NCT00406276|Drug|Docetaxel|In combination with RAD001
301938|NCT00406289|Procedure|18F-FDG-PET radiotherapy|
301939|NCT00406302|Drug|Docetaxel|75mg/m², day 1,22
301940|NCT00406302|Drug|oxaliplatin|40mg/m², d1,2,22,23
301941|NCT00406302|Drug|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
301942|NCT00003270|Procedure|umbilical cord blood transplantation|IV
301943|NCT00406302|Procedure|surgery|28 days after end of induction chemotherapy
301944|NCT00406315|Drug|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
301945|NCT00406341|Drug|Difluprednate Ophthalmic Emulsion|
302314|NCT00400465|Procedure|Pressure dressing|Pressure dressing
302315|NCT00400478|Drug|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
302316|NCT00400491|Drug|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
302317|NCT00400491|Drug|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
302318|NCT00400517|Biological|sargramostim|
302319|NCT00400517|Drug|thalidomide|
301232|NCT00377182|Drug|Copegus|1000/1200mg po daily for 4 weeks
301233|NCT00377182|Drug|PEGASYS|180 micrograms sc weekly for 4 weeks
301234|NCT00377182|Drug|RO5024048|1500mg po bid for 4 weeks
301235|NCT00377182|Drug|RO5024048|3000mg po bid for 4 weeks
301566|NCT00412334|Drug|Copegus|1200-1600mg/day po
301567|NCT00412334|Drug|Copegus|1000-1200mg/day po
301568|NCT00367822|Drug|Ropinirole|
301569|NCT00367822|Drug|Placebo|
301570|NCT00367835|Drug|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
301571|NCT00367835|Drug|Placebo|Placebo
301572|NCT00367861|Drug|interruption of Glivec®|interruption of Glivec®
301573|NCT00367874|Drug|Buprenorphine|
301574|NCT00367874|Drug|Valproate|
301575|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
301576|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
301577|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
301578|NCT00003093|Drug|etoposide|
301579|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
301580|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
301581|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
301582|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
301583|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
301584|NCT00367913|Drug|Addition of clarithromycin to rifampicin and ethambutol|
301585|NCT00367913|Drug|Addition of Ciprofloxacin to rifampicin and ethambutol|
300891|NCT00382863|Device|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
300892|NCT00382863|Drug|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
300893|NCT00382889|Drug|beclomethasone/salbutamol combination|
300894|NCT00385541|Drug|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
300895|NCT00385554|Drug|UC-781 carbomer gel, 0.1% and 0.25%|
300896|NCT00385567|Drug|PEHRG214|
300897|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
300898|NCT00003174|Drug|bryostatin 1|
300899|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
300900|NCT00385593|Drug|Symbicort (budesonide/formoterol) Turbuhaler|
300901|NCT00385593|Drug|Conventional treatment|
300902|NCT00385606|Drug|gemcitabine|
300903|NCT00385606|Drug|prolonged continuous infusion gemcitabine|
300904|NCT00385606|Drug|cisplatin|
301236|NCT00377195|Radiation|Involved Field Radiotherapy|The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.
Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days.
301237|NCT00377208|Behavioral|Web-Based Intervention|"My Expert Doctor" is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor.
301238|NCT00377234|Drug|Risedronate|35mg po weekly for 12 weeks
301239|NCT00377234|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
301240|NCT00003136|Drug|cyclophosphamide|
301241|NCT00377247|Biological|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
300194|NCT00399607|Procedure|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
300544|NCT00391144|Procedure|intravitreal triamcinolone injection of avastin (1.25 mg)|
300545|NCT00391157|Drug|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
300546|NCT00391170|Drug|Topical Dexamethasone|
300547|NCT00391170|Drug|Placebo|
300548|NCT00391183|Procedure|Biliary stenting|ERCP and stenting
300549|NCT00391196|Drug|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
300550|NCT00391196|Drug|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
300551|NCT00391196|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
300552|NCT00393679|Drug|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
300553|NCT00393679|Drug|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
300554|NCT00393679|Drug|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.
TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008.
300555|NCT00393705|Drug|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
300556|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
300557|NCT00393705|Drug|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
300558|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
300559|NCT00393718|Drug|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
300560|NCT00003212|Drug|doxorubicin hydrochloride|
299840|NCT00408447|Drug|Fludarabine|Fludarabine 30 mg/m2/d x 6d
299841|NCT00408447|Drug|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
299842|NCT00408447|Procedure|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
299843|NCT00408460|Drug|imatinib mesylate|Given PO
299844|NCT00408460|Drug|paclitaxel|Given IV
299845|NCT00408460|Other|immunohistochemistry staining method|Optional correlative studies
299846|NCT00408473|Drug|Flecainide|
299847|NCT00408499|Drug|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
299848|NCT00003282|Drug|EF5|Given IV
299849|NCT00408499|Drug|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
299850|NCT00408512|Drug|thiazides|Up to 25 mg per day
299851|NCT00408512|Procedure|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
300195|NCT00399607|Procedure|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
300196|NCT00402441|Drug|Risedronate (HMR4003)|
300197|NCT00402454|Drug|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
300198|NCT00402467|Drug|Rivaroxaban (BAY59-7939)|2.5mg bid
300199|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|5mg bid
300200|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|10 mg bid
300201|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|20mg bid
300202|NCT00003255|Drug|topotecan hydrochloride|
299488|NCT00373022|Behavioral|exercise intervention|
299852|NCT00408525|Drug|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
299853|NCT00408538|Drug|UC-781 microbicide gel (0.1% and 0.25%)|
299854|NCT00411242|Drug|placebo|
299855|NCT00411255|Procedure|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
299856|NCT00411268|Drug|OROS hydromorphone HCI SR (slow release)|
299857|NCT00411281|Drug|cytarabine|Given subcutaneously
299858|NCT00411281|Procedure|observation|No intervention
299859|NCT00411307|Drug|OROS hydromorphone HCI|
299860|NCT00411320|Drug|oral steroid-dexamethasone|2 week steroid trial
299861|NCT00411333|Drug|triamcinolone acetonide (Kenalog)|
299862|NCT00003298|Drug|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
299863|NCT00411346|Procedure|Nurse-led telemonitoring|
299864|NCT00411359|Behavioral|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
299865|NCT00411372|Drug|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
299866|NCT00411385|Drug|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
299867|NCT00411385|Drug|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
299868|NCT00411385|Drug|Ribavirin|800mg/day for 24 weeks
299869|NCT00411398|Drug|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
299870|NCT00411411|Drug|Januvia|200 mg t.i.d
299871|NCT00411411|Drug|Placebo|Placebo
299872|NCT00411424|Drug|ASK8007|IV
333622|NCT00429299|Drug|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
333623|NCT00429299|Drug|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
333624|NCT00429299|Drug|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
333625|NCT00429312|Biological|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
333626|NCT00429338|Procedure|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
333627|NCT00429338|Procedure|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
333628|NCT00429364|Drug|Losartan Potassium|Losartan .3 - 1.4 mg/kg
333629|NCT00429364|Drug|Atenolol|Atenolol .5 - 4 mg/kg
333630|NCT00429377|Drug|tacrolimus|
333631|NCT00003394|Drug|carboplatin|
333632|NCT00429390|Behavioral|Ramadan Fasting|
333633|NCT00429403|Drug|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
333634|NCT00429416|Drug|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
333635|NCT00429416|Drug|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
333636|NCT00429416|Drug|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
333984|NCT00421057|Behavioral|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
333985|NCT00000511|Behavioral|dietary supplements|
333986|NCT00003351|Drug|irinotecan hydrochloride|
333987|NCT00423657|Drug|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
333988|NCT00423670|Drug|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
333989|NCT00423670|Drug|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
332924|NCT00003455|Procedure|alternative product therapy|
332925|NCT00446212|Drug|Propofol|target controlled infusion of propofol
332926|NCT00446212|Drug|desflurane|Anaesthetic maintenance with desflurane
332927|NCT00446225|Drug|Erlotinib (Tarceva)|150 mg/day
333271|NCT00437710|Procedure|cell therapy, bone marrow derived stem cell|
333272|NCT00437723|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
333273|NCT00437736|Drug|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
333274|NCT00437749|Drug|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
333275|NCT00437749|Other|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
333276|NCT00437762|Drug|Botulinum Toxin A Injection|Botulinum Toxin A Injection
333277|NCT00437762|Drug|Placebo injection|Placebo Injection
333278|NCT00003417|Radiation|radiation therapy|
333279|NCT00437814|Drug|Ketamine, effect on intracranial pressure|
333280|NCT00437827|Other|Star*D algorithm|Standard of care based upon the therapies selected in the Star*D study.
333281|NCT00437827|Other|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
333282|NCT00437840|Drug|GSK598809|
333283|NCT00437853|Drug|Anastrozole|
333284|NCT00437892|Drug|atorvastatin|tablets, 40 mg day, 3 months
333285|NCT00437892|Drug|atorvastatin|tablets, 40 mg once daily
333286|NCT00437892|Behavioral|diet|daily
333287|NCT00437892|Behavioral|diet|daily diet
333288|NCT00437905|Procedure|angioplasty|
333289|NCT00003418|Drug|exemestane|
333290|NCT00437918|Drug|nateglinide|
332564|NCT00454818|Genetic|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
332565|NCT00454818|Procedure|Placebo Infusion|Saline; epicardial coronary artery infusion
332566|NCT00454818|Genetic|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
332567|NCT00454831|Device|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
332568|NCT00454857|Other|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
332569|NCT00003505|Procedure|complementary and alternative therapy|
332570|NCT00454857|Other|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
332571|NCT00454857|Other|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
332572|NCT00454870|Drug|MEM 3454|
332573|NCT00454883|Drug|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
332574|NCT00454896|Drug|VESIcare®|Oral
332575|NCT00454896|Drug|placebo|Oral
332928|NCT00446225|Drug|Carboplatin // Gemcitabine // Docetaxel //Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2); Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8); Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)
332929|NCT00446238|Behavioral|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
332930|NCT00446238|Behavioral|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
332931|NCT00446251|Drug|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
332932|NCT00446251|Drug|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
332933|NCT00446264|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
331896|NCT00425477|Biological|sargramostim|
332228|NCT00416871|Biological|recombinant interferon alfa|
332229|NCT00416884|Drug|Campath|30 mg on day -8 over 5-6 hours
332230|NCT00416884|Drug|Fludarabine|Fludarabine 30 mg/m^2 on day -4 through day -2
332231|NCT00416884|Radiation|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
332232|NCT00416884|Other|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
332233|NCT00003334|Drug|paclitaxel|
332234|NCT00416897|Drug|chemotherapy|
332235|NCT00416897|Drug|dexamethasone|
332236|NCT00416897|Procedure|plasmapheresis|
332237|NCT00416910|Biological|filgrastim|
332238|NCT00416910|Drug|cyclophosphamide|
332239|NCT00416910|Drug|fludarabine phosphate|
332240|NCT00416910|Drug|mitoxantrone hydrochloride|
332241|NCT00416923|Biological|rituximab|
332242|NCT00416949|Procedure|computed tomography|
332243|NCT00416949|Procedure|radionuclide imaging|
332244|NCT00000510|Drug|aspirin|
332245|NCT00003334|Drug|pegylated liposomal doxorubicin hydrochloride|
332246|NCT00416949|Procedure|single photon emission computed tomography|
332247|NCT00416949|Radiation|iodine I 131|
332248|NCT00416962|Drug|amantadine hydrochloride|
332249|NCT00416962|Drug|oseltamivir phosphate|
331542|NCT00431561|Drug|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
331543|NCT00431561|Drug|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
331544|NCT00434278|Drug|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
331545|NCT00434278|Drug|placebo|2.5 mg inhalation dose twice daily for 14±2 days
331546|NCT00434291|Drug|TG-873870(Nemonoxacin)|
331547|NCT00434304|Drug|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
331548|NCT00003405|Biological|recombinant interferon alfa|
331549|NCT00434317|Drug|Zoledronic acid|
331550|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
331897|NCT00425477|Drug|bexarotene|
331898|NCT00003380|Drug|etoposide|
331899|NCT00425477|Genetic|cytogenetic analysis|
331900|NCT00425477|Genetic|fluorescence in situ hybridization|
331901|NCT00425477|Other|flow cytometry|
331902|NCT00425477|Other|laboratory biomarker analysis|
331903|NCT00425477|Procedure|biopsy|
331904|NCT00425490|Drug|sitagliptin|
331905|NCT00425503|Drug|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
330808|NCT00450983|Other|flow cytometry|
330809|NCT00450983|Other|immunologic technique|
331155|NCT00439855|Drug|unfractionated heparin|
331156|NCT00439868|Drug|WellbutrinXL|
331157|NCT00439868|Drug|placebo|
331158|NCT00442702|Drug|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
331159|NCT00442702|Drug|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
331160|NCT00442715|Procedure|Exercise chalenge test|
331161|NCT00442728|Device|ELECTRICAL STIMULATION|
331162|NCT00442741|Drug|Patupilone|
331163|NCT00442741|Drug|Patupilone + Omeprazole|
331164|NCT00003436|Drug|methotrexate|
331165|NCT00442754|Biological|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
331166|NCT00442767|Drug|Pramlintide acetate|Pramlintide given before meal and insulin given after meal
331167|NCT00442780|Drug|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
331168|NCT00442780|Drug|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
331169|NCT00442793|Drug|Epoetin beta|As prescribed, 3 times weekly
331170|NCT00442793|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
331171|NCT00442806|Drug|Injection of ADRC's|ADRC's are injected
331172|NCT00442806|Other|Injection of Placebo|Placebo is injected
331173|NCT00442819|Procedure|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
331174|NCT00442832|Drug|TD-1792|TD-1792 2 mg/kg/day IV
331175|NCT00000522|Behavioral|diet, sodium-restricted|
330483|NCT00582439|Device|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
330484|NCT00582452|Other|Telephone survey|Telephone survey
330485|NCT00582478|Behavioral|questionnaires|Participants will be followed regularly at 3, 6, 12, and 18-month intervals
330486|NCT00582491|Drug|Modafinil|Modafinil 400mg orally every day for 16 days
330487|NCT00582491|Drug|Placebo|Placebo orally everyday for 16 days
330488|NCT00004150|Drug|leucovorin calcium|
330489|NCT00585195|Drug|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
Single and Multiple Dose Design:200 mg QD administered from Day -3 to Cycle 1, Day 16 (19 days) in combination with PF-02341066.
330490|NCT00585208|Drug|Ramelteon|Ramelteon 8mg daily
330491|NCT00585208|Drug|Placebo|matching placebo for ramelteon 8mg daily
330492|NCT00004164|Drug|cisplatin|
330493|NCT00585221|Drug|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
330494|NCT00585221|Drug|Imatinib|Continue imatinib until progression.
330495|NCT00585234|Other|Digital Photography|Digital Photography
330496|NCT00585247|Drug|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
330497|NCT00585247|Other|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
330810|NCT00450983|Procedure|allogeneic hematopoietic stem cell transplantation|
330811|NCT00450983|Procedure|in vitro-treated peripheral blood stem cell transplantation|
330812|NCT00450983|Radiation|total-body irradiation|
330813|NCT00450996|Drug|Topical Steroids|
330814|NCT00451009|Device|Viacell's product Media Kits|
330815|NCT00451035|Drug|LBH589|
330816|NCT00451048|Drug|sunitinib malate|Given orally
329913|NCT00559962|Drug|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
329914|NCT00559962|Drug|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
329915|NCT00559975|Biological|Subunit influenza vaccine|0.5 mL single dose vaccine
330195|NCT00552422|Drug|domperidone|10mg orally four times per day
330196|NCT00552435|Device|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
330197|NCT00552448|Device|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
330198|NCT00552461|Drug|rituximab|IV, 1000 mg, two weeks, 2 times
330199|NCT00552474|Device|Libra Deep Brain Stimulation System|Active DBS Therapy
330200|NCT00552474|Device|Libra Deep Brain Stimulation System|Implanted system but no stimulation
330201|NCT00552487|Drug|synacthen|1 µg synacthen in the vein
330202|NCT00003996|Drug|cisplatin|
330203|NCT00552500|Drug|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
330204|NCT00552513|Procedure|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (and within 24 hours of randomisation).
330205|NCT00552513|Procedure|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
330206|NCT00552526|Dietary Supplement|Ketogenic diet|Ketogenic diet is a very strict high fat diet
330207|NCT00552526|Drug|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
330208|NCT00552539|Other|'educational video'|'educational video'
330209|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
303328|NCT00000486|Procedure|coronary artery bypass|
303329|NCT00003125|Biological|aldesleukin|
303330|NCT00374985|Procedure|Radiotherapy|regular fractions
303331|NCT00374998|Biological|FP9-PP (FP9 polyprotein)|
303332|NCT00374998|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
303333|NCT00375024|Procedure|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
303334|NCT00375024|Procedure|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
303335|NCT00375037|Behavioral|feedback|
303336|NCT00375037|Behavioral|Education|
303337|NCT00375037|Other|usual care|
303338|NCT00375050|Drug|Riluzole|
303339|NCT00375050|Drug|Placebo|placebo
303340|NCT00003125|Biological|sargramostim|
303341|NCT00375063|Procedure|Percutaneous Coronary Intervention|
303342|NCT00375063|Procedure|Coronary Artery Bypass Grafting|
303343|NCT00375076|Drug|enoxaparin|
303344|NCT00375089|Other|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
303345|NCT00375089|Other|Group 2|Individuals with Early-onset Morbid Obesity.
303346|NCT00375102|Procedure|Acupuncture|
303347|NCT00375102|Behavioral|Relaxation Response|
303348|NCT00375115|Drug|Sambucol|
303349|NCT00375128|Biological|FP9-PP (FP9 polyprotein)|
303350|NCT00002599|Drug|methylprednisolone|
303351|NCT00228319|Dietary Supplement|Oral Ascorbic Acid|4 grams per day for 12 months
303352|NCT00228319|Drug|Paclitaxel|Six cycles
302657|NCT00391976|Drug|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
302658|NCT00391989|Drug|Dasatinib|
302659|NCT00392002|Drug|Esomeprazole|
302660|NCT00392015|Biological|NMRC-M3V-Ad-PfCA|Malaria Vaccine
302661|NCT00392015|Biological|NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA|Malaria Vaccines
302662|NCT00392028|Drug|ertapenem|
302663|NCT00392041|Drug|Eszopiclone|3mg qpm for 12 weeks
302664|NCT00392041|Drug|placebo|1 pill qpm for 12 weeks
302992|NCT00383578|Drug|Vildagliptin 100 mg qd|
302993|NCT00383578|Drug|Metformin 1500 mg daily|
302994|NCT00383591|Biological|Hepatitis B adjuvanted vaccine|
302995|NCT00003163|Biological|filgrastim|
302996|NCT00383591|Biological|Engerix-B|
302997|NCT00383630|Biological|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
302998|NCT00383630|Biological|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
302999|NCT00383630|Device|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
303000|NCT00383643|Drug|zolpidem tartrate|
303001|NCT00383643|Drug|sodium oxybate|
303002|NCT00383643|Drug|Matching Placebos|
303003|NCT00383656|Drug|synthetic gonadotropin releasing hormone (GnRH)|75 ng/kg GnRH IV
303004|NCT00383656|Device|Mini-infusion pump|portable, infusion pump for GnRH
303005|NCT00383669|Dietary Supplement|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
302320|NCT00003241|Drug|phenylacetate|
302321|NCT00400517|Procedure|conventional surgery|
302322|NCT00400517|Procedure|neoadjuvant therapy|
302323|NCT00400530|Drug|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
302324|NCT00400530|Drug|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
302325|NCT00400543|Device|Continuous positive airway pressure (CPAP)|
302326|NCT00400556|Drug|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
302327|NCT00400569|Drug|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
302328|NCT00400582|Drug|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
302329|NCT00400595|Drug|Mupirocin ointment|topical ointment (already in widespread clinical use)
302330|NCT00400595|Drug|Polysporin Triple|
302331|NCT00003242|Drug|bryostatin 1|
302332|NCT00400608|Drug|ADVAIR HFA|
302333|NCT00400608|Drug|ADVAIR DISKUS|
302334|NCT00400621|Drug|acetaminophen|
302335|NCT00400634|Genetic|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10^11 vg
302336|NCT00400634|Procedure|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
302337|NCT00400647|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
302338|NCT00400647|Drug|Mycophenolate mofetil|
302339|NCT00400660|Drug|GSK615915|
302665|NCT00003204|Drug|prednisone|Given PO
302666|NCT00392054|Procedure|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
302667|NCT00392054|Drug|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
301586|NCT00367913|Biological|Vaccination with M.vaccae|
301587|NCT00367926|Drug|American ginseng root / polysaccharides|
301588|NCT00367939|Drug|valsartan + amlodipine|
301589|NCT00003093|Procedure|conventional surgery|
301590|NCT00367952|Drug|apricitabine|800mg apricitabine twice daily orally for 96 weeks
301591|NCT00367965|Drug|Eszopiclone|eszopiclone 3 mg
301592|NCT00367965|Drug|placebo|placebo tablet
301946|NCT00406354|Drug|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
301947|NCT00406354|Drug|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
301948|NCT00406367|Drug|incobotulinumtoxinA (Xeomin)|incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection
301949|NCT00406367|Drug|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
301950|NCT00406380|Drug|Bevacizumab|
301951|NCT00406380|Procedure|Intravitreal injection of Bevacizumab|
301952|NCT00406393|Drug|Tacrolimus|Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.
The target serum level for tacrolimus is 5-10 ng/mL.
301953|NCT00000147|Drug|Prednisone|
301954|NCT00000504|Drug|moricizine|
301955|NCT00409305|Behavioral|Dietary counseling|
301956|NCT00409318|Drug|Etanercept|50 mg SC q week
301957|NCT00003284|Procedure|peripheral blood stem cell transplantation|
301958|NCT00409318|Drug|Placebo|SC q week
301242|NCT00377260|Drug|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
301243|NCT00377260|Drug|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
301244|NCT00377273|Drug|fluorouracil cream 0.5%|
301245|NCT00377286|Dietary Supplement|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
301246|NCT00377286|Other|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
301247|NCT00377299|Drug|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
301248|NCT00377299|Drug|Placebo|Placebo matching active medication in all other physical aspects
301249|NCT00377312|Drug|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
301250|NCT00377325|Drug|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
301251|NCT00003136|Procedure|peripheral blood stem cell transplantation|
301252|NCT00377364|Drug|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
301253|NCT00377377|Drug|EP1572 (ghrelin agonist) oral and duodenal application|
301254|NCT00377390|Biological|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
301593|NCT00367978|Drug|Amlodipine/benazepril|
301594|NCT00367991|Drug|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
301595|NCT00367991|Drug|Placebo|Normal saline to match active drug (rHuEpo)
301596|NCT00368017|Drug|pioglitazone|30 mg once a day for 12 weeks
301597|NCT00368017|Drug|placebo|1 pill once a day for 12 weeks
301598|NCT00368030|Drug|Eszopiclone|Eszopiclone 3 mg QD
301599|NCT00368030|Other|Placebo|Placebo tablet
300561|NCT00393718|Drug|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
300562|NCT00393718|Drug|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
300563|NCT00393718|Drug|placebo|glibenclamide placebo. Given orally once or twice daily.
300564|NCT00393731|Drug|Misoprostol|
300565|NCT00393731|Drug|oxytocin|
300905|NCT00385606|Drug|rofecoxib|
300906|NCT00385632|Drug|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
300907|NCT00385645|Drug|Combivir+Kaletra|
300908|NCT00385645|Drug|Combivir+Reyataz|
300909|NCT00003174|Drug|cladribine|
300910|NCT00385658|Drug|Fluvastatin extended release, fenofibrate|
300911|NCT00385658|Drug|Fixed combination simvastatin/ezetimibe|
300912|NCT00385671|Drug|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
300913|NCT00385671|Drug|pregabalin|Pregabalin (PGB) orally (PO)
300914|NCT00385671|Drug|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
300915|NCT00385684|Drug|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
300916|NCT00385684|Drug|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
300917|NCT00385684|Drug|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
300918|NCT00385697|Drug|Teplizumab|IV dosing daily for 14 days times 2 courses
300919|NCT00385697|Other|Placebo|IV dosing daily for 14 days times 2 courses
300920|NCT00000494|Drug|indomethacin|
300921|NCT00003175|Drug|fluorouracil|
300203|NCT00402467|Drug|Enoxaparine|30mg bid
300204|NCT00402467|Drug|Enoxaparine|30mg bid
300205|NCT00402480|Drug|Hydroxyurea|
300206|NCT00402493|Drug|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
300207|NCT00402493|Drug|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
300208|NCT00402493|Drug|Ibuprofen|ibuprofen 200mg
300209|NCT00402506|Drug|(MC-1) Pyridoxal 5'-phosphate|
300210|NCT00402519|Radiation|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
300211|NCT00402519|Radiation|External beam whole breast irradiation|Standard Whole breast irradiation
300212|NCT00402532|Drug|Everolimus|Initial dosage 2 x 0.75 mg/d
300213|NCT00000502|Procedure|cardiopulmonary resuscitation|
300214|NCT00003256|Drug|alvocidib|
300215|NCT00402532|Drug|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
300216|NCT00402545|Drug|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
300217|NCT00402545|Drug|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
300566|NCT00393744|Drug|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
300567|NCT00393744|Drug|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
300568|NCT00393770|Drug|L-acetylcarnitine|250-500 mg/kg/die.
300569|NCT00393783|Biological|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
300570|NCT00393796|Drug|SUTENT|50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to "crossover" and receive SU011248.
300571|NCT00003212|Drug|ifosfamide|
332816|NCT00434798|Biological|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10^6-10^9 CFU
332817|NCT00434811|Biological|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
332818|NCT00434811|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
332819|NCT00434811|Drug|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
332820|NCT00434811|Drug|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
332821|NCT00434811|Biological|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
332822|NCT00000518|Drug|mexiletine|
332823|NCT00003405|Drug|mitoxantrone hydrochloride|
332824|NCT00434811|Procedure|Islet Transplantation|Transplantation of pancreatic islet cell
332825|NCT00434811|Biological|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
332826|NCT00434824|Drug|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
332827|NCT00434824|Drug|Placebo|treatment for 12 months with placebo in divided doses
332828|NCT00434837|Procedure|Initial graft tension during ACL reconstruction surgery|The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg. When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg. Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown.
332829|NCT00434850|Biological|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
332830|NCT00434850|Drug|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
332831|NCT00434850|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
332832|NCT00434850|Biological|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
332833|NCT00434850|Drug|Sirolimus|Maintenance immunosuppressive therapy
332130|NCT00451594|Drug|Prednisolone|Conventional dose prednisone (Arm 2)
Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.
Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months
332131|NCT00451620|Drug|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
332132|NCT00451620|Drug|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
332133|NCT00451633|Drug|E2007|
332134|NCT00451646|Drug|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
332135|NCT00451672|Drug|bromocriptine|
332136|NCT00003489|Drug|antineoplaston AS2-1|
332137|NCT00451698|Drug|acyanotic erythropoietin|Single dose IV push
332138|NCT00451698|Drug|acyanotic placebo|Single dose IV push
332139|NCT00451711|Drug|Liposomal amphotericin B|
332140|NCT00451724|Drug|Intranasal ketamine|
332141|NCT00451737|Device|Isokinetic test|
332142|NCT00451750|Drug|Cortisol|20 mg for 3 times
332470|NCT00443404|Procedure|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
332471|NCT00443417|Drug|SK-PC-B70M|dosage, frequency
332472|NCT00443430|Drug|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
332473|NCT00443430|Drug|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
332474|NCT00443456|Drug|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
331773|NCT00413686|Drug|Gemcitabine|weekly intravenous infusion
331774|NCT00413699|Drug|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
331775|NCT00003311|Drug|cytarabine|
331776|NCT00413699|Drug|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
331777|NCT00413712|Drug|Calcium Channel Blocker & Adenosine|
331778|NCT00413725|Biological|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
331779|NCT00413725|Other|Placebo|Placebo
331780|NCT00413738|Device|Antiseptic-coated central venous catheters|
331781|NCT00413751|Drug|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
331782|NCT00413764|Drug|tibolone|tibolone (2.5 mg) over 24 weeks
331783|NCT00413764|Drug|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
331784|NCT00413777|Drug|tolvaptan|45 mg tablet in the morning, 15 mg tablet 8 hours later for up to 4 years
331785|NCT00413777|Drug|tolvaptan|60 mg tablet in the morning, 30 mg tablet 8 hours later for up to 4 years
331786|NCT00003311|Drug|dexamethasone|
331787|NCT00413777|Drug|tolvaptan|30mg/15mg, 45mg/15mg, 60mg/30mg, 90mg/30mg tablets with the higher strength taken in the morning and the second dose 8 hours later. Split-dose regimens titrated weekly to maximally tolerated dose group. Maximum tolerated dose maintained up to 2 months.
331788|NCT00413790|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
331789|NCT00413790|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
331790|NCT00413790|Drug|Placebo|Placebo tablet once daily
331791|NCT00413803|Procedure|4-hour thrice weekly in center hemodialysis|conventional hemodialysis
331792|NCT00413803|Procedure|8-hour thrice weekly in center hemodialysis|long dialysis
331793|NCT00413829|Drug|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
338082|NCT00529529|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
338083|NCT00529542|Drug|Lipitor|40mg caplets per day for six weeks
338084|NCT00529542|Drug|Placebo|1 placebo caplet per day for six weeks.
338085|NCT00529555|Drug|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
338086|NCT00529555|Procedure|Scaling and root planing|scaling and root planing
338087|NCT00529568|Drug|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
338088|NCT00529568|Drug|placebo|double-blind matched placebo control daily oral administration
338089|NCT00529581|Drug|C105|
338090|NCT00529594|Drug|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
338091|NCT00529594|Drug|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
338092|NCT00003863|Genetic|fluorescence in situ hybridization|
338093|NCT00529607|Drug|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
338094|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
338417|NCT00521261|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
338418|NCT00521274|Biological|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
338419|NCT00524017|Biological|cetuximab|given IV
338420|NCT00524017|Procedure|standard follow-up care|Patients receive regular follow-up care
338421|NCT00003834|Drug|oxaliplatin|
338422|NCT00524030|Drug|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
338423|NCT00524030|Drug|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
337736|NCT00003907|Procedure|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
337737|NCT00537394|Drug|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
337738|NCT00537394|Drug|Etravirine|Two 100-mg tablets twice daily
337739|NCT00537394|Drug|Maraviroc|Dosage dependent on regimen in which maraviroc is included
337740|NCT00537407|Drug|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
337741|NCT00537407|Drug|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
337742|NCT00537407|Drug|Ribavirin|Ribavirin supplied as 200 mg tablets
337743|NCT00537420|Drug|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
337744|NCT00537420|Drug|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
337745|NCT00537420|Drug|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
337746|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
337747|NCT00003908|Drug|carboplatin|
337748|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
337749|NCT00537420|Drug|Sibutramine|Sibutramine will be taken once daily with or without food
337750|NCT00539994|Drug|Retapamulin|200mg BID retapamulin 5 days
337751|NCT00539994|Drug|Placebo|200mg BID placebo 5 days
337752|NCT00540007|Drug|Lenalidomide|
337753|NCT00540020|Other|Rehabilitation|
337754|NCT00540033|Dietary Supplement|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
337755|NCT00540033|Dietary Supplement|infloran|Study group was fed with infloran [Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)] and Bifidobacteria bifidum [(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)]; Laboratorio Farmaceutico S.I.T S.r.I ITALY] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
337024|NCT00419029|Behavioral|control|brief telephone check-in (no motivational interviewing)
337025|NCT00419042|Drug|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
337026|NCT00419042|Drug|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein—called intravenous infusion (IV). This will take about 30 minutes
337027|NCT00419055|Procedure|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
337028|NCT00419068|Drug|Cholecalciferol|
337029|NCT00419068|Drug|Migliol Placebo Oil|
337030|NCT00003341|Procedure|quality-of-life assessment|
337031|NCT00419081|Drug|Forodesine Hydrochloride Sterile Solution, 5 mg/mL|
337032|NCT00419081|Drug|Forodesine Hydrochloride Capsules (100 mg)|
337033|NCT00419094|Drug|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
337034|NCT00419094|Drug|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
337383|NCT00457366|Drug|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary upto a maximum dose of Quetiapine 600mg PO QD
337384|NCT00003517|Drug|leuprolide acetate|
337385|NCT00457366|Drug|Cocktail (Haloperidol, Lorazepam, Cogentin)|Haloperidol 5 mg im, Lorazepam 2 mg im, Cogentin 2 mg im; repeated at 2 hours as deemed clinically necessary
337386|NCT00457379|Behavioral|physical exercise|
337387|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
337388|NCT00457392|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
337389|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
337390|NCT00457392|Drug|placebo|Placebo daily by oral capsules in a continuous regimen
337391|NCT00457405|Drug|dipyridamole|dipyridamole 200mg twice daily
337392|NCT00457418|Drug|PEG-Intron|
337393|NCT00460356|Other|Laboratory Biomarker Analysis|Correlative studies
336292|NCT00436332|Biological|bevacizumab|
336293|NCT00436332|Drug|erlotinib hydrochloride|
336637|NCT00424697|Drug|placebo|
336638|NCT00424697|Drug|lorazepam|
336639|NCT00424697|Drug|GW876008|
336640|NCT00424710|Drug|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
336641|NCT00003377|Drug|cisplatin|
336642|NCT00424723|Drug|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
336643|NCT00424736|Procedure|whole body CT scan|
336644|NCT00424749|Drug|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m^2.
336645|NCT00424749|Drug|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
336646|NCT00427505|Drug|Deferasirox|
336647|NCT00427531|Other|physiologic testing|
336648|NCT00427544|Drug|PRA-027|
336649|NCT00427557|Drug|Fludarabine|30 mg/m^2 by vein for 4 Days (Day -10 through Day -7).
336650|NCT00427557|Drug|Melphalan|140 mg/m^2 by vein for 1 Day (Day -7).
336651|NCT00427557|Procedure|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
336652|NCT00427557|Drug|Rituximab|375 mg/m^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
336653|NCT00427557|Other|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
336654|NCT00427570|Biological|BCG vaccine|
336655|NCT00003388|Drug|pegylated liposomal doxorubicin hydrochloride|
336656|NCT00427570|Biological|biological therapy|
336657|NCT00427570|Drug|fluorouracil|
336658|NCT00427570|Drug|semustine|
335929|NCT00441766|Drug|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
335930|NCT00441766|Drug|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
335931|NCT00441766|Drug|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
335932|NCT00441766|Drug|placebo|Part A: placebo capsule every 12 hours for 4 weeks
335933|NCT00441792|Drug|Etomidate|Etomidate at induction dose based on weight
335934|NCT00444860|Biological|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
335935|NCT00444873|Drug|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
335936|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
335937|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
335938|NCT00444899|Behavioral|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
335939|NCT00444899|Other|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
335940|NCT00003444|Radiation|radiation therapy|
336294|NCT00003411|Radiation|radiation therapy|
336295|NCT00436345|Drug|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
336296|NCT00436345|Drug|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
336297|NCT00436358|Other|Not applicable: none|Please refer to the detailed description section
336298|NCT00436371|Drug|Amisulpride|Oral tablets
336299|NCT00436384|Procedure|Monitoring-blood samples drawn for CMV testing|
336300|NCT00436397|Radiation|radiation therapy|
336301|NCT00436410|Biological|colloidal gold-bound tumor necrosis factor|
335207|NCT00459537|Drug|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
335208|NCT00459537|Drug|amorolfine nail lacquer|5 % amorolfine nail lacquer
335209|NCT00415389|Behavioral|interactive educational program|2-session interactive stroke educational program
335564|NCT00450398|Drug|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
335565|NCT00450398|Drug|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
335566|NCT00450411|Radiation|brachytherapy|
335567|NCT00450411|Radiation|125-Iodine|
335568|NCT00453219|Procedure|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
335569|NCT00453219|Procedure|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
335570|NCT00453219|Genetic|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
335571|NCT00453219|Procedure|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
335572|NCT00453219|Procedure|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
335573|NCT00453232|Biological|bleomycin sulfate|
335574|NCT00453232|Biological|pegfilgrastim|
335575|NCT00453232|Drug|cisplatin|
335576|NCT00003498|Drug|antineoplaston A10|
335577|NCT00453232|Drug|etoposide|
335578|NCT00453258|Other|Eye Examination|Subjects receiving eye examination
335579|NCT00453271|Drug|NB-002|
335580|NCT00453271|Drug|Vehicle control|
334857|NCT00423865|Other|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
334858|NCT00423865|Other|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
334859|NCT00423865|Procedure|biopsy|"Pre-treatment Research Biopsy:" Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy:" Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day.
334860|NCT00003370|Drug|irofulven|
334861|NCT00423878|Drug|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
334862|NCT00423878|Drug|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
334863|NCT00423878|Drug|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
335210|NCT00415389|Behavioral|usual medical care|standard educational materials and usual care
335211|NCT00415402|Drug|Vitamin D3|
335212|NCT00415428|Behavioral|Patient adherence to national educational guidelines.|
335213|NCT00415441|Procedure|Physiotherapy program|
335214|NCT00003321|Procedure|psychosocial assessment and care|
335215|NCT00415441|Procedure|Placebo physiotherapy treatment|
335216|NCT00415454|Genetic|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
335217|NCT00415467|Device|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
335218|NCT00415493|Other|Cold-dry air provocation|15 minute exposure to cold-dry air by nasal mask
335219|NCT00415493|Other|Warm-moist air provocation|15 minute exposure to warm-moist air by nasal mask
335220|NCT00415506|Drug|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
329925|NCT00562120|Drug|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
329926|NCT00562120|Drug|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
329927|NCT00562133|Drug|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
329928|NCT00562133|Drug|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
329929|NCT00562146|Procedure|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
329930|NCT00562159|Drug|Placebo|Placebo sublingual tablet
329931|NCT00562159|Biological|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units [BAU] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
329932|NCT00562159|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
329933|NCT00000594|Drug|cholestyramine|
329934|NCT00004054|Drug|warfarin|To keep international normalized ratio (INR) > 1.5 and < 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
329935|NCT00562159|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
330215|NCT00554970|Drug|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
330216|NCT00000584|Drug|immunoglobulins|
330217|NCT00004010|Drug|cyclophosphamide|
330218|NCT00554970|Drug|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
330219|NCT00554983|Biological|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
330220|NCT00554983|Biological|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
330221|NCT00554996|Device|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
330222|NCT00555009|Drug|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
329284|NCT00574431|Other|Data Collection|Collection of patient data before implementation of a nutritional management protocol
329285|NCT00574431|Other|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
329612|NCT00566826|Behavioral|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
329613|NCT00566826|Behavioral|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
329614|NCT00566839|Procedure|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
329615|NCT00566839|Procedure|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
329616|NCT00566852|Drug|memantine hydrochloride|Given orally
329617|NCT00004080|Biological|recombinant adenovirus-p53 SCH-58500|
329618|NCT00566852|Other|placebo|Given orally
329619|NCT00566852|Radiation|radiation therapy|Patients undergo whole-brain radiotherapy (WBRT) 5 days a week for 3 weeks.
329620|NCT00566865|Drug|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
329621|NCT00566865|Drug|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
329622|NCT00566878|Biological|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
329623|NCT00566891|Drug|tirofiban|tirofiban high dose bolus 25µ/Kg
329624|NCT00566891|Drug|Clopidogrel|
329625|NCT00566904|Drug|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
329626|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|Multiple basal rates
329627|NCT00569465|Drug|Arginine|1200 mg, once a day
329628|NCT00569465|Drug|Acetylcysteine|600 mg twice a day
329629|NCT00569465|Drug|Placebo|3 vials a day
329630|NCT00569478|Other|rehabilitation|Nursing consultations and physical training
328980|NCT00581594|Procedure|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
328981|NCT00581607|Drug|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
328982|NCT00581607|Drug|Placebo|Placebo twice a day
328983|NCT00581607|Drug|Bosentan|drug given for 16 weeks
328984|NCT00581607|Drug|Placebo|placebo
328985|NCT00581620|Biological|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
328986|NCT00004145|Procedure|peripheral blood stem cell transplantation|
328987|NCT00581633|Other|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
328988|NCT00581646|Behavioral|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
329286|NCT00574444|Procedure|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
329287|NCT00574457|Other|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
329288|NCT00574470|Drug|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
329289|NCT00004107|Biological|filgrastim|as prescribed by physician
329290|NCT00574483|Drug|quinacrine|100 mg day
329291|NCT00574496|Drug|cyclophosphamide|
329292|NCT00574496|Drug|cyclosporine|
329293|NCT00574496|Drug|fludarabine phosphate|
329294|NCT00574496|Drug|gemcitabine hydrochloride|
328678|NCT00000161|Drug|Vitamin C|
328679|NCT00000610|Drug|magnesium|
328680|NCT00004172|Procedure|peripheral blood stem cell transplantation|
328681|NCT00587301|Device|Lap-Band|Obesity and adolescents
328682|NCT00587314|Other|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
328683|NCT00587327|Drug|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
328684|NCT00587327|Drug|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
328685|NCT00587327|Drug|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
328686|NCT00587353|Other|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
328687|NCT00587379|Drug|Atorvastatin|40 mg atorvastatin pill daily
328688|NCT00587379|Drug|placebo|40 mg pill per day
328689|NCT00587392|Device|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
328690|NCT00589862|Drug|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
328691|NCT00004181|Drug|cyclophosphamide|
328692|NCT00589875|Biological|AdV-tk|Single dose of 3x10e11 vector particles of AdV-tk delivered to the tumor bed after resection on day 0.
328693|NCT00589875|Drug|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
328694|NCT00589888|Drug|Intralipid 20%|Intralipid 20% IV continuous infusion at 20cc/hour for 8 hours
328695|NCT00589888|Drug|Intralipid 20%|Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours
328696|NCT00589888|Drug|Normal Saline|0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours
328697|NCT00589888|Dietary Supplement|32-gram oral fat load|oral liquid fat load prepared by the GCRC every 2 hours for 8 hours.
333512|NCT00417300|Behavioral|Client centered therapy (CCT)|CCT is an individual therapy. The therapist will talk to the adolescent and help her to discuss all of the thoughts and feelings she wishes to talk about. The therapist is an active listener and helps the child to clarify and understand her feelings and offer non-directive problem solving.
333513|NCT00417313|Device|periosteal electro-acupuncture (osteopuncture).|
333514|NCT00417326|Drug|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
333515|NCT00417326|Drug|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
333516|NCT00417339|Procedure|hemodialysis|individualised
333517|NCT00417352|Device|Brace|
333869|NCT00455403|Drug|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
333870|NCT00455403|Drug|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
333871|NCT00455416|Drug|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
333872|NCT00455416|Drug|Selenium (L-Selenomethionine),|100mcgx2 daily
333873|NCT00455416|Drug|Garlic extract (Allicin)|6 garlic pearls daily
333874|NCT00455416|Drug|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
333875|NCT00455416|Drug|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
333876|NCT00455416|Drug|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
333877|NCT00455429|Drug|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram [mg]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
333878|NCT00003512|Drug|antineoplaston A10|
333879|NCT00458822|Drug|bortezomib|Given IV
333880|NCT00458822|Drug|dexamethasone|Given orally
333881|NCT00458835|Drug|Ciclesonide|
333882|NCT00003521|Drug|antineoplaston AS2-1|
333883|NCT00458848|Drug|asparaginase|
333884|NCT00458848|Drug|daunorubicin hydrochloride|
333175|NCT00426023|Drug|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
333176|NCT00426023|Drug|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
333177|NCT00426036|Drug|Licarbazepine|
333178|NCT00426049|Drug|Everolimus|
333179|NCT00426075|Device|Elastic stockings|
333180|NCT00426101|Drug|Dexamethasone|Dexamethasone 10 mg/m2 daily, for the first 2 weeks (week 1-2).
Dexamethasone 5 mg/m2 daily, for another 2 weeks (week 3-4).
Dexamethasone 2.5 mg/m2 daily, for another 2 weeks (week 5-6)
Dexamethasone 1.25 mg/m2 daily, for another week (week 7). Steroids are tapered and discontinued during week 8.
If continuation therapy is provided, then:
- Dexamethasone pulses every second week, 10 mg/m2 for 3 days.
333181|NCT00426101|Drug|Etoposide|150 mg/m2 iv twice weekly (week 1-2).
150 mg/m2 iv once weekly (week 3-8).
If continuation therapy is provided, then:
- 150 mg/m2 iv, every second week.
333182|NCT00426101|Drug|Cyclosporin|WEEK 1-8:
- The blood levels determine the dosages, aim at levels around 200 microgram/L (trough value) (monoclonal antibody assay of whole blood). Start with 6 mg/kg daily (divided in 2 daily doses) already week 1, if kidney function is normal.
If continuation therapy is provided, then:
- Aim for blood levels around 200 microgram/L, as above. Monitor GFR.
333183|NCT00426101|Procedure|Intrathecal therapy|The CSF is evaluated at diagnosis and after 2 weeks. If after 2 weeks there is clinical evidence of progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, additional CNS-therapy is initiated with 4 weekly intrathecal injections. Be aware that some patients may have increased intracranial pressure.
Methotrexate: <1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, >3 yrs 12 mg.
Prednisolone: <1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, >3 yrs 10 mg.
333518|NCT00417352|Device|Added mass|
333519|NCT00417365|Device|WaterWorks Douching Device|
333520|NCT00417378|Device|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
333521|NCT00417378|Device|Intraaortic Balloon Pump|Counterpulsation
333522|NCT00003336|Biological|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
333523|NCT00417391|Drug|RR110 (Tamibarotene)|1 mg RR110
333524|NCT00417391|Drug|RR110 (Tamibarotene)|4 mg RR110
333525|NCT00417404|Drug|Aquasol A|IM Aquasol A 10,000IU three times weekly
333526|NCT00420654|Drug|Growth Hormone|1.25 mg, 6 months
332834|NCT00003406|Drug|carboplatin|
332835|NCT00434850|Drug|Tacrolimus|Maintenance immunosuppressive therapy
333184|NCT00426101|Procedure|Stem cell transplant|Suggested regimen:
Preparative Regimen
Day -8,-7,-6,-5 Busulfan 2mg/kg po, or eq iv (as 1.6mg/kg), twice daily.
Day -4 Etoposide 30 mg/kg iv (6 hr inf) (maximum 1800 mg)
Day -3, -2 Cyclophosphamide 60 mg/kg iv (1 hr inf)
Day 0 Marrow infusion (preferably ³3 x 108 nucleated cells/kg, non T-cell-depleted).
GVHD Prophylaxis:
CSA continuous infusion starting day -1 pre-transplant with 3 mg/kg until oral nutrition re-established, thereafter 12.5 mg/kg orally daily. Monitoring of CSA through concentration levels. The immunosuppression is discontinued after 6-12 months, if possible.
Short course methotrexate:
Day +1 15 mg/m2 iv
Day +3 10 mg/m2 iv
Day +6 10 mg/m2 iv Methotrexate may be substituted by mycophenolate mofetil (MMF).
Additional Treatment for URD
ATG (12 hr inf iv) on days -3, -2 and -1 (according to manufacturers rec).
Metronidazole 22 mg/kg daily (po or iv) from day -8 until discharge.
333185|NCT00003385|Drug|paclitaxel|
333186|NCT00429091|Drug|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
333187|NCT00429091|Drug|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
333188|NCT00000149|Drug|Beta Blocker|
333189|NCT00000514|Drug|atenolol|
333190|NCT00003392|Drug|melphalan|140 mg/m2 IV , approximately day 63
333191|NCT00429091|Drug|placebo|Subjects will take BID for up to four weeks
333192|NCT00429104|Drug|Herceptin|4 mg/kg IV Over 90 Minutes
333193|NCT00429104|Drug|GM-CSF|250 mcg/m^2 Subcutaneously
333194|NCT00429117|Behavioral|Survey|Internet survey lasting 30 to 40 minutes.
333195|NCT00429143|Radiation|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
333196|NCT00429143|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
333197|NCT00429143|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
333198|NCT00429143|Drug|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
333199|NCT00429143|Drug|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
333200|NCT00429143|Biological|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
333201|NCT00003392|Drug|paclitaxel|170 mg/m2 IV day 1
332475|NCT00443469|Device|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
332476|NCT00003437|Drug|dexamethasone|
332477|NCT00443469|Device|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
332478|NCT00443482|Drug|formoterol|
332479|NCT00443495|Drug|Chitin microparticles by nasal route|
332480|NCT00443508|Drug|adding Certican to therapy|
332481|NCT00443508|Drug|reducing Tacrolimus|
332482|NCT00443521|Drug|Triamcinolone Acetonide 4 mg intravitreal injection|
332483|NCT00443521|Procedure|Panretinal photocoagulation|
332484|NCT00446030|Drug|Docetaxel|75 mg/m^2 administered IV on Day 1 for Cycles 1-6
All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg).
332485|NCT00446030|Drug|Doxorubicin|50 mg/m^2 administered IV on Day 1 for Cycles 1-6
332486|NCT00446030|Drug|Carboplatin|6 mg/mL/min (target area under the curve [AUC] dose) administered IV on Day 1 for Cycles 1-6
332487|NCT00446030|Drug|Cyclophosphamide|500 mg/m^2 administered IV on Day 1 for Cycles 1-6
332836|NCT00437463|Drug|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
332837|NCT00437476|Drug|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
332838|NCT00437476|Drug|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
332839|NCT00437476|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
332840|NCT00437476|Drug|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
331794|NCT00413855|Procedure|laparoscopic appendectomy or not (surgery)|
331795|NCT00413868|Procedure|LASIK|
331796|NCT00413868|Procedure|PRK|
332143|NCT00451763|Drug|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
332144|NCT00451776|Drug|etomidate|patients who received etomidate
332145|NCT00451776|Drug|propofol|patients who received propofol
332146|NCT00451815|Drug|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
332147|NCT00000525|Drug|hydrochlorothiazide|
332148|NCT00003490|Biological|sargramostim|
332149|NCT00451815|Drug|placebo|
332150|NCT00451828|Drug|Simvastatin|40mg/day
332151|NCT00451841|Device|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
332152|NCT00451854|Procedure|Random, no advanced notice drug and alcohol testing|
332153|NCT00451867|Drug|Mycophenolate Mofetil|
332154|NCT00454649|Drug|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m^2) 60-minute infusion on Day 1 of each cycle.
332155|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
332156|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
332157|NCT00454649|Drug|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m^2) infusion on Day 1 of each cycle.
332158|NCT00454649|Drug|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m^2) 10-minute infusion followed by cisplatin (75 mg/m^2) infusion on Day 1 of each cycle.
338424|NCT00524043|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
338425|NCT00524043|Drug|Placebo|Once daily for 6 weeks
338426|NCT00524043|Drug|Paliperidone ER|6 mg tablet once daily for 6 weeks
338427|NCT00524056|Drug|Carisbamate|two 100 mg tablets twice per day
338428|NCT00524056|Drug|Placebo|two placebo tablets twice per day
338429|NCT00524069|Biological|bevacizumab|
338430|NCT00524069|Drug|capecitabine|
338431|NCT00524069|Drug|gemcitabine hydrochloride|
338432|NCT00003835|Drug|leucovorin calcium|Given IV
338433|NCT00524069|Other|flow cytometry|
338434|NCT00524069|Other|laboratory biomarker analysis|
338435|NCT00524069|Procedure|adjuvant therapy|
338436|NCT00524069|Procedure|computed tomography|
338437|NCT00524069|Procedure|neoadjuvant therapy|
338438|NCT00524095|Drug|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
338439|NCT00524095|Drug|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
338440|NCT00524121|Drug|erlotinib hydrochloride|Oral
338441|NCT00524121|Other|immunohistochemistry staining method|Correlative Study
338765|NCT00515970|Procedure|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
338766|NCT00515970|Procedure|Curettage|Curettage with a 7 mm ring curette with the "potato-peeler technique" (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining.
337756|NCT00003925|Drug|gemcitabine hydrochloride|
337757|NCT00540046|Device|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
337758|NCT00540072|Drug|daptomycin|
338095|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
338096|NCT00003876|Drug|polifeprosan 20 with carmustine implant|
338097|NCT00532298|Biological|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
338098|NCT00532298|Biological|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
338099|NCT00532311|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
338100|NCT00532311|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
338101|NCT00532324|Other|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
338102|NCT00532337|Drug|ONO-5334|Placebo - 24/mos.
338103|NCT00532337|Drug|ONO-5334|100mg QD /24 months
338104|NCT00532337|Drug|ONO-5334|50mg BID /24 mos.
338105|NCT00532337|Drug|ONO-5334|300mg QD /24 mos.
338106|NCT00532337|Drug|ONO-5334|Alendronate 70mg once weekly / 24 mos
338107|NCT00003876|Procedure|surgical procedure|
338108|NCT00532350|Drug|QAT370|
338109|NCT00532350|Drug|Placebo|
338110|NCT00532350|Drug|Tiotropium|
338111|NCT00532389|Drug|LBH589|
338112|NCT00532415|Drug|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
337394|NCT00460356|Procedure|Lymphadenectomy|Undergo lymphadenectomy
337395|NCT00460369|Drug|sulfadoxine-pyrimethamine|tablets 1,25/25 mg
1 tablet per 20 kg of body weight Single drug intake
337396|NCT00460369|Drug|artemether-lumefantrine|tablets 20/120 mg
1 tablet twice daily for 3 days below 15 kg of bodyweight
2 tablets twice daily for 3 days below 24 kg of bodyweight
3 tablets twice daily for 3 days below 35 kg of bodyweight
337397|NCT00460369|Drug|amodiaquine-artesunate coformulation|one 25mg/67,5mg tablet, once daily for 3 days below 9 kg
one 50/135mg tablet, once daily for 3 days below 18 kg
337398|NCT00460382|Drug|raltegravir potassium|400 mg twice a day
337399|NCT00460382|Drug|darunavir/ritonavir|2 pills of 300 mg twice a day
337400|NCT00460382|Drug|etravirine|2 pills of 100 mg twice a day
337401|NCT00460382|Drug|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
337402|NCT00003535|Drug|antineoplaston A10|
337403|NCT00460395|Procedure|Surgery|
337404|NCT00460395|Procedure|Stereotactic radiosurgery|
337405|NCT00460408|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
337406|NCT00460421|Drug|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
337759|NCT00540085|Drug|Rocuronium|0.6 mg/kg given intravenously before intubation
337760|NCT00540098|Drug|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
337761|NCT00540098|Drug|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
337762|NCT00540098|Drug|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
337763|NCT00540098|Drug|Placebo + relaxation|placebo pill once daily + regular relaxation training
337764|NCT00540111|Dietary Supplement|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
337765|NCT00540124|Drug|Tadalafil|5 mg once a day
337766|NCT00540124|Drug|Placebo|once a day
336659|NCT00427570|Drug|vincristine sulfate|
336660|NCT00427583|Drug|imatinib mesylate|
336661|NCT00427596|Drug|Solabegron|
336662|NCT00427609|Drug|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
337035|NCT00419120|Biological|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
337036|NCT00422097|Drug|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
337037|NCT00422097|Drug|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
337038|NCT00422097|Drug|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
337039|NCT00003358|Drug|chemotherapy|
337040|NCT00422110|Drug|Seletracetam|
337041|NCT00422123|Drug|Quetiapine fumarate (Seroquel) SR|
337042|NCT00422149|Drug|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
337043|NCT00422149|Drug|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
337044|NCT00422149|Drug|Placebo treatment|Placebo treatment
337045|NCT00422162|Drug|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
337046|NCT00422162|Drug|Placebo|placebo capsule by mouth
337047|NCT00422175|Drug|BAF 312|
337048|NCT00422188|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
337049|NCT00422188|Drug|Placebo|Administered via intralipomal injection.
337050|NCT00003358|Drug|cisplatin|
337051|NCT00422201|Drug|Mifepristone|Singe dose
336302|NCT00436410|Other|electron microscopy|
336303|NCT00436410|Other|pharmacological study|
336304|NCT00436410|Procedure|conventional surgery|
336305|NCT00000149|Procedure|Trabeculectomy|
336306|NCT00000518|Drug|quinidine|
336307|NCT00003412|Biological|recombinant interleukin-12|
336308|NCT00436423|Drug|gemcitabine, TS-1|
336309|NCT00436436|Drug|O6-benzylguanine|
336310|NCT00436436|Drug|temozolomide|
336311|NCT00436449|Drug|Avotermin|
336312|NCT00436475|Drug|Vitamin D3 2,000 IU orally once daily|Vitamin D3 2,000 IU orally once daily
336313|NCT00436475|Drug|Calcium Carbonate 400 mg orally twice daily|Calcium Carbonate 400 mg orally twice daily
336314|NCT00436475|Drug|Vitamin D3-Placebo|Vitamin D3-Placebo
336315|NCT00436475|Drug|Calcium-Placebo|Calcium-Placebo
336316|NCT00436501|Drug|docetaxel|25 mg/m^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
336317|NCT00436501|Biological|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
336318|NCT00003413|Biological|filgrastim|
336319|NCT00436501|Other|laboratory biomarker analysis|Correlative studies
336663|NCT00427622|Other|physiologic testing|
336664|NCT00427635|Drug|Esomeprazole|
336665|NCT00427648|Drug|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
336666|NCT00003388|Drug|prednisone|
336667|NCT00427648|Drug|placebo|normal saline
335581|NCT00453297|Drug|MF101|
335582|NCT00453310|Drug|sunitinib malate|
335583|NCT00453323|Drug|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
335584|NCT00453323|Drug|Capecitabine|capecitabine 900mg/m2 bid po on day 1~14, 1 weeks rest, until disease progression
335585|NCT00453336|Drug|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
335941|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
335942|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5*10^6 CD34+ cells/kg were collected.
335943|NCT00444912|Biological|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
335944|NCT00444925|Drug|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
335945|NCT00444925|Drug|placebo|once daily (OD)for 12 weeks
335946|NCT00444925|Drug|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
335947|NCT00444938|Device|H1 -coil TMS device|
335948|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
335949|NCT00444951|Biological|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
335950|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
335951|NCT00003445|Drug|docetaxel|
335952|NCT00444964|Drug|Nutropin AQ|
335953|NCT00444977|Behavioral|Case-management linkage intervention|dental care
335221|NCT00415519|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
335222|NCT00415519|Drug|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
335223|NCT00415532|Drug|Medical Standard of Care for ITP|
335224|NCT00415532|Biological|Romiplostim|
335225|NCT00003321|Procedure|quality-of-life assessment|
335226|NCT00415545|Behavioral|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
335227|NCT00415545|Behavioral|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
335228|NCT00415558|Device|Microwave Ablation System|
335229|NCT00415571|Drug|Fispemifene (once daily for 8 weeks)|
335230|NCT00415584|Drug|Cinacalcet HCl|
335586|NCT00453336|Procedure|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
335587|NCT00000525|Behavioral|diet, magnesium supplementation|
335588|NCT00003498|Drug|antineoplaston AS2-1|
335589|NCT00453349|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
335590|NCT00453349|Drug|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
335591|NCT00453362|Other|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
335592|NCT00453362|Other|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
335593|NCT00453362|Drug|erlotinib HCl|Tablets taken orally 150 mg/day.
330223|NCT00555009|Drug|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
330224|NCT00555022|Drug|GSK1160724|
330225|NCT00555035|Drug|GSK1349572|
330226|NCT00555048|Biological|alemtuzumab|
330227|NCT00555048|Drug|busulfan|
330228|NCT00004010|Drug|dacarbazine|
330229|NCT00555048|Drug|cyclophosphamide|
330230|NCT00555048|Drug|methotrexate|
330231|NCT00555048|Drug|tacrolimus|
330232|NCT00555048|Procedure|allogeneic hematopoietic stem cell transplantation|
330233|NCT00555048|Procedure|peripheral blood stem cell transplantation|
330234|NCT00555061|Drug|Retapamulin Ointment, 1%|1% Ointment
330235|NCT00555074|Drug|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
330236|NCT00555074|Drug|Placebo|Placebo, BID, oral route during 6 weeks
330237|NCT00555087|Drug|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
330238|NCT00555100|Drug|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
330239|NCT00004010|Drug|doxorubicin hydrochloride|
330518|NCT00588107|Behavioral|print materials|tailored print materials designed to aid in smoking reduction and cessation
330519|NCT00588120|Drug|C-13 labeled oxalate|A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.
Take one capsule by mouth for one day.
330520|NCT00588133|Drug|tranexamic acid|Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr
Renal Insufficiency (normal loading dose and prime dose):
Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = >6.6: reduce infusion to 1.5 mg/kg/hr
330521|NCT00588133|Drug|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
330522|NCT00588146|Drug|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
329631|NCT00569491|Device|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
329632|NCT00569517|Behavioral|CBT|6-CBT based sesions
329633|NCT00569517|Other|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
329634|NCT00569530|Drug|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14.
329635|NCT00000599|Drug|niacin|
329936|NCT00562159|Drug|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
329937|NCT00562159|Drug|Prednisone 5 mg Rescue Treatment|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day
(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray.
329938|NCT00562159|Drug|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
329939|NCT00562159|Drug|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
329940|NCT00562159|Drug|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
329941|NCT00562172|Drug|Insulin glargine|Once daily in the morning
329942|NCT00564564|Drug|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
329943|NCT00564564|Drug|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
329944|NCT00564577|Other|CS17 expressing ETEC strain|Wild type ETEC strain expressing the colonization factor CS17, and LT enterotoxin
329945|NCT00564590|Drug|Melatonin|4 mg of Melatonin once a day for 3 months
329946|NCT00564590|Other|omeprazole|omeprazole 20 mg once a day
329947|NCT00564590|Drug|Placebo|Placebo once a day
329948|NCT00564603|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
329295|NCT00576927|Drug|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
329296|NCT00576927|Drug|Placebo|
329297|NCT00576940|Drug|Reconvan|isocaloric, immunomodulating entral diet
329298|NCT00576940|Drug|Peptisorb|isocaloric, isopeptic standard diet
329299|NCT00576979|Drug|cyclophosphamide|Given IV
329300|NCT00576979|Drug|etoposide|Given IV
329301|NCT00576979|Procedure|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
329302|NCT00576979|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
329303|NCT00004124|Drug|mitoxantrone hydrochloride|
329304|NCT00576979|Procedure|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
329305|NCT00576979|Radiation|intensity-modulated radiation therapy|Undergo IMRT
329306|NCT00576979|Radiation|tomotherapy|Undergo IMRT using helical tomotherapy
329307|NCT00577005|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
329636|NCT00004089|Drug|fluorouracil|
329637|NCT00569530|Drug|Infasurf (ONY Inc.)|Infants will not receive additional doses of Infasurf.
329638|NCT00569543|Other|high performance liquid chromatography|urine analysis
329639|NCT00569543|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
329640|NCT00569543|Other|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
329641|NCT00569543|Other|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
328989|NCT00581672|Behavioral|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
328990|NCT00581685|Drug|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
328991|NCT00581711|Other|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
328992|NCT00581711|Other|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
328993|NCT00581711|Other|1-part intervention|Provision of feedback on otitis media quality indicators
328994|NCT00581724|Behavioral|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
328995|NCT00581750|Other|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
328996|NCT00581776|Drug|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
328997|NCT00000607|Device|Left ventricular assist device|A type of implantable heart pump
328998|NCT00004146|Radiation|radiation therapy|Undergo radiotherapy
328999|NCT00581776|Drug|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
329000|NCT00581776|Drug|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
329001|NCT00584428|Procedure|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
329002|NCT00584454|Biological|Q-Fever Vaccine, NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
329003|NCT00584480|Other|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
329004|NCT00584493|Drug|CP-675,206|This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma
Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206.
333885|NCT00458848|Drug|etoposide|
333886|NCT00458848|Drug|idarubicin|
333887|NCT00458848|Drug|imatinib mesylate|
333888|NCT00458848|Drug|mercaptopurine|
333889|NCT00458848|Drug|methotrexate|
333890|NCT00458848|Drug|methylprednisolone|
333891|NCT00458848|Drug|mitoxantrone hydrochloride|
333892|NCT00458848|Drug|prednisone|
333893|NCT00003522|Drug|antineoplaston A10|
333894|NCT00458848|Drug|vincristine sulfate|
333895|NCT00458848|Procedure|allogeneic hematopoietic stem cell transplantation|
328698|NCT00589888|Dietary Supplement|64-gram oral fat load|60-gram oral fat load intake every 2 hours for 8 hours
328699|NCT00589901|Drug|capecitabine and cyclophosphamide|capecitabine 1000 mg/m2 oral Bid d1-14
cyclophosphamide 65 mg/m2 oral Qd d1-14
328700|NCT00589914|Drug|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
328701|NCT00589914|Drug|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
328702|NCT00004181|Procedure|allogeneic bone marrow transplantation|
328703|NCT00589927|Drug|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
328704|NCT00589927|Drug|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
328705|NCT00589953|Drug|Erythropoietin|5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.
The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour.
328706|NCT00589953|Drug|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
333527|NCT00420654|Drug|Placebo|Equivalent to 1.25 mg, 6 months
333528|NCT00420654|Other|Healthy controls|Healthy controls
333529|NCT00420667|Drug|Enoxaparin|
333530|NCT00420680|Drug|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
333531|NCT00003350|Drug|paclitaxel|Given IV
333532|NCT00420680|Drug|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
333533|NCT00420680|Drug|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
333534|NCT00420693|Drug|sevoflurane|
333535|NCT00420706|Drug|SCA-136|
333536|NCT00420719|Device|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
333537|NCT00420732|Biological|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
333538|NCT00420745|Biological|Rotarix™|Two-dose oral vaccination.
333539|NCT00420745|Biological|Placebo|Two-dose oral administration
333540|NCT00420758|Dietary Supplement|Food supplement: fortified spread|Provision of fortified spread
333541|NCT00420758|Dietary Supplement|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
333542|NCT00003350|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
333896|NCT00458848|Procedure|autologous hematopoietic stem cell transplantation|
333897|NCT00458848|Procedure|peripheral blood stem cell transplantation|
333898|NCT00458848|Radiation|radiation therapy|
333899|NCT00458861|Biological|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
333900|NCT00458861|Other|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
333202|NCT00429156|Device|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
333203|NCT00429156|Device|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
333204|NCT00429169|Drug|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
333543|NCT00420771|Drug|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
333544|NCT00420784|Drug|Telaprevir|tablet
333545|NCT00420784|Drug|Ribavirin|tablet
333546|NCT00420784|Drug|Pegylated Interferon Alfa 2a|Solution for injection
333547|NCT00420784|Drug|Matching Placebo|Tablet
333548|NCT00420797|Drug|10% Phenylephrine hydrochloride gel|
333549|NCT00420810|Drug|MK0928 / Duration of Treatment : 8 Weeks|
333550|NCT00420823|Drug|Taurine 4g|
333551|NCT00420836|Drug|Tobramycin|
333552|NCT00420849|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
333553|NCT00003350|Other|laboratory biomarker analysis|Correlative studies
333554|NCT00423501|Drug|taspoglutide|20mg sc weekly
333555|NCT00003365|Drug|quercetin|
333556|NCT00423501|Drug|taspoglutide|10mg sc every 2 weeks
333557|NCT00423501|Drug|taspoglutide|5mg sc weekly
333558|NCT00423501|Drug|taspoglutide|10mg sc weekly
333559|NCT00423501|Drug|taspoglutide|20mg sc every 2 weeks
333560|NCT00423514|Biological|filgrastim|
332841|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
332842|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
332843|NCT00437502|Biological|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
332844|NCT00437502|Biological|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
332845|NCT00000519|Behavioral|diet, reducing|
332846|NCT00003416|Drug|melphalan|
332847|NCT00437541|Device|Insulation retrofitted into house|
332848|NCT00437554|Drug|Glimepiride|
332849|NCT00437567|Dietary Supplement|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
332850|NCT00437567|Other|Placebo|Similar quantity of sterile water to be added to milk
332851|NCT00437580|Drug|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
332852|NCT00437593|Procedure|ppVE, MP, ICG|surgery with ILM staining
332853|NCT00437593|Procedure|ppVE, MP, MB|Surgery with ERM staining
332854|NCT00437606|Drug|GK Activator (2)|100mg po
332855|NCT00437606|Drug|Ethanol|40g po
332856|NCT00437619|Drug|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.
332857|NCT00003416|Procedure|peripheral blood stem cell transplantation|
332858|NCT00437632|Drug|GSK598809/Placebo|
332859|NCT00437645|Drug|Valsartan 160 mg capsules|
333205|NCT00429169|Drug|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
333206|NCT00429182|Drug|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
332159|NCT00454662|Drug|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
332160|NCT00454662|Drug|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
332161|NCT00454688|Drug|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
332488|NCT00446030|Drug|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
332489|NCT00446030|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
332490|NCT00446043|Drug|Adapalene/Benzoyl Peroxide|
332491|NCT00446056|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
332492|NCT00003455|Drug|antineoplaston A10|
332493|NCT00446056|Drug|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
332494|NCT00446069|Drug|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
332495|NCT00446082|Drug|Pasireotide|
332496|NCT00446095|Drug|fostamatinib|200 mg PO BID
332497|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
332498|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
332499|NCT00446134|Drug|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
332500|NCT00446134|Drug|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
332501|NCT00446147|Drug|Pyridoxine|100mg BID/daily, Per oral
338767|NCT00515983|Biological|DC/Apo-Nec|
338768|NCT00516009|Drug|DEXAMETHASONE|
338769|NCT00516009|Other|PLACEBO|
338770|NCT00516022|Drug|Mistletoe extract|The drug will be administered 3 times a week at home.
338771|NCT00518726|Biological|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
338772|NCT00518739|Drug|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 & beyond).
338773|NCT00518752|Procedure|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
338774|NCT00518752|Procedure|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
338775|NCT00518765|Drug|Aliskiren|
338776|NCT00518765|Drug|Aliskiren plus placebo|
338777|NCT00518765|Drug|Aliskiren|
338778|NCT00518765|Drug|Aliskiren plus placebo|
338779|NCT00518791|Other|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
338780|NCT00003810|Drug|docetaxel|
338781|NCT00518791|Other|Usual Care|No altered organisation of care
338782|NCT00518804|Behavioral|Functional Behavioural Skills Group and Parent Training|
338783|NCT00518830|Other|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
338784|NCT00518830|Other|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
339108|NCT00510536|Drug|Acetaminophen|dose to be determined by investigator
339109|NCT00510536|Drug|NSAID|dose to be determined by investigator
339110|NCT00510549|Procedure|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
338113|NCT00532428|Drug|Raloxifene|60 mg QD
338114|NCT00532428|Drug|Raloxifene|120 mg QD
338115|NCT00532428|Drug|Placebo|Placebo
338116|NCT00532441|Drug|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
338117|NCT00532441|Drug|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
338118|NCT00003876|Radiation|iodine I 125|
338442|NCT00524121|Radiation|radiation therapy|Radiation Treatment
338443|NCT00003835|Drug|fluorouracil|Given IV
338444|NCT00524134|Drug|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
338445|NCT00524147|Procedure|Pigtail drainage|
338446|NCT00524160|Drug|Fentanyl transdermal patch|
338447|NCT00524173|Drug|Tenofovir/ & amp; Emtricitabine|
338448|NCT00524173|Drug|Tenofovir|
338449|NCT00524186|Drug|fluorouracil|Given IV
338450|NCT00524186|Drug|irinotecan hydrochloride|Given IV
338451|NCT00527007|Other|External cooling|External cooling
338452|NCT00527020|Drug|active Comparator Nicotine|
338453|NCT00527020|Drug|GSK1018921|
338454|NCT00003853|Drug|4'-iodo-4'-deoxydoxorubicin|
338455|NCT00527033|Drug|YM178|Oral
338456|NCT00527033|Drug|Placebo|Oral
338457|NCT00527046|Drug|CP-424,391|
338458|NCT00527059|Drug|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
338459|NCT00527059|Drug|spironolactone, beta-blockers,ecc|
337767|NCT00003925|Drug|leucovorin calcium|
337768|NCT00540124|Drug|Tamsulosin|0.2 mg once a day
337769|NCT00540137|Drug|nevirapine|400mg once daily
337770|NCT00540137|Drug|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
337771|NCT00540150|Biological|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
337772|NCT00540176|Drug|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
337773|NCT00540189|Procedure|Initial appendectomy|
337774|NCT00540189|Procedure|Interval appendectomy|
337775|NCT00540202|Drug|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
337776|NCT00540202|Drug|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
337777|NCT00540215|Other|Glucagonlike peptide|450 nmol native form, synthetic
337778|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
337779|NCT00003935|Radiation|radiation therapy|
337780|NCT00542633|Drug|VIAject™|Dosage as individually required
337781|NCT00542633|Drug|Regular Human Insulin|Dosage as individually required
337782|NCT00542646|Procedure|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
338119|NCT00532454|Drug|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
338120|NCT00532467|Drug|SRX251|
338121|NCT00532480|Drug|Duloxetine|60 mg capsules
338122|NCT00534976|Drug|Comparator: Comparator: placebo (unspecified)|Patients 4-5 years: 4 mg Pbo chewable tablet daily
Patients 6-14 years: 5 mg Pbo chewable tablet daily
338123|NCT00534989|Procedure|FDG PET|FDG PET
338124|NCT00535002|Drug|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
337052|NCT00422214|Drug|Quetiapine fumarate (Seroquel) SR|
337053|NCT00422227|Drug|Etanercept , Methotrexate|Etanercept: 25 mg twice weekly over 16 weeks, SC
Methotrexate: > 7.5 mg/week and no more than 25 mg/week, PO
337054|NCT00422227|Drug|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO
Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO
Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day
Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily
337055|NCT00422240|Drug|Adapalene/Benzoyl Peroxide|
337056|NCT00422253|Behavioral|dietary intervention|
337057|NCT00422266|Drug|Omega 3 fatty acids and plant sterol enriched drink|
337407|NCT00460421|Radiation|Total Body irradiation|
337408|NCT00460421|Drug|Chemotherapy|High dose etoposide, Cyclophosphamide
337409|NCT00460434|Device|TVT|Prophylactic TVT
337410|NCT00460434|Other|Sham|Sham TVT
337411|NCT00460447|Drug|Gemtuzumab Ozogamicin|
337412|NCT00460460|Drug|AZD4877|
337413|NCT00003535|Drug|antineoplaston AS2-1|
337414|NCT00460473|Drug|Dexmedetomidine|
337415|NCT00460473|Drug|Placebo|
337416|NCT00460486|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
337417|NCT00460499|Drug|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
337418|NCT00460499|Drug|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
337419|NCT00460499|Drug|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
337420|NCT00460512|Drug|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
337421|NCT00003326|Drug|paclitaxel|
336668|NCT00427661|Drug|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
336669|NCT00427674|Drug|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
336670|NCT00427687|Drug|AGG-523|
336671|NCT00427700|Drug|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
336672|NCT00427700|Drug|raloxifene|100mg PO on days 5-9 of the menstrual cycle
336673|NCT00427713|Drug|capecitabine|
336674|NCT00427713|Drug|oxaliplatin|
336675|NCT00427713|Procedure|adjuvant therapy|
336676|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
336677|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
336678|NCT00003397|Drug|cisplatin|
336679|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
336680|NCT00430534|Biological|EBV vaccine (268664)|
336681|NCT00430547|Drug|Carbimazole, radio-active iodine (I131)|
336682|NCT00430560|Behavioral|cognitive rehabilitation|computer training
336683|NCT00430560|Procedure|work therapy|opportunity to work in carefully supervised hospital job
336684|NCT00430560|Behavioral|work therapy|work therapy
336685|NCT00430573|Drug|D-cycloserine|Single dosage prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
336686|NCT00430573|Drug|Placebo|Single dosage prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
337058|NCT00422266|Dietary Supplement|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
337059|NCT00422279|Device|Implant|Bone inductive implant
335954|NCT00444990|Device|Magnetic Flex Pad|
335955|NCT00003461|Procedure|surgical procedure|
335956|NCT00447603|Drug|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
335957|NCT00447603|Drug|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
335958|NCT00447603|Drug|Placebo for Losartan|
335959|NCT00447603|Drug|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
335960|NCT00447629|Drug|PPM-204|
336320|NCT00436501|Other|pharmacological study|Correlative studies
336321|NCT00436514|Behavioral|diet and absorption of ColoPEG|4l of PEG during 2 days
336322|NCT00436514|Procedure|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
336323|NCT00439153|Device|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
336324|NCT00439166|Drug|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
336325|NCT00000519|Behavioral|diet, fat-restricted|
336326|NCT00003422|Drug|leucovorin calcium|
336327|NCT00439166|Drug|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
336328|NCT00439166|Drug|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
336329|NCT00439166|Drug|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
336330|NCT00439179|Drug|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
336331|NCT00439179|Drug|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
336332|NCT00439179|Drug|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
336333|NCT00439179|Drug|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
336334|NCT00439192|Drug|ELB245|
336335|NCT00439192|Drug|Tolterodine|
335594|NCT00456092|Drug|CC-10004|20mg CC-10004 twice a day orally following dose titration)
335595|NCT00456092|Drug|CC-10004|40 mg CC-10004 QD following dose titration
335596|NCT00456092|Drug|Matching Placebo|: Placebo identical to CC-10004 orally BID or QD following dose titration
335597|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
335598|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
335599|NCT00456105|Behavioral|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
335600|NCT00003514|Procedure|biologically based therapies|
335601|NCT00456131|Behavioral|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
335602|NCT00456144|Drug|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
335603|NCT00456157|Drug|Intra-articular Injection of OP-1 to affected knee|
335604|NCT00456170|Procedure|Performing Vaginal hysterectomy with Harmonic Scalpel|
335605|NCT00456183|Biological|MVA 85A|
335606|NCT00456222|Behavioral|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
335607|NCT00456235|Drug|Mycophénolate Mofétil|
335961|NCT00447642|Drug|LX201|LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.
LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
335962|NCT00447642|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
335963|NCT00447655|Behavioral|Self-management and peer support|
335964|NCT00447668|Behavioral|Yoga|Yoga for back pain
335965|NCT00447668|Behavioral|Exercise|exercises for back pain
335966|NCT00003461|Radiation|astatine At 211 monoclonal antibody 81C6|
330523|NCT00588146|Other|Standard care|Standard care
330524|NCT00588159|Drug|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
330525|NCT00588159|Drug|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
330526|NCT00004174|Radiation|radiation therapy|
330527|NCT00588172|Drug|Metformin|1000mg bid for 1 week
330528|NCT00588185|Drug|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
330529|NCT00588211|Behavioral|Interviews|45-minute individual interviews after the conclusion of their dental appointment
330530|NCT00588211|Behavioral|focus group|A focus group of the preliminary cancer-related risk perception item pool.
330531|NCT00588211|Behavioral|Survey|Quantitative item analysis of the final item pool.
330532|NCT00590785|Drug|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
330533|NCT00004186|Drug|topotecan hydrochloride|
330859|NCT00457431|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
330860|NCT00457444|Drug|Pollen|
330861|NCT00000526|Drug|moricizine|
330862|NCT00003517|Procedure|alternative product therapy|
330863|NCT00457457|Drug|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
330864|NCT00457457|Drug|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (>80 fold) compared to sildenafil (~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
329949|NCT00564603|Other|0.9% Saline|Saline, in same volume of 2mL
329950|NCT00564616|Device|video cell phone|the "voice group" received voice CPR instruction via a voice-only cell phone, and the "video group" received interactive voice and video instruction via a video cell phone
329951|NCT00564629|Drug|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
329952|NCT00004066|Biological|filgrastim|
329953|NCT00564629|Drug|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
329954|NCT00564629|Biological|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
330240|NCT00555100|Drug|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
330241|NCT00555126|Device|Forced Air Warming|Warming after Randomization
330242|NCT00557401|Drug|Placebo|After the washout period, subjects will be randomized to receive placebo or XP19986 SR study treatments. XP19986 Sustained Release (SR) Tablet will be dosed orally, QD or BID, for approximately 32 days with titration and taper periods
330243|NCT00557427|Drug|hypericum|250mg tablets twice daily for 8 weeks
330244|NCT00557427|Drug|fluoxetine|20mg - 40mg daily for 8 weeks
330245|NCT00557440|Drug|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
330246|NCT00557440|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
330247|NCT00557440|Drug|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
330248|NCT00557440|Drug|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
330249|NCT00004026|Drug|CT-2584|
330250|NCT00557453|Drug|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
330251|NCT00557453|Drug|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
330252|NCT00557466|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
329642|NCT00569556|Other|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
329643|NCT00569569|Drug|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
329644|NCT00569582|Drug|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
329645|NCT00569595|Behavioral|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
329646|NCT00569595|Behavioral|Fighting Cancer with Advice|Patient health counseling program by lay health educators entitled "Fighting Cancer with Advice."
329647|NCT00004089|Drug|hydroxyurea|
329648|NCT00569608|Other|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
329649|NCT00569621|Drug|Moxaverine|intravenous administration
329650|NCT00569621|Drug|physiological saline|intravenous administration
329651|NCT00571974|Device|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
329652|NCT00571974|Drug|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
329653|NCT00571974|Procedure|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
329654|NCT00571987|Device|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
329655|NCT00004095|Drug|irinotecan hydrochloride|
329955|NCT00564642|Drug|N Acetylcysteine|1200 mg, BD, 2weeks
329956|NCT00564655|Procedure|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
329957|NCT00564655|Procedure|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
329005|NCT00584519|Other|non-interventional|non-interventional
329006|NCT00584532|Drug|Placebo|10 Placebo Capsules taken orally every day.
329308|NCT00577018|Drug|Prucalopride|4 mg o.d.
329309|NCT00577018|Drug|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
329310|NCT00577018|Other|Placebo|o.d.
329311|NCT00577031|Drug|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
329312|NCT00577031|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
329313|NCT00577031|Drug|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
329314|NCT00004124|Drug|prednisone|
329315|NCT00577057|Procedure|Conventional Radiotherapy|
329316|NCT00577057|Procedure|Accelerated Radiotherapy|
329317|NCT00577057|Drug|Cisplatin|
329318|NCT00577057|Drug|5-fluorouracil|
329319|NCT00577057|Drug|Capecitabine|
329320|NCT00577070|Device|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
329321|NCT00579189|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
329322|NCT00579202|Device|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
329323|NCT00579215|Behavioral|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
328707|NCT00589966|Behavioral|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
328708|NCT00589966|Behavioral|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
328709|NCT00589979|Drug|Lidoderm (Lidocaine 5% Patch)|Topical Patch
328710|NCT00589979|Drug|Placebo Patch|Topical Patch
328711|NCT00551707|Drug|dipyridamole|dipyridamole 360 mg
328712|NCT00551707|Drug|placebo|placebo
328713|NCT00551707|Drug|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
328714|NCT00003994|Procedure|therapeutic conventional surgery|Undergo surgical resection
328715|NCT00551720|Behavioral|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
329007|NCT00584532|Drug|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
329008|NCT00584558|Procedure|Catheter Ablation|Catheter Ablation of arrhythmias
329009|NCT00584571|Procedure|Sensory Adaptation Training with Barostat|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
329010|NCT00584571|Drug|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
329011|NCT00004161|Drug|fenretinide|
329012|NCT00584584|Drug|QAX576|
329013|NCT00584584|Drug|Placebo|
329014|NCT00584597|Drug|Saline|Saline Control
329015|NCT00584597|Drug|Traumeel S|Traumeel S 1 mL
329016|NCT00584597|Drug|Traumeel S|Traumeel S 2mL
329017|NCT00584597|Drug|Traumeel S|Traumeel S 3mL
333901|NCT00458874|Behavioral|CIMT results|Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison "normal" scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. "Interpreting Your CIMT Results" tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial.
333902|NCT00458887|Procedure|management of therapy complications|Undergo hearing tests
333903|NCT00458900|Drug|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
333904|NCT00003522|Drug|antineoplaston AS2-1|
333905|NCT00458913|Drug|bortezomib|
333906|NCT00458913|Drug|cisplatin|
333907|NCT00458952|Drug|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
333908|NCT00458978|Drug|Cediranib Maleate|Given orally
333909|NCT00414869|Drug|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets BID PC x 16 days
333910|NCT00414869|Drug|Placebo|Inactive powder matching NCX-1000
333911|NCT00414908|Drug|Pancrelipase delayed release capsule|24,000 unit capsule
333912|NCT00414908|Drug|Placebo Comparator|Placebo
333913|NCT00414921|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
333914|NCT00003316|Drug|gemcitabine hydrochloride|
333915|NCT00414921|Drug|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
333916|NCT00414921|Other|placebo|inactive substance
333917|NCT00414947|Drug|Vildagliptin (LAF237)|
333918|NCT00414960|Drug|enzastaurin|500 mg, daily, oral, 6 months
328716|NCT00551720|Behavioral|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
328717|NCT00551733|Drug|carboplatin|Given IV
328718|NCT00551733|Drug|paclitaxel|Given IV
333561|NCT00423514|Drug|clofarabine|
333562|NCT00423514|Drug|melphalan|
333563|NCT00423514|Drug|mycophenolate mofetil|
333564|NCT00423514|Drug|tacrolimus|
333565|NCT00423514|Drug|thiotepa|
333566|NCT00003365|Drug|sulindac|
333567|NCT00423514|Procedure|allogeneic bone marrow transplantation|
333568|NCT00423514|Procedure|allogeneic hematopoietic stem cell transplantation|
333919|NCT00414960|Drug|placebo|oral, daily
333920|NCT00414973|Drug|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
333921|NCT00414973|Drug|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
333922|NCT00414986|Behavioral|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
333923|NCT00414986|Behavioral|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
333924|NCT00414986|Behavioral|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
333925|NCT00003317|Drug|carboplatin|
333926|NCT00414999|Drug|TG100801|
333927|NCT00415025|Procedure|adjuvant therapy|
333928|NCT00415025|Procedure|management of therapy complications|
333929|NCT00415025|Procedure|quality-of-life assessment|
333930|NCT00415025|Radiation|intensity-modulated radiation therapy|
333931|NCT00415038|Drug|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
333932|NCT00415038|Drug|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
333207|NCT00429182|Drug|Cyclophosphamide|1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
333208|NCT00429182|Drug|Thiotepa|120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
333209|NCT00429182|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0.
333210|NCT00429195|Behavioral|Dietary Fatty Acid Modification|
333211|NCT00429208|Drug|Nicotine|
333212|NCT00003392|Procedure|bone marrow ablation with stem cell support|
333213|NCT00429221|Behavioral|Tailored Medication Messages for Parents|
333214|NCT00432094|Drug|Mesna|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
333215|NCT00432094|Biological|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
333216|NCT00003399|Drug|etoposide|
333217|NCT00432107|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
333218|NCT00432120|Drug|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
333219|NCT00432133|Behavioral|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
333220|NCT00432133|Behavioral|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
333221|NCT00432146|Drug|lugol's solution|
333222|NCT00432159|Device|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
333223|NCT00432159|Device|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
333224|NCT00432172|Drug|Standard treatment|EC x 4 -> Tx4
333225|NCT00432172|Drug|Selective treatment|Postmenopausic patients: exemestane x 6 months; Premenopausic Patients: goserelin x 6 months + exemestane x 6 months
333226|NCT00432172|Drug|Standard treatment|ECx4-> Tx4
332502|NCT00446147|Drug|Placebo|placebo 100mg BID/daily, Per oral
332503|NCT00003455|Drug|antineoplaston AS2-1|
332504|NCT00446173|Drug|Busulfan|130 mg/m^2 IV Daily Over 3 Hours x 4 Days
332505|NCT00446173|Drug|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
332506|NCT00446173|Drug|G-CSF|10 mcg/kg Subcutaneously Once Daily
332507|NCT00449059|Drug|acute infusion of nitroglycerine into the pulmonary artery|
332508|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
332860|NCT00437645|Drug|Amlodipine 5 mg capsules|
332861|NCT00437645|Drug|placebo|capsules
332862|NCT00437658|Drug|NBI-56418|NBI-56418 is a novel GnRH antagonist being studied for the management of pain associated with endometriosis.
332863|NCT00437658|Drug|depo-subQ provera 104|Depo-subQ provera 104 is indicated for the management of pain associated with endometriosis.
332864|NCT00440362|Biological|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
332865|NCT00003425|Drug|cyclophosphamide|
332866|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
332867|NCT00440362|Biological|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
332868|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
332869|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the IM route
332870|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the SC route
332871|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
332872|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
332873|NCT00440375|Drug|Rosiglitazone|
332874|NCT00440388|Drug|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
339111|NCT00510562|Procedure|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
339112|NCT00510562|Procedure|Sham/Placebo|A laying on of hands with no treatment being performed.
339113|NCT00510575|Device|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
339114|NCT00003771|Drug|norethindrone acetate|
339115|NCT00510588|Other|training|regular physical exercise training for 6 months
339116|NCT00510588|Other|training + metformin|regular physical exercise training in combination with metformin for 6 months
339117|NCT00510588|Other|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
339118|NCT00510601|Device|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
339119|NCT00510614|Drug|tinidazole|1 gram twice weekly for 12 weeks
339120|NCT00510614|Drug|Placebo|one pill twice weekly for 12 weeks
339121|NCT00510627|Device|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
339122|NCT00510627|Drug|Chemotherapy|Standard of care chemotherapy regimen
339123|NCT00510640|Drug|Sunitinib|Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
339124|NCT00003783|Drug|idarubicin|
339125|NCT00513383|Drug|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
339126|NCT00513383|Drug|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
339127|NCT00513396|Drug|Isoniazid|High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
339128|NCT00513396|Drug|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
339129|NCT00513409|Biological|Synflorix|Intramuscular injection, 1 or 2 doses
339453|NCT00003960|Drug|busulfan|
338460|NCT00527072|Biological|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
338461|NCT00527085|Drug|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
338462|NCT00527085|Drug|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
338463|NCT00527111|Drug|Cetuximab|
338464|NCT00527111|Drug|5-fluorouracil|
338465|NCT00003854|Other|immunohistochemistry staining method|
338466|NCT00527111|Radiation|Pelvic irradiation|
338467|NCT00527124|Drug|cediranib maleate|Given orally
338785|NCT00518843|Behavioral|FBT-BN|Mobilizing parents to curtail binge eating and purging
338786|NCT00518843|Behavioral|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
338787|NCT00518856|Other|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
338788|NCT00518856|Other|Standard of care|continued with current standard of care for birth attendants
338789|NCT00518869|Drug|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
338790|NCT00518882|Drug|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
338791|NCT00000556|Drug|verapamil|
338792|NCT00003810|Drug|gemcitabine hydrochloride|
338793|NCT00518882|Drug|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
338794|NCT00518895|Drug|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
338795|NCT00521274|Drug|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
338125|NCT00535002|Drug|Placebo|
338126|NCT00535015|Drug|Betamarc|2 tabs BID
338127|NCT00535028|Drug|AER 001|AER 001 25 mgs s.c. once daily for 28 days
338128|NCT00535028|Drug|placebo|sterile saline
338129|NCT00535041|Drug|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
338130|NCT00003893|Drug|methotrexate|
338131|NCT00535054|Drug|Tears Again|Liposome Eye Spray
338132|NCT00535067|Behavioral|Questionnaire|Questionnaires taking 60 minutes total to complete.
338133|NCT00535080|Drug|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
338134|NCT00535093|Device|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
338135|NCT00535106|Device|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
338136|NCT00535106|Device|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
338137|NCT00535106|Other|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
338138|NCT00535119|Drug|Carboplatin|Given IV
338139|NCT00535119|Other|Laboratory Biomarker Analysis|Correlative studies
338140|NCT00535119|Drug|Paclitaxel|Given IV
338141|NCT00003893|Drug|mitomycin C|
338142|NCT00535119|Other|Pharmacological Study|Correlative studies
338468|NCT00527124|Drug|docetaxel|Given IV
338469|NCT00527124|Drug|prednisone|Given orally
338470|NCT00527124|Other|laboratory biomarker analysis|Correlative studies
337422|NCT00416351|Drug|clofarabine|
337423|NCT00416377|Biological|bleomycin sulfate|
337424|NCT00416377|Drug|chlorambucil|
337425|NCT00416377|Drug|dacarbazine|
337426|NCT00416377|Drug|doxorubicin hydrochloride|
337427|NCT00416377|Drug|prednisolone|
337428|NCT00416377|Drug|procarbazine hydrochloride|
337429|NCT00416377|Drug|vinblastine sulfate|
337430|NCT00416377|Drug|vincristine sulfate|
337431|NCT00416377|Radiation|radiation therapy|
337432|NCT00003327|Drug|paclitaxel|
337433|NCT00416390|Dietary Supplement|lycopene|
337783|NCT00542685|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
337784|NCT00542685|Drug|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
337785|NCT00542685|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
337786|NCT00542685|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
337787|NCT00542698|Behavioral|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
337788|NCT00542711|Drug|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
337789|NCT00542724|Drug|VIAject™|Dosage as individually required
337790|NCT00003936|Drug|bryostatin 1|
337791|NCT00542724|Drug|Regular Human Insulin|Dosage as individually required
337792|NCT00542737|Behavioral|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
337060|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
337061|NCT00003358|Drug|gemcitabine hydrochloride|
337062|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
337063|NCT00424762|Drug|rosiglitazone|6 months of treatment of blinded study drug
337064|NCT00424762|Drug|placebo|blinded treatment with matching placebo
337065|NCT00424775|Drug|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
337066|NCT00424788|Procedure|Plasma exchange|
337067|NCT00424788|Drug|natalizumab treatment|
337068|NCT00424801|Drug|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
337069|NCT00003377|Drug|paclitaxel|
337070|NCT00424801|Drug|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
337071|NCT00424801|Drug|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
337072|NCT00424801|Drug|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
337073|NCT00424801|Drug|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
337074|NCT00424801|Drug|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
337075|NCT00424801|Drug|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
337076|NCT00424814|Drug|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
337077|NCT00424814|Drug|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
337078|NCT00424827|Drug|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
337434|NCT00416390|Other|laboratory biomarker analysis|
336336|NCT00439205|Device|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
336337|NCT00003422|Procedure|adjuvant therapy|
336338|NCT00439205|Device|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
336339|NCT00439218|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
336340|NCT00439231|Drug|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
336341|NCT00439244|Drug|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
336342|NCT00439244|Drug|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
336687|NCT00430586|Drug|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
336688|NCT00430586|Drug|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
336689|NCT00003397|Drug|cyclophosphamide|
336690|NCT00430625|Biological|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
336691|NCT00430638|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
336692|NCT00430638|Drug|Placebo|Oral tablets administered for once daily for 12 weeks
336693|NCT00430651|Drug|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
336694|NCT00430651|Drug|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
336695|NCT00430664|Procedure|Pleurodesis with either talc or iodopovidone|
336696|NCT00430677|Drug|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
336697|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
335967|NCT00447668|Behavioral|Self-care book recommendations|Self-care book for back pain
335968|NCT00447681|Drug|ILV-094|
335969|NCT00447694|Drug|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
335970|NCT00447707|Behavioral|Positive Choice|
335971|NCT00447720|Behavioral|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
335972|NCT00447733|Behavioral|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
335973|NCT00447733|Behavioral|Treatment as usual|Non-standardized psychiatric outpatient treatment
335974|NCT00447746|Procedure|D1 or D2 lymphadenectomy for gastric cancer patients|
335975|NCT00447759|Drug|Celecoxib|200-400mg daily in divided doses
335976|NCT00447759|Drug|non-selective Non steroidal anti inflammatory Drug|taken orally
335977|NCT00003462|Drug|busulfan|
335978|NCT00447772|Drug|Botulinum type A toxin (Dysport®)|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
335979|NCT00447798|Behavioral|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building & strengths based case management
335980|NCT00447811|Drug|MOA-728|
335981|NCT00450411|Radiation|103-palladium|
336343|NCT00439244|Drug|Teriparatide|Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.
Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days.
336344|NCT00439270|Drug|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
336345|NCT00439270|Drug|Docetaxel|Infusion, 60 or 75 mg/m^2, administered every 3 weeks.
330865|NCT00457470|Drug|AG-014699|
330866|NCT00457483|Drug|hydrochlorothiazide|12.5 mg once-a-day
330867|NCT00457483|Drug|valsartan, 80 mg once-a-day|80 mg once-a-day
330868|NCT00457496|Behavioral|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
330869|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
330870|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
330871|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
330872|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
330873|NCT00003517|Procedure|antiandrogen therapy|
330874|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
330875|NCT00457522|Behavioral|Nurse/community health worker telephone intervention|
330876|NCT00457548|Behavioral|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
330877|NCT00457574|Drug|GMX1777|
330878|NCT00457600|Procedure|patient-driven health IT product|
330879|NCT00457613|Drug|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
330880|NCT00457626|Drug|Valsartan|All patients started with dose 1 mg/kg once daily for first 2 weeks, up-titration to 2mg/kg (then to 4mg/kg) depending on MSSBP.
330881|NCT00457639|Drug|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
331233|NCT00448630|Other|No intervention|Non-interventional study
331234|NCT00448643|Radiation|Vaginal Brachytherapy|High-Dose Rate [HDR] or Low-Dose Rate [LDR], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
331235|NCT00448643|Drug|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
330253|NCT00557466|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
330254|NCT00557466|Drug|placebo to indacaterol|Placebo TWISTHALER® device
330255|NCT00557466|Drug|placebo to formoterol|Placebo AEROLIZER® device
330256|NCT00557466|Drug|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
330257|NCT00557492|Drug|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
330258|NCT00557492|Drug|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
330259|NCT00557492|Radiation|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
330260|NCT00004026|Drug|chemotherapy|
330534|NCT00590785|Drug|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
330535|NCT00590798|Behavioral|Walking|Patient will walk within 30 minutes of vascular closure system procedure
330536|NCT00590824|Drug|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
330537|NCT00590824|Drug|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
330538|NCT00590837|Drug|Lomustine|Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.
Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.
Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1.
330539|NCT00590850|Device|ORIF with Plate and Screws|ORIF with plate and screws
330540|NCT00590850|Device|Pin Fixation|Clavicle fixation with clavicle pin
330541|NCT00590863|Drug|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
330542|NCT00590863|Drug|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
330543|NCT00590863|Drug|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
329958|NCT00564668|Drug|biphasic insulin aspart|
329959|NCT00564681|Biological|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
329960|NCT00564681|Biological|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
329961|NCT00564681|Drug|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
329962|NCT00564694|Procedure|psychosocial assessment and care|
329963|NCT00004066|Drug|docetaxel|
329964|NCT00564694|Procedure|quality-of-life assessment|
329965|NCT00564707|Behavioral|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
329966|NCT00566904|Drug|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
329967|NCT00566904|Other|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
329968|NCT00004080|Procedure|conventional surgery|
329969|NCT00566917|Procedure|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
329970|NCT00566917|Procedure|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
329971|NCT00566930|Other|spinal manipulation|Monthly cervical spinal manipulation
329972|NCT00566930|Other|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
329973|NCT00566943|Device|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
329974|NCT00566943|Procedure|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
330261|NCT00557505|Drug|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
330262|NCT00557518|Drug|Alagebrium|200 mg bid
330263|NCT00557518|Drug|Placebo|bid
329324|NCT00579215|Behavioral|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
329325|NCT00004135|Biological|therapeutic allogeneic lymphocytes|
329656|NCT00572000|Biological|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
329657|NCT00572013|Drug|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
329658|NCT00572013|Drug|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
329659|NCT00572013|Procedure|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
329660|NCT00572026|Drug|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
329661|NCT00572039|Behavioral|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
329662|NCT00572039|Behavioral|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
329663|NCT00572052|Device|NovoFine® needle 6 mm|
329664|NCT00572052|Device|Ultra-Fine needle 12.7 mm|
329665|NCT00572065|Drug|arsenic trioxide|Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.
Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.
329666|NCT00004096|Drug|carboplatin|
329667|NCT00572065|Drug|cytarabine|Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.
Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.
329668|NCT00572078|Drug|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
329669|NCT00572091|Device|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
329018|NCT00584610|Device|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
329019|NCT00584610|Device|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
329020|NCT00584636|Drug|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
329021|NCT00584649|Procedure|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
329022|NCT00000608|Behavioral|diet, sodium-restricted|
329023|NCT00004161|Drug|Placebo|
329024|NCT00587405|Procedure|cryotherapy|The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.
A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy.
329025|NCT00004172|Radiation|radiation therapy|
329326|NCT00579241|Procedure|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
329327|NCT00579254|Drug|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
329328|NCT00579267|Other|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
329329|NCT00579280|Drug|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
329330|NCT00579280|Drug|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
329331|NCT00579280|Drug|placebo|placebo
329332|NCT00579332|Dietary Supplement|brassica intervention|diet and phyto-chemical intervention
329333|NCT00579345|Biological|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 ml single dose in the deltoid muscle, preferably of the non-dominant arm.
329334|NCT00579345|Biological|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 ml single dose in the deltoid muscle, preferably of the non-dominant arm.
328719|NCT00551733|Drug|paclitaxel poliglumex|Given IV
328720|NCT00551746|Dietary Supplement|Purple Grape Juice|Grape Juice
328721|NCT00551759|Drug|5-Fluorouracil|given IV
328722|NCT00551759|Drug|Oxaliplatin|given IV
328723|NCT00551759|Drug|Cetuximab|given IV
328724|NCT00551759|Drug|Docetaxel|given IV
328725|NCT00003994|Drug|cisplatin|Given IV
328726|NCT00551759|Procedure|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
328727|NCT00551759|Radiation|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
328728|NCT00551772|Drug|SB-742457|
328729|NCT00551798|Procedure|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
328730|NCT00551811|Drug|SB-656933-AAA|
328731|NCT00551824|Drug|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
328732|NCT00551850|Drug|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
328733|NCT00551863|Behavioral|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
328734|NCT00551876|Drug|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
328735|NCT00551876|Drug|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
328736|NCT00003994|Drug|vincristine sulfate|Given IV
328737|NCT00551889|Drug|celecoxib|
328738|NCT00551889|Drug|cyclophosphamide|
328739|NCT00551889|Other|laboratory biomarker analysis|
328740|NCT00551902|Procedure|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
333933|NCT00415038|Drug|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
333934|NCT00415038|Drug|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
333935|NCT00415038|Drug|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
333936|NCT00003317|Drug|paclitaxel|
333937|NCT00417404|Drug|aquasol A|10,000 IU three times weeks, by intramuscular injection
333938|NCT00417404|Other|sham injection|sham injection
333939|NCT00417417|Drug|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
328741|NCT00554333|Biological|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
328742|NCT00554346|Drug|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
328743|NCT00554359|Drug|I5NP (a small interfering RNA)|Single IV injection of experimental drug
328744|NCT00004006|Drug|topotecan hydrochloride|
328745|NCT00554359|Drug|placebo|Single IV injection of saline
328746|NCT00554372|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
328747|NCT00554385|Drug|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
328748|NCT00554398|Drug|MK-0518 400mg twice a day|Raltegravir, MK-0518
328749|NCT00554424|Drug|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
328750|NCT00554424|Drug|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
333569|NCT00423514|Procedure|peripheral blood stem cell transplantation|
333570|NCT00423527|Drug|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
333571|NCT00423540|Drug|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
333572|NCT00423566|Biological|MVA85A (Tuberculosis vaccine)|
333573|NCT00423579|Drug|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
333574|NCT00423579|Drug|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
333575|NCT00423592|Drug|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
333576|NCT00423605|Drug|Xyrem®|flexible dosing
333577|NCT00003367|Dietary Supplement|green tea|
333578|NCT00423618|Procedure|adjuvant therapy|
333579|NCT00423618|Radiation|radiation therapy|
333580|NCT00423631|Behavioral|Standard care and web|A static web site containing cognitive and behavioral self management instructions.
333581|NCT00423631|Behavioral|Standard Care|Standard care delivered by the primary care provider.
333582|NCT00423644|Drug|Darinaparson|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
333583|NCT00423657|Drug|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
333584|NCT00423657|Drug|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
333585|NCT00426114|Drug|Administration of an IV glucose-injection|
333586|NCT00426127|Drug|Docetaxel|
333587|NCT00426127|Drug|Liposomal Doxorubicin|
333588|NCT00426127|Drug|Enoxaparin|
333589|NCT00426140|Drug|Patupilone|
333590|NCT00426153|Drug|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
332875|NCT00440388|Drug|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
332876|NCT00000520|Drug|aspirin|
332877|NCT00003425|Drug|melphalan|
332878|NCT00440401|Drug|fibrinogen (human) + thrombin (human)|
332879|NCT00440401|Drug|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
332880|NCT00440414|Drug|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
332881|NCT00440414|Drug|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
332882|NCT00440427|Drug|Desvenlafaxine Sustained Release (DVS SR)|
332883|NCT00440440|Drug|Testosterone gel|Testosterone gel to be applied daily, starting does 5g.
332884|NCT00440440|Drug|placebo|placebo gel apply daily
333227|NCT00003399|Drug|melphalan|
333228|NCT00432172|Drug|Selective treatment|EC x4->CBPT x4
333229|NCT00432185|Drug|PEP005|0.25% PEP005 Gel
333230|NCT00432198|Drug|Zolpidem (Myslee®)|Oral
333231|NCT00432198|Drug|placebo|Oral
333232|NCT00432211|Drug|Avotermin|Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.
Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration.
333233|NCT00432224|Procedure|photodynamic therapy|
333234|NCT00432237|Drug|MK0974 50 mg|
333235|NCT00432237|Drug|MK0974 150 mg|
333236|NCT00432237|Drug|MK0974 300 mg|
339454|NCT00548665|Device|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
339455|NCT00548665|Behavioral|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
339456|NCT00548678|Drug|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
339457|NCT00548678|Drug|ketorolac|intravenous ketorolac
339458|NCT00548678|Drug|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
339459|NCT00548678|Drug|aspirin|oral aspirin
339460|NCT00548691|Drug|Ferric Carboxymaltose|
339461|NCT00548691|Drug|Standard Medical Care (SMC)|
339462|NCT00548704|Drug|Dexrazoxane|
339463|NCT00548717|Drug|Sirolimus|
339464|NCT00003960|Drug|cyclophosphamide|
339465|NCT00548717|Drug|Mycophenolate mofetil|
339466|NCT00548717|Drug|Bortezomib|
339467|NCT00548730|Procedure|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
339468|NCT00548743|Behavioral|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
339469|NCT00548743|Behavioral|Usual care|usual care for identification and management of postpartum depression
339470|NCT00548756|Procedure|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
339471|NCT00548756|Other|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
339472|NCT00548756|Behavioral|Questionnaire|Questionnaire taking 40 minutes to complete.
339473|NCT00548769|Drug|firategrast (SB683699)|
339474|NCT00548782|Other|Paleolithic diet|diet
338796|NCT00521287|Other|Immune profiling and DC vaccine|For observational study (immune profiling): blood sampling 3-5 mL
For DC vaccine: one dose of DC vaccine(~10 million cells)/2 week for at least 6 month or until progression.
338797|NCT00521300|Drug|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
338798|NCT00521300|Procedure|Direct surgery for acromegaly|Direct transsphenoidal surgery
338799|NCT00521339|Drug|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
338800|NCT00521352|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
338801|NCT00521352|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
339130|NCT00513409|Biological|Infanrix Hexa|1 Intramuscular injection
339131|NCT00513409|Biological|Havrix|1 Intramuscular injection
339132|NCT00513422|Dietary Supplement|Glucosamine sulphate and chondroitin|Glucosamine: Two 750mg capsules once daily for two years;
Chondroitin: Two 400mg capsules once daily for two years.
339133|NCT00513422|Dietary Supplement|Glucosamine sulphate|Glucosamine: Two 750mg capsules once daily for two years;
Placebo Chondroitin: Two capsules once daily for two years.
339134|NCT00513422|Dietary Supplement|Chondroitin sulphate|Chondroitin sulphate: Two 400mg capsules once daily for two years;
Placebo glucosamine: Two capsules once daily for two years.
339135|NCT00003783|Drug|leucovorin calcium|
339136|NCT00513422|Dietary Supplement|Placebo capsules for glucosamine and chondroitin|Two placebo glucosamine capsules once daily for two years;
Two placebo chondroitin capsules once daily for two years.
339137|NCT00513435|Drug|saracatinib|Given PO
339138|NCT00513435|Other|laboratory biomarker analysis|Correlative studies
339139|NCT00513448|Other|Group wellness intervention|
339140|NCT00513448|Other|Individualized physical rehabilitation|
339141|NCT00513461|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
339142|NCT00513461|Other|placebo|Given PO
338471|NCT00527137|Drug|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
338472|NCT00527137|Drug|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
338473|NCT00527150|Drug|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
338474|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
338475|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
338476|NCT00003854|Procedure|lymphangiography|
338477|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
338478|NCT00529607|Procedure|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
338479|NCT00529607|Procedure|cardiac MRI|before discharge and after 6 months
338480|NCT00529607|Procedure|blood sampling|routine lab work plus infarction and inflammation biomarkers
1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3
338481|NCT00529620|Drug|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
338482|NCT00529620|Drug|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
338483|NCT00529620|Drug|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
338484|NCT00529633|Drug|thalidomide|100 mg by mouth at night for 4 weeks 200 mg by mouth at night for 20 weeks
338485|NCT00529646|Drug|APD791|
338486|NCT00529659|Drug|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
338487|NCT00003863|Genetic|gene rearrangement analysis|
338488|NCT00529659|Drug|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
338489|NCT00529672|Procedure|crossectomy and short stripping|under spinal or complete anaesthesia
337793|NCT00542750|Drug|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
337794|NCT00542763|Drug|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
337795|NCT00542776|Other|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
337796|NCT00542789|Drug|Esomeprazole|20mg once daily oral
337797|NCT00542789|Drug|Placebo|once daily oral
337798|NCT00542802|Drug|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
337799|NCT00542802|Drug|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
337800|NCT00542815|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
337801|NCT00000159|Drug|Sorbinil|
337802|NCT00545311|Drug|Placebo|
338143|NCT00535119|Drug|Veliparib|Given PO
338144|NCT00535132|Drug|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
338145|NCT00535132|Drug|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
338146|NCT00535145|Drug|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
338147|NCT00535158|Drug|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
338148|NCT00535197|Procedure|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
338149|NCT00537433|Other|Pictogram|The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.
Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home.
337435|NCT00416390|Procedure|biopsy|
337436|NCT00416403|Drug|fluvastatin sodium|Given orally
337437|NCT00416403|Procedure|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
337438|NCT00416429|Biological|aldesleukin|
337439|NCT00416429|Biological|recombinant interferon alpha-2a|
337440|NCT00416429|Drug|medroxyprogesterone|
337441|NCT00416442|Drug|RSV604|
337442|NCT00416455|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
337443|NCT00003328|Drug|porfiromycin|
337444|NCT00416455|Procedure|positron emission tomography|Undergo FDG PET/CT
337445|NCT00416455|Procedure|computed tomography|Undergo FDG PET/CT
337446|NCT00416455|Drug|ferumoxtran-10|Undergo femoxtran-10 MRI
337447|NCT00416455|Procedure|magnetic resonance imaging|Undergo femoxtran-10 MRI
337448|NCT00416455|Procedure|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
337449|NCT00416455|Procedure|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
337450|NCT00416468|Drug|Aliskiren|
337451|NCT00416468|Drug|Valsartan|
337452|NCT00416481|Behavioral|quality of life questionnaires|
337453|NCT00416494|Biological|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
337454|NCT00003328|Radiation|radiation therapy|
337455|NCT00419133|Biological|Killed bivalent whole cell oral cholera vaccine|Each 1.5 mL dose, given orally, contains:
V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS
337456|NCT00419133|Biological|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
337457|NCT00419146|Drug|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
336698|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
336699|NCT00430677|Drug|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
336700|NCT00003397|Drug|dexamethasone|
336701|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
336702|NCT00000518|Procedure|electrocardiography, ambulatory|
336703|NCT00003401|Procedure|peripheral blood stem cell transplantation|
336704|NCT00433485|Genetic|gene expression analysis|
336705|NCT00433485|Genetic|microarray analysis|
336706|NCT00433485|Genetic|protein expression analysis|
336707|NCT00433485|Genetic|proteomic profiling|
336708|NCT00433485|Other|laboratory biomarker analysis|
336709|NCT00433485|Other|mass spectrometry|
337079|NCT00424840|Drug|Bortezomib|The primary objective of phase I study is to define the maximum tolerated dose (MTD) of weekly bortezomib in combination with carboplatin and bevacizumab.
337080|NCT00003377|Radiation|brachytherapy|
337081|NCT00424853|Drug|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
337082|NCT00424853|Drug|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
337083|NCT00424866|Drug|FGF-1|Doses of FGF-1:
Vehicle: 0 µg/kg Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg
337084|NCT00424892|Drug|Desvenlafaxine Sustained Release|
337085|NCT00424905|Drug|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
337086|NCT00424918|Behavioral|Physical Activity, reduced sedentary behavior|
337087|NCT00427713|Procedure|standard follow-up care|
337088|NCT00003388|Drug|vincristine sulfate|
331604|NCT00439972|Drug|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
331605|NCT00439972|Drug|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
331606|NCT00439985|Behavioral|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
331607|NCT00439998|Procedure|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
331608|NCT00440011|Drug|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
331609|NCT00003423|Drug|prednisolone|
331610|NCT00440011|Drug|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
331611|NCT00440024|Drug|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
331612|NCT00440024|Drug|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
331613|NCT00440024|Drug|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
331969|NCT00431691|Drug|vitamin and mineral supplement|dose: 4 tablets daily for two weeks
vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg
331970|NCT00431691|Drug|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
331971|NCT00003398|Radiation|radiation therapy|
331972|NCT00431691|Drug|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
331973|NCT00434382|Drug|Isoflurane|
331974|NCT00434382|Drug|Desflurane|
331975|NCT00434382|Drug|Propofol|
331976|NCT00434382|Drug|Fentanyl|
331977|NCT00434382|Drug|Sufentanil|
331978|NCT00434382|Drug|Alfentanil|
331236|NCT00448643|Radiation|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated [2-Levels]; 6 -8 hours after administration of Cisplatin chemotherapy
331237|NCT00448656|Procedure|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
331238|NCT00448669|Drug|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.
331239|NCT00003468|Drug|antineoplaston A10|
331240|NCT00448669|Drug|TDF-FTC placebo|Placebo comparator for TDF-FTC
331241|NCT00448682|Drug|Docetaxel|
331242|NCT00448682|Drug|Floxuridine|
331243|NCT00448682|Drug|Leucovorin|
331244|NCT00448682|Drug|Oxaliplatin|
331245|NCT00448695|Procedure|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
331246|NCT00448708|Device|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm^2 paclitaxel
331247|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
331248|NCT00451152|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
331249|NCT00451152|Other|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
331250|NCT00451165|Procedure|laparoscopic colorectal surgery|laparoscopic colorectal surgery
331251|NCT00451178|Drug|enzastaurin|1125 mg then 500 mg, oral, daily, six 21 day cycles or up to 3 years
331252|NCT00451178|Drug|rituximab|375 mg/m2, IV, day 1 every 21 days, six 21 day cycles
331253|NCT00451178|Drug|cyclophosphamide|750 mg/m2, IV, day 1 every 21 days, six 21 day cycles
331254|NCT00451178|Drug|doxorubicin|50 mg/m2, IV, day 1 every 21 days, six 21 day cycles
331255|NCT00451178|Drug|vincristine|1.4 mg/m2, IV, day 1 every 21 days, six 21 day cycles
330544|NCT00004186|Radiation|radiation therapy|
330545|NCT00590889|Device|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
330546|NCT00590902|Drug|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
330547|NCT00590915|Drug|Erwinia L-asparaginase|Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.
NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics.
330548|NCT00590928|Drug|esomeprazole|40mg once daily
330549|NCT00590928|Drug|ranitidine|50mg every h hours
330550|NCT00590941|Procedure|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
330551|NCT00590954|Drug|Perifosine|Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.
In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4.
330882|NCT00457652|Drug|Rosuvastatin|7 day treatment rosuvastatin 20mg
330883|NCT00457665|Drug|Viracept versus Sustiva with stavudine and epivir|
330884|NCT00003517|Procedure|biological therapy|
330885|NCT00457678|Drug|Visudyne|
330886|NCT00457678|Drug|Lucentis|
330887|NCT00460525|Biological|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
330888|NCT00460525|Biological|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
330889|NCT00460538|Dietary Supplement|Lectranal|Dosage form: capsule
1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks
330890|NCT00003536|Drug|antineoplaston A10|
330891|NCT00460538|Dietary Supplement|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
330892|NCT00460551|Biological|Zalutumumab|8 mg/kg
330264|NCT00557531|Device|BL-1040|2 mL of BL-1040
330265|NCT00557544|Drug|metoclopramide|metoclopramide 0,15 mg/kg
330266|NCT00557544|Drug|placebo|placebo per os
330267|NCT00557544|Drug|ketoprofen|ketoprofen 1 mg/Kg
330268|NCT00559988|Drug|Home Monitoring Guided OAC|Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.
OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
330269|NCT00559988|Drug|Physician-Directed OAC|Patients will receive physician-directed anticoagulation therapy based on conventional criteria.
OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
330270|NCT00560001|Behavioral|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
330271|NCT00560014|Dietary Supplement|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
330272|NCT00560014|Dietary Supplement|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
330273|NCT00560027|Other|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
330274|NCT00000591|Procedure|lymphocyte depletion|
330275|NCT00004039|Drug|prednisone|
330276|NCT00560053|Drug|Alternating chemotherapy|4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.
VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20.
330277|NCT00560053|Procedure|Autologous Transplantation|Autologous Transplantation :
BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria
330552|NCT00003996|Drug|etoposide|
330553|NCT00552565|Drug|Rezular|Rezular 37.5mg 3xday up to 12 weeks
330554|NCT00552565|Drug|Rezular|Rezular 75mg 3xday up to 12 weeks
329670|NCT00572104|Other|exercise intervention|12 month training intervention of either plyometrics or weight resistance exercise.
329671|NCT00574496|Drug|ifosfamide|
329672|NCT00574496|Drug|mechlorethamine hydrochloride|
329673|NCT00574496|Drug|melphalan|
329674|NCT00574496|Drug|methotrexate|
329675|NCT00574496|Drug|mycophenolate mofetil|
329975|NCT00566956|Procedure|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
329976|NCT00566969|Drug|sugar pill|randomly given 25mg or 50mg of a sugar pill or the active comparator
329977|NCT00566969|Drug|carvedilol|randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.
329978|NCT00566969|Drug|Methadone|Maintenance
329979|NCT00004081|Drug|docetaxel|
329980|NCT00566982|Drug|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
329981|NCT00566982|Drug|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
329982|NCT00566995|Drug|ZACTIMA (Vandetanib) (ZD6474)|
329983|NCT00567008|Drug|varenicline|1.0 mg BID for 8 weeks
329984|NCT00567008|Drug|placebo|placebo BID for 8 weeks
329985|NCT00567034|Drug|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
329986|NCT00567034|Drug|placebo|lactose placebo, 1 capsule every day for 12 weeks
329987|NCT00567047|Drug|vildagliptin|
329988|NCT00567060|Drug|Piracetam|
329989|NCT00567073|Biological|alglucosidase alpha|
329990|NCT00004082|Drug|carboplatin|
329335|NCT00579345|Biological|cTIV or eTIV_a|0.5 ml, Single dose of either cell cultured trivalent influenza vaccine (cTIV)or egg based trivalent influenza vaccine eTIV_a administered.
329336|NCT00004135|Drug|cyclophosphamide|
329337|NCT00579345|Biological|cTIV+PV OR eTIV_a+PV|0.5 ml, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
329338|NCT00579371|Other|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
329339|NCT00581776|Drug|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
329340|NCT00581776|Drug|Vincristine|1 mg administered by IV on day 3 of each cycle.
329341|NCT00581776|Drug|Dexamethasone|40 mg orally on days 1-4 of each cycle.
329342|NCT00581789|Drug|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
329343|NCT00581815|Device|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
329676|NCT00004107|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
329677|NCT00574496|Drug|prednisone|
329678|NCT00574496|Drug|procarbazine hydrochloride|
329679|NCT00574496|Drug|vincristine sulfate|
329680|NCT00574496|Drug|vinorelbine tartrate|
329681|NCT00574496|Procedure|allogeneic bone marrow transplantation|
329682|NCT00574496|Procedure|allogeneic hematopoietic stem cell transplantation|
329683|NCT00574496|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
329684|NCT00574496|Procedure|peripheral blood stem cell transplantation|
329685|NCT00574496|Procedure|umbilical cord blood transplantation|
329686|NCT00574496|Radiation|total-body irradiation|
329026|NCT00587405|Procedure|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
329027|NCT00587418|Dietary Supplement|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
329028|NCT00587418|Dietary Supplement|Placebo|Placebo powder 9.2g bid for 7 days
329029|NCT00587431|Drug|GnRh (Leuprolide)|Leuprolide LUPRON
329030|NCT00587431|Drug|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
329031|NCT00587431|Drug|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
329032|NCT00587444|Drug|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is < 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is>480 seconds
329033|NCT00587444|Drug|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is <600 seconds anytime during CPB
329034|NCT00587444|Drug|heparin concentration HC|will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.
All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%
329035|NCT00587457|Drug|CAT-8015|Maximum Tolerated Dose
329036|NCT00004173|Drug|oxaliplatin|
329037|NCT00587470|Drug|Candesartan|Maximum vasodilation.
329038|NCT00587470|Drug|atacand|maximum vasodilation
329039|NCT00587470|Drug|Placebo|Placebo
329040|NCT00587483|Drug|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
329041|NCT00587483|Drug|Amiodarone|300 mg
329042|NCT00587483|Drug|Placebo|Saline
329043|NCT00587496|Drug|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
329044|NCT00587496|Drug|placebo|lactose placebo capsule, six per day for 30 days
328751|NCT00554437|Behavioral|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
328752|NCT00554450|Drug|Dapagliflozin|Tablets, Oral, once daily
328753|NCT00554463|Biological|Filgrastim|5mcg/kg/day subcutaneously on days 4-13 and 25-34 after each concurrent chemotherapy cycle for a total of 20 doses.
328754|NCT00554463|Biological|Pegfilgrastim|6 mg subcutaneously on day 4 of each adjuvant chemotherapy cycle.
328755|NCT00004006|Procedure|autologous bone marrow transplantation|
328756|NCT00554463|Drug|Concurrent chemotherapy|Beginning day 1 of radiation threapy (+/- 24 hours), repeat cycle every 3 weeks for two cycles:
Day 1: Cisplatin, 60 mg/m^2 i.v.; Days 1-3: Etoposide, 120 mg/m^2 i.v.
328757|NCT00554463|Drug|Adjuvant chemotherapy|Cycle 1: Day 43: Cisplatin, 60 mg/m^2 i.v. and Etoposide, 120 mg/m^2 i.v.; Days 44 & 45: Etoposide, 120 mg/m^2 i.v.
Cycle 2: Day 64: Cisplatin, 60 mg/m^2 i.v. and Etoposide, 120 mg/m^2; Days 65 & 66: Etoposide, 120 mg/m^2 i.v.
328758|NCT00554463|Radiation|radiation therapy|A total of 61.2 Gy in 5 weeks: 1.8 Gy daily x 5 week, for 3 weeks (days 1-16); 1.8 Gy, BID, in 4th week (days 17-20) with off cord boost in p.m.; Off-cord boost, 1.8 Gy BID, in 5th week (days 21-25).
328759|NCT00554476|Drug|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
329047|NCT00590018|Drug|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --> 25mg/m2/day) over 5 days intravenously.
329048|NCT00004181|Radiation|radiation therapy|
329049|NCT00590018|Drug|Placebo|Placebo for 5 days intravenously.
329050|NCT00590031|Drug|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
329051|NCT00590031|Drug|Irinotecan|Irinotecan will be given 65 mg/m2
329052|NCT00590031|Radiation|External Beam Radiation Therapy|will be delivered with multiple (>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
329053|NCT00590044|Drug|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
329054|NCT00590044|Drug|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
329055|NCT00590070|Drug|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
333591|NCT00426153|Drug|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
333592|NCT00426166|Device|Low Level Laser Therapy|Low Level Laser Therapy on Wound
333940|NCT00417417|Drug|Placebo|Normal saline subcutaneously at each treatment visit.
333941|NCT00417430|Drug|ICI 182,780 (Faslodex)|
333942|NCT00417443|Drug|Clonidine|
333943|NCT00417456|Other|Evisit|Asynchronous,remote care delivery via a secure web platform
333944|NCT00003336|Drug|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
333945|NCT00417456|Other|Office visit|Conventional office-based care
333946|NCT00417469|Device|NADGL|
333947|NCT00417482|Drug|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
333948|NCT00417495|Behavioral|Sentinel Lymph Node Technique|
333949|NCT00417508|Dietary Supplement|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
333950|NCT00417508|Dietary Supplement|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
333951|NCT00417521|Behavioral|Family-Based Treatment|
333952|NCT00417560|Biological|inactivated influenza A/H5N1 vaccine|
333953|NCT00417573|Drug|IV Gamunex 10%|
333954|NCT00417586|Device|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
333955|NCT00000510|Drug|dipyridamole|
333956|NCT00003336|Drug|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
333957|NCT00417599|Behavioral|Behavior Therapy|
333958|NCT00417612|Drug|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
333237|NCT00432237|Drug|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
333238|NCT00434850|Biological|Etanercept|Blocks TNF-alpha which is toxic to islet cells
333239|NCT00434863|Drug|botulinum toxin type A|
333240|NCT00434876|Drug|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
333241|NCT00434876|Drug|Placebo.|Inactive or inert pill which will be used as a comparator.
333242|NCT00434915|Drug|DHEA|
333243|NCT00434941|Other|Radiotherapy + Capecitabine|Experimetal treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
333244|NCT00434954|Drug|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
333245|NCT00434954|Drug|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
333246|NCT00434967|Drug|Candesartan cilexetil|32 mg oral tablet
333247|NCT00003406|Drug|docetaxel|
333248|NCT00434967|Drug|Hydrochlorothiazide|25 mg oral tablet
333593|NCT00426179|Drug|Imatinib|
333594|NCT00426192|Drug|i.v. mannitol|
333595|NCT00003385|Drug|pegylated liposomal doxorubicin hydrochloride|
333596|NCT00426192|Procedure|hemofiltration|
333597|NCT00426205|Biological|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
333598|NCT00426218|Drug|ACZ885|
333599|NCT00426231|Behavioral|Navigation by a health worker|Help provided by health worker to navigate medication access programs
333600|NCT00426231|Behavioral|Information control|Information about medication access programs provided to the participant and their healthcare provider
333601|NCT00426244|Other|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
339475|NCT00003960|Drug|methylprednisolone|
339476|NCT00508027|Drug|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
339814|NCT00543595|Drug|MK0916|
339815|NCT00543608|Drug|iclaprim|
339816|NCT00543608|Drug|vancomycin|
339817|NCT00000577|Drug|Albuterol|
339818|NCT00003941|Biological|filgrastim|
339819|NCT00543621|Other|daily enteral nutritional product and/or behavioral changes|
339820|NCT00543634|Drug|Premarin/MPA|0.625 mg/2.5 mg X4
339821|NCT00543634|Drug|Premarin/MPA|0.625 mg/5 mg X 2
339822|NCT00543634|Drug|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
339823|NCT00543647|Drug|Fenofibrate 160 mg tablet|
339824|NCT00543647|Drug|Placebo|
339825|NCT00543660|Procedure|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
339826|NCT00543673|Other|Milk based formula A|feed as per HCP directions
339827|NCT00543673|Other|#2 Standard formula|Feed as per HCP directions
339828|NCT00543673|Other|#3 Human Milk|Feed as per HCP directions
339829|NCT00003941|Drug|cisplatin|
339830|NCT00543673|Other|Milk based formula C|Feed as per HCP direction
339831|NCT00543686|Drug|Montelukast|Intake of Montelukast
339832|NCT00543686|Drug|Fluticasone|Intake of Fluticasone
339833|NCT00543712|Drug|PRO95780|Intravenous repeating dose
339834|NCT00543725|Drug|TMC278|25 mg tablet once daily for 96 weeks
339835|NCT00543725|Drug|efavirenz|600 mg tablet once daily for 96 weeks
339836|NCT00543738|Drug|MK0767|
339143|NCT00513461|Other|laboratory biomarker analysis|Correlative studies
339144|NCT00513461|Other|immunoenzyme technique|Correlative studies
339145|NCT00513461|Other|high performance liquid chromatography|Correlative studies
339146|NCT00003783|Drug|mercaptopurine|
339147|NCT00513474|Drug|busulfan|
339148|NCT00513474|Drug|cyclophosphamide|
339149|NCT00513474|Drug|cyclosporine|
339150|NCT00513474|Drug|etoposide|
339151|NCT00513474|Drug|methotrexate|
339152|NCT00516035|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
339153|NCT00516048|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
339154|NCT00516074|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
339477|NCT00508040|Drug|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
339478|NCT00508040|Drug|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
339479|NCT00508053|Procedure|Small stitches|
339480|NCT00508053|Procedure|Mass closure|
339481|NCT00003751|Drug|penicillamine|
339482|NCT00508066|Drug|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
339483|NCT00508066|Drug|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
339484|NCT00508092|Procedure|local anesthetic administration|Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight
OR
Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight
339485|NCT00508105|Procedure|tenotomy|This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.
338802|NCT00521365|Drug|Quetiapine 600mg|300 mg quetiapine fumarate tablets for oral use.
Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day.
338803|NCT00003817|Drug|granisetron hydrochloride|
338804|NCT00521391|Other|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
338805|NCT00521404|Drug|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
338806|NCT00521404|Drug|gemcitabine|Gemcitabine - 1000mg/meter sq
338807|NCT00521417|Behavioral|Verbal interactions|interpretations, confrontations, clarifications
338808|NCT00521417|Behavioral|verbal interchange|Interpretation, confrontation, clarification according to manual
338809|NCT00521417|Behavioral|verbal interventions|confrontation, clarification, interpretation
338810|NCT00521417|Behavioral|Psychotherapy|verbal interchange
338811|NCT00521417|Behavioral|Psychotherapy|Verbal interchange
338812|NCT00521417|Behavioral|verbal interchange|clarification, confrontation, interpretation
338813|NCT00521430|Biological|anti-thymocyte globulin|
338814|NCT00003817|Drug|ondansetron|
338815|NCT00521430|Drug|busulfan|
338816|NCT00521430|Drug|cyclosporine|
338817|NCT00521430|Drug|fludarabine phosphate|
338818|NCT00521430|Drug|methotrexate|
338819|NCT00521430|Drug|methylprednisolone|
338820|NCT00524186|Drug|leucovorin calcium|Given IV
338821|NCT00524186|Drug|sunitinib malate|Taken Orally
338822|NCT00524186|Other|flow cytometry|Correlative Study
338823|NCT00003835|Drug|irinotecan hydrochloride|Given IV
338824|NCT00524186|Other|pharmacological study|Correlative Study
338150|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
338151|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
338152|NCT00537459|Drug|16448|
338153|NCT00537472|Drug|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
338154|NCT00537472|Drug|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
338155|NCT00537485|Drug|SPM 962|transdermal application, 1 time per day
338156|NCT00537485|Drug|placebo|transdermal application, 1 time per day
338157|NCT00003908|Drug|docetaxel|
338158|NCT00537498|Drug|Urokinase|Daily intravenous application of urokinase over 30 minutes
Dosage:
If plasma fibrinogen is > 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is < 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is < 1,6g/l treatment must be stopped and continued after rising up to >2g/l
338159|NCT00537511|Drug|Pomalidomide|
338160|NCT00537511|Drug|Cisplatin|
338161|NCT00537511|Drug|Etoposide|
338490|NCT00529672|Procedure|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein>
338491|NCT00529672|Procedure|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
338492|NCT00529698|Biological|Biologically active recombinant Tat protein|
338493|NCT00529711|Drug|Hypertonic lactate|Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
338494|NCT00529711|Drug|Ringer's lactate|Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
338495|NCT00529724|Behavioral|Energy metabolism by chronic bilateral subthalamic stimulation|Patients will be studied before and after STN-DBS surgery
338496|NCT00529737|Procedure|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
337458|NCT00419146|Drug|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
337803|NCT00545324|Drug|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
337804|NCT00545324|Drug|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
337805|NCT00545337|Drug|Insuline glulisine|
337806|NCT00545350|Other|Fall prevention exercise program|Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.
The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises.
337807|NCT00545363|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
337808|NCT00545363|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
337809|NCT00003953|Drug|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
337810|NCT00545376|Procedure|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
337811|NCT00545376|Procedure|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
337812|NCT00545376|Other|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
337813|NCT00545389|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
337814|NCT00545402|Drug|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
337815|NCT00545402|Drug|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
337816|NCT00545402|Drug|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
337817|NCT00545402|Drug|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
337818|NCT00545402|Drug|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
337089|NCT00427739|Procedure|Cardiac CT|64 slice spiral computerized tomography
337090|NCT00427752|Procedure|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
337091|NCT00427765|Drug|Busulfan|Test Dose = 32 mg/m^2 IV for 1 Day; 130 mg/m^2 IV for 4 Days
337092|NCT00427765|Drug|Melphalan|70 mg/m^2 IV for 2 Days
337093|NCT00427778|Device|incontinence ring (Milex)|Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.
Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra.
337094|NCT00427791|Drug|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
337095|NCT00427791|Radiation|Total Body Irradiation|3 Gy Daily for 4 Days
337096|NCT00427791|Drug|Rituximab|375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
337097|NCT00427804|Drug|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
337098|NCT00427830|Biological|MVA85A|
337099|NCT00003388|Radiation|radiation therapy|
337459|NCT00419146|Other|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
337460|NCT00003342|Biological|filgrastim|
337461|NCT00419146|Other|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
337462|NCT00419159|Drug|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
337463|NCT00419172|Drug|Deferasirox|
337464|NCT00419172|Drug|Rifampicin|
337465|NCT00419185|Procedure|Delamination of the Internal limiting membrane|
337466|NCT00419198|Procedure|Postconditioning|Postconditioning during angioplasty
337467|NCT00419198|Procedure|standard angioplasty|standard angioplasty without postconditioning
337468|NCT00419211|Behavioral|Exercise|Tailored exercise program
337469|NCT00419224|Biological|inactivated split-virus influenza vaccine|
337470|NCT00419237|Drug|GW685698X|
331979|NCT00434382|Drug|Remifentanil|
331980|NCT00003405|Drug|bromodeoxyuridine|
331981|NCT00434382|Device|Midlatency auditory evoked potentials|
331982|NCT00434395|Drug|MOA-728|
331983|NCT00434408|Behavioral|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
331984|NCT00434408|Behavioral|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
331985|NCT00434408|Behavioral|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
331986|NCT00434421|Drug|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters [mL], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose [0.42 mL, 1:10 wt/vol] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
331987|NCT00434421|Drug|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
331988|NCT00434434|Drug|omalizumab|Aged Liquid; subcutaneous repeating dose
331989|NCT00434434|Drug|omalizumab|Lyophilized; subcutaneous repeating dose
331990|NCT00434434|Drug|placebo|Subcutaneous repeating dose
332321|NCT00425672|Other|enzyme-linked immunosorbent assay|Correlative studies
332322|NCT00003382|Drug|gemcitabine hydrochloride|
332323|NCT00425672|Other|laboratory biomarker analysis|Correlative studies
332324|NCT00425672|Genetic|protein expression analysis|Correlative studies
332325|NCT00425698|Drug|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
332326|NCT00425698|Drug|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
332327|NCT00425711|Drug|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
331614|NCT00440037|Biological|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
331615|NCT00442936|Drug|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
331616|NCT00442936|Drug|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
331617|NCT00442936|Drug|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
331618|NCT00442936|Drug|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
331619|NCT00442936|Drug|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
331620|NCT00442936|Drug|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
331621|NCT00442949|Procedure|Catheterization immediate PCI|Catheterization immediate PCI
331622|NCT00442949|Procedure|delayed PCI|delayed PCI
331623|NCT00442962|Drug|Efavirenz|600-mg tablet taken orally daily
331624|NCT00003436|Procedure|allogeneic bone marrow transplantation|
331625|NCT00442962|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
331626|NCT00442975|Biological|Fluarix|
331627|NCT00443001|Device|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
331628|NCT00443014|Device|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
331629|NCT00443027|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
331630|NCT00443040|Drug|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
331631|NCT00443040|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
330893|NCT00460551|Drug|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
330894|NCT00460551|Radiation|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
330895|NCT00460564|Drug|GSK1358820|botulinum toxin type A
330896|NCT00460564|Drug|Placebo|Placebo
330897|NCT00460577|Drug|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
330898|NCT00460577|Drug|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
330899|NCT00460590|Biological|MVA 85A|ID vaccine
330900|NCT00460603|Drug|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
330901|NCT00000528|Behavioral|diet, reducing (Phase III)|
330902|NCT00003536|Drug|methotrexate|
330903|NCT00460603|Drug|AG-013726|AG-013726 5 mg bid every 2 weeks
330904|NCT00460603|Drug|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
331256|NCT00451178|Drug|prednisone|100 mg, oral, days 1-5, six 21 day cycles
331257|NCT00451191|Drug|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
331258|NCT00003486|Procedure|complementary and alternative therapy|
331259|NCT00451204|Drug|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
331260|NCT00451204|Drug|Placebo|Placebo capsule, once a day, treatment duration is 2 years
331261|NCT00451217|Drug|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg Org25969 was to be administered
331262|NCT00451217|Drug|neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
331263|NCT00451230|Drug|cocaine|
331264|NCT00451230|Drug|hydrocortisone|
331265|NCT00451256|Drug|AVI-5126|
330555|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
330556|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
330557|NCT00552591|Behavioral|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
330558|NCT00552604|Drug|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
330559|NCT00552604|Drug|Placebo|Matching placebo capsules, twice daily
330560|NCT00552617|Drug|sugammadex (Org 25969)|After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arms 2-5) or 0.1 mg/kg vecuronium (arms 7-10).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
330561|NCT00552617|Drug|Placebo|After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of Placebo IV was administered
330562|NCT00552630|Device|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
330563|NCT00003996|Radiation|radiation therapy|
330564|NCT00552630|Drug|placebo|placebo with same characteristics as drug
330565|NCT00552643|Device|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
330566|NCT00552643|Device|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
330567|NCT00552656|Device|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
330568|NCT00552669|Drug|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
330569|NCT00552669|Device|Drug Eluting stent|Any Drug eluting stent
329991|NCT00567073|Other|No Treatment|
329992|NCT00569634|Procedure|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always < 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
329993|NCT00569647|Device|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
329994|NCT00569647|Device|Placebo|no use of device
329995|NCT00569660|Drug|Azacitidine|75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle)
329996|NCT00569673|Biological|filgrastim|
329997|NCT00569673|Biological|pegfilgrastim|
330278|NCT00560053|Drug|Maintenance|At 3 months of transplantation or with >1.500 neutrophiles/ > 75.000 platelets mm 3 .
Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse.
330279|NCT00560053|Procedure|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
330280|NCT00560053|Procedure|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
330281|NCT00560066|Biological|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
330282|NCT00560066|Biological|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
330283|NCT00560079|Drug|Allopurinol|Allopurinol 600mg/day bid for 28 days
330284|NCT00560079|Drug|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
330285|NCT00560079|Drug|Placebo|Placebo
330286|NCT00004039|Drug|vincristine sulfate|
330287|NCT00560092|Drug|intrathecal magnesium sulfate|intrathecal magnesium sulfate
330288|NCT00562172|Drug|Glimepiride|Once daily in the morning
330289|NCT00562172|Drug|Metformin|At least 1000 mg/day
330290|NCT00562185|Drug|carboplatin|
330291|NCT00004055|Biological|filgrastim|
330292|NCT00562185|Drug|doxorubicin hydrochloride|
329687|NCT00004107|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
329688|NCT00574509|Radiation|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
329689|NCT00574522|Radiation|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
329690|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
329691|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
329692|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
329693|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
329694|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
329695|NCT00574574|Dietary Supplement|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
329696|NCT00574587|Drug|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
329697|NCT00574587|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
329698|NCT00004107|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
329998|NCT00569673|Drug|docetaxel|
329999|NCT00004089|Drug|paclitaxel|
330000|NCT00569673|Drug|trabectedin|
330001|NCT00569686|Drug|lovaza|lovaza 4 gm po daily
330002|NCT00569686|Drug|placebo|placebo
330003|NCT00569699|Drug|S-1, Bevacizumab|S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25 m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15.
330004|NCT00569712|Drug|budesonide/formoterol fumarate dihydrate inhalation aerosol|
330005|NCT00569712|Genetic|DNA methylation analysis|
329045|NCT00587496|Drug|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
329046|NCT00589992|Drug|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
329344|NCT00581815|Device|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
329345|NCT00581828|Drug|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
329346|NCT00581841|Other|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
329347|NCT00004146|Drug|carboxyamidotriazole|Given orally
329348|NCT00581854|Drug|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
329349|NCT00581867|Drug|Insulin Aspart|40IU insulin aspart applied intranasally
329350|NCT00581867|Drug|Placebo|Placebo
329351|NCT00581880|Behavioral|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
329352|NCT00581893|Drug|Phenytoin|Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
329353|NCT00581906|Radiation|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) & group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite & will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st & 2nd weeks of treatment & the 2nd intra-treatment DCE-MRI is recommended between the 3rd & 4th weeks of treatment.
329354|NCT00581919|Drug|Bortezomib, Dexamethasone, Doxorubicin, Acetyl-L-Carnitine|Bortezomib, Dexamethasone, and Doxorubicin, 4-8 cycles of 21 days. ALCAR will also be given daily.
329355|NCT00581945|Drug|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
329356|NCT00581945|Drug|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
329056|NCT00590070|Drug|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
329057|NCT00590070|Drug|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
329058|NCT00590083|Biological|CTL administration|Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.
One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2.
329059|NCT00004182|Drug|irinotecan hydrochloride|
329060|NCT00590109|Other|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
329061|NCT00590109|Other|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
329062|NCT00590122|Drug|Parcopa|at subjects current stable dose of comparator
329063|NCT00590122|Drug|carbidopa-levodopa|at subjects current stable dose
329064|NCT00590135|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
329065|NCT00590161|Drug|pentoxifylline (PTX)|400 mg PO tid
329066|NCT00590161|Drug|placebo|placebo tid
329067|NCT00590174|Drug|Aspirin|stopping clopidogrel at 1 year after DES implantation
329068|NCT00590174|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
329069|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
329361|NCT00584701|Drug|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
329362|NCT00584727|Device|senofilcon A toric contact lens|contact lens
329363|NCT00584727|Device|alphafilcon A toric|contact lens
329364|NCT00584727|Device|etafilcon A sphere|contact lens
329365|NCT00584740|Drug|AIN457|10 mg/kg
329366|NCT00584740|Drug|Placebo|Matching placebo to AIN457
329367|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
333959|NCT00417612|Other|Placebo|Placebo sugar pill
333960|NCT00417638|Device|Endovascular cooling by the Celsius Control System|
333961|NCT00417638|Other|Standard of care|
333962|NCT00417664|Drug|dexmedetomidine|
333963|NCT00417664|Drug|midazolam|
328760|NCT00554489|Behavioral|exercise intervention|participation in physical activity intervention program weeks 2 through 5
328761|NCT00554502|Drug|supportive therapy with: ACE-inhibitor / ARB / Statin|Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).
ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)
Other antihypertensive medications depending on the clinical decision and following current guidelines.
Statin therapy
Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day.
328762|NCT00556842|Device|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
328763|NCT00556842|Device|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
328764|NCT00004024|Biological|aldesleukin|
328765|NCT00556855|Other|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
328766|NCT00556855|Other|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
328767|NCT00556868|Other|Breakfast/no breakfast|A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.
B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention
328768|NCT00556894|Drug|CF101|orally q12h
328769|NCT00556907|Radiation|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
328770|NCT00556907|Device|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
328771|NCT00556920|Drug|COREG CR|
328772|NCT00556933|Drug|rabbit anti-thymocyte globulin|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
333602|NCT00426244|Other|Placebo Ultrasound|In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.
The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects.
333603|NCT00426257|Procedure|Secondary debulking|Secondary debulking
333604|NCT00426257|Procedure|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
333605|NCT00426270|Drug|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
333606|NCT00003386|Biological|BCG vaccine|
333607|NCT00426283|Drug|Flovent|1760 mcg daily
333608|NCT00426283|Other|Placebo|1760 mcg daily
333609|NCT00426296|Drug|atazanavir (Reyataz)|
333610|NCT00426296|Drug|ritonavir (Norvir)|
333611|NCT00429234|Drug|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
333612|NCT00429234|Drug|Gemcitabine|Starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
333613|NCT00429247|Drug|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
333964|NCT00420849|Drug|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
333965|NCT00420862|Procedure|Spiral Computed Tomography|
333966|NCT00420875|Device|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
333967|NCT00420888|Drug|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
339837|NCT00543751|Drug|MK0767|
339838|NCT00543764|Other|Use of an intraoperative pathway|Utilization of an intraoperative pathway
339839|NCT00543777|Procedure|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
334365|NCT00415116|Drug|lenalidomide|
334366|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
334367|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
334368|NCT00415142|Drug|saredutant (SR48968)|oral administration (capsules)
334369|NCT00415142|Drug|placebo|oral administration (capsules)
334370|NCT00415142|Drug|escitalopram|oral administration (capsules)
334371|NCT00415155|Drug|LY2181308|Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)
Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle.
334372|NCT00003317|Procedure|surgery|
334373|NCT00415168|Drug|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
334374|NCT00415168|Drug|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
334375|NCT00415194|Drug|pemetrexed|500 mg/m^2, IV, every 21 days, six 21 day cycles
334376|NCT00415194|Drug|cisplatin|75 mg/m^2, administered IV, every 21 days, six 21 day cycles
334377|NCT00415194|Drug|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
334378|NCT00415220|Procedure|Spinal Manipulation, Microdiscectomy|
334379|NCT00415233|Biological|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
334380|NCT00417664|Drug|propofol|
334381|NCT00417677|Drug|Combination of Temsirolimus and Sunitinib|
334382|NCT00417690|Drug|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
339486|NCT00508105|Procedure|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
339487|NCT00508118|Drug|Nicardipine|on bypass
339488|NCT00508118|Drug|0.9% saline|on bypass
339489|NCT00508131|Other|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
339490|NCT00508144|Drug|Alimta|500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks
339491|NCT00508157|Drug|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
339492|NCT00003751|Radiation|radiation therapy|
339493|NCT00508157|Drug|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
339494|NCT00508170|Behavioral|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
339495|NCT00508183|Procedure|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
339496|NCT00508183|Procedure|double row fixation|This technique, "double row" fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair.
339497|NCT00508196|Procedure|Dual chamber pacing with long AV delay|for 1 week
339498|NCT00508196|Procedure|VVI pacing|30 min
339840|NCT00546117|Drug|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing >30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
339841|NCT00546117|Drug|placebo|Placebo Solutab in 15 and 30 mg dosages.
339842|NCT00546130|Drug|Irinotecan hydrochloride|Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
339843|NCT00546130|Drug|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
339844|NCT00546130|Drug|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
339845|NCT00546143|Drug|Omalizumab|
339846|NCT00546143|Drug|Omalizumab|
338825|NCT00524199|Drug|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
338826|NCT00524199|Other|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
339155|NCT00516074|Drug|placebo|subcutaneous injection, volume equivalent to active, twice a day
339156|NCT00003793|Genetic|microsatellite instability analysis|
339157|NCT00516087|Genetic|Genetically modified CTLs|LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
Four different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:
Group One Day 0 2x107 cells/m2 Day 14 2x107 cells/m2
Group Two Day 0 2x107 cells/m2 Day 14 1x108 cells/m2
Group Three Day 0 1x108 cells/m2 Day 14 2x108 cells/m2
Group Four Day 0 2x108 cells/m2 Day 14 4x108 cells/m2
339158|NCT00516100|Drug|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
339159|NCT00516113|Drug|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
339160|NCT00516139|Drug|Lamotrigine|Open-label
339161|NCT00516152|Drug|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|Day Preparative Regimen for GVHD Prophylaxis
7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
3 Fludarabine 30 mg/m(2)IV
2 REST Tacrolimus 0.01 mg/kg CIVI
1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion
1 Methotrexate 5mg/m(2)IV
3 Methotrexate 5mg/m(2)IV
6 Methotrexate 5mg/m(2)IV
7 G-CSF 5mcg/kg SQ daily
11 Methotrexate 5mg/m(2)IV
90 Evaluate Response
339162|NCT00516165|Drug|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
339163|NCT00516178|Drug|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
339164|NCT00516178|Drug|Saline|3 infusions, perioperative or post-PTCA
339165|NCT00516191|Drug|Liposomal Doxorubicin/Melphalan/Bortezomib|Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV
The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)
339166|NCT00516217|Biological|galiximab|
339167|NCT00003793|Genetic|mutation analysis|
339168|NCT00516243|Other|placebo|Given PO
339169|NCT00516243|Other|quality-of-life assessment|Ancillary studies
338497|NCT00529737|Procedure|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
338498|NCT00003864|Drug|carboplatin|
338499|NCT00529750|Drug|IRBESARTAN|Tablets
338500|NCT00529750|Drug|Atenolol|Tablets
338501|NCT00529763|Drug|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
338502|NCT00529776|Procedure|Continuous lateral rotation therapy|
338503|NCT00532493|Drug|prazosin|Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized "first dose" effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually.
338504|NCT00532493|Other|placebo|"sugar" pill
338505|NCT00532506|Drug|SK-0403|
338506|NCT00532519|Drug|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
338507|NCT00532532|Drug|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
338508|NCT00532532|Drug|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
338827|NCT00524225|Drug|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
338828|NCT00524238|Drug|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
338829|NCT00524251|Drug|esomeprazole|
338830|NCT00524264|Drug|ketorolac|Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.
Placebo
338831|NCT00524277|Biological|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
338832|NCT00524277|Biological|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
337819|NCT00545415|Dietary Supplement|Order 1|Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
337820|NCT00000577|Drug|Adrenergic-Beta Agonists|
337821|NCT00003953|Drug|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
338162|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
338163|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
338164|NCT00537537|Drug|Telbivudine|
338165|NCT00537550|Drug|Vincristine|Steroids pre-treatment
338166|NCT00537550|Drug|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
338167|NCT00537563|Drug|Telithromycin|
338168|NCT00003909|Drug|motexafin gadolinium|Given IV
338169|NCT00537576|Drug|LACTIN-V|Arm 1: 5.0 x 10^8 cfu/dose 1x/day x 5 days total intravaginal. Arm 2: 1.0 x 10^9 cfu/dose 1x/day x 5 days total intravaginal. Arm 3: 2.0 x 10^9 cfu/dose 1x/day x 5 days total intravaginal. Arm 4: placebo 1x/day x 5 days total intravaginal.
338170|NCT00537589|Procedure|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
338171|NCT00537602|Drug|miglustat|
338172|NCT00003925|Drug|tegafur-uracil|
338173|NCT00540228|Biological|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
338174|NCT00540228|Biological|Fluarix™|Single dose, Intramuscular injection
338175|NCT00540241|Drug|Pemetrexed|in-label use
338176|NCT00540254|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
338177|NCT00540254|Other|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
337471|NCT00003342|Drug|carboplatin|
337472|NCT00419250|Drug|lenalidomide|
337473|NCT00419250|Drug|lenalidomide|
337474|NCT00419250|Drug|lenalidomide|
337475|NCT00419250|Drug|lenalidomide|
337476|NCT00419250|Drug|lenalidomide|
337477|NCT00419263|Drug|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
337478|NCT00419263|Drug|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
337479|NCT00419263|Drug|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
337480|NCT00419276|Procedure|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
337481|NCT00419289|Behavioral|follow-up rehabilitation of participants with COPD|
337482|NCT00000511|Dietary Supplement|mineral supplements|
337483|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
337822|NCT00545415|Dietary Supplement|Order 2|Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
337823|NCT00547950|Drug|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid*1year.
337824|NCT00003958|Drug|vincristine sulfate|Given IV
337825|NCT00547963|Behavioral|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
337826|NCT00547976|Drug|[C-11]PBR28|
337827|NCT00547989|Drug|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
337828|NCT00547989|Drug|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
337829|NCT00547989|Drug|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
332328|NCT00425724|Drug|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
332329|NCT00425737|Biological|Rotarix|
332330|NCT00425750|Drug|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
332331|NCT00425750|Drug|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
332332|NCT00425750|Other|laboratory biomarker analysis|Tissue and blood collection.
332333|NCT00003382|Drug|topotecan hydrochloride|
332334|NCT00425750|Other|pharmacological study|Blood collection.
332335|NCT00428714|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 28 day cycles until disease progression, unacceptable toxicity or 3 years
332336|NCT00428727|Drug|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
332337|NCT00428727|Drug|placebo patch|daily application during 90 days
332338|NCT00428766|Drug|MORAb-003|
332339|NCT00428779|Procedure|running during 24 hours without sleep|patients running during 24 hours without sleep
332340|NCT00428779|Other|no sleeping|patients without sleep during 24 hours
332341|NCT00428792|Drug|Methylphenidate 20 mg long-acting capsules|
332676|NCT00417053|Radiation|radiation therapy|
332677|NCT00420277|Drug|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
332678|NCT00420290|Drug|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
332679|NCT00420290|Drug|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
332680|NCT00420303|Drug|Etanercept|50 mg injection once weekly
332681|NCT00420303|Other|Placebo|placebo
331632|NCT00443053|Drug|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
331633|NCT00443079|Drug|IdB 1016 (Siliphos)|1 pill 3 times daily x 3 months
331991|NCT00003405|Drug|cytarabine|
331992|NCT00434447|Drug|Zoledronic acid|
331993|NCT00434460|Behavioral|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
331994|NCT00434473|Drug|A-001|A-001
331995|NCT00434473|Other|Placebo|Placebo
331996|NCT00434486|Drug|SKI-606|
331997|NCT00434499|Drug|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
331998|NCT00434512|Biological|HIV vaccine 732461|
331999|NCT00434525|Procedure|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
332000|NCT00434525|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
332001|NCT00437164|Drug|Insulin|
332002|NCT00437164|Drug|Oral GW677954 Capsules (15 mg)|
332003|NCT00003415|Drug|amifostine trihydrate|
332004|NCT00437177|Drug|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
332005|NCT00437177|Drug|[(123)I] iodobenzamide|[(123)I] iodobenzamide 185 MBq I.V., at discharge.
332006|NCT00437190|Device|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
332007|NCT00437190|Device|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
332008|NCT00437203|Drug|PF-00477736|Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion.
331266|NCT00451269|Device|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
331267|NCT00451282|Behavioral|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
331268|NCT00451295|Drug|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
331269|NCT00003486|Procedure|differentiation therapy|
331270|NCT00451295|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
331271|NCT00451308|Procedure|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
331272|NCT00451308|Procedure|Induction of labor with foley balloon with 30cc|30cc of saline in foley
331273|NCT00451321|Drug|Otelixizumab|Infusion
331274|NCT00454467|Procedure|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
331275|NCT00454467|Procedure|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
331276|NCT00454467|Procedure|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
331634|NCT00443092|Other|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
331635|NCT00003437|Drug|asparaginase|
331636|NCT00443092|Other|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
331637|NCT00443105|Drug|Tacrolimus 0.03% ointment (Protopic)|
331638|NCT00443118|Device|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
331639|NCT00445783|Genetic|mutation analysis|
331640|NCT00003452|Drug|antineoplaston AS2-1|
331641|NCT00445783|Other|immunohistochemistry staining method|
331642|NCT00445783|Other|laboratory biomarker analysis|
330905|NCT00460616|Drug|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
330906|NCT00460629|Procedure|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
330907|NCT00460642|Drug|GnRH Antagonist (Cetrotide)|
330908|NCT00460655|Drug|GSK1358820|botulinum toxin type A
330909|NCT00460655|Drug|Placebo|Placebo
330910|NCT00460668|Behavioral|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
330911|NCT00460681|Drug|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
330912|NCT00460694|Biological|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
330913|NCT00003536|Procedure|alternative product therapy|
330914|NCT00416494|Drug|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
330915|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
330916|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
330917|NCT00416507|Drug|fluorouracil|
330918|NCT00416507|Drug|gemcitabine hydrochloride|
330919|NCT00416507|Drug|liposomal cisplatin|
330920|NCT00416520|Drug|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
330921|NCT00416520|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
330922|NCT00416520|Drug|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
330923|NCT00416533|Drug|docetaxel|
330924|NCT00000509|Behavioral|diet, potassium-supplementation|
330925|NCT00003329|Genetic|gene mapping|
330926|NCT00416533|Drug|doxorubicin hydrochloride|
330293|NCT00562198|Drug|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
330294|NCT00562198|Drug|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
330295|NCT00562211|Drug|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
330296|NCT00562211|Drug|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
330297|NCT00562224|Drug|PCI-24781|Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart ("TID"), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart ("BID"). If a DLT occurs on the "BID" schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached.
330298|NCT00562237|Biological|S205 placebo|2 i.m. injections per subject (0.5 mL each)
330299|NCT00562237|Biological|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
330570|NCT00552682|Drug|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
330571|NCT00552695|Device|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
330572|NCT00552695|Device|Placebo|Placebo patch identical in appearance to Synera
330573|NCT00552708|Drug|COREG CR|
330574|NCT00555126|Device|Warming with endovascular catheter + forced air warming|Warming after Randomization
330575|NCT00555139|Drug|GSK561679|
330576|NCT00555139|Drug|GW876008|
330577|NCT00555139|Drug|alprazolam|
330578|NCT00555152|Drug|lapatinib ditosylate|Given PO
330579|NCT00555152|Other|placebo|Given PO
330580|NCT00555152|Other|laboratory biomarker analysis|Correlative studies
330581|NCT00555165|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
330582|NCT00004010|Drug|etoposide|
330583|NCT00555191|Behavioral|diet restriction|each meal should contain less than 2 gm fructose
330006|NCT00569712|Genetic|comparative genomic hybridization|
330007|NCT00569712|Genetic|microarray analysis|
330008|NCT00569712|Other|bronchoalveolar lavage|
330009|NCT00569712|Other|immunoenzyme technique|
330010|NCT00004089|Procedure|conventional surgery|
330011|NCT00569712|Other|laboratory biomarker analysis|
330012|NCT00569712|Procedure|bronchoscopy|
330013|NCT00569738|Procedure|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
330014|NCT00569751|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
330015|NCT00569777|Device|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
330016|NCT00569777|Device|Placebo Lens|contact lens without drug
330017|NCT00569790|Drug|S-1, Irinotecan, Bevacizumab|S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15.
330018|NCT00569803|Drug|belatacept|single dose, 116 days
330019|NCT00572117|Drug|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
330020|NCT00572130|Genetic|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
330300|NCT00562237|Biological|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
330301|NCT00562237|Biological|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
330302|NCT00004055|Drug|paclitaxel|
330303|NCT00562237|Biological|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
330304|NCT00562237|Biological|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
330305|NCT00562237|Biological|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
329357|NCT00581958|Other|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
329358|NCT00584662|Drug|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
329359|NCT00584675|Device|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
329360|NCT00584688|Drug|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
329699|NCT00577083|Device|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
329700|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
329701|NCT00577096|Behavioral|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
329702|NCT00577096|Biological|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
329703|NCT00004125|Drug|cyclophosphamide|
329704|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
329705|NCT00577096|Drug|Thalidomide|Fifty percent of the participants received 400 mg daily
329706|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
329707|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
329708|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
329709|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
329710|NCT00577096|Drug|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
329711|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
329368|NCT00004162|Biological|sargramostim|
329369|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
329370|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
329371|NCT00584766|Procedure|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
329372|NCT00584779|Drug|Gabapentin|CLcr:14-5 mL/min
329373|NCT00584779|Drug|Gabapentin|CLcr: 29-15 mL/min
329374|NCT00584779|Drug|Gabapentin|Hemodialysis
329375|NCT00584779|Drug|Gabapentin|CLcr: 29-30 mL/min
329376|NCT00584805|Biological|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is < 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
329377|NCT00584818|Drug|PB127 for Injectable Suspension|Stages 1 & 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.
Stage 3 - will utilize infusion rate and dose established in Stages 1 & 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions.
329378|NCT00584831|Device|senofilcon A|toric contact lens
329379|NCT00004162|Drug|methotrexate|
329380|NCT00584831|Device|balafilcon A|toric contact lens
329381|NCT00584831|Device|omafilcon A|toric contact lens
329382|NCT00584831|Device|lotrafilcon B|toric contact lens
329719|NCT00577109|Drug|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
329720|NCT00577109|Drug|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
329721|NCT00577109|Drug|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
329722|NCT00577109|Drug|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
329723|NCT00579384|Drug|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
329724|NCT00579384|Drug|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
328773|NCT00556933|Drug|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
328774|NCT00556933|Drug|rabbit anti-thymocyte globulin|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
328775|NCT00004024|Biological|autologous tumor cell vaccine|
328776|NCT00556933|Drug|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
329070|NCT00004183|Drug|capecitabine|
329071|NCT00590187|Drug|sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
329072|NCT00590187|Drug|sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
329073|NCT00551902|Procedure|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
329074|NCT00551915|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
329075|NCT00551915|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
329076|NCT00551915|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
329077|NCT00551915|Biological|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
329078|NCT00551915|Biological|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
329079|NCT00003994|Drug|fluorouracil|Given IV
329080|NCT00551928|Drug|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
329081|NCT00551928|Drug|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
329082|NCT00551928|Drug|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
329083|NCT00551928|Drug|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
329084|NCT00551941|Procedure|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
333968|NCT00420888|Drug|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
333969|NCT00420901|Drug|sildenafil|
333970|NCT00420914|Procedure|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
333971|NCT00420927|Biological|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
333972|NCT00420927|Drug|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
333973|NCT00420927|Biological|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
333974|NCT00003350|Procedure|quality-of-life assessment|Ancillary studies
333975|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
333976|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
333977|NCT00420953|Drug|Cordarone|
333978|NCT00420992|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
333979|NCT00420992|Drug|Placebo|capsules, bid
333980|NCT00421005|Drug|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
333981|NCT00421018|Drug|Single corticosteroid inhalers and Singulair|Treatment steps according to preset algorithm
333982|NCT00421031|Drug|DVS-233 SR|
333983|NCT00421044|Drug|Patupilone/EPO906|
328777|NCT00556933|Drug|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
328778|NCT00556946|Drug|Treatment of Port Wine Stains|Treatment of Port Wine Stains
328779|NCT00556959|Drug|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
328780|NCT00556959|Drug|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
328781|NCT00556959|Drug|placebo|placebo tablets for 8 weeks
334383|NCT00003336|Drug|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
334384|NCT00417690|Drug|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
334385|NCT00417716|Drug|Intravitreal Bevacizumab|
334386|NCT00417729|Drug|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
334732|NCT00455650|Drug|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
334733|NCT00455650|Drug|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
334734|NCT00455650|Drug|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
334735|NCT00455663|Behavioral|Cognitive Adaptation Training|Environmental supports for all independent living skills
334736|NCT00455663|Behavioral|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
334737|NCT00455663|Other|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
334738|NCT00455676|Procedure|Chevron osteotomy versus Scarf osteotomy|
334739|NCT00455689|Drug|Leuprolide acetate (Lupron)|Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection
Leuprolide is a widely used GnRH agonist that is manufactured by TAP Pharmaceutical Products. Leuprolide is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women.
334740|NCT00455702|Drug|d-cycloserine|50mg dose d-cycloserine v placebo
334741|NCT00455715|Drug|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
334742|NCT00003514|Drug|antineoplaston A10|
334743|NCT00455741|Drug|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
339847|NCT00546143|Drug|Omalizumab|
339848|NCT00000578|Drug|theophylline|
339849|NCT00003954|Radiation|total-body irradiation|Undergo TBI
339850|NCT00546156|Drug|Doxorubicin|Standard chemotherapy regimen
339851|NCT00546156|Drug|Cyclophosphamide|Standard chemotherapy regimen
339852|NCT00546156|Drug|Paclitaxel|Standard chemotherapy regimen
339853|NCT00546156|Drug|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
339854|NCT00546169|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
339855|NCT00546221|Behavioral|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
339856|NCT00546221|Behavioral|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
339857|NCT00546234|Drug|tiotropium|18 mcg daily via Handihaler
339858|NCT00546234|Drug|long acting beta agonist|Turbohaler, 6 & 12 mcg
339859|NCT00546247|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
339860|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo donor PBSCT
334387|NCT00417742|Behavioral|Service delivery through a Headache Management Program|
334388|NCT00417768|Drug|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
334389|NCT00417768|Other|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
334390|NCT00417794|Drug|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
334391|NCT00417794|Drug|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
339170|NCT00516243|Procedure|questionnaire administration|Ancillary studies
339171|NCT00516243|Procedure|laboratory biomarker analysis|Correlative studies
339172|NCT00516243|Drug|defined green tea catechin extract|Given PO
339173|NCT00516256|Behavioral|CHESS System|Internet-based computer program for 6 months.
339499|NCT00508209|Drug|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
339500|NCT00508222|Drug|Kaletra Tablets|Kaletra 800/200 OD
339501|NCT00510653|Drug|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
339502|NCT00003772|Procedure|quality-of-life assessment|
339503|NCT00510666|Drug|Saline|Saline infusion adjunct to morphine PCA pump
339504|NCT00510666|Drug|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
339505|NCT00510666|Drug|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
339506|NCT00510666|Drug|Saline|Preemptive saline as a control group to tramadol one
339507|NCT00510679|Behavioral|Health worker supports (supervision, job aids, incentives)|
339508|NCT00510692|Drug|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
339509|NCT00510692|Procedure|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
339510|NCT00510692|Procedure|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
339511|NCT00510692|Drug|Placebo|2 x 500mg placebo capsules twice daily for 6 months
339512|NCT00510705|Other|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
339513|NCT00003773|Drug|oglufanide disodium|
339514|NCT00510705|Other|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
339515|NCT00510705|Other|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
338833|NCT00524277|Biological|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
338834|NCT00000559|Drug|estrogen replacement therapy|
338835|NCT00003835|Other|laboratory biomarker analysis|Correlative studies
338836|NCT00524277|Biological|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
338837|NCT00524303|Drug|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
338838|NCT00524303|Drug|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
338839|NCT00524303|Drug|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
338840|NCT00524303|Drug|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
338841|NCT00524316|Drug|doxorubicin hydrochloride|Transarterial chemoembolization
338842|NCT00524316|Drug|sunitinib malate|Given Orally
338843|NCT00524316|Other|laboratory biomarker analysis|Correlative Study
338844|NCT00524316|Procedure|hepatic artery embolization|Surgical procedure
338845|NCT00524316|Procedure|quality-of-life assessment|Correlative Study
338846|NCT00003837|Drug|nelarabine|
338847|NCT00524342|Drug|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
338848|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
339174|NCT00516256|Behavioral|Cancer Information Mentor|Phone calls to the patient for 6 months.
339175|NCT00518895|Drug|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
339176|NCT00518908|Drug|Sevoflurane|3.2 Vol % for postconditioning
338178|NCT00540267|Other|No Intervention|No Intervention
338179|NCT00540280|Radiation|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
338180|NCT00540293|Drug|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
338181|NCT00540306|Device|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
338182|NCT00540319|Behavioral|HIP|The Health in Pregnancy (HIP) computer program provides tailored, interactive "Video Doctor" counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers.
338509|NCT00532532|Drug|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
338510|NCT00003877|Biological|filgrastim|
338511|NCT00532545|Drug|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
338512|NCT00532558|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
338513|NCT00532558|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
338514|NCT00532571|Drug|CoQ10|
338515|NCT00532584|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
338516|NCT00532597|Procedure|On-line hemodiafiltration|
338517|NCT00532597|Procedure|Low flux hemodialysis|
338518|NCT00532610|Drug|GSK189075|
338519|NCT00532623|Drug|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
338520|NCT00532623|Drug|Sequential|Gemcitabine monotherapy followed by Vinorelbine monotherapy:
-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles.
338521|NCT00003877|Drug|carboplatin|
338522|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
338523|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
337830|NCT00548002|Drug|trovafloxacin and levofloxacin|Trovafloxacin: <60 kg 200 mg iv/orally once daily and >60 kg 300 mg iv/orally once daily Levofloxacin: < 60 kg 500 mg iv/orally once daily and >60 kg 500 mg iv/orally bid
337831|NCT00548015|Behavioral|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
337832|NCT00548041|Other|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
337833|NCT00548054|Biological|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
337834|NCT00548054|Biological|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
337835|NCT00003958|Drug|cyclophosphamide|Given IV
337836|NCT00548067|Drug|Valsartan/hydrochlorothiazide (HCTZ)|
337837|NCT00548067|Drug|Valsartan/amlodipine|
337838|NCT00548067|Drug|Amlodipine/hydrochlorothiazide(HCTZ)|
337839|NCT00548067|Drug|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
337840|NCT00548080|Drug|MK0991, caspofungin acetate / Duration of Treatment:|
337841|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
337842|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
337843|NCT00548106|Dietary Supplement|partially hydrolyzed whey|Total infant feeding by study formula.
338183|NCT00003926|Drug|amifostine trihydrate|Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.
Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined.
338184|NCT00540332|Drug|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
338185|NCT00540332|Drug|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
338186|NCT00540345|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
338187|NCT00540345|Drug|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
332682|NCT00420316|Biological|Rotarix (primary vaccination study)|
332683|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
332684|NCT00003346|Drug|acetaminophen|
332685|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
332686|NCT00420342|Drug|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
332687|NCT00420355|Drug|atazanavir|Atazanavir 300 mg daily on Days 6-12.
332688|NCT00420355|Drug|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
332689|NCT00420368|Dietary Supplement|No food supplement|
332690|NCT00420368|Dietary Supplement|Food supplement: fortified spread|
332691|NCT00420368|Dietary Supplement|Food supplement: maize-soy flour|
332692|NCT00420381|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
332693|NCT00420394|Procedure|Chemotherapy|
332694|NCT00420394|Procedure|surgery|
332695|NCT00003346|Drug|acetylcysteine|
332696|NCT00420394|Procedure|radiotherapy|
332697|NCT00420407|Drug|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
332698|NCT00420407|Drug|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
332699|NCT00420420|Drug|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
332700|NCT00420420|Drug|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
333040|NCT00458536|Drug|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
333041|NCT00458549|Dietary Supplement|omega-3 fatty acids|
333042|NCT00458549|Other|immunohistochemistry staining method|
332009|NCT00437203|Drug|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
332010|NCT00437216|Drug|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
332011|NCT00437216|Drug|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
332012|NCT00437229|Drug|GW679769 Oral Tablets|
332013|NCT00437229|Drug|dexamethasone oral tablets & intravenous|
332342|NCT00428805|Behavioral|classroom curriculum|classroom curriculum for 3 & 4 year old children includes activities to increase intake of fruits, vegetables, & whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.
Teachers are trained to carry out the classroom curriculum.
332343|NCT00003391|Biological|monoclonal antibody muJ591|
332344|NCT00428805|Behavioral|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
332345|NCT00428805|Behavioral|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
332346|NCT00428805|Behavioral|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
332347|NCT00428805|Behavioral|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
332348|NCT00428805|Behavioral|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
332349|NCT00428805|Behavioral|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
332350|NCT00428818|Drug|trimethoprim-sulfamethoxazole or doxycycline|
332351|NCT00428844|Drug|daptomycin|6 mg/kg
332352|NCT00428844|Drug|daptomycin|8 mg/kg
332353|NCT00428844|Drug|vancomycin|1 gram
332354|NCT00003392|Biological|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
332355|NCT00428844|Drug|teicoplanin|6 mg/kg; used only at UK sites
331643|NCT00445783|Procedure|examination|
331644|NCT00445783|Procedure|mutation carrier screening|
331645|NCT00445783|Procedure|study of high risk factors|
331646|NCT00445796|Drug|Artesunate|
331647|NCT00445796|Drug|Amodiaquine|
331648|NCT00445835|Other|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
331649|NCT00445835|Other|Conservative arm|Conservative medical approach
331650|NCT00445848|Biological|bevacizumab|
331651|NCT00003453|Drug|antineoplaston A10|
331652|NCT00445848|Drug|erlotinib hydrochloride|
331653|NCT00445861|Biological|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
331654|NCT00445861|Biological|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
331655|NCT00445861|Biological|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
331656|NCT00445861|Procedure|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
332014|NCT00003415|Drug|topotecan hydrochloride|
332015|NCT00437229|Drug|ondansetron oral tablets & intravenous|
332016|NCT00437242|Drug|Odiparcil|
332017|NCT00437255|Drug|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
332018|NCT00437255|Drug|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
332019|NCT00437268|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, 21 day cycles until progressive disease
332020|NCT00437268|Drug|irinotecan|300 mg/m2, IV, day 1 every 21 days until progressive disease
330927|NCT00416533|Drug|prednisone|
330928|NCT00416546|Drug|AEB071|
331277|NCT00454467|Procedure|Cost Data|Cost Data will be collected via hospital billing databases.
331278|NCT00454467|Procedure|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
331279|NCT00454480|Biological|alemtuzumab|
331280|NCT00003502|Procedure|differentiation therapy|
331281|NCT00454480|Drug|arsenic trioxide|
331282|NCT00454480|Drug|azacitidine|
331283|NCT00454480|Drug|busulfan|
331284|NCT00454480|Drug|clofarabine|
331285|NCT00454480|Drug|cytarabine|
331286|NCT00454480|Drug|daunorubicin hydrochloride|
331287|NCT00454480|Drug|fludarabine phosphate|
331288|NCT00454480|Drug|gemtuzumab ozogamicin|
331289|NCT00454480|Drug|melphalan|
331290|NCT00454480|Drug|tipifarnib|
331291|NCT00003505|Drug|antineoplaston A10|
331292|NCT00454480|Genetic|DNA methylation analysis|
331293|NCT00454480|Genetic|cytogenetic analysis|
331294|NCT00454480|Genetic|gene expression analysis|
331295|NCT00454480|Genetic|mutation analysis|
331296|NCT00454480|Other|diagnostic laboratory biomarker analysis|
331297|NCT00454480|Other|immunologic technique|
331298|NCT00454480|Procedure|allogeneic hematopoietic stem cell transplantation|
331299|NCT00454480|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
330584|NCT00555204|Drug|ABT-089|10 mg - capsules once daily for 12 weeks
330585|NCT00555204|Drug|ABT-089|5 mg - capsules once daily for 12 weeks
330586|NCT00555204|Drug|ABT-089|15 mg - capsules once daily for 12 weeks
330587|NCT00555204|Drug|ABT-089|20 mg - capsules once daily for 12 weeks
330588|NCT00555204|Drug|ABT-089|30 mg - capsules once daily for 12 weeks
330589|NCT00555204|Drug|ABT-089|35 mg - capsules once daily for 12 weeks
330590|NCT00555204|Drug|placebo|placebo - capsules once daily for 12 weeks
330591|NCT00555217|Drug|losartan|50 or 100mg/day
330592|NCT00555217|Drug|lisinopril|10, 20 or 40 mg/day
330593|NCT00004010|Drug|prednisone|
330594|NCT00555230|Drug|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
330595|NCT00555230|Drug|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
330929|NCT00416559|Other|clinical observation|
330930|NCT00416572|Behavioral|behavioral dietary intervention|
330931|NCT00416572|Other|educational intervention|
330932|NCT00416572|Other|preventative dietary intervention|
330933|NCT00416572|Procedure|psychosocial assessment and care|
330934|NCT00416572|Procedure|quality-of-life assessment|
330935|NCT00416585|Drug|isotretinoin (Roaccutane)|
330936|NCT00003330|Biological|recombinant interleukin-12|
330937|NCT00416598|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
330938|NCT00416598|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
330939|NCT00416598|Drug|Busulfan|Given IV
330940|NCT00416598|Drug|Cytarabine|Given IV
330306|NCT00562250|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
330307|NCT00562250|Drug|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
330308|NCT00562250|Drug|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
330309|NCT00562263|Behavioral|Lifestyle modification|Dietary modification and regular physical activity
330310|NCT00562276|Procedure|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
330311|NCT00562289|Drug|aspirin|during the follow up
330312|NCT00562289|Drug|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
330313|NCT00004055|Drug|topotecan hydrochloride|
330314|NCT00562289|Device|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
330315|NCT00564707|Procedure|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
330316|NCT00564720|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
330317|NCT00564720|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
330318|NCT00564720|Drug|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
330319|NCT00564720|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
330320|NCT00564733|Drug|carboplatin|Given IV
330321|NCT00564733|Drug|docetaxel|Given IV
330322|NCT00564733|Drug|gemcitabine hydrochloride|Given IV
330323|NCT00004066|Drug|gemcitabine hydrochloride|
330324|NCT00564733|Drug|paclitaxel|Given IV
330596|NCT00555243|Procedure|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
330597|NCT00555243|Procedure|Traditional Surgical Education|Traditional surgical teaching (no simulator)
330598|NCT00555256|Drug|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
329712|NCT00577096|Drug|Thalidomide|Fifty percent of participants received 400 mg daily
329713|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
329714|NCT00000604|Procedure|cardiopulmonary bypass|
329715|NCT00004125|Drug|docetaxel|
329716|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
329717|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
329718|NCT00577109|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
330021|NCT00572130|Genetic|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
330022|NCT00572143|Other|ca coli follow-up by GP|patients randomized to follow up by GP
330023|NCT00572156|Drug|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
330024|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
330025|NCT00004096|Drug|vinorelbine ditartrate|
330026|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
330027|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
330028|NCT00572169|Drug|Bortezomib (Velcade)|
330029|NCT00572169|Drug|Thalidomide|
330030|NCT00572169|Drug|Dexamethasone|
330031|NCT00572169|Drug|Melphalan|
330032|NCT00572169|Drug|Cisplatin|
330033|NCT00572169|Drug|Doxorubicin|
330034|NCT00572169|Drug|Cyclophosphamide|
330035|NCT00572169|Drug|Etoposide|
330036|NCT00004097|Drug|fluorouracil|
329725|NCT00579423|Biological|QS21|Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.
Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.
Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient.
329726|NCT00579436|Drug|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
329727|NCT00579436|Drug|placebo|4 inert capsules daily by mouth for 12 weeks.
329728|NCT00579449|Behavioral|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
329729|NCT00579449|Behavioral|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
329730|NCT00579462|Other|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
329731|NCT00004135|Drug|fludarabine phosphate|
329732|NCT00579475|Drug|Mifegyne|tablets, 50 mg every other day
329733|NCT00579475|Drug|placebo|
329734|NCT00579501|Drug|Trabectedin|Trabectedin 1.5 mg/m^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
329735|NCT00579501|Drug|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
329736|NCT00579514|Genetic|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
329737|NCT00579527|Biological|Thymus Tissue for Transplantation|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and donor's biological mother are screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue if transplanted into the subject's quadriceps. Two to three months post thymus transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
330042|NCT00572221|Behavioral|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
330043|NCT00574587|Drug|Trastuzumab|Part A: Trastuzumab 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
330044|NCT00574587|Drug|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
329085|NCT00551941|Procedure|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
329086|NCT00551954|Drug|acarbose|100 mg (tablets) t.i.d.
329087|NCT00551954|Drug|placebo|one tablet t.i.d.
329088|NCT00551967|Procedure|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
329089|NCT00551980|Behavioral|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
329090|NCT00003994|Drug|amifostine trihydrate|Given IV
329091|NCT00551993|Procedure|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
329092|NCT00551993|Procedure|Laparoscopic Sacral Colpopexy|Standard laparoscopy
329383|NCT00584844|Biological|Live Francisella Tularensis Vaccine|Subjects will receive one drop of reconstituted vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (< 1:20).
329384|NCT00587522|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
329385|NCT00004173|Drug|paclitaxel|
329386|NCT00587548|Other|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
329387|NCT00587561|Behavioral|Social Cognition Interaction Training|manualized group therapy
329388|NCT00587561|Behavioral|WLC|wait-list control for 6 months, followed by the experimental group therapy
329389|NCT00587587|Device|Apligraf|Application at Day 0, potential re-application at Week 4
329390|NCT00587587|Other|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
329391|NCT00587600|Procedure|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
329392|NCT00587600|Procedure|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
328782|NCT00556972|Device|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
328783|NCT00559416|Drug|Cell Transfer|
328784|NCT00559429|Drug|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
328785|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
328786|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
328787|NCT00000590|Drug|immunoglobulins|
328788|NCT00004036|Drug|amifostine trihydrate|
328789|NCT00559429|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
328790|NCT00559442|Other|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
328791|NCT00559455|Drug|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
328792|NCT00559455|Drug|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
328793|NCT00559455|Drug|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
328794|NCT00559468|Drug|Sugammadex|single dose 4.0 mg/kg-1 Org 25969, administered at T1 3-10% after continuous infusion of rocuronium
328795|NCT00559481|Drug|dexamethasone|
328796|NCT00559481|Drug|ketoconazole|
328797|NCT00559481|Drug|therapeutic hydrocortisone|
328798|NCT00559481|Procedure|pharmacological study|
328799|NCT00004036|Drug|carboplatin|
328800|NCT00559494|Drug|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
328801|NCT00559494|Drug|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
334744|NCT00455741|Drug|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
334745|NCT00455754|Drug|Esomeprazole|
334746|NCT00455767|Drug|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
334747|NCT00455767|Drug|Placebo|Placebo
334748|NCT00455780|Behavioral|Weight Loss Phase|Weight loss using CBT and meal replacements
334749|NCT00455780|Behavioral|Continued CBT|Using CBT during weight loss maintenance
334750|NCT00455780|Behavioral|reduced energy density education|Additional nutritional learning
335089|NCT00447343|Procedure|fMRI and MRS scan|A scan pre-op and 6 months post-op.
335090|NCT00447356|Drug|recombinant interferon alfa|
335091|NCT00447369|Drug|Pregabalin|
335092|NCT00447369|Drug|sodium valproate|
335093|NCT00447382|Drug|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
335094|NCT00450203|Drug|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
335095|NCT00450203|Procedure|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
335096|NCT00450203|Procedure|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
335097|NCT00003478|Radiation|iodine I 131 monoclonal antibody 81C6|
335098|NCT00450203|Procedure|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
335099|NCT00450203|Drug|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
335100|NCT00450216|Drug|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
335101|NCT00450216|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
335102|NCT00450229|Drug|diindolylmethane|Given PO
335103|NCT00450229|Drug|placebo|Given PO
334392|NCT00417807|Drug|Imatinib mesilate|
334393|NCT00417820|Drug|BCT194|
334394|NCT00003336|Drug|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
334395|NCT00417833|Drug|Intravitreal Bevacizumab|
334396|NCT00417859|Device|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
334397|NCT00417872|Drug|Nitazoxanide|
334398|NCT00417872|Drug|Metronidazole|
334399|NCT00417885|Drug|exemestane|25 mg, oral, daily dosing
334400|NCT00417885|Drug|sunitinib malate|37.5 mg, oral, continuous dosing, daily
334401|NCT00417898|Drug|Aspirin|
334402|NCT00417911|Drug|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
334403|NCT00417924|Behavioral|Patient education|
334404|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
334405|NCT00003336|Procedure|bone marrow ablation with stem cell support|
334406|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
334407|NCT00421057|Behavioral|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
334408|NCT00421070|Procedure|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
334751|NCT00459186|Drug|Docetaxel|Infusion once per cycle
334752|NCT00459186|Drug|Prednisone|Prednisone 5 mg by mouth twice daily
334753|NCT00459212|Drug|GTI-2040|Given IV
334754|NCT00003524|Drug|antineoplaston AS2-1|
339516|NCT00510718|Drug|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
339517|NCT00510744|Drug|Creon|4 caps with meals, 2 with snacks
339518|NCT00510770|Device|CPAP application|
339519|NCT00510783|Drug|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
339520|NCT00510783|Drug|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
339521|NCT00510783|Drug|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
339861|NCT00546260|Drug|placebo|administration of iv bolus prior to angiography
339862|NCT00546260|Drug|PRT060128 Potassium|administration of iv bolus prior to angiography
339863|NCT00546273|Biological|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
339864|NCT00548782|Other|ADA ( American Diabetes Association) recommended diet|diet
339865|NCT00548808|Drug|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
339866|NCT00548808|Drug|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
339867|NCT00548808|Drug|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
339868|NCT00548821|Drug|Cisplatin|
339869|NCT00548834|Drug|CDP870|
339870|NCT00548847|Drug|GM-CSF, Interferon-α-2b|Dosing schedule: GM-CSF, 250 mcg/m2 Mon-Wed-Fri; Pegylated Interferon-α-2b 1.5 mcg/kg Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
339871|NCT00548860|Drug|Ferric Carboxymaltose|
339872|NCT00548860|Drug|Standard Medical Care (SMC)|
339177|NCT00518921|Drug|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
339178|NCT00518921|Drug|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
339179|NCT00518921|Drug|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
339180|NCT00518921|Drug|Placebo|Placebo, double dummy
339181|NCT00518934|Other|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
339182|NCT00518947|Drug|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
339183|NCT00003811|Biological|bleomycin sulfate|
339184|NCT00518947|Drug|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
339185|NCT00518947|Drug|verapamil plus lithium|
339186|NCT00518960|Drug|ProAlgaZyme|
339187|NCT00518973|Drug|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
339188|NCT00518986|Drug|armodafinil|200 mg/day
339189|NCT00518986|Drug|placebo|placebo
339190|NCT00519012|Drug|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
339522|NCT00510796|Behavioral|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
339523|NCT00510809|Drug|Policosanol|Policosanol 20 mg daily
339524|NCT00003775|Drug|leflunomide|
338524|NCT00532662|Drug|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
338525|NCT00532675|Drug|LBH589|
338526|NCT00532688|Drug|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
338527|NCT00535210|Behavioral|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
338528|NCT00535210|Behavioral|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
338849|NCT00527189|Behavioral|Balance Exercises|Home based balance exercises based on Otago Exercise programme
338850|NCT00527202|Drug|botulinum toxin A and saline|
338851|NCT00527215|Drug|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
338852|NCT00527228|Drug|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
338853|NCT00527228|Drug|placebo|
338854|NCT00527241|Behavioral|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
338855|NCT00527254|Device|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
338856|NCT00527267|Drug|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
338857|NCT00003854|Procedure|sentinel lymph node biopsy|
338858|NCT00527267|Drug|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
338188|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
338189|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
338190|NCT00540358|Drug|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
338191|NCT00540358|Drug|iniparib|Body weight adjusted dose
1 hour intravenous infusion
338192|NCT00540371|Other|Port wine stain Birthmark|Port wine stain Birthmark
338193|NCT00540384|Drug|Placebo|Placebo
338194|NCT00003926|Drug|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
338195|NCT00000576|Drug|beclomethasone|
338196|NCT00003937|Drug|cisplatin|
338197|NCT00542815|Drug|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
338198|NCT00542828|Biological|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
338199|NCT00542841|Procedure|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
338200|NCT00542854|Device|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
338201|NCT00542880|Drug|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
338202|NCT00542880|Drug|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
338529|NCT00535223|Behavioral|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
338530|NCT00003893|Drug|mitoxantrone hydrochloride|
338531|NCT00535223|Behavioral|Present Centered Group Therapy|Present Centered Group Therapy includes psych-education about PTSD and a problem solving "here and now" focus.
333043|NCT00458549|Other|laboratory biomarker analysis|
333044|NCT00458549|Other|liquid chromatography|
333045|NCT00458549|Procedure|biopsy|
333046|NCT00458549|Procedure|complementary or alternative medicine procedure|
333047|NCT00003520|Drug|antineoplaston A10|
333048|NCT00414336|Drug|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
333049|NCT00414349|Drug|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
333050|NCT00414349|Drug|oral intake|300 to 600 mg per day taken orally
333051|NCT00414349|Drug|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
333052|NCT00414375|Procedure|Operation on Admission|Laparoscopic appendectomy on admission
333053|NCT00414375|Procedure|Drainage and Interval Appendectomy|drainage with interval appendectomy
333054|NCT00414388|Drug|Sorafenib|400mg twice daily
333055|NCT00003313|Drug|carboplatin|
333056|NCT00414401|Behavioral|Clinical Reminder|
333057|NCT00414414|Drug|Prednisone|
333058|NCT00414414|Drug|placebo|placebo
333059|NCT00414427|Procedure|Intraarticular steroids|
333060|NCT00414440|Drug|Placebo|placebo comparator
333061|NCT00414440|Drug|Everolimus|experimental
333062|NCT00414453|Drug|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
333063|NCT00414453|Drug|Extended-release oxycodone|extended-release oxycodone titrating schedule
333064|NCT00414453|Drug|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
333065|NCT00414453|Drug|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
332356|NCT00428844|Drug|nafcillin|1-2 gram
332357|NCT00428844|Drug|oxacillin|1-2 gram
332358|NCT00428844|Drug|flucloxacillin|1-2 mg
332359|NCT00428857|Procedure|non invasive ventilation|non invasive ventilation
332360|NCT00431691|Drug|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
332361|NCT00431704|Drug|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
332362|NCT00431704|Drug|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
332701|NCT00420433|Procedure|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
332702|NCT00420433|Procedure|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
332703|NCT00420433|Procedure|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
332704|NCT00420446|Behavioral|Adjusted diet|
332705|NCT00423228|Drug|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
332706|NCT00423228|Drug|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
332707|NCT00423241|Device|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
332708|NCT00423241|Device|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
332709|NCT00423254|Biological|PSMA/PRAME|Low dose
332710|NCT00003364|Drug|vincristine sulfate|
332711|NCT00423254|Biological|PSMA/PRAME|high dose
332712|NCT00423267|Drug|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
332021|NCT00437268|Drug|cetuximab|400 mg/m2, IV, day 1, 250 mg/m2 day 8, day 15 cycle 1 then 250 mg/m2, IV, day 1, 8 and 15 of each cycle, IV, 21 day cycles until progressive disease
332022|NCT00437281|Drug|Placebo|Placebo
332023|NCT00437281|Drug|Pregabalin|Orally-administered pregabalin
332024|NCT00437294|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 21 day cycles until progressive disease
332025|NCT00003416|Biological|filgrastim|
332026|NCT00437294|Drug|placebo|oral, daily, 21 day cycles until progressive disease
332027|NCT00440050|Drug|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
332028|NCT00440050|Drug|Placebo|2 placebo capsules twice a day for 18 months
332029|NCT00440063|Drug|epoetin beta [NeoRecormon]|
332030|NCT00440076|Drug|Velcade|
332031|NCT00440089|Behavioral|Hands-on-Healing|
332032|NCT00003423|Drug|thioguanine|
332033|NCT00440102|Drug|Ketamine|Ketamine
332034|NCT00440102|Drug|Etomidate|Etomidate
332035|NCT00440115|Behavioral|High intensity disease management|Health education mailings, free nicotine replacement therapy or bupropion, 6 motivation interviews/counselling
332036|NCT00440115|Behavioral|Low intensity disease management|Health education mailings, free nicotine replacement therapy or bupropion, one motivation interview/counselling
332037|NCT00440115|Other|Comparison group|Health education mailings, free nicotine replacement therapy or bupropion
332038|NCT00440128|Drug|Docetaxel|Docetaxel
332363|NCT00431704|Drug|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
332364|NCT00431730|Procedure|flicker light stimulation|
332365|NCT00431743|Drug|Hydroxyethylstarch 130/0,4|
332366|NCT00431743|Drug|Lactated Ringer's solution|
331300|NCT00454493|Drug|Omacor (omega-3-acid ethyl esters)|
331301|NCT00454519|Procedure|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
331302|NCT00003505|Drug|antineoplaston AS2-1|
331303|NCT00454519|Procedure|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
331657|NCT00445874|Drug|Ketotifen with a Contact Lens (no generic name)|
331658|NCT00445887|Drug|levonorgestrel|Given orally
331659|NCT00445887|Other|placebo|Given orally
331660|NCT00445900|Drug|cyclophosphamide|
331661|NCT00445900|Drug|prednisone|
331662|NCT00000522|Drug|chlorthalidone|
331663|NCT00003453|Drug|antineoplaston AS2-1|
331664|NCT00445900|Drug|thalidomide|
331665|NCT00445900|Other|immunohistochemistry staining method|
331666|NCT00445900|Other|laboratory biomarker analysis|
331667|NCT00445900|Procedure|biopsy|
331668|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
331669|NCT00448721|Drug|Perifosine|Patients will begin perifosine at 100 mg PO daily with food.
331670|NCT00003468|Drug|antineoplaston AS2-1|
331671|NCT00448734|Drug|Picoplatin|The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.
Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion.
331672|NCT00448734|Drug|docetaxel|The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.
Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion.
331673|NCT00448747|Drug|diagnostic|A single administration of AEZS-130
330941|NCT00416598|Drug|Daunorubicin Hydrochloride|Given IV
330942|NCT00416598|Drug|Decitabine|Given IV
330943|NCT00416598|Drug|Etoposide|Given IV
330944|NCT00416598|Biological|Filgrastim|Given SC
330945|NCT00416598|Other|Laboratory Biomarker Analysis|Correlative studies
330946|NCT00416598|Other|Pharmacological Study|Correlative studies
330947|NCT00003342|Drug|doxorubicin hydrochloride|
330948|NCT00419302|Drug|Technosphere/Insulin|
330949|NCT00419315|Behavioral|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
330950|NCT00419315|Behavioral|Usual Care|Usual care included a referral to a specialty addiction treatment program.
330951|NCT00419328|Drug|NGR-hTNF|iv q3W escalating dose up 1.6 mcg/sqm
330952|NCT00419341|Biological|Human Normal Immunoglobulin for Subcutaneous Administration|
330953|NCT00419367|Drug|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
331304|NCT00457678|Drug|Dexamethasone|
331305|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
331306|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
331307|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
331308|NCT00457691|Drug|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
331309|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
331310|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
331311|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
331312|NCT00003517|Procedure|biologically based therapies|
330599|NCT00555282|Device|central venous catheter|coated central venous catheter
330600|NCT00555282|Device|central venous catheter|standard central venous catheter
330601|NCT00555308|Other|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
330602|NCT00555321|Drug|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term [ST]), in accordance with local practice and the package insert, 4 years (Long-Term Extension [LTE])
330603|NCT00555321|Drug|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
330604|NCT00557557|Drug|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
330605|NCT00557557|Drug|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
330606|NCT00557583|Drug|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
330607|NCT00004028|Drug|carmustine|
330608|NCT00557596|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
330609|NCT00557609|Drug|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
330610|NCT00557622|Drug|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
330611|NCT00557622|Other|placebo|placebo
330612|NCT00557635|Procedure|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
330613|NCT00557648|Behavioral|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
330614|NCT00557648|Behavioral|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
330615|NCT00557661|Drug|CD-NP|24 hr intravenous infusion
330616|NCT00557700|Drug|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
330954|NCT00419380|Drug|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment [dornase alfa (Pulmozyme®)]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
330037|NCT00572169|Drug|Filgrastim|
330038|NCT00572169|Drug|Lenalidomide|
330039|NCT00572182|Drug|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
330040|NCT00572195|Device|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
330041|NCT00572208|Drug|Gabapentin group|Gabapentin group:
Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)
st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
330325|NCT00564733|Procedure|computed tomography|Undergo FDG PET/CT
330326|NCT00564733|Procedure|positron emission tomography|Undergo FDG PET/CT
330327|NCT00564733|Radiation|fludeoxyglucose F 18|Given IV
330328|NCT00564733|Other|imaging biomarker analysis|Correlative studies
330329|NCT00564746|Drug|A single 10mg (50 μCi) oral dose of [14C]SB-681323|This intervention will be dosed IV.
330330|NCT00564759|Drug|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
330331|NCT00564772|Drug|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
330332|NCT00564785|Drug|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
330333|NCT00564785|Other|Placebo patch|placebo patch applied 20 minutes prior to epidural
330334|NCT00004067|Biological|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
330335|NCT00564811|Dietary Supplement|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
330336|NCT00564824|Drug|Caffeine|Caffeine 200 mg tablet
330337|NCT00564824|Drug|Placebo|Placebo pills
330338|NCT00564837|Procedure|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
330045|NCT00574587|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
330046|NCT00574587|Procedure|Mastectomy or Lumpectomy|Surgical excision of tumor from breast
330047|NCT00574587|Drug|Post surgery therapy (Trastuzumab)|Part D: After Surgical intervention Post Protocol Therapy- Trastuzumab 8 mg/kg as a loading dose, then 6 mg/kg every 3 weeks for a total of 14 doses
330048|NCT00574600|Biological|SAAVI DNA-C2 vaccine|DNA vaccine
330049|NCT00574600|Biological|SAAVI MVA-C vaccine|Boost vaccine
330050|NCT00574600|Biological|Placebo|Placebo vaccine
330051|NCT00574613|Drug|P144|Cream 0,3 ml once a day (3 months)
330052|NCT00574613|Drug|placebo|Cream 0,3 ml once a day (3 months)
330053|NCT00004107|Radiation|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
330054|NCT00574626|Procedure|PBSCT|Peripheral Blood Stem Cell Transplant
330055|NCT00574626|Procedure|Bone Marrow Transplant|Bone Marrow Transplant
330056|NCT00574639|Drug|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
330057|NCT00574639|Drug|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
330058|NCT00574652|Drug|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
330059|NCT00574665|Other|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
330060|NCT00574678|Other|Tear collection|A tear sample (~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an "eye wash" method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed.
330061|NCT00574691|Device|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
330062|NCT00574704|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
330063|NCT00574704|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
330347|NCT00567112|Drug|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
329393|NCT00587626|Device|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
329394|NCT00587626|Device|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
329395|NCT00587639|Device|rTMS Treatment|Active rTMS treatment.
329396|NCT00004174|Biological|filgrastim|
329397|NCT00587665|Drug|ketamine|Single IV dose of 0.1 mg/kg of ketamine
329398|NCT00587665|Drug|Placebo|Saline given of equal volume to drug
329399|NCT00587678|Drug|Simvastatin|40mg each night
329400|NCT00587678|Drug|Ezetimibe|10mg daily
329401|NCT00587678|Drug|Simvastatin/Ezetimibe|40mg/10mg each night
329402|NCT00587691|Biological|Tovaxin Autologous T Cell Vaccine|Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.
Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.
Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods.
329738|NCT00579527|Other|Thymus Tissue and Parental Parathyroid Transplantation|If the recipient has hypoparathyroidism, and is eligible, the subject may receive both a thymus and parathyroid transplant. If the subject is not eligible the subject will receive only a thymus transplant. For parathyroid transplant, parental parathyroid donors screened. If both parents met criteria, parathyroid harvested from the parent who shares the most HLA alleles with the thymus donor. Parathyroid harvest is done under general anesthesia. One parathyroid gland is minced and placed in quadriceps muscle of 1 leg; there is no dose. No biopsy is done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
329739|NCT00579527|Procedure|Blood Draw|Biological Mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab amy be done.
329740|NCT00004146|Other|pharmacological study|Correlative studies
329741|NCT00581971|Drug|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
329742|NCT00581971|Drug|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
329743|NCT00581971|Drug|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
329744|NCT00581971|Radiation|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
329745|NCT00581997|Drug|QAX576|
329746|NCT00581997|Drug|Placebo|
329093|NCT00552006|Behavioral|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.
NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.
329094|NCT00554502|Drug|supportive and immunosuppressive therapy|supportive therapy as outlined above
depending on GFR:
methylprednisolone and prednisolone
cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone
Concomitant medication with the immunosuppressive treatment following current clinical practice
329095|NCT00554515|Drug|aldesleukin (Proleukin)|Eligible patients will receive treatment with IL-2 alone following the FDA approved schedule. A treatment course consists of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 8-12 weeks of rest. A cycle is defined as 5 days of treatment.
Patients will receive IL-2, 600,000 International Units/kg/dose (Chiron) intravenously (IV) every 8 (q8) hours for five days (maximum of 14 doses), beginning on day 1 and again on day 15.
329096|NCT00554528|Device|cervical disc prosthesis with a mobile insert named Mobi-C|Stage 1: partial discectomy
stage 2: location of the medial axis
stage 3: centering pin
stage 4: installation of the caspar spacer
stage 5: total discectomy
stage 6: parallel distraction
stage 7: depth measurement
stage 8: trial implant
stage 9: assembly
stage 10: implant insertion
stage 11: anchorage optimization
329097|NCT00554528|Procedure|arthrodesis - cervical disk surgery|discectomy and arthrodesis
329098|NCT00004006|Radiation|radiation therapy|
329099|NCT00554567|Behavioral|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
329100|NCT00554580|Procedure|Continuous Positive Airway Pressure (CPAP)|Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:
stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status.
329101|NCT00554580|Procedure|usual care of acute pulmonary oedema|Usual treatment of acute pulmonary oedema including :
Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.
Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.
As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min.
329102|NCT00554606|Drug|ACZ885|ACZ885
329103|NCT00554619|Drug|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
329104|NCT00554632|Drug|Ethinyl estradiol and norgestimate|Oral contraceptive
329105|NCT00554632|Drug|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
329106|NCT00554645|Behavioral|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
335104|NCT00450229|Procedure|therapeutic conventional surgery|Undergo surgical resection
335105|NCT00450229|Other|laboratory biomarker analysis|Correlative studies
335106|NCT00450229|Other|pharmacological study|Correlative studies
335107|NCT00450242|Drug|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
335108|NCT00003478|Radiation|radiation therapy|
335109|NCT00450242|Drug|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
335110|NCT00450255|Biological|ziv-aflibercept|Given IV
335111|NCT00450255|Other|pharmacological study|Correlative studies
335112|NCT00450268|Procedure|blood draw, skin shave biopsy|
335113|NCT00450281|Genetic|chromogenic in situ hybridization|
335472|NCT00441454|Device|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
335473|NCT00003433|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
335474|NCT00441454|Device|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
335475|NCT00441467|Drug|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
335476|NCT00441480|Dietary Supplement|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
335477|NCT00441480|Dietary Supplement|placebo|4 gr of corn oil
335478|NCT00441493|Drug|fluvastatin|
335479|NCT00441506|Drug|daily interruption of sedatives|
335480|NCT00441519|Drug|aspirin|
335481|NCT00441519|Drug|omeprazole|
335482|NCT00441532|Drug|Lidocaine|
335483|NCT00441545|Drug|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
335484|NCT00003434|Biological|carcinoembryonic antigen peptide 1|
334755|NCT00459212|Procedure|pharmacological study|Correlative study
334756|NCT00459212|Procedure|laboratory biomarker analysis|Correlative study
334757|NCT00459225|Drug|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
334758|NCT00459238|Other|counseling intervention|subjects will receive telephone based counseling
334759|NCT00459238|Other|educational intervention|subjects will received telephone based education
334760|NCT00459264|Drug|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
334761|NCT00459264|Drug|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
334762|NCT00459277|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|
334763|NCT00459290|Drug|mifepristone|
334764|NCT00459303|Device|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
334765|NCT00003525|Drug|antineoplaston A10|
334766|NCT00459303|Device|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
334767|NCT00459316|Biological|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
334768|NCT00459329|Behavioral|Program to Encourage Active, Rewarding Lives (PEARL)|Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).
PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.
Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.
After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success.
334769|NCT00459342|Drug|dasatinib|Given orally
335114|NCT00450281|Genetic|gene expression analysis|
339873|NCT00548886|Drug|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
339874|NCT00003960|Procedure|allogeneic bone marrow transplantation|
339875|NCT00548899|Drug|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
339876|NCT00548912|Drug|Spironolactone|
339877|NCT00548925|Drug|ABT-894|6 mg BID tablets, 8 weeks of treatment
339878|NCT00548925|Drug|placebo|BID tablets, 8 weeks of treatment
339879|NCT00548938|Drug|Gliadel wafer|Implanted at surgery
339880|NCT00548938|Drug|Temozolomide|During External Beam Radiation
334409|NCT00421083|Drug|tadalafil|
334410|NCT00421096|Drug|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
334411|NCT00421096|Procedure|Radiotherapy|45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)
+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area
334412|NCT00421096|Drug|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
334413|NCT00421109|Drug|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
334414|NCT00421109|Drug|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
334415|NCT00421109|Drug|Placebo|Encapsulated tablet. Once daily for 28 days
334416|NCT00421122|Drug|budesonide/formoterol (Symbicort)|inhalation therapy
334417|NCT00003352|Drug|cyclophosphamide|600 mg/m2, IV, every 3 weeks
334418|NCT00421122|Drug|budesonide (Pulmicort)|inhalation
334419|NCT00421122|Drug|terbutaline sulfate (Bricasol)|inhalation therapy
334420|NCT00421135|Drug|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
339525|NCT00510809|Other|Placebo|Placebo daily
339526|NCT00510809|Drug|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
339527|NCT00510822|Drug|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
339528|NCT00513474|Drug|rasburicase|
339529|NCT00513474|Drug|sirolimus|
339530|NCT00513474|Drug|tacrolimus|
339531|NCT00513474|Other|diagnostic laboratory biomarker analysis|
339532|NCT00513474|Other|flow cytometry|
339533|NCT00000556|Drug|propafenone|
339534|NCT00003783|Drug|methotrexate|
339535|NCT00513474|Other|immunologic technique|
339536|NCT00513474|Procedure|allogeneic hematopoietic stem cell transplantation|
339537|NCT00513474|Procedure|peripheral blood stem cell transplantation|
339538|NCT00513474|Radiation|total-body irradiation|
339539|NCT00513487|Drug|Dust mite extract, Fluticasone, Methacholine|Dust mite extract, Fluticasone, Methacholine
339540|NCT00513500|Drug|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
339541|NCT00513500|Drug|Coartem|Give Coartem without RDT and refer fast breathing
339542|NCT00513513|Drug|TMC114 (darunavir) / ritonavir|
339543|NCT00513526|Biological|Gardasil|week 0, 8, 24, 128
339544|NCT00513539|Drug|porfimer sodium|
339545|NCT00003783|Drug|prednisone|
339546|NCT00513539|Procedure|biliary stenting|
339547|NCT00513552|Drug|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
339548|NCT00513565|Drug|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
338859|NCT00527280|Procedure|Feasibility ot face transplantation|Feasibility ot face transplantation
338860|NCT00527293|Procedure|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
338861|NCT00527293|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
338862|NCT00527293|Radiation|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
338863|NCT00527306|Dietary Supplement|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
338864|NCT00527319|Drug|VT-122 low dose|VT-122 low dose, dose escalated
338865|NCT00527319|Drug|VT-122 high dose|VT-122 high dose, dose escalated
338866|NCT00527332|Drug|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
338867|NCT00527332|Drug|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
338868|NCT00000560|Drug|adrenergic beta antagonists|
339191|NCT00519012|Drug|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
339192|NCT00521430|Procedure|allogeneic hematopoietic stem cell transplantation|
339193|NCT00521430|Procedure|peripheral blood stem cell transplantation|
339194|NCT00521443|Procedure|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
339195|NCT00521456|Drug|ketorolac eye drops|1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day
Placebo
339196|NCT00521469|Device|Pro Adjuster|
339197|NCT00003817|Drug|tropisetron|
339198|NCT00521482|Drug|Temozolomide|
339199|NCT00521482|Drug|Temozolomide plus Thalidomide|
338532|NCT00535236|Biological|Comparator: V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
338533|NCT00535236|Biological|Comparator: Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
338534|NCT00535262|Drug|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
338535|NCT00535275|Drug|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
338536|NCT00535275|Drug|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
338537|NCT00535288|Drug|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
338538|NCT00535288|Drug|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
338539|NCT00535301|Device|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
338540|NCT00535301|Procedure|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
338541|NCT00003893|Procedure|adjuvant therapy|
338542|NCT00535314|Drug|RTA 402 Dose1|
338543|NCT00535314|Drug|RTA 402 Dose2|
338544|NCT00535340|Drug|SR58611A|
338545|NCT00535353|Drug|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
338546|NCT00537602|Drug|placebo|
338547|NCT00537615|Drug|PD 0332334|
338548|NCT00537654|Drug|GI198745|
338549|NCT00537667|Drug|anakinra|anakinra
338869|NCT00003854|Procedure|therapeutic conventional surgery|
338870|NCT00529789|Drug|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is >40 kg, initial dose is 30 mg, then titrated up.
333407|NCT00452413|Drug|enzastaurin|Phase 1: 500 mg oral loading dose day 1, 250 mg oral daily day 2-28, 28 day cycle until disease progression
Dose Escalation:1125 mg oral loading dose day 1, 500 mg oral daily until disease progression
Phase 2: phase 1 determined dose, oral, daily, 28 day cycles until disease progression
333408|NCT00452413|Drug|erlotinib|150 mg, oral, daily, 28 day cycles until disease progression
333409|NCT00452426|Device|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
333410|NCT00003492|Drug|antineoplaston AS2-1|
333411|NCT00452426|Other|benzodiazepines and opioid sedation|per site's current standard of care
333412|NCT00452439|Drug|Actonel (Risedronate)|35 mg (pill) by mouth weekly
333413|NCT00452439|Dietary Supplement|Calcium|500 mg by mouth twice a day for a total of 24 months.
333414|NCT00452439|Dietary Supplement|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
333415|NCT00452452|Biological|13-valent Pneumococcal Conjugate Vaccine|
333416|NCT00452465|Behavioral|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
333417|NCT00452478|Drug|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
333418|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
333419|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
333420|NCT00452504|Drug|SRA-444|
333421|NCT00003493|Drug|dexamethasone|
333422|NCT00455156|Drug|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
333423|NCT00455169|Biological|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
333424|NCT00003509|Drug|antineoplaston A10|
333425|NCT00455182|Procedure|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
332713|NCT00423267|Drug|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
332714|NCT00423280|Drug|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
332715|NCT00423293|Drug|fluorouracil|1000 mg/m^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
332716|NCT00423293|Drug|mitomycin C|10 mg/m^2 intravenous therapy on day 1 and day 29 of radiation therapy.
332717|NCT00423293|Radiation|Intensity-modulated radiation therapy|Prescription dose depends on tumor staging.
T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.
T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.
For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes > 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx.
332718|NCT00423306|Drug|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
333066|NCT00003313|Drug|paclitaxel|
333067|NCT00414466|Drug|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
333068|NCT00414479|Drug|praziquantl, iron, ACT|
333069|NCT00414505|Device|Intradermal Acupuncture Treatment|
333070|NCT00414518|Drug|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
333071|NCT00414518|Drug|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
333072|NCT00414531|Drug|Atorvastatin|20 to 80 mg per day
333073|NCT00414544|Device|CosmetaLife|Dermal filler
333074|NCT00414544|Device|Restylane|Dermal filler
333075|NCT00414557|Procedure|Quadriceps strengthening|
333076|NCT00414570|Procedure|Positron-Emission Tomography (PET) 18F-FLT|
333077|NCT00003313|Radiation|radiation therapy|
333078|NCT00417066|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
332367|NCT00431769|Drug|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
332368|NCT00431782|Drug|ATI-5923|
332369|NCT00003399|Drug|carmustine|
332370|NCT00431795|Drug|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m^2 IV every 4 weeks for 6 consecutive cycles
332371|NCT00431795|Drug|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m^2 IV every 3 weeks for 6 consecutive cycles
332372|NCT00431808|Biological|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
332373|NCT00431808|Biological|AMA1|50 micrograms of AMA1
332374|NCT00431821|Behavioral|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
332375|NCT00431821|Other|Stroke education|Stroke education program with matched attention phone calls
332376|NCT00431834|Device|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
332377|NCT00431834|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
332378|NCT00431847|Procedure|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
332379|NCT00431860|Procedure|Coronary computed tomographic angiography|
332380|NCT00003399|Drug|cisplatin|
332381|NCT00431873|Drug|MGCD0103|MGCD0103 Administered orally three times per week.
332382|NCT00431886|Procedure|64 multi-detector computed tomography|
332719|NCT00423319|Drug|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
332720|NCT00423319|Drug|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
331674|NCT00448760|Drug|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
331675|NCT00448760|Drug|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
331676|NCT00448760|Drug|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
331677|NCT00448760|Drug|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
331678|NCT00448760|Genetic|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
331679|NCT00448760|Genetic|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
331680|NCT00448760|Procedure|Conventional surgery|Surgical removal of tumor for correlative studies
332039|NCT00440128|Drug|Casopitant/Docetaxel|Casopitant/Docetaxel
332040|NCT00440141|Drug|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
332041|NCT00440141|Drug|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
332042|NCT00440154|Drug|AVE5530|
332043|NCT00003423|Drug|vincristine sulfate|
332044|NCT00440154|Drug|placebo|
332045|NCT00440154|Drug|ezetimibe|
332046|NCT00440167|Drug|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
332047|NCT00440167|Drug|Capecitabine|Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause ("Flat Dosing")
332048|NCT00440167|Drug|Erlotinib|Erlotinib 150 mg/d oral, daily without break
332049|NCT00440180|Drug|Anastrozole|1 mg qd for 4 months
332050|NCT00440180|Drug|Placebo|Placebo Comparator
332051|NCT00440193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
332052|NCT00440193|Drug|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
331313|NCT00457691|Drug|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
331314|NCT00457717|Drug|0.25 % atropine|
331315|NCT00457717|Drug|0.5 % atropine|
331316|NCT00457717|Procedure|0.25 % atropine+auricular acupoints|
331317|NCT00457730|Drug|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
331318|NCT00457730|Drug|Placebo|Subjects are randomized to either Duloxetine or Placebo
331319|NCT00457743|Drug|Sunitinib malate (SU011248)|SU011248
331320|NCT00457756|Dietary Supplement|BiosLife Complete|
331321|NCT00457756|Dietary Supplement|Placebo|
331322|NCT00457769|Drug|Donepezil|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
331323|NCT00003517|Procedure|cancer prevention intervention|
331324|NCT00457769|Drug|Donepezil|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
331325|NCT00457782|Drug|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
331326|NCT00457795|Drug|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
331327|NCT00457808|Drug|Rapamycin, sirolimus|
331328|NCT00457821|Drug|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
331681|NCT00003469|Drug|antineoplaston A10|
331682|NCT00448773|Behavioral|Online education|
331683|NCT00448786|Drug|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
331684|NCT00448786|Drug|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
331685|NCT00448786|Drug|AMG 706|AMG 706 125 mg daily continuously (Arm A)
331686|NCT00448799|Radiation|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of [123I] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
330955|NCT00419393|Drug|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
330956|NCT00419406|Procedure|UVA1 phototherapy|
330957|NCT00419406|Procedure|NB-UVB phototherapy|
330958|NCT00003342|Drug|gemcitabine hydrochloride|
330959|NCT00419419|Drug|Topical AmphiMatrix with nitroglycerin (MQX-503)|
330960|NCT00419432|Other|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
330961|NCT00419432|Other|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
330962|NCT00419445|Drug|GTS21/Placebo|
330963|NCT00419458|Procedure|inspiratory muscle strength training|
330964|NCT00419471|Drug|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
330965|NCT00419471|Drug|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
330966|NCT00419484|Drug|pioglitazone|
330967|NCT00419497|Behavioral|Paleolithic diet|
330968|NCT00419510|Behavioral|Culturally Tailored Genetic Counseling|
330969|NCT00003342|Drug|paclitaxel|
330970|NCT00419536|Drug|LBH589|
330971|NCT00419549|Drug|Glyceryl - trinitrate|Transdermal Patch once only
330972|NCT00419549|Drug|Valdecoxib|Single parenteral administration
330973|NCT00422487|Drug|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
330974|NCT00422487|Drug|Placebo for MBX-2044|Placebo Intervention
330975|NCT00422500|Behavioral|Questionnaire|Surveys about symptoms, mood, and quality of life.
330339|NCT00564837|Procedure|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
330340|NCT00564850|Drug|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|One intra muscular injection at day 1 and month 3.
330341|NCT00564863|Other|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
330342|NCT00567086|Drug|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
330343|NCT00567099|Drug|Aripiprzole|Dosage form, dosage, frequency and duration:
Aripiprazole 5-30 mg tabs po qday x 3 months
330344|NCT00567112|Drug|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
330345|NCT00567112|Drug|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
330346|NCT00567112|Drug|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
330617|NCT00557700|Drug|Administration of placebo|Administration of placebo
330618|NCT00004028|Procedure|conventional surgery|
330619|NCT00557713|Drug|bevacizumab|-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)
-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))
-Surgery (6-8 weeks after last bevacizumab dose)
-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)
330620|NCT00557739|Drug|mometasone furoate|Topical 0.1% mometasone furoate
330621|NCT00557739|Drug|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
330622|NCT00557739|Drug|Vehicle (placebo)|Topical placebo
330623|NCT00557752|Device|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
330624|NCT00557791|Drug|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
330625|NCT00557791|Drug|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
330626|NCT00557804|Device|MUSE clinical system|non-invasive external monitoring device
330627|NCT00433953|Behavioral|Drug Diary|
330348|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
330349|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
330350|NCT00567164|Drug|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
330351|NCT00004082|Drug|docetaxel|
330352|NCT00567177|Drug|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
330353|NCT00567190|Drug|Pertuzumab|Patients received a loading dose of 840 mg IV.
330354|NCT00567190|Drug|Placebo|
330355|NCT00567190|Drug|Trastuzumab|Patients received a loading dose of 8 mg/kg IV.
330356|NCT00567190|Drug|Docetaxel|At the investigator's discretion, the docetaxel dose could be increased to 100 mg/m^2 for patients who tolerated at least 1 cycle without significant toxicities.
330357|NCT00567203|Drug|PF-3463275|PF-3463275 10mg
330358|NCT00567203|Drug|PF-3463275|PF-3463275 25mg
330359|NCT00567203|Drug|Placebo|Placebo
330360|NCT00567216|Drug|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
330361|NCT00567229|Biological|rituximab|
330362|NCT00004082|Drug|gemcitabine hydrochloride|
330363|NCT00567229|Drug|lenalidomide|
330364|NCT00567229|Genetic|microarray analysis|
330365|NCT00567229|Other|flow cytometry|
330366|NCT00567229|Other|laboratory biomarker analysis|
330367|NCT00567242|Behavioral|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
330368|NCT00569816|Drug|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
329747|NCT00582010|Drug|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
329748|NCT00582010|Drug|nitrogen gas|inhaled
329749|NCT00582036|Drug|Regular Insulin|Use of sliding scale insulin as per Appendix 1
329750|NCT00582036|Device|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
329751|NCT00004147|Drug|incyclinide|
329752|NCT00582062|Other|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
329753|NCT00582075|Drug|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
329754|NCT00582088|Biological|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer <1:20.
329755|NCT00582101|Behavioral|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
329756|NCT00582101|Behavioral|General Health Promotion|7 hour one-day workshop on general health promotion topics
330064|NCT00000601|Drug|hormone replacement therapy|
330065|NCT00004108|Drug|exatecan mesylate|
330066|NCT00574704|Drug|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
330067|NCT00574704|Drug|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
330068|NCT00577122|Drug|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
330069|NCT00577122|Drug|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
330070|NCT00577135|Drug|Furosemide-Q12 hour bolus|Q12 hours bolus
330071|NCT00004125|Drug|doxorubicin hydrochloride|
330072|NCT00577135|Drug|Furosemide-Continuous Infusion|Continuous infusion
330073|NCT00577135|Drug|Furosemide-Low Intensification|1x oral dose
330074|NCT00577135|Drug|Furosemide-High Intensification|2.5x oral dose
329107|NCT00554645|Other|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
329403|NCT00587704|Procedure|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
329404|NCT00587704|Procedure|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
329405|NCT00587717|Drug|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
329406|NCT00587717|Drug|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
329407|NCT00004174|Drug|cyclophosphamide|
329408|NCT00587730|Device|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
329409|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
329410|NCT00590187|Drug|sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
329411|NCT00590187|Drug|sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
329412|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
329413|NCT00590187|Drug|Sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
329414|NCT00590187|Drug|sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
329415|NCT00590213|Drug|Casodex 150mg|
329416|NCT00590213|Procedure|Radiotherapy|
329417|NCT00004184|Biological|monoclonal antibody 4B5 anti-idiotype vaccine|
329418|NCT00590213|Procedure|Haematology|
329419|NCT00590226|Drug|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
329420|NCT00590226|Drug|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
329421|NCT00590265|Device|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
329422|NCT00590265|Device|Northern Light Technology (SADelite lamp) Dim light-therapy|<100 lux for 30 minutes
329423|NCT00590278|Drug|Tomudex|
329424|NCT00590278|Procedure|Radiotherapy|
335485|NCT00441545|Drug|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
335486|NCT00441558|Drug|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
335487|NCT00441571|Drug|177Lu-CYT-500|
335488|NCT00444626|Drug|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
335489|NCT00003441|Drug|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
335490|NCT00444639|Drug|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
335491|NCT00444652|Drug|Enoxaparin|injection of enoxaparin a few time
335492|NCT00444665|Drug|Travatan-Z|
335493|NCT00444678|Drug|Cetuximab|500 mg/m2, IV every two weeks
335494|NCT00444678|Drug|Oxaliplatin|85 mg/m2, IV, q 2 weeks
335495|NCT00444678|Drug|Capecitabine|2500 mg, po bid x 7 days every two weeks
335846|NCT00433368|Drug|L-Ornithine L-Aspartate|
335847|NCT00436215|Drug|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
335848|NCT00436215|Drug|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
335849|NCT00436241|Drug|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
335850|NCT00436241|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
335851|NCT00436254|Biological|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
335852|NCT00436254|Biological|sargramostim|Given intradermally
335853|NCT00436254|Other|flow cytometry|Correlative studies
335854|NCT00003410|Procedure|surgical procedure|
335855|NCT00436254|Other|immunologic technique|Correlative studies
335856|NCT00436254|Other|immunoenzyme technique|Undergo ELIspot (correlative studies)
335115|NCT00450281|Genetic|mutation analysis|
335116|NCT00450281|Genetic|polymerase chain reaction|
335117|NCT00450281|Genetic|polymorphism analysis|
335118|NCT00450281|Other|fluorescent antibody technique|
335119|NCT00003479|Drug|antineoplaston A10|
335120|NCT00450281|Other|immunohistochemistry staining method|
335121|NCT00450281|Other|laboratory biomarker analysis|
335122|NCT00450281|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
335123|NCT00450281|Other|study of socioeconomic and demographic variables|
335124|NCT00450281|Procedure|study of high risk factors|
335125|NCT00453063|Drug|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
335126|NCT00453063|Drug|Placebo|Two sprays in each nostril once daily in the morning
335127|NCT00453076|Device|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
335128|NCT00003496|Drug|antineoplaston AS2-1|
335129|NCT00453089|Drug|VG101|
335130|NCT00453102|Drug|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
335131|NCT00453102|Drug|Ibritumomab Tiuxetan|IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:
0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
335132|NCT00453115|Drug|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
335133|NCT00453115|Drug|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
335134|NCT00453141|Drug|dosing of Betamethasone|
335135|NCT00453154|Drug|sunitinib malate|Given PO
335136|NCT00453154|Drug|cisplatin|Given IV
334421|NCT00421148|Drug|Sugammadex 0.5 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 0.5 mg/kg sugammadex will be given.
334422|NCT00421148|Drug|Sugammadex 1.0 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 1.0 mg/kg sugammadex will be given.
334423|NCT00421148|Drug|Sugammadex 2.0 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 2.0 mg/kg sugammadex will be given.
334424|NCT00421148|Drug|Sugammadex 4.0 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 4.0 mg/kg sugammadex will be given.
334425|NCT00421148|Drug|Placebo|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of placebo will be given.
334426|NCT00421161|Drug|olive oil and omega 3 in a combined cream|
334427|NCT00421174|Drug|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
334428|NCT00003352|Drug|Taxotere|60 mg/m2, IV, every 3 weeks
334429|NCT00423800|Drug|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks
200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks
334770|NCT00459355|Behavioral|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
334771|NCT00415233|Radiation|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
334772|NCT00415246|Drug|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
334773|NCT00415259|Device|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
334774|NCT00003320|Procedure|surgical procedure|
334775|NCT00415259|Device|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
334776|NCT00415272|Behavioral|Pulmonary Rehabilitation|
334777|NCT00415285|Drug|Docetaxel|
334778|NCT00415285|Drug|Capecitabine|
339881|NCT00548938|Radiation|External Beam Radiation Therapy|60 Gy
339882|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
339883|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
339884|NCT00548951|Other|Control|Receive no sessions in a Snoezelen Room.
339885|NCT00000579|Drug|Lysofylline|
339886|NCT00003960|Procedure|in vitro-treated bone marrow transplantation|
339887|NCT00548964|Drug|Lithium|600-900mg of Li carbonate
339888|NCT00508235|Behavioral|Questionnaire|Questionnaire about the patient's relationship with their best friend.
339889|NCT00508248|Dietary Supplement|omega 3 fatty acids|1g daily
339890|NCT00003752|Drug|bexarotene|
339891|NCT00508248|Dietary Supplement|placebo|olive oil capsule
339892|NCT00508261|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection
339893|NCT00508261|Biological|Infanrix™ hexa|Single dose intramuscular injection
339894|NCT00508261|Biological|Meningitec™|Single dose intramuscular injection
339895|NCT00508274|Drug|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
339896|NCT00508287|Drug|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
339897|NCT00508287|Drug|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
339898|NCT00508287|Drug|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
339899|NCT00508300|Procedure|Epidural analgesia|Thoracic epidural analgesia until day 2
339900|NCT00508300|Procedure|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
339901|NCT00000555|Drug|progesterone|
339902|NCT00003753|Drug|dexamethasone|
339903|NCT00508313|Procedure|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
339200|NCT00521495|Device|neodymium permanent magnet|3/4" diameter by 1/8" thick permanent magnet
339201|NCT00521495|Device|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
339202|NCT00521495|Device|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
339203|NCT00521508|Procedure|gene transcription and cytometry|samply of 30 ml of blood
339204|NCT00521521|Drug|docetaxel and cisplatin|
339205|NCT00521521|Drug|docetaxel|
339206|NCT00521534|Device|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
339207|NCT00521547|Procedure|Electroacupuncture|
339208|NCT00003817|Procedure|quality-of-life assessment|
339209|NCT00521560|Drug|Zevalin|All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.
High dose therapy will be given as BEAM
339210|NCT00521573|Other|Dark chocolate|
339211|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
339212|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
339549|NCT00513578|Biological|PR1 leukemia peptide vaccine|
339550|NCT00513578|Biological|incomplete Freund's adjuvant|
339551|NCT00513578|Biological|sargramostim|
339552|NCT00513604|Biological|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
339553|NCT00513604|Biological|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10^11 lymphocytes (minimum of 1 x 10^9), day 0
339554|NCT00513604|Drug|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
339555|NCT00513604|Drug|Fludarabine phosphate|Given intravenously 25 mg/m^2/day over 15-30 minutes, day -5 to -1
339556|NCT00003783|Drug|vincristine sulfate|
339557|NCT00513604|Radiation|Total body irradiation|600 cGy
338871|NCT00529802|Drug|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
338872|NCT00529815|Device|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
338873|NCT00529815|Device|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
338874|NCT00529828|Procedure|Consumption of CLA enriched food|
338875|NCT00529841|Drug|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
338876|NCT00003864|Drug|docetaxel|
338877|NCT00529854|Other|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
338878|NCT00529867|Drug|Artemether/lumefantrine tablets|Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine
Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets
Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2
338879|NCT00529867|Drug|Artemether/Lumefantrine suspension|Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension
Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml
Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2
338880|NCT00529880|Drug|Fludarabine , cytarabine|
338881|NCT00529919|Dietary Supplement|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
338882|NCT00529932|Other|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
338883|NCT00529932|Other|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
338884|NCT00529945|Device|PFx Closure System|
338885|NCT00529958|Procedure|Patellar Tendon|Patellar Tendon autograft
338886|NCT00529958|Procedure|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
338887|NCT00003865|Drug|toremifene|
338888|NCT00529958|Procedure|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
338889|NCT00529971|Behavioral|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
339213|NCT00521599|Drug|Mometasone furoate dry powder inhaler|
333426|NCT00455182|Procedure|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
333427|NCT00455182|Procedure|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
333776|NCT00003455|Procedure|complementary and alternative therapy|
333777|NCT00446550|Drug|AT2101|Arm 1: AT2101 oral capsules, dose 1, regimen 1
Arm 2: AT2101 oral capsules, dose 1, regimen 2
333778|NCT00446563|Drug|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
333779|NCT00446563|Drug|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
333780|NCT00446563|Drug|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
333781|NCT00446563|Drug|Losartan|100 mg tablets taken orally once daily in the morning.
333782|NCT00446576|Drug|Epoetin Alfa|
333783|NCT00446589|Drug|ibandronate|iv 1mg ibandronate monthly for one year
333784|NCT00446589|Drug|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
333785|NCT00446602|Drug|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
333786|NCT00446615|Behavioral|computer decision support tool|
333787|NCT00000522|Drug|acebutolol|
333788|NCT00003455|Procedure|differentiation therapy|
333789|NCT00446615|Behavioral|audit and feedback|
333790|NCT00446615|Behavioral|group learning session|
333791|NCT00446628|Behavioral|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
333792|NCT00446641|Drug|Cilostazol|cilostazol 100mg twice a day for 4 weeks
333793|NCT00446641|Drug|placebo|placebo 1 tablet twice a day matching for cilostazol
333794|NCT00446654|Drug|CGC-11047|16.5 mg (3.3%) subconjunctival injection
333795|NCT00446667|Drug|mannitol|400mg BD for 2 days
333079|NCT00417066|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
333080|NCT00417079|Drug|cabazitaxel (XRP6258) (RPR116258)|25 mg/m^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
333081|NCT00417079|Drug|mitoxantrone|12 mg/m^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
333082|NCT00417079|Drug|prednisone|10 mg daily administered by oral route
333083|NCT00417092|Procedure|Postoperative Pacing|
333084|NCT00417105|Procedure|hemodialysis|group 1: twice weekly, four hours
333085|NCT00417105|Procedure|hemodialysis|group 2: twice weekly, eight hours
333086|NCT00417105|Procedure|hemodialysis|group 3: every other day, eight hours
333087|NCT00003335|Drug|melphalan|melphalan IV for three days on days -4 to -2
333088|NCT00417105|Procedure|hemodialysis|group 4: six days a week, eight hours
333089|NCT00417118|Drug|Saredutant|oral administration (capsules)
333090|NCT00417118|Drug|Escitalopram|oral administration (capsules)
333428|NCT00455195|Biological|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
333429|NCT00455208|Drug|Cura-100|
333430|NCT00455221|Biological|Bcr-abl multipeptide vaccine|The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
333431|NCT00455221|Genetic|Cytokine gene adjuvant|Cytokine gene adjuvant
333432|NCT00455234|Drug|Intramuscular Olanzepine 10 mg|
333433|NCT00455234|Drug|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
333434|NCT00455247|Drug|Glutamine|
333435|NCT00003509|Drug|antineoplaston AS2-1|
332721|NCT00000512|Drug|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
332722|NCT00003364|Radiation|radiation therapy|
332723|NCT00423319|Drug|Enoxaparin-matching placebo|Administered as injection
332724|NCT00423319|Drug|Apixaban-matching placebo|Administered as oral tablets
332725|NCT00423332|Drug|Cediranib|45 mg oral tablet
332726|NCT00425763|Drug|AQAS|AQAS dosed by body weight, on days 0, 1, 2
332727|NCT00425776|Device|acupuncture|
332728|NCT00425776|Device|Sham acupuncture|
332729|NCT00425789|Procedure|Treatment with Hyperbaric oxygen|
332730|NCT00425802|Biological|anti-thymocyte globulin|
332731|NCT00425802|Biological|filgrastim|
332732|NCT00425802|Biological|graft-versus-tumor induction therapy|
332733|NCT00425802|Biological|rituximab|
332734|NCT00425802|Drug|cyclophosphamide|
332735|NCT00003384|Other|Cervical Papanicolaou Test|Undergo Pap smear
332736|NCT00425802|Drug|cyclosporine|
332737|NCT00425802|Drug|fludarabine phosphate|
332738|NCT00425802|Drug|mycophenolate mofetil|
332739|NCT00425802|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
332740|NCT00425802|Radiation|total-body irradiation|
332741|NCT00425815|Drug|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
332742|NCT00425815|Other|Placebo|Placebo comparison
332743|NCT00425841|Drug|gemcitabine hydrochloride|
332053|NCT00440219|Drug|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
332054|NCT00003424|Drug|tamoxifen citrate|
332055|NCT00440219|Drug|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
332056|NCT00443118|Device|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
332057|NCT00443118|Device|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
332058|NCT00443131|Biological|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
332059|NCT00443144|Drug|recombinant human growth hormone|
332060|NCT00443157|Biological|Meningococcal B Vaccine NZ|
332383|NCT00431899|Behavioral|fish oil supplementation|
332384|NCT00434538|Device|BST-DermOn|
332385|NCT00003405|Drug|idarubicin|
332386|NCT00434564|Procedure|Stress nuclear scan|
332387|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A|Single or two-dose intramuscular injection.
332388|NCT00434577|Biological|Placebo|Single intramuscular injection
332389|NCT00434590|Drug|Enteric coated mycophenolate sodium (Myfortic®)|
332390|NCT00434603|Behavioral|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
332391|NCT00434616|Procedure|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
332392|NCT00434616|Biological|saline injection|saline injections
332393|NCT00434629|Drug|Bexxar|Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.
1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein).
331687|NCT00448825|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
331688|NCT00448825|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
331689|NCT00448838|Biological|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
331690|NCT00448838|Drug|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
331691|NCT00448838|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
331692|NCT00003469|Drug|antineoplaston AS2-1|
331693|NCT00451347|Device|Quadriceps strength training|
331694|NCT00451347|Device|Taping|
331695|NCT00451347|Device|Home exercise|
331696|NCT00451360|Drug|diacerein|
331697|NCT00451373|Device|CVVH and SLED|
331698|NCT00451373|Drug|Vancomycin|
331699|NCT00003487|Drug|antineoplaston A10|
331700|NCT00451373|Drug|Daptomycin|
331701|NCT00451373|Device|FX60, AV600 (dialyzer)|
331702|NCT00451386|Drug|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
331703|NCT00451386|Drug|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
331704|NCT00451399|Drug|metformin|
331705|NCT00451399|Behavioral|lifestyle intervention|
331706|NCT00451412|Drug|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
332061|NCT00443170|Drug|GSK626616, placebo, midazolam|
332062|NCT00443170|Drug|omeprazole, caffeine, flurbiprofen, rosiglitazone|
332063|NCT00003437|Drug|cyclophosphamide|
331329|NCT00457821|Drug|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
331330|NCT00457821|Drug|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
331331|NCT00457821|Drug|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
331332|NCT00457834|Device|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
331333|NCT00457860|Drug|Immunotoxin therapy|
331334|NCT00460707|Drug|Casopitant|
331335|NCT00460707|Drug|Ketoconazole|
331336|NCT00460720|Other|Observational treatment compliance survey|Observational treatment compliance survey
331337|NCT00460733|Drug|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
331338|NCT00460733|Drug|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
331339|NCT00460746|Drug|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
331340|NCT00460759|Drug|Moxifloxacin|
331341|NCT00460759|Drug|Rifapentine|
331342|NCT00460785|Drug|Opioid|
331343|NCT00460798|Other|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
331344|NCT00003536|Procedure|biological therapy|
331345|NCT00460811|Drug|Linaclotide Acetate|Oral, once daily
331346|NCT00460811|Drug|Matching placebo|Oral, once daily
331347|NCT00460837|Drug|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
331348|NCT00460850|Drug|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
331349|NCT00460863|Procedure|using cool versus warm dialysate during hemodialysis|
331350|NCT00460876|Drug|Topotecan|
330628|NCT00433953|Procedure|Blood Sampling|
330629|NCT00433966|Drug|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
330630|NCT00433966|Drug|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
330631|NCT00433966|Device|Bare metal stent|Uncoated bare metal stent
330632|NCT00433966|Device|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
330633|NCT00433979|Drug|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
330634|NCT00434005|Drug|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
330635|NCT00434005|Drug|Placebo|matched appearance to acetylcysteine and ascorbate intervention
330636|NCT00003402|Procedure|peripheral blood stem cell transplantation|
330637|NCT00434018|Behavioral|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
330976|NCT00422500|Behavioral|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
330977|NCT00422500|Other|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
330978|NCT00003361|Drug|decitabine|
330979|NCT00422513|Drug|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
330980|NCT00422513|Drug|Epoetin alfa|As prescribed, iv, 3 times weekly
330981|NCT00422526|Drug|Micronised progesterone (Utrogestan)|
330982|NCT00422539|Drug|70% trichloroacetic acid|
330983|NCT00422552|Drug|Indacaterol (QAB149)|
330984|NCT00422565|Device|Endeavor, Medtronic|Zotarolimus-eluting stent
330985|NCT00422565|Device|Cypher, Cordis|Sirolimus-eluting stent
330986|NCT00422565|Device|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
330369|NCT00569829|Behavioral|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
330638|NCT00434018|Behavioral|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
330639|NCT00434031|Drug|docetaxel|
330640|NCT00434031|Drug|cyclophosphamide|
330641|NCT00434031|Drug|trastuzumab|
330642|NCT00434031|Drug|liposomal doxorubicin|
330643|NCT00434044|Drug|Enbrel (etanercept)|
330644|NCT00434057|Device|MelaFind(R)|Biopsy ratio comparison
330645|NCT00434083|Drug|sumatriptan|
330646|NCT00434083|Drug|naproxen sodium|
330647|NCT00000518|Drug|imipramine|
330648|NCT00003403|Drug|GPX-100|
330649|NCT00434096|Drug|rimonabant (SR141716)|oral administration once daily
330650|NCT00434096|Drug|placebo|oral administration once daily
330651|NCT00434109|Drug|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
330652|NCT00434109|Procedure|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
330653|NCT00434122|Drug|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
330654|NCT00436735|Genetic|protein expression analysis|
330655|NCT00436735|Other|immunoenzyme technique|
330656|NCT00436735|Other|immunologic technique|
330657|NCT00436735|Other|laboratory biomarker analysis|
330658|NCT00436735|Other|mass spectrometry|
330075|NCT00577148|Drug|rimonabant (SR141716)|20 mg daily
330076|NCT00577148|Drug|Placebo|daily administration
330077|NCT00577161|Drug|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
330078|NCT00577161|Drug|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
330079|NCT00577187|Device|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
330080|NCT00577200|Drug|Midazolam|Midazolam
330081|NCT00577200|Drug|Sufentanil|Sufentanil
330082|NCT00004125|Drug|paclitaxel|
330083|NCT00577200|Drug|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
330084|NCT00577278|Biological|rituximab|Given IV
330085|NCT00577278|Drug|fludarabine phosphate|Given IV
330086|NCT00577278|Drug|melphalan|Given IV
330087|NCT00577278|Drug|sirolimus|Given PO
330088|NCT00577278|Drug|tacrolimus|Given PO or IV
330089|NCT00577278|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
330370|NCT00004089|Radiation|radiation therapy|
330371|NCT00569855|Drug|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
330372|NCT00569868|Drug|Velcade|Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.
The platelet Aggregation Test will be done only if Platelet count is 100 000.
330373|NCT00569881|Drug|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
330374|NCT00569894|Biological|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
330375|NCT00569894|Biological|TIV (Injection)|One or two injections of TIV depending on previous status.
330376|NCT00569894|Other|Unvaccinated Control|no vaccine
329425|NCT00590278|Procedure|Haematology|
329426|NCT00590278|Procedure|Biochemistry|
329427|NCT00590317|Drug|Prochlorperazine|Patients receiving Prochlorperazine
329428|NCT00004184|Biological|sargramostim|
329757|NCT00582114|Drug|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
329758|NCT00582114|Drug|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
329759|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
329760|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
329761|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
329762|NCT00004148|Biological|recombinant vaccinia-B7.1 vaccine|
329763|NCT00584857|Drug|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
329764|NCT00584870|Drug|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
329765|NCT00584870|Drug|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
329766|NCT00584870|Drug|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
329767|NCT00584883|Drug|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
329768|NCT00584896|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
335857|NCT00436254|Genetic|protein expression analysis|Undergo ELISA (correlative studies)
335858|NCT00436254|Procedure|biopsy|Undergo punch biopsy (correlative studies)
335859|NCT00436267|Drug|fluorouracil|
335860|NCT00436267|Radiation|selective external radiation therapy|
335861|NCT00436267|Radiation|tomotherapy|
335862|NCT00436267|Radiation|yttrium Y 90 glass microspheres|
335863|NCT00436267|Radiation|yttrium Y 90 resin microspheres|
335864|NCT00436280|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
335865|NCT00003411|Drug|motexafin gadolinium|
335866|NCT00436280|Drug|gemcitabine|1000 mg/m2, IV, once, every two weeks, four to eight 2 week cycles
335867|NCT00436280|Drug|rituximab|375 mg/m2, IV, once every 2 weeks, four to eight 2 week cycles
335868|NCT00436280|Drug|oxaliplatin|100 mg/m2, IV, once every two weeks, four to eight 2 week cycles
335869|NCT00436293|Drug|Docetaxel|75 mg/m²
335870|NCT00436293|Drug|Cisplatin|75 mg/m²
335871|NCT00436306|Behavioral|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
336220|NCT00427375|Procedure|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
336221|NCT00427375|Procedure|total mesorectal excision|standard surgery
336222|NCT00003388|Drug|cytarabine|
336223|NCT00427388|Drug|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
336224|NCT00427388|Other|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
336225|NCT00427401|Drug|PF-00915275|
336226|NCT00427414|Drug|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
336227|NCT00427427|Drug|Trastuzumab|
335137|NCT00453154|Drug|carboplatin|Given IV
335138|NCT00453154|Drug|etoposide|Given IV
335496|NCT00444691|Device|ultra-sonography|o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).
The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline.
335497|NCT00444704|Drug|PRA-027|
335498|NCT00444717|Drug|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
335499|NCT00444730|Procedure|Radical Prostatectomy|Surgical procedure for prostate cancer.
335500|NCT00003443|Drug|bryostatin 1|
335501|NCT00444730|Procedure|InterStim Implantation|surgical placement of the interstim
335502|NCT00444730|Procedure|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
335503|NCT00444743|Drug|MM-093|60 mg, administered subcutaneously, weekly
335504|NCT00444743|Other|Placebo|Placebo
335505|NCT00444756|Procedure|J-tip jet injection of 1% buffered lidocaine|
335506|NCT00444769|Drug|GW842166|
335507|NCT00444782|Biological|GV1001|
335508|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
335509|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
335510|NCT00444795|Drug|sunitinib malate|Sunitinib : dosing not pre-determined
335511|NCT00003444|Biological|recombinant interferon alfa|
335512|NCT00444808|Drug|Intranasal calcitonin|
335513|NCT00444821|Device|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
335514|NCT00444834|Drug|Carvedilol|50 mg
335515|NCT00444847|Device|Hyperbaric chamber|
334779|NCT00415285|Drug|Docetaxel/Capecitabine|
334780|NCT00415298|Drug|DACH polymer platinate AP5346|
334781|NCT00415298|Drug|oxaliplatin|
334782|NCT00415298|Genetic|gene expression analysis|
334783|NCT00415298|Other|immunohistochemistry staining method|
334784|NCT00415298|Other|pharmacological study|
334785|NCT00003320|Radiation|radiation therapy|
334786|NCT00415298|Procedure|biopsy|
334787|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
334788|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
334789|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
334790|NCT00415324|Drug|eribulin mesylate|Given IV
334791|NCT00415324|Drug|cisplatin|Given IV
334792|NCT00415324|Other|laboratory biomarker analysis|correlative study
334793|NCT00415324|Other|pharmacological study|correlative study
334794|NCT00415337|Procedure|endobronchial ultrasound|EBUS
335139|NCT00003497|Drug|antineoplaston A10|
335140|NCT00453154|Other|placebo|Given PO
335141|NCT00453154|Other|laboratory biomarker analysis|Correlative studies
335142|NCT00453167|Drug|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
335143|NCT00453167|Drug|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
335144|NCT00453180|Drug|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
339904|NCT00508326|Drug|Paclitaxel|Starting dose 150 mg/m^2 HAI once every 4 weeks
339905|NCT00508339|Behavioral|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
334430|NCT00423813|Drug|placebo|Oral Solution
334431|NCT00423813|Drug|Xyrem®|two doses
334432|NCT00423826|Drug|Busulfan|3 mg/kg intravenously over 3 hours
334433|NCT00423826|Drug|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
334434|NCT00003369|Drug|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
334435|NCT00423826|Drug|Fludarabine phosphate|25 mg/M2/day IV
334436|NCT00423826|Drug|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
334437|NCT00423826|Drug|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
334438|NCT00423826|Procedure|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
334439|NCT00423826|Procedure|umbilical cord blood transplantation|10 days post drug intervention
334440|NCT00423826|Radiation|total-body irradiation|10 days post drug intervention
334441|NCT00423839|Biological|MVA85A (Tuberculosis vaccine)|
334442|NCT00423852|Biological|filgrastim|
334443|NCT00423852|Drug|carboplatin|
334444|NCT00423852|Drug|ifosfamide|
334445|NCT00000512|Other|Placebo for colestipol|Placebo for colestipol.
334446|NCT00003369|Drug|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
334447|NCT00423852|Drug|paclitaxel|
334448|NCT00423852|Procedure|autologous hematopoietic stem cell transplantation|
334449|NCT00423852|Procedure|peripheral blood stem cell transplantation|
334450|NCT00423865|Drug|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
339558|NCT00516269|Drug|Methylphenidate|18 mg by mouth daily for 2 weeks
339559|NCT00516269|Drug|Placebo|Capsule by mouth daily for 2 weeks
339560|NCT00516282|Drug|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
339561|NCT00003794|Procedure|psychosocial assessment and care|
339562|NCT00516282|Drug|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
339563|NCT00516295|Drug|topotecan hydrochloride|Given IV
339564|NCT00516295|Drug|vincristine sulfate|Given IV
339565|NCT00516295|Drug|cyclophosphamide|Given IV
339566|NCT00516295|Biological|bevacizumab|Given IV
339567|NCT00516308|Device|NightHawk|
339568|NCT00516321|Drug|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
339569|NCT00516321|Drug|placebo|matched placebo taken once daily orally
339570|NCT00516347|Genetic|comparative genomic hybridization|
339571|NCT00516347|Genetic|genetic linkage analysis|
339572|NCT00003794|Procedure|quality-of-life assessment|
334075|NCT00432523|Biological|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
334076|NCT00432536|Other|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
334077|NCT00003400|Drug|carmustine|
334078|NCT00432549|Drug|Almotriptan|
334079|NCT00432549|Drug|Topiramate|
334080|NCT00432562|Drug|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
339214|NCT00521599|Drug|Placebo|
339215|NCT00521612|Drug|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
339216|NCT00521612|Drug|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
339217|NCT00524368|Drug|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
339218|NCT00524368|Drug|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
339219|NCT00524381|Drug|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
339220|NCT00524381|Drug|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
339221|NCT00524407|Drug|Epoetin alfa|
339222|NCT00524420|Device|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
339223|NCT00524420|Device|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
339224|NCT00524433|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
339225|NCT00524433|Drug|placebo|
339226|NCT00003838|Procedure|Stem cell transplantation|
339227|NCT00524446|Dietary Supplement|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
339228|NCT00524446|Dietary Supplement|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
339229|NCT00524446|Dietary Supplement|Maize-soy flour|Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
339230|NCT00524459|Drug|docetaxel|
333796|NCT00446680|Drug|Mannitol|400mg BD for 6 months followed by a 6 month open label period
333797|NCT00446680|Drug|placebo|placebo BD for 6 months
333798|NCT00446693|Device|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
333799|NCT00003456|Drug|antineoplaston A10|
333800|NCT00446719|Drug|Rellidep|2000 mg P.O. daily for 8 weeks
328614|NCT00579033|Other|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
328615|NCT00579046|Drug|Darbepoetin alfa|Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).
Frequency: every week for 2 months: 8 injections
328616|NCT00579059|Device|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
328617|NCT00579059|Device|Regular Maxim® Knee System|Used for total knee replacements
328618|NCT00579072|Behavioral|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 140 men with prostate cancer. All 140 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 140 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 70 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
328619|NCT00581399|Device|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
328620|NCT00581399|Device|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
328621|NCT00581425|Biological|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
328622|NCT00581451|Drug|bifeprunox|oral tablet once daily
328623|NCT00581464|Behavioral|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
328624|NCT00581464|Behavioral|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
328625|NCT00581477|Drug|droxidopa|up to 300mg four times daily
328626|NCT00581477|Drug|placebo|same frequency as experimental medication
333436|NCT00455260|Drug|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
333437|NCT00455260|Device|hGH-ViaDerm™ System|The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).
The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system.
333438|NCT00455286|Drug|Methotrexate|
333439|NCT00455286|Drug|Methylprednisolone|
333440|NCT00455286|Drug|Temozolomide|
333441|NCT00455299|Procedure|Laparoscopic ventral hernia repair|
333442|NCT00455312|Drug|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
333443|NCT00458575|Drug|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
333444|NCT00458588|Other|physiologic testing|
333445|NCT00458588|Other|questionnaire administration|
333446|NCT00458588|Procedure|breast imaging study|
333801|NCT00449618|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
333802|NCT00449618|Procedure|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
333803|NCT00449618|Drug|Placebo|Use of placebo on awakening versus bedtime
333804|NCT00449644|Drug|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
333805|NCT00449644|Drug|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
333806|NCT00449644|Drug|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
332744|NCT00425841|Drug|oxaliplatin|
333091|NCT00417118|Drug|Placebo|oral administration (capsules)
333092|NCT00417144|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
333093|NCT00417144|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
333094|NCT00417157|Drug|recombinant FSH (Puregon, Organon, The Netherlands)|
333095|NCT00417157|Drug|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
333096|NCT00417157|Drug|hCG (Pregnyl, Organon, The Netherlands)|
333097|NCT00417170|Drug|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
333098|NCT00003335|Drug|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
333099|NCT00417170|Drug|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
333100|NCT00417170|Drug|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
333101|NCT00417170|Drug|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
333102|NCT00417183|Drug|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
333103|NCT00417183|Drug|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
333104|NCT00417196|Drug|QAX576|
333105|NCT00417209|Drug|larotaxel (XRP9881)|IV infusion
333106|NCT00417209|Drug|5-Fluorouracil|administered either by IV or oral route
333107|NCT00417222|Drug|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
333108|NCT00420459|Drug|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
333109|NCT00003346|Drug|carmustine|
333110|NCT00420472|Drug|mycophenolate mofetil [CellCept]|
333111|NCT00420485|Drug|gimatecan|
333112|NCT00420498|Drug|Atomoxetine (Strattera™)|
332394|NCT00434642|Drug|Carboplatin|Carboplatin was provided as commercially available drug.
332395|NCT00434642|Drug|Gemcitabine|Gemcitabine was provided as commercially available drug.
332396|NCT00003405|Drug|idoxuridine|
332397|NCT00434642|Drug|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL [25 mg/mL]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
332398|NCT00434642|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
332399|NCT00434655|Procedure|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
332400|NCT00434668|Drug|cisplatin/docetaxel|
332401|NCT00434668|Drug|cisplatin/vinorelbine|
332402|NCT00434681|Drug|paracetamol 4.8% paediatric oral suspension|
332403|NCT00434694|Procedure|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
332404|NCT00434720|Device|GlideScope Specific Stylet|
332745|NCT00425841|Procedure|adjuvant therapy|
332746|NCT00000513|Behavioral|diet, sodium-restricted|
332747|NCT00003384|Procedure|Conization|Undergo cone biopsy
332748|NCT00425841|Procedure|neoadjuvant therapy|
332749|NCT00425841|Radiation|hypofractionated radiation therapy|
332750|NCT00425841|Radiation|stereotactic radiosurgery|
332751|NCT00425854|Drug|BIBW 2992|high dose once daily
332752|NCT00425867|Behavioral|PAR1 polymoprhisms and placental invasion|
332753|NCT00425893|Behavioral|hand hygiene|alcohol-based hand wash
332754|NCT00425893|Other|health education|Proper nutrition, etc.
332755|NCT00425893|Device|face masks|face masks
332756|NCT00425906|Drug|nicotine|
332064|NCT00443183|Behavioral|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
332065|NCT00443183|Behavioral|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
332066|NCT00443196|Procedure|MiCK Assay|Physician determined treatment
332067|NCT00443209|Drug|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
332068|NCT00443209|Drug|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
332069|NCT00443209|Drug|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
332070|NCT00443209|Drug|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
332071|NCT00443209|Drug|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
332072|NCT00443209|Drug|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
332073|NCT00443222|Drug|Infliximab|
332074|NCT00003437|Drug|cytarabine|
332075|NCT00443235|Drug|Melphalan/Prednisone/Velcade|One cycle:
Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)
332076|NCT00443235|Drug|Thalidomide/Prednisone/Velcade|One cycle:
Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)
Five cycles:
Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)
332077|NCT00443248|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
332078|NCT00443261|Drug|Azacitidine|SC azacitidine
332079|NCT00443261|Drug|Cisplatin|cisplatin 75 mg/m2 day 8 every 28 days
332080|NCT00443287|Drug|ataciguat (HMR1766)|oral administration
332405|NCT00434733|Biological|Pandemic influenza vaccine|
332406|NCT00434746|Drug|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
332407|NCT00003405|Drug|isotretinoin|
331351|NCT00460889|Procedure|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
331352|NCT00460902|Device|Transcranial Magnetic Stimulation (TMS)|
331353|NCT00460915|Drug|Lacidipine & Amlodipine|
331707|NCT00451412|Drug|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
331708|NCT00451425|Behavioral|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
331709|NCT00451451|Drug|BG00012|
331710|NCT00003487|Drug|antineoplaston AS2-1|
331711|NCT00451451|Drug|Placebo|
331712|NCT00451451|Drug|Glatiramer Acetate|
331713|NCT00451490|Drug|Agomelatine|
331714|NCT00451490|Drug|Fluoxentine|
331715|NCT00451503|Device|Middle Ear Implant|surgery
331716|NCT00451516|Drug|Herbal medicine (St. John's wort and Kava)|
331717|NCT00451555|Drug|enzastaurin|1125 mg loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
331718|NCT00451555|Drug|placebo|oral, daily
331719|NCT00451555|Drug|fulvestrant|500 mg, IM, day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, q 28 days, until disease progression
331720|NCT00451568|Drug|Metformin|500 mg 2 tablets 2 times a day
331721|NCT00003489|Drug|antineoplaston A10|
331722|NCT00451568|Drug|Desorelle|1 tablet/day in 21 days
331723|NCT00451581|Procedure|Endoscopic papillary balloon dilation-5 minutes|
331724|NCT00451581|Procedure|Endoscopic papillary balloon dilation-1 minute|
331725|NCT00454532|Drug|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
331726|NCT00454545|Drug|Atorvastatin|
330987|NCT00422578|Drug|tadalafil|
330988|NCT00422591|Drug|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
330989|NCT00000512|Drug|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
330990|NCT00003362|Biological|QS21|
330991|NCT00422591|Drug|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
330992|NCT00422604|Drug|salmeterol|
330993|NCT00422604|Drug|tiotropium|
330994|NCT00422604|Drug|GSK233705|
330995|NCT00422617|Drug|Alefacept (Amevive)|
330996|NCT00422630|Behavioral|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
331354|NCT00460928|Drug|intravenous immune globulin (IVIG)|
331355|NCT00003536|Procedure|biologically based therapies|
331356|NCT00460941|Drug|Placebo|sc weekly
331357|NCT00460941|Drug|taspoglutide|20mg sc weekly
331358|NCT00460941|Drug|taspoglutide|20mg-30mg sc weekly
331359|NCT00460941|Drug|taspoglutide|20mg-40mg sc weekly
331360|NCT00460954|Drug|Sinemet® controlled release (Carbidopa/levodopa)|
331361|NCT00460967|Device|Rheopheresis|8 rheopheresis treatments over 10 wks.
331362|NCT00460967|Device|Rheopheresis|Sham treatment
331363|NCT00003331|Drug|fluorouracil|
331364|NCT00416611|Behavioral|Implementation of guidelines|
331365|NCT00416624|Drug|darbepoetin alfa|
330659|NCT00436748|Drug|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
330660|NCT00436748|Drug|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
330661|NCT00436761|Biological|anti-thymocyte globulin|
330662|NCT00436761|Biological|graft-versus-tumor induction therapy|
330997|NCT00422630|Behavioral|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
330998|NCT00425178|Drug|FGF-1|
330999|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
331000|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
331001|NCT00425191|Drug|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
331002|NCT00003378|Drug|paclitaxel|
331003|NCT00425204|Drug|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
331004|NCT00425217|Drug|Rituximab|
331005|NCT00425230|Drug|Duloxetine|
331006|NCT00425243|Drug|zolpidem-MR (SL800750)|
331007|NCT00425256|Drug|Bremelanotide|
331008|NCT00425269|Behavioral|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
331009|NCT00425282|Drug|RWJ-333369|
331010|NCT00425295|Behavioral|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
330377|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
330378|NCT00569920|Drug|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
330379|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
330380|NCT00569933|Behavioral|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
330381|NCT00004090|Drug|cisplatin|
330382|NCT00569946|Drug|AG-013736|AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.
Number of cycles: until progression or unacceptable toxicity develops.
330383|NCT00569959|Other|fasting 12+ hours|fasting 12+ hours
330384|NCT00569959|Other|Non-fasting|Non-fasting
330385|NCT00569972|Drug|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
330386|NCT00569972|Drug|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
330387|NCT00569972|Drug|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
330388|NCT00569972|Drug|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
330389|NCT00569972|Drug|Placebo|Matched oral placebo for weeks 2-7.
330390|NCT00569985|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
330663|NCT00436761|Biological|sargramostim|
330664|NCT00003414|Biological|aldesleukin|
330665|NCT00436761|Drug|busulfan|
330666|NCT00436761|Drug|cyclosporine|
330667|NCT00436761|Drug|melphalan|
330668|NCT00436761|Drug|methylprednisolone|
330669|NCT00436761|Other|flow cytometry|
329769|NCT00004162|Drug|pegylated liposomal doxorubicin hydrochloride|
329770|NCT00584909|Drug|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
329771|NCT00584922|Procedure|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
329772|NCT00584935|Drug|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
336968|NCT00460239|Drug|Placebo|IM; double blind; once per week
336969|NCT00460252|Procedure|insulin titration applying a computer algorithm|
336970|NCT00460265|Drug|ARM 2|Subjects will receive Cisplatin plus 5FU
336971|NCT00003534|Drug|antineoplaston A10|
336972|NCT00460265|Drug|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
336973|NCT00460278|Drug|XL418|
336974|NCT00460291|Device|Implantation of the ProVena vein graft during bypass surgery|
336975|NCT00460304|Drug|pramlintide|
336976|NCT00460304|Procedure|continuous glucose monitoring|
336977|NCT00460317|Drug|AMG 706|125 mg QD orally every day
336978|NCT00460317|Drug|placebo|125 mg QD orally every day
336979|NCT00460317|Drug|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
336980|NCT00460317|Drug|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
336981|NCT00460343|Other|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
336982|NCT00003534|Drug|antineoplaston AS2-1|
336983|NCT00460343|Other|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
336228|NCT00427440|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
336229|NCT00427440|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
336230|NCT00427453|Biological|MVA85A|
336231|NCT00427466|Drug|Pemetrexed|
336232|NCT00427492|Drug|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
336233|NCT00000513|Drug|atenolol|
336234|NCT00003388|Drug|methotrexate|
336235|NCT00427492|Drug|Placebo|
336236|NCT00430326|Drug|Avotermin|
336237|NCT00430352|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
336238|NCT00430365|Drug|lenalidomide|oral drug
336239|NCT00430365|Drug|placebo|oral placebo
336240|NCT00430378|Procedure|Acupuncture|Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.
336241|NCT00003397|Biological|sargramostim|
336242|NCT00430378|Other|Standard Care|No Acupuncture.
336243|NCT00430391|Other|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
336244|NCT00430391|Other|Routine Control|Participants are assigned to the routine, standard consent.
336245|NCT00430404|Other|Collaborative care (Intervention)|Structured shared care with treatment protocol & support
336594|NCT00418964|Procedure|Double bundle hamstring|Double bundle hamstring
336595|NCT00421993|Drug|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
336596|NCT00421993|Drug|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
336597|NCT00422006|Procedure|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
336598|NCT00003357|Biological|GM2-KLH vaccine|
335516|NCT00447382|Drug|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
335517|NCT00447382|Drug|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
335518|NCT00447408|Behavioral|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
335872|NCT00436306|Behavioral|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
335873|NCT00436319|Procedure|Duration of GnRH agonist downregulation|This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.
The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2<80 pg/ml and progesterone <1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.
The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history.
335874|NCT00003421|Drug|vincristine sulfate|
335875|NCT00438945|Drug|Eprosartan|
335876|NCT00438958|Biological|filgrastim|Given on day 0.
335877|NCT00438958|Procedure|allogeneic bone marrow transplantation|Given on day 0
335878|NCT00438958|Procedure|peripheral blood stem cell transplantation|Given on day 0
335879|NCT00438971|Drug|Duloxetine|Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
335880|NCT00438984|Drug|cyclophosphamide|Given IV
335881|NCT00438984|Biological|therapeutic autologous lymphocytes|Given IV
335882|NCT00438984|Biological|aldesleukin|Given IV or SC
335883|NCT00438984|Other|immunohistochemistry staining method|Correlative studies
335884|NCT00438984|Procedure|biopsy|Optional correlative studies
335885|NCT00003421|Radiation|radiation therapy|
335886|NCT00438984|Other|laboratory biomarker analysis|Correlative studies
335887|NCT00438984|Other|immunologic technique|Correlative studies
335888|NCT00438984|Genetic|polymerase chain reaction|Correlative studies
335145|NCT00453180|Drug|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
335146|NCT00453193|Drug|Pentostatin|4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
335147|NCT00453193|Drug|Alemtuzumab|30 mg IV three times weekly
335148|NCT00453206|Procedure|allogeneic bone marrow transplantation|
335149|NCT00453206|Procedure|allogeneic hematopoietic stem cell transplantation|
335150|NCT00003497|Drug|antineoplaston AS2-1|
335151|NCT00453206|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
335152|NCT00453206|Procedure|peripheral blood stem cell transplantation|
335153|NCT00455780|Behavioral|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
335154|NCT00455806|Drug|esomeprazole|
335155|NCT00003514|Drug|antineoplaston AS2-1|
335156|NCT00455806|Drug|moxifloxacin|
335157|NCT00455806|Drug|amoxicillin|
335158|NCT00455819|Procedure|home treatment|
335159|NCT00455832|Procedure|peginterferon alpha and ribavirin|sperm collection
335160|NCT00455845|Device|Levonorgestrel IUD|levonorgestrel IUD
335161|NCT00455858|Drug|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
335162|NCT00455871|Drug|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
335163|NCT00455871|Drug|Lucentis|Lucentis intravitreal injection
335519|NCT00447408|Behavioral|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
335520|NCT00003460|Drug|antineoplaston A10|
335521|NCT00447421|Drug|pemetrexed|Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)
Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles
334451|NCT00423865|Drug|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
334452|NCT00423865|Genetic|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
334795|NCT00415350|Drug|Azithromycin|Azithromycin Tablet 250 mg daily
334796|NCT00003320|Radiation|stereotactic radiosurgery|
334797|NCT00415350|Other|Placebo|Placebo tablet 1 daily
334798|NCT00415363|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
334799|NCT00415363|Drug|placebo|oral, daily
334800|NCT00415376|Drug|levetiracetam|
334801|NCT00415376|Procedure|quality-of-life assessment|
334802|NCT00417950|Drug|Acarbose|
334803|NCT00417963|Device|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
334804|NCT00417976|Drug|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
334805|NCT00417976|Drug|Bevacizumab|10 mg/kg every 2 weeks.
334806|NCT00417976|Drug|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
334807|NCT00417989|Device|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
334808|NCT00418002|Drug|AQW051|
334809|NCT00418015|Procedure|Blood Draw|Blood for OPRM1 analysis
334810|NCT00418028|Drug|drug: capecitabine|800 mg/m2 twice a day orally continuous administration until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
334811|NCT00003336|Procedure|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
334812|NCT00418028|Drug|capecitabine|1250 mg/m2 twice a day orally x 14 days every 3 weeks until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
334813|NCT00418054|Drug|Nitazoxanide plus peginterferon alfa-2b|
334081|NCT00432575|Drug|surinabant (SR147778)|oral administration
334082|NCT00432575|Drug|placebo|oral administration
334083|NCT00432588|Drug|misoprostol|
334084|NCT00432588|Drug|dinoprostone|
334085|NCT00432601|Behavioral|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
334086|NCT00432614|Drug|SR58611A|oral administration
334087|NCT00432614|Drug|escitalopram|oral administration
334088|NCT00003400|Drug|cisplatin|
334089|NCT00432614|Drug|placebo|oral administration
334090|NCT00432627|Drug|Deferasirox|one dose of 20 mg/kg/day
334091|NCT00432640|Procedure|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
334092|NCT00432640|Procedure|Surgical staging|Surgical staging
334093|NCT00432653|Drug|rituximab|
334094|NCT00432666|Drug|IncobotulinumtoxinA (Xeomin)|incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection
334095|NCT00003406|Procedure|peripheral blood stem cell transplantation|
334096|NCT00435292|Dietary Supplement|flavocoxid 500 mg|flavonoid mixture
334097|NCT00435305|Drug|Meropenem|
334098|NCT00435305|Drug|Vancomycin|
334099|NCT00435305|Drug|Linezolid|
334453|NCT00423865|Other|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
339231|NCT00524459|Drug|pegylated liposomal doxorubicin hydrochloride|
339573|NCT00516347|Other|laboratory biomarker analysis|
339574|NCT00516347|Other|questionnaire administration|
339575|NCT00516347|Procedure|study of high risk factors|
339576|NCT00516360|Device|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
339577|NCT00516373|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
339578|NCT00516386|Drug|RhIGF-1|35-40 mcg/k/dose twice daily SC
339579|NCT00516399|Drug|povidone-iodine 1.25% ophthalmic solution|
339580|NCT00516399|Drug|natamycin ophthalmic suspension, USP 5%|
339581|NCT00516412|Drug|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
339582|NCT00516412|Genetic|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
339583|NCT00003795|Procedure|quality-of-life assessment|
339584|NCT00516425|Biological|pegfilgrastim|
339585|NCT00519038|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
339586|NCT00519038|Other|Usual Care|Usual care is the current practice actually performed in the hospital
339587|NCT00003811|Drug|amifostine trihydrate|
339588|NCT00519051|Other|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
339589|NCT00519064|Biological|Adjuvanted influenza vaccine|
339590|NCT00519077|Drug|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
328627|NCT00004145|Drug|cyclophosphamide|
328628|NCT00581477|Drug|alpha-methyldopa|up to 250mg two times daily
328629|NCT00581477|Drug|carbidopa|up to 25mg four times daily
328630|NCT00581477|Drug|metyrosine|up to 1000mg three times daily
328631|NCT00581477|Drug|levodopa|up to 250mg three times daily
328632|NCT00581477|Drug|atomoxetine|up to 40mg twice daily
328633|NCT00581477|Drug|metoclopramide|up to 10mg four times daily
328634|NCT00581503|Device|diagnostic|oct imaging
328936|NCT00574301|Procedure|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
328937|NCT00574314|Other|No Intervention|Participants will be consented.
328938|NCT00574340|Other|Hyperinsulinemic Hypoglycemic Clamp|hyperinsulinemic glucose clamp separated by 8 weeks
328939|NCT00576771|Procedure|PSV|Pressure Support Ventilation
328940|NCT00576771|Procedure|NAVA|Neurally Adjusted Ventilatory Assist
328941|NCT00576771|Procedure|patient-controlled|assisted controlled MV through a button
328942|NCT00576784|Drug|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
328943|NCT00576810|Drug|sodium picosulphate|
328944|NCT00004124|Drug|bicalutamide|
328945|NCT00576823|Drug|Alfuzosin|Dose: 0.2 mg/kg/day
Route: oral
328946|NCT00576836|Biological|Thymus Tissue for Transplantation|Thymus tissue (from unrelated donor), donor, and donor's mother screened for safety. Thymus transplantation done under general anesthesia. Thymus transplanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not >18 grams/m2 body surface area (1.0 grams/kg body weight). At time of transplant, skin biopsy obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy done to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples.
333807|NCT00449657|Drug|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
333808|NCT00449657|Procedure|Radiotherapy|Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.
Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5
333809|NCT00449657|Drug|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 & 9
333810|NCT00003475|Drug|antineoplaston A10|
333811|NCT00449657|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 & 9
333812|NCT00449670|Biological|Influenza Vaccine GSK1562902A - 6 different formulations|3 doses for experimental groups & 4 doses for control groups, intramuscular injection
333813|NCT00449683|Drug|terazosin|
333814|NCT00449696|Device|Gel-200|Single intra-articular injection
333815|NCT00449696|Device|Placebo|Single intra-articular injection
333816|NCT00449709|Drug|GSK221149|
333817|NCT00449722|Drug|mesalazine|
333818|NCT00449748|Drug|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
333819|NCT00449761|Drug|panobinostat|LBH589
333820|NCT00449774|Drug|Lamotrigine|
333821|NCT00000523|Behavioral|exercise|
333822|NCT00003475|Drug|antineoplaston AS2-1|
333823|NCT00449787|Drug|Sumatriptan 100 mg|Sumatriptan 100mg tablet
333824|NCT00449787|Drug|Naproxen|Naproxen 500mg tablet
328635|NCT00581529|Radiation|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
328636|NCT00581542|Drug|moxifloxacin|1-2 drops three times a day for 8-10 days.
328637|NCT00581542|Drug|polytrim|1-2 drops four times a day for 8-10 days.
328638|NCT00004145|Drug|fludarabine phosphate|
328639|NCT00581555|Drug|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
333113|NCT00420511|Drug|Sitagliptin|sitagliptin 100 mg once a day
333114|NCT00420511|Drug|Placebo|placebo once a day
333115|NCT00420511|Drug|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
333116|NCT00420524|Drug|Patupilone/EPO906|
333447|NCT00458588|Procedure|dual x-ray absorptometry|
333448|NCT00458588|Procedure|evaluation of cancer risk factors|
333449|NCT00458588|Procedure|magnetic resonance imaging|
333450|NCT00458601|Drug|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF
333451|NCT00458601|Drug|temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles , intolerance or progression.
333452|NCT00458614|Drug|Lansoprazole|
333453|NCT00003520|Drug|antineoplaston AS2-1|
333454|NCT00458653|Biological|Dendritic Cell Tumor Fusion|Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.
Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT
333455|NCT00458679|Biological|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10^7) of IL-2 secreting B-cells together with (2 x 10^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
333456|NCT00458705|Drug|bortezomib|
333457|NCT00458705|Drug|dexamethasone|
333458|NCT00458705|Drug|pegylated liposomal doxorubicin hydrochloride|
333459|NCT00458705|Drug|thalidomide|
333460|NCT00458718|Drug|rimonabant (SR141716)|
333461|NCT00458731|Biological|bevacizumab|Given IV
333462|NCT00458731|Drug|cediranib maleate|Given orally
333463|NCT00458744|Drug|talotrexin|
333464|NCT00003521|Drug|antineoplaston A10|
332757|NCT00425906|Other|Placebo|
332758|NCT00003384|Other|Laboratory Biomarker Analysis|Correlative studies
332759|NCT00425906|Procedure|Quality of life|
332760|NCT00428870|Procedure|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
332761|NCT00428883|Drug|N-acetylcysteine (NAC)|
332762|NCT00428896|Drug|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
332763|NCT00428909|Drug|Imatinib/Acetaminophen|
332764|NCT00428922|Drug|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
332765|NCT00003392|Drug|carboplatin|18 AUC IV, approximately days 21, 42
332766|NCT00428922|Drug|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
332767|NCT00428922|Drug|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
333117|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 100 and 150
333118|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
333119|NCT00420537|Drug|Mycophenolate mofetil|mycophenolate with low doses
333120|NCT00003348|Drug|O6-benzylguanine|
333121|NCT00420537|Drug|Everolimus|
333122|NCT00420550|Behavioral|Relaxation Response using Guided Imagery|
333123|NCT00420563|Drug|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
333124|NCT00420563|Drug|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
333125|NCT00420576|Drug|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
332408|NCT00434759|Behavioral|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
332409|NCT00437294|Drug|capecitabine|1250 mg/m2, BID, days 1-14 of each 21 day cycle until progressive disease
332410|NCT00437307|Drug|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
332411|NCT00437320|Procedure|Metvix PDT|Metvix PDT
332412|NCT00437320|Procedure|placebo|placebo
332413|NCT00437333|Drug|Metformin cloridrate|
332414|NCT00437346|Procedure|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
332415|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
332416|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
332417|NCT00437359|Drug|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
332418|NCT00003416|Biological|recombinant interferon alfa|
332419|NCT00437359|Drug|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
332420|NCT00437372|Drug|Sunitinib|The use of the FDA approved drug sunitinib, used in an "off-label" manner with external beam radiation therapy.
332421|NCT00437372|Radiation|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
332422|NCT00437385|Drug|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
332423|NCT00437385|Procedure|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
332768|NCT00428935|Biological|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
332769|NCT00428948|Drug|tolvaptan|oral tablet split-dose regimens (45/15mg, 60/30 mg or 90/30 mg) by mouth twice a day on awakening and approximately 9 hours later for 36 months. Daily dose regimen based on maximally tolerated dose.
331727|NCT00454558|Drug|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
331728|NCT00454571|Drug|pazopanib hydrochloride|Given PO
331729|NCT00454571|Drug|leuprolide acetate|
331730|NCT00454571|Drug|goserelin acetate|
331731|NCT00454584|Drug|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
331732|NCT00454584|Drug|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
332081|NCT00445913|Biological|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
332082|NCT00445913|Biological|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
332083|NCT00445926|Device|deep TMS H-coil|
332084|NCT00445939|Biological|adalimumab|160 mg at Week 0, 80 mg at Week 2
332085|NCT00445939|Biological|adalimumab|80 mg at Week 0, 40 mg at Week 2
332086|NCT00445939|Biological|placebo|Placebo at Week 0 and Week 2
332087|NCT00003454|Drug|antineoplaston A10|
332088|NCT00445952|Other|clinical observation|
332089|NCT00445952|Procedure|management of therapy complications|
332090|NCT00445965|Genetic|DNA analysis|
332091|NCT00445965|Other|immunologic technique|
332092|NCT00445965|Other|pharmacological study|
332093|NCT00445965|Radiation|iodine I 131 monoclonal antibody 3F8|
331366|NCT00416624|Drug|epoetin alfa|
331367|NCT00416624|Procedure|fatigue assessment and management|
331368|NCT00416624|Procedure|quality-of-life assessment|
331369|NCT00416637|Biological|bevacizumab|
331370|NCT00416650|Drug|erlotinib hydrochloride|All patients will receive 150 mg orally daily
331371|NCT00416663|Procedure|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
331372|NCT00416676|Drug|carboplatin|
331373|NCT00416676|Drug|cisplatin|
331374|NCT00003331|Drug|leucovorin calcium|
331375|NCT00416676|Drug|cyclophosphamide|
331376|NCT00416676|Drug|etoposide|
331377|NCT00416676|Drug|vincristine sulfate|
331378|NCT00416676|Procedure|adjuvant therapy|
331379|NCT00416676|Procedure|conventional surgery|
331380|NCT00416676|Procedure|neoadjuvant therapy|
331381|NCT00416676|Radiation|radiation therapy|
331733|NCT00454584|Drug|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
331734|NCT00003505|Procedure|alternative product therapy|
331735|NCT00454597|Procedure|omentectomy|surgery omentectomy
331736|NCT00454610|Behavioral|FLOW|
331737|NCT00454610|Behavioral|SelfHelp|
331738|NCT00454623|Behavioral|drawing serum adiponectin level|
331739|NCT00454636|Drug|Standard chemotherapy|As prescribed
331740|NCT00454636|Drug|capecitabine [Xeloda]|625mg/m2 po bid increasing to 1000mg/m2 po bid
331011|NCT00425308|Drug|Everolimus + Cyclosporine|
331012|NCT00425308|Drug|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
331013|NCT00000513|Behavioral|diet, reducing|
331014|NCT00003379|Drug|cisplatin|
331015|NCT00425308|Drug|Steroids|
331016|NCT00425321|Drug|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
331017|NCT00425321|Drug|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
331382|NCT00416689|Procedure|assessment of therapy complications|
331383|NCT00416689|Procedure|quality-of-life assessment|
331384|NCT00416702|Drug|QAB149|
331385|NCT00003331|Drug|topotecan hydrochloride|
331386|NCT00416715|Drug|letrozole|Given PO
331387|NCT00416715|Dietary Supplement|calcium carbonate|Given PO
331388|NCT00416715|Other|laboratory biomarker analysis|Optional correlative studies
331389|NCT00416715|Dietary Supplement|calcium citrate|Given PO
331390|NCT00416715|Dietary Supplement|calcium glucarate|Given PO
331391|NCT00416715|Drug|calcium gluconate|Given PO
331392|NCT00416715|Dietary Supplement|cholecalciferol|Given PO
331393|NCT00416715|Procedure|assessment of therapy complications|Ancillary studies
331394|NCT00416715|Procedure|musculoskeletal complications management/prevention|Correlative studies
331395|NCT00416728|Drug|Aliskiren|
331396|NCT00003332|Drug|cisplatin|
331397|NCT00419562|Drug|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
331398|NCT00419601|Drug|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
330670|NCT00436761|Other|immunologic technique|
330671|NCT00436761|Other|laboratory biomarker analysis|
330672|NCT00436761|Procedure|allogeneic hematopoietic stem cell transplantation|
330673|NCT00436761|Procedure|umbilical cord blood transplantation|
330674|NCT00436774|Procedure|assessment of therapy complications|
330675|NCT00003414|Biological|recombinant interferon gamma|
330676|NCT00436774|Procedure|quality-of-life assessment|
330677|NCT00436787|Drug|Fondaparinux Sodium|
330678|NCT00436800|Drug|Gemcitabine|1000mg/m² over 10mg/m²/min
330679|NCT00436800|Drug|Oxaliplatin|100 mg/m² over 2 hours.
330680|NCT00436826|Drug|Cladribine|Subjects will receive cladribine tablets orally as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the double blind (DB) period of 96 weeks. Subjects who will complete the DB period will to enter in open label (OL) extension period, if they meet the eligibility criteria they will be given total cladribine dose of 3.5 mg/kg over 48 weeks.
330681|NCT00436826|Drug|Placebo|Subjects will receive matching placebo tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total matching placebo dose of 3.5 mg/kg during the DB period of 96 weeks.
330682|NCT00436826|Drug|Interferon-beta (IFN-beta)|Subjects will receive IFN-beta therapy (Rebif® new formulation [RNF] 44 microgram [mcg] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
330683|NCT00439569|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
330684|NCT00439582|Dietary Supplement|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
330685|NCT00439582|Dietary Supplement|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
331018|NCT00425321|Drug|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
331019|NCT00425321|Drug|Placebo|Placebo once daily for up to 12 weeks
331020|NCT00425334|Drug|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
331021|NCT00425334|Drug|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
336984|NCT00416143|Procedure|bed rest|
336985|NCT00416143|Drug|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
336986|NCT00416156|Behavioral|Lifestyle modification|
336987|NCT00416169|Drug|galantamine hydrobromide|
336988|NCT00416182|Drug|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
336989|NCT00416182|Drug|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
336990|NCT00416195|Drug|E2007|
336991|NCT00416195|Drug|Placebo|
336992|NCT00416208|Drug|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
337333|NCT00450957|Dietary Supplement|lycopene|Given orally
337334|NCT00450957|Other|pharmacological study|Correlative studies
337335|NCT00454077|Procedure|radioiodine therapy after rhTSH|
337336|NCT00454090|Drug|AZD8330|oral tablet
337337|NCT00454103|Drug|123I-Iodometomidate|
337338|NCT00454116|Drug|Vandetanib|once daily oral tablet two doses
337339|NCT00454116|Drug|FOLFIRI|Intravenous infusion
337340|NCT00454129|Procedure|cholangiography via double-balloon enteroscopy|
337341|NCT00454129|Procedure|MR cholangiography|
337342|NCT00454142|Drug|pazopanib hydrochloride|Given PO
337343|NCT00454142|Other|pharmacological study|Correlative studies
337344|NCT00003502|Procedure|alternative product therapy|
337345|NCT00454142|Procedure|computed tomography|Correlative studies
337346|NCT00454155|Drug|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
337347|NCT00454168|Biological|PR1 leukemia peptide vaccine|Given subcutaneously
336599|NCT00422006|Procedure|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
336600|NCT00422006|Behavioral|diet|diet
336601|NCT00422006|Other|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
336602|NCT00422019|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
336603|NCT00422019|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
336604|NCT00422032|Drug|Clofarabine|Group A: 15 mg/m^2 IV over 1 hour daily for 5 days
Group B: 30 mg/m^2 IV over 1 hour daily for 5 days
336605|NCT00422045|Device|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
336606|NCT00422058|Drug|liraglutide|Injected s.c. (under the skin) once daily
336607|NCT00422058|Drug|orlistat|120 mg capsule. Administered thrice daily
336608|NCT00422058|Drug|placebo|Injected s.c. (under the skin) once daily
336609|NCT00003357|Biological|QS21|
336610|NCT00422084|Drug|Pyronaridine artesunate|once a day for 3 days
336611|NCT00422084|Drug|Coartem® (artemether lumefantrine)|twice a day for 3 days
336612|NCT00422097|Drug|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
336613|NCT00422097|Drug|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
336614|NCT00422097|Drug|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
336993|NCT00003324|Radiation|radiation therapy|
336994|NCT00416221|Drug|Lexapro, an antidepressant medicine|
336995|NCT00416221|Behavioral|Physical Activity|
336996|NCT00416221|Behavioral|Mood Management Skills|
335889|NCT00439010|Drug|[123I] AV 39|
335890|NCT00439023|Procedure|dialysis with glucose in dialysis water|
335891|NCT00439036|Behavioral|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
335892|NCT00439036|Behavioral|Drug Counseling|
335893|NCT00439049|Drug|modafinil|400 mg daily
336246|NCT00430430|Procedure|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
336247|NCT00430430|Procedure|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
336248|NCT00430443|Drug|Liposomal Annamycin|3-day IV infusion
336249|NCT00430456|Procedure|Exercise|Treadmill Training
336250|NCT00430469|Drug|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
336251|NCT00430482|Behavioral|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
336252|NCT00000515|Behavioral|diet, reducing|
336253|NCT00003397|Drug|carmustine|
336254|NCT00430482|Behavioral|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
336255|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
336256|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
336257|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
336258|NCT00430495|Drug|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
336259|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
336260|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
335522|NCT00447421|Drug|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
335523|NCT00447421|Radiation|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
335524|NCT00447434|Drug|Natto extract (Nattokinase)|
335525|NCT00447460|Procedure|Mesenchymal stem cell (MSC)|
335526|NCT00447473|Drug|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
335527|NCT00447473|Drug|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
335528|NCT00447473|Drug|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
335529|NCT00447486|Drug|GW842166|
335530|NCT00447499|Drug|Somatuline Autogel (lanreotide acetate)|Injections
335531|NCT00000522|Drug|doxazosin|
335532|NCT00003460|Drug|antineoplaston AS2-1|
335533|NCT00447499|Behavioral|Home administration|Questionnaire
335534|NCT00447512|Drug|ghrelin|acylated ghrelin
335535|NCT00447525|Biological|REVAXIS®|
335536|NCT00447525|Biological|DT-Polio®|
335537|NCT00447551|Drug|Poly-L-Lactic Acid|Deep dermal injection
335538|NCT00447564|Drug|Probuphine|4 implants
335539|NCT00447564|Drug|placebo|4 implants
335540|NCT00447577|Drug|Loteprednol etabonate and tobramycin ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
335541|NCT00447577|Drug|Tobramycin and dexamethasone ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
335894|NCT00439049|Drug|d-amphetamine|60mg daily
335895|NCT00439049|Drug|L-Dopa|800/200mg daily
335896|NCT00003422|Drug|fluorouracil|
334814|NCT00418054|Drug|Peginterferon alfa-2b|
334815|NCT00418067|Device|Endeavor|Zotarolimus-eluting stent
334816|NCT00418067|Device|Cypher|Sirolimus-eluting stent
334817|NCT00418067|Device|Taxus Liberte|Paclitaxel-eluting stent
334818|NCT00418080|Drug|bicalutamide|
334819|NCT00418093|Drug|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
335164|NCT00455897|Drug|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
335165|NCT00455897|Drug|CHOP|Administered as part of standard care
335166|NCT00003514|Procedure|alternative product therapy|
335167|NCT00455897|Drug|Rituximab|Administered as part of standard treatment
335168|NCT00455910|Drug|Thalidomide|
335169|NCT00455923|Drug|Seretide|
335170|NCT00455923|Drug|Flixotide|
335171|NCT00455936|Drug|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
335172|NCT00455936|Procedure|chemotherapy|gemcitabine(1250mg/m2 iv on D1 & 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
335173|NCT00455962|Drug|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
335174|NCT00455962|Drug|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
335175|NCT00455975|Drug|Bevacizumab|Bevacizumab
335176|NCT00456014|Drug|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
335177|NCT00003514|Procedure|biological therapy|
335178|NCT00456014|Drug|Desipramine|Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
334454|NCT00426517|Drug|Granulocyte Colony Stimulating Factor (G-CSF)|For mobilization of sibling donors
334455|NCT00426517|Other|hematopoietic progenitor cells|Allogeneic Stem Cells (sibling donor, Unrelated Donor (MUD) or Cord Blood Unit (CBU)
334456|NCT00426530|Drug|everolimus (RAD001)|
334457|NCT00426543|Drug|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
334458|NCT00003386|Drug|cisplatin|
334459|NCT00426543|Drug|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
334460|NCT00426556|Drug|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
334461|NCT00426556|Drug|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel & Trastuzumab
334462|NCT00426556|Drug|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
334463|NCT00426582|Drug|Patupilone|
334464|NCT00426595|Drug|Administration of omeprazole suspension|
334465|NCT00426595|Drug|omeprazole administered as a multi-unit-pellet system|
334466|NCT00426608|Drug|Single dose of metyrapone|
334467|NCT00426608|Drug|Single dose of alprazolam|
334468|NCT00426608|Drug|Single dose of placebo|
334469|NCT00003386|Drug|cyclophosphamide|
334470|NCT00426608|Drug|Single dose of GSK561679|
334471|NCT00426621|Drug|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
334472|NCT00426621|Drug|Placebo|4 grams per knee, 4 times per day, for 12 weeks
334820|NCT00418093|Drug|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
339591|NCT00519090|Drug|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
339592|NCT00519090|Drug|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
339593|NCT00519103|Other|exercise|
334100|NCT00435305|Drug|Piperacillin/Tazobactam|
334101|NCT00435305|Drug|Cefepim|
334102|NCT00435305|Drug|Ceftazidim|
334103|NCT00435318|Procedure|Iontophoresis|
334104|NCT00435331|Drug|sapropterin dihydrochloride (6R-BH4)|2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
334105|NCT00435344|Behavioral|Pediatric Practice-Based Smoking Intervention|
334106|NCT00003407|Drug|amifostine trihydrate|
334107|NCT00435357|Device|mobile-bearing TKA|
334108|NCT00435357|Device|fixed- bearing TKA|
334109|NCT00435370|Drug|Tropisetron|10 mg/day
334110|NCT00435370|Drug|Placebo|placebo
334111|NCT00435370|Drug|Risperidone|6mg/day
334112|NCT00435396|Biological|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
334113|NCT00435409|Drug|Sunitinib + Capecitabine|Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.
Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day [1000 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons.
334114|NCT00435409|Drug|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day [1250 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
334115|NCT00435422|Procedure|Stroke volume optimization|Stroke volume optimization
334116|NCT00435435|Drug|Disulfiram|
334117|NCT00003407|Drug|cytarabine|
334118|NCT00435435|Drug|Acamprosate|
328947|NCT00576836|Other|Parathyroid Tissue for Transplantation|Parental parathyroid donors screened for eligibility and transplant safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most HLA alleles with thymus donor. Parathyroid harvest & transplant preferably done at same time as thymus transplant. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of thymus transplant.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced & placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
328948|NCT00576849|Drug|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
328949|NCT00576849|Drug|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
328950|NCT00576849|Drug|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
329250|NCT00569439|Drug|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
329251|NCT00569439|Drug|NS|Normal Saline solution at 125 cc/hr
329252|NCT00004089|Biological|filgrastim|
329253|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|One basal rate
329254|NCT00571870|Drug|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
329255|NCT00571883|Other|questionnaire administration|
329256|NCT00004094|Radiation|radiation therapy|
329257|NCT00571883|Procedure|psychosocial assessment and care|
329258|NCT00571883|Procedure|quality-of-life assessment|
329259|NCT00571883|Procedure|regional lymph node dissection|
329260|NCT00571883|Procedure|therapeutic conventional surgery|
329261|NCT00571896|Drug|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
328640|NCT00581555|Other|Placebo|Randomized to placebo during taper of ciclosporin
328641|NCT00581568|Other|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
328642|NCT00581594|Procedure|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
328643|NCT00584246|Drug|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
328644|NCT00004160|Drug|gemcitabine hydrochloride|
328645|NCT00584246|Drug|Placebo|50 - 150 mg po qhs for 2 months
328646|NCT00584259|Other|Coffee|3 cups of coffee over a 24 hour period
328647|NCT00584285|Other|Comparison of fluorescein patterns|Compare conventional contact lens fitting to fitting contact lenses based on corneal topography measurement
328648|NCT00584298|Drug|SMS995|
328649|NCT00584298|Drug|Placebo|
328650|NCT00584311|Other|MRI and Ultrasound|MRI and US of the joint
328651|NCT00584324|Behavioral|Mini-mental state exam|For subjects > 60, this exam will be administered pre-operatively.
328652|NCT00584324|Behavioral|Spielberg's State-Trait anxiety test|Operative phase of study: Spielberg test just before being taken to the operating room.
328653|NCT00584324|Behavioral|Spoken word-stem completion test|After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.
328654|NCT00584324|Device|Bispectral Index Monitor|The physiologic monitor is used intraoperatively to assess surgical anesthesia
328655|NCT00004160|Drug|paclitaxel|
328656|NCT00584324|Other|Audio File|Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure.
328951|NCT00576862|Drug|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
328952|NCT00576888|Other|no intervention|no intervention - observational only
333465|NCT00458744|Procedure|chemotherapy|
333466|NCT00458770|Procedure|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
333467|NCT00458783|Biological|Prolonged RBC storage|Transfusion with oldest available matching RBCs
333468|NCT00458783|Biological|Short RBC storage|Transfusion with youngest available matching RBCs
333469|NCT00458796|Drug|zoledronic acid|
333470|NCT00458796|Procedure|quality-of-life assessment|
333471|NCT00458809|Drug|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
333825|NCT00449800|Drug|ceftriaxone|
333826|NCT00449813|Drug|Pantoprazole|40 mg Pantoprazole
333827|NCT00449826|Procedure|Computed Tomographic Angiography|CT scan
333828|NCT00452517|Procedure|Percutaneous Coronary Intervention|
333829|NCT00452530|Drug|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
333830|NCT00452530|Drug|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
333831|NCT00452530|Drug|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
333832|NCT00452530|Drug|Apixaban-matching placebo|Oral tablet administered twice daily
333833|NCT00452543|Drug|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
333834|NCT00452543|Drug|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
333835|NCT00452543|Behavioral|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
333836|NCT00452543|Drug|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
333837|NCT00452556|Drug|Docetaxel|Weekly
333838|NCT00003493|Drug|pegylated liposomal doxorubicin hydrochloride|
333839|NCT00452556|Drug|Leuprolide Acetate (Eligard®)|2.5 years
333126|NCT00420589|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
333127|NCT00420589|Drug|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
333128|NCT00420602|Dietary Supplement|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
333129|NCT00420615|Drug|Patupilone and Omeprazole|
333130|NCT00420615|Drug|Patupilone + Midalzolam|
333131|NCT00003348|Drug|carmustine|
333132|NCT00420628|Drug|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
333133|NCT00420628|Drug|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
333134|NCT00420641|Drug|GSK372475|GSK372475 1.0-1.5 mg/day
333135|NCT00420641|Drug|Paroxetine|Paroxetine 20-30 mg/day
333136|NCT00420641|Other|Placebo|Placebo to Match
333137|NCT00423332|Drug|Cediranib Placebo|oral tablet
333138|NCT00423358|Dietary Supplement|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
333139|NCT00423358|Dietary Supplement|placebo|matching placebo
333472|NCT00414583|Other|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
333473|NCT00414596|Device|DRX9000™|
333474|NCT00414609|Drug|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
333475|NCT00414609|Drug|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
333476|NCT00414622|Drug|DMXB-A|
333477|NCT00414635|Drug|efavirenz|
333478|NCT00414635|Drug|tenofovir|
333479|NCT00414635|Drug|emtricitabine|
332770|NCT00428948|Drug|Placebo|oral tablet split-dose regimens (45/15mg Placebo, 60/30 mg Placebo or 90/30 mg Placebo) by mouth twice a day on awakening and approximately 9 hours later for 36 months. Daily dose regimen based on maximally tolerated dose.
332771|NCT00428974|Drug|CF101|CF101 1 mg q12 hours for 12 weeks
332772|NCT00428974|Drug|CF101|CF101 2 mg q12 hours for 12 weeks
332773|NCT00428974|Drug|CF101|CF101 4 mg q12 hours for 12 weeks
332774|NCT00428974|Drug|Placebo|Placebo tablets q12 hours for 12 weeks
332775|NCT00429000|Device|thermospot|
332776|NCT00003392|Drug|cyclophosphamide|4 gm/m2 IV, day 1
332777|NCT00429013|Device|Tongue Display Unit|lingual electric stimulation
332778|NCT00429026|Drug|Fludarabine|25 mg/m^2 intravenous (IV) daily for 5 Days
332779|NCT00429026|Drug|Melphalan|70 mg/m^2 IV Daily for 2 Days
332780|NCT00429026|Drug|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
332781|NCT00429026|Procedure|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
332782|NCT00429039|Drug|L-leucyl-L-leucine methyl ester (LLME)|
332783|NCT00429065|Drug|Rituximab|
332784|NCT00429078|Genetic|2nd Generation Designer T Cells|
332785|NCT00431912|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
332786|NCT00431951|Drug|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
332787|NCT00431951|Drug|Placebo|Capsules to match experimental drug
332788|NCT00431964|Drug|azithromycin 250 mg tablets|One (1) tablet three times weekly for patients who weigh 40-79 lbs
Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs
332789|NCT00431964|Drug|placebo tablets|One (1) tablet three times weekly for patients who weigh 40-79 lbs
Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs
332790|NCT00431977|Procedure|coronary computed tomography angiography|
332094|NCT00445965|Radiation|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
332095|NCT00445978|Drug|6R-BH4 (sapropterin dihydrochloride)|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) of 6R-BH4 during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
332096|NCT00446004|Drug|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
332097|NCT00446004|Drug|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
332098|NCT00003454|Drug|antineoplaston AS2-1|
332424|NCT00437385|Behavioral|Cognitive behavioral group therapy|The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called "EffECTive". This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up.
332425|NCT00437398|Biological|Islet Transplant|Purified pancreatic islets
332426|NCT00437411|Behavioral|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
332427|NCT00437424|Drug|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
332428|NCT00437437|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
332429|NCT00003416|Drug|dexamethasone|
332430|NCT00437450|Drug|Epoetin/Atra|
332431|NCT00440232|Drug|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
332432|NCT00440232|Drug|Placebo|Inert tab identical in appearance to Frovatriptan
332433|NCT00440245|Drug|salbutamol|200 micrograms salbutamol from MDI
332434|NCT00440258|Drug|Cabergoline|
332435|NCT00440258|Procedure|MR|
332436|NCT00440258|Procedure|Ultrasound|
331741|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel [200 milligram/square meter (mg/m^2)] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram*minute/milliliter (mg*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
331742|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
331743|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
331744|NCT00454649|Drug|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
331745|NCT00003505|Procedure|biological therapy|
331746|NCT00454649|Drug|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
331747|NCT00003517|Procedure|complementary and alternative therapy|
331748|NCT00457860|Drug|CAT-8015 immunotoxin|
331749|NCT00457860|Procedure|Biological therapy|
331750|NCT00457873|Drug|0.9% saline in 5% dextrose (intravenous)|
331751|NCT00457873|Drug|0.45% saline in 5% dextrose (intravenous)|
332099|NCT00446017|Drug|adrenaline|
332100|NCT00446017|Drug|milrinone|
332101|NCT00448851|Biological|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
332102|NCT00448864|Drug|Ecallantide|
332103|NCT00448864|Drug|Placebo|
332104|NCT00448877|Device|fNIR light emitting and sensing device|
331399|NCT00419601|Drug|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
331400|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
331401|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
331402|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
331403|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
331404|NCT00003343|Drug|endocrine-modulating drug therapy|
331405|NCT00419653|Drug|Amisulpride|
331406|NCT00419653|Drug|Olanzapine|
331407|NCT00419653|Drug|Haloperidol|
331752|NCT00457899|Drug|Quetiapine IR (Immediate Release)|oral
331753|NCT00457925|Drug|GSK221149A|
331754|NCT00457938|Other|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
331755|NCT00457938|Other|Diet|10 % versus 35 % fat in diet
331756|NCT00457951|Drug|Normal Saline infusion|Bolus infusion followed by a 4 day continuous infusion of placebo
331757|NCT00457951|Drug|ODSH|Bolus infusion followed by a 4 day continuous infusion of ODSH
331758|NCT00003517|Procedure|differentiation therapy|
331759|NCT00457964|Drug|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
331760|NCT00457977|Biological|Pneumovax (PPSV23)|Injection
331761|NCT00457977|Biological|Prevnar (PCV7)|Injection
331762|NCT00457990|Drug|Oral administration of ferrous sulphate|
331763|NCT00458003|Drug|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
331022|NCT00425347|Drug|HuLuc63|Not applicable for HuLuc63.
331023|NCT00425360|Biological|sargramostim|
331024|NCT00425360|Biological|telomerase peptide vaccine GV1001|
331025|NCT00428103|Procedure|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
331026|NCT00428116|Drug|HAART|Combination first line antiretrovirals as previously described.
331027|NCT00003389|Drug|Dacarbazine|given IV
331028|NCT00428129|Drug|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
331029|NCT00428142|Biological|rituximab|375mg/m2 day 1
331030|NCT00428142|Drug|bortezomib|1.3mg/m2 days 1 & 8
331031|NCT00428142|Drug|cyclophosphamide|750mg/m2 day 1
331032|NCT00428142|Drug|prednisone|40mg/m2 days 1-5
331033|NCT00428142|Drug|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
331034|NCT00428155|Device|closure device placement|
331035|NCT00428168|Drug|Betahistine|Betahistine 24mg BID
331036|NCT00428181|Behavioral|Brief alcohol intervention|Brief alcohol intervention
331037|NCT00428181|Behavioral|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
331038|NCT00003389|Drug|Vincristine|given IV
331039|NCT00428194|Drug|cisplatin|40 mg/m^2 every 7 days during radiation
331040|NCT00428194|Drug|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m^2 by mouth once a day beginning day 1.
331041|NCT00428194|Procedure|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
331408|NCT00419666|Drug|Calcitriol|BID
331409|NCT00419679|Procedure|x-ray diffraction of human hair|
331410|NCT00419692|Drug|Ropinirole|
337348|NCT00454168|Biological|sargramostim|Given subcutaneously
337349|NCT00454168|Other|placebo|Given subcutaneously
337350|NCT00454181|Drug|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
337351|NCT00454181|Other|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
337352|NCT00454194|Drug|pemetrexed disodium|given IV
337353|NCT00454194|Drug|sorafenib tosylate|given orally
337354|NCT00454207|Drug|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
337355|NCT00000525|Drug|triamterene|
337356|NCT00003502|Procedure|biological therapy|
337357|NCT00454220|Other|Placebo|33 patients to placebo + 131-I arm
337358|NCT00454220|Drug|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
337359|NCT00454220|Drug|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
337714|NCT00534911|Behavioral|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
337715|NCT00534924|Drug|Vit C|
337716|NCT00534924|Procedure|Postconditioning|
337717|NCT00534924|Other|no intervention|
337718|NCT00534937|Procedure|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
337719|NCT00534937|Procedure|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
337720|NCT00534950|Radiation|5 vs 6 weekly fraction of RT|Chemotherapy
337721|NCT00000568|Drug|ipratropium|
337722|NCT00003893|Drug|fluorouracil|
337723|NCT00534963|Procedure|cervical vs. uterine placement of balloon catheter|
336997|NCT00416221|Behavioral|Personalized support from a Family Nurse Practitioner|
336998|NCT00416234|Procedure|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
336999|NCT00416234|Procedure|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
337000|NCT00416247|Behavioral|Hypnosis|Hypnosis
337001|NCT00416260|Other|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
337002|NCT00416273|Drug|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
337003|NCT00416273|Drug|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
337004|NCT00003325|Procedure|Sentinel lymph node mapping|Sentinel lymph node mapping
337005|NCT00416312|Biological|rituximab|
337006|NCT00416312|Device|computed tomography|
337007|NCT00416312|Procedure|positron emission tomography|
337008|NCT00416312|Procedure|radionuclide imaging|
337009|NCT00416312|Procedure|single photon emission computed tomography|
337010|NCT00416312|Radiation|tositumomab and iodine I 131 tositumomab|
337011|NCT00416312|Radiation|yttrium Y 90 ibritumomab tiuxetan|
337012|NCT00416325|Dietary Supplement|lycopene|
337013|NCT00416325|Other|laboratory biomarker analysis|
337014|NCT00416338|Device|film dressing by adhesive|
337015|NCT00418964|Procedure|Bone patellar tendon bone|Bone patellar tendon bone
337360|NCT00454233|Drug|YM543|Oral
337361|NCT00454233|Drug|Metformin|Oral
337362|NCT00454233|Drug|Placebo|oral
336261|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
336262|NCT00433381|Drug|irinotecan hydrochloride|Given IV
336263|NCT00433381|Biological|bevacizumab|Given IV
336264|NCT00433381|Drug|temozolomide|Given orally
336265|NCT00433394|Procedure|cancer prevention intervention|
336266|NCT00433394|Procedure|educational intervention|
336267|NCT00433407|Biological|trastuzumab|
336268|NCT00433420|Biological|pegfilgrastim|
336615|NCT00422097|Drug|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
336616|NCT00422097|Drug|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
336617|NCT00424567|Procedure|Fracture surgery|
336618|NCT00424567|Drug|Cultured Bone Marrow Tissue|
336619|NCT00003376|Drug|paclitaxel|
336620|NCT00424580|Drug|Montelukast (10mg) and Desloratadine (5mg)|
336621|NCT00424593|Drug|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
336622|NCT00424593|Drug|Placebo|every day (QD), by mouth (PO), 13 weeks
336623|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
336624|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
336625|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
336626|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
335897|NCT00439049|Drug|Naltrexone|50mg daily
335898|NCT00439062|Drug|Roxithromycin|
335899|NCT00439075|Drug|Standard treatment: isosorbide dinitrate|
335900|NCT00439075|Drug|furosemide|
335901|NCT00439101|Drug|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
335902|NCT00439101|Other|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
335903|NCT00439140|Biological|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
335904|NCT00439140|Drug|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
335905|NCT00441584|Biological|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
335906|NCT00441584|Drug|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
335907|NCT00441597|Drug|atorvastatin|atorvastatine 80mg, during 3 days
335908|NCT00441610|Drug|Gimatecan|
335909|NCT00441623|Behavioral|observational|effect of protein-bound uremic retention solutes
335910|NCT00441636|Device|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
335911|NCT00441649|Drug|Methylphenidate|
335912|NCT00003434|Biological|hepatitis B antigen peptide|
335913|NCT00441662|Drug|Sub-Tenon triamcinolone 40mg|
335914|NCT00441675|Procedure|Symptom Score|Symptom Score
335915|NCT00441675|Procedure|Symptom Score and PD20|Symptom Score and PD20
335916|NCT00441701|Drug|Navarixin 1 mg|Navarixin 1 mg capsules
335917|NCT00441701|Drug|Navarixin 10 mg|Navarixin 10 mg capsules
335918|NCT00441701|Drug|Placebo to match navarixin|Placebo to navarixin capsules
336269|NCT00433420|Drug|cyclophosphamide|
335179|NCT00456027|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
335180|NCT00456053|Drug|FG2216|
335181|NCT00456066|Device|Export Aspiration System|Patients scheduled for emergency angioplasty
335182|NCT00459368|Behavioral|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
335183|NCT00459368|Behavioral|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
335184|NCT00459381|Drug|pazopanib hydrochloride|Given orally
335185|NCT00459381|Other|laboratory biomarker analysis|Correlative studies
335542|NCT00447590|Device|LAP-BAND System|Restriction of food intake
335543|NCT00450307|Biological|monoclonal antibody 3F8|
335544|NCT00450307|Biological|sargramostim|
335545|NCT00450320|Drug|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
335546|NCT00450333|Drug|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
335547|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
335548|NCT00003479|Drug|antineoplaston AS2-1|
335549|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
335550|NCT00450333|Drug|Dynepo|subcutaneous, Q2W for 24 weeks
335551|NCT00450359|Procedure|breast imaging study|
335552|NCT00450359|Procedure|comparison of screening methods|
335553|NCT00450359|Procedure|radiomammography|
334821|NCT00418093|Drug|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
334822|NCT00003336|Radiation|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
334823|NCT00418119|Drug|erythropoietin|
334824|NCT00418132|Drug|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
334825|NCT00418132|Drug|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
334826|NCT00418145|Drug|megadose oral methylprednisolone|1400 mg qd/5 days
334827|NCT00418145|Drug|IV methylprednisolone|1000 mg/qd/5 days
334828|NCT00418158|Behavioral|use of Airlife (therapy)|
334829|NCT00421174|Drug|Placebo + corticosteroid|Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.
Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
334830|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
334831|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
334832|NCT00421200|Drug|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
334833|NCT00421200|Drug|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
334834|NCT00421213|Drug|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
334835|NCT00421226|Drug|ACZ885|
334836|NCT00421252|Drug|clopidogrel 600 mg|
334837|NCT00421278|Drug|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
334838|NCT00421291|Behavioral|Education|
334839|NCT00003352|Drug|Adriamycin|60 mg/m2, IV, every 3 weeks
334840|NCT00421304|Biological|Motavizumab|Will receive a single dose of IV of Motavizumab (100mg/kg)
334119|NCT00435435|Drug|Naltexone|
334120|NCT00435448|Drug|Lonidamine|
334121|NCT00435461|Drug|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
334122|NCT00435474|Procedure|Wound treatment|wound treatment (silver product, alginate and foam dressing)
334123|NCT00435474|Procedure|wound treatment|wound treatment (honey product, alginate and foam dressing)
334124|NCT00435474|Other|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
334473|NCT00426647|Drug|Buprenorphine|
334474|NCT00426647|Drug|Tramadol|
334475|NCT00426660|Drug|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
334476|NCT00426673|Drug|Brivaracetam (ucb34714)|
334477|NCT00426712|Biological|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
334478|NCT00426712|Biological|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
334479|NCT00003394|Drug|goserelin acetate|
334480|NCT00429572|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
334481|NCT00429585|Device|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
334482|NCT00429585|Device|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
334483|NCT00429611|Procedure|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
334484|NCT00429624|Procedure|Chiropractic manipulation|
334485|NCT00429624|Drug|acetaminophen|
334486|NCT00429650|Behavioral|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
334487|NCT00429650|Behavioral|diet|Use a prescribed diet to maintain weight loss
329262|NCT00571896|Drug|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
329263|NCT00571909|Procedure|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
329264|NCT00571922|Drug|Acamprosate|2 gr/day (333 mg, TID)
329265|NCT00571922|Drug|placebo|matching placebo
329266|NCT00571935|Drug|insulin aspart|
329267|NCT00004095|Drug|gemcitabine hydrochloride|
329268|NCT00571935|Drug|soluble human insulin|
329591|NCT00564512|Biological|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
329592|NCT00564512|Drug|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
329593|NCT00564512|Drug|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
329594|NCT00564525|Drug|Amitriptyline|Medication taken for 4 weeks
329595|NCT00564525|Drug|Placebo|Medication taken for 4 weeks
329596|NCT00564538|Drug|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
329597|NCT00564538|Drug|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
329598|NCT00564551|Behavioral|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
329599|NCT00564551|Behavioral|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
329600|NCT00004065|Drug|tanespimycin|
329601|NCT00566735|Drug|Placebo|4 mg, 2 times a day
329602|NCT00566761|Drug|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
328953|NCT00576901|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
328954|NCT00576901|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
328955|NCT00004124|Drug|goserelin|
328956|NCT00576901|Drug|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
328957|NCT00576914|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
328958|NCT00579072|Behavioral|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 80 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 80 men in the 2-Year Androgen Ablation Group to the 140 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
328959|NCT00579072|Device|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within four weeks of the neurocognitive testing. The fMRI will be performed only once at baseline.
328960|NCT00579085|Drug|Ketamine|IV Ketamine .35mg/kg times ten days.
328961|NCT00004132|Radiation|radiation therapy|
328962|NCT00579085|Other|IV NSS|Placebo inactive ingredients
328963|NCT00579085|Other|Normal Saline|INFUSION PLAN:
All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)
328964|NCT00579098|Drug|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
328965|NCT00579098|Drug|Placebo|Placebo tablet taken by mouth once daily for 90 days
328966|NCT00579111|Drug|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
328967|NCT00579111|Drug|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
328968|NCT00579111|Drug|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
328969|NCT00579111|Procedure|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
333840|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
333841|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
333842|NCT00452569|Drug|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
333843|NCT00452569|Drug|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
333844|NCT00452582|Drug|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
333845|NCT00452582|Other|Usual care|Physical therapy, occupational therapy, speech therapy
328657|NCT00584350|Other|Hydratation according LVEDP + NaHCO3|Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.
At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours.
328658|NCT00584350|Other|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
328659|NCT00584350|Other|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
328660|NCT00584376|Drug|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
328661|NCT00584376|Drug|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
328662|NCT00584389|Drug|rimonabant|20mg/d (oral) once daily for 12 weeks
328663|NCT00584389|Behavioral|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
328664|NCT00584402|Drug|perflutren lipid microspheres|IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
328665|NCT00584415|Device|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
333480|NCT00414648|Drug|Sirolimus|A sirolimus dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
333481|NCT00414648|Drug|Placebo sirolimus|A placebo dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
333482|NCT00003315|Biological|sargramostim|
333483|NCT00414661|Drug|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
333484|NCT00414687|Drug|Ventavis (Iloprost, BAYQ6256)|
333485|NCT00414700|Drug|ChondroCelect implantation|10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.
The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm².
333486|NCT00414700|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
333487|NCT00414713|Procedure|red blood cell transfusion|red blood cell transfusion
333488|NCT00414726|Drug|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
333489|NCT00414726|Drug|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
333490|NCT00414739|Drug|Benzalkonium chloride|
333491|NCT00414752|Drug|AFQ065|
333492|NCT00414765|Drug|Aldesleukin|
333493|NCT00003315|Drug|liposomal amphotericin B|
333494|NCT00414778|Drug|LHT344|
333495|NCT00414804|Device|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
333846|NCT00452595|Drug|DVS-233 SR (desvenlafaxine sustained release )|
333847|NCT00452608|Drug|amido pill|one pill of amido/d by mouth for 10 days
333848|NCT00452608|Drug|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
333849|NCT00000525|Behavioral|diet, potassium supplementation|
333850|NCT00003493|Drug|vincristine sulfate|
333140|NCT00423371|Device|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
333141|NCT00423371|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
333142|NCT00423384|Drug|Placebo|Placebo
333143|NCT00423384|Drug|Ibandronate|I.v.
333144|NCT00003365|Dietary Supplement|curcumin|
333145|NCT00423397|Biological|PEG-interferon alfa-2a|
333146|NCT00423397|Drug|gefitinib|
333147|NCT00423410|Drug|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
333148|NCT00423436|Behavioral|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
333149|NCT00423436|Behavioral|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
333150|NCT00423436|Behavioral|IVR Plus Triage|IVR system will "triage," or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit.
333151|NCT00423449|Drug|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
333152|NCT00423449|Drug|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
333153|NCT00423449|Drug|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
333154|NCT00423462|Behavioral|Brief dynamic psychotherapy|
333155|NCT00003365|Dietary Supplement|rutin|
333156|NCT00423475|Drug|goserelin acetate|
333157|NCT00423475|Procedure|adjuvant therapy|
333158|NCT00423475|Radiation|radiation therapy|
333159|NCT00423488|Drug|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
333160|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
332437|NCT00440258|Procedure|Blood Analysis|
332438|NCT00440271|Drug|tipranavir|
332439|NCT00440271|Drug|ritonavir|
332440|NCT00003425|Biological|filgrastim|
332441|NCT00440271|Drug|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
332442|NCT00440284|Drug|conventional vs. flexible, intensive insulin therapy|
332443|NCT00440297|Biological|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
332444|NCT00440297|Biological|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
332445|NCT00440310|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
332791|NCT00431990|Drug|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
332792|NCT00003399|Drug|cyclophosphamide|
332793|NCT00431990|Drug|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
332794|NCT00431990|Drug|dexamethasone|20mg for 2 days with each dose of bortezomib
332795|NCT00432016|Drug|zidovudine|
332796|NCT00432016|Drug|amdoxovir|
332797|NCT00432016|Procedure|pharmacokinetic sampling|
332798|NCT00432029|Procedure|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
332799|NCT00432029|Device|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
332800|NCT00432042|Biological|ProQuad® and Infanrix® hexa|
332801|NCT00432055|Drug|Botulinum toxin type A (Botox)|
332802|NCT00432055|Drug|placebo (saline)|
332803|NCT00000517|Drug|warfarin|
332105|NCT00448890|Drug|GSK729327|Tablets
332106|NCT00448890|Drug|Placebo|GSK729327 Matching placebo - Tablets
332107|NCT00448903|Drug|Bemiparin|Bemiparin sodium
332108|NCT00448903|Drug|Placebo|Sodium Chloride 0,9%
332109|NCT00448916|Drug|Pregabalin|Orally-administered pregabalin
332110|NCT00448929|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
332111|NCT00003470|Drug|antineoplaston A10|
332112|NCT00448942|Behavioral|Daily bathing with Chlorhexidine based product|
332113|NCT00448955|Drug|ARD-0403|ARD-0403
332114|NCT00448981|Behavioral|Hand hygiene and educational material|
332115|NCT00448981|Device|Mask, alcohol and hand sanitizer|
332116|NCT00449007|Drug|fluoxetine|6 months
332117|NCT00449007|Drug|bupropion|6 months
332118|NCT00449020|Drug|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
332119|NCT00449020|Drug|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
332120|NCT00449020|Drug|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
332121|NCT00449020|Radiation|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
332122|NCT00000522|Drug|enalapril|
332446|NCT00440310|Procedure|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
332447|NCT00440310|Device|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
331764|NCT00458003|Drug|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
331765|NCT00458016|Drug|MB07803|Daily oral administration
331766|NCT00458016|Drug|Placebo|Daily oral administration
331767|NCT00458029|Behavioral|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
331768|NCT00458042|Drug|treprostinil sodium|
331769|NCT00003517|Procedure|endocrine therapy|
331770|NCT00458055|Drug|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
331771|NCT00458068|Drug|Oral administration of ferrous sulphate|
331772|NCT00413686|Drug|AZD7762|intravenous infusion
332123|NCT00003470|Drug|antineoplaston AS2-1|
332124|NCT00449033|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
332125|NCT00449033|Drug|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
332126|NCT00449033|Drug|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m^2 IV
332127|NCT00449033|Drug|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m^2 IV
332128|NCT00449046|Drug|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
332129|NCT00451594|Drug|Dexamethasone|Pulse high dose dexamethasone (Arm 1)
Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.
Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14
If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.
If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.
Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments.
331411|NCT00419705|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
331412|NCT00419718|Drug|inhaled human insulin|
331413|NCT00419731|Drug|Bupropion|Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.
Placebo, 25 mg, q.d., for 7 weeks.
331414|NCT00419731|Drug|Bupropion + Naltrexone|Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.
Naltrexone, 25 mg, q.d., for 7 weeks.
331415|NCT00003343|Drug|mitoxantrone hydrochloride|
331416|NCT00419744|Drug|Budesonide/formoterol (SYMBICORT) pMDI|
331417|NCT00419744|Drug|Formoterol Turbuhaler|
331418|NCT00419757|Drug|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
331419|NCT00419757|Drug|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
331420|NCT00419770|Drug|deferasirox|20 mg/kg enterally per day
331421|NCT00419770|Drug|Placebo|
331422|NCT00419770|Drug|Liposomal amphotericin B|
331423|NCT00419783|Drug|bilastine|20 mg tablets.
331424|NCT00419783|Drug|Bilastine|100 mg (5 tablets of 20 mg)
331425|NCT00419783|Drug|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
331426|NCT00003343|Drug|prednisone|
331427|NCT00422630|Behavioral|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
331428|NCT00422643|Drug|Sodium hyaluronate (hyaluronic acid)|
331429|NCT00422656|Drug|Perifosine|Taken orally every night for 6 back to back 28 day cycles. Participant may continue on treatment if there is no disease progression at the discretion of the treating investigator
331430|NCT00003362|Biological|gp100 antigen|
331431|NCT00422669|Device|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
331432|NCT00422669|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
337724|NCT00534976|Drug|Comparator: montelukast sodium|Patients 4-5 years: 4 mg Montelukast chewable tablet daily
Patients 6-14 years: 5 mg chewable tablet daily
337725|NCT00003907|Drug|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
337726|NCT00537355|Biological|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
337727|NCT00537355|Drug|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
337728|NCT00537368|Drug|CNTO 888|
337729|NCT00537381|Drug|Docetaxel|Docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks.
337730|NCT00537381|Drug|Prednisone|Prednisone 5 mg orally twice daily.
337731|NCT00537381|Biological|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
337732|NCT00537381|Drug|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
337733|NCT00537394|Drug|Enfuvirtide|90mg subcutaneously twice daily
337734|NCT00537394|Drug|Raltegravir|400 mg twice daily
337735|NCT00537394|Drug|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
338073|NCT00529503|Drug|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
338074|NCT00529503|Drug|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
338075|NCT00529516|Biological|Fluarix|Single dose, Intramuscular injection
338076|NCT00529516|Biological|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
338077|NCT00529529|Drug|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
338078|NCT00529529|Drug|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
338079|NCT00529529|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
338080|NCT00000563|Drug|dexamethasone|
338081|NCT00003863|Genetic|cytogenetic analysis|
337363|NCT00454246|Drug|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
337364|NCT00454246|Drug|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
337365|NCT00457171|Drug|GI-270384|
337366|NCT00457184|Procedure|Blood tests|
337367|NCT00457197|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
337368|NCT00457197|Drug|Quetiapine|Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
337369|NCT00457210|Procedure|Brain Radiotherapy/Stereotactic Radiosurgery|
337370|NCT00457223|Procedure|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
337371|NCT00457249|Biological|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
337372|NCT00457249|Biological|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
337373|NCT00003517|Drug|flutamide|
337374|NCT00457262|Procedure|soy consumption|
337375|NCT00457275|Drug|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
337376|NCT00457288|Drug|TF 002|
337377|NCT00457301|Behavioral|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
337378|NCT00457314|Behavioral|Exercise|Regular exercise training
337379|NCT00457327|Procedure|protective ileostomy|
337380|NCT00457340|Drug|Atorvastatin 80mg|
337381|NCT00457353|Drug|Bacillus Clausii|For 5 days
337382|NCT00457353|Other|Oral rehydration therapy|For 5 days
336627|NCT00424619|Drug|Vitamin D2|50 000 IU vitamin D2, one time bolus dose
336628|NCT00424619|Drug|Vitamin D2|100 000 IU vitamin D2, one time bolus dose
336629|NCT00424619|Drug|Placebo|Placebo, 1 time bolus dose
336630|NCT00003376|Drug|vinblastine|
336631|NCT00424632|Drug|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
336632|NCT00424645|Drug|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
336633|NCT00424645|Drug|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
336634|NCT00424658|Procedure|SAHS diagnosis|
336635|NCT00424671|Drug|Licarbazepine|
336636|NCT00424684|Procedure|collection of blood sample|
337016|NCT00418977|Behavioral|Family-Based Therapy ("Maudsley Method")|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
337017|NCT00418977|Behavioral|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
337018|NCT00418990|Drug|Multivitamin/Mineral supplements|
337019|NCT00003341|Biological|epoetin alfa|
337020|NCT00419003|Drug|Lamotrigine|anticonvulsant medication
337021|NCT00419003|Drug|Ketamine|subanesthetic dose of NMDAR antagonist
337022|NCT00419003|Drug|Riluzole|glutamate release inhibitor
337023|NCT00419029|Behavioral|telephone-administered motivational interviewing|telephone motivational interviewing
336270|NCT00003401|Drug|paclitaxel|
336271|NCT00433420|Drug|epirubicin hydrochloride|
336272|NCT00433420|Drug|fluorouracil|
336273|NCT00433420|Drug|paclitaxel|
336274|NCT00433420|Procedure|adjuvant therapy|
336275|NCT00433433|Drug|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
336276|NCT00433433|Drug|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes>1.0x109/l
336277|NCT00433433|Radiation|IN-RT 30 Gy (+ boost 6 Gy residual)|
336278|NCT00433433|Procedure|FDG-PET scan|
336279|NCT00433446|Biological|CNTO 328|
336280|NCT00433459|Drug|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
336281|NCT00003401|Procedure|bone marrow ablation with stem cell support|
336282|NCT00433459|Drug|dacarbazine|drug is used in first line treatment in combination (COPDAC)
336283|NCT00433459|Drug|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
336284|NCT00433459|Drug|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
336285|NCT00433459|Drug|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
336286|NCT00433459|Drug|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
336287|NCT00433459|Radiation|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
336288|NCT00433459|Radiation|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
336289|NCT00433472|Device|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
336290|NCT00433485|Drug|sirolimus|
336291|NCT00433485|Genetic|comparative genomic hybridization|
335554|NCT00450372|Biological|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
335555|NCT00450372|Other|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
335556|NCT00450385|Drug|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
335557|NCT00450385|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
335558|NCT00450385|Drug|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
335559|NCT00000524|Drug|cyclosporine|
335560|NCT00003483|Drug|antineoplaston A10|
335561|NCT00450385|Drug|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
335562|NCT00450385|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
335563|NCT00450385|Genetic|Lymphoma Tissue Specimen|Diagnostic Lymphoma Tissue specimen for gene expression analysis taken at Baseline. The following correlative studies will be performed:
1. RNA-based gene array studies
2. Real time polymerase chain reaction (PCR) gene expression studies
3. Tissue-array immunohistochemical studies
4. Immunoglobulin G Fc receptor genotypes determination
335919|NCT00441701|Drug|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
335920|NCT00441714|Procedure|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
335921|NCT00441727|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
335922|NCT00441727|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
335923|NCT00003435|Biological|anti-thymocyte globulin|
335924|NCT00441727|Drug|Placebo|Placebo once daily
335925|NCT00441740|Drug|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
335926|NCT00441740|Drug|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
335927|NCT00441740|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
335928|NCT00441740|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
334841|NCT00421304|Other|Biological/Vaccine: Motavizumab|A single IV dose of placebo (30 mg/kg).
335186|NCT00459407|Dietary Supplement|defined green tea catechin extract|Given orally
335187|NCT00003525|Drug|antineoplaston AS2-1|
335188|NCT00459407|Drug|placebo|Given orally
335189|NCT00459407|Other|immunohistochemistry staining method|Correlative studies
335190|NCT00459407|Other|immunoenzyme technique|Correlative studies
335191|NCT00459407|Other|laboratory biomarker analysis|Correlative studies
335192|NCT00459407|Procedure|biopsy|Undergo biopsy
335193|NCT00459407|Other|mass spectrometry|Correlative studies
335194|NCT00459407|Other|high performance liquid chromatography|Correlative studies
335195|NCT00459420|Drug|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
335196|NCT00459420|Drug|placebo|placebo
335197|NCT00459433|Procedure|Biopsychosocial intervention|Psychosocial versus usual care
335198|NCT00003526|Drug|antineoplaston A10|
335199|NCT00459446|Drug|MS-325 Injection (Gadofosveset Trisodium)|
335200|NCT00459459|Procedure|Fine needle aspiration of the thyroid|
335201|NCT00459472|Behavioral|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
335202|NCT00459485|Dietary Supplement|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
335203|NCT00459485|Dietary Supplement|Placebo|Daily placebo for 3 weeks
335204|NCT00459511|Procedure|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
335205|NCT00459524|Behavioral|Questionnaire|Questionnaires taking about 30 minutes to complete.
335206|NCT00459524|Behavioral|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
334488|NCT00429650|Behavioral|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
334489|NCT00429663|Device|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
334490|NCT00003394|Drug|leuprolide acetate|
334491|NCT00429663|Device|locking periarticular plate|Standard of care device for femur fractures
334492|NCT00429676|Drug|Haloperidol|
334493|NCT00429689|Procedure|Saliva sample|
334494|NCT00429702|Drug|Decadron®|Given IV
334495|NCT00429702|Drug|Benadryl®|Given IV
334496|NCT00429702|Drug|Ativan®|Given IV
334842|NCT00421304|Other|Placebo|A single IV dose of placebo (30 or 100 mg/kg).
334843|NCT00421317|Drug|Imatinib|800 mg/day until disease progression or toxicity
334844|NCT00421330|Procedure|Open Aneurysm Repair|
334845|NCT00421330|Procedure|Endovascular Aneurysm Repair|
334846|NCT00421343|Drug|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
334847|NCT00421343|Drug|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
334848|NCT00421343|Behavioral|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
334849|NCT00421369|Drug|sertraline|
334850|NCT00003353|Biological|filgrastim|
334851|NCT00421369|Drug|triiodothyronine (T3)|
334852|NCT00421369|Drug|reboxetine|
334853|NCT00421395|Biological|90Y-hLL2|weekly dosing for either 2 or 3 weeks
334854|NCT00421408|Dietary Supplement|Whey protein supplement|40-g whey protein supplement daily for 18 months
334855|NCT00421408|Dietary Supplement|Placebo|Placebo supplement daily for 18 months
334856|NCT00421421|Drug|Dutasteride|
329603|NCT00566774|Other|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
329604|NCT00566774|Other|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
329605|NCT00566787|Device|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
329606|NCT00004079|Other|laboratory biomarker analysis|Correlative studies
329607|NCT00566800|Drug|erlotinib hydrochloride|
329608|NCT00566800|Other|laboratory biomarker analysis|
329609|NCT00566800|Procedure|biopsy|
329610|NCT00566813|Drug|Edmonton Protocol of steroid free immunosuppression|Islet of Langerhans 1-3 transplantations, daclizumab, sirolimus, tacrolimus
329611|NCT00566813|Drug|Islets of Langerhans Transplantation|Islets of Langerhans 1-3 transplantations, Edmonton protocol of steroid free immunosuppression (daclizumab 5 doses, sirolimus daily,tacrolimus BID, with additional etanercept 3 doses, and exenatide BID-TID for 6 months after each transplant.
329916|NCT00004039|Drug|doxorubicin hydrochloride|
329917|NCT00559975|Biological|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
329918|NCT00559975|Biological|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
329919|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
329920|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
329921|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
329922|NCT00004054|Radiation|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
329923|NCT00562120|Drug|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
329924|NCT00562120|Drug|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
329269|NCT00571948|Other|more meat and a vegetable oil rich in omega-3 fatty acids|The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.
The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids).
329270|NCT00571948|Other|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
329271|NCT00571961|Drug|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
329272|NCT00571961|Drug|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
329273|NCT00571961|Other|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
329274|NCT00574353|Radiation|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
329275|NCT00574366|Drug|erlotinib|Levels:
1 Erlotinib 50 mg/d
2 Erlotinib 50 mg/d
1 Erlotinib 100 mg/d
2 Erlotinib 100 mg/d
3 Erlotinib 150 mg/d
4 Erlotinib 150 mg/d
329276|NCT00574366|Drug|RAD001|Levels
minus 1: RAD001 2.5 mg/d
minus 2: RAD001 2.5 every other day
RAD001 2.5 mg per day
RAD001 5 mg per day
RAD001 10 mg per day
RAD001 10 mg per day
329277|NCT00574379|Drug|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
329278|NCT00004106|Drug|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
329279|NCT00574379|Drug|Placebo|Placebo tablets twice daily for 14 days
329280|NCT00574392|Device|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
329281|NCT00574405|Drug|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
329282|NCT00574405|Device|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
329283|NCT00574418|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
328666|NCT00004160|Radiation|radiation therapy|
328667|NCT00004172|Drug|thiotepa|
328668|NCT00587171|Procedure|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
328669|NCT00587171|Procedure|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
328670|NCT00587223|Device|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
328671|NCT00587223|Other|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
328672|NCT00587249|Biological|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
328673|NCT00587249|Biological|Alhydrogel|Aluminum hydroxide gel.
328674|NCT00587275|Drug|AST-120|Oral, sachet, 2 grams daily for 4 weeks
328675|NCT00587275|Drug|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
328970|NCT00579111|Drug|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
328971|NCT00579124|Device|CliniMACs|T and B Cell depletion
328972|NCT00000605|Drug|estrogens|
328973|NCT00004135|Biological|filgrastim|
328974|NCT00579137|Biological|Campath -1H|Given intravenous on Days -8,-7, and -6
Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients >15 kg to 30 kg the dose 5 mg; for patients > 30 kg the dose is 10 mg
328975|NCT00579137|Drug|Fludarabine|Given intravenous on Days -8,-7,-6,-5, and -4
Dose is 30 mg/m2
328976|NCT00579137|Biological|Anti-CD45|Given intravenous over 6 hours on Days -5,-4,-3, and -2
Dose is 400 microgram/kg
328977|NCT00579137|Procedure|Stem cell infusion|stem cells are infused on day 0
328978|NCT00579189|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
328979|NCT00579189|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
333851|NCT00452621|Procedure|blood draw|
333852|NCT00452634|Drug|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
333853|NCT00455312|Drug|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
333854|NCT00455312|Drug|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
333855|NCT00455312|Procedure|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
333856|NCT00003511|Drug|antineoplaston A10|
333857|NCT00455312|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
333858|NCT00455312|Drug|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
333859|NCT00455312|Drug|Methylprednisolone|2mg/kg IV is given before each dose of ATG.
333860|NCT00455325|Drug|Placebo Comparator Limb 1|1 chloroquine placebo tablet for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
333861|NCT00455325|Drug|Chloroquine|80mg chloroquine or placebo tablet weekly for Weeks 1-3;euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
333862|NCT00455325|Drug|Chloroquine|80mg tablet daily for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
333863|NCT00455325|Drug|Chloroquine|250mg tablet daily for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
333864|NCT00455338|Behavioral|Meal Composition|
333865|NCT00455351|Drug|Vorinostat|Increasing dosing, phase I
333866|NCT00455364|Drug|Voriconazole|
333867|NCT00003511|Drug|antineoplaston AS2-1|
333868|NCT00455390|Procedure|Post-immediate Psychotherapeutic Intervention|
328676|NCT00587288|Biological|Reslizumab|IV (in the vein) on Day 0 of each 28 day cycle (+/- 7 days) Number of Cycles=4
328677|NCT00587288|Other|Saline|IV (in the vein) on Day 0 of each 28 day cycle (+/-7 days) Number of Cycles=4
333161|NCT00423488|Drug|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
333162|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
333163|NCT00423488|Drug|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
333496|NCT00414804|Procedure|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
333497|NCT00414817|Behavioral|Telephone-Based Medication Adherence Intervention|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
333498|NCT00414856|Drug|AFQ056|
333499|NCT00417235|Device|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
333500|NCT00003335|Procedure|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
333501|NCT00417235|Behavioral|3-day or 7-day catheter dressing frequency|dressing changes every 7 days versus every 3 days
333502|NCT00417248|Drug|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
333503|NCT00417248|Drug|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
333504|NCT00417248|Procedure|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
333505|NCT00417248|Drug|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
333506|NCT00417261|Drug|ATF936|
333507|NCT00417261|Drug|AXT914|
333508|NCT00417274|Drug|Quinacrine|100 mg daily
333509|NCT00417287|Drug|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
333510|NCT00417300|Behavioral|Prolonged exposure (PE) therapy for adolescents|PE is an individual therapy. The treatment involves talking about thoughts and feelings about the assault and confronting the memory of the assault. The therapy also involves doing homework outside of session.
333511|NCT00003335|Radiation|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
332804|NCT00003399|Drug|dexamethasone|
332805|NCT00432068|Drug|Octreotide pamoate|
332806|NCT00432081|Drug|indomethacin|
332807|NCT00432094|Drug|carboplatin|Days -6, -5, -4: 500mg/m2^/day intravenously (IV) over 60 minutes
332808|NCT00432094|Drug|etoposide|600mg/m^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
332809|NCT00432094|Drug|ifosfamide|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
332810|NCT00432094|Drug|paclitaxel|225 mg/m^2 intravenous over 3 hours on Day -7.
332811|NCT00432094|Drug|thiotepa|150mg/m^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
332812|NCT00432094|Procedure|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (< 4 x 10^6 CD34+ cells/kg)
332813|NCT00434759|Behavioral|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
332814|NCT00434772|Drug|glucagon|
333164|NCT00423501|Drug|Placebo|sc weekly
333165|NCT00425919|Drug|PPM-204|
333166|NCT00425932|Biological|Rituximab|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
333167|NCT00425945|Drug|Pine Bark Extract (Flavangenol®)|Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.
Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks.
333168|NCT00425971|Drug|BMEC-1217B|
333169|NCT00425984|Procedure|Adult male circumcision|
333170|NCT00425997|Drug|Valsartan/HCTZ|
333171|NCT00425997|Drug|amlodipine|
333172|NCT00425997|Drug|HCTZ|
333173|NCT00426010|Drug|caffeine/placebo|caffeine or placebo, either overt or covert
333174|NCT00003385|Drug|carboplatin|
332448|NCT00440310|Drug|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
332449|NCT00440310|Drug|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
332450|NCT00440323|Drug|SB-649868|
332451|NCT00003425|Drug|amifostine trihydrate|
332452|NCT00440323|Drug|Zolpidem|
332453|NCT00440336|Drug|Cosopt|
332454|NCT00440336|Drug|Xalatan|
332455|NCT00440349|Drug|Tamoxifen|
332456|NCT00440349|Drug|Prednisone|
332457|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at t=0 via IM route
332458|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
332459|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
332460|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
332461|NCT00443287|Drug|placebo|oral administration
332462|NCT00443287|Drug|cilostazol|oral administration
332463|NCT00443326|Drug|AMG 714|Dosing Regimen is 6 Doses over 3 Months
332464|NCT00443339|Drug|Darbepoetin|
332465|NCT00003437|Drug|daunorubicin hydrochloride|
332466|NCT00443352|Drug|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
332467|NCT00443365|Procedure|Mitral valve repair|mitral valve annuloplasty
332468|NCT00443378|Behavioral|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
332469|NCT00443391|Drug|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
332815|NCT00434785|Drug|AGG-523|
302797|NCT00406731|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
303139|NCT00397904|Other|laboratory biomarker analysis|
303140|NCT00397904|Procedure|biopsy|
303141|NCT00397917|Drug|Folic acid: 4 mg versus 0.4 mg per day|Folic acid
303142|NCT00003225|Drug|irinotecan hydrochloride|10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
Administered every 14 days for 3 cycles
303143|NCT00397930|Procedure|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
303144|NCT00397930|Procedure|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
303145|NCT00397943|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
303146|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
303147|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
303148|NCT00397943|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
303149|NCT00400907|Procedure|management of therapy complications|
303150|NCT00400933|Behavioral|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
303151|NCT00400946|Drug|asparaginase|Given intramuscularly
303152|NCT00400946|Drug|cyclophosphamide|Given IV
303153|NCT00400946|Drug|cytarabine|Given IV and intrathecally
303154|NCT00400946|Drug|dexamethasone|Given orally
303155|NCT00400946|Drug|dexrazoxane hydrochloride|Given IV
303156|NCT00003243|Biological|filgrastim|
302458|NCT00368355|Biological|Campath-1H|day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
>30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
302459|NCT00368355|Radiation|Total Body Irradiation|day-4 through day-1
175 cGy x 2 at 24 cGy/min
302460|NCT00368355|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
302461|NCT00368368|Drug|GK Activator (2)|100mg po
302462|NCT00368381|Drug|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
302463|NCT00368394|Drug|Insulin glulisine|
302464|NCT00368407|Device|308-nm excimer laser|
302465|NCT00000143|Drug|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
302466|NCT00000483|Drug|estrogen|
302467|NCT00371384|Procedure|massage|UP to 10 massages over 10 weeks
302798|NCT00406731|Drug|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
302799|NCT00003273|Drug|cyclophosphamide|
302800|NCT00406731|Drug|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
302801|NCT00409591|Drug|Maternal and infant nevirapine|In women, one NVP 200 mg tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately
302802|NCT00409591|Drug|Maternal placebo and infant nevirapine|In women, one placebo tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours
Comparison between Arms 1 and 2 is double-blinded.
302803|NCT00409591|Drug|Maternal lopinavir+ritonavir|- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
302804|NCT00409591|Drug|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
302805|NCT00003287|Drug|leucovorin calcium|
302806|NCT00409604|Device|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
302807|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Other Week dosing
302102|NCT00377637|Drug|Cyclophosphamide|Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.
Dosing was started at 0.75 g/m^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m^2. The target dose was 1.0 g/m^2, but doses were titrated by 0.25 g/m^2 increments to maintain nadir leukocyte count between 2500-4000/mm^3.
302103|NCT00377637|Drug|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
302104|NCT00003138|Procedure|Transfusion|Red cell and platelet transfusions
302105|NCT00377637|Drug|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
302106|NCT00377637|Drug|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
302107|NCT00377637|Drug|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
302108|NCT00377650|Device|Percutaneous thrombectomy|
302109|NCT00377663|Behavioral|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
302110|NCT00377676|Drug|Cycloset|Usual diabetes therapy plus Cycloset
302111|NCT00377676|Drug|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
302112|NCT00377689|Behavioral|high intensity functional exercise|high intensity functional exercise
302113|NCT00377715|Drug|Dimebon|
302114|NCT00377715|Drug|Placebo|
302115|NCT00380393|Biological|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
302116|NCT00380393|Biological|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
302117|NCT00380406|Drug|Leuprolide acetate|
302118|NCT00380419|Behavioral|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
302119|NCT00380445|Drug|Vildagliptin|
302120|NCT00380458|Device|Coblation (radiofrequency-based device)|
302121|NCT00000489|Procedure|coronary artery bypass|
301376|NCT00003203|Drug|cyclophosphamide|Given IV
301377|NCT00391573|Procedure|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
301378|NCT00391586|Drug|Erlotinib|Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.
Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient
301379|NCT00391586|Drug|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
301380|NCT00391599|Procedure|enema|
301381|NCT00391612|Device|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
301382|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
301383|NCT00393952|Drug|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
301384|NCT00393952|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
301733|NCT00003159|Drug|vinblastine sulfate|
301734|NCT00383188|Drug|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
301735|NCT00383188|Drug|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
301736|NCT00383201|Device|OptiFree Multi-Purpose Disinfecting Solution|
301737|NCT00385853|Procedure|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
301738|NCT00385866|Behavioral|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
301739|NCT00385866|Behavioral|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
301740|NCT00385879|Behavioral|Case management|
301741|NCT00003178|Biological|filgrastim|
301742|NCT00385892|Device|Abdominal binder|
301743|NCT00385905|Device|Excel Drug-eluting stent|
301038|NCT00003240|Drug|ifosfamide|
301039|NCT00399919|Drug|Propionyl-L-Carnitine|2 grams per day for six months
301040|NCT00399919|Drug|PLC|2 grams/day for six months
301041|NCT00399945|Drug|Tobramycin|
301042|NCT00399971|Procedure|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
301043|NCT00399971|Drug|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
301044|NCT00399984|Behavioral|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
301045|NCT00399997|Behavioral|Exercise on Prescription|
301046|NCT00400010|Behavioral|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
301047|NCT00400023|Drug|S-1|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.
301048|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
301049|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
301050|NCT00402727|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
301051|NCT00402727|Drug|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
301052|NCT00402740|Device|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
301053|NCT00402753|Behavioral|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
301054|NCT00003260|Drug|FOLFOX regimen|
301055|NCT00402766|Drug|Cisplatin|Starting Dose: 60 mg/m^2 by vein, Over 2 Hours
300339|NCT00370435|Drug|GW274150|
300340|NCT00370448|Behavioral|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
300341|NCT00370474|Device|Bi-ventricular lead placement|
300342|NCT00370500|Drug|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
300343|NCT00003105|Drug|paclitaxel|
300344|NCT00370513|Drug|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
300345|NCT00370526|Procedure|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
300346|NCT00370539|Drug|verteporfin, bevacizumab, triamcinolone acetonide|
300347|NCT00370552|Drug|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
300696|NCT00408785|Drug|sodium chloride|sodium chloride 0.9 mg
300697|NCT00408798|Drug|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
300698|NCT00408850|Drug|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
300699|NCT00408850|Drug|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
300700|NCT00408863|Drug|tibolone|tibolone 2.5 mg/day
300701|NCT00408863|Drug|placebo|
300702|NCT00003284|Biological|filgrastim|
300703|NCT00408876|Drug|Duloxetine|
300704|NCT00408876|Drug|Placebo|
300705|NCT00411671|Drug|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
300706|NCT00411684|Drug|CDB-2914|
300707|NCT00000507|Drug|streptokinase|
299997|NCT00379457|Drug|vincristine sulfate|
299998|NCT00379457|Drug|vinorelbine tartrate|
299999|NCT00379457|Procedure|conventional surgery|
300000|NCT00003145|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
300001|NCT00379457|Radiation|radiation therapy|
300002|NCT00379470|Device|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
300003|NCT00379483|Drug|Deferasirox|
300004|NCT00379496|Procedure|Antidepressants|
300005|NCT00379496|Procedure|acupuncture|
300006|NCT00379509|Drug|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
300007|NCT00379509|Genetic|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
300008|NCT00379509|Genetic|gene expression analysis|Genetic analysis of tumor tissue.
300009|NCT00379509|Genetic|microarray analysis|Genetic analysis of tumor tissue.
300010|NCT00379509|Other|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
300011|NCT00003145|Other|Laboratory Biomarker Analysis|Correlative studies
300012|NCT00379509|Procedure|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
300013|NCT00379509|Radiation|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
300014|NCT00379522|Drug|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
300015|NCT00379522|Drug|Saline placebo|Placebo for arginine vasopressin
300016|NCT00379535|Drug|potassium iodide|per os
299264|NCT00003217|Biological|filgrastim|
299265|NCT00396084|Drug|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
299266|NCT00396084|Drug|Isoniazid|Isoniazid 300 mg/day x 7 days.
299267|NCT00396084|Drug|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
299268|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
299269|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
299270|NCT00396136|Device|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
299271|NCT00396149|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
299643|NCT00000495|Behavioral|diet, sodium-restricted|
299644|NCT00003187|Drug|methylprednisolone|
299645|NCT00387998|Other|Risk primer|Know your chances booklet
299646|NCT00388011|Drug|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
299647|NCT00388011|Drug|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
299648|NCT00388011|Drug|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
299649|NCT00388011|Drug|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
299650|NCT00388011|Drug|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
299651|NCT00388011|Drug|Intranasal placebo|Intranasal placebo
299652|NCT00388037|Drug|sunitinib malate|Given PO
299653|NCT00388037|Other|laboratory biomarker analysis|Correlative studies
299654|NCT00388050|Behavioral|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
299655|NCT00003187|Procedure|allogeneic bone marrow transplantation|
304816|NCT00240500|Biological|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
304817|NCT00240513|Drug|Minocycline|100 mg capsules OD for 3 months
304818|NCT00240513|Drug|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
304819|NCT00240526|Biological|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
304820|NCT00240526|Biological|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
304821|NCT00000403|Drug|Doxycycline|
304822|NCT00002634|Procedure|in vitro-treated bone marrow transplantation|
304823|NCT00240539|Procedure|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
304824|NCT00240552|Drug|fosamprenavir|
304825|NCT00240552|Drug|Telzir®|
304826|NCT00240565|Drug|Tositumomab 450 mg|Unlabeled TST
304827|NCT00240565|Drug|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
304828|NCT00240604|Drug|Rosiglitazone|4 mg rosiglitazone per day
304829|NCT00240617|Drug|sumatriptan succinate/naproxen sodium|comparator
304830|NCT00240617|Drug|placebo|placebo to match
304831|NCT00240630|Drug|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
304832|NCT00240630|Drug|placebo|placebo to match
304833|NCT00002634|Radiation|low-LET cobalt-60 gamma ray therapy|
304834|NCT00240643|Drug|SB424323|
304835|NCT00240656|Drug|spironolactone captopril carvedilol|
304836|NCT00240669|Device|Resorbable device PLLA/PGA|
304837|NCT00240669|Device|Titanium device|
304081|NCT00260533|Drug|atomoxetine|Flexible dose, up to 50 mg per day
304082|NCT00260533|Drug|placebo|placebo (matching to atomoxetine)
304083|NCT00260546|Procedure|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
304084|NCT00206154|Drug|Formoterol Turbuhaler|
304085|NCT00206167|Drug|Budesonide/formoterol pMDI|
304086|NCT00206167|Drug|Formoterol Turbuhaler|
304087|NCT00206180|Drug|esomeprazole magnesium (oral medication)|
304088|NCT00206193|Drug|mifepristone|
304089|NCT00206193|Drug|misoprostol|
304090|NCT00002550|Radiation|radiation therapy|
304451|NCT00250835|Other|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
304452|NCT00250861|Drug|Rituximab|
304453|NCT00250861|Drug|Aldesleukin|
304454|NCT00250874|Drug|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
304455|NCT00250887|Drug|Gefitnib|
304456|NCT00002665|Drug|prednisone|ind: 60 mg/m2/d PO 1 - 21*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.
ind2: 60 mg/m2/d PO through day 42
304457|NCT00250900|Behavioral|Prescription Fill Status|
304458|NCT00253578|Drug|sorafenib tosylate|Given PO
304459|NCT00253578|Other|laboratory biomarker analysis|Correlative studies
304460|NCT00253591|Drug|cisplatin|
304461|NCT00253591|Drug|vinorelbine tartrate|
304462|NCT00253591|Radiation|radiation therapy|
304463|NCT00253617|Drug|porfimer sodium|
318665|NCT00309491|Drug|Aminoglutethimide|
318666|NCT00309517|Drug|Fluourouracil|
318667|NCT00309517|Drug|Leucovorin|
318668|NCT00309517|Drug|MAb 17-1A|
318669|NCT00309530|Drug|5-fluorouracil, levamisol, interferon|
318670|NCT00002835|Drug|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
318671|NCT00309543|Drug|Fluorouracil|
318672|NCT00309543|Drug|Leucovorin|
318673|NCT00309556|Drug|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
318674|NCT00309556|Drug|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
318675|NCT02718638|Other|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
318676|NCT02718664|Other|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
318677|NCT02718690|Device|TENS|TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
318678|NCT02718690|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
319041|NCT00300430|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
319042|NCT00300430|Drug|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
319043|NCT00002812|Drug|daunorubicin hydrochloride|Given IV
319044|NCT00300430|Drug|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
319045|NCT00303303|Biological|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
317950|NCT00276796|Drug|cisplatin|
317951|NCT00276796|Drug|paclitaxel|
317952|NCT00276796|Drug|topotecan hydrochloride|
317953|NCT00276809|Biological|alemtuzumab|
317954|NCT00276809|Biological|filgrastim|
317955|NCT00276809|Drug|carmustine|
317956|NCT00002755|Radiation|low-LET cobalt-60 gamma ray therapy|
318305|NCT00266929|Procedure|conservative treatment|conservative stabilization of fractures
318306|NCT00002714|Radiation|radiation therapy|
318307|NCT00266981|Device|APOS - exercise component|
318308|NCT00267007|Drug|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
318309|NCT00267007|Drug|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
318310|NCT00267020|Drug|enzastaurin|1200 mg loading dose then 500 mg, oral, daily, six 28 day cycles
318311|NCT00267020|Drug|gemcitabine|1000 mg/m2, IV, days 1, 8 and 15 per cycle, six 28 day cycles
318312|NCT00267033|Procedure|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
318313|NCT00267046|Drug|Palifermin|180 mcg/kg 3 days prior to chemotherapy
318314|NCT00270192|Behavioral|individual lactation counseling and educational material|
318315|NCT00270192|Behavioral|educational material alone|
318316|NCT00270192|Behavioral|routine antenatal care without educational intervention|
318317|NCT00270205|Biological|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
318318|NCT00270205|Biological|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
318319|NCT00002721|Procedure|drug resistance inhibition treatment|
318320|NCT00270205|Biological|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
317584|NCT00286624|Drug|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
317585|NCT00002783|Drug|fluorouracil|
317586|NCT00286624|Drug|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
317587|NCT00286650|Procedure|3rd molar teeth extraction|
317588|NCT00286676|Drug|Nutropin|
317589|NCT00286676|Procedure|Oral Glucose Tolerance Test|
317590|NCT00286676|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
317591|NCT00286676|Procedure|Computed Tomography (CT) Scan|
317592|NCT00286689|Drug|Growth Hormone|
317593|NCT00286689|Procedure|Whole body Protein turnover|
317594|NCT00286689|Procedure|DEXA scan|
317595|NCT00286702|Device|hand splint|
317596|NCT00002783|Drug|leucovorin calcium|
317597|NCT00289783|Biological|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
317598|NCT00289783|Biological|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
317599|NCT00289796|Biological|Pertussis vaccine|
317600|NCT00289796|Biological|DTPa-HBV-IPV/Hib|
317601|NCT00289809|Drug|combination of TLC D-99 and Ifosfamide|TLC D-99: 40 mg/m2 Day 1 every 3 weeks;
Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks
317602|NCT00289822|Drug|intracoronary infusion of progenitor cells|
317603|NCT00002787|Biological|aldesleukin|Given SC
317957|NCT00276809|Drug|cyclophosphamide|
317958|NCT00276809|Drug|cytarabine|
317959|NCT00280228|Behavioral|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
322919|NCT00002779|Drug|octreotide acetate|
322920|NCT00285623|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
322921|NCT00285649|Procedure|Spinal Manipulation|HVLA-SM, LVVA-SM
322922|NCT00285662|Drug|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
322923|NCT00285675|Drug|DN-101 (calcitriol) - Drug|
322924|NCT00285688|Procedure|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
322925|NCT00285701|Drug|hexaminolevulinate|
322926|NCT00285714|Procedure|3D stereophotogrammetric imaging|
322927|NCT00285714|Procedure|3D CT-imaging with cone-beam CT|
322928|NCT00285714|Procedure|Case report form|
317242|NCT00353418|Drug|Ribavirin|800 mg orally daily for 48 weeks
317243|NCT00353418|Drug|Ribavirin|1000 mg or 1200 mg (based on patient weight of < 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
317244|NCT00353431|Drug|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
317245|NCT00353457|Drug|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
317246|NCT00353457|Radiation|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
317247|NCT00003026|Radiation|radiation therapy|
317248|NCT00353470|Behavioral|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
317249|NCT00353470|Behavioral|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
317250|NCT00356135|Drug|clopidogrel|75 mg tablet taken orally
317251|NCT00356135|Drug|prasugrel placebo|oral, as blinding mechanism.
322544|NCT00291928|Drug|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
322545|NCT00291941|Biological|Henogen HBV vaccine|20µg, Month 0, 2 and 6
322546|NCT00002792|Drug|tacrolimus|
322547|NCT00295282|Drug|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
322548|NCT00295295|Device|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
322549|NCT00295295|Other|Standing|Standing 10 min/day
322550|NCT00295308|Drug|Clonidine|clonidine up to 0.3 mg/day oral
322551|NCT00295308|Drug|Placebo|oral capsules daily
322552|NCT00295334|Drug|alcohol|
322553|NCT00295347|Drug|Spironolactone|
322554|NCT00002802|Drug|dacarbazine|
322555|NCT00295347|Drug|fludrocortisone|
322556|NCT00295347|Drug|escitalopram|
322557|NCT00295360|Behavioral|no intervention, pathophysiological study|
322558|NCT00295373|Drug|Rosuvastatin|
322559|NCT00295373|Behavioral|Exercise Training|
322560|NCT00295386|Behavioral|Cognitive behavior therapy (CBT)|
322561|NCT00295386|Drug|Zopiclone|
322562|NCT00295399|Device|The Jerusalem Telerehabilitation System|
322563|NCT00295412|Drug|quetiapine (drug)|
322564|NCT00295425|Drug|Cyclosporine A versus mycophenolate mofetil for psoriasis|
322565|NCT00002802|Drug|doxorubicin hydrochloride|
322566|NCT00295438|Device|Robot-Based Tele-Echography : the TER system|Robot-Based Tele-Echography
321834|NCT00262223|Behavioral|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
321835|NCT00262223|Drug|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
321836|NCT00262223|Drug|Pill placebo|
321837|NCT00262236|Drug|Aliskiren|
321838|NCT00002701|Drug|busulfan|
321839|NCT00262249|Drug|somatropin|
321840|NCT00262262|Drug|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
321841|NCT00262275|Drug|Aspirin, Clopidogrel|
321842|NCT00262288|Drug|i.v. recombinant human C1 inhibitor|
321843|NCT00262301|Drug|recombinant human C1 inhibitor|IV
321844|NCT00262301|Drug|Placebo|IV
321845|NCT00262327|Drug|Antangiogenesis|
321846|NCT00262327|Genetic|endostatin gene|
322200|NCT00304499|Drug|Oxybutynin|
322201|NCT00304512|Drug|AT1001 (migalastat hydrochloride)|25mg capsules every other day for 12 weeks
322202|NCT00304525|Drug|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg stengths.
322203|NCT00304538|Drug|very low dose (VLD) glucagon|
322204|NCT00304551|Drug|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
322205|NCT00304551|Drug|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
322206|NCT00304551|Drug|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
322207|NCT00304564|Behavioral|Music Listening|subjects listen to music
322208|NCT00002824|Procedure|conventional surgery|
303157|NCT00400946|Drug|doxorubicin hydrochloride|Given IV
303158|NCT00400946|Drug|etoposide|Given IV
303159|NCT00400946|Drug|leucovorin calcium|Given IV
303160|NCT00400946|Drug|mercaptopurine|Given orally
303494|NCT00000408|Procedure|Patient education evaluation|
303495|NCT00002655|Procedure|cryosurgery|
303496|NCT00246532|Drug|Placebo|Patients will receive placebo tablets.
303497|NCT00246545|Behavioral|exercise|
303498|NCT00246571|Drug|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
303499|NCT00246571|Drug|Chemotherapy|The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.
Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks
Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles
Docetaxel - 75-100 mg/m2 every 3 weeks
Paclitaxel - 175-200 mg/m2 every 3 weeks
Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.
Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248.
303500|NCT00246584|Drug|SPP100|
303501|NCT00246597|Drug|epoetin alfa|
303502|NCT00246610|Drug|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg [dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
303503|NCT00246623|Drug|Exubera (inhaled insulin)|
303504|NCT00246623|Procedure|8-point glucose diary (to assess pre- and post prandial glucoses)|
303505|NCT00246623|Procedure|Meal Tolerance Test|
303506|NCT00002656|Drug|pyrazoloacridine|Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)
303507|NCT00246623|Procedure|24-hour continuous glucose monitoring (at select sites)|
302808|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
302809|NCT00409630|Drug|fluticasone|
302810|NCT00409643|Drug|valsartan+amlodipine combination|
302811|NCT00409643|Drug|valsartan|
302812|NCT00409643|Drug|amlodipine|
302813|NCT00409656|Drug|Basiliximab|
302814|NCT00409669|Device|Barraquer tonometer|barraquer tonometer
302815|NCT00409682|Biological|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
302816|NCT00003287|Drug|oxaliplatin|
302817|NCT00409682|Biological|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
303161|NCT00400946|Drug|methotrexate|Given IV, intrathecally, and intramuscularly
303162|NCT00400946|Drug|methylprednisolone|Given IV
303163|NCT00400946|Drug|pegaspargase|Given IV
303164|NCT00400946|Drug|prednisolone|Given orally
303165|NCT00400946|Drug|therapeutic hydrocortisone|Given intrathecally
303166|NCT00400946|Drug|vincristine sulfate|Given IV
303167|NCT00003243|Biological|therapeutic allogeneic lymphocytes|
303168|NCT00400946|Radiation|radiation therapy|Some patients may undergo cranial radiotherapy
303169|NCT00400959|Procedure|cd133+cell intracoronary administration|
303170|NCT00400972|Device|GlideScope videolaryngoscope|
302122|NCT00003150|Drug|cyclophosphamide|
302123|NCT00380471|Device|Bath PUVA|
302124|NCT00380484|Drug|Budesonide|200µg daily
302468|NCT00371397|Behavioral|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
302469|NCT00371397|Behavioral|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
302470|NCT00371410|Procedure|vitrectomy|
302471|NCT00371410|Drug|intravitreal triamcinolone acetonide|
302472|NCT00371410|Procedure|macular focal laser photocoagulation|
302473|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
302474|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
302475|NCT00371436|Procedure|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
302476|NCT00371436|Procedure|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
302477|NCT00003111|Procedure|neoadjuvant therapy|
302478|NCT00371462|Behavioral|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
302479|NCT00371462|Behavioral|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
302480|NCT00371475|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
302481|NCT00371475|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
301744|NCT00385918|Device|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
301745|NCT00385918|Other|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
301746|NCT00385931|Drug|Valsartan and simvastatin|
301747|NCT00385944|Drug|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
301748|NCT00385944|Drug|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
301749|NCT00385957|Drug|AZT+3TC+IDV+RTV|
301750|NCT00385957|Drug|AZT+3TC+EFV|
301751|NCT00385970|Drug|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
301752|NCT00003178|Drug|cladribine|
301753|NCT00385970|Drug|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
301754|NCT00385970|Drug|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
301755|NCT00385983|Device|Harmonic Scalpel|
302125|NCT00380484|Drug|Montelukast|5 mg daily
302126|NCT00380497|Drug|PEG-Lyte®|
302127|NCT00380497|Drug|Pico-Salax®|
302128|NCT00380523|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
302129|NCT00380536|Behavioral|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
302130|NCT00380549|Device|Blood ion levels|Blood ion levels
302131|NCT00380562|Behavioral|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
302132|NCT00380575|Drug|YM087|
301056|NCT00402766|Drug|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
301385|NCT00393965|Drug|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
301386|NCT00393978|Drug|quetiapine + placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
301387|NCT00393978|Drug|Quetiapine + Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
301388|NCT00393991|Drug|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
301389|NCT00393991|Drug|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
301390|NCT00393991|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
301391|NCT00003213|Drug|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
301392|NCT00393991|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
301393|NCT00394017|Behavioral|Reminder letters|3 mailed reminder letters
301394|NCT00394030|Drug|GSK716155 subcutaneous injections|
301395|NCT00394043|Procedure|Osteopathic Manipulative Treatment|
301396|NCT00394043|Procedure|Placebo Sub-Therapeutic Ultrasound|
301397|NCT00394043|Procedure|Standard Medical Care|
301398|NCT00394056|Drug|Vestipitant|NK1 receptor antagonist
301399|NCT00394056|Drug|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
301400|NCT00394056|Other|Placebo|Placebo
301401|NCT00394069|Drug|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
301402|NCT00000498|Behavioral|alcohol restriction|
301403|NCT00003214|Drug|carboplatin|
301404|NCT00394082|Drug|ABI-007|125 mg/m^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
300708|NCT00003298|Procedure|surgery|The surgical procedure performed involved a radical subtotal or total gastrectomy.
A complete surgical resection was required
300709|NCT00411697|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
300710|NCT00411723|Drug|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
300711|NCT00411723|Drug|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
300712|NCT00411736|Drug|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
300713|NCT00411736|Drug|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
300714|NCT00411749|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
300715|NCT00411749|Biological|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
300716|NCT00411762|Drug|Capecitabine|
300717|NCT00411762|Drug|PHY906|
300718|NCT00411788|Drug|Rapamycin|oral rapamycin 6 mg daily
300719|NCT00003298|Radiation|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
301057|NCT00402766|Drug|Pemetrexed|Starting Dose: 500 mg/m^2 by vein, Over 40 Minutes
301058|NCT00402766|Drug|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
301059|NCT00402779|Drug|Erlotinib|150 mg by mouth daily
301060|NCT00402779|Drug|Placebo|Tablet by mouth daily
301061|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
301062|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
301063|NCT00402792|Drug|Placebo|2 tablets q 12 hours
301064|NCT00402805|Biological|Trivalent Inactivated Influenza Vaccine|
301065|NCT00003260|Drug|fluorouracil|
300017|NCT00379535|Drug|placebo|per os
300348|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
300349|NCT00373256|Drug|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
300350|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
300351|NCT00373269|Drug|Insulin|
300352|NCT00373282|Drug|Triamcinolone acetonide|
300353|NCT00373295|Drug|Baclofen|measured baclofen's effects on marijuana withdrawal and relapse relative to placebo
300354|NCT00373295|Drug|Marijuana|measured baclofen's effects on marijuana withdrawal and relapse
300355|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
300356|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
300357|NCT00003118|Procedure|surgical procedure|
300358|NCT00373334|Drug|placebo|placebo
300359|NCT00373360|Drug|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
300360|NCT00373373|Drug|Sorafenib|2 x 400 mg/d
300361|NCT00373373|Drug|Placebo|Chemotherapy + Placebo
300362|NCT00373386|Drug|growth hormone|
300363|NCT00373399|Drug|Marijuana|
300364|NCT00373412|Biological|VCL CT02 pDNA vaccine|
300365|NCT00373412|Biological|Towne CMV vaccine|
300366|NCT00373425|Drug|Erlotinib|150 mg tablet
300367|NCT00373425|Drug|Placebo|Placebo tablet
300368|NCT00003118|Radiation|radiation therapy|
300369|NCT00373438|Procedure|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
299656|NCT00388050|Behavioral|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
299657|NCT00388063|Drug|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
299658|NCT00388076|Drug|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
299659|NCT00388076|Drug|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
299660|NCT00388076|Drug|paclitaxel|in combination with pazopanib
299661|NCT00388076|Drug|carboplatin|in combination with pazopanib
299662|NCT00388089|Drug|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
299663|NCT00388089|Drug|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
299664|NCT00388089|Other|flow cytometry|No description
299665|NCT00390676|Drug|ADH -1 and carboplatin|
299666|NCT00390676|Drug|ADH -1 and docetaxel|
299667|NCT00390676|Drug|ADH -1 and capecitabine|
300018|NCT00379548|Behavioral|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
300019|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
300020|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
300021|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
300022|NCT00382239|Drug|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
300023|NCT00382252|Procedure|computed tomography|
300024|NCT00382252|Procedure|positron emission tomography|
300025|NCT00003158|Drug|carboplatin|
300026|NCT00382252|Procedure|radiofrequency ablation|
300027|NCT00382265|Drug|tamsulosin|tamsulosin 0.4mg po qd for 28 days
304838|NCT00244127|Drug|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
299272|NCT00396149|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
299273|NCT00396162|Drug|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
299274|NCT00396175|Drug|MK0906, finasteride / Duration of Treatment : 48 Weeks|
299275|NCT00003217|Drug|cyclophosphamide|
299276|NCT00396175|Drug|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
299277|NCT00396201|Drug|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
299278|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
299279|NCT00396214|Drug|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
299280|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
299281|NCT00399061|Drug|Systane, Optive, Restasis|Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
299282|NCT00399074|Drug|sulfadoxine pyrimethamine|Monthly SP
299283|NCT00399087|Drug|Perifosine|Perifosine oral administration
299284|NCT00399087|Drug|Docetaxel|IV administration
299285|NCT00399087|Drug|Prednisone|Oral administration
299286|NCT00399100|Procedure|HBO - hyperbaric oxygen treatment|
299287|NCT00399113|Drug|188Re-PTI-6D2|monoclonal antibody
299288|NCT00399126|Drug|Perifosine|Perifosine oral dose
299289|NCT00399126|Drug|Paclitaxel|Paclitaxel IV
304464|NCT00253617|Procedure|adjuvant therapy|
304465|NCT00253617|Procedure|laser therapy|
304466|NCT00002676|Drug|doxorubicin hydrochloride|
304467|NCT00253617|Procedure|photodynamic therapy|
304468|NCT00253617|Procedure|phototherapy|
304469|NCT00253630|Other|Laboratory Biomarker Analysis|Correlative studies
304470|NCT00253630|Drug|Vorinostat|Given PO
304471|NCT00253643|Dietary Supplement|green tea catechin extract|Given orally 2 times/day
304472|NCT00253643|Dietary Supplement|fish oil|Given orally 3 times/day
304473|NCT00253643|Other|placebo|Given olive oil placebo orally 3 times/day
304474|NCT00253643|Other|placebo|Given green tea placebo orally 2 times/day
304475|NCT00253669|Other|laboratory biomarker analysis|
304476|NCT00253669|Other|physiologic testing|
304477|NCT00002676|Drug|methotrexate|
304839|NCT00244140|Drug|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
304840|NCT00244140|Drug|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
304841|NCT00244153|Drug|intraarticular morphine|
304842|NCT00244153|Drug|intraarticular dexamethasone|
304843|NCT00244166|Drug|prednisolone|
304844|NCT00244179|Drug|interferon-gamma|
304845|NCT00244179|Drug|infliximab|
304846|NCT00244179|Drug|dmard|
304847|NCT00244192|Drug|infliximab (Remicade)|
304848|NCT00002643|Radiation|low-LET cobalt-60 gamma ray therapy|
304849|NCT00244205|Procedure|Identifying genes methylated in urine|
319046|NCT00002819|Procedure|autologous bone marrow transplantation|
319047|NCT00303303|Biological|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
319048|NCT00303303|Biological|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
319049|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
319050|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
319051|NCT00303329|Drug|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
319052|NCT00303342|Behavioral|mind body treatment|regulation of attention, respiration and posture
319053|NCT00303342|Behavioral|desensitization|mentation on insomnia behaviors and cognitive activity
319054|NCT00303381|Drug|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
319055|NCT00303381|Drug|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
319056|NCT00303381|Drug|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
319057|NCT00002819|Procedure|peripheral blood stem cell transplantation|
319058|NCT00303394|Drug|IL-1Ra|
319059|NCT00303407|Drug|nadroparin|
319060|NCT00303420|Drug|Alteplase "push" protocol|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
319061|NCT00303420|Drug|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
319412|NCT00293787|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
319413|NCT00002798|Drug|thioguanine|Given PO
319414|NCT00293787|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
318321|NCT00270218|Biological|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
318322|NCT00270218|Biological|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
318323|NCT00270218|Biological|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
318324|NCT00270218|Biological|PBS|phosphate buffered saline
318325|NCT00270231|Drug|Naltrexone|All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.
Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg.
318326|NCT00270231|Drug|Placebo|All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.
Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule.
318679|NCT02718703|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
318680|NCT02718716|Drug|UCB7665|Intervention Type: Biological/Vaccine
Pharmaceutical Form: Powder for solution for infusion
Concentration: 100 mg/ml
Route of Administration: Subcutaneous infusion
318681|NCT02718729|Procedure|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
318682|NCT00002548|Radiation|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
318683|NCT00204412|Dietary Supplement|Flax lignan|543 mg SDG per day
318684|NCT02718742|Other|Laboratory Biomarker Analysis|Correlative studies
318685|NCT02718742|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
318686|NCT02718742|Other|Quality-of-Life Assessment|Ancillary studies
318687|NCT02718755|Drug|Fludarabine|Induction Phase:
30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.
Consolidation Phase:
30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle.
318688|NCT02718755|Drug|Cytarabine|Induction Phase:
2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.
Consolidation Phase:
2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle.
318689|NCT02718755|Drug|Erwinase|Induction Phase:
25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.
Consolidation Phase:
25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle.
318690|NCT02718781|Behavioral|Health talk|Health talk on zero-time exercise.
317960|NCT00280228|Behavioral|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
317961|NCT00280241|Drug|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
317962|NCT00280241|Drug|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
317963|NCT00280241|Drug|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
317964|NCT00280254|Procedure|Hemodynamically Oriented Echocardiography-based Strategy|
317965|NCT00280267|Drug|Testosterone gel|
317966|NCT00280280|Drug|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
317967|NCT00002762|Procedure|blood sampling|
317968|NCT00280293|Drug|Lamotrigine|Lamotrigine
317969|NCT00280293|Drug|Placebo|Placebo
317970|NCT00280306|Other|No interventions|No intervention
317971|NCT00280319|Behavioral|interpersonal psychotherapy for groups|
317972|NCT00280319|Behavioral|creative play therapy|
317973|NCT00280332|Procedure|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
317974|NCT00280345|Procedure|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
317975|NCT00280345|Procedure|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
317976|NCT00280345|Procedure|Cataract surgery|Removal of the cataract from the eye
317977|NCT00280358|Drug|Fluticasone Propionate|
317978|NCT00002763|Biological|recombinant interferon alfa|
317252|NCT00356135|Drug|prasugrel 60 mg|60 mg (six 10-mg tablets) taken orally
317253|NCT00356135|Drug|clopidogrel placebo|oral, as blinding mechanism
317254|NCT00356148|Drug|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
317255|NCT00356161|Device|interventionally implanted hepatic arterial port catheter|
317256|NCT00000478|Drug|diltiazem|
317257|NCT00003042|Drug|melphalan|
317258|NCT00356187|Drug|Propranolol|
317259|NCT00356200|Drug|Fluphenazine Decanoate|Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: "APP Pharmaceuticals" is the name of the pharmaceutical company; APP is not an acronym.
317260|NCT00356200|Drug|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
317261|NCT00356213|Procedure|sleeve gastrectomy|laparoscopic sleeve gastrectomy
317262|NCT00356213|Procedure|Roux-Y-gastric bypass|laparoscopic gastric bypass
317263|NCT00356226|Drug|clonidine|
317604|NCT00289835|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
317605|NCT00289848|Drug|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
317606|NCT00289848|Drug|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
317607|NCT00289861|Drug|Risperidone|
317608|NCT00289861|Drug|placebo|
317609|NCT00289874|Drug|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
317610|NCT00289874|Drug|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
317611|NCT00289887|Drug|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
322567|NCT00295464|Drug|Betamethasone sodium phos (drug)|
322568|NCT00295477|Genetic|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
322569|NCT00295490|Drug|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
322929|NCT00285727|Drug|Ropinirole CR|
322930|NCT00002780|Biological|aldesleukin|
322931|NCT00285740|Behavioral|Cognitive Behavioral Therapy (CBT) in a Group Format|
322932|NCT00285753|Behavioral|support groups|cognitive behavioral intervention with psychoeducation
322933|NCT00285766|Drug|Selegiline Transdermal System|
322934|NCT00285779|Drug|Etanercept|etanercept 50 mg twice weekly for 12 weeks
322935|NCT00285779|Drug|Placebo|
322936|NCT00285792|Behavioral|Physical Activity|
322937|NCT00285805|Drug|Rosiglitazone versus placebo|
322938|NCT00285805|Drug|response (sodium excretion) to amiloride infusion|
322939|NCT00285805|Drug|response (sodium excretion) to furosemide infusion|
322940|NCT00285818|Drug|Mifepristone|
322941|NCT00002780|Biological|cytokine therapy|
322942|NCT00285844|Behavioral|weight loss|
322943|NCT00285844|Drug|thiazolidinedione|
322944|NCT00285857|Drug|Lovastatin|80 mg; 40 mg orally twice per day
322945|NCT00285883|Drug|Invirase|
322946|NCT00285883|Drug|Norvir|
322947|NCT00285896|Drug|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
322948|NCT00285896|Drug|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
322949|NCT00285909|Behavioral|Alcohol: 25 gday (white wine)|
322209|NCT00304577|Procedure|Bilateral recession|
322210|NCT00304577|Procedure|Unilateral recession and resection|
322211|NCT00304590|Drug|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
322212|NCT00304603|Other|No intervention|No treatment was given to the patients as this is an observational study.
322213|NCT00304616|Drug|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
322214|NCT00304629|Drug|galantamine|
322215|NCT00304642|Drug|dapivirine (TMC120) vaginal gel|
322216|NCT00304655|Drug|Aripiprazole|
322217|NCT00304668|Drug|dapivirine (TMC120) vaginal gel|
322218|NCT00304681|Drug|OROS*-Methylphenidate|
322219|NCT00002825|Biological|filgrastim|
322220|NCT00304707|Drug|Bupropion|300 mg QD
322221|NCT00304707|Drug|placebo|placebo
322222|NCT00304720|Drug|Tacrolimus and MMF|
322223|NCT00304733|Device|cast vs. shoe|
322224|NCT00307723|Drug|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
322570|NCT00295490|Drug|Placebo|Placebo has same dosing freq as for active intervention and for same time period
322571|NCT00295503|Drug|bevacizumab|15 mg/kg IV every 3 weeks
322572|NCT00295503|Drug|cisplatin|75 mg/m2 IV every 3 weeks
322573|NCT00295503|Drug|pemetrexed|500 mg/m2 every 3 weeks
322574|NCT00295516|Procedure|Fetal Middle Cerebral Artery Doppler measurement|
322575|NCT00295529|Behavioral|Multifaceted educational intervention|Educational materials available at end of study
322576|NCT00002802|Drug|etoposide|
303508|NCT00246623|Procedure|Pulmonary Function Testing|
303509|NCT00246623|Procedure|Hypoglycemic Event Monitoring|
303510|NCT00246623|Procedure|Laboratory Assessments|
303511|NCT00246623|Behavioral|Nutritional Counseling and Diabetes Education|
303877|NCT00236483|Drug|tramadol hydrochloride + acetaminophen|
303878|NCT00002624|Radiation|radiation therapy|
303879|NCT00236496|Drug|topiramate|
303880|NCT00236509|Drug|topiramate|
303881|NCT00236522|Drug|levofloxacin|
303882|NCT00236535|Drug|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
303883|NCT00236548|Drug|risperidone|
303884|NCT00236561|Drug|topiramate, propranolol|
303885|NCT00236574|Drug|Galantamine hydrobromide|
303886|NCT00236587|Drug|risperidone|
303887|NCT00236600|Drug|topiramate|
303888|NCT00236613|Drug|topiramate|
303889|NCT00002625|Drug|topotecan hydrochloride|
303890|NCT00236626|Drug|topiramate|
303891|NCT00236639|Drug|topiramate|
303892|NCT00239863|Drug|FTY720|
303893|NCT00239876|Drug|FTY720|
303894|NCT00239889|Drug|Salmon calcitonin|
303895|NCT00239902|Drug|FTY720|
303896|NCT00239915|Drug|Pagoclone|
303897|NCT00239928|Drug|pegaptanib sodium|1 drop per dosed eye per protocol.
303898|NCT00239954|Drug|Escitalopram|
303171|NCT00400985|Device|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is not a randomized trial. Study divided in 3 phases among which the first is blinded to the diagnostic data.
303172|NCT00400998|Drug|Fluticasone Propionate|Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:
- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate.
303173|NCT00400998|Other|Matched FPANS placebo|Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:
Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL.
303174|NCT00401011|Drug|Perifosine|All patients will received perifosine qhs daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks.
303175|NCT00401011|Drug|Bortezomib|All patients will received perifosine qhs daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks.
303176|NCT00403663|Drug|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
303177|NCT00403676|Other|Follow up bu a nurse|Follow up bu a nurse
303178|NCT00403676|Other|Follow up by a medical doctor|Follow up by a medical doctor
303179|NCT00403689|Dietary Supplement|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
303180|NCT00403689|Dietary Supplement|placebo|1.5 g waxy maize starch daily
303181|NCT00403702|Drug|Oxane HD [oil-RMN3-mixture]|
303182|NCT00003262|Drug|doxorubicin hydrochloride|
303183|NCT00403702|Drug|Densiron [(F6H8)|
303512|NCT00250263|Drug|(agent for immunotherapy) Staloral|Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures
Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures
Maintenance phase Day 12 to 364 - 8 pressures daily
The first year will be followed by a second year open label period (optional)- 8 pressures daily
303513|NCT00250263|Drug|Placebo|Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.
First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures
Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures
Maintenance phase Day 12 to 364 - 8 pressures daily
303514|NCT00250276|Biological|HPV-16/18 L1/AS04|
303515|NCT00250289|Device|a mucosal sticker with herbal formula|
302482|NCT00371488|Drug|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
302483|NCT00371501|Drug|Rosuvastatin|10mg/day
302484|NCT00371501|Drug|placebo|one tablet/day
302485|NCT00371501|Drug|aspirin|80mg/day
302486|NCT00371501|Drug|placebo|placebo
302818|NCT00409682|Biological|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
302819|NCT00409695|Drug|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
302820|NCT00409695|Drug|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
302821|NCT00409708|Drug|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
302822|NCT00409708|Behavioral|Behavior Therapy|
302823|NCT00412737|Drug|oseltamivir [Tamiflu]|30-75mg po daily for 12 weeks
302824|NCT00412737|Drug|Placebo|po daily for 12 weeks
302825|NCT00412750|Drug|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
302826|NCT00412750|Drug|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
302827|NCT00003307|Drug|amifostine trihydrate|
302828|NCT00412763|Drug|Silymarin (Silybum marianum)|
302829|NCT00412776|Drug|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
302830|NCT00412789|Drug|Patupilone|
302831|NCT00412802|Drug|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
302832|NCT00412802|Drug|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
302133|NCT00003150|Drug|doxorubicin hydrochloride|
302134|NCT00380588|Drug|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
302135|NCT00380588|Drug|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
302136|NCT00380601|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
302137|NCT00380614|Drug|Lamivudine|
302138|NCT00380627|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
302139|NCT00380640|Drug|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
302140|NCT00380640|Drug|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
302141|NCT00380653|Drug|sapacitabine|
302142|NCT00380666|Procedure|PET/CT scan|
302143|NCT00380679|Biological|Influenza vaccination|
302144|NCT00003150|Drug|prednisone|
302145|NCT00383214|Drug|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
302146|NCT00383214|Other|Placebo|Intravenous
302147|NCT00383227|Biological|Hepatitis B adjuvanted vaccine|
302148|NCT00383240|Drug|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
302149|NCT00383240|Drug|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
302487|NCT00371527|Drug|ipratropium|
302488|NCT00003111|Procedure|surgical procedure|
302489|NCT00371540|Behavioral|Control Group|Routine care in the clinic on a monthly basis
302490|NCT00374413|Device|Artificial disk|Implant
302491|NCT00003122|Procedure|surgical procedure|
302492|NCT00374413|Device|Artificial disc|Implant
302493|NCT00374426|Drug|sertraline|
301405|NCT00394082|Drug|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
301406|NCT00394095|Drug|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
301407|NCT00394095|Drug|Placebo|Matched placebo to Experimental arm
301756|NCT00385996|Drug|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
301757|NCT00386009|Drug|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
301758|NCT00386009|Drug|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
301759|NCT00386022|Drug|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr in random order, with the exception that the highest dose will always be administered last
301760|NCT00386022|Drug|NAL-GLU GnRH antagonist|a single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg
301761|NCT00386022|Drug|Estrogen patch (Climara)|transdermal estrogen patches (Climara 0.05mg/day, changing the patch every 86 hr)
301762|NCT00388960|Drug|Amrubicin|Amrubicin 45mg/m<2> IV days 1, 2 3 of each 21-day cycle until disease progression.
Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression.
301763|NCT00003193|Procedure|conventional surgery|
301764|NCT00388960|Drug|Cisplatin|Amrubicin 40mg/m<2> IV days 1, 2, 3 plus Cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression.
Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
301765|NCT00388960|Drug|Etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
301766|NCT00388973|Drug|Quetiapine|
301767|NCT00388986|Drug|GK Activator (2)|100mg po bid
301768|NCT00388986|Drug|Glyburide|10-20mg po daily
301769|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
301770|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
301066|NCT00402831|Biological|ProQuad® (prevention of measles, mumps, rubella and varicella)|route
301067|NCT00402844|Device|Transvaginal mesh- PROLIFT®-system|
301068|NCT00402857|Behavioral|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
301069|NCT00402870|Device|ProSeal LMA|ProSeal LMA vs Tracheal Tube
301070|NCT00402870|Device|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
301071|NCT00402883|Drug|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
301072|NCT00402883|Drug|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
301073|NCT00405756|Drug|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
301074|NCT00405769|Drug|red yeast rice|600 mg 3 caps bid
301075|NCT00405769|Drug|placebo|3 caps bid
301076|NCT00405782|Behavioral|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
301077|NCT00405795|Device|Envision® Patient Support System|
301078|NCT00003270|Biological|filgrastim|IV
301079|NCT00405808|Drug|Rimonabant|Once daily in the morning
301080|NCT00405808|Drug|Placebo|Once daily in the morning
301408|NCT00396877|Drug|placebo|Form: reconstituted solution using matching placebo powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight
301409|NCT00396903|Device|catheter|
301410|NCT00396916|Device|PET/CT imaging|
301411|NCT00396929|Drug|local intracoronary dosis of Paclitaxel|
301412|NCT00396955|Drug|PLA-695|
301413|NCT00396968|Drug|AMD3100|
301414|NCT00396968|Procedure|Allogeneic Stem Cell Transplantation|
300370|NCT00373451|Drug|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute [maximum of 10 µg/minute] infusion for 12 hours)
300371|NCT00373451|Drug|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
300372|NCT00373451|Drug|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
300720|NCT00411788|Drug|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
300721|NCT00411801|Biological|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
300722|NCT00411801|Biological|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
300723|NCT00411814|Drug|GSK679586|Active Drug
300724|NCT00411814|Drug|Placebo|Saline
300725|NCT00411827|Procedure|PRK with conjunctival impression cytology before and after surgery|
300726|NCT00411827|Procedure|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
300727|NCT00411840|Procedure|intraarterial and intramuscular injection of BMCs|
300728|NCT00411853|Drug|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
300729|NCT00411866|Drug|SB773812|
300730|NCT00003299|Drug|cisplatin|
300731|NCT00411866|Drug|Ketoconazole|
300732|NCT00367341|Drug|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
300733|NCT00367341|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
300734|NCT00367367|Procedure|Hysteroscopy and Curettage|
300735|NCT00367380|Other|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
300736|NCT00367380|Other|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
300737|NCT00367380|Other|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
300028|NCT00382278|Procedure|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
300029|NCT00382291|Drug|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
300030|NCT00382291|Drug|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
300031|NCT00382291|Drug|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
300032|NCT00382304|Drug|tolevamer potassium-sodium (GT267-004)|
300033|NCT00382317|Drug|Iobitridol|
300034|NCT00382330|Drug|Ciclopirox|
300035|NCT00382343|Drug|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
300036|NCT00003158|Drug|etoposide|
300037|NCT00382356|Drug|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
300038|NCT00382382|Other|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
300039|NCT00382395|Device|SOLX Gold Shunt GMS-plus|Single use implant
300040|NCT00382395|Device|Ahmed FP7 Glaucoma Valve|Single use implant
300373|NCT00373464|Drug|etoricoxib|
300374|NCT00373477|Procedure|Generalist Care Manager vs Usual Care|
300375|NCT00373490|Drug|Vorinostat|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
300376|NCT00373490|Drug|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
300377|NCT00376818|Other|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
300378|NCT00376818|Other|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
299290|NCT00399152|Drug|Perifosine|Perifosine Oral Dose
299291|NCT00003236|Biological|ISIS 3521|
299292|NCT00399152|Drug|Sunitinib Malate|Sunitinib oral dose
299668|NCT00003199|Biological|sargramostim|Given SC
299669|NCT00390689|Drug|Pramipexole 0.125 mg tablet|
299670|NCT00390689|Drug|Pramipexole 0.5 mg tablet|
299671|NCT00390702|Device|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
299672|NCT00390715|Drug|chemotherapy|
299673|NCT00390728|Drug|Insulin Glargine|
299674|NCT00390741|Behavioral|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
299675|NCT00390754|Behavioral|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
299676|NCT00390767|Biological|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
299677|NCT00390780|Drug|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
299678|NCT00390780|Drug|Clotrimazole|10mg troches administered Five Times a Day for 14 days
299679|NCT00003199|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
299680|NCT00390793|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2 & 3
299681|NCT00390793|Drug|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days
299682|NCT00390793|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours on day 4
299683|NCT00390793|Drug|Dexamethasone|40 mg IV or by mouth days 1-4 +/- 2 days and days 11-14 +/- 2 days
299684|NCT00390793|Drug|Dasatinib|100 mg by mouth (PO) daily on days 1-14; 70 mg PO daily continuously for Course 2 - 8.
299685|NCT00390793|Drug|Methotrexate|200 mg/m^2 over 2 hours followed by 800 mg/m^2 over 22 hours on day 1.
304850|NCT00244218|Drug|tetrahydrobiopterin (BH4)|Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
304851|NCT00244231|Drug|Nidadd|
304852|NCT00244244|Drug|arimoclomol|
304853|NCT00244257|Biological|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
304854|NCT00244257|Biological|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
304855|NCT00244257|Biological|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
304856|NCT00244257|Biological|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
304857|NCT00244257|Biological|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
304858|NCT00244270|Device|totally implantable vascular access device|totally implantable vascular access device
304859|NCT00000134|Drug|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
304860|NCT00000407|Behavioral|Vocational counseling intervention|
304861|NCT00002643|Radiation|low-LET electron therapy|
304862|NCT00244283|Drug|Sevoflurane|
304863|NCT00244283|Procedure|High thoracic epidural analgesia|
304864|NCT00244296|Drug|Duloxetine hydrochloride|
299293|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
299294|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
299295|NCT00399165|Drug|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
299296|NCT00399165|Other|placebo sesame oil|placebo sesame oil
299297|NCT00399165|Drug|Dutasteride|24.5 mg po once (Day 0)
299298|NCT00399178|Drug|Transdermal delivery system|
299299|NCT00399191|Drug|stable isotope of iron, dysprosium|
319415|NCT00293800|Drug|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
319416|NCT00293800|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
319417|NCT00293800|Drug|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
319418|NCT00293800|Other|Timolol Vehicle|Placebo
319419|NCT00293813|Drug|Alendronate|Alendronate 70 mg PO QW
319420|NCT00293813|Drug|Denosumab|denosumab 60 mg SC q 6 mos
319421|NCT00293813|Drug|Placebo|Placebo for alendronate and placebo for denosumab
319422|NCT00293826|Drug|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
319423|NCT00293826|Drug|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
319424|NCT00002798|Drug|etoposide|Given IV
319425|NCT00293826|Drug|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
319426|NCT00293826|Drug|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
319427|NCT00293839|Drug|oxybutynin chloride|
319428|NCT00293852|Procedure|Outpatient clinic follow-up|
319429|NCT00293865|Procedure|sentinel node|detection of the sentinel node in breast cancer
319430|NCT00293865|Procedure|GAS|
319431|NCT00293878|Drug|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
319432|NCT00293891|Drug|Tacrolimus Cream|
319433|NCT00296777|Drug|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
319434|NCT00296777|Drug|Imipramine|8 weeks: up to 300mg/day
*if patient does not have contraindication.
319435|NCT00296790|Drug|zolpidem tartrate|
319436|NCT00296803|Drug|clopidogrel|
318691|NCT02718781|Behavioral|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
318692|NCT02718781|Device|Handgrip|This is a home-based equipment
318693|NCT02718794|Procedure|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
318694|NCT00204412|Behavioral|Exercise (walking)|walking 45 minutes per day 5 days per week
318695|NCT02718794|Procedure|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
318696|NCT00263770|Device|soft palate implant|
318697|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
318698|NCT00263783|Drug|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. [As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.]
318699|NCT00263796|Drug|Oxytocin|10 international units = 1 cc, IV over 4 hours
318700|NCT00263796|Drug|Placebo|Normal Saline, IV over 4 hours
319062|NCT00303433|Drug|Namenda|
319063|NCT00303446|Drug|Dutasteride|Dutasteride 0.5 mg/day
319064|NCT00303446|Drug|Placebo|Matched placebo
319065|NCT00303459|Drug|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
319066|NCT00303459|Drug|placebo|Matching bosentan placebo/b.i.d.
319067|NCT00303472|Drug|Romiplostim|
319068|NCT00002822|Drug|carboplatin|
319069|NCT00303485|Drug|Placebo|po monthly for 6 months
319070|NCT00303485|Drug|Vitamin D and calcium supplementation|As prescribed
319071|NCT00306293|Drug|valacyclovir|
319072|NCT00306306|Device|Reprieve Endovascular Temperature Therapy System|
319073|NCT00306319|Drug|moxifloxacin|
319074|NCT00306332|Procedure|T-cell and B-cell depletion|
318327|NCT00270244|Behavioral|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions—one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
318328|NCT00270244|Behavioral|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
318329|NCT00270257|Drug|Buprenorphine/Naloxone|Oral tablet
318330|NCT00002722|Drug|cisplatin|
318331|NCT00270270|Drug|epoetin alfa|
318332|NCT00270283|Drug|epoetin alfa|
318333|NCT00270296|Drug|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
318334|NCT00270296|Drug|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
318335|NCT00270296|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
318336|NCT00270296|Drug|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
318337|NCT00270309|Behavioral|Self-management|
318338|NCT00270322|Drug|Marcaine 0.166% + Fentanyl 3.33 mcg/ml|
318339|NCT00273741|Drug|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
318340|NCT00273741|Drug|placebo comparator|placebo capsules
318341|NCT00273754|Drug|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
318342|NCT00273754|Drug|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
318343|NCT00273767|Drug|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
318344|NCT00273767|Drug|placebo|60ml of NaCl IV slow
318345|NCT00273780|Behavioral|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
318346|NCT00273780|Device|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
317612|NCT00289887|Drug|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
317613|NCT00289900|Drug|MK-0524A|
317614|NCT00002787|Other|laboratory biomarker analysis|Correlative studies
317615|NCT00289900|Drug|Atorvastatin|
317616|NCT00289900|Drug|Simvastatin|
317617|NCT00289913|Biological|Comparator: VAQTA™|VAQTA™ (Hepatitis A Vaccine, Inactivated).
Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.
317618|NCT00289913|Biological|Comparator: Infanrix™|Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis
Vaccine Adsorbed, GlaxoSmithKline).
One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit.
317619|NCT00289913|Biological|Comparator: PedvaxHIB™|PedvaxHIB™ (Haemophilus B Conjugate Vaccine [Meningococcal Protein Conjugate]).
One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit.
317620|NCT00289926|Drug|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
317621|NCT00289926|Drug|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
317622|NCT00002796|Biological|recombinant interferon gamma|Given subcutaneously
317623|NCT00292968|Behavioral|Computer based care|
317624|NCT00292968|Behavioral|Telephone counseling|
317625|NCT00292968|Behavioral|Group visits|
317979|NCT00280358|Drug|Formoterol Fumarate|
317980|NCT00280371|Drug|Formoterol Fumarate|
317981|NCT00280384|Drug|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
317982|NCT00283153|Other|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
317983|NCT00283166|Behavioral|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
322950|NCT00288899|Other|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
322951|NCT00288912|Behavioral|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
322952|NCT00288912|Behavioral|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
322953|NCT00288925|Drug|Z-360|
317264|NCT00356252|Drug|mixed carotenoids|
317265|NCT00356265|Drug|Procedure: Regional phenylephrine arterial infusion|
317266|NCT00356278|Drug|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
317267|NCT00356278|Drug|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
317268|NCT00003042|Drug|mesna|
317269|NCT00356278|Behavioral|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
317270|NCT00356278|Drug|Placebo|Placebo will be administered in the same manner as the active drugs.
317271|NCT00356291|Behavioral|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
317272|NCT00356291|Behavioral|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
317273|NCT00356304|Behavioral|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
317274|NCT00356304|Behavioral|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
317275|NCT00359112|Drug|metformin|
317276|NCT00359112|Drug|sulphonylurea|
317277|NCT00359112|Drug|Avandamet|
322577|NCT00295542|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
322578|NCT00298259|Procedure|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
322579|NCT00002805|Radiation|low-LET photon therapy|
322580|NCT00298272|Biological|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
322581|NCT00298272|Drug|Placebo|Participants will receive placebo on Day 1 and Day 15
322582|NCT00298272|Drug|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
322583|NCT00298272|Drug|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
322584|NCT00298272|Drug|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
322585|NCT00298272|Drug|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
322586|NCT00298272|Dietary Supplement|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
322587|NCT00298285|Drug|enoxaparin|
322588|NCT00298298|Biological|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
322589|NCT00298311|Procedure|Peer Support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
322590|NCT00002806|Drug|lomustine|
322591|NCT00298324|Drug|Myfortic|1440mg twice daily
322592|NCT00298324|Drug|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
322954|NCT00288951|Drug|Travoprost 0.004% with and without BAK|
322955|NCT00288964|Device|Hattler Respiratory Assist Catheter|
322956|NCT00288977|Procedure|Islet Infusion|
322957|NCT00002785|Drug|prednisone|
322958|NCT00289003|Drug|Soluble beta-1,3/1,6-glucan|
303899|NCT00239967|Drug|Rimonabant (SR141716)|
303900|NCT00239967|Drug|Placebo|
303901|NCT00002634|Drug|doxorubicin hydrochloride|
303902|NCT00239980|Drug|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
303903|NCT00239993|Drug|glatiramer acetate|
303904|NCT00239993|Procedure|Warm compress prior to injection of glatiramer acetate|
303905|NCT00240006|Procedure|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
304267|NCT00225173|Drug|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
304268|NCT00225173|Drug|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
304269|NCT00228917|Biological|DTPw-HBV/Hib-MenAC-TT vaccine|
304270|NCT00228930|Drug|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
304271|NCT00228943|Dietary Supplement|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
304272|NCT00002600|Biological|filgrastim|
304273|NCT00228943|Dietary Supplement|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
304274|NCT00228956|Drug|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
304275|NCT00228969|Drug|RWJ-333369|
304276|NCT00228982|Drug|Ceftobiprole medocaril|
304277|NCT00228982|Drug|Vancomycin|
304278|NCT00228995|Drug|epoetin alfa|
304279|NCT00229008|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
304280|NCT00229008|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
303516|NCT00002665|Drug|dexamethasone|main: 10 mg/m2/day PO 1 - 28
303517|NCT00250302|Procedure|autologous mesenchymal stem cells implantation|
303518|NCT00250315|Drug|Dobutamine|
303519|NCT00250328|Device|LapCAC Laparoscopic Compression Anastomosis Clip|
303520|NCT00250341|Drug|QVAR|480 mcg
303521|NCT00250341|Drug|Advair|250/50 mcg
303522|NCT00250341|Drug|Servent Diskus|50 mcg
303523|NCT00250354|Drug|Risperidone oral solution|
303524|NCT00250367|Drug|risperidone|
303525|NCT00250393|Drug|Istradefylline (KW-6002)|
303526|NCT00250406|Device|Ureteral Stent|triclosan-eluting ureteral stent
303527|NCT00002665|Drug|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
303528|NCT00250406|Device|Ureteral Stent|Percuflex Plus Stent as the control
303529|NCT00250419|Biological|V930|
303530|NCT00250432|Drug|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. Duration of Treatment - 14-90 days.
303531|NCT00250445|Drug|MK0663, etoricoxib|
303532|NCT00250445|Drug|Comparator: Diclofenac sodium|
303533|NCT00250458|Drug|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
303534|NCT00250458|Drug|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
303906|NCT00240019|Drug|Addition of furosemide 20 mg oral bid to baseline regimen|
303907|NCT00240032|Drug|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
303908|NCT00240032|Drug|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
303909|NCT00240045|Drug|Midodrine, albumin, octreotide LAR|
302833|NCT00412815|Behavioral|Exercise training|
302834|NCT00412828|Drug|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
302835|NCT00412841|Drug|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
302836|NCT00412841|Procedure|MRI, Venipuncture|MRIs done baseline, four and nine months
302837|NCT00412841|Drug|Placebo|Tablets identical to atorvastatin 40mg
302838|NCT00003307|Radiation|radiation therapy|
302839|NCT00412854|Biological|Infanrix™/Hib|
302840|NCT00412854|Biological|Infanrix|
303184|NCT00403715|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
303185|NCT00403728|Drug|ciclosporine A|
303186|NCT00403741|Behavioral|motivational interviewing|
303187|NCT00403754|Drug|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
303188|NCT00403754|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
303189|NCT00403754|Drug|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
303190|NCT00403767|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
303191|NCT00403767|Drug|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
303192|NCT00403767|Drug|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
303193|NCT00003262|Drug|epirubicin hydrochloride|
303194|NCT00403767|Drug|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
302494|NCT00374439|Behavioral|Cognitive-behavioral and Interpersonal Therapy|
302495|NCT00374452|Behavioral|ATHENA-Hypertension clinical decision support system|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
302496|NCT00374465|Drug|Verapamil|
302497|NCT00374465|Drug|Carvedilol|
302498|NCT00374478|Drug|Scopolamine|
302499|NCT00374517|Drug|Pimonidazole hydrochloride|
302500|NCT00374530|Drug|PGE2|
302501|NCT00374543|Drug|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
302502|NCT00003123|Drug|amifostine trihydrate|
302503|NCT00374543|Drug|Placebo|Placebo administered daily for 8 weeks
302504|NCT00374556|Drug|eszopiclone, 2 mg, qhs|
302505|NCT00374569|Procedure|Gymnastic Routine|A combination of gymnastic movements are performed
302506|NCT00374582|Device|Bodystat Quadscan 4000|device determining body composition and nutritional status
302507|NCT00374582|Device|bodystat quadscan 400|device determining body composition and nutritional status
302508|NCT00374621|Drug|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
302509|NCT00374634|Drug|rFSH drug dose|"Individual" rFSH dose (50, 75 or 100 IU rFSH/day)
302510|NCT00374634|Drug|"Standard" rFSH dose|"Standard" rFSH dose was 75 IU/day
302511|NCT00374647|Drug|mycophenolate mofetil|
302512|NCT00374647|Drug|sirolimus|
302841|NCT00412854|Biological|Hiberix|
302842|NCT00412867|Drug|Alteplase|0.6 mg/kg of Alteplase is intravenously administered
302843|NCT00412880|Drug|BI 2536|
302844|NCT00412893|Drug|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
301771|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
301772|NCT00389012|Procedure|exercise therapy|
301773|NCT00389012|Procedure|walking rehabilitation|
301774|NCT00003193|Radiation|radiation therapy|
301775|NCT00389025|Drug|Olopatadine (generic name)|
301776|NCT00389038|Behavioral|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
302150|NCT00383240|Drug|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
302151|NCT00383240|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
302152|NCT00003159|Drug|vinorelbine tartrate|
302153|NCT00383253|Behavioral|caloric restriction - 10%|Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
302154|NCT00383253|Behavioral|caloric restriction - 25%|Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
302155|NCT00383253|Behavioral|caloric restriction - 50%|Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
302156|NCT00383253|Behavioral|caloric restriction - Control|Subjects maintained on their baseline caloric intake (caloric restriction = none)
302157|NCT00383266|Drug|Pemetrexed|
302158|NCT00383266|Drug|Carboplatin|
302159|NCT00383279|Other|counseling intervention|
302160|NCT00383279|Other|study of socioeconomic and demographic variables|
302161|NCT00383292|Drug|LY573636|LY573636 dose is dependent on patient's height, weight, and gender and is adjusted to target a specific Cmax based on patient laboratory parameters. LY573636 is administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met.
302162|NCT00383305|Device|Cool-Cap|
302163|NCT00003159|Procedure|conventional surgery|
302164|NCT00383318|Procedure|Gene mutation sample|
301415|NCT00396981|Device|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
301416|NCT00396981|Device|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
301417|NCT00003222|Biological|incomplete Freund's adjuvant|
301418|NCT00396994|Device|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
301419|NCT00396994|Device|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
301420|NCT00397007|Behavioral|Biofeedback-based cognitive-behavioural intervention|
301421|NCT00397020|Drug|divalproex ER|
301422|NCT00397020|Drug|quetiapine|
301423|NCT00397033|Drug|Paliperidone ER|6mg/day paliperidone er for 6 weeks
301424|NCT00397033|Drug|Paliperidone ER|12mg/day paliperidone er for 6 weeks
301425|NCT00397033|Drug|Placebo|Placebo for 6 weeks
301426|NCT00397046|Drug|neratinib|HKI-272
301427|NCT00397059|Drug|Escitalopram|
301428|NCT00003222|Biological|sargramostim|
301429|NCT00397072|Drug|ZK 219477|
301430|NCT00397098|Drug|SR58611A|
301431|NCT00397124|Device|PET/CT imaging|
301432|NCT00397137|Procedure|Circular stapled anopexy|
301433|NCT00397137|Procedure|Closed diathermy haemorrhoidectomy|
301777|NCT00389038|Behavioral|Headache Education|Behavioral Treatment 2 (headache education)
301778|NCT00389038|Drug|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
301779|NCT00389051|Drug|bendamustine hydrochloride|
301780|NCT00389064|Drug|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
300738|NCT00367393|Drug|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
300739|NCT00367406|Device|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
300740|NCT00367419|Drug|Erythromycin|
300741|NCT00003093|Biological|filgrastim|
300742|NCT00367432|Drug|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
300743|NCT00367445|Drug|Inhaled Human Insulin (Exubera)|
301081|NCT00405821|Drug|Acyclovir|400mg twice daily for 24 months
301082|NCT00405821|Drug|Placebo|Placebo tablet twice daily for 24 months
301083|NCT00405834|Device|Envision® Patient Support System|
301084|NCT00405847|Drug|Dexmedetomidine|
301085|NCT00405860|Drug|CellCept (mycophenolate mofetil)|
301086|NCT00405873|Drug|AMT2003|
301087|NCT00405886|Drug|Neramexane|Oral tablets, duration: 16 weeks
301088|NCT00405886|Drug|Placebo|Oral tablets, duration: 16 weeks
301089|NCT00003270|Drug|busulfan|IV
301090|NCT00405912|Drug|Placebo|Placebo (inactive drug) given 3 times per day
301091|NCT00405912|Drug|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
301092|NCT00405912|Drug|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
301093|NCT00405925|Drug|Trizivir|
301094|NCT00405925|Drug|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
301095|NCT00405938|Drug|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
301096|NCT00405938|Drug|Anastrozole|anastrozole (1 mg orally daily)
301097|NCT00405938|Drug|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
300379|NCT00376818|Behavioral|mind-body intervention procedure|Meditation practice in this study will consist of 15 minutes of "body scan" to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges.
300380|NCT00376818|Procedure|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
300381|NCT00376831|Drug|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
300382|NCT00376831|Drug|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
300383|NCT00376844|Other|clinical observation|
300384|NCT00376844|Procedure|adjuvant therapy|
300385|NCT00376844|Radiation|brachytherapy|
300386|NCT00003135|Drug|pegylated liposomal doxorubicin hydrochloride|
300387|NCT00376844|Radiation|radiation therapy|
300388|NCT00376857|Drug|Surgery with and without the aid of Indocyanine Green (ICG)|
300389|NCT00376870|Drug|Pioglitazone|pioglitazone 30 mg/d
300390|NCT00376870|Drug|Placebo|Placebo 30 mg/d
300391|NCT00376883|Drug|pamidronate|
300392|NCT00376896|Drug|GW876008 200mcg|GW876008
300393|NCT00376896|Drug|GW876008 20mcg|GW876008 20mcg
300394|NCT00376896|Other|Placebo|placebo
300395|NCT00376909|Other|educational intervention|
300744|NCT00367445|Drug|Insulin Glargine (Lantus)|
300745|NCT00367458|Drug|Atorvastatin|80 mg atorvastatin oral daily
300746|NCT00367471|Drug|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
300747|NCT00367471|Drug|carboplatin|An alkylating agent used in the treatment of ome cancers
299686|NCT00390793|Drug|Ara-C|3 g/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
299687|NCT00390806|Drug|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
299688|NCT00390806|Radiation|Radiation|Whole brain radiation
299689|NCT00390832|Drug|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
300041|NCT00382408|Biological|DR-5001|1 tablet x 1
300042|NCT00382408|Other|Placebo|1 tablet x 1
300043|NCT00382421|Drug|bisoprolol|
300044|NCT00382421|Drug|amlodipine|
300045|NCT00382421|Drug|molsidomine|
300046|NCT00382421|Drug|acetylsalicylic acid|
300047|NCT00003158|Drug|paclitaxel|
300048|NCT00385008|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
300049|NCT00385008|Drug|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
300050|NCT00385021|Drug|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
300051|NCT00385034|Device|Interactive computer based health-risk survey before doctor's visit|
300052|NCT00385047|Biological|Group A FMP2.1/AS01B|
300053|NCT00385047|Biological|Group B FMP2.1/AS02A|
300054|NCT00385086|Drug|TNF blocker|Treatment with TNF-alpha blocker
300055|NCT00385086|Drug|Placebo|Treatment with placebo
300056|NCT00385099|Drug|GW876008|
300057|NCT00003172|Drug|hydroxyurea|
300058|NCT00385112|Procedure|Echocardiogram|2D echocardiogram with Doppler flow
300059|NCT00385125|Drug|Bendamustine|
300060|NCT00385125|Drug|Rituximab|
299300|NCT00399204|Drug|Pioglitazone vs Metformin|
299301|NCT00399217|Device|Subcutaneous Implantable Defibrillator (S-ICD) system|
299302|NCT00003236|Drug|ISIS 5132|
299303|NCT00399217|Device|ICD|
299304|NCT00399230|Drug|Optive|
299305|NCT00399243|Drug|Sumatriptan 4mg Statdose injection|4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
299306|NCT00399256|Drug|Acetylcysteine|
299307|NCT00399256|Drug|Zinc|
299308|NCT00399269|Drug|Recombinant Human Erythropoietin alpha|
299309|NCT00399282|Drug|Omega-3 and Vitamin E supplementation|
299310|NCT00399295|Drug|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
299311|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
299312|NCT00402155|Behavioral|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
299313|NCT00402168|Drug|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
299314|NCT00402168|Drug|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2X daily for one year
299315|NCT00402168|Drug|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2X daily for one year
299316|NCT00402181|Biological|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
299317|NCT00402181|Drug|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
299690|NCT00003199|Radiation|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
299691|NCT00390832|Other|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
299692|NCT00393341|Procedure|Blood Draw|Blood sample will be drawn from a vein in the arm.
299693|NCT00393354|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
319810|NCT00284089|Drug|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
319811|NCT00284102|Procedure|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
319812|NCT00284115|Device|Gait trainer|Mechanical gait repetitive training
319813|NCT00284115|Device|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
319814|NCT00002773|Biological|sargramostim|
319815|NCT00284128|Drug|AVE7688|oral administration (capsules)
319816|NCT00284128|Drug|Losartan-potassium|oral administration (capsules)
319817|NCT00287677|Biological|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
319818|NCT00287677|Drug|HAART|HAART all over the trial
319819|NCT00287690|Drug|Genistein|Drink taken once daily
319820|NCT00287690|Drug|Placebo|Drink taken once daily
319821|NCT00287703|Device|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
319822|NCT00002784|Procedure|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
319823|NCT00287703|Device|Pulsating Electro-Magnetic Fields sham|sham PEMF
319824|NCT00287716|Drug|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
319825|NCT00287716|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
319826|NCT00287729|Drug|Pirfenidone|2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
319827|NCT00287729|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
319828|NCT00287742|Drug|risperidone|
319829|NCT00287755|Drug|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
319830|NCT00287768|Drug|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
319075|NCT00306345|Behavioral|Outreach|
319076|NCT00306358|Drug|Vitamin B12 (Cyanocobalamin)|
319077|NCT00306371|Device|1450nm diode laser|
319078|NCT00306384|Drug|Alogliptin|Alogliptin tablets.
319079|NCT00002831|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
319080|NCT00306397|Drug|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
319081|NCT00306410|Drug|colecalciferol|
319082|NCT00306423|Procedure|Other: Exercise|exercise 3 times per week for 12 weeks
319083|NCT00306436|Procedure|comprehensive management|
319084|NCT00306449|Behavioral|Small group seminar-based educational intervention|
319085|NCT00306462|Drug|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is < 6/hour.
319086|NCT00306462|Drug|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is < 6/hour.
319437|NCT00296816|Drug|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
319438|NCT00296816|Drug|Docetaxel (Taxotere®)|75 mg/m^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
319439|NCT00002804|Radiation|brachytherapy|
319440|NCT00296816|Drug|Oxaliplatin (Eloxatin®)|85 mg/m^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
319441|NCT00296829|Biological|Inactivated, split-virion influenza vaccine|
319442|NCT00296842|Behavioral|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
319443|NCT00296855|Drug|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
319444|NCT00296868|Drug|ascorbic acid (vitamin C) versus placebo|
318347|NCT00002740|Radiation|low-LET photon therapy|
318348|NCT00273793|Behavioral|Contingency Management|incentives are available for reduced smoking on each study visit which occur each weekday.
318701|NCT00263809|Device|Pathogen Reduction Technology|
318702|NCT00263822|Drug|erlotinib hydrochloride|
318703|NCT00263835|Behavioral|Empowerment|
318704|NCT00263861|Procedure|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
318705|NCT00002704|Drug|daunorubicin hydrochloride|
318706|NCT00263874|Drug|UK-500,001|
318707|NCT00263887|Drug|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
318708|NCT00263887|Drug|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
318709|NCT00263900|Device|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
318710|NCT00263926|Biological|wasp venom|
318711|NCT00263939|Behavioral|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
318712|NCT00263952|Biological|bee venom|
318713|NCT00263965|Drug|Tesaglitazar|
318714|NCT00263965|Drug|Metformin|
318715|NCT00263965|Behavioral|Dietary and lifestyle modification counseling|
318716|NCT00002704|Drug|dexamethasone|
318717|NCT00263978|Drug|Defibrotide|
318718|NCT00263991|Device|EEC-techniques|
318719|NCT00264004|Drug|AZD2171|30 mg & 45 mg oral tablet
318720|NCT00264030|Device|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
318721|NCT00264030|Other|PTCA|PTCA
317984|NCT00283179|Drug|Aripiprazole|
317985|NCT00283179|Drug|Risperidone|
317986|NCT00283192|Drug|Sertraline|
317987|NCT00002772|Drug|carmustine|
317988|NCT00283205|Behavioral|Yoga|
317989|NCT00283218|Drug|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
317990|NCT00283231|Behavioral|Paced Respiration|
317991|NCT00283244|Drug|erlotinib hydrochloride|given orally
317992|NCT00283244|Drug|gemcitabine hydrochloride|given IV
317993|NCT00283257|Behavioral|Patients and caregivers are taught problem solving skills|
317994|NCT00283270|Behavioral|Brief counselling|
317995|NCT00283270|Behavioral|Behavior|
317996|NCT00283283|Biological|Fluzone® (Aventis Pasteur inactivated influenza vaccine)|A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
317997|NCT00283296|Device|Endeavor|Collapsible, forward folding manual wheelchair
317998|NCT00002772|Drug|cisplatin|
317999|NCT00283309|Drug|Memantine|
318000|NCT00283309|Drug|Riluzole|
318001|NCT00283322|Other|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
318002|NCT00283335|Drug|gemfibrozil|
318349|NCT00273806|Behavioral|Intervention for 4 behavioral risks by medical assistants.|
318350|NCT00273819|Procedure|CT angiography|
318351|NCT00273832|Procedure|coronary artery computed tomography angiogram|
318352|NCT00273832|Procedure|single photon emission computed tomography|
318353|NCT00273845|Behavioral|Motivational interviewing|One session
317278|NCT00359125|Drug|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
317279|NCT00359125|Other|Placebo|Placebo, 600 mg/day for 1 week.
317280|NCT00359138|Drug|desloratadine|5 mg tablet once daily
317281|NCT00359138|Drug|levocetirizine|5 mg capsule once daily
317282|NCT00003058|Drug|troglitazone|
317283|NCT00359138|Drug|Desloratadine placebo tablet|once daily
317284|NCT00359138|Drug|Levocetirizine placebo capsule|once daily
317626|NCT00292968|Behavioral|Usual care|
317627|NCT00292981|Drug|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
317628|NCT00292994|Behavioral|Exercise|
317629|NCT00292994|Behavioral|Weight Loss|
317630|NCT00293020|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
317631|NCT00293033|Drug|BEMA™ Fentanyl|
317632|NCT00293046|Biological|ALK Grass tablet - use of compliance device|
317633|NCT00002798|Drug|asparaginase|
317634|NCT00293059|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
317635|NCT00293059|Drug|Placebo|Matching placebo to be taken orally daily.
317636|NCT00293072|Drug|Rituximab|
317637|NCT00293085|Drug|Docetaxel|
317638|NCT00293085|Drug|Docetaxel|Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.
Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.
Premedication:
Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.
All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.
Hyperhydration Patients will require intravenous hydration according to institutional guidelines.
317639|NCT00293098|Drug|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
322959|NCT00289016|Drug|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
322960|NCT00289029|Drug|Iopamidol 370 mgI/mL|
322961|NCT00289042|Drug|Enoxaparin|
322962|NCT00289055|Device|stent|Cordis SMART™ Nitinol Stent
322963|NCT00289055|Device|angioplasty|balloon angioplasty
322964|NCT00289068|Procedure|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
322965|NCT00289068|Procedure|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
322966|NCT00289068|Procedure|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
322967|NCT00289081|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
322968|NCT00002785|Drug|therapeutic hydrocortisone|
322969|NCT00289081|Device|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
322970|NCT00289094|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
322971|NCT00289094|Device|Total knee replacement|Fixed Cruciate Retaining Knee System
322972|NCT00289107|Device|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
322973|NCT00289107|Device|Total knee replacement|Fixed Cruciate Substituting Knee System
322974|NCT00289120|Drug|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
322975|NCT00289120|Drug|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
322976|NCT00289133|Other|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial bearing component
322977|NCT00291941|Biological|FENDRIX|20 µg,Months 0, 1, 2 and 6
322978|NCT00291954|Biological|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
317285|NCT00359151|Drug|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
304281|NCT00229021|Drug|doripenum|
304282|NCT00229060|Drug|doripenem|
304283|NCT00002600|Drug|carboplatin|
304284|NCT00229073|Drug|dapoxetine|
304285|NCT00229086|Device|Gatekeeper Reflux Repari System (Device)|
304286|NCT00229099|Drug|GerEPO|
304287|NCT00229112|Drug|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
304288|NCT00229112|Drug|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
304289|NCT00229125|Drug|Gabapentin|
304290|NCT00229125|Drug|Lorazepam|
304291|NCT00229138|Drug|EC-MPS, Tacrolimus|
304648|NCT00217776|Behavioral|Open Airways Educational Intervention|
304649|NCT00217776|Behavioral|Peer Asthma Action Educational Intervention|
304650|NCT00217789|Procedure|Bronchoalveolar Lavage and Venipuncture|
304651|NCT00217802|Behavioral|six-session telephone counseling program|
304652|NCT00217815|Drug|Mycograb, Docetaxel|
304653|NCT00217828|Drug|citalopram|
304654|NCT00217841|Drug|Aurograb|
304655|NCT00217854|Procedure|Bronchoscopic|Bronchoscopic procedure
304656|NCT00217867|Behavioral|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
304657|NCT00217880|Procedure|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
304658|NCT00002575|Procedure|laparoscopic surgery|
304659|NCT00217893|Behavioral|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
303910|NCT00240045|Drug|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
303911|NCT00240058|Procedure|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
303912|NCT00002634|Drug|etoposide|
303913|NCT00240071|Drug|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
303914|NCT00240071|Drug|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or SERM (tamoxifen 20mg/d PO)
303915|NCT00240084|Drug|nesiritide (Natrecor(TM))|administration of IV nesiritide
303916|NCT00240097|Drug|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
303917|NCT00240097|Drug|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
303918|NCT00240110|Drug|Valproate vs. Placebo|Valproate with dose titration to achieve blood levels within the therapeutic range wil be compared to placebo
303919|NCT00240123|Drug|Benadryl versus Placebo|
303920|NCT00240149|Drug|Regular Insulin via Insulin-Glucose Algorithm|
303921|NCT00243685|Other|Mick Assay|Chemotherapy doctor determined from results
303922|NCT00243698|Drug|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
303923|NCT00002643|Drug|etoposide|
303924|NCT00243711|Drug|Carboxymethylcellulose sodium and Glycerin|
303925|NCT00243724|Drug|Esomeprazole|
303926|NCT00243737|Drug|Artesunate-Mefloquine|
303927|NCT00243750|Drug|Methotrexate|
303928|NCT00243763|Drug|TKI258|
304292|NCT00229151|Behavioral|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
303195|NCT00403780|Drug|pregabalin|Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.
Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
303196|NCT00403780|Drug|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
303197|NCT00403793|Drug|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
303198|NCT00403793|Drug|Placebo|42 or 44 weeks with placebo implant and placebo injections
303199|NCT00403806|Drug|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
303200|NCT00406731|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
303201|NCT00406731|Device|Goldmann applanation tonometer|Intraocular pressure measurements
303202|NCT00406731|Device|HP-CMS patient monitor|blood pressure and pulse rate measurements
303535|NCT00250471|Procedure|Percutaneous Coronary Intervention (PCI)|
303536|NCT00250484|Device|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
303537|NCT00250484|Device|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
303538|NCT00002665|Drug|etoposide|60 mg/kg based on ideal body weight day -3
303539|NCT00253409|Procedure|conventional surgery|
303540|NCT00253409|Procedure|neoadjuvant therapy|
303541|NCT00253409|Radiation|radiation therapy|
303542|NCT00253422|Drug|anastrozole|
303543|NCT00253422|Drug|exemestane|
303544|NCT00253422|Drug|fulvestrant|
303545|NCT00253435|Biological|filgrastim|
303546|NCT00253435|Drug|carboplatin|
303547|NCT00002675|Drug|mesna|
303548|NCT00253435|Drug|etoposide|
302845|NCT00412893|Drug|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
302846|NCT00412906|Drug|Escherichia Coli Endotoxin|
302847|NCT00412919|Drug|Azacitidine|
302848|NCT00412932|Drug|Olmesartan medoxomil|Tablets
302849|NCT00003308|Radiation|stereotactic radiosurgery|
302850|NCT00412932|Drug|Olmesartan medoxomil/hydrochlorothiazide|Tablets
302851|NCT00412958|Drug|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
302852|NCT00412958|Drug|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
302853|NCT00003096|Genetic|fluorescence in situ hybridization|
302854|NCT00368459|Drug|raloxifene|Raloxifene is a selective estrogen receptor modulator
302855|NCT00368459|Drug|Placebo|Identical appearing placebo
302856|NCT00368472|Drug|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
302857|NCT00368485|Device|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
302858|NCT00368498|Drug|teicoplanin|
302859|NCT00368511|Procedure|Music Listening|Listen to music and posture measurements
302860|NCT00368524|Behavioral|contingency management and behavioral day treatment|
302861|NCT00368537|Drug|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
302862|NCT00368537|Drug|ampicillin-sulbactam|Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.
A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued.
303203|NCT00406731|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
303204|NCT00406744|Drug|Intravitreal injection of Bevacizumab|
302165|NCT00383331|Drug|Pemetrexed|A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles
B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles
302166|NCT00383331|Drug|Gemcitabine|A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles
B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles
302167|NCT00383344|Procedure|FDG PET/CT|
302168|NCT00383357|Drug|zolpidem|
302169|NCT00383370|Drug|VEGF Trap|VEGF Trap formulation 1, ITV-1
302170|NCT00383370|Biological|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
302171|NCT00383383|Biological|Hepatitis B adjuvanted vaccine|
302172|NCT00383383|Biological|Engerix-B|
302173|NCT00383396|Drug|Topical Cyclosporine|
302513|NCT00003124|Drug|flutamide|
302514|NCT00374660|Drug|Irofulven + oxaliplatin|Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. Starting dose 40 mg/m^2, dose escalation 50, 60, 70, and 80 mg/m^2 every 28 days if no dose-limiting toxicity.
Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered in a 30-minute infusion on Days 1 and 15 of a 28-day cycle. Starting dose 0.30 mg/kg, dose escalation to 0.40 mg/kg every 28 days if no dose-limiting toxicity.
302515|NCT00374673|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
302516|NCT00374686|Drug|Valganciclovir|
302517|NCT00374699|Drug|Velcade|
302518|NCT00374725|Behavioral|Administration of probiotic (L. rhamnosus and L. acidophilus)|
302519|NCT00003139|Drug|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
302520|NCT00377728|Drug|GSK256066|
302521|NCT00377741|Drug|valganciclovir [Valcyte]|900mg po
302522|NCT00377767|Behavioral|To change structure and roles of primary care teams to optimize prevention of obesity|
302523|NCT00377780|Drug|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
302524|NCT00377793|Drug|Levitra (Vardenafil, BAY38-9456)|
302525|NCT00377793|Drug|Placebo|
301781|NCT00389064|Drug|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
301782|NCT00389077|Drug|Perifosine Daily Dose|Daily Dose Perifosine
301783|NCT00389077|Drug|Perifosine|Weekly Dose
301784|NCT00389090|Drug|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
301785|NCT00003194|Biological|filgrastim|
301786|NCT00389103|Biological|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
301787|NCT00389116|Drug|gastrograffin|ingestion
301788|NCT00391612|Device|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
301789|NCT00391625|Drug|GA-GCB|15-60 U/kg every other week via intravenous infusion
301790|NCT00391638|Drug|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
301791|NCT00391638|Biological|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
301792|NCT00391651|Drug|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
301793|NCT00003203|Drug|vincristine sulfate|Given IV
301794|NCT00391651|Drug|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
301795|NCT00391664|Behavioral|Psychosocial|
301796|NCT00391677|Behavioral|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
301797|NCT00391677|Behavioral|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
301798|NCT00391690|Drug|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
302174|NCT00386035|Drug|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
302175|NCT00003178|Drug|idarubicin|
301098|NCT00405951|Drug|Obatoclax mesylate + Docetaxel|
301099|NCT00405964|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
301100|NCT00003270|Drug|cyclophosphamide|IV
301101|NCT00405964|Drug|Placebo tablet|Placebo tablet, once daily for 12 weeks
301102|NCT00405977|Drug|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
301103|NCT00408902|Drug|tandutinib|Given orally, 500 mg bid daily
301104|NCT00408902|Other|laboratory biomarker analysis|Correlative studies
301105|NCT00408915|Drug|Continuous Subcutaneous Lisuride Infusion|
301434|NCT00397150|Behavioral|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
301435|NCT00397163|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
301436|NCT00397163|Procedure|Placebo|Deflated cuff on upper arm and thigh for 20 min
301437|NCT00397176|Drug|desvenlafaxine succinate sustained release (DVS SR)|
301438|NCT00397189|Drug|Circadin|Prolonged release melatonin 2 mg
301439|NCT00400023|Drug|FT|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
301440|NCT00003240|Drug|mitomycin C|
301441|NCT00400036|Behavioral|Cod protein NCEP-diet|
301442|NCT00400075|Drug|azathioprine|
301443|NCT00400075|Drug|cyclophosphamide|
301444|NCT00400088|Drug|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
301445|NCT00400088|Drug|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
301446|NCT00400101|Biological|Virosome-formulated synthetic peptides (malaria vaccine)|
301447|NCT00400114|Drug|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
300748|NCT00367471|Drug|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
300749|NCT00367471|Drug|paclitaxel|A mitotic inhibitor used in cancer treatment
300750|NCT00367484|Biological|Rebif® (clone 484-39)|s.c. administered Rebif®
300751|NCT00367497|Drug|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
300752|NCT00003093|Biological|sargramostim|
300753|NCT00367536|Drug|bazedoxifene/conjugated estrogens combination tablet|
300754|NCT00367549|Dietary Supplement|Energy-containing soft drink|Commercial energy/sports drink
300755|NCT00367562|Drug|ENALAPRIL VALSARTAN METHYLPREDNISONE|
300756|NCT00367575|Procedure|Internet personalized alcohol feedback (PAF)|
300757|NCT00367588|Behavioral|Low bacterial diet|
300758|NCT00367601|Drug|Erlotinib|Erlotinib 150 mg qd days 1-21
300759|NCT00367601|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
300760|NCT00367614|Drug|pantoprazole|
300761|NCT00367627|Drug|Albendazole|
300762|NCT00370552|Drug|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
300763|NCT00370552|Drug|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
300764|NCT00370565|Drug|Inhaled Human Insulin|
300765|NCT00370578|Device|repeated thrombus aspiration during primary PCI|
300766|NCT00370591|Drug|Salmeterol/fluticasone propionate and fluticasone propionate|
301106|NCT00408928|Drug|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
300061|NCT00385138|Drug|Cangrelor|cangrelor bolus (30 mcg/kg) & cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
300062|NCT00385138|Drug|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
300063|NCT00385138|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
300064|NCT00385138|Drug|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
300065|NCT00385138|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
300066|NCT00385164|Procedure|PET/CT scan for RT planning|
300396|NCT00376909|Other|study of socioeconomic and demographic variables|
300397|NCT00003135|Procedure|hyperthermia treatment|
300398|NCT00376922|Procedure|music therapy|music played for patient during bone marrow biopsy collection
300399|NCT00376935|Drug|Palifermin|Keratinocyte growth factor administered via injection
300400|NCT00376935|Drug|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
300401|NCT00376948|Dietary Supplement|genistein|
300402|NCT00376948|Drug|erlotinib hydrochloride|
300403|NCT00376948|Drug|gemcitabine hydrochloride|
300404|NCT00376961|Biological|rituximab|375 mg/m^2 on day 1 for cycles 1-6.
300405|NCT00379561|Drug|PSA-Activated PSA-PAH1|
300406|NCT00379574|Drug|Bortezomib|Bortezomib:
For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.
For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks.
300407|NCT00379574|Drug|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
300408|NCT00000488|Behavioral|diet, fat-restricted|
300409|NCT00003146|Drug|busulfan|
300410|NCT00379574|Drug|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
320552|NCT00271206|Drug|sugar pill|Compared to progesterone
320553|NCT00271219|Drug|Methadone|daily oral dosing 20-140 mg
320554|NCT00271219|Drug|Buprenorphine|sl daily 2-32 mg
320555|NCT00271232|Device|Cardiac resynchronization therapy|
320556|NCT00271245|Dietary Supplement|200 µg selenium as selenate|200 µg selenium as selenate
320557|NCT00002733|Biological|recombinant interferon alfa|
320558|NCT00271245|Dietary Supplement|400 µg selenium as selenate|400 µg selenium as selenate
320559|NCT00271245|Dietary Supplement|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
320560|NCT00271245|Dietary Supplement|Placebo|Placebo
320561|NCT00271258|Drug|SODIUM DIVALPROATE|
320562|NCT00271271|Drug|oxaliplatine / gemcitabine / Vinorelbine|
320563|NCT00271284|Drug|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
320564|NCT00271284|Drug|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
320565|NCT00271297|Behavioral|Pelvic floor muscle training|
320566|NCT00271310|Drug|hypertonic saline|
320567|NCT00271323|Drug|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
320568|NCT00002733|Biological|therapeutic tumor infiltrating lymphocytes|
320947|NCT00261950|Drug|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
320948|NCT00261963|Device|ultraviolet light|
320949|NCT00261976|Drug|Infliximab (Remicade)|This is an non-interventional study. Participants took the study product as part of their medical routine.
319831|NCT00287768|Drug|S-1|S-1 po days 1-28 every 6 weeks
319832|NCT00287781|Drug|Lidocaine|
320206|NCT00281242|Other|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
320207|NCT00281255|Drug|Allopurinol|
320208|NCT00281255|Drug|Dobutamine|
320209|NCT00281268|Procedure|pulmonary artery catheter|
320210|NCT00281268|Procedure|central venous catheter|
320211|NCT00281268|Procedure|fluid management|
320212|NCT00281281|Drug|vancomycin|
320213|NCT00281294|Drug|Fontolizumab|
320214|NCT00281307|Drug|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
320215|NCT00281320|Drug|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
320216|NCT00002766|Drug|daunorubicin hydrochloride|
320217|NCT00281333|Behavioral|"Karate" exercises and strengthening exercises|
320218|NCT00281346|Procedure|Doppler echocardiography|Echocardiography
320219|NCT00281359|Device|With heat|heat pad followed by dynamic splinting
320220|NCT00281359|Device|No heat|No heat added to tissue prior to dynamic splinting
320221|NCT00281385|Behavioral|traditional vs. lifestyle exercise|
320222|NCT00281398|Behavioral|Questionnaire|
320223|NCT00281411|Procedure|Computed Tomography Angiography|Computed Tomography Angiography
320224|NCT00281411|Procedure|Magnetic Resonance Angiography|Magnetic Resonance Angiography
320225|NCT00281424|Behavioral|pedometer|
320226|NCT00281437|Behavioral|choice of exercise program|
320227|NCT00002766|Drug|doxorubicin hydrochloride|
319445|NCT00296881|Device|PERIOWAVE|
319446|NCT00296894|Drug|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
319447|NCT00296894|Drug|Placebo|Placebo
319448|NCT00296907|Behavioral|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
319449|NCT00296920|Device|Deep Brain Stimulation|
319450|NCT00002804|Radiation|low-LET cobalt-60 gamma ray therapy|
319451|NCT00296933|Drug|Escitalopram|
319452|NCT00296933|Drug|Bupropion XL|
319453|NCT00296946|Drug|ipratropium bromide (drug)|
319454|NCT00296959|Drug|topiramate (drug)|
319455|NCT00296972|Drug|peg interferon plus ribavirin|
319456|NCT00296985|Device|Fresenius Cellsaver|
319457|NCT00297011|Drug|valacyclovir+clobetasol gel|
319458|NCT00297024|Procedure|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
319459|NCT00297037|Drug|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
319460|NCT00297050|Drug|Peramivir|
319461|NCT00002804|Radiation|low-LET electron therapy|
319833|NCT00002784|Radiation|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
319834|NCT00287794|Drug|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
319835|NCT00287807|Behavioral|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
319836|NCT00287820|Drug|Olanzapine|olanzapine 5-40 mg/day
319837|NCT00287820|Drug|olanzapine|olanzapine 5-40 ,mg/day
318722|NCT00264043|Device|emboli capturing guidewire device combined with stent|AngioGuard™ device and Bx Velocity™ stent
318723|NCT00264056|Device|hyperthermia|
318724|NCT00264069|Drug|antipsychotic|as prescribed
318725|NCT00264069|Drug|antidepressants|as prescribed
319087|NCT00306475|Drug|divalproex sodium ER|divalproex sodium ER1000 mg
319088|NCT00306475|Drug|placebo|placebo identical in appearance to active comparator
319089|NCT00306488|Drug|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
319090|NCT00002831|Drug|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
319091|NCT00306501|Procedure|Swallowing Training|Swallowing Training with press of button
319092|NCT00306514|Biological|CYT004-MelQbG10|
319093|NCT00306527|Biological|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
319094|NCT00306527|Biological|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
319095|NCT00306540|Drug|Quetiapine Fumarate|oral flexible dose
319096|NCT00306540|Drug|quetiapine fumarate placebo|oral 0 mg
319097|NCT00306553|Biological|CYT004-MelQbG10|
319098|NCT00306566|Biological|CYT004-MelQbG10|
319099|NCT00309556|Drug|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
319100|NCT00309556|Drug|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
319101|NCT00309569|Drug|Cyclophosphamide|
319102|NCT00309569|Drug|Methotrexate|
319103|NCT00309569|Drug|Fluorouracil|
319104|NCT00309569|Drug|Epirubicine|
319105|NCT00002835|Drug|Vincristine Sulfate|
318354|NCT00273845|Behavioral|Strengths-Based Case Management|5 sessions
318355|NCT00273858|Other|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
318356|NCT00273871|Drug|Cyclosporin or tacrolimus|
318357|NCT00273884|Drug|Amonafide L-Malate|
318358|NCT00002742|Drug|amphotericin B deoxycholate|
318359|NCT00273884|Drug|Cytarabine|
318360|NCT00273897|Device|Phoresor II|
318361|NCT00273910|Drug|gp100:209-217 (210M)|
318362|NCT00273910|Drug|Montanide ISA-51|
318363|NCT00273910|Drug|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
318364|NCT00273936|Drug|AVN-944 capsules for oral administration|
318365|NCT00273949|Drug|lactulose|
318366|NCT00273962|Drug|ipratropium plus salbutamol UDV|
318367|NCT00273962|Drug|salbutamol UDV|
318368|NCT00273975|Drug|Nevirapine|
318369|NCT00276809|Drug|dexamethasone|
318370|NCT00276809|Drug|etoposide|
318371|NCT00276809|Drug|fludarabine phosphate|
318372|NCT00276809|Drug|melphalan|
318373|NCT00276809|Procedure|autologous bone marrow transplantation|
318374|NCT00276809|Procedure|peripheral blood stem cell transplantation|
318375|NCT00276809|Radiation|radiation therapy|
318726|NCT00267046|Drug|Placebo|Single dose 3 days prior to chemotherapy
318727|NCT00267046|Drug|Adriamycin (Doxorubicin)|30 mg/m^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m^2).
317640|NCT00293111|Drug|SDX-101 (R-Etodolac)|
317641|NCT00293124|Drug|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
317642|NCT00293150|Drug|eplerinone|
317643|NCT00293163|Device|Hylaform, Hylaform Plus (hylan B gel)|
317644|NCT00002798|Drug|daunorubicin hydrochloride|
317645|NCT00293176|Drug|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
317646|NCT00293176|Drug|Placebo|Subjects will receive matching placebo tablets.
318003|NCT00283335|Other|Placebo|Matching placebo tablets taken once per day
318004|NCT00283361|Drug|ZP120|
318005|NCT00283361|Procedure|I.v. catherization|
318006|NCT00283361|Procedure|6-minutes walk performance|
318007|NCT00283361|Behavioral|Dyspnea severity assessment|
318008|NCT00283361|Procedure|Blood sampling for laboratory tests|
318009|NCT00002772|Drug|cyclophosphamide|
318010|NCT00283361|Procedure|ECG|
318011|NCT00283361|Procedure|Physical examination|
318012|NCT00283374|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
318013|NCT00286728|Behavioral|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
318014|NCT00286741|Other|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
318015|NCT00286754|Behavioral|SMI|Stage-matched intervention
318016|NCT00286754|Behavioral|HEI|Health Education Intervention
318017|NCT00286754|Behavioral|UC|Usual Care
318018|NCT00286754|Behavioral|SMI|Stage-matched intervention
317286|NCT00359151|Drug|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
317287|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds [light dose of 25 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an "as needed" basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
317288|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an "as needed" basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
317289|NCT00359164|Drug|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an "as needed" basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
317290|NCT00359177|Drug|GW679769|
317291|NCT00359190|Drug|lapatinib|
317292|NCT00359203|Device|Dual chamber pacemeker|
317293|NCT00003060|Biological|filgrastim|
317294|NCT00359216|Drug|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
317295|NCT00359216|Drug|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
317296|NCT00359229|Drug|Zolpidem|Administration of Zolpidem 5mg
317297|NCT00359242|Behavioral|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
317298|NCT00359242|Behavioral|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
317299|NCT00362219|Drug|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
317300|NCT00362219|Drug|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
317301|NCT00003072|Drug|paclitaxel|
317302|NCT00362232|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
317303|NCT00362232|Drug|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
304660|NCT00217893|Behavioral|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
304661|NCT00217893|Behavioral|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
304662|NCT00217893|Behavioral|Usual education program|Participants will receive the usual education about ETS.
304663|NCT00217906|Behavioral|A+ Asthma early intervention program|
304664|NCT00221507|Behavioral|Reminder-Recall-Outreach|
304665|NCT00221507|Behavioral|Case Management|
304666|NCT00221507|Behavioral|Patient Navigator|
304667|NCT00221520|Drug|midazolam with 2 different levels of sedation scores|
304668|NCT00221546|Drug|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
304669|NCT00221559|Procedure|Blood sampling for determination of serum Zn|
304670|NCT00221572|Procedure|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
304671|NCT00221585|Behavioral|Psychosocial treatment/Psychodynamic treatment|
305024|NCT00206778|Drug|Lamotrigine|
305025|NCT00206778|Drug|Sodium Valproate|
305026|NCT00206791|Device|MBCP-Gel (tm)|
305027|NCT00206817|Device|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
305028|NCT00002552|Drug|carmustine|
305029|NCT00206830|Device|Triage Profiler S.O.B. Panel|
305030|NCT00206843|Device|Triage BNP Test|
305031|NCT00206856|Device|Triage® B-Type Natriuretic Peptide (BNP) Test|
305032|NCT00206869|Behavioral|exercise|
305033|NCT00210158|Procedure|Nitrous oxyde|
305034|NCT00210171|Procedure|Toxicity : Time to progression, 1 and 2 years survival|
304293|NCT00229151|Other|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
304294|NCT00002600|Drug|cyclophosphamide|
304295|NCT00229164|Device|Transcutaneous Electric Nerve Stimulation (TENS)|
304296|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
304297|NCT00232882|Drug|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
304298|NCT00232882|Drug|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
304299|NCT00232882|Drug|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
304300|NCT00002615|Drug|fluorouracil|
304301|NCT00232895|Drug|lipuro propofol|
304302|NCT00232895|Drug|standard formulation propofol|
304303|NCT00232908|Drug|ARV regimen|As prescribed
304304|NCT00232908|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
304305|NCT00232921|Drug|caudal volume 1|
304306|NCT00232921|Biological|caudal volume 2|
304307|NCT00232921|Drug|caudal volume 3|
304308|NCT00232934|Drug|Thalidomide|
304309|NCT00232947|Biological|Influenza virus vaccine (Fluviral)|
304310|NCT00232947|Biological|Influenza virus vaccine (Fluzone)|
304311|NCT00002615|Procedure|conventional surgery|
304312|NCT00232960|Procedure|Radiotherapy 50 Gy|
304313|NCT00232973|Drug|ICXP007|
304314|NCT00232999|Drug|Nebulized IVX-0142|
304315|NCT00233012|Drug|Topiramate|
304316|NCT00233025|Drug|Duloxetine|
303549|NCT00253435|Drug|melphalan|
303550|NCT00253435|Procedure|autologous bone marrow transplantation|
303551|NCT00253435|Procedure|peripheral blood stem cell transplantation|
303552|NCT00253435|Radiation|iobenguane I 131|
303553|NCT00253435|Radiation|radiation therapy|
303554|NCT00253448|Radiation|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
303555|NCT00253448|Radiation|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
303556|NCT00253461|Procedure|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
303557|NCT00253461|Procedure|positron emission tomography|Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.
Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan.
303558|NCT00002675|Drug|vincristine sulfate|
303559|NCT00253461|Radiation|11C topotecan|Phase I and II: IV over 10 minutes
303560|NCT00253461|Radiation|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
303929|NCT00243789|Drug|Pentoxifylline|Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.
Based on weight at screening, <30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day.
303930|NCT00243815|Drug|ibuprofen|
303931|NCT00243828|Device|Total Face Mask|
303932|NCT00243841|Radiation|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
303933|NCT00243854|Drug|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
303934|NCT00002643|Drug|ifosfamide|
303935|NCT00243867|Drug|Taxoprexin|
303936|NCT00243880|Drug|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
303205|NCT00406757|Drug|Nelarabine injection 400mg/m2|Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.
Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.
303206|NCT00406757|Drug|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
303207|NCT00406757|Drug|Nelarabine injection 1000mg/m2|Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.
Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
303208|NCT00406757|Drug|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
303209|NCT00003273|Drug|etoposide|
303210|NCT00406770|Device|Light therapy|
303211|NCT00406783|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
303212|NCT00406783|Drug|Placebo|Placebo tablet, once daily for 15 days
303213|NCT00406796|Drug|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
303214|NCT00406809|Drug|ABT-263|Oral solution
Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.
- 55 subjects with relapsed or refractory lymphoid malignancies. Enrollment is closed in Phase 1 of the study.
Oral solution and tablets
Phase 2a dosing under 21 day continuous dosing.
150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.
26 subjects in two arms: Arm A and Arm B. Enrollment is closed in Phase 2a of the study.
Oral tablets
Extension portion of the study is to allow Phase 2a subjects who remain active 1 year after the last subject enrolls or who have been on study approximately 1 year to continue receiving ABT-263 under 21 day continuous dosing.
303215|NCT00406822|Device|OculusGen Biodegradable Collagen Matrix Implant|
303216|NCT00406835|Procedure|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
303217|NCT00406848|Drug|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
303218|NCT00406848|Drug|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
303219|NCT00406861|Drug|montelukast in treatment of ENL reaction|
303220|NCT00003273|Drug|leucovorin calcium|
303221|NCT00406874|Drug|omega 3 fats|1,000 mg daily
302526|NCT00377806|Drug|Diclofenac gel|
302527|NCT00377819|Drug|alendronate|70 mg oral QW
302528|NCT00377819|Drug|Denosumab (AMG 162)|60 mg SC q 6 mos
302529|NCT00377832|Drug|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
302530|NCT00003139|Other|Placebo|
302531|NCT00377845|Procedure|Regular Tampax used in 3 hours|
302532|NCT00377858|Drug|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
302533|NCT00377858|Drug|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
302534|NCT00377871|Device|biological heart valve prosthesis|Two heart valve designs
302535|NCT00377897|Procedure|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
302536|NCT00377910|Drug|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
302863|NCT00368550|Drug|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
302864|NCT00003097|Other|preventative dietary intervention|
302865|NCT00368550|Drug|Placebo|Placebo for 14-week treatment period
302866|NCT00368563|Drug|Helioblock SX|
302867|NCT00368576|Drug|SB 480848, tablets|
302868|NCT00368589|Drug|atorvastatin|
302869|NCT00368602|Drug|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
302870|NCT00368602|Other|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
302871|NCT00368628|Procedure|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
302872|NCT00368641|Drug|Extraneal|Periotneal Dialysis
302873|NCT00368654|Drug|Methotrexate|Initial dose 5 mg, then 15 mg per week
302874|NCT00368654|Drug|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
302176|NCT00386035|Drug|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
302177|NCT00386048|Behavioral|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
302178|NCT00386061|Drug|rimonabant (SR141716)|
302179|NCT00386074|Drug|NaFeEDTA, Electrolytic Iron|
302180|NCT00386087|Drug|Enzastaurin Hydrochloride|
302181|NCT00386100|Drug|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
302182|NCT00386100|Drug|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
302183|NCT00386100|Drug|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
302184|NCT00386100|Drug|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
302185|NCT00386100|Drug|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
302186|NCT00003179|Drug|medroxyprogesterone|
302187|NCT00386100|Drug|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
302188|NCT00386100|Drug|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
302189|NCT00386100|Drug|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
302190|NCT00386113|Biological|Fluarix and adjuvanted influenza vaccine|
302191|NCT00386126|Drug|Iron Sucrose IV 200mg, once a week, for 5 weeks|
302192|NCT00386126|Drug|Ferrous sulfate 200mg PO TID, for 8 weeks|
302193|NCT00386139|Drug|Aliskiren/HCTZ|
301448|NCT00400114|Drug|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
301449|NCT00400114|Procedure|Radiation|Radiation 50 Gy (weeks 4-9)
301450|NCT00400114|Procedure|Surgery|Esophagectomy
301451|NCT00003240|Drug|vinblastine sulfate|
301452|NCT00400114|Drug|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
301453|NCT00400127|Device|Silesian suspension belt|
301454|NCT00400140|Device|Hyperopic lens|+3 D glasses
301455|NCT00400153|Drug|Atrovent Respimat (20 mcg)|
301456|NCT00400153|Drug|COMBIVENT MDI (36/206 mcg)|
301457|NCT00400153|Drug|Combivent Respimat (20 mcg/100 mcg)|
301458|NCT00400153|Drug|Placebo via corresponding inhaler for blinding purposes|
301799|NCT00391703|Behavioral|Electrostimulation programme: using a cycloergometer|Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
301800|NCT00391703|Behavioral|Usual sport activity|Usual sport activity performed prior to an endurance retraining program using a cycloergometer
301801|NCT00391716|Drug|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
301802|NCT00391716|Behavioral|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
301803|NCT00391716|Drug|placebo|lactose capsule compounded to mimic gabapentin capsules
301804|NCT00003203|Procedure|adjuvant therapy|
301805|NCT00391716|Drug|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
301806|NCT00391729|Drug|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
301807|NCT00391729|Drug|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
301808|NCT00391742|Behavioral|Brief intervention|
301809|NCT00391755|Drug|ramelteon|ramelteon 8mg po qhs with sleep and headache diary
placebo 1 po qhs with sleep and headache diary
301107|NCT00408941|Drug|Propofol|
301108|NCT00408941|Drug|Prilocaine|
301109|NCT00408954|Drug|UK-369,003|100 mg MR tablet once daily for 2 weeks
301110|NCT00408954|Drug|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
301111|NCT00003284|Drug|carboplatin|
301112|NCT00408967|Drug|Tucotuzumab celmoleukin (EMD 273066)|
301113|NCT00408980|Behavioral|Fat and calorie controlled diet|
301114|NCT00408993|Drug|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
301115|NCT00408993|Drug|Placebo|Placebo every day (QD), by mouth (PO)
301116|NCT00409006|Drug|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
301117|NCT00409006|Drug|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
301118|NCT00409006|Drug|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
301119|NCT00409019|Drug|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
301120|NCT00409019|Drug|Adefovir|
301121|NCT00409019|Drug|Tenofovir|
301122|NCT00003284|Drug|etoposide|
301123|NCT00409032|Drug|Strontium malonate|
301124|NCT00409058|Behavioral|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
301125|NCT00409071|Drug|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
300411|NCT00379574|Drug|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
300412|NCT00379574|Drug|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
300413|NCT00379574|Drug|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
300414|NCT00379587|Drug|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
300415|NCT00379587|Drug|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
300416|NCT00379600|Drug|rosiglitazone XR|
300417|NCT00379613|Drug|sugammadex|After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)
At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered
300418|NCT00379613|Drug|Placebo|After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)
At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered
300419|NCT00379626|Drug|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
300767|NCT00370604|Device|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
300768|NCT00003107|Biological|recombinant interleukin-12|
300769|NCT00370604|Device|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
300770|NCT00370617|Drug|metformin|
300771|NCT00370630|Drug|Avastin (Bevacizumab) and triamcinolone|
300772|NCT00370643|Drug|human regular insulin|
300773|NCT00370656|Drug|Pregabalin|capsule, 150mg bd, 300mg bd
300774|NCT00370656|Drug|Duloxetine|Capsule, 60mg on, 60mg bd
300775|NCT00370656|Drug|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
300776|NCT00370669|Drug|bevacizumab|
300777|NCT00370669|Drug|triamcinolone acetonide|
300778|NCT00370682|Biological|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
320950|NCT00262002|Biological|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
320951|NCT00262002|Biological|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
320952|NCT00262002|Biological|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
320953|NCT00262002|Biological|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
320954|NCT00000416|Other|Rehabilitation counseling|Provided in 2 in-person meetings and in follow-up phone calls
320955|NCT00002700|Procedure|allogeneic bone marrow transplantation|
320956|NCT00262002|Biological|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
320957|NCT00262002|Biological|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
320958|NCT00264823|Behavioral|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
320959|NCT00264849|Drug|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
320960|NCT00264849|Other|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
320961|NCT00264862|Procedure|DynaCT|
320962|NCT00264875|Drug|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
320963|NCT00264888|Drug|PTC124|
320964|NCT00264901|Drug|insulin detemir|
320965|NCT00264914|Drug|SR121463B|
321325|NCT00304135|Drug|cisplatin|
321326|NCT00002832|Drug|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
320228|NCT00281450|Behavioral|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
320569|NCT00271323|Radiation|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
320570|NCT00271336|Drug|Pentoxifylline|
320571|NCT00271349|Drug|Budesonide|
320572|NCT00271362|Behavioral|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
320573|NCT00271362|Procedure|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
320574|NCT00271375|Behavioral|Caring For You, Caring For Me|5-week Education and Support Program for Caregivers of older adults.
320575|NCT00274846|Drug|cyclophosphamide|Days -5 and -4: 60 mg/kg
320576|NCT00274846|Drug|fludarabine phosphate|Days -5 through -2: 25 mg/m^2
320577|NCT00274846|Procedure|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
320578|NCT00274859|Drug|gemcitabine hydrochloride|
320579|NCT00274859|Drug|oxaliplatin|
320580|NCT00274872|Drug|fluorouracil|
320581|NCT00274872|Drug|leucovorin calcium|
320582|NCT00274872|Drug|oxaliplatin|
320583|NCT00274885|Drug|oxaliplatin|
320584|NCT00274885|Procedure|management of therapy complications|
320585|NCT00002744|Drug|thioguanine|
320586|NCT00274898|Drug|celecoxib|
320587|NCT00274898|Drug|docetaxel|
320588|NCT00274898|Procedure|adjuvant therapy|
320589|NCT00274898|Radiation|radiation therapy|
319838|NCT00287820|Drug|risperidone|risperidone 1-12 mg/day
319839|NCT00287833|Other|placebo|Given orally
319840|NCT00287833|Drug|Bowman-Birk inhibitor concentrate|Given orally
319841|NCT00287846|Drug|imatinib mesylate|
319842|NCT00287859|Drug|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
319843|NCT00287872|Drug|bortezomib|
319844|NCT00290537|Drug|Paclitaxel|200 mg/m2 IV Over 3 Hours On Day 1
319845|NCT00290550|Drug|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
319846|NCT00290563|Drug|MK0594|
319847|NCT00002789|Procedure|allogeneic bone marrow transplantation|
319848|NCT00290576|Dietary Supplement|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
319849|NCT00290589|Drug|intramuscular methylprednisolone acetate|
319850|NCT00290602|Drug|Methylprednisolone sodium succinate|
319851|NCT00290615|Biological|bevacizumab|
319852|NCT00290615|Biological|cetuximab|
319853|NCT00290615|Drug|capecitabine|
319854|NCT00290615|Drug|oxaliplatin|
319855|NCT00290628|Drug|anti-thymocyte globulin|
319856|NCT00290628|Drug|busulfan|
319857|NCT00290628|Drug|cyclophosphamide|
320229|NCT00284141|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.
Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
320230|NCT00284154|Drug|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
320231|NCT00284167|Behavioral|tailored web-based weight management intervention|
319106|NCT00309595|Device|stent|Cordis SMART™ Nitinol Stent System
319107|NCT00309595|Device|balloon|balloon angioplasty
319108|NCT00309608|Drug|Linagliptin|Linagliptin medium dose tablet once daily
319109|NCT00309608|Drug|Linagliptin|Linagliptin high dose tablet once daily
319110|NCT00309608|Drug|Linagliptin|Linagliptin low dose tablet once daily
319111|NCT00309608|Drug|Placebo|Placebo tablets once daily
319112|NCT00309608|Drug|Glimepiride|Glimepiride tablets once daily
319462|NCT00297063|Drug|Rosiglitazone|
319463|NCT00300443|Drug|bimatoprost|
319464|NCT00300456|Drug|ABT-335|135 mg, daily, 12 weeks
319465|NCT00300456|Drug|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
319466|NCT00300456|Drug|Placebo|Daily, 12 weeks, see Arm Description for placebo information
319467|NCT00300469|Drug|ABT-335|135 mg, daily, 12 weeks
319468|NCT00300469|Drug|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
319469|NCT00300469|Drug|Placebo|daily, 12 weeks, see Arm Description for placebo information
319470|NCT00300482|Drug|ABT-335|135 mg, daily, 12 weeks
319471|NCT00300482|Drug|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
319472|NCT00002812|Drug|dexamethasone|Given IV
319473|NCT00300482|Drug|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
319474|NCT00300495|Drug|Amiodarone|Perioperative orally administered
319475|NCT00300495|Drug|Amiodarone|Perioperative oral amiodarone
319476|NCT00300495|Other|Control arm, standard care|Control
319477|NCT00300508|Drug|Anastrozole|
319478|NCT00300521|Genetic|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
318728|NCT00267046|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m^2); for patients receiving the AI Regimen.
318729|NCT00002715|Biological|bleomycin sulfate|
318730|NCT00267046|Drug|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
318731|NCT00267046|Drug|Cisplatin|120 mg/m^2 on day 0, for patients receiving the AP Regimen.
318732|NCT00267059|Drug|Lenalidomide|10 mg/day, orally once a day for 28 days
318733|NCT00267085|Biological|Synthetic Tumor-Specific Breakpoint Peptide Vaccine|CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
318734|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
318735|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
318736|NCT00267111|Drug|Eucerin plus|1g, single application
318737|NCT00267111|Drug|Amethocaine gel 4%|1 g, single application
318738|NCT00267137|Device|Pacing Algorithms|
318739|NCT00267150|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
318740|NCT00002715|Drug|Stanford V regimen|
318741|NCT00267163|Drug|donepezil|
318742|NCT00267163|Drug|Placebo|
318743|NCT00267176|Drug|lumiracoxib|
318744|NCT00267189|Drug|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
318745|NCT00267189|Drug|Calcineurin inhibitors (CNI)|
318746|NCT00267189|Drug|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
318747|NCT00267189|Drug|Steroids|
318748|NCT00267202|Drug|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
318749|NCT00267202|Drug|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
318019|NCT00286754|Behavioral|HEI|Health Education Intervention
318020|NCT00286754|Behavioral|UC|Usual Care
318021|NCT00286780|Drug|AT-101|80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
318022|NCT00286793|Drug|AT-101|Oral
318023|NCT00002783|Procedure|conventional surgery|
318024|NCT00286806|Drug|AT-101|
318025|NCT00286819|Drug|the FEC75 and 95 regimen|Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.
Arm B: the FEC90 regimen will be given at the following doses:
Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.
All three drugs will be administered intravenously on Day 1 of each 14-day cycles.
Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.
Six cycles of adjuvant chemotherapy will be administered in both arms (A + B
318026|NCT00286832|Procedure|PET scan|One extra PET scan after 1 cycle of treatment.
318376|NCT00276822|Other|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
318377|NCT00002755|Radiation|low-LET electron therapy|
318378|NCT00276835|Biological|High-dose interleukin-2|Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
318379|NCT00276835|Dietary Supplement|genistein|Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
318380|NCT00276848|Drug|cyclophosphamide|
318381|NCT00276848|Drug|fludarabine phosphate|
318382|NCT00276861|Drug|gemcitabine hydrochloride|
318383|NCT00276861|Drug|oxaliplatin|
318384|NCT00276874|Drug|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
318385|NCT00276887|Behavioral|Cognitive Behavior Therapy|
318386|NCT00276887|Behavioral|Psychiatric Consultation Letter|
318387|NCT00276900|Drug|Sertraline|
318388|NCT00002755|Radiation|low-LET photon therapy|
317647|NCT00296062|Drug|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
317648|NCT00296062|Drug|oxaliplatin|Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Phase II: oxaliplatin (during even-numbered courses) as in phase I
317649|NCT00296101|Behavioral|Physical Activity|
317650|NCT00296114|Procedure|Serum and DNA Samples|To collect serum and DNA samples from subjects
317651|NCT00296127|Drug|Celecoxib|
317652|NCT00296140|Behavioral|self management of PSD symptoms|
317653|NCT00002803|Drug|cyclophosphamide|
317654|NCT00296140|Procedure|screening and treatment of PSD|
317655|NCT00296153|Drug|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
317656|NCT00296166|Procedure|Catheter ablation|
317657|NCT00296166|Procedure|Thoracoscopic epicardial ablation|
317658|NCT00296179|Drug|zolpidem tartrate|
317659|NCT00296192|Drug|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
317660|NCT00296192|Other|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
317661|NCT00296205|Drug|Cyclophosphamide|
317662|NCT00296218|Drug|Irbesartan|
317663|NCT00296231|Other|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
317664|NCT00002803|Drug|doxorubicin hydrochloride|
317665|NCT00296244|Drug|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
317666|NCT00296244|Drug|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
305035|NCT00210184|Drug|Irinotecan associated to fluorouracil and leucovorin|
305036|NCT00210197|Procedure|Blood collection (pre and postoperative): plasma coagulation parameters|
305037|NCT00210210|Drug|Ketamine|
305038|NCT00210223|Procedure|Radiofrequency|
305039|NCT00210236|Procedure|Conventional surgery|
305040|NCT00210262|Behavioral|Feedback and Education|
305041|NCT00210275|Behavioral|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
305042|NCT00210288|Biological|SC599|
305043|NCT00002558|Drug|etoposide|
305044|NCT00210301|Drug|Provigil (modafinil)|
305045|NCT00210314|Drug|high dose methotrexate|
305046|NCT00210314|Drug|high dose cytarabine|
305047|NCT00210314|Radiation|radiotherapy|
305048|NCT00210327|Drug|Bortezomib (drug)|
305049|NCT00210340|Drug|intrathecal rituximab|
305050|NCT00210353|Drug|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
299489|NCT00373022|Other|flow cytometry|
299490|NCT00373022|Other|laboratory biomarker analysis|
299491|NCT00373022|Procedure|management of therapy complications|
299492|NCT00373022|Procedure|psychosocial assessment and care|
299493|NCT00373022|Procedure|quality-of-life assessment|
299494|NCT00373035|Genetic|proteomic profiling|
299495|NCT00373035|Other|immunological diagnostic method|
299496|NCT00373035|Other|laboratory biomarker analysis|
304317|NCT00233025|Drug|Placebo|
304318|NCT00233038|Procedure|Ethanol injection into a cyst|
304672|NCT00221598|Procedure|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
304673|NCT00221611|Drug|Administration of intrathecal baclofen|
304674|NCT00002582|Drug|methotrexate|
304675|NCT00221624|Drug|Peginterferon alfa-2a|
304676|NCT00221624|Drug|ribavirin|
304677|NCT00221624|Drug|amantadine|
304678|NCT00221637|Drug|Sodium Valproate|
304679|NCT00221650|Drug|Peginterferon alfa2a|
304680|NCT00221650|Drug|Ribavirin|
304681|NCT00221663|Device|surgery techniques (sternotomy for aortic valve replacement)|
304682|NCT00221676|Biological|Alfarix|
304683|NCT00221689|Drug|baclofen (drug)|
304684|NCT00221702|Drug|PegIntron|100 mcg SC/week for 36 months
304685|NCT00000389|Drug|Fluvoxamine|
304686|NCT00002582|Drug|tamoxifen citrate|
304687|NCT00221702|Drug|intron A|3mui TIWW SC for 18 months
304688|NCT00221715|Device|femoropopliteal artery bypass|Bypass by autologous saphenous vein
304689|NCT00221715|Device|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
304690|NCT00221728|Device|Radiofrequency|
304691|NCT00221728|Procedure|conservative surgery|
304692|NCT00221741|Drug|Fresh Frozen Plasma (blood product)|
304693|NCT00221754|Drug|Pravastatin (drug)|
304694|NCT00221767|Device|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
303937|NCT00243893|Drug|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
303938|NCT00243893|Drug|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
303939|NCT00243906|Drug|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
303940|NCT00243906|Procedure|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS >/= 10) treated within 3 hours of symptoms onset.
303941|NCT00243919|Behavioral|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
303942|NCT00243919|Behavioral|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
303943|NCT00243919|Behavioral|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
303944|NCT00243932|Drug|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
303945|NCT00246636|Drug|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
303946|NCT00246636|Drug|Antara (fenofibrate)|Antara (fenofibrate) + placebo
303947|NCT00246649|Procedure|Ex vivo expansion of mafosfamide purged marrow or mobilized stem cells with growth factors (rhSCF and rhTPO)|
304319|NCT00233051|Drug|Salmeterol or Salmeterol/Fluticasone|
304320|NCT00233064|Biological|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
304321|NCT00233064|Biological|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
304322|NCT00002616|Biological|aldesleukin|
304323|NCT00233077|Behavioral|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer & its treatment, experience with & access to health care system, trust, depression, social support & self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
303561|NCT00253474|Biological|PEG-interferon alfa-2a|
303562|NCT00253487|Drug|O6-benzylguanine|
303563|NCT00253487|Drug|busulfan|
303564|NCT00253487|Drug|temozolomide|
303565|NCT00253487|Procedure|adjuvant therapy|
303566|NCT00253487|Procedure|autologous bone marrow transplantation|
303567|NCT00253487|Procedure|conventional surgery|
303568|NCT00253487|Procedure|peripheral blood stem cell transplantation|
303569|NCT00002676|Drug|carmustine|
303570|NCT00253487|Radiation|radiation therapy|
303571|NCT00253500|Biological|pegfilgrastim|6 mg in a syringe
303572|NCT00256308|Procedure|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
303573|NCT00256321|Drug|Oxaliplatin|
303574|NCT00256321|Drug|Capecitabine|
303575|NCT00256321|Drug|Celecoxib|
303576|NCT00256334|Drug|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
303577|NCT00002687|Biological|aldesleukin|
303578|NCT00256347|Drug|intramuscular injections of morphine|
303579|NCT00256360|Drug|dose dense with neulasta|
303580|NCT00256373|Procedure|Mod. functional restoration-Individ. dynamic back-muscle|
303581|NCT00256386|Device|Electronic Medical Record (EMR) to clinician's in-basket|
303582|NCT00256386|Device|Automated Voice Message (AVM) reminder to patient's phone|
303583|NCT00256386|Procedure|Pharmacy Team phone call-letter followup|
302875|NCT00003098|Other|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
302876|NCT00368680|Device|Early Bubble CPAP|
302877|NCT00371540|Other|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
302878|NCT00371553|Drug|SU011248 (Sunitinib)|
302879|NCT00371566|Drug|Lapatinib oral tablets|
302880|NCT00371566|Drug|Placebo|
302881|NCT00371579|Drug|rosuvastatin|
302882|NCT00371592|Drug|Acyclovir|800 mg tablet taken orally twice daily
302883|NCT00371592|Drug|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
302884|NCT00371618|Procedure|Fluoroscopy|
302885|NCT00371631|Biological|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
303222|NCT00406874|Drug|folic acid|800 micrograms daily
303223|NCT00409721|Drug|Memantine|
303224|NCT00409747|Drug|Minocycline|
303225|NCT00409760|Drug|valsartan+amlodipine combination, valsartan, amlodipine|
303226|NCT00409773|Drug|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
303227|NCT00003288|Biological|filgrastim|
303228|NCT00409773|Drug|Comparator: atorvastatin calcium|Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.
Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
303229|NCT00409773|Drug|Comparator: Placebo (unspecified)|Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.
ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.
Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
302537|NCT00377923|Drug|Progesterone|
302538|NCT00377936|Drug|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
302539|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
302540|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
302541|NCT00003140|Drug|letrozole|Given orally
302542|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
302543|NCT00377962|Drug|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
302544|NCT00377962|Drug|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
302545|NCT00377962|Drug|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
302546|NCT00377962|Drug|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
302547|NCT00377975|Drug|Ephedrine|
302548|NCT00380679|Biological|Pneumococcal polysaccharide vaccination|
302549|NCT00380692|Drug|Atomoxetine|
302550|NCT00380692|Drug|Placebo|
302551|NCT00380705|Drug|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
302552|NCT00380718|Drug|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.
*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets <50 x 10^9/L; absolute neutrophil count <1.0 x 10^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade >2; Skin Grade >2; Serum bilirubin >3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase >10 x ULN; Other non-hematologic toxicities Grade >2 (except nausea, vomiting).
302553|NCT00380731|Behavioral|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
302554|NCT00380744|Drug|LY2189102|
302555|NCT00380744|Drug|placebo|
302556|NCT00380757|Procedure|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
301810|NCT00394108|Procedure|Determination of neuropsychological status|
301811|NCT00394121|Drug|Fluticasone propionate/formoterol fumarate|
301812|NCT00394134|Behavioral|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
301813|NCT00394147|Drug|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
301814|NCT00394147|Drug|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
301815|NCT00394160|Drug|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
301816|NCT00003214|Drug|cisplatin|
301817|NCT00394173|Drug|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
301818|NCT00394173|Drug|Placebo|Matching placebo
301819|NCT00394186|Drug|GW427353|
301820|NCT00394186|Drug|Placebo|
301821|NCT00394199|Drug|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
302194|NCT00386152|Drug|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
302195|NCT00386152|Drug|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
302196|NCT00386165|Drug|AT-1001|
302197|NCT00389116|Drug|water|oral water ingestion
302198|NCT00389129|Drug|acetylsalicylic acid|
302199|NCT00389155|Drug|Vinflunine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
302200|NCT00389155|Drug|Gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
302201|NCT00389155|Other|Placebo|
302202|NCT00389168|Drug|Irbesartan|Titrated to 300 mg od, 48 weeks.
302203|NCT00389168|Drug|Atenolol|Titrated to 100 mg od, 48 weeks.
301126|NCT00409071|Drug|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
301459|NCT00400166|Behavioral|Recovery Mentor|Provided Recovery Mentor services
301460|NCT00400179|Drug|S-1/Cisplatin|In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
301461|NCT00400179|Drug|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
301462|NCT00003240|Drug|vindesine|
301463|NCT00400205|Drug|Taxotere|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
301464|NCT00400205|Drug|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
301465|NCT00400205|Drug|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
301466|NCT00402883|Procedure|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
301467|NCT00402883|Other|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
301468|NCT00402883|Other|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
301469|NCT00003260|Drug|irinotecan hydrochloride|
301470|NCT00402883|Drug|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
301471|NCT00402896|Drug|ZD6474|300 mg/day orally for 10 weeks.
301472|NCT00402909|Drug|Nateglinide|
301473|NCT00402935|Other|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
301474|NCT00402935|Procedure|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
301475|NCT00402935|Procedure|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
300779|NCT00003108|Drug|bryostatin 1|
300780|NCT00370682|Biological|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
300781|NCT00370682|Other|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
300782|NCT00370695|Device|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
300783|NCT00370708|Procedure|Oral Intake following admittance to the postpartum ward|
300784|NCT00370721|Drug|bevacizumab|
300785|NCT00370734|Drug|Botulinum toxin A injection|
300786|NCT00373503|Drug|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
300787|NCT00373503|Drug|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
300788|NCT00003119|Biological|filgrastim|
300789|NCT00373503|Drug|Marijuana|marijuana intoxication, withdrawal and relapse assessed
300790|NCT00373516|Drug|Vehicle (Placebo) applied BID|
301127|NCT00409084|Procedure|endoscopic variceal band ligation|endoscopic variceal band ligation
301128|NCT00411879|Drug|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin [20 IU IV maximum dose = 100 IU] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
301129|NCT00411879|Drug|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
301130|NCT00411892|Drug|pioglitazone|Tablets, 45 mg/day.
301131|NCT00411892|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
301132|NCT00411905|Drug|Bortezomib|
301133|NCT00411931|Drug|Multihance|0.5M administered as a single injection
301134|NCT00411957|Drug|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
301135|NCT00411970|Device|20- and 23 gauge vitreoretinal surgery systems|
321327|NCT00307437|Drug|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
321328|NCT00307437|Drug|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
321329|NCT00307450|Drug|Levetiracetam|up to 200 mg per day in two dosages per day.
321330|NCT00307463|Procedure|strict volume control policy|strict volume control by UF and dietary salt restriction
321331|NCT00307463|Procedure|antihypertensive drugs administration|continue antihypertensive medications
321332|NCT00307476|Device|Rusch Nasopharyngeal Airway|
321333|NCT00307489|Drug|tenofovir DF|300 mg tablet, once daily (QD)
321334|NCT00307489|Drug|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
321335|NCT00307502|Drug|Nevirapine|tablets 200 mg, 400 mg/day
321336|NCT00307502|Drug|Efavirenz|tablets 600 mg, 600 mg/day
321337|NCT00002832|Drug|Decitabine|IV for 6 hours every 12 hr for 5 days.
321338|NCT00307502|Drug|Indinavir/ritonavir|Indinavir: capsules 400 mg, 1600 mg/day
Ritonavir: capsules 100 mg, 200 mg/day
321339|NCT00307502|Drug|Nelfinavir|tablets 250 mg, 2500 mg/day
321340|NCT00307502|Drug|Saquinavir/ritonavir|Saquinavir: tablets 500 mg, 2000 mg/day
Ritonavir: tablets 100 mg, 200 mg/day
321341|NCT00307502|Drug|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
321342|NCT00307502|Drug|Atazanavir|capsules 200 mg, 400 mg/day
321343|NCT00307502|Drug|Atazanavir/ritonavir|Atazanavir: capsules 150 mg, 300 mg/day
Ritonavir: capsules 100 mg, 200 mg/day
321344|NCT00307502|Drug|Fos-amprenavir/ritonavir|Fos-amprenavir: capsules 700 mg, 1400 mg/day
Ritonavir: capsules 100 mg, 200 mg/day
321345|NCT00307502|Drug|Tipranavir/ ritonavir|Tipranavir: tablets 250 mg, 1000 mg/day
Ritonavir: capsules 100 mg, 400 mg/day
321346|NCT00307502|Drug|Darunavir/ritonavir|Darunavir: tablets 300 mg, 1200 mg/day
Ritonavir: capsules 100 mg, 200 mg/day
321704|NCT00297973|Procedure|Blood samples|
320590|NCT00274911|Drug|cisplatin|
320591|NCT00274911|Drug|lomustine|
320592|NCT00274911|Drug|vincristine sulfate|
320593|NCT00274911|Procedure|adjuvant therapy|
320594|NCT00274911|Radiation|radiation therapy|
320595|NCT00274924|Biological|filgrastim|Given subcutaneously or intravenous bolus.
320966|NCT00264927|Drug|SR121463B|
320967|NCT00002704|Radiation|low-LET photon therapy|
320968|NCT00264953|Drug|Adriamycin|
320969|NCT00264953|Drug|Bleomycin|
320970|NCT00264953|Drug|Vinblastine|
320971|NCT00264953|Drug|DTIC|
320972|NCT00264953|Drug|Etoposide|
320973|NCT00264953|Drug|Procarbazine|
320974|NCT00264953|Drug|Prednisone|
320975|NCT00264953|Drug|Vincristine|
320976|NCT00264953|Radiation|radiation therapy|20 or 30Gy IF-RT
320977|NCT00264966|Drug|ASM8|
320978|NCT00002705|Drug|topotecan hydrochloride|
320979|NCT00264979|Procedure|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
320980|NCT00264979|Procedure|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
320981|NCT00265005|Drug|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
320982|NCT00265018|Drug|Adriamycin|
320983|NCT00265018|Drug|Bleomycin|
320984|NCT00265018|Drug|Vinblastine|
320232|NCT00284180|Drug|Vinflunine|Novel second generation vinca alkaloid
320233|NCT00284180|Drug|Trastuzumab|Anti-HER2 monoclonal antibody
320234|NCT00284193|Drug|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
320235|NCT00284193|Drug|FEIBA- Activated Prothrombin Complexes|
320236|NCT00284206|Drug|long-acting injectable risperidone|
320237|NCT00002773|Drug|cyclophosphamide|
320238|NCT00284219|Device|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
320239|NCT00284219|Device|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
320240|NCT00284232|Behavioral|Use and interpretation of blood glucose results|
320241|NCT00284232|Drug|Insulin dosing based on SMBG chart and education|
320242|NCT00284258|Drug|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
320243|NCT00284258|Drug|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
320244|NCT00284271|Drug|Cyclophosphamide|
320245|NCT00284271|Drug|Adramycin|
320246|NCT00284271|Drug|Procarbacine|
320247|NCT00284271|Drug|Prednisone|
320248|NCT00000436|Behavioral|Self-efficacy and muscle strength training|
320596|NCT00002744|Drug|vincristine sulfate|
320597|NCT00274924|Biological|rituximab|Given IV
320598|NCT00274924|Drug|carboplatin|Given IV
320599|NCT00274924|Drug|cyclophosphamide|Given IV
319479|NCT00300534|Device|Abbott Laboratories Determine test for syphilis|
319480|NCT00300534|Device|Investigational syphilis immunochromatographic strip test|
319481|NCT00300547|Procedure|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
319482|NCT00300560|Drug|Colistin|
319483|NCT00002812|Drug|doxorubicin hydrochloride|Given IV
319484|NCT00300573|Drug|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
319485|NCT00300586|Drug|observation|observation, second line chemotherapy if progression
319486|NCT00300586|Drug|gemcitabine|1250 mg/m² D1, D8 q21 days
319487|NCT00300586|Drug|erlotinib|150 mg daily
319858|NCT00002789|Procedure|peripheral blood stem cell transplantation|
319859|NCT00290628|Drug|cyclosporine|
319860|NCT00290628|Drug|filgrastim|
319861|NCT00290628|Drug|melphalan|
319862|NCT00290628|Drug|methylprednisolone|
319863|NCT00290628|Drug|mycophenolate mofetil|
319864|NCT00290628|Procedure|radiation therapy|
319865|NCT00290628|Procedure|umbilical cord blood transplantation|
319866|NCT00290641|Biological|filgrastim|
319867|NCT00290641|Biological|graft-versus-tumor induction therapy|
319868|NCT00290641|Drug|cyclophosphamide|
319869|NCT00002790|Drug|cyclosporine|
319870|NCT00290641|Drug|cyclosporine|
319871|NCT00290641|Drug|fludarabine phosphate|
319872|NCT00290641|Drug|mycophenolate mofetil|
319873|NCT00290641|Procedure|umbilical cord blood transplantation|
319113|NCT00309621|Drug|alitretinoin|
319114|NCT00309634|Biological|4 adjuvanted pandemic influenza candidate vaccines|
319115|NCT00309634|Biological|4 non-adjuvanted pandemic influenza candidate vaccines|
319116|NCT00002835|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
319117|NCT00309647|Biological|4 adjuvanted pandemic influenza candidate vaccines|
319118|NCT00309647|Biological|4 non-adjuvanted pandemic influenza candidate vaccines|
319119|NCT00309660|Drug|Rosiglitazone|
319120|NCT00309673|Drug|lidocaine / Prilocaine|
319121|NCT00309686|Drug|Paliperidone ER|
319122|NCT00309699|Drug|Placebo|Daily for 3 weeks
319123|NCT00309699|Drug|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
319124|NCT00309699|Drug|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
319125|NCT00309712|Drug|fenofibrate 160 mg and placebo|
319126|NCT00309712|Drug|simvastatin 20 mg and placebo|
319127|NCT00002835|Radiation|Radiation Therapy|
319128|NCT00309712|Drug|fenofibrate 160 mg and simvastatin 20 mg|
319129|NCT00309725|Drug|galantamine|
319130|NCT00309738|Drug|pitavastatin|
319131|NCT00309738|Drug|simvastatin|
319132|NCT00260754|Behavioral|Community-Popular Opinion Leader Model|
319133|NCT00260754|Behavioral|Diffusion of Innovations|
319134|NCT00260767|Drug|HEC placebo gel|
319135|NCT00260780|Behavioral|The MISTERS Intervention for Post Jail Release Men|
319136|NCT00260793|Drug|Ropinirole Hydrochloride|
318389|NCT00276913|Drug|STA-5312|
318390|NCT00276926|Drug|STI571|
318391|NCT00276939|Behavioral|Low-fat, low-Glycemic Index, vegan diet|
318392|NCT00276952|Drug|Gonyautoxin|
318393|NCT00276965|Drug|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
318394|NCT00276965|Drug|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
318395|NCT00276978|Drug|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
318396|NCT00280384|Drug|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
318397|NCT00280397|Drug|E7080|E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
318398|NCT00280410|Drug|E7337|
318750|NCT00267202|Drug|Immunotherapy|Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or "maintenance" solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.
318751|NCT00002715|Drug|doxorubicin hydrochloride|
318752|NCT00270322|Drug|Morphine sulphate|
318753|NCT00270335|Drug|Propofol|
318754|NCT00002722|Drug|fluorouracil|
318755|NCT00270348|Drug|ciclesonide|
318756|NCT00270361|Drug|nesiritide|
318757|NCT00270361|Drug|usual long term cardiac medications|
318758|NCT00270361|Drug|nesiritide|
318759|NCT00270374|Drug|nesiritide|
317667|NCT00296244|Drug|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
318027|NCT00286845|Drug|Standard Chemotherapy|physician determined
318028|NCT00286858|Device|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
318029|NCT00286871|Drug|Neoral|
318030|NCT00286871|Drug|Tacrolimus|
318031|NCT00286884|Procedure|Monitoring of heart rate variability|
318032|NCT00286897|Drug|E2007|
318033|NCT00286923|Drug|Topiramate|
318034|NCT00002784|Biological|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
318035|NCT00286936|Drug|Zolpidem|
318036|NCT00286949|Drug|Atomoxetine (Strattera)|
318037|NCT00286962|Device|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
318038|NCT00286962|Device|continuous subcutaneous insulin infusion (CSII) or MDI|
318039|NCT00286975|Behavioral|Leadership development program educational intervention|
318040|NCT00286988|Drug|Topiramate|
318041|NCT00287001|Device|Cold air cooling|
318042|NCT00289939|Behavioral|Motivational interviewing to reduce risk for HIV and DV|
318043|NCT00289952|Drug|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
318044|NCT00289952|Drug|HAART|As per standard of care.
318045|NCT00002788|Biological|filgrastim|
318046|NCT00289965|Behavioral|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
299497|NCT00003116|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
299498|NCT00373035|Other|mass spectrometry|
299499|NCT00373035|Procedure|biopsy|
299500|NCT00373035|Procedure|ultrasound imaging|
299501|NCT00373048|Drug|mefloquine|tablet, once weekly
299502|NCT00373048|Drug|placebo|tablet, once weekly
299503|NCT00373074|Other|Epidural Blood Patch|Use 15 cc of blood
299504|NCT00373074|Other|Epidural Blood Patch|Inject 20 cc of blood into epidural space
299505|NCT00373074|Other|Epidural Blood Patch|Inject 30 cc of autologous blood
299506|NCT00373087|Drug|entacapone|entacapone
299507|NCT00373087|Drug|l dopa versus placebo|l dopa versus placebo
299508|NCT00003117|Drug|carboplatin|
299509|NCT00373100|Drug|Zinc acetate|
299510|NCT00373100|Drug|Placebo|Placebo
299511|NCT00373113|Drug|Capecitabine|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
299512|NCT00373113|Drug|Sunitinib malate|37.5 mg daily, continuous dosing
299513|NCT00373126|Drug|transdermal nicotine patch|
299514|NCT00373152|Procedure|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
299515|NCT00376506|Device|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
299877|NCT00411450|Biological|Panitumumab|Administered by intravenous infusion
299878|NCT00411450|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
299879|NCT00411463|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.
Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms.
304695|NCT00221780|Device|left ventricular pacing|
304696|NCT00221793|Procedure|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
304697|NCT00002594|Drug|cyclophosphamide|Given IV
304698|NCT00225173|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
305051|NCT00210353|Drug|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
305052|NCT00210353|Drug|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
305053|NCT00210366|Drug|Idarubicin|
305054|NCT00002558|Drug|ifosfamide|
305055|NCT00210379|Drug|rituximab|
305056|NCT00210379|Drug|CHOP|
305057|NCT00210379|Drug|intrathecal methotrexate|
305058|NCT00210379|Procedure|radiotherapy|
305059|NCT00210392|Drug|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
305060|NCT00210405|Dietary Supplement|"Sprinkles" containing mulitple micronutrients|
305061|NCT00210405|Behavioral|Education/communication on use of micronutrient sprinkles|
305062|NCT00210405|Dietary Supplement|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
305063|NCT00214578|Drug|Seroquel (quetiapine)|
305064|NCT00214591|Drug|GALIDA|
305065|NCT00214604|Drug|Rosuvastatin|10mg
305066|NCT00214604|Drug|rosuvastatin|20mg
305067|NCT00214604|Drug|pravastatin|40mg
305068|NCT00002566|Drug|vinblastine sulfate|
305069|NCT00214617|Drug|Rosuvastatin at 5 mg/day and 40 mg/day|
304324|NCT00233077|Behavioral|Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
304325|NCT00233090|Drug|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
304326|NCT00236652|Drug|levofloxacin|
304327|NCT00236665|Drug|topiramate|
304328|NCT00236678|Drug|Epoetin alfa|
304329|NCT00236691|Drug|topiramate|
304330|NCT00236704|Drug|topiramate|
304331|NCT00236717|Drug|Topiramate; Carbamazepine; Valproate|
304332|NCT00236730|Drug|topiramate|
304333|NCT00236743|Drug|topiramate|
304334|NCT00002625|Radiation|low-LET electron therapy|
304335|NCT00236756|Drug|topiramate|
304336|NCT00236769|Drug|norelgestromin + ethinyl estradiol|
304337|NCT00236782|Drug|norelgestromin + ethinyl estradiol; mercilon|
304338|NCT00236795|Drug|norelgestromin + ethinyl estradiol; triphasil.|
304339|NCT00236808|Drug|levofloxacin|
304340|NCT00236821|Drug|levofloxacin|
304341|NCT00236834|Drug|levofloxacin; imipenem/cilastitin|
304342|NCT00236847|Drug|topiramate|
304699|NCT00225173|Drug|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
304700|NCT00225173|Drug|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
304701|NCT00225186|Drug|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
304702|NCT00225199|Drug|Visanne (BAY86-5258, SH T00660AA)|orally once daily
304703|NCT00225199|Drug|Placebo|orally once daily
303584|NCT00256399|Drug|Alfuzosin 10 mg|
303585|NCT00256412|Drug|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
303586|NCT00256412|Drug|Placebo|4 capsules of placebo each day
303948|NCT00246662|Drug|SNS-595 Injection|All patients receive SNS-595 Injection
303949|NCT00246675|Drug|Frusemide|
303950|NCT00002657|Biological|bleomycin sulfate|5 mg/m^2
303951|NCT00246688|Drug|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
303952|NCT00246701|Drug|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
303953|NCT00246701|Drug|Simvastatin|Simvastatin
303954|NCT00246714|Drug|repeated injections of endotoxin during 5 days|
303955|NCT00246727|Drug|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
303956|NCT00246740|Drug|Periostat|In addition to standard care, patients will receive oral administration of 20 mg of doxycycline or placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
303957|NCT00246753|Drug|lapatinib ditosylate|1500 mg, daily until disease progression
303958|NCT00246779|Procedure|Modified ultrafiltration|
303959|NCT00246792|Behavioral|Group treatment|
303960|NCT00246805|Device|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
303961|NCT00002657|Biological|recombinant interferon alfa|3.0 x 10^6 IU/m^2
303962|NCT00246818|Procedure|Tai Chi Chuan|
303963|NCT00246883|Procedure|Exercise|
303964|NCT00246896|Behavioral|care management|
303965|NCT00246909|Drug|Pantoprazole|
303230|NCT00409786|Behavioral|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
303231|NCT00409799|Drug|I-0401 (a new bone graft substitute)|1 time application
303232|NCT00409825|Drug|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
303233|NCT00409825|Procedure|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
303234|NCT00409838|Drug|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg <60 kg); (750 mg 60-100 kg); (1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
303235|NCT00409838|Drug|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
303236|NCT00409838|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
303237|NCT00409838|Drug|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
303238|NCT00003288|Drug|cyclophosphamide|
303239|NCT00409838|Drug|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
303240|NCT00409851|Drug|valsartan+amlodipine|
303241|NCT00409864|Procedure|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
303242|NCT00409890|Drug|Hyoscine Butyl Bromide|
303587|NCT00256425|Behavioral|Cognitive rehabilitation|
303588|NCT00002688|Drug|cyclosporine|
303589|NCT00256438|Device|Transcranial Direct Current Stimulation|
303590|NCT00256451|Drug|Naltrexone|50 mg/day for two days prior to the alcohol challenge session
303591|NCT00256451|Drug|placebo|placebo pills
303592|NCT00256451|Other|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice.
303593|NCT00256451|Other|placebo alcohol|non-alcoholic placebo alcohol
303594|NCT00256464|Behavioral|Multi-component Yoga Intervention|
302557|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
302886|NCT00003111|Radiation|radiation therapy|
302887|NCT00371644|Behavioral|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
302888|NCT00371644|Behavioral|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
302889|NCT00371670|Drug|balicatib (AAE581)|
302890|NCT00371683|Drug|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
302891|NCT00371683|Drug|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
302892|NCT00371696|Drug|diclofenac|
302893|NCT00371696|Drug|paracetamol|
302894|NCT00371696|Device|heat retaining knee support|
302895|NCT00371696|Device|standard knee support|
302896|NCT00371709|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
302897|NCT00003113|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
302898|NCT00371709|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
302899|NCT00371722|Procedure|Appendectomy|
302900|NCT00371735|Drug|chlorproguanil-dapsone-artesunate|
302901|NCT00371735|Drug|chlorproguanil-dapsone|
302902|NCT00371748|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
302903|NCT00371748|Device|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
302904|NCT00374738|Behavioral|Guided Imagery for Trauma (GIFT)|
302204|NCT00389181|Procedure|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
302205|NCT00003194|Drug|carboplatin|
302206|NCT00389181|Other|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
302207|NCT00389194|Drug|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
302208|NCT00389207|Drug|nevirapine bid|nevirapine twice daily
302209|NCT00389207|Drug|nevirapine qd|nevirapine once daily
302210|NCT00389207|Drug|atazanavir|atazanavir once daily
302211|NCT00389220|Device|Coronary stent placement|Coronary stent placement
302212|NCT00389233|Drug|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/"P" + 2 x Vitamin C/"C") sachets for the 2L of 2 sachets (1 x "P" plus 1 x "C") will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid.
302213|NCT00389233|Drug|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/"P/E". Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour.
302214|NCT00389246|Behavioral|Consultation without genetic information|
302215|NCT00389246|Behavioral|Consultation with genetic information|
302558|NCT00003150|Drug|vincristine sulfate|
302559|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
302560|NCT00380783|Drug|AGN 203818|
302561|NCT00380796|Drug|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
302562|NCT00380809|Procedure|Rotational Atherectomy + PES|
302563|NCT00380809|Procedure|Standard Treatment (PES without Rotational Atherectomy)|
302564|NCT00380822|Drug|miglitol|
301476|NCT00402935|Procedure|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
301477|NCT00402948|Drug|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
301478|NCT00402948|Drug|ASM8|inhalation 0.25mg daily for 14 days
301822|NCT00394199|Drug|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
301823|NCT00394199|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
301824|NCT00394212|Device|Transoral Suturing|suturing of anastomosis
301825|NCT00394212|Other|Sham Endoscopy|suturing not performed
301826|NCT00394225|Drug|Oxygen|
301827|NCT00003214|Drug|cyclophosphamide|
301828|NCT00394225|Drug|Helium|
301829|NCT00394238|Procedure|Ultrasonographic imaging|
301830|NCT00394251|Drug|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m^2 intravenous, plus Cytoxan 600 mg/m^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
301831|NCT00394251|Drug|ABI-007|260 mg/m^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
301832|NCT00394251|Drug|Taxol|175 mg/m^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
301833|NCT00394251|Drug|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
301834|NCT00394251|Drug|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
301835|NCT00394264|Procedure|Soft Tissue|
301836|NCT00394264|Procedure|Myofascial release|
301837|NCT00394264|Procedure|Counterstrain|
301838|NCT00003222|Biological|tetanus peptide melanoma vaccine|
301839|NCT00397189|Drug|placebo circadin|placebo circadin tablets
301136|NCT00411996|Drug|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
301137|NCT00003299|Drug|etoposide|
301138|NCT00412009|Procedure|Comprehensive package of activities|
301139|NCT00412022|Drug|tamoxifen|20 mg daily for 5 years
301140|NCT00412022|Drug|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
301141|NCT00412022|Drug|letrozole|2.5 mg daily for 5 years
301142|NCT00412022|Drug|zoledronic acid|4 mg every 6 months
301143|NCT00412035|Drug|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
301144|NCT00412035|Drug|saline injection|10 units per kilo to maximum of 400 units
301145|NCT00412048|Procedure|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
301146|NCT00412061|Drug|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
301147|NCT00412061|Drug|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
301148|NCT00003299|Drug|paclitaxel|
301149|NCT00412061|Drug|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
301150|NCT00412074|Drug|vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given to her infant
301479|NCT00402961|Other|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
301480|NCT00003260|Drug|leucovorin calcium|
301481|NCT00402961|Other|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
301482|NCT00402974|Drug|menaquinone 7|
321705|NCT00297986|Device|Helmet|Evaluation of different interfaces for NPPV
321706|NCT00298012|Drug|Methotrexate|
321707|NCT00298025|Drug|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is >=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
321708|NCT00002805|Procedure|peripheral blood stem cell transplantation|
321709|NCT00298025|Drug|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is >=14 mm until r-hCG day.
321710|NCT00298025|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
321711|NCT00298025|Drug|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
321712|NCT00298025|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
321713|NCT00298038|Drug|Rifaximin|550 mg tablets BID
321714|NCT00298051|Procedure|Delayed umbilical cord clamping|
321715|NCT00298064|Genetic|Tissue Repository|
321716|NCT00298090|Device|StO2 monitoring|placement of the StO2 device/ external noninvasive
321717|NCT00301483|Other|Standard of Care|Standard Therapy
321718|NCT00301496|Device|Coban 2 Layer Compression System|
321719|NCT00301509|Drug|peginterferon and ribavirin|
321720|NCT00301522|Device|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
321721|NCT00301522|Device|Express2|Coronary Stent System
321722|NCT00002814|Biological|filgrastim|
321723|NCT00301535|Drug|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
320985|NCT00265018|Drug|DTIC|
320986|NCT00265018|Radiation|30 Gy IF-RT|
320987|NCT00265018|Radiation|20 Gy IF-RT|
320988|NCT00268359|Drug|irinotecan hydrochloride|
320989|NCT00002716|Procedure|laparotomy|
320990|NCT00268372|Drug|cisplatin|
320991|NCT00268372|Drug|docetaxel|
320992|NCT00268372|Drug|5-fluorouracil|
320993|NCT00268372|Procedure|surgery|
320994|NCT00268372|Radiation|radiation therapy|
321347|NCT00307515|Drug|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
321348|NCT00002832|Procedure|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
321349|NCT00307515|Device|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
321350|NCT00307528|Biological|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
321351|NCT00307528|Biological|Pneumovax 23™|Single dose intramuscular injection.
321352|NCT00310284|Behavioral|Computerized delivery of cognitive-behavioral treatment of insomnia|
321353|NCT00310284|Behavioral|Self-help manual to improve insomnia symptoms|
321354|NCT00310297|Drug|Insulin Glulisine|
321355|NCT00310310|Behavioral|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
321356|NCT00310310|Behavioral|Usual care|Usual sleep apnea and cpap care
321357|NCT00310323|Drug|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
321358|NCT00002837|Procedure|Peripheral Blood Stem Cell Transplantation|
321359|NCT00310323|Drug|Caffeine|Administered as 4 ounces of Coca-Cola
321360|NCT00310336|Drug|S-adenosyl-L-methionine|
320600|NCT00274924|Drug|doxorubicin hydrochloride|Given IV
320601|NCT00274924|Drug|etoposide|Given IV
320602|NCT00274924|Drug|ifosfamide|Given IV
320603|NCT00274924|Drug|prednisone|Taken orally
320604|NCT00274924|Drug|vincristine|Given IV
320605|NCT00274937|Drug|amifostine trihydrate|Given subcutaneously
320606|NCT00274937|Drug|fluorouracil|Given IV
320607|NCT00002744|Radiation|low-LET cobalt-60 gamma ray therapy|
320608|NCT00274937|Drug|cisplatin|Given IV
320609|NCT00274937|Other|laboratory biomarker analysis|Correlative studies
320610|NCT00278044|Procedure|blood sampling and medical records|
320611|NCT00278057|Drug|dialysisis with and without glucose in the dialysis|
320612|NCT00278070|Drug|vinorelbine oral formulation|Patients will take three times a week [Monday, Wednesday and Friday] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
320613|NCT00278083|Drug|Study drug administration|
320614|NCT00278083|Procedure|Tuberculin intradermal skin test|
320615|NCT00278083|Procedure|Lung function test for FEV1|
320616|NCT00278083|Procedure|Asthma symptom scores diary|
320617|NCT00278083|Procedure|Quality of life diary|
320618|NCT00278083|Procedure|Breath nitric oxide|
320619|NCT00002756|Drug|therapeutic hydrocortisone|
320620|NCT00278083|Procedure|Breath condensate|
320621|NCT00278083|Procedure|Sputum induction|
320622|NCT00278083|Procedure|Blood sampling|
320623|NCT00278083|Procedure|Urinalysis|
319874|NCT00290641|Radiation|radiation therapy|
319875|NCT00290654|Drug|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
319876|NCT00290654|Procedure|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
319877|NCT00293904|Biological|CYT005-AllQbG10|
319878|NCT00293917|Drug|Tacrolimus Cream|
319879|NCT00002798|Drug|methotrexate|Given IT
319880|NCT00293930|Drug|Tacrolimus|
319881|NCT00293943|Procedure|Pulmonary vein ablation|
319882|NCT00293969|Drug|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
319883|NCT00293982|Behavioral|Physician knowledge of parental expectations for the visit|
319884|NCT00293995|Procedure|Laparaoscopic repair, with closure of contralateral patent processus vaginalis|
319885|NCT00293995|Procedure|open repair|
320249|NCT00002774|Drug|Tirapazamine|Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.
Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.
Tirapazamine dose was as follows:
Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)
Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)
Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)
320250|NCT00284271|Drug|Vincristine|
320251|NCT00284271|Drug|Bleomycin|
320252|NCT00002784|Radiation|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
320253|NCT00287872|Drug|thalidomide|
320254|NCT00287885|Drug|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m^2/day up to dose level 6 of 6.4 mg/m^2/day
320255|NCT00287898|Genetic|mutation analysis|Blood specimen will be analyzed for gene mutations
320256|NCT00287898|Other|counseling intervention|subjects will receive genetic counseling
319137|NCT00260819|Drug|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
319138|NCT00260819|Drug|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
319139|NCT00002700|Drug|cytarabine|
319488|NCT00300599|Device|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
319489|NCT00300599|Other|Placebo|Placebo
319490|NCT00300612|Biological|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
319491|NCT00300625|Procedure|Application of the San Francisco Syncope Rule|
319492|NCT00303485|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
319493|NCT00303498|Drug|Sitaxsentan sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
319494|NCT00303498|Drug|Placebo|placebo identical to the study drug in description, dose and duration
319495|NCT00303524|Drug|Goserelin acetate|Injection 3.6 mg monthly
319496|NCT00303524|Drug|Goserelin acetate|injection 10.8 mg every 3 months
319497|NCT00303537|Drug|metformin|
319498|NCT00303550|Drug|Intravenous iclaprim|
319499|NCT00303550|Drug|Intravenous linezolid|
319500|NCT00002822|Drug|cisplatin|
319501|NCT00303563|Drug|P38 Inhibitor (4)|50mg po qd
319502|NCT00303563|Drug|P38 Inhibitor (4)|150mg po qd
319503|NCT00303563|Drug|P38 Inhibitor (4)|300mg po qd
319504|NCT00303563|Drug|Placebo|po qd
319505|NCT00303576|Drug|dapivirine (TMC120) vaginal gel|
318760|NCT00270387|Drug|Natrecor (nesiritide)|
318761|NCT00270400|Drug|nesiritide|
318762|NCT00270413|Drug|SU11248|sutent 50 mg daily 4w on 2w off
318763|NCT00270426|Drug|Benazepril|
318764|NCT00270439|Procedure|removal of omentum|patients with type 2 diabetes had their omentum removed
318765|NCT00002722|Drug|leucovorin calcium|
318766|NCT00270452|Drug|WT1 and PR1 Peptide Vaccine|
318767|NCT00270465|Drug|VRC-HIVDNA016-00-VP|
318768|NCT00270465|Drug|VRC-HIVADV014-00-VP|
318769|NCT00270478|Drug|Erythropoietin and Hydroxyurea|
318770|NCT00270491|Drug|Paclitaxel|
318771|NCT00270491|Drug|Capecitabine|
318772|NCT00270504|Device|Memokath stenting|Urethral Stenting
318773|NCT00270517|Drug|EDP-420 / Duration of Treatment – 3 days|
318774|NCT00270517|Drug|Telithromycin / Duration of Treatment – 7 days|
318775|NCT00270530|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
319140|NCT00260832|Drug|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one invervention.)
319141|NCT00260832|Drug|Dacogen (decitabine) only|20mg/m^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
319142|NCT00260858|Drug|Test Meal: Reference food (glucose or white bread)|
319143|NCT00260858|Drug|Test Meal: Pirate's Booty|
319144|NCT00260858|Drug|Test Meal: Ceaprove wafer|
319145|NCT00260858|Drug|Test Meal: Stretch Island Strawberry Fruit Leather|
319146|NCT00260884|Behavioral|conventional gastrectomy or radical lymph node dissection|
318047|NCT00289965|Behavioral|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
318048|NCT00289965|Behavioral|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
318049|NCT00289978|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
318399|NCT00280423|Drug|GW679769|
318400|NCT00280436|Drug|GW679769|
318401|NCT00280449|Behavioral|strengths-based case managed proactive service model|
318402|NCT00280462|Drug|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
318403|NCT00002764|Biological|filgrastim|
318404|NCT00280462|Drug|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
318405|NCT00280462|Drug|Placebo|Placebo
318406|NCT00280475|Device|Whole brain radiation therapy arm|Whole brain radiation therapy arm
318407|NCT00280475|Device|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
318408|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
318409|NCT00280488|Behavioral|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
318410|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
318411|NCT00280501|Drug|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
318412|NCT00280501|Drug|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
318413|NCT00280501|Drug|Placebo|Placebo
318414|NCT00002764|Drug|doxorubicin hydrochloride|
318415|NCT00280514|Drug|cefpirome and moxifloxacin administration|
299880|NCT00366964|Device|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
299881|NCT00366964|Device|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
299882|NCT00366977|Behavioral|Multi-session telephone counseling|
299883|NCT00003089|Radiation|radiation therapy|
299884|NCT00366977|Drug|NRT patches|
299885|NCT00366990|Behavioral|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics with a focus on lowering sodium intake.
299886|NCT00366990|Behavioral|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics.
299887|NCT00367003|Device|Deep Brain Stimulator, implantable|Deep Brain Stimulator
299888|NCT00367016|Drug|Xolair (Omalizumab)|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
299889|NCT00367016|Drug|Placebo|Placebo
299890|NCT00367029|Behavioral|Individualized Print-Based Motivational Program|Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.
Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff.
299891|NCT00367042|Device|Scalpel for tissue scoring|During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
299892|NCT00367042|Device|Surgical marker for tissue marking|You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
299893|NCT00367055|Drug|rosiglitazone-metformin|
299894|NCT00003090|Biological|aldesleukin|
299895|NCT00367055|Drug|Metformin|
300238|NCT00405548|Drug|Placebo|
300239|NCT00405561|Drug|AMT2003|
300240|NCT00405574|Drug|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
305070|NCT00214630|Drug|rosuvastatin calcium|
305071|NCT00214630|Drug|atorvastatin|
305072|NCT00214643|Drug|Fosmidomycin|30 mg/kg
305073|NCT00214643|Drug|clindamycin|10 mg/kg
305074|NCT00214656|Drug|Recombinant Activated Factor VII|
305075|NCT00214669|Behavioral|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
299516|NCT00376506|Device|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
299517|NCT00376519|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
299518|NCT00376519|Drug|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of >200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
299519|NCT00376519|Drug|fludarabine phosphate|Fludarabine 25 mg/m^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
299520|NCT00376519|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
299521|NCT00376519|Procedure|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10^6/kg, 0.3 x 10^6/kg, 1 x 10^6/kg and 3 x 10^6/kg weight (determined on the day prior to administration of the preparative therapy).
299522|NCT00003133|Drug|doxorubicin hydrochloride|
299523|NCT00376519|Procedure|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
299524|NCT00376519|Radiation|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
299525|NCT00376558|Behavioral|Community Reinforcement Approach|
299526|NCT00376571|Procedure|Percutaneous coronary intervention|Comparing treatment of either "no side branch treatment" versus "stenting of main vessel and side branch treatment"
299527|NCT00376584|Drug|MK-0524A|
299528|NCT00376584|Drug|ER Niacin|
299529|NCT00376584|Drug|Placebo|
304704|NCT00225212|Drug|Rituximab 375 mg/m2|
304705|NCT00225225|Drug|Rosiglitazone|
304706|NCT00225225|Behavioral|dietary recommendation for weight maintenance|
304707|NCT00225238|Drug|esomeprazole (PPI)|
304708|NCT00000392|Drug|Placebo|
304709|NCT00002594|Drug|melphalan|Given IV
304710|NCT00225251|Drug|bupropion XL|Antidepressant medication
304711|NCT00225251|Other|Placebo|Placebo
304712|NCT00225264|Drug|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
304713|NCT00225264|Drug|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
304714|NCT00225277|Drug|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
304715|NCT00225277|Drug|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
304716|NCT00225290|Drug|Thalidomide(Thado)|
304717|NCT00225303|Drug|TMC125|
304718|NCT00225316|Procedure|Acupuncture|See Detailed Description.
304719|NCT00225329|Procedure|Labour assessment and support|
304720|NCT00002594|Procedure|autologous bone marrow transplantation|
304721|NCT00225342|Drug|Rosiglitazone|
304722|NCT00225342|Drug|Gliclazide (Comparison drug)|
304723|NCT00225355|Drug|Rosiglitazone|
304724|NCT00225368|Device|Insecticide treated bednets|
305076|NCT00214669|Behavioral|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
305077|NCT00214669|Behavioral|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
303966|NCT00246922|Drug|Roflumilast|
303967|NCT00246935|Drug|Roflumilast|
303968|NCT00246948|Procedure|Active conservative treatment of sciatica|
303969|NCT00246974|Drug|Gemcitabine|intravenous
303970|NCT00246974|Drug|Cisplatin|intravenous
303971|NCT00246974|Drug|Gefitinib|oral
304343|NCT00236860|Drug|topiramate|
304344|NCT00236873|Drug|topiramate|
304345|NCT00002625|Radiation|low-LET photon therapy|
304346|NCT00236886|Drug|topiramate|
304347|NCT00236899|Drug|Gemcitabine|Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).
Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
304348|NCT00236899|Drug|Docetaxel|Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
304349|NCT00236899|Drug|Paclitaxel|Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
304350|NCT00236912|Drug|levofloxacin; metronidazole|
304351|NCT00236925|Drug|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
304352|NCT00236925|Drug|Placebo|Placebo
304353|NCT00240162|Drug|PTK787/ZK 222584|
304354|NCT00240175|Other|No Intervention|No Intervention
304355|NCT00002634|Drug|mesna|
304356|NCT00240188|Procedure|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
303595|NCT00256477|Behavioral|Sudarshan KRIYA Breathing Technique|
303596|NCT00256490|Procedure|PET/CT 20 days after the first cycle of chemotherapy|
303597|NCT00256503|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
303598|NCT00256516|Other|Eco-Atkins diet (high vegetable protein and vegetable fat)|
303599|NCT00002688|Drug|etoposide|
303600|NCT00256516|Other|NCEP diet|
303601|NCT00256529|Procedure|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
303602|NCT00260091|Procedure|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
303603|NCT00260117|Behavioral|Exercise|Referal to a website
303604|NCT00260130|Other|food in fluid form|dietary intake of fluid forms of vegetables
303605|NCT00260130|Other|food in solid form|dietary intake of solid forms of vegetables
303606|NCT00260143|Drug|testosterone enanthate|
303607|NCT00260156|Drug|vildagliptin|
303608|NCT00260156|Drug|placebo|
303609|NCT00260169|Behavioral|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
303610|NCT00260169|Behavioral|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
303972|NCT00002657|Drug|cyclophosphamide|650 mg/m^2
303973|NCT00246987|Drug|Muraglitazar|
303974|NCT00250497|Behavioral|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
302905|NCT00374751|Drug|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
302906|NCT00374764|Drug|Risperidone|
302907|NCT00374764|Behavioral|ABA|
303243|NCT00409903|Drug|Eprosartan|
303244|NCT00409916|Device|BioZ Dx|
303245|NCT00409929|Drug|AEB071|
303246|NCT00409942|Drug|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
303247|NCT00409942|Drug|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
303248|NCT00409955|Procedure|Lamellar transplant with lyophilized corneas|
303249|NCT00412958|Drug|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
303250|NCT00412958|Drug|Placebo|Intravitreal injection of placebo
303251|NCT00412971|Drug|Hexvix|Single installation, TURB
303252|NCT00412971|Other|Standard white light cystoscopy|
303253|NCT00412984|Drug|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
303254|NCT00412984|Drug|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
303255|NCT00412997|Drug|LBH589|
303256|NCT00003309|Biological|filgrastim|
303257|NCT00413010|Drug|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
303258|NCT00413010|Drug|placebo|placebo + concurrent GAD treatment from the open-label study period
303259|NCT00413023|Drug|GW679769|
303260|NCT00413036|Drug|lenalidomide|once daily oral capsule
303261|NCT00413049|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
302565|NCT00380835|Drug|Amrubicin|
302566|NCT00380848|Procedure|Hemodiafiltration|
302567|NCT00380861|Device|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
302568|NCT00380861|Device|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
302569|NCT00003151|Dietary Supplement|bismuth subcitrate|
302570|NCT00380874|Drug|Pregabalin|150- 600 mg/day (double blind in divided doses)
302571|NCT00380874|Drug|Placebo|Placebo
302572|NCT00380887|Drug|Premarin|
302573|NCT00380900|Drug|AGG-523|
302574|NCT00380913|Drug|Cesamet™ (nabilone)|
302575|NCT00003159|Procedure|neoadjuvant therapy|
302576|NCT00383409|Drug|multivitamins|
302577|NCT00383409|Drug|placebo|
302578|NCT00383422|Drug|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
302579|NCT00383422|Drug|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
302580|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
302581|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
302582|NCT00383435|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
302908|NCT00374777|Drug|zolpidem MR|oral
302909|NCT00003124|Drug|leuprolide acetate|
302910|NCT00374777|Drug|nitrazepam|oral
302911|NCT00374777|Drug|placebo|oral
302912|NCT00374790|Drug|Ferrous sulfate|
302913|NCT00374803|Drug|Mycophenolic Acid (Myfortic)|Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
301840|NCT00397202|Device|Diva Cup TM|See Detailed Description.
301841|NCT00397215|Biological|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
301842|NCT00397215|Biological|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
301843|NCT00397228|Drug|ALTROPANE®|ALTROPANE® dosing and SPECT imaging
301844|NCT00397241|Drug|Drug: dorzolamide/timolol|
302216|NCT00003194|Drug|cyclophosphamide|
302217|NCT00389259|Drug|Placebo|IV placebo q4h
302218|NCT00389272|Drug|Ibuprofen, acetaminophen|
302219|NCT00389285|Drug|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
302220|NCT00389285|Drug|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
302221|NCT00389298|Drug|VCH-759 (BCH-27759)|
302222|NCT00389311|Drug|Normosol-R|
302223|NCT00389311|Drug|Nonoxynol-9|
302224|NCT00391768|Drug|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
302225|NCT00391781|Procedure|Temperature of contrast medium|
302226|NCT00391794|Behavioral|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
302227|NCT00391794|Behavioral|Educational Seminar|4 hour education session led by trained facilitators
302228|NCT00391807|Drug|Norethindrone acetate/ethinyl estradiol|one tablet per day
302229|NCT00003203|Radiation|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT*
302230|NCT00391820|Drug|TD-5108|
301483|NCT00402987|Drug|celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
301484|NCT00402987|Drug|celecoxib followed by placebo|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
301485|NCT00402987|Drug|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
301486|NCT00402987|Drug|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
301487|NCT00403000|Drug|dutasteride|Oral
301488|NCT00403013|Procedure|Positioning and anesthesia|Positioning during axillary plexus block
301489|NCT00405977|Drug|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
301490|NCT00405990|Behavioral|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
301491|NCT00405990|Behavioral|VCT|HIV VCT for PMTCT
301492|NCT00406003|Drug|Paroxetine controlled Release 12.5mg, 25mg and37.5mg|
301493|NCT00406016|Drug|ATI355|
301494|NCT00406029|Drug|SCH 420814|1 mg twice daily
301495|NCT00406029|Drug|SCH 420814|2 mg twice daily
301496|NCT00406029|Drug|SCH 420814|5 mg twice daily
301497|NCT00003270|Drug|cyclosporine|IV
301498|NCT00406029|Drug|Placebo|twice daily
301499|NCT00406029|Drug|SCH 420814|Following an interim analysis, a new dose group of 10 mg BID may be added after 40 subjects completed the trial.
301845|NCT00397241|Drug|Drug: latanoprost/timolol|
301846|NCT00397241|Drug|dorzolamide/timolol and latanoprost|
301847|NCT00397241|Drug|placebo (artificial tears)|
301848|NCT00397254|Drug|rizatriptan|10mg ODT 27 tablets
301849|NCT00000499|Drug|hydralazine|
301850|NCT00003222|Biological|tyrosinase peptide|
321724|NCT00301548|Drug|perioperative chemotherapy|
322077|NCT00002791|Radiation|radioisotope therapy|
322078|NCT00291512|Behavioral|Theory-based counseling program|
322079|NCT00291525|Device|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered Coumadin
322080|NCT00291525|Device|On-X Valve with Standard Coumadin Therapy|Valve replacement with standard dosage Coumadin
322081|NCT00291538|Drug|bortezomib|
322082|NCT00291551|Device|Placement of the PVSS Implant|Implant is placed on epicardial surface of the heart surrounding both the right and left ventricles, to provide mechanical support to the ventricular walls.
322083|NCT00291564|Device|Cardiac Resynchronization Therapy Device|
322084|NCT00291577|Drug|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
322085|NCT00291577|Drug|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
322086|NCT00291590|Behavioral|DHEP|
322087|NCT00291603|Device|FX-class of dialyser|
322088|NCT00002792|Drug|busulfan|
322089|NCT00291616|Drug|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
322090|NCT00291616|Drug|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
322091|NCT00291629|Drug|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
322092|NCT00291629|Procedure|collection of mobilized peripheral blood stem cells|
322093|NCT00291629|Procedure|Intracoronary infusion of mobilized cells|
322094|NCT00291642|Drug|Levocetirizine|
322095|NCT00291655|Drug|Levetiracetam|500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
322096|NCT00291668|Biological|Certolizumab Pegol|Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use
322097|NCT00291668|Other|Placebo|Active Substance: isotonic sodium chloride solution
Pharmaceutical Form: Solution for injection
Concentration: 1 mL
Route of Administration: Subcutaneous use
321361|NCT00310336|Drug|betaine|
321362|NCT00310336|Drug|pegylated interferon alpha2b|
321363|NCT00310336|Drug|ribavirin|
321364|NCT00310349|Biological|23 valent pneumococcal polysaccharide vaccine|
321365|NCT00310362|Behavioral|Use of IVR system to improve adherene to GI appointments and prep procedures|Interactive voice response system calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
321366|NCT00310375|Drug|Ezogabine: USAN Retigabine: INN|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
321367|NCT00310388|Drug|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
321368|NCT00310401|Drug|Albuterol|5 mg nebulized q4h
321725|NCT00301561|Procedure|Simplified follow-up approach of ARV treatment|Simplify treatment follow-up :
some clinical consultations will be performed by nurses under the physicians' responsibility ;
the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;
the biologic assessment for tolerability will be limited
321726|NCT00301561|Procedure|Standard follow-up approach of ARV treatment|Standard treatment follow-up :
all clinical consultations will be performed by physicians ;
the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;
the biologic assessment for tolerability will be available as needed
321727|NCT00301574|Drug|galantamine|
321728|NCT00301587|Drug|Norgestimate-ethinyl estradiol, with or without folic acid|
321729|NCT00301600|Drug|Mycophenolate mofetil|MMF,1.0g/d
321730|NCT00301613|Drug|Mycophenolate mofetil|MMF,1.0g/d
321731|NCT00301626|Behavioral|smoking reduction intervention (including NRT)|
321732|NCT00301639|Drug|OROS methylphenidate hydrochloride|
321733|NCT00002814|Drug|paclitaxel|
321734|NCT00301639|Drug|methylphenidate hydrochloride|
321735|NCT00301652|Drug|mycophenolate mofetil|MMF,1.0g/d
321736|NCT00301665|Drug|Botulinum toxin type A|
320995|NCT00268385|Other|Laboratory Biomarker Analysis|Correlative studies
320996|NCT00268385|Other|Pharmacological Study|Correlative studies
320997|NCT00268385|Drug|Temozolomide|Given orally
320998|NCT00268385|Drug|Vorinostat|Given orally
320999|NCT00268398|Drug|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1&2) continuous 5FU 600mg/m² (day 1 to 2)
321000|NCT00002716|Procedure|conventional surgery|
321001|NCT00268398|Drug|oxaliplatin, irinotecan, folinic acid, fluorouracil|FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)
FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)
321002|NCT00268411|Drug|gemcitabine hydrochloride|
321003|NCT00268411|Drug|oxaliplatin|
321004|NCT00268437|Drug|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
321005|NCT00268437|Drug|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
321006|NCT00268437|Procedure|conventional surgery|
321007|NCT00268437|Procedure|neoadjuvant therapy|
321008|NCT00268437|Radiation|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
321009|NCT00268450|Biological|bevacizumab|
321010|NCT00268450|Drug|cisplatin|
321011|NCT00002717|Drug|cisplatin|
321012|NCT00268450|Drug|gemcitabine hydrochloride|
321013|NCT00268450|Drug|paclitaxel|
321014|NCT00268450|Procedure|adjuvant therapy|
321015|NCT00268450|Procedure|conventional surgery|
321016|NCT00268450|Procedure|neoadjuvant therapy|
320257|NCT00287911|Drug|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
320258|NCT00287911|Drug|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
320259|NCT00287911|Radiation|brachytherapy|Some patients may also undergo brachytherapy
320260|NCT00287911|Radiation|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
320261|NCT00287924|Drug|methotrexate|
320262|NCT00287924|Procedure|adjuvant therapy|
320263|NCT00002785|Biological|filgrastim|
320264|NCT00287937|Drug|vorinostat|Given orally
320265|NCT00287937|Drug|paclitaxel|Given IV
320266|NCT00287937|Drug|carboplatin|Given IV
320267|NCT00287937|Other|laboratory biomarker analysis|Correlative studies
320268|NCT00287937|Other|pharmacological study|Correlative studies
320269|NCT00287950|Drug|carboplatin|
320270|NCT00287950|Drug|cisplatin|
320624|NCT00278096|Behavioral|occupational therapy|
320625|NCT00278109|Drug|cyclophosphamide|chemotherapy
320626|NCT00278109|Drug|doxorubicin hydrochloride|chemotherapy
320627|NCT00278109|Procedure|adjuvant therapy|chemotherapy
320628|NCT00278109|Radiation|radiation therapy|chemotherapy
320629|NCT00278122|Biological|sargramostim|
320630|NCT00002756|Drug|vincristine sulfate|
320631|NCT00278122|Drug|paclitaxel|
320632|NCT00278135|Dietary Supplement|DHA (nutritional supplement) or placebo|oral 900mg/day
320633|NCT00278148|Drug|carboplatin|AUC2 weekly x 3 weeks
319506|NCT00303589|Drug|Standard care|As prescribed
319507|NCT00303589|Drug|beta-lactam|750mg iv q8h
319508|NCT00303589|Drug|beta-lactam|1500mg iv q8h
319509|NCT00303602|Drug|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
319510|NCT00303602|Drug|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
319886|NCT00294008|Drug|Risperdal Consta|flexible dosage for 24 months
319887|NCT00294034|Device|Pacemaker|
319888|NCT00294047|Biological|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
319889|NCT00294047|Biological|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
319890|NCT00002798|Drug|cyclophosphamide|Given IV
319891|NCT00294073|Procedure|Fascia Iliaca Block|
319892|NCT00294073|Procedure|Femoral Block (with stimulating catheter)|
319893|NCT00294073|Procedure|Femoral Block (without stimulating catheter)|
319894|NCT00294086|Drug|valsartan 160 mg|
319895|NCT00294086|Drug|valsartan 160 mg BID|
319896|NCT00294099|Biological|Aluminum hydroxide|Aluminum hydroxide adjuvant.
319897|NCT00294099|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
319898|NCT00294112|Drug|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
319899|NCT00294112|Drug|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
319900|NCT00294125|Drug|Flavocoxid|Daily flavocoxid for 12 weeks
319901|NCT00002798|Biological|aldesleukin|
319902|NCT00294125|Drug|Placebo|Daily placebo for 12 weeks
319147|NCT00260923|Drug|aliskiren|
319148|NCT00260949|Procedure|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
319149|NCT00260962|Drug|Olanzapine|Double blind, placebo controlled drug trial with 14 subjects randomized to Olanzapine,14 randomized to placebo. Olanzapine was started at 2.5 mg/day and titrated slowly (2.5 mg/week) to a maximum of 10 mg/day. Drug or placebo given daily for 10 weeks.
319150|NCT00002700|Drug|daunorubicin hydrochloride|
319151|NCT00260988|Drug|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
319152|NCT00260988|Drug|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
319153|NCT00261001|Biological|Transcutaneous mode of administration|
319154|NCT00261001|Biological|Intramuscular mode of administration|
319155|NCT00261027|Drug|Exemestane|
319156|NCT00261040|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
319157|NCT00261040|Procedure|Standard|standard approach hip surgery
319158|NCT00261053|Drug|i.v. recombinant human C1 inhibitor|
319159|NCT00261079|Drug|Fexofenadine|
319160|NCT00261092|Drug|Oxaliplatin|
319161|NCT00264082|Drug|Zometa(drug)|
319162|NCT00002704|Drug|etoposide|
319163|NCT00264095|Procedure|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
319511|NCT00002822|Drug|cyclophosphamide|
319512|NCT00303615|Drug|Fluoxymesterone 10 mg|
319513|NCT00303615|Drug|Anastrozole 1 mg|
319514|NCT00303628|Drug|oxaliplatin|Given IV
319515|NCT00303628|Drug|fluorouracil|Given IV
319516|NCT00303628|Drug|leucovorin calcium|Given IV
318416|NCT00280540|Drug|Valsartan/Hydrochlorothiazide|
318417|NCT00280553|Drug|bupivicaine|PCA and bupivicaine infusion for up to five days
318418|NCT00280553|Other|Saline infusion|PCA and pump with saline infusion for up to five days
318419|NCT00280566|Drug|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
318420|NCT00283387|Drug|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
318776|NCT00002723|Drug|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
318777|NCT00270543|Drug|Taxotere, Fluorouracil, Leucovorin|
318778|NCT00270556|Drug|tenofovir disoproxil fumarate|
318779|NCT00270556|Drug|Abacavir|
318780|NCT00270569|Drug|PhyxolTM, Cisplatin|
318781|NCT00270582|Drug|Taxotere, Cisplatin, Gemcitabine|
318782|NCT00270608|Procedure|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
318783|NCT00270608|Procedure|MRI of the spine and the right knee|a single time 45 minutes procedure
318784|NCT00270608|Procedure|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
318785|NCT00002742|Drug|nystatin|
318786|NCT00273975|Drug|Lamivudine|
318787|NCT00273975|Drug|Zidovudine|
318788|NCT00273988|Drug|nevirapine|
318789|NCT00274001|Drug|Nevirapine|
318790|NCT00274014|Drug|Tiotropium|
318791|NCT00274027|Drug|tiotropium bromide|
318792|NCT00274040|Drug|Tiotropium|
300241|NCT00405587|Drug|PLX4032|Oral capsules administered BID
300242|NCT00000504|Drug|encainide|
300243|NCT00003269|Drug|cyclophosphamide|
300244|NCT00405600|Procedure|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
300245|NCT00405613|Drug|Aspirin|
300246|NCT00405626|Drug|Bellis Perenis ,Arnica montana|
300247|NCT00405639|Drug|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
300248|NCT00408538|Drug|placebo|
300249|NCT00408551|Drug|floxuridine|Given IV
300250|NCT00408551|Drug|fluorouracil|Given IV
300251|NCT00408551|Drug|irinotecan hydrochloride|Given IV
300252|NCT00408551|Drug|leucovorin calcium|Given IV
300253|NCT00003282|Procedure|therapeutic conventional surgery|Undergo resection
300254|NCT00408551|Drug|oxaliplatin|Given IV
300255|NCT00408564|Biological|cetuximab|
300256|NCT00408564|Drug|capecitabine|
300257|NCT00408564|Drug|oxaliplatin|
300258|NCT00408564|Procedure|conventional surgery|
300259|NCT00408564|Procedure|neoadjuvant therapy|
300260|NCT00408564|Radiation|radiation therapy|
300261|NCT00408564|Drug|Gemcitabine|
300262|NCT00408577|Drug|L-arginine|
300263|NCT00408590|Biological|carcinoembryonic antigen-expressing measles virus|
299530|NCT00376597|Other|quality of life assessment|Ancillary studies
299531|NCT00376597|Other|educational intervention|Receive lymphedema educational materials
299532|NCT00376597|Procedure|Physical therapy|Complete physical therapy-focused intervention
299533|NCT00003133|Drug|gemcitabine hydrochloride|
299534|NCT00376610|Device|ASR/Re-cap|
299535|NCT00376623|Drug|BI 2536|
299536|NCT00376636|Drug|SPP635 (drug)|
299537|NCT00376649|Behavioral|lifestyle changing workshop|
299538|NCT00376662|Drug|Hormone Replacement Therapy and Etidronate|
299896|NCT00367055|Drug|metformin+ gliclazide|
299897|NCT00367068|Drug|baclofen, intrathecal|
299898|NCT00367068|Device|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
299899|NCT00367081|Drug|TMX-SMX (Bactrim(R))|
299900|NCT00367081|Drug|Pyrimethamine plus Sulfadiazine plus leucoverin|
299901|NCT00367094|Drug|Benazepril plus hydrochlorothiazide|
299902|NCT00367120|Drug|Azithromycin Extended Release|
299903|NCT00367120|Drug|Amoxicillin/Clavulanate|
299904|NCT00367133|Procedure|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
299905|NCT00003091|Biological|aldesleukin|
299906|NCT00370071|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
299907|NCT00370084|Drug|Itopride Hydrochloride (prokinetic)|oral , tid
299908|NCT00003105|Drug|cisplatin|
299909|NCT00370084|Drug|Itopride|oral, tid
299910|NCT00370084|Other|placebo|oral tid
305078|NCT00214682|Drug|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
305079|NCT00002566|Procedure|autologous bone marrow transplantation|
305080|NCT00214682|Behavioral|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
305081|NCT00214682|Behavioral|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
305082|NCT00217919|Behavioral|Health-Counselor Mediated Telephone Counseling Intervention|A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.
We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity.
305083|NCT00217932|Drug|Divalproex Sodium (Depakote)|
305084|NCT00217945|Behavioral|Shared-Decision Making|
305085|NCT00217958|Behavioral|SHS reduction intervention based on social cognitive learning theory|
305086|NCT00217971|Drug|Dronabinol|Dronabinol
305087|NCT00000387|Behavioral|Self-management therapy|
305088|NCT00002576|Drug|cyclophosphamide|
305089|NCT00217971|Drug|Placebo|placebo
299539|NCT00376675|Drug|methylphenidate hydrochloride|Given orally
304357|NCT00240188|Procedure|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
304358|NCT00240214|Drug|sirolimus|Tablet, dosage is determined by trough level
304359|NCT00240227|Drug|Prazosin|FDA approved medication for hypertension
304360|NCT00240227|Drug|placebo|
304361|NCT00240253|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC injection
304362|NCT00240266|Drug|Rosuvastatin|
304363|NCT00240279|Drug|Rosuvastatin|
304725|NCT00225381|Device|connection of measuring device to anesthesia circuit|same as name
304726|NCT00225381|Procedure|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
304727|NCT00225381|Procedure|changing operating room bed position (head down and up position)|same
304728|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
304729|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
304730|NCT00229190|Procedure|Nasal lavage|
304731|NCT00229190|Procedure|Allergy skin testing|
304732|NCT00229190|Procedure|Peak nasal inspiratory flow|
304733|NCT00229190|Procedure|Acoustic rhinometry|
304734|NCT00229190|Procedure|Nasal examination|
304735|NCT00229190|Procedure|Quality of Life Questionnaire|
304736|NCT00002600|Procedure|autologous bone marrow transplantation|
304737|NCT00229190|Procedure|Physical examination|
304738|NCT00229203|Drug|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
304739|NCT00229216|Drug|Tinidazole|
304740|NCT00229229|Other|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
303975|NCT00250510|Behavioral|Simulated insurance reimbursement|Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
303976|NCT00250536|Drug|nandrolone decanoate|
303977|NCT00250536|Behavioral|resistance exercise training|
303978|NCT00250549|Behavioral|Post test video|We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
303979|NCT00250562|Drug|valsartan plus hydrochlorothiazide|
303980|NCT00250575|Drug|Clozapine|
303981|NCT00250588|Behavioral|Problem solving skills training|See description in Results
303982|NCT00250588|Behavioral|Asthma care coordination|See description in Results
303983|NCT00250588|Other|Usual Care|Usual clinical care
303984|NCT00000409|Procedure|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
303985|NCT00002665|Drug|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC < 3,000 /μl
303986|NCT00250601|Drug|Saredutant succinate (SR48968C)|
303987|NCT00250614|Drug|Saredutant succinate (SR48968C)|
303988|NCT00250627|Drug|Saredutant succinate (SR48968C)|
303989|NCT00250640|Drug|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
303990|NCT00250653|Drug|Saredutant succinate (SR48968C)|
303991|NCT00250666|Procedure|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
304364|NCT00240279|Procedure|aortic pulse wave velocity measurements|
304365|NCT00240292|Drug|Rosuvastatin|
303262|NCT00413049|Drug|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
303263|NCT00413062|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
303264|NCT00413062|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
303265|NCT00413075|Drug|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
303611|NCT00002697|Drug|ifosfamide|
303612|NCT00260195|Behavioral|School-based cognitive behavioral support group|
303613|NCT00260208|Drug|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
303614|NCT00260208|Drug|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
303615|NCT00260221|Behavioral|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
303616|NCT00260234|Biological|Allogeneic Cultured Islet Cells (human); Encapsulated|
303617|NCT00260247|Drug|carbamazepine oxcarbazepine|
303618|NCT00260260|Drug|Oxycodone|
303619|NCT00260273|Behavioral|Cognitive Behaviour Therapy|therapy
303620|NCT00260286|Behavioral|Energy availability|
303621|NCT00260312|Biological|Inactivated Polio Vaccine given at an accelerated schedule|
303622|NCT00002697|Procedure|autologous bone marrow transplantation|
303623|NCT00260325|Drug|valdecoxib|
303624|NCT00260338|Biological|stem cell|mesenchymal stromal cell
303625|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
303626|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
303627|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
302914|NCT00374829|Behavioral|An IT-based patient follow-up and reminder system|
302915|NCT00374842|Biological|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
302916|NCT00374842|Biological|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
302917|NCT00374855|Drug|PPAR alpha|
302918|NCT00374855|Drug|Hydrochlorothiazide|
302919|NCT00374855|Drug|Placebo|
302920|NCT00003124|Radiation|radiation therapy|
302921|NCT00374868|Drug|pemetrexed|Phase 1: 300 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m^2, 400 mg/m^2, and 500 mg/m^2)
Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy
302922|NCT00374868|Drug|cisplatin|Phase 1: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles
Phase 2: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy
302923|NCT00374881|Drug|Morphine|Morphine
302924|NCT00374881|Drug|Morphine|Morphine low dose
302925|NCT00374881|Drug|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
302926|NCT00374881|Drug|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
302927|NCT00374881|Drug|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
302928|NCT00374894|Drug|2,3-dimercaptosuccinic acid|
302929|NCT00374907|Drug|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
302930|NCT00374907|Drug|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
302931|NCT00003125|Biological|ALVAC-CEA vaccine|
303266|NCT00413088|Drug|bemiparin|
303267|NCT00003309|Drug|cisplatin|
303268|NCT00413101|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/L
303269|NCT00413114|Drug|Obatoclax mesylate (GX15-070MS)|
302231|NCT00391833|Drug|Panax Ginseng|
302232|NCT00391846|Drug|Captopril|
302233|NCT00391846|Drug|Enalapril|
302234|NCT00391846|Drug|Lisinopril|
302235|NCT00391846|Drug|Ramipril|
302236|NCT00391846|Drug|Trandolapril|
302237|NCT00391846|Drug|Bisoprolol|
302238|NCT00391846|Drug|Carvedilol|
302239|NCT00391846|Drug|Metoprolol succinate|
302240|NCT00003204|Drug|cyclophosphamide|Given IV
302583|NCT00383435|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
302584|NCT00383435|Drug|Placebo|Placebo MDI twice a day for 26 weeks
302585|NCT00383448|Drug|Clofarabine|days -7 through -3: 40 mg/m^2 intravenously over 2 hours
302586|NCT00000492|Drug|propranolol|
302587|NCT00003160|Drug|paclitaxel|
302588|NCT00383448|Procedure|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
302589|NCT00383448|Drug|Melphalan|day -2: 140 mg/m^2 intravenously over 30 minutes
302590|NCT00383448|Biological|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
302591|NCT00383448|Drug|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
302592|NCT00383448|Drug|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR<25 mL/minute corrected)
302593|NCT00383448|Device|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).
CsA taper begins at day +100.
301851|NCT00397254|Drug|rizatriptan|10mg ODT 9 tablets
301852|NCT00397267|Drug|inhalation of corticosteroids|
301853|NCT00397293|Drug|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
301854|NCT00397293|Drug|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
301855|NCT00397306|Device|Bioimpedance Analysis|
301856|NCT00397319|Drug|Growth Hormone|
301857|NCT00397332|Drug|Alefacept|IM Alefacept
301858|NCT00397345|Biological|Trovax|1ml IM injection 2-8 weeks apart.
301859|NCT00397358|Drug|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
301860|NCT00397384|Drug|cetuximab|Given IV
301861|NCT00003223|Drug|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
301862|NCT00397384|Drug|erlotinib hydrochloride|Given PO
301863|NCT00397384|Other|laboratory biomarker analysis|Correlative studies
301864|NCT00397410|Device|Hip protectors|
301865|NCT00397423|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd*5 days,3 months interval for 4 times
301866|NCT00397423|Drug|NS|NS 1ml iH Qd*5 days, 3 months interval for 4 times
301867|NCT00397436|Procedure|UV Irradiation|UV irradiation
301868|NCT00400218|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
301869|NCT00400231|Drug|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
301870|NCT00400231|Drug|Study Drug: Metformin|2000mg/day
302241|NCT00391846|Drug|Candesartan|
302242|NCT00391846|Drug|Valsartan|
302243|NCT00391846|Drug|Eplerenone|
322098|NCT00291694|Drug|celecoxib|Celecoxib 400 mg BID
322099|NCT00000441|Drug|carbamazepine (Tegretol)|
322100|NCT00002792|Drug|cyclophosphamide|
322447|NCT00281944|Procedure|positron emission tomography|Undergo PET scan
322448|NCT00281944|Procedure|computed tomography|Undergo PET/CT scan
322449|NCT00281957|Drug|sorafenib tosylate|Given orally
322450|NCT00000434|Behavioral|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
322451|NCT00002768|Drug|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
322452|NCT00281957|Drug|tipifarnib|Given orally
322453|NCT00281957|Drug|temsirolimus|Given IV
322454|NCT00281970|Drug|cisplatin|
322455|NCT00281970|Drug|docetaxel|
322456|NCT00281970|Procedure|adjuvant therapy|
322457|NCT00281983|Biological|alemtuzumab|
322458|NCT00281983|Biological|anti-thymocyte globulin|
322459|NCT00281983|Biological|filgrastim|
322460|NCT00281983|Biological|rituximab|
322461|NCT00281983|Biological|therapeutic allogeneic lymphocytes|
322462|NCT00285298|Drug|Pentoxifylline|
322463|NCT00285298|Drug|Placebo|
322464|NCT00285337|Procedure|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
322465|NCT00285350|Drug|mycophenolate mofetil|
322466|NCT00285376|Drug|vilazodone|titration to 40mg tablets qd for 8 weeks
322467|NCT00285389|Drug|Adriblastin|
322468|NCT00285389|Drug|dexamethasone|
321737|NCT00301678|Behavioral|behavioral dietary intervention|
321738|NCT00301678|Other|educational intervention|
321739|NCT00301678|Other|preventative dietary intervention|
321740|NCT00301691|Behavioral|behavioral dietary intervention|
321741|NCT00301691|Other|educational intervention|
321742|NCT00301691|Other|preventative dietary intervention|
321743|NCT00301730|Biological|aldesleukin|
321744|NCT00002814|Drug|topotecan hydrochloride|
321745|NCT00301730|Biological|therapeutic tumor infiltrating lymphocytes|
321746|NCT00301730|Biological|trastuzumab|
321747|NCT00002823|Radiation|radiation therapy|
321748|NCT00304135|Drug|gemcitabine hydrochloride|
321749|NCT00304135|Drug|oxaliplatin|
321750|NCT00304161|Drug|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
322101|NCT00291694|Other|placebo|placebo
322102|NCT00291707|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
322103|NCT00291707|Drug|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if >6000 cGy to be delivered)
322104|NCT00295035|Drug|CURCUMIN|
322105|NCT00295048|Behavioral|Computer Assisted Cognitive Remediation (CACR)|
322106|NCT00002802|Drug|carboplatin|
322107|NCT00295061|Drug|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
322108|NCT00295061|Drug|alpha-1 proteinase inhibitor (human)|Prolastin
322109|NCT00295074|Procedure|neuropsychologic testing|
322110|NCT00295100|Drug|Tamoxifen|
321017|NCT00268463|Drug|capecitabine|Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1
Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2
321018|NCT00268463|Drug|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
321369|NCT00002838|Biological|Filgrastim (G-CSF)|
321370|NCT00310401|Drug|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
321371|NCT00310427|Drug|LY686017|50 mg administered orally on a daily basis
321372|NCT00310427|Drug|Placebo|Administered on a daily basis
321373|NCT00310440|Device|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
321374|NCT00310440|Other|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
321375|NCT00310453|Biological|ALK Grass tablet|
321376|NCT00310466|Biological|Sublingual immunotherapy|once daily intake of sublingual drops
321377|NCT00310466|Biological|Placebo|once daily intake of sublingual drops
321378|NCT00310479|Device|Magnetic Resonance Spectroscopy (3Tesla)|
321379|NCT00262002|Biological|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
321380|NCT00262002|Biological|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
321381|NCT00262015|Biological|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
321382|NCT00262028|Biological|MenACWY-CRM Vaccine|
321383|NCT00262028|Biological|MenACWY-PS Vaccine|
321384|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
321385|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
321386|NCT00262041|Biological|MenACWY polysaccharide vaccine|
321387|NCT00002700|Procedure|autologous bone marrow transplantation|
320634|NCT00278148|Drug|Tarceva|Daily
320635|NCT00278148|Drug|paclitaxel|50mg/m2/weekly x 3 weeks
320636|NCT00278148|Procedure|conventional surgery|conventional surgery
320637|NCT00278148|Radiation|radiation therapy|150 cGy bid
320638|NCT00278161|Biological|pegfilgrastim|
320639|NCT00278161|Biological|rituximab|
320640|NCT00278161|Drug|cyclophosphamide|
320641|NCT00000430|Drug|Alendronate|
320642|NCT00002757|Biological|filgrastim|
320643|NCT00278174|Biological|recombinant interferon alpha-1b|
320644|NCT00281463|Device|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
320645|NCT00281476|Drug|Simvastatine|
320646|NCT00281489|Device|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
320647|NCT00281489|Behavioral|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
320648|NCT00281502|Drug|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
321019|NCT00271388|Device|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
321020|NCT00271401|Other|Angioplasty|
321021|NCT00271401|Other|Intracoronary Stent|
321022|NCT00271401|Drug|Abxicimab|
321023|NCT00002733|Drug|cimetidine|
321024|NCT00271401|Drug|Heparin|
321025|NCT00271401|Drug|Placebo|
319903|NCT00294151|Procedure|Vertebroplasty|
319904|NCT00294164|Drug|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
319905|NCT00294164|Drug|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
319906|NCT00297076|Drug|GW873140|
319907|NCT00297089|Drug|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
319908|NCT00297089|Drug|pemetrexed|Standard pemetrexed every 21 days
319909|NCT00297089|Drug|placebo|Placebo daily for 14 days every 21 days
320271|NCT00287950|Drug|cyclophosphamide|
320272|NCT00287950|Drug|etoposide|
320273|NCT00287950|Drug|vincristine sulfate|
320274|NCT00000438|Drug|naltrexone (Revia)|
320275|NCT00002785|Drug|asparaginase|
320276|NCT00287950|Procedure|adjuvant therapy|
320277|NCT00287950|Procedure|conventional surgery|
320278|NCT00287950|Procedure|neoadjuvant therapy|
320279|NCT00287950|Radiation|radiation therapy|
320280|NCT00287963|Drug|topotecan hydrochloride|
320281|NCT00287963|Drug|vinorelbine tartrate|
320282|NCT00287976|Drug|irinotecan hydrochloride|
320283|NCT00290654|Radiation|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
320284|NCT00290667|Biological|pegfilgrastim|
320285|NCT00290667|Biological|rituximab|
320286|NCT00002790|Drug|methotrexate|
320287|NCT00290667|Drug|cyclophosphamide|
319517|NCT00303628|Drug|bevacizumab|Given IV
319518|NCT00303641|Device|Medtronic Resting Heart Bypass System|
319519|NCT00303654|Procedure|biopsy|
319520|NCT00303654|Procedure|therapeutic conventional surgery|
319521|NCT00306592|Biological|BG00002 (natalizumab)|
319522|NCT00306605|Behavioral|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
319523|NCT00002831|Drug|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
319524|NCT00306618|Drug|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
319525|NCT00306631|Drug|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
319526|NCT00306644|Drug|Rosiglitazone|
319527|NCT00306657|Procedure|Optic nerve sheath fenestration|
319528|NCT00306670|Drug|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
319529|NCT00306670|Drug|prednisone|<30 mg/day
319530|NCT00306683|Drug|DIAZOXIDE|
319531|NCT00306696|Drug|Rosiglitazone|
319532|NCT00306696|Drug|spironolactone|
319533|NCT00306696|Drug|hydrochlorothiazide|
319534|NCT00002831|Drug|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
319535|NCT00306696|Drug|frusemide|
319536|NCT00306709|Behavioral|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
319910|NCT00297102|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
319911|NCT00297102|Drug|Placebo|once daily
319912|NCT00297115|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
318793|NCT00274040|Drug|Ipratropium|
318794|NCT00274053|Drug|tiotropium|
318795|NCT00274066|Drug|Tiotropium + placebo|
318796|NCT00002744|Drug|asparaginase|
318797|NCT00274066|Drug|Tiotropium + ipratropium|
318798|NCT00274066|Drug|Tiotropium + fenoterol|
318799|NCT00274079|Drug|SPIRIVA|
318800|NCT00274092|Drug|tiotropium inhalation capsules (18 mcg once daily)|
318801|NCT00274092|Drug|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
318802|NCT00274105|Drug|telmisartan|
318803|NCT00274105|Drug|Placebo|
319164|NCT00264108|Drug|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
319165|NCT00264108|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length.
319166|NCT00264134|Drug|Docetaxel|
319167|NCT00264134|Drug|Irinotecan|
319168|NCT00264134|Drug|Carboplatin|
319169|NCT00264147|Drug|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
319170|NCT00264147|Drug|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
319171|NCT00264147|Drug|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
319172|NCT00264147|Drug|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
319173|NCT00002704|Drug|leucovorin calcium|
319174|NCT00264147|Drug|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
319175|NCT00264147|Drug|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
319176|NCT00264147|Drug|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
300604|NCT00399672|Drug|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
300605|NCT00003239|Drug|Cytarabine|Daily by subcutaneous injection.
300606|NCT00399672|Drug|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
300607|NCT00399685|Drug|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
300608|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
300609|NCT00399685|Drug|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
300610|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
300611|NCT00399698|Drug|Risperdal|
300612|NCT00399711|Drug|repaglinide and metformin combination tablet|
300613|NCT00399711|Drug|rosiglitazone and metformin combination tablet|
300614|NCT00399724|Drug|Insulin glargine|
300615|NCT00399737|Drug|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
300616|NCT00003239|Drug|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
300617|NCT00399750|Drug|oxaliplatin|
300618|NCT00399750|Drug|fluoropyrimidine|
300619|NCT00399750|Drug|bevacizumab|
300620|NCT00399763|Drug|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
300621|NCT00399763|Drug|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
300622|NCT00003257|Biological|Ad5CMV-p53 gene|
300623|NCT00402558|Drug|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
300624|NCT00402558|Drug|Methotrexate|5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
299911|NCT00370097|Drug|FLOVENT (fluticasone propionate) HFA|
299912|NCT00370110|Drug|Itopride Hydrochloride (prokinetic)|
299913|NCT00370136|Drug|ultrasound contrast|
299914|NCT00370149|Device|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
299915|NCT00370149|Device|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
299916|NCT00370162|Drug|lactoserum|
299917|NCT00370188|Drug|Topiramate|
299918|NCT00370201|Drug|colchicine|
299919|NCT00003105|Drug|doxorubicin hydrochloride|
299920|NCT00370227|Biological|10 valent pneumococcal conjugate (vaccine)|
299921|NCT00370240|Drug|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
300264|NCT00003282|Procedure|biopsy|Undergo biopsy
300265|NCT00408590|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|
300266|NCT00408590|Genetic|reverse transcriptase-polymerase chain reaction|
300267|NCT00408590|Other|laboratory biomarker analysis|
300268|NCT00408603|Drug|Voreloxin Injection|All patients will receive voreloxin injection.
300269|NCT00408616|Biological|Grazax-R|Grass tablet, 75.000 SQ per day for one year
300270|NCT00408616|Biological|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
300271|NCT00408629|Biological|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
300272|NCT00408629|Biological|placebo|Matching Placebo for prefilled syringe, 40 mg,
300273|NCT00408642|Behavioral|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
299540|NCT00376675|Other|placebo|Given orally
299541|NCT00376688|Other|Laboratory Biomarker Analysis|Correlative studies
299542|NCT00379288|Drug|Fluticasone/Salmeterol 500/50 mcg BID|F/SC 500/50 twice daily for 1 year
299543|NCT00379301|Procedure|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
299544|NCT00379314|Procedure|TVT and TVT-O minimally invasive surgical procedures|
299545|NCT00379314|Procedure|Surgery for female stress urinary incontinence|
299546|NCT00003145|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
299547|NCT00379327|Procedure|Acupuncture|Acupuncture administered in last three weeks of pregnancy
299548|NCT00379327|Device|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
299549|NCT00379340|Drug|doxorubicin hydrochloride|Given IV
299550|NCT00379340|Drug|liposomal vincristine sulfate|Given IV
299551|NCT00379340|Procedure|conventional surgery|
299552|NCT00379340|Radiation|3-dimensional conformal radiation therapy|
299553|NCT00379340|Biological|dactinomycin|Given IV
299554|NCT00379340|Drug|cyclophosphamide|Given IV
299555|NCT00379340|Drug|etoposide|Given IV
299556|NCT00379353|Drug|Thalidomide|100 mg capsules orally, once a day for 14 days.
299557|NCT00003145|Drug|Cyclosporine|Given PO or IV
299558|NCT00379353|Drug|Placebo|Two placebo capsules orally, once a day for 14 days.
299559|NCT00379366|Device|External ionizing radiations|14 Gy in one time
299560|NCT00379379|Device|electroacupuncture|
299561|NCT00379392|Behavioral|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
304741|NCT00229229|Other|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
304742|NCT00229229|Other|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
304743|NCT00229229|Other|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
304744|NCT00229242|Drug|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
304745|NCT00229255|Other|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
304746|NCT00229255|Other|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
304747|NCT00002600|Procedure|peripheral blood stem cell transplantation|
304748|NCT00229281|Behavioral|Group therapy|
304749|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|20 minutes exposure
305090|NCT00217984|Other|Usual Care|Referral to smoking cessation clinic
305091|NCT00217984|Behavioral|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
305092|NCT00218023|Drug|Naltrexone|Naltrexone hydrochloride 50mg per day, A 2-day dose run up procedure starting at 25mg and increasing by 25 mg will be followed by a fixed daily dose administered as 25 mg bid. Subjects will be instructed to take one pill by mouth twice a day and to continue to do so throughout the 12-week treatment phase of the study.
305093|NCT00218023|Drug|Modafinil|A 2-day dose run up procedure starting at 200 mg modafinil per day will be followed by a fixed daily dose administered as 400 mg/day.
305094|NCT00218023|Drug|Levodopa/Carbidopa|Levodopa/carbidopa, 800/200 mg per day, in the sustained release formulation (Sinemet CR) will be the pharmacotherapy in this condition. A 2-day dose run up procedure starting at 400mg l-dopa and 100 mg carbidopa per day will be followed by a fixed daily dose administered as 400/100 bid
305095|NCT00218023|Drug|Placebo|Placebo
305096|NCT00218036|Drug|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
305097|NCT00218036|Drug|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
305098|NCT00218036|Drug|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
305099|NCT00002576|Drug|doxorubicin hydrochloride|
304366|NCT00002634|Drug|perfosfamide|
304367|NCT00240305|Drug|Rosuvastatin|
304368|NCT00240318|Drug|Rosuvastatin calcium|
304369|NCT00240331|Drug|10mg Rosuvastatin|
304370|NCT00240331|Drug|Placebo|
304371|NCT00240357|Procedure|Lifestyle Regulation|
304372|NCT00240370|Drug|Muraglitazar|
304373|NCT00240383|Drug|Muraglitazar|
304374|NCT00240396|Drug|Narcotics alone|
304375|NCT00240396|Drug|Narcotics and NSAIDS|
304376|NCT00240409|Drug|Pramipexole|
304377|NCT00002634|Drug|vincristine sulfate|
304378|NCT00240409|Drug|Bromocriptine|
304379|NCT00240422|Drug|Telmisartan|
304380|NCT00240422|Drug|Ramipril|
304381|NCT00240435|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
304382|NCT00240435|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
304383|NCT00240448|Drug|telmisartan 80 mg/hydrochlorothiazide 25 mg|
304384|NCT00240448|Drug|valsartan 160 mg/hydrochlorothiazide 25 mg|
304385|NCT00240448|Drug|placebo|
304386|NCT00240461|Dietary Supplement|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
304387|NCT00002643|Drug|topotecan hydrochloride|
304388|NCT00243932|Drug|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
304389|NCT00243945|Drug|Rotigotine|
304390|NCT00243971|Drug|SPM 962|
303628|NCT00260364|Drug|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
303629|NCT00260364|Drug|Capecitabine orally days 1 -21|
303630|NCT00205894|Device|bion microstimulator|
303631|NCT00205907|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
303632|NCT00205920|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
303633|NCT00205946|Drug|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
303634|NCT00205946|Drug|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
303635|NCT00205959|Device|Locking proximal humerus plate|
303992|NCT00250679|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
303993|NCT00250679|Drug|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
303994|NCT00250679|Drug|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
303995|NCT00250679|Drug|Placebo|Placebo nebule or placebo aerolizer
303996|NCT00002665|Drug|mercaptopurine|con: 60 mg/m2 PO 1 - 28
303997|NCT00250692|Drug|Nitrous Oxide|
303998|NCT00253500|Drug|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
303999|NCT00253500|Procedure|conventional surgery|to remove small piece of cancer
304000|NCT00253513|Drug|fludarabine|30 mg/m2, IV for 5 days
304001|NCT00253513|Drug|treosulfan|12 or 14 g/m2, IV for 5 days
304002|NCT00253513|Procedure|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
304003|NCT00253526|Drug|bevacizumab|
304004|NCT00253526|Drug|gemcitabine hydrochloride|
304005|NCT00253526|Procedure|adjuvant therapy|
304006|NCT00002676|Drug|cyclophosphamide|
304007|NCT00253526|Procedure|anti-cytokine therapy|
303270|NCT00413127|Drug|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
303271|NCT00413127|Drug|NaCl 0,9%|Administration of placebo i.v.
303272|NCT00413153|Drug|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
303273|NCT00413153|Drug|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
303274|NCT00413166|Drug|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
303275|NCT00413166|Drug|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
303276|NCT00368693|Device|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
303277|NCT00368706|Drug|solifenacin succinate|Oral
303278|NCT00368706|Drug|tolterodine|oral
303279|NCT00368719|Drug|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
303280|NCT00368745|Drug|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
303281|NCT00368745|Drug|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
303282|NCT00368758|Drug|Probiotic bacteria (Trevis R)|
303283|NCT00368771|Behavioral|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
303636|NCT00205959|Device|Proximal Humerus Internal Locking System|
303637|NCT00002550|Drug|cisplatin|
302594|NCT00383448|Drug|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
302595|NCT00383461|Behavioral|smoking cessation intervention|
302596|NCT00383461|Other|counseling intervention|
302597|NCT00383474|Drug|Bortezomib|Given IV
302598|NCT00003162|Procedure|pain therapy|
302599|NCT00383474|Other|Laboratory Biomarker Analysis|Correlative studies
302600|NCT00383474|Drug|Tipifarnib|Given orally
302601|NCT00383487|Drug|Calcitriol|0.5 micrograms/kilogram q weekly
302602|NCT00003181|Biological|aldesleukin|
302603|NCT00386178|Drug|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
302604|NCT00386191|Drug|clopidogrel (SR25990C)|oral administration
302605|NCT00386204|Device|Q-switched Ruby Laser|
302932|NCT00374907|Drug|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
302933|NCT00377975|Drug|Pioglitazone|
302934|NCT00377975|Drug|Caffeine|
302935|NCT00377988|Drug|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
302936|NCT00377988|Drug|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
302937|NCT00003140|Other|placebo|Given orally
302938|NCT00378001|Drug|FSH-IBSA|
302939|NCT00378001|Drug|GONAL-F|
302940|NCT00378014|Drug|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
302244|NCT00391846|Drug|Spironolactone|
302245|NCT00391846|Drug|Diuretics|
302246|NCT00391846|Drug|HF treatment according to Swedish guidelines|
302247|NCT00391846|Procedure|Blood samples|
302248|NCT00391846|Procedure|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
302249|NCT00391859|Procedure|Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)|See Detailed Description.
302250|NCT00391872|Drug|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
302251|NCT00003204|Drug|fludarabine phosphate|Given IV
302252|NCT00391872|Drug|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
302253|NCT00391885|Device|Closed-loop anesthesia system|
302254|NCT00003214|Drug|doxorubicin hydrochloride|
302255|NCT00394264|Procedure|Muscle energy|
302256|NCT00394264|Procedure|Sacro-iliac articulation|
302257|NCT00394264|Procedure|High-velocity, low amplitude|
302258|NCT00394277|Drug|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
302259|NCT00394277|Drug|Ribavirin|1200 mg po daily for 48 weeks
302260|NCT00394277|Drug|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
302261|NCT00394277|Drug|Ribavirin|1400-1600 mg po daily for 48 weeks
302262|NCT00394290|Device|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
302263|NCT00394303|Drug|Intraoperative continuous insulin infusion|Nomogram specified in appendix
302264|NCT00394303|Other|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels <200 mg.dl, reflecting current practice.
302265|NCT00003214|Drug|in vitro sensitivity-directed chemotherapy|
302266|NCT00394316|Drug|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
322469|NCT00002778|Procedure|in vitro-treated bone marrow transplantation|
322470|NCT00285389|Drug|Chlorambucil|
322471|NCT00285389|Drug|rituximab|
322472|NCT00285389|Drug|cyclophosphamide|
322473|NCT00285389|Drug|alkeran|
322474|NCT00285389|Procedure|Total body irradiation (8Gy/4fr)|
322837|NCT00275678|Procedure|Blood stem cell versus bone marrow transplant|Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.
Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.
Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.
Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels.
322838|NCT00275704|Drug|Flaxseed|
322839|NCT00275730|Drug|indometacine (drug) effect on ocular blood flow|
322840|NCT00000428|Drug|Amitriptyline|Amitriptyline 25 mg po
322841|NCT00002750|Drug|melphalan|
322842|NCT00275743|Procedure|MRI|
322843|NCT00275756|Drug|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp & Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
322844|NCT00275756|Drug|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp & Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
322845|NCT00275756|Drug|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
322846|NCT00275756|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
322847|NCT00275756|Device|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
322848|NCT00275756|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
322849|NCT00275769|Device|Pacemaker|
322111|NCT00295113|Procedure|EFR|
322112|NCT00295126|Procedure|cellular therapy : Autologous platelet concentrate (APC)|
322113|NCT00295139|Behavioral|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
322114|NCT00295139|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
322115|NCT00295139|Behavioral|Critical Time Intervention (CTI)|Case management component
322116|NCT00295152|Behavioral|community occupational therapy in dementia|
322117|NCT00002802|Drug|cisplatin|
322118|NCT00295165|Drug|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
322119|NCT00295165|Drug|Placebo|Placebo subcutaneously once daily
322120|NCT00295178|Drug|Daptomycin|
322121|NCT00295178|Drug|Vancomycin|
322122|NCT00295191|Procedure|high-flux membrane|high-flux dialyser
322475|NCT00285389|Drug|vincristine|0,4 mg/day day 1 to day 4
322476|NCT00285402|Drug|AST-726 Low dose|
322477|NCT00285402|Drug|AST-726 High dose|
322478|NCT00285402|Drug|AST-726 Placebo|
322479|NCT00285415|Drug|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
322480|NCT00002779|Drug|fludarabine phosphate|
322481|NCT00285428|Drug|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
322482|NCT00285454|Procedure|Retrograde coronary venous delivery of cells.|
321388|NCT00262054|Drug|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
321389|NCT00262054|Drug|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
321390|NCT00262067|Drug|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
321751|NCT00304161|Drug|Placebo|40 to 80 mg orally once daily for 8 weeks
321752|NCT00304174|Behavioral|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
321753|NCT00304187|Drug|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
321754|NCT00304187|Drug|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
321755|NCT00304200|Drug|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
321756|NCT00304213|Drug|Testosterone|
321757|NCT00304226|Drug|valsartan|
321758|NCT00000452|Drug|naltrexone (Revia)|
321759|NCT00002824|Biological|gene therapy|
321760|NCT00304226|Drug|amlodipine|
321761|NCT00304239|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
321762|NCT00304252|Drug|Interferon beta-1a|
321763|NCT00304265|Biological|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
321764|NCT00304278|Drug|Erlotinib (Tarceva)|150 mg daily X 7 weeks
321765|NCT00304278|Drug|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
321766|NCT00304278|Radiation|Radiation Therapy (RAD)|5 days per week X 7 weeks
321026|NCT00271414|Drug|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
321027|NCT00271427|Drug|L-Selenomethionine|
321028|NCT00271440|Procedure|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
321029|NCT00271453|Drug|Durogesic® (fentanyl transdermal drug delivery system)|
321030|NCT00271466|Drug|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
321031|NCT00271479|Biological|A, C, Y, W135 meningococcal polysaccharide vaccine|
321032|NCT00271492|Drug|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
321033|NCT00271492|Drug|Atrasentan|1 10mg capsule per day for the 6 month study period.
321034|NCT00002734|Biological|recombinant interferon alfa|
321035|NCT00271492|Drug|atrasentan|One 10 mg capsule per day for 6 month study period
321036|NCT00271505|Drug|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
321037|NCT00271505|Drug|Carboplatin|AUC 6 IV every 3 weeks
321038|NCT00271505|Drug|Docetaxel|75 mg/m2 IV every 3 weeks
321039|NCT00271518|Drug|growth hormone (somatropin)|dosing regimen is weight based.
321040|NCT00271544|Device|Pacing Lead|implant and follow-up of study device
321041|NCT00271557|Drug|nesiritide|
321042|NCT00271570|Drug|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
321043|NCT00271570|Biological|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
321044|NCT00271583|Drug|CDB-2914|
321045|NCT00002734|Drug|chemotherapy|
321391|NCT00262067|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
320288|NCT00290667|Drug|doxorubicin hydrochloride|
320289|NCT00290667|Drug|prednisone|
320290|NCT00290667|Drug|vincristine sulfate|
320291|NCT00290667|Other|pharmacological study|
320292|NCT00290667|Radiation|radiation therapy|
320293|NCT00290680|Drug|bortezomib|
320294|NCT00290680|Drug|celecoxib|
320295|NCT00290693|Drug|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
320296|NCT00290693|Drug|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
320297|NCT00002790|Drug|sirolimus|
320649|NCT00281515|Drug|Lonafarnib|100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
320650|NCT00281528|Drug|ABI-007 (Abraxane)|30 minute infusions
320651|NCT00281528|Drug|bevacizumab|infusions
320652|NCT00281541|Drug|YM155|
320653|NCT00002766|Drug|etoposide|
320654|NCT00281554|Drug|RSD1235|IV
320655|NCT00281567|Drug|Tiotropium|
320656|NCT00281567|Device|Respimat SMI|
320657|NCT00281567|Device|HandiHaler|
320658|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
320659|NCT00281580|Drug|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
320660|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
320661|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
320662|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
320663|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
319913|NCT00297115|Drug|Placebo|once daily
319914|NCT00297128|Drug|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
319915|NCT00002804|Radiation|low-LET photon therapy|
319916|NCT00297128|Drug|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
319917|NCT00297141|Drug|Capecitabine|chemotherapy oral use
319918|NCT00297141|Drug|Oxaliplatin|chemotherapy intravenous use
319919|NCT00297154|Behavioral|Lifestyle Modification (diet, exercise, and behavior)|
319920|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
319921|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
319922|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
319923|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
319924|NCT00297180|Drug|GW869682|
319925|NCT00297193|Procedure|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
319926|NCT00002805|Biological|filgrastim|
319927|NCT00297206|Drug|Valaciclovir|
319928|NCT00297219|Drug|Low dialysate calcium|1.25 mmol/L dialysate calcium
319929|NCT00297219|Drug|high dialysate calcium|1.75 mmol/L dialysate calcium
319177|NCT00264160|Drug|AMN107|
319178|NCT00264173|Drug|Valproate sodium|
319179|NCT00264186|Drug|LPS 2 ng/kg intravenous (IV) bolus|
319180|NCT00264186|Drug|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
319181|NCT00264186|Drug|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
319182|NCT00264186|Drug|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
319183|NCT00264186|Drug|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
319184|NCT00000418|Procedure|Psychosocial intervention|
319185|NCT00002704|Drug|liposomal cytarabine|
319186|NCT00264199|Drug|GLP-1|iv. by weight (1.0 pmol/kg/min )
319187|NCT00264199|Drug|placebo|same rate of infusion as GLP-1
319188|NCT00264212|Drug|irbesartan and irbesartan-hydrochlorothiazide|
319537|NCT00306722|Drug|AQUAVAN® (fospropofol disodium) Injection|
319538|NCT00306735|Drug|Palonosetron|
319539|NCT00306748|Drug|MD-1100 Acetate|
319540|NCT00306761|Device|Dynamic Wheelchair Seating System|
319541|NCT00306774|Dietary Supplement|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
319542|NCT00306774|Dietary Supplement|Placebo|Placebo capsule per day for 2 years
319543|NCT00306787|Drug|Famciclovir|Famciclovir 500 mg tablet
319544|NCT00306787|Drug|Valacyclovir|Valacyclovir 500 mg capsule
319545|NCT00002831|Drug|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
319546|NCT00306787|Drug|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
319547|NCT00306787|Drug|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
300625|NCT00402558|Drug|Interleukin-2|0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
300626|NCT00402571|Drug|acetaminophen|
300973|NCT00003203|Drug|carboplatin|Given IV
300974|NCT00391404|Drug|Alendronate|Alendronate 70 mg weekly (oral)
300975|NCT00391404|Drug|Placebo|Placebo
300976|NCT00391417|Drug|estradiol gel|
300977|NCT00393848|Drug|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
300978|NCT00393848|Drug|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
300979|NCT00393848|Drug|Placebo|Placebo for Ketoconazole
300980|NCT00393861|Drug|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
300981|NCT00393874|Behavioral|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
300982|NCT00003213|Drug|dexamethasone|4 mg Dexamethasone in the morning
300983|NCT00393874|Drug|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
300984|NCT00393874|Drug|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
300985|NCT00393887|Device|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
300986|NCT00393887|Device|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
300274|NCT00408642|Behavioral|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
300275|NCT00000505|Drug|tissue plasminogen activator|
300276|NCT00003282|Other|pharmacological study|Correlative studies
300277|NCT00408655|Drug|paclitaxel|Given IV
300278|NCT00408655|Drug|carboplatin|Given IV
300279|NCT00411463|Drug|Seroquel|Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day
Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.
This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.
Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder. Subjects receiving standard of care treatment will continue to be seen and assessed per the protocol schedule.
300280|NCT00411489|Procedure|endolumenal surgery|
300281|NCT00411515|Drug|Mycophenolate Mofetil 2x 1g|
300282|NCT00411528|Drug|Patupilone|
300283|NCT00003298|Drug|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
300284|NCT00411541|Drug|vincristine|
300627|NCT00402584|Drug|sibutramine|
300628|NCT00402597|Drug|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
300629|NCT00402597|Drug|Placebo|1 placebo tablet twice daily for 6 months.
300630|NCT00402597|Drug|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
300631|NCT00402610|Drug|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
300632|NCT00402623|Dietary Supplement|quercetin|1000 mg quercetin within 24 hours
300633|NCT00003259|Drug|vinorelbine tartrate|
300634|NCT00402623|Other|placebo|
300635|NCT00402636|Device|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
299562|NCT00379392|Procedure|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
299563|NCT00379405|Drug|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
299922|NCT00370240|Other|placebo|The PCB group received saline solution in equal volume.
299923|NCT00370253|Drug|Terlipressin|1mg/4 h per day
299924|NCT00370253|Drug|Noradrenalin|0,1 mcg/kg/min
299925|NCT00370266|Drug|Triamcinolone|
299926|NCT00370279|Procedure|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
299927|NCT00370292|Drug|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
299928|NCT00370292|Drug|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
299929|NCT00370305|Drug|rosiglitazone|
299930|NCT00003105|Drug|gemcitabine hydrochloride|
299931|NCT00370318|Biological|10 valent pneumococcal conjugate vaccine|
299932|NCT00370318|Biological|Infanrix Hexa|
299933|NCT00370318|Biological|Rotarix|
299934|NCT00370318|Drug|Paracetamol|
299935|NCT00373152|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
299936|NCT00373152|Procedure|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
299937|NCT00373152|Radiation|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
299938|NCT00373165|Drug|Ganciclovir|
299939|NCT00003117|Drug|paclitaxel|
305100|NCT00218036|Drug|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
305101|NCT00218036|Drug|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
305102|NCT00218049|Drug|GBR 12909|50mg GBR 12909 over 12 days
305103|NCT00218049|Drug|GBR 12909|GBR 12909 75 mg over 12 day period
305104|NCT00218049|Drug|GBR 12909|GBR 12909 100 mg over 12 day period
305105|NCT00002582|Procedure|oophorectomy|
305106|NCT00221806|Device|endothelialised prosthesis|
305107|NCT00221819|Device|heated humidifier (device)|
305108|NCT00221819|Device|Heat and moisture exchanger (device)|
305109|NCT00221845|Drug|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
305110|NCT00221845|Drug|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
299564|NCT00379418|Drug|Abciximab|
299565|NCT00379431|Drug|Administration of rituximab and methylprednisolone|Rituximab:
Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use.
299566|NCT00379444|Behavioral|Standard intervention (counseling + self-help written materials)|counseling
299567|NCT00379444|Behavioral|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
299568|NCT00003145|Drug|Mycophenolate Mofetil|Given PO or IV
299569|NCT00379457|Biological|dactinomycin|
299570|NCT00379457|Drug|carboplatin|
299571|NCT00382070|Drug|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
299572|NCT00382070|Other|Placebo|Placebo tablet taken orally once daily for 5 years
299573|NCT00382083|Drug|1000 mg acetaminophen|
299574|NCT00382083|Drug|800 mg ibuprofen|
304391|NCT00243984|Drug|topiramate|
304750|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|40 minutes exposure
304751|NCT00229320|Behavioral|Group therapy|
304752|NCT00229333|Drug|Escitalopram|
304753|NCT00229372|Behavioral|Prolonged Exposure (PE) therapy|
304754|NCT00229385|Drug|Ziprasidone|40-80 mg BID
304755|NCT00229411|Behavioral|simulation training|
304756|NCT00229424|Drug|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
304757|NCT00229424|Drug|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
304758|NCT00002601|Biological|filgrastim|5 ug/kg daily following stem cell reinfusion
304759|NCT00233090|Drug|Placebo|daily dose of placebo for four weeks.
304760|NCT00233103|Drug|Sertraline|Sertraline arm
304761|NCT00233103|Drug|Placebo|Placebo
304762|NCT00233129|Behavioral|Top Down|Six months
304763|NCT00233129|Other|cognitive rehabilitation day treatment program|six months
304764|NCT00233142|Behavioral|Expressive writing|Writing as therapeutic intervention
304765|NCT00233142|Behavioral|Neutral writing|Non-expressive writing
304766|NCT00002616|Biological|filgrastim|
304767|NCT00233155|Drug|Capsaicin Dermal Patch|
304768|NCT00233168|Behavioral|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
304769|NCT00233168|Behavioral|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
304770|NCT00233181|Behavioral|Home-based adherence monitoring|
304771|NCT00233194|Procedure|Observational follow-up study of adenotonsillectomy|Studies of sleep, behavior, cognition, and daytime sleepiness
304008|NCT00253526|Procedure|antiangiogenesis therapy|
304009|NCT00253526|Procedure|antibody therapy|
304010|NCT00253526|Procedure|biological therapy|
304011|NCT00253526|Procedure|chemotherapy|
304012|NCT00253526|Procedure|conventional surgery|
304013|NCT00253526|Procedure|growth factor antagonist therapy|
304014|NCT00253526|Procedure|monoclonal antibody therapy|
304015|NCT00253526|Procedure|surgery|
304016|NCT00253539|Drug|arzoxifene hydrochloride|Given orally
304017|NCT00002676|Drug|cytarabine|
304018|NCT00253539|Drug|tamoxifen citrate|Given orally
304019|NCT00253539|Other|placebo|Given orally
304392|NCT00243997|Behavioral|Becoming Parents Program|Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
304393|NCT00244010|Device|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
304394|NCT00244023|Drug|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
304395|NCT00244023|Drug|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
304396|NCT00244023|Other|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
304397|NCT00244049|Behavioral|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
304398|NCT00002643|Drug|vincristine sulfate|
304399|NCT00244049|Other|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
304400|NCT00244062|Behavioral|counseling|
303638|NCT00205959|Device|Proximal Humerus Nail|
303639|NCT00205972|Device|Humerus Nail or LC Plate|
303640|NCT00205985|Device|Scaphoid screw|Conservative treatment versus application of scaphoid screw
303641|NCT00205998|Device|Locking Compression Plate 2,4mm|
303642|NCT00205998|Device|Locking Compression Plate 3,5mm|
303643|NCT00206011|Procedure|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
303644|NCT00206024|Drug|Esomeprazole magnesium (Nexium)|
303645|NCT00206037|Device|COLLOSS E|
303646|NCT00206037|Device|TomoFix Plate|
303647|NCT00206050|Drug|Esomeprazole|
303648|NCT00002550|Drug|etoposide|
303649|NCT00206050|Drug|pantoprazole|
303650|NCT00206063|Drug|EXANTA|
303651|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
303652|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil monotherapy
303653|NCT00206089|Drug|EXANTA|
303654|NCT00206102|Drug|quetiapine fumarate|flexible dose oral
303655|NCT00206102|Drug|risperidone|flexible dose oral
303656|NCT00206115|Drug|Seroquel Sustained Release (SR)|
303657|NCT00206115|Drug|Seroquel Immediate Release (IR)|
303658|NCT00206115|Drug|Placebo|
303659|NCT00002550|Procedure|conventional surgery|
303660|NCT00206128|Drug|Seroquel SR|
303661|NCT00206141|Drug|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
303662|NCT00206154|Drug|Budesonide/formoterol pMDI|
302941|NCT00378014|Drug|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
302942|NCT00378014|Drug|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
302943|NCT00378066|Drug|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
302944|NCT00378079|Other|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
302945|NCT00378079|Drug|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
302946|NCT00378079|Drug|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
302947|NCT00378092|Drug|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
302948|NCT00003141|Biological|filgrastim|Given IV
302949|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
302950|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
303284|NCT00368771|Behavioral|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
303285|NCT00003098|Other|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
303286|NCT00368771|Behavioral|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
303287|NCT00368797|Drug|XRP0038 (NV1FGF)|
303288|NCT00368823|Device|Electronic point-of-care delivery system|
302606|NCT00386217|Behavioral|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
302607|NCT00386230|Drug|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
302608|NCT00386230|Drug|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
302609|NCT00386230|Drug|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
302610|NCT00386230|Drug|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
302611|NCT00386243|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
302612|NCT00386243|Behavioral|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
302613|NCT00003181|Biological|sargramostim|
302614|NCT00386243|Drug|Co-Analgesic Therapy|Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg
Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin
Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram
302615|NCT00386243|Drug|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
302616|NCT00386256|Device|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
302617|NCT00386256|Other|Telephone counseling|
302618|NCT00386269|Drug|Codeine Phosphate Analgesia|
302619|NCT00386282|Drug|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
302620|NCT00386308|Drug|Tranexamic acid tablets|3900 mg/Day
322850|NCT00275795|Procedure|NAET Procedures|
322851|NCT00275821|Drug|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
322852|NCT00002751|Biological|monoclonal antibody Me1-14 F(ab')2|
322853|NCT00275821|Drug|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
317169|NCT00346697|Drug|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
317170|NCT00346697|Drug|Placebo|Corn-oil placebo
317171|NCT00346710|Behavioral|fellowship communication training|
317172|NCT00346723|Biological|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
317173|NCT00346736|Procedure|Acupuncture (Procedure)|
317174|NCT00346749|Drug|Salmeterol|
317175|NCT00346749|Drug|Fluticasone Propionate/Salmeterol Combination Product|
317176|NCT00346762|Behavioral|Education|HIV prevention education and risk reduction counselig
317177|NCT00000471|Behavioral|smoking cessation|
317178|NCT00002995|Biological|filgrastim|
317179|NCT00346775|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate
317180|NCT00346775|Drug|Flunisolide|Flunisolide
317181|NCT00346788|Procedure|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
317182|NCT00346801|Drug|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
317183|NCT00346801|Drug|Cisplatin|25 mg/m^2 IV over 60 minutes on Day 1, Weeks 2-8
317184|NCT00346801|Drug|CPT-11|30 mg/m^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
322483|NCT00285467|Drug|doxercalciferol and cholecalciferol|subjects will be randomized to either doxercalciferol0.5mcg or cholecalciferol 2000u, one capsule daily for 3 months
322484|NCT00285493|Drug|Antibiotics|
322485|NCT00285519|Drug|Doxazosin (drug)|
322486|NCT00285558|Behavioral|cognitive-behavioral group treatment with peer component|
322487|NCT00285571|Behavioral|Controlled Feeding Intervention|
322488|NCT00285584|Drug|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
322489|NCT00285584|Drug|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
322490|NCT00000439|Drug|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
322491|NCT00002785|Drug|methotrexate|
322492|NCT00288691|Drug|Asoprisnil (BAY86-5294)|25mg/day
322493|NCT00288691|Drug|Placebo|Placebo
322494|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
322854|NCT00275821|Drug|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
322855|NCT00275834|Drug|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
322856|NCT00275912|Drug|Oxcarbazepine|
322857|NCT00275925|Drug|Oxcarbazepine|
322858|NCT00279045|Drug|metformin|
322859|NCT00279058|Procedure|Immunotherapy treatment for melanoma|
321767|NCT00304291|Drug|Mitoxantrone|
321768|NCT00304304|Behavioral|Asthma education|Research assistant worked with CCC staff on asthma prevention
321769|NCT00304317|Drug|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
321770|NCT00002824|Drug|chemotherapy|
321771|NCT00304317|Other|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
321772|NCT00304356|Drug|Nitazoxanide|
321773|NCT00304369|Drug|Metronidazole|
321774|NCT00304382|Biological|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
322123|NCT00295191|Procedure|low-flux membrane|low-flux dialyser
322124|NCT00295191|Procedure|conventional dialysate|conventional dialysate
322125|NCT00295191|Procedure|ultrapure dialysate|ultrapure dialysate
322126|NCT00295217|Device|ExAblate 2000|
322127|NCT00295230|Procedure|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
322128|NCT00000445|Drug|naltrexone (Revia)|
322129|NCT00002802|Drug|cyclophosphamide|
322130|NCT00295243|Drug|Topotecan|
322131|NCT00295256|Behavioral|nurse case manager|
322132|NCT00295269|Drug|Mythylprednisolone|
322133|NCT00298129|Device|Ambulatory blood pressure monitoring|
322134|NCT00298142|Procedure|Usual Care provided by a medical doctor (GP or Neurologist)|
322135|NCT00002805|Radiation|low-LET cobalt-60 gamma ray therapy|
322136|NCT00298142|Procedure|Usual care plus Physio-/ Manual Therapy|
322137|NCT00298155|Drug|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
321392|NCT00262067|Drug|Chemotherapy|The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.
Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
Docetaxel 75-100 mg/m^2 IV
Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
5-fluorouracil 500 mg/m^2 IV + epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV
5-fluorouracil 500 mg/m^2 IV + doxorubicin 50 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV
Doxorubicin 50-60 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV
Epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV
Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle
321393|NCT00262080|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
321394|NCT00262080|Drug|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
321395|NCT00262106|Drug|PRO 2000/5|Gel
321396|NCT00262106|Drug|Placebo|Placebo
321397|NCT00262119|Device|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
321398|NCT00002700|Radiation|radiation therapy|
321399|NCT00262132|Drug|Mycophenolate|
321400|NCT00262145|Drug|tea extracts|
321401|NCT00262184|Drug|Soy Isoflavone|
321402|NCT00265031|Drug|Cyclophosphamide|
321403|NCT00000419|Drug|Premarin and Provera|
321404|NCT00002706|Procedure|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
321405|NCT00265031|Drug|Adriamycin|
321406|NCT00265031|Drug|Etoposide|
321407|NCT00265031|Drug|Procarbazine|
321408|NCT00265031|Drug|Prednisone|
321409|NCT00265031|Drug|Vincristine|
321410|NCT00265031|Drug|Bleomycin|
321411|NCT00265031|Procedure|radiation therapy|
321412|NCT00265044|Behavioral|Provider Education|
321413|NCT00265044|Behavioral|Hypertension Alert|
320664|NCT00000433|Drug|Anti-Tumor Necrosis Factor|
320665|NCT00002766|Drug|mercaptopurine|
320666|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
320667|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
320668|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
320669|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
320670|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
320671|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
320672|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
320673|NCT00284271|Drug|Erythropoietin beta|
320674|NCT00284284|Device|Use of a rehabilitation brace|
320675|NCT00284297|Procedure|History taken and clinical examination|History is taken and clinical examination is followed
321046|NCT00271583|Drug|levonorgestrel|
321047|NCT00271596|Drug|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
321048|NCT00271596|Drug|Placebo|a daily matching placebo administered over 16 weeks
321049|NCT00271609|Drug|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
321050|NCT00271635|Drug|Placebo|Placebo 4 capsules b.i.d. during 1 year
321051|NCT00274937|Radiation|radiation therapy|Undergo radiotherapy
321052|NCT00274950|Biological|bleomycin sulfate|
321053|NCT00274950|Drug|carboplatin|
321054|NCT00274950|Drug|cisplatin|
321055|NCT00274950|Drug|etoposide|
321056|NCT00274950|Drug|ifosfamide|
321057|NCT00274950|Drug|vinblastine sulfate|
320298|NCT00290706|Drug|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
320299|NCT00290706|Drug|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
320300|NCT00290719|Drug|cisplatin|
320301|NCT00290719|Drug|gefitinib|
320302|NCT00290719|Drug|irinotecan hydrochloride|
320303|NCT00290719|Procedure|conventional surgery|
320304|NCT00290719|Procedure|neoadjuvant therapy|
320305|NCT00290719|Radiation|radiation therapy|
320306|NCT00290732|Drug|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
320307|NCT00290732|Drug|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
320308|NCT00000441|Drug|lorazepam (Ativan)|
320309|NCT00002791|Biological|filgrastim|
320310|NCT00290745|Drug|letrozole|
320311|NCT00290745|Drug|tamoxifen citrate|
320312|NCT00290745|Procedure|conventional surgery|
320313|NCT00294177|Device|atomic force microscopy|
320314|NCT00294177|Device|dual polarisation interferometry|
320315|NCT00294190|Drug|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
320316|NCT00294203|Drug|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
319548|NCT00306800|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
319549|NCT00306813|Drug|Revlimid|
319550|NCT00306826|Drug|pioglitazone|
319551|NCT00309751|Drug|Pitavastatin|Pitavastatin 4 mg QD
319552|NCT00309751|Drug|Atorvastatin|Atorvastatin 20 mg
319553|NCT00309764|Behavioral|Telemedicine|
319554|NCT00309777|Drug|Pitavastatin|Pitavastatin once daily
319555|NCT00309777|Drug|Simvastatin|Simvastatin once daily
319556|NCT00309790|Drug|sildenafil|
319557|NCT00002836|Biological|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
319558|NCT00309803|Device|FiberNet Embolic Protection Device|
319559|NCT00309816|Drug|sildenafil|
319560|NCT00309842|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days.
319930|NCT00300638|Procedure|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
319931|NCT00300638|Behavioral|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
319932|NCT00002812|Drug|idarubicin|Given IV
319933|NCT00300651|Behavioral|Cognitive Behavioral Therapy|
319934|NCT00300664|Drug|Human Growth hormone|
319935|NCT00300677|Drug|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
319936|NCT00300690|Device|6 mm Uni-graft® (B-Braun)|
300987|NCT00393913|Device|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
300988|NCT00393926|Device|TheraDrive Assistive Device|
300989|NCT00393926|Procedure|Rote Therapy versus Fun Therapy|
301318|NCT00385788|Drug|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
301319|NCT00385788|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
301320|NCT00385801|Drug|Risperidone|
301321|NCT00385827|Drug|Mitoxantrone|Mitoxantrone 12 mg/m^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2)
301322|NCT00003176|Drug|temozolomide|
301323|NCT00385827|Drug|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
301324|NCT00385827|Drug|Prednisone|Prednisone 5 mg orally twice daily
301325|NCT00385840|Biological|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
301326|NCT00385840|Biological|FluarixTM|Single dose, intramuscular injection
301327|NCT00385853|Drug|PTK787/ZK 222584|Twice daily for each 28-day cycle
301328|NCT00385853|Drug|Temozolomide|Daily for each 28-day cycle
301329|NCT00388713|Procedure|carotid intima-media thickening ultrasound|
301330|NCT00388726|Drug|E7389|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
301331|NCT00388726|Drug|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
301332|NCT00388739|Drug|Pulmicort|
301333|NCT00388739|Behavioral|TEDAS ED Educational Intervention|
301334|NCT00388752|Procedure|Acupuncture|
301335|NCT00388778|Drug|Doxycycline|
300636|NCT00402636|Device|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
300637|NCT00402649|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
300638|NCT00402662|Drug|everolimus|
300639|NCT00402662|Drug|Imatinib|
300640|NCT00402675|Procedure|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
300641|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
300642|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
300643|NCT00402688|Drug|levofloxacin|500mg tablet once daily for 4 weeks.
300644|NCT00003260|Drug|FOLFIRI regimen|
300645|NCT00402701|Behavioral|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
300646|NCT00402714|Procedure|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
300647|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
300648|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
300649|NCT00405639|Drug|Placebo|Normal saline will be used for placebo.
300650|NCT00405652|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
300990|NCT00393939|Drug|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
300991|NCT00393939|Drug|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
300992|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
300993|NCT00003213|Drug|granisetron hydrochloride|1 mg Granisetron in the morning
300994|NCT00393952|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
300995|NCT00396695|Procedure|Blood test|
299940|NCT00373178|Drug|rosiglitazone|
299941|NCT00373178|Drug|metformin|
299942|NCT00373178|Drug|Anti-diabetic medications|
299943|NCT00373191|Drug|chemotherapy|N/A- not dictated by study
299944|NCT00373191|Drug|endocrine therapy|N/A- not dictated by study
300285|NCT00411541|Drug|dexamethasone|
300286|NCT00411554|Drug|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
300287|NCT00411554|Drug|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
300288|NCT00411567|Drug|inhaled corticosteroid therapy|
300289|NCT00411580|Biological|CAD106|
300290|NCT00411580|Drug|Placebo|
300291|NCT00411593|Drug|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
300292|NCT00411593|Drug|Bortezomib|Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.
Phase II: MTD from Phase I.
300293|NCT00411606|Procedure|Thermography|Subjects will have a picture of their face taken with a thermal camera
300294|NCT00003298|Drug|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
300295|NCT00411619|Drug|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
300296|NCT00411632|Drug|Bexarotene|400 mg/m^2 by mouth daily x 28 Days
300297|NCT00411632|Drug|Erlotinib|150 mg by mouth daily x 28 Days
300298|NCT00411645|Drug|maribavir|100 mg twice daily for up to 12 weeks
300299|NCT00411645|Other|placebo|twice daily for up to 12 weeks
300300|NCT00411658|Device|Investigational Device|
299575|NCT00382083|Drug|1 oz 4% lidocaine gel|
299576|NCT00382096|Drug|Vildagliptin|
299577|NCT00382096|Drug|Metformin|
299578|NCT00003157|Drug|cisplatin|
299579|NCT00382096|Drug|Vildagliptin + Metformin|
299580|NCT00382109|Drug|thiotepa|Given IV
299581|NCT00382109|Drug|cyclophosphamide|Given IV
299582|NCT00382109|Drug|tacrolimus|Given IV or orally
299583|NCT00382109|Drug|methotrexate|Given IV
299584|NCT00382109|Drug|sirolimus|Given orally
299585|NCT00382109|Radiation|total body irradiation|Part of the transplant preparatory regimen
299586|NCT00382135|Drug|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
299587|NCT00382135|Drug|placebo|Placebo tablet taken by mouth once a day for 40 weeks
299588|NCT00382148|Drug|omalizumab|SC repeating dose
299589|NCT00003157|Drug|gemcitabine hydrochloride|
299590|NCT00382161|Drug|Fluvastatin-sodium|
299945|NCT00373191|Genetic|DNA methylation analysis|laboratory analysis
299946|NCT00373191|Genetic|protein analysis|laboratory analysis
299947|NCT00373191|Other|laboratory biomarker analysis|laboratory analysis
299948|NCT00373191|Other|questionnaire administration|questionnaire
299949|NCT00373191|Procedure|adjuvant therapy|N/A- not dictated by study
299950|NCT00000485|Drug|diuretics|
299951|NCT00003118|Drug|cisplatin|
299952|NCT00373191|Procedure|conventional surgery|N/A- not dictated by study
299953|NCT00373191|Radiation|radiation therapy|N/A- not dictated by study
304772|NCT00233207|Drug|IC14|
299198|NCT00390494|Procedure|Hysterectomy|
299199|NCT00390494|Procedure|Myomectomy|
299200|NCT00390494|Procedure|Uterine Fibroid Embolization|
299201|NCT00390507|Procedure|Post-tetanic count frequency|
299202|NCT00390520|Drug|Vildagliptin|
299203|NCT00390533|Drug|Saredutant|oral administration (capsules)
299204|NCT00390533|Drug|Placebo|oral administration (capsules)
299205|NCT00390546|Drug|Digoxin|
299206|NCT00390546|Drug|Propranolol|
299207|NCT00003199|Drug|melphalan|Given IV
299208|NCT00390559|Drug|nicotine transdermal system|21 mg nicotine transdermal system
299209|NCT00390559|Drug|Nicotine transdermal system|Placebo nicotine patch
299210|NCT00390559|Other|Nicotine containing cigarette|Nicotine containing cigarette
299211|NCT00390559|Other|Placebo cigarette|Non nicotine containing cigarette
299212|NCT00390572|Behavioral|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
299213|NCT00390585|Drug|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
299214|NCT00390585|Drug|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
299215|NCT00390598|Drug|PEG (solution given 4 L)|
299216|NCT00390598|Drug|senna glycoside 36 mg and PEG (solution given 2 L)|
299217|NCT00390611|Drug|Sorafenib|
299218|NCT00000496|Drug|dipyridamole|
299219|NCT00003199|Biological|aldesleukin|Given SC
304401|NCT00244075|Dietary Supplement|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
304402|NCT00244075|Drug|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
304403|NCT00244075|Behavioral|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
304404|NCT00244101|Drug|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
304405|NCT00244101|Device|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
304406|NCT00244101|Drug|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
304407|NCT00244114|Drug|blood draw|Single blood sample collected to perform histamine release assay.
304408|NCT00244114|Procedure|Blood draw|Single blood sample collected to perform histamine release assay.
304409|NCT00002643|Procedure|conventional surgery|
304410|NCT00247000|Device|Routine Care in a HF clinic vs Home Telehealth Care for HF|
304773|NCT00233220|Behavioral|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
304774|NCT00233220|Behavioral|Usual Care|Patients will receive usual care.
304775|NCT00233233|Behavioral|Standardized Asthma Education Program|
304776|NCT00233246|Procedure|FFP Infusion|
304777|NCT00002616|Drug|carboplatin|
304778|NCT00233259|Behavioral|Mediterranean Diet|Mediterranean dietary program
304779|NCT00233259|Behavioral|Physical Activity|Physical activity program
303663|NCT00206154|Drug|Budesonide pMDI|
304020|NCT00253552|Biological|filgrastim|
304021|NCT00253552|Drug|busulfan|
304022|NCT00253552|Drug|cyclophosphamide|
304023|NCT00253552|Drug|cyclosporine|
304024|NCT00253552|Drug|etoposide|
304025|NCT00253552|Drug|methotrexate|
304026|NCT00253552|Procedure|allogeneic bone marrow transplantation|
304027|NCT00253552|Radiation|radiation therapy|
304028|NCT00000411|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
304029|NCT00002676|Drug|dexamethasone|
304030|NCT00253565|Drug|capecitabine|
304031|NCT00253565|Drug|imatinib mesylate|
304032|NCT00256542|Drug|Alkalinized Lidocaine-Heparin|
304033|NCT00256555|Drug|Nutropin AQ|
304034|NCT00256568|Behavioral|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
304035|NCT00256581|Procedure|Additional rest and stress image sets on new camera|
304036|NCT00256594|Device|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
304037|NCT00256620|Procedure|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
304038|NCT00256646|Drug|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
304039|NCT00256659|Behavioral|Early assessment and referral to ancillary care services vs. standard care|
304040|NCT00000412|Drug|Placebo Calcitriol|
304041|NCT00002688|Drug|mitoxantrone hydrochloride|
303289|NCT00368836|Device|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
303290|NCT00371748|Device|Express2|Coronary Stent System
303291|NCT00371761|Biological|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
303292|NCT00371761|Drug|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
303293|NCT00371787|Device|Soft contact lens|Soft contact lens
303294|NCT00000484|Drug|chlorothiazide|
303295|NCT00003113|Drug|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
303296|NCT00371800|Drug|cinnamon|
303297|NCT00371813|Drug|Varenicline tartrate|
303298|NCT00371813|Drug|Placebo|
303299|NCT00371826|Drug|Everolimus (RAD001)|
303300|NCT00371826|Drug|Cyclosporine (Calcineurin Inhibitor (CNI))|
303301|NCT00371826|Drug|Methylprednisone/prednisone|
303302|NCT00371826|Drug|Mycophenolate sodium (MPA)|
303303|NCT00371839|Procedure|Audiological Evaluation|Tests of hearing, cognition, and speech perception
303664|NCT00209482|Drug|glucophage XR|
303665|NCT00209495|Drug|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
303666|NCT00209508|Drug|GPI 1485|
303667|NCT00209521|Drug|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
303668|NCT00209521|Drug|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
303669|NCT00209534|Drug|fospropofol disodium|
303670|NCT00209547|Drug|fospropofol disodium|
302621|NCT00386308|Drug|Placebo tablets|
302622|NCT00389311|Procedure|Gastrointestinal instrumentation|
302951|NCT00378105|Drug|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
302952|NCT00378105|Drug|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
302953|NCT00378105|Drug|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
302954|NCT00378118|Other|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
302955|NCT00380926|Drug|polyunsatturated fatty acids (fish oil)|
302956|NCT00380939|Drug|Atorvastatin|
302957|NCT00380939|Drug|Pravastatin|
302958|NCT00380952|Device|Dune Device|
302959|NCT00380965|Drug|Cesamet™ (nabilone)|
302960|NCT00003151|Drug|amoxicillin|
302961|NCT00380978|Procedure|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
302962|NCT00380978|Procedure|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
302963|NCT00380991|Drug|lactoserum|
302964|NCT00381004|Drug|Cyclophosphamide|Course 1: 250 mg/m^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
302965|NCT00381004|Drug|Fludarabine|Course 1: 25 mg/m^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
302966|NCT00381004|Drug|Sargramostim|Course 1: 250 mcg/m^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m^2 SQ on Days -1 and Days 4 - 10
317185|NCT00346801|Radiation|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
317186|NCT00346814|Drug|intravitreal injection|
317187|NCT00346827|Drug|Apomorphine Nasal Powder|
317188|NCT00346840|Drug|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
317189|NCT00002995|Biological|sargramostim|
317190|NCT00346840|Drug|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
317191|NCT00346840|Drug|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
317192|NCT00346840|Drug|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
317193|NCT00346853|Drug|4-Methylpyrazole|15 mg/kg dose
317540|NCT00334503|Drug|Miglitol|
317541|NCT00334529|Drug|Oseltamivir|
317542|NCT00002945|Biological|aldesleukin|IV
317543|NCT00334542|Drug|simvastatin|24-28 weeks of simvastatin
317544|NCT00334555|Other|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
317545|NCT00334555|Other|partner delivered meds|patient given meds to give to her partner
317546|NCT00334555|Other|field intervention|health worker finds partners
317547|NCT00334568|Drug|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
317548|NCT00334568|Drug|Placebo|Placebo
317549|NCT00334581|Drug|Irbesartan|Administration throughout the study period
317550|NCT00282997|Drug|pregabalin|
317551|NCT00283010|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
317552|NCT00283010|Other|Educational DVDs|
317553|NCT00283023|Procedure|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
322860|NCT00279071|Device|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
322861|NCT00279084|Drug|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
322862|NCT00279084|Drug|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
322863|NCT00279097|Device|High Frequency Chest Wall Oscillation|
322864|NCT00279110|Behavioral|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
322865|NCT00279123|Drug|pantoprazole infusion|
322866|NCT00279123|Drug|pantoprazole bolus|
322867|NCT00279123|Drug|no treatment|
322868|NCT00002759|Drug|phenobarbital|
322869|NCT00279149|Procedure|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
322870|NCT00279162|Drug|Calcipotriene/betamethasone gel and ointment|
322871|NCT00279175|Biological|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
322872|NCT00279175|Biological|Placebo medium supplemented with autologous serum|
322873|NCT00279188|Procedure|Guiding therapy by bronchial hyperrsponsiveness|
322874|NCT00279201|Drug|Insulin glargine|Subcutaneous injection daily
322875|NCT00279201|Drug|Lispro Low Mix|Subcutaneous injection twice daily.
322876|NCT00279201|Drug|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
322877|NCT00279201|Drug|Lispro|Lispro subcutaneous injection 3 times daily.
322878|NCT00279214|Drug|drotrecogin alfa (activated)|
317194|NCT00346853|Other|saline|
317195|NCT00346866|Drug|anecortave acetate|
322138|NCT00298155|Drug|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
322139|NCT00298155|Drug|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
322140|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
322141|NCT00298168|Drug|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
322142|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
322143|NCT00298181|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
322144|NCT00298194|Drug|Z-338|
322145|NCT00298207|Behavioral|Walking (behavior)|
322495|NCT00288704|Drug|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
322496|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
322497|NCT00288717|Drug|Candesartan|
322498|NCT00288717|Drug|Telmisartan|
322499|NCT00288730|Drug|nesiritide|
322500|NCT00288743|Drug|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
322501|NCT00288756|Procedure|lv injection of contrast|
322502|NCT00002785|Drug|methylprednisolone|
322503|NCT00288769|Drug|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
322504|NCT00288782|Drug|Mirtazapine|
322505|NCT00288795|Other|Massage Therapy|Therapeutic Touch
322506|NCT00288795|Other|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
321414|NCT00265044|Behavioral|Patient Education|
321415|NCT00002706|Other|Quality-of-Life Assessment|Ancillary studies
321775|NCT00304382|Biological|Pneumovax|0.5 ml IM one time
321776|NCT00307541|Biological|Pneumococcal (vaccine)|
321777|NCT00307554|Biological|Pneumococcal (vaccine)|
321778|NCT00307567|Biological|Pneumococcal (vaccine)|
321779|NCT00307580|Drug|Cathflo Activase (Alteplase)|
321780|NCT00307593|Drug|Infliximab|Infliximab
321781|NCT00307593|Drug|Rituximab|Rituximab
321782|NCT00307606|Drug|Solu-medrol 125 mg|
321783|NCT00002832|Procedure|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
321784|NCT00307619|Drug|topiramate|
321785|NCT00307632|Drug|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
321786|NCT00307645|Drug|Cyclophosphamide|
321787|NCT00307645|Drug|Mycophenolate mofetil|
321788|NCT00307645|Drug|Azathioprine|
321789|NCT00307645|Drug|Prednisone (and methylprednisolone)|
321790|NCT00307658|Drug|Intravenous immunoglobulins (human immunoglobulins G)|
321791|NCT00307671|Drug|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
321792|NCT00307671|Drug|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
321793|NCT00307671|Drug|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
321794|NCT00000455|Drug|naltrexone|
321795|NCT00002833|Biological|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
321058|NCT00274950|Procedure|adjuvant therapy|
321059|NCT00002744|Radiation|low-LET photon therapy|
321060|NCT00274950|Procedure|conventional surgery|
321061|NCT00274963|Drug|bendamustine hydrochloride|
321062|NCT00274963|Drug|mitoxantrone hydrochloride|
321063|NCT00274976|Biological|alemtuzumab|
321064|NCT00274989|Biological|rituximab|
321065|NCT00274989|Drug|bendamustine hydrochloride|
321066|NCT00275002|Drug|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
321067|NCT00275002|Drug|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
321068|NCT00275015|Biological|filgrastim|
321069|NCT00275015|Drug|carmustine|
321070|NCT00000427|Drug|Alendronate|
321416|NCT00265057|Drug|ADH -1 (Exherin™)|
321417|NCT00265070|Drug|Gefitinib|250 mg tablet oral daily dose
321418|NCT00265083|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
321419|NCT00265083|Biological|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
321420|NCT00265083|Biological|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
321421|NCT00265096|Biological|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
320317|NCT00294203|Other|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
320318|NCT00294216|Drug|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
320319|NCT00002798|Drug|busulfan|
320676|NCT00284310|Procedure|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
320677|NCT00284323|Drug|Adenosine|
320678|NCT00284336|Drug|Caelyx|
320679|NCT00284336|Drug|endoxan|
320680|NCT00284349|Device|Use of a rehabilitation brace instead of a plaster|
320681|NCT00002774|Drug|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
320682|NCT00284362|Procedure|Arthroscopic or open surgery for hallux rigidus|
320683|NCT00284375|Procedure|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
320684|NCT00284388|Procedure|Simultaneous controlled power measurement|
320685|NCT00284388|Procedure|Surface EMG measurement|
320686|NCT00284401|Procedure|Evaluation of the placement of the Delta prosthesis|
320687|NCT00284414|Procedure|Ultrasonography or MRI|
320688|NCT00284427|Drug|vitamin C|IV Vitamin C given 2-3 times a week
320689|NCT00284453|Procedure|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving >2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
320690|NCT00284466|Procedure|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
320691|NCT00284479|Behavioral|Walking 45 mins 2x p.w.|
320692|NCT00002774|Drug|5-fluorouracil|100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.
The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT.
320693|NCT00284492|Procedure|Traditional chinese medicine type acupuncture|10 acupuncture sessions
319937|NCT00300690|Device|6 mm Gore-Tex® (WL Gore)|
319938|NCT00300716|Drug|Memantine|
319939|NCT00300729|Drug|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
319940|NCT00300729|Drug|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
319941|NCT00300742|Drug|Topiramate|Topiramate up to 300 mg per day.
319942|NCT00300755|Drug|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
319943|NCT00002812|Drug|mercaptopurine|Given IV
319944|NCT00300768|Drug|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
319945|NCT00300768|Drug|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
319946|NCT00300768|Drug|4 mg moxidectin|Single dose, tablets encapsulated for blinding
319947|NCT00300768|Drug|8 mg moxidectin|single dose, tablets encapsulated for blinding
319948|NCT00300781|Drug|HKI-272 (neratinib)|80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen.
319949|NCT00300781|Drug|HKI-272 (neratinib)|80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen.
319950|NCT00300794|Drug|Ketamine|
319951|NCT00300807|Drug|XTL 6865|
302056|NCT00371371|Procedure|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
302057|NCT00371371|Procedure|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
302058|NCT00371371|Procedure|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
302059|NCT00003111|Drug|paclitaxel|
302060|NCT00374166|Drug|SSR149415|Oral administration (capsules)
301336|NCT00000495|Behavioral|alcohol restriction|
301337|NCT00003193|Drug|amifostine trihydrate|
301338|NCT00388791|Drug|Systane Free|
301339|NCT00388804|Procedure|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
301340|NCT00388804|Drug|Bicalutamide|50 mg By Mouth (PO) Daily
301341|NCT00388804|Drug|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
301687|NCT00003149|Biological|recombinant interleukin-12|
301688|NCT00380133|Drug|Prednisolone|5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
301689|NCT00380133|Drug|Placebo|Tablets matched to SB681323 or prednisolone
301690|NCT00380146|Drug|sulfadoxine-pyrimethamine|
301691|NCT00380159|Drug|elvucitabine|elvucitabine 10 mg in combination with background ART
301692|NCT00380159|Drug|Lamivudine|
301693|NCT00380159|Drug|Emtricitabine|
301694|NCT00380172|Device|Rheopheresis blood filtration|
301695|NCT00380198|Drug|Apadenoson|
301696|NCT00380211|Biological|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
301697|NCT00380211|Biological|Fluarix|
301698|NCT00003150|Biological|rituximab|
301699|NCT00380224|Drug|bifeprunox, olanzapine|
301700|NCT00380237|Biological|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
301701|NCT00380250|Drug|Lubiprostone|
301702|NCT00380250|Drug|Placebo|
301703|NCT00380263|Drug|PACAP38|10 pmol/kg/min given one time
301704|NCT00380276|Drug|MPC-7869|800 mg BID Oral dosing
300996|NCT00396708|Device|myomo e100 neurorobotic elbow brace|
300997|NCT00396721|Drug|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
300998|NCT00003220|Drug|bryostatin 1|
300999|NCT00396721|Drug|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
301000|NCT00396734|Drug|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
301001|NCT00396734|Drug|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
301002|NCT00396747|Drug|Infliximab, methylprednisolone, methotrexate|
301003|NCT00396747|Drug|Methotrexate|
301004|NCT00396747|Drug|Methotrexate + Methylprednisolone|
301005|NCT00396747|Drug|Methotrexate + Infliximab|
301006|NCT00396760|Drug|aprotinin or tranexamic acid|
301007|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
301008|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
301009|NCT00003222|Biological|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
301010|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
301011|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
301012|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
301342|NCT00388804|Drug|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
301343|NCT00388804|Drug|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
301344|NCT00388804|Behavioral|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
301345|NCT00388817|Behavioral|Pharmacist intervention|
301346|NCT00388830|Procedure|Ultrasound|
300301|NCT00411658|Device|Experimental|
300302|NCT00411658|Other|Cryopreserved|
300303|NCT00367133|Drug|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
300304|NCT00367133|Drug|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
300651|NCT00405665|Drug|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
300652|NCT00405665|Drug|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
300653|NCT00405678|Behavioral|Exercise Training|Subjects receiving chemo with exercise training
300654|NCT00405678|Behavioral|Chemo only|Subjects receiving chemo only
300655|NCT00003269|Drug|etoposide|
300656|NCT00405691|Device|"TOPS System" - Total Posterior Arthroplasty Implant|
300657|NCT00405704|Drug|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
300658|NCT00405704|Drug|Placebo|Cherry flavored liquid suspension matched to active comparator.
300659|NCT00405717|Drug|atorvastatin,pravastatin|
300660|NCT00405730|Drug|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
300661|NCT00405730|Drug|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
300662|NCT00405730|Other|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
300663|NCT00405743|Drug|CP-4055|CP-4055 Continuous IV infusion
300664|NCT00405743|Drug|CP-4055|CP4055 2 and 4 hour IV infusion
299954|NCT00373204|Drug|Motexafin Gadolinium|On Day 1 of each 3 week cycle for up to 12 cycles:
MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour.
299955|NCT00373217|Biological|MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine|Given intradermally or subcutaneously
299956|NCT00373217|Biological|tetanus toxoid helper peptide|Given intradermally or subcutaneously
299957|NCT00373217|Drug|carboplatin|Given IV
299958|NCT00373217|Drug|paclitaxel|Given IV
299959|NCT00373217|Procedure|conventional surgery|Patients undergo primary optimal cytoreductive surgery
299960|NCT00373230|Behavioral|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
299961|NCT00373243|Drug|GW406381|
299962|NCT00003118|Drug|fluorouracil|
299963|NCT00373256|Drug|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
299964|NCT00376688|Drug|Temsirolimus|Given IV
299965|NCT00376701|Drug|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
299966|NCT00000144|Procedure|Argon Laser Treatment|
299967|NCT00000487|Behavioral|smoking cessation|
299968|NCT00003133|Drug|paclitaxel|
299969|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
299970|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
300305|NCT00367146|Drug|MMF|
300306|NCT00367159|Procedure|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
300307|NCT00367172|Behavioral|Directly Administered Antiretroviral Therapy|
300308|NCT00367185|Drug|Thalidomide|
300309|NCT00367198|Dietary Supplement|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
300310|NCT00367211|Drug|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
299220|NCT00390611|Drug|Paclitaxel|Paclitaxel
299221|NCT00390611|Drug|Carboplatin|Carboplatin
299222|NCT00390624|Drug|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
299591|NCT00382174|Drug|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
299592|NCT00382174|Drug|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
299593|NCT00382187|Biological|MF59 adjuvanted H5N1 influenza vaccine|MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1
non-adjuvanted influenza vaccine containing 15 ug of H5N1
299594|NCT00382200|Drug|decitabine|
299595|NCT00382200|Drug|tretinoin|
299596|NCT00382200|Genetic|DNA methylation analysis|
299597|NCT00382200|Genetic|cytogenetic analysis|
299598|NCT00382200|Genetic|microarray analysis|
299599|NCT00382200|Other|flow cytometry|
299600|NCT00003157|Radiation|radiation therapy|
299601|NCT00382200|Other|immunohistochemistry staining method|
299602|NCT00382213|Drug|Olmesartan medoxomil|
299603|NCT00382213|Drug|Placebo|
299604|NCT00382226|Drug|Azopt|
299605|NCT00384852|Drug|rhBMP-2/CPM|
299606|NCT00384865|Drug|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
299607|NCT00384865|Drug|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
299608|NCT00384865|Drug|Placebo|Placebo, taken orally, once a day for 6 months
299609|NCT00000493|Drug|hyaluronidase|
299610|NCT00003172|Drug|docetaxel|
299611|NCT00384878|Drug|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
304780|NCT00233259|Behavioral|Stress Management|Stress management program
304781|NCT00233259|Behavioral|Social Support|Social support
304782|NCT00233259|Behavioral|Smoking Cessation|Smoking cessation program
304783|NCT00233259|Other|Control group|Usual Diabetes Care Control group
304784|NCT00233324|Drug|Surfactant|Intubation and administration of surfactant by 1 hour of age.
304785|NCT00236938|Drug|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
304786|NCT00236938|Drug|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
304787|NCT00236951|Drug|iron sucrose injection USP|
304788|NCT00002627|Biological|filgrastim|
304789|NCT00236951|Drug|stable erythropoietin therapy|
304790|NCT00236964|Drug|Iron Sucrose + Erythropoietin|
304791|NCT00236964|Drug|Ferrous Sulfate + Erythropoietin|
304792|NCT00236977|Drug|Venofer|iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
304793|NCT00236977|Drug|Ferrous Sulfate|oral iron tablets; 325 mg three times a day orally for 56 days
304794|NCT00236990|Drug|pentosan polysulfate sodium|
299223|NCT00390624|Drug|MANNITOL|
299224|NCT00390637|Behavioral|High or low Glycemic Index and high or low Protein Diet|
299225|NCT00390650|Drug|Saredutant|
299226|NCT00390663|Procedure|Nasal Cautery|
299227|NCT00393094|Biological|Bevacizumab|10 mg/kg intravenous injection
299228|NCT00393094|Drug|Irinotecan hydrochloride|125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
299229|NCT00393107|Drug|rituximab|
304042|NCT00256672|Device|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
304043|NCT00256685|Drug|DVS-233 SR|
304044|NCT00256698|Drug|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
304045|NCT00256698|Drug|Anastrozole|1 mg oral tablet
304411|NCT00247013|Behavioral|Breast Cancer Screening Compliance|
304412|NCT00247026|Drug|curcumin; coenzyme q10|
304413|NCT00247039|Dietary Supplement|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
304414|NCT00247039|Other|Placebo capsules|placebo capsules
304415|NCT00247052|Drug|diclofenac|diclofenac 50 mg bid versus placebo bid
304416|NCT00247052|Drug|diclofenac|diclofenac 100 mg per day for 14 days
304417|NCT00247052|Drug|matching placebo|
304418|NCT00247078|Biological|widow spider antivenom|3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
304419|NCT00002657|Drug|cytarabine|300 mg/m^2
304420|NCT00247078|Biological|Placebo|
304421|NCT00247091|Biological|standard-titer measles vaccine|
304422|NCT00247104|Drug|Cranberries - Vaccinium macrocarpon|
304423|NCT00247117|Drug|Metformin|
304424|NCT00247130|Drug|Omeprazole|
304425|NCT00247130|Drug|Ranitidine|
304426|NCT00247143|Drug|Kaletra (drug)|
304427|NCT00247156|Procedure|Acupressure treatments and NAET treatments|
304428|NCT00247169|Drug|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
304429|NCT00247182|Behavioral|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
303671|NCT00209560|Drug|fospropofol disodium|
303672|NCT00209573|Drug|fospropofol disodium|
303673|NCT00209586|Drug|fospropofol disodium|
303674|NCT00002556|Biological|recombinant interferon alfa-2b|Given SC
303675|NCT00209599|Drug|fospropofol disodium|
303676|NCT00209612|Drug|Taxol|Day1,15 X mg/m2, IV (in the vein)
303677|NCT00209612|Drug|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
303678|NCT00209625|Drug|irinotecan|
303679|NCT00209625|Drug|leucovorin|
303680|NCT00209625|Drug|fluorouracil|
303681|NCT00209638|Drug|irinotecan|
303682|NCT00209638|Drug|S-1|
303683|NCT00209651|Drug|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
303684|NCT00209651|Drug|TS-1|80 mg/m2, PO (oral) on day 1~14 of each 28 day cycle.
303685|NCT00002556|Other|laboratory biomarker analysis|Correlative studies
303686|NCT00209664|Drug|irinotecan|
303687|NCT00209664|Drug|S-1|
303688|NCT00209677|Drug|Gemcitabine|
303689|NCT00209677|Drug|S-1|
303690|NCT00209690|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
304046|NCT00256711|Drug|Gefitinib|
304047|NCT00256711|Drug|Vinorelbine|
304048|NCT00256724|Device|Impedance Threshold Device|Active impedance threshold device
304049|NCT00256724|Device|sham ITD|sham impedance threshold device
304050|NCT00256737|Drug|Omeprazole|
302967|NCT00381004|Drug|Rituximab|Course 1: 375 mg/m^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m^2 by vein over 2-6 Hours on Day 1
302968|NCT00381017|Drug|Peg interferon alpha-2b|
302969|NCT00381030|Drug|carvedilol plus nurse management|
303304|NCT00371852|Drug|lactoserum|
303305|NCT00371865|Behavioral|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
303306|NCT00003113|Drug|etoposide|Etoposide is given on days 1-3.
303307|NCT00371865|Behavioral|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
303308|NCT00371878|Biological|7-valent pneumococcal conjugate vaccine (Prevnar)|
303309|NCT00371891|Procedure|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
303310|NCT00371904|Drug|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
303311|NCT00371904|Drug|Standard Care|Standard care
303312|NCT00371930|Procedure|application of a dye suspension followed by a laser intervention|
303313|NCT00371943|Procedure|band ligation|
303314|NCT00371956|Drug|raloxifene|60mg/day
303315|NCT00371956|Drug|placebo|tab 1 daily
303316|NCT00371969|Behavioral|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
303317|NCT00003113|Drug|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
303318|NCT00371969|Behavioral|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
303319|NCT00374907|Drug|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
303320|NCT00374920|Drug|MEM 1003|
303321|NCT00374933|Drug|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic" delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
317554|NCT00002772|Biological|filgrastim|
317555|NCT00283036|Drug|Irbesartan|
317556|NCT00283049|Drug|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
317557|NCT00283049|Drug|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
317558|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|75 mg/m^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.
Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
317559|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
317560|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|75 mg/m^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.
Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
317905|NCT00273598|Procedure|Moss Miami Spine Instrumentation System|
317906|NCT00273598|Procedure|Universal Spine Instrumentation System|
317907|NCT00273611|Behavioral|Pharmacist Education about Vitamin D|
317908|NCT00000426|Drug|Calcium supplement|
317909|NCT00002740|Procedure|peripheral blood stem cell transplantation|
317910|NCT00273624|Drug|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
317911|NCT00273624|Drug|Placebo|placebo
317912|NCT00273650|Drug|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
317913|NCT00273650|Other|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
317914|NCT00273663|Device|TCES|
317915|NCT00273676|Procedure|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
317196|NCT00349934|Biological|IMP321|This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).
Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.
The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy.
317197|NCT00349947|Behavioral|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
317198|NCT00349960|Drug|NeoRecormon SC once-weekly versus once-every-other-week|
317199|NCT00349973|Drug|Dipyridamole|Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
317200|NCT00349973|Other|Olanzapine|Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
317201|NCT00000473|Drug|fatty acids, omega-3|
317202|NCT00003009|Biological|aldesleukin|
317203|NCT00349986|Drug|Insuline glargine|
317204|NCT00350025|Drug|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
317205|NCT00350025|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
317206|NCT00350038|Drug|Irbesartan|
317207|NCT00350038|Drug|Ciprofibrate|
317208|NCT00350051|Drug|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
317209|NCT00350064|Behavioral|Exercise Training|16 weeks of aerobic exercise training at two different intensities
317210|NCT00350077|Drug|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
317211|NCT00350077|Drug|Vitamin C|IV vitamin C
317212|NCT00350090|Drug|Epoetin Alfa|
317213|NCT00003010|Drug|marimastat|
317214|NCT00350103|Drug|SPM 929|
322507|NCT00288808|Device|Hemosense (PT/InR point of care device)|
322508|NCT00288834|Behavioral|dysphagia rehabilitation|
322509|NCT00288860|Behavioral|Telephone case monitoring|Three months of biweekly telephone monitoring and support in addition to usual outpatient mental health care (psychotherapy and/or medications)
322510|NCT00288860|Other|Treatment as Usual Control|Usual outpatient mental health care (psychotherapy and/or medications)
322511|NCT00288873|Drug|Ergocalciferol|
322512|NCT00288873|Drug|Cholecalciferol|
322513|NCT00002785|Drug|pegaspargase|
322514|NCT00288886|Behavioral|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
322515|NCT00288886|Behavioral|Control arm|Routine residential treatment and orientation to continuing care.
322516|NCT00288899|Other|Enhanced surgical iMedConsent process (with "repeat back")|Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to "repeat back"what they understand.
322517|NCT00291707|Procedure|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
322879|NCT00002760|Drug|ketoconazole|400 mg PO tid for as long as treatment is effective
322880|NCT00279240|Drug|Metformin|
322881|NCT00279253|Drug|clonidine (drug) intravenously|
322882|NCT00279266|Drug|Thiamine|
322883|NCT00279279|Device|Implanted Device|
322884|NCT00279292|Procedure|Celiac Plexus Neurolysis|
322885|NCT00279305|Drug|Anti-CD20 (rituximab)|
322886|NCT00279344|Drug|Fentanyl (Matrifen)|
322887|NCT00279357|Procedure|Narrow Band Imaging|
322888|NCT00279383|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
322889|NCT00002768|Drug|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
321796|NCT00307684|Drug|double blind placebo|matching placebo tablets once daily for 4 weeks
321797|NCT00307684|Drug|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
321798|NCT00307684|Drug|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
321799|NCT00307697|Procedure|receipt of copy of psychiatic assessment letter|
322146|NCT00000448|Drug|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
322147|NCT00002805|Radiation|low-LET electron therapy|
322148|NCT00298220|Behavioral|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
322149|NCT00298220|Behavioral|Dissemination guideline and patient information letters|
322150|NCT00298220|Behavioral|Tailored educational training|for GP(T)s
322151|NCT00298220|Behavioral|Tailored outreach based facilitator support|in the practices of the GPTs
322152|NCT00298220|Behavioral|Facilitation of co-operation with local addiction services|
322153|NCT00298220|Behavioral|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
322154|NCT00298220|Behavioral|Reminder-card for GP's desk|
322155|NCT00298220|Behavioral|Personal feedback to patients|Patients receive advise based on their premeasurement answers
322156|NCT00298233|Drug|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
322157|NCT00301730|Drug|paclitaxel|
322158|NCT00301730|Procedure|conventional surgery|
322159|NCT00301756|Drug|belinostat|Given IV
322160|NCT00301769|Drug|SJG-136|Given IV
322161|NCT00301782|Biological|bleomycin sulfate|
322162|NCT00301782|Drug|carboplatin|
322163|NCT00301782|Drug|cisplatin|
321422|NCT00265096|Biological|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
321423|NCT00265096|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
321424|NCT00265109|Drug|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
321425|NCT00265122|Drug|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
321426|NCT00002706|Procedure|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
321427|NCT00268463|Drug|oxaliplatin|Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1
Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2
321428|NCT00268476|Drug|celecoxib|
321429|NCT00268476|Drug|docetaxel|
321430|NCT00002717|Drug|paclitaxel|
321431|NCT00268476|Drug|prednisolone|
321432|NCT00268476|Drug|ADT|
321433|NCT00268476|Drug|zoledronic acid|
321434|NCT00268476|Drug|abiraterone|
321435|NCT00268476|Procedure|orchiectomy|
321436|NCT00268476|Radiation|Radiotherapy to the prostate|
321800|NCT00307710|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
321801|NCT00307723|Drug|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
321802|NCT00307723|Drug|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
321803|NCT00307723|Drug|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
321804|NCT00310492|Biological|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
320694|NCT00284492|Behavioral|Self Care|Lifestyle advice on diet, physical activity
320695|NCT00284505|Drug|thalidomide|
320696|NCT00284518|Biological|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
320697|NCT00284518|Drug|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
320698|NCT00284531|Drug|Daclizumab|
321071|NCT00002745|Drug|aminocamptothecin|850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
321072|NCT00275015|Drug|cyclophosphamide|
321073|NCT00275015|Drug|cytarabine|
321074|NCT00275015|Drug|dexamethasone|
321075|NCT00275015|Drug|etoposide|
321076|NCT00275015|Drug|fludarabine phosphate|
321077|NCT00275015|Drug|melphalan|
321078|NCT00275015|Procedure|bone marrow ablation with stem cell support|
321079|NCT00275015|Procedure|peripheral blood stem cell transplantation|
321080|NCT00275015|Radiation|radiation therapy|
321081|NCT00275028|Drug|cediranib maleate|Given orally
321082|NCT00278187|Biological|volociximab|
321083|NCT00278187|Drug|erlotinib hydrochloride|
321084|NCT00278200|Biological|autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine|
321085|NCT00278213|Biological|alemtuzumab|
321086|NCT00278213|Drug|cyclophosphamide|
321087|NCT00278213|Drug|fludarabine phosphate|
321088|NCT00278213|Drug|mitoxantrone hydrochloride|
321089|NCT00278226|Behavioral|smoking cessation intervention|
302061|NCT00374166|Drug|Placebo|Oral administration (capsules)
302062|NCT00374166|Drug|Paroxetine|Oral administration (capsules)
302063|NCT00374179|Drug|CT-322|IV solution, weekly or bi-weekly
302064|NCT00374192|Drug|Eszopiclone|3 mg per day
302065|NCT00374192|Drug|Placebo|Placebo
302066|NCT00374205|Drug|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
302067|NCT00374205|Drug|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
302068|NCT00374218|Drug|High Fructose Corn Syrup|
302069|NCT00003119|Radiation|radiation therapy|
302070|NCT00374218|Drug|Sucromalt|
302071|NCT00374231|Drug|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
302072|NCT00374231|Drug|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
302073|NCT00374231|Drug|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
302074|NCT00374244|Drug|Pimozide|half of the subjects are randomized to the active drug group
302075|NCT00374244|Drug|placebo|half of the subjects are randomized to placebo group
302076|NCT00374257|Procedure|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
302077|NCT00374270|Behavioral|Lifestyle Counselling; Opinion Leader Influence Statements|
302078|NCT00374296|Drug|MGCD0103|MGCD0103 administered orally three-times per week
302423|NCT00412581|Drug|Dacarbazine|600 mg/m^2 intravenously on Day 1 of every study cycle.
302424|NCT00412594|Drug|Cladribine|5.6 mg/m^2 by vein over 2 hours daily for 5 days
302425|NCT00412594|Drug|Rituximab|375 mg/m^2 by vein weekly x 8 starting on day 28 (plus or minus 4 days) following 2CDA treatment.
301705|NCT00380289|Drug|Thiazide and beta blocker|
301706|NCT00380302|Drug|AVE1625|
301707|NCT00380315|Drug|AG1321001(drug)|
301708|NCT00380328|Drug|neratinib|HKI-272
301709|NCT00003150|Drug|CHOP regimen|
301710|NCT00380341|Procedure|Instrument-applied spinal manipulative therapy|
301711|NCT00380354|Drug|GSK256066|
301712|NCT00380367|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6,11,16,18) given on day 1, month 2 & month 6, 7 months of treatment
301713|NCT00380380|Drug|Vildagliptin|
302079|NCT00374309|Drug|VRC-EBOADV018-00-VP|
302080|NCT00003120|Drug|paclitaxel|135 mg/m2 IV every 28 days
302081|NCT00374322|Drug|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
302082|NCT00374322|Other|placebo|6 tablets daily for 12 months
302083|NCT00374335|Procedure|abdominal ultrasound|abdominal ultrasound to detect hepatic hemangiomas
302084|NCT00374335|Other|Dermatologic Examination|Complete dermatologic examination
302085|NCT00374348|Drug|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
302086|NCT00374374|Behavioral|Administration of probiotic|
302087|NCT00374387|Drug|Nuvaring|
302088|NCT00374387|Drug|low-dose combination pill|
302089|NCT00374387|Drug|minipill|
302090|NCT00377572|Biological|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
302091|NCT00377585|Biological|Fluarix|
302092|NCT00377585|Biological|adjuvanted influenza vaccine|
301347|NCT00388856|Drug|Vitamin C 1000mg and E 400IU|
301348|NCT00003193|Drug|paclitaxel|
301349|NCT00388882|Drug|tiotropium|
301350|NCT00388882|Drug|ipratropium bromide / albuterol|
301351|NCT00388895|Drug|chemotherapy|
301352|NCT00388895|Drug|Glivec|
301353|NCT00388908|Behavioral|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
301354|NCT00388908|Other|Usual Care|
301355|NCT00388921|Drug|Vitamin A|
301356|NCT00388934|Device|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
301357|NCT00388947|Device|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
301358|NCT00391430|Drug|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
301359|NCT00391430|Behavioral|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
301360|NCT00391443|Drug|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight > 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight < 40 kg)
301361|NCT00391443|Drug|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
301362|NCT00391456|Behavioral|Animal-assisted Therapy|
301363|NCT00391469|Other|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
301364|NCT00391469|Drug|Rapid infusion of cold normal saline|
301714|NCT00383071|Biological|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
301715|NCT00383071|Procedure|Apheresis|Once subjects achieved a high antibody titer (>1:160), they could begin apheresis to collect plasma.
300665|NCT00405756|Drug|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
300666|NCT00003270|Biological|anti-thymocyte globulin|IV
300667|NCT00405756|Drug|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
300668|NCT00405756|Drug|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
300669|NCT00405756|Drug|Aspirin|Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.
Double-blind maintenance: at the investigator's discretion
301013|NCT00396786|Drug|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
301014|NCT00396799|Drug|bazedoxifene/conjugated estrogens|
301015|NCT00396812|Drug|Rituximab|Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.
Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid.
301016|NCT00396825|Behavioral|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
301017|NCT00396851|Drug|Gurmar|
301018|NCT00396851|Drug|Metformin|
301019|NCT00396864|Drug|NPI-0052|IV injection, three times every 28 days, escalating dosing cohorts
301020|NCT00003222|Biological|gp100 antigen|
301021|NCT00396877|Drug|Clopidogrel (SR25990)|Form: reconstituted solution using Clopidogrel powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight
301022|NCT00399776|Radiation|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
301023|NCT00399789|Drug|Perifosine|Perifosine will be tested in 3 dose forms
301024|NCT00399802|Drug|Odanacatib|odanacatib 50 mg tablet once weekly, 4 week treatment period.
301025|NCT00399802|Drug|Comparator: zoledronic acid|one time zoledronic acid 4 mg IV infusion.
301026|NCT00399802|Drug|Comparator: Placebo (unspecified)|odanacatib Pbo tablet once weekly, 4 week treatment period.
300311|NCT00367211|Drug|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
300312|NCT00367224|Procedure|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
300313|NCT00003091|Biological|recombinant interferon alfa|
300314|NCT00367224|Procedure|Skin biopsies|4 mm punch biopsies of the skin
300315|NCT00367237|Drug|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
300316|NCT00367237|Drug|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
300317|NCT00367250|Drug|Cetuximab|weekly i.v.
300318|NCT00367250|Drug|Trastuzumab|weekly i.v.
300319|NCT00367263|Drug|Alvesco (Ciclesonide) 160 ug/day|
300320|NCT00367276|Drug|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
300321|NCT00367302|Drug|buprenorphine|maintenance
300322|NCT00367302|Drug|methadone|maintenance
300323|NCT00367315|Drug|Lumiracoxib|
300324|NCT00003092|Drug|paclitaxel|
300325|NCT00367328|Device|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
300326|NCT00370331|Drug|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
300670|NCT00405756|Drug|Placebo|Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.
Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
300671|NCT00405756|Drug|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
300672|NCT00408655|Drug|temsirolimus|Given IV
299612|NCT00384891|Device|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
299613|NCT00384891|Drug|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
299614|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
299615|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
299616|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
299971|NCT00376701|Drug|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
299972|NCT00376714|Drug|GSK233705|
299973|NCT00376727|Biological|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
299974|NCT00376727|Genetic|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
299975|NCT00376727|Other|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
299976|NCT00376727|Other|laboratory biomarker analysis|Cetuximab Pharmacodynamics
299977|NCT00376740|Drug|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
299978|NCT00376766|Drug|levetiracetam|
299979|NCT00003134|Drug|irinotecan hydrochloride|
299980|NCT00376779|Biological|Infanrix hexa Vaccine|
299981|NCT00376792|Drug|docetaxel|
299982|NCT00376792|Other|active surveillance|
299983|NCT00376792|Procedure|adjuvant therapy|
299984|NCT00376805|Drug|Fludarabine|administered intravenously 25 mg/m^2 times 5 doses
299985|NCT00376805|Drug|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
299986|NCT00376805|Radiation|Total body irradiation|200 cGy (gray) on day -1
299230|NCT00393107|Drug|rituximab,fludarabine, cyclophosphamide|
299231|NCT00003211|Biological|filgrastim|
299232|NCT00393120|Drug|INCB009471|100mg SR (sustained release) orally once daily
299233|NCT00393120|Drug|INCB009471|300mg SR (sustained release) orally once daily
299234|NCT00393120|Drug|Placebo comparator|Orally once daily
299235|NCT00393146|Drug|GW856553|Study drug
299236|NCT00393159|Device|Ear Popper|
299237|NCT00393172|Behavioral|exercise|5 days per week exercise for 4 months
299238|NCT00393185|Biological|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
299239|NCT00393198|Drug|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
299240|NCT00393198|Drug|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
299241|NCT00393198|Drug|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
299242|NCT00003211|Drug|amifostine trihydrate|
299243|NCT00393211|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
299244|NCT00393211|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
299245|NCT00393250|Behavioral|Hypnosis|
299246|NCT00393263|Drug|pimecrolimus and clobetasol|
299247|NCT00393263|Drug|clobetasol 0.05% cream|twice daily for three months
299617|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
299618|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
299619|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
299620|NCT00384917|Drug|Ketoconazole|
304430|NCT00002657|Drug|doxorubicin hydrochloride|25 mg/m^2
304431|NCT00247182|Behavioral|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
304432|NCT00247182|Behavioral|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
304433|NCT00247195|Behavioral|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
304795|NCT00237003|Behavioral|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
304796|NCT00237016|Drug|doxycycline treatment|
304797|NCT00237042|Behavioral|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
304798|NCT00237042|Behavioral|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
304799|NCT00002627|Drug|carboplatin|
304800|NCT00237042|Drug|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
304801|NCT00237068|Drug|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
304802|NCT00237094|Behavioral|Nurse Practitioner led multidisciplinary team approach|
304803|NCT00237107|Procedure|Curretage|
304804|NCT00237120|Drug|Imatinib|
304805|NCT00237133|Drug|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
304806|NCT00237146|Drug|Zoledronic acid|
304807|NCT00237159|Drug|Zoledronic acid|
304051|NCT00256750|Drug|CsA|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months months (ST), 100-250 ng/mL, daily, 24 months (LT)
304052|NCT00002689|Drug|dexamethasone|
304053|NCT00256750|Drug|Belatacept LI|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
304054|NCT00256750|Drug|Belatacept MI|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
304055|NCT00256776|Drug|Velcade (Bortezomib)|
304056|NCT00256776|Drug|Thalidomide|
304057|NCT00256776|Drug|Dexamethasone|
304058|NCT00256789|Procedure|Radiation|
304059|NCT00256789|Drug|Chemotherapy|
304060|NCT00256802|Device|MR-angiography, GTN|
304061|NCT00256815|Drug|chemotherapy|
304062|NCT00260364|Drug|Erlotinib 100 mg orally days 1-28|
304063|NCT00260364|Drug|Bevacizumab 5 mg/kg intravenously every 2 weeks|
304064|NCT00260377|Procedure|Coronary artery bypass surgery|
304065|NCT00002697|Procedure|bone marrow ablation with stem cell support|
304066|NCT00260390|Drug|Testoviron|
304067|NCT00260403|Procedure|Photodynamic therapy versus Transpupillary thermotherapy|
304068|NCT00260416|Procedure|Primary angioplasty with stent and abciximab|
304069|NCT00260429|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
304070|NCT00260442|Behavioral|Resistance Training|12 weeks, 3 times a week whole body resistance training
304434|NCT00247208|Device|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
304435|NCT00247208|Device|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
303322|NCT00374933|Drug|"Prophylactic" delayed ADLI|"Prophylactic" ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
303323|NCT00374933|Drug|"Prophylactic" delayed activated donor lymphocyte infusion|"Prophylactic" delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
303324|NCT00374946|Device|THA|
303325|NCT00374959|Drug|ceftriaxone|
303326|NCT00374959|Device|Endotracheal tube for aspiration of subglottic secretions.|
303691|NCT00209690|Drug|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
303692|NCT00209690|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
303693|NCT00209703|Drug|Oxaliplatin|
303694|NCT00209703|Drug|l-Leucovorin|
303695|NCT00209703|Drug|5-Fluorouracil|
303696|NCT00213629|Other|transcriptome analysis|transcriptome analysis from muscle biopsy
303697|NCT00213629|Other|T cell repertoire analysis|blood T cell repertoire analysis
303698|NCT00213655|Biological|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
303699|NCT00213668|Dietary Supplement|glutamine (dipeptiven)|
303700|NCT00213681|Device|Boussignac CPAP - bilevel ventilation support|
303701|NCT00213694|Drug|docetaxel and celecoxib|
303702|NCT00213759|Drug|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
303703|NCT00002565|Drug|prednisone|
303704|NCT00213759|Drug|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
303705|NCT00213798|Procedure|Biopsy samples|
303706|NCT00213811|Behavioral|clinical, biological, and radiological|
317916|NCT00273689|Drug|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
317917|NCT00273689|Drug|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
317918|NCT00273702|Drug|N-Acetyl Cysteine|
317919|NCT00273715|Procedure|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
317920|NCT00002740|Radiation|low-LET cobalt-60 gamma ray therapy|
317921|NCT00273715|Procedure|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
317922|NCT00273728|Drug|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
317923|NCT00002755|Drug|thiotepa|
317924|NCT00276731|Drug|etoposide|
317925|NCT00276731|Drug|vincristine sulfate|
317926|NCT00276731|Procedure|conventional surgery|
317927|NCT00276731|Procedure|neoadjuvant therapy|
318284|NCT00263744|Other|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
318285|NCT00263757|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
318286|NCT00002704|Drug|cyclophosphamide|
318287|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
318288|NCT00266786|Drug|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
318289|NCT00266786|Drug|Intranasal Placebo|Intranasal Placebo
318290|NCT00266799|Drug|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
318291|NCT00266799|Drug|Capecitabine|capecitabine (1250 mg/m^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
317215|NCT00350116|Drug|topical vitamin B12|
317561|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
317562|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
317563|NCT00283075|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kg
317564|NCT00283088|Procedure|hypothermia|Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.
Subjects are stratified by time to six groups.
317565|NCT00002772|Drug|carboplatin|
317566|NCT00283088|Drug|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
317567|NCT00283101|Drug|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
317568|NCT00283114|Drug|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
317569|NCT00283127|Procedure|Home sampling (urine test) for uro-genital C.trachomatis.|
317570|NCT00283153|Behavioral|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
317571|NCT00286507|Procedure|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
317572|NCT00286520|Procedure|Transanal irrigation with Peristeen Anal Irrigation|
317573|NCT00286533|Procedure|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
317574|NCT00002783|Drug|floxuridine|
317575|NCT00286533|Procedure|Questionnaires|Questionnaires are used.
317576|NCT00286559|Drug|SonoVue|
317577|NCT00286559|Drug|Optison|
317578|NCT00286585|Drug|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
322890|NCT00281983|Drug|busulfan|
322891|NCT00281983|Drug|cyclophosphamide|
322892|NCT00281983|Drug|cyclosporine|
322893|NCT00281983|Drug|fludarabine phosphate|
322894|NCT00281983|Drug|methotrexate|
322895|NCT00281983|Drug|mycophenolate mofetil|
322896|NCT00281983|Procedure|peripheral blood stem cell transplantation|
322897|NCT00281983|Radiation|radiation therapy|
322898|NCT00281996|Drug|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
322899|NCT00281996|Drug|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
322900|NCT00002768|Drug|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
322901|NCT00282009|Behavioral|Basic Internet|Basic Internet control intervention
322902|NCT00282009|Behavioral|Enhanced Internet|enhanced Internet cessation intervention
322903|NCT00282009|Behavioral|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
322904|NCT00282022|Drug|laromustine|
317216|NCT00350142|Radiation|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
317217|NCT00350142|Drug|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
317218|NCT00350155|Drug|Lumiracoxib|
317219|NCT00350168|Drug|valsartan + amlodipine|
317220|NCT00350181|Drug|Sirolimus|
317221|NCT00350181|Drug|Mycophenolate Mofetil|
317222|NCT00353288|Biological|MMR, Varicella vacc (control)|
317223|NCT00353301|Drug|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
322164|NCT00301782|Drug|etoposide phosphate|
322165|NCT00000138|Drug|Acyclovir|
322166|NCT00000449|Behavioral|cue exposure treatment|
322167|NCT00002816|Drug|cytarabine|Given IV
322168|NCT00301782|Drug|vincristine sulfate|
322169|NCT00301795|Biological|oblimersen sodium|Given IV
322170|NCT00301795|Biological|rituximab|Given IV
322518|NCT00291720|Drug|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
322519|NCT00291720|Drug|Placebo|matching placebo
322520|NCT00291733|Drug|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
322521|NCT00291733|Drug|Placebo|Placebo tabl
322522|NCT00291746|Drug|Esomeprazole|
322523|NCT00291746|Procedure|Bravo technique|
322524|NCT00002792|Drug|cyclosporine|
322525|NCT00291759|Drug|Tamoxifen|
322526|NCT00291759|Drug|Anastrozole|
322527|NCT00291772|Drug|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
322528|NCT00291785|Drug|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 & 29 of each 42-day cycle
322529|NCT00291785|Drug|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
322530|NCT00291785|Drug|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
322531|NCT00291798|Procedure|rate of remission|
322532|NCT00291811|Drug|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
322533|NCT00291824|Behavioral|Cardiovascular risk factors and willingness to change|
322534|NCT00291837|Drug|CT-2106|
321805|NCT00002838|Drug|Cyclophosphamide|
321806|NCT00310505|Drug|Amphotericin B deoxycholate given as daily administration|
321807|NCT00310518|Drug|ARQ 501|
321808|NCT00310531|Drug|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
321809|NCT00310531|Drug|Raloxifene|Raloxifene tbl. (60 mg/day)
321810|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
321811|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
321812|NCT00310557|Drug|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
321813|NCT00310570|Device|Circumferential thermoplastic thimble splint|
321814|NCT00310570|Device|dorsal aluminium foam "Mexican Hat" splint|
321815|NCT00310570|Device|stack splint (control)|
321816|NCT00000457|Drug|bupropion (Wellbutrin)|1 pill in the am of 150 mg of Bupropion
1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks.
321817|NCT00002838|Drug|Fludarabine Phosphate|
321818|NCT00310583|Drug|Pregabalin|
321819|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
321820|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
321821|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
321822|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
322171|NCT00301795|Other|laboratory biomarker analysis|Correlative studies
322172|NCT00301808|Drug|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
322173|NCT00301808|Drug|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
321090|NCT00278226|Other|educational intervention|
321091|NCT00002757|Drug|cyclophosphamide|
321092|NCT00278239|Procedure|cognitive assessment|
321093|NCT00278239|Procedure|psychosocial assessment and care|
321094|NCT00278239|Procedure|quality-of-life assessment|
321095|NCT00278252|Drug|etoposide|
321096|NCT00278252|Procedure|conventional surgery|
321097|NCT00278265|Drug|fludarabine phosphate|
321098|NCT00278265|Drug|methotrexate|
321437|NCT00268476|Drug|enzalutamide|
321438|NCT00268489|Biological|bevacizumab|
321439|NCT00268489|Drug|pemetrexed disodium|
321440|NCT00268502|Other|study of socioeconomic and demographic variables|
321441|NCT00000422|Behavioral|Cognitive-behavioral psychotherapy and physical exercise|
321442|NCT00002718|Biological|anti-thymocyte globulin|
321443|NCT00268502|Procedure|fatigue assessment and management|
321444|NCT00268502|Procedure|management of therapy complications|
321445|NCT00268502|Procedure|psychosocial assessment and care|
321446|NCT00268502|Procedure|quality-of-life assessment|
321447|NCT00268515|Drug|cyclosporine|
321448|NCT00268515|Drug|tacrolimus|
321449|NCT00268515|Drug|prednisone|
321450|NCT00268515|Drug|azathioprine|
321451|NCT00268528|Behavioral|compliance monitoring|
321452|NCT00268528|Other|study of socioeconomic and demographic variables|
302426|NCT00412607|Device|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
302427|NCT00412620|Drug|ABT-925|
302428|NCT00412620|Drug|Placebo|
302429|NCT00412633|Behavioral|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
302430|NCT00003305|Drug|leucovorin calcium|
302431|NCT00412633|Behavioral|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
302432|NCT00412646|Drug|TMC125|
302433|NCT00412659|Procedure|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
302434|NCT00412659|Procedure|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
302435|NCT00412698|Drug|rimonabant|Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.
White film-coated tablets, for oral administration containing 20 mg of active rimonabant
302436|NCT00412698|Drug|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
302437|NCT00368264|Drug|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
302438|NCT00368264|Drug|placebo|azathioprine (2 mg/kg) plus four placebo infusions
302439|NCT00368277|Drug|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
302440|NCT00368277|Drug|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
302441|NCT00368277|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
302442|NCT00368277|Drug|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
302443|NCT00003096|Genetic|comparative genomic hybridization|
302444|NCT00368290|Drug|Modafinil|300mg a day for 8 weeks
302093|NCT00003138|Biological|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
302094|NCT00377598|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
302095|NCT00377598|Drug|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
302096|NCT00377598|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
302097|NCT00377598|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
302098|NCT00377598|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
302099|NCT00377611|Biological|Fluarix™|
302100|NCT00377624|Drug|sodium hyaluronate|
302101|NCT00377637|Drug|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
302445|NCT00368290|Drug|placebo|placebo pills for 8 weeks
302446|NCT00368290|Behavioral|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
302447|NCT00368303|Drug|Paroxetine CR|
302448|NCT00368303|Drug|Paroxetine IR|
302449|NCT00368316|Biological|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
302450|NCT00368329|Drug|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg & 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
302451|NCT00368329|Drug|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
302452|NCT00368329|Drug|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
302453|NCT00368329|Drug|Carboplatin|AUC 2, based onCalvert formula IV infusion
302454|NCT00003096|Genetic|cytogenetic analysis|
302455|NCT00368342|Drug|Erythromycin, Azithromycin , Clarithromycin|
302456|NCT00368355|Drug|Ara-C|day-8 through day-5
3 g/m2 q 12 hours
302457|NCT00368355|Drug|Cyclophosphamide|day-7 and day-6
45 mg/kg
301716|NCT00383084|Behavioral|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
301717|NCT00383084|Behavioral|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
301718|NCT00383097|Genetic|LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
301719|NCT00383097|Genetic|LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
301720|NCT00383123|Biological|Fluarix™|Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.
*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1.
301721|NCT00383123|Biological|Fluzone|Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.
*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1.
301722|NCT00003159|Drug|paclitaxel|
301723|NCT00383136|Drug|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
301724|NCT00383136|Drug|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
301725|NCT00383149|Drug|Ixabepilone|Intravenous Infusion (IV), 32 mg/m^2 every 21 days.
301726|NCT00383149|Drug|Cetuximab|Initial dose of 400 mg/m^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m^2 IV over 1 hour.
301727|NCT00383162|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
301728|NCT00383162|Drug|Placebo|Matching placebo tablet.
301729|NCT00383175|Other|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
301730|NCT00383188|Drug|placebo|Capsule, once daily (QD) for 12 weeks
301731|NCT00383188|Drug|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
301732|NCT00383188|Drug|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
301027|NCT00003240|Drug|cisplatin|
301028|NCT00399802|Drug|Comparator: Placebo (unspecified)|zoledronic acid Pbo IV infusion, 4 week treatment period.
301029|NCT00399828|Device|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
301030|NCT00399841|Device|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
301031|NCT00399854|Device|Dhermia® – Industra Mecânica Fina Ltda|
301032|NCT00399867|Drug|Simvastatin|
301033|NCT00399880|Behavioral|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
301034|NCT00399893|Drug|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
301035|NCT00399893|Drug|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
301365|NCT00003203|Drug|cisplatin|Given IV
301366|NCT00391482|Behavioral|Peer Mentoring Intervention for HCV-Infected IDUs|
301367|NCT00391495|Procedure|Blood drawing|
301368|NCT00391521|Drug|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
301369|NCT00391521|Drug|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
301370|NCT00391521|Drug|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
301371|NCT00391534|Drug|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
301372|NCT00391534|Drug|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
301373|NCT00391547|Drug|Frio Oral Rinse|
301374|NCT00391560|Drug|perifosine|Perifosine Daily Dose
301375|NCT00391573|Procedure|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
300673|NCT00408668|Biological|PEV3A|
300674|NCT00408668|Biological|FP9 ME-TRAP|
300675|NCT00408668|Biological|MVA ME-TRAP|
300676|NCT00408681|Drug|lithium carbonate|Given orally
300677|NCT00408681|Other|laboratory biomarker analysis|Correlative studies
300678|NCT00408694|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
300679|NCT00408694|Radiation|intensity-modulated radiation therapy|Undergo IMRT
300680|NCT00003283|Drug|octreotide acetate|
300681|NCT00408694|Biological|bevacizumab|Given IV
300682|NCT00408694|Drug|cisplatin|Given IV
300683|NCT00408694|Drug|fluorouracil|Given IV
300684|NCT00408707|Procedure|local infiltration analgesia|
300685|NCT00408733|Other|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
300686|NCT00408746|Behavioral|palatal development|Impressions of preterm and term palates.
300687|NCT00408759|Behavioral|hypnosis|
300688|NCT00408772|Biological|bevacizumab|
300689|NCT00408772|Drug|capecitabine|
300690|NCT00408772|Drug|oxaliplatin|
300691|NCT00003283|Drug|prednisone|
300692|NCT00408772|Procedure|conventional surgery|
300693|NCT00408772|Procedure|neoadjuvant therapy|
300694|NCT00408772|Procedure|radiofrequency ablation|
300695|NCT00408785|Drug|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
301036|NCT00399906|Drug|BMS-582949|Tablets, Oral, Once daily, 12 weeks
301037|NCT00399906|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks
299987|NCT00376805|Other|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
299988|NCT00376805|Biological|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
299989|NCT00376818|Behavioral|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
299990|NCT00003135|Drug|fluorouracil|
299991|NCT00376818|Other|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
299992|NCT00379457|Drug|cyclophosphamide|
299993|NCT00379457|Drug|doxorubicin hydrochloride|
299994|NCT00379457|Drug|etoposide|
300327|NCT00370331|Drug|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
300328|NCT00370344|Procedure|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
300329|NCT00370344|Procedure|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
300330|NCT00370357|Drug|3% w/w SPL7013 Gel (VivaGel™)|
300331|NCT00370370|Drug|bevacizumab|Injection of intravitreal bevacizumab
300332|NCT00003105|Drug|ifosfamide|
300333|NCT00370370|Drug|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
300334|NCT00370383|Drug|Erlotinib|erlotinib 150 mg/day once daily
300335|NCT00370383|Drug|Satraplatin|satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).
Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound.
300336|NCT00370396|Biological|10 valent pneumococcal conjugate (vaccine)|
300337|NCT00370409|Procedure|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
300338|NCT00370422|Drug|Triamcinolone, Bevacizumab|
299621|NCT00003172|Drug|doxorubicin hydrochloride|
299622|NCT00384930|Drug|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
299623|NCT00384930|Drug|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
299624|NCT00384930|Drug|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
299625|NCT00384930|Drug|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
299626|NCT00384930|Drug|placebo|Placebo tablet taken by mouth one a day for twelve weeks
299627|NCT00384943|Behavioral|Moderate-intensity Exercise|
299628|NCT00384956|Drug|Azacitidine|
299629|NCT00384969|Drug|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
299630|NCT00384982|Procedure|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
299631|NCT00384995|Drug|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
299632|NCT00003172|Drug|fluorouracil|
299633|NCT00384995|Drug|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
299634|NCT00387959|Drug|cyclosporine|
299635|NCT00387959|Drug|fludarabine phosphate|
299636|NCT00387959|Drug|mycophenolate mofetil|
299637|NCT00387959|Procedure|allogeneic hematopoietic stem cell transplantation|
299638|NCT00387959|Procedure|umbilical cord blood transplantation|
299639|NCT00387959|Radiation|total-body irradiation|
299640|NCT00387972|Drug|denagliptin (GW823093)|
299641|NCT00387985|Drug|MOA-728|
299642|NCT00387998|Other|AHRQ staying healthy booklet|educational booklet about prevention
299995|NCT00379457|Drug|ifosfamide|
299996|NCT00379457|Drug|topotecan hydrochloride|
304808|NCT00237172|Drug|Imatinib Mesylate|once daily
304809|NCT00240461|Dietary Supplement|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
304810|NCT00002634|Procedure|autologous bone marrow transplantation|
304811|NCT00240461|Other|Placebo|crystalline substance 200 mg twice daily for 6 months
304812|NCT00240474|Drug|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
304813|NCT00240474|Drug|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
304814|NCT00240487|Drug|Nitric Oxide|Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
299248|NCT00393276|Biological|Twinrix|Combined hepatitis A and hepatitis B immunization
299249|NCT00393276|Biological|Decavac|Diphtheria and tetanus toxoid vaccine
299250|NCT00393289|Behavioral|Calcium controlled diet|
299251|NCT00393302|Procedure|HIV screening in pregnancy|
299252|NCT00393315|Device|paclitaxel coated balloon catheter|
299253|NCT00000498|Behavioral|diet, reducing|
299254|NCT00003211|Drug|cisplatin|
299255|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
299256|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
299257|NCT00396032|Drug|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
299258|NCT00396045|Drug|Revlimid (CC-5013)|
299259|NCT00396058|Drug|Methylphenidate|
299260|NCT00396071|Drug|vildagliptin|vildagliptin 100 mg
299261|NCT00396071|Drug|Placebo|matching placebo
299262|NCT00396084|Drug|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
299263|NCT00396084|Drug|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
304436|NCT00250705|Drug|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: < 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study.
304437|NCT00250718|Drug|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
304438|NCT00250718|Drug|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
304439|NCT00250718|Drug|Rituximab|The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.
Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.
Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses
304440|NCT00250718|Drug|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
304441|NCT00250718|Drug|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
304442|NCT00250731|Behavioral|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
304443|NCT00250731|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
304444|NCT00250744|Drug|Aprepitant vs. Gabapentin|Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
304445|NCT00002665|Drug|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
304446|NCT00250744|Drug|Aprepitant vs. Gabapentin|Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
304447|NCT00250796|Drug|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
304448|NCT00250796|Drug|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
304449|NCT00250809|Procedure|Placement of a central venous catheter|Placement of a central venous catheter
304450|NCT00250822|Drug|Gemcitabine and Oxaliplatin|Dose:
Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 & 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 & 16
304815|NCT00240487|Other|No Intervention|Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
303707|NCT00213837|Device|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
303708|NCT00213850|Procedure|EFR|
303709|NCT00213863|Device|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
303710|NCT00213889|Other|None: molecular genetics diagnosis procedure only|None: molecular genetics diagnosis procedure only
303711|NCT00213915|Drug|12 g of L-arginine glutamate during 6 weeks twice a day|
304071|NCT00260442|Behavioral|Sedentary|Absence of physical activity
304072|NCT00260468|Other|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
304073|NCT00260481|Drug|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
304074|NCT00260481|Drug|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
304075|NCT00260494|Other|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
304076|NCT00002697|Procedure|peripheral blood stem cell transplantation|
304077|NCT00260494|Other|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
304078|NCT00260507|Behavioral|Standard Vocational Rehabilitation|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
304079|NCT00260507|Behavioral|Supportive Employment|Supported Employment (SE) involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
304080|NCT00260520|Drug|Dalteparin|
318292|NCT00266812|Drug|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
318293|NCT00266812|Procedure|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
318294|NCT00266825|Drug|DHA|600 mg DHA
318295|NCT00002714|Drug|vincristine sulfate|
318296|NCT00266825|Other|Placebo capsule|Placebo capsule
318297|NCT00266838|Drug|Maxidex; Lacrystat|6 times daily, for 20 weeks.
318298|NCT00266851|Drug|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
318299|NCT00266851|Drug|Placebo|Matching placebo
318300|NCT00266864|Drug|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
318301|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
318302|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
318303|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
318304|NCT00266929|Procedure|surgical|surgical treatment of odontoid fractures
318657|NCT00309465|Drug|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
318658|NCT00309478|Drug|cyclophosphamide|
318659|NCT00002835|Drug|Methylprednisolone|
318660|NCT00309478|Drug|Methotrexate|
318661|NCT00309478|Drug|Fluorouracil|
318662|NCT00309478|Drug|Goserelin|
318663|NCT00309478|Drug|Tamoxifen|
318664|NCT00309491|Drug|Tamoxifen|
317579|NCT00286585|Drug|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
317580|NCT00286598|Behavioral|Feet First Intervention program|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
317928|NCT00276731|Radiation|radiation therapy|
317929|NCT00276744|Biological|cetuximab|
317930|NCT00276744|Drug|bortezomib|
317931|NCT00276744|Drug|capecitabine|
317932|NCT00276744|Drug|docetaxel|
317933|NCT00276744|Drug|erlotinib hydrochloride|
317934|NCT00002755|Procedure|autologous bone marrow transplantation|
317935|NCT00276744|Drug|gemcitabine hydrochloride|
317936|NCT00276744|Drug|irinotecan hydrochloride|
317937|NCT00276744|Drug|mitomycin C|
317938|NCT00276744|Drug|sirolimus|
317939|NCT00276744|Drug|thalidomide|
317940|NCT00276744|Other|antitumor drug screening assay|
317941|NCT00276744|Procedure|conventional surgery|
317942|NCT00276757|Drug|leucovorin calcium|
317943|NCT00276757|Drug|methotrexate|
317944|NCT00276757|Drug|prednisolone|
317945|NCT00002755|Procedure|peripheral blood stem cell transplantation|
317946|NCT00276757|Drug|vinblastine sulfate|
317947|NCT00276770|Other|fluorine F 18 fluorothymidine|
317948|NCT00276770|Procedure|positron emission tomography|
317949|NCT00276783|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
317224|NCT00000476|Drug|digitalis|
317225|NCT00003026|Drug|flutamide|
317226|NCT00353301|Drug|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
317227|NCT00353327|Procedure|Plasma infusion|
317228|NCT00353340|Drug|n acetylcysteine|
317229|NCT00353340|Drug|sodium bicarbonate|
317230|NCT00353340|Drug|sodium chloride|
317231|NCT00353353|Procedure|consumption of fortified bread|
317232|NCT00353366|Biological|Rotarix|Two doses of the oral vaccine
317233|NCT00353366|Other|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
317234|NCT00353379|Drug|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
317235|NCT00353379|Drug|Placebo|Participants will take placebo for 6 weeks.
317236|NCT00003026|Drug|triptorelin|
317237|NCT00353392|Device|Laser Therapy|
317238|NCT00353405|Behavioral|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
317239|NCT00353405|Behavioral|Mass media|Mass media provides messages that support sexual health skills.
317240|NCT00353405|Behavioral|Control|Control group received no social skills training and no media mass media messages.
317241|NCT00353418|Drug|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
317581|NCT00286611|Procedure|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
317582|NCT00286624|Biological|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
317583|NCT00286624|Drug|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
322535|NCT00002792|Drug|methotrexate|
322536|NCT00291850|Drug|Paclitaxel, Cisplatin, Pegfilgrastim|
322537|NCT00291863|Drug|Simvastatin|
322538|NCT00291876|Biological|Havrix™|2 doses at 12 months interval
322539|NCT00291889|Biological|Mtb72F/AS02.|
322540|NCT00291902|Drug|SB-681323|
322541|NCT00291915|Drug|Adalimumab|
322542|NCT00291915|Drug|Methotrexate|
322543|NCT00291928|Drug|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
322905|NCT00282035|Radiation|3D-CRT APBI|Accelerated partial breast irradiation utilizing 3D-CRT
322906|NCT00282035|Radiation|WBI|Whole breast irradiation
322907|NCT00282048|Drug|AG-013736 (axitinib)|AG-013736 5 mg twice daily [bid] continuous dosing in 28 day cycles.
322908|NCT00282061|Drug|Melatonin|
322909|NCT00282074|Procedure|laparoscopic bilateral hernia repair|
322910|NCT00282087|Drug|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
322911|NCT00002768|Drug|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
322912|NCT00282100|Drug|Iressa|
322913|NCT00282113|Dietary Supplement|ProBioPlus|ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
322914|NCT00282113|Dietary Supplement|Culturelle|Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
322915|NCT00282113|Other|Placebo|A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
322916|NCT00282126|Dietary Supplement|Potassium citrate|kcitrate
322917|NCT00282139|Drug|Aripiprazole|
322918|NCT00285597|Drug|Ursodeoxycholic Acid|
322174|NCT00301808|Drug|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
322175|NCT00301808|Radiation|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
322176|NCT00301821|Biological|epratuzumab|
322177|NCT00301821|Biological|rituximab|
322178|NCT00002816|Drug|dexamethasone|Given IV
322179|NCT00301821|Drug|cyclophosphamide|
322180|NCT00301821|Drug|doxorubicin hydrochloride|
322181|NCT00301821|Drug|prednisone|
322182|NCT00301821|Drug|vincristine sulfate|
322183|NCT00301834|Biological|alemtuzumab|
322184|NCT00301834|Drug|busulfan|
322185|NCT00301834|Drug|cyclosporine|
322186|NCT00301834|Drug|fludarabine phosphate|
322187|NCT00301834|Drug|methotrexate|
322188|NCT00301834|Drug|methylprednisolone|
322189|NCT00002816|Drug|etoposide|Given IV
322190|NCT00301834|Procedure|allogeneic bone marrow transplantation|
322191|NCT00301834|Procedure|allogeneic hematopoietic stem cell transplantation|
322192|NCT00304421|Drug|rabeprazole|
322193|NCT00304421|Drug|pantoprazole|
322194|NCT00304434|Drug|Oseltamivir|
322195|NCT00304434|Drug|Probenecid|
322196|NCT00304447|Drug|Mylotarg|
322197|NCT00002824|Drug|ganciclovir|
322198|NCT00304460|Biological|aldesleukin|
322199|NCT00304473|Drug|Quetiapine fumarate|
321453|NCT00002718|Biological|filgrastim|
321454|NCT00268528|Drug|mercaptopurine tablet|Given orally
321455|NCT00268528|Drug|methotrexate|Given orally
321456|NCT00268541|Behavioral|Physical activity|
321457|NCT00268554|Drug|dipyridamole|
321458|NCT00268554|Drug|caffeine|
321459|NCT00268567|Drug|leflunomide combined with prednisone|
321460|NCT00268580|Behavioral|Clinical pathway for asthma in the emergency department|
321461|NCT00271635|Drug|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
321462|NCT00271674|Device|Q-switched YAG laser|
321463|NCT00271687|Behavioral|Exercise training|
321464|NCT00271700|Behavioral|Order Set, Education, Feedback|
321823|NCT00310596|Drug|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
321824|NCT00310596|Drug|Placebo|0,9% saline at 0,6mL/kg at bolus rate
321825|NCT00310609|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
321826|NCT00310622|Device|HyperQ Signal recording|
321827|NCT00310635|Biological|Meningococcal C conjugate vaccine|
321828|NCT00002838|Procedure|Peripheral Blood Stem Cell Transplantation|
321829|NCT00310648|Biological|Influenza vaccine|
321830|NCT00310661|Drug|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
321831|NCT00262197|Behavioral|Customized Physician Intervention|
321832|NCT00262197|Behavioral|Customized Patient Intervention|
321833|NCT00262210|Drug|Cyclophosphamide Epirubicin Etoposide Prednisolone|
302782|NCT00406614|Behavioral|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
302783|NCT00406640|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
302784|NCT00406640|Drug|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
302785|NCT00406653|Drug|abatacept|Dextrose 5% in water, intravenous (IV).
Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;
3 mg/kg on days IP-1, IP-15,IP-29, IP-57;
~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,
or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57.
Induction Period 3 months
Maintenance Period 12 months
302786|NCT00406653|Drug|placebo|Normal saline, IV, 0 mg/kg, every 28 days.
Induction Period 3 months
Maintenance Period 12 months
302787|NCT00406653|Drug|abatacept|~10 mg/kg, every 28 days.
Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued
302788|NCT00003273|Drug|cisplatin|
302789|NCT00406679|Drug|Paracetamol (acetaminophen) solution experimental|1 gm IV
302790|NCT00406679|Drug|paracetamol (acetaminophen) solution commercial|1 gm IV
302791|NCT00406679|Drug|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
302792|NCT00406692|Drug|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
302793|NCT00406705|Behavioral|Helium-Hyperoxia|
302794|NCT00406718|Behavioral|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
302795|NCT00406718|Behavioral|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
302796|NCT00406718|Behavioral|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
359625|NCT00673985|Device|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
359626|NCT00673998|Device|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
359627|NCT00674011|Drug|Bevacizumab|Given as part of standard of care or another research protocol
359628|NCT00005104|Drug|metformin|
359629|NCT00674024|Drug|Pazopanib|
359630|NCT00674024|Drug|Pazopanib (GW786034)(GW786034)|
359631|NCT00674037|Other|monetary incentive|75 euros for each patient included
359632|NCT00674050|Drug|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
359633|NCT00674050|Drug|Albuterol (Salbutamol)|2 puff= 200ug total dose
359634|NCT00674050|Drug|Fluticasone|2 puffs= 500ug total dose
359635|NCT00674063|Drug|alefacept|IV
359636|NCT00674089|Dietary Supplement|Vitamin A|Vitamin A 50,000 IU
359637|NCT00674089|Dietary Supplement|Placebo|Vitamin A Placebo
359638|NCT00674102|Drug|ASA404|
359639|NCT00005106|Drug|Lamivudine/Zidovudine|
359640|NCT00676403|Drug|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
359962|NCT00005596|Drug|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
359963|NCT00681928|Drug|anastrozole|As determined by the subject's physician
359964|NCT00681928|Drug|letrozole|As determined by the subject's physician
359965|NCT00684034|Other|Sampling of blood|A sampling of bood will be made before the dialysis
359966|NCT00684034|Other|Sampling of blood|A sampling of blood will be made.
359967|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
359968|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
359314|NCT00690651|Procedure|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
359315|NCT00690677|Drug|LBH589|LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study.
359316|NCT00690690|Behavioral|Video (group-delivered video-based intervention)|group-delivered video-based intervention
359317|NCT00690690|Behavioral|HCT|Offer of HIV counseling and testing
359318|NCT00690703|Device|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
359319|NCT00005647|Drug|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
359320|NCT00690716|Drug|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
359321|NCT00690716|Drug|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
359322|NCT00690729|Behavioral|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
359323|NCT00690729|Behavioral|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
359324|NCT00690768|Drug|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
359325|NCT00690768|Procedure|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
359326|NCT00690781|Dietary Supplement|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
359327|NCT00690781|Dietary Supplement|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
359328|NCT00693108|Drug|Transdermal testosterone|
359329|NCT00693121|Drug|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
359330|NCT00693121|Drug|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
358680|NCT00673322|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
358681|NCT00673335|Drug|letrozole|
358682|NCT00673361|Drug|Concurrent decrescendo biochemotherapy regimen|Temozolomide: 200mg/m^2, daily, PO, days 1-4
Vinblastine: 1.5mg/m^2, daily, IV, days 1-4
Cisplatin: 20mg/m^2, daily IV, days 1-4
IL (interleukin)-2: - 18 milli-International unit (MIU)/m^2, IVCI (intravenous continual infusion), day 1
9 MIU/m^2, IVCI, day 2
4.5 MIU/m^2, IVCI, days 3 & 4
Interferon (IFN) alpha: 5 MIU/m^2, daily, SC (subcutaneously), days 1-5
5-day inpatient regimen, to be repeated every 21 days
358683|NCT00673361|Drug|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
358684|NCT00673374|Device|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
359003|NCT00683488|Behavioral|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
359004|NCT00683488|Behavioral|First Intervention Trial|Intervention will comprise of approximately 15 weekly sessions.
Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.
Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.
Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility.
359005|NCT00683488|Behavioral|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
359006|NCT00683501|Drug|DNB-001|four dosages of DNB-001, one placebo dosage
359007|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|q 28 days :
50 mg/m2 oral vinorelbine d1, d8, d15
20 mg/m2/d cisplatin from d1 to d4
359008|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|q 21 days :
60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2
80 mg/m2 cisplatin d1
359009|NCT00000668|Drug|Ganciclovir|
359010|NCT00005603|Drug|cyclophosphamide|
359011|NCT00683527|Drug|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
359012|NCT00683553|Drug|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
359013|NCT00683553|Drug|Placebo|Single IV injection of saline
358353|NCT00687856|Procedure|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
358354|NCT00687869|Behavioral|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
358355|NCT00687869|Behavioral|Case management|Usual stroke aftercare plus patient-information-notes
358356|NCT00005631|Drug|carboplatin|
358357|NCT00689897|Procedure|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
358358|NCT00689897|Procedure|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
358359|NCT00689936|Drug|Lenalidomide and low-dose dexamethasone|Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules ,given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.
Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression
358360|NCT00689936|Drug|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.
Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles
358361|NCT00689936|Drug|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
358362|NCT00689949|Dietary Supplement|folic acid|0.4 mg of folic acid per day
358363|NCT00689962|Device|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
358364|NCT00689962|Device|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
358365|NCT00005641|Procedure|allogeneic bone marrow transplantation|
358366|NCT00689975|Behavioral|behavioral dietary intervention|
358367|NCT00689975|Behavioral|exercise intervention|
358368|NCT00689975|Other|counseling intervention|
358369|NCT00689975|Other|flow cytometry|
358685|NCT00673387|Drug|pramlintide acetate|subcutaneous injection, twice a day
357761|NCT00677794|Drug|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
357762|NCT00677794|Drug|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
357763|NCT00677807|Drug|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
357764|NCT00677807|Drug|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
358041|NCT00682981|Drug|Obatoclax|A 24-hour IV infusion for 3 consecutive days of Obatoclax with carboplatin and etoposide.
358042|NCT00682981|Drug|Obatoclax|A 3-hour IV infusion for 3 consecutive days of Obatoclax with carboplatin and etoposide.
358043|NCT00682981|Drug|Carboplatin and etoposide|Carboplatin and etoposide with NO Obatoclax.
358044|NCT00682994|Behavioral|Interview|Interview lasting about 5-10 minutes.
358045|NCT00682994|Behavioral|Questionnaire|Questionnaires taking 20-30 minutes to complete.
358046|NCT00683007|Other|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
358047|NCT00005601|Drug|cisplatin|
358048|NCT00683007|Other|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
358049|NCT00683020|Behavioral|ATSM Intervention|The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.
For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients.
358050|NCT00683033|Behavioral|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
358051|NCT00683033|Behavioral|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
358052|NCT00683046|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
358053|NCT00005611|Drug|BMS-188797|
357448|NCT00631488|Drug|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
357449|NCT00672685|Dietary Supplement|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
357450|NCT00005090|Drug|etoposide|60 mg/kg on day -4 (4 days before transplant).
357451|NCT00672685|Behavioral|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
357452|NCT00672685|Drug|Placebo|OMEGA-3 placebo
357453|NCT00672698|Procedure|SURGERY|ELECTIVE SURGICAL PROCEDURES
357454|NCT00672724|Drug|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
357455|NCT00672724|Drug|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
357456|NCT00672737|Drug|Remifentanil|
357765|NCT00677820|Biological|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
357766|NCT00677820|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
357767|NCT00677833|Drug|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (~30 mg/kg) + chloroquine (~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
357768|NCT00677833|Drug|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
357769|NCT00677859|Biological|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
357770|NCT00677859|Biological|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
357771|NCT00005581|Drug|cyclophosphamide|
357772|NCT00677872|Drug|PRX-08066|
357773|NCT00677898|Behavioral|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
357774|NCT00677898|Behavioral|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
357159|NCT00689520|Drug|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
357160|NCT00689520|Drug|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
357161|NCT00689559|Drug|AZD3480|AZD3480 capsules qd, oral, 22 days
357162|NCT00689559|Drug|Placebo|Placebo qd, 12 days
357163|NCT00689559|Drug|Aripiprazole|single dose on day 5
357164|NCT00691652|Biological|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
357165|NCT00691652|Drug|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
357166|NCT00691652|Genetic|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
357167|NCT00691652|Genetic|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
357168|NCT00691652|Genetic|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals << 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
357169|NCT00691652|Genetic|polymerase chain reaction|
357457|NCT00672737|Procedure|Ice water used to assess cold pain threshold and tolerance|
357458|NCT00672737|Device|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), Used to assess heat pain threshold and tolerance|
357459|NCT00672763|Drug|Colecalciferol D3 (Vigantol Oil)|Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;
Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;
Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses).
357460|NCT00672763|Drug|Medium chain triglycerides|Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;
Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;
Migliol Oil 5ml oral fortnightly (2 doses)
356841|NCT00607555|Device|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
356842|NCT00607568|Drug|Atomoxetine|atomoxetine 40mg per day or placebo
For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II.
356843|NCT00607581|Drug|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
356844|NCT00607581|Drug|lenalidomide|lenalidomide: 15 mg orally on days 1-21
356845|NCT00607581|Drug|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
356846|NCT00609830|Behavioral|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
356847|NCT00609830|Behavioral|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
356848|NCT00609830|Behavioral|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
356849|NCT00609830|Behavioral|No Information|Participants received no informational materials.
356850|NCT00609843|Other|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
356851|NCT00609856|Drug|pioglitazone|tablet, 30 mg, once daily, 26 weeks
356852|NCT00609856|Drug|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
356853|NCT00609869|Drug|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
356854|NCT00609869|Drug|Rituximab|Rituximab was administered at 375 mg/m^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
356855|NCT00609882|Other|Nasal CPAP|Infants randomized to the Standard nasal CPAP via "bubble" or ventilator support at levels of 4-8 cm H2O post extubation
356856|NCT00000621|Drug|13 cis retinoic acid|
356857|NCT00004261|Other|immunohistochemistry staining method|
361410|NCT00643266|Behavioral|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
361411|NCT00643279|Device|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead.
361412|NCT00643292|Drug|amoxicillin/clavulanate postassium (Augmentin ES-600)|amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
361413|NCT00643292|Drug|azithromycin SR|azithromycin SR 60 mg/kg x 1 dose
361414|NCT00643305|Behavioral|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
361415|NCT00643305|Behavioral|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
356534|NCT00614523|Drug|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
356535|NCT00614523|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
356536|NCT00614536|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
356537|NCT00614562|Device|Neurally adjusted ventilatory assist (NAVA)|NAVA for 72 hours
356538|NCT00614588|Device|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
356539|NCT00614601|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
356540|NCT00004344|Drug|testosterone|
356541|NCT00617097|Drug|lidocaine|paracervical block with lidocaine
356542|NCT00617097|Drug|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
356543|NCT00004396|Drug|heme arginate|
356544|NCT00617110|Other|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
356545|NCT00617110|Other|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
356546|NCT00617123|Drug|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
361079|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
361080|NCT00004904|Biological|anti-thymocyte globulin|
361081|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
361082|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
361083|NCT00650715|Device|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
361084|NCT00650715|Device|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
361085|NCT00650728|Procedure|placing gastric tube|
361086|NCT00650754|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
361087|NCT00650754|Other|Placebo|Placebo
361088|NCT00650767|Drug|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
361089|NCT00650767|Drug|Placebo; oral|matching placebo
361090|NCT00650793|Drug|Extended Release OROS® Paliperidone|
361416|NCT00643318|Radiation|CyberKnife Stereotactic Radiosurgery|Central tumors defined as < 2 cm from carina and < 2 cm from right and left mainstem bronchus and/or < 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)
Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)
361417|NCT00643331|Behavioral|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
361418|NCT00643344|Behavioral|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
361419|NCT00004867|Radiation|Radiotherapy|
357887|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
357888|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
357889|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
357890|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
357891|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
357892|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
358183|NCT00670982|Drug|vinorelbine|Given intravenously once a week
358184|NCT00670982|Drug|trastuzumab|Given intravenously once a week
358185|NCT00670995|Behavioral|Interactive Tobacco Education|Increase perceived behavioral control (self-efficacy) Decrease willingness to use tobacco Decrease intentions to use tobacco
358186|NCT00671008|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
358187|NCT00671008|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
358188|NCT00673179|Drug|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m^2/day for 2 days continuous infusion.
358189|NCT00673179|Drug|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m^2, max 20 gm over 4 hours.
358190|NCT00673179|Drug|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
358191|NCT00673179|Drug|Dexrazoxane|Dose 900 mg/m^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
358192|NCT00673179|Drug|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2. Dose 2.8 grams m^2/day.
358193|NCT00673179|Behavioral|Questionnaire|Questionnaires to be completed on 5 different days during the study.
358194|NCT00005092|Procedure|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
358195|NCT00673179|Drug|Gemcitabine|IV over 1 hour, every other week.
357591|NCT00685035|Device|VEST Airway Clearance System, Model 205|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
357592|NCT00685048|Behavioral|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
357593|NCT00685048|Behavioral|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
357594|NCT00687232|Drug|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
357595|NCT00687232|Drug|Placebo|
357596|NCT00687245|Drug|esomeprazole magnesium|capsules, oral, qd, one day
357597|NCT00687258|Device|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
357598|NCT00687258|Device|APS-U (Asahi Polysulfone APS)|PS Polysulfone dialyser without vitamin E alpha-tocopherol
357599|NCT00687271|Drug|MK6213|MK6213 160mg for 4 weeks.
357600|NCT00005627|Drug|docetaxel|
357893|NCT00005675|Drug|Placebo|CI placebo daily for 15 months
357894|NCT00692120|Dietary Supplement|Placebo|oral placebo capsule once daily for 12 months
357895|NCT00692146|Drug|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
357896|NCT00692146|Drug|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
357897|NCT00692159|Drug|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
357898|NCT00692172|Drug|Alefacept|intramuscular injection (IM)
357899|NCT00692185|Drug|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
357900|NCT00692185|Drug|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
357901|NCT00692198|Behavioral|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
357294|NCT00680043|Drug|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
357295|NCT00680056|Drug|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
357296|NCT00680056|Drug|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
357297|NCT00682500|Drug|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
357298|NCT00682526|Device|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
357299|NCT00682539|Drug|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
357300|NCT00682539|Drug|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
357601|NCT00687271|Drug|Comparator: atorvastatin calcium|atorvastatin calcium 20mg for 4 weeks.
357602|NCT00687271|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 4 Weeks
357603|NCT00687284|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
357604|NCT00687297|Drug|vandetanib induction|100 mg daily by mouth
357605|NCT00687297|Drug|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
357606|NCT00687297|Drug|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
357607|NCT00687297|Drug|Placebo|
357608|NCT00687297|Drug|Vandetanib maintenance|300 mg daily by mouth
356661|NCT00628420|Drug|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
356662|NCT00004635|Drug|leuprolide acetate|Injections of leuprolide once a month for six months.
356663|NCT00628433|Drug|Placebo|Placebo
356664|NCT00628433|Drug|HE3286|daily for 28 days
356665|NCT00628459|Dietary Supplement|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
356666|NCT00628472|Drug|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
356667|NCT00628485|Device|BION|The second group will have a "High Stimulation" paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated.
356668|NCT00628485|Device|BION|The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal "twitch" stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each.
356669|NCT00628485|Device|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
356670|NCT00628498|Drug|Defibrotide|Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.
Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days.
356671|NCT00628498|Drug|Defibrotide|
356672|NCT00628511|Device|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
356673|NCT00004635|Drug|goserelin|Injections of Goserelin once a month for six months.
356988|NCT00672490|Drug|Quetiapine Fumarate|Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.
Tablets
356989|NCT00672490|Drug|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
360882|NCT00667706|Procedure|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of <50, and >50, respectively.
360883|NCT00667719|Drug|aliskiren /amlodipine/hydrochlorothiazide|1x aliskiren/amlodipine/hydrochlorothiazide
360884|NCT00667732|Drug|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
361204|NCT00660985|Drug|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
361205|NCT00660998|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
361206|NCT00660998|Drug|Placebo|Matching placebo
361207|NCT00661011|Procedure|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
361208|NCT00663169|Other|placebo matching dexamethasone|Placebo intravenous infusion.
361209|NCT00005023|Biological|sargramostim|
361210|NCT00663182|Drug|Entecavir|Entecavir 0.5 mg/d
361211|NCT00663195|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
361212|NCT00663208|Drug|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
361213|NCT00663208|Drug|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
361214|NCT00663221|Dietary Supplement|Anthocyans, Calcium and Vitamin D|
361215|NCT00663221|Dietary Supplement|placebo|
361216|NCT00663234|Drug|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
361217|NCT00663247|Device|Mesalazine|3 grams daily for 3 months
361218|NCT00663247|Drug|Placebo|3 grams daily for 3 months
361219|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
361220|NCT00005024|Drug|carboplatin|
361221|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
360277|NCT00691301|Drug|pemetrexed disodium|
360278|NCT00005655|Biological|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
360279|NCT00691314|Device|Stent implantation (Wingspan, Coroflex, and TiTAN2)|Stent Implantation:
Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent
Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
Arms: 1
360280|NCT00691314|Drug|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
360281|NCT00691327|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
360282|NCT00691379|Drug|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
360283|NCT00691379|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
360575|NCT00005578|Drug|cyclophosphamide|
360576|NCT00677053|Drug|Placebo|Stages I, II & III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
360577|NCT00677066|Procedure|Home oxygen therapy|Administer oxygen at home or in hospital
360578|NCT00677079|Drug|Iniparib|Body weight adjusted dose
1 hour intravenous infusion
360579|NCT00677092|Drug|Imatinib mesylate|400 mg p.o. daily for four months
360580|NCT00677105|Drug|JNJ-26481585|
360581|NCT00677118|Drug|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
360582|NCT00677118|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
360583|NCT00677131|Other|Reading the package insert of the drug|package insert of the drug
360584|NCT00677131|Other|Reading the education information provided by the Pharmacy of NTUH|education information
360585|NCT00677131|Other|Oral education provided by the pharmacist|Oral education provided by the pharmacist
359969|NCT00684047|Procedure|Manual Compression|Manual Compression. Primary Part (II)
359970|NCT00684060|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
359971|NCT00684060|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
359972|NCT00684073|Drug|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
359973|NCT00684073|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
359974|NCT00684086|Behavioral|Diabetes Self Management Program|
359975|NCT00005603|Drug|thioguanine|
359976|NCT00684099|Drug|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
359977|NCT00684099|Drug|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
359978|NCT00684112|Drug|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
359979|NCT00684112|Drug|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
359980|NCT00684125|Device|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
359981|NCT00684125|Device|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
359982|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
359983|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
359984|NCT00684164|Drug|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
360284|NCT00691379|Drug|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
360285|NCT00691392|Drug|Linezolid|Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
360286|NCT00693758|Device|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
360287|NCT00005765|Drug|nicotine|
360288|NCT00693758|Device|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
359331|NCT00693147|Procedure|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
359641|NCT00676403|Drug|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
359642|NCT00676403|Drug|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
359643|NCT00676403|Drug|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
359644|NCT00676416|Drug|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
359645|NCT00676429|Drug|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
359646|NCT00676429|Drug|Placebo|Placebo as oral solution, individually titrated
359647|NCT00676442|Drug|PN400|naproxen/esomeprazole
359648|NCT00676468|Other|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
359649|NCT00676468|Other|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
359650|NCT00005575|Behavioral|Cognitive-behavior therapy|
359651|NCT00676468|Other|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
359652|NCT00676481|Behavioral|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
359653|NCT00676494|Device|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
359654|NCT00676507|Biological|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
359655|NCT00676507|Other|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
359656|NCT00676520|Device|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
359657|NCT00676533|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
359658|NCT00676559|Drug|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
359014|NCT00683566|Procedure|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
359015|NCT00683579|Drug|Early Treatment with HAART|HAART with possibility of de-intensification
359016|NCT00683579|Other|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
359017|NCT00683579|Drug|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA >100,000 copies/ml
359018|NCT00683592|Drug|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
359019|NCT00683592|Drug|placebo|placebo
359020|NCT00683618|Drug|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
359021|NCT00005603|Drug|cytarabine|
359022|NCT00683618|Drug|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
359332|NCT00693160|Drug|ketorolac|single intrathecal injection of ketorolac 2 mg
359333|NCT00693160|Drug|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
359334|NCT00693160|Drug|remifentanil|All subjects will receive a remifentanil infusion
359335|NCT00693160|Drug|Capsaicin|Topical capsaicin pain model utilized for each subject
359336|NCT00693186|Biological|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
359337|NCT00693186|Biological|Engerix B® 10 µg / 0.5 mL|10 µg
359338|NCT00005762|Drug|Ritonavir|
359339|NCT00693199|Drug|amlodipine|amlodipine 5mg once daily for 28 days
359340|NCT00693199|Drug|terazosin|terazosin 2 mg once daily for 28 days
359341|NCT00693199|Drug|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
359342|NCT00693212|Drug|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
359343|NCT00693212|Drug|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
358686|NCT00673387|Drug|metreleptin|subcutaneous injection, twice a day
358687|NCT00673387|Drug|placebo-P|subcutaneous injection, twice a day
358688|NCT00673387|Drug|placebo-M|subcutaneous injection, twice a day
358689|NCT00673400|Procedure|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
358690|NCT00005094|Drug|celecoxib|Given orally
358691|NCT00673426|Biological|Enoxaparin sodic|
358692|NCT00673439|Drug|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
358693|NCT00673439|Drug|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
358694|NCT00673452|Drug|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
358695|NCT00673452|Drug|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
358696|NCT00673465|Drug|SCH 497079|100 mg, administered orally, once-daily x 28 days
358697|NCT00675805|Device|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
358698|NCT00675818|Device|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
358699|NCT00675818|Device|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
358700|NCT00675831|Device|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
358701|NCT00675844|Drug|elvucitabine|10 mg elvucitabine daily as part of an ART regimen
358702|NCT00675857|Drug|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
358703|NCT00005520|Drug|Candesartan|
358704|NCT00675857|Other|placebo|Dosage: 4 capsules BID for 26 weeks
358054|NCT00685204|Drug|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
358055|NCT00685217|Procedure|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
358056|NCT00685217|Procedure|TVT (Gynecare)|Sling procedure for stress urinary incontinence
358057|NCT00685230|Biological|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
358058|NCT00685230|Other|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
358059|NCT00685243|Procedure|Laser treatment|Fraxel and pulsed dye laser
358370|NCT00689975|Other|immunoenzyme technique|
358371|NCT00689975|Other|laboratory biomarker analysis|
358372|NCT00689975|Procedure|complementary or alternative medicine procedure|
358373|NCT00689975|Procedure|standard follow-up care|
358374|NCT00689988|Behavioral|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
358375|NCT00690014|Drug|probenecid|500 mg q 6 hrs
358376|NCT00005641|Procedure|in vitro-treated bone marrow transplantation|
358377|NCT00690027|Procedure|Emergency portacaval shunt|
358378|NCT00690027|Procedure|Emergency and long-term endoscopic sclerotherapy|
358379|NCT00690040|Device|Foley catheter|Single balloon catheter
358380|NCT00690040|Device|Atad catheter|Double balloon catheter
358381|NCT00690053|Procedure|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
358382|NCT00005711|Behavioral|Asthma self-management education|Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma ("triggers"), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish.
358383|NCT00692380|Radiation|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
357775|NCT00677911|Behavioral|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
357776|NCT00677924|Drug|Zalutumumab|Solution for infusion
357777|NCT00677937|Behavioral|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
357778|NCT00005589|Drug|carmustine|
357779|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
357780|NCT00680316|Drug|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
357781|NCT00680316|Drug|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
357782|NCT00680329|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
357783|NCT00680329|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
357784|NCT00680342|Drug|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
357785|NCT00680342|Drug|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
358060|NCT00685256|Other|counseling intervention|subjects and parents will receive genetic counseling
358061|NCT00685256|Other|educational intervention|subjects and parents will receive education re: genetic testing
358062|NCT00685256|Other|survey administration|surveys will be administered to subjects and parents
358063|NCT00685256|Behavioral|psychosocial assessment and care|psychosocial assessment and counseling will be provided
358064|NCT00005612|Biological|filgrastim|
358065|NCT00685256|Behavioral|supportive care|parents and children will be provided with supportive care
358066|NCT00685269|Drug|Eszopiclone|Eszopiclone 3 mg QD
358067|NCT00685269|Drug|Placebo|Placebo tablet
357461|NCT00005090|Drug|vinblastine|6 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
357462|NCT00672776|Drug|paroxetine|
357463|NCT00672776|Drug|placebo|
357464|NCT00672789|Behavioral|Blood smear education|education at baseline and three month follow-up
357465|NCT00672789|Other|standard education|standard education
357466|NCT00672802|Drug|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
357467|NCT00672828|Behavioral|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
357468|NCT00672828|Behavioral|Interactive computer intervention|
357469|NCT00672841|Drug|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
357470|NCT00672841|Drug|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
357471|NCT00672854|Drug|ClinOleic|TPN with ClinOleic (20%)
357472|NCT00005090|Procedure|peripheral blood stem cell transplantation|2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight
357473|NCT00675129|Behavioral|Dialectical behavioral therapy for adolescents (DBT-A)|Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.
The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively.
357786|NCT00680342|Other|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
357787|NCT00680355|Dietary Supplement|golden rice|An acute dose of cooked golden rice containing ~ 1 mg of ß-carotene
357788|NCT00680355|Dietary Supplement|corn oil 0g|0 g of corn oil in the golden rice meal
357789|NCT00005589|Drug|cyclophosphamide|
357790|NCT00680355|Dietary Supplement|corn oil 10g|10g corn oil in the golden rice meal
356858|NCT00609882|Other|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
357170|NCT00691652|Other|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
357171|NCT00005668|Drug|Itraconazole oral solution|
357172|NCT00691652|Other|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
357173|NCT00691665|Drug|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
357174|NCT00691665|Drug|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
357175|NCT00691678|Drug|Glucosamine Chondroitin|Glucosamine [500mg three times daily (TID) x 24 weeks] plus chondroitin (400mg TID x 24 weeks)
357176|NCT00691691|Radiation|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
357177|NCT00691704|Drug|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
357178|NCT00694187|Drug|Zaleplon|
357179|NCT00694200|Drug|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
357180|NCT00694200|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
357181|NCT00694213|Biological|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
357182|NCT00694213|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
357183|NCT00694213|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
357184|NCT00694213|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
356547|NCT00617123|Drug|Placebo|matching placebo oral tablet
356548|NCT00617136|Device|Intraoperative warming (Bair Hugger)|Intraoperative warming
356549|NCT00617136|Device|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
356550|NCT00617136|Device|Intraoperative warming (HotDog)|Intraoperative warming
356551|NCT00617149|Behavioral|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
356552|NCT00617175|Device|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
356553|NCT00617175|Device|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
356554|NCT00004396|Drug|tin mesoporphyrin|
356859|NCT00609895|Drug|INSULIN GLARGINE|
356860|NCT00609908|Procedure|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
356861|NCT00609908|Procedure|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
356862|NCT00609908|Procedure|serial excision|as much scar as possible is excised, whereafter the wound is closed
356863|NCT00609908|Procedure|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
356864|NCT00609921|Drug|ARQ197|treatment
356865|NCT00609934|Drug|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
356866|NCT00609934|Radiation|external beam radiotherapy|3000cGy in 10 fractions
356867|NCT00609947|Device|Endeavor Zotarolimus-Eluting Coronary Stent|
356868|NCT00004261|Procedure|biopsy|
356869|NCT00609960|Behavioral|clowns present|clowns present during the proccess of induction of anesthesia
361420|NCT00643357|Drug|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
361421|NCT00643357|Drug|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
361422|NCT00643370|Other|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
361423|NCT00643383|Drug|Combination drug (Acetaminophen + Tramadol)|
361424|NCT00643383|Drug|Placebo|
361425|NCT00643396|Radiation|thoracic radiotherapy|
361426|NCT00643409|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
361427|NCT00643409|Other|placebo|placebo
361428|NCT00645632|Drug|cisplatin|
361429|NCT00645632|Drug|doxorubicin hydrochloride|
361430|NCT00645632|Drug|ifosfamide|
361431|NCT00645632|Drug|methotrexate|
361432|NCT00004884|Drug|gemcitabine hydrochloride|
361433|NCT00645632|Procedure|adjuvant therapy|
361434|NCT00645632|Procedure|neoadjuvant therapy|
361435|NCT00645632|Procedure|therapeutic conventional surgery|
361436|NCT00645658|Drug|Testim (1% testosterone gel)|Subjects apply contents of gel packet to skin daily.
356555|NCT00617188|Drug|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
356556|NCT00617201|Drug|atomoxetine|Once daily oral dosing
356557|NCT00617201|Drug|placebo|Once daily oral dosing - matched placebo
356558|NCT00617240|Drug|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
356559|NCT00617240|Drug|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
356560|NCT00617253|Drug|recombinant interleukin-21|3 mcg/kg, s.c. injection
358196|NCT00673179|Drug|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
358197|NCT00673179|Procedure|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
358198|NCT00673179|Drug|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2/day.
358199|NCT00673192|Procedure|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
358200|NCT00673205|Drug|Bicalutamide|150mg p.o. daily
358201|NCT00673205|Drug|Placebo|
358202|NCT00673218|Drug|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
358524|NCT00005591|Biological|cetuximab|
358525|NCT00680901|Drug|Capecitabine|1700mg/m2/day in two daily doses
358526|NCT00680901|Drug|Oxaliplatin|130mg/m2 on day 1
358527|NCT00680914|Biological|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
358528|NCT00680914|Biological|Prevenar|3 doses administered intramuscularly.
358529|NCT00680914|Biological|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
358530|NCT00680927|Other|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
358531|NCT00680940|Drug|Paclitaxel & Cisplatin|Chemotherapeutic agent
358532|NCT00680940|Biological|Mycobacterium w.|Immunomodulator
358533|NCT00680953|Drug|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
358534|NCT00680953|Drug|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
358535|NCT00005591|Drug|gemcitabine hydrochloride|
358536|NCT00680953|Drug|Alendronate sodium hydrate|Oral tablet once a week for 24 months
358537|NCT00683202|Drug|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
357902|NCT00692211|Other|Mailed fecal occult blood tests|Stool blood test
357903|NCT00692211|Other|Mailed fecal immunochemical tests|Stool blood test
357904|NCT00005684|Drug|warfarin|
357905|NCT00694694|Drug|artemether-lumefantrine|Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.
For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days
357906|NCT00694707|Drug|Placebo|Placebo oral administration once daily for 6 weeks
357907|NCT00694707|Drug|RGH-188|RGH-188 low dose once daily for 6 weeks
357908|NCT00694707|Drug|RGH-188|RGH-188 medium dose once daily for six weeks
357909|NCT00694707|Drug|RGH-188|RGH-188 high dose oral administration once daily for six weeks
357910|NCT00694707|Drug|Risperidone|Risperidone oral administration once daily for six weeks
357911|NCT00694720|Drug|AVE0657|capsules once a day at bedtime
357912|NCT00694720|Drug|placebo|capsules once a day at bedtime
357913|NCT00694733|Drug|Placebo injection|Normal saline injection IM monthly for 4 months
357914|NCT00694733|Drug|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
358203|NCT00673218|Drug|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
358204|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
358205|NCT00005092|Procedure|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
358206|NCT00673231|Drug|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
358207|NCT00673231|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
358208|NCT00673231|Drug|Placebo|Placebo
358209|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
357609|NCT00687310|Behavioral|Educational intervention|Tailored asthma education based on needs assessment
357610|NCT00687323|Drug|temozolomide|
357611|NCT00005627|Drug|estramustine phosphate sodium|
357612|NCT00687336|Other|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
357613|NCT00687336|Other|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
357614|NCT00687349|Behavioral|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
357615|NCT00687362|Biological|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
357616|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
357617|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
357618|NCT00687388|Drug|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
357619|NCT00687388|Drug|celecoxib|200mg daily for 8 weeks
357620|NCT00687388|Drug|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
357621|NCT00005641|Drug|cyclophosphamide|
357622|NCT00689728|Biological|LY2127399|30 mg of LY2127399 will be administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
357623|NCT00689728|Biological|LY2127399|80 mg of LY2127399 will be administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
357915|NCT00005774|Drug|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
357916|NCT00694733|Drug|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
357917|NCT00694733|Drug|placebo|Placebo Cream 1ml applied twice daily for four months
357918|NCT00694733|Drug|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
357919|NCT00694746|Drug|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
356990|NCT00672529|Dietary Supplement|Orthomolecular Therapy or Placebo Comparator|The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.
Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function.
356991|NCT00674713|Other|Sham acupuncture|
356992|NCT00005110|Drug|Albuterol|
356993|NCT00674726|Other|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
356994|NCT00674739|Drug|Imiquimod|daily topical application for up to 8 weeks
356995|NCT00674739|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
356996|NCT00674739|Drug|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
356997|NCT00674752|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
356998|NCT00674752|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
356999|NCT00674752|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
357000|NCT00674765|Drug|Seroquel|400 mg/day
357001|NCT00674765|Drug|Placebo|400 mg/day
357002|NCT00674778|Procedure|Any percutaneous cardiovascular procedure|
357003|NCT00005112|Drug|Human recombinant growth hormone|
357004|NCT00674791|Biological|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
357005|NCT00674817|Drug|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
357006|NCT00674817|Drug|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
357007|NCT00674830|Behavioral|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
357008|NCT00674830|Behavioral|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
361222|NCT00663260|Drug|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
361223|NCT00663273|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
361224|NCT00663286|Drug|IDP-110|Topical application for 12 weeks
361225|NCT00663286|Drug|Clindamycin|Topical application for 12 weeks
361226|NCT00663286|Drug|Benzoyl peroxide|Topical application for 12 weeks
361227|NCT00663286|Drug|Vehicle|Topical application for 12 weeks
356356|NCT00596752|Drug|Alprostadil|Active Substance: Prostaglandin E1
Pharmaceutical Form: solution for infusion
Concentration: 40 μg b.d.
Route of Administration: intravenous infusion
356357|NCT00596752|Other|Placebo|Active Substance: Lactose
Pharmaceutical Form: solution for infusion
Concentration: 40 μg b.d.
Route of Administration: intravenous infusion
356358|NCT00596765|Behavioral|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
356359|NCT00596778|Other|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
356360|NCT00596791|Drug|tafluprost|prostaglandine analoque
356361|NCT00596804|Drug|veltuzumab|once weekly intravenous dosing for 4 weeks
356362|NCT00596817|Drug|Placebo|capsules, daily, orally
356363|NCT00596817|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
356364|NCT00596830|Drug|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
356365|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
356366|NCT00004206|Drug|FOLFOX regimen|
356367|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
360586|NCT00005578|Drug|dexrazoxane hydrochloride|
360587|NCT00677144|Drug|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
360588|NCT00677144|Drug|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
360589|NCT00677170|Drug|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
360590|NCT00677196|Device|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
360591|NCT00677196|Device|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
360592|NCT00677209|Biological|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
360593|NCT00677222|Biological|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
360594|NCT00677235|Device|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
360595|NCT00677235|Procedure|PTA|Treatment of stenoses with PTA only
360885|NCT00667732|Drug|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
360886|NCT00005058|Procedure|ultrasound imaging|
360887|NCT00667745|Drug|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
360888|NCT00670215|Drug|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
360889|NCT00670228|Drug|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
360890|NCT00670228|Drug|Insulin Glulisine (Apidra)|Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.
Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL.
360891|NCT00670228|Drug|Standard Therapy|Standard insulin therapy titrated to blood sugar control
360289|NCT00693771|Drug|Insulin Glargine|Once daily and up-titrate accordingly
360290|NCT00693784|Biological|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
360291|NCT00693823|Procedure|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
360292|NCT00693823|Device|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
360293|NCT00693836|Genetic|genetic linkage analysis|
360294|NCT00693836|Genetic|loss of heterozygosity analysis|
360295|NCT00693836|Genetic|mutation analysis|
360296|NCT00693836|Genetic|polymerase chain reaction|
360297|NCT00693836|Genetic|polymorphism analysis|
360298|NCT00005765|Drug|alcohol|
360299|NCT00693836|Other|biologic sample preservation procedure|
360300|NCT00693836|Other|medical chart review|
360301|NCT00693836|Other|questionnaire administration|
360302|NCT00693836|Procedure|evaluation of cancer risk factors|
360303|NCT00693849|Drug|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
360304|NCT00693849|Drug|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
360305|NCT00693849|Drug|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
360306|NCT00693862|Drug|levodopa, carbidopa, entacapone|
360307|NCT00693862|Drug|levodopa, carbidopa|
360596|NCT00677248|Drug|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
360597|NCT00005578|Drug|doxorubicin hydrochloride|
360598|NCT00677248|Drug|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
360599|NCT00005585|Drug|thioguanine|Given orally
359659|NCT00676559|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
359660|NCT00676572|Other|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
359985|NCT00684164|Other|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
359986|NCT00005603|Drug|vincristine sulfate|
359987|NCT00684177|Drug|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
359988|NCT00684177|Drug|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
359989|NCT00684190|Drug|AZD3355|150 mg bid, oral, 7 days
359990|NCT00684190|Drug|Esomeprazole|40 mg od, oral, 7 days
359991|NCT00686257|Device|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
359992|NCT00000671|Drug|Zidovudine|
359993|NCT00005616|Radiation|iodine I 131 monoclonal antibody F19|
359994|NCT00686257|Device|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
359995|NCT00686270|Drug|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
359996|NCT00686283|Behavioral|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
359997|NCT00686296|Other|Taliderm™|taliderm™ dressing application once
359998|NCT00686296|Other|Taliderm™|Taliderm™ dressing application up to three applications
359999|NCT00686296|Other|standard wet to dry dressing with gauze|wet to dry dressing standard of care
359344|NCT00693212|Drug|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
359345|NCT00693225|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
359346|NCT00693238|Radiation|Low Risk Proton Radiation|
359347|NCT00693238|Radiation|Intermediate Risk Proton Radiation|
359348|NCT00693251|Procedure|Crush technique|Crush technique
359349|NCT00005762|Drug|Amprenavir|
359350|NCT00693251|Procedure|provisional T stenting|Provisional T stenting
359351|NCT00693264|Dietary Supplement|Hoodia Gordonii|750 mg capsule will be taken one time
359352|NCT00693264|Dietary Supplement|Placebo|Placebo capsule to be taken one time
359353|NCT00693277|Behavioral|web-based nutritional educational intervention|
359354|NCT00693290|Other|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
359355|NCT00693303|Behavioral|Training on My Scrivenor|Subjects received 20 minutes twice per week on the My Scrivenor
359661|NCT00005576|Biological|monoclonal antibody Ch14.18|Given IV
359662|NCT00676585|Drug|Normal Saline|Normal Saline
359663|NCT00676585|Drug|Hydrocortisone|Hydrocortisone 100mg
359664|NCT00679042|Drug|Islets of Langerhans transplantation|Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant
359665|NCT00679055|Drug|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
359666|NCT00679055|Drug|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
359667|NCT00679068|Drug|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
359668|NCT00000664|Drug|Interleukin-2, Polyethylene Glycolated|
359023|NCT00683631|Radiation|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
359024|NCT00685802|Drug|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
359025|NCT00685802|Drug|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
359026|NCT00685815|Drug|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
359027|NCT00685815|Drug|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
359028|NCT00685828|Drug|imatinib mesylate|By mouth
359029|NCT00005613|Drug|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
359030|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
359031|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
359032|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
359033|NCT00685841|Drug|Salmeterol MDI|Salmeterol MDI 42 mcg BID
359034|NCT00685841|Drug|Placebo|Placebo BID MDI
359035|NCT00685854|Drug|Ranibizumab|
359036|NCT00685867|Other|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
359037|NCT00685867|Behavioral|Hand hygiene promotion|Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance
Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)
Isolation precautions according to the hospitals' capacity and strategy
Additional basic infection control interventions (if necessary)
359038|NCT00685880|Drug|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
359039|NCT00685880|Drug|Betamethasone|CELESTONE® SOLUSPAN® * (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
359040|NCT00005613|Drug|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
358384|NCT00692393|Procedure|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
358385|NCT00692393|Procedure|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
358386|NCT00692406|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
358387|NCT00692419|Behavioral|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
358388|NCT00692419|Behavioral|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
358389|NCT00692445|Drug|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
358705|NCT00675870|Drug|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
358706|NCT00675896|Drug|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
358707|NCT00675896|Drug|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
358708|NCT00675909|Drug|Aerosolized Intranasal midazolam|Midazolam will be administered via aerosolization (using "atomizer") with half of dose in each nostril. Total dose is 0.3mg/kg.
358709|NCT00675909|Drug|Aerosolized Buccal Midazolam|0.3mg/kg total dose administered with aerosolization device ("atomizer") sprayed onto buccal mucosa inside the cheek on both sides of mouth.
358710|NCT00675909|Drug|Oral midazolam|oral midazolam 0.5mg/kg
358711|NCT00675922|Drug|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
358712|NCT00675935|Other|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
358713|NCT00675948|Drug|Sativex|Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.
Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
358714|NCT00005553|Procedure|Catheter Ablation|
358068|NCT00685282|Behavioral|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
358069|NCT00685295|Drug|Fentanyl rapid dissolving tablet 100mcg|Fentanyl rapid dissolving tablet 100mcg will be given
358070|NCT00685295|Drug|lansoprazole 15mg rapidly dissolving tablet + Percocet PO|lansoprazole 15mg rapidly dissolving tablet + Percocet PO will be given
358071|NCT00685308|Procedure|Stenting of atherosclerotic intracranial stenosis|Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.
All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%.
358072|NCT00685321|Device|H1 deep TMS coil|20 daily deep rTMS treatment
358073|NCT00685321|Device|Sham|inactive treatment
358074|NCT00685334|Drug|Olanzapine|Participants will take olanzapine daily for 12 weeks.
358075|NCT00005612|Drug|carboplatin|
358076|NCT00685334|Drug|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
358077|NCT00687570|Dietary Supplement|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg*dag-1, seven days before surgery
358078|NCT00687570|Drug|Laxabon®|Laxabon® 4 litres starting the day before surgery
358079|NCT00687596|Drug|TAC-101|Patients randomized to TAC 101 will receive TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle will be repeated every 21 days.
358390|NCT00692445|Drug|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
358391|NCT00692458|Drug|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
358392|NCT00692458|Drug|Comparator: placebo|placebo; oral, once daily for approximately 60 months
358393|NCT00005713|Behavioral|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
357791|NCT00680355|Dietary Supplement|coren oil 5 g|golden rice meal with 5 g corn oil
357792|NCT00680381|Behavioral|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
357793|NCT00680381|Behavioral|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
357794|NCT00680381|Behavioral|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
357795|NCT00680394|Drug|mifepristone|200 mg mifepristone
357796|NCT00680394|Drug|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
357797|NCT00680394|Drug|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
357798|NCT00680407|Other|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
357799|NCT00680407|Drug|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
357800|NCT00005589|Drug|cytarabine|
357801|NCT00680407|Drug|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
357802|NCT00680420|Procedure|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
357803|NCT00680433|Drug|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
357804|NCT00680433|Drug|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
357805|NCT00682747|Drug|oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)
358080|NCT00687596|Drug|Placebo|Patients randomized to placebo will receive 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
358081|NCT00687609|Drug|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
358082|NCT00005630|Biological|ras peptide cancer vaccine|
358083|NCT00687622|Drug|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
357474|NCT00675129|Behavioral|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
357475|NCT00675142|Procedure|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
357476|NCT00675155|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
357477|NCT00005116|Behavioral|psychotherapy|
357478|NCT00675168|Radiation|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
357479|NCT00675181|Drug|Melatonin|5mg per os
357480|NCT00675181|Drug|Placebo|per os
357481|NCT00675194|Drug|Cisplatin, Irinotecan, Capecitabine|
357482|NCT00675207|Drug|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
357483|NCT00675207|Drug|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
357484|NCT00675207|Drug|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
357485|NCT00675220|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
357486|NCT00675233|Drug|HPPH|Given IV
357487|NCT00675233|Procedure|laser therapy|Escalating light doses with 665 nm light
357488|NCT00005117|Drug|pravastatin|
357489|NCT00675246|Drug|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
357490|NCT00675259|Drug|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days [1 cycle] for 5 cycles
357491|NCT00675259|Drug|carboplatin|AUC 2 IV on days 1, 8, and 15
357492|NCT00675259|Drug|nab-paclitaxel|100 mg/M2 IV
357493|NCT00675259|Procedure|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
356870|NCT00686842|Other|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
356871|NCT00686842|Procedure|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
356872|NCT00686855|Drug|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
356873|NCT00686855|Drug|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
356874|NCT00005622|Radiation|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
356875|NCT00686868|Other|placebo|placebo
356876|NCT00686868|Drug|ofatumumab|fully human anti-CD20 monoclonal antibody
356877|NCT00686881|Biological|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
356878|NCT00686881|Drug|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
356879|NCT00686894|Procedure|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
356880|NCT00686894|Drug|Infliximab|5 mg/kg
IV
Frequency : weeks 0,2,6
356881|NCT00686907|Drug|Melatonin|Dose range: 0.01 mg - 20 mg, daily, up to 5 years (based on each subject's circadian rhythms and response to the dose).
357185|NCT00694226|Behavioral|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
357186|NCT00694226|Behavioral|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
357187|NCT00694239|Behavioral|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
357188|NCT00005771|Procedure|Abdominal Hollowing Exercise|
356561|NCT00617253|Drug|sunitinib|Hard gelatine capsules, 12.5 mg
356562|NCT00617253|Drug|recombinant interleukin-21|10 mcg/kg, s.c. injection
356563|NCT00617253|Drug|recombinant interleukin-21|30 mcg/kg, s.c. injection
356564|NCT00617253|Drug|recombinant interleukin-21|100 mcg/kg, s.c. injection
356565|NCT00004397|Drug|heme arginate|
356566|NCT00617266|Other|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
356567|NCT00619424|Drug|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
356568|NCT00004424|Drug|propofol|
356569|NCT00619450|Other|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
356570|NCT00619463|Behavioral|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
356571|NCT00619463|Behavioral|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
356572|NCT00619476|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
356573|NCT00619476|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
356574|NCT00619476|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
356575|NCT00619476|Drug|Placebo|placebo
356576|NCT00619489|Drug|vedolizumab|Vedolizumab for intravenous (IV) infusion
356577|NCT00619502|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
356882|NCT00686920|Drug|rifaximin|Tablets
356883|NCT00686933|Drug|ABT-089|Subjects will take up to 80 mg daily for 24 months
356884|NCT00686959|Drug|Pemetrexed|infusion over 10 minutes
356885|NCT00005623|Drug|cyproterone acetate|
358538|NCT00683202|Drug|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
358539|NCT00683228|Behavioral|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
358540|NCT00683241|Biological|DCVac-L|Subjects will receive three doses of intradermal vaccination with ~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
358541|NCT00005601|Drug|sargramostim|
358542|NCT00683267|Drug|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
358543|NCT00683267|Drug|Placebo|One dose administered by direct instillation into the surgical site
358544|NCT00683280|Behavioral|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
358545|NCT00683280|Drug|varenicline (smoking cessation medication)|0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
358863|NCT00692770|Drug|Placebo|Placebo 2 tablets twice daily (BID)
358864|NCT00692796|Other|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
358865|NCT00692835|Procedure|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
358866|NCT00692835|Procedure|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
358867|NCT00692848|Other|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
358868|NCT00692887|Device|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
358869|NCT00692900|Drug|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
358870|NCT00692900|Drug|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
358871|NCT00005743|Behavioral|weight loss|
358210|NCT00675584|Drug|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
358211|NCT00675597|Drug|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
358212|NCT00675610|Behavioral|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
358213|NCT00675623|Drug|Dimebon|Dimebon, 5 mg orally three times daily for six months
358214|NCT00675623|Drug|Dimebon|Dimebon 20 mg orally three times daily for six months
358215|NCT00675623|Drug|Placebo|Placebo three times daily for six months
358216|NCT00675636|Other|study of socioeconomic and demographic variables|database, no intervention
358217|NCT00675636|Procedure|evaluation of cancer risk factors|database, no intervention
358218|NCT00675636|Procedure|study of high risk factors|database, no intervention
358219|NCT00675649|Biological|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
358220|NCT00005137|Other|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
358221|NCT00675649|Biological|placebo|placebo sc injection every 4 weeks from week 0 to week 20
358222|NCT00675662|Behavioral|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
358546|NCT00683280|Behavioral|Brief counseling for quitting smoking|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
358547|NCT00683293|Procedure|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
358548|NCT00683293|Procedure|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
358549|NCT00683306|Drug|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
358550|NCT00683319|Drug|carboplatin|
358551|NCT00683319|Drug|cisplatin|
357920|NCT00694746|Drug|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
357921|NCT00694759|Drug|pioglitazone|30 mg for 2 weeks, then 45 mg daily
357922|NCT00694759|Drug|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
357923|NCT00694759|Drug|placebo|capsule twice daily
357924|NCT00694772|Procedure|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
357925|NCT00694772|Procedure|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
357926|NCT00005775|Drug|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
357927|NCT00694785|Drug|ARC1779|Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.
Group "NT3"
357928|NCT00694785|Drug|ARC1779|Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.
Group "T3"
357929|NCT00694785|Drug|ARC1779|Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.
Group "NT6"
357930|NCT00670748|Biological|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 CCID50 (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
357931|NCT00670761|Drug|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
357932|NCT00670761|Procedure|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
358223|NCT00675662|Behavioral|waiting list control|waiting list control
358224|NCT00675675|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
358225|NCT00675675|Behavioral|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
358226|NCT00675688|Drug|Bazedoxifene/Conjugate Estrogens (CE)|
358227|NCT00675688|Drug|Raloxifene|
358228|NCT00675688|Drug|Placebo|
357301|NCT00682539|Drug|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
357302|NCT00682539|Procedure|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
357303|NCT00682552|Procedure|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
357304|NCT00682565|Drug|CK-1827452|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
357305|NCT00005598|Drug|amifostine trihydrate|
357306|NCT00682565|Drug|CK-1827452|12.5mg oral immediate release capsule
357307|NCT00682565|Drug|CK-1827452|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
357308|NCT00682565|Drug|CK-1827452|25mg oral immediate release capsule
357309|NCT00682565|Drug|Placebo|I.V. infusion for 20 hours
357310|NCT00682565|Drug|Placebo|Matching placebo oral immediate release capsule
357311|NCT00682565|Drug|Placebo|Matching placebo oral immediate release capsule
357312|NCT00684723|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
357313|NCT00684762|Drug|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
357314|NCT00684762|Drug|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
357315|NCT00684775|Behavioral|employment-based reinforcement|Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the "Work Plus Naltrexone Contingency" condition will earn access to working and earning salary by taking depot naltrexone injections once per month. "Work Plus Naltrexone Prescription" participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.
356368|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
356369|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
356370|NCT00596843|Behavioral|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
356371|NCT00596843|Behavioral|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
356372|NCT00596856|Behavioral|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
356674|NCT00628537|Device|BION stimulation|BION™ Experimental Group
The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.
Surface Stimulation Group
Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.
Control Group with conservative therapy (Range of motion exercises)
The research participant is instructed in self-administered, standard range of motion stretching exercises.
356675|NCT00628550|Drug|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
356676|NCT00628550|Drug|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
356677|NCT00630877|Drug|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
356678|NCT00004685|Drug|albuterol|
356679|NCT00630890|Radiation|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
356680|NCT00630903|Drug|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
356681|NCT00630903|Drug|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
356682|NCT00630916|Device|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
360892|NCT00670241|Drug|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
360893|NCT00670241|Drug|LEO 80185 vehicle|Once daily application
360894|NCT00670241|Drug|Tacalcitol ointment|Once daily application
360895|NCT00005078|Drug|paclitaxel|
360896|NCT00670254|Drug|Placebo|Application is identical to experimental arm
360897|NCT00670254|Drug|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
360898|NCT00670267|Drug|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
360899|NCT00670280|Behavioral|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
360900|NCT00670280|Behavioral|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
360901|NCT00670280|Behavioral|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
361228|NCT00663299|Device|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
361229|NCT00663312|Behavioral|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
361230|NCT00663325|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
361231|NCT00000655|Drug|Atovaquone|
361232|NCT00005024|Drug|cyclophosphamide|
361233|NCT00663338|Drug|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
361234|NCT00663351|Device|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
360600|NCT00679536|Drug|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
360601|NCT00679536|Radiation|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
360602|NCT00679549|Device|CPAP Therapy|CPAP therapy is provided as an inpatient.
360603|NCT00679562|Drug|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
360604|NCT00679562|Other|Distilled water|Application of patches containing distilled water for 24 hours
360605|NCT00679588|Drug|Semuloparin Sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
360606|NCT00679588|Drug|Enoxaparin sodium|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
360607|NCT00679588|Drug|Placebo|0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component
Subcutaneous injection
360608|NCT00679601|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
360609|NCT00679614|Drug|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
360610|NCT00005585|Drug|vincristine sulfate|Given IV
360611|NCT00679614|Drug|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
360612|NCT00679614|Drug|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
360902|NCT00670293|Radiation|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
360000|NCT00686322|Drug|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
360001|NCT00686335|Drug|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
360002|NCT00686335|Drug|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
360308|NCT00693888|Behavioral|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
360309|NCT00005766|Drug|Creatinine|
360310|NCT00693901|Behavioral|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
360311|NCT00672165|Biological|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
360312|NCT00672178|Radiation|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
360313|NCT00005089|Drug|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
360314|NCT00672191|Biological|AGS-004|HIV-1 Immune Therapy
360315|NCT00672204|Biological|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
360316|NCT00672204|Drug|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
360317|NCT00672204|Drug|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
360318|NCT00672204|Drug|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
359669|NCT00005585|Drug|cyclophosphamide|Given IV
359670|NCT00679081|Device|CelTx|Single application; split-mouth design
359671|NCT00679081|Other|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
359672|NCT00679094|Drug|Bowman-Birk inhibitor concentrate|Given orally
359673|NCT00679094|Other|placebo|Given orally
359674|NCT00679094|Other|pharmacological study|Correlative studies
359675|NCT00679094|Other|laboratory biomarker analysis|Correlative studies
359676|NCT00679107|Device|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
359677|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
359678|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
359679|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
359680|NCT00005585|Drug|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
359681|NCT00679133|Drug|MGCD265|Oral daily administration; 7 days on / 7 days off
359682|NCT00679146|Drug|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
360003|NCT00686361|Drug|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
360004|NCT00005617|Biological|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
360005|NCT00686374|Biological|Adalimumab|Pre-filled syringe, 40mg (subjects >or =40kg) /20mg EOW (subjects <40kg)or 40mg(subjects >or =40kg)/20mg EW(subjects <40kg) for up to 336 weeks.
360006|NCT00686400|Other|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
360007|NCT00686413|Drug|AZD3480|single dose, oral
360008|NCT00686413|Radiation|2-[18F]-F-A85380|Single dose, IV
359041|NCT00685893|Behavioral|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
359356|NCT00671541|Drug|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
359357|NCT00671541|Drug|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
359358|NCT00671554|Biological|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
359359|NCT00671567|Drug|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
359360|NCT00671567|Drug|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
359361|NCT00671567|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
359362|NCT00005087|Drug|paclitaxel|
359363|NCT00671580|Drug|PZ-601|750 mg
359364|NCT00671580|Drug|PZ-601|1000 mg
359365|NCT00671580|Drug|Standard of Care|as directed
359366|NCT00671593|Biological|House Dust Mite|Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,
1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml
359367|NCT00671593|Biological|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
359368|NCT00671606|Procedure|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
359369|NCT00671619|Drug|ESBA105|eye drops
359370|NCT00671632|Drug|Ramelteon, triazolam, and placebo (56 possible combinations total)|Randomized sequence over eight consecutive days to include the following:
Ramelteon 16 mg, tablets, orally, one day only;
Ramelteon 80 mg, tablets, orally, one day only;
Ramelteon 160 mg, tablets, orally, one day only;
Triazolam 0.25 mg, capsules, orally, one day only;
Triazolam 0.50 mg, capsules, orally, one day only;
Triazolam 0.75 mg, capsules, orally, one day only;
Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;
Additional dose of study medication or placebo, tablets or capsules, orally, one day only.
358715|NCT00675948|Drug|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
358716|NCT00675961|Behavioral|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
358717|NCT00678405|Behavioral|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
358718|NCT00678418|Drug|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
358719|NCT00678418|Drug|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
358720|NCT00678431|Dietary Supplement|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
359042|NCT00685893|Behavioral|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
359043|NCT00685893|Behavioral|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
359044|NCT00688181|Device|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
359045|NCT00688194|Drug|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
359046|NCT00688194|Drug|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
359047|NCT00688194|Drug|fulvestrant|Given intramuscularly
359048|NCT00688194|Drug|lapatinib ditosylate|Given orally
359049|NCT00688194|Drug|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
359050|NCT00688194|Other|placebo|Given orally
359051|NCT00688207|Drug|Rosiglitazone (Extended Release)|
359052|NCT00688233|Device|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
358394|NCT00692471|Device|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
358395|NCT00692484|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
358396|NCT00692484|Drug|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
358397|NCT00692497|Behavioral|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
358398|NCT00692510|Drug|AZD3480|Capsule, oral, dose once daily, 7 days
358399|NCT00692510|Drug|Placebo|Capsule, oral, dose once daily, 7 days
358400|NCT00692510|Drug|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|Cocktail mix which contains the following:
CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)
single dose of mix
358401|NCT00692523|Other|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
358402|NCT00671021|Other|Platelet aggregation|Platelet aggregation TxA2 formation
358403|NCT00005084|Procedure|conventional surgery|
358404|NCT00671034|Drug|calaspargase pegol|Given IV
358405|NCT00671034|Drug|daunorubicin hydrochloride|Given IV
358406|NCT00671034|Drug|doxorubicin hydrochloride|Given IV
358407|NCT00671034|Drug|cytarabine|Given IV, IT, PO, or SC
358408|NCT00671034|Drug|prednisone|Given IV or PO
358409|NCT00671034|Drug|methotrexate|Given IV, IT, or PO
358410|NCT00671034|Drug|cyclophosphamide|Given IV
358411|NCT00671034|Drug|mercaptopurine tablet|Given PO
358721|NCT00678431|Dietary Supplement|Placebo|Liquid placebo
358722|NCT00005583|Procedure|conventional surgery|
358723|NCT00678444|Other|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
358084|NCT00687648|Drug|anastrozole|Given as previously prescribed
358085|NCT00687648|Drug|cyclophosphamide|Given by mouth
358086|NCT00687648|Drug|exemestane|Given as previously prescribed
358087|NCT00687648|Drug|letrozole|Given as previously prescribed
358088|NCT00687648|Drug|methotrexate|Given by mouth
358089|NCT00687648|Drug|prednisolone|Given by mouth
358090|NCT00687661|Drug|Bisphosphonate|35mg given orally once weekly for 24 months
358091|NCT00687661|Drug|Placebo|identical placebo pill once weekly for 24 months
358092|NCT00687674|Drug|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
358093|NCT00000175|Drug|Testosterone|
358094|NCT00000672|Drug|Didanosine|
358095|NCT00005630|Biological|sargramostim|
358096|NCT00687674|Drug|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM & 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
358097|NCT00687674|Drug|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
358098|NCT00687687|Drug|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
358099|NCT00687687|Drug|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
358100|NCT00687687|Drug|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
358101|NCT00687700|Drug|GSK961081|
358102|NCT00687700|Drug|Propanolol|
358412|NCT00671034|Drug|dexamethasone|Given PO or IV
358413|NCT00671034|Drug|thioguanine|Given PO
358414|NCT00005084|Procedure|magnetic resonance spectroscopic imaging|
357494|NCT00675259|Drug|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
357495|NCT00675272|Drug|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
357806|NCT00682760|Drug|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
357807|NCT00682773|Other|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
357808|NCT00005599|Drug|paclitaxel|
357809|NCT00682786|Drug|5FU|
357810|NCT00682786|Radiation|Radiation|
357811|NCT00682786|Procedure|Surgery of resectable lesions|
357812|NCT00682786|Drug|Irinotecan|
357813|NCT00682812|Other|2 cervical takings and 2 sampling of blood|2 cervical takings
2 sampling of blood before and after the total hysterectomy
357814|NCT00682812|Other|2 cervical takings and 2 sampling of blood|cervical taking during the cervical conization
2 sampling of blood before and after the intervention
357815|NCT00682812|Other|2 cervical takings and 2 sampling of blood|cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation
2 sampling of blood before and after the intervention
357816|NCT00682825|Behavioral|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
357817|NCT00682825|Behavioral|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
357818|NCT00682838|Behavioral|Self-management|Self-management
357819|NCT00000667|Biological|gp160 Vaccine (MicroGeneSys)|
357820|NCT00005600|Procedure|management of therapy complications|
357821|NCT00682838|Behavioral|Telemonitored care|Telemonitored care
357822|NCT00682851|Device|OSOM Trichomonas Rapid Test|Rapid test run using vaginal discharge collected via a cotton swab
357189|NCT00694252|Drug|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
357190|NCT00694265|Procedure|Decompression|Surgical decompression of the median nerve
357191|NCT00694265|Procedure|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
357192|NCT00694291|Drug|Sorafenib|400 mg orally twice daily
357193|NCT00694291|Drug|Placebo|Matching Placebo
357194|NCT00694304|Drug|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
357195|NCT00694317|Drug|Zaleplon|Short term treatment of insomnia
357196|NCT00694330|Biological|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
357197|NCT00694343|Drug|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
357198|NCT00694343|Drug|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
357199|NCT00005772|Device|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
357200|NCT00694356|Drug|MK0646|MK0646 (5 or 10 mg/kg) IV infusion once weekly for 4 consecutive weeks
357496|NCT00675272|Drug|sodium chloride|sodium chloride every 6 hours iv
357497|NCT00677586|Procedure|simultaneous resection of liver metastasis and the colorectal primary tumor|simultaneous resection of liver metastasis and the colorectal primary tumor
357498|NCT00677586|Procedure|staged resection of liver metastasis and the colorectal primary tumor|Patients received resection of the colorectal tumor. 1 months later received resection of liver metastasis
357499|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
357500|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
357501|NCT00677612|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
357502|NCT00000662|Drug|Zidovudine|
356886|NCT00686959|Drug|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
356887|NCT00686959|Drug|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
356888|NCT00686959|Drug|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
356889|NCT00686959|Drug|Paclitaxel|administered as a 3-hour infusion
356890|NCT00686959|Drug|Carboplatin|administered per local practice guidelines over 30 minutes
356891|NCT00686959|Radiation|Thoracic Radiation Therapy (TRT)|
356892|NCT00686972|Drug|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
356893|NCT00686985|Drug|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
356894|NCT00686998|Drug|AZD2624|Oral Suspension
356895|NCT00686998|Drug|Olanzapine|PO BID
356896|NCT00000671|Drug|Didanosine|
356897|NCT00005623|Procedure|quality-of-life assessment|
356898|NCT00689247|Drug|AZD1305|oral solution, single dose
356899|NCT00689247|Drug|AZD1305|iv infusion, single dose
356900|NCT00689260|Device|easypod|Subjects is aware that the device records injection information that can be viewed by user
356901|NCT00005640|Procedure|Preoperative Endoscopy|
356902|NCT00689260|Device|easypod|Subjects is not aware that the device records injection information that can be viewed by user
356903|NCT00689273|Drug|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
356904|NCT00689273|Drug|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
358872|NCT00692913|Drug|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
358873|NCT00692913|Dietary Supplement|Calcium Supplement 500 mg|Calcium supplied locally by the investigator (containing 500 mg
calcium supplement) daily for 52 weeks (unless the patient's dietary intake of
calcium exceeds 1000 mg per day).
358874|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
358875|NCT00692926|Biological|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
358876|NCT00692939|Biological|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
358877|NCT00692952|Drug|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
358878|NCT00692952|Drug|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
358879|NCT00692978|Drug|Fluticasone Propionate|Dose 50 micrograms (total dose), Monodisperse aerosol with diofferemt particle size of drug (1.5, 3.0, 6.0 microns), inhaled
358880|NCT00005086|Drug|docetaxel|
358881|NCT00671281|Drug|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
359190|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
359191|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
359192|NCT00005584|Drug|BEACOPP regimen|
359193|NCT00678704|Drug|Placebo|Placebo tablet prior to intercourse on demand
359194|NCT00678717|Device|"Sham"|Physiological stimuli
359195|NCT00678717|Device|Medtronic or ANS spinal cord stimulator|Spinal cord stimulator implant
359196|NCT00678730|Drug|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
359197|NCT00678743|Drug|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
359198|NCT00678756|Drug|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
358552|NCT00005602|Drug|carboplatin|
358553|NCT00683319|Drug|cyclophosphamide|
358554|NCT00683319|Drug|methotrexate|
358555|NCT00683319|Drug|vincristine sulfate|
358556|NCT00683319|Procedure|adjuvant therapy|
358557|NCT00683319|Procedure|cognitive assessment|
358558|NCT00683319|Procedure|magnetic resonance imaging|
358559|NCT00683319|Procedure|magnetic resonance spectroscopic imaging|
358560|NCT00683319|Procedure|quality-of-life assessment|
358561|NCT00683332|Drug|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
358562|NCT00683345|Drug|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
358563|NCT00685516|Dietary Supplement|green tea|6 cups of green tea daily for 2-8 weeks
358564|NCT00685516|Dietary Supplement|placebo|6 cups of water daily for 2-8 weeks
358565|NCT00685529|Drug|Racemic formoterol|12 µg of racemic formoterol fumarate BID
358566|NCT00685529|Drug|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
358567|NCT00685529|Drug|Racemic formoterol|24 µg of racemic formoterol fumarate BID
358568|NCT00685542|Drug|diacerein|Diacerein 50mg bid
358569|NCT00685542|Drug|placebo|placebo
358570|NCT00005612|Drug|paclitaxel|
358882|NCT00671294|Drug|Ramelteon and Placebo (9 possible combinations total)|Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:
Ramelteon 4 mg, tablets, orally over two nights
Ramelteon 8 mg, tablets, orally over two nights
Ramelteon placebo-matching tablets, orally over two nights
358883|NCT00671307|Drug|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
358884|NCT00671307|Drug|Placebo|Vehicle control given as IV infusion over 1 hour
358229|NCT00675701|Drug|placebo|capsules
358230|NCT00675701|Drug|lixivaptan|capsules
358231|NCT00005195|Procedure|Catheter ablation|
358232|NCT00675701|Drug|moxifloxacin|tablets
358233|NCT00675714|Procedure|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
358234|NCT00675714|Procedure|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
358235|NCT00678145|Behavioral|exercise|Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
358236|NCT00005581|Drug|paclitaxel|
358237|NCT00678158|Radiation|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
358238|NCT00678171|Device|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
358239|NCT00678184|Drug|Atorvastatin|80 mg atorvastatin on two following days each
358240|NCT00678197|Other|Access Intervention|
358241|NCT00678197|Other|Bonus/Pay-for-Performance Intervention|
358242|NCT00678210|Drug|CP-690,550|tablets, 2 mg BID for 12 weeks
358243|NCT00678210|Drug|CP-690,550|tablets, 5 mg BID for 12 weeks
358244|NCT00678210|Drug|CP-690,550|tablets, 15 mg BID for 12 weeks
358571|NCT00685555|Behavioral|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
357316|NCT00684788|Behavioral|Contingency management|
357624|NCT00689728|Drug|Placebo|Placebo will be administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
357625|NCT00689741|Biological|Cervarix|3 doses of IM injection
357626|NCT00689741|Biological|placebo|3 doses of IM injection of Al(OH)3 placebo
357627|NCT00689754|Procedure|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
357628|NCT00689767|Device|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
357629|NCT00689767|Device|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
357630|NCT00689780|Drug|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
357631|NCT00689780|Drug|Midazolam|Oral solution given orally once daily on day -1 and day 14
357632|NCT00000674|Drug|Leucovorin calcium|
357633|NCT00005641|Drug|cyclosporine|
357634|NCT00689793|Drug|Ferrous sulphate|Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue (" Fatigue Severity Scale"). We will also check depression and anxiety symptoms (" Prime MD ") and health survey (" SF-12 "). An evaluation of the menstruation (" Pictorial Bleeding Assessment Chart " of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.
357635|NCT00689793|Drug|Placebo|Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue (" Fatigue Severity Scale"). We will also check depression and anxiety symptoms (" Prime MD ") and health survey (" SF-12 "). An evaluation of the menstruation (" Pictorial Bleeding Assessment Chart " of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.
357636|NCT00689806|Drug|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not > 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
357637|NCT00689806|Drug|Placebo|Placebo by mouth once daily for weeks 1-4.
356683|NCT00630929|Drug|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
356684|NCT00630929|Drug|Placebo|Matched placebo orally for 6 weeks
356685|NCT00630929|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
356686|NCT00630942|Drug|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
356687|NCT00630955|Drug|memantine|Memantine 20 mg once per day for 7 days
356688|NCT00630955|Drug|Memantine|Memantine 40 mg once per day for 7 days
356689|NCT00004686|Drug|methotrexate|
356690|NCT00630955|Drug|Placebo|Placebo once per day for 7 days
356691|NCT00630968|Drug|Levetiracetam (Keppra)|
356692|NCT00630981|Behavioral|Psychotherapy|Specific psychotherapy for dissociative disorders
356693|NCT00630981|Drug|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
357009|NCT00674830|Behavioral|placebo|usual care
357010|NCT00674843|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
357011|NCT00674856|Drug|naproxcinod|750mg
357012|NCT00674869|Other|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
357013|NCT00674882|Other|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
357014|NCT00005113|Drug|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
357015|NCT00674895|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
357016|NCT00674908|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
357017|NCT00674908|Biological|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
357018|NCT00677261|Procedure|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
361235|NCT00665574|Other|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
361236|NCT00665587|Procedure|Cox-MAZE III|Maze procedure according to standards of the department
361237|NCT00665600|Drug|Levalbuterol HCl|Levalbuterol 0.63 TID
361238|NCT00005041|Drug|tipifarnib|
361239|NCT00665600|Drug|Levalbuterol HCl|Levabuterol 1.25 mg TID
361240|NCT00665600|Drug|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
361241|NCT00665600|Drug|Placebo|Placebo TID
361242|NCT00665626|Drug|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
361243|NCT00665639|Drug|micafungin|IV
361244|NCT00665639|Drug|caspofungin|IV
361245|NCT00665652|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
361246|NCT00665665|Drug|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
361247|NCT00665665|Drug|placebo|Placebo for s.c. injection
361248|NCT00665665|Drug|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
361249|NCT00005042|Drug|semaxanib|
356373|NCT00596882|Other|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
356374|NCT00596882|Other|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
356375|NCT00599482|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
356376|NCT00004217|Drug|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
356377|NCT00599495|Procedure|allogeneic HSCT|dose-reduced conditioning regimen
356378|NCT00599508|Dietary Supplement|purple grape juice|Several ounces three times a day for 16 weeks. Specific dosage determined by subject's weight.
360903|NCT00670293|Drug|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
360904|NCT00670293|Procedure|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
360905|NCT00670306|Drug|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
360906|NCT00005078|Drug|tirapazamine|
360907|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
360908|NCT00633711|Device|Automatic (variable, automatically controlled) pressure CPAP|CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.
Home nocturnal usage. Two-month treatment.
360909|NCT00633711|Device|fixed continuous positive airway pressure (CPAP)|CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.
Home nocturnal usage. Two-month treatment.
360910|NCT00633724|Biological|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
360911|NCT00633737|Behavioral|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
360912|NCT00633750|Drug|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
360913|NCT00633750|Genetic|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
360914|NCT00633750|Genetic|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
360915|NCT00633750|Other|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
360916|NCT00633750|Other|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
360917|NCT00633750|Other|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
360918|NCT00004736|Drug|Isoniazid|
360919|NCT00633750|Other|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
360319|NCT00672217|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
360320|NCT00672217|Behavioral|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
360321|NCT00672230|Dietary Supplement|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
360322|NCT00672243|Drug|Erlotinib + sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
360613|NCT00679627|Drug|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
360614|NCT00679627|Drug|Placebo|Matching placebo
360615|NCT00679640|Drug|Candesartan|Oral tablets
360616|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
360617|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
360618|NCT00679653|Drug|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
360619|NCT00682214|Drug|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
360620|NCT00682214|Drug|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
360621|NCT00682227|Biological|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
360622|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - single-session
360623|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - multi-session
360624|NCT00682240|Procedure|laser treatment with PASCAL®|grid / focal laser treatment
360625|NCT00005596|Drug|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; > or = 1 day after the IT MTX
360626|NCT00682240|Procedure|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
360009|NCT00686426|Dietary Supplement|Dairy Foods|Adequate dairy (> 3 standard daily servings)
360010|NCT00688805|Drug|Placebo|matching capsule containing no active medication
360011|NCT00688818|Drug|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
360012|NCT00688818|Drug|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
360013|NCT00688831|Drug|AZD1305|Solution for iv infusion , single dose
360014|NCT00688831|Drug|Placebo|NaCl solution for iv infusion, single dose
360015|NCT00688844|Drug|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
360016|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
360017|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
360018|NCT00688870|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
360019|NCT00005637|Drug|temozolomide|
360020|NCT00688870|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
360021|NCT00688883|Drug|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
360323|NCT00672256|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
360324|NCT00005089|Drug|vincristine sulfate|1.4 mg/m^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
360325|NCT00672282|Drug|Bicalutamide|150mg p.o. daily
360326|NCT00672282|Drug|Placebo|
359371|NCT00671645|Drug|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
359372|NCT00671658|Drug|Rituximab|375 mg/m2 by vein
359373|NCT00005087|Procedure|conventional surgery|
359374|NCT00671658|Drug|Cyclophosphamide (CTX)|300 mg/m2 by vein
359375|NCT00671658|Drug|Doxorubicin|50 mg/m2 by vein
359376|NCT00671658|Drug|Vincristine|2 mg by vein
359683|NCT00679146|Drug|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
359684|NCT00679159|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
359685|NCT00679159|Biological|Prevenar|Streptococcus pneumoniae vaccine
359686|NCT00679172|Biological|M01ZH09|Live attenuated typhoid vaccine, single dose, oral administration
359687|NCT00679172|Other|Placebo|Excipients only
359688|NCT00679185|Behavioral|expressive writing|four non-emotional writing assignments
359689|NCT00681577|Biological|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
359690|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|400 IU daily (low dose)
359691|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|2000 IU daily (high dose)
359692|NCT00681603|Drug|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
359693|NCT00681616|Device|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement & Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
359694|NCT00681616|Device|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
359695|NCT00681616|Device|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
359053|NCT00005633|Biological|gp209-2M antigen|
359054|NCT00688246|Other|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture [Lønning 2005]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk [Looker 2000]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
359055|NCT00688246|Procedure|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
359056|NCT00688259|Other|supportive therapy|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
359057|NCT00688259|Other|cognitive-behavioral therapy for psychosis|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
359058|NCT00688272|Drug|Ciprofloxacin|Given 500mg BID x 6 days
359059|NCT00688272|Drug|Eltrombopag|Given QD x 6 days
359377|NCT00671658|Drug|Dexamethasone|40 mg by vein or by mouth (P.O.)
359378|NCT00671658|Drug|Methotrexate (MTX)|12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7
200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8
359379|NCT00671658|Drug|Cytarabine|100 mg intrathecal for Courses 1,3,5,7
3 gm/m2 by vein for Courses 2,4,6,8
359380|NCT00673738|Radiation|Conformal Thoracic Radiotherapy (CTRT)|Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.
Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC >1,000 and platelets >75,000) required. Patient may be delayed for a max. of 2 weeks. If > 2 week delay occurs, patient will come off study.
359381|NCT00673751|Drug|GLP-2|450 nmol subcutaneous
359382|NCT00673751|Drug|Placebo|
359383|NCT00673764|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
359384|NCT00005096|Drug|docetaxel|
359385|NCT00673764|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
358724|NCT00678457|Drug|Ondansetron|ondansetron (4 μg/kg b.i.d.)
358725|NCT00678457|Drug|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
358726|NCT00678457|Drug|Placebo|placebo
358727|NCT00678470|Drug|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
358728|NCT00678483|Drug|rimonabant (SR141716)|once daily
358729|NCT00678496|Other|CBT Software|Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute "Introduction to Therapy" video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one.
358730|NCT00678496|Other|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
358731|NCT00678509|Biological|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
358732|NCT00678522|Drug|Atorvastatin|80 mg atorvastatin daily on two following days
358733|NCT00005583|Radiation|radiation therapy|
358734|NCT00678535|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
358735|NCT00678535|Drug|Capecitabine|Capecitabine 1000 mg/m^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
358736|NCT00678535|Drug|Cisplatin|Cisplatin 80 mg/m^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
358737|NCT00678548|Behavioral|Pleasant guided imagery|CD with pleasant guided imagery
358738|NCT00680966|Behavioral|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
359060|NCT00688272|Drug|Placebo|Given QD x 6 days
359061|NCT00688285|Other|automated clinical alerts|automated clinical alerts in the electronic medical record
358415|NCT00671034|Drug|pegaspargase|Given IV
358416|NCT00671034|Drug|vincristine sulfate|Given IV
358417|NCT00671034|Radiation|radiation therapy|Some patients undergo RT
358418|NCT00671034|Other|laboratory biomarker analysis|Correlative studies
358419|NCT00671034|Other|pharmacological study|Correlative studies
358420|NCT00671047|Other|non-interventional|SLE nature history observational
358421|NCT00671060|Drug|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
358422|NCT00671060|Drug|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
358423|NCT00671073|Drug|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
358424|NCT00671073|Drug|Placebo|Placebo, oral administration, once daily for 12 weeks
358425|NCT00005084|Radiation|radiation therapy|
358426|NCT00671073|Drug|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
358427|NCT00671073|Drug|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
358428|NCT00671086|Drug|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
358429|NCT00671086|Drug|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
358430|NCT00671099|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
358431|NCT00671099|Dietary Supplement|Placebo|Placebo
358432|NCT00673231|Drug|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
358433|NCT00673244|Drug|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
358434|NCT00673257|Drug|daunorubicin hydrochloride|Given IV
358435|NCT00673257|Other|pharmacological study|pharmacological studies
357823|NCT00682851|Device|OSOM BVBlue Test|Rapid test run using vaginal discharge collected using a cotton swab
357824|NCT00682890|Drug|placebo|placebo birth control pill daily
357825|NCT00682890|Drug|metformin|2000 mg per day for 3 months daily birth control pill
357826|NCT00682903|Device|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
358103|NCT00687713|Drug|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
358104|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
358105|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
358106|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
358107|NCT00689832|Drug|Tacrolimus 0.03%|ointment
358108|NCT00689832|Drug|Fluticasone 0.005%|ointment
358109|NCT00689845|Biological|bleomycin sulfate|Given IV
358110|NCT00689845|Biological|filgrastim|Given subcutaneously
358111|NCT00689845|Biological|rituximab|given IV
358112|NCT00689845|Drug|cyclophosphamide|Given IV
358113|NCT00005641|Drug|methotrexate|
357503|NCT00005579|Drug|dolastatin 10|
357504|NCT00677638|Device|Ventor Embracer|Implantation of Ventor Embracer
357505|NCT00677651|Procedure|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
357506|NCT00677651|Procedure|Blood sample|Blood will be sampled from an IV line
357507|NCT00677651|Radiation|CT Scan|Single image at the level of the liver
357508|NCT00677651|Radiation|DEXA|Whole body scan
357509|NCT00677664|Drug|Glatiramer acetate (Copaxone)|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
357510|NCT00677664|Drug|Mannitol|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
357511|NCT00677677|Biological|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
357512|NCT00677690|Other|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
357513|NCT00677690|Other|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
357514|NCT00005580|Drug|bryostatin 1|
357827|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
357828|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
357829|NCT00685048|Behavioral|four 50-minute individual therapy sessions of MET & CBT|MET & CBT
357830|NCT00685061|Drug|Thymoglobulin|Induction
357831|NCT00005609|Biological|rituximab|
357832|NCT00685061|Drug|Campath-1H|Induction
357833|NCT00685061|Drug|Daclizumab|Induction
357834|NCT00685074|Behavioral|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
359505|NCT00686075|Biological|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
359506|NCT00686075|Other|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
359507|NCT00686075|Biological|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
359508|NCT00686075|Other|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
359509|NCT00686088|Drug|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
359510|NCT00686114|Drug|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
359511|NCT00686114|Drug|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
359512|NCT00005616|Procedure|conventional surgery|
359513|NCT00686114|Drug|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
359838|NCT00693563|Behavioral|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
359839|NCT00693576|Drug|simvastatin|20 mg simvastatin daily
359840|NCT00693589|Drug|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
359841|NCT00693602|Drug|Erwinase|Chemotherapy
359842|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
359843|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
359844|NCT00671814|Drug|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
359845|NCT00671827|Behavioral|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
359846|NCT00671853|Drug|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
359199|NCT00678756|Radiation|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
359200|NCT00678769|Drug|Cixutumumab|Given IV
359201|NCT00678769|Other|Laboratory Biomarker Analysis|Correlative studies
359202|NCT00678769|Other|Pharmacological Study|Correlative studies
359203|NCT00005584|Drug|epirubicin hydrochloride|
359204|NCT00678769|Drug|Temsirolimus|Given IV
359205|NCT00678782|Drug|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
359206|NCT00678782|Drug|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
359207|NCT00678795|Drug|Sativex®|Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.
Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours
359208|NCT00678795|Drug|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
359209|NCT00678821|Procedure|Excerise Training|
359210|NCT00678821|Procedure|Patient Education (Placebo)|
359211|NCT00678834|Dietary Supplement|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
359212|NCT00678834|Dietary Supplement|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
359514|NCT00686114|Radiation|Radiotherapy|Enlarged field radiotherapy
359515|NCT00686114|Radiation|Radiotherapy|Conventional field radiotherapy
359516|NCT00688493|Drug|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
359517|NCT00688506|Device|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
359518|NCT00688506|Device|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
359519|NCT00688519|Drug|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
358885|NCT00671320|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
358886|NCT00671320|Drug|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
358887|NCT00671333|Procedure|LRTI|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using "Fibre Wire" suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
358888|NCT00671333|Procedure|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
358889|NCT00671359|Drug|TR-701 600mg|TR-701 600mg
358890|NCT00671372|Drug|FOLFIRI regimen|Intravenous repeating dose
358891|NCT00005086|Drug|gemcitabine hydrochloride|
358892|NCT00671372|Drug|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
358893|NCT00671372|Drug|cetuximab|Intravenous repeating dose
358894|NCT00671372|Drug|dulanermin|Intravenous repeating dose
358895|NCT00671372|Drug|irinotecan|Intravenous repeating dose
358896|NCT00671398|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
358897|NCT00671398|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
358898|NCT00671398|Drug|Placebo|Ramelteon placebo-matching tablets, orally for one night only
359213|NCT00678834|Dietary Supplement|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
359214|NCT00005584|Drug|prednisone|
359215|NCT00678847|Device|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
359216|NCT00681252|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
358572|NCT00685555|Behavioral|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
358573|NCT00685568|Drug|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
358574|NCT00685568|Other|placebo|Orally, twice daily for 3 months
358575|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
358576|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
358577|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
358578|NCT00685594|Drug|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
358579|NCT00685594|Drug|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
358580|NCT00685607|Drug|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
358581|NCT00005612|Drug|topotecan hydrochloride|
358582|NCT00685607|Drug|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
358583|NCT00685620|Behavioral|Reinforcement-Based Treatment|3 group random assignment to receive, standard care, recovery housing alone, or recovery housing plus behavioral treatment
358584|NCT00685633|Drug|bicalutamide|Given orally
358585|NCT00687882|Other|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
358586|NCT00687882|Other|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
358587|NCT00687882|Other|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
357638|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
357639|NCT00691860|Device|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
357933|NCT00670774|Drug|Eculizumab|Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.
Patients will be given 900 mg of eculizumab on Day 1 post-transplant.
Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant
At week 4, patients will be assessed for B cell FCXM. Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FXCM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar "discontinuation assessments" will be performed at week 9, 26, 39 and 52.
In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period
357934|NCT00670787|Drug|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
357935|NCT00670800|Drug|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
357936|NCT00005083|Procedure|conventional surgery|
357937|NCT00670813|Drug|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
357938|NCT00670813|Drug|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
357939|NCT00670826|Device|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand & forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
357940|NCT00670826|Device|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
357941|NCT00670839|Biological|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
357942|NCT00670839|Biological|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
357019|NCT00677261|Procedure|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
357020|NCT00677261|Procedure|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
357021|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
357022|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
357023|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
357024|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
357025|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
357026|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
357027|NCT00005578|Drug|etoposide|
357028|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
357317|NCT00684801|Other|questionnaire administration|Patients complete questionnaires.
357318|NCT00005607|Drug|irinotecan hydrochloride|
357319|NCT00684801|Procedure|quality-of-life assessment|Patients undergo quality-of-life assessments.
357320|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
357321|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
357322|NCT00684827|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
Arm #A
Xopenex HFA MDI, Pirbuterol HFA MDI
357323|NCT00684827|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
Arm #B
Pirbuterol HFA MDI, Xopenex HFA MDI
357324|NCT00684853|Drug|bevacizumab|1.25 mg of bevacizumab intravitreal
357325|NCT00684853|Drug|vetaporfin|full fluence of vetaporfin
356379|NCT00599508|Dietary Supplement|placebo juice|several ounces consumed three times a day for 16 weeks; dosage determined according to subject's weight
356380|NCT00599521|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
356381|NCT00599521|Drug|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
356382|NCT00599534|Drug|Montelukast|4 mg oral tablets
356383|NCT00599534|Drug|Placebo|5mg tablets
356384|NCT00599547|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
356385|NCT00599560|Genetic|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
356386|NCT00599573|Drug|ondansetron|Ondansetron 4mg BID for six weeks
356387|NCT00004217|Drug|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
356388|NCT00599586|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
356389|NCT00599599|Behavioral|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
356390|NCT00599612|Drug|GW856553|
356391|NCT00599625|Drug|Pravastatin|80mg administered daily for 6 consecutive weeks
356392|NCT00599638|Drug|pregabalin|75mg bid titrating to 150mg bid on day 4
356393|NCT00599638|Drug|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
356394|NCT00599638|Drug|Placebo|Placebo
356694|NCT00630994|Drug|Dacogen|
356695|NCT00631007|Drug|INT131 besylate|Once-daily, oral
356696|NCT00631007|Drug|Pioglitazone HCl|Once-daily, oral
356697|NCT00631007|Drug|Placebo|Once-daily, oral
356698|NCT00631020|Behavioral|CBME|6 weeks of once a week one-on-one CBME
356699|NCT00631020|Drug|Optional NRT|NicoDerm CQ nicotine transdermal patch
361250|NCT00665665|Drug|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
361251|NCT00665665|Drug|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
361252|NCT00665678|Drug|paroxetine|treatment for three months with paroxetine
361253|NCT00665678|Drug|placebo|treatment for three months with placebo
361254|NCT00665691|Other|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
361255|NCT00665704|Behavioral|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
361256|NCT00665717|Drug|Pravastatin|40 mg tablet; QD; 4 days
361257|NCT00665717|Drug|Raltegravir|400mg tablet; BD 4 days
361258|NCT00665717|Drug|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
361259|NCT00665730|Device|Sepraspray|
361260|NCT00005044|Drug|bicalutamide|
361261|NCT00665743|Drug|PN400|naproxen 500 mg /esomeprazole 20 mg
361262|NCT00665743|Drug|naproxen|naproxen 500 mg tablet
361263|NCT00665743|Drug|naproxen|naproxen 500 mg
361264|NCT00667745|Drug|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
361265|NCT00667758|Drug|Cetrorelix|3-5 mg s.c. on days 1-5
361266|NCT00667758|Drug|Placebo|3-5 ml NaCl s.c. on days 1-5
361267|NCT00667771|Drug|Naltrexone|
361268|NCT00667784|Behavioral|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
361269|NCT00667797|Drug|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
360627|NCT00682266|Behavioral|intensity controlled interval training (AIT)|4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
360628|NCT00682266|Behavioral|Multidisciplinary approach (MTG)|exercise, dietary and psychological advice, twice a month for 12 months
360629|NCT00682279|Drug|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
360630|NCT00682292|Drug|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
360631|NCT00682292|Drug|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
360920|NCT00633750|Other|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
360921|NCT00633750|Procedure|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
360922|NCT00633763|Drug|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
360923|NCT00633763|Drug|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
360924|NCT00633776|Drug|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
360925|NCT00633789|Drug|brivanib|Tablets, Oral, 800 mg, once daily, until progression
360926|NCT00633789|Drug|Placebo|Tablets, Oral, 0 mg, once daily, until progression
360927|NCT00633802|Drug|Risperidone|1 mg/d risperidone for 10 weeks or placebo
360928|NCT00633815|Other|Supine and upright positioning|Subjects will undergo exercise testing in both the supine and upright positions
360929|NCT00004736|Drug|Pyrazinamide|
360930|NCT00635804|Drug|MK3281|Part I, 4 serial panels (Panels A, B, C, and D) will be administered oral doses (ranging from 100 mg to 800 mg) of MK3281 twice daily for 10 consecutive days. In Part II, another panel, Panel E, consisting of HCV-infected patients be administered 800 mg oral doses of MK3281, or matching placebo, twice daily for 7 consecutive days.
360931|NCT00635804|Drug|Comparator: placebo (unspecified)|Part I, 4 serial panels (Panels A, B, C, and D) will be administered oral doses of matching placebo, twice daily for 10 consecutive days. In Part II, another panel, Panel E, consisting of HCV-infected patients be administered matching placebo, twice daily for 7 consecutive days.
360327|NCT00672295|Drug|Dasatinib, Paclitaxel, and Carboplatin|Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.
Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m^2) IV infused over 3 hours on day #1 of each cycle.
Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.
All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn.
360328|NCT00672308|Other|Benefiber|
360329|NCT00672308|Other|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
360330|NCT00674466|Drug|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
360331|NCT00674466|Drug|Placebo|twice-a-week
360332|NCT00674479|Drug|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
360333|NCT00674505|Device|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
360334|NCT00674518|Behavioral|One on one counseling|Motivational Interviewing
360335|NCT00674518|Behavioral|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
360336|NCT00674518|Behavioral|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
360337|NCT00005107|Drug|N-monomethyl-L-arginine|
360338|NCT00674531|Procedure|Artery resection|Artery resection
360339|NCT00674544|Behavioral|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
360340|NCT00674557|Drug|SOD1 inhibitor ATN-224|
360341|NCT00674557|Drug|exemestane|
360342|NCT00674557|Genetic|protein expression analysis|
360343|NCT00674557|Genetic|proteomic profiling|
360344|NCT00674557|Other|laboratory biomarker analysis|
359696|NCT00681629|Drug|Quetiapine XR|400-800 mg, oral, bid
359697|NCT00681629|Other|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
359698|NCT00681655|Drug|Alcohol 6%|Alcohol 6% infused for 2.8 hour long clamping session
359699|NCT00005596|Drug|cyclophosphamide|
359700|NCT00681655|Drug|Placebo|1. Each subject will complete a total of 4 2.8 hr-long clamping sessions, conducted as two pairs of infusion sessions.Within each session, procedures differed only by the content of the infusate during the two clamping session. In one admission (AA), both sessions infused 6% ethanol; in the other (PA), the 1st session (always 1st) infused only the vehicle, quantifying the placebo response for every subject. The 2nd session of the PA was always another alcohol clamp.
360022|NCT00688896|Drug|JTT-705 600 mg and pravastatin 40 mg|JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment
Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
360023|NCT00688896|Drug|JTT-705 300 mg and pravastatin 40 mg|JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment
Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
360024|NCT00688896|Drug|Placebo and pravastatin 40 mg|Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
360025|NCT00688909|Drug|letrozole|2.5 mg daily by mouth for 6 months
360026|NCT00688922|Drug|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
360027|NCT00688935|Biological|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
360028|NCT00688948|Drug|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
360029|NCT00688961|Drug|Aspirin|generic aspirin
360030|NCT00005638|Drug|cisplatin|
360031|NCT00688961|Drug|omega-3 acid ethyl esters|4, 1 g capsules q.d.
360032|NCT00688974|Procedure|Gastric Bypass|L-GB
360033|NCT00688974|Procedure|Adjustable Gastric Banding|L-AGB
360034|NCT00691067|Drug|mifepristone|200 mg po per day x 6 weeks
360035|NCT00691067|Drug|placebo|placebo
359386|NCT00673777|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
359387|NCT00673790|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration
359388|NCT00673790|Drug|HCTZ|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration.
359389|NCT00673790|Drug|Placebo|Placebo
359390|NCT00673803|Procedure|cataract surgery|cataract surgery with implantation of an IOL
359391|NCT00673816|Drug|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
359392|NCT00673829|Biological|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
359393|NCT00673829|Biological|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
359394|NCT00673842|Device|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved (in each geography) single chamber or dual chamber implantable cardioverter defibrillator (ICD)
359701|NCT00681668|Drug|Quetiapine|150-800 mg, oral, twice a day (bid)
359702|NCT00681694|Radiation|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
359703|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
359704|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
359705|NCT00681720|Drug|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
359706|NCT00681720|Drug|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
359707|NCT00681733|Drug|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
359708|NCT00681733|Drug|Pioglitazone|30 mg OD
359709|NCT00681733|Drug|Pentoxifylline|1200 mg/d
359710|NCT00005596|Drug|cytarabine|
359062|NCT00688285|Other|provider education|PCP education session on CKD
359063|NCT00688298|Device|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
359064|NCT00005633|Biological|recombinant 70-kD heat-shock protein|
359065|NCT00688298|Device|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
359066|NCT00688311|Dietary Supplement|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10^10 each) combined with 4 types of dietary fiber (2.5g each).
359067|NCT00690430|Drug|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
359068|NCT00690443|Drug|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
359069|NCT00690443|Drug|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
359070|NCT00690456|Drug|rimonabant (SR141716)|added to metformin
359071|NCT00690456|Drug|placebo|added to metformin
359072|NCT00690469|Other|questionnaire administration|Ancillary studies
359073|NCT00690469|Other|laboratory biomarker analysis|Correlative studies
359074|NCT00000674|Drug|Clindamycin|
359075|NCT00005644|Drug|paclitaxel|
359076|NCT00690482|Drug|AZD1981|Oral tablet, twice daily
359077|NCT00690482|Drug|Placebo|Placebo Oral tablet, twice daily
359078|NCT00690495|Drug|Propofol|Propofol (drug), intravenous, induction of anesthesia
359079|NCT00690495|Drug|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
359080|NCT00690508|Procedure|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
359081|NCT00690521|Drug|metolazone or hydrochlorothiazide|The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
358739|NCT00680979|Behavioral|Interpersonal Psychotherapy|
358740|NCT00680979|Behavioral|Health Education|
358741|NCT00680992|Drug|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
358742|NCT00681005|Drug|rabeprazole|20 mg bid for 14 days
358743|NCT00681005|Drug|pantoprazole|pantoprazole 40 mg bid
358744|NCT00681018|Other|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
358745|NCT00681018|Other|Powder human milk fortifier|Powder human milk fortifier added to human milk
358746|NCT00681031|Biological|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain,(live attenuated) not less than 19400 PFU
358747|NCT00005592|Biological|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
358748|NCT00681044|Biological|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
358749|NCT00681044|Drug|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
358750|NCT00681044|Procedure|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
358751|NCT00681070|Other|fast-absorbing catgut|use of absorbable sutures in pediatric facial lacerations
358752|NCT00681083|Device|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
358753|NCT00681083|Device|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
358754|NCT00681109|Drug|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
358755|NCT00681109|Drug|Placebo|custom eye drop to be applied three times a day in both eyes for three months
358756|NCT00681109|Drug|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
358757|NCT00681135|Device|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
358114|NCT00689845|Drug|cytarabine|Given subcutaneously
358115|NCT00689845|Drug|doxorubicin hydrochloride|Given IV
358116|NCT00689845|Drug|etoposide phosphate|Given IV
358117|NCT00689845|Drug|ifosfamide|Given IV
358118|NCT00689845|Drug|methotrexate|Given IV
358119|NCT00689845|Drug|prednisolone|Given orally
358120|NCT00689845|Drug|prednisone|Given orally
358121|NCT00689845|Drug|vincristine sulfate|Given IV
358436|NCT00673257|Procedure|dual x-ray absorptimetry|
358437|NCT00673270|Drug|Fludrocortisone|50 µg of fludrocortisone per os
358438|NCT00000174|Drug|Rivastigmine|
358439|NCT00000658|Drug|Dexamethasone|
358440|NCT00005092|Radiation|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
358441|NCT00673270|Drug|Hydrocortisone|50 mg of intravenous hydrocortisone
358442|NCT00673270|Drug|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
358443|NCT00673270|Drug|Placebo of Hydrocortisone|2 ml of isotonic saline solution
358444|NCT00673283|Device|bi-plane chest radiography|Bi-plane radiography of the thorax
358445|NCT00673296|Drug|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
358446|NCT00673309|Procedure|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
358447|NCT00673309|Procedure|Stable Isotope Infusion study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
358448|NCT00673309|Procedure|Radiology testing: DEXA, K+ counter, ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
358449|NCT00673309|Drug|IGF-1|Administration of randomized drug daily throughout hospitalization to 95% wound healing
357835|NCT00685074|Behavioral|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
357836|NCT00685100|Other|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
357837|NCT00685113|Drug|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
357838|NCT00685113|Drug|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
357839|NCT00685113|Drug|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
357840|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
357841|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
357842|NCT00005610|Biological|sargramostim|
357843|NCT00685126|Drug|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
357844|NCT00685139|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
357845|NCT00685139|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
357846|NCT00685152|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
357847|NCT00685165|Drug|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
358122|NCT00689845|Drug|vindesine|Given IV
358123|NCT00689858|Drug|Cilostazol, Ginkgo biloba and placebo|dosing time
358124|NCT00005641|Drug|methylprednisolone|
358125|NCT00689871|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
358126|NCT00689884|Drug|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
358127|NCT00692224|Drug|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
359847|NCT00671853|Drug|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
359848|NCT00671879|Drug|Carisoprodol SR 700 mg|700 mg twice daily tablet
359849|NCT00671879|Drug|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
359850|NCT00671879|Drug|Placebo|placebo tablet
359851|NCT00671892|Biological|Lipopolysaccharide endotoxin|Delivered in nebulized form expressed in activity units(endotoxin units -EU).
Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:
Challenge One first saline then 5000 EU 10,000 EU 20,000 EU
Challenge 1 and 2 must be at least 2 weeks apart.
Challenge 2 Saline 40,000 EU 80,000 EU
359852|NCT00671905|Procedure|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
359853|NCT00671905|Procedure|PV isolation|Circumferential PV isolation
359854|NCT00000658|Drug|Leucovorin calcium|
359855|NCT00005089|Biological|rituximab|375 mg/m^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
360166|NCT00679367|Drug|dexamethasone|40 mg/QD once weekly
360167|NCT00679367|Drug|lenalidomide|10 mg/day D1-21
360168|NCT00679367|Drug|melphalan|5 mg/m2 D1-4
360169|NCT00679380|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
360170|NCT00679380|Drug|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
360171|NCT00679380|Drug|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
360172|NCT00679380|Drug|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
360173|NCT00679380|Drug|Placebo|Placebo
360174|NCT00679393|Procedure|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
360175|NCT00005585|Drug|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
360176|NCT00681928|Other|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
360177|NCT00681928|Procedure|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
359520|NCT00688519|Drug|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
359521|NCT00005635|Biological|trastuzumab|
359522|NCT00688545|Drug|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
359523|NCT00688545|Drug|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
359524|NCT00688558|Drug|JTT-705 600 mg and simvastatin 40 mg|JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment
Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments
359525|NCT00688558|Drug|Placebo and simvastatin 40 mg|Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
359526|NCT00688571|Device|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
359527|NCT00688584|Behavioral|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
359528|NCT00688584|Behavioral|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
359529|NCT00688597|Drug|AT2220|low dose regimen 1
powder in a bottle for dissolution in water for oral administration
359530|NCT00688597|Drug|AT2220|high dose, regimen 1
359531|NCT00688597|Drug|AT2220|high dose, regimen 2
359532|NCT00005635|Drug|paclitaxel|
359856|NCT00671918|Drug|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
359857|NCT00671931|Drug|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
359858|NCT00671931|Drug|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
359859|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
359217|NCT00681265|Drug|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
359218|NCT00681265|Drug|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
359219|NCT00681291|Device|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
359220|NCT00681291|Device|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
359221|NCT00681304|Other|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
359222|NCT00681317|Drug|AZD6280|oral
359223|NCT00681330|Biological|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
359224|NCT00681343|Drug|Thymoglobulin|Induction
359225|NCT00005593|Drug|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
359226|NCT00681343|Drug|Campath-1H|Induction
359227|NCT00681343|Drug|Daclizumab|Induction
359228|NCT00681356|Drug|4975, 15 and 5 mg|Direct instillation into the surgical site
359229|NCT00681356|Drug|Placebo Comparator|Direct instillation into the surgical site
359230|NCT00681356|Drug|4975 - 5 mg|Direct instillation into the surgical site
359231|NCT00681395|Drug|ABT-143|once daily for 6 days
359232|NCT00681395|Drug|ABT-335|once daily for six days
359233|NCT00681395|Drug|Rosuvastatin|Once daily for 6 days
359533|NCT00688610|Other|laboratory value procalcitonin|A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is not recommended, patient shall not take antibiotic. In case of "retention of decision": patient may take the antibiotic.
B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is recommended, patient has to be informed about. In case of "retention of decision": no change.
358899|NCT00671411|Drug|Ultrasound with intravenous microbubble contrast injection|Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings & Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 & 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of "flash" bubble destruction may be optionally triggered using manufacturer's preset settings & energy w/i FDA guidelines. This will only be performed while imaging the kidney.
358900|NCT00671424|Drug|Hydrochlorothiazide (HCTZ)|
358901|NCT00673465|Drug|Placebo|Placebo capsules matching SCH 497079 administered once daily x 28 days
358902|NCT00673465|Drug|Metformin extended release|1500 mg, administered orally, once-daily x 28 days
358903|NCT00673478|Drug|Tiotropium+Salmeterol|
358904|NCT00673478|Drug|Salmeterol|
358905|NCT00005094|Other|placebo|Given orally
358906|NCT00673478|Drug|Tiotropium|
358907|NCT00673491|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
358908|NCT00673504|Drug|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
358909|NCT00673504|Drug|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
358910|NCT00673530|Behavioral|evidence based clinical nutrition concept|The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
358911|NCT00673530|Behavioral|care as usual|Unchanged treatment of hospital patients without interference by the study.
358912|NCT00673556|Drug|alefacept|Intramuscular (IM)
358913|NCT00673556|Drug|placebo|Intramuscular (IM)
358914|NCT00673569|Drug|erlotinib hydrochloride|
358915|NCT00673569|Genetic|gene expression analysis|
357943|NCT00670852|Procedure|X-rays and CT scan|CT Scan x-rays
357944|NCT00670865|Other|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
357945|NCT00670878|Drug|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
358245|NCT00678210|Drug|Placebo|tablets, BID for 12 weeks
358246|NCT00678236|Other|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
358247|NCT00005583|Drug|cisplatin|
358248|NCT00678236|Other|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
358249|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
358250|NCT00678249|Procedure|PTA|Percutaneous Transluminal Angioplasty
358251|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
358252|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
358253|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
358254|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
358255|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
358256|NCT00678301|Biological|Pneumococcal vaccine GSK1024850A|3 IM doses.
358257|NCT00678301|Biological|GSK Biologicals' Polio Sabin™|3 oral doses
358258|NCT00005583|Drug|doxorubicin hydrochloride|
358259|NCT00678301|Biological|GSK Biologicals' Zilbrix™ Hib|3 IM doses.
358260|NCT00680615|Behavioral|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
357326|NCT00684866|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
357327|NCT00684866|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
357328|NCT00684892|Device|Chartis System|Assessment of airway flow and pressure
357329|NCT00005607|Drug|leucovorin calcium|
357330|NCT00684905|Drug|bicalutamide|
357331|NCT00684905|Drug|leuprolide acetate|
357332|NCT00684905|Procedure|adjuvant therapy|
357333|NCT00684905|Procedure|neoadjuvant therapy|
357334|NCT00684905|Procedure|quality-of-life assessment|
357335|NCT00684905|Radiation|brachytherapy|
357336|NCT00687115|Behavioral|Weight Loss|liquid diet at 50% of weight maintaining intake
357337|NCT00687115|Behavioral|Overfeeding|Overfeeding at 150% of weight maintaining intake
357338|NCT00687115|Behavioral|Overfeeding Low Pro|Overfeeding 150% of normal intake at & lt; 5% protein
357339|NCT00687128|Behavioral|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
357640|NCT00691860|Procedure|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
357641|NCT00691873|Drug|Placebo|placebo
357642|NCT00691873|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
357643|NCT00691886|Drug|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
357644|NCT00691899|Drug|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
357645|NCT00005673|Drug|Capravirine|
357646|NCT00691899|Drug|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
356700|NCT00004686|Drug|prednisone|
356701|NCT00631033|Drug|Placebo|
356702|NCT00631033|Drug|Diazoxide|
356703|NCT00631033|Drug|Metformin + Diazoxide|
356704|NCT00631046|Dietary Supplement|Fish Oil|Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
356705|NCT00631046|Dietary Supplement|Sunflower Oil|Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
356706|NCT00593853|Drug|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
356707|NCT00593853|Drug|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
356708|NCT00593866|Radiation|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
356709|NCT00593866|Drug|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
356710|NCT00004196|Biological|recombinant interferon alfa|
356711|NCT00593879|Drug|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
356712|NCT00593905|Drug|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
356713|NCT00593905|Drug|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
356714|NCT00593931|Other|fMRI|Functional Magnetic Resonance Imaging without contrast
356715|NCT00593944|Biological|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
356716|NCT00593957|Drug|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
357029|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
357030|NCT00677287|Biological|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
361270|NCT00667797|Drug|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
361271|NCT00667810|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
356395|NCT00599651|Device|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
356396|NCT00599651|Other|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
356397|NCT00599664|Drug|OMS201|OMS201 irrigation solution during surgery
356398|NCT00004218|Drug|chlorambucil|
356399|NCT00599664|Drug|Vehicle|Vehicle irrigation solution during surgery
356400|NCT00599677|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
356401|NCT00599677|Drug|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
356402|NCT00601991|Biological|VEGF Trap|Drug under investigation
356403|NCT00601991|Procedure|Bone marrow biopsy|To determine response to treatment
356404|NCT00601991|Procedure|bone marrow aspiration|To determine response to treatment
356405|NCT00601991|Procedure|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
356406|NCT00004228|Drug|daunorubicin hydrochloride|Given IV
356407|NCT00602004|Drug|losartan|losartan 50 mg a day
356408|NCT00602017|Drug|Amlodipine|
356409|NCT00602030|Drug|entinostat|Dose cohort 1: SNDX-275 5mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)
Dose cohort 2: SNDX-275 10mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)
356410|NCT00602030|Drug|SNDX-275|entinostat 5mg or 10mg (determined by Lead in study findings) on days 1 and 15 of a 28-day cycle until progression or unacceptable toxicity develops; maximum of 6 cycles
356411|NCT00602030|Drug|erlotinib|erlotinib 150mg PO QD
356412|NCT00602043|Radiation|F-18 16 alpha-fluoroestradiol|Undergo [^18F] FES PET
360932|NCT00635817|Drug|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
360933|NCT00635817|Drug|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
360934|NCT00635830|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
360935|NCT00635843|Device|MAVERICK™ Disc|The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
360936|NCT00635843|Device|LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft|The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
360937|NCT00004767|Drug|Sodium Benzoate|
360938|NCT00635856|Drug|Gefitinib|Iressa
360939|NCT00635869|Behavioral|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
361272|NCT00667810|Drug|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
361273|NCT00000658|Drug|Vincristine sulfate|
361274|NCT00005059|Drug|carboplatin|
361275|NCT00667810|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
361276|NCT00667823|Drug|Macitentan|tablet oral administration, 10 mg dose once daily
361277|NCT00667849|Device|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
361278|NCT00667849|Device|Sham|sham device identical to active device with the exception of administration of ultrasound
361279|NCT00667862|Drug|Panobinostat|
361280|NCT00667875|Drug|Placebo|placebo
361281|NCT00667875|Drug|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
361282|NCT00667875|Drug|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
361283|NCT00667888|Radiation|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
360632|NCT00682305|Procedure|Hematopoietic stem cell transplantation|conditioning regimen:
day -7: 12g/m^2 Treosulfan
day -6: 12g/m^2 Treosulfan
day -5: 12g/m^2 Treosulfan
day -4: 30mg/kg BW Etoposide
day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide
day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide
day -1: 20mg/kg ATG Fresenius (OPTIONAL)
day 0: SCT
360633|NCT00682318|Drug|Fish Oil|Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;
Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;
Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days
360634|NCT00682318|Dietary Supplement|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
360635|NCT00682318|Dietary Supplement|Ethanol|Part 1 & Part 1.1:
Dose of 0.9 g/kg body weight 98% alcohol solution
Part 2a:
Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution
Part 2b, Part 3:
Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution
360636|NCT00005596|Drug|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC > or = 500/ul and platelets > or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
360637|NCT00684489|Drug|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
360638|NCT00005606|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
360639|NCT00684489|Drug|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
360640|NCT00684502|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
360641|NCT00684502|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
360642|NCT00684515|Drug|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
360643|NCT00684515|Drug|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
360644|NCT00684515|Drug|Placebo|oral tablets; once daily for 60 days
360645|NCT00684515|Drug|Aspirin 75-150 mg|oral tablets; once daily for 60 days
360036|NCT00691093|Drug|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
360037|NCT00691106|Drug|etanercept|Etanercept 50mg will be administered twice weekly by subcutaneous injection for 12 weeks. Those subjects continuing on etanercept beyond 12 weeks will receive a dose of 25mg twice weekly.
360038|NCT00691119|Behavioral|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
360039|NCT00691119|Other|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
360040|NCT00005652|Drug|rituximab|
360041|NCT00691132|Drug|phenethyl isothiocyanate|Given orally
360042|NCT00691132|Other|placebo|Given orally
360043|NCT00691145|Drug|tacrolimus ointment|transdermal
360044|NCT00691158|Drug|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
360345|NCT00674557|Other|pharmacological study|
360346|NCT00674570|Drug|Hydrocortisone|25 mg/oral one hour prior to extinction task
360347|NCT00674570|Drug|D-Cycloserine|50 mg/oral one hour prior to extinction task
360348|NCT00005108|Drug|Estradiol|
360349|NCT00674570|Drug|Placebo|One hour prior to extinction task
360350|NCT00674583|Biological|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
360351|NCT00674583|Biological|Menjugate|Intramuscular administration, 1 dose
360352|NCT00674596|Drug|ramipril|ramipril 10 mg/day during 3 months
360353|NCT00674609|Drug|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
360354|NCT00674609|Drug|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
360355|NCT00674609|Drug|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
359711|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
359712|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
359713|NCT00005603|Drug|mercaptopurine|
359714|NCT00683917|Drug|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
359715|NCT00683917|Drug|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
359716|NCT00683917|Drug|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
359717|NCT00683930|Drug|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
359718|NCT00683930|Drug|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
359719|NCT00683930|Drug|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
359720|NCT00683943|Drug|Lithium Carbonate|
359721|NCT00683956|Device|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
359722|NCT00683956|Drug|Propofol|
360045|NCT00691158|Drug|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
360046|NCT00691158|Drug|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
360047|NCT00691158|Drug|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
360048|NCT00691184|Drug|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
360049|NCT00691184|Drug|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
360050|NCT00691184|Drug|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
360051|NCT00000675|Drug|CD4-IgG|
360052|NCT00005654|Drug|clomiphene citrate|
359082|NCT00690534|Drug|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
359395|NCT00005097|Drug|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
359396|NCT00673842|Other|Usual care|Usual post-MI care
359397|NCT00673855|Other|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
359398|NCT00673855|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
359399|NCT00673868|Other|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
359400|NCT00673881|Drug|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
359401|NCT00673894|Drug|Glutamine, sitagliptin|Glutamine 15g and 30g/sitagliptin 100mg
359402|NCT00676260|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
359403|NCT00676273|Device|TVT-Obturator (TVT-O)|sub urethral sling
359404|NCT00676273|Device|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
359405|NCT00005571|Drug|h5G1.1-mAb|
359406|NCT00676286|Procedure|3T MR Imaging|3TR Imaging
359407|NCT00676286|Procedure|C-Choline PET Scanning|C-Choline PET Scanning
359408|NCT00676286|Procedure|Gene Rearrangement|Gene Rearrangement
359409|NCT00676299|Drug|JNJ-26483327|
359410|NCT00676312|Drug|PTH134|
359411|NCT00676325|Procedure|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
359412|NCT00676325|Device|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
358758|NCT00005592|Biological|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
358759|NCT00681135|Device|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
359083|NCT00690534|Drug|L-NMMA|variable rate for 3 hours
359084|NCT00690534|Drug|Sodium Nitroprusside|variable rate for 3 hours
359085|NCT00690534|Other|mixed meal|mixed meal
359086|NCT00005645|Drug|ILX-295501|
359087|NCT00690547|Other|muscle activation|activation of the muscle quadriceps femoris
359088|NCT00690560|Biological|rituximab|
359089|NCT00690560|Drug|cyclophosphamide|
359090|NCT00690560|Drug|doxorubicin hydrochloride|
359091|NCT00690560|Drug|prednisone|
359092|NCT00690560|Drug|vincristine sulfate|
359093|NCT00690560|Radiation|yttrium Y 90 ibritumomab tiuxetan|
359094|NCT00690573|Biological|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
359095|NCT00690612|Drug|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
359096|NCT00692978|Drug|Fluticasone Propionate|Inhaled, Metered dose inhaler, 250 micrograms dose (total dose)
359097|NCT00693004|Drug|PRX-03140|
359098|NCT00005758|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
359099|NCT00693004|Drug|Donepezil|
359100|NCT00693004|Drug|Placebo|
359101|NCT00693017|Drug|Zonisamide|50-400 mg capsules once daily in the evening orally.
Maximum study duration 28 weeks comprising:
Baseline Period (Week -8 to Week 0): no treatment
Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)
Down Titration Period (4 Weeks)
358450|NCT00673309|Drug|Insulin|Insulin IV administered continuously to maintain serum glucose between 80-110 throughout hospitalization until wounds are 95% healed.
358451|NCT00005093|Drug|gemcitabine hydrochloride|
358452|NCT00673309|Drug|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
358453|NCT00673309|Drug|Propranolol|Propranolol to be given daily to decrease HR and BP throughout hospitalization until 95% wound healing.
358454|NCT00673309|Drug|Clonidine|Clonidine administered daily throughout hospitalization until 95% wound healing to decrease HR, BP, and anxiety.
358455|NCT00673309|Drug|Ketoconazole|Ketoconazole administered PO every 12 hours throughout hospitalization until 95% wound healing.
358456|NCT00673309|Drug|Dehydroepiandrosterone-sulfate|The hormone Dehydroepiandrosterone-sulfate will be given daily until 95% wound healing.
358457|NCT00673309|Drug|Fenofibrate|Fenofibrate administered daily until 95% wound healing.
358458|NCT00673309|Drug|Metformin|metformin to be administered daily throughout hospitalization until 95% wound healing.
358760|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
358761|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
358762|NCT00005602|Drug|cereport|
358763|NCT00683345|Drug|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
358764|NCT00683358|Biological|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
358765|NCT00683371|Procedure|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
358766|NCT00683371|Procedure|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
358767|NCT00683384|Drug|Etanercept (Enbrel)|
358768|NCT00683397|Other|Blood sampling|Screening of thrombophilia
358769|NCT00683410|Biological|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
358128|NCT00692224|Drug|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
358129|NCT00692237|Drug|Sildenafil|100 mg daily (3 capsules/day)
358130|NCT00692237|Drug|Placebo|Placebo 100 mg (3 capsules/day)
358131|NCT00692250|Drug|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
358132|NCT00692263|Drug|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
358133|NCT00692263|Drug|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
358134|NCT00692263|Drug|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
358135|NCT00692276|Device|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
358136|NCT00692276|Device|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
358137|NCT00005684|Drug|heparin|
358138|NCT00692302|Behavioral|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
358139|NCT00692302|Behavioral|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
358140|NCT00692315|Dietary Supplement|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
358141|NCT00692315|Dietary Supplement|Folinic acid|400 ug b.i.d.
358142|NCT00692328|Behavioral|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
358143|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
358459|NCT00675714|Procedure|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
358460|NCT00675714|Drug|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
358461|NCT00675714|Drug|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
360178|NCT00681928|Procedure|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
360179|NCT00681941|Drug|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
360180|NCT00681967|Drug|Gefitinib|250 mg; oral
360181|NCT00681967|Drug|Gefitinib|250mg; oral
360182|NCT00681980|Drug|Valproic acid|15 mg/kg/day
360183|NCT00681980|Drug|costicosteroids|metypredsolone 1 g/day
360184|NCT00005596|Drug|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
360185|NCT00681980|Drug|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
360186|NCT00681993|Other|Standard Dose Dense Doxorubucin and Cyclophosphomide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphomide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
360187|NCT00681993|Other|Standard Doxorubucin and Cyclophosphomide|4 cycles of Standard Dose Doxorubucin and Cyclophosphomide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
360472|NCT00689221|Drug|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
360473|NCT00689221|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
360474|NCT00689221|Radiation|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
360475|NCT00689234|Procedure|diaphragm plication 6 months after inclusion|thoracotomy
360476|NCT00689234|Procedure|diaphragm plication at time of inclusion|thoracotomy
360477|NCT00691392|Drug|Microcrystalline Methylcellulose - Placebo|The placebo will be over-encapsulated microcrystalline methylcellulose
360478|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
360479|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
359860|NCT00671931|Drug|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
359861|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
359862|NCT00671944|Other|Low protein diet|Low protein diet for 6.5 weeks
359863|NCT00671970|Drug|Bevacizumab and Erlotinib|Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs & 500 mg/day for pts on EIAEDs.
It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
359864|NCT00671983|Procedure|Neurocognitive Testing|
359865|NCT00674115|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
359866|NCT00674115|Drug|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
359867|NCT00674115|Drug|sodium bicarbonate|Sodium bicarbonate. Single dose.
359868|NCT00674128|Device|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
359869|NCT00674128|Device|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
359870|NCT00674141|Drug|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
359871|NCT00674154|Drug|Cholecalciferol|2800 IE daily in 52 weeks
359872|NCT00674167|Drug|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
359873|NCT00674167|Drug|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
360188|NCT00681993|Other|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
360189|NCT00681993|Other|Standard Docetaxel, Doxorubucin and Cyclophosphomide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphomide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
359534|NCT00688623|Drug|Everolimus|
359535|NCT00688636|Drug|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
359536|NCT00688636|Drug|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
359537|NCT00688649|Dietary Supplement|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
359538|NCT00690781|Dietary Supplement|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
359539|NCT00690781|Dietary Supplement|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
359540|NCT00005647|Drug|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
359541|NCT00690794|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
359542|NCT00690794|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
359543|NCT00690807|Drug|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
359544|NCT00690820|Drug|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
359545|NCT00690820|Drug|Placebo Comparator|Placebo
359546|NCT00690833|Drug|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
359547|NCT00690846|Drug|adalimumab|40 mg weekly adalimumab injection.
359548|NCT00690872|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
359549|NCT00690872|Drug|carboplatin|
359550|NCT00690872|Drug|gemcitabine hydrochloride|
359874|NCT00674167|Drug|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
358916|NCT00005095|Other|laboratory biomarker analysis|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
358917|NCT00673569|Genetic|protein expression analysis|
359234|NCT00681408|Drug|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
359235|NCT00681408|Drug|Placebo|Fish oil placebo pills
359236|NCT00005593|Drug|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
359237|NCT00681421|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
359238|NCT00681434|Behavioral|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
359239|NCT00683644|Dietary Supplement|Zinc sulfate|Zinc sulfate taken once daily
359240|NCT00683657|Drug|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
359241|NCT00683657|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
359242|NCT00683670|Drug|cyclophosphamide|
359243|NCT00683670|Biological|Mature dendritic cell vaccine|
359244|NCT00683683|Behavioral|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
359245|NCT00683696|Device|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
359246|NCT00683709|Behavioral|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
359247|NCT00005603|Drug|daunorubicin hydrochloride|
359248|NCT00683709|Behavioral|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
358261|NCT00680628|Drug|Tenecteplase + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: <60Kg=30mg; ≥60Kg to <70Kg=35mg; ≥70Kg to <80Kg=40mg; ≥80Kg to <90Kg=45mg; ≥90Kg=50mg
358262|NCT00680628|Drug|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
358263|NCT00680641|Drug|Simvastatin|40mg of Simvastatin once daily
358264|NCT00680641|Drug|Placebo|40mg of placebo once daily
358265|NCT00680654|Drug|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
358588|NCT00687882|Other|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
358589|NCT00687895|Procedure|Clinical algorithm and microscopy diagnosis of malaria|Clinical alogarithm
The content of the package included
description of signs and symptoms of malaria disease
history taking relevant to malaria and physical examination
identification of danger signs and severe illness for referral
appropriate treatment
counseling patients on the use of drugs.
Malaria microscopy. contents
make thick blood smears from patients with fever and stain with Giemsa
identify and count malaria parasites
maintain the microscope and store blood slides.
358590|NCT00687908|Drug|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
358591|NCT00687908|Drug|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
358592|NCT00687934|Drug|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
358593|NCT00687947|Drug|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
358594|NCT00687960|Dietary Supplement|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
358595|NCT00005631|Drug|etoposide|
358596|NCT00687960|Dietary Supplement|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
358597|NCT00687960|Dietary Supplement|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
358598|NCT00687960|Dietary Supplement|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
358599|NCT00687973|Drug|Valsartan/amlodipine 80/5 mg tablets|
358600|NCT00687973|Drug|Amlodipine 5 mg capsules|
357647|NCT00691912|Drug|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
357648|NCT00691912|Drug|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
357649|NCT00691938|Drug|LBH589|
357650|NCT00691938|Drug|Decitabine|
357651|NCT00691951|Drug|budesonide and budesonide/formoterol|
357652|NCT00691964|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
357653|NCT00691964|Biological|etanercept|SQ injection 50 mg BIW
357654|NCT00691964|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
357655|NCT00691977|Radiation|Radiation Therapy followed by prostatectomy|Radiation Therapy
357656|NCT00005674|Drug|Creatine|
357657|NCT00691990|Procedure|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
357658|NCT00692003|Drug|Zonisamide|25-400 mg capsules orally once daily in the evening.
Maximum study duration of 28 weeks comprising:
Baseline Period (Week-8/-4 to Week 0) no treatment
Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)
Down Titration Period (4 weeks)
357659|NCT00692003|Drug|Placebo|25-400 mg Zonisamide Placebo capsules orally once daily in the evening.
Maximum study duration of 28 weeks comprising:
Baseline Period (Week-8/-4 to Week 0) no treatment
Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)
Down Titration Period (4 weeks)
357660|NCT00692016|Drug|Naproxen sodium|Administered under fasting condition
357946|NCT00673010|Radiation|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
357947|NCT00673023|Other|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
357948|NCT00673036|Other|Blood sample|60 ml of whole blood
357031|NCT00677300|Drug|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
357032|NCT00677300|Drug|Darunavir|800 mg P.O. (orally) once daily
357033|NCT00677300|Drug|Ritonavir|100mg once daily
357034|NCT00677300|Drug|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
357035|NCT00677313|Drug|metreleptin|metreleptin injection
357036|NCT00677326|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
357037|NCT00677339|Drug|L-arginine|L-arginine 6g orally daily
357038|NCT00005578|Drug|prednisone|
357039|NCT00677339|Drug|Vitamin D|Cholecalciferol 50000 IU once monthly orally
357040|NCT00677339|Drug|Placebo L-arginine|placebo L-arginine once daily
357041|NCT00677339|Drug|Placebo Vitamin D|placebo vitamin D orally once monthly
357042|NCT00677352|Drug|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
357043|NCT00679653|Drug|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
357044|NCT00679653|Drug|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
357045|NCT00000664|Drug|Zidovudine|
357046|NCT00005586|Drug|L-leucovorin|
357047|NCT00679666|Drug|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
357048|NCT00679666|Drug|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
357049|NCT00679679|Drug|Metformin|Metformin 750 mg BID for 4 months
357050|NCT00679679|Drug|Placebo|Diet counseling and exercise
357051|NCT00679705|Drug|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
357052|NCT00679705|Drug|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
356413|NCT00602043|Radiation|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
356414|NCT00602043|Procedure|positron emission tomography|Undergo [^18F] FES PET
356415|NCT00602043|Procedure|positron emission tomography|Undergo standard clinical FDG PET/CT
356416|NCT00602043|Procedure|computed tomography|Undergo standard clinical FDG PET/CT
356417|NCT00004228|Drug|dexamethasone|Given IV
356418|NCT00602043|Other|laboratory biomarker analysis|Correlative studies
356717|NCT00593957|Drug|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
356718|NCT00593983|Behavioral|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
356719|NCT00593983|Behavioral|Time-matched health education|Health education and standard of care treatment
356720|NCT00593996|Other|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
356721|NCT00004196|Procedure|lymphangiography|
356722|NCT00594009|Device|Rotaflow centrifugal pump (Maquet, Inc.)|Patients who meet criteria will be placed on an extracorporeal device for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
356723|NCT00594035|Device|Spinal Sealant System|
356724|NCT00594035|Device|Standard of care|Standard of care: devices intended to provide a watertight closure
356725|NCT00594048|Device|Resperate|Use of the device 15 minutes a day for 9 weeks
356726|NCT00594048|Device|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
356727|NCT00594061|Device|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
356728|NCT00594074|Other|white wine|3.25 ounces of white wine twice a day with lunch and dinner
356729|NCT00594087|Drug|eszopiclone|eszopiclone 2mg or 3mg at bedtime
356730|NCT00596895|Dietary Supplement|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
356731|NCT00596934|Drug|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
361284|NCT00667888|Radiation|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
361285|NCT00005059|Drug|paclitaxel|
361286|NCT00667901|Drug|riluzole|
361287|NCT00667901|Genetic|protein expression analysis|
361288|NCT00667901|Genetic|reverse transcriptase-polymerase chain reaction|
361289|NCT00667901|Genetic|western blotting|
361290|NCT00667901|Other|immunohistochemistry staining method|
361291|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
361292|NCT00670319|Drug|Placebo|Placebo one tab orally per day
361293|NCT00670345|Drug|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
361294|NCT00670345|Drug|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
361295|NCT00670358|Biological|pegfilgrastim|
361296|NCT00670358|Biological|rituximab|
356419|NCT00602056|Other|Redesigned immunization card|A low cost nad simplified redesigned immunization card
356420|NCT00602056|Other|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
356421|NCT00602056|Other|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
356422|NCT00602069|Behavioral|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
356423|NCT00602069|Behavioral|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
356424|NCT00602082|Drug|capecitabine|
356425|NCT00602082|Drug|cisplatin|
356426|NCT00602082|Drug|streptozocin|
356427|NCT00602082|Genetic|DNA analysis|
360646|NCT00684528|Drug|Metformin 1500 mg daily|500 mg thrice daily
360940|NCT00635869|Behavioral|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
360941|NCT00635869|Behavioral|Placebo|didactic education sessions on physical assessment
360942|NCT00635882|Drug|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
360943|NCT00635882|Drug|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
360944|NCT00635882|Drug|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
360945|NCT00635882|Drug|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
360946|NCT00635882|Drug|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
360947|NCT00635882|Drug|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
360948|NCT00004767|Drug|Sodium Phenylacetate|
360949|NCT00635895|Other|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
360950|NCT00635921|Drug|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
360951|NCT00635921|Drug|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
360952|NCT00638261|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
360953|NCT00638274|Procedure|Air|3 mls used for identifying epidural space
360954|NCT00638274|Procedure|Saline|3 mls of saline used to identify epidural space
360955|NCT00638300|Device|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
360956|NCT00004806|Genetic|Cystic fibrosis transmembrane conductance regulator|
360957|NCT00638300|Other|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
360958|NCT00638300|Other|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
360356|NCT00676936|Drug|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
360357|NCT00676936|Drug|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
360358|NCT00676949|Biological|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
360359|NCT00676962|Behavioral|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
360360|NCT00676975|Drug|Traditional Chinese Medicine|A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.
The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale
360361|NCT00676975|Drug|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
360362|NCT00677001|Drug|R306465|
360363|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|All subjects in this trial receive the same device. For the purpose of this trial. "intervention" is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.
360647|NCT00684528|Drug|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
360648|NCT00684541|Behavioral|Interpretation Modification Program|The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. "graceful" or "clumsy") word on the computer screen. They will then see an ambiguous sentence (e.g. "You dance at the party") and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., "You are correct!") when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., "You are incorrect.") when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence.
360649|NCT00005606|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
360650|NCT00684541|Behavioral|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
360651|NCT00684554|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
360652|NCT00684567|Radiation|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
360053|NCT00691184|Drug|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
360054|NCT00691197|Device|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
360055|NCT00691197|Device|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
360056|NCT00691210|Drug|Vorinostat|Dose escalation scheme (400 mg)
Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.
360057|NCT00691210|Drug|Niacinamide|Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)
Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer.
360058|NCT00691210|Drug|Etoposide|Dose escalation scheme (0, 25, 50, 100 mg/m2)
Etoposide is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as a "plant alkaloid" and "topoisomerase II inhibitor."
360059|NCT00691236|Drug|Zoledronic acid|4mg IV 3 weekly for 6 doses
360060|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
360061|NCT00693628|Device|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
360062|NCT00005764|Drug|Abacavir sulfate|
360063|NCT00693641|Other|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
360064|NCT00693641|Other|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
360364|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|All subjects in this trial receive the same device. For the purpose of this trial. "intervention" is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.
360365|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|All subjects in this trial receive the same device. For the purpose of this trial. "intervention" is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.
360366|NCT00005578|Biological|filgrastim|
360367|NCT00677027|Other|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
359413|NCT00676325|Procedure|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
359414|NCT00676338|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
359415|NCT00676338|Drug|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
359723|NCT00683969|Drug|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
359724|NCT00005603|Drug|methotrexate|
359725|NCT00683969|Drug|placebo|po bid for 36 weeks
359726|NCT00683982|Drug|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
359727|NCT00683982|Drug|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
359728|NCT00683982|Other|Oral hydration solutions|Oral hydration solutions as needed
359729|NCT00683995|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
359730|NCT00684008|Drug|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
359731|NCT00684008|Drug|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
359732|NCT00684021|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
359733|NCT00684021|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
359734|NCT00684034|Other|Sampling of blood|A sampling of blood will be made
359735|NCT00005603|Drug|prednisone|
359736|NCT00686127|Drug|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
359737|NCT00686127|Drug|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
359738|NCT00686140|Drug|celecoxib|400mg/day, twice a day, 12 weeks
359739|NCT00686140|Drug|Placebo|twice a day, 12 weeks
359102|NCT00693017|Drug|Placebo|50-400 mg Zonisamide Placebo capsules once daily in the evening orally.
Maximum study duration 28 weeks comprising:
Baseline Period (Week -8 to Week 0): no treatment
Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)
Down Titration Period (4 Weeks)
359103|NCT00693030|Device|sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)|comparison of multiple drug eluting stents
359104|NCT00693030|Device|paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)|comparison of multiple drug eluting coronary stents
359105|NCT00693030|Device|zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)|comparison of multiple drug eluting coronary stents
359416|NCT00005574|Drug|Gentamicin|
359417|NCT00676338|Drug|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
359418|NCT00676338|Drug|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
359419|NCT00676351|Procedure|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
359420|NCT00676364|Drug|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
359421|NCT00676364|Drug|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
359422|NCT00676377|Drug|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
359423|NCT00676377|Drug|Saline|Saline Placebo
359424|NCT00676390|Other|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
359425|NCT00676403|Drug|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
359426|NCT00676403|Drug|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
359427|NCT00005575|Drug|Imipramine|
359428|NCT00678847|Device|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
359429|NCT00678873|Procedure|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
359430|NCT00678886|Biological|otelixizumab infusion plus physician determined standard of care|infusion
358770|NCT00683423|Drug|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
358771|NCT00683423|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
358772|NCT00683436|Drug|Adipiplon|bilayer tablets 6 mg
358773|NCT00005602|Radiation|radiation therapy|
358774|NCT00683436|Drug|Placebo|Placebo
358775|NCT00683436|Drug|Ambien CR|Ambien CR 12.5 mg
358776|NCT00683436|Drug|Adipiplon|bilayer tablets 9 mg
358777|NCT00683449|Drug|Dose Group 1|IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
358778|NCT00683449|Drug|MN-221 placebo|i.v. infusion of placebo for 15 minutes
358779|NCT00683449|Drug|Dose Group 2|i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
358780|NCT00683449|Drug|Dose Group 3|i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
358781|NCT00683462|Drug|Placebo|
359106|NCT00693030|Device|Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)|comparison of DES in overlap vs BMS in overlap
359107|NCT00693043|Drug|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
359108|NCT00693056|Drug|Placebo|Placebo (w/o API)
359109|NCT00005758|Biological|HIV-1 Immunogen|
359110|NCT00693056|Drug|RX-10100 5mg|5 mg/dose of RX-10100
359111|NCT00693056|Drug|RX-10100 10mg|10 mg/dose of RX-10100
359112|NCT00693056|Drug|RX-10100 15mg|15 mg/dose of RX-10100
359113|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
359114|NCT00693069|Drug|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
359115|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
358462|NCT00675714|Drug|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
358463|NCT00675714|Drug|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
358464|NCT00675714|Drug|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
358465|NCT00675714|Drug|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
358466|NCT00005398|Other|There is no intervention|No applicable
358467|NCT00675714|Drug|Placebo|placebo to be given once a day for up to two years post burn injury.
358468|NCT00675714|Behavioral|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
358469|NCT00675714|Behavioral|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
358470|NCT00675727|Biological|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
358471|NCT00675740|Drug|rosiglitazone|tablets 4 mg daily
358472|NCT00675740|Behavioral|physical exercise|stationary bike 5-6 times a week
358473|NCT00675740|Other|control|control without intervention
358474|NCT00675753|Genetic|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
358475|NCT00675779|Drug|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
358476|NCT00675779|Drug|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
358477|NCT00005520|Drug|Hydrochlorothiazide|
358478|NCT00675792|Drug|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
358479|NCT00675792|Drug|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
358782|NCT00683462|Drug|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
358783|NCT00683462|Drug|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
360480|NCT00005655|Biological|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
360481|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
360482|NCT00691405|Drug|Placebo|Placebo inhalation solution BID
360483|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
360484|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
360485|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
360486|NCT00691405|Drug|Placebo|Placebo inhalation solution QD
360487|NCT00691418|Dietary Supplement|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
360488|NCT00691418|Dietary Supplement|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
360489|NCT00691431|Device|LASIK|
360490|NCT00691444|Dietary Supplement|Melatonin|Subjects will be given up to 0.5 mg daily.
0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns).
360491|NCT00005658|Drug|Glycine|
360492|NCT00691444|Dietary Supplement|Melatonin|Subjects will be given up to 10 mg daily.
0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns).
360788|NCT00658099|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
360789|NCT00658099|Drug|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
360790|NCT00658112|Drug|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
360791|NCT00658125|Procedure|Deep Brain Stimulation (Fornix DBS)|Fornix DBS for Alzheimer Disease
360792|NCT00658138|Device|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
360793|NCT00658138|Device|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
360794|NCT00658164|Other|Iron depletion treatment|Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
360190|NCT00681993|Other|Standard Docetaxel and Cyclophosphomide|4 cycles of Standard Docetaxel and Cyclophosphomide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
360191|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
360192|NCT00682006|Other|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
360193|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
360194|NCT00682019|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
360195|NCT00000666|Drug|Pyrimethamine|
360196|NCT00684203|Drug|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
360197|NCT00684203|Drug|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
360198|NCT00684203|Drug|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
360199|NCT00684203|Drug|Clopidogrel|100 mg two or three times daily for 60 days.
360200|NCT00684216|Drug|capecitabine|200 mg, BID, PO, QD until progression of disease
360201|NCT00684216|Drug|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
360202|NCT00000669|Drug|Didanosine|
360203|NCT00005604|Biological|recombinant interleukin-12|Given IV
360204|NCT00684229|Procedure|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
360205|NCT00684229|Drug|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
360206|NCT00684242|Drug|Lenalidomide|10 mg by mouth daily
360493|NCT00691444|Biological|Melatonin|Subjects will be given up to 20 mg daily.
0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns).
360494|NCT00691457|Device|Opti-Free contact lens solution|Solution
360495|NCT00691457|Device|ReNu Multiplus contact lens solution|Solution
359875|NCT00005106|Drug|Abacavir sulfate|
359876|NCT00674180|Behavioral|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
359877|NCT00674180|Behavioral|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
359878|NCT00674180|Behavioral|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
359879|NCT00674193|Other|pharmacological study|Correlative studies
359880|NCT00674193|Other|laboratory biomarker analysis|Correlative studies
359881|NCT00674206|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
359882|NCT00674206|Drug|Oxaliplatin|Oxaliplatin 100mg/m^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
359883|NCT00674219|Drug|Namenda (Memantine)|Namenda 10mg BID for 12 weeks
359884|NCT00674232|Drug|600 mcg misoprostol|single dose of misoprostol taken orally
359885|NCT00674232|Procedure|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
359886|NCT00005106|Drug|Nelfinavir mesylate|
359887|NCT00674245|Drug|Pantoprazole|40 mg once daily for 4 weeks
359888|NCT00676637|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
359889|NCT00676637|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
359890|NCT00676650|Drug|Prednisone|5 mg BID, oral
359891|NCT00676650|Drug|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
359892|NCT00676650|Drug|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
359893|NCT00676650|Drug|Prednisone|5 mg BID, oral
359249|NCT00683722|Drug|PROCHYMAL™|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
359250|NCT00683722|Drug|Placebo|Intravenous infusion of excipient of PROCHYMAL™
359251|NCT00683735|Drug|Sitagliptin|100 mg once daily in the morning
359252|NCT00683735|Drug|Metformin|up to 2000 mg/day
359253|NCT00683735|Drug|Placebo|500mg 1-0-0-0
359551|NCT00005648|Drug|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
359552|NCT00690872|Genetic|polymerase chain reaction|
359553|NCT00690872|Other|fluorescence activated cell sorting|
359554|NCT00690872|Other|immunoenzyme technique|
359555|NCT00690885|Drug|interferon-alpha lozenges|150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
359556|NCT00690885|Drug|placebo lozenges|matching placebo lozenges
359557|NCT00690898|Drug|Lanreotide autogel 120 mg|12 months
359558|NCT00690911|Drug|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
359559|NCT00690924|Drug|calcitriol|Oral
359560|NCT00690924|Other|laboratory biomarker analysis|Correlative Study
359561|NCT00690924|Other|pharmacological study|Correlative Study
359562|NCT00693316|Drug|ORM-12741|Alternating panel single dose escalation.
359563|NCT00693342|Biological|immunological adjuvant OPT-821|Given subcutaneously
359564|NCT00693342|Biological|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
359565|NCT00693355|Other|Sodium butyrate|sodium butyrate
359566|NCT00005762|Drug|Nelfinavir mesylate|
359567|NCT00693355|Other|NaCl|NaCl
358601|NCT00687973|Drug|Amlodipine 10 mg capsules|
358602|NCT00687973|Drug|Atenolol 50 mg tablets|
358603|NCT00687973|Drug|Atenolol 100 mg tablets|
358604|NCT00687986|Radiation|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
358605|NCT00687986|Procedure|primary surgery|an anatomical surgical resection with lymph node dissection
358606|NCT00005631|Drug|ifosfamide|
358607|NCT00687999|Drug|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
358608|NCT00688012|Drug|SPC3649|
358609|NCT00690066|Drug|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
358918|NCT00673569|Other|immunoenzyme technique|
358919|NCT00673569|Other|immunologic technique|
358920|NCT00673569|Other|laboratory biomarker analysis|
358921|NCT00673569|Procedure|needle biopsy|
358922|NCT00673582|Drug|Rosuvastatin|10 mg/day rosuvastatin
358923|NCT00673582|Drug|Placebo|Placebo, 10 mg a day for 96 weeks
358924|NCT00673595|Drug|Varenicline|Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.
The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day.
358925|NCT00673595|Drug|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
358926|NCT00675961|Drug|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
358927|NCT00675961|Other|BCI + Naltrexone|Combination of the two previous interventions
358928|NCT00675961|Behavioral|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
358929|NCT00675974|Device|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
357949|NCT00673049|Drug|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
357950|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
357951|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
357952|NCT00673062|Drug|SCH 900538|(4X50mg Capsules)
357953|NCT00673062|Drug|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
357954|NCT00005092|Drug|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
357955|NCT00673062|Drug|Placebo Capsules|Placebo
357956|NCT00673075|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
357957|NCT00673075|Drug|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
357958|NCT00673088|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
357959|NCT00673114|Biological|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
357960|NCT00673127|Drug|Ketoconazole, Hydrocortisone and Dutasteride|Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.
Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal
357961|NCT00673140|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
357962|NCT00673140|Radiation|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
357963|NCT00673153|Drug|gemtuzumab ozogamicin|Given IV
357964|NCT00673153|Drug|vorinostat|Given orally
357965|NCT00005092|Drug|Thiotepa|IV over 2 hours on day 1
357966|NCT00673153|Other|laboratory biomarker analysis|Correlative studies
358266|NCT00680667|Biological|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
358267|NCT00005589|Procedure|bone marrow ablation with stem cell support|
357340|NCT00687128|Behavioral|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
357341|NCT00687128|Behavioral|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
357342|NCT00687141|Drug|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
357343|NCT00687141|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
357344|NCT00687154|Procedure|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
357345|NCT00005626|Drug|Irinotecan|Irinotecan as outlined in treatment arm
357346|NCT00687154|Procedure|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
357347|NCT00687167|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
357348|NCT00687167|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
357349|NCT00687180|Drug|Treatment with mycophenolat mofetil|
357350|NCT00687180|Drug|Treatment with azathioprin|
357351|NCT00687193|Drug|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
357352|NCT00687193|Drug|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
357353|NCT00687193|Drug|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
357354|NCT00687193|Drug|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
357355|NCT00687193|Drug|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
357356|NCT00005627|Drug|carboplatin|
357357|NCT00687193|Drug|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
357358|NCT00687206|Drug|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
357359|NCT00687219|Biological|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
356732|NCT00004206|Drug|fluorouracil|
356733|NCT00596947|Drug|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
356734|NCT00596947|Drug|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
357053|NCT00679705|Drug|Placebo|Glucose 5%, IV
357054|NCT00679718|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
357055|NCT00679731|Drug|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
357056|NCT00679731|Drug|Methotrexate|5.0 to 25 mg weekly
357057|NCT00005586|Drug|fluorouracil|
357058|NCT00679744|Drug|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
357059|NCT00679770|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
357060|NCT00679770|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
357061|NCT00679770|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
357062|NCT00679770|Drug|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
357063|NCT00679783|Drug|AZD2281|PARP inhibitor
357064|NCT00679796|Procedure|Varicella (chickenpox) lesion sampling|
357065|NCT00679835|Drug|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
357066|NCT00679848|Device|RS2 (RESTORe Suturing System)|Suturing in stomach
357067|NCT00679861|Behavioral|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
357068|NCT00005586|Procedure|adjuvant therapy|
356428|NCT00004228|Drug|doxorubicin hydrochloride|Given IV
356429|NCT00602082|Genetic|RNA analysis|
356430|NCT00602082|Genetic|protein analysis|
356431|NCT00604513|Other|Ready. Set. ACTION! Protocol|The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a "check-in" about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun & Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception.
356432|NCT00604513|Other|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
356433|NCT00604526|Radiation|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL
*After 1 year, will follow up with doctor about every 6 months.
356434|NCT00604539|Drug|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
356435|NCT00604539|Drug|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
356436|NCT00604552|Device|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
356735|NCT00596947|Drug|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
356736|NCT00596947|Drug|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
356737|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
356738|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
360959|NCT00638313|Biological|Placebo|Subjects will be given either Placebo or PF-04603629.
360960|NCT00638313|Biological|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
360961|NCT00638326|Drug|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
361297|NCT00670358|Drug|cyclophosphamide|
361298|NCT00670358|Drug|doxorubicin hydrochloride|
361299|NCT00670358|Drug|lenalidomide|
361300|NCT00005079|Procedure|conventional surgery|
361301|NCT00670358|Drug|prednisone|
361302|NCT00670358|Drug|vincristine sulfate|
361303|NCT00670358|Genetic|polymorphism analysis|
361304|NCT00670358|Other|laboratory biomarker analysis|
361305|NCT00670384|Biological|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
361306|NCT00670384|Biological|Placebo|Sublingual drops
361307|NCT00670397|Drug|HPPH|IV
361308|NCT00670410|Procedure|Related donor stem cell transplant|Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
361309|NCT00670410|Procedure|unrelated cord blood transplant|patients with an matched unrelated cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
361310|NCT00670423|Drug|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
361311|NCT00005080|Drug|nelarabine|Given IV
361312|NCT00670423|Drug|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
361313|NCT00670423|Drug|Bortezomib|Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:
Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3
Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3
Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3
361314|NCT00670436|Device|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
360653|NCT00686712|Drug|Insulin glargine|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings <120 mg/dL)
360654|NCT00686712|Drug|Insulin glargine|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings <120 mg/dL)
360655|NCT00686712|Drug|NPH insulin|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses <120 mg/dL)
360656|NCT00686725|Drug|Temozolomide|
360657|NCT00686725|Radiation|Radiotherapy|
360658|NCT00005619|Other|immunohistochemistry staining method|
360659|NCT00686751|Drug|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
360660|NCT00686764|Other|Observational|Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.
We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36).
360661|NCT00686777|Biological|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
360662|NCT00686777|Drug|Ribavirin|Ribavirin 400 mg/day orally
360663|NCT00686790|Biological|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
360664|NCT00686803|Drug|PL3994|Study drug
360962|NCT00638326|Drug|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
360963|NCT00638365|Biological|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
360964|NCT00638365|Other|Placebo|Placebo single-dose administered intravenously
360965|NCT00638378|Drug|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
360966|NCT00638391|Drug|Anastrozole|
360967|NCT00004807|Drug|dextromethorphan|
360968|NCT00638417|Procedure|Maximal strength training|Group 1 intervention: maximal strength training Group 2 intervention: conventional rehabilitation programme
360969|NCT00638456|Drug|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
360368|NCT00677027|Other|placebo|Placebo
360369|NCT00677053|Drug|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
360370|NCT00677053|Drug|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
360371|NCT00677053|Drug|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
360372|NCT00677053|Drug|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
360373|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
360374|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
360375|NCT00677053|Drug|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
360376|NCT00679393|Procedure|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
360377|NCT00679406|Behavioral|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
360378|NCT00679432|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
360379|NCT00679432|Drug|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
360380|NCT00679432|Drug|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
360381|NCT00679432|Drug|Placebo|Placebo
360665|NCT00686803|Drug|Placebo|Placebo
360666|NCT00686816|Dietary Supplement|Low calorie diet|low calorie diet
360667|NCT00686816|Dietary Supplement|Olestra|low calorie Olestra diet
360668|NCT00686829|Drug|Vicriviroc maleate|30 mg tablet for once daily oral administration until vicriviroc becomes commercially available.
360669|NCT00005622|Drug|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
359740|NCT00686166|Biological|cetuximab|Chemotherapy cycle 1: Cetuximab, 400 mg/m^2, IV, Day 1; Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29
Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78
359741|NCT00686166|Drug|capecitabine|Chemotherapy Cycle 1: Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)
Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)
359742|NCT00686166|Drug|oxaliplatin|Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29
Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78
359743|NCT00005616|Procedure|neoadjuvant therapy|
359744|NCT00686166|Procedure|therapeutic surgical procedure|Surgical resection
359745|NCT00686166|Radiation|radiation therapy|IMRT (intensity-modulated radiation therapy)
360065|NCT00693654|Drug|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
360066|NCT00693654|Drug|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
360067|NCT00693667|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
360068|NCT00693680|Dietary Supplement|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
360069|NCT00693680|Dietary Supplement|Placebo|placebo + imipramine (100-200mg/day)
360070|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% preparation ointment|Apply medication twice a day to affected areas. Moisturize as needed.
360071|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% preparation cream|Apply medication twice a day to affected areas. Moisturize as needed.
360072|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% preparation lipocream|Apply medication twice a day to affected areas. Moisturize as needed.
360073|NCT00005764|Drug|Lamivudine|
360074|NCT00693706|Biological|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
360075|NCT00693706|Biological|Fluarix|IM injection on Day 0
360076|NCT00693719|Drug|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
360077|NCT00693719|Drug|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
359431|NCT00678886|Biological|placebo infusion plus physician determined standard of care|infusion
359432|NCT00678899|Device|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
359433|NCT00678912|Device|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
359434|NCT00678925|Dietary Supplement|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
359435|NCT00678925|Dietary Supplement|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
359436|NCT00678938|Behavioral|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
359437|NCT00005584|Drug|vinblastine sulfate|
359746|NCT00686179|Drug|AZD3480|Capsule, oral, single dose, 6 days
359747|NCT00686179|Drug|Moxifloxacin|Capsule(encapsulated), oral, single dose
359748|NCT00686179|Drug|PLACEBO|Capsule, oral, single dose
359749|NCT00686192|Dietary Supplement|Calcium Carbonate|1500 mg per day
359750|NCT00686205|Device|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
359751|NCT00686218|Drug|imatinib mesylate|Given orally
359752|NCT00686218|Drug|panobinostat|Given orally
359753|NCT00686218|Genetic|polymerase chain reaction|Testing
359754|NCT00005616|Procedure|radionuclide imaging|
359755|NCT00686218|Genetic|protein expression analysis|Testing
359756|NCT00686218|Genetic|western blotting|Testing
359757|NCT00686218|Other|flow cytometry|Testing
359758|NCT00686218|Other|laboratory biomarker analysis|Testing
359759|NCT00686218|Other|pharmacological study|Testing
359760|NCT00686231|Drug|Nitroglycerin|1 inch of Nitroglycerin vs 2 inches of Nitroglycerin
359761|NCT00686231|Drug|Placebo|Sorbolene cream
359116|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
359117|NCT00693082|Dietary Supplement|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
359118|NCT00693095|Biological|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
359119|NCT00693095|Biological|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
359120|NCT00005762|Drug|Indinavir sulfate|
359121|NCT00671424|Drug|Remogliflozin etabonate (GSK189075)|
359122|NCT00005086|Drug|methotrexate|
359123|NCT00671424|Drug|Furosemide|
359124|NCT00671437|Procedure|FDG-PET/CT|
359125|NCT00671437|Drug|Cetuximab|
359126|NCT00671463|Procedure|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
359127|NCT00671476|Drug|pegylated liposomal doxorubicin hydrochloride|
359128|NCT00671476|Genetic|DNA methylation analysis|
359129|NCT00671476|Genetic|TdT-mediated dUTP nick end labeling assay|
359438|NCT00678938|Behavioral|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
359439|NCT00678964|Drug|Erlotinib|Erlotinib 150 mg, p.o., once daily
359440|NCT00678964|Drug|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
359441|NCT00678977|Drug|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
359442|NCT00678977|Drug|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
359443|NCT00678977|Drug|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
359444|NCT00678990|Procedure|Transplantation of islets with heparin coating|
358784|NCT00005603|Drug|asparaginase|
358785|NCT00683475|Biological|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
358786|NCT00683475|Drug|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m^2) or until there is evidence of disease progression, death, or intolerable toxicity.
358787|NCT00685633|Drug|enzastaurin hydrochloride|Given orally
358788|NCT00685646|Drug|antiandrogen therapy|Up to 24 courses of therapy
358789|NCT00685646|Drug|zoledronic acid|Up to 24 courses of therapy
358790|NCT00685659|Other|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
358791|NCT00685659|Other|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
358792|NCT00685659|Other|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
358793|NCT00685672|Drug|adrenalin|adrenalin 2 microgram pr ml placebo
358794|NCT00000670|Drug|Zidovudine|
358795|NCT00005612|Procedure|peripheral blood stem cell transplantation|
358796|NCT00685672|Drug|placebo|Saline instead of adrenaline in the epidural mixture
358797|NCT00685685|Drug|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
358798|NCT00685685|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
358799|NCT00685698|Drug|TG-873870 (Nemonoxacin)|750 mg
358800|NCT00685711|Biological|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
358801|NCT00685724|Behavioral|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
358802|NCT00685724|Behavioral|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
360795|NCT00658177|Drug|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
360796|NCT00004939|Drug|,4-diaminopyridine|
360797|NCT00660647|Drug|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
360798|NCT00660660|Drug|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
360799|NCT00660660|Drug|Placebo|once daily
360800|NCT00660673|Drug|Levodopa-carbidopa intestinal gel|should be kept within a range of 0.5-10 ml/hour (10-200 mg levodopa/hour) and is usually 2-6 ml/hour (40-120 mg levodopa/hour);
360801|NCT00660673|Device|CADD-Legacy® 1400 ambulatory infusion pump|pump
360802|NCT00660686|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
360803|NCT00660686|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
360804|NCT00660699|Drug|Gemcitabine|
360805|NCT00005000|Drug|Didanosine|
360806|NCT00660699|Drug|Docetaxel|
360807|NCT00660699|Radiation|Radiation|
361117|NCT00653094|Device|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
361118|NCT00653107|Procedure|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
361119|NCT00653107|Radiation|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
361120|NCT00004910|Procedure|bowel obstruction management|
361121|NCT00653107|Radiation|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
361122|NCT00653120|Drug|Propranolol|ER capsules, 160 mg, single-dose
360496|NCT00691457|Device|Clear Care contact lens solution|Solution
360497|NCT00691470|Drug|ATI-5923|Dose Adjusted based on INR.
360498|NCT00691470|Drug|Coumadin (warfarin)|Dose adjusted based on INR.
360499|NCT00691483|Drug|placebo|placebo tablet taken orally twice daily for 12 weeks
360500|NCT00691483|Drug|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
360501|NCT00691496|Behavioral|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
360502|NCT00005663|Drug|Valacyclovir hydrochloride|
360503|NCT00691509|Genetic|gene expression analysis|
360504|NCT00693901|Behavioral|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
360505|NCT00693914|Behavioral|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
360506|NCT00693927|Procedure|Unmanipulated PBSC after nonmyeloablative conditioning|Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).
Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor
360507|NCT00693927|Procedure|CD8-depleted PBSC after nonmyeloablative conditioning|
360508|NCT00693940|Behavioral|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
360509|NCT00693940|Other|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
360510|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
359894|NCT00676663|Drug|entinostat|SNDX-275 5mg tablet PO once/week
360207|NCT00684255|Procedure|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
360208|NCT00684255|Drug|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
360209|NCT00684255|Drug|Busulfan|Busulfan 3.2 mg/kg Days _8, -7, -6, -5
360210|NCT00684255|Drug|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
360211|NCT00684268|Drug|Silibinin|comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days
sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion
360212|NCT00684268|Drug|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
360213|NCT00684281|Other|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
360214|NCT00005604|Biological|aldesleukin|Given SC
360215|NCT00684281|Other|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
360216|NCT00684294|Biological|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10^7 cells/ injection or TAG Vaccine 2.5 X 10^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
360217|NCT00684307|Drug|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
360218|NCT00684307|Drug|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
360219|NCT00684307|Drug|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
360220|NCT00686426|Dietary Supplement|Dairy Foods|< 1 standard dairy serving/day
360221|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg on alternate weeks
360222|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg every other week
360223|NCT00686465|Other|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
360224|NCT00686478|Drug|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
359568|NCT00693381|Drug|Tacrolimus|oral
359569|NCT00693381|Drug|Mycophenolate Mofetil|oral
359570|NCT00693381|Drug|methylprednisolone and prednisone|IV and oral
359571|NCT00693407|Procedure|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS >30 is reported.
359572|NCT00693420|Drug|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
359573|NCT00693420|Drug|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
359895|NCT00676663|Drug|exemestane|exemestane 25mg PO QD
359896|NCT00005576|Drug|isotretinoin|Given orally
359897|NCT00676676|Drug|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
359898|NCT00676689|Device|SAPIEN Transcatheter Valve Implantation|Device Implantation
359899|NCT00676702|Dietary Supplement|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
359900|NCT00676702|Drug|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
359901|NCT00676715|Drug|interferon beta-1a|Intramuscular repeating dose
359902|NCT00676715|Drug|methylprednisolone|IV repeating dose
359903|NCT00676715|Drug|ocrelizumab|IV repeating dose
359904|NCT00676715|Drug|placebo|Intravenous repeating dose
359905|NCT00676728|Drug|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
359906|NCT00676741|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
359907|NCT00005576|Biological|aldesleukin|Given IV
359908|NCT00676741|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
358930|NCT00675974|Device|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
358931|NCT00675987|Drug|losartan|losartan 100 mg tablets 1 tab po QD
358932|NCT00675987|Drug|Placebo control|Placebo 1 po QD
358933|NCT00676000|Procedure|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
358934|NCT00005555|Behavioral|Exercise|
358935|NCT00676000|Procedure|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
358936|NCT00676013|Biological|AlloDerm|Application of AlloDerm over full thickness burn following excision
358937|NCT00676013|Procedure|Skin Biopsy|Tissue Biopsy of study sites (AlloDerm, Integra, Homograft, Autograft only)
358938|NCT00676013|Biological|Integra|Application of skin substitute over full thickness burn following excision.
358939|NCT00676013|Biological|Autograft|Application of autograft over full thickness burn injury following excision of burn wound.
359254|NCT00683735|Drug|Placebo|100mg 1-0-0-0
359255|NCT00683761|Drug|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
359256|NCT00683774|Drug|diazoxide|100mg orally three times per day for 10 days
359257|NCT00683787|Drug|docetaxel|Given IV once every 3 weeks
359258|NCT00005603|Drug|dexamethasone|
359259|NCT00683787|Drug|vandetanib|Oral vandetanib once daily
359260|NCT00683800|Drug|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
359261|NCT00683800|Drug|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
358268|NCT00680680|Drug|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
358269|NCT00680693|Behavioral|Mindfulness training|8 weekly 2-hour classes
358270|NCT00680693|Behavioral|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
358271|NCT00680706|Drug|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
358272|NCT00680706|Drug|Placebo|D5W (50 ml)
358273|NCT00680719|Behavioral|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
358274|NCT00680719|Behavioral|IBFT|Integrated Behavioral and Family Therapy (IBFT).
358275|NCT00680732|Dietary Supplement|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
358276|NCT00680732|Dietary Supplement|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
358277|NCT00680732|Drug|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
358278|NCT00005589|Procedure|peripheral blood stem cell transplantation|
358279|NCT00680732|Drug|Sulphadoxyne-pyrimethamine (SP)|Tablets
358280|NCT00680745|Drug|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
358281|NCT00680745|Drug|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
358282|NCT00680745|Drug|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
358283|NCT00680745|Drug|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
358284|NCT00680745|Drug|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
358285|NCT00683046|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
358286|NCT00683046|Drug|Stem cells|Stem cell infusion on day 0.
358287|NCT00683046|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
358288|NCT00683059|Drug|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
357360|NCT00687219|Drug|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and <14g/dL; treatment duration is 48 weeks
357661|NCT00692016|Drug|Naproxen sodium|Administered under fed condition
357662|NCT00692042|Drug|AZD1704|One dose, by mouth
357663|NCT00694551|Biological|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
357664|NCT00694551|Drug|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
357665|NCT00694564|Drug|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
357666|NCT00694577|Radiation|Partial Breast Irradiation|32 Gy-8 Treatments, 4 Treatment Days
357667|NCT00694577|Radiation|Partial Breast Irradiation|36 Gy- 9 Treatments, 4 1/2 Treatment Days
357668|NCT00694577|Radiation|Partial Breast Irradiation|40 Gy-10 Treatments, 5 Treatment days
357669|NCT00694590|Drug|plerixafor|Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.
Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses.
357670|NCT00694603|Drug|Cetuximab|Given intravenously once per week.
357671|NCT00694616|Device|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
357672|NCT00694616|Device|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
357673|NCT00005773|Drug|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
357674|NCT00694629|Drug|rifampin|tablet, 10 mg/kg, daily, 8 weeks
357675|NCT00694629|Drug|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
357676|NCT00694629|Drug|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
357677|NCT00694629|Drug|rifapentine|20 mg/kg, daily, 8 weeks
357069|NCT00679861|Behavioral|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
357070|NCT00679874|Other|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
357071|NCT00679887|Procedure|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
357072|NCT00682318|Dietary Supplement|Omega-3 polyunsaturated fatty acids|Part 2b:
Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;
Part 3:
Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b.
357073|NCT00682318|Dietary Supplement|Omega-6 polyunsaturated fatty acid|Part 2b:
Control omega-6 fatty acid alimentary diet (<130 mg/day EPA/DHA)
357074|NCT00682344|Drug|Levobupivacaïne|1,75mg/kg
357075|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
357361|NCT00689572|Drug|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
357362|NCT00689572|Drug|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
357363|NCT00005641|Biological|anti-thymocyte globulin|
357364|NCT00689585|Drug|Placebo|250mg matching placebo capsules
357365|NCT00689585|Drug|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
357366|NCT00689598|Drug|Spironolactone|25 mg po qd 25 mg po bid
357367|NCT00689598|Drug|Placebo|Spironolactone 25 mg po qd
357368|NCT00689611|Drug|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
357369|NCT00689611|Drug|Placebo|Placebo
357370|NCT00689624|Drug|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
357371|NCT00689624|Drug|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
357372|NCT00689624|Drug|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
357373|NCT00689624|Drug|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
356739|NCT00596960|Behavioral|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
356740|NCT00596960|Behavioral|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
356741|NCT00596973|Procedure|Surgical Treatment|Ileal transposition with sleeve gastrectomy
356742|NCT00596986|Drug|Duloxetine|Duloxetine 30mg up to 120mg per day.
356743|NCT00004206|Drug|leucovorin calcium|
356744|NCT00596986|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
356745|NCT00596999|Procedure|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
356746|NCT00597012|Procedure|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
356747|NCT00599690|Procedure|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
356748|NCT00599703|Other|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
356749|NCT00599716|Drug|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
356750|NCT00599716|Drug|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
357076|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
357077|NCT00682357|Drug|Placebo and Lidocaine|Placebo and lidocaine 20 mg
357078|NCT00682370|Drug|saline solution|intravenous infusion, single dose
357079|NCT00682370|Drug|heme arginate|intravenous infusion, single dose
0.3 mg/kg heme arginate
357080|NCT00682370|Drug|heme arginate|intravenous infusion, single dose
1 mg/kg heme arginate
357081|NCT00682370|Drug|heme arginate|intravenous infusion, single dose
3 mg/kg heme arginate
357082|NCT00005596|Drug|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
361315|NCT00670436|Device|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
361316|NCT00670449|Drug|Fingolimod|Fingolimod was supplied in capsules.
361317|NCT00633828|Behavioral|Daily School physical education|Daily School physical education 40 minutes per day
361318|NCT00633841|Biological|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
356437|NCT00604565|Drug|soluble ferric pyrophosphate (SFP)|Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).
Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)
356438|NCT00604565|Other|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
356439|NCT00604578|Drug|Pioglitazone Hydrochloride|
356440|NCT00604591|Drug|Tolcapone|200 mg by mouth three times a day
356441|NCT00004233|Drug|leucovorin calcium|
356442|NCT00604604|Behavioral|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
356443|NCT00604617|Procedure|Interferon-Gamma Release Assay|IGRAs
356444|NCT00604617|Drug|RT-23|TST - tuberculin skin test
356445|NCT00604630|Drug|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
356446|NCT00604630|Drug|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
356447|NCT00604643|Device|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
356448|NCT00604656|Drug|insulin aspart|
356449|NCT00604682|Drug|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
356450|NCT00604695|Drug|Tenecteplase|Intracoronary injection of IV tenecteplase.
356451|NCT00607230|Biological|BCG|BCG vaccination at 0 and 4 weeks
356452|NCT00607230|Biological|Saline|Saline vaccination at 0 and 4 weeks
360970|NCT00638456|Drug|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
360971|NCT00638469|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
360972|NCT00638469|Other|No treatment|no UV exposure
360973|NCT00638482|Drug|Hydrochlorothiazide|Hydrochlorothiazide
360974|NCT00638495|Drug|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
360975|NCT00638495|Drug|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
360976|NCT00638508|Drug|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
360977|NCT00638508|Drug|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
360978|NCT00004807|Drug|topiramate|
360979|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
360980|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
360981|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
360982|NCT00640848|Drug|almorexant|1 dose of 400 mg in two treatment sequences
360983|NCT00640848|Drug|almorexant|1 dose of 200 mg in two treatment sequences
360984|NCT00640848|Drug|almorexant|1 dose of 100 mg in two treatment sequences
361319|NCT00633854|Procedure|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
361320|NCT00633867|Device|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
361321|NCT00633867|Device|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
361322|NCT00633880|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
360670|NCT00686842|Drug|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
360671|NCT00686842|Genetic|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
360672|NCT00686842|Genetic|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
360673|NCT00686842|Genetic|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
360674|NCT00686842|Other|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
360675|NCT00686842|Other|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
360676|NCT00648037|Drug|Rituximab|Rituximab 375 mg/m^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is > 200 cells/ul or a maximum of 6 doses have been given.
360677|NCT00004896|Procedure|allogeneic bone marrow transplantation|
360678|NCT00648050|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
360679|NCT00648050|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
360680|NCT00648063|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
360681|NCT00648063|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
360682|NCT00648076|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
360683|NCT00648076|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fed
360684|NCT00648089|Drug|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
360685|NCT00648102|Biological|CDX-1307|
360686|NCT00648115|Other|Basic Vocational Services|Vocational services
360985|NCT00640848|Drug|almorexant|1 dose of 50 mg mg in two treatment sequences
360986|NCT00640848|Drug|almorexant|1 dose of 1000 mg in two treatment sequences
360987|NCT00640861|Biological|CpG oligodeoxynucleotide|
360078|NCT00693732|Drug|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
360079|NCT00693732|Behavioral|Quantitative sensory testing|Rectal Distention Stimulation
360080|NCT00693758|Drug|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
360081|NCT00693758|Other|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
360082|NCT00693758|Other|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
360083|NCT00671996|Drug|Mangafodipir|Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.
Formulation content: MnDPDP 10 mmol/ml
Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy.
360382|NCT00679432|Drug|Asacol® 400 mg|2400 mg/day, 400 mg tablets
360383|NCT00679445|Device|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
360384|NCT00679458|Drug|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
360385|NCT00679458|Drug|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
360386|NCT00005585|Drug|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
360387|NCT00679484|Drug|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
360388|NCT00679484|Drug|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
360389|NCT00679497|Biological|MVA-B|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml
3 immunisations at week 0, 4 and 16
360390|NCT00679497|Biological|Placebo|-3 immunisations at week 0, 4 and 16
359762|NCT00686231|Drug|Lidocaine|Visit 2 lidocaine 1 inch + best dose Nitro vs Placebo + lidocaine
359763|NCT00686244|Other|Combined 3-monthly endurance and strength training|Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).
Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism
359764|NCT00688649|Dietary Supplement|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
359765|NCT00688662|Procedure|ERCP with biliary sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
359766|NCT00688662|Procedure|ERCP with biliary and pancreatic sphincterotomies|cutting the biliary and pancreatic sphincter muscles (sphincterotomy)
359767|NCT00688662|Procedure|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
359768|NCT00688688|Drug|Mirabegron|Tablets
359769|NCT00005636|Drug|cisplatin|
360084|NCT00005089|Drug|cyclophosphamide|750 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
360085|NCT00671996|Drug|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
360086|NCT00672009|Drug|Ixabepilone|Ixabepilone 35 mg/m^2 intravenously over 3 hours every 21 days for 4 cycles.
360087|NCT00672022|Drug|Zavesca (Miglustat)|
360088|NCT00672035|Biological|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
360089|NCT00672048|Other|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
360090|NCT00672048|Other|Continuing Education Course|Annual standard continuing education
360091|NCT00672048|Other|Continuing education|Annual standard continuing education materials
360092|NCT00672061|Drug|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
360093|NCT00672074|Drug|Ipamorelin|IV
360094|NCT00672074|Drug|placebo|IV
360095|NCT00005089|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
359445|NCT00679003|Behavioral|SLCBT|Social learning and cognitive behavioral therapy
359446|NCT00679003|Behavioral|ES|Education and support (information about nutrition and gastrointestinal system)
359447|NCT00679029|Drug|doxorubicin hydrochloride|Given IV
359448|NCT00005584|Radiation|radiation therapy|
359449|NCT00679029|Drug|cyclophosphamide|Given IV
359450|NCT00679029|Biological|bevacizumab|Given IV
359451|NCT00679029|Drug|paclitaxel|Given IV
359452|NCT00679029|Drug|gemcitabine hydrochloride|Given IV
359453|NCT00679029|Other|laboratory biomarker analysis|Correlative studies
359454|NCT00679029|Biological|pegfilgrastim|Given subcutaneously
359455|NCT00681434|Behavioral|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
359456|NCT00681447|Procedure|Lumbar Interlaminar Epidural|Lumbar interlaminar epidural injections under fluoroscopy
Epidural tray and needle
Drugs:
0.5% Xylocaine and non-particulate Celestone
359457|NCT00681447|Procedure|Lumbar Interlaminar Epidural injection|Lumbar interlaminar epidural injections under fluoroscopy
Epidural tray and needle
Drugs:
0.5% Xylocaine and non-particulate Celestone
359458|NCT00681460|Drug|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
359459|NCT00681460|Drug|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
359460|NCT00681473|Radiation|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
359770|NCT00688688|Drug|Tolterodine|Extended release capsules
359771|NCT00688688|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
359772|NCT00688688|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
359773|NCT00688701|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
359774|NCT00688701|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
359775|NCT00688701|Device|Pen auto-injector|
359130|NCT00671476|Genetic|fluorescence in situ hybridization|
359131|NCT00671476|Genetic|loss of heterozygosity analysis|
359132|NCT00671476|Genetic|polymerase chain reaction|
359133|NCT00005087|Biological|filgrastim|
359134|NCT00671476|Other|immunoenzyme technique|
359135|NCT00671476|Other|immunohistochemistry staining method|
359136|NCT00671476|Other|laboratory biomarker analysis|
359137|NCT00671476|Procedure|breast duct lavage|
359138|NCT00671476|Procedure|neoadjuvant therapy|
359139|NCT00671476|Procedure|therapeutic conventional surgery|
359140|NCT00671489|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
359141|NCT00671502|Drug|Carisoprodol SR|700 mg twice daily
359142|NCT00671502|Drug|Carisoprodol SR|500 mg twice daily
359143|NCT00671502|Drug|Placebo|Placebo tablet
359144|NCT00005087|Drug|cisplatin|
359145|NCT00671515|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
359146|NCT00671528|Drug|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
359147|NCT00671528|Drug|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
359148|NCT00671528|Drug|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
359149|NCT00673608|Drug|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
361123|NCT00653120|Drug|Inderal-LA|ER capsules, 160 mg, single-dose
361124|NCT00653133|Device|Ultrasound imaging|Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic
361125|NCT00653133|Device|Peripheral nerve stimulator|either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
361126|NCT00653146|Behavioral|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
361127|NCT00653146|Behavioral|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
361128|NCT00653159|Device|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
361129|NCT00653159|Device|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
361130|NCT00004921|Procedure|bone marrow ablation with stem cell support|
361131|NCT00655642|Drug|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
361132|NCT00655642|Drug|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
361133|NCT00655642|Drug|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
361134|NCT00655655|Drug|everolimus|Given orally
361135|NCT00655655|Drug|vatalanib|Given orally
361136|NCT00655655|Other|pharmacological study|Correlative study (Cohort IIA only)
361137|NCT00655655|Other|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
361461|NCT00648375|Drug|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
361462|NCT00004897|Drug|fluorouracil|
361463|NCT00648375|Drug|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
361464|NCT00648375|Behavioral|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
360808|NCT00660725|Drug|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
360809|NCT00660725|Drug|Gemcitabine|30-minute IV infusion of 1000 mg/m^2 gemcitabine on Day 1 of each 14-day cycle.
360810|NCT00660725|Drug|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m^2 oxaliplatin on Day 1 of each 14-day cycle.
360811|NCT00660751|Drug|Duloxetine|SNRIs
360812|NCT00660764|Drug|Rosuvastatin|Oral
360813|NCT00660777|Behavioral|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
360814|NCT00660777|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
360815|NCT00660803|Drug|Fulvestrant|
360816|NCT00005001|Biological|HIV-1 Immunogen|
360817|NCT00660816|Drug|erlotinib hydrochloride|Given orally once daily on days 2-19.
360818|NCT00660816|Drug|pemetrexed disodium|Given IV over 10 minutes on day 1
360819|NCT00660816|Drug|docetaxel|IV over 60 minutes on day 1.
360820|NCT00660829|Drug|Placebo|Placebo
360821|NCT00663091|Drug|Bacteriophage|WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages ("component bacteriophages" or "component phages") lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
360822|NCT00663091|Drug|WPP-201 Bacteriophage|WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages ("component bacteriophages" or "component phages") lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
361138|NCT00655655|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
360225|NCT00005617|Procedure|leukapheresis|Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
360226|NCT00686504|Drug|AZD2066|single dose of oral dose, 3 times per subject
360511|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
360512|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
360513|NCT00005768|Drug|Estrogen|
360514|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
360515|NCT00693979|Device|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
360516|NCT00693992|Other|Laboratory Biomarker Analysis|Correlative studies
360517|NCT00693992|Other|Placebo|Given PO
360518|NCT00693992|Other|Quality-of-Life Assessment|Ancillary studies
360519|NCT00693992|Drug|Sunitinib Malate|Given PO
360520|NCT00694005|Procedure|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
360521|NCT00694005|Procedure|without kissing balloon angioplasty "leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
360522|NCT00694018|Other|Education and standard care|Educational program for individuals with chronic back pain.
360523|NCT00672308|Other|Benefiber with ORS|
360524|NCT00672308|Other|Benefiber with ORS|
360525|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
360526|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
360527|NCT00672321|Genetic|gene expression analysis|
359909|NCT00676741|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
359910|NCT00676754|Procedure|Statens Serum Institut RT23 2TU tuberculin|
359911|NCT00676767|Dietary Supplement|Resistant Starch Type 4|
359912|NCT00676767|Dietary Supplement|Dextrose|
359913|NCT00676767|Dietary Supplement|Puffed wheat|
359914|NCT00676780|Drug|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
359915|NCT00676793|Drug|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
359916|NCT00679198|Behavioral|nurse-patient communication|We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.
Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting.
359917|NCT00679211|Drug|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
360227|NCT00686504|Drug|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
360228|NCT00686517|Biological|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
360229|NCT00686517|Drug|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
360230|NCT00686530|Procedure|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
360231|NCT00686530|Procedure|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
360232|NCT00686543|Drug|Posaconazole|Posaconazole will be used for prophylaxis
360233|NCT00686556|Drug|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
360234|NCT00686556|Drug|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of >200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
360235|NCT00686556|Drug|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
360236|NCT00005618|Drug|arsenic trioxide|
359262|NCT00685893|Behavioral|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
359263|NCT00685893|Behavioral|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
359264|NCT00685906|Drug|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
359265|NCT00685906|Drug|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
359266|NCT00685919|Drug|Carbidopa|200 mg every 6 hours for 5 doses given orally
359267|NCT00685919|Drug|Placebo|every 6 hours for 5 doses, given orally, and matching Intervention 1
359268|NCT00685932|Device|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
359269|NCT00005614|Drug|Gemcitabine hydrochloride|Gemcitabine via IV
359270|NCT00685945|Drug|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
359574|NCT00693433|Drug|dexamethasone|Given orally
359575|NCT00693433|Drug|temsirolimus|Given IV
359576|NCT00693433|Other|laboratory biomarker analysis|Correlative studies
359577|NCT00005762|Drug|Efavirenz|
359578|NCT00693446|Drug|Sirolimus|In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.
In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.
The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.
The dose of sirolimus will be administrated once a day.
359579|NCT00693446|Drug|Tacrolimus|Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.
The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.
Patients receive also rATG , mycophenolate mofetil and corticosteroids.
358610|NCT00690066|Drug|Placebo|Intravenous infusion of excipients of PROCHYMAL®
358611|NCT00690079|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol*h/L
358612|NCT00690079|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
358613|NCT00690092|Biological|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
358614|NCT00005641|Radiation|radiation therapy|
358615|NCT00690105|Drug|tacrolimus 0.1%|ointment
358616|NCT00690105|Drug|fluticasone 0.005 %|ointment
358617|NCT00690118|Drug|pioglitazone|45 mg/day, 18 months
358618|NCT00690118|Drug|placebo|once daily, 18 months
358619|NCT00690131|Behavioral|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
358620|NCT00690144|Device|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
358621|NCT00690170|Drug|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
358622|NCT00690170|Drug|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
358623|NCT00690170|Drug|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
358624|NCT00690170|Drug|Ketamine and Nicotine|0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.
13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)
358625|NCT00005642|Drug|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
358940|NCT00676013|Biological|Homograft|Application of homograft skin over full thickness burn injury following excision of burn wound.
357678|NCT00694642|Biological|Selected CD 133+ cells|Endothelial progenitor cell CD 133
357679|NCT00694655|Biological|Yellow fever vaccine|YFV will be given as injection
357680|NCT00694668|Behavioral|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
357681|NCT00694668|Behavioral|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
357967|NCT00673166|Procedure|Staff incentive & supervision|Control & management of funds for incentive of staff; supervision
357968|NCT00673166|Behavioral|Staff motivation|Supervision, control of funds
357969|NCT00673179|Drug|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m^2.
357970|NCT00675467|Behavioral|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
357971|NCT00675480|Procedure|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
357972|NCT00675480|Procedure|Primary angioplasty|Standard primary angioplasty with stent implantation
357973|NCT00000660|Drug|Etoposide|
357974|NCT00005119|Procedure|Measures of calcium and bone turnover|
357975|NCT00675493|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
357976|NCT00675506|Drug|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
357977|NCT00675506|Drug|Placebo|2-mg sub-cutaneous injections once daily for 12 months
357978|NCT00675519|Behavioral|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
357979|NCT00675532|Behavioral|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
357374|NCT00005641|Drug|busulfan|
357375|NCT00689624|Drug|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
357376|NCT00689637|Drug|AZD3480|AZD3480 capsules qd, 12 days
357377|NCT00689637|Drug|Placebo|Placebo capsules qd, 12 days
357378|NCT00689637|Drug|Warfarin|Warfarin: single dose on day 6
357379|NCT00689650|Device|1540 nm fractional laser|
357380|NCT00689663|Procedure|Laparoscopic cholecystectomy|Randomized to three arm.
357381|NCT00689689|Device|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
357382|NCT00689689|Device|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
357383|NCT00689702|Drug|cetuximab, capecitabine|Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).
Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.
Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks.
357682|NCT00694681|Behavioral|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
357683|NCT00694694|Drug|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
357684|NCT00005774|Drug|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
357685|NCT00670605|Other|study of socioeconomic and demographic variables|
357686|NCT00670618|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
357687|NCT00670618|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
357688|NCT00670618|Device|Fluoride (Elmex Medical Gel)|Fluoride
357689|NCT00670631|Other|tandem autologous transplantation|DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.
Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.
Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.
Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 & 15-18 every cycle.
Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle.
357083|NCT00682383|Drug|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|Cisplatin 75 mg/m2 day 1 and 22
Etoposide 80mg/m2 days 1-3, 22-24
Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)
Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34
Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles
Pegfilgrastim 6 mg SQ injection day 2 of each cycle
357084|NCT00682409|Other|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
357085|NCT00682435|Drug|Hydromorphone|1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers "yes" to the question, "Do you want more pain medication?"
357086|NCT00682448|Drug|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
357087|NCT00682448|Drug|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
357088|NCT00682461|Drug|Nicotine|Marketed nicotine replacement therapy formulation
357089|NCT00682461|Drug|Nicotine|Nicotine prototype
357090|NCT00682474|Behavioral|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
357091|NCT00682474|Behavioral|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
357092|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
357093|NCT00005597|Drug|temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
357094|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
357095|NCT00682500|Drug|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
357384|NCT00689715|Procedure|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
356453|NCT00607243|Biological|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
356454|NCT00607256|Drug|[S,S]-reboxetine|S_S reboxetine dosed daily.
356455|NCT00607269|Behavioral|Voucher-Based Reinforcement Therapy|Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).
Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol <0.05) urine sample.
356456|NCT00004250|Biological|dactinomycin|
356751|NCT00599742|Behavioral|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
356752|NCT00599742|Behavioral|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
356753|NCT00599755|Radiation|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
356754|NCT00000613|Behavioral|diet, soy proteins|
356755|NCT00004218|Drug|cyclophosphamide|
356756|NCT00599755|Drug|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
356757|NCT00599768|Other|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
356758|NCT00599781|Genetic|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
356759|NCT00599807|Dietary Supplement|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
356760|NCT00599820|Drug|Intravitreal Bevacizumab|
356761|NCT00599833|Biological|cetuximab|
356762|NCT00599833|Radiation|3-dimensional conformal radiation therapy|
356763|NCT00599859|Dietary Supplement|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
356764|NCT00599859|Dietary Supplement|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
361323|NCT00633880|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
361324|NCT00633893|Drug|Apixaban|Tablets, Oral, twice daily, 12 months
361325|NCT00633893|Drug|Placebo|Tablets, Oral, twice daily, 12 months
361326|NCT00633906|Behavioral|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
361327|NCT00000636|Drug|Rifampin|
361328|NCT00004736|Drug|Lamivudine|
361329|NCT00633906|Behavioral|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
361330|NCT00633919|Biological|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
361331|NCT00633919|Biological|Placebo|Sublingual immunotherapy once daily for 2 years
361332|NCT00633919|Drug|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
361333|NCT00633919|Drug|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
361334|NCT00633919|Drug|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
361335|NCT00633919|Drug|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
361336|NCT00633919|Drug|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
361337|NCT00633932|Drug|Esomeprazole|20mg once daily
361338|NCT00633932|Drug|Esomeprazole|40 mg once daily
356457|NCT00607282|Drug|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
356458|NCT00607295|Drug|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
356459|NCT00607308|Biological|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
356460|NCT00607308|Biological|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
360988|NCT00004852|Drug|Zidovudine|
360989|NCT00640861|Biological|HER-2/neu peptide vaccine|
360990|NCT00640861|Biological|MUC-1 peptide vaccine|
360991|NCT00640861|Biological|incomplete Freund's adjuvant|
360992|NCT00640861|Biological|sargramostim|
360993|NCT00640861|Other|immunoenzyme technique|
360994|NCT00640861|Other|immunologic technique|
360995|NCT00640887|Drug|rifabutin in combination with efavirenz|Ia. arm 1a:
D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);
Ib. arm 1b:
D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);
360996|NCT00640887|Drug|rifabutin in combination with nevirapine|IIa. arm 2a:
D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);
IIb. arm 2b :
D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);
360997|NCT00640887|Drug|rifabutin in combination with lopinavir/ritonavir|IIIa. arm 3a :
D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);
IIIb. arm 3b:
D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks).
360998|NCT00640900|Behavioral|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
360999|NCT00000639|Drug|Amphotericin B|
361000|NCT00004853|Biological|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC & gt; =10,000/microliter
361001|NCT00640900|Behavioral|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
361002|NCT00640913|Procedure|Reversal of defunctioning stoma|Reversal of defunctioning stoma
361003|NCT00640926|Drug|Radezolid|300 mg/day, orally for 7-10 days
361004|NCT00640926|Drug|Radezolid|450 mg/day orally for 7-10 days
361005|NCT00640926|Drug|Radezolid|900 mg/day orally for 7-10 days
361006|NCT00640939|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
361007|NCT00643162|Drug|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
361008|NCT00643162|Behavioral|Light touch|Light touch twice a week, for 8 weeks
360391|NCT00679510|Drug|rosuvastatin|tablet 10 mgs once daily
360392|NCT00679510|Drug|placebo|placebo
360393|NCT00679523|Drug|AN2690 Solution, 5.0%|Once daily application for 180 days
360394|NCT00679523|Drug|AN2690 Solution, 7.5%|Once daily application for 180 days
360395|NCT00679536|Drug|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
360396|NCT00679536|Drug|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m^2/day.
360397|NCT00005596|Drug|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC > 500/μL and platelets > 75,000/uL
360398|NCT00682019|Drug|Placebo|matching placebo
360399|NCT00682032|Dietary Supplement|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
360687|NCT00648115|Other|Self-Study|Veteran receives self-study resources
360688|NCT00004896|Procedure|bone marrow ablation with stem cell support|
360689|NCT00648115|Other|Group Program|Veteran participates in group vocational program
360690|NCT00648128|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
360691|NCT00648128|Drug|Clarithromycin|single-dose 500 mg immediate-release oral dose`
360692|NCT00648141|Drug|Celecoxib|200 mg oral capsule once daily for 12 weeks
360693|NCT00648141|Drug|Celecoxib|200 mg oral capsule twice daily for 12 weeks
360694|NCT00648141|Drug|Diclofenac|75 mg oral capsule twice daily for 12 weeks
360695|NCT00648154|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
360696|NCT00648154|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fed
360697|NCT00648167|Drug|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
360698|NCT00648180|Drug|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
360096|NCT00672087|Genetic|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
360097|NCT00672100|Drug|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
360098|NCT00672100|Drug|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
360099|NCT00672100|Drug|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
360100|NCT00672113|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
360101|NCT00672113|Drug|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
360102|NCT00672139|Drug|Methylnaltrexone bromide|Methynaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study)
360103|NCT00672152|Biological|WT1 derived peptides|WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:
WT peptide #1: HLA-A2 restricted: RMFPNAPYL
WT peptide #2: HLA-A24 restricted: CMTWNQMNL
WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL
WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT
Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs.
360104|NCT00674245|Drug|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
360400|NCT00682058|Procedure|Surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures in this study. Follow-up measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
360401|NCT00682084|Procedure|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
360402|NCT00682097|Drug|RO4998452|Escalating oral doses
360403|NCT00682097|Drug|placebo|Oral doses
360404|NCT00682123|Dietary Supplement|19-norandrostendione|Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.
The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects.
360405|NCT00682136|Procedure|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
360406|NCT00682149|Dietary Supplement|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
359776|NCT00688714|Drug|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
359777|NCT00688714|Drug|Placebo|
359778|NCT00688727|Behavioral|CBT|CBT, up to 12 sessions.
359779|NCT00688727|Behavioral|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
359780|NCT00005636|Drug|pemetrexed disodium|
359781|NCT00688740|Drug|Docetaxel|intravenous
359782|NCT00688740|Drug|5-fluorouracil|intravenous
359783|NCT00688740|Drug|Doxorubicin|intravenous
359784|NCT00688740|Drug|Cyclophosphamide|intravenous
359785|NCT00688753|Drug|RAD001|
359786|NCT00688766|Drug|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
359787|NCT00688766|Drug|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
359788|NCT00688766|Other|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
359789|NCT00688779|Drug|AZD8848|Concentrate for nasal spray,solution 60 mg/g
359790|NCT00688779|Drug|Placebo|
359791|NCT00005637|Drug|carmustine|
359792|NCT00688805|Drug|Propranolol|40 mg given as a single oral administration in an opaque capsule
359793|NCT00005648|Drug|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
360105|NCT00674245|Drug|placebo|40 mg once daily for 4 weeks
360106|NCT00674258|Biological|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
360107|NCT00674297|Drug|Fluvastatin|Fluvastatin 40 mg daily for 3 months
359150|NCT00005095|Other|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
359151|NCT00673621|Drug|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
359461|NCT00681486|Drug|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
359462|NCT00681486|Drug|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
359463|NCT00005594|Drug|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
359464|NCT00681512|Dietary Supplement|berry powder|All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.
The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.
All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks.
359465|NCT00681525|Drug|ABT-335|One ABT-335 135 mg capsule QD for 10 days
359466|NCT00681525|Drug|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
359467|NCT00681525|Drug|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
359468|NCT00681538|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
359469|NCT00681538|Drug|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
359470|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
359471|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
359472|NCT00681564|Procedure|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session
Tongue brushing with a 1% chlorhexidine gel (1 minute)
Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)
Subgingival chlorhexidine (1%) irrigation in all pockets
Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention
Basic oral hygiene instructions
Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
359473|NCT00681564|Procedure|Periodontal care|Basic oral hygiene instructions
Supragingival plaque removal
359474|NCT00005595|Drug|arsenic trioxide|
361465|NCT00648388|Drug|Cilostazol Tablets 100 mg|100mg, single dose fasting
361466|NCT00648388|Drug|Pletal® Tablets 100 mg|100 single dose fasting
361467|NCT00648401|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
361468|NCT00648401|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
361469|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
361470|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
361471|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
361472|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
361473|NCT00004897|Drug|hydroxyurea|
361474|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
361475|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
361476|NCT00648427|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
361477|NCT00648427|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
361478|NCT00648440|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
361479|NCT00648440|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
361480|NCT00648453|Drug|Clopidogrel (Plavix)|
361481|NCT00648466|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
361482|NCT00648466|Drug|Imitrex® Tablets 100 mg|100mg, single dose fasting
356595|NCT00621569|Behavioral|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
356596|NCT00621595|Dietary Supplement|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
361139|NCT00655655|Procedure|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
361140|NCT00655668|Drug|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
361141|NCT00004921|Procedure|peripheral blood stem cell transplantation|
361142|NCT00655681|Drug|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children < 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
361143|NCT00655681|Other|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
361144|NCT00655694|Procedure|sputum, blood, urine, exhaled breath, lung function|
361145|NCT00655707|Biological|Autologous Expanded CD34+ Haemopoietic cells|Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.
Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells
361146|NCT00655720|Other|infant formula|hydrolyzed infant formula without probiotics
hydrolyzed infant formula with probiotics
hydrolyzed infant formula with probiotics
361147|NCT00655733|Drug|HMPL004|HMPL004 1200mg/d
361148|NCT00655733|Drug|Placebo|Placebo
361149|NCT00655746|Drug|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
361150|NCT00655772|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
361151|NCT00655785|Biological|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
361152|NCT00004922|Drug|irinotecan hydrochloride|
361153|NCT00655785|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
361154|NCT00655798|Dietary Supplement|Placebo|plain yogurt and capsules containing cellulose
361155|NCT00658177|Drug|Placebo|Matching placebo
361156|NCT00658203|Device|New Living CHF|PEA CRT optimization
361157|NCT00658203|Device|New Living CHF|Standard optimized CRT.
360528|NCT00005089|Radiation|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
360529|NCT00672321|Genetic|mutation analysis|
360530|NCT00672321|Genetic|polymorphism analysis|
360531|NCT00672321|Other|laboratory biomarker analysis|
360532|NCT00672321|Other|questionnaire administration|
360823|NCT00663091|Drug|Bacteriophages|WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages ("component bacteriophages" or "component phages") lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
360824|NCT00663104|Behavioral|exercise|exercise: 3 joint sessions/week for 12 months
360825|NCT00663104|Behavioral|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
360826|NCT00663104|Behavioral|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
360827|NCT00663117|Drug|Naltrexone-HCl|naltrexone 4.5 mg
360828|NCT00005023|Biological|HER-2/neu peptide vaccine|
360829|NCT00663117|Drug|Placebo|Placebo
360830|NCT00663130|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
360831|NCT00663130|Drug|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
360832|NCT00663143|Procedure|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
360833|NCT00663156|Procedure|breast implants|patients will have breast augmentation using implants
360834|NCT00663156|Procedure|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
360835|NCT00663169|Biological|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
360237|NCT00686556|Drug|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients <40 kg, 3 gm/day for patients >40 kg.
360238|NCT00686556|Radiation|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
360239|NCT00686556|Procedure|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
360240|NCT00686556|Biological|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10^9/L for 3 consecutive days.
360241|NCT00688987|Drug|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
360242|NCT00688987|Dietary Supplement|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
360243|NCT00689000|Drug|CHR-2797 (tosedostat): Aminopeptidase inhibitor|Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort
Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study
360533|NCT00672334|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
360534|NCT00672334|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
360535|NCT00672347|Drug|Clonidine|1 mcg/kg
360536|NCT00672347|Drug|Morphine|20 mcg/kg
360537|NCT00672347|Drug|Bupivacaine plus clonidine and morphine|bupivacaine 0,166% 1 ml/kg
clonidine 1 mcg/kg
morphine 20 mcg/kg
360538|NCT00672347|Drug|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
360539|NCT00005090|Biological|bleomycin sulfate|10 U/m^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
360540|NCT00672360|Dietary Supplement|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
360541|NCT00672360|Dietary Supplement|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
359580|NCT00693459|Device|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
359581|NCT00693472|Drug|Preladenant|one 25 mg capsule twice daily for 13 days
359582|NCT00693472|Drug|Placebo|Matching placebo capsule twice daily for 13 days
359583|NCT00693472|Drug|Preladenant|one 25 mg capsule twice daily for 13 days
359584|NCT00693472|Drug|Anticholinergic agents or propanolol|Standard of care; Anticholinergic agents or propanolol as determined by the investigator according to the local standard of care
359585|NCT00671658|Drug|G-CSF|10 ug/kg subcutaneous injection
359586|NCT00671658|Drug|Mesna|600 mg/m2 a day by vein
359587|NCT00671658|Drug|Pegylated asparaginase|2000 International units/m2 by vein
359588|NCT00671658|Drug|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
359589|NCT00005087|Radiation|radiation therapy|
359590|NCT00671658|Drug|Solumedrol|40 mg by vein for Courses 2,4,6,8
359591|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
359592|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
359593|NCT00671684|Procedure|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
359918|NCT00005585|Drug|daunorubicin hydrochloride|Given IV
359919|NCT00679224|Drug|ambrisentan|ambrisentan
359920|NCT00679237|Behavioral|smoking cessation|NRT and varenicline
359921|NCT00679237|Drug|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
359922|NCT00679237|Drug|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
359923|NCT00679237|Behavioral|training|daily walking
359924|NCT00679237|Biological|influenza vaccine|vaccine (FLuarix, Influvac etc)
358941|NCT00676026|Drug|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
358942|NCT00676026|Drug|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
358943|NCT00676026|Drug|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
358944|NCT00676039|Drug|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
358945|NCT00005566|Behavioral|Desperation Scale|
358946|NCT00676039|Drug|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
358947|NCT00676039|Drug|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
358948|NCT00676039|Drug|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
358949|NCT00676052|Drug|GSK233705 12.5mcg|Once daily via dry powder inhaler
358950|NCT00676052|Drug|GSK233705 25mcg|once daily via dry powder inhaler
358951|NCT00676052|Drug|GSK233705 50mcg|Once daily via dry powder inhaler
358952|NCT00676052|Drug|GSK233705 100mcg|Once daily via dry powder inhaler
358953|NCT00676052|Drug|GSK233705 200mcg|Once daily via dry powder inhaler
358954|NCT00678548|Behavioral|Pain diary|Filling out a pain diary
358955|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
358956|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
358957|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
358958|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
358959|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
358960|NCT00005584|Biological|bleomycin sulfate|
358961|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
358962|NCT00678561|Drug|Placebo Vehicle|Topical treatment once daily for 28 days
358963|NCT00678561|Drug|Placebo Vehicle|Topical treatment twice daily for 28 days
357980|NCT00675532|Behavioral|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
357981|NCT00675545|Drug|Docetaxel, Carboplatin|Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.
Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available.
358289|NCT00683085|Biological|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
358290|NCT00005601|Drug|cytarabine|
358291|NCT00683111|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
358292|NCT00683111|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
358293|NCT00683124|Drug|Losartan and nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.
Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
358294|NCT00683124|Drug|Losartan|Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
358295|NCT00683124|Drug|Nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
358296|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
358297|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
358298|NCT00683137|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
358299|NCT00683150|Other|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
358300|NCT00683163|Drug|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
358301|NCT00005601|Drug|dexamethasone|
357690|NCT00670644|Other|questionnaire administration|Completed self-report form
357691|NCT00670644|Other|survey administration|Completed self-report form-other
357692|NCT00000658|Drug|Methotrexate|
357693|NCT00005082|Procedure|biopsy|
357694|NCT00670644|Procedure|quality-of-life assessment|Completed self-report form qol
357695|NCT00670657|Drug|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
357696|NCT00670670|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
357697|NCT00670670|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
357698|NCT00670683|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
357699|NCT00670696|Drug|Rapydan|Topical anaesthetic plaster
357700|NCT00670696|Drug|tetracaine gel|Topical tetracaine gel
357701|NCT00670722|Drug|insulin aspart|Intervention at the discretion of the physician
357702|NCT00670722|Drug|insulin detemir|Intervention at the discretion of the physician
357982|NCT00675558|Procedure|Initial Surgery|NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.
MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.
All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) & fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified.
357983|NCT00675558|Procedure|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
357984|NCT00675584|Drug|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
357985|NCT00005120|Drug|Calanolide A|
357986|NCT00677950|Procedure|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
357987|NCT00677963|Drug|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
357385|NCT00691704|Drug|Sequential Maintenance Therapy|Subjects who achieve >partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved > stable disease (SD) from maintenance (per discussion with physician):
325 mg aspirin for deep vein thrombosis (DVT) prophylaxis
Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle
Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7
Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle
Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle.
357386|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
357387|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
357388|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
357389|NCT00005669|Drug|Metformin HCL|Medication studied for ability to alter body weight and body composition.
357390|NCT00691717|Other|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
357391|NCT00691730|Other|laboratory biomarker analysis|Correlative studies
357392|NCT00691730|Other|pharmacological study|Correlative studies
357393|NCT00691756|Procedure|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
357394|NCT00691756|Procedure|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
357395|NCT00691782|Other|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
357396|NCT00691795|Drug|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
357397|NCT00691808|Drug|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
357398|NCT00691808|Drug|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
357703|NCT00670722|Drug|biphasic insulin aspart 30|Intervention at the discretion of the physician
357704|NCT00005082|Procedure|magnetic resonance imaging|
356765|NCT00599872|Biological|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
356766|NCT00004218|Drug|doxorubicin hydrochloride|
356767|NCT00599872|Biological|Placebo|Placebo, sublingual oral
356768|NCT00599885|Drug|telmisartan|telmisartan 40-80mg once per day for 8 months
356769|NCT00599885|Drug|valsartan|valsartan 80-160mg once per day for 8 months
356770|NCT00602082|Genetic|proteomic profiling|
356771|NCT00602082|Other|laboratory biomarker analysis|
356772|NCT00602095|Drug|misoprostol|0.025mg tablet vaginally every 4 hour until progress
356773|NCT00602095|Drug|dinoprostone|2mg vaginal gel every 6 hours until progress
357096|NCT00684567|Drug|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
357097|NCT00684580|Other|Data Collection|Continuing review of outcomes and late toxicities
357098|NCT00684593|Drug|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
357099|NCT00684593|Other|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
357100|NCT00684606|Drug|Oxytocin IV|5 miu/1000ml Glu/Saline
357101|NCT00684619|Drug|Nelarabine|1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
357102|NCT00684632|Drug|Placebo|Placebo
357103|NCT00005607|Drug|FOLFIRI regimen|
357104|NCT00684632|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
357105|NCT00684645|Drug|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
356461|NCT00607308|Biological|PF-04360365|Single dose of 1 mg/kg IV on Day 1
356462|NCT00607308|Biological|PF-04360365|Single dose of 5 mg/kg IV on Day 1
356463|NCT00607308|Drug|Placebo|Single dose of placebo IV on Day 1
356464|NCT00607308|Biological|PF-04360365|Single dose of 10 mg/kg IV on Day 1
356465|NCT00607321|Device|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
356466|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
356467|NCT00004250|Drug|isolated limb perfusion|
356468|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
356469|NCT00607347|Other|Glucose|Oral Glucose Tolerance Test
356470|NCT00607360|Behavioral|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
356471|NCT00607373|Drug|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
356472|NCT00607373|Drug|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
356473|NCT00607386|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
356474|NCT00607399|Drug|SGX523 Capsules|This is a dose escalation study
356475|NCT00607412|Behavioral|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
356476|NCT00609752|Drug|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
356477|NCT00004261|Drug|EF5|
356478|NCT00609752|Dietary Supplement|Alicalm (polymeric liquid formula)|Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a "normal" unrestricted diet by 10 weeks.
356774|NCT00602095|Device|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
356775|NCT00602108|Procedure|adjuvant therapy|
361339|NCT00004736|Drug|Rifabutin|
361340|NCT00633932|Drug|Omeprazole|20mg once daily
361341|NCT00635934|Device|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
361342|NCT00635947|Other|isotonic solution|1.5 L- during 2-4hours
361343|NCT00635947|Other|water|1.5 L- during 2-4hours
361344|NCT00635947|Other|water|200mL- during 2-4hours
361345|NCT00635960|Drug|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
361346|NCT00635960|Drug|Placebo|Same as for Growth hormone group
361347|NCT00635973|Drug|Gefitinib (Iressa)|Iressa
361348|NCT00004767|Drug|Sodium Phenylbutyrate|
361349|NCT00635986|Drug|Fentanyl|100 mcg Fentanyl intravenous or epidural route
361350|NCT00635999|Behavioral|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
361351|NCT00635999|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CBT will include 14 weekly sessions.
361352|NCT00636012|Procedure|verum acupuncture|acupuncture at St36 and Pe6
361353|NCT00636012|Procedure|sham acupuncture|superficial needling at sham points
361354|NCT00636038|Dietary Supplement|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
361355|NCT00636064|Drug|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
360699|NCT00004896|Radiation|radiation therapy|
360700|NCT00648180|Drug|Adoxa Tablets 100 mg|100mg, single dose fed
360701|NCT00648193|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
360702|NCT00648193|Drug|Paxil® 40 mg Table|40mg, single dose fasting
360703|NCT00648219|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
360704|NCT00648219|Drug|Benicar® Tablets 40 mg|40mg, single dose fed
360705|NCT00650585|Behavioral|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
360706|NCT00004903|Drug|melphalan|
360707|NCT00650598|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
360708|NCT00650598|Drug|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
361009|NCT00643162|Behavioral|Massage|Massage twice a week, for 8 weeks.
361010|NCT00643175|Behavioral|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
361011|NCT00643188|Procedure|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
361012|NCT00643188|Other|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
361013|NCT00643201|Drug|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
361014|NCT00643201|Drug|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
361015|NCT00643201|Drug|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
361016|NCT00004867|Radiation|fludeoxyglucose F 18|
360407|NCT00682162|Device|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
360408|NCT00005596|Drug|methotrexate|IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.
IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22.
360409|NCT00682162|Device|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
360410|NCT00682175|Other|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
360411|NCT00682188|Behavioral|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
360412|NCT00682188|Behavioral|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
360709|NCT00650611|Drug|Ziprasidone|Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.
Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1.
360710|NCT00650611|Drug|Ziprasidone|Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.
Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1.
360711|NCT00650624|Drug|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
360712|NCT00650624|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
360713|NCT00650624|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
360714|NCT00650624|Drug|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
360715|NCT00650637|Drug|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
360108|NCT00674310|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
360109|NCT00674323|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, light application of 50 J/cm^2 to the study eye was begun 15 minutes after the start of infusion.
360110|NCT00674323|Drug|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
360111|NCT00674336|Procedure|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
360112|NCT00674349|Procedure|surgery|staging surgery
360113|NCT00005106|Drug|Lamivudine|
360114|NCT00674362|Biological|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
360115|NCT00674362|Biological|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
360116|NCT00674375|Other|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
360117|NCT00674401|Procedure|Radiofrequency catheter ablation|In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:
Empirical pulmonary vein antrum circumferential isolation, or
High frequency sites ablation in the LA
In case of Persistent AF, patients will be randomized into one of 2 in the study:
Empirical circumferential PV antrum isolation w/out roof line, or
A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation.
360118|NCT00674414|Biological|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
360119|NCT00674414|Drug|everolimus|Oral everolimus once daily
360120|NCT00674414|Procedure|therapeutic conventional surgery|Patients undergo surgery
360121|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
360122|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
360123|NCT00674440|Drug|F-DOPA|0.08-0.16 mCi/kg once
360124|NCT00005106|Drug|Stavudine|
359475|NCT00683813|Behavioral|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
359794|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
359795|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
359796|NCT00690937|Drug|Colesevelam Cholestagel|Drug comparator
359797|NCT00690937|Drug|Placebo|Placebo
359798|NCT00690937|Drug|Placebo|Placebo
359799|NCT00690950|Drug|Dutasteride|0.5mg capsule, taken once daily for 12 months
359800|NCT00690963|Procedure|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
359801|NCT00690976|Behavioral|Proyecto SOL|Group intervention
359802|NCT00690976|Behavioral|HCT|Offer of HIV counseling and testing
359803|NCT00691002|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
359804|NCT00005649|Drug|capecitabine|
359805|NCT00691015|Biological|rituximab|Given IV
359806|NCT00691015|Drug|busulfan|Given IV
359807|NCT00691015|Drug|carmustine|Given IV
359808|NCT00691015|Drug|cyclophosphamide|Given IV
359809|NCT00691015|Drug|cytarabine|Given IV
359810|NCT00691015|Drug|etoposide|Given IV
359811|NCT00691015|Drug|fludarabine phosphate|Given IV
359812|NCT00691015|Drug|melphalan|Given IV
359813|NCT00691015|Radiation|total-body irradiation|Given once or twice daily
356597|NCT00621608|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
356598|NCT00004450|Drug|thalidomide|
356599|NCT00621608|Procedure|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
356600|NCT00621621|Device|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
356601|NCT00621634|Dietary Supplement|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
356602|NCT00621634|Dietary Supplement|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
356603|NCT00621647|Drug|Quetiapine Fumarate|
356604|NCT00621647|Drug|Quetiapine Fumarate|
356605|NCT00621647|Drug|Placebo|
356606|NCT00621660|Procedure|Acupuncture|Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a "cun" in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred.
356607|NCT00623857|Dietary Supplement|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
356608|NCT00623857|Dietary Supplement|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
356609|NCT00623857|Dietary Supplement|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
356610|NCT00623870|Drug|RO5045337|Multiple ascending doses
356611|NCT00623883|Procedure|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
356925|NCT00691509|Other|questionnaire administration|
356926|NCT00691522|Drug|Xerecept|
361483|NCT00648479|Device|The Guiding Star|
361484|NCT00004897|Drug|leucovorin calcium|
361485|NCT00650884|Device|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
361486|NCT00650897|Drug|Escitalopram|10-20 mg once daily
361487|NCT00650910|Drug|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
361488|NCT00650910|Drug|Digoxin|0.5mg on Days 1 and 9
361489|NCT00650923|Drug|ziv-aflibercept|Given IV
361490|NCT00650923|Procedure|radiation therapy|Undergo RT
361491|NCT00650923|Drug|temozolomide|Given PO
361492|NCT00650923|Procedure|pharmacological study|Correlative studies
361493|NCT00650923|Procedure|laboratory biomarker analysis|Correlative studies
361494|NCT00000645|Drug|Hypericin|
361495|NCT00004904|Drug|cyclophosphamide|
361496|NCT00650936|Device|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
361497|NCT00650949|Drug|CYT997|Escalating doses (100mg/m^2 to 150mg/m^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
361498|NCT00650949|Drug|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
361499|NCT00650962|Other|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
361500|NCT00650962|Other|Rhythm analysis|Rhythm analysis as soon as AED is ready
361501|NCT00650975|Device|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
361502|NCT00650975|Device|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
360836|NCT00663169|Drug|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
360837|NCT00663169|Other|placebo matching canakinumab|5% glucose in water intravenous infusion.
360838|NCT00665457|Drug|doxorubicin hydrochloride|
360839|NCT00665457|Genetic|gene expression analysis|
360840|NCT00665457|Genetic|polymorphism analysis|
360841|NCT00665457|Genetic|protein expression analysis|
360842|NCT00665457|Genetic|reverse transcriptase-polymerase chain reaction|
361158|NCT00658229|Behavioral|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
361159|NCT00658255|Drug|budesonide/formoterol|
361160|NCT00658255|Drug|formoterol|
361161|NCT00658268|Drug|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
361162|NCT00658268|Drug|Placebo|10 ml, single dose mixed in bone graft at operation
361163|NCT00658281|Procedure|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
361164|NCT00658281|Procedure|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
361165|NCT00004940|Drug|cysteine hydrochloride|
361166|NCT00658294|Other|Stop treatment|
361167|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|1 Hz
The rTMS device is the "MagPro X100 Series" (produced by Magventure A/S, Farum, Denmark)
361168|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|20Hz
The rTMS device is the "MagPro X100 Series" (produced by Magventure A/S, Farum, Denmark)
361169|NCT00658307|Device|sham repetitive transcranial magnetic stimulation (rTMS)|The rTMS device is the "MagPro X100 Series" (produced by Magventure A/S, Farum, Denmark)
361170|NCT00658320|Drug|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
361171|NCT00658320|Drug|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
360542|NCT00672373|Drug|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
360543|NCT00672373|Drug|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
360544|NCT00672386|Drug|JNJ16269110|5 mg twice daily for 12 weeks
360545|NCT00672386|Drug|JNJ16269110|10 mg twice daily for 12 weeks
360546|NCT00672386|Drug|JNJ16269110|15 mg twice daily for 12 weeks
360547|NCT00672386|Drug|Placebo|twice daily for 12 weeks
360548|NCT00672386|Drug|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
360549|NCT00674622|Drug|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
360550|NCT00674622|Procedure|Placebo|Saline/lidocaine
360551|NCT00674635|Drug|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
360552|NCT00005108|Drug|Progesterone|
360553|NCT00674635|Drug|Placebo|matching placebo
360843|NCT00665457|Other|imaging biomarker analysis|
360844|NCT00665457|Other|immunohistochemistry staining method|
360845|NCT00665457|Other|laboratory biomarker analysis|
360846|NCT00665457|Other|pharmacogenomic studies|
360847|NCT00005039|Other|laboratory biomarker analysis|Correlative studies
360848|NCT00665457|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
360849|NCT00665457|Procedure|needle biopsy|
360850|NCT00665457|Procedure|neoadjuvant therapy|
360851|NCT00665457|Procedure|radiomammography|
360852|NCT00665457|Procedure|ultrasound imaging|
360853|NCT00665470|Drug|Aldesleukin|High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks
359925|NCT00679237|Drug|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
359926|NCT00679237|Behavioral|weight reduction|diet tips
359927|NCT00679250|Drug|levocetirizine|5 mg once nightly before visit
359928|NCT00679250|Drug|placebo to levocetirizine|1 tablet once nightly before visit
359929|NCT00005585|Drug|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
359930|NCT00679263|Drug|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
359931|NCT00679263|Drug|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
359932|NCT00679263|Drug|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
359933|NCT00679276|Procedure|Prolift|surgical repair of vaginal prolapse
359934|NCT00679289|Drug|Interferon alpha|20 MU/m2 IV QD x 5 Days for 4 weeks, then 10 MU/m2 SC TIW until disease progression
359935|NCT00679289|Drug|KW2871|5 mg/m2 IV Q2W until disease progression
359936|NCT00679289|Drug|KW2871|10 mg/m2 IV Q2W until disease progression
359937|NCT00679289|Drug|interferon alpha|20 MU/m2 IV QD x 5 Days for 4 weeks, then 10 MU/m2 SC TIW until disease progression
359938|NCT00679289|Drug|KW2871|20 mg/m2 IV Q2W until disease progression
359939|NCT00679289|Drug|Interferon alpha|20 MU/m2 IV QD x 5 Days for 4 weeks, then 10 MU/m2 SC TIW until disease progression
359940|NCT00005585|Drug|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
359941|NCT00681746|Drug|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
360244|NCT00689013|Other|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
360245|NCT00689013|Other|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
358964|NCT00678574|Drug|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
359271|NCT00685945|Drug|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
359272|NCT00685945|Drug|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
359273|NCT00685945|Drug|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
359274|NCT00685958|Drug|enoxaparin (XRP4563)|14 days of treatment
359275|NCT00685971|Dietary Supplement|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
359276|NCT00685971|Dietary Supplement|placebo|5 drops once daily for 12 weeks
359277|NCT00686010|Drug|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
359278|NCT00686010|Drug|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
359279|NCT00686010|Drug|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
359280|NCT00005615|Biological|Interferon alfa|Interferon alfa as outlined in treatment arm.
359281|NCT00688311|Dietary Supplement|Placebo|Placebo
359282|NCT00688324|Drug|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
359283|NCT00688350|Behavioral|Feedback-based behavioral medication adherence intervention|The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
359284|NCT00688363|Procedure|weekly blood glucose profile|once daily self-control of urinary-glucose
359285|NCT00688363|Procedure|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
359286|NCT00688363|Procedure|no blood-glucose self-control|once daily self-control of urinary-glucose
358302|NCT00683163|Drug|Ibandronate|150mg by mouth once monthly
358303|NCT00683163|Other|Placebo injection|Daily injections as placebo for PTS 1-84
358304|NCT00683163|Other|Placebo pills|Monthly pills as placebo for oral ibandronate
358305|NCT00683176|Drug|Choline Fenofibrate|135 mg
358306|NCT00683176|Drug|Placebo|Placebo
358307|NCT00683189|Drug|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
358626|NCT00690196|Behavioral|Tai Chi Chih|Tai Chi Chih (TCC) employs "meditation through movement" as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up.
358627|NCT00692523|Other|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
358628|NCT00692536|Behavioral|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
358629|NCT00005739|Behavioral|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
358630|NCT00692536|Behavioral|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
358631|NCT00692549|Device|ultrasound|
358632|NCT00692562|Procedure|simultaneous islet-kidney transplantation|
358633|NCT00692575|Behavioral|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
358634|NCT00692575|Other|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
357988|NCT00677989|Procedure|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
357989|NCT00677989|Procedure|Open appendectomy|open appendectomy: did appendectomy by laparotomy
357990|NCT00005581|Drug|epirubicin hydrochloride|
357991|NCT00678015|Drug|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
357992|NCT00678041|Drug|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing CISC and for three more days after stopping CISC
357993|NCT00678041|Drug|Placebo|Placebo
357994|NCT00678054|Drug|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
357995|NCT00678067|Dietary Supplement|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
357996|NCT00678067|Dietary Supplement|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
357997|NCT00678067|Dietary Supplement|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
357998|NCT00678067|Other|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake <30% of total calories, Saturated fat intake <10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
357999|NCT00678080|Drug|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
358308|NCT00685347|Drug|Levalbuterol HFA MDI|levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).
Arm #A
Xopenex HFA MDI
358309|NCT00685347|Drug|Racemic Albuterol|racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).
Arm #B
Proventil HFA MDI
358310|NCT00685360|Drug|OPC-67683|100 mg BID will be administered as two 50 mg tablets together with two matching placebo tablets for a total of four tablets administered twice a day (total daily dose of OPC-67683 is 200 mg) for 56 days. .
358311|NCT00685360|Drug|OPC-67683|200 mg BID will be administered as four 50 mg tablets administered twice a day for (total daily dose of OPC-67683 is 400 mg) 56 days.
358312|NCT00685360|Drug|Placebo|Placebo will be administered as four 50 mg tablets matching the OPC-67683 tablets administered twice a day for 56 days
358313|NCT00685373|Drug|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
357705|NCT00670748|Biological|Anti-NY ESO-1 TCR PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 TCR PBL and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
357706|NCT00670748|Drug|aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
357707|NCT00670748|Drug|cyclophosphaide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
357708|NCT00670748|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
357709|NCT00672854|Drug|Intralipid|TPN with Intralipid (20%)
357710|NCT00672867|Drug|Clevudine|30mg
357711|NCT00672867|Drug|Adefovir dipivoxil|10mg
357712|NCT00672880|Behavioral|Self-System Therapy|12 sessions of structured Self-System Therapy
357713|NCT00672880|Behavioral|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
357714|NCT00672880|Other|Standard Care|Study participants continue with their usual medical care, no changes.
357715|NCT00672893|Other|Vibration Response Imaging|12 seconds of recording lung sounds
357716|NCT00672906|Behavioral|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
357717|NCT00672906|Behavioral|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
357718|NCT00672919|Drug|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
357719|NCT00005091|Drug|exatecan mesylate|
357720|NCT00672932|Drug|raltegravir|400 mg two times daily for three months
357721|NCT00672945|Drug|PRX-03140|
357722|NCT00672945|Drug|Placebo|
357723|NCT00672958|Drug|Vortioxetine|Encapsulated immediate-release tablets.
357724|NCT00672958|Drug|Placebo|Vortioxetine placebo-matching capsules.
357106|NCT00684658|Behavioral|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
357107|NCT00684658|Behavioral|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
357108|NCT00684671|Biological|Twinrix|Intramuscular injection, single dose in left deltoid.
357109|NCT00684671|Biological|Engerix-B|Intramuscular injection, single dose in left deltoid.
357110|NCT00684671|Biological|Havrix|Intramuscular injection, single dose in right deltoid.
357111|NCT00684671|Biological|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
357112|NCT00684671|Biological|Vaqta|Intramuscular injection, single dose in right deltoid.
357113|NCT00684684|Device|Chartis System|Assessment of airway flow and pressure
357114|NCT00005607|Drug|fluorouracil|
357399|NCT00691808|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
357400|NCT00000676|Drug|Clotrimazole|
357401|NCT00005669|Drug|Placebo|Control capsules for metformin
357402|NCT00691821|Other|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
357403|NCT00691821|Device|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
357404|NCT00691834|Biological|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
357405|NCT00691834|Biological|Placebo|Plasma and culture medium (10 ml)
357406|NCT00694369|Drug|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
357407|NCT00694369|Drug|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
356776|NCT00602108|Procedure|conventional surgery|
356777|NCT00602108|Radiation|hypofractionated radiation therapy|
356778|NCT00004228|Drug|leucovorin calcium|Given IV
356779|NCT00602108|Radiation|intraoperative radiation therapy|
356780|NCT00602134|Drug|6-Mercaptopurine|
356781|NCT00602147|Other|laboratory biomarker analysis|Blood or cheek cells wil be collected.
356782|NCT00602160|Drug|FAHF-2 (TM)|We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.
Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy.
356783|NCT00602173|Drug|Cilostazol|
356784|NCT00602186|Drug|tamsolusin|0.4 mg /day
356785|NCT00602186|Drug|prazosin|1 mg/day
356786|NCT00602199|Drug|ABT-510|
356787|NCT00602199|Other|immunoenzyme technique|
356788|NCT00602199|Other|immunohistochemistry staining method|
356789|NCT00004228|Drug|mercaptopurine|Given IV
356790|NCT00602199|Other|laboratory biomarker analysis|
356791|NCT00602199|Other|pharmacological study|
356792|NCT00602199|Procedure|biopsy|
356793|NCT00602212|Behavioral|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
356794|NCT00602212|Behavioral|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
356795|NCT00602225|Drug|clofarabine|Given IV
356796|NCT00602225|Drug|cytarabine|Given IV
356797|NCT00602225|Biological|filgrastim|Given subcutaneously
356798|NCT00602251|Drug|Terbinafine|
361356|NCT00636064|Drug|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
356479|NCT00609765|Drug|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
356480|NCT00609765|Drug|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m^2 iv bolus daily days 1-5
356481|NCT00609765|Drug|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m^2 iv bolus day 1
356482|NCT00609765|Drug|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
356483|NCT00609765|Drug|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
356484|NCT00609765|Drug|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
356485|NCT00609778|Device|LUCAS|Mechanical chest compression
356486|NCT00609778|Other|Conventional manual resuscitation method|Manual compression
356487|NCT00609791|Drug|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
356488|NCT00004261|Other|flow cytometry|
356489|NCT00609791|Other|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
356490|NCT00609791|Other|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
356491|NCT00609791|Other|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
356492|NCT00609791|Other|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
356493|NCT00609791|Procedure|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
356494|NCT00609791|Procedure|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
356495|NCT00609804|Drug|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
356496|NCT00609804|Drug|Erlotinib|Erlotinib 150 mg once daily by mouth
361017|NCT00643201|Drug|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
361018|NCT00643201|Drug|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
361019|NCT00643201|Drug|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
361020|NCT00643214|Device|Tetrix|Twice daily topical application
361021|NCT00643214|Device|Tetrix|Twice daily topical application
361022|NCT00643227|Drug|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
361023|NCT00643227|Drug|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
361024|NCT00643240|Radiation|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
361025|NCT00643240|Radiation|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
361026|NCT00643253|Behavioral|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
361357|NCT00636064|Other|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
361358|NCT00636077|Device|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
361359|NCT00004767|Behavioral|Dietary Intervention|
361360|NCT00638534|Drug|Telithromycin (HMR3647)|
361361|NCT00638547|Drug|IRT Laronidase|Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.
Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture
360716|NCT00650637|Drug|nelfinavir|1250 mg twice a day
360717|NCT00004903|Procedure|peripheral blood stem cell transplantation|
360718|NCT00650637|Drug|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
360719|NCT00650637|Drug|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
360720|NCT00650637|Other|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
360721|NCT00650637|Drug|nelfinavir|nelfinavir 1250 mg twice a day
360722|NCT00650637|Drug|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
360723|NCT00650663|Drug|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
360724|NCT00650663|Drug|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
360725|NCT00652899|Radiation|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
360726|NCT00652899|Biological|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 * 10^7/kg
360727|NCT00652899|Biological|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
361027|NCT00004867|Drug|chemotherapy|
361028|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
361029|NCT00645437|Drug|Levofloxacin|
361030|NCT00645450|Drug|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
361031|NCT00645450|Drug|Placebo|Weekly doses of placebo following recollection of traumatic memory
361032|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
361033|NCT00004884|Drug|cisplatin|
361034|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 alone
360413|NCT00684320|Behavioral|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
360414|NCT00684320|Behavioral|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
360415|NCT00684333|Device|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
360416|NCT00684346|Other|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
360417|NCT00684372|Drug|leflunomide|Screening: If BK viremia (BK PCR >10 000 copies/ml in serum) i. Reduced immunosuppression
MMF / AZA withdrawal
CNI reduction
Tacrolimus 5 ng/ml in serum
Cyclosporin 100 ng/ml in serum
Prednisolone to maintenance level
If effective => continue
Stable renal function (P-Krea)
>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis
Negative PCR at > 3 months after diagnosis
If failure => add leflunomide
Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy
<50% reduction in PCR at 4 weeks after diagnosis
Positive PCR at >3 months after diagnosis
Leflunomide dosing:
ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)
Starting at 20 mgx1 PO daily
Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 >40 ug/ml
360418|NCT00005604|Other|laboratory biomarker analysis|Correlative studies
360419|NCT00684385|Drug|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H&NC will take two tablets at each dose administration.
360420|NCT00684411|Drug|Imatinib mesylate|Given orally continuously
360421|NCT00684424|Other|Non-Interventional Study|Observational Only
360422|NCT00684437|Behavioral|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
360423|NCT00684437|Behavioral|Questionnaire|Questionnaires taking 15-30 minutes to complete.
360424|NCT00684450|Procedure|Titration protamine|10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
360425|NCT00684450|Drug|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
359814|NCT00691028|Drug|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
359815|NCT00005649|Drug|paclitaxel|
359816|NCT00691028|Drug|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
359817|NCT00691028|Drug|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
360125|NCT00674440|Radiation|PET scan|
360126|NCT00674453|Drug|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
360127|NCT00674453|Other|Placebo|Matching placebo tablet given once daily for 2 years
360128|NCT00676806|Biological|Umbilical Cord Blood Transplantation After Myeloablative Conditioning|Fully-myeloablative Conditioning Regimen: cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.
360129|NCT00676806|Biological|Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning|Reduced Intensity Conditioning Regimen: Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
360130|NCT00005576|Biological|sargramostim|Given IV
360131|NCT00676819|Drug|insulin aspart|
360132|NCT00676819|Drug|human insulin|
360133|NCT00676832|Drug|Placebo|Placebo solid capsule dosage form administered orally once daily.
360134|NCT00676832|Drug|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
360135|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
360136|NCT00676845|Drug|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
360137|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
360138|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
360139|NCT00676871|Drug|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
356927|NCT00691548|Drug|Cetuximab-Zr. 89|Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.
On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.
Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg).
356928|NCT00691561|Behavioral|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
356929|NCT00691574|Dietary Supplement|Melatonin|up to 3 mg, daily, for up to 1 year
356930|NCT00005665|Drug|interferon alpha|
356931|NCT00691574|Device|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
356932|NCT00691587|Biological|KB001|Single low-dose, administered intravenously
356933|NCT00691587|Biological|KB001|Single high-dose, administered intravenously
356934|NCT00691587|Biological|Placebo|Placebo single-dose, administered intravenously
356935|NCT00691600|Drug|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
356936|NCT00691600|Drug|Placebo|Placebo caps or suspension every 12 hours for 10 days
356937|NCT00691600|Other|Observational Unit Short Stay|Patients with abscesses greater that 5cm to 10cm randomized to Observational Short Stay unit for up to 23 hrs.
356938|NCT00691600|Other|Hospitalization|Patients with abscesses 5-10cm may be randomized to inpatient treatment
356939|NCT00691613|Drug|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
356940|NCT00691613|Drug|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
356941|NCT00005666|Procedure|PET scan use in radiotherapy planning|
356942|NCT00691626|Behavioral|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
356943|NCT00691626|Behavioral|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
361503|NCT00650988|Procedure|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
361504|NCT00651014|Drug|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
356612|NCT00623883|Procedure|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
356613|NCT00623909|Device|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
356614|NCT00623922|Behavioral|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
356615|NCT00004489|Drug|cholecalciferol|
356616|NCT00623935|Drug|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
356617|NCT00623935|Drug|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
356618|NCT00623935|Radiation|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
356619|NCT00623935|Procedure|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
356620|NCT00623948|Device|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
356621|NCT00623974|Drug|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
356622|NCT00623974|Drug|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
356623|NCT00623974|Drug|Calcitriol|0.25 micrograms PO Every 12 Hours
356624|NCT00623987|Drug|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
356625|NCT00624000|Drug|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
356626|NCT00000629|Drug|Zidovudine|
356627|NCT00004490|Drug|sodium dichloroacetate|
356628|NCT00624013|Drug|sertraline|50 mg up to 100 mg daily for 6 months
356629|NCT00624026|Drug|Memantine-HCl|20 mg per day (once daily)
361172|NCT00658320|Drug|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
361173|NCT00658320|Drug|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
361174|NCT00658320|Drug|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
361175|NCT00658333|Drug|Enteric-coated Mycophenolate Acid (EC-MPA)|
361176|NCT00004941|Drug|monoclonal antibody cA2|
361177|NCT00658333|Drug|Mycophenolate Mofetil (MMF)|
361178|NCT00658333|Drug|Placebo MMF|
361179|NCT00658333|Drug|Placebo EC-MPA|
361505|NCT00651014|Drug|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
361506|NCT00004904|Drug|etoposide|
361507|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class A
361508|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class B
361509|NCT00651027|Drug|PF-868554|200 mg, healthy volunteers
361510|NCT00651040|Drug|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
361511|NCT00653172|Drug|NXL103|600mg orally twice daily
361512|NCT00004910|Procedure|quality-of-life assessment|
361513|NCT00653172|Drug|comparator|comparator twice daily
361514|NCT00653172|Drug|NXL103|500mg orally twice daily
361515|NCT00653185|Drug|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
361516|NCT00653185|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
361517|NCT00653185|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
361518|NCT00653185|Drug|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
360854|NCT00665483|Other|Skin Prick Test|Skin Prick Test
360855|NCT00665496|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
360856|NCT00665496|Drug|Placebo|Matching Placebo
360857|NCT00665509|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
360858|NCT00005040|Drug|arsenic trioxide|
360859|NCT00665522|Drug|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
360860|NCT00665522|Drug|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
360861|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
360862|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
360863|NCT00665548|Radiation|X-ray; magnetic resonance imaging|Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.
3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences.
360864|NCT00665561|Drug|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
360865|NCT00665561|Drug|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
361180|NCT00660829|Drug|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
361181|NCT00660842|Procedure|carboplatin|AUC 6 IV day 1 every 21 days
361182|NCT00660842|Drug|paclitaxel|175 mg/m2 IV day 1 every 21 days
361183|NCT00660842|Drug|carboplatin|AUC 2 IV every week
361184|NCT00660842|Drug|paclitaxel|60mg/m2 IV every week
361185|NCT00660855|Drug|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
361186|NCT00005002|Drug|Lamivudine/Zidovudine|
361187|NCT00660868|Drug|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
360246|NCT00689013|Other|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
360247|NCT00689026|Drug|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
360248|NCT00005638|Drug|irinotecan hydrochloride|
360249|NCT00689026|Other|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
360250|NCT00689039|Drug|AZD1305|ER tablet, administered as single and repeated doses.
360251|NCT00689039|Drug|Placebo|Tablet, administered as single and repeated doses.
360252|NCT00689052|Drug|pramipexole ER|
360253|NCT00689052|Drug|placebo|
360254|NCT00689065|Drug|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
360255|NCT00689078|Drug|Prednisolone Acetate 1%|One drop OU
360256|NCT00689078|Drug|Prednisolone Acetate 0.12%|One drop OU
360257|NCT00689078|Drug|Loteprednol Etabonate 0.2%|One drop OU
360258|NCT00689078|Drug|Artificial tears|One drop OU
360259|NCT00000674|Drug|Pyrimethamine|
360260|NCT00005638|Radiation|radiation therapy|
360261|NCT00689091|Device|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
360262|NCT00689091|Device|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
360263|NCT00689104|Drug|Mirabegron|Tablets
360264|NCT00691236|Drug|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
359287|NCT00688376|Drug|Donepezil hydrochloride|During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.
During the Blinded Extension Phase, all subjects will receive active treatment (donepezil).
359288|NCT00688376|Drug|Placebo|During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.
During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil).
359289|NCT00000673|Drug|Ganciclovir|
359594|NCT00671697|Drug|Arsenic Trioxide|
359595|NCT00671697|Drug|Decitabine|
359596|NCT00671710|Drug|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
359597|NCT00671723|Drug|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
359598|NCT00671723|Drug|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
359599|NCT00671723|Drug|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
359600|NCT00005088|Drug|cisplatin|
359601|NCT00671736|Drug|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
359602|NCT00671736|Drug|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
359603|NCT00671749|Drug|adapalene gel, 0.3%|Applied once daily at bedtime
359604|NCT00671749|Drug|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
359605|NCT00671788|Drug|Dasatinib|Given orally
359606|NCT00671788|Other|Laboratory Biomarker Analysis|Correlative studies
359607|NCT00671801|Drug|Irinotecan|200 mg/m^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
359608|NCT00671801|Drug|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
359609|NCT00671814|Drug|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
358635|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
358636|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
358637|NCT00692601|Dietary Supplement|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
358638|NCT00692614|Drug|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
358639|NCT00692640|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
358640|NCT00000676|Drug|Fluconazole|
358641|NCT00005739|Behavioral|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
358965|NCT00678587|Drug|Eltrombopag|75 mg, once daily, oral
358966|NCT00678587|Drug|Placebo|placebo, once daily, oral
358967|NCT00678600|Other|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
358968|NCT00678600|Other|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
358969|NCT00678613|Drug|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
358970|NCT00678613|Drug|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
358971|NCT00005584|Drug|ABVD regimen|
358972|NCT00678626|Drug|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
358973|NCT00678626|Drug|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
358974|NCT00678639|Other|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
358314|NCT00685386|Other|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
358315|NCT00685386|Other|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
358316|NCT00685399|Drug|AIN457 subcutaneous dose|
358317|NCT00005612|Drug|cyclophosphamide|
358318|NCT00685399|Drug|AIN457 low dose (i.v)|
358319|NCT00685399|Drug|AIN457 high dose (i.v)|
358320|NCT00685412|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
358321|NCT00685425|Drug|Levalbuterol HFA MDI|levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).
Arm #A
Xopenex HFA MDI
358322|NCT00685425|Drug|Racemic Albuterol|racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).
Arm #B
Proventil HFA MDI
358323|NCT00685451|Behavioral|Cognitive Behavioral Therapy (CBT)|
358324|NCT00685464|Drug|Abciximab|Intravenous.
358325|NCT00685464|Drug|Abciximab|Intracoronary
358326|NCT00685477|Drug|CCK-8 0.02mg/kg|Drug will be given over 15
358327|NCT00685477|Drug|CCK-8 0.02 mg/kg|Drug infused over 30 min
358328|NCT00005612|Drug|etoposide|
358329|NCT00685477|Drug|CCK-8 0.02 mg/kg|Drug will be given over 60 min infusion
358642|NCT00692640|Drug|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
358643|NCT00692653|Behavioral|P4|Tailored online decision support system for prostate cancer treatment decision making
358644|NCT00692692|Procedure|DermaMatrix|DermaMatrix acellular dermis with tissue expanders after mastectomy for breast reconstruction
358645|NCT00692692|Procedure|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care muscle coverage over Tissue expander for breast reconstruction
358646|NCT00692705|Drug|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
357725|NCT00672971|Other|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
358000|NCT00678080|Drug|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
358001|NCT00005581|Drug|fluorouracil|
358002|NCT00678093|Other|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
358003|NCT00678106|Drug|Dalbavancin|Subjects weighing > 60 Kg: 1 gram IV single dose Subjects weighing < 60 Kg: 15 mg/Kg IV
358004|NCT00678119|Biological|AGS-003|Dendritic cell Immunotherapeutic
358005|NCT00678119|Drug|Sunitinib|An approved drug for the treatment of RCC
358006|NCT00678132|Drug|AZD 2281|
358007|NCT00678132|Drug|Cisplatin|
358008|NCT00678132|Drug|Gemcitabine|
358009|NCT00678145|Drug|naloxone|Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
358010|NCT00678145|Dietary Supplement|fructose|Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
358011|NCT00680446|Drug|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
358012|NCT00680459|Drug|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
358013|NCT00680459|Drug|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
358014|NCT00680472|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
358015|NCT00680472|Other|Placebo Patch|Treatment with Placebo Patch
358016|NCT00680485|Drug|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
358017|NCT00000175|Drug|Estrogen|
357408|NCT00694369|Drug|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
357409|NCT00694369|Drug|Comparator: placebo|matching placebo over three Days
357410|NCT00694382|Drug|Semuloparin sodium|0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection
357411|NCT00694382|Drug|Placebo (for semuloparin)|0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component
Subcutaneous injection
357412|NCT00694408|Drug|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
357413|NCT00694408|Other|No steroids|
357414|NCT00694447|Procedure|Acupuncture|
357415|NCT00005772|Device|Control|Control group: standard care
357416|NCT00694460|Biological|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
357417|NCT00694460|Biological|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
357418|NCT00694460|Biological|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
357726|NCT00672971|Other|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
357727|NCT00672984|Drug|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
357728|NCT00672984|Drug|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
357729|NCT00672984|Drug|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
357730|NCT00005092|Drug|Cyclophosphamide|IV over 2 hours on days 2 and 3
357731|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
357732|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
357115|NCT00684697|Dietary Supplement|iron|High, intermediate and low iron dosage orally for 2 months
357116|NCT00684710|Drug|PAZ-417|
357117|NCT00684710|Drug|Placebo|
357118|NCT00684723|Drug|Lovastatin 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
357119|NCT00686998|Drug|Placebo|
357120|NCT00687011|Drug|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
357121|NCT00687024|Procedure|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
357122|NCT00687024|Procedure|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
357123|NCT00687024|Procedure|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
357124|NCT00687037|Drug|Cetylpyridinium chloride|
357125|NCT00687050|Dietary Supplement|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
357126|NCT00687050|Dietary Supplement|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
357127|NCT00687063|Drug|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
357128|NCT00687076|Drug|Ezetimibe|Daily dose of 10 mg of Ezetimibe
357129|NCT00005624|Drug|CI-994|CI-994 as outlined in treatment arm.
357130|NCT00687076|Drug|Niaspan|Daily dose of 1500 mg of Niaspan
357131|NCT00687076|Drug|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
357132|NCT00687076|Behavioral|Standard care|Standard of medical care for PAD
357133|NCT00687076|Drug|Aspirin|Daily dose of 325 mg of aspirin
356497|NCT00609817|Drug|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
356498|NCT00609817|Drug|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
356499|NCT00004261|Other|fluorescent antibody technique|
356799|NCT00602277|Other|Laboratory Biomarker Analysis|Correlative studies
356800|NCT00604695|Drug|Sterile Saline|Intracoronary injection of IV sterile saline
356801|NCT00004233|Drug|triacetyluridine|
356802|NCT00604708|Biological|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
356803|NCT00604708|Biological|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
356804|NCT00604721|Drug|selumetinib|Given orally
356805|NCT00604721|Other|pharmacological study|
356806|NCT00604734|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
356807|NCT00604747|Other|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
356808|NCT00604760|Drug|MEM 3454|Capsule 5 mg once a day
356809|NCT00604760|Drug|MEM 3454|Capsule 15 mg once a day
356810|NCT00604760|Drug|MEM 3454|Capsule 50 mg once a day
356811|NCT00604760|Drug|Placebo for MEM 3454|Capsule once a day
356812|NCT00004234|Procedure|management of therapy complications|
356813|NCT00604786|Drug|omalizumab|IgE 30-100 int. units/mL:
30-90 kg: 150 mg every 4 weeks >90-150 kg: 300 mg every 4 weeks
IgE >100-200 int. units/mL:
30-90 kg: 300 mg every 4 weeks >90-150 kg: 225 mg every 2 weeks
IgE >200-300 int. units/mL:
30-60 kg: 300 mg every 4 weeks >60-90 kg: 225 mg every 2 weeks >90-150 kg: 300 mg every 2 weeks
IgE >300-400 int. units/mL:
30-70 kg: 225 mg every 2 weeks >70-90 kg: 300 mg every 2 weeks >90 kg: Do not administer dose
IgE >400-500 int. units/mL:
30-70 kg: 300 mg every 2 weeks >70-90 kg: 375 mg every 2 weeks >90 kg: Do not administer dose
IgE >500-600 int. units/mL:
30-60 kg: 300 mg every 2 weeks >60-70 kg: 375 mg every 2 weeks >70 kg: Do not administer dose
IgE >600-700 int. units/mL:
30-60 kg: 375 mg every 2 weeks >60 kg: Do not administer dose
361362|NCT00638560|Dietary Supplement|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
361363|NCT00638560|Dietary Supplement|Antioxidant treatment|no treatment
361364|NCT00638599|Device|LMA®|LMA® is placed after anesthesia induction and removed after the operation
361365|NCT00638599|Device|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
361366|NCT00638612|Biological|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
361367|NCT00638612|Drug|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
361368|NCT00638638|Drug|Abciximab|Abciximab: 0.25 mg/Kg bolus
Abciximab placebo bolus
Abciximab infusion 10 µg/Kg/min
361369|NCT00638638|Drug|Abciximab placebo|Abciximab placebo Bolus
Abciximab: 0.25 mg/Kg bolus
Abciximab infusion 10 µg/Kg/min
361370|NCT00004807|Drug|Donepezil|
361371|NCT00638651|Device|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
361372|NCT00638651|Drug|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
361373|NCT00638677|Dietary Supplement|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
356500|NCT00612144|Drug|Metformin HCl|Metformin HCl 500mg~1250mg bid for 12~26 weeks
Maintenance dose for 10 weeks after 2~14 weeks of dose titration
Dose titration according to titration algorithm based on daily mean SMBG
356501|NCT00612157|Drug|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
356502|NCT00612157|Drug|Placebo control|Matching placebo
356503|NCT00612170|Drug|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
356504|NCT00612170|Drug|Placebo|0 mg oral tablet once a day dosing
356505|NCT00612170|Drug|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
356506|NCT00612170|Drug|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
361035|NCT00645476|Drug|Memantine|Week 0 Memantine 5 mg q.d.
Week 1 if mild side effects -continue previous dose Memantine, 5 mg q.d. if well tolerated - Memantine 5 mg b.i.d
Weeks 2-3 if well tolerated - Memantine 5 mg b.i.d - if mild side effects - continue Memantine , 5 mg b.i.d. if well tolerated - Memantine 5 mg q.a.m and 10 mg q.p.
Week 4-12 if well tolerated - Memantine 5 mg q.a.m and 10 mg q.p.m - if mild side effects - continue Memantine, 5 mg q.a.m and 10 mg q.p.m if well tolerated - Memantine 10 mg b.i.d
361036|NCT00645476|Drug|Placebo|Week 0 placebo 5 mg q.d.
Week 1 if mild side effects -continue previous dose placebo, 5 mg q.d. if well tolerated - placebo 5 mg b.i.d
Weeks 2-3 if well tolerated - placebo 5 mg b.i.d - if mild side effects - continue placebo , 5 mg b.i.d. if well tolerated - placebo 5 mg q.a.m and 10 mg q.p.
Week 4-12 if well tolerated - placebo 5 mg q.a.m and 10 mg q.p.m - if mild side effects - continue placebo, 5 mg q.a.m and 10 mg q.p.m if well tolerated - placebo 10 mg b.i.d
361037|NCT00645489|Behavioral|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
361038|NCT00645489|Other|wait list|Wait list
361039|NCT00645502|Drug|risperidone|
361040|NCT00645515|Drug|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
361041|NCT00645515|Drug|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
361042|NCT00645528|Other|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
361043|NCT00645541|Procedure|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
361044|NCT00000641|Drug|Amikacin sulfate|
361045|NCT00004884|Drug|docetaxel|
361046|NCT00645554|Drug|Galantamine oral solution|
361047|NCT00645580|Drug|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
361374|NCT00638677|Dietary Supplement|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
361375|NCT00638677|Dietary Supplement|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
361376|NCT00638690|Drug|Placebo|Four tablets once daily until disease progression
361377|NCT00638690|Drug|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
361378|NCT00638690|Drug|Prednisone/prednisolone|5 mg twice daily until disease progression
360426|NCT00684463|Drug|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
360427|NCT00684476|Drug|venom immunotherapy|
360728|NCT00652912|Drug|Clonazepam|ODT, 1 mg
360729|NCT00652912|Drug|Klonopin Wafers|ODT, 1 mg
360730|NCT00652925|Drug|Celecoxib|Higher dose, 6 mg/kg/dose BID
360731|NCT00652925|Drug|Celecoxib|Active drug at lower dose
360732|NCT00652925|Drug|Naproxen|Control comparator, 15 mg/kg/dy target dose
360733|NCT00652938|Biological|HPV Vaccine (GSK580299) Cervarix TM|IM administration
360734|NCT00652938|Biological|Engerix B|IM administration
360735|NCT00004908|Drug|cyclophosphamide|
360736|NCT00652951|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
360737|NCT00652951|Biological|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
360738|NCT00652951|Biological|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
360739|NCT00652951|Biological|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
360740|NCT00652964|Device|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
360741|NCT00652977|Procedure|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
360742|NCT00652977|Procedure|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
360743|NCT00653003|Drug|Leflunomide|tablets, 20mg, single-dose
360744|NCT00653003|Drug|ARAVA|Tablets, 20mg, single-dose
360745|NCT00653016|Drug|norelgestromin; ethinyl estradiol|
360140|NCT00676871|Drug|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
360141|NCT00000661|Drug|Zidovudine|
360142|NCT00005577|Drug|gemcitabine hydrochloride|
360143|NCT00676871|Drug|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
360144|NCT00676871|Drug|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
360145|NCT00676871|Drug|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
360146|NCT00676871|Drug|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
360428|NCT00686556|Biological|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10^8 nucleated cells/kg recipient weight, minimum 3x10^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
360429|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
360430|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
360431|NCT00686582|Procedure|Blood Draw Only|
360432|NCT00686595|Biological|Infliximab|Infliximab 5 mg/kg IV infusion.
360433|NCT00686608|Dietary Supplement|glucose|0.3mg/kg of glucose
360434|NCT00005619|Genetic|polymerase chain reaction|
360435|NCT00686608|Dietary Supplement|fructose|fructose IV bolus
360436|NCT00686608|Dietary Supplement|saline|IV saline
360437|NCT00686621|Drug|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
360438|NCT00686634|Drug|Sitagliptin|Sitagliptin 100 mg by mouth once daily
360439|NCT00686647|Device|AngioSculpt® Scoring Balloon Catheter|Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion
360440|NCT00686647|Device|AngioSculpt Scoring Balloon Catheter|Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device
356944|NCT00691639|Other|Blood Collection Only|Blood Collection Only
357245|NCT00675077|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
357246|NCT00675090|Drug|GSK239512|GSK239512 oral tablets once a day
357247|NCT00675090|Drug|Placebo|Placebo tablets to match once a day
357248|NCT00675103|Drug|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
357249|NCT00675116|Drug|GW823296|
357250|NCT00677352|Drug|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
357251|NCT00677365|Drug|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
357252|NCT00677365|Drug|Placebo|same frequency as study drug using the same nebulizer
357253|NCT00677391|Drug|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
357254|NCT00677391|Drug|Placebo|Capsules, once daily
357255|NCT00677404|Biological|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
357256|NCT00005578|Drug|vincristine sulfate|
357257|NCT00677430|Behavioral|Questionnaire|A brief questionnaire packet will be completed.
357258|NCT00677430|Procedure|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
357259|NCT00677443|Drug|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
357260|NCT00677443|Drug|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
357261|NCT00677456|Procedure|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
357262|NCT00677456|Procedure|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
356630|NCT00624039|Other|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
356631|NCT00624052|Drug|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
356632|NCT00624052|Drug|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
356633|NCT00625898|Drug|Bevacizumab|15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B
15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B
356945|NCT00694018|Behavioral|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
356946|NCT00005769|Drug|Hormone Replacement Therapy|
356947|NCT00694031|Procedure|Hemodialysis|3 times per week
356948|NCT00694031|Procedure|On-line hemodiafiltration|3 times per week
356949|NCT00694044|Drug|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
356950|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
356951|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
356952|NCT00694044|Drug|Placebo|Placebo for 21 days
356953|NCT00694057|Drug|HE3286|HE3286 10 mg per day (5 mg BID)
356954|NCT00694057|Drug|Placebo|Placebo capsules BID
356955|NCT00694083|Drug|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
356956|NCT00694096|Drug|Sunitinib|Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.
Imaging studies include:
FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans
356957|NCT00005770|Device|Acupuncture|
356958|NCT00694109|Drug|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
356959|NCT00694122|Drug|Lantus (glargine)|Described in Arm Description
361519|NCT00653185|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
361520|NCT00653198|Other|No intervention|
361521|NCT00653224|Drug|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
361522|NCT00653224|Drug|placebo|0 mg daily (matching oral tablet) for 14 days
361523|NCT00004911|Procedure|bowel obstruction management|
361524|NCT00653237|Device|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
361525|NCT00653250|Drug|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
361526|NCT00653250|Procedure|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
361527|NCT00653250|Procedure|therapeutic conventional surgery|surgery to remove the lung tumor
361528|NCT00653276|Drug|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
356634|NCT00625898|Drug|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
356635|NCT00625898|Drug|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
356636|NCT00625898|Drug|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
356637|NCT00625911|Drug|morphine|intravenous patient controlled analgesia, standard protocol
356638|NCT00004562|Procedure|PTCA and stents|Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
356639|NCT00625911|Drug|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
356640|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
356641|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
356642|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
361188|NCT00660881|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
361189|NCT00660894|Drug|folinate calcium|
361190|NCT00660894|Drug|tegafur-uracil|
361191|NCT00660894|Drug|tegafur-gimeracil-oteracil potassium|
361192|NCT00660907|Drug|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
361193|NCT00660907|Drug|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
361194|NCT00660907|Drug|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
361195|NCT00660920|Drug|Ponatinib|Comparison of different dosages of drug given orally once per day.
361196|NCT00660933|Drug|Iron sucrose|Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
361197|NCT00005002|Biological|HIV-1 Immunogen|
361198|NCT00660933|Drug|NaCl|NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
361199|NCT00660959|Drug|lixivaptan|oral capsule
361200|NCT00660959|Drug|placebo|oral capsule
361201|NCT00660972|Drug|Raltegravir|400 mg tablet taken orally twice daily
361202|NCT00660972|Drug|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
361203|NCT00660985|Drug|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
361529|NCT00653276|Drug|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
361530|NCT00653302|Drug|Lantus (insulin glargine) + Glucophage (Metformin)|
361531|NCT00653315|Drug|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
361532|NCT00653315|Drug|Ultracet|Tablets, 37.5mg/325mg
361533|NCT00653328|Drug|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
361534|NCT00004911|Procedure|quality-of-life assessment|
360554|NCT00674648|Biological|CMV-Peptide-Specific T cells|In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).
The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose.
360555|NCT00674661|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
360556|NCT00674661|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
360557|NCT00674674|Drug|Topotecan|Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.
The Induction period is the first 4 weeks of therapy.
360558|NCT00674674|Drug|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
360559|NCT00674674|Drug|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
360560|NCT00674687|Drug|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
360561|NCT00674687|Drug|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
360562|NCT00674700|Drug|Sublingual Immunotherapy Tablets of house dust mites allergen extract|House dust mite allergen-based tablets, 300 IR, once daily, 12 months
360563|NCT00000659|Drug|Zidovudine|
360564|NCT00005110|Drug|Salmeterol|
360565|NCT00674700|Drug|Sublingual Immunotherapy Tablets of house dust mites allergen extract|House dust mite allergen-based tablets, 500 IR, once daily, 12 months
360566|NCT00674700|Drug|placebo|placebo tablets, once daily, 12 months
360567|NCT00674713|Other|Acupuncture|
360568|NCT00674713|Drug|Ondansetron|
360569|NCT00674713|Drug|Physiological saline solution|
360570|NCT00674713|Other|Sham acupuncture|
360571|NCT00674713|Drug|Ondansetron|
360572|NCT00674713|Other|Acupuncture at P6 point|
359610|NCT00671814|Drug|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
359611|NCT00005088|Radiation|radiation therapy|
359612|NCT00673907|Other|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
359613|NCT00673920|Drug|methotrexate|Oral or parenteral repeating dose
359614|NCT00673920|Drug|ocrelizumab|Intravenous repeating dose
359615|NCT00673920|Drug|placebo|Intravenous repeating dose
359616|NCT00000659|Drug|CD4 Antigens|
359617|NCT00005104|Drug|clomiphene citrate|
359942|NCT00681746|Drug|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
359943|NCT00681772|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
359944|NCT00681785|Drug|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
359945|NCT00681798|Drug|Vandetanib|100mg/300mg
359946|NCT00681811|Drug|HGT-1111|Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
359947|NCT00681824|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
359948|NCT00681824|Procedure|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
359949|NCT00681863|Drug|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
359950|NCT00681863|Drug|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
359951|NCT00005596|Drug|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
359952|NCT00681863|Drug|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
358975|NCT00678652|Biological|Group B Meningococcal 8570 HOPS-G NOMV Vaccine|
358976|NCT00678678|Device|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
358977|NCT00678678|Device|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
358978|NCT00678691|Drug|armodafinil|50-250mg/d
358979|NCT00678691|Drug|placebo|matching placebo
358980|NCT00681148|Drug|Botox injection|Intraprostatic injection of Botox (100 units for < 30 cc prostate; 200 units for > 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
358981|NCT00681148|Drug|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
358982|NCT00681161|Other|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
358983|NCT00681174|Drug|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
359290|NCT00005633|Biological|tyrosinase peptide|
359291|NCT00688389|Genetic|CLEC5A|SNP (Single Nucleotide Polymorphism) genetic analysis of CLEC5A receptor (from exon 1 to exon 7)
359292|NCT00688402|Drug|AZD3355|Single dose
359293|NCT00688415|Drug|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
359294|NCT00688428|Drug|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
359295|NCT00688428|Drug|Esomeprazole|40mg capsule, administered as a single dose
359296|NCT00688428|Drug|ASA|325mg tablet, administered as a single oral dose
359297|NCT00688441|Drug|Nasal CO2|Twice daily during the 14 day Treatment Period
359298|NCT00688441|Drug|Placebo|Use of the study drug dispenser at the same frequency as the active arm
359299|NCT00688467|Drug|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
359300|NCT00688467|Drug|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
358647|NCT00692705|Drug|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
358648|NCT00692718|Drug|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
358649|NCT00671112|Drug|Bortezomib|Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.
The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line.
358650|NCT00671112|Drug|Everolimus|Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
358651|NCT00671125|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
358652|NCT00671125|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
358653|NCT00005085|Drug|becatecarin|
358654|NCT00671125|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
358655|NCT00671138|Biological|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
358656|NCT00671138|Other|Sham inoculation|A diluted amount of McIlhenny & Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
358657|NCT00671151|Drug|Theophylline|Theophylline 100 mg bid for 3 months
358658|NCT00671177|Procedure|water immersion colonoscopy|instillation of 300cc of water in the rectum
358659|NCT00671177|Procedure|standard air colonoscopy|air instillation in colon for visualization
358660|NCT00671190|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
358661|NCT00671190|Drug|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
358662|NCT00671190|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
358663|NCT00671190|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
358984|NCT00681174|Drug|oxycodone|20 mg p.o. 1 h before the start of anesthesia
358985|NCT00681174|Procedure|Paravertebral block|Three injections of 0.5% ropivacaine, 5 ml each
Injections at the T5, T6 and T7 levels
A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be "walked off" the process and the injection will be made 1 cm deeper.
358018|NCT00000665|Drug|Foscarnet sodium|
358019|NCT00005589|Drug|etoposide|
358020|NCT00680498|Drug|Ranibizumab|Ranibizumab 0.5 mg
358021|NCT00680498|Drug|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
358330|NCT00685490|Procedure|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
358331|NCT00685503|Drug|Ranibizumab|
358332|NCT00687713|Other|Placebo|Placebo
358333|NCT00687726|Behavioral|Standing balance exercise|Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
358334|NCT00005631|Biological|filgrastim|
358335|NCT00687726|Behavioral|Isometric knee extension exercise|Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
358336|NCT00687739|Drug|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
358337|NCT00687739|Drug|Estradiol Transdermal|0.075 mg patch per day for 5 months
358338|NCT00687739|Behavioral|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
358339|NCT00687765|Drug|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
358340|NCT00687791|Device|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
358341|NCT00687804|Drug|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
358342|NCT00687804|Procedure|Laser|Laser photocoagulation treatment
358343|NCT00687804|Procedure|Sham laser|Sham to laser procedure.
358344|NCT00687804|Drug|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
358345|NCT00005631|Biological|rituximab|
357733|NCT00675285|Drug|montelukast sodium|one tablet 5 mg once/day for 4 weeks
357734|NCT00675285|Drug|placebo|one tablet 5 mg once/day for 4 weeks
357735|NCT00005118|Drug|Indinavir sulfate|
357736|NCT00675311|Behavioral|DM-Standard|Device/t+ Medical Diabetes Management System
357737|NCT00675311|Behavioral|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
357738|NCT00675324|Drug|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
357739|NCT00675324|Dietary Supplement|Fresubin Energy drink|30 kcal/kg*day five days before colonoscopy
357740|NCT00675337|Procedure|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
357741|NCT00675337|Procedure|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
357742|NCT00675350|Drug|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
357743|NCT00675363|Procedure|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
357744|NCT00675363|Procedure|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
357745|NCT00675389|Behavioral|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for ~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
358022|NCT00680511|Behavioral|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
358023|NCT00680511|Behavioral|Functional Family Therapy (FFT)|FFT
358024|NCT00680524|Other|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
358025|NCT00680537|Procedure|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
358026|NCT00680563|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
357134|NCT00687076|Drug|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
357135|NCT00687076|Drug|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
357419|NCT00694460|Biological|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
357420|NCT00694460|Biological|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
357421|NCT00694473|Device|Freestyle Navigator|Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
357422|NCT00694512|Dietary Supplement|Low fat diet|20% fat diet
357423|NCT00694512|Dietary Supplement|High fat diet|40% fat diet
357424|NCT00694512|Dietary Supplement|MCT diet|Medium chain triglyceride diet
357425|NCT00694538|Device|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
357426|NCT00005773|Drug|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had <=20 mm Hg increase in PaO2 (less than full response).
357427|NCT00631345|Behavioral|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
357428|NCT00631358|Drug|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
357429|NCT00631358|Other|No treatment|Healthy normal control group receiving no treatment
357430|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
357431|NCT00631371|Drug|Temsirolimus|Temsirolimus 25 mg IV weekly
357432|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
356814|NCT00604786|Drug|placebo|IgE 30-100 int. units/mL:
30-90 kg: placebo every 4 weeks >90-150 kg: placebo every 4 weeks
IgE >100-200 int. units/mL:
30-90 kg: placebo every 4 weeks >90-150 kg: placebo every 2 weeks
IgE >200-300 int. units/mL:
30-60 kg: placebo every 4 weeks >60-90 kg: placebo every 2 weeks >90-150 kg: placebo every 2 weeks
IgE >300-400 int. units/mL:
30-70 kg: placebo every 2 weeks >70-90 kg: placebo every 2 weeks >90 kg: Do not administer dose
IgE >400-500 int. units/mL:
30-70 kg: placebo every 2 weeks >70-90 kg: placebo every 2 weeks >90 kg: Do not administer dose
IgE >500-600 int. units/mL:
30-60 kg: placebo every 2 weeks >60-70 kg: placebo every 2 weeks >70 kg: Do not administer dose
IgE >600-700 int. units/mL:
30-60 kg: placebo every 2 weeks >60 kg: Do not administer dose
356815|NCT00604799|Device|Talent Thoracic Stent Graft|TEVAR
356816|NCT00604812|Drug|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
356817|NCT00604812|Drug|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
356818|NCT00604812|Drug|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
357136|NCT00687076|Drug|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
357137|NCT00687076|Procedure|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
357138|NCT00687089|Other|Sexual, cognitive functional tests and measurement weight|
357139|NCT00687102|Drug|tamoxifen|oral tamoxifen plus placebo daily for 5 years
357140|NCT00005625|Drug|trabectedin|
357141|NCT00687102|Drug|raloxifene|oral raloxifene plus placebo daily for 5 years
357142|NCT00689390|Other|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
357143|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
357144|NCT00005640|Procedure|Gamma Probe|
357145|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
357146|NCT00689416|Drug|rosuvastatin|40 mg, tablet, once daily for 3 months.
357147|NCT00689416|Drug|placebo|40 mg, tablet, once daily for 3 months
357148|NCT00689442|Drug|JTT-705 600 mg and atorvastatin 20 mg|JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment
Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments
356507|NCT00612183|Drug|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
356508|NCT00004300|Drug|sertraline hydrochloride|
356509|NCT00612196|Drug|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
356510|NCT00612196|Drug|Placebo|
356511|NCT00612209|Drug|ARQ 197|Treatment with ARQ 197
356512|NCT00612222|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
356513|NCT00612222|Biological|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
356514|NCT00612222|Biological|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
356515|NCT00612222|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
356516|NCT00612222|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
356517|NCT00612248|Other|Splint|Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
356819|NCT00604812|Drug|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
356820|NCT00604825|Drug|Other: Placebo|
356821|NCT00604825|Drug|GSK232802|
356822|NCT00604825|Drug|PREMARIN|
356823|NCT00004234|Radiation|radiation therapy|
356824|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
356825|NCT00607412|Behavioral|12-step based supportive therapy|supportive psychotherapy based on 12-step model
356826|NCT00607438|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
361379|NCT00638703|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU Oxalobacter formigenes twice daily for 24 weeks
361380|NCT00638703|Drug|Placebo|placebo
361381|NCT00004808|Drug|fluconazole|
361382|NCT00638716|Drug|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
361383|NCT00640939|Drug|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
361384|NCT00640952|Drug|acamprosate|333 mg 2 tabs tid
361385|NCT00640965|Drug|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
361386|NCT00640965|Drug|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
361387|NCT00004853|Biological|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
361388|NCT00640978|Drug|RAD001|30 mg orally weekly for 4 weeks
361389|NCT00640978|Drug|Erlotinib|150 mg by mouth daily for 28 Days
361390|NCT00640991|Drug|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
361391|NCT00641004|Drug|Rebamipide and Esomeprazole|Rebamipide 100mg TID for 12 weeks
Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
361392|NCT00641017|Biological|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
361393|NCT00641017|Biological|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
361394|NCT00641030|Drug|clofarabine|Administered at the appropriate dose level(dose level one = 30 mg/m2, dose level two and three = 40 mg/m2)on days -9 to day -5 from transplant
361395|NCT00641030|Drug|melphalan|Administered at the appropriate dose level (dose level one and two = 100 mg/m2, dose level three = 140 mg/m2) on day -4 from transplant
361396|NCT00641030|Genetic|gene expression analysis|Peripheral blood draw on day -9 and day -4 prior to transplant
356518|NCT00612261|Procedure|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
360746|NCT00004908|Procedure|peripheral blood stem cell transplantation|
360747|NCT00653042|Drug|Nesiritide|
360748|NCT00653055|Drug|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
360749|NCT00653055|Drug|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
360750|NCT00653068|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSC rescue
361048|NCT00645593|Drug|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
361049|NCT00645593|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
361050|NCT00645593|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
361051|NCT00645606|Biological|Rituximab|rituximab :500 mg/m² every 8 weeks every 2 years
361052|NCT00648232|Behavioral|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
361053|NCT00648232|Behavioral|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
361054|NCT00648232|Behavioral|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
361055|NCT00648232|Behavioral|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
361056|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
361057|NCT00004897|Biological|recombinant interferon alfa|
361058|NCT00648245|Drug|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
361059|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
361060|NCT00648245|Drug|Placebo|Placebo given once daily for 21 days by nebulizer
360441|NCT00686660|Behavioral|cycling, walking|In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years.
360442|NCT00686660|Behavioral|cycling, non-walking|In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients don't receive walk training.
360443|NCT00686660|Behavioral|walking, walking|In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years.
360444|NCT00686660|Behavioral|walking, non-walking|In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients don't walking at community.
360445|NCT00005619|Other|flow cytometry|
360446|NCT00686673|Behavioral|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
360447|NCT00686673|Behavioral|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
360751|NCT00653068|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
360752|NCT00655512|Drug|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
360753|NCT00655512|Drug|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
360754|NCT00655525|Dietary Supplement|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
360755|NCT00655525|Dietary Supplement|placebo|placebo administered orally every day for 3 months
360756|NCT00655538|Drug|Placebo|po daily for 36 weeks
360757|NCT00655538|Drug|dalcetrapib|600mg po daily for 36 weeks
360758|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
360759|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
360760|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
357263|NCT00677456|Procedure|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
357556|NCT00682669|Behavioral|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
357557|NCT00682669|Behavioral|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
357558|NCT00682682|Other|Virtual Reality video distraction|Virtual Reality involves wearing a helmet and playing a game called "Snow world". This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are "in" the game.
357559|NCT00682682|Other|Virtual Reality video game|Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being "in" the game. The game used for this study is "Snow World"
357560|NCT00682708|Dietary Supplement|PlumpyNut|
357561|NCT00005599|Drug|bryostatin 1|
357562|NCT00682708|Dietary Supplement|PlumpyDoz|
357563|NCT00682721|Drug|Placebo|Matching placebo two pills once daily
357564|NCT00682721|Drug|Valacyclovir|1 gram daily x number of days active in the study
357565|NCT00682734|Drug|metoclopramide|metoclopramide 20 mg
357566|NCT00682734|Drug|metoclopramide|metoclopramide 40 mg
357567|NCT00682734|Drug|metoclopramide|metoclopramide 10 mg
357568|NCT00682734|Drug|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
357569|NCT00684918|Drug|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
357570|NCT00684931|Other|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
357571|NCT00684944|Drug|TRx0014|Gelatin capsule, tid
357572|NCT00684957|Drug|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
357573|NCT00005608|Drug|leucovorin calcium|
357574|NCT00684957|Drug|Recombinant human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
356960|NCT00694135|Drug|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
356961|NCT00694135|Drug|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
356962|NCT00694135|Drug|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
356963|NCT00694135|Drug|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
356964|NCT00694148|Drug|NT 201|A Botulinum neurotoxin type A, free of complexing proteins
Detailed described in study protocol
356965|NCT00694161|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
357264|NCT00677456|Procedure|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
357265|NCT00677469|Drug|Cholestyramine|2 grams BID
357266|NCT00677469|Drug|Cholestyramine|1 gram BID
357267|NCT00005578|Radiation|radiation therapy|
357268|NCT00677469|Drug|Placebo powder|1 gram BID
357269|NCT00677495|Dietary Supplement|Gluten-free diet|Gluten-free diet
357270|NCT00677521|Drug|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
357271|NCT00677534|Drug|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
357272|NCT00677573|Drug|Fostimon|450 IU for 4 days then adjusted
357273|NCT00679900|Drug|eplivanserin (SR46349)|5 mg/day
357274|NCT00679900|Drug|lormetazepam|1 mg/day
357275|NCT00679913|Procedure|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
357276|NCT00679913|Procedure|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
357277|NCT00679926|Drug|Lopinavir/ritonavir and tenofovir|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
356643|NCT00625937|Drug|cisplatin|
356644|NCT00625937|Drug|docetaxel|
356645|NCT00625937|Drug|tegafur-gimeracil-oteracil potassium|
356646|NCT00625937|Radiation|radiation therapy|
356647|NCT00625950|Procedure|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
356648|NCT00625976|Behavioral|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
356649|NCT00004562|Drug|ACE Inhibitors|Participants will receive ACE inhibitors.
356650|NCT00625976|Behavioral|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
356651|NCT00625989|Drug|Aeroallergen|
356652|NCT00626002|Drug|ABT-874|100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
356653|NCT00626015|Biological|PEP-3-KLH conjugate vaccine|Given intradermally
356654|NCT00626015|Biological|daclizumab|Given IV
356655|NCT00626015|Drug|temozolomide|Given by mouth.
356966|NCT00694174|Drug|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
356967|NCT00694174|Drug|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
356968|NCT00000678|Drug|Zidovudine|
356969|NCT00005771|Device|Visual utrasound feedback|
356970|NCT00672386|Other|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
356971|NCT00005090|Drug|carmustine|150/m^2 on days -6 to -4 (4-6 days before transplant).
356972|NCT00672399|Drug|exenatide|Subcutaneously injected, 10 mcg, single doses
356973|NCT00672399|Drug|Moxifloxacin|oral, 400 mg tablet, single doses
356974|NCT00672399|Drug|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
361535|NCT00653328|Drug|doxil|50 mg/m2 intravenously every 28 days
361536|NCT00653341|Drug|insulin glargine|
361537|NCT00653341|Drug|NPH human insulin|
361538|NCT00653354|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
361539|NCT00653354|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
361540|NCT00655798|Dietary Supplement|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
361541|NCT00655798|Dietary Supplement|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
361542|NCT00655798|Dietary Supplement|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
361543|NCT00655811|Drug|Capsaicin|Topical application
361544|NCT00655824|Drug|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
361545|NCT00655837|Drug|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
361546|NCT00655837|Drug|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
361547|NCT00655837|Drug|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
361548|NCT00004923|Drug|docetaxel|
361549|NCT00655850|Drug|Paclitaxel|Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:
Dexamethasone 20mg, intravenously (IV)
Diphenhydramine 50 mg IV
Ranitidine 50 mg IV
Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.
The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)
Paclitaxel Dose Levels:
Dose Level 1 ________80 mg/m2/weekly
Dose Level -1 ________70 mg/m2/weekly
356656|NCT00626015|Other|placebo|Given IV
356657|NCT00626015|Biological|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
356658|NCT00628394|Drug|Placebo|40mg 2po qam
356659|NCT00628420|Drug|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
356660|NCT00628420|Drug|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
360573|NCT00674713|Drug|Physiological saline solution|
360574|NCT00677053|Drug|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
360866|NCT00667602|Biological|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
360867|NCT00667602|Biological|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
360868|NCT00667615|Drug|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
360869|NCT00667628|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
360870|NCT00667628|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
360871|NCT00667641|Drug|bortezomib|Starting dose level 0.70mg/m2
360872|NCT00667641|Drug|paclitaxel|Starting dose level 40mg/m2
360873|NCT00667654|Drug|4975|Testing a range of dosing configurations to optimize patient tolerability
360874|NCT00667667|Device|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
360875|NCT00005057|Drug|ganciclovir|
360876|NCT00667667|Device|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
360877|NCT00667667|Behavioral|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
360878|NCT00667680|Device|Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator|real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
360879|NCT00667693|Device|Macintosh intubation|Macintosh intubation
360880|NCT00667693|Device|Pentax AWS|Intubation with Pentax AWS
360881|NCT00667706|Procedure|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
359953|NCT00681863|Drug|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
359954|NCT00681863|Drug|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
359955|NCT00681876|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
359956|NCT00681876|Drug|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
359957|NCT00681876|Drug|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
359958|NCT00681889|Drug|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
359959|NCT00681902|Drug|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
359960|NCT00681902|Drug|Placebo|Jet saline
359961|NCT00681915|Drug|AZD7325|Oral
360265|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|Low Dose- 70g bar
360266|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|High Dose- 100g bar
360267|NCT00005654|Drug|metformin|
360268|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
360269|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|High dose: 100g bar
360270|NCT00691249|Dietary Supplement|Shredded Wheat|70g bar
360271|NCT00691262|Drug|tacrolimus ointment|transdermal
360272|NCT00691275|Drug|Ondansetron|
360273|NCT00691275|Drug|Saline|
360274|NCT00691288|Drug|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
360275|NCT00691288|Drug|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
360276|NCT00691301|Drug|cisplatin|
359301|NCT00005634|Drug|vorinostat|
359302|NCT00688480|Drug|Placebo|1 capsule, orally for 9 months
359303|NCT00688480|Drug|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
359304|NCT00688493|Drug|Dapagliflozin|3 x 50 mg tablets, single oral dose
359305|NCT00688493|Drug|Dapagliflozin|2 x 10 mg capsules, single oral dose
359306|NCT00688493|Drug|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
359307|NCT00690625|Drug|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
359308|NCT00005646|Drug|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
359309|NCT00690625|Drug|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
359310|NCT00690638|Drug|PHX1149T|200 mg
359311|NCT00690638|Drug|PHX1149T|400 mg
359312|NCT00690638|Drug|Placebo|Placebo
359313|NCT00690651|Procedure|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
359618|NCT00673933|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
359619|NCT00673946|Other|True saturation values displayed|Physicians will be presented with real saturations.
359620|NCT00673946|Other|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
359621|NCT00673959|Other|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
359622|NCT00673959|Other|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
359623|NCT00673972|Radiation|gastric scintigraphy|All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.
Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window.
359624|NCT00673985|Other|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
358986|NCT00681174|Drug|Propofol|Plasma concentration target-controlled infusion based on bispectral index values
Acceptable range of concentrations: 2-4 µg/mL
Target bispectral index values: 40-60
Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)
358987|NCT00005592|Radiation|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
358988|NCT00681174|Drug|Remifentanil|50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min
Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)
Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.
Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)
358989|NCT00681174|Drug|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
358990|NCT00681174|Drug|Morphine|Patient-controlled intravenous infusion pump (IV-PCA).
50 mg morphine in 50 ml saline solution (1 mg/ml)
Incremental dose: 1 mg
Lock-out time: 8 min
Limit: 40 mg in 4 h
Background infusion: none
358991|NCT00681187|Drug|lanreotide (Autogel formulation)|90 mg or 120 mg once every 28th day
358992|NCT00681200|Behavioral|Enhanced health education|health education and social support
358993|NCT00681200|Behavioral|Transcendental Meditation program|The TM program plus didactic-based health education classes
358994|NCT00681213|Drug|Tacrolimus/Sirolimus|
358995|NCT00681213|Drug|Tacrolimus/MMF|
358996|NCT00681213|Drug|Neoral/Sirolimus|
358997|NCT00681226|Drug|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
358998|NCT00000665|Drug|Ganciclovir|
358999|NCT00005593|Drug|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
359000|NCT00681239|Dietary Supplement|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
359001|NCT00683475|Drug|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
359002|NCT00683475|Biological|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
358346|NCT00687817|Drug|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
358347|NCT00687830|Drug|Polythylene Glycol|Prescribed the standard dose of 4L or 1 Gallon to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
358348|NCT00687830|Drug|Polythylene Glycol|Prescribed the standard dose of 4L or 1 Gallon to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
358349|NCT00687830|Drug|Polyethylene glycol|Prescribed the standard dose of 4L or 1 Gallon to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
358664|NCT00005086|Drug|cisplatin|
358665|NCT00671190|Drug|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
358666|NCT00671203|Procedure|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
358667|NCT00671216|Drug|GSK233705|
358668|NCT00671216|Drug|GW642444|
358669|NCT00671255|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
358670|NCT00671255|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
358671|NCT00671255|Drug|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
358672|NCT00671268|Biological|AL0704rP|strict subcutaneous
358673|NCT00671268|Biological|Placebo|strict subcutaneous
358674|NCT00671281|Drug|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
358675|NCT00000658|Drug|Cytarabine|
358676|NCT00673309|Drug|Byetta|Byetta administered daily throughout hospitalization until 95% wound healing.
358677|NCT00673309|Drug|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
358678|NCT00673309|Drug|Pioglitazone|Pioglitazone administered daily throughout hospitalization until 95% wound healing
358679|NCT00005093|Drug|tacedinaline|
358027|NCT00680576|Behavioral|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
358028|NCT00680576|Behavioral|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
358029|NCT00680589|Biological|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
358030|NCT00005589|Drug|melphalan|
358031|NCT00680602|Behavioral|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
358032|NCT00680602|Drug|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
358033|NCT00680615|Behavioral|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
358034|NCT00682929|Drug|Smoked Cannabis|20 people will be enrolled in this arm of the study and will receive study drug for 7 weeks. Subjects in this arm of the study will be instructed to take their oral medication (placebo for this group) two and a half hours prior to the inhaled medication. Subjects will take two pills and smoke one cannabis cigarette, daily.
358035|NCT00682929|Drug|Smoked Cannabis and oral marinol|20 people will be enrolled in this arm of the study and will receive study drug for 7 weeks. Subjects in this arm of the study will be instructed to take their oral medication (two 5mg dronabinol tablets) two and a half hours prior to the inhaled medication (placebo for this group). Subjects will take two pills and smoke one cigarette, daily.
358036|NCT00005601|Biological|rituximab|
358037|NCT00682929|Drug|Placebo|20 people will be enrolled in this arm of the study and will receive study drug for 7 weeks. Subjects in this arm of the study will be instructed to take their oral medication (placebo) two and a half hours prior to the inhaled medication (placebo). Subjects will take two pills and smoke one cigarette, daily.
358038|NCT00682955|Drug|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
358039|NCT00682955|Drug|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
358040|NCT00682981|Drug|Obatoclax|A 3-hour IV infusion for 3 consecutive days of Obatoclax with carboplatin and etoposide.
358350|NCT00687830|Drug|Polyethylene glycol|Bowel prep given on the morning of the day of the afternoon colonoscopy. Between 6AM and 10AM on the same day of colonoscopy.
358351|NCT00687843|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
358352|NCT00687843|Drug|Krestin (PSK)|3 g, PO from day 1 to day 336
357433|NCT00631371|Drug|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
357434|NCT00631384|Behavioral|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
357435|NCT00631384|Behavioral|Individual VCT|Women to receive individual VCT
357436|NCT00004689|Drug|clarithromycin|
357746|NCT00005118|Drug|Ritonavir|
357747|NCT00675389|Behavioral|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
357748|NCT00675402|Other|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
357749|NCT00675415|Device|Capnography (Specific device name: Capnostream 20)|Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
357750|NCT00675415|Device|Sham|sham
357751|NCT00675428|Drug|BG00002 (natalizumab)|
357752|NCT00675441|Drug|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
357753|NCT00675467|Behavioral|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
357754|NCT00677742|Other|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
357755|NCT00677742|Other|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
357756|NCT00677755|Drug|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
357757|NCT00677755|Drug|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
357758|NCT00677768|Other|No intervention|Sample collection
357759|NCT00677794|Drug|Clear fluids|Clear fluids only after lunch.
357760|NCT00005580|Drug|fludarabine phosphate|
357149|NCT00689442|Drug|Placebo and atorvastatin 20 mg|Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
357150|NCT00689468|Procedure|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
357151|NCT00689468|Dietary Supplement|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
357152|NCT00689468|Procedure|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
357153|NCT00689468|Dietary Supplement|"Echinacea purpurea" placebo|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
357437|NCT00631397|Device|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
357438|NCT00631410|Drug|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
357439|NCT00631410|Drug|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
357440|NCT00631449|Drug|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
357441|NCT00631449|Drug|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
357442|NCT00631462|Drug|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
357443|NCT00631475|Drug|Bosentan|For patients who were administered Bosentan during BUILD 3 (NCT00391443):
continue on same dose
For patients who were administered placebo during BUILD 3 (NCT00391443):
Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs < 90 lbs.)
357444|NCT00631488|Drug|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
357445|NCT00631488|Drug|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
357446|NCT00631488|Drug|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
357447|NCT00004689|Drug|ethambutol|
356827|NCT00004250|Drug|melphalan|
356828|NCT00607438|Drug|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
356829|NCT00607451|Drug|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
356830|NCT00607464|Device|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
356831|NCT00607477|Drug|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
356832|NCT00607477|Drug|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
356833|NCT00607490|Behavioral|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
356834|NCT00607490|Behavioral|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
356835|NCT00607503|Drug|Terbutaline|Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.
Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.
The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly.
356836|NCT00607516|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
356837|NCT00607516|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
356838|NCT00004251|Drug|letrozole|2.5 mg of letrozole per day
356839|NCT00607529|Other|hand-held POC creatinine analyzer-blood test|This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the "investigational" hand-held creatinine analyzer using special test strips for the analysis.
357154|NCT00689481|Drug|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
357155|NCT00005640|Procedure|Biopsy of Sentinel Lymph Nodes|
357156|NCT00689481|Drug|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
357157|NCT00689494|Other|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
357158|NCT00689507|Biological|LY2127399|monoclonal antibody
356519|NCT00004307|Behavioral|Protein and calorie controlled diet|
356520|NCT00614419|Device|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
356521|NCT00614419|Device|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
356522|NCT00614445|Drug|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
356523|NCT00614445|Drug|Placebo|2 to 4 tablets daily titrated according to the protocol
356524|NCT00614458|Drug|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
356525|NCT00614471|Drug|Entecavir|0.5mg po daily for 24 weeks
356526|NCT00614471|Drug|Entecavir|0.5mg po daily from week 13 to week 36
356527|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
356528|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
356529|NCT00004344|Drug|leuprolide|
356530|NCT00614484|Radiation|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
356531|NCT00614484|Drug|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
356532|NCT00614484|Drug|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
356533|NCT00614510|Device|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
356840|NCT00607542|Drug|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
361061|NCT00648245|Drug|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
361062|NCT00648258|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
361063|NCT00648258|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
361064|NCT00648271|Drug|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
361065|NCT00648271|Drug|Lopressor® Tablets 50 mg|1x50mg, single dose fed
361066|NCT00648297|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
361067|NCT00648297|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
361397|NCT00641030|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood draw on day -9 and day -4 prior to transplant
361398|NCT00004854|Drug|Carvedilol|
361399|NCT00641030|Other|flow cytometry|Bone marrow aspirate and biopsy to confirm diagnosis prior to transplant, day -9 pre-transplant, day 30 post-transplant, day 100 post-transplant, 6 months post-transplant, one year post-transplant, then yearly through year 5 post-transplant
361400|NCT00641030|Other|laboratory biomarker analysis|Peripheral blood draw day -9 or earlier pre-transplant, day 14 post-transplant, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, 6 months and one year post-transplant.
361401|NCT00641030|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of allogeneic hematopoietic stem cells on day 0 of transplant
361402|NCT00641043|Drug|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
361403|NCT00641043|Drug|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
361404|NCT00641056|Drug|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
361405|NCT00641056|Drug|Insulin Glargine|subcutaneous injection, variable dose, QD
361406|NCT00641069|Device|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
361407|NCT00641082|Drug|Clevudine|30mg for 48 weeks
361408|NCT00641082|Drug|Adefovir dipivoxil|10mg for 48 weeks
361409|NCT00643266|Behavioral|Recollection Training|Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond "yes" only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session.
360761|NCT00655564|Drug|Alefacept|Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose).
360762|NCT00000648|Drug|Penicillin G potassium|
360763|NCT00004921|Procedure|adjuvant therapy|
360764|NCT00655577|Behavioral|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
360765|NCT00655590|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
360766|NCT00655590|Drug|Sildenafil|100 mg daily dosing
360767|NCT00655590|Drug|Placebo|Matching placebos
360768|NCT00655603|Other|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
360769|NCT00655616|Drug|Montelukast Placebo|Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast
Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast
Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast
Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily
361068|NCT00000642|Drug|CD4-IgG|
361069|NCT00004897|Drug|cisplatin|
361070|NCT00648310|Drug|Tolterodine 4 mg|
361071|NCT00648310|Drug|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
361072|NCT00648323|Drug|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
361073|NCT00648336|Drug|Mercaptopurine 50 mg|50mg, single dose fasting
361074|NCT00648336|Drug|Purinethol® Tablets 50 mg|50mg, single dose fasting
361075|NCT00648349|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
361076|NCT00648349|Drug|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
361077|NCT00650689|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
361078|NCT00650689|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
357575|NCT00684970|Drug|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
357576|NCT00684983|Drug|Capecitabine|Given PO
357577|NCT00684983|Biological|Cixutumumab|Given IV
357578|NCT00684983|Other|Laboratory Biomarker Analysis|Correlative studies
357579|NCT00684983|Drug|Lapatinib Ditosylate|Given PO
357875|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
357876|NCT00005641|Drug|leucovorin calcium|
357877|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
357878|NCT00692055|Drug|PN400|naproxen 375 mg / esomeprazole 20 mg
357879|NCT00692055|Drug|Naproxen|naproxen 375 mg
357880|NCT00692081|Behavioral|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
357881|NCT00692081|Behavioral|Special vocational training|as provided in German special centres for vocational training
357882|NCT00005675|Drug|Oral bovine type I collagen|500 mcg of CI daily for 15 months
357883|NCT00692094|Biological|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
357884|NCT00692094|Biological|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
357885|NCT00692094|Biological|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
357886|NCT00692094|Biological|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
357278|NCT00679939|Drug|Rosiglitazone|up to 8mg/day
357279|NCT00679939|Drug|Metformin|up to 2000mg/day
357280|NCT00005587|Radiation|radiation therapy|
357281|NCT00679952|Procedure|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
357282|NCT00679952|Procedure|natural drainage of pancreatic duct|Natural drainage group
357283|NCT00679965|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
357284|NCT00679965|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
357285|NCT00679965|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
357286|NCT00679965|Drug|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
357580|NCT00684983|Other|Quality-of-Life Assessment|Ancillary studies
357581|NCT00684996|Drug|etaracizumab|Given IV
357582|NCT00684996|Biological|bevacizumab|Given IV
357583|NCT00685009|Drug|Estrogen hormone therapy|Estrogen pill daily
357584|NCT00000670|Drug|Probenecid|
357585|NCT00005608|Drug|tegafur-uracil|
357586|NCT00685009|Drug|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
357587|NCT00685009|Drug|Placebo|Placebo pill daily
357588|NCT00685022|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
Arm #A
Xopenex HFA MDI, albuterol HFA MDI
357589|NCT00685022|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
Arm #B
albuterol HFA MDI, Xopenex HFA MDI
357590|NCT00685035|Device|VEST Airway Clearance System, Model 205|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
356975|NCT00672412|Drug|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
356976|NCT00672412|Drug|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
356977|NCT00672412|Drug|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
356978|NCT00672412|Drug|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
356979|NCT00672438|Drug|Alfentanil|Target steady state infusion of alfentanil at a plasma concentration of 100ng/ml
356980|NCT00672451|Dietary Supplement|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
356981|NCT00672451|Dietary Supplement|placebo|placebo titrated up to 6 pills daily as patient tolerates
356982|NCT00005090|Drug|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
356983|NCT00672464|Drug|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
356984|NCT00672464|Drug|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
356985|NCT00672464|Drug|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
356986|NCT00672477|Drug|Methylnaltrexone bromide|Methylnatrexone (either 0.2ml, 0.4ml or 0.6ml) subcutaneously every other day for 14 days (ie, 7 doses)
356987|NCT00672477|Drug|Placebo|Placebo (either 0.2ml, 0.4ml or 0.6ml) subcutaneously every other day for 14 days (ie, 7 doses)
357287|NCT00679991|Drug|PRT-201|Applied topically to AVF during surgery
357288|NCT00679991|Drug|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
357289|NCT00680017|Drug|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
357290|NCT00680017|Drug|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
357291|NCT00005588|Radiation|radiation therapy|
357292|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
357293|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
324974|NCT00560144|Drug|RG1507|Pharmacokinetic-derived dose, <=16mg/kg iv weekly
324975|NCT00560157|Dietary Supplement|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
324976|NCT00004040|Biological|recombinant interferon alfa|
324977|NCT00560170|Drug|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
324978|NCT00560170|Drug|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
324979|NCT00560183|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
324980|NCT00560183|Drug|Placebo|Capsules
324981|NCT00560196|Other|Observation|N.A.
324982|NCT00560209|Drug|ONO-1101|placebo for 1 minute IV
324983|NCT00560209|Drug|ONO-1101|0.06 mg/kg for 1 minute IV
324984|NCT00560209|Drug|ONO-1101|0.125 mg/kg for 1 minute IV
324985|NCT00560222|Dietary Supplement|bovine lactoferrin|1gm of lactoferrin will be given each day
324986|NCT00560222|Dietary Supplement|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
324987|NCT00004040|Biological|rituximab|
324988|NCT00560235|Drug|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
324989|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
324990|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
324991|NCT00560274|Drug|Pegasys|As prescribed
324992|NCT00560274|Drug|Ribavirin|As prescribed
325284|NCT00553046|Other|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
325285|NCT00553059|Drug|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
325286|NCT00553059|Drug|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
324332|NCT00295997|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
324333|NCT00295997|Procedure|peripheral blood stem cell transplantation|
324334|NCT00296010|Drug|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
324697|NCT00282971|Other|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
324698|NCT00282971|Drug|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
324699|NCT00282984|Drug|placebo|1 mg placebo twice daily by mouth for 12 weeks
324700|NCT00282984|Drug|Varenicline|1 mg twice daily by mouth for 12 weeks
324701|NCT00567242|Behavioral|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
324702|NCT00567255|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
324703|NCT00567255|Drug|Placebo|
324704|NCT00567255|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
324705|NCT00567268|Drug|Gabapentin|GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.
Dosage, frequency: According to Japanese LPD, "Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg)".
Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration.
324706|NCT00000598|Behavioral|diet, fat-restricted|
324707|NCT00004083|Drug|cisplatin liposomal|
324708|NCT00567281|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
323975|NCT00305565|Device|VNS Therapy|Received output current of 0.5-1.0 mA
323976|NCT00305565|Device|VNS Therapy|Received output current of 1.0-1.5 mA
323977|NCT00002827|Drug|vincristine sulfate|Given IV
323978|NCT00305578|Drug|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
323979|NCT00305578|Drug|Placebo|No active medication, only placebo
323980|NCT00305591|Drug|l-ornithine l-aspartate|
323981|NCT00305604|Drug|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
323982|NCT00305604|Drug|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
323983|NCT00305617|Other|antitumor drug screening assay|
323984|NCT00305630|Drug|Periocular injection of triamcinolone acetonide 40mg|
323985|NCT00305643|Drug|Capecitabine|Initial dose of 750-1500 mg/m^2 orally twice a day for each 21 day cycle.
323986|NCT00305643|Drug|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
323987|NCT00305643|Procedure|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
323988|NCT00002827|Radiation|low-LET cobalt-60 gamma ray therapy|
323989|NCT00305643|Drug|Placebo|Oral placebo twice daily on days 1-21
323990|NCT00305656|Drug|cediranib maleate|Given orally
324335|NCT00296010|Drug|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
324336|NCT00296010|Drug|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
324337|NCT00296010|Procedure|adjuvant therapy|
324338|NCT00296010|Radiation|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
323274|NCT00272649|Biological|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
323615|NCT00262886|Biological|therapeutic allogeneic lymphocytes|
323616|NCT00262886|Drug|cyclophosphamide|
323617|NCT00262886|Drug|fludarabine phosphate|
323618|NCT00262886|Drug|mycophenolate mofetil|
323619|NCT00262886|Drug|tacrolimus|
323620|NCT00262886|Procedure|allogeneic bone marrow transplantation|
323621|NCT00262886|Procedure|peripheral blood stem cell transplantation|
323622|NCT00002701|Procedure|autologous bone marrow transplantation|
323623|NCT00262899|Behavioral|counseling intervention|
323624|NCT00262899|Other|educational intervention|
323625|NCT00262899|Procedure|psychosocial assessment and care|
323626|NCT00262925|Biological|alemtuzumab|Given subcutaneously
323627|NCT00262925|Drug|asparaginase|Given IM
323628|NCT00262925|Drug|methotrexate|Given IV or orally
323629|NCT00262925|Drug|dexamethasone|Given orally
323630|NCT00262925|Drug|leucovorin calcium|Given IV
323631|NCT00262925|Drug|mercaptopurine|Given orally
323632|NCT00262925|Drug|vincristine|Given IV
323633|NCT00002701|Radiation|radiation therapy|
323634|NCT00262938|Behavioral|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
323635|NCT00262938|Other|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
328401|NCT00556712|Drug|Placebo|po daily
328402|NCT00556738|Procedure|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
328403|NCT00556738|Procedure|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
328404|NCT00556764|Drug|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
328405|NCT00556764|Drug|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
328406|NCT00556777|Procedure|axillary lymph node dissection|
328407|NCT00556777|Procedure|conventional surgery|
328408|NCT00004022|Procedure|surgical procedure|
328409|NCT00556777|Procedure|sentinel lymph node biopsy|
328410|NCT00556777|Radiation|intraoperative radiation therapy|
328411|NCT00556790|Procedure|Standard Care|standard fluid regime, delayed feeding
328412|NCT00556790|Procedure|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
328413|NCT00556803|Procedure|radiofrequency ablation|radiofrequency ablation
328414|NCT00556803|Procedure|TACE after RFA|TACE after RFA within one month
328415|NCT00556816|Behavioral|on demand clinic|Outpatient on demand clinic
323275|NCT00272662|Drug|peginesatide|
323276|NCT00272675|Drug|Chlorhexidine gluconate (drug) vs placebo|
323277|NCT00272688|Drug|Levodopa (drug), intraduodenal administration|
323278|NCT00272701|Drug|Esomeprazole|
323279|NCT00002737|Drug|isotretinoin|
323280|NCT00272701|Drug|Other PPI marketed in Sweden|
323281|NCT00272714|Drug|Afimoxifene (0.057%) in hydroalcoholic gel|
323282|NCT00272727|Behavioral|Dialog tool for caregivers|
328091|NCT00561444|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
328092|NCT00561457|Device|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
328093|NCT00563641|Other|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
328094|NCT00563641|Other|bubble NCPAP|Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach "yes or no" treatment failure criteria.
328095|NCT00563654|Drug|Alfuzosin GITS (Xatral XL)|
328096|NCT00563667|Procedure|pterygium excision|
328097|NCT00563680|Drug|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand‑dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
328098|NCT00563693|Device|ASV|Adaptive servo ventilator
328099|NCT00004061|Procedure|peripheral blood stem cell transplantation|
328100|NCT00563693|Other|without Autoset CS2|without Autoset CS2
328101|NCT00563706|Drug|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
328102|NCT00563706|Drug|risperidone|
328103|NCT00563706|Other|placebo|
328104|NCT00563732|Drug|Lecozotan|
328105|NCT00563745|Device|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
328106|NCT00563758|Drug|tegaserod|
328107|NCT00563771|Drug|Rasburicase|
328108|NCT00563784|Drug|Erlotinib|150 mg by mouth daily for 7 Weeks
328109|NCT00563784|Drug|Carboplatin|2 AUC by vein weekly for 7 Weeks
328110|NCT00004061|Procedure|quality-of-life assessment|
327459|NCT00576381|Drug|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
327460|NCT00578565|Drug|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
327461|NCT00578578|Dietary Supplement|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
327462|NCT00578591|Drug|Rituximab|Rituximab 375 mg/m^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).
Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver.
327786|NCT00571298|Drug|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
327787|NCT00571324|Drug|exendin-(9-39)|A short term intravenous infusion of exendin-(9-39) over 6 hours.
327788|NCT00571337|Drug|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
327789|NCT00571350|Procedure|tvt-o operation|transvaginal tention free obturator tape
327790|NCT00571350|Procedure|tvt o operation|transobturator vaginal tape insertion
327791|NCT00571363|Procedure|standard surgery|excision with 4 mm margins
327792|NCT00571363|Procedure|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
327793|NCT00571376|Other|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
327794|NCT00571402|Behavioral|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
327795|NCT00571402|Behavioral|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
327796|NCT00004093|Drug|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
327797|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
327798|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
327799|NCT00571428|Drug|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
327138|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327139|NCT00000608|Behavioral|diet, fat-restricted|
327140|NCT00004158|Drug|melphalan|
327141|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327142|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327143|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327144|NCT00586547|Drug|Mesna|(45mg/kg, divided into 5 doses) administered 15 minutes prior to each dose of cyclophosphamide and 3, 6, 9 and 12 hours after each dose of cyclophosphamide.
327145|NCT00586547|Biological|Campath 1H|Days -3,-2, and -1:
Intravenous, according to age and weight.
327146|NCT00586547|Radiation|TBI|Days -4,-3,-2, and-1:
Total dose 14.0 Gy will be delivered in 8 fractions of 1.75 Gy in two fractions. The dose rate will be 10cGy/min.
327147|NCT00004171|Drug|busulfan|
327148|NCT00586547|Procedure|Stem Cells Infusion|once
327149|NCT00586547|Procedure|T-cell Infusion|30 Days after stem cell infusion
Patients will be entered starting at level 1, according to the following doses:
Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg).
327463|NCT00578617|Drug|Rate Control|Metoprolol 50-100mg
327464|NCT00578617|Device|Ablation Therapy|
327465|NCT00578617|Drug|Rate Control|Atenolol 50-100mg,
327466|NCT00578617|Drug|Rate control|Propranolol 40-80mg
327467|NCT00578617|Drug|Rate control|Acebutolol 200mg
327468|NCT00004129|Radiation|brachytherapy|
327469|NCT00578617|Drug|Rate control|Carvedilol 6.25mg
327470|NCT00578617|Drug|Rate Control|Diltiazem 180-240mg
327471|NCT00578617|Drug|Rate Control|Verapamil 180-240mg
353974|NCT00625079|Drug|sildenafil|sildenafil 20mg three times per day (orally)
354297|NCT00618644|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection
354298|NCT00618657|Drug|Carboplatin|Given IV
354299|NCT00618657|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
354300|NCT00618657|Drug|bevacizumab|Given IV
354301|NCT00618657|Drug|trastuzumab|Given IV
354302|NCT00004414|Drug|sincalide|
354303|NCT00618657|Procedure|magnetic resonance imaging|Optional correlative studies
354304|NCT00618657|Procedure|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
354305|NCT00618670|Behavioral|Walking Exercise|Three times per week for 3 months
354306|NCT00618670|Behavioral|Control--Resistance Training|Three times per week for 3 months
354307|NCT00618683|Procedure|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
354308|NCT00620854|Drug|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
354309|NCT00620867|Drug|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
354310|NCT00620867|Drug|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
354311|NCT00620867|Other|placebo|matched placebo orally for 6 weeks
354312|NCT00620880|Behavioral|Blood sample|
354313|NCT00620893|Drug|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
354314|NCT00620893|Drug|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
354315|NCT00620906|Procedure|Manipulation|HVLA manipulation to Sacroiliac Joint
354316|NCT00620919|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
353667|NCT00592228|Device|Cypher, Taxus or Endeavor|percutaneous drug-eluting stent implantation,
FFR group: if FFR<0.75
Routine DES group
353668|NCT00592241|Device|"Adi" Insulin Pump Usability|no intervention
353669|NCT00592280|Device|Two-Layer Method pancreas preservation system|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
353670|NCT00004188|Procedure|peripheral blood stem cell transplantation|
353671|NCT00592293|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
353672|NCT00592306|Drug|rabbit antithymocyte globulin + placebo|All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.
Each arm will also receive a single placebo dose.
Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses.
353673|NCT00592306|Drug|placebo + rabbit antithymocyte globulin|All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.
Each arm will also receive a single placebo dose.
Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin.
353674|NCT00592319|Drug|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
353675|NCT00592319|Device|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
353975|NCT00625079|Drug|sildenafil|sildenafil (placebo) 20mg three times per day (orally)
353976|NCT00625092|Drug|fluorouracil|Post-operative day 1 and day 2, 600mg/m^2 intraperitoneal (IP) held for 23 hours
353977|NCT00625092|Drug|leucovorin calcium|Day 0 200 mg/m^2 intraperitoneal held for 2 hours
353978|NCT00625092|Drug|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m^2
353979|NCT00625092|Procedure|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
353980|NCT00004549|Procedure|Magnetic resonance imaging|
353981|NCT00625105|Behavioral|Biofeedback|
353982|NCT00625131|Drug|Nicotine|Delivered through transdermal nicotine patch
353983|NCT00625131|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
327562|NCT00589485|Device|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
327563|NCT00589498|Dietary Supplement|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
327890|NCT00004143|Drug|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
327891|NCT00581087|Drug|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
327892|NCT00581087|Drug|Placebo|Treatment : 200 mg/day hard gelatine capsule
327893|NCT00581100|Drug|etanercept|Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.
Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period.
327894|NCT00581113|Radiation|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
327895|NCT00581126|Drug|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
327896|NCT00581139|Behavioral|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
327897|NCT00581139|Drug|Midazolam|0.5 mg/kg oral midazolam
327898|NCT00581139|Behavioral|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
327899|NCT00581139|Other|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
327900|NCT00581165|Drug|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
327901|NCT00004144|Drug|bryostatin 1|
327902|NCT00581191|Drug|SLV-351|SLV-351 capsules taken once
327903|NCT00581204|Device|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
327904|NCT00581217|Other|Aquacel Ag|Aquacel Ag will be applied to one donor site.
327905|NCT00581217|Other|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
327906|NCT00581230|Device|Rapid Airway Management Positioner|inflatable positioning ramp
327242|NCT00556166|Device|Enterra Therapy Gastric Stimulator|The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2" x 2" x 1/2" and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.
The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control.
327243|NCT00004015|Procedure|adjuvant therapy|
327244|NCT00556179|Drug|Lactoserum (Dermacyd Femina®)|Once a day during three months
327245|NCT00556192|Drug|rituximab|Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.
A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.
Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period.
327246|NCT00556205|Drug|Sunitinib|Sunitinib orally once daily
327247|NCT00556205|Drug|Bevacizumab|Intravenously every 14 days
327248|NCT00556218|Behavioral|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
327249|NCT00556218|Behavioral|No Meditation|No meditation; usual care.
327564|NCT00589524|Device|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
327565|NCT00589537|Other|questionnaire administration|
327566|NCT00589537|Procedure|computed tomography|
327567|NCT00589537|Procedure|magnetic resonance imaging|
327568|NCT00589537|Procedure|quality-of-life assessment|
327569|NCT00589550|Biological|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
327570|NCT00004179|Drug|doxorubicin hydrochloride|
327571|NCT00589550|Drug|Sorafenib|
327572|NCT00589550|Genetic|gene expression analysis|
327573|NCT00589550|Genetic|polymerase chain reaction|
326922|NCT00561041|Behavioral|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
326923|NCT00561054|Drug|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
326924|NCT00004059|Drug|7-hydroxystaurosporine|
326925|NCT00563056|Drug|Flixotide plus Foradil|
326926|NCT00563069|Drug|Midazolam|
326927|NCT00563095|Procedure|Transcatheter Arterial Chemoembolization (TACE)|
326928|NCT00563095|Procedure|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
326929|NCT00563108|Drug|Basiliximab|
326930|NCT00563108|Drug|Placebo|
326931|NCT00563121|Procedure|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
326932|NCT00563134|Drug|GR270774|
326933|NCT00563147|Drug|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
326934|NCT00563160|Drug|gemcitabine, carboplatin|
326935|NCT00004059|Drug|fluorouracil|
326936|NCT00563160|Procedure|surgery|
326937|NCT00563173|Drug|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
326938|NCT00563186|Other|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance of private rooms, absence of shared bathrooms/curtains, etc.)
326939|NCT00563199|Behavioral|nurse-delivered stage-matched smoking cessation counseling|
326940|NCT00563212|Drug|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
326941|NCT00563225|Drug|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
327250|NCT00556244|Procedure|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
327251|NCT00556257|Drug|Cyclosporine|Standard of care
326275|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement Therapy. questionaires|brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., "Smoking Cessation Guide for Cancer Patients and Their Families") tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status.
326610|NCT00568100|Procedure|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
326611|NCT00568113|Drug|acetylcysteine in arm 1|Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.
Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy.
326612|NCT00568126|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
326613|NCT00568126|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks
326614|NCT00568152|Dietary Supplement|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
326615|NCT00568152|Dietary Supplement|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
326616|NCT00568152|Drug|Aspirin|75mg dispersable aspirin taken daily for 14 days
326617|NCT00004086|Procedure|peripheral blood stem cell transplantation|
326618|NCT00568165|Procedure|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
326619|NCT00568165|Procedure|Standard care|Standard care
326620|NCT00570791|Device|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
326621|NCT00570804|Behavioral|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
326622|NCT00570804|Behavioral|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
326623|NCT00570817|Other|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
326624|NCT00004092|Drug|thiotepa|Given IV
325937|NCT00580359|Drug|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
325938|NCT00004139|Drug|gemcitabine hydrochloride|
325939|NCT00580372|Drug|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
325940|NCT00580372|Drug|High-Dose cyclophosphamide|Approximately 5-6 weeks after VAD 2 or 3:
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1
325941|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.
The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction.
325942|NCT00582946|Device|Hearing Aid|Amplification of sound for hearing impaired subjects
325943|NCT00004152|Procedure|positron emission tomography|
325944|NCT00582959|Other|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
325945|NCT00582972|Drug|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
325946|NCT00582985|Drug|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
325947|NCT00582998|Procedure|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
325948|NCT00582998|Device|VAC|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
325949|NCT00583011|Drug|Local anesthesia - lidocaine|Local anesthesia: 2 cc of 1% Lidocaine
325280|NCT00552994|Device|Xience V stent|Drug eluting stent
325281|NCT00553007|Procedure|Periodontal therapy|Normal periodontal therapy is performed.
325282|NCT00553020|Drug|Insulin glargine|Lantus (commercial formulation, Reference):
10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)
NPH-insulin (Protaphan) (Test):
10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)
325283|NCT00553033|Procedure|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
325586|NCT00586014|Procedure|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
325587|NCT00586040|Procedure|tissue bonding|application of rose bengal and treatment with green light
325588|NCT00586040|Procedure|sutures|interrupted superficial sutures
325589|NCT00586066|Drug|Memantine|Week 0 - 5mg Memantine or placebo q.d. Week 1 - 5mg Memantine or placebo b.i.d. Week 2-3 - 5mg Memantine or placebo q.a.m./10mg q.p.m. Week 4-12 - 10mg Memantine or placebo b.i.d.
325590|NCT00586066|Drug|Placebo|Inactive comparator
325591|NCT00004166|Procedure|quality-of-life assessment|
325592|NCT00588588|Procedure|Bronchoscopy|Bronchoscopy procedure
325593|NCT00588588|Procedure|Clinical pulmonary infection score (CPIS)|Calculate CPIS
325594|NCT00588640|Drug|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
325595|NCT00004175|Procedure|conventional surgery|
325596|NCT00588640|Drug|d-Methadone|8 subjects to receive 80 mg d-Methadone twice a day
325597|NCT00588640|Drug|d-Methadone|160 mg d-Methadone twice a day
325598|NCT00588640|Drug|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
325599|NCT00588640|Drug|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
325287|NCT00553059|Drug|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
325288|NCT00553059|Other|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
325289|NCT00553072|Drug|Magnesium sulphate|Magnesium sulphate 250mg/kg/dose for 3 doses
325290|NCT00003998|Procedure|surgical procedure|
325291|NCT00553098|Biological|Alemtuzumab|Given IV
325292|NCT00553098|Procedure|Allogeneic Bone Marrow Transplantation|Undergo HCT
325293|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
325294|NCT00004010|Drug|vincristine sulfate|
325295|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
325296|NCT00555438|Drug|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
325297|NCT00555451|Drug|HE3286|Dose escalating cohort driven study. 6 planned cohorts.
HE3286 5 mg or placebo QD for 28 days;
HE3286 10 mg (5 mg BID) or placebo BID for 28 days
HE3286 20 mg (10 mg BID) or placebo BID for 28 days
HE3286 40 mg (20 mg BID) or placebo BID for 28 days
HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days
HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)
325298|NCT00555464|Drug|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
325299|NCT00555464|Drug|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
325300|NCT00555477|Drug|anastrozole|1 mg tablet by mouth once a day
325301|NCT00555490|Dietary Supplement|Soy protein|35 % of protein from soy protein for 4-years
325302|NCT00555516|Other|EW02|Name: EW02
Dosage form: capsule.
Dose(s): 350mg per capsule, 2 capsule tid.
Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3.
325303|NCT00555529|Procedure|radial artery applanation tonometry (RAAP)|non-invasive tonometry
325606|NCT00004176|Drug|amifostine trihydrate|
324709|NCT00567281|Device|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
324710|NCT00567294|Behavioral|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
324993|NCT00560274|Drug|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
324994|NCT00560287|Device|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
324995|NCT00562302|Device|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
324996|NCT00562315|Drug|[18F]FACBC|[18F]FACBC is given intravenously prior to PET scan
324997|NCT00562328|Biological|Alemtuzumab|Week 1 (dose escalation):
Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously
Weeks 2-5:
30mg subcutaneously three times a week.
324998|NCT00562328|Biological|Rituximab|Weeks 2-5:
375 mg/m^2 by IV once weekly
324999|NCT00562328|Biological|Sargramostim|Week 1-6:
250 mcg subcutaneously three time as week
325000|NCT00562341|Procedure|Bariatric Surgery|one time lapb-band gastric bypass surgery
325001|NCT00562354|Biological|13vPnC|13vPnC for both stratum
325002|NCT00562367|Drug|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
325003|NCT00562380|Biological|ganitumab|
325004|NCT00004056|Biological|filgrastim|
325005|NCT00562380|Other|laboratory biomarker analysis|
325006|NCT00562380|Other|pharmacological study|
325007|NCT00562380|Procedure|biopsy|
325008|NCT00562393|Other|Nutritional|Overfeeding high fat diet for 28 days
325009|NCT00562406|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
324339|NCT00296023|Biological|anti-thymocyte globulin|
324340|NCT00296023|Biological|filgrastim|
324341|NCT00002802|Radiation|low-LET photon therapy|
324342|NCT00296023|Biological|therapeutic allogeneic lymphocytes|
324343|NCT00296023|Drug|busulfan|
324344|NCT00296023|Drug|fludarabine phosphate|
324345|NCT00296023|Drug|methotrexate|
324346|NCT00296023|Drug|tacrolimus|
324347|NCT00296023|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
324348|NCT00296023|Procedure|peripheral blood stem cell transplantation|
324349|NCT00296036|Dietary Supplement|pyridoxine hydrochloride|Given orally
324350|NCT00296036|Drug|urea/lactic acid-based topical cream|Applied topically
324351|NCT00296036|Other|placebo|Given orally or applied topically
324352|NCT00002802|Radiation|radioisotope therapy|
324353|NCT00296049|Drug|daptomycin|
324354|NCT00296049|Drug|vancomycin|
324355|NCT00296062|Biological|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
324356|NCT00296062|Drug|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
324357|NCT00299182|Drug|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,& 5.
324358|NCT00299182|Drug|Methotrexate|200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 & 6.
324711|NCT00567294|Behavioral|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
323636|NCT00262938|Other|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
323637|NCT00262938|Other|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
323638|NCT00262938|Procedure|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
323991|NCT00305669|Biological|sargramostim|
323992|NCT00305669|Other|immunohistochemistry staining method|
323993|NCT00305669|Other|immunological diagnostic method|
323994|NCT00305669|Other|laboratory biomarker analysis|
323995|NCT00305669|Procedure|conventional surgery|
323996|NCT00305669|Procedure|neoadjuvant therapy|
323997|NCT00305682|Biological|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
323998|NCT00305682|Drug|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
323999|NCT00002827|Radiation|low-LET electron therapy|
324000|NCT00305682|Drug|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
324001|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
324002|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
324003|NCT00308581|Other|Placebo|placebo administered 4-weekly in Active 1
324004|NCT00308594|Drug|Dexamethasone|
324005|NCT00308607|Drug|Bevacizumab (Avastin)|
324006|NCT00308607|Drug|dacarbazine|
324007|NCT00308607|Drug|interferon-alfa-2a (Roferon-A)|
324008|NCT00308620|Drug|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
324009|NCT00308620|Drug|Placebo|Placebo once daily for 8 weeks
323283|NCT00272740|Drug|Fulvestrant|
323284|NCT00272753|Drug|budesonide/formoterol Turbuhaler|
323285|NCT00272753|Drug|formoterol Turbuhaler|
323286|NCT00272753|Drug|salbutamol|
323287|NCT00272766|Drug|pegaptanib sodium|
323288|NCT00272779|Drug|ATV|300mg Oral capsules for 96 weeks
323289|NCT00272779|Drug|RTV|100mg Oral Capsules for 96 weeks
323290|NCT00000425|Drug|Acetaminophen|
323291|NCT00002738|Drug|leucovorin calcium|
323292|NCT00272779|Drug|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
323293|NCT00272779|Drug|LPV|400 mg (3 133mg capsules) BID for 96 weeks
323294|NCT00272792|Drug|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
323295|NCT00272792|Drug|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
323296|NCT00275938|Drug|interferon alpha 2b plus ribavirin|
323297|NCT00275938|Drug|interferon alpha 2b plus placebo|
323298|NCT00275951|Drug|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
323299|NCT00275964|Drug|TMN-1|
323639|NCT00265889|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
323640|NCT00265889|Radiation|radiation therapy|radiation therapy
323641|NCT00265902|Procedure|diagnostic imaging|
323642|NCT00265915|Biological|rituximab|
323643|NCT00265915|Biological|sargramostim|
328111|NCT00563784|Drug|Paclitaxel|45 mg/m^2 by vein weekly for 7 Weeks
328112|NCT00563784|Radiation|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
328416|NCT00556816|Behavioral|Control|conventional outpatient clinic
328417|NCT00559312|Drug|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
328418|NCT00559338|Drug|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
328419|NCT00559338|Drug|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
328420|NCT00559351|Procedure|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
328421|NCT00559351|Drug|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
328422|NCT00559351|Radiation|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
328423|NCT00559364|Drug|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
328424|NCT00559364|Drug|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
328425|NCT00559364|Drug|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
328426|NCT00559364|Drug|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
328427|NCT00004036|Biological|sargramostim|
328428|NCT00559377|Other|18F-fluoromisonidazole|Undergo ^18F FMISO PET scan
328429|NCT00559377|Radiation|fluorodeoxyglucose F 18|Undergo ^18F FDG PET scan
328430|NCT00559377|Procedure|positron emission tomography|Undergo ^18F-FMISO and ^18F FDG PET scan
328431|NCT00559377|Other|tissue oxygen measurement|Undergo ^18 F FMISO PET and ^18F FDG PET
327800|NCT00571454|Behavioral|telephone depression care management|1 call per week for first 4 weeks
1 call every other week for next 8 weeks
327801|NCT00571467|Drug|PRTX-100 (Staphylococcal protein A)|4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:
Cohort 1: 0.075 mcg/kg
Cohort 2: 0.15 mcg/kg
Cohort 3: 0.30 mcg/kg
327802|NCT00571480|Other|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
327803|NCT00571480|Other|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
327804|NCT00571480|Other|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
328113|NCT00563797|Drug|Mecamylamine|mecamylamine 10mg/day for 12 weeks
328114|NCT00563810|Drug|MYO-029|
328115|NCT00563823|Drug|vatalanib|
328116|NCT00563836|Drug|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
328117|NCT00563849|Drug|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
328118|NCT00563862|Procedure|Conventional RT|
328119|NCT00563862|Procedure|Accelerated RT|
328120|NCT00566202|Drug|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
328121|NCT00566215|Procedure|Duodenal exclusion plus omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
Additionally, total omentectomy is performed.
328122|NCT00566215|Procedure|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
328123|NCT00566228|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
328124|NCT00566228|Procedure|leukapheresis|Stem cells collected
328125|NCT00566241|Drug|recombinant human IGF-1|rhIGF-1
328126|NCT00566241|Drug|Placebo|Placebo
327472|NCT00578617|Drug|Rate Control|Digoxin 0.125mg
327473|NCT00578617|Drug|Rhythm Control|Propafenone 450mg
327474|NCT00578617|Drug|Rhythm control|Flecainide 200mg
327475|NCT00578617|Drug|Rhythm control|Sotalol 240mg
327476|NCT00578617|Drug|Rhythm control|Dofetilide 500mcg
327477|NCT00578617|Drug|Rhythm control|Amiodarone 200mg
327478|NCT00578617|Drug|Rhythm control|Quinidine 600-900mg
327479|NCT00004129|Radiation|phosphorus P32|
327480|NCT00578630|Other|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
327481|NCT00578643|Drug|Busulfan|Days -9 through -6
1 mg/kg initially (based on weight)
327482|NCT00578643|Biological|Alemtuzumab|Day -5 through Day -2
Dose is based on weight:
Less than 15 kg: 3 mg
More than 15 kg to 30 kg: 5 mg
More than 30 kg: 15 mg
327483|NCT00578643|Drug|Cyclophosphamide|Days -5 through -2
50 mg/kg
327484|NCT00578643|Drug|Fludarabine|Day -5 through Day -2
30 mg/m^2
327485|NCT00578643|Drug|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
327486|NCT00578643|Procedure|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10^8/kg recipient weight; for cord blood ≥ 3 X 10^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10^/kg CD34+ cells.
327487|NCT00578656|Dietary Supplement|Baked Milk|Extensively heated milk
327805|NCT00571493|Drug|Bortezomib|Velcade will be administered in four dose cohorts, 0.8 mg/m², 1.0mg/m², 1.3mg/m² and 1.5mg/m². Three patients will be accrued in each dose cohort with enrollment starting at dose cohort 1, 0.8mg/m². Subjects participating in this study will receive Velcade on Days -11, -8, -5, and -2.
327806|NCT00571493|Drug|BEAM|carmustine 300mg/m2, etoposide 100mg/m2 BID, cytarabine 100mg/m2 BID, melphalan 140mg/m2 BID
327807|NCT00573690|Drug|pemetrexed disodium|Given IV
327808|NCT00573690|Drug|sorafenib tosylate|Given orally
327809|NCT00573703|Procedure|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
354317|NCT00004444|Drug|streptomycin|
354318|NCT00620932|Behavioral|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
354612|NCT00004327|Drug|octreotide|
354613|NCT00613678|Behavioral|Education|The health education program is based on educational materials from the Arthritis Foundation.
354614|NCT00613691|Drug|SPI-1620|SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
354615|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vits A & D + iron postnatally|Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D.
354616|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vitamins A & D postnatally|Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D.
354617|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D + iron postnatally|Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D.
354618|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D postnatally|Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D.
354619|NCT00613730|Drug|Gemcitabine|Intravenous administration
354620|NCT00613730|Drug|panitumumab|Intravenous administration
354621|NCT00613743|Drug|mouth wash with morphine|morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
354622|NCT00613743|Drug|placebo|placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
354623|NCT00004328|Drug|enalapril|
354624|NCT00613769|Drug|trimethoprim-sulfamethoxazole + metronidazole|trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
354625|NCT00616304|Drug|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
354626|NCT00004378|Procedure|Stem Cell Transplantation|
353984|NCT00625131|Drug|Bupropion Sustained Release (SR)|Antidepressant
353985|NCT00627380|Other|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
353986|NCT00627393|Drug|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
353987|NCT00627393|Biological|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10^10 per collection (or proportionately less for participants less than 30 kg in weight).
353988|NCT00627393|Drug|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
353989|NCT00627393|Device|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
353990|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
353991|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
353992|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
353993|NCT00004582|Drug|Lopinavir/Ritonavir|
353994|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
354319|NCT00620945|Drug|Phenoxybenzamine|Use of Phenoxybenzamine:
Loading dose given at the time of going on CPB:
For patients with obstructing lesions on systemic side:
0.25 mg/kg dose in the bypass circuit
None intravenous
For patients without obstructing left sided lesions:
0.5 mg/kg in the bypass circuit
0.5 mg/kg I.V. at cannulation
Maintenance dose given in the post-operative period:
0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours
0.3 mg/kg P.O. every 8 hours for next 24 hours
0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop
Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group
354320|NCT00620958|Behavioral|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
354321|NCT00620958|Behavioral|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
354322|NCT00620958|Behavioral|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
327907|NCT00583869|Drug|Placebo|Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
328226|NCT00576537|Biological|Dendritic Cell Vaccine|Four vaccines
328227|NCT00576537|Biological|Dendritic Cell Vaccine|Four vaccines will be given to patients
328228|NCT00004123|Drug|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
328229|NCT00576550|Drug|Urea|Urea cream applied twice daily up to six months
328230|NCT00576550|Drug|betamethasone valerate|Application once daily for two weeks
328231|NCT00576550|Drug|betamethasone valerate|Application twice daily for two weeks
328232|NCT00576563|Drug|FDG|contrast medium
328233|NCT00576576|Drug|Atorvastatin|Atorvastatin 80 mg a day
328234|NCT00576589|Drug|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
328235|NCT00576589|Drug|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
328236|NCT00576602|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
328237|NCT00576602|Drug|Supportive treatment|As prescribed
328238|NCT00576615|Drug|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
328239|NCT00004123|Procedure|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
328240|NCT00576615|Drug|propofol|On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.
Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
327574|NCT00589550|Genetic|reverse transcriptase-polymerase chain reaction|
327575|NCT00589550|Other|flow cytometry|
327576|NCT00589550|Other|immunoenzyme technique|
327577|NCT00589550|Other|laboratory biomarker analysis|
327578|NCT00589563|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
327579|NCT00589563|Drug|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
327580|NCT00551265|Biological|Oregovomab|Given IV
327581|NCT00551265|Drug|Cyclophosphamide|Given IV
327582|NCT00551265|Procedure|Laboratory Biomarker Analysis|Correlative studies
327583|NCT00551278|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|For in vitro diagnostic use only.
The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra‑operative or post-operative decision to remove additional lymph nodes.
Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required.
327584|NCT00551291|Drug|CellCept|1g po twice daily
327585|NCT00551291|Drug|Prednisone|As prescribed
327586|NCT00551291|Drug|epoetin beta [NeoRecormon]|30,000IU sc/week (starting dose)
327587|NCT00551304|Device|Ardian Catheter|
327908|NCT00583869|Drug|Pregabalin|Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
327909|NCT00583869|Drug|Pregabalin|Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
327910|NCT00583882|Other|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
327252|NCT00556257|Drug|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
327253|NCT00556270|Drug|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
327254|NCT00004016|Biological|recombinant interferon gamma|
327255|NCT00556283|Device|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
327256|NCT00556283|Behavioral|Biofeedback|electromyographic-based treatment sessions
327257|NCT00556296|Drug|NRP104|NRP104 30mg capsule once daily in a.m.
327258|NCT00556296|Drug|NRP104|NRP104 50mg capsule once daily in a.m.
327259|NCT00556296|Drug|NRp104|NRP104 70mg capsule once daily in a.m.
327260|NCT00556296|Drug|Placebo|Placebo
327261|NCT00556309|Device|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
327262|NCT00556322|Drug|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
327263|NCT00556322|Drug|erlotinib [Tarceva]|150mg po daily
327264|NCT00556335|Procedure|manual aspiration|air aspiration
327265|NCT00004017|Procedure|conventional surgery|
327266|NCT00558688|Procedure|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
327267|NCT00558701|Device|Microcurrent with Silver Coated Dressing|Microcurrent stimulation from 15-50 microamps
327268|NCT00558701|Device|Silver coated dressing without active microcurrent|Silver coated dressing only
327269|NCT00558727|Drug|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
327270|NCT00558740|Other|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
327271|NCT00558753|Drug|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
327272|NCT00558753|Drug|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
327273|NCT00004031|Procedure|peripheral blood stem cell transplantation|
326625|NCT00570830|Device|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
326626|NCT00570843|Drug|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
326627|NCT00570843|Drug|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
326628|NCT00570856|Drug|Folic acid|Folic acid 5 mg/day
326629|NCT00570856|Drug|Placebo|Placebo similar to the folic acid tablets, 1/day
326942|NCT00563238|Drug|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
326943|NCT00563251|Drug|Azithromycin|
326944|NCT00563251|Drug|Placebo tablet|
326945|NCT00563264|Behavioral|KAN-DO|The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).
The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children.
326946|NCT00004060|Drug|exatecan mesylate|
326947|NCT00563277|Procedure|combined pterygium and cataract operation|
326948|NCT00563277|Procedure|pterygium excision followed by cataract operation|
326949|NCT00563290|Drug|dasatinib|Given PO
326950|NCT00563290|Other|laboratory biomarker analysis|Correlative studies
326951|NCT00565773|Drug|Belatacept|Belatacept will be given as an IV infusion at 10mg/kg over 30 minutes on the day of transplantation. This dose will be repeated on study days 4, 8, and 15, then every 2 weeks for 5 additional doses. After week 24, belatacept will be given as an infusion of 5 mg/kg once every 4 weeks indefinitely.
326952|NCT00004071|Drug|prednisone|
326953|NCT00565773|Drug|Alemtuzumab|All patients will receive a single dose of 30 mgs. on the day of transplantation.
326276|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
326277|NCT00575731|Behavioral|Weight management strategies|
326278|NCT00575744|Procedure|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
326279|NCT00575796|Drug|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
326280|NCT00004113|Drug|temozolomide|
326281|NCT00575809|Other|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
326282|NCT00575822|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
326283|NCT00578149|Drug|Carboplatin|
326284|NCT00578149|Drug|Paclitaxel|
326285|NCT00578162|Behavioral|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
326286|NCT00578175|Biological|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
326287|NCT00004128|Drug|cyclophosphamide|
326288|NCT00578175|Biological|ProQuad®|One subcutaneous injection.
326289|NCT00578175|Biological|Havrix®|Two intramuscular injections.
325600|NCT00588653|Device|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
325601|NCT00588666|Drug|Bevacizumab|
325602|NCT00588666|Drug|Carboplatin|
325603|NCT00588666|Drug|Gemcitabine|
325604|NCT00588679|Other|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
325605|NCT00588692|Device|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
325950|NCT00583011|Drug|Placebo Group|Placebo Group: 2cc Normal Saline
325951|NCT00583024|Biological|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
325952|NCT00583037|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
325953|NCT00583050|Device|Endovascular Stent-graft implantation|Research Endovascular Stent-graft
325954|NCT00004152|Radiation|fludeoxyglucose F 18|
325955|NCT00583063|Drug|sunitinib|25 mg daily (oral dosing)
325956|NCT00583063|Drug|rapamycin|4 mg daily (oral dosing)
325957|NCT00583076|Drug|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
325958|NCT00583102|Drug|Lovastatin and Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7. Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
325959|NCT00583115|Drug|Gleevec|260 mg/M2/day, given once daily by mouth
325960|NCT00583128|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
325961|NCT00586079|Procedure|Deep brain stimulation surgery.|Deep brain stimulation surgery.
325607|NCT00588705|Behavioral|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
325608|NCT00588731|Drug|Cannabidiol|Active Cannabidiol daily over 6 weeks
325609|NCT00588731|Drug|Placebo|Placebo
325610|NCT00588757|Device|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
325611|NCT00588757|Device|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
325612|NCT00588770|Biological|Bevacizumab|Given IV
325613|NCT00588770|Drug|Carboplatin|Given IV
325614|NCT00588770|Drug|Cisplatin|Given IV
325615|NCT00588770|Other|Cytology Specimen Collection Procedure|Correlative studies
325616|NCT00588770|Drug|Docetaxel|Given IV
325617|NCT00004176|Drug|cisplatin|
325618|NCT00507702|Procedure|phlebotomy|Standard of care
325619|NCT00507715|Drug|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
325620|NCT00507715|Other|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
325621|NCT00003749|Procedure|adjuvant therapy|
325622|NCT00507728|Drug|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
325623|NCT00507728|Drug|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
325624|NCT00507728|Drug|Placebo|Placebo by mouth for 12 weeks.
325625|NCT00507728|Behavioral|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
325626|NCT00507741|Drug|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
325010|NCT00562406|Procedure|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
325011|NCT00562419|Drug|CT-322|IV solution, weekly
325012|NCT00562419|Drug|irinotecan hydrochloride|IV solution, biweekly
325013|NCT00562432|Device|Plexisyl-AF|Plexisyl-AF implants
325014|NCT00562432|Other|No Treatment|CABG without the experimental treatment
325015|NCT00004056|Drug|asparaginase|
325016|NCT00562458|Drug|anastrozole|
325304|NCT00555542|Drug|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
325305|NCT00004010|Radiation|radiation therapy|
325306|NCT00555555|Biological|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
325307|NCT00555568|Behavioral|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
325308|NCT00555568|Behavioral|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
325309|NCT00555581|Drug|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
325310|NCT00555594|Drug|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
325311|NCT00557960|Drug|Atomoxetine hydrochloride|
325312|NCT00557973|Drug|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) Tablet or matching Placebo dosed orally, BID, for approximately 26 days with titration and taper periods
325313|NCT00557973|Drug|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) Tablet or matching Placebo dosed orally, BID, for approximately 26 days with titration and taper periods
325314|NCT00557973|Drug|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) Tablet or matching Placebo dosed orally, BID, for approximately 26 days with titration and taper periods
324712|NCT00567294|Behavioral|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
324713|NCT00567307|Drug|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
324714|NCT00567307|Other|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
324715|NCT00567320|Drug|Varenicline|Varenicline up to 2 mg a day
324716|NCT00004090|Drug|gemcitabine hydrochloride|
324717|NCT00569985|Drug|cyclophosphamide|Given IV
324718|NCT00569985|Drug|etoposide|Given IV
324719|NCT00569985|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
324720|NCT00569998|Device|NovoPen™ 4|
324721|NCT00569998|Device|NovoPen® 3|
324722|NCT00570011|Drug|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
324723|NCT00570011|Drug|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
324724|NCT00570024|Procedure|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
324725|NCT00570024|Procedure|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
324726|NCT00570037|Biological|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
324727|NCT00004091|Other|Papanicolaou test|
324728|NCT00570050|Drug|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
324010|NCT00308659|Procedure|FOB protected distal microbiological samplings|
324011|NCT00002835|Drug|Cisplatin (CDDP)|
324012|NCT00308685|Drug|Albuterol 90mcg|
324013|NCT00308685|Drug|Placebo|Placebo
324014|NCT00308711|Drug|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
324359|NCT00299182|Drug|Cytarabine|3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,& 6.
324360|NCT00299182|Drug|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
324361|NCT00299195|Drug|sulindac|Sulindac 150 mg po bid x 24 weeks
324362|NCT00299195|Drug|Placebo|Placebo bid x 24 weeks
324363|NCT00299208|Drug|Artesunate|
324364|NCT00299208|Drug|Azithromycin|
324365|NCT00002809|Drug|methotrexate|
324366|NCT00299208|Drug|Quinine|
324367|NCT00299221|Drug|Tacrolimus|tacrolimus
324368|NCT00299221|Drug|combination therapy|MMF
324369|NCT00299234|Drug|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
324370|NCT00299247|Drug|sulfadoxine/pyrimethamine|
324371|NCT00299260|Biological|CMV gB vaccine|20 micrograms
324372|NCT00299260|Drug|Placebo|normal saline
324373|NCT00299273|Behavioral|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
323644|NCT00002711|Drug|paclitaxel|
323645|NCT00265928|Drug|bortezomib|
323646|NCT00265928|Drug|rituximab|
323647|NCT00265928|Procedure|antibody therapy|
323648|NCT00265928|Procedure|biological therapy|
323649|NCT00265928|Procedure|enzyme inhibitor therapy|
323650|NCT00265928|Procedure|monoclonal antibody therapy|
323651|NCT00265941|Biological|cetuximab|Given IV
323652|NCT00265941|Drug|cisplatin|Given IV
323653|NCT00265954|Behavioral|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
323654|NCT00265967|Drug|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
323655|NCT00002711|Radiation|low-LET electron therapy|
323656|NCT00265980|Drug|Placebo|twice daily iinjections of saline in the same volume as will be used for B-2 leptin injections
323657|NCT00265980|Drug|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8AM circulating leptin concentrations measured in the same subjects prior to weight loss.
323658|NCT00265980|Drug|placebo|Subjects will receive a once daily oral placebo that looks identical to the tri-iodothyronine administered in arm C-2.
323659|NCT00265980|Drug|Tri-iodothyronine|Subjects will receive a once daily oral dose of T3 which will be titrated until 8AM T3 levels are similar to those measured in the same subjects prior to weight loss.
323660|NCT00265993|Drug|enoxaparin|All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.
Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months.
323661|NCT00266006|Drug|activated recombinant human factor VII|
323662|NCT00266019|Behavioral|Weight Management (diet, exercise, and behavior modification)|
324015|NCT00308711|Drug|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
328432|NCT00559403|Behavioral|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
323300|NCT00275977|Procedure|Coronary catherization and stem cell infusion|
323301|NCT00002752|Radiation|iodine I 131 monoclonal antibody 81C6|
323302|NCT00275990|Device|rheolytic thrombectomy with direct stenting|
323303|NCT00275990|Device|direct stenting|
323304|NCT00276003|Drug|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
323305|NCT00276016|Drug|phenylephrine|immediate-release 12 mg capsules for oral administration
323306|NCT00276016|Drug|pseudoephedrine|60 mg immediate-release tablets for oral administration
323307|NCT00276016|Drug|placebo|placebo capsules
323308|NCT00276029|Drug|Etanercept|
323309|NCT00276042|Drug|Faropenem Medoxomil|
323310|NCT00276055|Drug|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
323311|NCT00276068|Drug|topical lidocaine + oral desipramine, and/or placebo|
323312|NCT00002753|Radiation|iodine I 131 monoclonal antibody 81C6|
323313|NCT00276081|Drug|Gabapentin, Estrogen and placebo administration|
323314|NCT00276094|Drug|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
323315|NCT00276094|Drug|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
323316|NCT00276094|Drug|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
328127|NCT00566254|Drug|Zonisamide|8mg/kg per day for approximately 24 weeks.
328128|NCT00004075|Drug|tanespimycin|
328129|NCT00566254|Drug|Placebo|
328130|NCT00566267|Drug|simvastatin 20 mg/ezetimibe|see protocol
328131|NCT00566280|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
328132|NCT00566306|Other|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
328133|NCT00566319|Behavioral|PREPARE with pedometer|Structured educational programme with pedometer use
328134|NCT00566319|Behavioral|PREPARE|Structured educational programme
328433|NCT00559403|Behavioral|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
328434|NCT00561470|Drug|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
328435|NCT00561470|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
328436|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1
The FOLFIRI regimen included:
180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:
5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:
5-FU 2400 mg/m² continuous IV infusion over 46-hours
328437|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1
The FOLFIRI regimen included:
180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:
5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:
5-FU 2400 mg/m² continuous IV infusion over 46-hours
328438|NCT00561496|Drug|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
328439|NCT00004052|Biological|QS21|
328440|NCT00561509|Drug|SSRIs|Use within normal clinical practice
328441|NCT00561509|Drug|Dual antidepressants|Use within clinical practice
327810|NCT00573703|Procedure|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
327811|NCT00573729|Other|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
327812|NCT00573729|Other|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
327813|NCT00573742|Drug|Candesartan Cilexeotil 16mg|
327814|NCT00004103|Procedure|conventional surgery|
327815|NCT00573755|Drug|anastrozole|given orally
327816|NCT00573755|Drug|exemestane|given orally
327817|NCT00573755|Drug|letrozole|given orally
327818|NCT00573755|Drug|sorafenib tosylate|given orally
327819|NCT00573755|Other|placebo|given orally
327820|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
327821|NCT00573768|Drug|Placebo|Vehicle 2 times daily
327822|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
327823|NCT00573781|Dietary Supplement|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
327824|NCT00573781|Dietary Supplement|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
327825|NCT00004103|Procedure|neoadjuvant therapy|
327826|NCT00573781|Dietary Supplement|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
328135|NCT00566332|Drug|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
328136|NCT00566332|Drug|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
328137|NCT00566345|Biological|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
328138|NCT00566345|Biological|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
354627|NCT00616304|Other|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
354628|NCT00616330|Drug|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
354629|NCT00616330|Drug|clindamycin phosphate|semi solid, single dose
354945|NCT00609284|Drug|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
354946|NCT00609284|Radiation|Radiotherapy|70 Gy in 7 weeks
354947|NCT00609297|Other|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
354948|NCT00609297|Other|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
354949|NCT00000621|Drug|all trans retinoic acid|
354950|NCT00004257|Radiation|radiation therapy|
354951|NCT00609297|Other|survey administration|Given to patient and caregivers throughout the study
354952|NCT00609310|Dietary Supplement|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
354953|NCT00609323|Drug|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
354954|NCT00609323|Drug|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
354955|NCT00609336|Drug|gemcitabine hydrochloride|Given IV
354956|NCT00609336|Drug|docetaxel|Given IV
354957|NCT00609336|Drug|capecitabine|Given PO
354958|NCT00609336|Radiation|intensity-modulated radiation therapy|Undergo IMRT
354959|NCT00609336|Drug|oxaliplatin|Given IV
354960|NCT00609336|Procedure|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
354961|NCT00004258|Drug|cilengitide|dose escalation of cilengitide
354962|NCT00609336|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
354323|NCT00620971|Drug|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
354324|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
354325|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
354326|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
354327|NCT00620971|Drug|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
354328|NCT00004445|Procedure|Surgery|
354329|NCT00623051|Procedure|Male Circumcision|
354330|NCT00623064|Drug|cisplatin|
354331|NCT00623064|Drug|gemcitabine hydrochloride|
354332|NCT00004482|Drug|Muromonab-CD3|
354333|NCT00623064|Drug|lapatinib ditosylate|
354334|NCT00623064|Other|pharmacological study|
354335|NCT00623077|Biological|filgrastim|Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm^2.
Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses.
354336|NCT00623077|Drug|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age),every 6 hours on Days -8 through -6.
354337|NCT00623077|Drug|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m^2/day intravenous (IV) over 1 hour for 5 days.
354630|NCT00616330|Drug|butoconazole nitrate|semi solid, single dose
354631|NCT00616343|Drug|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
354632|NCT00616382|Drug|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
354633|NCT00616382|Drug|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
328241|NCT00576628|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg sc monthly
328242|NCT00576641|Biological|autologous dendritic cells|
328243|NCT00576654|Drug|Irinotecan Hydrochloride|Given IV
328244|NCT00576654|Other|Laboratory Biomarker Analysis|Correlative studies
328537|NCT00571649|Drug|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
328538|NCT00571649|Drug|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
328539|NCT00571649|Drug|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
328540|NCT00571662|Drug|Pentostatin|4 mg/m^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
328541|NCT00571662|Radiation|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
328542|NCT00004094|Drug|hydroxyurea|
328543|NCT00571662|Drug|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
328544|NCT00571662|Drug|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
328545|NCT00571662|Drug|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
328546|NCT00571675|Drug|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
328547|NCT00571675|Drug|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
328548|NCT00571688|Drug|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) YMRS score > 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
327911|NCT00583895|Drug|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
327912|NCT00583895|Drug|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
327913|NCT00004159|Drug|gemcitabine hydrochloride|
327914|NCT00583908|Device|senofilcon A|toric contact lens
327915|NCT00583908|Device|balafilcon A toric|toric contact lens
327916|NCT00583908|Device|lotrafilcon B toric|toric contact lens
327917|NCT00583908|Device|omafilcon A|toric contact lens
327918|NCT00583947|Drug|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
327919|NCT00583947|Drug|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
327920|NCT00583986|Drug|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
327921|NCT00583999|Other|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
327922|NCT00584012|Drug|Lovastatin and Docetaxel|Docetaxel (60 mg/m2) will be given on day 0 every three weeks in Phase I with incrementally increasing doses of lovastatin. Lovastatin will be administered p.o. following a four times a day schedule, for four consecutive days (days -1 to +2) and repeated every three weeks. For purposes of this phase I/II study, intermittent drug administration, six dose levels, ranging from 2 to 24 mg/kg/day (2, 4, 7, 10, 13, 18, and 24 mg) will be used. Once the maximum tolerated dose (MTD) of lovastatin has been determined, docetaxel will be escalated in a stepwise scheme from 60 to 80 to 100 mg/m2.
327923|NCT00586820|Drug|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
328245|NCT00578864|Drug|Protracted Oral Etoposide|IV Cisplatin and Oral Protracted Etoposide for induction
Induction chemotherapy will consist of five cycles 21 days apart. Cycles 1, 2 and 4 will be IV cisplatin and etoposide. Patients on the phase II window will receive the first two cycles of chemo with IV cisplatin and oral protracted etoposide. If their tumor responds with a CR, VGPR or PR, it will be repeated during cycle 4. If their tumor does not respond cycle 4 will include bolus etoposide
Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4
Day 1 - 5
Hour 0: Etoposide 50 mg/m2 po daily
Hours 1 to 7: Cisplatin 40 mg/m2
Day 6 - 14
Etoposide 50 mg/m2 po once daily
328246|NCT00578864|Drug|Adriamycin and Cyclophosphamide|Induction chemotherapy will consist of 5 cycles given 21 days apart. Cycle 3 and 5 will be adriamycin and cyclophosphamide.
Day 1 and 2
Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if < 12 kg) with Mesna 400 mg/m2 (13 mg/kg if < 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr
Hours 6 to 6.25: Adriamycin 37.5 mg/m2 (1.25 mg/kg if < 12 kg) IV over 15 minutes
327588|NCT00551317|Drug|Darapladib (SB480848)|
327589|NCT00003992|Biological|trastuzumab|
327590|NCT00551330|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily
327591|NCT00551330|Drug|Placebo|One tablet of placebo once daily
327592|NCT00551343|Drug|Exenatide|10ug Exenatide single s.c. injection
327593|NCT00551356|Drug|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
327594|NCT00551356|Drug|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
327595|NCT00551369|Procedure|conventional surgery|
327596|NCT00551369|Radiation|stereotactic body radiation therapy|
327597|NCT00551382|Drug|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
327598|NCT00551382|Drug|Placebo|Look alike tablets or granules 1 per day for 12 weeks
327599|NCT00551395|Procedure|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
327600|NCT00003992|Drug|cyclophosphamide|
327601|NCT00551395|Procedure|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
327602|NCT00551421|Biological|pertuzumab|Given IV
327603|NCT00551421|Biological|cetuximab|Given IV
327604|NCT00551421|Drug|irinotecan hydrochloride|Given IV
327605|NCT00551421|Other|immunohistochemistry staining method|Correlative study
327606|NCT00551421|Other|fluorescence in situ hybridization|Correlative study
327607|NCT00551421|Other|gene expression analysis|Correlative study
327608|NCT00551421|Other|mutation analysis|Correlative study
327609|NCT00553774|Dietary Supplement|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
327610|NCT00553774|Other|Placebo|Placebo (BD 21 - 28 Days)
326954|NCT00565773|Other|donor bone marrow|The bone marrow was given as an IV infusion over 3 hours on postoperative day 7 (study day 8) in the initial group of 20 randomized subjects. The formulated dose was 1 x 10(8th power) unfractionated nucleated cells/kg recipient ideal body weight.
A proposed total of forty patients will be enrolled in this study. Enrollment was reopened December of 2012 to include 20 additional living or deceased donor kidney recipients.
Half of the first group of 20 recipients were randomized to receive a single donor bone marrow infusion. Half did not receive the infusion. Donor bone marrow infusion in the second group of 20 subjects has been eliminated.
326955|NCT00565786|Device|ArCom® Polyethylene|Argon packaged compression molded polyethylene
326956|NCT00565786|Device|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
326957|NCT00565799|Procedure|Omentectomy|Removing the omentum
326958|NCT00565799|Other|No intervention|Only LAGB without Omentectomy
326959|NCT00565812|Drug|SD-6010|200 mg tablets once a day for 2 years
326960|NCT00565812|Drug|SD-6010|50 mg tablets once a day for 2 years
326961|NCT00565812|Drug|Placebo|Placebo tablets once a day for 2 years
327274|NCT00558779|Procedure|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
327275|NCT00558779|Procedure|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
327276|NCT00558792|Drug|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
327277|NCT00558792|Drug|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
327278|NCT00558792|Drug|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
327279|NCT00558805|Behavioral|FISP + Usual Care|
327280|NCT00558805|Behavioral|Usual Care|
327281|NCT00558818|Drug|Clevudine|clevudine 30 mg qd
327282|NCT00558831|Drug|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
327283|NCT00558831|Drug|Moisturizing Lotion|
327284|NCT00004031|Radiation|radiation therapy|
326290|NCT00578175|Biological|Prevnar®|One intramuscular injection.
326291|NCT00578201|Drug|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
326630|NCT00570869|Other|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
326631|NCT00570882|Drug|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
326632|NCT00570882|Drug|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
326633|NCT00570895|Dietary Supplement|Vitamin C|Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.
Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.
Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2.
326634|NCT00570908|Drug|sunitinib|Sutent
326635|NCT00004092|Procedure|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
326636|NCT00570908|Drug|capecitabine|concurrently
326637|NCT00570908|Radiation|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
326638|NCT00570921|Drug|Everolimus|Everolimus tablets, two-5 mg tablets a day
326639|NCT00570921|Drug|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
326640|NCT00570934|Dietary Supplement|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
326641|NCT00570934|Dietary Supplement|Calcium Carbonate|1 gm calcium as calcium carbonate
326642|NCT00570934|Dietary Supplement|2000IU cholecalciferol plus 1 gm calcium|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
326643|NCT00573157|Drug|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
326644|NCT00573170|Drug|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)
326645|NCT00004102|Drug|fluorouracil|
326646|NCT00573170|Drug|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]
326647|NCT00573170|Drug|placebo|placebo
325962|NCT00586092|Drug|bevacizumab, ABT-510|Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days*
Stage 2 (RPTD) ABT-510: X mg SC BID**, bevacizumab: Y mg/kg IV every 14 days**
Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.
*Both agents begin on Day 1 of Cycle 1.
**At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination.
325963|NCT00586105|Drug|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
325964|NCT00586118|Drug|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
325965|NCT00586118|Drug|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
325966|NCT00586131|Other|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
325967|NCT00586131|Other|Ammonium chloride or sodium citrate/citric acid|dictated by pH
325968|NCT00586157|Drug|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
325969|NCT00586157|Drug|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
326292|NCT00578214|Drug|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
326293|NCT00578214|Other|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
326294|NCT00578214|Drug|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
326295|NCT00578214|Drug|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
326296|NCT00578227|Biological|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
326297|NCT00578227|Biological|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
326298|NCT00004128|Drug|cytarabine|
326299|NCT00578266|Drug|Cyclophosphamide,Campath IH and TBI|DAY 5 TREATMENT
6 5 CYTOXAN 50 mg/kg WITH MESNA
5 CYTOXAN 50 mg/kg WITH MESNA;
4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg
3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;
2 TBI; CAMPATH; TACROLIMUS
1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)
326300|NCT00578279|Drug|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
325627|NCT00507741|Drug|Ertafolide|
325970|NCT00586170|Device|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
325971|NCT00004169|Drug|carboplatin|
325972|NCT00586183|Procedure|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
325973|NCT00586196|Drug|donepezil|5 mg each day for 30 days
325974|NCT00586196|Drug|Placebo|Encapsulated cornstarch One capsule daily for 30 days
325975|NCT00586209|Drug|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (>66.7 kg)
325976|NCT00586209|Drug|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
325977|NCT00586222|Dietary Supplement|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
325978|NCT00586222|Other|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
325979|NCT00586261|Drug|Pioglitazone|Pioglitazone 30 mg daily for 6 months
325980|NCT00586261|Drug|Placebo|Placebo 30 mg daily for 6 months
325981|NCT00586261|Drug|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
325982|NCT00004169|Drug|cyclophosphamide|
325983|NCT00586274|Procedure|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
325984|NCT00586274|Drug|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m^2
325985|NCT00588770|Drug|Fluorouracil|Given IV
325986|NCT00588770|Other|Laboratory Biomarker Analysis|Correlative studies
325987|NCT00588783|Device|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
325988|NCT00588783|Device|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
325989|NCT00588809|Drug|selumetinib|Given PO
325315|NCT00557986|Procedure|Primary surgery|Primary breast surgery before systemic therapy
325316|NCT00557999|Other|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
325317|NCT00558012|Drug|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
325318|NCT00004030|Drug|VX-853|
325319|NCT00558012|Dietary Supplement|Vitamin D 800 IU/daily|Daily divided dose
325320|NCT00558012|Dietary Supplement|Calcium 1200 mg/daily|supplement plus diet
325321|NCT00558025|Drug|Pramipexole Extended Release|
325322|NCT00558025|Drug|Pramipexole Immediate Release|
325323|NCT00558038|Drug|AST-120|AST-120
325628|NCT00507754|Other|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
325629|NCT00507767|Drug|dasatinib|Given PO or via PEG tube
325630|NCT00507767|Procedure|pharmacological study|Correlative studies
325631|NCT00507767|Procedure|laboratory biomarker analysis|Correlative studies
325632|NCT00003749|Procedure|conventional surgery|
325633|NCT00507780|Drug|GnRH antagonist|
325634|NCT00507793|Drug|Sirolimus|
325635|NCT00507793|Drug|Cyclosporine|
325636|NCT00507806|Drug|perflutren lipid microsphere|
325637|NCT00507819|Drug|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
325638|NCT00507819|Drug|Placebo|One placebo capsule will be taken by mouth three times-a-day.
325639|NCT00507832|Drug|Pimecrolimus|twice daily topical
325640|NCT00507832|Drug|Hydrocortisone|twice daily topical
325641|NCT00507832|Drug|Pimecrolimus|topical application as a cream twice daily
325017|NCT00562471|Other|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
325018|NCT00562471|Other|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
325019|NCT00562484|Biological|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
325020|NCT00562484|Biological|Placebo|Placebo
325021|NCT00562497|Drug|Prochymal|Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the active treatment group will receive Prochymal™ at 2 x 106 hMSC/kg per infusion.
325022|NCT00564876|Drug|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
325023|NCT00564889|Drug|cyclophosphamide|300 mg/m^2 days 1, 8 & 15 of a 28 day cycle taken orally with food
325024|NCT00564889|Drug|dexamethasone|40 mg weekly taken orally
325025|NCT00004067|Drug|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
325026|NCT00564889|Drug|lenalidomide|15 mg daily days 1-21 of a 28 day cycle taken orally with food
325027|NCT00564902|Drug|3R 3'R Zeaxanthin|8 mg per day during 12 months
325028|NCT00564902|Dietary Supplement|Lutein|9 mg of Lutein during 12 months
325029|NCT00564902|Dietary Supplement|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
325030|NCT00564915|Dietary Supplement|Ketogenic diet|Ketogenic diet
325031|NCT00564928|Drug|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
325032|NCT00564941|Drug|deferasirox|
325033|NCT00564954|Drug|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
324374|NCT00299286|Drug|Lapatinib|In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).
Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle.
324375|NCT00299286|Drug|Lapatinib-Placebo|In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).
Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose.
324376|NCT00002809|Drug|tacrolimus|
324377|NCT00299325|Drug|Rimonabant|White-opaque tablets, for oral administration containing 20 mg of active rimonabant
324378|NCT00299325|Drug|Placebo|Undistinguishable placebo tablets
324379|NCT00299338|Drug|SP01A|
324380|NCT00299351|Drug|Depsipeptide|
324729|NCT00570050|Drug|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
324730|NCT00570063|Drug|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
324731|NCT00570063|Drug|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
324732|NCT00570089|Drug|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
324733|NCT00570089|Drug|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
324734|NCT00570102|Dietary Supplement|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
324735|NCT00570102|Dietary Supplement|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
324736|NCT00570128|Drug|Donepezil hydrochloride|Oral liquid.
324737|NCT00570128|Drug|Placebo|Oral liquid.
324738|NCT00004091|Other|cytology specimen collection procedure|
324016|NCT00308711|Drug|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
324017|NCT00308724|Behavioral|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
324018|NCT00308724|Behavioral|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
324019|NCT00308737|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
324020|NCT00308737|Drug|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
324021|NCT00308750|Drug|enzastaurin|1125-1200 mg loading dose then 500 mg, oral, daily, until disease progression
324022|NCT00002835|Drug|Cyclophosphamide|
324023|NCT00308750|Drug|pemetrexed|500 mg/m2, IV, q 21 days, six 21 day cycles or progressive disease
324024|NCT00308750|Drug|docetaxel|75 mg/m2, IV, q 21 days, six 21 day cycles or progressive disease
324025|NCT00308750|Drug|carboplatin|AUC 6, IV, q 21 days, six 21 day cycles or progressive disease
324026|NCT00002840|Drug|vincristine sulfate|
324027|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
324028|NCT00311324|Behavioral|Special Intervention|
324029|NCT00311324|Behavioral|Delayed Intervention|
324030|NCT00311337|Drug|bortezomib|
324031|NCT00311350|Drug|MOA-728|
324032|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
324033|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
324381|NCT00299364|Drug|Black Cohosh (iCR) or tibolone|
323317|NCT00276094|Drug|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
323318|NCT00276107|Biological|Prevenar|
323319|NCT00276133|Drug|Effects of atorvastatin versus probucol on small dense LDL|
323320|NCT00276146|Drug|oral dipyridamole, oral magnesium, or a combination of both|
323321|NCT00276159|Drug|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
323663|NCT00266032|Drug|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
323664|NCT00269321|Procedure|Chiropractic Manual treatment + home exercise (procedure+behavior)|The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.
Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
323665|NCT00269321|Procedure|Supervised rehabilitative exercise+home exercise|The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.
Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
323666|NCT00269321|Behavioral|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
323667|NCT00269334|Drug|Using Citalopram(drug) or Paroxetine(drug)|
323668|NCT00269347|Procedure|Chiropractic Spinal Manipulation|
323669|NCT00269347|Procedure|Exercise|
323670|NCT00002719|Drug|carmustine|
323671|NCT00269347|Behavioral|Self-care|
323672|NCT00269360|Procedure|Chiropractic + Supervised Rehabilitative Exercise|Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.
Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
328442|NCT00561522|Drug|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
328443|NCT00561522|Other|No other preventive treatment|No other preventive treatment
328444|NCT00561535|Dietary Supplement|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
328445|NCT00561535|Dietary Supplement|placebo (starch)|Once daily
328446|NCT00561548|Procedure|rectosigmoïdal biopsies|rectosigmoïdal biopsies
328447|NCT00561561|Procedure|acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
328448|NCT00561574|Drug|Esmirtazapine|One tablet daily
328449|NCT00561587|Drug|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
328450|NCT00004052|Biological|bcr-abl peptide vaccine|
323322|NCT00279409|Drug|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
323323|NCT00002760|Drug|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
323324|NCT00279422|Drug|visilizumab|
323325|NCT00279422|Drug|visilizumab|
323326|NCT00279435|Drug|visilizumab|
323327|NCT00279448|Drug|exemestane|On tablet of 25 mg per day during 5 years
323328|NCT00279448|Drug|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
323329|NCT00279461|Drug|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
323330|NCT00279461|Drug|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
323331|NCT00279474|Behavioral|cognitive-behavior groups|
323332|NCT00279487|Drug|Gabapentin|
323333|NCT00279500|Device|Argus 16 Retinal Stimulation System|
328139|NCT00004076|Drug|mureletecan|
328140|NCT00566358|Procedure|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
328141|NCT00566371|Drug|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
328142|NCT00566371|Drug|placebo|placebo
328143|NCT00568685|Drug|Atomoxetine hydrochloride|Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.
Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days
328144|NCT00000599|Drug|colestipol|
328145|NCT00004087|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
328146|NCT00568698|Drug|Hydroxyurea|
328147|NCT00568711|Drug|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
328148|NCT00568711|Drug|rifampin|a 5-day course of daily 600-mg doses of rifampin
328149|NCT00568737|Drug|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
328150|NCT00568737|Drug|Placebo|0.9% sodium chloride
328151|NCT00568750|Drug|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
328152|NCT00568763|Biological|sargramostim|
328153|NCT00568763|Other|immunoenzyme technique|
328154|NCT00568763|Other|immunohistochemistry staining method|
328155|NCT00568763|Other|immunologic technique|
328156|NCT00004088|Biological|filgrastim|
328451|NCT00561600|Device|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
354963|NCT00609336|Other|laboratory biomarker analysis|Correlative studies
354964|NCT00609349|Device|ETED, CPET, RHC|exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)
right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values
354965|NCT00609362|Drug|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
354966|NCT00611572|Drug|iomazenil|Given as IV infusion
354967|NCT00611572|Drug|iomazenil|saline IV infusion
354968|NCT00004285|Procedure|Dialysis|
355272|NCT00603993|Biological|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
355273|NCT00604006|Drug|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
355274|NCT00604006|Drug|Placebo|Placebo (lactose in capsules for blinding) once daily
355275|NCT00604019|Drug|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
355276|NCT00604019|Drug|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
355277|NCT00604032|Drug|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
355278|NCT00004232|Drug|cyclosporine|
355279|NCT00604045|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
355280|NCT00604045|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
355281|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
355282|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
355283|NCT00604084|Drug|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
354634|NCT00616395|Device|No intervention|
354635|NCT00616408|Drug|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
354636|NCT00616421|Biological|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
354637|NCT00004380|Drug|relaxin|
354638|NCT00616421|Biological|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
354639|NCT00616421|Biological|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
354640|NCT00616434|Drug|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
354641|NCT00616434|Drug|Placebo|Placebo IM injection, self-administered per protocol.
354642|NCT00616447|Device|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
354643|NCT00618696|Biological|anti-CD45 monoclonal antibody AHN-12|150 mg/m^2 cold antibody at Day 0
354644|NCT00618696|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m^2
354645|NCT00618709|Drug|ATX-101|ATX-101 single dose
354646|NCT00618722|Drug|Deoxycholic Acid Injection|
354647|NCT00618722|Drug|Placebo|
354648|NCT00004415|Device|Medlink spinal cord electrode|
354969|NCT00611585|Device|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
354970|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
354971|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
354972|NCT00611611|Biological|fluzone|once
328549|NCT00571701|Drug|celebrex (celecoxib)|Adults: 400 mg daily Pediatrics: 100 mg daily for weight between 12-25 kg or 200 mg daily for weight >25 kg
328550|NCT00571701|Drug|placebo capsules|Not relevant
328551|NCT00571714|Drug|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
328552|NCT00574067|Drug|Buprenorphine|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
323439|NCT00292227|Other|Placebo|Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):
Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;
323440|NCT00292227|Drug|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
323441|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
323442|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
323443|NCT00292240|Behavioral|Brief motivational substance use intervention|
323444|NCT00292253|Device|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
323445|NCT00292253|Device|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
323446|NCT00292266|Drug|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
323447|NCT00292266|Drug|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
323448|NCT00002793|Drug|leucovorin calcium|
323449|NCT00292279|Drug|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
323450|NCT00292279|Drug|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
323451|NCT00292292|Device|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
323452|NCT00292292|Device|Charite Artificial Disc|Insertion of the Charite
328247|NCT00578864|Drug|IV Cisplatin and IV Bolus Etoposide|Induction chemotherapy will consist of five cycles of chemotherapy given 21 days apart. The 1st, 2nd and 4th cycles will the IV Cisplatin and Etoposide. Patients ineligible to participate on the phase II window will receive IV bolus etoposide during cycles 1, 2 and 4.
Cisplatin with Bolus IV Etoposide
Day 1
Hours 0 to 6: Cisplatin 40 mg/m2
Days 2, 3, 4:
Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2
Day 5:
Hours 0 to 6: Cisplatin 40 mg/m2
328248|NCT00578877|Device|SILCS Diaphragm|used with 5 ml gel
328249|NCT00578890|Procedure|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
328250|NCT00578903|Drug|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
328251|NCT00004132|Drug|etoposide|
328252|NCT00578903|Drug|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
328253|NCT00578903|Radiation|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
328254|NCT00578903|Drug|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
328255|NCT00578903|Drug|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
328256|NCT00578903|Procedure|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10^6 CD 34+ cells/kg should be collected, with a target of 10 X 10^6/kg.
328257|NCT00578916|Drug|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
328258|NCT00578929|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
328259|NCT00578929|Drug|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
323084|NCT00301990|Biological|bevacizumab|
323085|NCT00302003|Radiation|radiation therapy|Undergo radiation therapy
323086|NCT00002816|Drug|pegaspargase|Given IV
323087|NCT00302003|Drug|doxorubicin hydrochloride|Given IV
323088|NCT00302003|Drug|vincristine sulfate|Given IV
327611|NCT00553787|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
327612|NCT00553787|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
327613|NCT00553787|Drug|VI-0521|placebo
327924|NCT00586833|Procedure|O2 consumption max bike test|Single visit exercise study
327925|NCT00586846|Drug|Cisplatin|Cisplatin 120 mg/m^2
327926|NCT00586846|Drug|Doxorubicin|75mg/m^2
327927|NCT00586846|Drug|Methotrexate|Methotrexate 12g/m^2
327928|NCT00004172|Drug|carboplatin|
327929|NCT00586859|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
327930|NCT00586885|Drug|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
327931|NCT00586898|Drug|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
327932|NCT00586898|Drug|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
327933|NCT00586898|Drug|Bicalutamide|A pure nonsteroidal antiandrogen
327934|NCT00586898|Drug|Testosterone transdermal gel|an androgenic anabolic steroid
327935|NCT00586898|Drug|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
327936|NCT00586911|Drug|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
327937|NCT00586911|Drug|Identical Placebo|Placebo
327938|NCT00586924|Biological|CAT 8015 (Moxetumomab Pasudotox)|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60… μg/kg until toxicity supervenes.
327939|NCT00004172|Drug|cyclophosphamide|
327285|NCT00558844|Drug|Arikace™|Subjects will be randomly assigned to study drug dose of of Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikace™ and placebo. They will be blinded whether they receive Arikace™ or Placebo Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
327286|NCT00558857|Device|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
327287|NCT00558870|Drug|Morphine|Arm 1: 2 Doses of "Slow-Release" Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)."Immediate-release" morphine may be used, if needed, for pain.
327288|NCT00558870|Drug|Methadone|1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)
Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).)."Immediate-release" morphine may be used, if needed, for pain.
327289|NCT00558883|Drug|acarbose|oral application
327290|NCT00558896|Drug|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
327291|NCT00561067|Drug|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
327292|NCT00561067|Drug|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
327293|NCT00561080|Biological|Zostavax|One dose (0.65 mL)
327294|NCT00561080|Biological|Zostavax|Two doses (0.65 mL) at one month interval
327614|NCT00553800|Drug|bevacizumab|
327615|NCT00553800|Drug|Erlotinib|
327616|NCT00553813|Drug|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
327617|NCT00553839|Drug|ketamine hydrochloride|Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
327618|NCT00004005|Radiation|radiation therapy|
327619|NCT00553852|Drug|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
327620|NCT00553865|Drug|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo/day for 8 weeks. Other(Reference group): Reference Drug/day for 8 weeks.
326648|NCT00573183|Behavioral|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
326649|NCT00573183|Behavioral|Treatment as Usual|
326962|NCT00565838|Procedure|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
326963|NCT00004072|Drug|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
326964|NCT00565851|Biological|Bevacizumab|Given IV
326965|NCT00565851|Drug|Carboplatin|Given IV
326966|NCT00565851|Drug|Docetaxel|Given IV
326967|NCT00565851|Drug|Gemcitabine Hydrochloride|Given IV
326968|NCT00565851|Other|Laboratory Biomarker Analysis|Correlative studies
326969|NCT00565851|Drug|Paclitaxel|Given IV
326970|NCT00565851|Other|Quality-of-Life Assessment|Ancillary studies
326971|NCT00565864|Drug|L-thyroxine (L-T4)|L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
326972|NCT00565877|Other|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
326973|NCT00565890|Drug|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
326974|NCT00000597|Drug|antilymphocyte serum|
326975|NCT00004072|Drug|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
326976|NCT00568178|Drug|Losartan Potassium|Losartan Use During the Double-Blind Treatment Phase:
Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed <50 kg)
or 100 mg/day (if the patient weighed ≥50 kg).
Losartan Use During the Treatment Extension Phase:
Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance.
326977|NCT00568178|Other|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
326301|NCT00578292|Drug|Busulfan|4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
326302|NCT00578292|Drug|Fludarabine|30mg/m2 Day -5 through Day -2
326303|NCT00578292|Drug|Campath 1H|Per institutional guidelines Days -5 through -2
326304|NCT00578292|Drug|Cyclophosphamide|50 mg/kg Days -5 through -2
326305|NCT00578292|Drug|MESNA|10 mg/kg x 5 Days -5 through -2
326306|NCT00578305|Biological|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
326307|NCT00578305|Drug|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
326308|NCT00580372|Procedure|Hemopoietic stem cell procurement|Collection target = 10 x 10^6 cells/kg
326309|NCT00580372|Drug|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
326310|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
326311|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
326312|NCT00580372|Drug|Maintenance|3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse
326650|NCT00573196|Radiation|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
326651|NCT00573209|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
326652|NCT00573222|Drug|Symbicort|
326653|NCT00573248|Drug|Nicotine|21 mg nicotine patches for smokers for 2 days
7 mg nicotine patches for nonsmokers for 2 days
326654|NCT00573248|Other|Placebo|Placebo Patch
326655|NCT00573261|Drug|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
326656|NCT00000601|Drug|estrogens|
326657|NCT00004102|Drug|leucovorin calcium|
326658|NCT00573261|Drug|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
325990|NCT00588822|Biological|Rituximab|Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
325991|NCT00588835|Drug|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
325992|NCT00588835|Drug|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
326313|NCT00580385|Biological|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
326314|NCT00580398|Behavioral|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
326315|NCT00580398|Drug|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
326316|NCT00004139|Drug|irinotecan hydrochloride|
326317|NCT00580424|Drug|Norethindrone|Norethindrone 0.35 mg orally daily
326318|NCT00580437|Procedure|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
326319|NCT00580450|Drug|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
326320|NCT00580489|Drug|either fentanyl or morphine|either morphine 4mg IV or fentanyl 50mcg IV
326321|NCT00580502|Device|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m^2
326322|NCT00580515|Behavioral|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
326323|NCT00580515|Behavioral|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
326324|NCT00580515|Behavioral|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
325642|NCT00507845|Drug|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
325643|NCT00003749|Radiation|brachytherapy|
325644|NCT00507858|Drug|Pemetrexed|Starting dose of 500 mg/m^2 IV Once Over 10 Minutes Every 3 Weeks
325645|NCT00553098|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
325646|NCT00553098|Drug|Cyclosporine|Given PO or IV
325647|NCT00553098|Drug|Fludarabine Phosphate|Given IV
325648|NCT00553098|Other|Laboratory Biomarker Analysis|Correlative study
325649|NCT00553098|Drug|Mycophenolate Mofetil|Given PO or IV
325650|NCT00553098|Radiation|Total-Body Irradiation|Undergo low dose TBI
325651|NCT00553111|Other|educational video|educational video
325652|NCT00553124|Drug|selenium|
325653|NCT00004001|Drug|docetaxel|
325654|NCT00553124|Drug|vitamin E|
325993|NCT00588848|Device|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
325994|NCT00588848|Device|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
325995|NCT00004176|Drug|etoposide|
325996|NCT00588861|Device|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
325997|NCT00588861|Device|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
325998|NCT00588887|Device|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
325999|NCT00588887|Device|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
326000|NCT00588900|Drug|cediranib maleate|
326001|NCT00588900|Drug|irinotecan hydrochloride|
325034|NCT00564954|Drug|Placebo|orally once a day for 7 days
325324|NCT00558038|Drug|lactulose|lactulose
325325|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
325326|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
325327|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
325328|NCT00558064|Drug|telmisartan+amlodipine|
325329|NCT00004030|Drug|pegylated liposomal doxorubicin hydrochloride|
325330|NCT00558064|Drug|amlodipine|
325331|NCT00558077|Drug|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
325332|NCT00558077|Procedure|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
325333|NCT00558090|Drug|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
325334|NCT00560287|Device|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
325335|NCT00560300|Drug|1 alpha D2|Vitamin D sterol
325336|NCT00560300|Drug|1,25 dihydroxy vitamin D3|Active vitamin D sterol
325337|NCT00004041|Biological|Ad5CMV-p53 gene|
325338|NCT00560300|Drug|Sevelamer HCl|Phosphate binder
325339|NCT00560300|Drug|Calcium Carbonate|Phosphate binder
325340|NCT00560313|Biological|Men ACWY CRM|a single dose of a 0.5 mL injectable solution
324739|NCT00572455|Drug|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
324740|NCT00572455|Drug|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
324741|NCT00572455|Drug|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
324742|NCT00572455|Drug|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
324743|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
324744|NCT00004097|Radiation|radiation therapy|
324745|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
324746|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
324747|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
324748|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
325035|NCT00564967|Behavioral|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
325036|NCT00004067|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
325037|NCT00564967|Behavioral|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
325038|NCT00564980|Procedure|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
325039|NCT00564980|Procedure|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
325040|NCT00564993|Drug|Dobutamin|10&20 µg/kg/min
325041|NCT00565006|Drug|MK0859|
324382|NCT00299377|Drug|Abciximab i.v.|
324383|NCT00299377|Drug|Abciximab i.c.|
324384|NCT00302393|Drug|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
324385|NCT00302393|Drug|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
324386|NCT00302406|Drug|methylphenidate hydrochloride|
324387|NCT00002816|Radiation|low-LET photon therapy|
324388|NCT00302406|Drug|OROS methylphenidate hydrochloride (CONCERTA)|
324389|NCT00302419|Drug|intracoronary infusion,|streptokinase, 250,000 units
324390|NCT00302419|Procedure|primary percutaneous coronary angioplasty|
324391|NCT00302432|Behavioral|Behavior therapy, cigarette holders, Flowers Menthol|
324392|NCT00302445|Drug|Efalizumab|
324393|NCT00302445|Device|Narrow Band Phototherapy|
324394|NCT00302458|Drug|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
324395|NCT00302458|Drug|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
324396|NCT00302458|Drug|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
324397|NCT00302471|Drug|Comparator: MK0429|Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.
Disease.
324398|NCT00002816|Drug|Methotrexate|Given IV
324399|NCT00302471|Drug|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
324400|NCT00302471|Drug|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
323673|NCT00269360|Procedure|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
323674|NCT00269360|Behavioral|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
323675|NCT00269373|Procedure|PET-CT|no drugs included
323676|NCT00269386|Drug|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
323677|NCT00269386|Drug|Placebo|
324034|NCT00311363|Drug|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
324035|NCT00311376|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
324036|NCT00311376|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
324037|NCT00000457|Drug|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
324038|NCT00002840|Radiation|radiation therapy|
324039|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
324040|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
324041|NCT00311389|Drug|Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
324042|NCT00311389|Drug|Latanoprost 0.005%/Timolol 0.005% ophthalmic solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
324043|NCT00311402|Drug|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
324044|NCT00311402|Other|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
324045|NCT00311415|Biological|Meningococcal C conjugate vaccine|Meningococcal conjugate vaccine, active comparator.
Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age
324046|NCT00311428|Biological|Influenza|
323334|NCT00002760|Other|Withdrawal of antiandrogen therapy|no drugs given
323335|NCT00279513|Drug|Traumeel S|
323336|NCT00279539|Genetic|Vascular Endothelial Growth Factor (VEGF1)|
323337|NCT00279552|Drug|Recombinant human intrinsic factor|
323338|NCT00279565|Drug|buprenorphine|
323339|NCT00279565|Drug|methadone|
323340|NCT00279565|Drug|pegylated interferon alfa-2b plus ribavirin|
323341|NCT00279578|Drug|ReFacto (Recombinant factor VIII) and Tranexamic acid|
323342|NCT00279591|Device|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
323343|NCT00279591|Device|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
323344|NCT00279604|Behavioral|'Problem Profile Intervention' vs. WHO-Brief Intervention|
323345|NCT00002761|Biological|filgrastim|
323346|NCT00279617|Drug|levetiracetam|open label levetricetam
323678|NCT00269399|Drug|Rifaximin (Xifaxan)|
323679|NCT00269412|Drug|Rifaximin|
323680|NCT00269425|Behavioral|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
323681|NCT00002719|Drug|cytarabine|
323682|NCT00269425|Behavioral|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
323683|NCT00269438|Drug|5 ASA, enemas, suppositories, corticosteroids|
323684|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
323685|NCT00272805|Drug|carvedilol|
323686|NCT00272831|Drug|Cilostazol|Cilostazol 100 mg twice daily
323687|NCT00272831|Drug|Placebo|1 tablet twice daily
328452|NCT00561600|Device|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
328453|NCT00561613|Other|SILCS and lubricant|
328454|NCT00561613|Other|SILCS and spermicide|
328455|NCT00561626|Dietary Supplement|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
328456|NCT00563862|Drug|Cisplatin|
328457|NCT00004061|Radiation|radiation therapy|
328458|NCT00563862|Drug|5-fluorouracil|
328459|NCT00563875|Drug|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
328460|NCT00563888|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
328461|NCT00563914|Drug|ferroquine (SSR97193)|associated with artesunate
328462|NCT00563914|Drug|amodiaquine|associated with artesunate
328463|NCT00563927|Procedure|Conventional RT|
328464|NCT00563927|Drug|Cisplatin|
328465|NCT00563927|Drug|5-fluorouracil|
328466|NCT00563953|Drug|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
328467|NCT00563979|Dietary Supplement|VitaluxPlus®|1 tablet daily
328468|NCT00004062|Drug|azacitidine|
328469|NCT00563979|Dietary Supplement|Omega 3|1 tablet daily
328470|NCT00563992|Drug|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
328471|NCT00563992|Drug|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
328472|NCT00564005|Other|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
355284|NCT00604084|Drug|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
355285|NCT00604097|Behavioral|Attachment-Based Family Therapy|12-16 week family-based therapy
355286|NCT00604097|Behavioral|Enhanced Usual Care|Rapid referral to community outpatient care with weekly monitoring of symptoms by study team
355287|NCT00604110|Other|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF<45%), is hemodynamically favourable.
355288|NCT00604123|Drug|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
355289|NCT00004232|Drug|methylprednisolone|
355290|NCT00606632|Drug|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
355291|NCT00606632|Procedure|CT|contrast enhanced CT scan
355617|NCT00596544|Behavioral|questionnaires|Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
355618|NCT00596557|Drug|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
355619|NCT00596570|Procedure|PCI|Percutaneous coronary interventiom
355620|NCT00599105|Procedure|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
355621|NCT00599131|Drug|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a < 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, > 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
355622|NCT00599131|Drug|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
355623|NCT00599131|Drug|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
355624|NCT00599131|Drug|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
355625|NCT00004216|Drug|trimethoprim-sulfamethoxazole|
355626|NCT00599144|Procedure|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
324144|NCT00273182|Device|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
324145|NCT00273195|Device|Implantable Cardioverter Defibrillator|
324146|NCT00273208|Behavioral|10 week behavioral intervention program|
324147|NCT00002740|Drug|doxorubicin hydrochloride|
324148|NCT00273221|Procedure|Glaucoma Implant Surgery|
324149|NCT00273221|Procedure|trabeculectomy|
324150|NCT00273221|Procedure|phacoemulsification|
324151|NCT00273234|Procedure|Autologous Platelet Gel (APG)|
324152|NCT00273247|Drug|Interferon alpha-2b|
324153|NCT00273260|Behavioral|individualised bone density feedback and education|
324154|NCT00273273|Procedure|blood draw|
324155|NCT00273286|Behavioral|family diabetes management intervention|a clinic-integrated, low intensity, multi-component behavioral intervention
324156|NCT00273299|Drug|valsartan plus hydrochlorothiazide|
324157|NCT00273312|Drug|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
324158|NCT00276458|Drug|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
324159|NCT00276458|Drug|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
324160|NCT00276458|Drug|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
324161|NCT00276458|Drug|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
324162|NCT00276471|Device|Implantable pulse generator and electrodes|
324163|NCT00276484|Drug|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
324164|NCT00276484|Drug|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
324165|NCT00002755|Drug|cyclophosphamide|
324166|NCT00276484|Drug|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
323453|NCT00292305|Procedure|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
323454|NCT00292318|Behavioral|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
323455|NCT00292318|Behavioral|control group|Medical counseling and ano-sphinctal exercises.
323456|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
323457|NCT00002802|Drug|mesna|
323458|NCT00295750|Drug|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
323799|NCT00282464|Drug|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
323800|NCT00282490|Device|Nerve stimulator|
323801|NCT00286182|Drug|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
323802|NCT00286182|Drug|Placebo|Placebo
323803|NCT00286195|Device|Multi-Link Frontier Coronary Stent System|Bare metal stent
323804|NCT00286208|Drug|Mifepristone, misoprostol|
323805|NCT00286221|Drug|IVPCA fentanyl|
323806|NCT00286221|Drug|PRN fentanyl|
323807|NCT00286234|Drug|omega-3 acid ethyl esters|4 q qd
323808|NCT00286234|Drug|extended release niacin|2 g qpm
323809|NCT00002780|Drug|thiotepa|
323810|NCT00286234|Drug|placebo|omacor placebo plus niaspan placebo
323811|NCT00286234|Drug|omega-3 acid ethyl esters|4 g qd
323089|NCT00302003|Drug|prednisone|Given orally
323090|NCT00302003|Drug|cyclophosphamide|Given IV
323091|NCT00302003|Drug|ifosfamide|Given IV
323092|NCT00302003|Drug|vinorelbine tartrate|Given IV
323093|NCT00302003|Drug|dexamethasone|Given IV
323094|NCT00302003|Drug|etoposide phosphate|Given IV
323095|NCT00302003|Drug|cisplatin|Given IV
323096|NCT00302003|Drug|cytarabine|Given IV
323097|NCT00002816|Drug|therapeutic hydrocortisone|
323098|NCT00302003|Biological|filgrastim|Given IV or subcutaneously
323099|NCT00302016|Drug|AMN107|
323100|NCT00302042|Behavioral|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
323101|NCT00002826|Drug|valspodar|
323102|NCT00304993|Drug|rosiglitazone|
323103|NCT00305006|Procedure|Constraint-Induced Movement Therapy|90 hours
323104|NCT00305006|Procedure|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
323105|NCT00305019|Drug|clevudine|
323106|NCT00305032|Procedure|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
323107|NCT00305045|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
323108|NCT00305058|Drug|Morphine 0.05 mg/kg Intravenous|
323109|NCT00305058|Drug|Hydromorphone 0.0075 mg/kg intravenous|
323110|NCT00305071|Drug|compound cranberry extract tablet|
323459|NCT00295763|Drug|Thyrogen (thyrotropin alfa for injection)|No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.
For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO.
327940|NCT00586937|Behavioral|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
327941|NCT00586976|Drug|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
327942|NCT00586976|Drug|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
327943|NCT00586989|Procedure|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
328260|NCT00578942|Drug|Campath Purged Non-myeloablative ASCT|Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.
Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45.
328261|NCT00581243|Drug|SLV-313 SR|sustained relase tablets taken once daily for 14 days
328262|NCT00581256|Radiation|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
328263|NCT00581256|Radiation|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
328264|NCT00581269|Behavioral|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
328265|NCT00581269|Dietary Supplement|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
328266|NCT00004144|Drug|gemcitabine hydrochloride|
328267|NCT00581282|Radiation|PET scan|positron emission tomography PET scan
328268|NCT00581282|Other|fMRI|functional magnetic resonance imaging fMRI
328269|NCT00581295|Device|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
328270|NCT00581308|Device|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
328271|NCT00581321|Dietary Supplement|water|water 500 ml x 1
327621|NCT00553878|Drug|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
327622|NCT00553891|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
327623|NCT00553891|Drug|placebo nasal spray|One spray in each nostril once daily for 3 months.
327624|NCT00553904|Dietary Supplement|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
327625|NCT00553930|Drug|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
327626|NCT00553930|Drug|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of >= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
327627|NCT00553943|Drug|Rituximab, Cytarabine|Intravenous chemotherapy associated with IV rituximab and intrathecal cytarabine
327628|NCT00553956|Behavioral|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
327629|NCT00004006|Biological|filgrastim|
327630|NCT00553969|Drug|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
327631|NCT00553969|Drug|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
327632|NCT00556335|Procedure|conventional drainage|drainage, pneumocath
327944|NCT00587002|Procedure|IVUS|Intravascular ultrasound with virtual histology
327945|NCT00587015|Drug|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
327946|NCT00589563|Drug|etoposide|60mg/kg on day -4 from stem cell transplant
327947|NCT00004179|Drug|prednisone|
327948|NCT00589563|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
327949|NCT00589563|Drug|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
327950|NCT00589563|Drug|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
326978|NCT00568178|Drug|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
326979|NCT00568178|Other|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
326980|NCT00568178|Other|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
326981|NCT00568178|Drug|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
327295|NCT00004048|Procedure|peripheral blood stem cell transplantation|
327296|NCT00561080|Biological|Zostavax|Two doses (0.65 mL) at 3 months interval
327297|NCT00561093|Drug|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
327298|NCT00561093|Dietary Supplement|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
327299|NCT00561093|Dietary Supplement|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
327300|NCT00561093|Drug|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
327301|NCT00561093|Dietary Supplement|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
327302|NCT00561093|Dietary Supplement|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
327303|NCT00561106|Drug|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
327304|NCT00561106|Drug|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
327305|NCT00561119|Drug|gemcitabine , paclitaxel|Gemcitabine 1250 mg/m2 i.v. Day 1 & 8
Paclitaxel 175 mg/m2 i.v. day 1
repeat every 3 weeks
327306|NCT00004048|Radiation|indium In 111 monoclonal antibody MN-14|
327307|NCT00561132|Dietary Supplement|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
327308|NCT00561132|Other|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (<50 mg) twice daily for a period of 4 weeks
326659|NCT00573274|Device|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
326660|NCT00573287|Drug|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
326661|NCT00573287|Drug|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
326662|NCT00573300|Procedure|Phlebotomy|Single blood draw
326663|NCT00573313|Drug|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
326664|NCT00573313|Drug|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
326665|NCT00573326|Drug|Imatinib|200 mg p.o. once a day for 6 months
326666|NCT00573339|Other|Cardiac MRI|up to 3 CMRI scans per participant in 1-4 months
326667|NCT00573352|Radiation|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
326668|NCT00004102|Drug|oxaliplatin|
326669|NCT00575822|Device|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
326670|NCT00575835|Dietary Supplement|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
326671|NCT00575835|Dietary Supplement|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
326982|NCT00568204|Device|Mexyn-A|Atomised topical self-chilled pressurised spray
326983|NCT00568217|Drug|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature > 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still < 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature < 38 degree Celsius
326984|NCT00004086|Radiation|indium In 111 LL2 IgG|
326985|NCT00568230|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
326986|NCT00568256|Behavioral|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
326987|NCT00568269|Procedure|Open repair|Open repair is according to the Lichtenstein technique
326325|NCT00580528|Behavioral|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
326326|NCT00580528|Behavioral|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
326327|NCT00004141|Drug|Cisplatin|
326328|NCT00583128|Drug|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
326329|NCT00583154|Drug|BLI-801|Dose 1
326330|NCT00583154|Drug|BLI-801|Dose 2
326672|NCT00575848|Dietary Supplement|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
326673|NCT00575848|Dietary Supplement|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
326674|NCT00575861|Drug|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
326675|NCT00575874|Drug|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
326676|NCT00575874|Drug|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
326677|NCT00004114|Biological|filgrastim|
326678|NCT00575874|Drug|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
326679|NCT00575874|Drug|pioglitazone HCl|30 mg capsules once daily for 12 weeks
326680|NCT00575874|Drug|placebo|matching tablets or capsule once daily for 12 weeks
326681|NCT00575887|Drug|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
326682|NCT00575900|Behavioral|dietary intervention|12 weeks of dietary intervention
326683|NCT00575913|Drug|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
326684|NCT00575926|Drug|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
326002|NCT00588913|Biological|aldesleukin|
326003|NCT00588913|Biological|therapeutic autologous lymphocytes|
326004|NCT00588913|Drug|zoledronic acid|
326005|NCT00588926|Drug|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
326006|NCT00004176|Radiation|radiation therapy|
326007|NCT00588939|Device|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
326008|NCT00588952|Drug|Ketamine|Ketamine: 0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute for 60 minutes, IV
326009|NCT00588952|Drug|Placebo|Placebo: loading dose and an infusion for 60 minutes saline solution
326010|NCT00588965|Drug|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
326011|NCT00588965|Drug|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
326012|NCT00550849|Drug|RTA 402|5 mg oral capsules
326013|NCT00550849|Drug|RTA 402|25 mg oral capsules
326014|NCT00550849|Drug|RTA 402|50 mg oral capsules
326015|NCT00003977|Biological|human papillomavirus 16 E7 peptide|
326331|NCT00583154|Drug|BLI-801|Dose 3
326332|NCT00004153|Genetic|reverse transcriptase-polymerase chain reaction|
326333|NCT00583154|Drug|BLI-801|Dose 4
326334|NCT00583180|Drug|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
326335|NCT00583193|Drug|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
326336|NCT00583219|Drug|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
325341|NCT00560313|Biological|4CMenB|All subjects will receive the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
325342|NCT00560326|Drug|Tacrolimus Ointment 0.03%|Once or twice daily topical application
325655|NCT00553124|Procedure|biopsy|
325656|NCT00553124|Procedure|chemoprevention|
325657|NCT00553124|Procedure|cryopreservation|
325658|NCT00553124|Procedure|cytology specimen collection procedure|
325659|NCT00553124|Procedure|diagnostic procedure|
325660|NCT00553124|Procedure|gene expression analysis|
325661|NCT00553124|Procedure|immunohistochemistry staining method|
325662|NCT00553124|Procedure|laboratory biomarker analysis|
325663|NCT00553124|Procedure|medical chart review|
325664|NCT00004001|Drug|estramustine|
325665|NCT00553124|Procedure|mutation analysis|
325666|NCT00553124|Procedure|polymerase chain reaction|
325667|NCT00553124|Procedure|quality-of-life assessment|
325668|NCT00553124|Procedure|questionnaire administration|
325669|NCT00553124|Procedure|study of socioeconomic and demographic variables|
325670|NCT00553137|Drug|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
325671|NCT00553137|Drug|fluconazole|150 mg fluconazole tablets once daily for 14 days
325672|NCT00553150|Drug|everolimus|
325673|NCT00553150|Drug|temozolomide|
325674|NCT00553150|Radiation|radiation|
325675|NCT00004001|Drug|mitoxantrone|
325676|NCT00553163|Behavioral|Gut focussed hypnotherapy|Gut focussed hypnotherapy
325042|NCT00565019|Drug|Triamcinolone Acetonide|Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.
Doses will range from 60-120 mg depending on extent of the disease.
Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.
PI will determine the dosages. Estimates will be made based on the following:
Size of nodule/cord: 1-2 cm2, dosage 20-40 mg
Size of nodule/cord: 2-6 cm2, dosage 40-80 mg
Size of nodule/cord: 6-10 cm2, dosage 80-100 mg
Size of nodule/cord: >10 cm2, dosage 100-120 mg
325043|NCT00567320|Drug|Sugar pill or Placebo|Placebo
325044|NCT00567333|Other|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
325045|NCT00004084|Radiation|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
325046|NCT00567333|Other|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
325047|NCT00567346|Drug|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
325048|NCT00567346|Drug|grass pollen extract|Patients will receive matching placebo sublingually
325049|NCT00567359|Drug|Erlotinib|Oral drug taken daily around the same time.
325050|NCT00567372|Drug|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
325051|NCT00567385|Drug|somatropin|
325052|NCT00567398|Drug|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
325053|NCT00567398|Drug|Physioneal|Physioneal 40 or Physioneal 35
325343|NCT00560352|Drug|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
325344|NCT00560352|Drug|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m^2 QD, 1.3 mg/m^2 QD
325345|NCT00560352|Drug|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
325346|NCT00560365|Other|laboratory biomarker analysis|
325347|NCT00560365|Procedure|computed tomography|
325348|NCT00004041|Procedure|conventional surgery|
325349|NCT00560365|Procedure|magnetic resonance imaging|
325350|NCT00560365|Procedure|quality-of-life assessment|
324401|NCT00302471|Drug|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
324749|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
324750|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
324751|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
324752|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
324753|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
324754|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
324755|NCT00000601|Drug|estrogen replacement therapy|
324756|NCT00004099|Drug|cisplatin|
324757|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
324758|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
324759|NCT00572455|Drug|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
324760|NCT00572468|Drug|Simvastatin|40 mg of simvastatin
324761|NCT00572468|Other|Placebo|placebo
324762|NCT00572481|Procedure|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
324763|NCT00574873|Drug|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
324764|NCT00004109|Radiation|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
324765|NCT00574886|Biological|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
324047|NCT00311441|Biological|Tick-Borne Encephalitis vaccine|
324048|NCT00311454|Drug|T.R.U.E.Test|
324049|NCT00002842|Drug|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
324050|NCT00262951|Biological|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
324051|NCT00262951|Drug|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
324052|NCT00262951|Drug|fluorouracil|administered at a dose of 175 mg/m^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
324053|NCT00262951|Radiation|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
324402|NCT00302484|Drug|Zoledronate|
324403|NCT00302497|Drug|basiliximab|
324404|NCT00302510|Procedure|immunoadsorption|immunoadsorption
324405|NCT00302523|Drug|Tacrolimus|FK506,0.1mg/kg/d
324406|NCT00302536|Drug|Tacrolimus|Tacrolimus
324407|NCT00302549|Drug|FK506|FK506,0.1mg/kg/d
324408|NCT00302575|Behavioral|Collaborative Behavioral Management|
324409|NCT00002817|Biological|sargramostim|
324410|NCT00305682|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
324411|NCT00305682|Procedure|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
324412|NCT00305682|Radiation|total body irradiation|Administered Day -1, 200 cGy
324413|NCT00305682|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
324414|NCT00305695|Drug|zoledronic acid|Given IV
324415|NCT00305695|Other|clinical observation|Patients are observed for 18 months after surgery.
323688|NCT00272844|Drug|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
323689|NCT00272857|Genetic|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
323690|NCT00272870|Drug|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
323691|NCT00002738|Drug|trimetrexate glucuronate|
323692|NCT00272870|Genetic|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
323693|NCT00272870|Device|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
323694|NCT00272896|Drug|Vasoactive intestinal peptide|
323695|NCT00272909|Drug|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
323696|NCT00272909|Drug|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
323697|NCT00272909|Drug|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
323698|NCT00272922|Device|hernia repair|
323699|NCT00272935|Drug|Cenestin 0.3 mg Tablets|1 tablet daily
323700|NCT00272935|Other|Placebo|1 tablet daily
323701|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d
324054|NCT00262951|Procedure|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
324055|NCT00002702|Biological|aldesleukin|
324056|NCT00262964|Drug|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
324057|NCT00262964|Drug|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
328473|NCT00564005|Other|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
323347|NCT00279630|Procedure|Orthoses and Exercise|orthrose and exercise - daily
323348|NCT00279643|Procedure|Laser Hair Removal|
323349|NCT00279656|Behavioral|Pharmaceutical care|
323350|NCT00279669|Procedure|Ultrasound examination|contact ultrasound examination
323351|NCT00279682|Behavioral|treatment guidelines and depression care management|
323352|NCT00282152|Device|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. DBS is not approved for early stage PD. The STN is a part of the brain that is very small in size and is located in the middle of the right and left sides of the brain. In this disease, this part of the brain becomes overactive and causes the symptoms of PD. It is thought that using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
323353|NCT00282152|Drug|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
323354|NCT00282165|Drug|naratriptan|four weeks double blind experimental treatment using oral naratriptan
323355|NCT00282165|Drug|placebo|four weeks double blind placebo treatment
323356|NCT00002768|Procedure|peripheral blood stem cell transplantation|Infusion on Day 0
323357|NCT00282178|Drug|Hydrochlorothiazide|25-50 mg once daily
323358|NCT00282178|Drug|Placebo|Once daily
323359|NCT00282178|Drug|Candesartan|16-32 mg once daily 12 weeks
323360|NCT00282204|Behavioral|antenatal hypnosis + audio compact disc on hypnosis|
323361|NCT00282204|Behavioral|Audio compact disc on hypnosis|
323362|NCT00282217|Drug|Sirolimus|
323363|NCT00282230|Drug|FK778|
323364|NCT00282243|Drug|tacrolimus modified release (MR)|Oral
323365|NCT00282243|Drug|tacrolimus|Oral
323366|NCT00282256|Drug|tacrolimus modified release (MR)|Oral
355627|NCT00599144|Procedure|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
355628|NCT00599144|Procedure|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
355629|NCT00599170|Drug|Rituximab|375 mg/m2 IV
355630|NCT00599183|Other|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
355631|NCT00599196|Drug|Rotigotine|Rotigotine trans-dermal patches, once daily:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);
Optimal dosing:
During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.
After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.
355632|NCT00599209|Other|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
355633|NCT00599222|Biological|ranibizumab|0.5 mg intravitreal injection
355634|NCT00599222|Procedure|TTT|Transpupillary thermotherapy (TTT)
355635|NCT00599222|Procedure|Sham TTT|Sham Transpupillary thermotherapy (TTT)
355932|NCT00630656|Drug|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
355933|NCT00630669|Procedure|Rubber band ligation|placing rubber bands around the internal hemorrhoids
355934|NCT00630669|Procedure|Bipolar coagulation|using electricity to cauterize
355935|NCT00630682|Drug|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
355936|NCT00004669|Drug|hydrocortisone|
355937|NCT00630682|Drug|Placebo|9 weeks of placebo 60mg capsules QD.
355938|NCT00630695|Drug|Lanreotide LP 90|Lanreotide LP 90
355939|NCT00630695|Drug|Placebo lanreotide|Placebo
355940|NCT00630708|Drug|Benazepril|20 mg per day
355941|NCT00630708|Drug|Losartan|100 mg per day
355942|NCT00630708|Drug|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
324167|NCT00276497|Drug|Pioglitazone|
324168|NCT00276510|Drug|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
324524|NCT00266136|Drug|G-CSF|see protocol
324525|NCT00266136|Procedure|Autologous stem cell transplantation|for details see protocol
324526|NCT00266136|Procedure|Allogeneic stem cell transplantation|for details see protocol
324527|NCT00002714|Drug|Stanford V regimen|
324528|NCT00266149|Drug|Oral contraception|
324529|NCT00266149|Drug|Lamotrigine|
324530|NCT00266162|Drug|Bosentan administration|
324531|NCT00266214|Drug|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
324532|NCT00266227|Drug|placebo|Intravenous repeating dose
324533|NCT00266227|Drug|rituximab|Intravenous repeating dose
324534|NCT00266227|Drug|methotrexate|Oral or parenteral repeating dose
324535|NCT00266227|Drug|folate|Intravenous repeating dose
324536|NCT00266240|Drug|GK Activator (2)|Escalating doses po bid
324537|NCT00266240|Drug|Placebo|po bid
324538|NCT00002714|Drug|doxorubicin hydrochloride|
324539|NCT00266253|Drug|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
324540|NCT00266253|Drug|Metformin|As prescribed, for 12 weeks
324541|NCT00266279|Drug|Oxaliplatin, Capecitabine|Agent, DOSE AND SCHEDULE (28-days cycle):
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21
324542|NCT00266292|Behavioral|Fish oil (Bio-Marine, Pharma Nord)|
324543|NCT00266292|Behavioral|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
324544|NCT00266305|Behavioral|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
324545|NCT00266318|Drug|Interferon Alfacon-1 and Ribavirin|
323812|NCT00286234|Drug|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
323813|NCT00286247|Genetic|INGN 201|
323814|NCT00286260|Drug|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
323815|NCT00286273|Drug|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
323816|NCT00286273|Drug|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
323817|NCT00286286|Device|Intraperitoneal Aerosolization System, IntraMyst|
323818|NCT00286299|Other|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
324169|NCT00276510|Other|Placebo|1 tablet twice a day, oral route, during 5 years.
324170|NCT00276523|Biological|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
324171|NCT00276523|Procedure|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
324172|NCT00276523|Procedure|Neoadjuvant therapy|
324173|NCT00276536|Biological|recombinant interferon alpha-1b|interferon
324174|NCT00276536|Drug|IFN|IFN daily
324175|NCT00276549|Drug|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
324176|NCT00002755|Drug|doxorubicin hydrochloride|
324177|NCT00276549|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
324178|NCT00276575|Biological|bevacizumab|
324179|NCT00276575|Drug|erlotinib hydrochloride|
324180|NCT00276575|Drug|everolimus|
324181|NCT00276588|Drug|carboplatin|
323460|NCT00295776|Drug|Lamictal in the treatment of Post-Herpetic Neuralgia|
323461|NCT00295789|Drug|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
323462|NCT00295789|Drug|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
323463|NCT00295802|Device|Integrated Imaging High Intensity Focused Ultrasound|
323464|NCT00295802|Device|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
323465|NCT00295815|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
323466|NCT00295815|Drug|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
323467|NCT00295828|Other|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
323468|NCT00002802|Drug|vincristine sulfate|
323469|NCT00295828|Procedure|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
323470|NCT00295841|Drug|clofarabine|
323471|NCT00295841|Drug|cytarabine|
323472|NCT00295854|Drug|MN-001 BID|Eligible patients received 500 mg MN-001 bid
323473|NCT00295854|Drug|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
323474|NCT00295854|Drug|Placebo|Eligible patients received placebo
323475|NCT00295867|Drug|zoledronic acid|
323476|NCT00295880|Procedure|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
323477|NCT00295893|Biological|trastuzumab|Given IV
323478|NCT00295893|Drug|carboplatin|Given IV
323479|NCT00002802|Drug|vindesine|
323480|NCT00295893|Drug|cyclophosphamide|Given IV
323481|NCT00295893|Drug|docetaxel|Given IV
323482|NCT00295893|Drug|doxorubicin hydrochloride|Given IV
328272|NCT00581334|Procedure|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
328273|NCT00581347|Other|outreach services|Tracking/reminder/recall/home visit strategy.
328274|NCT00581360|Drug|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
323111|NCT00305084|Drug|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
323112|NCT00002827|Biological|bleomycin sulfate|Given IV
323113|NCT00305084|Drug|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
323114|NCT00305097|Behavioral|Decaffeinated coffee|5 cups per day for 8 weeks
323115|NCT00305097|Behavioral|caffeinated coffee|5 cups per day for 8 weeks
323116|NCT00305110|Drug|Hydromorphone 2mg intravenous|
323117|NCT00305149|Procedure|interim therapy scintigraphy study gallium scan or PET/CT|
323118|NCT00305149|Procedure|"interim gallium or PET/CT"|
323119|NCT00305162|Drug|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) & infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
323120|NCT00305162|Drug|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
323121|NCT00305162|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
323122|NCT00305162|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
323123|NCT00002827|Biological|filgrastim|Given IV
327951|NCT00589563|Drug|sirolimus|Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.
Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
327952|NCT00589563|Drug|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
327953|NCT00589563|Procedure|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
327954|NCT00589563|Procedure|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
327955|NCT00589563|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
327956|NCT00589563|Procedure|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
327957|NCT00589563|Radiation|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
327958|NCT00004179|Drug|vincristine sulfate|
327959|NCT00589589|Device|Endo Tool|Computer tool to help achieve glucose control
327960|NCT00589602|Biological|peripheral blood lymphocyte therapy|T-cell depletion
327961|NCT00589602|Drug|cyclophosphamide|T-cell depletion
327962|NCT00589602|Drug|tacrolimus|T-cell depletion
327963|NCT00589602|Procedure|allogeneic hematopoietic stem cell transplantation|T-cell depletion
327964|NCT00589602|Procedure|peripheral blood stem cell transplantation|T-cell depletion
327965|NCT00589602|Radiation|total-body irradiation|T-cell depletion
328275|NCT00581373|Other|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
328276|NCT00581386|Device|LTS-D|supra-glottic airway device
328277|NCT00004145|Biological|anti-thymocyte globulin|
328278|NCT00581386|Device|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
328279|NCT00581386|Device|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
328280|NCT00584025|Drug|levetiracetam|100 - 500mg IV q 15 min
327309|NCT00561145|Other|Energy restriction period|The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
327310|NCT00563303|Drug|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
327311|NCT00563303|Drug|NaCl|48mL from Day 1 to Day 6
327312|NCT00563316|Drug|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
327313|NCT00563316|Drug|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
327633|NCT00556348|Drug|bevacizumab|1.25mg
327634|NCT00556361|Drug|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
327635|NCT00556361|Drug|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
327636|NCT00556374|Drug|Placebo|
327637|NCT00556374|Drug|Denosumab|
327638|NCT00556374|Drug|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
327639|NCT00556387|Drug|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
327640|NCT00556387|Drug|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
327641|NCT00556400|Drug|Lo-Ovral Oral Contraceptive Pills|
327642|NCT00000160|Procedure|Argon Photocoagulation|
327643|NCT00000586|Drug|hydroxyurea|
327644|NCT00004017|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
327645|NCT00556400|Drug|Placebo - sugar pill|
327646|NCT00556413|Biological|cetuximab|
327647|NCT00556413|Drug|fluorouracil|
327648|NCT00556413|Drug|irinotecan hydrochloride|
327649|NCT00556413|Drug|leucovorin calcium|
326988|NCT00568269|Procedure|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
326989|NCT00568282|Procedure|phlebotomy|Standard of care
326990|NCT00568295|Drug|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
326991|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
326992|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
326993|NCT00568308|Drug|PI-88|160mg subcutaneous injection
326994|NCT00568308|Drug|placebo|matched placebo
326995|NCT00570947|Other|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
326996|NCT00570960|Drug|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
326997|NCT00570960|Biological|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
326998|NCT00004093|Drug|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
326999|NCT00570973|Procedure|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
327000|NCT00570973|Procedure|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
327314|NCT00563329|Procedure|Reduction Intervention + Adherence Intervention|
327315|NCT00563329|Behavioral|Reduction Intervention|
327316|NCT00004061|Biological|filgrastim|
327317|NCT00563329|Procedure|control|
327318|NCT00563342|Drug|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
327319|NCT00563355|Drug|erythropoietin|
326685|NCT00575952|Drug|Doxorubicin Hydrochloride|Given IV
326686|NCT00575952|Drug|Cisplatin|Given IV or IP
326687|NCT00575952|Drug|Paclitaxel|Given IV or IP
326688|NCT00004114|Drug|cyclophosphamide|
326689|NCT00575952|Biological|Filgrastim|Given SC
326690|NCT00575952|Biological|Pegfilgrastim|Given SC
326691|NCT00575965|Drug|Simvastatin|Oral tablets taken daily
326692|NCT00575978|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
326693|NCT00578305|Drug|Methylprednisolone|
326694|NCT00004128|Drug|daunorubicin hydrochloride|
327001|NCT00570986|Drug|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
327002|NCT00570986|Biological|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
327003|NCT00570986|Biological|ABT-874|100mg every 12 weeks.
327004|NCT00570999|Drug|Palifermin|60 mg/kg/day
327005|NCT00570999|Other|Placebo|1,2 mL once daily
327006|NCT00571025|Behavioral|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
327007|NCT00571038|Behavioral|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
327008|NCT00571038|Behavioral|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
327009|NCT00000161|Drug|Aspirin|
327010|NCT00000600|Drug|Vitamin E|
327011|NCT00004093|Drug|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
327012|NCT00571051|Behavioral|Mindfulness Based Stress Reduction|8 week course in mindfulness training
326337|NCT00583219|Drug|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
326338|NCT00583232|Other|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
326339|NCT00583245|Other|Gait Training|Gait training with physical therapist 2/week for 3 months
326340|NCT00583258|Drug|Alfuzosin (Xatral)|10 mg PO once a day
326341|NCT00583258|Drug|Placebo Alfuzosin|10 mg PO once a day
326342|NCT00583271|Drug|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
326343|NCT00004153|Procedure|sentinel lymph node biopsy|
326344|NCT00583271|Drug|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
326345|NCT00583297|Other|Blood Draw|No Intervention.
326346|NCT00583310|Behavioral|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
326347|NCT00583323|Drug|Lomotil|Orally 10ml of Lomotil
326348|NCT00583323|Other|Normal saline|10 ml orally
326349|NCT00583336|Device|ShuntCheck|Thermal dilution test for CSF flow
326350|NCT00583349|Drug|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
326351|NCT00583362|Biological|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
326352|NCT00583375|Device|GEM OS1|GEM OS1 with sodium acetate buffer containing rhPDGF-BB
326353|NCT00583375|Procedure|Standard of Care|Autologous Bone Graft
326695|NCT00578305|Drug|Methotrexate|
326696|NCT00578305|Drug|Folic acid or folate|
326697|NCT00578318|Behavioral|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
326698|NCT00578331|Drug|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
326699|NCT00578331|Drug|Placebo Nasal Spray|2 sprays each nostril twice daily
325677|NCT00553163|Behavioral|Controlled educational sessions|Controlled educational sessions
325678|NCT00555607|Drug|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
325679|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
325680|NCT00555620|Drug|oxaliplatin|Oxaliplatin is given 110mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
326016|NCT00550862|Drug|INT-747|Once a day (QD) by mouth (PO)
326017|NCT00550862|Drug|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
326018|NCT00550862|Drug|Placebo|Placebo
326019|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
326020|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
326021|NCT00550875|Biological|placebo|Sublingual. 2 drops/daily 2 years
326022|NCT00550888|Procedure|suture techniques|
326023|NCT00550901|Drug|cisplatin|
326024|NCT00550901|Drug|dexrazoxane hydrochloride|
326025|NCT00550901|Other|high performance liquid chromatography|
326026|NCT00003977|Procedure|in vitro-treated peripheral blood stem cell transplantation|
326027|NCT00550901|Other|laboratory biomarker analysis|
326028|NCT00550901|Other|mass spectrometry|
326029|NCT00550901|Other|pharmacological study|
326030|NCT00550927|Biological|bevacizumab|
326031|NCT00550927|Drug|enzastaurin hydrochloride|
326032|NCT00550927|Other|diagnostic laboratory biomarker analysis|
326033|NCT00550927|Other|pharmacological study|
326034|NCT00550953|Drug|telmisartan+amlodipine|
325351|NCT00560378|Drug|Tacrolimus ointment 0.1%|Topical
325352|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
325353|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
325354|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
325355|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
325356|NCT00560391|Drug|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
325357|NCT00560404|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
325358|NCT00560404|Drug|Epoetin alfa|As prescribed
325359|NCT00562497|Other|Placebo|Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the non active treatment group will receive placebo (excipient, less cells). It is recommended that all subjects receive all six infusions. The discontinuation of investigational agent is allowed for GVHD worsening with subsequent need for salvage therapy. All infusions must be given at least 3 days apart.
325360|NCT00562510|Drug|Raltegravir|Raltegravir 400 mg BID added to stable HAART
325361|NCT00562510|Drug|Placebo|Placebo BID added to stable HAART
325362|NCT00562523|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
325681|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
325682|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
325683|NCT00004011|Drug|carboplatin|
325684|NCT00555620|Drug|cisplatin|Cisplatin is given 80mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
325685|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
324766|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.
Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat.
324767|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.
Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat.
325054|NCT00567398|Drug|Extraneal|Extraneal - 7.5% Icodextrin
325055|NCT00567398|Drug|Nutrineal|Nutrineal - 1.1% Amino Acids
325056|NCT00004084|Radiation|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
325057|NCT00567411|Drug|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
325058|NCT00567411|Drug|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
325059|NCT00567424|Drug|GW273225|
325060|NCT00567437|Other|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
325061|NCT00567450|Drug|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
325062|NCT00567450|Drug|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
325063|NCT00567463|Device|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
325064|NCT00567476|Drug|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
325065|NCT00567476|Drug|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
325066|NCT00567476|Drug|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
325067|NCT00004085|Biological|filgrastim|as prescribed by physician
325068|NCT00567476|Drug|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
325069|NCT00567489|Drug|Physioneal|Physioneal 40 or Physioneal 35
325070|NCT00570141|Device|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
324416|NCT00305708|Biological|anti-thymocyte globulin|
324417|NCT00305708|Drug|busulfan|
324418|NCT00305708|Drug|fludarabine phosphate|
324419|NCT00002827|Radiation|low-LET photon therapy|
324420|NCT00305708|Procedure|allogeneic bone marrow transplantation|
324421|NCT00305708|Procedure|peripheral blood stem cell transplantation|
324422|NCT00305708|Procedure|umbilical cord blood transplantation|
324423|NCT00305708|Radiation|radiation therapy|
324424|NCT00305734|Drug|bortezomib|Given IV
324425|NCT00305734|Drug|gemcitabine hydrochloride|Given IV
324426|NCT00305734|Other|laboratory biomarker analysis|Correlative studies
324768|NCT00574912|Drug|Placebo or Insulin Glargine|administering single dose of Placebo injected s/c at 8am and monitoring blood glucose over 24 hours, then 8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
324769|NCT00574925|Drug|Esomeprazole|
324770|NCT00574951|Drug|motesanib diphosphate|
324771|NCT00574964|Other|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
324772|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.
Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u.
324773|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.
Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u.
324774|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|Eligible subjects will receive 1 infusion of vvDD-CDSR.
Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u.
324775|NCT00004110|Biological|monoclonal antibody 3F8|
324776|NCT00575003|Drug|CYT003-QbG10|6 subcutaneous injections
324777|NCT00575016|Biological|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U > Week 12; injection into the detrusor
324058|NCT00262964|Drug|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
324059|NCT00262977|Behavioral|Electronic prompt plus patient-directed intervention|
324060|NCT00262977|Behavioral|Electronic prompt to clinician to prescribe aspirin|
324061|NCT00262990|Drug|EPO906 (Patupilone)|
324062|NCT00262990|Drug|doxorubicin|
324063|NCT00263003|Drug|Irbesartan/hydrochlorothiazide|
324064|NCT00263003|Drug|Irbesartan|
324065|NCT00263016|Drug|Docetaxel|
324066|NCT00002702|Procedure|adjuvant therapy|
324067|NCT00263029|Drug|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
324068|NCT00263029|Drug|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
324069|NCT00263029|Radiation|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
324070|NCT00263042|Drug|rimonabant (SR141716)|20 mg once daily
324071|NCT00263042|Drug|placebo|once daily
324072|NCT00263055|Drug|oxaliplatin|
324073|NCT00263068|Drug|Rotigotine|Transdermal Patch 1 per day for 24 hours containing:
1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day
324074|NCT00263081|Drug|Lapaquistat acetate and current lipid-lowering treatment|Cohort 1: Weight is less than 50 kg:
Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
Cohort 2: Weight is more than 50 kg:
Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
324427|NCT00305747|Drug|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
324428|NCT00305760|Drug|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
324429|NCT00305760|Biological|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
324430|NCT00002828|Drug|fluorouracil|
323367|NCT00002771|Biological|recombinant interferon alfa|
323368|NCT00282256|Drug|tacrolimus|Oral
323369|NCT00282269|Procedure|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
323370|NCT00282282|Drug|tacrolimus|Given orally just prior to and following stem cell transplant
323702|NCT00002740|Biological|filgrastim|
323703|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
323704|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
323705|NCT00272961|Drug|Placebo|placebo tablet once daily for 12 weeks
323706|NCT00272961|Drug|TBC3711|10 mg tablets once daily for 10 weeks
323707|NCT00272961|Drug|TBC3711|50 mg tablet once daily for 10 weeks
323708|NCT00272961|Drug|TBC3711|100 mg tablet once daily for 10 weeks
323709|NCT00272961|Drug|TBC3711|200 mg tablet once daily for 10 weeks
323710|NCT00272974|Behavioral|Clinic-based counseling|
323711|NCT00272987|Drug|lapatinib|(GW572016) 1000 mg QD
323712|NCT00272987|Drug|paclitaxel|80 mg/m2 IV weekly for three weeks
323713|NCT00002740|Drug|carboplatin|
323714|NCT00276172|Drug|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
323715|NCT00002754|Biological|monoclonal antibody Me1-14 F(ab')2|
323716|NCT00276185|Drug|Time delay treatment of botulinum toxin|
323717|NCT00276198|Dietary Supplement|Sprinkles|Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
323718|NCT00276198|Dietary Supplement|Ferripel-3, Vitamins A&D drops|Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
323719|NCT00276224|Drug|ferrous sulphate (drug)|
355943|NCT00593489|Other|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
355944|NCT00593502|Drug|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; > 40 kg, 75 mg twice daily, for 5 days
355945|NCT00593502|Drug|placebo|The dosage of placebo will be similar to the active drug
355946|NCT00593515|Behavioral|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
355947|NCT00593515|Behavioral|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
355948|NCT00593528|Device|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
355949|NCT00593528|Device|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
355950|NCT00593528|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
355951|NCT00593554|Radiation|Total Body Irradiation|8 Gy on Day -9
355952|NCT00593554|Drug|Thiotepa|5 mg/kg/d on Day -8 to -7
355953|NCT00004193|Drug|ISIS 2503|
356270|NCT00625846|Drug|Pazopanib Hydrochloride|Given PO
356271|NCT00625859|Drug|GSK189075|
356272|NCT00625859|Drug|bupropion|
356273|NCT00625859|Drug|placebo|
356274|NCT00000631|Biological|HIVAC-1e|
356275|NCT00004562|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
356276|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
324546|NCT00266331|Drug|Reduced glutathione|
324547|NCT00266344|Drug|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
324548|NCT00266344|Drug|Placebo / Duration of Treatment 3 Weeks|
324549|NCT00002714|Drug|etoposide|
324858|NCT00585559|Drug|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
324859|NCT00585559|Drug|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
324860|NCT00585559|Drug|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
324861|NCT00004164|Radiation|radiation therapy|
324862|NCT00585559|Drug|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
324863|NCT00585585|Drug|Betahistine dihydrochloride|oral, 50 mg/day - 300 mg/day
324864|NCT00585598|Other|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
324865|NCT00588211|Behavioral|Survey|A second confirmatory factor analysis.
324866|NCT00588224|Other|3D ultrasound|measurement of stomach volume by 3D ultrasound
324867|NCT00588237|Drug|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
324868|NCT00588250|Other|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
324869|NCT00588276|Radiation|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three *IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
324870|NCT00000611|Drug|hormone replacement therapy|
324871|NCT00004175|Drug|cyclophosphamide|
324872|NCT00588302|Drug|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
324182|NCT00276588|Drug|gemcitabine hydrochloride|
324183|NCT00276588|Drug|paclitaxel|
324184|NCT00276601|Drug|arsenic trioxide|
324185|NCT00276601|Drug|cytarabine|
324186|NCT00276601|Drug|daunorubicin hydrochloride|
324187|NCT00002755|Drug|fluorouracil|
324188|NCT00279929|Procedure|DHEA Replacement|
324189|NCT00279942|Dietary Supplement|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
324190|NCT00279942|Other|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
324191|NCT00279955|Device|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
324192|NCT00279968|Device|ICD|
324193|NCT00279981|Device|Diagnostic|
324550|NCT00266357|Drug|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
324551|NCT00266357|Drug|Placebo / Duration of Treatment: 2 days for screening period|
324552|NCT00266396|Behavioral|Weight-bearing recommendation|
324553|NCT00266409|Drug|Niravam|
324554|NCT00266409|Drug|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
324555|NCT00269724|Drug|OROS® oxybutynin|
324556|NCT00269737|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
324557|NCT00269750|Drug|OROS® oxybutynin or Ditropan®|
324558|NCT00269763|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
324559|NCT00269776|Drug|Placebo|Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
323483|NCT00295893|Drug|paclitaxel|Given IV
323819|NCT00286299|Other|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
323820|NCT00000437|Drug|naltrexone (Revia)|
323821|NCT00002780|Procedure|peripheral blood stem cell transplantation|
323822|NCT00286299|Other|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
323823|NCT00286312|Drug|Atorvastatin|
323824|NCT00289354|Drug|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
323825|NCT00289367|Drug|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
323826|NCT00289367|Drug|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
323827|NCT00289393|Behavioral|Perceived outcome by both patient and physician|
323828|NCT00289406|Drug|S-amlodipine gentisate|
323829|NCT00289406|Drug|Amlodipine besylate|
323830|NCT00289419|Drug|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
323831|NCT00289419|Drug|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
323832|NCT00002785|Radiation|low-LET photon therapy|
323833|NCT00289432|Behavioral|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
323834|NCT00289432|Other|Support group|Standard Hospital follow-up support group
323835|NCT00289445|Drug|Mitomycin C|
323836|NCT00289445|Drug|5-FU|
323837|NCT00289445|Drug|Folinic acid|
323124|NCT00305162|Drug|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
323125|NCT00305188|Drug|xaliproden (SR57746A)|oral administration
323126|NCT00305188|Drug|Placebo|oral administration
323127|NCT00305188|Drug|oxaliplatin|in combination with 5-Fluorouracil and Leucovorin
323128|NCT00305201|Drug|pravastatin|
323129|NCT00308126|Drug|Hydroxyethyl Starch 130/0.4 (Voluven)|
323130|NCT00308139|Drug|exenatide, long acting release|
323131|NCT00308139|Drug|exenatide|
323132|NCT00308152|Procedure|Infusion of 1 litre of normal saline before colonoscopy|
323133|NCT00002833|Drug|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
323484|NCT00295906|Other|educational intervention|
323485|NCT00295906|Other|internet-based intervention|
323486|NCT00298779|Drug|omeprazole and bortezomib|
323487|NCT00298792|Behavioral|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
323488|NCT00298792|Behavioral|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
323489|NCT00298831|Drug|sugammadex|Each subject will receive an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block is required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium may be administered.
At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 will be administered.
323490|NCT00298857|Drug|Valproic acid|
323491|NCT00298870|Drug|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
323492|NCT00298870|Drug|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
323493|NCT00002809|Biological|anti-thymocyte globulin|
323494|NCT00298883|Drug|Myfortic|Myfortic 360mg PO BID for six weeks
323495|NCT00298896|Drug|SNS-595 Injection|
328281|NCT00004159|Drug|paclitaxel|
328282|NCT00584025|Drug|Placebo|Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
328283|NCT00584038|Behavioral|educational instruction and phone follow-up|Educational instruction and phone follow-up.
328284|NCT00584038|Behavioral|educational instruction in clinic|Educational instruction in clinic.
328285|NCT00584064|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
328286|NCT00584090|Drug|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
328287|NCT00584090|Drug|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
328288|NCT00584103|Device|Beta P prosthesis|A prefabricated below elbow prosthesis will be compared to each patient's custom fitted prosthesis. Subjects will serve as their own controls.
328289|NCT00584129|Other|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
328290|NCT00584129|Other|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
328291|NCT00584142|Behavioral|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
328292|NCT00004160|Drug|cisplatin|
328293|NCT00584155|Drug|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
328294|NCT00584155|Drug|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
328295|NCT00584168|Drug|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
323134|NCT00308165|Procedure|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
323135|NCT00308165|Drug|Topotecan|chemotherapeutic drug for the treatment of brain tumors
323136|NCT00308178|Drug|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
327650|NCT00556413|Drug|oxaliplatin|
327651|NCT00556426|Device|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
327652|NCT00556439|Drug|Abatacept|Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:
Participants weighing less than 60kg will receive 500mg of abatacept.
Participants weighing 60 to 100kg will receive 750mg of abatacept.
Participants weighing more than 100kg will receive 1000mg of abatacept.
Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A participants will continue on abatacept.
327653|NCT00556439|Drug|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
327654|NCT00556452|Drug|Clofarabine/Busulfan x 4|Clofarabine IV (dose levels)
1st dose level: 20 mg/m2/day x 5 days
2nd dose level: 30 mg/m2/day x 5 days
3rd dose level: 40 mg/m2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days
327655|NCT00004022|Biological|aldesleukin|
327966|NCT00589615|Behavioral|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
327967|NCT00589628|Drug|infliximab|5mg/kg/dose IV at 4 week intervals
327968|NCT00589628|Drug|infliximab|10mg/kg/dose IV at 4 week intervals
327969|NCT00004180|Drug|rosiglitazone maleate|
327970|NCT00589641|Behavioral|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
327971|NCT00551421|Other|polymerase chain reaction|Correlative study
327972|NCT00551421|Other|laboratory biomarker analysis|Correlative study
327973|NCT00000579|Procedure|Pulmonary Artery Catheter|
327974|NCT00003992|Drug|doxorubicin hydrochloride|
327975|NCT00551434|Dietary Supplement|Creatine|Creatine 21 g daily
327976|NCT00551434|Dietary Supplement|L-arginine and creatine|L-arginine
327977|NCT00551434|Dietary Supplement|l-arginine|l-arginine 9 g daily
327978|NCT00551434|Dietary Supplement|placebo, double|placebo
327320|NCT00563368|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
327321|NCT00563368|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
327322|NCT00563368|Drug|topiramate|topiramate 46 mg, po once daily
327323|NCT00563368|Drug|topiramate|topiramate 92 mg, po once daily
327324|NCT00563368|Drug|phentermine|phentermine 7.5 mg, po once daily
327325|NCT00563368|Drug|phentermine|phentermine 15 mg, po once daily
327326|NCT00563368|Drug|VI-0521|placebo, po once daily
327327|NCT00004061|Biological|palifermin|
327328|NCT00563381|Drug|Tiotropium bromide|18 mcg/daily
327329|NCT00563381|Drug|Salmeterol|100 mcg/daily
327330|NCT00563381|Drug|Placebo Salmeterol|Placebo identical to Salmeterol device
327331|NCT00563381|Drug|Placebo Tiotropium|Placebo identical to Tiotropium device
327332|NCT00563394|Drug|ofloxacin|400 mg twice a day for 14 days
327333|NCT00563394|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
327334|NCT00563420|Procedure|Bronchoscopy|
327335|NCT00563433|Drug|ofloxacin|400 mg twice a day for 14 days
327336|NCT00563433|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
327337|NCT00563446|Drug|Darbepoetin alfa|
327338|NCT00004061|Drug|cyclophosphamide|
327339|NCT00563459|Drug|carisbamate|400-1200 mg/day for 12 months
327340|NCT00563459|Drug|topiramate|200-400mg/day for 12 months
327656|NCT00556452|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
327657|NCT00556452|Radiation|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
327658|NCT00556465|Drug|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
327013|NCT00571064|Drug|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
327014|NCT00571077|Device|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
327015|NCT00571090|Procedure|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
327016|NCT00571103|Drug|acamprosate|Two 333mg tablets taken three times daily.
327017|NCT00571116|Drug|Disulfiram|Given PO
327018|NCT00571116|Drug|Arsenic trioxide|Given IV
327019|NCT00573365|Device|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
327020|NCT00573365|Radiation|Radiation|Weekly radiation treatment
327021|NCT00573365|Radiation|Radiation|Weekly radiation treatment
327341|NCT00565916|Drug|Estrogen|HRT with estrogen involves wearing a topical patch of 0.3 mg estradiol. The patch is to be placed on the lower abdomen and worn for 3 days. All participants will also undergo various heart metabolism tests, including a positron-emission tomographic (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO).
327342|NCT00565916|Drug|Progesterone|Progesterone therapy involves taking a daily pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
327343|NCT00565916|Drug|Placebo Progesterone|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
327344|NCT00565929|Drug|Placebo|Sterile saline (0.9%).
327345|NCT00565929|Biological|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10^7 or 1X10^8 TCID 50.
327346|NCT00565942|Procedure|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
327347|NCT00565942|Procedure|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
326700|NCT00578344|Drug|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
326701|NCT00578344|Biological|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
326702|NCT00578344|Drug|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
326703|NCT00578357|Behavioral|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
326704|NCT00578370|Drug|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
326705|NCT00004128|Drug|etoposide|
326706|NCT00578370|Drug|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
326707|NCT00578370|Drug|0.1% betamethasone|Solution 200µl once a day (26 days)
326708|NCT00578370|Drug|0.005% calcipotriol|Solution 200µl once a day (26 days)
326709|NCT00578370|Drug|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
326710|NCT00578383|Device|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
326711|NCT00578396|Dietary Supplement|grapes|1 pound of seedless red grapes
326712|NCT00578396|Dietary Supplement|grapes|2/3 lb/day fresh red grapes
326713|NCT00578396|Dietary Supplement|grapes|1/3 lb/day fresh red grapes
326714|NCT00578422|Other|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
326715|NCT00578422|Procedure|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
327022|NCT00573378|Drug|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
326035|NCT00550953|Drug|telmisartan|
326036|NCT00550966|Behavioral|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
326037|NCT00003979|Drug|CHS 828|
326038|NCT00550992|Biological|anti-thymocyte globulin|
326039|NCT00550992|Drug|asparaginase|
326040|NCT00550992|Drug|busulfan|
326041|NCT00550992|Drug|cyclophosphamide|
326354|NCT00004154|Drug|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
326355|NCT00586274|Biological|T cell infusion|At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are > 1000/ul.
Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)
326356|NCT00586274|Biological|Campath 1h|10 mg iv over 4 hours day-8 through day-6
326357|NCT00586274|Biological|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
326358|NCT00586287|Other|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
326359|NCT00586287|Other|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
326360|NCT00586287|Drug|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
326361|NCT00586300|Other|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
325686|NCT00555646|Drug|PH-10 (rose bengal disodium 0.001%)|PH-10 with 544 nm LED light illumination
OR
PH-10 with ambient light exposure
325687|NCT00555646|Drug|Control|No treatment control.
325688|NCT00555672|Drug|5-fluorouracil|5- fluorouracil is given as 4000 mg/m^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
325689|NCT00555672|Drug|cisplatin|Cisplatin is given 80 mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
325690|NCT00555672|Drug|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
325691|NCT00555685|Drug|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
325692|NCT00555685|Drug|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
325693|NCT00555698|Device|Deep Brain Stimulation|The stimulation target is two small groups of nerve fibers deep in the brain called the anterior limb of the internal capsule. These fibers connect areas of the brain believed to be involved in causing the symptoms of depression.
325694|NCT00000585|Drug|penicillin|
325695|NCT00004011|Drug|paclitaxel|
325696|NCT00555711|Device|Modulated Imaging|Modulated Imaging
325697|NCT00555724|Drug|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
325698|NCT00555737|Device|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
325699|NCT00555750|Drug|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
325700|NCT00555750|Drug|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
325701|NCT00555763|Device|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
325702|NCT00555776|Drug|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
326042|NCT00550992|Drug|cyclosporine|
326043|NCT00550992|Drug|cytarabine|
326044|NCT00553176|Other|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
325071|NCT00570167|Procedure|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
325072|NCT00570167|Procedure|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
325073|NCT00570180|Drug|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
325363|NCT00004056|Drug|cytarabine|
325364|NCT00562536|Procedure|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
325365|NCT00562549|Drug|SLx-2101|
325366|NCT00562562|Other|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
325367|NCT00562575|Drug|SLx-4090|
325368|NCT00562575|Drug|Placebo|
325369|NCT00562588|Drug|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
325370|NCT00562588|Drug|ASA 100 mg qd|
325371|NCT00562614|Drug|SLx-2101|
325372|NCT00562627|Drug|ropivacaine|intraoperative and 1. postoperative day
325373|NCT00562627|Drug|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
325374|NCT00004056|Drug|daunorubicin hydrochloride|
325375|NCT00562627|Drug|ketorolac|intraoperative and 1. postoperative day
325376|NCT00562627|Drug|morphine|intraoperative
325377|NCT00562627|Drug|fentanyl|continuous postoperatively
325378|NCT00562627|Drug|bupivacaine|continuous postoperatively
325379|NCT00562640|Biological|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
324778|NCT00575016|Biological|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
324779|NCT00575016|Biological|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
324780|NCT00575016|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
324781|NCT00575029|Drug|megestrol acetate|600 mg by mouth daily
324782|NCT00575042|Drug|Fenofibrate (Insoluble Drug Delivery-Micro Particle Fenofibrate (IDD-P)|160 mg per day
324783|NCT00577590|Drug|Lovaza|Dosage of 4 g to be taken daily for 2 months
324784|NCT00577590|Drug|Metformin|Dosage of at least 1000 mg to be taken daily for 4 months
324785|NCT00577603|Procedure|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
324786|NCT00577603|Other|no intervention|
325074|NCT00570193|Drug|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
325075|NCT00570193|Drug|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
325076|NCT00570206|Behavioral|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
325077|NCT00570219|Drug|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
325078|NCT00570232|Drug|Erlotinib|150 mg per day by mouth for 12 months
325079|NCT00570245|Drug|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
325080|NCT00004091|Other|fluorescent antibody technique|
325081|NCT00570245|Drug|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
325082|NCT00570258|Drug|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
325083|NCT00570258|Drug|erlotinib|150 mg PO QD
324431|NCT00305760|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
324432|NCT00305773|Drug|vorinostat|Given orally once daily
324433|NCT00305773|Drug|vorinostat|Given orally three times daily
324434|NCT00305786|Drug|gemcitabine hydrochloride|
324435|NCT00305786|Drug|oxaliplatin|
324436|NCT00308763|Drug|Nicotine Patch|After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.
If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off.
324437|NCT00308763|Drug|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
324438|NCT00308776|Procedure|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
324439|NCT00308776|Procedure|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
324440|NCT00308789|Procedure|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
324441|NCT00308789|Procedure|CPAP|Continuous positive airway pressure
324442|NCT00308802|Procedure|Kidney transplantation|Participants in this study will have had a kidney transplant
324443|NCT00002835|Drug|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
324787|NCT00577616|Procedure|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
324788|NCT00577629|Drug|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
324789|NCT00004126|Drug|paclitaxel|
323720|NCT00276250|Drug|Human Islets|final dosage is according to participant's weight and yield from islet isolation. up to 3 transplants per participant.
323721|NCT00276250|Drug|abatacept|monthly, weight-dosed, intravenous abatacept infusions, given for as long as transplanted islets are functioning
323722|NCT00276263|Drug|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
323723|NCT00276276|Drug|topotecan|
323724|NCT00276289|Drug|Spironolactone|
324075|NCT00266032|Drug|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
324076|NCT00266032|Drug|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
324077|NCT00002711|Radiation|low-LET photon therapy|
324078|NCT00266058|Drug|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
324079|NCT00266071|Behavioral|Cutaneous response|
324080|NCT00266097|Drug|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
324081|NCT00266097|Drug|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
324082|NCT00266097|Drug|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
324083|NCT00266097|Radiation|radiation therapy|5040 cGy, every week, up to 6 weeks
324084|NCT00266097|Drug|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
324085|NCT00266097|Drug|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
324086|NCT00266110|Biological|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
356277|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
356278|NCT00625898|Drug|Docetaxel|75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B
100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B
356279|NCT00625898|Drug|Trastuzumab|First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B
First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B
356280|NCT00625898|Drug|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
356281|NCT00628264|Drug|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
356282|NCT00628264|Drug|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
356283|NCT00628277|Behavioral|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
356284|NCT00628277|Behavioral|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
356285|NCT00628290|Drug|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
356286|NCT00628290|Drug|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
356287|NCT00628303|Biological|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
356288|NCT00004604|Biological|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
356289|NCT00628303|Other|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
356290|NCT00628316|Dietary Supplement|caffeine|caffeine daily intake will be reduced form 150 ml per day
351477|NCT00594282|Device|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
351478|NCT00594308|Drug|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
351479|NCT00594308|Drug|Fludarabine|25mg/m2/day for 5 consecutive days
351480|NCT00594308|Drug|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
351481|NCT00594308|Drug|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
324873|NCT00588328|Device|PET/CT scan|PET/CT scans
324874|NCT00588341|Drug|Temozolomide|At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.
Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.
After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient.
325171|NCT00580034|Drug|Campath Purged Non-myeloablative ASCT|Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.
Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45.
325172|NCT00580034|Procedure|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
325173|NCT00580047|Drug|Zoledronic Acid|4mg IV Annually
325174|NCT00580047|Drug|calcium and Vitamin D|1200 mg Calcium 800 International Units Vitamin D
325175|NCT00580047|Drug|Alendronate|70mg weekly
325176|NCT00580060|Biological|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
325177|NCT00580073|Drug|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
325178|NCT00580073|Drug|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
325179|NCT00580086|Other|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
325180|NCT00000605|Drug|medroxyprogesterone|
325181|NCT00582712|Drug|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
325182|NCT00004151|Drug|acridine carboxamide|
325183|NCT00582725|Drug|R-CHOP+GM-CSF|addition of GM-CSF
324560|NCT00269776|Drug|OROS (methylphenidate HCl)|Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
324561|NCT00269776|Drug|Ritalin (methylphenidate)|Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
324562|NCT00269789|Drug|Ritalin|
324563|NCT00269789|Drug|OROS Methylphenidate HCl|
324564|NCT00002719|Procedure|peripheral blood stem cell transplantation|
324565|NCT00269789|Drug|Placebo|
324566|NCT00269802|Drug|OROS methylphenidate HCl|
324567|NCT00269802|Drug|Ritalin|
324568|NCT00269802|Drug|Placebo|
324569|NCT00269815|Drug|methylphenidate HCl|
324570|NCT00269828|Drug|paclitaxel|
324571|NCT00269828|Drug|paclitaxel poliglumex|
324572|NCT00269841|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
324573|NCT00269841|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
324875|NCT00588354|Drug|Clonidine|200 or 400 micrograms clonidine
324876|NCT00588354|Drug|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
324877|NCT00588354|Drug|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
324878|NCT00588367|Device|Mayo Interactive Breath Hold Monitor|Biofeedback device
324879|NCT00588380|Drug|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
324880|NCT00588393|Drug|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
324881|NCT00588406|Drug|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
324882|NCT00004175|Drug|docetaxel|
323838|NCT00289458|Behavioral|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
323839|NCT00289458|Behavioral|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
324194|NCT00000431|Drug|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
324195|NCT00002761|Drug|cyclosporine|
324196|NCT00279994|Procedure|Exercise therapy|
324197|NCT00279994|Device|Accelerometer (PAM; Personal Activity Monitor)|
324198|NCT00279994|Procedure|Oral Exercise Therapy advise|
324199|NCT00280007|Drug|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
324200|NCT00280020|Behavioral|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
324201|NCT00280020|Behavioral|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
324202|NCT00280020|Behavioral|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
324203|NCT00280033|Biological|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
324204|NCT00280033|Biological|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
324205|NCT00280033|Biological|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
324206|NCT00002761|Drug|cytarabine|
324207|NCT00280033|Drug|Placebo|Saline placebo.
324208|NCT00280046|Drug|biphasic insulin aspart|
324209|NCT00280059|Drug|Pregabalin|dose 150-600 mg/day given BID
324210|NCT00280059|Drug|Lamotrigine|dose 100-500 mg/day given BID
324211|NCT00280072|Device|Renal Assist Device|
323496|NCT00298909|Behavioral|physical exercise|physical exercise
323497|NCT00298909|Drug|niaspan (extended-release niacin)|niaspan (extended-release niacin)
323498|NCT00298909|Drug|niacin|niacin extended-release
323499|NCT00298909|Other|control|control
323500|NCT00298922|Drug|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
323501|NCT00298922|Drug|Placebo|tablet orally thrice weekly for 24 weeks
323502|NCT00298935|Procedure|Osteopathic manipulative treatment (OMT)|
323503|NCT00298961|Device|Videoconference equipment FALCON/IP|
323504|NCT00002809|Biological|filgrastim|
323505|NCT00298974|Drug|hydrocodone / acetaminophen extended release|2 tablets twice daily
323506|NCT00298974|Drug|Placebo|2 tablets twice daily
323507|NCT00298987|Drug|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
323508|NCT00299000|Drug|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
323840|NCT00289458|Behavioral|Control|no exercise
323841|NCT00289471|Other|No intervention delivered.|No intervention delivered.
323842|NCT00289484|Drug|Omega-3 Polyunsaturated Fatty Acids|
323843|NCT00002786|Biological|aldesleukin|
323844|NCT00289497|Device|TempTouch®|
323845|NCT00289510|Biological|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
323846|NCT00289510|Biological|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
323847|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
323848|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
323849|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
323137|NCT00308191|Drug|Formoterol Fumarate|
323138|NCT00308191|Drug|Tiotropium Bromide|
323139|NCT00308204|Drug|Raptiva (efalizumab)|
323140|NCT00308230|Procedure|Six minute walk test|
323141|NCT00308230|Behavioral|Minnesota Living with Heart Failure Questionnaire|
323142|NCT00308243|Drug|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
323143|NCT00308256|Behavioral|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
323144|NCT00002833|Procedure|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
323145|NCT00308269|Drug|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
323146|NCT00308269|Drug|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
323147|NCT00308282|Drug|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein)in weeks 0, 3 and 6. Treatment duration: 6 weeks.
323148|NCT00308282|Drug|Placebo|IV (in vein) in weeks 0,3 and 6. Treatment duration: 6 weeks.
323149|NCT00308295|Drug|Fish oil capsules|
323150|NCT00308295|Drug|matched placebo capsules|
323151|NCT00308308|Drug|Technosphere Insulin|Inhalation, 15U/30U
323152|NCT00308308|Drug|Active comparator|sc injectable insulin
323153|NCT00308321|Drug|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
323154|NCT00308321|Drug|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
323155|NCT00002835|Biological|Bleomycin Sulfate (BLM)|
323156|NCT00308334|Drug|Domperidone|10 mg po TID X 14 days
323157|NCT00308334|Drug|Placebo- Sugar pill|placebo po TID x 14 days
323158|NCT00308347|Drug|MK0954, losartan / Duration of Treatment: mean 3.4 years|
327979|NCT00551447|Drug|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
327980|NCT00551447|Drug|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
327981|NCT00551447|Drug|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
327982|NCT00551460|Drug|arsenic trioxide|
327983|NCT00551460|Drug|gemtuzumab ozogamicin|
327984|NCT00551460|Drug|mercaptopurine|
327985|NCT00003992|Drug|paclitaxel|
327986|NCT00551460|Drug|methotrexate|
327987|NCT00551460|Drug|tretinoin|
327988|NCT00551473|Drug|Lavoltidine|
327989|NCT00551486|Procedure|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
328296|NCT00584168|Drug|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
328297|NCT00584194|Biological|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|Part A: RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
328298|NCT00584207|Procedure|radiofrequency ablation|Intraoperative RFA of uterine fibroids
328299|NCT00584220|Device|senofilcon A toric|contact lens
328300|NCT00584220|Device|alphafilcon A toric|contact lens
328301|NCT00584233|Radiation|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
328302|NCT00587041|Dietary Supplement|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
328303|NCT00587041|Dietary Supplement|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
328304|NCT00587041|Other|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
327659|NCT00558896|Drug|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
327660|NCT00558909|Drug|BI 44847|
327661|NCT00558909|Drug|placebo for BI 44847|
327662|NCT00558922|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
327663|NCT00004032|Biological|ALVAC-hB7.1|Given IP
327664|NCT00558935|Dietary Supplement|Red Wine|20g alcohol daily/red wine for 4 weeks
327665|NCT00558961|Drug|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
327666|NCT00558987|Behavioral|Discipline Video|The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.
A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers.
327667|NCT00558987|Behavioral|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
327668|NCT00559000|Behavioral|KIDNET|Narrative Exposure Therapy for Children
327669|NCT00559013|Device|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
327670|NCT00559026|Biological|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
327671|NCT00559026|Other|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
327672|NCT00559039|Other|questionnaire administration|
327673|NCT00559039|Procedure|evaluation of cancer risk factors|
327674|NCT00004032|Biological|recombinant interferon gamma|Given IP
327675|NCT00559052|Drug|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
327676|NCT00559078|Other|Interview|Hour-long, qualitative, phone interview
327348|NCT00565955|Drug|montelukast|Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:
5-12 years: 5 mg chewable tablet of montelukast; > 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid.
327349|NCT00565955|Drug|Placebo|The patients will receive placebo tablets.
327350|NCT00565968|Drug|melphalan|
327351|NCT00004073|Drug|suramin|
327352|NCT00565968|Drug|sorafenib tosylate|
327353|NCT00565968|Genetic|gene expression analysis|
327354|NCT00565968|Genetic|protein expression analysis|
327355|NCT00565968|Genetic|western blotting|
327356|NCT00565968|Other|pharmacological study|
327357|NCT00565981|Drug|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
327358|NCT00565981|Drug|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
327677|NCT00559091|Drug|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
327678|NCT00559104|Drug|carmustine|Unique to the Carmustine in Conditioning arm
327679|NCT00559104|Drug|cyclophosphamide|Used in Both Arms
327680|NCT00559104|Drug|etoposide|Used in Both Arms
327681|NCT00559104|Procedure|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
327682|NCT00559104|Procedure|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
327683|NCT00561158|Behavioral|Eat Well Live Well Nutrition Program|12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.
The group sessions included are:
Rate Your Plate: determining high fat foods
Label Reading: reading food labels
Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income
Recipe Modification: preparing old recipes in new ways to reduce fat
Eating Out: order healthier fast foods
Coping with High Risk Situations: coping with situations in which these new habits may be threatened
Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:
Substituting fat-modified foods for high fat foods
Avoiding fat as a seasoning or flavoring
Avoiding fried foods
Modifying meat
Replacing high fat foods with fruits, vegetables, grains and breads
327023|NCT00573391|Drug|Velcade, Thalidomide, and Dexamethasone|Velcade - Into vein (IV) Days 1, 4, 8, 11
Yr 1: Every 28-35 days-12 cycles
Yr 2: Every 8-10 weeks- 6 cycles
Thalidomide - By Mouth Days 1-28
Yr 1: Every 28-35 days-12 cycles
Yr 2: Every 8-10 weeks- 6 cycles
327024|NCT00573391|Drug|Velcade, Melphalan, and Dexamethasone|Velcade - Into vein (IV) Days 1, 4, 8, 11
Yr 1: Every 28-35 days-12 cycles
Yr 2: Every 8-10 weeks- 6 cycles
327025|NCT00573404|Drug|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
327026|NCT00573404|Drug|sunitinib malate|Not specified
327027|NCT00573404|Other|pharmacological study|Not specified
327028|NCT00573417|Drug|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
327029|NCT00004103|Drug|cisplatin|
327030|NCT00573417|Drug|Placebo|
327031|NCT00573430|Drug|Candesartan Cilexetil|8 mg oral once daily dose
327032|NCT00573430|Drug|Candesartan Cilexetil|16 mg oral once daily dose
327033|NCT00573430|Drug|Candesartan Cilexetil 32mg|32 mg oral once daily dose
327034|NCT00573443|Drug|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
327035|NCT00573443|Drug|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
327036|NCT00573443|Drug|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
327037|NCT00573456|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
327038|NCT00573469|Drug|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
327039|NCT00573469|Drug|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
327040|NCT00004103|Drug|floxuridine|
327041|NCT00573469|Drug|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
326362|NCT00586300|Behavioral|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
326363|NCT00004169|Drug|etoposide|
326364|NCT00586300|Other|Physical training and self-management training programs|This "multidimensional" intervention will combine both the physical training and self-management training programs described for Groups 1 and 2.
326365|NCT00586313|Device|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
326366|NCT00586313|Device|Tru-cut biopsy|Try-cut biopsy may prove to be a safe alternative to percutaneous and transjugular liver biopsy methods in obtaining liver biopsy samples
326367|NCT00586326|Device|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
326716|NCT00004128|Procedure|autologous bone marrow transplantation|
326717|NCT00578422|Drug|Atorvastatin|Blindly randomized to Control Group-Low dose Atorvastatin (10 mg daily)or Treatment Group- Atorvastatin (80 mg daily)
326718|NCT00580541|Behavioral|variety|variety and nonvariety
326719|NCT00580580|Drug|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
326720|NCT00580580|Drug|Definity|intravenous injection at 0.05-0.20 mL
326721|NCT00580580|Drug|PESDA|intravenous injections dosage 0.05-0.20 mL
326722|NCT00580593|Device|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
326723|NCT00580593|Other|sham-NIPPV|a sham-device
326724|NCT00580606|Drug|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
326725|NCT00580606|Drug|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
326726|NCT00580619|Other|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
326045|NCT00553189|Drug|ABT-888|
326046|NCT00553189|Drug|Topotecan|
326047|NCT00553202|Biological|anti-thymocyte globulin|Given IV
326048|NCT00553202|Drug|busulfan|Given IV
326049|NCT00553202|Drug|cyclophosphamide|Given IV
326050|NCT00553202|Drug|cyclosporine|Given IV or orally
326051|NCT00553202|Drug|methotrexate|Given IV
326052|NCT00004001|Drug|prednisone|
326053|NCT00553202|Drug|methylprednisolone|Given IV
326054|NCT00553202|Drug|tacrolimus|Given IV
326055|NCT00553202|Other|laboratory biomarker analysis|Correlative studies
326056|NCT00553202|Other|pharmacological study|Correlative studies
326057|NCT00553202|Procedure|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
326058|NCT00553202|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
326059|NCT00553215|Procedure|quality-of-life assessment|
326060|NCT00553215|Procedure|questionnaire administration|
326061|NCT00553228|Biological|Tdap|0.5 mL IM once at visit #2
326062|NCT00553228|Biological|Td|0.5 mL IM once at visit #2
326063|NCT00004002|Drug|bortezomib|
326064|NCT00553254|Drug|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
326065|NCT00553267|Drug|fixed dose combination of telmisartan+amlodipine|
326066|NCT00553267|Drug|amlodipine|
326067|NCT00553280|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
326368|NCT00586339|Biological|Cervarix TM|Intramuscular injection, 3 doses
325380|NCT00562640|Biological|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
325381|NCT00562640|Drug|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
325382|NCT00565045|Device|Neuromuscular electrical stimulator|Intervention Characteristics Common to Both Groups
• 6-week intervention
Home "exercise", daily
Exercise (at home) 2 sessions/day
A "session" consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest
A "set" entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions
Lab "therapy", 2x/week
Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible).
325703|NCT00558103|Drug|lapatinib|Oral administration
325704|NCT00558103|Drug|Pazopanib|Oral administration
325705|NCT00558116|Device|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
325706|NCT00558129|Device|X-STOP®|Surgical implantation of X-STOP IPD device
325707|NCT00558129|Procedure|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
325708|NCT00558142|Drug|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
325709|NCT00004031|Biological|rituximab|375 mg/m2 IV every 21 days
325710|NCT00558142|Drug|Visipaque 320|100mls IV dose as single dose
325711|NCT00558142|Drug|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
325712|NCT00558155|Drug|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
325713|NCT00558155|Drug|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
325714|NCT00558155|Drug|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
325084|NCT00570258|Drug|Fulvestrant|250 mg IM Q 4 weeks
325085|NCT00570258|Drug|Placebo|Placebo 150 mg PO QD
325086|NCT00570271|Other|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
325087|NCT00570271|Other|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
325088|NCT00570271|Other|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
325089|NCT00570271|Other|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
325090|NCT00570271|Other|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
325091|NCT00000599|Behavioral|diet, fat-restricted|
325092|NCT00004091|Procedure|colposcopic biopsy|
325093|NCT00572494|Device|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
325383|NCT00565058|Biological|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
325384|NCT00565071|Device|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
325385|NCT00565084|Drug|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
325386|NCT00000596|Drug|dapsone|
325387|NCT00004067|Drug|taxol|175 mg/m2 IV every 21 days for 4 cycles
325388|NCT00565084|Drug|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
325389|NCT00565097|Drug|Placebo|
325390|NCT00565097|Drug|Lanreotide|
324790|NCT00577629|Drug|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
324791|NCT00577629|Drug|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
324792|NCT00577629|Drug|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
324793|NCT00577629|Drug|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
324794|NCT00577629|Drug|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
324795|NCT00577642|Drug|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
324796|NCT00577655|Drug|Albuterol|Albuterol HFA MDI 180 mcg
324797|NCT00577655|Drug|Placebo|Placebo HFA MDI
324798|NCT00577668|Drug|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
324799|NCT00577681|Drug|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
324800|NCT00004127|Drug|FOLFOX regimen|
324801|NCT00577694|Drug|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
324802|NCT00577694|Drug|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
324803|NCT00577707|Drug|pemetrexed, cisplatin and erlotinib before surgery then erlotinib is given to patients after surgery for 2 years|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days on this study and then a CT scan will be performed. After the CT scan you will start treatment with intravenous pemetrexed and cisplatin (pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment. The duration of each cycle is 21 days. You will receive treatment for 4 cycles. You will be asked to stop taking the erlotinib at least 2 days before surgery. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
324804|NCT00579826|Drug|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
324805|NCT00579826|Drug|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
324806|NCT00004137|Drug|carboplatin|
324087|NCT00266110|Biological|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
324088|NCT00002714|Biological|bleomycin sulfate|
324089|NCT00266110|Biological|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
324090|NCT00266110|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
324444|NCT00308815|Device|Automatic CPR machine|
324445|NCT00308841|Drug|Lidocaine (drug)|
324446|NCT00308854|Procedure|Photodynamic Therapy|
324447|NCT00308867|Procedure|Photodynamic Therapy|
324448|NCT00308867|Procedure|Cryosurgery|
324449|NCT00308880|Drug|Transamin|
324450|NCT00308893|Genetic|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
324451|NCT00308906|Drug|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
324452|NCT00308919|Drug|WST09|Treatment with WST09 Vascular Photodynamic therapy
324453|NCT00308932|Drug|HFA FP MDI|
324454|NCT00002835|Drug|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
324455|NCT00308945|Drug|travoprost 0.004% (drug)|local drop application
324456|NCT00308945|Drug|latanoprost 0.005% (drug)|local drop application
324457|NCT00308958|Device|High frequency chest wall oscillator|
324458|NCT00311467|Drug|Capecitabine, Interferon, Interleukin|Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.
Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.
Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.
Group B
Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.
Efficacy evaluations will be performed every 14 weeks of treatment in both groups
351482|NCT00594308|Drug|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
351483|NCT00594321|Device|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
351484|NCT00594321|Device|standard vertebroplasty|standard vertebroplasty
351485|NCT00004197|Biological|tumor cell-based vaccine therapy|
351486|NCT00594334|Drug|Risedronate|Weekly Risedronate
351487|NCT00594347|Biological|Pneumo 23|Vaccine (Pneumo 23)
351488|NCT00594347|Biological|Prevnar|Vaccine (Prevnar)
351489|NCT00594360|Behavioral|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
351490|NCT00594373|Drug|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
351491|NCT00594373|Drug|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
351492|NCT00594386|Drug|Rotigotine|Rotigotine transdermal patches:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)
Optimal dosing:
During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.
After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.
351493|NCT00594399|Behavioral|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
351494|NCT00594412|Procedure|Diagnostic Radiology: 1H-MRS of the liver|
351495|NCT00594425|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
351496|NCT00004197|Drug|cyclophosphamide|
351497|NCT00597207|Device|AutoPulse|Mechanical device that provides chest compression
351498|NCT00597207|Other|Manual|Manual chest compression
351818|NCT00000631|Biological|gp160 Vaccine (MicroGeneSys)|
351819|NCT00004639|Procedure|Furlow double z-plasty palatoplasty palate repair|
351820|NCT00628901|Device|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
325184|NCT00582738|Drug|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
325185|NCT00582738|Drug|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
325186|NCT00582764|Other|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
325187|NCT00582777|Behavioral|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
325490|NCT00575393|Other|fluorine F 18 fluorothymidine|
325491|NCT00575393|Other|mass spectrometry|
325492|NCT00575393|Other|pharmacological study|
325493|NCT00575406|Drug|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
325494|NCT00575406|Drug|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
325495|NCT00575406|Drug|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
325496|NCT00575406|Drug|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
325497|NCT00575406|Drug|Vincristin|i.v., 2mg, d1 of each treatment cycle
325498|NCT00575406|Drug|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
325499|NCT00004112|Drug|cyclophosphamide|
325500|NCT00575419|Drug|N-acetylcysteine|Dose Level 1: 150 mg/kg/day
Dose Level 2: 300 mg/kg/day
Dose Level 3: 600 mg/kg/day
Dose Level 4: 900 mg/kg/day
Dose Level 5: 1200 mg/kg/day
325501|NCT00575432|Radiation|diffusion MRI|diffusion MRI
325502|NCT00575432|Radiation|BOLD MRI|BOLD MRI
325503|NCT00575432|Other|Clinical Outcome|Clinical outcome
325504|NCT00575471|Drug|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
325505|NCT00575471|Drug|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
324883|NCT00588406|Drug|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
324884|NCT00588406|Drug|Ipratropium bromide|2.5 mg, one dose
324885|NCT00588406|Drug|Prednisone|60mg PO
324886|NCT00590967|Radiation|IMRT extended field external beam radiation therapy|
324887|NCT00590967|Radiation|Brachytherapy|
324888|NCT00590967|Drug|Cisplatin|
324889|NCT00004187|Drug|capecitabine|
324890|NCT00590993|Other|MRI and MRSI|Compare treatment impact when using MRI and MRSI
324891|NCT00591006|Drug|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
324892|NCT00591006|Drug|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
324893|NCT00591006|Drug|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
324894|NCT00591019|Drug|Modafinil|200 mg/day, morning dose
324895|NCT00591019|Other|Placebo|Sugar pill once per day in the morning.
324896|NCT00591045|Drug|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
325188|NCT00582777|Behavioral|HS DOSING|Take your usual BP meds at bed time
325189|NCT00582777|Drug|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
325190|NCT00582790|Drug|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
325191|NCT00582790|Drug|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
325192|NCT00582816|Device|Clinimacs Cell Separation System|Depletion of T-cells
324212|NCT00280085|Procedure|MR imaging|
324213|NCT00280085|Procedure|Glucose clamp|
324214|NCT00280085|Drug|Arginine|
324215|NCT00280098|Drug|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
324574|NCT00269841|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
324575|NCT00002720|Drug|tamoxifen citrate|
324576|NCT00269854|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
324577|NCT00269854|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
324578|NCT00269854|Drug|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
324579|NCT00269854|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
324580|NCT00269867|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
324581|NCT00269867|Drug|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
324582|NCT00002740|Drug|etoposide|
324583|NCT00273338|Drug|calcitriol|
324584|NCT00273338|Drug|docetaxel|
324585|NCT00273351|Drug|[123I]B-CIT|Subjects will receive up to 6 mCi of [123I] B-CIT injected intravenously
324586|NCT00273364|Procedure|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
324587|NCT00273364|Drug|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), mitoxantrone, Tysabri (natalizumab), or GILENYATM (fingolimod)
324588|NCT00273377|Other|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
324589|NCT00273377|Other|Supplemental oxygen (80% vs. 30%)|
324590|NCT00273377|Drug|Dexamethasone|4 mg
324591|NCT00273377|Drug|Placebo|placebo
323850|NCT00289549|Drug|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
323851|NCT00289562|Drug|forodesine hydrochloride (BCX-1777)|
323852|NCT00289575|Device|MBCP|
323853|NCT00292331|Procedure|cyanoacrylate injection to treat gastric variceal hemorrhage|
323854|NCT00292344|Drug|Rifaximin and loperamide|
323855|NCT00292357|Procedure|Application of autologous bone marrow|
323856|NCT00002794|Drug|carboplatin|
323857|NCT00292370|Drug|Open Label (OL) Paroxetine|Open-label Paroxetine
323858|NCT00292370|Drug|Placebo|Double-blind placebo taken with OL paroxetine
323859|NCT00292370|Drug|Quetiapine|Double-blind quetiapine taken with OL paroxetine
323860|NCT00292383|Procedure|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
323861|NCT00292396|Drug|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
323862|NCT00292396|Drug|placebo|12 doses
323863|NCT00292409|Drug|Aripiprazole|
323864|NCT00292422|Drug|BG9924|
323865|NCT00292435|Drug|Read vine leaf extract (AS 195)|
324216|NCT00282503|Drug|Methoxsalen+ECP, Methylprednisolone|Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:
Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),
Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be > 4 days between the ECP treatments within a week.)
Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:
Daily Dose (mg/kg)
1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10
324217|NCT00282503|Procedure|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
324218|NCT00002771|Drug|idarubicin|
324219|NCT00282516|Procedure|In-home telemonitoring of pediatric patients with persistent asthma|
324220|NCT00282529|Device|High Risk Lymphedema Education and Device Intervention|
323509|NCT00299013|Drug|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
323510|NCT00299013|Drug|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
323511|NCT00299026|Device|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
323512|NCT00299039|Drug|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
323513|NCT00299039|Drug|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
323514|NCT00302042|Behavioral|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
323515|NCT00302055|Behavioral|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
323516|NCT00302055|Behavioral|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
323517|NCT00302068|Behavioral|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
323518|NCT00302068|Drug|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
323519|NCT00302068|Drug|Placebo Pill.|Placebo pill, daily, for 16 weeks.
323520|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
323521|NCT00002816|Drug|thioguanine|
323522|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
323523|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
323524|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
323525|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
323526|NCT00302107|Drug|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
323527|NCT00302107|Drug|Placebo|Look-a-like placebo tablets under double-blind conditions
323528|NCT00302120|Procedure|Contrast-enhanced MR mammography|
328305|NCT00587054|Drug|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.
Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines.
328306|NCT00004172|Drug|ifosfamide|
328307|NCT00587054|Drug|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.
Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines.
328308|NCT00587067|Drug|FLOXURIDINE|[0.16* mg/kg/day X 30 ml] / pump flow rate
* If the patient is >25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles.
323159|NCT00311051|Drug|montelukast|
323160|NCT00311064|Behavioral|physical activity|
323161|NCT00311077|Drug|Insulin Glulisine|
323162|NCT00311090|Drug|Idrabiotaparinux sodium|0.5 mL pre-filled syringe for 3.0 mg
Subcutaneous injection
323163|NCT00311090|Drug|Idraparinux sodium|0.5 mL pre-filled syringe for 2.5 mg
Subcutaneous injection
323164|NCT00311090|Drug|Avidin|100 mg in 10 mg/mL solution
Intravenous infusion for 30 minutes
323165|NCT00311090|Drug|Placebo (for Avidin)|Avidin matching powder in 10 mg/mL solution
Intravenous infusion for 30 minutes
323166|NCT00311103|Procedure|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
323167|NCT00311116|Drug|Vitamin E|
327990|NCT00551499|Device|CRT in combination with Atrial Overdrive Pacing|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
327991|NCT00551512|Drug|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
327992|NCT00551525|Radiation|3-dimensional conformal radiation therapy (3D-CRT)|
327993|NCT00551525|Radiation|intensity-modulated radiation therapy (IMRT)|
327994|NCT00551525|Radiation|samarium Sm 153 lexidronam pentasodium|
327995|NCT00551538|Drug|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
327996|NCT00003992|Drug|tamoxifen citrate|
327997|NCT00551538|Drug|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
327998|NCT00553969|Drug|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
327999|NCT00553969|Drug|placebo and placebo|capsule once daily for 9 months; dosage unknown
328000|NCT00553982|Procedure|Patellar component|Resurfacing with onlay technique
328001|NCT00553982|Procedure|No patellar component|Trimming of osteophytes when appropriate
328002|NCT00553995|Drug|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
328003|NCT00553995|Drug|Placebo|
328004|NCT00554008|Procedure|laparoscopic appendectomy|appendix removal via scope
328005|NCT00554008|Procedure|open appendectomy|open operation for removal of appendix
328006|NCT00004006|Drug|carboplatin|
328007|NCT00554034|Drug|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
328008|NCT00554047|Other|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
327684|NCT00561171|Drug|SPP635|oral once daily
327685|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
327686|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
327687|NCT00561197|Drug|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
327688|NCT00561210|Dietary Supplement|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
327689|NCT00561210|Dietary Supplement|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
327690|NCT00004048|Radiation|yttrium Y 90 monoclonal antibody MN-14|
327691|NCT00561223|Drug|iloprost Inhalation|inhale 2.5 mg, repeat times one
327692|NCT00561223|Drug|iloprost|inhaled 2.5 mg, repeat times one
327693|NCT00561249|Procedure|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
327694|NCT00561262|Other|questionnaire administration|
328010|NCT00554086|Drug|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
328011|NCT00554099|Drug|Mesalamine|6 - 400 mg tablets once daily
328012|NCT00554099|Drug|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
328013|NCT00554099|Drug|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
328014|NCT00554099|Other|Dietary Advice|Dietary advice
328015|NCT00554099|Drug|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
328016|NCT00554112|Behavioral|Exercise|Exercise
328017|NCT00004006|Drug|cyclophosphamide|
328018|NCT00554125|Drug|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
327359|NCT00565994|Procedure|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
327360|NCT00566007|Procedure|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
327361|NCT00566007|Drug|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
327362|NCT00004073|Radiation|radiation therapy|
327363|NCT00004086|Radiation|yttrium Y 90 epratuzumab|
327364|NCT00568321|Drug|RN624|50 mcg/kg
327365|NCT00568321|Drug|RN624|200 mcg/kg
327366|NCT00568321|Drug|Placebo|placebo
327367|NCT00568334|Biological|Varilrix (inactivated varicella vaccine)|
327368|NCT00568347|Drug|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
327369|NCT00568347|Drug|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
327370|NCT00568347|Drug|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
327371|NCT00568347|Drug|Salmeterol|salmeterol 50mcg bid X 3months
327372|NCT00568347|Drug|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
327373|NCT00568360|Device|Oximeter|
327374|NCT00004087|Biological|filgrastim|as prescribed by physician
327375|NCT00568373|Device|Enterra Gastric Pacemaker|Gastric Pacemaker
327376|NCT00568386|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
327377|NCT00568386|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
327378|NCT00568399|Drug|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
327379|NCT00568412|Device|Zarzenda|Topical cream, applied twice daily for three weeks
327380|NCT00568412|Drug|Elidel|1% cream, applied topically twice daily for three weeks
326727|NCT00580619|Other|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
326728|NCT00004141|Drug|dacarbazine|
326729|NCT00580619|Drug|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
326730|NCT00580619|Drug|methyldopa|Aldomet oral twice a day for 12 weeks
326731|NCT00580645|Drug|varenicline|Studies 1A and 1B: 2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered twice daily during laboratory session (day 8) and for 4 weeks after laboratory session.
Study 1C: 2mg/day (see above) or 1mg/day with 1-week medication lead-in period. The starting dose is 0.5 mg/day for days 1-5, followed by 0.5mg twice daily for days 6-7. 0.5mg twice daily administered during laboratory session (day 8) and for 4 weeks after laboratory session.
326732|NCT00580645|Drug|bupropion|Study 1A only: 300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8) and for 4 weeks after laboratory session.
326733|NCT00580645|Drug|placebo|placebo
326734|NCT00580658|Device|Medtronic Activa Gpi|Activa Therapy, Gpi
326735|NCT00580671|Behavioral|MET/CBT|Weekly Individual Counseling Sessions
327042|NCT00575991|Dietary Supplement|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
327043|NCT00576004|Procedure|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
327044|NCT00576017|Drug|Fentanyl-TTS|
327045|NCT00576030|Other|hab cof with water|habitual coffee drinker provided with water
327046|NCT00576030|Other|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
327047|NCT00576030|Other|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
327048|NCT00004114|Drug|cytarabine|
327049|NCT00576030|Other|non-hab cof with water|non-habitual coffee drinkers given water
327050|NCT00576030|Other|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
327051|NCT00576030|Other|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
326369|NCT00586339|Biological|Placebo Control|Intramuscular injection, 3 doses
326370|NCT00586352|Other|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
326371|NCT00586365|Drug|Naproxen|500 mg Naproxen twice a day for two weeks
326372|NCT00588978|Behavioral|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
326373|NCT00588991|Drug|Carboplatin|Given IV
326374|NCT00588991|Other|Laboratory Biomarker Analysis|Correlative study
326375|NCT00588991|Drug|Topotecan Hydrochloride|Given IV
326376|NCT00588991|Drug|Veliparib|Given orally
326377|NCT00004177|Biological|filgrastim|as prescribed by physician
326378|NCT00589017|Drug|tamoxifen citrate|
326379|NCT00589017|Other|immunohistochemistry staining method|
326380|NCT00589017|Other|laboratory biomarker analysis|
326381|NCT00589030|Radiation|brachytherapy|The target dose of TheraSphere® is 80-150Gy
326382|NCT00589030|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
326383|NCT00589056|Drug|cisplatin|
326384|NCT00589056|Drug|etoposide|
326385|NCT00589056|Drug|nelfinavir mesylate|
326386|NCT00589056|Genetic|protein expression analysis|
326387|NCT00589056|Other|immunohistochemistry staining method|
326388|NCT00004177|Procedure|peripheral blood stem cell transplantation|1-2 weeks from treatment
326389|NCT00589056|Other|laboratory biomarker analysis|
326390|NCT00589056|Procedure|biopsy|
326391|NCT00589056|Radiation|radiation therapy|
326392|NCT00589082|Drug|DaunoXome|
325715|NCT00558155|Drug|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
325716|NCT00558181|Drug|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
325717|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
325718|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
325719|NCT00558207|Drug|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
325720|NCT00004031|Drug|CHOP regimen|
325721|NCT00558207|Drug|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
325722|NCT00558220|Procedure|immunotherapy|Given together with induction chemotherapy:
Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses
326068|NCT00553293|Drug|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
326069|NCT00553293|Drug|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
326070|NCT00553306|Biological|therapeutic autologous lymphocytes|Given IV
326071|NCT00553306|Biological|aldesleukin|Given subcutaneously
326072|NCT00553306|Drug|cyclophosphamide|Given IV
326073|NCT00553306|Procedure|biopsy|Optional correlative studies
326074|NCT00004003|Drug|cisplatin|
326075|NCT00553306|Other|immunohistochemistry staining method|Optional correlative studies
326076|NCT00555776|Drug|placebo|placebo is given with the same definition as Gabapentin
326077|NCT00555789|Drug|AEB071|200mg oral b.i.d.
326078|NCT00555789|Drug|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
326079|NCT00004011|Procedure|conventional surgery|
326080|NCT00555802|Other|exercise|exercise
325391|NCT00565110|Behavioral|Alleviating Depression Among Patients with Cancer|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultantation who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
325392|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
325393|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
325394|NCT00565136|Device|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
325395|NCT00565149|Behavioral|PROOF|dietary overfeeding with high, low or normal protein content
325396|NCT00565162|Drug|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
325397|NCT00565175|Drug|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
325398|NCT00004068|Drug|irinotecan hydrochloride|
325399|NCT00565175|Drug|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
325400|NCT00565188|Drug|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
325401|NCT00565201|Drug|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
325723|NCT00558220|Procedure|Induction treatment part 1|cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.
3 cycles consisting of combination treatment of above mentioned drugs are given.
325724|NCT00004042|Biological|monoclonal antibody F19|
325725|NCT00560417|Drug|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
325726|NCT00560417|Drug|Insulin Glargine|Administered subcutaneously once a day at bedtime
325727|NCT00560430|Drug|telmisartan|80 mg per day, orally, weeks 1-14
325728|NCT00560430|Drug|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
325094|NCT00572494|Device|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
325095|NCT00572507|Device|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
325096|NCT00572520|Behavioral|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
325097|NCT00004099|Drug|fluorouracil|
325098|NCT00572520|Behavioral|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
325099|NCT00572520|Behavioral|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
325100|NCT00572533|Other|ESA Dose Adjustment per standard Anemia Management Protocol|Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
325101|NCT00572533|Other|ESA Dose Adjustment per "Smart Anemia Manager" Algorithm|Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by "Smart Anemia Manager" algorithm
325102|NCT00572559|Drug|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
325103|NCT00572559|Drug|Linezolid|600 mg every 12 hours (intravenously [IV] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
325104|NCT00572572|Drug|Aprepitant|Aprepitant 125mg PO day 3 then 80mg on days 4 through 7
Subjects will be stratified prior to randomization based on previous administration of chemotherapy.
Subjects will randomize to aprepitant versus placebo with their first study cycle of chemotherapy and then cross over to opposite arm with the second study cycle.
Arm A, Study Cycle 1
Arm B, Study Cycle 2
325105|NCT00572572|Drug|Placebo|Matched placebo PO daily on days 3 through 7
Subjects will be stratified prior to randomization based on previous administration of chemotherapy.
Subjects will randomize to aprepitant versus placebo with their first study cycle of chemotherapy and then cross over to opposite arm with the second study cycle.
Arm A, Study Cycle 2
Arm B, Study Cycle 1
325106|NCT00572585|Drug|AEB071|
325107|NCT00572585|Drug|Placebo|
325108|NCT00004099|Drug|leucovorin calcium|
325109|NCT00572598|Drug|4- [F-18] fluoropaclitaxel|4- [F-18] fluoropaclitaxel, <84 micrograms, <10 mCi, IV followed by PET/CT imaging
324459|NCT00311480|Biological|Influenza vaccine surface antigen adjuvanted with MF59|
324460|NCT00311493|Biological|Tick-Borne Encephalitis vaccine|
324461|NCT00311519|Drug|Hylenex|
324462|NCT00311545|Biological|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
324463|NCT00311558|Biological|recombinant interferon alfa-2b|SSG x 5 week
324464|NCT00311558|Drug|sodium stibogluconate|SSG & IFN
324465|NCT00311558|Drug|SSG & interferon|1 arm study with SSG & interferon
324466|NCT00311571|Drug|Ethidronate|
324467|NCT00311571|Behavioral|Physical training|
324468|NCT00002842|Drug|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
324807|NCT00579839|Procedure|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
324808|NCT00579839|Procedure|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
324809|NCT00579852|Procedure|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
324810|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
324811|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
324812|NCT00579878|Drug|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
324813|NCT00579878|Drug|Methotrexate-Sulfasalazine-Hydroxychloroquine|Methotrexate:
dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.
Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
351821|NCT00628914|Drug|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
351822|NCT00628914|Drug|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
351823|NCT00628914|Drug|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
351824|NCT00628940|Radiation|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
351825|NCT00628953|Drug|Esomeprazole|40mg twice a day
351826|NCT00628953|Drug|Placebo|40mg twice a day
351827|NCT00628979|Behavioral|CBT|cognitive- behavioral treatment for panic disorder.
351828|NCT00628992|Other|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
351829|NCT00628992|Other|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
351830|NCT00004639|Procedure|Von Langenbeck palatoplasty palate repair|
351831|NCT00628992|Other|Cycloergometer training|Muscular rehabilitation of the leg
351832|NCT00628992|Other|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
351833|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
351834|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
351835|NCT00629018|Biological|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
351836|NCT00629018|Drug|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
351837|NCT00629018|Biological|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
325506|NCT00575471|Drug|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
325507|NCT00577863|Drug|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
325508|NCT00577876|Procedure|Trimix Injection with Doppler Ultrasound|In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.
Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
325509|NCT00577889|Drug|gemcitabine hydrochloride|750 mg/m2 Given IV
325510|NCT00577889|Drug|tanespimycin|154 mg/m2 Given IV
325511|NCT00577902|Other|Observation|Head and neck cancer patients receiving chemoradiation
325851|NCT00572845|Other|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
325852|NCT00004100|Drug|gemcitabine hydrochloride|
325853|NCT00572858|Procedure|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
325854|NCT00572858|Genetic|Blood test|Blood test for genetic testing
325855|NCT00572858|Procedure|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
325856|NCT00572858|Procedure|Saliva test|Saliva test for cotisol levels
325857|NCT00572871|Other|plyometric exercise|single bout of plyometric with and without caloric supplement
325858|NCT00572871|Other|resistance exercise|single bout of resistance exercise with and without caloric supplement
325859|NCT00572884|Other|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
325860|NCT00572897|Drug|Fludarabine, Melphalan +/- ATG|Conditioning regimen for Allogenic Stem Cell Transplant:
Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)
Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 [given over 6 hours], and 2 mg/kg on days -2 and -1 [given over 4 hours])
325861|NCT00572910|Biological|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
325193|NCT00000607|Device|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
325194|NCT00004152|Drug|iodinated contrast dye|
325195|NCT00582816|Drug|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
325196|NCT00582816|Other|DLI|NK Cell selected DLI
325197|NCT00582829|Other|Generic Print Intervention|Generic Print Intervention: The generic print intervention will consist of the pamphlet, "Colorectal Cancer Screening Saves Lives" published by the Center for Disease Control that will be mailed to the participant.
325198|NCT00582829|Other|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
325199|NCT00582829|Other|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
325200|NCT00585611|Drug|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
325201|NCT00585611|Other|placebo|placebo
325202|NCT00585624|Dietary Supplement|Impact Advanced Recovery|Nutritional supplement
325203|NCT00585624|Dietary Supplement|No supplement|No supplement
325204|NCT00585637|Drug|Vitamin D|Taken orally every day for three months
325205|NCT00585637|Dietary Supplement|Placebo|Placebo pill taken once daily for 3 month
325206|NCT00585650|Biological|Entercept|Subcutaneous injections 50 mg Entercept or placebo will occur twice weekly over the first 12-week treatment period. At the end of the first 12 weeks, all subjects will be treated with etanercept 50 mg twice a week for an additional 12 weeks.
325207|NCT00004165|Biological|filgrastim|
325512|NCT00000604|Procedure|heart arrest, induced|
325513|NCT00004127|Drug|oxaliplatin|
325514|NCT00577915|Other|Radiology/MRI scan|MRI spectroscopy
325515|NCT00577954|Procedure|Multimodal MRI|Multimodal MRI
325516|NCT00577967|Drug|Gabapentin|
324592|NCT00273390|Drug|Remicade (infliximab)|
324593|NCT00002740|Drug|mesna|
324594|NCT00273403|Behavioral|Maintenance in Care Services|
324595|NCT00273403|Behavioral|Access to Care Services|
324596|NCT00273416|Drug|PF-00592379|
324597|NCT00273416|Drug|Sildenafil 100mg|
324897|NCT00591058|Drug|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
324898|NCT00591071|Other|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
324899|NCT00591071|Other|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
324900|NCT00004187|Drug|oxaliplatin|
324901|NCT00591084|Drug|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
324902|NCT00591084|Drug|placebo|infusion placebo (group B)once a day and continued for 14 days
324903|NCT00591084|Drug|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
324904|NCT00591110|Behavioral|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
324905|NCT00591110|Behavioral|Social-contact control|Participants receive an engaging informational session on a non-health related topic
324906|NCT00591123|Drug|FOLFOX and Erlotinib|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions, after which 5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home. All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
324907|NCT00591136|Drug|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
324908|NCT00003997|Drug|irofulven|
324909|NCT00552708|Drug|Lisinopril|
324910|NCT00552721|Other|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
324221|NCT00282542|Procedure|Hepatocyte Infusion|
324222|NCT00282555|Drug|S-Tenatoprazole-Na (STU-Na)|
324223|NCT00282568|Drug|Tacrolimus Modified Release (MR)|Oral
324224|NCT00282568|Drug|tacrolimus|Oral
324225|NCT00282581|Biological|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
324226|NCT00282594|Drug|Novolin R (human recombinant Insulin)|
324227|NCT00282607|Drug|DA-8159|
324228|NCT00282620|Drug|Magnesium L-lactate|
324229|NCT00000435|Drug|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
324230|NCT00002771|Procedure|allogeneic bone marrow transplantation|
324231|NCT00282633|Device|Dermabond|
324232|NCT00282646|Procedure|intraarterial stem cell therapy|catheter delivery of stem cells
324233|NCT00282646|Other|Stem cells|intraarterial application of bone marrow mononuclear cells versus placebo
324234|NCT00282659|Drug|magnesium L-lactate|
324235|NCT00282672|Device|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
324236|NCT00282672|Device|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
324237|NCT00282685|Procedure|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
324238|NCT00282698|Drug|Insulin infusion with a goal|
324598|NCT00273429|Drug|timolol maleate 0.5%|
324599|NCT00273429|Drug|dorzolamide/timolol maleate fixed combination|
324600|NCT00273429|Drug|latanoprost 0.005%|
324601|NCT00273429|Drug|placebo|
324602|NCT00273442|Drug|timolol maleate|
323529|NCT00302133|Drug|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
323530|NCT00302159|Procedure|adjuvant therapy|
323866|NCT00292448|Drug|Ba 679 BR Respimat|
323867|NCT00002794|Drug|vincristine sulfate|
323868|NCT00292448|Drug|Tiotropium (Spiriva) inhalation capsule 18 ug|
323869|NCT00292461|Drug|Zonisamide|Tablet once or twice daily orally for 16 weeks
323870|NCT00292461|Drug|Lamotrigine|Tablet once daily orally for 16 weeks
323871|NCT00292474|Device|percutaneous coronary intervention|
323872|NCT00292487|Drug|Iopamidol 370 mgI/mL|
323873|NCT00292500|Device|Automated distal anastomotic device|CABG
323874|NCT00292513|Device|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
323875|NCT00292526|Drug|oral enalapril|
323876|NCT00292539|Device|Any pacemaker with right ventricular pacing option|
323877|NCT00292552|Other|Novel endpoint determination|Novel endpoint determination
323878|NCT00000442|Drug|naltrexone (Revia)|
323879|NCT00002796|Drug|fluorouracil|Given IV
323880|NCT00292578|Procedure|NAET Testing Modalities|
323881|NCT00292591|Drug|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
323882|NCT00292591|Drug|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
323883|NCT00292656|Procedure|NAET|
323884|NCT00295919|Drug|fenretinide lipid matrix|
323885|NCT00295919|Drug|ketoconazole|
323886|NCT00295919|Other|laboratory biomarker analysis|
323887|NCT00295919|Other|pharmacological study|
323168|NCT00002840|Drug|lomustine|
323169|NCT00311129|Drug|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
323170|NCT00311129|Drug|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
323171|NCT00311155|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
323172|NCT00311168|Procedure|VIP On vs VIP Off|
323173|NCT00311181|Device|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
323174|NCT00311194|Behavioral|6 months readmission rate to hospital|
323175|NCT00311220|Drug|tuberculin for skin test|
323176|NCT00311246|Drug|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcuetaneous injection for a total of 45 weeks.
323531|NCT00302159|Drug|Temozolomide|Orally 75mg/m^2 first day of radiation until completion. Restart 4 weeks post radiation.
323532|NCT00000450|Drug|naltrexone (Revia)|
323533|NCT00002816|Drug|vincristine sulfate|Given IV
323534|NCT00302159|Drug|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
323535|NCT00302159|Radiation|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
323536|NCT00302172|Drug|ARQ 197|Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).
Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.
All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted.
328009|NCT00554047|Other|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
328309|NCT00587093|Other|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
328310|NCT00587119|Drug|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
328311|NCT00587132|Drug|Synthetic Human Secretin|0.2mcg/kg one time dose.
328312|NCT00587145|Drug|S-1,Docetaxel|S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8
328313|NCT00587158|Drug|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
328314|NCT00587158|Other|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
328315|NCT00587171|Device|Patching|2 hours daily patching
328316|NCT00587171|Procedure|Near activities|30 minutes daily near activities at home
328317|NCT00589641|Behavioral|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
328318|NCT00589654|Other|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
328319|NCT00589667|Drug|Pemetrexed plus Gemcitabine|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.
For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist.
328320|NCT00589693|Drug|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
328321|NCT00589693|Drug|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
328322|NCT00589693|Drug|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
328019|NCT00554138|Drug|placebo|1 dd for 7-10 days
328020|NCT00554138|Drug|rosuvastatin|1 dd 20 mg for 7-10 days
328021|NCT00554151|Device|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
328022|NCT00554164|Drug|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
328023|NCT00554164|Drug|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
328024|NCT00556478|Drug|PSD502, contains a mixture of lidocaine and prilocaine|PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.
Approximately 5 minutes before intercourse the study spray (PSD502 or Placebo) can be applied and any excess should be wiped off with a damp cloth or tissue.
During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing
During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
328025|NCT00556478|Drug|PSD502 Placebo|The placebo is a metered dose aerosol spray that is identical in appearance to the PSD502 spray and contains the same propellant (norflurane) but has no lidocaine or prilocaine.
Approximately 5 minutes before intercourse the study spray (PSD502 or Placebo) can be applied and any excess should be wiped off with a damp cloth or tissue.
During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.
During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
328026|NCT00556491|Drug|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
328027|NCT00556491|Drug|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
328326|NCT00000611|Drug|progestins|
328327|NCT00004181|Drug|busulfan|
328328|NCT00589745|Other|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
328329|NCT00589771|Drug|Saccharomyces boulardii|Saccharomyces boulardii one capsule 250mg TDS for 6 weeks
Ispaghula husk 1 Tsf daily after dinner for six weeks
328330|NCT00589771|Drug|Placebo|Cap Placebo TDS for six weeks
Ispaghula husk 1 Tsf daily after dinner for six weeks
328331|NCT00589784|Drug|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
327381|NCT00568451|Drug|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
327382|NCT00568451|Drug|paclitaxel|100mg/m^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
327695|NCT00561262|Procedure|high-intensity focused ultrasound ablation|
327696|NCT00561262|Procedure|quality-of-life assessment|
327697|NCT00561275|Biological|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
327698|NCT00561288|Drug|acetaminophen|2 x 1000 mg doses per day
327699|NCT00561288|Other|cornstarch|2 x 1000 mg cornstarch per day
327700|NCT00561301|Drug|GemDOx|gemcitabine oxliplatin
327701|NCT00004049|Drug|apomine|
327702|NCT00561314|Other|questionnaire administration|
327703|NCT00561314|Procedure|biopsy|
327704|NCT00561314|Procedure|high-intensity focused ultrasound ablation|
327705|NCT00561314|Procedure|magnetic resonance imaging|
327706|NCT00561314|Procedure|quality-of-life assessment|
327707|NCT00563459|Drug|levetiracetam|1000-3000mg/day for 12 months
327708|NCT00563472|Drug|estetrol|10 mg orally per day for 28 days
327709|NCT00563472|Drug|estetrol|20 mg orally per day for 28 days
327710|NCT00563472|Drug|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
327711|NCT00563472|Drug|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
327712|NCT00563485|Drug|Doxazosin GITS (Cardura XL)|
327713|NCT00563485|Drug|Terazosin (Hytrin)|
327714|NCT00563498|Drug|Glutamine|
327715|NCT00000160|Procedure|Photocoagulation|
327716|NCT00000596|Drug|prednisone|
327052|NCT00576043|Procedure|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
327053|NCT00576056|Drug|Sorafenib|Oral sorafenib (400 mg BID) will be start the next day after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
327054|NCT00576056|Drug|Transcatheter Arterial Chemoembolization (TACE)|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin
327055|NCT00576069|Drug|budesonide/formoterol|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or budesonide 160ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days
327056|NCT00576069|Drug|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
327057|NCT00576069|Drug|mometasone/formoterol|200/5 mcg two puffs bid
327058|NCT00576069|Drug|Prednisone|0-15 mg daily as needed
327059|NCT00004114|Drug|fludarabine phosphate|
327060|NCT00576082|Other|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
327061|NCT00576108|Drug|KD7040 Topical Gel|KD7040 topical gel
327062|NCT00576108|Drug|Placebo gel|Placebo gel
327063|NCT00576134|Device|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
327383|NCT00568451|Drug|temozolomide|150mg/m^2 at cycle 1, 200mg/m^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
327384|NCT00568464|Drug|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
327385|NCT00004087|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
327386|NCT00568477|Drug|MabThera|Rituximab (MabThera):
375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes
327387|NCT00568490|Procedure|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
327388|NCT00568490|Procedure|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
326393|NCT00589082|Drug|Daunorubicine|
326394|NCT00589095|Other|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
326736|NCT00580671|Behavioral|CM|Abstinence-based incentives delivered contingent on drug-negative urine test results.
326737|NCT00580671|Behavioral|BPT|Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
326738|NCT00580684|Biological|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
326739|NCT00004141|Drug|Granulocyte-macrophage colony-stimulating factor|
326740|NCT00580723|Other|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
326741|NCT00583388|Dietary Supplement|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
326742|NCT00583388|Device|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
326743|NCT00583401|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
326744|NCT00583414|Device|Endovascular Stent-graft Implantation|Endovascular Repair of Aortic Aneurysm
326745|NCT00583427|Drug|Sulodexide|200 mg per day in an oral gelcap form
326746|NCT00583440|Behavioral|12-step facilitation|12 weekly individual 12-step facilitation sessions
326747|NCT00583440|Behavioral|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
326748|NCT00583453|Drug|Celecoxib|Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery
326749|NCT00583453|Drug|Placebo|Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery
326750|NCT00583466|Drug|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
326751|NCT00004156|Biological|MUC1-KLH vaccine/QS21|
326081|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
326082|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
326083|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
326084|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
326085|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
326086|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
326087|NCT00555841|Drug|ALC and Placebo|ALC and Placebo
326088|NCT00555854|Behavioral|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
326089|NCT00555867|Drug|Anastrozole|oral
326090|NCT00004012|Drug|capecitabine|
326091|NCT00555880|Drug|Midodrine hydrochloride|one dose, 10-30mg, given orally
326092|NCT00555880|Drug|Placebo|Placebo
326395|NCT00589108|Device|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
326396|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
326397|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
326398|NCT00589121|Drug|chemotherapy|Up to 6 courses of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
326399|NCT00000611|Drug|estrogens|
326400|NCT00004177|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
326401|NCT00589121|Radiation|3-dimensional conformal radiation therapy|Performed preoperatively once daily, 5 days a week, for 4½-5 weeks
326402|NCT00550992|Drug|daunorubicin hydrochloride|
326403|NCT00550992|Drug|etoposide|
325729|NCT00560430|Drug|placebo|placebo; orally weeks 1-14
325730|NCT00560443|Drug|ketorolac|0,5 mg/kg per os one time
325731|NCT00560443|Drug|tramadol|2,5 mg/ kg per os in one dose
325732|NCT00560456|Other|Chronic sleep restriction and driving simulator|One night of normal sleep
Driving simulator
Night 1: night of total sleep deprivation
Night 2: night of sleep recovery
Night 1 to 5: nights of sleep restriction
Driving simulator after night 1 to 5
Night 6: night of sleep recovery
Driving simulator
325733|NCT00560469|Other|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
325734|NCT00560482|Drug|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
325735|NCT00004042|Radiation|iodine I 131 monoclonal antibody F19|
325736|NCT00560482|Drug|Placebo|Identical appearing gelatin capsules containing placebo
325737|NCT00560495|Drug|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
325738|NCT00560495|Other|immunoenzyme technique|
325739|NCT00560495|Other|laboratory biomarker analysis|
325740|NCT00560495|Radiation|Tc 99m sestamibi|
325741|NCT00560495|Radiation|radiation therapy|once daily, 5 days a week, for 6-7 weeks
325742|NCT00560508|Drug|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
325743|NCT00560508|Drug|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
325744|NCT00560521|Behavioral|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
326093|NCT00555893|Drug|Oseltamivir|Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:
for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)
326094|NCT00555893|Drug|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
325110|NCT00572611|Drug|[14C]-bilastine|Single oral dose of 20 mg [14C]-bilastine. 1 capsule. 1 day dosing only
325402|NCT00567489|Drug|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
325403|NCT00567489|Drug|Extraneal|7.5% Icodextrin
325404|NCT00567489|Drug|Nutrineal|Amino Acids 1.1%
325405|NCT00567515|Device|AtriCure LAA Exclusion System|Placement of clip of LAA.
325406|NCT00567528|Drug|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
325407|NCT00567528|Drug|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
325408|NCT00567541|Device|Battery Powered Microstimulator (BBPM)|The Battery Powered Microstimulator (BBPM) will be programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, they will be reprogrammed to receive therapeutic stimulation.
325409|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel|
325410|NCT00004085|Procedure|autologous bone marrow transplantation|1-2 weeks prior to treatment
325411|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
325412|NCT00567554|Drug|paclitaxel|
325413|NCT00567554|Drug|paclitaxel + everolimus (RAD001)|
325414|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
325415|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + lapatinib|
325416|NCT00567567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
325417|NCT00567567|Drug|Carboplatin|Given IV
325418|NCT00567567|Drug|Cisplatin|Given IV
325419|NCT00567567|Drug|Cyclophosphamide|Given IV
325420|NCT00567567|Drug|Doxorubicin Hydrochloride|Given IV
325421|NCT00004085|Procedure|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
324814|NCT00579878|Drug|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
324815|NCT00579878|Drug|Leflunomide|a loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations).
324816|NCT00579904|Dietary Supplement|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
324817|NCT00004137|Drug|paclitaxel|
324818|NCT00579904|Dietary Supplement|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
324819|NCT00579917|Behavioral|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
325111|NCT00572624|Behavioral|Weight Loss Management Program|Selected overweight participants will set a goal of 10% body weight loss over a 6-month period, followed by a 1- to 2-month weight loss stabilization period. After the stabilization period, participants will undergo repeat abdominal fat and insulin sensitivity studies and imaging tests.
325112|NCT00575055|Drug|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
325113|NCT00575055|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
325114|NCT00575055|Drug|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
325115|NCT00004110|Drug|etoposide|
325116|NCT00575068|Drug|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A & II-B - Dosage start at the MTD (up to 375 mg/m2)
325117|NCT00575081|Device|Deep Brain Stimulator|Deep Brain Stimulation, GPi for Dystonia
325118|NCT00575094|Drug|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
325119|NCT00575107|Other|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
352131|NCT00622310|Behavioral|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (~6.8 kg) during the 6 month intervention.
352132|NCT00622336|Drug|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
352133|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 23 hours at 0.05 mg/kg/hr
352134|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 23 hours at 0.1 mg/kg/hr
352135|NCT00004495|Drug|pyridoxine|
352136|NCT00624455|Drug|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
352137|NCT00624455|Drug|Placebo|Placebo
352138|NCT00624468|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
352139|NCT00624468|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
352140|NCT00624481|Drug|Teriparatide|20ug subcutaneous injection daily for 24 weeks
352141|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
352142|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
352143|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
352144|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
352145|NCT00624494|Device|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
352146|NCT00004496|Drug|alpha-melanocyte stimulating hormone|
352147|NCT00624494|Device|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
352148|NCT00624520|Behavioral|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
352149|NCT00624520|Other|Patient Education|10 week program of "Patient Education" group sessions, involving presentations of educational materials relating to heart disease.
325862|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA
Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA
325863|NCT00004100|Drug|vinorelbine tartrate|
325864|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA
Group 4B: V710 (60 mcg / PBO / PBO) with MAA
325865|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA
Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA
325866|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA
Group 2B: V710 (60 mcg / PBO / PBO) without MAA
325867|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA
Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA
325868|NCT00572936|Drug|prostaglandin|One drop, each eye, twice a day
325869|NCT00572962|Procedure|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
325870|NCT00575471|Drug|Placebo|Matching placebo tablets once daily for 12 weeks
326187|NCT00567801|Procedure|conventional embolectomy/thrombectomy|
326188|NCT00567801|Procedure|embolectomy/thrombectomy with controlled reperfusion|
326189|NCT00567814|Drug|Metyrapone|Twice daily
326190|NCT00567814|Drug|Oxazepam|Twice Daily
326191|NCT00567814|Drug|Placebo|Twice daily
326192|NCT00004086|Drug|cytarabine|
326193|NCT00567840|Drug|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
326194|NCT00567853|Device|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
326195|NCT00567866|Drug|Quetiapine|50 or 100 mg of quetiapine orally
326196|NCT00567879|Drug|panobinostat, trastuzumab|
326197|NCT00567892|Device|rTMS|Stimulation Settings:
Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)
326198|NCT00567905|Dietary Supplement|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
325517|NCT00577980|Drug|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
325518|NCT00577993|Drug|Fludarabine|Group 1= 25 mg/m^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
325519|NCT00577993|Drug|Novantrone|Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.
325520|NCT00577993|Drug|Decadron|Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
325521|NCT00577993|Drug|Rituximab|Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.
325522|NCT00577993|Drug|Interferon|Group 1 = After Completion of Fludarabine, Novantrone, & Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine & Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.
325523|NCT00577993|Drug|Doxorubicin|25 mg/m^2 IV Days 2 & 3 of 1st Sequence.
325524|NCT00004128|Biological|aldesleukin|
325525|NCT00577993|Drug|Vincristine|.7 mg/m^2 IV Days 2 & 3 of 1st Sequence; 1.4 mg/m^2 IV Day 2 of 3rd Sequence.
325526|NCT00577993|Drug|Bleomycin|5 unit/m^2 IV Days 2 & 3 of 1st Sequence.
325527|NCT00577993|Drug|Cyclophosphamide|750 mg/m^2 IV Day 2 of 1st Sequence.
325528|NCT00577993|Drug|Etoposide|40 mg/m^2 IV Days 1 through 4 of 2nd Sequence.
325529|NCT00004138|Procedure|positron emission tomography|
325530|NCT00580099|Other|assisted exercise|4 weeks of passive range of motion exercise
325531|NCT00580099|Other|cuddle|cuddle infant for 20 minutes
325532|NCT00580112|Drug|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
325871|NCT00575484|Drug|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium </=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
324911|NCT00552721|Other|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
324912|NCT00552734|Device|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
324913|NCT00552747|Drug|fenofibrate|fenofibrate 160 mg capsules qd
324914|NCT00552747|Drug|placebo|capsules placebo
324915|NCT00552760|Drug|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
325208|NCT00585650|Other|Placebo injections|Placebo injections twice weekly for first 12 weeks
325209|NCT00585663|Radiation|Iodofiltic acid I-125|Iodofiltic acid I-125 (4.0-5.0 mCi) is injected within 30 hours of the cessation of chest pain as a single injection. Single photon emission computed tomography is then performed 10-15 minutes after the injection.
325210|NCT00585689|Drug|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
325211|NCT00585689|Drug|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
325212|NCT00585689|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
325213|NCT00585689|Procedure|Radical Cystectomy|
325214|NCT00585715|Device|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
325215|NCT00585728|Procedure|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
325216|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
325217|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
325218|NCT00004165|Drug|melphalan|
325219|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
325220|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
325221|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
324603|NCT00273442|Drug|dorzolamide/timolol maleate fixed combination|
324604|NCT00002740|Drug|vincristine sulfate|
324605|NCT00273455|Drug|bimatoprost 0.03%|
324606|NCT00273455|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
324607|NCT00273455|Drug|placebo|
324608|NCT00273468|Drug|Granisetron|
324609|NCT00273481|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
324610|NCT00273481|Drug|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
324611|NCT00273481|Drug|timolol maleate 0.5%|
324612|NCT00273481|Drug|placebo|
324613|NCT00273494|Procedure|Surgery|
324614|NCT00273507|Drug|Carboplatin and Paclitaxel|
324615|NCT00276601|Drug|mercaptopurine|
324616|NCT00276601|Drug|methotrexate|
324617|NCT00276601|Drug|tretinoin|
324618|NCT00276614|Drug|bortezomib|
324619|NCT00276627|Behavioral|communication lecture|lecture on communication skills with oncology patients
324620|NCT00276627|Behavioral|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
324621|NCT00276640|Drug|vincristine, carboplatin|vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21
carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21
324622|NCT00276640|Drug|vincristine, carboplatin, etoposide|vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21
carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21
etoposide: 100 mg/m² i.v., week 1,4,7,10
324623|NCT00276640|Radiation|radiation therapy|intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks
spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks
324916|NCT00552760|Drug|Placebo|one tablet at bedtime for up to 6 months
324917|NCT00552773|Drug|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
323888|NCT00002802|Procedure|autologous bone marrow transplantation|
323889|NCT00295932|Biological|rituximab|Given IV
323890|NCT00295932|Drug|bortezomib|Given IV
323891|NCT00295932|Drug|cyclophosphamide|Given IV
323892|NCT00295932|Drug|prednisone|Given orally
324239|NCT00282724|Drug|Liarozole|
324240|NCT00282750|Device|Bar coded sponge and scanner|
324241|NCT00002771|Procedure|autologous bone marrow transplantation|
324242|NCT00282763|Drug|MK0686|
324243|NCT00286325|Drug|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
324244|NCT00286351|Drug|Combined treatment with Arimidex and Zoladex before IVF|
324245|NCT00286364|Drug|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
324246|NCT00286377|Drug|prosaptide|
324247|NCT00286390|Procedure|Acupuncture|
324248|NCT00286403|Drug|Fenoldopam Mesylate and/or MESNA|
324249|NCT00286416|Drug|omalizumab (Xolair)|
324250|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
324251|NCT00002781|Drug|boronophenylalanine-fructose complex|
324252|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
324253|NCT00286429|Drug|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
324254|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
324255|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
324256|NCT00286442|Drug|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
323537|NCT00305214|Procedure|T Wave Alternans Test|
323538|NCT00305227|Drug|Lactin-V|
323539|NCT00305227|Drug|Placebo|
323540|NCT00305240|Procedure|T Wave Alternans Test|
323541|NCT00305253|Device|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
323542|NCT00000452|Behavioral|Compliance Enhancement Tech.|
323543|NCT00002827|Drug|dexrazoxane hydrochloride|Given IV
323544|NCT00305266|Drug|intravenous gammaglobulin|individual dose
323545|NCT00305279|Other|Dietary|Dietary
323546|NCT00305279|Other|Dietary|Dietary
323547|NCT00305279|Other|Dietary|Dietary
323548|NCT00305292|Drug|Modafinil-Alcohol Interactions|
323549|NCT00305331|Drug|Domperidone (drug)|
323550|NCT00305344|Procedure|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
323551|NCT00305344|Biological|Cord blood|Develop Cord blood vaccine
323552|NCT00305370|Drug|Aripiprazole|
323553|NCT00305383|Drug|Viramidine|
323554|NCT00002827|Drug|doxorubicin hydrochloride|Given IV
323893|NCT00295945|Drug|fentanyl citrate|
323894|NCT00295945|Drug|hydromorphone hydrochloride|
323895|NCT00295945|Drug|ropivacaine hydrochloride|
323896|NCT00295958|Biological|LMB-2 immunotoxin|
323897|NCT00295958|Biological|MART-1 antigen|
323898|NCT00295958|Biological|gp100 antigen|
323899|NCT00000446|Drug|sertraline (Zoloft)|
328323|NCT00589706|Drug|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
328324|NCT00589706|Drug|MAb-425|All patient receive MAb-425 along with Iodine-125 as an injection for a total of three treatments.Each treatment is separated by one week.
328325|NCT00589732|Drug|Valsartan|Valsartan 160mg per day
323177|NCT00311259|Drug|Melatonin (drug)|
323178|NCT00311259|Drug|Laktose|
323179|NCT00002840|Drug|procarbazine hydrochloride|
323180|NCT00311272|Biological|MelCancerVac|
323181|NCT00262704|Behavioral|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
323182|NCT00262717|Device|HIV drug resistance tests based upon genotype testing|
323183|NCT00262730|Drug|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
323184|NCT00262730|Drug|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
323185|NCT00262730|Radiation|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
323186|NCT00262743|Biological|Polyphenon E|Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day
Phase II: 2000 mg orally twice a day
323187|NCT00262769|Drug|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
323188|NCT00262769|Drug|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
323189|NCT00262782|Drug|fludarabine phosphate|
323190|NCT00262795|Drug|chlorambucil|
323191|NCT00002701|Drug|thioguanine|
323192|NCT00262795|Drug|fludarabine phosphate|
323193|NCT00262808|Biological|sargramostim|
323194|NCT00262808|Drug|fluorouracil|
323195|NCT00262808|Drug|leucovorin calcium|
328332|NCT00589797|Device|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
328333|NCT00589797|Device|ProDisc Total Disc Replacement or Charite Atifical Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
328334|NCT00589823|Drug|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
328335|NCT00589823|Drug|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
328336|NCT00589849|Procedure|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
328337|NCT00551551|Other|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
328338|NCT00551551|Other|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
328339|NCT00551564|Drug|rosiglitazone maleate|
328340|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
328341|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
328342|NCT00551590|Drug|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
328343|NCT00551590|Drug|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
328344|NCT00551590|Drug|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
328345|NCT00551590|Drug|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
328346|NCT00003993|Biological|aldesleukin|
323203|NCT00262834|Drug|vorinostat|Given orally
323204|NCT00262834|Other|conventional surgery|Undergo surgery
323205|NCT00262847|Biological|Bevacizumab|Given IV
323206|NCT00262847|Drug|Carboplatin|Given IV
323207|NCT00262847|Other|Laboratory Biomarker Analysis|Correlative studies
323208|NCT00262847|Drug|Paclitaxel|Given IV
327717|NCT00004061|Drug|etoposide|
327718|NCT00563511|Procedure|adherence intervention|
327719|NCT00563511|Procedure|intervention without adherence advice|
327720|NCT00563511|Procedure|control|
327721|NCT00563524|Drug|ILV-094|SC and IV administration on days 1, 14, 28, and 42
328028|NCT00556504|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
328029|NCT00556504|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
328030|NCT00556504|Drug|Ribavirin|conventional treatment of Hepatitis C
328031|NCT00004022|Biological|autologous tumor cell vaccine|
328032|NCT00556504|Drug|Placebo|Placebo, without acting ingredient.
328033|NCT00556543|Device|U-plate fracture repair system|All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
328034|NCT00556569|Other|CHAM JAM|CHAM JAM (previously known as Moving Smart" (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity
328035|NCT00556595|Procedure|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
328036|NCT00556595|Procedure|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
328037|NCT00556608|Device|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
328038|NCT00556608|Device|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
328039|NCT00556621|Drug|cisplatin|
328040|NCT00556621|Drug|gemcitabine hydrochloride|
328041|NCT00556621|Procedure|biopsy|
328042|NCT00004022|Biological|muromonab-CD3|
328043|NCT00556621|Procedure|cystoscopy|
327389|NCT00571129|Procedure|DCR|The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.
In revision group patients were randomized into the two groups,ether with or without application of mitomycin "C" after DCR
327390|NCT00571142|Procedure|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
327391|NCT00571142|Procedure|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
327392|NCT00004093|Drug|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
327393|NCT00571155|Drug|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
327394|NCT00571168|Drug|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
327395|NCT00571168|Drug|Placebo|Placebo capsules on day 1-4
327396|NCT00571181|Device|Closed-loop system|Automatic delivery of propofol and remifentanil
327397|NCT00571181|Device|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
327398|NCT00571194|Drug|pravastatin|single dose
327399|NCT00571207|Device|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
327400|NCT00571207|Behavioral|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
327401|NCT00571220|Procedure|gastric bypass surgery|weight loss bariatric surgery
327402|NCT00571220|Other|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
327722|NCT00563537|Radiation|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
327723|NCT00563563|Drug|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
327724|NCT00563563|Behavioral|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
327725|NCT00563576|Drug|Femring®|Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.
Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months.
326752|NCT00583466|Drug|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
326753|NCT00583466|Drug|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
326754|NCT00583479|Other|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
327064|NCT00576147|Device|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
327065|NCT00576160|Behavioral|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
327066|NCT00576173|Drug|tramadol hydrochloride; acetaminophen|
327067|NCT00578435|Procedure|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
327068|NCT00578448|Drug|Belatacept|IV infusion
327069|NCT00578461|Drug|Ara C|3000 mg/m^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
327070|NCT00578461|Drug|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
327071|NCT00578461|Drug|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
327072|NCT00578461|Radiation|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
327073|NCT00578474|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
327074|NCT00578474|Drug|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
327075|NCT00578474|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
327076|NCT00004128|Procedure|peripheral blood stem cell transplantation|
327077|NCT00578500|Procedure|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
327078|NCT00578526|Drug|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
327079|NCT00578526|Drug|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
326404|NCT00550992|Drug|leucovorin calcium|
326405|NCT00550992|Drug|melphalan|
326406|NCT00000579|Procedure|Fluid Management|
326407|NCT00003980|Drug|BIBX 1382|
326408|NCT00550992|Drug|mercaptopurine|
326409|NCT00550992|Drug|methotrexate|
326410|NCT00550992|Drug|mitoxantrone hydrochloride|
326411|NCT00550992|Drug|pegaspargase|
326412|NCT00550992|Drug|prednisolone|
326413|NCT00550992|Drug|prednisone|
326414|NCT00550992|Drug|therapeutic hydrocortisone|
326415|NCT00550992|Drug|thioguanine|
326416|NCT00550992|Drug|vincristine sulfate|
326417|NCT00550992|Procedure|allogeneic bone marrow transplantation|
326418|NCT00003981|Drug|indisulam|
326419|NCT00550992|Procedure|allogeneic hematopoietic stem cell transplantation|
326420|NCT00550992|Procedure|umbilical cord blood transplantation|
326421|NCT00551005|Drug|celecoxib|
326755|NCT00583479|Other|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
326756|NCT00583492|Biological|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
326757|NCT00583492|Radiation|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
326758|NCT00583505|Device|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
326759|NCT00583518|Drug|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
326760|NCT00583531|Drug|AST-120|Oral, 2 grams TID in sachets for 4 weeks
326095|NCT00555906|Drug|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
326096|NCT00555906|Drug|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
326097|NCT00555906|Drug|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
326098|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
326099|NCT00558220|Procedure|Induction treatment part 2 with PBPC collection|Starts three weeks after last cycle of Induction part 1.
Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.
Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are >20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood.
326100|NCT00558220|Procedure|Induction treatment part 3|Part 3 of induction treatment is given approximately one week after the end of Part 2.
Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart.
326101|NCT00558220|Procedure|Consolidation treatment part 1: HD-chemotherapy with ASCT|Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.
High dose chemotherapy (HD-chemotherapy) consists of:
BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.
On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery.
326102|NCT00558220|Radiation|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
326103|NCT00558233|Behavioral|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
326104|NCT00558233|Behavioral|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
326422|NCT00551005|Drug|etoposide|
326423|NCT00551005|Other|immunoenzyme technique|
326424|NCT00551005|Other|laboratory biomarker analysis|
326425|NCT00551018|Drug|Vicriviroc|one 30 mg tablet QD
325422|NCT00567567|Drug|Etoposide|Given IV
325423|NCT00567567|Radiation|External Beam Radiation Therapy|Undergo EBRT
325424|NCT00567567|Biological|Filgrastim|Given IV or SC
325425|NCT00567567|Drug|Isotretinoin|Given orally
325745|NCT00560534|Procedure|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
325746|NCT00004043|Dietary Supplement|calcitriol|
325747|NCT00560547|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
325748|NCT00560560|Biological|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
325749|NCT00560573|Drug|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
325750|NCT00562640|Other|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
325751|NCT00562666|Other|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
325752|NCT00562679|Other|There is no intervention|
325753|NCT00004056|Drug|melphalan|
325754|NCT00562692|Drug|Nesiritide|Nesiritide 4 hour infusion
325755|NCT00562692|Drug|Placebo|Placebo infusion
325756|NCT00562705|Behavioral|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|A combined treatment of growth hormone (Genotropin or NorditropinSimplex or "Biotropin") and nutritional intervention
325757|NCT00562705|Behavioral|growth hormone-Genotropin or NorditropinSimplex or "Biotropin"|Growth hormone treatment (Genotropin, or NorditropinSimplex or "Biotropin").
325758|NCT00562718|Drug|capecitabine|
325759|NCT00562718|Procedure|adjuvant therapy|
325760|NCT00562718|Radiation|radiation therapy|
325761|NCT00562731|Drug|ARD-0403|Daily transdermal ARD-0403
325120|NCT00575107|Other|Exercise|Standard training of leg extension
325121|NCT00575120|Other|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
325122|NCT00575146|Dietary Supplement|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
325123|NCT00575159|Drug|GSK189075|investigational drug
325124|NCT00575159|Drug|placebo|placebo comparator
325125|NCT00575185|Drug|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
325126|NCT00004110|Drug|isotretinoin|
325127|NCT00575185|Drug|placebo|Placebo tablets orally twice daily for 21 days.
325128|NCT00575198|Other|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
325129|NCT00575198|Other|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
325130|NCT00575224|Drug|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
325131|NCT00575237|Procedure|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
325426|NCT00567567|Other|Laboratory Biomarker Analysis|Correlative studies
325427|NCT00567567|Drug|Melphalan|Given IV
325428|NCT00567567|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
325429|NCT00567567|Other|Pharmacological Study|Correlative studies
325430|NCT00567567|Drug|Thiotepa|Given IV
325431|NCT00570271|Other|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
325432|NCT00570284|Drug|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
325433|NCT00570310|Drug|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
325434|NCT00570310|Drug|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
352150|NCT00624533|Behavioral|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
352427|NCT00617838|Other|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
352428|NCT00617851|Biological|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
352429|NCT00617851|Biological|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
352430|NCT00617851|Biological|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
352431|NCT00617851|Biological|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
352432|NCT00617851|Biological|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
352433|NCT00617864|Drug|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
352434|NCT00617864|Drug|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
352435|NCT00000626|Drug|Vinblastine sulfate|
352436|NCT00620139|Biological|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
352437|NCT00620152|Behavioral|1|Low glycemic load diet by telephone counseling
352438|NCT00620152|Behavioral|2|Low fat diet by telephone counseling
352439|NCT00620165|Drug|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
352440|NCT00620165|Drug|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
352441|NCT00620178|Drug|Candesartan Cilexetil|oral once daily dose
352442|NCT00620178|Drug|Losartan|once daily oral dose
352443|NCT00004436|Drug|prednisone|
326199|NCT00567918|Drug|FK506|Ophthalmic suspension
326200|NCT00567931|Drug|1-methyl-d-tryptophan|Given orally
326201|NCT00567931|Other|pharmacological study|Correlative studies
326202|NCT00567931|Other|laboratory biomarker analysis|Correlative studies
326203|NCT00000598|Behavioral|exercise|
326204|NCT00004086|Drug|etoposide|
326205|NCT00567944|Device|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
326206|NCT00567957|Drug|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
326207|NCT00567957|Drug|Saline|same volume iv bolus before induction followed by same volume infusion
326208|NCT00567970|Procedure|quality-of-life assessment|
326209|NCT00567970|Radiation|stereotactic body radiation therapy|
326210|NCT00567983|Drug|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
326211|NCT00567983|Drug|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
326539|NCT00560885|Device|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
326540|NCT00560898|Drug|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
326541|NCT00560898|Drug|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
326542|NCT00562913|Drug|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
326543|NCT00562926|Procedure|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
326544|NCT00562939|Biological|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
326545|NCT00562939|Biological|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
325872|NCT00575484|Drug|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
325873|NCT00004112|Drug|doxorubicin hydrochloride|
325874|NCT00575497|Procedure|More frequent hemodialysis|Six Day per week short daily hemodialysis
325875|NCT00575497|Procedure|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
325876|NCT00575497|Procedure|More frequent hemodialysis|Every other day short daily hemodialysis
325877|NCT00575497|Procedure|More frequent hemodialysis|Every other night hemodialysis
325878|NCT00575497|Procedure|More frequent hemodialysis|5 days per week short daily hemodialysis
325879|NCT00575497|Procedure|More frequent hemodialysis|5 nights per week hemodialysis
325880|NCT00575497|Procedure|Conventional Hemodialysis|3 days per week short daily hemodialysis
325881|NCT00575510|Behavioral|Intervention|Multiple component intervention based in the unified theory of behavior
325882|NCT00575510|Behavioral|Active control|Partial intervention (full intervention minus cultural-specific component)
325883|NCT00575523|Drug|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
325884|NCT00000602|Drug|hydroxyurea|
325885|NCT00004112|Drug|prednisone|
325886|NCT00575523|Drug|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
325887|NCT00575536|Procedure|Optical Stimulation in Rhizotomy Surgery|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
325888|NCT00575549|Other|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
325889|NCT00575562|Drug|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
325890|NCT00575575|Behavioral|cognitive behavior therapy|cognitive behavior therapy once a week
325891|NCT00575588|Drug|Metformin|open-label metformin
325222|NCT00585754|Drug|Guanfacine|1.5mg BID
325223|NCT00585754|Drug|Placebo|placebo
325224|NCT00585780|Drug|Prazosin|three week dose titration schedule at the start of study with the full dose schedule of 5.0mg in the morning, 5.0mg at 3pm, and 11.0mg at bedtime for 8 weeks and then a 5-day taper in week 12.
325225|NCT00585780|Drug|placebo|placebo
325226|NCT00585793|Drug|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
325227|NCT00585819|Procedure|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
325228|NCT00588419|Behavioral|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
325533|NCT00580112|Drug|Trabectedin|Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
325534|NCT00580125|Drug|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
325535|NCT00580125|Other|Placebo|Placebo, oral capsule, once daily for 21 days
325536|NCT00580125|Drug|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
325537|NCT00580125|Drug|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
325538|NCT00580125|Drug|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
325539|NCT00580151|Drug|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
325540|NCT00004138|Procedure|radionuclide imaging|
325541|NCT00580151|Drug|placebo|1 dose every 6 hours
325542|NCT00580177|Procedure|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
325543|NCT00580177|Procedure|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
325544|NCT00580177|Procedure|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
325545|NCT00580190|Drug|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
324918|NCT00552786|Drug|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
324919|NCT00003998|Drug|carboplatin|
324920|NCT00552786|Drug|glucose|1 gm glucose capsule
324921|NCT00552799|Drug|Penicillin VK|Biconcave tablet 250mg oral, b.d.
324922|NCT00552799|Other|placebo|biconcave tablet matching active comparator as much as possible in size and shape
324923|NCT00552812|Device|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
324924|NCT00552838|Behavioral|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
324925|NCT00552851|Drug|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
324926|NCT00552864|Drug|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
324927|NCT00552864|Drug|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
324928|NCT00004010|Drug|procarbazine hydrochloride|
324929|NCT00555321|Drug|Belatacept More Intensive (MI)|Intravenous (IV),
10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.
After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension [LTE])
324930|NCT00555321|Drug|Belatacept Less Intensive (LI)|Intravenous (IV),
10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.
After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)
324931|NCT00555321|Drug|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term [ST]), ≤ 1 g/day, 4 years (Long-term extension [LTE])
324932|NCT00555334|Procedure|RFA|radiofrequency ablation
324933|NCT00555334|Drug|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
324257|NCT00286455|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
324258|NCT00286455|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
324259|NCT00286455|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
324260|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
324261|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
324262|NCT00002783|Drug|cisplatin|
324263|NCT00286468|Drug|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
324624|NCT00276666|Drug|cisplatin|
324625|NCT00000428|Drug|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
324626|NCT00002755|Drug|methotrexate|
324627|NCT00276666|Drug|lomustine|
324628|NCT00276666|Drug|vincristine sulfate|
324629|NCT00276666|Procedure|adjuvant therapy|
324630|NCT00276666|Radiation|radiation therapy|
324631|NCT00276679|Drug|temozolomide|
324632|NCT00276692|Drug|irinotecan hydrochloride|
324633|NCT00276705|Drug|cisplatin|
324634|NCT00276705|Drug|cyclophosphamide|
324635|NCT00276705|Drug|doxorubicin hydrochloride|
324636|NCT00276705|Drug|thalidomide|
324637|NCT00002755|Drug|tamoxifen citrate|
324638|NCT00276705|Procedure|adjuvant therapy|
324639|NCT00276705|Procedure|conventional surgery|
324640|NCT00276705|Procedure|neoadjuvant therapy|
323900|NCT00002802|Procedure|conventional surgery|
323901|NCT00295958|Biological|incomplete Freund's adjuvant|
323902|NCT00295971|Biological|anti-thymocyte globulin|
323903|NCT00295971|Biological|therapeutic allogeneic lymphocytes|
323904|NCT00295971|Drug|fludarabine phosphate|
323905|NCT00295971|Drug|thiotepa|
323906|NCT00295971|Procedure|allogeneic bone marrow transplantation|
323907|NCT00295971|Procedure|allogeneic hematopoietic stem cell transplantation|
323908|NCT00295971|Procedure|in vitro-treated peripheral blood stem cell transplantation|
323909|NCT00295971|Radiation|total-body irradiation|
323910|NCT00295984|Drug|nicotine|
323911|NCT00002802|Radiation|low-LET cobalt-60 gamma ray therapy|
323912|NCT00295997|Biological|anti-thymocyte globulin|
323913|NCT00295997|Biological|filgrastim|
323914|NCT00295997|Biological|graft-versus-tumor induction therapy|
323915|NCT00295997|Biological|therapeutic allogeneic lymphocytes|
323916|NCT00295997|Drug|busulfan|
323917|NCT00295997|Drug|cyclophosphamide|
323918|NCT00295997|Drug|fludarabine phosphate|
323919|NCT00299052|Device|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
323920|NCT00002809|Biological|sargramostim|
324264|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
324265|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
324266|NCT00286481|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
323196|NCT00262808|Drug|oxaliplatin|
323197|NCT00262808|Procedure|adjuvant therapy|
323198|NCT00262808|Procedure|conventional surgery|
323199|NCT00262808|Procedure|neoadjuvant therapy|
323200|NCT00262821|Drug|cisplatin|Given IV
323201|NCT00262821|Drug|tirapazamine|Given IV
323202|NCT00002701|Drug|tretinoin|
323555|NCT00305383|Drug|Peginterferon alfa-2b|
323556|NCT00305396|Drug|Sirolimus|
323557|NCT00305409|Drug|Synbiotic (Synergy I / B.longum)|
323558|NCT00305422|Drug|Quetiapine fumarate|
323559|NCT00305422|Drug|Risperidone|
323560|NCT00305435|Drug|Romiplostim (AMG-531)|Romiplostim (AMG-531)
323561|NCT00305448|Drug|Fulvestrant|250 intramuscular injection
323562|NCT00305448|Drug|Fulvestrant|500 mg intramuscular injection
323563|NCT00305461|Drug|Ciclesonide|Effect of Ciclesonide on Quality of Life
323564|NCT00305474|Drug|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
323565|NCT00002827|Drug|etoposide|Given IV
323566|NCT00305487|Drug|Ciclesonide nasal spray|
323567|NCT00305500|Drug|escitalopram|
323568|NCT00305513|Procedure|The phasic alerting treatment|
323569|NCT00305526|Device|Contak Renewal (CRT-D)|
323570|NCT00305539|Drug|adalimumab|40 mg sc / for 3 months
323571|NCT00308347|Drug|Placebo / Duration of Treatment: mean 3.4 years|
323572|NCT00308360|Drug|Risperidone, divalproex|
323209|NCT00262847|Other|Placebo|Given IV
323210|NCT00262847|Other|Quality-of-Life Assessment|Ancillary studies
323211|NCT00262860|Drug|bortezomib|
323212|NCT00262860|Drug|gemcitabine hydrochloride|
323213|NCT00265772|Drug|MODULEN IBD (R) (specific Enteral Nutrition)|
323214|NCT00002708|Radiation|stereotactic radiosurgery|
323215|NCT00265772|Drug|prednisolon|
323216|NCT00265785|Drug|pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
323217|NCT00265798|Drug|Sorafenib Tosylate|
323218|NCT00265811|Biological|cetuximab|
323219|NCT00265811|Drug|fluorouracil|
323220|NCT00265811|Drug|leucovorin calcium|
323221|NCT00265811|Drug|oxaliplatin|
323222|NCT00265811|Procedure|adjuvant therapy|
323223|NCT00265824|Drug|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
323224|NCT00265824|Drug|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
323225|NCT00000420|Drug|Ortho-Novum 777|
323226|NCT00002711|Drug|chemotherapy|
323227|NCT00265837|Biological|graft versus host disease prophylaxis/therapy|
323228|NCT00265837|Procedure|allogeneic bone marrow transplantation|
323229|NCT00265837|Procedure|in vitro-treated bone marrow transplantation|
323581|NCT00308451|Drug|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
323582|NCT00308464|Drug|PHA-794428|
323583|NCT00308477|Drug|dexamethasone|
328044|NCT00556621|Procedure|therapeutic conventional surgery|
328045|NCT00559104|Radiation|total-body irradiation|Unique to the Radiation in Conditioning Arm
328046|NCT00559104|Drug|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
328047|NCT00004032|Other|laboratory biomarker analysis|Correlative studies
328048|NCT00559117|Drug|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
328049|NCT00559130|Device|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
328347|NCT00551603|Drug|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
328348|NCT00551603|Drug|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
328349|NCT00551616|Drug|CDB-2914|Single dose
328350|NCT00551616|Drug|Levonorgestrel|Single dose
328351|NCT00551629|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
328352|NCT00551629|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
328353|NCT00551629|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
328354|NCT00551629|Biological|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
328355|NCT00551642|Drug|Nitric Oxide for inhalation|inhaled nitric oxide given at 5 parts per million (ppm) for 7-21 days
328356|NCT00551642|Drug|Nitrogen|nitrogen gas given at 5ppm for 7-21 days
328357|NCT00003993|Drug|bryostatin 1|
328358|NCT00551668|Procedure|proximal patellar surgery|Initial proximal patellar surgery
328359|NCT00551668|Procedure|Nonoperative|Nonoperative without surgery
328360|NCT00551681|Device|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
328361|NCT00551681|Device|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
328362|NCT00551694|Drug|GSK256073A tablets|
327726|NCT00563576|Drug|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
327727|NCT00563589|Drug|mycophenolate mofetil, methotrexate, cyclosporin|
327728|NCT00004061|Drug|ifosfamide|
327729|NCT00563589|Drug|Methotrexate and cyclosporin|
327730|NCT00563602|Other|Hemodynamic guided therapy|To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:
1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)
327731|NCT00563615|Drug|Tegaserod|
327732|NCT00563628|Device|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
327733|NCT00566007|Drug|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
327734|NCT00566020|Drug|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
327735|NCT00566033|Behavioral|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
327736|NCT00566046|Drug|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
327737|NCT00566046|Drug|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
327738|NCT00566072|Behavioral|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
327739|NCT00566085|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
328050|NCT00559143|Other|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
328051|NCT00559156|Dietary Supplement|arginine/omega-3 fatty acids/nucleotides oral supplement|
328052|NCT00559156|Drug|cisplatin|
328053|NCT00559156|Procedure|adjuvant therapy|
328054|NCT00559156|Radiation|radiation therapy|
327080|NCT00578539|Drug|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
327081|NCT00578539|Drug|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
327082|NCT00578539|Drug|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
327083|NCT00578539|Radiation|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
327403|NCT00004093|Drug|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
327404|NCT00571246|Drug|lamotrigine and topiramate|lamotrigine (250 mg/day) 2 times a day, topiramate (250mg/day) 2 times a day, placebo
327405|NCT00571259|Drug|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
327406|NCT00571259|Drug|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
327407|NCT00571285|Dietary Supplement|Vitamin D3|600 IU Vitamin D3 capsule daily
327408|NCT00571285|Dietary Supplement|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
327409|NCT00571285|Dietary Supplement|Placebo|Placebo capsule given once a week
327410|NCT00571298|Procedure|Extrapleural pneumonectomy (EPP), Pleurectomy/Decortication|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
327411|NCT00571298|Drug|cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
327412|NCT00571298|Drug|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
327413|NCT00571298|Drug|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
327414|NCT00573482|Behavioral|REDE|The intervention group received the education in REDE techniques.
The intervention in this study comprised four components:
Four group education sessions to introduce the REDE principles of eating;
Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;
Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.
Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions.
327415|NCT00573482|Behavioral|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
326761|NCT00583544|Drug|TC-2216|Multiple ascending dose groups will be explored.
326762|NCT00004157|Biological|filgrastim|
326763|NCT00586378|Device|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
326764|NCT00586391|Genetic|CD19CAR-28-zeta T cells|Intravenous injection
Dose Level 1:
CD19CAR-28zeta - 2x10^7 cells/m^2
Dose Level 2:
CD19CAR-28zeta - 1 x10^8 cells/m^2
Dose Level 3:
CD19CAR-28zeta - 2x10^8 cells/m^2
326765|NCT00000609|Device|defibrillators, implantable|
326766|NCT00004169|Procedure|peripheral blood stem cell transplantation|
326767|NCT00586391|Drug|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
326768|NCT00586417|Other|punch biopsy|skin biopsies
326769|NCT00586430|Drug|lorazepam|single 2 mg dose of lorazepam
326770|NCT00586430|Drug|placebo|single dose of placebo
326771|NCT00586443|Drug|bevacizumab, everolimus, panitumumab|Cohort # subjects Bevacizumab Everolimus Panitumumab
3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks
2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks
1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks
3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks
3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD* RPTD* RPTD* 3b 10 RPTD** RPTD** RPTD**
Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. **Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15.
326772|NCT00586469|Biological|Fluviral|One dose, Intramuscular injection
326773|NCT00586482|Drug|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
326774|NCT00586482|Drug|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
327084|NCT00578539|Biological|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
327085|NCT00578539|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
327086|NCT00578552|Drug|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
327087|NCT00000161|Drug|Beta-Carotene|
327088|NCT00000605|Drug|hormone replacement therapy|
326426|NCT00551018|Drug|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
326427|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal (ID)
326428|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal (ID)
326429|NCT00003982|Drug|sabarubicin|
326430|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular (IM)
326431|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular (IM)
326432|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular (IM)
326433|NCT00551044|Drug|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
326434|NCT00551057|Behavioral|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
326435|NCT00553306|Other|flow cytometry|Correlative studies
326436|NCT00553306|Genetic|polymerase chain reaction|Correlative studies
326437|NCT00553319|Drug|Placebo|Placebo group
326438|NCT00553319|Drug|Adderall-XR|Adderall-XR 60mg/day
326439|NCT00553319|Drug|Adderall-XR|Adderall-XR 80mg/day
326440|NCT00553332|Drug|selumetinib|Given orally
326441|NCT00553332|Other|laboratory biomarker analysis|Correlative studies
326442|NCT00553345|Drug|selenium|
326443|NCT00553345|Drug|vitamin E|
326444|NCT00004003|Drug|fluorouracil|
326445|NCT00553345|Procedure|chemoprevention|
326446|NCT00553358|Drug|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
326447|NCT00553358|Biological|Trastuzumab|Therapeutic Monoclonal Antibody
326448|NCT00553358|Drug|Paclitaxel|antimicrotubule agent
325762|NCT00562744|Other|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
325763|NCT00562770|Drug|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
325764|NCT00004056|Drug|thioguanine|
325765|NCT00562770|Drug|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
325766|NCT00562783|Drug|Vitaliver|
325767|NCT00562783|Drug|Placebo|
326105|NCT00558246|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
326106|NCT00004031|Drug|carmustine|
326107|NCT00558246|Device|Suture|Topical Suturing
326108|NCT00558259|Drug|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
326109|NCT00558259|Drug|matching placebo twice daily (BID)|Matching placebo BID
326110|NCT00558272|Drug|AZD0530|Daily oral dose
326111|NCT00558272|Drug|Zoledronic Acid|
326112|NCT00558285|Drug|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
326113|NCT00558285|Drug|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
326114|NCT00558285|Drug|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
326115|NCT00558285|Drug|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
326116|NCT00558298|Drug|risperidone|
326117|NCT00004031|Drug|cyclophosphamide|
326118|NCT00558311|Drug|clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h for the duration of the treatment
326119|NCT00560573|Drug|Cisplatin|Cisplatin 75* mg/m2 or 80* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.
* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine
326120|NCT00560573|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
325435|NCT00570323|Drug|Arimidex with Faslodex|Arimidex with Faslodex
325436|NCT00570323|Drug|Arimidex without Faslodex|Arimidex without Faslodex
325437|NCT00570336|Drug|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
325438|NCT00570336|Other|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
325439|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
325440|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
325441|NCT00004091|Procedure|study of high risk factors|
325442|NCT00570349|Drug|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
325443|NCT00570375|Drug|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
325444|NCT00570388|Drug|Prometa Treatment Program|Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.
Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.
Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN
Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN
Days 4 through 28•Gabapentin 1200 mg po 9 PM
Days 29 through 31•Gabapentin 900 mg po 9 PM
Days 32 through 34•Gabapentin 600 mg po 9 PM
Days 35 through 38•Gabapentin 300 mg po 9 PM
Flumazenil Dosing Schedule
2 mg flumazenil is given as a slow IV push. Subjects in the "placebo group" will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol.
325445|NCT00570401|Drug|dasatinib|
325768|NCT00562809|Drug|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
325769|NCT00562822|Procedure|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
325770|NCT00562822|Other|Physical and medical therapy|Treatment with physical and medical therapy alone
325771|NCT00562835|Drug|Methylprednisolone|Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25*‡ 0.25 mg/kg/day; Days 26 to 28*‡ 0.125 mg/kg/day
*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.
†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.
‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion
352444|NCT00620191|Drug|metformin|metformin 1000 mg twice a day titrated from 500 mg once a day
352445|NCT00620191|Drug|placebo|placebo identical to metformin 2 tablets twice a day titrated from one table once a day
352446|NCT00620204|Drug|atorvastatin|atorvastatin 40mg qd for 1 year
352447|NCT00620217|Genetic|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
352731|NCT00610805|Other|Usual Care|Participants will receive usual care per their primary care physician.
352732|NCT00610818|Other|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
352733|NCT00004265|Drug|paclitaxel|
352734|NCT00610831|Device|DIRECTVIEW CR Mammography|4 views screening mammogram
352735|NCT00610844|Procedure|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
352736|NCT00610857|Drug|Anti-CTLA4 monoclonal antibody and HDI|One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.
Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.
Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months.
352737|NCT00610870|Drug|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
352738|NCT00610883|Drug|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
352739|NCT00612898|Drug|lamivudine|150mg BID lamivudine orally for 48 weeks
352740|NCT00612911|Other|Cell therapy|bone marrow mononuclear cell
352741|NCT00612924|Device|Anaconda Stent Graft System|Endovascular device
352742|NCT00612924|Device|Anaconda ONE-LOK Stent Graft System|Endovascular device
352743|NCT00612950|Drug|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
352744|NCT00004317|Drug|Leucovorin calcium|See arm descriptions
352745|NCT00612950|Drug|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
326546|NCT00562952|Drug|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
326547|NCT00562952|Drug|placebo|no intervention
326548|NCT00562965|Drug|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
326549|NCT00004057|Drug|paclitaxel|
326550|NCT00562965|Drug|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
326551|NCT00562965|Drug|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
326552|NCT00562965|Drug|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
326553|NCT00562965|Drug|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
326554|NCT00562965|Drug|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
326555|NCT00562965|Drug|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
326556|NCT00562965|Drug|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
326557|NCT00562965|Drug|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
326558|NCT00562978|Biological|filgrastim|
326559|NCT00562978|Drug|cyclophosphamide|
326560|NCT00004058|Drug|tetradecanoylphorbol acetate|
326561|NCT00562978|Drug|etoposide|
326878|NCT00558519|Drug|thioguanine|
326879|NCT00558519|Drug|vincristine sulfate|
326880|NCT00558519|Radiation|radiation therapy|
326881|NCT00558532|Procedure|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
326882|NCT00558545|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
326883|NCT00558558|Dietary Supplement|Haelan|4 oz orally twice daily for 8 Weeks
326212|NCT00567996|Drug|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
326213|NCT00567996|Drug|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
326214|NCT00567996|Drug|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
326215|NCT00004086|Drug|ifosfamide|
326216|NCT00567996|Drug|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
326217|NCT00570661|Drug|ITF2357|ITF2357 will be supplied as hard gelatine capsule for oral administration at the dose strengths of 7.5, 10, 12.5, 15, 20 and 50 mg, identifiable by different colours. The dose of 1.5 mg/kg/day will be achieved by administration, at 12-hour interval, of an appropriate number of capsules of definite strength(s) as specified here below
326218|NCT00570674|Drug|Abraxane|Dose will vary depending upon when enrolled on trial. Given as an infusion.
326219|NCT00570674|Drug|Erbitux|One dose is given prior to the start of radiation, then weekly by infusion.
326220|NCT00570674|Drug|Carboplatin|Given weekly as an infusion.
326221|NCT00570674|Radiation|Intensity Modulated Radiation Therapy|Monday through Friday for about seven weeks.
326222|NCT00570687|Drug|Technosphere Insulin|Inhalation 15U/30U
326223|NCT00570700|Drug|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
326224|NCT00570713|Drug|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
326225|NCT00570713|Drug|Placebo|As per package insert.
326226|NCT00004092|Drug|doxorubicin hydrochloride|Given IV
326227|NCT00570713|Drug|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
326228|NCT00570726|Drug|Ranibizumab (Lucentis)|
326229|NCT00570739|Drug|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
326230|NCT00570739|Drug|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
326231|NCT00570739|Drug|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
325546|NCT00580190|Other|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
325547|NCT00580190|Drug|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
325548|NCT00580216|Drug|Idrabiotaparinux sodium|Pre-filled syringes containing:
0.5 mL for the 3.0 mg dosage;
0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);
0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).
Subcutaneous injection
325549|NCT00580216|Drug|Warfarin|Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)
Oral administration
325550|NCT00580216|Drug|Placebo (for idrabiotaparinux)|Matching pre-filled syringes containing:
0.5 mL for the 3.0 mg dosage;
0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);
0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).
Subcutaneous injection
325551|NCT00004138|Radiation|fludeoxyglucose F 18|
325552|NCT00580216|Drug|Placebo (for warfarin)|Warfarin matching capsules
Oral administration
325553|NCT00580216|Drug|Avidin|Vial containing 105 mg of lyophilized powder for dilution
Intravenous infusion for 30 minutes
325892|NCT00575588|Drug|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
325893|NCT00575588|Drug|Saxagliptin|Saxagliptin 5 mg tablets
325894|NCT00575601|Drug|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
325895|NCT00577993|Drug|Cisplatin|25 mg/m^2 IV Days 1 through 4 of 2nd Sequence
325896|NCT00577993|Drug|Ara-C|1.5 gm/m^2 IV Day 5 of 2nd Sequence.
325897|NCT00577993|Drug|Methyl-Prednisolone|500 mg IV Days 1 through 5 of 2nd Sequence.
325898|NCT00577993|Drug|Procarbazine|100 mg/m^2 PO Days 2 through 11 of 3rd Sequence.
325899|NCT00577993|Drug|Prednisone|100 mg PO Days 1 through 5 of 3rd Sequence.
325900|NCT00578006|Behavioral|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
325901|NCT00004128|Biological|filgrastim|
325902|NCT00578006|Behavioral|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
325229|NCT00588445|Drug|Gefitinib|Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.
Patients who have had at least a minor response to gefitinib therapy preoperatively (> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.
Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy.
325230|NCT00588458|Procedure|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
325231|NCT00588471|Drug|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
325232|NCT00588471|Drug|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
325233|NCT00588497|Procedure|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
325234|NCT00588497|Radiation|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
325235|NCT00004175|Drug|doxorubicin hydrochloride|
325236|NCT00588497|Procedure|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
325237|NCT00588497|Radiation|Hysterosalpingogram|Performed 3 months after micro-inserts placement
325238|NCT00588510|Other|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
325239|NCT00588523|Drug|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
325240|NCT00588536|Drug|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
325241|NCT00588536|Drug|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
324641|NCT00276718|Biological|bleomycin sulfate|
324642|NCT00276718|Drug|carboplatin|
324643|NCT00276718|Drug|etoposide|
324644|NCT00276718|Procedure|conventional surgery|
324645|NCT00276731|Drug|carboplatin|
324646|NCT00276731|Drug|cisplatin|
324647|NCT00276731|Drug|cyclophosphamide|
324648|NCT00280111|Biological|116E AGMK|Single dose of 116E 10^5 FFu
324649|NCT00002761|Drug|idarubicin|
324650|NCT00280111|Drug|I321|Single dose of I321 10^5 FFu
324651|NCT00280111|Drug|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
324652|NCT00280150|Biological|bevacizumab|Given IV
324934|NCT00555347|Drug|Armodafinil|Dosage 150-250 mg
324935|NCT00555347|Drug|Placebo|Placebo
324936|NCT00555360|Behavioral|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
324937|NCT00555360|Behavioral|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
324938|NCT00555373|Drug|Sirolimus|Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.
Sirolimus (Rapamune®):
At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours).
324939|NCT00004010|Drug|vinblastine sulfate|
324940|NCT00555386|Dietary Supplement|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
324941|NCT00555399|Drug|Vorinostat|Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.
Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days.
324267|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
324268|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
324269|NCT00286494|Drug|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
324270|NCT00289588|Drug|Mupirocin (drug)|
324271|NCT00000440|Drug|naltrexone (Revia)|
324272|NCT00002786|Biological|therapeutic tumor infiltrating lymphocytes|
324273|NCT00289601|Drug|eptifibatide|
324274|NCT00289614|Drug|Iopamidol 370 mgI/dL|
324275|NCT00289627|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
324276|NCT00289640|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
324277|NCT00289640|Drug|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
324278|NCT00289640|Drug|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
324279|NCT00289653|Drug|Nicoderm|
324280|NCT00289679|Device|Hip prosthesis revision|
324281|NCT00289705|Procedure|Surgery|Laparoscopic Roux-en-Y gastric bypass
324282|NCT00289718|Biological|Twinrix™ adult|Intramuscular administration
324283|NCT00002787|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
324284|NCT00289731|Biological|TWINRIX™|Intramuscular injection, 3 doses
324285|NCT00289731|Biological|Engerix™-B|Intramuscular injection, 3 doses
324286|NCT00289731|Biological|HAVRIX™|Intramuscular injection, 2 doses
324287|NCT00289731|Biological|HB VAX PRO™|Intramuscular injection, 3 doses
324653|NCT00280150|Drug|carboplatin|Given IV
323573|NCT00308373|Drug|Metformin vs Thiazolidinedione (Pioglitazone)|
323574|NCT00308386|Behavioral|Nurse Case Management intervention|Intervention is meeting with nurse case managers
323575|NCT00308399|Drug|Itopride|
323576|NCT00308412|Biological|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
323577|NCT00308412|Biological|Placebo|Placebo for rHPIV3cp45 vaccine
323578|NCT00002835|Biological|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
323579|NCT00308425|Drug|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
323580|NCT00308438|Drug|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
323921|NCT00299052|Biological|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
323922|NCT00299065|Drug|Zileuton injection|
323923|NCT00299091|Drug|Efavirenz capsules 600 mg|Efavirenz capsules 600 mg
323924|NCT00299091|Drug|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
323925|NCT00299104|Drug|folate|Intravenous repeating dose
323926|NCT00299104|Drug|methotrexate|Oral or parenteral repeating dose
323927|NCT00299104|Drug|methylprednisolone|Intravenous repeating dose
323928|NCT00299104|Drug|placebo|Intravenous repeating dose
323929|NCT00299104|Drug|rituximab|Intravenous repeating dose
323930|NCT00299117|Behavioral|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
323931|NCT00000448|Drug|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
323932|NCT00002809|Biological|therapeutic immune globulin|
323933|NCT00299130|Drug|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
323584|NCT00308490|Drug|iron sucrose|
323585|NCT00308503|Drug|eplivanserin (SR46349)|oral administration
323586|NCT00308503|Drug|placebo|oral administration
323587|NCT00308516|Drug|5-Fluorouracil|Combined Modality Treatment:
fluorouracil 225mg/m2 IV continuous infusion days 1-42
Systemic Treatment:
5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15
323588|NCT00308516|Drug|Bevacizumab|Combined Modality Treatment:
bevacizumab 5mg/kg IV infusion days 1, 15, and 29
Systemic Treatment:
bevacizumab 5 mg/kg days 1 and 15
323589|NCT00000456|Drug|naltrexone (Revia)|
323590|NCT00002835|Biological|Recombinant Interferon Alfa|
323591|NCT00308516|Procedure|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
323592|NCT00308516|Drug|Oxaliplatin|Systemic Treatment:
oxaliplatin 85 mg/m2 days 1 and 15
323593|NCT00308516|Drug|Leucovorin|Systemic Treatment:
leucovorin 350 mg prior to FU on days 1 and 15
323594|NCT00308529|Drug|irinotecan|
323595|NCT00308529|Drug|carboplatin|
323596|NCT00308529|Drug|bevacizumab|
323597|NCT00308529|Procedure|Radiation Therapy|
323598|NCT00308542|Drug|dexamethasone|
323599|NCT00308555|Drug|Cannabis|
323600|NCT00308568|Behavioral|Mailed educational brochure|
323601|NCT00002835|Drug|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
323602|NCT00311285|Device|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
323603|NCT00311298|Dietary Supplement|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
323944|NCT00299182|Drug|Vincristine|1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,& 5.
328363|NCT00551707|Drug|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
328364|NCT00551707|Drug|prednisolone|prednisolone (2.7 mg)
328365|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
328366|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
328367|NCT00554177|Drug|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
328368|NCT00554177|Drug|Placebo|2 doses of 1200mg, administered 2-3 days apart
328369|NCT00000583|Biological|hepatitis B vaccines|
323230|NCT00265850|Biological|bevacizumab|Given IV
323231|NCT00265850|Biological|cetuximab|Given IV
323232|NCT00265850|Drug|FOLFOX or|Patients receive oxaliplatin 85 mg/m^2 IV infused over two hours followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus, then 2400 mg/m^2 continuous IV infusion over 46-48 hours
323233|NCT00265850|Drug|FOLFIRI|Patients receive irinotecan 180 mg/m^2 IV infused over 90 minutes followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus following leucovorin then 2400 mg/m^2 continuous IV infusion over 46-48 hours.
323234|NCT00265863|Drug|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
323235|NCT00265876|Drug|AZD0530|Taken daily every 4 weeks
323236|NCT00265876|Drug|gemcitabine hydrochloride|1000mg/m2 IV weekly
323237|NCT00002711|Drug|cisplatin|
323238|NCT00265889|Biological|filgrastim|480 mcg beginning day +5
323239|NCT00265889|Drug|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
323240|NCT00265889|Drug|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
323241|NCT00265889|Drug|etoposide|60 mg/kg, IV
323242|NCT00265889|Drug|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
328055|NCT00559169|Drug|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
328056|NCT00559182|Drug|Comparator: MK-8033|MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at ~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).
Enrollment in Parts A and B has been completed.
328057|NCT00559182|Drug|Comparator: MK-8033 +/- omeprazole|Part C will occur at only one of the investigational sites.
In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.
Enrollment for Part C has been suspended.
328058|NCT00004033|Drug|liposomal NDDP|
328059|NCT00559195|Biological|epoetin beta|
328060|NCT00559195|Procedure|quality-of-life assessment|
328061|NCT00559221|Drug|FLAG+IDA|Fludarabine, cytarabine, G-CSF
328062|NCT00559247|Drug|BMS-650032 or Placebo|Oral, Once daily, Single Dose
328063|NCT00559260|Device|Passive monitoring with pulse-oximetry, NIBP and ECG|
328064|NCT00559273|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|1.2 micrograms/kg sc monthly, starting dose
328065|NCT00559273|Drug|Darbepoetin alfa|0.45 micrograms/kg sc weekly, starting dose
328066|NCT00559286|Drug|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
328067|NCT00559299|Drug|GSK163090|
328068|NCT00559312|Drug|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
328069|NCT00004033|Procedure|therapeutic thoracoscopy|
328070|NCT00561327|Drug|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
328370|NCT00004006|Drug|doxorubicin hydrochloride|
328371|NCT00554190|Device|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
328372|NCT00554190|Device|Merogel Injectable|Bioresorbable hyaluronic acid product
327416|NCT00573495|Biological|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
327417|NCT00573508|Drug|Placebo|Oral Administration
327418|NCT00573508|Drug|Solifenacin Succinate|Oral Administration
327419|NCT00573534|Drug|lisdexamfetamine|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
327420|NCT00573534|Drug|Lisdexamfetamine|Lisdexamfetamine capsules 30-70 mgs per day titrated by efficacy and tolerability for up to six months
327421|NCT00573547|Drug|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
327740|NCT00566098|Biological|therapeutic autologous lymphocytes|
327741|NCT00566098|Biological|therapeutic tumor infiltrating lymphocytes|
327742|NCT00566098|Drug|melphalan|
327743|NCT00004074|Biological|recombinant interleukin-12|Given IV
327744|NCT00566098|Procedure|autologous hematopoietic stem cell transplantation|
327745|NCT00566111|Drug|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
327746|NCT00566111|Drug|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
327747|NCT00566124|Drug|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
327748|NCT00566124|Drug|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
327749|NCT00566124|Drug|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
327750|NCT00566150|Drug|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
327751|NCT00566150|Drug|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
327752|NCT00566176|Device|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
327753|NCT00566189|Procedure|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
327754|NCT00004074|Biological|ABI-007/carboplatin/trastuzumab|Given IV
327089|NCT00004128|Radiation|radiation therapy|
327090|NCT00578552|Drug|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
327091|NCT00578552|Drug|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
327092|NCT00580736|Device|Optical Clearing|Optical Clearing
327093|NCT00580749|Procedure|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
327094|NCT00580749|Procedure|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
327095|NCT00580762|Procedure|Roux-en-y gastric bypass (RYGB)|Procedure is done laparoscopically while subject is anticipating renal transplant.
327096|NCT00580788|Drug|PTHrP (1-36)|IND # 49,175
327097|NCT00580801|Drug|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
327098|NCT00580801|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
327099|NCT00580801|Drug|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
327100|NCT00580801|Drug|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
327101|NCT00004142|Drug|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
327102|NCT00580814|Drug|Methylphenidate|Methylphenidate
327103|NCT00580827|Drug|Placebo|Matched placebo.
327104|NCT00580827|Drug|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
327105|NCT00580827|Drug|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
327106|NCT00580827|Drug|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
327422|NCT00573560|Device|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
327423|NCT00004103|Drug|irinotecan hydrochloride|
327424|NCT00573573|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
327425|NCT00573586|Device|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
326775|NCT00586482|Behavioral|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
326776|NCT00586495|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
326777|NCT00004169|Radiation|radiation therapy|
326778|NCT00586508|Drug|enzastaurin|1125 mg loading dose then 500 or 875 mg, oral, daily, 4 week cycles with patients evaluated after each cycle. The dose difference is for patients who are on enzyme-inducing antiepileptic drugs versus non-enzyme inducing antiepileptic drugs.
326779|NCT00586508|Drug|bevacizumab|10mg/kg, IV, every 2 weeks, patients are evaluated after each cycle
326780|NCT00586521|Drug|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
326781|NCT00586534|Behavioral|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
326782|NCT00586534|Behavioral|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
326783|NCT00586547|Drug|Ara-C|Day -8,-7,-6, and-5:
(3g/m2) IV every 12 hours for 6 doses
326784|NCT00586547|Drug|Cyclophosphamide|Days -7 and -6:
Intravenous 45mg/kg
326785|NCT00589121|Radiation|intensity-modulated radiation therapy|Performed preoperatively once daily, 5 days a week, for 4½-5 weeks
326786|NCT00589134|Dietary Supplement|Gatorade Endurance Formula|carbohydrate electrolyte beverage
326787|NCT00589134|Other|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
326788|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
326789|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
326790|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
326791|NCT00589173|Behavioral|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
326792|NCT00589173|Behavioral|"Standard" preventive care|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
326793|NCT00589186|Biological|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
326121|NCT00560573|Drug|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
326122|NCT00560586|Drug|Budesonide|1 ouff each nostril (32 micrograms) at bedtime
326123|NCT00560599|Drug|mupirocin and chlorhexidine|Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.
Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.
326124|NCT00560599|Behavioral|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
326125|NCT00560599|Drug|mupirocin, chlorhexidine, & household cleaning/disinfection|Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.
Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.
Environmental cleaning with topical ethanol and laundering of clothes and linen.
326126|NCT00004045|Drug|exatecan mesylate|
326449|NCT00553371|Other|biomarker analysis|
326450|NCT00553371|Procedure|computed tomography|
326451|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
326452|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
326453|NCT00553423|Drug|Lactulose|Lactulose 30 ml q6h for 48 hrs
326454|NCT00553423|Drug|Placebo|Placebo 30 ml q6hrly for 48 hrs
326455|NCT00000582|Drug|factor ix|
326456|NCT00004003|Drug|gemcitabine hydrochloride|
326457|NCT00553436|Device|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
326458|NCT00553449|Drug|rabeprazole|
326459|NCT00553462|Drug|carboplatin|
326460|NCT00553462|Drug|erlotinib hydrochloride|
326461|NCT00553462|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
326462|NCT00553462|Radiation|radiation therapy|
326463|NCT00553475|Drug|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
325772|NCT00565201|Drug|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
325773|NCT00565214|Dietary Supplement|Vitamin C, Vitamin E, Selenium|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
325774|NCT00565214|Dietary Supplement|Placebo|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
325775|NCT00565227|Drug|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
325776|NCT00565227|Drug|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
325777|NCT00565240|Drug|Marvelon|oral contraceptive
325778|NCT00565240|Drug|Nuvaring|contraceptive vaginal ring
325779|NCT00004068|Drug|temozolomide|
325780|NCT00565240|Drug|Letrozole|Aromatase Inhibitors
325781|NCT00565253|Drug|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
325782|NCT00565266|Drug|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
325783|NCT00565266|Drug|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
325784|NCT00565266|Drug|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
325785|NCT00565279|Drug|ASF1057|Twice daily, topical
325786|NCT00565279|Drug|ASF1057|Twice daily, Topical
353643|NCT00627380|Behavioral|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
353644|NCT00629668|Genetic|TNF-alpha and HBV genotype|
353645|NCT00629668|Other|TNF-alpha and HBV genotypes|
352746|NCT00612950|Drug|Saline|continuous infusion of Saline for 120 min
352747|NCT00612963|Drug|Frio Oral Rinse|Prescription Mouth Rinse
352748|NCT00612989|Drug|Temodar and O6-Benzylguanine|O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.
Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle & every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.
Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar & continue fasting 2 hrs after administration of each Temodar dose.
352749|NCT00613002|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
352750|NCT00613002|Drug|placebo gel|once daily transdermal placebo gel
353024|NCT00603031|Other|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
353025|NCT00603031|Other|NaCl|infusion with NaCl for 120 minutes as placebo-arm
353026|NCT00603031|Other|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
353027|NCT00603044|Drug|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
353028|NCT00004231|Drug|busulfan|
353029|NCT00603070|Other|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
353030|NCT00603070|Other|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
353031|NCT00605748|Procedure|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
353032|NCT00004238|Drug|pralatrexate|
353033|NCT00605748|Procedure|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
353034|NCT00605761|Drug|SB656933|50 mg treatment
353035|NCT00605761|Drug|SB656933|150 mg treatment
353036|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
353037|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
353038|NCT00605787|Drug|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
326884|NCT00558571|Drug|BI 10773 low dose|
326885|NCT00558571|Drug|placebo to BI 10773|
326886|NCT00558571|Drug|BI 10773 medium dose|
326887|NCT00000589|Procedure|platelet transfusion|
326888|NCT00004031|Drug|vincristine sulfate|
326889|NCT00558571|Drug|BI 10773 high dose|
326890|NCT00558584|Device|protein A immunoadsorption|protein-A immunoadsorption and i.v. IgG substitution
326891|NCT00558584|Device|pseudo-immunoadsorption|pseudo-immunoadsorption followed by an intravenous infusion without IgG
326892|NCT00558623|Dietary Supplement|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
326893|NCT00558636|Drug|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
326894|NCT00558636|Drug|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
326895|NCT00558649|Biological|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
326896|NCT00558662|Device|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
326897|NCT00558662|Device|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
326898|NCT00558675|Biological|AlloStim|single intravenous infusion of 1 x 10^9 AlloStim cells
326899|NCT00004031|Procedure|bone marrow ablation with stem cell support|
327206|NCT00551213|Drug|FOLFOX|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
327207|NCT00551213|Drug|CAPEOX/XELOX|Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
327208|NCT00551213|Drug|FOLFIRI|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
327209|NCT00551239|Biological|rituximab|Given IV
326232|NCT00570739|Drug|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
326233|NCT00570752|Other|Placebo|
326234|NCT00570752|Drug|BMS-582949|
326562|NCT00562978|Procedure|autologous hematopoietic stem cell transplantation|
326563|NCT00562978|Procedure|peripheral blood stem cell transplantation|
326564|NCT00562978|Radiation|yttrium Y 90 ibritumomab tiuxetan|
326565|NCT00562991|Device|measurement of exhaled NO is used to guide treatment|exhaled NO
326566|NCT00563004|Dietary Supplement|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
326567|NCT00563004|Dietary Supplement|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
326568|NCT00563017|Drug|Long-acting Risperidone microspheres injection|
326569|NCT00563043|Procedure|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
326570|NCT00563056|Drug|Flutiform|
326571|NCT00565500|Drug|placebo|placebo capsules tid for 1 week
326572|NCT00565513|Procedure|blood test|cord blood and maternal milk test
326573|NCT00565539|Drug|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
326574|NCT00565552|Drug|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
326575|NCT00565565|Drug|BAY60-4552|Single dose escalation starting with 1 mg
326576|NCT00004071|Drug|leflunomide|
326577|NCT00565591|Drug|Albuterol sulfate|Single dose dry powder by inhalation
326578|NCT00565604|Device|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
326579|NCT00565617|Device|Electroconvulsive therapy (ECT)|Naturalistic follow up of ECT outpatient maintenance therapy with/without psychotropic medications
326580|NCT00565617|Device|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
325903|NCT00578019|Procedure|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith & Nephew supracondylar nail.
325904|NCT00578019|Procedure|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
325905|NCT00578032|Behavioral|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
325906|NCT00578045|Procedure|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
325907|NCT00578058|Other|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
325908|NCT00578071|Drug|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
325909|NCT00578071|Drug|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
325910|NCT00578071|Drug|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
325911|NCT00578071|Radiation|Radiation Therapy (RT)|Daily for 6 weeks
325912|NCT00004128|Drug|busulfan|
325913|NCT00578097|Drug|Botulinum type A (Dysport®)|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
326235|NCT00570752|Drug|Atorvastatin|
326236|NCT00570752|Drug|Statin|
326237|NCT00004092|Drug|paclitaxel|Given IV
326238|NCT00570765|Drug|Placebo|Placebo
326239|NCT00570765|Drug|INT-747|10 mg po qd
326240|NCT00570765|Drug|INT-747|50 mg po qd
326241|NCT00570778|Drug|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
326242|NCT00570778|Drug|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
326243|NCT00570778|Drug|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
325242|NCT00588536|Drug|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
325554|NCT00582842|Behavioral|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
325555|NCT00582842|Behavioral|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
325556|NCT00582855|Drug|AQW051|
325557|NCT00582855|Drug|Placebo|
325558|NCT00582868|Device|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
325559|NCT00004152|Procedure|computed tomography|
325560|NCT00582868|Other|CSF|analysis of CSF for cleaved tau protein
325561|NCT00582868|Other|Whole blood|Analysis of whole blood for cleaved-tau protein
325562|NCT00582894|Drug|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
325563|NCT00582907|Drug|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
325564|NCT00582907|Drug|Placebo|placebo by subcutaneous injection weekly for 3 months
325565|NCT00582920|Radiation|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
325566|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.
The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction.
324942|NCT00555399|Drug|Isotretinoin|Phase I/Arm 1: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.
Phase I/Arm 2: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.
Phase I/Arm 3: Level -II = 100 mg/m^2/day PO x 21 days; Level -I = 100 mg/m^2/day PO x 21 days; Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.
324943|NCT00555399|Procedure|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
324944|NCT00555399|Drug|Temozolomide|Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.
Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days.
324945|NCT00555412|Drug|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
324946|NCT00555412|Drug|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
324947|NCT00555412|Drug|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
324948|NCT00555412|Drug|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
324949|NCT00557817|Drug|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to > 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases < 13 g/dL. If the Hb decreases to < 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
325243|NCT00591149|Drug|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
325244|NCT00591149|Drug|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
325245|NCT00591149|Drug|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
325246|NCT00004188|Biological|filgrastim|Given IV
325247|NCT00591162|Drug|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
325248|NCT00591162|Radiation|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
325249|NCT00591162|Procedure|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
325250|NCT00591175|Behavioral|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
324654|NCT00280150|Drug|erlotinib hydrochloride|Given orally
324655|NCT00280150|Drug|paclitaxel|Given IV
324656|NCT00280150|Radiation|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
324657|NCT00280176|Drug|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
324658|NCT00280176|Drug|fluorouracil|225mg/m2 given weekly, up to 6 weeks
324659|NCT00280176|Radiation|radiation therapy|180 cGy, every 5 days, up to six weeks
324660|NCT00002761|Procedure|peripheral blood stem cell transplantation|
324661|NCT00280189|Procedure|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
324662|NCT00280189|Behavioral|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
324663|NCT00280189|Behavioral|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
324664|NCT00280202|Procedure|Biopsy of the major carinal area|Biopsy performed intraoperatively
324665|NCT00280202|Procedure|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
324666|NCT00280202|Procedure|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
324667|NCT00280202|Procedure|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
324668|NCT00280202|Procedure|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
324669|NCT00280202|Procedure|Analysis of lymph nodes|Tissues banked for future analysis
324670|NCT00280215|Drug|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
324671|NCT00002762|Behavioral|patient interviewing to obtain menstrual history|
324672|NCT00280215|Drug|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
323934|NCT00299130|Drug|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
323935|NCT00299130|Drug|Methylprednisolone|Intravenous infusion
323936|NCT00299130|Drug|Placebo|Placebo to rituximab intravenous infusion
323937|NCT00299130|Drug|Rituximab|Intravenous infusion
323938|NCT00299156|Drug|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
323939|NCT00299169|Behavioral|N of 1 Trials|N of 1 Trials of statin therapy
323940|NCT00299182|Drug|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
323941|NCT00299182|Drug|Rituximab|375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.
323942|NCT00299182|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, & 5.
323943|NCT00002809|Drug|cyclophosphamide|
324288|NCT00289731|Biological|Vaqta™|Intramuscular injection, 2 doses
324289|NCT00289744|Biological|TWINRIX™ ADULT|2 doses IM injection in primary study
324290|NCT00289744|Biological|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
324291|NCT00289757|Biological|Havrix™|2 doses at 6 months interval
324292|NCT00289770|Biological|Twinrix™|Intramuscular injection, 3 doses
324293|NCT00289783|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
324294|NCT00002787|Biological|sargramostim|Given SC
324295|NCT00289783|Biological|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
324296|NCT00289783|Biological|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
324297|NCT00289783|Biological|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
323945|NCT00299182|Drug|Doxorubicin|50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,& 5.
323946|NCT00302185|Procedure|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
323947|NCT00302185|Behavioral|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
323948|NCT00302198|Behavioral|ALS Registry|
323949|NCT00302211|Drug|Iloprost Inhalation Solution (Ventavis)|iloprost inhalation solution (Ventavis) (5 mcg) 6×/day
323950|NCT00302211|Drug|Iloprost Inhalation Solution (Ventavis)|iloprost inhalation solution (Ventavis) (5 mcg) 4×/day
323951|NCT00302211|Drug|Inhaled Placebo|inhaled placebo 6×/day (5 mcg)
323952|NCT00302211|Drug|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
323953|NCT00002816|Radiation|low-LET cobalt-60 gamma ray therapy|
323954|NCT00302211|Drug|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
323955|NCT00302224|Drug|2S, 4R Ketoconazole (DIO-902)|
323956|NCT00302237|Device|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
323957|NCT00302250|Drug|ALT-711 (alagebrium chloride)|
323958|NCT00302263|Drug|Metobes-compound|
323959|NCT00302276|Drug|Metobes-compound|
323960|NCT00302289|Drug|tyrosine, green tea, caffeine|
323961|NCT00302302|Drug|L-arabinose|
323962|NCT00302315|Device|transcutaneous electrical nerve stimulation|
323963|NCT00302328|Procedure|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
323964|NCT00002816|Radiation|low-LET electron therapy|
323965|NCT00302341|Drug|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
323243|NCT00269191|Drug|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
323244|NCT00269191|Drug|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
323245|NCT00269204|Drug|niacin (+) laropiprant|Duration of Treatment - 24 weeks
323246|NCT00269204|Drug|ER-niacin|Duration of Treatment - 24 weeks
323247|NCT00002719|Biological|filgrastim|
323248|NCT00269217|Drug|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
323249|NCT00269217|Drug|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
323250|NCT00269217|Drug|Comparator: simvastatin|Duration of Treatment 12 Weeks
323251|NCT00269230|Device|Pacing Lead|Left ventricular pacing lead
323252|NCT00269243|Drug|Quinapril|
323253|NCT00269269|Drug|antihypertensive drug|
323254|NCT00269269|Behavioral|placebo|
323604|NCT00311298|Dietary Supplement|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
323605|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
323606|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
328373|NCT00554203|Drug|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
328374|NCT00554216|Drug|VI-0521|3.75 mg phentermine/23 mg topiramate
328375|NCT00554216|Drug|VI-0521|15 mg phentermine/92 mg topiramate
328376|NCT00554216|Drug|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
328377|NCT00554229|Drug|ZD4054|ZD4054 10 mg oral tablet once daily
328378|NCT00554229|Drug|Placebo|Matching placebo oral tablet once daily
328379|NCT00554242|Dietary Supplement|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
328380|NCT00554255|Drug|SB751689|
328381|NCT00004006|Drug|etoposide|
328382|NCT00554268|Drug|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
328383|NCT00554281|Device|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
328384|NCT00554294|Behavioral|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
328385|NCT00554307|Device|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
328386|NCT00554320|Procedure|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
328387|NCT00554320|Procedure|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
328388|NCT00554333|Biological|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
328389|NCT00556621|Radiation|radiation therapy|
328390|NCT00556634|Drug|Efavirenz|Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)
OR
Efavirenz usual dosage (600 mg/day from the first day)
328391|NCT00556647|Procedure|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
323255|NCT00269282|Behavioral|Self-Management Training|Asthma education and self-monitoring strategies
327755|NCT00566202|Drug|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
327756|NCT00566202|Drug|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
327757|NCT00568503|Drug|QAX028|
327758|NCT00568503|Drug|Placebo|
327759|NCT00568503|Drug|Tiotropium bromide|
327760|NCT00568503|Drug|QAX028|
327761|NCT00568503|Drug|QAX028|
327762|NCT00568516|Drug|ASP3550|subcutaneous administration
327763|NCT00568529|Drug|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
328071|NCT00561340|Dietary Supplement|Pediasure|50% will be randomized to pediasure with nutritional counseling
328072|NCT00561340|Behavioral|Nutritional counseling|50% randomized to nutritional counseling only
328073|NCT00561353|Drug|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
328074|NCT00561353|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
328075|NCT00004050|Biological|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
328076|NCT00561353|Drug|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
328077|NCT00561353|Drug|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
328078|NCT00561366|Drug|Placebo|Placebo t.i.d.
328079|NCT00561366|Drug|Arimoclomol|capsule, 400 mg t.i.d.
328080|NCT00561379|Drug|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
328081|NCT00561379|Drug|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
328082|NCT00561392|Drug|Rivastigmine 5 and 10 cm^2 patch|
327426|NCT00573599|Drug|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
327427|NCT00573599|Drug|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
327428|NCT00573612|Behavioral|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
327429|NCT00573612|Behavioral|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
327430|NCT00573638|Device|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
327431|NCT00573651|Other|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
327432|NCT00573664|Drug|Gabapentin|single oral dose of 600mg gabapentin
327433|NCT00573664|Other|lactose|Single dose
327434|NCT00004103|Procedure|adjuvant therapy|
327435|NCT00573690|Drug|carboplatin|Given IV
327436|NCT00573690|Drug|cisplatin|Given IV
327437|NCT00573690|Drug|etoposide|Given IV
327438|NCT00576199|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
327439|NCT00576199|Procedure|Transarterial chemoembolisation (TACE)|TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.
Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE.
327440|NCT00576212|Behavioral|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
327441|NCT00004114|Procedure|peripheral blood stem cell transplantation|
327764|NCT00004087|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
327765|NCT00568542|Drug|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
326794|NCT00004177|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
326795|NCT00589186|Drug|celecoxib|
327107|NCT00580840|Drug|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
327108|NCT00580840|Drug|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
327109|NCT00580840|Other|Placebo|placebo (saline) administered as two injections every 2 weeks
327110|NCT00580853|Drug|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
327111|NCT00580853|Drug|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
327112|NCT00000606|Procedure|Lung volume reduction surgery|
327113|NCT00004142|Drug|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
327114|NCT00580853|Drug|Placebo|Placebo
327115|NCT00580866|Device|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
327116|NCT00580892|Device|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
327117|NCT00580905|Drug|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
327118|NCT00583557|Drug|belimumab|IV 10mg/kg Q28 days
327119|NCT00583570|Behavioral|dietary education|dietary education
327120|NCT00583583|Device|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
327121|NCT00583596|Device|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
327122|NCT00583596|Other|Objective Performance Criteria|Compare results of device closure to objective performance criteria
327123|NCT00583609|Drug|PEG3350|PEG3350
327124|NCT00583622|Drug|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
327125|NCT00583622|Drug|Carboplatin|333 mg/m^2 by vein over 2 hours for 3 Days
326464|NCT00553475|Drug|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
326465|NCT00553475|Drug|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
326466|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
326467|NCT00555932|Procedure|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
326468|NCT00004013|Biological|trastuzumab|
326469|NCT00555945|Procedure|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
326470|NCT00555945|Procedure|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
326471|NCT00555958|Device|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
326796|NCT00589186|Other|flow cytometry|
326797|NCT00589186|Other|immunoenzyme technique|
326798|NCT00589186|Other|laboratory biomarker analysis|
326799|NCT00589199|Procedure|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
326800|NCT00589212|Device|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
326801|NCT00589225|Genetic|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
326802|NCT00589238|Drug|carboplatin|
326803|NCT00589238|Drug|cyclophosphamide|
326804|NCT00589238|Drug|doxorubicin hydrochloride|
326805|NCT00004178|Biological|therapeutic autologous lymphocytes|
353646|NCT00629681|Drug|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
353647|NCT00629694|Procedure|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
353648|NCT00629694|Procedure|A-M|adenoidectomy and myringotomy alone
353649|NCT00629707|Other|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
353650|NCT00629720|Drug|alfuzosin (SL770499)|
353651|NCT00629733|Drug|RO-14|
353652|NCT00629746|Device|Medtronic Xomed Nerve Integrity Monitor (NIM)|patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system
The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor
A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.
The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.
The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen.
353653|NCT00004652|Drug|pimozide|
353654|NCT00629759|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
353655|NCT00629772|Drug|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
353656|NCT00629772|Drug|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
353657|NCT00629798|Drug|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients > or = to 4 years of age or 1.0 mg/kg IV for patients < 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
353658|NCT00629811|Drug|Avotermin (Juvista)|Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:
Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)
Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)
Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds.
353039|NCT00605800|Other|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
353040|NCT00605800|Other|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
353041|NCT00605813|Drug|Sertraline hydrochloride|J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.
Dosage, Frequency: According to Japanese LPD, "The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms".
Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration.
353042|NCT00605826|Device|NASHA/Dx Injectable Gel|Injection of 4 x 1ml of NASHA/Dx Gel
353043|NCT00004239|Drug|Compound 506U78|
353329|NCT00595361|Drug|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
353330|NCT00595374|Drug|insulin detemir|
353331|NCT00595374|Drug|insulin NPH|
353332|NCT00595374|Drug|insulin aspart|
353333|NCT00595387|Other|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
353334|NCT00597935|Procedure|SSLF|sacrospinous ligament fixation (SSLF)
353335|NCT00597935|Procedure|ULS|uterosacral vaginal vault ligament suspension (ULS)
353336|NCT00597935|Behavioral|PMT|Pelvic muscle training and exercises (PMT)
353337|NCT00597948|Behavioral|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
353338|NCT00597974|Procedure|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
353339|NCT00597974|Device|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson & Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson & Johnson), Wallstent® (Boston Scientific Medi-Tech)
353340|NCT00597974|Other|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
353341|NCT00597974|Procedure|Angiography|(non-experimental) Coronary angiography
327210|NCT00551239|Drug|fludarabine phosphate|Given IV
327211|NCT00551239|Drug|pixantrone dimaleate|Given IV
327212|NCT00003991|Drug|histamine dihydrochloride|
327213|NCT00551252|Drug|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
327214|NCT00553592|Drug|Bicifadine|600mg/day
327215|NCT00553592|Drug|Bicifadine|placebo tablet
327216|NCT00553592|Drug|Bicifadine|1200 mg
327217|NCT00553605|Drug|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
327218|NCT00004005|Drug|irinotecan hydrochloride|
327219|NCT00553605|Drug|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
327220|NCT00553618|Drug|Proleukin and Dacarbazine|IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.
Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks.
327221|NCT00553631|Biological|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
327222|NCT00553631|Biological|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
327223|NCT00553644|Drug|Bortezomib|Given IV
327224|NCT00553644|Other|Laboratory Biomarker Analysis|Correlative studies
327225|NCT00553644|Drug|Lenalidomide|Given PO
327226|NCT00553657|Drug|DETROL LA (drug)|
327227|NCT00553683|Drug|cyclophosphamide|
327228|NCT00553683|Drug|poly ICLC|
327229|NCT00004005|Drug|leucovorin calcium|
327230|NCT00553683|Procedure|hepatic artery embolization|
326581|NCT00565630|Device|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
326582|NCT00565643|Device|modified sodium hyaluronic acid and carboxymethylcellulose (Seprafilm Adhesion Barrier)|Adhesion barrier applied at the time of initial cesarean delivery
326583|NCT00565643|Device|Placebo|Routine abdominal closure without placement of adhesion barrier
326584|NCT00565656|Drug|BEVACIZUMAB|Administration of Bevacizumab
326585|NCT00565669|Drug|Cyclosporin A Restasis®|systane to be used twice a day for the duration of the study
326900|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7
326901|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14
326902|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21
326903|NCT00560898|Drug|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
326904|NCT00560898|Drug|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
326905|NCT00560911|Behavioral|educational program for the self-management of OAC|Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.
After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly.
326906|NCT00004048|Drug|doxorubicin hydrochloride|
326907|NCT00560911|Behavioral|1 hour education - afterwards physician leaded OAC control|Patients in the routine control group participated a single 90-minute session
During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic.
326908|NCT00560924|Drug|estradiol, 25 mcg|
326909|NCT00560937|Drug|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
326910|NCT00560937|Drug|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
326911|NCT00560950|Biological|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
326912|NCT00560963|Drug|everolimus|
326244|NCT00572975|Other|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.
in breakfast shake x1
326245|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
326246|NCT00573001|Drug|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
326247|NCT00573001|Drug|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
326248|NCT00004101|Biological|apolizumab|
326249|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
326250|NCT00573014|Procedure|Cervical spine clearance|Cervical spine clearance
326251|NCT00573027|Procedure|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
326252|NCT00573053|Other|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
326253|NCT00573053|Other|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
326254|NCT00573066|Drug|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
326255|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
326256|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
326586|NCT00565682|Drug|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
326587|NCT00004071|Drug|mitoxantrone hydrochloride|
326588|NCT00565695|Device|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
326589|NCT00565708|Other|placebo|Placebo Comparator
326590|NCT00565708|Drug|Acetylsalicylic acid|Adjuvant Therapy
326591|NCT00565721|Drug|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
326592|NCT00565747|Device|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
325914|NCT00578097|Other|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
325915|NCT00578110|Device|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
325916|NCT00578123|Behavioral|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
325917|NCT00578136|Drug|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
325918|NCT00578149|Drug|Bevacizumab|
325919|NCT00580216|Drug|Placebo (for avidin)|Vial containing 105 mg of matching lyophilized powder for dissolution
Intravenous infusion for 30 minutes
325920|NCT00580229|Drug|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
325921|NCT00580242|Drug|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
325922|NCT00580242|Drug|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
325923|NCT00580242|Drug|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
325924|NCT00580242|Drug|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
325925|NCT00580281|Other|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
325926|NCT00580294|Drug|Oxymorphone|IV PO
325927|NCT00004139|Drug|docetaxel|
325928|NCT00580307|Procedure|Septoplasty|Surgical straightening of nasal septum
325929|NCT00580307|Procedure|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
325930|NCT00580320|Drug|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
325931|NCT00580333|Drug|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
325251|NCT00591175|Behavioral|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
325252|NCT00591175|Behavioral|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
325253|NCT00591188|Drug|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
325254|NCT00591201|Drug|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
325255|NCT00591201|Drug|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
325256|NCT00591214|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
325257|NCT00004188|Drug|carboplatin|Given IV
325258|NCT00591227|Drug|insulins aspart and detemir|insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER. If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.
325259|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
325260|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
325261|NCT00591253|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
325567|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.
The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction.
325568|NCT00585819|Procedure|Freebreathing in Body fix mold|Freebreathing in Body fix mold
325569|NCT00004165|Procedure|peripheral blood stem cell transplantation|
325570|NCT00585832|Behavioral|DASH-4-Teens|24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
324673|NCT00280215|Drug|Placebo|Patients will receive placebo for 24 months
324950|NCT00557817|Drug|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin > 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS > 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation < 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
324951|NCT00004029|Biological|recombinant viral vaccine therapy|
324952|NCT00557830|Drug|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
324953|NCT00557830|Drug|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
324954|NCT00557843|Drug|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
324955|NCT00557843|Drug|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
324956|NCT00557856|Drug|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
324957|NCT00557882|Device|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
324958|NCT00557908|Drug|VWF/FVIII products|Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)
Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.
Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses
324959|NCT00557921|Drug|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
324960|NCT00557921|Drug|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
324961|NCT00557934|Other|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
324962|NCT00000588|Drug|chelation therapy|
324963|NCT00004029|Biological|sargramostim|
324298|NCT00289783|Biological|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
324299|NCT00292695|Other|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12
324300|NCT00292708|Drug|Cefmetazole (drug)|
324301|NCT00292721|Drug|Celecoxib|celecoxib: loading and maintenance for 6 months
324302|NCT00292734|Drug|Zolpidem|
324303|NCT00292747|Drug|Drotaverine|
324304|NCT00292760|Drug|Alemtuzumab|
324305|NCT00002796|Drug|sodium phenylbutyrate|Given IV
324306|NCT00292760|Drug|Methyprednisolone|
324307|NCT00292773|Procedure|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
324308|NCT00292786|Behavioral|Walking Practice with Functional Electrical Stimulation|
324309|NCT00292786|Behavioral|Walking Practice|
324674|NCT00282776|Behavioral|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
324675|NCT00282776|Behavioral|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
324676|NCT00282789|Device|bilevel positive airway pressure|
324677|NCT00282789|Device|bilevel positive airway pressure (Device)|
324678|NCT00282815|Device|continuous positive airway pressure or CPAP|RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
324679|NCT00282815|Device|sham CPAP|sham CPAP
323966|NCT00302341|Drug|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
324310|NCT00292799|Drug|Orlistat Vs Metformin|
324311|NCT00292812|Drug|Nutritional supplementation (nucleotides)|
324312|NCT00292825|Device|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
324313|NCT00292825|Device|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
324314|NCT00292838|Drug|fluticasone 25, 50, 100, 200 mcg|
324315|NCT00292864|Drug|SNS-032 Injection|
324316|NCT00002796|Drug|indomethacin|Given orally
324317|NCT00292877|Drug|SB-240563 (Mepolizumab)|
324318|NCT00292890|Device|insulin needle|
324319|NCT00292903|Behavioral|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
324320|NCT00292903|Behavioral|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
324321|NCT00292916|Behavioral|whole body vibration|
324322|NCT00292916|Behavioral|resistance exercise|
324323|NCT00292916|Behavioral|"wellness"|
324324|NCT00292929|Drug|Intravenous artesunate|
324325|NCT00292942|Drug|Intravenous artesunate|
324326|NCT00292955|Drug|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
324327|NCT00295997|Drug|methotrexate|
324328|NCT00295997|Drug|mycophenolate mofetil|
324329|NCT00295997|Drug|tacrolimus|
324330|NCT00002802|Radiation|low-LET electron therapy|
324331|NCT00295997|Procedure|allogeneic bone marrow transplantation|
323607|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
323608|NCT00311311|Drug|sirolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.
On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant.
323609|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
323610|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
323611|NCT00002701|Procedure|allogeneic bone marrow transplantation|
323612|NCT00262873|Drug|bortezomib|
323613|NCT00262886|Biological|anti-thymocyte globulin|
323614|NCT00262886|Biological|graft-versus-tumor induction therapy|
323967|NCT00302354|Drug|OROS methylphenidate HCl|
323968|NCT00302354|Drug|SODAS methylphenidate HCl|
323969|NCT00302367|Drug|OROS methylphenidate hydrochloride|
323970|NCT00302367|Drug|immediate release methylphenidate hydrochloride|
323971|NCT00302380|Radiation|PET imaging using C-11 altropane as the ligand.|A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
323972|NCT00305539|Drug|placebo|placebo
323973|NCT00305552|Drug|THALIDOMIDE|THALIDOMIDE
323974|NCT00305565|Device|VNS Therapy|Received output current of 0.25 milliamps (mA)
323256|NCT00269282|Behavioral|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
323257|NCT00269295|Biological|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10^7 cfu, 5 X 10^8 cfu, and 5 X 10^9 cfu.
323258|NCT00000136|Drug|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
323259|NCT00000423|Behavioral|Social support group|
323260|NCT00002719|Drug|amsacrine|
323261|NCT00269295|Drug|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
323262|NCT00269308|Procedure|Chiropractic Manual treatment + home exercise ( procedure+behavior)|The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.
Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active
323263|NCT00269308|Procedure|Supervised rehabilitative exercise + home exercise|The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.
Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active
323264|NCT00269308|Behavioral|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
323265|NCT00272558|Drug|Carboplatin and Vinorelbine|
323266|NCT00272571|Procedure|External counter pulsation therapy|
323267|NCT00272584|Drug|Risperidone|
323268|NCT00002737|Drug|chemotherapy|
323269|NCT00272597|Drug|Risperidone|See Detailed Description.
323270|NCT00272610|Drug|0.4% Retinol Cream|
323271|NCT00272623|Procedure|Seldinger technique or venous cut-down for port placement|
323272|NCT00272636|Procedure|Radiofrequency catheter ablation|
323273|NCT00272636|Drug|Amiodarone and cardioversion|
328083|NCT00561405|Behavioral|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
328084|NCT00561405|Behavioral|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
328085|NCT00561418|Drug|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
328086|NCT00000593|Procedure|blood transfusion|
328087|NCT00004051|Drug|irinotecan hydrochloride|
328088|NCT00561418|Other|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
328089|NCT00561431|Device|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
328090|NCT00561431|Device|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
328392|NCT00556647|Procedure|conventional diagnosis|out-patient diagnosis
328393|NCT00556660|Procedure|SPECT scan|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
328394|NCT00556673|Drug|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
328395|NCT00556673|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
328396|NCT00556673|Drug|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
328397|NCT00004022|Biological|therapeutic autologous lymphocytes|
328398|NCT00556699|Drug|rituximab|Escalating intravenous repeating dose
328399|NCT00556699|Drug|SGN-40|Escalating intravenous repeating dose
328400|NCT00556712|Drug|erlotinib [Tarceva]|150mg po daily
327766|NCT00568542|Drug|placebo|35 I.E. kg body weight placebo to erythropoetin beta
327767|NCT00568555|Drug|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
327768|NCT00568555|Drug|Placebo - sugar pill|Placebo pill once daily
327769|NCT00568568|Drug|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
327770|NCT00568594|Drug|APL180|
327771|NCT00568594|Drug|Placebo|
327772|NCT00568607|Drug|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
327773|NCT00568620|Procedure|Placement of nasogastric feeding tube|Glucose tolerance test via nasogastric feeding tube
50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3
327774|NCT00568620|Procedure|Nasojejunal feeding tube|Glucose tolerance test via nasojejunal feeding tube
50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3
327775|NCT00004087|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
327776|NCT00568633|Procedure|Hematopoietic Cell Transplantation|Standard of care
327777|NCT00568633|Drug|Anti-Thymocyte Globulin|1.5 mg/kg x 5 days, iv
327778|NCT00568633|Drug|Cyclosporine|6.25mg/kgBID, po
327779|NCT00568633|Drug|Cellcept|15mg/kgBID, po
327780|NCT00568646|Drug|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
327781|NCT00568659|Procedure|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
327782|NCT00568672|Drug|Olanzapine|Olanzapine 5 mg / day for 6 months
327783|NCT00568685|Drug|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
327784|NCT00568685|Drug|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
327785|NCT00004093|Radiation|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
327126|NCT00583622|Drug|Docetaxel|300 mg/m^2 by vein over 2 hours for 1 Day
327127|NCT00583622|Drug|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
327128|NCT00004157|Biological|recombinant interleukin-11|
327129|NCT00583622|Drug|Melphalan|50 mg/m^2 by vein over 15 minutes for 3 Days
327442|NCT00576225|Drug|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
327443|NCT00576225|Drug|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
327444|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
327445|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
327446|NCT00576238|Drug|urea|Topical application twice daily for up to 6 months
327447|NCT00576251|Drug|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
327448|NCT00576251|Drug|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
327449|NCT00576277|Drug|AV411|
327450|NCT00576303|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
327451|NCT00576316|Drug|Symbicort Turbuhaler 160/4.5|
327452|NCT00004115|Radiation|yttrium Y 90 monoclonal antibody HMFG1|
327453|NCT00576329|Drug|Ketorolac|Topical use before surgery
327454|NCT00576342|Drug|AL-3862+timolol ophthalmic suspension|
327455|NCT00576342|Drug|Dorzolamide+timolol ophthalmic solution|
327456|NCT00576355|Behavioral|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
327457|NCT00576355|Behavioral|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
327458|NCT00576368|Drug|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
326806|NCT00589238|Drug|paclitaxel|
326807|NCT00551070|Drug|selumetinib|Given PO
326808|NCT00551070|Other|pharmacological study|Correlative studies
326809|NCT00551070|Other|laboratory biomarker analysis|Correlative studies
326810|NCT00551083|Other|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
326811|NCT00551083|Other|Usual Care (UC)|Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they "usually" would.
326812|NCT00003984|Biological|lintuzumab|
326813|NCT00551096|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
326814|NCT00551096|Drug|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
327130|NCT00583622|Procedure|Stem Cell Transplant|Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest
Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen
327131|NCT00583648|Other|Urinanlysis|sending a Urine sample to the laboratory for processing
327132|NCT00583661|Device|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
327133|NCT00583674|Drug|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327134|NCT00583674|Drug|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327135|NCT00583674|Drug|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327136|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
327137|NCT00583674|Drug|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
353959|NCT00623012|Drug|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
353960|NCT00623012|Drug|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
353961|NCT00623025|Drug|Creon 25000|6 to 9 capsules Creon 25000 per day
353962|NCT00623025|Drug|Placebo|6 to 9 capsules placebo per day
353963|NCT00625053|Procedure|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
353964|NCT00625053|Procedure|Open midline incisional hernia repair|Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.
Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need.
353965|NCT00625066|Other|biologic sample preservation procedure|
353966|NCT00625066|Other|cytology specimen collection procedure|
353967|NCT00625066|Other|medical chart review|
353968|NCT00625066|Other|questionnaire administration|
353969|NCT00004547|Drug|Postoperative dwell with paclitaxel and 5-FU|Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M^2) and 1 L of normal saline containing paclitaxel (125 mg/M^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
353970|NCT00625066|Other|survey administration|
353971|NCT00625066|Procedure|biopsy|
353972|NCT00625066|Procedure|evaluation of cancer risk factors|
353973|NCT00625066|Procedure|screening colonoscopy|
353342|NCT00598000|Behavioral|questionnaires|QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.
Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits.
353343|NCT00004211|Biological|PSA RNA-pulsed dendritic cell vaccine|
353344|NCT00598000|Behavioral|questionnaires|QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.
Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits.
353345|NCT00598013|Drug|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
353346|NCT00598026|Other|Tele- follow-up|Remote transmission to the implantation centre every 3 months
353347|NCT00598026|Other|Conventional follow-up|Visits at the implantation centre every 3 months
353348|NCT00598052|Drug|Escitalopram|10mg/day
353349|NCT00598065|Other|PET/CT|Synchronized PET/CT Imaging
353350|NCT00598078|Drug|Sodium Oxybate|Dose 1
353659|NCT00629811|Drug|Placebo|Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.
Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.
Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug.
353660|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
353661|NCT00592150|Drug|Placebo|Placebo infusion for 3 hours
353662|NCT00592163|Drug|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (>8 hours between doses) for 3 weeks followed by 1 week of rest
353663|NCT00592176|Drug|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
353664|NCT00592189|Procedure|blood draw|blood collection
353665|NCT00592202|Device|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
353666|NCT00592215|Drug|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
327543|NCT00586755|Procedure|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
327544|NCT00004172|Biological|filgrastim|
327545|NCT00586781|Device|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
327546|NCT00586794|Drug|Sildenafil|3x per day 20 mg TID
327547|NCT00586794|Drug|Placebo|3x per day, 20 mg TID
327548|NCT00586807|Other|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
327549|NCT00586820|Drug|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
327550|NCT00589394|Biological|pneumococcal vaccination (Pneumovax)|pneumovax was given
327551|NCT00589420|Drug|docetaxel|
327552|NCT00589420|Drug|sorafenib tosylate|
327553|NCT00589446|Device|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
327554|NCT00589472|Drug|Bicalutamide|Given PO
327555|NCT00589472|Drug|Goserelin Acetate|Given SC
327556|NCT00589472|Other|Laboratory Biomarker Analysis|Correlative studies
327557|NCT00589472|Drug|Leuprolide Acetate|Given IM
327558|NCT00589472|Procedure|Therapeutic Conventional Surgery|Undergo radical prostatectomy
327559|NCT00004179|Drug|cyclophosphamide|
327560|NCT00589472|Drug|Vorinostat|Given PO
327561|NCT00589485|Device|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
326913|NCT00560976|Drug|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
326914|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
326915|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
326916|NCT00561015|Drug|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
326917|NCT00004048|Procedure|autologous bone marrow transplantation|
326918|NCT00561015|Drug|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
327231|NCT00553683|Radiation|3-dimensional conformal radiation therapy|
327232|NCT00553696|Drug|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
327233|NCT00553696|Drug|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
327234|NCT00553696|Drug|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
327235|NCT00553709|Drug|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
327236|NCT00553722|Drug|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
327237|NCT00553722|Drug|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
327238|NCT00553735|Drug|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
327239|NCT00553748|Drug|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
327240|NCT00004005|Procedure|conventional surgery|
327241|NCT00553761|Device|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
326593|NCT00565747|Device|Control culture|The same standard culture medium, but without any additions (ready-to-use)
326594|NCT00565760|Drug|Q8003|Capsules
326595|NCT00565760|Drug|Placebo|Capsules
326596|NCT00565773|Drug|Belatacept|Belatacept will be given as an IV infusion of 10mg /kg over 30 minutes. This will be repeated on study days 4 and 8 (prior to bone marrow infusion in the first group of subjects) and 15 then every 2 weeks for 5 additional doses. After week 24, belatacept will be given at a dose of 5 mg/kg once every 4 weeks indefinitely.
326597|NCT00568009|Drug|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
326598|NCT00568022|Drug|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m^2, once every 3 weeks, up to 6 cycles
326599|NCT00568022|Drug|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m^2, twice daily for 2 weeks, one week off, up to 6 cycles
326600|NCT00568035|Drug|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
326601|NCT00568048|Biological|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
326602|NCT00568048|Drug|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
326603|NCT00568061|Drug|nitric oxide for inhalation|MI size at 48-72 hours
326604|NCT00568074|Drug|repaglinide|
326605|NCT00568074|Drug|Glurenorm®|
326606|NCT00004086|Procedure|autologous bone marrow transplantation|
326607|NCT00568074|Drug|Glucobay®|
326608|NCT00568087|Drug|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
326609|NCT00568087|Drug|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
326919|NCT00561015|Drug|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
326920|NCT00561028|Other|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
326921|NCT00561041|Behavioral|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
325932|NCT00580333|Drug|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
326257|NCT00573131|Drug|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
326258|NCT00573131|Drug|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
326259|NCT00004102|Drug|FOLFOX regimen|
326260|NCT00573131|Drug|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
326261|NCT00573131|Radiation|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
326262|NCT00573131|Procedure|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
326263|NCT00573144|Drug|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
326264|NCT00573144|Drug|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
326265|NCT00573157|Drug|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
326266|NCT00573157|Drug|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
326267|NCT00573157|Drug|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
326268|NCT00575614|Drug|prucalopride|1 mg o.d.
326269|NCT00004112|Drug|vincristine sulfate|
326270|NCT00575614|Drug|placebo|o.d.
326271|NCT00575627|Drug|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
326272|NCT00575640|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
326273|NCT00575666|Drug|Insulin or Placebo|intranasal, 40IU, 4 times daily
326274|NCT00575679|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
325571|NCT00585832|Other|Routine Care|individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
325572|NCT00585845|Biological|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.
325573|NCT00585871|Drug|clonidine|0.1 mg tid
325574|NCT00585871|Drug|metoprolol|25 mg tid
325575|NCT00585897|Behavioral|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
325576|NCT00585910|Drug|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
325577|NCT00585923|Device|C-Tek™ Plate|Fixed hole C-Tek™ Plate
325578|NCT00585923|Device|C-Tek™ Plate|Slotted hole C-Tek™ Plate
325579|NCT00585949|Procedure|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
325580|NCT00004166|Drug|amifostine trihydrate|
325581|NCT00585962|Radiation|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
325582|NCT00585975|Drug|bromfenac ophthalmic solution|sterile opthalmic solution
325583|NCT00585988|Device|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
325584|NCT00585988|Device|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
325585|NCT00586001|Behavioral|Unified treatment|Cognitive-behavioral treatment in development for emotional disorders
325933|NCT00580333|Drug|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
325934|NCT00580333|Drug|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
325935|NCT00580333|Drug|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
325936|NCT00580346|Device|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
324964|NCT00557947|Device|Suture|intradermal and topical suturing
324965|NCT00557947|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
324966|NCT00557960|Drug|Mixed salts of a single-entity amphetamine|
325262|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
325263|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
325264|NCT00591266|Drug|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
325265|NCT00552877|Device|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
325266|NCT00552890|Other|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
325267|NCT00000581|Procedure|leukocyte transfusions|
325268|NCT00003998|Drug|docetaxel|
325269|NCT00552890|Other|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
325270|NCT00552903|Behavioral|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
325271|NCT00552916|Device|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
325272|NCT00552916|Device|Compex Motion Stimulator|'False' FES
325273|NCT00552929|Drug|Sugammadex|4 Doses of Sugammadex Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium
325274|NCT00552929|Drug|Placebo|4 Doses of placebo Administered at 1-2 PTC After Rocuronium or Vecuronium
325275|NCT00552942|Procedure|laparoscopic gastric bypass plus omentectomy|
325276|NCT00552981|Procedure|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
325277|NCT00552981|Procedure|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
325278|NCT00552994|Device|Cypher Select plus|Drug eluting stent
325279|NCT00003998|Drug|paclitaxel|
324680|NCT00282828|Drug|Sertraline|
324681|NCT00282828|Drug|Venlafaxine|
324682|NCT00282828|Drug|Placebo|
324683|NCT00002771|Procedure|peripheral blood stem cell transplantation|
324684|NCT00282828|Drug|Clonazepam|
324685|NCT00282841|Procedure|ultrasound|single intravenous administration of max. 1.5ml ultrasound contrast agent (Definity), followed by max. 15min transcranial insonation using diagnostic ultrasound.
324686|NCT00282867|Drug|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
324687|NCT00282867|Other|standard care|usual care
324688|NCT00282893|Procedure|transluminal ballooning|
324689|NCT00282893|Other|currently existing therapies for the treatment of vasospasm|
324690|NCT00282906|Device|hybrid PET-CT imaging system|15 mCi of FDG
324691|NCT00282919|Drug|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
324692|NCT00282932|Drug|Detrol LA|
324693|NCT00282945|Drug|Rosiglitazone|
324694|NCT00002771|Radiation|radiation therapy|
324695|NCT00282945|Drug|Metformin|
324696|NCT00282958|Drug|Botulinum Toxin type a (Botox)|
324967|NCT00560105|Device|Lung Flute|8 weeks home use, twice daily
324968|NCT00560105|Device|Acapella|8 weeks home use, twice daily
324969|NCT00560118|Drug|fotemustine|
324970|NCT00560118|Genetic|gene expression analysis|
324971|NCT00560118|Genetic|polymerase chain reaction|
324972|NCT00560144|Drug|RG1507|3mg/kg iv weekly
324973|NCT00560144|Drug|RG1507|9mg/kg iv weekly
356087|NCT00607152|Drug|Rasburicase|0.20mg/kg per day IV
356088|NCT00607152|Drug|Allopurinol|100mg tablets
356089|NCT00004249|Drug|polysialic acid|
356090|NCT00607178|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
356091|NCT00607178|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
356092|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
356093|NCT00607217|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
356094|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
356095|NCT00609687|Procedure|Diagnostic Vitrectomy|Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.
Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance.
356096|NCT00609713|Behavioral|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
356097|NCT00609713|Other|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
356098|NCT00004260|Biological|rituximab|
356099|NCT00609739|Drug|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients >40 kg with normal renal function (creatinine <1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
355460|NCT00621283|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
355461|NCT00621296|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
355462|NCT00621309|Drug|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
355463|NCT00621309|Dietary Supplement|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
355464|NCT00004449|Behavioral|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
355780|NCT00614172|Radiation|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
355781|NCT00614198|Other|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
355782|NCT00614211|Procedure|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
355783|NCT00614211|Procedure|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
355784|NCT00004339|Drug|trientine|
355785|NCT00616785|Radiation|radiation therapy|
355786|NCT00004390|Drug|desipramine|
355787|NCT00616798|Drug|RO4917838|10mg po daily
355788|NCT00616798|Drug|RO4917838|30mg po daily
355789|NCT00616798|Drug|RO4917838|60mg po daily
355790|NCT00616798|Drug|Placebo|po daily
355791|NCT00616798|Drug|Standard antipsychotic therapy|As prescribed
355792|NCT00616811|Drug|vildagliptin|
355793|NCT00616811|Drug|Sitagliptin|
355127|NCT00627848|Drug|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
355128|NCT00004584|Drug|Ritonavir|
355129|NCT00627861|Drug|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
355130|NCT00627861|Drug|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
355131|NCT00627874|Device|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
355132|NCT00627887|Procedure|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
355133|NCT00627887|Drug|venlafaxine|extended release target dose of 300mg/day duration of one year
355134|NCT00627887|Drug|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
355135|NCT00627900|Device|bare metal stent|implantation of a bare metal stent
355136|NCT00627900|Device|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
355137|NCT00627913|Procedure|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
355138|NCT00627913|Procedure|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
355139|NCT00000633|Biological|gp160 Vaccine (Immuno-AG)|
355140|NCT00004584|Drug|Saquinavir|
355141|NCT00627926|Biological|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
355465|NCT00621309|Dietary Supplement|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
355466|NCT00623428|Drug|Ribavirin|
355467|NCT00004486|Drug|fluoxetine|
355468|NCT00623441|Device|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
354516|NCT00603603|Other|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
354818|NCT00596011|Drug|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
354819|NCT00596011|Drug|Placebo|Matching placebo BID
354820|NCT00596024|Dietary Supplement|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
354821|NCT00596024|Dietary Supplement|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
354822|NCT00596037|Drug|Growth hormone - LB03002|
354823|NCT00596050|Drug|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
354824|NCT00596050|Drug|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
354825|NCT00596063|Biological|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
354826|NCT00596063|Biological|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
354827|NCT00004202|Drug|chemotherapy|
354828|NCT00596076|Behavioral|Back School|All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.
A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month.
354829|NCT00596102|Biological|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
354830|NCT00596115|Drug|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
354831|NCT00596128|Behavioral|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
354832|NCT00596141|Device|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
354195|NCT00609050|Behavioral|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
354196|NCT00609050|Behavioral|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
354197|NCT00609063|Drug|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
354198|NCT00609063|Drug|Placebo|Placebo capsules taken daily for 6 months
354199|NCT00609089|Behavioral|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
354200|NCT00611325|Drug|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, & 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs & 2.5 mg/m2 for patients taking EIAEDs.
354201|NCT00611338|Behavioral|HIV Skills-based Prevention|
354202|NCT00611351|Biological|anti-thymocyte globulin|
354203|NCT00611351|Drug|busulfan|
354517|NCT00603616|Drug|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
354518|NCT00603616|Drug|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
354519|NCT00603642|Drug|Placebo|Subcutaneously administered, once a week, for 12 weeks
354520|NCT00603642|Drug|AMG 531|Subcutaneously administered, once a week, for 12 weeks
354521|NCT00603655|Other|Low glycemic load diet|Low glycemic load diet
354522|NCT00000162|Procedure|Macular Argon Laser Photocoagulation|
354523|NCT00000616|Behavioral|diet, reducing|
354524|NCT00004231|Drug|vincristine sulfate|
354525|NCT00603655|Other|High glycemic load diet|High glycemic load diet
354526|NCT00603668|Biological|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
353881|NCT00616031|Drug|paclitaxel|
353882|NCT00616044|Procedure|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
353883|NCT00616044|Procedure|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
353884|NCT00004373|Drug|alprazolam|
353885|NCT00616044|Procedure|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
353886|NCT00616057|Dietary Supplement|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
353887|NCT00616057|Dietary Supplement|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
353888|NCT00616070|Drug|Difluprednate|Difluprednate
353889|NCT00616070|Other|Placebo|Vehicle
353890|NCT00616096|Procedure|immunoadsorption|First cycle: week 1, day 1-5
Second cycle: week 5, day 1-5
353891|NCT00618449|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
353892|NCT00618462|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
353893|NCT00004409|Drug|collagenase|
353894|NCT00618462|Behavioral|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
353895|NCT00618462|Behavioral|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
354204|NCT00611351|Drug|cyclophosphamide|
354205|NCT00611351|Drug|mycophenolate mofetil|
354206|NCT00611351|Drug|tacrolimus|
354207|NCT00611351|Genetic|polymerase chain reaction|
354208|NCT00611351|Genetic|polymorphism analysis|
354209|NCT00611351|Other|flow cytometry|
353287|NCT00592007|Drug|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
353288|NCT00592020|Procedure|Short Transverse Incision|Short Transverse Incision for kidney transplantation
353585|NCT00622869|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
353586|NCT00622869|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
353587|NCT00622869|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
353588|NCT00622869|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
353589|NCT00622869|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
353590|NCT00622882|Other|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
353591|NCT00622895|Drug|fludarabine phosphate|Given IV
353592|NCT00622895|Drug|Mycophenolic Acid|Given PO
353593|NCT00622895|Drug|tacrolimus|Given PO
353594|NCT00004481|Procedure|genetic testing|
353595|NCT00622895|Radiation|total-body irradiation|Undergo TBI
353596|NCT00622895|Procedure|bone marrow transplantation|Undergo transplantation
353597|NCT00622895|Procedure|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
353598|NCT00622895|Procedure|quality-of-life assessment|Ancillary studies
353599|NCT00622895|Other|laboratory biomarker analysis|Correlative studies
352991|NCT00600743|Drug|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
352992|NCT00600743|Drug|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
352993|NCT00004221|Drug|Paclitaxel|Given IV
352994|NCT00600756|Drug|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
352995|NCT00600756|Drug|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
352996|NCT00600769|Drug|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
352997|NCT00600782|Biological|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
352998|NCT00600795|Other|CSF collection|CSF collection at time of VPS insertion
352999|NCT00600808|Drug|BPLG-003|
353000|NCT00600821|Drug|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
353289|NCT00592020|Procedure|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
353290|NCT00592033|Other|oxygen from a portable concentrator|2 l/minute during exercise
353291|NCT00592046|Drug|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
353292|NCT00592072|Dietary Supplement|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
353293|NCT00592072|Other|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
353294|NCT00592085|Behavioral|Questionnaires|Participants will use a computer to complete a series of questionnaires.
353295|NCT00592085|Behavioral|Motivational Relapse Prevention Counseling|Total of 6 counseling calls: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
353296|NCT00592085|Behavioral|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
353297|NCT00004188|Procedure|bone marrow ablation with stem cell support|
352719|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 10 mg
352720|NCT00610727|Drug|Placebo|Staccato Placebo
352721|NCT00610740|Drug|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
352722|NCT00004264|Drug|docetaxel|
352723|NCT00610740|Procedure|therapeutic conventional surgery|hysterectomy
352724|NCT00610753|Behavioral|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
352725|NCT00610753|Behavioral|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
352726|NCT00610779|Dietary Supplement|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
352727|NCT00610779|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
352728|NCT00610792|Drug|bortezomib|1.3 mg/m2 on Days 1, 4, 8 & 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
352729|NCT00610792|Drug|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
352730|NCT00610805|Other|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
353001|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
353002|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
353003|NCT00600821|Drug|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
353004|NCT00004221|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
353005|NCT00000616|Behavioral|exercise|
353006|NCT00004231|Biological|filgrastim|
352129|NCT00622284|Drug|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
352130|NCT00004471|Genetic|pGT-1 gene lipid complex|
352408|NCT00615394|Procedure|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
352409|NCT00615420|Dietary Supplement|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
352410|NCT00004361|Drug|sodium citrate|
352411|NCT00617734|Biological|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 mg/m2 over 2 hours. This sequence will be repeated every 2 weeks. Patients will continue on study until evidence of disease progressive disease or unacceptable toxicity develops.
352412|NCT00617747|Drug|Zolmitriptan|5mg Nasal Spray
352413|NCT00004402|Drug|interferon gamma|
352414|NCT00617747|Drug|Placebo|
352415|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
352416|NCT00617760|Biological|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
352417|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
352418|NCT00617773|Biological|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
352419|NCT00617786|Procedure|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
352420|NCT00617799|Biological|aldesleukin|
352421|NCT00617799|Genetic|gene expression analysis|
352422|NCT00617799|Genetic|mutation analysis|
352423|NCT00617799|Other|flow cytometry|
353354|NCT00004212|Biological|filgrastim|
353355|NCT00598091|Drug|dasatinib|50mg, PO, QD
353356|NCT00598091|Drug|gemcitabine|1000mg/m2, days 1, 8, 15
353357|NCT00598091|Drug|dasatinib|50mg, PO, BID
353358|NCT00598104|Drug|QAX576|
353359|NCT00598104|Drug|Placebo|
353360|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
353361|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
353362|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 20mg
353363|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 5 mg
353364|NCT00600847|Drug|placebo|single dose for 7 days, oral
353365|NCT00600860|Other|No interventions|Only registration of clinical practice
353366|NCT00600873|Drug|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
353367|NCT00600886|Drug|Pasireotide|SOM230 LAR
353368|NCT00600886|Drug|Octreotide|Sandostatin LAR
353369|NCT00600899|Procedure|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
353370|NCT00004221|Drug|Topotecan Hydrochloride|Given IV
353371|NCT00600899|Procedure|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
353372|NCT00600912|Drug|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
353373|NCT00600912|Drug|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
353374|NCT00600925|Drug|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
352781|NCT00617877|Drug|Comparator: Hydrochlorothiazide|Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
352782|NCT00617890|Drug|SCH 717454 (19D12)|SCH 717454 will be administered intravenously once every two weeks until disease progression.
352783|NCT00617903|Drug|Azelaic acid|15% foam to be applied topically twice daily
352784|NCT00617903|Drug|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
353064|NCT00608543|Drug|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
353065|NCT00608569|Drug|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
353066|NCT00608569|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
353067|NCT00608569|Drug|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
353068|NCT00608569|Drug|Zidovudine|300-mg tablet taken orally twice daily
353069|NCT00608569|Drug|Emtricitabine|200-mg tablet taken orally once daily
353070|NCT00608582|Device|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
353071|NCT00608595|Drug|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
353072|NCT00608595|Genetic|gene expression analysis|not noted
353073|NCT00608595|Genetic|protein expression analysis|Not noted
353074|NCT00000620|Drug|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
353075|NCT00004255|Drug|tacrolimus|
353076|NCT00608595|Other|immunohistochemistry staining method|not noted
353077|NCT00610909|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
352498|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|(may use alone or in combination)
Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.
Vasopressin - 0.04 international units/hour
Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.
Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.
Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.
In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of < 60
352499|NCT00000630|Biological|HIVAC-1e|
352500|NCT00004498|Genetic|Adenoviral Vector-Mediated Gene Transfer|
352501|NCT00626639|Radiation|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation [one fraction per day])
352502|NCT00626639|Drug|Cisplatin|100 mg/m^2 intravenously (IV) on days 1, 22 and 43.
352503|NCT00626652|Drug|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
352785|NCT00617929|Biological|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
352786|NCT00617929|Biological|rituximab|administered 375 mg/m^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
352787|NCT00617929|Drug|clofarabine|administered 30 mg/m^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
352788|NCT00617929|Procedure|stem cell transplantation|administered on Day 0 per institutional guidelines.
352789|NCT00617942|Drug|Carboplatin|Carboplatin AUC 6
352790|NCT00004403|Drug|phenytoin|
352791|NCT00617942|Drug|nab-paclitaxel|Abraxane 100 mg/m2
352792|NCT00617942|Drug|trastuzumab|trastuzumab 2 mg/kg
352793|NCT00617955|Drug|Aprotinin|compare outcomes of Aprotinin versus Amicar
352794|NCT00617955|Drug|Amicar|compare outcomes of Aprotinin versus Amicar
352795|NCT00617968|Drug|DOCETAXEL|
352796|NCT00617981|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
352797|NCT00617981|Drug|5% Dextrose Solution|Single 30 minute intravenous infusion
352798|NCT00617994|Drug|INCB018424|INCB018424 1.5% cream BID for 28 days
352206|NCT00591643|Radiation|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
352207|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
352208|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
352209|NCT00591682|Drug|MSX-122|Dosage form = capsule
Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)
If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.
If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.
If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort.
352210|NCT00591695|Procedure|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
352211|NCT00591695|Procedure|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
352212|NCT00591708|Dietary Supplement|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
352213|NCT00591708|Dietary Supplement|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
352214|NCT00004188|Drug|melphalan|Given IV
352215|NCT00594620|Dietary Supplement|Flav-ein capsules|Soy/isoflavone supplementation
352216|NCT00594620|Drug|Placebo|Placebo
352217|NCT00004197|Drug|mitoxantrone hydrochloride|
352504|NCT00626665|Drug|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
352505|NCT00626678|Drug|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
352506|NCT00626678|Drug|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
351598|NCT00607841|Drug|Ispinesib (SB-715992)|Phase I: Dose escalation of I.V. injection starting at 10mg/m2 on Days 1 and 15 of a 28 day cycle.
351599|NCT00607841|Drug|Ispinesib (SB-715992)|Phase II: Fixed dose to be determined based on Phase I findings on Days 1 and 15 of a 28 day cycle
351600|NCT00607854|Drug|Ibritumomab Tiuxetan (Zevalin)|Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.
Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)
351601|NCT00607867|Other|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
351904|NCT00600210|Radiation|Radiation Therapy|Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.
Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions.
351905|NCT00600223|Behavioral|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
351906|NCT00600236|Procedure|blood sample|
351907|NCT00600249|Drug|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
351908|NCT00600249|Drug|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
351909|NCT00600262|Drug|intravitreal bevacizumab|
351910|NCT00600275|Drug|BGT226|
351911|NCT00600288|Drug|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
351912|NCT00600288|Drug|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
351913|NCT00004219|Radiation|radiation therapy|
351914|NCT00600301|Drug|Triamcinolone Acetonide and Bevacizumab|
351915|NCT00600327|Device|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
351916|NCT00600327|Device|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
351917|NCT00600340|Biological|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
351290|NCT00612456|Drug|Pazopanib|Pazopanib eye drops formulation
351291|NCT00004310|Drug|Clomipramine|
351292|NCT00612469|Drug|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
351293|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
351294|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
351295|NCT00614796|Behavioral|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
351296|NCT00614809|Drug|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
351297|NCT00614822|Drug|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
351298|NCT00614835|Drug|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
351602|NCT00607867|Other|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
351603|NCT00607880|Procedure|vascular access device placement|
351604|NCT00004253|Drug|carboplatin|
351605|NCT00607893|Device|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
351606|NCT00607893|Device|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
351607|NCT00607906|Drug|SB756050|
351608|NCT00607919|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
351609|NCT00607919|Drug|Placebo|oral, daily, for 16 weeks
351610|NCT00607932|Behavioral|behavioral dietary intervention|Not specified
351611|NCT00607932|Dietary Supplement|Brassica vegetable|Not specified
351612|NCT00607932|Drug|indole-3-carbinol|follow up at 2,4,6 months post baseline.
351299|NCT00614848|Device|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
351300|NCT00614861|Other|Non-cancer pain management survey|Non-cancer pain management survey
351301|NCT00614874|Drug|rosiglitazone|2mg, 4mg, 8mg
351302|NCT00004347|Behavioral|diet|
351303|NCT00614913|Radiation|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
351304|NCT00614926|Drug|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
351305|NCT00614926|Drug|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
351306|NCT00614939|Drug|Saxagliptin|2.5 mg once daily oral dose
351307|NCT00614939|Drug|Placebo|Placebo
351308|NCT00614952|Device|PSG (polysomnography)|POLYSOMNOGRAPHY
351309|NCT00614952|Other|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
351310|NCT00614965|Drug|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
351311|NCT00614965|Drug|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
351312|NCT00614965|Drug|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
351313|NCT00004357|Drug|Methylprednisolone|IV
351314|NCT00614978|Drug|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
351315|NCT00614991|Drug|Raltegravir|400mg BID
351316|NCT00614991|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
351317|NCT00614991|Drug|Ritonavir|100 mg BID or QD
351318|NCT00615017|Drug|AZD9773 (CytoFab)|intravenous infusions
351319|NCT00615017|Other|Placebo|Placebo
355794|NCT00616824|Procedure|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
355795|NCT00616824|Procedure|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
355796|NCT00616837|Other|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
355797|NCT00004390|Drug|methadone|
355798|NCT00616837|Other|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
355799|NCT00616850|Procedure|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
355800|NCT00616850|Drug|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
355801|NCT00616850|Other|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
355802|NCT00616863|Drug|Oxcarbazepine|
356100|NCT00609739|Drug|cytarabine|3000 mg/m^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m^2/day) on days -9 through -4.
356101|NCT00609739|Drug|filgrastim|Patients with absolute neutrophil count (ANC) <0.2 x 10^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
356102|NCT00609739|Drug|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m^2 IV on days +3, +6, and +11.
356103|NCT00609739|Drug|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
356104|NCT00609739|Drug|mitoxantrone hydrochloride|10 mg/m^2 over 30 minutes intravenously (IV) on days -9 through -7.
356105|NCT00609739|Procedure|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 >10^8/kg recipient weight. Infused on Day 0.
356106|NCT00609739|Procedure|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
356107|NCT00609739|Drug|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
355469|NCT00623454|Behavioral|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
355470|NCT00623467|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
355471|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
355472|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
355473|NCT00623506|Drug|Pregnenolone|Placebo for two weeks (during placebo lead-in), then:
Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)
355474|NCT00623506|Drug|Placebo|Placebo for two weeks (placebo lead in), then:
Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)
355475|NCT00623532|Behavioral|Mind-body exercises|
355476|NCT00623532|Behavioral|Adapted Tai-chi|
355477|NCT00623545|Drug|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
355478|NCT00004487|Drug|chondrocyte-alginate gel suspension|
355479|NCT00623558|Drug|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
355480|NCT00623558|Drug|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
355481|NCT00623558|Drug|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
355482|NCT00623571|Other|Treatment of elderly patients in a GMW|
355483|NCT00623571|Other|Treatment of elderly patients in GHHS|
355484|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
355485|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
355803|NCT00616876|Drug|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
354833|NCT00596154|Other|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.
On day 2 you will be admitted to the hospital and will receive 3 other drugs:
Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.
Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle.
354834|NCT00596167|Drug|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
355142|NCT00630266|Device|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
355143|NCT00630279|Drug|Placebo|Placebo
355144|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
355145|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
355146|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
355147|NCT00630292|Other|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
355148|NCT00630305|Device|toric contact lenses|30 minutes of contact lens wear for each arm for two states; open eye and closed eye
355149|NCT00004660|Procedure|Radiotherapy|
355150|NCT00630305|Device|toric contact lenses|30 minutes of contact lens wear for each arm for two states; open eye and closed eye
355151|NCT00630305|Device|toric contact lenses|30 minutes of contact lens wear for each arm for two states; open eye and closed eye
355152|NCT00630318|Device|MRI|15-20 minutes MR imaging
355153|NCT00630331|Biological|Cell culture-derived influenza vaccine|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
355154|NCT00630331|Biological|Egg-derived influenza virus vaccine|One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
355155|NCT00630331|Biological|Placebo|One dose (0.5 mL) of phosphate buffered solution.
355156|NCT00630344|Drug|RAD001|Taken orally once daily
355157|NCT00630344|Drug|Bicalutamide|Taken orally once daily
355158|NCT00630357|Drug|Levetiracetam (Keppra)|
354527|NCT00603681|Drug|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
354528|NCT00603681|Drug|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
354529|NCT00603720|Drug|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
354530|NCT00603720|Drug|L-Arginine|aids in nitric oxide production
354531|NCT00603720|Drug|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
354532|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
354533|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet
354534|NCT00603746|Drug|GW685698X|GW685698X
354535|NCT00004231|Procedure|allogeneic bone marrow transplantation|
354536|NCT00603759|Drug|celecoxib|100 mg qid
354537|NCT00603759|Drug|placebo|1 cap qid
354538|NCT00603772|Drug|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
354539|NCT00603785|Drug|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive placebo treatment for 6 months.
354540|NCT00603785|Drug|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
354835|NCT00598663|Device|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
354836|NCT00598676|Device|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
354837|NCT00598676|Device|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
354838|NCT00598676|Device|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
354839|NCT00598689|Drug|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
354840|NCT00598702|Drug|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
354210|NCT00004276|Drug|thalidomide|
354211|NCT00611351|Other|laboratory biomarker analysis|
354212|NCT00611351|Other|pharmacogenomic studies|
354213|NCT00611351|Other|pharmacological study|
354214|NCT00611351|Procedure|allogeneic bone marrow transplantation|
354215|NCT00611351|Procedure|allogeneic hematopoietic stem cell transplantation|
354216|NCT00611351|Procedure|peripheral blood stem cell transplantation|
354217|NCT00611364|Other|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
354218|NCT00611364|Other|education meetings|This group only participed of education meeting (every fifteen days)
354219|NCT00611390|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
354220|NCT00611390|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
354221|NCT00004278|Drug|ganciclovir|
354222|NCT00611403|Drug|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
354223|NCT00611403|Drug|Artificial Tears REFRESH ENDURA®|REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
354224|NCT00611416|Dietary Supplement|green tea|different catechin combinations
354225|NCT00611416|Dietary Supplement|Mix of catechins and caffeine|3 tablet a day
354226|NCT00611416|Dietary Supplement|EGCG|3 tablets a day
354227|NCT00611416|Dietary Supplement|EGC|3 tablets a day
354228|NCT00611416|Dietary Supplement|Caffeine|3 tablets a day
354229|NCT00611416|Dietary Supplement|Placebo|3 tablets a day
354541|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
353600|NCT00624858|Drug|naltrexone SR 32 mg/ bupropion SR 360 mg daily|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
During the study, subjects will receive ancillary therapy including advice on diet and exercise
353601|NCT00624871|Drug|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
353602|NCT00624871|Drug|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
353603|NCT00624871|Drug|Placebo|
353896|NCT00618462|Behavioral|Case management|Case management will assist participants in obtaining additional services from the community as needed.
353897|NCT00618462|Behavioral|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
353898|NCT00618475|Behavioral|Cognitive behavioral therapy|10 sessions
1 hour per week
353899|NCT00618488|Dietary Supplement|Probiotic BB12 - Bifidobacterium lactis|Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks
353900|NCT00618488|Dietary Supplement|Placebo|Placebo administered once a day for 6 weeks
353901|NCT00618501|Drug|cytarabine|
353902|NCT00618501|Drug|daunorubicin hydrochloride|
353903|NCT00618501|Drug|etoposide|
353904|NCT00004410|Drug|tauroursodeoxycholic acid|
353905|NCT00618501|Drug|imatinib mesylate|
353906|NCT00618501|Drug|leucovorin calcium|
353907|NCT00618501|Drug|methotrexate|
353908|NCT00618501|Drug|prednisolone|
353909|NCT00618501|Drug|therapeutic hydrocortisone|
353910|NCT00618501|Drug|vincristine sulfate|
353911|NCT00618501|Procedure|allogeneic hematopoietic stem cell transplantation|
353912|NCT00618514|Device|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
353298|NCT00592098|Drug|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
353299|NCT00592098|Drug|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
353300|NCT00592111|Drug|COPP/ABV|4 courses of COPP/ABV hybrid
353301|NCT00592111|Drug|COPP/ABV|6 courses of COPP/ABV hybrid
353302|NCT00592111|Drug|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
353303|NCT00592124|Drug|Tenofovir disoproxil fumarate|300 mg tablet daily
353304|NCT00592124|Drug|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
353305|NCT00592137|Dietary Supplement|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
353306|NCT00592137|Dietary Supplement|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
353307|NCT00592137|Dietary Supplement|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
353308|NCT00004188|Procedure|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
353604|NCT00004547|Procedure|Surgery|Patients will undergo cytoreductive surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected.
353605|NCT00624910|Drug|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
353606|NCT00624910|Drug|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
353607|NCT00624923|Drug|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
353608|NCT00624923|Drug|Placebo|Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months
353609|NCT00624936|Drug|azacitidine|
353610|NCT00624936|Drug|bortezomib|
353007|NCT00602901|Drug|Usual medical care (Celebrex, Aleve, Bextra, Naproxen)|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
353008|NCT00602914|Device|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
353009|NCT00602914|Device|MicronJet|MicronJet, Intradermal Injection
353010|NCT00602927|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
353011|NCT00602927|Drug|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
353012|NCT00602940|Procedure|Acupuncture|12 treatments over 8 weeks
353013|NCT00602940|Procedure|Sham Acupuncture|12 treatments over 8 weeks
353014|NCT00602953|Other|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
353015|NCT00602979|Device|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
353016|NCT00602979|Device|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
353017|NCT00004231|Biological|recombinant interferon alfa|
353018|NCT00602979|Device|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
353019|NCT00602979|Device|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
353020|NCT00602979|Device|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
353021|NCT00603005|Device|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
353022|NCT00603018|Drug|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
353023|NCT00603018|Other|No drug|No drug/control group
353309|NCT00592150|Drug|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
353310|NCT00595205|Other|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
353311|NCT00595218|Behavioral|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
353312|NCT00595218|Other|Patient Preference Results|Knowledge of Patient Preference Results
352424|NCT00004403|Drug|albendazole|
352425|NCT00617812|Biological|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
352426|NCT00617825|Other|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
358840|NCT00690287|Drug|AZD6370|Oral single doses a+b+c, o.d., suspension
358841|NCT00690287|Drug|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
358842|NCT00005643|Drug|pegylated liposomal doxorubicin hydrochloride|
358843|NCT00690287|Drug|Placebo|Placebo
358844|NCT00690300|Drug|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
358845|NCT00690300|Drug|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
358846|NCT00690313|Drug|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
358847|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|treatment type: behavioral (lifestyle counseling)
treatment name: behavioral change communication to promote physical activity
358848|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|Arm B given placebo comparator ie pamphlet
Audiovisual module Physical activity frequency questionnaire
358849|NCT00690339|Device|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
358850|NCT00690352|Behavioral|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
358851|NCT00690378|Drug|NXL104/ceftazidime|125mg/500mg TID
358852|NCT00690378|Drug|Imipenem/Cilastatin|4 x daily
358853|NCT00005644|Drug|gemcitabine hydrochloride|
358854|NCT00690404|Drug|AZD2066|single oral dose
358855|NCT00690417|Dietary Supplement|Cholecalciferol (vitamin D3)|low calorie (~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
358856|NCT00690430|Drug|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
353676|NCT00592319|Procedure|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
353677|NCT00592332|Drug|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
353678|NCT00592332|Other|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
353679|NCT00592345|Radiation|Proton Beam Radiation|Administered over a period of 12 weeks.
353680|NCT00592345|Radiation|Photon Beam Radiation|Administered over a period of 12 weeks.
353681|NCT00000611|Drug|calcium|
353682|NCT00595387|Other|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
353683|NCT00595413|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
353684|NCT00004199|Drug|prinomastat|
353685|NCT00595413|Drug|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
353686|NCT00595413|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
353687|NCT00595413|Biological|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
353688|NCT00595426|Drug|YM150|Oral
353689|NCT00595426|Drug|Warfarin|Oral
353690|NCT00595465|Biological|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
353691|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
353692|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
353078|NCT00610909|Drug|Placebo|Placebo
353079|NCT00610922|Dietary Supplement|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
353080|NCT00610935|Drug|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
353081|NCT00610935|Drug|Placebo|Single intramuscular injection
353082|NCT00004266|Drug|Lisinopril|
353083|NCT00610948|Biological|panitumumab|Given IV
353084|NCT00610948|Drug|everolimus|Given orally
353375|NCT00600938|Drug|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
353376|NCT00600938|Drug|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
353377|NCT00600938|Drug|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
353378|NCT00600938|Drug|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
353379|NCT00600938|Drug|Deferasirox|
353380|NCT00600938|Drug|Deferoxamine|
353381|NCT00004223|Drug|docetaxel|
353382|NCT00600964|Drug|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
353383|NCT00600964|Drug|GX15-070MS|GX15-070MS at various doses and schedules
353384|NCT00600977|Drug|Doxorubicine|9mg/m² J1 J4 2 COURSES
353385|NCT00600977|Drug|Doxorubicine pegylated|40 MG/M² J1 2 courses
353386|NCT00600990|Drug|GW597599|
353387|NCT00603083|Drug|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
353388|NCT00603083|Drug|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
352799|NCT00618007|Drug|PF-00734200 30 mg QD|30 mg QD
352800|NCT00618007|Drug|PF-00734200 20 mg QD|20 mg QD
352801|NCT00004404|Drug|clotrimazole|
352802|NCT00618007|Drug|Placebo|Placebo
352803|NCT00618020|Device|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
352804|NCT00618033|Procedure|Hemodialysis|varying concentration of glucose in dialysate
352805|NCT00618046|Drug|Oxcarbazepine|
352806|NCT00618059|Drug|Pilocarpine|
352807|NCT00618072|Drug|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
352808|NCT00620282|Drug|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
352809|NCT00620282|Drug|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
352810|NCT00620282|Drug|glimepiride|Tablets, 1 - 4 mg daily
353085|NCT00610948|Drug|fluorouracil|Given IV
353086|NCT00610948|Drug|leucovorin calcium|Given IV
353087|NCT00610948|Drug|oxaliplatin|Given IV
353088|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
353089|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
353090|NCT00610987|Drug|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
353091|NCT00610987|Drug|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
352507|NCT00626678|Drug|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
352508|NCT00626691|Behavioral|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
352509|NCT00004578|Drug|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
352510|NCT00626704|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
352511|NCT00626704|Other|Placebo|Inactive dummy AMG 655 (to maintain blind)
352512|NCT00626704|Drug|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
352513|NCT00626717|Procedure|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
352514|NCT00626717|Procedure|Sham treatment|Fluorescein eye drops. Exposure with blue light
352515|NCT00626730|Procedure|adjuvant therapy|
352516|NCT00626730|Radiation|radiation therapy|
352517|NCT00626743|Drug|SK3530 100mg, Placebo, Amlodipine|
352518|NCT00626756|Device|LiDCO technology|non invasive monitoring of cardiac output
352519|NCT00626769|Dietary Supplement|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
352520|NCT00004578|Drug|Lamivudine|150 mg, every 12 hours
352521|NCT00626769|Dietary Supplement|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
352522|NCT00626782|Drug|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
352523|NCT00626782|Drug|Mitomycin C 0.4 mg/ml|Mitomycin C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
352524|NCT00626795|Drug|TD1414 2% cream|BID 7 days
352811|NCT00620295|Drug|bortezomib|Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
351918|NCT00600340|Biological|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
351919|NCT00600353|Drug|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
351920|NCT00602563|Behavioral|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
351921|NCT00602563|Behavioral|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
352218|NCT00594633|Other|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
352219|NCT00594646|Drug|TRUVADA + raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
352220|NCT00594659|Behavioral|Psychotherapy|Nine session treatment
352221|NCT00594659|Behavioral|Computerized Psychotherapy|Nine session computer delivered treatment
352222|NCT00594659|Behavioral|Motivational enhancement therapy|Two session treatment
352223|NCT00594698|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
352224|NCT00594724|Procedure|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
352225|NCT00594737|Drug|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
352226|NCT00594776|Device|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
352227|NCT00594789|Other|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
352228|NCT00004197|Drug|prednisone|
352229|NCT00594815|Drug|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
351613|NCT00607932|Other|counseling intervention|2, 4, 6 months post baseline
351614|NCT00607932|Other|medical chart review|2,4,6 months post baseline
351615|NCT00004253|Drug|paclitaxel|
351616|NCT00607932|Other|questionnaire administration|not specified
351617|NCT00607932|Procedure|adjuvant therapy|not specified
351618|NCT00607945|Drug|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
351619|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
351620|NCT00610285|Other|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
351621|NCT00610298|Device|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
351622|NCT00004262|Drug|motexafin gadolinium|Given IV
351623|NCT00610311|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
351624|NCT00610311|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
351922|NCT00602563|Behavioral|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
351923|NCT00004229|Biological|recombinant human endostatin|
351924|NCT00602576|Drug|sorafenib tosylate|Given orally
351925|NCT00602576|Drug|temozolomide|Given orally
351926|NCT00602589|Drug|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
351927|NCT00602602|Biological|bevacizumab|
351928|NCT00602602|Drug|fluorouracil|
351320|NCT00617409|Drug|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
351321|NCT00004398|Drug|heme arginate|
351625|NCT00610311|Biological|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
351626|NCT00610311|Biological|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL)
351627|NCT00610311|Biological|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10^8 cells will be given.
351628|NCT00610324|Drug|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
351629|NCT00610324|Drug|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
351630|NCT00610337|Drug|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
351631|NCT00610337|Procedure|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
351632|NCT00610350|Drug|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
351633|NCT00004262|Procedure|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
351634|NCT00610350|Drug|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
351635|NCT00610363|Biological|rilonacept|160mg sc once a week
351636|NCT00610363|Other|placebo|placebo sc once a week
351637|NCT00610376|Behavioral|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
351638|NCT00610376|Behavioral|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
351639|NCT00610389|Biological|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
351640|NCT00610402|Other|blood sample tear drop sample|blood sample tear drop sample
356108|NCT00611975|Drug|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
356109|NCT00611988|Behavioral|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
356110|NCT00004297|Drug|diazepam|
356111|NCT00611988|Other|Control group|Attention control group will receive routine follow-up phone calls
356112|NCT00612001|Biological|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
356113|NCT00612014|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
356114|NCT00612014|Drug|TZP-101|40 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days
356115|NCT00612014|Drug|TZP-101|80 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days
356116|NCT00612014|Drug|TZP-101|160 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days
356117|NCT00612014|Drug|TZP-101|320 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days
356118|NCT00612014|Drug|TZP-101|600 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days
351322|NCT00617409|Biological|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
351323|NCT00617409|Drug|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
351324|NCT00617435|Dietary Supplement|vaccenic acid enriched diet|The experimental milk fat, entitled "vaccenic acid enriched milk fat" (VAMF), has been obtained by feeding cows with a diet containing sunflower oil.
351325|NCT00617435|Dietary Supplement|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
351326|NCT00617435|Dietary Supplement|control diet|Mixed of different oil
355804|NCT00616876|Dietary Supplement|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
355805|NCT00616889|Drug|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
355806|NCT00616902|Drug|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
355807|NCT00616902|Drug|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
355808|NCT00004390|Drug|morphine|
355809|NCT00619151|Device|Regent|Implant of the St. Jude Medical Regent mechanical valve
355810|NCT00619164|Drug|E5555|E5555, 50 mg (tablet), taken orally, once a day.
355811|NCT00619164|Drug|E5555|E5555, 100 mg (tablet), taken orally, once a day.
355812|NCT00619164|Drug|E5555|E5555, 200 mg (tablet), taken orally, once a day.
355813|NCT00619164|Drug|Placebo|Placebo tablet taken orally, once a day.
355814|NCT00619190|Drug|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
355815|NCT00004422|Drug|immune globulin|
355816|NCT00619203|Drug|Glycerol and paracetamol|glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses
paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7
355817|NCT00619203|Drug|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
355818|NCT00619203|Drug|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
355819|NCT00619203|Drug|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
355820|NCT00619203|Drug|Placebo|2 placebos, one po, one suppository
355821|NCT00619203|Drug|Paracetamol and glycerol|35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol
1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses
355822|NCT00619203|Drug|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
355159|NCT00630370|Drug|Placebo|2 Placebo tablets, TID, orally, 58 days
355160|NCT00004662|Drug|dehydroepiandrosterone|
355161|NCT00630370|Drug|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
355162|NCT00630370|Drug|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
355163|NCT00630370|Drug|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
355164|NCT00630383|Biological|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
355165|NCT00630383|Other|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
355486|NCT00623597|Drug|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
355487|NCT00623597|Drug|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
355488|NCT00623610|Procedure|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
355489|NCT00004488|Drug|alendronate sodium|
355490|NCT00623623|Procedure|primary PCI|Standard primary PCI
355491|NCT00623623|Drug|enoxaparin|Adjunctive treatment
355492|NCT00623623|Procedure|catheterisation|Routine or rescue coronary intervention
355493|NCT00625547|Drug|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
355494|NCT00625560|Drug|Entecavir|entecavir 1.0 mg QD
355495|NCT00625560|Drug|Lamivudine|lamivudine 100 mg QD
355496|NCT00625573|Drug|Abraxane|100mg/m2 every week X's 3
355497|NCT00625586|Biological|RAV12 plus gemcitabine|Initial dose of gemcitabine plus RAV12 at 0.375 mg/kg qw escalated to 0.75 mg/kg qw.
During the efficacy segment, 63 pts were to be treated with gemcitabine 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days plus RAV12 at Maximum Tolerated Dose (MTD) iv days 1; 4 or 5; 8, 11 or 12; and 15, 18 or 19 of each 28-day cycle until progression.
355498|NCT00625599|Other|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
354841|NCT00598715|Device|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
354842|NCT00598715|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
354843|NCT00598728|Behavioral|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
354844|NCT00598741|Other|DCE-MRI|Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.
MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner.
354845|NCT00004216|Biological|salmonella VNP20009|
354846|NCT00598793|Drug|biphasic insulin aspart|
354847|NCT00598793|Drug|insulin glargine|
354848|NCT00598793|Drug|metformin|
354849|NCT00598793|Drug|pioglitazone|
354850|NCT00598806|Drug|EOquin® (Apaziquone)|4mg in 40 mL for intravesical instillation
354851|NCT00598819|Device|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
354852|NCT00598832|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
354853|NCT00598832|Drug|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
354854|NCT00598845|Procedure|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
354855|NCT00598858|Drug|Docetaxel|Given IV
354856|NCT00000613|Drug|genistein|
355166|NCT00630396|Drug|Minocycline|Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.
Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.
Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.
Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses
355167|NCT00630409|Drug|Gemcitabine|800 mg IV day 1 and 8
355168|NCT00630409|Drug|Doxil|24 mg/m2 every 21 days IV
354542|NCT00606424|Drug|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
354543|NCT00606437|Procedure|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
354544|NCT00606450|Drug|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
354545|NCT00606450|Drug|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
354546|NCT00606450|Drug|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
354547|NCT00606476|Drug|Bapineuzumab (AAB-001)|IV q13w
354548|NCT00606489|Drug|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
354549|NCT00606489|Drug|Placebo|Placebo
354550|NCT00606502|Drug|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.
Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.
Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
354551|NCT00004244|Biological|recombinant interferon alfa|
354552|NCT00606502|Drug|Erlotinib|150 mg orally in tablet form
Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
354553|NCT00606502|Dietary Supplement|Vitamin B12|1 mg intramuscular injection
Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment.
354554|NCT00606502|Dietary Supplement|Folic Acid|1-1.25 mg orally
Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.
354555|NCT00606515|Drug|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
354857|NCT00004216|Drug|cefixime|
353913|NCT00618514|Device|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
353914|NCT00618527|Drug|mycophenolate mofetil (Cellcept)|1 gram po, bid
353915|NCT00004412|Drug|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
353916|NCT00618527|Drug|human interferon beta 1a (Rebif)|44mcg sq injection every other day
353917|NCT00620763|Other|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
354230|NCT00613496|Drug|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
354231|NCT00613509|Biological|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
354232|NCT00613509|Biological|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
354233|NCT00613522|Other|polygraphic study|Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale > 2.
Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).
Controls will be evaluated at 3 months using a phone interview
354234|NCT00613535|Device|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
354235|NCT00613535|Device|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
354236|NCT00613535|Procedure|Lavage debridement|Remove loose chondral fragments
354237|NCT00613535|Device|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
354238|NCT00613535|Device|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
354239|NCT00613548|Procedure|CABG alone|CABG alone
354240|NCT00004323|Drug|methotrexate|
354241|NCT00613548|Procedure|CABG + Mitral repair|CABG + Mitral repair
354242|NCT00613561|Drug|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
354243|NCT00613574|Drug|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
353611|NCT00624962|Dietary Supplement|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
353612|NCT00624962|Dietary Supplement|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
353613|NCT00624975|Biological|Peru-15 Vaccine|up to 1 x 10^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
353614|NCT00624975|Biological|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
353615|NCT00004547|Procedure|Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|
353616|NCT00624988|Procedure|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
353617|NCT00625014|Drug|Haloperidol|Haloperidol 3 mg/day for 8 days
353618|NCT00625027|Other|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
353619|NCT00625040|Other|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|OGTT: The test is performed with 50 g of glucose deluded in 300 ml water
Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT
Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water
Gastric Emptying Rate: Paracetamol absorption test.
353620|NCT00627211|Procedure|Room air insufflation through the endoscopy rack|CO2 will be insufflated during oesophagogastroduodenoscopy in the intervention group, the control group will be examined with room air.
353621|NCT00627211|Procedure|CO2 insufflation using an Olympus CO2 insufflator|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
353918|NCT00620776|Behavioral|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
353919|NCT00620776|Drug|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
353920|NCT00620789|Drug|Escitalopram + CBT-I|Escitalopram, 10 mg daily for the duration of the study (6 months)
CBT-I, four biweekly sessions during eight week Treatment phase.
353921|NCT00620789|Behavioral|CBT-I plus placebo antidepressant medication|CBT-I, 4 biweekly sessions, eight week Treatment phase.
Placebo,daily for duration of study(6 months).
353313|NCT00000612|Drug|estrogens, conjugated|
353314|NCT00004199|Drug|cisplatin|
353315|NCT00595231|Drug|SYN111 - Placebo|SYN111 - Placebo
353316|NCT00595231|Drug|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
353317|NCT00595244|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
353318|NCT00595257|Device|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
353319|NCT00595270|Biological|IC51|
353320|NCT00595283|Behavioral|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
353321|NCT00595283|Behavioral|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
353322|NCT00595296|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
353323|NCT00595309|Biological|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
353324|NCT00595322|Other|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains < 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
353325|NCT00004199|Drug|gemcitabine hydrochloride|
353326|NCT00595335|Drug|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
353327|NCT00595335|Drug|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
353328|NCT00595335|Drug|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
353622|NCT00627237|Behavioral|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
358857|NCT00692731|Dietary Supplement|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
358858|NCT00692731|Other|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
358859|NCT00692757|Drug|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
358860|NCT00005743|Behavioral|exercise|
358861|NCT00692757|Drug|Iodopovidone|Iodopovidone
358862|NCT00692770|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
359171|NCT00005567|Behavioral|Parental knowledge and beliefs about infant sleep position|
359172|NCT00676091|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
359173|NCT00676104|Device|CoolSystems Discrete Cerebral Hypothermia System|The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
359174|NCT00676117|Drug|Esomeprazole (D961H)|20mg
359175|NCT00676117|Drug|Loxoprofen|60mg tablet
359176|NCT00676130|Drug|trimethoprim-sulfamethoxazole|Weight-based dosing in capsule or suspension form according to the following scale:
15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily
20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily
25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily
29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily
60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily
60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily
> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily
359177|NCT00676130|Drug|Cephalexin|Weight-based dosing in capsule or suspension form according to the following scale:
15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily
20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily
25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily
29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily
60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily
> 80 kg (176 lbs): Cephalexin 1000 mg four times daily
359178|NCT00676143|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
359179|NCT00676143|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
359180|NCT00676156|Drug|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
359181|NCT00676156|Drug|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
359182|NCT00005569|Drug|SLPI (Secretory Leukocyte Protease Inhibitor)|
353693|NCT00595491|Biological|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
353995|NCT00627419|Drug|IPI-504|Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
353996|NCT00627432|Drug|gemcitabine hydrochloride|
353997|NCT00627432|Drug|oxaliplatin|
353998|NCT00627445|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
353999|NCT00627445|Drug|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
354000|NCT00627445|Drug|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
354001|NCT00627458|Biological|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
354002|NCT00627471|Drug|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
354003|NCT00627471|Drug|Insulin Glargine|In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.
For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.
354004|NCT00004582|Drug|Efavirenz|
354005|NCT00627484|Procedure|Gastric bypass|NOTE: the surgery is not paid for by the study
354006|NCT00627484|Procedure|Gastric banding|NOTE: the surgery is not paid for by the study
354007|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
354008|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
353389|NCT00603096|Device|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
353390|NCT00603109|Drug|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
353391|NCT00603109|Drug|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
353392|NCT00603122|Behavioral|ascent protocol|ascent protocol for the two groups has different acclimatization time
353393|NCT00603135|Drug|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
353394|NCT00603174|Device|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
353395|NCT00004231|Drug|cyclophosphamide|
353694|NCT00595504|Drug|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
353695|NCT00004200|Drug|prinomastat|
353696|NCT00595504|Drug|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
353697|NCT00595517|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
353698|NCT00595530|Drug|ketamine|The medication will be administered intravenously. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hour, 0.1 mg/kg/hour, 0.15 mg/kg/hour, and 0.2 mg/kg/hour.
Dosing Regimen:
All patients will begin the ketamine infusion at 0.05 mg/kg/hour.
4 or more hours after the infusion is started, the dose may be increased to 0.1 mg/kg/hour if:
the patient's pain has not improved to an acceptable level (pain score is still ≥5)
side effects remain acceptable
4 hours or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hour
4 hours or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour
The maximum dose of ketamine will be limited to 300 mg per 24 hours
The patient may receive ketamine up to 72 hours after initiation.
353699|NCT00595543|Drug|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
353700|NCT00595543|Drug|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
353701|NCT00598117|Behavioral|Questionnaires|Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)
Initial QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)
Follow up QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)
Follow up QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)
Follow up QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS
353702|NCT00598130|Biological|Fleece|Fibrin Patch
353092|NCT00611000|Dietary Supplement|folic acid|
353093|NCT00004266|Drug|nifedipine|
353094|NCT00611000|Genetic|DNA methylation analysis|
353095|NCT00611000|Genetic|gene expression analysis|
353096|NCT00611000|Genetic|microarray analysis|
353097|NCT00611000|Genetic|polymorphism analysis|
353098|NCT00611000|Other|laboratory biomarker analysis|
353099|NCT00611013|Device|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
353100|NCT00613067|Drug|escitalopram|Start with escitalopram 10mg
According to patient's symptoms, stay on 10mg or increase up to 20mg
Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages
Length of washout period will be at least 2 weeks for any psychotropic drugs
353101|NCT00613080|Drug|capecitabine|1650 mg/m^2/day orally 5 days/week during radiotherapy.
353102|NCT00613080|Drug|oxaliplatin|
353103|NCT00613080|Procedure|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
353104|NCT00613080|Radiation|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
353396|NCT00603187|Drug|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
353397|NCT00603213|Procedure|Blood Volume Analysis, Echocardiogram|Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.
Echocardiogram is an ultrasound of the heart.
353398|NCT00603239|Drug|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
353399|NCT00603239|Drug|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
353400|NCT00603252|Biological|Twinrix|
353401|NCT00603252|Biological|Engerix-B|
353402|NCT00603252|Biological|Havrix|
353403|NCT00603252|Biological|HBVAXPRO|
353404|NCT00603252|Biological|Vaqta|
352812|NCT00620295|Drug|gemcitabine hydrochloride|Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m^2) on day 1 and day 8 of a 21 day cycle.
352813|NCT00004438|Drug|leuprolide|
352814|NCT00620308|Drug|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
352815|NCT00620308|Drug|Placebo|Dextrose 5% in water (the vehicle)
352816|NCT00620321|Drug|LY2181308 sodium|750 mg is administered as a 3 hour intravenous (IV) infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycle 2 until disease progression or unacceptable toxicity develops.
352817|NCT00620321|Drug|cytarabine|1.5g/m2 will be administered as a 4 hour IV infusion on Days 3, 4, 5 of Cycle 1 and Days 1, 2, 3 of Cycle 2 until disease progression or unacceptable toxicity develops.
352818|NCT00620321|Drug|idarubicin|12mg/m2 will be administered as a 30 minute IV infusion on Days 3, 4, 5 of Cycle 1 and on Days 1, 2, 3 of Cycle 2 until disease progression or unacceptable toxicity develops.
352819|NCT00620347|Drug|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
352820|NCT00620360|Dietary Supplement|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
352821|NCT00620360|Dietary Supplement|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
352822|NCT00620373|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
352823|NCT00620373|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
352824|NCT00004440|Drug|ibuprofen|
352825|NCT00620373|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
352826|NCT00620386|Device|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
352827|NCT00620386|Device|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
352828|NCT00620399|Other|lumbar corset|
352829|NCT00620412|Dietary Supplement|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10^10 LGG organisms.
352830|NCT00620412|Dietary Supplement|placebo control|2 capsules by mouth twice a day for 28 days
352230|NCT00594828|Device|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
352231|NCT00594828|Device|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
352232|NCT00594841|Procedure|Open Reduction Internal Fixation of AC joint dislocation|Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:
Anatomic reduction of the AC joint
Definitive fixation with a hook plate and screws
352233|NCT00594841|Other|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
352525|NCT00629161|Drug|placebo|12 months period of placebo plus 1 month period without placebo
352526|NCT00629174|Behavioral|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
352527|NCT00629174|Behavioral|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
352528|NCT00629187|Drug|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
352529|NCT00004642|Drug|SDZ MSL-109|
352530|NCT00629200|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
352531|NCT00629200|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
352532|NCT00629213|Drug|acarbose|
352533|NCT00629213|Drug|placebo|
352534|NCT00629226|Biological|cetuximab|Given IV
352535|NCT00629226|Drug|bortezomib|Given IV
352536|NCT00629226|Drug|cisplatin|Given IV
352537|NCT00629226|Radiation|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
352538|NCT00629239|Drug|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
352539|NCT00629239|Drug|Placebo|
351929|NCT00602602|Drug|gemcitabine hydrochloride|
351930|NCT00602602|Drug|oxaliplatin|
351931|NCT00602602|Other|immunohistochemistry staining method|
351932|NCT00602602|Other|laboratory biomarker analysis|
351933|NCT00602602|Procedure|conventional surgery|
351934|NCT00004230|Drug|captopril|
351935|NCT00602602|Procedure|endoscopic biopsy|
351936|NCT00602602|Procedure|laparoscopy|
351937|NCT00602602|Radiation|radiation therapy|
351938|NCT00602615|Drug|Torsemide|
351939|NCT00602628|Other|questionnaire administration|
351940|NCT00602628|Procedure|adjuvant therapy|
351941|NCT00602628|Procedure|biopsy|
351942|NCT00602628|Procedure|computed tomography|
351943|NCT00602628|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
351944|NCT00602628|Procedure|magnetic resonance imaging|
351945|NCT00004230|Drug|cyclophosphamide|
351946|NCT00602628|Procedure|therapeutic conventional surgery|
352234|NCT00004209|Drug|mitomycin C|
352235|NCT00597493|Drug|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
352236|NCT00597506|Drug|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
352237|NCT00597506|Drug|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
351641|NCT00610415|Procedure|tumor biopsy|
351642|NCT00610428|Drug|Staccato Prochlorperazine|Low dose
351643|NCT00610428|Drug|Staccato Prochlorperazine|High dose
351644|NCT00612469|Drug|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
351947|NCT00602628|Procedure|ultrasound imaging|
351948|NCT00602628|Radiation|radiation therapy|
351949|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
351950|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
351951|NCT00605176|Drug|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
351952|NCT00605189|Device|Powered Suction Pump (VAC Freedom)|continuous suction
351953|NCT00605189|Device|Powered Suction Pump|continuous suction
351954|NCT00605202|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
351955|NCT00605202|Dietary Supplement|Licorice|Licorice candy 32 grams a day for 14 days.
351956|NCT00605215|Drug|laquinimod|0.6 mg oral once daily for 24 months
351957|NCT00004237|Drug|doxorubicin hydrochloride|
351958|NCT00605215|Drug|placebo|oral placebo once daily for 24 months
351959|NCT00605215|Drug|Interferon β-1a (Avonex®)|Interferon β-1a (Avonex®) 30 mcg IM once weekly for 24 months
351960|NCT00605228|Drug|MOVIPREP|2L Drug
351961|NCT00605228|Drug|COLOPEG|4L Drug
351962|NCT00605241|Drug|GSK598809|Drug
351963|NCT00605267|Drug|Tamoxifen|20 mg once daily oral dose
351327|NCT00617448|Procedure|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
351328|NCT00617448|Procedure|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
351329|NCT00617448|Procedure|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
351330|NCT00617448|Procedure|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
351331|NCT00617461|Drug|GEn 1200mg/day|1200mg/day gabapentin enacarbil
351332|NCT00004398|Drug|tin mesoporphyrin|
351333|NCT00617461|Drug|GEn 3600mg/day|3600mg/day gabapentin enacarbil
351334|NCT00617474|Drug|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
351335|NCT00617474|Drug|Placebo|placebo
351336|NCT00617500|Other|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
351337|NCT00617500|Other|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
351645|NCT00612482|Other|drug prevention curriculum|Participants in the "experimental" arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes.
351646|NCT00612495|Drug|oxaliplatin, 5 FU|Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.
5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks.
351647|NCT00612508|Drug|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
351648|NCT00612508|Drug|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
351649|NCT00612521|Drug|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
356119|NCT00612040|Drug|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
356120|NCT00612040|Drug|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
356121|NCT00004297|Drug|lorazepam|
356122|NCT00612040|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
356123|NCT00612040|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
356124|NCT00612066|Drug|rosiglitazone maleate|
356125|NCT00612079|Drug|Sertindole|oral 3 x 4mg
356126|NCT00612079|Drug|Placebo|3 x 4mg Placebo
356127|NCT00612092|Radiation|Spiral image acquisition|standard spiral scan protocol
356128|NCT00612092|Radiation|sequential image acquisition|sequential CT scan protocol
356129|NCT00612105|Drug|Retigabine|150mg/day up to 900mg/day
356130|NCT00612105|Drug|Placebo|daily
356131|NCT00612118|Drug|GSK256066|200mcg bd
356132|NCT00004300|Drug|bromocriptine|
356133|NCT00612118|Drug|azelastine hydrochloride|140mcg
356134|NCT00612144|Drug|Glimepiride/metformin fixed combination|Amaryl M 1/250mg~4/1000mg bid for 12~26 weeks
Maintenance dose for 10 weeks after 2~14 weeks of dose titration
Dose titration according to titration algorithm based on daily mean SMBG
356135|NCT00614224|Behavioral|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
356136|NCT00614250|Drug|AVE0657|capsules once a day at bedtime
356137|NCT00614250|Drug|placebo|capsules once a day at bedtime
356138|NCT00614276|Behavioral|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
356139|NCT00614276|Behavioral|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
355499|NCT00625612|Drug|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
355500|NCT00625612|Drug|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
355501|NCT00004558|Behavioral|dietary n-3 polyunsaturated fatty acids|
355502|NCT00625625|Drug|isosulfan blue|
355503|NCT00625625|Genetic|polymerase chain reaction|
355504|NCT00625625|Other|diagnostic laboratory biomarker analysis|
355505|NCT00625625|Other|immunohistochemistry staining method|
355506|NCT00625625|Procedure|diagnostic lymphadenectomy|
355507|NCT00625625|Procedure|therapeutic conventional surgery|
355508|NCT00625625|Procedure|therapeutic lymphadenectomy|
355823|NCT00619216|Drug|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
355824|NCT00619229|Drug|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
355825|NCT00619229|Other|Placebo|Placebo/d i.v. for 15 days
355826|NCT00000626|Drug|Filgrastim|
355827|NCT00004423|Drug|-aminosalicylic acid|
355828|NCT00619242|Drug|sorafenib|2 tablets with water by mouth twice a day for two weeks.
355829|NCT00619255|Behavioral|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
355830|NCT00619268|Drug|Temsirolimus|25 mg once per week administered intravenously
355831|NCT00619268|Drug|Bevacizumab|10 mg/kg * 1 time /2 weeks administered intravenously
355832|NCT00619268|Drug|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
355833|NCT00619268|Drug|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
355169|NCT00593125|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
355170|NCT00593138|Drug|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
355171|NCT00593151|Other|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
355172|NCT00004192|Biological|pegfilgrastim|
355173|NCT00593151|Biological|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
355174|NCT00593164|Device|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
355175|NCT00593164|Device|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
355176|NCT00593177|Drug|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
355177|NCT00593190|Drug|Gas SF6 (Sulfur Hexafluoride)|ONCE
355178|NCT00593216|Device|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
355179|NCT00593242|Biological|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
355180|NCT00593242|Other|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
355181|NCT00593255|Drug|soluble human insulin|
355182|NCT00593255|Drug|insulin aspart|
355183|NCT00004192|Drug|cisplatin|
355184|NCT00593255|Drug|insulin NPH|
355509|NCT00625638|Behavioral|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
355510|NCT00625638|Other|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
354858|NCT00598858|Drug|Prednisone|Given PO
354859|NCT00598871|Drug|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
354860|NCT00601471|Other|distal tibiofibular manipulation|distal tibiofibular manipulation
354861|NCT00601471|Other|no intervention|no intervention / control
354862|NCT00004224|Radiation|radiation therapy|
354863|NCT00601484|Drug|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
354864|NCT00601484|Drug|Placebo|placebo IV, single dose
354865|NCT00601497|Device|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
354866|NCT00601510|Drug|capecitabine|
354867|NCT00601510|Drug|cisplatin|
354868|NCT00601510|Drug|imatinib mesylate|
354869|NCT00601523|Drug|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
354870|NCT00601523|Drug|Pramipexole|ER 0.375-4,5 mg
354871|NCT00601536|Drug|Lithium|
354872|NCT00601549|Procedure|Laparoscopic surgery|Laparoscopic surgery
354873|NCT00004225|Biological|Ad5CMV-p53 gene|
354874|NCT00601549|Procedure|Traditional open surgery|Open surgery
354875|NCT00601562|Drug|Zidovudine|
354876|NCT00601575|Drug|Lithium|
354877|NCT00601588|Drug|Sertraline|
354878|NCT00601614|Drug|temozolomide|
354879|NCT00601614|Drug|vandetanib|
354880|NCT00601614|Other|immunoenzyme technique|
354881|NCT00601614|Other|laboratory biomarker analysis|
354244|NCT00613600|Dietary Supplement|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
354245|NCT00613600|Dietary Supplement|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
354246|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
354247|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
354248|NCT00613626|Drug|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
354249|NCT00613626|Drug|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
354250|NCT00613626|Drug|Placebo|Matched placebo oral daily
354251|NCT00004323|Drug|methylprednisolone|
354556|NCT00606515|Drug|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
354557|NCT00606528|Other|No intervention|None. This is an observational study.
354558|NCT00606541|Drug|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
354559|NCT00609089|Behavioral|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
354560|NCT00004257|Drug|fluorouracil|
354561|NCT00609102|Drug|Placebo|one capsule BID
354562|NCT00609102|Drug|n-aceylcysteine|450 mgm BID
354563|NCT00609115|Device|AMES device|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
354564|NCT00609115|Device|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
354565|NCT00609115|Device|AMES device|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
354566|NCT00609128|Drug|olopatadine|olopatadine one drop in one eye for two weeks
353922|NCT00620789|Drug|Escitalopram|Escitalopram, 10 mg daily for the duration of the study (6 months)
SH, four biweekly sessions during eight week Treatment phase
353923|NCT00620802|Drug|CGT-2168|(CGT-2168, one capsule each daily)
353924|NCT00620802|Drug|Plavix|(clopidogrel, 75 mg)
353925|NCT00620815|Biological|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
353926|NCT00004443|Drug|NTBC|
353927|NCT00620815|Biological|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
353928|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
353929|NCT00620815|Biological|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
353930|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
353931|NCT00620815|Biological|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
353932|NCT00620828|Other|Placebo saline injection|20 cc of sterile, injectable saline
353933|NCT00620828|Drug|Ropivicaine 0.5%|Ropivicaine
353934|NCT00620841|Other|genotyping|Restriction fragment lenght polymorphisms
353935|NCT00620854|Drug|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
354252|NCT00613626|Drug|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
354253|NCT00613652|Drug|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
354254|NCT00613665|Biological|helicobacter pylori vaccine|Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
354255|NCT00616109|Drug|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
354256|NCT00616122|Drug|cyclophosphamide|
353623|NCT00627237|Behavioral|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
353624|NCT00627250|Drug|Amantadine|Amantadine 100 mg every morning and 12 noon
353625|NCT00627263|Behavioral|Stress reduction treatment (SRT) program|The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
353626|NCT00627276|Dietary Supplement|omega-3 fatty acid|Oral, 3 times daily
353627|NCT00627276|Other|placebo|Oral, 3 times daily
353628|NCT00627302|Drug|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
353629|NCT00000632|Biological|Env 2-3|
353630|NCT00004581|Drug|Lopinavir/Ritonavir|
353631|NCT00627302|Drug|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
353632|NCT00627315|Procedure|Gastric bypass|NOTE: Surgery will not be paid by the study
353633|NCT00627315|Procedure|Gastric banding|NOTE: Surgery will not be paid by the study
353634|NCT00627341|Behavioral|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
353635|NCT00627341|Behavioral|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
353636|NCT00627354|Drug|etoposide|
353637|NCT00627354|Drug|mitoxantrone hydrochloride|
353638|NCT00627354|Drug|prednisone|
353639|NCT00627354|Drug|vinorelbine tartrate|
353640|NCT00627367|Drug|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
353641|NCT00004581|Drug|Nevirapine|
353642|NCT00627367|Drug|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
359183|NCT00676156|Drug|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
359184|NCT00676182|Other|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
359185|NCT00676195|Drug|N-Acetyl Cysteine|Dosage of orally administered N-Acetyl Cysteine is as follows:
Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day
359186|NCT00676208|Behavioral|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
359187|NCT00676221|Drug|Myfortic|Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.
Cellcept 1000mg bid = Myfortic 720mg bid
359188|NCT00676234|Drug|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
359189|NCT00676260|Drug|Pioglitazone|Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
359493|NCT00686023|Procedure|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
359494|NCT00686036|Drug|vandetanib|300 mg orally, once daily for up to 18 months
359495|NCT00686036|Drug|Placebo|
359496|NCT00686062|Other|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
359497|NCT00686062|Other|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
359498|NCT00686075|Biological|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
359499|NCT00686075|Other|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
359500|NCT00686075|Biological|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
359501|NCT00005615|Radiation|Radiation therapy|Radiation therapy as outlined in treatment arm.
359502|NCT00686075|Other|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
359503|NCT00686075|Biological|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
359504|NCT00686075|Other|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
354009|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 [13mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
354010|NCT00004654|Drug|soy protein isolate|
354011|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 [22mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
354012|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 [13mg of liposomes/kg]
354013|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 [22mg of liposomes/kg]
354338|NCT00623077|Drug|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day intravenous (IV) over 1 hour on for 5 days.
354339|NCT00623077|Drug|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m^2 intravenous (IV) over 30 min on Days -5 through -4.
354340|NCT00623077|Drug|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m^2 intravenously (IV) over 2 hrs on Days -3 through -2.
354341|NCT00623077|Procedure|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
354342|NCT00623077|Radiation|tomotherapy|We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy
/minute (instantaneous dose rate).
354343|NCT00004482|Drug|prednisone|
354344|NCT00623077|Radiation|total marrow irradiation|TMI will be delivered to all bony sites as part of the conditioning. Additional "spot" therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9.
354345|NCT00623077|Drug|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day divided in every 6 hrs dosing for 5 days.
354346|NCT00623077|Radiation|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
354347|NCT00623090|Behavioral|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
354348|NCT00623090|Behavioral|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
353703|NCT00598143|Behavioral|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
353704|NCT00598143|Behavioral|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
353705|NCT00598156|Drug|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
353706|NCT00004212|Drug|exatecan mesylate|
353707|NCT00598156|Drug|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
353708|NCT00598169|Biological|rituximab|375mg/m2 on Day 1
353709|NCT00598169|Drug|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
353710|NCT00598169|Drug|carboplatin|Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x [creatinine clearance + 25]; the maximum dose of carboplatin is 750 mg.
Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2.
354014|NCT00629850|Device|Powerlung Performer|Inspiratory/Expiratory muscle trainer
354015|NCT00629863|Drug|cisplatin|
354016|NCT00629863|Drug|fluorouracil|
354017|NCT00629863|Other|questionnaire administration|
354018|NCT00629863|Procedure|diagnostic endoscopic procedure|
354019|NCT00629863|Procedure|neoadjuvant therapy|
354020|NCT00629863|Procedure|quality-of-life assessment|
354021|NCT00004656|Procedure|Metabolic assessment with body composition evaluation|
354022|NCT00629863|Procedure|therapeutic conventional surgery|
354023|NCT00629863|Procedure|therapeutic endoscopic surgery|
354024|NCT00629863|Procedure|ultrasound imaging|
354025|NCT00629863|Radiation|radiation therapy|
354026|NCT00629863|Radiation|radioisotope therapy|
353405|NCT00603265|Drug|ADL5859|
353406|NCT00004231|Drug|cytarabine|
353407|NCT00603265|Drug|Duloxetine|
353408|NCT00603265|Drug|Placebo|
353409|NCT00603278|Drug|GW685698X|GW685698X
353410|NCT00603278|Drug|placebo|placebo
353411|NCT00603291|Drug|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
353412|NCT00603291|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
353413|NCT00603291|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
353414|NCT00605891|Drug|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
353415|NCT00004241|Drug|tanespimycin|Given IV
353416|NCT00605891|Drug|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
353417|NCT00605904|Drug|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
353418|NCT00605904|Drug|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
353419|NCT00605904|Drug|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
353420|NCT00605904|Drug|Saline|Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the "Saline Infusion" milestone, and one time immediately following the "Yohimbine Infusion" milestone)
353711|NCT00598169|Drug|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
353712|NCT00598169|Drug|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
353713|NCT00598169|Drug|ifosfamide|Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.
Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2.
353714|NCT00598169|Genetic|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
353105|NCT00613080|Drug|FOLFOX|Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m^2, IV over 2 hours, day 1.
Leucovorin 400 mg/m^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m^2, IV continuous infusion over 46 hours, day 1.
353106|NCT00613093|Drug|Temodar and O6-Benzylguanine (BG)|Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).
BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.
353107|NCT00004317|Drug|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
353108|NCT00613106|Drug|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
353109|NCT00613106|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
353110|NCT00613132|Drug|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort & will be increased to 600 mg po/day & then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 & hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
353111|NCT00613145|Drug|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:
Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
353112|NCT00613145|Drug|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
353113|NCT00613171|Drug|STI571|STI571 tablets taken orally once a day
353114|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
353115|NCT00615576|Drug|SB656933|
353116|NCT00004363|Drug|desmopressin|
352540|NCT00004643|Drug|cytarabine|
352541|NCT00629252|Drug|Sertindole|oral 12-20 mg/day
352542|NCT00629252|Drug|Risperidone|oral 2-6mg / day
352543|NCT00629265|Device|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
352544|NCT00629278|Biological|trastuzumab|
352545|NCT00629278|Drug|aromatase inhibition therapy|
352546|NCT00629278|Drug|cyclophosphamide|
352547|NCT00629278|Drug|docetaxel|
352548|NCT00629278|Drug|doxorubicin hydrochloride|
352549|NCT00629278|Drug|epirubicin hydrochloride|
352831|NCT00622570|Drug|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
352832|NCT00622570|Drug|thiopental|2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.
Maintenance: 3 mg/kg/h in perfusion
352833|NCT00622596|Drug|buprenorphine|Day 1: 8 mg of buprenorphine, then Day 2 on: 16 mg daily of buprenorphine sublingually
352834|NCT00004474|Procedure|Bone marrow transplantation|Given on Day 0
352835|NCT00622609|Drug|GSK249320|IV Infusion
352836|NCT00622609|Drug|Placebo|Placebo Comparator
352837|NCT00622622|Biological|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
352838|NCT00622635|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
352839|NCT00622635|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
352840|NCT00622635|Drug|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
352841|NCT00622648|Drug|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
352238|NCT00597519|Drug|Fludarabine, Cyclophosphamide|Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.
Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).
Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery.
352239|NCT00597519|Procedure|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
352240|NCT00597532|Dietary Supplement|Soy|soy (soy protein supplementation 50 grams/day)
352241|NCT00597532|Dietary Supplement|Milk|placebo (milk protein supplementation 50 grams/day)
352242|NCT00597545|Procedure|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
352243|NCT00597545|Device|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
352244|NCT00597558|Drug|Egg white protein|Egg white protein powder
352245|NCT00004209|Drug|vinblastine sulfate|
352246|NCT00597584|Drug|peginesatide|Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.
The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
352247|NCT00597584|Drug|Epoetin alfa or Epoetin beta|Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.
The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
352248|NCT00597597|Drug|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
352550|NCT00629278|Drug|fluorouracil|
352551|NCT00004644|Drug|acyclovir|
352552|NCT00629278|Drug|paclitaxel|
352553|NCT00629278|Drug|releasing hormone agonist therapy|
351964|NCT00605267|Drug|Anastrazole (Arimidex)|1 mg once daily oral dose
351965|NCT00605267|Drug|Goserelin acetate (Zoladex)|3.6mg/month depot injection
351966|NCT00605280|Drug|Standard of Care|Clinicians decision to use optional laser therapy.
351967|NCT00605280|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
351968|NCT00000617|Drug|azithromycin|
351969|NCT00004237|Drug|epirubicin hydrochloride|
351970|NCT00605293|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv/month (starting dose)
352249|NCT00597610|Other|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
352250|NCT00600353|Drug|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
352251|NCT00600353|Drug|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
352252|NCT00600366|Drug|biphasic insulin aspart|
352253|NCT00600379|Device|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
352254|NCT00004220|Drug|gemcitabine hydrochloride|
352255|NCT00600405|Drug|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
352256|NCT00600405|Drug|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
352257|NCT00600444|Procedure|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
352258|NCT00600444|Procedure|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
352259|NCT00600457|Device|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
351650|NCT00612534|Drug|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
351651|NCT00004311|Drug|leuprolide acetate|
351652|NCT00612534|Drug|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
351653|NCT00612534|Drug|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
351654|NCT00612534|Drug|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
351655|NCT00612547|Drug|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|Tablet:
Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day
351656|NCT00612560|Drug|Anastrozole|1 mg per day
351657|NCT00612560|Dietary Supplement|flaxseed|25 g per day ground
351658|NCT00612560|Drug|Placebo|Placebo pill 1 per day
351659|NCT00612573|Drug|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
351660|NCT00612573|Drug|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
351661|NCT00612573|Drug|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
351662|NCT00004311|Drug|spironolactone|
351663|NCT00612573|Drug|Placebo|Placebo, 12 weeks
351664|NCT00612586|Drug|Enzastaurin|1125 mg loading dose, then 250 mg twice daily, oral(up to 1 yr or until progressive disease)
351665|NCT00612586|Drug|Placebo|oral, daily (up to 1 yr or until progressive disease)
351971|NCT00605293|Drug|Epoetin alfa|As prescribed
351972|NCT00605306|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
351973|NCT00605306|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
351974|NCT00605319|Drug|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
351975|NCT00605332|Device|inferior vena cava filter|Crux Biomedical IVC Filter
351976|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
356140|NCT00614276|Behavioral|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
356141|NCT00614276|Behavioral|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
351338|NCT00619723|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
351339|NCT00619723|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
351340|NCT00619736|Drug|NSA-789|
351341|NCT00619736|Other|Placebo|
351342|NCT00619749|Dietary Supplement|juice rich in polyphenols|juice during 2 weeks
351343|NCT00619749|Dietary Supplement|juice poor in polyphenols|juice during 2 weeks
351344|NCT00619762|Device|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
351345|NCT00619775|Device|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
351346|NCT00004430|Drug|Dihematoporphyrin derivative|
351347|NCT00619788|Device|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
351348|NCT00619801|Drug|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
351349|NCT00619801|Drug|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
351350|NCT00619814|Procedure|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
351351|NCT00619827|Biological|Sublingual immunotherapy tablets of grass pollen allergen extract|300IR allergen-based tablets once daily during four months
351352|NCT00619840|Drug|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
355834|NCT00619307|Drug|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
355835|NCT00621322|Biological|Control vaccine with physiological saline|Intramuscular injection, 2 doses
355836|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations|Intramuscular injection, 2 doses
355837|NCT00621322|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses
355838|NCT00621348|Drug|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
355839|NCT00621348|Drug|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
355840|NCT00621348|Drug|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
355841|NCT00621361|Drug|AZD2171|Oral
355842|NCT00621361|Drug|Etoposide|Intravenous
355843|NCT00621361|Drug|Cisplatin|Intravenous
355844|NCT00004449|Behavioral|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
356142|NCT00614289|Device|Epikeia Coatings|Topical skin coating
356143|NCT00614302|Drug|TPV|
356144|NCT00614315|Device|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
356145|NCT00004340|Drug|calcitriol|
356146|NCT00614328|Drug|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
356147|NCT00614341|Device|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
356148|NCT00614354|Drug|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
356149|NCT00614380|Drug|telmisartan/amlodipine 40/5 mg fixed combination|
356150|NCT00614380|Drug|telmisartan/amlodipine 80/5 mg fixed combination|
355511|NCT00625651|Drug|Placebo|Inactive dummy AMG 655 (to maintain blind)
355512|NCT00004559|Behavioral|dietary polyunsaturated fatty acid|
355513|NCT00625651|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
355514|NCT00625651|Drug|Modified FOLFOX6|Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)] administered by intravenous infusion once every 14 days (+3 days)
355515|NCT00625651|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
355516|NCT00625664|Drug|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
355517|NCT00625664|Drug|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
355518|NCT00625664|Drug|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
355519|NCT00627926|Drug|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
355520|NCT00627926|Drug|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
355521|NCT00627926|Other|Placebo|Telaprevir matching placebo
355522|NCT00627952|Drug|amlodipine 10 mg|amlodipine 10 mg once daily
355523|NCT00627952|Drug|manidipine 20 mg|manidipine 20 mg once daily
355524|NCT00627952|Drug|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
355525|NCT00627952|Drug|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
355526|NCT00627965|Drug|Sildenafil citrate|50mg tds
355527|NCT00627965|Drug|Placebo|Placebo tds
355528|NCT00004585|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
355529|NCT00627978|Drug|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
355530|NCT00627991|Drug|Valsartan|
354882|NCT00601627|Biological|panitumumab|
354883|NCT00601627|Drug|capecitabine|
355185|NCT00593281|Drug|Hylenex|Add Hylenex to SC injection of Morphine
355186|NCT00593294|Behavioral|Physical exercise|45 minutes each day for three times/week for 6 months
355187|NCT00593294|Drug|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
355188|NCT00593294|Dietary Supplement|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
355189|NCT00593307|Other|high GI|high GI and high carb breakfast
355190|NCT00593307|Other|Low GI|low GI, high carb breakfast
355191|NCT00593307|Other|Low GI Low Carb|low GI low carb breakfast
355192|NCT00593307|Other|High GI Low carb|high GI low carb breakfast
355193|NCT00596180|Drug|HBOT|total body exposure to greater than atmospheric pressure oxygen
355194|NCT00596206|Drug|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
355195|NCT00596219|Drug|celecoxib|celecoxib
355196|NCT00000161|Drug|Vitamin E|
355197|NCT00000612|Behavioral|diet, soy proteins|
355198|NCT00004202|Drug|efaproxiral|
355199|NCT00596245|Drug|MT400|MT 400, naproxen sodium 550mg
355200|NCT00596258|Drug|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
355201|NCT00596271|Biological|IC51|
355202|NCT00596271|Biological|HAVRIX|
355203|NCT00596271|Other|Placebo|
355204|NCT00596284|Behavioral|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
354567|NCT00609141|Biological|cixutumumab|Given IV
354568|NCT00609141|Other|pharmacological study|Correlative studies
354569|NCT00609141|Other|laboratory biomarker analysis|Correlative studies
354570|NCT00609154|Drug|glucagon like peptide-1|GLP-1 1 pmole/kg/min
354571|NCT00004257|Drug|oxaliplatin|
354572|NCT00609154|Drug|glucose control|glucose without GLP-1
354573|NCT00609167|Drug|bortezomib|First 33 patients: 1.3 mg/m^2 IV Days 1, 4, 8 & 11
Remaining 30 patients: 1.5 mg/m^2 IV Days 1, 8, 15 & 22
354574|NCT00609167|Drug|cyclophosphamide|300mg/m^2 PO days 1, 8, 15 & 22
354575|NCT00609167|Drug|dexamethasone|First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20
Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond
354884|NCT00004225|Radiation|radiation therapy|
354885|NCT00601627|Drug|fluorouracil|
354886|NCT00601627|Drug|gemcitabine hydrochloride|
354887|NCT00601627|Radiation|radiation therapy|
354888|NCT00601640|Drug|diclofenac sodium gel|Given topically twice daily on days 1-90
354889|NCT00601640|Drug|eflornithine hydrochloride ointment|Given topically twice daily on days 1-90
354890|NCT00601653|Behavioral|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
354891|NCT00601653|Behavioral|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
354892|NCT00603798|Drug|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
354893|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
354894|NCT00603811|Biological|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
354257|NCT00616122|Drug|methotrexate|
354258|NCT00616122|Drug|sunitinib malate|
354259|NCT00004375|Procedure|ultraviolet A-1 light treatment|
354260|NCT00616122|Other|laboratory biomarker analysis|
354261|NCT00616135|Procedure|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
354262|NCT00616148|Drug|YKP3089|Oral dosage form
354263|NCT00616148|Drug|Placebo|
354264|NCT00616161|Drug|Istaroxime|0.5 microgram/kg/min IV for 6 hours
354265|NCT00616161|Drug|Istaroxime|1.0 microgram/kg/min IV for 6 hours
354266|NCT00616161|Drug|Istaroxime|1.5 microgram/kg/min IV for 6 hours
354267|NCT00616161|Drug|Placebo|Placebo
354268|NCT00616174|Procedure|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
354269|NCT00616187|Drug|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
354270|NCT00004376|Drug|guanfacine|
354271|NCT00616187|Drug|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
354272|NCT00616200|Other|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
354273|NCT00616213|Biological|filgrastim|filgrastim will be administered at a standard dose and schedule
354576|NCT00609180|Behavioral|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
354577|NCT00609180|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
353936|NCT00620854|Drug|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
353937|NCT00004444|Drug|paromomycin|
353938|NCT00620854|Drug|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
353939|NCT00622895|Other|flow cytometry|Correlative studies
353940|NCT00622895|Procedure|biopsy|Punch biopsy of skin involved with scleroderma
353941|NCT00622895|Drug|cyclophosphamide|Given IV
353942|NCT00622908|Drug|ISV-403|0.6% TID, 5 days
353943|NCT00622908|Drug|Vehicle|Vehicle of ISV-403 TID, 5 days
353944|NCT00004482|Drug|Cyclosporine|
353945|NCT00622921|Behavioral|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
353946|NCT00622934|Drug|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
353947|NCT00622934|Drug|placebo|placebo
353948|NCT00622947|Procedure|right temporal low frequency (1 hz) rTMS|A Magstim Rapid stimulator (the Magstim Company Ltd, Whiteland, UK)with a 90 mm circular coil is used. Low frequency rTMS at 1 Hz of right temporal cortex. Each session covering 2 trains of 60 sec. and 180 sec intertrain interval.
353949|NCT00622947|Procedure|Sham-rTMS|The coil is angled 90 degrees away from the scalp
353950|NCT00622960|Other|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
353951|NCT00622960|Other|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
353952|NCT00622973|Other|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
353953|NCT00622973|Other|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
353954|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
353955|NCT00004482|Drug|methylprednisolone|
353956|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
354973|NCT00611611|Biological|pneumovax|once
354974|NCT00611624|Radiation|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
354975|NCT00611637|Biological|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
354976|NCT00611650|Drug|defined green tea catechin extract|Given orally
354977|NCT00611650|Other|placebo|Given orally
354978|NCT00611663|Biological|Prevenar® and Pneumo23®|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
354979|NCT00004286|Drug|immune globulin|
354980|NCT00611663|Biological|Placebo, Pneumo23®|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
354981|NCT00611676|Drug|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
354982|NCT00611689|Drug|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in < 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
354983|NCT00611702|Procedure|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
354984|NCT00611715|Drug|erlotinib hydrochloride|OSI-774 150 mg/day
354985|NCT00611715|Drug|letrozole|Letrozole 2.5 mg/day
354986|NCT00611715|Genetic|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
355292|NCT00606645|Biological|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
355293|NCT00004246|Drug|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
355294|NCT00606658|Procedure|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
354349|NCT00623090|Behavioral|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
354350|NCT00623103|Drug|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
354351|NCT00625131|Drug|Placebo patch|Pre-treatment placebo transdermal patch
354352|NCT00625157|Drug|ASF 1096 0.5 % cream|
354353|NCT00625157|Drug|ASF 1096 placebo cream|
354354|NCT00625170|Drug|olanzapine|olanzapine 10 mg/day for 8 days
354355|NCT00625170|Drug|Haloperidol|haloperidol 3 mg/day for 8 days
354356|NCT00625183|Dietary Supplement|selenomethionine|
354357|NCT00004551|Drug|nicotine replacement patch|
354649|NCT00618735|Drug|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
354650|NCT00618735|Drug|BIIB021|Twice daily dosing
354651|NCT00618748|Drug|Olanzapine|5-20 mg/day, oral, daily
354652|NCT00618761|Other|hyperglycemic clamp test|hyperglycemic clamp test
354653|NCT00618774|Drug|telmisartan40/amlodipine5|
354654|NCT00618774|Drug|telmisartan80/amlodipine5|
354655|NCT00618787|Device|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
354656|NCT00618787|Device|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
354657|NCT00618800|Behavioral|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
354658|NCT00618800|Other|Written Materials|Participants receive written information about falls prevention.
354659|NCT00004416|Drug|botulinum toxin type A|
354660|NCT00618813|Other|radiation therapy|Undergo radiation therapy
354661|NCT00618813|Other|therapeutic conventional surgery|Undergo surgery
354027|NCT00629876|Drug|Peginesatide|Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.
Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen.
354028|NCT00629889|Drug|levetiracetam|After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.
Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.
354029|NCT00629889|Drug|pregabalin|After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.
Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.
354030|NCT00629928|Drug|Esomeprazole|20mg oral capsule daily
354031|NCT00004188|Radiation|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
354032|NCT00592345|Radiation|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
354033|NCT00592358|Drug|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
354034|NCT00592384|Drug|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
354035|NCT00592384|Drug|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
354358|NCT00625183|Drug|capecitabine|
354359|NCT00625183|Drug|oxaliplatin|
354360|NCT00625183|Other|laboratory biomarker analysis|
354361|NCT00625183|Other|pharmacological study|
354362|NCT00625183|Procedure|adjuvant therapy|
354363|NCT00625183|Procedure|neoadjuvant therapy|
354364|NCT00625183|Procedure|therapeutic conventional surgery|
354365|NCT00625183|Radiation|radiation therapy|
354366|NCT00625196|Drug|GW642444M, GW685698X|
354367|NCT00625209|Drug|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
353715|NCT00598169|Genetic|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
353716|NCT00598195|Drug|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
353717|NCT00004213|Drug|triapine|
353718|NCT00598208|Drug|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
353719|NCT00601003|Drug|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
353720|NCT00601003|Drug|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
353721|NCT00601003|Drug|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
353722|NCT00601016|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
353723|NCT00601042|Other|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
353724|NCT00004223|Drug|gemcitabine hydrochloride|
353725|NCT00601042|Other|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
353726|NCT00601055|Behavioral|Problem-solving therapy (PST)|In PST, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
353727|NCT00601055|Behavioral|Adherence-enhanced procedures (AE)|In AE, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
353728|NCT00601068|Other|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
354036|NCT00592397|Other|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
354037|NCT00592410|Drug|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
353117|NCT00615589|Drug|Fludarabine/Busulfan x 4 days|Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.
Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.
The Fludarabine shall be administered prior to the Busulfan each day.
353118|NCT00615589|Procedure|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
353421|NCT00605917|Drug|Sertraline hydrochloride|J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.
Dosage, Frequency: According to Japanese LPD, "The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms".
Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration.
353422|NCT00605930|Dietary Supplement|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
353423|NCT00605930|Dietary Supplement|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
353424|NCT00605956|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
353425|NCT00605956|Drug|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
353426|NCT00004241|Other|pharmacological study|Correlative studies
353427|NCT00605956|Drug|Blank Patch|Blank Patch
353428|NCT00605969|Procedure|Motion analysis|Motion analysis and CT
353429|NCT00605969|Procedure|Motion analysis|Motion analysis and CT
353430|NCT00605982|Procedure|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
353431|NCT00605995|Drug|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
353432|NCT00606008|Drug|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
353433|NCT00606021|Drug|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
353434|NCT00606021|Drug|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
353435|NCT00606034|Drug|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
352842|NCT00622648|Drug|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
352843|NCT00622661|Other|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
352844|NCT00622661|Other|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
352845|NCT00004475|Procedure|genetic testing|
352846|NCT00622674|Biological|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
352847|NCT00622674|Drug|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
352848|NCT00622687|Drug|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
352849|NCT00622687|Drug|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
352850|NCT00622687|Drug|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
352851|NCT00622700|Drug|Teriflunomide|Film-coated tablet Oral administration
352852|NCT00622700|Drug|Placebo|Film-coated tablet Oral administration
353119|NCT00615602|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
353120|NCT00615602|Drug|Trastuzumab|Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
353121|NCT00615602|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
353122|NCT00615602|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
353123|NCT00615602|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
353124|NCT00615602|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
353125|NCT00615602|Drug|Trastuzumab|Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
353126|NCT00615615|Drug|Levetiracetam|
353127|NCT00004364|Drug|desmopressin|
352554|NCT00629278|Drug|tamoxifen citrate|
352555|NCT00629278|Procedure|adjuvant therapy|
352556|NCT00591721|Behavioral|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
352557|NCT00591734|Drug|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
352558|NCT00591734|Drug|Everolimus|10 mg by mouth daily
352559|NCT00591747|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
352560|NCT00591747|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
352561|NCT00591760|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
352562|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
352563|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
352564|NCT00591773|Drug|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
352565|NCT00591786|Drug|Sugammadex|4 Doses of Sugammadex Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium
352566|NCT00004188|Drug|topotecan hydrochloride|Given IV
352567|NCT00591786|Drug|Placebo|4 Doses of placebo Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium
352853|NCT00622713|Drug|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm^2.
352260|NCT00600470|Behavioral|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
352261|NCT00600470|Behavioral|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
352262|NCT00600483|Drug|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
352263|NCT00600496|Drug|AZD6244|twice daily oral dose
352264|NCT00600496|Drug|Dacarbazine|intravenous infusion
352265|NCT00004220|Drug|oxaliplatin|
352266|NCT00600496|Drug|Erlotinib|daily oral dose
352267|NCT00600496|Drug|Docetaxel|intravenous infusion
352268|NCT00600496|Drug|Temsirolimus|intravenous infusion
352269|NCT00600509|Drug|Levetiracetam|
352568|NCT00591799|Device|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
352569|NCT00591825|Drug|D-cycloserine|D-cycloserine
352570|NCT00591825|Drug|Placebo|Placebo
352571|NCT00591838|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
352572|NCT00591851|Drug|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|No Intervention
352573|NCT00591864|Device|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
352574|NCT00594854|Drug|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
352575|NCT00594854|Drug|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
352576|NCT00594867|Drug|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
352577|NCT00594867|Drug|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
351977|NCT00607958|Drug|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
351978|NCT00607971|Drug|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
351979|NCT00607984|Drug|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
351980|NCT00607997|Drug|voreloxin|All patients receive voreloxin Injection
351981|NCT00608010|Procedure|Vitrification|Embryos were vitrified according to a previously described technique
351982|NCT00004253|Radiation|radiation therapy|
351983|NCT00608010|Procedure|Slow freezing|Embryos were frozen with slow freezing technique
351984|NCT00608023|Drug|Tesamorelin|
351985|NCT00608023|Drug|Placebo for Tesamorelin|
351986|NCT00608049|Behavioral|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
351987|NCT00608049|Behavioral|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
351988|NCT00608049|Behavioral|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
351989|NCT00608049|Behavioral|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
351990|NCT00608062|Drug|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
351991|NCT00608062|Drug|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
352270|NCT00600522|Procedure|Ultrasound-guided hepatectomy|After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:
Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.
Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.
Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended.
351353|NCT00619840|Drug|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
351354|NCT00619853|Behavioral|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
351355|NCT00619853|Behavioral|treatment approach - HABIT|HABIT-2 months, 2Hr per day
351356|NCT00619866|Drug|NBI-56418|150 mg tablet
351357|NCT00004430|Drug|prednisolone|
351358|NCT00619866|Drug|NBI-56418|250 mg tablet
351666|NCT00612586|Drug|Leucovorin|400 mg/m2 IV, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
351667|NCT00612586|Drug|5-FU|400 mg/m2 bolus then 2400 mg/m2 IV over 46 hours, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
351668|NCT00612586|Drug|Bevacizumab|5 mg/kg IV, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
351669|NCT00615030|Drug|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
351670|NCT00615030|Drug|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
351671|NCT00615030|Drug|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
351672|NCT00615030|Drug|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
351673|NCT00000623|Drug|Decitabine|
351674|NCT00004357|Drug|Prednisolone|Oral
351675|NCT00615043|Procedure|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
351676|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous [IV] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
351677|NCT00615056|Drug|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous [IV] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
351678|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
351679|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion [IV] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
356151|NCT00614393|Drug|dalotuzumab|Dalotuzumab 7.5 mg/kg infusion over 60-120 minutes; Dalotuzumab 10 mg/kg infusion over 60-120 minutes; Dalotuzumab 15 mg/kg infusion over 60-120 minutes.
356152|NCT00614393|Drug|irinotecan hydrochloride|Dosage of irinotecan will be the same as most recent pre-study therapy
356153|NCT00614393|Drug|cetuximab|Dosage of cetuximab 400 mg/m2 infusion over 120 minutes followed by weekly infusions of 250 mg/m2 over 60 minutes.
356154|NCT00614393|Drug|Placebo|placebo to dalotuzumab, infusion over 60-120 minutes once weekly.
356155|NCT00614406|Drug|Celebrex|One 400mg tablet daily.
356156|NCT00004340|Drug|growth hormone|
356157|NCT00614406|Drug|Placebo|One tablet daily.
356158|NCT00616915|Drug|Wellbutrin XL|Wellbutrin XL 300mg daily
356159|NCT00616928|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
356160|NCT00616928|Biological|Placebo|Two intramuscular injections at Days 0 and 21.
356161|NCT00616941|Biological|NY-ESO-1 OLP4|1 mg of NY-ESO-1 OLP4 will be diluted in 0.5 mL of D5W and administered subcutaneously as a single injection.
356162|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide|1 mg of NY-ESO-1 OLP4 will be diluted in 0.5 mL of D5W, mixed with 0.5mL of Montanide and administered subcutaneously as a single injection.
356163|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1 mg NY-ESO-1 OLP4 + 1.4 mg Poly-ICLC emulsified in 1 mL Montanide and administered subcutaneously as two injections.
351359|NCT00619866|Drug|placebo|placebo tablet to match NBI-56418
351360|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.
Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.
Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2.
351361|NCT00621803|Drug|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
351362|NCT00621816|Drug|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
351363|NCT00004464|Drug|cyclophosphamide|
351364|NCT00621816|Drug|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
351365|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
355845|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
355846|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT)|One treatment module is we will study is called "cognitive restructuring" or "cognitive-behavior therapy" (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain.
355847|NCT00621374|Behavioral|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
355848|NCT00621374|Behavioral|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
355849|NCT00621387|Drug|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
355850|NCT00621387|Drug|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
355851|NCT00621400|Drug|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
355852|NCT00621400|Drug|Melphalan|0,18mg/Kg/day from day 1- 4
355853|NCT00621400|Drug|Dexamethasone|40mg/day from day 1- 4.
355854|NCT00623623|Drug|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
355855|NCT00623623|Drug|clopidogrel|Adjunctive treatment
355856|NCT00623636|Drug|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
355857|NCT00623636|Drug|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
355858|NCT00623649|Drug|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
355205|NCT00596284|Behavioral|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
355206|NCT00596297|Drug|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
355207|NCT00596297|Procedure|pars plana vitrectomy|4 weeks after baseline
355208|NCT00596310|Other|CT|Screening CT
355531|NCT00628017|Dietary Supplement|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
355532|NCT00628030|Behavioral|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
355533|NCT00628030|Other|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
355534|NCT00628043|Drug|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
355535|NCT00628043|Drug|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
355536|NCT00628056|Drug|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
355537|NCT00628095|Drug|CE-224,535|500 mg po BID
355538|NCT00628095|Drug|Placebo|no active ingredient
355539|NCT00004585|Drug|Lamivudine/Zidovudine|
355540|NCT00628108|Drug|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
355541|NCT00628108|Other|Placebo|Placebo oral liquid once a day for two weeks
355542|NCT00628121|Drug|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
355543|NCT00628134|Drug|calfactant aerosol|single inhaled dose by nebulizer
355544|NCT00628134|Drug|isotonic saline aerosol|single inhaled dose by nebulizer
355545|NCT00630435|Drug|Premarin®/MPA formulation A|
355546|NCT00630435|Drug|Premarin®/MPA formulation B|
354895|NCT00603811|Biological|Placebo|Placebo
354896|NCT00004231|Procedure|autologous bone marrow transplantation|
354897|NCT00603824|Drug|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg
354898|NCT00603824|Drug|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
354899|NCT00603837|Device|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
354900|NCT00603837|Device|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
354901|NCT00603850|Device|ForeseeHome|human factor
354902|NCT00603863|Biological|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
354903|NCT00603876|Dietary Supplement|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
354904|NCT00603889|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
355209|NCT00004202|Drug|paclitaxel|
355210|NCT00596336|Drug|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
355211|NCT00596336|Drug|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
355212|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
355213|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
355214|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
354578|NCT00609180|Dietary Supplement|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
354579|NCT00609180|Dietary Supplement|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
354580|NCT00609193|Drug|lithium|standard clinical care
354581|NCT00609193|Drug|quetiapine|standard clinical care
354582|NCT00004257|Procedure|conventional surgery|
354583|NCT00611429|Behavioral|Counseling sessions|The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
354584|NCT00611429|Behavioral|Group workshop|During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
354585|NCT00004284|Drug|potassium citrate|
354586|NCT00611442|Drug|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
354587|NCT00611442|Drug|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
354588|NCT00611455|Drug|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
354589|NCT00611455|Drug|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
354590|NCT00611468|Drug|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
354591|NCT00611468|Drug|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
354592|NCT00611481|Behavioral|Tai Chi|a set of pre-designed Tai Chi Movements
354593|NCT00611481|Behavioral|Strength training|Lower-extremity strength training exercises
354594|NCT00611481|Behavioral|Low-Impact Exercise Control|a set of chair-based low-impact exercises
354595|NCT00611494|Drug|MMF|Gradual optimization of drug dosage, as clinically tolerated.
354905|NCT00603902|Drug|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
353957|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
353958|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
354274|NCT00616213|Drug|PR104|PR104 is administered intravenously once every 21 days
354275|NCT00616213|Other|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
354276|NCT00616239|Drug|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
354277|NCT00616239|Drug|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
354278|NCT00616265|Device|CPAP|Pressure device on airway to maintain it open
354279|NCT00616291|Biological|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
354280|NCT00618540|Biological|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
354281|NCT00618540|Drug|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age <12 months)
354282|NCT00618540|Drug|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age <12 months)
354283|NCT00618540|Procedure|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
354284|NCT00618553|Other|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
354285|NCT00618553|Behavioral|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
354286|NCT00618566|Behavioral|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
354287|NCT00618579|Drug|LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects|Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
354288|NCT00618592|Dietary Supplement|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
354289|NCT00000162|Procedure|Scatter Argon Laser Photocoagulation|
354290|NCT00000626|Drug|Dacarbazine|
354291|NCT00004412|Other|Standard local care dressing|To heal leg ulcers.
355295|NCT00606684|Drug|GW642444 6.25|GW642444 6.25
355296|NCT00606684|Drug|GW642444 3mcg|once daily
355297|NCT00606684|Drug|GW642444 12.5mcg|GW642444 12.5mcg
355298|NCT00606684|Drug|GW642444 25mcg|GW642444 25mcg
355299|NCT00606684|Drug|GW642444 50mcg|GW642444 50mcg
355300|NCT00606684|Other|placebo|placebo
355301|NCT00606697|Drug|GR205171|
355302|NCT00606697|Drug|GW597599|
355303|NCT00606710|Device|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
355304|NCT00004246|Radiation|Radiation Therapy (RT)|Days 1-5 for 7 weeks
355305|NCT00606723|Biological|Hematopoietic stem cells from bone marrow or peripheral blood|> = 2 x 10*8 nucleated cells (WBC)/kg body weight of the recipient or rather > = 4 x 10*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
355306|NCT00606749|Drug|KC706|300 mg once daily (QD) for 12 weeks.
355307|NCT00606762|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
355308|NCT00606775|Drug|Carvedilol|2.5-5mg/day
355309|NCT00606788|Device|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
355310|NCT00606788|Procedure|Conventional weaning|Patients received physician-directed non-protocolized weaning
355311|NCT00606801|Drug|Galantamine|Galantamine 8 mg/day
355312|NCT00606801|Drug|placebo|sugar pill
355313|NCT00606814|Drug|IPI-504, docetaxel|IPI-504 administered IV at a dose of 300mg/m2
Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration
355314|NCT00606827|Drug|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
355315|NCT00004248|Biological|aldesleukin|
355636|NCT00004217|Biological|filgrastim|5 μg/kg/day IV or SC
354662|NCT00618813|Drug|etoposide|Given IV
354663|NCT00618813|Drug|ifosfamide|Given IV
354664|NCT00618813|Drug|doxorubicin hydrochloride|Given IV
354665|NCT00618813|Drug|cyclophosphamide|Given IV
354666|NCT00618813|Drug|vincristine sulfate|Given IV
354667|NCT00618813|Drug|topotecan hydrochloride|Given IV
354668|NCT00618813|Biological|filgrastim|Given SC
354669|NCT00618826|Drug|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
354670|NCT00004418|Drug|glyceryl trierucate|Glyceryl trierucate is an oil to reduce very long chain fatty acids
354671|NCT00618826|Drug|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
354672|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
354673|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
354987|NCT00611715|Other|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
354988|NCT00613769|Drug|cefuroxime and metronidazole|cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
354989|NCT00613782|Drug|Reandron 1000|1000mg at 0,6,18,30 weeks
354990|NCT00613782|Drug|placebo|placebo injection 0,6.18.30 weeks
354991|NCT00613795|Dietary Supplement|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
354992|NCT00613795|Dietary Supplement|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
354993|NCT00613808|Drug|Nitric Oxide 200ppm Group B|200 ppm, 8hrs / day for 6 weeks
354994|NCT00613821|Drug|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
354368|NCT00004551|Behavioral|mood management|
354369|NCT00625209|Drug|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
354370|NCT00625209|Drug|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
354371|NCT00625209|Drug|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
354372|NCT00625222|Procedure|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
354373|NCT00625235|Dietary Supplement|VLED followed by a high protein or high carbohydrate diet|
354374|NCT00625248|Drug|Antithrombotics|With or without or discontinuted use of Antithrombotics
354375|NCT00625261|Other|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
354376|NCT00625274|Drug|Esomeprazole|40mg Oral
354377|NCT00625274|Drug|Lansoprazole|30mg Oral
354378|NCT00627484|Procedure|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
354674|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
354675|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
354676|NCT00620997|Drug|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
354677|NCT00620997|Drug|saline drops|saline drops continuously PRN for up to 7 days
354678|NCT00621010|Drug|CTS21166 (ZPQ-21166)|Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.
Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion
354038|NCT00592423|Other|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
354039|NCT00592449|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
354040|NCT00592449|Behavioral|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
354041|NCT00592462|Procedure|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
354042|NCT00004189|Biological|filgrastim|
354043|NCT00592475|Drug|conivaptan|IV
354044|NCT00592475|Drug|Placebo|IV
354045|NCT00592488|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
354046|NCT00592501|Radiation|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
354047|NCT00592501|Drug|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
354048|NCT00592501|Drug|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
354049|NCT00592527|Drug|insulin detemir|
354050|NCT00592540|Procedure|unrelated donor bone marrow transplantation|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
354051|NCT00592553|Drug|PTC124|PTC124 Low Dose
354052|NCT00592553|Drug|PTC124|PTC124 High Dose
354053|NCT00004189|Drug|becatecarin|
354054|NCT00592553|Drug|PTC124|Placebo
354055|NCT00592566|Drug|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
354056|NCT00595543|Drug|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
353436|NCT00608595|Other|laboratory biomarker analysis|not noted
353437|NCT00608595|Other|mass spectrometry|Not specified
353438|NCT00608595|Procedure|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
353439|NCT00608595|Procedure|neoadjuvant therapy|not noted
353440|NCT00608595|Procedure|therapeutic conventional surgery|not noted
353729|NCT00601094|Biological|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
353730|NCT00601107|Drug|Doxercalciferol|
353731|NCT00601107|Drug|Placebo|
353732|NCT00601120|Procedure|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
353733|NCT00601133|Other|Walking Test|Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back
Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later
353734|NCT00601133|Other|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
353735|NCT00004224|Drug|cyclophosphamide|
353736|NCT00601133|Behavioral|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
353737|NCT00601133|Behavioral|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
353738|NCT00601146|Procedure|chest computed tomography scan|Once a year for three years
353739|NCT00601159|Drug|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
353740|NCT00601172|Drug|Casopitant|Experimental NK-1 receptor antagonist
353741|NCT00601172|Drug|Dexamethasone and Ondansetron|Standard antiemetics
353742|NCT00601172|Drug|Placebo|Placebo to match IV casopitant
353743|NCT00603304|Drug|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
353128|NCT00615654|Other|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
353129|NCT00615667|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
353130|NCT00615693|Drug|AEB071|
353131|NCT00615706|Other|No intervention|no intervention
353132|NCT00615732|Procedure|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
353133|NCT00615732|Procedure|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
353134|NCT00615745|Drug|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
353135|NCT00615758|Drug|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
353136|NCT00615771|Procedure|Day of embryo transfer|Women receive their embryo transfer 1 day earlier than standard of care.
353137|NCT00615784|Drug|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
353138|NCT00004366|Procedure|Physical therapy|
353139|NCT00615797|Biological|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
353441|NCT00608634|Drug|perillyl alcohol|Applied as topical cream
353442|NCT00608634|Other|placebo|Applied as topical cream
353443|NCT00608660|Other|acupuncture|staging acupuncture
353444|NCT00608660|Other|acupuncture and moxibustion|staging acupuncture and moxibustion
353445|NCT00004255|Procedure|allogeneic bone marrow transplantation|
353446|NCT00608660|Other|electroacupuncture|staging electroacupuncture
353447|NCT00608660|Other|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
353448|NCT00608660|Other|acupuncture|non-staging acupuncture
353449|NCT00608673|Drug|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
352854|NCT00622726|Drug|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
352855|NCT00624650|Drug|Dobutamine|Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.
Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.
If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.
Used in patients with a measured cardiac index < 2.5
352856|NCT00624650|Drug|Dobutamine|Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.
Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.
If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.
352857|NCT00624650|Other|Concentrate all drips and nutrition|Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.
EVLW arm: Patients with a MAP > 60 and off vasopressors for >12 hours, as well as patients with a measured cardiac index >2.5 that also have a measured GEDI > goal.
352858|NCT00624650|Drug|Diuresis (furosemide) part II|Withhold furosemide if:
Significant hypokalemia (K+ <= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists
Dialysis dependence
Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF
More than 800mg has been given in less then 24 hours
Creatinine increases > 1.5 mg/dl in any 24 hour period
352859|NCT00624650|Procedure|Dialysis|Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.
CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.
EVLW arm: Fluid balance as per algorithm
When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm.
352860|NCT00624663|Drug|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
352861|NCT00624676|Drug|Lipo Hydroxy Acid|Twice a day
352862|NCT00624676|Drug|5% benzoyl peroxide gel|Once a day
352863|NCT00624689|Dietary Supplement|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
352864|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
352865|NCT00004500|Drug|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
352578|NCT00594867|Drug|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
352579|NCT00004197|Drug|vincristine sulfate|
352580|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
352581|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
352582|NCT00594893|Procedure|Mini Incision Approach|Mini Incision Approach
352583|NCT00594893|Procedure|2 Incision Approach|2 Incision Approach
352584|NCT00594906|Drug|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
352585|NCT00594906|Drug|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
352586|NCT00594932|Drug|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
352587|NCT00594932|Other|placebo|oral placebo will be given in ascending "doses" during the first month and at full "dose" during the second and third month (or at lower "dose" if tolerance issues warrant)
352588|NCT00594932|Drug|Mycophenolate mofetil|Please see the Arm Description
352866|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
352867|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
352868|NCT00624702|Drug|Placebo|
352869|NCT00624715|Drug|THC|High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint
Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint
Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint
352870|NCT00624715|Drug|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
352871|NCT00626795|Drug|TD1414 2% cream|TID 7 days
352872|NCT00626795|Drug|Bactroban® (mupirocin) 2% cream|BID 7 days
352873|NCT00626808|Drug|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
352271|NCT00600535|Drug|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
352272|NCT00602641|Drug|melphalan|Given PO
352273|NCT00602641|Drug|prednisone|Given PO
352274|NCT00602641|Drug|thalidomide|Given PO
352275|NCT00602641|Drug|lenalidomide|Given PO
352276|NCT00602667|Drug|Induction Chemotherapy|All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
352277|NCT00602667|Drug|Low-Risk Therapy|Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
352278|NCT00602667|Drug|High-Risk Therapy|High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
352279|NCT00004230|Procedure|autologous bone marrow transplantation|
352280|NCT00602667|Drug|Intermediate-Risk Therapy|Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
352281|NCT00602680|Drug|SSR180711C|duration of treatment: 4 weeks
352282|NCT00602680|Drug|donepezil|duration of treatment: 4 weeks
352283|NCT00602680|Drug|placebo|duration of treatment: 4 weeks
352284|NCT00602693|Biological|umbilical cord blood transplantation|Infusion of umbilical cord blood
352285|NCT00602693|Drug|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
352286|NCT00602693|Drug|fludarabine phosphate|40 mg/m^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
352589|NCT00594945|Drug|Clonazepam|1 Dose
352590|NCT00004198|Biological|keyhole limpet hemocyanin|
352591|NCT00594958|Biological|IC51|6 mcg, intramuscularly [i.m.], 0.5 mL
351680|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
351681|NCT00615056|Drug|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
351682|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous infusion [IV] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
351683|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
351992|NCT00608062|Drug|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
351993|NCT00004254|Drug|raltitrexed|
351994|NCT00608075|Drug|lithium|600 mg - 1800 mg per day
351995|NCT00608075|Drug|Lithium|600 - 1800 mg
351996|NCT00608088|Behavioral|Usual Care|The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A "warm-line" was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls.
351997|NCT00004262|Procedure|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
351998|NCT00610428|Drug|Staccato Placebo|Placebo
351999|NCT00610441|Drug|MK-8777|
352000|NCT00610441|Drug|Placebo|
352001|NCT00610454|Drug|Levetiracetam|
352002|NCT00610467|Device|combined optical and MR imaging|MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
352003|NCT00610480|Drug|Optive|Instillation of Optive followed by Evaporametry assessment at 30 and 60 minutes
352004|NCT00610480|Drug|Systane|Instillation of Systane followed by Evaporametry assessment at 30 and 60 minutes
352005|NCT00610480|Drug|Systane|
352006|NCT00610493|Drug|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
351366|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
351367|NCT00621842|Drug|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
351368|NCT00621842|Drug|Lamotrigine novel formulation|Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.
Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
351369|NCT00621855|Drug|placebo|matched placebo
351370|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
351371|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
351372|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
351373|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
351374|NCT00000628|Drug|L-697,661|
351375|NCT00004464|Drug|filgrastim|
351376|NCT00621868|Drug|ASP1941|Oral
351377|NCT00621868|Drug|Placebo|Oral
351378|NCT00621881|Drug|naproxcinod|750 mg bid
351684|NCT00615069|Device|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
351685|NCT00004358|Drug|calcitonin|
351686|NCT00615082|Behavioral|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
351687|NCT00615082|Behavioral|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
351688|NCT00617500|Other|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
355859|NCT00623649|Drug|Placebo|Dose escalation study with a full review of all safety data following each cohort.
356164|NCT00616954|Drug|ATG-F|ATG-f
356165|NCT00616967|Drug|carboplatin|Given IV
356166|NCT00616967|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
356167|NCT00616967|Drug|vorinostat|Given orally
356168|NCT00004390|Drug|nortriptyline|
356169|NCT00616967|Other|placebo|Given orally
356170|NCT00616980|Biological|CD34-positive cells|
356171|NCT00616980|Biological|CD34-positive cells|
356172|NCT00616980|Biological|Saline and 5% autologous plasma|
356173|NCT00616993|Drug|Difluprednate|Difluprednate
356174|NCT00616993|Other|Placebo|Vehicle
356175|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
356176|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
356177|NCT00617032|Genetic|tgAAC94 placebo|Single dose
356178|NCT00617045|Drug|duloxetine|Total treatment period is 12 weeks
30mg po qd times 1 week
60mg po qd times 11 weeks
356179|NCT00004393|Drug|risperidone|
356180|NCT00617058|Drug|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
356181|NCT00617058|Behavioral|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
356182|NCT00617071|Other|medical chart review|
356183|NCT00617071|Other|survey administration|
356184|NCT00617071|Procedure|fecal occult blood test|
356185|NCT00617071|Procedure|screening colonoscopy|
356186|NCT00617084|Device|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
355547|NCT00004664|Drug|megestrol|
355548|NCT00630435|Drug|Premarin®/MPA formulation C|
355549|NCT00630435|Drug|Premarin®/MPA currently marketed product|
355550|NCT00630461|Biological|Clinical Center Reference Endotoxin|single inhalation challenge
355551|NCT00630474|Drug|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
355552|NCT00630487|Drug|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
355860|NCT00623662|Other|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
355861|NCT00004488|Drug|calcium carbonate|
355862|NCT00623662|Other|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
355863|NCT00623675|Dietary Supplement|Mineralox C|Mineralox C 2 capsules three times a day.
355864|NCT00623688|Device|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
355865|NCT00623688|Device|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
355866|NCT00623701|Biological|Allerslit forte|sublingual placebo preparation, daily
355867|NCT00623701|Biological|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
355868|NCT00623714|Drug|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
355869|NCT00623714|Drug|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
355870|NCT00623727|Biological|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
355871|NCT00623727|Biological|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
355215|NCT00598871|Other|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
355216|NCT00598884|Behavioral|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
355217|NCT00598897|Drug|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
355218|NCT00598910|Drug|Omacor|n-3 PUFA
355219|NCT00598910|Drug|Placebo|Placebo
355220|NCT00598923|Drug|topiramate|100 mg twice per day for 3 months
355221|NCT00598923|Drug|topiramate|100 twice per day for 6 days after loading dose of phenytoin
355222|NCT00598923|Drug|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
355223|NCT00004216|Drug|ceftriaxone sodium|
355224|NCT00598936|Device|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
355225|NCT00598962|Drug|Azithromycin, Rifabutin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
355553|NCT00630487|Drug|Somatropin|Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
355554|NCT00630500|Drug|Memantine|Tablets, 5 or 10 mg, twice daily
355555|NCT00630500|Drug|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
355556|NCT00630513|Drug|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
355557|NCT00630513|Drug|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
355558|NCT00004664|Behavioral|Exercise|
355559|NCT00630539|Drug|Placebo|1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
354906|NCT00603902|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
354907|NCT00004231|Procedure|peripheral blood stem cell transplantation|
354908|NCT00603902|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
354909|NCT00603915|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) day 1 and day 8
354910|NCT00603915|Drug|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m^2 (Cisplatin) intravenous (IV) day 1
354911|NCT00603915|Drug|erlotinib|150mg daily (post GC therapy)
354912|NCT00603941|Drug|CS7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.25, 0.35, and 0.50mg BID. At Phase 2, CS-7017 will be administered at the RP2D. Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
354913|NCT00603941|Drug|Paclitaxel|
354914|NCT00603954|Drug|Conditioning regimen TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
354915|NCT00603954|Drug|Conditioning regimen II (TLI 8 Gy + ATG [Thymoglobulin])|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
354916|NCT00603967|Procedure|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
354917|NCT00606541|Drug|Placebo|Placebo
354918|NCT00606554|Device|Computer-driven weaning program - Drager Evita Smartcare System|Closed-loop, knowledge-based, computer driven weaning program initiated at the start of ventilator weaning.
354919|NCT00606554|Behavioral|Standard of Care weaning|Evidence-based standard of care weaning process.
354920|NCT00004244|Biological|recombinant interleukin-12|
354921|NCT00606567|Other|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
354922|NCT00606580|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
354923|NCT00606580|Drug|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
354924|NCT00606580|Drug|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
354292|NCT00618605|Biological|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
354293|NCT00618618|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
354294|NCT00618618|Drug|Placebo|
354295|NCT00618631|Drug|Nicotine|
354296|NCT00618631|Drug|Carfentanil|
354596|NCT00004284|Drug|potassium phosphate|
354597|NCT00611494|Drug|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
354598|NCT00611507|Drug|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
354599|NCT00611533|Drug|atomoxetine|Twenty subjects will be enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
354600|NCT00611533|Drug|placebo|placebo
354601|NCT00611546|Other|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
354602|NCT00611546|Other|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
354603|NCT00611559|Biological|Infanrix™ penta|Subjects received a booster dose
354604|NCT00611559|Biological|Infanrix™ hexa|Subjects received a booster dose
354605|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
354606|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
354607|NCT00613665|Biological|helicobacter pylori vaccine|Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
355637|NCT00599235|Drug|sildenafil|50mg 3 times daily for 7 days
355638|NCT00599235|Drug|hydralazine|25mg 3 times daily for 7 days
355639|NCT00599235|Drug|placebo|3 times daily for 7 days
355640|NCT00599248|Biological|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
355641|NCT00599248|Biological|Placebo|Placebo control (DMEM)
355642|NCT00599261|Procedure|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
355643|NCT00601744|Behavioral|Questionnaire|5-10 minute questionnaire to be completed after the interview.
355644|NCT00601757|Behavioral|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
355645|NCT00601757|Behavioral|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
355646|NCT00601770|Biological|IC41|injection
355647|NCT00601796|Biological|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
355648|NCT00601796|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
355649|NCT00601796|Drug|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
355650|NCT00601809|Other|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
355651|NCT00601809|Drug|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
355652|NCT00601822|Behavioral|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
355653|NCT00004227|Radiation|radiation therapy|
354995|NCT00613821|Drug|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
354996|NCT00613834|Drug|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
354997|NCT00004328|Drug|polystyrene sulfonate|
354998|NCT00613834|Drug|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
354999|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
355000|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
355001|NCT00613860|Device|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
355002|NCT00613873|Procedure|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
355316|NCT00606827|Drug|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
355317|NCT00606840|Behavioral|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
355318|NCT00609362|Drug|Placebo pill|One encapsulated placebo pill a day for 14 weeks
355319|NCT00609375|Drug|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
355320|NCT00609375|Drug|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
355321|NCT00609388|Drug|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
355322|NCT00609388|Other|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
354679|NCT00621023|Drug|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
354680|NCT00621036|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
354681|NCT00621036|Biological|sargramostim|
354682|NCT00004445|Device|IRS-8|
354683|NCT00621036|Drug|methotrexate|
354684|NCT00621036|Drug|thiotepa|
354685|NCT00621036|Radiation|radiation therapy|
354686|NCT00621049|Drug|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1
Docetaxel should be administered before carboplatin.
After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:
Maintenance Treatment for patients in Cohort A:
Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily
Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity.
354687|NCT00621049|Drug|Docetaxel/Carboplatin|Adjuvant Treatment Cohort B:
Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1
Docetaxel should be administered before carboplatin.
Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment.
354688|NCT00621062|Procedure|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
355003|NCT00613886|Device|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
355004|NCT00616447|Device|placebo sham|Sham treatment will mimic active treatment mentioned above.
355005|NCT00616460|Drug|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT < 250
355006|NCT00616486|Device|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
355007|NCT00616486|Device|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
354379|NCT00627484|Behavioral|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
354380|NCT00627497|Procedure|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
354381|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
354382|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
354383|NCT00627497|Device|Fusion|Posterolateral Interbody Fusion
354384|NCT00627510|Other|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
354385|NCT00627523|Drug|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
354386|NCT00004583|Drug|Lopinavir/Ritonavir|
354387|NCT00627523|Drug|Control-no treatment|Control-no treatment
354388|NCT00627536|Drug|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
354389|NCT00627536|Drug|Placebo|Matched to avotermin dosage strength
354390|NCT00627549|Procedure|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
354391|NCT00627549|Procedure|Conventional surgery (anterior repair)|Anterior repair surgery
354392|NCT00627562|Device|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
354393|NCT00627575|Drug|lamotrigine|
354394|NCT00627575|Drug|atorvastatin|
354395|NCT00627575|Drug|phenytoin|
354396|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
354397|NCT00004583|Drug|Nelfinavir mesylate|
354398|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
353744|NCT00603304|Drug|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
353745|NCT00603304|Drug|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
353746|NCT00004231|Drug|doxorubicin hydrochloride|
353747|NCT00603304|Drug|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
353748|NCT00603304|Drug|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
353749|NCT00603304|Drug|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
354057|NCT00595556|Drug|zonisamide|flexible dosages of 100-500mg/day
354058|NCT00595556|Drug|Placebo|Placebo
354059|NCT00595569|Behavioral|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
354060|NCT00595582|Dietary Supplement|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
354061|NCT00004200|Drug|temozolomide|
354062|NCT00595608|Drug|Sterimar Spray|Post-op nasal spray, three times a day
354063|NCT00595608|Drug|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
354064|NCT00595621|Device|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
354065|NCT00595647|Device|Drug eluting stent|Implantation of stent
354066|NCT00595647|Device|Bare metal stent|Implantation of stent
354067|NCT00595660|Procedure|FNA - fine needle aspiration|Fine Needle aspiration
354068|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
354069|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
354070|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
354071|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
353450|NCT00608673|Drug|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
353451|NCT00608686|Dietary Supplement|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
353452|NCT00608699|Drug|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
353453|NCT00608712|Drug|Esomeprazole|Esomeprazole 20mg oral tablet
353454|NCT00608725|Radiation|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
353455|NCT00608725|Procedure|QSweat|Quantitative Sweat Testing
353456|NCT00004255|Procedure|in vitro-treated bone marrow transplantation|
353457|NCT00608725|Drug|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
353458|NCT00608738|Other|informational intervention|
353459|NCT00608738|Other|medical chart review|
353460|NCT00608738|Other|questionnaire administration|
353461|NCT00608738|Procedure|assessment of therapy complications|
353462|NCT00608738|Procedure|management of therapy complications|
353463|NCT00608751|Radiation|IMRT|
353464|NCT00608777|Drug|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
353465|NCT00608790|Drug|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
353750|NCT00603317|Drug|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
353751|NCT00603317|Drug|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
353752|NCT00603330|Biological|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
353753|NCT00603343|Drug|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
353754|NCT00603343|Drug|placebo|placebo corresponding to body weight
353140|NCT00618085|Behavioral|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
353141|NCT00618085|Other|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
353142|NCT00618098|Drug|prothrombin complex concentrate|The OCTAPLEX dose will depend on the weight and baseline INR of the patient and will be calculated by the responsible treating investigator based on the dosing formula and the pre-defined INR to a value of <1.5.
353143|NCT00618098|Biological|Fresh Frozen Plasma|The dose of FFP will depend on the weight and baseline INR of the patient. FFP will be given as a continuous intravenous infusion. The dosage should be 10 mL/kg for a patient that has an initial INR of <3 and 15 mL/kg for a patient that has an initial INR of >3. This will be given over 90 minutes or as fast as clinically indicated or tolerated by the patient at the discretion of the investigator (each unit of FFP contains roughly 200 mL).
353144|NCT00004404|Drug|hydroxyurea|
353145|NCT00618111|Drug|Granisetron|
353146|NCT00618124|Drug|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
353147|NCT00618150|Behavioral|Patient education|An educational program: Three lessons spaced over 2 weeks.
353148|NCT00618163|Drug|Meloxicam|
353149|NCT00618176|Drug|Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W>60Kg)125mg bid (W<60Kg) Nevirapine (NVP) 200mg bid
353150|NCT00618176|Drug|Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)|Stavudine (d4T) 30mg bid (W>60Kg)20mg bid (W<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
353151|NCT00618176|Drug|Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
353152|NCT00618202|Drug|Balsalazide|
353153|NCT00618215|Behavioral|peer group educational implementation strategy|Delivery CPG
Education session IQual group
Online training website (individual feed back)
Reminder (flow chart), individual feed back record form
Feed back by email
Registration in practice
353154|NCT00618228|Drug|Balsalazide|
353155|NCT00004406|Drug|human parathyroid hormone|
353156|NCT00618241|Drug|lamotrigine|100 mg
352874|NCT00626821|Device|SenSura|Real life assessment of SenSura
352875|NCT00626834|Drug|Vigabatrin|Dose 1 BID
352876|NCT00626834|Drug|Vigabatrin|Dose 2 BID
352877|NCT00004578|Drug|Stavudine|40 mg every 12 hours
352878|NCT00626834|Drug|Vigabatrin|Dose 3 BID
352879|NCT00626834|Drug|Matching placebo|Matching placebo BID
352880|NCT00626860|Biological|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
352881|NCT00626873|Drug|perflutren lipid microspheres|
352882|NCT00626873|Other|medical chart review|
352883|NCT00626886|Drug|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
352884|NCT00626886|Drug|placebo collagen sponge|collagen
352885|NCT00626912|Procedure|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
352886|NCT00626925|Drug|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
352887|NCT00626925|Drug|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
352888|NCT00004579|Biological|gp160 MN/LAI-2|
352889|NCT00626951|Device|LMA Supreme|Extraglottic airway devices
353160|NCT00618293|Drug|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
353161|NCT00618293|Other|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
353162|NCT00618319|Drug|BIIB021|Dose, schedule, and duration specified in protocol
353163|NCT00620412|Biological|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
353164|NCT00620425|Drug|Sumatriptan|injection
353165|NCT00620438|Drug|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
352592|NCT00594971|Other|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
352593|NCT00594971|Other|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
352594|NCT00594984|Drug|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
352595|NCT00594984|Drug|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
352596|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
352597|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
352598|NCT00594984|Drug|Brivanib Placebo|Oral, tablet, QD, until progression
352599|NCT00597623|Other|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
352600|NCT00597623|Other|Placebo|syringes under cutaneous vol = 8 ml
352601|NCT00597636|Behavioral|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
352602|NCT00597636|Behavioral|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
352603|NCT00597649|Drug|Bicifadine|SR dosage form of 400 mg bid or tid for one year
352604|NCT00597662|Device|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
352605|NCT00004210|Other|loss of heterozygosity analysis|
352606|NCT00597662|Device|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
352607|NCT00597675|Biological|Peanut flour|Defatted peanut flour to be administered
352608|NCT00597675|Biological|Oat|Oat flour
352609|NCT00597688|Drug|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
352610|NCT00597688|Drug|Placebo gel|Oral mucosal application of placebo gel
352611|NCT00597701|Drug|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
352612|NCT00597701|Drug|Placebo|Placebo
352007|NCT00610493|Drug|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
352008|NCT00004263|Drug|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
352009|NCT00610493|Procedure|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
352010|NCT00610493|Procedure|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
352011|NCT00610493|Procedure|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
352012|NCT00610506|Drug|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
352287|NCT00602693|Drug|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
352288|NCT00602693|Radiation|Total body irradiation|200 cGy on Day -1
352289|NCT00602693|Biological|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10^5 Treg/kg.
352290|NCT00004230|Procedure|peripheral blood stem cell transplantation|
352291|NCT00602693|Drug|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
352292|NCT00602706|Biological|sargramostim|
352293|NCT00602706|Drug|melphalan|
352294|NCT00602706|Procedure|autologous hematopoietic stem cell transplantation|
352295|NCT00602706|Procedure|peripheral blood stem cell transplantation|
352296|NCT00605345|Drug|Darbepoetin alfa|As prescribed
352297|NCT00605345|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
352298|NCT00605358|Behavioral|Open Door intervention|Open Door intervention subjects will:
receive an evaluation
receive a referral to a local mental health provider
identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources.
352299|NCT00605371|Drug|Lamotrigine|
352300|NCT00004237|Drug|mitoxantrone hydrochloride|
351689|NCT00617500|Drug|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
351690|NCT00617513|Drug|Prucalopride|0.5 mg once daily
351691|NCT00617513|Other|Placebo|o.d.
351692|NCT00617513|Drug|Prucalopride|1 mg o.d.
351693|NCT00004399|Drug|magnesium sulfate|
351694|NCT00617513|Drug|Prucalopride|2 mg o.d.
351695|NCT00617526|Drug|RDEA806 400 mg|
351696|NCT00617526|Drug|Placebo|Placebo
351697|NCT00617526|Drug|RDEA806 1000 mg|
351698|NCT00617526|Drug|RDEA806 600 mg|
351699|NCT00617526|Drug|RDEA806 800 mg|
351700|NCT00617539|Drug|irinotecan hydrochloride|
351701|NCT00617539|Drug|temozolomide|
351702|NCT00617552|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
351703|NCT00617552|Drug|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
351704|NCT00004399|Drug|nimodipine|
351705|NCT00617552|Drug|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
351706|NCT00617552|Drug|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
351707|NCT00617552|Drug|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
351708|NCT00617552|Drug|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
352013|NCT00610519|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
352014|NCT00610519|Dietary Supplement|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
352015|NCT00610532|Drug|phenytoin|intravenous phenytoin (15 mg/kg) single dose
352016|NCT00610532|Drug|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
356187|NCT00617084|Device|Abbott Xience V|Abbott Xience V
356188|NCT00619307|Drug|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
351379|NCT00621894|Drug|LGD-4665|LGD-4665 Thrombopoietin mimetic
351380|NCT00621894|Drug|Placebo|Placebo
351381|NCT00621907|Drug|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
351382|NCT00621907|Drug|sodium chloride|sodium chloride : 0,9% 30 ml
351383|NCT00621920|Drug|FM-601|Dose-escalation, split dosage, liquid
351384|NCT00621946|Drug|Placebo|Placebo Matching Escitalopram
351385|NCT00621946|Drug|Escitalopram|Active Escitalopram
351386|NCT00004465|Drug|SYNSORB Pk|
351387|NCT00624208|Drug|saline and saline|saline and saline
351388|NCT00624221|Procedure|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
351389|NCT00624234|Behavioral|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
351390|NCT00624234|Behavioral|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
351391|NCT00624247|Other|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
351392|NCT00624260|Other|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
351393|NCT00004493|Drug|sodium dichloroacetate|
355872|NCT00004488|Drug|cholecalciferol|
355873|NCT00623740|Drug|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
355874|NCT00623740|Drug|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
355875|NCT00623753|Biological|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
355876|NCT00625677|Biological|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
355877|NCT00625677|Biological|Menjugate (Meningococcal C conjugate vaccine)|Dosage
356189|NCT00619320|Behavioral|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
356190|NCT00619333|Drug|follitropin and lutropin|follitropin and lutropin
356191|NCT00004424|Drug|fentanyl|
356192|NCT00619346|Drug|Placebo|Placebo tablets, BID X 14 days
356193|NCT00619346|Drug|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
356194|NCT00619359|Drug|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
356195|NCT00619359|Drug|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
356196|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
356197|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
356198|NCT00619359|Drug|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
356199|NCT00619372|Drug|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
356200|NCT00619372|Drug|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
355560|NCT00630539|Drug|Ospemifene 5 mg|1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
355561|NCT00630539|Drug|Ospemifene 15 mg|1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
355562|NCT00630539|Drug|Ospemifene 30 mg|1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
355563|NCT00630552|Other|Placebo|Inactive dummy of AMG 655.
355564|NCT00630552|Drug|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
355565|NCT00630552|Drug|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
355566|NCT00630565|Biological|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
355567|NCT00630565|Drug|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
355568|NCT00630565|Drug|cyclophosphamide|4 gm/m^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
355569|NCT00004665|Drug|dehydroepiandrosterone|
355570|NCT00593320|Radiation|Stereotactic Radiosurgery|
355571|NCT00004192|Drug|cytarabine|
355572|NCT00593333|Device|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
355878|NCT00625690|Other|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
355879|NCT00625690|Procedure|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
355880|NCT00004560|Device|defibrillator|
354925|NCT00606593|Drug|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
355226|NCT00598975|Drug|NKTR-102 + Cetuximab|Drug: NKTR-102 + Cetuximab
355227|NCT00598988|Procedure|traditional Chinese acupuncture|10 treatments over 6 weeks
355228|NCT00598988|Other|standard medical care|standard care as provided by primary physician
355229|NCT00599001|Drug|SD-101|Single subcutaneous escalating dose
355230|NCT00599001|Drug|placebo|placebo
355231|NCT00599027|Drug|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
355232|NCT00599027|Drug|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
355233|NCT00599040|Behavioral|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
355234|NCT00004216|Drug|ciprofloxacin|
355235|NCT00599040|Behavioral|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
355236|NCT00599040|Behavioral|Dairy diet|participants are given a high dairy, reduced calorie diet
355237|NCT00599053|Drug|Azithromycin|10 mg/kg IV per dose given for 10 days
355238|NCT00599066|Device|Entropy monitor (Datex-Ohmeda S/5 EntropyTM Module)|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
355239|NCT00599079|Drug|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
355240|NCT00601666|Drug|Zolpidem|
355241|NCT00601679|Other|NT-proBNP guided care|knowledge of NT-proBNP results
355242|NCT00601692|Drug|cisplatin|Given IV
355243|NCT00004226|Radiation|radiation therapy|
355244|NCT00601692|Drug|docetaxel|Given IV
355245|NCT00601692|Drug|irinotecan hydrochloride|Given IV
355246|NCT00601692|Radiation|radiation therapy|Given 5 days a week for 3 weeks
354608|NCT00613665|Biological|Placebo|Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
354609|NCT00613665|Biological|helicobacter pylori vaccine|Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
354610|NCT00613665|Biological|helicobacter pylori vaccine|Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
354611|NCT00613678|Behavioral|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
354926|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354927|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354928|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354929|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354930|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354931|NCT00004245|Drug|sodium salicylate|
354932|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354933|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354934|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354935|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
354936|NCT00606606|Other|Clinical Decision Support|
354937|NCT00606619|Other|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
355954|NCT00593554|Drug|Fludarabine|40 mg/m2/d on Day -6 to -3
355955|NCT00593554|Biological|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
355956|NCT00593554|Drug|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
355957|NCT00593567|Drug|gentamicin-collagen sponge|Inserted daily into open ulcer
355958|NCT00593567|Drug|Levofloxacin|750mg oral levofloxacin daily
355959|NCT00593580|Drug|placebo|placebo
355960|NCT00593580|Drug|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
355961|NCT00593606|Drug|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
355962|NCT00593619|Drug|Iron dextran|300mg in 250cc normal saline given over 2 hours
355963|NCT00593619|Drug|Iron sucrose|300mg in 250cc normal saline given over 2 hours
355964|NCT00004194|Drug|fludarabine phosphate|
355965|NCT00593632|Dietary Supplement|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
355966|NCT00593645|Drug|Clofarabine|
355967|NCT00593645|Drug|Cytarabine|
355968|NCT00593645|Drug|Thymoglobulin|
355969|NCT00596583|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
355970|NCT00596583|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
355971|NCT00004204|Drug|temozolomide|
355972|NCT00596596|Drug|prucalopride|0,5 mg once daily
355973|NCT00596596|Drug|prucalopride|1 mg once daily
355974|NCT00596596|Drug|2 mg prucalopride|2 mg once daily
355975|NCT00596596|Drug|4 mg prucalopride|4 mg once daily
355976|NCT00596596|Other|Placebo|placebo once daily
355323|NCT00609401|Drug|Nexavar (Sorafenib)|400 mg bid
355324|NCT00004259|Drug|Nitrosourea (BCNU or CCNU)|
355325|NCT00609401|Drug|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
355326|NCT00609427|Behavioral|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
355327|NCT00609427|Behavioral|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
355328|NCT00609440|Other|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
355329|NCT00609453|Behavioral|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
355330|NCT00609466|Drug|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
355331|NCT00609466|Drug|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
355332|NCT00609466|Drug|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
355333|NCT00609479|Procedure|Osteosynthesis|Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.
Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12.
355334|NCT00609492|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
355335|NCT00004259|Drug|temozolomide|
355336|NCT00609492|Biological|Infanrix™-IPV/Hib|Single dose, intramuscular injection
355654|NCT00601822|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
355655|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
355656|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
355657|NCT00601848|Drug|chemotherapy|
355658|NCT00601848|Drug|porfimer sodium|
355659|NCT00601848|Other|immunohistochemistry staining method|
355008|NCT00616499|Drug|gefitinib|
355009|NCT00004381|Drug|tin mesoporphyrin|
355010|NCT00616499|Procedure|neoadjuvant therapy|
355011|NCT00616499|Procedure|therapeutic conventional surgery|
355012|NCT00616512|Procedure|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
355013|NCT00616538|Device|Epiceram(r)|Topical barrier repair emulsion cream
355014|NCT00616538|Drug|Fluticasone Propionate 0.05%|Topical mid-strength steroid
355015|NCT00616551|Drug|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
355016|NCT00616551|Drug|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
355017|NCT00616564|Drug|GM-CSF|Concomitant Priming with GM-CSF
355018|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
355019|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
355020|NCT00004382|Drug|tin mesoporphyrin|
355021|NCT00616577|Drug|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
355022|NCT00616590|Other|medical chart review|
355023|NCT00616590|Other|questionnaire administration|
355337|NCT00609505|Other|Telemedicine|Telemedicine genetic counseling
355338|NCT00609505|Other|Face-to-Face|Face-to-face genetic counseling
355339|NCT00609518|Drug|pemetrexed|500 mg/m^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
355340|NCT00609518|Dietary Supplement|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
355341|NCT00609518|Dietary Supplement|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
354399|NCT00627614|Other|breast imaging study|1. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.
2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure.
354400|NCT00627627|Drug|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
354689|NCT00621062|Procedure|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
354690|NCT00623103|Drug|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm^2/day delivering 9.5 mg over a 24 hour period.
354691|NCT00623116|Drug|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
354692|NCT00623129|Other|questionnaire administration|
354693|NCT00004485|Drug|cyclosporine|
354694|NCT00623129|Procedure|electroacupuncture therapy|
354695|NCT00623129|Procedure|management of therapy complications|
354696|NCT00623129|Procedure|quality-of-life assessment|
354697|NCT00623142|Drug|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
354698|NCT00623155|Drug|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
354699|NCT00623168|Drug|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
354700|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
354701|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
354702|NCT00623194|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
354072|NCT00004201|Drug|carboplatin|
354073|NCT00595673|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
354074|NCT00595686|Drug|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
354075|NCT00595699|Drug|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
354076|NCT00595699|Drug|placebo|Placebo
354077|NCT00595712|Procedure|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
354078|NCT00595712|Procedure|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
354079|NCT00595725|Other|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
354401|NCT00627640|Drug|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
354402|NCT00627640|Drug|Matching Placebo|Matching Placebo
354403|NCT00627653|Drug|fenofibrate|148mg daily for 30 days
354404|NCT00629928|Drug|Esomeprazole|40mg oral capsule daily
354405|NCT00004658|Drug|ribose|
354406|NCT00629928|Drug|Placebo|
354407|NCT00629941|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
354408|NCT00629967|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
354409|NCT00629967|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
354410|NCT00629980|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
354411|NCT00629993|Behavioral|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
353755|NCT00603356|Drug|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
353756|NCT00603369|Behavioral|group intervention|13-session intervention
353757|NCT00004231|Drug|leucovorin calcium|
353758|NCT00603369|Behavioral|group intervention|2-session intervention
353759|NCT00603382|Drug|GW685698X|GW685698X
353760|NCT00603382|Drug|Placebo|placebo comparator
353761|NCT00603395|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
353762|NCT00603408|Drug|Cisplatin|
353763|NCT00603408|Radiation|Radiation Therapy|
353764|NCT00603408|Procedure|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
353765|NCT00603421|Other|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
353766|NCT00603421|Other|treatment as usual|Treatment as usual
353767|NCT00603434|Drug|OROS-MPH|18 mg bid on days 1 and 2
353768|NCT00004231|Drug|methotrexate|
353769|NCT00603434|Drug|OROS-MPH|27mg bid on days 3 and 4
353770|NCT00603434|Drug|OROS-MPH|35 mg bid on days 5-9
353771|NCT00606060|Drug|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
353772|NCT00004242|Drug|fluorouracil|
354080|NCT00595738|Other|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
354081|NCT00595764|Behavioral|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
354082|NCT00598208|Drug|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
353157|NCT00618241|Drug|Raltegravir|400 mg BD
353158|NCT00618254|Drug|Granisetron|
353159|NCT00618280|Drug|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
353466|NCT00611026|Drug|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
353467|NCT00611026|Drug|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
353468|NCT00611026|Drug|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
353469|NCT00611039|Drug|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
353470|NCT00004266|Drug|simvastatin|
353471|NCT00611039|Drug|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
353472|NCT00611052|Behavioral|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
353473|NCT00611052|Behavioral|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
353474|NCT00611052|Other|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
353475|NCT00611065|Device|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
353476|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
353477|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
353478|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
353479|NCT00611104|Dietary Supplement|standardized freeze-dried table grape powder|
353480|NCT00611104|Other|laboratory biomarker analysis|
353481|NCT00004268|Drug|midodrine|
353482|NCT00611104|Other|pharmacological study|
353483|NCT00611117|Other|Physical Activity Level|High vs. low physical activity during a high fat diet consumption.
353166|NCT00620438|Drug|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
353167|NCT00004441|Drug|tauroursodeoxycholic acid|
353168|NCT00620438|Drug|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
353169|NCT00620451|Drug|larazotide acetate (AT-1001)|4 mg three times a day for 8 weeks
353170|NCT00620451|Drug|larazotide acetate (AT-1001)|8 mg three times a day for 8 weeks
353171|NCT00620451|Drug|placebo|placebo three times a day for 8 weeks
353172|NCT00620464|Drug|Radiopaque Implanon|Radiopaque rod for 3 years
353173|NCT00620464|Drug|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
353174|NCT00620477|Drug|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
353175|NCT00620477|Drug|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
353176|NCT00620490|Drug|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
353177|NCT00620490|Other|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
353178|NCT00004441|Drug|ursodiol|
353179|NCT00620503|Drug|Proellex 25 mg|One Proellex 25 mg capsule for one day administered after being fed
353180|NCT00620503|Drug|Proellex 25 mg|One 25 mg Proellex capsule for one day administered while fasting
353181|NCT00620529|Dietary Supplement|Ocean Nutrition 2050|1000mg capsules, 4 capsules/day for 8 weeks
353182|NCT00620529|Dietary Supplement|Olive oil capsules|Olive oil capsules, 4 per day for 8 weeks
353489|NCT00611156|Dietary Supplement|horseradish|Added to a brunch meal
353490|NCT00611156|Dietary Supplement|mustard|Added to a brunch meal
353491|NCT00611156|Dietary Supplement|placebo|Added to a bruch meal
353492|NCT00004274|Drug|Estrogen|
353493|NCT00611169|Drug|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
352890|NCT00626951|Device|LMA ProSeal|
352891|NCT00626964|Procedure|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
352892|NCT00626964|Behavioral|Conservative Treatment:|Conservative Treatment: Intensive Lifestyle Intervention Program
352893|NCT00626977|Drug|ropivacaine|15 ml of ropivacaine 0.125% peridural once
352894|NCT00626977|Drug|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
352895|NCT00626990|Drug|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
352896|NCT00626990|Genetic|DNA methylation analysis|MGMT methylation status is used for stratification at randomization.
352897|NCT00626990|Other|laboratory biomarker analysis|Prognostic factor analyses
352898|NCT00626990|Procedure|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
352899|NCT00004579|Biological|ALVAC-HIV MN120TMG (vCP205)|
352900|NCT00629278|Radiation|radiation therapy|
352901|NCT00629304|Device|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
352902|NCT00629304|Device|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
352903|NCT00629304|Device|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
352904|NCT00629317|Other|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
352905|NCT00629317|Drug|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
352906|NCT00004645|Procedure|Plasma exchange|
352907|NCT00629330|Behavioral|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
352908|NCT00629343|Drug|Azacitidine In Combination With Temozolomide|mg, oral
352909|NCT00629356|Genetic|dengue fever|
352301|NCT00605384|Drug|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
352302|NCT00605384|Drug|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
352303|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
352304|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
352305|NCT00605410|Drug|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
352306|NCT00605410|Drug|placebo|Matched placebo
352307|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
352308|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
352309|NCT00605436|Behavioral|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
352613|NCT00597701|Drug|Lorazepam|Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard "symptom-triggered dosing" of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms.
352614|NCT00597714|Drug|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
352615|NCT00597727|Drug|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
352616|NCT00004210|Other|microsatellite instability analysis|
352617|NCT00597727|Drug|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
352618|NCT00597753|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
352619|NCT00597753|Drug|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
352017|NCT00610545|Drug|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
352018|NCT00610545|Drug|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
352019|NCT00004263|Drug|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
352020|NCT00610558|Device|positron emission tomography (PET)|FDG-glucose (10 mCi)
352021|NCT00610571|Drug|Oral Topotecan and Temodar|Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.
Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose.
352022|NCT00612599|Drug|biphasic insulin aspart|
352023|NCT00612612|Drug|obatoclax mesylate|Given IV
352024|NCT00612612|Drug|fludarabine phosphate|Given IV
352025|NCT00612612|Biological|rituximab|Given IV
352026|NCT00000623|Drug|Deferiprone|
352027|NCT00004313|Drug|dehydroepiandrosterone|
352028|NCT00612612|Other|laboratory biomarker analysis|Correlative study
352029|NCT00612625|Drug|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
352030|NCT00612625|Drug|Saline|continuous infusion of saline
352031|NCT00612638|Drug|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 & 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
352310|NCT00605449|Drug|GSK376501|
352311|NCT00004237|Drug|vinorelbine tartrate|
352312|NCT00605475|Drug|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
352313|NCT00605475|Drug|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
351394|NCT00624260|Other|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
351395|NCT00624273|Drug|Sildenafil therapy|oral use
351396|NCT00624286|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
351397|NCT00624286|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
351398|NCT00624299|Drug|Botox|Botox injection (100 ius) per muscle
351709|NCT00617552|Drug|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
351710|NCT00617552|Drug|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
351711|NCT00617565|Drug|biphasic insulin aspart|
351712|NCT00617565|Drug|biphasic human insulin|
351713|NCT00617578|Device|ATP One Shot ON|The new antitachycardia pacing algorithm "ATP One Shot" attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery
351714|NCT00617578|Device|ATP One Shot OFF|Standard defibrillation shock delivery
351715|NCT00004400|Drug|testosterone|
351716|NCT00617591|Drug|Lenalidomide|25 mg orally on days 1-21
351717|NCT00617591|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated)
351718|NCT00617591|Drug|Dexamethasone|40 mg orally on days on 1-4
351719|NCT00617604|Drug|Alefacept|IV and subcutaneous injection
351720|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|Busulfan administration:
For children >/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.
For children < 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.
Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols*min for the 16 doses.
Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.
Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.
Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2.
351721|NCT00619879|Other|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
356201|NCT00619372|Drug|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
356202|NCT00004424|Drug|Midazolam|
356203|NCT00619372|Drug|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
356204|NCT00619372|Drug|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
356205|NCT00619372|Drug|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
356206|NCT00619385|Drug|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
356207|NCT00619398|Drug|Prograf|Oral
356208|NCT00619398|Drug|FK506MR capsule|Oral
356209|NCT00619411|Behavioral|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
356210|NCT00619424|Drug|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
351399|NCT00624299|Other|Saline|Saline injection
351400|NCT00624312|Drug|Procrit|10 days prior to surgery - injection of 60,000 IU of Procrit
Day of surgery - injection of 60,000 IU of Procrit
351401|NCT00624312|Drug|Placebo|10 days prior to surgery - injection with 60,000 IU of placebo
Day of surgery - injection with 60,000 IU of placebo
351402|NCT00624325|Drug|interferon alfa-2b|12 MU daily continuously subcutaneous
351403|NCT00624325|Drug|interferon alfa-2b|9 MU daily continuously subcutaneous
351404|NCT00004494|Drug|vasoactive intestinal peptide|
351405|NCT00624325|Drug|interferon alfa-2b|6 MU daily continuously subcutaneous
351406|NCT00624338|Drug|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
351407|NCT00624338|Drug|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
351408|NCT00626184|Drug|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
351409|NCT00004564|Drug|Clopidogrel|
351410|NCT00626197|Drug|corticosteroids|Intravenous and oral repeating dose
355881|NCT00625690|Procedure|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
355882|NCT00625690|Procedure|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
355883|NCT00625703|Drug|Linezolid|Pharmacokinetics
daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid.
355884|NCT00625729|Biological|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
355885|NCT00625729|Biological|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10^7 cells/kg).
355886|NCT00625729|Biological|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m^2
355887|NCT00625729|Drug|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
355888|NCT00625729|Drug|fludarabine phosphate|Day -6 through day -2, 25 mg/m^2 intravenous (IV)
355889|NCT00625742|Behavioral|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
355890|NCT00625742|Behavioral|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
355891|NCT00004561|Behavioral|exercise|
355892|NCT00625742|Drug|Melatonin|20 mg by mouth (PO) Daily
355893|NCT00625742|Dietary Supplement|Juven|90 calories of Juven, twice a day.
356211|NCT00619424|Drug|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
356212|NCT00621439|Drug|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
356213|NCT00004450|Drug|glyceryl trierucate|
356214|NCT00621439|Drug|Placebo|Patients will receive placebo.
355247|NCT00601705|Drug|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
355248|NCT00601705|Drug|epirubicin hydrochloride|50 mg/m2 IV bolus
355249|NCT00601705|Drug|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
355250|NCT00601705|Drug|oxaliplatin|130 mg/m2 IV infusion over 2 hours
355573|NCT00593333|Device|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
355574|NCT00593346|Radiation|brachytherapy|brachytherapy (radioactive implants)
355575|NCT00593372|Behavioral|Spaced Retrieval Training|Increasing time to remember important information.
355576|NCT00593385|Device|iCAST covered stent|iliac stent implantation
355577|NCT00593424|Other|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
355578|NCT00593424|Other|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
355579|NCT00593450|Drug|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
355580|NCT00593450|Drug|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
355581|NCT00593463|Drug|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
355582|NCT00000611|Drug|vitamin D|
355583|NCT00004192|Drug|etoposide|
355584|NCT00593463|Drug|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
355585|NCT00593463|Drug|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
355586|NCT00593463|Drug|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
355587|NCT00593463|Drug|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
355588|NCT00593463|Drug|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
355589|NCT00593463|Drug|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
355590|NCT00593463|Device|Saline|Saline: I.M. injection may possibly be given
354938|NCT00606619|Other|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
354939|NCT00609219|Biological|autologous EBV specific CTLs|30-40cc of peripheral blood will be used to generate EBV specific CTLs
Group One:
Day 0 - 2 x 10^7 cells/m2 Day 14 - 2 x 10^7 cells/m2
Group Two:
Day 0 - 2 x 10^7 cells/m2 Day 14 - 1 x 10^8 cells/m2
Group Three:
Day 0 - 1 x 10^8 cells/m2 Day 14 - 2 x 10^8 cells/m2
354940|NCT00609245|Drug|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous Na VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
354941|NCT00609245|Drug|placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
354942|NCT00609271|Behavioral|low carbohydrate|<40 grams carbohydrate/day
354943|NCT00609271|Behavioral|TLC diet|<35% fat, <7% saturated fat
354944|NCT00609284|Drug|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
355251|NCT00601705|Procedure|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
355252|NCT00601705|Procedure|neoadjuvant therapy|Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).
Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible.
355253|NCT00601718|Drug|vorinostat|Given PO
355254|NCT00004227|Biological|cetuximab|
355255|NCT00601718|Biological|rituximab|Given IV
355256|NCT00601718|Drug|ifosfamide|Given IV
355257|NCT00601718|Drug|carboplatin|Given IV
355258|NCT00601718|Drug|etoposide|Given IV
355259|NCT00601718|Other|pharmacological study|Correlative studies
355260|NCT00601718|Other|laboratory biomarker analysis|Correlative studies
355261|NCT00601718|Genetic|gene expression analysis|Correlative studies
355262|NCT00601731|Biological|MenACWY-CRM197|Blood test, 40-months and 60-months children
355977|NCT00596609|Drug|Intrathecal Morphine|In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled "Baseline." These will serve as controls for subsequent recording comparisons.
In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection.
356291|NCT00628342|Drug|Esomeprazole|20mg Oral tablet once daily
356292|NCT00628342|Drug|Esomeprazole|40mg Oral tablet once daily
356293|NCT00628342|Drug|Placebo|Oral once daily
356294|NCT00628355|Drug|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
356295|NCT00628355|Procedure|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
356296|NCT00628368|Genetic|gene expression analysis|
356297|NCT00628368|Genetic|mutation analysis|
356298|NCT00628368|Genetic|polymorphism analysis|
356299|NCT00004635|Drug|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
356300|NCT00628368|Other|laboratory biomarker analysis|
356301|NCT00628368|Procedure|biopsy|
356302|NCT00628368|Procedure|endoscopic biopsy|
356303|NCT00628381|Dietary Supplement|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
356304|NCT00628381|Dietary Supplement|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
356305|NCT00628394|Drug|Atomoxetine|40mg 2po qam
356306|NCT00630721|Other|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
356307|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
355660|NCT00601848|Other|laboratory biomarker analysis|
355661|NCT00601848|Procedure|spectroscopy|
355662|NCT00601848|Procedure|therapeutic conventional surgery|
355663|NCT00601861|Drug|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
355664|NCT00000616|Behavioral|diet, sodium-restricted|
355665|NCT00004228|Drug|asparaginase|Given IV
355666|NCT00604123|Drug|Placebo|Placebo nasal spray twice daily for 2 weeks.
355667|NCT00604136|Biological|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
355668|NCT00604162|Device|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
355669|NCT00604162|Procedure|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
355670|NCT00604175|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
355671|NCT00604188|Drug|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
355672|NCT00604188|Drug|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
355673|NCT00604201|Other|Umbilical Cord Blood|
355978|NCT00596622|Drug|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
355979|NCT00596622|Behavioral|Picture response during fMRI|While undergoing an fMRI scan, participants will be presented with pictures, letters, words, and sounds to evoke emotional responses. There will be a maximum of three MRI scans over 9 weeks.
355980|NCT00596635|Dietary Supplement|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
355981|NCT00596635|Dietary Supplement|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
355342|NCT00611715|Other|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
355343|NCT00611728|Drug|SU011248 & Irinotecan|Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 & 1/2 hrs on 1st day of each cycle & then again on days 14 & 28.
Sutent is approved for adult subjects w some forms of kidney cancer. It is considered "investigational" for brain tumors. Dosing will begin on day 1 of cycle 1 & continue daily for 4 wks by mouth.
Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered "investigational" for brain tumors. Irinotecan dose will depend on your height & weight. Irinotecan will be given intravenously over 90 min on days 1, 14 & 28 of 6wk cycle.
You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, & then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, & then within 1 week prior to completion of every other cycle.
355344|NCT00004287|Genetic|H5.001CBCFTR|
355345|NCT00611741|Drug|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
355346|NCT00611754|Drug|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
355347|NCT00611767|Drug|Thiopental|A 2-day test design involving 2 conditions: saline or thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
355348|NCT00611767|Drug|Placebo|Placebo
355349|NCT00611780|Radiation|tube voltage|standard 120 kV
355350|NCT00611780|Radiation|tube voltage|reduced voltage of 100 kV
355351|NCT00611793|Drug|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
355352|NCT00611806|Dietary Supplement|Folic Acid|Folic acid 2mg po daily
355353|NCT00611806|Dietary Supplement|B12|B12 400 micrograms po daily
355674|NCT00604201|Other|Haploidentical Stem Cells|
355675|NCT00604201|Device|Miltenvi CliniMACs CD34 Reagent System|
355676|NCT00004232|Drug|prednisone|
355677|NCT00604214|Drug|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
354703|NCT00623194|Drug|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
354704|NCT00004485|Drug|fludarabine|
354705|NCT00623207|Drug|Atropine|I.V Atropine 0.5mg up to 2 mg
354706|NCT00623220|Other|N2O|EMONO
354707|NCT00623220|Other|oxygen|oxygen
355024|NCT00616590|Procedure|fatigue assessment and management|
355025|NCT00616590|Procedure|quality-of-life assessment|
355026|NCT00616603|Drug|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
355027|NCT00616603|Drug|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
355028|NCT00616603|Drug|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
355029|NCT00616603|Drug|Normal Saline|2ml of normal saline given once intravenously.
355030|NCT00616616|Procedure|single incision laparoscopic surgery|Surgery will be performed with ine laparoscopic incision
355031|NCT00004382|Procedure|Phototherapy|
355032|NCT00618826|Drug|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
355033|NCT00618839|Biological|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
355034|NCT00618839|Procedure|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
355035|NCT00618852|Drug|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
355036|NCT00618852|Drug|Saline|1 mg/kg by intravenous bolus injection
355037|NCT00618865|Dietary Supplement|Omega-3 fatty acids|
355038|NCT00618878|Procedure|Electroacupuncture|twice a week for 26 treatments in total
355039|NCT00618878|Procedure|Laser Therapy|twice a week for a total of 26 treatments
354412|NCT00630006|Genetic|TNF-alpha and IL-10|
354413|NCT00630019|Drug|1.5% levofloxacin ophthalmic solution|Topical application
354414|NCT00630019|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
354415|NCT00630032|Drug|cyclophosphamide|500 mg/m2 every 3 weeks
354416|NCT00004658|Drug|thymidine|
354417|NCT00630032|Drug|Docetaxel|100 mg/m2 every 3 weeks
354418|NCT00630032|Drug|epirubicin hydrochloride|100 mg/m2 every 3 weeks
354419|NCT00630032|Drug|fluorouracil|500 mg/m2 every 3 weeks
354420|NCT00630032|Drug|ixabepilone|40 mg/m2 every 3 weeks
354421|NCT00630045|Drug|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
354422|NCT00630045|Procedure|resection of liver metastasis|surgery with the aim of R0 resection
354423|NCT00630058|Drug|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
354708|NCT00623233|Drug|Gemcitabine|Gemcitabine 2500 mg/m^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
354709|NCT00623233|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event [AE], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)
Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.
354710|NCT00623246|Behavioral|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
354711|NCT00623246|Behavioral|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
354712|NCT00625274|Drug|Pantoprazole|40mg Oral
354713|NCT00000110|Procedure|magnetic resonance spectroscopy|
354714|NCT00000167|Procedure|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
354715|NCT00000630|Biological|gp160 Vaccine (MicroGeneSys)|
354083|NCT00598234|Drug|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
354084|NCT00598247|Drug|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
354085|NCT00598260|Procedure|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
354086|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
354087|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
354088|NCT00598273|Drug|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
354089|NCT00598286|Drug|[18F]FMPEP-d2|
354090|NCT00598299|Procedure|venous puncture|venous puncture
354091|NCT00004215|Biological|filgrastim|
354092|NCT00598299|Other|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
354093|NCT00598312|Drug|Leuprolide Acetate for Injectable Suspension|Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product
354094|NCT00598325|Biological|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
354095|NCT00598338|Drug|Prucalopride|4 mg o.d.
354096|NCT00598338|Other|Placebo|o.d.
354097|NCT00598377|Drug|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
354098|NCT00598390|Drug|[11C]MePPEP|
354099|NCT00598403|Drug|cefditoren pivoxil|400 mg, oral, single dose during 3 days
354424|NCT00630058|Drug|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
354425|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
353484|NCT00611130|Drug|vigabatrin|Tablets twice a day for 12 weeks
353485|NCT00611130|Drug|placebo|tablets twice daily for 12 weeks
353486|NCT00611143|Drug|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
353487|NCT00611156|Dietary Supplement|ginger|added to a brunch meal
353488|NCT00611156|Dietary Supplement|black pepper|Added to a brunch meal
353773|NCT00606073|Other|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
353774|NCT00606086|Drug|GI-5005|40YU, subcutaneous
353775|NCT00606086|Drug|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
353776|NCT00606099|Drug|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
353777|NCT00606099|Drug|adefovir dipivoxil|Active Comparator
353778|NCT00606112|Drug|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
353779|NCT00606125|Drug|Nexavar (Sorafenib, BAY43-9006)|The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
353780|NCT00606138|Drug|ranibizumab|One 0.5 mg intravitreal injection
353781|NCT00606138|Procedure|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
353782|NCT00606164|Drug|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
353783|NCT00000619|Procedure|catheterization, Swan-Ganz|
353784|NCT00004242|Drug|gemcitabine hydrochloride|
353785|NCT00606164|Drug|Placebo|A single one-hour intravenous infusion of placebo on Day 1
353786|NCT00606177|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
353494|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
353495|NCT00613197|Drug|Epanova|4g/day in divided doses
353496|NCT00613223|Drug|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 & 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
353497|NCT00004317|Drug|Sulfadiazine|See arm descriptions
353498|NCT00613249|Drug|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
353499|NCT00613249|Drug|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
353500|NCT00613249|Drug|HEC-based Placebo Gel|intravaginal gel, dosed daily
353501|NCT00613262|Other|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
353502|NCT00613275|Other|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
353503|NCT00613288|Drug|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.
The four days will include treatment on the examination day, Day 1 with:
Placebo (hypogonadism after leuprorelide injection)
Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).
Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).
No treatment.
353504|NCT00613327|Drug|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
353505|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
353506|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
353507|NCT00613353|Other|Behavioral|Participants will be asked to wear an accelerometer
353508|NCT00004323|Drug|anti-thymocyte globulin|
353793|NCT00606216|Procedure|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
353794|NCT00608790|Drug|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
352910|NCT00629369|Device|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
353183|NCT00620542|Drug|Rosuvastatin|capsule, oral, once daily
353184|NCT00620542|Drug|Atorvastatin|capsule, oral, one daily
353185|NCT00620555|Drug|gabapentin|Orally administered gabapentin
353186|NCT00620568|Drug|SLV-313 SR|sustained release tablets taken once daily for 14 days
353187|NCT00620581|Drug|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
353188|NCT00620594|Drug|BEZ235|
353189|NCT00000626|Drug|Doxorubicin hydrochloride|
353190|NCT00004442|Drug|chenodeoxycholic acid|
353191|NCT00622726|Procedure|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
353192|NCT00000628|Drug|Zidovudine|
353193|NCT00004478|Drug|droxidopa|
353194|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
353195|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
353196|NCT00622752|Drug|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
353197|NCT00622752|Drug|placebo|2 X placebo tablets to match EVT 302 5 mg
353198|NCT00622752|Drug|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
353199|NCT00622752|Device|NRT placebo|Medically inert plaster cut to match the NRT plaster
353200|NCT00622765|Drug|placebo|Placebo capsule twice daily
353201|NCT00622765|Drug|R256918|5 mg capsule twice daily
353202|NCT00622765|Drug|R256918|10 mg capsule twice daily
352620|NCT00597766|Drug|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
352621|NCT00600535|Drug|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
352622|NCT00600535|Drug|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
352623|NCT00600535|Drug|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
352624|NCT00600535|Drug|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
352625|NCT00000614|Drug|warfarin|
352626|NCT00004221|Drug|Carboplatin|Given IV
352627|NCT00600535|Drug|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
352628|NCT00600535|Drug|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
352629|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
352911|NCT00629382|Device|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
352912|NCT00629382|Other|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
352913|NCT00629395|Behavioral|Captain's Log Computer Program|12 Computer Program
352914|NCT00629434|Other|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
352915|NCT00629434|Other|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
352916|NCT00629447|Drug|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
352917|NCT00000634|Drug|Nevirapine|
352918|NCT00004646|Drug|prednisone|
352919|NCT00629473|Drug|NPI-0052|IV injection
352314|NCT00605475|Drug|Metformin|Participants continued on their stable daily dose of metformin throughout the study
352315|NCT00605488|Procedure|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
352316|NCT00605514|Drug|VRC-EBODNA023-00-VP|
352317|NCT00605514|Drug|VRC-MARDNA025-00-VP|
352318|NCT00605553|Drug|Placebo|Placebo oral capsules
Placebo for 7 days
352319|NCT00605553|Drug|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
352320|NCT00608088|Behavioral|Community Health Nurse/Peer Councelor Team|Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.
The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months.
352321|NCT00608101|Drug|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
352322|NCT00608101|Drug|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
352323|NCT00608127|Device|LupusorbTM|Single treatment
352324|NCT00608140|Procedure|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
352630|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
352631|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
351722|NCT00619879|Radiation|CNS radiation treatment for ALL with prior CNS disease patients|Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.
Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) < 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:
Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count
Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count
351723|NCT00619892|Drug|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
351724|NCT00619892|Drug|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
351725|NCT00619905|Drug|ACZ885|
351726|NCT00619905|Drug|ACZ885|
351727|NCT00000626|Drug|Bleomycin sulfate|
351728|NCT00004430|Procedure|Laser surgery|
352032|NCT00612651|Drug|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated & escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle & escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning & evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 & 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
352033|NCT00612664|Drug|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
352034|NCT00612677|Drug|Oxaliplatin|Dose Regimen: 120 mg/m^2 on Days 1 every 21 days
352035|NCT00612677|Drug|Pemetrexed|Dose Regimen: 500 mg/m^2 on Days 1 every 21 days
352036|NCT00612690|Behavioral|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
352037|NCT00612690|Behavioral|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
352038|NCT00004314|Drug|aminomidazole carboxamide riboside|
352039|NCT00612703|Drug|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
352040|NCT00612716|Drug|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
351411|NCT00626197|Drug|cyclophosphamide|Intravenous repeating dose
351412|NCT00626197|Drug|mycophenolate mofetil|oral repeating dose
351413|NCT00626197|Drug|ocrelizumab|Intravenous repeating dose
351414|NCT00626197|Drug|placebo|Intravenous repeating dose
351415|NCT00626210|Drug|modafinil|100-400 mg daily for 4 weeks
351416|NCT00626223|Drug|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
351417|NCT00626223|Drug|folic acid|5 mg per day of oral folic acid
351418|NCT00626236|Drug|SPN-810|capsule taken three times a day
351419|NCT00626236|Drug|SPN-810|capsule taken TID
351420|NCT00004564|Drug|Atorvastatin|
351421|NCT00626236|Drug|SPN-810|capsule taken TID
351422|NCT00626236|Drug|SPN-810|capsule taken TID
351423|NCT00626249|Drug|Technosphere Inhalation Powder|Technosphere Inhalation Powder
351729|NCT00619918|Drug|Nebulized 3% saline|4 ml inhaled q8h
351730|NCT00619918|Drug|Placebo|normal saline
351731|NCT00619931|Drug|APD791|APD791 or matching placebo in escalating doses
351732|NCT00619944|Drug|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
351733|NCT00619944|Drug|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
351734|NCT00619957|Drug|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
351735|NCT00619957|Drug|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
351736|NCT00619970|Procedure|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
351737|NCT00619970|Drug|xifaxan|xifaxan 550mg TID x10days
351738|NCT00619970|Drug|placebo|placebo TID x 10days
356215|NCT00621452|Biological|therapeutic autologous lymphocytes|Given IV
356216|NCT00621452|Drug|cyclophosphamide|Given IV
356217|NCT00621452|Biological|aldesleukin|Given subcutaneously
356218|NCT00621452|Genetic|polymerase chain reaction|Correlative studies
356219|NCT00621452|Genetic|gene rearrangement analysis|Correlative studies
356220|NCT00621452|Procedure|lymph node biopsy|Optional correlative studies
356221|NCT00621452|Biological|genetically engineered lymphocyte therapy|Receive genetically modified T cells
356222|NCT00621452|Procedure|bone marrow aspiration|Optional correlative studies
356223|NCT00621452|Other|flow cytometry|Correlative studies
356224|NCT00004450|Drug|glyceryl trioleate|
356225|NCT00621452|Other|laboratory biomarker analysis|Correlative studies
356226|NCT00621452|Other|enzyme-linked immunosorbent assay|Correlative studies
356227|NCT00621465|Behavioral|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
356228|NCT00621465|Behavioral|Usual care|Usual care will include the standard aftercare and community care services.
356229|NCT00621478|Drug|lorazepam or diazepam|Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.
The medication will be administered as a slow IV push.
356230|NCT00621491|Drug|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
356231|NCT00621504|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
351424|NCT00626262|Drug|Esomeprazole|Oral and Intravenous
351425|NCT00626275|Drug|ADL5859|
351426|NCT00626275|Drug|Naproxen|
355591|NCT00593463|Drug|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
355592|NCT00593476|Other|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
355593|NCT00593476|Other|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
355594|NCT00004192|Drug|methylprednisolone|
355894|NCT00625742|Drug|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted.
355895|NCT00628147|Device|Narrow band imaging colonoscope (CF-H180AL, CF-Q180AL, Evis Exera II CV-180)|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
355896|NCT00628160|Drug|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
355897|NCT00628160|Drug|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
355898|NCT00628173|Procedure|AGV implantation|
355899|NCT00628186|Device|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
355900|NCT00004585|Drug|Abacavir sulfate|
355901|NCT00628186|Device|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
355902|NCT00628199|Procedure|Improving the scientific process of human cell reprogramming|
355903|NCT00628212|Drug|Teneligliptin 10mg|
355904|NCT00628212|Drug|Teneligliptin 20 mg|
355905|NCT00628212|Drug|Teneligliptin 40 mg|
355906|NCT00628212|Drug|Placebo|
355907|NCT00628225|Behavioral|Counseling and Nicotine replacement (CN)|Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.
Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement.
355263|NCT00601731|Biological|Blood test|Blood test, 40-months and 60-months children
355264|NCT00601744|Behavioral|Audio-Taped Interview|Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours
Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)
Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration.
355265|NCT00004227|Procedure|conventional surgery|
355266|NCT00603967|Procedure|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
355267|NCT00004232|Biological|filgrastim|
355268|NCT00603967|Behavioral|Questionnaire|Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months
Cognitive tests - baseline, 6 months, 12 months
Depression assessment - baseline, 6 months, 12 months
Dietary calcium intake questionnaire - baseline
355269|NCT00603980|Drug|alprazolam|Staccato Alprazolam, single dose
355270|NCT00603980|Drug|alprazolam|oral, immediate release
355271|NCT00603980|Drug|placebo|Staccato placebo + oral placebo
355595|NCT00596362|Drug|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
355596|NCT00596375|Procedure|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
355597|NCT00596375|Drug|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
355598|NCT00596414|Procedure|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
355599|NCT00596414|Drug|placebo|
355600|NCT00004202|Radiation|radiation therapy|
355601|NCT00596414|Drug|midazolam|
355602|NCT00596414|Drug|midazolam + pethidine|
355603|NCT00596427|Drug|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
355604|NCT00596427|Drug|Placebo|Placebo tablets: 3 tablets twice per day
356308|NCT00630734|Drug|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
356309|NCT00630734|Drug|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
356310|NCT00004670|Procedure|pallidotomy|
356311|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
356312|NCT00630734|Other|Washout|Washout (no medication) on days 5-11.
356313|NCT00630747|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
351499|NCT00597220|Dietary Supplement|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
351500|NCT00597220|Drug|Placebo|Placebo
351501|NCT00597233|Drug|insulin aspart|
351502|NCT00597233|Drug|soluble human insulin|
351503|NCT00597233|Drug|insulin NPH|
351504|NCT00004208|Drug|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
351505|NCT00597246|Drug|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
351506|NCT00597246|Other|PET Scan|GE Advance PET scanner for sequential body imaging
351507|NCT00597259|Drug|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
351508|NCT00597259|Drug|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
351509|NCT00597272|Biological|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
355982|NCT00004205|Drug|letrozole|Letrozole 2.5 mg daily oral administration.
355983|NCT00596648|Drug|XL184|Capsules administered orally daily
355984|NCT00596648|Drug|erlotinib|Tablets administered orally daily.
355985|NCT00596661|Device|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
355986|NCT00596674|Behavioral|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
355987|NCT00596674|Other|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
355988|NCT00596687|Drug|Insulin glargine|Insulin glargine once daily SQ
355989|NCT00596687|Drug|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
355990|NCT00596687|Drug|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
355991|NCT00596700|Device|Given® Diagnostic System including PillCamTM SB Capsules|Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.
An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa
355992|NCT00596726|Device|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
355993|NCT00004205|Drug|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
355994|NCT00599274|Drug|Interferon beta-1a|injection once a week
355995|NCT00599274|Drug|Interferon beta-1a|injection three times a week
355996|NCT00599287|Drug|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
355997|NCT00599287|Drug|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
355998|NCT00004217|Biological|sargramostim|5 μg/kg/day IV or SC starting d 15
356314|NCT00630760|Drug|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
356315|NCT00630786|Drug|Panitumumab|Administered by intravenous infusion
356316|NCT00630786|Drug|Conatumumab|Administered by intravenous infusion
355678|NCT00604214|Drug|Placebo|0.9% sodium chloride, intravenous, 96 hours
355679|NCT00604227|Other|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
355680|NCT00604253|Drug|insulin detemir|
355681|NCT00604253|Drug|insulin NPH|
355682|NCT00604279|Drug|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
355683|NCT00604279|Drug|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
355684|NCT00604305|Device|Acrysof|Monofocal IOL
355685|NCT00604305|Device|Acuity's AIOL|Accommodating IOL
355686|NCT00604318|Drug|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
355687|NCT00606840|Behavioral|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
355688|NCT00606853|Behavioral|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
355689|NCT00606866|Drug|placebo|Placebo for four weeks
355690|NCT00606866|Drug|Sorafenib|Sorafenib 200 mg twice daily
355691|NCT00606866|Drug|Sorafenib|Sorafenib, 400 mg twice daily
355692|NCT00606879|Drug|SGX523 Capsules|This is a dose escalation study
355693|NCT00606892|Drug|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
355694|NCT00606892|Drug|Placebo|Sugar Pill
355695|NCT00000620|Drug|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control <6%; standard control 7.0-7.9%).
355696|NCT00004248|Drug|doxorubicin hydrochloride|
355999|NCT00599287|Drug|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
355040|NCT00618904|Dietary Supplement|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
355041|NCT00004418|Drug|glyceryl trioleate|Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.
355042|NCT00618904|Dietary Supplement|Placebo|Placebo administered bid for 6 weeks.
355043|NCT00618917|Genetic|MnSOD|15 ml of a liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL. This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
355044|NCT00618930|Drug|Moviprep®|use of Moviprep®
355045|NCT00618930|Drug|Fleet|Use of Fleet
355354|NCT00611806|Other|Placebo|1 capsule po daily
355355|NCT00004288|Drug|olsalazine|
355356|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
355357|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
355358|NCT00611832|Behavioral|Triple P Media Series -- Standard "Information-Only" version|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
355359|NCT00611832|Behavioral|Triple P Media Series -- Enhanced "Behavior Activation" version|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
355360|NCT00611845|Drug|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
355361|NCT00611858|Drug|Cetuximab|Given once a week for 9 weeks
355362|NCT00613886|Behavioral|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
355363|NCT00613899|Other|telesurveillance|A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
355364|NCT00613912|Other|Magnetic Resonance Imaging|Morphological sequences
Arterial Spin Labelling (Perfusion)
Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter
355365|NCT00613925|Device|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
354716|NCT00004552|Drug|acamprosate (Campral)|
354717|NCT00625300|Device|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
354718|NCT00625300|Device|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
354719|NCT00625313|Device|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
354720|NCT00625326|Drug|COL-121|75 µg/g COL-121 Ointment
354721|NCT00625326|Drug|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
354722|NCT00625326|Drug|Placebo|Placebo
354723|NCT00625326|Drug|COL-121|150 µg/g COL-121 Ointment
354724|NCT00625326|Drug|COL-121|300 µg/g COL-121 Ointment
354725|NCT00625339|Drug|Entecavir|entecavir 0.5 mg QD
354726|NCT00625339|Drug|Lamivudine|lamivudine 100 mg QD
354727|NCT00004553|Procedure|Electromyography|
354728|NCT00625352|Drug|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
355046|NCT00618943|Behavioral|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
355047|NCT00618956|Drug|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily [BID]), oral administration.
355048|NCT00618956|Drug|Placebo|Placebo
355049|NCT00618969|Other|haploidentical allogeneic PBSC transp|Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days
Day -3: IV melphalan 100 mg/m2 as a single dose
Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days
Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight
354426|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
354427|NCT00004658|Drug|uridine|
354428|NCT00630097|Drug|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
354429|NCT00630110|Drug|docetaxel|docetaxel (75 mg/m2)
354430|NCT00592579|Drug|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
354431|NCT00592592|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
354432|NCT00592618|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
354433|NCT00592631|Device|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
354434|NCT00592631|Device|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
354435|NCT00592644|Procedure|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
354436|NCT00592644|Procedure|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
354437|NCT00592670|Drug|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
354438|NCT00004189|Drug|cisplatin|
354439|NCT00592670|Drug|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
354440|NCT00592683|Drug|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
354441|NCT00592683|Dietary Supplement|fish oil|1600mg (4 capsules) daily for 12 weeks
354442|NCT00592683|Drug|Placebo|Placebo
354443|NCT00592735|Procedure|laparoscopic gastric banding|standard surgical procedure
354444|NCT00592748|Radiation|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
354445|NCT00592761|Behavioral|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
354446|NCT00592774|Drug|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
353787|NCT00606177|Drug|placebo|oral, 0mg(4tablets)/day
353788|NCT00606190|Procedure|Retrograde brain perfusion|observational
353789|NCT00606190|Procedure|Antegrade brain perfusion|observational
353790|NCT00606203|Drug|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
353791|NCT00606203|Drug|placebo|placebo
353792|NCT00606216|Procedure|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
354100|NCT00598403|Drug|Ciprofloxacin|250 mg, oral, twice a day for 3 days
354101|NCT00598416|Behavioral|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
354102|NCT00004215|Biological|leridistim|
354103|NCT00598429|Drug|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
354104|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
354105|NCT00601185|Procedure|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
354106|NCT00601198|Drug|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
354107|NCT00601211|Drug|Pilocarpine|
354108|NCT00004224|Drug|etoposide|
354109|NCT00601224|Behavioral|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
354110|NCT00601224|Behavioral|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
354111|NCT00601237|Behavioral|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
353795|NCT00004255|Radiation|radiation therapy|
353796|NCT00608803|Drug|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
353797|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
353798|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
353799|NCT00608829|Device|GORE TAG® Thoracic Endoprosthesis|Implant
353800|NCT00608842|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
353801|NCT00608842|Drug|Placebo|Matching vehicle placebo administered via intralipomal injection.
353802|NCT00608855|Other|questionnaire administration|
353803|NCT00608855|Procedure|cryosurgery|
353804|NCT00608855|Procedure|pain therapy|
353805|NCT00608855|Procedure|quality-of-life assessment|
353806|NCT00004256|Biological|sargramostim|
353807|NCT00608868|Drug|Gefitinib|Gefitinib tablet 250mg once daily orally
353808|NCT00608881|Drug|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
353809|NCT00608881|Other|placebo|an inactive substance
353810|NCT00608894|Drug|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
353811|NCT00608894|Drug|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
353812|NCT00608907|Drug|bortezomib|1.3 mg/m^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
353813|NCT00608907|Drug|bortezomib, rifampicin|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
353814|NCT00608907|Drug|bortezomib, dexamethasone|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
354121|NCT00601289|Genetic|DNA methylation analysis|
353203|NCT00622765|Drug|R256918|15 mg capsule twice daily
353204|NCT00004479|Drug|midodrine|
353205|NCT00622804|Procedure|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
353509|NCT00613366|Drug|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
353510|NCT00613366|Dietary Supplement|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
353511|NCT00613379|Drug|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
353512|NCT00613379|Drug|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
353513|NCT00613379|Drug|Placebo|PBO, one IV dose (N=10)
353514|NCT00613392|Dietary Supplement|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
353515|NCT00613392|Dietary Supplement|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
353516|NCT00613405|Other|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
353517|NCT00615797|Drug|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
353518|NCT00615810|Drug|Atripla|Open label once daily for oral administration to be taken on an empty stomach
353519|NCT00615810|Drug|Kivexa plus Sustiva|Open label once daily for oral administration
353520|NCT00615823|Drug|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
353521|NCT00615823|Drug|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
353522|NCT00615836|Drug|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
352920|NCT00629486|Genetic|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
352921|NCT00629499|Drug|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
352922|NCT00629499|Drug|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
352923|NCT00591877|Procedure|Acupuncture|Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.
The acupoints that will be used are:
ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.
PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.
CV-12: 4 finger breadths superior to the umbilicus.
352924|NCT00591877|Procedure|Sham Acupuncture|The acupoints for SAC are:
LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.
GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.
UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae.
352925|NCT00591877|Other|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
352926|NCT00004188|Drug|vincristine sulfate|Given IV
353206|NCT00622804|Procedure|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
353207|NCT00622804|Procedure|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
353208|NCT00622817|Drug|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
353209|NCT00622817|Drug|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
353210|NCT00622830|Drug|SB-480848 (Darapladib)|
352632|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
352633|NCT00600561|Behavioral|MBSR|Mindfulness-Based Stress Reduction Intervention
352634|NCT00600574|Other|physical therapy|weekly pool physiotherapy with muscle stretching
352635|NCT00600574|Other|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
352636|NCT00600587|Drug|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
352637|NCT00004221|Drug|Cyclophosphamide|Given IV
352638|NCT00600587|Drug|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
352639|NCT00600600|Drug|Tigecycline|Standard dose Tigecycline 50 mg daily IV; however, daily dose may be dependent on clinical factors such as age, weight and patient-specific health status
352640|NCT00600613|Radiation|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
352641|NCT00600626|Drug|biphasic insulin aspart|
352642|NCT00600626|Drug|insulin NPH|
352643|NCT00600626|Drug|insulin aspart|
352644|NCT00600639|Device|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
352645|NCT00602706|Radiation|samarium Sm 153 lexidronam pentasodium|
352646|NCT00602719|Drug|Zolpidem|
352647|NCT00602732|Behavioral|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
352648|NCT00602732|Behavioral|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
352649|NCT00602745|Drug|S-1|oral administration
352650|NCT00004230|Radiation|radiation therapy|
352041|NCT00612716|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
352042|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
352043|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
352044|NCT00615095|Other|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
352045|NCT00615134|Drug|enfuvirtide [Fuzeon]|90mg sc bid
352046|NCT00615134|Drug|Optimized background ARV therapy|As prescribed
352325|NCT00608140|Drug|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
352326|NCT00608179|Drug|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
352327|NCT00004255|Biological|anti-thymocyte globulin|
352328|NCT00608179|Drug|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
352329|NCT00608179|Other|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
352330|NCT00608179|Other|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
352331|NCT00608192|Behavioral|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
352332|NCT00608192|Behavioral|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
352333|NCT00608205|Drug|cisplatin|Given IV
351739|NCT00004431|Drug|L-baclofen|
351740|NCT00619983|Drug|donepezil|Group 1: Will receive donepezil 5mg once a day
351741|NCT00619983|Drug|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
351742|NCT00621959|Drug|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
351743|NCT00621959|Drug|placebo|0mg (matching oral tablet)for 14 days
351744|NCT00621985|Drug|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
351745|NCT00621985|Drug|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
351746|NCT00621998|Drug|risperidone|0.5-6 mg/day
351747|NCT00621998|Drug|olanzapine|2.5-20 mg/day
351748|NCT00622011|Drug|Risperidone and Zolpidem for delirium|try risperidone or zolpidem in the treatment of delirium
351749|NCT00622037|Drug|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
351750|NCT00622037|Drug|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
352047|NCT00615147|Procedure|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
352048|NCT00615160|Drug|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
352049|NCT00615160|Drug|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
352050|NCT00004359|Drug|methoxsalen|
352051|NCT00615173|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
352052|NCT00615173|Drug|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
352053|NCT00615186|Drug|Neuradiab + Radiotherapy + Temozolomide|Prior Surgery
Rickham Catheter placement 99mTc-DTPA Flow Study
Neuradiab Dosimetry Study
Neuradiab Therapeutic Dose Administration
Radiation Therapy (XRT) + Temozolomide:
XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.
Post-Radiation Temozolomide Therapy:
Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.
351427|NCT00626275|Drug|Placebo|
351428|NCT00626275|Drug|ADL5859|
351429|NCT00626275|Drug|Placebo|
351430|NCT00626288|Drug|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
351431|NCT00004567|Drug|Mycophenolate Mofetil|
351432|NCT00626288|Drug|Placebo|Placebo cpr, t.i.d. 12 weeks
351433|NCT00626301|Drug|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
351434|NCT00626314|Biological|myoblast|autologous myoblast
351435|NCT00626314|Biological|sham|sham injection procedure
351436|NCT00626327|Biological|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
351437|NCT00626327|Biological|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
351438|NCT00626327|Biological|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
351439|NCT00628784|Procedure|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
351440|NCT00628784|Procedure|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
351441|NCT00628797|Radiation|UVA1|intraindividual half body irradiation
351442|NCT00628797|Other|UVA1|60 J/cm2 at least 36 tx
351443|NCT00628810|Biological|bevacizumab|
351444|NCT00628810|Drug|fluorouracil|
351445|NCT00004638|Procedure|pathogenesis study|
355908|NCT00628225|Behavioral|Counseling, Nicotine replacement and Bupropion (CNB)|Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.
Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR.
355909|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
356232|NCT00621504|Drug|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
356233|NCT00621504|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
356234|NCT00621504|Drug|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
356235|NCT00623766|Drug|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
356236|NCT00623766|Drug|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
356237|NCT00623766|Drug|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
356238|NCT00623766|Drug|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
356239|NCT00623766|Drug|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
356240|NCT00623766|Drug|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
356241|NCT00623766|Drug|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
356242|NCT00004489|Drug|alendronate sodium|
355605|NCT00596440|Drug|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
355606|NCT00596453|Drug|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
355607|NCT00596453|Drug|Placebo|Placebo twice a day for 14 days
355608|NCT00596466|Drug|pregabalin|pregabalin
355609|NCT00596479|Drug|Filgrastim (rG-CSF)|
355610|NCT00596492|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
355611|NCT00004203|Drug|oxaliplatin|
355612|NCT00596492|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
355613|NCT00596518|Drug|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
355614|NCT00596531|Drug|Acamprosate|Oral administration, 666 mg, tid, for 4 months
355615|NCT00596531|Drug|Placebo|Oral administration of 2 pills, tid, for 4 months
355616|NCT00596544|Behavioral|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
355910|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
355911|NCT00004585|Drug|Efavirenz|
355912|NCT00628251|Drug|AZD2281|400mg Oral twice daily
355913|NCT00628251|Drug|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
355914|NCT00628251|Drug|AZD2281|200mg oral twice daily
355915|NCT00630565|Drug|dexamethasone|20 mg/m^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
355916|NCT00630565|Drug|etoposide|300 mg/m^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
355917|NCT00630565|Procedure|bone marrow transplantation|Day 0 infusion of bone marrow cells
351510|NCT00597298|Device|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
351511|NCT00597298|Device|sham threshold|non-training physical activity
351512|NCT00597311|Radiation|radiotherapy|Short term radiotherapy 5x5 Gy during 5 days
Chemoradiotherapy 50 Gy + 5Fu/Lv
351513|NCT00597324|Procedure|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
351514|NCT00597337|Behavioral|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
351515|NCT00004208|Behavioral|Supportive care|Patients randomized to this arm will be treated as outpatients.
351838|NCT00629031|Drug|Paromomycin|11 mg/kg for 14 days
351839|NCT00629031|Drug|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
351840|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
351841|NCT00004640|Drug|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
351842|NCT00591474|Dietary Supplement|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
351843|NCT00591487|Drug|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
351844|NCT00000611|Behavioral|diet, fat-restricted|
351845|NCT00004188|Drug|doxorubicin hydrochloride|Given IV
351846|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
351847|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
356317|NCT00630799|Drug|leuprolide acetate|17 mg i.m.
356318|NCT00630812|Drug|inhaled mannitol|400 mg BD for 26 + 26 weeks
356319|NCT00630812|Drug|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
356320|NCT00630825|Drug|LY2189265|
356321|NCT00000635|Drug|Bacitracin zinc/Polymyxin B sulfate|
356322|NCT00004682|Drug|immune globulin|
356323|NCT00630825|Drug|Placebo|
356324|NCT00630838|Drug|VSL#3|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.
E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.
356325|NCT00630838|Drug|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
356326|NCT00630851|Drug|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
356327|NCT00630851|Drug|Placebo|Matching placebo tablets orally once daily for 6 months
356328|NCT00630864|Drug|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
356329|NCT00630877|Drug|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
356330|NCT00630877|Drug|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
356331|NCT00630877|Drug|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
356332|NCT00593645|Procedure|Stem cell infusion|
356333|NCT00593658|Drug|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
356334|NCT00593671|Procedure|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
351516|NCT00597350|Dietary Supplement|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
356000|NCT00599287|Other|No intervention|No intervention
356001|NCT00599313|Drug|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
356002|NCT00599326|Drug|Deferasirox|250 mg of deferasirox once daily for 6 months
356003|NCT00599352|Dietary Supplement|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
356004|NCT00599365|Other|Pharmacy care arm|The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.
You will need to give a complete list of medications to the pharmacist.
You will need to describe how you take these medications.
The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.
The pharmacist will give you a medication schedule, and other papers about your medications.
356005|NCT00599378|Behavioral|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
356006|NCT00599391|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
356007|NCT00599404|Drug|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
356008|NCT00599417|Drug|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
356009|NCT00004217|Drug|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
356010|NCT00599417|Drug|placebo|placebo controlled
356011|NCT00599430|Dietary Supplement|Placebo|Inert excipient
356012|NCT00599430|Dietary Supplement|Lactobacillus acidophilus NCFM|1e10 CFU/day
356013|NCT00599430|Dietary Supplement|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
356014|NCT00599443|Biological|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
356015|NCT00599443|Biological|Placebo Comparator|0.5 mL im, single dose
356016|NCT00599456|Dietary Supplement|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
356017|NCT00599456|Dietary Supplement|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
356018|NCT00599469|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
356019|NCT00601874|Drug|Pilocarpine|
355366|NCT00004330|Drug|luteinizing hormone-releasing factor|
355367|NCT00613925|Device|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
355368|NCT00613938|Drug|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
355369|NCT00613938|Drug|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
355370|NCT00613938|Drug|oxycodone|10mg capsule q4-6 hrs for 3 days
355371|NCT00613938|Drug|placebo|1 capsule q4-6 hrs for 3 days
355372|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
355373|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
355697|NCT00606892|Drug|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
355698|NCT00606905|Biological|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
355699|NCT00606905|Other|normal saline|equivalent volume of normal saline
355700|NCT00606931|Device|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
355701|NCT00606944|Behavioral|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
355702|NCT00606957|Dietary Supplement|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
355703|NCT00606970|Dietary Supplement|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
355704|NCT00606970|Dietary Supplement|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
355705|NCT00606983|Drug|Tamsulosin|oral administration of Tamsulosin
355706|NCT00606996|Behavioral|Group interpersonal psychotherapy (IPT-G)|
355707|NCT00004249|Biological|QS21|
355050|NCT00618982|Drug|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
355051|NCT00618995|Drug|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
355052|NCT00621062|Procedure|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
355053|NCT00621062|Procedure|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
355054|NCT00621075|Other|Pulmonary Arterial Hypertension - Lung Perfusion Scans|Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
355055|NCT00004446|Drug|fluoxetine|
355056|NCT00621088|Procedure|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
355057|NCT00621101|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
355058|NCT00621101|Drug|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
355374|NCT00613951|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
355375|NCT00613951|Drug|metformin|Tablets, 1500-2000 mg/daily
355376|NCT00613964|Drug|Carperitide heart failure therapy|carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
355377|NCT00004333|Drug|NTBC|
355378|NCT00613964|Drug|Standard heart failure therapy|Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
355379|NCT00614003|Behavioral|Decision support skills building Intervention|Decision support skills
354729|NCT00625365|Drug|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
354730|NCT00625378|Drug|Sorafenib (Nexavar, BAY43-9006)|All patients are treated with sorafenib according to the dosage scheme of their previous trial.
354731|NCT00625391|Drug|Placebo|500 mg medicinal starch pills daily
354732|NCT00625391|Drug|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
354733|NCT00625391|Drug|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
354734|NCT00625391|Drug|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
354735|NCT00625404|Drug|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
354736|NCT00625404|Other|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
354737|NCT00625417|Procedure|breast biopsy|
354738|NCT00004554|Drug|naltrexone (Revia)|100mg/day
354739|NCT00627666|Biological|anti-thymocyte globulin|
354740|NCT00627666|Drug|busulfan|
354741|NCT00627666|Drug|fludarabine phosphate|
354742|NCT00627666|Drug|leucovorin calcium|
354743|NCT00004583|Drug|Lamivudine|
354744|NCT00627666|Drug|methotrexate|
354745|NCT00627666|Procedure|allogeneic bone marrow transplantation|
354746|NCT00627666|Procedure|allogeneic hematopoietic stem cell transplantation|
354747|NCT00627666|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
354748|NCT00627679|Drug|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
354749|NCT00627679|Drug|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
354750|NCT00627679|Drug|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
354112|NCT00601237|Behavioral|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
354113|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
354114|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
354115|NCT00601263|Drug|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
354116|NCT00601276|Drug|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
354117|NCT00601276|Drug|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
354118|NCT00601289|Drug|temozolomide|
354119|NCT00000615|Behavioral|diet, reducing|
354120|NCT00004224|Drug|vincristine sulfate|
354447|NCT00592774|Drug|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
354448|NCT00592813|Behavioral|Enhanced Strong for Life|The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.
Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars.
354449|NCT00004190|Drug|gemcitabine hydrochloride|
354450|NCT00592813|Behavioral|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
354451|NCT00592839|Drug|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
354452|NCT00592839|Drug|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
354453|NCT00592852|Drug|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
354454|NCT00592891|Drug|Hyperbaric oxygen therapy|Total body pressurized oxygen
354455|NCT00595764|Behavioral|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
354456|NCT00004201|Drug|cisplatin|
354122|NCT00601289|Genetic|microarray analysis|
354123|NCT00601289|Genetic|protein expression analysis|
354124|NCT00601289|Genetic|proteomic profiling|
354125|NCT00601289|Other|laboratory biomarker analysis|
354126|NCT00601302|Drug|Amlodipine|
354127|NCT00601315|Drug|Clarithromycin|
354128|NCT00601328|Drug|Calcitriol|
354129|NCT00601341|Other|lumbosacral joint manipulation|lumbosacral joint manipulation
354130|NCT00601341|Other|lumbar passive range of motion|lumbar passive range of motion
354131|NCT00004224|Procedure|adjuvant therapy|
354132|NCT00601341|Other|No active intervention|Lie on exam table for 3 minutes
354133|NCT00603447|Drug|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
354134|NCT00603447|Drug|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
354135|NCT00603447|Drug|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
354136|NCT00603460|Biological|DCVax-L and T Cells|Arm A
Optional DCVax-L prior to chemotherapy
Apheresis
Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)
Infusion of activated T cells
DCVax-L vaccine
End of study visit
Arm B
Optional DCVax-L prior to chemotherapy
Apheresis
Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)
Infusion of activated T cells
DCVax-L vaccine
Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks
End of study visit
354137|NCT00603473|Drug|gabapentin|Orally administered gabapentin
354138|NCT00603486|Device|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
354139|NCT00603499|Dietary Supplement|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
354140|NCT00603499|Other|Placebo|Subjects in the control group received inert placebo once per day during 4 months
354141|NCT00004231|Drug|prednisone|
354142|NCT00603512|Drug|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
353523|NCT00615849|Procedure|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
353524|NCT00615862|Other|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
353525|NCT00615875|Drug|naproxen|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
353526|NCT00000625|Drug|Zidovudine|
353815|NCT00608920|Other|Single Photon Emission Computed Tomography (SPECT)|
353816|NCT00608933|Other|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
353817|NCT00004256|Procedure|quality-of-life assessment|
353818|NCT00608933|Other|questionnaire administration|Patients complete questionnaires
353819|NCT00611195|Drug|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
353820|NCT00611208|Biological|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
353821|NCT00611221|Procedure|Massage|Massage therapy by an RMT during labour
353822|NCT00611221|Procedure|Massage|Massage by anyone else, eg. husband, nurse, doula
353823|NCT00611247|Drug|Temozolomide|Priming, Group 2 only, 100 mg/m2/day temozolomide.
Induction (both arms) 200 mg/m2/day temozolomide
353824|NCT00611260|Behavioral|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
353825|NCT00611260|Other|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
353826|NCT00611273|Device|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
353827|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
353211|NCT00624728|Radiation|18F Fluorothymidine PET CT|18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).
Specific activity of 18FLT will be more than 37 GBq/µmol (>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (> 95%) via HPLC technique and thin layer chromatography.
18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.
PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction.
353212|NCT00624741|Drug|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
353213|NCT00624754|Drug|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
353214|NCT00624754|Drug|lactose|Lactose 2 puffs b.i.d for 1 month
353215|NCT00624767|Drug|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
353216|NCT00004500|Other|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
353217|NCT00624767|Drug|NovoLog|NovoLog at doses up to 30 IU
353218|NCT00624780|Drug|Pregabalin|Pregabalin 150-300 mg given twice a day
353219|NCT00624780|Drug|Lorazepam|Lorazepam 3-4 mg given twice a day
353220|NCT00624780|Drug|Pregabalin|Pregabalin 450-600 mg given twice a day
353527|NCT00004367|Procedure|Clinical vestibular tests|
353528|NCT00615875|Drug|placebo|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
353529|NCT00615888|Procedure|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
353530|NCT00615888|Procedure|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
353531|NCT00615901|Drug|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
352927|NCT00591890|Drug|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
352928|NCT00591916|Drug|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
352929|NCT00591916|Procedure|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
352930|NCT00591916|Procedure|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
352931|NCT00591929|Other|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
352932|NCT00591942|Device|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inlcusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
352933|NCT00591968|Device|SonoSite Titan portable ultrasound coupled with email telediagnosis|Sonographic exam will be performed by principal investigator. A "first-look" diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and "Request for Interpretation" (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience.
352934|NCT00591968|Other|Control|This group will receive the current standard of care (referral to tertiary medical center for sonographic exam).
352935|NCT00591981|Behavioral|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
352936|NCT00591994|Drug|piribedil|50 mg once a day, after lunch 3 month therapy
352937|NCT00004188|Procedure|autologous bone marrow transplantation|
352938|NCT00594997|Behavioral|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
352939|NCT00594997|Behavioral|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
352940|NCT00004198|Biological|sargramostim|
352941|NCT00595010|Behavioral|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
352334|NCT00608205|Drug|fluorouracil|Given IV
352335|NCT00608205|Radiation|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
352336|NCT00608218|Drug|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
352337|NCT00610584|Procedure|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
352338|NCT00610584|Procedure|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
352339|NCT00610584|Drug|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
352340|NCT00610610|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
352341|NCT00610610|Drug|Placebo|Same shape Placebo
352342|NCT00610623|Drug|azithromycin|300 mg/day, IV from day 1 to 20
352651|NCT00602745|Drug|5-Fluorouracil|intravenous bolus
352652|NCT00602758|Behavioral|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
352653|NCT00602758|Behavioral|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
352654|NCT00602771|Drug|tipifarnib|Given orally
352655|NCT00602771|Drug|etoposide|Given orally
352656|NCT00602784|Biological|IC41|
352657|NCT00602797|Drug|vinorelbine tartrate|Given IV
352658|NCT00602797|Drug|paclitaxel|Given IV
352659|NCT00602797|Procedure|quality-of-life assessment|Ancillary studies
352660|NCT00602797|Other|questionnaire administration|Ancillary studies
352661|NCT00004231|Biological|aldesleukin|
352054|NCT00615186|Drug|Radiation Therapy + Temozolomide|Prior Surgery: Gross total resection (< 1 cm. enhancing rim)
Radiation Therapy (XRT) + Temozolomide:
XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks
Post-Radiation Temozolomide Therapy:
Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.
352055|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
352056|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
352057|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
352058|NCT00615199|Drug|Placebo|administration via oral route twice daily
352059|NCT00615212|Drug|GSK376501|
352060|NCT00615225|Procedure|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
352061|NCT00004360|Drug|chlorothiazide|
352062|NCT00617604|Drug|placebo|IV and subcutaneous injection
352063|NCT00617604|Drug|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
352064|NCT00617604|Drug|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
352065|NCT00617604|Drug|Steroids|Methylprednisolone or equivalent:
Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus
Prednisone or equivalent:
Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
352066|NCT00617617|Dietary Supplement|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
352343|NCT00610623|Drug|placebo|once per day, IV from day 1 to 20
352344|NCT00610636|Procedure|Hepatic resection|Hepatic resection
352345|NCT00000621|Drug|placebo|
352346|NCT00004264|Drug|amifostine trihydrate|
352347|NCT00610649|Drug|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
352348|NCT00610649|Drug|Placebo|Orally administered matching placebo capsules.
352349|NCT00610675|Drug|Org 50081|One tablet daily
351751|NCT00622050|Behavioral|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
351752|NCT00004466|Drug|atorvastatin|
351753|NCT00622050|Behavioral|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
351754|NCT00622063|Drug|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
351755|NCT00622076|Procedure|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
351756|NCT00622089|Drug|DIO-902|150mg DIO-902 + 10mg atorvastatin
351757|NCT00622089|Drug|DIO-902|300mg dose once per day for 24 weeks
351758|NCT00622089|Drug|DIO-902|450mg dose once per day for 24 weeks
351759|NCT00622102|Behavioral|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
351760|NCT00622102|Behavioral|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
351761|NCT00622115|Drug|Enoxaparin|
351762|NCT00622128|Behavioral|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
351763|NCT00004467|Drug|acetylcysteine|
351764|NCT00622141|Drug|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
351765|NCT00622167|Device|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
351766|NCT00624338|Other|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
351767|NCT00624351|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
351768|NCT00624351|Other|Placebo|Phosphate-buffered Saline (PBS) infusion.
351769|NCT00624364|Drug|biphasic insulin aspart|
356243|NCT00623766|Drug|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
356244|NCT00623766|Drug|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
356245|NCT00623766|Drug|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
356246|NCT00623779|Drug|AZD0837|ER formulation
356247|NCT00623779|Drug|Aspirin|Oral form
356248|NCT00623792|Behavioral|Preoperative lifestyle Intervention|6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 "booster" telephone calls after surgery
351446|NCT00628810|Drug|irinotecan hydrochloride|
351447|NCT00628810|Drug|leucovorin calcium|
351448|NCT00628823|Dietary Supplement|Gluten-free diet|Gluten containing foods removed from diet
351449|NCT00628836|Device|BION stimulation|The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.
Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.
If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated.
351450|NCT00628862|Drug|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
351451|NCT00628862|Drug|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
351452|NCT00628862|Drug|Turbuhaler® placebo|placebo inhaled twice daily
351453|NCT00628888|Behavioral|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
355918|NCT00630565|Procedure|hematopoietic stem cell transplantation|Stem cell infusion (>48 hours after the last dose of cyclophosphamide)
355919|NCT00630565|Procedure|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
355920|NCT00630565|Radiation|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
355921|NCT00630578|Behavioral|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
355922|NCT00630591|Behavioral|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
355923|NCT00630591|Behavioral|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
355924|NCT00630591|Behavioral|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
355925|NCT00004667|Drug|von Willebrand factor|
355926|NCT00630617|Behavioral|Diet, Physical activity, Physical inactivity|Community based participatory research design
355927|NCT00630630|Drug|Levetiracetam|
355928|NCT00630630|Other|Placebo|
355929|NCT00630643|Biological|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
355930|NCT00630643|Drug|Placebo|Placebo
355931|NCT00630656|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
356249|NCT00623805|Drug|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
356250|NCT00623805|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
356251|NCT00623805|Drug|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
356252|NCT00623831|Biological|Mixed Bacterial Vaccine|Each patient of the arm 1 received Mixed Bacterial Vaccine (MBV) subcutaneously at the starting dose of 250 EU twice weekly. In the absence of a dose-limiting toxicity (DLT), the MBV dose was escalated in each patient to the MBV dose level that elicited a body temperature of 38C -39.5C or up to the maximum dose level 8.
Each patient of the arm 2 received Mixed Bacterial Vaccine (MBV) at the fixed pyrogenic dose level 6 (60,800 EU).
356253|NCT00004489|Drug|calcium carbonate|
351848|NCT00591513|Device|Autologous engineered skin substitutes|Autologous skin cells combined with a biopolymer sponge which is transplanted to excised, full-thickness burns, excised or incised burn scars, or excised full-thickness congenital giant melanocytic nevus. Repeated administrations until all skin wounds are closed.
351849|NCT00591526|Drug|Arac|Ommit ARAC in the chemotherapy
351850|NCT00591539|Procedure|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
351851|NCT00591552|Device|Harmonic ACE23P Scalpel|Lymph node dissection
351852|NCT00591552|Device|Electrocautery|
351853|NCT00591565|Drug|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
351854|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
351855|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
351856|NCT00004188|Drug|etoposide|Given IV
352151|NCT00624533|Behavioral|Conventional Physical Therapy in Primary Health Care|Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.
Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks.
352152|NCT00624546|Drug|Prevacid Solutabs|BID Prevacid Solutabs
352153|NCT00624546|Procedure|Antireflux surgery|Lap Nissen
352154|NCT00624559|Drug|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
352155|NCT00624559|Other|Placebo|Placebo pill taken twice per day on each day of the diet
352156|NCT00004573|Drug|ganciclovir|
352157|NCT00626483|Drug|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
352158|NCT00626509|Drug|sunitinib malate|
352159|NCT00626509|Procedure|adjuvant therapy|
352160|NCT00626509|Procedure|neoadjuvant therapy|
352161|NCT00626509|Procedure|therapeutic conventional surgery|
352162|NCT00626522|Drug|Aclidinium bromide and formoterol|once daily
351517|NCT00600002|Biological|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
351518|NCT00600015|Drug|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
351519|NCT00600015|Drug|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
351520|NCT00600028|Drug|Thalidomide|thalidomide 50 - 100 mg by mouth daily
351521|NCT00004218|Drug|vincristine sulfate|
351522|NCT00600028|Drug|Placebo|Placebo 50-100 mg by mouth per day
351523|NCT00600041|Drug|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
351524|NCT00600041|Drug|Placebo|Identical infusion manner like experimental arm
351525|NCT00600054|Biological|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
351526|NCT00600067|Drug|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
351527|NCT00600067|Drug|Placebo|Oral placebo capsules, once daily, 28 weeks
351528|NCT00600080|Device|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
351529|NCT00600080|Device|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
351530|NCT00600093|Drug|Amantadine|IV Amantadine 200mg *1/d at the beginning of surgery and 24 hours following surgery
351531|NCT00600119|Drug|placebo|placebo, oral, once daily (QD)
351532|NCT00004219|Drug|granisetron hydrochloride|
351533|NCT00600119|Drug|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
351534|NCT00600145|Drug|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
351535|NCT00600145|Other|Placebo|Placebo
351536|NCT00600158|Drug|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
356020|NCT00601887|Drug|Meloxicam|
356335|NCT00593684|Device|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
356336|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel|Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:
A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
356337|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
356338|NCT00004195|Drug|eniluracil|Will be given to either subject pre-operative and metastatic disease
356339|NCT00593710|Drug|Losartan|Losartan (25mg OD)
356340|NCT00593710|Drug|Atenolol|Atenolol (25-50mg OD)
356341|NCT00593723|Radiation|IMRT|
356342|NCT00593736|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
356343|NCT00593736|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
356344|NCT00593736|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
356345|NCT00593736|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
356346|NCT00593749|Behavioral|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
356347|NCT00593749|Behavioral|Control|control group in study
356348|NCT00593775|Procedure|assisted hatching|assisted hatching with laser
356349|NCT00004195|Procedure|conventional colon surgery|Only if the subject is amenable to surgical resections
356350|NCT00593801|Drug|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
356351|NCT00593801|Drug|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
356352|NCT00593814|Device|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
355708|NCT00606996|Behavioral|Psychoeducation on co-occurring disorders (PSYCHOED)|
355709|NCT00607009|Behavioral|ALIVE|email-based behavioral program
355710|NCT00607022|Device|dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach.
355711|NCT00609518|Dietary Supplement|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
355712|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
355713|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
355714|NCT00609531|Drug|Citalopram|Pill, 5-20mg once a day for twelve weeks
355715|NCT00004259|Radiation|radiation therapy|
356021|NCT00601900|Biological|Bevacizumab|Given IV
356022|NCT00601900|Other|Laboratory Biomarker Analysis|Correlative studies
356023|NCT00601900|Drug|Letrozole|Given PO
356024|NCT00601900|Other|Questionnaire Administration|Ancillary studies
356025|NCT00601900|Drug|Tamoxifen Citrate|Given PO
356026|NCT00601913|Drug|erlotinib hydrochloride|
356027|NCT00601913|Genetic|protein analysis|
356028|NCT00601913|Genetic|western blotting|
356029|NCT00004228|Drug|cyclophosphamide|Given IV
356030|NCT00601913|Other|immunohistochemistry staining method|
356031|NCT00601913|Other|laboratory biomarker analysis|
356032|NCT00601913|Other|liquid chromatography|
356033|NCT00601913|Other|mass spectrometry|
356034|NCT00601913|Procedure|neoadjuvant therapy|
355380|NCT00614016|Drug|Sodium ST20|single administration of oral dosage form
355381|NCT00614029|Device|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
355382|NCT00614042|Drug|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
355383|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
355384|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
355385|NCT00614055|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
355386|NCT00616629|Drug|AZD1305|Intravenous infusion
355387|NCT00616642|Drug|rosiglitazone maleate|Given orally
355388|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
355389|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
355390|NCT00616655|Drug|Placebo|Placebo total daily dose 0.9 mg
355391|NCT00616668|Device|Air- Limb|
355392|NCT00616681|Drug|Oxcarbazepine|
355393|NCT00616694|Drug|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
355394|NCT00616720|Biological|aldesleukin|
355395|NCT00616720|Biological|idiotype-pulsed autologous dendritic cell vaccine APC8020|
355396|NCT00000625|Drug|Zalcitabine|
355397|NCT00004386|Genetic|recombinant adenovirus containing the ornithine transcarbamylase gene|
355398|NCT00616720|Biological|recombinant interferon gamma|
355716|NCT00609531|Drug|Placebo|Placebo pill once a day for twelve weeks
355717|NCT00609544|Drug|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
355718|NCT00609557|Drug|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
354751|NCT00627679|Drug|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
354752|NCT00627692|Drug|Prucalopride|0.5 mg o.d.
355059|NCT00621101|Drug|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
355060|NCT00621114|Device|GamCath® central venous catheter|Choice of central venous catheter type
355061|NCT00621114|Device|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
355062|NCT00621140|Drug|linagliptin|active
355063|NCT00621140|Drug|placebo|placebo
355064|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
355065|NCT00621153|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
355066|NCT00004448|Drug|omega-3 fatty acids|
355067|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
355068|NCT00621166|Drug|generic lopinavir/ritonavir|Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.
Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional.
355069|NCT00621179|Drug|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
355070|NCT00623259|Biological|MVA-mBN120B|
355071|NCT00623272|Other|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
355072|NCT00623285|Drug|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
355073|NCT00000629|Drug|Valproic acid|
355074|NCT00004485|Drug|mycophenolate mofetil|
354457|NCT00595777|Behavioral|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
354458|NCT00595790|Biological|IC51|
354459|NCT00595816|Other|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
354460|NCT00595829|Drug|XL019|XL019 capsules administered orally
354461|NCT00595855|Procedure|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis
354462|NCT00595855|Procedure|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
354463|NCT00595868|Drug|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
354464|NCT00595868|Drug|Placebo|same as Varenicline arm
354753|NCT00627692|Other|Placebo|o.d.
354754|NCT00004583|Drug|Stavudine|
354755|NCT00627692|Drug|Prucalopride|1 mg o.d.
354756|NCT00627692|Drug|Prucalopride|2 mg o.d.
354757|NCT00627692|Drug|Prucalopride|4 mg o.d.
354758|NCT00627705|Drug|N-Acetyl Cysteine|Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks
Entire intervention lasts for 12 weeks (drug administration is continuous).
354759|NCT00627705|Other|Placebo - sugar pill|Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks
Entire intervention lasts for 12 weeks (drug administration is continuous).
354760|NCT00627718|Device|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
354761|NCT00627731|Drug|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
354762|NCT00627731|Drug|prednisolone (PSL)|PSL 40 mg per day for 10 days
354763|NCT00627744|Drug|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
354143|NCT00603512|Drug|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
354465|NCT00595881|Device|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
354466|NCT00595920|Biological|Tovaxin|2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
354467|NCT00004201|Drug|gemcitabine hydrochloride|
354468|NCT00595933|Other|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
354469|NCT00595933|Other|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
354470|NCT00595933|Other|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
354471|NCT00595933|Other|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
354472|NCT00595933|Drug|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
354473|NCT00595933|Drug|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
354474|NCT00595946|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
354475|NCT00595946|Drug|Placebo|0 mcg capsules twice daily (BID)
354476|NCT00595959|Device|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
354477|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
354478|NCT00598442|Drug|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
354479|NCT00598481|Genetic|Gene transduced CD34+ cells|infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with Busulphan
354480|NCT00598507|Drug|ZK-EPO|Participants were treated with 16 mg/m^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
354481|NCT00598533|Device|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
353828|NCT00004275|Drug|growth hormone|
353829|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
353830|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
353831|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
353832|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
353833|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
354144|NCT00603512|Drug|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
354145|NCT00603512|Drug|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
354146|NCT00603512|Drug|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
354147|NCT00603525|Drug|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
354148|NCT00603525|Drug|Placebo|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
354149|NCT00603538|Drug|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
354150|NCT00603564|Procedure|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
354151|NCT00603577|Drug|placebo|placebo
354152|NCT00004231|Drug|teniposide|
354153|NCT00603577|Drug|xaliproden|1.0 mg capsule or matching placebo. One capsule of investigational product (IP) daily for 6 months or until resolution of PSN (whichever comes first).
354154|NCT00603590|Drug|Polypill|Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
354155|NCT00603590|Drug|Placebo drug|Inactive tablet Once a day Identical in appearance to intervention drug
353532|NCT00615901|Drug|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|If Cohort 1 is deemed safe according to stopping criteria listed, the next cohort of patients, Cohort 2, C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 N (filgrastim/Neupogen ®) 300 mcg or 480 mcg. Eight doses of CMF q 10-11 days with filgrastim (Neupogen®) given days 1-5 beginning the day after chemotherapy. 300 μg/kg for patients < 60 kg or 480 μg for patients > or = to 60 kg subcutaneous from day 2 until day 8 (7 days).
353533|NCT00618332|Drug|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
353534|NCT00618332|Drug|placebo|2 puffs in each nostril once a day for 2 weeks
353535|NCT00618345|Drug|everolimus|
353536|NCT00004407|Drug|immune globulin|
353537|NCT00618345|Genetic|DNA analysis|
353538|NCT00618345|Genetic|protein analysis|
353539|NCT00618345|Genetic|western blotting|
353540|NCT00618345|Other|flow cytometry|
353541|NCT00618345|Other|laboratory biomarker analysis|
353542|NCT00618345|Procedure|biopsy|
353543|NCT00618358|Device|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
353544|NCT00618358|Other|Gelfoam/Thrombin|
353545|NCT00618371|Drug|Raltegravir (MK-0518)|Raltegravir 400mg PO every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
353546|NCT00618384|Drug|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
353547|NCT00004408|Drug|poloxamer 188|
353548|NCT00618397|Drug|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
353834|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
353835|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
353836|NCT00611299|Dietary Supplement|BB-12 and CRL 431|
353837|NCT00611312|Behavioral|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
352942|NCT00595023|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
352943|NCT00595049|Drug|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
353221|NCT00624780|Drug|Placebo|Placebo
353222|NCT00624793|Other|Acupuncture|Standard Acup point protocol for treating nausea
353223|NCT00624793|Other|Individualized Acup based on TCM diagnosis|Acup
353224|NCT00624793|Other|Sham Acup|Sham Acup - Non-Active
353225|NCT00624806|Behavioral|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
353226|NCT00624806|Behavioral|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
353227|NCT00004533|Drug|Adeno-associated virus-CFTR vector|
353228|NCT00624819|Biological|GSK1024805A|No vaccination in this trial
353229|NCT00624819|Biological|Prevenar|No vaccination in this trial
353230|NCT00624832|Drug|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
353231|NCT00624832|Drug|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
353232|NCT00624845|Drug|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
353233|NCT00624845|Drug|Vehicle|Maximum of 6 bags of vehicle irrigation solution
353234|NCT00626990|Procedure|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
353235|NCT00626990|Radiation|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
353236|NCT00627003|Drug|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
353237|NCT00627003|Other|Placebo|Placebo oral tablets administered daily for 5 weeks
353238|NCT00627016|Drug|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
352662|NCT00602836|Biological|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m^2 by IV on day 2 Cycle 2-6: 375 mg/m^2 by IV on day 1 (every 21 days)
352663|NCT00602836|Drug|Cyclophosphamide|600 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
352664|NCT00602836|Drug|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
352665|NCT00602836|Drug|Pentostatin|2 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
352666|NCT00602849|Drug|Sertraline|
352667|NCT00602862|Drug|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
352668|NCT00602862|Drug|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
352669|NCT00602862|Drug|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
352670|NCT00602901|Other|Spinal manipulation|High-velocity low amplitude spinal manipulation (HVLA-SM)
352671|NCT00602901|Other|Spinal manipulation|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
352944|NCT00595062|Radiation|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
352945|NCT00595075|Drug|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
352946|NCT00595075|Drug|placebo|placebo identical in appearance to active experimental drug x 1 dose
352947|NCT00595088|Biological|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
352948|NCT00595101|Drug|PF-03187207|
352949|NCT00595101|Drug|Latanoprost 0.005%|
352950|NCT00595101|Drug|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
352951|NCT00004198|Biological|tumor cell-based vaccine therapy|
352952|NCT00595101|Drug|Latanoprost Vehicle|
352953|NCT00595127|Drug|Cyclophosphamide and Fludarabine|Cyclophosphamide and Fludarabine
352350|NCT00610688|Drug|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
352351|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
352352|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
352353|NCT00610701|Device|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
352354|NCT00610701|Device|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
352355|NCT00610714|Drug|AZD0530|oral once daily dose
352356|NCT00610714|Drug|Carboplatin|intravenous injection
352357|NCT00004264|Drug|cisplatin|
352358|NCT00610714|Drug|Paclitaxel|intravenous infusion
352359|NCT00610727|Drug|Prochlorperazine|10 mg IV over 2 min
352360|NCT00610727|Drug|Prochlorperazine|0.5 mg IV over 5 sec
352361|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 0.625 mg
352362|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 1.25 mg
352363|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 2.5 mg
352364|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 5 mg
352365|NCT00612716|Biological|Stem cell infusion|Infused on Day 0
352366|NCT00612716|Radiation|Total body irradiation|165 cGy morning and evening on days -4 through -1.
352367|NCT00612729|Procedure|Polylens Y30 intraocular lens|cataract surgery
352368|NCT00612729|Procedure|Orange Series Model PC 440 Y intraocular lens|cataract surgery
352672|NCT00605566|Drug|sorafenib and cyclophosphamide|During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After "run-in" period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.
351770|NCT00624364|Drug|metformin|
351771|NCT00624377|Drug|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
351772|NCT00624390|Device|Sepraspray|
352067|NCT00617617|Other|Placebo|Control Group - Control Group participants will receive an identical placebo.
352068|NCT00004401|Drug|botulism immune globulin|
352069|NCT00617643|Drug|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
352070|NCT00617643|Drug|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
352071|NCT00617656|Drug|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
352072|NCT00617656|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
352073|NCT00617656|Drug|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
352074|NCT00617656|Drug|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
352075|NCT00617669|Drug|Docetaxel|intravenous infusion given every three weeks
352076|NCT00617669|Drug|ZD4054|10 mg oral once daily dose
352077|NCT00617669|Drug|Placebo|placebo oral tablet once daily
352078|NCT00617682|Biological|PNCRM9|0.5 mL IM at 30-35 wks gestation
352079|NCT00004402|Drug|calcitriol|
352080|NCT00617682|Biological|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
352081|NCT00617695|Drug|Zolmitriptan|5mg nasal spray
352082|NCT00617695|Drug|Placebo|
352083|NCT00617708|Biological|cixutumumab|Given IV
352084|NCT00617708|Drug|erlotinib hydrochloride|Given PO
352085|NCT00617708|Drug|gemcitabine hydrochloride|Given IV
351454|NCT00628901|Procedure|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
351455|NCT00628901|Device|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
351456|NCT00631241|Procedure|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
351457|NCT00631254|Procedure|Allergen challenge|Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.
Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.
Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa.
351458|NCT00004688|Drug|streptozocin|
351459|NCT00631254|Procedure|Allergen challenge|Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.
Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa.
351460|NCT00631267|Procedure|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
351773|NCT00004495|Drug|cyanocobalamin|
351774|NCT00624403|Device|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
351775|NCT00624403|Device|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
351776|NCT00624416|Drug|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
351777|NCT00624429|Drug|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
351778|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.125 mg/kg/hr followed by 1 hour at 0.0625 mg/kg/hr
351779|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 1 hour at 0.125 mg/kg/hr
351780|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 1 hour at 0.25 mg/kg/hr
351781|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.75 mg/kg/hr followed by 1 hour at 0.375 mg/kg/hr
351782|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 1 hour at 0.5 mg/kg/hr
356254|NCT00623844|Behavioral|physical activity|activity program at kindergarten 5 * 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
356255|NCT00623857|Dietary Supplement|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
356256|NCT00625742|Drug|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
356257|NCT00625755|Biological|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
356258|NCT00625768|Drug|AS1409|Study drug
356259|NCT00625781|Drug|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
356260|NCT00625794|Drug|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
356261|NCT00625794|Behavioral|Smoking cessation counseling|8 weeks or counseling
356262|NCT00625807|Behavioral|RR|A well-validated 8 week stress reduction course. Classes meet once a week from 5-8:30 PM. Participants will be asked to perform stress reduction techniques each night for 25 minutes throughout the entire 8-week course
356263|NCT00004562|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
356264|NCT00625807|Behavioral|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week from 5-8:30 PM. Participants will be asked to perform stress reduction techniques each night for 25 minutes throughout the entire 8-week course
356265|NCT00625820|Drug|Tetrahydrobiopterin (6R BH4)|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks
356266|NCT00625820|Dietary Supplement|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
356267|NCT00625833|Drug|Placebo|Oral tablet once a day dosing for 10 weeks.
356268|NCT00625833|Drug|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
356269|NCT00625846|Other|Laboratory Biomarker Analysis|Correlative studies
351461|NCT00631267|Procedure|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
351462|NCT00631280|Behavioral|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
352163|NCT00626522|Drug|Aclidinium bromide and formoterol placebo|once daily
352164|NCT00626535|Drug|Esomeprazole|20mg Oral Once Daily
352165|NCT00626535|Drug|Matching placebo|Oral Once Daily
352166|NCT00626548|Drug|ZD4054|10 mg once daily oral dose
352167|NCT00004575|Drug|Miconazole, L-NMMA, Bradykinin|
352168|NCT00626548|Drug|Palcebo|Matching Plcebo oral tablet once daily
352169|NCT00626561|Drug|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
352170|NCT00626561|Drug|Paclitaxel|60 mg/m^2 IV weekly on days 1, 8, 15, and 22.
352171|NCT00626574|Drug|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
352172|NCT00626574|Drug|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
352173|NCT00626587|Device|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
352448|NCT00620230|Drug|NVP-VAK694|
352449|NCT00620230|Drug|NVP-VAK694|
352450|NCT00620243|Procedure|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
352451|NCT00620256|Drug|AL-37807 ophthalmic suspension, 0.1%|
352452|NCT00620256|Drug|Timolol gel forming solution, 0.5%|
352453|NCT00620256|Other|AL-37807 ophthalmic solution vehicle|
352454|NCT00004437|Device|Multichannel Auditory Brain Stem Implant|
352455|NCT00620256|Drug|Latanoprost ophthalmic solution|
352456|NCT00620269|Drug|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
351537|NCT00600158|Drug|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients > 70 kg)
351857|NCT00591578|Drug|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
351858|NCT00591591|Device|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
351859|NCT00591604|Drug|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
351860|NCT00591617|Other|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
351861|NCT00591630|Drug|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
351862|NCT00594438|Device|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
351863|NCT00594438|Device|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
351864|NCT00594464|Drug|Rotigotine|2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;
Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;
One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery.
351865|NCT00594477|Radiation|IMRT|
351866|NCT00594503|Drug|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
351867|NCT00594516|Drug|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
351868|NCT00594516|Drug|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
356353|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
356354|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
356355|NCT00593840|Radiation|IMRT|
351538|NCT00600171|Drug|GW642444M|GW642444M
351539|NCT00600171|Drug|Placebo|Placebo mulit-dose dry powder inhaler
351540|NCT00600184|Device|The AMES device|The AMES device is a investigational device which cyclically rotates the ankle while muscle vibrators stimulate sensory receptors in the muscles opposite to the joint being rotated. Each subject will be tested before and after the 10-week treatment period. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
351541|NCT00600197|Behavioral|back school|A kind of educational program for low back pain
351542|NCT00602368|Other|laboratory biomarker analysis|
351543|NCT00602368|Procedure|colposcopic biopsy|
351544|NCT00602368|Procedure|colposcopy|
351545|NCT00602368|Procedure|light-scattering spectroscopy|
351546|NCT00602368|Procedure|loop electrosurgical excision procedure|
351547|NCT00602381|Drug|Lithium|
351548|NCT00602394|Drug|Lithium|
351549|NCT00602407|Drug|Cilostazol|
351550|NCT00602420|Drug|naproxen|Oral naproxen twice daily for 5-8 days.
351551|NCT00602420|Other|placebo|Oral placebo twice daily for 5-8 days.
351552|NCT00004228|Drug|vincristine sulfate|Given IV
351553|NCT00602446|Drug|deferasirox|20 mg/kg once daily orally for 6 months
351554|NCT00602459|Drug|Cyclophosphamide|Given IV
351555|NCT00602459|Drug|Fludarabine Phosphate|Given IV or PO
351556|NCT00602459|Other|Laboratory Biomarker Analysis|Correlative studies
356035|NCT00601913|Procedure|therapeutic conventional surgery|
356036|NCT00601926|Biological|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
356037|NCT00601939|Behavioral|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
356038|NCT00601939|Behavioral|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
356039|NCT00601952|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
356040|NCT00004228|Drug|cytarabine|Given IV
356041|NCT00601952|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
356042|NCT00601965|Drug|Escitalopram|20 mg daily oral escitalopram
356043|NCT00601965|Drug|Placebo|Placebo pill of daily oral escitalopram
351249|NCT00607737|Drug|insulin detemir|3 cutaneous injections
351250|NCT00607737|Drug|saline|3 cutaneous injections
351251|NCT00607750|Drug|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
351252|NCT00607750|Drug|Placebo|Placebo eyedrops, BID, 48 weeks
351253|NCT00607763|Drug|Micafungin (Mycamine)|IV
351254|NCT00607776|Drug|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
351255|NCT00607776|Drug|Systane|Drops
351256|NCT00607789|Drug|Duloxetine|30 mg/day - 120 mg/day
351257|NCT00607789|Drug|Placebo|identical to study drug
351258|NCT00607802|Biological|leukocyte therapy|
355719|NCT00609570|Dietary Supplement|NanoGreens|fruits and vegetables
355720|NCT00609570|Dietary Supplement|Whey protein|Whey
355721|NCT00609570|Dietary Supplement|Calcium pills|CA
355722|NCT00609596|Drug|GI198745|
355723|NCT00609609|Procedure|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
355724|NCT00609609|Drug|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
355725|NCT00609622|Drug|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
355726|NCT00004260|Biological|recombinant interleukin-12|
355727|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
355728|NCT00609622|Drug|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
355729|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
355730|NCT00609648|Behavioral|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
355731|NCT00609648|Behavioral|Pamphlet|A pamphlet reassuring patients about dental injections.
355732|NCT00609674|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
355733|NCT00609674|Drug|Placebo|Placebo
355734|NCT00611858|Drug|5-Fluorouracil|Given by continuous infusion for weeks 4 through 9
355735|NCT00611858|Radiation|External Beam Pelvis Radiation Therapy|Monday through Friday beginning after the 2nd sigmoidoscopy and biopsy is completed
355736|NCT00611871|Drug|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
356044|NCT00601965|Behavioral|Cognitive behavioral therapy (CBT)|16 weekly 1-hour sessions
356045|NCT00601978|Drug|carbidopa/levodopa|
355075|NCT00623285|Drug|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
355076|NCT00623298|Behavioral|Narrative Exposure Therapy|
355077|NCT00623298|Behavioral|group IPT|
355399|NCT00616720|Genetic|polymerase chain reaction|
355400|NCT00616720|Genetic|reverse transcriptase-polymerase chain reaction|
355401|NCT00616720|Other|flow cytometry|
355402|NCT00616720|Other|laboratory biomarker analysis|
355403|NCT00616733|Drug|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
355404|NCT00616733|Drug|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
355405|NCT00616733|Drug|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
355406|NCT00616746|Drug|Nicotine|1.0 microg/kg/min IV x 10 minutes
355407|NCT00616746|Drug|Ethanol|IV
355408|NCT00004387|Procedure|fetal nigral transplantation|
355409|NCT00616759|Procedure|electroconvulsive therapy|electroconvulsive therapy as usual
355410|NCT00616759|Procedure|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
355411|NCT00616759|Drug|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
355412|NCT00616772|Drug|ABT-335|Capsule
355413|NCT00616772|Drug|Placebo|Capsule
355414|NCT00616772|Other|Atorvastatin|Capsule
355415|NCT00616785|Drug|cisplatin|
355416|NCT00616785|Drug|etoposide|
355417|NCT00616785|Drug|irinotecan hydrochloride|
354764|NCT00627770|Device|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
354765|NCT00004584|Drug|Atazanavir|
354766|NCT00627783|Other|a bicycle exercise test|
354767|NCT00630110|Drug|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
354768|NCT00630136|Behavioral|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
354769|NCT00630149|Drug|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
354770|NCT00630162|Genetic|amoeba|
354771|NCT00630175|Drug|zolpidem-MR (modified release)|
354772|NCT00630175|Drug|zolpidem (SL800750)|
354773|NCT00630175|Drug|placebo|
354774|NCT00630188|Other|You Decide|For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician
For Physicians: a one-time educational session on prostate cancer and the value of shared decision making
354775|NCT00000635|Drug|Trifluridine|
354776|NCT00004659|Procedure|irradiation|
355078|NCT00623298|Other|6 months-baseline|
355079|NCT00623324|Drug|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
355080|NCT00623324|Drug|Placebo|Placebo tablets to match the number of active tablets
355081|NCT00623337|Behavioral|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy & 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify & refer sick babies
355082|NCT00623350|Other|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
355083|NCT00623350|Other|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
355084|NCT00623363|Drug|piclozotan|piclozotan, IV
355085|NCT00004485|Procedure|Bone Marrow Transplantation|
354482|NCT00598533|Device|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
354777|NCT00630188|Other|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
354778|NCT00630201|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
354779|NCT00630214|Dietary Supplement|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
354780|NCT00630214|Dietary Supplement|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
354781|NCT00630227|Biological|Biologic Lung Volume Reduction|20 mL Hydrogel
354782|NCT00630253|Biological|anti-thymocyte globulin|30 mg/kg/day will be administered after MP on days -6, - 5, -4, -3 and -2.
354783|NCT00630253|Drug|cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
354784|NCT00630253|Drug|fludarabine phosphate|35 mg/m^2 intravenously (IV) on days -6 through -2.
354785|NCT00630253|Procedure|hematopoietic stem cell transplantation|Bone marrow or umbilical cord blood infusion on day 0.
354786|NCT00630253|Drug|methylprednisolone|MP 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day +15 at which time it will be tapered 50% every 4 days to be discontinued by day +24 (i.e. MP 1 mg/kg/day on days +16-19, then 0.5 mg/kg/day on days +20-23, then discontinue). MP will be used as a premedication for ATG on day -6 to -2.
354787|NCT00004659|Procedure|radiosurgery|
354788|NCT00630253|Drug|filgrastim|Initiate G-CSF 5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count > or = 2.5 x 10^9/L
354789|NCT00630253|Drug|cyclosporine|cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper
354790|NCT00630253|Drug|Mycophenolate Mofetil|Patients will receive Mycophenolate Mofetil (MMF) therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
354791|NCT00592904|Drug|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
354792|NCT00592917|Dietary Supplement|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
354793|NCT00592930|Drug|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
354156|NCT00606216|Procedure|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
354157|NCT00004242|Drug|oxaliplatin|
354158|NCT00606229|Drug|Aripiprazole|oral, 24mg/day
354159|NCT00606242|Drug|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
354160|NCT00606268|Drug|Micafungin|IV
354161|NCT00606281|Drug|Aripiprazole|oral, 24mg/day
354162|NCT00606281|Drug|placebo|oral, 0mg(4tablets)/day
354163|NCT00606294|Radiation|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
354164|NCT00606294|Device|18F-FMISO PET scan|
354165|NCT00606294|Device|MRI|
354166|NCT00606294|Device|FDG PET/CT scan|
354483|NCT00598546|Behavioral|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
354484|NCT00598559|Drug|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
354485|NCT00004215|Drug|cytarabine|
354486|NCT00598572|Drug|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
354487|NCT00598585|Drug|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) or Placebo for first week. 50 mg tid of either Sildenafil (Viagra)or Placebo for second week. 100 mg tid of either Sildenafil (Viagra)or Placebo for 3rd,4th, 5th and 6th week of study participation.
354488|NCT00598585|Drug|Placebo|Placebo
354489|NCT00598611|Drug|desloratadine|singel dose, oral, 20 mg
354490|NCT00598611|Drug|desloratadine|single dose, oral, 5 mg
353838|NCT00611325|Drug|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
353839|NCT00000162|Procedure|Peripheral Scatter Argon Laser Photocoagulation|
353840|NCT00000622|Drug|Anti-Asthmatic Agents|
353841|NCT00004275|Drug|oxandrolone|
353842|NCT00613405|Other|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
353843|NCT00613418|Device|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
353844|NCT00004323|Drug|cyclophosphamide|
353845|NCT00613431|Drug|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
353846|NCT00613431|Drug|Placebo|Some subjects will receive matching placebo instead of CS-8080.
353847|NCT00613444|Device|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
353848|NCT00613457|Drug|dexamethasone|10 mg/sqm/day from for 21 days
353849|NCT00613457|Drug|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
353850|NCT00613457|Drug|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
353851|NCT00613457|Drug|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
353852|NCT00613457|Drug|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
353853|NCT00613457|Drug|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
353854|NCT00613457|Drug|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
353855|NCT00000623|Drug|Arginine|
353856|NCT00004323|Drug|cyclosporine|
354167|NCT00606307|Drug|ITF2357|50 mg b.i.d. PO every day
354168|NCT00004243|Drug|docetaxel|
354169|NCT00606320|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
353239|NCT00627016|Drug|Placebo|1 capsule, orally, once daily for 4 weeks
353240|NCT00627029|Behavioral|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
353241|NCT00627042|Biological|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
353242|NCT00627055|Drug|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
353549|NCT00618410|Device|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
353550|NCT00618410|Other|Placebo|Nasal placebo
353551|NCT00618423|Drug|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
353552|NCT00618423|Drug|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
353553|NCT00618436|Drug|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
353554|NCT00618436|Drug|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
353555|NCT00618449|Drug|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 & Day 30 for a total of 2 doses.
353556|NCT00620607|Drug|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
353557|NCT00620620|Drug|zaleplon|Staccato Zaleplon
353558|NCT00620620|Drug|placebo|Staccato Placebo
353559|NCT00620633|Biological|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
352954|NCT00595140|Drug|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
352955|NCT00595140|Drug|combination with somatostatin analogue octreotide|s.c., 100µg, one time
352956|NCT00595140|Drug|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
352957|NCT00595153|Drug|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
352958|NCT00595166|Device|Vaginal Speculum Sheath|Patients randomized to the sheathed speculum exam will also have their exam timed by the study coordinator from the moment of randomization to the complete visualization of the cervical os.
Upon randomization to the sheathed speculum group the clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
352959|NCT00597766|Drug|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
352960|NCT00597766|Drug|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
352961|NCT00597766|Drug|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
353243|NCT00627055|Drug|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
353244|NCT00004580|Drug|Lopinavir/Ritonavir|
353245|NCT00627081|Drug|remifentanil|dosage
353246|NCT00627107|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
353247|NCT00627120|Drug|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
353248|NCT00627133|Drug|levetiracetam|2 gram iv load, 500mg bid
353249|NCT00627146|Drug|ChAgly CD3|6 days treatment 8mg/d intravenous
353250|NCT00627146|Drug|Placebo|6 days
353251|NCT00627159|Other|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
352673|NCT00605592|Procedure|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
352674|NCT00004237|Procedure|conventional surgery|
352675|NCT00605605|Drug|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
352676|NCT00605618|Drug|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
352677|NCT00605631|Device|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
352678|NCT00605644|Drug|MOA-728|Oral Capsules
352679|NCT00605644|Drug|Placebo|Placebo
352680|NCT00605657|Drug|Valproic Acid|Oral administration of valproic acid
352681|NCT00605657|Procedure|CT Scan|CT scans were done before and after treating the patient with valproic acid
352682|NCT00605657|Procedure|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
352683|NCT00605670|Behavioral|questionnaires|patients will fill out two questionnaires post surgery
352684|NCT00605670|Behavioral|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
352685|NCT00004237|Radiation|radiation therapy|
352686|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
352687|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
352688|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
352689|NCT00605696|Drug|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) either in the ED or 48 hours after admission to the ICU.
352690|NCT00605709|Drug|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
352962|NCT00597779|Device|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
352086|NCT00617721|Other|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
352087|NCT00617734|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg over one hour every two weeks. A cycle is defined as four weeks of therapy. Patients will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
352088|NCT00619983|Drug|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
352089|NCT00619983|Drug|placebo|Group 4: Will receive placebo pills
352369|NCT00612742|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
352370|NCT00612742|Drug|placebo gel|once daily transdermal placebo gel
352371|NCT00612755|Drug|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
352372|NCT00004315|Drug|ursodiol|
352373|NCT00612768|Biological|TRUE TEST Skin patch test Bioequivalence|Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose
Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone
Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin
Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin
Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours.
352374|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
352375|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
352376|NCT00612794|Drug|exenatide once weekly|subcutaneous injection, once weekly
352377|NCT00612794|Drug|placebo|subcutaneous injection, once weekly
352378|NCT00612807|Behavioral|Weekly marital therapy|Weekly marital therapy for 6 months.
352379|NCT00612807|Drug|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).
SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)
SNRIs (e.g., venlafaxine)
Bupropion SR (achieve dose of at least 150 mg BID)
Mirtazapine
Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)
Lithium augmentation
MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)
352380|NCT00612820|Drug|GSK256066|200mcg bd,
352381|NCT00612820|Drug|fluticasone propionate|200mcg od,100mcg bd
352382|NCT00612833|Procedure|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
351783|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 1 hour at 0.125 mg/kg/hr followed by 22 hours at 0.025 mg/kg/hr
351784|NCT00004495|Drug|folic acid|
351785|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 1 hour at 0.25 mg/kg/hr followed by 22 hours at 0.05 mg/kg/hr
351786|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 1 hour at 0.5 mg/kg/hr followed by 22 hours at 0.1 mg/kg/hr
351787|NCT00624442|Drug|Placebo|I.V. infusion for 2 hours
351788|NCT00624442|Drug|Placebo|I.V. infusion for 24 hours
351789|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0mg/kg/hr followed 1 hour at 0.5mg/kg/hr followed by 70 hours at 0.1mg/kg/hr
351790|NCT00624442|Drug|Placebo|I.V. infusion for 72 hours
351791|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.75 mg/kg/hr followed 1 hour at 0.5mg/kg/hr followed by 70 hours at 0.1 mg/kg/hr
351792|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 23 hours at 0.025 mg/kg/hr
351793|NCT00626340|Drug|estrogen alone|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
351794|NCT00626340|Drug|fluoxetine alone|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
352090|NCT00619983|Drug|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
352091|NCT00619996|Drug|Sorafenib (Nexavar)|Sorafenib 400 mg bid orally continuously
Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease.
352092|NCT00619996|Drug|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
352093|NCT00620009|Behavioral|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
352094|NCT00620022|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
352095|NCT00620022|Drug|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
352096|NCT00004433|Drug|pergolide|
352097|NCT00620035|Drug|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
351463|NCT00631280|Behavioral|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
351464|NCT00631293|Dietary Supplement|lactisole|administration of lactisole followed by placebo
351465|NCT00631293|Other|placebo|administration of placebo followed by lactisole
351466|NCT00631319|Drug|OROS HYDROMORPHONE|QD opioid pain reliever for OA pain-patients.
351467|NCT00631345|Behavioral|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
351468|NCT00631345|Other|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
351469|NCT00004689|Drug|amithiozone|
351470|NCT00631345|Behavioral|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
351471|NCT00594269|Drug|Escitalopram|Discontinuation
351472|NCT00594269|Drug|Citalopram|Discontinuation
351473|NCT00000611|Behavioral|dietary supplements|
351474|NCT00004197|Biological|sargramostim|
351475|NCT00594269|Drug|Sertraline|Discontinuation
351476|NCT00594269|Drug|Paroxetine|Discontinuation
351795|NCT00626340|Drug|estrogen and fluoxetine together|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
351796|NCT00004569|Procedure|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
352457|NCT00620269|Drug|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
352458|NCT00620269|Drug|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 & 8 every 3 weeks X 2 cycles
352459|NCT00620269|Radiation|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
352460|NCT00622349|Drug|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
352461|NCT00622349|Drug|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
352462|NCT00622349|Drug|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
352463|NCT00622362|Biological|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
352464|NCT00622362|Biological|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
352465|NCT00622362|Biological|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
352466|NCT00622375|Drug|mesalamine|encapsulated mesalamine granules
352467|NCT00622388|Drug|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
352468|NCT00004474|Drug|Anti-thymocyte globulin|Given via IV over 4 hours
352469|NCT00622401|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
352751|NCT00613015|Drug|Guanfacine|
352752|NCT00613015|Drug|Modafinil|
352753|NCT00613015|Drug|Placebo|
352754|NCT00613028|Drug|Temo + Avastin|Patients have progressed/had gr3/> toxicity related to etoposide, with no had progression/gr 3/> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
352755|NCT00004317|Drug|Pyrimethamine|See arm descriptions
352756|NCT00613028|Drug|VP-16 + Avastin|Patients have progressed/had gr3/> toxicity related to temozolomide, but have not progressed/gr3/> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
351869|NCT00594516|Drug|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
351870|NCT00594529|Procedure|Surgery|Liver resection for metastatic liver lesions
352174|NCT00626600|Drug|Oxycodone Hydrochloride|
352175|NCT00626613|Drug|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
352176|NCT00626626|Drug|Dose Level I|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
352177|NCT00626626|Drug|Dose Level 2|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
352178|NCT00004576|Drug|LY300164|
352179|NCT00626639|Drug|Placebo|Administered by intravenous (IV) bolus injection
352180|NCT00626639|Drug|palifermin|Administered by intravenous (IV) bolus injection
352181|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
352182|NCT00629044|Biological|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
352183|NCT00629057|Biological|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
352184|NCT00629057|Biological|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
352185|NCT00629057|Biological|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
352186|NCT00629070|Other|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
352187|NCT00629070|Other|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
352188|NCT00629083|Device|Bulkamid|Bulking injection with Bulkamid injection device
351557|NCT00602459|Drug|Lenalidomide|Given PO
351558|NCT00602459|Biological|Rituximab|Given IV
351559|NCT00602472|Drug|linagliptin|active
351560|NCT00602472|Drug|placebo|placebo to linagliptin 5 mg
351561|NCT00602485|Other|Action Control Education|30 minute educational intervnetion
351562|NCT00602498|Drug|Clarithromycin|
351563|NCT00004228|Radiation|radiation therapy|
351871|NCT00594542|Drug|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
351872|NCT00004197|Drug|doxorubicin hydrochloride|
351873|NCT00594555|Drug|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
351874|NCT00594555|Drug|CLAG|Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2
Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2
G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days
351875|NCT00594568|Drug|LY450139|Administered orally once daily
351876|NCT00594568|Drug|Placebo|Administered orally once daily
351877|NCT00594581|Drug|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
351878|NCT00594594|Other|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
351879|NCT00594607|Device|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
351880|NCT00594607|Device|Fx8 (Fresenius)|Polysulphone dialysis membrane
351881|NCT00597363|Device|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH & Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
351882|NCT00597363|Other|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
351883|NCT00597376|Other|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
351259|NCT00000620|Drug|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control <120 mm Hg; standard control <140 mm Hg).
351260|NCT00004252|Drug|semaxanib|
351261|NCT00607802|Genetic|polymerase chain reaction|
351262|NCT00610142|Drug|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
351263|NCT00004262|Radiation|3-dimensional conformal radiation therapy|
351264|NCT00610155|Drug|Placebo|BID
351265|NCT00610155|Drug|Pregabalin|Dose 75 mg titrated to 150 mg, bid
351266|NCT00610155|Drug|Tramadol SR|Dose 50mg titrated to 200 mg, bid
351267|NCT00610168|Biological|Boostrix TM|Single booster dose of vaccine
351268|NCT00610181|Procedure|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
351269|NCT00610194|Drug|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
351270|NCT00610207|Device|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
351271|NCT00610220|Device|Fiberglass short arm cast|Cast will be applied for a 4-week period
351272|NCT00610220|Device|Prefabricated wrist splint|Splint will be applied for a 4-week period
351564|NCT00602511|Drug|Bortezomib|Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles
Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity
351565|NCT00602511|Drug|Thalidomide|Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day
Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity
351566|NCT00602524|Drug|Pilocarpine|
351567|NCT00602537|Drug|Venlafaxine|75 to 375 mg
351568|NCT00602537|Drug|Lithium Carbonate|300 to 2400 mg
351569|NCT00602550|Drug|Zidovudine|
356046|NCT00601978|Drug|Carbidopa/Levodopa/Entacapone|
356047|NCT00004232|Procedure|allogeneic bone marrow transplantation|
356048|NCT00604331|Drug|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
356049|NCT00604344|Drug|insulin detemir|
356050|NCT00604344|Drug|insulin NPH|
356051|NCT00604357|Drug|anti-CD 25 mAb, Sirolimus, MMF|Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)
MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)
Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)
Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter).
356052|NCT00604383|Drug|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
356053|NCT00604383|Drug|placebo|1 tablet, orally, daily, up to 42 months
356054|NCT00604396|Drug|insulin detemir|
356055|NCT00604396|Drug|insulin NPH|
356056|NCT00604409|Radiation|SIRT|Undergo SIRT
356057|NCT00604409|Drug|capecitabine|Given PO
356058|NCT00004232|Procedure|peripheral blood stem cell transplantation|
356059|NCT00604435|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
356060|NCT00604435|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
356061|NCT00604448|Other|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
356062|NCT00604448|Other|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
356063|NCT00604461|Drug|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
356064|NCT00604474|Device|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
355418|NCT00004419|Drug|insulin-like growth factor I|
355419|NCT00618995|Drug|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
355420|NCT00618995|Drug|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
355421|NCT00618995|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
355422|NCT00619008|Other|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
355423|NCT00619008|Other|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
355737|NCT00611871|Drug|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
355738|NCT00004293|Drug|glucocerebrosidase|
355739|NCT00611884|Drug|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
355740|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
355741|NCT00611884|Drug|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
355742|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
355743|NCT00611884|Drug|metformin|Tablets, 1500-2000 mg/day
355744|NCT00611897|Drug|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
355745|NCT00611897|Drug|placebo and ketamine|placebo N-acetylcysteine
355746|NCT00611910|Device|sirolimus-eluting stent|due to randomization Cypher stent will be implanted
355747|NCT00611910|Device|paclitaxel-eluting stent|due to randomization Taxus stent will be implanted
355748|NCT00611910|Device|biodegradable-polymer-based sirolimus-eluting stent|due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted
355749|NCT00000623|Drug|Deferoxamine|
355750|NCT00004294|Genetic|human glucocerebrosidase gene into autologous peripheral blood stem cells|
355751|NCT00611910|Device|bare metal stents|Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
355086|NCT00623363|Drug|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline)
355087|NCT00623376|Drug|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
355088|NCT00623376|Drug|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
355089|NCT00623389|Device|IST-16 (16-channel implanted stimulator-telemeter)|Pre-surgical exercise with surface electrical stimulation, surgery including electrode insertion and IST-16 stimulator/telemeter implantation, exercise and physical therapy with the implanted system, functional training and laboratory assessment of clinical and technical performance.
355090|NCT00623402|Drug|Sorafenib|2x 400 mg orally per day (4 tablets)
355091|NCT00623402|Drug|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
355092|NCT00623415|Drug|Flupirtine|300 mg daily (divided in two doses)
355093|NCT00623415|Drug|Placebo|twice daily
355094|NCT00623428|Drug|peginterferon alfa-2a|
355095|NCT00625417|Procedure|histopathologic examination|
355096|NCT00625417|Procedure|light-scattering spectroscopy|
355097|NCT00625417|Procedure|therapeutic conventional surgery|
355098|NCT00625430|Biological|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.
Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.
If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.
Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6.
355424|NCT00619008|Other|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
355425|NCT00619021|Drug|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m^2, 800 mg/m^2, 1000 mg/m^2, 1200 mg/m^2
355426|NCT00619034|Drug|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
355427|NCT00619034|Drug|Diclofenac|dicolfenac eyedrops twice daily i one eye
355428|NCT00619034|Drug|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
355429|NCT00004420|Drug|gamma-Linolenic acid|
354794|NCT00592930|Drug|placebo|
354795|NCT00592943|Drug|armodafinil|tablet, taken by mouth, once each study day
354796|NCT00004190|Drug|oxaliplatin|
354797|NCT00592969|Drug|metformin|
355099|NCT00625443|Drug|Blinded (placebo)|Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)
Duration - 6 months
355100|NCT00625443|Drug|Open Label (AKR-501 tablets)|Dose 10 mg
Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)
Duration - 6 months
355101|NCT00625443|Drug|Blinded (AKR-501 tablets)|Dose: 2.5, 5, 10, or 20 mg
Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)
Duration - 6 months
355102|NCT00625456|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10^5 pfu/kg to 3 x 10^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
355103|NCT00625469|Drug|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
355104|NCT00625469|Other|No specific intervention|No specific intervention
355105|NCT00004554|Drug|sertraline (Zoloft)|200mg/day
355106|NCT00625469|Other|No specific intervention|No specific intervention
355107|NCT00625482|Biological|OPV|
355108|NCT00625482|Biological|OPV plus BCG|
355109|NCT00625482|Biological|OPV|
355110|NCT00625482|Biological|OPV plus BCG|
355111|NCT00625495|Drug|Esomeprazole|40mg Intravenous infusion over 3 minutes
355112|NCT00625495|Drug|Esomeprazole|40mg Oral
355113|NCT00625521|Drug|ASF 1096 0.5 % cream applied twice daily|
355114|NCT00625521|Drug|Cream vehicle for ASF 1096 cream applied twice daily|
355115|NCT00625534|Procedure|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
355116|NCT00004554|Drug|Placebo|Placebo
354491|NCT00598624|Drug|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
354492|NCT00598637|Device|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
354493|NCT00598637|Device|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
354494|NCT00598650|Drug|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
354495|NCT00598663|Device|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
354496|NCT00004215|Drug|daunorubicin hydrochloride|
354497|NCT00601354|Behavioral|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
354498|NCT00601354|Drug|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
354499|NCT00601367|Drug|flibanserin flexible dose|Initial dosage:
Patients were to take one 50 mg flibanserin tablet in the evening.
Subsequent dosage titrations:
Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.
Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.
Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site.
354798|NCT00592969|Drug|biphasic insulin aspart|
354799|NCT00592995|Drug|Creatine monohydrate|10 to 30 grams daily
354800|NCT00592995|Drug|Placebo|10 to 30 grams daily
354801|NCT00593008|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
354802|NCT00593008|Drug|Gemcitabine|Given intravenously every other week of each 28-day cycle.
354803|NCT00593047|Drug|KB2115|tablet formulation given once daily for 12 weeks
354804|NCT00593060|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
354805|NCT00593060|Drug|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
354170|NCT00606333|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
354171|NCT00606333|Device|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
354172|NCT00606346|Biological|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
354173|NCT00606346|Drug|No Biologics|Treatments will be prescribed according to investigator judgement.
354174|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
354175|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
354176|NCT00606372|Procedure|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
354177|NCT00606385|Procedure|Liver resection|Laparoscopic or Open hepatectomy
354178|NCT00606398|Procedure|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
354179|NCT00004243|Drug|oxaliplatin|
354180|NCT00606411|Drug|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
354181|NCT00608946|Dietary Supplement|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
354182|NCT00608946|Dietary Supplement|placebo|placebo
354183|NCT00608959|Drug|omiganan 1% gel|Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).
In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site.
354184|NCT00608959|Drug|chlorhexidine 2% solution|Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.
Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only.
354185|NCT00608972|Drug|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
353560|NCT00620646|Drug|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
353561|NCT00620646|Drug|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
353562|NCT00620659|Drug|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
353563|NCT00620659|Drug|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
353564|NCT00620659|Drug|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
353857|NCT00613457|Drug|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
353858|NCT00613457|Drug|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
353859|NCT00613457|Drug|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
353860|NCT00613457|Drug|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
353861|NCT00613457|Drug|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
353862|NCT00613457|Drug|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
353863|NCT00613457|Drug|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
353864|NCT00613457|Drug|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
353865|NCT00613470|Drug|citalopram and escitalopram|escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.
citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.
353866|NCT00613496|Drug|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
353867|NCT00004323|Drug|mesna|
353252|NCT00627159|Other|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
353253|NCT00627185|Behavioral|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
353254|NCT00627185|Other|No intervention arm|
353255|NCT00004580|Drug|Nevirapine|
353256|NCT00627198|Drug|PTK787/ZK222584 - Experimental|250mg tablets; 500mg (2 tablets) in the am and 750mg (3 tablets) in the pm.
353257|NCT00629499|Drug|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
353258|NCT00629512|Drug|Esomeprazole|20mg oral daily
353259|NCT00629512|Drug|Esomeprazole|40mg oral daily
353260|NCT00629512|Drug|Placebo|
353261|NCT00629525|Drug|RAD001|RAD001 at a dose of 10 mg PO daily
353262|NCT00629538|Procedure|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
353263|NCT00004647|Drug|mexiletine|
353264|NCT00629551|Drug|saredutant (SR48968)|once daily
353565|NCT00620672|Dietary Supplement|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
353566|NCT00004442|Drug|cholic acid|
353567|NCT00620672|Dietary Supplement|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
353568|NCT00620685|Drug|Placebo|Tablet, once daily for 4 weeks
353569|NCT00620685|Drug|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
353570|NCT00620685|Drug|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
353571|NCT00620711|Device|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
352963|NCT00597792|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
352964|NCT00597805|Behavioral|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
352965|NCT00004210|Other|mutation analysis|
352966|NCT00597818|Drug|Cobiprostone|6 mcg and 12 mcg capsules
352967|NCT00597818|Drug|Placebo|0 mcg capsules
352968|NCT00597844|Other|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
352969|NCT00597844|Other|undergo voice evaluation and fMRI prior|in approximately one month and six months
352970|NCT00597857|Drug|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
352971|NCT00597857|Drug|placebo|receipt of a placebo pill for 16 days
352972|NCT00597870|Device|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
352973|NCT00597896|Drug|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
352974|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
352975|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
352976|NCT00000613|Behavioral|dietary supplements|
352977|NCT00004210|Other|counseling intervention|
352978|NCT00597909|Drug|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
352383|NCT00004316|Drug|capsaicin|
352384|NCT00612846|Procedure|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
352385|NCT00612846|Procedure|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
352386|NCT00612859|Drug|levetiracetam|
352387|NCT00612872|Drug|[123I]CLINDE|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
352388|NCT00612898|Drug|apricitabine|800mg BID apricitabine orally for 48 weeks
352691|NCT00605722|Drug|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
352692|NCT00605722|Drug|erlotinib (Tarceva)|150 mg orally (po) daily.
352693|NCT00605735|Drug|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
352694|NCT00605735|Drug|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
352695|NCT00608231|Drug|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
352696|NCT00004255|Biological|filgrastim|
352697|NCT00608231|Drug|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
352698|NCT00608244|Drug|LCP Tacro|In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.
LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.
Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.
352699|NCT00608244|Drug|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
352700|NCT00608322|Drug|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
352701|NCT00608322|Other|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
352702|NCT00608335|Drug|Micafungin|IV
352703|NCT00608348|Procedure|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
352098|NCT00620048|Biological|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
352099|NCT00620061|Drug|Lubiprostone|24 mcg capsules twice daily (BID) for 9 months
352100|NCT00620074|Drug|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
352101|NCT00620074|Drug|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
352102|NCT00620087|Device|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
352103|NCT00620100|Drug|Docetaxel|
352104|NCT00620113|Drug|odanacatib|Odanacatib 10 mg; 25 mg; 50 mg once weekly for 52 weeks.
352105|NCT00620113|Dietary Supplement|cholecalciferol|cholecalciferol 5600 IU once weekly for 52 weeks.
352106|NCT00620113|Dietary Supplement|calcium carbonate|calcium carbonate 500 mg daily for 52 weeks.
352107|NCT00004436|Drug|leuprolide|
352108|NCT00620113|Drug|Comparator: Placebo (unspecified)|Odanacatib Placebo once weekly for 52 weeks.
352109|NCT00620126|Other|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
352110|NCT00620126|Other|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
352389|NCT00615238|Behavioral|diet-plus-continuous bouts of vigorous aerobic exercise|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
352390|NCT00615238|Behavioral|diet plus shorts bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
352391|NCT00615238|Behavioral|diet plus lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
352392|NCT00615251|Drug|DR-2011|Progesterone vaginal ring for approximately 10 weeks
352393|NCT00615251|Drug|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
352394|NCT00615264|Drug|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
351797|NCT00626353|Other|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
351798|NCT00626353|Other|Standard care|Standard care during hospital stay and in the municipality after discharge
351799|NCT00626366|Radiation|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
351800|NCT00626366|Drug|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
351801|NCT00626366|Drug|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
351802|NCT00626392|Drug|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
351803|NCT00626392|Drug|aspirin (ASA)|325 mg tablets administered once daily
351804|NCT00626392|Drug|aspirin placebo (ASA Pbo)|Tablets administered once daily
351805|NCT00626405|Biological|bevacizumab|Given IV over 30-90 minutes
351806|NCT00626405|Drug|carboplatin|Given IV over 30 minutes
351807|NCT00004572|Procedure|Sustacal challenge|
351808|NCT00626405|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
351809|NCT00626405|Drug|temozolomide|Oral temozolomide on days 1-5
351810|NCT00626418|Drug|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
351811|NCT00626418|Drug|Placebo|Placebo tablets
351812|NCT00626431|Drug|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
351813|NCT00626431|Drug|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
351814|NCT00626444|Drug|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
351815|NCT00626457|Behavioral|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
351816|NCT00626470|Procedure|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
351817|NCT00626483|Biological|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10^7) is being assessed.
352757|NCT00613041|Procedure|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
352758|NCT00613054|Drug|Zactima, Gleevec, Hydroxyurea|Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate & hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs & 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate & that such doses are safe & well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.
Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety & pharmacokinetic parameters as required.
Treatment cycle is defined as daily administration of Zactima + imatinib mesylate & hydroxyurea for 28 days for purpose of scheduling evaluations.
352759|NCT00615420|Dietary Supplement|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
352760|NCT00615433|Drug|Lurasidone|120mg/day
352761|NCT00615433|Drug|Olanzapine|15mg/day
352762|NCT00615433|Drug|Placebo comparator|Placebor Comparator
352763|NCT00615433|Drug|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
352764|NCT00615446|Drug|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
352765|NCT00615459|Drug|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
352766|NCT00615459|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
352767|NCT00615459|Drug|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
353044|NCT00605826|Device|Sham Injection|Sham injection
353045|NCT00605839|Device|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
353046|NCT00605839|Device|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
353047|NCT00605839|Other|Usual Care|This intervention was usual care, without either device.
353048|NCT00605852|Drug|GSK835726|
352189|NCT00629083|Device|Contigen|Transurethral bulking injection
352190|NCT00629096|Procedure|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
352191|NCT00004641|Drug|timolol|
352470|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 30ng/kg
352471|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 100ng/kg
352472|NCT00622414|Biological|ziv-aflibercept|Given IV
352473|NCT00622427|Drug|Ramelteon|8 mg tablets every night for 2 weeks
352474|NCT00622427|Drug|Placebo|placebo tablets for every night for 2 weeks
352475|NCT00622440|Drug|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
352476|NCT00622440|Drug|Placebo|Placebo twice daily for 48 weeks.
352477|NCT00622453|Other|Screening|Electrocardiography Blood Test
352478|NCT00622466|Drug|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
352479|NCT00004474|Drug|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
352480|NCT00622466|Drug|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
352481|NCT00622479|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
352482|NCT00622492|Other|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
352483|NCT00622505|Drug|zoledronic acid|4 mg either 4 or 12 weeks for 96 weeks
352484|NCT00622518|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
352485|NCT00622531|Device|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
352486|NCT00622531|Other|hidden BNP value|no intervention
352487|NCT00624572|Drug|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
352488|NCT00004497|Drug|UT-15|
351884|NCT00597376|Other|Cerefolin NAC placebo|Placebo tablet once a day
351885|NCT00597389|Drug|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
351886|NCT00597402|Drug|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
351887|NCT00597402|Drug|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
351888|NCT00597402|Radiation|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
352192|NCT00629122|Drug|Tacrolimus/Clotrimazole Troche|Study day 1 (9 am): Initiate sublingual tacrolimus and clotrimazole troche x 5 doses.
Study day 3 (9 am): Collection of pharmacokinetic parameters around the 5th sublingual tacrolimus dose.
Study day 3 (9 pm): Start washout period, no drug administration (tacrolimus, clotrimazole).
Study day 5 (9pm): End washout period.
Study day 6 (9am): Initiate oral tacrolimus and clotrimazole troche x 5 doses.
Study day 8 (9 am): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose.
Study day 15: Participants will be contacted by telephone to assess for any adverse effects.
To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
352193|NCT00629122|Drug|Tacrolimus/Nystatin Suspension|Study day 1 (9 am): Initiate sublingual tacrolimus and nystatin suspension x 5 doses.
Study day 3 (9 am): Collection of pharmacokinetic parameters around the 5th sublingual tacrolimus dose.
Study day 3 (9 pm): Start washout period, no drug administration (tacrolimus, nystatin).
Study day 5 (9pm): End washout period.
Study day 6 (9am): Initiate oral tacrolimus and nystatin suspension x 5 doses.
Study day 8 (9 am): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose.
Study day 15: Participants will be contacted by telephone to assess for any adverse effects.
To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
352194|NCT00629135|Drug|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
352195|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
352196|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
352197|NCT00629161|Drug|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
352198|NCT00591630|Drug|Carmustine|300 mg/m^2 by vein.
352199|NCT00591630|Drug|Etoposide|200 mg/m^2 by vein every 12 hours.
351570|NCT00602563|Behavioral|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
351571|NCT00604981|Behavioral|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
351572|NCT00605020|Drug|insulin detemir|
351573|NCT00605020|Drug|insulin aspart|
351574|NCT00605020|Device|biphasic insulin aspart|
351575|NCT00605033|Drug|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
351576|NCT00605033|Drug|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
351577|NCT00605046|Drug|SPECT scan|AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
351578|NCT00605059|Drug|[123I]AV94|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
351579|NCT00605072|Drug|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
351580|NCT00605072|Drug|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
351581|NCT00004236|Drug|pegylated liposomal doxorubicin hydrochloride|
351582|NCT00605072|Drug|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
351583|NCT00605072|Drug|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
351889|NCT00597402|Drug|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
351890|NCT00004209|Drug|cisplatin|
351891|NCT00597415|Drug|celecoxib|celecoxib 200mg
351892|NCT00597415|Drug|placebo|placebo
351273|NCT00610233|Procedure|deep brain stimulation ON|deep brain stimulation in the ON state
351274|NCT00004262|Radiation|stereotactic radiosurgery|
351275|NCT00610233|Procedure|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
351276|NCT00610246|Drug|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
351277|NCT00610259|Behavioral|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
351278|NCT00610259|Other|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
351279|NCT00610272|Radiation|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
351280|NCT00610272|Radiation|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
351281|NCT00610272|Radiation|Radiotherapy|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
351282|NCT00610272|Radiation|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
351283|NCT00612378|Device|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
351284|NCT00612391|Procedure|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
355752|NCT00611923|Drug|Flutamide|Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
355753|NCT00611923|Drug|Placebo|Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
355754|NCT00611936|Drug|Placebo|Placebo
355755|NCT00611936|Drug|Atomoxetine|20mg maximum of d-amphetamine
355756|NCT00611949|Other|Geranium oil|2 applications of topical oil per week for 2 weeks
355757|NCT00611962|Drug|Oxaliplatin, Paclitaxel|Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient
Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL.
356065|NCT00604487|Device|ARD (Atad Ripener Device)|Atad double balloon ripener device
356066|NCT00604487|Device|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
356067|NCT00604487|Device|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
356068|NCT00604500|Drug|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
356069|NCT00000616|Behavioral|alcohol drinking|
356070|NCT00004233|Drug|fluorouracil|
356071|NCT00607035|Drug|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
356072|NCT00607035|Drug|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
356073|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
356074|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
356075|NCT00607061|Procedure|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
355430|NCT00619060|Drug|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
355431|NCT00619060|Drug|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
355432|NCT00619073|Drug|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
355433|NCT00619073|Drug|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
355434|NCT00619073|Drug|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
355435|NCT00619086|Drug|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
355436|NCT00619086|Drug|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
355437|NCT00619099|Drug|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
355438|NCT00619099|Drug|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
355439|NCT00619112|Drug|temozolomide|single arm study
355440|NCT00004421|Device|implanted pulse generator|
355441|NCT00619125|Other|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
355442|NCT00619138|Behavioral|individual cognitive-behavioural therapy|1 session per week for 12 weeks
355443|NCT00619138|Behavioral|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
355444|NCT00619151|Device|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
355445|NCT00621179|Drug|Leuprolide acetate|leuprolide acetate 20 mcg subcutaneously twice daily for two days or 0.5 mg daily for 7 days prior to initiation of controlled ovarian stimulation
355758|NCT00611975|Drug|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
355759|NCT00614055|Drug|metformin|Tablets, 1500-2000 mg/day
355760|NCT00614068|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
355117|NCT00625534|Procedure|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
355118|NCT00625547|Drug|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
355119|NCT00627796|Drug|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were < 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels <1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
355446|NCT00621179|Drug|leuprolide acetate|Leuprolide acetate 20 mcg subcutaneously twice daily or 0.5 mg subcutaneously once daily prior to initiation of gonadotropin stimulation
355447|NCT00621192|Drug|meropenem|Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.
20 mg/kg every 12 hours in infants <32 weeks GA and PNA < 2 weeks 20 mg/kg every 8 hours in infants <32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA < 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks
355448|NCT00621205|Behavioral|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
355449|NCT00621218|Drug|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
355450|NCT00621218|Drug|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
355451|NCT00621231|Dietary Supplement|Placebo|Placebo
355452|NCT00000627|Drug|Fluconazole|
355453|NCT00004448|Drug|prednisone|
355454|NCT00621231|Dietary Supplement|Protein|30 E% from protein
355455|NCT00621244|Drug|LBH589|
355456|NCT00621244|Drug|LBH589|
355457|NCT00621257|Dietary Supplement|ergocalciferol|8000 units/ml
355458|NCT00621257|Dietary Supplement|Cholecalciferol|400 units per drop
355459|NCT00621270|Drug|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
354806|NCT00593073|Behavioral|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
354807|NCT00004192|Biological|filgrastim|
354808|NCT00593073|Behavioral|General Reminder Message|General CRC health education message and reminder to get screened.
354809|NCT00593086|Procedure|Pain management|Pain mamagement for burn care procedures.
354810|NCT00593086|Other|Standard of care/no virtual reality game|no intervention for standard of care
354811|NCT00593099|Drug|Bupropion|BUP [as the intermediate-release (IR) formulation] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg [as BUP SR formulation] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
354812|NCT00593099|Drug|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
354813|NCT00593112|Drug|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
354814|NCT00593112|Other|No intervention|No intervention
354815|NCT00595972|Drug|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
354816|NCT00004202|Drug|carboplatin|
354817|NCT00595985|Drug|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
355120|NCT00627809|Drug|Streptokinase|intracoronary infusion, 250.000 Units
355121|NCT00627809|Procedure|primary percutaneous coronary intervention|balloon catheter, stent
355122|NCT00627835|Drug|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
355123|NCT00627835|Drug|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
355124|NCT00627835|Drug|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
355125|NCT00627835|Drug|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
355126|NCT00627835|Drug|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
354500|NCT00601393|Behavioral|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
354501|NCT00601393|Other|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
354502|NCT00601406|Genetic|gene expression analysis|
354503|NCT00601406|Genetic|gene rearrangement analysis|
354504|NCT00601406|Genetic|polymorphism analysis|
354505|NCT00601406|Other|laboratory biomarker analysis|
354506|NCT00004224|Procedure|conventional surgery|
354507|NCT00601406|Radiation|radiation therapy|
354508|NCT00601419|Drug|Somatropin|Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.
Dosage, Frequency: According to Japanese LPD, "The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day".
Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration.
354509|NCT00601432|Drug|levofloxacin oral solution|
354510|NCT00601445|Behavioral|Amount of sleep and wake|4 groups with different patterns of sleep and wake
354511|NCT00601458|Drug|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
354512|NCT00601458|Drug|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
354513|NCT00601458|Drug|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
354514|NCT00601471|Other|proximal tibiofibular manipulation|proximal tibiofibular manipulation
354515|NCT00603603|Other|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
353868|NCT00615927|Drug|Imatinib Mesylate & Hydroxyurea|Imatinib administered orally on daily. Imatinib is local irritant & must be taken in sitting position; mini of 2hrs should be allowed between last drug intake & going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.
Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 & continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts.
353869|NCT00615940|Drug|WX-671|capsules taken per os once daily until progression or toxicity
353870|NCT00615940|Drug|placebo|capsule taken per os once daily until progression or toxicity
353871|NCT00615953|Drug|Norditropin Growth Hormone|Patients are on Norditropin Growth Hormone
353872|NCT00615966|Drug|Diannexin|single dose, 200 µg/kg IV
353873|NCT00004368|Drug|colchicine|
353874|NCT00615966|Drug|Placebo|Single dose, IV
353875|NCT00615966|Drug|Diannexin|Single dose, 400 µg/kg IV
353876|NCT00615992|Drug|Tiotropium|
354186|NCT00608972|Drug|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
354187|NCT00608972|Drug|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
354188|NCT00608985|Drug|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
354189|NCT00608985|Drug|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
354190|NCT00004256|Radiation|radiation therapy|
354191|NCT00608985|Drug|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
354192|NCT00608985|Drug|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
354193|NCT00609011|Drug|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
354194|NCT00609050|Behavioral|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
353572|NCT00620724|Drug|Placebo|Placebo three times daily
353573|NCT00620724|Drug|Nifedipine|20 mg of slow-release Nifedipine three times daily
353574|NCT00620737|Biological|Autologous Human Fibroblasts (Isolagen TherapyTM)|Collection of skin biopsy.
Administration of 2 study injections
Performance of various study assessments during clinic visits
353575|NCT00620737|Biological|Placebo|Collection of skin biopsy.
Administration of 2 study injections
Performance of various study assessments during clinic visits
353576|NCT00620750|Drug|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
353577|NCT00004442|Drug|ursodiol|
353578|NCT00620763|Other|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
353579|NCT00622843|Biological|pneumococcal conjugate vaccine|Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:
2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension.
353580|NCT00622843|Biological|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
353581|NCT00622856|Behavioral|psychological intervention|Psychological intervention
353582|NCT00622856|Behavioral|Diabetes education|5 sessions with diabetes nurse
353583|NCT00004480|Drug|botulinum toxin type A|
353584|NCT00622869|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
353877|NCT00616005|Drug|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle & every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, & 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
353878|NCT00616018|Drug|acetaminophen|4 g/day for 10 consecutive days
353879|NCT00616031|Drug|carboplatin|
353880|NCT00616031|Drug|nitroglycerin|
353265|NCT00629551|Drug|paroxetine|once daily
353266|NCT00629551|Drug|placebo|once daily
353267|NCT00629564|Drug|Esomeprazole|20mg oral
353268|NCT00629564|Drug|Esomeprazole|15 minute intravenous infusion
353269|NCT00629577|Genetic|microarray analysis|
353270|NCT00629577|Other|flow cytometry|
353271|NCT00629577|Procedure|biopsy|
353272|NCT00629577|Procedure|colposcopy|
353273|NCT00629590|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~12 days
353274|NCT00004650|Drug|conjugated estrogens|
353275|NCT00629603|Genetic|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
353276|NCT00629603|Genetic|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
353277|NCT00629603|Genetic|cytokine polymorphism|fibrosis-relating cytokine polymorphism
353278|NCT00629616|Drug|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
353279|NCT00629616|Drug|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
353280|NCT00629629|Behavioral|Dietary Advice|
353281|NCT00629642|Drug|Solifenacin Succinate|Oral, 10mg
353282|NCT00629642|Drug|Solifenacin Succinate|Oral, 5mg
353283|NCT00629642|Drug|Oxybutynin Hydrochloride|Oral, 15mg
353284|NCT00629642|Drug|Placebo|Oral
353285|NCT00004650|Drug|Medroxyprogesterone|
353286|NCT00629655|Other|motor task, sensory stimulation|motor task: finger tapping, simple type and complex type
sensory stimulation: electric or tactile stimulation
352704|NCT00608348|Procedure|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
352705|NCT00608361|Drug|Dasatinib|Given PO
352706|NCT00608361|Other|Pharmacological Study|Correlative studies
352707|NCT00004255|Drug|cyclophosphamide|
352708|NCT00608374|Drug|chlorambucil|
352709|NCT00608374|Drug|fludarabine phosphate|
352710|NCT00608374|Procedure|quality-of-life assessment|
352711|NCT00608387|Behavioral|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
352712|NCT00608400|Dietary Supplement|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
352979|NCT00600639|Drug|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
352980|NCT00600639|Drug|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
352981|NCT00600665|Behavioral|PAINReportIt|A pain assessment data collection tool
352982|NCT00004221|Biological|Filgrastim|Given SQ
352983|NCT00600665|Behavioral|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
352984|NCT00600665|Behavioral|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
352985|NCT00600678|Dietary Supplement|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
352986|NCT00600691|Drug|Finasteride|one tablet (5mg) of finasteride
352987|NCT00600704|Procedure|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
352988|NCT00600704|Procedure|Free fluid infusion|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
352989|NCT00600730|Procedure|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
352990|NCT00600730|Procedure|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
352395|NCT00615264|Drug|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
352396|NCT00615277|Dietary Supplement|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
352397|NCT00615290|Drug|tipranavir|
352398|NCT00615303|Drug|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
352399|NCT00004361|Drug|calcium gluconate|
352400|NCT00615303|Drug|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
352401|NCT00615316|Drug|Guaraná|Guaraná extract 75mg/day
352402|NCT00615316|Drug|Placebo|Placebo 1tab/d
352403|NCT00615355|Radiation|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
352404|NCT00615355|Device|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
352405|NCT00615368|Drug|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
352406|NCT00615368|Drug|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
352407|NCT00615381|Drug|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
352713|NCT00608426|Behavioral|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
352714|NCT00608439|Drug|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
352715|NCT00608439|Other|Placebo|Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated "dose" from week 12 to 52.
352716|NCT00608452|Other|Symptom Assessment Scale|Memorial Symptom Assessment Scale
History and neurologic examination
352717|NCT00608465|Drug|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
352718|NCT00004255|Drug|fludarabine phosphate|
352111|NCT00622167|Device|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
352112|NCT00622180|Device|Daavlin Spectra UVB Hand/Foot Box|Narrow-band ultraviolet B hand box
352113|NCT00622180|Device|Excilite Focal 308-nm light|Excilite Focal 308-nm light
352114|NCT00622193|Drug|anamorelin HCl|50 mg tablet
352115|NCT00622193|Drug|anamorelin HCl|100 mg tablet
352116|NCT00622193|Drug|placebo|placebo tablet
352117|NCT00622206|Drug|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
352118|NCT00622219|Other|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
352119|NCT00004468|Drug|calcitriol|
352120|NCT00622232|Genetic|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
352121|NCT00622245|Drug|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
352122|NCT00622245|Drug|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
352123|NCT00622245|Drug|Placebo|per oral doses, twice daily as capsules during 13 weeks
352124|NCT00622258|Drug|Everolmus|
352125|NCT00622271|Behavioral|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
352126|NCT00622284|Drug|Placebo identical to BI 1356 5mg|Placebo tablet once daily
352127|NCT00622284|Drug|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
352128|NCT00622284|Drug|BI 1356|5mg, once daily in the morning for 104 weeks
353049|NCT00605865|Drug|Sertraline hydrochloride|J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.
Dosage, Frequency: According to Japanese LPD, "The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms".
Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration.
353050|NCT00605891|Drug|carmoterol (CHF 4226)|carmoterol pMDI 2.0 μg once a day, in the morning
(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)
353051|NCT00605891|Drug|carmoterol (CHF 4226)|carmoterol pMDI 1.0 μg once a day, in the morning
(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))
353052|NCT00605891|Drug|carmoterol (CHF 4226)|carmoterol pMDI 4.0 μg once a day, in the morning
(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)
353053|NCT00608465|Drug|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
353054|NCT00608491|Drug|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
353055|NCT00608491|Device|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
353056|NCT00608517|Biological|anti-thymocyte globulin|Given IV
353057|NCT00608517|Drug|cyclophosphamide|Given IV
353058|NCT00608517|Drug|fludarabine phosphate|Given IV
353059|NCT00608517|Drug|methylprednisolone|Given IV
353060|NCT00608517|Radiation|total-body irradiation|Given daily for 1-4 days
353061|NCT00608530|Behavioral|Cognitive behavioral therapy|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms
353062|NCT00608530|Behavioral|Rogerian psychotherapy|Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach
353063|NCT00004255|Drug|methylprednisolone|
353351|NCT00598078|Drug|Sodium Oxybate|Dose 2
353352|NCT00598078|Other|Placebo|Dose 3
353353|NCT00598091|Drug|gemcitabine|1000mg/m2, Days 1, 8, 15
352489|NCT00624585|Drug|Dasatinib|DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE
Dose Level and Dose of dasatinib:
Starting dose (1-8 weeks)= 100 mg orally (po) daily
+1 (<8 weeks if no PR and well tolerated) = 150 mg po daily
DOSE MODIFICATION OF DASATINIB
Dose Level and Dose of dasatinib:
Starting dose = 100 mg po daily
-1 = 70 mg po daily
-2 = 50 mg po daily
OR
Dose Level and Dose of dasatinib:
Starting dose = 150 mg po daily
-1 = 120 mg po daily
-2 = 90 mg po daily
-3 = 50 mg po daily
352490|NCT00624598|Behavioral|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
352768|NCT00615472|Drug|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
352769|NCT00004363|Drug|chlorpropamide|
352770|NCT00615472|Drug|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
352771|NCT00615472|Drug|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
352772|NCT00615511|Dietary Supplement|placebo pregnenolone|Sugar pill, taken twice a day
352773|NCT00615511|Dietary Supplement|pregnenolone|500mg in tablet form taken orally twice a day
352774|NCT00615524|Drug|exemestane and pazopanib|
352775|NCT00615537|Procedure|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
352776|NCT00615550|Drug|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
352777|NCT00615550|Drug|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
352778|NCT00615563|Behavioral|NO BI Drug administered|
352779|NCT00004403|Drug|dexamethasone|
352780|NCT00617877|Drug|losartan potassium|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
352200|NCT00591630|Drug|Cytarabine|200 mg/m^2 by vein every 12 hours.
352201|NCT00591630|Drug|Melphalan|140 mg/m^2 by vein.
352202|NCT00591630|Drug|Rituximab|Arm 1, Arm 2 = 250 mg/m^2 by vein;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.
352203|NCT00004188|Drug|isotretinoin|Given IV
352204|NCT00591630|Procedure|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
352491|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
352492|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
352493|NCT00624637|Other|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
352494|NCT00624650|Drug|Diuresis (furosemide) part I|Goal: Overall I/O net negative 50ml/hour
Initiation:
Continuous IV furosemide at 3mg/hour or last known protocol specified dose
Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal
Do not exceed 30mg/hour
Furosemide Bolus:
If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows
By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour
Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period
352495|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP<8 or measured PaOP <12mmHg in addition to concurrent urine output of <0.5 ml/kg/hr
352496|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.
Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases > 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map < 60 or who are on vasopressors that also have a measured GEDI less than goal
352497|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|(may use any alone or in combination)
Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.
Vasopressin - 0.04 international units/hour
Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.
Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.
Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.
351893|NCT00597428|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
351894|NCT00597428|Drug|Placebo|0 mcg capsules twice daily (BID)
351895|NCT00597441|Biological|Thymic Transplantation for Recipients of UCB transplant|Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
351896|NCT00597454|Other|Patient Navigation|we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.
We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose.
351897|NCT00597467|Device|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
351898|NCT00597467|Device|Acuvue 2 Soft Contact Lens|Control device
351899|NCT00597480|Drug|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
351900|NCT00597480|Drug|rhGH norditropine simple Xx|the dose to achieve a "treat-to target" value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)
351901|NCT00600210|Drug|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
351902|NCT00004219|Drug|lerisetron|
351903|NCT00600210|Drug|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
352205|NCT00591643|Procedure|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
351285|NCT00612391|Procedure|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
351584|NCT00605072|Drug|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
351585|NCT00605085|Biological|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
351586|NCT00605085|Biological|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
351587|NCT00605098|Drug|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
351588|NCT00605098|Drug|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
351589|NCT00605111|Drug|biphasic insulin aspart|
351590|NCT00605124|Other|Knee muscle exercises|Home exercises three times a week, control every three months
351591|NCT00605137|Drug|insulin detemir|
351592|NCT00004237|Drug|cyclophosphamide|
351593|NCT00605137|Drug|insulin NPH|
351594|NCT00605150|Radiation|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
351595|NCT00607815|Behavioral|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
351596|NCT00607815|Behavioral|Present Centered Therapy|Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called "present centered therapy" to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors
351597|NCT00607828|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
356076|NCT00607074|Drug|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
356077|NCT00607074|Drug|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
356078|NCT00004249|Biological|keyhole limpet hemocyanin|
356079|NCT00607074|Drug|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
356080|NCT00607087|Drug|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
356081|NCT00607087|Drug|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
356082|NCT00607087|Drug|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
356083|NCT00607113|Drug|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
356084|NCT00607113|Drug|RAD001|10 mg By Mouth Daily For 21 Days
351286|NCT00612417|Drug|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
351287|NCT00612430|Drug|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG & 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data & order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
351288|NCT00612443|Behavioral|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
351289|NCT00612443|Behavioral|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
355761|NCT00004338|Drug|zinc acetate|
355762|NCT00614068|Behavioral|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
355763|NCT00614081|Device|Contrast-enhanced dynamic MRI|
355764|NCT00614120|Drug|liraglutide|0.6 mg/day, s.c. (under the skin) injection
355765|NCT00614120|Drug|placebo|Glimepiride placebo, capsules
355766|NCT00614120|Drug|liraglutide|1.2 mg/day, s.c. (under the skin) injection
355767|NCT00614120|Drug|liraglutide|1.8 mg/day, s.c. (under the skin) injection
355768|NCT00614120|Drug|glimepiride|Capsules, 4.0 mg/day
355769|NCT00614120|Drug|metformin|Tablets, 1.5-2.0 g/day
355770|NCT00614120|Drug|placebo|Liraglutide placebo, s.c. (under the skin) injection
355771|NCT00614133|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
355772|NCT00000623|Drug|Sildenafil|
355773|NCT00004339|Drug|tetrathiomolybdate|
355774|NCT00614133|Other|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
355775|NCT00614146|Device|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
355776|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
355777|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
355778|NCT00614159|Drug|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
355779|NCT00614159|Drug|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
356085|NCT00607126|Device|Lokomat|locomotor training using body weight support on a treadmill
356086|NCT00607126|Procedure|resistive training|resistive training using theraband and/or weights
344249|NCT00493896|Drug|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
344250|NCT00493909|Procedure|intrathecal opioids and thoracic paravertebral analgesia|
344251|NCT00493909|Procedure|thoracic epidural analgesia|
344252|NCT00493922|Procedure|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
344253|NCT00493922|Procedure|Microscopy|Microscopy for diagnosis of malaria
344254|NCT00493922|Procedure|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
344255|NCT00493948|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
344256|NCT00493961|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
344257|NCT00493974|Drug|Zileuton|Zyflo tablets, 600 mg, 4 times a day
344258|NCT00493974|Drug|Placebo|Placebo 4 x daily
344259|NCT00003671|Drug|mercaptopurine|
344260|NCT00493987|Drug|Testosterone Enanthate|testosterone ester
344261|NCT00493987|Drug|Dutasteride|5 alpha-reductase inhibitor
344611|NCT00485394|Drug|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
344612|NCT00485407|Drug|Atomoxetine Hydrochloride|
344613|NCT00485420|Other|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
344614|NCT00488423|Procedure|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test & hyperglycemic clamp to assess insulin secretion & sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp & mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting & specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass & gastric banding.
344615|NCT00488436|Drug|Antithymocyte globulin|
344616|NCT00488436|Drug|Cyclosporine|
344617|NCT00488449|Drug|GSK256073A tablets|
343575|NCT00512668|Drug|flutamide|Given PO
343576|NCT00512668|Drug|temsirolimus|Given IV
343577|NCT00512668|Other|laboratory biomarker analysis|Optional correlative studies
343578|NCT00512681|Drug|Irinotecan, Oxaliplatin, TS-1|S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1
Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1
343900|NCT00547742|Procedure|PET/CT Scan|
343901|NCT00003957|Procedure|peripheral blood stem cell transplantation|
343902|NCT00547742|Procedure|phlebotomy|
343903|NCT00547768|Drug|Fexofenadine HCI|
343904|NCT00547781|Procedure|PGD|
343905|NCT00547807|Other|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
343906|NCT00547807|Other|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
343907|NCT00547820|Other|placebo|
343908|NCT00547820|Device|Urinary sensor|
343909|NCT00547846|Drug|PDC-748|
343910|NCT00547872|Procedure|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
343911|NCT00547885|Drug|Dihydrocodeine|Group 1: 2* 60 mg dihydrocodeine long acting + up to four placebo short action
Group 2: 3* 60 mg dihydrocodeine long acting + up to six placebo short action
Group 3: 4* 60 mg dihydrocodeine long acting + up to eight placebo short action
Group 4: 2 placebo for long acting + up to 4*30 mg dihydrocodeine short acting
Group 5: 3 placebo for long acting + up to 6*30 mg dihydrocodeine short acting
Group 6: 3 placebo for long acting + up to 8*30 mg dihydrocodeine short acting
343912|NCT00003958|Biological|dactinomycin|Given IV
343913|NCT00547898|Drug|Crofelemer 125 mg|Crofelemer 125 mg
343914|NCT00547898|Drug|Crofelemer 250 mg|Crofelemer 250 mg
343915|NCT00547898|Drug|Crofelemer 500 mg|Crofelemer 500 mg
343916|NCT00547898|Drug|Placebo|Placebo
343917|NCT00547911|Drug|Droxidopa|
343240|NCT00517933|Drug|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day [TID] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
343241|NCT00517933|Other|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
343242|NCT00517946|Drug|pseudoephedrine hydrochloride|
343243|NCT00517946|Drug|cetirizine hydrochloride|
343244|NCT00003804|Biological|dactinomycin|
343245|NCT00517959|Radiation|Stereotactic Conformal radiotherapy|SCRT
343246|NCT00517959|Radiation|Conventional radiotherapy|
343247|NCT00517972|Drug|Omacor (omega-3-acid ethyl esters)|
343248|NCT00520572|Drug|AZD9056|
343249|NCT00520572|Drug|Etanercept|
343250|NCT00520572|Drug|Placebo|
343251|NCT00520585|Drug|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
343252|NCT00003815|Procedure|autologous bone marrow transplantation|
343253|NCT00520598|Biological|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
343254|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
343255|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
343256|NCT00520598|Biological|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
343579|NCT00512707|Drug|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
343580|NCT00512707|Drug|Testosterone gel 1% (active or placebo)|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
343581|NCT00512707|Drug|Topical testosterone gel 1%|Testosterone Gel: Starting dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinded achieved by combining a total of 3 tubes of active or placebo gel.
342558|NCT00003871|Biological|recombinant vaccinia prostate-specific antigen vaccine|
342559|NCT00531518|Behavioral|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
342911|NCT00526149|Other|pharmacological study|
342912|NCT00526162|Device|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
342913|NCT00526175|Drug|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
342914|NCT00526175|Drug|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
342915|NCT00526175|Drug|Daunorubicin|30 mg/m2, i.v., days 8 and 15
342916|NCT00526175|Drug|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
342917|NCT00526175|Drug|Cyclophosphamide|1000 mg/m2, i.v., day 22.
342918|NCT00526175|Drug|Methotrexate|Age <1 year 1-2 years 2-3 years > 3 years MTX 5 mg 8 mg 10 mg 12 mg
342919|NCT00526175|Drug|Cytosine Arabinoside|Edad <1 year 1-2 years 2-3 years > 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
342920|NCT00003851|Drug|gemcitabine hydrochloride|
342921|NCT00526175|Drug|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
342922|NCT00526175|Drug|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
342923|NCT00526188|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
342924|NCT00526201|Behavioral|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
342925|NCT00526201|Behavioral|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
342926|NCT00528892|Drug|Raltegravir|switching PI to raltegravir
342927|NCT00528892|Drug|boosted PI|continue on boosted-PI
342928|NCT00528905|Drug|AZD3480|oral capsule
342217|NCT00003915|Drug|estramustine phosphate sodium|
342218|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
342219|NCT00539071|Drug|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
342220|NCT00539071|Drug|long acting injectable risperidone|Study dose remains 50 mg for the length of the study.
342221|NCT00539071|Drug|long acting injectable risperidone|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
342222|NCT00539084|Device|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
342223|NCT00539097|Dietary Supplement|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
342224|NCT00539110|Drug|zolipidem|dosed at 2200 and 0200 per feeding tube
342225|NCT00539110|Drug|ramelteon|medication dosed at 2200 and 0200 per feeding tube
342226|NCT00539123|Behavioral|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
342227|NCT00539123|Behavioral|abstinence-contingent take-home buprenorphine (ACB)|Patients achieving heroin abstinence receive take-home doses of buprenorphine
342228|NCT00003915|Drug|leuprolide acetate|
342560|NCT00531518|Behavioral|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
342561|NCT00531544|Drug|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
342562|NCT00531557|Drug|Darunavir ritonavir|
342563|NCT00531583|Drug|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
342564|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
342565|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
341562|NCT00508989|Drug|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
341904|NCT00544557|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
341905|NCT00546936|Drug|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
341906|NCT00546949|Procedure|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
341907|NCT00003955|Drug|vincristine sulfate|
341908|NCT00546949|Procedure|Interspinous Process Decompression (IPD)|Interspinous device
341909|NCT00546975|Dietary Supplement|Resource Support®|
341910|NCT00546975|Dietary Supplement|Resource Protein®|
341911|NCT00546975|Dietary Supplement|Placebo|
341912|NCT00546988|Biological|allogeneic stem cell transplant|
341913|NCT00547001|Drug|Estradiol|1mg during stabilization & then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
341914|NCT00547014|Drug|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
341915|NCT00547014|Drug|52364 3 mg|3 mg capsule single dose administered orally as a single dose
341916|NCT00547014|Drug|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
341917|NCT00547014|Drug|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
341918|NCT00003955|Radiation|radiation therapy|
341919|NCT00547014|Drug|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
341920|NCT00547014|Drug|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
341921|NCT00547014|Drug|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
341922|NCT00547027|Behavioral|print-based physical activity intervention|individually-based, print-based physical activity intervention
341923|NCT00547027|Behavioral|usual care|print-based materials of nutritional information
341924|NCT00547040|Other|no intervention|no intervention
341232|NCT00003799|Drug|leucovorin calcium|Given IV
341233|NCT00517036|Dietary Supplement|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
341234|NCT00517036|Dietary Supplement|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
341235|NCT00517049|Drug|PRO95780|Intravenous repeating dose
341236|NCT00517049|Drug|rituximab|Intravenous repeating dose
341237|NCT00517062|Drug|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
341238|NCT00517062|Drug|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
341239|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
341563|NCT00000555|Drug|hormone replacement therapy|
341564|NCT00003758|Drug|idarubicin|
341565|NCT00508989|Drug|L-NMMA|
341566|NCT00508989|Drug|Acetylcholine|
341567|NCT00511589|Other|chagas disease diagnostic|
341568|NCT00511602|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
341569|NCT00511602|Drug|Technosphere Placebo|Technosphere Inhalation Powder
341570|NCT00511615|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
341571|NCT00511628|Drug|Risperidone|As prescribed
341572|NCT00511641|Behavioral|Questionnaire|Questionnaires lasting up to 30 minutes.
341573|NCT00511654|Drug|Orvepitant|
341574|NCT00511667|Drug|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
341575|NCT00511667|Drug|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
323729|NCT00276341|Drug|EGb 761® (Tanakan®)|
323730|NCT00276354|Drug|PEG 4000 (Forlax ®)|
323731|NCT00276380|Drug|EGb761 (Tanakan) and acetylsalicylic acid|EGb761 (Tanakan) 40mg tablets (2 tablets tid) 240mg/day AND acetylsalicylic acid (1 tablet once daily), 325 mg/day, for 6 months
323732|NCT00276380|Drug|Placebo and acetylsalicylic acid|Placebo 40 mg tablets (2 tablets tid) AND acetylsalicylic acid, 325 mg/day (1 tablet once daily) for 6 months
323733|NCT00276393|Drug|Basal insulin|
323734|NCT00276406|Drug|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
323735|NCT00276406|Drug|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
323736|NCT00276419|Drug|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
323737|NCT00002755|Drug|CMF regimen|
323738|NCT00276419|Drug|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
323739|NCT00276432|Device|iSTAT point of care analyzer|
323740|NCT00276445|Drug|beta-1,3-glucan|
323741|NCT00279695|Procedure|high frequency ultrasound examination|high frequency ultrasound examination of the eye
323742|NCT00279708|Drug|Atorvastatin|Placebo vs. Atorvastatin
323743|NCT00279721|Procedure|IMRT|
323744|NCT00279734|Drug|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
323745|NCT00002761|Biological|recombinant interferon gamma|
323746|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
323747|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
324091|NCT00266123|Drug|Sirolimus|
324092|NCT00266136|Drug|Cytarabine|see protocol
324093|NCT00266136|Drug|Thioguanine|see protocol
328510|NCT00568880|Other|immunologic technique|
328511|NCT00568880|Other|laboratory biomarker analysis|
328512|NCT00568880|Other|mass spectrometry|
328513|NCT00568880|Other|pharmacological study|
328514|NCT00004088|Drug|busulfan|
328515|NCT00568880|Procedure|biopsy|
328516|NCT00568893|Drug|drotrecogin alfa (activated)|
328517|NCT00568945|Drug|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
323395|NCT00286091|Biological|Placebo|Same volume subcutaneous injection
323396|NCT00286104|Device|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
323397|NCT00286104|Device|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
323398|NCT00286117|Drug|Anastrozole|oral
323399|NCT00286117|Drug|Tamoxifen|oral
323400|NCT00286130|Drug|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
323401|NCT00286130|Drug|FOLFOX 6|FOLFOX 6:
Oxaliplatin 100 mg/m² d1 concurrent with
Leucovorin 400 mg/m², followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:
323402|NCT00286130|Drug|FOLFIRI|FOLFIRI:
Irinotecan 180 mg/m² day 1 concurrent with
Leucovorin 400 mg/m² followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
323403|NCT00286143|Drug|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
323404|NCT00002780|Drug|cyclophosphamide|
323405|NCT00286156|Drug|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
323406|NCT00286169|Drug|Amrubicin Hydrochloride|
323407|NCT00289133|Device|total knee arthroplasty|cross-linked polyethylene tibial bearing component
323408|NCT00289172|Biological|Live attenuated human rotavirus vaccine|
323409|NCT00002785|Drug|vincristine sulfate|
328212|NCT00573989|Procedure|quality-of-life assessment|
328213|NCT00573989|Radiation|intensity-modulated radiation therapy|
328214|NCT00574015|Drug|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
328215|NCT00574015|Drug|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
328216|NCT00574041|Drug|Interferon beta-1a|injected, once a week
328217|NCT00574054|Radiation|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
328218|NCT00574067|Drug|Buprenorphine|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
328219|NCT00574067|Drug|Buprenorphine|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center. Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
328220|NCT00000601|Drug|progesterone|
328221|NCT00004104|Biological|recombinant interferon alfa|
328222|NCT00576511|Drug|placebo|Placebo o.d.
328223|NCT00576524|Device|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
328224|NCT00576524|Device|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
328225|NCT00576537|Biological|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
328518|NCT00568958|Behavioral|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
328519|NCT00568958|Drug|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
328520|NCT00568958|Drug|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
328521|NCT00568971|Drug|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
328522|NCT00568984|Drug|repaglinide|
341691|NCT00522678|Drug|GW685698X|
341692|NCT00522691|Procedure|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
341693|NCT00522704|Other|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
341694|NCT00522717|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
341695|NCT00522717|Behavioral|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
341696|NCT00522730|Other|Parenteral nutrition|Duration : 5 days
341697|NCT00522730|Other|Enteral nutrition|Duration : 5 days
341698|NCT00522743|Drug|growth hormone and gonadotropin-releasing hormone agonist|GH & GNRHa treatment
341699|NCT00003827|Drug|cytarabine|
341700|NCT00522743|Drug|growth hormone|GH treatment
341701|NCT00522756|Drug|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
341702|NCT00522756|Drug|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
341703|NCT00525655|Behavioral|Questionnaire|Questionnaires taking 10-15 minutes to complete.
341704|NCT00525668|Drug|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
342034|NCT00514670|Other|Alcohol-based hand sanitizer & quaternary ammonium wipes|
342035|NCT00517283|Drug|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
342036|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
341017|NCT00538603|Drug|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
341018|NCT00538603|Drug|Paclitaxel & Carboplatin|Chemotherapy
341019|NCT00538616|Drug|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
341343|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
341344|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
341345|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
341346|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
341347|NCT00003870|Drug|cyclophosphamide|
341348|NCT00530972|Drug|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg <75 kg, 1200 mg >75 kg)
341349|NCT00530985|Behavioral|Benefits Counseling|Help deciding whether to work
341350|NCT00530985|Behavioral|VA Orientation|Orientation to services available at VA
341351|NCT00530998|Procedure|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
341352|NCT00530998|Procedure|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
341353|NCT00531011|Device|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
341354|NCT00531011|Device|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
341355|NCT00531024|Drug|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
341356|NCT00531024|Drug|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
341357|NCT00531050|Drug|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
341358|NCT00003870|Drug|methotrexate|
341359|NCT00531050|Drug|Placebo|Single dose indacaterol matching placebo via Concept 1 device
341360|NCT00531050|Drug|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
340675|NCT00546377|Procedure|biopsy|
340676|NCT00003954|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
340677|NCT00546390|Device|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
340678|NCT00546403|Drug|Modafinil|Adjunctive treatment with titrated dose of modafinil
340679|NCT00546403|Drug|Placebo|Adjunctive treatment with placebo
340680|NCT00546429|Device|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
340681|NCT00546442|Drug|Metformine|850-2550 mg/daily for 48 weeks
340682|NCT00546442|Other|Placebo of metformine|850-2550 mg/daily for 48 weeks
340683|NCT00546455|Drug|Fenretinide|200 mg/day
340684|NCT00546455|Drug|Placebo|2 capsules/day
340685|NCT00546468|Procedure|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
340686|NCT00546468|Procedure|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
341020|NCT00538616|Drug|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
341021|NCT00538629|Other|no intervention|No intervention
341022|NCT00538642|Drug|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
341023|NCT00538655|Drug|modafinil|400mg vs. 200mg (PO) daily
341024|NCT00538668|Drug|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
341025|NCT00003913|Procedure|umbilical cord blood transplantation|
341026|NCT00538681|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
340331|NCT00508547|Biological|ustekinumab|as prescribed
340332|NCT00508547|Biological|Biological therapies other than infliximab and ustekinumab|as prescribed
340333|NCT00508547|Drug|conventional systemic agents|as prescribed
340334|NCT00508547|Biological|infliximab|as prescribed
340335|NCT00508560|Behavioral|Contingency Management|Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement ("Good job!") or VA canteen vouchers of varying monetary value.
340336|NCT00511043|Drug|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
340337|NCT00003776|Drug|doxorubicin hydrochloride|
340338|NCT00511069|Drug|Bortezomib|
340339|NCT00511082|Drug|OPB-31121|Patients will receive OPB-31121 administered orally, once daily for 4 weeks.
340340|NCT00511095|Biological|1018 immunostimulatory sequence (ISS) immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0 and Week 4
340341|NCT00511108|Drug|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
340342|NCT00511108|Drug|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
340343|NCT00511108|Drug|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
340344|NCT00511108|Drug|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
340345|NCT00511121|Drug|STI571 and PEG INTRON|
340346|NCT00511134|Drug|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
340347|NCT00511134|Drug|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
340348|NCT00003776|Drug|ifosfamide|
340349|NCT00511147|Biological|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day is given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
345264|NCT00467298|Behavioral|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
345265|NCT00467324|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
345266|NCT00467337|Procedure|Medial-Wedge Insole intervention|
345267|NCT00467350|Drug|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
345268|NCT00003567|Drug|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
345269|NCT00470158|Dietary Supplement|Zinc|Children >= 12 months received an average of 5mg zinc/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
345270|NCT00470158|Dietary Supplement|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
345271|NCT00470171|Drug|Ursodesoxycholic acid|
345272|NCT00470184|Drug|capecitabine|Oral
345273|NCT00470184|Drug|oxaliplatin|IV
345274|NCT00470184|Genetic|gene expression analysis|Correlative Study
345275|NCT00470184|Genetic|microarray analysis|Correlative Study
345276|NCT00470184|Genetic|reverse transcriptase-polymerase chain reaction|Correlative Study
345277|NCT00470184|Procedure|adjuvant therapy|Metastatic growth control
345278|NCT00470184|Procedure|biopsy|Examination of tissue type
345279|NCT00003577|Drug|fluorouracil|
345280|NCT00470184|Procedure|conventional surgery|Tissue removal
345281|NCT00470184|Procedure|neoadjuvant therapy|Tumor shrinkage
339999|NCT00516607|Other|pharmacological study|
340000|NCT00519207|Drug|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
344605|NCT00485355|Procedure|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
344606|NCT00485355|Procedure|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
344607|NCT00485368|Drug|Coversyl (perindopril)|
344608|NCT00003640|Drug|cisplatin|
344609|NCT00485394|Drug|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
344610|NCT00485394|Drug|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
344935|NCT00476203|Other|Delayed yoga classes|Delayed yoga classes (after 6 months) offered [wait list control group]
344936|NCT00476216|Drug|Combination of Arixtra with chemotherapy|Single arm, 2 cohort feasibility study:
Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.
Patients in both cohorts 1 & 2 will receive standard chemotherapy alone during cycle 1.
Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.
Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy.
344937|NCT00476229|Drug|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
344938|NCT00476229|Radiation|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
344939|NCT00479388|Drug|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
344940|NCT00479388|Drug|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
344941|NCT00479388|Drug|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
344942|NCT00479401|Drug|Pramipexol Extended Release|
344943|NCT00479401|Drug|Pramipexol Immediate Release|
344944|NCT00479401|Drug|Placebo|
344945|NCT00479414|Drug|Duloxetine hydrochloride|
344946|NCT00479427|Drug|GW842166|
344947|NCT00479440|Drug|SAM-315|
344948|NCT00003613|Other|laboratory biomarker analysis|Correlative studies
344618|NCT00488462|Device|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
344619|NCT00488475|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
344620|NCT00488488|Drug|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
344621|NCT00003650|Radiation|radiation therapy|
344622|NCT00488514|Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
344623|NCT00488527|Drug|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (<6.0 mmol/L), and the active treatment is to be continued for three more months.
344624|NCT00488540|Drug|Paracetamol (Acetaminophen)|
344625|NCT00488553|Behavioral|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
344626|NCT00488566|Drug|GSK drug|GSK drug
344627|NCT00488566|Other|Placebo|Placebo
344628|NCT00488566|Other|Lamictal|Positive control
344629|NCT00488579|Drug|Two policies of iron prophylaxis|Routine: 60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb>9g/dl only folic acid, Hb<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
344956|NCT00479492|Drug|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
344957|NCT00479492|Drug|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
344958|NCT00479492|Drug|placebo|placebo administered QD for 84 days
344959|NCT00003614|Drug|estramustine phosphate sodium|
344960|NCT00479505|Drug|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
344961|NCT00479505|Drug|Placebo|Placebo
344962|NCT00479531|Device|AirCast Sequential Compression Device|
344963|NCT00479557|Biological|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
343918|NCT00547911|Drug|Carbidopa|
343919|NCT00547911|Drug|Entacapone|
343920|NCT00547924|Behavioral|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
343921|NCT00547937|Device|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
343922|NCT00550550|Drug|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to <18 years with asthma symptoms .
344262|NCT00494013|Drug|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
344263|NCT00496652|Radiation|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
344264|NCT00496652|Drug|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
344265|NCT00496665|Drug|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
344266|NCT00496665|Drug|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
344267|NCT00496665|Drug|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
344268|NCT00003685|Procedure|fatigue assessment and management|
344269|NCT00496678|Behavioral|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
344270|NCT00496678|Behavioral|Standard of Care|Cancer patients receive standard of care for their cancer treatment
344271|NCT00496691|Behavioral|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
344272|NCT00496704|Drug|capecitabine|
344273|NCT00496704|Drug|gemcitabine hydrochloride|
344274|NCT00496704|Drug|oxaliplatin|
344275|NCT00496717|Device|Helicoidal fast scann|Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
344276|NCT00496730|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
343582|NCT00512746|Other|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
343583|NCT00003781|Procedure|quality-of-life assessment|
343584|NCT00512746|Other|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
343585|NCT00512746|Procedure|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
343586|NCT00512746|Procedure|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
343587|NCT00512759|Other|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®), transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
343588|NCT00512759|Drug|Early goal-directed therapy|Goal-directed pre- and afterload decrement using Nitroglycerin Streuli®, Nitroderm TTS 10®, Triatec®, Atacand®
343589|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
343590|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
343591|NCT00512798|Drug|PS-341 (VELCADE)|Dose Levels PS-341 (day 1)
Level -1 0.7 mg/m2
Level 1 1.0 mg/m2
Level 2 1.0 mg/m2
Level 3 1.3 mg/m2
Level 4 1.5 mg/m2
343592|NCT00512798|Drug|temozolomide|Temozolomide (day 8)
Level - 1 50 mg/m2
Level 1 50 mg/m2
Level 2 75/mg/m2
Level 3 75 mg/m2
Level 4 75 mg/m2
343593|NCT00512798|Other|immunoenzyme technique|Not noted
343594|NCT00003782|Drug|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
343595|NCT00515112|Drug|AndroGel|Androgel 1%, 10g daily
343596|NCT00515112|Drug|placebo|placebo
343597|NCT00515125|Behavioral|Dietary Advice|Dietary Advice sheet
343923|NCT00550550|Drug|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to <18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
343924|NCT00550550|Drug|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
342929|NCT00528918|Drug|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
342930|NCT00528931|Biological|collagenase clostridium histolyticum|Single dose of AA4500 0.58 mg into the cord
343257|NCT00520598|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
343258|NCT00520598|Biological|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
343259|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
343260|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
343261|NCT00520624|Device|inspiratory muscle strength training|
343262|NCT00520624|Procedure|Surgery|
343263|NCT00003815|Radiation|radiation therapy|
343264|NCT00520637|Drug|EZN-2208|
343265|NCT00520650|Drug|Aripiprazole|
343266|NCT00520663|Drug|14C-SB649868|
343267|NCT00520676|Drug|pemetrexed|500 mg/m^2, IV, q 21 days x 6 cycles maximum
343268|NCT00520676|Drug|docetaxel|75 mg/m^2, IV, q 21 days x 6 cycles maximum
343269|NCT00520676|Drug|carboplatin|AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum
343270|NCT00520689|Device|Silicone Hydrogel Contact Lens|use of lens over 2 days
343271|NCT00520702|Procedure|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
343272|NCT00520702|Procedure|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
343273|NCT00520728|Behavioral|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
342566|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
342567|NCT00531622|Drug|saredutant (SR48968)|oral administration
342568|NCT00531622|Drug|escitalopram|oral administration
342569|NCT00003873|Drug|fluorouracil|Given IV or orally
342570|NCT00531622|Drug|placebo|oral administration
342571|NCT00531635|Drug|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
342572|NCT00531661|Device|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
342573|NCT00534235|Device|Implantation of coflex Interlaminar Technology|
342574|NCT00534248|Biological|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
342575|NCT00534248|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
342576|NCT00003888|Drug|cisplatin|
342577|NCT00534261|Drug|Interferon beta-1a|IM injection
342578|NCT00534274|Other|3'-deoxy-3'-[18F]fluorothymidine|
342579|NCT00534287|Drug|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
342580|NCT00534287|Drug|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
342581|NCT00534300|Drug|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
342582|NCT00534300|Drug|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
342931|NCT00528957|Drug|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants > 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants <= 37 kg. During the extension phase, participants whose weight increases to > 37 kg may be switched from the oral powder to the tenofovir DF tablet.
342932|NCT00528957|Drug|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry.
342933|NCT00528957|Drug|Stavudine|Stavudine as prescribed by the investigator prior to study entry.
341925|NCT00547053|Drug|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
341926|NCT00547066|Biological|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
342229|NCT00539123|Behavioral|Physician Management (PM)|medically focused advice and brief counseling
342230|NCT00539136|Drug|GSK561679 tablet or solution|
342231|NCT00539149|Drug|Amoxycillin|50 mg/kg/day twice daily
342232|NCT00539149|Drug|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
342233|NCT00539162|Behavioral|Questionnaire|Completed during follow up visits.
342234|NCT00539175|Device|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
342235|NCT00539175|Device|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
342236|NCT00539188|Drug|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
342237|NCT00539188|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
342238|NCT00539201|Drug|GSK706769|
342239|NCT00003916|Radiation|radiation therapy|
342240|NCT00541840|Drug|Sorafenib|Phase I:
Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration
Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration
Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .
Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration
Phase II:
Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity.
342241|NCT00003930|Radiation|radiation therapy|
342242|NCT00541853|Drug|Candesartan|Candesartan upto 8mg
342243|NCT00541853|Drug|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
342244|NCT00541853|Drug|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
341576|NCT00003777|Drug|cisplatin|
341577|NCT00511680|Behavioral|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
341578|NCT00511693|Behavioral|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
341579|NCT00511693|Behavioral|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
341580|NCT00511706|Drug|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
341581|NCT00511706|Biological|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
341582|NCT00511706|Other|sham|Sham needle-less injection administered in the study eye at Day 1.
341583|NCT00511719|Drug|Technosphere Insulin|48U
341927|NCT00547092|Drug|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
341928|NCT00547092|Drug|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
341929|NCT00003956|Drug|fluorouracil|
341930|NCT00547105|Drug|erlotinib hydrochloride|
341931|NCT00547105|Radiation|stereotactic body radiation therapy|
341932|NCT00547118|Drug|Rimonabant|Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
341933|NCT00547118|Drug|Placebo|Placebo
341934|NCT00549783|Biological|Botulinum Toxin Type A 900kD|The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.
First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
324094|NCT00266136|Drug|Daunorubicin|see protocol
324095|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
324096|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
324097|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
324098|NCT00269490|Behavioral|Yoga Nidra|
324099|NCT00269503|Procedure|Prone Distraction|
324100|NCT00269503|Procedure|Side-Posture Manipulation|
324101|NCT00269503|Procedure|Side-Posture Manipulation & Prone Distraction|
324102|NCT00002719|Drug|etoposide|
324103|NCT00269503|Procedure|Usual Care (Control Group)|
324104|NCT00269516|Drug|pardoprunox|fixed dose 6 mg
324105|NCT00269516|Drug|Pardoprunox|fixed dose 12 mg
324106|NCT00269516|Drug|Pardoprunox|12-42mg
324107|NCT00269516|Drug|Placebo|Placebo
324108|NCT00269529|Procedure|femoral nerve block|
324109|NCT00269529|Procedure|knee infiltration and injection via catheter|
324110|NCT00269542|Drug|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
324111|NCT00269542|Drug|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
324112|NCT00269555|Drug|Genistein Combined Polysaccharide (GCP)|
324113|NCT00002719|Drug|idarubicin|
324114|NCT00269568|Drug|mifepristone and misoprostol|
324115|NCT00269581|Other|Educational CD-rom|Educational CD-Rom
324116|NCT00269581|Other|Headstrong CD-rom|Headstrong CD-rom
324117|NCT00269594|Drug|Lamictal (lamotrigine)|
323410|NCT00289185|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
323411|NCT00289185|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
323412|NCT00289185|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
323413|NCT00289198|Drug|FF|fluticasone furoate 110 μg nasal spray
323414|NCT00289198|Drug|Placebo|placebo nasal spray
323415|NCT00289211|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
323416|NCT00289211|Drug|Placebo (saline)|
323417|NCT00289224|Biological|bivalent killed whole cell oral cholera vaccine|Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:
V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS
323748|NCT00279734|Drug|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
323749|NCT00279747|Drug|meloxicam 0.25 mg/kg|
323750|NCT00279747|Drug|meloxicam 0.125 mg/kg|
323751|NCT00279747|Drug|naproxen 10 mg/kg|
323752|NCT00279760|Drug|Belatacept|
323753|NCT00279760|Drug|Abatacept|
323754|NCT00279773|Drug|TKI258|
323755|NCT00279786|Procedure|Blood draw|blood drawn
323756|NCT00002761|Drug|busulfan|
323757|NCT00279799|Behavioral|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
323758|NCT00279799|Behavioral|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
323759|NCT00279812|Behavioral|Selenomethionine (supplement) and selenium enriched onions|
323760|NCT00279825|Drug|IPX054|IPX054 200 mg
323761|NCT00279825|Drug|Carbidopa-levodopa immediate-release tablets|IPX054 250 mg
323762|NCT00279825|Drug|CD-LD IR|200 mg
328523|NCT00568984|Drug|metformin|
328524|NCT00568984|Drug|glicazide|
328525|NCT00004088|Drug|cyclophosphamide|
328526|NCT00568997|Drug|Pimecrolimus|Pimecrolimus 1% cream
328527|NCT00569010|Drug|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days
328528|NCT00569010|Drug|Ara-C|Group 1 and 2 at Low-Dose = 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days
Arms 3 and 4 at High-dose = 1 g/m^2 Daily CIV for 4 days (age<65 years) or 3 days (age>=65 years)
328529|NCT00569023|Dietary Supplement|alga Dunaliella bardawil|Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.
Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers
328530|NCT00569036|Drug|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
328531|NCT00569049|Procedure|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
328532|NCT00569062|Drug|GW856553X|GW856553X 7.5mg BID for 6 weeks
328533|NCT00569062|Other|Placebo|Placebo to match GW856553X
328534|NCT00571636|Drug|Fentanyl|The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.
Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is > 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage.
328535|NCT00571636|Drug|5% glucose solution|ev continuous infusion
328536|NCT00571649|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
323418|NCT00289224|Biological|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
323419|NCT00289237|Behavioral|Lifestyle intervention|
323420|NCT00002785|Procedure|allogeneic bone marrow transplantation|
323421|NCT00289250|Drug|Sulfadoxine-pyrimethamine|
323422|NCT00289250|Drug|Sulfadoxine-pyrimethamine plus artesunate|
342037|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
342038|NCT00003800|Other|laboratory biomarker analysis|
342039|NCT00517296|Procedure|Rectal Endoscopic Ultrasound(EUS)|Rectal Endoscopic Ultrasound(EUS) performed at screening and every 12 weeks with additional interventions performed as warranted based on the results of the EUS.
342040|NCT00517296|Procedure|Rectal endoscopic ultrasound (EUS)|Rectal endoscopic ultrasound(EUS) performed at screening and at study completion
342041|NCT00517309|Biological|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
342042|NCT00517309|Biological|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
342043|NCT00517322|Drug|ramipril|ramipril 2.5- 5 mg once daily
342044|NCT00517322|Drug|irbesartan|irbesartan 150-300 mg once daily
342045|NCT00517335|Procedure|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
342046|NCT00517348|Biological|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
342047|NCT00517361|Drug|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
342048|NCT00517361|Drug|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
342049|NCT00003800|Procedure|radionuclide imaging|
342050|NCT00517387|Drug|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
342051|NCT00517400|Device|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
342371|NCT00509249|Other|laboratory biomarker analysis|Correlative studies
342372|NCT00003759|Biological|BCG vaccine|
342373|NCT00509249|Other|pharmacological study|Correlative studies
342374|NCT00509262|Drug|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
341361|NCT00531063|Drug|Everolimus (RAD001)|
341362|NCT00531076|Biological|bevacizumab|Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.
In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles
341363|NCT00533624|Drug|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
341364|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
341705|NCT00525668|Drug|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
341706|NCT00525681|Drug|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
341707|NCT00525681|Drug|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
341708|NCT00525694|Other|Glucose tolerance test|10 ounces glucose tolerance test solution
341709|NCT00525694|Other|glucose tolerance test solution|75 grams glucose load
341710|NCT00003846|Procedure|peripheral blood stem cell transplantation|
341711|NCT00525694|Other|Diet Coke|10 ounces of Diet Coke
341712|NCT00525694|Other|Coke Zero|10 ounces of Coke Zero
341713|NCT00525707|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
341714|NCT00525720|Procedure|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
341715|NCT00525720|Behavioral|Questionnaire|Questionnaires taking 30 total minutes.
341716|NCT00525733|Drug|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
341717|NCT00525733|Drug|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
341718|NCT00525733|Drug|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
341719|NCT00525733|Drug|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
341720|NCT00525733|Drug|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
341721|NCT00003846|Radiation|radiation therapy|
341027|NCT00538681|Drug|pemetrexed|500 mg/m2, IV, q 21 days, six 21 day cycles
341028|NCT00538681|Drug|cisplatin|75 mg/m2, IV, q 21 days, six 21 day cycles
341029|NCT00538681|Drug|placebo|oral, daily
341030|NCT00538694|Drug|daptomycin|
341031|NCT00538707|Behavioral|2-minute Bondet test|2-minute Bondet test
341032|NCT00538720|Drug|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
341033|NCT00538720|Device|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
341034|NCT00538733|Drug|thalomid|Cycles 1-4
• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)
341035|NCT00538733|Drug|lenalidomide|Cycles 1-4
• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)
341036|NCT00003913|Radiation|radiation therapy|
341037|NCT00538733|Drug|clarithromycin|Cycles 1-4
• Clarithromycin (500mg twice daily for each 28 day cycle)
341038|NCT00538733|Drug|dexamethasone|Cycles 1-4
• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)
341039|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
341040|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
341041|NCT00541229|Drug|Comparator: Placebo|sitagliptin 100 mg & 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
341365|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
341366|NCT00533637|Drug|Placebo|Citrate buffer with preservatives
341367|NCT00533650|Drug|MK0429|
341368|NCT00533663|Procedure|Healing Touch|every other week (during their infusion)
341369|NCT00533663|Drug|Standard care|
341370|NCT00533663|Drug|guided relaxation|
341371|NCT00533676|Drug|MK0524A, /Duration of Treatment : 8 Weeks|
340350|NCT00511160|Procedure|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
340351|NCT00511160|Procedure|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
340687|NCT00003955|Biological|dactinomycin|
340688|NCT00546481|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg every 2 weeks
340689|NCT00546481|Drug|Epoetin|As prescribed, iv, 3 times weekly
340690|NCT00546494|Drug|Effexor® (Venlafaxine)|
340691|NCT00546507|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
340692|NCT00546507|Drug|celecoxib|
340693|NCT00546507|Other|placebo|
340694|NCT00546520|Drug|Ciclesonide|
340695|NCT00546533|Drug|Etanercept|
340696|NCT00546546|Drug|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
340697|NCT00546559|Drug|statins (simvastatin, pravastatin)|
340698|NCT00003955|Biological|filgrastim|
340699|NCT00546572|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
340700|NCT00546572|Biological|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
340701|NCT00003963|Biological|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
340702|NCT00549237|Dietary Supplement|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
340703|NCT00549237|Other|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
340704|NCT00549263|Drug|SB797620|
340705|NCT00549289|Drug|cyclosporine A|
340001|NCT00519207|Drug|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
340002|NCT00519220|Other|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
340003|NCT00519233|Drug|AGS-1C4D4|IV
340004|NCT00519246|Drug|Saline|Saline 5 ml administrated intravenously
340005|NCT00519246|Drug|Opioid|Butorphanol tartrate 1 mg i.v.
340006|NCT00519246|Drug|Opioid|Butorphanol Tartrate 2 mg i.v.
340007|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 50 mg i.v.
340008|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 100 mg i.v.
340009|NCT00003811|Procedure|conventional surgery|
340010|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 10 mg i.v.
340011|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 20 mg i.v.
340012|NCT00519259|Drug|Lobeline|
340013|NCT00519272|Behavioral|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
340014|NCT00519285|Drug|Aflibercept|25 mg/ml solution
6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle
340015|NCT00519285|Drug|Placebo (for aflibercept)|Sterile aqueous buffered solution identical to aflibercept
1-hour IV on Day 1 of each 3-Week cycle
340016|NCT00519285|Drug|Docetaxel|Marketed formulation
75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)
340017|NCT00519285|Drug|Prednisone or Prednisolone|Marketed formulation
5 mg twice daily PO from day 1 continuously
340018|NCT00519298|Drug|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
340019|NCT00519298|Other|placebo|placebo
340020|NCT00003812|Biological|filgrastim|
340021|NCT00519298|Drug|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
340022|NCT00519311|Behavioral|Health Intervention Package|CHAP and Ask Diary
340023|NCT00519324|Drug|Everolimus|10 mg/day (2 tablets of 5 mg each)
344949|NCT00479453|Drug|duloxetine hydrochloride|
344950|NCT00479466|Drug|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
344951|NCT00479466|Drug|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
344952|NCT00479466|Drug|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
344953|NCT00479466|Drug|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
344954|NCT00479479|Drug|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
344955|NCT00479492|Drug|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
345282|NCT00470184|Procedure|quality-of-life assessment|Correlative Study
345283|NCT00470184|Radiation|radiation therapy|Undergoing radiation therapy
345284|NCT00470197|Drug|alvocidib|Given IV
345285|NCT00470197|Drug|cytarabine|Given IV
345286|NCT00470197|Drug|mitoxantrone hydrochloride|Given IV
345287|NCT00470197|Other|pharmacological study|Correlative study
345288|NCT00470210|Drug|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
345289|NCT00470210|Drug|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
345290|NCT00000535|Behavioral|diet, reducing|
345291|NCT00003577|Drug|methotrexate|
345292|NCT00470210|Drug|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
345293|NCT00470223|Drug|cisplatin|
345294|NCT00470223|Drug|doxorubicin hydrochloride|
345295|NCT00470223|Drug|etoposide|
345296|NCT00470223|Drug|ifosfamide|
345297|NCT00470223|Drug|methotrexate|
344964|NCT00479557|Biological|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
344965|NCT00479557|Biological|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
344966|NCT00479557|Drug|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
344967|NCT00479570|Drug|PF-00446687|Single 200mg dose
344968|NCT00479570|Drug|Placebo|
344969|NCT00482625|Procedure|conventional surgery|Undergo pancreatectomy
344970|NCT00482625|Other|immunohistochemistry staining method|Correlative studies
344971|NCT00482625|Genetic|protein expression analysis|Correlative studies
344972|NCT00482625|Procedure|biopsy|Correlative studies
344973|NCT00482625|Other|pharmacological study|Correlative studies
344974|NCT00482625|Other|laboratory biomarker analysis|Correlative studies
344975|NCT00482638|Drug|MK0493|
344976|NCT00482651|Radiation|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
344977|NCT00003631|Drug|carboplatin|
344978|NCT00482651|Procedure|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
344979|NCT00482651|Procedure|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
344980|NCT00482651|Procedure|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
345307|NCT00473486|Drug|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
345308|NCT00473499|Device|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
345309|NCT00473512|Drug|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
345310|NCT00473512|Drug|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
345311|NCT00473512|Drug|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
344277|NCT00496730|Drug|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
344278|NCT00496743|Device|Low-dose total skin electron beam therapy (4 Gy)|
344279|NCT00003685|Procedure|nausea and vomiting therapy|
344280|NCT00496756|Drug|sorafenib tosylate|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
344281|NCT00496756|Other|flow cytometry|15 ml of blood drawn for flow cytometry of T4/T8, NK, CD25+, and Fox p3 testing obtained at baseline and on days 28, 56, 84, and 112
344282|NCT00496756|Other|laboratory biomarker analysis|15 ml of plasma and urine for storage and future determination of VEGF concentration will be obtained at baseline.10 ml of plasma and urine for storage and future determination of VEGF concentration will be obtained on days 28, 56, 84 and 112
344630|NCT00488592|Biological|WT1:126-134|Subjects were given 6 doses of PR1:169-177 in "Montanide" adjuvant and 6 doses of WT1:126-134 in "Montanide" adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
344631|NCT00488592|Biological|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
344632|NCT00003652|Drug|cisplatin|
344633|NCT00491322|Drug|Ergocalciferol|Ergocalciferol 50000 international units or matching placebo q week for 12 weeks
344634|NCT00491348|Drug|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
344635|NCT00491374|Drug|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
344636|NCT00491374|Drug|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
344637|NCT00003661|Drug|melphalan|
344638|NCT00491387|Drug|Sustained release metoprolol|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
344639|NCT00491400|Drug|Fenofibrate|140 mg/day for 8 weeks
344640|NCT00491400|Drug|Atorvastatin|20 mg/day for 8 weeks
343925|NCT00000579|Drug|Ketoconazole|
343926|NCT00003972|Procedure|peripheral blood stem cell transplantation|
343927|NCT00550563|Dietary Supplement|cholecalciferol|Oral
343928|NCT00550563|Genetic|polymerase chain reaction|companion study
343929|NCT00550563|Genetic|polymorphism analysis|companion study
343930|NCT00550563|Genetic|protein expression analysis|companion study
343931|NCT00550563|Genetic|reverse transcriptase-polymerase chain reaction|companion study
343932|NCT00550563|Genetic|western blotting|companion study
343933|NCT00550563|Other|high performance liquid chromatography|companion study
343934|NCT00550563|Other|laboratory biomarker analysis|companion study
343935|NCT00550563|Other|pharmacological study|companion study
343936|NCT00550563|Procedure|adjuvant therapy|Additional therapy
343937|NCT00003972|Radiation|radiation therapy|
343938|NCT00550563|Procedure|immunoscintigraphy|additional testing
343939|NCT00550576|Drug|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
343940|NCT00550589|Drug|cidofovir|1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
343941|NCT00550589|Genetic|DNA methylation analysis|formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
343942|NCT00550589|Genetic|gene expression analysis|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
343943|NCT00550589|Genetic|polymerase chain reaction|performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
343944|NCT00550589|Procedure|biopsy|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
344283|NCT00496769|Drug|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
343274|NCT00003816|Biological|anti-thymocyte globulin|Given IV
343275|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
343276|NCT00523185|Drug|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
343277|NCT00523211|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
343278|NCT00523211|Drug|Placebo|One tablet of placebo once daily.
343279|NCT00523224|Procedure|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
343598|NCT00515125|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes.
A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period.
343599|NCT00515138|Drug|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
343600|NCT00515151|Drug|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
343601|NCT00003789|Other|laboratory biomarker analysis|Correlative studies
343602|NCT00515151|Drug|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
343603|NCT00515164|Drug|Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel|20 mL Hydrogel
343604|NCT00515177|Behavioral|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
343605|NCT00515177|Drug|eszopiclone|One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of "as needed" use
343606|NCT00515190|Drug|S-1,oxaliplatin|Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.
Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
343607|NCT00515203|Drug|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
342934|NCT00528970|Drug|MOA-728|
342935|NCT00003861|Other|flow cytometry|
342936|NCT00528970|Other|placebo|
342937|NCT00528983|Drug|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
342938|NCT00528983|Drug|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
342939|NCT00528983|Drug|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
342940|NCT00528996|Drug|BEA 2180 BR|
342941|NCT00528996|Drug|tiotropium|
342942|NCT00529009|Drug|UDCA|
342943|NCT00529022|Drug|Azacitidine|75 mg/m^2 Subcutaneous Injection or by vein Daily for 5 Days.
342944|NCT00529022|Drug|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
342945|NCT00529022|Drug|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
342946|NCT00003862|Drug|cisplatin|
342947|NCT00529035|Drug|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
342948|NCT00529048|Other|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
342949|NCT00529048|Other|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
342950|NCT00531674|Dietary Supplement|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
342951|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
342952|NCT00531674|Dietary Supplement|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
343280|NCT00523224|Biological|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
343281|NCT00523237|Drug|Raltegravir|400 mg Twice daily for 24 weeks
342245|NCT00541866|Drug|voreloxin injection and cytarabine|Stage 1 - Escalating doses of voreloxin on days 1 and 4 in combination with a 5-day continuous IV (in the vein) infusion dose of 400 mg/m2 cytarabine
Stage 2 - Same as stage 1 except voreloxin administered at the maximum tolerated dose established in stage 1
342246|NCT00541879|Behavioral|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
342247|NCT00541879|Other|comparison|
342248|NCT00541892|Other|Medium with no human serum albumine added|See above
342583|NCT00534313|Drug|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
342584|NCT00534313|Drug|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
342585|NCT00534326|Procedure|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
342586|NCT00534326|Procedure|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirator
342587|NCT00000568|Behavioral|smoking cessation|
342588|NCT00003888|Drug|docetaxel|
342589|NCT00534339|Device|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
342590|NCT00534352|Drug|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
342591|NCT00534365|Device|tension-free vaginal tape|Retropubic mid-urethral sling
342592|NCT00534365|Device|TVT-SECUR device|Mid-urethral mini-sling
342593|NCT00534378|Drug|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
342594|NCT00534391|Drug|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
342595|NCT00534391|Drug|Artificial tear|4 times daily
342596|NCT00534404|Drug|Nicotine patches|Participants will wear nicotine patches.
342597|NCT00534404|Behavioral|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
342598|NCT00534404|Behavioral|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
341935|NCT00549783|Biological|Placebo|The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.
First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
341936|NCT00549796|Other|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
341937|NCT00549809|Procedure|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
341938|NCT00549822|Drug|Letrozole|Intermittently
341939|NCT00000108|Behavioral|Exercise|
341940|NCT00000160|Procedure|Xenon Photocoagulation|
341941|NCT00000579|Drug|Methylprednisolone|
341942|NCT00003970|Drug|irinotecan hydrochloride|Given IV
341943|NCT00549835|Procedure|Real Acupuncture|
341944|NCT00549835|Procedure|Sham Acupuncture|Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.
All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility.
341945|NCT00549848|Drug|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
342249|NCT00541892|Other|Conventional medium|See above
342250|NCT00541905|Drug|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
342251|NCT00541918|Drug|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
342252|NCT00003931|Genetic|reverse transcriptase-polymerase chain reaction|
342253|NCT00541918|Drug|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
342254|NCT00541931|Drug|Dietary Supplement: LifePak Nano|Daily use
342255|NCT00541957|Behavioral|behavior therapy|10 sessions over 4 months
324469|NCT00311584|Drug|irinotecan hydrochloride|Given IV
324470|NCT00311584|Drug|temozolomide|Given IV
324471|NCT00311597|Procedure|Radiosurgery|single fractionated radiation therapy
324472|NCT00311610|Drug|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
324473|NCT00311623|Drug|sirolimus|
324474|NCT00311623|Other|immunohistochemistry staining method|
324475|NCT00311623|Procedure|neoadjuvant therapy|
324476|NCT00311636|Drug|cyclophosphamide|
324477|NCT00311636|Drug|docetaxel|
324478|NCT00311636|Drug|doxorubicin hydrochloride|
324479|NCT00002842|Drug|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
324480|NCT00311636|Drug|epirubicin hydrochloride|
324481|NCT00311636|Drug|fluorouracil|
324482|NCT00311636|Drug|methotrexate|
324483|NCT00311636|Drug|paclitaxel|
324484|NCT00311636|Drug|triptorelin|
324485|NCT00311636|Procedure|adjuvant therapy|
324486|NCT00311649|Biological|Inactivated Influenza A Vaccine A/H5N1|
324487|NCT00311662|Drug|Tonabersat|Tablet 40mg daily for 12 weeks
324488|NCT00311662|Drug|Placebo|Tablet once daily for 12 weeks
324489|NCT00263081|Drug|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
324490|NCT00263094|Drug|Rofecoxib|
324491|NCT00002702|Procedure|conventional surgery|
324492|NCT00263107|Procedure|telerounding versus bedside rounding|
323763|NCT00279825|Drug|CD-LD ER|200 mg
323764|NCT00279838|Procedure|Computer Assisted Navigation Knee Replacement|
323765|NCT00279877|Procedure|Kyphoplasty|kyphoplasty
323766|NCT00279890|Drug|Topical SR-01|
323767|NCT00002761|Drug|cyclophosphamide|
323768|NCT00279903|Drug|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
323769|NCT00279903|Drug|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
323770|NCT00279916|Drug|triamcinolone acetonide|2 metered sprays in each nostril daily (55 mcg/spray)
323771|NCT00279916|Drug|placebo nasal spray|aqueous solution lacking triamcinolone, 2 metered sprays in each nostril daily
323772|NCT00282308|Biological|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
324118|NCT00269607|Drug|Implantation of naltrexone implants|
324119|NCT00269620|Drug|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
324120|NCT00269620|Drug|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
324121|NCT00269633|Device|Light Box|
324122|NCT00269646|Behavioral|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
324123|NCT00269672|Biological|13-valent Pneumococcal Conjugate Vaccine|
324124|NCT00002719|Drug|mitoxantrone hydrochloride|
324125|NCT00269685|Drug|vasopressin|
324126|NCT00272987|Drug|trastuzumab|4 mg/kg loading dose and 2 mg/kg weekly IV
324127|NCT00273000|Drug|GLP-2|
324128|NCT00273013|Drug|GW274150|
324129|NCT00273013|Drug|Singulair|
323423|NCT00289263|Drug|Paclitaxel|
323424|NCT00289276|Device|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
323425|NCT00289289|Device|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
323426|NCT00289302|Device|Cardiac resynchronization therapy device|
323427|NCT00289315|Behavioral|Primary weight gain prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
323428|NCT00289315|Behavioral|Primary Prevention|School-based environmental program to promote healthy eating and physical activity.
323429|NCT00289315|Behavioral|Primary and Secondary Prevention|School-based program that combines an environmental weight gain prevention program with a curriculum/internet-based program to promote weight loss in overweight students
323430|NCT00289315|Behavioral|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
323431|NCT00002785|Radiation|low-LET cobalt-60 gamma ray therapy|
323432|NCT00289341|Biological|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
323433|NCT00289341|Biological|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
323434|NCT00292188|Drug|Placebo|placebo
323435|NCT00292201|Drug|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
323436|NCT00292214|Drug|Paracetamol (acetaminophen)|
323437|NCT00002793|Drug|fluorouracil|
323438|NCT00292227|Drug|Rotigotine|Rotigotine patch applied once daily for a 24-hour period.
Rotigotine dose schedule (patch application days):
Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;
323773|NCT00282308|Biological|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
323774|NCT00282308|Biological|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
323775|NCT00282321|Behavioral|High Protein diet|
342375|NCT00509262|Drug|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
342376|NCT00509262|Drug|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
342377|NCT00509262|Drug|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
342378|NCT00511992|Drug|Avastin|Initial Treatment:
Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles, Cisplatin 75mg/m2 IP Day 2 every 21 days x 6 cycles, Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)
Consolidation Treatment:
Avastin 15mg/kg IV every 21 days x 12 cycles
342379|NCT00512005|Device|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
342380|NCT00512018|Device|NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as "Russian current".
342381|NCT00512018|Other|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
342382|NCT00512044|Procedure|Local anesthesia (pudendal block)|local anesthesia as indicated
342383|NCT00512044|Procedure|general anesthesia (spinal and general)|general according to guidelines
342384|NCT00512057|Drug|allopurinol|allopurinol 300mg twice a day
342385|NCT00512057|Drug|placebo|placebo
342386|NCT00512070|Drug|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
342387|NCT00512083|Drug|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
342388|NCT00000556|Drug|amiodarone|
342389|NCT00003779|Biological|Connaught|Compare two strains of BCG
342741|NCT00550186|Other|placebo|
342742|NCT00550186|Drug|Ringers Lactate|
342743|NCT00550186|Drug|HaemoHES 6%|
341722|NCT00525746|Behavioral|Interview|Interview lasting about 50 minutes.
341723|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
341724|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
341725|NCT00525772|Drug|ciclesonide|low dose- 50ug and 200ug
341726|NCT00525772|Drug|ciclesonide|high dose- 100ug and 400ug
342052|NCT00517413|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
342053|NCT00517426|Drug|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
342054|NCT00517439|Drug|Copegus|1000/1200mg po daily for 24 weeks
342055|NCT00517439|Drug|Pegasys|180 micrograms sc weekly for 24 weeks
342056|NCT00520130|Drug|Conditioning Chemotherapy|Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3
342057|NCT00520130|Drug|TMS|Tacrolimus: 0.02 mg/kg , start day 3. Continue IV or PO. Taper will begin at day +63 if no acute GVHD then at day +119 and discontinue at day +180 as tolerated Methotrexate: 5 mg/m2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 63, followed by a taper if GVHD does not develop.
342058|NCT00520130|Drug|FLAG|Fludarabine:25 mg/m2 per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m2 IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy
342059|NCT00520130|Drug|EPOCH-F|Fludarabine:25 mg/m2 per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m2 per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m2/day CIV, days 1-4 Vincristine:0.4 mg/m2 per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m2 IV infusion over 30 minutes on day 5
342060|NCT00520130|Biological|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
342061|NCT00003815|Drug|doxorubicin hydrochloride|
342062|NCT00520143|Biological|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
341372|NCT00003882|Drug|anhydrovinblastine|
341373|NCT00533676|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
341374|NCT00533689|Procedure|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
341375|NCT00533702|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
341376|NCT00533702|Drug|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
341377|NCT00533728|Drug|Soluble beta-glucan (SBG)|
341378|NCT00533741|Drug|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
341379|NCT00533741|Drug|Placebo|Saline for injection.
341380|NCT00533741|Biological|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
341381|NCT00533754|Procedure|drawing blood|
341382|NCT00533780|Procedure|Healing Touch|
341383|NCT00003883|Drug|fluconazole|
341384|NCT00533793|Procedure|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
341385|NCT00533806|Behavioral|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
341386|NCT00533806|Behavioral|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
341727|NCT00525785|Drug|5-Fluorouracil|2.2 Gm/m^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.
Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump.
341728|NCT00528411|Drug|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
341729|NCT00528424|Biological|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
340706|NCT00549302|Drug|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
340707|NCT00549302|Drug|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
340708|NCT00549315|Device|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
340709|NCT00549328|Drug|Pazopanib (GW786034)|Pazopanib monotherapy
341042|NCT00541242|Drug|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
341043|NCT00541242|Drug|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
341044|NCT00541268|Device|ICD|Intracardioverter defibrillators from 2 differnt manufactors
341045|NCT00003929|Drug|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
341046|NCT00541268|Other|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
341047|NCT00541281|Drug|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
341048|NCT00541281|Drug|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
341049|NCT00541281|Drug|prednisone|2x5 mg a day
341050|NCT00541307|Device|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
341051|NCT00541320|Drug|GW813893|
341052|NCT00541333|Drug|Copaxone Injection|
341053|NCT00541346|Drug|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
341054|NCT00541359|Drug|bortezomib|Given IV
341055|NCT00541359|Drug|topotecan hydrochloride|Given IV
340352|NCT00511173|Genetic|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
340353|NCT00511186|Drug|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
340354|NCT00511186|Drug|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
340355|NCT00511199|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg
NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
340356|NCT00511199|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
340357|NCT00511212|Drug|intravenous immunoglobulin|
340358|NCT00511225|Dietary Supplement|cholecalciferol|10,000 IU weekly
340359|NCT00513747|Biological|rituximab|Given IV over 4 hours
340360|NCT00513747|Drug|fludarabine phosphate|Given IV over 30 minutes
340361|NCT00513760|Dietary Supplement|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
340362|NCT00513760|Dietary Supplement|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
340363|NCT00513760|Dietary Supplement|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
340364|NCT00513786|Drug|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
340365|NCT00003784|Drug|cyclophosphamide|
340366|NCT00513786|Drug|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
340367|NCT00513786|Drug|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
340368|NCT00513799|Drug|Mupirocin ointment|Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.
340369|NCT00513799|Genetic|Chlorhexidine showers|Apply Clorhexidine wash to entire body once daily for 5 days.
340370|NCT00513799|Procedure|Bleach baths (dilute)|Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.
340371|NCT00513799|Behavioral|Intensive education on personal hygiene|Repeat hygiene methods for 5 days.
345298|NCT00470223|Drug|zoledronic acid|
345299|NCT00470223|Procedure|conventional surgery|
345300|NCT00473447|Behavioral|Modified Constraint-induced movement therapy|
345301|NCT00473460|Drug|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
345302|NCT00473460|Drug|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
345303|NCT00473473|Drug|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
345304|NCT00473473|Drug|Placebo homeopathic remedy|identical to treatment without active component
345305|NCT00003587|Drug|gemcitabine|IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3
345306|NCT00473486|Drug|pemetrexed, carboplatin, sorafenib|Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19
Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1
340024|NCT00519337|Drug|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
340025|NCT00519337|Drug|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
340026|NCT00519350|Procedure|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
340027|NCT00519363|Drug|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
340028|NCT00519376|Drug|GW642444M|drug
340029|NCT00003819|Biological|Thomsen-Friedenreich antigen|
340030|NCT00521820|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
340031|NCT00521833|Procedure|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
340032|NCT00521846|Device|Explore Modular Radial Head|Patient will receive a modular radial head replacement.
340033|NCT00521859|Drug|Cloretazine|800 mg/m^2 by vein daily
340034|NCT00521859|Drug|Fludarabine|25 mg/m^2 by vein daily x 5 Days
340035|NCT00521872|Procedure|STARR Operation|
345312|NCT00473525|Drug|Placebo|Placebo QD
345313|NCT00473525|Drug|PF-00734200 10 mg QD|10 mg QD
345314|NCT00473525|Drug|PF-00734200 20 mg QD|20 mg QD
345315|NCT00473525|Drug|PF-00734200 5 mg QD|5 mg QD
345316|NCT00003587|Drug|paclitaxel|IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
345317|NCT00473525|Drug|PF-00734200 2 mg QD|2 mg QD
345318|NCT00473538|Behavioral|Structured exercise training|
345319|NCT00473538|Behavioral|Hypocaloric hyperproteic diet|
345320|NCT00473551|Drug|Rituximab|375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8.
345321|NCT00473551|Drug|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
345322|NCT00473551|Drug|Fludarabine|40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
345323|NCT00473551|Drug|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
345324|NCT00473551|Radiation|Radiation Treatment|2Gy Total body radiation day before transplantation
345325|NCT00473551|Procedure|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
345326|NCT00473551|Drug|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
345327|NCT00000537|Behavioral|relaxation|
345328|NCT00476229|Procedure|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
345329|NCT00476229|Drug|Rituximab|375 mg/m^2 by vein on days -13, -6, 1, & 8. Only those patients whose tumors express CD20 will receive Rituximab.
345330|NCT00476242|Drug|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
340046|NCT00521989|Drug|CRx-102 (2.7/90)|CRx-102 dose 1
340047|NCT00521989|Drug|Prednisolone|Prednisolone
340048|NCT00521989|Drug|Placebo|Placebo
340049|NCT00521989|Drug|CRx-102 (2.7/180)|CRx-102 dose 2
344641|NCT00491413|Drug|epoetin|
344642|NCT00491426|Drug|Ampicillin|Drug prescribed per routine medical care.
344643|NCT00491426|Drug|Metronidazole|Drug prescribed per routine medical care.
344644|NCT00491426|Drug|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
344645|NCT00491426|Drug|Acyclovir|Drug prescribed per routine medical care.
344646|NCT00491426|Drug|Amphotericin B|Drug prescribed per routine medical care.
344647|NCT00491426|Drug|Ambisome|Drug prescribed per routine medical care.
344648|NCT00000543|Drug|calcium|
344649|NCT00003661|Drug|methylprednisolone|
344650|NCT00491426|Drug|Anidulafungin|Drug prescribed per routine medical care.
344981|NCT00482664|Drug|CP-866,087|Tablets for oral administration
344982|NCT00482664|Drug|CP-866,087|Tablets for oral administration
344983|NCT00482664|Drug|CP-866,087|Tablets for oral administration
344984|NCT00482664|Drug|Placebo|Tablets for oral administration
344985|NCT00482677|Drug|temozolomide|Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
344986|NCT00482677|Genetic|DNA methylation analysis|A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
344987|NCT00482677|Procedure|quality-of-life assessment|prior to randomization until end of study
344988|NCT00003631|Drug|carmustine|
344989|NCT00482677|Radiation|Radiation|Short course radiotherapy
344990|NCT00482690|Drug|nicotine polacrilex|
344991|NCT00482690|Drug|nicotine transdermal system|
344992|NCT00482690|Drug|nicotine inhaler|
344993|NCT00482703|Drug|Dasatinib|tablets, Oral, 100 mg, once daily
344284|NCT00496769|Drug|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
344285|NCT00499096|Behavioral|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
344286|NCT00499109|Drug|Docetaxel|GD Group: 40 mg/m^2 on days 1 and 8, every 21 days
DCb Group: 75 mg/m^2 on day 1
DV Group: 50 mg/m^2 on days 1 and 15, every 28 days
344287|NCT00499109|Drug|Vinorelbine|DV Group: 35 mg/m^2 on days 1 and 15
344288|NCT00499109|Drug|Carboplatin|GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days
DCb Group: AUC 6 on day 1, every 21 days
Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.
344289|NCT00499109|Drug|Gemcitabine|GCb Group: 1,250 mg/m^2 on days 1 and 8
GD Group: 1,250 mg/m^2 on days 1 and 8
Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.
344290|NCT00499122|Drug|Cyclophosphamide|
344291|NCT00499122|Drug|Docetaxel|
344292|NCT00499122|Drug|Doxorubicin hydrochloride|
344293|NCT00003700|Drug|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I & IV (pts < 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II & V
344294|NCT00499122|Drug|Glutathione disulfide NOV-002|
344295|NCT00499122|Procedure|conventional surgery|
344296|NCT00499135|Other|Computed Tomography|Correlative studies
344297|NCT00499135|Other|Fluorothymidine F-18|Correlative studies
344298|NCT00499135|Other|Laboratory Biomarker Analysis|Correlative studies
344299|NCT00499135|Other|Pharmacological Study|Correlative studies
344300|NCT00499135|Other|Positron Emission Tomography|Correlative studies
344301|NCT00499135|Drug|Sunitinib Malate|Given PO
344302|NCT00499148|Other|herbal extract; root of woody shrub grown in India/Sri-Lanka|
344303|NCT00499161|Behavioral|New model of nursing care|
344304|NCT00003700|Drug|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, & 3: Courses II & V
343608|NCT00515203|Drug|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
343609|NCT00515216|Drug|5-fluorouracil|
343610|NCT00515216|Drug|Oxaliplatin|
343611|NCT00515216|Drug|Leucovorin|
343612|NCT00003790|Genetic|polymerase chain reaction|
343613|NCT00515229|Drug|amitriptyline|Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.
Placebo: 25 mg corn starch
343614|NCT00515242|Behavioral|massage|therapeutic massage
343615|NCT00515242|Behavioral|thermotherapy|heat therapy
343616|NCT00515242|Behavioral|relaxing environment|time in a relaxing environment
343945|NCT00550589|Procedure|histopathologic examination|Evaluated at baseline and 6 weeks after treatment discontinuation
343946|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
343947|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
343948|NCT00509756|Drug|FXR-450|capsule, single oral doses from 10 mg to 450 mg
343949|NCT00003763|Radiation|indium In 111 folic acid|
343950|NCT00509756|Drug|Placebo|capsule similar to active drug
343951|NCT00509769|Drug|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
343952|NCT00509782|Drug|ZIO-101|Starting Dose 78 mg/m^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
343953|NCT00509795|Biological|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
343954|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
343955|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
343282|NCT00523250|Drug|AR-102 0.003% Ophthalmic Solution|
343283|NCT00523250|Drug|AR-102 0.005% Ophthalmic Solution|
343284|NCT00523250|Drug|AR-102 0.01% Ophthalmic Solution|
343285|NCT00523250|Drug|AR-102 0.03% Ophthalmic Solution|
343286|NCT00003831|Procedure|conventional surgery|
343287|NCT00523250|Drug|AR-102 Vehicle Ophthalmic Solution|
343288|NCT00523263|Device|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
343289|NCT00523263|Device|Human umbilical vein femoro-popliteal bypass|
343290|NCT00523289|Drug|Bupivacaine|Dosage: 150mg at once for anesthesia induction
343291|NCT00523289|Drug|Ropivacaine|Single dose of ropivacaine, 150mg
343292|NCT00523302|Device|Neotonus model 2100 xxx|TMS stimulates cortical neurons by creating a time varying magnetic field generated by brief but powerful electrical currents. 59 high intensity current is rapidly turned on and off in the electromagnetic coil through the discharge of capacitors. The end result of TMS is thus electrical stimulation of the brain, and some refer to TMS as electrodeless electrical stimulation. Electrical energy stored in a capacitor discharges and creates about 3,000 Amps. Through Maxwell's equations and Faraday's law, this creates a powerful magnetic field, on the order of 2 Tesla. This rapidly changing magnetic field (~30KT/s) then travels across the scalp and skull and induces an electric field within the brain (~30V/m). This induces current to flow in the brain by creating a transmembrane potential (for a thorough discussion see 60). This localized pulsed magnetic field over the surface of the head depolarizes underlying superficial neurons 61, 62 which then induces electrical currents in the brain.
343293|NCT00523302|Device|Neotonus model 2100 xxx|A specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials.
343294|NCT00523328|Drug|BG9924|dosage administered as per Biogen-idec protocol
343295|NCT00523341|Drug|denosumab|1cc SC injection - 60mg every 6 months
343296|NCT00523354|Drug|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
343297|NCT00003832|Drug|bromodeoxyuridine|Given IV
343298|NCT00523367|Procedure|24 hour pH testing|24 hour pH testing will be used to screen patients
343299|NCT00523380|Drug|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
343300|NCT00526214|Drug|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
342599|NCT00536809|Drug|oxaliplatin|Day one of each cycle
342600|NCT00536809|Drug|capecitabine|given BID days 1-14
342601|NCT00536835|Drug|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
342602|NCT00536848|Dietary Supplement|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
342603|NCT00536848|Dietary Supplement|Placebo|
342604|NCT00536848|Drug|Metronidazole|
342953|NCT00531674|Dietary Supplement|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
342954|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
342955|NCT00531674|Dietary Supplement|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
342956|NCT00531687|Drug|Paclitaxel|Paclitaxel 175 mg/m2 day 1 (3 hour infusion)
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.
342957|NCT00003873|Drug|eniluracil|Given orally
342958|NCT00531687|Drug|Cisplatin|cisplatin 50 mg/m2 day 1 and 2
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.
342959|NCT00531687|Drug|Gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered
342960|NCT00531700|Other|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
342961|NCT00531700|Other|Health messages|community level health messages unrelated to the study originating exposures
342962|NCT00531713|Drug|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
342963|NCT00531726|Device|DBS of Cg25|
342964|NCT00531739|Other|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
342965|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
342256|NCT00541957|Drug|Medication prescribed by PCP|Can include any antidepressant medication
342257|NCT00541970|Biological|Cervarix|Intramuscular injection, different dosing /schedule
342258|NCT00541970|Drug|Placebo|Intramuscular injection, different dosing /schedule
342259|NCT00541983|Drug|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
342260|NCT00541983|Drug|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
342261|NCT00541996|Drug|vabicaserin|
342262|NCT00542009|Drug|CE-326,597 100 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
342263|NCT00003933|Other|laboratory biomarker analysis|
342264|NCT00544570|Biological|filgrastim|
342265|NCT00544570|Drug|carmustine|
342266|NCT00544570|Drug|cyclophosphamide|
342267|NCT00544570|Drug|etoposide|
342268|NCT00544570|Drug|melphalan|
342269|NCT00544570|Procedure|autologous hematopoietic stem cell transplantation|
342270|NCT00544570|Procedure|peripheral blood stem cell transplantation|
342271|NCT00544570|Radiation|radiation therapy|
342272|NCT00544570|Radiation|total-body irradiation|
342273|NCT00003944|Biological|filgrastim|
342605|NCT00536861|Drug|erlotinib|Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity
Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity
342606|NCT00536874|Drug|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
342607|NCT00536874|Drug|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
342608|NCT00003901|Procedure|biopsy|
324493|NCT00263120|Behavioral|Pain Questionnaire|
324494|NCT00263133|Drug|Sertraline|
324495|NCT00263146|Procedure|recruitment maneuver|
324820|NCT00582504|Biological|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
324821|NCT00582517|Device|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
324822|NCT00582517|Procedure|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
324823|NCT00582530|Other|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
324824|NCT00582543|Other|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
324825|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
324826|NCT00582556|Drug|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
324827|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
324828|NCT00582582|Drug|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
324829|NCT00582582|Drug|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
324830|NCT00004150|Procedure|adjuvant therapy|
324831|NCT00582608|Drug|MAB 131-I LABELED 8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled 8H9.
324832|NCT00582634|Drug|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
324833|NCT00582660|Drug|Celecoxib|400 mg twice a day for 7 days prior to surgery
324834|NCT00582660|Drug|Placebo|one tablet of placebo will be given for 7 days prior to surgery
324130|NCT00273026|Drug|salmeterol xinafoate/fluticasone propionate|
324131|NCT00273039|Drug|paroxetine|
324132|NCT00273052|Drug|Carvedilol Phosphate modified release formulation|
324133|NCT00273052|Drug|metoprolol succinate|
324134|NCT00273065|Drug|Neosaxitoxin|
324135|NCT00273091|Device|ICD with CRT therapy|permanently CRT pacing
324136|NCT00002740|Drug|cyclophosphamide|
324137|NCT00273104|Procedure|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
324138|NCT00273104|Behavioral|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
324139|NCT00273117|Procedure|transnasal gastroscopy|
324140|NCT00273130|Procedure|transnasal endoscopy|
324141|NCT00273130|Procedure|transoral thin endoscopy|
324142|NCT00273156|Behavioral|Telephone quitline|
324143|NCT00273182|Device|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
324496|NCT00263159|Procedure|Pharmaceutical care for asthma patients|
324497|NCT00263172|Behavioral|behavior modification for weight loss|
324498|NCT00263185|Dietary Supplement|Vitamin D|
324499|NCT00263185|Dietary Supplement|Calcium carbonate|
324500|NCT00263185|Drug|Vitamin D|
324501|NCT00263185|Other|Placebo|
324502|NCT00002702|Procedure|neoadjuvant therapy|
324503|NCT00263198|Drug|PTK787/ZK222584|
324504|NCT00263198|Drug|Letrozole|
324505|NCT00263211|Drug|Plavix/Aspirin|
324506|NCT00263237|Drug|STA-5326|
323776|NCT00282321|Behavioral|High carbohydrate diet|
323777|NCT00282334|Device|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
323778|NCT00282347|Drug|Rituximab|Rituximab was provided as a sterile solution for injection.
323779|NCT00282347|Drug|Placebo|Placebo was provided as a sterile solution for injection.
323780|NCT00282347|Drug|Mycophenolate mofetil|
323781|NCT00002771|Drug|cytarabine|
323782|NCT00282347|Drug|Methylprednisolone|
323783|NCT00282347|Drug|Diphenhydramine|
323784|NCT00282347|Drug|Acetaminophen|
323785|NCT00282347|Drug|Prednisone|
323786|NCT00282360|Drug|Trimetazidine|
323787|NCT00282373|Device|mild hypothermia|
323788|NCT00282386|Drug|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
323789|NCT00282386|Drug|Placebo/ Duration of Treatment: 156 weeks|
323790|NCT00282399|Drug|Subcutaneous Decitabine|
323791|NCT00282412|Biological|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
323792|NCT00002771|Drug|hydroxyurea|
323793|NCT00282425|Biological|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
323794|NCT00282438|Biological|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
323795|NCT00282438|Biological|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
323796|NCT00282451|Drug|biphasic insulin aspart|
323797|NCT00282451|Drug|insulin aspart|
323798|NCT00282464|Drug|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
342744|NCT00550199|Drug|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
342745|NCT00550212|Drug|neratinib|HKI-272, Single-dose capsule and solution
342746|NCT00550225|Drug|GSK961081|
342747|NCT00550238|Drug|pimavanserin tartrate (ACP-103)|tablets once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
342748|NCT00550251|Device|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
342749|NCT00003972|Drug|cyclophosphamide|
342750|NCT00550251|Device|Placebo wristbands|Elasticated wrist bands without active bead.
342751|NCT00550264|Other|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
342752|NCT00550277|Drug|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
342753|NCT00550290|Drug|Cefazolin (or Clindamycin in patients with allergy to cephalosporins or PCN)|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
342754|NCT00550303|Drug|bazedoxifene/conjugated estrogens combination|
342755|NCT00550329|Drug|Glipizide GITS|
342756|NCT00550342|Drug|rituximab|375 mg/m2 intravenously for 4 doses
342757|NCT00509275|Drug|W0027|capsule
342758|NCT00509275|Drug|Placebo|Placebo
342759|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor|Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.
A minimum of approximately 5 X 10^8 cells will be given up to 3x10^11 anti-MART-1 F5 TCR engineered TIL or PBL.
342760|NCT00509288|Drug|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
342761|NCT00509288|Drug|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
342762|NCT00003759|Drug|valrubicin|
342063|NCT00520156|Device|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
342064|NCT00520169|Drug|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
342065|NCT00520182|Behavioral|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids [MUFA]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
342066|NCT00520182|Behavioral|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
342390|NCT00512096|Drug|Ifosfamide|1200 mg/m^2 By Vein Over 2 Hours on Days 1-3
342391|NCT00512096|Drug|Paclitaxel (Taxol)|175 mg/m^2 By Vein Over 3 Hours on Day 1
342392|NCT00512096|Drug|Cisplatin|25 mg/m^2 By Vein Over 2 Hours on Days 1-3
342393|NCT00512122|Other|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
342394|NCT00512122|Drug|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
342395|NCT00512135|Drug|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
342396|NCT00512148|Device|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
342397|NCT00512174|Other|BladderScan BVI 3000|
342398|NCT00512187|Other|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
342399|NCT00514683|Drug|low dose BIBF1120 once daily|low dose BIBF1120 once daily
342400|NCT00514683|Drug|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
341730|NCT00528437|Drug|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
341731|NCT00528450|Drug|arsenic trioxide|
341732|NCT00528450|Drug|idarubicin|
341733|NCT00528450|Drug|tretinoin|
341734|NCT00528463|Procedure|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
341735|NCT00528489|Biological|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
341736|NCT00003859|Radiation|radiation therapy|
341737|NCT00528489|Biological|IL-12|Cytokine injection
341738|NCT00528489|Biological|IL-15|Cytokine injection
341739|NCT00528502|Drug|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
341740|NCT00528502|Drug|Saline|Saline is misted into the air that you breathe during the surgery.
341741|NCT00528515|Drug|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
341742|NCT00528515|Drug|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
341743|NCT00528528|Drug|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
341744|NCT00528528|Drug|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
341745|NCT00528528|Drug|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
341746|NCT00528528|Drug|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
341747|NCT00003860|Biological|filgrastim|
341748|NCT00528528|Drug|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
342067|NCT00520182|Behavioral|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
341056|NCT00003929|Radiation|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
341057|NCT00541359|Other|immunohistochemistry staining method|Correlative studies
341058|NCT00541359|Other|pharmacological study|Correlative studies
341059|NCT00541372|Device|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
341060|NCT00541385|Drug|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
341061|NCT00541385|Drug|arthemeter lumefantrine|Artemether 20 mg and lumefantrine 120 mg fixed dose combination, 6 dose regimen 120 mg artemether and 720 mg lumefantrine total (Novartis).
The posology is twice daily for 3 consecutive days 1 tablet for patients weighing ≥5 kg to <15 kg, 2 tablets for patients weighing ≥15 to <25 kg.
341387|NCT00533819|Other|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
341388|NCT00533832|Device|vagus nerve stimulation (VNS)|intermittent vagus nerve stimulation
Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.
341389|NCT00536289|Device|Blunt needle|Blunt tipped suture needle
341390|NCT00003899|Drug|melphalan|
341391|NCT00536302|Dietary Supplement|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
341392|NCT00536302|Dietary Supplement|Placebo|Matching placebo solution per day by mouth for 48 weeks.
341393|NCT00536341|Drug|lenalidomide, fludarabine, rituximab|Phase I Non-stratified, dose-escalation: >=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed.
Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation.
341394|NCT00536354|Other|Postural Orientation|
341395|NCT00536367|Other|No intervention - observational study only|
341396|NCT00536380|Drug|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
341397|NCT00536380|Drug|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
341398|NCT00536380|Drug|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
340372|NCT00513825|Drug|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
340710|NCT00549341|Drug|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
340711|NCT00549341|Other|Physiologic saline|Single injection.
340712|NCT00003963|Drug|vinorelbine ditartrate|Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.
Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated.
340713|NCT00549354|Device|Endoluminal Graft|
340714|NCT00549367|Behavioral|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
340715|NCT00549380|Device|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
340716|NCT00549393|Drug|2% Chlorhexidine gluconate cloth|Daily bathing
340717|NCT00549406|Procedure|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
340718|NCT00549406|Procedure|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
340719|NCT00549406|Procedure|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
340720|NCT00549419|Drug|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
340721|NCT00549419|Drug|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
340722|NCT00549419|Drug|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
340723|NCT00508560|Behavioral|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
340724|NCT00508573|Behavioral|Questionnaire|Follow-up questionnaire done once a year for five years.
340725|NCT00508586|Drug|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
340036|NCT00521885|Drug|fondaparinux|fondaparinux 2.5mg qd, enoxaparin 40mg qd
340037|NCT00521898|Procedure|Descemet Membrane Endothelial Keratoplasty (DMEK)|
340038|NCT00521911|Behavioral|Cognitive Behavioural Therapy|
340039|NCT00521924|Biological|infliximab|infliximab 3 mg/kg and basic treatment
340040|NCT00003819|Biological|keyhole limpet hemocyanin|
340041|NCT00521924|Drug|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
340042|NCT00521937|Other|Dermagen®|Weekly topical applications
340043|NCT00521950|Genetic|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT*2, *3A, *3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.
Patients are advised an initial treatment dose based on the enzyme activity:
Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;
Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;
340044|NCT00521950|Drug|azathioprine (AZA) or 6-mercaptopurine (6-MP)|Patients will be advised a standard initial treatment dose:
AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
340045|NCT00521963|Biological|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
340373|NCT00513851|Drug|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
340374|NCT00513851|Drug|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
340375|NCT00513864|Drug|Dextromethorphan|one time dose - 0.3mg/kg PO
340376|NCT00003784|Drug|doxorubicin hydrochloride|
340377|NCT00513864|Drug|Codeine|one time dose - 2mg/kg PO
340378|NCT00513864|Drug|Morphine|one time dose - 0.15mg/kg IV
340379|NCT00513877|Drug|bortezomib|
340380|NCT00513877|Procedure|quality-of-life assessment|
340381|NCT00513890|Device|Infantflow [EME, Brighton, England]|
340382|NCT00513903|Behavioral|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
340050|NCT00521989|Drug|CRx-102 (2.7/360)|CRx-102 dose 3
340051|NCT00003820|Drug|Rituximab|An initial course of rituximab at 375 mg/m2 weekly for 4 consecutive weeks. Patients who have an objective response or stable disease to the initial course will receive additional courses of rituximab treatment every six months for 4 courses.
340052|NCT00522015|Drug|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
340053|NCT00522041|Drug|nitroglycerin 0.4%|ointment
340054|NCT00522041|Drug|Placebo|ointment
340055|NCT00522054|Other|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
340056|NCT00524810|Drug|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
340057|NCT00524836|Drug|levocetirizine dihydrochloride|
340058|NCT00524849|Biological|Zoledronic acid|Zometa 1 mg weekly (intravenous)
340059|NCT00524849|Drug|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
340060|NCT00524862|Drug|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
340061|NCT00524862|Device|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
340062|NCT00524875|Drug|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
340063|NCT00524888|Procedure|suturing laceration|suturing simple lacerations of the hand
340064|NCT00524888|Procedure|bioadhesive|using bioadhesive on simple lacerations of the hand
340065|NCT00524901|Drug|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
340066|NCT00003843|Drug|irinotecan hydrochloride|
340067|NCT00524901|Drug|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
340068|NCT00524914|Drug|apomorphine|Acute apomorphine subcutaneous 3 mg
340069|NCT00524914|Drug|placebo|placebo subcutaneous
344994|NCT00482703|Drug|dasatinib|tablets, Oral, 50 mg, twice daily
344995|NCT00482716|Biological|epoetin alfa|
344996|NCT00482716|Biological|epoetin beta|
344997|NCT00482716|Dietary Supplement|iron dextran complex|
344998|NCT00482716|Dietary Supplement|iron sucrose injection|
344999|NCT00485433|Drug|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
345000|NCT00485433|Drug|SKY0402|SKY0402 given during hernia repair
345001|NCT00485446|Procedure|blood analysis|
345002|NCT00485459|Drug|Atomoxetine Hydrochloride|
345003|NCT00485459|Drug|Placebo|
345004|NCT00003640|Drug|doxorubicin hydrochloride|
345005|NCT00485472|Drug|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
345006|NCT00485472|Other|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
345331|NCT00003597|Biological|G-CSF|
345332|NCT00476242|Drug|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
345333|NCT00476255|Behavioral|Enhanced Standard Care (ESC)|Reading material
345334|NCT00476255|Behavioral|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
345335|NCT00476268|Drug|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
345336|NCT00476268|Drug|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
345337|NCT00476268|Drug|Formoterol powder 12 µg/unit dose|2 inhalations bid
345338|NCT00476281|Procedure|Urinary collect|
345339|NCT00476281|Procedure|Continuous Glucose Monitoring System (CGMS)|
345340|NCT00476294|Other|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
344305|NCT00499174|Procedure|conventional surgery|Radical prostatectomy
344651|NCT00491426|Drug|Caspofungin|Drug prescribed per routine medical care.
344652|NCT00491465|Behavioral|Intensive Physical activity|
344653|NCT00491465|Behavioral|Control- regular physical activity|
344654|NCT00491478|Drug|sertraline|
344655|NCT00491491|Drug|ibritumomab tiuxetan|0.4 mCi/kg
344656|NCT00491491|Procedure|BEAM chemotherapy and autologous stem-cell transplantation|
344657|NCT00491504|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
344658|NCT00491504|Other|Placebo|Placebo: 2 sprays in each nostril
344659|NCT00491517|Drug|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
344660|NCT00003661|Procedure|umbilical cord blood transplantation|
344661|NCT00491517|Drug|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
344662|NCT00494013|Drug|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
344663|NCT00494026|Drug|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
344664|NCT00494026|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
344665|NCT00494026|Procedure|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
344666|NCT00494039|Procedure|Radioactive seed implant to prostate|
344667|NCT00494052|Behavioral|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
344668|NCT00494052|Behavioral|Physician Education Session|A physician education session will be included in the program.
344669|NCT00003671|Drug|methotrexate|
344670|NCT00494065|Other|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
343956|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
343957|NCT00509808|Device|Electrostimulation|1st month GN wearing (activated or sham mode)
2nd month wearing (opposite mode)
3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes
6th - 8th month: activated GN wearing for 1, 5 or 10 minutes
9th - 11th month: activated GN wearing for 1, 5 or 10 minutes
343958|NCT00509821|Drug|enzastaurin|Safety Run in Regimen 1: 1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression
Regimen 2: 1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression
343959|NCT00509821|Radiation|radiation|Involved-field radiotherapy will be administered D1 after 7 day lead in enzastaurin treatment at a dose of 54 to 60 Gy, given in individual doses of 1.8 to 2 Gy 5 days a week for 6 weeks
343960|NCT00003764|Drug|cyclophosphamide|
343961|NCT00509834|Drug|hLF1-11|The study treatment consists of IV administration of:
(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10
343962|NCT00509834|Drug|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
343963|NCT00509834|Drug|Placebo|Placebo
344306|NCT00499174|Radiation|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
344307|NCT00499174|Radiation|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
344308|NCT00499174|Procedure|Biopsies|Periodic repeat biopsies
344309|NCT00499187|Procedure|Blood Draws|A single whole blood sample was collected for genomic analysis.
344310|NCT00499200|Drug|SRA-444|
344311|NCT00499213|Procedure|Home Care Assisted Peritoneal Dialysis|
344312|NCT00501852|Drug|Tiotropium|Handihaler inhaler
344313|NCT00501865|Drug|GW273225|
344314|NCT00501878|Drug|2.5% or 10% phenylephrine|
344315|NCT00501891|Drug|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
344316|NCT00501891|Drug|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
344317|NCT00501904|Drug|Metformin|
343617|NCT00515255|Drug|Minocycline|Capsules
343618|NCT00517985|Drug|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
343619|NCT00517998|Drug|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
343620|NCT00518011|Drug|Gemcitabine|As prescribed
343621|NCT00518011|Drug|erlotinib [Tarceva]|150mg po daily
343622|NCT00518024|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
343623|NCT00518037|Behavioral|surveys|anxiety surveys
343624|NCT00518050|Behavioral|Focus group|Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:
Screening, skin self-examination, sun protection, and other cancer preventive practices;
Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,
Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment
343625|NCT00000556|Drug|adrenergic beta antagonists|
343626|NCT00003804|Drug|vincristine sulfate|
343627|NCT00518050|Behavioral|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
343628|NCT00518089|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
343629|NCT00518089|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
343630|NCT00518102|Drug|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
343631|NCT00518102|Other|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
343632|NCT00518115|Drug|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
343633|NCT00518128|Procedure|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
342966|NCT00531752|Drug|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
342967|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
342968|NCT00003874|Biological|monoclonal antibody CD19|
342969|NCT00531765|Other|sodium bicarbonate infusion|short infusion of sodium bicarbonate
342970|NCT00531791|Drug|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
342971|NCT00003888|Drug|fluorouracil|
343301|NCT00526227|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator will be implanted
343302|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
343303|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
343304|NCT00526253|Procedure|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
343305|NCT00003851|Procedure|Gonzalez regimen|
343306|NCT00526266|Behavioral|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
343307|NCT00526266|Behavioral|Diaphragmatic Breathing (DB)|Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the "Setup Statements" and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping.
343308|NCT00526292|Biological|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
343309|NCT00526292|Drug|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
343310|NCT00526292|Drug|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
343311|NCT00526305|Drug|Vincristine|1,5 mg/m2 i.v., days 1 and 8
343312|NCT00526305|Drug|Daunorubicin|60 mg/m2, i.v., days 1 and 8
342609|NCT00536874|Genetic|protein expression analysis|
342610|NCT00536874|Genetic|proteomic profiling|
342611|NCT00536874|Other|diagnostic laboratory biomarker analysis|
342612|NCT00536874|Procedure|adjuvant therapy|
342613|NCT00536874|Procedure|neoadjuvant therapy|
342614|NCT00536874|Procedure|therapeutic conventional surgery|
342615|NCT00536887|Drug|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
342616|NCT00536900|Behavioral|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
342617|NCT00536900|Behavioral|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
342618|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25ug + spacer|
342619|NCT00003901|Procedure|surgery|
342620|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25 ug|
342621|NCT00536926|Device|Home spirometry with data transfer via cell phone|home spirometry recording
342622|NCT00536926|Device|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
342623|NCT00536926|Device|Home spirometer w/o BT|Standard home spirometry
342624|NCT00536939|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, until progressive disease
342625|NCT00536939|Drug|bevacizumab|10 mg/kg, IV, Day 1 and 15 every 28 days, until disease progression
342626|NCT00536939|Drug|paclitaxel|90 mg/m2, IV, Days 1 ,8, and 15 every 28 days until disease progression
342627|NCT00539227|Procedure|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
325787|NCT00565292|Drug|MK0859|
325788|NCT00565305|Behavioral|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
324835|NCT00582673|Drug|AFQ056|
324836|NCT00582673|Drug|Placebo|
324837|NCT00582686|Procedure|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
324838|NCT00582686|Procedure|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
325132|NCT00575250|Behavioral|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
325133|NCT00575250|Behavioral|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
325134|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
325135|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
325136|NCT00575328|Drug|Maca Root|3g/day of Maca Root for 12 weeks
325137|NCT00577720|Drug|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
325138|NCT00577720|Drug|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
325139|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
325140|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
325141|NCT00577759|Other|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
325142|NCT00577759|Other|Passive Intervention|Provision of tools to help with referrals to community resources
325143|NCT00577759|Other|No intervention|No intervention
325144|NCT00004127|Drug|fluorouracil|
325145|NCT00577772|Drug|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
325146|NCT00577772|Device|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
324507|NCT00263250|Procedure|watchful waiting or tension-free hernia repair|
324508|NCT00263263|Device|sirolimus-eluting stent|
324509|NCT00263263|Device|bare metal stent|
324510|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
324511|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
324512|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
324513|NCT00000417|Device|Informational film|
324514|NCT00002702|Radiation|radiation therapy|
324515|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
324516|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
324517|NCT00263276|Drug|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
324518|NCT00263276|Drug|metformin|Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.
324519|NCT00263289|Procedure|preprocedural fasting|
324520|NCT00263302|Drug|dexamethasone|
324521|NCT00263315|Drug|nebulised liposomal amphotericin B|
324522|NCT00263328|Drug|Tacrolimus|Standard of care
324523|NCT00266136|Drug|Cyclophosphamide|see protocol
324839|NCT00582699|Behavioral|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
324840|NCT00585390|Dietary Supplement|Omega-3 Fatty Acids|Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams
Docosahexaenoic acid fish oil concentrate at 1.6 grams
324841|NCT00585390|Other|Olive oil placebo|Olive oil capsules, 8 capsules per day
324842|NCT00585390|Dietary Supplement|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
343419|NCT00537173|Procedure|Core Biopsy|biopsy
343420|NCT00537173|Procedure|Blood Collection|Blood/serum sample
343421|NCT00537173|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
343422|NCT00537173|Drug|Avastin|Avastin 10 mg/kg IV, day 1 and 15
343423|NCT00537186|Drug|Iron oligosaccharide|
343424|NCT00537199|Other|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
343425|NCT00539617|Drug|erlotinib|Tarceva single agent therapy: 150 mg/day PO
343426|NCT00539617|Drug|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
343427|NCT00539617|Drug|leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
343428|NCT00003920|Procedure|peripheral blood stem cell transplantation|
343429|NCT00539617|Drug|oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
343740|NCT00003875|Drug|busulfan|Given PO or IV
343741|NCT00531986|Drug|HAART|Patients will continued their current HAART
343742|NCT00531999|Drug|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
343743|NCT00531999|Drug|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
343744|NCT00532012|Drug|RhuDex®|
343745|NCT00532025|Drug|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
343746|NCT00532038|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
343087|NCT00544830|Radiation|intensity-modulated radiation therapy|All sites will be treated using one of the following fractionation schemes: 1) 300 cGy/day to 3000 cGy; 2) 250 cGy/day to 3750 cGy; 3) 200 cGy/day to 4000 cGy.
343088|NCT00544830|Radiation|tomotherapy|All sites will be treated using one of the following fractionation schemes: 1) 300 cGy/day to 3000 cGy; 2) 250 cGy/day to 3750 cGy; 3) 200 cGy/day to 4000 cGy.
343089|NCT00544856|Behavioral|complex cognitive training|
343090|NCT00544869|Drug|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
343091|NCT00544882|Drug|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
343092|NCT00544882|Drug|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
343093|NCT00544882|Drug|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
343094|NCT00003945|Drug|cisplatin|
343095|NCT00544908|Drug|dasatinib|
343096|NCT00544908|Other|immunoenzyme technique|
343097|NCT00544908|Other|immunohistochemistry staining method|
343098|NCT00544908|Other|laboratory biomarker analysis|
343099|NCT00544908|Procedure|quality-of-life assessment|
343100|NCT00544921|Drug|GLY-230|
343101|NCT00544921|Other|Placebo|No drug administered
343102|NCT00544934|Drug|GLY-230|125, 250 0r 375 mg bid for 14 days
343103|NCT00544934|Other|Placebo|No drug administered
343104|NCT00544960|Drug|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
343105|NCT00003945|Drug|topotecan hydrochloride|
343106|NCT00544960|Drug|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
343107|NCT00547417|Drug|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
343108|NCT00547443|Drug|carboplatin|Given IV
342401|NCT00514683|Drug|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
342402|NCT00514683|Drug|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
342403|NCT00514683|Drug|placebo|placebo
342404|NCT00514696|Drug|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
342405|NCT00514709|Biological|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
342406|NCT00514709|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, IM
342407|NCT00514709|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine.
342408|NCT00003788|Procedure|surgical procedure|
342409|NCT00514722|Other|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
342410|NCT00514735|Procedure|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
342763|NCT00509288|Biological|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e^11 (with a minimum of 5x10e^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
342764|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
342765|NCT00509301|Drug|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
342766|NCT00509314|Behavioral|melanocyte self-assembly and functional analysis|
342767|NCT00509327|Drug|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
342768|NCT00509327|Drug|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
342769|NCT00509340|Behavioral|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
342770|NCT00509353|Drug|irinotecan hydrochloride|
342771|NCT00509353|Drug|vincristine sulfate|
342772|NCT00509353|Radiation|iobenguane I 131|
342773|NCT00003759|Procedure|conventional surgery|
342068|NCT00520195|Behavioral|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
342069|NCT00520208|Drug|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
342070|NCT00520234|Drug|Caspofungin|50 mg IV daily
342071|NCT00522769|Behavioral|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
342072|NCT00522782|Drug|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
342073|NCT00522782|Device|Nitric Oxide Analyzer|Niox NO analyzer
342074|NCT00522795|Drug|PPX with cisplatin and radiation|weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
342075|NCT00522808|Drug|A-831|
342076|NCT00522821|Drug|intravenous immunoglobulins|Adults: 600 mg/kg bodyweight every 3 weeks
Children: 800 mg/kg bodyweight every 3 week
342077|NCT00522821|Drug|antibiotics|Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.
Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.
342078|NCT00003827|Drug|topotecan hydrochloride|
342079|NCT00522834|Drug|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
342080|NCT00522834|Drug|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
342081|NCT00522860|Procedure|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
342082|NCT00522860|Procedure|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
342083|NCT00522873|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
341399|NCT00536393|Drug|Doxorubicin|
341400|NCT00536393|Drug|Doxorubicin pegylated|
341401|NCT00003899|Drug|paclitaxel|
341402|NCT00536406|Behavioral|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
341403|NCT00536406|Behavioral|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
341404|NCT00536419|Drug|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
341405|NCT00536419|Other|Placebo|Placebo, daily dose, 4 days, oral administration
341406|NCT00536445|Device|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
341407|NCT00536458|Procedure|radiotherapy|mini chep+ radiotherapy
341408|NCT00536458|Drug|MINI CHEP|chemotherapy minichep 6 courses
341409|NCT00536471|Drug|Duloxetine hydrochloride|
341749|NCT00528541|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
341750|NCT00528541|Biological|botulinum toxin type A|750 Units at Visit 1 (Day 1)
341751|NCT00528554|Procedure|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
341752|NCT00528554|Procedure|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
341753|NCT00531089|Drug|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
341754|NCT00531102|Other|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
341755|NCT00531102|Other|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
340726|NCT00508599|Other|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
340727|NCT00508612|Behavioral|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
340728|NCT00003753|Procedure|conventional surgery|
340729|NCT00508612|Behavioral|High school classes|The control group will attend regular high school classes.
341062|NCT00541398|Behavioral|Implementation of guideline|Outreach visits with interactive education for health staff
341063|NCT00544115|Drug|tacrolimus|
341064|NCT00003942|Biological|RevM10/polAS gene|
341065|NCT00544115|Procedure|allogeneic hematopoietic stem cell transplantation|
341066|NCT00544115|Procedure|peripheral blood stem cell transplantation|
341067|NCT00544115|Radiation|total-body irradiation|
341068|NCT00544128|Drug|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
341069|NCT00544128|Drug|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
341070|NCT00544154|Drug|CDP870|
341071|NCT00544167|Drug|Doxorubicin|
341072|NCT00544167|Drug|Cyclophosphamide|
341073|NCT00544167|Drug|Paclitaxel|
341074|NCT00544167|Drug|Sorafenib|
341075|NCT00003942|Procedure|in vitro-treated peripheral blood stem cell transplantation|
341076|NCT00544180|Drug|Risedronate|
341077|NCT00544193|Drug|gemcitabine hydrochloride|
341078|NCT00544193|Genetic|polymerase chain reaction|
341079|NCT00544193|Other|immunohistochemistry staining method|
341080|NCT00544193|Procedure|conventional surgery|
340383|NCT00513903|Behavioral|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
340384|NCT00513916|Dietary Supplement|soy isoflavones|High or low dose of soy isoflavones in the diet.
340385|NCT00516620|Behavioral|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
340386|NCT00516620|Behavioral|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
340387|NCT00003797|Drug|gemcitabine hydrochloride|
340388|NCT00516620|Behavioral|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
340389|NCT00516620|Behavioral|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
340390|NCT00516620|Behavioral|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
340730|NCT00508625|Drug|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5). It is given at a dose of either 8mg/kg for 5 days or 20mg/kg for 2 days per 21 day cycle until disease progression, drug intolerability, withdrawal of consent, or end of study.
340731|NCT00508625|Drug|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF). It is given at a dose of 15mg/kg on day 1 of a 21 day cycle until disease progression, drug intolerability, withdrawal of consent or end of study.
340732|NCT00508625|Drug|Carboplatin|Standard chemotherapy given at a dose of AUC=6.0mg/ml.min on day 1 of a 21 day cycle for up to a maximum of 6 cycles
340733|NCT00508625|Drug|Paclitaxel|Standard chemotherapy given at a dose of 200mg/m2 on day 1 of a 21 day cycle for up to a maximum of 6 cycles.
340734|NCT00508651|Biological|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
340735|NCT00508651|Biological|Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
340736|NCT00508664|Radiation|Radiation|Radiation start in week 11
340391|NCT00516620|Behavioral|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
340392|NCT00516620|Behavioral|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
340393|NCT00516620|Behavioral|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
340394|NCT00516633|Behavioral|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
340395|NCT00516646|Drug|ALT-711|200 mg bid
340396|NCT00516646|Drug|Placebo|bid
340397|NCT00516659|Biological|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
340398|NCT00003798|Drug|motexafin gadolinium|
340399|NCT00516659|Biological|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
340400|NCT00516672|Drug|pazopanib|Pazopanib oral tablet
340401|NCT00516672|Drug|Lapatinib|Lapatinib oral tablet
340402|NCT00516685|Biological|Recombinant Human rEGF-P64K/Montanide Vaccine|
340403|NCT00516698|Genetic|polymorphism analysis|
340404|NCT00519376|Drug|GW642444H|drug
340405|NCT00519376|Drug|placebo|
340406|NCT00003812|Drug|carboplatin|
340407|NCT00519389|Biological|H5N1 VLP Vaccine|Two doses - Day 0 & Day 28
340408|NCT00519389|Biological|Placebo|Two doses - Day 0 & Day 28
340409|NCT00519402|Other|tonsillar examination and questionnaire completion|
345341|NCT00476307|Biological|Fluarix™/Influsplit SSW® 2007/2008|
345342|NCT00003598|Drug|tretinoin|
345343|NCT00476320|Procedure|Magnetic Resonance Imaging|
345344|NCT00476320|Procedure|Revascularization|
345345|NCT00476320|Procedure|Echocardiography with myocardial deformation imaging|
345346|NCT00476333|Device|APOS biomechanical gait system|
345347|NCT00476346|Dietary Supplement|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
345348|NCT00476359|Drug|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
345349|NCT00476385|Drug|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
345350|NCT00476398|Procedure|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
345351|NCT00476411|Biological|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
345352|NCT00476424|Drug|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
345353|NCT00003599|Dietary Supplement|Vitamin E (AT)|Orally daily
345354|NCT00476437|Drug|biphasic insulin aspart|
345355|NCT00476437|Drug|biphasic human insulin|
340070|NCT00524927|Drug|Methoxyflurane|
340071|NCT00524927|Drug|Normal Saline|
340072|NCT00524940|Biological|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
340073|NCT00524953|Device|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last ~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
340074|NCT00524966|Procedure|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
340075|NCT00525005|Drug|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
344671|NCT00494065|Other|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
345007|NCT00485485|Drug|Imatinib Mesylate|400 mg by mouth daily
345008|NCT00485485|Drug|Docetaxel|60 mg/m^2 by vein (IV) over 1 hour every 3 weeks
345009|NCT00485498|Drug|Olanzapine Hydrochloride|
345010|NCT00485498|Drug|Risperidone|
345011|NCT00485511|Drug|Hydroxyurea|
345012|NCT00485537|Procedure|oocyte retrieval and ICSI procedure|
345013|NCT00485550|Drug|Atomoxetine Hydrochloride|
345014|NCT00485550|Drug|Methylphenidate Hydrochloride|
345015|NCT00003640|Drug|methotrexate|
345016|NCT00485550|Drug|Placebo|
345017|NCT00485563|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
345018|NCT00485563|Biological|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
345019|NCT00485563|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
345020|NCT00485563|Drug|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
345021|NCT00485563|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
345022|NCT00485576|Drug|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
345023|NCT00485589|Drug|methotrexate|Oral repeating dose
345024|NCT00485589|Drug|ocrelizumab|Intravenous repeating dose
344318|NCT00501917|Drug|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
344319|NCT00501930|Drug|GSK189075|
344320|NCT00003717|Drug|estramustine phosphate sodium|
344321|NCT00501943|Drug|Avonex (Interferon beta 1a)|
344322|NCT00501943|Drug|Riluzole|
344323|NCT00501943|Drug|Placebo|
344324|NCT00501956|Drug|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
344325|NCT00501969|Drug|Rotigotine|Rotigotine trans-dermal patches once daily:
20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)
344326|NCT00501982|Drug|Poractant alfa (Curosurf®)|
344327|NCT00501995|Drug|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
344328|NCT00502008|Drug|Coccinia Cordifolia (herbal extract)|
344329|NCT00502021|Dietary Supplement|Placebo|Manioc powder (placebo) 60 g/day
344330|NCT00502021|Dietary Supplement|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
344331|NCT00003717|Drug|paclitaxel|
344672|NCT00494078|Device|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
344673|NCT00494078|Drug|intensive insulin therapy|intensive insulin therapy according to an algorithm
344674|NCT00494091|Drug|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
344675|NCT00494091|Drug|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
344676|NCT00494104|Dietary Supplement|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
344677|NCT00494117|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
344678|NCT00494143|Device|CESR Prosthetic Foot|a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle
343634|NCT00518128|Procedure|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
343635|NCT00518141|Drug|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
343964|NCT00509847|Drug|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
343965|NCT00509860|Drug|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
343966|NCT00509873|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
343967|NCT00509873|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
343968|NCT00509886|Drug|Drysol|20% aluminum chloride hexahydrate
343969|NCT00512798|Drug|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
343970|NCT00512798|Drug|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
343971|NCT00512811|Drug|furosemide|
343972|NCT00512824|Dietary Supplement|low calcium milk of 180 ml|twice daily for 24 weeks
343973|NCT00512824|Dietary Supplement|regular milk of 180 ml|twice daily for 24 weeks
343974|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
343975|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
343976|NCT00512837|Behavioral|Mobile phone technology|
343977|NCT00512850|Dietary Supplement|Folic acid|Intervention group 1g folic acid per day
343978|NCT00512850|Other|Placebo|One placebo pill per day
343979|NCT00003782|Drug|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
343980|NCT00512863|Drug|Humira (adalimumab)|
343981|NCT00512876|Drug|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
343982|NCT00512889|Biological|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
343313|NCT00526305|Drug|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
343314|NCT00526305|Drug|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
343315|NCT00526305|Drug|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
343316|NCT00003852|Biological|filgrastim|
343317|NCT00526305|Drug|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
343318|NCT00526305|Drug|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
343319|NCT00526305|Drug|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
343320|NCT00526305|Drug|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
343321|NCT00526305|Drug|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
343322|NCT00526318|Biological|filgrastim|
343636|NCT00518154|Drug|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
343637|NCT00003804|Procedure|conventional surgery|
343638|NCT00518167|Behavioral|Intensive lifestyle counselling|Individualized dietary and physical activity counselling aiming at
weight reduction
dietary fibre 15 g /1000 kcal or more
energy proportion of dietary fat less than 30%
energy proportion of saturated fat less than 10%
moderate physical activity >30 minutes per day or 4 hours per week
343639|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
343640|NCT00520754|Drug|levocetirizine dihydrochloride|
343641|NCT00520767|Drug|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
343642|NCT00520767|Drug|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
343643|NCT00520767|Drug|melphalan|Melphalan 9 mg/m2/day days 1-4
343644|NCT00520767|Genetic|microarray analysis|≤28 days prior to enrollment
343645|NCT00520767|Other|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
343646|NCT00520767|Other|laboratory biomarker analysis|≤28 days prior to enrollment
343647|NCT00520767|Procedure|quality-of-life assessment|Start of each cycle
325789|NCT00565305|Radiation|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
325790|NCT00004068|Procedure|conventional surgery|
325791|NCT00565318|Drug|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
325792|NCT00565318|Drug|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
325793|NCT00565331|Drug|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
325794|NCT00565331|Drug|Placebo|saline solution
325795|NCT00567567|Drug|Topotecan Hydrochloride|Given IV
325796|NCT00004085|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
325797|NCT00567567|Drug|Vincristine Sulfate Liposome|Given IV
325798|NCT00567580|Drug|bicalutamide|Oral, daily
325799|NCT00567580|Drug|flutamide|Oral, daily
325800|NCT00567580|Radiation|radiation therapy|Once daily, 5 days a week
325801|NCT00567593|Drug|Rosiglitazone|8mg tablet once a day for 14 days
325802|NCT00567606|Other|risedronate, calcium/vit D, strength weight training|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine. G2 group receives the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
325803|NCT00567658|Drug|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
325804|NCT00567671|Procedure|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
325805|NCT00567671|Procedure|Sham comparator|Sham treatment
325806|NCT00567684|Other|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
325807|NCT00004086|Biological|filgrastim|
325808|NCT00567684|Other|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
326127|NCT00560612|Drug|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
326128|NCT00560612|Drug|Placebo|Placebo: same as paroxetine (active comparator)
325147|NCT00577772|Procedure|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
325148|NCT00577785|Other|tissue procurement|No intervention. Tissue procurement study.
325149|NCT00577798|Drug|doxorubicin hydrochloride|Standard therapy for patients undergoing chemotherapy for their non-Hogdkin's lyphoma and Hogdkin's lymphoma
325150|NCT00577798|Procedure|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake).
325151|NCT00577824|Drug|exenatide|subcutaneous injection, 5mcg, twice a day
325446|NCT00570414|Device|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
325447|NCT00570414|Device|Endotracheal tube|Airway management by the use of endotracheal tube
325448|NCT00570427|Behavioral|Problem Solving Therapy (PST)|Counseling
325449|NCT00570427|Behavioral|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
325450|NCT00570440|Drug|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
325451|NCT00570466|Behavioral|Behavior Change Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
325452|NCT00004092|Biological|filgrastim|Given IV or subcutaneously
325453|NCT00572637|Drug|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
325454|NCT00572650|Drug|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
325455|NCT00572663|Drug|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
325456|NCT00572689|Drug|Exenatide|10 microgram injected sub-cutaneously once
325457|NCT00572689|Genetic|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
324843|NCT00585390|Drug|Placebo|Olive oil capsule
324844|NCT00585416|Drug|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
324845|NCT00585442|Drug|calcitriol|1.0 mcg daily
324846|NCT00585455|Drug|sertraline|open label 25-50 mg daily as tolerated
324847|NCT00585468|Drug|Myfortic|Drug-immunosuppressant
324848|NCT00585481|Procedure|Samples collection for viral diagnosis|At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).
Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment.
324849|NCT00000609|Drug|amiodarone|
324850|NCT00004164|Drug|leucovorin calcium|
324851|NCT00585481|Procedure|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
324852|NCT00585507|Drug|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
324853|NCT00585520|Drug|Progesterone|200mg BID for 5 days
324854|NCT00585520|Drug|Placebo|Placebo
324855|NCT00585533|Drug|Erlotinib (Tarceva)|Erlotinib
324856|NCT00585546|Drug|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
324857|NCT00585559|Drug|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
325152|NCT00577824|Drug|exenatide|subcutaneous injection, 10mcg, twice a day
325153|NCT00577824|Drug|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
325154|NCT00577837|Drug|risedronate|tablet, 5 mg risedronate daily for 6 months
325155|NCT00004127|Drug|leucovorin calcium|
325156|NCT00577837|Drug|risedronate|tablet, 100 mg risedronate monthly for 6 months
343747|NCT00532051|Device|OCT measurements|This study is about a new imaging method to study the front part of the eye. This imaging method is called Optical Coherence Tomography (OCT) which provides detailed cross-sectional (layered) views of structures in the eye. The OCT system scans a beam of light across the eye to take a picture. OCT provides a more detailed image than other imaging methods of the eye such as ultrasound, CT scan (computed tomography), and MRI (magnetic resonance imaging). In addition, OCT imaging does not touch the eye. OCT is routinely used in imaging structures in the back of the eye (retina) and cornea. This study uses high-speed FDA approved OCT systemsThe measurements from the OCT systems are used in selecting IOL power.
343748|NCT00532064|Behavioral|Questionnaire|Symptom questionnaire taking about 10-15 minutes.
343749|NCT00532077|Drug|rhPTH(1-34)|
343750|NCT00532077|Drug|SB-751689 100 mg|
343751|NCT00003875|Drug|etoposide|Given IV
343752|NCT00532077|Drug|SB-751689 400 mg|
343753|NCT00532090|Drug|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
343754|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
343755|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
343756|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
343757|NCT00534625|Drug|zileuton|Single injection of zileuton 150 mg
343758|NCT00534625|Drug|placebo|Single injection of placebo
343759|NCT00534625|Drug|zileuton|Single injection of zileuton 300 mg
344098|NCT00003833|Genetic|gene mapping|
344099|NCT00523770|Procedure|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
344100|NCT00523809|Drug|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
344101|NCT00526409|Drug|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
344102|NCT00526409|Drug|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
344103|NCT00526422|Procedure|Dental Preventive|
344104|NCT00526435|Behavioral|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
343109|NCT00547443|Drug|paclitaxel|Given IV
343110|NCT00003957|Drug|cytarabine|
343111|NCT00547443|Drug|sorafenib tosylate|Given orally
343430|NCT00539630|Drug|Docetaxel|
343431|NCT00539643|Device|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
343432|NCT00539643|Other|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
343433|NCT00539656|Device|Ex vivo expansion of cord blood|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
343434|NCT00539669|Drug|Docetaxel|
343435|NCT00539695|Biological|IL-2|IL2 Administration:
Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed >grade I side effects to IL-2 and has not developed >grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection.
343436|NCT00539708|Procedure|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
343437|NCT00539721|Drug|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
343438|NCT00539721|Drug|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
343439|NCT00003920|Radiation|indium In 111 monoclonal antibody m170|
343440|NCT00539721|Drug|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
343441|NCT00539721|Drug|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
343442|NCT00539721|Drug|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
343443|NCT00539721|Drug|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
343444|NCT00539734|Drug|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
342774|NCT00509366|Drug|Cisplatin & Gemcitabine|Squamous Cell NSCLC:
Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles
342775|NCT00509366|Drug|Cisplatin & Pemetrexed|Non-Squamous Cell NSCLC:
Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles
342776|NCT00509366|Drug|Docetaxel & Gemcitabine|Squamous Cell NSCLC:
Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
342777|NCT00509366|Drug|Pemetrexed & Gemcitabine|Non-Squamous Cell NSCLC:
Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
342778|NCT00509379|Drug|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
342779|NCT00509379|Drug|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
342780|NCT00512213|Dietary Supplement|Immunonutrition for 5 days preoperative|Impact vs Meritene
342781|NCT00003779|Biological|Tice|Compare two strains of BCG
342782|NCT00512213|Dietary Supplement|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
343112|NCT00547443|Radiation|radiation therapy|Given 5 days a week for 7.5 weeks
343113|NCT00547456|Drug|Oxygen|Oxygen 2-3L Nasal cannula
343114|NCT00547469|Drug|DDP733|
343115|NCT00547482|Device|TANTALUS(TM) System|All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the "Treatment Group" or "Control Group" after surgery at Week 1, Visit 5 (device activation).
343116|NCT00547495|Drug|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
343117|NCT00547495|Drug|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
343118|NCT00547495|Drug|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
343119|NCT00547495|Drug|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
343120|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
343121|NCT00000579|Procedure|Low Tidal Volume Ventilation|
342411|NCT00514735|Drug|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
342412|NCT00514748|Procedure|DIEP|flap survival, operation time, flap complications, donor site morbidity.
342413|NCT00514748|Procedure|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
342414|NCT00514761|Drug|AZD6244|oral vial
342415|NCT00514761|Drug|Capecitabine|oral tablet
342416|NCT00514774|Drug|ursodiol|ursodiol 300 mg twice daily for study days 0 through 28
ursodiol 600mg twice daily on study days 0 through 28
342417|NCT00514774|Drug|placebo|placebo 600mg twice daily for study days 0 through 28
342418|NCT00514800|Behavioral|Intervention - a validated home BP monitor and support from the specialist nurse|
342419|NCT00003788|Radiation|radiation therapy|
342420|NCT00514800|Behavioral|Control - usual care (BP monitoring by their practice)|Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.
GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings.
342421|NCT00514813|Drug|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
342422|NCT00514826|Other|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
342423|NCT00514839|Behavioral|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
342424|NCT00514852|Drug|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
342425|NCT00517439|Drug|Pegasys|90 micrograms sc weekly for 24 weeks
342426|NCT00517439|Drug|RO4588161|1000mg po bid for 24 weeks
342427|NCT00517439|Drug|RO4588161|500mg po bid for 24 weeks
342428|NCT00517439|Drug|RO4588161|1500mg po bid for 24 weeks
342429|NCT00003801|Procedure|management of therapy complications|
342430|NCT00517465|Drug|Placebo|po bid
341756|NCT00531115|Drug|cetuximab 5mg/ml|Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).
The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment.
341757|NCT00531128|Behavioral|High/Low Sitosterol|
341758|NCT00531141|Other|examination only|OCT performed twice
341759|NCT00000565|Procedure|intermittent positive-pressure breathing|
341760|NCT00003870|Procedure|allogeneic bone marrow transplantation|
341761|NCT00531167|Drug|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
341762|NCT00531180|Procedure|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
341763|NCT00531180|Procedure|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
341764|NCT00531193|Drug|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
341765|NCT00531193|Other|[11C]SCH442416|11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
341766|NCT00531206|Drug|Tipranavir|
341767|NCT00531206|Drug|Ritonavir|low dose
342084|NCT00522873|Drug|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
342085|NCT00522886|Drug|Cetuximab|Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.
14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.
Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.
Vinorelbine:
Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73.
342086|NCT00522899|Behavioral|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
341081|NCT00544193|Radiation|intraoperative radiation therapy|
341082|NCT00544193|Radiation|radiation therapy|
341083|NCT00544206|Other|standard enteral feeding product|16 hrs daily x 5 days
341084|NCT00544206|Other|Diabetes specific feeding product|16 hrs daily for 5 days
341085|NCT00544219|Biological|rituximab|375 mg/m2 i.v. per cycle
341086|NCT00003942|Procedure|peripheral blood stem cell transplantation|
341087|NCT00544219|Drug|cyclophosphamide|750 mg/m2 i.v. per cycle
341088|NCT00544219|Drug|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
341410|NCT00536471|Drug|Placebo|
341411|NCT00536484|Drug|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
341412|NCT00000570|Drug|pulmonary surfactant|
341413|NCT00003899|Drug|thiotepa|
341414|NCT00536484|Drug|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
341415|NCT00536497|Drug|GW842166X|
341416|NCT00538746|Device|BIPAP|
341417|NCT00538746|Device|PSV|
341418|NCT00538746|Device|PSV + CPAP|
341419|NCT00538759|Device|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
341420|NCT00538772|Other|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
341421|NCT00538785|Biological|Motavizumab|15 mg/kg IM administered at monthly intervals
341422|NCT00538785|Biological|Palivizumab|15 mg/kg IM administered at monthly intervals
341423|NCT00538798|Drug|[18F]SP203|
341424|NCT00003914|Drug|dolastatin 10|
340737|NCT00508664|Drug|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
340738|NCT00508664|Drug|Docetaxel|75 mg/m2 i.v. day 1 3 times
340739|NCT00003754|Drug|cyclophosphamide|
340740|NCT00508664|Drug|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
340741|NCT00508664|Drug|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
340742|NCT00508690|Drug|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
340743|NCT00508690|Drug|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
340744|NCT00508703|Radiation|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
340745|NCT00508703|Procedure|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
340746|NCT00000555|Drug|vitamin e|
340747|NCT00003776|Drug|leucovorin calcium|
340748|NCT00511225|Dietary Supplement|placebo|placebo capsule
340749|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
341089|NCT00544219|Drug|prednisone|100 mg/day p.o. per cycle
341090|NCT00544219|Drug|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
341091|NCT00544219|Procedure|positron emission tomography|PET Scan during treatment
341092|NCT00544232|Drug|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel
341093|NCT00546585|Biological|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
341094|NCT00546585|Drug|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
341095|NCT00546598|Device|Total hip replacement/arthroplasty|Hip replacement
340410|NCT00519415|Other|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
340750|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
340751|NCT00511277|Drug|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
340752|NCT00511290|Other|no generic names|
340753|NCT00511303|Drug|STI571|
340754|NCT00511316|Drug|Montelukast/ Singulair|20 mg daily for six months
340755|NCT00511316|Drug|Placebo|Placebo 20 mg daily for 6 months
340756|NCT00511329|Drug|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
340757|NCT00511342|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
340758|NCT00003776|Drug|methotrexate|
340759|NCT00511342|Drug|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
340760|NCT00511355|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
340761|NCT00511355|Drug|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
340762|NCT00511368|Drug|matching placebo|
340763|NCT00511368|Drug|Bevirimat|
340764|NCT00511381|Genetic|No intervention|No intervention
340765|NCT00511394|Drug|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
340766|NCT00511394|Drug|Normal Saline|Infusion of 100 mL of Normal Saline
340076|NCT00525018|Device|contact heat evoked potential stimulator|
340077|NCT00003843|Genetic|mutation analysis|
340078|NCT00525031|Drug|Temozolomide (TMZ)|150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
340079|NCT00525031|Drug|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
340080|NCT00525044|Drug|Ambroxol|
340081|NCT00525044|Drug|Placebo|
340082|NCT00525057|Drug|Dalteparin|5000 units subcutaneous injection once daily, for 7 - 10 days.
340083|NCT00527657|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
340084|NCT00527657|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
340085|NCT00527657|Drug|Thalidomide|200 mg/m^2 by mouth daily.
340086|NCT00527670|Other|No Intervention|NC is the control group to compare genomic information.
340087|NCT00527670|Other|No Intervention|RH is the group we are trying to find genetic proof of hernias being inherited.
340088|NCT00527683|Drug|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
340089|NCT00003857|Drug|tamoxifen citrate|
340090|NCT00527683|Drug|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
340091|NCT00527683|Behavioral|Group therapy|Participants attend group sessions once a week
340092|NCT00527696|Procedure|transvaginal obturator tape|
340411|NCT00519415|Other|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
340412|NCT00519428|Drug|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
340413|NCT00519428|Drug|bupropion XL|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
340414|NCT00519428|Drug|escitalopram + bupropion|same dosing schedule as for monotherapy
345025|NCT00485589|Drug|placebo|Intravenous repeating dose
345026|NCT00003640|Drug|vinblastine sulfate|
345027|NCT00488592|Drug|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
345356|NCT00476463|Drug|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
345357|NCT00479583|Drug|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
345358|NCT00003614|Drug|paclitaxel|
345359|NCT00479583|Drug|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
345360|NCT00479596|Drug|Botox|
345361|NCT00479609|Drug|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
345362|NCT00479609|Drug|Placebo|Placebo gel
345363|NCT00479622|Drug|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
345364|NCT00479635|Drug|TPI 287|160 mg/m2 every three weeks for six cycles
345365|NCT00479635|Drug|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
345366|NCT00479648|Biological|CSL412|
345367|NCT00479648|Biological|Inactivated trivalent influenza vaccine|
345368|NCT00479661|Drug|Dexmedetomidine|Continuous infusion
345369|NCT00003615|Biological|denileukin diftitox|
345370|NCT00479661|Drug|Propofol|Continuous infusion
345371|NCT00479674|Drug|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
345372|NCT00479674|Drug|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
344679|NCT00494143|Device|typical prosthetic foot|patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team
344680|NCT00003671|Drug|thioguanine|
344681|NCT00494143|Device|standardized prosthetic foot|a standard foot that has had weights applied to match the mass of the CESR foot
344682|NCT00494156|Drug|heparin|
344683|NCT00494156|Drug|aspirin and clopidogrel|
344684|NCT00494182|Drug|Sorafenib|400 mg by mouth twice daily on Day 2-19
344685|NCT00494182|Drug|Carboplatin|6 area under the plasma drug concentration-time curve (AUC) by vein over 30 Minutes On Day 1
344686|NCT00494182|Drug|Paclitaxel|200 mg/m^2 by vein over 3 hours on Day 1
344687|NCT00496782|Drug|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
344688|NCT00496782|Procedure|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
344689|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
344690|NCT00496808|Drug|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
344691|NCT00496821|Drug|ALN-RSV01|
344692|NCT00003685|Procedure|pain therapy|
345028|NCT00488592|Biological|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
343983|NCT00512889|Genetic|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
343984|NCT00512889|Drug|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
343985|NCT00512889|Radiation|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
344332|NCT00502021|Dietary Supplement|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
344333|NCT00502021|Dietary Supplement|Placebo|Safflower oil 30 ml/day
344334|NCT00502034|Drug|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
344335|NCT00502034|Drug|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
344336|NCT00502047|Drug|Plantago ovata husk|
344337|NCT00502060|Drug|AZD2171|
344338|NCT00502060|Drug|ZD1839|
344339|NCT00502073|Drug|cyclosporine|
344340|NCT00502086|Dietary Supplement|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
344341|NCT00502086|Other|Placebo|Placebo three sachets daily during 96 weeks
344342|NCT00003718|Drug|temozolomide|
344343|NCT00504790|Drug|GSK923295|anti-mitotic compound
344344|NCT00003728|Drug|vindesine|
344345|NCT00504803|Procedure|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
344346|NCT00504816|Drug|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
344347|NCT00504816|Drug|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
344348|NCT00504829|Drug|LCP-AtorFen|anti-dyslipidemia
344349|NCT00504829|Drug|atorvastatin|anti-dyslipidemia
344350|NCT00504829|Drug|fenofibrate|anti-dyslipidemia
344351|NCT00504842|Drug|MRX-801|
343648|NCT00003816|Drug|busulfan|Given IV
343649|NCT00520780|Drug|Ferinject ® (Ferric carboxymaltose)|Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.
After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
343650|NCT00520780|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
343651|NCT00520806|Drug|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
343652|NCT00520806|Drug|Placebo|Intravenous infusion for 48 h
343653|NCT00520819|Drug|Antioxidant-rich food items|
343654|NCT00520832|Device|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
343655|NCT00520832|Device|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
343656|NCT00520845|Drug|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
343657|NCT00520845|Drug|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
343986|NCT00512902|Drug|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
343987|NCT00512902|Drug|Imatinib|Up to 600 mg QD PO for up to 1 year.
343988|NCT00512915|Device|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
343989|NCT00512928|Drug|acenocoumarol|max 5 mg per day during 10 weeks
343990|NCT00003782|Drug|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
343991|NCT00512928|Dietary Supplement|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
343992|NCT00512980|Drug|prednisone|
343993|NCT00512980|Drug|vinblastine|
343994|NCT00512980|Drug|doxorubicin|
326129|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|TID
326130|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|QID
326131|NCT00560638|Drug|vehicle of loteprednol etabonate|TID or BID according to the randomization
326132|NCT00560651|Procedure|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
326133|NCT00560664|Procedure|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
326134|NCT00560664|Procedure|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
326135|NCT00560690|Drug|Metformin|500 mg oral three times a day for 6 months
326136|NCT00560690|Drug|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
326137|NCT00000592|Procedure|blood transfusion|
326138|NCT00004046|Drug|exatecan mesylate|
326139|NCT00560690|Drug|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
326140|NCT00560703|Drug|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
326141|NCT00560703|Drug|placebo|sugar capsule
326142|NCT00560716|Drug|CYC116|Dose escalation of CYC116
326143|NCT00560729|Dietary Supplement|Renutryl 500|
326144|NCT00560729|Dietary Supplement|Generique|
326145|NCT00562835|Other|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc [prednisolone + diluting fluid], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
326146|NCT00562848|Drug|GSK962040|
325458|NCT00572702|Procedure|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
325459|NCT00572702|Procedure|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
325460|NCT00004099|Procedure|neoadjuvant therapy|
325461|NCT00572728|Procedure|CT|Undergo 18F-FLT PET/CT
325462|NCT00572728|Drug|18F-FLT|Undergo 18F-FLT PET/CT
325463|NCT00572728|Procedure|PET|Undergo 18F-FLT PET/CT
325464|NCT00572741|Dietary Supplement|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
325465|NCT00572741|Dietary Supplement|Placebo|cellulose
325466|NCT00572741|Dietary Supplement|folate|Folinic acid: Dose: 400 µg twice a day (BID)
325809|NCT00567697|Drug|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
325810|NCT00567697|Drug|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
325811|NCT00567710|Drug|BL - 1020|10 mg/day
325812|NCT00567710|Drug|BL - 1020|BL 1020 20-30 mg/day
325813|NCT00567710|Drug|Placebo|Capsules
325814|NCT00567710|Drug|Risperidone|Capsules
325815|NCT00567736|Drug|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
325816|NCT00567736|Drug|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
325817|NCT00567762|Drug|FK506|Opthalmic suspension
325818|NCT00004086|Drug|cisplatin|
325819|NCT00567762|Drug|placebo|placebo eye drops
325820|NCT00567775|Drug|human insulin|
325821|NCT00567775|Drug|inhaled human insulin|
325157|NCT00577837|Drug|risedronate|tablet, 150 mg risedronate monthly for 6 months
325158|NCT00577837|Drug|experimental|tablet, 200 mg risedronate monthly for 6 months
325159|NCT00577850|Drug|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
325160|NCT00577850|Drug|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
325161|NCT00579917|Behavioral|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
325162|NCT00579956|Drug|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
325163|NCT00579956|Drug|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
325164|NCT00579969|Drug|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
325165|NCT00579969|Drug|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
325166|NCT00579982|Drug|Lamotrigine|Experimental formulation
325167|NCT00579995|Drug|Oral N-Acetylcysteine|600 mg
325168|NCT00579995|Drug|Intravenous Sodium Bicarbonate|3mL/kg/hr for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
325169|NCT00004137|Drug|topotecan hydrochloride|
325170|NCT00580021|Other|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
325467|NCT00572741|Dietary Supplement|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
325468|NCT00572741|Dietary Supplement|vitamin C|Vitamin C 500 mg
325469|NCT00572741|Dietary Supplement|cod liver oil|Cod liver oil 1/2 teaspoon
325470|NCT00572741|Dietary Supplement|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
344105|NCT00526435|Behavioral|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
344106|NCT00526448|Drug|ribavirin|2000 mg/day
344107|NCT00000559|Drug|medroxyprogesterone|
344108|NCT00003852|Drug|etoposide|
344109|NCT00526448|Drug|ribavirin|1000-1200 mg/day
344110|NCT00526448|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
344111|NCT00526448|Drug|epoetin beta|epoetin beta 450 UI/week
344112|NCT00526461|Drug|HPPH|IV
344113|NCT00526474|Drug|Vorapaxar|2.5-mg tablet daily for at least 1 year
344114|NCT00526474|Drug|Placebo|matching tablet daily for at least 1 year
344115|NCT00526487|Device|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
344116|NCT00526487|Device|Endovascular Repair|Endovascular Repair
344117|NCT00526500|Behavioral|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
344118|NCT00526513|Drug|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
344119|NCT00003852|Drug|ifosfamide|
344120|NCT00526539|Other|Total hip replacement, Spectron and Taperloc|
344474|NCT00469963|Radiation|yttrium Y 90 resin microspheres|radiation therapy
344475|NCT00469976|Drug|bevacizumab|
344476|NCT00469976|Drug|carboplatin|
344477|NCT00469976|Drug|enzastaurin hydrochloride|
344478|NCT00469976|Drug|gemcitabine hydrochloride|
344479|NCT00469989|Procedure|Infection with hookworm larvae|
343445|NCT00539760|Drug|GSK1827771|
343446|NCT00539773|Drug|BCG, Interferon|Chemotherapy
343447|NCT00539786|Drug|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
343448|NCT00539799|Drug|prednisolone|5 - 7.5 mg/day
343449|NCT00542295|Drug|placebo|
343760|NCT00534638|Biological|GSK Biologicals' HPV Vaccine GSK580299|Intramuscular injection, 3 doses
343761|NCT00534638|Biological|Engerix-B™|Intramuscular injection, 3 doses
343762|NCT00534651|Drug|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
343763|NCT00003893|Drug|CMF regimen|
343764|NCT00534664|Device|TheraBionic device|Daily outpatient treatment with theraBionic device
343765|NCT00534677|Drug|Terlipressin|2 mg stat & then 1 mg q6h iv and Placebo of Octreotide
343766|NCT00534677|Drug|Octreotide|Octreotide 50mcg/hr infusion & a placebo of Terlipressin
343767|NCT00534690|Procedure|One-Lung ventilation|Low Vt, High PEP
343768|NCT00534690|Procedure|One-Llung ventilation|High Vt, low PEP
343769|NCT00534703|Genetic|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10^13 DRP (DNase resistant particles)
343770|NCT00534703|Drug|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
343771|NCT00534729|Drug|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
343772|NCT00534755|Other|Breast Cancer database|prospective breast cancer database
343773|NCT00534768|Procedure|active debridement|debridement on 1st, 3-5th and 7th postoperative days
343774|NCT00003893|Drug|cyclophosphamide|
343775|NCT00534768|Procedure|control group|Postoperative debridement on 7th postoperative day
343776|NCT00534781|Device|plasma microdebrider|Coblation of the Achilles
343122|NCT00003957|Drug|etoposide|
343123|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
343124|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
343125|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
343126|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
343127|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
343128|NCT00547521|Drug|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
343129|NCT00547521|Drug|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
343130|NCT00547534|Drug|bortezomib|1.3 mg/m^2 on days 1, 4, 8, 11
343131|NCT00547534|Drug|bendamustine|90 mg/m^2 days 1 and 4
343132|NCT00547534|Drug|rituximab|375 mg/m^2 day 1
343133|NCT00003957|Drug|melphalan|
343450|NCT00542308|Drug|Zalutumumab|Individual dose titration weekly i.v. doses
343451|NCT00542321|Other|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
343452|NCT00542321|Device|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
343453|NCT00542347|Drug|Esomeprazole first|esomeprazole 20mg po once per day for 7 days
24hr pH study on day 7
followed by washout for 7 days
generic omeprazole 20mg po once per day for 7 days
24hr pH study on day 7
343454|NCT00003934|Drug|methotrexate|Given IV
343455|NCT00542347|Drug|Generic omeprazole first|generic omeprazole 20mg po once per day for 7 days
24hr pH study on day 7
followed by washout for 7 days
esomeprazole 20mg po once per day for 7 days
24hr pH study on day 7
342431|NCT00517465|Drug|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
342432|NCT00517478|Procedure|Blood Sample|
342783|NCT00512226|Other|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2* MRI analysis.
342784|NCT00512252|Drug|AMD3100|
342785|NCT00512252|Drug|Mitoxantrone|
342786|NCT00512252|Drug|Etoposide|
342787|NCT00512252|Drug|Cytarabine|
342788|NCT00512265|Drug|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
342789|NCT00512265|Drug|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
342790|NCT00512278|Drug|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
342791|NCT00512278|Other|Placebo|Placebo
342792|NCT00003780|Biological|tumor infiltrating lymphocyte therapy|
342793|NCT00512291|Drug|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
342794|NCT00512304|Procedure|association chemotherapy and radiochemotherapy|
342795|NCT00512317|Drug|ganaxolone|liquid suspension dosed tid
342796|NCT00512356|Biological|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
342797|NCT00512382|Device|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
342798|NCT00512395|Drug|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
342799|NCT00512408|Drug|testosterone|
342800|NCT00512421|Procedure|computer-assisted surgery|
342801|NCT00512434|Procedure|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
342087|NCT00522899|Behavioral|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
342088|NCT00522899|Behavioral|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
342089|NCT00003828|Drug|vinorelbine|
342090|NCT00522899|Behavioral|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
342091|NCT00525785|Drug|Folinic Acid|200 mg/m^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
342092|NCT00525785|Drug|Oxaliplatin|100 mg/m^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.
Chemoradiotherapy: 45 mg/m2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week).
342093|NCT00525785|Radiation|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
342094|NCT00525798|Drug|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
342095|NCT00003847|Drug|biricodar dicitrate|
342096|NCT00525798|Drug|SMC021 Placebo|SMC021 - Placebo, once daily
342097|NCT00525811|Other|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
342098|NCT00525811|Other|patient information|Information on acute low back pain, information on depression
342099|NCT00525824|Drug|Rosuvastatin (Crestor)|10mg and 20 mg
342100|NCT00525824|Drug|Ezetimibe|10 mg
342101|NCT00525824|Drug|Simvastatin|40mg and 80 mg
342102|NCT00525837|Drug|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
342103|NCT00525837|Drug|varenicline|up to 1 mg twice daily
342433|NCT00517491|Drug|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
342434|NCT00517504|Drug|Methylphenidate|1-week single blind placebo lead-in phase.
step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.
Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.
After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control.
341425|NCT00538811|Drug|interferon alpha-2b, ribavirin, interferon-gamma,|
341426|NCT00538811|Drug|interferon alpha-2b, ribavirin, amantadine|
341427|NCT00538824|Drug|dexamethasone|Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.
After completing 4 cycles:
Patients who demonstrate disease progression at any time will be taken off study.
Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.
Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.
Maintenance therapy will consist of:
• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)
341428|NCT00538824|Drug|thalidomide|Cycles 1-4
• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.
After completing 4 cycles:
Patients who demonstrate disease progression at any time will be taken off study.
Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.
Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.
341768|NCT00531219|Procedure|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
341769|NCT00531219|Procedure|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
341770|NCT00531232|Drug|clofarabine|Oral daily x 5 every 28 days. 25 mg/day. Up to 8 cycles
341771|NCT00003870|Radiation|iodine I 131 monoclonal antibody BC8|
341772|NCT00531245|Drug|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
341773|NCT00531258|Device|rTMS|Bilateral rTMS
341774|NCT00531258|Device|Sham rTMS|sham rTMS
341775|NCT00533845|Drug|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
341776|NCT00533858|Drug|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
341777|NCT00533884|Other|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
341778|NCT00533884|Other|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
341779|NCT00533884|Other|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
341096|NCT00546598|Device|Hip replacement/arthroplasty|Hip replacement
341097|NCT00546611|Drug|PEP005|
341098|NCT00546624|Drug|MK0777|
341099|NCT00546637|Drug|Fesoterodine|Fesoterodine 4mg or 8mg
341100|NCT00546637|Drug|Placebo|Placebo
341101|NCT00003955|Biological|pegfilgrastim|
341102|NCT00546650|Drug|Sumatriptan succinate|NP101 iontophoretic transdermal system
341103|NCT00546650|Drug|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
341104|NCT00546663|Drug|inhaled 7% hypertonic saline (HS)|7% hypertonic saline administered twice daily for 14 days by nebulization.
A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).
To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler
341105|NCT00546676|Drug|Telithromycin|
341106|NCT00546702|Drug|Insuline Glulisine|
341107|NCT00546715|Drug|Daclatasvir|Oral Solution, Oral, Single Dose
341108|NCT00546715|Drug|Placebo|Oral Solution, Oral, Single Dose
341109|NCT00546728|Drug|Exenatide|exenatide 10 mcg twice daily
341110|NCT00546728|Drug|Metformin|metformin 500 twice daily
341111|NCT00546741|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
341112|NCT00003955|Biological|sargramostim|
341429|NCT00538824|Drug|lenalidomide|Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.
After completing 4 cycles:
Patients who demonstrate disease progression at any time will be taken off study.
Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.
Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.
Maintenance therapy will consist of:
• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of < 40cc/min*
340767|NCT00511407|Device|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
340768|NCT00511420|Dietary Supplement|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
340769|NCT00003776|Drug|trimetrexate glucuronate|
340770|NCT00511420|Dietary Supplement|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
341113|NCT00546741|Drug|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
341114|NCT00546741|Drug|Dapagliflozin + Metformin|Tablets, Oral, once daily, single dose
Dapagliflozin: 20 mg
Metformin: 1000 mg
341115|NCT00546754|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
341116|NCT00546754|Drug|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
341117|NCT00546767|Behavioral|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
341118|NCT00546767|Behavioral|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
341119|NCT00003966|Drug|defibrotide|
341120|NCT00549432|Device|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
341121|NCT00549445|Drug|Azithromycin|250 mg daily
341122|NCT00549445|Drug|Placebo|Daily
341123|NCT00549458|Behavioral|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
340415|NCT00519441|Other|pH study|All patients will have 48 hour pH study
340416|NCT00519454|Other|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
340417|NCT00003812|Drug|etoposide|
340418|NCT00519467|Drug|Chlorproguanil-dapsone-artesunate (CDA)|
340419|NCT00519480|Drug|GSK189075|
340420|NCT00519480|Drug|Metformin|
340421|NCT00519493|Procedure|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
340422|NCT00519493|Device|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
340423|NCT00519506|Other|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
340424|NCT00519519|Drug|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
340425|NCT00519532|Drug|Rotigotine|Rotigotine transdermal patches:
10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)
Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h
340426|NCT00519545|Behavioral|Prayer|Data collection on physiological biomarkers
340427|NCT00519558|Drug|somatropin|
340428|NCT00003812|Drug|paclitaxel|
340429|NCT00519571|Device|ImplantLock device|dental implant
340430|NCT00519584|Drug|Ropivacaine|40 ml 0.5%
340431|NCT00519584|Drug|Dexamethasone|8 mg (2 ml)
340432|NCT00522067|Biological|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
340433|NCT00522093|Drug|TJ-100|TJ-100 2.5g three times per day for 6 weeks
340771|NCT00513929|Dietary Supplement|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
340772|NCT00513942|Other|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
340773|NCT00003784|Drug|prednisone|
345373|NCT00479674|Drug|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
345374|NCT00479687|Device|SUPARTZ|Supartz injection into the glenohumeral joint space.
345375|NCT00479687|Device|Phosphate Buffered Saline|Saline injection into the glenohumeral joint space.
345376|NCT00479700|Drug|SAM-531|
345377|NCT00479713|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
345378|NCT00479713|Drug|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
345379|NCT00479713|Drug|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
340093|NCT00527722|Device|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
340094|NCT00527722|Other|No lung plug|Standard lung biopsy without placement of the plug.
340095|NCT00527735|Drug|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
340096|NCT00527735|Drug|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
340097|NCT00527735|Drug|Paclitaxel|175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
340098|NCT00527735|Drug|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
340099|NCT00527748|Device|Non-Measuring Ankle Exerciser (Ankle Recovery Mechanism)|Stretching exercise performed 10 times per day, for six (6) weeks.
340100|NCT00003857|Procedure|adjuvant therapy|
340101|NCT00527761|Drug|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
340102|NCT00527761|Drug|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
340103|NCT00527761|Drug|Temodar|150 mg by mouth (PO) on Days 1 - 5.
345029|NCT00488605|Drug|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
345030|NCT00488605|Drug|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
345031|NCT00488618|Drug|Cariprazine (RGH-188)|Cariprazine 3mg - 12mg oral administration, once per day.
345032|NCT00488618|Drug|Placebo|Dose-matched placebo. Oral administration, once per day.
345033|NCT00488631|Biological|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
345034|NCT00488631|Biological|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
345035|NCT00488631|Biological|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
345036|NCT00488631|Biological|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
345037|NCT00003652|Drug|fluorouracil|
345038|NCT00488644|Drug|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
345039|NCT00488644|Drug|Liothyronine|15 mcg PO Daily for 8 Weeks
345040|NCT00488657|Device|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
345041|NCT00488670|Drug|Escitalopram|See Detailed Description.
345042|NCT00491530|Drug|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
345380|NCT00003616|Drug|irinotecan hydrochloride|
344352|NCT00504842|Drug|Placebo|
344353|NCT00504855|Other|Casting using Gortex (waterproof) cast padding materials|
344354|NCT00504855|Other|Casting using cotton/cotton-poly cast padding materials|
344355|NCT00003728|Procedure|allogeneic bone marrow transplantation|
344356|NCT00504881|Drug|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
344357|NCT00504881|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
344693|NCT00496834|Drug|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
344694|NCT00496834|Drug|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
344695|NCT00496834|Drug|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
344696|NCT00496834|Drug|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
344697|NCT00496847|Drug|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
344698|NCT00496847|Drug|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
344699|NCT00496860|Biological|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
344700|NCT00496873|Drug|Cytoxan|600 mg/m^2 on Day 1 of 21-day cycle.
344701|NCT00496873|Drug|Nipent|4 mg/m^2 on Day 1 of 21 Day Cycle.
344702|NCT00496873|Drug|Rituxan|375 mg/m^2 on Day 1 of 21 Day Cycle.
344703|NCT00003685|Procedure|quality-of-life assessment|
343995|NCT00512980|Drug|gemcitabine|
343996|NCT00515268|Drug|GSK256066|
343997|NCT00515281|Drug|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
343998|NCT00515281|Drug|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
343999|NCT00515294|Drug|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
344000|NCT00515294|Drug|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
344001|NCT00003790|Other|flow cytometry|
344002|NCT00515294|Drug|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
344003|NCT00515294|Drug|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
344004|NCT00515307|Procedure|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
344005|NCT00515320|Drug|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
344006|NCT00515320|Drug|Placebo|Oral dispersible tablet placebo
344007|NCT00515333|Drug|TRx0014|Hard capsule; 60 milligrams; t.i.d.
344358|NCT00504894|Drug|Thiopental|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
344359|NCT00504894|Drug|Propofol|A low dose given intravenously while the subject is shown visually stimulating images in an MRI machine.
344360|NCT00504907|Drug|BTA9881|Single oral escalating doses
344361|NCT00504907|Drug|Placebo|
344362|NCT00504920|Behavioral|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
344363|NCT00504933|Drug|bilastine|20 mg (encapsulated) tablets QD/14days
344364|NCT00504933|Drug|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
344365|NCT00504933|Drug|Placebo|(encapsulated) Tablets QD/14 days
326147|NCT00562861|Drug|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
326472|NCT00555971|Drug|Omalizumab|aspirin desensitization will be carried out for all subjects with aspirin exacerbated respiratory disease who participate in the study, with subjects randomized 2:1 to receive either omalizumab or placebo, which will allow us to evaluate the study hypothesis
326473|NCT00555971|Drug|placebo|aspirin desensitization will be carried out for all subjects with aspirin exacerbated respiratory disease who participate in the study, with subjects randomized 2:1 to receive either omalizumab or placebo, which will allow us to evaluate the study hypothesis
326474|NCT00555984|Drug|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
326475|NCT00555984|Drug|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
326476|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
326477|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
326478|NCT00555997|Drug|Placebo|0mg Placebo per day. "Dose increases" and "dose decreases" may occur, but patient will remain at 0mg placebo
326479|NCT00004013|Drug|paclitaxel|
326480|NCT00556023|Drug|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
326481|NCT00556049|Drug|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
326482|NCT00556049|Drug|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
326483|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
326484|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
326485|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
326486|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
326487|NCT00558311|Drug|placebo|Placebo administered by continuous infusion at 5 mg/h for the duration of the treatment.
325822|NCT00567788|Drug|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
325823|NCT00567788|Drug|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
325824|NCT00570466|Behavioral|Control group|Web and DVD based knowledge games
325825|NCT00570479|Drug|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
325826|NCT00570492|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
325827|NCT00570492|Drug|Placebo nasal spray|Placebo nasal spray
325828|NCT00570505|Device|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
325829|NCT00570531|Drug|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
325830|NCT00570531|Drug|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
325831|NCT00570531|Drug|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
326148|NCT00000595|Drug|deferoxamine|
326149|NCT00004056|Procedure|peripheral blood stem cell transplantation|
326150|NCT00562861|Procedure|FDG PET scans|Two scans will be acquired in two separate PET imaging sessions, 6 weeks apart (baseline vs. end-of-acute treatment phase). The exploratory imaging component of this study will be limited to 60 individuals (30 in each arm) taking lithium as a sole mood stabilizer.
326151|NCT00562861|Procedure|MRI structural scans|MRI acquisitions will be acquired using a Siemens 3T whole body scanner (Trio) with a 60 cm diameter bore.
Anatomical imaging will be conducted for anatomic reference for precise spatial normalization of co-registered PET images for the planned functional analyses.
The exploratory imaging component of this study will be limited to 60 individuals (30 in each arm) taking lithium as a sole mood stabilizer.
326152|NCT00562861|Procedure|Genotyping|Subjects will be asked to provide a blood sample at the start of the study and after 6 weeks for the genotyping portion of the study.
326153|NCT00562861|Procedure|Blood Draw|Subjects will have their blood drawn at Tufts Medical Center at the same time as their safety labs are performed.
326154|NCT00562861|Drug|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
325471|NCT00004100|Drug|cisplatin|
325472|NCT00572741|Dietary Supplement|carnitine|Acetyl L-Carnitine Dose: 250 mg
325473|NCT00572754|Procedure|Circumcision|Circumcision by tying a ligature around the foreskin.
325474|NCT00572767|Drug|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
325475|NCT00572767|Other|Glucose|After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
The treatment of the control group will be the same as for the experimental group except the content of the drug capsule.
325476|NCT00572806|Drug|insulin aspart|
325477|NCT00004112|Biological|rituximab|
325478|NCT00575328|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks
325479|NCT00575341|Drug|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
325480|NCT00575341|Drug|placebo|placebo, oral, once daily
325481|NCT00575354|Drug|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
325482|NCT00575354|Drug|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
325483|NCT00575367|Drug|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
325484|NCT00575367|Drug|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
325485|NCT00575380|Drug|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
325486|NCT00575380|Drug|Vigamox Eye Drops|One drop three times a day for seven days
325487|NCT00575393|Drug|gold sodium thiomalate|
325488|NCT00004112|Drug|CHOP regimen|
325489|NCT00575393|Genetic|gene expression analysis|
325832|NCT00570531|Drug|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
344480|NCT00470002|Drug|Somatropin|
344481|NCT00470015|Biological|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
344482|NCT00472849|Drug|Pegfilgrastim|6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
344483|NCT00472862|Behavioral|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
344484|NCT00472875|Drug|Glibenclamide|
344485|NCT00472901|Drug|Afamelanotide (CUV1647)|16mg implant
344486|NCT00003585|Drug|isotretinoin|
344487|NCT00472914|Device|portable surface electromyography|
344488|NCT00472927|Drug|Premarin/MPA 0.45 mg/1.5 mg|
344489|NCT00472953|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
344490|NCT00472953|Drug|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
344491|NCT00472966|Drug|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
344492|NCT00473005|Drug|Capecitabine|825 mg/m2 bid, Oral
344493|NCT00473005|Drug|RAD001|2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral
344494|NCT00473018|Behavioral|standard versus enhanced risk reduction counseling|
344495|NCT00473031|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
344496|NCT00473031|Behavioral|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
344497|NCT00003585|Procedure|surgical procedure|
344498|NCT00473031|Behavioral|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
344821|NCT00463827|Drug|matched placebo|Matched placebo
344822|NCT00463840|Drug|Oxaliplatin|
344823|NCT00463840|Drug|5FU|
343777|NCT00534781|Procedure|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
343778|NCT00534794|Drug|Elestat|Elestat BID for 2 days
343779|NCT00534794|Drug|Pataday|Pataday QD for 2 days
343780|NCT00534807|Drug|Vinflunine|
343781|NCT00534807|Drug|Rifampin|
343782|NCT00534820|Procedure|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
343783|NCT00534833|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
343784|NCT00534833|Biological|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
344121|NCT00526565|Behavioral|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
344122|NCT00482235|Drug|MK0359|
344123|NCT00482248|Drug|Omalizumab|
344124|NCT00482261|Drug|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
344125|NCT00482261|Drug|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
344126|NCT00482261|Drug|aspirin|100mg/day
344127|NCT00482274|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
344128|NCT00482287|Drug|MTR105|Intravenous administration, dose escalating (4 arms), single dose
344129|NCT00482300|Procedure|Systematic pelvic lymphadenectomy|
344130|NCT00482313|Drug|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
344131|NCT00000541|Drug|vitamin C|
344132|NCT00003627|Drug|cisplatin|
343456|NCT00542360|Behavioral|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
343457|NCT00542373|Procedure|Portable Spectroscopy System|Imaging system that shines different wavelengths (colors) of light in the mouth and can collect and analyze fluorescence and reflected light.
343458|NCT00542373|Procedure|Multispectral Digital Microscope|Imaging system that takes fluorescence and reflectance pictures through a dental microscope. Different colors of light are used to shine in the mouth and pictures are taken using a digital camera.
343459|NCT00542373|Procedure|Fast Excitation-Emission Matrix System|Different colors of light are directed through fibers to the lining of the mouth and then light is collected and sent to a special camera and a computer to be analyzed.
343460|NCT00542386|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
343461|NCT00542386|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
343462|NCT00542399|Drug|Levemir (insulin detemir)|Levemir once a day
343463|NCT00542399|Drug|Levemir twice a day|Levemir twice a day
343464|NCT00542412|Drug|Riluzole|
343465|NCT00003934|Drug|arsenic trioxide|Given IV
343466|NCT00542425|Drug|teriparatide|teriparatide 20 µg subcutaneous daily
343467|NCT00542425|Drug|Placebo|Placebo subcutaneous daily
343468|NCT00542425|Drug|BA058 20 µg|BA058 20 µg subcutaneous daily
343469|NCT00542425|Drug|BA058 40 µg|BA058 40 µg subcutaneous daily
343470|NCT00542425|Drug|BA058 80 µg|BA058 80 µg subcutaneous daily
343785|NCT00003893|Drug|doxorubicin hydrochloride|
343786|NCT00534833|Biological|Oral Polio Vaccine|0.5 mL, Oral
343787|NCT00537199|Drug|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
343788|NCT00003907|Drug|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
342802|NCT00512460|Drug|RTA 744|4.8 mg/m^2 by vein Over 2 Hours On Days 1-3.
342803|NCT00003780|Drug|gemcitabine hydrochloride|
342804|NCT00512473|Drug|Saline infusion|0.9 % NaCl
342805|NCT00512473|Drug|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
342806|NCT00512473|Drug|Pegvisomant|30 mg Somavert administered at t = - 36 hours
343134|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
343135|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
343136|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
343137|NCT00003972|Drug|melphalan|
343138|NCT00550355|Drug|Placebo|3 doses of Placebo administered over 12 weeks
343139|NCT00550368|Biological|Biological intervention: Enteropathogenic E. coli|
343140|NCT00550381|Drug|HKI-357|Single-dose capsule
343141|NCT00550394|Drug|quetiapine + placebo|Dosing Schedule and Titration of Quetiapine:
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1
Dosing Schedule and Titration of Topiramate:
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.
343142|NCT00550394|Drug|Quetiapine + Topiramate|Dosing Schedule and Titration of Quetiapine:
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1
Dosing Schedule and Titration of Topiramate:
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.
343143|NCT00550407|Drug|lamotrigine|lamotrigine 100mg/day or 200mg/day
343144|NCT00550407|Drug|Placebo|placebo once daily
343145|NCT00550420|Drug|Rosiglitazone XR|experimental drug
343146|NCT00550433|Device|Bazedoxifene/Conjugated Estrogens|
343147|NCT00550446|Drug|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
343148|NCT00003972|Drug|paclitaxel|
343149|NCT00550446|Drug|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
342435|NCT00517517|Biological|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
342436|NCT00517530|Drug|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
342437|NCT00517543|Drug|GW856553|
342438|NCT00517556|Drug|Continuous Monophasic oral gestodene/ethinyl estradiol treatment|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
342439|NCT00517556|Drug|Traditional Monophasic oral gestodene/ethinyl estradiol treatment|(traditional OCP) (21 active days/7 inactive days) treatment regimen
342440|NCT00003801|Procedure|quality-of-life assessment|
342441|NCT00517569|Genetic|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
342442|NCT00517569|Drug|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
342443|NCT00517582|Drug|HOE-140|Subcutaneous at time 0 and 6 hours
342444|NCT00517582|Other|Placebo|Subcutaneous at time 0 and 6 hours
342445|NCT00517595|Drug|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m^2 and gemcitabine 1500 mg/m^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
342446|NCT00517608|Device|Laparoscopic colectomy|
342447|NCT00517621|Drug|Paclitaxel|
342448|NCT00517621|Drug|EPO|
342449|NCT00520234|Drug|Normal Saline|100 cc IV daily
342450|NCT00003815|Drug|etoposide|
342451|NCT00520247|Drug|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
342452|NCT00520260|Drug|bromfenac|0.09%, BID, 6 weeks
342807|NCT00514852|Drug|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
342808|NCT00514865|Drug|ONO-2333Ms|5-10 mg QD for 8 weeks
341780|NCT00003883|Drug|itraconazole|
341781|NCT00533897|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
341782|NCT00533897|Drug|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
341783|NCT00533910|Drug|Rifaximin|550mg BID rifaximin for 8 weeks
341784|NCT00533910|Drug|placebo|same as the experimental arm
341785|NCT00533923|Drug|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
341786|NCT00533936|Biological|trastuzumab|
341787|NCT00533936|Drug|cyclophosphamide|
341788|NCT00533936|Drug|doxorubicin hydrochloride|
341789|NCT00533936|Drug|fluorouracil|
341790|NCT00533936|Drug|paclitaxel|
341791|NCT00003884|Drug|zoledronic acid|
342104|NCT00525850|Other|high fat diet|high saturated fat no starch diet
342105|NCT00525850|Other|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
342106|NCT00003847|Drug|doxorubicin hydrochloride|
342107|NCT00525863|Drug|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to ~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
342108|NCT00525876|Drug|Cyclophosphamide|Matched Donors:
750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.
Unrelated or Mismatched Donors:
1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
342109|NCT00525876|Drug|Fludarabine|30 mg/m^2 given intravenously on Days -5 and -3 before transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
342110|NCT00525876|Drug|Rituximab|Matched Donors:
375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
Unrelated/Mismatched Donors:
375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m^2 given intravenously, then 1000 mg/m^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.
DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:
375 mg/m^2 then 1000 mg/m^2 weekly x 3 if immunomanipulation is undertaken for persistent disease.
341430|NCT00538850|Drug|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
341431|NCT00538850|Drug|Placebo|Matching placebo to fentanyl sublingual spray.
341432|NCT00538863|Drug|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
341433|NCT00541411|Drug|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
341434|NCT00541424|Procedure|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
341435|NCT00541450|Drug|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
341436|NCT00541450|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
341437|NCT00003930|Drug|cisplatin|
341438|NCT00541450|Drug|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
341439|NCT00541450|Drug|Matching placebo to pioglitazone|matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.
Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks.
341440|NCT00541450|Drug|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
341441|NCT00541450|Drug|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
341442|NCT00541463|Drug|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
341443|NCT00541463|Drug|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
341444|NCT00541489|Drug|Naproxcinod|750 mg, bid
341445|NCT00541489|Drug|Naproxen|500 mg, bid
341792|NCT00533936|Procedure|adjuvant therapy|
341793|NCT00533936|Procedure|conventional surgery|
341794|NCT00533936|Procedure|neoadjuvant therapy|
341124|NCT00549458|Procedure|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
341125|NCT00549471|Other|physiotherapy|CG children will undergo a program of intensive physiotherapy
341126|NCT00549471|Other|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
341127|NCT00549497|Drug|GW870086X|
341128|NCT00549510|Drug|COREG CR and lisinopril (FDC)|
341446|NCT00541489|Drug|Placebo|bid
341447|NCT00541515|Device|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
341448|NCT00003930|Drug|gemcitabine hydrochloride|
341449|NCT00541541|Procedure|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
341450|NCT00541554|Drug|Abilify (aripiprazole)|
341451|NCT00541567|Drug|ibipinabant|oral, tablet, once daily
341452|NCT00541593|Procedure|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
341453|NCT00541606|Other|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
341454|NCT00541606|Other|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
341455|NCT00541658|Drug|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
340774|NCT00513955|Drug|bortezomib|
340775|NCT00513955|Drug|cyclophosphamide|
340776|NCT00513955|Drug|doxorubicin hydrochloride|
340777|NCT00513955|Drug|prednisolone|
340778|NCT00513955|Drug|vincristine sulfate|
340779|NCT00513955|Other|questionnaire administration|
340780|NCT00513955|Procedure|quality-of-life assessment|
340781|NCT00513968|Genetic|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
340782|NCT00513968|Drug|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
340783|NCT00513981|Drug|leucovorin calcium|
340784|NCT00003784|Drug|vincristine sulfate|
340785|NCT00513981|Drug|methotrexate|
340786|NCT00513981|Other|mass spectrometry|
340787|NCT00513981|Other|pharmacological study|
340788|NCT00513994|Drug|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
340789|NCT00514007|Drug|OSI-906|OSI-906 administered orally
340790|NCT00514020|Drug|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
340791|NCT00514020|Drug|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
340792|NCT00514020|Drug|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
340793|NCT00514020|Genetic|gene expression analysis|Blood collection
340794|NCT00514020|Genetic|polymorphism analysis|Blood collection
340795|NCT00003784|Radiation|tositumomab and iodine I 131 tositumomab|
341129|NCT00549523|Other|Sutherlandia|Capsules containing 0 mg bid (placebo), 400 mg bid, 800 mg bid, or 1200 mg bid of L. frutescens.
341130|NCT00003967|Drug|etoposide|
340104|NCT00527787|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
340105|NCT00527787|Drug|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
340106|NCT00527800|Drug|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
340107|NCT00530296|Behavioral|Cognitive Behavioral Therapy|Group therapy, 12 sessions (90 minutes each, one session per week) manual "Coping with depression course"
340108|NCT00530309|Drug|GSK716155 for injection|
340109|NCT00530322|Procedure|Laparoscopy|A "second-look" laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy).
340110|NCT00530335|Drug|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
340111|NCT00530348|Biological|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
340434|NCT00522106|Behavioral|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
340435|NCT00522106|Other|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
340436|NCT00522132|Drug|Artesunate|intravenous application
340437|NCT00522145|Drug|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
340438|NCT00003821|Drug|aminopterin|
340439|NCT00522158|Drug|simvastatin|
340440|NCT00522158|Drug|atorvastatin|
340441|NCT00522171|Device|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
340442|NCT00522184|Procedure|intra-articular injection of etanercept|
340443|NCT00522184|Procedure|intra-articular injection of steroid|
345381|NCT00479713|Drug|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
345382|NCT00479726|Drug|duloxetine hydrochloride|
345383|NCT00479739|Drug|Salmeterol/fluticasone propionate or formoterol/budesonide|
345384|NCT00003631|Drug|cyclophosphamide|
345385|NCT00482729|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
345386|NCT00482729|Drug|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
345387|NCT00482742|Device|CiTop(TM) Guidewire|
345388|NCT00482755|Drug|sunitinib malate|
345389|NCT00482755|Other|immunohistochemistry staining method|
345390|NCT00482755|Other|laboratory biomarker analysis|
345391|NCT00482755|Other|pharmacological study|
345392|NCT00482755|Procedure|needle biopsy|
345393|NCT00482755|Procedure|neoadjuvant therapy|
345394|NCT00482768|Behavioral|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
345395|NCT00003631|Drug|cytarabine|
345396|NCT00482781|Biological|Infanrix|
345397|NCT00482781|Biological|Pediatrix|
345398|NCT00482807|Drug|bicalutamide|
345399|NCT00482807|Drug|docetaxel|
345400|NCT00482807|Drug|goserelin|
345401|NCT00482807|Radiation|intensity-modulated radiation therapy|
345402|NCT00482820|Behavioral|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
344704|NCT00496912|Drug|Peginterferon/Ribavirin|peginterferon, ribavirin, standard doses
344705|NCT00496938|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
344706|NCT00499239|Drug|GS-9219|GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.
GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days.
344707|NCT00499252|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
344708|NCT00499265|Drug|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
344709|NCT00003700|Drug|daunorubicin hydrochloride|80mg/sq m (pts<60y/o)OR 60mg/sq m (pts =/>60y/o) IV infusion over 5-10 min Days 1,2,& 3: Courses I & IV
344710|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
344711|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
345043|NCT00491530|Drug|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
345044|NCT00491530|Drug|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
345045|NCT00491530|Drug|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
345046|NCT00491543|Drug|ALT-2074|
345047|NCT00491556|Procedure|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
345048|NCT00491556|Procedure|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
345049|NCT00491569|Drug|Sarcosine and D-serine|
345050|NCT00491582|Drug|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
345051|NCT00003661|Radiation|radiation therapy|
345052|NCT00491595|Drug|High Dose Soy isoflavones|
344366|NCT00003728|Procedure|peripheral blood stem cell transplantation|
344367|NCT00504946|Drug|prednisone, lactose|Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
20mg prednisone+ 0.3mg lactose
344368|NCT00504946|Drug|prednisone, colecalciferol, lactose|Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
20mg prednisone + 1000j colecalciferol + 0.3mg lactose
344369|NCT00504946|Drug|lactose|Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
0.3mg lactose
344370|NCT00003746|Drug|2-chlorodeoxyadenosine (CDA) daily|Daily administration
344371|NCT00507338|Procedure|PCI|early PCI for NSTEMI; primary PCI for STEMI
344372|NCT00507351|Behavioral|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
344373|NCT00507364|Drug|Local injection of activated macrophages to anal fissure|
344374|NCT00507390|Dietary Supplement|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
344375|NCT00507390|Dietary Supplement|olive oil|1 capsule day
344376|NCT00507403|Drug|infliximab|
344377|NCT00507416|Drug|Bortezomib|Bortezomib bolus intravenous (IV) injection
344378|NCT00507416|Drug|Dexamethasone|Dexamethasone for oral administration
344379|NCT00507416|Drug|Melphalan|Melphalan for oral administration
344380|NCT00507416|Drug|Prednisone|Prednisone for oral administration
344381|NCT00003746|Drug|2-chlorodeoxyadenosine weekly|Weekly administration
344712|NCT00499278|Behavioral|Rehabilitation after joint replacement surgery|
344713|NCT00499291|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
344714|NCT00499291|Procedure|gene expression analysis|
344715|NCT00499291|Procedure|laboratory biomarker analysis|
344716|NCT00499291|Procedure|pharmacological study|
344717|NCT00499291|Procedure|polymerase chain reaction|
344718|NCT00499330|Procedure|lobectomy|
326488|NCT00558324|Procedure|LASIK|Mechanical microkeratome Hansatome 160 microns
326489|NCT00558324|Procedure|LASIK|Mechanical microkeratome K 3000 130 microns
326490|NCT00558324|Procedure|LASIK|Femtoseconds laser 100 microns
326491|NCT00558337|Drug|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
326815|NCT00551096|Drug|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
326816|NCT00551109|Drug|placebo|placebo, oral administration, once daily for 8 weeks
326817|NCT00551109|Drug|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
326818|NCT00551109|Drug|SA4503 High|High dose, oral administration, once daily for 8 weeks
326819|NCT00551122|Biological|filgrastim|
326820|NCT00551122|Biological|lenograstim|
326821|NCT00551122|Biological|pegfilgrastim|
326822|NCT00551122|Drug|cisplatin|
326823|NCT00003985|Drug|KRN7000|
326824|NCT00551122|Drug|gemcitabine hydrochloride|
326825|NCT00551122|Drug|ifosfamide|
326826|NCT00551122|Drug|paclitaxel|
326827|NCT00551135|Drug|Pregabalin|150 mg BID
326828|NCT00551135|Drug|placebo|Placebo
326829|NCT00551135|Drug|Pregabalin|75 mg BID
326830|NCT00551135|Drug|Pregabalin|25 mg BID
326831|NCT00551148|Drug|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
326832|NCT00551148|Drug|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
326833|NCT00551148|Drug|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
326155|NCT00562874|Dietary Supplement|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
326156|NCT00562874|Dietary Supplement|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
326157|NCT00562874|Dietary Supplement|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
326158|NCT00562887|Biological|Placebo|every 4 weeks, IV
326159|NCT00562887|Biological|ABT-874|400 mg IV every 4 weeks
326160|NCT00004057|Drug|L-778,123|
326161|NCT00562887|Biological|ABT-874|700 mg IV every 4 weeks
326162|NCT00562900|Procedure|robotic assisted cholecystectomy|robotic assisted cholecystectomy
326163|NCT00562900|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
326164|NCT00565357|Device|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
326165|NCT00565357|Other|Control|Standard care in the neonatal intensive care unit
326166|NCT00565370|Drug|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
326492|NCT00558363|Drug|Avodart|0.5 mg administered orally once daily
326493|NCT00558363|Other|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
326494|NCT00558376|Drug|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
326495|NCT00558376|Drug|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
326496|NCT00004031|Drug|doxorubicin hydrochloride|
326497|NCT00558402|Behavioral|Meditation|meditation class 1/week for 8 weeks
326498|NCT00558402|Behavioral|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
326499|NCT00558402|Behavioral|Respite only|Respite care 90 mins per week for 8 weeks
325833|NCT00570531|Radiation|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
325834|NCT00004092|Drug|carboplatin|Given IV
325835|NCT00570531|Procedure|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
325836|NCT00570544|Drug|tiotropium|18ug capsule daily for 30 days
325837|NCT00570557|Other|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
325838|NCT00570570|Procedure|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
325839|NCT00570570|Other|conventional physiotherapy|trice a week during 6 weeks
325840|NCT00570609|Other|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
325841|NCT00570622|Drug|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
325842|NCT00570622|Drug|Placebo|Patients receive placebo once a day orally for 9 days
325843|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
325844|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
325845|NCT00004092|Drug|cyclophosphamide|Given IV
325846|NCT00570648|Drug|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
325847|NCT00572819|Drug|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
325848|NCT00572819|Drug|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
325849|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
325850|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
344824|NCT00463840|Radiation|Radiation|
344825|NCT00463840|Procedure|Surgery|
344826|NCT00463840|Drug|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
344827|NCT00463853|Procedure|Autologous stem cell therapy|
344828|NCT00463853|Procedure|CABG|
344829|NCT00463853|Radiation|CMRI|
344830|NCT00463866|Drug|Budesonide/formoterol|
344831|NCT00003549|Drug|methotrexate|
344832|NCT00463879|Drug|Galantamine|
344833|NCT00463892|Procedure|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
344834|NCT00463905|Procedure|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
344835|NCT00463918|Drug|varenicline|
344836|NCT00463944|Behavioral|Effect of an electronic voting system|
344837|NCT00463957|Drug|sildenafil|
344838|NCT00467025|Drug|Sorafenib|400 mg PO BID
344839|NCT00467025|Drug|AMG 386 placebo IV|AMG 386 placebo IV
344840|NCT00467038|Behavioral|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
344841|NCT00467051|Drug|paclitaxel|Given IV dosage 135 mg/m2/dose
344842|NCT00467051|Drug|carboplatin|Given IV dosage in mg/m2 = Target AUC (mg•min/mL) x [(0.93 x GFR mL/min/m2) + 15]= 6.5 x [(0.93 x GFR mL/min/m2) + 15]. (BSA = body surface area in square meters). GFR is reported in institutions as "uncorrected" or "raw" (not normalized to BSA) or "corrected." This number needs to be converted to GFR in mL/min/m2.
344843|NCT00003567|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
344844|NCT00467051|Drug|ifosfamide|Given IV dosage 1800 mg/m2/dose
344845|NCT00467051|Biological|filgrastim|Given IV or subcutaneously dosage 1,080mg/m2/day divided to three equal doses of 360mg/m2
344133|NCT00482313|Drug|Placebo|Sugar pill
344134|NCT00482352|Other|laboratory biomarker analysis|Correlative studies
344135|NCT00482365|Other|biologic sample preservation procedure|biologic sample preservation procedure
344136|NCT00482365|Other|medical chart review|review of patients' medical records at study entry and every 6 months
344137|NCT00482365|Other|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
344138|NCT00482378|Drug|Pamidronate|90 mg by IV monthly.
344139|NCT00482378|Drug|Zoledronic acid|4 mg by IV monthly.
344140|NCT00482378|Radiation|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
344141|NCT00482391|Biological|trastuzumab|
344142|NCT00482391|Drug|cyclophosphamide|
344499|NCT00473044|Behavioral|Sisters in Motion|
344500|NCT00473057|Other|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
344501|NCT00473070|Drug|Tobradex AF|
344502|NCT00473083|Drug|minocycline; Lotion (clindamycin 2% /hydrocortisone 1%)|Subjects (Approximately 50) will be treated for the rash caused by erlotinib when it develops and the treatment will be a medicated lotion, (clindamycin 2% and hydrocortisone 1%,), applied to the rash and if the rash is more severe, minocycline 100mg orally twice daily. Scalp lesions will be treated with a topical clindamycin 2 %, triamcinolone acetonide 0.1% solution
344503|NCT00473083|Drug|minocycline|Arm 1: Subjects (approximately 50) will be given minocycline (an antibiotic pill) 100mg orally to take for 4 weeks at the same time as starting their erlotinib to see if the rash can be prevented. If rash occurs then subjects will be treated using a medicated lotion, (clindamycin 2% and hydrocortisone 1%,) to be applied to the rash and if the rash is more severe, minocycline may be continued for more than 4 weeks.
344504|NCT00473083|Drug|clindamycin 2% and hydrocortisone 1%,|Arm 3: Subjects (Approximately 50) that develop the rash caused by erlotinib will only be treated if their rash becomes severe to see if it will go away itself. The treatment for severe rash will be medicated lotion, (clindamycin 2% and hydrocortisone 1%,), applied to the rash and minocycline 100mg orally twice daily. Scalp lesions will be treated with a topical clindamycin 2 %, triamcinolone acetonide 0.1% solution.
344505|NCT00473096|Behavioral|Informed breast cancer surgical treatment|
344506|NCT00476008|Drug|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
344507|NCT00476008|Drug|Placebo|One tablet placebo morning and evening (BID) for 12 months
343789|NCT00537212|Other|The South Beach Diet|Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of "The South Beach Diet."
343790|NCT00537212|Other|The Ornish Diet|Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of "The Ornish Diet" book.
343791|NCT00537212|Other|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
343792|NCT00537225|Behavioral|exercise|tailored multifactor CVD risk reduction
343793|NCT00537238|Drug|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
343794|NCT00537238|Drug|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
343795|NCT00537251|Drug|Insulin glargine|
343796|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
343797|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
343798|NCT00537277|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
343799|NCT00003907|Drug|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
343800|NCT00537290|Drug|Rituximab|Rituximab 1000mg IV on Days 0 and 15
343801|NCT00537303|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
343802|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
343803|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
343804|NCT00537316|Biological|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
344143|NCT00003627|Drug|fluorouracil|
344144|NCT00482391|Drug|doxorubicin hydrochloride|
344145|NCT00482391|Drug|lapatinib ditosylate|
343150|NCT00550446|Drug|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
343151|NCT00550446|Drug|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
343152|NCT00550446|Drug|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
343153|NCT00550446|Drug|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
343154|NCT00550446|Drug|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
343155|NCT00550459|Drug|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
343156|NCT00550459|Drug|Placebo|Placebo tablet given once daily for 21 days
343471|NCT00542438|Behavioral|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
343472|NCT00544986|Drug|Anastrozole|
343473|NCT00544999|Drug|cytarabine|
343474|NCT00544999|Drug|daunorubicin hydrochloride|
343475|NCT00544999|Drug|everolimus|
343476|NCT00544999|Other|laboratory biomarker analysis|
343477|NCT00544999|Other|pharmacological study|
343478|NCT00545012|Drug|Levetiracetam|
343479|NCT00545025|Biological|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
343480|NCT00545025|Biological|Fluarix™|Single dose, Intramuscular injection
343481|NCT00003946|Drug|danazol|
343482|NCT00545051|Drug|Placebo|po monthly for 12 months
343483|NCT00545051|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months
343484|NCT00545064|Drug|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
343485|NCT00545077|Drug|Endocrine treatment consisting of either letrozole or fulvestrant.|The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
342809|NCT00514865|Drug|ONO-2333Ms|0 mg QD for 8 weeks
342810|NCT00514865|Drug|ONO-2333Ms|1-2 mg QD for 8 weeks
342811|NCT00514891|Biological|Vitamin A|The effect of vitamin A given with different vaccines will be studied
342812|NCT00000556|Drug|quinidine|
342813|NCT00003789|Drug|isolated limb perfusion|Undergo isolated limb perfusion
342814|NCT00514904|Biological|Meningococcal vaccine GSK134612|Single dose, intramuscular injection
342815|NCT00514904|Biological|Mencevax™|Single dose, subcutaneous injection
342816|NCT00514917|Drug|Docetaxel|75 mg/m^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
342817|NCT00514917|Drug|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
342818|NCT00514917|Drug|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
342819|NCT00514930|Device|Hexablate|
342820|NCT00514943|Drug|BIBW 2992|experimental drug taken once daily orally
342821|NCT00514943|Drug|Cetuximab|active comparator administered weekly intravenously
342822|NCT00514956|Behavioral|Emotional Freedom Techniques (EFT)|
342823|NCT00514969|Drug|Imatinib (STI571)|
342824|NCT00003789|Drug|melphalan|Given via limb perfusion
342825|NCT00514982|Drug|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
342826|NCT00514982|Drug|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
342827|NCT00514982|Drug|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
342828|NCT00514982|Drug|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
342829|NCT00514982|Drug|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
342111|NCT00525876|Drug|Alemtuzumab|Unrelated/Mismatched Donors:
15 mg per day given intravenously days 1 through 3 after transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
342112|NCT00525876|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells.
342113|NCT00528567|Drug|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
342114|NCT00528567|Drug|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
342115|NCT00528580|Drug|Simvastatin|80 mg once daily PO/NG x 4 days
342116|NCT00528580|Drug|Identical-appearing placebo|once daily x 4 days
342117|NCT00528593|Drug|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
342118|NCT00003860|Drug|carboplatin|
342119|NCT00528606|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
342120|NCT00528606|Biological|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
342453|NCT00520260|Drug|ketorolac|0.4%, BID, 6 weeks
342454|NCT00520273|Device|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
342455|NCT00520286|Drug|Modafinil|200 mg or 400 mg /daily
342456|NCT00520286|Drug|Placebo|Placebo / daily
342457|NCT00520299|Drug|ADI PEG 20|Intramuscular injection once weekly for 9 weeks.
342458|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
342459|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
342460|NCT00520338|Drug|celecoxib|placebo
celecoxib 400 mg oral single dose
342461|NCT00003815|Drug|melphalan|
342462|NCT00520351|Drug|ClearCare|contact lens care system
341795|NCT00533949|Biological|cetuximab|Given IV (arm IV closed to accrual effective 6/17/11)
341796|NCT00533949|Drug|carboplatin|Given IV over 30 minutes
341797|NCT00533949|Drug|paclitaxel|Given IV over 1 hour (arm II closed to accrual effective 6/17/11)
341798|NCT00533949|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiation therapy 5 days a week (arm II closed to accrual effective 6/17/11)
341799|NCT00533962|Drug|Anterior Juxtascleral Depot of Anecortave Acetate|
341800|NCT00533988|Device|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
341801|NCT00534001|Drug|bupropion hydrochloride|Given orally
341802|NCT00003884|Procedure|quality-of-life assessment|
341803|NCT00534001|Other|placebo|Given orally
341804|NCT00536510|Drug|laropiprant/niacin (MK0524A)|Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks
Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.
All patients will receive placebo for a 4 week run-in period before randomization
341805|NCT00536510|Drug|Comparator: placebo|Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks
Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.
All patients will receive placebo for a 4 week run-in period before randomization.
341806|NCT00536536|Behavioral|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
341807|NCT00536549|Device|Guardian RT|
341808|NCT00536549|Behavioral|Education about the self monitoring blood glucose|
341809|NCT00536562|Behavioral|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition & psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
341810|NCT00536575|Drug|Bortezomib|Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.
Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.
Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.
341811|NCT00536575|Drug|Sorafenib|Dose Levels 1 and 2: 200 mg by mouth twice daily
Dose Level 3: 400 mg by mouth twice daily
341456|NCT00544232|Drug|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF
341457|NCT00544245|Behavioral|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
341458|NCT00544258|Drug|PEP005|
341459|NCT00544271|Biological|INFANRIX|
341460|NCT00000577|Drug|Colchicine|
341461|NCT00003943|Biological|filgrastim|5 ug/kg
341462|NCT00544271|Biological|BOOSTRIX|
341463|NCT00544271|Biological|HAVRIX|
341464|NCT00544284|Drug|bortezomib|
341465|NCT00544284|Drug|temozolomide|
341466|NCT00544284|Other|pharmacological study|
341467|NCT00544297|Drug|PEP005 gel|Two day application, 0.05%
341812|NCT00003899|Procedure|autologous bone marrow transplantation|
341813|NCT00536588|Genetic|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10^9 to 3 x 10^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
341814|NCT00536601|Drug|etoposide|Given IV
341815|NCT00536601|Drug|cyclophosphamide|Given IV
341816|NCT00536601|Drug|carmustine|Given IV
341817|NCT00536601|Drug|melphalan|Given IV
341818|NCT00536601|Drug|busulfan|Given IV
341819|NCT00536601|Drug|carboplatin|Given IV
341820|NCT00536601|Drug|thiotepa|Given IV
341821|NCT00536601|Radiation|total-body irradiation|Undergo TBI
341822|NCT00536601|Procedure|autologous hematopoietic stem cell transplantation|Undergo ASCT
341131|NCT00549536|Dietary Supplement|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
341132|NCT00549549|Drug|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
341133|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
341134|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
341135|NCT00549549|Drug|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
341136|NCT00549562|Drug|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
341137|NCT00549575|Drug|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
341138|NCT00549575|Drug|Placebo|After double blind randomization, patients received a placebo.
341139|NCT00549588|Other|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
341140|NCT00508716|Behavioral|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
341141|NCT00508729|Drug|Qingyi granules|
341142|NCT00508742|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
341143|NCT00508742|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
341144|NCT00003754|Drug|thalidomide|
341145|NCT00508755|Device|Gait Robot|gait training with the use of a gait robot
341146|NCT00508755|Device|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
341147|NCT00508768|Drug|Oral SCIO-469 capsule|
341148|NCT00508781|Behavioral|Multiphoton laser image in cutaneous pathology|
341149|NCT00508794|Behavioral|Yoga Group|3 sessions of yoga each week for 6 weeks.
341150|NCT00508794|Behavioral|Stretching Control Group|3 sessions of stretching each week for 6 weeks
340444|NCT00522197|Dietary Supplement|multi-herbal agent ACAPHA|
340445|NCT00522197|Dietary Supplement|Sugar Pill|
340446|NCT00522210|Drug|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
340447|NCT00522210|Other|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
340448|NCT00522223|Behavioral|Questionnaire|Participants who are treated with radiation therapy: Questionnaires 5 times.
Participants who undergo a radical hysterectomy: Questionnaires 4 times.
340449|NCT00003822|Drug|apomine|
340450|NCT00522236|Biological|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:
A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)
A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)
B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.
The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.
A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm.
340796|NCT00514020|Genetic|protein expression analysis|Blood collection
340797|NCT00514020|Other|pharmacological study|Blood collection
340798|NCT00514033|Biological|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
340799|NCT00514046|Drug|Vandetanib|once daily continuously (28 day cycles)
340800|NCT00514059|Drug|Boostrix polio|1 dose (0.5 ml) i.m.
340801|NCT00516698|Other|high performance liquid chromatography|
340802|NCT00516698|Other|laboratory biomarker analysis|
340803|NCT00516698|Procedure|radiomammography|
340804|NCT00516711|Drug|Sevoflurane|
340805|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
340806|NCT00003798|Radiation|radiation therapy|
340807|NCT00516724|Drug|Carboplatin|intravenous injection
345403|NCT00482833|Drug|arsenic trioxide|Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.
Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28).
340112|NCT00530348|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
340113|NCT00530361|Drug|Nesiritide|
340114|NCT00530374|Dietary Supplement|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
340115|NCT00530374|Dietary Supplement|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
340116|NCT00530387|Drug|19 organic sunscreen filters and 5 topical NSAIDs|
340117|NCT00003868|Procedure|peripheral blood stem cell transplantation|
340118|NCT00530400|Drug|cefuroxime|preoperative intravenous 1.5g cefuroxime
340119|NCT00530400|Drug|placebo|preoperative intravenous placebo
340120|NCT00530413|Drug|Phenobarbital|Phenobarbital will be given based on weight range
340121|NCT00530413|Other|Placebo|Placebo group
340122|NCT00530439|Other|Lifestyle intervention|Dietician counselling and physical training
340123|NCT00530439|Other|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
340124|NCT00530439|Behavioral|Physical activity, dietetic counselling|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
340125|NCT00530452|Drug|CG100649|Dual-acting COX-2 inhibitor & carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
340126|NCT00530452|Drug|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
340127|NCT00530478|Drug|Donepezil|
340128|NCT00003868|Radiation|iodine I 131 monoclonal antibody BC8|
345053|NCT00491608|Biological|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
345054|NCT00491621|Procedure|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
345055|NCT00491634|Drug|treosulfan|12 g/m2 x 3 days
345056|NCT00491634|Drug|Treosulfan|12 g/m2 x 3
345057|NCT00491660|Behavioral|supine positioning|
345058|NCT00491660|Behavioral|lateral positioning|
345059|NCT00491673|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
345060|NCT00491673|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
345061|NCT00491686|Drug|AZD6765|intravenous infusion
345062|NCT00003662|Biological|anti-thymocyte globulin|
345404|NCT00482833|Drug|idarubicin|Induction
Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .
If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.
Consolidation
1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.
3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1.
345405|NCT00482833|Drug|mercaptopurine|Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
345406|NCT00003631|Drug|etoposide|
345407|NCT00482833|Drug|methotrexate|Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
345408|NCT00485602|Procedure|orthodontic treatment with "Rafenalign" appliance|
345409|NCT00485615|Drug|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
345410|NCT00485628|Drug|Atomoxetine Hydrochloride|
345411|NCT00485641|Device|SaeboFlex Dynamic Hand Orthosis|
345412|NCT00485641|Procedure|Saebo F.T.M. Arm Training Program|
345413|NCT00485667|Drug|SKY0402|Subects received either 300mg or 450mg
345414|NCT00485667|Drug|Moxifloxacin 400mg|
345415|NCT00485667|Drug|Placebo injection|
344719|NCT00499330|Procedure|segmentectomy or wedge resection|
344720|NCT00003700|Drug|leucovorin calcium|Courses III & VI:
25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX <0.05 uM after ea IV dose
344721|NCT00499343|Drug|Etoposide|150 mg/m^2 given intravenously over 2 hours every 12 hours x 6 doses.
344722|NCT00499343|Drug|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
344723|NCT00499343|Drug|GM-CSF|250 mcg/m^2 injection given every evening till the completion of apheresis.
344724|NCT00499343|Drug|Isophosphamide|10 g/m^2 given intravenously continuous infusion over 72 hours.
344725|NCT00499343|Drug|Rituximab|Days +1 (375 mg/m^2) and +8 (1000 mg/m^2) given intravenously.
344726|NCT00499343|Procedure|Apheresis|Peripheral blood stem cell collection.
344727|NCT00499356|Device|pressure reducing insole|
344728|NCT00499356|Device|GlideSoft®|
344729|NCT00499369|Drug|irinotecan hydrochloride|Given IV
344730|NCT00499369|Drug|leucovorin calcium|Given IV
344731|NCT00003700|Drug|mercaptopurine|60mg/sq m/d PO every day Course VII
344732|NCT00499369|Drug|fluorouracil|Given IV
344733|NCT00499369|Biological|cetuximab|Given IV
344734|NCT00499369|Biological|bevacizumab|Given IV
344735|NCT00499382|Procedure|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
344736|NCT00502099|Drug|Pegylated interferon alpha 2a|Injections: 180 ug once per week
344737|NCT00502099|Drug|Ribavirin|Tablets, 1000-1200 daily
345063|NCT00491699|Drug|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
345064|NCT00491712|Procedure|Glaucoma drainage implant with/without triamcinolone|
345065|NCT00491725|Drug|repaglinide|
326834|NCT00553488|Drug|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
326835|NCT00004004|Drug|procarbazine hydrochloride|
326836|NCT00553488|Drug|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
326837|NCT00553501|Biological|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, & 36: 360mg/sq m IV
326838|NCT00553501|Biological|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, & 36: 375mg/sq m IV
327150|NCT00586560|Drug|Kareniticin and cyclophosphamide|An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).
Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity.
327151|NCT00586573|Drug|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
327152|NCT00586586|Behavioral|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
327153|NCT00586599|Other|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
327154|NCT00586612|Biological|Menitorix™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
327155|NCT00586612|Biological|Infanrix™ penta|Intramuscular injection, 3 doses in the primary study
327156|NCT00586612|Biological|Prevenar™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
327157|NCT00586612|Biological|Infanrix™ IPV|Intramuscular injection, 1 dose in the Booster study.
327158|NCT00004171|Drug|cyclophosphamide|
327159|NCT00586625|Drug|Bepreve|One drop, both eyes, twice a day
327160|NCT00586625|Drug|Placebo|One drop, both eyes, twice a day
327161|NCT00586638|Behavioral|Video game based training|36 one-hour sessions over 12 weeks
327162|NCT00586651|Drug|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
326500|NCT00558428|Drug|fixed dose combination of telmisartan+amlodipine|
326501|NCT00558428|Drug|amlodipine|
326502|NCT00558441|Device|IVMRI|Intra Vascular Magnetic Resonance Imaging
326503|NCT00558454|Drug|Iron|Ferrous succinate mixture
326504|NCT00558467|Drug|pramipexole immediate release (IR)|
326505|NCT00558467|Drug|Placebo|
326506|NCT00558480|Drug|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
326507|NCT00004031|Drug|etoposide|
326508|NCT00558480|Drug|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
326509|NCT00558493|Drug|Clevudine|clevudine 30 mg qd for 24 seeks
326510|NCT00558506|Drug|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
326511|NCT00558519|Drug|cyclophosphamide|
326512|NCT00558519|Drug|cytarabine|
326513|NCT00558519|Drug|daunorubicin hydrochloride|
326514|NCT00558519|Drug|dexamethasone|
326515|NCT00558519|Drug|doxorubicin hydrochloride|
326516|NCT00558519|Drug|mercaptopurine|
326517|NCT00558519|Drug|methotrexate|
326518|NCT00004031|Drug|prednisone|
326839|NCT00553514|Drug|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
326840|NCT00553514|Drug|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
326841|NCT00553514|Drug|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
326167|NCT00565383|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural
326168|NCT00565383|Procedure|Intravenous fentanyl (50mcg)|Intravenous fentanyl
326169|NCT00565396|Drug|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
326170|NCT00004068|Radiation|radiation therapy|
326171|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
326172|NCT00565409|Drug|Methotrexate|Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.
If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).
326173|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
326174|NCT00565409|Drug|Methotrexate|Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.
If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).
326175|NCT00565409|Drug|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
326176|NCT00565409|Drug|Methotrexate|Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.
If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).
326177|NCT00565422|Drug|Escitalopram|10 mg/day
326178|NCT00565448|Drug|docetaxel|Pharmaceutical form:solution for infusion
Route of administration:intravenous
326179|NCT00565448|Drug|cisplatin|Pharmaceutical form:solution for infusion
Route of administration:intravenous
326180|NCT00565448|Drug|5-fluorouracil|Pharmaceutical form:solution for infusion
Route of administration:intravenous
326181|NCT00004070|Biological|interleukin-12 gene|
326182|NCT00565461|Biological|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
326183|NCT00565474|Drug|Fluvastatin|Graft vasculopathy
326184|NCT00565487|Drug|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication & will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine & Tarceva is continued daily until the completeness of the radiation or toxicity.
345175|NCT00505089|Drug|ACZ885|
345176|NCT00505089|Drug|ACZ885|
345177|NCT00505089|Drug|ACZ885|
345178|NCT00505102|Drug|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
345179|NCT00003729|Drug|idarubicin|
345180|NCT00505128|Procedure|Endoscopic sphincterotomy|procedure
345181|NCT00505154|Drug|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
345182|NCT00505154|Drug|placebo|placebo
345183|NCT00505167|Drug|Memantine|Patients randomized to receive either memantine or donepezil
345184|NCT00505167|Drug|Donepezil|Patients randomized to receive either memantine or donepezil
345185|NCT00505219|Procedure|Core decompression|Core decompression of the femoral head to remove necrotic tissue for both arms of the study with BRCs given to Treatment arm only.
345186|NCT00505219|Biological|Autologous Bone Repair Plasma|Autologous plasma
345187|NCT00505232|Drug|Y-90 Ibritumomab tiuxetan|Study Design
The present study will be split into two cohorts:
Patients younger than 60 years who will receive 8 chemotherapy cycles
Patients older than 60 years who will receive 6 chemotherapy cycles
The induction schema summarises as follows :
Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).
Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) [0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets < 100,000/µl] will be administered 8 to 12 weeks after last chemotherapy.
345188|NCT00505245|Behavioral|Survey|Surveys taking about 20 minutes to complete; collected at multiple time points for some patient populations.
345189|NCT00505258|Drug|ceftobiprole medocaril|
345190|NCT00003730|Drug|fluorouracil|
345191|NCT00505271|Genetic|Rexin-G|Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.
At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity.
345192|NCT00505284|Drug|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
344508|NCT00476021|Device|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
344509|NCT00476034|Drug|lumiracoxib|
344510|NCT00476047|Radiation|Tositumomab and Iodine I 131 Tositumomab|Give IV
344511|NCT00476047|Other|Laboratory Biomarker Analysis|Correlative studies
344512|NCT00476060|Procedure|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
344513|NCT00003597|Biological|recombinant human thrombopoietin|
344514|NCT00476073|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
344515|NCT00476086|Drug|Gemcitabine|Given intravenously on the first and third week of each 4 week cycle
344516|NCT00476086|Drug|Oxaliplatin|Given intravenously on the first and third week of each 4 week cycle
344517|NCT00476086|Radiation|Radiation|After 3 cycles of treatment with oxaliplatin and gemcitabine, radiation therapy will be given five days a week for five weeks
344518|NCT00476099|Drug|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
344846|NCT00467051|Other|laboratory biomarker analysis|Optional correlative studies
344847|NCT00467064|Behavioral|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
344848|NCT00467064|Other|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
344849|NCT00467077|Biological|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
344850|NCT00467077|Drug|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
344851|NCT00467116|Biological|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
344852|NCT00467116|Drug|gemcitabine hydrochloride|Dose Level Gemcitabine dose Gemcitabine infusion
-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes
300mg/m2 30 minutes
400mg/m2 40 minutes
344853|NCT00467116|Radiation|radiation therapy|50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.
The prescription point will be designated at the intersection of the multiple beams.
There are no planned interruptions > 3 days.
344146|NCT00482391|Drug|paclitaxel|
344147|NCT00482391|Other|laboratory biomarker analysis|
344148|NCT00482404|Behavioral|Romantic kissing|
344149|NCT00482417|Drug|MK0359|
344150|NCT00482430|Drug|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
344151|NCT00482430|Drug|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
344152|NCT00482443|Other|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
344153|NCT00000542|Drug|Inhibitors, ACE|
344154|NCT00003639|Drug|chlorambucil|
344155|NCT00485056|Drug|Pioglitazone|45mgs daily
344156|NCT00485069|Drug|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
344157|NCT00485069|Drug|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
344158|NCT00485095|Behavioral|Intake of plant sterols|
344159|NCT00485108|Drug|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
344160|NCT00485108|Drug|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
344161|NCT00485108|Drug|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
344162|NCT00485121|Drug|Ezetimibe|
344163|NCT00485134|Biological|Invaplex 50 Vaccine|
344164|NCT00485147|Procedure|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
343486|NCT00545077|Drug|Bevacizumab + Endocrine treatment consisting of either letrozole or fulvestrant.|Bevacizumab will be administered every 21 days (day 1 of cycle 2 will be day 22 of the treatment.The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. Those patients in treatment with bevacizumab who end the study without having progressed will continue to receive the drug out of the study.
343487|NCT00545090|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
343488|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
343489|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 2.4g administered Once Daily (QD)
343490|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 4.8g administered Once Daily (QD)
343491|NCT00545103|Drug|Placebo|Placebo administered Once Daily (QD)
343492|NCT00003950|Drug|cyclosporine|
343493|NCT00545116|Other|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
343805|NCT00537316|Drug|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
343806|NCT00537316|Drug|Placebo to Azathioprine|Placebo to AZA tablet orally every day
343807|NCT00537316|Drug|Placebo infusion|Placebo to IFX intravenous (IV) infusion
343808|NCT00537329|Drug|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
343809|NCT00537342|Biological|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
343810|NCT00539799|Drug|Placebo|Matched placebo to prednisolone
343811|NCT00003920|Radiation|yttrium Y 90 monoclonal antibody m170|
343812|NCT00539812|Behavioral|Standard Care|Standard 40 hour state mandated batterer intervention program
343813|NCT00539812|Behavioral|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
343814|NCT00539825|Drug|GSK704838|
343815|NCT00539838|Drug|corticosteroids|Oral repeating dose
343816|NCT00539838|Drug|immunosuppressive regime|Oral repeating dose
343817|NCT00539838|Drug|methylprednisolone|Intravenous repeating dose
342830|NCT00514982|Drug|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
343157|NCT00550472|Dietary Supplement|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
343158|NCT00550485|Drug|escitalopram|escitalopram 10 mg
343159|NCT00003972|Drug|tamoxifen citrate|
343160|NCT00509392|Device|Segmental RF ablation with the ClosureFAST catheter|radiofrequency catheter
343161|NCT00509392|Device|Endovenous Laser|laser catheter
343162|NCT00509405|Drug|potassium citrate|6 times 10 mEq per day, oral for 24 months
343163|NCT00509418|Dietary Supplement|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
343164|NCT00003760|Drug|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
343165|NCT00509418|Other|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
343166|NCT00509431|Drug|Erlotinib + Sirolimus|In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
343167|NCT00509444|Behavioral|Educational materials|
343168|NCT00509444|Behavioral|educational materials, plus patient navigation|
343169|NCT00509457|Biological|GV 1001 Telomerase peptide|
343170|NCT00509470|Drug|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
343171|NCT00509483|Radiation|Radioactive iodine|Radioactive iodine preceded by rhTSH
343172|NCT00509496|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days.
343173|NCT00509496|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenous
343174|NCT00509496|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
343175|NCT00003761|Biological|recombinant vaccinia DF3/MUC1 vaccine|
342463|NCT00520351|Drug|Optifree Replenish|contact lens care system
342464|NCT00520364|Other|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
342465|NCT00520377|Drug|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
342466|NCT00520377|Device|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
342467|NCT00520390|Drug|EZN-2208|
342468|NCT00520403|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
342469|NCT00520403|Drug|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
342470|NCT00520403|Drug|Vinblastine|0.1mg/kg iv every 3 weeks
342471|NCT00520416|Procedure|Carbon dioxide angiogram|see description of procedure
342472|NCT00000156|Procedure|Ambient Light Reduction|
342473|NCT00000556|Drug|digoxin|
342474|NCT00003815|Drug|prednisolone|
342475|NCT00522912|Procedure|Trichiasis surgery|Posterior lamella tarsal rotation
342476|NCT00522912|Procedure|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
342477|NCT00522925|Drug|PS433540|200mg capsule, once daily for 28 days
342831|NCT00514995|Drug|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
342832|NCT00517634|Drug|FP|Fluticasone Propionate 100 mcg BD
342833|NCT00517634|Drug|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
342834|NCT00003802|Drug|pyrazoloacridine|
342835|NCT00517634|Drug|Placebo|Matching Placebo
342836|NCT00517647|Drug|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
342837|NCT00517673|Drug|GSK945237|
342121|NCT00528619|Drug|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg*min/mL until progression or unacceptable toxicity.
342122|NCT00528632|Other|Specimen biopsy and serum laboratory tests|Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy
Laboratory tests measuring levels of plasma total cholesterol and triglycerides
342123|NCT00528645|Drug|saracatinib|Given orally
342124|NCT00528658|Drug|Paracetamol|1g qid
342125|NCT00528658|Drug|Ibuprofen|400mg tid
342126|NCT00528658|Drug|Paracetamol Placebo|equivalent to 1g qid
342127|NCT00528658|Drug|Ibuprofen placebo|Equivalent to 400mg tid
342128|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
342129|NCT00003860|Drug|etoposide|
342130|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
342131|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
342132|NCT00528684|Biological|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
342133|NCT00528697|Drug|ABT-089|Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
342134|NCT00528697|Drug|atomoxetine|Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
342135|NCT00528697|Drug|placebo|Subject will take a tablet once daily for 8 weeks
342136|NCT00531271|Drug|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
342137|NCT00531284|Drug|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
342138|NCT00531284|Drug|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
342139|NCT00531297|Procedure|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
341823|NCT00003899|Procedure|peripheral blood stem cell transplantation|
341824|NCT00536601|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
341825|NCT00536614|Genetic|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
341826|NCT00536627|Biological|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
341827|NCT00536640|Drug|Erlotinib|150 mg per os, given daily until tumor progression
341828|NCT00538876|Drug|decitabine|Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard "7+3" induction chemotherapy will begin.
341829|NCT00538889|Drug|Lecozotan SR|
341830|NCT00003915|Drug|bicalutamide|
341831|NCT00538889|Drug|Citalopram|
341832|NCT00538902|Biological|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
341833|NCT00538902|Biological|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
341834|NCT00538902|Biological|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
342141|NCT00531323|Drug|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
342142|NCT00531323|Drug|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
342143|NCT00003870|Radiation|radiation therapy|
342144|NCT00531336|Drug|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
342145|NCT00531336|Drug|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
342146|NCT00531349|Procedure|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
342147|NCT00531349|Drug|Sevoflurane|General anesthesia
342148|NCT00531362|Drug|Plain aspirin|Plain aspirin 75 mg or 150 mg
341151|NCT00508794|Behavioral|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
341468|NCT00544310|Biological|Anti adhesion agent|Adhesions prevention
341469|NCT00544323|Device|oral implant|
341470|NCT00544336|Other|questionnaire administration|no intervention
341471|NCT00544336|Other|survey administration|no intervention
341472|NCT00003943|Drug|carboplatin|AUC 5
341473|NCT00544336|Procedure|quality-of-life assessment|no intervention
341474|NCT00544349|Biological|cetuximab|
341475|NCT00544349|Drug|fluorouracil|
341476|NCT00544349|Drug|leucovorin calcium|
341477|NCT00544349|Drug|oxaliplatin|
341478|NCT00544362|Biological|cetuximab|
341479|NCT00544362|Drug|cisplatin|
341480|NCT00544362|Drug|fluorouracil|
341481|NCT00544362|Procedure|conventional surgery|
341482|NCT00544362|Procedure|neoadjuvant therapy|
341483|NCT00003943|Drug|cyclophosphamide|3 gm/m2
341484|NCT00544375|Device|Optical measurement|Optical measurement neonatal tissues
341485|NCT00544388|Drug|levocetirizine dihydrochloride|
341486|NCT00544401|Other|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
341487|NCT00544414|Drug|cisplatin|
341488|NCT00544414|Drug|docetaxel|
341489|NCT00546767|Behavioral|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
340808|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
340809|NCT00516724|Drug|Paclitaxel|Intravenous injection
340810|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
340811|NCT00516724|Drug|Paclitaxel + Carboplatin|Intravenous injection
340812|NCT00516737|Drug|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
340813|NCT00516737|Drug|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
340814|NCT00516750|Drug|cisplatin|
340815|NCT00516750|Drug|doxorubicin hydrochloride|
340816|NCT00516750|Drug|methotrexate|
340817|NCT00003799|Drug|fluorouracil|Given IV
340818|NCT00516750|Drug|vinblastine|
340819|NCT00516750|Genetic|gene expression profiling|
340820|NCT00516750|Procedure|neoadjuvant therapy|
340821|NCT00516802|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
340822|NCT00516802|Drug|dacarbazine|intravenous injection over at least 20 minutes
341152|NCT00508794|Other|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
341153|NCT00508807|Drug|RTA 402|5 mg by mouth (PO) daily for 21 days
341154|NCT00508820|Biological|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
341155|NCT00003755|Drug|MKC-1|
341156|NCT00508833|Biological|287615 containing HBsAg with adjuvants|
341157|NCT00508846|Behavioral|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
341158|NCT00508859|Drug|Sertraline|maintenance treatment with sertraline
341159|NCT00508859|Drug|placebo|placebo
340129|NCT00530491|Procedure|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
340130|NCT00533104|Procedure|PB-MNC preparation|Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.
Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection).
340451|NCT00522249|Drug|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
340452|NCT00525096|Drug|placebo|2 tablets twice a day per os
340453|NCT00525096|Drug|Celecoxib|2*200 mg tablets twice a day per os
340454|NCT00525096|Drug|Exemestane|Exemestane 25 mg per day per os
340455|NCT00525109|Other|No Intervention|No intervention
340456|NCT00525135|Drug|Valproic Acid|OUTLINE: This is a pilot study.
Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.
Quality of life is assessed at the end of every week through a study diary.
Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months.
340457|NCT00003843|Genetic|polymorphism analysis|
340458|NCT00525148|Drug|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
340459|NCT00525161|Drug|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
340460|NCT00525174|Device|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
340461|NCT00525174|Device|Patching|2 hours daily patching of the sound eye
340462|NCT00525174|Procedure|Near activities|one hour near visual activities
340463|NCT00525200|Drug|5-Fluoruracil, Cisplatinum|5 FU 1000mg/m2; days 1-5; 3 cycles: q21
Cisplatin 80mg/m2; day 1; 3 cycles: q21
340464|NCT00525200|Drug|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
340465|NCT00525213|Drug|Rob 803|two capsules per day during 12 weeks
340466|NCT00525213|Drug|Placebo|two capsules per day during 12 weeks
340467|NCT00525239|Drug|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
345416|NCT00485667|Drug|Placebo tablet|
345417|NCT00485680|Drug|Olanzapine Hydrochloride|
345418|NCT00003640|Procedure|surgical procedure|
345419|NCT00485680|Drug|Lithium Carbonate|
345420|NCT00485693|Drug|Bupivacaine HCl|150 mg Bupivacaine HCl
345421|NCT00485693|Drug|SKY0402|600 mg SKY0402 (study drug)
345422|NCT00485706|Procedure|high calcium dialysate|
345423|NCT00485719|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
345424|NCT00485732|Biological|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
345425|NCT00485732|Biological|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
345426|NCT00485758|Drug|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
345427|NCT00485758|Drug|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
340131|NCT00533117|Drug|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
340132|NCT00533117|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
340133|NCT00533117|Behavioral|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
340134|NCT00533130|Procedure|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
340135|NCT00533130|Procedure|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
340136|NCT00003878|Procedure|conventional surgery|
340137|NCT00533143|Other|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
340138|NCT00533156|Device|Vascular access site closure (7F Ensure)|
345066|NCT00494195|Genetic|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.
In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
345067|NCT00494195|Genetic|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
345068|NCT00494208|Drug|Testosterone|Testosterone ester
345069|NCT00494221|Drug|AZD2171|oral tablet
345070|NCT00000546|Behavioral|meditation|
345071|NCT00003671|Drug|vincristine sulfate|
345072|NCT00494221|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
345073|NCT00494221|Drug|Placebo Cediranib|oral tablet
345074|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|oral
345075|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|
345076|NCT00494247|Device|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
345077|NCT00494260|Behavioral|social learning and cognitive behavioral therapy|
345078|NCT00494273|Behavioral|Cognitive Behavioral and Standard Care with Healthy Living|
345079|NCT00494286|Behavioral|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
345080|NCT00494286|Behavioral|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
345081|NCT00494299|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
345428|NCT00485771|Drug|Olanzapine|
345429|NCT00003640|Radiation|radiation therapy|
327163|NCT00586664|Drug|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
327164|NCT00586664|Drug|placebo comparator|sterile ophthalmic solution
327165|NCT00586664|Drug|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
327166|NCT00586677|Behavioral|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
327167|NCT00586677|Behavioral|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
327488|NCT00578669|Drug|Fluoxetine|20mg once daily for 16 weeks
327489|NCT00580905|Drug|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
327490|NCT00580905|Drug|Adenosine|The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.
A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion.
327491|NCT00580918|Other|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
327492|NCT00580931|Drug|Nicotinamide|1500 mg twice a day for 6 months
327493|NCT00580931|Drug|Enduramide placebo|1 tab twice a day
327494|NCT00580944|Procedure|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
327495|NCT00004142|Procedure|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
327496|NCT00580957|Drug|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
327497|NCT00580957|Drug|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
327498|NCT00580970|Drug|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovaststin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
326842|NCT00553514|Drug|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
326843|NCT00553514|Drug|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
326844|NCT00553514|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to [=<] 3 follicles with a mean diameter of greater than or equal to [>=] 14 millimeter [mm], and one or two of these follicles with a diameter of >= 17 mm).
326845|NCT00553527|Procedure|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
326846|NCT00004005|Drug|fluorouracil|
326847|NCT00553540|Device|Back supports|The spinal supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
326848|NCT00553553|Drug|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
326849|NCT00553553|Drug|Morphine hydrochloride, remifentanil hydrochloride|Pre-induction intrathecal morphine HCl (< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram
Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure
326850|NCT00553566|Procedure|medical chart review|
326851|NCT00553566|Procedure|questionnaire administration|
326852|NCT00553566|Procedure|study of socioeconomic and demographic variables|
326853|NCT00556075|Drug|Proellex 25 mg|1 capsule daily for 4 months
326854|NCT00556075|Drug|Placebo|1 capsule daily for 4 months
326855|NCT00556075|Drug|Proellex 50 mg|2 capsules daily for 4 months
327168|NCT00589251|Other|penicillin skin test|Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.
Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique.
327169|NCT00589264|Dietary Supplement|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
326185|NCT00565500|Drug|celecoxib|celecoxib capsules 200 mg bid for 1 week
326186|NCT00565500|Drug|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
326519|NCT00560729|Dietary Supplement|Generique + Renutryl 500|
326520|NCT00560742|Procedure|Control|Coronary artery bypass grafting without bone marrow cells injection
326521|NCT00560742|Procedure|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
326522|NCT00560742|Procedure|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
326523|NCT00004047|Drug|exatecan mesylate|
326524|NCT00560755|Biological|ProQuad® manufactured with rHA|Measles-Mumps-Rubella-Varicella live vaccine
326525|NCT00560768|Device|Ovatio VR 6250 or DR6550|The study requires the implantation of locally approved material:
A right ventricular defibrillation lead
In case of use of a dual chamber ICD a right atrial pacing lead
A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.
Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar.
326526|NCT00560781|Drug|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
326527|NCT00560794|Biological|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
326528|NCT00560807|Procedure|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
326529|NCT00560820|Drug|Deferasirox|30 mg/kg/day
326530|NCT00560833|Drug|esmirtazapine|
326531|NCT00560833|Drug|Placebo|
326532|NCT00560846|Dietary Supplement|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
326533|NCT00560846|Dietary Supplement|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
326534|NCT00004048|Biological|filgrastim|
345193|NCT00505284|Drug|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
345194|NCT00413517|Procedure|Epi-Lasik|A vision correcting surgery
339906|NCT00508352|Procedure|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
339907|NCT00508365|Drug|carvedilol CR + lisinopril|
339908|NCT00508378|Behavioral|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
339909|NCT00508378|Behavioral|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
339910|NCT00508391|Device|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
339911|NCT00508404|Drug|Panitumumab|Administered by intravenous infusion
339912|NCT00508404|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
339913|NCT00003753|Drug|floxuridine|
339914|NCT00508430|Drug|ASP8825|oral
339915|NCT00508430|Drug|Placebo|oral
339916|NCT00508443|Radiation|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
339917|NCT00510822|Drug|Placebo|tablet
339918|NCT00510835|Procedure|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
339919|NCT00510835|Procedure|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
339920|NCT00510835|Procedure|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
339921|NCT00510848|Procedure|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
339922|NCT00510848|Procedure|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
339923|NCT00510874|Biological|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
344854|NCT00003567|Biological|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
344855|NCT00467129|Genetic|microarray analysis|
344856|NCT00467129|Genetic|mutation analysis|
344857|NCT00467129|Genetic|polymerase chain reaction|
344858|NCT00467129|Genetic|polymorphism analysis|
344859|NCT00467129|Other|laboratory biomarker analysis|
344860|NCT00467129|Other|questionnaire administration|
344861|NCT00467142|Biological|bevacizumab|
344862|NCT00467142|Drug|fluorouracil|
344863|NCT00467142|Drug|irinotecan hydrochloride|
344864|NCT00470015|Biological|IL-2|0.5x10^6/m^2
344865|NCT00470015|Biological|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
344866|NCT00003577|Drug|CMF regimen|
344867|NCT00470015|Biological|GM-CSF|300mcg
344868|NCT00470015|Biological|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
344869|NCT00470028|Device|Transcranial Magnetic Stimulation|
345195|NCT00413530|Drug|Pomegranate Juice|Subjects will orally receive 8 ounces of pomegranate liquid extract (equivalent to 1.6 mmol of total polyphenols per day) or matching placebo daily.
345196|NCT00413530|Other|Placebo|Subjects will orally receive 8 ounces of placebo liquid daily.
345197|NCT00413530|Behavioral|Questionnaire|Food-frequency questionnaires and quality of life questionnaires will be administered before and during the study.
345198|NCT00003311|Biological|filgrastim|
345199|NCT00413543|Other|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
345200|NCT00413556|Biological|ALK Grass tablet|
345201|NCT00413569|Procedure|cervical spine surgery|
344519|NCT00476099|Drug|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
344520|NCT00476099|Drug|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
344521|NCT00476112|Drug|Vernakalant Injection 20 mg/mL|
344522|NCT00476125|Behavioral|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
344523|NCT00476125|Behavioral|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
344524|NCT00003597|Drug|carboplatin|
344525|NCT00476125|Behavioral|16 Hour Fast|Subjects will fast for 16 hours.
344526|NCT00476138|Drug|Epigallocatechin-gallate|
344527|NCT00476151|Drug|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
344528|NCT00476151|Drug|placebo cream|inactive placebo cream applied two times daily
344529|NCT00476164|Drug|Rituximab|2 doses of 1g 14 days apart
344530|NCT00476164|Other|Control arm|Continue of optimised oral immunosuppression
344531|NCT00476177|Biological|Infusion of donor dendritic cells|Given in the outpatient setting
344532|NCT00476177|Biological|Infusion of donor lymphocytes|Given in outpatient setting
344533|NCT00476190|Drug|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
344534|NCT00479193|Drug|Polymem|single layer of polymen, change every 3 days
344535|NCT00479206|Drug|Artesunate|
344536|NCT00479219|Drug|GSI-953|
344537|NCT00479219|Other|Placebo|
344538|NCT00000539|Drug|vitamin C|
344539|NCT00003612|Drug|paclitaxel|
344540|NCT00479232|Drug|vorinostat|
344541|NCT00479232|Drug|decitabine|
343818|NCT00539838|Drug|ocrelizumab|Intravenous repeating dose
343819|NCT00539838|Drug|placebo|Intravenous repeating dose
343820|NCT00539864|Biological|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
343821|NCT00539864|Biological|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
343822|NCT00000574|Drug|ibuprofen|
343823|NCT00003923|Drug|porfimer sodium|
343824|NCT00539877|Drug|irinotecan|Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.
If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment.
343825|NCT00539890|Drug|Technosphere Insulin|
343826|NCT00539903|Behavioral|Physical activity (PA) and immigrants|
343827|NCT00539916|Behavioral|Regular orange juice consumption|600 mL /day.
343828|NCT00539929|Drug|E6201|Cream, twice daily.
344165|NCT00003639|Drug|dexamethasone|
344166|NCT00485160|Drug|Continuous indomethacin|
344167|NCT00485160|Drug|ibuprofen|
344168|NCT00485173|Device|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
344169|NCT00485199|Procedure|Pneumatic Retinopexy|
344170|NCT00485199|Procedure|Vitrectomy with Gas|
344171|NCT00485212|Device|compression bandage|
344172|NCT00485225|Drug|EN3270|Transdermal Therapeutic System
344173|NCT00485238|Procedure|Argon laser Iridoplasty|
344174|NCT00485238|Drug|Intravenous acetazolamide|
344175|NCT00485251|Procedure|hand-assisted laparoscopic right hemicolectomy|using the lap disc that allows the insertion of single and into the abdomen for operation
344176|NCT00003639|Drug|idarubicin|
343176|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL .
The cells are infused intravenously over 20-30 minutes.
343177|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered PBL.
The cells are infused intravenously over 20-30 minutes.
343494|NCT00545129|Drug|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
343495|NCT00545129|Drug|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
343496|NCT00545142|Drug|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
343497|NCT00545142|Drug|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
343498|NCT00545168|Drug|Spinosad|10 minute topical application of product, followed by a complete rinse off.
343499|NCT00547547|Dietary Supplement|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
343500|NCT00547547|Drug|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
343501|NCT00547547|Drug|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
343502|NCT00547560|Drug|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
343503|NCT00547573|Drug|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
343504|NCT00547573|Drug|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
343505|NCT00547573|Drug|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
343506|NCT00547586|Drug|N-methylnaltrexone bromide (MOA-728)|Oral
343507|NCT00547586|Other|placebo|placebo
343508|NCT00547599|Drug|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
343509|NCT00003957|Drug|mitoxantrone hydrochloride|
342838|NCT00517673|Drug|Sugar Pill|Placebo
342839|NCT00517686|Other|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
342840|NCT00517699|Drug|rituximab [MabThera/Rituxan]|750mg/m2 iv
342841|NCT00517699|Drug|Methotrexate|8g/m2 iv
342842|NCT00517699|Drug|Cytarabine|2g/m2 iv
342843|NCT00517712|Drug|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
342844|NCT00517725|Drug|carvedilol|
342845|NCT00003803|Drug|cisplatin|
342846|NCT00517725|Drug|bisoprolol|
342847|NCT00517725|Drug|Nebivolol|
342848|NCT00517738|Other|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
342849|NCT00517738|Other|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
342850|NCT00517751|Device|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
342851|NCT00517764|Drug|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
342852|NCT00517777|Device|continuous positive airway pressure ventilation|nighttime
343178|NCT00509535|Drug|vitreoscilla filiformis cream|
343179|NCT00509548|Drug|TG100801|Eye drop, twice a day, 30 days.
343180|NCT00509561|Biological|cetuximab|
343181|NCT00509561|Drug|capecitabine|
343182|NCT00509561|Drug|cisplatin|
343183|NCT00509561|Radiation|radiation therapy|
343184|NCT00509587|Drug|pazopanib hydrochloride|Given orally
342140|NCT00531310|Drug|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
342478|NCT00522925|Drug|placebo|placebo capsule, once daily for 28 days
342479|NCT00522925|Drug|PS433540|500mg capsule, once daily for 28 days
342480|NCT00522938|Drug|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
342481|NCT00522938|Drug|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
342482|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
342483|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
342484|NCT00003829|Drug|cyclophosphamide|
342485|NCT00522951|Drug|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
342486|NCT00522964|Behavioral|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
342487|NCT00522990|Drug|AT9283|Three weekly intravenous administration of AT9283
342488|NCT00523003|Dietary Supplement|high protein|2.2 g protein/kg of LBM per day
342489|NCT00523003|Dietary Supplement|standard protein|1.1 g protein/kg LBM/day standard protein diet
342490|NCT00523016|Procedure|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
342491|NCT00523016|Procedure|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
342492|NCT00523029|Behavioral|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
342493|NCT00523042|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
342149|NCT00531375|Device|Silicone hydrogel contact lens|
342150|NCT00531401|Drug|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
342151|NCT00531427|Drug|Buprenorphine|transdermal system 10 and 20 applied for 7-day wear
342152|NCT00531427|Drug|Placebo|transdermal system (placebo) applied for 7-day wear
342153|NCT00531440|Drug|Everolimus (RAD001)|
342154|NCT00003871|Biological|fowlpox virus vaccine vector|
342155|NCT00531453|Drug|bortezomib, dexamethasone, and thalidomide|VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)
Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.
Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).
342156|NCT00531453|Drug|bortezomib, dexamethasone, thalidomide, and cyclophosphamide|VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).
Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.
Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).
Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles.
342157|NCT00531466|Drug|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
342158|NCT00534014|Dietary Supplement|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
342159|NCT00534027|Drug|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
342496|NCT00523055|Drug|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
342497|NCT00525889|Drug|IL-2|administered by subcutaneous injection at a dose of 4.5x106 IU/day, three times weekly for 28 days starting on day 0
342498|NCT00525889|Drug|sirolimus|administered orally, initial daily dose of 2mg PO. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml
342499|NCT00525902|Drug|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
342500|NCT00525915|Drug|5-Fluorouracil|Arm A = 250 mg/m^2 IV over 24 hours for 5 days weekly for 5 weeks.
Arm B = 2.2 mg/m^2 IV over 48 hours on days 1 and 15.
342501|NCT00000559|Drug|estradiol|
342502|NCT00003847|Drug|vincristine sulfate|
341490|NCT00546767|Behavioral|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
341491|NCT00546780|Drug|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
341492|NCT00546780|Drug|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
341493|NCT00003955|Drug|cyclophosphamide|
341835|NCT00538915|Biological|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% [Immune Globulin Intravenous (Human), 10%] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
341836|NCT00538928|Other|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
341837|NCT00538941|Dietary Supplement|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
341838|NCT00538941|Dietary Supplement|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
341839|NCT00538954|Drug|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
341840|NCT00538954|Dietary Supplement|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
341841|NCT00003915|Drug|docetaxel|
341842|NCT00538954|Other|Standard ERAS group|
341843|NCT00538967|Drug|doxycycline|2 weeks once daily
341844|NCT00538980|Drug|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
341845|NCT00538993|Behavioral|Stage based counseling|
341846|NCT00539006|Drug|FPNS|fluticasone propionate nasal spray
341847|NCT00539006|Drug|FFNS|fluticasone furoate nasal spray
341848|NCT00539006|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
341849|NCT00539006|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
341160|NCT00508872|Drug|5-Fluorouracil|400 mg/m^2 IV over 15 minutes, followed by 2400 mg/m^2 IV Over 46 Hours
341161|NCT00508872|Drug|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
341162|NCT00508872|Drug|Leucovorin|400 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
341163|NCT00508872|Drug|Oxaliplatin|85 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
341164|NCT00508885|Drug|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
341165|NCT00508885|Drug|Placebo|Placebo
341166|NCT00003757|Biological|rituximab|
341167|NCT00508898|Drug|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
341168|NCT00511420|Dietary Supplement|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
341169|NCT00511420|Dietary Supplement|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
341170|NCT00511433|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28
for 6 consecutive 28-day menstrual cycles.
341171|NCT00511433|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
341172|NCT00511446|Drug|docetaxel, oxaliplatin, capecitabine|Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.
341173|NCT00511459|Drug|AMG 386 Placebo|AMG 386 Placebo [blinded]
341494|NCT00546793|Biological|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
341495|NCT00546806|Other|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
341496|NCT00546819|Biological|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
341497|NCT00546819|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
341498|NCT00546832|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
341499|NCT00546832|Drug|celecoxib|
340468|NCT00000559|Drug|hormone replacement therapy|
340469|NCT00003846|Biological|filgrastim|
340470|NCT00525252|Drug|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
340471|NCT00525252|Drug|placebo|Placebo will be orally administered for 12 consecutive weeks
340472|NCT00525265|Drug|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
340823|NCT00516828|Drug|cytarabine|subcutaneously twice daily from Day 1 to 10
340824|NCT00516841|Drug|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
340825|NCT00516854|Drug|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
340826|NCT00516867|Radiation|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
340827|NCT00516867|Radiation|UV radiation|UVB 1.4 % and UVA 98.6
340828|NCT00003799|Drug|oxaliplatin|Given IV
340829|NCT00516880|Drug|rosiglitazone|
340830|NCT00516893|Biological|BG00002-E (natalizumab high titer)|
340831|NCT00516906|Drug|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
340832|NCT00516906|Drug|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
340833|NCT00519584|Drug|placebo|0.9% saline; systemic and local
340834|NCT00519597|Device|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
340835|NCT00519610|Other|Chart Review|Patients' charts will be reviewed for relevant medical information.
340836|NCT00519623|Other|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
340837|NCT00519636|Drug|FPNS|fluticasone propionate nasal spray
340838|NCT00519636|Drug|FFNS|fluticasone furoate nasal spray
340839|NCT00519636|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
340139|NCT00533169|Drug|ZD6474|Part A = Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m^2 by mouth daily on days 2-28.
340140|NCT00533169|Drug|Retinoic Acid|Part B, C = 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
340141|NCT00533195|Drug|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
340142|NCT00533195|Device|UVA1 phototherapy|Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.
No maintenance therapy except emollients.
340143|NCT00533208|Drug|MK0524|
340144|NCT00533221|Drug|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
340145|NCT00533221|Drug|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
340146|NCT00533234|Device|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
340147|NCT00003880|Biological|recombinant adenovirus-p53 SCH-58500|
340148|NCT00533247|Drug|Celecoxib|
340149|NCT00533273|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
340150|NCT00533286|Drug|benzodiacepine|diazepam (2 x 5 mg/ die)
340473|NCT00525265|Drug|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
340474|NCT00525278|Drug|Levocetirizine dihydrochloride|
340475|NCT00525291|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
340476|NCT00527800|Drug|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
340477|NCT00527800|Drug|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
340478|NCT00527813|Procedure|prone position|prone position for at least 16 hours per day
345430|NCT00485771|Drug|Fluoxetine|
345431|NCT00485771|Drug|Lamotrigine|
345432|NCT00485784|Other|Blood test|Blood test
345433|NCT00485797|Drug|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
345434|NCT00485810|Drug|Olanzapine Hydrochloride|
345435|NCT00485823|Drug|Olanzapine Hydrochloride|
345436|NCT00485823|Procedure|Weight Management Program|
345437|NCT00485836|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
345438|NCT00485836|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
345439|NCT00488683|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
345440|NCT00488683|Biological|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
345441|NCT00488683|Biological|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
345442|NCT00488683|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
345443|NCT00488683|Biological|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
345444|NCT00488696|Device|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
345445|NCT00003652|Procedure|neoadjuvant therapy|
345446|NCT00488709|Drug|Topotecan|
345447|NCT00488709|Drug|Fludarabine|
345448|NCT00488709|Drug|Cytarabine|
345449|NCT00488722|Drug|Zoladex|
345450|NCT00488735|Behavioral|Cognitive-behavioral rehabilitation|
327499|NCT00580983|Radiation|IMRT|
327500|NCT00580983|Drug|Paclitaxel|
327501|NCT00580983|Drug|Carboplatin|
327502|NCT00580983|Drug|Cisplatin|
327503|NCT00580983|Drug|5-Fluorouracil|
327504|NCT00580996|Other|water high dose|water 16 oz PO x 1
327505|NCT00580996|Other|water tiny dose|water 1 oz PO x 1
327506|NCT00004142|Procedure|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
327827|NCT00573794|Biological|adalimumab|Prefilled syringes 40 mg EOW subcutaneous and prefilled syringes 40 mg weekly subcutaneous
327828|NCT00573807|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
327829|NCT00573820|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
327830|NCT00573833|Other|questionnaire administration|
327831|NCT00573833|Procedure|quality-of-life assessment|
327832|NCT00573833|Radiation|brachytherapy|
327833|NCT00573859|Drug|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
327834|NCT00576394|Drug|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
327835|NCT00576394|Drug|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
327836|NCT00576407|Biological|Thymus Tissue for Transplantation|Thymus transplantation is done using allogeneic cultured postnatal tissue from unrelated donors. Thymus tissue, the donor, & donor's mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were transplanted into the recipient's quadriceps. Dose is number of grams of transplanted tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of transplantation, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-transplant, subjects followed by routine research immune evaluations, using blood samples for 2 years.
327837|NCT00004122|Biological|BCG vaccine|
327170|NCT00589264|Dietary Supplement|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
327171|NCT00589277|Behavioral|"Yale coaching"|Novel messages for quitting smoking
327172|NCT00589277|Behavioral|Standard care|Standard messages for quitting smoking
327173|NCT00589290|Drug|Belinostat (PDX101)|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
327174|NCT00589303|Drug|FDA approved rate and rhythm control drugs|Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.
Rate Control:
Beta-Blocker:
metoprolol
atenolol
carvedilol
Calcium Channel Blocker:
verapamil
diltiazem
Rhythm Control:
procainamide
quinidine
disopyramide
propafenone
flecainide
sotalol
dofetilide
amiodarone
327175|NCT00589303|Device|AV Node ablation and device implant|Pacing Systems:
Enpusle Premarket Approval Number (PMA#) P980035
EnRhythm PMA# P980035
Adapta PMA# P980035
Cardiac Resynchronization Therapy (CRT) Pacing Systems:
- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031
Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:
EnTrust PMA# P980016
Virtuoso PMA# P980016
ICD CRT Pacing Systems:
InSync Maximo PMA# P980016
InSync Sentry PMA# P890003
Concerto PMA# P980016
327176|NCT00589316|Procedure|Allogeneic Bone Marrow Transplantation|Given via central line
327177|NCT00004179|Biological|rituximab|
327178|NCT00589316|Drug|Cyclophosphamide|Given IV
327179|NCT00589316|Drug|Fludarabine Phosphate|Given IV
327180|NCT00589316|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
327181|NCT00589316|Other|Laboratory Biomarker Analysis|Correlative studies
327182|NCT00589316|Drug|Mycophenolate Mofetil|Given IV or PO
327183|NCT00589316|Drug|Tacrolimus|Given IV or PO
327184|NCT00589316|Radiation|Total-Body Irradiation|Undergo TBI
327185|NCT00589329|Drug|erythromycin and metronidazole (antibiotics)|Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days
327186|NCT00589329|Drug|placebo|IV and pill placebo
327507|NCT00581009|Other|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
326535|NCT00560859|Procedure|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
326536|NCT00560859|Other|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
326537|NCT00560872|Device|remote magnetic catheter navigation|use of the Stereotaxis system
326538|NCT00560872|Procedure|cavotricuspid isthmus ablation|conventional (manual) approach
326856|NCT00004014|Drug|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
326857|NCT00556088|Drug|LBH589, Paclitaxel, Carboplatin, Bevacizumab|LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.
Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer.
326858|NCT00556101|Procedure|Whole body magnetic resonance angiography|
326859|NCT00556114|Device|Optical Coherence Tomography|Optical Coherence Tomography
326860|NCT00556127|Drug|Rituximab|375 mg/m2 on day 1
326861|NCT00556127|Drug|Epirubicin|110 mg/m2 on day 3
326862|NCT00556127|Drug|Cyclophosphamide|1200 mg/m2 on day 3
326863|NCT00556127|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
326864|NCT00556127|Drug|Prednisone|40 mg/m2 from day 1 to 5
326865|NCT00556127|Drug|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
326866|NCT00556127|Drug|Mitoxantrone|8 mg/m2 for 3-day
326867|NCT00004015|Drug|sodium borocaptate|
326868|NCT00556127|Drug|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
326869|NCT00556127|Drug|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
326870|NCT00556127|Drug|Carmustine BCNU|300 mg/m2 on day -7
326871|NCT00556127|Drug|Etoposide|100 mg/m2/12 hours
326872|NCT00556127|Drug|Melphalan|140 mg/m2 on day -2
339924|NCT00003776|Biological|filgrastim|
339925|NCT00510874|Biological|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
339926|NCT00510887|Drug|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
339927|NCT00510887|Drug|Rituximab|Rituximab 375 mg/m2 IV on day 1
340262|NCT00546299|Drug|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
340263|NCT00003954|Drug|cyclosporine|Given IV and PO
340264|NCT00546312|Device|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
340265|NCT00546325|Drug|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
340266|NCT00546325|Drug|Placebo|Matching placebo tablets. Once daily before breakfast
340267|NCT00546351|Drug|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
340268|NCT00546364|Drug|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
340269|NCT00546364|Drug|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
340270|NCT00546364|Drug|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
340271|NCT00546377|Biological|filgrastim|
340272|NCT00546377|Biological|pegfilgrastim|
340273|NCT00546377|Biological|rituximab|
340274|NCT00003954|Drug|mycophenolate mofetil|Given PO
340275|NCT00546377|Biological|sargramostim|
340276|NCT00546377|Drug|cyclophosphamide|
340277|NCT00546377|Drug|mitoxantrone hydrochloride|
345202|NCT00413582|Drug|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
345203|NCT00413582|Drug|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are > 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of > 4/10 throughout the duration of PCA use.
345204|NCT00413595|Other|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
345205|NCT00413608|Drug|Clopidogrel|Clopidogrel
345206|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; patients will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the patient specific anagrelide dose will be administered from a controlled study specific supply.
345207|NCT00413647|Drug|CardioPET|
345208|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
345209|NCT00003311|Drug|cyclophosphamide|
345210|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
345211|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
345212|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
345213|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
339928|NCT00510887|Drug|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
339929|NCT00510887|Drug|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
339930|NCT00510887|Drug|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
339931|NCT00510913|Drug|tacrolimus|
339932|NCT00510926|Drug|Imatinib Mesilate (Glivec)|
339933|NCT00510939|Drug|Tipifarnib plus Bortezomib|
344542|NCT00479245|Other|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
344543|NCT00479258|Drug|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
344870|NCT00470041|Drug|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
344871|NCT00470054|Drug|dasatinib|Given PO
344872|NCT00470067|Drug|carboplatin|IV
344873|NCT00470067|Drug|pegylated liposomal doxorubicin hydrochloride|IV
344874|NCT00470080|Procedure|venepuncture|venepuncture
344875|NCT00470093|Biological|recombinant interferon alfa|
344876|NCT00470093|Biological|recombinant interleukin-6|
344877|NCT00003577|Drug|cyclophosphamide|
344878|NCT00470106|Behavioral|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
344879|NCT00470106|Behavioral|Social Cognitive remediation|Group training on emotion perception, social perception, and understanding others' mental states.
344880|NCT00470106|Behavioral|Combined cognitive and social cognitive remediation|A combination of the two groups listed above.
344881|NCT00470106|Behavioral|Social skills training|Skills training in how to identify symptoms of illness and medication side effects.
344882|NCT00470119|Behavioral|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
344883|NCT00470119|Behavioral|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
344884|NCT00470145|Drug|SB-568859|
344885|NCT00470158|Dietary Supplement|iron and zinc combined|Children >= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
344886|NCT00470158|Dietary Supplement|iron and zinc on separate days|Children >= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
344177|NCT00485251|Procedure|total laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
344178|NCT00485251|Procedure|hand-assisted right hemicolectomy|hand-assisted right hemicolectomy
344179|NCT00000542|Drug|chlorthalidone|
344180|NCT00003650|Drug|mitoxantrone hydrochloride|
344181|NCT00488176|Drug|cetirizine|cetirizine
344182|NCT00488176|Drug|montelukast and cetirizine|montelukast and cetirizine
344183|NCT00488176|Drug|placebo|placebo
344184|NCT00488189|Drug|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
344185|NCT00488215|Drug|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
344186|NCT00488215|Other|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
344187|NCT00488228|Behavioral|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
344188|NCT00488241|Device|Zarzenda|Topically applied daily for 2 weeks
344544|NCT00479258|Drug|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
344545|NCT00479271|Behavioral|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
344546|NCT00479271|Behavioral|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
344547|NCT00479284|Procedure|Average volume assured pressure support (AVAPS)|
344548|NCT00479297|Drug|SAM-531|
344549|NCT00479310|Drug|Summers 5% L.A.|
344550|NCT00003613|Drug|O6-benzylguanine|Given IV
344551|NCT00479323|Biological|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
343510|NCT00547612|Other|high performance liquid chromatography|
343511|NCT00547612|Other|pharmacological study|
343512|NCT00547612|Radiation|[18F]-labeled substance P antagonist receptor quantifier|
343513|NCT00547625|Drug|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
343514|NCT00547625|Drug|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
343829|NCT00539929|Drug|E6201|Cream, twice daily.
343830|NCT00539929|Drug|E6201|Cream, twice daily.
343831|NCT00539929|Drug|E6201|Cream, once daily.
343832|NCT00539942|Drug|Fondaparinux sodium|Treatment will consist of daily injections of pharmacy prepared syringes of fondaparinux sodium 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
343833|NCT00539955|Behavioral|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
343834|NCT00003924|Biological|recombinant interferon alfa|
343835|NCT00539955|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
343836|NCT00539968|Drug|Docetaxel plus lonafarnib|Docetaxel: 60-75 mg/m2
Lonafarnib: 150-375 mg PO BID
343837|NCT00539981|Biological|Influenza Vaccine, recombinant hemagglutinin, FluBlok|0.5mL dose for IM injection
343838|NCT00539994|Drug|retapamulin|200mg BID retapamulin 3 days
343839|NCT00542438|Behavioral|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
343840|NCT00542451|Drug|Paclitaxel|Every week for 12 weeks
343841|NCT00542451|Drug|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
343842|NCT00542464|Biological|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
343843|NCT00003935|Drug|etoposide|
343185|NCT00509587|Procedure|pharmacological study|Correlative studies
343186|NCT00512486|Biological|MEDI-563|BIW-8405/MEDI-563 administered at one of five dose levels:
0.03 mg/kg intravenous injection
0.1 mg/kg intravenous injection
0.3 mg/kg intravenous injection
1.0 mg/kg intravenous injection
3.0 mg/kg intravenous injection
Following the -3.0 mg/kg dose level,
BIW-8405/MEDI-563 administered at one of two lower dose levels:
0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection
343187|NCT00512499|Behavioral|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
343188|NCT00512499|Behavioral|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
343189|NCT00512499|Behavioral|Intensive Intervention|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)
343190|NCT00512512|Procedure|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
343191|NCT00512525|Drug|Ghrelin and saline (as placebo)|Intravenous infusion
343192|NCT00512538|Device|Bi-layered cell therapy (Apligraf)|
343193|NCT00003781|Drug|docetaxel|
343194|NCT00512551|Procedure|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
343195|NCT00512564|Other|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
343196|NCT00512577|Other|Red cell blood transfusion|
343515|NCT00547638|Device|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
343516|NCT00547638|Device|cyanoacrylate|Topical Skin Adhesive
343517|NCT00547651|Drug|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
342494|NCT00523042|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
342495|NCT00003829|Drug|fludarabine phosphate|
342853|NCT00517777|Behavioral|dietary and life style recommendations|
342854|NCT00517777|Behavioral|dietary and life style recommendations|
342855|NCT00517790|Drug|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
342856|NCT00003803|Drug|gemcitabine hydrochloride|
342857|NCT00517790|Drug|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
342858|NCT00520429|Behavioral|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
342859|NCT00520442|Drug|ibuprofen|
342860|NCT00520442|Drug|acetamin w codeine|
342861|NCT00520455|Drug|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
342862|NCT00520468|Drug|Erythropoietin|40,000 units injected under the skin (SQ) weekly
342863|NCT00520468|Drug|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
342864|NCT00520468|Drug|G-CSF|300 mcg injected under the skin (SQ) two times per week
342865|NCT00520468|Drug|Prednisone|60 mg per day for 7 days, taper over 1 month
342866|NCT00520481|Drug|IMC-A12 (Cixutumumab)|10 mg/kg intravenous (i.v.)infusion over 1 hour every 2 weeks or 20 mg/kg I.V. infusion over 1 hour every 3 weeks.
342867|NCT00520494|Drug|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
342868|NCT00003815|Drug|vincristine sulfate|
342503|NCT00525915|Drug|Oxaliplatin|Arm A: 40 mg/m^2 IV daily over 2 hours for 5 weeks
Arm B: 100 mg/m^2 IV on Day 1 and 15
342504|NCT00525915|Radiation|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
342505|NCT00525915|Procedure|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
342506|NCT00525928|Drug|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
342507|NCT00525941|Drug|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
342508|NCT00525954|Drug|A-002|
342509|NCT00525967|Drug|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
342510|NCT00525980|Behavioral|Computer Program|Participants will be given a program to learn about breast cancer risk and genetic testing.
Arm 3 Only = Participants will use the program with the assistance of a promotora (female "promoter," community health worker, sometimes known as a lay health advisor).
342511|NCT00525980|Behavioral|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
342512|NCT00525980|Other|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
342513|NCT00003849|Biological|rituximab|
342514|NCT00525980|Behavioral|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
342515|NCT00525993|Drug|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
342516|NCT00525993|Drug|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
342517|NCT00526006|Drug|esomeprazole|40 mg od for 8 wks
342872|NCT00520533|Drug|Sunitinib malate|First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.
Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.
Up to 2 cycles available on-study.
341850|NCT00539019|Other|calories measured 5x following wound healing|measure REE at various time points postburn
341851|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
341852|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
341853|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
341854|NCT00541671|Drug|Saline|10 c of saline
341855|NCT00003930|Drug|paclitaxel|
342160|NCT00534027|Other|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
342161|NCT00534053|Other|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
342162|NCT00534079|Drug|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
342163|NCT00534079|Drug|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
342164|NCT00534092|Device|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
342165|NCT00534105|Other|Total Cholesterol|
342166|NCT00534105|Other|Triglyceride|
342167|NCT00003885|Drug|arsenic trioxide|
342168|NCT00534105|Other|HDL|
342169|NCT00534105|Other|LDL|
342170|NCT00534118|Biological|donor lymphocytes|Given IV
342171|NCT00534131|Procedure|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
342172|NCT00534131|Procedure|APPEAR Procedure|Perineal incision to reach the distal rectum
342173|NCT00534131|Procedure|Proctectomy|standard rectal excision which does not preserve the anal canal
342174|NCT00534144|Drug|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
341500|NCT00546832|Other|placebo|
341501|NCT00546845|Device|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
341502|NCT00546845|Device|Use of self-expanding Expert stent|Nitinol stent
341503|NCT00546858|Other|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
341504|NCT00000578|Drug|beclomethasone|
341505|NCT00003955|Drug|irinotecan hydrochloride|
341506|NCT00546871|Drug|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
341507|NCT00546884|Behavioral|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
341508|NCT00546884|Behavioral|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
341509|NCT00546897|Drug|Lenalidomide|
341510|NCT00546910|Drug|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
341511|NCT00546910|Drug|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
341512|NCT00546923|Drug|Venlafaxine XR|
341513|NCT00546936|Drug|ranibizumab|0.5mg ranibizumab
341514|NCT00549588|Other|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
341515|NCT00003967|Drug|topotecan hydrochloride|
341516|NCT00549588|Other|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
341517|NCT00549588|Other|Intervention: none (only UV)|n.a.
341856|NCT00541671|Drug|Phenergan|Physician ordered dose
341857|NCT00541684|Drug|MK0954, /Duration of Treatment : 16 Weeks|
341858|NCT00541684|Drug|Comparator : atenolol /Duration of Treatment : 16 Weeks|
341859|NCT00541697|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
340840|NCT00000556|Drug|diltiazem|
340841|NCT00003812|Drug|topotecan hydrochloride|
340842|NCT00519636|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
340843|NCT00519649|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
340844|NCT00519662|Drug|SNS-314|Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15
Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1
340845|NCT00519675|Drug|alitretinoin|
340846|NCT00519688|Drug|Thalidomide|100 mg, BID
340847|NCT00519688|Drug|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
341174|NCT00511459|Drug|AMG 386|AMG 386 3mg/kg IV QW [blinded]
341175|NCT00511459|Drug|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
341176|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [Open-Label]
341177|NCT00003776|Procedure|surgical procedure|
341178|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [blinded]
341179|NCT00511459|Drug|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
341180|NCT00511472|Drug|MK-0941|In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.
Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2.
341181|NCT00511472|Drug|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
341182|NCT00511472|Drug|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
341183|NCT00511485|Drug|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
341184|NCT00511485|Drug|Etarfolatide|
341185|NCT00511498|Drug|Sildenafil|50 mg daily at bedtime
341186|NCT00511524|Drug|GW842166X|
340479|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
340480|NCT00003857|Radiation|radiation therapy|
340481|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
340482|NCT00527852|Device|Flocked swab|
340483|NCT00527865|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
340484|NCT00527865|Drug|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
340485|NCT00527878|Drug|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
340486|NCT00527878|Drug|Placebo|
340487|NCT00527891|Procedure|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
340488|NCT00527904|Drug|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
340489|NCT00527904|Drug|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
340490|NCT00527917|Device|placebo|bladder instillation
340491|NCT00003858|Drug|mitoxantrone hydrochloride|
340492|NCT00527917|Device|Uracyst|20 ml sterile solution for weekly intravesical instillation
340848|NCT00519701|Drug|hydroxyurea|
340849|NCT00519714|Dietary Supplement|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
340850|NCT00519714|Dietary Supplement|Placebo|Placebo
340851|NCT00519727|Drug|ISIS 325568|4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg
Placebo: 0.9% Sodium Chloride
340852|NCT00003812|Radiation|radiation therapy|
340853|NCT00519740|Other|inhalative specific bronchial provocation with grass-pollen|
340151|NCT00535834|Procedure|molecular diagnostic method|
340152|NCT00535834|Procedure|protein expression analysis|
340153|NCT00535847|Drug|Telaprevir|Tablet
340154|NCT00535847|Drug|Ribavirin|Tablet
340155|NCT00535847|Drug|Pegylated interferon alfa 2a|Solution for Injection
340156|NCT00535860|Drug|Teriparatide|Daily for 96 days
340157|NCT00003896|Drug|paclitaxel|
340158|NCT00535873|Drug|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
340159|NCT00535886|Dietary Supplement|Man-made Trans FA|EA as 6% of total energy
340160|NCT00535886|Dietary Supplement|Natural Trans FA|VA as 6% of total energy
340161|NCT00535886|Dietary Supplement|Oleic Acid|OA as 6% of total energy
340162|NCT00535912|Procedure|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
340163|NCT00535925|Drug|current therapy|the patients have to be treated according the standard good medical practice by any center
340164|NCT00535925|Drug|irbesartan|Therapy for hypertension:
- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
340165|NCT00535925|Drug|ramipril|Therapy for hypertension:
- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
340166|NCT00535925|Drug|hydrochlorothiazide|Therapy for hypertension
- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
340167|NCT00535925|Drug|furosemide|Therapy for hypertension
- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
340168|NCT00003897|Biological|gp100 antigen|
340169|NCT00535925|Drug|amlodipine|Therapy for hypertension
- Step 3: amlodipine up to 10 mg/die
340170|NCT00535925|Drug|atenolol|Therapy for hypertension
- Step 4: atenolol up to 100 mg/die
340171|NCT00535925|Drug|doxazosin|Therapy for hypertension
- Step 5: doxazosin up to 4 mg/die
340172|NCT00535925|Drug|clonidine|Therapy for hypertension
- Step 6: clonidine
327838|NCT00576420|Biological|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
327839|NCT00576420|Biological|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
327840|NCT00576420|Procedure|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
327841|NCT00576433|Drug|Methotrexate|As prescribed
327842|NCT00576433|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
327843|NCT00576446|Biological|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
327844|NCT00576459|Drug|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
327845|NCT00576459|Drug|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
328157|NCT00568763|Other|laboratory biomarker analysis|
328158|NCT00568763|Procedure|biopsy|
328159|NCT00568763|Procedure|cryosurgery|
328160|NCT00568763|Procedure|radiofrequency ablation|
328161|NCT00568776|Drug|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
328162|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
328163|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
328164|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
328165|NCT00568789|Drug|Ramelteon, zolpidem and placebo|Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3
Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3
Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3
328166|NCT00568802|Drug|Hydroxyurea|
328167|NCT00004088|Biological|recombinant interferon alfa|
328168|NCT00568815|Drug|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
327508|NCT00581009|Drug|sertraline, lithium|Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.
Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks.
327509|NCT00583687|Device|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
327510|NCT00583687|Other|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
327511|NCT00583687|Other|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
327512|NCT00583687|Device|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
327513|NCT00583700|Drug|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
327514|NCT00583700|Drug|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
327515|NCT00583713|Drug|BLI-800|BLI-800 oral solution (two doses)
327516|NCT00004158|Procedure|peripheral blood stem cell transplantation|
327517|NCT00583726|Behavioral|motivational interviewing|telephone counseling
327518|NCT00583726|Behavioral|written materials only|dietary guidance materials and pedometers
327519|NCT00583739|Behavioral|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
327520|NCT00583752|Biological|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
327521|NCT00583765|Drug|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
327522|NCT00583778|Drug|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
327523|NCT00583791|Device|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
327524|NCT00583804|Device|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
327525|NCT00583817|Device|Endovascular stent-graft implantation|Endovascular repair with a research device
326873|NCT00556127|Radiation|Radiotherapy|Involved Field Radiotherapy (IF-RT)
326874|NCT00556127|Procedure|PBSC reinfusion|ASCT
326875|NCT00556140|Drug|Aripiprazole|Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.
Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.
You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day.
326876|NCT00556153|Drug|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
326877|NCT00558519|Drug|pegaspargase|
327187|NCT00589368|Behavioral|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
327188|NCT00004179|Drug|CHOP regimen|
327189|NCT00589381|Drug|fenretinide lipid matrix|
327190|NCT00003989|Biological|ISIS 3521|
327191|NCT00551148|Drug|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
327192|NCT00551148|Other|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
327193|NCT00551161|Drug|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
327194|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
327195|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
327196|NCT00551187|Biological|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
327197|NCT00551187|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
327198|NCT00551187|Biological|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
340278|NCT00546377|Drug|pentostatin|
340279|NCT00546377|Genetic|fluorescence in situ hybridization|
340280|NCT00546377|Genetic|gene rearrangement analysis|
340281|NCT00548964|Drug|Ketamine|0.5mg/kg of ketamine
340282|NCT00548977|Other|Drawing blood to study genetic polymorphism|
340283|NCT00548990|Behavioral|cardiovascular exercise training|
340284|NCT00548990|Behavioral|flexibility/balance control|
340610|NCT00541112|Biological|cetuximab|
340611|NCT00003928|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
340612|NCT00541112|Drug|capecitabine|
340613|NCT00541112|Drug|fluorouracil|
340614|NCT00541112|Drug|leucovorin calcium|
340615|NCT00541112|Drug|oxaliplatin|
340616|NCT00541112|Procedure|adjuvant therapy|
340617|NCT00541112|Procedure|conventional surgery|
340618|NCT00541112|Procedure|neoadjuvant therapy|
340619|NCT00541112|Radiation|radiation therapy|
340620|NCT00541125|Biological|bevacizumab|
340621|NCT00541125|Biological|filgrastim|
340622|NCT00003929|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
340623|NCT00541125|Drug|fluorouracil|
340624|NCT00541125|Drug|irinotecan hydrochloride|
340625|NCT00541125|Drug|leucovorin calcium|
340626|NCT00541138|Drug|carboplatin|CBDCA AUC=3
339934|NCT00510952|Drug|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
339935|NCT00003776|Drug|cisplatin|
339936|NCT00510952|Drug|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
339937|NCT00510965|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
339938|NCT00510978|Biological|Bifidobacterium infantis 35624|1 sachet/day for one year
339939|NCT00510978|Biological|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
339940|NCT00510978|Biological|Placebo|1 sachet per day for 1 year
339941|NCT00510991|Device|nippv|
339942|NCT00511004|Drug|Albendazole|Comparing 400 mg to 800 mg dose
339943|NCT00511004|Drug|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
339944|NCT00511017|Drug|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
339945|NCT00513617|Drug|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
339946|NCT00513617|Drug|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
339947|NCT00513630|Drug|Glipizide|
339948|NCT00513630|Drug|Metformin|
339949|NCT00513643|Drug|insulin aspart|6, 12, 24 U s.c.
339950|NCT00513643|Drug|human regular insulin|6, 12 and 24 IU sc
339951|NCT00513656|Drug|Oxycodone|
340285|NCT00549003|Device|Rapid Diagnostic Test for P. falciparum malaria|
340286|NCT00549016|Device|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
340287|NCT00549029|Genetic|DNA|withdraw 5~10mL blood from vein only once during the whole design
344887|NCT00470158|Dietary Supplement|iron|Children >= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
344888|NCT00003577|Drug|epirubicin hydrochloride|
344889|NCT00473109|Procedure|Dialysis without systemic heparinization|Dialysis without systemic heparinization
345214|NCT00413660|Drug|CP-690,550|Oral tablets
345215|NCT00413660|Other|placebo|Placebo
345216|NCT00413673|Procedure|PRK|PRK
345217|NCT00463957|Drug|tadalafil|
345218|NCT00463957|Drug|placebo|
345219|NCT00463970|Behavioral|Brief Intervention|Physical examination, education and follow up by a physiotherapist
345220|NCT00463970|Behavioral|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
345221|NCT00003551|Drug|aminocamptothecin colloidal dispersion|
345222|NCT00463970|Dietary Supplement|Seal oil|20 capsules per day for 3 months
345223|NCT00463970|Dietary Supplement|Soy oil|20 capsules per day for 3 months
345224|NCT00463983|Drug|octreotide|
345225|NCT00464009|Behavioral|Continuing medical education|Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using "learning collaborative" methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist.
345226|NCT00464022|Device|Carbon dioxide|
345227|NCT00464035|Behavioral|high calcium intake|
345228|NCT00464048|Procedure|controlled physical exercise|
345229|NCT00464061|Drug|volinanserin (M100907)|oral administration
345230|NCT00464061|Drug|placebo|oral administration
344552|NCT00479336|Drug|OPC-41061 7.5mg|7.5mg, 1 tablet a day
344553|NCT00479336|Drug|OPC-41061 placebo|placebo, 1 tablet a day
344554|NCT00479336|Drug|OPC-41061 15mg|15mg, 1 tablet a day
344555|NCT00479336|Drug|OPC-41601 30mg|30mg, 1 tablet a day
344556|NCT00479349|Drug|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
344557|NCT00479362|Drug|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
344558|NCT00479362|Drug|Aspirin|Aspirin is continued without interruption prior to device implantation
344559|NCT00479362|Device|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
344560|NCT00479362|Device|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
344561|NCT00003613|Drug|carmustine|Given topically
344562|NCT00479375|Procedure|Adding Human Papillomavirus testing to organised cervical screening|
344563|NCT00482443|Other|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
344564|NCT00003627|Radiation|radiation therapy|
344565|NCT00482456|Drug|Nitrous oxide|
344566|NCT00482482|Behavioral|psychoeducation|on weekly basis for 8 weeks
344567|NCT00482482|Behavioral|Yoga|on weekly basis for 8 weeks
344890|NCT00473122|Procedure|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Reconstruction: If XRT is not needed, immediate reconstruction. If XRT is needed, delayed reconstruction until XRT is complete.
344891|NCT00003587|Drug|carboplatin|AUC=5.5 day 1 every 21 days X 3
344892|NCT00473135|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10^3 PFU
344893|NCT00473135|Biological|Placebo|Placebo for rDEN1delta30
344894|NCT00473148|Procedure|BNP-guided weaning|BNP-guided weaning
344895|NCT00473148|Procedure|Standard physician-directed weaning|Standard physician-directed weaning
343844|NCT00542490|Radiation|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
343845|NCT00542516|Drug|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
343846|NCT00542516|Drug|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
343847|NCT00542529|Biological|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
343848|NCT00542542|Procedure|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
343849|NCT00542542|Drug|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
343850|NCT00542542|Drug|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
344189|NCT00488267|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
344190|NCT00488267|Drug|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
344191|NCT00003650|Drug|prednisone|
344192|NCT00488267|Drug|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
344193|NCT00488280|Behavioral|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
344194|NCT00488293|Procedure|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
344195|NCT00488306|Drug|tigecycline|
344196|NCT00488319|Drug|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
344197|NCT00488332|Procedure|Optical Coherence Tomography|Before radiation treatment and once a week thereafter.
344198|NCT00488332|Procedure|Fluorescence Spectroscopy|Before radiation treatment and once a week thereafter.
344199|NCT00488332|Behavioral|Pain Scale Questionnaire|Administered before the examination, OCT, and FS and immediately afterward.
344200|NCT00488345|Drug|Tygacil|
344201|NCT00488371|Biological|Pneumococcal Conjugated Vaccine (Prevnar®)|
344202|NCT00003650|Drug|vincristine sulfate|
343518|NCT00547651|Drug|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
343519|NCT00547664|Drug|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
343520|NCT00003957|Drug|paclitaxel|
343521|NCT00547664|Other|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
343522|NCT00547677|Radiation|stereotactic radiosurgery|
343523|NCT00547690|Other|Acupuncture and Strengthening|Acupuncture and strengthening
343524|NCT00550498|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
343525|NCT00550511|Radiation|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
343526|NCT00550524|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
343527|NCT00550537|Drug|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
343528|NCT00550537|Drug|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
343529|NCT00550537|Drug|erlotinib hydrochloride|150 mg taken by mouth daily
343530|NCT00550537|Drug|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
343531|NCT00550537|Genetic|gene expression analysis|Blood and tissue collection.
343851|NCT00542542|Drug|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
342869|NCT00520507|Drug|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
342870|NCT00520507|Drug|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
342871|NCT00520533|Biological|Chimeric monoclonal antibody cG250|First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st & 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (¹²⁴I-cG250)
Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No ¹²⁴I-cG250 will be used in the 2nd cycle.
Up to 2 cycles available.
343197|NCT00512590|Behavioral|Relaxation and Guided Imagery|The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.
Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10.
343198|NCT00512616|Drug|Ceftriaxone|
343199|NCT00512629|Drug|Omegaven|Omegaven is a fish based intravenous fat emulsion
343200|NCT00512629|Drug|Intralipid|Intralipid is a plant based intravenous fat emulsion
343201|NCT00512655|Behavioral|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
343202|NCT00512668|Drug|leuprolide acetate|Given intramuscularly
343203|NCT00512668|Drug|goserelin acetate|Given subcutaneously
343204|NCT00003781|Procedure|pain therapy|
343205|NCT00515008|Behavioral|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
343206|NCT00515008|Behavioral|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
343207|NCT00515021|Drug|Eplerenone (Morning vs. evening drug regimen)|Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks or 50mg, by mouth, daily, in the evening x 2 weeks
100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks.
342873|NCT00520546|Other|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a "cold" transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq [18F]Fluoroethylcholine chloride (FEC; Eckert & Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure.
342874|NCT00520546|Other|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
342875|NCT00523068|Drug|Tolterodine|
342876|NCT00523068|Procedure|tension free vaginal tape|
342877|NCT00523081|Behavioral|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
342878|NCT00523081|Behavioral|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
342879|NCT00523107|Drug|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
342880|NCT00523107|Drug|Placebo|500 ml normal saline t.i.w. per week
342881|NCT00523120|Drug|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
342882|NCT00523120|Drug|dexotc|aural drops
342883|NCT00523133|Drug|naltrexone|50 mg naltrexone daily for 3 months
342884|NCT00003830|Procedure|conventional surgery|Sentinel node resection immediately followed by axillary dissection.
342885|NCT00523133|Drug|naltrexone|50 mg of naltrexone daily for 6 months
342886|NCT00523133|Behavioral|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
342887|NCT00523133|Behavioral|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
342888|NCT00523146|Drug|Kanion Capsule|
342175|NCT00534144|Drug|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
342176|NCT00534170|Dietary Supplement|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
342177|NCT00534183|Drug|Olanzapine|Olanzapine in dose range of 10-20mg
342178|NCT00003887|Biological|peripheral blood lymphocyte therapy|
342179|NCT00534183|Drug|Risperidone|Risperidone 1-6mg
342180|NCT00534183|Drug|Haloperidol|Haloperidol 10-20mg
342181|NCT00534196|Radiation|iodine I 125|
342182|NCT00534209|Biological|Allogeneic B7.1/HLA-A1 transfected tumor cell vaccine|Dose: At least 4x10^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
342183|NCT00534209|Other|Placebo|Given intradermally
342518|NCT00526032|Procedure|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
342519|NCT00526045|Drug|AUY922|
342520|NCT00526058|Device|Secura Device: Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
342521|NCT00526058|Device|Futura Device: Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
342522|NCT00528710|Dietary Supplement|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
342523|NCT00528723|Drug|salbutamol 100 mcg|To be used as needed for symptom relief
342524|NCT00528723|Drug|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
342525|NCT00528723|Drug|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
342526|NCT00003860|Drug|ifosfamide|
342527|NCT00528749|Other|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
342528|NCT00528762|Behavioral|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
341860|NCT00541697|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
341861|NCT00541710|Dietary Supplement|genistein|pills of 27 mg, twice per day for 12 months
341862|NCT00541710|Dietary Supplement|placebo|sugar pills twice per day for 12 months
341863|NCT00541723|Drug|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
341864|NCT00541723|Drug|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
341865|NCT00541736|Drug|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
341866|NCT00003930|Procedure|conventional surgery|
341867|NCT00541749|Drug|rhuMAb IFNalpha|Intravenous repeating dose
341868|NCT00541762|Dietary Supplement|Fat perfusion to the small intestine|Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine
Orlistat perfused to the small intestine
DEXLOX as CCK-1 receptor antagonist
341869|NCT00541775|Drug|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
341870|NCT00541775|Drug|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
341871|NCT00541775|Drug|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
341872|NCT00541775|Drug|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
341873|NCT00541788|Other|Administration of Common Sage|Administration of Common Sage
341874|NCT00541801|Device|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
341875|NCT00541814|Drug|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
341876|NCT00544414|Drug|fluorouracil|
341877|NCT00544414|Drug|gemcitabine hydrochloride|
341878|NCT00544414|Drug|leucovorin calcium|
341879|NCT00544414|Genetic|gene expression analysis|
342184|NCT00534235|Procedure|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
341187|NCT00511563|Drug|GW876008 and GSK561679|GW876008 and GSK561679
341188|NCT00003777|Drug|amifostine trihydrate|
341189|NCT00511576|Drug|MGCD0103 & Docetaxel|In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.
In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.
There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks.
341190|NCT00514072|Biological|BCG vaccine|given intradermally
341191|NCT00514072|Biological|prostate cancer vaccine ONY-P1|given intradermally
341192|NCT00514072|Other|placebo|given intradermally
341193|NCT00514085|Biological|recombinant human interleukin-21|Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.
Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle
341194|NCT00514085|Other|immunohistochemistry staining method|﻿Cycle 1 Day 1 and Cycle 1 Day 29
341518|NCT00549601|Drug|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
341519|NCT00549601|Drug|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
341520|NCT00549601|Drug|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
341521|NCT00549614|Drug|acipimox|capsule, 250 mg, 4 times daily for 28 days
341522|NCT00549614|Drug|placebo|capsule, 250 mg, 4 times daily for 28 days
341523|NCT00549627|Device|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
341524|NCT00549640|Drug|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
341525|NCT00549640|Drug|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
341526|NCT00003968|Drug|bryostatin 1|
341527|NCT00549653|Drug|GW856553|
341528|NCT00549666|Drug|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
340854|NCT00519753|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
340855|NCT00519779|Dietary Supplement|omega-3 supplementation|2.5 g/day omega-3
340856|NCT00519779|Dietary Supplement|Oral omega-3 fish oil placebo|to match experimental dosage
340857|NCT00519792|Drug|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
340858|NCT00519805|Drug|dalteparin|
340859|NCT00519805|Procedure|quality-of-life assessment|
340860|NCT00519818|Drug|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
340861|NCT00522249|Drug|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
340862|NCT00522249|Drug|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
340863|NCT00522262|Behavioral|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
340864|NCT00522275|Drug|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
340865|NCT00522288|Device|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
340866|NCT00522288|Device|Spectacle|Spectacles for the treatment of myopia
340867|NCT00522301|Drug|sorafenib tosylate|
340868|NCT00522301|Other|immunoenzyme technique|
340869|NCT00003824|Drug|cephalexin|500 mg oral bid for 3 days starting the night before resection
340870|NCT00522301|Other|immunohistochemistry staining method|
341195|NCT00000556|Drug|flecainide|
341196|NCT00003786|Drug|irofulven|
341197|NCT00514085|Other|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
341198|NCT00514085|Other|pharmacological study|Starting dose of 50μg/kg/day as an IV push
340173|NCT00535925|Drug|insulin|Therapy for Hyperglycaemia (to achieve HbA1c <7):
- insulin
340174|NCT00535925|Drug|simvastatin|Therapy for hypercholesterolemia:
- for reducing LDL cholesterol < 100 mg/dl: simvastatin up to 80 mg/die
340493|NCT00527930|Drug|TS-1 and Eloxatin|S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week
Number of Cycles: until progression or unacceptable toxicity
340494|NCT00527943|Drug|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
340495|NCT00527943|Drug|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
340496|NCT00527969|Drug|HT1001 extract of Panax quinquefolius L|
340497|NCT00527982|Drug|Celecoxib|600 mg by mouth daily for a total of 12 months.
340498|NCT00527995|Drug|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
340499|NCT00528008|Other|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
340500|NCT00528008|Other|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
340501|NCT00528021|Drug|Placebo|Vehicle Only
340502|NCT00530504|Device|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
340503|NCT00530517|Device|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
340504|NCT00530530|Drug|ASP8825|oral
340505|NCT00530530|Drug|Placebo|oral
340506|NCT00530543|Procedure|Robot-assisted gait training|
340507|NCT00530556|Drug|zolpidem|
340508|NCT00530569|Procedure|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
340509|NCT00530582|Drug|progesterone|300mg progesterone /placebo each for 21 days
340510|NCT00530595|Drug|candesartan or valsartan or losartan|
340511|NCT00003868|Radiation|radiation therapy|
328169|NCT00568841|Drug|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
328170|NCT00568841|Procedure|FDG-/FLT-PET|
328171|NCT00004093|Drug|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
328172|NCT00571493|Procedure|autologous peripheral blood stem cell transplantation|Peripheral blood stem cells will be collected as per the discretion of the treating physician. Once an adequate number of CD34+ cells/kg have been collected (as per existing institutional guidelines) the patient will begin the preparative regimen with for transplant. On day 0 of treatment, the previously stored hematopoietic stem cells will be re-infused. The cells will be removed from the storage freezer, brought to the patient area, thawed in a 370C water bath, and administered intravenously through a central line to the patient. Patients will then be cared for as standard transplant patients.
328173|NCT00571506|Drug|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
328174|NCT00571506|Drug|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
328175|NCT00571519|Drug|Rivoglitazone HCl|0.5 mg tablets
328176|NCT00571519|Drug|rivoglitazone HCl|1.0 mg tablets
328177|NCT00571519|Drug|rivoglitazone HCl|1.5 mg tablets
328178|NCT00571519|Drug|placebo|placebo tablets matching rivoglitazone tablets
328179|NCT00571519|Drug|pioglitazone HCl|15 mg tablets
328474|NCT00564005|Other|Combined therapy (CT)|combined different treatment approaches
328475|NCT00564005|Behavioral|Control intervention|Conventional treatment program
328476|NCT00564018|Drug|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
328477|NCT00564018|Drug|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
328478|NCT00564018|Drug|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
328479|NCT00004062|Drug|liothyronine sodium|
328480|NCT00564031|Drug|Femanest|2mg/day
328481|NCT00564031|Drug|gestapuran|5mg/day
328482|NCT00564031|Drug|placebo|daily
328483|NCT00564031|Drug|Femanest plus Gestapuran|combined daily
327846|NCT00576459|Procedure|standard of care laser photocoagulation|standard of care laser photocoagulation
327847|NCT00576472|Drug|Methylphenidate|Please see detailed description for dosing information and study design.
327848|NCT00000603|Procedure|stem cell transplantation|
327849|NCT00004122|Biological|recombinant interferon alfa|
327850|NCT00576485|Procedure|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
327851|NCT00576498|Other|NBI-AFI imaging|Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.
Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence.
327852|NCT00576498|Other|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
327853|NCT00576511|Drug|prucalopride|4 mg o.d.
327854|NCT00578669|Drug|Dextrose|Once daily for 16 weeks
327855|NCT00004132|Biological|filgrastim|
327856|NCT00578682|Biological|MEDI-557|Single IV dose of 3 mg/kg
327857|NCT00578682|Biological|MEDI-557|Single IV dose of 15 mg/kg
327858|NCT00578682|Biological|MEDI-557|Single IV dose of 30 mg/kg
327859|NCT00578682|Biological|MEDI-557|Single IV dose of 0.3 mg/kg
327860|NCT00578695|Drug|lixivaptan|Oral Capsule
327861|NCT00578695|Drug|Placebo|Oral Capsule
327862|NCT00578708|Device|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
327863|NCT00578721|Drug|Aspirin|325 mg taken daily with an arginine-restricted diet
327864|NCT00578734|Drug|Lucinactant|Slow intra-tracheal instillation
327865|NCT00578734|Other|Sham Comparator|Slow intra-tracheal instillation
327866|NCT00004132|Biological|palifermin|
327199|NCT00551200|Drug|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
327200|NCT00551200|Drug|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
327201|NCT00003991|Biological|aldesleukin|
327202|NCT00551213|Biological|Robatumumab|
327203|NCT00551213|Drug|Irinotecan|
327204|NCT00551213|Biological|Cetuximab|
327205|NCT00551213|Drug|Capecitabine|
327526|NCT00583830|Biological|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
327527|NCT00004158|Radiation|holmium Ho 166 DOTMP|
327528|NCT00583830|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
327529|NCT00583830|Drug|Paclitaxel|200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle
327530|NCT00583830|Drug|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
327531|NCT00583843|Procedure|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
327532|NCT00586677|Behavioral|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
327533|NCT00004171|Procedure|peripheral blood stem cell transplantation|
327534|NCT00586690|Device|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
340627|NCT00541138|Drug|tamoxifen citrate|Tamoxifen 100mg bid
340628|NCT00541138|Drug|topotecan hydrochloride|Topotecan 0.75 g/m2/d
340629|NCT00541138|Other|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
340630|NCT00541151|Device|MiniArc|sling system
340631|NCT00541164|Drug|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
340632|NCT00541164|Dietary Supplement|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
340633|NCT00000575|Drug|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
340634|NCT00003929|Drug|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
340635|NCT00541177|Drug|atropine|0.25% atropine
340983|NCT00533546|Drug|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 g/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
340984|NCT00533559|Drug|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
340985|NCT00533559|Drug|Placebo|Placebo comparator
340986|NCT00533585|Drug|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
340987|NCT00533585|Drug|Paclitaxel|200 mg/m^2 By Vein Over 3 Hours on Day 1.
340988|NCT00533585|Drug|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
340989|NCT00533585|Drug|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
340990|NCT00533598|Drug|MK0557|
340991|NCT00533611|Drug|MK0524A, /Duration of Treatment : 4 Weeks|
340992|NCT00533611|Drug|Comparator : niacin /Duration of Treatment : 1 Weeks|
340993|NCT00003881|Drug|paclitaxel|
340994|NCT00533624|Drug|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
340288|NCT00549042|Drug|Drug: OROS® hydromorphone at 4, 8, 16, and 32 mg tablets will be used to provide doses of 12-64mg.|hydromorphone 4, 8, 16, and 32 mg tablets
340289|NCT00549042|Drug|Oros Hydromorphone|Oros Hydromorphone
340290|NCT00003961|Biological|sargramostim|
340291|NCT00549055|Drug|Macugen|Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
340292|NCT00549068|Drug|Risedronate Sodium (Actonel)|
340293|NCT00549081|Dietary Supplement|DHEA|oral DHEA tablets 75 mg daily
340294|NCT00549107|Drug|Levosimendan|
340295|NCT00549107|Drug|Milrinone|
340296|NCT00549120|Drug|Propranolol|40 mg tablets
340297|NCT00549120|Drug|Salbutamol|Metered dose inhaler (600 μg)
340298|NCT00549120|Drug|Ipratropium|Metered dose inhaler (40 μg)
340299|NCT00549120|Drug|Placebo|Placebo for propranolol tablets
340300|NCT00549133|Drug|Irbesartan|
340301|NCT00003962|Biological|aldesleukin|
340302|NCT00549146|Drug|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
340303|NCT00549146|Drug|fluticasone propionate DISKUS 500mcg|
340304|NCT00549159|Device|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
340305|NCT00549159|Device|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
340306|NCT00549172|Procedure|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
340307|NCT00549172|Procedure|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
340308|NCT00549185|Drug|SAR3419|Intravenous infusion
340309|NCT00549198|Drug|Abacavir/lamivudine and efavirenz|
340636|NCT00541177|Drug|tropicamide|0.5% tropicamide
345231|NCT00464087|Drug|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
345232|NCT00003552|Drug|allogeneic lymphocytes|
345233|NCT00464113|Drug|XL228|1-hour IV infusion
345234|NCT00464126|Other|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
345235|NCT00464126|Other|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
345236|NCT00464139|Procedure|Laparoscopy|Laparoscopy
345237|NCT00464165|Drug|rimonabant|
339952|NCT00513656|Drug|Oxycodone/Naloxone|
339953|NCT00513669|Biological|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
339954|NCT00003783|Radiation|radiation therapy|
339955|NCT00513669|Biological|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
339956|NCT00513682|Drug|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
339957|NCT00513695|Drug|sunitinib malate|Given PO
339958|NCT00513695|Drug|paclitaxel|Given IV
339959|NCT00513695|Drug|doxorubicin hydrochloride|Given IV
339960|NCT00513695|Drug|cyclophosphamide|Given PO
339961|NCT00513695|Biological|filgrastim|Given SC
339962|NCT00513695|Procedure|therapeutic conventional surgery|Undergo surgery
339963|NCT00513695|Other|laboratory biomarker analysis|Correlative studies
339964|NCT00513695|Other|flow cytometry|Correlative studies
339965|NCT00003784|Drug|CHOP regimen|
344896|NCT00473161|Device|surface EMG biofeedback|
344897|NCT00473174|Drug|Ramipril|Dosing on awakening versus bedtime
344898|NCT00473174|Device|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
344899|NCT00473187|Drug|somatropin|
344900|NCT00473200|Dietary Supplement|S-adenosylmethionine|1200 mg daily
344901|NCT00473213|Drug|Interferon Beta 1|
344902|NCT00003587|Drug|cisplatin|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3
344903|NCT00473239|Drug|cholecalciferol.|100,000 IU of Vitamin D
344904|NCT00473265|Drug|PTH|
344905|NCT00473304|Device|Johnson&Johnson Acuevue daily disposable lenses|
344906|NCT00473317|Behavioral|Sun Exposure|Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
344907|NCT00473330|Drug|Ranibizumab|Sterile solution for intravitreal injection.
344908|NCT00473330|Drug|Sham injection|
344909|NCT00473343|Procedure|Photodynamic therapy with Metvix 160 mg/g cream|
344910|NCT00473356|Dietary Supplement|receive amino acid supplement|Receive amino acid supplement
344911|NCT00473382|Drug|Ranibizumab|Sterile solution for intravitreal injection.
344912|NCT00473382|Drug|Sham injection|
344913|NCT00003587|Drug|docetaxel|IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
344914|NCT00473408|Device|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
345238|NCT00464178|Drug|Bortezomilb|Bortezomilb will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
345239|NCT00464191|Drug|escitalopram|
345240|NCT00464204|Drug|6 % Hydroxyethylstarch 130/0.4 = "Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
344203|NCT00488384|Drug|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
344204|NCT00488397|Other|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
344205|NCT00488410|Device|Doppler echocardiography|
344206|NCT00003661|Biological|anti-thymocyte globulin|
344207|NCT00491010|Procedure|radiofrequency catheter ablation|
344208|NCT00491036|Device|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
344209|NCT00491049|Drug|0.5% levofloxacin eye drops|
344210|NCT00491062|Procedure|Biopsies|
344211|NCT00491075|Drug|Pemetrexed|500 mg/m^2 IV Over 10 Minutes on Day 1.
344212|NCT00491075|Drug|Gemcitabine|1500 mg/m^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
344213|NCT00491088|Device|CPAP|CPAP for 12 weeks
344568|NCT00482495|Biological|bevacizumab|
344569|NCT00482495|Genetic|gene expression analysis|
344570|NCT00482495|Genetic|protein expression analysis|
344571|NCT00482495|Other|laboratory biomarker analysis|
344572|NCT00482508|Drug|Omalizumab|
344573|NCT00482521|Drug|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
344574|NCT00482547|Device|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
344575|NCT00003630|Drug|arsenic trioxide|
344576|NCT00482547|Device|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
344577|NCT00482560|Drug|Sucrose solution 30%1 ml|
344578|NCT00482560|Behavioral|Breastfeeding|
343852|NCT00542542|Drug|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
343853|NCT00542555|Drug|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
343854|NCT00003935|Drug|vincristine sulfate|
343855|NCT00542555|Drug|Naproxcinod 375 mg|
343856|NCT00542555|Drug|Naproxen|
343857|NCT00542555|Drug|Naproxcinod 750 mg|
343858|NCT00542568|Biological|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
343859|NCT00542581|Device|The Acrysof toric SN60T3 IOL|Intraocular Lens
343860|NCT00542607|Drug|levocetirizine dihydrochloride|
343861|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
343862|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
343863|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
343864|NCT00545168|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
343865|NCT00545168|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
343866|NCT00545181|Drug|Vaginal acidifying gel (RepHresh)|placement of vaginal acidifying gel into vagina to restore "normal" vaginal pH.
343867|NCT00545181|Drug|Metronidazole control|oral metronidazole therapy alone
343868|NCT00003950|Drug|CPT-11|
343869|NCT00545194|Drug|Prostaglandin E2|
343870|NCT00545207|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
343871|NCT00545207|Drug|Placebo|po monthly for 2 years
343872|NCT00545220|Behavioral|problem-solving training|
343873|NCT00545220|Behavioral|sham intervention|
343208|NCT00003789|Biological|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
343209|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
343210|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
343211|NCT00515034|Drug|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
343212|NCT00515034|Drug|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
343532|NCT00550537|Genetic|protein expression analysis|Blood and tissue collection.
343533|NCT00550537|Genetic|proteomic profiling|Blood and tissue collection.
343534|NCT00003972|Drug|thiotepa|
343535|NCT00550537|Other|laboratory biomarker analysis|Blood and tissue collection.
343536|NCT00550550|Drug|Placebo|Placebo sublingual tablet, once daily
343537|NCT00550550|Biological|SCH 697243|Grass sublingual tablet, once daily
343538|NCT00550550|Drug|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to <6 years of age and at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
343539|NCT00550550|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
343540|NCT00550550|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
343541|NCT00550550|Drug|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to <12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to <18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
343542|NCT00003762|Drug|docetaxel|
343543|NCT00509587|Procedure|laboratory biomarker analysis|Correlative studies
343544|NCT00509600|Drug|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
343545|NCT00509613|Drug|Sorafenib|
343213|NCT00515060|Other|Sensory Tests|Tests to find the threshold at which perceive stimuli.
343214|NCT00515073|Drug|Paclitaxel|50 mg/m^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
343215|NCT00515073|Radiation|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
343216|NCT00515073|Drug|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
343217|NCT00515073|Drug|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
343218|NCT00515073|Drug|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
343219|NCT00003789|Other|pharmacological study|Correlative studies
343220|NCT00515086|Drug|Everolimus|Tablets taken once a day with a full glass of water.
343221|NCT00515086|Procedure|Surgery|Salvage surgical resection
343222|NCT00515099|Drug|Antithymocyte globulin|Daily 4-day escalating dose
343223|NCT00515099|Drug|Placebo|Daily 4-day saline solution
343224|NCT00517803|Dietary Supplement|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
343225|NCT00517803|Dietary Supplement|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
343226|NCT00517803|Dietary Supplement|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
343227|NCT00517803|Dietary Supplement|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
343228|NCT00517816|Drug|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
343229|NCT00517829|Drug|Docetaxel + oxaliplatin|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours
343230|NCT00517829|Drug|Docetaxel + oxaliplatin + cetuximab|Taxotere 60 mg/m2 as an IV infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
343231|NCT00517842|Drug|ViNeuro|
343232|NCT00517855|Biological|PRTX-100 (Staphylococcal protein A)|
342529|NCT00528775|Drug|HPPH|4 mg/m2 IV
342530|NCT00528775|Procedure|endoscopic procedure|Treatment with 150 joules from laser
342531|NCT00528788|Drug|doxercalciferol|
342532|NCT00528801|Behavioral|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
342533|NCT00528801|Procedure|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
342534|NCT00528814|Other|Active Hand Sanitizer|Active Hand Sanitizer
342535|NCT00528827|Drug|Cardene® I.V.|5 mcg/kg/min Cardene I.V.
2.5 mcg/kg/min Cardene I.V.
0.5 mcg/kg/min Cardene I.V.
342536|NCT00528840|Biological|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
342537|NCT00003860|Procedure|in vitro-treated peripheral blood stem cell transplantation|
342538|NCT00528866|Drug|bicalutamide|
342539|NCT00528866|Drug|docetaxel|
342540|NCT00528866|Drug|flutamide|
342889|NCT00523159|Drug|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
342890|NCT00523159|Drug|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
342891|NCT00523172|Procedure|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
342892|NCT00523172|Procedure|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
342893|NCT00523172|Procedure|Supportive Care|Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.
Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed.
342894|NCT00523185|Drug|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
342185|NCT00534235|Device|Posterolateral Fusion and Implantation of Pedicle Screws|
342186|NCT00536640|Drug|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
342187|NCT00536640|Drug|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
342188|NCT00536640|Drug|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
342189|NCT00536653|Drug|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
342190|NCT00536653|Drug|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
342191|NCT00536653|Drug|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
342192|NCT00003900|Drug|docetaxel|
342193|NCT00536666|Drug|Iron oligosaccharide|
342194|NCT00536679|Drug|GSK163090|
342195|NCT00536692|Drug|mecamylamine|topical ocular drops
342196|NCT00536705|Drug|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
342197|NCT00536718|Genetic|gene expression analysis|
342198|NCT00536718|Genetic|molecular diagnostic method|
342199|NCT00536718|Genetic|polymorphism analysis|
342200|NCT00536718|Genetic|protein expression analysis|
342201|NCT00536718|Other|medical chart review|
342202|NCT00536718|Other|questionnaire administration|
342203|NCT00003900|Drug|irinotecan hydrochloride|
342204|NCT00536731|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
342205|NCT00536731|Drug|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
342206|NCT00536731|Drug|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
341529|NCT00549666|Drug|Placebo 40 mg|Placebo 40 mg once daily during treatment period
341530|NCT00549666|Drug|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
341531|NCT00549679|Drug|GSK256066|PDE4 inhibitor
341532|NCT00549679|Drug|Placebo|Placebo
341533|NCT00549692|Drug|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
341534|NCT00549718|Drug|Lurasidone HCl|Once daily
341535|NCT00549744|Drug|GSK256066|
341536|NCT00549757|Drug|Aliskiren|Aliskiren 150 mg film-coated tablets
341537|NCT00003969|Drug|tanespimycin|
341538|NCT00549757|Drug|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
341539|NCT00549770|Drug|LCZ696|
341540|NCT00549770|Drug|Valsartan|
341541|NCT00549770|Drug|AHU377|
341542|NCT00549770|Drug|Placebo|
341880|NCT00544414|Genetic|protein expression analysis|
341881|NCT00003943|Drug|paclitaxel|250 mg/m2
341882|NCT00544414|Other|laboratory biomarker analysis|
341883|NCT00544414|Procedure|adjuvant therapy|
341884|NCT00544414|Procedure|biopsy|
341885|NCT00544414|Procedure|conventional surgery|
341886|NCT00544414|Procedure|neoadjuvant therapy|
341887|NCT00544414|Procedure|quality-of-life assessment|
341888|NCT00544414|Radiation|radiation therapy|
341889|NCT00544427|Device|Optical coherence tomography|Optical coherence tomography imaging
341890|NCT00544440|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
341199|NCT00514111|Drug|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
341200|NCT00514137|Drug|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
341201|NCT00514150|Drug|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
341202|NCT00514150|Drug|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
341203|NCT00514163|Drug|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
341204|NCT00514163|Drug|gemcitabine|gemcitabine DIV on day one , 8th and 15th
341205|NCT00514189|Biological|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
341206|NCT00514202|Drug|Placebo|matched placebo
341207|NCT00003787|Behavioral|educational/counseling intervention|
341208|NCT00514202|Drug|Dextroamphetamine SR|60 mg/day
341209|NCT00514215|Biological|sargramostim|250 μg, inhaled, two times a day, on days 4-10 and days 36-42
341210|NCT00514215|Other|flow cytometry|Days 1 & 32
341211|NCT00514215|Other|immunoenzyme technique|Days 1 & 32
341212|NCT00514215|Procedure|biopsy|CT guided biopsy on days 1 & 32
341213|NCT00514215|Procedure|cryosurgery|Days 1 and 32
341214|NCT00514228|Drug|sunitinib malate|Starting dose: 37.5 mg 3 x 12.5 mg capsule
Reduced dose: 25 mg 2 x 12.5 mg capsule
341215|NCT00516919|Drug|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
341216|NCT00516919|Behavioral|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
341217|NCT00516945|Drug|Lamivudine|
341543|NCT00508898|Drug|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
340512|NCT00530621|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
340513|NCT00530621|Drug|placebo|oral, daily
340514|NCT00530621|Drug|pemetrexed|500 mg/m2, IV, day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
340515|NCT00530634|Drug|cisplatin|
340516|NCT00530634|Drug|gemcitabine hydrochloride|
340871|NCT00522301|Other|laboratory biomarker analysis|
340872|NCT00522301|Other|pharmacological study|
340873|NCT00522314|Device|NIV and ACBT|
340874|NCT00522314|Other|Active Cycle of Breathing Techniques|
340875|NCT00522327|Other|remote simultaneous medical interpreting|remote simultaneous medical interpretation
340876|NCT00522327|Other|usual and customary|usual and customary interpreting
340877|NCT00522327|Other|ENglish speaking|English speakers
340878|NCT00522340|Behavioral|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
340879|NCT00522353|Dietary Supplement|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
340880|NCT00003824|Procedure|surgical procedure|
340881|NCT00522353|Dietary Supplement|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
340882|NCT00522379|Drug|Rotigotine|2 mg/24 hr (one 10 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
340883|NCT00522379|Drug|Rotigotine|4 mg/24 hr (one 20 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
340884|NCT00522379|Other|Placebo|Placebo transdermal patch applied daily
340885|NCT00522379|Drug|Rotigotine|6 mg/24 hr (one 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
340886|NCT00522379|Drug|Rotigotine|8 mg/24 hr (two 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
340887|NCT00522392|Drug|bortezomib|Given IV
328484|NCT00564044|Procedure|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm*5mm*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
328485|NCT00566384|Drug|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
328486|NCT00566384|Drug|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
328487|NCT00566397|Drug|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
328488|NCT00566397|Drug|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
328489|NCT00566397|Drug|Placebo|Placebo
328490|NCT00566410|Drug|Dichloroacetate|Continuous daily oral dosage (bid).
328491|NCT00566423|Other|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
328492|NCT00004077|Drug|cisplatin|
328493|NCT00566436|Procedure|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
328494|NCT00566436|Procedure|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
323371|NCT00282282|Drug|sirolimus|Given orally just prior to and following stem cell transplant
323372|NCT00282282|Drug|fludarabine|Given once daily over 30 minutes for 4 days
323373|NCT00282282|Drug|busulfex|Given intravenously over 3 hours for 4 days
323374|NCT00282295|Biological|Boostrix|
323375|NCT00282308|Drug|Rituximab|Rituximab was supplied in single-use vials.
323376|NCT00282308|Drug|Methotrexate|
323377|NCT00282308|Drug|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
323378|NCT00002771|Drug|busulfan|
327867|NCT00578760|Drug|aspirin|325mg ASA OD for the duration of the cisplatin
327868|NCT00578760|Drug|placebo|OD for course of cisplatin chemotherapy
328180|NCT00571519|Drug|pioglitazone HCl|30 mg tablets
328181|NCT00571519|Drug|pioglitazone HCl 45 mg|45 mg tablets
328182|NCT00004094|Drug|carboplatin|
328183|NCT00571519|Drug|placebo|placebo capsules for pioglitazone
328184|NCT00571519|Drug|metformin|Oral tablets. Rescue medication.
328185|NCT00571545|Behavioral|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
328186|NCT00571545|Behavioral|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
328187|NCT00571558|Drug|aminolevulinic acid hydrochloride|Given PO
328188|NCT00571558|Drug|photodynamic therapy|Undergo photodynamic therapy
328189|NCT00571558|Other|laboratory biomarker analysis|Correlative studies
328190|NCT00571571|Behavioral|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
328191|NCT00571571|Behavioral|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
328192|NCT00571584|Drug|activated recombinant human factor VII|
328193|NCT00004094|Drug|fluorouracil|
328194|NCT00571610|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
328195|NCT00571623|Other|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
328196|NCT00573859|Drug|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
328197|NCT00573872|Radiation|Radiosurgery|Phase I: 20-25 Gy in 5 fractions
Phase II: 9-24 GY in 1 fraction
328198|NCT00004104|Biological|liposomal interleukin-2|
328199|NCT00573885|Drug|defined green tea catechin extract|Given orally
327535|NCT00586690|Procedure|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
327536|NCT00586703|Device|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
327537|NCT00586716|Drug|invenous immune globulins|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
327538|NCT00586729|Device|Vashe|Antimicrobial irrigant
327539|NCT00586729|Drug|Mafenide acetate|Antimicrobial solution
327540|NCT00586742|Procedure|labral repair|labral repair with suture anchors
327541|NCT00586742|Procedure|biceps tenodesis|biceps tenodesis with suture anchor
327542|NCT00586742|Procedure|diagnostic arthroscopy|diagnostic arthroscopy
327869|NCT00578773|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
327870|NCT00578773|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
327871|NCT00578773|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
327872|NCT00578786|Drug|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
327873|NCT00578799|Dietary Supplement|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
327874|NCT00578799|Dietary Supplement|placebo|placebo capsules (potato starch
327875|NCT00578812|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
327876|NCT00578812|Device|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
327877|NCT00004132|Drug|cyclophosphamide|
340995|NCT00536159|Other|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
340996|NCT00536172|Drug|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
340997|NCT00536172|Drug|Placebo|Placebo distribution matches the active medication.
340998|NCT00536185|Dietary Supplement|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
340999|NCT00536185|Dietary Supplement|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
341000|NCT00536198|Drug|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
341001|NCT00536198|Drug|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
341319|NCT00528320|Device|Ovatio CRT|
341320|NCT00528333|Drug|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
341321|NCT00528333|Drug|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
341322|NCT00003859|Drug|vincristine sulfate|
341323|NCT00528333|Drug|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
341324|NCT00528346|Behavioral|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies—allowing them to view their brain activity.
341325|NCT00528346|Behavioral|placebo|Some participants will see simulated data that does not come from their own brains.
341326|NCT00528359|Drug|quetiapine or olanzapine or risperidone or aripiprazole|
341327|NCT00528372|Drug|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
341328|NCT00528372|Drug|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
341329|NCT00528372|Drug|Metformin|
340637|NCT00541190|Other|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
340638|NCT00541216|Drug|Ephedrine|
340639|NCT00543946|Drug|GAP-134|24-Hour IV infusion, SAD
340640|NCT00003941|Procedure|bone marrow ablation with stem cell support|
340641|NCT00543959|Drug|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
340642|NCT00543959|Drug|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
340643|NCT00543959|Drug|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
340644|NCT00543972|Drug|AVE9633|Intravenous Infusion
340645|NCT00543985|Behavioral|diet and exercise|Exercise training and weight loss with regain with or without continued weight loss
340646|NCT00543998|Device|Optical Measurement transillumination|Optical Measurement of sinus
340647|NCT00544011|Biological|bevacizumab|
340648|NCT00544011|Drug|capecitabine|
340649|NCT00544011|Drug|fluorouracil|
340650|NCT00544011|Drug|irinotecan hydrochloride|
340651|NCT00003941|Procedure|peripheral blood stem cell transplantation|
340652|NCT00544011|Other|diagnostic laboratory biomarker analysis|
340653|NCT00544037|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
340654|NCT00544050|Drug|Levetiracetam|
340655|NCT00544063|Drug|irinotecan hydrochloride|
340656|NCT00544063|Drug|oxaliplatin|
340657|NCT00544076|Drug|sildenafil citrate|Given orally
340658|NCT00544076|Drug|alprostadil|Given intraurethrally
340659|NCT00544076|Procedure|robotic-assisted laparoscopic surgery|Undergo prostatectomy
339966|NCT00513708|Behavioral|Motivation Enhancement Therapy (MET)|Participants assigned to this arm will receive a 60-minute MET intervention in addition to "usual care" while hospitalized for detoxification.
339967|NCT00513708|Behavioral|Peer-Twelve Step Facilitation (P-TSF)|In addition to "usual care" while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are "recovering from alcoholism" and who are active in 12-step oriented self-help programs.
339968|NCT00513734|Other|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
339969|NCT00513734|Other|Lacrilube ointment|lubricant put into eye (inferior formix)
339970|NCT00516425|Drug|cyclophosphamide|
339971|NCT00516425|Drug|doxorubicin hydrochloride|
339972|NCT00516425|Drug|epirubicin hydrochloride|
339973|NCT00516425|Genetic|proteomic profiling|
339974|NCT00516425|Other|diagnostic laboratory biomarker analysis|
340310|NCT00549198|Drug|Tenofovir/Emtricitabine and efavirenz|
340311|NCT00549211|Drug|GSK557296|
340312|NCT00508456|Drug|Temodar (Temozolomide)|150 mg/m^2 orally once a day for 7 consecutive days (days 8 through 15).
340313|NCT00508456|Dietary Supplement|Hominex-2|Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only "shakes" containing Hominex-2®.
340314|NCT00508469|Drug|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
340315|NCT00508469|Drug|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
340316|NCT00508469|Drug|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
340317|NCT00508469|Device|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
340318|NCT00508482|Other|deep needling|Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.
Once a day, five times a week, four weeks.
340319|NCT00003753|Drug|irinotecan hydrochloride|
340320|NCT00508482|Drug|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
345241|NCT00464204|Drug|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
345242|NCT00464217|Drug|ARA-C|
345243|NCT00467142|Drug|leucovorin calcium|
345244|NCT00000151|Procedure|Argon Laser Photocoagulation|
345245|NCT00000532|Behavioral|diet, fat-restricted|
345246|NCT00003567|Biological|therapeutic autologous lymphocytes|
345247|NCT00467142|Genetic|polymorphism analysis|
345248|NCT00467168|Behavioral|Diet|
345249|NCT00467181|Drug|Fenoldopam|
345250|NCT00467194|Drug|Rapamycin|
345251|NCT00467194|Drug|Bevacizumab|
345252|NCT00467207|Drug|Botulinum Toxin A|
345253|NCT00467207|Behavioral|Strength training|
345254|NCT00467220|Behavioral|calorie restriction|Subjects in the "calorie restriction" arm and the "alternate day fasting" arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction.
345255|NCT00467233|Procedure|Laser Treatment|Laser treatment to half of the face at each study visit
345256|NCT00467233|Procedure|Acid Peel|Acid peel to half of the face at each study visit
345257|NCT00003567|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
345258|NCT00467246|Drug|Levemir|
345259|NCT00467259|Drug|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
345260|NCT00467259|Drug|Placebo patch|placebo patch, changed twice a week for 52 weeks
339975|NCT00516425|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
339976|NCT00516425|Other|pharmacological study|
344579|NCT00482573|Procedure|Dental local anesthesia|2% lidocaine solution with epinephrine 1:100,000
infusion of 1,8 mL (one cartridge)
Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)
344580|NCT00482573|Procedure|Dental local anesthesia|2% lidocaine solution without vasoconstrictor
infusion of 1,8 mL (one cartridge)
Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)
344581|NCT00482586|Other|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
344582|NCT00482586|Other|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
344583|NCT00482586|Procedure|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
344584|NCT00482599|Drug|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
344585|NCT00482612|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
344586|NCT00003631|Biological|filgrastim|
344587|NCT00482612|Drug|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
344588|NCT00482625|Drug|erlotinib hydrochloride|Given PO
344589|NCT00485251|Procedure|laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
344915|NCT00473408|Procedure|Blood sample|n.a.
344916|NCT00473408|Procedure|Tumor sample|See protocol.
344917|NCT00473421|Procedure|Barium Sulphate and Zirconium Oxide|
344918|NCT00473434|Drug|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
344919|NCT00476190|Drug|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
344920|NCT00003597|Drug|etoposide|
343874|NCT00545233|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
344214|NCT00491101|Other|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
344215|NCT00491101|Other|spirometry|spirometry
344216|NCT00491114|Drug|Gemcitabine|
344217|NCT00003661|Drug|busulfan|
344218|NCT00491127|Drug|gemcitabine|
344219|NCT00491127|Drug|cisplatin|
344220|NCT00491127|Drug|dexamethasone|
344221|NCT00491140|Genetic|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
344222|NCT00491166|Drug|Bromfenac ophthalmic solution|
344223|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
344224|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
344225|NCT00491192|Drug|Diclofenac|
344226|NCT00491244|Drug|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
344227|NCT00491244|Drug|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
344228|NCT00003661|Drug|cyclosporine|
344229|NCT00491257|Biological|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
344230|NCT00491270|Device|VS Sense|An applicator to diagnose pH increase above 5.2
344231|NCT00491283|Device|Swab Specimen Collection (QuickVue)|
344232|NCT00491296|Device|SYNERGO|
344233|NCT00491296|Device|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
344234|NCT00491309|Behavioral|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
343546|NCT00509613|Drug|Sirolimus|
343547|NCT00509626|Behavioral|exercise intervention|
343548|NCT00509626|Other|questionnaire administration|
343549|NCT00509626|Procedure|CAM exercise therapy|
343550|NCT00509626|Procedure|management of therapy complications|
343551|NCT00509626|Procedure|psychosocial assessment and care|
343552|NCT00509626|Procedure|quality-of-life assessment|
343553|NCT00000555|Drug|supplementation, food|
343554|NCT00003762|Drug|gemcitabine hydrochloride|
343875|NCT00545233|Drug|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
343876|NCT00545233|Drug|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
343877|NCT00545246|Drug|aflibercept (AVE0005)|intravenous infusion
343878|NCT00545246|Drug|docetaxel|intravenous infusion
343879|NCT00003951|Drug|exatecan mesylate|
343880|NCT00545259|Drug|AEB071|
343881|NCT00545272|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
343882|NCT00545272|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
343883|NCT00545272|Drug|placebo to indacaterol|Placebo TWISTHALER® device
343884|NCT00545272|Drug|placebo to formoterol|Placebo AEROLIZER® device
343885|NCT00545272|Drug|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
343886|NCT00545285|Procedure|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
343887|NCT00545298|Drug|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
343888|NCT00545298|Drug|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
343233|NCT00003803|Radiation|radiation therapy|
343234|NCT00517868|Drug|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
343555|NCT00509639|Drug|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
343556|NCT00509652|Procedure|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
343557|NCT00509652|Procedure|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
343558|NCT00509665|Drug|doxorubicin hydrochloride|
343559|NCT00509665|Drug|gemcitabine hydrochloride|
343560|NCT00509665|Other|laboratory biomarker analysis|
343561|NCT00509665|Other|liquid chromatography|
343562|NCT00509665|Other|mass spectrometry|
343563|NCT00509678|Drug|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
343564|NCT00509691|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
343565|NCT00003763|Procedure|radionuclide imaging|
343566|NCT00509691|Genetic|polymerase chain reaction|
343567|NCT00509691|Other|diagnostic laboratory biomarker analysis|
343568|NCT00509691|Other|flow cytometry|
343569|NCT00509691|Other|immunologic technique|
343570|NCT00509717|Other|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
343571|NCT00509717|Other|control|educational manual
343572|NCT00509730|Procedure|Urodynamics|
343573|NCT00512668|Drug|bicalutamide|Given PO
343574|NCT00512668|Drug|nilutamide|Given PO
342895|NCT00003830|Procedure|Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
342896|NCT00526071|Drug|AT1001|AT1001
342897|NCT00526097|Drug|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
342898|NCT00003850|Drug|thalidomide|
342899|NCT00526097|Drug|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
342900|NCT00526110|Drug|5-Fluorouracil|2.2 Gm/m^2 IV over 48 hours on Day 1.
342901|NCT00526110|Drug|Docetaxel|20 mg/m^2 IV over 60 minutes
342902|NCT00526110|Drug|Oxaliplatin|85 mg/m^2 IV over 120 minutes on Day 1.
342903|NCT00526123|Device|Symmetric Tip Catheter|Dialysis catheter
342904|NCT00526123|Device|Conventional Split-tip Catheter|Dialysis Catheter
342905|NCT00526136|Drug|Placebo|
342906|NCT00526136|Drug|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
342907|NCT00526149|Drug|BI 2536|
342908|NCT00526149|Other|high performance liquid chromatography|
342909|NCT00003851|Biological|proteolytic enzymes|
342910|NCT00526149|Other|mass spectrometry|
343235|NCT00517868|Drug|Placebo|Liquid formulation without active URG101 drug components
343236|NCT00517881|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly, starting dose
343237|NCT00517894|Drug|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
343238|NCT00517907|Drug|Preimplantation factor (PIF-1)|The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.
Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration.
343239|NCT00517920|Drug|ABT-869|0.25 mg/kg QD
342207|NCT00536744|Device|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
342541|NCT00528866|Drug|goserelin acetate|
342542|NCT00528866|Drug|leuprolide acetate|
342543|NCT00528866|Procedure|adjuvant therapy|
342544|NCT00528866|Radiation|3-dimensional conformal radiation therapy|
342545|NCT00528866|Radiation|intensity-modulated radiation therapy|
342546|NCT00528879|Drug|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
342547|NCT00528879|Drug|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
342548|NCT00000562|Procedure|extracorporeal membrane oxygenation|
342549|NCT00003861|Genetic|reverse transcriptase-polymerase chain reaction|
342550|NCT00528879|Drug|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
342551|NCT00531466|Drug|Placebo|One tablet orally three times a day for 28 days
342552|NCT00531479|Drug|voriconazole|First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.
Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.
Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,
OR
Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
342553|NCT00531479|Drug|anidulafungin|First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.
Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.
Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,
OR
Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
342554|NCT00531479|Drug|voriconazole|First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.
Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.
Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,
OR
Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
342555|NCT00531492|Behavioral|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
342556|NCT00531492|Other|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
342557|NCT00531518|Drug|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
341891|NCT00544440|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
341892|NCT00003943|Drug|topotecan hydrochloride|10 mg/m2
341893|NCT00544453|Drug|[123I] MNI-308|Injection of [123I] MNI-308 and SPECT scanning
341894|NCT00544466|Drug|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
341895|NCT00544466|Drug|melphalan|140 mg/m2 day -2 prior to transplant
341896|NCT00544466|Procedure|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
341897|NCT00544466|Radiation|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
341898|NCT00544492|Device|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
341899|NCT00544505|Drug|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
341900|NCT00544518|Drug|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
341901|NCT00544518|Drug|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
341902|NCT00544544|Drug|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
341903|NCT00003943|Procedure|peripheral blood stem cell transplantation|harvest via apheresis
342208|NCT00536744|Other|Sham|Non-energized (inactive - Sham) application + standard of care
342209|NCT00536770|Drug|placebo + gemcitabine + erlotinib|
342210|NCT00536770|Drug|Placebo + gemcitabine|
342211|NCT00536770|Drug|calcitriol + gemcitabine|
342212|NCT00536770|Drug|calcitriol + gemcitabine + erlotinib|
342213|NCT00536783|Drug|Quetiapine|
342214|NCT00003901|Other|immunohistochemistry staining method|
342215|NCT00536809|Drug|lapatinib|onced daily Days 1-21
342216|NCT00000573|Procedure|enteral nutrition|
341544|NCT00508911|Drug|GW876008 Oral Contraceptive|
341545|NCT00508924|Drug|Argatroban|
341546|NCT00508924|Drug|Argatroban|
341547|NCT00508924|Drug|Argatroban|
341548|NCT00508924|Drug|Heparin|
341549|NCT00508937|Other|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
341550|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
341551|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
341552|NCT00003758|Drug|cytarabine|
341553|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
341554|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
341555|NCT00508950|Procedure|Large volume blood draw|Large volume blood draw
341556|NCT00508963|Drug|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
341557|NCT00508976|Drug|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
341558|NCT00508976|Drug|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
341559|NCT00508976|Drug|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
341560|NCT00508976|Drug|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
341561|NCT00508989|Drug|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
340888|NCT00522392|Drug|lenalidomide|Given PO
340889|NCT00525291|Device|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
340890|NCT00525304|Behavioral|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
340891|NCT00525317|Drug|"Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks)|120 mg x 3 or placebo
340892|NCT00525330|Drug|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
341218|NCT00516958|Drug|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
341219|NCT00516958|Drug|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
341220|NCT00516958|Drug|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
341221|NCT00003799|Radiation|radiation therapy|Undergo radiotherapy
341222|NCT00516971|Drug|Esomeprazole 20mg once daily|
341223|NCT00516984|Procedure|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
341224|NCT00516984|Procedure|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
341225|NCT00516984|Procedure|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
341226|NCT00516997|Other|fat emulsions|Intravenous Fat Emulsions were increased by 0.5 grams/kg/day daily until goal 3 gm/kg/d
341227|NCT00516997|Other|fat emulsions|IVFE were increased daily by 05 gm/kg/d until goal of 3 gm/kg/d
341228|NCT00517010|Other|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
341229|NCT00517023|Device|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
341230|NCT00517023|Other|Other|Routine care and tests usually offered for syncope patients.
341231|NCT00517036|Dietary Supplement|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
323379|NCT00282308|Biological|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
323380|NCT00285935|Drug|Treatment with SSRI|Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label "treatment-as-usual" manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.
Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)
323381|NCT00285948|Device|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
323382|NCT00002780|Biological|sargramostim|
323383|NCT00285961|Device|Cork splint materials (instead of plaster splint)|
323384|NCT00285974|Device|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
323385|NCT00285987|Procedure|Reconstruction of the cruciate ligament|
323386|NCT00286000|Drug|Administration of high dose simplified folfiri|
323387|NCT00286013|Drug|Association of gemcitabine, oxaliplatin and radiotherapy|
323388|NCT00286026|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
323389|NCT00286039|Procedure|Blood sampling|Blood sampling is used.
323390|NCT00286052|Drug|Low Dose Naloxone|
323391|NCT00286065|Drug|AeroLEF|
323392|NCT00286078|Device|Precision|Implantable neurostimulator
323393|NCT00002780|Drug|carboplatin|
323394|NCT00286091|Biological|Denosumab|Administered by subcutaneous injection
323725|NCT00276302|Drug|IPI-504|IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.
For both Schedule A and B doses will be administered ≥ 72 hours apart.
323726|NCT00002755|Biological|filgrastim|
323727|NCT00276315|Drug|Botulinum type A toxin (Dysport®) - one single injection|
323728|NCT00276328|Drug|Diosmectite (Smecta®)|
328200|NCT00573885|Other|placebo|Given orally
328201|NCT00573911|Procedure|Endoscopy and pH study|endoscopy and PH study done one time
328202|NCT00573924|Drug|Proton pump inhibitor (lansoprazole)|120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs
90 mg IV bolus followed 9 mg/hr infusion for 24 hrs
328203|NCT00573937|Drug|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
328495|NCT00566449|Drug|Placebo|one dose daily for 4 weeks
328496|NCT00566449|Drug|JNJ-31001074|10 mg daily for 4 weeks
328497|NCT00566449|Drug|JNJ-31001074|30 mg daily for 4 weeks
328498|NCT00566462|Drug|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
328499|NCT00566462|Drug|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
328500|NCT00566475|Other|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
328501|NCT00566488|Biological|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, & parental parathyroid donor screened for transplant safety. Depending on T cell phenotype & function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre & post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis & graft rejection.
328502|NCT00566501|Drug|23 mg SR in Study 326|Patients will receive 23 mg donepezil SR orally, once daily for 12 months.
328503|NCT00004077|Drug|ifosfamide|
328504|NCT00566501|Drug|10 mg IR in Study 326|Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.
328505|NCT00566514|Dietary Supplement|D-ribose|5 grams administered orally TID
328506|NCT00566514|Other|dextrose|5 grams orally TID
328507|NCT00568854|Biological|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
328508|NCT00568880|Drug|bortezomib|
328509|NCT00568880|Drug|hydroxychloroquine|
327878|NCT00578825|Drug|Lopinavir / Ritonavir plus Ribavirin|
327879|NCT00578838|Other|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
327880|NCT00578838|Other|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
327881|NCT00578851|Device|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
327882|NCT00581009|Radiation|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
327883|NCT00581022|Procedure|Polysomnography|Overnight Sleep Study
327884|NCT00581035|Biological|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
327885|NCT00581035|Biological|Prevenar|1 dose at 2,3.5,6 and 12 months
327886|NCT00581035|Biological|Meningitec|1 dose at 2,6 and 12 months
327887|NCT00581048|Drug|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
327888|NCT00581061|Drug|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
327889|NCT00581074|Behavioral|diet (grapefruit or grapefruit juice)|weight loss diet
328204|NCT00573937|Drug|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
328205|NCT00573950|Drug|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
328206|NCT00573950|Drug|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
328207|NCT00573963|Drug|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
328208|NCT00573963|Drug|saline solution|2 injections of 20mL plain saline solution - one on each side.
328209|NCT00004104|Biological|polyvalent melanoma vaccine|
328210|NCT00573989|Drug|erlotinib hydrochloride|
328211|NCT00573989|Drug|pemetrexed disodium|
341330|NCT00528385|Drug|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
341331|NCT00528398|Drug|cytarabine|
341332|NCT00528398|Drug|idarubicin|
341333|NCT00003859|Procedure|surgical procedure|
341334|NCT00528411|Drug|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
341335|NCT00528411|Drug|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
341336|NCT00003869|Other|laboratory biomarker analysis|Correlative studies
341337|NCT00530907|Drug|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
341338|NCT00530920|Drug|tipranavir|
341339|NCT00530920|Drug|ritonavir|
341340|NCT00530933|Procedure|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
341341|NCT00530933|Procedure|Transcutaneous tibial nerve stimulation|30 minutes once weekly
341342|NCT00530933|Procedure|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
341682|NCT00522613|Behavioral|Recovery Group Project|Recovery Group Workbook & Group Sessions
341683|NCT00522626|Device|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
341684|NCT00522639|Other|18F-deoxyglucose (FDG)|contrast medium
341685|NCT00522652|Drug|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
341686|NCT00522665|Drug|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
341687|NCT00000557|Behavioral|social support|
341688|NCT00003827|Drug|amifostine trihydrate|
341689|NCT00522665|Biological|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
341690|NCT00522665|Biological|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
340660|NCT00544076|Procedure|quality-of-life assessment|Ancillary studies
340661|NCT00544076|Other|questionnaire administration|Ancillary studies
341002|NCT00536211|Behavioral|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at ~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
341003|NCT00536211|Drug|Metformin|oral tablet, 1000 mg daily for 17 days
341004|NCT00536224|Behavioral|Enhanced counseling|The health educator will generate a computerized report for the patient that outlines his/her cardiovascular risk factors, Framingham risk score, the goal for each risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the 5A's framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) will be provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). A full report will also be sent to the patient's primary care physician (if any) at the conclusion of counseling.
341005|NCT00003899|Drug|cyclophosphamide|
341006|NCT00536224|Behavioral|Minimal counseling|Patients assigned to minimal intervention will receive an AHA brochure ("Controlling your risk factors") with general information on management of cardiovascular risk factors. These patients will be mailed a personalized cardiovascular risk assessment report (based on baseline questionnaire and laboratory data) at the end of 6-month follow-up.
341007|NCT00536237|Drug|Comparator: niacin / Duration of Treatment: 17 Weeks|
341008|NCT00536237|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
341009|NCT00536237|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
341010|NCT00536263|Drug|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
341011|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
341012|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
341013|NCT00536276|Dietary Supplement|Vitamin D2|Daily enteral dose of 100IU/kg
341014|NCT00536276|Dietary Supplement|Vitamin D3|Daily enteral dose of 100IU/kg
341015|NCT00538590|Device|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
341016|NCT00538590|Drug|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
340321|NCT00508482|Other|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
340322|NCT00508495|Drug|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
340323|NCT00508495|Drug|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
340324|NCT00508495|Drug|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
340325|NCT00508508|Behavioral|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
340326|NCT00508508|Behavioral|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
340327|NCT00508521|Device|Functional Electrical Stimulation|commercially available surface electrical stimulator
340328|NCT00508521|Other|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
340329|NCT00508534|Drug|SB-751689|
340330|NCT00003753|Procedure|adjuvant therapy|
340662|NCT00003942|Biological|RevM10 gene|
340663|NCT00544115|Drug|busulfan|
340664|NCT00544115|Drug|cyclophosphamide|
340665|NCT00544115|Drug|cyclosporine|
340666|NCT00544115|Drug|etoposide|
340667|NCT00544115|Drug|fludarabine phosphate|
340668|NCT00544115|Drug|melphalan|
340669|NCT00544115|Drug|methotrexate|
340670|NCT00544115|Drug|mycophenolate mofetil|
340671|NCT00544115|Drug|sirolimus|
340672|NCT00546377|Genetic|polymerase chain reaction|
340673|NCT00546377|Genetic|protein expression analysis|
340674|NCT00546377|Other|flow cytometry|
339977|NCT00516425|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
339978|NCT00516425|Procedure|adjuvant therapy|
339979|NCT00000556|Drug|disopyramide|
339980|NCT00003796|Drug|irofulven|
339981|NCT00516438|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
339982|NCT00516438|Drug|Topotecan|intravenous infusion
339983|NCT00516451|Drug|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
339984|NCT00516464|Drug|Lucentis (ranibizumab)|
339985|NCT00516477|Biological|AAV2-hRPE65v2|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
339986|NCT00516490|Drug|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
339987|NCT00516490|Drug|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
339988|NCT00516503|Drug|baclofen/amitriptyline/ketamine gel|Applied topically
339989|NCT00516503|Other|placebo|Applied topically
339990|NCT00516516|Dietary Supplement|L-Carnitine|L-Carnitine, 1g orally, twice daily
339991|NCT00003797|Biological|trastuzumab|
339992|NCT00516516|Dietary Supplement|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
339993|NCT00516542|Drug|letrozole|A daily dose of 2.5 mg will be used throughout the study.
339994|NCT00516542|Drug|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
339995|NCT00516542|Other|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
339996|NCT00516594|Procedure|Diet with polyfructans and viscous fibers or soy protein|
339997|NCT00516607|Drug|enzastaurin hydrochloride|
339998|NCT00516607|Drug|temozolomide|
344921|NCT00476190|Drug|Methotrexate|Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).
Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks.
344922|NCT00476190|Drug|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
344923|NCT00476190|Drug|Cyclophosphamide|Consolidation IB: Intravenously on day 1
344924|NCT00476190|Drug|Methylprednisone|Prophase: Intravenously on days 1-3
344925|NCT00476190|Drug|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
344926|NCT00476190|Drug|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
344927|NCT00476190|Drug|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
344928|NCT00476190|Drug|PEG-Asparaginase|Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.
Consolidation II: Intravenously every 3 weeks.
344929|NCT00476190|Drug|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
344930|NCT00476190|Drug|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
344931|NCT00003597|Drug|ifosfamide|
344932|NCT00476190|Procedure|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
344933|NCT00476190|Drug|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
344934|NCT00476203|Behavioral|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
345261|NCT00467272|Drug|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria.
345262|NCT00467298|Behavioral|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
345263|NCT00467298|Behavioral|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
344235|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks
344236|NCT00493818|Drug|GSK690693|
344237|NCT00003671|Drug|dexamethasone|
344590|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
344591|NCT00485264|Drug|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
344592|NCT00485264|Drug|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
344593|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet.
344594|NCT00485277|Biological|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
344595|NCT00485290|Behavioral|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
344596|NCT00485303|Drug|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
344597|NCT00003640|Biological|filgrastim|
344598|NCT00485303|Drug|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
344599|NCT00485316|Procedure|Laparoscopic assisted resection of colorectal carcinoma|
344600|NCT00485329|Other|Papain|15,000 USP U/ml
344601|NCT00485329|Other|Papain|30,000 USP U/ml
344602|NCT00485329|Other|Papain|60,000 USP U/ml
344603|NCT00485342|Drug|Peg-interferon alpha 2a and ribavin|Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg).
Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
344604|NCT00485342|Drug|ribavirin with adaptation dose|Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.
The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
343889|NCT00545311|Drug|NVA237|
343890|NCT00003953|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
343891|NCT00545311|Drug|NVA237|
343892|NCT00545311|Drug|NVA237|
343893|NCT00545311|Drug|NVA237|
343894|NCT00547690|Other|Strengthening Alone|Strengthening training program
343895|NCT00547703|Drug|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
343896|NCT00547703|Drug|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
343897|NCT00547716|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
343898|NCT00547716|Drug|Placebo comparator|
343899|NCT00547729|Device|Left Atrial Pressure monitoring|HeartPOD™ device automatically measures heart pressures throughout the day. This data is collected at follow up visits.
344238|NCT00493831|Drug|nicotine polacrilex, transdermal system or inhaler|
344239|NCT00493844|Other|Exercise testing|Exercise testing
344240|NCT00493844|Other|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
344241|NCT00493857|Drug|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
344242|NCT00493857|Drug|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
344243|NCT00493870|Drug|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
344244|NCT00493870|Drug|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
344245|NCT00493870|Drug|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
344246|NCT00493883|Device|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
344247|NCT00493896|Drug|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
344248|NCT00003671|Drug|leucovorin calcium|
350235|NCT00504478|Other|high complex carbohydrate diet|
350236|NCT00504491|Drug|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
350576|NCT00496522|Procedure|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
350577|NCT00496535|Drug|TNFerade biologic|
350578|NCT00496548|Procedure|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
350579|NCT00496548|Procedure|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
350580|NCT00003684|Drug|theophylline|
350581|NCT00496561|Biological|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
350582|NCT00496561|Other|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
350583|NCT00496574|Biological|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
350584|NCT00496587|Drug|Capecitabine|800 mg/m^2 By Mouth Twice Daily On Days 1-21.
350585|NCT00496587|Drug|Gemcitabine|900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15.
350586|NCT00496587|Drug|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
350587|NCT00496600|Drug|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
350588|NCT00496600|Drug|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
350589|NCT00496613|Behavioral|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
350590|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
350591|NCT00000549|Drug|estrogen replacement therapy|
350592|NCT00003684|Procedure|quality-of-life assessment|
349888|NCT00463047|Drug|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
349889|NCT00466323|Behavioral|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
349890|NCT00466362|Behavioral|The Evje Model|
349891|NCT00466375|Genetic|Cheek cell samples or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
349892|NCT00466375|Genetic|Cheek cell sample or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
349893|NCT00003561|Biological|recombinant interferon alfa|
349894|NCT00466388|Drug|Cevimeline|
349895|NCT00466401|Drug|Simvastatin|
349896|NCT00466401|Drug|Ezetimibe|
349897|NCT00466414|Device|Polycaprolactone Scaffold|
349898|NCT00466440|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression, toxicity, or maximum 3 years
349899|NCT00466440|Drug|placebo|oral, daily
350237|NCT00504504|Drug|Rituximab|375 mg/m^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
350238|NCT00504504|Drug|Adriamycin|25 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
350239|NCT00504504|Drug|Bleomycin|10 U/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
350240|NCT00504504|Drug|Vinblastine|6 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
350241|NCT00504504|Drug|Dacarbazine (DTIC)|375 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
350242|NCT00003728|Drug|prednisolone|
350243|NCT00504517|Other|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
349200|NCT00481533|Drug|Methyl-Ergonovine-Oxytocin|
349201|NCT00481533|Drug|Oxytocin|
349202|NCT00481546|Genetic|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
349203|NCT00481559|Drug|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
349204|NCT00481572|Drug|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
349205|NCT00481572|Drug|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
349547|NCT00472069|Procedure|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
349548|NCT00472082|Drug|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
349549|NCT00472095|Procedure|fotonovela|
349550|NCT00472108|Procedure|PDT with Metvix 160 mg/g cream|
349551|NCT00472108|Procedure|PDT with placebo cream|
349552|NCT00003583|Drug|etoposide|
349553|NCT00472121|Device|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
349554|NCT00472134|Drug|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
349555|NCT00472134|Device|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
349556|NCT00475293|Drug|Panitumumab and CPT-11|Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg
Irinotecan: 350 or 300 mg/m2. day 1
One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities
349557|NCT00475306|Drug|metoclopramide 10 mg|an anti-emetic medication
349558|NCT00003595|Biological|rituximab|
349559|NCT00475306|Drug|Diphenhydramine 25 mg|used for prophylaxis against akathisia
349560|NCT00475306|Drug|Placebo|placebo
348847|NCT00490126|Other|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
348848|NCT00490139|Drug|Lapatinib|Small molecule inhibitor
348849|NCT00003657|Drug|etoposide|
348850|NCT00490139|Biological|Trastuzumab|Antibody
348851|NCT00490152|Behavioral|Automated diary system|Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study. They will also have the opportunity to send emails to "Juliana" during the course of the study.
348852|NCT00490178|Drug|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
348853|NCT00490191|Drug|Somatropin|
348854|NCT00490204|Drug|Cetirizine|
348855|NCT00490230|Drug|WR 279396|
348856|NCT00490243|Drug|budesonide and montelukast|
348857|NCT00490243|Drug|budesonide and formoterol|
348858|NCT00490243|Drug|montelukast|
348859|NCT00490243|Drug|budesonide|
348860|NCT00003657|Drug|ifosfamide|
348861|NCT00490243|Drug|placebo|
348862|NCT00490256|Procedure|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
348863|NCT00490269|Drug|Placebo|
349206|NCT00481572|Drug|Norepinephrine|titrated norepinephrine over a period of 48 hrs
349207|NCT00481598|Procedure|magnet resonance spectroscopy|magnet resonance spectroscopy
349208|NCT00000541|Behavioral|dietary supplements|
349209|NCT00003623|Dietary Supplement|multivitamin|
349210|NCT00484159|Procedure|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
348114|NCT00503841|Drug|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
348115|NCT00503841|Other|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
348116|NCT00503841|Other|laboratory biomarker analysis|Correlative studies
348496|NCT00498537|Drug|spironolactone|
348497|NCT00498550|Drug|Clozapine|Clozapine up to 550mg per day
348498|NCT00498550|Drug|Treatment as usual|Remain on pre-study antipsychotic treatment
348499|NCT00498563|Procedure|altitude exposure in hypobaric chamber|
348500|NCT00498589|Drug|methotrexate|25 mg per week IM or SC during 24 weeks
348501|NCT00498589|Drug|placebo|one intramuscular injection per week
348502|NCT00498602|Biological|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
348503|NCT00498602|Biological|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
348504|NCT00003694|Other|laboratory biomarker analysis|Correlative studies
348505|NCT00498602|Other|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
348506|NCT00498602|Biological|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
348507|NCT00498615|Drug|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
348508|NCT00498628|Drug|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
348509|NCT00498628|Other|Placebo|Placebo
348510|NCT00498641|Procedure|computer program and patching|
348511|NCT00498654|Biological|Ty800 (Salmonella typhi) Oral Vaccine|
348512|NCT00498680|Drug|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
347760|NCT00465257|Drug|artesunate + amodiaquine|
347761|NCT00465270|Device|AMPLATZER PFO Occluder|patent foramen ovale closure device
347762|NCT00465270|Other|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
347763|NCT00465283|Drug|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
347764|NCT00465296|Drug|rosiglitazone|
347765|NCT00465309|Procedure|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat < 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH > 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
347766|NCT00465322|Drug|fluvastatin|
347767|NCT00465361|Procedure|performance feedback with an educational module|individual performance feedback with an educational module
347768|NCT00003556|Biological|ALVAC-hB7.1|
347769|NCT00465374|Procedure|Change ventilatory parameters with stress index monitoring|
347770|NCT00465387|Behavioral|Falls, Fractures & Osteoporosis Risk Assessment & Management|
347771|NCT00465413|Device|Small volume spacer and/or Rinsing the mouth with water|
347772|NCT00465439|Drug|Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine|10 ml subcutaneously
347773|NCT00465452|Drug|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
347774|NCT00465465|Biological|MVA 85A|i.d. injection
347775|NCT00465478|Procedure|Autologous bone marrow mononuclear cell transplantation|
348117|NCT00503841|Procedure|biopsy|14 days prior to surgery
348118|NCT00503841|Procedure|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
348119|NCT00503841|Procedure|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
348120|NCT00003728|Drug|cyclophosphamide|
348121|NCT00503854|Behavioral|Questionnaire|Questionnaires taking about 15 to 30 minutes total.
348122|NCT00503867|Device|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
347077|NCT00483431|Dietary Supplement|10 mcg Vitamin K for 3 months daily|10 mcg Vitamin K for 3 months daily
347426|NCT00474461|Biological|Intracoronary Injection (cardiac stem cell therapy)|Intracoronary injection of cardiac stem cells
347427|NCT00474474|Procedure|Virtual patient is NOT introduced|
347428|NCT00474487|Biological|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
347429|NCT00474487|Biological|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
347430|NCT00474487|Biological|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
347431|NCT00474487|Biological|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
347432|NCT00003593|Drug|asparaginase|Given IV
347433|NCT00474500|Drug|Coca, Cola, Diet Coke|
347434|NCT00474513|Drug|GSK239512|
347435|NCT00474526|Biological|Meningococcal ACWY Conjugate Vaccine|
347436|NCT00474526|Biological|DTaP-IPV-HBV|
347437|NCT00474526|Biological|Hib|
347438|NCT00474526|Biological|Rotavirus|
347439|NCT00474526|Biological|Pneumococcal 7-valent Conjugate Vaccine|
347440|NCT00474526|Biological|HAV|
347441|NCT00474526|Biological|MMR-V|
347442|NCT00474526|Biological|DTaP|
347443|NCT00003593|Drug|cytarabine|Given IT
347444|NCT00474539|Biological|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
347445|NCT00474539|Biological|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
347446|NCT00477386|Drug|decitabine|Decitabine dose will be escalated as follows.
Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4.
346731|NCT00492284|Drug|ranibizumab|0.5 mg intravitreal injection
346732|NCT00492284|Drug|dexamethasone|0.5 mg intravitreal injection
346733|NCT00003663|Drug|dexamethasone|
346734|NCT00492297|Drug|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
346735|NCT00492310|Behavioral|yoga|vinyasa yoga
346736|NCT00492310|Behavioral|cognitive therapy|cognitive behavioral therapy once weekly
346737|NCT00492310|Behavioral|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
346738|NCT00492310|Behavioral|wellness|wellness program with smoking cessation
346739|NCT00492323|Drug|placebo|twice daily for 4 weeks
346740|NCT00492323|Drug|carisbamate|200 mg tablet twice daily for 4 weeks
346741|NCT00492336|Drug|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
346742|NCT00492336|Drug|Placebo|Placebo 1 tablet each day
346743|NCT00492349|Drug|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
346744|NCT00003664|Biological|aldesleukin|
346745|NCT00492349|Drug|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
346746|NCT00492362|Behavioral|ergometer exercise during hemodialysis|
346747|NCT00492362|Behavioral|pedometer activity outside of hemodialysis|
347078|NCT00483431|Dietary Supplement|20 mcg Vitamin K for 3 months daily|20 mcg Vitamin K for 3 months daily
347079|NCT00483431|Dietary Supplement|45 mcg Vitamin K for 3 months daily|45 mcg Vitamin K for 3 months daily
347080|NCT00483431|Dietary Supplement|90 mcg Vitamin K for 3 months daily|90 mcg Vitamin K for 3 months daily
347081|NCT00483431|Dietary Supplement|180 mcg Vitamin K for 3 months daily|180 mcg Vitamin K for 3 months daily
347082|NCT00003632|Drug|etoposide|
347083|NCT00483431|Genetic|360 mcg Vitamin K for 3 months daily|360 mcg Vitamin K for 3 months daily
346064|NCT00461487|Behavioral|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
346392|NCT00499746|Drug|placebo|oral dose, once per day
346393|NCT00499759|Behavioral|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
346394|NCT00499759|Behavioral|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
346395|NCT00499759|Behavioral|Timed Get-up and Go test (TGUG).|The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command "Go"), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word "Go" and stopped when the subject gets back to starting position.
346396|NCT00499759|Behavioral|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
346397|NCT00499759|Behavioral|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
346398|NCT00499759|Behavioral|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
346399|NCT00499811|Drug|vorinostat|Given orally
346400|NCT00499811|Other|pharmacological study|Correlative studies
346401|NCT00003701|Drug|vinblastine sulfate|
346402|NCT00502944|Behavioral|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
345719|NCT00470262|Drug|Fenofibrate|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
345720|NCT00470262|Drug|Pioglitazone and Fenofibrate|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
345721|NCT00470275|Drug|cytarabine|Given IV
345722|NCT00470288|Procedure|bladder flap during cesarean section|
345723|NCT00003577|Radiation|radiation therapy|
345724|NCT00470301|Drug|tipifarnib|Given orally
345725|NCT00470301|Drug|paclitaxel|Given IV
345726|NCT00470301|Drug|doxorubicin|Given IV
345727|NCT00470301|Drug|cyclophosphamide|Given IV
346065|NCT00461487|Behavioral|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
346066|NCT00461500|Drug|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
346067|NCT00003537|Drug|antineoplaston AS2-1|
346068|NCT00461500|Drug|Fluticasone propionate|FP 100
346069|NCT00461513|Behavioral|Intervention|Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
346070|NCT00461526|Drug|crofelemer|125 mg crofelemer vs. placebo
346071|NCT00461539|Other|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
346072|NCT00461539|Behavioral|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
346073|NCT00461552|Drug|Metreleptin (Leptin)|weight based, sub-cutaneous injection, twice daily
363784|NCT00644163|Behavioral|Eban Health Promotion Intervention|The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
363785|NCT00644176|Drug|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
363786|NCT00644176|Other|placebo|placebo
363787|NCT00644176|Drug|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
363788|NCT00644176|Other|placebo|placebo
363789|NCT00644189|Drug|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
363790|NCT00644202|Behavioral|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
363791|NCT00644202|Behavioral|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
363792|NCT00644202|Behavioral|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
363793|NCT00644215|Drug|5-FU and Mitomycin|5-FU injection 5mg
Mitomycin drop 0.02%
364107|NCT00637078|Other|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
364108|NCT00637091|Drug|Cetuximab, irinotecan|cetuximab, irinotecan
364109|NCT00637104|Device|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
364110|NCT00637104|Device|Vision Co-Cr stent implant|Implant of the Vision stent
364111|NCT00637117|Biological|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
364112|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0008%|
364113|NCT00004786|Drug|iloprost|
364114|NCT00637130|Drug|Travoprost ophthalmic solution, 0.001%|
364115|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0012%|
364116|NCT00637130|Drug|TRAVATAN|
363461|NCT00649311|Drug|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
363462|NCT00649324|Drug|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
363463|NCT00651664|Drug|MLN8237|MLN8237 will be administered orally once a day for 7 to 21 consecutive days followed by a 14-day recovery period.
363464|NCT00651677|Procedure|HAL proctectomy|Hand-assisted laparoscopic proctectomy
363465|NCT00651677|Procedure|"straight" laparoscopic proctectomy|"straight" laparoscopic proctectomy
363466|NCT00651677|Procedure|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
363467|NCT00651677|Procedure|SL Proctectomy|Straight laparoscopic proctectomy
363468|NCT00004905|Drug|idarubicin|
363469|NCT00651690|Biological|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
363470|NCT00651690|Biological|Placebo|Saline injection on Day 0
363471|NCT00651703|Biological|CYT004-MelQbG10 + Montanide|
363472|NCT00651703|Biological|CYT004-MelQbG10 + Montanide + Imiquimod|
363473|NCT00651703|Biological|CYT004-MelQbG10 + Imiquimod|
363474|NCT00651703|Biological|CYT004-MelQbG10 intra nodal injection|
363475|NCT00651716|Other|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
363476|NCT00651716|Other|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
363477|NCT00651716|Other|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
363478|NCT00651729|Biological|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
363794|NCT00004875|Drug|heparin|
363795|NCT00644228|Drug|dexamethasone|Given PO
362833|NCT00663962|Drug|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
362834|NCT00663975|Drug|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
362835|NCT00663988|Procedure|human transplantation|Allograft composite tissue transplantation. procedure. medication
362836|NCT00664001|Dietary Supplement|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
362837|NCT00664001|Dietary Supplement|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
362838|NCT00664014|Drug|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
362839|NCT00005027|Drug|becatecarin|
363146|NCT00656500|Behavioral|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
363147|NCT00656513|Drug|pilocarpine hydrochloride|Given by mouth 3 times a day for up to 12 weeks
363148|NCT00004929|Biological|MUC-2-KLH vaccine|
363149|NCT00656513|Procedure|acupuncture-like transcutaneous electrical nerve stimulation|Given twice a week for up to 12 weeks
363150|NCT00656526|Drug|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
363151|NCT00656526|Drug|Lidocaine|0.5 cc %2 lidocaine,single injection
363152|NCT00656539|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
363153|NCT00658983|Other|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
363154|NCT00658996|Device|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
363155|NCT00658996|Device|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
363156|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
363157|NCT00659009|Other|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
363158|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
346177|NCT00473889|Drug|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
346178|NCT00473889|Drug|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
346179|NCT00473889|Drug|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
346180|NCT00476697|Device|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
346181|NCT00476710|Drug|Colesevelam HCl|
346182|NCT00476736|Drug|Effect on small airways (N-Acetylcystein)|
346183|NCT00476775|Behavioral|after school ethnic dance program - ballet folklorica|
346184|NCT00476775|Behavioral|culturally-tailored, home-based screen time reduction|
346185|NCT00476775|Behavioral|culturally-tailored health and nutrition education|
346186|NCT00003600|Other|placebo|
346187|NCT00476788|Device|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
346188|NCT00476801|Device|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
346189|NCT00476827|Drug|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
346190|NCT00476827|Drug|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
346191|NCT00476827|Drug|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
346192|NCT00476827|Drug|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
346193|NCT00476827|Drug|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
346511|NCT00467844|Drug|Placebo|Matching Placebo
346512|NCT00467857|Procedure|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
351207|NCT00602355|Behavioral|Interpersonal psychotherapy (IPT)|IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
345837|NCT00482924|Other|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
345838|NCT00482937|Drug|CD-NP|
345839|NCT00003631|Drug|melphalan|
345840|NCT00482950|Drug|PHX1149T|
345841|NCT00485836|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
345842|NCT00000542|Drug|amlodipine|
345843|NCT00003641|Biological|recombinant interferon alfa|Given IV
345844|NCT00485849|Drug|Atomoxetine Hydrochloride|
345845|NCT00485862|Drug|Atomoxetine Hydrochloride|
345846|NCT00485862|Drug|Sertraline|
345847|NCT00485862|Drug|Placebo|
345848|NCT00485875|Drug|Atomoxetine Hydrochloride|
345849|NCT00485888|Drug|Cipralex|10-20mg; one per day
345850|NCT00485888|Drug|Placebo|Matched to Cipralex
345851|NCT00485901|Drug|Olanzapine Hydrochloride|
345852|NCT00485901|Drug|Haloperidol|
345853|NCT00485914|Behavioral|worksite intervention|Researchers will measure the effects of worksite assessment through educational materials or an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The two groups involved in the research will either receive educational information or on-site work visits. The scope of the information will either be through educational materials to develop strategies to compensate or one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
345854|NCT00003641|Other|clinical observation|Patients undergo observation for 4 weeks.
345855|NCT00485927|Behavioral|stress|
345856|NCT00485940|Drug|Prucalopride|2 mg o.d.
350903|NCT00609986|Drug|NPH Insulin or glargine insulin and aspartame insulin|The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.
The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.
Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL
350904|NCT00609999|Drug|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
350905|NCT00610025|Procedure|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
350906|NCT00610038|Drug|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
350907|NCT00610051|Drug|Alprostadil|central venous access continuous delivery with 2.5ng/kg/min
350908|NCT00004262|Procedure|conventional surgery|
350909|NCT00610064|Radiation|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
350910|NCT00610064|Radiation|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
350911|NCT00610077|Drug|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
351208|NCT00602355|Behavioral|Clinical management|Clinical management includes treatment as usual for those receiving medication for depression.
351209|NCT00602355|Behavioral|Mothercrafting|Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
351210|NCT00602368|Other|histological technique|
351211|NCT00000616|Behavioral|diet, fat-restricted|
351212|NCT00004228|Drug|thioguanine|Given PO
351213|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
351214|NCT00604851|Drug|lansoprazole|participants < 30 kg: 15 mg by mouth once daily; participants >= 30 kg: 30 mg by mouth once daily
351215|NCT00604851|Drug|placebo|placebo medication taken by mouth once daily
350593|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
350594|NCT00496626|Biological|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
350912|NCT00610077|Drug|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
350913|NCT00610090|Device|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
350914|NCT00610103|Drug|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
350915|NCT00610116|Device|Electronic Repositioning|Change of pacing vectors for CRT pacing
350916|NCT00610129|Drug|MK-0646|MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
350917|NCT00610142|Drug|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
350918|NCT00612261|Procedure|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
350919|NCT00612274|Drug|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
350920|NCT00612274|Drug|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
350921|NCT00612274|Drug|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
350922|NCT00612287|Drug|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
350923|NCT00612300|Behavioral|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
350244|NCT00504530|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
350245|NCT00504543|Drug|AEB071|oral, twice daily
350246|NCT00504543|Drug|Certican|twice daily
350247|NCT00504543|Drug|Neoral|twice daily
350248|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet once daily
350249|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet once daily
350250|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet two times a day
350251|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet two times a day
350252|NCT00504556|Drug|warfarin|warfarin tablets
350253|NCT00003728|Drug|therapeutic hydrocortisone|
350254|NCT00504582|Drug|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
350255|NCT00504595|Drug|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
350256|NCT00504595|Drug|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
350257|NCT00504608|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
350258|NCT00504634|Drug|Bortezomib|1 mg/m^2 IV On Days 1, 4, 8, and 11.
350259|NCT00506961|Drug|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
350260|NCT00506974|Drug|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
350595|NCT00496626|Biological|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
350596|NCT00496639|Procedure|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
350597|NCT00496639|Procedure|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
349561|NCT00475306|Drug|Metoclopramide 20 mg|Metoclopramide 20 mg
349562|NCT00475319|Drug|placebo|comparison of different dosages of drug
349563|NCT00475319|Drug|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
349564|NCT00475319|Drug|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
349565|NCT00475332|Drug|Iodine I -01 Tositumomab (Bexxar)|Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed "dosimetric dose," involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm^3) total body radiation dose can be calculated.
349566|NCT00475332|Procedure|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
349567|NCT00475345|Behavioral|Bedtime snacks|
349900|NCT00466440|Drug|docetaxel|75 mg/m2, IV, q 21 days, six 21 day cycles, maximum 10 cycles
349901|NCT00466440|Drug|prednisone|5 mg, oral, BID, six 21 day cycles
349902|NCT00466453|Behavioral|knowledge-adaptive Web-based instruction|
349903|NCT00466466|Drug|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
349904|NCT00003561|Biological|sargramostim|
349905|NCT00466479|Drug|brimonidine|
349906|NCT00466479|Procedure|laser trabeculoplasty|
349907|NCT00466492|Procedure|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
349908|NCT00466505|Biological|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
349909|NCT00466505|Drug|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
349910|NCT00466505|Genetic|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
349911|NCT00466505|Other|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
349211|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
349212|NCT00484172|Procedure|blood draws|
349213|NCT00484185|Drug|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
349214|NCT00484198|Drug|pioglitazone|Tablets
349215|NCT00484198|Drug|placebo|Tablets
349216|NCT00484198|Drug|rivoglitazone HCl|Tablets
349217|NCT00000541|Drug|folic acid/Vitamin B6/Vitamin B12|
349218|NCT00003636|Procedure|conventional surgery|
349219|NCT00484198|Drug|rivoglitazone HCl|Tablets
349220|NCT00484211|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
349221|NCT00484237|Drug|etanercept|
349222|NCT00484250|Drug|metronidazole,doxycycline|
349223|NCT00484263|Drug|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
349224|NCT00484276|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
349225|NCT00484289|Drug|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants > 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
349226|NCT00484302|Behavioral|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
349227|NCT00484302|Behavioral|Non-manualized standard treatment|Treatment by case-manager
349228|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
349229|NCT00003636|Procedure|neoadjuvant therapy|
349568|NCT00475358|Drug|Duloxetine|
349569|NCT00003595|Drug|CHOP regimen|
349570|NCT00475358|Drug|Placebo|
348513|NCT00498680|Drug|Sildenafil|100mg
348514|NCT00498680|Drug|Vardenafil|20mg
348515|NCT00500604|Drug|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
348516|NCT00003708|Drug|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
348864|NCT00490269|Drug|Dronabinol|
348865|NCT00490282|Radiation|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
348866|NCT00490282|Radiation|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
348867|NCT00490308|Drug|Treatment with estradiol valerate|
348868|NCT00490321|Device|VentrAssistTM Left Ventricular Assist Device|
348869|NCT00490347|Device|VentrAssist Left Ventricular Assist Device|
348870|NCT00493025|Drug|cisplatin|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348871|NCT00493025|Drug|gefitinib|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348872|NCT00493025|Drug|paclitaxel|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348873|NCT00493025|Genetic|gene expression analysis|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348874|NCT00493025|Other|immunohistochemistry staining method|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348875|NCT00493025|Other|laboratory biomarker analysis|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348876|NCT00493025|Other|pharmacological study|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348877|NCT00493025|Procedure|adjuvant therapy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348878|NCT00493025|Procedure|biopsy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348879|NCT00493025|Procedure|conventional surgery|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348123|NCT00503880|Biological|filgrastim|subcutaneously one day prior to treatment
348124|NCT00503880|Drug|clofarabine|single IV dose over 1 hour daily for 5 days
348125|NCT00503880|Drug|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
348126|NCT00506155|Drug|Cisplatin|70 mg/m^2 by vein over 4 hours
348127|NCT00506155|Drug|Doxorubicin|30 mg/m^2 by vein over 15 minutes
348128|NCT00506155|Drug|Methotrexate|30 mg/m^2 by vein over 30 minutes
348129|NCT00506155|Drug|Vinblastine Sulfate|3 mg/m^2 by vein over 30 minutes
348130|NCT00506168|Drug|Irinotecan, Capecitabine|
348131|NCT00506181|Drug|probiotic mixture|"Jarro-Dophilus" probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day.
348132|NCT00506181|Drug|Placebo|
348133|NCT00506194|Drug|Insulin|
348134|NCT00003736|Procedure|biopsy|
348135|NCT00506194|Drug|OAD|Gliclazide-MR, Metformin, Glimepiride
348136|NCT00506207|Drug|S-1, Irinotecan, Oxaliplatin|
348137|NCT00506233|Behavioral|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
348138|NCT00506246|Drug|Propofol|intravenous (total intravenous anaesthesia)
induction and maintenance
348139|NCT00506259|Drug|dTR Melatonin (NIH CC PDS)|
348140|NCT00506259|Device|Phototherapy (Bright Light)|
348141|NCT00506259|Drug|Melatonin CR|
348517|NCT00500604|Drug|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
348518|NCT00500604|Drug|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
348519|NCT00500617|Genetic|Blood draw|Collection of peripheral blood samples for DNA and RNA
348520|NCT00500630|Device|Body fixed 3D sensors|
347447|NCT00477399|Behavioral|The Evje Model|
347448|NCT00003603|Drug|cyclophosphamide|
347449|NCT00477412|Drug|Bortezomib|1st Combination = 1.3 mg/m^2 IV Push Over 3-5 Seconds Days 2 & 5; 2nd Combination = 0.7 mg/m^2 IV Push Days 1 & 6.
347450|NCT00477412|Drug|Rituximab|375 mg/m^2 IV Over 6-8 Hours On Day 1 each cycle.
347776|NCT00465491|Drug|picoplatin|IV picoplatin 150mg/m2 q3wk
347777|NCT00465491|Other|best supportive care|best supportive care
347778|NCT00468325|Procedure|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
347779|NCT00468325|Procedure|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
347780|NCT00468325|Procedure|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
347781|NCT00468338|Device|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
347782|NCT00468351|Procedure|Intravitreal Injection of 1,5 mg of bevacizumab|
347783|NCT00468351|Procedure|Intravitreal injection of 4 mg of Triamcinolone acetonide|
347784|NCT00468364|Drug|insulin glargine|
347785|NCT00468364|Drug|NPH insulin|
347786|NCT00468377|Drug|Rituximab|1 g. rituximab i.v. on Day 1 and 15
347787|NCT00003572|Drug|tacrolimus|
347788|NCT00468403|Biological|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
347789|NCT00468403|Biological|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
347084|NCT00483444|Behavioral|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
347085|NCT00483457|Drug|enzyme inhibitor therapy|enzyme inhibitor therapy
347086|NCT00483457|Genetic|protein expression analysis|protein expression analysis
347087|NCT00483457|Other|immunohistochemistry staining method|immunohistochemistry staining method
347088|NCT00483457|Other|laboratory biomarker analysis|laboratory biomarker analysis
347089|NCT00486460|Drug|Celebrex|
347090|NCT00486473|Drug|Multihance|0.5 Molar at a single dose injection
347091|NCT00486473|Drug|Magnevist|0.5M at a single dose injection
347092|NCT00486486|Drug|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
347093|NCT00486486|Drug|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
347094|NCT00486499|Procedure|I-125 versus Pd-103 radioactive seed insertion|
347095|NCT00486512|Drug|aspirin, 1,25-dihydroxycholecalciferol, calcium|Oral Calcitriol (1α 25-dihydroxy cholecalciferol) capsules, 0.5 µg (QD) Oral acetylsalicylic acid 37.5 mg and calcium carbonate 625 mg combination tablets (bid)
347096|NCT00486512|Drug|placebo|placebo to oral Calcitriol (1α 25-dihydroxy cholecalciferol) capsules, 0.5 µg (QD) placebo to oral acetylsalicylic acid 37.5 mg and calcium carbonate 625 mg combination tablets (bid)
347097|NCT00486525|Procedure|Yoga Therapy|Patients will undergo yoga therapy
347098|NCT00486538|Drug|ABT-869|One oral dose daily.
347099|NCT00003643|Drug|paclitaxel|
347100|NCT00486551|Behavioral|Anger control training|
347101|NCT00486564|Drug|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
347451|NCT00477412|Drug|Cyclophosphamide|1st Combination = 300 mg/m^2 IV Over 3 Hours Twice Daily Days 2,3,& 4.
347452|NCT00477412|Drug|Vincristine|1st Combination = 1.4 mg/m^2 (maximum 2 mg) IV Push Days 5 & 12.
347453|NCT00477412|Drug|Methotrexate|2nd Combination = 200 mg/m^2 IV over 2 hours on Day 1, then 800 mg/m^2 IV over 22 hours on Day 2.
346403|NCT00003727|Biological|recombinant interferon alfa|
346404|NCT00502944|Behavioral|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
346405|NCT00502957|Behavioral|Biofeedback|
346748|NCT00492388|Drug|PMI-150 (intranasal ketamine)|intranasal dosing
346749|NCT00492388|Drug|placebo|placebo
346750|NCT00492401|Drug|decitabine|Given IV
346751|NCT00494858|Behavioral|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
346752|NCT00494858|Behavioral|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
346753|NCT00003678|Procedure|adjuvant therapy|
346754|NCT00494871|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL [creatinine clearance] >= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
346755|NCT00494871|Drug|Warfarin|Participants orally administered a warfarin potassium tablet (INR [international normalized ratio] target was 1.6-2.6 for patients >70 years and 2.0-3.0 for patients <70 years)
346756|NCT00494871|Drug|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
346757|NCT00494871|Drug|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
346758|NCT00494884|Drug|vildagliptin|
346759|NCT00494897|Drug|Asparaginase|
346760|NCT00494897|Drug|Cyclophosphamide|
346761|NCT00494897|Drug|Cytarabine|
346762|NCT00494897|Drug|Daunorubicin|
346763|NCT00494897|Drug|Mercaptopurine|
346764|NCT00003679|Drug|cyclophosphamide|
346765|NCT00494897|Drug|Prednisone|
346766|NCT00494897|Drug|Vincristine|
346074|NCT00464373|Drug|Placebo|4ml NaCl 0.9%
346075|NCT00464386|Device|Continuous Glucose Monitoring|measure glucose levels on burn patients
346076|NCT00464399|Drug|everolimus|
346077|NCT00464412|Behavioral|Education|
346078|NCT00003553|Biological|anti-thymocyte globulin|Given IV
346079|NCT00464425|Procedure|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
346080|NCT00464425|Procedure|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
346081|NCT00464425|Other|No Acupuncture|Control
346082|NCT00464438|Drug|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
346083|NCT00464438|Drug|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
346406|NCT00502970|Drug|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
346407|NCT00502970|Drug|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
346408|NCT00502983|Behavioral|Interview|Interview lasting approximately 50 minutes.
346409|NCT00502996|Drug|Methotrexate|>=15 mg po/week
346410|NCT00502996|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
346411|NCT00503009|Drug|fluticasone propionate/salmeterol|comparator
346412|NCT00503009|Drug|fluticasone propionate|Comparator
346413|NCT00503009|Drug|placebo|Placebo
346414|NCT00003727|Biological|sargramostim|
346415|NCT00503022|Drug|ACZ885|
346416|NCT00503035|Drug|Celecoxib|400 mg by mouth twice daily x 6 months
346417|NCT00503035|Procedure|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
364117|NCT00637130|Other|Vehicle|
364118|NCT00637143|Drug|Tacrolimus|Oral
364119|NCT00639717|Drug|tacrolimus (standard GVHD prophylaxis)|Tacrolimus(or cyclosporine when necessary)
Tacrolimus will begin on day -3, IV or oral.
Target trough level for tacrolimus is 8-12 ng/ml.
In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
364120|NCT00639717|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
364121|NCT00639717|Drug|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
364122|NCT00639717|Drug|methoxsalen|Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.
On day +70 post transplant ECP frequency will be given every other week.
On day +100 post transplant ECP will be given monthly until day +180 and stopped.
364123|NCT00639730|Dietary Supplement|modified Atkins diet|High fat, low carbohydrate diet
364124|NCT00639743|Drug|placebo ( group B)|placebo ( group B)
364125|NCT00639743|Drug|tenecteplase (group A)|tenecteplase (group A)
364126|NCT00004829|Drug|tobramycin|
364127|NCT00639756|Drug|Allopurinol|Allopurinol 300 mg
364128|NCT00639756|Drug|Placebo|Placebo given for 2 weeks
364129|NCT00639769|Drug|cisplatin|Starting dose 30 mg/m2 Dose level -1 20 mg/m2
364480|NCT00634920|Drug|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
364481|NCT00634920|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
364482|NCT00634920|Drug|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
364483|NCT00634920|Drug|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
364484|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
364485|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
363796|NCT00644228|Drug|lenalidomide|Given PO
363797|NCT00644228|Drug|bortezomib|Given IV
363798|NCT00644228|Other|laboratory biomarker analysis|Optional correlative studies
363799|NCT00644241|Biological|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
363800|NCT00644241|Procedure|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
363801|NCT00644254|Procedure|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
363802|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
363803|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
363804|NCT00646620|Drug|budesonide/formoterol (Symbicort)|
363805|NCT00646620|Drug|fluticasone/salmeterol (Advair Diskus)|
363806|NCT00646620|Drug|albuterol (Ventolin)|
363807|NCT00646633|Procedure|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
363808|NCT00646646|Drug|propofol|sedative
363809|NCT00646646|Drug|dexmedetomidine|Sedative
363810|NCT00646646|Drug|Midazolam|sedative
363811|NCT00004888|Drug|docetaxel|Given IV
363812|NCT00646646|Drug|saline placebo|saline placebo
363813|NCT00646659|Biological|cetuximab|
363814|NCT00646659|Drug|carboplatin|
363815|NCT00646659|Drug|cisplatin|
363816|NCT00646659|Drug|docetaxel|
363817|NCT00646659|Drug|fluorouracil|
363159|NCT00659022|Procedure|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
363160|NCT00004983|Behavioral|diabetes self-management education|
363161|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
363162|NCT00659022|Drug|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
363163|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
363164|NCT00659048|Drug|Ciclesonide|Ciclesonide 200µg versus Placebo
363165|NCT00659048|Drug|Placebo|placebo
363166|NCT00659061|Dietary Supplement|SPRINKLES|Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).
Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services.
363479|NCT00004905|Procedure|peripheral blood stem cell transplantation|
363480|NCT00651742|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
363481|NCT00651755|Drug|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
363482|NCT00651755|Drug|Cyclophosphamide|750 mg/m^2 By Vein On Day 1
363483|NCT00651755|Drug|Doxorubicin|25 mg/m^2 By Vein Over 48 Hours On Days 1-2
363484|NCT00651755|Drug|Vincristine|2 mg By Vein On Day 1
363485|NCT00651755|Drug|Prednisone|100 mg PO for 5 Days
363486|NCT00651755|Drug|Rituximab|375 mg/m^2 By Vein On Day 1.
363487|NCT00651755|Drug|Ondansetron|8 mg daily for 2 days
363488|NCT00651768|Drug|budesonide/formoterol|
363489|NCT00654082|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
363490|NCT00654082|Drug|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
346513|NCT00467857|Other|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
346514|NCT00467870|Drug|Testosterone Undecanoate|750 mg or 1000 mg dose testosterone undecanoate
346515|NCT00467883|Drug|Liposomal Amphotericin B|high dosage
346516|NCT00467896|Drug|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
346517|NCT00467896|Drug|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
346518|NCT00467909|Behavioral|micronutrients|
346519|NCT00467922|Drug|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
346520|NCT00003569|Drug|dimesna|
346521|NCT00467922|Drug|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
346522|NCT00467935|Drug|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
346523|NCT00467948|Drug|cefazolin|
346524|NCT00003578|Drug|cytarabine|
346525|NCT00470548|Drug|pemetrexed disodium|Alimta® (pemetrexed) 500 mg/m2 IV administration on Day 1 of each cycle with Abraxane® (ABI 007) 260 mg/m2IV administration following pemetrexed on Day 1 of each cycle
346526|NCT00470561|Drug|Aspirin|Two 325 mg doses of aspirin per day for 6 months
346527|NCT00470561|Drug|Placebo|Two placebo pills per day for 6 months
346528|NCT00470574|Biological|QS21|
346529|NCT00470574|Biological|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
346530|NCT00470574|Other|immunoenzyme technique|
346531|NCT00470574|Other|immunologic technique|
346532|NCT00470574|Other|laboratory biomarker analysis|
346533|NCT00470600|Drug|Caldolor|800 milligrams intravenous
345857|NCT00485940|Other|Placebo|Placebo o.d.
345858|NCT00485940|Drug|Prucalopride|4 mg o.d.
345859|NCT00485953|Drug|risedronate|risedronate 35 mg per week
345860|NCT00485966|Drug|CX-3543|360 mg/m2 daily x 5 q 21 days
345861|NCT00485979|Drug|larotaxel (XRP9881)|intravenous administration
346194|NCT00476827|Drug|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
346195|NCT00476853|Drug|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
346196|NCT00476866|Device|intermittent positive-pressure breathing (IPPB)|
346197|NCT00003601|Drug|fenretinide|
346198|NCT00476879|Drug|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
346199|NCT00476892|Procedure|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
346200|NCT00476905|Device|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
346201|NCT00476918|Drug|Intravitreal injection (triamcinolone acetonide)|
346202|NCT00479921|Biological|Trivalent influenza subunit vaccine|
346203|NCT00479934|Drug|imatinib mesylate|6 month treatment with 400mg/day (per os)
346204|NCT00000539|Drug|warfarin|
346205|NCT00003617|Drug|omeprazole|
346206|NCT00479947|Drug|Probiotics (Natural product)|
346207|NCT00479947|Drug|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
346208|NCT00479960|Behavioral|commercially available omega-3 fatty acids supplementation|
351216|NCT00604864|Drug|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
351217|NCT00604864|Drug|placebo|Placebo
351218|NCT00604877|Behavioral|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
351219|NCT00604877|Behavioral|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
351220|NCT00604890|Drug|API 31510 Topical Cream|Topical treatment to lesion twice daily of randomized treatments that include 1.5% active cream, 3% active cream or placebo cream
351221|NCT00604903|Device|Remon ImPressure implantable pulmonary artery pressure monitor|Remon ImPressure implantable pulmonary artery pressure monitor responding to ultrasonic signal.
351222|NCT00004235|Drug|docetaxel|
351223|NCT00604916|Other|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
351224|NCT00604916|Other|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
351225|NCT00604929|Dietary Supplement|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
351226|NCT00604942|Procedure|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
351227|NCT00604942|Procedure|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
351228|NCT00604942|Drug|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
345862|NCT00485979|Drug|docetaxel|intravenous administration
345863|NCT00485979|Drug|trastuzumab|intravenous administration
345864|NCT00486005|Drug|Olanzapine Hydrochloride|
345865|NCT00003642|Drug|cisplatin|
345866|NCT00486005|Drug|Nizatidine|
345867|NCT00486005|Drug|Placebo|
345868|NCT00486018|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
350924|NCT00612300|Behavioral|Physical therapy - Lokomat|B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.
A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks.
350925|NCT00612313|Drug|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
350926|NCT00612313|Behavioral|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
351229|NCT00604942|Drug|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
351230|NCT00604955|Drug|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
351231|NCT00604968|Drug|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
351232|NCT00604981|Behavioral|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
351233|NCT00004235|Drug|irinotecan hydrochloride|
351234|NCT00607594|Drug|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
351235|NCT00607607|Drug|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
351236|NCT00607620|Behavioral|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
351237|NCT00004252|Drug|fluorouracil|
351238|NCT00607646|Drug|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
351239|NCT00607646|Drug|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
351240|NCT00607659|Other|No intervention, only observational|No intervention, only observational
351241|NCT00607672|Drug|Placebo|Placebo
351242|NCT00607672|Drug|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
350598|NCT00499083|Other|immunoenzyme technique|Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.
CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
350599|NCT00499083|Other|immunohistochemistry staining method|Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.
CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
350600|NCT00499083|Other|laboratory biomarker analysis|Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.
CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
350601|NCT00499083|Procedure|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
350602|NCT00499083|Procedure|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
350603|NCT00499083|Procedure|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
350604|NCT00003700|Drug|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I & IV
350927|NCT00612326|Procedure|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
350928|NCT00004307|Genetic|Ornithine transcarbamylase vector|
349912|NCT00466505|Other|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
349913|NCT00466505|Other|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
349914|NCT00466518|Drug|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
349915|NCT00469261|Drug|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
349916|NCT00469261|Drug|Current medical therapy for AMI|Current medical therapy for AMI
349917|NCT00003574|Radiation|intraoperative radiation therapy|
349918|NCT00469274|Drug|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
349919|NCT00469274|Drug|Antibiotic PEP|TMP-SMX DS po BID for 14 days
349920|NCT00469300|Drug|Iontophoretic delivery of acyclovir|
349921|NCT00469326|Drug|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
350261|NCT00506987|Drug|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
350262|NCT00506987|Drug|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
350263|NCT00507000|Drug|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
350264|NCT00507000|Drug|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
350265|NCT00507013|Device|QuickClose device|
350266|NCT00507026|Drug|IV Diclofenac|IV Diclofenac q6h
350267|NCT00507026|Drug|IV ketorolac|IV ketorolac q6h
350268|NCT00003742|Drug|paclitaxel|
350269|NCT00507026|Drug|Placebo|Placebo q6h
350270|NCT00507039|Procedure|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
349571|NCT00475371|Drug|MKC253 Inhalation Powder|Inhalation powder
349572|NCT00475384|Drug|Fludarabine|40 mg/m^2 By Vein Over 30 Minutes x 5 Days
349573|NCT00475384|Drug|Thiotepa|5 mg/kg By Vein Daily x 2 Days
349574|NCT00475384|Radiation|Total Body Irradiation|200 centigray (cGy) (BID) Twice Daily Over 20-40 Minutes x 3 Days
349575|NCT00475384|Drug|Melphalan|140 mg/m^2 by vein x 1 Day
349576|NCT00475384|Biological|Stem Cell Transplant (SCT)|Infusion of normal donor stem cells on Day 0
349577|NCT00475384|Procedure|Anergized Cell Infusion|Infusion of stem cells treated with the anti-B7 antibodies on Day 35+ or 42+.
349578|NCT00475397|Drug|Duloxetine|
349579|NCT00475397|Drug|Placebo|
349580|NCT00003595|Drug|cyclophosphamide|
349581|NCT00475410|Drug|ASCs (Cx401, company code)|Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.
Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then.
349582|NCT00478309|Other|educational intervention|
349583|NCT00478322|Drug|Placebo|Matching placebo of 100 mg BID
349584|NCT00478322|Drug|INCB013739|INCB013739 100 mg BID
349585|NCT00478335|Drug|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
349586|NCT00478335|Drug|calcitonin|one nasal spray daily for 4 days
349587|NCT00478335|Drug|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
349588|NCT00478335|Drug|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
349589|NCT00478335|Drug|Placebo for sildenafil|one tablet daily for 4 days
349590|NCT00478335|Drug|placebo for calcitonin|one nasal spray daily
349591|NCT00478348|Procedure|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
349592|NCT00003606|Radiation|radiation therapy|
348880|NCT00003667|Drug|doxorubicin hydrochloride|
348881|NCT00493025|Procedure|neoadjuvant therapy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348882|NCT00493025|Radiation|radiation therapy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
348883|NCT00493038|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
348884|NCT00493038|Drug|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
348885|NCT00493051|Biological|GAM501|Ad5PDGF-B formulated in a collagen gel
348886|NCT00493051|Biological|Placebo|Collagen gel
349230|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
349231|NCT00484328|Drug|Ribavirin|different dosing regimes of Ribavirin
349232|NCT00484341|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
349233|NCT00484341|Drug|NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
349234|NCT00484341|Drug|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
349235|NCT00484354|Other|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
349236|NCT00484354|Other|Normal saline|IV Normal saline with volume given determined by patient weight
349237|NCT00003649|Biological|Ad5CMV-p53 gene|
349238|NCT00487331|Other|Acupuncture|Acupuncture sessions 1-3 times per week.
349239|NCT00487331|Behavioral|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
349240|NCT00487344|Procedure|Non-Personalized Meal Planning|
349241|NCT00487344|Procedure|Personalized Meal Planning and Dietetic Consultation|
349242|NCT00487357|Behavioral|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
349243|NCT00487370|Procedure|Implantation of gold beads around a knee through needles|
348521|NCT00500656|Drug|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
348522|NCT00500656|Drug|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
348523|NCT00500656|Drug|Oral Placebo|hard capsule matched to tranexamic acid
348524|NCT00500656|Drug|S.C. Placebo|solution for injection, matched to icatibant for injection
348525|NCT00500669|Drug|Betadine|Topically
348526|NCT00500682|Drug|Placebo|9g /day (3 times a day)
348527|NCT00000552|Procedure|angioplasty, transluminal, percutaneous coronary|
348528|NCT00003709|Drug|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
348529|NCT00500682|Drug|AST-120|9g /day (3 times a day)
348530|NCT00500695|Behavioral|Motivational Interviewing|Motivational Interviewing
348531|NCT00500695|Behavioral|Psychoeducation|Psychoeducation
348532|NCT00500721|Drug|HCV-796|HCV-796 500mg BID x 14 days
348533|NCT00500721|Drug|Desipramine|Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.
Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.
Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10.
348534|NCT00500734|Procedure|Blood Sample|One time blood draw of 2 teaspoons.
348535|NCT00500747|Biological|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
348536|NCT00500747|Drug|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
348537|NCT00500760|Drug|Cisplatin|Administered intravenously (IV; in a vein)
348887|NCT00493051|Other|Standard of care|moist dressing changes daily
348888|NCT00493064|Drug|Nicotinic acid|topical eye drops
347790|NCT00468403|Biological|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
347791|NCT00468403|Drug|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
347792|NCT00468403|Drug|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
348142|NCT00506272|Procedure|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
348143|NCT00506272|Procedure|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
348144|NCT00506285|Drug|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
348145|NCT00003736|Procedure|breast imaging study|
348146|NCT00506285|Other|placebo patch|This patch is designed to appear identical to the actual intervention patch
348147|NCT00506298|Drug|bezafibrate + diflunisal|bezafibrate + diflunisal
348148|NCT00506298|Drug|bezafibrate + placebo|bezafibrate + placebo
348149|NCT00506311|Drug|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
348150|NCT00506337|Drug|Qingyi granules|Control group: The therapeutic methods accord to the concert schemes cited in the "Guides to diagnosis and treatment of severe acute pancreatitis" introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.
Treatment group: In addition to the concert schemes cited in the "Guides to diagnosis and treatment of severe acute pancreatitis", during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD.
348151|NCT00462280|Drug|lovastatin|Given PO
348152|NCT00462280|Other|placebo|Given PO
348153|NCT00462280|Procedure|biopsy|Correlative studies
348154|NCT00462280|Procedure|laboratory biomarker analysis|Correlative studies
347454|NCT00477412|Drug|Cytarabine|2nd Combination = 3g/m2 grams/m^2 IV over 2 Hours Twice a Day,On Days 3 & 4.
347455|NCT00477412|Drug|Doxorubicin|Arm 1: 50 mg/m^2 IV Push Over 15-30 min on Day 5
347456|NCT00477451|Drug|placebo|Alprazolam Placebo
347457|NCT00477451|Drug|alprazolam|Staccato Alprazolam
347458|NCT00477464|Drug|Lapatinib|1250mg once daily
347459|NCT00003603|Drug|dexamethasone|
347460|NCT00477464|Drug|capecitabine|2000mg/m^2 twice daily (14 days out of 21 days)
347461|NCT00477477|Other|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
347462|NCT00477477|Other|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
347463|NCT00477490|Drug|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
347464|NCT00477490|Drug|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
347465|NCT00477503|Drug|Gallium-67 Citrate (Ga-67)|Group A: Ga-67 citrate injection alone, in the baseline study.
Group B: Ga-67 and In 111 DTPA injection in the baseline study.
Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.
347466|NCT00477503|Drug|In-111 DTPA (In-111 pentetate)|Group B: Ga-67 and In 111 DTPA injection in the baseline study.
Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.
347467|NCT00477516|Procedure|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
347468|NCT00477529|Drug|ABI-008|nab-docetaxel
347469|NCT00477542|Drug|clofarabine|Cohort- n- Clofarabine (mg/m2/day)
-1 3-10 20
3-6 30
3-6 40
3-6 50
3-6 60
6-10 70
347470|NCT00000539|Drug|vitamin E|
347471|NCT00003603|Drug|idarubicin|
347472|NCT00480597|Drug|gemcitabine|
347793|NCT00468403|Procedure|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant[s]) will occur intraportally.
346767|NCT00494897|Drug|Methotrexate|
346768|NCT00494897|Procedure|Intrathecally treatment|
346769|NCT00494910|Behavioral|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
347102|NCT00486577|Procedure|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
347103|NCT00486577|Procedure|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
347104|NCT00486590|Procedure|Prolact-Plus Human Milk Fortifier|
347105|NCT00486603|Drug|hydroxychloroquine|
347106|NCT00486603|Drug|temozolomide|
347107|NCT00486603|Genetic|mutation analysis|
347108|NCT00486603|Genetic|polymerase chain reaction|
347109|NCT00486603|Other|immunologic technique|
347110|NCT00000542|Drug|lisinopril|
347111|NCT00003644|Drug|carboplatin|
347112|NCT00486603|Other|laboratory biomarker analysis|
347113|NCT00486603|Other|pharmacological study|
347114|NCT00486603|Procedure|adjuvant therapy|
347115|NCT00486603|Radiation|3-dimensional conformal radiation therapy|
347116|NCT00486603|Radiation|intensity-modulated radiation therapy|
347117|NCT00486616|Device|electrical impedance tomography|
347118|NCT00486616|Procedure|double-lumen tube placement|
347119|NCT00489307|Drug|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
347120|NCT00489307|Drug|Placebo|Placebo PO twice daily x 14 days
346418|NCT00503074|Behavioral|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
346419|NCT00503074|Behavioral|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
346420|NCT00503087|Procedure|Saline Injection|
346421|NCT00503087|Device|Pneumatic Skin Flattening (PSF)|
346422|NCT00503100|Device|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
346423|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
346424|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
346425|NCT00003727|Biological|therapeutic autologous lymphocytes|
346426|NCT00503113|Drug|Alendronate|70mg per oral (po) weekly
346427|NCT00503126|Drug|bivalirudin|anticoagulation
346428|NCT00503139|Drug|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
346429|NCT00505661|Drug|Letrozole|2.5 mg PO Once Daily
346770|NCT00494910|Behavioral|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
346771|NCT00494949|Drug|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
346772|NCT00494949|Drug|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
346773|NCT00494962|Drug|lecozotan SR|
346774|NCT00494975|Device|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
346775|NCT00000547|Drug|enalapril|
346776|NCT00003679|Drug|docetaxel|
364486|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
364487|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
364488|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
364489|NCT00004756|Procedure|Educational materials|
364490|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
364491|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
364492|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
364493|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
364494|NCT00634946|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
364495|NCT00634946|Drug|Placebo|Placebo is administrated into the nucleus pulposus of an intervertebral disc.
364496|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
364497|NCT00634959|Drug|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
364498|NCT00637143|Drug|Cyclosporine|Oral
364824|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
364825|NCT00666939|Drug|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
364826|NCT00666939|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
364827|NCT00666939|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
364828|NCT00669331|Drug|matched control|10 capsules twice a day for 52 weeks
364829|NCT00669344|Drug|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
364830|NCT00669344|Drug|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
363818|NCT00646659|Genetic|fluorescence in situ hybridization|
364130|NCT00639769|Drug|irinotecan hydrochloride|50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
364131|NCT00639782|Device|On-X Heart valve replacement|On-X Heart valve replacement
364132|NCT00639782|Device|SJM Heart valve replacement|SJM Heart valve replacement
364133|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
364134|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
364135|NCT00639808|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
364136|NCT00639808|Drug|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
364137|NCT00004831|Drug|cysteine hydrochloride|
364138|NCT00639834|Biological|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
364139|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
364140|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
364141|NCT00642018|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously on day one of every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
364142|NCT00642018|Drug|LY2181308 sodium|LY2181308 administered weekly plus docetaxel 75 mg/m2 intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
364143|NCT00642018|Drug|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
364144|NCT00642031|Drug|Triciribine|15 mg/m^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
364145|NCT00004860|Drug|tegafur-uracil|
363491|NCT00654095|Drug|Ezetimibe|Ezetimibe 10 mg once daily
363492|NCT00654095|Drug|atorvastatin|atorvastatin 20 mg once daily
363493|NCT00654108|Drug|Ciprofloxacin 500 mg|500 milligrams(mg) will be administered orally twice daily for 5 days.
363494|NCT00654108|Biological|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10^7; 1 X 10^8; 1 X 10^9; and 1 X 10^10.
363495|NCT00654108|Drug|Placebo|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
363496|NCT00654121|Drug|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
363497|NCT00004916|Drug|paclitaxel|
363498|NCT00654134|Biological|Clinical Center Reference Endotoxin|20,000 EU inhaled
363499|NCT00654147|Drug|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
363500|NCT00654147|Drug|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
363501|NCT00654160|Drug|fluorouracil|
363819|NCT00646659|Genetic|molecular genetic technique|
363820|NCT00646659|Genetic|reverse transcriptase-polymerase chain reaction|
363821|NCT00646659|Other|immunoenzyme technique|
363822|NCT00004888|Biological|trastuzumab|Given IV
363823|NCT00646659|Other|immunohistochemistry staining method|
363824|NCT00646659|Other|laboratory biomarker analysis|
363825|NCT00646659|Procedure|biopsy|
363826|NCT00646659|Radiation|3-dimensional conformal radiation therapy|
363827|NCT00646659|Radiation|intensity-modulated radiation therapy|
363828|NCT00646685|Procedure|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
363829|NCT00646685|Procedure|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
346871|NCT00505895|Drug|Melphalan|Arm 1 = 140 mg/m^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m^2 intravenous over 20 Minutes on Day -1.
346872|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
346873|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
346874|NCT00461773|Drug|Letrozole|Letrozole 2.5 mg po qd
346875|NCT00003539|Biological|trastuzumab|
346876|NCT00461773|Drug|Bevacizumab|bevacizumab 10 mg/kg IV
346877|NCT00461786|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
346878|NCT00461799|Drug|orlistat|
346879|NCT00461812|Drug|Mometasone or Advair|
346880|NCT00461825|Drug|Cyclosporin A: C0: 75–125ng/ml-dose adapted in the 3 groups|
346881|NCT00461825|Drug|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
346882|NCT00461825|Drug|Group B: CsA + CellCept(500 mg x 2/day)|
346883|NCT00461825|Drug|Group C: CsAm|
346884|NCT00461838|Procedure|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
346885|NCT00461838|Other|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
346886|NCT00003539|Drug|paclitaxel|
346887|NCT00461851|Drug|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
346888|NCT00461851|Drug|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
346889|NCT00461851|Drug|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
346890|NCT00461864|Procedure|ultrasound examination of the hip|
346891|NCT00461890|Drug|Injectable Naltrexone|
346209|NCT00479973|Dietary Supplement|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
2 capsules after the two largest meals of the day
346210|NCT00479973|Dietary Supplement|Placebo|Placebo. 2 capsules after the two largest meals of the day
346211|NCT00479986|Drug|pioglitazone|
346212|NCT00479986|Drug|placebo|
346213|NCT00479999|Drug|VRC-HIVADV027-00-VP|
346214|NCT00479999|Drug|VRC-HIVADV038-00-VP|
346215|NCT00480012|Device|rTMS|repetitive transcranial meagnetic stimulation of the brain
346534|NCT00470600|Other|Normal Saline|Placebo comparator
346535|NCT00003578|Drug|doxorubicin hydrochloride|
346536|NCT00470613|Genetic|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
346537|NCT00470626|Device|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
346538|NCT00470639|Device|Transcranial Magnetic Stimulation|
346539|NCT00470652|Device|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was >4/10. After a 10-day test period, the post-intervention data collection started.
346540|NCT00470665|Drug|Rapamune|
346541|NCT00470678|Drug|ranibizumab|
346542|NCT00470691|Procedure|plaster cast|complete circular plaster cast
346543|NCT00470691|Procedure|dorsal splint|dorsal plaster splint
346544|NCT00470704|Drug|Lapatinib|Oral dose taken daily
346545|NCT00470704|Drug|Herceptin|Given intravenously once a week or once every 3 weeks
345869|NCT00486018|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
345870|NCT00003653|Drug|bicalutamide|Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
345871|NCT00488826|Biological|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
345872|NCT00488839|Drug|Baclofen|single oral dose of IPX056 20mg capsule
345873|NCT00488839|Drug|Baclofen|single oral dose of IPX056 40mg capsule
345874|NCT00488839|Drug|Baclofen|single oral dose of Baclofen 20mg capsule
345875|NCT00488839|Drug|Placebo|single oral dose of placebo capsule
345876|NCT00488865|Device|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
345877|NCT00488878|Behavioral|Data Collection|Data collection from ovarian cancer patients seen at M.D. Anderson since January, 1950.
345878|NCT00488891|Drug|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
345879|NCT00488891|Drug|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
345880|NCT00488904|Dietary Supplement|supportan|2 sip feed pr. day
346216|NCT00003617|Drug|tinidazole|
346217|NCT00480025|Biological|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
346218|NCT00480025|Biological|Placebo Control|Intramuscular administration, 13 doses
346219|NCT00480038|Other|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
346220|NCT00480051|Device|Cardiac Resynchronization Pacing|
346221|NCT00480064|Drug|Lomustine, intermediate dose cytarabine|
351243|NCT00607672|Drug|Candesartan|Candesartan 16mg/d
351244|NCT00607685|Drug|5 Fluorouracil with hyaluronic acid|Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
351245|NCT00607685|Drug|5 Fluorouracil|Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
351246|NCT00607711|Drug|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
351247|NCT00607724|Drug|GDC-0449|
351248|NCT00004252|Drug|leucovorin calcium|
345881|NCT00003653|Drug|buserelin|Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
345882|NCT00488904|Dietary Supplement|supportan placebo|2 sip feed pr. day
345883|NCT00488930|Other|Observational|data collection ONLY
345884|NCT00488943|Device|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
345885|NCT00488969|Drug|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
345886|NCT00488969|Drug|Placebo|
345887|NCT00488982|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days
345888|NCT00488982|Drug|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
345889|NCT00491868|Drug|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
345890|NCT00491868|Drug|R744 placebo|0 μg/4week for 24 weeks
345891|NCT00491868|Drug|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks
345892|NCT00491881|Behavioral|no added salt diet|
350929|NCT00612339|Drug|Avastin and Temozolomide|This is Phase II study with the combination of Avastin & Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin & Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI & repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy & requests discontinuation, patients will receive up to 4 cycles of Avastin & Temozolomide, then proceed with standard XRT therapy, & future therapy after 4 cycles will be at discretion of patient & treating physicians.
350930|NCT00612352|Drug|Ethanol High Dose and Ethanol Low Dose|Test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
350931|NCT00614614|Biological|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
350932|NCT00614614|Biological|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
350933|NCT00614614|Biological|Infanrix®|One dose as intramuscular injection
350934|NCT00614614|Biological|ActHIB®|Three doses in the priming phase as intramuscular injection
350935|NCT00614614|Biological|Pediarix®|Three doses in the priming phase as intramuscular injection
350936|NCT00614640|Biological|DermaVir patch|DNA Vaccine
350937|NCT00614640|Biological|Placebo patch|10% dextrose (D-glucose) solution
350938|NCT00614653|Drug|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
350939|NCT00614653|Drug|Erlotinib|100 mg by mouth Once Daily on days with radiation.
350940|NCT00614653|Drug|Capecitabine|400 mg/m^2 PO Twice Daily on days with radiation.
350941|NCT00004346|Drug|chenodeoxycholic acid|
350942|NCT00614653|Radiation|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
350943|NCT00614666|Drug|nikkomycin Z|Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.
50 mg BID (n=8) vs placebo capsule BID (n=2)
250 mg BID (n=8) vs Placebo capsule BID (n=2)
500 mg BID (n=8) vs Placebo capsule BID (n=2)
750 mg TID (n=8) vs Placebo capsule TID (n=2)
At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.
Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization.
345548|NCT00497315|Drug|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
350271|NCT00507052|Drug|N-acetylcysteine|
350272|NCT00507065|Drug|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
350273|NCT00507065|Drug|Placebo|
350274|NCT00507078|Procedure|Surgical treatment for OSA|
350275|NCT00507091|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
350276|NCT00507091|Drug|Irinotecan|intravenous infusion
350277|NCT00507091|Drug|5-Fluorouracil|intravenous infusion
350278|NCT00507091|Drug|Leucovorin|intravenous infusion
350279|NCT00003743|Biological|aldesleukin|
350280|NCT00507091|Drug|ZD6474 (vandetanib) 300mg|once daily oral tablet
350281|NCT00507117|Drug|Lunesta|Lunesta 3mg prior to PSG
350282|NCT00507117|Drug|Placebo control|matching placebo
350283|NCT00507130|Biological|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
350605|NCT00499083|Procedure|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
350606|NCT00499083|Radiation|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
350607|NCT00501683|Drug|Radiolabelled GSK189075|
350608|NCT00003715|Drug|chemotherapy|
350609|NCT00501696|Drug|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
350610|NCT00501696|Drug|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
350611|NCT00501709|Drug|Belatacept|IV infusion - 10mg per kilo at day 0,4,14,28,56,84 and then 5mg per kilo monthly through month 12 and then 5mg per kilo every 4-6 weeks for the remainder of the study.
350612|NCT00501722|Drug|satavaptan (SR121463B)|
349922|NCT00469339|Behavioral|Family Health History|
349923|NCT00469352|Drug|Ranibizumab|Ranibizumab as needed
349924|NCT00469365|Behavioral|pharmacist contact with the patient via telephone|
349925|NCT00469365|Behavioral|Pharmacist contact with the patient's physician via fax|
349926|NCT00469365|Behavioral|Usual care|
349927|NCT00469378|Drug|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
349928|NCT00003574|Radiation|iodine I 125|
349929|NCT00469391|Device|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
349930|NCT00469391|Procedure|Sham Procedure|Weight loss
349931|NCT00469404|Drug|Buprenorphine|
349932|NCT00469417|Procedure|Cryotherapy or Photodynamic therapy with methyl aminolevulinate cream|
349933|NCT00469430|Drug|cefotaxim and metronidazol|iv administration for at least 24 h
349934|NCT00469443|Drug|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
349935|NCT00469443|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
349936|NCT00469443|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
349937|NCT00469443|Drug|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
349938|NCT00469443|Drug|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
349939|NCT00003575|Biological|filgrastim|
349940|NCT00469443|Drug|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
349941|NCT00469443|Drug|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
349942|NCT00469456|Drug|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
349943|NCT00469456|Drug|placebo|Placebo oral administration twice daily for 12 weeks
349944|NCT00469469|Drug|Bevacizumab|
349244|NCT00487370|Procedure|Sham implantation: Insertion of needles around a knee|
349245|NCT00487396|Device|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
349246|NCT00487409|Procedure|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
349247|NCT00487409|Procedure|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
349248|NCT00003650|Drug|asparaginase|
349249|NCT00487422|Drug|prucalopride|2 mg o.d.
349250|NCT00487422|Drug|Prucalopride|4 mg o.d.
349251|NCT00487422|Other|Placebo|o.d.
349252|NCT00487435|Drug|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
349253|NCT00487448|Drug|Fludarabine|
349593|NCT00478361|Drug|Gemcitabine hydrochloride|Gemcitabine 900 mg/m^2 IV over 90 minutes repeat every 14 days.
349594|NCT00478361|Drug|Paclitaxel|135 mg/m^2 IV over 1 hour
349595|NCT00478361|Drug|Doxorubicin hydrochloride|Doxorubicin 40 mg/m^2 IV over 20 minutes
349596|NCT00478361|Drug|Pegfilgrastim|Subcutaneously injection on day 1.
349597|NCT00478374|Drug|Sorafenib|Sorafenib 400mg bid
349598|NCT00478374|Procedure|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
349599|NCT00478387|Biological|The current season's trivalent killed influenza vaccine|
349600|NCT00478426|Drug|Sunitinib Malate|Given PO
349601|NCT00478439|Dietary Supplement|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
349602|NCT00478439|Dietary Supplement|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
349603|NCT00003607|Radiation|radiation therapy|
349604|NCT00478452|Biological|DC-Ova|
349605|NCT00478465|Drug|valganciclovir|
348889|NCT00493064|Drug|Prednisolone acetate|topical eye drops
348890|NCT00493077|Drug|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
348891|NCT00003667|Drug|vincristine sulfate|
348892|NCT00493090|Behavioral|modification of an interactive seminar|
348893|NCT00493116|Drug|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
348894|NCT00493116|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
348895|NCT00493129|Drug|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
348896|NCT00493142|Behavioral|Exercise|physical therapy home exercise
348897|NCT00495807|Behavioral|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
348898|NCT00495807|Behavioral|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
348899|NCT00000548|Procedure|mechanical ventilation|
348900|NCT00003680|Drug|thiotepa|
348901|NCT00495820|Drug|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
348902|NCT00495820|Other|Placebo|Standard inactive pill.
348903|NCT00495833|Behavioral|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
348904|NCT00495833|Behavioral|Promotional gift|half of participants who go to a fire station will receive a gift card.
348905|NCT00495846|Drug|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
348906|NCT00495846|Other|Locoregional treatments|
348907|NCT00495859|Dietary Supplement|Immunonutrition|food for special medical purpose (FSMP)
348908|NCT00495859|Dietary Supplement|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
348909|NCT00495872|Drug|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
348910|NCT00495872|Drug|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
348155|NCT00462306|Procedure|Survey: Berlin questionnaire|Completion of questionnaire
348156|NCT00462319|Behavioral|Education, weight reduction and physical exercise|
348157|NCT00462332|Drug|Fludarabine|Induction therapy
348158|NCT00462332|Drug|Campath|Induction therapy
348159|NCT00462332|Procedure|Transplant|Post-induction therapy
348160|NCT00462332|Drug|Campath|Post-induction therapy
348161|NCT00003541|Drug|doxorubicin hydrochloride|
348162|NCT00462332|Drug|Fludarabine|Induction therapy
348163|NCT00462332|Drug|Campath|Induction therapy
348538|NCT00503880|Genetic|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
348539|NCT00503880|Procedure|biopsy|bone marrow biopsy
348540|NCT00503893|Behavioral|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
348541|NCT00503893|Other|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
348542|NCT00503906|Drug|Bevacizumab|Bevacizumab 10 mg/kg BW IV over 30 minutes (+/- 5 minutes). One cycle is 28 days with chemotherapy Gemcitabine, Abraxane® and Bevacizumab given on day 1 and 15 of each treatment cycle.
348543|NCT00003728|Drug|cytarabine|
348544|NCT00503906|Drug|Gemcitabine|Gemcitabine 1500 mg/m2 BSA IV over 30 minutes (+/- 5 minutes). One cycle is 28 days with chemotherapy Gemcitabine, Abraxane® and Bevacizumab given on day 1 and 15 of each treatment cycle.
348545|NCT00503906|Drug|Abraxane|Abraxane® 150 mg/m2 IV over 30 minutes (+/- 5 minutes). One cycle is 28 days with chemotherapy Gemcitabine, Abraxane® and Bevacizumab given on day 1 and 15 of each treatment cycle.
348546|NCT00503906|Genetic|Analysis of SPARC Expression|A sample of tumor block will be sent to Abraxis Bioscience for analysis of SPARC expression, at a time and location to be determined by the Principal Investigator
348547|NCT00503906|Other|Circulating Tumor Cells (CTC) Analysis|CTC will be measured in peripheral blood, as reference to the CellSearch System. Samples will be drawn within 48 hours of the day # 1 infusion for first cycle and again within 48 hours of the day #1 infusion for every other cycle (i.e. every odd cycle).
348548|NCT00503919|Procedure|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
347794|NCT00468416|Device|Compression Anastomosis Ring (CAR)|
347795|NCT00468429|Drug|Subconjunctival Bevacizumab|
347796|NCT00468442|Biological|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
347797|NCT00468442|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
347798|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
347799|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (monthly)|
347800|NCT00471172|Behavioral|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
347801|NCT00471172|Behavioral|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
347802|NCT00471172|Behavioral|Self help|
347803|NCT00471185|Drug|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
347804|NCT00471211|Drug|PBT2|
347805|NCT00471224|Other|Observational Trial|No intervention is being used in this study.
347806|NCT00003580|Drug|amifostine trihydrate|
347807|NCT00471237|Drug|Ronacaleret|100mg, 200mg, 300mg, 400mg
347808|NCT00471237|Drug|Teriparatide|PTH (1-34)
347809|NCT00471237|Drug|Alendronate|Bisphosphonate
347810|NCT00471263|Drug|Casigold|
347811|NCT00471263|Drug|Casimax|
347812|NCT00471263|Drug|Placebo|
347813|NCT00471276|Drug|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
347814|NCT00471289|Device|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
347815|NCT00471289|Device|PTA|PTA
347816|NCT00471315|Drug|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
347121|NCT00489320|Device|Cypher Stent|
347122|NCT00003653|Drug|nilutamide|Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
347123|NCT00489333|Drug|ProAlgaZyme|
347124|NCT00489346|Drug|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
347473|NCT00480597|Drug|cisplatin|
347474|NCT00480597|Drug|vinorelbine|
347475|NCT00003619|Drug|isotretinoin|
347476|NCT00480597|Drug|capecitabine|
347477|NCT00480610|Drug|tacrolimus ointment|Topical application
347478|NCT00480610|Drug|Placebo ointment|Topical application
347479|NCT00480623|Drug|Satraplatin plus radiation therapy|
347480|NCT00480636|Drug|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
347481|NCT00480649|Drug|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
347482|NCT00480662|Drug|alendronate|Duration of Treatment : 6 Months
347483|NCT00480675|Procedure|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
347484|NCT00480675|Procedure|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
347485|NCT00480688|Biological|BCG|
347486|NCT00003619|Drug|topotecan hydrochloride|
347487|NCT00480701|Drug|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
347488|NCT00480714|Biological|BCG (SSI Strain)|
346777|NCT00497731|Drug|AZD1152|2-hour continuous intravenous infusion
346778|NCT00497744|Drug|Intraperitoneal Cefepime|
346779|NCT00497757|Device|Hematopoietic stem cell transplantation|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
346780|NCT00497770|Drug|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
346781|NCT00003691|Biological|filgrastim|
346782|NCT00497783|Drug|Lactoserum|
346783|NCT00497796|Drug|maribavir|100mg twice a day for 14 weeks.
346784|NCT00497796|Drug|ganciclovir|1000mg three times per day for 14 weeks.
346785|NCT00497809|Drug|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
346786|NCT00497822|Procedure|Aerobic exercise training|
346787|NCT00497848|Behavioral|motivational interviewing|An individual intervention building on the "Motivational Interviewing" by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy
346788|NCT00497848|Other|The System-Orientated Intervention|Principles in this intervention come from "Clinical Risk Managing" and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on.
346789|NCT00497861|Procedure|Activator Methods Chiropractic Technique|
346790|NCT00497874|Behavioral|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
347125|NCT00489346|Drug|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
347126|NCT00489359|Drug|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
347127|NCT00489359|Drug|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
347128|NCT00489359|Drug|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m^2, administered IV, every 21 days x 6 cycles
347129|NCT00489359|Drug|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL*min, administered IV, every 21 days x 6 cycles
364831|NCT00669357|Device|Abiocor Implantable Replacement Heart|Replacement of heart
364832|NCT00669370|Drug|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
364833|NCT00669383|Drug|betamethasone|12 mg IM q 24 hours x 2 doses
364834|NCT00669383|Drug|placebo|Placebo IM q 24 hours x 2 doses
364835|NCT00669396|Drug|Copper T380 IUD|Copper T380 IUD
364836|NCT00000658|Drug|Cyclophosphamide|
364837|NCT00005069|Drug|arsenic trioxide|
364838|NCT00669396|Drug|levonorgestrel|1.5 mg
364839|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
364840|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
364841|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
364842|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
364843|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
364844|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of Placebo IV
364845|NCT00669435|Drug|Losartan + Simvastatin|tablets; 50, 100 mg; od; 12 months
tablets; 20 mg; od; 6 months
364846|NCT00669435|Drug|Amlodipine + Simvastatin|tablets; 5, 10 mg; od; 12 months
tablets; 20 mg; od; 6 months
364847|NCT00669448|Behavioral|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
365152|NCT00005018|Drug|Hydroxyurea|
365153|NCT00662506|Drug|Cediranib Maleate|Given PO
365154|NCT00662506|Procedure|Diffusion Tensor Imaging|Undergo DTI
365155|NCT00662506|Procedure|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
365156|NCT00662506|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
364146|NCT00642044|Procedure|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
364147|NCT00642057|Drug|tetrabenazine|25 mg titrated to optimal dose per patient
364499|NCT00637156|Device|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
364500|NCT00637156|Device|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
364501|NCT00637169|Other|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
364502|NCT00637182|Drug|Anastrozole|
364503|NCT00004787|Drug|filgrastim|
364504|NCT00637195|Biological|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
364505|NCT00637195|Biological|Engerix™|Intramuscular administration, 4 doses.
364506|NCT00637208|Procedure|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
364507|NCT00637221|Drug|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
364508|NCT00637234|Drug|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
364509|NCT00637234|Drug|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
364510|NCT00637247|Drug|imexon in combination with gemcitabine|875 mg/m^2 imexon IV + 1000 mg/m^2 gemcitabine IV
364511|NCT00637247|Drug|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m^2 gemcitabine IV
364512|NCT00637260|Device|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
364513|NCT00637260|Device|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
364514|NCT00000638|Drug|Pyridoxine hydrochloride|
364515|NCT00004789|Drug|heme arginate|
364516|NCT00637273|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
363830|NCT00646711|Drug|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
363831|NCT00646711|Drug|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
363832|NCT00649324|Drug|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
363833|NCT00649337|Procedure|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.
The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed.
363834|NCT00649350|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
363835|NCT00649350|Drug|Glucophage XR 750 mg|750mg, single dose fed
363836|NCT00649363|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
363837|NCT00004900|Drug|anastrozole|
363838|NCT00649363|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
363839|NCT00649376|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fasting
363840|NCT00649376|Drug|Allegra® Tablets 180 mg|180mg, single dose fasting
364148|NCT00642083|Device|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
364149|NCT00642096|Drug|Metoprolol Succinate|
364150|NCT00642096|Drug|Hydrochlorothiazide|
364151|NCT00642109|Procedure|midurethral sling procedure|quality of life, voiding dysfunction
364152|NCT00642122|Drug|Budesonide|0.5mg once daily
364153|NCT00642122|Drug|Budesonide|1mg once daily
364154|NCT00642122|Drug|Budesonide|1mg twice daily
364155|NCT00642122|Drug|Budesonide|2mg once daily
346892|NCT00461903|Drug|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
346893|NCT00461916|Drug|Half-Dose Depot Triptorelin|
346894|NCT00461916|Drug|Reduced-Dose Daily Buserelin|
347239|NCT00500058|Drug|interleukin-18, Rituxan, Rituximab|
347240|NCT00500071|Drug|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
347241|NCT00500084|Drug|Liprotamase|Administered orally
347242|NCT00500097|Device|Digital retina image|
347243|NCT00500097|Device|direct ophthalmoscopy|
347244|NCT00500097|Procedure|comprehensive eye exam|
347245|NCT00500110|Drug|Docetaxel|30 mg/m^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
347246|NCT00003704|Drug|capecitabine|
347247|NCT00500110|Drug|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
347248|NCT00500110|Drug|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
347249|NCT00500110|Drug|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
347250|NCT00500123|Procedure|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
347251|NCT00500136|Procedure|mortality salience|
347252|NCT00500149|Drug|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
347253|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
347254|NCT00503334|Dietary Supplement|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
347255|NCT00503347|Drug|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
347256|NCT00503360|Drug|SAD448|
346546|NCT00003578|Drug|etoposide|
346547|NCT00470717|Procedure|Weekly telephone call|Details of feeding and health/sickness will be obtained
346548|NCT00470743|Drug|Ibuprofen|
346549|NCT00470743|Drug|Indomethacin|
346550|NCT00470756|Other|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
346551|NCT00473902|Behavioral|Training|
346552|NCT00473902|Drug|Creatine Monohydrate, Conjugated Linoleic Acid|
346553|NCT00473915|Drug|fluticasone furoate|corticosteroid nasal spray
346554|NCT00003589|Drug|paclitaxel|
346555|NCT00473928|Drug|POT-4|Single intravitreal injection.
346895|NCT00461929|Procedure|bone marrow aspiration|
346896|NCT00461942|Drug|Green Tea Polyphenols (EGCG/ECG)|
346897|NCT00003540|Drug|gemcitabine hydrochloride|
346898|NCT00461955|Procedure|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
346899|NCT00461968|Drug|Ezetimibe and Simvastatin|
346900|NCT00461981|Biological|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
346901|NCT00464685|Procedure|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
346902|NCT00464698|Drug|Duloxetine|Week 1 dose: 30mg, Weeks 2-4 dose: 60mg, Weeks 5-17 dose: 120mg
346903|NCT00464711|Drug|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
346904|NCT00464724|Procedure|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
346905|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
346906|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
346222|NCT00480077|Device|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
346223|NCT00480090|Drug|Ara-C (Cytarabine)|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
346224|NCT00480103|Device|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
346225|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
346226|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
346227|NCT00003619|Biological|filgrastim|
346228|NCT00480116|Biological|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
346229|NCT00480129|Behavioral|Probiotic or placebo yogurt consumed daily|
346230|NCT00480129|Device|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
346231|NCT00480129|Procedure|Blood sample|
346232|NCT00482963|Drug|levonorgestrel, efavirenz|
346233|NCT00482976|Drug|Ruboxistaurin|
346234|NCT00482976|Drug|Placebo|
346235|NCT00482989|Biological|MEDI 545|MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.
Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.
346236|NCT00482989|Other|Placebo|Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.
Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.
346237|NCT00483002|Drug|varenicline|As prescribed by physician in usual clinical practice.
346238|NCT00483015|Behavioral|smoking|
346239|NCT00483028|Drug|donezepil (Aricept)|
346556|NCT00473941|Behavioral|Expressive writing|Quality of life measures through writing
345893|NCT00491894|Drug|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
345894|NCT00491907|Drug|folic acid 5mg/day|
345895|NCT00491920|Drug|cholecalciferol (Vitamin D3)|20 000 Iu x2/week
+ calcium 500 mg/cholecalciferol 400 IU x2/d
345896|NCT00491920|Drug|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
345897|NCT00491933|Procedure|Quantiferon-TB Gold assay|
345898|NCT00003662|Drug|melphalan|
345899|NCT00491933|Procedure|Tuberculin skin test|
345900|NCT00491946|Drug|Actinomycin-D|
345901|NCT00491946|Drug|Vincristine|
346240|NCT00483041|Other|PLACEBO|Placebo administered as a single intravenous infusion
346241|NCT00003631|Procedure|bone marrow ablation with stem cell support|
346242|NCT00483041|Biological|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
346243|NCT00483054|Drug|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
346244|NCT00483054|Drug|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
346245|NCT00483067|Drug|2-CdA|12 mg/m^2/day by vein (IV) Continuous Infusion x 5 Days
346246|NCT00483067|Drug|Ara-C|1 gm/m^2/day IV Over 2 Hours x 5 Days
346247|NCT00483067|Drug|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
346248|NCT00483080|Drug|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
346249|NCT00483093|Drug|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
346250|NCT00483093|Drug|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
346251|NCT00483106|Drug|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
346252|NCT00003631|Procedure|peripheral blood stem cell transplantation|
346253|NCT00483106|Drug|Placebo|taken orally twice a day for 7 consecutive days
345549|NCT00497315|Radiation|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
345550|NCT00497328|Drug|N-acetylcysteine|
345551|NCT00499473|Drug|sunitinib malate|Given orally
345552|NCT00499473|Other|pharmacological study|Correlative studies
345553|NCT00499486|Drug|sirolimus|
345554|NCT00003700|Drug|vincristine sulfate|2 mg total IV infusion Days 1,8,15,& 22 Courses I & IV and Days 1, 8, & 15 Courses III & VI, and Day 1 of ea 4 wk cycle in Course VII
345555|NCT00499486|Genetic|polymorphism analysis|
345556|NCT00499486|Genetic|reverse transcriptase-polymerase chain reaction|
345557|NCT00499486|Other|immunohistochemistry staining method|
345558|NCT00499486|Other|laboratory biomarker analysis|
345559|NCT00499486|Other|liquid chromatography|
345560|NCT00499486|Other|mass spectrometry|
345561|NCT00499486|Other|pharmacological study|
345562|NCT00499486|Procedure|biopsy|
345563|NCT00499499|Drug|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
345564|NCT00499512|Behavioral|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
345565|NCT00003700|Drug|Allopurinol|300mg PO q day Days 1-14 Course I
345566|NCT00499525|Drug|paclitaxel|given IV
345567|NCT00499525|Drug|sorafenib tosylate|given orallly
345568|NCT00499525|Other|placebo|given orally
345569|NCT00499538|Drug|SKI-606|
345570|NCT00499551|Device|Iontophoresis second generation Eyegate II device|
345571|NCT00499577|Biological|CMV pp65 peptide|Given intramuscularly
350613|NCT00501735|Drug|Forodesine 200 mg|2 x 100mg tablets once daily
350614|NCT00501748|Drug|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
350615|NCT00501761|Behavioral|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
350616|NCT00501761|Behavioral|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
350617|NCT00501761|Behavioral|Suggested Exercise Program|Exercise program performed over 7 days.
350618|NCT00501787|Drug|Metformin|
350619|NCT00003715|Drug|cyclophosphamide|
350620|NCT00501813|Procedure|Hepatectomy|irregular Hepatectomy
350621|NCT00501813|Procedure|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
350622|NCT00501826|Drug|Doxorubicin|Hyper-CVAD (odd courses 1, 3, 5, 7):
50 mg/m^2 IV over 24 hours on day 4 after last dose of Cyclophosphamide (CTX)
350623|NCT00501826|Drug|Cyclophosphamide|Hyper-CVAD (odd courses 1, 3, 5, 7):
300 mg/m^2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2).
350624|NCT00501826|Drug|Cytarabine|High-dose Methotrexate plus cytarabine (even courses 2, 4, 6, 8):
Cytarabine 3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3
350944|NCT00614679|Drug|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
350945|NCT00614705|Drug|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
350946|NCT00614705|Drug|Placebo|oral capsule form, once daily for 28 days
350947|NCT00614731|Biological|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
350948|NCT00614744|Procedure|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
350949|NCT00614744|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
350950|NCT00614757|Drug|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
349945|NCT00472147|Procedure|shock efficacy|
349946|NCT00472160|Procedure|Non Invasive Ventilation|Non Invasive Ventilation
350284|NCT00507130|Biological|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
350285|NCT00507130|Biological|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
350286|NCT00463060|Drug|sunitinib malate (Sutent)|
350287|NCT00463060|Procedure|radiotherapy|
350288|NCT00463073|Drug|Cetuximab|
350289|NCT00463073|Drug|Bevacizumab|
350290|NCT00463073|Drug|Irinotecan|
350291|NCT00463086|Drug|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
350292|NCT00463086|Drug|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
350293|NCT00463112|Drug|Sibutramine|
350294|NCT00463125|Drug|Platelet Gel|
350295|NCT00003544|Drug|irinotecan hydrochloride|
350296|NCT00463138|Behavioral|Crisis intervention|
350297|NCT00463151|Drug|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
350298|NCT00463190|Drug|Biothree|
350299|NCT00463203|Drug|Bevacizumab|10 mg/kg every 2 weeks
350300|NCT00463203|Drug|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
350301|NCT00463216|Behavioral|A multidisciplinary diagnostic evaluation|
350302|NCT00463229|Other|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
350303|NCT00463242|Drug|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
349606|NCT00478478|Procedure|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
349607|NCT00478504|Drug|Letrozole|
349608|NCT00478504|Drug|Clomifene citrate|
349609|NCT00478517|Drug|Erythropoetin (rHuEPO, EPREX®)|
349610|NCT00478530|Procedure|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
349611|NCT00478543|Drug|Furosemide|
349612|NCT00481624|Drug|Epoetin Alfa plus Iron|One (1) injection of Procrit®, by needle, inserted just under the skin;
125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.
These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.
In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan.
349613|NCT00481650|Drug|Leios/Alesse|
349614|NCT00481663|Drug|Sitagliptin|
349615|NCT00481663|Drug|Placebo to sitagliptin|
349947|NCT00472173|Drug|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
349948|NCT00472173|Drug|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
349949|NCT00472186|Drug|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
349950|NCT00472186|Drug|Placebo|Placebo will also be administered based on weight.
349951|NCT00472199|Drug|Pramipexole|
349952|NCT00003583|Radiation|radiation therapy|
349953|NCT00472199|Drug|Placebo|
349954|NCT00472212|Device|Glasses for the correction of low to moderate farsightedness|
349955|NCT00472212|Device|Glasses with placebo lens|
349956|NCT00472225|Drug|Rituximab|Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks
Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months
349254|NCT00487448|Drug|Cytarabine|
349255|NCT00487448|Drug|G-CSF|
349256|NCT00487448|Drug|Idarubicin|
349257|NCT00487448|Procedure|Peripheral blood stem cell transplantation|
349258|NCT00487448|Procedure|Bone marrow transplantation|
349259|NCT00003650|Drug|cyclophosphamide|
349260|NCT00487461|Drug|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
349261|NCT00487461|Drug|Placebo|Placebo tablet
349262|NCT00487461|Drug|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
349263|NCT00487474|Device|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
349264|NCT00487500|Device|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
349265|NCT00487513|Procedure|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
349266|NCT00487526|Procedure|duodenal jejunal bypass|
349267|NCT00490360|Drug|Gemcitabine / Cisplatin|
349268|NCT00003657|Procedure|peripheral blood stem cell transplantation|
349269|NCT00490373|Drug|pemetrexed|
349270|NCT00490399|Drug|gemcitabine|
349271|NCT00490399|Drug|cisplatin|
349272|NCT00490412|Dietary Supplement|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
349273|NCT00490412|Other|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
349274|NCT00490425|Drug|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
349275|NCT00490451|Drug|LY573636|LY573636 dose is dependent on patient's height, weight, and gender to target a specific Cmax. LY573636 is administered every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
348549|NCT00503932|Procedure|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
348550|NCT00503932|Drug|Capecitabine|825 mg/m^2 by mouth (PO) twice daily on days receive radiation.
348551|NCT00503945|Device|Nasal continuous positive airway pressure (nCPAP)|
348552|NCT00503958|Genetic|DNA methylation analysis|
348553|NCT00503958|Genetic|DNA stability analysis|
348554|NCT00003728|Drug|daunorubicin hydrochloride|
348555|NCT00503958|Genetic|gene expression analysis|
348556|NCT00503958|Other|epidemiologic study|
348557|NCT00503958|Other|study of socioeconomic and demographic variables|
348558|NCT00503958|Procedure|biopsy|
348559|NCT00503958|Procedure|evaluation of cancer risk factors|
348911|NCT00003680|Procedure|peripheral blood stem cell transplantation|
348912|NCT00495872|Drug|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
348913|NCT00495872|Drug|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
348914|NCT00495872|Drug|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
348915|NCT00495872|Drug|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
348916|NCT00495872|Drug|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
348917|NCT00495885|Drug|volinanserin (M100907)|one tablet taken around bedtime
348918|NCT00495885|Drug|Placebo|one tablet taken around bedtime
348919|NCT00495898|Device|CYPHER sirolimus-eluting stent|drug-eluting stent
348920|NCT00495898|Device|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
348921|NCT00495924|Procedure|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
348922|NCT00003680|Radiation|radiation therapy|
347817|NCT00003580|Drug|cisplatin|
347818|NCT00471328|Drug|Nilotinib|Nilotinib 400 mg twice daily (bid)
348164|NCT00462332|Drug|Campath|Post-induction therapy
348165|NCT00462345|Drug|rituximab|1000 mg i.v. on Days 1 and 15
348166|NCT00462345|Drug|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
348167|NCT00462345|Drug|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
348168|NCT00462345|Dietary Supplement|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
348169|NCT00462358|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
348170|NCT00462358|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
348171|NCT00462371|Device|Insulin pump (CSII)|
348172|NCT00000530|Drug|nifedipine|
348173|NCT00003541|Drug|etoposide|
348174|NCT00462384|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|1.2 micrograms/kg sc monthly, starting dose
348175|NCT00462397|Drug|carboplatin|
348176|NCT00462397|Drug|cisplatin|
348177|NCT00462397|Drug|paclitaxel|
348178|NCT00462397|Procedure|neoadjuvant therapy|
348179|NCT00462397|Radiation|brachytherapy|
348180|NCT00462397|Radiation|radiation therapy|
348181|NCT00462410|Other|counseling intervention|
348182|NCT00462410|Procedure|psychosocial assessment and care|
348183|NCT00465504|Procedure|iontophoresis|See Detailed Description.
348184|NCT00003556|Biological|canarypox-hIL-12 melanoma vaccine|
348185|NCT00465517|Drug|Ganaxolone|Oral suspension 200-500 mg 3x/day
347489|NCT00480727|Procedure|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
347490|NCT00480727|Procedure|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
347491|NCT00480740|Drug|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
347492|NCT00480753|Drug|Nitroglycerin|
347493|NCT00480766|Drug|MK0217/Duration of Treatment : 12 Months|
347494|NCT00480779|Behavioral|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program.
347495|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
347496|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
347819|NCT00471328|Other|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
347820|NCT00471341|Drug|Celecoxib|
347821|NCT00471341|Drug|placebo|
347822|NCT00471354|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
347823|NCT00471367|Drug|AZD4877|intravenous infusion administered twice a week for 2 weeks
347824|NCT00471380|Drug|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
347825|NCT00471380|Drug|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
347826|NCT00471393|Drug|1.5% diclofenac in 45.5% DMSO (topical treatment)|
347827|NCT00474552|Drug|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
347828|NCT00474565|Procedure|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
347829|NCT00474591|Drug|Fondaparinux|
365481|NCT00657410|Procedure|quality-of-life assessment|
365482|NCT00657423|Drug|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
365483|NCT00657423|Drug|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
365484|NCT00004934|Drug|paclitaxel|
365485|NCT00657449|Drug|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
365486|NCT00657449|Drug|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
365487|NCT00657462|Other|Reminders|Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
365488|NCT00657475|Drug|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
365489|NCT00657475|Drug|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
365490|NCT00657488|Drug|Thalidomide|Thalidomide 100mg/day or 400 mg/day at bed time during one year
365491|NCT00657501|Drug|testosterone gel|once daily transdermal gel, 300 mcg
365828|NCT00650208|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
365829|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release oral tablet
365830|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release tablet
365831|NCT00650234|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
365832|NCT00650234|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
365833|NCT00650247|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fed
365834|NCT00650247|Drug|Imitrex® Tablets 100 mg|100mg, single dose fed
365835|NCT00650260|Device|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
365157|NCT00662506|Radiation|Fludeoxyglucose F-18|Undergo 18 FDG PET
365158|NCT00664690|Drug|placebo|placebo given preop and BID postop
365159|NCT00664703|Drug|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
365160|NCT00664703|Drug|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
365161|NCT00664703|Drug|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
365162|NCT00664716|Biological|Baminercept alfa 1|experimental - one dose level
365163|NCT00664716|Biological|Placebo|Placebo comparator
365164|NCT00664716|Biological|Baminercept alfa 2|experimental - second dose level
365165|NCT00664716|Biological|Baminercept alfa 3|experimental - third dose level
365166|NCT00664716|Biological|Baminercept alfa 4|experimental - fourth dose level
365167|NCT00000656|Drug|Zidovudine|
365168|NCT00005036|Drug|irinotecan hydrochloride|Given IV
365169|NCT00664716|Biological|Baminercept alfa 5|experimental - fifth dose level
365170|NCT00664729|Behavioral|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
365171|NCT00664729|Behavioral|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
365172|NCT00664729|Behavioral|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
365173|NCT00664742|Drug|Fluvastatin XL®|Fluvastatin extended release 80 mg
365174|NCT00664755|Drug|varenicline|Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID
Varenicline is taken for a duration of 4 weeks in this study.
365492|NCT00657501|Drug|placebo gel|once daily transdermal placebo gel
365493|NCT00657514|Drug|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
365494|NCT00657514|Drug|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
364517|NCT00637273|Drug|sitagliptin|oral tablet, 100mg, once a day
364518|NCT00637273|Drug|pioglitazone|oral tablet, 45mg, once a day
364519|NCT00637273|Drug|placebo tablet|oral tablet, once a day
364520|NCT00637273|Drug|placebo once weekly|subcutaneous injection, once a week
364521|NCT00637286|Drug|Zolmitriptan|5mg Nasal Spray
364848|NCT00005070|Drug|irofulven|
364849|NCT00669461|Drug|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
364850|NCT00669474|Procedure|Suction curettage|Suction curettage
364851|NCT00669474|Drug|Treatment with Botox|Treatment with Botox
364852|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
364853|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
364854|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
364855|NCT00669500|Behavioral|Lifestyle intervention|Alive!TM web-based, 12 week lifestyle intervention sent via NutritionQuest.
364856|NCT00632749|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
364857|NCT00632749|Drug|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
364858|NCT00632749|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
364859|NCT00632762|Drug|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
364860|NCT00632775|Drug|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|Total daily fluid infusion equal to:
100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg.
364861|NCT00632775|Drug|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|Total daily fluid infusion equal to:
100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg.
364862|NCT00632788|Other|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
364156|NCT00004861|Drug|gemcitabine hydrochloride|
364157|NCT00642122|Drug|Budesonide|4.00mcg twice daily
364158|NCT00642135|Drug|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
364159|NCT00642135|Drug|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
364160|NCT00642148|Drug|GW856553|Active tablet
364161|NCT00642148|Drug|Placebo|Placebo tablet and inhaler
364162|NCT00642148|Drug|Seretide|Active comparator inhaler
364163|NCT00642161|Drug|budesonide|
364164|NCT00642174|Drug|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
364165|NCT00642174|Drug|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
364166|NCT00642187|Drug|budesonide|
364167|NCT00004861|Drug|tacedinaline|
364168|NCT00644267|Behavioral|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
364169|NCT00644280|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
364170|NCT00644293|Drug|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
364171|NCT00004876|Drug|carboplatin|
348326|NCT00481065|Biological|MF59-eH5N1 + eTIV_a|
348327|NCT00481078|Drug|vorinostat|Given PO
348328|NCT00003621|Drug|carmustine|
348329|NCT00481078|Drug|paclitaxel|Given IV
348330|NCT00481078|Drug|carboplatin|Given IV
348331|NCT00481078|Other|placebo|Given PO
348332|NCT00481078|Other|laboratory biomarker analysis|Correlative studies
347257|NCT00503386|Drug|Palonosetron|
347258|NCT00503386|Drug|Granisetron|
347259|NCT00503399|Drug|Teriparatide|20 µg/day sc for 18 months
347260|NCT00503399|Drug|Risedronate|35 mg/week po for 18 months
347261|NCT00503412|Drug|AZD2171|oral 14C
347262|NCT00003727|Drug|etoposide|
347263|NCT00503425|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
347610|NCT00495209|Other|Qigong|EQT daily for 5 consecutive days prior to surgery.
347611|NCT00003679|Procedure|conventional surgery|
347612|NCT00495222|Procedure|Tissue plication|Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
347613|NCT00495222|Device|Endoscopic Suturing System|Tissue plication of dilated GJ stoma
347614|NCT00495222|Device|Tissue Plication|Tissue plication for GJ stoma reduction
347615|NCT00495235|Behavioral|Questionnaire|Questionnaire taking about 20 minutes to complete.
347616|NCT00495248|Behavioral|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
347617|NCT00495248|Behavioral|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
347618|NCT00495261|Behavioral|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
347619|NCT00495261|Behavioral|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
347620|NCT00495274|Drug|SB-649868|
347621|NCT00495287|Drug|cytosine arabinoside|Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.
Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.
347622|NCT00003679|Radiation|radiation therapy|
347623|NCT00495313|Drug|doxycycline|COL-101, QD plus metronidazole
347624|NCT00495313|Drug|doxycycline|40 mg with metronidazole QD
346907|NCT00464737|Other|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
346908|NCT00464750|Device|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
346909|NCT00464763|Drug|Dexmedetomidine|
346910|NCT00003553|Drug|mycophenolate mofetil|Given as GVHD prophylaxis
346911|NCT00464763|Drug|Placebo|
346912|NCT00464776|Drug|Aliskiren|
346913|NCT00464776|Drug|Aliskiren|
346914|NCT00464776|Drug|Aliskiren|
346915|NCT00464776|Drug|Aliskiren|
346916|NCT00464789|Drug|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
346917|NCT00464802|Drug|MOA-728|
346918|NCT00464815|Biological|Mencevax™ ACWY|One subcutaneous dose
347264|NCT00503438|Device|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
347265|NCT00503451|Drug|LBH589|
347266|NCT00503477|Drug|AZD2171|oral tablet
347267|NCT00503490|Drug|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
347268|NCT00503490|Drug|placebo|BID
347269|NCT00503503|Drug|Enbrel (etanercept)|
347270|NCT00503516|Drug|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
347271|NCT00503516|Drug|Placebo|1 sachet of 160 mg of placebo b.i.d.
347272|NCT00503529|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
347273|NCT00003727|Drug|gemcitabine hydrochloride|
347274|NCT00503542|Drug|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
346557|NCT00473954|Genetic|EGEN-001 (phIL-12-005/PPC)|In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.
Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals.
346558|NCT00473967|Biological|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
346559|NCT00473980|Drug|Indomethacin, celecoxib, esomeprazole|
346560|NCT00474006|Drug|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
346561|NCT00474019|Drug|esomeprazole|IV qd for 4 days
346562|NCT00474032|Drug|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
346563|NCT00474045|Drug|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
346564|NCT00474045|Drug|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
346565|NCT00003590|Drug|hydroxyurea|20 mg/kg/day PO
346566|NCT00474045|Drug|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
346567|NCT00474058|Drug|Rotigotine|Rotigotine transdermal patches:
10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)
Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h
346568|NCT00474058|Other|Placebo|Placebo transdermal patches
346569|NCT00474071|Drug|Remifentanil|See Detailed Description.
346570|NCT00474084|Device|Intravascular Coronary Stent|
346571|NCT00474110|Drug|Ketamine & hydromorphone|See Detailed Description
346572|NCT00474123|Drug|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
346573|NCT00474123|Drug|Ezetimibe 10 mg / Simvastatin 20 mg|Ezetimibe 10 mg / Simvastatin 20 mg
Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
346574|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
346575|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
346576|NCT00003591|Drug|paclitaxel|
346254|NCT00483119|Drug|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
346255|NCT00483119|Drug|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
346256|NCT00483132|Drug|interferon alpha 2a|
346257|NCT00483145|Device|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
346258|NCT00483145|Device|Long-pulsed dye laser|
346259|NCT00483145|Device|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
346260|NCT00483158|Drug|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
346261|NCT00486018|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
346262|NCT00486031|Drug|Balsalazide Disodium|
346263|NCT00486044|Drug|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
346264|NCT00486044|Drug|Placebo|Matching tablet each night for 9 months
346578|NCT00476931|Biological|SB-509|60 mg dose
346579|NCT00476931|Other|Placebo|Saline
346580|NCT00476944|Procedure|Percutaneous Coronary Intervention (PCI)|
346581|NCT00476957|Device|Stent|Stent implantation
346582|NCT00476957|Device|Stent|Stent implantation
346583|NCT00476970|Behavioral|multilingual navigator|
346584|NCT00003601|Drug|tretinoin|
346585|NCT00476983|Drug|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
346586|NCT00476996|Drug|leflunomide|Oral repeating dose
346587|NCT00476996|Drug|methotrexate|Oral or parenteral repeating dose
346588|NCT00476996|Drug|ocrelizumab|Intravenous repeating dose (200mg)
346589|NCT00476996|Drug|ocrelizumab|Intravenous repeating dose (500mg)
345572|NCT00499577|Biological|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
345902|NCT00491959|Procedure|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
345903|NCT00491985|Biological|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
345904|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
345905|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
345906|NCT00491998|Drug|V1512|6 doses of IMP at 2-hourly intervals
345907|NCT00491998|Drug|V1512|3-hourly dosing
345908|NCT00491998|Drug|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
345909|NCT00003662|Drug|methylprednisolone|
345910|NCT00492011|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
345911|NCT00492011|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
345912|NCT00492011|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
345913|NCT00492011|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
345914|NCT00492024|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
345915|NCT00492024|Drug|Placebo|Placebo - 380 mg Microcrystalline Cellulose
345916|NCT00492037|Drug|YM087 oral|
345917|NCT00492050|Drug|Bortezomib|1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22.
345918|NCT00492050|Drug|Rituximab|375 mg/m^2 IV on Day 8 and 22.
345919|NCT00494611|Drug|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
345920|NCT00494624|Drug|prednisolone|
345921|NCT00494637|Drug|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
350951|NCT00614757|Drug|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
350952|NCT00004346|Drug|lovastatin|
350953|NCT00614770|Procedure|standard of care colonoscopy|Standard White Light Colonoscopy
one exam per patient
350954|NCT00614770|Procedure|colonoscopy|Narrow Band Imaging Colonoscopy
one exam per patient
350955|NCT00614770|Procedure|standard of care colonoscopy|High Definition White Light Colonoscopy
one exam per patient
350956|NCT00617266|Other|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
350957|NCT00617266|Other|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
350958|NCT00617266|Other|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
350959|NCT00617279|Device|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
350960|NCT00617279|Procedure|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
350961|NCT00617305|Drug|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
350962|NCT00617305|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
350963|NCT00617305|Drug|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
350964|NCT00617305|Drug|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
350965|NCT00000625|Drug|Didanosine|
345573|NCT00499577|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
345574|NCT00499577|Biological|survivin Sur1M2 peptide vaccine|Given subcutaneously
345575|NCT00499590|Drug|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
345576|NCT00003701|Drug|carboplatin|
345577|NCT00499590|Drug|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
350304|NCT00463242|Drug|paroxetine|
350305|NCT00463242|Drug|placebo|
350306|NCT00003544|Procedure|surgical procedure|
350307|NCT00463255|Behavioral|diet|
350308|NCT00463268|Drug|alendronate|alendronate 70 mg every 2 weeks
350625|NCT00501826|Drug|Dexamethasone|Hyper-CVAD (odd courses 1, 3, 5, 7):
40 mg IV or by mouth (PO) daily days 1-4 and 11-14.
350626|NCT00501826|Drug|Methotrexate|High-dose Methotrexate plus cytarabine (even courses 2, 4, 6, 8):
200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours on day 1.
350627|NCT00501826|Drug|Vincristine|Hyper-CVAD (odd courses 1, 3, 5, 7):
2 mg IV days 4 and 11 (+/- 2 days)
350628|NCT00501826|Drug|Nelarabine|650 mg/m^2 IV over 2 hours daily x 5 days every 21 to 35 days x 2 courses.
350629|NCT00501839|Drug|clomiphene citrate|
350630|NCT00003716|Biological|rituximab|
350631|NCT00501852|Drug|NVA237|single-dose dry-powder inhaler (SDDPI)
350632|NCT00501852|Drug|Placebo|single-dose dry-powder inhaler (SDDPI)
350633|NCT00504647|Device|Biventricular Pacemaker|
350634|NCT00504660|Drug|Capecitabine|Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
350635|NCT00504660|Drug|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
350636|NCT00504660|Drug|Temozolomide|Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
350637|NCT00504660|Drug|Lomustine|Arms 2,3 = 100 mg/m^2 PO on Day 4.
350638|NCT00000553|Drug|antioxidants|
350639|NCT00003728|Drug|thioguanine|
350640|NCT00504660|Drug|6-Thioguanine|Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
350641|NCT00504673|Drug|insulin detemir|
350642|NCT00504673|Drug|insulin NPH|
350643|NCT00504673|Drug|insulin aspart|
349957|NCT00472238|Behavioral|endurance training|control group.
349958|NCT00472238|Behavioral|exercise training|Treadmill exercise training to optimize physical endurance
349959|NCT00472264|Procedure|PET imaging|Medical imaging assessment
349960|NCT00472290|Drug|Romiplostim (formerly AMG 531)|Subjects will begin the study at an initial dose of 750 µg.
Except for:
Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.
Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count.
349961|NCT00472303|Drug|Tapentadol Extended Release|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
349962|NCT00472303|Drug|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
349963|NCT00003584|Drug|estramustine phosphate sodium|
349964|NCT00472303|Drug|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
349965|NCT00472316|Behavioral|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
349966|NCT00472329|Procedure|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
349967|NCT00472329|Drug|fludarabine|
350309|NCT00463268|Dietary Supplement|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
350310|NCT00463268|Drug|placebo|identical placebo every 2 weeks
350311|NCT00463294|Procedure|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
350312|NCT00463294|Procedure|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
350313|NCT00463320|Drug|Pazopanib eye drops and Allergen Refresh Plus eye drops|
350314|NCT00463346|Drug|Acamprosate|Acamprosate 1998 mg tid
350315|NCT00000531|Drug|sotalol|
350316|NCT00003562|Drug|carboplatin|
349276|NCT00490464|Drug|Nicardipine and Nipride|
349277|NCT00490477|Device|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
349616|NCT00481663|Drug|Metformin|
349617|NCT00481663|Drug|Rescue|Patients whose FPG >240 mg/dL from Week 16 or HbA1C >8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently >240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C >8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C >7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
349618|NCT00481676|Drug|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
349619|NCT00481676|Drug|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
349620|NCT00481676|Drug|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
349621|NCT00481676|Drug|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
349622|NCT00003623|Other|Placebo|
349623|NCT00481689|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
349624|NCT00481702|Drug|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
349625|NCT00481702|Drug|MK0826, /Duration of Treatment : 8 Weeks|
349626|NCT00481702|Drug|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
349627|NCT00481715|Behavioral|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
349628|NCT00481715|Behavioral|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
349629|NCT00481728|Drug|Tolterodine|Single dose per patient as determined by protocol.
349630|NCT00481728|Procedure|Filling cystometry|This is a procedure.
348923|NCT00495950|Behavioral|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
348924|NCT00495963|Procedure|bronchoaleolar lavage|
348925|NCT00495963|Procedure|Bronchoscopy|
348926|NCT00003695|Drug|chemotherapy|
348927|NCT00498680|Drug|Sildenafil & Vardenafil|50mg & 10 mg
348928|NCT00498706|Behavioral|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
348929|NCT00498706|Behavioral|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
348930|NCT00498719|Behavioral|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
348931|NCT00498719|Other|Control Group|Standard educational support.
348932|NCT00498732|Device|CPAP|CPAP treatment for 4 weeks
348933|NCT00498745|Drug|neratinib|HKI-272
349278|NCT00490490|Drug|Tositumomab and iodine I 131 tositumomab|patient specific, calculated, IV
349279|NCT00003658|Biological|filgrastim|
349280|NCT00490490|Procedure|External beam radiotherapy|patient specific, calculated
349281|NCT00490490|Drug|SSKI|130 mg, PO
349282|NCT00490503|Procedure|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
349283|NCT00490503|Procedure|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
349284|NCT00490516|Drug|ACP-104|200 mg, tablet, BID, 6 weeks
349285|NCT00490516|Drug|ACP-104|100 mg, tablet, BID, 6 weeks
349286|NCT00490516|Drug|Placebo|placebo, tablet BID, 6 weeks
348186|NCT00465530|Drug|Saline|Intranasal Saline
348187|NCT00465530|Drug|Gentamycin|Intranasal irrigation
348188|NCT00465543|Other|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
348560|NCT00503958|Procedure|study of high risk factors|
348561|NCT00503971|Drug|Vorinostat plus Erlotinib|Phase I:
Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily
Phase II:
Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily
348562|NCT00503984|Drug|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
348563|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A)|Subjects are planned to receive one or two booster doses of the pandemic influenza candidate vaccine (GSK1562902A). Different formulations (adjuvanted and non-adjuvanted) will be tested.
348564|NCT00506363|Procedure|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
348565|NCT00506376|Behavioral|Interview|Interview that will take about 20 minutes to complete.
348566|NCT00506389|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name corn starch), magnesium stearate, and lactose monohydrate.
348567|NCT00506389|Drug|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
348568|NCT00003736|Procedure|comparison of screening methods|
348569|NCT00506402|Drug|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
348570|NCT00506415|Drug|Rivastigmine 5 cm^2|5 cm^2 transdermal patch
348571|NCT00506415|Drug|Rivastigmine 10 cm^2|10 cm^2 transdermal patch.
348572|NCT00506415|Drug|Rivastigmine 15 cm^2|15 cm^2 transdermal patch.
348573|NCT00506415|Drug|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm^2.
348574|NCT00506415|Drug|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm^2.
347830|NCT00474604|Procedure|diffusion-weighted magnetic resonance imaging|A scan will be performed.
347831|NCT00474604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
347832|NCT00474604|Procedure|magnetic resonance spectroscopic imaging|A scan will be performed.
347833|NCT00474617|Drug|Sugammadex|After the intubation dose or last maintenance dose of rocuronium, at reappearance of T2, subjects were to receive a dose of 2.0 mg/kg Org 25969.
347834|NCT00474630|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
347835|NCT00003593|Drug|daunorubicin hydrochloride|Given IV
347836|NCT00474630|Drug|Placebo|
347837|NCT00474630|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
347838|NCT00474656|Device|High-frequency oscillation|
347839|NCT00474656|Device|Conventional lung-open mechanical ventilation|
347840|NCT00474669|Drug|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
348189|NCT00465543|Other|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
348190|NCT00465556|Behavioral|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
348191|NCT00465556|Behavioral|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
348192|NCT00465569|Drug|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
348193|NCT00465595|Drug|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
348194|NCT00465608|Drug|propranolol|propranolol by mouth (per os)
348195|NCT00000531|Drug|amiodarone amiodarone|
348196|NCT00003557|Drug|dolastatin 10|
365836|NCT00000644|Drug|Clarithromycin|
365837|NCT00004903|Biological|recombinant interferon alfa|
365838|NCT00652496|Drug|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
365839|NCT00652496|Drug|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
365840|NCT00652496|Drug|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
365841|NCT00652496|Drug|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
365842|NCT00652496|Drug|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
365843|NCT00652509|Behavioral|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
365844|NCT00652509|Behavioral|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
365845|NCT00004906|Procedure|peripheral blood stem cell transplantation|
365846|NCT00652522|Device|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
365847|NCT00652522|Procedure|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
366162|NCT00645112|Drug|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
366163|NCT00645112|Drug|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
366164|NCT00645125|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
366165|NCT00004880|Biological|dendritic cell vaccine therapy|
366166|NCT00645125|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
366167|NCT00645138|Procedure|Paravertebral Block|Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be "walked off" the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered.
365495|NCT00004934|Procedure|conventional surgery|
365496|NCT00657527|Drug|Rosuvastatin|
365497|NCT00657527|Behavioral|Cholesterol lowering diet|
365498|NCT00657540|Drug|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
365499|NCT00657540|Drug|Saline|50 mL of saline infused over 10 minutes
365500|NCT00657553|Drug|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
365501|NCT00657566|Other|duration of antibiotics|4 +/- 1 days of antibiotics
365502|NCT00657566|Other|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
365503|NCT00660036|Drug|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m^2, 6 mg/m^2 or 9 mg/m^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
365504|NCT00660036|Drug|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
365505|NCT00660036|Drug|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
365506|NCT00660049|Device|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
365507|NCT00660049|Other|SNaP|Daily use
365508|NCT00660049|Other|SNaP|Daily application per protocol
365509|NCT00660062|Drug|escitalopram|10 mg daily
365510|NCT00660062|Drug|escitalopram|20 mg daily dosage
365511|NCT00004999|Drug|Lamivudine/Zidovudine|
365512|NCT00660062|Drug|escitalopram|30 mg daily dosage
365513|NCT00660062|Drug|nortriptyline|100 mg daily dosage
365514|NCT00660075|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
365515|NCT00660075|Drug|Placebo|Placebo for 6 weeks
364863|NCT00632801|Other|chewing gum|The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
364864|NCT00004729|Behavioral|Ketogenic diet|
364865|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
364866|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
365175|NCT00664755|Device|transdermal nicotine patch|Weeks 0-3: 21mg patch
Transdermal nicotine patch is used for a duration of 3 weeks in this study.
365176|NCT00664768|Dietary Supplement|Neocate Infant|minimum of 8 fl. oz daily
365177|NCT00664768|Dietary Supplement|new Neocate|minimum of 8 fl oz daily
365178|NCT00664781|Drug|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
365179|NCT00005036|Drug|oxaliplatin|Given IV
365180|NCT00664781|Genetic|protein expression analysis|
365181|NCT00664781|Genetic|western blotting|
365182|NCT00664781|Other|immunohistochemistry staining method|
365183|NCT00664781|Other|liquid chromatography|
365184|NCT00664781|Other|mass spectrometry|
365185|NCT00664781|Other|pharmacological study|
365186|NCT00666952|Other|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
365187|NCT00666952|Other|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
365188|NCT00666965|Drug|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
365189|NCT00005051|Drug|carboplatin|
348333|NCT00481091|Drug|ABT-263|Phase 1 dosing under two different schedules: 14 days on drug, 7 days or (14/21) or continuous dosing.
Phase 2a dosing at the recommended phase 2a dose and schedule
348334|NCT00481104|Drug|Tesofensine|
348335|NCT00481117|Drug|LY2405319|
348336|NCT00481117|Drug|Placebo|
348337|NCT00481143|Drug|ICL670/Deferasirox|
348338|NCT00481156|Behavioral|Cognitive Remediation|
348339|NCT00003621|Drug|cisplatin|
348340|NCT00481156|Behavioral|Cognitive Behavioral Social Skills Training|
348341|NCT00481169|Drug|Bazedoxifene Acetate (TSE-424)|
348342|NCT00481182|Drug|fosamprenavir + ritonavir + methadone|
348343|NCT00481195|Drug|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day [2 tablets]) was allowed. The dosage could not be increased after it was decreased.
348344|NCT00483743|Drug|Budesonide|400mcg mcg capsules- 2 capsules BID
348345|NCT00483743|Drug|Placebo|2 caps BID x42 days
348346|NCT00483756|Drug|Cyclosporine|Standard of care
348347|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
348348|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
348349|NCT00003633|Drug|mitoxantrone hydrochloride|
348350|NCT00483769|Drug|Glargine|
348696|NCT00471744|Drug|Treatment with levetiracetam or sulthiame over a six-month period.|
348697|NCT00474929|Drug|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
348698|NCT00474955|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
347625|NCT00495326|Drug|Nevirapine based therapy|Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg
Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)
347626|NCT00495326|Drug|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
347627|NCT00495326|Drug|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.
Continuation phase: 4 months daily H(RMP).
Patients with meningitis will receive Streptomycin instead of E during intensive phase.
347628|NCT00495339|Drug|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
347629|NCT00495352|Drug|Hihg-doseNRT, Low-dose NRT, bupropion|
347630|NCT00495365|Drug|Epoetin alfa|
347631|NCT00495378|Drug|epoetin alfa|
347958|NCT00486863|Other|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
347959|NCT00486876|Drug|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
347960|NCT00486889|Biological|alglucosidase alfa|Intravenous (IV) infusion: 20mg/kg every 2 weeks
347961|NCT00486902|Drug|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
347962|NCT00003647|Drug|allovectin-7|
347963|NCT00486902|Drug|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
347964|NCT00003654|Radiation|technetium Tc 99m sulfur colloid|
347965|NCT00489710|Procedure|flow cytometry|
347966|NCT00489710|Procedure|laboratory biomarker analysis|
347967|NCT00489710|Procedure|non-specific immune-modulator therapy|
347968|NCT00489723|Drug|tamsulosin 0.4mg|
347969|NCT00489736|Drug|dronedarone (SR33589)|oral administration
347970|NCT00489736|Drug|amiodarone|oral administration
347971|NCT00489749|Procedure|Protected early weightbearing/Achilles tendon surgery|
347972|NCT00489762|Procedure|Installation of an energy efficient heater|
347275|NCT00503542|Drug|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
347276|NCT00503542|Drug|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
347277|NCT00503542|Other|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
347278|NCT00503568|Biological|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10^7 cells twice weekly, maximum 36 vaccines/patient
347279|NCT00503581|Procedure|Biopsy|Undergo biopsy
347280|NCT00503581|Other|Laboratory Biomarker Analysis|Correlative studies
347281|NCT00503581|Drug|Megestrol Acetate|given orally
347282|NCT00505895|Drug|Fludarabine|30 mg/m^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
347283|NCT00505895|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
347284|NCT00505895|Drug|Rituximab|375 mg/m^2 intravenous on Day -5, +2 +9 and +16.
347285|NCT00505921|Drug|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
347286|NCT00003734|Drug|flutamide|
347287|NCT00505921|Drug|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
347632|NCT00498212|Biological|1018 ISS immunostimulatory oligonucleotide with recombinant HB surface antigen|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
347633|NCT00498225|Drug|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
347634|NCT00498225|Drug|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
347635|NCT00498225|Drug|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
347636|NCT00498238|Drug|Levothyroxine|
347637|NCT00498251|Drug|inhalation of salbutamol (5 mg)|
347638|NCT00498251|Drug|ipratropium|
347639|NCT00498264|Behavioral|walking program, resistance muscular exercise|
346577|NCT00474136|Drug|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
346919|NCT00464815|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
346920|NCT00464828|Procedure|Internal jugular vein cannulation|
346921|NCT00003554|Biological|rituximab|
346922|NCT00464828|Device|ultrasound|
346923|NCT00464841|Procedure|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
346924|NCT00464841|Procedure|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
346925|NCT00464854|Drug|Glargine and insulin aspart or lispro|
346926|NCT00464867|Biological|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
346927|NCT00464880|Drug|Aliskiren|
346928|NCT00467961|Device|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
346929|NCT00467974|Procedure|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
346930|NCT00467974|Procedure|TACE|Transarterial chemoembolisation (TACE)
346931|NCT00467987|Drug|androgel|androgel 1%
346932|NCT00467987|Drug|placebo|placebo
346933|NCT00468000|Biological|autologous bone marrow cells|IM injection
346934|NCT00468000|Biological|electrolyte solution (without cells)|IM Injection
346935|NCT00000533|Behavioral|social support|
346936|NCT00003569|Drug|paclitaxel|
346937|NCT00468013|Behavioral|Resilience Building Exercises|Weekly exercises for 6 weeks
346938|NCT00468013|Behavioral|Journaling|Weekly exercises for 6 weeks
346939|NCT00468026|Device|ProstaPlant Stent|
346590|NCT00476996|Drug|placebo|Intravenous repeating dose
346591|NCT00477009|Device|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
346592|NCT00477022|Device|Vasotrain-447|
346593|NCT00477035|Drug|CIK cells|2x10e8 cells/kg
346594|NCT00477035|Drug|busulfan|1 mg/kg
346595|NCT00003602|Drug|cytarabine|
346596|NCT00477035|Drug|etoposide|60 mg/kg
346597|NCT00477035|Drug|bcnu|15 mg/kg
346598|NCT00477035|Drug|cyclophosphamide|100 mg/kg
346599|NCT00477035|Drug|gemcitabine|1250 mg/m2
346600|NCT00477035|Drug|vinorelbine|30 mg/m2
346601|NCT00477035|Drug|melphalan|200 mg/m2
346602|NCT00477048|Drug|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
346603|NCT00477061|Drug|Morphine|
346604|NCT00477074|Procedure|bronchoalveolar lavage, blood analysis|
346943|NCT00468065|Device|VeinViewer|Veinveiwer is used to view veins subQ
346944|NCT00468065|Device|Veinviewer|near infrared light reveals veins subcutaneously
346945|NCT00468078|Procedure|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
346946|NCT00468078|Drug|F-18 FPCIT|5mCi, intravenous injection
346947|NCT00003571|Genetic|mutation analysis|
346948|NCT00468091|Drug|exendin(9-39)amide|
346949|NCT00468091|Drug|atropine|
346950|NCT00468104|Drug|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
346951|NCT00468104|Drug|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
345922|NCT00494650|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
345923|NCT00494650|Behavioral|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
345924|NCT00494663|Drug|DIO-902|150mg tablet once per day for 16 weeks
346265|NCT00486083|Drug|Atomoxetine Hydrochloride|
346266|NCT00486083|Drug|Methylphenidate Hydrochloride|
346267|NCT00003642|Drug|fluorouracil|
346268|NCT00486109|Device|I-Port(TM) Injection Port|
346269|NCT00486122|Drug|Atomoxetine Hydrochloride|
346270|NCT00486122|Drug|Placebo|
346271|NCT00486135|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
346272|NCT00486135|Drug|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
346273|NCT00486148|Other|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
346274|NCT00486174|Drug|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
346275|NCT00486187|Drug|rosiglitazone|
346276|NCT00486187|Drug|metformin or sulfonylurea|
346277|NCT00486200|Drug|ASP2151|Oral administration.
346278|NCT00003642|Radiation|radiation therapy|
346279|NCT00486200|Drug|valacyclovir|Oral administration of active comparator.
346280|NCT00486200|Drug|Placebo|Oral administration of placebo.
346281|NCT00486213|Dietary Supplement|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
346282|NCT00486213|Other|Placebo|
346283|NCT00486226|Device|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
345578|NCT00499603|Drug|Paclitaxel|80 mg/m^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
345579|NCT00499603|Drug|5-Fluorouracil|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
345580|NCT00499603|Drug|Epirubicin|100 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
345581|NCT00502567|Drug|FOLFOX|intravenous infusion
345582|NCT00502567|Drug|Pemetrexed|intravenous infusion
345583|NCT00502567|Drug|Irinotecan (administered with & without Cetuximab)|intravenous injection
345584|NCT00502567|Drug|Docetaxel|intravenous infusion
345585|NCT00502580|Behavioral|Interview|Interview taking about 10 minutes to complete.
345586|NCT00502593|Biological|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
345587|NCT00502593|Biological|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
345588|NCT00502619|Procedure|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
345589|NCT00502619|Other|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
345590|NCT00502632|Drug|Urokinase and Dornase alfa|Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days
345591|NCT00003725|Drug|valrubicin|
345592|NCT00502632|Drug|Urokinase|Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
25ml normal saline, twice daily for 4 days
345593|NCT00502645|Device|CS-1 DECISION SUPPORT SYSTEM|
345594|NCT00502658|Behavioral|Dietary supplement containing vitamins, minerals, and herbs|
345595|NCT00502658|Behavioral|Shakes with nutrients and herbs|
345596|NCT00502658|Behavioral|Control dietary supplement|
345925|NCT00494663|Drug|DIO-902|300mg tablet once per day for 16 weeks
345926|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
350644|NCT00504686|Other|manual therapy|manual therapy - thoracic spine thrust manipulation
350645|NCT00504686|Other|exercise|therapeutic exercise
350646|NCT00504699|Procedure|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
350647|NCT00504712|Drug|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
350648|NCT00504712|Drug|0.9% saline|Saline injection every two weeks
350649|NCT00504725|Drug|Ketamine|Interventional
350650|NCT00003728|Drug|vincristine sulfate|
350966|NCT00004397|Drug|tin mesoporphyrin|
350967|NCT00617318|Dietary Supplement|Pomegranate|All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as "A" and "B," and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks.
350968|NCT00617318|Dietary Supplement|Placebo|All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as "A" and "B," and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks.
350969|NCT00617331|Biological|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
350970|NCT00617344|Biological|ChimeriVax™ Tetravalent Dengue Vaccine|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
350971|NCT00617344|Biological|ChimeriVax™ Tetravalent Dengue Vaccine|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
350972|NCT00617344|Biological|ChimeriVax™ Tetravalent Dengue Vaccine|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
350973|NCT00617357|Device|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
350974|NCT00617370|Drug|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
350975|NCT00617396|Drug|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
350317|NCT00466531|Biological|therapeutic autologous lymphocytes|
350318|NCT00466531|Drug|cyclophosphamide|
350319|NCT00466544|Device|Plasmaknife|
350320|NCT00466544|Device|Monopolar|
350321|NCT00466570|Drug|gatifloxacin, moxifloxacin|
350322|NCT00466583|Drug|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
350323|NCT00466596|Drug|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
350324|NCT00466609|Drug|clomipramine and fluoxetine|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
350325|NCT00466609|Drug|quetiapine and fluoxetine|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
350326|NCT00466609|Drug|placebo and fluoxetine|Placebo plus fluoxetine at maximum dosage of 80mg per day
350327|NCT00003562|Drug|docetaxel|
350328|NCT00466622|Drug|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
350329|NCT00466622|Drug|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
350330|NCT00466635|Drug|GT267-004 (tolevamer potassium sodium)|
350331|NCT00466648|Procedure|Tissue adhesive|
350651|NCT00504725|Drug|0.9% saline|placebo
350652|NCT00504751|Drug|bortezomib, dexamethasone, ifosfamide|VIPER chemotherapy will be administered every 28 days at the following doses:
Dexamethasone 40 mg IV days 1-4
Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4
Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)
Cisplatin 25 mg IV days 1-4
Etoposide 100 mg/m2 CIVI over 24 hours days 1-4
Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)
VELCADE 1.5 mg/m2 on days 2 and 5
350653|NCT00504751|Drug|mesna, cisplatin, etoposide, rituximab|VIPER chemotherapy will be administered every 28 days at the following doses:
Dexamethasone 40 mg IV days 1-4
Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4
Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)
Cisplatin 25 mg IV days 1-4
Etoposide 100 mg/m2 CIVI over 24 hours days 1-4
Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)
VELCADE 1.5 mg/m2 on days 2 and 5
349631|NCT00481728|Procedure|Intravesical neurostimulation|This is a procedure.
349632|NCT00484354|Other|Bicarbonate|IV bicarbonate, dosed by weight
349633|NCT00484354|Other|Placebo|Normal saline, with volume given based on patient weight
349634|NCT00484367|Behavioral|Adolescent group therapy|Adolescent group therapy
349968|NCT00472329|Procedure|TBI|
349969|NCT00472342|Behavioral|exercise prescription|
349970|NCT00472355|Drug|apomorphine|
349971|NCT00475410|Drug|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
349972|NCT00475423|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
349973|NCT00475436|Drug|GSK573719|
349974|NCT00475449|Procedure|percutaneous coronary intervention|
349975|NCT00475449|Procedure|coronary artery bypass grafting|
349976|NCT00475462|Drug|metoprolol|
349977|NCT00475462|Drug|conventional treatment|
349978|NCT00475475|Behavioral|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
349979|NCT00475475|Behavioral|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
349980|NCT00003595|Drug|doxorubicin hydrochloride|
349981|NCT00475475|Behavioral|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
349982|NCT00475488|Procedure|coronary angiogram or multi slice computed tomography scan|
349983|NCT00475501|Drug|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
349984|NCT00475501|Drug|Finasteride|5 mg, oral, once/day, for 52 weeks
349985|NCT00475501|Drug|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
349287|NCT00490529|Biological|CpG-MCL vaccine, primed T-cells|
349288|NCT00490529|Procedure|Autologous peripheral blood stem cell transplantation|Standard of Care
349289|NCT00490529|Procedure|CT scan|Standard of Care
349290|NCT00003658|Biological|rituximab|
349291|NCT00490529|Procedure|PET-CT scan|Standard of Care
349292|NCT00490529|Drug|PF-3512676|18 mg subcutaneous injection
349293|NCT00490529|Drug|Rituximab|375 mg/m2 iv Standard of care.
349294|NCT00490542|Drug|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
349295|NCT00493155|Drug|RG1530|Administered po at escalating doses (10 cohorts)
349296|NCT00493181|Drug|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
349297|NCT00493194|Drug|sirolimus|
349298|NCT00493194|Drug|cyclosporine|
349299|NCT00493194|Drug|daclizumab|
349300|NCT00003667|Procedure|surgical procedure|
349301|NCT00493220|Drug|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
349635|NCT00003637|Drug|cisplatin|
349636|NCT00484367|Behavioral|Transitional family therapy|Transitional family therapy
349637|NCT00484380|Procedure|Coronary scanner|multislice spiral computed tomography coronary angiography
349638|NCT00484393|Drug|tetracaine 4% gel|tetracaine applied prior to 1 injection
349639|NCT00484393|Drug|Placebo|placebo applied prior to 1 injection
349640|NCT00484419|Drug|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
349641|NCT00484419|Drug|rosiglitazone maleate|rosiglitazone tablets 4mg
348575|NCT00506428|Behavioral|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
348576|NCT00506441|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
348577|NCT00506441|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
348578|NCT00506454|Drug|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
348579|NCT00003736|Procedure|magnetic resonance imaging|
348934|NCT00498758|Device|APOS System - biomechanical wedge shoe|
348935|NCT00498771|Behavioral|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
348936|NCT00498784|Drug|Mirena|Mirena 52mg during 1 year
348937|NCT00003695|Procedure|surgical procedure|
348938|NCT00498797|Drug|Zactima (vandetanib)|
348939|NCT00498797|Drug|Docetaxel|
348940|NCT00498797|Drug|Prednisolone|
348941|NCT00498810|Procedure|complete repair|
348942|NCT00498810|Procedure|partial repair of the abdominal wall|
348943|NCT00498836|Drug|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
348944|NCT00498836|Drug|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
348945|NCT00498849|Device|CPAP|
348946|NCT00498875|Behavioral|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
348947|NCT00498875|Behavioral|Depression Intervention|Sessions given over 7 weeks and each lasting 30-45 minutes, that use "cognitive-behavioral" techniques.
348948|NCT00003696|Drug|carboplatin|
348197|NCT00465621|Drug|Xalatan|
348198|NCT00465647|Drug|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
348199|NCT00465660|Behavioral|Progressive resistance training|
348200|NCT00465673|Drug|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
348201|NCT00465686|Device|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
348202|NCT00465686|Device|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
348203|NCT00465699|Drug|Topical B12 0.07%|
348204|NCT00465712|Procedure|transabdominal amnioinfusion|transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
348205|NCT00465725|Drug|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
348206|NCT00003572|Procedure|allogeneic bone marrow transplantation|
348207|NCT00468442|Biological|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
348208|NCT00468442|Biological|Rituximab|Depletes transient B-cells
348580|NCT00506454|Drug|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
348581|NCT00506467|Procedure|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
348582|NCT00506480|Procedure|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
348583|NCT00462423|Drug|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
348584|NCT00003541|Drug|ifosfamide|
348585|NCT00462423|Drug|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
348586|NCT00462436|Behavioral|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
366168|NCT00645138|Procedure|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
366169|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
366170|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
366171|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
366172|NCT00647556|Drug|adapalene gel, 0.3%|applied topically once daily in the evening
366173|NCT00004892|Drug|O6-benzylguanine|
366174|NCT00647556|Drug|tretinoin 0.05% emollient cream|applied topically once daily in the evening
366175|NCT00647569|Procedure|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
366176|NCT00647569|Procedure|Conventional facial closure|The abdominal facia is closed with with continuous running suture
366177|NCT00647582|Procedure|adjuvant therapy|
366178|NCT00647582|Procedure|therapeutic conventional surgery|
366511|NCT00640614|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP
Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.
366512|NCT00004845|Drug|Naproxen|
366513|NCT00640627|Drug|Celecoxib|200 mg oral capsule once daily for 6 weeks
366514|NCT00640627|Drug|Placebo|Matched oral placebo for 6 weeks
366515|NCT00640640|Device|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
365848|NCT00652522|Other|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
365849|NCT00652561|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
365850|NCT00652574|Drug|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
365851|NCT00652587|Procedure|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
365852|NCT00652587|Procedure|hepatectomy|hepatectomy alone
365853|NCT00652600|Drug|Propranolol|ER Capsules, 160 mg, single-dose
365854|NCT00652600|Drug|Inderal-LA|ER Capsules, 160 mg, single-dose
365855|NCT00652613|Radiation|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
365856|NCT00004907|Drug|busulfan|
365857|NCT00652613|Radiation|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
365858|NCT00652626|Drug|azacitidine|
365859|NCT00652639|Drug|Clonazepam|Tablets, 1 mg, single-dose
365860|NCT00652639|Drug|Klonopin|tablets, 1 mg, single-dose
365861|NCT00652652|Drug|nesiritide, furosemide|
365862|NCT00652665|Drug|Leflunomide|Tablets, 20mg, single-dose
365863|NCT00655057|Behavioral|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
365864|NCT00655057|Procedure|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using [99mTc]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
365865|NCT00655070|Device|Timi3 Transthoracic ultrasound|Low frequency ultrasound over the chest using Timi3 ultrasound device
365866|NCT00655083|Drug|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
365190|NCT00666978|Behavioral|smoking cessation intervention|
365191|NCT00666978|Drug|bupropion hydrochloride|
365192|NCT00666978|Genetic|gene expression analysis|
365193|NCT00666978|Genetic|polymerase chain reaction|
365194|NCT00666978|Other|counseling intervention|
365195|NCT00666978|Other|educational intervention|
365196|NCT00666978|Procedure|psychosocial assessment and care|
365197|NCT00666991|Drug|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
365198|NCT00667004|Drug|ecabet ophthalmic solution|sterile ophthalmic solution
365516|NCT00660088|Other|Ketasyn|10g for 7 days, 20g for 7 or 14 days
365517|NCT00660101|Biological|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
365518|NCT00660140|Drug|Gemcitabine|
365519|NCT00660140|Drug|Carboplatin|
365520|NCT00660153|Drug|Tivozanib (AV-951) plus FOLFOX6|Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):
Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.
Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15.
365521|NCT00660166|Biological|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
365522|NCT00004999|Drug|Capravirine|
365523|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
348699|NCT00474968|Device|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector [SoftPAP(R)]
348700|NCT00474968|Device|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
348701|NCT00474981|Behavioral|IMNCI|Implementation of IMNCI in the intervention sites
348702|NCT00474994|Drug|sunitinib malate|
348703|NCT00475007|Device|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
348704|NCT00475020|Drug|Busulfan|Test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days
348705|NCT00003594|Drug|fluorouracil|
348706|NCT00475020|Drug|Fludarabine|40 mg/m^2 by vein daily over 1 hour x 4 days
348707|NCT00475020|Drug|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
348708|NCT00475033|Biological|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
348709|NCT00475033|Biological|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
348710|NCT00475046|Behavioral|Motivational Interviewing|
348711|NCT00475059|Drug|cimetidine arrow|patients who received cimétidine
348712|NCT00475072|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
348713|NCT00475072|Drug|ribavirin|1000/1200mg po daily for 48 weeks
348714|NCT00475085|Drug|aprepitant|Given orally or IV
348715|NCT00475085|Drug|dexamethasone|Given orally or IV
348716|NCT00003594|Drug|leucovorin calcium|
348717|NCT00475085|Drug|granisetron hydrochloride|Given orally or IV
348718|NCT00475085|Drug|palonosetron hydrochloride|Given orally or IV
348719|NCT00475085|Drug|prochlorperazine|Given orally or IV
349067|NCT00466141|Behavioral|Daily Self-weighing for weight loss maintenance|
347973|NCT00489775|Drug|Duloxetine|
347974|NCT00489775|Drug|Paroxetine|
347975|NCT00000542|Behavioral|diet, fat-restricted|
347976|NCT00003656|Biological|recombinant interferon alfa|
347977|NCT00489801|Other|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
347978|NCT00489814|Behavioral|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
347979|NCT00489827|Drug|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
347980|NCT00489827|Other|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
347981|NCT00489840|Drug|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
348351|NCT00483782|Biological|bevacizumab|
348352|NCT00483782|Drug|carboplatin|
348353|NCT00483782|Drug|paclitaxel|
348354|NCT00483782|Other|questionnaire administration|
348355|NCT00483782|Other|study of socioeconomic and demographic variables|
348356|NCT00483782|Procedure|quality-of-life assessment|
348357|NCT00483795|Drug|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
348358|NCT00483808|Device|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
348359|NCT00483821|Other|medical chart review|medical chart review
348360|NCT00003633|Drug|prednisone|
348361|NCT00483834|Drug|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
348362|NCT00483834|Drug|Irinotecan|200mg/m^2, IV, day 1 each cycle
348363|NCT00483834|Drug|Capecitabine|1000mg/m^2 or 750mg/m^2 for patients over 65yrs old PO BID, day 1-14 each cycle
347640|NCT00498277|Procedure|Magnetic Resonance Imaging|One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
347641|NCT00003692|Procedure|video-assisted surgery|
347642|NCT00498290|Procedure|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
347643|NCT00498290|Procedure|control|normal recovery protocol as usually
347644|NCT00498303|Biological|trivalent split influenza vaccine|
347645|NCT00498316|Procedure|Cord Blood Infusion|Cord blood transplantation performed on day 0.
347646|NCT00498316|Drug|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
347647|NCT00498316|Drug|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
347648|NCT00498316|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
347982|NCT00489840|Drug|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
347983|NCT00489853|Drug|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
347984|NCT00489853|Drug|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
347985|NCT00489853|Other|Placebo|Placebo, 1 inhalation twice daily
347986|NCT00489866|Drug|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
347987|NCT00003656|Drug|tretinoin liposome|
347988|NCT00489866|Drug|Placebo|Same as active drug.
347989|NCT00489879|Device|Mobile Health Care System (DrUB)|
346940|NCT00468039|Drug|vildagliptin + metformin|
346941|NCT00468052|Drug|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
346942|NCT00468052|Drug|fentanyl|1 microgram/kilogram as a bolus
347288|NCT00505921|Drug|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
347289|NCT00505921|Drug|BCNU|300 mg/m2 IV over 1 hour on day -6
347290|NCT00505921|Drug|Stem Cell Transplant|Stem cell infusion on Day 0.
347291|NCT00505921|Drug|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
347292|NCT00505921|Drug|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
347293|NCT00505921|Drug|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
347294|NCT00505921|Drug|Melphalan|140 mg/m2 IV on day -1.
347295|NCT00505921|Drug|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
347296|NCT00505921|Drug|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
347297|NCT00003734|Drug|triptorelin|
347298|NCT00505921|Drug|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
347299|NCT00505921|Radiation|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
347300|NCT00505934|Drug|Levetiracetam|Intravenous 100 mg/mL, twice a day, maximum of 4 days
Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.
Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);
Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).
For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:
Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily).
Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily).
347301|NCT00505947|Drug|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
347302|NCT00505947|Drug|placebo|placebo 5 mg/Kg body weight by intravenous infusion
347303|NCT00505960|Behavioral|Diabetes Care for Korean Americans|Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
346952|NCT00468117|Procedure|Islet transplantation|
346953|NCT00468117|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
346954|NCT00468117|Biological|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
346955|NCT00468117|Biological|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
346956|NCT00468117|Biological|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
346957|NCT00470769|Procedure|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
346958|NCT00470795|Other|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
346959|NCT00470795|Procedure|placebo/sham acupuncture|acupuncture at sham points without skin penetration
346960|NCT00470808|Drug|POMx|
346961|NCT00470821|Drug|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
346962|NCT00470821|Drug|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
346963|NCT00003578|Drug|melphalan|
346964|NCT00470834|Drug|dutasteride|0.5mg dutasteride (Investigation Product)
346965|NCT00470834|Drug|placebo|making placebo
346966|NCT00470834|Drug|bicalutamide|50 mg Casodex or generic equivalent
347309|NCT00461994|Behavioral|diet|
347310|NCT00461994|Behavioral|exercise|
347311|NCT00461994|Behavioral|diet and exercise|
347312|NCT00462007|Drug|Stalevo|Oral 3-4 daily doses for 6 weeks
347313|NCT00462020|Drug|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
347314|NCT00462020|Drug|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
347315|NCT00003541|Biological|filgrastim|
346284|NCT00486239|Behavioral|neuropsychological evaluation|
346285|NCT00486252|Other|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
346286|NCT00486265|Drug|AZD4877|intravenous infusion administered on days 1, 2 and 3
346287|NCT00486278|Drug|eptacog alfa (activated)|90 mcg/kg, injected i.v.
346288|NCT00486278|Drug|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
346289|NCT00003643|Biological|bleomycin sulfate|
346290|NCT00486278|Drug|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
346605|NCT00477087|Drug|Mitoxantrone|14mg/m2 IV
346606|NCT00003602|Drug|etoposide|
346607|NCT00477087|Drug|GM-CSF|250mg 3/week
346608|NCT00477100|Other|Interview|Personal Interview
346609|NCT00477100|Procedure|Blood and Tissue Collection|Blood (about 4 tablespoons) collected during routine blood draw, breast tissue collected at the time of standard diagnostic procedure, and a core and a skin biopsy collected at the time of standard diagnostic procedure.
346610|NCT00480129|Procedure|Nasal lavage|
346611|NCT00480142|Drug|Oxycodone 10 mg|
346612|NCT00480155|Biological|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
346613|NCT00480155|Other|Placebo|
346614|NCT00480181|Drug|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
346615|NCT00480181|Other|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
346616|NCT00003619|Dietary Supplement|vitamin E|
346617|NCT00480194|Drug|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
346618|NCT00480207|Dietary Supplement|folic acid|
346619|NCT00480207|Dietary Supplement|omega-3|
346620|NCT00480207|Dietary Supplement|vit B12|
345927|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
345928|NCT00494663|Drug|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
345929|NCT00003675|Drug|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
345930|NCT00494663|Drug|DIO-902|300mg DIO-902 tablet daily for 16 weeks
345931|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet for 16 weeks
345932|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
345933|NCT00494676|Device|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
345934|NCT00494676|Device|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
345935|NCT00494702|Procedure|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
345936|NCT00494702|Procedure|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
345937|NCT00494715|Drug|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
345938|NCT00494715|Drug|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
345939|NCT00003687|Drug|morphine sulfate|
345940|NCT00497328|Drug|Sodium Bicarbonate|
345941|NCT00497341|Drug|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
345942|NCT00497341|Drug|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
345943|NCT00497354|Drug|Variation in volume of local anesthetic|
345944|NCT00497354|Procedure|Ultrasound-guided interscalene brachial plexus block|
350976|NCT00619593|Other|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
350977|NCT00619606|Device|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
350978|NCT00619606|Device|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
350979|NCT00004426|Drug|leuprolide|
350980|NCT00619606|Device|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
350981|NCT00619606|Device|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
350982|NCT00619619|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
345597|NCT00502658|Behavioral|Isocaloric, isonitrogenous control shakes without herbs|
345598|NCT00502658|Behavioral|Personal energy tracking tool|
345599|NCT00502671|Drug|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
345600|NCT00502684|Drug|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
345601|NCT00502697|Behavioral|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
345602|NCT00003725|Procedure|conventional surgery|
345603|NCT00502697|Other|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
345604|NCT00502710|Drug|Placebo|po daily
345605|NCT00502710|Drug|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily
345606|NCT00502723|Procedure|Radical retropubic prostatectomy|Radical retropubic prostatectomy
345607|NCT00505284|Drug|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
350654|NCT00504764|Drug|Arsenic Trioxide|Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.
Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks
350655|NCT00504764|Procedure|Autologous Transplantation|Autologous Transplantation
350656|NCT00504764|Procedure|Allogenic Transplantation|Allogenic Transplantation
350657|NCT00504764|Drug|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
350658|NCT00504777|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
350659|NCT00504777|Drug|Methotrexate|10-25mg/week po or parenteral
350660|NCT00507130|Other|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
350661|NCT00507143|Drug|irinotecan|
350662|NCT00507156|Procedure|Standard primary PCI|Acute re-opening of the occluded coronary artery
350663|NCT00507156|Procedure|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
350664|NCT00003744|Drug|gemcitabine hydrochloride|
350665|NCT00507169|Drug|SVT-40776|
350666|NCT00507182|Procedure|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
350667|NCT00507195|Drug|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
350668|NCT00507208|Device|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
350669|NCT00507208|Other|Tongue Blades|Tongue Blades to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint System for another 3 months.
350670|NCT00507221|Drug|Albendazole|Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):
400mg/day X 3 days
350671|NCT00507221|Drug|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
350983|NCT00619632|Behavioral|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
350984|NCT00619632|Behavioral|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
349986|NCT00475501|Drug|Finasteride|5 mg, oral, once/day, for 52 weeks
349987|NCT00475514|Drug|Frovatriptan 2.5mg QD|
349988|NCT00475514|Drug|Frovatriptan 2.5 mg BID|
349989|NCT00475514|Drug|placebo|
349990|NCT00475527|Drug|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
349991|NCT00003595|Drug|prednisone|
349992|NCT00475540|Device|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
350332|NCT00466661|Drug|Acamprosate|666 mg po TID
350333|NCT00466661|Drug|Placebo|2 tabs po TID
350334|NCT00466674|Drug|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
350335|NCT00466687|Biological|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
350336|NCT00466687|Drug|erlotinib hydrochloride|150mg PO qd
350337|NCT00466687|Genetic|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
350338|NCT00003563|Radiation|WBRT|3 GY of WBRT daily for a total of 10 days
350339|NCT00466687|Genetic|gene expression analysis|gene expression analysis
350340|NCT00466687|Other|immunologic technique|immunologic technique
350341|NCT00466687|Other|laboratory biomarker analysis|laboratory biomarker analysis
350342|NCT00466687|Procedure|biopsy|biopsy
350343|NCT00466713|Drug|Rosiglitazone therapy|
350344|NCT00466726|Biological|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
350345|NCT00469482|Device|RASS Targeting plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
350346|NCT00469482|Other|RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
350347|NCT00469495|Drug|Anti-helminthic|
350348|NCT00469495|Drug|meglumine antimony|
349642|NCT00484419|Drug|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
349643|NCT00484432|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
349644|NCT00484432|Drug|doxorubicin|Doxorubicin: 60mg/m2 every 3 weeks, until cumulative dose of 550 mg/m²
349645|NCT00484458|Device|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
349646|NCT00003637|Drug|fluorouracil|
349647|NCT00484458|Device|Total Disc Replacement|Total disc
349648|NCT00484471|Drug|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
349649|NCT00484471|Drug|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
349650|NCT00484471|Drug|placebo|placebo to aripiprazole, 22 weeks
349651|NCT00484484|Drug|Ketamine|Ketamine
349652|NCT00484497|Drug|cyclamax|
349653|NCT00484510|Drug|Ascorbic acid (Vitamin C)|Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
349654|NCT00484510|Drug|placebo|Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
349655|NCT00484523|Procedure|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
349656|NCT00484536|Drug|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
349657|NCT00003637|Radiation|radiation therapy|
349658|NCT00484536|Drug|placebo|capsules, once daily
349659|NCT00484536|Drug|CDP323|250 mg Capsules, 500 mg, once daily
349993|NCT00475553|Other|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
349994|NCT00475553|Other|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
348949|NCT00498888|Procedure|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
348950|NCT00500760|Radiation|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
348951|NCT00003710|Drug|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
348952|NCT00500760|Drug|Panitumumab|Administered intravenously
348953|NCT00500786|Biological|CYT006-AngQb|
348954|NCT00500812|Drug|Cethrin|(BA-210)
349302|NCT00493220|Drug|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
349303|NCT00493220|Drug|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
349304|NCT00493233|Drug|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the "second" antipsychotic drug will remain fixed throughout the study period.
349305|NCT00493233|Drug|main antipsychotic medication and placebo|The "main" antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the "main" antipsychotic drug will remain open and flexible at the discretion of the attending physician.
349306|NCT00493246|Drug|IV Acetaminophen|This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)
Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
349307|NCT00493246|Drug|IV Acetaminophen|This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)
Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
349308|NCT00493259|Behavioral|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
349309|NCT00493259|Behavioral|Depression Scale for Children (CES-DC)|questionnaire
348587|NCT00462449|Device|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
348588|NCT00462462|Drug|Ethanol 96% Gel|
348589|NCT00462462|Drug|Ethanol 98% Solution|
348590|NCT00462475|Drug|Recombinant Growth Hormone, Genotropin (Pfizer)|
348591|NCT00462488|Drug|Vicinium|Intravesical administration of Vicinium
348592|NCT00462501|Biological|bevacizumab|
348593|NCT00462501|Drug|fluorouracil|
348594|NCT00462501|Drug|leucovorin calcium|
348595|NCT00003541|Drug|prednisone|
348596|NCT00462501|Drug|oxaliplatin|
348597|NCT00462501|Procedure|conventional surgery|
348598|NCT00462501|Radiation|radiation therapy|
348599|NCT00462540|Drug|Formoterol Fumurate inhalation solution 20 mcg|
348600|NCT00462540|Drug|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
348601|NCT00462553|Drug|sunitinib malate|Given orally
348602|NCT00462553|Drug|gemcitabine hydrochloride|Given IV
348955|NCT00500825|Procedure|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
348956|NCT00500838|Device|Transthoracic Impedance|Impedance measures will be automatically collected via the device
348957|NCT00500851|Device|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
348958|NCT00500851|Device|Endoscopy|Endoscopic placement of jejunal feeding tubes
348959|NCT00500864|Drug|Magnesium Sulfate 2 grams|
348960|NCT00500877|Behavioral|Mood Management Phone Counseling for Smoking Cessation|
348961|NCT00500890|Drug|Carboplatin|350 mg/m^2 by vein, Over 2 Hours x 2 Days
366516|NCT00640640|Drug|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
366517|NCT00640640|Drug|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
366518|NCT00640653|Behavioral|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
366519|NCT00640653|Behavioral|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
366520|NCT00640653|Behavioral|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
366521|NCT00640653|Behavioral|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
366522|NCT00640653|Behavioral|Health promotion control intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for "Hawthorne effects" to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention.
366523|NCT00642863|Dietary Supplement|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
366524|NCT00642863|Dietary Supplement|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
366861|NCT00004736|Drug|Ethambutol hydrochloride|
366862|NCT00635648|Drug|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
366863|NCT00635674|Device|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
366864|NCT00635687|Device|Fibroscan|transient elastography measure - Liver stiffness
365867|NCT00655083|Drug|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
365868|NCT00655109|Drug|Olopatadine|Ophthalmic solution
366179|NCT00647582|Radiation|intraoperative radiation therapy|
366180|NCT00647582|Radiation|radiation therapy|
366181|NCT00647595|Behavioral|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
366182|NCT00647608|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
366183|NCT00647608|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fed
366184|NCT00000641|Drug|Clofazimine|
366185|NCT00004892|Drug|polifeprosan 20 with carmustine implant|
366186|NCT00647621|Drug|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
366187|NCT00647621|Drug|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
366188|NCT00647634|Drug|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
366189|NCT00647634|Drug|Xanax XR® Tablets (3 mg|3mg, single dose fasting
366190|NCT00647647|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
366191|NCT00647647|Drug|Lamisil® Tablets 250 mg|250mg, single dose fasting
366192|NCT00647660|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
366193|NCT00647660|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
366194|NCT00647673|Drug|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
366195|NCT00647673|Drug|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
366196|NCT00650260|Device|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
365524|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
365525|NCT00660179|Drug|placebo|Matching placebo, once daily
365526|NCT00662506|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
365527|NCT00662506|Other|Laboratory Biomarker Analysis|Correlative studies
365528|NCT00662506|Procedure|Perfusion Magnetic Resonance Imaging|Undergo PWI
365529|NCT00662506|Procedure|Positron Emission Tomography|Undergo 18 F FDG-PET
365530|NCT00662506|Drug|Temozolomide|Given PO
365531|NCT00005018|Drug|Abacavir sulfate|
365532|NCT00662519|Drug|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
365533|NCT00662519|Drug|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
365534|NCT00662519|Dietary Supplement|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
365869|NCT00655109|Drug|Fluticasone|Nasal spray
365870|NCT00655109|Drug|Saline|Nasal spray
365871|NCT00004920|Drug|cisplatin|
365872|NCT00655109|Drug|Artificial tears|Ophthalmic Solution
365873|NCT00655122|Drug|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
365874|NCT00655122|Drug|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
365875|NCT00655135|Drug|LDP-02|Each patient in arms 2 & 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
365876|NCT00655135|Drug|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
365877|NCT00655148|Biological|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
365878|NCT00655148|Biological|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
349068|NCT00466141|Behavioral|Education for weight loss maintenance|
349069|NCT00003558|Drug|paclitaxel|
349070|NCT00466154|Drug|Aspirin|
349071|NCT00466167|Drug|Pramipexol Extended Release|
349072|NCT00466167|Drug|Pramipexol Immediate Release|
349073|NCT00466167|Drug|Placebo|
349074|NCT00466180|Behavioral|Nevirapine from twice-a-day to once-a-day|
349075|NCT00466193|Drug|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
349076|NCT00466193|Drug|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
349077|NCT00468858|Biological|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
349078|NCT00468858|Biological|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
349079|NCT00003573|Drug|etoposide|
349080|NCT00468871|Drug|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
349081|NCT00468871|Drug|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
349082|NCT00468884|Drug|Increasing doses of GLP-1|
349083|NCT00468884|Drug|PYY3-36|
349084|NCT00468897|Drug|BRL-049653|
349085|NCT00468910|Drug|acetylsalicylic acid|Given orally
349086|NCT00468910|Drug|placebo|Given orally
349087|NCT00468910|Other|laboratory biomarker analysis|Correlative study
349088|NCT00468923|Drug|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
349089|NCT00468923|Drug|Rosuvastatin|Rosuvastatin 10 mg once daily
348364|NCT00483860|Drug|Topotecan|once a day
348365|NCT00483886|Drug|Prucalopride|2 mg o.d.
348366|NCT00483886|Other|Placebo|Placebo o.d.
348367|NCT00483886|Drug|Prucalopride|4 mg o.d.
348368|NCT00483899|Drug|GW870086X|
348369|NCT00483912|Device|Molecular adsorbent recirculating system|
348370|NCT00483938|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
348371|NCT00003634|Biological|oregovomab|
348372|NCT00483938|Drug|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 72 weeks
348373|NCT00483938|Drug|ribavirin|1000-1400mg po daily for 48 weeks
348374|NCT00483938|Drug|ribavirin|1000-1400mg po daily for 72 weeks
348375|NCT00483964|Drug|Bacopa monnieri|
348376|NCT00483964|Drug|Nardostachys jatamansi|
348377|NCT00486915|Procedure|Left Atrial Appendage Ligation|
348720|NCT00475085|Drug|placebo|Given orally
348721|NCT00475098|Drug|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
348722|NCT00475111|Behavioral|Cognitive Behavior Therapy for Pain (CBT-P)|
348723|NCT00475111|Behavioral|Mindfulness Meditation for Emotion Regulation (MM-ER)|
348724|NCT00475111|Behavioral|Rheumatoid arthritis education|
348725|NCT00475124|Device|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
348726|NCT00477958|Other|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
348727|NCT00477958|Procedure|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
348728|NCT00003605|Biological|rituximab|
347990|NCT00489892|Drug|Modafinil|
347991|NCT00489905|Drug|Zolderonic acid (Zometa)|
347992|NCT00492661|Drug|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
347993|NCT00492674|Device|APOS biomechanical gait system|
347994|NCT00492674|Procedure|Physical Therapy|
347995|NCT00492687|Drug|carboplatin|
347996|NCT00003665|Biological|therapeutic tumor infiltrating lymphocytes|
347997|NCT00492687|Drug|tamoxifen citrate|
347998|NCT00492687|Drug|temozolomide|
347999|NCT00492687|Procedure|adjuvant therapy|
348000|NCT00492687|Radiation|radiation therapy|
348001|NCT00492700|Drug|rosiglitazone|
348002|NCT00492713|Other|dark chocolate|dark chocolate
348003|NCT00492713|Other|Milk chocolate 1|Milk chocolate 1
348004|NCT00492713|Other|Milk chocolate 2|Milk chocolate 2
348005|NCT00492726|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
348006|NCT00492726|Drug|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
348378|NCT00486941|Behavioral|Exercise and diet - based on DPS and DPP|
348379|NCT00486954|Drug|Lapatinib|6 pills at 250 mg each once daily
348380|NCT00486954|Drug|Paclitaxel|Infusion at 80 mg/m2 weekly
348381|NCT00486980|Drug|Peramivir 150mg|
348382|NCT00486980|Drug|Peramivir 300mg|
348383|NCT00486993|Behavioral|Dietary and nutritional modification|
348384|NCT00486993|Behavioral|Stop smoking|
347304|NCT00505973|Drug|SCA-136|
347305|NCT00505986|Procedure|endometrial biopsy|
347306|NCT00505999|Behavioral|Questionnaire|Questionnaire taking 30-40 minutes to complete.
347307|NCT00506012|Drug|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
347308|NCT00461981|Biological|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
347649|NCT00498316|Other|ATG|1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
347650|NCT00498316|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
347651|NCT00500149|Drug|Placebo|Placebo
347652|NCT00500162|Behavioral|Tri-Luma Maintenance regimen|
347653|NCT00500175|Device|TempTouchRM|
347654|NCT00500175|Device|Offloading|
347655|NCT00003704|Radiation|radiation therapy|
347656|NCT00500188|Drug|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
347657|NCT00500201|Drug|SB- 773812|
347658|NCT00500214|Procedure|elective ilioinguinal nerve excision|
347659|NCT00500240|Drug|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
347660|NCT00500240|Drug|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
347661|NCT00500253|Device|exhaled nitric oxide measurement|exhaled nitric oxide measurement
347662|NCT00500253|Procedure|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
347663|NCT00500253|Procedure|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
347664|NCT00500266|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
347316|NCT00462046|Drug|Berberine|
347317|NCT00462059|Behavioral|Treatment|
347318|NCT00462072|Drug|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
347319|NCT00462098|Device|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
347320|NCT00462098|Device|non-treated control group|no change from routine care, no HBO
347321|NCT00462111|Drug|Indometacin|
347322|NCT00462124|Device|BioProtect biodegradable balloon implant|biodegradable balloon implant to extend the distance between prostate and anterior rectal wall
347323|NCT00462124|Device|Ballon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
347324|NCT00462137|Procedure|Sleep Studies|
347325|NCT00462150|Behavioral|home-based emotional disclosure|
347326|NCT00003541|Drug|CHOP regimen|
347327|NCT00462150|Behavioral|time management control condition|
347328|NCT00462176|Procedure|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
347329|NCT00462176|Other|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
347330|NCT00462189|Drug|Immunotoxin therapy|
347331|NCT00462189|Drug|CAT-8015 Immunotoxin|
347332|NCT00462189|Procedure|Biological therapy|
347333|NCT00462202|Drug|sulodexide|
347672|NCT00500331|Drug|GSK189075|Experimental Drug
347673|NCT00500331|Drug|pioglitazone|Active Control
347674|NCT00500331|Other|Placebo|Placebo Comparator
347675|NCT00500344|Drug|Lucentis (ranibizumab)|intravitreal injection
346621|NCT00480207|Other|folic acid placebo|
346622|NCT00480207|Other|omega-3 placebo|
346623|NCT00480220|Procedure|Global care and support program|
346624|NCT00480246|Drug|BL 1020|
346625|NCT00480246|Drug|Perphenazine|
346626|NCT00480259|Behavioral|hyperproteic nutrition|
346627|NCT00003619|Drug|busulfan|
346628|NCT00480272|Drug|adalimumab plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
346629|NCT00480285|Procedure|Laparoscopic Nissen Fundoplication|
346630|NCT00480285|Procedure|Laparoscopic anterior partial fundoplication|
346967|NCT00470847|Drug|Lapatinib|Orally twice daily
346968|NCT00470847|Procedure|Whole Brain Radiation|15 treatments over a period of 3 weeks
346969|NCT00470847|Drug|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
346970|NCT00470860|Behavioral|Participation in LOFTS online tutorial|
346971|NCT00470873|Drug|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
346972|NCT00470886|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
346973|NCT00470899|Procedure|drainage of placenta of fetal blood|
346974|NCT00000535|Behavioral|diet, sodium-restricted|
346975|NCT00003578|Drug|prednisone|
346976|NCT00470912|Drug|sunscreen RV 2547C|
346977|NCT00470925|Procedure|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
346291|NCT00486278|Drug|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
346292|NCT00488995|Drug|CP-675,206|
346293|NCT00489008|Procedure|Stereotactic Body Radiation Therapy (SBRT)|Cohorts 1 & 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments
Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments
346294|NCT00489021|Procedure|sub-acute hospitalization|
346295|NCT00000542|Drug|pravastatin|
346296|NCT00003653|Drug|cyproterone acetate|Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
346297|NCT00489060|Procedure|Cryoablation and External Beam Radiation|
346298|NCT00489073|Drug|duloxetine|
346299|NCT00489073|Drug|placebo|
346300|NCT00489086|Drug|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
346301|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot A|
346302|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot B|
346303|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot C|
346304|NCT00489099|Biological|V232 Current Process Hepatitis B Vaccine|
346305|NCT00489112|Drug|Alfuzocine XL 10 mg once a day|
346306|NCT00489125|Other|physiologic testing|physical testing of range of motion, grip strength etc.
346307|NCT00003653|Drug|flutamide|Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
346308|NCT00489138|Drug|Ertapenem|1g a day by drip of 30 min
345608|NCT00505284|Drug|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
345609|NCT00505284|Drug|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
345610|NCT00505310|Behavioral|Writing|20 minutes of writing on different topics at four different times.
345611|NCT00505310|Behavioral|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
345612|NCT00505323|Device|Implantation of neurostimulators and their auxiliary components|Implantation neurostimulators and their auxiliary components :
Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482
345613|NCT00505336|Drug|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
345614|NCT00003730|Drug|vinorelbine tartrate|
345615|NCT00505336|Other|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
345616|NCT00505336|Drug|Atorvastatin|oral Atorvastatin 40mg
345945|NCT00497367|Device|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
345946|NCT00497380|Dietary Supplement|Arginine|Oral nutritional supplement
345947|NCT00497393|Behavioral|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
345948|NCT00497406|Procedure|Salivary gland transfer|Retrograde flow method
345949|NCT00497406|Procedure|Helical Tomotherapy treatment|total of 30 fractions
345950|NCT00000549|Drug|hormone replacement therapy|
345951|NCT00003688|Biological|dactinomycin|
345952|NCT00497419|Procedure|fast track|
345953|NCT00497445|Procedure|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
345954|NCT00497445|Procedure|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
345955|NCT00497458|Drug|Testosterone|testosterone 40 or 80 mg once a day
345956|NCT00497471|Drug|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
350985|NCT00619632|Behavioral|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
350986|NCT00619645|Drug|busulfan|
350987|NCT00619645|Drug|cyclosporine|
350988|NCT00619645|Drug|fludarabine phosphate|
350989|NCT00619645|Drug|mycophenolate mofetil|
350990|NCT00004428|Drug|CPX|
350991|NCT00619645|Procedure|allogeneic hematopoietic stem cell transplantation|
350992|NCT00619645|Procedure|peripheral blood stem cell transplantation|
350993|NCT00619658|Other|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
350994|NCT00619671|Drug|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
350995|NCT00619684|Drug|lenalidomide|Given PO
350996|NCT00619697|Drug|biphasic insulin aspart|
350997|NCT00619697|Drug|insulin glargine|
350998|NCT00619697|Drug|metformin|
350999|NCT00619697|Drug|glimepiride|
351000|NCT00619710|Drug|Meropenem|Intravenous
351001|NCT00004429|Drug|growth hormone|
351002|NCT00619710|Drug|Imipenem-cilastatin|Intravenous
351003|NCT00619723|Drug|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
351004|NCT00621660|Procedure|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
351005|NCT00621673|Drug|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
350349|NCT00469508|Drug|Modafinil|400mg pills taken orally daily for 12 wks.
350350|NCT00003575|Biological|recombinant interleukin-12|
350351|NCT00469508|Drug|Placebo|400mg pills taken orally daily for 12 wks
350352|NCT00469521|Drug|Refresh Tears, 9582X|
350353|NCT00469534|Procedure|IMRT|
350354|NCT00469547|Other|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
350355|NCT00469547|Drug|Placebo|15% ethanol in emollient gel used as a topical male microbicide
350356|NCT00469547|Other|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
350357|NCT00469560|Drug|Deferasirox|
350672|NCT00507221|Drug|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
350673|NCT00507234|Drug|formoterol fumarate inhalation solution|
350674|NCT00507247|Drug|Daptomycin|6mg/kg/day IV for at least 10 days.
350675|NCT00003745|Drug|topotecan hydrochloride|
350676|NCT00507260|Behavioral|Food Record|A record of the amount and kind of food and drink you intake will be completed.
350677|NCT00507260|Other|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
350678|NCT00507273|Other|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
350679|NCT00507286|Drug|combination of various doses of sildenefil and alprostadil|
350680|NCT00507299|Behavioral|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
350681|NCT00507299|Behavioral|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
350682|NCT00507312|Device|HD medical device (ViScope)|Device
350683|NCT00507312|Device|CSIRO device|device
349995|NCT00475566|Device|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
349996|NCT00475566|Device|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
349997|NCT00478556|Drug|Omnipaque|Oral CT contrast
349998|NCT00478556|Drug|Gastroview|Oral CT contrast
349999|NCT00003610|Dietary Supplement|capsaicin|
350000|NCT00478569|Drug|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
350001|NCT00478582|Procedure|Estimation of Hb concentrations with the HemoHue card|
350002|NCT00478595|Drug|rimonabant (SR141716)|one tablet/day
350003|NCT00478595|Drug|Placebo|one tablet/day
350004|NCT00478608|Drug|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
350005|NCT00478621|Biological|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
350006|NCT00478621|Biological|Cervarix TM|Intramuscular administration
350007|NCT00478634|Drug|RAD001, Cetuximab, Irinotecan|
350008|NCT00478647|Biological|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
350009|NCT00478660|Drug|adalimumab (Humira)|
350010|NCT00003610|Other|placebo|
350011|NCT00478673|Device|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
350012|NCT00478673|Device|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
350013|NCT00478686|Procedure|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
350358|NCT00469573|Drug|1. Optive|Optive 15ml- (in the eye) Instill one drop twice daily in each eye
350359|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
349310|NCT00493272|Drug|Fibrinogen|Fibrinogen behandling
349311|NCT00003667|Radiation|radiation therapy|
349312|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
349313|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
349314|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.
349315|NCT00493298|Drug|natalizumab|According to the local prescribing information
349316|NCT00495976|Other|A commercially produced cordial drink|
349317|NCT00495989|Procedure|saliva sampling + dental calculus collection|
349318|NCT00496002|Drug|Clevudine|
349319|NCT00496002|Drug|Adefovir|
349660|NCT00484549|Procedure|Blood sample|Ischemic stroke hospitalized
349661|NCT00484562|Device|portable pulse dose oxygen therapy|
349662|NCT00487539|Biological|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
349663|NCT00487539|Biological|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -> 50 mg arm group and at Week 2 for Golimumab 200 mg -> 100 mg arm group.
349664|NCT00487539|Biological|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -> 100 mg arm group and at Week 2 for Golimumab 400 mg -> 200 mg arm group.
349665|NCT00003650|Drug|cytarabine|
349666|NCT00487539|Biological|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -> 200 mg arm group.
349667|NCT00487539|Biological|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -> 50 mg arm group.
349668|NCT00487552|Device|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
349669|NCT00487565|Device|Total knee arthroplasty|Total knee arthroplasty using a posterior stabilized implant
349670|NCT00487578|Drug|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
349671|NCT00487591|Drug|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
348962|NCT00003710|Drug|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
348963|NCT00500890|Drug|Cyclophosphamide|1 g/m^2 by vein, Over 1 Hour x 2 Days
348964|NCT00500890|Drug|Etoposide|100 mg/m^2 by vein, Over 1 Hour x 5 Days
348965|NCT00500890|Drug|Vincristine|1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5
348966|NCT00500890|Radiation|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
348967|NCT00500903|Drug|MLN8237|MLN8237 will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
348968|NCT00500916|Device|ProSeal LMA|GEB vs digital vs introducer tool
348969|NCT00500929|Drug|CMI X-11S|
348970|NCT00500942|Behavioral|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
348971|NCT00500955|Drug|Rosiglitazone|
348972|NCT00500968|Procedure|stent|ERCP guided stent insertion before transection of the gland
348973|NCT00003711|Drug|irinotecan hydrochloride|
348974|NCT00503984|Drug|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
348975|NCT00503984|Drug|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
348976|NCT00000553|Drug|niacin|
349320|NCT00496015|Biological|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
349321|NCT00496015|Biological|Infanrix hexa.|1 intramuscular injection.
349322|NCT00496015|Biological|Meningococcal vaccine GSK134612.|1 intramuscular injection.
349323|NCT00003681|Biological|epoetin alfa|
349324|NCT00496015|Drug|Paracetamol.|Body weight of < 7 kg: none Body weight of ≥ 7 kg to < 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination.
Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
366865|NCT00635700|Drug|ziprasidone|20-160 mg/d
366866|NCT00635700|Drug|placebo|placebo
366867|NCT00635713|Drug|Fulvestrant|125mg
366868|NCT00635713|Drug|Anastrozole|ARIMIDEX
366869|NCT00635713|Drug|Fulvestrant|250mg
366870|NCT00635726|Drug|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
366871|NCT00004763|Drug|leuprolide|
366872|NCT00635726|Drug|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
366873|NCT00635726|Drug|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
366874|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
366875|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
366876|NCT00635726|Drug|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
366877|NCT00635739|Dietary Supplement|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
366878|NCT00635739|Dietary Supplement|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
366879|NCT00635752|Other|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
366880|NCT00635752|Other|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
366881|NCT00635765|Drug|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
366882|NCT00000638|Drug|Isoniazid|
361733|NCT00636103|Drug|CUF2|0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).
The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.
Duration: 6 months
361734|NCT00636103|Other|Placebo|Dark coloured corn starch
The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.
Duration: 6 months
366197|NCT00650273|Drug|Azithromycin Tablets 600 mg|600mg, single dose fasting
366198|NCT00650273|Drug|Zithromax® Tablets 600 mg|600mg, single dose fasting
366199|NCT00650286|Drug|Modafinil Tablets 200 mg|200mg, single dose fed
366200|NCT00650286|Drug|Provigil® Tablets 200 mg|200mg, single dose fed
366201|NCT00650299|Drug|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
366525|NCT00642876|Device|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
366526|NCT00642876|Device|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
366527|NCT00642889|Drug|Safinamide|
366528|NCT00642889|Drug|Safinamide|
366529|NCT00642889|Drug|Placebo|
366530|NCT00004865|Drug|paclitaxel|
366531|NCT00642902|Drug|atacicept|Atacicept high, mid and low-dose, respectively
366532|NCT00642902|Drug|Placebo|Placebo will be supplied in a transparent, sterile solution for injection in pre-filled syringes matching the Atacicept pre-filled syringes, each containing 1mL. The placebo formulation to be used in this study contains trehalose and 10 mmol sodium acetate buffer (pH 5)."
366533|NCT00642915|Drug|Lantus, Amaryl|
366534|NCT00642928|Drug|Placebo|1 capsule per day during 4 weeks
366535|NCT00642928|Drug|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
366536|NCT00642928|Drug|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
366537|NCT00642928|Drug|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
366538|NCT00642928|Drug|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
366539|NCT00642941|Drug|RG1507|9mg/kg iv weekly
366540|NCT00642954|Drug|Comparator: vorinostat|Dose escalation study. Level 1: 300 mg q.d. vorinostat p.o. for 14 days. Level 2,3, 4 & 5: 400 mg q.d. vorinostat p.o. for 14 days. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
Participants who do not have disease progression and who continue to meet the eligibility criteria after the 8 cycles will be offered continued treatment at the same dose level and schedule.
365879|NCT00655161|Biological|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
365880|NCT00655174|Drug|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
365881|NCT00655174|Drug|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
365882|NCT00004920|Drug|raltitrexed|
365883|NCT00655174|Drug|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
365884|NCT00655187|Other|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
365885|NCT00655187|Procedure|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
365886|NCT00657579|Drug|DE-104 ophthalmic solution, low concentration|
365887|NCT00657579|Drug|DE-104 ophthalmic solution, medium concentration|
365888|NCT00657579|Drug|DE-104 ophthalmic solution, high concentration|
365889|NCT00004935|Drug|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
365890|NCT00657579|Drug|DE-104 vehicle|
366202|NCT00650299|Drug|Xanax XR® Tablets 3 mg|3mg, single dose fed
366203|NCT00650312|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
366204|NCT00650312|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
366205|NCT00650325|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fasting
366206|NCT00004903|Drug|cisplatin|
366207|NCT00650325|Drug|Zoloft® Tablets 100 mg|100mg, single dose fasting
366208|NCT00650338|Drug|DE-104 ophthalmic solution, low concentration|Topical ocular application
366209|NCT00650338|Drug|DE-104 ophthalmic solution, medium concentration|Topical ocular application
349090|NCT00003573|Drug|vincristine sulfate|
349091|NCT00468936|Drug|Myfortic|enteric coated Cellcept pills in applicable dose for patient
349444|NCT00506727|Drug|Atomoxetine hydrochloride|
349445|NCT00506740|Device|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
349446|NCT00506740|Device|monopolar electrosurgery generator and tip|
349447|NCT00506753|Behavioral|Motivation Intervention, Cognitive Behavior Therapy|Comparison of 2 treatment combinations for assisting incarcerated teens with alcohol and marijuana use and associated problems. The two treatments being compared are, Motivational Intervention/Cognitive Behavior Therapy and Relaxation Treatment/Substance Education Treatment.
349448|NCT00506766|Behavioral|Bladder Health Class consisting of 6 weekly group sessions|1 time
349449|NCT00003740|Biological|trastuzumab|
349450|NCT00506766|Behavioral|Practice PFMT and BT|As needed for 4 years
349451|NCT00506766|Behavioral|Clinic examination for pelvic muscle function|1/year for 4 years
349452|NCT00506766|Behavioral|Record keeping in 3-day voiding diary|Every 6 months for 4 years
349453|NCT00506779|Drug|Imatinib Mesylate|Phase I = 400 mg by mouth daily
Phase II (Arm 2) = 400 mg by mouth daily
349454|NCT00506779|Drug|Paclitaxel|175 mg/m^2 by vein Over 3 Hours Every 21 Days
349455|NCT00506792|Drug|QAU145|
349456|NCT00506792|Drug|Placebo|
349457|NCT00506805|Drug|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
349458|NCT00506818|Other|Multifactorial vascular-risk-factor-intervention|
349459|NCT00506831|Drug|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
349460|NCT00000555|Drug|estrogen replacement therapy|
349461|NCT00462761|Drug|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
349462|NCT00462774|Procedure|Intramyocardial injection of autologous CD133+ marrow cells|
349463|NCT00462787|Biological|filgrastim|
348729|NCT00477958|Procedure|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
348730|NCT00477971|Biological|filgrastim|No administration information given
348731|NCT00477971|Drug|dexamethasone|Given orally
348732|NCT00477971|Drug|melphalan|Given IV or orally
348733|NCT00477971|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
348734|NCT00477984|Drug|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
348735|NCT00477997|Device|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
348736|NCT00478010|Other|counseling intervention|
348737|NCT00478010|Other|study of socioeconomic and demographic variables|
348738|NCT00478010|Procedure|psychosocial assessment and care|
348739|NCT00003605|Drug|cyclophosphamide|
348740|NCT00478010|Procedure|quality-of-life assessment|
348741|NCT00478023|Drug|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
348742|NCT00478023|Drug|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
348743|NCT00478023|Drug|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
348744|NCT00478023|Drug|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
349092|NCT00468962|Drug|FACOS (functional food)|
349093|NCT00468975|Drug|PF-610,355|
349094|NCT00468975|Drug|Salmeterol|
349095|NCT00468988|Drug|Travatan® Z|
349096|NCT00468988|Drug|Xalatan®|
349097|NCT00469001|Procedure|Treatment according NT Pro BNP level|
349098|NCT00469014|Drug|Clofarabine|Arm 1 = 10 mg/m^2 intavenous (IV) Daily; Arm 2 = 20 mg/m^2 IV Daily; Arm 3 = 30 mg/m^2 IV Daily; Arm 4 = 40 mg/m^2 IV Daily
349099|NCT00469014|Drug|Busulfan|Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily; Arm 4: 40 mg/m^2 IV Daily
348385|NCT00486993|Behavioral|Regular physical activities|
348386|NCT00003647|Drug|allovectin-7/dacarbazine|
348387|NCT00486993|Behavioral|Weight reduction to normal ranges|
348388|NCT00486993|Behavioral|Regular intake of polyphenols, esp. from Ilex paraguayensis|
348389|NCT00487006|Other|Serum Lab testing|Serum Lab testing
348390|NCT00487032|Drug|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
348391|NCT00487032|Drug|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
348392|NCT00487032|Drug|Prazosin hydrochloride|Prazosin 1mg one dose only
348393|NCT00487032|Drug|Placebo to Prazosin|Placebo 1 tablet one dose only
348394|NCT00487045|Device|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
348395|NCT00487058|Drug|Gimatecan|
348396|NCT00487071|Device|Anal fistula plug|
348397|NCT00003647|Drug|dacarbazine|
348398|NCT00487084|Drug|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
348399|NCT00487084|Drug|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
348400|NCT00487084|Drug|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
348401|NCT00487097|Dietary Supplement|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
348745|NCT00478023|Drug|Placebo|4 - 6 hourly; Total 72 hours
348746|NCT00478036|Drug|Acular LS|Details covered in arm description
348747|NCT00478036|Drug|Pred Forte|Details covered in arm description
348748|NCT00478036|Other|Refresh Tears|Placebo
347665|NCT00500279|Drug|Celecoxib|
347666|NCT00003705|Drug|BMS-184476|
347667|NCT00500292|Drug|Vandetanib|once daily oral tablet two dose strengths
347668|NCT00500292|Drug|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
347669|NCT00500305|Procedure|Withhold standard INDO dose if BNP < 100 pg/ml|
347670|NCT00500318|Drug|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
347671|NCT00500318|Drug|Placebo|Dose matched placebo, once daily oral inhalation.
348007|NCT00000545|Behavioral|exercise|
348008|NCT00003665|Biological|tyrosinase peptide|
348009|NCT00492739|Biological|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
348010|NCT00492752|Drug|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
348011|NCT00492752|Drug|Placebo|Matching placebo (orally) twice daily
348012|NCT00492765|Drug|Interferon-beta-1a|dosage and frequency as per label
348013|NCT00492765|Drug|Simvastatin|dosage and frequency as per Biogen Idec protocol
348014|NCT00492765|Drug|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
348015|NCT00492778|Radiation|3-Dimensional Conformal Radiation Therapy|Given to the pelvis
348016|NCT00492778|Drug|Cisplatin|Given IV
348017|NCT00492778|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
348018|NCT00492778|Radiation|Internal Radiation Therapy|Given intracavitarily or interstitially
348019|NCT00003666|Drug|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
348020|NCT00492791|Device|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
348021|NCT00492804|Procedure|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
348022|NCT00492804|Procedure|Neurectomy|Neurectomy
347676|NCT00500357|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
347677|NCT00003706|Drug|pemetrexed disodium|
347678|NCT00500370|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
347679|NCT00500370|Drug|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
347680|NCT00500396|Procedure|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
347681|NCT00500409|Drug|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
347682|NCT00503581|Other|Pharmacological Study|Correlative studies
347683|NCT00503581|Other|Quality-of-Life Assessment|Ancillary studies
347684|NCT00003727|Drug|melphalan|
347685|NCT00503581|Procedure|Therapeutic Conventional Surgery|undergo hysterectomy
347686|NCT00503594|Drug|Methotrexate and temozolomide|Methotrexate and temozolomide
347687|NCT00503594|Drug|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
347688|NCT00503607|Drug|BLI-800|
347689|NCT00503607|Drug|Polyethylene glycol 3350 based bowel preparation|
347690|NCT00503620|Drug|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
347691|NCT00503646|Other|communication intervention|
347692|NCT00503646|Other|counseling intervention|
347693|NCT00503646|Other|questionnaire administration|
347694|NCT00503646|Procedure|psychosocial assessment and care|
347695|NCT00003727|Procedure|bone marrow ablation with stem cell support|
347696|NCT00503659|Procedure|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
348032|NCT00495469|Drug|GSK189075|12 weeks experimental drug
346978|NCT00470938|Device|SpineForce Reactive Neuromuscular Trainer|
346979|NCT00470951|Procedure|open rectal resection|open rectal resection
346980|NCT00470951|Procedure|laparoscopic rectal resection|laparoscopic assisted rectal resection
346981|NCT00470964|Procedure|Titanium Sapphire laser trabeculoplasty|
346982|NCT00470977|Drug|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
346983|NCT00474162|Drug|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
346984|NCT00474162|Drug|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
346985|NCT00474175|Drug|Placebo gel|single dose (less than 1g) of a matching placebo gel
346986|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
346987|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
346988|NCT00474188|Drug|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
347334|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
347335|NCT00464893|Drug|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
347336|NCT00464893|Drug|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
347337|NCT00464919|Drug|Sorafenib|
347338|NCT00464919|Drug|tegafur/uracil (UFUR®)|
347339|NCT00003554|Drug|melphalan|
347340|NCT00464932|Drug|Vasoactive Intestinal Peptide (VIP)|
347341|NCT00464945|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
347342|NCT00464958|Drug|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
347343|NCT00464971|Drug|estradiol, 25 mcg|
346309|NCT00489151|Drug|adefovir dipivoxil|
346310|NCT00489151|Drug|lamivudine|
346631|NCT00480298|Drug|Administration of oral methylprednisolone|
346632|NCT00480311|Other|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
346633|NCT00480324|Biological|Rotarix|Two-dose oral vaccination.
346634|NCT00480324|Biological|Placebo|Two-dose oral administration.
346635|NCT00480337|Procedure|In Vitro Maturation of immature oocytes|
346636|NCT00480350|Behavioral|rice based food supplement|
346637|NCT00480363|Procedure|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
346638|NCT00003619|Drug|cytarabine|
346639|NCT00480376|Drug|ofloxacin|
346640|NCT00480376|Drug|gentamicin|
346641|NCT00483171|Drug|CP-945,598|CP-945,598
346642|NCT00483171|Behavioral|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
346643|NCT00003631|Radiation|radiation therapy|
346644|NCT00483171|Behavioral|Low Calorie Diet|Low calorie diet
346645|NCT00483184|Biological|Veldona,|Very low dose oral natural human interferon alpha lozenges
346646|NCT00483197|Device|VentrAssistTM Left Ventricular Assist Device|
346647|NCT00483210|Drug|Fenofibrate|
346648|NCT00483223|Drug|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
346649|NCT00483223|Drug|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
346650|NCT00483249|Device|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
345957|NCT00497471|Drug|iron (2 mg/kg/daily)|
345958|NCT00497484|Drug|recombinant human somatotropin|
345959|NCT00497497|Drug|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
345960|NCT00497497|Drug|cetuximab|Intravenous repeating dose
345961|NCT00497497|Drug|FOLFIRI regimen|Intravenous repeating dose
345962|NCT00003690|Drug|alvocidib|
345963|NCT00497497|Drug|irinotecan|Intravenous repeating dose
345964|NCT00497497|Drug|PRO95780|Intravenous repeating dose
345965|NCT00497510|Procedure|Chiropractic manipulation|
345966|NCT00497523|Drug|Beclomethasone dipropionate|
345967|NCT00497523|Drug|Beclomethasone dipropionate/Salbutamol combination|
345968|NCT00497523|Drug|Salbutamol|
345969|NCT00499603|Drug|Cyclophosphamide|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
345970|NCT00499603|Drug|RAD001|30 mg by mouth weekly on Days 1, 8, & 15 for 12 cycles.
346311|NCT00489164|Device|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
346312|NCT00489177|Device|A|QuickOpt intra-cardiac electrogram optimization
346313|NCT00489177|Device|B|Single optimization in initial month post-implant
346314|NCT00489190|Drug|Insulin Glulisine|
346315|NCT00489203|Drug|beclomethasone dipropionate|Given orally
346316|NCT00489203|Drug|placebo|Given orally
346317|NCT00492050|Drug|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
346318|NCT00003662|Procedure|umbilical cord blood transplantation|
346319|NCT00492063|Biological|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
345617|NCT00505349|Behavioral|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
345618|NCT00505362|Procedure|Rectus closure vs. non-closure|Closure of the Rectus muscle vs. non-closure of the rectus muscle at cesarean section.
345619|NCT00505375|Drug|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
345620|NCT00505375|Other|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
345621|NCT00505401|Biological|recombinant HIV-1 Tat protein|
345622|NCT00505414|Drug|Tapentadol Extended Release (CG5503)|Titration phase: Starting at 100 mg Tapentadol twice daily, increasing as necessary up to a maximum of 250 mg Tapentadol twice daily. Re-randomization to continue on Tapentadol Extended Release or Matched Placebo in the Maintenance phase. Maintenance phase: continuing on the dose level established in titration phase.
345623|NCT00505414|Drug|Morphine Sulphate Controlled Release|Titration phase: Starting at 45 mg, increasing at a minimum of 3 day intervals by 15 mg, with a maximum dose of 90 mg. Maintenance phase: continuing on the dose level established in titration phase.
345624|NCT00505414|Drug|Matching Placebo|At the end of the titration phase subjects on Tapentadol (CG5503) Extended Release were re-randomized to continue on either Tapentadol Extended Release or Matched Placebo in the Maintenance phase. Maintenance phase: continuing on the dose level established in titration phase.
345625|NCT00000154|Procedure|Vitrectomy|
345626|NCT00000554|Procedure|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
345627|NCT00003731|Drug|temozolomide|
345628|NCT00505427|Dietary Supplement|Alpha Lipoic Acid|
345629|NCT00461162|Behavioral|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
345630|NCT00461162|Behavioral|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
345631|NCT00461201|Procedure|Nurse practitioner care of patients|
345632|NCT00003536|Procedure|complementary and alternative therapy|
345633|NCT00461214|Other|Participation in laparoscopic training curriculum|General Surgery Training Outcome
350684|NCT00507325|Procedure|Blood Sample|Blood samples will be collected.
350685|NCT00507325|Procedure|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
350686|NCT00463346|Drug|Placebo|Placebo
350687|NCT00463359|Drug|Imiquimod cream|
350688|NCT00003545|Drug|nelarabine|
350689|NCT00463359|Procedure|curettage and cautery|
350690|NCT00463372|Drug|PF-02545920|
350691|NCT00463385|Drug|Pomalidomide|
350692|NCT00463385|Drug|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
350693|NCT00463385|Drug|Placebo to pomalidomide|Matching pomalidomide placebo tablets
350694|NCT00463385|Drug|Placebo to prednisone|Matching prednisone placebo tablets
351006|NCT00004451|Drug|Glucose|
351007|NCT00621686|Biological|bevacizumab|
351008|NCT00621686|Drug|sorafenib tosylate|
351009|NCT00621699|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
351010|NCT00621699|Drug|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
351011|NCT00621699|Drug|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
351012|NCT00621712|Device|GamCath® central venous catheter|choice of catheter type
351013|NCT00621712|Device|GamCath Dolphin® Protect central venous catheter|choice of catheter type
351014|NCT00621725|Drug|AZD2171|Oral dose
351015|NCT00621751|Drug|Carbamazepine|800 mg daily
351016|NCT00621751|Drug|Placebo|Placebo
350360|NCT00469586|Drug|metformin|Tablets, 2000 mg/day.
350361|NCT00000534|Behavioral|dietary supplements|
350362|NCT00003575|Drug|etoposide|
350363|NCT00469586|Drug|glimepiride|Tablets, 4 mg/day.
350364|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
350365|NCT00469599|Drug|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
350366|NCT00469599|Drug|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
350367|NCT00469612|Device|NeuroVision's NVC treatment for Low Myopia|NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).
The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress.
350368|NCT00469612|Other|Control - No intervention|In this group, subjects will not be given any intervention. However, similar to the intervention group, every 5th session subject's visual performance (visual acuity and CSF) will be tested in order to compare the performance with the treatment group.
350369|NCT00469625|Drug|paricalcitol (initial dose 1 mcg orally per day)|
350370|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
350371|NCT00472368|Drug|LBH589|
350372|NCT00472381|Drug|Insulin|Insulin
350373|NCT00472407|Device|NPC targets|
350374|NCT00003584|Drug|prednisone|
350375|NCT00472420|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
350376|NCT00472420|Drug|First line chemotherapy|As prescribed
350377|NCT00472433|Drug|Alemtuzumab|
350378|NCT00472446|Procedure|superficial cervical block|
350379|NCT00472459|Procedure|Photodynamic therapy with Metvix 160 mg/g cream|
349672|NCT00487591|Drug|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
349673|NCT00487617|Procedure|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
349674|NCT00487630|Drug|recombinant alpha-galactosidase A|
349675|NCT00487643|Procedure|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
349676|NCT00003650|Drug|daunorubicin hydrochloride|
349677|NCT00487656|Drug|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
349678|NCT00487656|Drug|placebo|6 mg/ml ampule solution for injection at .01mg/kg
350014|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
350015|NCT00478699|Drug|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
350016|NCT00478699|Drug|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
350017|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
350018|NCT00478725|Drug|GW786034, oral|oral, 800 mg
350019|NCT00478725|Drug|GW786034, IV|IV, 5 mg
350020|NCT00478725|Drug|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
350021|NCT00003610|Radiation|radiation therapy|
350022|NCT00478738|Drug|GSK961081|
350023|NCT00478764|Drug|intraocular triamcinolone and gatifloxicin|
350024|NCT00478777|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
350025|NCT00481741|Device|SafeSeal(TM) Hemostasis Patch|
350026|NCT00003624|Drug|amifostine trihydrate|
350027|NCT00481767|Biological|CervarixTM|Three doses of vaccine/control will be administered according to a 0, 1, 6 month schedule
349325|NCT00496028|Drug|AZD0530|oral tablet
349326|NCT00496028|Drug|Carboplatin|intravenous infusion
349327|NCT00496028|Drug|Paclitaxel|intravenous infusion
349328|NCT00496041|Procedure|Registry|A Registry will be used.
349329|NCT00496054|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 & P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
349330|NCT00496067|Device|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
349331|NCT00496080|Device|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
349332|NCT00496093|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
349333|NCT00496106|Behavioral|Telephone counseling|6 telephone counseling sessions
349334|NCT00003681|Drug|amifostine trihydrate|
349335|NCT00496106|Behavioral|Telephone interview|telephone interview
349336|NCT00496119|Radiation|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
349337|NCT00496119|Radiation|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
349338|NCT00496132|Drug|PRO131921|Escalating doses by IV infusion
349339|NCT00496145|Behavioral|Spanish Diabetes Self-Management Program|
349340|NCT00496158|Drug|Clevudine|
349341|NCT00496158|Drug|Adefovir|
349342|NCT00496184|Drug|Nifedipine cream topical application|
349343|NCT00498888|Procedure|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
349679|NCT00487669|Drug|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
361735|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
361736|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
361737|NCT00636116|Biological|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
361738|NCT00636129|Behavioral|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
361739|NCT00636142|Biological|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
361740|NCT00004770|Drug|thioctic acid|
361741|NCT00636155|Drug|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
361742|NCT00636155|Drug|Rituximab|375 mg/m2 on day 2
361743|NCT00636155|Drug|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
361744|NCT00636155|Drug|Fludarabine|25 mg/m2 on days 2, 3, and 4
361745|NCT00636168|Drug|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
361746|NCT00636168|Drug|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
361747|NCT00636181|Device|Auto AFlex|Positive pressure therapy treatment
361748|NCT00636181|Device|Auto CPAP|Positive pressure therapy treatment
361749|NCT00636181|Device|CPAP|Positive pressure therapy treatment
361750|NCT00636194|Device|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
361751|NCT00004771|Drug|leuprolide|
361752|NCT00636194|Device|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
361753|NCT00636207|Drug|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
361754|NCT00638716|Drug|Placebo|Placebo
362079|NCT00005064|Drug|bortezomib|Given IV
366541|NCT00004866|Drug|exatecan mesylate|
366542|NCT00642954|Drug|Comparator: lenalidomide|Dose escalation study. Level 1 & 2: 10 mg q.d. lenalidomide p.o. for 21 days. Level 3: 15 mg q.d. lenalidomide p.o. for 21 days. Level 4: 20 mg q.d. lenalidomide p.o. for 21 days. Level 5: 25 mg q.d. lenalidomide p.o. for 21 days. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
366543|NCT00642954|Drug|Comparator: dexamethasone|Dose escalation study. 40 mg q.d. Dexamethasone p.o. will be given in each level on days 1, 8, 15, and 22 of each treatment cycle. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
366544|NCT00642967|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|s.c. every 4 weeks (starting dose based on previous ESA therapy)
366545|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
366883|NCT00004763|Drug|Ethinyl estradiol/norethindrone|
366884|NCT00635778|Drug|MK-0646|Patients receive an intravenous (IV) infusion over one to two hours, at escalating dose levels (2.5, 5 10, 15, and 20 mg/kg).
366885|NCT00635791|Drug|Sorafenib|Given by mouth
366886|NCT00635791|Drug|Vorinostat|Given by mouth
366887|NCT00638066|Drug|botulinum toxin|500 units of botulinum toxin for the second arm
366888|NCT00638066|Drug|botulinum toxin A|250 units of botulinum toxin A once
366889|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
366890|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
366891|NCT00638092|Drug|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
366892|NCT00638092|Drug|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
366893|NCT00638118|Drug|Fexofenadine|
366894|NCT00638131|Drug|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
366895|NCT00638157|Drug|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
366896|NCT00004804|Drug|interferon alfa|
366897|NCT00638157|Drug|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
366210|NCT00650338|Drug|DE-104 ophthalmic solution, high concentration|Topical ocular application
366211|NCT00650338|Drug|Placebo|placebo
366212|NCT00650338|Drug|0.005% latanoprost|Topical ocular application
366213|NCT00650351|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
366214|NCT00650351|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
366215|NCT00650364|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
366216|NCT00650364|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fasting
366217|NCT00004903|Drug|cyclophosphamide|
366218|NCT00650377|Drug|Finasteride Tablets 5 mg|5mg, single dose fed
366219|NCT00650377|Drug|Proscar® Tablets 5 mg|5mg, single dose fed
366220|NCT00650390|Biological|adalimumab|40 mg adalimumab every other week
366221|NCT00650403|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
366222|NCT00650403|Drug|Paxil® 40 mg Tablet|40mg, single dose fed
366223|NCT00650416|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
366224|NCT00650416|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
366225|NCT00652665|Drug|ARAVA|Tablets, 20mg,single-dose
366226|NCT00652691|Biological|filgrastim|
366227|NCT00652691|Drug|carboplatin|
366228|NCT00652691|Drug|cyclophosphamide|
366546|NCT00642980|Drug|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
366547|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
366548|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
349464|NCT00462787|Drug|clofarabine|
349465|NCT00462787|Drug|dexamethasone|
349466|NCT00003543|Biological|monoclonal antibody A33|
349467|NCT00462787|Drug|thiotepa|
349468|NCT00462787|Drug|topotecan hydrochloride|
349788|NCT00501228|Drug|Filgrastim|5 mg/kg ID Once Daily x 1 Week
349789|NCT00501241|Drug|ATI-7505|Tablet,placebo, BID
349790|NCT00003713|Drug|intoplicine|
349791|NCT00501241|Drug|ATI-7505|ATI-7505 20 mg BID for 4 weeks
349792|NCT00501241|Drug|ATI-7505|tablet, 40 mg, BID, $ weeks
349793|NCT00501241|Drug|ATI-7505|80 mg ATI-7505, BID for 4 weeks
349794|NCT00501241|Drug|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
349795|NCT00501254|Drug|Slow release acetyl salicylic acid|
349796|NCT00501254|Behavioral|Antithrombotic effect|
349797|NCT00501267|Drug|solabegron and oxybutynin|
349798|NCT00501280|Behavioral|Interview|Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
349799|NCT00501293|Drug|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
349800|NCT00501319|Behavioral|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
349801|NCT00003714|Drug|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
349802|NCT00501319|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
349803|NCT00501332|Biological|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
349804|NCT00501345|Drug|Aspirin|325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
349805|NCT00501371|Drug|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
349100|NCT00469014|Drug|Fludarabine|Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily
349101|NCT00003573|Radiation|radiation therapy|
349102|NCT00469027|Biological|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
349103|NCT00469040|Drug|GW642444M for 14 days|M salt
349104|NCT00469053|Drug|Buprenorphine|
349105|NCT00469079|Drug|Nicotine gum and lozenge|Nicotine replacement
349106|NCT00469079|Other|Taboka|smokeless tobacco product
349107|NCT00469079|Other|Camel Snus|smokeless tobacco product
349108|NCT00471783|Procedure|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
349109|NCT00471796|Behavioral|Biofeedback|
349110|NCT00471809|Drug|Budesonide + Salmeterol + Azithromycin|
349111|NCT00471809|Drug|Budesonide + Salmeterol + Montelukast|
349112|NCT00471809|Drug|Budesonide + Salmeterol + Placebo|
349113|NCT00471835|Procedure|computed tomography|
349114|NCT00471835|Procedure|positron emission tomography|
349115|NCT00471835|Radiation|stereotactic body radiation therapy|
349116|NCT00471848|Drug|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
349117|NCT00003582|Radiation|radiation therapy|
349469|NCT00462787|Drug|vinorelbine tartrate|
349470|NCT00462813|Drug|oral microencapsulated diindolylmethane|
349471|NCT00462813|Genetic|polymerase chain reaction|
349472|NCT00462813|Other|cervical Papanicolaou test|
349473|NCT00462813|Other|cytology specimen collection procedure|
349474|NCT00462813|Procedure|colposcopic biopsy|
348749|NCT00478049|Drug|Gefitinib|250 mg oral tablet
348750|NCT00003606|Drug|cisplatin|
348751|NCT00478049|Drug|Docetaxel|intravenous infusion
348752|NCT00478062|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
348753|NCT00478062|Procedure|adjuvant therapy|
348754|NCT00478075|Drug|bortezomib|
348755|NCT00478075|Other|immunologic technique|
348756|NCT00478075|Radiation|samarium Sm 153 lexidronam pentasodium|
348757|NCT00478088|Device|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
348758|NCT00481195|Drug|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
348759|NCT00481221|Procedure|Observation of results from laboratory tests|Laboratory data summary only
348760|NCT00481234|Device|Heart Rate Variability analysis|
348761|NCT00481247|Drug|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
348762|NCT00481247|Drug|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
348763|NCT00481260|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
348764|NCT00003621|Drug|etoposide|
348765|NCT00481273|Drug|Azacitidine|Physician's discretion
348766|NCT00481286|Behavioral|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
348767|NCT00481286|Behavioral|Standard of Care|Standard of care for diabetes patients
348023|NCT00495391|Drug|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
348024|NCT00003680|Drug|CMF regimen|
348025|NCT00495391|Drug|Placebo|One oral placebo tablet twice daily for 52 weeks.
348026|NCT00495391|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
348027|NCT00495391|Drug|Ribavirin|1000 mg (if <75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
348028|NCT00495404|Behavioral|Physician Treatment Guidelines|
348029|NCT00495417|Biological|AFFITOPE AD01|s.c. injection
348030|NCT00495417|Biological|AFFITOPE AD01 adjuvanted|s.c. injection
348031|NCT00495443|Device|Peterio|
348402|NCT00487110|Drug|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
348403|NCT00487110|Drug|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
348404|NCT00487123|Drug|Valsartan+/- Hydrochlorothiazide|
348405|NCT00489918|Drug|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
348406|NCT00489918|Drug|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
348407|NCT00489931|Drug|VRC-AVIDNA036-00-VP|
348408|NCT00489944|Drug|cisplatin|
348409|NCT00489944|Drug|sunitinib malate|
348410|NCT00489944|Drug|tamoxifen citrate|
348411|NCT00003657|Biological|filgrastim|
348412|NCT00489944|Procedure|adjuvant therapy|
348413|NCT00489970|Procedure|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
348414|NCT00489970|Biological|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
348033|NCT00495495|Device|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
348034|NCT00495495|Device|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
348035|NCT00003680|Drug|cyclophosphamide|
348036|NCT00495508|Drug|Quinine|
348037|NCT00495508|Drug|artemether / lumefantrine|
348038|NCT00495521|Drug|PASER or placebo granules|Granules for oral administration administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable amount in the placebo arm
348039|NCT00495547|Drug|Azacitidine|Azacitidine
348040|NCT00495547|Drug|Beta Erythropoietin|Beta Erythropoietin
348041|NCT00495560|Drug|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
348042|NCT00495573|Drug|acyclovir|400 mg acyclovir, orally three times a day for 5 days
348043|NCT00495586|Drug|Placebo|One pill to be taken every eight hours for 8 days
348044|NCT00495586|Drug|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
348045|NCT00495599|Procedure|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
348046|NCT00003680|Drug|fluorouracil|
348047|NCT00495612|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
348048|NCT00495612|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
348049|NCT00495625|Drug|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
348050|NCT00495651|Drug|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
348051|NCT00498316|Drug|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
348052|NCT00000153|Procedure|Red Krypton Laser Treatment|
347344|NCT00464984|Behavioral|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
347345|NCT00465010|Behavioral|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
347346|NCT00465023|Procedure|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
347347|NCT00465036|Dietary Supplement|Whole flaxseeds, flaxseed mucilage, glucomannan|
347348|NCT00465049|Other|PRIMARY CLOSRE|SUTURE
347349|NCT00465049|Other|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
347350|NCT00003554|Drug|prednisone|
347351|NCT00465049|Other|SPONTANEOUS HALING|SECONDARY HEALING AFTER I&D
347352|NCT00465075|Drug|Bazedoxifene/conjugated estrogens combination|
347353|NCT00465088|Drug|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
347354|NCT00465088|Drug|atorvastatin|40 mg at bedtime
347355|NCT00465101|Device|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
347356|NCT00465114|Procedure|Hemodynamic Monitoring|
347697|NCT00503659|Procedure|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
347698|NCT00503685|Biological|IMC-A12|10 mg/kg intravenous (I.V.) infusion every 2 weeks.
347699|NCT00503685|Biological|cetuximab|Patients will receive cetuximab 500 mg/m2 I.V. over 2 hours every 2 weeks.
347700|NCT00503698|Drug|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
347701|NCT00503698|Drug|placebo|Placebo injected s.c (under the skin)
347702|NCT00503711|Drug|Vandetanib|100 mg every other day, 100mg once daily
347703|NCT00503711|Drug|Vandetanib 300 mg|300mg once daily
346651|NCT00483262|Drug|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
346652|NCT00483262|Drug|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
346653|NCT00483275|Drug|Alfacalcidol|
346654|NCT00003632|Biological|filgrastim|
346989|NCT00474188|Drug|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
346990|NCT00474201|Drug|Lopinavir/Ritonavir|lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
346991|NCT00474201|Drug|Gemfibrozil|Control arm (no intervention used in this arm)
346992|NCT00003591|Radiation|radiation therapy|
346993|NCT00474214|Behavioral|Early hospital discharge facilitated by close nurse practitioner follow-up|
346994|NCT00474227|Behavioral|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
346995|NCT00474240|Drug|Atorvastatin 20 mg|
346996|NCT00474240|Drug|AEGR-733 5 mg|
346997|NCT00474240|Drug|AEGR-733 10 mg|
346998|NCT00474240|Drug|Placebo|
346999|NCT00474240|Drug|AEGR-733 5 mg + atorvastatin 20 mg|
347000|NCT00474240|Drug|AEGR-733 10 mg + atorvastatin 20 mg|
347001|NCT00474253|Drug|Sugammadex|Subjects were to receive an intubating dose of 1.2 mg/kg rocuronium followed by 16.0 mg/kg Org 25969 three minutes after the start of rocuronium administration.
347002|NCT00474253|Drug|succinylcholine|Subjects were to receive an intubation dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
347003|NCT00003592|Drug|methotrexate|
347004|NCT00474266|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection
347005|NCT00474266|Biological|Priorix-Tetra™|2-dose subcutaneous injection
347006|NCT00474266|Biological|Meningitec™|Single dose intramuscular injection
346320|NCT00492063|Biological|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
346321|NCT00492076|Biological|Pangramin Plus D. pteronyssinus 100%|Active. Pangramin Plus D. pteronyssinus 100%
Placebo. Pangramin Plus placebo
346322|NCT00492089|Drug|bevacizumab|Given IV
346323|NCT00492089|Drug|placebo|Given IV
346324|NCT00492089|Procedure|magnetic resonance imaging|
346325|NCT00492089|Procedure|quality-of-life assessment|
346326|NCT00492102|Drug|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing >1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
346327|NCT00492115|Device|Continuous positive airway pressure (CPAP)|therapeutic CPAP
346328|NCT00492115|Device|Placebo CPAP|Ineffective CPAP
346329|NCT00000544|Behavioral|diet therapy|
346330|NCT00003662|Radiation|radiation therapy|
346331|NCT00492128|Drug|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
346332|NCT00492141|Drug|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
346655|NCT00483275|Behavioral|Balance, gait and strength training|
346656|NCT00483275|Behavioral|Patient education|
346657|NCT00483288|Other|educational intervention|
346658|NCT00483288|Other|questionnaire administration|
346659|NCT00483288|Other|study of socioeconomic and demographic variables|
346660|NCT00483288|Other|survey administration|
346661|NCT00483301|Drug|Sorafenib (BAY 43-9006)|dosage
346662|NCT00483301|Drug|ABI-007(Abraxane)|dosage
345634|NCT00461253|Device|Levonorgestrel-releasing IUD|This is a case-control-study; strictly speaking the category "intervention type" does not apply to this study.
345635|NCT00461253|Device|Copper IUD|This is a case-control-study; strictly speaking the category "intervention type" does not apply to this study.
345971|NCT00499616|Drug|carboplatin|Given IV
345972|NCT00499616|Drug|cyclophosphamide|Given IV
345973|NCT00499616|Drug|doxorubicin hydrochloride|Given IV
345974|NCT00499616|Drug|etoposide|Given orally
345975|NCT00003701|Drug|cisplatin|
345976|NCT00499616|Drug|topotecan hydrochloride|Given IV
345977|NCT00499616|Drug|Isotretinoin|Given orally
345978|NCT00499629|Drug|FXR 450|capsule, single oral doses from 10 mg to 450 mg
345979|NCT00499629|Drug|placebo|capsule similar to active drug
345980|NCT00499642|Drug|Lecozotan SR|
345981|NCT00499642|Drug|Moxifloxacin|
345982|NCT00499655|Drug|erlotinib hydrochloride|Given orally
345983|NCT00499655|Drug|celecoxib|Given orally
345984|NCT00499655|Other|placebo|Given orally
345985|NCT00499655|Other|laboratory biomarker analysis|Correlative studies
345986|NCT00003701|Drug|doxorubicin hydrochloride|
345987|NCT00499655|Other|immunohistochemistry staining method|Correlative studies
345988|NCT00499655|Genetic|fluorescence in situ hybridization|Correlative studies
345989|NCT00499655|Genetic|mutation analysis|Correlative studies
345990|NCT00499655|Genetic|protein expression analysis|Correlative studies
345991|NCT00499655|Genetic|gene expression analysis|Correlative studies
345992|NCT00499668|Drug|aprepitant|125 mg orally for 7 days
351017|NCT00004454|Genetic|lymphocyte gene therapy|
351018|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
351019|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
351020|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
351021|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
351022|NCT00621777|Drug|Varenicline|At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.
In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks.
351023|NCT00621777|Drug|Placebo|At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.
In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks.
351024|NCT00621790|Drug|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
351025|NCT00621790|Drug|placebo|placebo
345636|NCT00461266|Drug|enfuvirtide [Fuzeon]|90mg sc bid
345637|NCT00461266|Drug|Antiretroviral therapy|As prescribed
345638|NCT00461279|Behavioral|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
345639|NCT00461279|Behavioral|Interpersonal Psychotherapy|Established psychotherapy for depression
345640|NCT00461292|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
345641|NCT00461292|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
345642|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
345643|NCT00003536|Procedure|differentiation therapy|
345644|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
350380|NCT00472472|Device|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
350695|NCT00463424|Device|NeuFlex metacarpophalangeal implant|
350696|NCT00463424|Device|Swanson metacarpophalangeal implant|
350697|NCT00463437|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
350698|NCT00463437|Biological|Prevenar|Intramuscular injection, 1 dose.
350699|NCT00003546|Drug|gemcitabine hydrochloride|given IV
350700|NCT00463437|Biological|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
350701|NCT00463437|Biological|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
350702|NCT00463437|Biological|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
350703|NCT00463437|Biological|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
350704|NCT00463437|Biological|Meningitec|Intramuscular injection, 1 dose.
350705|NCT00463437|Biological|NeisVac-C|Intramuscular injection, 1 dose.
350706|NCT00463437|Biological|Menitorix|Intramuscular injection, 1 dose.
350707|NCT00463450|Drug|Gynodian® Depot (BAY86-5032)|Injection monthly
350708|NCT00463450|Drug|BAY86-4980|orally
350709|NCT00463463|Drug|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
350710|NCT00003546|Radiation|radiation therapy|1.8 Gy to tumor bed
350711|NCT00463476|Biological|Japanese encephalitis live attenuated SA 14-14-2 vaccine|
350712|NCT00463489|Behavioral|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
350713|NCT00463489|Behavioral|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
350714|NCT00463502|Drug|Metformin|
350028|NCT00481767|Biological|Placebo vaccine (Al(OH)3)|Three doses of vaccine/control will be administered according to a 0, 1, 6 month schedule
350029|NCT00481780|Device|plain balloon angioplasty|
350030|NCT00481780|Device|cutting balloon angioplasty|
350031|NCT00481819|Drug|FK506MR|oral
350032|NCT00481819|Drug|Prograf|oral
350033|NCT00481819|Drug|Mycophenolate Mofetil|oral
350034|NCT00481819|Drug|Methylprednisolone|oral
350035|NCT00481819|Drug|Prednisolone|oral
350036|NCT00481832|Drug|Cyclophosphamide|4gm/m2and100mg/kg
350037|NCT00003624|Drug|cisplatin|
350038|NCT00481832|Drug|Carmustine|15mg/kg, IV over 2 hours
350039|NCT00481832|Drug|Etoposide|60mg/kg, IV over 4 hours
350040|NCT00481832|Drug|Filgrastim|5-10mcg/kg, SQ
350381|NCT00472485|Procedure|eye movement therapy|
350382|NCT00472524|Procedure|Mydriasis/cycloplegia via different modes of administration|
350383|NCT00472537|Procedure|Retromuscular Mesh repair of midline incisional hernia|
350384|NCT00472537|Procedure|Laparoscopic repair of midline incisional hernia|
350385|NCT00003584|Drug|vinorelbine tartrate|
350386|NCT00472550|Drug|esomeprazole 20 mg|
350387|NCT00472563|Drug|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
350388|NCT00472576|Drug|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
350389|NCT00472576|Drug|Placebo|Daily double-blind administration of placebo
350390|NCT00472628|Procedure|Blood samples collected|
350391|NCT00472641|Drug|Ziprasidone/Geodon|Ziprasidone/Geodon
349680|NCT00487682|Drug|ASP2151|oral
349681|NCT00487682|Drug|Valacyclovir hydrochloride|oral
349682|NCT00487695|Device|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
349683|NCT00487695|Device|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
349684|NCT00490542|Drug|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
349685|NCT00490555|Drug|Testosterone gel|Testosterone gel 10 g
349686|NCT00490555|Drug|Dutasteride|dutasteride 0.5 mg orally
349687|NCT00490555|Drug|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
349688|NCT00490555|Other|Placebo Testosterone gel|Place gel applied daily for 12 weeks
349689|NCT00490555|Other|Placebo dutasteride|placebo pill for 12 weeks
349690|NCT00000153|Procedure|Blue-Green Argon Laser Treatment|
349691|NCT00000543|Behavioral|dietary supplements|
349692|NCT00003658|Drug|cyclophosphamide|
349693|NCT00490555|Other|Placebo DMPA|placebo DMPA injection Once
349694|NCT00490568|Drug|Rosiglitazone XR|Experimental drug
349695|NCT00490581|Other|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
349696|NCT00490594|Device|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
349697|NCT00490620|Drug|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
349698|NCT00490620|Drug|Placebo|placebo BID for 6 months
349699|NCT00490633|Behavioral|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
362080|NCT00668148|Biological|IMC-A12 (cixutumumab)|Synovial sarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
362081|NCT00668161|Behavioral|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
362082|NCT00668174|Behavioral|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
362083|NCT00668200|Drug|Reclast (ZOL446, zoledronic acid)|5 mg i.v. annually ("real-life, physician prescribed")
362084|NCT00631488|Drug|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
362085|NCT00631488|Drug|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
362086|NCT00631501|Drug|Placebo|
362087|NCT00631501|Drug|Doxycycline|
362088|NCT00631514|Drug|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
362089|NCT00631514|Drug|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
362090|NCT00631514|Drug|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
362091|NCT00631527|Drug|Leuprolide|Injections given through a needle in the muscle every 3 months.
362092|NCT00631527|Drug|Goserelin|Subcutaneous injections given once every 3 months.
362093|NCT00000636|Drug|Isoniazid|
362094|NCT00004689|Drug|rifampin|
362095|NCT00631527|Drug|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
362096|NCT00631527|Drug|Casodex|Once a day by mouth for 2 weeks.
362097|NCT00631527|Radiation|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
362098|NCT00631540|Device|Formula Balloon-Expandable Stent|renal artery stenting
362099|NCT00631553|Drug|perflutren lipid microspheres|1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
366898|NCT00638170|Biological|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
366899|NCT00638170|Biological|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
366900|NCT00638196|Drug|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
366901|NCT00638209|Drug|Human insulin|
366902|NCT00638209|Drug|Saline|
366903|NCT00638222|Other|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
366904|NCT00638235|Device|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic)|Mesh implant for posterior wall pelvic organ prolapse
366905|NCT00638235|Device|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
361755|NCT00638729|Drug|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
361756|NCT00638729|Drug|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
361757|NCT00638729|Drug|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
361758|NCT00638742|Drug|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
361759|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
361760|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
361761|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
361762|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
361763|NCT00000639|Drug|Itraconazole|
361764|NCT00004809|Procedure|gene therapy|
361765|NCT00638768|Other|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
361766|NCT00638781|Drug|Desmoteplase|Desmoteplase 62.5 µg/kg BW
361767|NCT00638781|Drug|Desmoteplase|Desmoteplase 90 µg/kg BW
366549|NCT00645164|Other|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
366550|NCT00645164|Drug|Xenaderm|20 mg under Finn chambers
366551|NCT00645177|Drug|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
366552|NCT00645177|Drug|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
366553|NCT00004880|Procedure|conventional surgery|
366554|NCT00645177|Drug|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
366555|NCT00645190|Drug|Galantamine HBr|
366556|NCT00645203|Drug|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
366557|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 alone for 21 days
366558|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
366559|NCT00645229|Drug|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
366560|NCT00645242|Drug|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
366561|NCT00645255|Drug|placebo|placebo one capsule daily
366562|NCT00645255|Drug|sibutramine or placebo|one capsule daily
366563|NCT00645268|Drug|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
366564|NCT00004881|Biological|MVA-MUC1-IL2 vaccine|
366565|NCT00645268|Drug|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
366566|NCT00645268|Drug|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
366906|NCT00638235|Device|AMS Apogee™ with IntePro Lite and/or AMS Perigee™ with IntePro Lite|Mesh implant for the treatment of anterior and/or posterior wall pelvic organ prolapse.
366907|NCT00004805|Behavioral|CPR instruction|
349806|NCT00501371|Drug|Placebo|soft-gel capsule, Qd, 12 weeks
349807|NCT00501384|Drug|satavaptan (SR121463B)|
349808|NCT00501397|Drug|ketoconazole|
349809|NCT00501397|Drug|GSK189075|
349810|NCT00501410|Drug|5-FU|2400 mg/m^2 by vein over 46 Hours On Days 1 & 2.
349811|NCT00501410|Drug|Cetuximab|Initial Dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8
349812|NCT00003715|Biological|BCG vaccine|
349813|NCT00501410|Drug|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
350154|NCT00493623|Drug|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
350155|NCT00493636|Drug|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
350156|NCT00493636|Drug|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
350157|NCT00493636|Drug|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
350158|NCT00493636|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
350159|NCT00496340|Procedure|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
350160|NCT00496353|Drug|MK2461|MK2461 treatment, bid, 28-day
350161|NCT00496366|Drug|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
350162|NCT00496366|Drug|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
350163|NCT00496379|Drug|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
350164|NCT00003683|Drug|doxorubicin hydrochloride|
350165|NCT00496392|Drug|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
350166|NCT00496405|Drug|bevacizumab|
350167|NCT00496418|Device|Mesh in permanent colostomy|
349475|NCT00462826|Biological|ziv-aflibercept|
349476|NCT00462839|Procedure|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
349477|NCT00003543|Drug|carmustine|
349478|NCT00462852|Drug|dalteparin|
349479|NCT00462852|Drug|gemcitabine hydrochloride|
349480|NCT00462852|Other|diagnostic laboratory biomarker analysis|
349481|NCT00462865|Drug|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
349482|NCT00462878|Drug|Meropenem|antibiotic
349483|NCT00462878|Drug|Vancomycin|Antibiotic
349484|NCT00462878|Drug|Teicoplanin|Antibiotic
349485|NCT00462891|Other|IT System|
349486|NCT00462904|Drug|opebacan|
349487|NCT00462917|Behavioral|Pleiotropic info, in-person disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.
Genetic counselors communicate results to participants during an in-person disclosure session.
349488|NCT00003543|Drug|fluorouracil|
349814|NCT00501410|Drug|Leucovorin|400 mg/m^2 by vein on day 1.
349815|NCT00504270|Drug|RG3421|120mg po daily
349816|NCT00504270|Drug|RG3421|20mg po daily
349817|NCT00504283|Drug|Toradol|
349818|NCT00504283|Drug|Morphine|
349819|NCT00504296|Drug|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
349118|NCT00471887|Biological|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
349119|NCT00471900|Drug|dehydroepiandrosterone (DHEA)|
349120|NCT00471913|Device|Femoral Nailing with Different Entry Points|See Detailed Description.
349121|NCT00471939|Drug|I-020502|1 mcg/mL TG-PDGF.AB
349122|NCT00471952|Drug|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
349123|NCT00471952|Drug|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
349124|NCT00471952|Drug|Placebo + Placebo|One migraine attack will be treated with double placebo
349125|NCT00471965|Drug|Oxaliplatin + 5-Fluorouracil/Leucovorin|Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.
Repeated every 2 weeks
349126|NCT00471965|Drug|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
349127|NCT00471978|Genetic|polymerase chain reaction|
349128|NCT00003583|Drug|amifostine trihydrate|
349129|NCT00471978|Genetic|polymorphism analysis|
349130|NCT00471978|Other|diagnostic laboratory biomarker analysis|
349131|NCT00471991|Drug|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
349132|NCT00475124|Device|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
349133|NCT00000106|Device|Whole body hyperthermia unit|
349134|NCT00000152|Drug|Aspirin|
349135|NCT00000539|Drug|niacin|
349136|NCT00003594|Drug|oxaliplatin|
348415|NCT00489970|Biological|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
348416|NCT00489983|Drug|pemetrexed|
348417|NCT00489983|Drug|gemcitabine|
348418|NCT00489996|Drug|gemcitabine|
348419|NCT00489996|Drug|cisplatin|
348420|NCT00490009|Drug|Tositumomab and iodine I 131 tositumomab|patient specific, IV
348421|NCT00490009|Drug|Tylenol|650 mg, oral
348422|NCT00003657|Drug|amifostine trihydrate|
348423|NCT00490009|Drug|Benadryl|50 mg, oral
348424|NCT00490009|Drug|SSKI|130 mg, oral
348425|NCT00490022|Drug|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
348426|NCT00490022|Drug|Placebo gel|Placebo gel for one month
348427|NCT00490035|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
348768|NCT00481312|Drug|Dexmedetomidine|Continuous Infusion
348769|NCT00481312|Drug|Midazolam|Continuous Infusion
348770|NCT00481325|Drug|pexacerfont|Tablets & Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
348771|NCT00481325|Drug|escitalopram|Tablets & Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
348772|NCT00481325|Drug|placebo|Tablets & Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
348773|NCT00481338|Procedure|X-rays|X-rays (hip and knee) every 2 years
348774|NCT00481338|Biological|biological samples|biological sample (blood and urine) every 2 years
348775|NCT00003621|Radiation|radiation therapy|
348776|NCT00481338|Other|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
348053|NCT00000549|Drug|estrogens|
348428|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
348429|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
348430|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
348431|NCT00490048|Procedure|Induced sputum (inhalation of 3.5% saline)|
348432|NCT00490061|Drug|Lapatinib|1500 mg po daily orally
348433|NCT00003657|Drug|carboplatin|
348434|NCT00490061|Procedure|Radiotherapy|Standard of Care
348435|NCT00492817|Procedure|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
348436|NCT00492830|Drug|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
348437|NCT00492843|Drug|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
348438|NCT00492856|Drug|mercaptopurine|Given orally
348439|NCT00492856|Drug|methotrexate|Given orally
348440|NCT00492856|Drug|tretinoin|Given orally
348441|NCT00492869|Drug|AEB071|
348442|NCT00003667|Drug|cyclophosphamide|
348443|NCT00492882|Drug|usual administration of exogenous recombinant FSH|
348444|NCT00492895|Drug|Discontinuation of Azathioprin|Discontinuation of Azathioprin
348445|NCT00492908|Device|Helistent Titan2 (Titanium coated stent)|Titan2
348446|NCT00492908|Device|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
348447|NCT00492921|Biological|filgrastim|
348448|NCT00492921|Drug|cyclophosphamide|
347704|NCT00503724|Drug|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
347705|NCT00503737|Behavioral|National Colorectal Cancer Roundtable Toolbox|
347706|NCT00003727|Procedure|in vitro-treated peripheral blood stem cell transplantation|
347707|NCT00503750|Drug|Pre operativeTrastuzumab|Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.
As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
347708|NCT00503750|Drug|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
347709|NCT00003734|Radiation|radiation therapy|
347710|NCT00506025|Dietary Supplement|Cranberries|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
347711|NCT00506025|Other|De-Activated Cranberry juice|
347712|NCT00506038|Procedure|fine needle technique|
347713|NCT00506051|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
347714|NCT00506051|Drug|pemetrexed|intravenous infusion
347715|NCT00506051|Drug|ZD6474 (vandetanib) 300mg|
347716|NCT00506064|Drug|Melatonin|0.15 mg/kg by mouth (PO) Daily
347717|NCT00506064|Drug|Placebo|Two, three, or four starch tablet or capsules before bed
347718|NCT00506064|Behavioral|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
348054|NCT00003693|Drug|Dolastatin 10|IV bolus once every 3 weeks.
348055|NCT00498316|Radiation|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
348056|NCT00498316|Drug|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
348057|NCT00498316|Drug|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
347007|NCT00474279|Drug|Orally active growth hormone secretagogue (MK-677)|
347008|NCT00474305|Behavioral|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
347009|NCT00474357|Behavioral|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
347010|NCT00474370|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
347011|NCT00477126|Drug|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
347357|NCT00465140|Drug|creatine supplementation|
347358|NCT00465140|Behavioral|aerobic exercise training|
347359|NCT00465153|Dietary Supplement|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
347360|NCT00465153|Behavioral|Resistance exercise training|Resistance training
347361|NCT00003555|Drug|amifostine trihydrate|
347362|NCT00465166|Procedure|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
347363|NCT00465179|Drug|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
347364|NCT00468130|Drug|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole or placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
347365|NCT00003571|Genetic|tumor replication error analysis|
347366|NCT00468143|Drug|Adderall ® and Adderall XR ®|
347367|NCT00468156|Behavioral|written materials only|related to fruit/vegetable servings/day
347368|NCT00468156|Behavioral|written materials|related to fruit/vegetable servings/day
347369|NCT00468156|Behavioral|telephone support|related to fruit/vegetable servings/day
347370|NCT00468169|Drug|Cetuximab|Cetuximab - Arm A:250mg/m2(day 1, weekly x 10); Cetuximab - Arm B:250mg/m2(day 1, weekly x 7)
347371|NCT00468182|Drug|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
346663|NCT00483314|Drug|N-acetylcysteine|2 g p.o. BID x 60 days
346664|NCT00483327|Drug|Megestrol Acetate|
346665|NCT00003632|Drug|carmustine|
346666|NCT00483353|Procedure|Intra-nasal allergen challenge with Phleum pratense.|
346667|NCT00483353|Procedure|Collection of nasal effluent using filter paper.|
346668|NCT00483353|Procedure|Measurement of nasal congestion using acoustic rhinometry.|
346669|NCT00483366|Drug|capecitabine|Dose level Capecitabine
-1 400 mg/m2 bid
0 500 mg/m2 bid
500 mg/m2 bid
600 mg/m2 bid
600 mg/m2 bid
725 mg/m2 bid
725 mg/m2 bid
850 mg/m2 bid
850 mg/m2 bid
346670|NCT00486278|Drug|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
346671|NCT00486278|Drug|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
346672|NCT00486291|Drug|VI-0521|phentermine 15mg/topiramate 100mg
346673|NCT00486291|Drug|Placebo|matched placebo
346674|NCT00486304|Other|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
346675|NCT00486304|Other|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
346676|NCT00486317|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
346677|NCT00486330|Drug|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
346678|NCT00003643|Biological|filgrastim|
347012|NCT00477152|Drug|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
347013|NCT00477165|Drug|Citalopram|
347014|NCT00477191|Drug|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
347015|NCT00477204|Drug|Simvastatin|simvastatin 20 mg daily
347016|NCT00477204|Drug|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
345993|NCT00499668|Drug|ondansetron hydrochloride|24 mg orally for 7 days
345994|NCT00499681|Drug|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
345995|NCT00499681|Drug|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
345996|NCT00499681|Other|placebo|Given once daily for 2 weeks
345997|NCT00003701|Drug|methotrexate|
346333|NCT00492141|Drug|L9-NC|Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.
Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.
Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.
Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3.
346334|NCT00492167|Biological|beta-glucan|
346335|NCT00492167|Biological|monoclonal antibody 3F8|
346336|NCT00492167|Other|immunohistochemistry staining method|
346337|NCT00492167|Other|laboratory biomarker analysis|
346338|NCT00492206|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
346339|NCT00492219|Device|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
346340|NCT00494715|Drug|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
346341|NCT00003677|Drug|Dolastatin 10|IV bolus once every 21 days.
346342|NCT00494728|Behavioral|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
346343|NCT00494728|Behavioral|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
346344|NCT00494728|Behavioral|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
345645|NCT00461305|Drug|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
345646|NCT00461305|Drug|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
345647|NCT00461318|Procedure|Individual placement and support (vocational rehabilitation)|
345648|NCT00461331|Drug|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
345649|NCT00461331|Drug|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
345650|NCT00461344|Drug|Docetaxel|
345651|NCT00461344|Drug|Doxorubicin|
345652|NCT00461370|Drug|SRX251|
345653|NCT00003552|Drug|anti-thymocyte globulin|
345654|NCT00464217|Drug|Idarubicin|
345655|NCT00464217|Drug|Leucomax|
345656|NCT00464230|Procedure|Bipolar hemiarthroplasty (Charnley/Hastings)|
345657|NCT00464230|Procedure|Internal fixation with two parallel screws (Olmed)|
345658|NCT00464243|Drug|volinanserin (M100907)|oral administration
345998|NCT00499694|Biological|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
345999|NCT00499694|Drug|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
346000|NCT00499707|Drug|rosiglitazone maleate/metformin hydrochloride|
346001|NCT00502723|Procedure|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
346002|NCT00502736|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
346003|NCT00502749|Behavioral|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
346004|NCT00502749|Behavioral|Questionnaires|Questionnaires taking 15 minutes to complete.
346005|NCT00502762|Drug|topotecan|
350715|NCT00466726|Biological|sargramostim|
350716|NCT00466752|Drug|sorafenib tosylate|Given PO
350717|NCT00466752|Genetic|microarray analysis|Correlative studies
350718|NCT00466752|Other|immunohistochemistry staining method|Correlative studies
351026|NCT00624065|Drug|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
351027|NCT00624065|Drug|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
351028|NCT00624078|Drug|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
351029|NCT00624091|Procedure|Cardiac surgery|Cardiac surgery within 48 hours of randomization
351030|NCT00624091|Procedure|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
351031|NCT00004492|Drug|clotrimazole|
351032|NCT00624104|Dietary Supplement|Food (fat free meal)|Fat free meal (40% of REE)
351033|NCT00624117|Behavioral|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
351034|NCT00624130|Drug|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
351035|NCT00624130|Drug|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
351036|NCT00624143|Drug|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
351037|NCT00624156|Behavioral|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
351038|NCT00624156|Behavioral|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
351039|NCT00624169|Procedure|An optimized perioperative course|A number of interventions before, during and after surgery
351040|NCT00624182|Biological|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
350392|NCT00472654|Behavioral|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
350393|NCT00472654|Dietary Supplement|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
350394|NCT00472654|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 weeks
350395|NCT00472667|Procedure|Procalcitonin guided strategy|Procalcitonin guided strategy
350396|NCT00000537|Behavioral|meditation|
350397|NCT00003585|Biological|aldesleukin|
350398|NCT00472680|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
350399|NCT00472680|Behavioral|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
350400|NCT00472680|Behavioral|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
350401|NCT00475579|Procedure|tube with subglottic drainage and polyurethane cuff|
350402|NCT00475592|Device|Esophageal Capsule Endoscopy|
350403|NCT00475618|Procedure|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
350404|NCT00475618|Procedure|professional cleaning|Daily use fluoride toothpaste 500 ppm.
350405|NCT00475618|Procedure|No fluoride toothpaste|Daily use no fluoride toothpaste.
350719|NCT00003563|Drug|MGd|5.0 mg /kg MGd plus WBRT
350720|NCT00466752|Genetic|gene expression analysis|Correlative studies
350721|NCT00466752|Procedure|needle biopsy|Correlative studies
350722|NCT00466752|Procedure|therapeutic conventional surgery|Undergo prostatectomy
350723|NCT00466752|Other|laboratory biomarker analysis|Correlative studies
350724|NCT00466752|Genetic|western blotting|Correlative studies
350725|NCT00466752|Genetic|RNA analysis|Correlative studies
350726|NCT00466765|Device|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
350041|NCT00481832|Drug|Antithymocyte globulin|1.5mg/kg/dx5, IV
350042|NCT00481832|Drug|Cyclosporine|5mg/kgbid,variable, po or IV
350043|NCT00481832|Drug|Mycophenolate mofetil|15mg/kg,variable, po or iv
350044|NCT00481832|Drug|rituximab|375mg/m2, IV
350045|NCT00481845|Drug|ZD6474|300 mg daily
350046|NCT00481845|Drug|Anastrozole|1 mg daily
350047|NCT00481845|Drug|Magnevist|0.2 ml/kg
350048|NCT00003624|Drug|paclitaxel|
350049|NCT00481871|Drug|Pralatrexate Injection|Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
350050|NCT00481871|Drug|Gemcitabine Hydrochloride|Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.
Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
350051|NCT00481871|Dietary Supplement|Vitamin B12|1 mg intramuscular injection
Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
350052|NCT00481871|Dietary Supplement|Folic Acid|1 mg orally
Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.
350053|NCT00484575|Drug|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
350054|NCT00484575|Drug|propofol|propofol given intravenously for sedation in control group
350055|NCT00484601|Drug|Ifosfamide; Doxorubicin|
350056|NCT00484614|Procedure|Positron Emission Mammography|Molecular Imaging Device
350057|NCT00484614|Procedure|Magnetic Resonance Imaging|Imaging Device
350058|NCT00484627|Procedure|Use of creatine monohydrate (a dietary supplement)|
350059|NCT00003638|Biological|Detox-B adjuvant|
350060|NCT00484627|Behavioral|Progressive resistance exercise training|
350061|NCT00484640|Drug|Coumadin|
362422|NCT00663845|Drug|Placebo|Matching placebo
362423|NCT00663858|Drug|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
362424|NCT00663858|Drug|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
362425|NCT00663858|Other|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
362426|NCT00663871|Dietary Supplement|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
362427|NCT00663871|Dietary Supplement|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
362428|NCT00005026|Drug|paclitaxel|
362429|NCT00663884|Drug|Mitiglinide|mitiglinide 10mg three times a day before a meal
362430|NCT00663884|Drug|Voglibose|voglibose 0.2mg three times a day before a meal
362431|NCT00663897|Drug|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
362432|NCT00663897|Drug|mosapride|mosapride, 5 mg, thrice daily for 14 days
362433|NCT00663910|Drug|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
362434|NCT00665990|Drug|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
362435|NCT00665990|Drug|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
362436|NCT00665990|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
362437|NCT00666016|Drug|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
362438|NCT00666029|Drug|atorvastatin|40 m.g. o.d. tablets for 6 months
362439|NCT00000657|Drug|Zidovudine|
362440|NCT00005045|Drug|carboxyamidotriazole|
362441|NCT00666029|Drug|placebo|Placebo
361768|NCT00638781|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW
361769|NCT00638781|Drug|Placebo|Placebo
361770|NCT00638794|Device|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
361771|NCT00638807|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
361772|NCT00638807|Other|Placebo|Matched oral placebo for 6 weeks
361773|NCT00638820|Procedure|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
361774|NCT00638820|Drug|Campath, Busulfan, Clofarabine|12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours
11 Campath-1H 0.3 mg/kg intravenously over 2 hours
10 Campath-1H 0.3 mg/kg intravenously over 2 hours
9 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours
8 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours
7 "Rest"
6 Clofarabine 40 mg/m2 intravenously over 2 hours
5 Clofarabine 40 mg/m2 intravenously over 2 hours
4 Clofarabine 40 mg/m2 intravenously over 2 hours
3 Clofarabine 40 mg/m2 intravenously over 2 hours
2 Clofarabine 40 mg/m2 intravenously over 2 hours
361775|NCT00004810|Drug|-aminosalicylic acid|
362100|NCT00631566|Drug|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).
pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.
Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.
362101|NCT00631566|Drug|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
362102|NCT00631579|Drug|Rasburicase (SR29142)|
362103|NCT00631592|Drug|GSK1349572|
362104|NCT00631618|Drug|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
362105|NCT00004689|Drug|streptomycin|
362106|NCT00631631|Drug|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
362107|NCT00631657|Drug|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
362108|NCT00631657|Drug|Placebo|One placebo tablet once a day
362109|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|15 Gy in one treatment
366908|NCT00638235|Device|AMS Elevate™ Apical & Posterior|Mesh implant for the treatment of apical and posterior wall pelvic organ prolapse
366909|NCT00638235|Device|AMS Elevate™ Apical & Anterior (original design)|Mesh implant for treatment of apical and anterior wall pelvic organ prolapse.
366910|NCT00638235|Device|AMS Elevate™ Apical & Anterior|Mesh implant for the treatment of apical and anterior wall pelvic organ prolapse.
366911|NCT00638248|Drug|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
366912|NCT00638248|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
366913|NCT00638248|Drug|Placebo|Placebo i.v. bolus
366914|NCT00004846|Drug|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
366915|NCT00640666|Behavioral|Exercise Behavior Change|Multidisciplinary
366916|NCT00640679|Drug|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
366917|NCT00640679|Drug|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
366918|NCT00640705|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
366919|NCT00640705|Drug|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
366920|NCT00640731|Device|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
366921|NCT00640744|Drug|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
366922|NCT00640757|Dietary Supplement|Methionine deficient diet|Hominex with a low protein diet
366923|NCT00640757|Dietary Supplement|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
366924|NCT00640770|Device|balloon angioplasty|balloon angioplasty
366925|NCT00004852|Drug|Efavirenz|
366926|NCT00640770|Device|drug eluting stent|Cypher Select+ Coronary or Infrapopliteal Stent
361776|NCT00638820|Procedure|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
361777|NCT00638833|Drug|Memantine|Memantine 30 mg/day (20-10-0)
350168|NCT00496431|Drug|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
350169|NCT00496444|Drug|Azacitidine|Starting Dose 20 mg/m^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
350170|NCT00496444|Drug|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
350171|NCT00496457|Drug|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
350172|NCT00496457|Drug|Placebo comparator|4 Capsules of PBO per day before noon meal
350173|NCT00496470|Drug|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
350174|NCT00496470|Drug|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
350175|NCT00003683|Drug|ifosfamide|
350509|NCT00488033|Procedure|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
350510|NCT00488046|Biological|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
350511|NCT00488059|Drug|enfuvirtide [Fuzeon]|90 mg SC twice daily
350512|NCT00488059|Drug|Optimized background ARV|As prescribed
350513|NCT00488059|Drug|Integrase inhibitor|As prescribed
350514|NCT00488059|Drug|enfuvirtide [Fuzeon]|180 mg SC once daily
350515|NCT00488072|Drug|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
350516|NCT00003650|Drug|methylprednisolone|
350517|NCT00488072|Drug|Placebo|One placebo tablet by mouth daily.
350518|NCT00488098|Drug|GSK372475|
350519|NCT00488111|Other|Ringer's Lactate|Ringer's Lactate was used 15min before operation
350520|NCT00488111|Other|6% Starch|6% Starch was used 15min before operation
350521|NCT00488124|Drug|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
350522|NCT00488137|Drug|Prucalopride|2 mg o.d.
349820|NCT00003728|Drug|methotrexate|
349821|NCT00504296|Other|immunoenzyme technique|
349822|NCT00504296|Other|immunohistochemistry staining method|
349823|NCT00504296|Other|immunologic technique|
349824|NCT00504296|Other|laboratory biomarker analysis|
349825|NCT00504296|Other|liquid chromatography|
349826|NCT00504296|Other|mass spectrometry|
349827|NCT00504296|Other|pharmacological study|
349828|NCT00504309|Drug|Omega-3 acid ethyl esters|4 g P-OM3
349829|NCT00504309|Other|Corn oil placebo|4 g Placebo
349830|NCT00504322|Genetic|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
349831|NCT00003728|Drug|methylprednisolone|
349832|NCT00504322|Genetic|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
349833|NCT00504335|Drug|BIO 300 Capsules|
349834|NCT00504348|Drug|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
349835|NCT00504374|Behavioral|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
349836|NCT00504400|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
350176|NCT00496483|Drug|LCP Tacro (tacrolimus)|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.
Other Names:
Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
349137|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
349489|NCT00466206|Device|Magnetic Mini-Mover Procedure (3MP)|A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.
A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.
In another outpatient procedure, the Magnimplant is explanted 18 months after implantation.
349490|NCT00466206|Device|Magnatract (external magnet in a removable external brace)|An external orthotic device "Magnatract" which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed.
349491|NCT00466206|Procedure|3MP (Magnetic Mini-Mover Procedure)|Subject has EKG performed to measure baseline cardiac activity.
Magnimplant is implanted.
After one week, "Magnatract" is fitted.
Chest x-ray and 2nd EKG performed 30 days post-implantation.
Patient and parents complete QoL questionnaire 30d post-implantation.
Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.
At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.
At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.
Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.
CT scan and third EKG performed after explanation.
Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation.
349492|NCT00003560|Drug|carboplatin|
349493|NCT00466219|Drug|Ribavirin|
349494|NCT00466219|Drug|Pegylated interferon alpha2a|
349495|NCT00466232|Drug|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
349496|NCT00466232|Drug|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
349497|NCT00466245|Drug|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
349498|NCT00466245|Drug|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
349499|NCT00466258|Drug|R-CHOP|Cyclophosphamide 750 mg/m2 i.v. day 1
Adriamycin 50 mg/m2 i.v. day 1
Vincristine 1,4 mg/m2 i.v. day 1
Prednisone 100 mg i.v or oral. days 1-5.
349500|NCT00466258|Drug|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
349501|NCT00466258|Drug|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
348777|NCT00481351|Drug|Simvastatin 20mg plus ezetimibe 10mg|simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
348778|NCT00481351|Drug|ezetimibe|ezetimiba 10mg once a day
348779|NCT00481351|Drug|simvastatin 20mg|simvastatin 20mg once a day
348780|NCT00481351|Drug|Simvastatin 80mg|simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
348781|NCT00481364|Drug|atorvastatin|atorvastatin 40 mg/day
348782|NCT00481364|Drug|placebo|1 tb/day
348783|NCT00483964|Drug|Olanzapine|
348784|NCT00483977|Drug|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
348785|NCT00483977|Drug|Placebo|Placebo: oral for 2 weeks.
348786|NCT00483977|Drug|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
348787|NCT00483990|Drug|PSD502|
348788|NCT00003635|Drug|nelarabine|
348789|NCT00484003|Drug|Pimecrolimus cream 1%|
348790|NCT00484029|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
348791|NCT00484029|Other|Air|Air (Medical Grade)
348792|NCT00484055|Drug|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
349138|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
349139|NCT00475150|Drug|cediranib maleate|Given orally
349140|NCT00475150|Other|laboratory biomarker analysis|Correlative studies
349141|NCT00475163|Behavioral|Behavior modification|
349142|NCT00475176|Drug|Peginterferon alfa-2a|
349143|NCT00475176|Drug|Ribavirin|
349144|NCT00475176|Drug|S-adenosyl methionine for Chronic Liver Disease|
348449|NCT00492934|Drug|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
348450|NCT00492947|Biological|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
348451|NCT00492960|Drug|AT-1001|capsules, TID
348793|NCT00484055|Procedure|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
348794|NCT00484068|Drug|enalapril|
348795|NCT00484068|Procedure|chicken diet|
348796|NCT00484081|Procedure|Microdissection Testicular Sperm Extraction|
348797|NCT00484081|Procedure|ICSI|
348798|NCT00484094|Drug|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
348799|NCT00003636|Drug|carboplatin|
348800|NCT00484107|Drug|Conjugated Estrogen Cream (Premarin®)|
348801|NCT00484120|Drug|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
348802|NCT00484120|Drug|Placebo cream|Placebo cream
348803|NCT00484133|Drug|Dopamine|
348804|NCT00484133|Drug|dobutamine|
348805|NCT00484133|Drug|enoximone|
348806|NCT00484133|Drug|nitroglycerine|
348807|NCT00484133|Drug|noradrenaline|
348808|NCT00484159|Procedure|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
348809|NCT00484159|Drug|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
348810|NCT00003636|Drug|cisplatin|
348811|NCT00484159|Drug|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
348812|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
348058|NCT00498316|Drug|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
348059|NCT00498316|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is > 2.5 x 109/L.
348060|NCT00498342|Drug|N-acetylcysteine|
348061|NCT00498355|Drug|Lucentis (ranibizumab)|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
348062|NCT00498368|Drug|Intravenous Rituximab|Group 1: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182 •• An ACE inhibitors and /or ARBs will be used to achieve a B/P goal of <130/80mmHg, plus Omega-3 Fatty Acid Fish Oil Supplements 3.6 gm EPA/day
348063|NCT00498368|Drug|ACE/ARB|An ACE inhibitors and /or ARBs will be used to achieve a B/P goal of <130/80mmHg. Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACEi + ARB
Omega-3 Fatty Acid Fish Oil Supplements 3.6 gm EPA/day
348064|NCT00498381|Device|CPAP|
348065|NCT00003694|Drug|omacetaxine mepesuccinate|Given IV
348066|NCT00498394|Behavioral|Clinical diet trial|
348067|NCT00498407|Drug|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
348068|NCT00498433|Drug|Aliskiren|300 mg tablet once daily
348069|NCT00498433|Drug|Amlodipine|5 mg capsule once daily
348070|NCT00498433|Drug|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
348071|NCT00498433|Drug|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
348072|NCT00498459|Behavioral|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
348073|NCT00498472|Procedure|Pre-discharge NT-ProBNP based treatment|Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.
Discharge may be postponed and medical treatment may be changed when NT-ProBNP is >3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy.
348452|NCT00492960|Drug|placebo|capsules, TID
348453|NCT00003667|Drug|dexrazoxane hydrochloride|
348454|NCT00492973|Drug|methylprednisolone acetate|Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
347372|NCT00468208|Drug|Abatacept|A participant's abatacept dose depended on body weight and will remain the same throughout the study:
500 mg of abatacept for body weight less than 60 kg
750 mg of abatacept for body weight between 60 and 100 kg
1000 mg of abatacept for body weight greater than 100 kg
Abatacept is administered in a 30-minute intravenous infusion.
347373|NCT00468221|Drug|Ozone Exposure|Low dose ozone exposure in chamber
347374|NCT00468234|Drug|nicotine polacrilex|
347375|NCT00468234|Drug|nicotine transdermal system|
347376|NCT00003572|Biological|peripheral blood lymphocyte therapy|
347377|NCT00468234|Drug|nicotine inhaler|
347378|NCT00468247|Device|Navigator|Navigator circulatory mgt system
347719|NCT00506077|Drug|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
347720|NCT00000554|Procedure|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
347721|NCT00003735|Drug|topotecan hydrochloride|given by mouth
347722|NCT00506077|Drug|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
347723|NCT00506090|Procedure|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
347724|NCT00506116|Behavioral|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
347725|NCT00506116|Behavioral|PME practice and record keeping (in diaries)|
347726|NCT00506116|Behavioral|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
347727|NCT00506116|Procedure|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
347728|NCT00506129|Drug|Fludarabine|25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
347729|NCT00506129|Drug|Melphalan|70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
347730|NCT00506129|Procedure|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
347017|NCT00477217|Drug|Zoledronic acid|
347018|NCT00003602|Drug|idarubicin|
347019|NCT00477230|Device|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
347020|NCT00477230|Drug|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
347021|NCT00477243|Behavioral|Questionnaire|8 questionnaires will take about 40 minutes to complete.
347022|NCT00477256|Behavioral|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
347023|NCT00477269|Drug|Imatinib mesylate|
347024|NCT00477269|Drug|Placebo|
347025|NCT00477282|Drug|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
347026|NCT00477282|Drug|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
347027|NCT00477295|Drug|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
347028|NCT00477295|Drug|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
347029|NCT00003602|Drug|mitoxantrone hydrochloride|
347030|NCT00477308|Procedure|salvage therapy|
347031|NCT00477321|Drug|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
347032|NCT00477334|Drug|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
347033|NCT00477334|Drug|Placebo|oral; two tablets twice a day; single day treatment
347034|NCT00477347|Device|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
347379|NCT00468247|Other|Conventional care|Conventional haemodynamic care
347380|NCT00468260|Drug|Patupilone|
347381|NCT00468273|Drug|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
346345|NCT00494741|Drug|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
346346|NCT00494741|Drug|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight > 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
346347|NCT00494767|Drug|GW869682|
346348|NCT00494767|Drug|GSK189075|
346349|NCT00494780|Drug|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
346679|NCT00486343|Drug|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
346680|NCT00486343|Drug|Placebo|Placebo tablets 2x600mg BID for 24 weeks
346681|NCT00486356|Drug|capecitabine|
346682|NCT00486356|Drug|carboplatin|
346683|NCT00486356|Drug|epirubicin hydrochloride|
346684|NCT00486356|Genetic|microarray analysis|
346685|NCT00486356|Genetic|polymorphism analysis|
346686|NCT00486356|Other|pharmacological study|
346687|NCT00486369|Drug|Oral salmon calcitonin|
346688|NCT00486382|Biological|Leish-111f + MPL-SE Adjuvant|
346689|NCT00003643|Drug|cisplatin|
346690|NCT00486395|Device|CPAP|CPAP administered via "Bubble" method or Infant Flow Driver
346691|NCT00486395|Device|Mechanical ventilation|Volume guarantee strategy
346692|NCT00486408|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5x10^10 Ad vg
346693|NCT00486421|Biological|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
346694|NCT00486421|Drug|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
346695|NCT00486434|Drug|SMC021 Oral Calcitonin|0.8mg SMC021 twice daily
346006|NCT00502775|Drug|fluticasone furoate, fexofenadine|
346007|NCT00003726|Biological|lepirudin|
346008|NCT00502788|Drug|Peginterferon Alfa-2a and Ribavirin|Patients will be treated with alfa-2a and ribavirin as follows:
Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly.
346009|NCT00502788|Drug|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight > 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
346010|NCT00502801|Drug|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
346011|NCT00502814|Procedure|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
346012|NCT00502814|Procedure|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
346013|NCT00502814|Procedure|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
346014|NCT00502814|Procedure|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
346015|NCT00502827|Behavioral|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
346016|NCT00502827|Other|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
346017|NCT00502840|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
346018|NCT00003727|Biological|filgrastim|
346019|NCT00502853|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
346350|NCT00494780|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
346351|NCT00494780|Drug|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
346352|NCT00003678|Drug|tamoxifen citrate|
346353|NCT00494780|Drug|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
346354|NCT00494780|Drug|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
351041|NCT00624182|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
351042|NCT00004492|Drug|hydroxyurea|
351043|NCT00624195|Drug|FDA Approved Antiretroviral Therapy (see list below)|Combinations of FDA approved antiretroviral agents:
Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress
Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir
345659|NCT00464243|Drug|placebo|oral administration
345660|NCT00464256|Drug|rimonabant|
345661|NCT00464269|Other|Placebo|Active Substance: Placebo
Pharmaceutical Form: Film-coated tablet
Concentration: 2.5 mg, 10 mg and 25 mg
Route of Administration: Oral use
345662|NCT00464269|Drug|Brivaracetam 2.5 mg|Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 2.5 mg
Route of Administration: Oral use
345663|NCT00464269|Drug|Brivaracetam 10 mg|Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 10 mg
Route of Administration: Oral use
345664|NCT00003552|Drug|cyclophosphamide|
345665|NCT00464269|Drug|Brivaracetam 25 mg|Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 25 mg
Route of Administration: Oral use
345666|NCT00464295|Drug|Capecitabine in HCC|
345667|NCT00464308|Drug|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
345668|NCT00464308|Drug|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
345669|NCT00464308|Drug|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
345670|NCT00464321|Biological|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
345671|NCT00464321|Biological|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
345672|NCT00464321|Biological|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
345673|NCT00464321|Biological|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
350727|NCT00466791|Drug|Methylphenidate Transdermal System|Placebo
350728|NCT00466804|Procedure|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
350729|NCT00466817|Other|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
350730|NCT00003564|Drug|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
350731|NCT00466817|Drug|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
350732|NCT00466830|Other|questionnaire administration|
350733|NCT00466830|Procedure|management of therapy complications|
350734|NCT00466830|Procedure|psychosocial assessment and care|
350735|NCT00466830|Procedure|quality-of-life assessment|
350736|NCT00466843|Drug|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
350737|NCT00466843|Drug|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
350738|NCT00466856|Drug|octreotide acetate|Lung/liver Ratio Dose of SIR-Spheres
<10% Administer full dose of SIR-Spheres
10% to 15% Reduce dose of SIR-Spheres by 20%
16% to 20% Reduce dose of SIR-Spheres by 40%
>20% Do not give SIR-Spheres
350739|NCT00466856|Radiation|yttrium Y 90 resin microspheres|radiation
350740|NCT00466869|Drug|Betahistine|
351044|NCT00624208|Drug|droperidol and saline|droperidol 20 mcg.kg-1 and saline
351045|NCT00624208|Drug|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
351046|NCT00624208|Drug|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
351047|NCT00626028|Drug|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent®
351048|NCT00626028|Drug|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent®
350062|NCT00484653|Procedure|cervical smear|biological analysis
350063|NCT00484666|Drug|Docetaxel|
350064|NCT00484666|Drug|Topotecan|
350406|NCT00003595|Drug|vincristine sulfate|
350407|NCT00475644|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, up to 3 years
350408|NCT00475657|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
350409|NCT00475657|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
350410|NCT00475670|Drug|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
350411|NCT00475670|Drug|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
350412|NCT00475683|Other|Mouth wash|Mouth wash with chlorehexidin, three times a day
350413|NCT00475683|Dietary Supplement|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
350414|NCT00475696|Drug|Duloxetine|
350415|NCT00475709|Device|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
350416|NCT00475722|Behavioral|1 Healthy Eating|6 months telephone counseling
350417|NCT00003596|Drug|cisplatin|
350418|NCT00475722|Behavioral|2 Mediterranean|6 months telephone counseling
350419|NCT00475735|Drug|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
350420|NCT00475735|Drug|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
350421|NCT00475735|Drug|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
362442|NCT00666042|Drug|Vigamox - administration in spray form|Vigamox will be administered in a spray form
362443|NCT00666042|Drug|Vigamox eye drops|Vigamox eye drops
362779|NCT00658827|Other|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
362780|NCT00658840|Drug|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
362781|NCT00658840|Radiation|Localization, simulation and immobilization|Radiation dose and planning
Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.
Dose prescription : 90% isodose volume of prescribed dose encompassed PTV
The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated.
362782|NCT00658853|Behavioral|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
362783|NCT00658866|Procedure|Microdialysis|PK measurements with microdialysis
362784|NCT00658879|Drug|Pegvisomant|Pegvisomant 10, 15 or 20mg powder and solvent for solution for injection.
Dosage, Frequency : According to Japanese LPD.
Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration.
362785|NCT00004981|Drug|Abacavir sulfate|
362786|NCT00658892|Biological|B7-DC cross-linking antibody rHIgM12B7|
362787|NCT00658892|Other|flow cytometry|
362788|NCT00658892|Other|immunologic technique|
362789|NCT00658892|Other|laboratory biomarker analysis|
362790|NCT00658905|Drug|rhBSSL|0.15 g/L rhBSSL added to infant formula; one week treatment
362791|NCT00658905|Drug|Placebo|One week treatment
362792|NCT00658918|Drug|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
362793|NCT00658918|Drug|Placebo|placebo
362794|NCT00658931|Drug|Drug treatment with Cymbalta|Drug treatment with Cymbalta
362795|NCT00658957|Drug|gentamicin-collagen sponge|5 × 5 cm sponge
362796|NCT00004982|Drug|Combination Iron Chelation Therapy|
362110|NCT00634075|Drug|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
362111|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
362112|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
362113|NCT00004736|Drug|Zidovudine|
362114|NCT00634088|Drug|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
362115|NCT00634088|Drug|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
362116|NCT00634101|Device|nelfilcon A|contact lens
362444|NCT00666055|Drug|ARV regimen chosen by treating physician|Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).
Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI).
362445|NCT00666068|Other|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
362446|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
362447|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
362448|NCT00666081|Drug|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
362449|NCT00666094|Behavioral|Endurance training|supervised endurance training. Three sessions per week in three months.
362450|NCT00666094|Behavioral|strength training|Supervised strength training. Three sessions per week in three months.
362451|NCT00005046|Drug|chemotherapy|
362452|NCT00666107|Biological|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
361778|NCT00638833|Drug|Placebo|Placebo pills
361779|NCT00638846|Device|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
361780|NCT00004855|Drug|Lopinavir/Ritonavir|
361781|NCT00641095|Biological|rituximab|
361782|NCT00641095|Drug|cyclophosphamide|
361783|NCT00641095|Drug|fludarabine phosphate|
361784|NCT00641095|Genetic|fluorescence in situ hybridization|
361785|NCT00641095|Other|immunohistochemistry staining method|
361786|NCT00641095|Other|immunologic technique|
361787|NCT00641095|Other|laboratory biomarker analysis|
361788|NCT00641108|Drug|ADAM SPECT plus Cognitive Therapy|
361789|NCT00641108|Drug|ADAM SPECT plus No Therapy|
361790|NCT00641134|Other|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
361791|NCT00004855|Drug|Abacavir sulfate|
361792|NCT00641147|Drug|Curcumin|Given PO
361793|NCT00641147|Other|Laboratory Biomarker Analysis|Correlative studies
361794|NCT00641147|Other|Placebo|Given PO
361795|NCT00641160|Drug|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
361796|NCT00641160|Drug|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
361797|NCT00641160|Drug|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
361798|NCT00641173|Drug|paroxetine|treatment with SSRI paroxetine
361799|NCT00641173|Drug|placebo|treatment with placebo
361800|NCT00641186|Drug|sodium oxybate|4.5 to 9.0 grams per night
361801|NCT00641199|Other|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
350523|NCT00488137|Other|Placebo|o.d.
350524|NCT00488137|Drug|Prucalopride|4 mg o.d.
350525|NCT00488163|Drug|Atomoxetine|
350526|NCT00488176|Drug|montelukast|montelukast sodium
350527|NCT00490815|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
350528|NCT00490828|Drug|Hydrocortisone|Hydrocortisone
350529|NCT00490841|Device|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
350530|NCT00490854|Drug|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
350531|NCT00490854|Drug|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
350532|NCT00003659|Drug|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
350853|NCT00482079|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
350854|NCT00482079|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
350855|NCT00003625|Drug|vincristine sulfate|
350856|NCT00482092|Drug|adult human mesenchymal stem cells|Intravenous infusion of suspension of adult human mesenchymal stem cells, total of 1200 million (high dose) or 600 million (low dose) cells infused in four visits over two weeks.
350857|NCT00482092|Drug|Placebo|Placebo
350858|NCT00482105|Other|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
350859|NCT00482144|Procedure|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
350860|NCT00482144|Procedure|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
350861|NCT00482157|Drug|Vitamin D (Calcitriol)|
350862|NCT00482170|Device|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
350177|NCT00496483|Drug|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.
Other Names:
Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
350178|NCT00496509|Drug|ZD6474 (Zactima) 100mg|
350179|NCT00496509|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
350180|NCT00496509|Procedure|Biomarker Draws|
350181|NCT00496509|Drug|ZD6474 (Zactima) 300mg|
350182|NCT00499044|Other|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
350183|NCT00499044|Other|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
350184|NCT00003698|Drug|fosbretabulin disodium|
350185|NCT00499057|Radiation|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
350186|NCT00499070|Genetic|polymerase chain reaction|
350187|NCT00499070|Other|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
350188|NCT00499070|Other|immunologic technique|
350189|NCT00499070|Procedure|biopsy|
350190|NCT00499083|Biological|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
350533|NCT00490867|Drug|Alpha lipoic acid|
350534|NCT00490880|Drug|gemcitabine|
350535|NCT00490880|Drug|cisplatin|
349502|NCT00466258|Drug|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
349503|NCT00003560|Drug|docetaxel|
349504|NCT00466284|Drug|Tarceva (erlotinib)|
349505|NCT00466297|Behavioral|Face-to-face communication interactions|
349506|NCT00466310|Drug|Aripiprazole|Aripiprazole for 4 weeks
349837|NCT00504413|Drug|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
349838|NCT00504413|Drug|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
349839|NCT00504413|Drug|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
349840|NCT00504426|Drug|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
349841|NCT00003741|Biological|monoclonal antibody HeFi-1|
349842|NCT00506844|Drug|Cetuximab, Irinotecan, Capecitabine|
349843|NCT00506857|Drug|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
349844|NCT00506857|Drug|Fludarabine|30 mg/m^2 by vein daily x 4 days.
349845|NCT00506870|Device|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
349846|NCT00506870|Device|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
349847|NCT00506883|Drug|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
349848|NCT00506883|Drug|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
349145|NCT00475189|Drug|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
349146|NCT00475189|Drug|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
349147|NCT00003595|Biological|filgrastim|
349148|NCT00475215|Drug|Sugammadex 2.0 mg/kg|After the intubation dose or last maintenance dose of rocuronium, at reappearance of T2, subjects were to receive a dose of 2.0 mg/kg Org 25969 in randomized order
349149|NCT00475215|Drug|Sugammadex 4.0 mg/kg|After the intubation dose or last maintenance dose of rocuronium, at reappearance of T2, subjects were to receive a dose of 4.0 mg/kg Org 25969 in randomized order
349150|NCT00475228|Drug|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
349151|NCT00475241|Behavioral|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
349152|NCT00475241|Behavioral|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
349153|NCT00475267|Device|Trifecta aortic heart valve|Intended as a replacement for a diseased, damaged, or malfunctioning aortic heart valve.
349154|NCT00475280|Procedure|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
349155|NCT00475280|Procedure|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
349156|NCT00478088|Device|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
349157|NCT00478101|Drug|oxycodone fentanyl|
349158|NCT00478114|Drug|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
349159|NCT00003606|Drug|cyclophosphamide|
349507|NCT00466310|Drug|Risperidone|Subjects will be randomized to risperidone for 4 weeks
349508|NCT00466310|Other|Healthy volunteers|Healthy volunteers
349509|NCT00466323|Behavioral|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
349510|NCT00469092|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
348813|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
348814|NCT00487136|Drug|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
348815|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
349160|NCT00478140|Biological|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
349161|NCT00478140|Other|laboratory biomarker analysis|Correlative studies
349162|NCT00478179|Drug|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
349163|NCT00478192|Drug|Conivaptan|premix bag
349164|NCT00478192|Drug|Placebo|premix bag
349165|NCT00478205|Drug|Aricept (donepezil SR 23 mg)|Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:
23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation.
349166|NCT00478205|Drug|Aricept (donepezil IR 10 mg)|Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:
10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation.
349167|NCT00478218|Drug|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
349168|NCT00478218|Drug|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 & 22
349169|NCT00478218|Drug|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
349170|NCT00003606|Drug|epirubicin hydrochloride|
349171|NCT00478231|Drug|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
349172|NCT00478244|Drug|busulfan|Day -9 through Day -6: 1.1 mg/kg if < 12 kg IV every 6 hours; 0.8 mg/kg if > 12 kg.
349173|NCT00478244|Drug|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
349174|NCT00478244|Drug|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
348455|NCT00492973|Drug|active comparator|bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
348456|NCT00492986|Drug|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
348457|NCT00492999|Drug|dexamethasone|Given by hepatic arterial infusion
348458|NCT00492999|Drug|floxuridine|Given by hepatic arterial infusion
348459|NCT00492999|Drug|fluorouracil|Given IV
348460|NCT00492999|Drug|irinotecan hydrochloride|Given IV
348461|NCT00492999|Drug|leucovorin calcium|Given IV
348462|NCT00492999|Drug|oxaliplatin|Given IV
348463|NCT00493012|Dietary Supplement|vitamin D|6 drops of a vitamin D containing oil
348464|NCT00003667|Drug|disaccharide tripeptide glycerol dipalmitoyl|
348465|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.
Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion
348466|NCT00495651|Drug|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
348467|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria
Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion
348468|NCT00495664|Device|Titan stent and Taxus-Liberte stent|
348469|NCT00495677|Drug|PF-00232798|Solution, 20 mg. once daily, 10 days
348470|NCT00495677|Drug|PF-00232798|Solution, 150 mg. once daily, 10 days
348471|NCT00003680|Drug|methotrexate|
348472|NCT00495677|Drug|PF-00232798|Solution, 5 mg. once daily, 10 days
348473|NCT00495677|Drug|PF-00232798|Solution, 40 mg. once daily, 10 days
348474|NCT00495677|Drug|PF-00232798|Solution, 300 mg. once daily, 10 days
348475|NCT00495677|Drug|PF-00232798|Solution, 400 mg. once daily, 10 days
347731|NCT00506129|Drug|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
347732|NCT00003736|Drug|motexafin gadolinium|
347733|NCT00506142|Drug|Marqibo® (vincristine sulfate liposomes injection)|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
347734|NCT00506155|Drug|Avastin|10 mg/kg by vein over 90 minutes
347735|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
347736|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
347737|NCT00003541|Drug|carboplatin|
348074|NCT00500409|Drug|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
348075|NCT00500422|Drug|Doxil|Starting dose of 20 mg/m^2 IV over 2 hours on Day 1, 21 day cycle
348076|NCT00500422|Drug|Gemcitabine|500 mg/m^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
348077|NCT00500422|Drug|Velcade|Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
348078|NCT00500435|Procedure|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
348079|NCT00500448|Device|Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System)|Estim will be delivered 3 times per week for 4 weeks
348080|NCT00003707|Drug|gemcitabine hydrochloride|
348081|NCT00500461|Drug|GSK233705|
348082|NCT00500474|Procedure|endolymphatic sac drainage with steroids|
348083|NCT00500487|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
348084|NCT00500487|Behavioral|HIV Prevention Skills|12-session group intervention including sexual health skills training.
348085|NCT00500487|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of health topics.
347382|NCT00468286|Drug|Degarelix|Experimental
Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
347383|NCT00468286|Drug|Degarelix|Experimental
Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
347384|NCT00468299|Drug|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
347385|NCT00468299|Drug|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
347386|NCT00468312|Drug|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
347387|NCT00003572|Drug|mycophenolate mofetil|
347388|NCT00468312|Drug|Placebo|Two sprays in each nostril in the morning
347389|NCT00470990|Drug|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
347390|NCT00471003|Drug|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
347391|NCT00471016|Behavioral|Guided intervention|
347392|NCT00003578|Drug|vincristine sulfate|
347393|NCT00471029|Drug|esomeprazole|
347394|NCT00471042|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
347395|NCT00471055|Drug|0.0125% Capsaicin gel "CAPSIKA gel"|
347396|NCT00471055|Drug|Placebo|Placebo
347397|NCT00471068|Drug|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
347398|NCT00471068|Drug|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
347399|NCT00471068|Drug|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
347400|NCT00471081|Biological|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
347401|NCT00471094|Drug|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
346696|NCT00486434|Drug|SMC021 Placebo|Placebo twice daily
346697|NCT00486447|Device|64 Channel VCT|cardiac CT angiography exam
346698|NCT00486460|Drug|Gemcitabine|
346699|NCT00486460|Drug|Curcumin|
346700|NCT00003643|Drug|etoposide|
346701|NCT00489203|Drug|tacrolimus|Given after transplant
346702|NCT00003653|Drug|goserelin|Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
346703|NCT00489203|Drug|methotrexate|Given after transplant
347035|NCT00477347|Device|Manual administration|intraoperative manual administration of propofol and remifentanil
347036|NCT00477360|Device|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
347037|NCT00477373|Drug|depakine chrono|Depakine Chrono 500 mg
347038|NCT00480389|Drug|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
347039|NCT00480402|Drug|200 mg of Progesterone|Administration of 200 mg of Progesterone
347040|NCT00480402|Drug|400 mg Progesterone|Administration of 400 mg Progesterone
347041|NCT00480402|Drug|Placebo|Administration of a Placebo
347042|NCT00480441|Drug|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
347043|NCT00480441|Behavioral|BRENDA therapy|weekly therapy sessions for 6 weeks
347044|NCT00480441|Drug|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
347045|NCT00480454|Biological|MVA 85A|intradermal vaccine
347046|NCT00003619|Drug|etoposide|
346355|NCT00494793|Procedure|VAWC and mesh mediated fascial traction|The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.
The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.
Finally the mesh is removed and the fascia is closed
346356|NCT00494806|Other|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
346357|NCT00494832|Drug|Dexmedetomidine|10 minutes loading dose of 0.9 mcg/kg
Maintenance dose of 0.6 mcg/kg/hour
346358|NCT00494832|Drug|Normal Saline|10 minutes loading dose of 0.9 mcg/kg
Maintenance dose of 0.6 mcg/kg/hour
346359|NCT00494845|Behavioral|Mindfulness|8-week mindfulness program will be compared to an education control group.
346360|NCT00494845|Behavioral|Control: Health Education Class|8-week education program
346361|NCT00497536|Drug|Insulin Aspart (IAsp)|IAsp 100 U.
≈ bolus protocol: From 6 pm until 6 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm
1 dose/h + 50 % s.c. (≈ bolus).
346362|NCT00497536|Drug|Insulin Aspart (IAsp).|IAsp 100 U From 6 pm until 8 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm 50 % increase of basal rate
346363|NCT00497536|Drug|Insulin Aspart (IAsp)|IAsp 100 U From 6 pm until 8 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm 50 % increase of basal rate
346364|NCT00497549|Procedure|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
346365|NCT00003690|Drug|carboplatin|
346366|NCT00497549|Procedure|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
346704|NCT00489203|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
346705|NCT00489216|Biological|efalizumab|Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at
1mg/kg
346706|NCT00489229|Drug|Rosiglitazone|
345674|NCT00464334|Biological|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
345675|NCT00003552|Drug|fludarabine|
345676|NCT00464334|Biological|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
345677|NCT00464334|Biological|Placebo to V950|
345678|NCT00464347|Drug|Avastin|
345679|NCT00464347|Procedure|Photodynamic Therapy (PDT)|
345680|NCT00464347|Drug|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
345681|NCT00464373|Drug|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
346020|NCT00502853|Drug|Methotrexate|10-25mg/week
346021|NCT00502879|Drug|Enbrel (etanercept)|
346022|NCT00502892|Drug|Topotecan|0.5 mg/m^2 IV Daily x 3 Days
346023|NCT00502892|Drug|Ifosfamide|1.8 grams/m^2 IV Over 1 Hour x 5 Days
346024|NCT00502892|Drug|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days [for patients > 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days]
346025|NCT00502905|Drug|Busulfan|130 mg/m^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
346026|NCT00502905|Drug|Fludarabine|40 mg/m^2 through a central venous catheter over one hour, once a day, for four days.
346027|NCT00502918|Device|CLM - HA Continuous Monitoring System Heart Application|
346028|NCT00505440|Behavioral|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
346029|NCT00505440|Behavioral|Usual care|Usual care with mailed screening results
346030|NCT00505453|Biological|Fluviral®|
346031|NCT00505466|Behavioral|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
346032|NCT00505492|Drug|Carboplatin|AUC 5 by vein once every 28 Days
351049|NCT00004563|Drug|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
351050|NCT00626028|Drug|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
351051|NCT00626041|Other|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
351052|NCT00626054|Drug|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
351053|NCT00626054|Drug|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
351054|NCT00626067|Device|Fully Functional Travatan Compliance Monitoring Dispenser|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
351055|NCT00626067|Device|Partially Functioning Travatan Compliance Monitoring Dispenser|Patient received a particually functional Travatan Compliance Monitoring Dispenser
351056|NCT00626067|Device|Non Functioning Travatan Compliance Monitoring Dispenser|Patient received a non functioning Travatan Compliance Monitoring Dispenser
351057|NCT00626080|Drug|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
351058|NCT00626080|Drug|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
351059|NCT00626093|Device|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).
Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions.
351060|NCT00004563|Drug|Placebo|Matching gelcaps 25 mgs
351061|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 2 - placebo with exemestane or fulvestrant
351062|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 3 - roll over to open-label AMG 479 with exemestane or fulvestrant
351063|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 1 - AMG 479 administered with exemestane or fulvestrant
345682|NCT00467350|Drug|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
345683|NCT00467363|Drug|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
345684|NCT00467363|Dietary Supplement|Folic acid|400micrograms of folic acid.
350422|NCT00475748|Procedure|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
350423|NCT00475774|Behavioral|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
350424|NCT00475787|Procedure|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
350741|NCT00003564|Drug|Procarbazine Hydrochloride|Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.
Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.
350742|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
350743|NCT00469651|Biological|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
350744|NCT00003575|Drug|ifosfamide|
350745|NCT00469651|Biological|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
350746|NCT00469651|Biological|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
350747|NCT00469651|Biological|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
350748|NCT00469651|Biological|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
350749|NCT00469664|Drug|Guanfacine/Tenex|
350750|NCT00469690|Drug|Acular, Xibrom|Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)
Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)
350751|NCT00469703|Drug|Thalidomide|
350752|NCT00469716|Drug|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
350753|NCT00469729|Drug|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
350754|NCT00469755|Drug|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
350755|NCT00003576|Drug|cisplatin|
350756|NCT00469755|Drug|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
350757|NCT00469755|Drug|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
362797|NCT00658957|Drug|placebo collagen sponge|5 × 5 cm sponge
362798|NCT00658970|Drug|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
362799|NCT00658983|Other|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
363102|NCT00653926|Drug|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
363103|NCT00653926|Drug|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
363104|NCT00653939|Drug|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
363105|NCT00653939|Drug|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
363106|NCT00653939|Drug|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
363107|NCT00653939|Drug|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
363108|NCT00653952|Drug|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
363109|NCT00653952|Drug|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
363110|NCT00653965|Drug|Rosuvastatin|
363111|NCT00653965|Drug|Atorvastatin|
363112|NCT00004915|Drug|raloxifene|
363113|NCT00653978|Procedure|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
363114|NCT00653978|Procedure|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
363115|NCT00653991|Behavioral|Socially Optimized Learning in a Virtual Environment (SOLVE)-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
363116|NCT00654017|Drug|placebo|Placebo comparator to be given per protocol.
362453|NCT00666120|Other|Enfamil LIPIL with iron|cow's milk based infant formula
362454|NCT00666120|Other|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
362455|NCT00666133|Device|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
362456|NCT00666159|Drug|tacrolimus ointment|topical
362457|NCT00666159|Drug|pimecrolimus cream|topical
362458|NCT00666172|Behavioral|Exercise|
362459|NCT00666172|Behavioral|Weight Loss|
362460|NCT00666185|Drug|Micafungin|IV
362461|NCT00666185|Drug|Fluconazole|IV
362462|NCT00668200|Dietary Supplement|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
362463|NCT00668200|Dietary Supplement|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
362464|NCT00668226|Drug|Lactic acid (Dermacid)|
362465|NCT00668239|Drug|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
362800|NCT00661531|Drug|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
362801|NCT00661544|Drug|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
362802|NCT00005009|Biological|Varicella Virus Vaccine Live|
362803|NCT00661544|Drug|Melphalan|Dose Levels 1, 2, & 3: 100 mg/m2 IV Days -4, -3.
362804|NCT00661544|Drug|Ascorbic Acid|Dose Levels 1, 2, & 3: 1000 mg IV Days -9 to -3.
362805|NCT00661557|Biological|Meningococcal vaccine GSK134612|one dose, as intramuscular injection
362806|NCT00661570|Device|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
361802|NCT00004855|Drug|Nevirapine|
362117|NCT00634101|Device|narafilcon A|contact lens
362118|NCT00634114|Drug|Esomeprazole|10mg once daily oral administration
362119|NCT00634114|Drug|Esomeprazole|20mg once daily oral administration
362120|NCT00634114|Drug|Omeprazole|10mg once daily oral administration
362121|NCT00634140|Drug|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
362122|NCT00634140|Drug|Placebo|placebo for 4-6 weeks
362123|NCT00634153|Other|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
362124|NCT00004739|Drug|Antiretroviral therapy|
362125|NCT00634166|Drug|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
362126|NCT00634166|Drug|Topical Antimicrobial/Antifungal Medications|Various topical antimicrobials and antifungals.
362127|NCT00634179|Drug|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
362128|NCT00634179|Biological|Rituximab|Rituximab 375 mg/m²
362129|NCT00634179|Drug|Doxorubicin|Doxorubicin 50 mg/m²
362130|NCT00634179|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m²
362131|NCT00634179|Drug|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
362132|NCT00636207|Drug|Placebo|Placebo dry powder inhaler
362133|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg [S,S]-reboxetine for 5 and one half weeks.
362134|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg [S,S]-reboxetine for 5 and one half weeks.
362135|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
350863|NCT00482170|Device|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
350864|NCT00482183|Drug|Pioglitazone|
350865|NCT00482196|Drug|MK0493|
350866|NCT00003625|Radiation|radiation therapy|
350867|NCT00482209|Drug|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
350868|NCT00482209|Drug|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
350869|NCT00482222|Biological|cetuximab|
350870|NCT00482222|Drug|capecitabine|
350871|NCT00482222|Drug|fluorouracil|
350872|NCT00482222|Drug|leucovorin calcium|
350873|NCT00482222|Drug|oxaliplatin|
350874|NCT00482222|Other|study of socioeconomic and demographic variables|
350875|NCT00482222|Procedure|adjuvant therapy|
350876|NCT00482222|Procedure|neoadjuvant therapy|
350877|NCT00003626|Drug|dolastatin 10|
351165|NCT00599898|Drug|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
351166|NCT00599911|Drug|Lu AA24530|per oral, once daily for 6 weeks
351167|NCT00599911|Drug|Duloxetine|per oral, once daily for 6 weeks
351168|NCT00599911|Drug|Placebo|per oral, once daily for 6 weeks
351169|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
351170|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
351171|NCT00004218|Drug|fludarabine phosphate|
351172|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
350536|NCT00490880|Procedure|radical cystectomy|
350537|NCT00490880|Procedure|radiotherapy|
350538|NCT00490893|Drug|Detemir|
350539|NCT00490906|Drug|Copaxone|20 mg, subcutaneous injections, taken daily
350540|NCT00490906|Drug|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
350541|NCT00490906|Drug|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
350542|NCT00490919|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
350543|NCT00003659|Drug|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
350544|NCT00490919|Drug|Placebo|transdermal system (placebo) worn for 7 days
350545|NCT00490932|Drug|Hypo-osmolar ORS|
350546|NCT00490945|Drug|VEC-162|
350547|NCT00490958|Drug|telmisartan|
350548|NCT00490971|Drug|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
350549|NCT00490971|Drug|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
350550|NCT00490971|Drug|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
350551|NCT00490984|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
350552|NCT00490997|Drug|Ketamine only|Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).
Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation
350553|NCT00490997|Drug|Ketamine - Propofol|Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).
Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation
350554|NCT00493649|Drug|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
350878|NCT00482222|Procedure|quality-of-life assessment|
349849|NCT00506883|Other|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
349850|NCT00506896|Drug|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
349851|NCT00506909|Drug|Oxytocin|20 IU BID or 40 IU BID
349852|NCT00003742|Drug|cisplatin|
349853|NCT00506909|Drug|Placebo|20 IU BID or 40 IU BID
349854|NCT00506922|Drug|Pentostatin|Given intravenously on days +8, +15, +22 and +30 post transplant:
Group 2 - Pentostatin 0.5 mg/m^2
Group 3 - Pentostatin 1 mg/m^2
Group 4 - Pentostatin 1.5 mg/m^2
Group 5 - Pentostatin 2 mg/m^2
350191|NCT00499083|Drug|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
350192|NCT00499083|Drug|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
350193|NCT00499083|Drug|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
350194|NCT00499083|Drug|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
350195|NCT00003700|Biological|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC > 5,000 uL after nadir: 7 day minimum for Courses I & IV
350196|NCT00499083|Drug|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
350197|NCT00499083|Genetic|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
350198|NCT00499083|Genetic|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
350199|NCT00499083|Genetic|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
350200|NCT00501410|Drug|Oxaliplatin|85 mg/m^2 by vein on day 1.
350201|NCT00501449|Behavioral|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
349511|NCT00469092|Drug|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
349512|NCT00469092|Drug|metformin|Tablets, 2550 mcg. Administered once daily.
349513|NCT00469092|Drug|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
349514|NCT00003574|Procedure|surgical procedure|
349515|NCT00469105|Behavioral|Literacy/Numeracy oriented educational intervention|Receives comprehensive literacy/num sensitive diabetes care
349516|NCT00469105|Behavioral|Control Group|Receives standard diabetes disease management
349517|NCT00469118|Device|DRX9000™|Nonsurgical spinal decompression
349518|NCT00469131|Drug|tacrolimus + steroid|
349519|NCT00469131|Drug|tacrolimus + mycophenolate mofetil|
349520|NCT00469144|Drug|Busulfan|Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days.
Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day.
Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%.
349521|NCT00469144|Drug|Fludarabine|40 mg/m^2 IV Daily Over 1 Hour x 4 Days
349522|NCT00469157|Drug|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
349523|NCT00469170|Device|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
349524|NCT00469183|Drug|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
349525|NCT00003574|Radiation|brachytherapy|
349526|NCT00469196|Procedure|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
349527|NCT00469209|Drug|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
349528|NCT00469209|Drug|Velcade (Bortezomib)|Arm 1 (Level 1):
1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).
Arm 2 (Level 2):
1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).
349855|NCT00506922|Drug|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
349856|NCT00506922|Drug|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
349175|NCT00478244|Procedure|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
349176|NCT00478257|Device|light box ( Litebook)|bright white light
349177|NCT00478257|Device|light box ( Litebook)|dim red light
349178|NCT00478270|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
349179|NCT00478283|Other|survey administration|
349180|NCT00478309|Other|counseling intervention|
349181|NCT00000539|Behavioral|dietary supplements|
349182|NCT00003606|Drug|etoposide|
349529|NCT00469209|Drug|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
349530|NCT00469209|Drug|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
349531|NCT00469222|Procedure|hypofractionated external beam|
349532|NCT00469235|Drug|Avotermin|10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.
10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.
349533|NCT00469248|Device|Intra-aortic balloon pump counterpulsation|
349534|NCT00471991|Drug|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
349535|NCT00472004|Drug|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
349536|NCT00472004|Drug|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
349537|NCT00472017|Drug|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
348816|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
348817|NCT00003648|Genetic|DNA stability analysis|
348818|NCT00487162|Procedure|strict glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
348819|NCT00487162|Drug|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
348820|NCT00487175|Drug|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
348821|NCT00487188|Drug|Enfuvirtide|90 mg subcutaneous injection twice a day
348822|NCT00487188|Drug|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
348823|NCT00487201|Procedure|endoscopic balloon dilatation|
348824|NCT00487201|Procedure|plastic stent placement|
348825|NCT00487227|Drug|caffeine|
348826|NCT00487227|Drug|Placebo|
348827|NCT00487240|Drug|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
348828|NCT00003648|Genetic|gene rearrangement analysis|
348829|NCT00487240|Drug|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
348830|NCT00487253|Drug|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
348831|NCT00487253|Drug|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
348832|NCT00487266|Other|Acupuncture|Acupuncture of low back and legs.
348833|NCT00487279|Device|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
348834|NCT00487279|Other|Control|No Intervention
348835|NCT00487292|Behavioral|naps and pulses of bright light|
348086|NCT00500500|Drug|EGb 761® (Tanakan®)|
348087|NCT00500513|Procedure|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
348088|NCT00500513|Procedure|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
348089|NCT00500513|Radiation|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
348090|NCT00500526|Other|Singing practice|
348091|NCT00003707|Drug|tipifarnib|
348092|NCT00500526|Other|Singing classes|
348093|NCT00500526|Other|Hand craft classes|
348094|NCT00500539|Drug|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
348095|NCT00500552|Drug|Perhexiline/Placebo|
348096|NCT00500565|Drug|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
348476|NCT00495690|Drug|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
348477|NCT00495703|Behavioral|Exercise|6-months of regular aerobic exercise
348478|NCT00495703|Behavioral|Usual Care|6-months of behavioral strategies to aid memory/cognition
348479|NCT00495716|Drug|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
348480|NCT00495716|Drug|acyclovir|400 mg acyclovir orally twice daily for 1 year
348481|NCT00495729|Drug|SB-649868|
348482|NCT00003680|Drug|tamoxifen citrate|
348483|NCT00495755|Drug|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
348484|NCT00495768|Behavioral|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
348485|NCT00495781|Procedure|%-hypo (laboratory parameter, functional iron deficiency)|
347738|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
347739|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
347740|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
347741|NCT00462228|Drug|memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo (provided by Forest Laboratories) per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study, arm AB or arm BA. Study personnel are blinded to A and B treatment identity.
347742|NCT00462228|Drug|placebo|Subjects will have the same dosage regimen for memantine or placebo as listed above. In arm BA, subjects will start with treatment B and crossover to treatment A.
347743|NCT00462241|Procedure|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
347744|NCT00462241|Other|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
347745|NCT00462254|Drug|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
347746|NCT00462254|Drug|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
347747|NCT00462267|Behavioral|Enriched lifestyle intervention|Multi-component lifestyle intervention
347748|NCT00003541|Drug|cyclophosphamide|
347749|NCT00465192|Drug|estradiol, 10 mcg|
347750|NCT00465192|Drug|estradiol, 25 mcg|
347047|NCT00480467|Drug|SAM-315|
347048|NCT00480480|Behavioral|Trauma and Grief Component Therapy for Adolescents (Group Version)|
347049|NCT00480493|Behavioral|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
347050|NCT00480519|Procedure|Meatotomy|
347051|NCT00480532|Drug|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
347052|NCT00480532|Drug|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
347053|NCT00480532|Drug|Oracea|40-mg tablet daily for 84 days
347054|NCT00480532|Drug|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
347055|NCT00480532|Drug|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
347056|NCT00480532|Drug|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
347402|NCT00471094|Drug|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
347403|NCT00003578|Procedure|autologous bone marrow transplantation|
347404|NCT00471094|Drug|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
347405|NCT00471094|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
347406|NCT00471107|Device|DC brain polarization|0.08 mA/cm2
347407|NCT00471120|Other|P2x7 assay|compare P2X7 assay to biopsy
347408|NCT00471133|Biological|Xenogeneic Tyrosinase DNA Vaccine|
347409|NCT00471133|Device|TriGrid Delivery System for Intramuscular Electroporation|
347410|NCT00471146|Drug|AG-013736|oral administration, starting dose 5 mg twice daily [BID] every day until unacceptable toxicity or tumor progression.
347411|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
346707|NCT00489229|Drug|Ramipril|
346708|NCT00489242|Procedure|Procedure / Percutaneous angioplasty|
346709|NCT00489255|Drug|Tigan®|Oral capsule, 300mg three times daily
346710|NCT00489255|Drug|Placebo|Oral capsule, three times daily
346711|NCT00489268|Device|HALO Ablation System|Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit
346712|NCT00489281|Drug|cyclophosphamide|Cyclophosphamide (CTX) 14.5 mg/kg intravenously for 2 days before and after transplant.
346713|NCT00003653|Drug|leuprolide acetate|Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
346714|NCT00489281|Drug|fludarabine phosphate|Fludarabine 30 mg/M2 intravenously for 5 days before bone marrow transplant
346715|NCT00489281|Drug|mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth three times a day daily for 30 days beginning 5 days after bone marrow transplant.
346716|NCT00489281|Drug|Sirolimus|The first dose of Sirolimus is 6 mg and is taken by mouth 5 days after bone marrow transplant. On the 6th day after bone marrow transplant, the dose of Sirolimus is 2 mg by mouth daily for 1 year.
346717|NCT00489281|Procedure|Allogeneic bone marrow transplantation|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
346718|NCT00489281|Radiation|total-body irradiation|Radiation of the total body will be administered the day before bone marrow transplant.
346719|NCT00489281|Drug|Levetiracetam|Levetiracetam 500 mg orally twice a day 6 days before transplant and for 1 year after transplant. Levetiracetam prevents seizures.
346720|NCT00489294|Drug|Syntropin|
346721|NCT00492219|Device|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
346722|NCT00003663|Biological|rituximab|
347057|NCT00003619|Drug|fludarabine phosphate|
347058|NCT00480532|Drug|placebo daily|Placebo daily for the first 84 days of the study
346033|NCT00505492|Drug|Cisplatin|40 mg/m^2 by vein (IV) Weekly Over 4 Hours
346034|NCT00505492|Drug|Paclitaxel|135 mg/m^2 by vein (IV) Once Every 28 Days
346035|NCT00505505|Drug|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
346036|NCT00505518|Drug|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
346037|NCT00003732|Drug|carboplatin|
346038|NCT00505518|Behavioral|Collaborative psychiatric and primary medical care|Regular care visits from health workers
346039|NCT00505544|Behavioral|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
346040|NCT00505544|Device|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
346041|NCT00505557|Procedure|Transaxillary dual plane technique|
346042|NCT00505570|Device|AMPLATZER® PFO Occluder Device|PFO device closure
346043|NCT00505583|Drug|MOA-728|
346367|NCT00497562|Drug|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
346368|NCT00497562|Drug|amitriptyline, fluoxetine and tramadol alone (control group)|
346369|NCT00497588|Procedure|surgery|
346370|NCT00497588|Radiation|radiotherapy|
346371|NCT00497601|Drug|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 & 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 & 5 mg/kg on day 1 & 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 & 2.5 mg/kg on day 1 & 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
346372|NCT00497601|Drug|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
346373|NCT00497601|Drug|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
346374|NCT00497614|Drug|adalimumab|
346375|NCT00497640|Procedure|Artificial Neural Network|Use of a predicted optimal CPAP
346376|NCT00003690|Drug|cisplatin|
345685|NCT00467376|Drug|Insulin Glulisine|3 times a day before each meal
345686|NCT00467376|Drug|Lispro|3 times a day before each meal
345687|NCT00467376|Drug|Insulin Glargine|once daily
345688|NCT00467389|Drug|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
345689|NCT00467389|Other|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
345690|NCT00467402|Drug|agomelatine|
345691|NCT00467402|Drug|placebo|
345692|NCT00003567|Drug|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
345693|NCT00467415|Behavioral|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
345694|NCT00467415|Behavioral|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
345695|NCT00467428|Drug|NS2359|
345696|NCT00467428|Drug|Placebo|
345697|NCT00467441|Drug|VSF-173|
345698|NCT00467454|Drug|Naltrexone|daily
345699|NCT00467454|Drug|Placebo|daily
345700|NCT00467467|Drug|Alfuzosin Hydrochloride|
345701|NCT00467493|Drug|Anastrozole|
345702|NCT00467506|Drug|bispecific antibody and di-DTPA-131I|
345703|NCT00003567|Procedure|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
345704|NCT00467519|Biological|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
346044|NCT00505596|Behavioral|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
350758|NCT00469768|Drug|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
350759|NCT00469768|Drug|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
350760|NCT00469768|Other|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
350761|NCT00469781|Drug|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
351064|NCT00626132|Dietary Supplement|Eucommia|two capsules three times a day orally for 2 weeks
351065|NCT00626145|Procedure|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
351066|NCT00626145|Procedure|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
351067|NCT00626158|Drug|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
351068|NCT00626158|Drug|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
351069|NCT00626171|Procedure|Allergen Challenge|Allergen challenge
351070|NCT00628576|Drug|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
351071|NCT00628576|Drug|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
351072|NCT00628589|Drug|loxapine|Staccato Loxapine, 5 mg
351073|NCT00628589|Drug|loxapine|Staccato Loxapine, 10 mg
351074|NCT00628589|Drug|placebo|Staccato Placebo
351075|NCT00628602|Device|BION|30 patients operated will be randomized into 2 equal groups, a BION Therapy Group ("Rx group") and a Control Group ("Control group").
351076|NCT00628628|Drug|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
351077|NCT00004635|Other|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
351078|NCT00628628|Drug|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
351079|NCT00628667|Drug|Esomeprazole|40mg orally twice daily
351080|NCT00628667|Drug|Placebo|
363117|NCT00654017|Drug|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
363118|NCT00654030|Drug|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
363119|NCT00654043|Drug|Torsemide|tablets, 20 Mg, single-dose
363120|NCT00654043|Drug|Demadex|Tablets, 20 mg, single-dose
363121|NCT00654056|Drug|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
363433|NCT00004888|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
363434|NCT00646594|Drug|fluticasone/salmeterol (Advair)|
363435|NCT00004899|Drug|etoposide|
363436|NCT00649142|Procedure|Open sutured mesh repair|Open sutured mesh repair
363437|NCT00649142|Procedure|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
363438|NCT00649155|Drug|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
363439|NCT00649155|Drug|Cipro® XR Tablets (500 mg|500mg, single dose fasting
363440|NCT00649168|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
363441|NCT00649168|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
363442|NCT00649181|Drug|Metolazone Tablets 5 mg|2x5mg, single dose fasting
363443|NCT00649181|Drug|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
363444|NCT00649194|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
363445|NCT00649194|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
363446|NCT00004899|Procedure|autologous bone marrow transplantation|
363447|NCT00649207|Drug|ABT-888|Oral Capsules
363448|NCT00649207|Radiation|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
362807|NCT00661583|Drug|ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
362808|NCT00661596|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg, 10 mg and 20 mg one hour prior to sexual intercourse
362809|NCT00661596|Drug|Placebo|Matching placebo
362810|NCT00661609|Drug|AZD4877|Intravenous (IV)25mg/weekly
362811|NCT00661622|Drug|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
362812|NCT00661622|Procedure|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
362813|NCT00005010|Drug|Irbesartan|
362814|NCT00661635|Drug|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
362815|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
362816|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
362817|NCT00661648|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
362818|NCT00661661|Drug|CP-690,550|5 mg BID up to 10 mg BID until launch
362819|NCT00661674|Drug|palonosetron|Over 3 study visits, patients will receive one of the following treatment regimens:
Placebo saline IV and sugar pill
0.75 mg Palonosetron IV and sugar pill
0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
363122|NCT00654069|Drug|Oxycodone HCl/Niacin Tablets 5/30 mg|Tablets 5/30 mg, 2 tablets every 6 hours for 48 hours
363123|NCT00004916|Drug|ifosfamide|
363124|NCT00654069|Drug|Oxycodone HCl/Niacin 7.5/30 mg|Tablets 7.5/30 mg, 2 tablets every 6 hours for 48 hours
363125|NCT00654069|Drug|Placebo|Tablets, 2 tablets every 6 hours for 48 hours
363126|NCT00004928|Dietary Supplement|calcitriol|
363127|NCT00656357|Drug|Saline|IV Cocaine Placebo
363128|NCT00656357|Drug|SYN117 160 mg|SYN117 160 mg
362136|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
362137|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks.
362138|NCT00636246|Drug|Placebo|Tablets, orally once per day for 8 weeks
362466|NCT00668239|Procedure|laser therapy|pan fotocoaglulation by laser therapy
362467|NCT00668265|Drug|Quetiapine|Dosage is 50 - 300 mg, once daily, at bedtime.
362468|NCT00005065|Drug|paclitaxel|Given IV
362469|NCT00668278|Device|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
362470|NCT00668278|Device|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
362471|NCT00668278|Other|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
362472|NCT00668304|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
362473|NCT00668317|Drug|Omeprazole|20 mg BD tablet 8 weeks duration
362474|NCT00668317|Drug|Ranitidine|300 mg od nocte tablet 8weeks duration
362475|NCT00668330|Drug|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
362476|NCT00668330|Drug|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
362477|NCT00668343|Drug|simvastatin|40 mg/ day
362478|NCT00668343|Drug|placebo|80 mg /day
362479|NCT00005065|Drug|carboplatin|Given IV
362480|NCT00668356|Drug|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
362481|NCT00668356|Drug|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
362482|NCT00668369|Procedure|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
351173|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
351174|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
351175|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
351176|NCT00599924|Drug|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
351177|NCT00599937|Drug|ATRA|early introduction of ATRA
351178|NCT00599937|Drug|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
351179|NCT00599950|Drug|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
351180|NCT00599963|Drug|paricalcitol|paricalcitol 1 mg/day
351181|NCT00599976|Procedure|Pulmonary vein isolation|Pulmonary vein isolation
351182|NCT00004218|Drug|prednisolone|
351183|NCT00599989|Procedure|adjuvant therapy|
351184|NCT00599989|Procedure|conventional surgery|
351185|NCT00599989|Radiation|3-dimensional conformal radiation therapy|
351186|NCT00599989|Radiation|brachytherapy|
351187|NCT00599989|Radiation|intracavitary balloon brachytherapy|
345817|NCT00482833|Drug|all-trans retinoic acid|Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.
Consolidation
st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.
nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.
rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.
Maintenance therapy
ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed.
345818|NCT00482833|Drug|all-trans retinoic acid (ATRA)|Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.
Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26).
350879|NCT00670462|Behavioral|weight loss intervention|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
350880|NCT00670475|Drug|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
350881|NCT00670475|Dietary Supplement|Olive Oil|virgin olive oil prepared directly from olive fruit from "olive gardens of north of iran, Gilan province" will packaged in a 60 g anonymous tubes.
350882|NCT00670488|Drug|MK2206|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 30 mg, 60 mg, 75 mg, and 90 mg on a schedule of once daily every other day in repeating 4 week cycles.
350883|NCT00670488|Drug|MK2206|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 90 mg, 135 mg, 200 mg, 250 mg, and 300 mg on a schedule of once weekly in repeating 4 week cycles.
350884|NCT00005081|Drug|O6-benzylguanine|
350885|NCT00670501|Drug|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
350886|NCT00670501|Drug|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
350887|NCT00670501|Drug|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
350888|NCT00670501|Drug|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
350889|NCT00670501|Drug|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
350890|NCT00670514|Behavioral|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
350891|NCT00670514|Behavioral|Fimpa dig fri|One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program ("Fimpa dig fri"). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires.
350892|NCT00670527|Procedure|[18F] Fluorocholine PET/CT|The patients fast 6 hours before the [18F]Fluorocholine PET/CT scan. [18F]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.
The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark.
350893|NCT00670540|Other|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
350202|NCT00501462|Drug|GSK189075|single 250 mg dose of drug
350203|NCT00501475|Drug|NAC Bicarbonate|
350204|NCT00501488|Drug|rosiglitazone|
350205|NCT00501501|Procedure|Cesarean section|
350206|NCT00501501|Procedure|Vaginal delivery|
350207|NCT00501514|Drug|Growth hormone|
350208|NCT00003715|Biological|autologous tumor cell vaccine|
350209|NCT00501527|Biological|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
350210|NCT00501527|Other|Placebo|Placebo 2 drops daily
350211|NCT00501540|Drug|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
350555|NCT00493649|Drug|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
350556|NCT00003671|Drug|cytarabine|
350557|NCT00493649|Drug|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
350558|NCT00493662|Drug|Polyethylene Glycol 400 0.4%|
350559|NCT00493662|Drug|Propylene Glycol 0.3%|
350560|NCT00493662|Drug|0.15% sodium Hyaluronate|
350561|NCT00493662|Drug|sodium chloride|
350562|NCT00493662|Drug|sodium phosphate monobasic|
350563|NCT00493675|Procedure|endoscopic bile duct stenting|
350564|NCT00493688|Other|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
349857|NCT00506935|Drug|GVG|5 grams GVG
349858|NCT00506935|Drug|placebo|placebo
349859|NCT00506948|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
349860|NCT00506948|Drug|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
349861|NCT00506948|Drug|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
349862|NCT00506948|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
349863|NCT00003742|Drug|irinotecan hydrochloride|
349864|NCT00506961|Drug|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
349865|NCT00462917|Behavioral|AD-only info, in-person disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.
Genetic counselors communicate results to participants during an in-person disclosure session.
349866|NCT00462917|Behavioral|Pleiotropic info, phone disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.
Genetic counselors communicate results to participants during a telephone disclosure session.
349867|NCT00462917|Behavioral|AD-only info, phone disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.
Genetic counselors communicate results to participants during an in-person disclosure session.
349868|NCT00462943|Drug|Omacetaxine mepesuccinate|Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days.
Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days.
Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.
349869|NCT00462956|Drug|Tykerb|lapatinib 1500mg daily
349870|NCT00462969|Procedure|Sonohysterography|Sonohysterography
349871|NCT00462982|Drug|sunitinib malate|
349872|NCT00462995|Drug|Erlotinib|150mg once a day for 28 days
349873|NCT00462995|Drug|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
349874|NCT00463008|Drug|methotrexate|
349875|NCT00000530|Behavioral|biofeedback (psychology)|
349876|NCT00003543|Drug|streptozocin|
349538|NCT00472030|Drug|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
349539|NCT00472030|Drug|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
349540|NCT00472043|Procedure|PDT with Metvix 160 mg/g cream and Placebo cream|
349541|NCT00003583|Drug|cisplatin|
349542|NCT00472056|Drug|Carmustine|300 mg/m^2 IV for 1 Day
349543|NCT00472056|Drug|Etoposide|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
349544|NCT00472056|Drug|Cytarabine|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
349545|NCT00472056|Drug|Melphalan|140 mg/m^2 IV x 1 Day
349546|NCT00472056|Drug|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion.
349877|NCT00463008|Other|pharmacological study|
349878|NCT00463021|Drug|Hectorol (doxercalciferol capsules)|
349879|NCT00463021|Drug|Zemplar (paricalcitol injection)|
349880|NCT00463034|Genetic|microarray analysis|
349881|NCT00463034|Genetic|polymerase chain reaction|
349882|NCT00463034|Genetic|polymorphism analysis|
349883|NCT00463034|Other|high performance liquid chromatography|
349884|NCT00463034|Other|immunohistochemistry staining method|
349885|NCT00463034|Other|laboratory biomarker analysis|
349886|NCT00463034|Other|questionnaire administration|
349887|NCT00003543|Drug|vincristine sulfate|
348836|NCT00487305|Biological|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
348837|NCT00487318|Drug|standard of care|peginterferon/RBV
348838|NCT00487318|Drug|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
349183|NCT00481377|Procedure|ablation|
349184|NCT00481390|Procedure|Cheek cells sample|Cheek cells sample
349185|NCT00481390|Procedure|Blood sample|Blood sample
349186|NCT00003622|Drug|paclitaxel|
349187|NCT00481403|Behavioral|Microarray analysis|Microarray analysis
349188|NCT00481403|Behavioral|Microarray|Microarray
349189|NCT00481416|Device|PillCam Eso|
349190|NCT00481429|Drug|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
349191|NCT00481442|Drug|Phenylephrine|
349192|NCT00481455|Drug|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
349193|NCT00481455|Drug|Temozolomide|Fixed dose
349194|NCT00481481|Drug|tacrolimus|immunosuppression
349195|NCT00481507|Drug|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
349196|NCT00481507|Drug|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
349197|NCT00003622|Drug|vinorelbine tartrate|
349198|NCT00481520|Drug|SAM-531|
349199|NCT00481520|Other|placebo|
348486|NCT00495781|Procedure|CHr (laboratory parameter, functional iron deficiency)|
348487|NCT00495781|Procedure|RET-HE (laboratory parameter, functional iron deficiency)|
348488|NCT00495794|Behavioral|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
348489|NCT00495807|Behavioral|No Words|Without any words was given during pain management
348490|NCT00495807|Behavioral|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
348491|NCT00498485|Drug|Xyrem [sodium oxybate]|Volunteers for this study will complete questionnaires about their symptoms and a computerized test to assess their degree of brain fog. They will be randomly assigned to one of two groups, placebo or drug. Volunteers will know what group they are in at end of the study. Only the drug group will receive the medication. The placebo group will receive a substance that looks like the real medicine but with no active ingredients. The medication comes as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
348492|NCT00498511|Procedure|upper gastrointestinal endoscopy, colonoscopy|
348493|NCT00003694|Drug|cytarabine|Given IV
348494|NCT00498524|Device|ICD|Received an ICD
348495|NCT00498524|Device|ICD|Have not received an ICD
348839|NCT00000542|Drug|doxazosin|
348840|NCT00490061|Device|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care
348841|NCT00490061|Procedure|Pet/CT|Standard of Care
348842|NCT00490074|Biological|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
348843|NCT00490074|Biological|NYVAC-C|NYVAC-C 1 ml IM
348844|NCT00490087|Device|Levonorgestrel intrauterine device (IUD)|
348845|NCT00490100|Drug|Increlex|
348846|NCT00490113|Drug|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
347751|NCT00465192|Drug|placebo|
348097|NCT00500565|Drug|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
348098|NCT00500578|Drug|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
348099|NCT00500578|Drug|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
348100|NCT00500591|Behavioral|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
348101|NCT00503750|Drug|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
348102|NCT00503763|Drug|Simvastatin|
348103|NCT00503776|Behavioral|exercise intervention|Patients undergo low weight resistance training.
348104|NCT00503776|Drug|amifostine trihydrate|Given subcutaneously
348105|NCT00503776|Procedure|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
348106|NCT00503789|Procedure|fecal bacteria analysis|ad lib feeding
348107|NCT00503802|Procedure|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
348108|NCT00503802|Procedure|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
348109|NCT00003728|Drug|asparaginase|
348110|NCT00503815|Drug|BLI-800|
348111|NCT00503815|Drug|Polyethylene glycol 3350 based bowel preparation|
348112|NCT00503828|Drug|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
348113|NCT00503828|Drug|naproxen|Naproxen 500 mg/day for 4 weeks
347412|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
347413|NCT00471146|Drug|placebo|placebo
347414|NCT00003578|Procedure|peripheral blood stem cell transplantation|
347415|NCT00471159|Drug|docetaxel|
347416|NCT00471159|Drug|PF-3512676|
347417|NCT00474370|Drug|Placebo|One tablet of placebo once daily.
347418|NCT00474383|Drug|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
347419|NCT00474383|Drug|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
347420|NCT00000538|Behavioral|diet, fat-restricted|
347421|NCT00003592|Drug|paclitaxel|
347422|NCT00474396|Behavioral|Low fat dairy diet|
347423|NCT00474409|Drug|Merislon|
347424|NCT00474422|Behavioral|Proactive assignment to attend a breastfeeding clinic|
347425|NCT00474435|Drug|Emtricitabine/tenofovir/efavirenz|Co-formulated in one tablet (taken once daily by oral administration):
emtricitabine 200 mg
tenofovir DF 300 mg
efavirenz 600 mg
347752|NCT00465205|Drug|Valacyclovir|500mg oral twice daily
347753|NCT00465205|Drug|Matching Placebo|500 mg oral twice daily
347754|NCT00465218|Procedure|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
347755|NCT00465231|Drug|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
347756|NCT00465231|Drug|preservative free saline|10mL saline solution
347757|NCT00003555|Drug|paclitaxel|
347758|NCT00465244|Drug|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
347759|NCT00465244|Drug|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
347059|NCT00480558|Biological|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10^7
347060|NCT00480571|Drug|BL-1020|BL-1020 Low Dose
347061|NCT00480571|Drug|BL 1020 High Dose|BL 1020 High Dose
347062|NCT00480584|Drug|gemcitabine|Levels 1 through 4: 1000 mg/m^2
347063|NCT00480584|Drug|capecitabine|Level 1: 500 mg/m^2; Level 2: 825 mg/m^2; Level 3: 1000 mg/m^2; Level 4: 1250 mg/m^2
347064|NCT00480584|Drug|erlotinib|Levels 1 through 4: 100 mg
347065|NCT00483366|Drug|gemcitabine hydrochloride|Dose level Gemcitabine
-1 400 mg/m2 0 450 mg/m2
550 mg/m2
550 mg/m2
675 mg/m2
675 mg/m2
825 mg/m2
825 mg/m2
1000 mg/m2
347066|NCT00483366|Drug|imatinib mesylate|Dose level Imatinib
-1 400 mg/d 0 400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d
347067|NCT00483366|Genetic|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
347068|NCT00483366|Genetic|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
347069|NCT00483366|Genetic|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
347070|NCT00483379|Biological|alglucosidase alfa|intravenous infusion
347071|NCT00003632|Drug|cytarabine|
347072|NCT00483392|Drug|metformin, rosiglitazone|
347073|NCT00483405|Biological|cetuximab|250 mg/m2, intravenously, once per week
347074|NCT00483405|Drug|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
347075|NCT00483405|Drug|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
347076|NCT00483431|Dietary Supplement|no vitamin K|no vitamin K
346377|NCT00497653|Drug|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
346378|NCT00497653|Drug|Placebo|Placebo, twice daily for 6 weeks
346379|NCT00497666|Drug|Rosiglitasone (retrospective observation)|
346380|NCT00497679|Drug|AZD1152|7-day continuous intravenous infusion
346381|NCT00497692|Drug|Lactoserum|
346382|NCT00497718|Procedure|Chiropractic Manipulation|
346383|NCT00499720|Drug|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
346384|NCT00499733|Drug|cyclophosphamide|
346385|NCT00499733|Other|laboratory biomarker analysis|
346386|NCT00499733|Procedure|biopsy|
346387|NCT00499733|Procedure|cryosurgery|
346388|NCT00499746|Drug|tramadol|oral dose, once per day
346389|NCT00499746|Drug|hydromorphone|oral dose, once per day
346390|NCT00003701|Drug|paclitaxel|
346391|NCT00499746|Drug|methylphenidate|oral dose, once per day
346723|NCT00492232|Drug|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
346724|NCT00492232|Drug|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
346725|NCT00492245|Procedure|PTK with mitomycin in Adenoviral Opacities|
346726|NCT00492258|Drug|sorafenib tosylate|
346727|NCT00492258|Procedure|adjuvant therapy|
346728|NCT00492271|Drug|Friulimicin B|Intravenous, once daily, single dose
346729|NCT00492284|Drug|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
346730|NCT00492284|Drug|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
346045|NCT00505609|Behavioral|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
346046|NCT00505622|Drug|Perampanel|
346047|NCT00505635|Drug|Temozolomide|250 mg/m^2 By Mouth Every 4 Hours x 3 Doses On Day 1
346048|NCT00003732|Drug|paclitaxel|
346049|NCT00505635|Drug|Velban|1.5 mg/m^2 By Vein Over 15-30 Minutes On Days 1-4
346050|NCT00505635|Drug|Cisplatin|20 mg/m^2 By Vein Over 45-120 Minutes On Days 1-4
346051|NCT00505635|Drug|Interleukin-2|9 MIU/m^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
346052|NCT00505635|Drug|Intron-A|5 mu/m^2 Subcutaneously (Under the skin) Daily On Days 1-5
346053|NCT00505635|Drug|Thalidomide|400 mg By Mouth Daily
346054|NCT00505648|Drug|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
346055|NCT00461396|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
346056|NCT00003537|Drug|antineoplaston A10|
346057|NCT00461409|Drug|Intravenous levetiracetam|IV levetiracetam escalating to 40mg/kg load and daily 10mg/kg maintenance
346058|NCT00461422|Drug|Ganirelix|sc injection of Ganirelix 0.25 mg per day
346059|NCT00461435|Procedure|hyperbaric oxygen therapy|
346060|NCT00461448|Dietary Supplement|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
346061|NCT00461461|Procedure|meeting nurses / physicians, quality improvement sessions|For each iatrogenic indicator, the interventions are:
Meeting with the ICU staff to discuss the epidemiology of patients on each theme.
Pocket card with guidelines on the theme and ICU protocol in each study ICU.
Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject.
346062|NCT00461474|Behavioral|Shoulder strengthening exercises|
346063|NCT00461474|Behavioral|Movement Optimization|
351081|NCT00628680|Device|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
351082|NCT00628680|Drug|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
351083|NCT00628706|Drug|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
351084|NCT00628719|Drug|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
351085|NCT00628719|Drug|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
351086|NCT00628732|Drug|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
345705|NCT00467519|Biological|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
345706|NCT00467545|Drug|telbivudine|
345707|NCT00467558|Drug|Naltrexone|daily
345708|NCT00467558|Drug|Sugar pill|daily
345709|NCT00467571|Drug|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
345710|NCT00470236|Radiation|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
345711|NCT00470236|Radiation|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
345712|NCT00003577|Procedure|adjuvant therapy|
345713|NCT00470236|Radiation|Standard WB fractionation+Boost|Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week.
345714|NCT00470236|Radiation|Shorter WB fractionation + Boost|Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week.
345715|NCT00470249|Drug|carboplatin|
345716|NCT00470249|Drug|gemcitabine hydrochloride|
345717|NCT00470262|Drug|Fenofibrate|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
345718|NCT00470262|Drug|Pioglitazone and Fenofibrate|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
363449|NCT00649220|Drug|Memantine|memantine tablets, twice a day (bid), for 20 weeks
363450|NCT00649233|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
363451|NCT00649233|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
363452|NCT00649259|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
363453|NCT00649259|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
363454|NCT00649272|Drug|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
363455|NCT00649272|Drug|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
363456|NCT00649285|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
363457|NCT00004900|Biological|filgrastim|
363776|NCT00641979|Drug|Placebo|
363777|NCT00642005|Procedure|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
363778|NCT00642005|Procedure|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
363779|NCT00644150|Drug|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
363780|NCT00644150|Behavioral|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
363781|NCT00644163|Behavioral|Eban HIV/STD Risk Reduction Intervention|The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
363782|NCT00000641|Drug|Ciprofloxacin hydrochloride|
363783|NCT00004875|Drug|enoxaparin|
363129|NCT00656370|Drug|recombinant human hyaluronidase|150 Units in 1mL
363130|NCT00656383|Other|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
363131|NCT00656383|Other|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
363132|NCT00656396|Device|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
363133|NCT00656396|Procedure|Control Intervention|Standard care
363134|NCT00656409|Drug|Conjugated pneumococcal vaccine (Prevenar)|
363135|NCT00656422|Drug|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
363136|NCT00656422|Drug|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
363137|NCT00004928|Drug|zoledronic acid|
363138|NCT00656435|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
363139|NCT00656448|Drug|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
363140|NCT00656461|Drug|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
363141|NCT00656474|Drug|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
363142|NCT00656474|Drug|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
363143|NCT00656487|Drug|rimonabant|double blind, placebo controlled, single dose
363144|NCT00656487|Drug|placebo|placebo
363145|NCT00656500|Behavioral|Standard brief advice|Brief general assistance with smoking cessation
363458|NCT00649285|Drug|Macrobid® Capsules 100 mg|100mg, single dose fed
363459|NCT00649298|Procedure|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
363460|NCT00649311|Drug|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
362483|NCT00668382|Biological|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
362484|NCT00668395|Drug|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
362485|NCT00668408|Other|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
362486|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
362487|NCT00631696|Drug|Pregabalin|pregabalin 600 mg given twice a day
362820|NCT00661674|Drug|hydroxyzine|Over 3 study visits, patients will receive one of the following treatment regimens:
Placebo saline IV and sugar pill
0.75 mg Palonosetron IV and sugar pill
0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
362821|NCT00661687|Device|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
362822|NCT00661687|Device|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
362823|NCT00663910|Procedure|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
362824|NCT00663910|Procedure|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
362825|NCT00663910|Procedure|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
362826|NCT00663923|Procedure|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
362827|NCT00663936|Drug|T-817MA|224 mg T-817 MA once daily
362828|NCT00005026|Drug|topotecan hydrochloride|
362829|NCT00663936|Drug|Placebo|Placebo once daily
362830|NCT00663949|Drug|Captopril|25 mg captopril tablet q8h
362831|NCT00663949|Drug|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
362832|NCT00663962|Drug|Pregabalin|PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
345819|NCT00482846|Biological|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
345820|NCT00482846|Drug|melphalan|Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:
Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;
Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:
Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;
345821|NCT00482846|Other|questionnaire administration|Day -5 to Day +28
345822|NCT00482846|Procedure|autologous peripheral blood stem cell transplantation|Day 0
345823|NCT00482846|Other|quality-of-life assessment|Day -5 to Day +28
345824|NCT00482872|Genetic|gene expression analysis|
345825|NCT00482872|Genetic|mutation analysis|
345826|NCT00000152|Drug|Beta-Carotene|
345827|NCT00000541|Drug|vitamin E|
345828|NCT00003631|Drug|ifosfamide|
345829|NCT00482872|Genetic|polymerase chain reaction|
345830|NCT00482872|Genetic|polymorphism analysis|
345831|NCT00482872|Other|flow cytometry|
345832|NCT00482872|Other|laboratory biomarker analysis|
345833|NCT00482898|Drug|MK0359|
345834|NCT00482911|Drug|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
345835|NCT00482911|Drug|lenalidomide|10 mg by mouth once daily on days 1-28.
345836|NCT00482911|Drug|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
346173|NCT00473863|Procedure|Coronary Computed Tomographic Angiography|CCTA will be performed
346174|NCT00473876|Drug|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
346175|NCT00473876|Drug|Matched Placebo (Capsules)|Similar dosing regime as active comparator
346176|NCT00473889|Drug|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
351188|NCT00599989|Radiation|proton beam radiation therapy|
351189|NCT00004228|Drug|methotrexate|Given IV
351190|NCT00602277|Biological|Wild-type Reovirus|
351191|NCT00602290|Drug|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were > 2 until treatment completion.
351192|NCT00602290|Drug|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
351193|NCT00602290|Drug|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
351194|NCT00602303|Drug|Torsemide|
351195|NCT00602316|Drug|gadolinium-chelate|
351196|NCT00602316|Procedure|conventional surgery|
351197|NCT00602316|Procedure|magnetic resonance imaging|
351198|NCT00602316|Procedure|magnetic resonance spectroscopic imaging|
351199|NCT00602329|Biological|bevacizumab|Given IV
351200|NCT00004228|Drug|prednisone|Given IV
351201|NCT00602329|Drug|fluorouracil|Given IV
351202|NCT00602329|Drug|leucovorin calcium|Given IV
351203|NCT00602329|Drug|oxaliplatin|Given IV
351204|NCT00602342|Drug|Terbinafine|
351205|NCT00602355|Drug|Sertraline|Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific "mother-crafting" techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care.
351206|NCT00602355|Drug|Placebo|Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific "mother-crafting" techniques as those taking sertraline.
350565|NCT00493701|Behavioral|High Fat Diet|Daily eating
350566|NCT00493701|Behavioral|Low Fat Diet|Life style eating habits
350567|NCT00003671|Drug|daunorubicin hydrochloride|
350568|NCT00493714|Behavioral|Questionnaire|Surveys lasting 30 minutes or more.
350569|NCT00493727|Drug|N-acetylcysteine(Mucomyst)|
350570|NCT00493740|Procedure|chocolate cake|
350571|NCT00493753|Procedure|Acupuncture|
350572|NCT00493766|Drug|LBH589|
350573|NCT00493779|Procedure|Blood Collection|4 weeks
350574|NCT00493792|Device|Stryker X3 crosslink|Radiographs, questionnaires and an exam will be obtained at key post-surgical follow up dates. 3months, 2years, 5 years, 7 years and 10 years.
350575|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization
350894|NCT00670553|Drug|panobinostat|
350895|NCT00005081|Drug|carmustine|
350896|NCT00670566|Drug|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
350897|NCT00670592|Drug|HCD122|
350898|NCT00670605|Other|medical chart review|
350899|NCT00609960|Drug|midazolam|midazolam
350900|NCT00609973|Drug|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
350901|NCT00609973|Drug|Placebo|Placebo bid for 6 months
350902|NCT00609986|Drug|insulin|The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.
After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.
Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140.
350212|NCT00501566|Drug|satavaptan (SR121463B)|
350213|NCT00501579|Drug|Difluprednate|
350214|NCT00501579|Drug|Prednisolone Acetate|
350215|NCT00501592|Drug|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
350216|NCT00501592|Drug|Placebo|Placebo
350217|NCT00501605|Drug|AZD2171|
350218|NCT00501618|Drug|Fazaclo|single-arm
350219|NCT00000552|Procedure|coronary artery bypass|
350220|NCT00003715|Biological|recombinant interferon alfa|
350221|NCT00501631|Drug|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
350222|NCT00501631|Drug|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
350223|NCT00501644|Drug|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
350224|NCT00501644|Drug|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
350225|NCT00501644|Drug|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
350226|NCT00501657|Drug|Sitagliptin|100mg mane for 2 days
350227|NCT00501657|Drug|Placebo|100mg mane for 2 days
350228|NCT00501670|Procedure|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
350229|NCT00501670|Procedure|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
350230|NCT00504439|Drug|SB-656933|
350231|NCT00003728|Drug|mitoxantrone hydrochloride|
350232|NCT00504452|Drug|KP-1461|Oral dosage, 1600 mg bid for 124 days
350233|NCT00504465|Drug|dinoprostone|
350234|NCT00504478|Dietary Supplement|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
351088|NCT00000633|Biological|Hepatitis B Vaccine (Recombinant)|
351089|NCT00004637|Drug|Vitamin E|
351090|NCT00628758|Drug|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
351091|NCT00628758|Drug|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
351092|NCT00628771|Behavioral|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
351093|NCT00628771|Behavioral|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
351094|NCT00631059|Other|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
351095|NCT00631072|Biological|in vitro expanded autologous invariant natural killer T cells|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
351096|NCT00631072|Drug|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
351097|NCT00631085|Drug|gamma tocopherol|Maxi Gamma softgels 1200mg QD
351098|NCT00631098|Procedure|venous cannulation|External jugular and cubital vein cannulation
351099|NCT00004688|Drug|carmustine|
351100|NCT00631111|Drug|effervescent ibuprofen tablets|
351101|NCT00631111|Drug|effervescent Aspirin plus Vitamin C tablets|
351102|NCT00631111|Drug|ibuprofen tablets|
351103|NCT00631111|Drug|placebo|
351104|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
351105|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
351106|NCT00631137|Drug|testosterone gel|
350453|NCT00481988|Device|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
350454|NCT00481988|Device|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
350455|NCT00481988|Device|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
350456|NCT00481988|Device|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
350457|NCT00482001|Drug|donepezil|donepezil 5mg, once daily for 2 weeks
350458|NCT00482001|Drug|Placebo (cornstarch)|1 capsule daily for 2 weeks
350459|NCT00482014|Drug|pemetrexed|Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles
Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles
Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase
350460|NCT00482014|Drug|cisplatin|Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43
Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles
350783|NCT00472810|Drug|MMC in glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
350784|NCT00472823|Dietary Supplement|Vitamin D3|Orally for one year
350785|NCT00472823|Dietary Supplement|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
350786|NCT00003585|Drug|fluorouracil|
350787|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
350788|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
350789|NCT00472849|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
350790|NCT00472849|Drug|Fludarabine|Fludarabine 30 mg/m^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
350791|NCT00472849|Drug|Cytarabine|Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
350118|NCT00490698|Drug|Zoledronate|4 mg IV Once Every 4 Weeks
350119|NCT00490698|Drug|Atorvastatin|20 mg PO Daily
350120|NCT00003659|Biological|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients > 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
350121|NCT00490711|Drug|gemcitabine|
350122|NCT00490711|Drug|carboplatin|
350123|NCT00490711|Drug|paclitaxel|
350124|NCT00490724|Drug|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
350125|NCT00490724|Drug|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
350126|NCT00490724|Drug|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
350127|NCT00490737|Drug|daptomycin|6mg/kg i.v.; every 48 hours for a total of 3 doses
350128|NCT00490750|Procedure|Dor fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
350129|NCT00490750|Procedure|Toupet fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
350130|NCT00490763|Behavioral|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
350131|NCT00003659|Biological|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
350132|NCT00490776|Drug|LBH589|
350133|NCT00490789|Drug|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
350134|NCT00490802|Drug|Oxytocin|Intranasal Oxytocin
350461|NCT00482014|Drug|carboplatin|Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter*minute (mg/mL*min), administered intravenously, Days 1, 8, 22, 29 and 43
Phase 2 - dosed at AUC 5 mg/mL*min, administered intravenously, every 21 days for 3 cycles
349436|NCT00506675|Device|Patching|two hours of daily patching for 4 weeks, then no treatment
349437|NCT00506675|Drug|Atropine|once weekly atropine for 4 weeks, then no treatment
349438|NCT00003739|Biological|filgrastim|
349439|NCT00506688|Drug|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
349440|NCT00506688|Drug|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
349441|NCT00506701|Drug|Tadalafil|40 mg tablet
349442|NCT00506714|Device|single point cane|Adjustable single point cane with SureGrip handle
349443|NCT00506727|Drug|Mixed amphetamine salts (ADDERALL XR)|
349761|NCT00498979|Drug|vinblastine|vinblastine
349762|NCT00498992|Dietary Supplement|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
349763|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
349764|NCT00000549|Drug|progestins|
349765|NCT00003696|Drug|paclitaxel|
349766|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
349767|NCT00499018|Drug|Rituximab|375 mg/m2 day 1
349768|NCT00499018|Drug|Ciclofosfamide|1200 mg/m2 day 1
349769|NCT00499018|Drug|Doxorubicina|70 mg/m2 day 1
349770|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
349771|NCT00499018|Drug|Prednisone|100 mg day g 1-5
349772|NCT00499018|Drug|Pegfilgrastim|6 mg day +1
349773|NCT00499018|Drug|Mitoxantrone|8 mg/m2/days 1-3
349774|NCT00499018|Drug|ARA-C|2000 mg/m2/12h day 1 - 3
349775|NCT00499018|Drug|Lenograstim|5 μg/Kg/days +2
349776|NCT00003697|Drug|vadimezan|
351107|NCT00631137|Procedure|questionnaire administration|
351108|NCT00631150|Drug|Levetiracetam (Keppra)|
345728|NCT00470314|Drug|L-Ornithine L-Aspartate|
345729|NCT00470340|Drug|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
345730|NCT00470353|Dietary Supplement|calcium carbonate|
345731|NCT00470353|Dietary Supplement|cholecalciferol|
345732|NCT00470353|Other|immunohistochemistry staining method|
345733|NCT00470353|Other|laboratory biomarker analysis|
345734|NCT00003578|Drug|CHOP regimen|
345735|NCT00470353|Other|pharmacological study|
345736|NCT00470353|Procedure|biopsy|
345737|NCT00470366|Biological|pegfilgrastim|
345738|NCT00470366|Drug|cisplatin|
345739|NCT00470366|Drug|ifosfamide|
345740|NCT00003587|Drug|vinorelbine|IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3
345741|NCT00473551|Procedure|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
345742|NCT00473564|Procedure|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
345743|NCT00473577|Drug|CRA-24781|
345744|NCT00473590|Drug|Bevacizumab|15 mg/kg administered by intravenous infusion
345745|NCT00473590|Drug|Bortezomib|1.3 mg/m^2 administered by intravenous bolus injection
345746|NCT00473590|Drug|placebo|Intravenous repeating dose
345747|NCT00473603|Drug|lipid/heparin or saline/heparin infusion|
345748|NCT00473616|Drug|AZD7762|intravenous infusion
345749|NCT00473616|Drug|Irinotecan|intravenous injection
350792|NCT00472849|Drug|Rituximab|Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).
350793|NCT00475787|Procedure|Detuned Ultrasound|US machine is turned on and set at "0 w/cm2"
350794|NCT00475800|Drug|Lumiracoxib|
350795|NCT00475813|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
350796|NCT00003596|Drug|fluorouracil|
350797|NCT00475826|Drug|Statins and Ezetimibe|
350798|NCT00475839|Device|Tension-free Vaginal Tape|
350799|NCT00475839|Device|Monarc sub-fascial hammock|
350800|NCT00475852|Drug|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
350801|NCT00475852|Drug|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
350802|NCT00475865|Drug|Teriflunomide|Film-coated tablet
Oral administration
350803|NCT00475865|Drug|Placebo (for teriflunomide)|Film-coated tablet
Oral administration
350804|NCT00475865|Drug|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
350805|NCT00475878|Drug|escitalopram|10mg escitalopram/day for 3 months
351109|NCT00631163|Drug|Deferasirox (ICL670)|The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
351110|NCT00004688|Drug|mercaptopurine|
351111|NCT00631176|Behavioral|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
351112|NCT00631189|Drug|Rosuvastatin|5mg oral
351113|NCT00631189|Drug|Pravastatin|40mg oral
351114|NCT00631189|Drug|Atorvastatin|10mg oral
351115|NCT00631202|Drug|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
350462|NCT00003625|Drug|etoposide|
350463|NCT00482014|Radiation|radiation therapy|Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51
Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45
350464|NCT00482027|Biological|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
350465|NCT00482040|Device|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
350466|NCT00482053|Procedure|Total lymphoid irradiation (TLI)|
350467|NCT00482053|Drug|Anti-thymocyte globulin (ATG)|
350468|NCT00484783|Procedure|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
350469|NCT00484796|Procedure|MED-SEP|intraoperative neurophysiological monitoring
350470|NCT00484796|Procedure|TRI-SEP|intraoperative neurophysiologic monitoring
350471|NCT00484796|Procedure|neuropsychological tests|neurological short- and longterm outcome
350472|NCT00484809|Drug|Enbrel (Etanercept)|
350473|NCT00484822|Drug|Bemiparina Sodica|3.500 UI/día.
350474|NCT00484822|Drug|Heparina Cálcica|10.000 UI/día.
350475|NCT00003638|Drug|cyclophosphamide|
350476|NCT00484835|Procedure|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
350477|NCT00484848|Device|Vortex port and Celsite port|
350478|NCT00484874|Drug|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
350479|NCT00484900|Drug|Co-Arinate FDC|
350480|NCT00484900|Drug|Coartem|
350481|NCT00484913|Procedure|abdominal hot compress|
350482|NCT00484926|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
350483|NCT00484926|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
349777|NCT00499018|Drug|BCNU|300 mg/m2 day -7
349778|NCT00499018|Drug|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
349779|NCT00499018|Drug|VP-16|100 mg/m2/12h days -6,-5,-4,-3
349780|NCT00499018|Procedure|ASCT|PBSC Reinfusion
349781|NCT00499018|Drug|Ciclofosfamide|750 mg/m2 day 1
349782|NCT00499018|Drug|Doxorubicina|50 mg/m2 day 1
349783|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
349784|NCT00499031|Biological|Cetuximab|Given IV
349785|NCT00501215|Behavioral|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
349786|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
349787|NCT00501215|Behavioral|Polysomnography (PSG)|2 overnight sleep tests
Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery
Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview
350135|NCT00490802|Drug|Placebo|Placebo Comparator
350136|NCT00490815|Drug|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
350137|NCT00493467|Drug|Ibritumomab Tiuxetan (Zevalin)|111In Zevalin (5 mCi of ^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.
90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8.
350138|NCT00493467|Drug|Rituximab|250 mg/m^2 Intravenously Over 4-6 Hours On Days 1 and 8.
350139|NCT00003671|Drug|asparaginase|
350140|NCT00493480|Drug|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
350141|NCT00493480|Drug|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
350142|NCT00493493|Procedure|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
350143|NCT00493506|Drug|ProAlgaZyme|
350144|NCT00493519|Procedure|chocolate cake|
350145|NCT00493532|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
345750|NCT00473642|Drug|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
345751|NCT00003588|Biological|Ad5CMV-p53 gene|
345752|NCT00473642|Drug|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
345753|NCT00473642|Drug|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
345754|NCT00473655|Drug|rosuvastatin|10mg or 20mg
346084|NCT00464451|Drug|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
346085|NCT00464451|Drug|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
346086|NCT00464464|Behavioral|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
346087|NCT00464490|Drug|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
346088|NCT00464503|Drug|Rosuvastatin-Crestor|
346089|NCT00003553|Drug|cyclophosphamide|Given IV
346090|NCT00464503|Drug|Pravastatin-Pravasine|
346091|NCT00464516|Drug|placebo|once daily for 14 days orally
346092|NCT00464516|Drug|Estetrol|once daily for 14 days orally
346093|NCT00464529|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
346094|NCT00464542|Drug|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
346095|NCT00464555|Procedure|Islet transplant|Transplantation of pancreatic islet cells
346096|NCT00464555|Drug|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
346097|NCT00464555|Drug|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
346098|NCT00464555|Drug|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
346099|NCT00464555|Drug|Sirolimus|Maintenance immunosuppressive therapy
351116|NCT00631215|Procedure|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
351117|NCT00631228|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
351118|NCT00631241|Procedure|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
351119|NCT00594087|Other|placebo|2 mg or 3 mg at bedtime
351120|NCT00594100|Device|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
351121|NCT00004196|Drug|Observation|
351122|NCT00594113|Other|Touch 2 Screen|Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of "implementation intentions," an advanced planning model taken from the Theory of Planned Behavior
351123|NCT00594113|Other|Touch screen intervention|Touch screen intervention
351124|NCT00594126|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
351125|NCT00594139|Biological|Autologous neobladder construct|provision of an autologous neo-bladder construct
351126|NCT00594152|Drug|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
351127|NCT00594165|Drug|Rotigotine|Rotigotine trans-dermal patches:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)
Optimal dosing:
During the first year:
The maximum Rotigotine dose allowed is 6 mg/24 hours.
After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.
345755|NCT00473668|Biological|DTPw-HBV/Hib Kft GSK32327A|Intramuscular injection, 1 dose
345756|NCT00473668|Biological|DTPw HBV/Hib2.5 GSK357939A|Intramuscular injection, 1 dose
345757|NCT00473668|Biological|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
345758|NCT00473681|Behavioral|Self-Help Intervention Program-High Blood Pressure|
345759|NCT00473694|Drug|sugammadex|Subjects received rocuronium or vecuronium in randomized order with single and maintenance (if applicable) dosing according to local treatment practice. After the last dose of rocuronium or vecuronium, a dose of 4.0 mg/kg Sugammadex (Org 25969) was to be administered.
345760|NCT00473694|Drug|neostigmine|Subjects received rocuronium or vecuronium in randomized order with single and maintenance (if applicable) dosing according to local treatment practice. After the last dose of rocuronium or vecuronium, a dose of 70 μg/kg neostigmine was to be administered. A maximum of 5 mg neostigmine was to be administered.
350484|NCT00484939|Drug|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
350806|NCT00475878|Drug|placebo|placebo capsule/day for 3 months
350807|NCT00000539|Drug|pravastatin|
350808|NCT00003596|Drug|mitomycin C|
350809|NCT00475904|Drug|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
350810|NCT00475904|Drug|Gabapentin Capsules|1800mg/day capsules for 4 weeks
350811|NCT00475904|Drug|placebo|placebo cream and caps
350812|NCT00475917|Drug|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
350813|NCT00475917|Drug|Gemcitabine|once-weekly 30-minute IV infusion
350814|NCT00475930|Drug|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
350815|NCT00475930|Drug|Comfort Bath cloths (placebo cloths)|self applied three times weekly
350816|NCT00475956|Drug|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
350817|NCT00475956|Drug|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
350818|NCT00475969|Drug|duloxetine|
350819|NCT00003596|Radiation|radiation therapy|
350820|NCT00475969|Drug|placebo|
350821|NCT00475982|Behavioral|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
350822|NCT00475982|Other|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
350823|NCT00478985|Behavioral|Imatinib ending|Interruption of the treatment by Imatinib
350824|NCT00478998|Drug|Tamsulosin|
350825|NCT00479011|Procedure|fluid management based on arterial pulse pressure variation|
350826|NCT00479024|Drug|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
350146|NCT00493545|Biological|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
350147|NCT00493558|Device|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
350148|NCT00493571|Drug|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
350149|NCT00493584|Procedure|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
350150|NCT00003671|Drug|cyclophosphamide|
350151|NCT00493584|Procedure|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
350152|NCT00493610|Drug|N-acetylcysteine(Mucomyst)|
350153|NCT00493623|Drug|Placebo|Placebo i.v. single dose
350485|NCT00484939|Drug|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
350486|NCT00003639|Biological|recombinant interferon alfa|
350487|NCT00484965|Procedure|Coronary stenting|
350488|NCT00484978|Procedure|Stereotactic Radiosurgery|
350489|NCT00484991|Drug|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
350490|NCT00485004|Device|Cutting balloon|Cutting balloon
350491|NCT00485004|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
350492|NCT00485017|Drug|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
350493|NCT00485017|Drug|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
346100|NCT00003553|Drug|cyclosporine|Given IV
346101|NCT00464555|Drug|Tacrolimus|Maintenance immunosuppressive therapy
346102|NCT00467584|Drug|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
346103|NCT00467584|Drug|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
346104|NCT00467584|Drug|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
346105|NCT00467597|Drug|Levodopa (delivered intravenously)|IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full "on" and "off" levodopa cycle while in the inpatient unit.
346430|NCT00505687|Drug|Rotigotine|Rotigotine transdermal patches:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)
Optimal dosing:
The maximum rotigotine dose allowed is 16 mg/24 hours.
346431|NCT00505700|Drug|velcade|
346432|NCT00505700|Drug|Idarubicin|
346433|NCT00003732|Drug|topotecan hydrochloride|
346434|NCT00505700|Drug|Cytarabine|
346435|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
346436|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
346437|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
346438|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
346439|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
346440|NCT00505726|Procedure|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
346441|NCT00505739|Drug|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
345761|NCT00473707|Procedure|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
345762|NCT00003588|Procedure|laparoscopic surgery|
345763|NCT00473707|Procedure|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
345764|NCT00473707|Drug|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
345765|NCT00473707|Drug|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
345766|NCT00476476|Drug|Erlotinib|Orally every day for about 4-6 weeks
345767|NCT00476502|Genetic|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
345768|NCT00476515|Drug|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
345769|NCT00476528|Behavioral|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
345770|NCT00476528|Behavioral|Reality Orientation|A quasiexperimental study
345771|NCT00476541|Drug|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
345772|NCT00476554|Drug|Sapacitabine|Sapacitabine
345773|NCT00003599|Drug|Isotretinoin|Orally daily
345774|NCT00476567|Other|standard|standard antenatal care
346106|NCT00003568|Biological|aldesleukin|
346107|NCT00467610|Drug|Panhematin|
346108|NCT00467636|Procedure|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
346109|NCT00467636|Drug|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI < 30 = 0.1 unit/kg. BMI > 30 = 0.2 unit/kg)
346110|NCT00467649|Drug|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
350827|NCT00479037|Drug|Full Length Parathyroid Hormone, PTH(1-84)|Once daily subcutaneous injection in the abdomen by self administration
350828|NCT00479037|Drug|Strontium Ranelate|The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
350829|NCT00479050|Procedure|chemoembolization ,Radiofrequency ablation|
351128|NCT00594178|Device|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
351129|NCT00594191|Drug|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
351130|NCT00594191|Drug|Placebo|Placebo with the same characteristics of the drug and at the same dose
351131|NCT00594204|Drug|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
351132|NCT00004197|Biological|keyhole limpet hemocyanin|
351133|NCT00594204|Drug|Placebo|matching placebo 1 tablet twice a day for 12 weeks
351134|NCT00594217|Drug|oral micronized P suspension|oral micronized P (100 mg p.o.) suspension
351135|NCT00594217|Other|Placebo|Placebo
351136|NCT00594230|Drug|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
351137|NCT00594243|Behavioral|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
351138|NCT00594243|Other|Wait-list control|No treatment given.
351139|NCT00594256|Drug|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
351140|NCT00594269|Drug|Risperidone|Discontinuation
350494|NCT00485030|Device|Cypher|sirolimus-eluting stent
350495|NCT00485030|Device|Xience-V|everolimus-eluting stent
350496|NCT00485043|Behavioral|Modified T'ai Chi: T'ai Chi for Arthritis|
350497|NCT00487942|Drug|armodafinil|100 mg/day armodafinil
350498|NCT00487942|Drug|armodafinil|200 mg/day armodafinil
350499|NCT00487942|Drug|placebo|placebo
350500|NCT00487955|Procedure|Resting Energy Expenditure examination|
350501|NCT00487968|Drug|eltrombopag|
350502|NCT00487981|Device|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
350503|NCT00487994|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
350504|NCT00487994|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
350505|NCT00003650|Drug|methotrexate|
350506|NCT00487994|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
350507|NCT00488007|Device|Hearing aids used : PHONAK Savia and Valeo|
350508|NCT00488020|Procedure|stem cells transplant|
350830|NCT00479076|Drug|aflibercept (AVE0005)|intravenous infusion
350831|NCT00479076|Drug|S-1|oral administration
350832|NCT00003612|Biological|trastuzumab|
350833|NCT00479089|Drug|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
350834|NCT00479089|Drug|ZD1839|250 mg by mouth daily, without break.
350835|NCT00479089|Drug|Dexamethasone|Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.
Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.
Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment.
347130|NCT00489372|Drug|Se-methyl-seleno-L-cysteine|Given orally
347131|NCT00489372|Other|placebo|Given orally
347132|NCT00489372|Other|pharmacological study|Correlative studies
347133|NCT00003654|Drug|patent blue V dye|
347134|NCT00489372|Other|laboratory biomarker analysis|Correlative studies
347135|NCT00489385|Drug|Albinterferon|
347136|NCT00489385|Drug|Ribavirin|
347137|NCT00489385|Drug|Albuferon|
347138|NCT00489398|Drug|epinastine HCL and olopatadine HCL|
347139|NCT00489411|Drug|duloxetine hydrochloride|Given orally
347140|NCT00489411|Other|placebo|Given orally
347141|NCT00489424|Drug|Placebo|
347142|NCT00489424|Drug|Acetaminophen|
347143|NCT00489424|Drug|Fluvastatin|
347144|NCT00003654|Procedure|lymphangiography|
347145|NCT00489437|Device|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
347146|NCT00492401|Other|laboratory biomarker analysis|Correlative studies
347147|NCT00492401|Other|pharmacological study|Correlative studies
347148|NCT00492401|Other|high performance liquid chromatography|Correlative studies
347149|NCT00492401|Genetic|microarray analysis|Correlative studies
347150|NCT00003664|Biological|recombinant interferon alfa|
347497|NCT00000540|Device|defibrillators, implantable|
347498|NCT00003619|Procedure|bone marrow ablation with stem cell support|
347499|NCT00480792|Biological|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
346442|NCT00505752|Drug|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
346443|NCT00505752|Drug|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
346444|NCT00003733|Drug|carboplatin|
346445|NCT00505752|Drug|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
346446|NCT00505752|Drug|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
346791|NCT00497900|Drug|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
346792|NCT00003691|Drug|cisplatin|
346793|NCT00497913|Drug|NaCl 0.9%|
346794|NCT00497913|Drug|Botulinum Toxin A|
346795|NCT00497926|Biological|Kidney and hematopoietic stem cell transplant/novel platform technology|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
346796|NCT00497939|Drug|Saw palmetto and sanmiaoshan capsule|
346797|NCT00497952|Biological|Enriched Hematopoetic Stem Cell Transplant|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
346798|NCT00497965|Procedure|Chiropractic Manipulation|
346799|NCT00497965|Behavioral|Balance Exercises|
346800|NCT00497978|Dietary Supplement|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
346801|NCT00497978|Dietary Supplement|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
346802|NCT00497991|Drug|AZD1152|
346111|NCT00467649|Drug|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
346112|NCT00467649|Drug|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
346113|NCT00467662|Drug|Acyclovir 5%|
346114|NCT00467662|Drug|Docosanol 10%|
346115|NCT00467662|Device|Superlysine gel|
346116|NCT00467675|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
346117|NCT00003568|Biological|gp100 antigen|
346118|NCT00467688|Device|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
346119|NCT00467714|Procedure|rhinoplasty|COLUMELLA STRUT PLACEMENT
346120|NCT00467727|Other|Phase Contrast Mammography|Standard and magnification views
346121|NCT00467740|Drug|BI 1744 CL|
346122|NCT00467753|Drug|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
346123|NCT00467753|Other|Placebo/sugar pill|Dosage similar to active drug
346124|NCT00467766|Behavioral|Psychosocial information, counseling, and support|
346125|NCT00467766|Drug|Donepezil (Aricept)|
346126|NCT00467779|Drug|midazolam|In Stage III only: single dose of midazolam
346127|NCT00470366|Drug|paclitaxel|
346447|NCT00505752|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to [>=] 18 millimeter [mm], two or more additional follicles with a diameter of >= 16 mm, and Estradiol [E2] levels will approximately 150 picogram per milliliter [pg/mL] per mature follicle).
346448|NCT00505765|Drug|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
351141|NCT00597012|Other|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
351142|NCT00597012|Other|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
351143|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
351144|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
345775|NCT00476567|Behavioral|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
345776|NCT00476580|Behavioral|Questionnaire|Questions to collect health information specific to Sri Lankans.
345777|NCT00476593|Drug|Diclofenac|Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.
The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.
345778|NCT00476593|Drug|Dexamethasone|Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.
Pharms). One drop four times daily in one eys for three days.
The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.
345779|NCT00476606|Drug|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
345780|NCT00476606|Drug|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
345781|NCT00476606|Drug|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
345782|NCT00476619|Drug|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
345783|NCT00476632|Behavioral|Questionnaire|50 Minute Interview
345784|NCT00000539|Drug|beta-carotene|
345785|NCT00003600|Biological|epoetin alfa|
345786|NCT00476645|Drug|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
345787|NCT00476671|Procedure|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
345788|NCT00476684|Procedure|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
350836|NCT00479102|Drug|Ferripel-3 - iron polysaccharide complex for prevention|
350837|NCT00479115|Drug|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
350838|NCT00479115|Device|AmCell CliniMACs|CD34+ cell selection from peripheral collection
350839|NCT00479128|Drug|Bortezomib|Starting dose: 0.8 mg/m^2 IV Over 3-5 Seconds
350840|NCT00479128|Drug|Gemcitabine|Starting dose: 225 mg/m^2 IV Up to 90 Minutes
350841|NCT00479128|Drug|Doxorubicin|Starting dose: 12.5 mg/m^2 IV Over 15-30 minutes
350842|NCT00479141|Behavioral|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
350843|NCT00003612|Drug|carboplatin|
350844|NCT00479141|Behavioral|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
350845|NCT00479154|Drug|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
350846|NCT00479167|Drug|Bortezomib and Tositumomab I-131|
350847|NCT00479180|Biological|Vascugel|One time implant on the day of surgery
350848|NCT00479180|Biological|Placebo Comparator|One time implant on the day of surgery
350849|NCT00479193|Drug|Polymem|single layer, change every 3 days
350850|NCT00482053|Procedure|Allogeneic hematopoietic cell transplantation|
350851|NCT00482053|Procedure|Autologous hematopoietic cell transplantation (AHCT)|
350852|NCT00482066|Drug|Abatacept (Orencia)|500mg for patients under 60kg 750mg for patients 60-100kg
1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v.
351145|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
351146|NCT00597038|Drug|Dasatinib and Dacarbazine (DTIC)|Arm A/ Phase I Potential Dose Levels.
Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m^2.
Arm B/Phase II Potential Dose Levels.
MTD1: Dasatinib 70 mg; DTIC 1000 mg/m^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m^2.
351147|NCT00597051|Drug|ARD-0403|
347500|NCT00480805|Drug|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
347501|NCT00483457|Procedure|biopsy|biopsy
347502|NCT00483470|Biological|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
347503|NCT00483470|Biological|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
347504|NCT00483483|Behavioral|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
347505|NCT00003632|Drug|melphalan|
347506|NCT00483483|Behavioral|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
347507|NCT00483496|Drug|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
347508|NCT00483496|Drug|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
347509|NCT00483496|Drug|bisoctrizole 10% alone (formula RV3131A-MV1237)|
347510|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
347511|NCT00483496|Drug|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
347512|NCT00483496|Drug|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
347513|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
347514|NCT00483496|Drug|V0096 CR vehicle (formula RV3131A-MV1197)|
347515|NCT00483509|Drug|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
347516|NCT00000541|Drug|beta-carotene|
347517|NCT00003632|Drug|methotrexate|
347518|NCT00483509|Drug|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
347519|NCT00483522|Behavioral|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
347520|NCT00483535|Drug|GW273225|
346803|NCT00499824|Behavioral|Education of general practitioners on the IDF-WPR guidelines|The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:
an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a "diabetes passport" to be held by the patient.
346804|NCT00499837|Drug|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
346805|NCT00499850|Drug|ZD6474 (vandetanib)|once daily oral dose
346806|NCT00499850|Drug|5-Fluorouracil|intravenous infusion
346807|NCT00499850|Drug|Leucovorin|intravenous infusion
346808|NCT00499850|Drug|Oxaliplatin|intravenous infusion
346809|NCT00499863|Drug|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
346810|NCT00499863|Drug|Placebo|Placebo patch
346811|NCT00499876|Drug|mefloquine|250mg weekly PO for 6 months
346812|NCT00499876|Other|placebo|1 tablet weekly PO for 6 months
347151|NCT00492401|Genetic|RNA analysis|Correlative studies
347152|NCT00492401|Other|mass spectrometry|Correlative studies
347153|NCT00492401|Genetic|DNA methylation analysis|Correlative studies
347154|NCT00492401|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
347155|NCT00492414|Drug|Paroxetine CR|
347156|NCT00492427|Drug|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25~250μg(s.c.)/4week for 24~26weeks in total.
347157|NCT00492427|Drug|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k~12000IU(s.c.)/2week for 24~26weeks in total.
347158|NCT00492440|Biological|recombinant interleukin-7|
347159|NCT00492440|Genetic|gene expression analysis|
347160|NCT00492440|Genetic|polymerase chain reaction|
346449|NCT00505765|Drug|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
346450|NCT00461565|Drug|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
346451|NCT00461565|Drug|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
346452|NCT00461565|Drug|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
346453|NCT00461565|Drug|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
346454|NCT00000529|Drug|tamoxifen|
346455|NCT00003538|Biological|graft versus host disease prophylaxis/therapy|
346456|NCT00461578|Drug|Chlorproguanil-dapsone + artesunate|
346457|NCT00461591|Drug|EOquin®|EOquin® for intravesical installation 4mg in 40ml
346458|NCT00461617|Drug|Mitiglinide|10mg tablet, 10mg TID
346459|NCT00461630|Drug|ER niacin/laropiprant|
346460|NCT00461630|Drug|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
346461|NCT00461630|Drug|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
346462|NCT00461643|Drug|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
346463|NCT00461656|Drug|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
346464|NCT00461669|Procedure|ultrasound examination of the hip|
346465|NCT00461682|Drug|SB-705498|
346466|NCT00003538|Procedure|allogeneic bone marrow transplantation|
346467|NCT00461695|Biological|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
346468|NCT00461708|Drug|Erlotinib|100 mg, PO, once per day
346813|NCT00000551|Behavioral|health education|
345789|NCT00476684|Procedure|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
345790|NCT00479752|Drug|FOLFOX4 (Oxaliplatin), Cetuximab|Arm A FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks
Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².
Arm B FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks
Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks.
345791|NCT00479765|Drug|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
345792|NCT00479778|Drug|Bazedoxifene/conjugated estrogens|
345793|NCT00479791|Behavioral|Test meals rich in different fatty acids|
346128|NCT00470379|Drug|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
346129|NCT00470392|Drug|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
346130|NCT00470392|Drug|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
346131|NCT00470405|Drug|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
346132|NCT00003578|Drug|carmustine|
346133|NCT00470405|Drug|pemetrexed disodium|a novel antifolate with multiple targets.
346134|NCT00470418|Drug|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
346135|NCT00470418|Drug|Placebo|placebo comparator
346136|NCT00470444|Procedure|Transfusion with Red Blood Cells|Units of donated Red blood cells
346137|NCT00470444|Biological|1 unit of donated red blood cells|Units of red blood cells
346138|NCT00470444|Biological|1 unit of donated red blood cells|Units of donated red blood cells
346139|NCT00470457|Biological|Allergen specific immunotherapy|
351148|NCT00000612|Behavioral|dietary supplements|
351149|NCT00004206|Drug|oxaliplatin|
351150|NCT00597064|Drug|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
351151|NCT00597077|Other|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
351152|NCT00597077|Other|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
351153|NCT00597103|Other|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
351154|NCT00597103|Other|Sleep Assessment Testing|Sleep Assessment will be performed using an "Actiwatch" with subjects wearing the watch for 72 hours continuously
351155|NCT00597103|Other|Periodic Leg Movement Syndrome Assessment|Subjects will wear and "Actiwatch" on both legs for three consecutive nights.
351156|NCT00597116|Drug|Vinorelbine|
351157|NCT00597116|Drug|Vandetanib|once daily oral dose
351158|NCT00597129|Biological|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
351159|NCT00597142|Device|Express™ Renal Premounted Stent System|This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:
Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery
Lesion length ≤15mm
Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen
RVD 4.0-7.0mm
351160|NCT00004207|Drug|liposomal daunorubicin citrate|
351161|NCT00597181|Procedure|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
351162|NCT00597181|Procedure|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
351163|NCT00597194|Procedure|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
351164|NCT00599898|Drug|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
345794|NCT00479804|Device|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
345795|NCT00479804|Device|spirometry|spirometry for testing the ventilatory function
347841|NCT00474682|Drug|Micronized dispersible ferric pyrophosphate|
347842|NCT00474695|Drug|Lucentis|0.05 mg intravitreal injection
347843|NCT00474708|Drug|Effexor|
347844|NCT00474708|Drug|SSRI|
347845|NCT00474721|Drug|ibuprofen|
347846|NCT00003593|Drug|methotrexate|Given IV
347847|NCT00474721|Drug|acetaminophen with codeine|
347848|NCT00474734|Device|Intravascular ultrasound of the liver|
347849|NCT00474747|Drug|Antithymocyte Globulin|3 mg/kg IV over no less than four (and preferably six) hours daily x 3 days
347850|NCT00474747|Drug|Cyclophosphamide|Starting maximum dose 50 mg/kg IV x 3 days (de-escalating doses follow).
347851|NCT00474747|Drug|Fludarabine|30 mg/m^2 IV over no less than 30 minutes daily x 4 days
347852|NCT00474747|Radiation|Total Body Irradiation (TBI)|TBI: 200 cGy from a linear accelerator at 20 cGy/min on Day -1 (single dose)
347853|NCT00474747|Procedure|Bone Marrow Transplant|Infusion of matched unrelated donor marrow on Day 0.
347854|NCT00474760|Drug|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
347855|NCT00474773|Drug|Celecoxib|
347856|NCT00477555|Device|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
347857|NCT00477581|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
347858|NCT00477581|Drug|sitagliptin|oral administration (100mg), once a day in the morning
347859|NCT00477594|Drug|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
347860|NCT00477607|Drug|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
347861|NCT00477607|Behavioral|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
347862|NCT00477607|Biological|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
347161|NCT00003664|Drug|fluorouracil|
347162|NCT00492440|Genetic|protein expression analysis|
347163|NCT00492440|Other|flow cytometry|
347164|NCT00492440|Other|immunoenzyme technique|
347165|NCT00492440|Other|immunologic technique|
347166|NCT00492440|Other|laboratory biomarker analysis|
347167|NCT00492440|Other|pharmacological study|
347168|NCT00492453|Procedure|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
347169|NCT00492466|Drug|Interferon-beta-1a|dosage and frequency as per label
347170|NCT00492466|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
347171|NCT00492479|Drug|Kinerase Pro+Therapy Line day repair, serum, night repair|
347172|NCT00003664|Drug|gemcitabine hydrochloride|
347173|NCT00492479|Drug|Kinerase Pro+Therapy Line Ultra rich day repair|
347174|NCT00492479|Drug|LubriDerm|
347175|NCT00492492|Procedure|trans-styloid and intrafocal pinning on the one side|
347176|NCT00492492|Procedure|volar fixed-angle plating on the other side|
347521|NCT00483548|Drug|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
347522|NCT00483548|Drug|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
347523|NCT00483561|Drug|etoposide|250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.
347524|NCT00483561|Drug|etoposide|50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
347525|NCT00483561|Other|laboratory biomarker analysis|The blood samples will be obtained in EDTA tubes, spun down, and the serum removed and stored at 80 degrees C in small aliquots for later use. When we have sufficient samples to use a kit, they will be thawed and sampled for the various biomarkers using ELISA kits from R&D Technology (Seattle). The antiEGFR antibodies will also be determined by using ELISA, but with kits prepared within our institution.
346814|NCT00003702|Biological|Dactinomycin|Given IV
346815|NCT00499889|Drug|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
346816|NCT00499889|Drug|Fludarabine (Fludara)|40 mg/m^2 by vein daily for 4 Days
346817|NCT00499889|Drug|Busulfan|130 mg/m^2 by vein daily for 2 Days
346818|NCT00499889|Drug|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
346819|NCT00499889|Drug|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
346820|NCT00499889|Drug|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
346821|NCT00499889|Procedure|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after >4 weeks of imatinib.
346822|NCT00499889|Procedure|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
346823|NCT00499902|Drug|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
346824|NCT00499915|Behavioral|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
346825|NCT00003702|Drug|Methotrexate|Given intramuscularly
346826|NCT00499915|Behavioral|Asthma Education|Asthma education will be provided at NICU discharge.
346827|NCT00499928|Drug|SB-751689|
346828|NCT00503152|Drug|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
346829|NCT00503152|Drug|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
347177|NCT00494988|Drug|insulin aspart|
346140|NCT00470470|Drug|imatinib mesylate|Given orally
346141|NCT00470470|Other|laboratory biomarker analysis|Correlative studies
346142|NCT00470483|Drug|Placebo treatment during 8 weeks|comparator
346143|NCT00003578|Drug|cyclophosphamide|
346144|NCT00470483|Drug|Paroxetine treatment during 8 weeks|treatment drug
346145|NCT00470496|Drug|HPPH|Given IV
346146|NCT00470496|Drug|photodynamic therapy|Undergo laser light exposure
346147|NCT00470496|Procedure|conventional surgery|Undergo surgery
346148|NCT00470509|Drug|adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)|
346149|NCT00470522|Drug|Methotrexate and folic acid|
346150|NCT00470535|Drug|erlotinib hydrochloride|Oral
346469|NCT00461708|Drug|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
346470|NCT00461734|Other|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
346471|NCT00461747|Drug|VBMCP/VBAD/Velcade|VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.
VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20.
346472|NCT00461747|Drug|Thalidomide/Dexamethasone|Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.
Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days
346473|NCT00461747|Drug|Velcade/Thalidomide/Dexamethasone|Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.
Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.
Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days
346474|NCT00464568|Drug|GSK256066|
346475|NCT00464594|Behavioral|Standard lifestyle guidance|
346476|NCT00464594|Drug|Lifestyle guidance and monotherapy with acarbose|
346477|NCT00464594|Drug|Lifestyle guidance and monotherapy with metformin|
346478|NCT00464594|Drug|Lifestyle guidance and monotherapy with gliclazide|
345796|NCT00479804|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
345797|NCT00003617|Drug|chlorambucil|
345798|NCT00479817|Drug|AMG 386|10mg/kg
345799|NCT00479817|Drug|AMG 386|3 mg/kg
345800|NCT00479817|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
345801|NCT00479817|Drug|AMG 386 Placebo|AMG 386 Placebo
345802|NCT00479830|Behavioral|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
345803|NCT00479830|Behavioral|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
345804|NCT00479830|Behavioral|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
345805|NCT00479843|Behavioral|Nutritional programme|
345806|NCT00479856|Drug|Lapatinib|Small molecule tyrosine kinase inhibitor
345807|NCT00479856|Drug|Capecitabine|Chemotherapy
345808|NCT00003617|Drug|clarithromycin|
345809|NCT00479856|Drug|Docetaxel|Chemotherapy
345810|NCT00479856|Drug|nab-Paclitaxel|Chemotherapy
345811|NCT00479882|Drug|MK0524B|MK0524B 0.9 g/40 mg; MK0524B 0.9 g/10 mg, Study period will run approximately 12 weeks.
345812|NCT00479882|Drug|niacin (+) laropiprant|niacin (+) laropiprant 1 g; Study period will run approximately 12 weeks.
345813|NCT00479882|Drug|Comparator: simvastatin|simvastatin 40 mg, Study period will run approximately 12 weeks.
345814|NCT00479895|Drug|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
345815|NCT00479908|Drug|Sildenafil citrate|
345816|NCT00479908|Drug|Glyceryl trinitrate|
346151|NCT00470535|Other|immunohistochemistry staining method|Correlative Study
346152|NCT00470535|Other|laboratory biomarker analysis|Correlative Study
347863|NCT00477607|Drug|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
347864|NCT00477620|Behavioral|Wearing of reading glasses during prolonged near work|
348209|NCT00468442|Drug|Sirolimus|Maintenance immunosuppressive therapy
348210|NCT00468455|Procedure|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
348211|NCT00468468|Behavioral|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
348212|NCT00468481|Drug|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
348213|NCT00468481|Drug|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
348214|NCT00468507|Dietary Supplement|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
348215|NCT00468520|Drug|low dose oxytocin|
348216|NCT00468533|Drug|Aripiprazole|
348217|NCT00003572|Radiation|radiation therapy|
348218|NCT00468546|Drug|MabThera/Rituxan|1
348219|NCT00468546|Drug|Methotrexate|2
348220|NCT00468546|Other|Placebo|3
348221|NCT00468559|Drug|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
348222|NCT00468559|Drug|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
348223|NCT00468559|Drug|Double Blind Placebo|Double Blind Placebo
348224|NCT00468572|Behavioral|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
348225|NCT00468572|Behavioral|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
348226|NCT00468585|Drug|Capecitabine|
347526|NCT00486629|Behavioral|Exercise and dietary education|Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
347527|NCT00486642|Drug|Bicalutamide|Given PO
347528|NCT00486642|Other|Laboratory Biomarker Analysis|Correlative studies
347529|NCT00003644|Drug|paclitaxel|
347530|NCT00486642|Drug|Pazopanib Hydrochloride|Given PO
347531|NCT00486642|Other|Pharmacological Study|Correlative studies
347532|NCT00486655|Procedure|NOTES-Assisted Cholecystectomy|
347533|NCT00486668|Drug|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
347534|NCT00486668|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
347535|NCT00486668|Drug|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
347536|NCT00486668|Drug|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
347537|NCT00486668|Drug|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
347538|NCT00486681|Device|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
347539|NCT00486694|Drug|Sulfadoxine-pyrimethamine + artesunate|
347540|NCT00003645|Drug|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
347541|NCT00486694|Drug|Chloroquine|
347865|NCT00477633|Drug|Norethindrone/ethinyl estradiol|1 tablet per day
347866|NCT00003603|Drug|lomustine|
347867|NCT00477646|Behavioral|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
347868|NCT00477659|Drug|donepezil HCl (Aricept)|Oral donepezil 5mg/day for 4 weeks, followed by 10 mg/day for 8 weeks
347869|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
347178|NCT00494988|Drug|insulin NPH|
347179|NCT00495014|Drug|GSK376501|
347180|NCT00495014|Drug|Placebo|
347181|NCT00495027|Behavioral|Internet-delivered Stress Innoculation Training|
347182|NCT00495040|Radiation|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
347183|NCT00495053|Genetic|hMaxi-K|Three dose levels (5000µg /90 mL intravesical instillation, 10000µg/90 mL intravesical instillation, and 15000µg/90 mL intravesical instillation)
347184|NCT00495053|Drug|hMaxi-K|Gene Transfer
347185|NCT00495053|Other|Placebo|placebo (PBS-20% sucrose)
347186|NCT00495066|Drug|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
347187|NCT00003679|Drug|doxorubicin hydrochloride|
347188|NCT00495079|Drug|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
347189|NCT00495092|Drug|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
347190|NCT00495092|Drug|Biperiden|Biperiden 2-4 mg/d p.o.
347191|NCT00495092|Drug|Placebo|Placebo + Placebo
347192|NCT00495105|Behavioral|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
347193|NCT00495118|Drug|risperidone|
347194|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
347195|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
347196|NCT00495144|Drug|TH-302|
347197|NCT00495157|Behavioral|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
346479|NCT00464607|Drug|hMG-IBSA|
346480|NCT00464607|Procedure|Ovarian stimulation|
346481|NCT00464620|Drug|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
346482|NCT00464633|Drug|alvocidib|1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion
Then, every treatment week, depending upon the patient's objective response to initial therapy:
30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or
30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours.
346483|NCT00000531|Device|defibrillators, implantable|
346484|NCT00003553|Drug|fludarabine phosphate|Given IV
346485|NCT00464646|Drug|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
346486|NCT00464646|Drug|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
346487|NCT00464646|Drug|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
346488|NCT00464646|Drug|Trastuzumab|Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV
Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses
346830|NCT00503152|Drug|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
346831|NCT00503165|Biological|Menitorix (MenC and Hib conjugate)|
346832|NCT00503178|Procedure|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
346833|NCT00503191|Behavioral|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
346834|NCT00503204|Drug|Cediranib|oral tablet
346835|NCT00003727|Drug|carmustine|
346836|NCT00503204|Drug|Lomustine|oral capsule
346837|NCT00503217|Drug|Tryptorelin|
346153|NCT00470548|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Alimta® (pemetrexed) 500 mg/m2 IV administration on Day 1 of each cycle with Abraxane® (ABI 007) 260 mg/m2IV administration following pemetrexed on Day 1 of each cycle .
346154|NCT00473720|Drug|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
346155|NCT00473720|Drug|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
346156|NCT00473733|Procedure|GLP receptors expression|
346157|NCT00473733|Procedure|ESOPHAGOGASTRODUODENOSCOPY|
346158|NCT00473746|Drug|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
346159|NCT00473746|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
346160|NCT00473746|Drug|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
346161|NCT00003589|Drug|cisplatin|
346162|NCT00473772|Device|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
346163|NCT00473785|Behavioral|Group-based motivational interviewing|
346164|NCT00473785|Behavioral|Individual CVD-risk factor feedback|
346165|NCT00473785|Behavioral|Education for protective health behavior change|
346166|NCT00473798|Behavioral|Questionnaire|Questionnaire
346167|NCT00473811|Behavioral|Low GI|low-GI education
346168|NCT00473811|Behavioral|ADA diet|ADA dietary education
346169|NCT00473824|Biological|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, [Civacir]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
346170|NCT00473837|Drug|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
346171|NCT00473837|Drug|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
348227|NCT00468585|Drug|Bevacizumab|
348228|NCT00003573|Biological|filgrastim|
348229|NCT00468611|Drug|MBP8298|500mg MBP8298 IV every six months for a period of two years
348230|NCT00468624|Drug|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
348231|NCT00468624|Procedure|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
348603|NCT00462566|Device|motor cortex stimulation|
348604|NCT00462592|Drug|budesonide|inhaled budesonide turbuhaler 200ug taken 1 puff morning & 1 puff evening.
348605|NCT00462592|Drug|montelukast|montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
348606|NCT00003541|Drug|vincristine sulfate|
348607|NCT00462592|Other|placebo|placebo
348608|NCT00462605|Drug|entinostat|Given PO
348609|NCT00462605|Drug|sargramostim|Given SC
348610|NCT00462618|Drug|Quetiapine|
348611|NCT00462618|Behavioral|Cogntive behavioral therapy|
348612|NCT00462631|Device|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
348613|NCT00462631|Device|paclitaxel eluting stent|paclitaxel eluting stent
348614|NCT00462631|Device|bare metal stent|bare metal stent
348615|NCT00465738|Drug|incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kD), free from complexing proteins")|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
348616|NCT00003558|Drug|carboplatin|
348617|NCT00465751|Drug|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
348618|NCT00465751|Drug|placebo capsules|placebo capsules containing mannitol tid po
348619|NCT00465764|Other|Alternate protein infant formula|Feed as per HCP directions
347870|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
347871|NCT00477672|Drug|Placebo|tablet, once daily by mouth, 6 weeks
347872|NCT00477685|Device|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
347873|NCT00477711|Drug|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
347874|NCT00477724|Behavioral|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
347875|NCT00477724|Other|sedentary control group|control group with no specific training
347876|NCT00477737|Drug|Sevoflurane|
347877|NCT00003603|Drug|melphalan|
347878|NCT00477737|Drug|propofol|
347879|NCT00477750|Drug|lenalidomide|Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression
Phase II - 10 mg orally days 1-21 every 28 days until progression
347880|NCT00480805|Drug|Comparator : ramipril /Duration of Treatment : 8 Weeks|
347881|NCT00480818|Drug|SAM-531|
347882|NCT00480831|Drug|bevacizumab|Intravenous repeating dose
347883|NCT00480831|Drug|carboplatin|Intravenous repeating dose
347884|NCT00480831|Drug|paclitaxel|Intravenous repeating dose
347885|NCT00480831|Drug|placebo|Intravenous repeating dose
347886|NCT00480831|Drug|PRO95780|Intravenous repeating dose
347887|NCT00480844|Drug|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
348232|NCT00468624|Procedure|blood sampling before and after pegvisomant/placebo|
348233|NCT00471393|Drug|45.5% DMSO (topical placebo)|
348234|NCT00003580|Radiation|radiation therapy|
348235|NCT00471406|Procedure|Photodynamic Therapy with Verteporfin|
347198|NCT00003679|Drug|tamoxifen citrate|
347542|NCT00486707|Behavioral|Questionnaire|A questionnaire will be completed.
347543|NCT00486720|Drug|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
347544|NCT00486720|Drug|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
347545|NCT00486733|Device|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
347546|NCT00486746|Behavioral|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
347547|NCT00486746|Behavioral|General information on healthy lifestyle habits|A single session
347548|NCT00486759|Drug|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
347549|NCT00486759|Drug|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
347550|NCT00489437|Procedure|Clinical Prediction Score-HIT Score Card|clinical prediction rule
rapid immunoassay
347551|NCT00489450|Drug|SK3530|
347552|NCT00489463|Device|intra-uterine device (TCu 380A)|
347553|NCT00489476|Drug|Loxapine Thermal Aerosol|
347554|NCT00489489|Drug|Teriflunomide|Film-coated tablet
Oral administration
347555|NCT00489489|Drug|Placebo (for Teriflunomide)|Film-coated tablet
Oral administration
347556|NCT00489489|Drug|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
347557|NCT00489502|Behavioral|Brief Counseling|
347558|NCT00489502|Device|REE Assessment|
347559|NCT00003654|Procedure|radionuclide imaging|
347560|NCT00489528|Drug|Somatropin; Recombinant human growth hormone (r hGH)|
346838|NCT00503230|Behavioral|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
346839|NCT00503230|Behavioral|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
346840|NCT00503243|Drug|Delayed and extended release mesalazine|
346841|NCT00503256|Behavioral|Questionnaire|Questionnaires each taking 60 minutes to complete.
346842|NCT00503269|Procedure|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
346843|NCT00503269|Procedure|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
346844|NCT00503295|Biological|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
346845|NCT00503308|Procedure|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
346846|NCT00000553|Drug|simvastatin|
346847|NCT00003727|Drug|cyclophosphamide|
346848|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
346849|NCT00505765|Drug|Placebo|Placebo- 3 sprays in each nostril, twice per day
346850|NCT00505765|Drug|Placebo|Placebo- one spray in each nostril, once per day
346851|NCT00505778|Drug|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
347199|NCT00495157|Behavioral|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
347200|NCT00495157|Behavioral|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
347201|NCT00495170|Drug|Carboplatin|2 AUC IV Weekly
347202|NCT00495170|Radiation|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
347203|NCT00003691|Drug|doxorubicin hydrochloride|
347204|NCT00498004|Drug|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
346172|NCT00003589|Drug|gemcitabine hydrochloride|
346489|NCT00464646|Drug|Bevacizumab|Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses
Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses
346490|NCT00464659|Device|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
346491|NCT00464659|Device|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
346492|NCT00464672|Biological|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
346493|NCT00464672|Biological|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
346494|NCT00464685|Drug|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
346495|NCT00003553|Drug|methotrexate|Given as GVHD prophylaxis
346496|NCT00464685|Drug|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
346497|NCT00467779|Drug|dextromethorphan|In Stage III only: single dose of dextromethorphan
346498|NCT00003568|Biological|incomplete Freund's adjuvant|
346499|NCT00467779|Drug|GDC-0973/XL518|Repeating oral dose
346500|NCT00467805|Procedure|Light therapy|
346501|NCT00467818|Dietary Supplement|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
346502|NCT00467818|Other|Placebo|Smae dosage as that of omega 3 fatty acids
346503|NCT00467831|Drug|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
346504|NCT00467831|Drug|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
346505|NCT00467831|Drug|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
346506|NCT00467831|Drug|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
348620|NCT00465764|Other|Standard infant formula|Feed as per HCP directions
348621|NCT00465777|Behavioral|Guideline adherence and financial incentive|
348622|NCT00465803|Drug|Travoprost 0.004%/timolol 0.5% ophthalmic solution|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
348623|NCT00465803|Drug|Travoprost ophthalmic solution, 0.004%|One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
348624|NCT00465803|Drug|Timolol maleate ophthalmic solution, 0.5%|One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
348625|NCT00465816|Biological|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
348977|NCT00003728|Drug|dexamethasone|
348978|NCT00503984|Genetic|GADD45α methylation and expression analysis|Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.
Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so.
348979|NCT00503984|Drug|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
348980|NCT00503984|Drug|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
348981|NCT00503997|Drug|oxaliplatin|Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.
Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.
348982|NCT00503997|Drug|pemetrexed disodium|Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.
Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.
348983|NCT00504010|Drug|Arnica Montana|Applied to lower extremity once a day for 3 days
348984|NCT00504010|Drug|placebo cream|placebo cream applied to leg daily for 3 days
348985|NCT00504023|Drug|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
348986|NCT00504023|Procedure|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
348987|NCT00504023|Procedure|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
348236|NCT00471419|Drug|Rimexolone|
348237|NCT00471432|Drug|custirsen sodium|
348238|NCT00471432|Drug|docetaxel|
348239|NCT00471432|Other|pharmacological study|
348240|NCT00471445|Drug|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
348241|NCT00471445|Other|placebo|Applied topically
348242|NCT00471471|Biological|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
348243|NCT00471471|Biological|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
348244|NCT00471471|Biological|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
348245|NCT00003582|Drug|amifostine trihydrate|
348246|NCT00471484|Biological|recombinant interferon alfa-2b|
348247|NCT00471484|Drug|doxorubicin hydrochloride|
348248|NCT00471484|Drug|fluorouracil|
348249|NCT00471484|Drug|oxaliplatin|
348250|NCT00471484|Other|diagnostic laboratory biomarker analysis|
348251|NCT00471484|Other|immunoenzyme technique|
348252|NCT00471484|Other|immunohistochemistry staining method|
348253|NCT00471484|Procedure|adjuvant therapy|
348254|NCT00471484|Procedure|biopsy|
348255|NCT00471484|Procedure|neoadjuvant therapy|
348256|NCT00003582|Drug|cisplatin|
348626|NCT00465816|Biological|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
347561|NCT00489541|Device|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
347562|NCT00489554|Biological|Synflorix|Intramuscular injection, 3 doses.
347563|NCT00489554|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
347888|NCT00003619|Procedure|peripheral blood stem cell transplantation|
347889|NCT00480844|Drug|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
347890|NCT00480857|Drug|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
347891|NCT00480870|Drug|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
347892|NCT00480870|Drug|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
347893|NCT00480883|Drug|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
347894|NCT00480883|Drug|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
347895|NCT00480883|Drug|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
347896|NCT00480896|Drug|tacrolimus ointment|Topical application
347897|NCT00480896|Drug|Placebo ointment|Topical application
347898|NCT00480922|Behavioral|Low glycemic load diet|Outpatient behavioral counseling
347899|NCT00003620|Drug|alvocidib|Given IV
347900|NCT00480922|Behavioral|Low fat diet|Outpatient behavioral counseling
347901|NCT00480935|Drug|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
347902|NCT00480948|Behavioral|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing ~49% of C16:0 at sn-2 position), 24 wk
347903|NCT00480948|Dietary Supplement|Control|Standard vegetable oil based infant formula
347904|NCT00480961|Procedure|intramiocardiac autograft of autologous stem cells|
347905|NCT00480974|Other|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
347205|NCT00498043|Drug|R-CHOP14 induction regimen|R-CHOP14 induction regimen
347206|NCT00498043|Drug|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
347207|NCT00498056|Biological|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
347208|NCT00498056|Biological|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
347209|NCT00498056|Biological|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
347210|NCT00498056|Biological|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
347211|NCT00498069|Device|Harvest Smartprep2 BMAC System|injection of 40cc bmac
347212|NCT00498069|Device|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
347213|NCT00498069|Biological|placebo|injection of placebo into ischemic tissue of the lower extremity
347214|NCT00003691|Drug|paclitaxel|
347215|NCT00498095|Procedure|Renal biopsy|
347216|NCT00498108|Drug|Rotigotine|
347217|NCT00498121|Device|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
347218|NCT00498134|Drug|Triple therapy for H. pylori infection|
347219|NCT00498134|Drug|Cox-2 inhibitor|
347564|NCT00489554|Biological|Rotarix|Oral, 2 doses.
347565|NCT00489567|Procedure|Blood sample collection|
347566|NCT00489580|Device|SaeboFlex Dynamic Hand Orthosis|
347567|NCT00489580|Procedure|Saebo F.T.M. Arm Training Program|
347568|NCT00489593|Drug|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
347569|NCT00489606|Drug|SK3530|
347570|NCT00003654|Procedure|sentinel lymph node biopsy|
347571|NCT00489632|Behavioral|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
346507|NCT00467831|Drug|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
346508|NCT00467844|Drug|GTx-024|1 mg GTx 024
346509|NCT00003569|Drug|cisplatin|
346510|NCT00467844|Drug|GTx-024|3 mg GTx-024
346852|NCT00505778|Drug|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
346853|NCT00505791|Drug|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
346854|NCT00003733|Drug|paclitaxel|
346855|NCT00505804|Drug|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
346856|NCT00505804|Drug|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
346857|NCT00505817|Drug|Cetrorelix and Leuprolide|
346858|NCT00505830|Other|questionnaires|Primary outcome:
Autism Spectrum Quotient (AQ)
Secondary outcome measure:
Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
346859|NCT00505843|Drug|MK0657|7mg MK0657 capsules
346860|NCT00505843|Drug|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
346861|NCT00505843|Drug|Comparator: levodopa|levodopa >/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
346862|NCT00505843|Drug|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
346863|NCT00505869|Behavioral|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
346864|NCT00505869|Behavioral|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
346865|NCT00003733|Drug|topotecan hydrochloride|
346866|NCT00505869|Behavioral|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
348988|NCT00003728|Drug|doxorubicin hydrochloride|
348989|NCT00504036|Device|inflatable intra-gastric balloon|inflatable intra-gastric balloon
348990|NCT00504062|Drug|budesonide|
348991|NCT00504062|Drug|fluticasone|
348992|NCT00504075|Biological|Gammaplex, intravenous immunoglobulin|Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).
The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
348993|NCT00504088|Procedure|Bypass|
348994|NCT00504088|Procedure|Silverhawk Plaque Excision|
348995|NCT00504101|Drug|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
349344|NCT00498888|Procedure|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
349345|NCT00498888|Procedure|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
349346|NCT00498901|Drug|goserelin|
349347|NCT00498901|Drug|letrozole|
349348|NCT00498901|Drug|leuprolide acetate|
349349|NCT00498901|Procedure|conventional surgery|
349350|NCT00498914|Drug|YM155|Continuous IV infusion
349351|NCT00498927|Drug|temozolomide|
349352|NCT00003696|Drug|cyclophosphamide|
349353|NCT00498927|Genetic|protein expression analysis|
349354|NCT00498927|Genetic|reverse transcriptase-polymerase chain reaction|
349355|NCT00498927|Other|diagnostic laboratory biomarker analysis|
349356|NCT00498927|Other|immunoenzyme technique|
348627|NCT00003558|Drug|etoposide|
348628|NCT00465855|Procedure|Hyperbaric oxygen therapy (HBO2)|Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.
For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods.
348629|NCT00465868|Procedure|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
348630|NCT00465881|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
348631|NCT00465894|Drug|Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks
348632|NCT00465894|Drug|Estrace Vaginal Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks
348633|NCT00465907|Drug|Paclitaxel, Carboplatin, Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
348634|NCT00465920|Behavioral|modified cognitive behavioural therapy (mCBT)|
348635|NCT00465933|Drug|AIDA|
348636|NCT00465946|Behavioral|Salt Supplementation|
348637|NCT00465959|Drug|trospium chloride inhalation powder (TrIP)|
348638|NCT00003558|Drug|fluorouracil|
348639|NCT00465959|Drug|Placebo|
348640|NCT00468624|Procedure|arginine stimulation test after each limb|
348641|NCT00468650|Drug|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
348642|NCT00468676|Behavioral|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
348643|NCT00468676|Behavioral|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
348644|NCT00468689|Drug|SB-751689 oral tablets (100 and 400 ng)|
347906|NCT00480987|Drug|Oxaliplatin|30 mg/m^2 IV days 1-4
347907|NCT00480987|Drug|Fludarabine|30 mg/m^2 IV days 2-6
347908|NCT00480987|Drug|Cytarabine|500 mg/m^2 by IV continuous infusion days 2-6
347909|NCT00483574|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
347910|NCT00483574|Biological|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
347911|NCT00003632|Procedure|peripheral blood stem cell transplantation|
348257|NCT00471484|Procedure|therapeutic conventional surgery|
348258|NCT00471497|Drug|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
348259|NCT00471497|Drug|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
348260|NCT00471510|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
348261|NCT00471523|Drug|Clomiphene citrate|
348262|NCT00474786|Drug|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
348263|NCT00003593|Drug|therapeutic hydrocortisone|Given IT
348264|NCT00474786|Drug|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
348265|NCT00474799|Drug|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
348266|NCT00474812|Drug|dasatinib|
348267|NCT00474812|Procedure|laboratory biomarker analysis|Correlative study
348268|NCT00474812|Procedure|physiologic testing|Correlative study
348269|NCT00474825|Drug|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
348270|NCT00474825|Drug|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
347572|NCT00489645|Drug|placebo|placebo SC during euglycemia
347573|NCT00489645|Drug|pramlintide|pramlintide SC during eglycemia
347574|NCT00489645|Drug|placebo|placebo during hyperglycemia
347575|NCT00489645|Drug|pramlintide|pramlintide SC during hyperglycemia
347576|NCT00489658|Drug|Eflornithine plus Nifurtimox combination therapy|
347577|NCT00489697|Device|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
347578|NCT00489710|Drug|talabostat mesylate|
347579|NCT00489710|Procedure|diagnostic procedure|
347580|NCT00489710|Procedure|enzyme inhibitor therapy|
347581|NCT00492505|Drug|cisplatin|
347582|NCT00492505|Drug|sorafenib tosylate|
347583|NCT00492505|Drug|tamoxifen citrate|
347584|NCT00492505|Procedure|adjuvant therapy|
347585|NCT00492518|Drug|Acetylcysteine|
347586|NCT00492518|Drug|Theophylline|
347587|NCT00003665|Biological|dendritic cell-MART-1 peptide vaccine|
347588|NCT00492518|Drug|Placebo|
347589|NCT00492531|Drug|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
347912|NCT00483574|Biological|Routine paediatric vaccine - Pneumococcal conjugate (PCV) and Hepatitis A|0.5 mL, Intramuscular at age 12 months
347913|NCT00483587|Drug|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
347914|NCT00483600|Drug|fondaparinux|injections of 2.5mg every other day for 4 weeks
347915|NCT00483613|Behavioral|Cognitive-behavioral therapy of Meichenbaum|
347916|NCT00483626|Drug|oral sildenafil|
346867|NCT00505882|Drug|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
346868|NCT00505882|Drug|Glargine|
346869|NCT00505882|Drug|Lispro|
346870|NCT00505882|Drug|Aspart|
347220|NCT00498147|Other|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
347221|NCT00498160|Device|Enriched Hematopoetic Stem Cell Transplant|Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
347222|NCT00498173|Drug|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
347223|NCT00498173|Drug|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
347224|NCT00498186|Drug|Rotigotine|Rotigotine transdermal patches once daily:
2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)
347225|NCT00003692|Procedure|therapeutic thoracoscopy|
347226|NCT00498199|Procedure|visual tests|
347227|NCT00499954|Procedure|Microdialysis|
347228|NCT00499954|Device|Guardian RT|
347229|NCT00499954|Device|Glucoday S|
347230|NCT00499967|Drug|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
347231|NCT00499967|Drug|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
349357|NCT00498940|Device|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
349358|NCT00498940|Device|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
349359|NCT00498953|Drug|carboplatin|
349360|NCT00498953|Drug|cisplatin|
349361|NCT00498953|Drug|docetaxel|
349362|NCT00498953|Drug|fluorouracil|
349363|NCT00003696|Drug|doxorubicin hydrochloride|
349364|NCT00498953|Drug|lapatinib ditosylate|
349365|NCT00498953|Genetic|cytogenetic analysis|
349366|NCT00498953|Genetic|fluorescence in situ hybridization|
349367|NCT00498953|Genetic|in situ hybridization|
349368|NCT00498953|Genetic|polymerase chain reaction|
349369|NCT00498953|Genetic|reverse transcriptase-polymerase chain reaction|
349700|NCT00490633|Behavioral|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
349701|NCT00490646|Drug|ixabepilone|Ixabepilone 40 mg/m^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.
For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.
349702|NCT00490646|Drug|docetaxel|Docetaxel 100 mg/m^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
349703|NCT00003658|Drug|pentostatin|
349704|NCT00490646|Drug|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
349705|NCT00490659|Drug|gemcitabine|
348996|NCT00506493|Device|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
348997|NCT00506493|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
348998|NCT00506506|Drug|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
348999|NCT00506506|Drug|Placebo|
349000|NCT00506519|Drug|antithrombin alfa (INN name)|
349001|NCT00506532|Drug|Surfactant (calfactant)|
349002|NCT00506545|Drug|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
349003|NCT00003736|Procedure|study of high risk factors|
349004|NCT00506545|Drug|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
349005|NCT00506558|Procedure|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
349006|NCT00506558|Procedure|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
349007|NCT00506571|Drug|S-1, irinotecan, oxaliplatin|
349008|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
349009|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
349010|NCT00506584|Dietary Supplement|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
349011|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
349012|NCT00506584|Dietary Supplement|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
348271|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
348272|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
348273|NCT00474838|Drug|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
348274|NCT00003593|Drug|thioguanine|Given IV
348275|NCT00474838|Drug|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
348276|NCT00474851|Drug|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
348277|NCT00474851|Drug|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
348645|NCT00468689|Drug|Ketoconazole (NIZORAL) oral tablets (200 mg)|
348646|NCT00003573|Drug|cisplatin|
348647|NCT00468702|Device|CoaguChek S|
348648|NCT00468715|Drug|bicalutamide|
348649|NCT00468715|Other|diagnostic laboratory biomarker analysis|
348650|NCT00468715|Other|immunohistochemistry staining method|
348651|NCT00468728|Drug|PAR-101/OPT-80|capsules
348652|NCT00468728|Drug|Vancomycin|Capsules
348653|NCT00468741|Behavioral|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
348654|NCT00468741|Behavioral|CHESS|informational services of CHESS available to subject
348655|NCT00468741|Behavioral|CHESS|CHESS informational services and social support available to subject
348656|NCT00468754|Device|Insulin pumps|
348657|NCT00000534|Drug|calcium|
348658|NCT00003573|Drug|cyclophosphamide|
348659|NCT00468767|Drug|Vernakalant Injection 20 mg/mL|
347917|NCT00483639|Other|Medical chart review|medical chart review
347918|NCT00483639|Other|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
347919|NCT00483639|Procedure|management of therapy complications|management of therapy complications
347920|NCT00483639|Procedure|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
347921|NCT00483639|Other|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
347922|NCT00003633|Drug|docetaxel|
347923|NCT00483652|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
347924|NCT00483652|Drug|Placebo|placebo (sugar pill)
347925|NCT00483665|Procedure|Computed tomography angiography|Computed tomography angiography
347926|NCT00483665|Procedure|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
347927|NCT00483678|Other|counseling intervention|
347928|NCT00483678|Other|questionnaire administration|
347929|NCT00483678|Procedure|psychosocial assessment and care|
347930|NCT00483691|Behavioral|Home Visit|Homw visits scheduled weekly for one year.
347931|NCT00483704|Drug|Telcagepant 140 mg|Telcagepant 140 mg tablets
347932|NCT00483704|Drug|Talcagepant 280 mg|Telcagepant 280 mg tablets
347933|NCT00003633|Drug|estramustine phosphate sodium|
347934|NCT00483704|Drug|Placebo|Placebo tablets
347935|NCT00483717|Drug|Ketorolac tromethamine|2 x 100uL IN sprays (15% ketorolac tromethamine and 6% lidocaine hydrochloride containing 31.5 mg of ketorolac)
347936|NCT00483717|Drug|Placebo|Intranasal (IN) placebo
348278|NCT00474864|Drug|GW856553|
348279|NCT00474877|Device|Static resting splints|
348280|NCT00474890|Drug|cetericine and pseudoephedrine|
347232|NCT00499967|Drug|Placebo|Placebo matching GS-9191 ointment
347233|NCT00499993|Drug|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
347234|NCT00500006|Drug|MK0457|Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.
Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour.
347235|NCT00003703|Drug|SarCNU|
347236|NCT00500006|Drug|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
347237|NCT00500032|Procedure|blood draw|Blood draw from subjects previously vaccinated in 6108A1-500 trial
347238|NCT00500045|Drug|nicotinic acid|niacin 1500 mg po qd
347590|NCT00492531|Drug|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
347591|NCT00492544|Biological|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
347592|NCT00492557|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
347593|NCT00492557|Biological|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
347594|NCT00492583|Drug|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
347595|NCT00492583|Drug|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
347596|NCT00492596|Device|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
347597|NCT00492596|Procedure|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
347598|NCT00003665|Biological|gp100 antigen|
347599|NCT00492622|Drug|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
347600|NCT00492622|Drug|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
349706|NCT00490659|Drug|cisplatin|
349707|NCT00493311|Drug|IV Placebo|IV Placebo
349708|NCT00493311|Drug|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
349709|NCT00493311|Biological|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
349710|NCT00493324|Drug|alefacept|Intramuscular
349711|NCT00493324|Drug|polyvalent pneumococcal vaccine|Injection
349712|NCT00493337|Behavioral|advanced adherence counseling+reminder|
349713|NCT00003669|Drug|arzoxifene hydrochloride|
349714|NCT00493337|Device|Compliance Card|
349715|NCT00493350|Procedure|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
349716|NCT00493363|Drug|artesunate 2 mg/kg/day versus 4 mg/kg/day icm mefloquine|
349717|NCT00493376|Procedure|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
349718|NCT00493376|Procedure|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
349719|NCT00493376|Procedure|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
350065|NCT00484679|Drug|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
350066|NCT00484692|Drug|sustained-release bupropion (Zyban(R))|
350067|NCT00484692|Behavioral|Psychodynamic Model Training (R) = PDM(R)|
350068|NCT00484705|Procedure|Electroacupuncture|
350069|NCT00484705|Procedure|Physical exercise|
350070|NCT00003638|Biological|THERATOPE STn-KLH vaccine|
350071|NCT00484705|Procedure|Untreated control|
350072|NCT00484718|Drug|celecoxib|oral, 100 mg bid
349013|NCT00506597|Drug|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
349014|NCT00003737|Drug|becatecarin|
349370|NCT00498953|Other|immunohistochemistry staining method|
349371|NCT00498953|Other|laboratory biomarker analysis|
349372|NCT00498953|Procedure|conventional surgery|
349373|NCT00498953|Procedure|neoadjuvant therapy|
349374|NCT00500968|Procedure|Distal pancreatectomy|conventional distal pancreatectomy
349375|NCT00500981|Procedure|Volume challenge|
349376|NCT00500981|Procedure|Ultrasound evaluation of internal jugular vein|
349377|NCT00501020|Drug|Rosiglitazone|
349378|NCT00501033|Device|Mechanical induction of labor|
349379|NCT00501033|Device|Double Balloon|
349380|NCT00501033|Device|Foley Catheter|
349381|NCT00501046|Drug|Placebo|9g /day (3 times a day)
349382|NCT00501046|Drug|AST-120|9g /day (3 times a day)
349383|NCT00501059|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
349384|NCT00003711|Drug|pemetrexed disodium|
349385|NCT00501059|Drug|Placebo|Placebo, taken daily
349386|NCT00501072|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
349387|NCT00501085|Device|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
349388|NCT00501098|Drug|Caspofungin|Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.
No stratification is planned.
349389|NCT00501111|Drug|AZD3480|3 oral doses
349390|NCT00501111|Drug|Donepezil|
348660|NCT00468793|Procedure|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
348661|NCT00468806|Drug|GSK598809, using [11C]-(+)-PHNO|
348662|NCT00468819|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
348663|NCT00468845|Drug|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
348664|NCT00468845|Drug|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
348665|NCT00468845|Drug|matched placebo|matched placebo
348666|NCT00468858|Other|Placebo|Lyophilized, single dose vials and sterile water for
> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months
348667|NCT00471523|Drug|Metformin|
348668|NCT00471536|Drug|pazopanib hydrochloride|800 mg Given orally
348669|NCT00471549|Drug|Statin (simvastatin)|
348670|NCT00471562|Biological|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
349015|NCT00506610|Drug|T-62|
349016|NCT00506623|Drug|Capecitabine, Irinotecan|
349017|NCT00506636|Behavioral|Tissue engineering for hair follicle regeneration|
349018|NCT00506649|Other|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
349019|NCT00462644|Drug|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
349020|NCT00462644|Drug|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
349021|NCT00003541|Procedure|peripheral blood stem cell transplantation|
349022|NCT00462657|Genetic|polymerase chain reaction|
349023|NCT00462657|Other|bronchoalveolar lavage|
349024|NCT00462657|Other|immunoenzyme technique|
349025|NCT00462657|Other|laboratory biomarker analysis|
349026|NCT00462657|Procedure|bronchoscopy|
348281|NCT00474903|Drug|acetylsalicylic acid|Given orally
348282|NCT00474903|Drug|esomeprazole magnesium|Given orally
348283|NCT00474903|Other|placebo|Given orally
348284|NCT00474916|Drug|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
348285|NCT00003594|Drug|irinotecan|
348286|NCT00474916|Drug|Placebo|Normal Saline given as dose escalation for placebo
348287|NCT00474929|Drug|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
348288|NCT00477750|Drug|melphalan|Phase I - dose escalating: 5mg/m^2 dose level -1, 5 mg/m^2 dose level 0, 8 mg/m^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression
Phase II - 5mg/m^2 orally days 1-4 every 28 days until progression
348289|NCT00477750|Drug|prednisone|60mg/m^2, orally days 1-4 every 28 days until progression
348290|NCT00477763|Drug|Restasis, Refresh Endura|Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening
Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening
348291|NCT00477776|Drug|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
348292|NCT00477776|Drug|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
348293|NCT00477789|Drug|allopurinol|
348294|NCT00477802|Biological|Botulinum Toxin Type A|Injected once during the course of the study.
348295|NCT00477802|Biological|Placebo|Injected once during the course of the study.
348296|NCT00003603|Drug|prednisolone|
348297|NCT00477815|Biological|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
348298|NCT00477815|Drug|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
348299|NCT00477815|Biological|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
348300|NCT00477815|Biological|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
348671|NCT00471575|Procedure|ultra sound examination|
347601|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
347602|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
347603|NCT00492635|Drug|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
347604|NCT00492648|Procedure|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
347605|NCT00495170|Drug|Paclitaxel|50 mg/m^2 IV Weekly
347606|NCT00495183|Drug|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
347607|NCT00495183|Drug|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
347608|NCT00495183|Drug|Placebo|Placebo
347609|NCT00495196|Procedure|Experimental lung function test|Administration of several CO2 gas mixtures
347937|NCT00483730|Drug|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
347938|NCT00483743|Drug|TPI 1020|250 mcg/caps 2 caps BID x 42 days
347939|NCT00486759|Drug|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
347940|NCT00003645|Drug|Leuprolide Acetate|50 mg tablet orally daily for 12 months
347941|NCT00486759|Drug|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
347942|NCT00486772|Drug|Sevelamer (Renagel), calcium acetate (Phos-ex)|
347943|NCT00486785|Drug|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
347944|NCT00486798|Drug|Quetiapine|
347945|NCT00486798|Procedure|Rating Scales|
347946|NCT00486798|Procedure|Self Assessment Form|
347947|NCT00486798|Procedure|Blood and urine samples|
350073|NCT00484718|Drug|Oxycodone|oral, 20 mg bid
350074|NCT00484718|Drug|placebo|oral bid
350075|NCT00484731|Procedure|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
350076|NCT00484731|Procedure|Infiltration with Bupivacaine|
350077|NCT00484744|Drug|Acetaminophen|
350078|NCT00484744|Drug|Avicel (placebo)|
350079|NCT00484744|Drug|Ibuprofen|
350080|NCT00484757|Drug|Orexine A|
350081|NCT00003638|Biological|keyhole limpet hemocyanin|
350082|NCT00484770|Device|Brain Natriuretic Peptide Levels -- Diagnostic testing|
350083|NCT00484770|Other|clinical assessment|
350084|NCT00484783|Procedure|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
350085|NCT00487708|Drug|canakinumab|
350086|NCT00487721|Drug|Silibin-Phytosome|Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
350087|NCT00487734|Radiation|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
350088|NCT00003650|Drug|dexamethasone|
350089|NCT00487734|Drug|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
350425|NCT00478777|Drug|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
350426|NCT00478790|Device|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
349391|NCT00501124|Drug|Clevudine|
349392|NCT00501124|Biological|Purified hepatitis B surface antigen|
349393|NCT00501137|Biological|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
349394|NCT00501150|Drug|linezolid|
349720|NCT00493376|Procedure|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
349721|NCT00493389|Drug|Adrenocorticotrophic hormone|
349722|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
349723|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
349724|NCT00000545|Behavioral|diet|
349725|NCT00003670|Drug|arzoxifene hydrochloride|
349726|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
349727|NCT00493415|Drug|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
349728|NCT00493415|Drug|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
349729|NCT00493428|Drug|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
349730|NCT00493441|Drug|AVN944|150, 200, 250, 300, or 400 mg q12h
349731|NCT00493454|Drug|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
349732|NCT00493454|Drug|Rituximab|250 mg/m^2 IV Over 6 to 8 Hours
349733|NCT00493454|Drug|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
349734|NCT00496197|Drug|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
349027|NCT00462657|Procedure|management of therapy complications|
349028|NCT00462670|Drug|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
349029|NCT00462696|Drug|docetaxel|
349030|NCT00462696|Drug|epirubicin hydrochloride|
349031|NCT00462696|Procedure|conventional surgery|
349032|NCT00003541|Radiation|radiation therapy|
349033|NCT00462696|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
349034|NCT00462696|Procedure|neoadjuvant therapy|
349035|NCT00462696|Procedure|radiomammography|
349036|NCT00462709|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
349037|NCT00462722|Drug|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
349038|NCT00462722|Drug|Placebo|with each exercise session (up to 5 days per week) for 9 months
349039|NCT00462722|Behavioral|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
349040|NCT00462735|Drug|cetuximab|
349395|NCT00003712|Drug|temsirolimus|•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.
•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II.
349396|NCT00501176|Procedure|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
349397|NCT00501189|Biological|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
349398|NCT00501202|Drug|placebo|twice daily for 4 weeks
349399|NCT00501202|Drug|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
349400|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
349401|NCT00504101|Drug|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
348672|NCT00003582|Drug|fluorouracil|
348673|NCT00471588|Drug|Pramipexole, Amisulpride|Study Drug
348674|NCT00471601|Behavioral|counseling intervention|
348675|NCT00471601|Behavioral|questionnaire administration|
348676|NCT00471601|Behavioral|psychosocial assessment and care|
348677|NCT00471601|Behavioral|quality-of-life assessment|
348678|NCT00471614|Drug|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
348679|NCT00471627|Procedure|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
348680|NCT00471640|Drug|dexamethasone|4 days 5 mg
348681|NCT00471653|Drug|temozolomide|
348682|NCT00471653|Genetic|comparative genomic hybridization|
348683|NCT00000536|Behavioral|sodium, dietary|
348684|NCT00003582|Drug|paclitaxel|
348685|NCT00471653|Genetic|polymorphism analysis|
348686|NCT00471653|Other|laboratory biomarker analysis|
348687|NCT00471653|Other|pharmacological study|
348688|NCT00471653|Radiation|radiation therapy|
348689|NCT00471679|Drug|ethanol|
348690|NCT00471692|Drug|Ropivicaine|
348691|NCT00471705|Drug|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
348692|NCT00471705|Device|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
348693|NCT00471705|Drug|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
347948|NCT00486798|Procedure|Sleeping pattern|
347949|NCT00486811|Drug|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
347950|NCT00486811|Drug|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
347951|NCT00003646|Drug|allovectin-7|
347952|NCT00486811|Drug|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
347953|NCT00486824|Drug|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
347954|NCT00486824|Drug|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
347955|NCT00486837|Drug|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
347956|NCT00486850|Other|Extubation to Nasal IPPV|Comparison of extubation to NIPPV versus NCPAP
347957|NCT00486863|Drug|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
348301|NCT00477815|Radiation|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
348302|NCT00477815|Biological|111In Zevalin|5.0 mCi by IV
348303|NCT00477828|Device|Continuous positive airway pressure|
348304|NCT00477841|Procedure|Esophageal stent placement|
348305|NCT00477841|Procedure|dysphagia scores|
348306|NCT00477841|Procedure|complications of therapy|
348307|NCT00003604|Biological|aldesleukin|
348308|NCT00477841|Procedure|survival time of therapy|
348309|NCT00477854|Drug|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
348310|NCT00477867|Procedure|quality-of-life assessment|
348311|NCT00477880|Biological|cetuximab|
350427|NCT00478803|Procedure|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|Remodeling procedure associated with a subvalvular aortic ring: a) Five "U" stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring "U" stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta.
350428|NCT00478803|Device|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
350429|NCT00478816|Biological|Fluad H5N1 Pandemic Influenza Vaccine|Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
350430|NCT00478842|Device|Deep brain stimulation|Deep brain stimulation
350431|NCT00478855|Drug|Tazocin (Piperacillin/Tazobactem)|
350432|NCT00003611|Drug|acitretin|
350433|NCT00478881|Drug|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
350434|NCT00478881|Drug|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
350435|NCT00478907|Drug|KETAMINE, PROPOFOL, THIOPENTAL|
350436|NCT00478933|Device|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
350437|NCT00478933|Procedure|Blood sampling|Blood sampling
350438|NCT00478946|Drug|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
350439|NCT00478946|Drug|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
350440|NCT00478946|Drug|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
350762|NCT00469781|Drug|1. Pred Forte|Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.
Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks.
349735|NCT00496197|Drug|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
349736|NCT00003682|Drug|doxorubicin hydrochloride|
349737|NCT00496197|Drug|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
349738|NCT00496223|Drug|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
350090|NCT00487747|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
350091|NCT00487773|Drug|budesonide|budesonide
350092|NCT00487773|Drug|D3 vitamin|D3 vitamin
350093|NCT00487773|Drug|montelukast sodium|montelukast sodium
350094|NCT00487773|Drug|salbutamol|salbutamol
350095|NCT00487786|Drug|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
350096|NCT00487786|Drug|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 & 7 only, together with appropriate dose of OGX-427 until withdrawn from study
350097|NCT00487799|Drug|Ularitide|
350098|NCT00487812|Procedure|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
350099|NCT00003650|Drug|etoposide|
350100|NCT00487825|Drug|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
350101|NCT00487825|Drug|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
350102|NCT00487825|Drug|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
350103|NCT00487851|Procedure|surgery|hepaticojejunostomy and gastroenterostomy
350104|NCT00487851|Procedure|endoscopic strategy|Stent insertion
349402|NCT00504101|Drug|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
349403|NCT00504101|Biological|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
349404|NCT00003728|Drug|etoposide|
349405|NCT00504114|Procedure|ACL Reconstruction Surgery|
349406|NCT00504114|Procedure|Cartilage Resurfacing Surgery|
349407|NCT00504114|Procedure|Total Knee Replacement|
349408|NCT00504127|Drug|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
349409|NCT00504127|Drug|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
349410|NCT00504127|Drug|Naproxen 500 mg bid|Naproxen 500 mg bid
349411|NCT00504127|Drug|placebo|placebo
349412|NCT00504140|Drug|Etoposide|100 mg/m^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
349413|NCT00504140|Drug|Interferon Alpha|5x10^6 mu/m^2 Subcutaneously Daily for 5 Days
349414|NCT00504153|Drug|dasatinib|
349415|NCT00003728|Drug|leucovorin calcium|
349416|NCT00504153|Other|laboratory biomarker analysis|Correlative studies
349417|NCT00504166|Drug|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
349739|NCT00496223|Drug|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
349740|NCT00496236|Drug|TNFerade biologic|
349741|NCT00496262|Biological|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
349742|NCT00496275|Drug|Zactima (ZD6474)|
349743|NCT00496275|Drug|Vinorelbine plus cisplatin|
349744|NCT00496275|Drug|Gemcitabine plus cisplatin|
348694|NCT00471718|Drug|ABT-751|Phase I:
Cohort / Number of Patients /Dose (mg) ABT-751 (BID)
-1 / 3-6 /100 mg BID
1 / 3-6 /125 mg BID
2 / 3-6 /150 mg BID
3 / 3-6 /175 mg BID
4 / 3-6 /200 mg BID
Phase II:
Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle
348695|NCT00003582|Procedure|quality-of-life assessment|
349041|NCT00462735|Drug|hydroxyurea|
349042|NCT00462735|Drug|fluorouracil|
349043|NCT00003542|Biological|pegylated interferon alfa|
349044|NCT00462735|Procedure|chemotherapy|
349045|NCT00462735|Procedure|radiotherapy|
349046|NCT00462748|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
349047|NCT00462748|Drug|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
349048|NCT00462748|Drug|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
349049|NCT00465972|Drug|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
349050|NCT00465972|Drug|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
349051|NCT00465972|Drug|Placebo|Placebo capsule nightly for duration of study
349052|NCT00465985|Drug|ACZ885|
349053|NCT00465985|Drug|Placebo|
349054|NCT00466024|Behavioral|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
349055|NCT00466024|Behavioral|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
349056|NCT00466037|Biological|Influenza vaccine|
349057|NCT00466063|Drug|Deferasirox|
349058|NCT00003558|Drug|leucovorin calcium|
349059|NCT00466076|Drug|Copaxone (Glatiramer acetate)|
349060|NCT00466089|Drug|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
348312|NCT00477893|Drug|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
348313|NCT00477893|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
348314|NCT00477906|Biological|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
348315|NCT00477945|Drug|clofarabine|Cohort N Clofarabine (mg/m2/day)
3-6 30
3-6 40
3-6 50
3-6 60
6-10 70
348316|NCT00481000|Behavioral|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
348317|NCT00003620|Other|laboratory biomarker analysis|Correlative studies
348318|NCT00481013|Drug|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
348319|NCT00481013|Drug|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
348320|NCT00481026|Device|transcranial direct current stimulation (tDCS)|tDCS
348321|NCT00481026|Device|active tDCS|Active tDCS
348322|NCT00481039|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
348323|NCT00481052|Drug|Nilotinib|
348324|NCT00481065|Biological|MF59-eH5N1|
348325|NCT00481065|Biological|eTIV_a|
367013|NCT00648024|Drug|Agrylin® Capsules 1 mg|1mg, single dose fasting
350763|NCT00469794|Procedure|stress test|
350764|NCT00469820|Biological|autologous tumor cell vaccine|
350765|NCT00469820|Biological|peripheral blood lymphocyte therapy|
350766|NCT00003576|Drug|fluorouracil|
350767|NCT00469833|Drug|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
350768|NCT00472693|Drug|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
350769|NCT00472706|Procedure|excision|excision 3 mm margin
350770|NCT00472706|Procedure|Photodynamic therapy|Photodynamic therapy
350771|NCT00472719|Biological|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
350772|NCT00472719|Biological|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
350773|NCT00472719|Biological|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
350774|NCT00472745|Behavioral|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
350775|NCT00003585|Biological|recombinant interferon alfa|
350776|NCT00472745|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 months
350777|NCT00472758|Biological|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
350778|NCT00472758|Other|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
350779|NCT00472771|Drug|INNO-206|
350780|NCT00472797|Drug|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
350781|NCT00472797|Drug|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
350782|NCT00472810|Device|ologen collagen matrix in glaucoma filtering surgery|If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
351087|NCT00628745|Other|None. Observational Study.|
350105|NCT00487877|Device|SenseWear Pro3 Armband|
350106|NCT00487877|Device|i-button DS2191 H|
350107|NCT00487903|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
350108|NCT00487916|Drug|AMA1-C1/ISA 720|
350109|NCT00487929|Device|nasal CPAP|Nocturnal
350110|NCT00003650|Drug|mercaptopurine|
350111|NCT00487929|Device|Sham CPAP|Nocturnal
350112|NCT00487942|Drug|armodafinil|50 mg/day armodafinil
350113|NCT00490659|Procedure|radical surgery|
350114|NCT00490659|Procedure|chemoradiotherapy|
350441|NCT00478959|Drug|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
350442|NCT00478972|Drug|rimonabant (SR141716)|oral administration
350443|NCT00003611|Other|placebo|
350444|NCT00478972|Drug|placebo|oral administration
350445|NCT00481884|Other|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
350446|NCT00481884|Other|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
350447|NCT00481897|Behavioral|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
350448|NCT00481923|Drug|rimonabant (SR141716)|
350449|NCT00481936|Drug|VB6-845|Intravenous infusion once weekly for 4 weeks
350450|NCT00481962|Drug|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
350451|NCT00003625|Drug|cyclosporine|
350452|NCT00481975|Drug|rimonabant (SR141716)|
349745|NCT00496288|Radiation|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
349746|NCT00496301|Drug|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
349747|NCT00003682|Drug|methylprednisolone|
349748|NCT00496314|Device|e2TM Cervical Cell Collector|
349749|NCT00496327|Biological|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) [Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
349750|NCT00496340|Drug|Pentostatin|Pre-conditioning therapy:
All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.
Participant will receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3.
349751|NCT00496340|Drug|Busulfan|Pre-conditioning therapy:
Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.
Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.
349752|NCT00496340|Drug|Rituximab|Pre-conditioning therapy:
Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines.
349753|NCT00003696|Drug|etoposide|
349754|NCT00498953|Radiation|fludeoxyglucose F 18|
349755|NCT00498953|Radiation|radiation therapy|
349756|NCT00498966|Drug|Perifosine|Perifosine 100 mg PO
349757|NCT00498979|Biological|recombinant interferon alfa-2b|recombinant interferon alfa-2b
349758|NCT00498979|Drug|cisplatin|recombinant interferon alfa-2b
349759|NCT00498979|Drug|sodium stibogluconate|sodium stibogluconate
349760|NCT00498979|Drug|dacarbazine|dacarbazine
350115|NCT00490672|Behavioral|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
350116|NCT00490672|Behavioral|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
350117|NCT00490685|Drug|Sorafenib (BAY-43-9006)|
349061|NCT00466102|Drug|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
349062|NCT00466102|Drug|Placebo|2 tablets are taken once daily during study therapy
349063|NCT00466115|Drug|MS-275|
349064|NCT00466115|Drug|GM-CSF|
349065|NCT00466128|Drug|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
349066|NCT00466141|Behavioral|Increased Exercise for weight loss maintenance|
349418|NCT00504166|Other|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
349419|NCT00504179|Procedure|Osteopathic Manipulative Treatment|
349420|NCT00504192|Drug|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
349421|NCT00504205|Drug|multitargeted receptor tyrosine kinase inhibitor MP470|
349422|NCT00504205|Other|laboratory biomarker analysis|
349423|NCT00504205|Other|pharmacological study|
349424|NCT00504205|Procedure|positron emission tomography|
349425|NCT00504231|Biological|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
349426|NCT00003728|Drug|mercaptopurine|
349427|NCT00504244|Drug|switch to Myfortic|Myfortic 2 dd 720 mg
349428|NCT00504244|Drug|continuation of azathioprine|Azathioprine 2 mg/kg
349429|NCT00504257|Drug|Avastin|Day 1, every 21 day cycle
349430|NCT00504257|Drug|Docetaxel|Day 1, 8, every 21 day cycle
349431|NCT00504270|Drug|Placebo|po daily
349432|NCT00506662|Drug|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
349433|NCT00506662|Drug|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
349434|NCT00506675|Device|Patching|42 hours per week of patching
349435|NCT00506675|Drug|Atropine|daily atropine (1%)
362938|NCT00634491|Drug|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
362939|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
363250|NCT00668564|Drug|Busulfan|Days before Transplant Drug Frequency
9 Busulfan Four times per day
8 Busulfan Four times per day
7 Busulfan Four times per day
6 Busulfan Four times per day
363251|NCT00668577|Drug|Lactic acid (Dermacid)|
363252|NCT00668590|Behavioral|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
363253|NCT00668590|Behavioral|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
363254|NCT00668603|Drug|17-b-estradiol|2mg oral daily for 6 months
363255|NCT00005065|Radiation|radiation therapy|Undergo radiation therapy
363256|NCT00668603|Drug|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
363257|NCT00668603|Drug|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
363258|NCT00668603|Drug|placebo pill + gel|placebo daily for 6 months
363259|NCT00668616|Drug|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
363260|NCT00668616|Drug|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
363261|NCT00668629|Drug|Lactic acid (Dermacid)|
363262|NCT00668642|Drug|Dutasteride|0.5 mg capsule given orally on daily basis
363263|NCT00668642|Drug|Placebo|Identical placebo
363264|NCT00668655|Drug|Metronidazole Gel|Topical, Once daily for 2 weeks
363265|NCT00668668|Drug|Lactic acid (Dermacid)|
363266|NCT00005066|Drug|O6-benzylguanine|
363267|NCT00668681|Device|EndoRefix|
363268|NCT00668694|Behavioral|Stimulation|Stimulation given to the child by mother
362601|NCT00641537|Drug|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
362602|NCT00641537|Drug|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
362603|NCT00641550|Other|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
362604|NCT00641563|Drug|Dexmedetomidine|Infusion of dexmedetomidine
362605|NCT00000640|Drug|Primaquine|
362606|NCT00004857|Drug|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
362607|NCT00643734|Drug|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
362608|NCT00643734|Other|placebo|placebo
362609|NCT00643734|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
362610|NCT00643734|Other|placebo|placebo
362611|NCT00643747|Biological|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
362612|NCT00643760|Drug|Placebo|placebo
362940|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
362941|NCT00636558|Drug|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
362942|NCT00636571|Behavioral|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
362943|NCT00636584|Drug|sodium nitroprusside|sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
362944|NCT00636584|Drug|placebo|placebo
362945|NCT00004778|Drug|dexamethasone|
362946|NCT00636610|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
362947|NCT00636610|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
362273|NCT00648700|Drug|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
362274|NCT00004898|Drug|cyclophosphamide|
362275|NCT00648713|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
362276|NCT00648713|Drug|Lamisil® Tablets 250 mg|250mg, single dose fed
362277|NCT00648726|Drug|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
362278|NCT00648726|Drug|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
362279|NCT00648726|Drug|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
362280|NCT00648739|Drug|ALXN6000|Part A is a comparison of different dosages of ALXN6000 by cohort ranging from 50 mg/m2 up to 600 mg/m2 given as a single IV dose. Once the most appropriate dose is determined it will be given over a 28 day cycle for 4 cycles in Part B Cohort 1 = 50 mg/m2 Cohort 2 = 100 mg/m2 Cohort 3 = 200 mg/m2 Cohort 4 = 300 mg/m2 Cohort 5 = 400 mg/m2 Cohort 6 = 500 mg/m2
362281|NCT00648765|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
362282|NCT00648765|Drug|Agrylin® Capsules 1 mg|1mg, single dose fed
362283|NCT00651235|Drug|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
362284|NCT00651261|Drug|cytarabine|Given IV
362285|NCT00651261|Drug|daunorubicin|Given IV
362286|NCT00004904|Procedure|allogeneic bone marrow transplantation|
362287|NCT00651261|Drug|midostaurin|Given orally
362288|NCT00651261|Other|placebo|Given orally
362289|NCT00651261|Drug|dexamethasone acetate|ocular medication administration
362290|NCT00651274|Drug|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
362291|NCT00651274|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
362613|NCT00643760|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
362614|NCT00643760|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
361630|NCT00663624|Drug|aspart insulin|subcutaneous aspart insulin every 2 hours
361631|NCT00663624|Drug|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
361632|NCT00663637|Device|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
361633|NCT00663650|Procedure|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
361955|NCT00656019|Drug|Vitamin D|2000, 4000, and 6000 IU, oral
361956|NCT00656032|Other|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
361957|NCT00656032|Other|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
361958|NCT00656045|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
361959|NCT00656045|Behavioral|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
361960|NCT00004924|Drug|paclitaxel|
361961|NCT00656045|Behavioral|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
361962|NCT00656058|Drug|Singular (Montelukast Sodium)|Montelukast treatment following allogeneic or autologous stem cell
361963|NCT00658489|Behavioral|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
361964|NCT00658515|Drug|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
361965|NCT00658515|Drug|Placebo|po daily
361966|NCT00658515|Drug|dalcetrapib|600mg po daily
361967|NCT00658528|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
361968|NCT00658528|Drug|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
361969|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
366758|NCT00663039|Drug|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
366759|NCT00663039|Drug|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
366760|NCT00663052|Drug|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
366761|NCT00005022|Radiation|radiation therapy|
366762|NCT00663052|Drug|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
366763|NCT00663065|Drug|PAZ-417|
366764|NCT00663078|Behavioral|Brief CBT Group therapy|CBT based therapy also expert patient programme
366765|NCT00665353|Drug|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
366766|NCT00665353|Drug|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
366767|NCT00665366|Drug|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
366768|NCT00005038|Drug|histamine dihydrochloride|
366769|NCT00665366|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
366770|NCT00665366|Drug|Lithium|Participant's ongoing dose
366771|NCT00665366|Drug|Valproate|Participant's ongoing dose
366772|NCT00665379|Other|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
366773|NCT00665379|Other|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
366774|NCT00665392|Drug|cisplatin|75 mg/m², day 1. 3 cycles
366775|NCT00665392|Drug|docetaxel|75 mg/m² Day 1. 3 cycles
366776|NCT00665392|Drug|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
366777|NCT00665392|Drug|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
366092|NCT00004800|Biological|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
366093|NCT00637858|Other|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
366094|NCT00637871|Drug|Casodex|150mg once daily
366095|NCT00637871|Drug|Tamoxifen|
366096|NCT00637884|Drug|Fexofenadine HCl|
366097|NCT00637897|Drug|docetaxel|
366098|NCT00637897|Drug|ixabepilone|
366099|NCT00637897|Drug|paclitaxel|
366100|NCT00637897|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
366431|NCT00669981|Behavioral|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
366432|NCT00005076|Drug|irinotecan hydrochloride|
366433|NCT00669994|Drug|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
366434|NCT00670007|Biological|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
366435|NCT00670020|Procedure|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
366436|NCT00670033|Drug|Travoprost ophthalmic solution (new formulation)|
366437|NCT00633386|Drug|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
366438|NCT00633386|Other|Placebo|Matched placebo
366439|NCT00633399|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
366440|NCT00004734|Drug|folic acid multivitamin|
366441|NCT00633399|Drug|Placebo|0mg Placebo per day (1-4 tablets per day). "Dose increases" and "dose decreases" may occur, but patient will remain at 0mg placebo.
366442|NCT00633412|Drug|Esomeprazole|20mg oral daily
366443|NCT00633412|Drug|Ranitidine|150mg oral twice daily
365757|NCT00644891|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
365758|NCT00644891|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
365759|NCT00644904|Dietary Supplement|Vitamin D3|
365760|NCT00644904|Dietary Supplement|Vitamin D3|
365761|NCT00644917|Drug|Xenaderm|20mg under Finn chambers
365762|NCT00644917|Drug|Placebo|20mg under Finn chambers
365763|NCT00644930|Device|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
365764|NCT00644930|Device|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist—control or synchronized intermittent mandatory ventilation (SIMV) mode.
365765|NCT00644943|Drug|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
365766|NCT00004878|Procedure|in vitro-treated peripheral blood stem cell transplantation|
365767|NCT00644943|Drug|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
365768|NCT00644956|Drug|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
365769|NCT00644956|Drug|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
365770|NCT00644969|Drug|placebo|Randomization 2:1 treatment to placebo
365771|NCT00644969|Drug|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
365772|NCT00644982|Drug|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
365773|NCT00644982|Drug|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
365774|NCT00644995|Behavioral|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
365775|NCT00644995|Behavioral|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
365776|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
365106|NCT00657319|Drug|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
365107|NCT00657332|Procedure|blood sample draw|
365108|NCT00657332|Procedure|urine sample|
365109|NCT00004934|Drug|epirubicin hydrochloride|
365110|NCT00657358|Drug|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
365111|NCT00657371|Device|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
365112|NCT00659906|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
365428|NCT00650117|Drug|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
365429|NCT00652353|Other|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
365430|NCT00652366|Drug|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
365431|NCT00652366|Drug|Erlotinib, standard dose|100mg, PO, once daily
365432|NCT00652366|Drug|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
365433|NCT00652379|Drug|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
365434|NCT00652379|Drug|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
365435|NCT00652392|Drug|budesonide/formoterol|
365436|NCT00652392|Drug|budesonide and placebo|
365437|NCT00652405|Dietary Supplement|alcohol|250 ml of white wine (13% vol; ~25 gram of alcohol per day)
365438|NCT00652405|Dietary Supplement|Placebo|250 ml of mineral water (Brand name: Vittel)
365439|NCT00004906|Drug|pamidronate disodium|
365440|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
364789|NCT00005033|Procedure|conventional surgery|
364790|NCT00664599|Drug|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
364791|NCT00664599|Drug|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
364792|NCT00664612|Device|AirTraq|Laryngoscopy with AirTraq
364793|NCT00664625|Drug|BMS-791325|Capsules, Oral, Once Daily, Single Dose
364794|NCT00664625|Drug|Placebo|Capsules, Oral, Once Daily, Single Dose
364795|NCT00664638|Device|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
364796|NCT00664664|Drug|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
364797|NCT00664664|Drug|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
364798|NCT00664664|Drug|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
364799|NCT00664677|Drug|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
364800|NCT00005035|Drug|oxaliplatin|
364801|NCT00664690|Drug|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
365113|NCT00659906|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
365114|NCT00659919|Drug|Placebo|
365115|NCT00659919|Drug|Trazodone|
365116|NCT00659932|Behavioral|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
365117|NCT00000173|Drug|Donepezil|
365118|NCT00000651|Drug|Zalcitabine|
365119|NCT00004998|Drug|Capravirine|
365120|NCT00659932|Behavioral|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
364104|NCT00637052|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
364105|NCT00637065|Drug|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
364106|NCT00637065|Drug|Placebo|Placebo tables - identical to active drug but without the active ingredient -
364461|NCT00632632|Drug|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
364462|NCT00632632|Other|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
364463|NCT00004728|Drug|Warfarin|
364464|NCT00632645|Drug|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
364465|NCT00632645|Drug|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
364466|NCT00632645|Drug|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
364467|NCT00632684|Behavioral|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
364468|NCT00632684|Behavioral|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
364469|NCT00632697|Drug|pentoxifylline|800 mg daily for six months
364470|NCT00632697|Drug|placebo|
364471|NCT00632710|Other|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
364472|NCT00632710|Other|phototherapy placebo|disconnected laser (same device - experimental group)
364473|NCT00632723|Drug|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
364474|NCT00004728|Drug|Aspirin|
364475|NCT00632736|Drug|Ropinirole XL (formerly CR)|
364476|NCT00632749|Drug|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
360770|NCT00655616|Drug|Salmeterol, Montelukast|Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast
Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast
Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast
Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast
Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily
360771|NCT00655629|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
360772|NCT00655629|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
360773|NCT00655642|Drug|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
360774|NCT00004937|Drug|acridine carboxamide|
360775|NCT00658008|Drug|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
360776|NCT00658021|Drug|Placebo|Subcutaneous injection, twice a day
360777|NCT00658021|Drug|Exenatide|Subcutaneous injection, 5 µg, twice a day
360778|NCT00658021|Drug|Exenatide|Subcutaneous injection,10 µg, twice a day
360779|NCT00658034|Procedure|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
360780|NCT00658034|Procedure|Placebo Acupuncture|Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.
Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture.
360781|NCT00658047|Drug|CH-1504|Comparison of different doses of CH-1504
360782|NCT00658047|Drug|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
360783|NCT00658073|Procedure|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
360784|NCT00658073|Procedure|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
360785|NCT00004938|Drug|fluconazole|
365213|NCT00669526|Behavioral|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
365214|NCT00669526|Behavioral|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
365215|NCT00005071|Procedure|biopsy|
365216|NCT00669552|Procedure|Percutaneous coronary intervention|PCI previously electively scheduled.
365217|NCT00669565|Drug|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
365218|NCT00669578|Drug|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
365219|NCT00669591|Drug|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
365220|NCT00669617|Drug|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
365535|NCT00662519|Other|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
365536|NCT00662519|Other|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
365537|NCT00662532|Drug|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
365538|NCT00662545|Drug|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
365539|NCT00662545|Drug|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
365540|NCT00662558|Drug|celecoxib|200 mg capsules BID for 6 weeks
365541|NCT00662558|Drug|tramadol HCL|50 mg capsules QID for 6 weeks
365542|NCT00005018|Drug|Efavirenz|
365543|NCT00662571|Drug|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
365544|NCT00662584|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
365545|NCT00662597|Drug|ASA404|
365546|NCT00662597|Drug|Placebo|
364896|NCT00635076|Other|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
364897|NCT00635076|Drug|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
364898|NCT00635089|Drug|reslizumab|initial dosing of reslizumab 1mg/kg i.v.monthly
364899|NCT00635102|Drug|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
364900|NCT00635102|Drug|Placebo|Placebo
364901|NCT00637312|Device|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
364902|NCT00637312|Device|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
364903|NCT00004789|Drug|tin mesoporphyrin|
364904|NCT00637325|Drug|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
364905|NCT00637338|Biological|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
364906|NCT00637338|Biological|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
364907|NCT00637351|Procedure|Blood sample|One blood sample will be collected at the time of screening for subjects
364908|NCT00637351|Procedure|Urine sample|One urine sample will be collected at the time of screening for subjects
365221|NCT00669617|Drug|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
365222|NCT00669617|Drug|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
365223|NCT00669617|Drug|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
365224|NCT00669617|Drug|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
365225|NCT00669617|Drug|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
364569|NCT00642317|Behavioral|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
364570|NCT00642330|Drug|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
364571|NCT00642330|Drug|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
364572|NCT00004862|Biological|oblimersen sodium|
364573|NCT00642343|Behavioral|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
364574|NCT00644423|Drug|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
364575|NCT00644423|Drug|Placebo|Matching Placebo
364576|NCT00644436|Device|Tetrix|single topical application
364577|NCT00644436|Device|Tetrix|Single topical application
364578|NCT00644449|Other|placebo|placebo
364579|NCT00644449|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
364580|NCT00644449|Other|placebo|placebo
364581|NCT00004878|Biological|therapeutic allogeneic lymphocytes|
364582|NCT00644449|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
364583|NCT00644462|Device|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
364584|NCT00644475|Drug|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
364585|NCT00644475|Drug|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
364586|NCT00644488|Drug|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
363901|NCT00654407|Drug|Atorvastatin|
363902|NCT00654407|Drug|Simvastatin|
363903|NCT00654420|Drug|Comparator: Dalotuzumab (MK0646)|Dalotuzumab IV infusion over 60 minutes at 5 mg/kg weekly and then dose escalate to 10 mg/kg weekly following the dose limiting toxicity (DLT) then the dose will be considered. Phase II will be IV infusion over 60 minutes at 5 mg/kg weekly.
363904|NCT00654420|Drug|Comparator: erlotinib|Erlotinib will be administrated orally by mouth (PO) at 150 mg daily.
363905|NCT00654433|Biological|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
364239|NCT00649610|Drug|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
364240|NCT00649623|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
364241|NCT00000643|Drug|Leucovorin calcium|
364242|NCT00004900|Drug|etoposide|
364243|NCT00649623|Drug|Benicar® Tablets 40 mg|40mg, single dose fasting
364244|NCT00649636|Drug|Fluoxetine Capsules 40 mg|40mg, single dose fasting
364245|NCT00649636|Drug|Prozac Pulvules 40 mg|40mg, single dose fasting
364246|NCT00649649|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
364247|NCT00649649|Drug|Accupril® Tablets 40 mg|40mg, single dose fed
364248|NCT00651937|Drug|Melphalan|100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
364249|NCT00651937|Procedure|Stem Cell Infusion|Stem Cell Infusion is Day 0.
Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 CD34/kg On Day 0
High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0.
364250|NCT00651937|Behavioral|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
364251|NCT00651937|Drug|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
364252|NCT00004906|Drug|anastrozole|
364253|NCT00651937|Procedure|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
364254|NCT00651963|Drug|ezetimibe|Ezetimibe 10 mg daily was added during 4 weeks.
The patients continued taking their usual Statin without titrating the dose.
363578|NCT00661882|Procedure|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
363579|NCT00661895|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
363580|NCT00661895|Drug|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
363581|NCT00661895|Drug|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
363582|NCT00661895|Drug|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
363583|NCT00005013|Drug|Hypericum perforatum (St. John's wort)|
363584|NCT00661895|Drug|Metoprolol tartrate|50 mg tablets & 100 mg tablets
363585|NCT00661895|Drug|Atenolol|50 mg tablet
363586|NCT00661895|Drug|Valsartan|80 mg tablets & 160 mg tablet
363587|NCT00661895|Drug|Doxazosin|4 mg tablets
363588|NCT00661895|Drug|Clonidine|0.2 mg tablets
363589|NCT00661895|Drug|Hydralazine|50 mg tablets
363590|NCT00661895|Drug|Metoprolol succinate|50 mg tablet & 100 mg tablet
363591|NCT00661895|Drug|Amlodipine|5 mg tablets & 10 mg tablets
363906|NCT00656682|Behavioral|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
363907|NCT00656695|Drug|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
363908|NCT00004931|Drug|leucovorin calcium|Given IV
363909|NCT00656695|Drug|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
363910|NCT00656708|Other|Kerlix AMD gauze|Use Kerlix AMD gauze as the wound dressing for the entire burn unit
363269|NCT00668707|Dietary Supplement|melatonin|20 mgs ingested nightly
363270|NCT00668707|Dietary Supplement|placebo|similar to experimental in all ways except for lack of active ingredient
363271|NCT00668720|Device|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
363592|NCT00661921|Biological|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
363593|NCT00005028|Drug|paclitaxel|
363594|NCT00664144|Drug|Rasburicase (SR29142)|
363595|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
363596|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
363597|NCT00664170|Drug|ANX-514|75 mg/m^2
363598|NCT00664170|Drug|docetaxel|75 mg/m^2
363599|NCT00664183|Drug|Vitreosolve|Intravitreal injection
363600|NCT00664196|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
363601|NCT00664209|Drug|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
363602|NCT00664209|Drug|placebo|placebo therapy
363603|NCT00664222|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
363604|NCT00005029|Drug|topotecan hydrochloride|
363605|NCT00664248|Drug|IDP-110|Topical application for 12 weeks
363606|NCT00664248|Drug|Clindamycin|Topical application for 12 weeks
363607|NCT00664248|Drug|Benzoyl peroxide|Topical application for 12 weeks
363608|NCT00664248|Drug|Vehicle|Topical application for 12 weeks
363609|NCT00664261|Behavioral|smoking cessation intervention|
363610|NCT00664261|Other|cancer prevention|
362948|NCT00636610|Drug|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
362949|NCT00636610|Drug|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
362950|NCT00636610|Drug|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then fluorouracil 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
362951|NCT00636623|Other|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
362952|NCT00636623|Other|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
362953|NCT00636636|Drug|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
362954|NCT00636636|Drug|Placebo|Once daily; 300 mg and 600 mg tablets
362955|NCT00636649|Drug|Escitalopram|10-20 mg
362956|NCT00004778|Drug|thyrotropin-releasing hormone|
362957|NCT00636649|Drug|Placebo|Placebo
362958|NCT00636662|Other|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
363272|NCT00668720|Device|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
363273|NCT00668746|Drug|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
363274|NCT00004697|Drug|choline chloride|
363275|NCT00632086|Drug|aspirin component of PA32540|The 325 mg aspirin component of PA32540
363276|NCT00632086|Drug|Ecotrin|325 mg Ecotrin
363277|NCT00632099|Drug|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
363278|NCT00632099|Drug|Placebo|matched placebo
363279|NCT00632125|Drug|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
362615|NCT00004872|Biological|recombinant human endostatin|
362616|NCT00643760|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
362617|NCT00643760|Drug|Pregabalin|pregabalin 300mg/day
362618|NCT00643773|Dietary Supplement|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
362619|NCT00643773|Dietary Supplement|Wheat flour|Wheat flour
362620|NCT00643786|Drug|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
362621|NCT00643786|Drug|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
362622|NCT00643799|Drug|Celecoxib|200 mg oral capsule once daily for 6 months
362623|NCT00643799|Drug|Naproxen|500 mg oral capsule twice daily for 6 months
362624|NCT00643799|Drug|Placebo|Matched oral placebo for 6 months
362625|NCT00643812|Other|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
362626|NCT00004873|Drug|cisplatin|
362627|NCT00643812|Other|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. "Late" arm received the gun locker 12 months after baseline.
362628|NCT00643825|Drug|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
362629|NCT00643825|Drug|Temozolomide|Observation till Progression then rechallenging with TMZ
362630|NCT00643838|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
362631|NCT00643851|Drug|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
362632|NCT00643851|Drug|Metformin XR|Tablets, Oral, Once daily, 24 weeks
362633|NCT00643864|Behavioral|motor training|Mirror training and motor imagery
362634|NCT00004887|Drug|carboplatin|
362635|NCT00646074|Behavioral|Self-Care Talk|6 conversational sessions
361970|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
361971|NCT00004979|Drug|topotecan hydrochloride|
361972|NCT00658554|Drug|ARQ 197|Treatment with ARQ 197
361973|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
361974|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
361975|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
361976|NCT00658580|Drug|Cisplatin + etoposide|Cisplatin 90 mg/m² day 1, every 3 weeks
Etoposide 100 mg/m² days 1-3, every 3 weeks
362292|NCT00651287|Drug|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
362293|NCT00651287|Drug|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
362294|NCT00651287|Drug|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
362295|NCT00651300|Drug|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
362296|NCT00651300|Drug|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
362297|NCT00004904|Procedure|in vitro-treated peripheral blood stem cell transplantation|
362298|NCT00651313|Drug|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
362299|NCT00651313|Drug|Placebo|Placebo vaginal gel administered once daily for 4 days
362300|NCT00651326|Drug|bicalutamide|
362301|NCT00651326|Drug|buserelin|
362302|NCT00651326|Drug|flutamide|
362303|NCT00651326|Drug|goserelin|
362304|NCT00651326|Drug|leuprolide acetate|
361634|NCT00663650|Procedure|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
361635|NCT00665756|Procedure|second Trabeculectomy|second trabeculectomy with mitomycin-c
361636|NCT00665756|Procedure|Ahmed Implant|Ahmed silicone drainage device
361637|NCT00665769|Other|Hypercapnia|transcutaenous CO2 50-60 mm Hg
361638|NCT00665769|Other|Normocapnia|transcutaneous CO2 35-45 mm Hg
361639|NCT00665782|Other|laboratory biomarker analysis|
361640|NCT00665782|Other|questionnaire administration|
361641|NCT00665782|Other|study of socioeconomic and demographic variables|
361642|NCT00005044|Drug|flutamide|
361643|NCT00665782|Procedure|assessment of therapy complications|
361644|NCT00665782|Procedure|psychosocial assessment and care|
361645|NCT00665782|Procedure|therapeutic conventional surgery|
361646|NCT00665808|Drug|insulin detemir|Observational study on treatment satisfaction of Levemir ® versus Protaphane® during "real-life" usage in Germany
361647|NCT00665808|Drug|isophane human insulin|Observational study on treatment satisfaction of Levemir ® versus Protaphane® during "real-life" usage in Germany
361648|NCT00665821|Behavioral|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
361649|NCT00665821|Behavioral|General health education|General health education: a booklet describing general norms for maintaining good health
361650|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
361651|NCT00665834|Drug|placebo|placebo 20 mg from day 0 to (maximum) day 6
361652|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
361653|NCT00005044|Drug|releasing hormone agonist therapy|
361654|NCT00665834|Drug|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
366444|NCT00633412|Drug|Esomeprazole|40mg oral tablet daily
366445|NCT00633425|Drug|GLIMEPIRIDE|
366446|NCT00633438|Other|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
366447|NCT00633438|Drug|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
366448|NCT00633451|Other|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
366449|NCT00633451|Other|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
366450|NCT00633464|Drug|ixabepilone|injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.
Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria.
366451|NCT00004735|Biological|Tetanus toxoid|
366778|NCT00665405|Radiation|CT scan|Thoracic CT scan
366779|NCT00005039|Biological|recombinant fowlpox-prostate specific antigen vaccine|Given IM
366780|NCT00665418|Drug|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
366781|NCT00665431|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
366782|NCT00665431|Drug|celebrex|200 mg celecoxib qd
366783|NCT00665431|Other|Placebo|sugar pill bid
366784|NCT00665431|Drug|Rescue Antacid|Antacid Tablets
366785|NCT00665444|Drug|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
366786|NCT00665457|Biological|filgrastim|
366787|NCT00665457|Drug|capecitabine|
366788|NCT00665457|Drug|celecoxib|
366789|NCT00665457|Drug|cyclophosphamide|
366790|NCT00000656|Drug|Didanosine|
365777|NCT00004878|Procedure|peripheral blood stem cell transplantation|
366101|NCT00637897|Drug|paricalcitol|
366102|NCT00637910|Drug|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
366103|NCT00000638|Drug|Rifampin|
366104|NCT00640458|Drug|Sildenafil 100 mg|
366105|NCT00640458|Drug|Placebo|
366106|NCT00004844|Procedure|tissue implantation|
366107|NCT00640471|Biological|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
366108|NCT00640471|Drug|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
366109|NCT00640484|Drug|carmoterol (CHF 4226)|carmoterol (CHF 4226) 2 μg once a day, in the morning
(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)
366110|NCT00640484|Drug|carmoterol (CHF 4226)|carmoterol (CHF 4226) 4 μg once a day, in the morning
(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)
366111|NCT00640484|Drug|placebo|placebo once a day, in the morning
(1 puff of placebo pMDI + 1 puff of placebo pMDI)
366112|NCT00640484|Drug|salmeterol|Salmeterol 50 μg twice daily, in the morning and in the evening
(1 blister of Serevent Diskus BID)
366113|NCT00640497|Biological|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
366114|NCT00640510|Drug|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
366115|NCT00640510|Drug|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
366116|NCT00640523|Drug|forodesine HCl|2 x 100mg capsules daily
366117|NCT00004845|Drug|Rofecoxib|
365441|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
365442|NCT00652431|Drug|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
365443|NCT00652431|Drug|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
365444|NCT00652431|Drug|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
365445|NCT00652444|Drug|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
365446|NCT00652444|Drug|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
365447|NCT00652444|Drug|Placebo (Unspecified)|Matching ezetimibe placebo
365448|NCT00652457|Drug|Memantine|10 mg BID x 3 months
365449|NCT00652470|Procedure|Endoscopic Third Ventriculostomy|A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
365450|NCT00004906|Drug|thiotepa|
365778|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
365779|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
365780|NCT00645034|Drug|placebo|placebo by mouth as a single dose
365781|NCT00645034|Drug|sildenafil|sildenafil 100 mg by mouth as a single dose
365782|NCT00647413|Behavioral|bio-chemical feedback and expert system intervention ETS|Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.
The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants
365783|NCT00647426|Drug|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
365784|NCT00647452|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
365785|NCT00647465|Drug|vaccine|IFNalpha 2b
365786|NCT00647465|Drug|Placebo|Placebo
365121|NCT00659945|Drug|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
365122|NCT00659945|Drug|Ondansetron plus placebo|Ondansetron plus placebo
365123|NCT00659958|Drug|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
365124|NCT00659971|Drug|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
365125|NCT00659984|Radiation|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg [3.7 MBq/kg] (minimum dose 1mCi [37MBq] but not to exceed 5 mCi [185 MBq]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
365126|NCT00659984|Radiation|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose (per table in section 4.3.2 of protocol) will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed > 23 Gy to the kidneys, > 30 Gy to the liver, or > 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given on this study.
365127|NCT00659984|Procedure|Peripheral blood stem cell infusion|If > 12mCi/kg therapeutic dose UltratraceTM is administered, stem cells will be given day 14 +/- 3 days post -treatment. See section 4.2.3
365128|NCT00659997|Drug|Albendazole|Single oral dose of 400mg
365129|NCT00659997|Drug|Levamisole|Single oral dose of 2.5mg/kg
365130|NCT00004998|Drug|Nelfinavir mesylate|
365131|NCT00660010|Drug|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
365451|NCT00652470|Procedure|CSF Shunt Insertion|The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
365452|NCT00652483|Drug|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
365453|NCT00652483|Drug|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
365454|NCT00654914|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
365455|NCT00654927|Drug|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
365456|NCT00654940|Drug|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
364477|NCT00634907|Other|Usual care warfarin dosing|For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management will be compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.
NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin is not specific to this study, nor is the duration of prophylaxis, however, warfarin dosing will be influenced by the study arm as noted above.
364478|NCT00004756|Procedure|Tailored educational program|
364479|NCT00634920|Drug|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
364802|NCT00666822|Behavioral|compliance monitoring|To examine the relationship between adherence to endocrine therapy and variables from the Health Belief Model (i.e., perceived risk, barriers to and benefits of adherence, and cues to action such as physician recommendation) as well as measures of patient's perceptions of patient- and family-centered care in women with estrogen receptor-positive stage I-IIIA breast cancer.
364803|NCT00666822|Other|medical chart review|Patient's medical records are reviewed for information about the time since diagnosis, tumor characteristics, treatment, and comorbidity.
364804|NCT00666822|Other|questionnaire administration|Patients complete a 15 minute questionnaire on-line or by mail comprising questions of demographic and medical variables (i.e., age, race/ethnicity, marital and educational status, and medication side effects) as well as health beliefs and selected aspects of patient- and family-centered care. Data collected from the questionnaire will be stored in an Excel database.
364805|NCT00666835|Drug|HX 575 Solution for i.v. injection|HX 575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
364806|NCT00666835|Drug|ERYPO®, Janssen-Cilag, Germany|Solution for i.v. injection
364807|NCT00666848|Drug|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
364808|NCT00666848|Drug|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
364809|NCT00005050|Drug|fluorouracil|
364810|NCT00666848|Drug|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
364811|NCT00666848|Drug|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
364812|NCT00666874|Behavioral|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
364813|NCT00666874|Behavioral|Control - general information|General information about healthy food choices and exercise
364814|NCT00666887|Drug|Minocycline|100 mg twice daily to be taken for up to 2 years
364815|NCT00666887|Drug|Placebo|placebo twice daily for 2 years
360786|NCT00658086|Drug|ALN-RSV01|administered by nebulization once daily for 3 days
360787|NCT00658086|Drug|normal saline|administered by nebulization once daily for 3 days
361091|NCT00004904|Biological|filgrastim|
361092|NCT00650806|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
361093|NCT00650806|Drug|Placebo|One matching placebo capsule orally once daily for 12 weeks.
361094|NCT00650819|Drug|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
361095|NCT00650819|Drug|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
361096|NCT00650819|Drug|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
361097|NCT00650832|Drug|TMC114; darunavir; Prezista|
361098|NCT00650845|Drug|Dotarem®-enhanced MRI|Single IV administration before MRI exam
361099|NCT00650845|Other|non-enhanced MRI|non injected MRI
361100|NCT00650858|Drug|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
361101|NCT00650871|Drug|GW679769|
361102|NCT00004904|Drug|cladribine|
361103|NCT00650871|Drug|Placebo|
361104|NCT00653068|Drug|methotrexate|Given IV
361105|NCT00653068|Drug|leucovorin calcium|Given IV or orally
361106|NCT00653068|Drug|etoposide|Given IV
361107|NCT00653068|Drug|cyclophosphamide|Given IV
361108|NCT00653068|Drug|cisplatin|Given IV
361109|NCT00004908|Radiation|radiation therapy|
361110|NCT00653068|Biological|filgrastim|Given IV or SC
361111|NCT00653068|Drug|carboplatin|Given IV
365547|NCT00662597|Drug|carboplatin|
365548|NCT00662597|Drug|Paclitaxel|
365549|NCT00662610|Drug|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
365550|NCT00662610|Drug|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
365551|NCT00662623|Behavioral|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
365552|NCT00662623|Behavioral|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
365553|NCT00005018|Drug|Didanosine|
365554|NCT00664794|Procedure|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
365555|NCT00664794|Procedure|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
365556|NCT00664820|Dietary Supplement|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
365557|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
365891|NCT00657592|Drug|oral Ziprasidone|Subjects in this group will receive one pill (20 mg) of Ziprasidone to be taken twice-a-day. This dose will be increased by 1 pill (20 mg) twice-a-day each week for 6 weeks, if well tolerated, to a maximum of 4 pills (80 mg) taken twice daily.
During Phase 2, you will receive the same dose and frequency of Ziprasidone as administered during Phase 1. If you had not reached the maximum dose of 4 pills taken twice daily, your dosage will continue to be increased (if tolerated) each week by 1 pill taken twice daily until you reach the maximum dosage level.
365892|NCT00657592|Drug|Placebo and Ziprasidone|If you are randomized to group 2, during Phase 1, you will receive one pill (20 mg) of placebo to be taken twice-a-day. This dose will be increased by 1 pill (20 mg) twice-a-day each week for 6 weeks.
During Phase 2, you will receive one pill (20 mg) of Ziprasidone to be taken twice-a-day. This dose will be increased by 1 pill (20 mg) twice-a-day each week for 6 weeks, if well tolerated, to a maximum of 4 pills (80 mg) taken twice daily.
365893|NCT00657592|Drug|Placebo|If you are randomized to group 3, during Phase 1, you will receive one pill (20 mg) of placebo to be taken twice-a-day. This dose will be increased by 1 pill (20 mg) twice-a-day each week for 6 weeks.
During Phase 2, you will continue to receive the same dose and frequency of placebo as administered during Phase 1. If you do not reach the maximum dose of 4 pills taken twice daily, your dosage will continue to be increased until you reach the maximum dosage level.
365894|NCT00657605|Drug|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
365895|NCT00657618|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
365226|NCT00005071|Procedure|bronchoscopy|
365227|NCT00669630|Behavioral|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
365228|NCT00669643|Drug|Rifampicin and Dapsone|Adult: 6 doses;
1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;
Children: 6 doses;
1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone
365229|NCT00669643|Drug|Rifampicin, Clofazimine and Dapsone|Adult: 6 doses;
1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;
Children: 6 doses;
1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
365230|NCT00669643|Drug|Rifampicin, Clofazimine and Dapsone|Adult: 12 doses;
1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;
Children: 12 doses;
1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
365231|NCT00669643|Drug|Rifampicin, Clofazimine and Dapsone|Adult: 6 doses
1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine
Children: 6 doses
1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
365232|NCT00669656|Drug|Prostate Health Cocktail|3 capsules daily PO up 12 months
365233|NCT00632931|Drug|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
365234|NCT00632931|Drug|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
365235|NCT00632957|Dietary Supplement|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
365236|NCT00632957|Dietary Supplement|Placebo|corn/soybean oil capsules 1g/three times daily
365237|NCT00632970|Drug|Raltegravir|1 400mg tablet twice a day
365238|NCT00632970|Drug|Lopinavir/Ritonavir|2 tablets twice a day
365558|NCT00005036|Drug|leucovorin calcium|Given IV
365559|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
365560|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
365561|NCT00664833|Other|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
364909|NCT00637364|Procedure|High intensity focused ultrasound, HIFU|The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).
The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue.
364910|NCT00637377|Drug|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
364911|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
364912|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
364913|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
364914|NCT00004794|Drug|cidofovir|
364915|NCT00637390|Drug|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
364916|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr >80 mL/min)
364917|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
364918|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - <50 mL/min)
364919|NCT00640003|Drug|Placebo|placebo drug
364920|NCT00640016|Drug|CAT-354|1 mg/kg CAT-354 on Day 0, 28, and 56 5 mg/kg CAT-354 on Day 0, 28, and 56 10 mg/kg CAT-354 on Day 0, 28, and 56
364921|NCT00640016|Drug|Placebo|Placebo to match all doses of CAT-354 on Day 0, 28, and 56.
364922|NCT00004834|Drug|imipramine|
364923|NCT00640029|Procedure|Arthrodesis|posterior,
anterior,
circumference approach
364255|NCT00651976|Drug|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
364256|NCT00651976|Other|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
364257|NCT00651976|Procedure|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
364258|NCT00651989|Other|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
364259|NCT00652002|Drug|budesonide/formoterol|
364260|NCT00652002|Drug|budesonide|
364261|NCT00652002|Drug|formoterol|
364587|NCT00644501|Drug|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
364588|NCT00644514|Biological|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
364589|NCT00644527|Other|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
364590|NCT00644527|Other|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
364591|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.
Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.
Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm.
364592|NCT00004878|Drug|cytarabine|
364593|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.
Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.
Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm.
364594|NCT00644553|Drug|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
364595|NCT00644553|Drug|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
363911|NCT00656721|Device|Flutter Valve|Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.
In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done.
363912|NCT00656734|Biological|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
363913|NCT00656747|Drug|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
363914|NCT00656747|Drug|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
363915|NCT00656760|Other|PET/CT|PET/CT is being performed on all patients in the study.
363916|NCT00656773|Drug|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
363917|NCT00656773|Drug|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
363918|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
363919|NCT00004931|Drug|fluorouracil|Given IV
363920|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
363921|NCT00656799|Drug|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
363922|NCT00656799|Drug|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
363923|NCT00656812|Drug|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
364262|NCT00652028|Drug|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
364263|NCT00004906|Drug|carboplatin|
364264|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
363611|NCT00664261|Other|counseling intervention|
363612|NCT00664261|Other|educational intervention|
363613|NCT00664261|Other|laboratory biomarker analysis|
363614|NCT00664261|Other|questionnaire administration|
363615|NCT00005030|Drug|SCH 66336|
363616|NCT00664261|Other|survey administration|
363617|NCT00664261|Procedure|study of high risk factors|
363924|NCT00656812|Drug|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
363925|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 100 μg/mL
363926|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 200 μg/mL
363927|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 300 μg/mL
363928|NCT00659308|Procedure|anterior stromal puncture|the other group is submitted to anterior stromal puncture
363929|NCT00659321|Drug|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
363930|NCT00659321|Drug|placebo|16 weeks treatment with placebo
363931|NCT00659334|Drug|Ferumoxtran-10 (Combidex)|2.6 mg/kg
363932|NCT00659334|Procedure|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
363933|NCT00659347|Drug|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
363934|NCT00659347|Drug|Placebo|Capsules,25 mg,BID,6weeks
363935|NCT00659360|Drug|saracatinib|Given orally
363936|NCT00659373|Procedure|cognitive assessment|Cognitive function will be evaluated using the CogState Questionnaire, the Cognitive Failures Questionnaire (subjective cognitive function) and the General Health Questionnaire.
363937|NCT00659373|Procedure|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
363280|NCT00632138|Behavioral|exercise intervention|
363281|NCT00632138|Other|questionnaire administration|
363282|NCT00632138|Procedure|biofeedback|
363283|NCT00632138|Procedure|management of therapy complications|
363284|NCT00632138|Procedure|psychosocial assessment and care|
363285|NCT00004699|Drug|insulin-like growth factor I|
363286|NCT00632138|Procedure|quality-of-life assessment|
363287|NCT00632190|Other|fluorophotometry|
363288|NCT00632190|Procedure|colposcopic biopsy|
363289|NCT00632190|Procedure|colposcopy|
363290|NCT00632190|Procedure|light-scattering spectroscopy|
363291|NCT00632203|Drug|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
363292|NCT00632216|Drug|Risedronate Sodium|
363293|NCT00632229|Drug|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
363294|NCT00632229|Drug|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
363295|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
363618|NCT00664274|Behavioral|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
363619|NCT00664274|Genetic|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
363620|NCT00664287|Drug|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
363621|NCT00664287|Drug|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
363622|NCT00664300|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
362636|NCT00646087|Drug|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
362959|NCT00636675|Behavioral|Falls QI|Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:
In-House Falls Coordinator training on content and falls processes.
Case-based modules about fall prevention and tailored for various team members.
Academic Detailing in which researcher consults with staff regarding challenging residents with falls.
Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.
Toolbox: Handbook of useful measures and worksheets.
362960|NCT00639197|Procedure|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
362961|NCT00639210|Other|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
362962|NCT00639223|Dietary Supplement|Red Yeast Rice|Four 600mg capsules twice daily for 12 weeks
362963|NCT00639223|Drug|Pravastatin|One 20mg capsule twice daily for 12 weeks
362964|NCT00639223|Behavioral|Lifestyle modification program|Weekly sessions each lasting 3 1/2 hours for 12 weeks
362965|NCT00639236|Other|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
362966|NCT00639249|Drug|placebo|Oral administration
362967|NCT00639249|Drug|SA4503 Low|Oral administration
362968|NCT00639249|Drug|SA4503 High|Oral administration
362969|NCT00639262|Drug|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
362970|NCT00004817|Drug|phenytoin|
362971|NCT00639262|Drug|Temozolomide|For Cohort 2 - Gliomas only.
362972|NCT00639262|Radiation|Radiotherapy|Radiation Therapy (XRT)
362973|NCT00639288|Other|modified CPT-C|modified CPT-C
362974|NCT00639301|Behavioral|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
362305|NCT00651326|Procedure|neoadjuvant therapy|
362306|NCT00651326|Procedure|quality-of-life assessment|
362307|NCT00651326|Radiation|radiation therapy|46 Gy in 23 fractions over < 5 weeks.
Boost:
24-28 Gy in 12-14 fractions over < 3 weeks
362308|NCT00004905|Biological|filgrastim|
362309|NCT00651326|Drug|Docetaxel|
362310|NCT00651339|Drug|botox|botox injection
362311|NCT00653549|Drug|Demadex|tablets, 20 mg, single-dose
362312|NCT00653562|Drug|zolpidem|Oral
362313|NCT00653575|Behavioral|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
362637|NCT00646087|Drug|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
362638|NCT00646100|Procedure|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
362639|NCT00646113|Device|OsseoSpeed™|OsseoSpeed™ 3.0 mm diameter
362640|NCT00646126|Drug|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
362641|NCT00646126|Drug|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
362642|NCT00646139|Drug|Src kinase inhibitor KX2-391|
362643|NCT00646139|Other|immunoenzyme technique|
362644|NCT00646139|Other|pharmacological study|
362645|NCT00004887|Drug|cisplatin|
362646|NCT00646152|Drug|Poly-ICLC|
362647|NCT00646165|Drug|Forodesine|
362648|NCT00646178|Drug|adalimumab|40 mg adalimumab eow Week 0 - Week 12
362649|NCT00646178|Drug|placebo for adalimumab|placebo eow Week 0 - Week 12
361655|NCT00665847|Drug|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
361977|NCT00658580|Drug|Epirubicin + ifosfamide + etoposide|Epirubicin 60 mg/m² day 1, every 3 weeks
Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks
Etoposide 100 mg/m² days 1-3, every 3 weeks
361978|NCT00658593|Drug|capecitabine|
361979|NCT00658593|Drug|gemcitabine hydrochloride|
361980|NCT00658593|Procedure|quality-of-life assessment|
361981|NCT00658606|Drug|alefacept|IM
361982|NCT00004980|Device|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
361983|NCT00658606|Procedure|Narrow Band UVB Phototherapy|UVB Phototherapy
361984|NCT00658619|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
361985|NCT00658619|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
361986|NCT00658619|Other|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
361987|NCT00658632|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
361988|NCT00658632|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
361989|NCT00658645|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
361990|NCT00661193|Drug|carboplatin|given IV
361991|NCT00661193|Drug|erlotinib hydrochloride|given orally
361992|NCT00661193|Drug|paclitaxel|given IV
361993|NCT00661206|Drug|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
361994|NCT00661206|Drug|Placebo|Patients randomized in this group will receive placebo for 6 months.
361995|NCT00661219|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
361996|NCT00661219|Drug|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
366791|NCT00005039|Biological|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
366792|NCT00665457|Drug|docetaxel|
366793|NCT00667485|Drug|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
366794|NCT00667485|Drug|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
366795|NCT00667498|Drug|Metformin|The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.
The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
366796|NCT00667498|Drug|Placebo|The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.
The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
366797|NCT00667511|Device|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
366798|NCT00667537|Drug|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
361656|NCT00665847|Drug|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir [LPV], darunavir [DRV], atazanavir [ATV] or saquinavir [SQV]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N[t]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
361657|NCT00665860|Dietary Supplement|Placebo|Three pills per day for two years
361658|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
361659|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
361660|NCT00665873|Device|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
361661|NCT00665873|Drug|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
361662|NCT00667901|Other|laboratory biomarker analysis|
361663|NCT00667901|Other|pharmacological study|
361664|NCT00667901|Procedure|neoadjuvant therapy|
361665|NCT00667901|Procedure|therapeutic conventional surgery|
366118|NCT00640549|Drug|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
366119|NCT00640549|Drug|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
366452|NCT00633464|Drug|ixabepilone + cetuximab|Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.
Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.
Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.
Cetuximab 400 mg/m^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria.
366453|NCT00633477|Drug|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
366454|NCT00633477|Drug|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
366455|NCT00633490|Drug|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
366456|NCT00633516|Device|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
366457|NCT00633529|Drug|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
366458|NCT00633542|Drug|thalidomide|100 mg/day orally until progression or severe toxicity
366459|NCT00004759|Drug|tirilazad|
366460|NCT00635492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
366461|NCT00635492|Drug|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
366462|NCT00635505|Drug|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
366463|NCT00635505|Drug|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
366464|NCT00635505|Drug|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
366465|NCT00635518|Behavioral|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
366466|NCT00635531|Other|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
365787|NCT00647491|Biological|adalimumab|20 mg sc eow
365788|NCT00647491|Biological|adalimumab|40 mg sc eow
365789|NCT00647491|Biological|adalimumab|80 mg sc eow
365790|NCT00647491|Biological|placebo|placebo sc eow
365791|NCT00004891|Radiation|fludeoxyglucose F 18|
365792|NCT00647517|Drug|Ultracet|For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.
For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day.
365793|NCT00647530|Biological|panitumumab|
365794|NCT00647530|Drug|capecitabine|
365795|NCT00647530|Drug|fluorouracil|
365796|NCT00647530|Drug|oxaliplatin|
365797|NCT00647530|Genetic|fluorescence in situ hybridization|
365798|NCT00647530|Genetic|gene expression analysis|
365799|NCT00647530|Genetic|microarray analysis|
365800|NCT00647530|Genetic|polymerase chain reaction|
365801|NCT00647530|Genetic|proteomic profiling|
365802|NCT00004891|Radiation|radiation therapy|
366120|NCT00640562|Drug|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
366121|NCT00640562|Drug|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
366122|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
366123|NCT00642759|Drug|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
366124|NCT00642759|Drug|Abraxane|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
365457|NCT00654940|Drug|Placebo|Oral, matched capsules, BID
365458|NCT00654953|Drug|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
365459|NCT00654953|Drug|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
365460|NCT00654953|Drug|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
365461|NCT00654966|Drug|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
365462|NCT00004919|Drug|amifostine trihydrate|Given IV
365463|NCT00654966|Drug|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
365464|NCT00654979|Device|SafeFlo IVC Filter|SafeFlo IVC Filter
365465|NCT00654992|Drug|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
365466|NCT00654992|Drug|Normal Saline|300 IU/kg of normal saline intravenously before surgery
365467|NCT00655005|Other|questionnaire administration|Newly diagnosed HNC patients
365468|NCT00655005|Procedure|quality-of-life assessment|following treatment
365469|NCT00655018|Dietary Supplement|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
365803|NCT00647530|Genetic|western blotting|
365804|NCT00647530|Other|immunohistochemistry staining method|
365805|NCT00647530|Procedure|adjuvant therapy|
365806|NCT00647530|Procedure|neoadjuvant therapy|
365807|NCT00647530|Procedure|quality-of-life assessment|
365808|NCT00647530|Procedure|therapeutic conventional surgery|
364816|NCT00666900|Drug|Low Strength IDP-107|Once a day for 12 weeks
364817|NCT00666900|Drug|High Strength IDP-107|Once a day for 12 weeks
364818|NCT00666900|Drug|Placebo Comparator|Once a day for 12 weeks
364819|NCT00666913|Other|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
364820|NCT00005050|Drug|oxaliplatin|
364821|NCT00666926|Drug|PF00562271|125 mg twice daily [BID] with food, tablet
364822|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
364823|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
365132|NCT00660023|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
365133|NCT00662350|Device|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
365134|NCT00662363|Drug|Lubiprostone|24 µg po BID given with meals for 6 days
365135|NCT00662363|Drug|Senna|2 tabs daily for 6 days
365136|NCT00662376|Dietary Supplement|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
365137|NCT00662389|Device|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
365138|NCT00662402|Other|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
365139|NCT00662415|Device|mirror-box treatment|15 minutes daily for 4 weeks
365140|NCT00662415|Behavioral|observation|observation
365141|NCT00005017|Drug|Stavudine|
365142|NCT00662428|Other|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
365143|NCT00662428|Other|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
361112|NCT00653068|Drug|thiotepa|Given IV
361113|NCT00653068|Drug|vincristine sulfate|Given IV
361114|NCT00653068|Other|laboratory biomarker analysis|Correlative studies
361115|NCT00653081|Procedure|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
361116|NCT00653081|Procedure|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
361437|NCT00645671|Drug|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
361438|NCT00645671|Drug|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
361439|NCT00645684|Procedure|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
361440|NCT00645710|Drug|gemcitabine hydrochloride|Given IV
361441|NCT00645710|Drug|floxuridine|Given via hepatic arterial infusion
361442|NCT00645710|Genetic|proteomic profiling|Correlative studies
361443|NCT00004885|Drug|FOLFIRI regimen|
361444|NCT00645710|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
361445|NCT00645710|Other|liquid chromatography|Correlative studies
361446|NCT00645710|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
361447|NCT00645710|Other|laboratory biomarker analysis|Correlative studies
361448|NCT00645710|Other|mass spectrometry|Correlative studies
361449|NCT00645710|Other|pharmacological study|Correlative studies
361450|NCT00645723|Drug|Colistin|intravenous colistin and nebulized colistin
361451|NCT00645723|Drug|Colistin and saline solution|intravenous colistin and nebulized saline solution
361452|NCT00645736|Other|No intervention|No intervention
361453|NCT00645749|Biological|Helminth ova|2500 ova per dose (liquid form)
361454|NCT00004885|Drug|fluorouracil|
365896|NCT00657631|Behavioral|Acceptance and Commitment Therapy|Considered part of the "third wave of CBT" along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl & Wilson, 1999).
365897|NCT00657644|Drug|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
365898|NCT00657657|Biological|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
365899|NCT00657670|Device|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
365900|NCT00004935|Drug|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
365901|NCT00660192|Drug|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
365902|NCT00660192|Other|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
366229|NCT00004907|Drug|cyclophosphamide|
366230|NCT00652691|Drug|topotecan hydrochloride|
366231|NCT00652691|Procedure|autologous hematopoietic stem cell transplantation|
366232|NCT00652691|Procedure|peripheral blood stem cell transplantation|
366233|NCT00652704|Drug|Doxycycline monohydrate|Capsules, 100 mg, fed
366234|NCT00652704|Drug|Monodox|Capsules, 100 mg, fed
366235|NCT00652704|Drug|Doxycycline Monohydrate|Capsules, 100 mg, fasting
366236|NCT00652717|Drug|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
366237|NCT00652717|Drug|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
366238|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
365562|NCT00664846|Drug|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
365563|NCT00664846|Drug|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
365564|NCT00664859|Drug|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
365565|NCT00664872|Other|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
365566|NCT00664872|Behavioral|case management|
365567|NCT00664885|Other|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
365568|NCT00664898|Drug|bortezomib|Escalating intravenous repeating dose
365569|NCT00005036|Drug|fluorouracil|Given IV
365570|NCT00664898|Drug|SGN-40|Escalating intravenous repeating dose
365571|NCT00664911|Other|chemotherapy|
365572|NCT00664937|Drug|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
365573|NCT00664937|Drug|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
365574|NCT00667069|Radiation|3-dimensional conformal radiation therapy|
365575|NCT00667082|Drug|NPI-0052 (marizomib) + vorinostat|NPI-0052 IV weekly vorinostat oral daily
365903|NCT00660218|Drug|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
365904|NCT00660218|Biological|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
364924|NCT00640029|Device|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|SYNTHES : PRODISC-C® , PRODISC-L®
LDR : Mobi-C®, Mobidisc®
MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®
SCIENT'X : DISCOCERV®
365239|NCT00632983|Drug|cyproterone acetate|
365240|NCT00004731|Drug|Coenzyme Q10|
365241|NCT00632983|Drug|releasing hormone agonist therapy|
365242|NCT00632983|Other|active surveillance|
365243|NCT00632983|Other|medical chart review|
365244|NCT00632983|Other|questionnaire administration|
365245|NCT00632983|Procedure|assessment of therapy complications|
365246|NCT00632983|Procedure|quality-of-life assessment|
365247|NCT00632983|Procedure|therapeutic conventional surgery|
365248|NCT00632983|Procedure|therapeutic lymphadenectomy|
365249|NCT00632983|Radiation|3-dimensional conformal radiation therapy|
365250|NCT00632996|Other|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
365251|NCT00004732|Procedure|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
365252|NCT00633009|Biological|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
365253|NCT00633009|Biological|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
365254|NCT00633022|Drug|GW856553 7.5 mg twice a day|GW856553 7.5 mg twice a day
365255|NCT00633022|Drug|placebo|placebo
365256|NCT00633022|Drug|GW856553 7.5 mg once a day|GW856553 7.5 mg once a day
365257|NCT00633035|Drug|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
365258|NCT00633035|Drug|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
365259|NCT00633048|Drug|NSA-789|
364596|NCT00646893|Procedure|Preimplantation Genetic Diagnosis (PGD)|one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by "no result rescue" (Colls et al. 2007)
364597|NCT00646906|Drug|Aspirin first|Subjects will receive 81 mg aspirin at approximately 8 am followed by 1000 or 2000 mg acetaminophen at approximately 10 am during this intervention phase.
364598|NCT00646906|Drug|Aspirin last|Subjects will receive 1000 or 2000 mg acetaminophen at approximately 8am followed by 81 mg aspirin at approximately 10 am during this intervention phase.
364599|NCT00004890|Biological|aldesleukin|
364600|NCT00646906|Drug|Acetaminophen|The data will be handled the same as Part A.
364601|NCT00646919|Procedure|Nose swab|
364602|NCT00646932|Drug|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
364603|NCT00646932|Drug|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
364925|NCT00640042|Drug|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
364926|NCT00640055|Other|Coordinator|Coordinator (non-physician) assigned cause of death
364927|NCT00640055|Other|Physician-assigned cause of death|Physician (gold standard) cause of death
364928|NCT00640081|Biological|cetuximab|
364929|NCT00640081|Drug|capecitabine|
364930|NCT00640081|Drug|fluorouracil|
364931|NCT00640081|Drug|leucovorin calcium|
364932|NCT00640081|Drug|oxaliplatin|
364933|NCT00004834|Behavioral|cognitive-behavioral therapy|
364934|NCT00640081|Other|immunohistochemistry staining method|
364935|NCT00640081|Other|laboratory biomarker analysis|
364936|NCT00640094|Drug|melatonin|Patients will receive a total intravenous melatonin dose of 11.61 mg (approximately 166 microgram/kg) or placebo. The dose will be distributed in a volume of 500 ml of a isotonic and sterile solution of 100 microMolar melatonin during 150 minutes with a drip rate of 4.2 ml/min.
364937|NCT00640120|Device|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
364265|NCT00652041|Drug|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is <Grade 2, dose should be increased to 200 mg/24 h. in day 15
364266|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
364267|NCT00652054|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
364268|NCT00652080|Drug|API 31510|Topical Cream; 3% active; AM & PM application
364269|NCT00652093|Drug|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
364270|NCT00652093|Drug|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
364271|NCT00654446|Drug|Rosuvastatin|
364272|NCT00654446|Drug|Simvastatin|
364273|NCT00654459|Dietary Supplement|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
364274|NCT00654485|Drug|Rosuvastatin|
364275|NCT00004917|Radiation|radiation therapy|
364276|NCT00654485|Drug|Atorvastatin|
364277|NCT00654498|Drug|Pramipexole|
364278|NCT00654498|Drug|Placebo|
364279|NCT00654511|Drug|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
364280|NCT00654511|Drug|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
364281|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
364282|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
364283|NCT00654524|Drug|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.& Livial 1.25-2.5mg p.o. q.d.) if needed.
364604|NCT00646932|Drug|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
363938|NCT00004987|Drug|Dextrin 2-sulfate|
363939|NCT00659373|Procedure|Psychological distress|Psychological distress will be evaluated using the General Health Questionnaire.
363940|NCT00659373|Procedure|Quality of Life and insomnia|QL and insomnia will be assessed using the QL Form, the QL module, NCI CATCAE version 3 and a patient-rated linear analogue self-assessment (LASA) scale.
363941|NCT00659386|Drug|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
363942|NCT00659399|Drug|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
363943|NCT00659412|Drug|Alefacept|Intramuscular
363944|NCT00659412|Drug|Methotrexate|Oral
363945|NCT00659412|Drug|Placebo|Intramuscular
364284|NCT00654537|Drug|Rosuvastatin|
364285|NCT00654537|Drug|Atorvastatin|
364286|NCT00004918|Biological|PR1 leukemia peptide vaccine|Given SC
364287|NCT00654537|Drug|Pravastatin|
364288|NCT00654537|Drug|Simvastatin|
364289|NCT00654550|Drug|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
364290|NCT00654576|Drug|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
364291|NCT00654576|Behavioral|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
364292|NCT00654589|Drug|Deferasirox|
364293|NCT00654602|Drug|Rosuvastatin|
364294|NCT00654602|Behavioral|Maintenance of specific diet|
364295|NCT00654615|Device|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
363623|NCT00666497|Drug|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
363624|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
363625|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
363626|NCT00666523|Dietary Supplement|phytalgic|3/day
363627|NCT00666523|Dietary Supplement|placebo|3/Day
363628|NCT00666536|Drug|valsartan and amlodipine|
363629|NCT00005047|Procedure|adjuvant therapy|
363630|NCT00666536|Drug|valsartan and amlodipine|
363631|NCT00666562|Dietary Supplement|defined green tea catechin extract|Given orally
363632|NCT00666562|Drug|placebo|Given orally
363633|NCT00666562|Procedure|therapeutic conventional surgery|Undergo surgery
363634|NCT00666562|Other|pharmacological study|Correlative studies
363635|NCT00666562|Other|laboratory biomarker analysis|Correlative studies
363636|NCT00666575|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
363637|NCT00666575|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
363638|NCT00666588|Drug|idarubicin|Given IV
363639|NCT00666588|Drug|cytarabine|Given IV or IT
363640|NCT00005048|Drug|estramustine phosphate sodium|
363641|NCT00666588|Drug|bortezomib|Given IV
363642|NCT00666588|Drug|etoposide|Given IV
363946|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|The dose level of the initial cohort will be 5 µg/kg. Cohorts will be at doses of 5, 10, 20, 30, 40, 50, 60.... µg/kg until toxicity supervenes. Following the identification of the MTCD, the MTCD cohort will be expanded to 12 subjects. Dose escalation to a new cohort may not occur until authorization by the medical monitor, which will require all patients from the prior cohorts have reached cycle 1 day 21 without dose limiting toxicity (DLT) if eligible for retreatment
363947|NCT00659438|Drug|ZD6474 (Vandetanib)|300mg orally, once daily
362975|NCT00639314|Procedure|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
362976|NCT00639314|Procedure|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
362977|NCT00639327|Drug|S-1 + irinotecan|Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
363296|NCT00004700|Drug|insulin-like growth factor I|
363297|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
363298|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
363299|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.
Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment.
363300|NCT00634491|Drug|normal salin|1 cc/kg/hr 6 hour before and after angiography
363301|NCT00634504|Drug|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
363302|NCT00634504|Drug|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
363303|NCT00634517|Drug|Armstrong Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
363304|NCT00634517|Drug|Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
363305|NCT00000637|Drug|Zidovudine|
363306|NCT00004748|Drug|ursodiol|
363307|NCT00634530|Behavioral|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
363308|NCT00634543|Drug|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
363309|NCT00634543|Drug|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
362650|NCT00646191|Drug|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
362651|NCT00646191|Drug|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
362652|NCT00646191|Drug|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
362653|NCT00646204|Drug|Memantine|10 mg bid
362654|NCT00646204|Drug|placebo|2 tabs bid
362655|NCT00646217|Behavioral|Self Care Talk|6 weekly telephone sessions
362656|NCT00000171|Drug|Melatonin|
362657|NCT00000641|Drug|Azithromycin|
362658|NCT00004887|Drug|ifosfamide|
362659|NCT00646230|Drug|fenretinide|
362660|NCT00646230|Other|high performance liquid chromatography|
362661|NCT00646230|Other|pharmacological study|
362662|NCT00646256|Behavioral|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
362978|NCT00639327|Drug|irinotecan|Irinotecan 150mg/m2 iv on day one every two weeks until PD
362979|NCT00639353|Device|senofilcon A toric soft contact lens|contact lens
362980|NCT00639353|Device|senofilcon A sphere soft contact lens|contact lens
362981|NCT00004817|Drug|valproate sodium|
362982|NCT00639366|Biological|trastuzumab|
362983|NCT00639366|Drug|chemotherapy|
362984|NCT00639366|Radiation|radiation therapy|
362985|NCT00639379|Device|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
362986|NCT00641563|Drug|Midazolam|Midazolam infusion
362987|NCT00641563|Drug|Remifentanil|Infusion of remifentanil
361997|NCT00005006|Drug|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
361998|NCT00661245|Device|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
361999|NCT00661245|Device|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
362314|NCT00653575|Behavioral|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
362315|NCT00653588|Drug|Rosuvastatin|40mg
362316|NCT00653588|Drug|Atorvastatin|80mg
362317|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
362318|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
362319|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
362320|NCT00004913|Drug|docetaxel|
362321|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
362322|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
362323|NCT00653614|Drug|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
362324|NCT00653614|Drug|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
362325|NCT00653614|Drug|Placebo|Placebo administration in each arm
362326|NCT00653627|Biological|BCG|Mycobacterium bovis Bacille Calmette-Guerin
362327|NCT00653640|Procedure|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
362328|NCT00653640|Procedure|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
362329|NCT00653666|Other|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is < 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
362330|NCT00653679|Other|exercise|1 hour of endurance or resistance exercise
361666|NCT00667914|Procedure|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
361667|NCT00005060|Drug|Taxotere-Cisplatin-5FU|Preoperatively
361668|NCT00667914|Procedure|Orthopedic care as usual|treatment in ordinary orthopedic unit
361669|NCT00667927|Drug|Busulfan|See Detailed Description section for description of treatment plan.
361670|NCT00667927|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
361671|NCT00667927|Drug|Mesna|See Detailed Description section for description of treatment plan.
361672|NCT00667940|Behavioral|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
361673|NCT00667953|Drug|Gleevec + Temozolomide|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle. Gleevec (600 mg) daily.
361674|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
361675|NCT00667966|Drug|Placebo|10/20 mg placebo in sequence in respective arm
361676|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
361677|NCT00667979|Drug|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
362000|NCT00661258|Behavioral|Electronic drug monitoring feedback intervention|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
362001|NCT00661271|Behavioral|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice.
362002|NCT00661271|Behavioral|Healthy topics|8 week health education program
362003|NCT00661297|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
362004|NCT00661297|Drug|Placebo|Matching placebo
362005|NCT00661310|Other|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
362006|NCT00661336|Drug|buthionine sulfoximine|
366467|NCT00635531|Drug|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
366468|NCT00635544|Other|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
366469|NCT00635544|Other|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
366470|NCT00004760|Behavioral|Exercise|
366799|NCT00667563|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
366800|NCT00667563|Genetic|DNA analysis|Weeks 0, 2, 10, 26, and 52.
366801|NCT00667563|Genetic|polymerase chain reaction|Screening, week 36, and week 52.
366802|NCT00005056|Drug|bryostatin 1|
366803|NCT00667563|Other|cytology specimen collection procedure|Screening, week 36, and week 52.
366804|NCT00667563|Procedure|colposcopic biopsy|Screening, week 36, and week 52.
366805|NCT00667576|Drug|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
366806|NCT00667576|Drug|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
366807|NCT00667589|Drug|urea 40% cream|urea 40% cream applied twice per day to affected areas
366808|NCT00667589|Drug|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
366809|NCT00667589|Drug|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
366810|NCT00667589|Drug|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
366811|NCT00667602|Biological|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
366812|NCT00667602|Biological|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
366125|NCT00642759|Drug|Bevacizumab|
366126|NCT00642772|Other|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
366127|NCT00642798|Drug|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
366128|NCT00642811|Drug|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
366129|NCT00642811|Drug|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
366130|NCT00642811|Drug|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
366131|NCT00642824|Drug|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
366132|NCT00004865|Drug|cisplatin|
366133|NCT00642824|Drug|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
366134|NCT00642837|Drug|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
366135|NCT00642837|Drug|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
366136|NCT00642837|Drug|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
366137|NCT00642837|Drug|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
366138|NCT00642837|Drug|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
366471|NCT00635557|Drug|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
366472|NCT00635570|Drug|Ortho Tri-cyclen Lo|Low dose oral contraceptive
366473|NCT00635570|Device|NuvaRing|Contraceptive vaginal ring
366474|NCT00635583|Other|Dairy Products|3 additional servings of dairy (two of which must be milk or yogurt)
8 oz milk
6 oz yogurt
1.5 oz cheese
366475|NCT00635596|Biological|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
365809|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
365810|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
365811|NCT00650117|Drug|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
365812|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
365813|NCT00650117|Drug|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
365814|NCT00004902|Drug|tocladesine|
365815|NCT00650143|Drug|Lenograstim (GRANOCYTE)=GCSF|10 µg/kg/d s.c. for 5 days divided in two dosages per day
365816|NCT00650143|Drug|Sitagliptin (Januvia)|100 mg p.o. per day for 28 days
365817|NCT00650143|Drug|Sodium Chloride (NaCl) 0.9 %|applied s.c. twice a day for 5 days
365818|NCT00650143|Drug|Gelatin|One capsule p.o. per day for 28 days
365819|NCT00650156|Biological|adalimumab|40 mg single sc dose
365820|NCT00650156|Biological|adalimumab|80 mg single sc dose
365821|NCT00650169|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
365822|NCT00650169|Drug|Plavix® Tablets 75 mg|75mg, single dose fed
365823|NCT00650182|Drug|fentanyl; naltrexone|
365824|NCT00650195|Drug|Metolazone Tablets 10 mg|10mg, single dose fasting
365825|NCT00004903|Biological|filgrastim|
365826|NCT00650195|Drug|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
365827|NCT00650208|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
366139|NCT00642837|Drug|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
366140|NCT00642837|Drug|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
366141|NCT00642837|Drug|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
365144|NCT00662441|Drug|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
365145|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
365146|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
365147|NCT00662467|Drug|aspirin + clopidogrel|Dual therapy
365148|NCT00662467|Drug|aspirin + clopidogrel + warfarin|Triple therapy
365149|NCT00662480|Procedure|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
365150|NCT00662493|Behavioral|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
365151|NCT00662493|Behavioral|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
365470|NCT00655018|Dietary Supplement|Placebo|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
365471|NCT00655031|Dietary Supplement|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
365472|NCT00655031|Dietary Supplement|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
365473|NCT00004919|Other|pharmacological study|Correlative studies
365474|NCT00655044|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
365475|NCT00655057|Drug|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
365476|NCT00657384|Drug|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
365477|NCT00657384|Drug|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
365478|NCT00657397|Drug|Methadone|Methadone sirup once daily
365479|NCT00657410|Drug|dexamethasone|
365480|NCT00657410|Drug|prednisone|
361455|NCT00645762|Device|RS-Series Rhinosinusitis Treatment System|Single arm
361456|NCT00645762|Device|FinESS Balloon|
361457|NCT00645775|Dietary Supplement|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
361458|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
361459|NCT00648362|Drug|Glimepiride Tablets 1 mg|1mg, single dose fasting
361460|NCT00648362|Drug|Amaryl® Tablets 1 mg|1mg, single dose fasting
356578|NCT00619515|Other|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
356579|NCT00004426|Drug|gonadotropin releasing hormone|
356580|NCT00619515|Procedure|implanted fiducial-based imaging|Undergo fiducial placement imaging
356581|NCT00619515|Radiation|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
356582|NCT00619528|Biological|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
356583|NCT00619541|Drug|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
356584|NCT00619541|Drug|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
356585|NCT00619567|Behavioral|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
356586|NCT00619593|Other|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|Assessment of general health status (weight, BP, NYHA)
Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)
Echocardiography (LVEF, LVEDD, mitral regurgitation)
Non-invasive ischemia evaluation
Coronary angiography (if indicated by ischemia evaluation)
Upgrade to CRT, if indicated
Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)
24 hrs ECG Holter (Heart rate variability)
Further treatment (if applicable)
Changes in ICD settings, or medication
356587|NCT00004450|Drug|interferon beta|
356588|NCT00621517|Drug|Bupropion|Partipants will receive 150 mg bupropion per night
366239|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
366240|NCT00004907|Drug|etoposide|
366241|NCT00652730|Drug|Buspar|Tablets, 30 mg, single-dose, fed conditions
366242|NCT00652743|Biological|Pandemic influenza vaccine GSK1562902A|IM administration
366243|NCT00652756|Device|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
366244|NCT00652756|Other|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
366245|NCT00652769|Procedure|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
366246|NCT00652769|Procedure|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
366247|NCT00652782|Drug|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
366248|NCT00652782|Drug|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
366249|NCT00652795|Drug|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
366250|NCT00652795|Drug|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
366251|NCT00004907|Procedure|allogeneic bone marrow transplantation|
366252|NCT00652808|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
366567|NCT00645281|Drug|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
366568|NCT00645294|Drug|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
366569|NCT00645294|Drug|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
366570|NCT00645294|Drug|Adefovir Dipivoxil|ADV 10 mg on Day 1
366571|NCT00645307|Drug|Extended Release OROS® Paliperidone|
366572|NCT00004892|Procedure|conventional surgery|
366573|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
366574|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h|single application
365905|NCT00660218|Radiation|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
365906|NCT00660231|Drug|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
365907|NCT00660231|Drug|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
365908|NCT00004999|Drug|Nelfinavir mesylate|
365909|NCT00660244|Drug|anastrozole|Oral
365910|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
365911|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
365912|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
365913|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
365914|NCT00660270|Procedure|Pancreatic Surgery|
365915|NCT00660270|Radiation|Radiation therapy|
365916|NCT00660270|Drug|Cisplatin|
365917|NCT00660270|Drug|5-FU|
365918|NCT00660270|Drug|Alpha-interferon|
365919|NCT00005000|Drug|Nelfinavir mesylate|
365920|NCT00660270|Drug|Gemcitabine|
365921|NCT00660283|Drug|Temozolomide|(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.
7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles.
365922|NCT00660296|Other|Air insufflation use in colonoscopy|Air insufflation for colonic distension
365923|NCT00660296|Other|CO2 use in colonoscopy|Co2 insufflation for colonic distension
365924|NCT00660309|Drug|Aliskiren|Aliskiren 300 mg tablets
366253|NCT00652808|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
365260|NCT00635115|Device|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
365261|NCT00635115|Device|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
365262|NCT00000637|Drug|Didanosine|
365263|NCT00004758|Drug|corticotropin|
365576|NCT00667095|Drug|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
365577|NCT00667095|Drug|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
365578|NCT00667108|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
365579|NCT00667108|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
365580|NCT00667108|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
365581|NCT00667121|Drug|citalopram hydrobromide|
365582|NCT00667121|Drug|escitalopram oxalate|
365583|NCT00667121|Drug|gabapentin|
365584|NCT00005051|Drug|topotecan hydrochloride|
365585|NCT00667121|Drug|sertraline hydrochloride|
365586|NCT00667121|Drug|tamoxifen citrate|
365587|NCT00667121|Drug|venlafaxine|
365588|NCT00667121|Genetic|molecular genetic technique|
365589|NCT00667121|Other|high performance liquid chromatography|
365590|NCT00667121|Other|laboratory biomarker analysis|
365591|NCT00667121|Other|pharmacological study|
365592|NCT00667121|Procedure|adjuvant therapy|
365593|NCT00667147|Drug|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
365594|NCT00667147|Drug|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
364938|NCT00640133|Device|Deep brain stimulation (DBS)|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, some participants will receive immediate DBS treatment; others will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
364939|NCT00640146|Drug|Methylnaltrexone bromide|Subcutaneous Methylnaltrexone
364940|NCT00640146|Drug|Placebo|Subcutaneous Placebo
364941|NCT00640159|Drug|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
364942|NCT00640185|Drug|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
364943|NCT00640185|Drug|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
364944|NCT00004838|Drug|succimer|
364945|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
364946|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
365264|NCT00635128|Biological|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
365265|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
365266|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
365267|NCT00635154|Biological|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
365268|NCT00635154|Drug|Dexamethasone acetate|Low dose - 20 mg/week
High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)
365269|NCT00635167|Procedure|Contrast Enhanced-Transrectal Ultrasound|Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline [Visit 2]); week 5 (middle of treatment [Visit 3]); week 10 (end of treatment [Visit 4]); week 18 (2 months after end of EBRT [Visit 5]); week 26 (4 months after end of EBRT [Visit 6]); and week 36 (6 months after end of EBRT [Visit 7]).
365270|NCT00635180|Behavioral|isometric exercise|
365271|NCT00635193|Drug|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
364605|NCT00646932|Drug|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
364606|NCT00646945|Drug|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
364607|NCT00646945|Drug|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
364608|NCT00646958|Drug|Radezolid|450mg PO QD
364609|NCT00646958|Drug|Radezolid|450mg PO BID
364610|NCT00000641|Drug|Rifampin|
364611|NCT00004890|Drug|Biomed 101|
364612|NCT00646958|Drug|Linezolid|600mg PO BID
364613|NCT00646971|Device|CPAP device|for 4 weeks
364614|NCT00646971|Device|Placebo device|for 4 weeks
364615|NCT00646984|Drug|Standard continuous antiretroviral therapy|
364616|NCT00646984|Drug|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
364617|NCT00646984|Drug|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
364618|NCT00647023|Drug|metformin|1000 mg metformin x 2 daily during 8 months
364619|NCT00647036|Dietary Supplement|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
364620|NCT00647036|Drug|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
364621|NCT00647049|Drug|methotrexate|8000mg/m2 i.v., max. 2 cycles
364622|NCT00004891|Drug|chemotherapy|
364623|NCT00647049|Drug|Rituximab|375mg/m2, max. 8 times
364624|NCT00647049|Drug|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
364625|NCT00647049|Drug|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
364626|NCT00649662|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fasting
364627|NCT00649662|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fasting
364296|NCT00656825|Drug|Placebo|Placebo will be randomly given to 4 subjects in each panel
364297|NCT00656838|Behavioral|Patients receives letter, phone call, office visit, educational materials|Behavioral
364298|NCT00004931|Drug|oxaliplatin|Given IV
364299|NCT00656851|Drug|Pioglitazone|30mg/day for 16 weeks
364300|NCT00656851|Behavioral|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
364301|NCT00656864|Drug|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
364302|NCT00656864|Drug|Placebo|placebo
364303|NCT00656890|Biological|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
364304|NCT00656890|Biological|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
364305|NCT00656916|Drug|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
364630|NCT00649688|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
364631|NCT00004900|Drug|thiotepa|
364632|NCT00649688|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
364633|NCT00649701|Behavioral|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
364634|NCT00649701|Behavioral|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
364635|NCT00649701|Behavioral|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
364636|NCT00649701|Behavioral|Both Videos|Morning After and Talking About HIV videos
364637|NCT00649714|Drug|Zonisamide Capsules 100 mg|100mg, single dose fed
364638|NCT00649714|Drug|Zonegran® Capsules 100 mg|100mg, single dose fed
364639|NCT00649727|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
364640|NCT00649727|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
364641|NCT00649740|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
363948|NCT00659438|Drug|Bicalutamide|150mg orally, once daily
363949|NCT00004988|Drug|VNP20009|
363950|NCT00659438|Drug|Placebo|orally, once daily
363951|NCT00659451|Drug|Losartan|tablets; 50, 100 mg; od; 12 months
363952|NCT00659451|Drug|Amlodipine|tablets; 5, 10 mg; od; 12 months
363953|NCT00661921|Biological|Placebo|AMG 108 volume matching placebo
363954|NCT00005014|Drug|Risperidone|
363955|NCT00661947|Other|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
363956|NCT00661960|Procedure|Upper Endoscopy and biopsies|5 HIV-Negative volunteers will only undergo this single procedure - A gastroenterologist (specialist in intestinal disease) will pass a flexible endoscope tube connected to a video camera, into the stomach and small intestine, will examine these areas, and will biopsy (take small pieces of tissue--about the size of a grain of rice) these areas.
363957|NCT00661960|Drug|raltegravir|400mg tablet twice daily by mouth for nine months
363958|NCT00661960|Drug|efavirenz|600mg capsule once daily by mouth without regard to food
363959|NCT00661973|Drug|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
363960|NCT00661986|Dietary Supplement|dark chocolate 6 g/day|dark chocolate 6 g/day
363961|NCT00661986|Dietary Supplement|dark chocolate 25 g/day|dark chocolate 25 g/day
363962|NCT00661999|Biological|darbepoetin alfa|Given by injection
363963|NCT00661999|Dietary Supplement|ferrous sulfate|Given by mouth
363964|NCT00661999|Drug|sodium ferric gluconate complex in sucrose|Given by IV
363965|NCT00005015|Drug|Fluoxetine|
363966|NCT00661999|Other|placebo|Given by mouth
363967|NCT00662012|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
364306|NCT00656929|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
363310|NCT00634556|Drug|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
363311|NCT00634556|Drug|placebo|normal saline
363312|NCT00634569|Biological|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
363313|NCT00634582|Drug|paricalcitol|
363314|NCT00634582|Other|immunoenzyme technique|
363315|NCT00634582|Other|laboratory biomarker analysis|
363643|NCT00666588|Other|laboratory biomarker analysis|Correlative studies
363644|NCT00666601|Drug|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
363645|NCT00666601|Drug|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
363646|NCT00666614|Other|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
363647|NCT00666614|Other|Normal Hospital Environment|Normal Hospital Environment
363648|NCT00666627|Drug|Ibandronate|once monthly
363649|NCT00666627|Drug|Risedronate|Risedronate 35mg once weekly
363650|NCT00666627|Drug|Alendronate|Alendronate 70mg once weekly
363651|NCT00005048|Drug|paclitaxel|
363652|NCT00668759|Drug|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
363653|NCT00668759|Drug|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
363654|NCT00668772|Drug|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
363655|NCT00005066|Drug|carmustine|
363656|NCT00668772|Drug|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
362988|NCT00641576|Device|ACE CONNECT Endosseous dental implant|Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.
Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration.
362989|NCT00641589|Drug|epoetin alfa|
362990|NCT00641602|Drug|Esomeprazole|40mg once daily
362991|NCT00641602|Drug|Lansoprazole|30mg once daily
362992|NCT00641615|Biological|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
362993|NCT00641628|Procedure|mastectomy|
362994|NCT00641641|Drug|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
362995|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
362996|NCT00004858|Biological|B43-genistein immunoconjugate|
362997|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
362998|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
362999|NCT00641667|Drug|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
363316|NCT00634582|Procedure|dual x-ray absorptometry|
363317|NCT00004751|Procedure|Surgery|
363318|NCT00634582|Procedure|quality-of-life assessment|
363319|NCT00634595|Drug|E10A|E10A 1*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
363320|NCT00634595|Drug|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
363321|NCT00634595|Drug|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
362331|NCT00004913|Drug|fluorouracil|
362332|NCT00653705|Other|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
362333|NCT00653705|Other|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
362334|NCT00653731|Behavioral|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
362335|NCT00653731|Behavioral|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
362663|NCT00646269|Behavioral|Standard intervention protocol|The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
362664|NCT00648778|Drug|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
362665|NCT00648778|Drug|Loxitane® Capsules 25 mg|25mg, single dose fasting
362666|NCT00004898|Drug|etoposide|
362667|NCT00648791|Drug|Finasteride Tablets 5 mg|5mg, single dose fasting
362668|NCT00648791|Drug|Proscar Tablets 5 mg|5mg, single dose fasting
362669|NCT00648804|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
362670|NCT00648804|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fed
362671|NCT00648817|Drug|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
362672|NCT00648817|Drug|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
362673|NCT00648830|Procedure|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
362674|NCT00648830|Drug|Clarithromycin|single-dose 250 mg immediate-release oral tablets
362675|NCT00648843|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
362676|NCT00648843|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
362677|NCT00004898|Procedure|peripheral blood stem cell transplantation|
362678|NCT00648856|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
362679|NCT00648856|Drug|Zoloft® Tablets 100 mg|100mg, single dose fed
362007|NCT00661336|Drug|melphalan|
362008|NCT00005006|Drug|Alendronate|Alendronate 70mg/week
362009|NCT00661336|Genetic|microarray analysis|
362010|NCT00661336|Other|high performance liquid chromatography|
362011|NCT00661336|Other|laboratory biomarker analysis|
362012|NCT00661336|Other|pharmacological study|
362013|NCT00661336|Procedure|biopsy|
362014|NCT00661349|Drug|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
362015|NCT00661349|Drug|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
362016|NCT00661362|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
362017|NCT00663663|Behavioral|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
362018|NCT00663663|Behavioral|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
362336|NCT00656084|Drug|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar-->Novantrone-->Rituxan.
362337|NCT00656084|Drug|mitoxantrone|Novantrone 10 mg/m2on Day 1. The order of administration will be:
Gemzar-->Novantrone-->Rituxan.
362338|NCT00656084|Drug|rituximab|Rituxan 375 mg/m2 on Day 1. The order of administration will be:
Gemzar-->Novantrone-->Rituxan.
362339|NCT00656097|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
362340|NCT00656097|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
362341|NCT00656097|Biological|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
366813|NCT00005057|Biological|adenovirus RSV-TK|
366814|NCT00667602|Biological|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
366815|NCT00670033|Drug|Travoprost ophthalmic solution, 0.004%|
366816|NCT00670033|Drug|Vehicle|Inactive ingredients used as a placebo
366817|NCT00670046|Drug|valproic acid|given orally
366818|NCT00670046|Procedure|standard follow-up care|no intervention
366819|NCT00670059|Genetic|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
366820|NCT00670059|Genetic|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
361678|NCT00005060|Drug|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
361679|NCT00667979|Drug|Placebo|Matching placebo
361680|NCT00667992|Drug|Budesonide HFA|standard daily inhaled dose
361681|NCT00667992|Drug|Budesonide CFC|standard daily inhaled dose
361682|NCT00668005|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
361683|NCT00668005|Drug|Placebo|Matching placebo
361684|NCT00668018|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
361685|NCT00668031|Drug|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
361686|NCT00668031|Drug|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
361687|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv BID
361688|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv TID
361689|NCT00005061|Biological|bevacizumab|
361690|NCT00591292|Drug|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
361691|NCT00591305|Dietary Supplement|diindolylmethane (DIM)|3-month DIM
366476|NCT00635609|Drug|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
366477|NCT00635609|Drug|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
366478|NCT00635622|Drug|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
366479|NCT00635622|Drug|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
366480|NCT00635635|Behavioral|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
366481|NCT00004762|Drug|cladribine|
366482|NCT00635635|Behavioral|Music Audio|Music only audio to be listened to 5x per week
366483|NCT00004800|Biological|diphtheria-tetanus vaccine|
366484|NCT00637910|Drug|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
366485|NCT00637923|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
366486|NCT00637923|Drug|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
366487|NCT00637923|Biological|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
366488|NCT00637923|Drug|Ribavirin|Weight-based ribavirin for 48 weeks.
366489|NCT00637936|Drug|Oxygen|Inspiratory fraction during anaesthesia
366490|NCT00637949|Device|lumiracoxib|400 mg once daily, oral over 6 weeks
366491|NCT00637949|Drug|rofecoxib|25 mg, oral, daily over 6 weeks
366821|NCT00005077|Drug|oxaliplatin|
366822|NCT00670098|Procedure|Bariatric surgery|patients receive either gastric bypass or lap-band
366823|NCT00670098|Behavioral|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
366142|NCT00642837|Drug|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
366143|NCT00000640|Drug|Dapsone|
366144|NCT00004865|Drug|fluorouracil|
366145|NCT00642837|Drug|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
366146|NCT00642850|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
366147|NCT00642863|Dietary Supplement|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
366148|NCT00645047|Behavioral|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
366149|NCT00645047|Behavioral|In-Person CBT|In-Person Provision Of Cognitive Therapy
366150|NCT00645060|Other|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
366151|NCT00645060|Other|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
366152|NCT00645060|Procedure|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
366153|NCT00645060|Procedure|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
366154|NCT00004879|Biological|panitumumab|
366155|NCT00645060|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
366156|NCT00645073|Drug|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
366157|NCT00645073|Drug|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
366158|NCT00645086|Drug|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
366159|NCT00645086|Drug|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
366160|NCT00645099|Drug|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
366161|NCT00645099|Drug|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
357201|NCT00672542|Biological|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
357202|NCT00672555|Procedure|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
357203|NCT00005090|Drug|dacarbazine|375 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
357204|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
357205|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
357206|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
357207|NCT00672568|Drug|Placebo|Solution, single dose, injection
357208|NCT00672581|Drug|ZD4054|10mg, Oral tablet, single dose
357209|NCT00672594|Drug|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
357210|NCT00672607|Drug|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
357211|NCT00672607|Drug|Placebo|Placebo
357212|NCT00672620|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
357213|NCT00672620|Drug|Duloxetine|Duloxetine capsules
357214|NCT00000658|Drug|Sargramostim|
357215|NCT00005090|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
357216|NCT00672620|Drug|Placebo|Placebo-matching capsules
357217|NCT00672633|Drug|Lovaza|Lovaza , 4 grams/day orally for 6 months
357218|NCT00672633|Drug|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
357219|NCT00672646|Drug|AZD1386|95mg, oral solution, single dose
356589|NCT00621517|Drug|Placebo|1 capsule nightly for six weeks
356590|NCT00621530|Drug|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
356591|NCT00621530|Drug|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
356592|NCT00621543|Device|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
356593|NCT00621556|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
356594|NCT00621569|Behavioral|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
356905|NCT00689286|Device|BION|They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) "twitch" stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.
In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises.
356906|NCT00689299|Biological|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
356907|NCT00689299|Biological|Placebo|Placebo Sublingual Drops
356908|NCT00689312|Drug|Enfalyte|Each patient will receive one 250 ml dose.
356909|NCT00689312|Drug|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
356910|NCT00689312|Drug|Pedialyte|Each patient will receive one 250 ml dose.
356911|NCT00689338|Drug|Anidulafungin|Anidulafungin Intravenous Administration
356912|NCT00005640|Radiation|Technetium Tc 99m Sulfur Colloid|
356913|NCT00689338|Drug|Fluconazole|Oral Administration of Fluconazole
356914|NCT00689338|Drug|Voriconazole|Oral Administration of Voriconazole
356915|NCT00689351|Biological|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
366575|NCT00647699|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
366576|NCT00647699|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
366577|NCT00647712|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
366578|NCT00647712|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fasting
366579|NCT00647725|Procedure|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
366580|NCT00647725|Procedure|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
366581|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablets
366582|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablet
366583|NCT00004893|Biological|recombinant interleukin-12|
366584|NCT00647751|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
366585|NCT00647751|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fed
366586|NCT00647764|Drug|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
366587|NCT00647777|Drug|Olanzapine Tablets 5 mg|5mg, single dose fed
366588|NCT00647777|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fed
366589|NCT00647790|Procedure|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
366927|NCT00640783|Behavioral|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
366928|NCT00640783|Behavioral|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, <30%).
366929|NCT00640796|Procedure|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
366254|NCT00652821|Drug|Tramadol/ APAP|Tablets 37.5mg /325mg
366255|NCT00655200|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
366256|NCT00655213|Device|Symphony D 2450|
366257|NCT00655213|Device|Symphony DR 2550|
366258|NCT00655226|Behavioral|Hepatitis C educational support groups|Hepatitis C educational support groups
366259|NCT00655226|Behavioral|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
366260|NCT00655239|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
366261|NCT00655239|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
366262|NCT00004921|Biological|filgrastim|
366263|NCT00655252|Drug|Everolimus|
366264|NCT00655265|Drug|Colesevelam hydrochloride film-coated tablets|tablets
366265|NCT00655265|Drug|Placebo|Tablets
366266|NCT00655278|Drug|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
366267|NCT00655291|Drug|XP20B|
366268|NCT00655291|Drug|Placebo|
366269|NCT00655304|Device|Prometheus (R) liver support dialysis|6-8 hours of dialysis
366270|NCT00655304|Device|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
366271|NCT00655317|Other|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
366272|NCT00655317|Other|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
366273|NCT00004921|Drug|carboplatin|
366274|NCT00655330|Drug|Valsartan|Valsartan (160mg/day)
365595|NCT00000658|Drug|Bleomycin sulfate|
365596|NCT00005052|Biological|GM2-KLH vaccine|
365597|NCT00667160|Drug|tacrolimus ointment|topical
365598|NCT00667160|Drug|pimecrolimus cream|topical
365599|NCT00667173|Drug|IDP-115|Topical application for 12 weeks
365600|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
365601|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
365925|NCT00660309|Drug|Irbesartan|Irbesartan 300 mg tablets
365926|NCT00662636|Drug|dasatinib|Given orally
365927|NCT00662636|Drug|lapatinib ditosylate|Given orally
365928|NCT00662636|Other|pharmacological study|Correlative study (cohort II only)
365929|NCT00662636|Other|laboratory biomarker analysis|Correlative study (cohort II only)
365930|NCT00662649|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
365931|NCT00662649|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
365932|NCT00662662|Behavioral|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
365933|NCT00662675|Drug|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
365934|NCT00662675|Drug|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
365935|NCT00662688|Drug|daltéparine|
365936|NCT00000654|Drug|Fialuridine|
365937|NCT00005021|Biological|filgrastim|
365938|NCT00662688|Drug|Chemotherapy at the investigator's discretion|
365939|NCT00662701|Procedure|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
365940|NCT00662701|Procedure|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
365272|NCT00635193|Drug|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
365273|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
365274|NCT00004758|Drug|nitrazepam|
365275|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
365276|NCT00635206|Device|BiPap auto with Fi Flex|MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
MaxIPAP = 25 cm H2O
MinPS = 2 cm H2O (cannot be adjusted)
MaxPS = 8 cm H2O
Bi-Flex setting of 3
365277|NCT00635206|Device|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
365278|NCT00635219|Drug|Placebo|capsules; daily; orally
365279|NCT00635219|Drug|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
365280|NCT00635219|Drug|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
365281|NCT00635219|Drug|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
365282|NCT00635219|Drug|Duloxetine|60 mg/day; encapsulated capsules; orally
365283|NCT00635232|Drug|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
365602|NCT00667186|Other|Targeted Screening|Selection method for screening is based on risk
365603|NCT00667186|Other|Routine Screening|Selection method for screening is not based on risk
365604|NCT00669669|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
365605|NCT00669669|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
365606|NCT00669669|Drug|Carmustine|Given IV
365607|NCT00669669|Biological|Filgrastim|Given SC
365608|NCT00005071|Procedure|computed tomography|
365609|NCT00669669|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
365610|NCT00669669|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
365611|NCT00669669|Other|Laboratory Biomarker Analysis|Correlative studies
364628|NCT00649675|Drug|Meloxicam Tablets 15 mg|15mg, single dose fed
364629|NCT00649675|Drug|Mobic® Tablets 15 mg|15mg, single dose fed
364947|NCT00642343|Behavioral|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
364948|NCT00642356|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
364949|NCT00642356|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
364950|NCT00642369|Drug|quetiapine fumarate|600-750mg/day
364951|NCT00642369|Drug|haloperidol|6-40mg/day
364952|NCT00642382|Device|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
364953|NCT00642382|Device|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
364954|NCT00004862|Drug|cytarabine|
364955|NCT00642395|Drug|Bortezomib|bortezomib-Melphalan
364956|NCT00642408|Dietary Supplement|Multiple micronutrient supplements (MMN)|Iron and folic acid: iron 60 mg and folic acid 400µg
364957|NCT00642408|Dietary Supplement|IFA|Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
364958|NCT00642421|Drug|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
364959|NCT00642421|Drug|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
364960|NCT00642434|Drug|carvedilol|variable
364961|NCT00642434|Drug|metoprolol|variable
364962|NCT00642447|Drug|helium:oxygen mixture|
364642|NCT00004900|Procedure|peripheral blood stem cell transplantation|
364643|NCT00649740|Drug|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
364644|NCT00649753|Procedure|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
364645|NCT00649753|Procedure|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
364646|NCT00649753|Procedure|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
364647|NCT00649766|Behavioral|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
364648|NCT00649766|Behavioral|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
364649|NCT00649779|Drug|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
364650|NCT00649779|Drug|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
364651|NCT00649792|Drug|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
364967|NCT00642460|Drug|methotrexate|as prescribed
364968|NCT00644566|Other|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
364969|NCT00644579|Drug|bLAC|bLAC high and low dose and placebo
364970|NCT00644579|Drug|Placebo|Placebo
364971|NCT00644592|Drug|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
364972|NCT00644592|Drug|Fenofibrate|160 mg/day orally for 4 weeks
364973|NCT00644605|Drug|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
364974|NCT00644605|Drug|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
364975|NCT00004878|Drug|fludarabine phosphate|
364307|NCT00656929|Other|Placebo|Placebo tablets
364308|NCT00656968|Drug|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
364309|NCT00000649|Drug|Nevirapine|
364310|NCT00004931|Other|laboratory biomarker analysis|Correlative studies
364311|NCT00656968|Drug|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
364312|NCT00656981|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
364313|NCT00656981|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
364314|NCT00656994|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
364315|NCT00656994|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
364316|NCT00657007|Biological|belimumab|1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).
1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5).
364317|NCT00657007|Biological|belimumab|4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).
4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6).
364318|NCT00657007|Biological|belimumab|10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).
10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7).
364319|NCT00657007|Biological|belimumab|20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).
20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8).
364320|NCT00659477|Drug|insulin glargine|once daily
364321|NCT00659490|Drug|AZD1940|800ug oral administration
364322|NCT00659490|Drug|Naproxen|500mg oral administration
364323|NCT00659490|Drug|Placebo|Placebo given pre-surgery
364324|NCT00659503|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
364325|NCT00659503|Drug|Placebo|placebo
363657|NCT00668772|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
363658|NCT00668772|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
363659|NCT00668772|Drug|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
363660|NCT00668785|Drug|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
363661|NCT00668811|Drug|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
363662|NCT00668824|Drug|Vasovist|
363968|NCT00662025|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
363969|NCT00662025|Drug|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
363970|NCT00662038|Drug|pirfenidone|2403 mg/day of pirfenidone administered in divided doses 3 times daily
363971|NCT00662077|Drug|Ibandronate|Ibandronate endovenous 3 mg every 3 months
363972|NCT00662077|Behavioral|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
363973|NCT00662103|Behavioral|exercise intervention|Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months.
363974|NCT00662103|Other|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health & Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
363975|NCT00662103|Other|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
363976|NCT00664313|Drug|Linezolid|600 mg po daily for 112 doses (16 weeks)
363977|NCT00664313|Drug|Placebo|Placebo given daily for 112 doses (16 weeks)
363322|NCT00634608|Other|Health Information Prescription - MedlinePlus link|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
363323|NCT00636675|Behavioral|Connect|Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:
In-class learning sessions introduce interaction strategies.
Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.
Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role.
363324|NCT00636688|Behavioral|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
363325|NCT00636688|Behavioral|Control - general information|General information about healthy food choices and exercise
363326|NCT00636701|Device|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
363327|NCT00636714|Behavioral|Nursing judgement|Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
363328|NCT00636714|Behavioral|Nomogram|A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
363329|NCT00636727|Procedure|arthrocentesis|Irrigate the TMJ with lactated ringers
363330|NCT00004779|Genetic|Ad5-CB-CFTR|
363331|NCT00636727|Procedure|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
363332|NCT00636727|Procedure|arthroplasty|The disc will be surgically repositioned with open surgery
363333|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
363334|NCT00636740|Drug|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
363663|NCT00668837|Drug|Paliperidone|
363664|NCT00668850|Drug|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
363665|NCT00668850|Drug|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
362680|NCT00648869|Drug|metformin tablet, metformin gum|500 mg, 250 mg
362681|NCT00648882|Drug|LEVOTHYROXINE SODIUM TABLETS,|2x300mcg, single dose fasting
362682|NCT00648882|Drug|SYNTHROID® 300 mcg Tablets|2x300mcg, single dose fasting
362683|NCT00648895|Drug|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
362684|NCT00648895|Drug|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
362685|NCT00648908|Drug|Fampridine-SR|Tablets, 10 mg, BID
362686|NCT00648921|Drug|Olanzapine Tablets 5 mg|5mg, single dose fasting
362687|NCT00648921|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fasting
363000|NCT00641680|Drug|Budesonide|
363001|NCT00641680|Drug|Fluticasone propionate|
363002|NCT00641680|Drug|Placebo|
363003|NCT00641693|Drug|Budesonide|16mg Nasal Spray
363004|NCT00641693|Drug|Budesonide|32mg Nasal Spray
363005|NCT00641693|Drug|Budesonide|64mg Nasal Spray
363006|NCT00641693|Drug|Placebo|
363007|NCT00004859|Drug|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
363008|NCT00641706|Drug|vorinostat|Given orally
363009|NCT00641706|Procedure|therapeutic conventional surgery|Patient undergoes surgery
363010|NCT00641706|Drug|bortezomib|Given IV
363011|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
363012|NCT00643877|Procedure|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
363013|NCT00643877|Procedure|surgery|radical surgery only
362342|NCT00656110|Drug|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
362343|NCT00656110|Drug|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
362344|NCT00004925|Biological|trastuzumab|
362345|NCT00656123|Biological|GM-K562 cell vaccine|
362346|NCT00656123|Biological|allogeneic tumor cell vaccine|
362347|NCT00656123|Drug|cyclophosphamide|
362348|NCT00656123|Genetic|gene expression analysis|
362349|NCT00656123|Genetic|protein analysis|
362350|NCT00656123|Other|immunoenzyme technique|
362351|NCT00656123|Other|immunologic technique|
362352|NCT00656123|Other|laboratory biomarker analysis|
362353|NCT00656136|Drug|placebo|Patients receive placebo once daily
362354|NCT00656136|Drug|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
362355|NCT00004925|Drug|pegylated liposomal doxorubicin hydrochloride|
362356|NCT00656149|Behavioral|FES-assisted In-home telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
362357|NCT00656149|Behavioral|Exercise training|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
362358|NCT00656175|Drug|raltegravir|raltegravir
362688|NCT00000643|Drug|Pyrimethamine|
362689|NCT00004898|Radiation|radiation therapy|
362690|NCT00648934|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
362691|NCT00648934|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
362692|NCT00648947|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
361692|NCT00591305|Device|585 nm pulsed dye laser|once-time PDL
361693|NCT00004188|Drug|cisplatin|Given IV
361694|NCT00591318|Drug|ceftriaxone|2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
361695|NCT00591318|Drug|Normal Saline|50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
361696|NCT00591331|Drug|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
361697|NCT00591331|Drug|placebo|
361698|NCT00591344|Behavioral|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
361699|NCT00591344|Behavioral|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
361700|NCT00591357|Drug|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
362019|NCT00663676|Drug|human recombinant growth hormone (Growth Hormone)|administered via a subcutaneous infusion pump for 24 hours
362020|NCT00663689|Drug|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
362021|NCT00663702|Drug|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
362022|NCT00005025|Biological|herpes simplex thymidine kinase|
362023|NCT00663715|Other|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
362024|NCT00663728|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
362025|NCT00663728|Drug|Placebo|Matching placebo
362026|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
362027|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
362028|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
366824|NCT00670111|Device|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
366825|NCT00670124|Device|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
366826|NCT00670150|Drug|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
366827|NCT00670150|Drug|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
366828|NCT00670163|Behavioral|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
366829|NCT00670163|Behavioral|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
366830|NCT00670163|Behavioral|Standard Care|Standard care will consist of usual care for STIs.
366831|NCT00670176|Behavioral|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
366832|NCT00005078|Drug|carboplatin|
366833|NCT00670189|Drug|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
366834|NCT00670202|Drug|fasudil|40 mg orally three times daily
366835|NCT00670215|Drug|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
366836|NCT00633542|Drug|interferon alpha|3 MU 3 times a week until progression or severe toxicity
366837|NCT00633568|Drug|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
361701|NCT00591357|Drug|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
361702|NCT00591370|Drug|Temozolomide (TMZ)|One group treatment study
366492|NCT00637962|Biological|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
366493|NCT00637962|Biological|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
366494|NCT00004801|Drug|monoclonal factor IX replacement therapy|
366495|NCT00637975|Drug|oxycodone|Arm A - 20 mg/day
Arm B - increasing dose startnig at 20 mg/day
For 15 days or until unacceptable toxicity develops.
366496|NCT00637975|Drug|pregabalin|Arm A - pregabalin at increasing dose starting from 50 mg/day
Arm B - pregabalin 50 mg/day
For 15 days or until unacceptable toxicity develops.
366497|NCT00637988|Drug|Esomeprazole|40mg twice daily
366498|NCT00637988|Drug|Aspirin|
366499|NCT00637988|Drug|Rofecoxib|25mg once daily
366500|NCT00638001|Device|custom-molded insoles and custom-molded shoes|custom-made insoles in "PELITE" foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy
custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy
366501|NCT00638014|Device|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
366502|NCT00638014|Device|Conventional wire closure|Conventional wire closure of sternum
366503|NCT00638027|Drug|placebo|matched tablets bid
366504|NCT00638027|Drug|memantine|10 mg bid
366505|NCT00004802|Drug|dichlorphenamide|
366506|NCT00638053|Genetic|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
366507|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
366508|NCT00640588|Drug|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
366509|NCT00640588|Drug|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
357220|NCT00672646|Drug|Naproxen|500mg, capsule, single dose
357221|NCT00672646|Drug|Placebo|AZD1386 Placebo oral solution
357515|NCT00677703|Other|Daily Text Messages|Text message reminders to take oral contraception daily:
Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors.
357516|NCT00677716|Drug|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
357517|NCT00677729|Drug|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
357518|NCT00677729|Drug|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
357519|NCT00680069|Biological|Influenza A/H5N1/Indonesia/05/05 (clade 2) inactivated vaccine|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Dosages: 15 or 90 mcg.
357520|NCT00680095|Drug|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
357521|NCT00680095|Drug|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
357522|NCT00680095|Drug|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
357523|NCT00680095|Other|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
357524|NCT00005589|Biological|filgrastim|
357525|NCT00680095|Other|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
357526|NCT00680108|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
357527|NCT00680121|Drug|Benfotiamine|Benfotiamine 600 mg
357528|NCT00680121|Drug|Placebo|Placebo
357529|NCT00680134|Drug|AN2690|AN2690 1% Solution, once daily for 180 days
357530|NCT00680134|Drug|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
357531|NCT00680147|Behavioral|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
357532|NCT00680160|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
356916|NCT00689351|Biological|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
356917|NCT00689390|Biological|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
356918|NCT00689390|Biological|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
356919|NCT00689390|Biological|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
356920|NCT00689390|Drug|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
356921|NCT00691509|Genetic|polymorphism analysis|
356922|NCT00691509|Other|high performance liquid chromatography|
356923|NCT00691509|Other|laboratory biomarker analysis|
356924|NCT00691509|Other|mass spectrometry|
357222|NCT00672659|Drug|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
357223|NCT00672659|Drug|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
357224|NCT00672672|Biological|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
357225|NCT00674921|Drug|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
357226|NCT00674921|Drug|Placebo|starch, magnesium stearate, sodium lauryl sulphate
357227|NCT00674934|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
357228|NCT00674947|Drug|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
357229|NCT00674960|Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
357230|NCT00674973|Drug|erlotinib [Tarceva]|150mg po daily
357231|NCT00674973|Drug|placebo|po daily
357232|NCT00005113|Drug|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
366930|NCT00640796|Drug|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
366931|NCT00640796|Device|CliniMACS|Cell selection system based on magnetic-activated cell sorting
366932|NCT00640809|Drug|Celecoxib|200 mg oral capsule twice daily for 2 weeks
366933|NCT00640809|Other|Placebo|Matched placebo for 2 weeks
366934|NCT00640809|Drug|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
366935|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
366936|NCT00004852|Drug|Lamivudine|
366937|NCT00640822|Drug|Tacalcitol Ointment|Once daily application for up to 8 weeks
366938|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
366939|NCT00642993|Drug|SCH 497079|administered orally
366940|NCT00642993|Drug|Placebo|Placebo capsules matching SCH 497079 administered orally
366941|NCT00643006|Behavioral|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
366942|NCT00643006|Behavioral|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
366943|NCT00004867|Procedure|conventional surgery|
366944|NCT00643019|Behavioral|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
366945|NCT00643019|Other|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
366946|NCT00643032|Procedure|Transcutaneous iliohypogastric|
366947|NCT00643032|Procedure|Perioperative administration near the nerve|
361803|NCT00641212|Drug|Budesonide|
361804|NCT00641212|Drug|Placebo|
361805|NCT00641225|Drug|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
361806|NCT00641238|Device|Radiofrequency ablation|Radiofrequency ablation
366275|NCT00655330|Drug|Placebo|Placebo
366276|NCT00655330|Drug|Probucol|Probucol (750mg/day)
366590|NCT00647816|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fasting
366591|NCT00647816|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fasting
366592|NCT00647829|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
366593|NCT00647829|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
366594|NCT00004895|Drug|octreotide acetate|
366595|NCT00647829|Drug|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
366596|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
366597|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h|single application
366598|NCT00647855|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
366599|NCT00650429|Drug|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
366600|NCT00650442|Drug|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
366601|NCT00650442|Drug|Estradiol Transdermal System Placebo - Current Adhesive|single application
366602|NCT00004903|Drug|cytarabine|
366603|NCT00650455|Drug|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
366604|NCT00650455|Drug|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
366605|NCT00650455|Drug|placebo|placebo tablet every morning and capsule every evening for 12 weeks
366606|NCT00650468|Drug|tacrolimus|Oral
366607|NCT00650468|Drug|CellCept|IV or Oral
366608|NCT00650468|Drug|steroids (methylprednisone or prednisone)|IV or Oral
366609|NCT00650481|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
365941|NCT00662714|Drug|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
365942|NCT00662714|Drug|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
365943|NCT00662727|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
365944|NCT00662727|Device|Placebo|Placebo
365945|NCT00662740|Drug|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
365946|NCT00662740|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
365947|NCT00662740|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
365948|NCT00005021|Drug|carboplatin|
366277|NCT00655343|Drug|ATG-Fresenius S|20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution
20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation
366278|NCT00655356|Biological|Autologous Human Fibroblasts (azficel-T)|Collection of 3 mm post auricular skin punch biopsies.
Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face.
366279|NCT00655356|Biological|Placebo|Collection of 3 mm post auricular skin punch biopsies.
Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face.
366280|NCT00655369|Drug|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
366281|NCT00657670|Device|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
366282|NCT00657683|Biological|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
366283|NCT00657683|Biological|Placebo|1 dose of placebo
366284|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
366285|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
366286|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
366287|NCT00657709|Biological|Infanrix Hexa|Routine vaccination
366288|NCT00657709|Biological|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
365612|NCT00669669|Drug|O6-Benzylguanine|Given IV
365613|NCT00669669|Drug|Plerixafor|Given SC
365614|NCT00669669|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
365615|NCT00669669|Drug|Temozolomide|Given PO
365616|NCT00669682|Other|Congestive heart failure|Spontaneous occurrence of fluid overload.
365617|NCT00669695|Drug|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
365618|NCT00669695|Other|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
365619|NCT00005071|Procedure|quality-of-life assessment|
365620|NCT00669695|Other|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
365621|NCT00669708|Device|cooling compound (ph5 Eucerin)|application twice daily to the skin
365622|NCT00669721|Drug|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
365623|NCT00669721|Drug|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
365624|NCT00669734|Biological|Falimarev|Given intratumorally or SC
365949|NCT00662740|Drug|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
365950|NCT00662740|Drug|Tiotropium|Tiotropium
365951|NCT00662753|Device|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
365952|NCT00662753|Other|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
365953|NCT00664950|Device|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
365954|NCT00664950|Device|IntertAn IM nail|interTAN IM nail
364963|NCT00642460|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (patients>=30kg) or 12mg/kg (patients <30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
364964|NCT00642460|Drug|Placebo|iv every 2 weeks for 12 weeks
364965|NCT00004862|Drug|fludarabine phosphate|
364966|NCT00642460|Drug|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
365284|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr <30 mL/min and not on hemodialysis)
365285|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
365286|NCT00637416|Drug|Lansoprazole|Lansoprazole 30 mg PO daily for 3 months
365287|NCT00637416|Drug|placebo|placebo PO daily for 3 months
365288|NCT00637442|Drug|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
365289|NCT00637455|Drug|fexofenadine HCl|
365290|NCT00004795|Drug|dehydroepiandrosterone|
365291|NCT00637468|Drug|Intravenous injection of heparin|
365292|NCT00637468|Drug|Intravenous injection of acetazolamide|
365293|NCT00637468|Procedure|Local intra-arterial fibrinolysis|
365294|NCT00637468|Procedure|Globe massage|
365295|NCT00637468|Drug|Topical use of beta-blocker|
365296|NCT00637468|Drug|Isovolaemic haemodilution|
365297|NCT00637468|Drug|Acetylsalicylic acid|
365298|NCT00637481|Drug|atorvastatin calcium|Given orally
365299|NCT00637481|Other|laboratory biomarker analysis|Correlative studies
365300|NCT00637494|Drug|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
365301|NCT00004796|Drug|lactulose|
364976|NCT00644605|Drug|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
364977|NCT00644605|Drug|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
364978|NCT00644618|Drug|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
364979|NCT00644618|Other|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
364980|NCT00644631|Drug|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
364981|NCT00644631|Drug|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
364982|NCT00644644|Other|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
364983|NCT00644657|Drug|Clopidogrel|All subjects will receive a 300 mg loading dose
364984|NCT00644670|Drug|Atorvastatin|In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
364985|NCT00644670|Drug|Atorvastatin|In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
365305|NCT00637546|Other|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
365306|NCT00637559|Drug|Esomeprazole Magnesium|
365307|NCT00637572|Drug|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
365308|NCT00637572|Drug|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
365309|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
364326|NCT00659529|Drug|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
364652|NCT00652093|Drug|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
364653|NCT00652093|Drug|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
364654|NCT00652093|Drug|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
364655|NCT00004906|Drug|cisplatin|
364656|NCT00652093|Drug|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
364657|NCT00652106|Drug|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
364658|NCT00652106|Drug|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
364659|NCT00652106|Drug|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
364660|NCT00652119|Drug|Paclitaxel|Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.
364661|NCT00652119|Drug|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
364662|NCT00652119|Drug|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
364663|NCT00652132|Drug|cisplatin|
364664|NCT00652132|Drug|sodium thiosulfate|
364665|NCT00652132|Genetic|gene rearrangement analysis|
364666|NCT00004906|Drug|cyclophosphamide|
364667|NCT00652132|Genetic|microarray analysis|
364668|NCT00652132|Genetic|proteomic profiling|
363978|NCT00664326|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
363979|NCT00005030|Procedure|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
363980|NCT00664339|Biological|Flu Vaccine|Single dose of Flu vaccine by year (1)
363981|NCT00664339|Other|Conventional medical therapy for heart failure|According with the international guidelines
363982|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
364327|NCT00004990|Drug|Dexamethasone|
364328|NCT00659542|Procedure|cyanoacrylate glue|1 ml glue
364329|NCT00659555|Drug|pazopanib eye drops and ketoconazole tablets|
364330|NCT00659568|Drug|metformin hydrochloride|
364331|NCT00659568|Drug|temsirolimus|
364332|NCT00659581|Drug|Telmisartan|Oral administration
364333|NCT00659594|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
364334|NCT00659594|Drug|Placebo|placebo
364335|NCT00659620|Biological|mesenchymal stem cell|transplantation of mesenchymal stem cell
364336|NCT00659633|Drug|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
364337|NCT00659646|Drug|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
364338|NCT00004992|Behavioral|Intensive lifestyle|
364339|NCT00659646|Drug|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
364340|NCT00659659|Drug|MEDI-563|1.0 mg/kg IV: MEDI-563
363666|NCT00005067|Drug|motexafin lutetium|Given IV
363667|NCT00668863|Drug|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
363668|NCT00668863|Drug|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
363669|NCT00668876|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
363670|NCT00668876|Dietary Supplement|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
363671|NCT00668876|Dietary Supplement|Parenteral nutrition|Parenteral nutrition
363672|NCT00668889|Drug|Lactic acid (Dermacid)|
363673|NCT00668902|Drug|[13C]Pantoprazole|[13C]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
363674|NCT00668928|Other|Polyphenols (flavon-3-ol monomers and oligomers)|Flavanols
363675|NCT00632242|Drug|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
363676|NCT00632255|Drug|Imatinib|Conventional therapy with imatinib
363677|NCT00632268|Drug|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
363678|NCT00632281|Radiation|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
363679|NCT00632294|Procedure|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
363680|NCT00632333|Biological|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
363014|NCT00643890|Genetic|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10^12 vector genomes in 35 uL.
363015|NCT00004873|Drug|docetaxel|
363016|NCT00643903|Behavioral|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
363017|NCT00643903|Behavioral|Standard care|Participants will receive standard of care for HIV infections.
363018|NCT00643903|Behavioral|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
363019|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
363020|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
363021|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
363335|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
363336|NCT00636766|Drug|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
363337|NCT00636766|Drug|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
363338|NCT00636766|Drug|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
363339|NCT00636766|Drug|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
363340|NCT00636792|Drug|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
363341|NCT00639379|Device|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
362693|NCT00648947|Drug|Plavix® Tablets 75 mg|75mg, single dose fasting
362694|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
362695|NCT00651352|Drug|4 mg nicotine lozenge|marketed formulation
362696|NCT00651352|Drug|2 mg nicotine lozenge|marketed formulation
362697|NCT00651352|Drug|2 mg nicotine prototype|2 mg
362698|NCT00651352|Drug|4 mg nicotine prototype|4 mg
362699|NCT00651365|Drug|JNJ-38877605|
362700|NCT00651378|Drug|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
362701|NCT00651378|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
362702|NCT00651378|Drug|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
362703|NCT00004905|Biological|recombinant interferon alfa|
362704|NCT00651391|Drug|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
362705|NCT00651391|Drug|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
362706|NCT00651391|Drug|Placebo|oral placebo once daily in the evening for 12 weeks
362707|NCT00651404|Drug|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
362708|NCT00651404|Drug|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
362709|NCT00651417|Dietary Supplement|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
362710|NCT00651417|Dietary Supplement|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
362711|NCT00651443|Drug|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
363022|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
363023|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
362029|NCT00663754|Behavioral|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
362030|NCT00663754|Behavioral|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
362031|NCT00663767|Drug|Placebo; oral|dose 1, dose 2
362032|NCT00663767|Drug|Placebo; oral|dose 1
362033|NCT00005025|Drug|ganciclovir|
362034|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
362035|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
362036|NCT00663767|Drug|Celecoxib, COX-2 inhibitor; oral|dose 1
362037|NCT00663767|Drug|Placebo; oral|dose 2
362038|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
362039|NCT00665886|Device|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
362359|NCT00656188|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
362360|NCT00656188|Drug|Placebo|Matching placebo
362361|NCT00656201|Drug|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
362362|NCT00658645|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
362363|NCT00658645|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
362364|NCT00658658|Drug|Panitumumab Treatment|Panitumumab will be given to all cohorts according to dose and age. Enrollment for subsequent cohorts will be determined according to a safety assessment by a Data Review Team made up of investigators and key members of the Amgen study team
362365|NCT00004980|Device|sham stimulation|132 minutes of stimulation given at 80% motor threshold with coil tilted "single wing" 45 degrees away from scalp deliverd to TP3 site
362366|NCT00658671|Drug|ENMD-2076|Capsules, daily dosing in 28 day cycles
361703|NCT00591383|Drug|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
361704|NCT00004188|Drug|cyclophosphamide|Given IV
361705|NCT00591383|Drug|erlotinib|erlotinib taken at 150 mg every morning with food.
361706|NCT00591396|Drug|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
361707|NCT00591409|Drug|sugammadex|After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arms 2-5) or 0.1 mg/kg vecuronium (arms 7-10).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered.
361708|NCT00591409|Drug|Placebo|After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of placebo IV was administered
361709|NCT00591422|Drug|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (>36 hours between doses) for 3 weeks with 1 week rest.
361710|NCT00591435|Other|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
361711|NCT00591448|Other|Virtual Reality (VR)|See above
361712|NCT00591474|Dietary Supplement|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
361713|NCT00633945|Drug|lenalidomide (Revlimid®)|The drug will be administered in oral form. The dosage of lenalidomide (REVLIMID®) will be lower or equivalent to the dosages indicated for the above uses. The dose will be as low as 5 mg every other day, or will be as high as 10 mg daily. Subjects will be treated with medication for 48 weeks.
361714|NCT00633958|Other|[18F]-Fluorothymidine|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
361715|NCT00633971|Other|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
361716|NCT00633984|Behavioral|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
362040|NCT00665886|Device|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
362041|NCT00005044|Procedure|neoadjuvant therapy|
366510|NCT00640601|Drug|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
366838|NCT00633568|Drug|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
366839|NCT00004735|Biological|Hepatitis A Vaccine (Inactivated)|
366840|NCT00633581|Dietary Supplement|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
366841|NCT00633581|Dietary Supplement|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
366842|NCT00633594|Drug|Rituximab|
366843|NCT00633594|Drug|Bortezomib|
366844|NCT00633594|Drug|Lenalidomide|
366845|NCT00633607|Other|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
366846|NCT00633620|Device|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
366847|NCT00633633|Other|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
366848|NCT00633633|Behavioral|Exercise Training|Exercise training 3 times a week.
366849|NCT00633633|Behavioral|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
366850|NCT00004736|Drug|Nelfinavir mesylate|
366851|NCT00633646|Dietary Supplement|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
366852|NCT00633659|Drug|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
366853|NCT00633659|Drug|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
366854|NCT00633672|Drug|Esomeprazole|20mg Oral tablet once daily
366855|NCT00633672|Drug|Ranitidine|150mg oral twice daily
366856|NCT00633672|Drug|Esomeprazole|40mg oral tablet once daily
357533|NCT00680173|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
357534|NCT00680186|Drug|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
357535|NCT00005589|Biological|rituximab|
357536|NCT00680186|Drug|Dabigatran etexilate|150mg bid
357848|NCT00685165|Drug|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
357849|NCT00685178|Drug|topiramate|topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.
capsules are administered from week 4 through 25 of the trial
357850|NCT00685178|Behavioral|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
357851|NCT00685178|Drug|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
357852|NCT00685191|Drug|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
357853|NCT00687401|Biological|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
357854|NCT00005628|Biological|vitespen|
357855|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group A:
Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.
Treatment will focus on the patient's needs and in accordance with the physicians requests.
Three months post initial treatment re-assessment will be conducted.
357856|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
357857|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
357858|NCT00687440|Drug|Pegylated Liposomal Doxorubicin|Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks
Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.
357859|NCT00687440|Drug|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
357860|NCT00687440|Drug|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
357233|NCT00674986|Device|Accu-Chek 360° View Blood Glucose Analysis Tool|
357234|NCT00674986|Device|Accu-Chek Aviva Glucose Meter|
357235|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
357236|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
357237|NCT00674999|Drug|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
357238|NCT00675012|Drug|NGR-hTNF|iv 0.8 or 45 mcg/sqm q3W
357239|NCT00675012|Drug|Oxaliplatin|iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
357240|NCT00675012|Drug|capecitabine|orally 825 mg/sqm 2qDx14
357241|NCT00675025|Drug|Donepezil Hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
357242|NCT00675038|Procedure|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2* MRI
357243|NCT00005113|Drug|Tacrolimus|dosage is in oral form titrated to target trough level
357244|NCT00675064|Drug|GSK369796|Anti-malarial
357537|NCT00680212|Dietary Supplement|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
357538|NCT00680212|Dietary Supplement|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
357539|NCT00680225|Drug|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
357540|NCT00680238|Drug|Human derived FSH|Customized for each patient
357541|NCT00680277|Dietary Supplement|spirulina ß-carotene|an acute dose of spirulina up to 5 g
357542|NCT00680277|Dietary Supplement|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
357543|NCT00680290|Procedure|Exercise|Exercise x 8 weeks
357544|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
357545|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
361807|NCT00641251|Other|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
361808|NCT00641251|Other|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
361809|NCT00641264|Drug|Omeprazole|
361810|NCT00641264|Behavioral|Quality of Life questionnaire|
361811|NCT00643409|Drug|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
361812|NCT00643409|Other|placebo|placebo
361813|NCT00004868|Drug|semaxanib|
361814|NCT00643422|Device|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
361815|NCT00643435|Behavioral|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
361816|NCT00643435|Behavioral|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
361817|NCT00643448|Drug|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
361818|NCT00643448|Drug|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
361819|NCT00643448|Drug|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
361820|NCT00643461|Device|Adhesive A|Applied per manufacturer's instructions.
361821|NCT00643461|Device|Adhesive B|Applied per manufacturer's instructions.
361822|NCT00643461|Device|Adhesive C|Applied per manufacturer's instructions.
361823|NCT00643474|Device|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
361824|NCT00000640|Drug|Clindamycin|
361825|NCT00004870|Biological|oblimersen sodium|
362139|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks
366610|NCT00650481|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
366611|NCT00650494|Drug|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
366612|NCT00650494|Drug|Valtrex® 1000 mg|1000mg, single dose fed
366613|NCT00004903|Drug|etoposide|
366948|NCT00643045|Drug|Safinamide|
366949|NCT00643045|Drug|Safinamide|
366950|NCT00643045|Drug|Placebo|
366951|NCT00643058|Biological|LPS endotoxin|Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated
High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated
Diluent Challenge: 3 X Sterile saline inhalation (2 ml)
366952|NCT00643071|Drug|Tacrolimus|Oral
366953|NCT00643084|Procedure|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
366954|NCT00004867|Procedure|positron emission tomography|
366955|NCT00643084|Procedure|standard bowel preparation|standard bowel preparation
366956|NCT00643097|Biological|PEP-3 vaccine|Given intradermally
366957|NCT00643097|Biological|sargramostim|Given intradermally
366958|NCT00643097|Drug|Temozolomide|Standard of care chemotherapy
366959|NCT00643110|Drug|D50 glucose|D50 glucose would be administered, if necessary.
366960|NCT00643123|Drug|Allopurinol|300-600 mg/day over a 4 week period
366961|NCT00643123|Drug|Placebo|Inactive substance
366962|NCT00643136|Drug|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
366963|NCT00643136|Drug|Placebo|Matching placebo capsules twice daily for 28 days
366964|NCT00643149|Drug|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
366965|NCT00004867|Procedure|radionuclide imaging|
366966|NCT00643149|Drug|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
366289|NCT00657709|Biological|Prevenar|Routine vaccination
366290|NCT00657722|Other|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
366291|NCT00000649|Drug|Zidovudine|
366292|NCT00004936|Drug|iodinated contrast dye|
366293|NCT00657735|Device|H-Coil deep TMS|20 daily deep rTMS treatments
366294|NCT00657735|Device|sham|inactive treatment
366295|NCT00657748|Drug|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
366296|NCT00657761|Drug|Enfuvirtide|90 mg/12h sc for 7 days
366297|NCT00657761|Drug|Placebo|0.9% saline solution/12h sc for 7 days
366614|NCT00650507|Procedure|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
366615|NCT00650507|Procedure|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
366616|NCT00650520|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
366617|NCT00650520|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
366618|NCT00650533|Drug|Glimepiride Tablets 1 mg|1mg, single dose fed
366619|NCT00650533|Drug|Amaryl® Tablets 1 mg|1mg, single dose fed
366620|NCT00650546|Drug|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
366621|NCT00650559|Procedure|Chest wall enlargement|Widening sternotomy
366622|NCT00650572|Drug|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
366623|NCT00652821|Drug|Ultracet|Tablets, 37.5mg/325mg
366624|NCT00652834|Procedure|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
365955|NCT00664963|Device|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
365956|NCT00664963|Device|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
365957|NCT00664976|Procedure|Electroconvulsive therapy|Electroconvulsive therapy
365958|NCT00664976|Other|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
365959|NCT00005036|Procedure|quality-of-life assessment|Ancillary studies
365960|NCT00665002|Biological|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
365961|NCT00665002|Drug|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
365962|NCT00665002|Drug|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
365963|NCT00665041|Drug|Quinagolide|• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.
placebo, oral.
365964|NCT00665054|Drug|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
365965|NCT00665054|Drug|Placebo|Matching placebo tablets orally prior to sexual activity
365966|NCT00665093|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
365967|NCT00665093|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
366298|NCT00657774|Drug|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
366299|NCT00657774|Drug|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
366300|NCT00657774|Drug|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
366301|NCT00657774|Drug|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
365302|NCT00637494|Drug|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
365303|NCT00637507|Other|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., >10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 >150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
365304|NCT00637533|Procedure|Lumbar sympathetic block with Botulinum Toxin type A|
365625|NCT00669734|Biological|Inalimarev|Given SC
365626|NCT00669734|Other|Laboratory Biomarker Analysis|Correlative studies
365627|NCT00669734|Biological|Sargramostim|Given SC
365628|NCT00669747|Drug|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 & 15
365629|NCT00669747|Drug|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
365630|NCT00005072|Biological|Leuvectin|1000 ug of Leuvectin injected intratumorally
365631|NCT00633048|Drug|placebo|
365632|NCT00633061|Drug|Enoxaparin|Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children >2 months and 1.5 mg/kg every 12 hours for infants <2 months. Duration of treatment is 6 weeks.
365633|NCT00004732|Device|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
365634|NCT00633074|Biological|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
365635|NCT00633074|Biological|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
365636|NCT00633087|Drug|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
365637|NCT00633113|Procedure|MPPA|- Medial Parapatellar Arthrotomy
365638|NCT00633113|Procedure|SV|- Subvastus Technique
365310|NCT00640198|Behavioral|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
365311|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
365312|NCT00640198|Drug|placebo|Placebo
365313|NCT00640224|Drug|rosiglitazone|4 mg daily for 6 months
365314|NCT00640224|Drug|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
365315|NCT00640237|Dietary Supplement|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
365316|NCT00640250|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2
Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.
365317|NCT00640263|Drug|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
365646|NCT00633165|Drug|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
365647|NCT00633178|Behavioral|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
365648|NCT00633178|Behavioral|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
365649|NCT00633191|Drug|Anti-pseudomonas IgY gargle|Gargle (solution), > 5FKU, every night after toothbrushing, life-long
364669|NCT00652132|Other|immunohistochemistry staining method|
364670|NCT00652132|Other|laboratory biomarker analysis|
364671|NCT00652132|Procedure|adjuvant therapy|
364672|NCT00652132|Procedure|neoadjuvant therapy|
364986|NCT00004878|Drug|idarubicin|
364987|NCT00644696|Drug|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
364988|NCT00647049|Drug|Carmustin|400mg/m2 i.v. for 1 day
364989|NCT00647075|Dietary Supplement|Yunzhi extract|3.5 g/day
364990|NCT00647075|Dietary Supplement|Placebo|Placebo (starch)
364991|NCT00647101|Drug|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
364992|NCT00647114|Biological|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
364993|NCT00647114|Biological|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
364994|NCT00647127|Drug|Buprenorphine|Buprenorphine: 20microg/h
364995|NCT00004891|Procedure|computed tomography|
364996|NCT00647127|Drug|Fentanyl|Fentanyl: 25microg/h
364997|NCT00647127|Drug|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
364998|NCT00647140|Other|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
364999|NCT00647153|Other|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
365000|NCT00647153|Procedure|single photon emission computed tomography|One day post infusion
365001|NCT00647153|Radiation|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
364341|NCT00659659|Drug|MEDI-563|100 mg, 200 mg SC
364342|NCT00659659|Other|Placebo Comp.|Placebo SC
364343|NCT00659659|Other|Placebo|Placebo as a single IV infusion (Certain number of subjects)
364344|NCT00659672|Dietary Supplement|Whey Protein|40 grams per day Whey Protein
364345|NCT00659672|Dietary Supplement|Soy Protein|40 grams per day soy protein
364346|NCT00659672|Dietary Supplement|Control (carbohydrate)|40 grams per day maltodextrin
364347|NCT00659685|Drug|Ondansetron|ODT, single-dose, fasting
364348|NCT00659685|Drug|Zofran ODT|
364349|NCT00004993|Drug|Parathyroid hormone (hPTH 1-34)|
364350|NCT00659698|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
364351|NCT00000653|Drug|Zalcitabine|
364352|NCT00005017|Drug|Ritonavir|
364673|NCT00652132|Procedure|therapeutic conventional surgery|
364674|NCT00652145|Drug|mesalamine|Increase dose by 2.4gm per day over baseline dose
364675|NCT00652158|Drug|MLN8054|10 mg doses of MLN8054 were given orally once daily following a schedule of "5 days on/2 days off/5 days on" repeated every 28 days
364676|NCT00654615|Procedure|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
364677|NCT00004918|Drug|Montanide ISA 51 VG|Given SC
364678|NCT00654628|Drug|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
364679|NCT00654641|Procedure|Negative pressure wound closure|Applying negative pressure to primary wound closure
364680|NCT00654641|Procedure|Standard wound closure|Standard wound closure
364681|NCT00654654|Biological|Autologous Human Fibroblasts (azficel-T)|Collection of 3 mm biopsies
Two injection treatments of facial wrinkles and creases
Conduct of study assessments
363983|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
363984|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
363985|NCT00664352|Drug|Mannose-6-Phophate (Juvidex)|300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
363986|NCT00664352|Drug|Placebo|100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site.
363987|NCT00664365|Drug|GSK958108|
363988|NCT00664378|Drug|CYT997|Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
363989|NCT00664391|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
363990|NCT00005031|Drug|irofulven|
363991|NCT00664404|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
363992|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
363993|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
363994|NCT00666640|Device|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
363995|NCT00666640|Device|CT scan of hip|Computed Tomography scan
363996|NCT00666653|Drug|pramipexole|
363997|NCT00666666|Drug|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
363998|NCT00666666|Drug|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
363342|NCT00639392|Drug|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
363343|NCT00639392|Drug|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
363344|NCT00639418|Biological|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
363345|NCT00639431|Behavioral|direct observation|direct observation of another person's foot moving
363346|NCT00639431|Behavioral|mental visualization|mentally imagining moving one's phantom foot/feet
363347|NCT00004825|Drug|recombinant human insulin-like growth factor I|
363348|NCT00639444|Dietary Supplement|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
363349|NCT00639457|Drug|Pioglitazone|Oral 30mg/day for 16 weeks
363350|NCT00639457|Behavioral|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
363351|NCT00639470|Other|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
363681|NCT00632359|Drug|Lenalidomide|10 mg daily given for 12 months
363682|NCT00004705|Drug|amiloride|
363683|NCT00632372|Device|Cardiac resynchronization therapy and HeartPOD® system|Devices automatically collect data which is downloaded by the physician at regular office visits.
363684|NCT00632385|Drug|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose
363685|NCT00632398|Behavioral|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
363686|NCT00632398|Behavioral|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
363687|NCT00632411|Drug|Nicotine Patch|Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.
Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.
Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.
The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment.
363024|NCT00643916|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to <6 years of age)
363025|NCT00643929|Drug|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
363026|NCT00004873|Drug|epirubicin hydrochloride|
363027|NCT00643942|Other|No intervention required|
363028|NCT00643955|Other|muscle strength|muscle strength
363029|NCT00643968|Drug|EFV+TDF|
363030|NCT00643968|Drug|EFV+3TC+TDF|
363031|NCT00643981|Biological|MESENDO|2 ml of the "final cell mixture" will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel.
363032|NCT00643994|Radiation|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
363033|NCT00644007|Drug|Placebo|Placebo as a substitute of SK3530 100mg
363034|NCT00644007|Drug|SK3530|SK3530 100 mg
363035|NCT00644020|Drug|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
363036|NCT00646269|Behavioral|Standard intervention protocol + Cognitive training therapy|"Cognitive training therapy" is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving…) related to activities of daily living is realized at each session.
363037|NCT00646269|Behavioral|Standard intervention protocol + Reminiscence therapy|"Reminiscence therapy" is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session.
363038|NCT00646269|Behavioral|Standard intervention protocol + "Made-to-measure" program|The "made to measure" program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies ("Cognitive training therapy" or "Reminiscence therapy") the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs.
363039|NCT00646282|Drug|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH <300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
363040|NCT00646295|Device|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
362367|NCT00658684|Drug|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
362368|NCT00658697|Drug|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
362369|NCT00658697|Drug|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
362370|NCT00658697|Drug|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
362371|NCT00658697|Drug|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
362372|NCT00658710|Behavioral|physical therapy sessions|two physical therapy sessions per week for two months
362373|NCT00658723|Drug|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
362374|NCT00658723|Device|SURGICEL™|Absorbable hemostat
362375|NCT00658736|Drug|Triamcinolone|
362376|NCT00004981|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
362377|NCT00658736|Drug|Bupivicaine alone|
362378|NCT00658749|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
362379|NCT00658749|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
362380|NCT00658762|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper
362712|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin)|Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)
Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)
362713|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)
Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)
Bevacizumab 15 mg/kg D1 (D1=D22, until progression)
362714|NCT00004905|Drug|cyclophosphamide|
362715|NCT00651469|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
362716|NCT00651469|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
362042|NCT00665899|Behavioral|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
362043|NCT00665899|Behavioral|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
362044|NCT00665899|Other|Cancer-Related Community and Internet Resources|Couples receive a list of names and contact information for community and national support groups, breast cancer organizations, and other resources; they do not meet with a health educator.
362045|NCT00665912|Procedure|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
362046|NCT00665912|Procedure|Standard post-lobectomy wound care|Standard post-lobectomy wound care
362047|NCT00665925|Drug|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day 150 mg tablet, orally, once-a-day
362048|NCT00665938|Other|Infant formula|Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)
Arm 2. partially hydrolyzed infant formula with probiotics
Arm 3. extensively hydrolyzed infant formula with probiotics
362049|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
362050|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
362051|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
362052|NCT00005044|Radiation|radiation therapy|
362053|NCT00665964|Device|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
362054|NCT00665964|Device|N2Vac polethylene|conventional polyethylene
362055|NCT00665977|Drug|Thermosmart & placebo|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
362056|NCT00665977|Drug|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
362381|NCT00658762|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper
362382|NCT00658762|Drug|paroxetine|Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper
366857|NCT00633685|Drug|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
366858|NCT00633685|Drug|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
366859|NCT00633698|Drug|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
366860|NCT00633698|Drug|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
361717|NCT00633984|Drug|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
361718|NCT00633984|Drug|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
361719|NCT00633997|Drug|Vildagliptin|50 mg orally twice daily for 10 days (last dose morning of day 10)
361720|NCT00633997|Drug|Vildagliptin|
361721|NCT00634010|Drug|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
361722|NCT00004736|Drug|Stavudine|
361723|NCT00634010|Drug|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
361724|NCT00634036|Drug|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
361725|NCT00634036|Drug|placebo|matching placebo (inert tablet)
361726|NCT00634049|Drug|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
361727|NCT00634062|Drug|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
361728|NCT00634062|Drug|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
357861|NCT00687453|Drug|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
357862|NCT00687453|Drug|NPH twice-daily|Addition of morning NPH to bedtime NPH
357863|NCT00687466|Drug|Insulin|Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.
Glargine should be administered once daily in the morning and always at the same hour.
357864|NCT00687505|Drug|FP-1039|Intravenous weekly administration
358144|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
358145|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
358146|NCT00692354|Drug|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
358147|NCT00692367|Behavioral|Physical Activity|1. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
358148|NCT00694785|Drug|ARC1779|Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.
Group "T6"
358149|NCT00694798|Biological|Mycobacterium w|Immunomodulator
358150|NCT00694811|Behavioral|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
358151|NCT00694837|Drug|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
358152|NCT00694850|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
358153|NCT00694863|Drug|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
358154|NCT00694889|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
358155|NCT00005775|Drug|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
357546|NCT00682578|Drug|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
357547|NCT00682578|Drug|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
357548|NCT00682617|Behavioral|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
357549|NCT00682617|Behavioral|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
357550|NCT00005598|Drug|azacitidine|
357551|NCT00682630|Drug|pyronaridine artesunate|720:240 mg of the reference tablet formulation; wash out period of 43 days; 720:240 mg of the to-be-marketed formulation; wash out period of 43 days
357552|NCT00682643|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray
357553|NCT00682643|Drug|vehicle placebo nasal spray|placebo
357554|NCT00682656|Drug|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
357555|NCT00682656|Drug|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
357865|NCT00005629|Biological|AFP gene hepatocellular carcinoma vaccine|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.
Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug
357866|NCT00687518|Drug|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
357867|NCT00687518|Drug|Placebo|Intravenous injection of equivalent volume of saline serum
357868|NCT00687531|Drug|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
357869|NCT00687544|Biological|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
357870|NCT00687544|Drug|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is <65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is >85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
362140|NCT00004771|Drug|testosterone|
362141|NCT00636246|Drug|[S,S]-reboxetine monotherapy|Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
362142|NCT00636259|Drug|Bicalutamide (Casodex)|150mg
362143|NCT00636285|Drug|Placebo|Placebo
362144|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
362145|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
362146|NCT00636298|Drug|Bevacizumab, cetuximab|Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly
Bevacizumab - 10 mg/kg every 2 weeks
362147|NCT00636311|Drug|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
362148|NCT00636311|Drug|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
362149|NCT00636324|Device|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
362150|NCT00636324|Device|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
362151|NCT00004772|Drug|Immune globulin|
362152|NCT00636337|Behavioral|Attention Training|Computer program training for attention difficulties.
362153|NCT00636337|Behavioral|Placebo|Comparison computer program
362154|NCT00636350|Dietary Supplement|Pepper|pepper carotenoids as meals
362155|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
362156|NCT00638846|Device|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
362157|NCT00638859|Drug|Telithromycin (HMR3647)|
362158|NCT00638872|Drug|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
362159|NCT00638872|Other|0.9% NaCl|same as PDRN
362160|NCT00638898|Drug|busulfan|Given IV
362161|NCT00638898|Drug|melphalan|Given IV
366967|NCT00645320|Drug|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
366968|NCT00645333|Drug|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
366969|NCT00645346|Biological|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
366970|NCT00004883|Biological|trastuzumab|Given IV
366971|NCT00645346|Biological|Placebo|Subjects will receive one dose of placebo
361826|NCT00643474|Device|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
361827|NCT00643487|Procedure|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
361828|NCT00643500|Drug|Levetiracetam|
361829|NCT00643526|Device|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
361830|NCT00643539|Drug|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
361831|NCT00643539|Drug|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
361832|NCT00643565|Drug|Standard chemotherapy|As prescribed
361833|NCT00643565|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
361834|NCT00643578|Drug|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
361835|NCT00645788|Drug|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
361836|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
361837|NCT00645788|Drug|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
361838|NCT00645801|Drug|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
366625|NCT00652834|Drug|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
366626|NCT00652847|Drug|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
366627|NCT00652847|Drug|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
366628|NCT00652860|Biological|aerosol sargramostim|
366629|NCT00652860|Biological|sargramostim|
366630|NCT00004907|Procedure|bone marrow ablation with stem cell support|
366631|NCT00652860|Drug|cisplatin|
366632|NCT00652860|Drug|doxorubicin hydrochloride|
366633|NCT00652860|Drug|ifosfamide|
366634|NCT00652860|Drug|mitomycin C|
366635|NCT00652860|Other|flow cytometry|
366636|NCT00652860|Other|immunological diagnostic method|
366972|NCT00645359|Procedure|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
366973|NCT00645372|Drug|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
366974|NCT00645372|Drug|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
366975|NCT00645385|Other|MRS Spectroscopy|Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the "spectroscopy" part of MRS. MRS is still experimental, and is available in only a few research centers.
Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI.
366976|NCT00645398|Drug|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
366977|NCT00645398|Drug|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
366978|NCT00645398|Drug|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
366302|NCT00657800|Behavioral|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
366303|NCT00004936|Procedure|computed tomography|
366304|NCT00657813|Drug|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
366305|NCT00657826|Device|ATS 3f(r) Aortic Bioprosthesis, Model 1000|Isolated aortic valve replacement
366306|NCT00660309|Drug|Captopril|Captopril 25 mg tablet
366307|NCT00660322|Behavioral|Telephone Asthma Program|The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:
Using asthma controller medications as prescribed
Having and Asthma Action Plan available to all who may need it.
Using asthma rescue medications with the child's first symptoms.
Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year.
366308|NCT00660335|Drug|RG1068 (synthetic human secretin)|Single-dose, IV infusion
366309|NCT00660348|Drug|morphine sulfate|This is morphine given in the traditional methods.
366310|NCT00005000|Drug|Efavirenz|
366311|NCT00660348|Device|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
366312|NCT00660374|Drug|insulin NPH|"Soft-treat-to-target" dose titration scheme, injection s.c.
366313|NCT00660374|Drug|EX1000|"Soft-treat-to-target" dose titration scheme, injection s.c.
366314|NCT00660387|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
366315|NCT00660387|Drug|Placebo Gel|
366316|NCT00660387|Drug|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
366317|NCT00660387|Drug|Placebo (PBO) oral capsules|
366318|NCT00660387|Device|CADD-Legacy® 1400 ambulatory infusion pump|
366637|NCT00652860|Other|laboratory biomarker analysis|
366638|NCT00652860|Procedure|adjuvant therapy|
366639|NCT00652860|Procedure|multimodality therapy|
366640|NCT00652860|Procedure|neoadjuvant therapy|
365639|NCT00633126|Drug|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
365640|NCT00633139|Biological|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
365641|NCT00633152|Drug|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
365642|NCT00633152|Drug|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
365643|NCT00633152|Drug|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
365644|NCT00000636|Drug|Pyridoxine hydrochloride|
365645|NCT00004733|Drug|levodopa|
365968|NCT00665106|Drug|NOVA63035 "Corticosteroid"|Single injection in the study eye
365969|NCT00665119|Drug|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
365970|NCT00005037|Drug|temozolomide|
365971|NCT00665119|Drug|placebo|NaCl 0.9 %
365972|NCT00665132|Device|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
365973|NCT00665145|Drug|SB-509|Active drug
365974|NCT00665145|Drug|SB-509|Active drug
365975|NCT00665145|Drug|Placebo|Placebo
365976|NCT00665145|Drug|SB-509|Active drug
365977|NCT00667199|Drug|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
365978|NCT00667212|Behavioral|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
365979|NCT00667212|Behavioral|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
365980|NCT00005052|Biological|QS21|
365981|NCT00667225|Drug|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
365650|NCT00633204|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
365651|NCT00635232|Drug|placebo|placebo capsules once daily for 12 weeks
365652|NCT00004758|Drug|pyridoxine|
365653|NCT00635232|Drug|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
365654|NCT00635232|Drug|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
365655|NCT00635232|Drug|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
365656|NCT00635245|Biological|figitumumab|
365657|NCT00635245|Other|imaging biomarker analysis|
365658|NCT00635245|Other|laboratory biomarker analysis|
365659|NCT00635245|Other|pharmacological study|
365660|NCT00635245|Procedure|conventional surgery|
365661|NCT00635245|Procedure|magnetic resonance spectroscopic imaging|
365662|NCT00635245|Procedure|neoadjuvant therapy|
365663|NCT00004758|Drug|valproic acid|
365664|NCT00635258|Drug|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
365665|NCT00635258|Drug|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
365666|NCT00635284|Drug|ABI-009|nab-rapamycin
365990|NCT00667290|Behavioral|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
365991|NCT00005052|Procedure|adjuvant therapy|
365992|NCT00667303|Other|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
365002|NCT00647166|Drug|corticosteroid and azathioprine|Corticosteroid 1 mg/kg/day with a conventional decrease dose
Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
365003|NCT00647166|Drug|corticosteroid and placebo|Corticosteroid 1 mg/kg/day with a conventional decrease dose
Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
365004|NCT00647179|Procedure|Transsphenoidal adenomectomy|Surgery
365005|NCT00647192|Drug|Eplerenone|50 mg per day
365006|NCT00004891|Procedure|conventional surgery|
365007|NCT00647192|Drug|Placebo|50 mg per day
365318|NCT00640263|Drug|Lamivudine (3TC)|Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.
The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
365319|NCT00000639|Drug|Fluconazole|
365320|NCT00004840|Drug|thyrotropin-releasing hormone|
365321|NCT00640276|Drug|pitavastatin|Pitavastatin 2mg daily once
365322|NCT00640276|Behavioral|Lifestyle Modification|conducting mainly exercises and diet
365323|NCT00640289|Drug|Fibrogammin P|Prophylaxis treatment
365324|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
365325|NCT00642460|Drug|corticosteroids|orally, as prescribed
365326|NCT00642473|Drug|erlotinib [Tarceva]|150mg po daily
365327|NCT00642473|Drug|metronidazole actavis 1% topical cream|Twice daily for 4 weeks
365328|NCT00642486|Other|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
365329|NCT00642486|Other|Standard polysomnography (PSG)|laboratory-based testing
365330|NCT00642499|Drug|Dronabinol|2.5 mg to 40 mg
365331|NCT00642499|Drug|Placebo|placebo
365332|NCT00642512|Drug|dronabinol|10 - 20 mg
364682|NCT00654667|Drug|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
364683|NCT00654667|Drug|Resveratrol|
364684|NCT00654680|Drug|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
364685|NCT00654680|Drug|Placebo|Matching placebo
364686|NCT00654693|Other|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
364687|NCT00654706|Drug|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
364688|NCT00004918|Biological|sargramostim|Given SC
364689|NCT00654706|Drug|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
364690|NCT00654719|Dietary Supplement|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
364691|NCT00654719|Dietary Supplement|Placebo|Nutritional supplementation containing only 12 kcal/day
364692|NCT00654732|Drug|Rituximab|375 mg/m^2 IV Weekly Over 7 Hours On Days 1, 8, 15, 22.
364693|NCT00654732|Drug|Adriamycin|25 mg/m^2 IV Over 1 Hour On Day 1 and 15.
365008|NCT00647205|Device|QuantiFERON TB Gold In-Tube|
365009|NCT00647205|Device|T-SPOT.TB®|
365010|NCT00647218|Drug|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
365011|NCT00647218|Drug|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
365012|NCT00647218|Procedure|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
365013|NCT00647218|Radiation|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
365014|NCT00649805|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
365015|NCT00004900|Radiation|radiation therapy|
365016|NCT00649805|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
363999|NCT00666666|Other|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
364000|NCT00666679|Drug|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
364353|NCT00662103|Other|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
364354|NCT00662103|Procedure|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
364355|NCT00662103|Procedure|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
364356|NCT00662103|Procedure|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
364357|NCT00662103|Procedure|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
364358|NCT00662116|Drug|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
364359|NCT00662116|Drug|placebo|placebo tablets - two tablets taken twice daily
364360|NCT00662129|Biological|bevacizumab|
364361|NCT00662129|Drug|gemcitabine hydrochloride|
364362|NCT00662129|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
364363|NCT00005017|Drug|Abacavir sulfate|
364364|NCT00662142|Dietary Supplement|docosahexaenoic acid|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
364365|NCT00662155|Drug|Zolpidem|sedative-hypnotic
364366|NCT00662207|Device|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
364367|NCT00662207|Procedure|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
364368|NCT00662220|Drug|ribavirin|25-29 mg/kg/day
363688|NCT00632411|Behavioral|Tobacco Quit Line Program|Phone session 1 will focus on smoking reduction.
Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.
Phone session 3 will focus on the first days after the quit date.
Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.
Phone session 5 will focus on short-term relapse prevention.
Phone session 6 will focus on long-term relapse prevention.
363689|NCT00632424|Drug|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
363690|NCT00632437|Procedure|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
363691|NCT00634621|Drug|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
363692|NCT00634634|Drug|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
363693|NCT00634634|Drug|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
363694|NCT00634647|Drug|Satraplatin|80 mg/m^2 days 1-5 of every 35 day cycle
363695|NCT00634647|Drug|prednisone|5 mg twice daily every 35 days
363696|NCT00004751|Procedure|Physical therapy|
363697|NCT00634660|Drug|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
364001|NCT00666679|Drug|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
364002|NCT00666679|Drug|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
364003|NCT00666692|Drug|M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab|Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
364004|NCT00000173|Drug|Vitamin E|
364005|NCT00000657|Drug|Didanosine|
364006|NCT00005049|Drug|carboplatin|
363352|NCT00639483|Drug|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
363353|NCT00639483|Drug|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
363354|NCT00639496|Drug|n-acetylcysteine|600 mg x 3, for 12 months
363355|NCT00639496|Drug|placebo|Placebo
363356|NCT00639509|Biological|cixutumumab|Given IV
363357|NCT00639509|Procedure|computed tomography|Undergo contrast-enhanced computed tomography
363358|NCT00000170|Device|Eye Patch|Patching
363359|NCT00000639|Drug|Flucytosine|
363360|NCT00004826|Drug|clozapine|
363361|NCT00639509|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
363362|NCT00639522|Drug|Liposomal paclitaxel and capecitabine|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
363363|NCT00639561|Dietary Supplement|10 g of fibres per day|10 g of fibres per day
363364|NCT00639561|Dietary Supplement|40 g of fibres per day|40g of fibres per day
363365|NCT00639574|Drug|Néfopam|There are two groups :
a group N : néfopam
a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes.
363366|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
363367|NCT00641732|Drug|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
363368|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
363369|NCT00641732|Drug|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
363370|NCT00641732|Drug|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
363371|NCT00641732|Drug|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
362717|NCT00651482|Drug|Everolimus|
362718|NCT00651482|Drug|Bevacizumab|
362719|NCT00651495|Behavioral|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
362720|NCT00653731|Behavioral|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
362721|NCT00653731|Behavioral|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
362722|NCT00653744|Drug|Rosuvastatin|
362723|NCT00653744|Drug|Atorvastatin|
362724|NCT00653757|Drug|goserelin acetate|
362725|NCT00653757|Drug|leuprolide acetate|
362726|NCT00004913|Drug|leucovorin calcium|
362727|NCT00653757|Radiation|image-guided radiation therapy|
362728|NCT00653757|Radiation|intensity-modulated radiation therapy|
362729|NCT00653770|Biological|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10^7 pfu)
362730|NCT00653770|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10^7 pfu)
362731|NCT00653796|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
362732|NCT00653796|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
362733|NCT00653822|Drug|alefacept|IC and SC
362734|NCT00653822|Drug|placebo|IV and SC
363041|NCT00004887|Drug|mitomycin C|
363042|NCT00646321|Drug|budesonide/formoterol (Symbicort)|
363043|NCT00646321|Drug|budesonide|
363044|NCT00646334|Device|Mesh Implantation|An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.
362383|NCT00658762|Drug|Placebo|Capsules, oral, BID, 8 weeks, with 2 week taper
362384|NCT00658775|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
362385|NCT00658775|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
362386|NCT00658788|Drug|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
362387|NCT00004981|Drug|Lamivudine/Zidovudine|
362388|NCT00658788|Drug|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
362389|NCT00661362|Drug|Placebo|oral tablet, once daily for 24 weeks
362390|NCT00661362|Drug|Metformin|oral tablet, once daily for 24 weeks
362391|NCT00000652|Drug|Didanosine|
362392|NCT00005006|Drug|Teriparatide|Teriparatide 20mcg/day
362393|NCT00661375|Drug|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
362394|NCT00661388|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
362395|NCT00661401|Biological|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
362396|NCT00661414|Biological|ASONEP (sonepcizumab/LT1009)|ASONEP [sonepcizumab/LT1009] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.
The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis.
362397|NCT00661427|Biological|cetuximab|Cetuximab 500 mg/m2 IV over 2 hours every other week
362398|NCT00661427|Biological|cetuximab|Cetuximab 750 mg/m2 IV over 3 hours every other week
362399|NCT00661440|Drug|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
362400|NCT00661453|Drug|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
362401|NCT00661466|Drug|Bupivacaine Collagen Sponge|
361729|NCT00634075|Drug|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
361730|NCT00636077|Device|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
361731|NCT00636077|Device|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
361732|NCT00636077|Device|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
362057|NCT00665977|Device|Placebo Arm|To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and "deactivated" Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still "appear" to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily.
362058|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
362059|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
362060|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
362061|NCT00668057|Drug|Placebo|5 mg matching placebo
362062|NCT00668057|Drug|Placebo|10 mg matching placebo
362063|NCT00668057|Drug|Placebo|20 mg matching placebo
362064|NCT00668070|Drug|ASP9831|Oral
362065|NCT00668070|Drug|Placebo|Oral
362066|NCT00668096|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
362067|NCT00668096|Drug|Placebo|Matching Placebo
362068|NCT00005062|Radiation|radiation therapy|
362069|NCT00668109|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
362070|NCT00668109|Drug|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
362071|NCT00668122|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
358156|NCT00694889|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
358157|NCT00694902|Drug|GSK610677|
358158|NCT00694915|Biological|Mycobacterium w|Immunomodulator
358159|NCT00694915|Biological|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
358160|NCT00694928|Drug|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
358161|NCT00694928|Drug|butoconazole nitrate|semi-solid, single dose
358162|NCT00694941|Drug|ONO-2506PO|1200mg QD / 5 years
358163|NCT00694954|Device|Diagnostic Test - Given Imaging Pillcam|Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.
Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)
358480|NCT00675792|Drug|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
358481|NCT00675805|Device|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
358482|NCT00678314|Drug|Ropivacaine 0.2%|10 ml
358483|NCT00678314|Drug|Ropivacaine 0.75%|3 ml
358484|NCT00678314|Drug|Normal saline|10 ml
358485|NCT00678327|Biological|bleomycin sulfate|Given IV
358486|NCT00678327|Biological|filgrastim|Given subcutaneously
358487|NCT00678327|Biological|pegfilgrastim|Given subcutaneously
358488|NCT00678327|Drug|cyclophosphamide|Given IV
358489|NCT00678327|Drug|dacarbazine|Given IV
358490|NCT00678327|Drug|doxorubicin hydrochloride|Given IV
358491|NCT00005583|Drug|epirubicin hydrochloride|
358492|NCT00678327|Drug|etoposide|Given IV
358493|NCT00678327|Drug|prednisolone|Given orally
357871|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
357872|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
357873|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
357874|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
358164|NCT00694954|Other|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
358165|NCT00694967|Procedure|McDonald cerclage placement|Transcervical McDonald cerclage placement
358166|NCT00670878|Drug|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
358167|NCT00005083|Procedure|magnetic resonance imaging|
358168|NCT00670891|Procedure|oxygen (Hyperbaric Oxygen Therapy)|Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International
Air or Gas Embolus
Decompression Illness
Carbon Monoxide poising
Clostridial Myonecrosis (Gas Gangrene)
Necrotizing Fasciitis
Crush Injury (Compartment syndromes)
Selected Problem Wounds
Compromised Skin Flaps or Grafts
Refractory Osteomyelitis
Exceptional Anemia due to Blood loss
Osteoradionecrosis
Thermal Burns and Radiation Tissue Damage
Diabetic Wounds
Intra-Cranial Abscess
Brain Injury and other Head Trauma
Cerebral Palsy
High Altitude Sickness
Lyme disease
362162|NCT00004811|Drug|itraconazole|
362488|NCT00631696|Drug|Placebo|Placebo
362489|NCT00631709|Other|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
362490|NCT00631722|Drug|Quatiapine Fumarate|600-750mg/day
362491|NCT00631722|Drug|Haloperidol|12-20mg/day
362492|NCT00004690|Drug|monolaurin cream|
362493|NCT00631748|Drug|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
362494|NCT00631748|Drug|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
362495|NCT00631748|Behavioral|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
362496|NCT00631761|Other|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
362497|NCT00631761|Other|no intervention (usual resident activities)|usual activities
362498|NCT00631774|Dietary Supplement|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
362499|NCT00631800|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
362500|NCT00631813|Drug|Prucalopride|0.5 mg bid
362501|NCT00631813|Drug|Prucalopride|1 mg bid
362502|NCT00631813|Drug|Prucalopride|2 mg bid
362503|NCT00004694|Drug|heparin|
362504|NCT00631813|Drug|Placebo|bid
362505|NCT00631839|Radiation|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies >=6MV.
361839|NCT00645801|Drug|Placebo|Amitiza Placebo
361840|NCT00645814|Drug|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
361841|NCT00004885|Drug|irinotecan hydrochloride|
361842|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
361843|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
362163|NCT00638898|Drug|topotecan hydrochloride|Given IV
362164|NCT00638898|Other|laboratory biomarker analysis|Correlative studies
362165|NCT00638898|Biological|filgrastim|Given IV or subcutaneously
362166|NCT00638898|Procedure|autologous hematopoietic stem cell transplantation|Undergo transplantation
362167|NCT00638898|Other|pharmacological study|Correlative studies
362168|NCT00638898|Procedure|autologous bone marrow transplantation|Undergo transplantation
362169|NCT00638924|Other|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
362170|NCT00638937|Drug|saracatinib|Given PO
362171|NCT00638950|Dietary Supplement|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
362172|NCT00638950|Dietary Supplement|Placebo|The placebo products were commercial dairy products with comparable fat contents.
362173|NCT00004812|Behavioral|Exercise|
362174|NCT00638963|Drug|temozolomide|Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles
362175|NCT00638976|Drug|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
362176|NCT00638976|Drug|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
362177|NCT00638989|Drug|CAT-354|CAT-354 following subcutaneous administration of 150 mg and 300 mg
366979|NCT00645398|Drug|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
366980|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
366981|NCT00004883|Other|laboratory biomarker analysis|Correlative studies
366982|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
366983|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
366984|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
366985|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
366986|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
366987|NCT00647855|Drug|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
366988|NCT00647868|Drug|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
366989|NCT00647868|Other|No treatment|24-h blood sampling in healthy, eugonadal men
361844|NCT00645827|Other|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
361845|NCT00645827|Other|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
361846|NCT00645840|Drug|Anakinra|Patients will receive daily anakinra therapy for 28 days
361847|NCT00645853|Drug|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
366641|NCT00000172|Drug|Galantamine|
366642|NCT00000647|Drug|Zidovudine|
366643|NCT00004907|Procedure|peripheral blood stem cell transplantation|
366644|NCT00652860|Procedure|therapeutic conventional surgery|
366645|NCT00652860|Radiation|intraoperative radiation therapy|
366646|NCT00652860|Radiation|selective external radiation therapy|
366647|NCT00652873|Drug|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
366648|NCT00652873|Drug|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
366649|NCT00652886|Drug|Oxandrolone|Tablets, 10mg, single-dose
366650|NCT00652886|Drug|Oxandrin|tablets, 10mg, single-dose
366651|NCT00652899|Biological|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
366652|NCT00652899|Drug|Cyclophosphamide|60 mg/m^2 on Days 4 and 5 preceding natural killer cell infusion.
366653|NCT00652899|Drug|Fludarabine phosphate|25 mg/m^2 on Days 6 through 2 preceding natural killer cell infusion.
366654|NCT00004907|Radiation|radiation therapy|
366655|NCT00655369|Drug|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
366656|NCT00655369|Drug|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
366657|NCT00655369|Drug|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
366658|NCT00004921|Drug|cyclophosphamide|
366659|NCT00655369|Drug|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
366660|NCT00655369|Drug|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
366661|NCT00655395|Drug|Laromustine (VNP40101M) and Ara-C|Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.
Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.
366990|NCT00647881|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
365982|NCT00667225|Drug|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
365983|NCT00667238|Behavioral|Questionnaire|
365984|NCT00667251|Biological|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
365985|NCT00667251|Drug|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
365986|NCT00667251|Drug|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
365987|NCT00667251|Drug|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
365988|NCT00667264|Procedure|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
365989|NCT00667277|Drug|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
366319|NCT00660387|Device|PEG tube|percutaneous endoscopic gastrostomy tube
366320|NCT00660387|Device|J-tube|jejunal tube
366321|NCT00005000|Drug|Lamivudine|
366322|NCT00660400|Drug|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
366323|NCT00660400|Procedure|Allogeneic Hematopoietic Cell Transplantation (HCT)|Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.
Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.
The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.
All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant.
366324|NCT00660413|Device|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
366325|NCT00660426|Drug|Oxaliplatin|
366326|NCT00660426|Drug|Gemcitabine|
366327|NCT00660426|Drug|Capecitabine|
366328|NCT00660439|Behavioral|Narrative Exposure Therapy|Psychological treatment, with narration of positive and traumatic events in patients history, including "in vivo" exposure of traumatic events. The narrative is written down by the therapist.
365993|NCT00667303|Other|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
365994|NCT00667303|Other|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
365995|NCT00667316|Behavioral|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
365996|NCT00667329|Drug|2CdA|1.5 mg/m^2 subcutaneous injection three times daily x 7 days.
365997|NCT00667329|Drug|Cyclophosphamide|40 mg/m^2 PO twice daily x 7 days.
365998|NCT00667329|Drug|Rituximab|375 mg/m^2 IV once weekly x 4 weeks.
365999|NCT00669747|Drug|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
366000|NCT00669760|Other|non-interventional study|does not apply
366001|NCT00669773|Drug|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
366002|NCT00669773|Drug|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
366003|NCT00669786|Drug|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
366004|NCT00669799|Drug|gentamyacin|topical internasal
366005|NCT00669799|Drug|gentamyacin|intranasal
366006|NCT00669812|Drug|carmustine|
366007|NCT00669812|Drug|cyclophosphamide|
366008|NCT00669812|Drug|cytarabine|
366009|NCT00005073|Drug|zoledronic acid|
366010|NCT00669812|Drug|doxorubicin hydrochloride|
366011|NCT00669812|Drug|epirubicin hydrochloride|
366012|NCT00669812|Drug|etoposide|
366341|NCT00662818|Drug|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
365333|NCT00004863|Drug|GEM 231|
365334|NCT00642512|Drug|ondansetron|8 - 16 mg
365335|NCT00642512|Drug|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
365336|NCT00642512|Drug|placebo|placebo
365337|NCT00642525|Procedure|Contrast swallow radiography, endoscopy|Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
365338|NCT00642538|Drug|MKC253 Inhalation Powder|Inhalation Powder, prandial
365339|NCT00642538|Drug|Technosphere Inhalation Powder|Inhalation Powder, prandial
365340|NCT00642538|Drug|subcutaneous injection|10µg Exenatide, prandial
365341|NCT00642551|Dietary Supplement|menaquinone-7|180 µg menaquinone-7 daily for three years
365667|NCT00635297|Procedure|Percutaneous vertebroplasty|PMMA injection 3-10 milliliter in each treated vertebrae
365668|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
365669|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
365670|NCT00635323|Drug|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
365671|NCT00635336|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
365672|NCT00635349|Drug|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
365673|NCT00635349|Drug|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
365674|NCT00004758|Procedure|Surgery|
365675|NCT00637585|Drug|Fexofenadine|
365676|NCT00637598|Radiation|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
365017|NCT00649818|Drug|Lorazepam Tablets 2 mg|2mg, single dose fasting
365018|NCT00649818|Drug|Ativan Tablets 2 mg|2mg, single dose fasting
365019|NCT00649831|Drug|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
365020|NCT00649831|Drug|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
365021|NCT00649844|Drug|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
365022|NCT00649844|Drug|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
365023|NCT00649857|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
365024|NCT00649857|Drug|Zyrtec® 10 mg|10mg, single dose fed
365025|NCT00649870|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
365026|NCT00004901|Drug|ethynyluracil|
365027|NCT00649870|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fed
365028|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
365342|NCT00642551|Dietary Supplement|placebo|1 placebo capsule daily for three years
365343|NCT00642564|Other|Observational study in Epileptic Patients|Observation study in Epileptic Patients with Migraine and Headache
365344|NCT00004863|Drug|paclitaxel|
365345|NCT00642577|Drug|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
365346|NCT00642577|Drug|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
365347|NCT00642577|Drug|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
365348|NCT00642577|Drug|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
365349|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
364369|NCT00662220|Drug|ribavirin|12-15 mg/kg/day
364370|NCT00662233|Drug|cyclophosphamide|
364371|NCT00662233|Drug|doxorubicin hydrochloride|
364372|NCT00662233|Drug|etoposide|
364373|NCT00662233|Drug|ifosfamide|
364694|NCT00654732|Drug|Bleomycin|10 U/m^2 IV Over 1 Hour On Day 1 and 15.
364695|NCT00654732|Drug|Vinblastine|6 mg/m^2 IV Over 1 Hour On Day 1 and 15.
364696|NCT00654732|Drug|Dacarbazine|375 mg/m^2 IV Over 1 Hour On Day 1 and 15.
364697|NCT00654745|Drug|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
364698|NCT00654745|Drug|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
364699|NCT00004918|Other|laboratory biomarker analysis|Correlative studies
364700|NCT00654745|Drug|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
364701|NCT00657007|Biological|Placebo|IV (in the vein) on Day 0 (Cohorts 1-4).
IV (in the vein) on Days 0 and 21 (Cohorts 5-8).
364702|NCT00004932|Drug|imatinib mesylate|
364703|NCT00657020|Drug|Nicotine|Nicotine lozenge containing 4 mg of nicotine
364704|NCT00657020|Drug|Placebo|Placebo lozenge
364705|NCT00657033|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
364706|NCT00657033|Drug|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
364707|NCT00657046|Drug|Droxidopa|Capsules containing 200 mg droxidopa
364708|NCT00657046|Drug|Placebo|Capsules with mannitol substituted for droxidopa
364709|NCT00657059|Drug|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( < 5 g NaCl/day), and then given a stable dose (150mg ~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
364007|NCT00666705|Drug|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
364008|NCT00666705|Drug|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
364009|NCT00666705|Drug|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
364010|NCT00666705|Drug|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
364011|NCT00666718|Drug|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
364012|NCT00666718|Drug|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
364013|NCT00666718|Drug|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
364014|NCT00666731|Other|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
364015|NCT00666731|Other|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
364016|NCT00668941|Drug|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
364017|NCT00668941|Drug|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
364018|NCT00005067|Drug|photodynamic therapy|Undergo photodynamic therapy
364019|NCT00668941|Dietary Supplement|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
364374|NCT00005017|Drug|Amprenavir|
364375|NCT00662233|Drug|vincristine sulfate|
364376|NCT00662233|Procedure|adjuvant therapy|
364377|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
364378|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
364379|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
363372|NCT00004859|Drug|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
363373|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
363374|NCT00641732|Drug|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
363698|NCT00634673|Other|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
363699|NCT00634686|Dietary Supplement|DHA/EPA|1.2 gram capsule daily for 6 months
363700|NCT00634686|Dietary Supplement|Placebo capsule|daily for 6 months
363701|NCT00634686|Dietary Supplement|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
363702|NCT00634699|Procedure|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
363703|NCT00634712|Drug|Candesartan|
363704|NCT00634712|Drug|Placebo|
363705|NCT00634725|Drug|capecitabine|
363706|NCT00634725|Drug|erlotinib hydrochloride|
363707|NCT00004754|Drug|epoprostenol|
363708|NCT00634725|Drug|gemcitabine hydrochloride|
363709|NCT00634725|Other|laboratory biomarker analysis|
363710|NCT00634725|Radiation|radiation therapy|
363711|NCT00634738|Procedure|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
363712|NCT00634751|Drug|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
363713|NCT00634751|Drug|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
363045|NCT00646334|Device|Mesh Implantation|Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
363046|NCT00646347|Other|Conventional upper limb stroke rehabilitation|Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.
Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks.
363047|NCT00646347|Device|Neuro Hand Orthosis Program (NHOP)|The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;
NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.
The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.
The intervention (NHOP) group will receive same treatment intensity as the control group but with a "Neuro Hand Orthosis".
363048|NCT00646360|Dietary Supplement|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
363049|NCT00646360|Dietary Supplement|Placebo|2 tablets daily during pregnancy
363050|NCT00646373|Other|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
363051|NCT00646386|Drug|adalimumab|40 mg eow Week 0 - Week 24
363052|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral dose
363053|NCT00648973|Drug|Diphenhydramine 50 mg|Three times daily: two diphenhydramine 25 mg capsules
Twice daily: one pseudoephedrine-matching placebo tablet
363054|NCT00648973|Drug|Diphenhydramine 25 mg|Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule
Twice daily: one pseudoephedrine-matching placebo tablet
363055|NCT00648973|Drug|Pseudoephedrine 120 mg|Three times daily: two diphenhydramine-matching placebo capsules
Twice daily: one pseudoephedrine 120 mg tablet
363056|NCT00648986|Drug|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
363057|NCT00004899|Biological|filgrastim|
363058|NCT00648999|Drug|lopinavir/ritonavir|lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
363375|NCT00641745|Drug|Lurasidone HCl|40 - 120mg per day
363376|NCT00641745|Drug|Risperidone|Risperidone
362735|NCT00653835|Drug|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
362736|NCT00653835|Drug|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
362737|NCT00004914|Biological|epoetin alfa|
362738|NCT00653848|Drug|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
362739|NCT00653861|Device|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
362740|NCT00653861|Device|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
362741|NCT00653874|Device|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
362742|NCT00653874|Procedure|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
362743|NCT00653874|Other|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
362744|NCT00653887|Other|Biofeedback|4 sessions of biofeedback one session each week
362745|NCT00653887|Other|Placebo|4 sessions, one each week, of discussion about anorectal disease
362746|NCT00653913|Drug|SCH 58235|SCH 58235 10 mg (once daily)
362747|NCT00653913|Drug|pitavastatin|Pitavastatin 2 mg (once daily)
362748|NCT00004914|Procedure|physical therapy|
362749|NCT00656201|Drug|Intramuscular Progesterone|Progesterone—50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
362750|NCT00656214|Drug|Lycopene|08 mg/day in two divided dosage
362751|NCT00656214|Drug|Placebo|Two divided dosage
362752|NCT00656227|Drug|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
362753|NCT00000648|Drug|Ceftriaxone sodium|
362754|NCT00004926|Dietary Supplement|vitamin D3 analogue ILX23-7553|
362755|NCT00656240|Drug|DE-104 ophthalmic solution|
362072|NCT00668122|Drug|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
362073|NCT00668135|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
362074|NCT00668135|Drug|Placebo|Matching placebo
362075|NCT00668148|Biological|IMC-A12 (cixutumumab)|Ewing's Sarcoma/peripheral neuroectodermal tumor (PNET)
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
362076|NCT00668148|Biological|IMC-A12 (cixutumumab)|Rhabdomyosarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
362077|NCT00668148|Biological|IMC-A12 (cixutumumab)|Leiomyosarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
362078|NCT00668148|Biological|IMC-A12 (cixutumumab)|Adipocytic sarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
362402|NCT00661466|Drug|Placebo|placebo
362403|NCT00005007|Drug|Etanercept|
362404|NCT00661479|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
362405|NCT00661479|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
362406|NCT00661479|Drug|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
362407|NCT00661479|Other|Sham (no implant)|Sham in the fellow eye on Day 1.
362408|NCT00661492|Drug|Erbitux (cetuximab) and Novantrone (mitoxantrone)|Arm 1: Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter and Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles
362409|NCT00661492|Drug|Novantrone (mitoxantrone)|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
362410|NCT00661505|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
362411|NCT00661531|Drug|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
362412|NCT00663793|Drug|Acyline|300 mcg/kg
358494|NCT00678327|Drug|procarbazine hydrochloride|Given orally
358495|NCT00678327|Drug|vinblastine sulfate|Given IV
358496|NCT00678327|Drug|vincristine sulfate|Given IV
358497|NCT00678340|Device|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
358498|NCT00678340|Device|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
358499|NCT00678366|Procedure|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
358500|NCT00678366|Procedure|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
358501|NCT00678379|Drug|lidocaine + bupivacaine|Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy with one of three injections.
B - lidocaine (1%) + bupivacaine (0.5%)
358502|NCT00000663|Drug|CD4-IgG|
358503|NCT00005583|Procedure|adjuvant therapy|
358803|NCT00685737|Drug|1-MNA|Capsule
358804|NCT00685737|Drug|Placebo|Capsule
358805|NCT00685750|Procedure|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
358806|NCT00005613|Drug|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
358807|NCT00685763|Other|Proton radiation and chemotherapy|Chemotherapy Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F)
Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .
Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses
358808|NCT00685776|Drug|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
358809|NCT00685776|Drug|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
358810|NCT00685789|Device|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
358811|NCT00685789|Device|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
358812|NCT00688038|Procedure|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
358169|NCT00670904|Other|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
358170|NCT00670904|Other|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
358171|NCT00670917|Other|questionnaire administration|
358172|NCT00670917|Procedure|acupressure therapy|
358173|NCT00670917|Procedure|biopsy|
358174|NCT00670917|Procedure|bone marrow aspiration|
358175|NCT00670917|Procedure|pain therapy|
358176|NCT00670930|Drug|omalizumab at a dose of 0.016mg/kg/IU/mL|
358177|NCT00670930|Drug|Placebo|
358178|NCT00005083|Procedure|magnetic resonance spectroscopic imaging|
358179|NCT00670943|Other|Platelet function testing|
358180|NCT00670956|Drug|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
358181|NCT00670956|Drug|Placebo|PLACEBO: IM x 2 doses 24 hours apart
358182|NCT00670982|Drug|bevacizumab|Given intravenously every 2 weeks
358504|NCT00678379|Drug|normal saline|Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy with one of three injections.
A - normal saline
358505|NCT00678379|Drug|lidocaine + bupivacaine + clonidine|Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy with one of three injections.
C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)
358506|NCT00678392|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosing
358507|NCT00678392|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing
362506|NCT00631852|Drug|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
362507|NCT00631865|Biological|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
362508|NCT00631878|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
362840|NCT00664014|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
362841|NCT00664027|Drug|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
362842|NCT00664040|Other|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
362843|NCT00005046|Drug|paclitaxel|
362844|NCT00666198|Drug|SILDENAFIL|Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, "For oral use, the adult dose is 20 mg three times a day".
Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration.
362845|NCT00666211|Other|educational intervention|Participants will be educated on pain management.
362846|NCT00666211|Other|Titrated pain management|Pain will be Monitored and Medication Titrated
362847|NCT00666211|Other|questionnaire administration|Participants will be given questionnaires to complete.
362848|NCT00666224|Drug|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
362849|NCT00666224|Drug|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
362850|NCT00666224|Drug|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
362851|NCT00666237|Procedure|Tube shunt surgery|350mm2 Baerveldt glaucoma implant
362852|NCT00666237|Procedure|Trabeculectomy with mitomycin C|Mitomycin C 0.4 mg/ml for 2 minutes
362853|NCT00666250|Dietary Supplement|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
362178|NCT00638989|Drug|CAT-354|CAT-354 following intravenous administration of 150 mg
362179|NCT00639002|Drug|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
362180|NCT00639002|Drug|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
362181|NCT00639015|Drug|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
362182|NCT00641290|Device|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
362183|NCT00641303|Procedure|acupuncture therapy|Given weekly for 8 sessions
362509|NCT00631917|Drug|Aliskiren|Aliskiren 300 mg once a day
362510|NCT00631917|Drug|Ramipril|Ramipril 10 mg once a day
362511|NCT00634179|Drug|Prednisone|Prednisone 100 mg/day given orally on days 1-5
362512|NCT00634192|Drug|tobramycin|1x300mg/d inhaled
362513|NCT00634192|Drug|tobramycin|2x300mg/d inhaled
362514|NCT00004740|Drug|isoniazid|
362515|NCT00634205|Drug|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
362516|NCT00634218|Behavioral|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
362517|NCT00634218|Behavioral|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
362518|NCT00634218|Behavioral|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
362519|NCT00634218|Behavioral|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
362520|NCT00634231|Biological|AdV-tk|
361848|NCT00645853|Drug|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
361849|NCT00645866|Drug|capecitabine|
361850|NCT00645866|Drug|docetaxel|
361851|NCT00645866|Drug|epirubicin hydrochloride|
361852|NCT00004885|Drug|leucovorin calcium|
361853|NCT00645866|Other|laboratory biomarker analysis|
361854|NCT00645866|Other|pharmacogenomic studies|
361855|NCT00645866|Procedure|biopsy|
361856|NCT00645866|Procedure|neoadjuvant therapy|
361857|NCT00645866|Procedure|therapeutic surgical procedure|
361858|NCT00648479|Device|fluoroscopy (OEC 9800 - General Electric)|
361859|NCT00648492|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
361860|NCT00648492|Drug|Glucophage® XR 500 mg|500mg, single dose fed
361861|NCT00648505|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
361862|NCT00648505|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
361863|NCT00648518|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
361864|NCT00648518|Drug|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
362184|NCT00004855|Drug|Lamivudine|
362185|NCT00641303|Procedure|sham intervention|Given weekly for 8 sessions
362186|NCT00641316|Procedure|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
362187|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
362188|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
366991|NCT00647881|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fed
366992|NCT00647894|Drug|Alprazolam Extended-Release Tablets 1 mg|
366993|NCT00004896|Drug|busulfan|
366994|NCT00647894|Drug|Xanax XR Tablets 1 mg|
366995|NCT00647907|Drug|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
366996|NCT00647920|Biological|adalimumab|40 mg adalimumab sc, every other week
366997|NCT00647920|Biological|placebo|placebo sc, every other week
366998|NCT00647933|Drug|Org 36286|Subcutaneous Org 36286
366999|NCT00647933|Drug|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
367000|NCT00647946|Drug|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
367001|NCT00647946|Drug|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
367002|NCT00647959|Drug|Doxycycline Tablets, 150mg|150mg, single dose fasting
367003|NCT00647959|Drug|Adoxa Tablets 150 mg|150mg, single dose fasting
367004|NCT00004896|Drug|cyclophosphamide|
367005|NCT00647972|Drug|Olanzapine Tablets 20 mg|20mg, single dose fasting
367006|NCT00647972|Drug|Zyprexa® Tablets 20 mg|20mg, single dose fasting
367007|NCT00647985|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fed
367008|NCT00647985|Drug|Allegra® Tablets 180 mg|180mg, single dose fed
367009|NCT00647998|Drug|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
367010|NCT00648011|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
366329|NCT00660452|Drug|Staloral|Sublingual immunotherapy with Staloral dust mites solution
366330|NCT00662766|Dietary Supplement|black currant seed press residue|Black currant seed press residue, baked into bread
366331|NCT00662766|Dietary Supplement|Bread without black currant seed press residues|Same bread but without seeds
366332|NCT00662766|Dietary Supplement|Baseline data|No supplement was administered.
366333|NCT00662779|Drug|arformoterol|15 mcg arformoterol nebulizer
366334|NCT00662779|Drug|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
366335|NCT00662779|Drug|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
366336|NCT00005021|Drug|paclitaxel|
366337|NCT00662792|Drug|Tiotropium plus Salmeterol|
366338|NCT00662792|Drug|Tiotropium|
366339|NCT00662792|Drug|Salmeterol|
366340|NCT00662805|Drug|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
366662|NCT00655408|Drug|elemental iron|Iron supplementation.
366663|NCT00655421|Other|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
366664|NCT00655421|Device|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
366665|NCT00655421|Other|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
366666|NCT00655460|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
366667|NCT00655473|Drug|Placebo|po daily for 24 months
366668|NCT00655473|Drug|dalcetrapib|600mg po daily for 24 months
366669|NCT00004921|Drug|melphalan|
366670|NCT00655486|Drug|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
366342|NCT00662818|Drug|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
366343|NCT00662818|Drug|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
366344|NCT00662818|Drug|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
366345|NCT00662831|Drug|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
366346|NCT00662831|Drug|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
366347|NCT00005021|Drug|topotecan hydrochloride|
366348|NCT00662844|Dietary Supplement|vitamin D3|Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
366349|NCT00662857|Drug|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
366350|NCT00662857|Drug|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
366351|NCT00662857|Drug|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
366352|NCT00662870|Biological|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
366353|NCT00662870|Biological|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
366354|NCT00662883|Drug|PMI-150 (intranasal ketamine HCl); mometasone furoate|1 dose PMI-150 (intranasal ketamine HCl); day 1
mometasone furoate, daily; days 2-15
1 dose PMI-150 (intranasal ketamine HCl); day 15
366355|NCT00662896|Drug|naproxcinod 375 mg bid|naproxcinod 375 mg bid
366356|NCT00662896|Drug|naproxcinod 750 mg bid|naproxcinod 750 mg bid
366357|NCT00662896|Drug|naproxen 250 mg bid|naproxen 250 mg bid
366358|NCT00665158|Behavioral|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
366359|NCT00665158|Behavioral|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
366360|NCT00665184|Behavioral|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
366361|NCT00665184|Behavioral|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
365677|NCT00637611|Drug|Fexofenadine HCl|
365678|NCT00004797|Drug|fructose|
365679|NCT00637624|Drug|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
365680|NCT00637624|Drug|Placebo|Placebo once every 3 weeks intravenous saline fluid
365681|NCT00637637|Drug|indinavir sulfate|
365682|NCT00637637|Drug|ritonavir|
365683|NCT00637637|Radiation|radiation therapy|
365684|NCT00637650|Procedure|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
365685|NCT00637650|Procedure|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
365686|NCT00637663|Drug|Entecavir|entecavir 0.5 mg QD
365687|NCT00637663|Drug|Lamivudine|lamivudine 100 mg QD
366013|NCT00669812|Drug|ifosfamide|
366014|NCT00669812|Drug|melphalan|
366015|NCT00669812|Drug|methotrexate|
366016|NCT00669812|Drug|prednisolone|
366017|NCT00669812|Drug|vincristine sulfate|
366018|NCT00669812|Procedure|autologous hematopoietic stem cell transplantation|
366019|NCT00669812|Procedure|biopsy|
366020|NCT00005074|Drug|alvocidib|
366021|NCT00669812|Procedure|peripheral blood stem cell transplantation|
366022|NCT00669825|Drug|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
366023|NCT00669825|Drug|Placebo|Placebo to be administered via intragastric tube
366024|NCT00669851|Drug|AI-700|
366025|NCT00669864|Drug|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
366026|NCT00669864|Drug|metformin|Tablets, 1000 - 2000 mg daily
365350|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
365351|NCT00642603|Drug|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
365352|NCT00642603|Drug|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
365353|NCT00642603|Drug|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
365354|NCT00644709|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
365355|NCT00644722|Device|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
365356|NCT00644722|Device|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
365357|NCT00644735|Drug|Esomeprazole|
365358|NCT00644735|Drug|Lansoprazole|
365359|NCT00644748|Drug|gabapentin|Gabapentin oral capsules:
Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg
365360|NCT00644761|Drug|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
365361|NCT00644774|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
365362|NCT00644774|Drug|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
365363|NCT00004878|Drug|methotrexate|
365688|NCT00637676|Procedure|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
365689|NCT00004797|Drug|placebo|
365690|NCT00637676|Procedure|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
365691|NCT00637702|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
365692|NCT00637715|Drug|Alfuzosin|
365693|NCT00637728|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
364710|NCT00657059|Drug|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
364711|NCT00657059|Drug|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt ＜ 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
364712|NCT00657111|Drug|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
364713|NCT00004933|Drug|hydroxyurea|0.5 to 5 grams PO per day
364714|NCT00657111|Other|Placebo|placebo capsules containing 25 mg lactose
365029|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
365030|NCT00649896|Drug|Mylan Estradiol Transdermal System 0.025 mg/day|
365031|NCT00649896|Drug|Climara® Transdermal System 0.025 mg/day|
365032|NCT00649922|Biological|adalimumab|80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
365033|NCT00649922|Biological|placebo|2 injections Day 1, 1 injection Days 15 and 29
365034|NCT00649922|Biological|adalimumab|40 mg adalimumab every other week
365035|NCT00649935|Drug|Azithromycin Tablets 600 mg|600mg, single dose fed
365036|NCT00649935|Drug|Zithromax® Tablets 600 mg|600mg, single dose fed
365037|NCT00004901|Drug|fluorouracil|
365038|NCT00649948|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
365039|NCT00649948|Drug|Glucophage XR 500 mg|500mg, single dose fed
365040|NCT00652171|Drug|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
365041|NCT00004906|Drug|docetaxel|
365042|NCT00652171|Dietary Supplement|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
365043|NCT00652184|Drug|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
364380|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
364381|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
364382|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
364383|NCT00664417|Biological|Physiological saline|0.5 mL, IM, 2 injections
364384|NCT00005032|Biological|oblimersen sodium|
364385|NCT00664430|Drug|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
364386|NCT00664430|Drug|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
364387|NCT00664443|Behavioral|Dispatch-assisted CPR Instructions|Pre and post assessment of bystander CPR frequency and impact on victim survival related to Dispatch-assisted CPR Instructions given since 2004
364388|NCT00664456|Drug|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
364389|NCT00664456|Drug|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
364390|NCT00664456|Radiation|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
364391|NCT00664469|Drug|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
364392|NCT00664469|Drug|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
364393|NCT00664469|Drug|Comparator: Atorvastatin|Atorvastatin 20, 40 & 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
364394|NCT00664469|Drug|Comparator: Rosuvastatin|Rosuvastatin 10, 20 & 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
364715|NCT00657124|Dietary Supplement|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
364716|NCT00657124|Dietary Supplement|Placebo|placebo
364717|NCT00657137|Drug|apricoxib + lapatinib + capecitabine|apricoxib: 100 mg tablets, 400 mg/day
lapatinib: per package insert
capecitabine: per package insert
363714|NCT00634751|Drug|Sorafenib|Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).
Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length
Sorafenib 200 mg BID Oral Daily Every 28 days
If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.
Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length
Sorafenib 400 mg BID Oral Daily Every 28 days
363715|NCT00004784|Drug|methotrexate|
363716|NCT00636792|Drug|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
363717|NCT00636792|Drug|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
363718|NCT00636805|Drug|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
364020|NCT00668941|Dietary Supplement|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
364021|NCT00668954|Dietary Supplement|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
364022|NCT00668954|Dietary Supplement|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
364023|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
364024|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
364025|NCT00668993|Behavioral|EFT - the Emotional Freedom technique|EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as "psychological acupuncture". Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published
364026|NCT00669019|Drug|saracatinib|
364027|NCT00669032|Device|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
364028|NCT00669032|Other|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
364029|NCT00005068|Drug|fluorouracil|
364030|NCT00669058|Drug|Lactic acid (Dermacid)|
364031|NCT00669071|Drug|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
363377|NCT00641758|Drug|Pycnogenol|Pycnogenol 100mg twice daily
363378|NCT00641758|Drug|Placebo|Placebo 100mg twice daily
363379|NCT00641771|Drug|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
363380|NCT00641771|Drug|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
363381|NCT00641784|Drug|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
363382|NCT00641784|Drug|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
363383|NCT00004859|Drug|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
363384|NCT00641797|Drug|Meclizine|medication administration 25mg PO once
363385|NCT00641797|Other|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
363386|NCT00641797|Drug|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
363387|NCT00641797|Drug|Diphenhydramine|25 - 50mg PO/IV once prn
363388|NCT00641797|Drug|Oldansetron|Oldansetron 4 - 8 mg PO/IV prn
363389|NCT00641810|Behavioral|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
363390|NCT00641836|Procedure|Transplantation of autologous endothelial progenitor cells|
363391|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
363392|NCT00004873|Drug|fluorouracil|
363393|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
363394|NCT00644033|Drug|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
363395|NCT00644046|Behavioral|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
362756|NCT00656240|Drug|DE-104 vehicle|
362757|NCT00656253|Drug|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
363059|NCT00649012|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
363060|NCT00649012|Drug|Actos® Tablets 45 mg|45mg, single dose fed
363061|NCT00649025|Drug|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
363062|NCT00649025|Drug|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
363063|NCT00649025|Drug|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
363064|NCT00649038|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
363065|NCT00649038|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
363066|NCT00649051|Drug|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
363067|NCT00649051|Drug|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
363068|NCT00004899|Drug|busulfan|
363069|NCT00649064|Drug|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
363070|NCT00649077|Drug|Meloxicam Tablets 15 mg|15mg, single dose fasting
363071|NCT00649077|Drug|Mobic® Tablets 15 mg|15mg, single dose fasting
363072|NCT00649090|Drug|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
363073|NCT00649103|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
363074|NCT00649103|Drug|Accupril® Tablets 40 mg|40mg, single dose fasting
363075|NCT00649116|Drug|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
363076|NCT00649116|Drug|Lopressor® Tablets 100 mg|100mg, single dose fed
363077|NCT00649129|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
362413|NCT00663793|Drug|Testosterone|24 hours after acyline administration on Day 2 "immediate release" Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by "external matrix fast release" T 300 mg once, followed 24 hours later (Day 4) by "external matrix slow release" T 300 mg once, followed 96 hours later (Day 8) by "immediate release" T 600 mg, followed 24 hours later (Day 9) by "external matrix fast release" T 600 mg po once, followed 48 hours later (Day 11) by "external matrix slow release" T 600 mg once.
362414|NCT00663793|Drug|Finasteride|1 mg PO once daily [day -2 to day 12) 14 days total
362415|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
362416|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
362417|NCT00005026|Drug|carboplatin|
362418|NCT00663819|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
362419|NCT00663819|Procedure|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
362420|NCT00663832|Drug|LBH589 (i.v. panobinostat)|i.v. LBH589 dose levels: 10, 15, or 20 mg/m2
i.v. docetaxel 75 or 60 mg/m2
oral prednisone 5mg bid.
LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle
362421|NCT00663845|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
362758|NCT00656253|Drug|Placebo|12 months period of placebo plus 1 month period without placebo
362759|NCT00656266|Drug|MMF (Cellcept)|
362760|NCT00656266|Drug|placebo|
362761|NCT00656279|Behavioral|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
362762|NCT00656292|Drug|simvastatin|40 mg po/NG every day for 6 days
362763|NCT00656292|Drug|placebo|1 pill po/NG every day x 6 days
362764|NCT00656305|Device|ExAblate 2000|MR guided focused ultrasound.
362765|NCT00004927|Drug|ixabepilone|
362766|NCT00656305|Device|Sham|sham comparator
358813|NCT00688038|Procedure|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
358814|NCT00688051|Other|My Life with CF game|Play the game My Life with CF
358815|NCT00688064|Drug|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
358816|NCT00688064|Drug|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
358817|NCT00688077|Drug|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
358818|NCT00688077|Drug|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
358819|NCT00688090|Biological|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
358820|NCT00005632|Biological|MUC1-KLH vaccine/QS21|
358821|NCT00688090|Biological|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
358822|NCT00688103|Drug|ETN Alone|etanercept (25 mg, twice/week, s.c.)
358823|NCT00688103|Drug|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
359152|NCT00673621|Drug|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
359153|NCT00673621|Drug|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
359154|NCT00673634|Procedure|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
359155|NCT00673634|Procedure|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
359156|NCT00673647|Behavioral|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
359157|NCT00673660|Behavioral|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
359158|NCT00673673|Drug|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
359159|NCT00673673|Drug|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
358508|NCT00678405|Behavioral|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer & non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
358509|NCT00680758|Drug|cisplatin|Dose Level: -3 20mg/m2/week 3-6 patients
Dose Level: -2 20mg/m2/week 3-6 patients
Dose Level: -1 25mg/m2/week 3-6 patients
Dose Level: 1 25mg/m2/week 3-6 patients
Dose Level: 2 25mg/m2/week 3-6 patients
Dose Level: 3 25mg/m2/week 3-6 patients
358510|NCT00680758|Drug|everolimus|Dose Level: -3 20mg/m2/week 3-6 patients
Dose Level: -2 20mg/m2/week 3-6 patients
Dose Level: -1 20mg/m2/week 3-6 patients
Dose Level: 1 20mg/m2/week 3-6 patients
Dose Level: 2 25mg/m2/week 3-6 patients
Dose Level: 3 30mg/m2/week 3-6 patients
358511|NCT00680758|Drug|paclitaxel|Dose Level: -3 65mg/m2/week 3-6 patients
Dose Level: -2 70mg/m2/week 3-6 patients
Dose Level: -1 70mg/m2/week 3-6 patients
Dose Level: 1 80mg/m2/week 3-6 patients
Dose Level: 2 80mg/m2/week 3-6 patients
Dose Level: 3 80mg/m2/week 3-6 patients
358512|NCT00680784|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
358513|NCT00005590|Drug|levofloxacin|
358514|NCT00680784|Other|Placebo Patch|Placebo Patch
358515|NCT00680797|Drug|Testosterone|Testosterone gel
358516|NCT00680797|Drug|Estrogen|Estrogen patch
358517|NCT00680823|Drug|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
358518|NCT00680823|Drug|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
358519|NCT00680836|Drug|Placebo|orally two times per day for 14 days
358520|NCT00680836|Drug|Rifaximin|550 mg orally two times per day for 14 days
358521|NCT00680875|Behavioral|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
358522|NCT00680901|Drug|Lapatinib|5 pills at 250mg each once daily
358523|NCT00680901|Drug|Placebo|5 pills once daily
358824|NCT00688116|Drug|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., [Monday, Thursday] or [Tuesday, Friday]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
362854|NCT00005047|Drug|cisplatin|
362855|NCT00666263|Biological|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
362856|NCT00666263|Biological|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
363167|NCT00659061|Behavioral|Advice only|No sprinkle sachets will be given by the LHW. However, the LHWs will provide the age-appropriate nutritional advice as per their regular routine monthly door to door community services
363168|NCT00659074|Drug|Ondansetron|ODT, single-dose, fasting
363169|NCT00659074|Drug|Zofran|ODT, single-dose, fasting
363170|NCT00659087|Procedure|Femoral Block|Those receiving femoral block postoperatively
363171|NCT00004984|Drug|Crystallized human recombinant insulin|
363172|NCT00659087|Other|Usual Care|Those receiving only usual pain management postoperatively
363173|NCT00659100|Drug|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
363174|NCT00659113|Drug|cisplatin|
363175|NCT00659113|Drug|tegafur-gimeracil-oteracil potassium|
363176|NCT00659113|Other|cytology specimen collection procedure|
363177|NCT00659113|Procedure|endoscopic biopsy|
363178|NCT00659126|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
363179|NCT00659126|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
363180|NCT00661700|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
363181|NCT00005010|Drug|Pravastatin|
363182|NCT00661700|Drug|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
363183|NCT00661713|Biological|rMenB+OMV NZ|
363184|NCT00661713|Biological|Placebo|
362521|NCT00634231|Drug|valacyclovir|
362522|NCT00634231|Radiation|Radiation|
362523|NCT00634244|Drug|alvocidib|Given IV
362524|NCT00634244|Drug|mitoxantrone hydrochloride|Given IV
362525|NCT00004744|Drug|immune globulin|
362526|NCT00634244|Drug|carboplatin|Given IV
362527|NCT00634244|Drug|cytarabine|Given IV
362528|NCT00634244|Drug|sirolimus|Given PO
362529|NCT00634244|Drug|etoposide|Given IV
362530|NCT00634244|Drug|topotecan hydrochloride|Given IV
362857|NCT00666276|Drug|linezolid (Zyvox)|Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.
Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration.
362858|NCT00666302|Drug|tacrolimus ointment|topical
362859|NCT00666302|Drug|pimecrolimus cream|topical
362860|NCT00666328|Drug|clevidipine|Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.
Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours.
362861|NCT00666341|Drug|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
362862|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
362863|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
362864|NCT00668408|Other|Pharmacological therapy of COPD and CHF|Optimal pharmacologic treatment will include :
Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)
Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)
Beta-blockers
Diuretics
Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics
Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).
The treatment of the deseases will follow the international guidelines.
362189|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
362190|NCT00641329|Drug|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
362191|NCT00641329|Drug|Placebo|Matching placebo tablets
362192|NCT00641342|Device|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
362193|NCT00641355|Procedure|No intervention|No intervention
362194|NCT00641368|Behavioral|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
362195|NCT00004855|Drug|Stavudine|
362196|NCT00641368|Other|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
362197|NCT00641381|Drug|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
362198|NCT00641381|Drug|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
362199|NCT00641381|Drug|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
362200|NCT00641381|Other|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
362201|NCT00641381|Procedure|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
362202|NCT00641381|Procedure|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
362203|NCT00641394|Behavioral|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
362531|NCT00634257|Behavioral|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
362532|NCT00634270|Drug|Sirolimus, Rapamycin|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
362533|NCT00634283|Drug|venlafaxine|venlafaxine IR 150mg
367011|NCT00648011|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
367012|NCT00648024|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
361865|NCT00648531|Drug|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
361866|NCT00648531|Drug|Colazal® Capsules 750 mg|3x750mg, single dose fasting
361867|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablet
361868|NCT00004897|Procedure|conventional surgery|
361869|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablets
361870|NCT00648557|Drug|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
361871|NCT00648557|Drug|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
361872|NCT00648570|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
361873|NCT00648570|Drug|Lexapro® Tablets (20 mg|20mg, single dose fasting
361874|NCT00648583|Drug|Ondansetron Tablets 24 mg|24mg, single dose fed
361875|NCT00648583|Drug|Zofran® Tablets 24 mg|24mg, single dose fed
361876|NCT00648596|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
361877|NCT00648596|Drug|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
361878|NCT00648609|Other|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
361879|NCT00004897|Radiation|radiation therapy|
361880|NCT00648609|Other|Standard of care|Usual care for COPD patients
361881|NCT00648622|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
361882|NCT00648622|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
361883|NCT00648635|Behavioral|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
361884|NCT00648648|Drug|MK1775|Dose escalation study. Part 1: MK1775 capsules will be given on Day 1 of a 14-day cycle: starting dose of MK1775 is 325 mg and will escalate up to 1300 mg or until MTD achieved. Dose Levels for MK1775: 325 mg, 650 mg, and 1300 mg.
366671|NCT00655499|Biological|panitumumab|
366672|NCT00655499|Drug|irinotecan hydrochloride|
366673|NCT00655499|Genetic|chromogenic in situ hybridization|
366674|NCT00655499|Genetic|fluorescence in situ hybridization|
366675|NCT00655499|Genetic|gene expression analysis|
366676|NCT00655499|Other|laboratory biomarker analysis|
366677|NCT00655512|Drug|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
366678|NCT00655512|Drug|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
366679|NCT00655512|Drug|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
366680|NCT00004921|Drug|paclitaxel|
366681|NCT00657839|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
366682|NCT00657839|Drug|Placebo|Matching placebo
366683|NCT00657852|Drug|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
366684|NCT00657852|Drug|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
361550|NCT00655850|Drug|Gemcitabine|Premedication
Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.
Prior to receiving paclitaxel chemotherapy
Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.
The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.
Gemcitabine Dose Levels:
Dose Level 2 ________300 mg/m2/weekly
Dose Level 1 ________200 mg/m2/weekly
Dose Level -1 ________150 mg/m2/weekly
361551|NCT00655850|Biological|Avastin|The dose of Avastin is 10 mg/kg IV every 2 weeks
It will be administered following the administration of chemotherapy
The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.
It should not be administered or mixed with dextrose solutions.
361552|NCT00655863|Drug|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
361553|NCT00655863|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
361554|NCT00655863|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
366362|NCT00005037|Drug|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
366685|NCT00657865|Drug|ramipril|oral intake
366686|NCT00657865|Drug|placebo|placebo
366687|NCT00657878|Drug|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
366688|NCT00657878|Drug|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
366689|NCT00004936|Procedure|magnetic resonance imaging|
366690|NCT00657878|Drug|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
366691|NCT00657878|Drug|Topotecan|dosing and schedule according to Institutional guidelines
366692|NCT00657878|Drug|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
366693|NCT00657891|Drug|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
366694|NCT00657891|Drug|Placebo|Placebo Injection
366695|NCT00657904|Drug|Bicalutamide|150mg daily
366696|NCT00657904|Drug|Placebo|once daily
366697|NCT00657917|Drug|Paromomycin +Gentamicin topical cream|Apply topically twice daily for 20 days
366698|NCT00657930|Drug|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
366699|NCT00657943|Drug|metformin|metformin tablets 2 g x 2
366700|NCT00004936|Radiation|gadopentetate dimeglumine|
366701|NCT00657943|Drug|insulin detemir|insulin as requested
366702|NCT00657943|Drug|insulin aspart + insulin aspart protamin|insulin as requested
366703|NCT00657943|Drug|Insulin aspart|insulin as requested
366704|NCT00657956|Device|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
366705|NCT00657982|Drug|RAD001|10mg BID
366706|NCT00657995|Device|Artificial Pancreas (STG-22)|safe tool
366027|NCT00669877|Drug|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
366028|NCT00669877|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
366029|NCT00669877|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
366030|NCT00633217|Drug|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
366031|NCT00633217|Drug|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
366032|NCT00633230|Drug|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
366033|NCT00633230|Other|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
366034|NCT00633243|Procedure|Modified Directly Observed Therapy (mDOT)|
366035|NCT00004734|Drug|pyridoxine|
366036|NCT00633243|Procedure|Self-Administered Therapy (SAT)|
366037|NCT00633256|Drug|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
366363|NCT00665197|Radiation|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
366364|NCT00665197|Radiation|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
366365|NCT00665223|Drug|ACR16|45 mg capsules Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
366366|NCT00665223|Drug|Placebo|Placebo capsules. Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
366367|NCT00665236|Other|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
366368|NCT00665236|Procedure|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
366369|NCT00665249|Behavioral|Motivational Interviewing|See MotivationalInterviewing.org
366370|NCT00665249|Behavioral|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
365694|NCT00637728|Drug|Placebo|Placebo oral suspension, 5 mL once daily
365695|NCT00637741|Device|Everflex 200|
365696|NCT00637767|Drug|melphalan|
365697|NCT00637767|Procedure|autologous hematopoietic stem cell transplantation|
365698|NCT00637767|Radiation|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
365699|NCT00637780|Drug|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
365700|NCT00004799|Biological|whole-cell pertussis vaccine|
365701|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
365702|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
365703|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
365704|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
365705|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
365706|NCT00640328|Drug|Ofatumumab 100|100mg
365707|NCT00640328|Drug|Ofatumumab 300|300mg
365708|NCT00640328|Drug|Ofatumumab 700|700mg
365709|NCT00640328|Drug|Placebo|matching placebo
365710|NCT00640341|Device|PureVision Contact Lens|contact lens for daily wear
365711|NCT00004842|Drug|budesonide|
365712|NCT00640341|Device|Acuvue Oasys Contact Lens|contact lens for daily wear
366038|NCT00633256|Drug|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
366039|NCT00633269|Drug|AZD2281|100mg Oral Dose
366040|NCT00633282|Behavioral|Life style intervention|calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment
activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50－70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate
365044|NCT00652184|Drug|placebo|placebo cream and placebo valaciclovir
365045|NCT00652184|Drug|valaciclovir|active valaciclovir
365046|NCT00652210|Other|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
365047|NCT00652223|Biological|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
365048|NCT00652236|Other|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
365049|NCT00652262|Drug|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
365050|NCT00652275|Biological|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
365051|NCT00652275|Biological|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
365364|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
365365|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
365366|NCT00644787|Drug|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
365367|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
365368|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
365369|NCT00644800|Drug|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
365370|NCT00644826|Behavioral|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
365371|NCT00644839|Drug|CP-945,598|Administration of CP-945,598 alone in period 1
365372|NCT00644839|Drug|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
364718|NCT00657137|Drug|placebo + lapatinib + capecitabine|placebo: 100 mg tablets, 400 mg/day
lapatinib: per package insert
capecitabine: per package insert
364719|NCT00657150|Drug|Enoxaparin|40 mg once daily
364720|NCT00657150|Drug|Dabigatran etexilate|220 mg once daily
364721|NCT00657163|Drug|fluoxetine|fluoxetine per os 20 mg daily
364722|NCT00657163|Drug|placebo|placebo per os daily
364723|NCT00657176|Drug|OPB-31121|100mg tablet
oral administration, Qd
364724|NCT00004933|Drug|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
364725|NCT00657189|Drug|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
364726|NCT00659711|Drug|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
364727|NCT00659711|Drug|Placebo|will be placed on a placebo for 12 weeks.
364728|NCT00659737|Drug|Aprepitant|40mg tablet
364729|NCT00659737|Drug|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
364730|NCT00659750|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
364731|NCT00659750|Drug|Placebo|placebo
364732|NCT00659763|Other|Exclusion diagnosis|Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.
3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy
364733|NCT00659763|Other|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
364734|NCT00659776|Drug|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
364735|NCT00004997|Drug|Leucovorin|
364736|NCT00659789|Drug|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally
365052|NCT00000647|Drug|CD4-IgG|
365053|NCT00004906|Drug|doxorubicin hydrochloride|
364032|NCT00669071|Drug|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
364033|NCT00669097|Drug|TKI258|
364034|NCT00669110|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|tablet
subjects randomly assigned to 10-200 mg/day by age group
6 month treatment period(~182 days)
364035|NCT00669123|Drug|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
364036|NCT00669123|Drug|Placebo|
364037|NCT00669136|Drug|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
364038|NCT00669149|Drug|clopidogrel + aspirin|
364039|NCT00669149|Drug|heparin + clopidogrel + aspirin|
364040|NCT00632463|Biological|RI-001|Dose 1
364395|NCT00005032|Drug|paclitaxel|
364396|NCT00664482|Biological|AGS-006|Autologous Therapy for Pancreatic Cancer
364397|NCT00664495|Behavioral|Diet Weight Loss|
364398|NCT00664495|Behavioral|Exercise Weight Loss|
364399|NCT00664495|Behavioral|Exercise Without Weight Loss|
364400|NCT00664508|Procedure|Motion analysis|Motion analysis
364401|NCT00664508|Procedure|Motion analysis|Motion analysis
364402|NCT00666731|Other|study of socioeconomic and demographic variables|Repository
364403|NCT00005049|Drug|cisplatin|
364404|NCT00666731|Procedure|Excess human biological tissue|Tissue procurement.
364405|NCT00666731|Procedure|quality-of-life assessment|Cancer care.
364406|NCT00666744|Other|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
364407|NCT00666757|Drug|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
363719|NCT00636818|Drug|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
363720|NCT00636831|Drug|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
363721|NCT00636857|Procedure|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
363722|NCT00636857|Procedure|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
363723|NCT00636870|Drug|Fexofenadine|
363724|NCT00636883|Drug|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
363725|NCT00636896|Drug|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
363726|NCT00004784|Drug|ursodiol|
363727|NCT00636896|Drug|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
363728|NCT00636909|Drug|Cyclophosphamide|preparative cytoreduction
363729|NCT00636909|Drug|fludarabine|preparative cytoreduction
363730|NCT00636909|Drug|cyclosporine|immunosuppressive therapy
363731|NCT00636909|Drug|methotrexate|immunosuppressive therapy
363732|NCT00636909|Biological|G-CSF|foster engraftment
363733|NCT00636922|Drug|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
363734|NCT00636935|Drug|Antibiotics only|Antibiotic only for treatment for mild (pO2 > 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
363735|NCT00636935|Drug|Antibiotics + Corticosteroids|Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
363736|NCT00636935|Drug|Corticosteroids + antibiotics|Drugs will be prescribed per standard of care for patients with PCP and pO2 < 70mmHg.
363078|NCT00649129|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
363079|NCT00651508|Drug|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
363080|NCT00651534|Drug|Ronacaleret|
363081|NCT00651547|Drug|budesonide/formoterol|
363082|NCT00651547|Drug|budesonide|
363396|NCT00644059|Biological|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
363397|NCT00644059|Biological|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
363398|NCT00644059|Biological|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|Meningococcal vaccine: two IM injections
Tick-borne encephalitis vaccine: two IM injections
363399|NCT00644072|Drug|SNX-5422|
363400|NCT00644085|Drug|aspirin|oral administration of aspirin 100 mg
363401|NCT00644085|Drug|placebo|oral administration of placebo
363402|NCT00644098|Dietary Supplement|soluble fibre complex and medium chain triglycerides|
363403|NCT00004874|Radiation|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
363404|NCT00644098|Dietary Supplement|cellulose and soybean oil|
363405|NCT00644111|Drug|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
363406|NCT00644111|Drug|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
363407|NCT00644124|Drug|aflibercept|in combination with standard treatment R-CHOP
363408|NCT00644137|Drug|pregabalin|Help stop smoking
363409|NCT00644137|Other|cigarettes|help stop smoking with study medication
362767|NCT00656318|Other|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
362768|NCT00656331|Drug|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
362769|NCT00656344|Other|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
362770|NCT00656357|Drug|SYN117 Placebo|Placebo
362771|NCT00656357|Drug|SYN117 80 mg|SYN117 80 mg
362772|NCT00656357|Drug|SYN117 80 mg|SYN117 160 mg
362773|NCT00656357|Drug|Cocaine 10mg|IV Cocaine 10mg
362774|NCT00656357|Drug|Cocaine 20mg|IV Cocaine 20mg
362775|NCT00656357|Drug|Cocaine 40mg|IV Cocaine 40mg
362776|NCT00658801|Radiation|Respiratory gated proton beam radiotherapy|Prescription dose to PTV as according to the following dose escalation schema:
Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
Group 2: 5cm <Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week.
362777|NCT00658814|Drug|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
362778|NCT00658814|Drug|Gemtuzumab Ozogamicin|Given IV
363083|NCT00651547|Drug|formoterol|
363084|NCT00004905|Drug|cytarabine|
363085|NCT00651560|Drug|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
363086|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 25%|transfusion
363087|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 28%|transfusion
363088|NCT00651586|Drug|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
359160|NCT00673686|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
359161|NCT00005095|Procedure|study of high risk factors|Subjects will be assessed for high risk factors.
359162|NCT00673686|Drug|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
359163|NCT00673699|Procedure|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
359164|NCT00673712|Device|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
359165|NCT00673712|Drug|Opioid based analgesia|Opioid Analgesic agents delivered by:
PCA on demand mode IV injections PRN IM injections PRN Oral PRN
359166|NCT00673725|Drug|Locobase® REPAIR|emollient
359167|NCT00673738|Drug|Cetuximab|Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.
Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.
359168|NCT00676052|Drug|Placebo|Once daily via dry powder imhaler
359169|NCT00676091|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
359170|NCT00000661|Drug|Oxazepam|
359476|NCT00683826|Dietary Supplement|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
359477|NCT00683826|Other|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
359478|NCT00683826|Dietary Supplement|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
358825|NCT00688129|Behavioral|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
358826|NCT00688155|Behavioral|Physical Activity Training (PAT)|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
358827|NCT00688155|Behavioral|Cognitive Training (CT)|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
358828|NCT00688155|Behavioral|Healthy Aging Education (HAE)|One 1-hour lecture each week for 3 months, then monthly.
358829|NCT00688168|Behavioral|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
358830|NCT00688168|Behavioral|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
358831|NCT00005633|Biological|OVA BiP peptide|
358832|NCT00688168|Behavioral|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
358833|NCT00690196|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
358834|NCT00690209|Procedure|Autologous bone marrow derived stem cells myocardial transplantation|
358835|NCT00690222|Procedure|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
358836|NCT00690235|Drug|Pramlintide|180mg subcutaneous injections, twice daily
358837|NCT00690235|Drug|Placebo|180mg subcutaneous injections, twice daily
358838|NCT00690274|Drug|BF2.649|up to 20mg per day
358839|NCT00690274|Drug|Placebo|up to 20mg per day
364172|NCT00644293|Drug|placebo|placebo
363185|NCT00661726|Drug|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
363186|NCT00661739|Drug|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
363187|NCT00661752|Device|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
363188|NCT00661752|Device|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
363502|NCT00654160|Drug|irinotecan hydrochloride|
363503|NCT00654160|Drug|leucovorin calcium|
363504|NCT00654160|Other|pharmacogenomic studies|
363505|NCT00654160|Other|pharmacological study|
363506|NCT00654173|Drug|Rosuvastatin|
363507|NCT00654173|Drug|Simvastatin|
363508|NCT00000647|Procedure|Peripheral lymphocyte infusion|
363509|NCT00004916|Drug|teniposide|
363510|NCT00654173|Drug|Atorvastatin|
363511|NCT00654186|Drug|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
363512|NCT00654212|Procedure|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
363513|NCT00654212|Procedure|open approach|emergency open surgery
363514|NCT00654225|Drug|Rosuvastatin|
363515|NCT00654225|Drug|Atorvastatin|
363516|NCT00654238|Drug|sorafenib|400mg PO BID daily
363517|NCT00654264|Procedure|Water immersion|Subjects will sit in tub for four hours.
363518|NCT00654277|Drug|Ondansetron|ODT, 8 mg, single-dose
362865|NCT00668421|Drug|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
362866|NCT00668434|Drug|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
362867|NCT00668434|Drug|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
362868|NCT00005065|Drug|motexafin gadolinium|Given IV
362869|NCT00668447|Dietary Supplement|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
362870|NCT00668447|Dietary Supplement|Control protein|20 grams of powder mixed in beverages or food daily for one year
362871|NCT00668447|Dietary Supplement|Novasoy isoflavones|3 tablets daily for one year
362872|NCT00668447|Dietary Supplement|Placebo tablets|3 tablets daily for one year
362873|NCT00668460|Drug|Lactic acid (Dermacid)|
362874|NCT00668486|Drug|Lactic acid (Dermacid)|
363189|NCT00661765|Drug|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
363190|NCT00661765|Drug|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
363191|NCT00661778|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
363192|NCT00005012|Drug|Peginterferon alfa-2b|
363193|NCT00661778|Drug|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
363194|NCT00661778|Drug|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
363195|NCT00661791|Behavioral|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
363196|NCT00661791|Behavioral|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
363197|NCT00661817|Behavioral|Lifestyle Modification Program|Participants will receive a behavior change "prescription" and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support.
363198|NCT00661817|Behavioral|Usual Care and Reading Materials|Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's "Aim for a Healthy Weight" brochure at the baseline study visit and again at the beginning of Year 2.
362534|NCT00634296|Other|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
362535|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
362536|NCT00636363|Device|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
362537|NCT00636376|Procedure|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
362538|NCT00636389|Device|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
362539|NCT00636389|Device|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
362540|NCT00636402|Procedure|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
362541|NCT00004776|Drug|topiramate|
362542|NCT00636402|Procedure|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
362543|NCT00636415|Drug|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
362544|NCT00636428|Drug|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
362545|NCT00636441|Drug|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
362546|NCT00636454|Behavioral|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
362547|NCT00636454|Other|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
362548|NCT00636467|Other|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
362875|NCT00668499|Drug|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
362876|NCT00668512|Biological|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
361885|NCT00648648|Drug|gemcitabine|gemcitabine - IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle. Dose Levels for Gemcitabine: 1000 mg/m^2, 800 mg/m^2, 600 mg/m^2
361886|NCT00651040|Drug|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
361887|NCT00651053|Device|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
362204|NCT00641394|Behavioral|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
362205|NCT00641407|Drug|NPL insulin|Starting dose 10 IU bedtime and then titration
362206|NCT00643578|Drug|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
362207|NCT00004870|Drug|irinotecan hydrochloride|
362208|NCT00643578|Device|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
362209|NCT00643591|Other|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
362210|NCT00643604|Drug|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
362211|NCT00643617|Radiation|CyberKnife Stereotactic Radiosurgery|38 Gy delivered in 4 fractions of 9.5 Gy per fraction
362212|NCT00643630|Device|Tetrix|Twice daily topical application
362213|NCT00643630|Device|Tetrix|Twice daily topical application
362214|NCT00643643|Drug|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
362215|NCT00643643|Drug|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
362216|NCT00643643|Drug|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
362217|NCT00643643|Drug|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
362218|NCT00004871|Drug|azacitidine|
362219|NCT00643643|Other|Placebo|Matching placebo oral tablet twice daily for 10 days
362220|NCT00643656|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
361555|NCT00655876|Biological|cetuximab|Given IV
361556|NCT00655876|Drug|cisplatin|Given IV
361557|NCT00655876|Drug|paclitaxel|Given IV
361558|NCT00655876|Radiation|radiation therapy|Given 5 days a week for 5½ weeks
361559|NCT00004923|Drug|irinotecan hydrochloride|
361560|NCT00655889|Biological|Autologous Human Fibroblasts (azficel-T)|Collection of biopsy from palate
Papillary priming procedure
Seven injection treatments to target sites
Performance of study assessments (investigator and subject)
361561|NCT00655902|Dietary Supplement|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
361562|NCT00658346|Drug|Treatment initiation for HIV-1 group O infected patients|The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)
If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)
If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)
361563|NCT00658346|Drug|Treatment initiation for HIV-1 group M infected patients|The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)
If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)
If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)
361564|NCT00658359|Drug|Cyclosporine|Standard of care
361565|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
361566|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
361567|NCT00658372|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
361568|NCT00658372|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
361888|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
361889|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
361890|NCT00651079|Drug|GSK1247303|
361891|NCT00651092|Procedure|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
361892|NCT00004904|Drug|methylprednisolone|
366707|NCT00658008|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
366708|NCT00658008|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
366709|NCT00658008|Drug|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
366710|NCT00658008|Drug|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
361569|NCT00004978|Drug|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
361570|NCT00658372|Drug|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
361571|NCT00658372|Drug|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
361572|NCT00658385|Genetic|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.
These will be done again 24 hours after your stem cells are collected.
361573|NCT00658398|Behavioral|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
361574|NCT00658411|Drug|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
361575|NCT00658437|Drug|CY-503|solution for subcutaneous injection, 350 ng twice weekly
361576|NCT00658450|Behavioral|Cognitive rehabilitation training|A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.
Children will complete these tasks in 16 session for 8 weeks.
361577|NCT00658463|Drug|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
361578|NCT00658463|Drug|Placebo|Placebo
361579|NCT00658476|Dietary Supplement|Fish Oil|Omega-3 fatty acid supplements.
361580|NCT00000650|Drug|Ditiocarb sodium|
361581|NCT00004979|Drug|paclitaxel|
361582|NCT00658476|Behavioral|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
361583|NCT00658476|Other|Placebo|
366371|NCT00665249|Other|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
366372|NCT00665262|Drug|tramacet|2 tablets every 6 hours for 5 days
366373|NCT00005038|Biological|aldesleukin|
366374|NCT00665314|Drug|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
366375|NCT00665314|Drug|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
366376|NCT00665327|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
366377|NCT00665327|Drug|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
366378|NCT00665340|Drug|Placebo|Matching placebo
366379|NCT00665340|Drug|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
366380|NCT00665353|Drug|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
366381|NCT00667342|Biological|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
366382|NCT00667342|Drug|Cisplatin|Given IV.
366383|NCT00667342|Drug|Doxorubicin|Given IV.
366711|NCT00660478|Device|Endeavor|Comparison of two different drug eluting coronary stents
366712|NCT00660478|Device|Cypher Select|Comparison of two different drug eluting coronary stents
366713|NCT00005000|Drug|Keyhole-Limpet Hemocyanin|
366714|NCT00660491|Other|exercise training|moderate intensity exercise group, and high intensity exercise group
366715|NCT00660504|Drug|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
366716|NCT00660504|Drug|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
366717|NCT00660517|Drug|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
366718|NCT00660517|Drug|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
366041|NCT00633282|Drug|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
366042|NCT00633282|Drug|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
366043|NCT00633295|Drug|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
366044|NCT00633308|Device|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
366045|NCT00633321|Biological|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
366046|NCT00004734|Drug|cyanocobalamin|
366047|NCT00633321|Biological|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
366048|NCT00633334|Other|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
366049|NCT00633347|Drug|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
366050|NCT00633347|Drug|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
366051|NCT00633360|Drug|Drospirenone and ethinyl estradiol|Once daily by mouth
366052|NCT00633360|Drug|Placebo|Once daily by mouth
366053|NCT00633373|Drug|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
366054|NCT00635349|Drug|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam [7.5 mg or 15 mg once daily] or aceclofenac [100 mg twice daily]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
366055|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
366056|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
366384|NCT00005053|Drug|glufosfamide|
366385|NCT00667342|Drug|Methotrexate|Given IV.
365373|NCT00644852|Other|Retrospective chart review study|Retrospective study chart review long acting risperidone
365374|NCT00000641|Drug|Ethambutol hydrochloride|
365375|NCT00004878|Drug|tacrolimus|
365376|NCT00647218|Drug|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
365377|NCT00647231|Drug|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
365378|NCT00647231|Other|Placebo Patch|Treatment with placebo patch
365379|NCT00004891|Procedure|neoadjuvant therapy|
365380|NCT00647244|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
365381|NCT00647244|Drug|Abacavir|Abacavir 300 mg oral tablet twice daily
365382|NCT00647257|Drug|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
365713|NCT00640341|Device|O2Optix Contact lens|contact lens for daily wear
365714|NCT00640354|Device|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
365715|NCT00640354|Device|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
365716|NCT00640367|Other|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
365717|NCT00640367|Drug|Alteplase IV|intravenous recombinant tissue plasminogen activator
365718|NCT00640380|Other|Nerve stimulation|CPVB with NS
365719|NCT00640380|Other|Loss of resistance to air|CPVB with LOR
365720|NCT00640393|Drug|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
365721|NCT00640393|Device|nbUVB|
365722|NCT00004843|Procedure|parathyroidectomy|
365054|NCT00652288|Drug|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
365055|NCT00652301|Drug|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
365056|NCT00652301|Drug|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
365057|NCT00652301|Drug|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
365058|NCT00652314|Device|Thrombi-Gel|Applicaton of Hemostatic product during surgery
365059|NCT00652327|Drug|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
365060|NCT00652327|Drug|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
365061|NCT00652340|Drug|apricoxib/erlotinib|apricoxib: 100 mg tablets, 400mg/day
erlotinib: per package insert
365062|NCT00652340|Drug|erlotinib/placebo|erlotinib: per package insert
placebo: 100 mg tablets, 400 mg/day
365063|NCT00652353|Other|44-55-66-PM|The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.
44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar
365064|NCT00004906|Drug|etoposide|
365065|NCT00654758|Drug|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
365066|NCT00654771|Other|urine collection|clean catch urine collection and catheterized urine collection
365067|NCT00654784|Drug|idebenone|idebenone 450 mg/day (150 mg three times a day)
365068|NCT00654784|Drug|placebo|
365069|NCT00654797|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
365070|NCT00654810|Behavioral|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
364408|NCT00666757|Drug|fluoxetine|20-80 mgs orally daily for 12 weeks
364409|NCT00666757|Drug|citalopram|20-40 mgs orally daily for 12 weeks
364410|NCT00666757|Drug|paroxetine|20-50 mgs orally daily for 12 weeks
364411|NCT00666757|Drug|sertraline|50-200 mgs orally daily for 12 weeks
364412|NCT00666770|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
364413|NCT00666770|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
364414|NCT00005049|Drug|floxuridine|
364415|NCT00666770|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
364416|NCT00666783|Drug|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
364417|NCT00666783|Drug|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
364418|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
364419|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
364737|NCT00659789|Drug|Sterile water|Sterile water for injection.
364738|NCT00659802|Drug|HMPL-004|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day), 600 mg (3 x 200 mg t.i.d. or placebo.
364739|NCT00659802|Drug|Placebo|Placebo
364740|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
364741|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
364742|NCT00659828|Drug|Recombinant methionyl human leptin|recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
364743|NCT00659841|Drug|Ciclesonide|200µg Ciclesonide versus placebo
364744|NCT00659841|Drug|Placebo|placebo
364745|NCT00659854|Dietary Supplement|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
363737|NCT00004785|Drug|dexamethasone|
363738|NCT00639587|Drug|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
364041|NCT00632463|Biological|RI-001|Dose 2
364042|NCT00000170|Drug|Atropine|Atropine
364043|NCT00000636|Drug|Pyrazinamide|
364044|NCT00004705|Drug|uridine|
364045|NCT00632463|Biological|RI-001|Placebo
364046|NCT00632476|Other|Placebo|Placebo capsule once a day
364047|NCT00632476|Dietary Supplement|Vitamin C|A 500-mg vitamin C capsule once a day
364048|NCT00632489|Drug|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
364049|NCT00632489|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
364050|NCT00632489|Drug|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
364051|NCT00632502|Drug|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
364052|NCT00632502|Drug|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
364053|NCT00632502|Drug|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
364054|NCT00632515|Behavioral|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
364055|NCT00004727|Drug|aspirin|
364056|NCT00632528|Drug|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
364057|NCT00632528|Drug|Medicinal air|Administration of medical air during postoperative physical therapy
364058|NCT00632541|Drug|Sorafenib|Sorafenib 200mg po daily
364059|NCT00632541|Drug|Bevacizumab|Bevacizumab 5mg/kg every other week
1 Cycle = 4 weeks
364060|NCT00632541|Other|Imaging|Imaging every third cycle
363410|NCT00644150|Behavioral|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
363411|NCT00004887|Drug|paclitaxel|
363412|NCT00646386|Drug|placebo for adalimumab|40 mg eow Week 0 - Week 24
363413|NCT00646399|Drug|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
363739|NCT00639587|Drug|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
363740|NCT00639600|Procedure|human pancreatic islet transplantation|human pancreatic islet transplantation
363741|NCT00639613|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
363742|NCT00639613|Other|Standard meal test|Liquid meal consisting of 100 g "Ny NAN" dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations.
363743|NCT00004827|Drug|docosahexaenoic acid|
363744|NCT00639626|Drug|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
363745|NCT00639639|Biological|tetanus toxoid|Given by injection
363746|NCT00639639|Biological|therapeutic autologous dendritic cells|Given intradermally
363747|NCT00639639|Biological|therapeutic autologous lymphocytes|Given IV
363748|NCT00639652|Procedure|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
363089|NCT00651586|Drug|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
363090|NCT00651599|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
363091|NCT00651599|Drug|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
363092|NCT00651612|Drug|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
363093|NCT00651612|Drug|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
363094|NCT00651625|Device|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
363095|NCT00000646|Drug|Pentoxifylline|
363096|NCT00004905|Drug|etoposide|
363097|NCT00651625|Device|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
363098|NCT00651638|Drug|Treatment with ARQ 197|Treatment with ARQ 197
363099|NCT00651651|Drug|budesonide/formoterol|
363100|NCT00651651|Drug|budesonide|
363101|NCT00651651|Drug|formoterol|
363414|NCT00646399|Drug|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
363415|NCT00646412|Device|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
363416|NCT00646425|Drug|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
363417|NCT00646425|Drug|Placebo|Placebo to match basiliximab
359479|NCT00683839|Behavioral|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
359480|NCT00683852|Drug|Aripiprazole|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
359481|NCT00683852|Drug|Aripiprazole|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
359482|NCT00005603|Drug|doxorubicin hydrochloride|
359483|NCT00683852|Drug|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
359484|NCT00683865|Drug|Ofloxacin|Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
359485|NCT00683865|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg po od for 14 days
359486|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
359487|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
359488|NCT00683878|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
359489|NCT00683878|Drug|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
359490|NCT00683891|Drug|FazaClo (clozapine, USP) ODT|
359491|NCT00686010|Drug|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
359492|NCT00686023|Procedure|internal fixation (DHS - richard nail)|internal fixation
359818|NCT00691041|Behavioral|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
359819|NCT00691054|Drug|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
359820|NCT00693485|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
359821|NCT00693485|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
359822|NCT00693485|Drug|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
364173|NCT00644293|Drug|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
364174|NCT00644293|Drug|placebo|placebo
364175|NCT00644306|Drug|Thalidomide|100 mg/day continuously for 18 months
364176|NCT00644306|Drug|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
364177|NCT00644306|Drug|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
364178|NCT00644319|Drug|ibuprofen|
364179|NCT00644319|Drug|morphine sulfate|
364180|NCT00644319|Procedure|management of therapy complications|
364181|NCT00644319|Procedure|pleurodesis|
364182|NCT00004876|Drug|thalidomide|
364183|NCT00644332|Drug|Ranolazine|Oral dosage form.
364184|NCT00644358|Drug|vilazodone|titration to 40mg qd for 1 year
364185|NCT00644371|Drug|Ibritumomab Tiuxetan (Zevalin)|Conditioning Regimen
Rituximab, 250 mg/m2 on days -21 and -14.
Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.
Chemotherapy:
Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.
Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.
Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:
Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.
Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.
Melphalan 70 mg/m2/day on day -2 as a 15-min infusion.
364186|NCT00644384|Drug|acitretin|
364187|NCT00644384|Genetic|gene expression analysis|
364188|NCT00644384|Genetic|northern blotting|
364189|NCT00644384|Genetic|polymerase chain reaction|
364190|NCT00644384|Genetic|protein expression analysis|
364191|NCT00644384|Other|laboratory biomarker analysis|
364192|NCT00644397|Device|95-degree Angled Blade Plate|
364193|NCT00004877|Drug|BMS-214662|
364194|NCT00644397|Device|4.5mm Condylar Locking Plate|
363519|NCT00656552|Drug|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
363520|NCT00656578|Drug|4975|Single dose, solution
363521|NCT00656578|Drug|Placebo|Single dose, solution
363522|NCT00656591|Drug|Methotrexate|Methotrexate
363523|NCT00656604|Genetic|proteomic profiling|at the time of each procedure.
363524|NCT00656604|Procedure|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
363525|NCT00004929|Biological|QS21|
363526|NCT00656604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
363527|NCT00656604|Procedure|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
363841|NCT00649389|Drug|Olmesartan medoxomil|40mg olmesartan medoxomil
363842|NCT00649389|Drug|Amlodipine|Amlodipine 10mg
363843|NCT00649389|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
363844|NCT00649402|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
363845|NCT00649402|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
363846|NCT00649415|Drug|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
363847|NCT00649415|Drug|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
363848|NCT00004900|Drug|carboplatin|
363849|NCT00649428|Biological|Autologous Human Fibroblast (azficel-T)|Collection of 3 mm post auricular skin punch biopsies.
Three injection treatments administered 5 ± 1 weeks apart on each side of the face.
363850|NCT00649428|Biological|Placebo|Collection of 3 mm post auricular skin punch biopsies.
Three injection visits administered 5 ± 1 weeks apart on each side of the face.
363851|NCT00649441|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
363852|NCT00649441|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
363199|NCT00661830|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
363200|NCT00661830|Drug|Placebo|Placebo
363201|NCT00661830|Drug|Sorafenib|Sorafenib 400 mg bid orally continuously
363202|NCT00664040|Other|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
363203|NCT00664040|Other|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
363204|NCT00664040|Other|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
363205|NCT00664053|Dietary Supplement|DHEA|50mg daily for 6 months
363528|NCT00656604|Procedure|magnetic resonance spectroscopy|Prior to initiation of treatment
363529|NCT00656617|Drug|Idarubicin|12 mg/m^2 IV over 1 hour daily for 3 days (days 4 to 6)
363530|NCT00656617|Drug|Cytarabine|1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
363531|NCT00656617|Drug|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
363532|NCT00656630|Drug|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
363533|NCT00656630|Drug|Naltrexone|50mg capsule, Once daily, 1 week duration
363534|NCT00656630|Drug|Placebo|Matched placebo capsule, 1 week duration
363535|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
363536|NCT00004930|Drug|doxorubicin hydrochloride|
363537|NCT00656643|Drug|Placebo|Two subconjunctival injections of placebo.
363538|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
362877|NCT00668525|Drug|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
362878|NCT00668525|Drug|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
362879|NCT00000658|Drug|Doxorubicin hydrochloride|
362880|NCT00005065|Procedure|conventional surgery|Undergo complete surgical resection
362881|NCT00668525|Drug|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
362882|NCT00668538|Drug|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
362883|NCT00668564|Procedure|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
362884|NCT00668564|Drug|Cyclophosphamide|Days before Transplant Drug Frequency
4 Cyclophosphamide Once, given over 2 hours
3 Cyclophosphamide Once, given over 2 hours
2 Cyclophosphamide Once, given over 2 hours
1 Cyclophosphamide Once, given over 2 hours
362885|NCT00631917|Other|Placebo to Ramipril|Placebo capsules to match ramipril.
362886|NCT00631917|Other|Placebo to Aliskiren|Placebo tablets to match aliskiren.
362887|NCT00631943|Drug|Pregabalin (Lyrica)|Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
362888|NCT00004695|Drug|PEG-interleukin-2|
362889|NCT00631969|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
362890|NCT00631969|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
362891|NCT00631982|Procedure|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
362892|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
362893|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
362894|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
363206|NCT00664053|Behavioral|Yoga|2 sessions per week for 6 months
362221|NCT00643656|Drug|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
362222|NCT00643669|Drug|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
362223|NCT00643682|Other|Educational card|A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: "Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
362224|NCT00643695|Behavioral|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
362225|NCT00643695|Other|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
362549|NCT00636480|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
362550|NCT00636480|Drug|ChloraPrep One Step|Administer topically
362551|NCT00636480|Drug|Sterile saline|0.9% NaCl solution
362552|NCT00000638|Drug|Pyrazinamide|
362553|NCT00004778|Drug|betamethasone|
362554|NCT00636493|Device|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
362555|NCT00636506|Device|AMS IPP 2005|
362556|NCT00636519|Biological|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
362557|NCT00636519|Biological|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
362558|NCT00639015|Drug|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
362559|NCT00639028|Other|Ankle echography|Ankle echography
362560|NCT00004814|Drug|copolymer 1|
362561|NCT00639028|Other|Ankle echography + stress radiography|Ankle echography + stress radiography
362562|NCT00639028|Other|stress radiography|ankle stress radiography
362563|NCT00639041|Dietary Supplement|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
361893|NCT00651092|Procedure|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
361894|NCT00651105|Drug|Vildagliptin|
361895|NCT00651105|Drug|Placebo|
361896|NCT00651118|Drug|Placebo|placebo
361897|NCT00651118|Drug|azelastine Hcl|azelastine Hcl 548 mcg
361898|NCT00651118|Drug|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
361899|NCT00651118|Drug|fluticasone propionate|fluticasone propionate 200 mcg
361900|NCT00651131|Drug|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
361901|NCT00651144|Drug|Ezetimibe + Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
361902|NCT00651144|Drug|Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
361903|NCT00004904|Drug|tacrolimus|
361904|NCT00651144|Drug|Placebo|oral tablets; two ezetimibe placebo once daily for 14 days
361905|NCT00651144|Drug|Ezetimibe|oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
361906|NCT00651157|Biological|wild-type reovirus|Given IV: Administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
361907|NCT00651183|Drug|Pramipexole immediate release|
361908|NCT00651209|Drug|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
361909|NCT00651222|Other|No intervention was required|Death records were reviewed, therefore, there was no intervention
362226|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
362227|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
362228|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
362229|NCT00004871|Drug|sodium phenylbutyrate|
361584|NCT00005002|Drug|Nelfinavir mesylate|
361585|NCT00661024|Procedure|intraoperative RLN visualization|intraoperative RLN visualization
361586|NCT00661024|Procedure|intraoperative neuromonitoring of the RLN|IONM
361587|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
361588|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
361589|NCT00661050|Procedure|Alternative Medicine|
361910|NCT00651235|Drug|Losartan and Atenolol or Propranolol|50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.
Losartan is 100 mg/day for adult and 50 mg/day for children.
361911|NCT00653354|Drug|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
361912|NCT00653367|Procedure|Nerve section|Intercostal nerve is divided during surgery
361913|NCT00653380|Drug|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
361914|NCT00653380|Drug|Monodox|Capsules, 100 mg, single-dose
361915|NCT00653393|Drug|Tranylcypromine|Tablets, 10 mg, single-dose
361916|NCT00004912|Drug|megestrol acetate|
361917|NCT00653393|Drug|Parnate|Tablets, 10 mg, single-dose
361918|NCT00653406|Drug|Risperidone long acting injectable|
361919|NCT00653419|Drug|buspirone HCl|Tablets, 30 mg, single-dose
361920|NCT00653419|Drug|Buspar|Tablets, 30 mg, single-dose
361921|NCT00653432|Device|MONOVISC|Intra-articular injection
361922|NCT00653445|Drug|Rosuvastatin|40mg
361923|NCT00653445|Drug|Ezetimibe|10mg
361924|NCT00653458|Drug|Ondansetron|ODT, 8 mg, single-dose, fed conditions
361925|NCT00653458|Drug|Zofran|ODT, 8 mg, single-dose, under fed conditions
361926|NCT00653471|Device|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
366719|NCT00660517|Drug|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
366720|NCT00660517|Drug|placebo|placebo nasal spray one spray per nostril two times a day
366721|NCT00660530|Drug|Lanthanum carbonate|Lanthanum carbonate 1 g to be chewed, three times daily with meals
366722|NCT00660530|Drug|Lanthanum carbonate|Lanthanum carbonate 1 g crushed into a fine powder, three times daily with meal
366723|NCT00660543|Drug|Gadolinium|Given IV
366724|NCT00005000|Drug|Stavudine|
366725|NCT00660543|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
366726|NCT00660543|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
366727|NCT00660543|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
366728|NCT00660543|Procedure|Diffusion Weighted Imaging|Undergo DWI
366729|NCT00660543|Procedure|MRI-Based Angiogram|Undergo TOF MR angiography
366730|NCT00660582|Drug|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
366731|NCT00660582|Drug|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
366732|NCT00660595|Drug|Quetiapine|Oral administration
366733|NCT00660595|Drug|Risperidone|Oral administration
361590|NCT00661050|Procedure|Tai Chi instruction and class participation or walking exercise and sitting meditation|
361591|NCT00661063|Drug|ketamine|ketamine 150 mcg/g bid
361592|NCT00661063|Drug|vehicle gel|bid - 12 weeks
361593|NCT00661063|Drug|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
361594|NCT00661063|Drug|clonidine gel 1%|bid 12 weeks
361595|NCT00005005|Drug|PTH|
361596|NCT00661076|Drug|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
361597|NCT00661076|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
366386|NCT00667342|Drug|Ifosfamide|Given IV.
366387|NCT00667342|Drug|etoposide|Given IV.
366388|NCT00667342|Procedure|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
366389|NCT00667342|Radiation|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
366390|NCT00667355|Biological|adalimumab|40 mg or 80 mg every other week, subcutaneous
366391|NCT00667368|Drug|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
366392|NCT00667381|Device|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
366393|NCT00667394|Biological|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
366394|NCT00667394|Drug|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
366395|NCT00005054|Drug|temozolomide|
366396|NCT00667394|Procedure|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
366397|NCT00667407|Drug|Levalbuterol 1.25 mg|levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.
Period II: TID for 3 days (same time of day), then PRN to TID for 7 days
366398|NCT00667407|Drug|Racemic Albuterol Sulfate|Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.
Period II: TID for 3 days then PRN to TID for 7 days
366399|NCT00667420|Drug|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
366400|NCT00667433|Drug|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
366401|NCT00667446|Drug|Leuprolide Acetate 3 Month Depot|
366402|NCT00667459|Device|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
366403|NCT00667459|Device|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
366404|NCT00667472|Drug|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
366405|NCT00667472|Device|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
365723|NCT00640406|Device|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
365724|NCT00640406|Drug|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
365725|NCT00640419|Drug|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
365726|NCT00640419|Drug|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
365727|NCT00640432|Drug|Diclofenac|75 mg oral capsule twice daily for 7 days
365728|NCT00640432|Drug|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
365729|NCT00640445|Behavioral|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
365730|NCT00640445|Behavioral|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
365731|NCT00642616|Drug|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
365732|NCT00004864|Drug|GEM 231|
365733|NCT00642616|Drug|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
366057|NCT00635375|Device|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
366058|NCT00635375|Device|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
366059|NCT00635375|Device|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
366060|NCT00635375|Device|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
366061|NCT00635388|Other|Placebo|oral, placebo, once/day for 12 weeks
366062|NCT00635388|Other|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
366063|NCT00635388|Other|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
366064|NCT00004759|Drug|methylprednisolone|
365071|NCT00654836|Biological|bevacizumab|Bevacizumab 15mg/kg on Days 1,22, 43.
365383|NCT00647257|Drug|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
365384|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
365385|NCT00647270|Drug|Placebo|Pre-filled syringe. See arm for more detail
365386|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
365387|NCT00647283|Procedure|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
365388|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 12.5 mg twice daily for 12 weeks
365389|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 37.5 mg twice daily for 12 weeks
365390|NCT00004891|Procedure|positron emission tomography|
365391|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 75 mg twice daily for 12 weeks
365392|NCT00647296|Drug|Placebo|Placebo oral tablet (2 tabs twice daily) for 12 weeks
365393|NCT00647322|Other|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
365394|NCT00647322|Procedure|No drug change|No change in anti-epileptic treatment
365395|NCT00647348|Drug|Simvastatin|80mg simvastatin oral once daily for 24 months
365396|NCT00647348|Drug|Placebo|Oral placebo tablet once daily for 24 months
365397|NCT00647361|Device|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
365398|NCT00647374|Other|this is an observational study|
365399|NCT00647387|Device|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
365400|NCT00647400|Biological|adalimumab|Adalimumab 40 mg every other week, subcutaneous
365401|NCT00004891|Procedure|radionuclide imaging|
365402|NCT00647400|Biological|adalimumab|Adalimumab 80 mg every other week, subcutaneous
364746|NCT00004998|Drug|Lamivudine/Zidovudine|
364747|NCT00659854|Dietary Supplement|milk based formula|Babies will be given a milk based formula for 12 weeks
364748|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
364749|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
364750|NCT00659880|Other|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
364751|NCT00659893|Drug|PEP005 Topical gel|0.05%, two day dose
364752|NCT00662233|Procedure|neoadjuvant therapy|
364753|NCT00662233|Procedure|therapeutic conventional surgery|
364754|NCT00662233|Radiation|brachytherapy|
364755|NCT00662233|Radiation|intraoperative radiation therapy|
364756|NCT00662233|Radiation|radiation therapy|
364757|NCT00662246|Radiation|respiratory gated proton beam radiotherapy|- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
364758|NCT00662259|Drug|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
364759|NCT00662259|Drug|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
364760|NCT00005017|Drug|Efavirenz|
365072|NCT00654836|Drug|carboplatin|Carboplatin AUC 6 Day 1, 22, 43.
365073|NCT00654836|Drug|ABI-007l albumin-stabilized nanoparticle formulation|ABI-007 100mg/m2 Days 1,8, 15, 22, 29, 36,43,50.
365074|NCT00004919|Drug|cisplatin|Given IV
365075|NCT00654849|Procedure|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
365076|NCT00654849|Procedure|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
365077|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
364061|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for three months|period of treatment
364062|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for six months|period of therapy
364063|NCT00632567|Procedure|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
364420|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
364421|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
364422|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
364423|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
364424|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
364425|NCT00005050|Drug|ethynyluracil|
364426|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
364427|NCT00666809|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
364428|NCT00666809|Drug|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
364429|NCT00005068|Drug|irinotecan hydrochloride|
364430|NCT00669149|Drug|enoxaparin + clopidogrel + aspirin|
364431|NCT00669149|Drug|bivalirudin + clopidogrel + aspirin|
364432|NCT00669162|Drug|Docetaxel|20mg/m2 IV weekly for 7 weeks
364433|NCT00669162|Radiation|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
364434|NCT00669162|Drug|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
364435|NCT00669188|Behavioral|Administration of information|
364436|NCT00669214|Drug|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
363749|NCT00639652|Procedure|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
363750|NCT00639665|Other|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
363751|NCT00639678|Drug|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
363752|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
363753|NCT00639678|Drug|placebo|40 mg/kg placebo, single dose (day 0), Group 4
363754|NCT00004828|Drug|liothyronine I 131|
363755|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
363756|NCT00639691|Biological|omalizumab|sc
364064|NCT00632567|Procedure|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
364065|NCT00632580|Drug|intraarticular injection with ropivacaine|
364066|NCT00004727|Drug|ticlopidine|
364067|NCT00632580|Drug|extraarticular injection with ropivacaine|
364068|NCT00634777|Other|pet scan|pet scan
364069|NCT00634790|Drug|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
364070|NCT00634803|Behavioral|CBT|Cognitive behavioral therapy
364071|NCT00004755|Drug|allopurinol|
364072|NCT00634803|Drug|Buprenorphine|buprenorphine/naloxone
364073|NCT00634803|Other|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
364074|NCT00634803|Other|Physician Management|Brief physician counseling
364075|NCT00634816|Radiation|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
363418|NCT00646438|Drug|Strict Glycemic Control for one year post-op CABG|The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.
Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.
For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control.
363419|NCT00646451|Drug|pregabalin|75 mg bid to 300 mg bid based on per subject tolerability
363420|NCT00646451|Drug|placebo capsules|up to 4 capsules bid as tolerated
363421|NCT00646477|Device|titration night|Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:
in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.
in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events.
363422|NCT00004887|Drug|vinblastine sulfate|
363423|NCT00646503|Drug|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
363424|NCT00646516|Drug|budesonide/formoterol (Symbicort)|
363425|NCT00646529|Drug|budesonide/formoterol (Symbicort)|
363426|NCT00646529|Drug|budesonide (Pulmicort)|
363427|NCT00646542|Drug|Vildagliptin|
363428|NCT00646542|Drug|Placebo|
363429|NCT00646568|Drug|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
363430|NCT00646581|Drug|Placebo|Placebo
363431|NCT00646581|Drug|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
363432|NCT00646594|Drug|budesonide/formoterol (Symbicort)|
363757|NCT00639717|Procedure|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
359823|NCT00000677|Drug|SCH 39304|
359824|NCT00005762|Drug|Saquinavir|
359825|NCT00693498|Biological|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
359826|NCT00693498|Biological|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
359827|NCT00693511|Behavioral|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
359828|NCT00693511|Behavioral|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
359829|NCT00693511|Behavioral|Control|Control (delayed intervention
359830|NCT00693524|Drug|tacrolimus|oral
359831|NCT00693524|Drug|Anti-IL2R AB|i.v.
359832|NCT00693524|Drug|Mycophenolate mofetil|oral
359833|NCT00693524|Drug|prednisone|oral
359834|NCT00693537|Procedure|Coronary angiography|At baseline, 4 weeks, and 6 months changes in diameter of coronary arteries in response to intracoronary infusion of acetylcholine were analyzed by quantitative coronary angiography, mean peak flow velocity by Doppler velocimetry, and intramural plaques by intravascular ultrasound.
359835|NCT00005764|Drug|Lamivudine/Zidovudine|
359836|NCT00693537|Behavioral|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
359837|NCT00693550|Other|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
360147|NCT00676871|Drug|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
360148|NCT00676884|Drug|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
360149|NCT00676884|Drug|placebo|1.5 mL s.c. b.i.d.
360150|NCT00676897|Drug|Simvastatin|Simvastatin 40mg PO or NGT
360151|NCT00676897|Drug|Placebo|Corn Starch
360152|NCT00676910|Drug|JNJ-26854165|
364195|NCT00644410|Biological|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
364196|NCT00644410|Biological|Saline|12 injection with 0.2 ml saline
364522|NCT00637299|Other|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
364523|NCT00637299|Other|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
364524|NCT00639860|Device|OSSIX-Plus|resorbable collagen membrane
364525|NCT00639873|Drug|Artesunate|2 or 4 mg/kg/day for 7 days
364526|NCT00639873|Drug|quinine-doxycycline|quinine-doxycycline for 7 days
364527|NCT00639899|Procedure|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
364528|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
364529|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
364530|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
364531|NCT00004832|Drug|3,4-diaminopyridine|
364532|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
364533|NCT00639925|Biological|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
364534|NCT00639938|Drug|Nevirapine|200 mg Nevirapine tablet
364535|NCT00639938|Drug|HIV immune globulin solution|5% intravenous HIV immune globulin solution
364536|NCT00639951|Biological|A|20 vials up front in a Single Dose of Antivipmyn
364537|NCT00639951|Biological|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
364538|NCT00639964|Other|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
364539|NCT00639964|Other|diet questionnaire|questions about nutrition before and during pregnancy
363853|NCT00649454|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
363854|NCT00649454|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
363855|NCT00649467|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
363856|NCT00649467|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
363857|NCT00651768|Drug|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg & budesonide HFA pMDI 4 X 160mcg
363858|NCT00004905|Radiation|radiation therapy|
363859|NCT00651781|Drug|Bortezomib|2 times per week of Velcade administration.
363860|NCT00651794|Behavioral|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years our group has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork. Adding teamwork instruction to NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
363861|NCT00651807|Drug|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
364197|NCT00646724|Biological|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
364198|NCT00004888|Other|laboratory biomarker analysis|Correlative studies
364199|NCT00646737|Drug|Mycophenolate sodium|Mycophenolate sodium
364200|NCT00646750|Drug|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|Day -21: rituximab. 250 mg/m2 iv
Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).
Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1.
364201|NCT00646763|Drug|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
364202|NCT00646763|Drug|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
364203|NCT00646776|Drug|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
363539|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
363540|NCT00656656|Drug|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks
Rituximab: 1000 mg i.v. given twice at a 2-week interval
Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks
Azathioprine: 2.5 mg/kg body weight daily p.o.
363541|NCT00656669|Drug|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
363542|NCT00656669|Drug|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
363543|NCT00656669|Drug|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
363544|NCT00656682|Behavioral|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
363545|NCT00659126|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
363546|NCT00659126|Drug|Ferumoxytol|Given IV
363547|NCT00000651|Drug|Zidovudine|
363548|NCT00004985|Drug|Capravirine|
363549|NCT00659126|Drug|Gadolinium|Given IV
363550|NCT00659126|Procedure|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
363862|NCT00651807|Drug|Placebo|Every day one tablet up to 8 weeks
363863|NCT00651820|Drug|Collagenase Santyl|Dermatome-induced skin wounds treated with drug active.
Each subject serves as his own control receiving both treatments in parallel.
363864|NCT00651820|Drug|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
363865|NCT00651833|Drug|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
363866|NCT00651846|Drug|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
363207|NCT00664053|Dietary Supplement|Placebo|Placebo supplement every day for 6 months
363208|NCT00664053|Behavioral|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
363209|NCT00005028|Drug|bryostatin 1|
363210|NCT00664066|Drug|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
363211|NCT00664079|Other|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
363212|NCT00664092|Other|Residential|living in a democratic, resident-run setting
363213|NCT00664092|Other|Residential|Professionally-run substance abuse recovery setting
363214|NCT00664105|Drug|Carboplatin|Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.
Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment.
363215|NCT00664105|Drug|Docetaxel|Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.
Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks).
363216|NCT00664105|Radiation|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
363217|NCT00664118|Procedure|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
363218|NCT00664118|Procedure|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
363219|NCT00664131|Other|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
363220|NCT00000655|Drug|Sulfamethoxazole-Trimethoprim|
363221|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
363222|NCT00005047|Drug|doxorubicin hydrochloride|
363223|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
363224|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
362564|NCT00639041|Dietary Supplement|Placebo|dairy products without special oils
362565|NCT00639054|Procedure|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
362566|NCT00639054|Procedure|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
362567|NCT00639067|Device|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
362568|NCT00639080|Other|Stop lipid lowering therapy (statin)|Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
362569|NCT00639093|Behavioral|psychoeducational / motivational combined with crushing|All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).
During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer).
362895|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
362896|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
362897|NCT00631995|Dietary Supplement|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
362898|NCT00632008|Drug|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
362899|NCT00004696|Drug|morphine|
362900|NCT00632008|Drug|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
362901|NCT00632021|Behavioral|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
362902|NCT00632034|Other|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
362903|NCT00632047|Other|active surveillance|
362904|NCT00632047|Other|educational intervention|
362905|NCT00632047|Procedure|examination|
362906|NCT00632047|Procedure|long-term screening|
362230|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
362231|NCT00643721|Other|dehydration|dehydration to 3% and 5% loss of total body water
362232|NCT00645879|Drug|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
362233|NCT00645879|Drug|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
362234|NCT00645879|Drug|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
362235|NCT00645892|Drug|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
362236|NCT00645892|Drug|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
362237|NCT00004886|Drug|docetaxel|
362238|NCT00645905|Drug|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
362239|NCT00645905|Drug|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
362240|NCT00645918|Drug|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
362241|NCT00645918|Drug|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
362242|NCT00645918|Drug|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
362243|NCT00645931|Behavioral|protein and calorie controlled diet and self-hypnotic relaxation|daily
362244|NCT00645944|Drug|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
362245|NCT00645944|Drug|Placebo|Placebo or inactive substance ("sugar pill")taken each night for all weeks of the study
362246|NCT00645957|Procedure|penrose drain|incision and drainage of the infection with placement of a penrose drain
362570|NCT00639093|Behavioral|psychoeducational / motivational combined with control|All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).
During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer).
362571|NCT00004815|Drug|growth hormone|
361927|NCT00000647|Drug|Interferon alfa-n1|
361928|NCT00004912|Procedure|physical therapy|
361929|NCT00653471|Device|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
361930|NCT00653471|Device|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
361931|NCT00653484|Behavioral|Physical Activity|
361932|NCT00653484|Behavioral|Energy Restriction|
361933|NCT00653484|Behavioral|Physical Activity and Energy Restriction|
361934|NCT00653497|Behavioral|Aquatic exercise|Arthritis Foundation Aquatics Program
community-based aquatic exercise program
participants asked to attend 2 classes per week for 20 weeks
each class 45-60 minutes in duration
362247|NCT00645957|Procedure|red rubber drain|incision and drainage of infection and placement of a red rubber drain
362248|NCT00004886|Drug|dofequidar fumarate|
362249|NCT00645983|Dietary Supplement|Chamomile Extract|220 mg - 1100 mg daily
362250|NCT00645983|Other|Placebo|1 to 5 capsules daily
362251|NCT00645996|Dietary Supplement|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
362252|NCT00645996|Dietary Supplement|Cornflor|Cornflour 2 gram daily
362253|NCT00646009|Drug|budesonide/formoterol|
362254|NCT00646009|Drug|fluticasone/salmeterol|
362255|NCT00646009|Drug|albuterol|
362256|NCT00646035|Drug|paricalcitol capsules|baseline iPTH/60
362257|NCT00646048|Device|TriVascular Stent-Graft System|TriVascular Stent-Graft System
362258|NCT00646061|Drug|buscopan|
362259|NCT00648648|Drug|cisplatin|cisplatin - IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle. Dose Levels for cisplatin 75 mg/m^2, 60 mg/m^2, 50 mg/m^2
362260|NCT00648648|Drug|carboplatin|carboplatin - IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle. Dose levels for carboplatin: AUC 5, AUC 4, AUC 3
361598|NCT00661089|Drug|Botulinum Toxin Type A - OnabotulinuntoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
361599|NCT00661102|Drug|Corticosteroids|As prescribed
361600|NCT00661102|Drug|Placebo|As prescribed
361601|NCT00661102|Drug|capecitabine [Xeloda]|As prescribed
361602|NCT00661102|Drug|dexpantenol [Bepantol]|As prescribed
361603|NCT00661115|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
361604|NCT00661115|Drug|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
361605|NCT00661141|Drug|fomepizole;|Each subject will, in a blinded controlled manner, receive alternating study treatment (fomepizole or placebo) on 2 sequential days (Study Day 1 and Study Day 2). In addition, the study drug (fomepizole or placebo) will be administered in the 4 subjects in each cohort 30 minutes prior to ethanol, and in 4 subjects in each cohort 30 minutes after the ethanol.
361606|NCT00005005|Drug|Alendronate|
361607|NCT00661154|Drug|Bevacizumab|2-12microCi IV injection
361608|NCT00661167|Drug|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
361609|NCT00661180|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
361610|NCT00663351|Device|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
361935|NCT00653510|Drug|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
361936|NCT00653523|Drug|Ezetimibe|Ezetimibe 10 mg once daily
361937|NCT00653523|Drug|Simvastatin|Simvastatin 20 mg daily
361938|NCT00653536|Device|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
361939|NCT00004913|Drug|cisplatin|
366734|NCT00660621|Drug|Temozolomide and Bevacizumab|Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).
No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week.
366735|NCT00000652|Drug|Zidovudine|
366736|NCT00005000|Drug|Zidovudine|
366737|NCT00660634|Procedure|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
366738|NCT00660647|Drug|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
366739|NCT00005022|Drug|cisplatin|
366740|NCT00662896|Drug|naproxen 500 mg bid|naproxen 500 mg bid
366741|NCT00662896|Drug|ibuprofen 600 mg tid|ibuprofen 600 mg tid
366742|NCT00662909|Drug|Mirabegron|Oral
366743|NCT00662909|Drug|Placebo|Oral
366744|NCT00662935|Procedure|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
366745|NCT00662948|Drug|Rituximab|375 mg/m2 every 8 weeks during 24 months
366746|NCT00662948|Drug|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
366747|NCT00662961|Procedure|Periosteum|Periosteum fixation
366748|NCT00662961|Procedure|Bone|Bone tunnel fixation
366749|NCT00662974|Other|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
366750|NCT00005022|Drug|etoposide|
366751|NCT00662974|Other|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
366752|NCT00662987|Drug|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
366753|NCT00662987|Drug|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
366065|NCT00635401|Drug|Varenicline|0.5 mg BID for 7 weeks
366066|NCT00635414|Drug|Esomeprazole|40mg oral
366067|NCT00635414|Drug|Esomeprazole|15 minute intravenous infusion
366068|NCT00635427|Biological|VPRIV®|Intravenous infusion, every other week (EOW)
366069|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
366070|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
366071|NCT00635453|Behavioral|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
366072|NCT00635466|Procedure|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (<8 cm).
366073|NCT00635479|Device|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
366074|NCT00635479|Other|Gauze dressing|Gauze dressing for surgical incision
366075|NCT00637806|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
366406|NCT00005055|Drug|glufosfamide|
366407|NCT00667485|Drug|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
366408|NCT00669877|Drug|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
366409|NCT00005075|Procedure|high-intensity focused ultrasound ablation|
366410|NCT00669877|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
366411|NCT00669877|Drug|G-CSF|10 mcg/kg
365403|NCT00649961|Drug|Melatonin injection|A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.
Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr.
365404|NCT00649974|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
365734|NCT00642629|Drug|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
365735|NCT00642629|Drug|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
365736|NCT00642642|Biological|Autologous Human Fibroblasts (azficel-T)|Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart.
365737|NCT00642642|Biological|Placebo|Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart.
365738|NCT00642655|Drug|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
365739|NCT00642668|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|1.2 micrograms/kg sc monthly (initial recommended dose)
365740|NCT00642681|Drug|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
365741|NCT00642694|Drug|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
365742|NCT00642694|Drug|Ramelteon|Ramelteon 8 mg qd
365743|NCT00004864|Drug|docetaxel|
365744|NCT00642694|Other|Placebo|Matching placebo qd
365745|NCT00642707|Drug|PRO 140 (humanized monoclonal antibody to CCR5)|
365746|NCT00642707|Drug|Placebo Comparator|
365747|NCT00642720|Drug|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
365748|NCT00642733|Drug|erlotinib [Tarceva]|100mg po daily
365749|NCT00642733|Drug|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
365750|NCT00642746|Drug|Erlotinib|Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.
Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage.
365078|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
365079|NCT00654875|Drug|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
365080|NCT00654875|Drug|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
365081|NCT00654888|Procedure|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
365082|NCT00654888|Drug|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
365083|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
365084|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
365085|NCT00000647|Procedure|Bone marrow transplant|
365086|NCT00004919|Drug|irinotecan hydrochloride|Given IV
365087|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
365088|NCT00654901|Biological|Infanrix Hexa™|0.5 mL, Intramuscular
365089|NCT00657189|Drug|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
365090|NCT00657189|Drug|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
365091|NCT00657189|Drug|MEDI-545|100 mg every week × 13 doses
365092|NCT00657189|Drug|Placebo|SC Placebo every week × 13 doses
365093|NCT00657202|Drug|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
365094|NCT00657228|Drug|Intravenous heparin|Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.
To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone.
365405|NCT00649974|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
365406|NCT00649987|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
365407|NCT00649987|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
365408|NCT00650000|Drug|Modafinil Tablets 200 mg|200mg, single dose fasting
364437|NCT00669214|Drug|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
364438|NCT00669227|Other|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
364439|NCT00669227|Other|placebo suspension|intracoronary administration at the same day as cell aspiration
364440|NCT00005068|Drug|leucovorin calcium|
364761|NCT00662272|Biological|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
364762|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
364763|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
364764|NCT00662285|Dietary Supplement|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
364765|NCT00662298|Drug|prednisolone|40mg of prednisolone once a day for 14 days
364766|NCT00662311|Drug|vorinostat|Given PO
364767|NCT00662311|Drug|paclitaxel|Given IV
364768|NCT00662311|Radiation|radiation therapy|Undergo radiation therapy
364769|NCT00662324|Behavioral|focus groups|Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.
During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.
The focus group to last from 60 to 90 minutes.
364770|NCT00662324|Behavioral|focus groups|Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.
During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.
We expect the focus group to last from 60 to 90 minutes.
364771|NCT00005017|Drug|Lamivudine|
364772|NCT00662324|Behavioral|focus groups|MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.
During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.
Expect the focus group to last from 60 to 90 minutes.
364076|NCT00634829|Drug|albuterol (Armstrong Albuterol HFA)|2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
364077|NCT00634829|Drug|Albuterol Sulfate (Provenetil-HFA)|2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
364078|NCT00634829|Drug|Placebo-HFA|Placebo containing HFA propellant without active drug substance
364079|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
364080|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
364081|NCT00634868|Other|Qray light therapy device|The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
364082|NCT00004755|Drug|glucantime|
364083|NCT00634868|Device|Qray light therapy device-Sham|non curative light- the device emits the same broad light, but with very low intensity
364084|NCT00634881|Biological|alemtuzumab|
364085|NCT00634881|Genetic|polymerase chain reaction|
364441|NCT00669240|Drug|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
364442|NCT00669253|Procedure|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
364443|NCT00669253|Procedure|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
364444|NCT00669253|Procedure|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
364445|NCT00669279|Drug|Carvedilol CR|Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
364446|NCT00669279|Drug|Atenolol|Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
364447|NCT00669292|Biological|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
364448|NCT00669318|Biological|alemtuzumab|
364449|NCT00669318|Biological|rituximab|
363758|NCT00641849|Behavioral|Email reminders|The subjects will be randomly assigned to either the minimum or maximum treatment group. Both groups will be sent an email reminder 7 days prior to their "follow-up" date. They will then be sent an email reminder 24 hours prior to their "follow-up" date. Subjects will receive an email reminder every 48 hours until 336 hours (14 days) post visit date. Reminder emails will also state that those subjects not completing their "follow-up" visit within the visit window will be withdrawn from the study. Subjects will be not be blinded as to how frequently they will be required to make "follow-up" visits to the site.
363759|NCT00641862|Dietary Supplement|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
363760|NCT00641862|Other|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
363761|NCT00004859|Radiation|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
363762|NCT00641875|Procedure|Nocturnal Hemodialysis|
363763|NCT00641901|Behavioral|counseling|The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.
Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.
First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires.
363764|NCT00641914|Drug|budesonide|
363765|NCT00641914|Drug|Placebo|
363766|NCT00641927|Drug|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
363767|NCT00641927|Drug|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
363768|NCT00641940|Behavioral|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
363769|NCT00641940|Behavioral|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
363770|NCT00641953|Drug|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
363771|NCT00641953|Drug|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
363772|NCT00004860|Drug|leucovorin calcium|
363773|NCT00641953|Drug|Placebo|0.5 g topically BID to each foot for 4 weeks
363774|NCT00641979|Drug|budesonide|Current product
360153|NCT00005578|Biological|bleomycin sulfate|
360154|NCT00679302|Drug|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
360155|NCT00679302|Drug|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
360156|NCT00679315|Drug|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
360157|NCT00679315|Drug|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
360158|NCT00679328|Device|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
360159|NCT00679341|Drug|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
360160|NCT00679341|Drug|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
360161|NCT00679341|Drug|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
360162|NCT00679354|Drug|cilengitide|Given IV
360163|NCT00679354|Other|laboratory biomarker analysis|Correlative studies
360164|NCT00005585|Drug|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
360165|NCT00679354|Other|pharmacological study|Correlative studies
360448|NCT00686686|Biological|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
360449|NCT00686699|Drug|Preladenant|one 25 mg capsule twice daily for 14 days
360450|NCT00686699|Drug|Placebo|one 25 mg matching capsule twice daily for 14 days
360451|NCT00689104|Drug|Tolterodine|Capsules
364540|NCT00639964|Other|umbilical cord blood collect|collected at the delivery
364541|NCT00639964|Other|placenta collect|collected at the delivery
364542|NCT00004833|Drug|Immune globulin|
364543|NCT00639977|Other|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
364867|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for patients in this group
364868|NCT00632827|Drug|REGIMEN|Induction chemotherapy
364869|NCT00632827|Drug|REGIMEN B|Induction Chemotherapy
364870|NCT00632840|Drug|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
364871|NCT00632853|Radiation|Standard Radiation Dose Therapy|45 Gy
364872|NCT00632853|Drug|cisplatin|IV
364873|NCT00632853|Drug|etoposide|IV
364874|NCT00632853|Radiation|High Radiation Dose Therapy|70 Gy
364875|NCT00004730|Drug|magnesium sulfate|
364876|NCT00632853|Drug|carboplatin|IV
364877|NCT00632866|Drug|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
364878|NCT00632866|Drug|Placebo|Placebo : 2cp/ day since 24 weeks
364879|NCT00634959|Drug|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
364880|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
364881|NCT00004757|Drug|acyclovir|
364882|NCT00634959|Other|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
364883|NCT00634972|Drug|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
364884|NCT00634972|Drug|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
364204|NCT00646776|Drug|Rifabutin + Atazanavir + Ritonavir|Capsules, Oral, 18 Days
Rifabutin (150 mg, 2x/wk)
Atazanavir (300 mg, once daily)
Ritonavir (100 mg, once daily)
364205|NCT00646789|Drug|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
364206|NCT00646802|Drug|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
364207|NCT00646802|Drug|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
364208|NCT00646815|Drug|growth hormone (genotropin)|Dosage regulation will follow the local recommendations of GHD treatment
364209|NCT00004889|Biological|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
364210|NCT00646841|Drug|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
364211|NCT00646854|Drug|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
364212|NCT00646854|Drug|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
364213|NCT00646867|Device|Tetrix|Twice daily topical application
364214|NCT00646867|Device|Placebo|Twice daily topical application
364544|NCT00639977|Other|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
364545|NCT00639990|Other|PEEP|Application of positive end expiratory pressure
364546|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
364547|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
364548|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
364549|NCT00640003|Drug|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
364550|NCT00642187|Drug|Placebo|
364551|NCT00642200|Procedure|Lichtenstein hernioplasty|
363867|NCT00651846|Drug|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
363868|NCT00651859|Drug|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
363869|NCT00004906|Biological|filgrastim|
363870|NCT00651859|Drug|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
363871|NCT00651859|Drug|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
363872|NCT00651885|Drug|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
363873|NCT00651885|Drug|Placebo|Placebo
363874|NCT00651911|Drug|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
363875|NCT00651924|Behavioral|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
363876|NCT00654277|Drug|Zofran|ODT, 8 mg, fasting conditions
363877|NCT00004916|Procedure|peripheral blood stem cell transplantation|
363878|NCT00654290|Drug|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
363879|NCT00654290|Drug|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
363880|NCT00654290|Drug|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
364215|NCT00646880|Drug|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
364216|NCT00646880|Drug|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
364217|NCT00649480|Drug|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
364218|NCT00649480|Drug|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
364219|NCT00004900|Drug|cisplatin|
363225|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
363551|NCT00659126|Procedure|Susceptibility Weighted Imaging|Undergo SWI
363552|NCT00659165|Drug|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
363553|NCT00659165|Drug|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
363554|NCT00659178|Drug|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
363555|NCT00659191|Drug|GSK1265744|
363556|NCT00659204|Drug|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
363557|NCT00659204|Drug|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
363558|NCT00659217|Biological|mesenchymal stem cell|Autologous MSC transplantation
363559|NCT00004985|Drug|Nelfinavir mesylate|
363560|NCT00659230|Drug|Nepicastat|100-800mg
363561|NCT00659230|Drug|Placebo|100-800mg placebo
363562|NCT00659243|Drug|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
363563|NCT00659243|Drug|Placebo|One week treatment
363564|NCT00659269|Dietary Supplement|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
363565|NCT00659269|Dietary Supplement|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
363566|NCT00659269|Drug|Chemotherapy|Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)
Ranges of cumulative doses (in mg/m2) are:
paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800
363567|NCT00659282|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
363568|NCT00659295|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
362907|NCT00632060|Procedure|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
362908|NCT00632073|Drug|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
362909|NCT00632086|Drug|PA32540|
362910|NCT00634309|Drug|Candesartan|
362911|NCT00004747|Drug|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
362912|NCT00634309|Drug|Placebo|
362913|NCT00634322|Drug|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
362914|NCT00634322|Drug|leucovorin|IV or po given every 6 hours
362915|NCT00634348|Drug|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
363226|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
363227|NCT00666367|Drug|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
363228|NCT00666367|Drug|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
363229|NCT00666380|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
363230|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
363231|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
363232|NCT00666406|Drug|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
363233|NCT00005047|Drug|methotrexate|
363234|NCT00666406|Drug|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
363235|NCT00666419|Other|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
363236|NCT00666432|Other|This is an observational study model that is family based|This is an observational study model that is family based
362572|NCT00639106|Procedure|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
362573|NCT00639106|Procedure|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
362574|NCT00639119|Drug|Ropinirole|8 + 8 weeks cross-over placebo controlled
362575|NCT00639158|Drug|ABT-335|135 mg capsule, daily, 12 weeks
362576|NCT00639158|Drug|placebo|placebo capsule, daily, 12 weeks
362577|NCT00639158|Drug|atorvastatin|40 mg, tablet, daily, 12 weeks
362578|NCT00639158|Drug|ezetimibe|10 mg capsule, daily, 12 weeks
362579|NCT00639184|Other|Early intervention counseling|Bi-monthly home visits by counselor
362580|NCT00639184|Other|Health education counseling|World Health Education health education counseling program at home visits,twice per month
362581|NCT00639197|Procedure|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
362582|NCT00004816|Drug|monoclonal antibody M-T412|
362583|NCT00004856|Biological|trastuzumab|Given IV
362584|NCT00641407|Drug|Insulin glargine|10 IU bedtime and then titration
362585|NCT00641420|Procedure|Fractionated Laser Resurfacing|
362586|NCT00641433|Device|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
362587|NCT00641433|Drug|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
362588|NCT00641446|Drug|budesonide|
362589|NCT00641446|Drug|varicella zoster virus|
362590|NCT00641459|Other|Observational BPSD treatment study|Observational BPSD treatment study
362591|NCT00641472|Drug|Budesonide inhalation suspension|0.5mg
362592|NCT00641472|Drug|Montelukast Sodium|4mg or 5mg
362261|NCT00648648|Drug|MK1775|Part 2-A: consists of three treatment arms, each combining a single starting dose of MK1775, 100 mg in a 21-28 day cycle. Dose Levels for MK1775: 50 mg, 100 mg, 200 mg, 325 mg, 475 mg, 675 mg, 900 mg, 1200 mg, 1600 mg (undetermined interim doses are allowed)
362262|NCT00648648|Drug|MK1775|Part 2-B: consists of three treatment arms, each combining a starting dose of MK1775, 50 mg (for gemcitabine) in a 28 day cycle. Dose Levels for MK1775: 25 mg, 50 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 325 mg, 425 mg (undetermined interim doses are allowed)
362263|NCT00004898|Biological|filgrastim|
362264|NCT00648648|Drug|MK1775|Part 3: consists of treatment with MTD of MK1775 from Part 2-B.
362265|NCT00648648|Drug|gemcitabine|gemcitabine - IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle.
362266|NCT00648648|Drug|cisplatin|cisplatin - IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle.
362267|NCT00648648|Drug|carboplatin|carboplatin - IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle.
362268|NCT00648661|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
362269|NCT00648661|Drug|Lexapro® Tablets 20 mg|20mg, single dose fed
362593|NCT00641498|Behavioral|Psychotherapy|Individual supportive
362594|NCT00004857|Biological|alemtuzumab|30 mg subQ injection tiw for 6 weeks
362595|NCT00641511|Drug|SYN117 (nepicastat)|120 mg per day
362596|NCT00641511|Drug|Placebo comparator|once per day placebo capsules
362597|NCT00641524|Procedure|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
362598|NCT00641537|Drug|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
362599|NCT00641537|Drug|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
362600|NCT00641537|Drug|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
361940|NCT00653549|Drug|Torsemide|Tablets, 20 mg, single-dose
361941|NCT00655902|Dietary Supplement|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
361942|NCT00655915|Other|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
361943|NCT00655928|Drug|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
361944|NCT00655928|Drug|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
361945|NCT00655941|Behavioral|Dietary instruction|Weekly instruction by dieticians
361946|NCT00655941|Other|Exercise|Supervised exercise in groups
361947|NCT00655954|Procedure|sputum, blood, condensate|
361948|NCT00655967|Drug|Acamprosate (Campral)|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above).
361949|NCT00004924|Drug|irinotecan hydrochloride|
361950|NCT00655967|Drug|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
361951|NCT00655980|Drug|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
361952|NCT00655993|Drug|simvastatin|40 mg po daily
361953|NCT00656006|Drug|Albuferon|
361954|NCT00656006|Drug|Ribavirin|
362270|NCT00648674|Device|Apligraf|Applied at Day 0, possible re-application at Week 6
362271|NCT00648687|Behavioral|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
362272|NCT00648700|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
366754|NCT00663013|Other|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
361611|NCT00663364|Drug|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
361612|NCT00663377|Drug|losartan|losartan 50-100mg for 16 weeks
361613|NCT00663390|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
361614|NCT00663403|Drug|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
361615|NCT00663416|Drug|NTx™-265: rhCG, then rEPO|rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then
rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
361616|NCT00663416|Drug|Saline placebo|Saline SC, on Day 1, 3, and 5 of study participation, then
Saline IV, on Day 7, 8, and 9 of study participation
361617|NCT00663429|Drug|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
361618|NCT00005024|Drug|doxorubicin hydrochloride|
361619|NCT00663442|Drug|OROS methylphenidate|18, 36, 54 mg
361620|NCT00663455|Drug|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
361621|NCT00663481|Drug|CoFactor|
361622|NCT00663481|Drug|Leucovorin|
361623|NCT00663533|Device|Vas-X|mechanical vasectomy device
361624|NCT00663559|Drug|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
361625|NCT00663585|Behavioral|Vipassana Meditation|12 day retreat where participants learn to meditate
361626|NCT00663598|Drug|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
361627|NCT00663611|Drug|Norditropin|A polypeptide hormone of recombinant DNA origin.
361628|NCT00663611|Drug|Placebo|
361629|NCT00005024|Drug|granisetron hydrochloride|
366412|NCT00669877|Drug|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
366413|NCT00669877|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
366414|NCT00669890|Drug|Gemtuzumab Ozogamicin|Dose Escalation
366415|NCT00669890|Drug|Busulfan|Conditioning Regimen
366416|NCT00669890|Drug|Cyclophosphamide|Conditioning Regimen
366417|NCT00669890|Drug|Thymoglobulin|(Unrelated Donors only)
366418|NCT00669890|Drug|Tacrolimus|GVHD Prophylaxis
366419|NCT00669890|Drug|Mycophenolate Mofetil|GVHD Prophylaxis
366420|NCT00000658|Drug|Allopurinol|
366421|NCT00005076|Biological|cetuximab|
366422|NCT00669890|Drug|Methotrexate|GVHD Prophylaxis
366423|NCT00669903|Drug|AZD0328|
366424|NCT00669903|Drug|Placebo|
366425|NCT00669916|Biological|AIN457|single infusion of 3 mg/kg
366426|NCT00669916|Drug|Placebo|single infusion of placebo
366427|NCT00669942|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
366428|NCT00669942|Drug|Placebo|Placebo to AIN457
366429|NCT00669955|Drug|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
366430|NCT00669955|Drug|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
366755|NCT00663026|Drug|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
366756|NCT00663026|Drug|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
366757|NCT00663026|Drug|placebo|Placebo subcutaneous injection once per week for 6 months
365751|NCT00642746|Drug|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
365752|NCT00642746|Drug|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
365753|NCT00642746|Drug|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
365754|NCT00004865|Biological|cetuximab|
365755|NCT00642746|Drug|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
366076|NCT00637806|Drug|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
366077|NCT00637806|Drug|Placebo|Placebo oral suspension, 5 mL once daily
366078|NCT00637819|Drug|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
366079|NCT00637832|Biological|rituximab|
366080|NCT00637832|Drug|cyclophosphamide|
366081|NCT00004799|Biological|diphtheria-tetanus vaccine|
366082|NCT00637832|Drug|doxorubicin hydrochloride|
366083|NCT00637832|Drug|prednisolone|
366084|NCT00637832|Drug|vincristine sulfate|
366085|NCT00637832|Radiation|yttrium Y 90 ibritumomab tiuxetan|
366086|NCT00637845|Drug|Esomeprazole Magnesium|40mg once daily
366087|NCT00637845|Drug|Lansoprazole|30mg twice daily
366088|NCT00637858|Dietary Supplement|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
366089|NCT00637858|Dietary Supplement|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
366090|NCT00637858|Dietary Supplement|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
366091|NCT00637858|Dietary Supplement|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
365409|NCT00650000|Drug|Provigil® Tablets 200 mg|200mg, single dose fasting
365410|NCT00650013|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
365411|NCT00004901|Drug|hydroxyurea|
365412|NCT00650013|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
365413|NCT00650026|Biological|adalimumab|40 mg adalimumab every other week
365414|NCT00650039|Drug|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
365415|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
365416|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
365417|NCT00650052|Drug|Zonisamide Capsules 100 mg|100mg, single dose fasting
365418|NCT00650052|Drug|Zonegran® Capsules 100 mg|100mg, single dose fasting
365419|NCT00650065|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
365420|NCT00650065|Drug|Zyrtec® Tablets 10 mg|10mg, single dose fasting
365421|NCT00650078|Drug|MR prednisone|1 x 5 mg daily
365422|NCT00004901|Radiation|radiation therapy|
365423|NCT00650078|Drug|Placebo|1x daily
365424|NCT00650091|Drug|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
365425|NCT00650091|Drug|Placebo|Participants will receive placebo each day.
365426|NCT00650104|Drug|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
365427|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
365756|NCT00644878|Drug|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
364773|NCT00662337|Drug|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
364774|NCT00664508|Procedure|Motion analysis|Motion analysis
364775|NCT00664521|Biological|Rituximab|Rituximab 1000 mg IV infusion, 2nd 1000 mg IV infusion given 2 weeks later, followed 28 days later by atacicept/placebo 150 mg/mL SC once weekly for 25 weeks
364776|NCT00664521|Biological|Atacicept / placebo|Atacicept/placebo 150 mg/mL SC once weekly for 25 weeks, given in combination with rituximab 1000 mg IV infusion on study day 10, 2nd 1000 mg IV infusion given 2 weeks later
364777|NCT00664534|Drug|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
364778|NCT00005033|Biological|trastuzumab|
365095|NCT00657228|Drug|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
365096|NCT00657241|Drug|carvedilol|Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).
365097|NCT00657241|Drug|valsartan|Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)
365098|NCT00004934|Drug|carboplatin|
365099|NCT00657254|Drug|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
365100|NCT00657267|Drug|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
365101|NCT00657280|Drug|Sitagliptin|No one is blinded to the treatments.
365102|NCT00657293|Behavioral|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
365103|NCT00657293|Behavioral|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
365104|NCT00657306|Drug|hydrocortisone|50 mg/6 h per day
365105|NCT00657306|Drug|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
364450|NCT00669318|Drug|pentostatin|
364451|NCT00005068|Drug|oxaliplatin|
364452|NCT00669318|Drug|sargramostim|
364453|NCT00669331|Drug|Inhaled mannitol|400mg BD for 52 weeks
364454|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
364455|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
364456|NCT00632606|Drug|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
364457|NCT00632606|Drug|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
364458|NCT00632619|Behavioral|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
364459|NCT00632619|Drug|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
364460|NCT00632619|Behavioral|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
364779|NCT00664534|Drug|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
364780|NCT00664547|Behavioral|Diet Weight Loss|
364781|NCT00664547|Behavioral|Exercise Weight Loss|
364782|NCT00664547|Behavioral|Exercise Without Weight Loss|
364783|NCT00664560|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
364784|NCT00664560|Drug|celebrex|200 mg celecoxib qd
364785|NCT00664560|Drug|Placebo|sugar pill bid
364786|NCT00664560|Drug|Rescue Antacid|Antacid Tablets
364787|NCT00664573|Biological|Baminercept alfa (BG9924)|dosage administered as per Biogen-Idec protocol
364788|NCT00664586|Drug|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
363775|NCT00641979|Device|Budesonide|New type device
364086|NCT00634881|Other|flow cytometry|
364087|NCT00634881|Other|laboratory biomarker analysis|
364088|NCT00634881|Other|pharmacological study|
364089|NCT00634894|Drug|Femara|2.5 mg by mouth daily x 12 weeks
364090|NCT00634894|Drug|Placebo|Placebo capsule by mouth daily x 12 weeks
364091|NCT00634907|Genetic|Pharmacogenetic-based warfarin dosing|Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which will be used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin will be compared between this group and the group in which warfarin doses are determined per usual care.
NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin is not specific to this study, nor is the duration of prophylaxis, however, warfarin dosing will be influenced by the study arm as noted above.
364092|NCT00636961|Drug|Indacaterol 300μg|300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
364093|NCT00636961|Drug|Placebo|Matching placebo devices and hard gelatin capsules
364094|NCT00636974|Procedure|Combined spinal epidural anaesthesia|
364095|NCT00636987|Device|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
364096|NCT00637000|Drug|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
364097|NCT00637000|Drug|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
364098|NCT00637000|Drug|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
364099|NCT00637013|Procedure|Acromioplasty|Arthroscopic or open acromioplasty
364100|NCT00637013|Procedure|Physiotherapy|Physiotherapy according to a standardized protocol
364101|NCT00637026|Drug|Gefitinib|Iressa
364102|NCT00004785|Drug|methylprednisolone|
364103|NCT00637039|Drug|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
360452|NCT00689104|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
360453|NCT00689104|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
360454|NCT00689117|Drug|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
360455|NCT00689117|Drug|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
360456|NCT00689117|Drug|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
360457|NCT00689117|Drug|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
360458|NCT00005639|Drug|azacitidine|
360459|NCT00689143|Drug|sargramostim|
360460|NCT00689156|Drug|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
360461|NCT00689156|Drug|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
360462|NCT00689169|Drug|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
360463|NCT00689169|Procedure|ASCT|ASCT : D0
360464|NCT00689169|Drug|Rituximab|Rituximab 250 mg/m² :D-21 D-14
360465|NCT00689182|Procedure|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
360466|NCT00689195|Dietary Supplement|Curcumin powder|oral capsules containing the investigational agent
360467|NCT00689195|Dietary Supplement|Ashwagandha extract|4.5% extract of ashwagandha
360468|NCT00689208|Drug|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
360469|NCT00005639|Drug|sodium phenylbutyrate|
360470|NCT00689208|Drug|Physostigmine|0,12ug/kg/min
360471|NCT00689208|Drug|Placebo Sodium|
364885|NCT00634972|Drug|placebo|
364886|NCT00634985|Drug|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet >2 hours from first dose if migraine reoccurred within 24 hours of achieving response
364887|NCT00634998|Dietary Supplement|Vitamin C|1000mg Vitamin C capsules orally twice daily
364888|NCT00634998|Dietary Supplement|Placebo|1000mg Placebo capsules orally twice daily for 90 days
364889|NCT00635011|Behavioral|psychotherapy|Cognitive Behavioral therapy
364890|NCT00635024|Biological|anti-thymocyte globulin|2.5 mg/kg
364891|NCT00635024|Drug|melphalan|16 mg/m^2
365199|NCT00667004|Drug|placebo|sterile ophthalmic solution
365200|NCT00005051|Drug|cisplatin|
365201|NCT00667017|Biological|RFT5-dgA immunotoxin|
365202|NCT00667017|Other|fluorescence activated cell sorting|
365203|NCT00667017|Other|immunohistochemistry staining method|
365204|NCT00667030|Behavioral|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
365205|NCT00667043|Drug|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
365206|NCT00667043|Drug|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
365207|NCT00667056|Drug|tacrolimus ointment|topical
365208|NCT00667056|Drug|placebo ointment|topical
365209|NCT00667069|Drug|triptorelin|
365210|NCT00667069|Procedure|adjuvant therapy|
365211|NCT00005051|Drug|paclitaxel|
365212|NCT00669513|Behavioral|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
364552|NCT00642200|Procedure|Laparoscopic TEP|
364553|NCT00642226|Procedure|Grid Laser|ETDRS Grid Laser
364554|NCT00642226|Procedure|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
364555|NCT00642239|Drug|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
364556|NCT00642239|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
364557|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
364558|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
364559|NCT00642265|Procedure|osteosynthesis|operative treatment
364560|NCT00000640|Drug|Sulfamethoxazole-Trimethoprim|
364561|NCT00004862|Biological|filgrastim|
364562|NCT00642265|Other|sling|conservative treatment
364563|NCT00642278|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
364564|NCT00642278|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
364565|NCT00642278|Drug|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
364892|NCT00004758|Drug|carbamazepine|
364893|NCT00635037|Drug|bupivacaine and acupuncture|trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.
acupuncture twice a week
364894|NCT00635050|Drug|Doxil, Paclitaxel, Cyclophosphamide, Avastin|Regimen A: Sequential Doxil 25 mg/m2 every 2 weeks for 3 doses will be followed by paclitaxel 175 mg/m2 i.v. every 2 weeks for 3 doses, then by cyclophosphamide 600 mg/M 2 i.v. every 2 weeks for 3 doses. Avastin 10 mg/kg i.v. every 2 weeks will be given concurrently with all 3 agents. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin at the same dose equivalent beginning 6-8 weeks after definitive operation.
Regimen B: Sequential Doxil 30 mg/m2 every 2 weeks for 3 doses will be followed by paclitaxel 175 mg/m2 i.v. every 2 weeks for 3 doses, then by cyclophosphamide 600 mg/m 2 i.v. every 2 weeks for 3 doses. Avastin 10 mg/kg i.v. every 2 weeks will be given concurrently with all 3 agents. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin at the same dose equivalent beginning 6-8 weeks after definitive operation.
364895|NCT00635063|Drug|AD 923|
364220|NCT00649493|Drug|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
364221|NCT00649493|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
364222|NCT00649506|Drug|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
364223|NCT00649506|Drug|Macrodantin® 100 mg Capsules|100mg, single dose fed
364224|NCT00649519|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
364225|NCT00649519|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
364226|NCT00649532|Drug|Ondansetron Tablets 24 mg|24mg, single dose fasting
364227|NCT00649532|Drug|Zofran® Tablets 24 mg|24mg, single dose fasting
364228|NCT00649545|Biological|adalimumab|40 mg every other week
364229|NCT00649558|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
364230|NCT00004900|Drug|cyclophosphamide|
364231|NCT00649558|Drug|Actos® Tablets 45 mg|45mg, single dose fasting
364232|NCT00649571|Drug|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
364233|NCT00649571|Drug|Adoxa Tablets 100 mg|100mg, single dose fasting
364234|NCT00649584|Drug|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
364235|NCT00649584|Drug|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
364236|NCT00649597|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
364237|NCT00649597|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
364238|NCT00649610|Drug|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
364566|NCT00642291|Drug|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
364567|NCT00642291|Drug|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
364568|NCT00642304|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
363569|NCT00659308|Procedure|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
363570|NCT00004986|Drug|Nitazoxanide|
363571|NCT00661843|Other|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
363881|NCT00654303|Drug|Rosuvastatin|
363882|NCT00654316|Biological|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
363883|NCT00654329|Drug|Saline|Normal saline, given intranasally
363884|NCT00654329|Drug|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
363885|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
363886|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
363887|NCT00654342|Procedure|Intraoperative injection (in vivo)|Intraoperative injection
363888|NCT00004917|Biological|epoetin alfa|
363889|NCT00654342|Procedure|Postoperative injection (ex vivo)|postoperative injection
363890|NCT00654355|Drug|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
363891|NCT00654368|Biological|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
363892|NCT00654368|Drug|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
363893|NCT00654381|Drug|BI 1356|5 mg/daily
363894|NCT00654381|Drug|BI 1356|10 mg/daily
363895|NCT00654381|Drug|voglibose placebo|three times daily
363896|NCT00654381|Drug|BI 1356 placebo|once daily
363897|NCT00654381|Drug|voglibose|0.6 mg/daily
363898|NCT00654394|Drug|Rosuvastatin|
363899|NCT00004917|Drug|cisplatin|
363900|NCT00654407|Drug|Rosuvastatin|
363237|NCT00666458|Drug|saxagliptin|tablet, per oral, once daily
363238|NCT00666458|Drug|sitagliptin|capsule, per oral, once daily
363239|NCT00666471|Procedure|MICE|MICE
363240|NCT00666471|Procedure|SPA ligation|SPA ligation
363241|NCT00666484|Drug|cyclophosphamide|
363242|NCT00666484|Drug|doxorubicin hydrochloride|
363243|NCT00666484|Drug|etoposide|
363244|NCT00005047|Drug|vinblastine|
363245|NCT00666484|Drug|prednisolone|
363246|NCT00666484|Drug|procarbazine hydrochloride|
363247|NCT00666484|Drug|vincristine sulfate|
363248|NCT00666484|Radiation|radiation therapy|
363249|NCT00668564|Drug|Campath-1H|Days before Transplant Drug Frequency
12 Campath-1H Once, given over 2 hours
11 Campath-1H Once, given over 2 hours
10 Campath-1H Once, given over 2 hours
363572|NCT00005013|Drug|Sertraline|
363573|NCT00661856|Dietary Supplement|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
363574|NCT00661869|Other|Wellness Program|36 weeks of educational and supportive interventions
363575|NCT00661882|Other|medical chart review|Medical information, called "protected health information" (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record.
363576|NCT00661882|Other|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
363577|NCT00661882|Other|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
362916|NCT00634348|Drug|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
362917|NCT00634361|Drug|ethyl-eicosapentaenoic acid|2 mg per day
362918|NCT00634374|Device|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
362919|NCT00634387|Dietary Supplement|Anthocyans|Anthocyans
362920|NCT00634387|Other|placebo|
362921|NCT00634387|Dietary Supplement|Anthocyans|
362922|NCT00004748|Drug|colchicine|
362923|NCT00634400|Drug|Candesartan|
362924|NCT00634400|Drug|Placebo|
362925|NCT00634413|Drug|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
362926|NCT00634413|Drug|Placebo|Inhaled matching placebo administered twice daily for 28 days
362927|NCT00634413|Drug|Budesonide|Inhaled budesonide twice daily for 28 days
362928|NCT00634426|Procedure|Surgical excision of the metastatic process|Surgical excision of the metastatic process
362929|NCT00634426|Radiation|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
362930|NCT00634439|Drug|atomoxetine|
362931|NCT00634439|Drug|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
362932|NCT00634439|Other|No intervention (general population)|
362933|NCT00004748|Drug|methotrexate|
362934|NCT00634452|Biological|MDX-1401|IV weekly for 4 weeks
362935|NCT00634465|Device|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
362936|NCT00634478|Radiation|Pre-lemniscal Radiation Deep Brain Stimulation|
362937|NCT00634491|Drug|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
